diff --git a/build_install.sh b/build_install.sh index 273df81..840a2e0 100755 --- a/build_install.sh +++ b/build_install.sh @@ -1 +1 @@ -mvn assembly:assembly -DskipTests && cp target/owlapi_wrapper-0.0.1-SNAPSHOT-jar-with-dependencies.jar ../ontologies_linked_data/bin/owlapi_wrapper.jar +mvn assembly:assembly -DskipTests && cp target/owlapi_wrapper-0.0.1-SNAPSHOT-jar-with-dependencies.jar ../owlapi_wrapper.jar diff --git a/pom.xml b/pom.xml index 5573d49..248ab3f 100644 --- a/pom.xml +++ b/pom.xml @@ -153,6 +153,12 @@ 1.10.0 + + javax.xml.bind + jaxb-api + 2.3.0 + + diff --git a/src/main/java/org/stanford/ncbo/owlapi/wrapper/OntologyParser.java b/src/main/java/org/stanford/ncbo/owlapi/wrapper/OntologyParser.java index 22433d1..a8c2e50 100644 --- a/src/main/java/org/stanford/ncbo/owlapi/wrapper/OntologyParser.java +++ b/src/main/java/org/stanford/ncbo/owlapi/wrapper/OntologyParser.java @@ -31,6 +31,7 @@ public class OntologyParser { private final static Logger log = LoggerFactory.getLogger(OntologyParser.class.getName()); + public static final String USE_IMPORTS_IRI = "http://omv.ontoware.org/2005/05/ontology#useImports"; public static final String VERSION_SUBJECT = "http://bioportal.bioontology.org/ontologies/versionSubject"; protected ParserInvocation parserInvocation = null; @@ -169,6 +170,33 @@ private void addOntologyIRI(OWLOntology sourceOnt) { } } + /** + * Get ontology imports and them to + * omv:useImports + * + * @param fact + * @param sourceOnt + */ + private void addOntologyImports(OWLDataFactory fact, OWLOntology sourceOnt){ + Optional sub = sourceOnt.getOntologyID().getOntologyIRI(); + + if(!sub.isPresent()){ + return; + } + + IRI ontologyIRI = sub.get(); + + // Get imports and add them as omv:useImports + OWLAnnotationProperty useImportProp = fact.getOWLAnnotationProperty(IRI.create(USE_IMPORTS_IRI)); + for (OWLOntology imported : sourceOnt.getImports()) { + if (!imported.getOntologyID().isAnonymous()) { + log.info("useImports: " + imported.getOntologyID().getOntologyIRI().get()); + OWLAnnotationAssertionAxiom useImportAxiom = fact.getOWLAnnotationAssertionAxiom(useImportProp, ontologyIRI, imported.getOntologyID().getOntologyIRI().get()); + this.targetOwlManager.addAxiom(targetOwlOntology, useImportAxiom); + } + } + } + /** * Copies ontology-level annotation axioms from the source ontology to the target ontology. *

@@ -188,6 +216,7 @@ private void addGroundMetadata(IRI documentIRI, OWLDataFactory factory, OWLOntol } for (OWLAnnotation annotation : sourceOntology.getAnnotations()) { + IRI subjectIRI = ontologyID.getOntologyIRI().get(); OWLAnnotationProperty annotationProperty = annotation.getProperty(); OWLAnnotationValue annotationValue = annotation.getValue(); @@ -212,6 +241,7 @@ private boolean buildOWLOntology(OWLOntology masterOntology, boolean isOBO) { try { targetOwlOntology = targetOwlManager.createOntology(); addOntologyIRI(masterOntology); + addOntologyImports(fact, masterOntology); } catch (OWLOntologyCreationException e) { log.error(e.getMessage()); parserLog.addError(ParserError.OWL_CREATE_ONTOLOGY_EXCEPTION, "Error buildOWLOntology" + e.getMessage()); @@ -232,51 +262,52 @@ private boolean buildOWLOntology(OWLOntology masterOntology, boolean isOBO) { boolean isPrefixedOWL = sourceOwlManager.getOntologyFormat(sourceOnt).isPrefixOWLOntologyFormat(); log.info("isPrefixOWLOntologyFormat: {}", isPrefixedOWL); - if (isPrefixedOWL == true && !isOBO) { + if (isPrefixedOWL && !isOBO) { generateSKOSInOwl(allAxioms, fact, sourceOnt); } } - targetOwlManager.addAxioms(targetOwlOntology, allAxioms); - for (OWLAnnotation ann : targetOwlOntology.getAnnotations()) { + + targetOwlManager.addAxioms(targetOwlOntology, allAxioms); + for (OWLAnnotation ann : targetOwlOntology.getAnnotations()) { + AddOntologyAnnotation addAnn = new AddOntologyAnnotation(targetOwlOntology, ann); + targetOwlManager.applyChange(addAnn); + } + + if (isOBO) { + String oboVersion = parserInvocation.getOBOVersion(); + if (oboVersion != null) { + log.info("Adding version: {}", oboVersion); + OWLAnnotationProperty prop = fact.getOWLAnnotationProperty(IRI.create(OWLRDFVocabulary.OWL_VERSION_INFO.toString())); + IRI versionSubjectIRI = IRI.create(VERSION_SUBJECT); + OWLAnnotationAssertionAxiom annVersion = fact.getOWLAnnotationAssertionAxiom(prop, versionSubjectIRI, fact.getOWLLiteral(oboVersion)); + targetOwlManager.addAxiom(targetOwlOntology, annVersion); + } + } + + addOntologyAnnotations(masterOntology); + escapeXMLLiterals(targetOwlOntology); + + OWLReasonerFactory reasonerFactory = new StructuralReasonerFactory(); + OWLReasoner reasoner = reasonerFactory.createReasoner(targetOwlOntology); + InferredSubClassAxiomGenerator isc = new InferredSubClassAxiomGenerator(); + Set subAxs = isc.createAxioms(targetOwlOntology.getOWLOntologyManager().getOWLDataFactory(), reasoner); + targetOwlManager.addAxioms(targetOwlOntology, subAxs); + deprecateBranch(); + + log.info("isOBO: {}", isOBO); + if (isOBO) { + replicateHierarchyAsTreeview(fact); + } + return true; + } + + private void addOntologyAnnotations(OWLOntology masterOntology){ + for (OWLAnnotation ann : masterOntology.getAnnotations()) { AddOntologyAnnotation addAnn = new AddOntologyAnnotation(targetOwlOntology, ann); targetOwlManager.applyChange(addAnn); } - - if (isOBO) { - String oboVersion = parserInvocation.getOBOVersion(); - if (oboVersion != null) { - log.info("Adding version: {}", oboVersion); - OWLAnnotationProperty prop = fact.getOWLAnnotationProperty(IRI.create(OWLRDFVocabulary.OWL_VERSION_INFO.toString())); - IRI versionSubjectIRI = IRI.create(VERSION_SUBJECT); - OWLAnnotationAssertionAxiom annVersion = fact.getOWLAnnotationAssertionAxiom(prop, versionSubjectIRI, fact.getOWLLiteral(oboVersion)); - targetOwlManager.addAxiom(targetOwlOntology, annVersion); - } - } - - for (OWLOntology sourceOnt : sourceOwlManager.getOntologies()) { - for (OWLAnnotation ann : sourceOnt.getAnnotations()) { - AddOntologyAnnotation addAnn = new AddOntologyAnnotation(targetOwlOntology, ann); - targetOwlManager.applyChange(addAnn); - } - } - - escapeXMLLiterals(targetOwlOntology); - - OWLReasonerFactory reasonerFactory = new StructuralReasonerFactory(); - OWLReasoner reasoner = reasonerFactory.createReasoner(targetOwlOntology); - InferredSubClassAxiomGenerator isc = new InferredSubClassAxiomGenerator(); - Set subAxs = isc.createAxioms(targetOwlOntology.getOWLOntologyManager().getOWLDataFactory(), reasoner); - targetOwlManager.addAxioms(targetOwlOntology, subAxs); - deprecateBranch(); - - log.info("isOBO: {}", isOBO); - if (isOBO) { - replicateHierarchyAsTreeview(fact); - } - return true; } - private void replicateHierarchyAsTreeview(OWLDataFactory fact) { Set treeViewAxs = new HashSet(); for (OWLAxiom axiom : targetOwlOntology.getAxioms()) { @@ -449,7 +480,7 @@ private void escapeXMLLiterals(OWLOntology target) { targetOwlManager.addAxiom(target, annAsse); Set del = new HashSet(); del.add(ann); - targetOwlManager.removeAxioms(target,del); + targetOwlManager.removeAxioms(target,del); } } } diff --git a/src/main/java/org/stanford/ncbo/owlapi/wrapper/preferred_labels/PreferredLabels.java b/src/main/java/org/stanford/ncbo/owlapi/wrapper/preferred_labels/PreferredLabels.java new file mode 100644 index 0000000..e723858 --- /dev/null +++ b/src/main/java/org/stanford/ncbo/owlapi/wrapper/preferred_labels/PreferredLabels.java @@ -0,0 +1,20 @@ +package org.stanford.ncbo.owlapi.wrapper.preferred_labels; + +import org.semanticweb.owlapi.model.OWLOntology; +import org.slf4j.Logger; +import org.slf4j.LoggerFactory; +import org.stanford.ncbo.owlapi.wrapper.ParserInvocation; +import org.stanford.ncbo.owlapi.wrapper.metrics.OntologyMetrics; + +public class PreferredLabels { + private static final Logger logger = LoggerFactory.getLogger(OntologyMetrics.class); + + private OWLOntology ontology; + + private ParserInvocation parserInvocation; + + public PreferredLabels(OWLOntology ontology, ParserInvocation parserInvocation) { + this.ontology = ontology; + this.parserInvocation = parserInvocation; + } +} diff --git a/src/test/java/org/stanford/ncbo/owlapi/wrapper/OntologyParserTest.java b/src/test/java/org/stanford/ncbo/owlapi/wrapper/OntologyParserTest.java index 12d4699..e311ed1 100644 --- a/src/test/java/org/stanford/ncbo/owlapi/wrapper/OntologyParserTest.java +++ b/src/test/java/org/stanford/ncbo/owlapi/wrapper/OntologyParserTest.java @@ -18,6 +18,19 @@ public class OntologyParserTest { public void setUp() throws Exception { } + + // Run this test: mvn -Dtest=OntologyParserTest#sifrTestParse test + // parse_OntologyENVO_ReturnsTrue fonctionne pour comparer + @Test + public void sifrTestParse() throws Exception { + ParserInvocation pi = new ParserInvocation("./src/test/resources/repo/input/sifr", + "./src/test/resources/repo/output/sifr", "foodon.owl", true); + // SKOS: anaee-france-thesaurus.rdf + // OWL: AnimalDiseasesOntology.owl.xml + OntologyParser parser = new OntologyParser(pi); + parser.parse(); + //assertFalse(parser.parse()); + } @Test public void getLocalOntologies_MultipleOntologies_Found() throws Exception { @@ -165,6 +178,25 @@ public void parse_ImportSKOSCoreVocab_ShouldLoad() throws Exception { OWLClass skosConceptClass = factory.getOWLClass(skosConceptIRI); assertNotNull(skosConceptClass); } + @Test + public void parse_OntologyAnnotationCount_ReturnsTrue() throws Exception { + String outputRepositoryFolder = "./src/test/resources/repo/output/cno"; + ParserInvocation pi = new ParserInvocation("./src/test/resources/repo/input/cno", + outputRepositoryFolder, "cnov0_5.owl", true); + assertTrue(pi.valid()); + + OntologyParser parser = new OntologyParser(pi); + assertTrue(parser.parse()); + assertEquals(1, parser.getLocalOntologies().size()); + + OWLOntology targetOwlOntology = parser.getTargetOwlOntology(); + OWLOntology sourceOntology = parser.getParsedOntologies().stream().findFirst().orElse(null); + + assertNotNull(sourceOntology); + assertEquals(sourceOntology.getAnnotations().size(), targetOwlOntology.getAnnotations().size()); + + } + @After public void tearDown() throws Exception { diff --git a/src/test/resources/repo/input/afo/afo.ttl b/src/test/resources/repo/input/afo/afo.ttl new file mode 100644 index 0000000..d9771d8 --- /dev/null +++ b/src/test/resources/repo/input/afo/afo.ttl @@ -0,0 +1,59616 @@ +@prefix : . +@prefix m: . +@prefix cl: . +@prefix co: . +@prefix ex: . +@prefix go: . +@prefix qb: . +@prefix ro: . +@prefix uo: . +@prefix bfo: . +@prefix dct: . +@prefix hdf: . +@prefix iao: . +@prefix ldp: . +@prefix map: . +@prefix mop: . +@prefix obi: . +@prefix ops: . +@prefix ore: . +@prefix org: . +@prefix owl: . +@prefix pav: . +@prefix rdf: . +@prefix xml: . +@prefix xsd: . +@prefix af-c: . +@prefix af-e: . +@prefix af-m: . +@prefix af-p: . +@prefix af-q: . +@prefix af-r: . +@prefix af-x: . +@prefix caro: . +@prefix chmo: . +@prefix envo: . +@prefix foaf: . +@prefix ncbi: . +@prefix omcd: . +@prefix pato: . +@prefix prov: . +@prefix qudt: . +@prefix rdfs: . +@prefix skos: . +@prefix time: . +@prefix void: . +@prefix af-cq: . +@prefix af-fn: . +@prefix af-re: . +@prefix af-rl: . +@prefix af-sp: . +@prefix afs-c: . +@prefix afs-q: . +@prefix chebi: . +@prefix shacl: . +@prefix vcard: . +@prefix adf-dc: . +@prefix adf-dp: . +@prefix af-cur: . +@prefix af-gaz: . +@prefix af-map: . +@prefix afs-dc: . +@prefix afs-hr: . +@prefix dctype: . +@prefix premis: . +@prefix uberon: . +@prefix af-math: . +@prefix qudt-ext: . +@prefix unit-ext: . +@prefix qudt-unit: . +@prefix adf-dc-hdf: . +@prefix quantity-ext: . +@base . + + rdf:type owl:Ontology ; + + owl:versionIRI ; + + prov:wasDerivedFrom ; + + dct:title "Allotrope Foundation Ontology MERGED (REC/2021/03)" ; + + dct:rights ; + + prov:wasDerivedFrom , + , + , + , + ; + + dct:rights ; + + prov:wasDerivedFrom , + , + , + , + , + ; + + dct:issued "2021-03-30T12:00:00Z"^^xsd:dateTime ; + + prov:wasDerivedFrom , + , + , + , + , + , + ; + + dct:contributor ; + + prov:wasDerivedFrom , + , + , + , + , + , + , + , + , + , + , + , + ; + + dct:publisher ; + + prov:wasDerivedFrom , + , + , + , + , + , + , + , + , + , + , + , + , + ; + + owl:versionInfo "REC/2021/03" ; + + prov:wasDerivedFrom , + , + , + , + ; + + dct:license ; + + prov:wasDerivedFrom , + , + , + , + , + . + + +################################################################# +# +# Annotation properties +# +################################################################# + + +### http://purl.allotrope.org/ontologies/property#AFX_0001144 + +af-x:AFX_0001144 rdf:type owl:AnnotationProperty ; + + rdfs:isDefinedBy ; + + skos:altLabel "has predicate" ; + + skos:definition "A reference to an object or datatype property. [Allotrope]" ; + + skos:prefLabel "has property" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0001166 + +af-x:AFX_0001166 rdf:type owl:AnnotationProperty ; + + rdfs:isDefinedBy ; + + skos:definition "A relation to a class of individuals. [Allotrope]" ; + + skos:prefLabel "has class" ; + + rdfs:range rdfs:Class . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0002794 + +af-x:AFX_0002794 rdf:type owl:AnnotationProperty ; + + rdfs:isDefinedBy ; + + skos:definition "Property is a note about a proposed logical expression in order to describe the term as defined class. [Allotrope]" ; + + skos:prefLabel "is equivalent to" ; + + rdfs:subPropertyOf skos:note . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0002795 + +af-x:AFX_0002795 rdf:type owl:AnnotationProperty ; + + rdfs:isDefinedBy ; + + skos:definition "Property is a note about a proposed expression of a restriction that the term should be a subclass of. [Allotrope]" ; + + skos:prefLabel "has proposed restriction" ; + + rdfs:subPropertyOf skos:note . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0002796 + +af-x:AFX_0002796 rdf:type owl:AnnotationProperty ; + + rdfs:isDefinedBy ; + + skos:definition "Property specifies level of granularity the term mainly belongs to. [Allotrope]" ; + + skos:prefLabel "has granularity" ; + + rdfs:subPropertyOf skos:note ; + + rdfs:range af-r:AFR_0001221 . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0002797 + +af-x:AFX_0002797 rdf:type owl:AnnotationProperty ; + + rdfs:isDefinedBy ; + + skos:definition "Property tracks terms that have been aligned with BFO during development. [Allotrope]" ; + + skos:prefLabel "is aligned with BFO" ; + + rdfs:subPropertyOf skos:editorialNote . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0002798 + +af-x:AFX_0002798 rdf:type owl:AnnotationProperty ; + + rdfs:isDefinedBy ; + + skos:definition "Is defined class flags a resource as being a class that can be defined by necessary and sufficient conditions. [Allotrope]" ; + + skos:prefLabel "is defined class" ; + + rdfs:subPropertyOf skos:note . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0002799 + +af-x:AFX_0002799 rdf:type owl:AnnotationProperty ; + + rdfs:isDefinedBy ; + + skos:definition "An annotation predicate used to identify entity replacement by a role. [Allotrope]" ; + + skos:prefLabel "is replaced by role" ; + + rdfs:subPropertyOf skos:note . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0002808 + +af-x:AFX_0002808 rdf:type owl:AnnotationProperty ; + + rdfs:isDefinedBy ; + + skos:definition "Has close match establishes a connection between two resources that have a high degree of agreement in meaning such that they can be used interchangeably. [Allotrope]" ; + + skos:note "Property is related to skos:closeMatch. Skos:closeMatch is an object property whereas this property is an annotation property to allow for weak semantic coupling. [Allotrope]" ; + + skos:prefLabel "has close match" ; + + rdfs:subPropertyOf skos:note . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0002809 + +af-x:AFX_0002809 rdf:type owl:AnnotationProperty ; + + rdfs:isDefinedBy ; + + skos:definition "Has exact match establishes a connection between two resources that have completely same meaning such that they can be used interchangeably. [Allotrope]" ; + + skos:note "Property is related to skos:exactMatch. Skos:exactMatch is an object property whereas this property is an annotation property to allow for weak semantic coupling. [Allotrope]" ; + + skos:prefLabel "has exact match" ; + + rdfs:subPropertyOf af-x:AFX_0002808 . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0002811 + +af-x:AFX_0002811 rdf:type owl:AnnotationProperty ; + + rdfs:isDefinedBy ; + + skos:definition "Has related establishes a connection between two resources that have an associative relationship. [Allotrope]" ; + + skos:note "Property is related to skos:related. Skos:related is an object property whereas this property is an annotation property to allow for weak semantic coupling. [Allotrope]" ; + + skos:prefLabel "has related" ; + + rdfs:subPropertyOf skos:note . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0002815 + +af-x:AFX_0002815 rdf:type owl:AnnotationProperty ; + + rdfs:isDefinedBy ; + + skos:definition "Reference that maps a class to a perspective. [Allotrope]" ; + + skos:prefLabel "has perspective" ; + + rdfs:subPropertyOf skos:scopeNote . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0002818 + +af-x:AFX_0002818 rdf:type owl:AnnotationProperty ; + + rdfs:isDefinedBy ; + + skos:definition "Is universal class flags a resource as being a primitive class that stands on its own. [Allotrope]" ; + + skos:prefLabel "is universal class" ; + + rdfs:subPropertyOf skos:note . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0002841 + +af-x:AFX_0002841 rdf:type owl:AnnotationProperty ; + + rdfs:isDefinedBy ; + + skos:definition "Has coordination annotates a class with some defining differentia. [Allotrope]" ; + + skos:prefLabel "has coordination" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0002850 + +af-x:AFX_0002850 rdf:type owl:AnnotationProperty ; + + rdfs:isDefinedBy ; + + skos:altLabel "design pattern" , + "has pattern" , + "pattern" ; + + skos:definition "Has design pattern annotates a resource with a reference to a design pattern. [Allotrope]" ; + + skos:prefLabel "has design pattern" ; + + rdfs:subPropertyOf skos:note . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0002865 + +af-x:AFX_0002865 rdf:type owl:AnnotationProperty ; + + af-x:AFX_0002808 pav:importedFrom ; + + rdfs:isDefinedBy ; + + skos:changeNote "2020-12-15 Property has been added in order to replace pav:importedFrom. The difference between af-x:AFX_0002865 and pav:importedFrom is that the former is an annotation property whereas the latter is an object property. We added a new property in order to avoid issues of redeclaration of pav:importedFrom as annotation property. [OSTHUS]" ; + + skos:definition "The original source of imported information. [PAV]" ; + + skos:prefLabel "imported from" ; + + rdfs:subPropertyOf skos:note . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0002866 + +af-x:AFX_0002866 rdf:type owl:AnnotationProperty ; + + af-x:AFX_0002808 pav:derivedFrom ; + + rdfs:isDefinedBy ; + + skos:definition "Derived from a different resource. [PAV]" ; + + skos:note "2020-12-15 Property has been added in order to replace pav:derivedFrom. The difference between af-x:AFX_0002866 and pav:derivedFrom is that the former is an annotation property whereas the latter is an object property. We added a new property in order to avoid issues of redeclaration of pav:derivedFrom as annotation property. [OSTHUS]" ; + + skos:prefLabel "derived from" ; + + rdfs:subPropertyOf skos:note . + + + +### http://purl.obolibrary.org/obo/BFO_0000179 + +bfo:_0000179 rdf:type owl:AnnotationProperty ; + + iao:_0000115 "Relates an entity in the ontology to the name of the variable that is used to represent it in the code that generates the BFO OWL file from the lispy specification." ; + + iao:_0000232 "Really of interest to developers only" ; + + rdfs:label "BFO OWL specification label" ; + + rdfs:subPropertyOf rdfs:label . + + + +### http://purl.obolibrary.org/obo/BFO_0000180 + +bfo:_0000180 rdf:type owl:AnnotationProperty ; + + iao:_0000115 "Relates an entity in the ontology to the term that is used to represent it in the the CLIF specification of BFO2" ; + + iao:_0000119 "Person:Alan Ruttenberg" ; + + iao:_0000232 "Really of interest to developers only" ; + + rdfs:label "BFO CLIF specification label" ; + + rdfs:subPropertyOf rdfs:label . + + + +### http://purl.obolibrary.org/obo/IAO_0000112 + +iao:_0000112 rdf:type owl:AnnotationProperty ; + + rdfs:isDefinedBy ; + + rdfs:label "example of usage" . + + + +### http://purl.obolibrary.org/obo/IAO_0000115 + +iao:_0000115 rdf:type owl:AnnotationProperty ; + + rdfs:isDefinedBy ; + + rdfs:label "definition" . + + + +### http://purl.obolibrary.org/obo/IAO_0000116 + +iao:_0000116 rdf:type owl:AnnotationProperty ; + + rdfs:isDefinedBy ; + + rdfs:label "editor note" . + + + +### http://purl.obolibrary.org/obo/IAO_0000117 + +iao:_0000117 rdf:type owl:AnnotationProperty ; + + rdfs:isDefinedBy ; + + rdfs:label "term editor" . + + + +### http://purl.obolibrary.org/obo/IAO_0000118 + +iao:_0000118 rdf:type owl:AnnotationProperty ; + + rdfs:isDefinedBy ; + + rdfs:label "alternative term" . + + + +### http://purl.obolibrary.org/obo/IAO_0000119 + +iao:_0000119 rdf:type owl:AnnotationProperty ; + + rdfs:isDefinedBy ; + + rdfs:label "definition source" . + + + +### http://purl.obolibrary.org/obo/IAO_0000232 + +iao:_0000232 rdf:type owl:AnnotationProperty ; + + rdfs:isDefinedBy ; + + rdfs:label "curator note" . + + + +### http://purl.obolibrary.org/obo/IAO_0000412 + +iao:_0000412 rdf:type owl:AnnotationProperty ; + + rdfs:isDefinedBy ; + + rdfs:label "imported from" . + + + +### http://purl.obolibrary.org/obo/IAO_0000600 + +iao:_0000600 rdf:type owl:AnnotationProperty ; + + rdfs:isDefinedBy ; + + rdfs:label "elucidation" . + + + +### http://purl.obolibrary.org/obo/IAO_0000601 + +iao:_0000601 rdf:type owl:AnnotationProperty ; + + rdfs:isDefinedBy ; + + rdfs:label "has associated axiom(nl)" . + + + +### http://purl.obolibrary.org/obo/IAO_0000602 + +iao:_0000602 rdf:type owl:AnnotationProperty ; + + rdfs:isDefinedBy ; + + rdfs:label "has associated axiom(fol)" . + + + +### http://purl.obolibrary.org/obo/IAO_0010000 + +iao:_0010000 rdf:type owl:AnnotationProperty ; + + rdfs:isDefinedBy ; + + rdfs:label "has axiom label" . + + + +### http://purl.org/dc/elements/1.1/contributor + + rdf:type owl:AnnotationProperty . + + + +### http://purl.org/dc/elements/1.1/coverage + + rdf:type owl:AnnotationProperty . + + + +### http://purl.org/dc/elements/1.1/creator + + rdf:type owl:AnnotationProperty . + + + +### http://purl.org/dc/elements/1.1/date + + rdf:type owl:AnnotationProperty . + + + +### http://purl.org/dc/elements/1.1/description + + rdf:type owl:AnnotationProperty . + + + +### http://purl.org/dc/elements/1.1/format + + rdf:type owl:AnnotationProperty . + + + +### http://purl.org/dc/elements/1.1/identifier + + rdf:type owl:AnnotationProperty . + + + +### http://purl.org/dc/elements/1.1/language + + rdf:type owl:AnnotationProperty . + + + +### http://purl.org/dc/elements/1.1/publisher + + rdf:type owl:AnnotationProperty . + + + +### http://purl.org/dc/elements/1.1/relation + + rdf:type owl:AnnotationProperty . + + + +### http://purl.org/dc/elements/1.1/rights + + rdf:type owl:AnnotationProperty . + + + +### http://purl.org/dc/elements/1.1/source + + rdf:type owl:AnnotationProperty . + + + +### http://purl.org/dc/elements/1.1/subject + + rdf:type owl:AnnotationProperty . + + + +### http://purl.org/dc/elements/1.1/title + + rdf:type owl:AnnotationProperty . + + + +### http://purl.org/dc/elements/1.1/type + + rdf:type owl:AnnotationProperty . + + + +### http://purl.org/dc/terms/abstract + +dct:abstract rdf:type owl:AnnotationProperty ; + + af-x:AFX_0002865 dct: ; + + rdfs:isDefinedBy ; + + skos:prefLabel "abstract" ; + + rdfs:subPropertyOf , + dct:description . + + + +### http://purl.org/dc/terms/accessRights + +dct:accessRights rdf:type owl:AnnotationProperty ; + + af-x:AFX_0002865 dct: ; + + rdfs:isDefinedBy ; + + skos:prefLabel "access rights" ; + + rdfs:subPropertyOf . + + + +### http://purl.org/dc/terms/alternative + +dct:alternative rdf:type owl:AnnotationProperty ; + + af-x:AFX_0002865 dct: ; + + rdfs:isDefinedBy ; + + skos:prefLabel "alternative" ; + + rdfs:subPropertyOf . + + + +### http://purl.org/dc/terms/available + +dct:available rdf:type owl:AnnotationProperty ; + + af-x:AFX_0002865 dct: ; + + rdfs:isDefinedBy ; + + skos:prefLabel "available" ; + + rdfs:subPropertyOf . + + + +### http://purl.org/dc/terms/bibliographicCitation + +dct:bibliographicCitation rdf:type owl:AnnotationProperty ; + + af-x:AFX_0002865 dct: ; + + rdfs:isDefinedBy ; + + skos:prefLabel "bibliographic citation" ; + + rdfs:subPropertyOf . + + + +### http://purl.org/dc/terms/conformsTo + +dct:conformsTo rdf:type owl:AnnotationProperty ; + + af-x:AFX_0002865 dct: ; + + rdfs:isDefinedBy ; + + skos:prefLabel "conforms to" ; + + rdfs:subPropertyOf , + dct:relation . + + + +### http://purl.org/dc/terms/contributor + +dct:contributor rdf:type owl:AnnotationProperty ; + + af-x:AFX_0002865 dct: ; + + rdfs:isDefinedBy ; + + skos:prefLabel "contributor" ; + + rdfs:subPropertyOf . + + + +### http://purl.org/dc/terms/coverage + +dct:coverage rdf:type owl:AnnotationProperty ; + + af-x:AFX_0002865 dct: ; + + rdfs:isDefinedBy ; + + skos:prefLabel "coverage" ; + + rdfs:subPropertyOf . + + + +### http://purl.org/dc/terms/created + +dct:created rdf:type owl:AnnotationProperty ; + + af-x:AFX_0002865 dct: ; + + rdfs:isDefinedBy ; + + skos:prefLabel "created" ; + + rdfs:subPropertyOf . + + + +### http://purl.org/dc/terms/creator + +dct:creator rdf:type owl:AnnotationProperty ; + + af-x:AFX_0002865 dct: ; + + rdfs:isDefinedBy ; + + skos:prefLabel "creator" ; + + rdfs:subPropertyOf . + + + +### http://purl.org/dc/terms/date + +dct:date rdf:type owl:AnnotationProperty ; + + af-x:AFX_0002865 dct: ; + + rdfs:isDefinedBy ; + + skos:prefLabel "date" ; + + rdfs:subPropertyOf . + + + +### http://purl.org/dc/terms/dateAccepted + +dct:dateAccepted rdf:type owl:AnnotationProperty ; + + af-x:AFX_0002865 dct: ; + + rdfs:isDefinedBy ; + + skos:prefLabel "date accepted" ; + + rdfs:subPropertyOf . + + + +### http://purl.org/dc/terms/dateCopyrighted + +dct:dateCopyrighted rdf:type owl:AnnotationProperty ; + + af-x:AFX_0002865 dct: ; + + rdfs:isDefinedBy ; + + skos:prefLabel "date copyrighted" ; + + rdfs:subPropertyOf . + + + +### http://purl.org/dc/terms/dateSubmitted + +dct:dateSubmitted rdf:type owl:AnnotationProperty ; + + af-x:AFX_0002865 dct: ; + + rdfs:isDefinedBy ; + + skos:prefLabel "date submitted" ; + + rdfs:subPropertyOf . + + + +### http://purl.org/dc/terms/description + +dct:description rdf:type owl:AnnotationProperty ; + + af-x:AFX_0002865 dct: ; + + rdfs:isDefinedBy ; + + skos:prefLabel "description" ; + + rdfs:subPropertyOf . + + + +### http://purl.org/dc/terms/extent + +dct:extent rdf:type owl:AnnotationProperty ; + + af-x:AFX_0002865 dct: ; + + rdfs:isDefinedBy ; + + skos:prefLabel "extend" ; + + rdfs:subPropertyOf . + + + +### http://purl.org/dc/terms/format + +dct:format rdf:type owl:AnnotationProperty ; + + af-x:AFX_0002865 dct: ; + + rdfs:isDefinedBy ; + + skos:prefLabel "format" ; + + rdfs:subPropertyOf . + + + +### http://purl.org/dc/terms/hasFormat + +dct:hasFormat rdf:type owl:AnnotationProperty ; + + af-x:AFX_0002865 dct: ; + + rdfs:isDefinedBy ; + + skos:prefLabel "has format" ; + + rdfs:subPropertyOf , + dct:relation . + + + +### http://purl.org/dc/terms/hasPart + +dct:hasPart rdf:type owl:AnnotationProperty ; + + af-x:AFX_0002865 dct: ; + + rdfs:isDefinedBy ; + + skos:prefLabel "has part" ; + + rdfs:subPropertyOf , + dct:relation . + + + +### http://purl.org/dc/terms/hasVersion + +dct:hasVersion rdf:type owl:AnnotationProperty ; + + af-x:AFX_0002865 dct: ; + + rdfs:isDefinedBy ; + + skos:prefLabel "has version" ; + + rdfs:subPropertyOf , + dct:relation . + + + +### http://purl.org/dc/terms/identifier + +dct:identifier rdf:type owl:AnnotationProperty ; + + af-x:AFX_0002865 dct: ; + + rdfs:isDefinedBy ; + + skos:prefLabel "identifier" ; + + rdfs:subPropertyOf . + + + +### http://purl.org/dc/terms/isFormatOf + +dct:isFormatOf rdf:type owl:AnnotationProperty ; + + af-x:AFX_0002865 dct: ; + + rdfs:isDefinedBy ; + + skos:prefLabel "is format of" ; + + rdfs:subPropertyOf , + dct:relation . + + + +### http://purl.org/dc/terms/isPartOf + +dct:isPartOf rdf:type owl:AnnotationProperty ; + + af-x:AFX_0002865 dct: ; + + rdfs:isDefinedBy ; + + skos:prefLabel "is part of" ; + + rdfs:subPropertyOf , + dct:relation . + + + +### http://purl.org/dc/terms/isReferencedBy + +dct:isReferencedBy rdf:type owl:AnnotationProperty ; + + af-x:AFX_0002865 dct: ; + + rdfs:isDefinedBy ; + + skos:prefLabel "is referenced by" ; + + rdfs:subPropertyOf , + dct:relation . + + + +### http://purl.org/dc/terms/isReplacedBy + +dct:isReplacedBy rdf:type owl:AnnotationProperty ; + + af-x:AFX_0002865 dct: ; + + rdfs:isDefinedBy ; + + skos:prefLabel "is replaced by" ; + + rdfs:subPropertyOf , + dct:relation . + + + +### http://purl.org/dc/terms/isRequiredBy + +dct:isRequiredBy rdf:type owl:AnnotationProperty ; + + af-x:AFX_0002865 dct: ; + + rdfs:isDefinedBy ; + + skos:prefLabel "is required by" ; + + rdfs:subPropertyOf , + dct:relation . + + + +### http://purl.org/dc/terms/isVersionOf + +dct:isVersionOf rdf:type owl:AnnotationProperty ; + + af-x:AFX_0002865 dct: ; + + rdfs:isDefinedBy ; + + skos:prefLabel "is version of" ; + + rdfs:subPropertyOf , + dct:relation . + + + +### http://purl.org/dc/terms/issued + +dct:issued rdf:type owl:AnnotationProperty ; + + af-x:AFX_0002865 dct: ; + + rdfs:isDefinedBy ; + + skos:prefLabel "issued" ; + + rdfs:subPropertyOf . + + + +### http://purl.org/dc/terms/language + +dct:language rdf:type owl:AnnotationProperty ; + + af-x:AFX_0002865 dct: ; + + rdfs:isDefinedBy ; + + skos:prefLabel "language" ; + + rdfs:subPropertyOf . + + + +### http://purl.org/dc/terms/license + +dct:license rdf:type owl:AnnotationProperty ; + + af-x:AFX_0002865 dct: ; + + rdfs:isDefinedBy ; + + skos:prefLabel "license" ; + + rdfs:subPropertyOf . + + + +### http://purl.org/dc/terms/medium + +dct:medium rdf:type owl:AnnotationProperty ; + + af-x:AFX_0002865 dct: ; + + rdfs:isDefinedBy ; + + skos:prefLabel "medium" ; + + rdfs:subPropertyOf . + + + +### http://purl.org/dc/terms/modified + +dct:modified rdf:type owl:AnnotationProperty ; + + af-x:AFX_0002865 dct: ; + + rdfs:isDefinedBy ; + + skos:prefLabel "modified" ; + + rdfs:subPropertyOf . + + + +### http://purl.org/dc/terms/publisher + +dct:publisher rdf:type owl:AnnotationProperty ; + + af-x:AFX_0002865 dct: ; + + rdfs:isDefinedBy ; + + skos:prefLabel "publisher" ; + + rdfs:subPropertyOf . + + + +### http://purl.org/dc/terms/references + +dct:references rdf:type owl:AnnotationProperty ; + + af-x:AFX_0002865 dct: ; + + rdfs:isDefinedBy ; + + skos:prefLabel "references" ; + + rdfs:subPropertyOf , + dct:relation . + + + +### http://purl.org/dc/terms/relation + +dct:relation rdf:type owl:AnnotationProperty ; + + af-x:AFX_0002865 dct: ; + + rdfs:isDefinedBy ; + + skos:prefLabel "relation" ; + + rdfs:subPropertyOf . + + + +### http://purl.org/dc/terms/replaces + +dct:replaces rdf:type owl:AnnotationProperty ; + + af-x:AFX_0002865 dct: ; + + rdfs:isDefinedBy ; + + skos:prefLabel "replaces" ; + + rdfs:subPropertyOf , + dct:relation . + + + +### http://purl.org/dc/terms/requires + +dct:requires rdf:type owl:AnnotationProperty ; + + af-x:AFX_0002865 dct: ; + + rdfs:isDefinedBy ; + + skos:prefLabel "requires" ; + + rdfs:subPropertyOf , + dct:relation . + + + +### http://purl.org/dc/terms/rights + +dct:rights rdf:type owl:AnnotationProperty ; + + af-x:AFX_0002865 dct: ; + + rdfs:isDefinedBy ; + + skos:prefLabel "rights" ; + + rdfs:subPropertyOf . + + + +### http://purl.org/dc/terms/rightsHolder + +dct:rightsHolder rdf:type owl:AnnotationProperty ; + + af-x:AFX_0002865 dct: ; + + rdfs:isDefinedBy ; + + skos:prefLabel "rights holder" . + + + +### http://purl.org/dc/terms/source + +dct:source rdf:type owl:AnnotationProperty ; + + af-x:AFX_0002865 dct: ; + + rdfs:isDefinedBy ; + + skos:prefLabel "source" ; + + rdfs:subPropertyOf , + dct:relation . + + + +### http://purl.org/dc/terms/spatial + +dct:spatial rdf:type owl:AnnotationProperty ; + + af-x:AFX_0002865 dct: ; + + rdfs:isDefinedBy ; + + skos:prefLabel "spatial" ; + + rdfs:subPropertyOf . + + + +### http://purl.org/dc/terms/subject + +dct:subject rdf:type owl:AnnotationProperty ; + + af-x:AFX_0002865 dct: ; + + rdfs:isDefinedBy ; + + skos:prefLabel "subject" ; + + rdfs:subPropertyOf . + + + +### http://purl.org/dc/terms/tableOfContents + +dct:tableOfContents rdf:type owl:AnnotationProperty ; + + af-x:AFX_0002865 dct: ; + + rdfs:isDefinedBy ; + + skos:prefLabel "table of contents" ; + + rdfs:subPropertyOf , + dct:description . + + + +### http://purl.org/dc/terms/temporal + +dct:temporal rdf:type owl:AnnotationProperty ; + + af-x:AFX_0002865 dct: ; + + rdfs:isDefinedBy ; + + skos:prefLabel "temporal" ; + + rdfs:subPropertyOf . + + + +### http://purl.org/dc/terms/title + +dct:title rdf:type owl:AnnotationProperty ; + + af-x:AFX_0002865 dct: ; + + rdfs:isDefinedBy ; + + skos:prefLabel "title" ; + + rdfs:subPropertyOf . + + + +### http://purl.org/dc/terms/type + +dct:type rdf:type owl:AnnotationProperty ; + + af-x:AFX_0002865 dct: ; + + rdfs:isDefinedBy ; + + skos:prefLabel "type" ; + + rdfs:subPropertyOf . + + + +### http://purl.org/dc/terms/valid + +dct:valid rdf:type owl:AnnotationProperty ; + + af-x:AFX_0002865 dct: ; + + rdfs:isDefinedBy ; + + skos:prefLabel "valid" ; + + rdfs:subPropertyOf . + + + +### http://purl.org/pav/importedFrom + +pav:importedFrom rdf:type owl:AnnotationProperty . + + + +### http://rdfs.org/ns/void#feature + +void:feature rdf:type owl:AnnotationProperty . + + + +### http://www.w3.org/2000/01/rdf-schema#isDefinedBy + +rdfs:isDefinedBy rdf:type owl:AnnotationProperty . + + + +### http://www.w3.org/2000/01/rdf-schema#seeAlso + +rdfs:seeAlso rdf:type owl:AnnotationProperty . + + + +### http://www.w3.org/2001/XMLSchema#minInclusive + +xsd:minInclusive rdf:type owl:AnnotationProperty . + + + +### http://www.w3.org/2002/07/owl#minQualifiedCardinality + +owl:minQualifiedCardinality rdf:type owl:AnnotationProperty . + + + +### http://www.w3.org/2004/02/skos/core#altLabel + +skos:altLabel rdf:type owl:AnnotationProperty ; + + af-x:AFX_0002865 ; + + rdfs:comment "The range of skos:altLabel is the class of RDF plain literals."@en , + "skos:prefLabel, skos:altLabel and skos:hiddenLabel are pairwise disjoint properties." ; + + rdfs:isDefinedBy ; + + rdfs:label "alternative label" ; + + skos:definition "An alternative lexical label for a resource." ; + + skos:example "Acronyms, abbreviations, spelling variants, and irregular plural/singular forms may be included among the alternative labels for a concept. Mis-spelled terms are normally included as hidden labels (see skos:hiddenLabel)." ; + + rdfs:subPropertyOf rdfs:label . + + + +### http://www.w3.org/2004/02/skos/core#changeNote + +skos:changeNote rdf:type owl:AnnotationProperty ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + rdfs:label "change note" ; + + skos:definition "A note about a modification to a concept." ; + + rdfs:subPropertyOf skos:note . + + + +### http://www.w3.org/2004/02/skos/core#definition + +skos:definition rdf:type owl:AnnotationProperty ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + rdfs:label "definition" ; + + skos:definition "A statement or formal explanation of the meaning of a concept." ; + + rdfs:subPropertyOf skos:note . + + + +### http://www.w3.org/2004/02/skos/core#editorialNote + +skos:editorialNote rdf:type owl:AnnotationProperty ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + rdfs:label "editorial note" ; + + skos:definition "A note for an editor, translator or maintainer of the vocabulary." ; + + rdfs:subPropertyOf skos:note . + + + +### http://www.w3.org/2004/02/skos/core#example + +skos:example rdf:type owl:AnnotationProperty ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + rdfs:label "example" ; + + skos:definition "An example of the use of a concept." ; + + rdfs:subPropertyOf skos:note . + + + +### http://www.w3.org/2004/02/skos/core#hiddenLabel + +skos:hiddenLabel rdf:type owl:AnnotationProperty ; + + af-x:AFX_0002865 ; + + rdfs:comment "The range of skos:hiddenLabel is the class of RDF plain literals."@en , + "skos:prefLabel, skos:altLabel and skos:hiddenLabel are pairwise disjoint properties." ; + + rdfs:isDefinedBy ; + + rdfs:label "hidden label" ; + + skos:definition "A lexical label for a resource that should be hidden when generating visual displays of the resource, but should still be accessible to free text search operations." ; + + rdfs:subPropertyOf rdfs:label . + + + +### http://www.w3.org/2004/02/skos/core#historyNote + +skos:historyNote rdf:type owl:AnnotationProperty ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + rdfs:label "history note" ; + + skos:definition "A note about the past state/use/meaning of a concept." ; + + rdfs:subPropertyOf skos:note . + + + +### http://www.w3.org/2004/02/skos/core#note + +skos:note rdf:type owl:AnnotationProperty ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + rdfs:label "note" ; + + skos:definition "A general note, for any purpose." ; + + skos:scopeNote "This property may be used directly, or as a super-property for more specific note types." . + + + +### http://www.w3.org/2004/02/skos/core#prefLabel + +skos:prefLabel rdf:type owl:AnnotationProperty ; + + af-x:AFX_0002865 ; + + rdfs:comment "A resource has no more than one value of skos:prefLabel per language tag, and no more than one value of skos:prefLabel without language tag."@en , + "The range of skos:prefLabel is the class of RDF plain literals."@en , + """skos:prefLabel, skos:altLabel and skos:hiddenLabel are pairwise + disjoint properties.""" ; + + rdfs:isDefinedBy ; + + rdfs:label "preferred label" ; + + skos:definition "The preferred lexical label for a resource, in a given language." ; + + rdfs:subPropertyOf rdfs:label . + + + +### http://www.w3.org/2004/02/skos/core#scopeNote + +skos:scopeNote rdf:type owl:AnnotationProperty ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + rdfs:label "scope note" ; + + skos:definition "A note that helps to clarify the meaning and/or the use of a concept." ; + + rdfs:subPropertyOf skos:note . + + + + + +################################################################# +# +# Datatypes +# +################################################################# + + +### http://www.w3.org/2001/XMLSchema#date + +xsd:date rdf:type rdfs:Datatype . + + + + + +################################################################# +# +# Object Properties +# +################################################################# + + +### http://purl.allotrope.org/ontologies/property#AFX_0000072 + +af-x:AFX_0000072 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf af-x:AFX_0002686 ; + + af-x:AFX_0002811 af-r:AFR_0000951 ; + + rdfs:isDefinedBy ; + + skos:altLabel "duration" , + "time" ; + + skos:definition "Time is a measure in which events can be ordered from the past through the present into the future, and also the measure of durations of events and the intervals between them. [Wikipedia]" ; + + skos:prefLabel "has duration" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0000180 + +af-x:AFX_0000180 rdf:type owl:ObjectProperty ; + + rdfs:isDefinedBy ; + + skos:altLabel "step size" ; + + skos:definition "The difference between two discrete points next to each other in a range of discrete values. [Allotrope]" ; + + skos:example "A device property can be set between a minimum and maximum value but only in steps of the increment value." , + "Step size of sweeping over 2Theta, unit °" ; + + skos:prefLabel "increment" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0000197 + +af-x:AFX_0000197 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0000057 ; + + owl:inverseOf af-x:AFX_0002864 ; + + rdfs:isDefinedBy ; + + skos:altLabel "applies" , + "uses" ; + + skos:changeNote "2020-11-12 Added alternative label and changed definition. [Allotrope]" ; + + skos:definition "A planned process selects a participant if the participant is chosen to influence the process towards some objective but is itself not essentially changed by a process. [Allotrope]" ; + + skos:example "For the process of titration a pH meter is used as well as a sample and a standard solution. [Allotrope]" ; + + skos:prefLabel "selects" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0000234 + +af-x:AFX_0000234 rdf:type owl:ObjectProperty ; + + rdfs:isDefinedBy ; + + skos:definition "This relation indicates that the subject is a more concrete instance of the object. [Allotrope]" ; + + skos:prefLabel "refines" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0000314 + +af-x:AFX_0000314 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf owl:topObjectProperty ; + + rdfs:isDefinedBy ; + + skos:definition "The lowest value of a range or a set of values. [Allotrope]" ; + + skos:prefLabel "minimum" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0000331 + +af-x:AFX_0000331 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf owl:topObjectProperty ; + + rdfs:isDefinedBy ; + + skos:definition "Highest value of a range. [Allotrope]" ; + + skos:prefLabel "maximum" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0000353 + +af-x:AFX_0000353 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0000056 ; + + owl:inverseOf af-x:AFX_0000395 ; + + rdfs:isDefinedBy ; + + skos:altLabel "is output of" ; + + skos:definition "Relates an output entity such as a material or information object with a process that exists at the end of the process. [Allotrope]" ; + + skos:prefLabel "output of" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0000354 + +af-x:AFX_0000354 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0000056 ; + + owl:inverseOf af-x:AFX_0000399 ; + + rdfs:isDefinedBy ; + + skos:altLabel "is input of" ; + + skos:definition "Relates an input entity such a material entity or information object with a process that exists at the start of the process. [Allotrope]" ; + + skos:prefLabel "input of" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0000355 + +af-x:AFX_0000355 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf iao:_0000136 ; + + owl:inverseOf af-x:AFX_0000408 ; + + rdfs:domain af-c:AFC_0000090 ; + + rdfs:isDefinedBy ; + + skos:definition "A condition that restricts an entity. [Allotrope]" ; + + skos:prefLabel "is condition for" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0000365 + +af-x:AFX_0000365 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf af-x:AFX_0002793 ; + + owl:inverseOf af-x:AFX_0002845 ; + + rdfs:domain af-m:AFM_0001038 ; + + rdfs:range chmo:_0000993 ; + + af-x:AFX_0002811 af-rl:AFRL_0000249 ; + + rdfs:isDefinedBy ; + + skos:altLabel "component" , + "has component" , + "ingredient" ; + + skos:definition "An ingredient is a material that enters into a compound or is part of any combination or mixture. [Allotrope]" ; + + skos:prefLabel "has ingredient" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0000386 + +af-x:AFX_0000386 rdf:type owl:ObjectProperty ; + + rdfs:isDefinedBy ; + + skos:altLabel "shape" ; + + skos:definition "Inverse of SHACL targets e.g. sh:targetClass or sh:targetNode. [Allotrope]" ; + + skos:prefLabel "has shape" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0000388 + +af-x:AFX_0000388 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf iao:_0000136 ; + + rdfs:isDefinedBy ; + + skos:altLabel "in context" , + "in scope" , + "in situation" , + "scope" ; + + skos:definition "A scope defines a situation or context in which a dependent entity such as a condition or contextual role occurs or is valid. [Allotrope]" ; + + skos:prefLabel "has scope" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0000395 + +af-x:AFX_0000395 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0000057 ; + + owl:propertyChainAxiom ( ro:_0002230 + af-x:AFX_0000395 + ) ; + + rdfs:isDefinedBy ; + + skos:changeNote "2020-06-08 Removed super property functionally related to. [Allotrope]" ; + + skos:definition "Relates a process with a continuant that participates in the process and exists at the end of the process. [Allotrope]" ; + + skos:prefLabel "has output" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0000399 + +af-x:AFX_0000399 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0000057 ; + + owl:propertyChainAxiom ( ro:_0002224 + af-x:AFX_0000399 + ) ; + + rdfs:isDefinedBy ; + + skos:changeNote "2020-06-08 Removed super property functionally related to. [Allotrope]" ; + + skos:definition "Relates a process with a continuant that participates in the process and exists at the start of the process. [Allotrope]" ; + + skos:prefLabel "has input" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0000408 + +af-x:AFX_0000408 rdf:type owl:ObjectProperty ; + + rdfs:range af-c:AFC_0000090 ; + + rdfs:isDefinedBy ; + + skos:definition "An entity has a condition that restricts the entity in some way. [Allotrope]" ; + + skos:prefLabel "has condition" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0000542 + +af-x:AFX_0000542 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf af-x:AFX_0000399 ; + + owl:inverseOf af-x:AFX_0000553 ; + + rdfs:range iao:_0000030 ; + + rdfs:isDefinedBy ; + + skos:definition "Relates a process with an information object that participates in a process and exists the start of the process. [Allotrope]" ; + + skos:prefLabel "has data input" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0000544 + +af-x:AFX_0000544 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf af-x:AFX_0000395 ; + + owl:inverseOf af-x:AFX_0002734 ; + + rdfs:range iao:_0000030 ; + + rdfs:isDefinedBy ; + + skos:definition "Relates a process with an information object that participates in the process and exists the end of the process. [Allotrope]" ; + + skos:prefLabel "has data output" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0000546 + +af-x:AFX_0000546 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf af-x:AFX_0000395 ; + + owl:inverseOf af-x:AFX_0002735 ; + + rdfs:range bfo:_0000040 ; + + rdfs:isDefinedBy ; + + skos:definition "The material that is output of the process. [Allotrope]" ; + + skos:prefLabel "has material output" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0000551 + +af-x:AFX_0000551 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0002351 ; + + owl:inverseOf af-x:AFX_0002720 ; + + rdf:type owl:AsymmetricProperty , + owl:IrreflexiveProperty ; + + rdfs:domain af-c:AFC_0000166 ; + + rdfs:range af-c:AFC_0000167 ; + + rdfs:isDefinedBy ; + + skos:altLabel "item" , + "member" ; + + skos:definition "This property links a collection to a member item. [Allotrope]" ; + + skos:prefLabel "has item" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0000553 + +af-x:AFX_0000553 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf af-x:AFX_0000354 ; + + rdfs:domain iao:_0000030 ; + + rdfs:range bfo:_0000015 ; + + rdfs:isDefinedBy ; + + skos:altLabel "is data input of" ; + + skos:definition "Inverse of 'has data input'. [Allotrope]" ; + + skos:prefLabel "data input of" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0000554 + +af-x:AFX_0000554 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf af-x:AFX_0000354 ; + + owl:inverseOf af-x:AFX_0000696 ; + + rdfs:domain af-m:AFM_0000275 ; + + rdfs:range bfo:_0000015 ; + + rdfs:isDefinedBy ; + + skos:altLabel "is material input of" ; + + skos:definition "Inverse of 'has material input'. [Allotrope]" ; + + skos:prefLabel "material input of" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0000557 + +af-x:AFX_0000557 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf af-x:AFX_0000331 ; + + rdfs:isDefinedBy ; + + skos:definition "The highest value of a range excluding the boundary value. [Allotrope]" ; + + skos:prefLabel "maximum exclusive" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0000558 + +af-x:AFX_0000558 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf af-x:AFX_0000331 ; + + rdfs:isDefinedBy ; + + skos:definition "The highest value of a range including the boundary value. [Allotrope]" ; + + skos:prefLabel "maximum inclusive" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0000560 + +af-x:AFX_0000560 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf af-x:AFX_0000314 ; + + rdfs:isDefinedBy ; + + skos:definition "The lowest value of a range or set of values excluding the boundary value. [Allotrope]" ; + + skos:prefLabel "minimum exclusive" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0000561 + +af-x:AFX_0000561 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf af-x:AFX_0000314 ; + + rdfs:isDefinedBy ; + + skos:definition "The lowest value of a range or set of values including the boundary value. [Allotrope]" ; + + skos:prefLabel "minimum inclusive" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0000696 + +af-x:AFX_0000696 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf af-x:AFX_0000399 ; + + rdfs:range af-m:AFM_0000275 ; + + rdfs:isDefinedBy ; + + skos:definition "Refers to the material entity that is an input of a process. [Allotrope]" ; + + skos:prefLabel "has material input" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0000834 + +af-x:AFX_0000834 rdf:type owl:ObjectProperty ; + + owl:inverseOf af-x:AFX_0002855 ; + + rdfs:domain bfo:_0000015 ; + + rdfs:range af-r:AFR_0000900 ; + + rdfs:isDefinedBy ; + + skos:altLabel "has protocol" , + "log" , + "protocol" ; + + skos:definition "The relation between a process and its log. A log is a steadily updated information object containing data of events in time such as process executions. [Allotrope]" ; + + skos:example "log files, auto export file of cell counter devices" ; + + skos:prefLabel "has log" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0000939 + +af-x:AFX_0000939 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf af-x:AFX_0002846 ; + + owl:inverseOf af-x:AFX_0000972 ; + + rdf:type owl:TransitiveProperty ; + + rdfs:domain bfo:_0000040 ; + + rdfs:range bfo:_0000040 ; + + rdfs:isDefinedBy ; + + skos:altLabel "is component of" ; + + skos:definition "A physical object that is a component that is a physical part of another physical object that is a system. [Allotrope]" ; + + skos:editorialNote "part of relation in the system perspective" ; + + skos:prefLabel "component of" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0000940 + +af-x:AFX_0000940 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf bfo:_0000051 ; + + rdfs:isDefinedBy ; + + skos:altLabel "consists of" , + "has material" ; + + skos:definition "The property specifies of which kind of general portion of material something is built of. [Allotrope]" ; + + skos:example "a weighing pan that is composed of platinum [Allotrope]" ; + + skos:prefLabel "composed of" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0000972 + +af-x:AFX_0000972 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf af-x:AFX_0002793 ; + + rdf:type owl:TransitiveProperty ; + + rdfs:domain ro:_0002577 ; + + rdfs:range bfo:_0000040 ; + + rdfs:isDefinedBy ; + + skos:altLabel "has physical part" ; + + skos:definition "A physical object that forms a system that has as part a physical entity that is one of its components. [Allotrope]" ; + + skos:editorialNote "has part relation in the system perspective" ; + + skos:prefLabel "has component" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0000974 + +af-x:AFX_0000974 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf af-x:AFX_0000972 ; + + rdf:type owl:TransitiveProperty ; + + rdfs:range af-e:AFE_0000847 ; + + rdfs:isDefinedBy ; + + skos:definition "Relation between a system and a component of it that has the role of a port in the system though which material, energy or information flows in or out of the system. [Allotrope]" ; + + skos:prefLabel "has port" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0000976 + +af-x:AFX_0000976 rdf:type owl:ObjectProperty ; + + owl:inverseOf af-x:AFX_0002856 ; + + rdfs:range af-r:AFR_0001103 ; + + rdfs:isDefinedBy ; + + skos:altLabel "capability" ; + + skos:definition "The relation of an entity to a description of it which refers to the qualification of an entity to perform a certain function. [Allotrope]" ; + + skos:example "a part of a data sheet" ; + + skos:prefLabel "has capability" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0001048 + +af-x:AFX_0001048 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0001015 ; + + owl:inverseOf af-x:AFX_0001049 ; + + rdfs:domain af-e:AFE_0000407 ; + + rdfs:range bfo:_0000040 ; + + rdfs:isDefinedBy ; + + skos:definition "The relation between a container and its physical content. A material entity a contains a material entity b if b is located in some cavity of a. [Allotrope]" ; + + skos:prefLabel "contains" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0001049 + +af-x:AFX_0001049 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0001025 ; + + rdfs:domain bfo:_0000040 ; + + rdfs:range af-e:AFE_0000407 ; + + rdfs:isDefinedBy ; + + skos:definition "Inverse of contains. [Allotrope]" ; + + skos:prefLabel "contained in" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0001154 + +af-x:AFX_0001154 rdf:type owl:ObjectProperty ; + + owl:inverseOf af-x:AFX_0002806 ; + + rdfs:range af-r:AFR_0000916 ; + + rdfs:isDefinedBy ; + + skos:altLabel "classification" , + "classified by" ; + + skos:definition "A classification is a kind of categorization in order to differentiate between different classes of objects. [Allotrope]" ; + + skos:prefLabel "has classification" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0001178 + +af-x:AFX_0001178 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0002170 ; + + rdfs:isDefinedBy ; + + skos:altLabel "attached to source" , + "has source" ; + + skos:definition "A system that is attached to another system by an ingoing port. [Allotrope]" ; + + skos:prefLabel "connected to source" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0001179 + +af-x:AFX_0001179 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0002170 ; + + rdfs:isDefinedBy ; + + skos:altLabel "attached to destination" , + "has destination" ; + + skos:definition "A system that is attached to another system by an outgoing port. [Allotrope]" ; + + skos:prefLabel "connected to destination" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0001550 + +af-x:AFX_0001550 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf owl:topObjectProperty ; + + rdfs:isDefinedBy ; + + skos:altLabel "reference" , + "reference object" ; + + skos:definition "Reference object relates an entity A to some entity B that is taken as a reference for A in a certain context. [Allotrope]" ; + + skos:example "reference for comparison" , + "reference object" , + "reference process" ; + + skos:prefLabel "has reference" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0002674 + +af-x:AFX_0002674 rdf:type owl:ObjectProperty ; + + rdfs:domain af-r:AFR_0000991 ; + + rdfs:range [ rdf:type owl:Class ; + owl:unionOf ( bfo:_0000015 + bfo:_0000035 + ) + ] ; + + rdfs:isDefinedBy ; + + skos:definition "The relation between a proposition about of a portion of reality and a process asserting that the process is described truthfully by the description. [Allotrope]" ; + + skos:prefLabel "satisfies" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0002677 + +af-x:AFX_0002677 rdf:type owl:ObjectProperty ; + + rdfs:domain bfo:_0000034 ; + + rdfs:range bfo:_0000034 ; + + rdfs:isDefinedBy ; + + skos:definition "The relation between a function with an objective and another function that when realized acts as a proxy to achieve the objective of the first. [Allotrope]" ; + + skos:prefLabel "by way of" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0002682 + +af-x:AFX_0002682 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf owl:topObjectProperty ; + + owl:inverseOf af-x:AFX_0002685 ; + + rdfs:domain af-p:AFP_0003281 ; + + rdfs:range bfo:_0000019 ; + + rdfs:isDefinedBy ; + + skos:definition "A relation between a process profile and a changing determinable quality of some participant of the process of the profile. [Allotrope]" ; + + skos:example "An profile of the absorption in a chromatography is quality process profile of the quality absorption of some participating material. [Allotrope]" ; + + skos:note "The relation is usually used with punning of the quality." ; + + skos:prefLabel "tracks quality" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0002684 + +af-x:AFX_0002684 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf af-x:AFX_0002802 ; + + owl:inverseOf af-x:AFX_0002816 ; + + rdfs:isDefinedBy ; + + skos:altLabel "has quantity value" ; + + skos:definition "Relation of something that is quantified by some quantity value which expresses it relative to some other thing. [Allotrope]" ; + + skos:example "The duration of a process expressed as 60 sec expresses it in quantitative relation to the duration of some second defining process specified in the SI systems of units." ; + + skos:prefLabel "quantified by" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0002685 + +af-x:AFX_0002685 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf owl:topObjectProperty ; + + rdfs:domain bfo:_0000019 ; + + rdfs:range af-p:AFP_0003281 ; + + rdfs:isDefinedBy ; + + skos:definition "The relation between a quality and a process profile in which the quality is changing. [Allotrope]" ; + + skos:prefLabel "quality tracked by" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0002686 + +af-x:AFX_0002686 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf af-x:AFX_0002718 ; + + rdfs:domain bfo:_0000015 ; + + rdfs:isDefinedBy ; + + skos:definition "Relation of some process that is quantified by some quantity value which expresses its duration relative to other process or a temporal aggregation function on the quantification of a quality of some participant over this duration. [Allotrope]" ; + + skos:example "The process of injection has a material flow profile of the injected material that is quantified by the volume of 1 mL/sec." ; + + skos:prefLabel "process quantified by" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0002687 + +af-x:AFX_0002687 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf af-x:AFX_0002686 ; + + rdfs:domain bfo:_0000144 ; + + rdfs:isDefinedBy ; + + skos:definition "The quantity value that is the result of averaging a quality of some participant of the process over the duration of the process or the quantification of the participant's quality at the temporal granularity of the duration of the process. [Allotrope]" ; + + skos:prefLabel "profile mean quantified by" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0002688 + +af-x:AFX_0002688 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf af-x:AFX_0002686 ; + + rdfs:domain bfo:_0000144 ; + + rdfs:isDefinedBy ; + + skos:definition "The temporal maximum quantified by is the maximum of the quantification of some quality of a participant that occurred during the process. [Allotrope]" ; + + skos:prefLabel "profile maximum quantified by" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0002689 + +af-x:AFX_0002689 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf af-x:AFX_0002686 ; + + rdfs:domain bfo:_0000144 ; + + rdfs:isDefinedBy ; + + skos:definition "The temporal minimum quantified by is the minimum of the quantification of some quality of a participant that occurred during the process. [Allotrope]" ; + + skos:prefLabel "profile minimum quantified by" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0002690 + +af-x:AFX_0002690 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf af-x:AFX_0002684 ; + + rdfs:domain bfo:_0000019 ; + + rdfs:isDefinedBy ; + + skos:definition "Quantification of some determinate quality which expresses it relative to some other (known) determinate quality. [Allotrope]" ; + + skos:example "A portion of water has some determinate temperature quality that is quantified by the quantity value of 15° C." ; + + skos:prefLabel "quality quantified by" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0002696 + +af-x:AFX_0002696 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf af-x:AFX_0002803 ; + + rdfs:range af-c:AFC_0000021 ; + + rdfs:isDefinedBy ; + + skos:definition "Relation to a data item that describes the boundaries of possible or existing qualities, process profiles or process durations that can be ordered. [Allotrope]" ; + + skos:prefLabel "has range" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0002699 + +af-x:AFX_0002699 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf iao:_0000136 ; + + owl:inverseOf af-x:AFX_0002802 ; + + rdfs:domain af-r:AFR_0000922 ; + + rdfs:isDefinedBy ; + + skos:altLabel "description of" ; + + skos:definition "Describes is a property of an entity which has the ability to indicate or denote certain characteristics in another entity. [Allotrope]" ; + + skos:prefLabel "describes" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0002703 + +af-x:AFX_0002703 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf bfo:_0000133 ; + + rdfs:domain af-p:AFP_0003281 ; + + rdfs:range bfo:_0000015 ; + + rdfs:isDefinedBy ; + + skos:definition "The relation of a process profile of some changing quality to a process. [Allotrope]" ; + + skos:example "A pressure profile in chromatography. [Allotrope]" ; + + skos:prefLabel "quality profile of" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0002704 + +af-x:AFX_0002704 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf iao:_0000136 ; + + owl:inverseOf af-x:AFX_0002805 ; + + rdfs:domain af-r:AFR_0000957 ; + + rdfs:isDefinedBy ; + + skos:definition "Specifies is a relation between a specification and the object specified. [Allotrope]" ; + + skos:prefLabel "specifies" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0002716 + +af-x:AFX_0002716 rdf:type owl:ObjectProperty ; + + owl:inverseOf af-x:AFX_0002717 ; + + rdfs:isDefinedBy ; + + skos:altLabel "identified by" , + "identifier" , + "is identified by" ; + + skos:definition "The relation of an entity to an identifier that denotes it. [Allotrope]" ; + + skos:prefLabel "has identifier" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0002717 + +af-x:AFX_0002717 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf iao:_0000219 ; + + rdfs:domain af-r:AFR_0000917 ; + + rdfs:isDefinedBy ; + + skos:definition "The relation of an identifier to the entity it denotes. [Allotrope]" ; + + skos:prefLabel "identifies" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0002718 + +af-x:AFX_0002718 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf af-x:AFX_0002684 ; + + rdfs:domain bfo:_0000003 ; + + rdfs:isDefinedBy ; + + skos:definition "Occurrent quantified by relates an occurrent entity with an information content entity that is a quantification of the occurrent (duration, rate). [Allotrope]" ; + + skos:prefLabel "occurrent quantified by" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0002720 + +af-x:AFX_0002720 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0002350 ; + + rdf:type owl:AsymmetricProperty , + owl:IrreflexiveProperty ; + + rdfs:range af-c:AFC_0000166 ; + + rdfs:isDefinedBy ; + + skos:altLabel "in collection" , + "is item in" , + "member of" ; + + skos:changeNote "2017-11-16 Changed pref label [OSTHUS]" , + "2018-07-23 Change hierarchy, subproperty of member of [Allotrope]" ; + + skos:definition "In collection relates an item to a collection entity. [Allotrope]" ; + + skos:prefLabel "item of" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0002722 + +af-x:AFX_0002722 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0002502 ; + + owl:inverseOf af-x:AFX_0002723 ; + + rdf:type owl:TransitiveProperty ; + + rdfs:isDefinedBy ; + + skos:altLabel "influenced by" ; + + skos:definition "Inverse of quality influences. [Allotrope]" ; + + skos:prefLabel "quality influenced by" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0002723 + +af-x:AFX_0002723 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0002609 ; + + rdf:type owl:TransitiveProperty ; + + rdfs:domain bfo:_0000019 ; + + rdfs:range bfo:_0000019 ; + + rdfs:isDefinedBy ; + + skos:altLabel "influences" ; + + skos:definition "Holds between qualities a and b such that if a process changes the quality to some other instance a' then for some a' it is necessary that b changes to another instance b'. [Allotrope]" ; + + skos:example "volume influences density" ; + + skos:prefLabel "quality influences" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0002724 + +af-x:AFX_0002724 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf af-x:AFX_0002723 ; + + rdfs:isDefinedBy ; + + skos:definition "Holds between qualities a and b such that if a process changes the quality to some other instance a' != a then for all a' it is necessary that b changes to another instance b' != b. [Allotrope]" ; + + skos:prefLabel "quality strongly influences" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0002725 + +af-x:AFX_0002725 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf af-x:AFX_0002722 ; + + rdfs:isDefinedBy ; + + skos:altLabel "strongly influenced by" ; + + skos:definition "Inverse of quality strongly influences. [Allotrope]" ; + + skos:prefLabel "quality strongly influenced by" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0002726 + +af-x:AFX_0002726 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf owl:topObjectProperty ; + + owl:inverseOf af-x:AFX_0002730 ; + + rdfs:isDefinedBy ; + + skos:altLabel "is contextual role of" ; + + skos:definition "Inverse of has contextual role. [Allotrope]" ; + + skos:prefLabel "contextual role of" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0002727 + +af-x:AFX_0002727 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf owl:topObjectProperty ; + + dct:source "W. Ceusters, P. Elkin, B. Smith Referent Tracking: The Problem of Negative Findings 2006" ; + + rdfs:isDefinedBy ; + + skos:definition "Property describing the absence of a particular in relation to another particular depending on its spatio-temporal existence. [Allotrope]" ; + + skos:editorialNote "if punning to a universal class: A particular is not the instance of a given class at some given time. A particular is not related in a specific way to any instance of a universal at some given time." ; + + skos:prefLabel "lacks" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0002729 + +af-x:AFX_0002729 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf owl:topObjectProperty ; + + owl:inverseOf af-x:AFX_0002807 ; + + rdfs:domain af-r:AFR_0000923 ; + + rdfs:range iao:_0000030 ; + + rdfs:isDefinedBy ; + + skos:altLabel "concretized as" , + "facet concretized as" , + "facet represented as" , + "implemented as" , + "represented as" ; + + skos:definition "The relation between the abstract facet and a specific information that represents the facet. [Allotrope]" ; + + skos:example "a label facet can be implemented as a barcode or written text" ; + + skos:note "This relation is intended to bridge between different perspectives on the taxonomy of information content entities." ; + + skos:prefLabel "facet implemented as" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0002730 + +af-x:AFX_0002730 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf iao:_0000136 ; + + rdfs:domain iao:_0000030 ; + + rdfs:range af-rl:AFRL_0000166 ; + + rdfs:isDefinedBy ; + + skos:definition "The relation between an information object and its contextual role. [Allotrope]" ; + + skos:prefLabel "has contextual role" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0002731 + +af-x:AFX_0002731 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf af-x:AFX_0000388 ; + + rdfs:domain af-rl:AFRL_0000166 ; + + rdfs:range bfo:_0000015 ; + + rdfs:isDefinedBy ; + + skos:altLabel "has contextual role in process" ; + + skos:definition "The relation between a conceptual role and the process where the contextual role is realized. [Allotrope]" ; + + skos:prefLabel "in process" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0002734 + +af-x:AFX_0002734 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf af-x:AFX_0000353 ; + + rdfs:domain iao:_0000030 ; + + rdfs:range bfo:_0000015 ; + + rdfs:isDefinedBy ; + + skos:altLabel "is data output of" ; + + skos:definition "Inverse of 'has data output'. [Allotrope]" ; + + skos:prefLabel "data output of" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0002735 + +af-x:AFX_0002735 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf af-x:AFX_0000353 ; + + rdfs:domain af-m:AFM_0000275 ; + + rdfs:range bfo:_0000015 ; + + rdfs:isDefinedBy ; + + skos:altLabel "is material output of" ; + + skos:definition "Inverse of 'has material output'. [Allotrope]" ; + + skos:prefLabel "material output of" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0002736 + +af-x:AFX_0002736 rdf:type owl:ObjectProperty ; + + rdfs:domain iao:_0000030 ; + + rdfs:range af-r:AFR_0000991 ; + + rdfs:isDefinedBy ; + + skos:altLabel "has content" ; + + skos:definition "The relation between a representation and its content independent of form. [Allotrope]" ; + + skos:prefLabel "has proposition" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0002737 + +af-x:AFX_0002737 rdf:type owl:ObjectProperty ; + + rdfs:domain iao:_0000030 ; + + rdfs:range af-r:AFR_0000992 ; + + rdfs:isDefinedBy ; + + skos:definition "The relation between the information and the way it is represented. [Allotrope]" ; + + skos:prefLabel "has representation form" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0002740 + +af-x:AFX_0002740 rdf:type owl:ObjectProperty ; + + rdfs:domain af-m:AFM_0000880 ; + + rdfs:range bfo:_0000019 ; + + rdfs:isDefinedBy ; + + skos:definition "Has effort component relates an energy with its quality of effort. [Allotrope]" ; + + skos:prefLabel "has effort component" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0002741 + +af-x:AFX_0002741 rdf:type owl:ObjectProperty ; + + rdfs:domain af-m:AFM_0000880 ; + + rdfs:range bfo:_0000019 ; + + rdfs:isDefinedBy ; + + skos:definition "Has flow component relates an energy with its quality of flow. [Allotrope]" ; + + skos:prefLabel "has flow component" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0002744 + +af-x:AFX_0002744 rdf:type owl:ObjectProperty , + owl:TransitiveProperty ; + + rdfs:domain iao:_0000030 ; + + rdfs:range iao:_0000030 ; + + rdfs:isDefinedBy ; + + skos:definition "An information content entity has information derived from some other information content entity, if there is a data processing that transforms the other into it, either transforming the representational form or the content. [Allotrope]" ; + + skos:prefLabel "has information derived from" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0002745 + +af-x:AFX_0002745 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0000057 ; + + owl:propertyChainAxiom ( ro:_0002224 + af-x:AFX_0002745 + ) , + ( ro:_0002230 + af-x:AFX_0002745 + ) ; + + rdfs:isDefinedBy ; + + skos:changeNote "2018-10-24 Moved to relation ontology. [Allotrope]" ; + + skos:definition "P has direct input c if and only if c is a participant in p, c is present at the start of p, and the state of c is modified during p, c is present at the end of p. [Allotrope]" ; + + skos:prefLabel "affects" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0002748 + +af-x:AFX_0002748 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf af-x:AFX_0000399 ; + + rdfs:isDefinedBy ; + + skos:definition "P has output c if and only if c is a participant in p, c is present at the start of p, and c is not present at the end of p. [Allotrope]" ; + + skos:example "An experimental step consumes a sample. [Allotrope]" ; + + skos:prefLabel "consumes" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0002750 + +af-x:AFX_0002750 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0000057 ; + + owl:inverseOf af-x:AFX_0002863 ; + + rdfs:isDefinedBy ; + + skos:altLabel "has focus" ; + + skos:changeNote "2020-11-12 Changed definition. [Allotrope]" ; + + skos:definition "A planned process targets a continuant if the continuant is a participant in the process and it in important part of towards the main objective of the process' plan. [Allotrope]" ; + + skos:example "A hardness test targets the hardness quality. [Allotrope]" ; + + skos:prefLabel "targets" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0002793 + +af-x:AFX_0002793 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf bfo:_0000051 ; + + owl:inverseOf af-x:AFX_0002846 ; + + rdf:type owl:TransitiveProperty ; + + af-x:AFX_0002809 ; + + rdfs:isDefinedBy ; + + skos:definition "Has proper part is an antisymmetric, irreflexive (normally transitive) relation between a whole and a distinct part. [SIO]" ; + + skos:example "An atom has subatomic particles as its proper parts." ; + + skos:prefLabel "has proper part" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0002800 + +af-x:AFX_0002800 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf af-x:AFX_0002846 ; + + owl:inverseOf af-x:AFX_0002803 ; + + rdf:type owl:TransitiveProperty ; + + rdfs:isDefinedBy ; + + skos:altLabel "is facet of" ; + + skos:definition "Facet of relates two information content entities where one information content entity is an aspect of the other one. [Allotrope]" ; + + skos:prefLabel "facet of" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0002801 + +af-x:AFX_0002801 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf af-x:AFX_0002803 ; + + rdfs:range af-c:AFC_0000050 ; + + rdfs:isDefinedBy ; + + skos:altLabel "has code" ; + + skos:changeNote "2020-12-01 Add alt label. [Allotrope]" ; + + skos:definition "Has categorical value is a facet that relates an information content entity to a code that describes a category for classification. [Allotrope]" ; + + skos:prefLabel "has categorical value" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0002802 + +af-x:AFX_0002802 rdf:type owl:ObjectProperty ; + + af-x:AFX_0002808 , + dct:description ; + + rdfs:isDefinedBy ; + + skos:altLabel "described by" , + "description" , + "is described by" ; + + skos:definition "Has description relates an entity to an information content entity that is its description. [Allotrope]" ; + + skos:prefLabel "has description" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0002803 + +af-x:AFX_0002803 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf af-x:AFX_0002793 ; + + rdf:type owl:TransitiveProperty ; + + rdfs:domain iao:_0000030 ; + + rdfs:range af-r:AFR_0000923 ; + + rdfs:isDefinedBy ; + + skos:definition "Relation between an information content entity and some part of it called a facet that is covers some general aspect of information context. [Allotrope]" ; + + skos:example "a timestamp" , + "a title" , + "an ordering" ; + + skos:prefLabel "has facet" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0002805 + +af-x:AFX_0002805 rdf:type owl:ObjectProperty ; + + rdfs:isDefinedBy ; + + skos:altLabel "specification" , + "specified by" ; + + skos:definition "Has specification relates an entity to an information content entity that is its specification. [Allotrope]" ; + + skos:prefLabel "has specification" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0002806 + +af-x:AFX_0002806 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf iao:_0000136 ; + + rdfs:domain af-r:AFR_0000916 ; + + rdfs:isDefinedBy ; + + skos:definition "The relation between a classification and something that is grouped by the classification. [Allotrope]" ; + + skos:prefLabel "classifies" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0002807 + +af-x:AFX_0002807 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf owl:topObjectProperty ; + + rdfs:isDefinedBy ; + + skos:altLabel "concretizes" , + "concretizes facet" , + "implements" , + "represents" , + "represents facet" ; + + skos:changeNote "2018-08-29 Changed pref label. [Allotrope]" ; + + skos:definition "Inverse of facet concretized as. [Allotrope]" ; + + skos:prefLabel "implements facet" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0002816 + +af-x:AFX_0002816 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf af-x:AFX_0002699 ; + + rdfs:isDefinedBy ; + + skos:definition "The relation of an information object to an entity that gives some indication of magnitude of a quality, information facet or process. [Allotrope]" ; + + skos:prefLabel "quantifies" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0002819 + +af-x:AFX_0002819 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf iao:_0000219 ; + + owl:inverseOf af-x:AFX_0002820 ; + + rdfs:domain af-r:AFR_0000928 ; + + rdfs:isDefinedBy ; + + skos:altLabel "is index of" ; + + skos:definition "The relation between an index and the entity in an aggregate or list it denotes. [Allotrope]" ; + + skos:prefLabel "index of" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0002820 + +af-x:AFX_0002820 rdf:type owl:ObjectProperty ; + + rdfs:range af-r:AFR_0000928 ; + + rdfs:isDefinedBy ; + + skos:definition "The relation between an object and an index that denotes the object within an aggregate the object is member of. [Allotrope]" ; + + skos:prefLabel "has index" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0002821 + +af-x:AFX_0002821 rdf:type owl:ObjectProperty ; + + rdfs:isDefinedBy ; + + skos:definition "The relation between a proxy entity and a target entity where the target entity is a real participant in some process or the subject of an information content entity but is not referenced directly, but instead the proxy is used as a surrogate or representation for it. [Allotrope]" ; + + skos:example "A measurement of a quality to indirectly measure another quality." , + "An object aggregate as a proxy for a collection." ; + + skos:prefLabel "proxy for" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0002822 + +af-x:AFX_0002822 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf owl:topObjectProperty ; + + rdfs:range skos:Concept ; + + rdfs:isDefinedBy ; + + skos:definition "The relation an entity and an associated SKOS concept. [Allotrope]" ; + + skos:note "The relation is intended to relate a classifying datum with a SKOS concept, but there might be other uses. [Allotrope]" ; + + skos:prefLabel "has concept" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0002832 + +af-x:AFX_0002832 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf af-x:AFX_0002793 ; + + owl:inverseOf af-x:AFX_0002847 ; + + af-x:AFX_0002809 ; + + rdfs:isDefinedBy ; + + skos:definition "A core relation that holds between a whole and a proper part without an intermediate part at a level of granularity. [Allotrope]" ; + + skos:prefLabel "has direct part" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0002833 + +af-x:AFX_0002833 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf af-x:AFX_0002858 ; + + owl:inverseOf af-x:AFX_0002834 ; + + rdf:type owl:TransitiveProperty ; + + af-x:AFX_0002808 ; + + rdfs:isDefinedBy ; + + skos:altLabel "before" , + "has follower" , + "has successor" , + "leading" , + "preceeds" , + "prior" ; + + skos:changeNote "2020-06-22 Added alt labels, subclassed under 'related by order'. [Allotrope]" ; + + skos:definition "Is followed by is a relation between entities that are items in an ordered sequence. For each pair of entities P, S being a member of the sequence, there exists an ordering function o so that o(P) < o(S). Iff o(P) < o(S) then P is followed by S. [Allotrope]" ; + + skos:prefLabel "is followed by" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0002834 + +af-x:AFX_0002834 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf af-x:AFX_0002858 ; + + rdf:type owl:TransitiveProperty ; + + af-x:AFX_0002808 ; + + rdfs:isDefinedBy ; + + skos:altLabel "after" , + "has predecessor" , + "post" , + "succeeds" , + "trailing" ; + + skos:changeNote "2020-06-22 Added alt labels, subclassed under 'related by order'. [Allotrope]" ; + + skos:definition "Follows is a relation between entities that are items in an ordered sequence. For each pair of entities P, S being a member of the sequence, there exists an ordering function o so that o(P) < o(S). Iff o(S) > o(P) the S follows P. [Allotrope]" ; + + skos:prefLabel "follows" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0002835 + +af-x:AFX_0002835 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf af-x:AFX_0002833 ; + + owl:inverseOf af-x:AFX_0002836 ; + + rdfs:isDefinedBy ; + + skos:altLabel "has next" , + "next" ; + + skos:definition "Is immediately followed by is a relation between entities that are items in an ordered sequence. For each pair of entities P, S being a member of the sequence, there exists an ordering function o so that o(P) < o(S). Iff for members P, S of the sequence, there is no member I that o(P) < o(I) < o(S), then P is immediately followed by S. [Allotrope]" ; + + skos:prefLabel "is immediately followed by" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0002836 + +af-x:AFX_0002836 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf af-x:AFX_0002834 ; + + rdfs:isDefinedBy ; + + skos:altLabel "has previous" , + "previous" ; + + skos:definition "Immediately follows is a relation between entities that are items in an ordered sequence. For each pair of entities P, S being a member of the sequence, there exists an ordering function o so that o(P) < o(S). Iff for members P, S of the sequence, there is no member I that o(S) > o(I) > o(P), then S follows P. [Allotrope]" ; + + skos:prefLabel "immediately follows" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0002837 + +af-x:AFX_0002837 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf owl:topObjectProperty ; + + rdfs:isDefinedBy ; + + skos:definition "Relation of is a relation of a relational entity to the referred entities. [Allotrope]" ; + + skos:example "A ratio quality is relation of two qualities of the same kind, whose magnitude is a ratio value." , + "A sum datum is relation of its summands." ; + + skos:note """This predicate is often used with punning, to avoid pre-coordination of ratios or differences. +A af-q:ratio 'af-x:relation of' pato:mass is a mass ratio quality.""" ; + + skos:prefLabel "relation of" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0002838 + +af-x:AFX_0002838 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf af-x:AFX_0002837 ; + + rdfs:isDefinedBy ; + + skos:definition "Relates to is a relation between a directed relational entity to the target of the relation. [Allotrope]" ; + + skos:example "A ratio relates to the denominator." ; + + skos:prefLabel "relates to" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0002839 + +af-x:AFX_0002839 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf af-x:AFX_0002837 ; + + rdfs:isDefinedBy ; + + skos:definition "Relates from is a relation between a directed relational entity to the source of the relation. [Allotrope]" ; + + skos:example "A ratio relates from the numerator." ; + + skos:prefLabel "relates from" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0002842 + +af-x:AFX_0002842 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf iao:_0000136 ; + + owl:inverseOf af-x:AFX_0002843 ; + + rdfs:domain af-r:AFR_0001561 ; + + rdfs:isDefinedBy ; + + skos:definition "The relation between a definition and the entity that is defined by it. [Allotrope]" ; + + skos:prefLabel "defines" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0002843 + +af-x:AFX_0002843 rdf:type owl:ObjectProperty ; + + rdfs:isDefinedBy ; + + skos:altLabel "defined by" , + "is defined by" ; + + skos:definition "Has definition relates an entity to an information content entity that is its definition. [Allotrope]" ; + + skos:prefLabel "has definition" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0002845 + +af-x:AFX_0002845 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf af-x:AFX_0002846 ; + + rdfs:isDefinedBy ; + + skos:altLabel "is ingredient of" ; + + skos:definition "Inverse of has ingredient. [Allotrope]" ; + + skos:prefLabel "ingredient of" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0002846 + +af-x:AFX_0002846 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf bfo:_0000050 ; + + rdfs:isDefinedBy ; + + skos:altLabel "is proper part of" ; + + skos:definition "Inverse of has proper part. [Allotrope]" ; + + skos:prefLabel "proper part of" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0002847 + +af-x:AFX_0002847 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf af-x:AFX_0002846 ; + + rdfs:isDefinedBy ; + + skos:altLabel "is direct part of" ; + + skos:definition "Inverse of has direct part. [Allotrope]" ; + + skos:prefLabel "direct part of" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0002848 + +af-x:AFX_0002848 rdf:type owl:ObjectProperty ; + + rdfs:domain bfo:_0000015 ; + + rdfs:range bfo:_0000015 ; + + rdfs:isDefinedBy ; + + skos:definition "A process observing process p observes a process q if p produces information about the process q, such as the duration, or about some independent continuant participating in q in an important active or passive role. [Allotrope]" ; + + skos:prefLabel "observes" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0002849 + +af-x:AFX_0002849 rdf:type owl:ObjectProperty ; + + rdfs:range [ rdf:type owl:Class ; + owl:unionOf ( af-r:AFR_0000957 + af-r:AFR_0001257 + ) + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "conforms to" , + "follows" ; + + skos:definition "An entity applies a specification or mathematical function, if the specification specifies the entity and the entity conforms or follows the specification. [Allotrope]" ; + + skos:prefLabel "applies" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0002853 + +af-x:AFX_0002853 rdf:type owl:ObjectProperty ; + + rdfs:domain bfo:_0000017 ; + + rdfs:range af-r:AFR_0001872 ; + + rdfs:isDefinedBy ; + + skos:altLabel "meets" ; + + skos:definition "A relation between a realizable entity and a requirement, that states that the process or process boundary that realizes it, satisfies all conditions of the requirement. [Allotrope]" ; + + skos:prefLabel "fulfills" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0002855 + +af-x:AFX_0002855 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf af-x:AFX_0002699 ; + + rdfs:domain af-r:AFR_0000900 ; + + rdfs:range bfo:_0000015 ; + + rdfs:isDefinedBy ; + + skos:altLabel "is protocol of" , + "log of" , + "protocol of" ; + + skos:definition "The relation between a log and the process the log is describing. [Allotrope]" ; + + skos:prefLabel "is log of" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0002856 + +af-x:AFX_0002856 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf iao:_0000136 ; + + rdfs:domain af-r:AFR_0001103 ; + + rdfs:isDefinedBy ; + + skos:altLabel "capability of" ; + + skos:definition "The relation between a capability proposition and the subject it is about. [Allotrope]" ; + + skos:prefLabel "is capability of" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0002858 + +af-x:AFX_0002858 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf owl:topObjectProperty ; + + rdfs:isDefinedBy ; + + skos:definition "A relation between entities that are ordered into a list. [Allotrope]" ; + + skos:prefLabel "related by order to" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0002863 + +af-x:AFX_0002863 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0000056 ; + + rdfs:isDefinedBy ; + + skos:altLabel "is focus of" , + "is target of" ; + + skos:definition "A continuant is target of a planned process if the continuant is a participant in the process and it in important part of towards the main objective of the process' plan. [Allotrope]" ; + + skos:prefLabel "target of" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0002864 + +af-x:AFX_0002864 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0000056 ; + + rdfs:isDefinedBy ; + + skos:altLabel "applied in" , + "used in" ; + + skos:definition "A continuant is selected or used in planned process if the participant is chosen to influence the process towards some objective but is itself not essentially changed by a process. [Allotrope]" ; + + skos:prefLabel "selected in" . + + + +### http://purl.obolibrary.org/obo/BFO_0000050 + +bfo:_0000050 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0002131 ; + + owl:inverseOf bfo:_0000051 ; + + rdf:type owl:TransitiveProperty ; + + rdfs:isDefinedBy ; + + skos:prefLabel "part of" . + + + +### http://purl.obolibrary.org/obo/BFO_0000051 + +bfo:_0000051 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0002131 ; + + rdf:type owl:TransitiveProperty ; + + rdfs:isDefinedBy ; + + skos:prefLabel "has part" . + + + +### http://purl.obolibrary.org/obo/BFO_0000054 + +bfo:_0000054 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf owl:topObjectProperty ; + + owl:inverseOf bfo:_0000055 ; + + rdfs:domain bfo:_0000017 ; + + rdfs:range bfo:_0000015 ; + + rdfs:isDefinedBy ; + + skos:prefLabel "realized in" . + + + +### http://purl.obolibrary.org/obo/BFO_0000055 + +bfo:_0000055 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf owl:topObjectProperty ; + + rdfs:domain bfo:_0000015 ; + + rdfs:range bfo:_0000017 ; + + rdfs:isDefinedBy ; + + skos:prefLabel "realizes" . + + + +### http://purl.obolibrary.org/obo/BFO_0000062 + +bfo:_0000062 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0002086 ; + + owl:inverseOf bfo:_0000063 ; + + rdf:type owl:TransitiveProperty ; + + owl:propertyChainAxiom ( bfo:_0000050 + bfo:_0000062 + ) , + ( ro:_0002091 + bfo:_0000062 + ) , + ( ro:_0002092 + bfo:_0000062 + ) ; + + rdfs:isDefinedBy ; + + skos:altLabel "is preceded by" ; + + skos:definition "X is preceded by y if and only if the time point at which y ends is before or equivalent to the time point at which x starts. Formally: x preceded by y if and only if ω(y) <= α(x), where α is a function that maps a process to a start point, and ω is a function that maps a process to an end point. [RO]" ; + + skos:prefLabel "preceded by" . + + + +### http://purl.obolibrary.org/obo/BFO_0000063 + +bfo:_0000063 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0002222 ; + + rdf:type owl:TransitiveProperty ; + + owl:propertyChainAxiom ( bfo:_0000050 + bfo:_0000063 + ) , + ( ro:_0002092 + bfo:_0000063 + ) ; + + rdfs:isDefinedBy ; + + skos:definition "X precedes y if and only if the time point at which x ends is before or equivalent to the time point at which y starts. Formally: x precedes y if and only if ω(x) <= α(y), where α is a function that maps a process to a start point, and ω is a function that maps a process to an end point. [RO]" ; + + skos:prefLabel "precedes" . + + + +### http://purl.obolibrary.org/obo/BFO_0000066 + +bfo:_0000066 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf owl:topObjectProperty ; + + owl:inverseOf bfo:_0000067 ; + + rdfs:domain bfo:_0000003 ; + + rdfs:range bfo:_0000004 ; + + owl:propertyChainAxiom ( bfo:_0000050 + bfo:_0000066 + ) , + ( bfo:_0000066 + bfo:_0000050 + ) ; + + rdfs:isDefinedBy ; + + skos:altLabel "unfolds in" ; + + skos:definition "b occurs_in c =def b is a process and c is a material entity or immaterial entity& there exists a spatiotemporal region r and b occupies_spatiotemporal_region r.& forall(t) if b exists_at t then c exists_at t & there exist spatial regions s and s’ where & b spatially_projects_onto s at t& c is occupies_spatial_region s’ at t& s is a proper_continuant_part_of s’ at t [RO]" ; + + skos:prefLabel "occurs in" . + + + +### http://purl.obolibrary.org/obo/BFO_0000067 + +bfo:_0000067 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf owl:topObjectProperty ; + + rdfs:isDefinedBy ; + + skos:altLabel "site of" ; + + skos:definition "inverse of occurs in" ; + + skos:prefLabel "contains process" . + + + +### http://purl.obolibrary.org/obo/BFO_0000083 + +bfo:_0000083 rdf:type owl:ObjectProperty ; + + rdfs:domain bfo:_0000004 ; + + rdfs:range bfo:_0000006 ; + + rdfs:isDefinedBy ; + + skos:altLabel "occupies spatial region" , + "occupies spatial region at some time" ; + + skos:definition "b located at r means that r is a spatial region in which independent continuant b is exactly located. [BFO]" ; + + skos:prefLabel "located at" . + + + +### http://purl.obolibrary.org/obo/BFO_0000108 + +bfo:_0000108 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf owl:topObjectProperty ; + + owl:inverseOf bfo:_0000157 ; + + rdfs:domain bfo:_0000001 ; + + rdfs:range bfo:_0000008 ; + + rdfs:isDefinedBy ; + + skos:definition "b exists_at t means: b is an entity which exists at some temporal region t. [BFO]" ; + + skos:prefLabel "exists at" . + + + +### http://purl.obolibrary.org/obo/BFO_0000117 + +bfo:_0000117 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf bfo:_0000051 , + ro:_0002222 ; + + owl:inverseOf bfo:_0000132 ; + + rdf:type owl:TransitiveProperty ; + + rdfs:domain bfo:_0000003 ; + + rdfs:range bfo:_0000003 ; + + rdfs:isDefinedBy ; + + skos:definition "b has occurrent part c =Def. b has part c & b and c are occurrents." ; + + skos:prefLabel "has occurrent part" . + + + +### http://purl.obolibrary.org/obo/BFO_0000118 + +bfo:_0000118 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf af-x:AFX_0002793 , + bfo:_0000117 ; + + owl:inverseOf bfo:_0000138 ; + + rdf:type owl:TransitiveProperty ; + + rdfs:isDefinedBy ; + + skos:definition "B has_proper_occurrent_part c =Def. b has_occurrent_part c & b and c are not identical. [BFO]" ; + + skos:prefLabel "has proper occurrent part" . + + + +### http://purl.obolibrary.org/obo/BFO_0000119 + +bfo:_0000119 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf owl:topObjectProperty ; + + owl:inverseOf bfo:_0000133 ; + + rdfs:domain bfo:_0000015 ; + + rdfs:range bfo:_0000144 ; + + rdfs:isDefinedBy ; + + skos:prefLabel "has profile" . + + + +### http://purl.obolibrary.org/obo/BFO_0000130 + +bfo:_0000130 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf owl:topObjectProperty ; + + rdfs:domain bfo:_0000003 ; + + rdfs:range bfo:_0000011 ; + + rdfs:isDefinedBy ; + + skos:definition "p occupies_spatiotemporal_region s. This is a primitive relation between an occurrent p and the spatiotemporal region s which is its spatiotemporal extent. [BFO]" ; + + skos:prefLabel "occupies spatiotemporal region" . + + + +### http://purl.obolibrary.org/obo/BFO_0000132 + +bfo:_0000132 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf bfo:_0000050 , + ro:_0002222 ; + + rdf:type owl:TransitiveProperty ; + + rdfs:domain bfo:_0000003 ; + + rdfs:range bfo:_0000003 ; + + rdfs:isDefinedBy ; + + skos:definition "b occurrent_part_of c =Def. b is a part of c & b and c are occurrents. [BFO]" ; + + skos:prefLabel "part of occurrent" . + + + +### http://purl.obolibrary.org/obo/BFO_0000133 + +bfo:_0000133 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf owl:topObjectProperty ; + + rdfs:isDefinedBy ; + + skos:prefLabel "process profile of" . + + + +### http://purl.obolibrary.org/obo/BFO_0000138 + +bfo:_0000138 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf af-x:AFX_0002846 , + bfo:_0000132 ; + + rdf:type owl:TransitiveProperty ; + + rdfs:domain bfo:_0000003 ; + + rdfs:range bfo:_0000003 ; + + rdfs:isDefinedBy ; + + skos:definition "B proper_occurrent_part_of c =Def. b occurrent_part_of c & b and c are not identical. [BFO]" ; + + skos:prefLabel "proper part of occurrent" . + + + +### http://purl.obolibrary.org/obo/BFO_0000139 + +bfo:_0000139 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf bfo:_0000132 ; + + rdf:type owl:TransitiveProperty ; + + rdfs:domain bfo:_0000003 ; + + rdfs:range bfo:_0000003 ; + + rdfs:isDefinedBy ; + + skos:definition "B temporal_part_of c =Def.b occurrent_part_of c & & for some temporal region t, b occupies_temporal_region t & for all occurrents d, t (if d occupies_temporal_region t & t? occurrent_part_of t then (d occurrent_part_of a iff d occurrent_part_of b)). [BFO]" ; + + skos:example "The 4th year of your life is a temporal part of your life. [BFO]" , + "The first quarter of a game of football is a temporal part of the whole game. [BFO]" , + "The process boundary which separates the 3rd and 4th years of your life. [BFO]" , + "The process of your heart beating from 4pm to 5pm today is a temporal part of the entire process of your heart beating. [BFO]" ; + + skos:prefLabel "temporal part of" . + + + +### http://purl.obolibrary.org/obo/BFO_0000157 + +bfo:_0000157 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf owl:topObjectProperty ; + + rdfs:domain bfo:_0000008 ; + + rdfs:range bfo:_0000001 ; + + rdfs:isDefinedBy ; + + skos:definition "inverse of exists at [BFO]" ; + + skos:prefLabel "during which exists" . + + + +### http://purl.obolibrary.org/obo/BFO_0000184 + +bfo:_0000184 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf bfo:_0000066 ; + + rdf:type owl:InverseFunctionalProperty ; + + rdfs:domain bfo:_0000015 ; + + rdfs:range bfo:_0000040 ; + + rdfs:isDefinedBy ; + + skos:definition "b history_of c if c is a material entity or site and b is a history that is the unique history of c" ; + + skos:prefLabel "history of" . + + + +### http://purl.obolibrary.org/obo/BFO_0000185 + +bfo:_0000185 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf bfo:_0000067 ; + + rdf:type owl:InverseFunctionalProperty ; + + rdfs:domain bfo:_0000040 ; + + rdfs:range bfo:_0000015 ; + + rdfs:isDefinedBy ; + + skos:definition "inverse of history of" ; + + skos:prefLabel "has history" . + + + +### http://purl.obolibrary.org/obo/IAO_0000136 + +iao:_0000136 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf owl:topObjectProperty ; + + rdfs:domain iao:_0000030 ; + + rdfs:isDefinedBy ; + + skos:example "This document is about information artifacts and their representations. [IAO]" ; + + skos:prefLabel "is about" . + + + +### http://purl.obolibrary.org/obo/IAO_0000219 + +iao:_0000219 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf iao:_0000136 ; + + rdfs:isDefinedBy ; + + skos:definition "Denotes is a primitive, instance-level, relation obtaining between an information content entity and some portion of reality. Denotation is what happens when someone creates an information content entity E in order to specifically refer to something. The only relation between E and the thing is that E can be used to 'pick out' the thing. This relation connects those two together. Freedictionary.com sense 3: To signify directly; refer to specifically [IAO]" ; + + skos:example "A person's name denotes the person. [IAO]" , + "A variable name in a computer program denotes some piece of memory. [IAO]" , + "Lexically equivalent strings can denote different things, for instance \"Alan\" can denote different people. In each case of use, there is a case of the denotation relation obtaining, between \"Alan\" and the person that is being named. [IAO]" ; + + skos:prefLabel "denotes" . + + + +### http://purl.obolibrary.org/obo/OBI_0000314 + +obi:_0000314 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf af-x:AFX_0002821 ; + + rdfs:domain bfo:_0000002 ; + + rdfs:range bfo:_0000002 ; + + rdfs:isDefinedBy ; + + skos:altLabel "is proxy for" ; + + skos:definition "A relation between continuant instances c1 and c2 where within a protocol application, measurement of c1 is related to a what would be the measurement of c2. [OBI]" ; + + skos:example "Florescent intensity is proxy for amount of protein labeled with GFP [OBI]" , + "position on a gel is proxy for mass and charge of molecule in an western blot [OBI]" ; + + skos:prefLabel "proxy for" . + + + +### http://purl.obolibrary.org/obo/OBI_0000643 + +obi:_0000643 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf af-x:AFX_0002793 ; + + owl:inverseOf obi:_0000645 ; + + rdf:type owl:TransitiveProperty ; + + rdfs:isDefinedBy ; + + skos:definition "The relation of the cells in the finger of the skin to the finger, in which an indeterminate number of grains are parts of the whole by virtue of being grains in a collective that is part of the whole, and in which removing one granular part does not nec- essarily damage or diminish the whole. Ontological Whether there is a fixed, or nearly fixed number of parts - e.g. fingers of the hand, chambers of the heart, or wheels of a car - such that there can be a notion of a single one being missing, or whether, by contrast, the number of parts is indeterminate - e.g., cells in the skin of the hand, red cells in blood, or rubber molecules in the tread of the tire of the wheel of the car. [OBI]" ; + + skos:prefLabel "has grain" . + + + +### http://purl.obolibrary.org/obo/OBI_0000645 + +obi:_0000645 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf af-x:AFX_0002846 ; + + rdf:type owl:TransitiveProperty ; + + rdfs:isDefinedBy ; + + skos:definition "A relation between granular parts and the whole of which they are a part. Granular parts have indeterminate number such that removing one granular part does not necessarily damage or diminish the whole. [OBI]" ; + + skos:prefLabel "is grain of" . + + + +### http://purl.obolibrary.org/obo/RO_0000052 + +ro:_0000052 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0002314 ; + + owl:inverseOf ro:_0000053 ; + + rdfs:isDefinedBy ; + + skos:prefLabel "inheres in" . + + + +### http://purl.obolibrary.org/obo/RO_0000053 + +ro:_0000053 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf owl:topObjectProperty ; + + rdfs:range bfo:_0000020 ; + + rdfs:isDefinedBy ; + + skos:altLabel "is bearer of" ; + + skos:definition "A relation between an independent continuant (the bearer) and a specifically dependent continuant (the dependent), in which the dependent specifically depends on the bearer for its existence. [RO]" ; + + skos:editorialNote "A bearer can have many dependents, and its dependents can exist for different periods of time, but none of its dependents can exist when the bearer does not exist. [RO]" ; + + skos:example "this apple is bearer of this red color" , + "this vase is bearer of this fragility" ; + + skos:prefLabel "bearer of" . + + + +### http://purl.obolibrary.org/obo/RO_0000056 + +ro:_0000056 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf owl:topObjectProperty ; + + owl:inverseOf ro:_0000057 ; + + rdfs:domain bfo:_0000002 ; + + rdfs:range bfo:_0000003 ; + + rdfs:isDefinedBy ; + + skos:altLabel "is participant of" ; + + skos:definition "A relation between a continuant and a process, in which the continuant is somehow involved in the process [RO]" ; + + skos:prefLabel "participates in" . + + + +### http://purl.obolibrary.org/obo/RO_0000057 + +ro:_0000057 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf owl:topObjectProperty ; + + rdfs:domain bfo:_0000003 ; + + rdfs:range bfo:_0000002 ; + + rdfs:isDefinedBy ; + + skos:definition "A relation between a process and a continuant, in which the continuant is somehow involved in the process [RO]" ; + + skos:example "this blood coagulation has participant this blood clot" , + "this investigation has participant this investigator" , + "this process has participant this input material (or this output material)" ; + + skos:prefLabel "has participant" . + + + +### http://purl.obolibrary.org/obo/RO_0000058 + +ro:_0000058 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf owl:topObjectProperty ; + + owl:inverseOf ro:_0000059 ; + + rdfs:domain bfo:_0000031 ; + + rdfs:range bfo:_0000020 ; + + rdfs:isDefinedBy ; + + skos:altLabel "is concretized as" ; + + skos:definition "A relationship between a generically dependent continuant and a specifically dependent continuant, in which the generically dependent continuant depends on some independent continuant in virtue of the fact that the specifically dependent continuant also depends on that same independent continuant. A generically dependent continuant may be concretized as multiple specifically dependent continuants. [RO]" ; + + skos:example "A journal article is an information artifact that inheres in some number of printed journals. For each copy of the printed journal there is some quality that carries the journal article, such as a pattern of ink. The journal article (a generically dependent continuant) is concretized as the quality (a specifically dependent continuant), and both depend on that copy of the printed journal (an independent continuant). [RO]" , + "An investigator reads a protocol and forms a plan to carry out an assay. The plan is a realizable entity (a specifically dependent continuant) that concretizes the protocol (a generically dependent continuant), and both depend on the investigator (an independent continuant). The plan is then realized by the assay (a process). [RO]" ; + + skos:prefLabel "concretized by" . + + + +### http://purl.obolibrary.org/obo/RO_0000059 + +ro:_0000059 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf owl:topObjectProperty ; + + rdfs:domain bfo:_0000020 ; + + rdfs:range bfo:_0000031 ; + + rdfs:isDefinedBy ; + + skos:definition "A relationship between a specifically dependent continuant and a generically dependent continuant, in which the generically dependent continuant depends on some independent continuant in virtue of the fact that the specifically dependent continuant also depends on that same independent continuant. Multiple specifically dependent continuants can concretize the same generically dependent continuant. [RO]" ; + + skos:example "A journal article is an information artifact that inheres in some number of printed journals. For each copy of the printed journal there is some quality that carries the journal article, such as a pattern of ink. The quality (a specifically dependent continuant) concretizes the journal article (a generically dependent continuant), and both depend on that copy of the printed journal (an independent continuant)." , + "An investigator reads a protocol and forms a plan to carry out an assay. The plan is a realizable entity (a specifically dependent continuant) that concretizes the protocol (a generically dependent continuant), and both depend on the investigator (an independent continuant). The plan is then realized by the assay (a process)." ; + + skos:prefLabel "concretizes" . + + + +### http://purl.obolibrary.org/obo/RO_0000079 + +ro:_0000079 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0000052 ; + + owl:inverseOf ro:_0000085 ; + + rdfs:domain bfo:_0000034 ; + + rdfs:isDefinedBy ; + + skos:altLabel "is function of" ; + + skos:definition "A relation between a function and an independent continuant (the bearer), in which the function specifically depends on the bearer for its existence. [RO]" ; + + skos:prefLabel "function of" . + + + +### http://purl.obolibrary.org/obo/RO_0000080 + +ro:_0000080 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0000052 ; + + owl:inverseOf ro:_0000086 ; + + rdfs:isDefinedBy ; + + skos:definition "Inverse of has quality [RO]" ; + + skos:prefLabel "quality of" . + + + +### http://purl.obolibrary.org/obo/RO_0000081 + +ro:_0000081 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0000052 ; + + owl:inverseOf ro:_0000087 ; + + rdfs:isDefinedBy ; + + skos:altLabel "is role of" ; + + skos:definition "A relation between a role and an independent continuant (the bearer), in which the role specifically depends on the bearer for its existence. [RO]" ; + + skos:prefLabel "role of" . + + + +### http://purl.obolibrary.org/obo/RO_0000085 + +ro:_0000085 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0000053 ; + + rdfs:domain bfo:_0000004 ; + + rdfs:range bfo:_0000034 ; + + rdfs:isDefinedBy ; + + skos:definition "A relation between an independent continuant (the bearer) and a function, in which the function specifically depends on the bearer for its existence. [RO]" ; + + skos:editorialNote "A bearer can have many functions, and its functions can exist for different periods of time, but none of its functions can exist when the bearer does not exist. A function need not be realized at all the times that the function exists. [RO]" ; + + skos:example "this enzyme has function this catalysis function (more colloquially: this enzyme has this catalysis function)" ; + + skos:prefLabel "has function" . + + + +### http://purl.obolibrary.org/obo/RO_0000086 + +ro:_0000086 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0000053 ; + + rdfs:range bfo:_0000019 ; + + rdfs:isDefinedBy ; + + skos:definition "A relation between an independent continuant (the bearer) and a quality, in which the quality specifically depends on the bearer for its existence. [RO]" ; + + skos:editorialNote "A bearer can have many qualities, and its qualities can exist for different periods of time, but none of its qualities can exist when the bearer does not exist. [RO]" ; + + skos:example "this apple has quality this red color" ; + + skos:prefLabel "has quality" . + + + +### http://purl.obolibrary.org/obo/RO_0000087 + +ro:_0000087 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0000053 ; + + rdfs:domain bfo:_0000004 ; + + rdfs:range bfo:_0000023 ; + + rdfs:isDefinedBy ; + + skos:definition "A relation between an independent continuant (the bearer) and a role, in which the role specifically depends on the bearer for its existence [RO]" ; + + skos:editorialNote "A bearer can have many roles, and its roles can exist for different periods of time, but none of its roles can exist when the bearer does not exist. A role need not be realized at all the times that the role exists. [RO]" ; + + skos:example "this person has role this investigator role (more colloquially: this person has this role of investigator) [RO]" ; + + skos:prefLabel "has role" . + + + +### http://purl.obolibrary.org/obo/RO_0000091 + +ro:_0000091 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0000053 ; + + owl:inverseOf ro:_0000092 ; + + rdfs:domain bfo:_0000004 ; + + rdfs:range bfo:_0000016 ; + + rdfs:isDefinedBy ; + + skos:definition "A relation between an independent continuant (the bearer) and a disposition, in which the disposition specifically depends on the bearer for its existence, [RO]" ; + + skos:prefLabel "has disposition" . + + + +### http://purl.obolibrary.org/obo/RO_0000092 + +ro:_0000092 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0000052 ; + + rdfs:isDefinedBy ; + + skos:definition "Inverse of has disposition [RO]" ; + + skos:prefLabel "disposition of" . + + + +### http://purl.obolibrary.org/obo/RO_0001000 + +ro:_0001000 rdf:type owl:ObjectProperty ; + + owl:inverseOf ro:_0001001 ; + + rdfs:isDefinedBy ; + + skos:definition "A relation between two distinct material entities, the new entity and the old entity, in which the new entity begins to exist when the old entity ceases to exist, and the new entity inherits the significant portion of the matter of the old entity. [RO]" ; + + skos:example "this cell derives from this parent cell (cell division)" , + "this nucleus derives from this parent nucleus (nuclear division)" ; + + skos:prefLabel "derives from" . + + + +### http://purl.obolibrary.org/obo/RO_0001001 + +ro:_0001001 rdf:type owl:ObjectProperty ; + + rdfs:isDefinedBy ; + + skos:definition "A relation between two distinct material entities, the old entity and the new entity, in which the new entity begins to exist when the old entity ceases to exist, and the new entity inherits the significant portion of the matter of the old entity. [RO]" ; + + skos:editorialNote "This is a very general relation. More specific relations are preferred when applicable, such as 'directly develops into'. To avoid making statements about a future that may not come to pass, it is often better to use the backward-looking 'derives from' rather than the forward-looking 'derives into'. [RO]" ; + + skos:prefLabel "derives into" . + + + +### http://purl.obolibrary.org/obo/RO_0001015 + +ro:_0001015 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf owl:topObjectProperty ; + + rdf:type owl:TransitiveProperty ; + + rdfs:domain bfo:_0000004 ; + + rdfs:range bfo:_0000004 ; + + rdfs:isDefinedBy ; + + skos:altLabel "is location of" ; + + skos:definition "a relation between two independent continuants, the location and the target, in which the target is entirely within the location [RO]" ; + + skos:example "this cage is the location of this rat" ; + + skos:prefLabel "location of" . + + + +### http://purl.obolibrary.org/obo/RO_0001025 + +ro:_0001025 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf owl:topObjectProperty ; + + rdf:type owl:TransitiveProperty ; + + rdfs:domain bfo:_0000004 ; + + rdfs:range bfo:_0000004 ; + + rdfs:isDefinedBy ; + + skos:definition "A relation between two independent continuants, the target and the location, in which the target is entirely within the location. [RO]" ; + + skos:prefLabel "located in" . + + + +### http://purl.obolibrary.org/obo/RO_0002000 + +ro:_0002000 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0002323 ; + + owl:inverseOf ro:_0002002 ; + + rdfs:isDefinedBy ; + + skos:altLabel "boundary of" , + "is 2D boundary of" , + "is boundary of" ; + + skos:definition "a relation between a 2D immaterial entity (the boundary) and a material entity, in which the boundary delimits the material entity [RO]" ; + + skos:editorialNote "A 2D boundary may have holes and gaps, but it must be a single connected entity, not an aggregate of several disconnected parts. [RO]" , + "Although the boundary is two-dimensional, it exists in three-dimensional space and thus has a 3D shape. [RO]" ; + + skos:example "the surface of my skin is a 2D boundary of my body" ; + + skos:prefLabel "2D boundary of" . + + + +### http://purl.obolibrary.org/obo/RO_0002002 + +ro:_0002002 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0002323 ; + + rdfs:domain bfo:_0000040 ; + + rdfs:range bfo:_0000040 ; + + rdfs:isDefinedBy ; + + skos:definition "a relation between a material entity and a 2D immaterial entity (the boundary), in which the boundary delimits the material entity [RO]" ; + + skos:editorialNote "A 2D boundary may have holes and gaps, but it must be a single connected entity, not an aggregate of several disconnected parts. [RO]" , + "Although the boundary is two-dimensional, it exists in three-dimensional space and thus has a 3D shape. [RO]" ; + + skos:prefLabel "has 2D boundary" . + + + +### http://purl.obolibrary.org/obo/RO_0002012 + +ro:_0002012 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf bfo:_0000050 , + ro:_0002418 ; + + rdfs:domain bfo:_0000003 ; + + rdfs:range bfo:_0000003 ; + + rdfs:isDefinedBy ; + + skos:definition "A part of relation that applies only between occurrents. [RO]" ; + + skos:prefLabel "occurrent part of" . + + + +### http://purl.obolibrary.org/obo/RO_0002081 + +ro:_0002081 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0002222 ; + + rdfs:isDefinedBy ; + + skos:definition "Primitive instance level timing relation between events [RO]" ; + + skos:prefLabel "before or simultaneous with" . + + + +### http://purl.obolibrary.org/obo/RO_0002082 + +ro:_0002082 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0002081 ; + + rdf:type owl:TransitiveProperty ; + + rdfs:isDefinedBy ; + + skos:definition "t1 simultaneous_with t2 iff:= t1 before_or_simultaneous_with t2 and not (t1 before t2) [RO]" ; + + skos:prefLabel "simultaneous with" . + + + +### http://purl.obolibrary.org/obo/RO_0002083 + +ro:_0002083 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0002081 ; + + rdf:type owl:TransitiveProperty ; + + rdfs:isDefinedBy ; + + skos:definition "t1 before t2 iff:= t1 before_or_simulataneous_with t2 and not (t1 simultaneous_with t2) [RO]" ; + + skos:prefLabel "before" . + + + +### http://purl.obolibrary.org/obo/RO_0002084 + +ro:_0002084 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0002222 ; + + owl:inverseOf ro:_0002093 ; + + rdfs:isDefinedBy ; + + skos:prefLabel "during which ends" . + + + +### http://purl.obolibrary.org/obo/RO_0002085 + +ro:_0002085 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0002088 ; + + owl:inverseOf ro:_0002092 ; + + rdf:type owl:TransitiveProperty ; + + rdfs:isDefinedBy ; + + skos:prefLabel "encompasses" . + + + +### http://purl.obolibrary.org/obo/RO_0002086 + +ro:_0002086 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0002222 ; + + rdf:type owl:TransitiveProperty ; + + owl:propertyChainAxiom ( ro:_0002093 + bfo:_0000062 + ) ; + + rdfs:isDefinedBy ; + + skos:definition "X ends_after Y iff: end(Y) before_or_simultaneous_with end(X) [RO]" ; + + skos:prefLabel "ends after" . + + + +### http://purl.obolibrary.org/obo/RO_0002087 + +ro:_0002087 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf bfo:_0000062 ; + + owl:inverseOf ro:_0002090 ; + + owl:propertyChainAxiom ( ro:_0002224 + ro:_0002230 + ) ; + + rdfs:isDefinedBy ; + + skos:altLabel "starts at end of" ; + + skos:definition "X immediately_preceded_by Y iff: end(X) simultaneous_with start(Y) [RO]" ; + + skos:prefLabel "immediately preceded by" . + + + +### http://purl.obolibrary.org/obo/RO_0002088 + +ro:_0002088 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0002222 ; + + owl:inverseOf ro:_0002091 ; + + rdfs:isDefinedBy ; + + skos:prefLabel "during which starts" . + + + +### http://purl.obolibrary.org/obo/RO_0002089 + +ro:_0002089 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0002222 ; + + rdf:type owl:TransitiveProperty ; + + owl:propertyChainAxiom ( ro:_0002091 + bfo:_0000062 + ) ; + + rdfs:isDefinedBy ; + + skos:prefLabel "starts before" . + + + +### http://purl.obolibrary.org/obo/RO_0002090 + +ro:_0002090 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf bfo:_0000063 ; + + owl:propertyChainAxiom ( ro:_0002230 + ro:_0002224 + ) ; + + rdfs:isDefinedBy ; + + skos:altLabel "ends at start of" , + "meets" ; + + skos:definition "X immediately_precedes_Y iff: end(X) simultaneous_with start(Y) [RO]" ; + + skos:prefLabel "immediately precedes" . + + + +### http://purl.obolibrary.org/obo/RO_0002091 + +ro:_0002091 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0002222 ; + + rdfs:isDefinedBy ; + + skos:definition "X starts_during Y iff: (start(Y) before_or_simultaneous_with start(X)) AND (start(X) before_or_simultaneous_with end(Y)) [RO]" ; + + skos:prefLabel "starts during" . + + + +### http://purl.obolibrary.org/obo/RO_0002092 + +ro:_0002092 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0002093 ; + + rdf:type owl:TransitiveProperty ; + + rdfs:isDefinedBy ; + + skos:altLabel "during" ; + + skos:definition "X happens_during Y iff: (start(Y) before_or_simultaneous_with start(X)) AND (end(X) before_or_simultaneous_with end(Y)) [RO]" ; + + skos:prefLabel "happens during" . + + + +### http://purl.obolibrary.org/obo/RO_0002093 + +ro:_0002093 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0002222 ; + + rdfs:isDefinedBy ; + + skos:definition "X ends_during Y iff: ((start(Y) before_or_simultaneous_with end(X)) AND end(X) before_or_simultaneous_with end(Y). [RO]" ; + + skos:prefLabel "ends during" . + + + +### http://purl.obolibrary.org/obo/RO_0002131 + +ro:_0002131 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0002323 ; + + owl:propertyChainAxiom ( bfo:_0000050 + bfo:_0000050 + ) , + ( bfo:_0000051 + bfo:_0000050 + ) , + ( bfo:_0000051 + ro:_0002131 + ) ; + + rdfs:isDefinedBy ; + + skos:definition "x overlaps y if and only if there exists some z such that x has part z and z part of y [RO]" ; + + skos:prefLabel "overlaps" . + + + +### http://purl.obolibrary.org/obo/RO_0002150 + +ro:_0002150 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0002323 ; + + rdfs:domain bfo:_0000004 ; + + rdfs:range bfo:_0000004 ; + + rdfs:isDefinedBy ; + + skos:definition "X continuous_with Y if and only if X and Y share a fiat boundary. [RO]" ; + + skos:prefLabel "continuous with" . + + + +### http://purl.obolibrary.org/obo/RO_0002163 + +ro:_0002163 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0002323 ; + + rdfs:isDefinedBy ; + + skos:definition "A is spatially_disjoint_from B if and only if they have no parts in common [RO]" ; + + skos:editorialNote "Note that it would be possible to use the relation to label the relationship between a near infinite number of structures - between the rings of saturn and my left earlobe. The intent is that this is used for parsiomoniously for disambiguation purposes - for example, between siblings in a jointly exhaustive pairwise disjointness hierarchy [RO]" ; + + skos:prefLabel "spatially disjoint from" . + + + +### http://purl.obolibrary.org/obo/RO_0002170 + +ro:_0002170 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0002323 ; + + owl:propertyChainAxiom ( [ owl:inverseOf ro:_0002176 + ] + ro:_0002176 + ) ; + + rdfs:isDefinedBy ; + + skos:definition "a is connected to b if and only if a and b are discrete structure, and there exists some connecting structure c, such that c connects a and b [RO]" ; + + skos:prefLabel "connected to" . + + + +### http://purl.obolibrary.org/obo/RO_0002176 + +ro:_0002176 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0002323 ; + + rdfs:domain bfo:_0000004 ; + + rdfs:isDefinedBy ; + + skos:definition "C connects a if and only if there exist some b such that a and b are similar parts of the same system, and c connects b, specifically, c connects a with b. When one structure connects two others it unites some aspect of the function or role they play within the system. [IAO]" ; + + skos:prefLabel "connects" . + + + +### http://purl.obolibrary.org/obo/RO_0002177 + +ro:_0002177 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0002323 ; + + rdfs:domain bfo:_0000040 ; + + rdfs:range bfo:_0000040 ; + + owl:propertyChainAxiom ( ro:_0002371 + bfo:_0000050 + ) ; + + rdfs:isDefinedBy ; + + skos:definition "A is attached to part of b if a is attached to b, or a is attached to some p, where p is part of b. [IAO]" ; + + skos:prefLabel "attached to part of" . + + + +### http://purl.obolibrary.org/obo/RO_0002180 + +ro:_0002180 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf bfo:_0000051 ; + + rdfs:isDefinedBy ; + + skos:definition "W 'has component' p if w 'has part' p and w is such that it can be directly disassembled into into n parts p, p2, p3, ..., pn, where these parts are of similar type. [RO]" ; + + skos:editorialNote "For use in recording has_part with a cardinality constraint, because OWL does not permit cardinality constraints to be used in combination with transitive object properties. In situations where you would want to say something like 'has part exactly 5 digit, you would instead use has_component exactly 5 digit. [RO]" ; + + skos:prefLabel "has component" . + + + +### http://purl.obolibrary.org/obo/RO_0002211 + +ro:_0002211 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0002418 ; + + owl:inverseOf ro:_0002334 ; + + rdfs:domain bfo:_0000015 ; + + rdfs:range bfo:_0000015 ; + + rdfs:isDefinedBy ; + + skos:definition "Process(P1) regulates process(P2) iff: P1 results in the initiation or termination of P2 OR affects the frequency of its initiation or termination OR affects the magnitude or rate of output of P2. [RO]" ; + + skos:prefLabel "regulates" . + + + +### http://purl.obolibrary.org/obo/RO_0002212 + +ro:_0002212 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0002211 , + ro:_0002305 ; + + rdfs:isDefinedBy ; + + skos:definition "Process(P1) negatively regulates process(P2) iff: P1 terminates P2, or P1 descreases the the frequency of initiation of P2 or the magnitude or rate of output of P2. [RO]" ; + + skos:prefLabel "negatively regulates (process to process)" . + + + +### http://purl.obolibrary.org/obo/RO_0002213 + +ro:_0002213 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0002211 , + ro:_0002304 ; + + rdfs:isDefinedBy ; + + skos:definition "Process(P1) positively regulates process(P2) iff: P1 initiates P2, or P1 increases the the frequency of initiation of P2 or the magnitude or rate of output of P2. [RO]" ; + + skos:prefLabel "positively regulates (process to process)" . + + + +### http://purl.obolibrary.org/obo/RO_0002215 + +ro:_0002215 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0002216 ; + + rdfs:isDefinedBy ; + + skos:altLabel "has function realized in" ; + + skos:definition "A relation between a material entity (such as a cell) and a process, in which the material entity has the ability to carry out the process. [RO]" ; + + skos:editorialNote "this relation has a shortcut definition in which the expression \"capable of some P\" expands to \"bearer_of (some realized_by only P)" ; + + skos:example "mechanosensory neuron capable of detection of mechanical stimulus involved in sensory perception [RO]" ; + + skos:prefLabel "capable of" . + + + +### http://purl.obolibrary.org/obo/RO_0002216 + +ro:_0002216 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0002328 , + ro:_0002500 ; + + owl:propertyChainAxiom ( ro:_0002215 + bfo:_0000050 + ) ; + + rdfs:isDefinedBy ; + + skos:altLabel "has function in" ; + + skos:definition "C stands in this relationship to p if and only if there exists some p' such that c is capable_of p', and p' is part_of p. [RO]" ; + + skos:prefLabel "capable of part of" . + + + +### http://purl.obolibrary.org/obo/RO_0002217 + +ro:_0002217 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0000056 ; + + owl:inverseOf ro:_0002218 ; + + rdfs:isDefinedBy ; + + skos:altLabel "agent in" ; + + skos:definition "X actively participates in y if and only if x participates in y and x realizes some active role [RO]" ; + + skos:prefLabel "actively participates in" . + + + +### http://purl.obolibrary.org/obo/RO_0002218 + +ro:_0002218 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0000057 ; + + rdfs:isDefinedBy ; + + skos:altLabel "has agent" ; + + skos:definition "X has participant y if and only if x realizes some active role that inheres in y [RO]" ; + + skos:prefLabel "has active participant" . + + + +### http://purl.obolibrary.org/obo/RO_0002219 + +ro:_0002219 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0002220 ; + + owl:inverseOf ro:_0002221 ; + + rdfs:isDefinedBy ; + + skos:definition "X surrounded_by y if and only if (1) x is adjacent to y and for every region r that is adjacent to x, r overlaps y (2) the shared boundary between x and y occupies the majority of the outermost boundary of x [RO]" ; + + skos:prefLabel "surrounded by" . + + + +### http://purl.obolibrary.org/obo/RO_0002220 + +ro:_0002220 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0002163 ; + + rdfs:isDefinedBy ; + + skos:definition "X adjacent to y if and only if x and y share a boundary. [RO]" ; + + skos:example "A caterpillar walking on the surface of a leaf is adjacent_to the leaf, if one of the caterpillar appendages is touching the leaf. In contrast, a butterfly flying close to a flower is not considered adjacent, unless there are any touching parts." , + "The epidermis layer of a vertebrate is adjacent to the dermis." , + "The plasma membrane of a cell is adjacent to the cytoplasm, and also to the cell lumen which the cytoplasm occupies." , + "The skin of the forelimb is adjacent to the skin of the torso if these are considered anatomical subdivisions with a defined border. Otherwise a relation such as continuous_with would be used." ; + + skos:prefLabel "adjacent to" . + + + +### http://purl.obolibrary.org/obo/RO_0002221 + +ro:_0002221 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0002220 ; + + rdfs:isDefinedBy ; + + skos:definition "Inverse of surrounded by [RO]" ; + + skos:prefLabel "surrounds" . + + + +### http://purl.obolibrary.org/obo/RO_0002222 + +ro:_0002222 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf owl:topObjectProperty ; + + rdfs:domain bfo:_0000003 ; + + rdfs:range bfo:_0000003 ; + + rdfs:isDefinedBy ; + + skos:definition "A relation that holds between two occurrents. This is a grouping relation that collects together all the Allen relations. [RO]" ; + + skos:prefLabel "temporally related to" . + + + +### http://purl.obolibrary.org/obo/RO_0002223 + +ro:_0002223 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf bfo:_0000050 , + ro:_0002222 ; + + owl:inverseOf ro:_0002224 ; + + rdfs:isDefinedBy ; + + skos:definition "Inverse of starts with [RO]" ; + + skos:prefLabel "starts" . + + + +### http://purl.obolibrary.org/obo/RO_0002224 + +ro:_0002224 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf bfo:_0000051 , + ro:_0002222 ; + + rdf:type owl:TransitiveProperty ; + + rdfs:isDefinedBy ; + + skos:definition "X starts with y if and only if x has part y and the time point at which x starts is equivalent to the time point at which y starts. Formally: α(y) = α(x) and ω(y) < ω(x), where α is a function that maps a process to a start point, and ω is a function that maps a process to an end point. [RO]" ; + + skos:prefLabel "starts with" . + + + +### http://purl.obolibrary.org/obo/RO_0002229 + +ro:_0002229 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf bfo:_0000050 , + ro:_0002222 ; + + owl:inverseOf ro:_0002230 ; + + rdfs:isDefinedBy ; + + skos:definition "Inverse of ends with [RO]" ; + + skos:prefLabel "ends" . + + + +### http://purl.obolibrary.org/obo/RO_0002230 + +ro:_0002230 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf bfo:_0000051 , + ro:_0002222 ; + + rdf:type owl:TransitiveProperty ; + + rdfs:isDefinedBy ; + + skos:definition "X ends with y if and only if x has part y and the time point at which x ends is equivalent to the time point at which y ends. Formally: α(y) > α(x) and ω(y) = ω(x), where α is a function that maps a process to a start point, and ω is a function that maps a process to an end point. [RO]" ; + + skos:prefLabel "ends with" . + + + +### http://purl.obolibrary.org/obo/RO_0002263 + +ro:_0002263 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0002264 ; + + owl:propertyChainAxiom ( ro:_0002327 + ro:_0002411 + ) ; + + rdfs:isDefinedBy ; + + skos:definition "C involved in regulation of p if c enables 'p' and p' causally upstream of p [RO]" ; + + skos:prefLabel "acts upstream of" . + + + +### http://purl.obolibrary.org/obo/RO_0002264 + +ro:_0002264 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0002500 ; + + rdfs:isDefinedBy ; + + skos:definition "C acts upstream of or within p if c is enables 'p' and p' causally upstream of or within p [RO]" ; + + skos:prefLabel "acts upstream of or within" . + + + +### http://purl.obolibrary.org/obo/RO_0002304 + +ro:_0002304 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0002411 ; + + rdfs:isDefinedBy ; + + skos:prefLabel "causally upstream of, positive effect" . + + + +### http://purl.obolibrary.org/obo/RO_0002305 + +ro:_0002305 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0002411 ; + + rdfs:isDefinedBy ; + + skos:definition "holds between x and y if and only if x is causally upstream of y and the progression of x decreases the frequency, rate or extent of y [RO]" ; + + skos:prefLabel "causally upstream of, negative effect" . + + + +### http://purl.obolibrary.org/obo/RO_0002314 + +ro:_0002314 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0002502 ; + + owl:propertyChainAxiom ( ro:_0000052 + bfo:_0000050 + ) , + ( ro:_0002314 + bfo:_0000050 + ) ; + + rdfs:isDefinedBy ; + + skos:definition "Q inheres in part of w if and only if there exists some p such that q inheres in p and p part of w. [RO]" ; + + skos:prefLabel "inheres in part of" . + + + +### http://purl.obolibrary.org/obo/RO_0002323 + +ro:_0002323 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf owl:topObjectProperty ; + + rdfs:isDefinedBy ; + + skos:definition "A mereological relationship or a topological relationship [RO]" ; + + skos:editorialNote "Do not use this relation directly. It is ended as a grouping for a diverse set of relations, all involving parthood or connectivity relationships [RO]" ; + + skos:prefLabel "mereotopologically related to" . + + + +### http://purl.obolibrary.org/obo/RO_0002326 + +ro:_0002326 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0002216 ; + + rdfs:isDefinedBy ; + + skos:definition "if and only if exists c', p' c part_of c' and c' capable_of p and c capable_of p' and p' part_of p then c contributes_to p [RO]" ; + + skos:prefLabel "contributes to" . + + + +### http://purl.obolibrary.org/obo/RO_0002327 + +ro:_0002327 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0002215 ; + + owl:inverseOf ro:_0002333 ; + + rdfs:isDefinedBy ; + + skos:altLabel "catalyzes" , + "executes" ; + + skos:editorialNote "This relation differs from the parent relation 'capable of' in that the parent is weaker and only expresses a capability that may not be actually realized, whereas this relation is always realized. [RO]" ; + + skos:example "a particular instances of akt-2 enables some instance of protein kinase activity [RO]" ; + + skos:prefLabel "enables" . + + + +### http://purl.obolibrary.org/obo/RO_0002328 + +ro:_0002328 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf owl:topObjectProperty ; + + rdfs:isDefinedBy ; + + skos:definition "This is a grouping relation that collects relations used for the purpose of connecting structure and function. [RO]" ; + + skos:prefLabel "functionally related to" . + + + +### http://purl.obolibrary.org/obo/RO_0002331 + +ro:_0002331 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0002431 ; + + owl:propertyChainAxiom ( ro:_0002327 + bfo:_0000050 + ) , + ( ro:_0002331 + bfo:_0000050 + ) ; + + rdfs:isDefinedBy ; + + skos:altLabel "actively involved in" , + "enables part of" ; + + skos:definition "C involved_in p if and only if c enables some process p', and p' is part of p [RO]" ; + + skos:prefLabel "involved in" . + + + +### http://purl.obolibrary.org/obo/RO_0002332 + +ro:_0002332 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0000057 ; + + rdfs:isDefinedBy ; + + skos:altLabel "regulates levels of" ; + + skos:definition "P regulates levels of c if p regulates some amount (PATO:0000070) of c [RO]" ; + + skos:example "every cellular sphingolipid homeostasis process regulates_level_of some sphingolipid" ; + + skos:prefLabel "regulates levels of (process to entity)" . + + + +### http://purl.obolibrary.org/obo/RO_0002333 + +ro:_0002333 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0002328 ; + + rdfs:isDefinedBy ; + + skos:definition "inverse of enables [RO]" ; + + skos:prefLabel "enabled by" . + + + +### http://purl.obolibrary.org/obo/RO_0002334 + +ro:_0002334 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0002427 ; + + rdf:type owl:TransitiveProperty ; + + rdfs:domain bfo:_0000015 ; + + rdfs:range bfo:_0000015 ; + + rdfs:isDefinedBy ; + + skos:prefLabel "regulated by" . + + + +### http://purl.obolibrary.org/obo/RO_0002335 + +ro:_0002335 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0002334 ; + + rdfs:isDefinedBy ; + + skos:definition "Inverse of negatively regulates [RO]" ; + + skos:prefLabel "negatively regulated by" . + + + +### http://purl.obolibrary.org/obo/RO_0002336 + +ro:_0002336 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0002334 ; + + rdfs:isDefinedBy ; + + skos:definition "Inverse of positively regulates [RO]" ; + + skos:prefLabel "positively regulated by" . + + + +### http://purl.obolibrary.org/obo/RO_0002337 + +ro:_0002337 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf owl:topObjectProperty ; + + rdfs:isDefinedBy ; + + skos:definition "A relationship that holds via some process of localization. [RO]" ; + + skos:prefLabel "related via localization to" . + + + +### http://purl.obolibrary.org/obo/RO_0002338 + +ro:_0002338 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0002344 ; + + rdfs:isDefinedBy ; + + skos:definition "This relationship holds between p and l when p is a transport or localization process in which the outcome is to move some cargo c from some initial location l to some destination. [RO]" ; + + skos:prefLabel "has target start location" . + + + +### http://purl.obolibrary.org/obo/RO_0002339 + +ro:_0002339 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0002344 ; + + rdfs:isDefinedBy ; + + skos:definition "This relationship holds between p and l when p is a transport or localization process in which the outcome is to move some cargo c from a an initial location to some destination l. [RO]" ; + + skos:prefLabel "has target end location" . + + + +### http://purl.obolibrary.org/obo/RO_0002341 + +ro:_0002341 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0002337 ; + + rdfs:isDefinedBy ; + + skos:definition "Holds between p and l when p is a transportation or localization process and the outcome of this process is to move c from one location to another, and the route taken by c follows a path that is aligned_with l. [RO]" ; + + skos:prefLabel "results in transport along" . + + + +### http://purl.obolibrary.org/obo/RO_0002342 + +ro:_0002342 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0002344 ; + + rdfs:isDefinedBy ; + + skos:definition "Holds between p and m when p is a transportation or localization process and the outcome of this process is to move c from one location to another, and the route taken by c follows a path that crosses m. [RO]" ; + + skos:prefLabel "results in transport across" . + + + +### http://purl.obolibrary.org/obo/RO_0002344 + +ro:_0002344 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0002337 ; + + rdfs:isDefinedBy ; + + skos:example "'mitochondrial transport' results_in_transport_to_from_or_in some mitochondrion (GO:0005739)" ; + + skos:prefLabel "results in transport to from or in" . + + + +### http://purl.obolibrary.org/obo/RO_0002350 + +ro:_0002350 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf af-x:AFX_0002846 ; + + owl:inverseOf ro:_0002351 ; + + rdf:type owl:AsymmetricProperty , + owl:IrreflexiveProperty ; + + rdfs:isDefinedBy ; + + skos:altLabel "member part of" ; + + skos:definition "Inverse of has member" ; + + skos:example "An organism that is a member of a population of organisms. [RO]" ; + + skos:prefLabel "member of" . + + + +### http://purl.obolibrary.org/obo/RO_0002351 + +ro:_0002351 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf af-x:AFX_0002793 ; + + rdf:type owl:AsymmetricProperty , + owl:IrreflexiveProperty ; + + rdfs:isDefinedBy ; + + skos:definition "Has member is a mereological relation between a collection and an item. [RO]" ; + + skos:prefLabel "has member" . + + + +### http://purl.obolibrary.org/obo/RO_0002371 + +ro:_0002371 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0002170 , + ro:_0002177 ; + + rdf:type owl:SymmetricProperty ; + + rdfs:isDefinedBy ; + + skos:definition "A is attached to b if and only if a and b are discrete objects or object parts, and there are physical connections between a and b such that a force pulling a will move b, or a force pulling b will move a. [IAO]" ; + + skos:prefLabel "attached to" . + + + +### http://purl.obolibrary.org/obo/RO_0002379 + +ro:_0002379 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0002131 ; + + rdfs:isDefinedBy ; + + skos:definition "X spatially_coextensive_with y if and only if x and y have the same location [RO]" ; + + skos:example "A lump of clay and a statue" ; + + skos:prefLabel "spatially coextensive with" . + + + +### http://purl.obolibrary.org/obo/RO_0002404 + +ro:_0002404 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf bfo:_0000062 , + ro:_0002427 ; + + owl:inverseOf ro:_0002411 ; + + rdfs:isDefinedBy ; + + skos:definition "inverse of upstream of [RO]" ; + + skos:prefLabel "causally downstream of" . + + + +### http://purl.obolibrary.org/obo/RO_0002405 + +ro:_0002405 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0002087 , + ro:_0002404 ; + + owl:inverseOf ro:_0002412 ; + + rdfs:isDefinedBy ; + + skos:definition "inverse of immediately causally upstream of" ; + + skos:prefLabel "immediately causally downstream of" . + + + +### http://purl.obolibrary.org/obo/RO_0002410 + +ro:_0002410 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0002609 ; + + rdfs:isDefinedBy ; + + skos:editorialNote "Do not use this relation directly. It is intended as a grouping for a diverse set of relations, all involving cause and effect. [IAO]" ; + + skos:note "This relation groups causal relations between material entities and causal relations between processes. [IAO]" ; + + skos:prefLabel "causally related to" . + + + +### http://purl.obolibrary.org/obo/RO_0002411 + +ro:_0002411 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf bfo:_0000063 , + ro:_0002418 ; + + rdfs:isDefinedBy ; + + skos:definition "P is causally upstream of q if and only if p precedes q and p and q are linked in a causal chain [RO]" ; + + skos:prefLabel "causally upstream of" . + + + +### http://purl.obolibrary.org/obo/RO_0002412 + +ro:_0002412 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0002090 , + ro:_0002411 ; + + rdfs:isDefinedBy ; + + skos:definition "P is immediately causally upstream of q if and only if both (a) p immediately precedes q and (b) p is causally upstream of q. In addition, the output of p must be an input of q. [RO]" ; + + skos:prefLabel "immediately causally upstream of" . + + + +### http://purl.obolibrary.org/obo/RO_0002418 + +ro:_0002418 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0002501 ; + + owl:inverseOf ro:_0002427 ; + + rdf:type owl:TransitiveProperty ; + + rdfs:isDefinedBy ; + + skos:altLabel "affects" ; + + skos:definition "P 'causally upstream or within' q if and only if (1) the end of p is before the end of q and (2) the execution of p exerts some causal influence over the outputs of q; i.e. if p was abolished or the outputs of p were to be modified, this would necessarily affect q. [RO]" ; + + skos:prefLabel "causally upstream of or within" . + + + +### http://purl.obolibrary.org/obo/RO_0002427 + +ro:_0002427 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0002501 ; + + rdf:type owl:TransitiveProperty ; + + rdfs:isDefinedBy ; + + skos:prefLabel "causally downstream of or within" . + + + +### http://purl.obolibrary.org/obo/RO_0002428 + +ro:_0002428 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0002263 , + ro:_0002431 ; + + owl:propertyChainAxiom ( ro:_0002327 + ro:_0002211 + ) , + ( ro:_0002331 + ro:_0002211 + ) ; + + rdfs:isDefinedBy ; + + skos:definition "C involved in regulation of p if c is involved in some 'p' and p' regulates some p [RO]" ; + + skos:prefLabel "involved in regulation of" . + + + +### http://purl.obolibrary.org/obo/RO_0002429 + +ro:_0002429 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0002428 ; + + owl:propertyChainAxiom ( ro:_0002327 + ro:_0002213 + ) , + ( ro:_0002331 + ro:_0002213 + ) ; + + rdfs:isDefinedBy ; + + skos:prefLabel "involved in positive regulation of" . + + + +### http://purl.obolibrary.org/obo/RO_0002430 + +ro:_0002430 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0002428 ; + + owl:propertyChainAxiom ( ro:_0002327 + ro:_0002212 + ) , + ( ro:_0002331 + ro:_0002212 + ) ; + + rdfs:isDefinedBy ; + + skos:prefLabel "involved in negative regulation of" . + + + +### http://purl.obolibrary.org/obo/RO_0002431 + +ro:_0002431 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0002264 , + ro:_0002328 , + ro:_0002500 ; + + rdfs:isDefinedBy ; + + skos:altLabel "involved in or regulates" ; + + skos:definition "C involved in or regulates p if and only if either (i) c is involved in p or (ii) c is involved in regulation of p [RO]" ; + + skos:prefLabel "involved in or involved in regulation of" . + + + +### http://purl.obolibrary.org/obo/RO_0002434 + +ro:_0002434 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf owl:topObjectProperty ; + + rdfs:domain bfo:_0000040 ; + + rdfs:range bfo:_0000040 ; + + rdfs:isDefinedBy ; + + skos:altLabel "pairwise interacts with" ; + + skos:definition "A relationship that holds between two entities in which the processes executed by the two entities are causally connected. [RO]" ; + + skos:editorialNote "This relation and all sub-relations can be applied to either (1) pairs of entities that are interacting at any moment of time (2) populations or species of entity whose members have the disposition to interact (3) classes whose members have the disposition to interact. [RO]" ; + + skos:prefLabel "interacts with" . + + + +### http://purl.obolibrary.org/obo/RO_0002461 + +ro:_0002461 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0000056 ; + + rdfs:isDefinedBy ; + + skos:definition "relation used for defining interaction relations. An interaction relation holds when there is an interaction event with two partners. In a directional interaction, one partner is deemed the subject, the other the target [RO]" ; + + skos:prefLabel "partner in" . + + + +### http://purl.obolibrary.org/obo/RO_0002462 + +ro:_0002462 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0002461 ; + + rdfs:isDefinedBy ; + + skos:altLabel "subject in" ; + + skos:definition "relation used for defining interaction relations; the meaning of s 'subject participant in' p is determined by the type of p, where p must be a directional interaction process. [RO]" ; + + skos:example "in a predator-prey interaction process the subject is the predator" ; + + skos:prefLabel "subject participant in" . + + + +### http://purl.obolibrary.org/obo/RO_0002463 + +ro:_0002463 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0002461 ; + + rdfs:isDefinedBy ; + + skos:altLabel "target in" ; + + skos:definition "Relation used for defining interaction relations; the meaning of s 'target participant in' p is determined by the type of p, where p must be a directional interaction process [RO]" ; + + skos:example "in a predator-prey interaction process the target is the prey" ; + + skos:prefLabel "target participant in" . + + + +### http://purl.obolibrary.org/obo/RO_0002500 + +ro:_0002500 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0002595 ; + + rdfs:isDefinedBy ; + + skos:altLabel "causal agent in" ; + + skos:definition "A relationship between a material entity and a process where the material entity has some causal role that influences the process. [RO]" ; + + skos:prefLabel "causal agent in process" . + + + +### http://purl.obolibrary.org/obo/RO_0002501 + +ro:_0002501 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0002410 ; + + rdf:type owl:TransitiveProperty ; + + rdfs:domain bfo:_0000003 ; + + rdfs:range bfo:_0000003 ; + + rdfs:isDefinedBy ; + + skos:definition "P is causally related to q if and only if p or any part of p and q or any part of q are linked by a chain of events where each event pair is one of direct activation or direct inhibition. p may be upstream, downstream, part of or a container of q. [RO]" ; + + skos:prefLabel "causal relation between processes" . + + + +### http://purl.obolibrary.org/obo/RO_0002502 + +ro:_0002502 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf owl:topObjectProperty ; + + rdfs:isDefinedBy ; + + skos:definition "Being determined, based or contingent on something. [Allotrope]" ; + + skos:prefLabel "depends on" . + + + +### http://purl.obolibrary.org/obo/RO_0002503 + +ro:_0002503 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0002502 ; + + rdfs:isDefinedBy ; + + skos:definition "Q towards e2 if and only if q is a relational quality such that q inheres-in some e, and e != e2 and q is dependent on e2 [RO]" ; + + skos:editorialNote "This relation is provided in order to support the use of relational qualities such as 'concentration of'; for example, the concentration of C in V is a quality that inheres in V, but pertains to C. [RO]" ; + + skos:prefLabel "towards" . + + + +### http://purl.obolibrary.org/obo/RO_0002505 + +ro:_0002505 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0000057 ; + + rdfs:isDefinedBy ; + + skos:altLabel "has intermediate product" ; + + skos:definition "P has intermediate c if and only if p has parts p1, p2 and p1 has output c, and p2 has input c [RO]" ; + + skos:prefLabel "has intermediate" . + + + +### http://purl.obolibrary.org/obo/RO_0002506 + +ro:_0002506 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0002410 ; + + rdfs:domain bfo:_0000040 ; + + rdfs:range bfo:_0000040 ; + + rdfs:isDefinedBy ; + + skos:editorialNote "Do not use this relation directly. It is intended as a grouping for a diverse set of relations, all involving cause and effect. [RO]" ; + + skos:prefLabel "causal relation between material entities" . + + + +### http://purl.obolibrary.org/obo/RO_0002507 + +ro:_0002507 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf bfo:_0000050 , + ro:_0002509 , + ro:_0002559 ; + + owl:inverseOf ro:_0002508 ; + + rdfs:domain ro:_0002577 ; + + rdfs:range bfo:_0000040 ; + + rdfs:isDefinedBy ; + + skos:altLabel "determined by" ; + + skos:definition "S determined by f if and only if s is a type of system, and f is a material entity that is part of s, such that f exerts a strong causal influence on the functioning of s, and the removal of f would cause the collapse of s. [RO]" ; + + skos:prefLabel "determined by (system to material entity)" . + + + +### http://purl.obolibrary.org/obo/RO_0002508 + +ro:_0002508 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0002566 ; + + rdfs:isDefinedBy ; + + skos:altLabel "determines" ; + + skos:prefLabel "determines (material entity to system)" . + + + +### http://purl.obolibrary.org/obo/RO_0002509 + +ro:_0002509 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0002131 , + ro:_0002506 ; + + rdfs:domain ro:_0002577 ; + + rdfs:range bfo:_0000040 ; + + owl:propertyChainAxiom ( ro:_0002507 + bfo:_0000050 + ) ; + + rdfs:isDefinedBy ; + + skos:definition "S 'determined by part of' w if and only if there exists some f such that (1) s 'determined by' f and (2) f part_of w, or f=w. [RO]" ; + + skos:prefLabel "determined by part of" . + + + +### http://purl.obolibrary.org/obo/RO_0002514 + +ro:_0002514 rdf:type owl:ObjectProperty ; + + rdfs:isDefinedBy ; + + skos:definition "A relation that holds between two entities that have the property of being sequences or having sequences. [RO]" ; + + skos:prefLabel "sequentially related to" . + + + +### http://purl.obolibrary.org/obo/RO_0002515 + +ro:_0002515 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0002527 ; + + rdfs:isDefinedBy ; + + skos:definition "x is sequentially adjacent to y if and only if x and y do not overlap and if there are no base units intervening between x and y [RO]" ; + + skos:prefLabel "sequentially adjacent to" . + + + +### http://purl.obolibrary.org/obo/RO_0002516 + +ro:_0002516 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0002524 ; + + owl:inverseOf ro:_0002517 ; + + rdf:type owl:TransitiveProperty ; + + rdfs:isDefinedBy ; + + skos:altLabel "started by" ; + + skos:definition "x has start sequence y if the start of x is identical to the start of y, and x has y as a subsequence [RO]" ; + + skos:prefLabel "has start sequence" . + + + +### http://purl.obolibrary.org/obo/RO_0002517 + +ro:_0002517 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0002524 ; + + rdf:type owl:TransitiveProperty ; + + rdfs:isDefinedBy ; + + skos:altLabel "starts" ; + + skos:definition "inverse of has start sequence [RO]" ; + + skos:prefLabel "is start sequence of" . + + + +### http://purl.obolibrary.org/obo/RO_0002518 + +ro:_0002518 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0002524 ; + + owl:inverseOf ro:_0002519 ; + + rdf:type owl:TransitiveProperty ; + + rdfs:isDefinedBy ; + + skos:altLabel "ended by" ; + + skos:definition "x has end sequence y if the end of x is identical to the end of y, and x has y as a subsequence [RO]" ; + + skos:prefLabel "has end sequence" . + + + +### http://purl.obolibrary.org/obo/RO_0002519 + +ro:_0002519 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0002525 ; + + rdf:type owl:TransitiveProperty ; + + rdfs:isDefinedBy ; + + skos:altLabel "ends" ; + + skos:definition "inverse of has end sequence [RO]" ; + + skos:prefLabel "is end sequence of" . + + + +### http://purl.obolibrary.org/obo/RO_0002522 + +ro:_0002522 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0002514 ; + + owl:inverseOf ro:_0002523 ; + + rdf:type owl:TransitiveProperty ; + + rdfs:isDefinedBy ; + + skos:definition "x bounds the sequence of y if and only if the upstream-most part of x is upstream of or coincident with the upstream-most part of y, and the downstream-most part of x is downstream of or coincident with the downstream-most part of y [RO]" ; + + skos:prefLabel "bounds sequence of" . + + + +### http://purl.obolibrary.org/obo/RO_0002523 + +ro:_0002523 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0002514 ; + + rdf:type owl:TransitiveProperty ; + + rdfs:isDefinedBy ; + + skos:definition "inverse of bounds sequence of [RO]" ; + + skos:prefLabel "is bound by sequence of" . + + + +### http://purl.obolibrary.org/obo/RO_0002524 + +ro:_0002524 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf bfo:_0000051 , + ro:_0002522 , + ro:_0002526 ; + + owl:inverseOf ro:_0002525 ; + + rdf:type owl:TransitiveProperty ; + + rdfs:isDefinedBy ; + + skos:altLabel "contains" ; + + skos:definition "x has subsequence y if and only if all of the sequence parts of x are sequence parts of y [RO]" ; + + skos:prefLabel "has subsequence" . + + + +### http://purl.obolibrary.org/obo/RO_0002525 + +ro:_0002525 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf bfo:_0000050 , + ro:_0002523 , + ro:_0002526 ; + + rdf:type owl:TransitiveProperty ; + + rdfs:isDefinedBy ; + + skos:altLabel "contained by" ; + + skos:definition "inverse of has subsequence [RO]" ; + + skos:prefLabel "is subsequence of" . + + + +### http://purl.obolibrary.org/obo/RO_0002526 + +ro:_0002526 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0002131 , + ro:_0002514 ; + + rdfs:isDefinedBy ; + + skos:definition "x overlaps the sequence of x if and only if x has a subsequence z and z is a subsequence of y. [RO]" ; + + skos:prefLabel "overlaps sequence of" . + + + +### http://purl.obolibrary.org/obo/RO_0002527 + +ro:_0002527 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0002514 ; + + rdf:type owl:SymmetricProperty ; + + rdfs:isDefinedBy ; + + skos:altLabel "disconnected from" ; + + skos:definition "x does not overlaps the sequence of x if and only if there is no z such that x has a subsequence z and z is a subsequence of y. [RO]" ; + + skos:prefLabel "does not overlap sequence of" . + + + +### http://purl.obolibrary.org/obo/RO_0002528 + +ro:_0002528 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0002527 ; + + owl:inverseOf ro:_0002529 ; + + rdf:type owl:TransitiveProperty ; + + rdfs:isDefinedBy ; + + skos:definition "inverse of downstream sequence of [RO]" ; + + skos:prefLabel "is upstream sequence of" . + + + +### http://purl.obolibrary.org/obo/RO_0002529 + +ro:_0002529 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0002527 ; + + rdf:type owl:TransitiveProperty ; + + rdfs:isDefinedBy ; + + skos:definition "x is downstream of the sequence of y if and only if either (1) x and y have sequence units, and all units of x are downstream of all units of y, or (2) x and y are sequence units, and x is either immediately downstream of y, or transitively downstream of y. [RO]" ; + + skos:prefLabel "is downstream of sequence of" . + + + +### http://purl.obolibrary.org/obo/RO_0002530 + +ro:_0002530 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0002515 , + ro:_0002529 ; + + owl:inverseOf ro:_0002531 ; + + rdfs:isDefinedBy ; + + skos:definition "x is immediately downstream of the sequence of y if and only if either (1) x and y have sequence units, and all units of x are downstream of all units of y, and x is sequentially adjacent to y, or (2) x and y are sequence units, in which case the immediately downstream relation is primitive and defined by context: for DNA bases, y would be adjacent and 5' to y [RO]" ; + + skos:prefLabel "is immediately downstream of sequence of" . + + + +### http://purl.obolibrary.org/obo/RO_0002531 + +ro:_0002531 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0002515 , + ro:_0002528 ; + + rdfs:isDefinedBy ; + + skos:definition "inverse of immediately downstream of [RO]" ; + + skos:prefLabel "is immediately upstream sequence of" . + + + +### http://purl.obolibrary.org/obo/RO_0002559 + +ro:_0002559 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0002506 ; + + owl:inverseOf ro:_0002566 ; + + rdfs:isDefinedBy ; + + skos:altLabel "causally influenced by" ; + + skos:prefLabel "causally influenced by (material entity to material entity)" . + + + +### http://purl.obolibrary.org/obo/RO_0002566 + +ro:_0002566 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0002506 ; + + rdfs:isDefinedBy ; + + skos:altLabel "causally influences" ; + + skos:definition "Holds between materal entities a and b if the activity of a is causally upstream of the activity of b, or causally upstream of a an activity that modifies b [RO]" ; + + skos:prefLabel "causally influences (material entity to material entity)" . + + + +### http://purl.obolibrary.org/obo/RO_0002570 + +ro:_0002570 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0002131 ; + + rdfs:domain bfo:_0000040 ; + + rdfs:range bfo:_0000040 ; + + rdfs:isDefinedBy ; + + skos:definition "X is a conduit for y if and only if y overlaps through the lumen_of of x, and y has parts on either side of the lumen of x. [RO]" ; + + skos:editorialNote "This relation holds between a thing with a 'conduit' (e.g. a bone foramen) and a 'conduee' (for example, a nerve) such that at the time the relationship holds, the conduee has two ends sticking out either end of the conduit. It should therefore note be used for objects that move through the conduit but whose spatial extent does not span the passage. For example, it would not be used for a mountain that contains a long tunnel through which trains pass. Nor would we use it for a digestive tract and objects such as food that pass through. [RO]" ; + + skos:prefLabel "conduit for" . + + + +### http://purl.obolibrary.org/obo/RO_0002584 + +ro:_0002584 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0002328 , + ro:_0002595 ; + + owl:propertyChainAxiom ( bfo:_0000051 + ro:_0002215 + ) ; + + rdfs:isDefinedBy ; + + skos:definition "S 'has part structure that is capable of' p if and only if there exists some part x such that s 'has part' x and x 'capable of' p [RO]" ; + + skos:prefLabel "has part structure that is capable of" . + + + +### http://purl.obolibrary.org/obo/RO_0002595 + +ro:_0002595 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0002410 ; + + rdfs:domain bfo:_0000040 ; + + rdfs:range bfo:_0000015 ; + + rdfs:isDefinedBy ; + + skos:definition "A relationship that holds between a material entity and a process in which causality is involved, with either the material entity or some part of the material entity exerting some influence over the process, or the process influencing some aspect of the material entity. [RO]" ; + + skos:prefLabel "causal relation between material entity and a process" . + + + +### http://purl.obolibrary.org/obo/RO_0002607 + +ro:_0002607 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0002610 ; + + rdfs:isDefinedBy ; + + skos:definition "C is marker for d if and only if the presence or occurrence of d is correlated with the presence of occurrence of c, and the observation of c is used to infer the presence or occurrence of d. Note that this does not imply that c and d are in a direct causal relationship, as it may be the case that there is a third entity e that stands in a direct causal relationship with c and d. [RO]" ; + + skos:prefLabel "is marker for" . + + + +### http://purl.obolibrary.org/obo/RO_0002609 + +ro:_0002609 rdf:type owl:ObjectProperty ; + + rdfs:isDefinedBy ; + + skos:definition "A relationship that holds between two entities, where the relationship holds based on the presence or absence of statistical dependence relationship. The entities may be statistical variables, or they may be other kinds of entities such as diseases, chemical entities or processes. [RO]" ; + + skos:editorialNote "Do not use this relation directly. It is intended as a grouping for a diverse set of relations, all involving cause and effect. [IAO]" ; + + skos:prefLabel "related via dependence to" . + + + +### http://purl.obolibrary.org/obo/RO_0002610 + +ro:_0002610 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0002609 ; + + rdfs:isDefinedBy ; + + skos:definition "A relationship that holds between two entities, where the entities exhibit a statistical dependence relationship. The entities may be statistical variables, or they may be other kinds of entities such as diseases, chemical entities or processes. [RO]" ; + + skos:editorialNote "Groups both positive and negative correlation" ; + + skos:prefLabel "correlated with" . + + + +### http://purl.obolibrary.org/obo/RO_0003000 + +ro:_0003000 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf owl:topObjectProperty ; + + owl:inverseOf ro:_0003001 ; + + rdfs:domain bfo:_0000040 ; + + rdfs:range bfo:_0000040 ; + + rdfs:isDefinedBy ; + + skos:definition "a produces b if some process that occurs_in a has_output b, where a and b are material entities. [RO]" ; + + skos:editorialNote "Note that this definition doesn't quite distinguish the output of a transformation process from a production process, which is related to the identity/granularity issue [RO]" ; + + skos:example "chondroblast produces avascular GAG-rich matrix" , + "hybridoma cell line produces monoclonal antibody reagent" ; + + skos:prefLabel "produces" . + + + +### http://purl.obolibrary.org/obo/RO_0003001 + +ro:_0003001 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf owl:topObjectProperty ; + + rdfs:domain bfo:_0000040 ; + + rdfs:range bfo:_0000040 ; + + rdfs:isDefinedBy ; + + skos:definition "inverse of produces" ; + + skos:prefLabel "produced by" . + + + +### http://purl.obolibrary.org/obo/RO_0003302 + +ro:_0003302 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0002410 ; + + rdfs:isDefinedBy ; + + skos:definition "A relationship between an entity (e.g. a genotype, genetic variation, chemical, or environmental exposure) and a condition (a phenotype or disease), where the entity has some causal or contributing role that influences the condition. [RO]" ; + + skos:prefLabel "causes or contributes to condition" . + + + +### http://purl.obolibrary.org/obo/RO_0003303 + +ro:_0003303 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0003302 ; + + rdfs:isDefinedBy ; + + skos:definition "A relationship between an entity (e.g. a genotype, genetic variation, chemical, or environmental exposure) and a condition (a phenotype or disease), where the entity has some causal role for the condition. [RO]" ; + + skos:prefLabel "causes condition" . + + + +### http://purl.obolibrary.org/obo/RO_0003304 + +ro:_0003304 rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf ro:_0003302 ; + + rdfs:isDefinedBy ; + + skos:definition "A relationship between an entity (e.g. a genotype, genetic variation, chemical, or environmental exposure) and a condition (a phenotype or disease), where the entity has some contributing role that influences the condition. [RO]" ; + + skos:prefLabel "contributes to condition" . + + + +### http://purl.org/linked-data/cube#attribute + +qb:attribute rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf qb:componentProperty ; + + rdfs:range qb:AttributeProperty ; + + rdfs:comment "An alternative to qb:componentProperty which makes explicit that the component is a attribute"@en ; + + rdfs:isDefinedBy ; + + rdfs:label "attribute"@en . + + + +### http://purl.org/linked-data/cube#codeList + +qb:codeList rdf:type owl:ObjectProperty ; + + rdfs:domain qb:CodedProperty ; + + rdfs:range [ rdf:type owl:Class ; + owl:unionOf ( qb:HierarchicalCodeList + skos:Collection + skos:ConceptScheme + ) + ] ; + + rdfs:comment "gives the code list associated with a CodedProperty"@en ; + + rdfs:isDefinedBy ; + + rdfs:label "code list"@en . + + + +### http://purl.org/linked-data/cube#component + +qb:component rdf:type owl:ObjectProperty ; + + rdfs:domain qb:DataStructureDefinition ; + + rdfs:range qb:ComponentSpecification ; + + rdfs:comment "indicates a component specification which is included in the structure of the dataset"@en ; + + rdfs:isDefinedBy ; + + rdfs:label "component specification"@en . + + + +### http://purl.org/linked-data/cube#componentAttachment + +qb:componentAttachment rdf:type owl:ObjectProperty ; + + rdfs:domain qb:ComponentSpecification ; + + rdfs:range rdfs:Class ; + + rdfs:comment "Indicates the level at which the component property should be attached, this might an qb:DataSet, qb:Slice or qb:Observation, or a qb:MeasureProperty."@en ; + + rdfs:isDefinedBy ; + + rdfs:label "component attachment"@en . + + + +### http://purl.org/linked-data/cube#componentProperty + +qb:componentProperty rdf:type owl:ObjectProperty ; + + rdfs:domain qb:ComponentSet ; + + rdfs:range qb:ComponentProperty ; + + rdfs:comment "indicates a ComponentProperty (i.e. attribute/dimension) expected on a DataSet, or a dimension fixed in a SliceKey"@en ; + + rdfs:isDefinedBy ; + + rdfs:label "component"@en . + + + +### http://purl.org/linked-data/cube#concept + +qb:concept rdf:type owl:ObjectProperty ; + + rdfs:domain qb:ComponentProperty ; + + rdfs:range skos:Concept ; + + rdfs:comment "gives the concept which is being measured or indicated by a ComponentProperty"@en ; + + rdfs:isDefinedBy ; + + rdfs:label "concept"@en . + + + +### http://purl.org/linked-data/cube#dataSet + +qb:dataSet rdf:type owl:ObjectProperty ; + + rdfs:domain qb:Observation ; + + rdfs:range qb:DataSet ; + + rdfs:comment "indicates the data set of which this observation is a part"@en ; + + rdfs:isDefinedBy ; + + rdfs:label "data set"@en . + + + +### http://purl.org/linked-data/cube#dimension + +qb:dimension rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf qb:componentProperty ; + + rdfs:range qb:DimensionProperty ; + + rdfs:comment "An alternative to qb:componentProperty which makes explicit that the component is a dimension"@en ; + + rdfs:isDefinedBy ; + + rdfs:label "dimension"@en . + + + +### http://purl.org/linked-data/cube#hierarchyRoot + +qb:hierarchyRoot rdf:type owl:ObjectProperty ; + + rdfs:domain qb:HierarchicalCodeList ; + + rdfs:comment "Specifies a root of the hierarchy. A hierarchy may have multiple roots but must have at least one."@en ; + + rdfs:isDefinedBy . + + + +### http://purl.org/linked-data/cube#measure + +qb:measure rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf qb:componentProperty ; + + rdfs:range qb:MeasureProperty ; + + rdfs:comment "An alternative to qb:componentProperty which makes explicit that the component is a measure"@en ; + + rdfs:isDefinedBy ; + + rdfs:label "measure"@en . + + + +### http://purl.org/linked-data/cube#measureDimension + +qb:measureDimension rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf qb:componentProperty ; + + rdfs:range qb:DimensionProperty ; + + rdfs:comment "An alternative to qb:componentProperty which makes explicit that the component is a measure dimension"@en ; + + rdfs:isDefinedBy ; + + rdfs:label "measure dimension"@en . + + + +### http://purl.org/linked-data/cube#measureType + +qb:measureType rdf:type owl:ObjectProperty ; + + rdfs:range qb:MeasureProperty . + + + +### http://purl.org/linked-data/cube#observation + +qb:observation rdf:type owl:ObjectProperty ; + + rdfs:domain qb:ObservationGroup ; + + rdfs:range qb:Observation ; + + rdfs:comment "indicates a observation contained within this slice of the data set"@en ; + + rdfs:isDefinedBy ; + + rdfs:label "observation"@en . + + + +### http://purl.org/linked-data/cube#observationGroup + +qb:observationGroup rdf:type owl:ObjectProperty ; + + rdfs:range qb:ObservationGroup ; + + rdfs:comment "Indicates a group of observations. The domain of this property is left open so that a group may be attached to different resources and need not be restricted to a single DataSet"@en ; + + rdfs:isDefinedBy ; + + rdfs:label "observation group"@en . + + + +### http://purl.org/linked-data/cube#parentChildProperty + +qb:parentChildProperty rdf:type owl:ObjectProperty ; + + rdfs:domain qb:HierarchicalCodeList ; + + rdfs:range rdf:Property ; + + rdfs:comment "Specifies a property which relates a parent concept in the hierarchy to a child concept."@en ; + + rdfs:isDefinedBy ; + + rdfs:label "parent-child property"@en . + + + +### http://purl.org/linked-data/cube#slice + +qb:slice rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf qb:observationGroup ; + + rdfs:domain qb:DataSet ; + + rdfs:range qb:Slice ; + + rdfs:comment "Indicates a subset of a DataSet defined by fixing a subset of the dimensional values"@en ; + + rdfs:isDefinedBy ; + + rdfs:label "slice"@en . + + + +### http://purl.org/linked-data/cube#sliceKey + +qb:sliceKey rdf:type owl:ObjectProperty ; + + rdfs:domain qb:DataStructureDefinition ; + + rdfs:range qb:SliceKey ; + + rdfs:comment "indicates a slice key which is used for slices in this dataset"@en ; + + rdfs:isDefinedBy ; + + rdfs:label "slice key"@en . + + + +### http://purl.org/linked-data/cube#sliceStructure + +qb:sliceStructure rdf:type owl:ObjectProperty ; + + rdfs:domain qb:Slice ; + + rdfs:range qb:SliceKey ; + + rdfs:comment "indicates the sub-key corresponding to this slice"@en ; + + rdfs:isDefinedBy ; + + rdfs:label "slice structure"@en . + + + +### http://purl.org/linked-data/cube#structure + +qb:structure rdf:type owl:ObjectProperty ; + + rdfs:domain qb:DataSet ; + + rdfs:range qb:DataStructureDefinition ; + + rdfs:comment "indicates the structure to which this data set conforms"@en ; + + rdfs:isDefinedBy ; + + rdfs:label "structure"@en . + + + +### http://qudt.org/schema/qudt#quantityKind + +qudt:quantityKind rdf:type owl:ObjectProperty ; + + rdfs:range qudt:QuantityKind ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + skos:prefLabel "has quantity kind" . + + + +### http://qudt.org/schema/qudt#quantityValue + +qudt:quantityValue rdf:type owl:ObjectProperty ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + skos:prefLabel "quantity value" . + + + +### http://qudt.org/schema/qudt#unit + +qudt:unit rdf:type owl:ObjectProperty ; + + rdfs:range qudt:Unit ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + skos:altLabel "has unit" ; + + skos:prefLabel "unit" . + + + +### http://www.w3.org/2004/02/skos/core#broadMatch + +skos:broadMatch rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf skos:broader , + skos:mappingRelation ; + + owl:inverseOf skos:narrowMatch ; + + rdfs:isDefinedBy ; + + rdfs:label "has broader match" ; + + skos:definition "skos:broadMatch is used to state a hierarchical mapping link between two conceptual resources in different concept schemes." . + + + +### http://www.w3.org/2004/02/skos/core#broader + +skos:broader rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf skos:broaderTransitive ; + + owl:inverseOf skos:narrower ; + + rdfs:comment "Broader concepts are typically rendered as parents in a concept hierarchy (tree)." ; + + rdfs:isDefinedBy ; + + rdfs:label "has broader" ; + + skos:definition "Relates a concept to a concept that is more general in meaning." ; + + skos:scopeNote "By convention, skos:broader is only used to assert an immediate (i.e. direct) hierarchical link between two conceptual resources." . + + + +### http://www.w3.org/2004/02/skos/core#broaderTransitive + +skos:broaderTransitive rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf skos:semanticRelation ; + + owl:inverseOf skos:narrowerTransitive ; + + rdf:type owl:TransitiveProperty ; + + rdfs:isDefinedBy ; + + rdfs:label "has broader transitive" ; + + skos:definition "skos:broaderTransitive is a transitive superproperty of skos:broader." ; + + skos:scopeNote "By convention, skos:broaderTransitive is not used to make assertions. Rather, the properties can be used to draw inferences about the transitive closure of the hierarchical relation, which is useful e.g. when implementing a simple query expansion algorithm in a search application." . + + + +### http://www.w3.org/2004/02/skos/core#closeMatch + +skos:closeMatch rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf skos:mappingRelation ; + + rdf:type owl:SymmetricProperty ; + + rdfs:isDefinedBy ; + + rdfs:label "has close match" ; + + skos:definition "skos:closeMatch is used to link two concepts that are sufficiently similar that they can be used interchangeably in some information retrieval applications. In order to avoid the possibility of \"compound errors\" when combining mappings across more than two concept schemes, skos:closeMatch is not declared to be a transitive property." . + + + +### http://www.w3.org/2004/02/skos/core#exactMatch + +skos:exactMatch rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf skos:closeMatch ; + + rdf:type owl:SymmetricProperty , + owl:TransitiveProperty ; + + rdfs:comment "skos:exactMatch is disjoint with each of the properties skos:broadMatch and skos:relatedMatch." ; + + rdfs:isDefinedBy ; + + rdfs:label "has exact match" ; + + skos:definition "skos:exactMatch is used to link two concepts, indicating a high degree of confidence that the concepts can be used interchangeably across a wide range of information retrieval applications. skos:exactMatch is a transitive property, and is a sub-property of skos:closeMatch." . + + + +### http://www.w3.org/2004/02/skos/core#hasTopConcept + +skos:hasTopConcept rdf:type owl:ObjectProperty ; + + owl:inverseOf skos:topConceptOf ; + + rdfs:domain skos:ConceptScheme ; + + rdfs:range skos:Concept ; + + rdfs:isDefinedBy ; + + rdfs:label "has top concept" ; + + skos:definition "Relates, by convention, a concept scheme to a concept which is topmost in the broader/narrower concept hierarchies for that scheme, providing an entry point to these hierarchies." . + + + +### http://www.w3.org/2004/02/skos/core#inScheme + +skos:inScheme rdf:type owl:ObjectProperty ; + + rdfs:range skos:ConceptScheme ; + + rdfs:isDefinedBy ; + + rdfs:label "is in scheme" ; + + skos:definition "Relates a resource (for example a concept) to a concept scheme in which it is included." ; + + skos:scopeNote "A concept may be a member of more than one concept scheme." . + + + +### http://www.w3.org/2004/02/skos/core#mappingRelation + +skos:mappingRelation rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf skos:semanticRelation ; + + rdfs:comment "These concept mapping relations mirror semantic relations, and the data model defined below is similar (with the exception of skos:exactMatch) to the data model defined for semantic relations. A distinct vocabulary is provided for concept mapping relations, to provide a convenient way to differentiate links within a concept scheme from links between concept schemes. However, this pattern of usage is not a formal requirement of the SKOS data model, and relies on informal definitions of best practice." ; + + rdfs:isDefinedBy ; + + rdfs:label "is in mapping relation with" ; + + skos:definition "Relates two concepts coming, by convention, from different schemes, and that have comparable meanings" . + + + +### http://www.w3.org/2004/02/skos/core#member + +skos:member rdf:type owl:ObjectProperty ; + + rdfs:domain skos:Collection ; + + rdfs:range [ rdf:type owl:Class ; + owl:unionOf ( skos:Collection + skos:Concept + ) + ] ; + + rdfs:isDefinedBy ; + + rdfs:label "has member" ; + + skos:definition "Relates a collection to one of its members." . + + + +### http://www.w3.org/2004/02/skos/core#memberList + +skos:memberList rdf:type owl:ObjectProperty , + owl:FunctionalProperty ; + + rdfs:domain skos:OrderedCollection ; + + rdfs:comment """For any resource, every item in the list given as the value of the + skos:memberList property is also a value of the skos:member property.""" ; + + rdfs:isDefinedBy ; + + rdfs:label "has member list" ; + + skos:definition "Relates an ordered collection to the RDF list containing its members." . + + + +### http://www.w3.org/2004/02/skos/core#narrowMatch + +skos:narrowMatch rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf skos:mappingRelation , + skos:narrower ; + + rdfs:isDefinedBy ; + + rdfs:label "has narrower match" ; + + skos:definition "skos:narrowMatch is used to state a hierarchical mapping link between two conceptual resources in different concept schemes." . + + + +### http://www.w3.org/2004/02/skos/core#narrower + +skos:narrower rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf skos:narrowerTransitive ; + + rdfs:comment "Narrower concepts are typically rendered as children in a concept hierarchy (tree)." ; + + rdfs:isDefinedBy ; + + rdfs:label "has narrower" ; + + skos:definition "Relates a concept to a concept that is more specific in meaning." ; + + skos:scopeNote "By convention, skos:broader is only used to assert an immediate (i.e. direct) hierarchical link between two conceptual resources." . + + + +### http://www.w3.org/2004/02/skos/core#narrowerTransitive + +skos:narrowerTransitive rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf skos:semanticRelation ; + + rdf:type owl:TransitiveProperty ; + + rdfs:isDefinedBy ; + + rdfs:label "has narrower transitive" ; + + skos:definition "skos:narrowerTransitive is a transitive superproperty of skos:narrower." ; + + skos:scopeNote "By convention, skos:narrowerTransitive is not used to make assertions. Rather, the properties can be used to draw inferences about the transitive closure of the hierarchical relation, which is useful e.g. when implementing a simple query expansion algorithm in a search application." . + + + +### http://www.w3.org/2004/02/skos/core#related + +skos:related rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf skos:semanticRelation ; + + rdf:type owl:SymmetricProperty ; + + rdfs:comment "skos:related is disjoint with skos:broaderTransitive" ; + + rdfs:isDefinedBy ; + + rdfs:label "has related" ; + + skos:definition "Relates a concept to a concept with which there is an associative semantic relationship." . + + + +### http://www.w3.org/2004/02/skos/core#relatedMatch + +skos:relatedMatch rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf skos:mappingRelation , + skos:related ; + + rdf:type owl:SymmetricProperty ; + + rdfs:isDefinedBy ; + + rdfs:label "has related match" ; + + skos:definition "skos:relatedMatch is used to state an associative mapping link between two conceptual resources in different concept schemes." . + + + +### http://www.w3.org/2004/02/skos/core#semanticRelation + +skos:semanticRelation rdf:type owl:ObjectProperty ; + + rdfs:domain skos:Concept ; + + rdfs:range skos:Concept ; + + rdfs:isDefinedBy ; + + rdfs:label "is in semantic relation with" ; + + skos:definition "Links a concept to a concept related by meaning." ; + + skos:scopeNote "This property should not be used directly, but as a super-property for all properties denoting a relationship of meaning between concepts." . + + + +### http://www.w3.org/2004/02/skos/core#topConceptOf + +skos:topConceptOf rdf:type owl:ObjectProperty ; + + rdfs:subPropertyOf skos:inScheme ; + + rdfs:domain skos:Concept ; + + rdfs:range skos:ConceptScheme ; + + rdfs:isDefinedBy ; + + rdfs:label "is top concept in scheme" ; + + skos:definition "Relates a concept to the concept scheme that it is a top level concept of." . + + + +### http://xmlns.com/foaf/0.1/homepage + +foaf:homepage rdf:type owl:ObjectProperty . + + + +### http://xmlns.com/foaf/0.1/mbox + +foaf:mbox rdf:type owl:ObjectProperty . + + + + + +################################################################# +# +# Data properties +# +################################################################# + + +### http://purl.allotrope.org/ontologies/property#AFX_0000604 + +af-x:AFX_0000604 rdf:type owl:DatatypeProperty ; + + rdfs:range [ rdf:type rdfs:Datatype ; + owl:onDatatype xsd:integer ; + owl:withRestrictions ( [ xsd:minInclusive 0 + ] + ) + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "number of objects" , + "objects count" , + "size" ; + + skos:definition "The number of objects counted. [Allotrope]" ; + + skos:prefLabel "count" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0000670 + +af-x:AFX_0000670 rdf:type owl:DatatypeProperty ; + + rdfs:isDefinedBy ; + + skos:definition "The lowest value of a range of literals. [Allotrope]" ; + + skos:prefLabel "minimum value" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0000671 + +af-x:AFX_0000671 rdf:type owl:DatatypeProperty ; + + rdfs:subPropertyOf af-x:AFX_0000670 ; + + rdfs:isDefinedBy ; + + skos:definition "The lowest value of a range excluding the boundary value. [Allotrope]" ; + + skos:prefLabel "minimum value exclusive" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0000672 + +af-x:AFX_0000672 rdf:type owl:DatatypeProperty ; + + rdfs:subPropertyOf af-x:AFX_0000670 ; + + rdfs:isDefinedBy ; + + skos:definition "The lowest value of a range including the boundary value. [Allotrope]" ; + + skos:prefLabel "minimum value inclusive" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0000674 + +af-x:AFX_0000674 rdf:type owl:DatatypeProperty ; + + rdfs:isDefinedBy ; + + skos:definition "The highest value of a range of literals. [Allotrope]" ; + + skos:prefLabel "maximum value" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0000675 + +af-x:AFX_0000675 rdf:type owl:DatatypeProperty ; + + rdfs:subPropertyOf af-x:AFX_0000674 ; + + rdfs:isDefinedBy ; + + skos:definition "The highest value of a range excluding the boundary value. [Allotrope]" ; + + skos:prefLabel "maximum value exclusive" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0000676 + +af-x:AFX_0000676 rdf:type owl:DatatypeProperty ; + + rdfs:subPropertyOf af-x:AFX_0000674 ; + + rdfs:isDefinedBy ; + + skos:definition "The highest value of a range including the boundary value. [Allotrope]" ; + + skos:prefLabel "maximum value inclusive" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0000678 + +af-x:AFX_0000678 rdf:type owl:DatatypeProperty ; + + rdfs:isDefinedBy ; + + skos:altLabel "valid" ; + + skos:definition "The property flags an information as correct and without errors. [Allotrope]" ; + + skos:prefLabel "is valid" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0000684 + +af-x:AFX_0000684 rdf:type owl:DatatypeProperty ; + + rdfs:range [ rdf:type rdfs:Datatype ; + owl:onDatatype xsd:integer ; + owl:withRestrictions ( [ xsd:minInclusive 0 + ] + ) + ] ; + + rdfs:isDefinedBy ; + + skos:definition "Position in an ordered list. [Allotrope]" ; + + skos:prefLabel "index" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0000685 + +af-x:AFX_0000685 rdf:type owl:DatatypeProperty ; + + rdfs:isDefinedBy ; + + skos:altLabel "step size value" ; + + skos:definition "The difference between two discrete points next to each other in a range of discrete values. [Allotrope]" ; + + skos:example "A device property can be set between a minimum and maximum value but only in steps of the increment value." ; + + skos:prefLabel "increment value" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0000690 + +af-x:AFX_0000690 rdf:type owl:DatatypeProperty ; + + rdfs:isDefinedBy ; + + skos:altLabel "value" ; + + skos:definition "The literal piece of information as part of some information entity object. [Allotrope]" ; + + skos:prefLabel "has value" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0001198 + +af-x:AFX_0001198 rdf:type owl:DatatypeProperty ; + + rdfs:subPropertyOf af-x:AFX_0000604 ; + + rdfs:domain af-c:AFC_0000166 ; + + rdfs:isDefinedBy ; + + skos:altLabel "count" , + "length" , + "size" ; + + skos:definition "The collection size is the number of entries in a collection. [Allotrope]" ; + + skos:prefLabel "collection size" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0001732 + +af-x:AFX_0001732 rdf:type owl:DatatypeProperty ; + + rdfs:subPropertyOf af-x:AFX_0000690 ; + + rdfs:isDefinedBy ; + + skos:definition "A value that used as a basis for comparison. [Allotrope]" ; + + skos:prefLabel "reference value" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0002705 + +af-x:AFX_0002705 rdf:type owl:DatatypeProperty ; + + rdfs:domain af-r:AFR_0000958 ; + + rdfs:range [ rdf:type rdfs:Datatype ; + owl:onDatatype xsd:integer ; + owl:withRestrictions ( [ xsd:minInclusive 0 + ] + ) + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "degree" , + "order" , + "rank" ; + + skos:definition "Tensor rank is the total number of indices required to identify each component of a tensor uniquely. It is equal to the dimension of the tensor. [Wikipedia]" ; + + skos:prefLabel "tensor rank" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0002742 + +af-x:AFX_0002742 rdf:type owl:DatatypeProperty ; + + rdfs:range [ rdf:type rdfs:Datatype ; + owl:onDatatype xsd:integer ; + owl:withRestrictions ( [ xsd:minInclusive 0 + ] + ) + ] ; + + rdfs:isDefinedBy ; + + skos:definition "The second index value in a multi-dimensional datum. [Allotrope]" ; + + skos:prefLabel "index 1" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0002743 + +af-x:AFX_0002743 rdf:type owl:DatatypeProperty ; + + rdfs:range [ rdf:type rdfs:Datatype ; + owl:onDatatype xsd:integer ; + owl:withRestrictions ( [ xsd:minInclusive 0 + ] + ) + ] ; + + rdfs:isDefinedBy ; + + skos:definition "The first index value in a multi-dimensional datum. [Allotrope]" ; + + skos:prefLabel "index 0" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0002861 + +af-x:AFX_0002861 rdf:type owl:DatatypeProperty ; + + rdfs:subPropertyOf af-x:AFX_0000671 ; + + rdfs:isDefinedBy ; + + skos:altLabel "error min exclusive" ; + + skos:definition "Minimum error exclusive is the absolute error amount (exclusive) by which the actual value could be lower than the stated value. [Allotrope]" ; + + skos:prefLabel "minimum error exclusive" . + + + +### http://purl.allotrope.org/ontologies/property#AFX_0002862 + +af-x:AFX_0002862 rdf:type owl:DatatypeProperty ; + + rdfs:subPropertyOf af-x:AFX_0000675 ; + + rdfs:isDefinedBy ; + + skos:altLabel "error max exclusive" ; + + skos:definition "Maximum error exclusive is the absolute error amount (exclusive) by which the actual value could be higher than the stated value. [Allotrope]" ; + + skos:prefLabel "maximum error exclusive" . + + + +### http://purl.org/linked-data/cube#componentRequired + +qb:componentRequired rdf:type owl:DatatypeProperty ; + + rdfs:domain qb:ComponentSpecification ; + + rdfs:range xsd:boolean ; + + rdfs:comment """Indicates whether a component property is required (true) or optional (false) in the context of a DSD. Only applicable + to components correspond to an attribute. Defaults to false (optional)."""@en ; + + rdfs:isDefinedBy ; + + rdfs:label "component required"@en . + + + +### http://purl.org/linked-data/cube#order + +qb:order rdf:type owl:DatatypeProperty ; + + rdfs:domain qb:ComponentSpecification ; + + rdfs:range xsd:int ; + + rdfs:comment "indicates a priority order for the components of sets with this structure, used to guide presentations - lower order numbers come before higher numbers, un-numbered components come last"@en ; + + rdfs:isDefinedBy ; + + rdfs:label "order"@en . + + + +### http://qudt.org/schema/qudt#numericValue + +qudt:numericValue rdf:type owl:DatatypeProperty ; + + rdfs:range xsd:double ; + + rdfs:isDefinedBy ; + + skos:prefLabel "numeric value" . + + + +### http://qudt.org/schema/qudt#relativeStandardUncertainty + +qudt:relativeStandardUncertainty rdf:type owl:DatatypeProperty ; + + rdfs:range xsd:double ; + + rdfs:isDefinedBy ; + + skos:definition "The relative standard uncertainty of a measurement is the (absolute) standard uncertainty divided by the magnitude of the exact value. [QUDT]" ; + + skos:prefLabel "relative standard uncertainty" . + + + +### http://qudt.org/schema/qudt#standardUncertainty + +qudt:standardUncertainty rdf:type owl:DatatypeProperty ; + + rdfs:range xsd:double ; + + rdfs:isDefinedBy ; + + skos:definition "The standard uncertainty of a quantity is the estimated standard deviation of the mean taken from a series of measurements. [QUDT]" ; + + skos:prefLabel "standard uncertainty" . + + + +### http://qudt.org/schema/qudt#symbol + +qudt:symbol rdf:type owl:DatatypeProperty ; + + rdfs:range xsd:string ; + + rdfs:isDefinedBy ; + + skos:definition "The symbol for a unit is a glyph that is used to represent the unit in a compact form. [QUDT]" ; + + skos:example "For example, the symbol for the US Dollar is $. This contrasts with unit:abbreviation, which gives a short alphanumeric abbreviation for the unit. (I.e. USD for US Dollar). [QUDT]" ; + + skos:prefLabel "symbol" . + + + +### http://www.w3.org/2004/02/skos/core#notation + +skos:notation rdf:type owl:DatatypeProperty ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy , + ; + + rdfs:label "notation" ; + + skos:definition "A notation, also known as classification code, is a string of characters such as \"T58.5\" or \"303.4833\" used to uniquely identify a concept within the scope of a given concept scheme." ; + + skos:prefLabel "notation" ; + + skos:scopeNote "By convention, skos:notation is used with a typed literal in the object position of the triple." . + + + +### http://xmlns.com/foaf/0.1/name + +foaf:name rdf:type owl:DatatypeProperty . + + + + + +################################################################# +# +# Classes +# +################################################################# + + +### http://purl.allotrope.org/ontologies/common#AFC_0000021 + +af-c:AFC_0000021 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000923 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A range is an interval of values with a lower and/or upper limit. [Allotrope]" ; + + skos:prefLabel "range" . + + + +### http://purl.allotrope.org/ontologies/common#AFC_0000036 + +af-c:AFC_0000036 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001059 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A set of codes in a controlled vocabulary. [Allotrope]" ; + + skos:prefLabel "codelist" . + + + +### http://purl.allotrope.org/ontologies/common#AFC_0000050 + +af-c:AFC_0000050 rdf:type owl:Class ; + + rdfs:subClassOf iao:_0000028 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + dct:source "2020-12-01 Changed parent to symbol. [Allotrope]" ; + + rdfs:isDefinedBy ; + + skos:altLabel "categorical value" , + "enumeration value" ; + + skos:definition "An entry in a list of controlled symbols denoting a classification. [Allotrope]" ; + + skos:prefLabel "code" . + + + +### http://purl.allotrope.org/ontologies/common#AFC_0000090 + +af-c:AFC_0000090 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000991 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A condition is an information content entity that is about the portion of reality under which something occurs or is valid. The condition is limited by its scope and may have preconditions. It restricts the possible realizations. [Allotrope]" ; + + skos:prefLabel "condition" . + + + +### http://purl.allotrope.org/ontologies/common#AFC_0000091 + +af-c:AFC_0000091 rdf:type owl:Class ; + + rdfs:subClassOf af-c:AFC_0000090 , + [ owl:intersectionOf ( af-c:AFC_0000166 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0002351 ; + owl:someValuesFrom af-c:AFC_0000090 + ] + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "and" ; + + skos:changeNote "2020-01-07 Changed definition. [Allotrope]" ; + + skos:definition "An and condition is a collection of conditions that is valid if all condition items of it are valid. [Allotrope]" ; + + skos:prefLabel "and condition" . + + + +### http://purl.allotrope.org/ontologies/common#AFC_0000092 + +af-c:AFC_0000092 rdf:type owl:Class ; + + rdfs:subClassOf af-c:AFC_0000090 , + [ owl:intersectionOf ( af-c:AFC_0000166 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0002351 ; + owl:someValuesFrom af-c:AFC_0000090 + ] + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "or" ; + + skos:changeNote "2020-01-07 Changed definition. [Allotrope]" ; + + skos:definition "An or condition is a collection of conditions that is valid if at least one of its condition items is valid. [Allotrope]" ; + + skos:prefLabel "or condition" . + + + +### http://purl.allotrope.org/ontologies/common#AFC_0000093 + +af-c:AFC_0000093 rdf:type owl:Class ; + + rdfs:subClassOf af-c:AFC_0000090 , + [ owl:intersectionOf ( af-c:AFC_0000166 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0002351 ; + owl:someValuesFrom af-c:AFC_0000090 + ] + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "exclusive or condition" , + "one of" , + "xor" , + "xor condition" ; + + skos:changeNote "2020-01-07 Changed definition. [Allotrope]" ; + + skos:definition "A one of condition is a collection of conditions that is valid if exactly one of its condition items is valid. [Allotrope]" ; + + skos:prefLabel "one of condition" . + + + +### http://purl.allotrope.org/ontologies/common#AFC_0000160 + +af-c:AFC_0000160 rdf:type owl:Class ; + + rdfs:subClassOf af-c:AFC_0000166 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "sequence" ; + + skos:definition "A list is an ordered collection of items. [Allotrope]" ; + + skos:prefLabel "list" . + + + +### http://purl.allotrope.org/ontologies/common#AFC_0000161 + +af-c:AFC_0000161 rdf:type owl:Class ; + + owl:equivalentClass [ rdf:type owl:Restriction ; + owl:onProperty ro:_0002350 ; + owl:someValuesFrom af-c:AFC_0000160 + ] ; + + rdfs:subClassOf af-c:AFC_0000167 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "item" ; + + skos:definition "An entry in a list. [Allotrope]" ; + + skos:prefLabel "list item" . + + + +### http://purl.allotrope.org/ontologies/common#AFC_0000162 + +af-c:AFC_0000162 rdf:type owl:Class ; + + rdfs:subClassOf af-c:AFC_0000160 , + [ owl:intersectionOf ( af-c:AFC_0000160 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000551 ; + owl:allValuesFrom af-c:AFC_0000163 + ] + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0002351 ; + owl:allValuesFrom af-c:AFC_0000163 + ] + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A series is a list (ordered collection) of literal values. [Allotrope]" ; + + skos:prefLabel "series" . + + + +### http://purl.allotrope.org/ontologies/common#AFC_0000163 + +af-c:AFC_0000163 rdf:type owl:Class ; + + owl:equivalentClass [ rdf:type owl:Restriction ; + owl:onProperty ro:_0002350 ; + owl:someValuesFrom af-c:AFC_0000162 + ] ; + + rdfs:subClassOf af-c:AFC_0000161 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "An individual entry in a series with an index and a numeric value. [Allotrope]" ; + + skos:prefLabel "series item" . + + + +### http://purl.allotrope.org/ontologies/common#AFC_0000166 + +af-c:AFC_0000166 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001054 ; + + rdfs:isDefinedBy ; + + skos:definition "An aggregation of data items for a purpose. [Allotrope]" ; + + skos:note "A collection itself is never an object aggregate, but an abstraction and might be about an object aggregate." ; + + skos:prefLabel "collection" . + + + +### http://purl.allotrope.org/ontologies/common#AFC_0000167 + +af-c:AFC_0000167 rdf:type owl:Class ; + + owl:equivalentClass [ rdf:type owl:Restriction ; + owl:onProperty ro:_0002350 ; + owl:someValuesFrom af-c:AFC_0000166 + ] ; + + rdfs:subClassOf af-r:AFR_0001054 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "element" ; + + skos:definition "An item is an individual member of some collection. [Allotrope]" ; + + skos:note "The item is not a physical object that is member of an object aggregate, but is an abstraction that might be about such an object." ; + + skos:prefLabel "item" . + + + +### http://purl.allotrope.org/ontologies/common#AFC_0000168 + +af-c:AFC_0000168 rdf:type owl:Class ; + + rdfs:subClassOf af-c:AFC_0000166 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A collection where each member is disjoint from another. [Allotrope]" ; + + skos:prefLabel "set" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000004 + +af-e:AFE_0000004 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000354 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000085 ; + owl:someValuesFrom [ rdf:type owl:Class ; + owl:unionOf ( af-fn:AFFN_0000137 + af-fn:AFFN_0000196 + ) + ] + ] ; + + dct:source "Bernhard Wolf (31 August 1995). Handbook of Ion Sources. CRC Press. ISBN 978-0-8493-2502-1." ; + + rdfs:isDefinedBy ; + + skos:altLabel "ionization source" ; + + skos:definition "A ion source is a device that has the function to produce or provide ions. [Allotrope]" ; + + skos:example "ion source of a mass spectrometer" ; + + skos:prefLabel "ion source" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000014 + +af-e:AFE_0000014 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( af-e:AFE_0000354 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000939 ; + owl:someValuesFrom af-e:AFE_0002153 + ] + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "piping components" , + "piping equipment" , + "plumbing components" , + "tubing components" , + "tubing equipment" ; + + skos:definition "Plumbing equipment are devices used as components of a plumbing system. [Allotrope]" ; + + skos:prefLabel "plumbing equipment" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000022 + +af-e:AFE_0000022 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000322 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A sample passage is the compartment of a device that handles the conveying of samples. [Allotrope]" ; + + skos:prefLabel "sample passage" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000023 + +af-e:AFE_0000023 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0002145 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A piece of apparatus that is used to measure the heat of chemical reactions or physical changes. [CHMO]" ; + + skos:prefLabel "calorimeter" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000024 + +af-e:AFE_0000024 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000392 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000056 ; + owl:someValuesFrom af-p:AFP_0000310 + ] ; + + af-x:AFX_0002809 chmo:_0002478 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "GC device" , + "gas chromatography device" ; + + skos:changeNote "2019-07-03 Changed alt labels from system to device [Allotrope]" , + "2020-03-20 Added restriction. [Allotrope]" ; + + skos:definition "A piece of apparatus, consisting of a gas supply system, an injection or sampling system, a column, detector and a data acquisition/processing system, that is used to carry out chromatographic separations. [CHMO]" ; + + skos:prefLabel "gas chromatograph" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000029 + +af-e:AFE_0000029 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0002231 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "block" , + "plate" , + "well block" ; + + skos:changeNote "2020-06-22 Moved under tray. [Allotrope]" , + "2020-12-10 Added labels. [Allotrope]" ; + + skos:definition "A plate is a tray with multiple \"wells\" used as small test tubes. [Wikipedia]" ; + + skos:prefLabel "well plate" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000038 + +af-e:AFE_0000038 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0002157 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "mass analyzer" ; + + skos:definition "A mass-to-charge analyzer is a separation device that separates ionized masses by their mass to charge ratio. [Allotrope]" ; + + skos:prefLabel "mass-to-charge analyzer" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000073 + +af-e:AFE_0000073 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0001711 ; + + af-x:AFX_0002808 chmo:_0002579 , + obi:_0000555 ; + + rdfs:isDefinedBy ; + + skos:altLabel "AS" , + "automated sampler" , + "autosampler module" ; + + skos:definition "A piece of equipment that allows for automated sampling or sample loading. [Allotrope]" ; + + skos:prefLabel "autosampler" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000074 + +af-e:AFE_0000074 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0002158 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000972 ; + owl:someValuesFrom af-e:AFE_0000354 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "system" ; + + skos:changeNote "2020-03-24 Added restriction. [Allotrope]" ; + + skos:definition "An artificial system that is mainly composed of devices. [Allotrope]" ; + + skos:prefLabel "device system" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000078 + +af-e:AFE_0000078 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000217 ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + af-x:AFX_0002809 chmo:_0000987 ; + + rdfs:isDefinedBy ; + + skos:definition "A piece of apparatus that has the form of a tube with a diameter of less than a millimeter and hosts the stationary bed in chromatography. [CHMO]" ; + + skos:prefLabel "capillary column" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000085 + +af-e:AFE_0000085 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000855 ; + + rdfs:isDefinedBy ; + + skos:definition "A piece of apparatus, consisting of an electrolytic cell, that is used to determine electric charge by measuring the amount of an element deposited or released at the cathode during a specified time. [Allotrope]" ; + + skos:prefLabel "electrochemical coulometer" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000088 + +af-e:AFE_0000088 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0002172 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + dct:license ; + + dct:rights ; + + dct:source "L.S. Ettre, \"Nomenclature for Chromatography\", Pure & Appl. Chem. 1993, Vol. 65, No. 4, pp. 819-872" ; + + rdfs:isDefinedBy ; + + skos:definition "A fraction collector is a collecting device for recovering fractional volumes of the column effluent. [IUPAC]" ; + + skos:prefLabel "fraction collector" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000090 + +af-e:AFE_0000090 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000317 , + af-e:AFE_0000734 , + af-e:AFE_0002200 ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + af-x:AFX_0002809 chmo:_0002503 ; + + rdfs:isDefinedBy ; + + skos:altLabel "DAD" , + "PDA" , + "PDAD" , + "photodiode array detector" ; + + skos:definition "A piece of apparatus, consisting of a two-dimensional pattern of diodes and a prism, that is used to detect organic compounds. As the sample passes through a cell or cuvette it is illuminated with light in the region 190-1100 nm and any light transmitted through the sample is dispersed by the prism, so that light of different wavelengths falls on different diodes. The output from the array is used to construct an absorption spectrum that can be compared with standard spectra for identification purposes. Alternatively, a single diode can be used to monitor a specific wavelength at which there is maximum absorption. [CHMO]" ; + + skos:prefLabel "diode array detector" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000097 + +af-e:AFE_0000097 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0002250 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "EMR source" , + "light source" ; + + skos:definition "A source of a range of electromagnetic waves. [Allotrope]" ; + + skos:prefLabel "electromagnetic radiation source" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000105 + +af-e:AFE_0000105 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000646 ; + + rdfs:isDefinedBy ; + + skos:definition "A flow cell is a measurement chamber that allows the sample to flow through. [Allotrope]" ; + + skos:prefLabel "flow cell" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000107 + +af-e:AFE_0000107 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000085 ; + + rdfs:isDefinedBy ; + + skos:altLabel "Karl Fischer coulometer" , + "Karl Fischer coulometric titrator" ; + + skos:definition "A Karl-Fischer coulometer is a piece of apparatus, consisting of an electrolytic cell with an anodic compartment containing sulfur dioxide (SO2), iodide and a cathodic compartment containing the sample, which is used to determine trace amounts of water in a sample by measuring the time and current flow required to reach the titration end-point. [CHMO]" ; + + skos:prefLabel "Karl-Fischer coulometer" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000114 + +af-e:AFE_0000114 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000753 ; + + dct:license ; + + dct:rights ; + + dct:source "K. K. Murray, R. K. Boyd, M. N. Eberlin, G. J. Langley, L. Li and Y. Naito, Pure Appl. Chem., 2013, 85, 1515-1609" ; + + rdfs:isDefinedBy ; + + skos:definition "A skimmer is a cone with a central orifice that intercepts the center of a spray or jet expansion to sample the central portion of the expansion, for example, as in a momentum separator. [IUPAC]" ; + + skos:prefLabel "skimmer" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000129 + +af-e:AFE_0000129 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000825 , + af-e:AFE_0001745 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000056 ; + owl:someValuesFrom af-p:AFP_0001404 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "light microscope" ; + + skos:definition "An optical microscope is a microscope that is consisting of an eyepiece, an objective lens, object turret, stage, and light source, which collects electromagnetic radiation in the visible range. [CHMO]" ; + + skos:prefLabel "optical microscope" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000135 + +af-e:AFE_0000135 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000217 ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A chromatography column used for analysis. [Allotrope]" ; + + skos:prefLabel "analytical column" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000139 + +af-e:AFE_0000139 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000812 ; + + rdfs:isDefinedBy ; + + skos:altLabel "stirring rod" ; + + skos:definition "An overhead stirrer is a stirrer that is made up of a stirring rod with a paddle, anchor or propeller end that is driven by an overhead motor on a stand. [Allotrope]" ; + + skos:prefLabel "overhead stirrer" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000145 + +af-e:AFE_0000145 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0002235 ; + + rdfs:isDefinedBy ; + + skos:altLabel "channel" , + "communication channel" ; + + skos:definition "A communication channel or channel, refers either to a physical transmission medium such as a wire, or to a logical connection over a multiplexed medium such as a radio channel. A channel is used to convey an information signal, for example a digital bit stream, from one or several senders (or transmitters) to one or several receivers. [Wikipedia]" ; + + skos:prefLabel "channel (communication)" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000153 + +af-e:AFE_0000153 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000407 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A reactor is a container for controlling a biological or chemical reaction or process. [Allotrope]" ; + + skos:prefLabel "reactor" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000158 + +af-e:AFE_0000158 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000354 ; + + rdfs:isDefinedBy ; + + skos:definition "A piece of apparatus that is planar and is or hosts the stationary bed in chromatography. [CHMO]" ; + + skos:prefLabel "open chromatographic bed" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000161 + +af-e:AFE_0000161 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000266 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000974 ; + owl:someValuesFrom af-e:AFE_0000462 + ] , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0001025 ; + owl:someValuesFrom af-e:AFE_0000024 + ] ; + + dct:source "K. Grob, Split and Splitless Injection for Quantitative Gas Chromatography: Concepts, Processes, Practical Guidelines, Sources of Error, 4th, Completely Revised Edition (Wiley, Hoboken, New Jersey, 2001)." ; + + rdfs:isDefinedBy ; + + skos:altLabel "GC injector" , + "GC inlet" , + "column injector" , + "column inlet" , + "gas chromatograph injector" ; + + skos:definition "An inlet into a gas chromatograph. [Allotrope]" ; + + skos:prefLabel "gas chromatograph inlet" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000171 + +af-e:AFE_0000171 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000224 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000056 ; + owl:someValuesFrom af-p:AFP_0002059 + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "RRLC" , + "RSLC" , + "UFLC" , + "UHPLC" , + "UPLC" , + "rapid resolution liquid chromatograph" , + "rapid separation liquid chromatograph" , + "ultra fast liquid chromatograph" , + "ultra performance liquid chromatograph" ; + + skos:changeNote "2020-03-20 Changed equivalentClass to subClass. [Allotrope]" ; + + skos:definition "Liquid chromatograph that implements the ultra high-performance liquid chromatography. [Allotrope]" ; + + skos:prefLabel "ultra high-performance liquid chromatograph" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000185 + +af-e:AFE_0000185 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0001515 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:changeNote "2018-03-06 Changed definition to Aristotelian form. [Allotrope]" ; + + skos:definition "A spectrophotometer is a photometer that measures the intensity of light at each individual wavelength. [Allotrope]" ; + + skos:prefLabel "spectrophotometer" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000199 + +af-e:AFE_0000199 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000354 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000939 ; + owl:someValuesFrom af-e:AFE_0000374 + ] ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A stir bar is a small magnetic bar used in a magnetic stirrer. [Allotrope]" ; + + skos:prefLabel "stir bar" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000201 + +af-e:AFE_0000201 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000693 ; + + dct:license ; + + dct:rights ; + + dct:source "RECOMMENDATIONS FOR TERMINOLOGY TO BE USED WITH PRECISION BALANCES, Pure and Applied Chemistry, 1(1), 171-176" ; + + rdfs:isDefinedBy ; + + rdfs:seeAlso "legal metrology definition of analytical balances" ; + + skos:definition "An analytical balance has a capacity of 50 - 200 g with a precision of 0.01 - 0.05 mg. [IUPAC]" ; + + skos:prefLabel "analytical balance" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000209 + +af-e:AFE_0000209 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000317 , + af-e:AFE_0002185 , + af-e:AFE_0002188 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000056 ; + owl:someValuesFrom af-p:AFP_0000142 + ] ; + + af-x:AFX_0002809 obi:_0000521 ; + + dct:source "https://en.wikipedia.org/wiki/Flame_ionization_detector" ; + + rdfs:isDefinedBy ; + + skos:altLabel "FID" ; + + skos:definition "A flame ionization detector is a measurement component that measures an analyte in a gas stream through the measurement of ions created via flame ionization. [Allotrope]" ; + + skos:prefLabel "flame ionization detector" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000217 + +af-e:AFE_0000217 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0002157 , + [ owl:intersectionOf ( af-e:AFE_0002157 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000056 ; + owl:someValuesFrom af-p:AFP_0001321 + ] + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "column" ; + + skos:definition "A chromatography column is a type of column that contains a stationary phase for chromatographic separation of compounds. [Allotrope]" ; + + skos:prefLabel "chromatography column" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000223 + +af-e:AFE_0000223 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000004 ; + + rdfs:isDefinedBy ; + + skos:altLabel "EI source" , + "electron impact source" ; + + skos:definition "An electron ionization source is an ion source that consists of an ionization chamber and a thin strip of metal that is heated electrically to incandescence or a temperature at which it emits free electrons that are accelerated through a potential to an energy where they ionize the sample. [CHMO]" ; + + skos:prefLabel "electron ionization source" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000224 + +af-e:AFE_0000224 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000808 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000056 ; + owl:someValuesFrom af-p:AFP_0000748 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "HPLC system" , + "high-performance liquid chromatography system" ; + + skos:changeNote "2020-03-20 Changed equivalentClass to subClass. [Allotrope]" ; + + skos:definition "A high-performance liquid chromatograph is an instrument used for HPLC that is a technique in analytical chemistry used to separate the components in a mixture, to identify each component, and to quantify each component. It has pumps to pass a pressurized liquid solvent containing the sample mixture through a column filled with a solid adsorbent material. Each component in the sample interacts slightly differently with the adsorbent material, causing different flow rates for the different components and leading to the separation of the components as they flow out the column. [Wikipedia]" ; + + skos:prefLabel "high-performance liquid chromatograph" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000231 + +af-e:AFE_0000231 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000217 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000056 ; + owl:someValuesFrom af-p:AFP_0000748 + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + af-x:AFX_0002809 chmo:_0000976 ; + + rdfs:isDefinedBy ; + + skos:altLabel "HPLC column" ; + + skos:definition "A chromatography column that contains very small particles and is capable of taking a high inlet pressure. [CHMO]" ; + + skos:prefLabel "high-performance liquid chromatography column" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000246 + +af-e:AFE_0000246 rdf:type owl:Class ; + + rdfs:subClassOf [ owl:intersectionOf ( af-e:AFE_0000317 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000056 ; + owl:someValuesFrom af-p:AFP_0001321 + ] + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + af-x:AFX_0002808 obi:_0000481 ; + + dct:source "PAC, 1993, 65, 819 (Nomenclature for chromatography (IUPAC Recommendations 1993))" ; + + rdfs:isDefinedBy ; + + skos:definition "A chromatography detector is a detector that is used in chromatography as component of a chromatography system. [Allotrope]" ; + + skos:prefLabel "chromatographic detector" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000252 + +af-e:AFE_0000252 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0002145 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000056 ; + owl:someValuesFrom [ owl:intersectionOf ( af-p:AFP_0002294 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000544 ; + owl:someValuesFrom af-r:AFR_0001844 + ] + ) ; + rdf:type owl:Class + ] + ] ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "weighing instrument" ; + + skos:definition "A weighing device is a measurement device for measuring mass by the gravitational force on earth. [Allotrope]" ; + + skos:prefLabel "weighing device" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000266 + +af-e:AFE_0000266 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0002168 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000085 ; + owl:someValuesFrom af-fn:AFFN_0000030 + ] ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "injector" ; + + skos:definition "A device that introduces objects into the inside of another object. [Allotrope]" ; + + skos:prefLabel "injection device" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000277 + +af-e:AFE_0000277 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000550 ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + af-x:AFX_0002808 chmo:_0002268 ; + + rdfs:isDefinedBy ; + + skos:altLabel "SAX column" ; + + skos:definition "A chromatography column where the stationary phase is a strong anion exchanger. [CHMO]" ; + + skos:prefLabel "strong anion-exchange column" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000299 + +af-e:AFE_0000299 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0002228 ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:definition "A homogenizer is a device used for homogenization of various types of material. [Wikipedia]" ; + + skos:prefLabel "homogenizer" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000301 + +af-e:AFE_0000301 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000550 ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + af-x:AFX_0002808 chmo:_0002269 ; + + rdfs:isDefinedBy ; + + skos:altLabel "WAX column" ; + + skos:definition "A chromatography column where the stationary phase is a weak anion exchanger. [CHMO]" ; + + skos:prefLabel "weak anion-exchange column" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000316 + +af-e:AFE_0000316 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000317 , + af-e:AFE_0002185 , + af-e:AFE_0002188 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000056 ; + owl:someValuesFrom af-p:AFP_0002206 + ] ; + + af-x:AFX_0002809 obi:_0000466 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:altLabel "TCD" ; + + skos:changeNote "2018-08-09 Moved under measuring device, detection is only secondary. [Allotrope]" , + "2018-12-20 Changed definition to align with other GC detectors. [Allotrope]" ; + + skos:definition "A thermal conductivity detector is a measurement component that measures changes in the thermal conductivity of the column effluent and compares it to a reference flow of carrier gas. [Allotrope]" ; + + skos:prefLabel "thermal conductivity detector" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000317 + +af-e:AFE_0000317 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000354 , + af-e:AFE_0002242 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000085 ; + owl:someValuesFrom af-fn:AFFN_0000037 + ] ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "Any piece of apparatus used to detect an analyte. [CHMO]" ; + + skos:prefLabel "detector" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000322 + +af-e:AFE_0000322 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0001028 , + af-sp:AFSP_0000005 , + af-sp:AFSP_0000007 ; + + rdfs:isDefinedBy ; + + skos:definition "A separate enclosed physical section of a device that can contain other devices. [Allotrope]" ; + + skos:prefLabel "compartment" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000327 + +af-e:AFE_0000327 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0002184 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A sensor that measures the pressure. [Allotrope]" ; + + skos:prefLabel "pressure sensor" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000340 + +af-e:AFE_0000340 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000718 ; + + af-x:AFX_0002808 ; + + rdfs:isDefinedBy ; + + skos:definition "A capillary is a tube with a small diameter. [Allotrope]" ; + + skos:prefLabel "capillary" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000350 + +af-e:AFE_0000350 rdf:type owl:Class ; + + rdfs:subClassOf [ owl:intersectionOf ( af-e:AFE_0000354 + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "temp controlled chamber" ; + + skos:definition "A temperature controlled chamber is a chamber or enclosed space in which a temperature can be controlled and set to a specific value. [Allotrope]" ; + + skos:prefLabel "temperature controlled chamber" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000354 + +af-e:AFE_0000354 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0002099 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy , + ; + + skos:altLabel "engineered artifact" ; + + skos:definition "A device is an artifact that is designed to perform a function primarily by means of its mechanical or electrical nature. [Allotrope]" ; + + skos:note "A device has a designed form or physical structure. This distinguishes a device from a chemical and a biological artifact, that are typical bulk or portions of materials without a designed form. [Allotrope]" ; + + skos:prefLabel "device" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000360 + +af-e:AFE_0000360 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000523 ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + af-x:AFX_0002808 chmo:_0002266 ; + + rdfs:isDefinedBy ; + + skos:altLabel "SCX column" ; + + skos:definition "A chromatography column where the stationary phase is a strong cation exchanger. [CHMO]" ; + + skos:prefLabel "strong cation-exchange column" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000363 + +af-e:AFE_0000363 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000317 , + af-e:AFE_0002185 , + af-e:AFE_0002200 ; + + af-x:AFX_0002809 chmo:_0002585 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "RI detector" , + "refractive-index detector" ; + + skos:changeNote "2018-08-09 Moved under measuring device, detection is only secondary. [Allotrope]" ; + + skos:definition "A piece of apparatus, consisting of a light source, a hollow prism and a photoelectric cell that is used to detect non-ultraviolet-absorbing molecules in a sample separated by chromatography. Light from the sample passes through a flow cell with two channels towards the photoelectric cell. One channel holds the eluent from the column, whereas the other holds a control sample (solvent that has not passed through the column). Detection occurs when the light is bent due to molecules eluting from the column, and this is read as a disparity between the two channels. [CHMO]" ; + + skos:prefLabel "refractive index detector" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000368 + +af-e:AFE_0000368 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000317 , + af-e:AFE_0002185 ; + + af-x:AFX_0002809 obi:_0000565 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "ECD" , + "Hall electrolytic conductivity detector" ; + + skos:changeNote "2018-08-09 Moved under measuring device, detection is only secondary. [Allotrope]" ; + + skos:definition "A conductivity probe to calculate the conductance value of a material at the selected reference temperature. [Allotrope]" ; + + skos:prefLabel "electrolytic conductivity detector" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000370 + +af-e:AFE_0000370 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000004 ; + + rdfs:isDefinedBy ; + + skos:altLabel "CI source" ; + + skos:definition "A chemical ionization source is an ion source that consists of a high-pressure ionization chamber containing a reagent gas (for example N2, O2 or H2O) which is ionized by high-energy electrons from a heated strip of metal and goes on to react with the analyte to ionize it. [CHMO]" ; + + skos:prefLabel "chemical ionization source" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000374 + +af-e:AFE_0000374 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000812 ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:definition "A magnetic stirrer or magnetic mixer is a laboratory device that employs a rotating magnetic field to cause a stir bar (also called \"flea\") immersed in a liquid to spin very quickly, thus stirring it. [Wikipedia]" ; + + skos:prefLabel "magnetic stirrer" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000378 + +af-e:AFE_0000378 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000407 ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + af-x:AFX_0002808 ; + + rdfs:isDefinedBy ; + + skos:definition "The reservoir is a container that stores solutions. [Allotrope]" ; + + skos:prefLabel "reservoir" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000392 + +af-e:AFE_0000392 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0002157 ; + + af-x:AFX_0002809 chmo:_0002477 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A piece of apparatus, consisting of a mobile phase supply system, an injection or sampling system, a column, detector and a data acquisition/processing system, that is used to carry out chromatographic separations. [CHMO]" ; + + skos:prefLabel "chromatograph" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000407 + +af-e:AFE_0000407 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000354 , + [ owl:intersectionOf ( [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000085 ; + owl:someValuesFrom af-fn:AFFN_0000139 + ] + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0001048 ; + owl:allValuesFrom bfo:_0000040 + ] + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002808 obi:_0000967 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "vessel" ; + + skos:definition "A device that has the function to contain material. [Allotrope]" ; + + skos:example "box, can, plate, rack" , + "tray, flask, vial" ; + + skos:prefLabel "container" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000410 + +af-e:AFE_0000410 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0002145 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000056 ; + owl:someValuesFrom [ owl:intersectionOf ( af-p:AFP_0002294 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000544 ; + owl:someValuesFrom af-r:AFR_0001584 + ] + ) ; + rdf:type owl:Class + ] + ] ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A thermometer is a device that measures temperature or a temperature gradient. [Allotrope]" ; + + skos:prefLabel "thermometer" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000421 + +af-e:AFE_0000421 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000185 ; + + rdfs:isDefinedBy ; + + skos:altLabel "UV spectrophotometer" , + "UV-VIS absorption spectrophotometer" , + "UV-VIS spectrometer" , + "UV-VIS spectrophotometer" , + "UV-Vis molecular absorption spectrometer" , + "UV-Vis spectrometer" , + "UV-vis absorption spectrometer" , + "UV-vis absorption spectrophotometer" , + "UV-vis spectrometer" , + "UV-vis spectrophotometer" , + "UV-visible spectrometer" , + "UV/VIS absorption spectrophotometer" , + "UV/VIS spectrometer" , + "UV/VIS spectrophotometer" , + "UV/Vis absorption spectrophotometer" , + "UV/Vis spectrometer" , + "UV/Vis spectrophotometer" , + "absorption spectrophotometer" , + "electronic absorption spectrometer" , + "molecular electronic absorption spectrometer" , + "ultra-violet-visible spectrometer" , + "ultraviolet-visible spectrometer" , + "ultraviolet-visible spectrophotometer" ; + + skos:definition "A piece of apparatus that consists of: a light source; a holder for the sample; a diffraction grating or monochromator to separate the different wavelengths of light; a detector, and is used to measure spectra in the range ultraviolet to visible (190--800 nm). [CHMO]" ; + + skos:prefLabel "ultraviolet-visible spectrometer" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000422 + +af-e:AFE_0000422 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000354 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "An electrode is an electrically-conducting device that exchanges electrons with an electrolyte as part of an electrical circuit. [Allotrope]" ; + + skos:prefLabel "electrode" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000430 + +af-e:AFE_0000430 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000217 ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + af-x:AFX_0002808 obi:_0000614 ; + + rdfs:isDefinedBy ; + + skos:definition "A short protective chromatography column used to protect the main analytical column from damaging impurities that are injected into the instrument. [Allotrope]" ; + + skos:prefLabel "guard column" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000431 + +af-e:AFE_0000431 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000392 ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "GPC" , + "gel permeation chromatograph" ; + + skos:definition "A piece of apparatus, consisting of an eluent supply system, an injection or sampling system, a column containing a swollen gel, a detector and a data acquisition/processing system, that is used to carry out chromatographic separations. [CHMO]" ; + + skos:prefLabel "gel filtration chromatograph" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000462 + +af-e:AFE_0000462 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0002190 ; + + rdfs:isDefinedBy ; + + skos:definition "A sample inlet is an in port of a measurement or separation device where sample material is passing in to the device. [Allotrope]" ; + + skos:prefLabel "sample inlet" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000466 + +af-e:AFE_0000466 rdf:type owl:Class ; + + rdfs:subClassOf [ owl:intersectionOf ( af-e:AFE_0000857 + af-e:AFE_0001745 + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A piece of apparatus used to measure a spectrum by illumination with light. [Allotrope]" ; + + skos:prefLabel "optical spectrometer" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000471 + +af-e:AFE_0000471 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0002254 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A damper is an inhibition device that deadens, restrains, or depresses. [Wikipedia]" ; + + skos:prefLabel "damper" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000499 + +af-e:AFE_0000499 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0002168 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A pump is a device that is used to pump. [CHMO]" ; + + skos:prefLabel "pump" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000523 + +af-e:AFE_0000523 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000803 ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + af-x:AFX_0002808 chmo:_0002263 ; + + rdfs:isDefinedBy ; + + skos:definition "A chromatography column where the stationary phase is a cation exchanger. [CHMO]" ; + + skos:prefLabel "cation-exchange column" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000524 + +af-e:AFE_0000524 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0002145 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000056 ; + owl:someValuesFrom af-p:AFP_0000032 + ] ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "cell counter analyzer" , + "cell counter device" , + "cell counter instrument" , + "cell density module" , + "cell viability module" , + "off-line analyzer" ; + + skos:definition "A device used to count the number of cells present in known volume of sample to determine the overall concentration cells per unit volume. [Allotrope]" ; + + skos:prefLabel "cell counter" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000527 + +af-e:AFE_0000527 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000648 ; + + dct:license ; + + dct:rights ; + + dct:source "K. K. Murray, R. K. Boyd, M. N. Eberlin, G. J. Langley, L. Li and Y. Naito, Pure Appl. Chem., 2013, 85, 1515-1609" ; + + rdfs:isDefinedBy ; + + skos:altLabel "QMS" , + "quad-MS" ; + + skos:definition "A piece of apparatus that consists of an ion source, a mass-to-charge analyzer, a detector and a vacuum system and is used to measure mass spectra. The detector is a quadrupole mass-to-charge analyzer, which holds the ions in a stable orbit by an electric field generated by four parallel electrodes. [IUPAC]" ; + + skos:prefLabel "quadrupole mass spectrometer" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000528 + +af-e:AFE_0000528 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0002148 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "temperature control" , + "temperature control device" , + "thermostat" ; + + skos:definition "A device used to control the temperature in a compartment. [Allotrope]" ; + + skos:prefLabel "temperature controller" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000534 + +af-e:AFE_0000534 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000317 , + af-e:AFE_0002185 , + af-e:AFE_0002188 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000056 ; + owl:someValuesFrom af-p:AFP_0001113 + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + af-x:AFX_0002809 obi:_0000509 ; + + dct:source "https://en.wikipedia.org/wiki/Electron_capture_detector" ; + + rdfs:isDefinedBy ; + + skos:altLabel "ECD" ; + + skos:definition "An electron capture detector is a measurement component that measures an analyte in a gas stream through the attachment of electrons via electron capture ionization. [Allotrope]" ; + + skos:prefLabel "electron capture detector" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000540 + +af-e:AFE_0000540 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0002231 ; + + af-x:AFX_0002808 ; + + rdfs:isDefinedBy ; + + skos:altLabel "tray" , + "vial tray" ; + + skos:changeNote "2020-06-22 Moved under tray, renamed and updated definition. [Allotrope]" ; + + skos:definition "A vial rack is a tray capable of holding multiple vials within a defined layout. [Allotrope]" ; + + skos:prefLabel "vial rack" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000541 + +af-e:AFE_0000541 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000625 ; + + dct:license ; + + dct:rights ; + + dct:source "K. K. Murray, R. K. Boyd, M. N. Eberlin, G. J. Langley, L. Li and Y. Naito, Pure Appl. Chem., 2013, 85, 1515-1609" ; + + rdfs:isDefinedBy ; + + skos:altLabel "QIT" , + "QUISTOR" , + "quadrupole ion storage trap" , + "quadrupole ion trap" ; + + skos:definition "Ion trapping device that depends on the application of radio frequency potentials between a ring electrode and two end-cap electrodes to confine the ion motion to a cyclic path described by an appropriate form of the Mathieu equation. The choice of these potentials determines the m/z value below which ions are not trapped. [IUPAC]" ; + + skos:prefLabel "Paul ion trap" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000550 + +af-e:AFE_0000550 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000803 ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + af-x:AFX_0002808 chmo:_0002265 ; + + rdfs:isDefinedBy ; + + skos:definition "A chromatography column where the stationary phase is an anion exchanger. [CHMO]" ; + + skos:prefLabel "anion-exchange column" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000551 + +af-e:AFE_0000551 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000857 , + af-e:AFE_0002145 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A Raman spectrometer is a piece of apparatus that allows for the measurement of Raman spectra. It consists of a laser and a detector. [Allotrope]" ; + + skos:prefLabel "Raman spectrometer" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000554 + +af-e:AFE_0000554 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000185 ; + + rdfs:isDefinedBy ; + + skos:altLabel "UV spectrometer" , + "UV spectrophotometer" , + "ultra-violet spectrometer" , + "ultraviolet spectrometry" ; + + skos:definition "A piece of apparatus that consists of: a light source; a holder for the sample; a diffraction grating or monochromator to separate the different wavelengths of light; a detector, and is used to measure spectra in the ultraviolet range (190-400 nm). [CHMO]" ; + + skos:prefLabel "ultraviolet spectrometer" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000555 + +af-e:AFE_0000555 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000354 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000056 ; + owl:someValuesFrom af-p:AFP_0003095 + ] ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A device to acquire signals or data. [Allotrope]" ; + + skos:prefLabel "data acquisition device" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000558 + +af-e:AFE_0000558 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0002193 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A device used to split a fluid into two component streams. [Allotrope]" ; + + skos:prefLabel "splitter" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000567 + +af-e:AFE_0000567 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000317 , + af-e:AFE_0002185 , + af-e:AFE_0002200 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000056 ; + owl:someValuesFrom af-p:AFP_0002788 + ] ; + + af-x:AFX_0002809 obi:_0000563 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "FLD" ; + + skos:changeNote "2018-08-09 Moved under measuring device, detection is only secondary. [Allotrope]" ; + + skos:definition "A fluorescence detector is a detector that detects material by way of the measurement of the emitted fluorescence light after excitation with light. [Allotrope]" ; + + skos:prefLabel "fluorescence detector" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000574 + +af-e:AFE_0000574 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000354 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000056 ; + owl:someValuesFrom af-p:AFP_0001047 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A blood gas analyzer is a device that is used for blood gas measurement. [Allotrope]" ; + + skos:prefLabel "blood gas analyzer" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000579 + +af-e:AFE_0000579 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000217 ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A capillary electrophoresis column is a type of column that is used in capillary electrophoresis. [Allotrope]" ; + + skos:prefLabel "capillary electrophoresis column" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000587 + +af-e:AFE_0000587 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0002157 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000056 ; + owl:someValuesFrom af-p:AFP_0000593 + ] , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000085 ; + owl:someValuesFrom af-fn:AFFN_0000108 + ] ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A degasser is a device to remove gasses from a fluid which could otherwise form bubbles. [Wikipedia]" ; + + skos:prefLabel "degasser" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000625 + +af-e:AFE_0000625 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000038 ; + + dct:license ; + + dct:rights ; + + dct:source "A. G. Marshall, C. L. Hendrickson, G. S. Jackson. Mass Spectrom. Rev. 17, 1 (1998)." , + "J. P. Holder, L. Gruber, H. E. DeWitt, B. R. Beck, D. A. Church, D. Schneider. Phys. Scr., T 92, 158 (2001)." , + "K. K. Murray, R. K. Boyd, M. N. Eberlin, G. J. Langley, L. Li and Y. Naito, Pure Appl. Chem., 2013, 85, 1515-1609" ; + + rdfs:isDefinedBy ; + + skos:altLabel "IT" , + "LCQ" , + "LTQ" ; + + skos:definition "A ion trap is a device for spatially confining ions using electric and magnetic fields alone or in combination. [IUPAC]" ; + + skos:prefLabel "ion trap" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000642 + +af-e:AFE_0000642 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000317 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "ion collector" ; + + skos:definition "A piece of apparatus that produces an output that depends on the number of ions that it encounters. [CHMO]" ; + + skos:prefLabel "ion detector" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000646 + +af-e:AFE_0000646 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000322 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "measurement cell" ; + + skos:definition "A measurement chamber is a closed space that contains the sample for measurement. [Allotrope]" ; + + skos:prefLabel "measurement chamber" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000648 + +af-e:AFE_0000648 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0002145 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + dct:license ; + + dct:rights ; + + dct:source "Murray, K., Boyd, R., Eberlin, M., et al. (2013). Definitions of terms relating to mass spectrometry (IUPAC Recommendations 2013). Pure and Applied Chemistry, 85(7), pp. 1515-1609." ; + + rdfs:isDefinedBy ; + + skos:definition "A mass spectrometer is a measurement device that measures the m/z values and abundances of gas-phase ions. [IUPAC]" ; + + skos:prefLabel "mass spectrometer" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000669 + +af-e:AFE_0000669 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000771 ; + + rdfs:isDefinedBy ; + + skos:altLabel "electrospray emitter" , + "electrospray needle" ; + + skos:definition "Inlet used for introducing the liquid sample into an electrospray ionization source. [PSI/MS]" ; + + skos:prefLabel "electrospray inlet" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000673 + +af-e:AFE_0000673 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000392 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000056 ; + owl:someValuesFrom af-p:AFP_0000253 + ] ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "SFC device" , + "supercritical-fluid chromatography device" ; + + skos:changeNote "2019-07-03 Changed alt labels from system to device [Allotrope]" , + "2020-03-20 Added restriction. [Allotrope]" ; + + skos:definition "A piece of apparatus, consisting of a mobile phase supply system, an injection or sampling system, a column, detector and a data acquisition/processing system, that is used to carry out chromatographic separations where the mobile phase is a fluid above and relatively close to tits critical temperature and pressure. [Allotrope]" ; + + skos:prefLabel "supercritical-fluid chromatograph" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000691 + +af-e:AFE_0000691 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000217 ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + af-x:AFX_0002808 obi:_0000606 ; + + rdfs:isDefinedBy ; + + skos:definition "A chromatography column in which either the inner tube wall or a liquid or active solid held stationary on the tube wall acts as the stationary phase and there is an open, unrestricted path for the mobile phase. [CHMO]" ; + + skos:prefLabel "open-tubular column" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000692 + +af-e:AFE_0000692 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000217 ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + af-x:AFX_0002808 chmo:_0000975 ; + + rdfs:isDefinedBy ; + + skos:definition "A chromatography column that contains a solid packing. [CHMO]" ; + + skos:prefLabel "packed column" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000693 + +af-e:AFE_0000693 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000252 ; + + rdfs:isDefinedBy ; + + skos:definition "A balance is a weighing device, intended predominantly for medium to low capacity weighments, with moderate to high resolutions, mostly used indoors. [Allotrope]" ; + + skos:prefLabel "balance" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000711 + +af-e:AFE_0000711 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000734 , + af-e:AFE_0002200 ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + af-x:AFX_0002809 chmo:_0002584 ; + + rdfs:isDefinedBy ; + + skos:altLabel "UV detector" ; + + skos:definition "A piece of apparatus, consisting of a light source, a photoelectric cell, a diffraction grating or monochromator to separate the different wavelengths of light, which is used to detect the absorbance of ultraviolet (190-400 nm) light by molecules in a sample separated by chromatography. [CHMO]" ; + + skos:prefLabel "ultraviolet detector" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000718 + +af-e:AFE_0000718 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000407 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "tubing" ; + + skos:definition "A tube, or tubing, is a long hollow cylinder used for moving fluids (liquids or gases) or to protect electrical or optical cables and wires. [Wikipedia]" ; + + skos:prefLabel "tube" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000733 + +af-e:AFE_0000733 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000023 ; + + rdfs:isDefinedBy ; + + skos:definition "A device that is used to measure the heat of chemical reactions or physical changes for both a sample and a reference. [CHMO]" ; + + skos:prefLabel "differential scanning calorimeter" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000734 + +af-e:AFE_0000734 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000317 , + af-e:AFE_0001745 , + af-e:AFE_0002185 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000056 ; + owl:someValuesFrom af-p:AFP_0002188 + ] ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:changeNote "2018-08-09 Moved under measuring device, detection is only secondary. [Allotrope]" ; + + skos:definition "An electronic absorbance detector is a detector that detects material by way of the electronic absorbance of a electromagnetic ray transmitted through the material. [Allotrope]" ; + + skos:prefLabel "electronic absorbance detector" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000742 + +af-e:AFE_0000742 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000217 ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "An array column is a column that contains multiple columns at the same time. [Allotrope]" ; + + skos:prefLabel "array column" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000746 + +af-e:AFE_0000746 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000266 ; + + af-x:AFX_0002809 obi:_0000422 ; + + rdfs:isDefinedBy ; + + skos:definition "A syringe is an injection device that is a simple pump consisting of a plunger that fits tightly in a tube. The plunger can be pulled and pushed along inside a cylindrical tube (called a barrel), allowing the syringe to take in and expel a liquid or gas through an orifice at the open end of the tube. [Wikipedia]" ; + + skos:prefLabel "syringe" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000753 + +af-e:AFE_0000753 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000354 ; + + dct:license ; + + dct:rights ; + + dct:source "K. K. Murray, R. K. Boyd, M. N. Eberlin, G. J. Langley, L. Li and Y. Naito, Pure Appl. Chem., 2013, 85, 1515-1609" ; + + rdfs:isDefinedBy ; + + skos:altLabel "ion guide" ; + + skos:definition "Devices designed to control the formation, focusing, and deflection of charged particle beams in a vacuum under the influence of electric and magnetic fields. [IUPAC]" ; + + skos:prefLabel "ion optics" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000755 + +af-e:AFE_0000755 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000161 ; + + rdfs:isDefinedBy ; + + skos:altLabel "SL" , + "splitless" , + "splitless injector" ; + + skos:definition "A splitless inlet is a gas chromatograph inlet enabling the carrier gas to sweep the volatilized sample onto the GC column. [Allotrope]" ; + + skos:prefLabel "splitless inlet" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000761 + +af-e:AFE_0000761 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000354 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000085 ; + owl:someValuesFrom af-fn:AFFN_0000052 + ] ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "display device" ; + + skos:definition "A display is a device or element of an instrument serving to represent information. [Allotrope]" ; + + skos:prefLabel "display" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000771 + +af-e:AFE_0000771 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000462 ; + + rdfs:isDefinedBy ; + + skos:definition "An ion source inlet is an inlet into an ion source of a mass spectrometer. [Allotrope]" ; + + skos:prefLabel "ion source inlet" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000775 + +af-e:AFE_0000775 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000523 ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + af-x:AFX_0002808 chmo:_0002267 ; + + rdfs:isDefinedBy ; + + skos:altLabel "WCX column" ; + + skos:definition "A chromatography column where the stationary phase is a weak cation exchanger. [CHMO]" ; + + skos:prefLabel "weak cation-exchange column" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000776 + +af-e:AFE_0000776 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000527 ; + + rdfs:isDefinedBy ; + + skos:altLabel "SQD" , + "single quadrupole" ; + + skos:definition "A single quadrupole mass spectrometer is a type of quadrupole mass spectrometer that uses one single quadrupole field. [Allotrope]" ; + + skos:prefLabel "single quadrupole mass spectrometer" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000785 + +af-e:AFE_0000785 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000354 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000085 ; + owl:someValuesFrom af-fn:AFFN_0000089 + ] ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "chiller" , + "cooler" ; + + skos:definition "A kind of heat exchanger or radiator designed to remove excess heat. [Wikipedia]" ; + + skos:prefLabel "cooling device" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000795 + +af-e:AFE_0000795 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0002148 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:changeNote "2020-06-18 Move under controller. [Allotrope]" ; + + skos:definition "A valve is a plumbing equipment that regulates, directs or controls the flow of a fluid (gases, liquids, fluidized solids, or slurries) by opening, closing, or partially obstructing various passageways. [Wikipedia]" ; + + skos:prefLabel "valve" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000800 + +af-e:AFE_0000800 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000185 ; + + rdfs:isDefinedBy ; + + skos:altLabel "UV-VIS-NIR spectrometer" , + "UV-Vis-NIR absorption spectrometer" , + "UV-Vis-NIR spectrometer" , + "UV-Vis-NIR spectrophotometer" , + "UV-vis-NIR absorption spectrometer" , + "UV-visible-near IR absorption spectrometer" , + "UV-visible-near IR spectrometer" , + "ultraviolet-visible-near infrared absorption spectrometer" , + "ultraviolet-visible-near infrared spectrometer" ; + + skos:definition "A piece of apparatus that consists of: a light source; a holder for the sample; a diffraction grating or monochromator to separate the different wavelengths of light; a detector, and is used to measure spectra in the range ultraviolet to near-infrared (190--2000 nm) resulting in electronic transitions within the sample. [CHMO]" ; + + skos:prefLabel "ultraviolet-visible-near infrared spectrometer" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000803 + +af-e:AFE_0000803 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000217 ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + af-x:AFX_0002808 chmo:_0002264 ; + + rdfs:isDefinedBy ; + + skos:definition "A chromatography column where the stationary phase is an ion exchanger. [CHMO]" ; + + skos:prefLabel "ion-exchange column" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000808 + +af-e:AFE_0000808 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000392 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000056 ; + owl:someValuesFrom af-p:AFP_0000225 + ] ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "LC device" , + "liquid chromatography device" , + "low pressure liquid chromatography device" ; + + skos:changeNote "2019-07-03 Changed alt labels from system to device [Allotrope]" , + "2020-03-20 Changed equivalentClass to subClass. [Allotrope]" ; + + skos:definition "A liquid chromatograph is a system used to perform bioseparation techniques that are based on interactions of the sample with the mobile and stationary phases. [Allotrope]" ; + + skos:example "The system consists of a chromatographic separation unit and a computer running the system control software. The system can be operated in a fully automated manner or in manual mode. It consists of different modules, components, and accessories. [Allotrope]" ; + + skos:prefLabel "liquid chromatograph" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000811 + +af-e:AFE_0000811 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000161 ; + + rdfs:isDefinedBy ; + + skos:altLabel "S" , + "split" , + "split injector" ; + + skos:definition "A split inlet is a gas chromatograph inlet followed by a splitter enabling the carrier gas to sweep a part of volatilized sample onto the GC column, with that remaining split/swept to waste. [Allotrope]" ; + + skos:prefLabel "split inlet" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000812 + +af-e:AFE_0000812 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000299 , + af-e:AFE_0001265 , + af-e:AFE_0001266 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000085 ; + owl:someValuesFrom af-fn:AFFN_0000205 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "agitator" , + "mixer" ; + + skos:definition "A stirrer is a mixing device used for stirring something. [Allotrope]" ; + + skos:prefLabel "stirrer" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000816 + +af-e:AFE_0000816 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0001128 ; + + rdfs:isDefinedBy ; + + skos:altLabel "furnace" , + "heater" ; + + skos:definition "An oven is a device for heating an enclosed space. [Allotrope]" ; + + skos:prefLabel "oven" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000825 + +af-e:AFE_0000825 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0002242 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000056 ; + owl:someValuesFrom af-p:AFP_0000044 + ] ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A microscope is a device which is used to visually magnify a specimen. [Allotrope]" ; + + skos:prefLabel "microscope" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000828 + +af-e:AFE_0000828 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0002151 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000085 ; + owl:someValuesFrom af-fn:AFFN_0000121 + ] ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "channel" , + "line" ; + + skos:definition "A solvent channel is a channel where a liquid can flow through. [Allotrope]" ; + + skos:example "A quaternary pump has 4 channels." ; + + skos:prefLabel "solvent channel" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000847 + +af-e:AFE_0000847 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000024 ; + + rdfs:isDefinedBy ; + + skos:definition "Connection point of a system through which flows material, energy or information. [Allotrope]" ; + + skos:example "A port is used to transfer sample from a sample container to the sample measuring device or instrument. [Allotrope]" ; + + skos:prefLabel "port" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000855 + +af-e:AFE_0000855 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0002145 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000056 ; + owl:someValuesFrom [ owl:intersectionOf ( af-p:AFP_0002294 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000544 ; + owl:someValuesFrom af-r:AFR_0002111 + ] + ) ; + rdf:type owl:Class + ] + ] ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "voltameter" ; + + skos:definition "Any piece of apparatus used to measure electric charge. [CHMO]" ; + + skos:prefLabel "coulometer" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000857 + +af-e:AFE_0000857 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0002145 ; + + rdfs:isDefinedBy ; + + skos:altLabel "spectrograph" , + "spectroscope" ; + + skos:definition "A piece of apparatus used to measure a spectrum. [CHMO]" ; + + skos:prefLabel "spectrometer" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000876 + +af-e:AFE_0000876 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000354 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "automatic burette" ; + + skos:definition "A titrator is a device that automates titrations. [Allotrope]" ; + + skos:prefLabel "titrator" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0000986 + +af-e:AFE_0000986 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000354 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A long narrow cut or opening. [Allotrope]" ; + + skos:prefLabel "slit" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0001028 + +af-e:AFE_0001028 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000029 ; + + rdfs:isDefinedBy ; + + skos:definition "A site that is related to a device. [Allotrope]" ; + + skos:prefLabel "device region" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0001045 + +af-e:AFE_0001045 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000038 ; + + rdfs:isDefinedBy ; + + skos:altLabel "quadripole" ; + + skos:definition "A quadrupole is a mass-to-charge analyzer that holds the ions in a stable orbit by an electric field generated by four parallel electrodes. [Allotrope]" ; + + skos:prefLabel "quadrupole" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0001128 + +af-e:AFE_0001128 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000354 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000085 ; + owl:someValuesFrom af-fn:AFFN_0000044 + ] ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "heater" , + "heating equipment" ; + + skos:definition "A device used for heating something. [Allotrope]" ; + + skos:prefLabel "heating device" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0001265 + +af-e:AFE_0001265 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000354 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:definition "An agitator is a device or mechanism to put something into motion. [Wikipedia]" ; + + skos:prefLabel "agitator" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0001266 + +af-e:AFE_0001266 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0002227 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000085 ; + owl:someValuesFrom af-fn:AFFN_0000119 + ] ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "mixing device" ; + + skos:definition "A mixer is a device used for mixing. [Allotrope]" ; + + skos:prefLabel "mixer" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0001410 + +af-e:AFE_0001410 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000407 ; + + af-x:AFX_0002808 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:definition "Jars are cylindrical containers with wide openings that may be sealed. [Wikipedia]" ; + + skos:prefLabel "jar" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0001515 + +af-e:AFE_0001515 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0002145 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:definition "A photometer, generally, is an instrument that measures light intensity or optical properties of solutions or surfaces. [Wikipedia]" ; + + skos:prefLabel "photometer" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0001519 + +af-e:AFE_0001519 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000153 ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:altLabel "CLR" , + "controlled laboratory reactor" ; + + skos:definition "A controlled lab reactor is a reactor that maintains temperature and other reaction parameters and has measuring devices. [Allotrope]" ; + + skos:prefLabel "controlled lab reactor" ; + + skos:scopeNote "In chemistry, a Controlled Lab Reactor or CLR is any reaction system where there is an element of automated control. Generally these devices refers to a jacketed glass vessel where a circulating chiller unit pumps a thermal control fluid through the jacket to accurately control the temperature of the vessel contents. Additional to this, it is common to have a series of sensors (temperature, pH, pressure) measuring and recording parameters about the reactor contents. It is additionally possible to control pumps to act on the reactor. [Wikipedia]" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0001622 + +af-e:AFE_0001622 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0001623 ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:changeNote "2020-03-23 Fixed definition. [Allotrope]" ; + + skos:definition "A differential scanning calorimetry pan is a pan for use in a differential scanning calorimeter that contains the sample under investigation. [Allotrope]" ; + + skos:example "TZero pan, TZero hermetic pan" ; + + skos:prefLabel "differential scanning calorimetry pan" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0001623 + +af-e:AFE_0001623 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000407 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A pan is a flat container. [Allotrope]" ; + + skos:prefLabel "pan" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0001671 + +af-e:AFE_0001671 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0002148 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A mass flow controller is a device that determines the mixture of different materials. [Allotrope]" ; + + skos:example "In DVS, the mass flow controller generates the required mixture of dry and saturated gas." ; + + skos:prefLabel "mass flow controller" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0001695 + +af-e:AFE_0001695 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000354 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "desktop computer" ; + + skos:definition "A computer is a general-purpose device that can be programmed to carry out a set of arithmetic or logical operations automatically. Since a sequence of operations can be readily changed, the computer can solve more than one kind of problem. [Wikipedia]" ; + + skos:prefLabel "computer" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0001703 + +af-e:AFE_0001703 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0002148 ; + + rdfs:isDefinedBy ; + + skos:definition "A pressure regulator is a controller that regulates a set pressure in a system. [Allotrope]" ; + + skos:prefLabel "pressure regulator" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0001711 + +af-e:AFE_0001711 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000354 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000085 ; + owl:someValuesFrom af-fn:AFFN_0000201 + ] ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + dct:source "PAC, 1989, 61, 1657 (Nomenclature for automated and mechanised analysis (Recommendations 1989))" ; + + rdfs:isDefinedBy ; + + skos:altLabel "sampling unit" ; + + skos:definition "A sample is a device that function to sample known amounts of material. [Allotrope]" ; + + skos:prefLabel "sampler" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0001745 + +af-e:AFE_0001745 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000354 ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "An optical device is a device that creates, manipulates, or measures electromagnetic radiation. [Wikipedia]" ; + + skos:prefLabel "optical device" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0001747 + +af-e:AFE_0001747 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000407 ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A cell holder is a type of container for samples in spectrophotometers. [Allotrope]" ; + + skos:prefLabel "cell holder" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0001754 + +af-e:AFE_0001754 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0001755 ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:altLabel "UV/VIS lamp" , + "excilamp" ; + + skos:definition "An excimer lamp is a light source of ultraviolet light produced by spontaneous emission of excimer (exciplex) molecules. [Wikipedia]" ; + + skos:prefLabel "excimer lamp" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0001755 + +af-e:AFE_0001755 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0001875 ; + + rdfs:isDefinedBy ; + + skos:definition "A UV lamp is a light source with an ultraviolet wavelength range of 190 to 380 nm. [Allotrope]" ; + + skos:prefLabel "UV lamp" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0001761 + +af-e:AFE_0001761 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0002151 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000085 ; + owl:someValuesFrom af-fn:AFFN_0000122 + ] ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "connector" ; + + skos:definition "A tubing connector is a part used to connect/install tubing, components, and accessories as part of a system flow path configuration. [Allotrope]" ; + + skos:prefLabel "tubing connector" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0001763 + +af-e:AFE_0001763 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000217 ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + af-x:AFX_0002808 obi:_0000570 ; + + rdfs:isDefinedBy ; + + skos:altLabel "spin concentrator" ; + + skos:definition "A spin column is a column used for concentration of biological samples containing membranes for ultrafiltration. The solid phase is made up of silica to which the biological sample binds. [Allotrope]" ; + + skos:prefLabel "spin column" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0001771 + +af-e:AFE_0001771 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0001875 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A visible lamp is a light source with a visible wavelength range of 380 to 780 nm. [Allotrope]" ; + + skos:prefLabel "visible lamp" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0001772 + +af-e:AFE_0001772 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0001755 ; + + rdfs:isDefinedBy ; + + skos:definition "A deuterium lamp is a low-pressure gas-discharge light source that emits light with a continuous spectrum mainly in the ultraviolet region. [Wikipedia]" ; + + skos:prefLabel "deuterium lamp" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0001774 + +af-e:AFE_0001774 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000354 ; + + rdfs:isDefinedBy ; + + skos:definition "The fibrette is a fiber optics device that consists of a thin fiber and defines the point where a beam of light is emitted into a sample. [Allotrope]" ; + + skos:prefLabel "fibrette" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0001775 + +af-e:AFE_0001775 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000354 ; + + rdfs:isDefinedBy ; + + skos:definition "A fibrette coupler connects a fibrette to a UV spectrophotometer and allows for precise adjustment of the path length. [Allotrope]" ; + + skos:prefLabel "fibrette coupler" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0001797 + +af-e:AFE_0001797 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000266 ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + dct:license ; + + dct:rights ; + + dct:source "L.S. Ettre, \"Nomenclature for Chromatography\", Pure & Appl. Chem. 1993, Vol. 65, No. 4, pp. 819-872" ; + + rdfs:isDefinedBy ; + + skos:altLabel "sampling valve" , + "valve injector" ; + + skos:definition "A device in which the sample is first introduced into a chamber (loop), temporarily isolated from the mobile phase system by valves, which can be switched to make an instantaneous diversion of the mobile phase stream through the chamber to carry the sample to the column. [IUPAC]" ; + + skos:prefLabel "bypass injector" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0001798 + +af-e:AFE_0001798 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000266 ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + dct:license ; + + dct:rights ; + + dct:source "L.S. Ettre, \"Nomenclature for Chromatography\", Pure & Appl. Chem. 1993, Vol. 65, No. 4, pp. 819-872" ; + + rdfs:isDefinedBy ; + + skos:definition "A device which directly introduces the sample into the mobile-phase stream. [IUPAC]" ; + + skos:prefLabel "direct injector" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0001799 + +af-e:AFE_0001799 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000266 ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + dct:license ; + + dct:rights ; + + dct:source "L.S. Ettre, \"Nomenclature for Chromatography\", Pure & Appl. Chem. 1993, Vol. 65, No. 4, pp. 819-872" ; + + rdfs:isDefinedBy ; + + skos:definition "A device which directly introduces the sample into the mobile-phase stream. [IUPAC]" ; + + skos:prefLabel "on-column injector" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0001860 + +af-e:AFE_0001860 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000354 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "In electronics, a diode is a two-terminal electronic component that conducts primarily in one direction (asymmetric conductance). [Wikipedia]" ; + + skos:prefLabel "diode" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0001875 + +af-e:AFE_0001875 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000097 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + dct:license ; + + dct:rights ; + + dct:source "PAC, 1996, 68, 2223 (Glossary of terms used in photochemistry (IUPAC Recommendations 1996))" ; + + rdfs:isDefinedBy ; + + skos:definition "A lamp is an electromagnetic radiation source of incoherent radiation. [IUPAC]" ; + + skos:prefLabel "lamp" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0002099 + +af-e:AFE_0002099 rdf:type owl:Class ; + + rdfs:subClassOf af-m:AFM_0000275 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy , + ; + + skos:definition "An artifact is a material that is designed and built for a purpose. [Allotrope]" ; + + skos:prefLabel "artifact" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0002102 + +af-e:AFE_0002102 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0002186 ; + + rdfs:isDefinedBy ; + + skos:definition "A needle is a device consisting of a very thin, hollow tube with a sharp tip which contains a small opening at the pointed end. It is commonly used with a syringe. [Wikipedia]" ; + + skos:prefLabel "needle" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0002141 + +af-e:AFE_0002141 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000074 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000085 ; + owl:someValuesFrom af-fn:AFFN_0000041 + ] ; + + rdfs:isDefinedBy ; + + skos:changeNote "202-01-21 Removed restrictions to MS. [Allotrope]" ; + + skos:definition "A measuring system is a device system which has the designed function of measurement. [Allotrope]" ; + + skos:prefLabel "measuring system" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0002144 + +af-e:AFE_0002144 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0002197 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000972 ; + owl:someValuesFrom af-e:AFE_0000711 + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:changeNote "2020-03-24 Changed equiventClass to subClass. [Allotrope]" ; + + skos:definition "A LC-UV system is a device system that has a liquid chromatograph and an ultra-violet detector component. [Allotrope]" ; + + skos:prefLabel "LC-UV system" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0002145 + +af-e:AFE_0002145 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000354 , + af-e:AFE_0002242 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000085 ; + owl:someValuesFrom af-fn:AFFN_0000041 + ] ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "analyzer" , + "instrument" , + "measuring apparatus" , + "measuring instrument" , + "measuring sensor" ; + + skos:definition "A device that measures some aspect of reality, such as a quality or the profile of a process. [Allotrope]" ; + + skos:prefLabel "measurement device" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0002148 + +af-e:AFE_0002148 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000354 , + [ owl:intersectionOf ( [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000085 ; + owl:someValuesFrom af-fn:AFFN_0000014 + ] + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0002428 ; + owl:someValuesFrom bfo:_0000015 + ] + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "regulator" ; + + skos:definition "A device that has the function to control some quality or process. [Allotrope]" ; + + skos:prefLabel "controller" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0002151 + +af-e:AFE_0002151 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0002227 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000085 ; + owl:someValuesFrom af-fn:AFFN_0000120 + ] ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "coupler" ; + + skos:changeNote "2020-06-18 Moved under connecting device. [Allotrope]" ; + + skos:definition "A device that has the function to couple things. [Allotrope]" ; + + skos:prefLabel "coupling device" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0002153 + +af-e:AFE_0002153 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000074 ; + + rdfs:isDefinedBy ; + + skos:altLabel "piping" , + "plumbing" , + "tubing" ; + + skos:definition "Plumbing is the system of pipes, tubing, drains, fittings, valves, and fixtures installed for the distribution of a liquid. [Wikipedia]" ; + + skos:prefLabel "plumbing system" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0002156 + +af-e:AFE_0002156 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000354 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:definition "A device that is used to provide data and control signals to an information processing system. [Wikipedia]" ; + + skos:prefLabel "input device" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0002157 + +af-e:AFE_0002157 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000354 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000085 ; + owl:someValuesFrom af-fn:AFFN_0000105 + ] ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "separating device" ; + + skos:definition "A device that has the function to separate materials. [Allotrope]" ; + + skos:prefLabel "separation device" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0002158 + +af-e:AFE_0002158 rdf:type owl:Class ; + + rdfs:subClassOf ro:_0002577 ; + + rdfs:isDefinedBy ; + + skos:altLabel "engineered system" ; + + skos:definition "A system that is created for a specific purpose. [Allotrope]" ; + + skos:prefLabel "artificial system" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0002165 + +af-e:AFE_0002165 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0002157 ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A separation column is a separation device of columnar shape where the separation occurs inside the column. [Allotrope]" ; + + skos:prefLabel "separation column" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0002168 + +af-e:AFE_0002168 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000354 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000085 ; + owl:someValuesFrom af-fn:AFFN_0000187 + ] ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A transferring device is a device that is designed to transfer material. [Allotrope]" ; + + skos:prefLabel "transferring device" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0002172 + +af-e:AFE_0002172 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000354 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000085 ; + owl:someValuesFrom af-fn:AFFN_0000007 + ] ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A collecting device is a device that has the function to collect things. [Allotrope]" ; + + skos:prefLabel "collecting device" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0002177 + +af-e:AFE_0002177 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000074 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000972 ; + owl:someValuesFrom af-e:AFE_0000499 + ] , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000085 ; + owl:someValuesFrom af-fn:AFFN_0000046 + ] ; + + rdfs:isDefinedBy ; + + skos:changeNote "2020-03-24 Add restrictions. [Allotrope]" ; + + skos:definition "A system intended for pumping. [Allotrope]" ; + + skos:prefLabel "pump system" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0002184 + +af-e:AFE_0002184 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000354 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000085 ; + owl:someValuesFrom af-fn:AFFN_0000023 + ] ; + + dct:source "https://jcgm.bipm.org/vim/en/3.8.html" ; + + rdfs:isDefinedBy ; + + skos:definition "A sensor is a component of a measuring system that is directly affected by a phenomenon, body, or substance carrying a quantity to be measured. [Allotrope]" ; + + skos:editorialNote "A sensor can be a measuring device on its own, but is typically a part of it." ; + + skos:prefLabel "sensor" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0002185 + +af-e:AFE_0002185 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0002145 ; + + rdfs:isDefinedBy ; + + skos:altLabel "measurement module" ; + + skos:definition "A measurement component is a component of a measuring system, that does measuring. [Allotrope]" ; + + skos:editorialNote "The criteria is compromise. Some measurement components can be fully standalone measurement devices used in a component role, but are not typically used as such. A UV spectrometer is an electromagnetic absorbance measuring instrument and an elecctromagnetic absorbance detector has the same function, but it is used as part of a larger system, such as a HPLC-UV system." ; + + skos:prefLabel "measurement component" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0002186 + +af-e:AFE_0002186 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( af-e:AFE_0000354 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000939 ; + owl:someValuesFrom af-e:AFE_0000266 + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:isDefinedBy ; + + skos:definition "An injection device component is a component of an injection device. [Allotrope]" ; + + skos:prefLabel "injection device component" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0002188 + +af-e:AFE_0002188 rdf:type owl:Class ; + + rdfs:subClassOf [ owl:intersectionOf ( af-e:AFE_0000246 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000056 ; + owl:someValuesFrom af-p:AFP_0000310 + ] + ) ; + rdf:type owl:Class + ] , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000939 ; + owl:someValuesFrom af-e:AFE_0002195 + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "GC detector" ; + + skos:definition "A gas chromatography detector is a detector that is used in gas chromatography as component of a GC system. [Allotrope]" ; + + skos:prefLabel "gas chromatography detector" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0002189 + +af-e:AFE_0002189 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000354 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000085 ; + owl:someValuesFrom af-fn:AFFN_0000115 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A guiding device is a device that has the function to direct a flow in a specific direction. [Allotrope]" ; + + skos:prefLabel "guiding device" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0002190 + +af-e:AFE_0002190 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000847 ; + + rdfs:isDefinedBy ; + + skos:altLabel "inlet" ; + + skos:definition "An in port is a port in a device where material is flowing into the system boundary. [Allotrope]" ; + + skos:prefLabel "in port" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0002191 + +af-e:AFE_0002191 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000847 ; + + rdfs:isDefinedBy ; + + skos:altLabel "outlet" ; + + skos:definition "An out port is a port in a device where material is flowing out of the system boundary. [Allotrope]" ; + + skos:prefLabel "out port" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0002192 + +af-e:AFE_0002192 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000847 ; + + rdfs:isDefinedBy ; + + skos:altLabel "bidirectional port" ; + + skos:definition "An in/out port is a port where a flow is going in both directions. [Allotrope]" ; + + skos:prefLabel "in/out port" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0002193 + +af-e:AFE_0002193 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000354 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000085 ; + owl:someValuesFrom af-fn:AFFN_0000106 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A distribution device is a device with the function to distribute a stream into multiple parts. [Allotrope]" ; + + skos:prefLabel "distribution device" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0002194 + +af-e:AFE_0002194 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000161 ; + + rdfs:isDefinedBy ; + + skos:definition "A split/splitless inlet is a gas chromatograph inlet that supports both split and splitless injection modes. [Allotrope]" ; + + skos:prefLabel "split/splitless inlet" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0002195 + +af-e:AFE_0002195 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( af-e:AFE_0000074 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000972 ; + owl:someValuesFrom af-e:AFE_0000024 + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:subClassOf af-e:AFE_0000074 ; + + rdfs:isDefinedBy ; + + skos:definition "A GC system is a device system that has a gas chromatograph component. [Allotrope]" ; + + skos:prefLabel "GC system" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0002197 + +af-e:AFE_0002197 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000074 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000972 ; + owl:someValuesFrom af-e:AFE_0000808 + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "liquid chromatography system" ; + + skos:definition "A LC system is a device system that has a liquid chromatograph component. [Allotrope]" ; + + skos:prefLabel "LC system" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0002198 + +af-e:AFE_0002198 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000322 ; + + rdfs:isDefinedBy ; + + skos:definition "A column compartment is a compartment in a chromatography system where the columns are held. [Allotrope]" ; + + skos:editorialNote "2019-04-01 Adding 'ro:location of' some 'af-e:chromatography column' breaks Hermit reasoner. [Allotrope]" ; + + skos:prefLabel "column compartment" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0002200 + +af-e:AFE_0002200 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000246 , + [ owl:intersectionOf ( af-e:AFE_0000317 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000056 ; + owl:someValuesFrom af-p:AFP_0000225 + ] + ) ; + rdf:type owl:Class + ] , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000939 ; + owl:someValuesFrom af-e:AFE_0002197 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "LC detector" ; + + skos:definition "A liquid chromatography detector is a detector that is used in liquid chromatography as component of a LC system. [Allotrope]" ; + + skos:prefLabel "liquid chromatography detector" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0002201 + +af-e:AFE_0002201 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000161 , + af-e:AFE_0001799 ; + + rdfs:isDefinedBy ; + + skos:definition "A packed injector is a GC injector device in which the entire sample aliquot is vaporized and directly introduced onto the column. [Allotrope]" ; + + skos:prefLabel "packed injector" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0002202 + +af-e:AFE_0002202 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000217 ; + + rdfs:isDefinedBy ; + + skos:definition "A monolithic columns is a chromatography column where the stationary phase synthesized in place as a single lattice structure in the column. [Allotrope]" ; + + skos:prefLabel "monolithic column" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0002204 + +af-e:AFE_0002204 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0002145 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000056 ; + owl:someValuesFrom [ owl:intersectionOf ( af-p:AFP_0002294 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000544 ; + owl:someValuesFrom [ rdf:type owl:Class ; + owl:unionOf ( af-r:AFR_0000937 + af-r:AFR_0000951 + ) + ] + ] + ) ; + rdf:type owl:Class + ] + ] ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:altLabel "chronometer" ; + + skos:definition "A clock is a measurement device used to measure, keep, and indicate time. [Wikipedia]" ; + + skos:prefLabel "clock" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0002205 + +af-e:AFE_0002205 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0002141 ; + + rdfs:isDefinedBy ; + + skos:altLabel "MS system" ; + + skos:definition "A mass spectrometry system is a measuring system that is designed and assembled to realize the measurement function by way of mass spectrometry. [Allotrope]" ; + + skos:prefLabel "mass spectrometry system" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0002206 + +af-e:AFE_0002206 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0002210 ; + + rdfs:isDefinedBy ; + + skos:altLabel "workbench" ; + + skos:definition "A bench is a large table in a workspace or laboratory. [Allotrope]" ; + + skos:prefLabel "bench" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0002209 + +af-e:AFE_0002209 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000354 ; + + rdfs:isDefinedBy ; + + skos:definition "A placement device is a device that is used to hold or place a material in a defined location. [Allotrope]" ; + + skos:prefLabel "placement device" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0002210 + +af-e:AFE_0002210 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0002209 ; + + rdfs:isDefinedBy ; + + skos:definition "A table is a placement device with a flat top and one or more legs, providing a level surface for placement. [Allotrope]" ; + + skos:prefLabel "table" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0002211 + +af-e:AFE_0002211 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0002145 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000056 ; + owl:someValuesFrom [ owl:intersectionOf ( af-p:AFP_0002294 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000544 ; + owl:someValuesFrom [ rdf:type owl:Class ; + owl:unionOf ( af-r:AFR_0001856 + af-r:AFR_0001916 + ) + ] + ] + ) ; + rdf:type owl:Class + ] + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A multimeter is an instrument designed to measure electric current, voltage, and usually resistance, typically over several ranges of value. [Allotrope]" ; + + skos:prefLabel "multimeter" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0002212 + +af-e:AFE_0002212 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000354 ; + + rdfs:isDefinedBy ; + + skos:altLabel "frequency generator" ; + + skos:definition "A frequency generator is an electrical device which creates a signal at a predetermined frequency. [Allotrope]" ; + + skos:example "Frequency generator with a single frequency, or adjustable to any frequency in the range that the generator supports." ; + + skos:prefLabel "frequency synthesizer" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0002215 + +af-e:AFE_0002215 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000004 , + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000050 ; + owl:someValuesFrom af-e:AFE_0000648 + ] ; + + af-x:AFX_0002809 chmo:_0000960 ; + + rdfs:isDefinedBy ; + + skos:altLabel "MS ionization source" , + "mass spectrometry ionization source" ; + + skos:definition "A mass spectrometer ionization source is a piece of apparatus that takes an analyte and generates ions which are passed to the rest of a mass spectrometer for analysis. [CHMO]" ; + + skos:prefLabel "mass spectrometer ionization source" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0002217 + +af-e:AFE_0002217 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000354 ; + + rdfs:isDefinedBy ; + + skos:altLabel "filament" ; + + skos:definition "A filament is a device that produces an electron stream to charge neutrals for analysis by mass spectrometry. [Allotrope]" ; + + skos:prefLabel "filament (ms)" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0002220 + +af-e:AFE_0002220 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000876 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000085 ; + owl:someValuesFrom [ owl:intersectionOf ( bfo:_0000034 + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000054 ; + owl:someValuesFrom af-p:AFP_0000441 + ] + ) ; + rdf:type owl:Class + ] + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "Karl Fischer titrator" ; + + skos:definition "A Karl-Fischer titrator is a titrator designed for Karl-Fischer titrations. [Allotrope]" ; + + skos:prefLabel "Karl-Fischer titrator" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0002221 + +af-e:AFE_0002221 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0001703 ; + + rdfs:isDefinedBy ; + + skos:definition "A backpressure regulator is a pressure regulator that regulates a defined pressure upstream of itself (at its own inlet). [Allotrope]" ; + + skos:prefLabel "backpressure regulator" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0002222 + +af-e:AFE_0002222 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0002168 ; + + rdfs:isDefinedBy ; + + skos:definition "A nozzle is a transferring device consisting of jet port with an opening for regulating and/or directing the flow of fluid. [Allotrope]" ; + + skos:prefLabel "nozzle" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0002223 + +af-e:AFE_0002223 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000074 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000972 ; + owl:someValuesFrom af-e:AFE_0000673 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "supercritical-fluid chromatography system" ; + + skos:definition "A SFC system is a device system that has a supercritical fluid chromatograph component. [Allotrope]" ; + + skos:prefLabel "SFC system" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0002224 + +af-e:AFE_0002224 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000528 , + af-e:AFE_0002226 ; + + rdfs:isDefinedBy ; + + skos:definition "A reactor jacket is a jacket that controls the temperature of a reactor. [Allotrope]" ; + + skos:prefLabel "reactor jacket" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0002225 + +af-e:AFE_0002225 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0002151 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000085 ; + owl:someValuesFrom af-fn:AFFN_0000203 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A covering device is a device that has the function to cover something. [Allotrope]" ; + + skos:prefLabel "covering device" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0002226 + +af-e:AFE_0002226 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0002225 ; + + rdfs:isDefinedBy ; + + skos:definition "A jacket is a covering device that is placed around something. [Allotrope]" ; + + skos:example "pipe jacket, reactor jacket" ; + + skos:prefLabel "jacket" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0002227 + +af-e:AFE_0002227 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000354 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000085 ; + owl:someValuesFrom af-fn:AFFN_0000008 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A connecting device is a device that has the function to connect things. [Allotrope]" ; + + skos:prefLabel "connecting device" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0002228 + +af-e:AFE_0002228 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000354 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000085 ; + owl:someValuesFrom af-fn:AFFN_0000130 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A shaping device is a conversion device that alters the shape of some material. [Allotrope]" ; + + skos:prefLabel "shaping device" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0002229 + +af-e:AFE_0002229 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000354 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000085 ; + owl:someValuesFrom af-fn:AFFN_0000136 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "converting device" ; + + skos:definition "A conversion device is a device that has the function to convert something. [Allotrope]" ; + + skos:prefLabel "conversion device" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0002231 + +af-e:AFE_0002231 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000407 ; + + rdfs:isDefinedBy ; + + skos:altLabel "plate" ; + + skos:definition "A tray is a shallow, flat container. [Allotrope]" ; + + skos:prefLabel "tray" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0002232 + +af-e:AFE_0002232 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0002158 ; + + rdfs:isDefinedBy ; + + skos:altLabel "IT system" , + "cyber-physical system" , + "information technology system" ; + + skos:definition "A data system is an artificial system of physical devices and software running on it designed to process information or control. [Allotrope]" ; + + skos:prefLabel "data system" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0002233 + +af-e:AFE_0002233 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0002232 ; + + rdfs:isDefinedBy ; + + skos:altLabel "CDS" ; + + skos:definition "A chromatography data system is a data system that controls a chromatography system and processes data participating in a chromatography run. [Allotrope]" ; + + skos:prefLabel "chromatography data system" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0002234 + +af-e:AFE_0002234 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0002232 ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:altLabel "LIMS" , + "LIS" , + "LMS" , + "laboratory information system" , + "laboratory management system" ; + + skos:definition "A laboratory information management system is a data system used in laboratories to manage laboratory operations. [Allotrope]" ; + + skos:prefLabel "laboratory information management system" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0002235 + +af-e:AFE_0002235 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000354 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000085 ; + owl:someValuesFrom af-fn:AFFN_0000045 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A communication device is a device that has the function to communicate (transport information). [Allotrope]" ; + + skos:prefLabel "communication device" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0002236 + +af-e:AFE_0002236 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0001745 , + af-e:AFE_0002193 ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:definition "A beam splitter is an optical device that splits a beam of light in two. [Wikipedia]" ; + + skos:prefLabel "beamsplitter" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0002240 + +af-e:AFE_0002240 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0002243 ; + + rdfs:isDefinedBy ; + + skos:definition "A array card block is a container that uses microfluidic cards to load and accept well plates. [Allotrope]" ; + + skos:prefLabel "array card block" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0002241 + +af-e:AFE_0002241 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0001028 , + af-sp:AFSP_0000009 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0001025 ; + owl:someValuesFrom af-e:AFE_0000029 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "well" ; + + skos:definition "A well (plate) is a well located in a well plate. [Allotrope]" ; + + skos:prefLabel "well (plate)" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0002242 + +af-e:AFE_0002242 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000354 ; + + rdfs:isDefinedBy ; + + skos:definition "An observation device is a device that has the function to observe something. [Allotrope]" ; + + skos:prefLabel "observation device" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0002243 + +af-e:AFE_0002243 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000407 ; + + rdfs:isDefinedBy ; + + skos:altLabel "block" , + "qPCR block" , + "reaction block" ; + + skos:definition "A qPCR reaction block is a container for samples used in qPCR instruments. [Allotrope]" ; + + skos:prefLabel "qPCR reaction block" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0002248 + +af-e:AFE_0002248 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000354 . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0002250 + +af-e:AFE_0002250 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000354 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A radiation source is a device that produces radiation used in a process. [Allotrope]" ; + + skos:prefLabel "radiation source" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0002252 + +af-e:AFE_0002252 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0002254 ; + + rdfs:isDefinedBy ; + + skos:definition "An aperture is an inhibition device that is a small opening with the function of limiting the passage of matter or energy. [Allotrope]" ; + + skos:prefLabel "aperture" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0002253 + +af-e:AFE_0002253 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0002227 ; + + rdfs:isDefinedBy ; + + skos:definition "A sample measurement interface is a connecting device through which measurements are captured. [Allotrope]" ; + + skos:prefLabel "sample measurement interface" . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0002254 + +af-e:AFE_0002254 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0000354 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000085 ; + owl:someValuesFrom af-fn:AFFN_0000135 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "inhibitor" ; + + skos:definition "An inhibition device is a device that has the function to inhibit flows (material, energy, information). A part of the flow is passing through the device. [Allotrope]" ; + + skos:prefLabel "inhibition device" . + + + +### http://purl.allotrope.org/ontologies/function#AFFN_0000002 + +af-fn:AFFN_0000002 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( af-fn:AFFN_0000113 + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000054 ; + owl:someValuesFrom af-p:AFP_0003575 + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:subClassOf af-fn:AFFN_0000113 ; + + rdfs:isDefinedBy ; + + skos:definition "To deliver material is the function to transfer a material to or into a destination. [Allotrope]" ; + + skos:prefLabel "to deliver material" . + + + +### http://purl.allotrope.org/ontologies/function#AFFN_0000003 + +af-fn:AFFN_0000003 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( af-fn:AFFN_0000002 + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000054 ; + owl:someValuesFrom [ owl:intersectionOf ( af-p:AFP_0003349 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002745 ; + owl:someValuesFrom af-rl:AFRL_0000011 + ] + ) ; + rdf:type owl:Class + ] + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:subClassOf af-fn:AFFN_0000002 ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "To deliver mobile phase is the function to deliver material that is in a mobile phase role. [Allotrope]" ; + + skos:prefLabel "to deliver mobile phase" . + + + +### http://purl.allotrope.org/ontologies/function#AFFN_0000004 + +af-fn:AFFN_0000004 rdf:type owl:Class ; + + rdfs:subClassOf af-fn:AFFN_0000123 ; + + rdfs:isDefinedBy ; + + skos:altLabel "equilibrating function" , + "equilibration function" ; + + skos:definition "To equilibrate is a function which is realized in the process of equilibration. [Allotrope]" ; + + skos:prefLabel "to equilibrate" . + + + +### http://purl.allotrope.org/ontologies/function#AFFN_0000006 + +af-fn:AFFN_0000006 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( af-fn:AFFN_0000206 + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000054 ; + owl:someValuesFrom af-p:AFP_0002389 + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:subClassOf af-fn:AFFN_0000206 ; + + dct:license ; + + dct:rights ; + + rdfs:isDefinedBy ; + + skos:definition "To calibrate is a function to establish, under specified conditions, the relationship between values of quantities indicated by a measuring instrument, or measuring system, or values represented by a material measure or a reference material, and the corresponding values realized by standards. [IUPAC]" ; + + skos:prefLabel "to calibrate" . + + + +### http://purl.allotrope.org/ontologies/function#AFFN_0000007 + +af-fn:AFFN_0000007 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( af-fn:AFFN_0000195 + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000054 ; + owl:someValuesFrom [ rdf:type owl:Class ; + owl:unionOf ( af-p:AFP_0003385 + af-p:AFP_0003564 + ) + ] + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:subClassOf af-fn:AFFN_0000195 ; + + rdfs:isDefinedBy ; + + skos:altLabel "adding function" , + "collecting function" , + "to add" ; + + skos:changeNote "2019-05-17 Changed pref label to align with process hierarchy. [Allotrope]" ; + + skos:definition "Function to add a member to an aggregate or to bring a flow together. [Allotrope]" ; + + skos:example "Solar panels collect ultraviolet sun rays to power small mechanisms. [NIST]" ; + + skos:prefLabel "to collect" . + + + +### http://purl.allotrope.org/ontologies/function#AFFN_0000008 + +af-fn:AFFN_0000008 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( af-fn:AFFN_0000195 + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000054 ; + owl:someValuesFrom af-p:AFP_0003354 + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:subClassOf af-fn:AFFN_0000195 ; + + rdfs:isDefinedBy ; + + skos:altLabel "connecting function" , + "connection function" ; + + skos:definition "To bring two or more flows (material, energy, signal) together. [NIST]" ; + + skos:prefLabel "to connect" . + + + +### http://purl.allotrope.org/ontologies/function#AFFN_0000009 + +af-fn:AFFN_0000009 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( bfo:_0000034 + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000054 ; + owl:someValuesFrom af-p:AFP_0003316 + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:subClassOf bfo:_0000034 ; + + rdfs:isDefinedBy ; + + skos:altLabel "consuming function" , + "consumption function" ; + + skos:definition "The to consume function is a function that is realized in a process where a participant exists at the start of the process but no longer exists at the end of the process. [Allotrope]" ; + + skos:prefLabel "to consume" . + + + +### http://purl.allotrope.org/ontologies/function#AFFN_0000010 + +af-fn:AFFN_0000010 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( af-fn:AFFN_0000138 + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000054 ; + owl:someValuesFrom af-p:AFP_0003488 + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:subClassOf af-fn:AFFN_0000138 ; + + rdfs:isDefinedBy ; + + skos:altLabel "indicating function" ; + + skos:definition "To make something known to the user about a flow. [NIST]" ; + + skos:example "A small window in the water container of a coffee maker indicates the level of water in the machine. [NIST]" ; + + skos:prefLabel "to indicate" . + + + +### http://purl.allotrope.org/ontologies/function#AFFN_0000014 + +af-fn:AFFN_0000014 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( bfo:_0000034 + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000054 ; + owl:someValuesFrom af-p:AFP_0003359 + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:subClassOf bfo:_0000034 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "controlling function" ; + + skos:definition "To alter or govern the size or amplitude of a flow (material, energy, signal). [NIST]" ; + + skos:prefLabel "to control" . + + + +### http://purl.allotrope.org/ontologies/function#AFFN_0000023 + +af-fn:AFFN_0000023 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( af-fn:AFFN_0000138 + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000054 ; + owl:someValuesFrom af-p:AFP_0003305 + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:subClassOf af-fn:AFFN_0000196 ; + + rdfs:isDefinedBy ; + + skos:altLabel "observing function" , + "sensing function" , + "to observe" ; + + skos:changeNote "2020-07-27 Change hierarchy to align with process. [Allotrope]" ; + + skos:definition "To sense is a signaling function that is perceiving or becoming aware, of a flow. [NIST]" ; + + skos:prefLabel "to sense" . + + + +### http://purl.allotrope.org/ontologies/function#AFFN_0000024 + +af-fn:AFFN_0000024 rdf:type owl:Class ; + + rdfs:subClassOf af-fn:AFFN_0000028 ; + + rdfs:isDefinedBy ; + + skos:altLabel "fixing function" , + "securing function" , + "to fix" ; + + skos:definition "To firmly fix a flow path. [NIST]" ; + + skos:example "On a bicycling glove, a Velcro strap secures the human hand in the correct place. [NIST]" ; + + skos:prefLabel "to secure" . + + + +### http://purl.allotrope.org/ontologies/function#AFFN_0000025 + +af-fn:AFFN_0000025 rdf:type owl:Class ; + + rdfs:subClassOf af-fn:AFFN_0000136 ; + + rdfs:isDefinedBy ; + + skos:altLabel "data processing function" , + "data transformation function" , + "data transforming function" , + "to process data" ; + + skos:definition "To submit information to a particular treatment or method having a set number of operations or steps. [NIST]" ; + + skos:example "A computer processes a login request signal before allowing a user access to its facilities. [NIST]" ; + + skos:prefLabel "to transform data" . + + + +### http://purl.allotrope.org/ontologies/function#AFFN_0000026 + +af-fn:AFFN_0000026 rdf:type owl:Class ; + + rdfs:subClassOf af-fn:AFFN_0000027 ; + + rdfs:isDefinedBy ; + + skos:altLabel "integration function" , + "to integrate" ; + + skos:definition "A information processing function that generates integrals on numerical data item. [Allotrope]" ; + + skos:prefLabel "to integrate (math)" . + + + +### http://purl.allotrope.org/ontologies/function#AFFN_0000027 + +af-fn:AFFN_0000027 rdf:type owl:Class ; + + rdfs:subClassOf af-fn:AFFN_0000025 ; + + rdfs:isDefinedBy ; + + skos:altLabel "calculating function" , + "calculation function" ; + + skos:definition "To calculate is a data transformation function to solve problems for numbers or quantities. [Allotrope]" ; + + skos:prefLabel "to calculate" . + + + +### http://purl.allotrope.org/ontologies/function#AFFN_0000028 + +af-fn:AFFN_0000028 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000034 ; + + rdfs:isDefinedBy ; + + skos:altLabel "supporting function" ; + + skos:definition "To firmly fix a material into a defined location, or secure an energy or signal into a specific course. [NIST]" ; + + skos:prefLabel "to support" . + + + +### http://purl.allotrope.org/ontologies/function#AFFN_0000029 + +af-fn:AFFN_0000029 rdf:type owl:Class ; + + rdfs:subClassOf af-fn:AFFN_0000109 ; + + rdfs:isDefinedBy ; + + skos:altLabel "cleaning function" ; + + skos:definition "The material processing function to get rid of dirt, impurities, or extraneous unwanted matter. [Allotrope]" ; + + skos:prefLabel "to clean" . + + + +### http://purl.allotrope.org/ontologies/function#AFFN_0000030 + +af-fn:AFFN_0000030 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( af-fn:AFFN_0000113 + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000054 ; + owl:someValuesFrom af-p:AFP_0003666 + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:subClassOf af-fn:AFFN_0000113 ; + + rdfs:isDefinedBy ; + + skos:altLabel "injecting function" , + "injection function" ; + + skos:definition "The function of a device realized when administering a substance applied particularly to the forcible insertion of a liquid or gas by means of a syringe, pump, etc. [OBI]" ; + + skos:prefLabel "to inject" . + + + +### http://purl.allotrope.org/ontologies/function#AFFN_0000031 + +af-fn:AFFN_0000031 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( af-fn:AFFN_0000105 + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000054 ; + owl:someValuesFrom af-p:AFP_0003533 + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:subClassOf af-fn:AFFN_0000076 ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "material separation function" ; + + skos:definition "A material separation function is a function that increases the resolution between two or more material entities. The to distinction between the entities is usually based on some associated physical quality. [OBI]" ; + + skos:prefLabel "to separate material" . + + + +### http://purl.allotrope.org/ontologies/function#AFFN_0000032 + +af-fn:AFFN_0000032 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( af-fn:AFFN_0000031 + af-fn:AFFN_0000107 + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000054 ; + owl:someValuesFrom af-p:AFP_0001321 + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:subClassOf af-fn:AFFN_0000105 ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "separation by chromatography function" ; + + skos:definition "A material separation function which is realized by chromatography. [Allotrope]" ; + + skos:prefLabel "to separate material by chromatography" . + + + +### http://purl.allotrope.org/ontologies/function#AFFN_0000036 + +af-fn:AFFN_0000036 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( af-fn:AFFN_0000041 + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000054 ; + owl:someValuesFrom af-p:AFP_0001645 + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:subClassOf af-fn:AFFN_0000025 ; + + rdfs:isDefinedBy ; + + skos:altLabel "counting function" ; + + skos:definition "To count is to observe the quantitative number of discrete things. [Allotrope]" ; + + skos:prefLabel "to count" . + + + +### http://purl.allotrope.org/ontologies/function#AFFN_0000037 + +af-fn:AFFN_0000037 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( af-fn:AFFN_0000023 + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000054 ; + owl:someValuesFrom af-p:AFP_0000925 + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:subClassOf af-fn:AFFN_0000023 ; + + rdfs:isDefinedBy ; + + skos:altLabel "detecting function" , + "detection function" ; + + skos:definition "To discover information about the presence of a flow. [NIST]" ; + + skos:example "A gauge on the top of a gas cylinder detects proper pressure ranges. [NIST]" ; + + skos:prefLabel "to detect" . + + + +### http://purl.allotrope.org/ontologies/function#AFFN_0000041 + +af-fn:AFFN_0000041 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( af-fn:AFFN_0000023 + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000054 ; + owl:someValuesFrom af-p:AFP_0002294 + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:subClassOf af-fn:AFFN_0000023 ; + + rdfs:isDefinedBy ; + + skos:altLabel "measuring function" ; + + skos:definition "To determine the magnitude of a flow. [NIST]" ; + + skos:example "An analog thermostat measures temperature through a bimetallic strip. [NIST]" ; + + skos:prefLabel "to measure" . + + + +### http://purl.allotrope.org/ontologies/function#AFFN_0000043 + +af-fn:AFFN_0000043 rdf:type owl:Class ; + + rdfs:subClassOf af-fn:AFFN_0000187 ; + + rdfs:isDefinedBy ; + + skos:altLabel "energy transfer function" , + "to transfer energy" , + "to transmit" , + "transmitting energy function" ; + + skos:definition "To move an energy from one place to another. [NIST]" ; + + skos:example "In a hand held power sander, the housing of the sander transmits human force to the object being sanded. [NIST]" ; + + skos:prefLabel "to transmit energy" . + + + +### http://purl.allotrope.org/ontologies/function#AFFN_0000044 + +af-fn:AFFN_0000044 rdf:type owl:Class ; + + rdfs:subClassOf af-fn:AFFN_0000128 ; + + rdfs:isDefinedBy ; + + skos:altLabel "heating function" ; + + skos:definition "A function that gives thermal energy to a recipient. [Allotrope]" ; + + skos:prefLabel "to heat" . + + + +### http://purl.allotrope.org/ontologies/function#AFFN_0000045 + +af-fn:AFFN_0000045 rdf:type owl:Class ; + + rdfs:subClassOf af-fn:AFFN_0000187 ; + + rdfs:isDefinedBy ; + + skos:altLabel "communicating function" , + "communication function" ; + + skos:definition "To communicate is the function to transferring information from one material entity to another. [Allotrope]" ; + + skos:prefLabel "to communicate" . + + + +### http://purl.allotrope.org/ontologies/function#AFFN_0000046 + +af-fn:AFFN_0000046 rdf:type owl:Class ; + + rdfs:subClassOf af-fn:AFFN_0000186 ; + + rdfs:isDefinedBy ; + + skos:altLabel "pumping function" ; + + skos:definition "To pump is to transport fluids by suction or pressure or both. [Allotrope]" ; + + skos:prefLabel "to pump" . + + + +### http://purl.allotrope.org/ontologies/function#AFFN_0000049 + +af-fn:AFFN_0000049 rdf:type owl:Class ; + + rdfs:subClassOf [ owl:intersectionOf ( af-fn:AFFN_0000031 + af-fn:AFFN_0000076 + ) ; + rdf:type owl:Class + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "material filtering function" , + "to filter" ; + + skos:definition "A filter function is a function to prevent the flow of certain entities based on a quality or qualities of the entity while allowing entities which have different qualities to pass through. [OBI]" ; + + skos:prefLabel "to filter material" . + + + +### http://purl.allotrope.org/ontologies/function#AFFN_0000052 + +af-fn:AFFN_0000052 rdf:type owl:Class ; + + rdfs:subClassOf af-fn:AFFN_0000010 ; + + rdfs:isDefinedBy ; + + skos:altLabel "display function" , + "displaying function" ; + + skos:definition "To reveal something about a flow to the mind or eye. [NIST]" ; + + skos:example "The xyz-coordinate display on a vertical milling machine displays the precise location of the cutting tool. [NIST]" ; + + skos:prefLabel "to display" . + + + +### http://purl.allotrope.org/ontologies/function#AFFN_0000053 + +af-fn:AFFN_0000053 rdf:type owl:Class ; + + rdfs:subClassOf af-fn:AFFN_0000025 ; + + rdfs:isDefinedBy ; + + skos:altLabel "converting a signal function" , + "signal conversion function" ; + + skos:definition "A signal conversion function is an information processor function which transforms a signal into another type of signal. [OBI]" ; + + skos:example "A synapse converts electrical action potentials into an intermediate chemical signal. The post synapse converts it back into an electric one passed on to the axon." , + "an analog-to-digital_converter" ; + + skos:prefLabel "to convert a signal" . + + + +### http://purl.allotrope.org/ontologies/function#AFFN_0000055 + +af-fn:AFFN_0000055 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( af-fn:AFFN_0000137 + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000054 ; + owl:someValuesFrom af-p:AFP_0003551 + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:subClassOf af-fn:AFFN_0000137 ; + + rdfs:isDefinedBy ; + + skos:altLabel "storing function" ; + + skos:definition "To accumulate a flow. [NIST]" ; + + skos:example "A DC electrical battery stores the energy in a flashlight. [NIST]" ; + + skos:prefLabel "to store" . + + + +### http://purl.allotrope.org/ontologies/function#AFFN_0000076 + +af-fn:AFFN_0000076 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( bfo:_0000034 + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000054 ; + owl:someValuesFrom [ rdf:type owl:Class ; + owl:unionOf ( [ owl:intersectionOf ( bfo:_0000015 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000395 ; + owl:someValuesFrom af-m:AFM_0000275 + ] + ) ; + rdf:type owl:Class + ] + [ owl:intersectionOf ( bfo:_0000015 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000399 ; + owl:someValuesFrom af-m:AFM_0000275 + ] + ) ; + rdf:type owl:Class + ] + ) + ] + ] + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A material function is a type of function that is realized in a process that has material entity as input and/or output. [Allotrope]" ; + + skos:prefLabel "material function" . + + + +### http://purl.allotrope.org/ontologies/function#AFFN_0000089 + +af-fn:AFFN_0000089 rdf:type owl:Class ; + + rdfs:subClassOf af-fn:AFFN_0000129 ; + + rdfs:isDefinedBy ; + + skos:altLabel "cooling function" ; + + skos:definition "A function to remove thermal energy. [Allotrope]" ; + + skos:prefLabel "to cool" . + + + +### http://purl.allotrope.org/ontologies/function#AFFN_0000093 + +af-fn:AFFN_0000093 rdf:type owl:Class ; + + rdfs:subClassOf af-fn:AFFN_0000009 ; + + rdfs:isDefinedBy ; + + skos:altLabel "consuming energy function" , + "energy consumption function" ; + + skos:definition "To consume energy is the function to consume energy. [Allotrope]" ; + + skos:prefLabel "to consume energy" . + + + +### http://purl.allotrope.org/ontologies/function#AFFN_0000103 + +af-fn:AFFN_0000103 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( bfo:_0000034 + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000054 ; + owl:someValuesFrom af-p:AFP_0000498 + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:subClassOf bfo:_0000034 ; + + rdfs:isDefinedBy ; + + skos:altLabel "planning function" ; + + skos:definition "To plan is the function of creating or modifying a plan specification. [OBI]" ; + + skos:prefLabel "to plan" . + + + +### http://purl.allotrope.org/ontologies/function#AFFN_0000104 + +af-fn:AFFN_0000104 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( bfo:_0000034 + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000054 ; + owl:someValuesFrom af-p:AFP_0003332 + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:subClassOf bfo:_0000034 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "branching function" ; + + skos:definition "To cause a flow (material, energy or signal) to no longer be joined or mixed. [NIST]" ; + + skos:prefLabel "to branch" . + + + +### http://purl.allotrope.org/ontologies/function#AFFN_0000105 + +af-fn:AFFN_0000105 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( af-fn:AFFN_0000104 + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000054 ; + owl:someValuesFrom af-p:AFP_0000422 + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:subClassOf af-fn:AFFN_0000104 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "separating function" , + "separation function" ; + + skos:definition "To isolate a flow (material, energy, signal) into distinct components. The separated components are distinct from the flow before separation, as well as each other. [NIST]" ; + + skos:example "A glass prism separates light into different wavelength components to provide a rainbow. [NIST]" ; + + skos:prefLabel "to separate" . + + + +### http://purl.allotrope.org/ontologies/function#AFFN_0000106 + +af-fn:AFFN_0000106 rdf:type owl:Class ; + + rdfs:subClassOf af-fn:AFFN_0000104 ; + + rdfs:isDefinedBy ; + + skos:altLabel "distributing function" , + "distribution function" ; + + skos:definition "To cause a flow (material, energy, signal) to break up. The individual bits are similar to each other and the undistributed flow. [NIST]" ; + + skos:example "An atomizer distributes (or sprays) hair-styling liquids over the head to hold ther hair in the desired style. [NIST]" ; + + skos:prefLabel "to distribute" . + + + +### http://purl.allotrope.org/ontologies/function#AFFN_0000107 + +af-fn:AFFN_0000107 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( bfo:_0000034 + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000054 ; + owl:someValuesFrom af-p:AFP_0003335 + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:subClassOf af-fn:AFFN_0000105 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "dividing function" ; + + skos:definition "To separate a flow. [NIST]" ; + + skos:example "A vending machine divides the sold form of coins into appropriate denominations. [NIST]" ; + + skos:prefLabel "to divide" . + + + +### http://purl.allotrope.org/ontologies/function#AFFN_0000108 + +af-fn:AFFN_0000108 rdf:type owl:Class ; + + rdfs:subClassOf af-fn:AFFN_0000105 ; + + rdfs:isDefinedBy ; + + skos:altLabel "removing function" ; + + skos:definition "To take away a part of a flow from its prefixed place. [NIST]" ; + + skos:example "A sander removes small pieces of the wood surface to smooth the wood. [NIST]" ; + + skos:prefLabel "to remove" . + + + +### http://purl.allotrope.org/ontologies/function#AFFN_0000109 + +af-fn:AFFN_0000109 rdf:type owl:Class ; + + rdfs:subClassOf af-fn:AFFN_0000105 ; + + rdfs:isDefinedBy ; + + skos:altLabel "extracting function" ; + + skos:definition "To draw, or forcibly pullout, a flow. [NIST]" ; + + skos:example "A vacuum cleaner extracts depris from the imported mixture and exports clean air to the environment. [NIST]" ; + + skos:prefLabel "to extract" . + + + +### http://purl.allotrope.org/ontologies/function#AFFN_0000110 + +af-fn:AFFN_0000110 rdf:type owl:Class ; + + rdfs:subClassOf af-fn:AFFN_0000106 ; + + rdfs:isDefinedBy ; + + skos:altLabel "sorting function" ; + + skos:definition "A sort function is a function to distinguish flows based on some associated physical quality or entity and to distribute the separate components into distinct fractions according to a defined order. [Allotrope]" ; + + skos:prefLabel "to sort" . + + + +### http://purl.allotrope.org/ontologies/function#AFFN_0000111 + +af-fn:AFFN_0000111 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( bfo:_0000034 + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000054 ; + owl:someValuesFrom af-p:AFP_0003348 + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:subClassOf bfo:_0000034 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "channeling function" , + "localizing function" , + "to channel" ; + + skos:definition "To cause a flow (material, energy, signal) to move from one location to another location. [NIST]" ; + + skos:prefLabel "to localize" . + + + +### http://purl.allotrope.org/ontologies/function#AFFN_0000112 + +af-fn:AFFN_0000112 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( af-fn:AFFN_0000111 + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000054 ; + owl:someValuesFrom af-p:AFP_0003350 + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:subClassOf af-fn:AFFN_0000111 ; + + rdfs:isDefinedBy ; + + skos:altLabel "exporting function" , + "taking function" , + "to take" ; + + skos:definition "To send a flow (material, energy, signal) outside the system boundary. [NIST]" ; + + skos:example "Pouring blended food out of a standard blender pitcher exports liquid from the system. [NIST]" ; + + skos:prefLabel "to export" . + + + +### http://purl.allotrope.org/ontologies/function#AFFN_0000113 + +af-fn:AFFN_0000113 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( af-fn:AFFN_0000111 + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000054 ; + owl:someValuesFrom af-p:AFP_0003349 + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:subClassOf af-fn:AFFN_0000111 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "delivering function" , + "importing function" , + "to deliver" ; + + skos:definition "To bring in a flow (material, energy, signal) from outside the system boundary. [NIST]" ; + + skos:example "A physical opening at the top of a blender pitcher imports a solid (food) into the system. [NIST]" ; + + skos:prefLabel "to import" . + + + +### http://purl.allotrope.org/ontologies/function#AFFN_0000115 + +af-fn:AFFN_0000115 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( af-fn:AFFN_0000111 + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000054 ; + owl:someValuesFrom af-p:AFP_0003351 + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:subClassOf af-fn:AFFN_0000111 ; + + rdfs:isDefinedBy ; + + skos:altLabel "directing function" , + "guiding function" , + "to direct" ; + + skos:definition "To direct the course of a flow (material, energy, signal) along a specific path. [NIST]" ; + + skos:prefLabel "to guide" . + + + +### http://purl.allotrope.org/ontologies/function#AFFN_0000116 + +af-fn:AFFN_0000116 rdf:type owl:Class ; + + rdfs:subClassOf af-fn:AFFN_0000115 ; + + rdfs:isDefinedBy ; + + skos:altLabel "allowing DOF function" , + "allowing degree of freedom function" , + "to allow DOF" ; + + skos:definition "To control the movement of a flow by a force external to the device into one or more directions. [NIST]" ; + + skos:prefLabel "to allow degree of freedom" . + + + +### http://purl.allotrope.org/ontologies/function#AFFN_0000117 + +af-fn:AFFN_0000117 rdf:type owl:Class ; + + rdfs:subClassOf af-fn:AFFN_0000115 ; + + rdfs:isDefinedBy ; + + skos:altLabel "rotating function" ; + + skos:definition "To fix the movement of a flow by a device around one axis. [NIST]" ; + + skos:prefLabel "to rotate" . + + + +### http://purl.allotrope.org/ontologies/function#AFFN_0000118 + +af-fn:AFFN_0000118 rdf:type owl:Class ; + + rdfs:subClassOf af-fn:AFFN_0000115 ; + + rdfs:isDefinedBy ; + + skos:altLabel "translating function" ; + + skos:definition "To fix the movement of the flow by a device into one linear direction. [NIST]" ; + + skos:prefLabel "to translate" . + + + +### http://purl.allotrope.org/ontologies/function#AFFN_0000119 + +af-fn:AFFN_0000119 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( af-fn:AFFN_0000008 + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000054 ; + owl:someValuesFrom af-p:AFP_0001135 + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:subClassOf af-fn:AFFN_0000008 ; + + rdfs:isDefinedBy ; + + skos:altLabel "mixing function" ; + + skos:definition "To combine two flows (material, energy, signal) into a single, uniform homogeneous mass. [NIST]" ; + + skos:example "A shaker mixes a paint base and its dyes to form a homogeneous liquid. [NIST]" ; + + skos:prefLabel "to mix" . + + + +### http://purl.allotrope.org/ontologies/function#AFFN_0000120 + +af-fn:AFFN_0000120 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( af-fn:AFFN_0000008 + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000054 ; + owl:someValuesFrom af-p:AFP_0003356 + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:subClassOf af-fn:AFFN_0000008 ; + + rdfs:isDefinedBy ; + + skos:altLabel "coupling function" , + "to bring together" ; + + skos:definition "To join or bring together flows (material, energy, signal) such that the members are still distinguishable from each other. [NIST]" ; + + skos:prefLabel "to couple" . + + + +### http://purl.allotrope.org/ontologies/function#AFFN_0000121 + +af-fn:AFFN_0000121 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( af-fn:AFFN_0000120 + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000054 ; + owl:someValuesFrom af-p:AFP_0003358 + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:subClassOf af-fn:AFFN_0000120 ; + + rdfs:isDefinedBy ; + + skos:altLabel "coupling function" , + "linking function" , + "to couple" ; + + skos:definition "To couple flows together by means of an intermediary flow. [NIST]" ; + + skos:example "A turnbuckle links two endsof a steering cable together. [NIST]" ; + + skos:prefLabel "to link" . + + + +### http://purl.allotrope.org/ontologies/function#AFFN_0000122 + +af-fn:AFFN_0000122 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( af-fn:AFFN_0000120 + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000054 ; + owl:someValuesFrom af-p:AFP_0003357 + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:subClassOf af-fn:AFFN_0000120 ; + + rdfs:isDefinedBy ; + + skos:altLabel "coupling function" , + "joining function" , + "to couple" ; + + skos:definition "To couple flows together in a predetermined manner. [NIST]" ; + + skos:example "A ratchet joins a socket on its square shaft interface. [NIST]" ; + + skos:prefLabel "to join" . + + + +### http://purl.allotrope.org/ontologies/function#AFFN_0000123 + +af-fn:AFFN_0000123 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( af-fn:AFFN_0000014 + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000054 ; + owl:someValuesFrom af-p:AFP_0003485 + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:subClassOf af-fn:AFFN_0000014 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "adjusting function" , + "regulating function" , + "to adjust" ; + + skos:definition "To adjust the flow of energy, signal, or material in response to a control signal, such as a characteristic of a flow. [NIST]" ; + + skos:example "Turning the valves regulates the flow rate of the liquid flowing from a faucet. [NIST]" ; + + skos:prefLabel "to regulate" . + + + +### http://purl.allotrope.org/ontologies/function#AFFN_0000124 + +af-fn:AFFN_0000124 rdf:type owl:Class ; + + rdfs:subClassOf af-fn:AFFN_0000014 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "actuating function" , + "commencing function" , + "to commence" ; + + skos:definition "To commence the flow of energy, signal or material in response to an imported control signal. [NIST]" ; + + skos:example "A circuit switch actuates the flow of electrical energy and turns on a light bulb. [NIST]" ; + + skos:prefLabel "to actuate" . + + + +### http://purl.allotrope.org/ontologies/function#AFFN_0000125 + +af-fn:AFFN_0000125 rdf:type owl:Class ; + + rdfs:subClassOf af-fn:AFFN_0000123 ; + + rdfs:isDefinedBy ; + + skos:altLabel "enlarging function" , + "increasing function" , + "to enlarge" ; + + skos:definition "To enlarge a flow in response to a control signal. [NIST]" ; + + skos:prefLabel "to increase" . + + + +### http://purl.allotrope.org/ontologies/function#AFFN_0000126 + +af-fn:AFFN_0000126 rdf:type owl:Class ; + + rdfs:subClassOf af-fn:AFFN_0000123 ; + + rdfs:isDefinedBy ; + + skos:altLabel "decreasing function" , + "reducing function" , + "to reduce" ; + + skos:definition "To reduce a flow in response to a control signal. [NIST]" ; + + skos:prefLabel "to decrease" . + + + +### http://purl.allotrope.org/ontologies/function#AFFN_0000127 + +af-fn:AFFN_0000127 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( af-fn:AFFN_0000111 + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000054 ; + owl:someValuesFrom af-p:AFP_0003486 + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:subClassOf af-fn:AFFN_0000014 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "adjusting function" , + "changing function" , + "to adjust" ; + + skos:definition "To adjust the flow of energy, signal, or material in a predetermined and fixed manner. [NIST]" ; + + skos:prefLabel "to change" . + + + +### http://purl.allotrope.org/ontologies/function#AFFN_0000128 + +af-fn:AFFN_0000128 rdf:type owl:Class ; + + rdfs:subClassOf af-fn:AFFN_0000127 ; + + rdfs:isDefinedBy ; + + skos:altLabel "enlarging function" , + "incrementing function" , + "to enlarge" ; + + skos:definition "To enlarge a flow in a predetermined and fixed manner. [NIST]" ; + + skos:prefLabel "to increment" . + + + +### http://purl.allotrope.org/ontologies/function#AFFN_0000129 + +af-fn:AFFN_0000129 rdf:type owl:Class ; + + rdfs:subClassOf af-fn:AFFN_0000127 ; + + rdfs:isDefinedBy ; + + skos:altLabel "decrementing function" , + "reducing function" , + "to reduce" ; + + skos:definition "To reduce a flow in a predetermined and fixed manner. [NIST]" ; + + skos:prefLabel "to decrement" . + + + +### http://purl.allotrope.org/ontologies/function#AFFN_0000130 + +af-fn:AFFN_0000130 rdf:type owl:Class ; + + rdfs:subClassOf af-fn:AFFN_0000127 ; + + rdfs:isDefinedBy ; + + skos:altLabel "forming function" , + "molding function" , + "shaping function" , + "to form" , + "to mold" ; + + skos:definition "To mold or form a flow. [NIST]" ; + + skos:prefLabel "to shape" . + + + +### http://purl.allotrope.org/ontologies/function#AFFN_0000131 + +af-fn:AFFN_0000131 rdf:type owl:Class ; + + rdfs:subClassOf af-fn:AFFN_0000127 ; + + rdfs:isDefinedBy ; + + skos:altLabel "conditioning function" ; + + skos:definition "To render a flow appropriate for the desired use. [NIST]" ; + + skos:example "To prevent damage to electrial equipment, a surge protector conditions electrical energy by excluding spikes and nose (usually through capacitors) from the energy path. [NIST]" ; + + skos:prefLabel "to condition" . + + + +### http://purl.allotrope.org/ontologies/function#AFFN_0000132 + +af-fn:AFFN_0000132 rdf:type owl:Class ; + + rdfs:subClassOf af-fn:AFFN_0000014 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "stopping function" ; + + skos:definition "To cease, or prevent, the transfer of a flow (material, energy, signal). [NIST]" ; + + skos:example "A reflective coating on a window stops the transmission of UV radiation through a window. [NIST]" ; + + skos:prefLabel "to stop" . + + + +### http://purl.allotrope.org/ontologies/function#AFFN_0000134 + +af-fn:AFFN_0000134 rdf:type owl:Class ; + + rdfs:subClassOf af-fn:AFFN_0000132 ; + + rdfs:isDefinedBy ; + + skos:altLabel "preventing function" ; + + skos:definition "To keep a flow from happening. [NIST]" ; + + skos:example "A submerged gate on a dam wall prevents water from flowing to the other side. [NIST]" ; + + skos:prefLabel "to prevent" . + + + +### http://purl.allotrope.org/ontologies/function#AFFN_0000135 + +af-fn:AFFN_0000135 rdf:type owl:Class ; + + rdfs:subClassOf af-fn:AFFN_0000132 ; + + rdfs:isDefinedBy ; + + skos:altLabel "inhibiting function" , + "restraining function" , + "to restrain" ; + + skos:definition "To significantly restrain a flow, though a portion of the flow continues to be transferred. [NIST]" ; + + skos:example "The structures of space vehicles inhibits the flow of radiation to protect crew and cargo. [NIST]" ; + + skos:prefLabel "to inhibit" . + + + +### http://purl.allotrope.org/ontologies/function#AFFN_0000136 + +af-fn:AFFN_0000136 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( bfo:_0000034 + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000054 ; + owl:someValuesFrom af-p:AFP_0003565 + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:subClassOf bfo:_0000034 ; + + rdfs:isDefinedBy ; + + skos:altLabel "changing function" , + "converting function" , + "to change" ; + + skos:definition "To change from one form of a flow (material, energy, signal) to another. [NIST]" ; + + skos:editorialNote "For completeness, any type of flow conversion is valid. In practice, conversions such as convert electricity to torque will be more common than convert solid to optical energy. [NIST]" ; + + skos:example "An electrical motor converts electricity to rotational energy. [NIST]" ; + + skos:prefLabel "to convert" . + + + +### http://purl.allotrope.org/ontologies/function#AFFN_0000137 + +af-fn:AFFN_0000137 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( bfo:_0000034 + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000054 ; + owl:someValuesFrom af-p:AFP_0003563 + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:subClassOf bfo:_0000034 ; + + rdfs:isDefinedBy ; + + skos:altLabel "provisioning function" ; + + skos:definition "To accumulate or provide a material or energy flow. [NIST]" ; + + skos:prefLabel "to provision" . + + + +### http://purl.allotrope.org/ontologies/function#AFFN_0000138 + +af-fn:AFFN_0000138 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( bfo:_0000034 + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000054 ; + owl:someValuesFrom af-p:AFP_0003552 + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:subClassOf bfo:_0000034 ; + + rdfs:isDefinedBy ; + + skos:altLabel "signaling function" ; + + skos:definition "To provide information on a material, energy or signal flow as an output signal flow. The information providing flow passes through the function unchanged. [NIST]" ; + + skos:prefLabel "to signal" . + + + +### http://purl.allotrope.org/ontologies/function#AFFN_0000139 + +af-fn:AFFN_0000139 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( af-fn:AFFN_0000055 + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000054 ; + owl:someValuesFrom af-p:AFP_0003306 + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:subClassOf af-fn:AFFN_0000055 ; + + rdfs:isDefinedBy ; + + skos:altLabel "containing function" ; + + skos:definition "To keep a flow within limits. [NIST]" ; + + skos:example "A vacuum bag contains debris vacuumed from a house. [NIST]" ; + + skos:prefLabel "to contain" . + + + +### http://purl.allotrope.org/ontologies/function#AFFN_0000140 + +af-fn:AFFN_0000140 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( af-fn:AFFN_0000137 + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000054 ; + owl:someValuesFrom af-p:AFP_0003553 + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:subClassOf af-fn:AFFN_0000137 ; + + rdfs:isDefinedBy ; + + skos:altLabel "supplying function" ; + + skos:definition "To provide a flow from storage. [NIST]" ; + + skos:example "In a flashlight, the battery supplies energy to the bulb. [NIST]" ; + + skos:prefLabel "to supply" . + + + +### http://purl.allotrope.org/ontologies/function#AFFN_0000141 + +af-fn:AFFN_0000141 rdf:type owl:Class ; + + rdfs:subClassOf af-fn:AFFN_0000010 ; + + rdfs:isDefinedBy ; + + skos:altLabel "tracking function" ; + + skos:definition "To observe and record data from a flow. [NIST]" ; + + skos:example "By tracking the performance of batteries, the low efficiency point can be determined. [NIST]" ; + + skos:prefLabel "to track" . + + + +### http://purl.allotrope.org/ontologies/function#AFFN_0000142 + +af-fn:AFFN_0000142 rdf:type owl:Class ; + + rdfs:subClassOf af-fn:AFFN_0000028 ; + + rdfs:isDefinedBy ; + + skos:altLabel "stabilization function" ; + + skos:definition "To prevent a flow from changing course or location. [NIST]" ; + + skos:example "On a typical canister vacuum, the center of gravity is placed at a low elevation to stabilize the vacuum when it is pulled by the hose. [NIST]" ; + + skos:prefLabel "to stabilize" . + + + +### http://purl.allotrope.org/ontologies/function#AFFN_0000143 + +af-fn:AFFN_0000143 rdf:type owl:Class ; + + rdfs:subClassOf af-fn:AFFN_0000028 ; + + rdfs:isDefinedBy ; + + skos:altLabel "placement function" , + "positioning function" , + "to place" ; + + skos:definition "To place a flow (material, energy, signal) into a specific location or orientation. [NIST]" ; + + skos:example "The coin slot on a soda machine positions the coin to begin the coin evaluation and transportation procedure. [NIST]" ; + + skos:prefLabel "to position" . + + + +### http://purl.allotrope.org/ontologies/function#AFFN_0000144 + +af-fn:AFFN_0000144 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( af-fn:AFFN_0000108 + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000054 ; + owl:someValuesFrom af-p:AFP_0003574 + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:subClassOf af-fn:AFFN_0000031 ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "To remove material is the function to remove material. [NIST]" ; + + skos:prefLabel "to remove material" . + + + +### http://purl.allotrope.org/ontologies/function#AFFN_0000185 + +af-fn:AFFN_0000185 rdf:type owl:Class ; + + rdfs:subClassOf af-fn:AFFN_0000009 ; + + rdfs:isDefinedBy ; + + skos:altLabel "decomposition function" ; + + skos:definition "To decompose is the function to breakdown a single phase into two or more phases by heating or treatment with acid, alkali or enzymes. [Allotrope]" ; + + skos:prefLabel "to decompose" . + + + +### http://purl.allotrope.org/ontologies/function#AFFN_0000186 + +af-fn:AFFN_0000186 rdf:type owl:Class ; + + rdfs:subClassOf af-fn:AFFN_0000187 ; + + rdfs:isDefinedBy ; + + skos:altLabel "material transport function" , + "to transfer material" , + "transport function" ; + + skos:definition "To transport is the function to transfer material. [Allotrope]" ; + + skos:prefLabel "to transport" . + + + +### http://purl.allotrope.org/ontologies/function#AFFN_0000187 + +af-fn:AFFN_0000187 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( af-fn:AFFN_0000111 + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000054 ; + owl:someValuesFrom af-p:AFP_0003312 + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:subClassOf af-fn:AFFN_0000111 ; + + rdfs:isDefinedBy ; + + skos:altLabel "conveying function" , + "shifting function" , + "to convey" , + "to shift" , + "transferring function" ; + + skos:definition "To shift, or convey, a flow (material, energy, signal) from one place to another. [NIST]" ; + + skos:prefLabel "to transfer" . + + + +### http://purl.allotrope.org/ontologies/function#AFFN_0000191 + +af-fn:AFFN_0000191 rdf:type owl:Class ; + + rdfs:subClassOf af-fn:AFFN_0000123 ; + + rdfs:isDefinedBy ; + + skos:altLabel "maintaining function" ; + + skos:definition "The function to maintain something. [Allotrope]" ; + + skos:prefLabel "to maintain" . + + + +### http://purl.allotrope.org/ontologies/function#AFFN_0000195 + +af-fn:AFFN_0000195 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( bfo:_0000034 + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000054 ; + owl:someValuesFrom af-p:AFP_0003475 + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:subClassOf bfo:_0000034 ; + + rdfs:isDefinedBy ; + + skos:altLabel "combining function" ; + + skos:definition "The function to make a whole out of many. [Allotrope]" ; + + skos:prefLabel "to combine" . + + + +### http://purl.allotrope.org/ontologies/function#AFFN_0000196 + +af-fn:AFFN_0000196 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( bfo:_0000034 + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000054 ; + owl:someValuesFrom af-p:AFP_0003315 + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:subClassOf bfo:_0000034 ; + + rdfs:isDefinedBy ; + + skos:definition "The function to bring something into existence. [Allotrope]" ; + + skos:editorialNote "Only information can be produced in the strict sense, because of physical conservation laws of energy and material, but this is function is a perspective on a system boundaries in the context. [Allotrope]" ; + + skos:prefLabel "to produce" . + + + +### http://purl.allotrope.org/ontologies/function#AFFN_0000198 + +af-fn:AFFN_0000198 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( af-fn:AFFN_0000036 + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000054 ; + owl:someValuesFrom af-p:AFP_0003629 + ] + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "To count cells is the function to count cells. [Allotrope]" ; + + skos:prefLabel "to count cells" . + + + +### http://purl.allotrope.org/ontologies/function#AFFN_0000201 + +af-fn:AFFN_0000201 rdf:type owl:Class ; + + rdfs:subClassOf af-fn:AFFN_0000104 , + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000054 ; + owl:someValuesFrom af-p:AFP_0003634 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "sampling function" ; + + skos:definition "To sample is the function of to take parts or partitions of an object aggregate or data set for the interest for studying it. [Allotrope]" ; + + skos:prefLabel "to sample" . + + + +### http://purl.allotrope.org/ontologies/function#AFFN_0000203 + +af-fn:AFFN_0000203 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( af-fn:AFFN_0000122 + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000054 ; + owl:someValuesFrom af-p:AFP_0003746 + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:subClassOf af-fn:AFFN_0000122 ; + + rdfs:isDefinedBy ; + + skos:altLabel "covering function" ; + + skos:definition "To cover is a joining function realized when something is joined to a surface in such way that it is preventing some kind of material or energy flow through that surface. [Allotrope]" ; + + skos:prefLabel "to cover" . + + + +### http://purl.allotrope.org/ontologies/function#AFFN_0000205 + +af-fn:AFFN_0000205 rdf:type owl:Class ; + + rdfs:subClassOf af-fn:AFFN_0000119 ; + + rdfs:isDefinedBy ; + + skos:definition "To stir is a mixing function involving the agitation of a solution through circular motion. [Allotrope]" ; + + skos:prefLabel "to stir" . + + + +### http://purl.allotrope.org/ontologies/function#AFFN_0000206 + +af-fn:AFFN_0000206 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( af-fn:AFFN_0000196 + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000054 ; + owl:someValuesFrom af-p:AFP_0003599 + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:subClassOf af-fn:AFFN_0000196 ; + + rdfs:isDefinedBy ; + + skos:altLabel "compare function" ; + + skos:definition "To compare is a function to observe or assess the similarities or dissimilarities between two things. [Allotrope]" ; + + skos:prefLabel "to compare" . + + + +### http://purl.allotrope.org/ontologies/function#AFFN_0000208 + +af-fn:AFFN_0000208 rdf:type owl:Class ; + + rdfs:subClassOf af-fn:AFFN_0000136 , + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000054 ; + owl:someValuesFrom af-p:AFP_0003771 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "coloring function" , + "dyeing function" , + "to color" ; + + skos:definition "To dye is a function to change the color of some target material. [Allotrope]" ; + + skos:prefLabel "to dye" . + + + +### http://purl.allotrope.org/ontologies/material#AFM_0000010 + +af-m:AFM_0000010 rdf:type owl:Class ; + + rdfs:subClassOf af-m:AFM_0000275 ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + af-x:AFX_0002808 chmo:_0002743 ; + + dct:license ; + + dct:rights ; + + dct:source "PAC, 1989, 61, 1657 (Nomenclature for automated and mechanised analysis (Recommendations 1989))" ; + + rdfs:isDefinedBy ; + + skos:altLabel "medium" ; + + skos:definition "The matrix are the components of a sample other than the analyte. [IUPAC]" ; + + skos:prefLabel "matrix" . + + + +### http://purl.allotrope.org/ontologies/material#AFM_0000012 + +af-m:AFM_0000012 rdf:type owl:Class ; + + rdfs:subClassOf af-m:AFM_0001035 ; + + af-x:AFX_0002796 af-r:AFR_0001223 ; + + dct:license ; + + dct:replaces af-e:AFE_0002103 ; + + dct:rights ; + + dct:source "Orange Book: IUPAC Compendium of Analytical Nomenclature. Second Edition, Blackwell Scientific Publications, Oxford, 1987." , + "PAC, 1994, 66, 533 (Standard quantities in chemical thermodynamics. Fugacities, activities and equilibrium constants for pure and mixed phases (IUPAC Recommendations 1994))" ; + + rdfs:isDefinedBy ; + + skos:definition "A solution is a homogeneous mixture composed of one phase where particles are not visible to the naked eye and the solution does not scatter a light beam. [Allotrope]" ; + + skos:prefLabel "solution" . + + + +### http://purl.allotrope.org/ontologies/material#AFM_0000077 + +af-m:AFM_0000077 rdf:type owl:Class ; + + rdfs:subClassOf chebi:_23367 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000086 ; + owl:someValuesFrom [ rdf:type owl:Class ; + owl:unionOf ( pato:_0002195 + pato:_0002196 + ) + ] + ] ; + + af-x:AFX_0002796 af-r:AFR_0001222 ; + + dct:license ; + + dct:rights ; + + dct:source "IUPAC. Compendium of Chemical Terminology, 2nd ed. (the \"Gold Book\"). Compiled by A. D. McNaught and A. Wilkinson. Blackwell Scientific Publications, Oxford (1997)." ; + + rdfs:isDefinedBy ; + + skos:definition "An ion is an atomic or molecular particle having a net electric charge. [IUPAC]" ; + + skos:prefLabel "ion" . + + + +### http://purl.allotrope.org/ontologies/material#AFM_0000085 + +af-m:AFM_0000085 rdf:type owl:Class ; + + rdfs:subClassOf af-m:AFM_0000275 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000085 ; + owl:someValuesFrom af-fn:AFFN_0000208 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A dye is a material that has the function to change the color of material. [Allotrope]" ; + + skos:prefLabel "dye" . + + + +### http://purl.allotrope.org/ontologies/material#AFM_0000105 + +af-m:AFM_0000105 rdf:type owl:Class ; + + rdfs:subClassOf af-m:AFM_0001060 , + [ rdf:type owl:Restriction ; + owl:onProperty obi:_0000643 ; + owl:someValuesFrom chebi:_15377 + ] ; + + af-x:AFX_0002796 af-r:AFR_0001223 ; + + af-x:AFX_0002808 chebi:_15377 ; + + rdfs:isDefinedBy ; + + skos:altLabel "water" ; + + skos:definition "Water is a transparent fluid which forms the world's streams, lakes, oceans and rain, and is the major constituent of the fluids of living things. [Wikipedia]" ; + + skos:prefLabel "portion of water" . + + + +### http://purl.allotrope.org/ontologies/material#AFM_0000154 + +af-m:AFM_0000154 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( af-m:AFM_0000394 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000086 ; + owl:someValuesFrom af-q:AFQ_0000114 + ] + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A gas is an airlike material that expands freely to fill any space available. It can be transported in compressed gas cylinders and acts as a gas upon release at normal temperatures and pressure. [Allotrope]" ; + + skos:prefLabel "gas" . + + + +### http://purl.allotrope.org/ontologies/material#AFM_0000161 + +af-m:AFM_0000161 rdf:type owl:Class ; + + rdfs:subClassOf af-m:AFM_0000077 ; + + rdfs:isDefinedBy ; + + skos:altLabel "negative ion" ; + + skos:definition "An anion (-) is an ion with more electrons than protons, giving it a net negative charge (since electrons are negatively charged and protons are positively charged). [Wikipedia]" ; + + skos:prefLabel "anion" . + + + +### http://purl.allotrope.org/ontologies/material#AFM_0000189 + +af-m:AFM_0000189 rdf:type owl:Class ; + + rdfs:subClassOf af-m:AFM_0000077 ; + + rdfs:isDefinedBy ; + + skos:altLabel "positive ion" ; + + skos:definition "A cation (+) is an ion with fewer electrons than protons, giving it a positive charge. [Wikipedia]" ; + + skos:prefLabel "cation" . + + + +### http://purl.allotrope.org/ontologies/material#AFM_0000226 + +af-m:AFM_0000226 rdf:type owl:Class ; + + rdfs:subClassOf chebi:_36347 ; + + af-x:AFX_0002796 af-r:AFR_0001492 ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + dct:license ; + + dct:rights ; + + dct:source "PAC, 1982, 54, 1533 (Glossary of terms used in nuclear analytical chemistry (Provisional))" ; + + rdfs:isDefinedBy ; + + skos:definition "The positively charged central portion of an atom, excluding the orbital electrons. [IUPAC]" ; + + skos:prefLabel "nucleus" . + + + +### http://purl.allotrope.org/ontologies/material#AFM_0000275 + +af-m:AFM_0000275 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000040 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000086 ; + owl:someValuesFrom pato:_0000125 + ] ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + af-x:AFX_0002865 , + ; + + rdfs:isDefinedBy , + , + ; + + skos:altLabel "matter" ; + + skos:definition "A material entity that occupies space and possesses a rest mass. [Allotrope]" ; + + skos:prefLabel "material" . + + + +### http://purl.allotrope.org/ontologies/material#AFM_0000341 + +af-m:AFM_0000341 rdf:type owl:Class ; + + rdfs:subClassOf caro:_0000006 ; + + af-x:AFX_0002809 cl:_0000000 , + go:_0005623 ; + + rdfs:isDefinedBy ; + + skos:definition "A material entity of anatomical origin (part of or deriving from an organism) that has as its parts a maximally connected cell compartment surrounded by a plasma membrane. [CL]" ; + + skos:prefLabel "cell" . + + + +### http://purl.allotrope.org/ontologies/material#AFM_0000386 + +af-m:AFM_0000386 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( chmo:_0000993 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000086 ; + owl:someValuesFrom af-q:AFQ_0000112 + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A solid is a substance that is in the solid material state. [Allotrope]" ; + + skos:prefLabel "solid" . + + + +### http://purl.allotrope.org/ontologies/material#AFM_0000394 + +af-m:AFM_0000394 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( chmo:_0000993 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000086 ; + owl:someValuesFrom af-q:AFQ_0000118 + ] + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A fluid is a substance that continually deforms (flows) under an applied shear stress. Fluids are a subset of the phases of matter and include liquids, gases, plasmas and, to some extent, plastic solids. [Wikipedia]" ; + + skos:prefLabel "fluid" . + + + +### http://purl.allotrope.org/ontologies/material#AFM_0000401 + +af-m:AFM_0000401 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( af-m:AFM_0000154 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000086 ; + owl:someValuesFrom af-q:AFQ_0000119 + ] + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + af-x:AFX_0002815 ; + + rdfs:isDefinedBy ; + + skos:definition "A supercritical fluid is a gas whose temperature and pressure are above the critical temperature and critical pressure. In this state, the distinction between liquid and gas disappears. [Wikipedia]" ; + + skos:prefLabel "supercritical fluid" . + + + +### http://purl.allotrope.org/ontologies/material#AFM_0000403 + +af-m:AFM_0000403 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( af-m:AFM_0000394 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000086 ; + owl:someValuesFrom af-q:AFQ_0000113 + ] + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A liquid is a nearly incompressible fluid that conforms to the shape of its container but retains a (nearly) constant volume independent of pressure. [Wikipedia]" ; + + skos:prefLabel "liquid" . + + + +### http://purl.allotrope.org/ontologies/material#AFM_0000404 + +af-m:AFM_0000404 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( af-m:AFM_0000394 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000086 ; + owl:someValuesFrom af-q:AFQ_0000115 + ] + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:definition "Plasma is a state of matter in which an ionized gaseous substance becomes highly electrically conductive to the point that long-range electric and magnetic fields dominate the behavior of the matter. [Wikipedia]" ; + + skos:prefLabel "plasma" . + + + +### http://purl.allotrope.org/ontologies/material#AFM_0000418 + +af-m:AFM_0000418 rdf:type owl:Class ; + + rdfs:subClassOf chebi:_36338 ; + + af-x:AFX_0002796 af-r:AFR_0001492 ; + + dct:license ; + + dct:rights ; + + dct:source , + "Green Book, 2nd ed., p. 93" ; + + rdfs:isDefinedBy ; + + skos:altLabel "e−" , + "β−" ; + + skos:definition "Elementary particle not affected by the strong force having a spin quantum number 1/2, a negative elementary charge and a rest mass of 0.000 548 579 903(13) u. [IUPAC]" ; + + skos:prefLabel "electron" . + + + +### http://purl.allotrope.org/ontologies/material#AFM_0000435 + +af-m:AFM_0000435 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000030 ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:altLabel "particle" ; + + skos:definition "A particle in the physical sciences is a small localized object to which can be ascribed physical properties. [Wikipedia]" ; + + skos:prefLabel "particle (physics)" . + + + +### http://purl.allotrope.org/ontologies/material#AFM_0000442 + +af-m:AFM_0000442 rdf:type owl:Class ; + + rdfs:subClassOf af-m:AFM_0001034 ; + + rdfs:isDefinedBy ; + + skos:definition "A suspension is a heterogeneous mixture in which the solute particles do not dissolve but get suspended throughout the bulk of the medium. [Wikipedia]" ; + + skos:example "sea water with sand" ; + + skos:prefLabel "suspension" . + + + +### http://purl.allotrope.org/ontologies/material#AFM_0000494 + +af-m:AFM_0000494 rdf:type owl:Class ; + + rdfs:subClassOf af-m:AFM_0000442 , + [ owl:intersectionOf ( [ owl:intersectionOf ( chmo:_0000993 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000086 ; + owl:someValuesFrom af-q:AFQ_0000114 + ] + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000087 ; + owl:someValuesFrom af-rl:AFRL_0000271 + ] + ) ; + rdf:type owl:Class + ] + [ owl:intersectionOf ( [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000051 ; + owl:someValuesFrom [ owl:intersectionOf ( chmo:_0000993 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000086 ; + owl:someValuesFrom af-q:AFQ_0000114 + ] + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000087 ; + owl:someValuesFrom af-rl:AFRL_0000271 + ] + ) ; + rdf:type owl:Class + ] + ] + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000087 ; + owl:someValuesFrom af-rl:AFRL_0000271 + ] + ) ; + rdf:type owl:Class + ] + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002796 af-r:AFR_0001223 ; + + rdfs:isDefinedBy ; + + skos:definition "A spray is a heterogeneous mixture where a small amount of liquid is dispersed into a gas. [Allotrope]" ; + + skos:prefLabel "spray" . + + + +### http://purl.allotrope.org/ontologies/material#AFM_0000877 + +af-m:AFM_0000877 rdf:type owl:Class ; + + rdfs:subClassOf af-m:AFM_0000275 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A natural material is any product or physical matter that comes from plants, animals, or the ground. Minerals and the metals that can be extracted from them (without further modification) are also considered to belong into this category. [Wikipedia]" ; + + skos:prefLabel "natural material" . + + + +### http://purl.allotrope.org/ontologies/material#AFM_0000880 + +af-m:AFM_0000880 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000040 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "Energy must be transferred to an object in order to perform work on, or to heat the object. It can be converted in form, but not created or destroyed. [Wikipedia]" ; + + skos:editorialNote "According to the annotations on material entity, energy is considered a material entity in BFO" ; + + skos:prefLabel "energy" . + + + +### http://purl.allotrope.org/ontologies/material#AFM_0000881 + +af-m:AFM_0000881 rdf:type owl:Class ; + + rdfs:subClassOf af-m:AFM_0000880 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A form of energy that is transferred between bodies as a result of a temperature difference. [NIST]" ; + + skos:prefLabel "thermal energy" . + + + +### http://purl.allotrope.org/ontologies/material#AFM_0000882 + +af-m:AFM_0000882 rdf:type owl:Class ; + + rdfs:subClassOf af-m:AFM_0000880 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "Energy flow generated or required by a translation or virtual translation. [NIST]" ; + + skos:prefLabel "mechanic translational energy" . + + + +### http://purl.allotrope.org/ontologies/material#AFM_0000883 + +af-m:AFM_0000883 rdf:type owl:Class ; + + rdfs:subClassOf af-m:AFM_0000880 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "Work resulting from the reactions by which substances are produced from or converted into other substances. [NIST]" ; + + skos:example "A battery converts the flow of chemical energy into electical energy." ; + + skos:prefLabel "chemical energy" . + + + +### http://purl.allotrope.org/ontologies/material#AFM_0000884 + +af-m:AFM_0000884 rdf:type owl:Class ; + + rdfs:subClassOf af-m:AFM_0000880 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "Work resulting from the flow of electrons from a negative to a positive source. [NIST]" ; + + skos:prefLabel "electrical energy" . + + + +### http://purl.allotrope.org/ontologies/material#AFM_0000885 + +af-m:AFM_0000885 rdf:type owl:Class ; + + rdfs:subClassOf af-m:AFM_0000880 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "Energy that results from a rotation or a virtual rotation. [NIST]" ; + + skos:prefLabel "mechanic rotational energy" . + + + +### http://purl.allotrope.org/ontologies/material#AFM_0000886 + +af-m:AFM_0000886 rdf:type owl:Class ; + + rdfs:subClassOf af-m:AFM_0000880 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "Work that results from the movement or force of a liquid, including hydrostatic forces. [NIST]" ; + + skos:prefLabel "hydraulic energy" . + + + +### http://purl.allotrope.org/ontologies/material#AFM_0000888 + +af-m:AFM_0000888 rdf:type owl:Class ; + + rdfs:subClassOf af-m:AFM_0000880 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "EMR" , + "electro-magnetic energy" , + "electro-magnetic radiation" , + "electromagnetic radiation" , + "radiation energy" ; + + skos:definition "Energy that is propagated through free space or through a material medium in the form of electro-magnetic waves. [NIST]" ; + + skos:prefLabel "electromagnetic energy" . + + + +### http://purl.allotrope.org/ontologies/material#AFM_0000889 + +af-m:AFM_0000889 rdf:type owl:Class ; + + rdfs:subClassOf af-m:AFM_0000880 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "Work resulting from a compressed gas. [NIST]" ; + + skos:prefLabel "pneumatic energy" . + + + +### http://purl.allotrope.org/ontologies/material#AFM_0001016 + +af-m:AFM_0001016 rdf:type owl:Class ; + + rdfs:subClassOf af-m:AFM_0001031 , + [ owl:intersectionOf ( [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000051 ; + owl:someValuesFrom [ owl:intersectionOf ( chmo:_0000993 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000086 ; + owl:someValuesFrom af-q:AFQ_0000113 + ] + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000087 ; + owl:someValuesFrom af-rl:AFRL_0000271 + ] + ) ; + rdf:type owl:Class + ] + ] + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000051 ; + owl:someValuesFrom [ owl:intersectionOf ( chmo:_0000993 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000086 ; + owl:someValuesFrom af-q:AFQ_0000113 + ] + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000087 ; + owl:someValuesFrom af-rl:AFRL_0000272 + ] + ) ; + rdf:type owl:Class + ] + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:isDefinedBy ; + + skos:definition "An is a colloid where the continuous phase is a liquid and the dispersed phase is a liquid. [Allotrope]" ; + + skos:example "milk that is mixed oil in water" ; + + skos:prefLabel "emulsion" . + + + +### http://purl.allotrope.org/ontologies/material#AFM_0001023 + +af-m:AFM_0001023 rdf:type owl:Class ; + + rdfs:subClassOf chebi:_33253 , + chebi:_36347 ; + + af-x:AFX_0002796 af-r:AFR_0001492 ; + + dct:license ; + + dct:rights ; + + dct:source "Green Book, 2nd ed.: IUPAC Quantities, Units and Symbols in Physical Chemistry. Second Edition, Blackwell Scientific Publications, Oxford, 1993." ; + + rdfs:isDefinedBy ; + + skos:altLabel "hydrogen nucleus" ; + + skos:definition "A proton is a nuclear particle of charge number +1, spin quantum number of 1/2 and rest mass of 1.00727647012 u. [IUPAC]" ; + + skos:prefLabel "proton" . + + + +### http://purl.allotrope.org/ontologies/material#AFM_0001027 + +af-m:AFM_0001027 rdf:type owl:Class ; + + rdfs:subClassOf chebi:_33253 , + chebi:_36347 ; + + af-x:AFX_0002796 af-r:AFR_0001222 ; + + dct:license ; + + dct:rights ; + + dct:source "IUPAC Green Book, 2nd ed., p. 93" ; + + rdfs:isDefinedBy ; + + skos:definition "A neutron is a nuclear particle of zero charge, spin quantum number 1/2 and a mass of 1.00866490414 u. [IUPAC]" ; + + skos:prefLabel "neutron" . + + + +### http://purl.allotrope.org/ontologies/material#AFM_0001028 + +af-m:AFM_0001028 rdf:type owl:Class ; + + rdfs:subClassOf chebi:_23367 , + [ rdf:type owl:Restriction ; + owl:onProperty obi:_0000643 ; + owl:someValuesFrom af-m:AFM_0000418 + ] , + [ rdf:type owl:Restriction ; + owl:onProperty obi:_0000643 ; + owl:someValuesFrom af-m:AFM_0001023 + ] ; + + af-x:AFX_0002796 af-r:AFR_0001222 ; + + af-x:AFX_0002809 chebi:_33250 ; + + dct:license ; + + dct:rights ; + + dct:source "IUPAC Red Book, p. 35" ; + + rdfs:isDefinedBy ; + + skos:definition "An atom is a smallest particle still characterizing a chemical element. It consists of a nucleus of a positive charge carrying almost all its mass (more than 99.9%) and Z electrons determining its size. [IUPAC]" ; + + skos:prefLabel "atom" . + + + +### http://purl.allotrope.org/ontologies/material#AFM_0001030 + +af-m:AFM_0001030 rdf:type owl:Class ; + + rdfs:subClassOf af-m:AFM_0001044 ; + + dct:source "Myers, D. (2002) Association Colloids: Micelles, Vesicles, and Membranes, in Surfaces, Interfaces, and Colloids: Principles and Applications, Second Edition, John Wiley & Sons, Inc., New York, USA. doi: 10.1002/0471234990.ch15" ; + + rdfs:isDefinedBy ; + + skos:definition "An association colloid is a homogeneous, non-structured substance composed of large molecules or ultramicroscopic suspended in a separate medium, which is largely comprised or reversible aggregations formed by the thermodynamics of molecular interactions. [Allotrope]" ; + + skos:prefLabel "association colloid" . + + + +### http://purl.allotrope.org/ontologies/material#AFM_0001031 + +af-m:AFM_0001031 rdf:type owl:Class ; + + rdfs:subClassOf af-m:AFM_0001044 ; + + dct:license ; + + dct:rights ; + + dct:source "PAC, 1972, 31, 577 (Manual of Symbols and Terminology for Physicochemical Quantities and Units, Appendix II: Definitions, Terminology and Symbols in Colloid and Surface Chemistry) on page 605" ; + + rdfs:isDefinedBy ; + + skos:altLabel "colloid dispersion" , + "colloidal dispersion" ; + + skos:definition "A dispersion colloid is a colloid that is a system in which particles of colloidal size of any nature (e.g. solid, liquid or gas) are dispersed in a continuous phase of a different composition (or state). [IUPAC]" ; + + skos:prefLabel "dispersion colloid" . + + + +### http://purl.allotrope.org/ontologies/material#AFM_0001032 + +af-m:AFM_0001032 rdf:type owl:Class ; + + rdfs:subClassOf af-m:AFM_0001031 , + [ owl:intersectionOf ( [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000051 ; + owl:someValuesFrom [ owl:intersectionOf ( chmo:_0000993 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000086 ; + owl:someValuesFrom af-q:AFQ_0000113 + ] + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000087 ; + owl:someValuesFrom af-rl:AFRL_0000272 + ] + ) ; + rdf:type owl:Class + ] + ] + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000051 ; + owl:someValuesFrom [ owl:intersectionOf ( chmo:_0000993 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000086 ; + owl:someValuesFrom af-q:AFQ_0000114 + ] + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000087 ; + owl:someValuesFrom af-rl:AFRL_0000271 + ] + ) ; + rdf:type owl:Class + ] + ] + ) ; + rdf:type owl:Class + ] ; + + dct:license ; + + dct:rights ; + + dct:source "PAC, 1972, 31, 577 (Manual of Symbols and Terminology for Physicochemical Quantities and Units, Appendix II: Definitions, Terminology and Symbols in Colloid and Surface Chemistry) on page 606" ; + + rdfs:isDefinedBy ; + + skos:definition "A foam is a colloid where the continuous phase is a liquid and the dispersed phase is a gas. [Allotrope]" ; + + skos:prefLabel "foam" . + + + +### http://purl.allotrope.org/ontologies/material#AFM_0001033 + +af-m:AFM_0001033 rdf:type owl:Class ; + + rdfs:subClassOf af-m:AFM_0001031 , + [ owl:intersectionOf ( [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000051 ; + owl:someValuesFrom [ owl:intersectionOf ( chmo:_0000993 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000086 ; + owl:someValuesFrom af-q:AFQ_0000112 + ] + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000087 ; + owl:someValuesFrom af-rl:AFRL_0000272 + ] + ) ; + rdf:type owl:Class + ] + ] + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000051 ; + owl:someValuesFrom [ owl:intersectionOf ( chmo:_0000993 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000086 ; + owl:someValuesFrom af-q:AFQ_0000113 + ] + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000087 ; + owl:someValuesFrom af-rl:AFRL_0000271 + ] + ) ; + rdf:type owl:Class + ] + ] + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002796 af-r:AFR_0001223 ; + + dct:license ; + + dct:rights ; + + dct:source "PAC, 2007, 79, 1801 (Definitions of terms relating to the structure and processing of sols, gels, networks, and inorganic-organic hybrid materials (IUPAC Recommendations 2007)) on page 1806" ; + + rdfs:isDefinedBy ; + + skos:definition "A gel is a colloid where the continuous phase is a solid and the dispersed phase is a liquid. [Allotrope]" ; + + skos:prefLabel "gel" . + + + +### http://purl.allotrope.org/ontologies/material#AFM_0001034 + +af-m:AFM_0001034 rdf:type owl:Class ; + + rdfs:subClassOf af-m:AFM_0001038 ; + + rdfs:isDefinedBy ; + + skos:definition "A heterogeneous mixture is a portion of mixed material that is not uniform in composition, but proportions of its components vary throughout the sample. [Wikipedia]" ; + + skos:example "sea water with sand" ; + + skos:prefLabel "heterogeneous mixture" . + + + +### http://purl.allotrope.org/ontologies/material#AFM_0001035 + +af-m:AFM_0001035 rdf:type owl:Class ; + + rdfs:subClassOf af-m:AFM_0001038 ; + + rdfs:isDefinedBy ; + + skos:definition "A homogeneous mixture is a portion of mixed material that has the same proportions of its components throughout a given sample. Homogeneous mixture can have a variable composition. [Wikipedia]" ; + + skos:example "air" , + "sea water" ; + + skos:prefLabel "homogeneous mixture" . + + + +### http://purl.allotrope.org/ontologies/material#AFM_0001036 + +af-m:AFM_0001036 rdf:type owl:Class ; + + rdfs:subClassOf af-m:AFM_0001031 , + [ owl:intersectionOf ( [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000051 ; + owl:someValuesFrom [ owl:intersectionOf ( chmo:_0000993 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000086 ; + owl:someValuesFrom af-q:AFQ_0000113 + ] + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000087 ; + owl:someValuesFrom af-rl:AFRL_0000271 + ] + ) ; + rdf:type owl:Class + ] + ] + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000051 ; + owl:someValuesFrom [ owl:intersectionOf ( chmo:_0000993 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000086 ; + owl:someValuesFrom af-q:AFQ_0000114 + ] + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000087 ; + owl:someValuesFrom af-rl:AFRL_0000272 + ] + ) ; + rdf:type owl:Class + ] + ] + ) ; + rdf:type owl:Class + ] ; + + dct:license ; + + dct:rights ; + + dct:source "PAC, 2007, 79, 1801 (Definitions of terms relating to the structure and processing of sols, gels, networks, and inorganic-organic hybrid materials (IUPAC Recommendations 2007)) on page 1805" ; + + rdfs:isDefinedBy ; + + skos:definition "A solid aerosol is an colloid where the continuous phase is a gas and the dispersed phase is a liquid. [Allotrope]" ; + + skos:prefLabel "liquid aerosol" . + + + +### http://purl.allotrope.org/ontologies/material#AFM_0001037 + +af-m:AFM_0001037 rdf:type owl:Class ; + + rdfs:subClassOf af-m:AFM_0001044 ; + + rdfs:isDefinedBy ; + + skos:definition "A molecular colloid is a type of colloid that consists of many molecules that combine to structures of colloidal size. [Allotrope]" ; + + skos:example "sulphur S8 colloid" ; + + skos:prefLabel "molecular colloid" . + + + +### http://purl.allotrope.org/ontologies/material#AFM_0001038 + +af-m:AFM_0001038 rdf:type owl:Class ; + + rdfs:subClassOf chmo:_0000993 ; + + rdfs:isDefinedBy ; + + skos:altLabel "blend" , + "mixture" , + "portion of mixture" ; + + skos:definition "An portion of mixed material is a material entity that consists of different kinds of grains if you inspect it at a higher level of granularity. [Allotrope]" ; + + skos:example "portion of milk" , + "sand" , + "sea water" , + "sea water with sand" ; + + skos:prefLabel "portion of mixed material" . + + + +### http://purl.allotrope.org/ontologies/material#AFM_0001039 + +af-m:AFM_0001039 rdf:type owl:Class ; + + rdfs:subClassOf chmo:_0000993 ; + + af-x:AFX_0002796 af-r:AFR_0001223 ; + + rdfs:isDefinedBy ; + + skos:definition "An portion of pure substance is a material entity that consists of one kind of grains if you inspect it at a higher level of granularity. [Allotrope]" ; + + skos:example "solution of distilled water" ; + + skos:prefLabel "portion of pure substance" . + + + +### http://purl.allotrope.org/ontologies/material#AFM_0001041 + +af-m:AFM_0001041 rdf:type owl:Class ; + + rdfs:subClassOf af-m:AFM_0001031 , + [ owl:intersectionOf ( [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000051 ; + owl:someValuesFrom [ owl:intersectionOf ( chmo:_0000993 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000086 ; + owl:someValuesFrom af-q:AFQ_0000112 + ] + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000087 ; + owl:someValuesFrom af-rl:AFRL_0000271 + ] + ) ; + rdf:type owl:Class + ] + ] + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000051 ; + owl:someValuesFrom [ owl:intersectionOf ( chmo:_0000993 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000086 ; + owl:someValuesFrom af-q:AFQ_0000113 + ] + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000087 ; + owl:someValuesFrom af-rl:AFRL_0000272 + ] + ) ; + rdf:type owl:Class + ] + ] + ) ; + rdf:type owl:Class + ] ; + + dct:license ; + + dct:rights ; + + dct:source "PAC, 2007, 79, 1801 (Definitions of terms relating to the structure and processing of sols, gels, networks, and inorganic-organic hybrid materials (IUPAC Recommendations 2007)) on page 1805" ; + + rdfs:isDefinedBy ; + + skos:definition "A sol is a fluid colloidal system of two or more components. [IUPAC]" ; + + skos:prefLabel "sol" . + + + +### http://purl.allotrope.org/ontologies/material#AFM_0001042 + +af-m:AFM_0001042 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( af-m:AFM_0001034 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000086 ; + owl:someValuesFrom af-q:AFQ_0000112 + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A solid heterogeneous mixture is a heterogeneous mixture in solid state. [Allotrope]" ; + + skos:prefLabel "solid heterogeneous mixture" . + + + +### http://purl.allotrope.org/ontologies/material#AFM_0001044 + +af-m:AFM_0001044 rdf:type owl:Class ; + + rdfs:subClassOf af-m:AFM_0001035 ; + + dct:license ; + + dct:rights ; + + dct:source "PAC, 1972, 31, 577 (Manual of Symbols and Terminology for Physicochemical Quantities and Units, Appendix II: Definitions, Terminology and Symbols in Colloid and Surface Chemistry) on page 605" ; + + rdfs:isDefinedBy ; + + skos:altLabel "colloidal system" ; + + skos:definition "A colloid is a homogeneous mixture in which one substance of microscopically dispersed insoluble particles is suspended throughout another substance. A colloid has a dispersed phase (the suspended particles) and a continuous phase (the medium of suspension). The molecules or polymolecular particles dispersed in a medium have at least in one direction a dimension roughly between 1 nanometer and 1 micrometer, or in a system discontinuities are found at distances of that order. [IUPAC]" ; + + skos:prefLabel "colloid" . + + + +### http://purl.allotrope.org/ontologies/material#AFM_0001054 + +af-m:AFM_0001054 rdf:type owl:Class ; + + rdfs:subClassOf af-m:AFM_0000888 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:altLabel "X-ray" ; + + skos:definition "A form of electromagnetic radiation with a wavelength ranging from 0.01 to 10 nanometers. [Wikipedia]" ; + + skos:prefLabel "X-ray radiation" . + + + +### http://purl.allotrope.org/ontologies/material#AFM_0001055 + +af-m:AFM_0001055 rdf:type owl:Class ; + + rdfs:subClassOf af-m:AFM_0000888 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:altLabel "light" ; + + skos:definition "Electromagnetic radiation which is visible to the human eye and is responsible for the sense of sight. Visible light is usually defined as having wavelengths in the range of 400-700 nanometers. [Wikipedia]" ; + + skos:prefLabel "visible light" . + + + +### http://purl.allotrope.org/ontologies/material#AFM_0001056 + +af-m:AFM_0001056 rdf:type owl:Class ; + + rdfs:subClassOf af-m:AFM_0000888 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:altLabel "UV" , + "ultraviolet light" ; + + skos:definition "An electromagnetic radiation with a wavelength from 10 nm to 400 nm. [Wikipedia]" ; + + skos:prefLabel "ultraviolet radiation" . + + + +### http://purl.allotrope.org/ontologies/material#AFM_0001057 + +af-m:AFM_0001057 rdf:type owl:Class ; + + rdfs:subClassOf af-m:AFM_0000888 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:altLabel "IR" , + "infrared" , + "infrared light" ; + + skos:definition "Electromagnetic radiation with longer wavelengths than those of visible light. It extends from the nominal red edge of the visible spectrum at 700 nanometer, to 1 micrometers. [Wikipedia]" ; + + skos:prefLabel "infrared radiation" . + + + +### http://purl.allotrope.org/ontologies/material#AFM_0001058 + +af-m:AFM_0001058 rdf:type owl:Class ; + + rdfs:subClassOf af-m:AFM_0000888 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:altLabel "gamma ray" , + "γ-ray" ; + + skos:definition "Electromagnetic radiation of a kind arising from the radioactive decay of atomic nuclei and having wavelengths less than 10 picometers. [Allotrope]" ; + + skos:prefLabel "gamma radiation" . + + + +### http://purl.allotrope.org/ontologies/material#AFM_0001059 + +af-m:AFM_0001059 rdf:type owl:Class ; + + rdfs:subClassOf ro:_0002577 ; + + rdfs:isDefinedBy ; + + skos:definition "A system that can be discovered in nature. [Allotrope]" ; + + skos:prefLabel "natural system" . + + + +### http://purl.allotrope.org/ontologies/material#AFM_0001060 + +af-m:AFM_0001060 rdf:type owl:Class ; + + rdfs:subClassOf af-m:AFM_0001039 , + af-m:AFM_0001097 ; + + owl:disjointWith af-m:AFM_0001061 ; + + rdfs:isDefinedBy ; + + skos:altLabel "compound" ; + + skos:definition "A portion of material that has grain only the same kind of molecules, ignoring minor impurities. [Allotrope]" ; + + skos:example "portion of tablesugar" , + "portion of water" ; + + skos:prefLabel "portion of compound" . + + + +### http://purl.allotrope.org/ontologies/material#AFM_0001061 + +af-m:AFM_0001061 rdf:type owl:Class ; + + rdfs:subClassOf af-m:AFM_0001039 , + af-m:AFM_0001097 ; + + rdfs:isDefinedBy ; + + skos:altLabel "element" ; + + skos:definition "A portion of material that has grain only the same kind of atoms, ignoring minor impurities. [Allotrope]" ; + + skos:example "portion of gold" , + "portion of helium" ; + + skos:prefLabel "portion of element" . + + + +### http://purl.allotrope.org/ontologies/material#AFM_0001064 + +af-m:AFM_0001064 rdf:type owl:Class ; + + rdfs:subClassOf af-m:AFM_0001039 ; + + owl:disjointWith af-m:AFM_0001097 ; + + rdfs:isDefinedBy ; + + skos:definition "A portion of material that has grain some multi-molecular objects or particles. [Allotrope]" ; + + skos:example "bag of nuts" , + "packet of rice" ; + + skos:prefLabel "portion of bulk stuff" . + + + +### http://purl.allotrope.org/ontologies/material#AFM_0001065 + +af-m:AFM_0001065 rdf:type owl:Class ; + + rdfs:subClassOf af-m:AFM_0000012 , + [ owl:intersectionOf ( [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000051 ; + owl:someValuesFrom [ owl:intersectionOf ( chmo:_0000993 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000086 ; + owl:someValuesFrom af-q:AFQ_0000114 + ] + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000087 ; + owl:someValuesFrom af-rl:AFRL_0000271 + ] + ) ; + rdf:type owl:Class + ] + ] + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000051 ; + owl:someValuesFrom [ owl:intersectionOf ( chmo:_0000993 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000086 ; + owl:someValuesFrom af-q:AFQ_0000114 + ] + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000087 ; + owl:someValuesFrom af-rl:AFRL_0000272 + ] + ) ; + rdf:type owl:Class + ] + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A gas mixture is a solution where the continuous phase is a gas and the dispersed phase is a gas. [Allotrope]" ; + + skos:example "air" ; + + skos:prefLabel "gas mixture" . + + + +### http://purl.allotrope.org/ontologies/material#AFM_0001066 + +af-m:AFM_0001066 rdf:type owl:Class ; + + rdfs:subClassOf af-m:AFM_0000012 , + [ owl:intersectionOf ( [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000051 ; + owl:someValuesFrom [ owl:intersectionOf ( chmo:_0000993 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000086 ; + owl:someValuesFrom af-q:AFQ_0000112 + ] + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000087 ; + owl:someValuesFrom af-rl:AFRL_0000272 + ] + ) ; + rdf:type owl:Class + ] + ] + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000051 ; + owl:someValuesFrom [ owl:intersectionOf ( chmo:_0000993 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000086 ; + owl:someValuesFrom af-q:AFQ_0000114 + ] + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000087 ; + owl:someValuesFrom af-rl:AFRL_0000271 + ] + ) ; + rdf:type owl:Class + ] + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A gas in solid solution is a solution where the continuous phase is a solid and the dispersed phase is a gas. [Allotrope]" ; + + skos:example "hydrogen in paladium metal" ; + + skos:prefLabel "gas in solid solution" . + + + +### http://purl.allotrope.org/ontologies/material#AFM_0001067 + +af-m:AFM_0001067 rdf:type owl:Class ; + + rdfs:subClassOf af-m:AFM_0000012 , + [ owl:intersectionOf ( [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000051 ; + owl:someValuesFrom [ owl:intersectionOf ( chmo:_0000993 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000086 ; + owl:someValuesFrom af-q:AFQ_0000113 + ] + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000087 ; + owl:someValuesFrom af-rl:AFRL_0000272 + ] + ) ; + rdf:type owl:Class + ] + ] + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000051 ; + owl:someValuesFrom [ owl:intersectionOf ( chmo:_0000993 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000086 ; + owl:someValuesFrom af-q:AFQ_0000114 + ] + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000087 ; + owl:someValuesFrom af-rl:AFRL_0000271 + ] + ) ; + rdf:type owl:Class + ] + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "solution" ; + + skos:definition "A gas in liquid solution is a solution where the continuous phase is a liquid and the dispersed phase is a gas. [Allotrope]" ; + + skos:example "carbon dioxide in water" ; + + skos:prefLabel "gas in liquid solution" . + + + +### http://purl.allotrope.org/ontologies/material#AFM_0001068 + +af-m:AFM_0001068 rdf:type owl:Class ; + + rdfs:subClassOf af-m:AFM_0000012 , + [ owl:intersectionOf ( [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000051 ; + owl:someValuesFrom [ owl:intersectionOf ( chmo:_0000993 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000086 ; + owl:someValuesFrom af-q:AFQ_0000113 + ] + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000087 ; + owl:someValuesFrom af-rl:AFRL_0000271 + ] + ) ; + rdf:type owl:Class + ] + ] + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000051 ; + owl:someValuesFrom [ owl:intersectionOf ( chmo:_0000993 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000086 ; + owl:someValuesFrom af-q:AFQ_0000113 + ] + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000087 ; + owl:someValuesFrom af-rl:AFRL_0000272 + ] + ) ; + rdf:type owl:Class + ] + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "solution" ; + + skos:definition "A liquid in liquid solution is a solution where the mixture phase is a liquid and the dispersed phase is a liquid. [Allotrope]" ; + + skos:example "alcoholic beverages" , + "gasoline" ; + + skos:prefLabel "liquid in liquid solution" . + + + +### http://purl.allotrope.org/ontologies/material#AFM_0001069 + +af-m:AFM_0001069 rdf:type owl:Class ; + + rdfs:subClassOf af-m:AFM_0000012 , + [ owl:intersectionOf ( [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000051 ; + owl:someValuesFrom [ owl:intersectionOf ( chmo:_0000993 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000086 ; + owl:someValuesFrom af-q:AFQ_0000112 + ] + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000087 ; + owl:someValuesFrom af-rl:AFRL_0000271 + ] + ) ; + rdf:type owl:Class + ] + ] + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000051 ; + owl:someValuesFrom [ owl:intersectionOf ( chmo:_0000993 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000086 ; + owl:someValuesFrom af-q:AFQ_0000113 + ] + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000087 ; + owl:someValuesFrom af-rl:AFRL_0000272 + ] + ) ; + rdf:type owl:Class + ] + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "solution" ; + + skos:definition "A solid in liquid solution is a solution where the continuous phase is a solid and the dispersed phase is a liquid. [Allotrope]" ; + + skos:example "salt or sugar in water" ; + + skos:prefLabel "solid in liquid solution" . + + + +### http://purl.allotrope.org/ontologies/material#AFM_0001070 + +af-m:AFM_0001070 rdf:type owl:Class ; + + rdfs:subClassOf af-m:AFM_0000012 , + [ owl:intersectionOf ( [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000051 ; + owl:someValuesFrom [ owl:intersectionOf ( chmo:_0000993 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000086 ; + owl:someValuesFrom af-q:AFQ_0000112 + ] + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000087 ; + owl:someValuesFrom af-rl:AFRL_0000272 + ] + ) ; + rdf:type owl:Class + ] + ] + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000051 ; + owl:someValuesFrom [ owl:intersectionOf ( chmo:_0000993 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000086 ; + owl:someValuesFrom af-q:AFQ_0000113 + ] + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000087 ; + owl:someValuesFrom af-rl:AFRL_0000271 + ] + ) ; + rdf:type owl:Class + ] + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "solution" ; + + skos:definition "A liquid in solid solution is a solution where the continuous phase is a solid and the dispersed phase is a liquid. [Allotrope]" ; + + skos:example "hexane in paraffin wax" , + "mercury amalgam" ; + + skos:prefLabel "liquid in solid solution" . + + + +### http://purl.allotrope.org/ontologies/material#AFM_0001071 + +af-m:AFM_0001071 rdf:type owl:Class ; + + rdfs:subClassOf af-m:AFM_0000012 , + [ owl:intersectionOf ( [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000051 ; + owl:someValuesFrom [ owl:intersectionOf ( chmo:_0000993 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000086 ; + owl:someValuesFrom af-q:AFQ_0000112 + ] + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000087 ; + owl:someValuesFrom af-rl:AFRL_0000271 + ] + ) ; + rdf:type owl:Class + ] + ] + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000051 ; + owl:someValuesFrom [ owl:intersectionOf ( chmo:_0000993 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000086 ; + owl:someValuesFrom af-q:AFQ_0000112 + ] + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000087 ; + owl:someValuesFrom af-rl:AFRL_0000272 + ] + ) ; + rdf:type owl:Class + ] + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A solid in solid solution is a solution where the continuous phase is a solid and the dispersed phase is a solid. [Allotrope]" ; + + skos:example "alloys" ; + + skos:prefLabel "solid in solid solution" . + + + +### http://purl.allotrope.org/ontologies/material#AFM_0001076 + +af-m:AFM_0001076 rdf:type owl:Class ; + + rdfs:subClassOf af-m:AFM_0001031 , + [ owl:intersectionOf ( [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000051 ; + owl:someValuesFrom [ owl:intersectionOf ( chmo:_0000993 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000086 ; + owl:someValuesFrom af-q:AFQ_0000112 + ] + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000087 ; + owl:someValuesFrom af-rl:AFRL_0000271 + ] + ) ; + rdf:type owl:Class + ] + ] + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000051 ; + owl:someValuesFrom [ owl:intersectionOf ( chmo:_0000993 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000086 ; + owl:someValuesFrom af-q:AFQ_0000114 + ] + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000087 ; + owl:someValuesFrom af-rl:AFRL_0000272 + ] + ) ; + rdf:type owl:Class + ] + ] + ) ; + rdf:type owl:Class + ] ; + + dct:license ; + + dct:rights ; + + dct:source "Everett, D. (2009). Manual of Symbols and Terminology for Physicochemical Quantities and Units, Appendix II: Definitions, Terminology and Symbols in Colloid and Surface Chemistry. Pure and Applied Chemistry, 31(4), pp. 577-638." ; + + rdfs:isDefinedBy ; + + skos:definition "A solid aerosol is an colloid where the continuous phase is a gas and the dispersed phase is a solid. [Allotrope]" ; + + skos:prefLabel "solid aerosol" . + + + +### http://purl.allotrope.org/ontologies/material#AFM_0001077 + +af-m:AFM_0001077 rdf:type owl:Class ; + + rdfs:subClassOf af-m:AFM_0001031 , + [ owl:intersectionOf ( [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000051 ; + owl:someValuesFrom [ owl:intersectionOf ( chmo:_0000993 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000086 ; + owl:someValuesFrom af-q:AFQ_0000112 + ] + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000087 ; + owl:someValuesFrom af-rl:AFRL_0000272 + ] + ) ; + rdf:type owl:Class + ] + ] + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000051 ; + owl:someValuesFrom [ owl:intersectionOf ( chmo:_0000993 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000086 ; + owl:someValuesFrom af-q:AFQ_0000114 + ] + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000087 ; + owl:someValuesFrom af-rl:AFRL_0000271 + ] + ) ; + rdf:type owl:Class + ] + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A solid foam is a colloid where the continuous phase is a solid and the dispersed phase is a gas. [Allotrope]" ; + + skos:prefLabel "solid foam" . + + + +### http://purl.allotrope.org/ontologies/material#AFM_0001078 + +af-m:AFM_0001078 rdf:type owl:Class ; + + rdfs:subClassOf af-m:AFM_0001031 , + [ owl:intersectionOf ( [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000051 ; + owl:someValuesFrom [ owl:intersectionOf ( chmo:_0000993 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000086 ; + owl:someValuesFrom af-q:AFQ_0000112 + ] + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000087 ; + owl:someValuesFrom af-rl:AFRL_0000271 + ] + ) ; + rdf:type owl:Class + ] + ] + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000051 ; + owl:someValuesFrom [ owl:intersectionOf ( chmo:_0000993 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000086 ; + owl:someValuesFrom af-q:AFQ_0000112 + ] + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000087 ; + owl:someValuesFrom af-rl:AFRL_0000272 + ] + ) ; + rdf:type owl:Class + ] + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A solid sol is a colloid where the continuous phase is a solid and the dispersed phase is a solid. [Allotrope]" ; + + skos:prefLabel "solid sol" . + + + +### http://purl.allotrope.org/ontologies/material#AFM_0001079 + +af-m:AFM_0001079 rdf:type owl:Class ; + + rdfs:subClassOf [ owl:intersectionOf ( af-m:AFM_0001034 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000056 ; + owl:someValuesFrom af-p:AFP_0003640 + ] + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + dct:license ; + + dct:rights ; + + dct:source , + "\"Terminology of polymers and polymerization processes in dispersed systems (IUPAC Recommendations 2011)\" . Pure and Applied Chemistry. 83 (12): 2229–2259. 2011." ; + + rdfs:isDefinedBy ; + + skos:changeNote "2017-07-03 Changed definition to IUPAC recommendation. [Allotrope]" ; + + skos:definition "A dispersions is a heterogeneous mixture that is comprising more than one phase where at least one of the phases consists of finely divided phase domains, often in the colloidal size range, dispersed throughout a continuous phase. [IUPAC]" ; + + skos:prefLabel "dispersion" . + + + +### http://purl.allotrope.org/ontologies/material#AFM_0001083 + +af-m:AFM_0001083 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( ncbi:_9606 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0002350 ; + owl:someValuesFrom af-m:AFM_0001084 + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:subClassOf af-m:AFM_0001090 , + bfo:_0000030 ; + + af-x:AFX_0002808 foaf:Person ; + + rdfs:isDefinedBy ; + + skos:definition "A person is a human that is member of a group or organization. [Allotrope]" ; + + skos:prefLabel "person" . + + + +### http://purl.allotrope.org/ontologies/material#AFM_0001084 + +af-m:AFM_0001084 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000027 , + [ owl:intersectionOf ( af-m:AFM_0001090 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0002351 ; + owl:someValuesFrom af-m:AFM_0001090 + ] + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002808 foaf:Group ; + + rdfs:isDefinedBy ; + + skos:definition "A group is a an aggregate of people. [Allotrope]" ; + + skos:prefLabel "group" . + + + +### http://purl.allotrope.org/ontologies/material#AFM_0001085 + +af-m:AFM_0001085 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000027 , + [ owl:intersectionOf ( af-m:AFM_0001090 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0002351 ; + owl:someValuesFrom af-m:AFM_0001090 + ] + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002808 org:Organization , + foaf:Organization ; + + rdfs:isDefinedBy ; + + skos:definition "A collection of people organized together into a community or other social, commercial or political structure. The group has some common purpose or reason for existence which goes beyond the set of people belonging to it and can act as an agent. [W3C ORG]" ; + + skos:editorialNote "By this hierarchy organizations are built of physical people, so no pure legal persons can be members of an organization." ; + + skos:prefLabel "organization" . + + + +### http://purl.allotrope.org/ontologies/material#AFM_0001086 + +af-m:AFM_0001086 rdf:type owl:Class ; + + rdfs:subClassOf af-m:AFM_0001085 ; + + owl:disjointWith af-m:AFM_0001087 ; + + af-x:AFX_0002808 org:FormalOrganization ; + + rdfs:isDefinedBy ; + + skos:definition "A formal organization is an organization which is recognized in the world at large, in particular in legal jurisdictions, with associated rights and responsibilities. [W3C ORG]" ; + + skos:prefLabel "formal organization" . + + + +### http://purl.allotrope.org/ontologies/material#AFM_0001087 + +af-m:AFM_0001087 rdf:type owl:Class ; + + rdfs:subClassOf af-m:AFM_0001085 , + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000050 ; + owl:someValuesFrom af-m:AFM_0001086 + ] ; + + af-x:AFX_0002808 org:OrganizationalUnit ; + + rdfs:isDefinedBy ; + + skos:definition "An organization such as a department or support unit which is part of some larger organization and only has full recognition within the context of that organization. In particular the unit would not be regarded as a legal entity in its own right. [W3C ORG]" ; + + skos:prefLabel "organizational unit" . + + + +### http://purl.allotrope.org/ontologies/material#AFM_0001090 + +af-m:AFM_0001090 rdf:type owl:Class ; + + owl:equivalentClass [ rdf:type owl:Class ; + owl:unionOf ( af-m:AFM_0001083 + af-m:AFM_0001084 + af-m:AFM_0001085 + ) + ] ; + + rdfs:subClassOf bfo:_0000040 ; + + rdfs:isDefinedBy ; + + skos:definition "An organizational entity is a person, group or organization that is defined by some social contract between humans. [Allotrope]" ; + + skos:prefLabel "organizational entity" . + + + +### http://purl.allotrope.org/ontologies/material#AFM_0001095 + +af-m:AFM_0001095 rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0002099 , + af-m:AFM_0000154 , + af-m:AFM_0001065 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002735 ; + owl:someValuesFrom [ owl:intersectionOf ( af-p:AFP_0000812 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000696 ; + owl:someValuesFrom envo:_00002005 + ] + ) ; + rdf:type owl:Class + ] + ] , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0001000 ; + owl:someValuesFrom envo:_00002005 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "Zero grade air is air that is purified to contain less than 0.1 ppm of hydrocarbons. [Allotrope]" ; + + skos:prefLabel "zero grade air" . + + + +### http://purl.allotrope.org/ontologies/material#AFM_0001096 + +af-m:AFM_0001096 rdf:type owl:Class ; + + rdfs:subClassOf af-m:AFM_0001042 ; + + rdfs:isDefinedBy ; + + skos:definition "A chromatographic packing is a solid heterogeneous mixture consisting of a substrate and stationary phase used in a chromatographic separation. [Allotrope]" ; + + skos:prefLabel "chromatographic packing" . + + + +### http://purl.allotrope.org/ontologies/material#AFM_0001097 + +af-m:AFM_0001097 rdf:type owl:Class ; + + rdfs:subClassOf chmo:_0000993 ; + + dct:license ; + + dct:rights ; + + dct:source "IUPAC. Compendium of Chemical Terminology, 2nd ed. (the \"Gold Book\"). Compiled by A. D. McNaught and A. Wilkinson. Blackwell Scientific Publications, Oxford (1997)." ; + + rdfs:isDefinedBy ; + + skos:definition "A chemical substance is a portion of material that is matter of constant composition best characterized by the entities (molecules, formula units, atoms) it is composed of. [IUPAC]" ; + + skos:prefLabel "chemical substance" . + + + +### http://purl.allotrope.org/ontologies/material#AFM_0001099 + +af-m:AFM_0001099 rdf:type owl:Class ; + + rdfs:subClassOf af-m:AFM_0001038 , + af-m:AFM_0001097 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000365 ; + owl:someValuesFrom af-m:AFM_0001097 + ] ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:altLabel "mixed chemical substances" , + "portion of mixed chemical substances" ; + + skos:definition "A portion of chemical mixture is a chemical substance that is composed of chemical substances. [Allotrope]" ; + + skos:prefLabel "chemical mixture" . + + + +### http://purl.allotrope.org/ontologies/material#AFM_0001101 + +af-m:AFM_0001101 rdf:type owl:Class ; + + rdfs:subClassOf af-m:AFM_0000880 ; + + rdfs:isDefinedBy ; + + skos:altLabel "collision energy" ; + + skos:definition "Collision energy is energy for an ion experiencing collision with a stationary gas particle resulting in dissociation of the ion. [PSI/MS]" ; + + skos:prefLabel "collision energy (material entity)" . + + + +### http://purl.allotrope.org/ontologies/material#AFM_0001103 + +af-m:AFM_0001103 rdf:type owl:Class ; + + rdfs:subClassOf af-m:AFM_0000012 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000056 ; + owl:someValuesFrom af-p:AFP_0001916 + ] , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000087 ; + owl:someValuesFrom af-rl:AFRL_0000269 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A titration solvent is a solvent used in a titration to dissolve the sample. [Allotrope]" ; + + skos:prefLabel "titration solvent" . + + + +### http://purl.allotrope.org/ontologies/material#AFM_0001104 + +af-m:AFM_0001104 rdf:type owl:Class ; + + rdfs:subClassOf af-m:AFM_0000012 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000056 ; + owl:someValuesFrom af-p:AFP_0001916 + ] , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000087 ; + owl:someValuesFrom af-rl:AFRL_0000234 + ] ; + + dct:license ; + + dct:rights ; + + dct:source "IUPAC Compendium on Analytical Nomenclature, Definitive Rules 1997, 3rd Edition, IUPAC Orange Book, prepared for publication by J. Inczedy, T. Lengyel, and A.M. Ure, Blackwell Science, 1998" ; + + rdfs:isDefinedBy ; + + skos:definition "A titrant solution is a solution containing the active agent with which a titration is made. [IUPAC]" ; + + skos:prefLabel "titrant solution" . + + + +### http://purl.allotrope.org/ontologies/material#AFM_0001105 + +af-m:AFM_0001105 rdf:type owl:Class ; + + rdfs:subClassOf af-m:AFM_0001060 , + [ rdf:type owl:Restriction ; + owl:onProperty obi:_0000643 ; + owl:someValuesFrom af-m:AFM_0000161 + ] , + [ rdf:type owl:Restriction ; + owl:onProperty obi:_0000643 ; + owl:someValuesFrom af-m:AFM_0000189 + ] ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:altLabel "ionic compound" , + "salt" ; + + skos:definition "A portion of salt is a portion of compound where the compound is composed of ions held together by electrostatic forces termed ionic bonding. [Wikipedia]" ; + + skos:prefLabel "portion of salt" . + + + +### http://purl.allotrope.org/ontologies/material#AFM_0001106 + +af-m:AFM_0001106 rdf:type owl:Class ; + + rdfs:subClassOf af-m:AFM_0001105 , + [ rdf:type owl:Restriction ; + owl:onProperty obi:_0000643 ; + owl:someValuesFrom chebi:_17632 + ] , + [ rdf:type owl:Restriction ; + owl:onProperty obi:_0000643 ; + owl:someValuesFrom chebi:_49468 + ] ; + + af-x:AFX_0002808 chebi:_32130 ; + + rdfs:isDefinedBy ; + + skos:altLabel "silver (1+) nitrate" , + "silver nitrate" ; + + skos:definition "A portion of silver nitrate is a portion of salt composed of silver (1+) and nitrate ions. [Allotrope]" ; + + skos:prefLabel "portion of silver nitrate" . + + + +### http://purl.allotrope.org/ontologies/material#AFM_0001107 + +af-m:AFM_0001107 rdf:type owl:Class ; + + rdfs:subClassOf af-m:AFM_0001104 ; + + rdfs:isDefinedBy ; + + skos:altLabel "Karl Fischer titrant solution" , + "Karl Fischer titration solution" , + "Karl-Fischer titration solution" ; + + skos:definition "A Karl-Fischer titration solution is a titrant solution used in a Karl-Fischer titration. [Allotrope]" ; + + skos:prefLabel "Karl-Fischer titrant solution" . + + + +### http://purl.allotrope.org/ontologies/material#AFM_0001108 + +af-m:AFM_0001108 rdf:type owl:Class ; + + rdfs:subClassOf af-m:AFM_0001104 ; + + rdfs:isDefinedBy ; + + skos:definition "A hydrochloric acid titrant solution is a titrant solution containing hydrochloric acid as the reactant. [Allotrope]" ; + + skos:prefLabel "hydrochloric acid titrant solution" . + + + +### http://purl.allotrope.org/ontologies/material#AFM_0001109 + +af-m:AFM_0001109 rdf:type owl:Class ; + + rdfs:subClassOf af-m:AFM_0001104 ; + + rdfs:isDefinedBy ; + + skos:definition "A perchloric acid titrant solution is a titrant solution containing perchloric acid as the reactant. [Allotrope]" ; + + skos:prefLabel "perchloric acid titrant solution" . + + + +### http://purl.allotrope.org/ontologies/material#AFM_0001110 + +af-m:AFM_0001110 rdf:type owl:Class ; + + rdfs:subClassOf af-m:AFM_0001104 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000365 ; + owl:someValuesFrom [ owl:intersectionOf ( af-m:AFM_0001106 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000087 ; + owl:someValuesFrom [ owl:intersectionOf ( af-rl:AFRL_0000231 + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000054 ; + owl:someValuesFrom af-p:AFP_0001916 + ] + ) ; + rdf:type owl:Class + ] + ] + ) ; + rdf:type owl:Class + ] + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A silver nitrate titrant solution is a titrant solution containing silver nitrate as the reactant. [Allotrope]" ; + + skos:prefLabel "silver nitrate titrant solution" . + + + +### http://purl.allotrope.org/ontologies/material#AFM_0001111 + +af-m:AFM_0001111 rdf:type owl:Class ; + + rdfs:subClassOf af-m:AFM_0001104 ; + + rdfs:isDefinedBy ; + + skos:definition "A sodium hydroxide titrant solution is a titrant solution containing sodium hydroxide as the reactant. [Allotrope]" ; + + skos:prefLabel "sodium hydroxide titrant solution" . + + + +### http://purl.allotrope.org/ontologies/material#AFM_0001112 + +af-m:AFM_0001112 rdf:type owl:Class ; + + rdfs:subClassOf af-m:AFM_0000154 , + [ rdf:type owl:Restriction ; + owl:onProperty obi:_0000643 ; + owl:someValuesFrom chebi:_18276 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "hydrogen" ; + + skos:definition "Hydrogen gas is a gas that is composed of hydrogen molecules. [Allotrope]" ; + + skos:prefLabel "hydrogen gas" . + + + +### http://purl.allotrope.org/ontologies/material#AFM_0001113 + +af-m:AFM_0001113 rdf:type owl:Class ; + + rdfs:subClassOf af-m:AFM_0000154 , + [ rdf:type owl:Restriction ; + owl:onProperty obi:_0000643 ; + owl:someValuesFrom chebi:_15379 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "oxygen" ; + + skos:definition "Oxygen gas is a gas that is composed of dioxygen molecules. [Allotrope]" ; + + skos:prefLabel "oxygen gas" . + + + +### http://purl.allotrope.org/ontologies/material#AFM_0001114 + +af-m:AFM_0001114 rdf:type owl:Class ; + + rdfs:subClassOf af-m:AFM_0000154 , + [ rdf:type owl:Restriction ; + owl:onProperty obi:_0000643 ; + owl:someValuesFrom chebi:_17997 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "nitrogen" ; + + skos:definition "Nitrogen gas is a gas that is composed of dinitrogen molecules. [Allotrope]" ; + + skos:prefLabel "nitrogen gas" . + + + +### http://purl.allotrope.org/ontologies/material#AFM_0001115 + +af-m:AFM_0001115 rdf:type owl:Class ; + + rdfs:subClassOf af-m:AFM_0000154 , + [ rdf:type owl:Restriction ; + owl:onProperty obi:_0000643 ; + owl:someValuesFrom chebi:_33681 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "helium" ; + + skos:definition "Helium gas is a gas that is composed of helium atoms. [Allotrope]" ; + + skos:prefLabel "helium gas" . + + + +### http://purl.allotrope.org/ontologies/material#AFM_0001116 + +af-m:AFM_0001116 rdf:type owl:Class ; + + rdfs:subClassOf af-m:AFM_0000154 , + [ rdf:type owl:Restriction ; + owl:onProperty obi:_0000643 ; + owl:someValuesFrom chebi:_16526 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "carbon dioxide" ; + + skos:definition "Carbon dioxide gas is a gas that is composed of carbon dioxide molecules. [Allotrope]" ; + + skos:prefLabel "carbon dioxide gas" . + + + +### http://purl.allotrope.org/ontologies/material#AFM_0001117 + +af-m:AFM_0001117 rdf:type owl:Class ; + + rdfs:subClassOf af-m:AFM_0000154 , + [ rdf:type owl:Restriction ; + owl:onProperty obi:_0000643 ; + owl:someValuesFrom chebi:_16134 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "ammonia" ; + + skos:definition "Ammonia gas is a gas that is composed of ammonia molecules. [Allotrope]" ; + + skos:prefLabel "ammonia gas" . + + + +### http://purl.allotrope.org/ontologies/material#AFM_0001118 + +af-m:AFM_0001118 rdf:type owl:Class ; + + rdfs:subClassOf af-m:AFM_0000154 , + [ rdf:type owl:Restriction ; + owl:onProperty obi:_0000643 ; + owl:someValuesFrom chebi:_16183 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "methane" ; + + skos:definition "Methane gas is a gas that is composed of methane molecules. [Allotrope]" ; + + skos:prefLabel "methane gas" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0000021 + +af-p:AFP_0000021 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0000225 ; + + rdfs:isDefinedBy ; + + skos:altLabel "HILIC" , + "hydrophilic interaction liquid chromatography" ; + + skos:changeNote "2016-02-03 Added altLabel [OSTHUS]" ; + + skos:definition "Liquid chromatography where the stationary phase is hydrophilic, the mobile phase is organic and separation is achieved based on polarity. [CHMO]" ; + + skos:prefLabel "hydrophilic interaction chromatography" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0000022 + +af-p:AFP_0000022 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0002294 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002750 ; + owl:someValuesFrom pato:_0000918 + ] ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "Volumetry is a type of quantitative analysis that measures the quantity of a compound by quantifying its volume. [Allotrope]" ; + + skos:prefLabel "volumetry" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0000032 + +af-p:AFP_0000032 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0000378 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000057 ; + owl:someValuesFrom af-m:AFM_0000341 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "cell counter analysis" , + "cell counting analysis" ; + + skos:definition "Cell counter assay is a cellular assay that uses various methods to quantify cells in a culture. [Allotrope]" ; + + skos:prefLabel "cell counter assay" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0000039 + +af-p:AFP_0000039 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0001698 ; + + rdfs:isDefinedBy ; + + skos:definition "Magnetic stirring is stirring that is achieved by rotating a magnetic stir bar in a solution. [CHMO]" ; + + skos:prefLabel "magnetic stirring" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0000044 + +af-p:AFP_0000044 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0001801 , + af-p:AFP_0003305 , + af-p:AFP_0003774 ; + + rdfs:isDefinedBy ; + + skos:definition "Microscopy is a imaging assay where a microscope is used to view a small object (or specimen) by producing a magnified image. [CHMO]" ; + + skos:prefLabel "microscopy" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0000047 + +af-p:AFP_0000047 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0001462 ; + + rdfs:isDefinedBy ; + + skos:altLabel "Raman scattering spectrometry" , + "Raman scattering spectroscopy" , + "Raman spectrometry" , + "laser Raman spectroscopy" ; + + skos:definition "Any type of vibrational spectroscopy where the Raman scattering of monochromatic light, usually from a laser in the visible, near infrared, or near ultraviolet range by a sample is detected. [CHMO]" ; + + skos:prefLabel "Raman spectroscopy" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0000057 + +af-p:AFP_0000057 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0002294 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "particle size analysis" , + "particle size measurement" , + "particle sizing" ; + + skos:definition "The measurement of the size distribution in a collection of grains. [CHMO]" ; + + skos:prefLabel "granulometry" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0000078 + +af-p:AFP_0000078 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0001916 ; + + rdfs:isDefinedBy ; + + skos:altLabel "argentimetric titration" ; + + skos:definition "Argentometric titration is a process of determining the quantity of a sample by adding measured increments of a titrant until the end-point, at which essentially all of the sample has reacted, is reached. The titration is followed by the observing the precipitation of silver compounds following the addition of silver nitrate. [CHMO]" ; + + skos:prefLabel "argentometric titration" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0000080 + +af-p:AFP_0000080 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0002294 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "O.D. measurement" , + "OD measurement" , + "optical densiometry" , + "optical densitometry" ; + + skos:definition "The measurement of the light transmitted through a sample for a given wavelength. [CHMO]" ; + + skos:prefLabel "optical density measurement" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0000109 + +af-p:AFP_0000109 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0002294 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "zeta potential analysis" , + "zeta potential measurement" , + "zeta-potential analysis" , + "zeta-potential measurements" , + "zeta-potential studies" , + "ζ-potential analysis" , + "ζ-potential measurement" ; + + skos:definition "The measurement of the overall charge a particle acquires in a specific medium. A number of different experimental methods can be used including electrophoretic light scattering and laser Doppler velocimetry. [CHMO]" ; + + skos:prefLabel "zeta-potential measurement" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0000112 + +af-p:AFP_0000112 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0001135 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A mixing step where a soluble component is mixed with a liquid component. [CHMO]" ; + + skos:prefLabel "dissolving" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0000119 + +af-p:AFP_0000119 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0000441 , + af-p:AFP_0000634 ; + + rdfs:isDefinedBy ; + + skos:altLabel "Karl Fischer volumetric titration" , + "volumetric Karl Fischer titration" , + "volumetric Karl-Fischer titration" ; + + skos:definition "Karl-Fischer volumetric titration is a process of determining trace amounts of water in a sample by the titration of sulfur dioxide in water using iodine. In this method the titrant is added directly to the sample using a burette. [CHMO]" ; + + skos:prefLabel "Karl-Fischer volumetric titration" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0000131 + +af-p:AFP_0000131 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0001321 ; + + rdfs:isDefinedBy ; + + skos:definition "Chromatography in which separation is based mainly on differences between the solubility of the sample components in the stationary phase (gas chromatography), or on differences between the solubilities of the components in the mobile and stationary phases (liquid chromatography). [CHMO]" ; + + skos:prefLabel "partition chromatography" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0000142 + +af-p:AFP_0000142 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0002294 ; + + rdfs:isDefinedBy ; + + skos:altLabel "FID" , + "flame ionization detection" , + "flame ionization process" ; + + skos:definition "A flame ionization measurement is a measurement which is sensitive to compounds containing C-H bonds. A flow of carrier gas containing the sample is mixed with H2 and air and ignited. Any positively-charged radicals resulting from this process are collected at a cathode, allowing the current to be measured. [CHMO]" ; + + skos:prefLabel "flame ionization measurement" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0000161 + +af-p:AFP_0000161 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003275 , + af-p:AFP_0003336 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "cleansing" , + "cleanup" ; + + skos:definition "Cleaning is the process of getting rid of dirt, impurities, or extraneous unwanted matter. [Allotrope]" ; + + skos:prefLabel "cleaning" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0000225 + +af-p:AFP_0000225 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0001321 ; + + af-x:AFX_0002809 chmo:_0001004 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "LC" ; + + skos:definition "Column chromatography where the mobile phase is a liquid. [CHMO]" ; + + skos:prefLabel "liquid chromatography" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0000229 + +af-p:AFP_0000229 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0002294 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "reflectivity measurement" ; + + skos:definition "Any method for determining structure by directing a beam of particles or X-rays onto an extremely flat surface and measuring the intensity of the reflected radiation as a function of angle. [CHMO]" ; + + skos:prefLabel "reflectometry" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0000246 + +af-p:AFP_0000246 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0002188 ; + + rdfs:isDefinedBy ; + + skos:altLabel "UV detection" , + "UV measurement" , + "ultra-violet detection" , + "ultra-violet measurement" , + "ultraviolet detection" , + "ultraviolet measurement" ; + + skos:changeNote "2019-08-14 Changed definition and preferred label. [Allotrope]" ; + + skos:definition "Ultraviolet absorbance measurement is electronic absorbance measurement of light in the wavelength region of 190-350 nm. [Allotrope]" ; + + skos:prefLabel "ultraviolet absorbance measurement" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0000253 + +af-p:AFP_0000253 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0001321 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "SFC" ; + + skos:definition "Column chromatography where the mobile phase is a fluid above and relatively close to its critical temperature and pressure. [CHMO]" ; + + skos:prefLabel "supercritical-fluid chromatography" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0000254 + +af-p:AFP_0000254 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0001135 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "Vortexing is a process of mixing that creates a vortex in the solution usually using a vortexer. [Allotrope]" ; + + skos:prefLabel "vortexing" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0000260 + +af-p:AFP_0000260 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0002294 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "The measurement of the pore diameter, pore-size distribution and total pore volume of a sample. [CHMO]" ; + + skos:prefLabel "porosimetry" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0000264 + +af-p:AFP_0000264 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003385 ; + + dct:license ; + + dct:rights ; + + dct:source "PAC, 1993, 65, 819 (Nomenclature for chromatography (IUPAC Recommendations 1993))" ; + + rdfs:isDefinedBy ; + + skos:definition "Fraction collection is the collection of fractional volumes of the column effluent. [IUPAC]" ; + + skos:prefLabel "fraction collection" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0000266 + +af-p:AFP_0000266 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0001655 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "MAS" , + "molecular absorption spectrophotometry" , + "molecular electronic absorption spectroscopy" ; + + skos:definition "A type of spectroscopy where the sample absorbs radiation in the range ultraviolet to near-infrared (0.1-2.5 µm) resulting in electronic transitions within the sample. [CHMO]" ; + + skos:prefLabel "spectrophotometry" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0000304 + +af-p:AFP_0000304 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0001916 ; + + rdfs:isDefinedBy ; + + skos:definition "Coulometric titration is the process of determining the quantity of a sample by adding measured increments of a titrant until the end-point, at which essentially all of the sample has reacted, is reached. In a coulometric titration the titrant is generated electrochemically by passing a constant current through an electrolyte. [CHMO]" ; + + skos:prefLabel "coulometric titration" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0000307 + +af-p:AFP_0000307 rdf:type owl:Class ; + + rdfs:subClassOf [ owl:intersectionOf ( bfo:_0000015 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000057 ; + owl:someValuesFrom iao:_0000030 + ] + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A process that affects, creates or destroys information content. [Allotrope]" ; + + skos:editorialNote "information processing is often dependent on a signal processing, but abstracts the bearer of information from the content [OSTHUS]" ; + + skos:prefLabel "information process" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0000310 + +af-p:AFP_0000310 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0001321 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "GC" , + "GC run" , + "gas chromatography run" ; + + skos:definition "Column chromatography where the mobile phase is a gas. [CHMO]" ; + + skos:example "An instance of gas chromatography can be a single-injection GC run." ; + + skos:prefLabel "gas chromatography" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0000326 + +af-p:AFP_0000326 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0000527 , + af-p:AFP_0000759 ; + + rdfs:isDefinedBy ; + + skos:altLabel "NMR" , + "NMR spectrometry" , + "NMR spectroscopy" , + "nuclear magnetic resonance (NMR) spectroscopy" , + "nuclear magnetic resonance spectrometry" ; + + skos:definition "A type of spectroscopy where the energy states of spin-active nuclei placed in a static magnetic field are interrogated by inducing transitions between the states via radio frequency irradiation. [CHMO]" ; + + skos:prefLabel "nuclear magnetic resonance spectroscopy" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0000373 + +af-p:AFP_0000373 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0002294 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "The measurement and study of dimensional changes in polymers as a function of temperature, fluid absorption, mechanical stress or chemical reaction. [CHMO]" ; + + skos:prefLabel "dilatometry" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0000378 + +af-p:AFP_0000378 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0001116 ; + + rdfs:isDefinedBy ; + + skos:definition "An assay that generates data about the presence, quantity, structure, function, behavior, or activity of cells, or a process that occurs at a cellular level of anatomical granularity (includes subcellular structures and organelles). [VIVO-ISF]" ; + + skos:prefLabel "cellular assay" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0000391 + +af-p:AFP_0000391 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0000955 ; + + rdfs:isDefinedBy ; + + skos:altLabel "UV-vis-DRS" , + "UV-vis-diffuse reflectance spectroscopy" , + "diffuse reflectance UV-vis spectroscopy" , + "diffuse reflectance UV-visible" ; + + skos:definition "A type of spectroscopy where the diffuse reflection of radiation in the range ultraviolet to visible (190-800 nm) by a sample is measured. [CHMO]" ; + + skos:prefLabel "diffuse reflectance ultraviolet-visible spectrophotometry" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0000422 + +af-p:AFP_0000422 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003332 ; + + af-x:AFX_0002808 chmo:_0000999 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "separation" ; + + skos:definition "A branching process that isolates flows into distinct component flows. The separated components are distinct from the flow before separation, as well as each other. [NIST]" ; + + skos:prefLabel "separating" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0000441 + +af-p:AFP_0000441 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0001916 ; + + rdfs:isDefinedBy ; + + skos:altLabel "Karl Fischer titration" ; + + skos:definition "Karl-Fischer titration is a process of determining trace amounts of water in a sample by the titration of sulfur dioxide in water using iodine. [CHMO]" ; + + skos:prefLabel "Karl-Fischer titration" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0000474 + +af-p:AFP_0000474 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0000669 ; + + rdfs:isDefinedBy ; + + skos:altLabel "CZE" , + "capillary zone electrophoresis" ; + + skos:definition "A capillary electrophoresis is an electrophoresis which takes place in a capillary. [CHMO]" ; + + skos:prefLabel "capillary electrophoresis" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0000498 + +af-p:AFP_0000498 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003299 , + [ owl:intersectionOf ( af-p:AFP_0000307 + af-p:AFP_0003452 + obi:_0000011 + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A process of creating or modifying a plan specification. [OBI]" ; + + skos:example "The process of a scientist thinking about and deciding what reagents to use as part of a protocol for an experiment. Note that the scientist could be human or a robot scientist executing software. [OBI]" ; + + skos:prefLabel "planning" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0000503 + +af-p:AFP_0000503 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0002294 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002750 ; + owl:someValuesFrom pato:_0000125 + ] ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:altLabel "weighment" , + "weight check" ; + + skos:definition "Weighing is the measuring of weight of an object. Weight related to the amount of force acting on the object, either due to gravity or to a reaction force that holds it in place. [Wikipedia]" ; + + skos:prefLabel "weighing" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0000516 + +af-p:AFP_0000516 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0000307 , + af-p:AFP_0003598 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "Peak picking is a data transformation to convert profile spectral data into centroided spectral data. [Allotrope]" ; + + skos:prefLabel "peak picking" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0000525 + +af-p:AFP_0000525 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0002294 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002750 ; + owl:someValuesFrom af-q:AFQ_0000267 + ] ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "conductimetry" ; + + skos:changeNote "2020-11-12 Changed definition. [Allotrope]" ; + + skos:definition "Conductometry is the measurement of the conductance of a solution as a function of concentration. Measurements are made indirectly across the resistance of the solution with alternating current. [CHMO]" ; + + skos:prefLabel "conductometry" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0000527 + +af-p:AFP_0000527 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003556 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "spectroscopy" ; + + skos:definition "The study of the interaction of a sample with radiation or particles for measurement or detection. [CHMO]" ; + + skos:prefLabel "spectrometry" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0000588 + +af-p:AFP_0000588 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( af-p:AFP_0001321 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000057 ; + owl:someValuesFrom af-e:AFE_0000217 + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:subClassOf af-p:AFP_0001321 ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A chromatography method where the stationary bed is within a tube (of standard length 25 cm). The particles of the solid stationary phase or support coated with a liquid stationary phase may fill the whole inside volume of the tube (packed column) or be concentrated on or along the inside tube wall leaving an open, unrestricted path for the mobile phase in the middle part of the tube (open-tubular column). [CHMO]" ; + + skos:prefLabel "column chromatography" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0000593 + +af-p:AFP_0000593 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0001159 , + af-p:AFP_0003473 ; + + rdfs:isDefinedBy ; + + skos:altLabel "degas" , + "degasification" ; + + skos:definition "Degassing is a sample preparation process whereby the adsorbed (dissolved) gas is removed from a solid or liquid. [Allotrope]" ; + + skos:prefLabel "degassing" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0000611 + +af-p:AFP_0000611 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0002294 , + af-p:AFP_0002313 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002750 ; + owl:someValuesFrom af-q:AFQ_0000269 + ] ; + + dct:license ; + + dct:rights ; + + dct:source "IUPAC. Compendium of Chemical Terminology, 2nd ed. (the \"Gold Book\"). Compiled by A. D. McNaught and A. Wilkinson. Blackwell Scientific Publications, Oxford (1997). Online version (2019-) created by S. J. Chalk. ISBN 0-9678550-9-8. https://doi.org/10.1351/goldbook." ; + + rdfs:isDefinedBy ; + + skos:altLabel "enthalpimetric analysis" , + "enthalpimetry" ; + + skos:changeNote "2018-11-01 Changed definition, previous definition: The measurement of thermodynamic parameters (e.g. enthalpy) during a chemical or biochemical reaction. [CHMO]" ; + + skos:definition "A measurement in which heat is measured as some chemical reaction or physical process occurs. [IUPAC]" ; + + skos:prefLabel "calorimetry" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0000620 + +af-p:AFP_0000620 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0002294 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "osometry" ; + + skos:definition "The measurement of the osmotic strength of a substance which often used to determine its molecular weight. [CHMO]" ; + + skos:prefLabel "osmometry" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0000634 + +af-p:AFP_0000634 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0001916 ; + + rdfs:isDefinedBy ; + + skos:definition "Volumetric titration is the process of determining the quantity of a sample by adding measured volumes of a titrant (normally via a burette) until the end-point, at which essentially all of the sample has reacted, is reached. [CHMO]" ; + + skos:prefLabel "volumetric titration" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0000669 + +af-p:AFP_0000669 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003275 , + af-p:AFP_0003335 , + obi:_0000011 ; + + rdfs:isDefinedBy ; + + skos:altLabel "cataphoresis" , + "electrophoretic analysis" ; + + skos:definition "An electrophoresis is a separation where colloidal particles move at different speeds according to their electrophoretic mobilities in a separation medium, across which an electric field is applied. [CHMO]" ; + + skos:prefLabel "electrophoresis" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0000698 + +af-p:AFP_0000698 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0000748 ; + + rdfs:isDefinedBy ; + + skos:altLabel "nHPLC" , + "nano HPLC" , + "nano flow HPLC" , + "nano high performance liquid chromatography" , + "nano high pressure liquid chromatography" , + "nano high-performance liquid chromatography" , + "nano high-pressure liquid chromatography" , + "nano-HPLC" , + "nanoHPLC" , + "nanoflow HPLC" , + "nanoflow high performance liquid chromatography" , + "nanoflow high pressure liquid chromatography" , + "nanoflow high-pressure liquid chromatography" , + "nanoflow-HPLC" , + "nanoflowHPLC" ; + + skos:definition "Column chromatography where the mobile phase is a liquid, the stationary phase consists of very small particles, the inlet pressure is relatively high and the flow rate is nL min-1. [CHMO]" ; + + skos:prefLabel "nanoflow high-performance liquid chromatography" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0000708 + +af-p:AFP_0000708 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003275 , + af-p:AFP_0003349 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:changeNote "2020-06-18 Changed definition. [Allotrope]" ; + + skos:definition "Loading is the importing of a material into a new location that contains the material. [Allotrope]" ; + + skos:example "The loading step of IEF is the mixing of the sample with the appropriate ampholytes and loading the mixture into the capillary. [Allotrope]" ; + + skos:prefLabel "loading" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0000733 + +af-p:AFP_0000733 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0002294 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "amperometric method" ; + + skos:definition "An electrochemical technique where the cell current is measured whilst the potential difference between the indicator and reference electrodes is controlled. [CHMO]" ; + + skos:prefLabel "amperometry" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0000747 + +af-p:AFP_0000747 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0001916 ; + + rdfs:isDefinedBy ; + + skos:definition "Catalymetric titration is he process of determining the quantity of a sample by adding measured increments of a titrant until the end-point is reached. The titration involves a catalyst, and the end-point is detected by the sudden increase or decrease in the rate of a reaction. [CHMO]" ; + + skos:prefLabel "catalymetric titration" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0000748 + +af-p:AFP_0000748 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0001192 ; + + af-x:AFX_0002809 chmo:_0001009 ; + + rdfs:isDefinedBy ; + + skos:altLabel "HPLC" , + "high performance liquid chromatography" , + "high pressure liquid chromatography" , + "high-pressure liquid chromatography" ; + + skos:definition "Column chromatography where the mobile phase is a liquid, the stationary phase consists of very small particles and the inlet pressure is relatively high. [CHMO]" ; + + skos:prefLabel "high-performance liquid chromatography" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0000759 + +af-p:AFP_0000759 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0002211 ; + + rdfs:isDefinedBy ; + + skos:altLabel "nuclear magnetic resonance method" ; + + skos:definition "A nuclear magnetic resonance assay is magnetic resonance assay that applies a technique which detects the response of nuclear spins to a perturbing magnetic field. [Allotrope]" ; + + skos:prefLabel "nuclear magnetic resonance assay" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0000780 + +af-p:AFP_0000780 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0000527 ; + + rdfs:isDefinedBy ; + + skos:altLabel "vibrational spectroscopic analysis" ; + + skos:definition "Vibrational spectroscopy is a spectroscopy which probes the vibrational degrees of freedom of a molecule. [CHMO]" ; + + skos:prefLabel "vibrational spectroscopy" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0000785 + +af-p:AFP_0000785 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0001135 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "Dilution is the process of adding a solvent to a solution to lower its concentration. [Allotrope]" ; + + skos:prefLabel "dilution" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0000792 + +af-p:AFP_0000792 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003566 ; + + rdfs:isDefinedBy ; + + skos:definition "A heat treatment that alters the microstructure of a material causing changes in its properties such as strength and hardness. [CHMO]" ; + + skos:prefLabel "annealing" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0000801 + +af-p:AFP_0000801 rdf:type owl:Class ; + + rdfs:subClassOf [ owl:intersectionOf ( af-p:AFP_0000307 + af-p:AFP_0003475 + af-p:AFP_0003598 + ) ; + rdf:type owl:Class + ] ; + + rdfs:isDefinedBy ; + + skos:definition "Spectra combination is a data transformation that combines multiple spectra. [Allotrope]" ; + + skos:prefLabel "spectra combination" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0000812 + +af-p:AFP_0000812 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003473 ; + + rdfs:isDefinedBy ; + + skos:definition "A purification is a removing process that is used to physically separate an analyte from byproducts, reagents or contaminating substances. [Allotrope, CHMO]" ; + + skos:prefLabel "purification" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0000813 + +af-p:AFP_0000813 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0000266 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A method where the absorption of radiation in the ultraviolet to near-infrared (0.1-2.5 µm) is used to calculate stability constants by equimolar dilution. [CHMO]" ; + + skos:prefLabel "equimolar spectrophotometry" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0000840 + +af-p:AFP_0000840 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0002294 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "rheological measurements" , + "rheology" ; + + skos:definition "The study of the flow of fluids which cannot be defined by a single value of viscosity. Rheometry is the measurement of the relationship between deformation and stress for these liquids. [CHMO]" ; + + skos:prefLabel "rheometry" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0000855 + +af-p:AFP_0000855 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0002294 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "adsorption-desorption" , + "adsorption/desorption" , + "sorption-desorption" , + "sorption/desorption" ; + + skos:definition "A method for determining surface area by measuring the amount of an inert gaseous or liquid substance (the 'sorbent', usually H2 or N2) which adsorbs onto the surface of interest (the 'sorbate'), and the subsequent amount that desorbs at a constant temperature. Regression analysis is then applied to the data, resulting in an isotherm. [CHMO]" ; + + skos:prefLabel "sorption-desorption measurements" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0000862 + +af-p:AFP_0000862 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0002294 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:altLabel "gravimetric mass measurement" ; + + skos:definition "Gravimetry is the measurement of the strength of a gravitational field. [Wikipedia]" ; + + skos:prefLabel "gravimetry" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0000869 + +af-p:AFP_0000869 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0002294 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "voltammetric method" ; + + skos:definition "An electrochemical technique where the cell current is measured as a function of time and as a function of the potential between the indicator and reference electrodes. [CHMO]" ; + + skos:prefLabel "voltammetry" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0000872 + +af-p:AFP_0000872 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0000955 ; + + rdfs:isDefinedBy ; + + skos:altLabel "DOAS" , + "differential optical absorbance spectrometry" , + "differential optical absorbance spectroscopy" , + "differential optical absorption spectrometry" , + "differential optical absorption spectroscopy" ; + + skos:definition "Ultraviolet-visible spectroscopy where the difference between incident and transmitted radiation is measured for a gaseous sample. [CHMO]" ; + + skos:prefLabel "differential optical absorption spectrophotometry" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0000896 + +af-p:AFP_0000896 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0000955 ; + + rdfs:isDefinedBy ; + + skos:altLabel "UV spectrophotometry" , + "UV spectroscopic measurements" , + "UV spectroscopy" , + "ultra-violet spectrometry" , + "ultra-violet spectrophotometry" , + "ultra-violet spectroscopy" , + "ultraviolet spectrometry" , + "ultraviolet spectroscopy" ; + + skos:definition "Spectroscopy where the sample absorbs radiation from the ultraviolet region (190-400 nm) resulting in electronic transitions within the sample. [CHMO]" ; + + skos:prefLabel "ultraviolet spectrophotometry" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0000925 + +af-p:AFP_0000925 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003305 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000395 ; + owl:someValuesFrom iao:_0000030 + ] ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:altLabel "detection" ; + + skos:changeNote "2018-08-09 Changed definition, removed alt label detection method. [Allotrope]" ; + + skos:definition "Detecting is observing the presence of an entity. This occurs when a threshold value of a quantity (quality, disposition, process property) is exceeded. [Allotrope]" ; + + skos:prefLabel "detecting" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0000955 + +af-p:AFP_0000955 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0000266 ; + + rdfs:isDefinedBy ; + + skos:altLabel "UV spectrometry" , + "UV-VIS" , + "UV-VIS absorption spectrophotometry" , + "UV-VIS absorption spectroscopy" , + "UV-VIS spectrophotometry" , + "UV-VIS spectroscopy" , + "UV-Vis molecular absorption spectrometry" , + "UV-Vis molecular absorption spectroscopy" , + "UV-Vis spectroscopy" , + "UV-vis" , + "UV-vis absorption spectrometry" , + "UV-vis absorption spectrophotometry" , + "UV-vis absorption spectroscopy" , + "UV-vis spectrometry" , + "UV-vis spectrophotometry" , + "UV-vis spectroscopy" , + "UV-visible" , + "UV-visible spectroscopy" , + "UV/VIS" , + "UV/VIS absorption spectrophotometry" , + "UV/VIS spectrometry" , + "UV/VIS spectrophotometry" , + "UV/VIS spectroscopy" , + "UV/Vis absorption spectrophotometry" , + "UV/Vis spectrometry" , + "UV/Vis spectrophotometry" , + "UV/Vis spectroscopy" , + "UV/vis" , + "absorption spectrophotometry" , + "electronic absorption spectroscopy" , + "molecular electronic absorption spectroscopy" , + "ultra-violet-visible spectrometry" , + "ultra-violet-visible spectroscopy" , + "ultraviolet-visible" , + "ultraviolet-visible spectrometry" , + "ultraviolet-visible spectrophotometry" , + "ultraviolet-visible spectroscopy" ; + + skos:definition "Spectroscopy where the sample absorbs radiation in the range ultraviolet to visible (190-800 nm) resulting in electronic transitions within the sample. [CHMO]" ; + + skos:prefLabel "ultraviolet-visible spectrophotometry" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0000970 + +af-p:AFP_0000970 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003282 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "The method used to obtain the integral of a function or curve. [Allotrope]" ; + + skos:prefLabel "integration" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0000979 + +af-p:AFP_0000979 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0000307 , + af-p:AFP_0003598 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "peak resolution method" , + "peak separation method" , + "resolution measurement method" ; + + skos:definition "Peak separation is a data transformation that allows to distinguish between two peaks. [Allotrope]" ; + + skos:prefLabel "peak separation" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0000983 + +af-p:AFP_0000983 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003598 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "Removing data is a data transformation that removes parts from an aggregate of data. [Allotrope]" ; + + skos:prefLabel "removing data" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0001001 + +af-p:AFP_0001001 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0000304 , + af-p:AFP_0000441 ; + + rdfs:isDefinedBy ; + + skos:altLabel "Karl Fischer coulometric titration" , + "Karl Fischer coulometry" , + "Karl-Fischer coulometry" , + "coulometric Karl Fischer titration" , + "coulometric Karl-Fischer titration" ; + + skos:definition "Karl-Fischer coulometric titration is a process of determining trace amounts of water in a sample by the titration of sulfur dioxide in water using iodine. In this method the I2 is generated electrochemically from I- and titrated with sulfur dioxide. [CHMO]" ; + + skos:prefLabel "Karl-Fischer coulometric titration" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0001023 + +af-p:AFP_0001023 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0001321 ; + + rdfs:isDefinedBy ; + + skos:definition "Chromatography in which separation is based mainly on differences between the adsorption affinities of the sample components for the surface of an active solid. [CHMO]" ; + + skos:prefLabel "adsorption chromatography" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0001026 + +af-p:AFP_0001026 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0001993 ; + + dct:license ; + + dct:rights ; + + dct:source "K. K. Murray, R. K. Boyd, M. N. Eberlin, G. J. Langley, L. Li and Y. Naito, Pure Appl. Chem., 2013, 85, 1515-1609" ; + + rdfs:isDefinedBy ; + + skos:altLabel "CI" ; + + skos:definition "Formation of a new ion in the gas phase by the reaction of a neutral with an ion. The process may involve transfer of an electron, a proton, or other charged species between the reactants. [IUPAC]" ; + + skos:prefLabel "chemical ionization" ; + + skos:scopeNote "This term is not synonymous with chemi-ionization. [IUPAC]" , + "When a positive ion results from chemical ionization, the term may be used without qualification. When a negative ion results, the term negative ion chemical ionization should be used. [IUPAC]" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0001046 + +af-p:AFP_0001046 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0000225 ; + + rdfs:isDefinedBy ; + + skos:altLabel "LCCC" , + "liquid chromatography at critical conditions" ; + + skos:definition "Column chromatography where the mobile phase is a liquid held at or near its critical point. Liquid chromatography at the critical condition is used to determine functionality distributions in polymers. [CHMO]" ; + + skos:prefLabel "liquid chromatography at the critical condition" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0001047 + +af-p:AFP_0001047 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0001114 ; + + rdfs:isDefinedBy ; + + skos:altLabel "ABG" , + "BGA" , + "arterial blood gas" , + "blood gas measurement" ; + + skos:definition "Blood gas analysis is the process of analyzing amount of dissolved gases in a blood sample. [Allotrope]" ; + + skos:prefLabel "blood gas analysis" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0001062 + +af-p:AFP_0001062 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0000047 ; + + rdfs:isDefinedBy , + ; + + skos:altLabel "FT Raman spectrometry" , + "FT Raman spectroscopy" , + "FT-Raman" , + "Fourier transform Raman spectrometry" , + "Fourier-transform Raman spectrometry" , + "Fourier-transform Raman spectroscopy" ; + + skos:definition "A type of vibrational spectroscopy where the Raman scattering of light by a sample is detected and the spectrum is subject to a Fourier transform. [CHMO]" , + "Fourier transform Raman spectroscopy is a type of vibrational spectroscopy where the Raman scattering of light by a sample is detected and the spectrum is subject to a Fourier transform. [CHMO]" ; + + skos:prefLabel "Fourier transform Raman spectroscopy" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0001106 + +af-p:AFP_0001106 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0000955 ; + + rdfs:isDefinedBy ; + + skos:altLabel "reflectance UV-VIS spectrometry" , + "reflectance UV-VIS spectroscopy" , + "reflectance UV/VIS spectrometry" , + "reflectance UV/VIS spectroscopy" , + "reflectance ultra-violet-visible spectrometry" , + "reflectance ultra-violet-visible spectrophotometry" , + "reflectance ultra-violet-visible spectroscopy" , + "reflectance ultraviolet-visible spectroscopy" , + "reflection UV-VIS spectrometry" , + "reflection UV-VIS spectroscopy" , + "reflection UV/VIS spectrometry" , + "reflection UV/VIS spectroscopy" , + "reflection ultra-violet-visible spectrometry" , + "reflection ultra-violet-visible spectroscopy" , + "reflection ultraviolet-visible spectrometry" , + "reflection ultraviolet-visible spectroscopy" ; + + skos:definition "Ultraviolet-visible spectroscopy where the reflection or scattering of radiation from the sample surface is detected. [CHMO]" ; + + skos:prefLabel "reflectance ultraviolet-visible spectrophotometry" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0001109 + +af-p:AFP_0001109 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0001427 ; + + rdfs:isDefinedBy ; + + skos:altLabel "QMS" , + "quadrapole mass spectrometry" , + "quadrupolar mass spectrometry" , + "quadrupolar mass spectroscopy" , + "quadrupole mass spectroscopy" ; + + skos:definition "Quadrapole mass spectrometry is a type of mass spectrometry where the mass-to-charge ratio of the sample ions is measured using an electric field generated by four parallel electrodes. [Allotrope]" ; + + skos:prefLabel "quadrupole mass spectrometry" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0001113 + +af-p:AFP_0001113 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0000925 , + af-p:AFP_0002294 ; + + dct:source "https://en.wikipedia.org/wiki/Electron_capture_detector#Gas_chromatograph_detector" ; + + rdfs:isDefinedBy ; + + skos:altLabel "ECD" , + "electron capture detection" , + "electron capture dissociation" ; + + skos:definition "Electron capture measurement is a measurement that is sensitive to electronegative compounds (e.g. halogenated compounds). A beta-particle emitter (e.g. 63Ni) is used to produce an electron beam, which is passed between two electrodes. As the sample is passed through the e-beam, organic functional groups interact with the electrons, interrupting the current. [Allotrope, CHMO]" ; + + skos:prefLabel "electron capture measurement" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0001114 + +af-p:AFP_0001114 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0002212 ; + + rdfs:isDefinedBy ; + + skos:definition "A measurement of the blood, it's contents, cells or other factors contained within the blood. [CMO]" ; + + skos:prefLabel "blood measurement method" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0001116 + +af-p:AFP_0001116 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0002680 ; + + rdfs:isDefinedBy ; + + skos:definition "The determination of the relative strength of a substance (e.g., a drug or hormone or toxicant) by comparing its effect on a test organism with that of a standard preparation. [Wikipedia]" ; + + skos:prefLabel "biological measurement method" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0001134 + +af-p:AFP_0001134 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0002294 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "optical rotation measurement" ; + + skos:changeNote "2020-11-12 Changed definition. [Allotrope]" ; + + skos:definition "Polarimetry is a measurement of the extent to which a sample interacts with polarized electromagnetic radiation by transmission, reflection, refraction, or diffraction. [CHMO]" ; + + skos:prefLabel "polarimetry" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0001135 + +af-p:AFP_0001135 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003354 , + [ owl:intersectionOf ( af-p:AFP_0003275 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000395 ; + owl:someValuesFrom af-m:AFM_0000275 + ] + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000399 ; + owl:someValuesFrom af-m:AFM_0000275 + ] + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "mixing material" ; + + skos:definition "The combining of components, particles or layers into a more homogeneous state. The mixing may be achieved manually or mechanically by shifting the material with stirrers or pumps or by revolving or shaking the container. The process must not permit segregation of particles of different size or properties. Homogeneity may be considered to have been achieved in a practical sense when the sampling error of the processed portion is negligible compared to the total error of the measurement system. [CHMO]" ; + + skos:prefLabel "mixing" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0001146 + +af-p:AFP_0001146 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0002294 ; + + rdfs:isDefinedBy ; + + skos:altLabel "scan" ; + + skos:definition "Scanning is measuring repeatedly or sweepingly. [Allotrope]" ; + + skos:prefLabel "scanning" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0001159 + +af-p:AFP_0001159 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003275 , + obi:_0000011 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000546 ; + owl:someValuesFrom [ owl:intersectionOf ( af-m:AFM_0000275 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000087 ; + owl:someValuesFrom af-rl:AFRL_0000035 + ] + ) ; + rdf:type owl:Class + ] + ] , + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000063 ; + owl:someValuesFrom af-p:AFP_0003634 + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "preparative method" , + "sample preparation step" , + "sample preparative method" , + "sample processing" , + "sample transformation method" ; + + skos:changeNote "2019-08-20 Changed pref label and definition. Fixed formal definition not to use equivalence. [Allotrope]" ; + + skos:definition "Sample preparation is a planned preparation process that synthesizes, converts or changes a sample. [Allotrope]" ; + + skos:prefLabel "sample preparation" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0001183 + +af-p:AFP_0001183 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0001321 ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "NPC" , + "normal phase chromatography" ; + + skos:definition "A separation method where the components are distributed between two phases, one of which is stationary and polar, while the other is non-polar and moves in a definite direction. [CHMO]" ; + + skos:prefLabel "normal-phase chromatography" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0001185 + +af-p:AFP_0001185 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003491 ; + + dct:license ; + + dct:rights ; + + dct:source "PAC, 1995, 67, 1699 (Nomenclature in evaluation of analytical methods including detection and quantification capabilities (IUPAC Recommendations 1995)) on page 1701" ; + + rdfs:isDefinedBy ; + + skos:altLabel "quantitative analysis" , + "quantitative determination method" ; + + skos:definition "A measurement method which obtains the concentration or quantity of a specified substance in an analyte. [CHMO]" ; + + skos:note "Analyses in which the amount or concentration of an analyte may be determined (estimated) and expressed as a numerical value in appropriate units. Qualitative analysis may take place without quantitative analysis, but quantitative analysis requires the identification (qualification) of the analytes for which numerical estimates are given. [IUPAC]" ; + + skos:prefLabel "quantitative analysis assay" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0001192 + +af-p:AFP_0001192 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0000225 ; + + af-x:AFX_0002809 chmo:_0002318 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "LSC" ; + + skos:definition "Column chromatography where the mobile phase is a liquid and the stationary phase is a solid. [CHMO]" ; + + skos:prefLabel "liquid-solid chromatography" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0001227 + +af-p:AFP_0001227 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0002294 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "Any technique for measuring charge transport. [CHMO]" ; + + skos:prefLabel "charge transport measurement" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0001266 + +af-p:AFP_0001266 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0002294 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "magnetic susceptibility measurements" ; + + skos:definition "The measurement of the strength and/or direction of magnetic fields, or the magnetic susceptibility of a sample. [CHMO]" ; + + skos:prefLabel "magnetometry" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0001292 + +af-p:AFP_0001292 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0001916 ; + + rdfs:isDefinedBy ; + + skos:altLabel "oxidation-reduction titration" , + "redox titration" ; + + skos:definition "Oxidation-reduction titration is the process of determining the quantity of a sample by monitoring a redox process until the endpoint, at which essentially all of the sample has reacted, is reached. [CHMO]" ; + + skos:prefLabel "oxidation-reduction titration" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0001319 + +af-p:AFP_0001319 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003634 ; + + rdfs:isDefinedBy ; + + skos:altLabel "sample taking" , + "sampling" ; + + skos:definition "Sampling material is sampling of a material of interest for studying. [Allotrope]" ; + + skos:editorialNote "sampling can be both separating or partitioning or a combination of it" ; + + skos:example "pulling a small sample outside a bioreactor" ; + + skos:prefLabel "sampling material" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0001321 + +af-p:AFP_0001321 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003275 , + af-p:AFP_0003335 , + obi:_0000011 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A chromatography is a separation where the components are distributed between two phases, one of which is stationary, while the other moves in a definite direction. [CHMO]" ; + + skos:prefLabel "chromatography" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0001348 + +af-p:AFP_0001348 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003275 , + af-p:AFP_0003315 , + obi:_0000011 , + [ rdf:type owl:Class ; + owl:unionOf ( af-p:AFP_0003566 + af-p:AFP_0003716 + ) + ] , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000395 ; + owl:someValuesFrom af-m:AFM_0000275 + ] ; + + rdfs:isDefinedBy ; + + skos:changeNote "2019-09-20 Changed subclassing. [Allotrope]" ; + + skos:definition "Synthesis is a planned material process that combines, changes or converts material to produce a new material. [Allotrope]" ; + + skos:prefLabel "synthesis" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0001367 + +af-p:AFP_0001367 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003312 , + af-p:AFP_0003469 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "electropermeabilization" ; + + skos:definition "A method for introducing polar molecules into a host cell through the cell membrane. A large electric pulse (300-400 mV for <1 ms) temporarily disturbs the phospholipid bilayer, allowing molecules like DNA to pass into the cell. [CHMO]" ; + + skos:prefLabel "electroporation" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0001404 + +af-p:AFP_0001404 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0000044 ; + + rdfs:isDefinedBy ; + + skos:altLabel "OM" , + "light microscopy" ; + + skos:definition "A type of microscopy where the specimen is illuminated with visible light and a system of lenses is used to produce an image. [CHMO]" ; + + skos:prefLabel "optical microscopy" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0001405 + +af-p:AFP_0001405 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0001916 ; + + rdfs:isDefinedBy ; + + skos:definition "Chelatometric titration is the process of determining the quantity of a sample (metal cation) by adding measured increments of a titrant (a chelating agent) until the end-point, at which essentially all of the sample has reacted, is reached. [CHMO]" ; + + skos:prefLabel "chelatometric titration" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0001410 + +af-p:AFP_0001410 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0000225 , + af-p:AFP_0002361 ; + + rdfs:isDefinedBy ; + + skos:altLabel "RPLC" , + "reversed phase liquid chromatography" ; + + skos:changeNote "2016-02-03 Removed altLabel [OSTHUS]" ; + + skos:definition "Liquid chromatography where the mobile phase is significantly more polar than the stationary phase, for example a microporous silica-based material with chemically bonded alkyl chains. [CHMO]" ; + + skos:prefLabel "reversed-phase liquid chromatography" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0001426 + +af-p:AFP_0001426 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0001348 ; + + rdfs:isDefinedBy ; + + skos:altLabel "formulation" ; + + skos:definition "The process of formulation allows the preparation of mixtures of components in accordance with a formula and documents the composition. [Allotrope]" ; + + skos:prefLabel "formulation process" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0001427 + +af-p:AFP_0001427 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0000527 , + af-p:AFP_0002567 ; + + dct:license ; + + dct:rights ; + + dct:source "Murray, K., Boyd, R., Eberlin, M., et al. (2013). Definitions of terms relating to mass spectrometry (IUPAC Recommendations 2013). Pure and Applied Chemistry, 85(7), pp. 1515-1609." ; + + rdfs:isDefinedBy ; + + skos:altLabel "MS" , + "mass spectroscopy" ; + + skos:definition "Mass spectrometry is a spectrometry that studies matter through the formation of gas-phase ions that are characterized using mass spectrometers by their mass, charge, structure, and/or physico-chemical properties. [IUPAC]" ; + + skos:note "Mass spectroscopy is an obsolete synonym for mass spectrometry that should not be used to avoid confusion with spectroscopies in which the measured quantity is the absorption or emission of electromagnetic radiation. [IUPAC]" , + "The term is a misnomer because it is m/z rather than mass that is the independent variable in a mass spectrum. [IUPAC]" ; + + skos:prefLabel "mass spectrometry" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0001457 + +af-p:AFP_0001457 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0001135 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "The process of making a polymer blend by mechanically mixing different polymers together in the melt. [CHMO]" ; + + skos:prefLabel "physical blending" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0001462 + +af-p:AFP_0001462 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0000527 ; + + rdfs:isDefinedBy ; + + skos:definition "Any method that measures the amount of light that a substance scatters at certain wavelengths, incident angles, and polarization angles. [CHMO]" ; + + skos:prefLabel "scattering spectroscopy" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0001478 + +af-p:AFP_0001478 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003367 ; + + rdfs:isDefinedBy ; + + skos:definition "The transfer of thermal energy from a material to its surrounding environment. [CHMO]" ; + + skos:prefLabel "cooling" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0001499 + +af-p:AFP_0001499 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003282 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "The method to obtain the derivative of a function or curve. [Allotrope]" ; + + skos:prefLabel "differentiation" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0001510 + +af-p:AFP_0001510 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0001916 ; + + rdfs:isDefinedBy ; + + skos:altLabel "acid/base titration" ; + + skos:definition "Acid-base titration is the process of determining the quantity of a sample (an acid or base) by adding measured increments of a titrant (a base or acid) until the endpoint, at which essentially all of the sample has reacted, is reached. [CHMO]" ; + + skos:prefLabel "acid-base titration" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0001530 + +af-p:AFP_0001530 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003336 ; + + rdfs:isDefinedBy ; + + skos:definition "The process of segregation of phases; the separation of suspended solids from a liquid or gas, usually by forcing a carrier gas or liquid through a porous medium. [CHMO]" ; + + skos:prefLabel "filtration" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0001543 + +af-p:AFP_0001543 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0000225 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "LLC" , + "liquid-liquid chromatography" ; + + skos:definition "Column chromatography where both the mobile phase and the stationary phase are liquids. The stationary phase must be immiscible and insoluble in the mobile phase and is usually supported on a suitable material such as a diatomaceous earth. [CHMO]" ; + + skos:prefLabel "liquid-liquid chromatography" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0001606 + +af-p:AFP_0001606 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003486 , + obi:_0000011 ; + + rdfs:isDefinedBy ; + + skos:definition "Equilibration is the process of bring the state of a system to an equilibrium. [Allotrope]" ; + + skos:prefLabel "equilibration" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0001611 + +af-p:AFP_0001611 rdf:type owl:Class ; + + rdfs:subClassOf [ owl:intersectionOf ( af-p:AFP_0000708 + af-p:AFP_0003666 + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "injection" , + "sample introduction" ; + + skos:changeNote "2018-10-24 Moved to chromatography domain ontology, subclassed under loading [Allotrope]" ; + + skos:definition "Process of loading a sample into a chromatography system. [Allotrope]" ; + + skos:prefLabel "injection (chromatography)" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0001640 + +af-p:AFP_0001640 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003357 ; + + rdfs:isDefinedBy ; + + skos:altLabel "assembly" ; + + skos:definition "The process of fitting device components together to form a system. [Allotrope]" ; + + skos:prefLabel "assembling" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0001645 + +af-p:AFP_0001645 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0002294 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "Piece counting is determining the number of objects in an object aggregate. [Allotrope]" ; + + skos:prefLabel "piece counting" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0001649 + +af-p:AFP_0001649 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0001135 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "The intensive mixing of mutually insoluble phases (sometimes with addition of surfactants) to obtain a soluble suspension or emulsion. [CHMO]" ; + + skos:prefLabel "homogenization" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0001650 + +af-p:AFP_0001650 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0002294 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "The measurement of the relative permittivity of a solution as a function of concentration. Measurements are made indirectly across the resistance of the solution with alternating current. [CHMO]" ; + + skos:prefLabel "dielectrometry" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0001655 + +af-p:AFP_0001655 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0000527 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "Any spectroscopic method which probes the electronic degrees of freedom of an atom or molecule. [CHMO]" ; + + skos:prefLabel "electronic spectroscopy" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0001657 + +af-p:AFP_0001657 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0002421 ; + + rdfs:isDefinedBy ; + + skos:altLabel "FT NIRS" , + "FT-NIRS" , + "FTNIRS" , + "Fourier transform near infra-red absorbance spectrometry" , + "Fourier transform near infra-red absorption spectrometry" , + "Fourier transform near infra-red spectrometry" , + "Fourier transform near infra-red spectroscopy" , + "Fourier transform near infrared absorbance spectrometry" , + "Fourier transform near infrared absorbance spectroscopy" , + "Fourier transform near infrared absorption spectroscopy" ; + + skos:definition "A type of spectroscopy where the sample absorbs a single pulse of radiation from the near infrared region (0.8-2 µm) and the spectrum obtained is subject to a Fourier transform. [CHMO]" ; + + skos:prefLabel "Fourier transform near infrared absorption spectrometry" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0001666 + +af-p:AFP_0001666 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0002294 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "densiometric measurements" , + "densiometry" , + "densitometric measurements" ; + + skos:definition "The measurement of the density of a sample. [CHMO]" ; + + skos:prefLabel "densitometry" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0001677 + +af-p:AFP_0001677 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0001321 ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A separation method where the components (in this case stereoisomers) are distributed between two chiral phases, one of which is stationary, while the other moves in a definite direction. [CHMO]" ; + + skos:prefLabel "chiral chromatography" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0001698 + +af-p:AFP_0001698 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0001135 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:changeNote "2020-06-18 Changed definition. [Allotrope]" ; + + skos:definition "Stirring is a mixing involving the agitation of a solution through circular motion. [Allotrope]" ; + + skos:prefLabel "stirring" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0001701 + +af-p:AFP_0001701 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0001993 ; + + dct:license ; + + dct:rights ; + + dct:source "K. K. Murray, R. K. Boyd, M. N. Eberlin, G. J. Langley, L. Li and Y. Naito, Pure Appl. Chem., 2013, 85, 1515-1609" ; + + rdfs:isDefinedBy ; + + skos:altLabel "EI" , + "electron impact" , + "electron impact ionization" ; + + skos:definition "Electron ionization is a ionization that removes one or more electrons from an atom or molecule through interactions with electrons that are typically accelerated to energies between 10 and 150 eV. [IUPAC]" ; + + skos:prefLabel "electron ionization" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0001707 + +af-p:AFP_0001707 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0001427 ; + + dct:license ; + + dct:rights ; + + dct:source "G. L. Glish. Analyst 119, 533 (1994)." , + "K. K. Murray, R. K. Boyd, M. N. Eberlin, G. J. Langley, L. Li and Y. Naito, Pure Appl. Chem., 2013, 85, 1515-1609" ; + + rdfs:isDefinedBy ; + + skos:altLabel "MSn" , + "MSn spectrometry" , + "MSn spectroscopy" , + "multiple-stage mass spectroscopy" ; + + skos:definition "Multiple-stage mass spectrometry is a mass spectrometry where multiple stages of precursor ion m/z selection are followed by product ion detection for successive nth-generation product ions. [IUPAC]" ; + + skos:prefLabel "multiple-stage mass spectrometry" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0001719 + +af-p:AFP_0001719 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0000748 ; + + rdfs:isDefinedBy ; + + skos:altLabel "RHPLC" , + "RP-HPLC" , + "gradient reverse HPLC" , + "gradient reverse high-performance liquid chromatography" , + "reverse phase high performance liquid chromatography" , + "reversed phase high-performance liquid chromatography" , + "reversed-phase HPLC" , + "reversed-phase high pressure liquid chromatography" , + "reversed-phase high-pressure liquid chromatography" ; + + skos:definition "Liquid chromatography where the inlet pressure is relatively high and the mobile phase is significantly more polar than the stationary phase (which consists of very small particles), for example a microporous silica-based material with chemically bonded alkyl chains. [CHMO]" ; + + skos:prefLabel "reversed-phase high-performance liquid chromatography" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0001750 + +af-p:AFP_0001750 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0001878 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "flushing" , + "purging" ; + + skos:definition "Rinsing is the process of washing quickly a device with a solution. [Allotrope]" ; + + skos:prefLabel "rinsing" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0001756 + +af-p:AFP_0001756 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003282 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "fourier transformation" ; + + skos:definition "The Fourier transformation decomposes a function of time (e.g. a signal) into the frequencies that make it up. [Wikipedia]" ; + + skos:prefLabel "Fourier transformation" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0001760 + +af-p:AFP_0001760 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0000955 ; + + rdfs:isDefinedBy ; + + skos:altLabel "optical absorption spectroscopy" , + "visible spectrometry" , + "visible spectroscopy" ; + + skos:definition "Spectroscopy where the sample absorbs radiation from the visible region (380-800 nm) resulting in electronic transitions within the sample. [CHMO]" ; + + skos:prefLabel "visible spectrophotometry" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0001763 + +af-p:AFP_0001763 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0000748 ; + + rdfs:isDefinedBy ; + + skos:altLabel "capillary HPLC" , + "capillary high performance liquid chromatography" , + "capillary high pressure liquid chromatography" , + "capillary high-pressure liquid chromatography" , + "capillary-HPLC" ; + + skos:definition "Column chromatography where the mobile phase is a liquid, the stationary phase consists of very small particles held in a tube of diameter less than a millimeter, and the inlet pressure is relatively high. [CHMO]" ; + + skos:prefLabel "capillary high-performance liquid chromatography" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0001787 + +af-p:AFP_0001787 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0002016 ; + + rdfs:isDefinedBy ; + + skos:altLabel "FT-IR" , + "FT-IR spectroscopy" , + "FTIR" , + "FTIR spectrometry" , + "FTIR spectroscopy" , + "Fourier transform infra-red absorption spectroscopy" , + "Fourier transform infra-red spectrometry" , + "Fourier transform infrared (FT-IR)" , + "Fourier transform infrared (FT-IR) spectroscopy" , + "Fourier transform infrared spectrometry" , + "Fourier transform infrared spectroscopy" , + "Fourier-transform infrared (FTIR) absorption spectroscopy" ; + + skos:definition "Fourier transform infrared spectroscopy is a type of vibrational spectroscopy where the sample absorbs radiation from the infrared region (0.78-1000 µm) and the spectrum obtained is subject to a Fourier transform. [CHMO]" ; + + skos:prefLabel "Fourier transform infrared absorption spectroscopy" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0001801 + +af-p:AFP_0001801 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003556 , + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000117 ; + owl:someValuesFrom af-p:AFP_0003774 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "An imaging assay is a physical characterization assay to produce a picture of an entity. [CHMO]" ; + + skos:prefLabel "imaging assay" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0001824 + +af-p:AFP_0001824 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003312 , + af-p:AFP_0003469 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "aspiration" ; + + skos:definition "Aspirating is the process of sample preparation that is to draw an amount of a liquid by suction and then expel the liquid. [Allotrope]" ; + + skos:prefLabel "aspirating" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0001861 + +af-p:AFP_0001861 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0002294 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002750 ; + owl:someValuesFrom pato:_0001842 + ] ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "measurement of pH" , + "pH sensing" , + "sensing of pH" ; + + skos:definition "The measurement of pH is the negative logarithm to base ten of the hydrogen ion activity in a solution, this measures the degree of acidity or alkalinity. Operationally the pH of a solution X, pH(X), is measured relative to that of a standard reference solution, pH(S), and defined as pH(X) = pH(S) - (E(X) - E(S))/(RT/F)ln 10, where E(X) and E(S) are the electromotive forces measured in cells containing the solution X and the reference solution respectively. [CHMO]" ; + + skos:prefLabel "pH measurement" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0001876 + +af-p:AFP_0001876 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003473 ; + + rdfs:isDefinedBy ; + + skos:altLabel "drying" , + "sample drying" ; + + skos:definition "The process of removing a solvent from a substance. [CHMO]" ; + + skos:prefLabel "drying" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0001878 + +af-p:AFP_0001878 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0000161 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "Washing is a process by which a material entity acting as contaminant (e.g. excess staining reagent) is removed by application of one or more cycles of solution in flow. [CHMO]" ; + + skos:prefLabel "washing" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0001909 + +af-p:AFP_0001909 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0002294 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "luminescence detection" ; + + skos:changeNote "2018-08-09 Changed definition and pref label. [Allotrope]" ; + + skos:definition "The measurement of luminescence from a material. [Allotrope]" ; + + skos:prefLabel "luminescence measurement" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0001916 + +af-p:AFP_0001916 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0001185 ; + + rdfs:isDefinedBy ; + + skos:altLabel "titrimetic analysis" , + "titrimetry" ; + + skos:definition "Titration is the process of determining the quantity of a sample by adding measured increments of a titrant until the end-point, at which essentially all of the sample has reacted, is reached. [CHMO]" ; + + skos:prefLabel "titration" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0001936 + +af-p:AFP_0001936 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0000611 ; + + rdfs:isDefinedBy ; + + skos:definition "The measurement of thermodynamic parameters (e.g. enthalpy) during a chemical or biochemical reaction by the known variation (step-wise or linear) of one variable, whilst a second is kept constant. [CHMO]" ; + + skos:prefLabel "scanning calorimetry" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0001951 + +af-p:AFP_0001951 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0000161 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "Priming is a type of cleaning that happens at the beginning of a period of time and results in the device being filled with the appropriate reagents. [Allotrope]" ; + + skos:example "prime of a cell counter analyzer at the beginning of a day" ; + + skos:prefLabel "priming" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0001953 + +af-p:AFP_0001953 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0001135 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "Inverting is a sample preparation step of mixing. It is homogenization by switching the y-axis of a sample several times, turning it upside down using a syringe. [Allotrope]" ; + + skos:prefLabel "inverting" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0001955 + +af-p:AFP_0001955 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0002294 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002750 ; + owl:someValuesFrom af-q:AFQ_0000273 + ] ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "An electrochemical technique where the total Coulombs of electricity required to complete (fully oxidize or fully reduce the sample in) an electrochemical reaction is measured. [CHMO]" ; + + skos:prefLabel "coulometry" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0001986 + +af-p:AFP_0001986 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003746 ; + + rdfs:isDefinedBy ; + + skos:altLabel "coating method" ; + + skos:definition "The application of a thin cover to a material. [CHMO]" ; + + skos:prefLabel "coating" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0001993 + +af-p:AFP_0001993 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003566 , + af-p:AFP_0003712 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000546 ; + owl:someValuesFrom af-m:AFM_0000077 + ] ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:altLabel "ionization method" ; + + skos:definition "Ionization is a converting chemical reaction by which an atom or a molecule acquires a negative or positive charge by gaining or losing electrons, often in conjunction with other chemical changes. [Wikipedia]" ; + + skos:prefLabel "ionization" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0001994 + +af-p:AFP_0001994 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003598 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "monitor" , + "trend analysis" ; + + skos:definition "Trending is a process of monitoring that consists of collecting information and identifying underlying patterns. [Allotrope]" ; + + skos:prefLabel "trending" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0002008 + +af-p:AFP_0002008 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0001707 ; + + dct:license ; + + dct:rights ; + + dct:source "E. de Hoffmann (1996). Tandem Mass Spectrometry: a Primer. Journal of Mass Spectrometry 31: 129–137." , + "K. K. Murray, R. K. Boyd, M. N. Eberlin, G. J. Langley, L. Li and Y. Naito, Pure Appl. Chem., 2013, 85, 1515-1609" ; + + rdfs:isDefinedBy ; + + skos:altLabel "SRM" ; + + skos:definition "Selected reaction monitoring is a multiple-stage mass spectrometry where data acquired from one or more specific product ions corresponding to m/z selected precursor ions are recorded via two or more stages of mass spectrometry. [IUPAC]" ; + + skos:note "Selected reaction monitoring applied to multiple product ions from one or more precursor ions is known as multiple reaction monitoring. [IUPAC]" , + "Selected reaction monitoring in multiple-stage mass spectrometry is known as consecutive reaction monitoring. [IUPAC]" ; + + skos:prefLabel "selected reaction monitoring" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0002014 + +af-p:AFP_0002014 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0001321 ; + + rdfs:isDefinedBy ; + + skos:altLabel "open bed chromatography" , + "open-bed chromatography" ; + + skos:definition "A chromatography method where the stationary phase is present as or on a plane. [CHMO]" ; + + skos:prefLabel "planar chromatography" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0002016 + +af-p:AFP_0002016 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0000780 ; + + rdfs:isDefinedBy ; + + skos:altLabel "IR" , + "IR absorption spectrometry" , + "IR absorption spectroscopy" , + "IR spectrometry" , + "IR spectrophotometry" , + "IR spectroscopy" , + "infra-red absorption spectrometry" , + "infra-red absorption spectroscopy" , + "infra-red spectrometry" , + "infra-red spectrophotometry" , + "infrared (IR) spectroscopy" , + "infrared absorption spectrometry" , + "infrared spectrometry" , + "infrared spectrophotometry" , + "infrared spectroscopy" ; + + skos:definition "Infrared absorption spectroscopy is a type of vibrational spectroscopy where the sample absorbs radiation from the infrared region. [CHMO]" ; + + skos:prefLabel "infrared absorption spectroscopy" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0002033 + +af-p:AFP_0002033 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0000748 ; + + rdfs:isDefinedBy ; + + skos:altLabel "NP-HPLC" , + "normal phase HPLC" , + "normal-phase HPLC" ; + + skos:definition "Column chromatography where the mobile phase is a liquid, the stationary phase consists of very small particles, and the inlet pressure is relatively high. In normal-phase HPLC, the stationary phase is more polar than the mobile phase. [CHMO]" ; + + skos:prefLabel "normal-phase high-performance liquid chromatography" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0002059 + +af-p:AFP_0002059 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0000748 ; + + rdfs:isDefinedBy ; + + skos:altLabel "RRLC" , + "RSLC" , + "UFLC" , + "UHPLC" , + "UPLC" , + "rapid resolution liquid chromatography" , + "rapid separation liquid chromatography" , + "ultra fast liquid chromatography" , + "ultra performance liquid chromatography" ; + + skos:definition "Column chromatography where the mobile phase is a liquid, the stationary phase consists of very small (< 2 µm) particles and the inlet pressure is relatively high. [CHMO]" ; + + skos:prefLabel "ultra high-performance liquid chromatography" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0002065 + +af-p:AFP_0002065 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0002294 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "laser interferometry" , + "optical interferometry" ; + + skos:definition "The measurement of the properties of two or more lasers or waves by studying the pattern of interference created by their superposition. [CHMO]" ; + + skos:prefLabel "interferometry" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0002089 + +af-p:AFP_0002089 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003598 ; + + rdfs:isDefinedBy ; + + skos:changeNote "2019-09-09 Moved under data transformation and fixed definition. [Allotrope]" ; + + skos:definition "Chromatography data processing is a data transformation on chromatograms. [Allotrope]" ; + + skos:prefLabel "chromatography data processing" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0002103 + +af-p:AFP_0002103 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0002573 ; + + dct:license ; + + dct:rights ; + + dct:source "J. B. Fenn, M. Mann, C. K. Meng, S. F. Wong, C. M. Whitehouse. Science 246, 64 (1989)." , + "K. K. Murray, R. K. Boyd, M. N. Eberlin, G. J. Langley, L. Li and Y. Naito, Pure Appl. Chem., 2013, 85, 1515-1609" , + "M. Dole, L. L. Mack, R. L. Hines, R. C. Mobley, L. D. Ferguson, M. B. Alice. J. Chem. Phys. 49, 2240 (1968)." ; + + rdfs:isDefinedBy ; + + skos:altLabel "ESI" , + "ionspray" ; + + skos:definition "Spray ionization process in which either cations or anions in solution are transferred to the gas phase via formation and desolvation at atmospheric pressure of a stream of highly charged droplets that result from applying a potential difference between the tip of the electrospray needle containing the solution and a counter electrode. [IUPAC]" ; + + skos:note "The term ionspray is deprecated unless describing the commercial product." ; + + skos:prefLabel "electrospray ionization" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0002122 + +af-p:AFP_0002122 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0002294 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "surface tensiometry" ; + + skos:definition "The measurement of the surface tension of a liquid. [CHMO]" ; + + skos:prefLabel "tensiometry" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0002124 + +af-p:AFP_0002124 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0001936 ; + + dct:license ; + + dct:rights ; + + dct:source "IUPAC. Compendium of Chemical Terminology, 2nd ed. (the \"Gold Book\"). Compiled by A. D. McNaught and A. Wilkinson. Blackwell Scientific Publications, Oxford (1997). Online version (2019-) created by S. J. Chalk. ISBN 0-9678550-9-8. https://doi.org/10.1351/goldbook." , + "Nomenclature for thermal analysis - IV (Recommendations 1985), Mackenzie, R.C., Pure and Applied Chemistry 1985, 57(11), 1737" ; + + rdfs:isDefinedBy ; + + skos:altLabel "DSC" , + "differential scanning calorimetric (DSC) analysis" , + "differential scanning calorimetric analysis" ; + + skos:definition "Differential scanning calorimetry is a thermal analysis method in which the difference in energy inputs into a substance and a reference material is measured as a function of temperature whilst the substance and reference material are subjected to a controlled temperature program. [IUPAC]" ; + + skos:prefLabel "differential scanning calorimetry" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0002142 + +af-p:AFP_0002142 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0000225 ; + + rdfs:isDefinedBy ; + + skos:altLabel "HIC" ; + + skos:definition "Separation using HIC is based on the reversible interaction between a protein and the hydrophobic ligand bound to the chromatography matrix. [Allotrope]" ; + + skos:prefLabel "hydrophobic interaction chromatography" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0002171 + +af-p:AFP_0002171 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0002294 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "The measurement of the viscosity of fluids by observing the relative motion of the fluid and an object. Viscometry is used to measure the molecular weight of polymers. [CHMO]" ; + + skos:prefLabel "viscometry" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0002185 + +af-p:AFP_0002185 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003368 ; + + rdfs:isDefinedBy ; + + skos:altLabel "preconcentration" ; + + skos:definition "A preparative step where the concentration of one component is increased. [CHMO]" ; + + skos:prefLabel "concentrating" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0002188 + +af-p:AFP_0002188 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0002294 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "electronic absorbance measuring" , + "electronic absorption detection" ; + + skos:definition "Electronic absorption measurement is a measurement that is based on the absorption of energy by electronic transitions. [Allotrope]" ; + + skos:editorialNote "Detecting has some overlap with measuring. Usually measuring is the way detecting works, but detection as response from a sensor without quantitation is also possible. [Allotrope]" ; + + skos:prefLabel "electronic absorbance measurement" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0002204 + +af-p:AFP_0002204 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003312 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "subculturing" ; + + skos:definition "In biology, a subculture is a new cell or microbiological culture made by transferring some or all cells from a previous culture to fresh growth medium. This action is called subculturing or passaging the cells. Subculture is used to prolong the life and/or expand the number of cells or microorganisms in the culture. [Wikipedia]" ; + + skos:prefLabel "passaging" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0002206 + +af-p:AFP_0002206 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0002294 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002750 ; + owl:someValuesFrom af-q:AFQ_0000057 + ] ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "TCD" , + "thermal conductivity detection" , + "thermal conductivity measuring" ; + + skos:changeNote "2018-08-09 Moved under measurement, and changed pref label [Allotrope]" ; + + skos:definition "A measuring that is sensitive to inorganic gases. A hot (450 deg. C) filament is used to heat a carrier gas containing the sample and the difference in thermal conductivity caused by the presence of the sample is measured. [CHMO]" ; + + skos:prefLabel "thermal conductivity measurement" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0002211 + +af-p:AFP_0002211 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0002680 ; + + rdfs:isDefinedBy ; + + skos:altLabel "magnetic resonance method" ; + + skos:definition "A magnetic resonance assay is an assay that applies a technique which detects the response of spins to a perturbing magnetic field. [Allotrope]" ; + + skos:prefLabel "magnetic resonance assay" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0002212 + +af-p:AFP_0002212 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003556 ; + + rdfs:isDefinedBy ; + + skos:altLabel "clinical measurement" ; + + skos:definition "A quantitative or qualitative value which is the result of an act of assessing a morphological or physiological state or property in a single individual or sample or a group of individuals or samples, based on direct observation or experimental manipulation. [CMO]" ; + + skos:prefLabel "clinical measurement method" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0002216 + +af-p:AFP_0002216 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0001185 ; + + rdfs:isDefinedBy ; + + skos:definition "Any technique used to measure the levels of oxygen in a sample. [CHMO]" ; + + skos:prefLabel "oximetry" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0002224 + +af-p:AFP_0002224 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0000925 ; + + rdfs:isDefinedBy ; + + skos:definition "An experiment in which a separation method is coupled to a detection method in order to detect one or more different components of a sample. [CHMO]" ; + + skos:prefLabel "separation method-detection method" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0002228 + +af-p:AFP_0002228 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0000266 ; + + rdfs:isDefinedBy ; + + skos:altLabel "UV-VIS-NIR" , + "UV-VIS-NIR spectrophotometry" , + "UV-Vis-NIR" , + "UV-Vis-NIR absorption spectroscopy" , + "UV-Vis-NIR spectroscopy" , + "UV-vis-NIR absorption spectroscopy" , + "UV-visible-near IR absorption spectroscopy" , + "UV-visible-near IR spectroscopy" , + "ultraviolet-visible-near infrared absorption spectroscopy" , + "ultraviolet-visible-near infrared spectrophotometry" , + "ultraviolet-visible-near infrared spectroscopy" ; + + skos:definition "Spectroscopy where the sample absorbs radiation in the range ultraviolet to near-infrared (190-2000 nm) resulting in electronic transitions within the sample. [CHMO]" ; + + skos:prefLabel "ultraviolet-visible-near infrared spectrophotometry" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0002239 + +af-p:AFP_0002239 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0002294 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002750 ; + owl:someValuesFrom af-q:AFQ_0000292 + ] ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "RI detection" , + "RID" , + "refractive index detection" , + "refractive index measuring" ; + + skos:changeNote "2018-08-09 Moved under measurement, and changed pref label [Allotrope]" , + "2020-11-12 Changed definition. [Allotrope]" ; + + skos:definition "A refractive index measurement is a measuring based on the change in refractive index of a solution. Light is passed through a hollow prism and focused on a photocell. When a liquid containing the sample is allowed to flow through the prism, the light diverges from its original path and the change in intensity and angle of the transmitted light is measured. [CHMO]" ; + + skos:prefLabel "refractive index measurement" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0002243 + +af-p:AFP_0002243 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0000748 ; + + rdfs:isDefinedBy ; + + skos:altLabel "CSP HPLC" , + "CSP-HPLC" , + "HPLC on a chiral stationary phase" , + "chiral HPLC" , + "chiral stationary phase high-pressure liquid chromatography" ; + + skos:definition "Column chromatography where the mobile phase is a liquid, the stationary phase consists of very small chiral particles and the inlet pressure is relatively high. [CHMO]" ; + + skos:prefLabel "chiral stationary phase high-performance liquid chromatography" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0002276 + +af-p:AFP_0002276 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0000780 ; + + rdfs:isDefinedBy ; + + skos:altLabel "IR transmission spectroscopy" , + "IR transmittance spectroscopy" , + "infrared transmittance spectroscopy" , + "transmission IR" ; + + skos:definition "Infrared transmission spectroscopy is a type of vibrational spectroscopy where the transmission of infrared radiation (0.78-1000 µm) through a sample is detected. [CHMO]" ; + + skos:prefLabel "infrared transmission spectroscopy" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0002293 + +af-p:AFP_0002293 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003349 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "The irradiation of a liquid sample with sound (20-20 000 Hz) waves resulting in agitation. Sound waves propagate into the liquid media result in alternating high-pressure (compression) and low-pressure (rarefaction) cycles. During rarefaction, high-intensity sonic waves create small vacuum bubbles or voids in the liquid, which then collapse violently (cavitation) during compression, creating very high local temperatures. [CHMO]" ; + + skos:prefLabel "sonication" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0002294 + +af-p:AFP_0002294 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0002849 , + af-p:AFP_0003305 , + obi:_0000011 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000395 ; + owl:someValuesFrom iao:_0000030 + ] , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000399 ; + owl:someValuesFrom bfo:_0000001 + ] ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:altLabel "measurement" ; + + skos:changeNote "2018-08-09 Changed definition [Allotrope]" ; + + skos:definition "Measuring is observing a property of an entity called a quantity, that has a magnitude that can be expressed as a number and a reference to another entity, and obtaining one or more quantity values for it. The observed entity is a quality or a disposition for a continuant, for a process it is a process property such as duration. [Allotrope]" ; + + skos:prefLabel "measuring" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0002296 + +af-p:AFP_0002296 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0000307 , + af-p:AFP_0003598 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "data massaging" ; + + skos:definition "A term used meaning the processing and manipulation of the spectral data produced for the purposes of improving spectral appearance, change the signal to noise ratio (S/N), or resolution. The term is often collectively used in conjunction with line broadening, sharpening, averaging, smoothing. [Allotrope]" ; + + skos:prefLabel "data apodization" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0002305 + +af-p:AFP_0002305 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0000225 ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "cap-LC" , + "capLC" ; + + skos:definition "Chromatography which takes place in a separation capillary and where the mobile phase is a liquid. [CHMO]" ; + + skos:prefLabel "capillary liquid chromatography" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0002309 + +af-p:AFP_0002309 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0002294 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "colorimetric method" , + "colourimetry" ; + + skos:definition "The determination of the spectral absorbance of a solution. This method is often used to determine the concentration of a chemical in a solution. [CHMO]" ; + + skos:prefLabel "colorimetry" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0002313 + +af-p:AFP_0002313 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003556 ; + + rdfs:isDefinedBy ; + + skos:altLabel "thermal analysis method" ; + + skos:definition "Thermal analysis is any measurement technique in which a physical property of the sample is measured as a function of temperature. [CHMO]" ; + + skos:prefLabel "thermal analysis" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0002314 + +af-p:AFP_0002314 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0001321 ; + + rdfs:isDefinedBy ; + + skos:definition "Chromatography where the mobile phase contains a compound (the displacer) more strongly retained than the components of the sample under examination. The sample is fed into the system as a finite slug. [CHMO]" ; + + skos:prefLabel "displacement chromatography" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0002328 + +af-p:AFP_0002328 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0000225 , + af-p:AFP_0001183 ; + + rdfs:isDefinedBy ; + + skos:definition "Liquid chromatography where the stationary phase is more polar than the mobile phase. This is the default for liquid chromatography. [CHMO]" ; + + skos:prefLabel "normal-phase liquid chromatography" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0002361 + +af-p:AFP_0002361 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0001321 ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "RPC" , + "reverse phase chromatography" , + "reverse-phase chromatography" , + "reversed phase chromatography" ; + + skos:definition "A separation method where the components are distributed between two phases, one of which is stationary and non-polar, while the other is polar and moves in a definite direction. [CHMO]" ; + + skos:prefLabel "reversed-phase chromatography" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0002389 + +af-p:AFP_0002389 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003599 , + obi:_0000011 ; + + dct:source , + "JCGM 200:2008 International vocabulary of metrology — Basic and general concepts and associated terms (VIM)" ; + + rdfs:isDefinedBy ; + + skos:definition "Calibration is the comparison of measurement values delivered by a device under test with those of a calibration standard of known accuracy. [Wikipedia]" ; + + skos:prefLabel "calibration" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0002397 + +af-p:AFP_0002397 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003312 , + af-p:AFP_0003469 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "Pipeting transfers a given amount of liquid solution using a pipette, dropper or pipettor. [Allotrope]" ; + + skos:prefLabel "pipeting" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0002421 + +af-p:AFP_0002421 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0000780 ; + + rdfs:isDefinedBy ; + + skos:altLabel "NIR absorbance spectrometry" , + "NIR absorbance spectroscopy" , + "NIRS" , + "near infra-red absorbance spectrometry" , + "near infra-red absorbance spectroscopy" , + "near infra-red absorption spectrometry" , + "near infra-red spectrometry" , + "near infrared absorbance spectrometry" , + "near infrared absorbance spectroscopy" , + "near infrared absorption spectrometry" , + "near infrared spectrometry" , + "near infrared spectroscopy" , + "near-infrared absorption spectroscopy" ; + + skos:definition "Near infrared absorption spectroscopy is a type of vibrational spectroscopy where the sample absorbs radiation from the near infrared region (0.8-2 µm). [CHMO]" ; + + skos:prefLabel "near infrared absorption spectroscopy" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0002423 + +af-p:AFP_0002423 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0000748 ; + + rdfs:isDefinedBy ; + + skos:altLabel "IE-HPLC" , + "IEX-HPLC" , + "ion exchange HPLC" , + "ion exchange high performance liquid chromatography" , + "ion-exchange HPLC" , + "ion-exchange high-pressure liquid chromatography" ; + + skos:definition "Column chromatography where the mobile phase is a liquid, the stationary phase consists of very small particles, the inlet pressure is relatively high and the separation is caused by differences in ion-exchange affinity. [CHMO]" ; + + skos:prefLabel "ion-exchange high-performance liquid chromatography" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0002434 + +af-p:AFP_0002434 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0002294 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "The measurement of the velocity of a moving object or medium. [CHMO]" ; + + skos:prefLabel "velocimetry" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0002437 + +af-p:AFP_0002437 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0001427 ; + + dct:license ; + + dct:rights ; + + dct:source "K. K. Murray, R. K. Boyd, M. N. Eberlin, G. J. Langley, L. Li and Y. Naito, Pure Appl. Chem., 2013, 85, 1515-1609" ; + + rdfs:isDefinedBy ; + + skos:altLabel "SIM" , + "SIR" , + "selected ion recording" ; + + skos:definition "Selected ion monitoring is mass spectrometry where the abundances of ions of one or more specific m/z values are recorded rather than the entire mass spectrum. [IUPAC]" ; + + skos:prefLabel "selected ion monitoring" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0002484 + +af-p:AFP_0002484 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0001321 ; + + rdfs:isDefinedBy ; + + skos:definition "Headspace chromatography is a type of chromatography that uses the gaseous headspace above a sample for analysis because very light volatiles can be efficiently partitioned as they diffuse to the gas volume above. [Allotrope]" ; + + skos:prefLabel "headspace chromatography" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0002515 + +af-p:AFP_0002515 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0001146 ; + + rdfs:isDefinedBy ; + + skos:definition "A mass spectrometry scan is a scan in a mass spectrometry run. [Allotrope]" ; + + skos:prefLabel "mass spectrometry scan" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0002535 + +af-p:AFP_0002535 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0002008 ; + + dct:license ; + + dct:rights ; + + dct:source "K. K. Murray, R. K. Boyd, M. N. Eberlin, G. J. Langley, L. Li and Y. Naito, Pure Appl. Chem., 2013, 85, 1515-1609" ; + + rdfs:isDefinedBy ; + + skos:altLabel "MRM" ; + + skos:definition "Multiple reaction monitoring is a selected reaction monitoring applied to multiple product ions from one or more precursor ions. [IUPAC]" ; + + skos:note "This term should not be confused with consecutive reaction monitoring, which involves the serial application of three or more stages of selected reaction monitoring. [IUPAC]" ; + + skos:prefLabel "multiple reaction monitoring" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0002541 + +af-p:AFP_0002541 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0000925 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "Ion detection is detecting the presence of ions. [Allotrope]" ; + + skos:prefLabel "ion detection" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0002567 + +af-p:AFP_0002567 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0002294 ; + + dct:license ; + + dct:rights ; + + dct:source "IUPAC. Analytical Division. Compendium of Analytical Nomenclature (the Orange Book). Definitive Rules, 1979" , + "IUPAC. Compendium of Chemical Terminology, 2nd ed. (the Gold Book). Compiled by A. D. McNaught and A.Wilkinson. Blackwell Scientific Publications, Oxford (1997)." , + "K. K. Murray, R. K. Boyd, M. N. Eberlin, G. J. Langley, L. Li and Y. Naito, Pure Appl. Chem., 2013, 85, 1515-1609" ; + + rdfs:isDefinedBy ; + + skos:definition "Mass analysis is a measuring process by which a mixture of ionic or neutral species is identified according to their m/z values (ions), or their aggregate atomic masses (neutrals), and their relative abundances. The analysis may be qualitative and/or quantitative. [IUPAC]" ; + + skos:prefLabel "mass analysis" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0002573 + +af-p:AFP_0002573 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0001993 ; + + dct:license ; + + dct:rights ; + + dct:source "K. K. Murray, R. K. Boyd, M. N. Eberlin, G. J. Langley, L. Li and Y. Naito, Pure Appl. Chem., 2013, 85, 1515-1609" ; + + rdfs:isDefinedBy ; + + skos:definition "Spray ionization is a ionization that involve dispersing the liquid into fine droplets as a component step. [IUPAC]" ; + + skos:note "Most of these techniques are examples of atmospheric pressure ionization. [IUPAC]" ; + + skos:prefLabel "spray ionization" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0002655 + +af-p:AFP_0002655 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0001321 ; + + rdfs:isDefinedBy ; + + skos:altLabel "multimodal chromatography" ; + + skos:definition "Mixed-mode chromatography (MMC), or multimodal chromatography, refers to chromatographic methods that utilize more than one form of interaction between the stationary phase and analytes in order to achieve separation. [Wikipedia]" ; + + skos:prefLabel "mixed-mode chromatography" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0002662 + +af-p:AFP_0002662 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0000307 ; + + rdfs:isDefinedBy ; + + skos:definition "Signal averaging is a process of combining spectra of repeated measurements in order to improve the signal-to-noise ratio. [Allotrope]" ; + + skos:prefLabel "signal averaging" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0002666 + +af-p:AFP_0002666 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0002294 ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "Background measurement is the process of determination of the base level of signals without presence of a sample. [Allotrope]" ; + + skos:example "background measurement of particle sizing in order to measure the electrical noise as well as laser scattering due to contamination of the optical parts or the dispersant" ; + + skos:prefLabel "background measurement" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0002670 + +af-p:AFP_0002670 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003321 , + af-p:AFP_0003566 ; + + rdfs:isDefinedBy ; + + skos:definition "The producing of vapor. [Allotrope]" ; + + skos:prefLabel "vapor generation" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0002677 + +af-p:AFP_0002677 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0002294 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002750 ; + owl:someValuesFrom pato:_0001025 + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A measurement that targets the pressure of some material entity. [Allotrope]" ; + + skos:note "Many techniques have been developed for the measurement of pressure and vacuum. Instruments used to measure pressure are called pressure gauges or vacuum gauges. A manometer is an instrument that uses a column of liquid to measure pressure, although the term is currently often used to mean any pressure measuring instrument. [Wikipedia]" ; + + skos:prefLabel "pressure measurement" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0002680 + +af-p:AFP_0002680 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003315 , + [ owl:intersectionOf ( obi:_0000011 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000399 ; + owl:someValuesFrom af-m:AFM_0000275 + ] + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002808 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "analysis" ; + + skos:changeNote "2020-03-23 Changed alt labels. [Allotrope]" ; + + skos:definition "A planned process with the objective to produce information about the material entity that is the evaluand, by physically examining it or its proxies. [OBI]" ; + + skos:prefLabel "assay" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0002683 + +af-p:AFP_0002683 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0000161 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "Dedusting is the process of removal of dust. [Allotrope]" ; + + skos:prefLabel "dedusting" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0002691 + +af-p:AFP_0002691 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003599 ; + + rdfs:isDefinedBy ; + + skos:definition "Fingerprinting is the process of comparison or overlay of measured spectra with existing reference spectra. [Allotrope]" ; + + skos:prefLabel "fingerprinting" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0002693 + +af-p:AFP_0002693 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0002834 ; + + rdfs:isDefinedBy ; + + skos:definition "The t-test is a process of quantifying the closeness of two sets of data points. It is defined as the ratio of the difference between the means of the two sets divided by the standard error of the difference. [Allotrope]" ; + + skos:prefLabel "t-test" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0002702 + +af-p:AFP_0002702 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0002670 ; + + rdfs:isDefinedBy ; + + skos:altLabel "closed loop" ; + + skos:definition "The closed loop uses feedback control for the regulation of the vapor generation. The system continuously detects deviations from the target partial pressure and adjusts the vapor generation correspondingly. [Allotrope]" ; + + skos:prefLabel "closed loop vapor generation" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0002715 + +af-p:AFP_0002715 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0002294 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "Sieve analysis is a process of particle sizing by filtering particles according to their size through sieves with decreasing pore size. [Allotrope]" ; + + skos:prefLabel "sieve analysis" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0002716 + +af-p:AFP_0002716 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0002294 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002750 ; + owl:someValuesFrom af-q:AFQ_0000026 + ] ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "particle size analysis" , + "particle size measurement" ; + + skos:definition "Particle sizing is an experimental method for the investigation of particle sizes in a sample. [Allotrope]" ; + + skos:prefLabel "particle sizing" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0002764 + +af-p:AFP_0002764 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0000161 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "Tube breeding is a process of cleaning vacuum tubes in order to remove any impurities. [Allotrope]" ; + + skos:prefLabel "tube breeding" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0002788 + +af-p:AFP_0002788 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0002294 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "fluorescence assay" , + "fluorescence detection" , + "fluorescence measurement" ; + + skos:changeNote "2018-12-11 Changed labels [Allotrope]" ; + + skos:definition "An assay in which a materials fluorescence is determined. [VIVO-ISF]" ; + + skos:prefLabel "fluorimetry" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0002792 + +af-p:AFP_0002792 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003312 , + af-p:AFP_0003469 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "Packing is the process of transferring an object into a container as a densely packed phase. [Allotrope]" ; + + skos:example "packing a column with the solid phase" , + "packing a sample into a ssNMR rotor" ; + + skos:prefLabel "packing" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0002800 + +af-p:AFP_0002800 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0002294 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002750 ; + owl:someValuesFrom pato:_0000033 + ] ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "An concentration measurement is the determination of the concentration of a compound in solution. [Allotrope]" ; + + skos:example "protein concentration measurement" , + "quick slope, linearity measurement, UV measurement in which the cell pathlength is varied. [Allotrope]." , + "simple read, i.e. simple measurement at a defined wavelength" ; + + skos:prefLabel "concentration measurement" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0002832 + +af-p:AFP_0002832 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003359 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000057 ; + owl:someValuesFrom pato:_0001025 + ] ; + + rdfs:isDefinedBy ; + + skos:changeNote "2020-03-09 Subclassed under controlling and fixed definition [Allotrope]" ; + + skos:definition "A pressure control is a controlling process that controls pressure of some material. [Allotrope]" ; + + skos:prefLabel "pressure control" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0002833 + +af-p:AFP_0002833 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003359 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000057 ; + owl:someValuesFrom pato:_0000146 + ] ; + + rdfs:isDefinedBy ; + + skos:changeNote "2020-03-09 Subclassed under controlling and fixed definition [Allotrope]" ; + + skos:definition "A temperature control is a controlling process that controls the temperature of some material. [Allotrope]" ; + + skos:prefLabel "temperature control" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0002834 + +af-p:AFP_0002834 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003315 , + obi:_0000011 ; + + rdfs:isDefinedBy ; + + skos:definition "A test can be considered a technical operation or procedure that consists of determination of one or more characteristics of a given product, process or service according to a specified procedure. Often a test is part of an experiment. The test result can be qualitative (yes/no), categorical, or quantitative (a measured value). It can be a personal observation or the output of a precision measuring instrument. [Wikipedia]" ; + + skos:prefLabel "test" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0002843 + +af-p:AFP_0002843 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003367 ; + + rdfs:isDefinedBy ; + + skos:definition "Compression is the act of reducing volume by applying a force. [Allotrope]" ; + + skos:example "In the case of tablets it is the act of forming a solid plug from individual powder / granule components." ; + + skos:prefLabel "compression" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0002846 + +af-p:AFP_0002846 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0001321 ; + + rdfs:isDefinedBy ; + + skos:definition "A chromatography method where the separation is based on the adsorption to membranes. [Allotrope]" ; + + skos:prefLabel "membrane chromatography" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0002849 + +af-p:AFP_0002849 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003315 , + obi:_0000011 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000544 ; + owl:someValuesFrom [ owl:intersectionOf ( af-r:AFR_0000922 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002816 ; + owl:someValuesFrom [ rdf:type owl:Class ; + owl:unionOf ( bfo:_0000015 + bfo:_0000019 + iao:_0000030 + ) + ] + ] + ) ; + rdf:type owl:Class + ] + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "quantitation" ; + + skos:definition "In mathematics and empirical science, quantification (or quantitation) is the act of counting and measuring that maps human sense observations and experiences into members of some set of numbers. [Wikipedia]" ; + + skos:prefLabel "quantification" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003095 + +af-p:AFP_0003095 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003385 ; + + rdfs:isDefinedBy ; + + skos:definition "Data acquisition is the process of sampling signals that measure real world physical conditions and converting the resulting samples into digital numeric values that can be manipulated by a computer. [Wikipedia]" ; + + skos:prefLabel "data acquisition" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003274 + +af-p:AFP_0003274 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0000307 , + af-p:AFP_0003299 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:definition "A chemical structure determination includes a chemist's specifying the molecular geometry and, when feasible and necessary, the electronic structure of the target molecule or other solid. [Wikipedia]" ; + + skos:prefLabel "structure determination" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003275 + +af-p:AFP_0003275 rdf:type owl:Class ; + + rdfs:subClassOf [ owl:intersectionOf ( bfo:_0000015 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000057 ; + owl:someValuesFrom af-m:AFM_0000275 + ] + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A process that affects the physical qualities of materials or creates, destroys or converts materials. [Allotrope]" ; + + skos:prefLabel "material process" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003281 + +af-p:AFP_0003281 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000144 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002682 ; + owl:someValuesFrom bfo:_0000019 + ] ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "quality profile" ; + + skos:definition "A quality process profile is a process profile that covers the change of a quality of an independent continuant that is participant of the profiles process. [Allotrope]" ; + + skos:editorialNote "suggested by Barry Smith, see comments on process profile" ; + + skos:prefLabel "quality process profile" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003282 + +af-p:AFP_0003282 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003598 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "computation" , + "computing" ; + + skos:definition "A calculation is a process by which a data transformation technique that involves problem solving for numbers or quantities is performed. [Allotrope]" ; + + skos:prefLabel "calculation" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003284 + +af-p:AFP_0003284 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003469 , + af-p:AFP_0003576 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "Drawing is the process by which an object or liquid is extracted from a container or receptacle. [Allotrope]" ; + + skos:prefLabel "drawing" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003286 + +af-p:AFP_0003286 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( bfo:_0000035 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0002229 ; + owl:someValuesFrom bfo:_0000015 + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:subClassOf bfo:_0000035 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "The process boundary when the process ends. [Allotrope]" ; + + skos:prefLabel "end" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003289 + +af-p:AFP_0003289 rdf:type owl:Class ; + + rdfs:subClassOf [ owl:intersectionOf ( bfo:_0000015 + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000051 ; + owl:someValuesFrom af-p:AFP_0001135 + ] + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000051 ; + owl:someValuesFrom af-p:AFP_0003312 + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:isDefinedBy ; + + skos:changeNote "2019-09-20 Changed definition. [Allotrope]" ; + + skos:definition "Mobile phase delivery is a process performed by a chromatography system in which the mobile phase is mixed and transported through the instrument for separation and detection. [Allotrope]" ; + + skos:prefLabel "mobile phase delivery" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003290 + +af-p:AFP_0003290 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003598 , + [ owl:intersectionOf ( [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000395 ; + owl:someValuesFrom af-r:AFR_0000947 + ] + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000399 ; + owl:someValuesFrom af-r:AFR_0000413 + ] + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A peak analysis is a data transformation on a peak that analyzes peak facets. [Allotrope]" ; + + skos:prefLabel "peak analysis" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003294 + +af-p:AFP_0003294 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003281 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002682 ; + owl:someValuesFrom pato:_0001025 + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "pressure profile" ; + + skos:changeNote "2020-06-15 Changed labels and definition. [Allotrope]" ; + + skos:definition "A pressure process profile is a quality process profile that tracks some pressure. [Allotrope]" ; + + skos:prefLabel "pressure process profile" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003297 + +af-p:AFP_0003297 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003282 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A ratio calculation is the process of performing the mathematical exercise of dividing a quotient of one quantity by another quotient to demonstrate the quantitative relation between two amounts showing the number of times one value contains or is contained within the other. [Allotrope]" ; + + skos:prefLabel "ratio calculation" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003298 + +af-p:AFP_0003298 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003282 ; + + rdfs:isDefinedBy ; + + skos:definition "The relative retention calculation is a process of performing the mathematical ratio quantification of the time a substance and a standard that remain in the stationary phase of a chromatography process. [Allotrope]" ; + + skos:prefLabel "relative retention calculation" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003299 + +af-p:AFP_0003299 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003315 , + af-p:AFP_0003452 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "Specifying is a process that produces an information object which describes constraints or objectives on characteristics like qualities, functions, dispositions, facets of continuants or processes. [Allotrope]" ; + + skos:prefLabel "specifying" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003300 + +af-p:AFP_0003300 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003281 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002682 ; + owl:someValuesFrom pato:_0000146 + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "temperature profile" ; + + skos:changeNote "2020-06-18 Changed labels and definition. [Allotrope]" ; + + skos:definition "Temperature profile is a quality process profile that tracks temperature. [Allotrope]" ; + + skos:prefLabel "temperature process profile" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003305 + +af-p:AFP_0003305 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0000307 , + af-p:AFP_0003315 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000544 ; + owl:someValuesFrom af-r:AFR_0000922 + ] ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "observation" , + "sensing" ; + + skos:definition "Observation is the active acquisition of information from a primary source. In living beings, observation employs the senses. [Wikipedia]" ; + + skos:prefLabel "observing" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003306 + +af-p:AFP_0003306 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003551 ; + + rdfs:isDefinedBy ; + + skos:altLabel "being contained" ; + + skos:definition "The state of keeping a flow within spatial limits. [Allotrope]" ; + + skos:example "A vacuum bag contains debris vacuumed from a house. [NIST]" ; + + skos:prefLabel "containing state" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003312 + +af-p:AFP_0003312 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003348 , + [ owl:intersectionOf ( af-p:AFP_0003348 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0002344 ; + owl:someValuesFrom bfo:_0000002 + ] + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "deliver" , + "transmitting" ; + + skos:definition "Transferring is channeling a flow (material, energy, signal) from one place to another. [NIST]" ; + + skos:prefLabel "transferring" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003313 + +af-p:AFP_0003313 rdf:type owl:Class ; + + rdfs:subClassOf [ owl:intersectionOf ( af-p:AFP_0003312 + af-p:AFP_0003321 + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "channeling energy" , + "conducting energy" , + "energy transmission" ; + + skos:definition "Transmitting energy is transferring an energy from one place to another. [Allotrope, NIST]" ; + + skos:prefLabel "transmitting energy" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003314 + +af-p:AFP_0003314 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0000307 , + af-p:AFP_0003312 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "transferring signal" , + "transmitting signal" ; + + skos:definition "Communicating is transferring information from one material entity to another. This can be by way of a material or energy connecting the entity or by transporting the material bearing the information between the locations. [Allotrope]" ; + + skos:prefLabel "communicating" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003315 + +af-p:AFP_0003315 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003620 ; + + af-x:AFX_0002808 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "creating" , + "creation" , + "production" ; + + skos:definition "A process where some new material entity or information content entity does not exists at the start of the process but is existing at the end by way of the process. [Allotrope]" ; + + skos:note "Producing is dependent on the granularity and perspective. Many producing processes are converting processes in a different granulary or perspective." ; + + skos:prefLabel "producing" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003316 + +af-p:AFP_0003316 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003620 ; + + rdfs:isDefinedBy ; + + skos:altLabel "consumption" ; + + skos:definition "A process where a essential material entity participant ceases to exist at the end and it was existing at the start. [Allotrope]" ; + + skos:editorialNote "needs FOL for full axiomization" ; + + skos:prefLabel "consuming" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003318 + +af-p:AFP_0003318 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003316 ; + + rdfs:isDefinedBy ; + + skos:altLabel "collecting energy" , + "energy consumption" ; + + skos:definition "Consuming energy is a consuming that consumes energy. [Allotrope]" ; + + skos:prefLabel "consuming energy" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003319 + +af-p:AFP_0003319 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003315 , + af-p:AFP_0003321 ; + + rdfs:isDefinedBy ; + + skos:altLabel "energy production" ; + + skos:definition "Producing energy is the producing of energy (from an unspecified energy source). [Allotrope]" ; + + skos:editorialNote "This is a black box perspective on the process only focussing on the energy flow out of the system. Within the system, this is a conversion process because of the physical laws of conservation. [Allotrope]" ; + + skos:prefLabel "producing energy" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003321 + +af-p:AFP_0003321 rdf:type owl:Class ; + + rdfs:subClassOf [ owl:intersectionOf ( bfo:_0000015 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000057 ; + owl:someValuesFrom af-m:AFM_0000880 + ] + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A process where an agent affects energy flowing in and out of a system or affecting the energetic state of materials. [Allotrope]" ; + + skos:prefLabel "energetic process" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003323 + +af-p:AFP_0003323 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( af-p:AFP_0003551 + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000055 ; + owl:someValuesFrom [ owl:intersectionOf ( af-rl:AFRL_0000487 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000081 ; + owl:someValuesFrom af-m:AFM_0000275 + ] + ) ; + rdf:type owl:Class + ] + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:subClassOf af-p:AFP_0003275 , + af-p:AFP_0003551 ; + + rdfs:isDefinedBy ; + + skos:definition "Storing material is the storing of material. [Allotrope]" ; + + skos:prefLabel "storing material" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003324 + +af-p:AFP_0003324 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( af-p:AFP_0003551 + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000055 ; + owl:someValuesFrom [ owl:intersectionOf ( af-rl:AFRL_0000487 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000081 ; + owl:someValuesFrom af-m:AFM_0000880 + ] + ) ; + rdf:type owl:Class + ] + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:subClassOf af-p:AFP_0003321 , + af-p:AFP_0003551 ; + + rdfs:isDefinedBy ; + + skos:altLabel "conserving energy" ; + + skos:definition "Storing energy is the storing of energy. [Allotrope]" ; + + skos:prefLabel "storing energy" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003325 + +af-p:AFP_0003325 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003565 , + [ owl:intersectionOf ( af-p:AFP_0000307 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000399 ; + owl:someValuesFrom iao:_0000030 + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:isDefinedBy ; + + skos:definition "The process of copying the information in a signal into a persistent information bearer. [Allotrope]" ; + + skos:prefLabel "recording" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003328 + +af-p:AFP_0003328 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( bfo:_0000035 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0002223 ; + owl:someValuesFrom bfo:_0000015 + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:subClassOf bfo:_0000035 ; + + rdfs:isDefinedBy ; + + skos:definition "The process boundary when the process starts. [Allotrope]" ; + + skos:prefLabel "start" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003329 + +af-p:AFP_0003329 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003403 ; + + rdfs:isDefinedBy ; + + skos:altLabel "material selection" ; + + skos:definition "The partitioning of some object aggregate. [Allotrope]" ; + + skos:editorialNote "Selection does not necessarily involve physical separation." ; + + skos:prefLabel "selecting" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003330 + +af-p:AFP_0003330 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003620 , + [ owl:intersectionOf ( af-p:AFP_0000307 + af-p:AFP_0003452 + ) ; + rdf:type owl:Class + ] ; + + rdfs:isDefinedBy ; + + skos:definition "Referencing is the process of mentioning or referring to an entity by using a denotation of the entity. [Allotrope]" ; + + skos:prefLabel "referencing" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003331 + +af-p:AFP_0003331 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003485 ; + + rdfs:isDefinedBy ; + + skos:altLabel "material maintenance" ; + + skos:definition "Maintaining is a regulating process that keeps some or all of the characteristics of a material over time within a specification. [Allotrope]" ; + + skos:prefLabel "maintaining" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003332 + +af-p:AFP_0003332 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003400 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "disconnecting" ; + + skos:definition "The process of causing a flow to no longer be topologically connected. [NIST]" ; + + skos:editorialNote "1 input flow to n output flows" , + "For data flows, branching does not mean that the input flow fully ceases to exist. [Allotrope]" ; + + skos:prefLabel "branching" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003335 + +af-p:AFP_0003335 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0000422 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "partioning" , + "portioning" , + "splitting" ; + + skos:definition "Dividing is a separating of flows focused on all parts of the flow. [Allotrope]" ; + + skos:prefLabel "dividing" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003336 + +af-p:AFP_0003336 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0000422 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "Separating by drawing, or forcibly pulling out, a flow that is of a different kind than that of the input flow. [Allotrope, NIST]" ; + + skos:example "A vacuum cleaner extracts debris from the imported mixture and exports clean air to the environment. [NIST]" ; + + skos:prefLabel "extracting" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003348 + +af-p:AFP_0003348 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003620 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0002337 ; + owl:someValuesFrom bfo:_0000002 + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "channeling" , + "localization" , + "spatial process" ; + + skos:definition "A processing that affects the spatial location or orientation of some participants. [Allotrope]" ; + + skos:prefLabel "localizing" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003349 + +af-p:AFP_0003349 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003348 , + [ owl:intersectionOf ( [ rdf:type owl:Restriction ; + owl:onProperty ro:_0002339 ; + owl:someValuesFrom bfo:_0000002 + ] + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0002342 ; + owl:someValuesFrom bfo:_0000002 + ] + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:changeNote "2020-06-18 Changed definition. [Allotrope]" ; + + skos:definition "Importing is a localization that brings in a flow (material, energy, signal) from outside of a boundary to the inside. [Allotrope, NIST]" ; + + skos:prefLabel "importing" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003350 + +af-p:AFP_0003350 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003348 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "Exporting is a channeling that sends a flow (material, energy, signal) from inside of a boundary to the outside. [Allotrope, NIST]" ; + + skos:prefLabel "exporting" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003351 + +af-p:AFP_0003351 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003348 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "directing the course" ; + + skos:definition "Guiding is directing the course of a flow (material, energy, signal) along a specific path. [Allotrope, NIST]" ; + + skos:prefLabel "guiding" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003354 + +af-p:AFP_0003354 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003475 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "Connecting is bringing two or more topological flows into connection. [Allotrope, NIST]" ; + + skos:editorialNote "n input flows to 1 output flow" ; + + skos:prefLabel "connecting" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003356 + +af-p:AFP_0003356 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003275 , + af-p:AFP_0003354 ; + + rdfs:isDefinedBy ; + + skos:definition "Coupling is connecting together material such that the members are still distinguishable from each other. [NIST]" ; + + skos:prefLabel "coupling" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003357 + +af-p:AFP_0003357 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003356 ; + + rdfs:isDefinedBy ; + + skos:definition "Joining is the direct coupling of flows without any intermediary flow. [Allotrope]" ; + + skos:prefLabel "joining" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003358 + +af-p:AFP_0003358 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003356 ; + + rdfs:isDefinedBy ; + + skos:definition "Linking is coupling flows together by means of an intermediary flow. [NIST]" ; + + skos:prefLabel "linking" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003359 + +af-p:AFP_0003359 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003620 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "Controlling is changing or regulating a flow in its magnitude. [NIST, Allotrope]" ; + + skos:prefLabel "controlling" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003360 + +af-p:AFP_0003360 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003359 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "activating" , + "starting" , + "switching on" , + "turning on" ; + + skos:definition "Actuating is the process of commencing the flow of energy, signal, or material in response to an imported control signal. [NIST]" ; + + skos:prefLabel "actuating" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003361 + +af-p:AFP_0003361 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003485 ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "Regulating material is adjusting a quality of material in response to a control signal. [Allotrope]" ; + + skos:example "regulating the temperature" ; + + skos:prefLabel "regulating material" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003362 + +af-p:AFP_0003362 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003275 , + [ owl:intersectionOf ( af-p:AFP_0003486 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000399 ; + owl:someValuesFrom af-m:AFM_0000275 + ] + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "modification" , + "modifying material" ; + + skos:definition "Changing is controlling a quality of the material in a predetermined and fixed manner. The identity of the material is maintained. [NIST]" ; + + skos:prefLabel "changing material" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003364 + +af-p:AFP_0003364 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003486 ; + + rdfs:isDefinedBy ; + + skos:altLabel "forming" , + "molding" ; + + skos:definition "Shaping is changing the material in regard to spatial form. [Allotrope]" ; + + skos:prefLabel "shaping" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003367 + +af-p:AFP_0003367 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003486 ; + + rdfs:isDefinedBy ; + + skos:altLabel "decrementing magnitude" ; + + skos:definition "Decrementing is reducing the magnitude of a quality in a predetermined and fixed manner. [Allotrope]" ; + + skos:prefLabel "decrementing" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003368 + +af-p:AFP_0003368 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003486 ; + + rdfs:isDefinedBy ; + + skos:altLabel "incrementing magnitude" ; + + skos:definition "Incrementing is enlarging the magnitude of a quality in a predetermined and fixed manner. [NIST]" ; + + skos:prefLabel "incrementing" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003370 + +af-p:AFP_0003370 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000035 ; + + dct:source "http://www.loa.istc.cnr.it/old/Papers/D18.pdf" ; + + rdfs:isDefinedBy ; + + skos:definition "A process boundary based on some physical characteristics at the start or end of some process changing these characteristics. [Allotrope]" ; + + skos:prefLabel "achievement" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003371 + +af-p:AFP_0003371 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000015 ; + + dct:source "http://www.loa.istc.cnr.it/old/Papers/D18.pdf" ; + + rdfs:isDefinedBy ; + + skos:definition "A non-cumulative process (event) that is non-atomic. [DOLCE]" ; + + skos:example "leaving a place" ; + + skos:note "An accomplishment is the process of what is coming out instead of what is going on. (Aristoteles kinesis vs. energeia). [Allotrope]" ; + + skos:prefLabel "accomplishment" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003374 + +af-p:AFP_0003374 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000015 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + dct:source "http://www.loa.istc.cnr.it/old/Papers/D18.pdf" ; + + rdfs:isDefinedBy ; + + skos:definition "A state is a homomeric, cumulative process in which all the temporal parts are described by the same expression used for the whole. [Allotrope]" ; + + skos:example "corroding" ; + + skos:prefLabel "state" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003385 + +af-p:AFP_0003385 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003475 ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:altLabel "collection" ; + + skos:definition "The act of gathering things together; having been brought together in one place. [NCI]" ; + + skos:prefLabel "collecting" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003393 + +af-p:AFP_0003393 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003370 ; + + rdfs:isDefinedBy ; + + skos:definition "Arrival is the achievement of reaching the destination site in a moving process. [Allotrope]" ; + + skos:prefLabel "arrival" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003394 + +af-p:AFP_0003394 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003464 ; + + rdfs:isDefinedBy ; + + skos:altLabel "keeping separated" ; + + skos:definition "A spatial change processing the increases the spatial distance from the start. [Allotrope]" ; + + skos:prefLabel "repelling" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003395 + +af-p:AFP_0003395 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003374 ; + + rdfs:isDefinedBy ; + + skos:altLabel "staying in place" ; + + skos:definition "A state when material object keeps its spatial location and orientation. [Allotrope]" ; + + skos:prefLabel "resting state" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003396 + +af-p:AFP_0003396 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003464 ; + + rdfs:isDefinedBy ; + + skos:altLabel "keeping close" ; + + skos:definition "A spatial change state the decreases the spatial distance at the end. [Allotrope]" ; + + skos:prefLabel "attracting" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003398 + +af-p:AFP_0003398 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003575 ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "insertion" ; + + skos:definition "A spatial processing of transferring material into a site. [Allotrope]" ; + + skos:prefLabel "inserting material" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003400 + +af-p:AFP_0003400 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003620 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A process that affects the topological connectedness or parthood of two or more flows. [Allotrope]" ; + + skos:prefLabel "mereotopological process" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003403 + +af-p:AFP_0003403 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003332 ; + + rdfs:isDefinedBy ; + + skos:altLabel "distributing" , + "distribution" ; + + skos:definition "A processing that causes a flow to break up into disconnected partitions. The individual bits are similar to each other and the undistributed material. [Allotrope]" ; + + skos:prefLabel "partitioning" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003404 + +af-p:AFP_0003404 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003456 ; + + rdfs:isDefinedBy ; + + skos:definition "A state of keeping two materials topologically disconnected by a separation medium. [Allotrope]" ; + + skos:prefLabel "blocking" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003408 + +af-p:AFP_0003408 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003370 ; + + rdfs:isDefinedBy ; + + skos:definition "Departure is the achievement of leaving the source site in a moving process. [Allotrope]" ; + + skos:prefLabel "departure" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003409 + +af-p:AFP_0003409 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003348 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "orienting" , + "spatial alignment" ; + + skos:definition "An achievement that aims for a specific the spatial location and orientation of a material entity. [Allotrope]" ; + + skos:prefLabel "positioning" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003416 + +af-p:AFP_0003416 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003565 , + [ owl:intersectionOf ( af-p:AFP_0003321 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000395 ; + owl:someValuesFrom af-m:AFM_0000880 + ] + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000399 ; + owl:someValuesFrom af-m:AFM_0000880 + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "transducing" ; + + skos:definition "Changing from one form of a flow energy to another. [NIST]" ; + + skos:example "A motor converts energy into mechanical energy." ; + + skos:prefLabel "converting energy" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003419 + +af-p:AFP_0003419 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003368 ; + + rdfs:isDefinedBy ; + + skos:altLabel "incrementing energy" , + "loading" ; + + skos:definition "Increasing the amount of energy in a system. [Allotrope]" ; + + skos:prefLabel "charging" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003420 + +af-p:AFP_0003420 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003367 ; + + rdfs:isDefinedBy ; + + skos:altLabel "decrementing energy" , + "unloading" ; + + skos:prefLabel "discharging" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003424 + +af-p:AFP_0003424 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003359 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "deactivating" , + "impeding" , + "turning off" ; + + skos:definition "Stopping it the process of ceasing or preventing the transfer of a flow. [NIST]" ; + + skos:example "A reflective coating on a window stops the transmission of UV radiation through a window. [NIST]" ; + + skos:prefLabel "stopping" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003431 + +af-p:AFP_0003431 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003349 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "importing signal" ; + + skos:definition "A process that transports a signal across a system boundary into the system. [Allotrope]" ; + + skos:prefLabel "receiving" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003432 + +af-p:AFP_0003432 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003350 ; + + rdfs:isDefinedBy ; + + skos:altLabel "exporting signal" ; + + skos:definition "A process that transports a signal across a system boundary out of the system. [Allotrope]" ; + + skos:prefLabel "sending" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003433 + +af-p:AFP_0003433 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003374 ; + + rdfs:isDefinedBy ; + + skos:definition "The state of perceiving or becoming aware of a signal. [Allotrope]" ; + + skos:prefLabel "sensing state" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003434 + +af-p:AFP_0003434 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003488 ; + + rdfs:isDefinedBy ; + + skos:definition "The process of transforming a signal into a visual signal (color, pattern). [Allotrope]" ; + + skos:prefLabel "displaying" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003437 + +af-p:AFP_0003437 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003370 ; + + rdfs:isDefinedBy ; + + skos:definition "The achievement that a signal has left a source in an information transmission. [Allotrope]" ; + + skos:prefLabel "emission" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003449 + +af-p:AFP_0003449 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003374 ; + + rdfs:isDefinedBy ; + + skos:altLabel "fixing" , + "securing" , + "supporting" ; + + skos:definition "A state of supporting a material to stay in a location or orientation. [Allotrope]" ; + + skos:prefLabel "holding in place" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003450 + +af-p:AFP_0003450 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003370 ; + + rdfs:isDefinedBy ; + + skos:definition "The accomplishment that a transferred signal reaches at its designated target. [Allotrope]" ; + + skos:prefLabel "reception" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003452 + +af-p:AFP_0003452 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0000307 ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "cognitive process" ; + + skos:definition "A physical process that occurs in the mind of a sentient being and is processing information. [Allotrope]" ; + + skos:prefLabel "mental process" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003454 + +af-p:AFP_0003454 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000144 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "rate profile" ; + + skos:changeNote "2020-06-18 Changed labels and fixed definition [Allotrope]" ; + + skos:definition "A rate profile is a process profile, which are changes to ratios of determinate quality magnitudes over time. [Allotrope]" ; + + skos:editorialNote "suggested by Barry Smith, see comments on process profile" ; + + skos:prefLabel "rate process profile" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003455 + +af-p:AFP_0003455 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003454 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "cyclic rate profile" ; + + skos:changeNote "2020-06-18 Changed labels. [Allotrope]" ; + + skos:definition "A cyclic rate profile is a rate profile of a process that follows a cyclic pattern. [Allotrope]" ; + + skos:prefLabel "cyclic rate process profile" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003456 + +af-p:AFP_0003456 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003374 ; + + rdfs:isDefinedBy ; + + skos:definition "A state s with participating materials m1 and m2, and m1 is not connected to m2. [Allotrope]" ; + + skos:prefLabel "disconnected state" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003457 + +af-p:AFP_0003457 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003374 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "being connected" , + "is connected" ; + + skos:definition "A state s with participating materials m1 and m2 and m1 is connected to m2. [Allotrope]" ; + + skos:prefLabel "connected state" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003458 + +af-p:AFP_0003458 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003374 ; + + rdfs:isDefinedBy ; + + skos:definition "The state of material becoming liquid from a solid. [Allotrope]" ; + + skos:prefLabel "melting" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003459 + +af-p:AFP_0003459 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003374 ; + + rdfs:isDefinedBy ; + + skos:definition "The state of material becoming solid from liquid. [Allotrope]" ; + + skos:prefLabel "solidifying" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003464 + +af-p:AFP_0003464 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003374 ; + + rdfs:isDefinedBy ; + + skos:altLabel "flowing" ; + + skos:definition "A state when material is changing its position in space. [Allotrope]" ; + + skos:prefLabel "moving" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003467 + +af-p:AFP_0003467 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003321 , + af-p:AFP_0003486 ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "Changing is controlling a quality of energy in a predetermined and fixed manner. [NIST]" ; + + skos:prefLabel "changing energy" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003469 + +af-p:AFP_0003469 rdf:type owl:Class ; + + rdfs:subClassOf [ owl:intersectionOf ( af-p:AFP_0003275 + af-p:AFP_0003312 + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "conveying" , + "material transportation" , + "shifting" , + "transferring material" ; + + skos:definition "Transporting is channeling by shifting, or conveying, a material from one place to another. [NIST]" ; + + skos:prefLabel "transporting material" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003470 + +af-p:AFP_0003470 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003374 ; + + rdfs:isDefinedBy ; + + skos:definition "The state when the role of a signal is realized independent of any other material entity that may sense (perceive) the signal. [Allotrope]" ; + + skos:prefLabel "indicating state" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003471 + +af-p:AFP_0003471 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003488 ; + + rdfs:isDefinedBy ; + + skos:altLabel "signal acquisition" ; + + skos:definition "The process of sensing signals and recording the information in the signals. [Allotrope]" ; + + skos:prefLabel "tracking" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003472 + +af-p:AFP_0003472 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003275 , + af-p:AFP_0003573 ; + + rdfs:isDefinedBy ; + + skos:definition "Sorting is the dividing of material by an ordering criteria. [Allotrope]" ; + + skos:prefLabel "sorting material" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003473 + +af-p:AFP_0003473 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0000422 ; + + rdfs:isDefinedBy ; + + skos:altLabel "removal" ; + + skos:definition "Taking away a part of a flow from its prefixed place. [NIST]" ; + + skos:prefLabel "removing" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003475 + +af-p:AFP_0003475 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003400 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "assembling" ; + + skos:definition "Combining is the building of a whole out of parts. [Allotrope]" ; + + skos:prefLabel "combining" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003481 + +af-p:AFP_0003481 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003321 , + af-p:AFP_0003553 ; + + rdfs:isDefinedBy ; + + skos:altLabel "energizing" , + "providing energy" , + "supplying energy" ; + + skos:definition "State of making energy available for a consumer. [Allotrope]" ; + + skos:prefLabel "energizing state" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003485 + +af-p:AFP_0003485 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003359 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "Regulating is the adjusting of a flow in response to a control signal. [NIST]" ; + + skos:example "Turning the valves regulates the flow rate of the liquid flowing from a faucet. [NIST]" ; + + skos:prefLabel "regulating" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003486 + +af-p:AFP_0003486 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003359 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "modifying" ; + + skos:definition "Changing is a processing by which an entity gains or looses parts, qualities, roles, dispositions, functions etc in a predetermined and fixed manner but maintains its identity. [Allotrope]" ; + + skos:prefLabel "changing" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003488 + +af-p:AFP_0003488 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003552 ; + + rdfs:isDefinedBy ; + + skos:definition "Indicating is signaling to make something known to the user about a flow. [NIST]" ; + + skos:prefLabel "indicating" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003491 + +af-p:AFP_0003491 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0002680 ; + + rdfs:isDefinedBy ; + + skos:altLabel "analysis" , + "analyte assay" ; + + skos:definition "An assay with the objective to capture information about the presence, concentration or amount of an analyte in the evaluand. [OBI]" ; + + skos:prefLabel "analysis assay" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003533 + +af-p:AFP_0003533 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( af-p:AFP_0000422 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000395 ; + owl:someValuesFrom af-m:AFM_0000275 + ] + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000399 ; + owl:someValuesFrom af-m:AFM_0000275 + ] + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A separating of materials. [Allotrope]" ; + + skos:prefLabel "separating material" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003538 + +af-p:AFP_0003538 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003315 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "Assessing is evaluating or estimating a quality or behavior. [Allotrope]" ; + + skos:prefLabel "assessing" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003540 + +af-p:AFP_0003540 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003598 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "Image analysis is the discovering of patterns in an image that are correlated to qualities of the material entity the image represents or of abstract patterns. [Allotrope]" ; + + skos:prefLabel "image analysis" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003541 + +af-p:AFP_0003541 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0002294 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002750 ; + owl:someValuesFrom pato:_0000146 + ] ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:changeNote "2020-11-12 Changed definition. [Allotrope]" ; + + skos:definition "A temperature measurement is a measurement that targets the temperature of some material entity. [Allotrope]" ; + + skos:prefLabel "temperature measurement" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003551 + +af-p:AFP_0003551 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003563 ; + + rdfs:isDefinedBy ; + + skos:altLabel "storing" ; + + skos:definition "Storing is containing or collecting flows to accumulate. [NIST]" ; + + skos:prefLabel "storing state" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003552 + +af-p:AFP_0003552 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003315 , + [ owl:intersectionOf ( af-p:AFP_0000307 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000395 ; + owl:someValuesFrom [ rdf:type owl:Class ; + owl:unionOf ( af-r:AFR_0001004 + [ owl:intersectionOf ( bfo:_0000040 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000087 ; + owl:someValuesFrom af-rl:AFRL_0000159 + ] + ) ; + rdf:type owl:Class + ] + ) + ] + ] + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "producing signal" ; + + skos:definition "Signaling is the process of providing information on a material, energy or signal flow as an output signal. [NIST]" ; + + skos:prefLabel "signaling" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003553 + +af-p:AFP_0003553 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003563 ; + + rdfs:isDefinedBy ; + + skos:altLabel "supplying" ; + + skos:definition "A supplying state is a providing state that makes energy or material available for processing or consumption. [Allotrope]" ; + + skos:example "In a flashlight, the battery supplies energy to the bulb. [NIST]" ; + + skos:prefLabel "supplying state" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003554 + +af-p:AFP_0003554 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003316 ; + + rdfs:isDefinedBy ; + + skos:definition "Consuming signal is consuming of signals. [Allotrope]" ; + + skos:prefLabel "consuming signal" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003556 + +af-p:AFP_0003556 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0002680 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "An assay that examines physical qualities of material. [Allotrope]" ; + + skos:prefLabel "physical characterization assay" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003563 + +af-p:AFP_0003563 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003374 ; + + rdfs:isDefinedBy ; + + skos:altLabel "providing" ; + + skos:definition "Providing is the state of accumulating or supplying a material or energy flow. [NIST]" ; + + skos:prefLabel "providing state" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003564 + +af-p:AFP_0003564 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003551 ; + + rdfs:isDefinedBy ; + + skos:altLabel "collecting" ; + + skos:definition "A storing state that brings a flow together at one place. [NIST]" ; + + skos:example "Solar panels collect ultraviolet sun rays to power small mechanisms. [NIST]" ; + + skos:prefLabel "collecting state" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003565 + +af-p:AFP_0003565 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003620 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002748 ; + owl:someValuesFrom [ rdf:type owl:Class ; + owl:unionOf ( af-m:AFM_0000275 + af-rl:AFRL_0000159 + ) + ] + ] ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "Converting is a process that changes from one form of a flow (material, energy, signal) to another. [NIST]" ; + + skos:prefLabel "converting" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003566 + +af-p:AFP_0003566 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003565 , + [ owl:intersectionOf ( af-p:AFP_0003275 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000395 ; + owl:someValuesFrom af-m:AFM_0000275 + ] + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000399 ; + owl:someValuesFrom af-m:AFM_0000275 + ] + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "Changing from one form of a flow material to another. [NIST]" ; + + skos:prefLabel "converting material" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003568 + +af-p:AFP_0003568 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003282 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:definition "Interpolation is the constructing new data points within the range of a discrete set of known data points. [Wikipedia]" ; + + skos:prefLabel "interpolation" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003570 + +af-p:AFP_0003570 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003290 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A peak analysis that determines the peak height following a specified algorithm. [Allotrope]" ; + + skos:prefLabel "peak height analysis" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003571 + +af-p:AFP_0003571 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003290 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A peak analysis that determines the peak width following a specified algorithm. [Allotrope]" ; + + skos:prefLabel "peak width analysis" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003572 + +af-p:AFP_0003572 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003282 , + af-p:AFP_0003656 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "adding" , + "summing" ; + + skos:definition "Totaling is the calculation of a sum or an integral. [Allotrope]" ; + + skos:prefLabel "totaling" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003573 + +af-p:AFP_0003573 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003403 ; + + rdfs:isDefinedBy ; + + skos:definition "Sorting is distributing flows based on some associated physical quality or entity into distinct fractions according to a defined order. [Allotrope]" ; + + skos:prefLabel "sorting" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003574 + +af-p:AFP_0003574 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003533 ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "extracting material" ; + + skos:definition "A spatial process of removing a material from a site. [Allotrope]" ; + + skos:prefLabel "removing material" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003575 + +af-p:AFP_0003575 rdf:type owl:Class ; + + rdfs:subClassOf [ owl:intersectionOf ( af-p:AFP_0003275 + af-p:AFP_0003349 + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "importing material" ; + + skos:definition "Delivering material is the importing of material to a location or site. [Allotrope]" ; + + skos:prefLabel "delivering material" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003576 + +af-p:AFP_0003576 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003350 ; + + rdfs:isDefinedBy ; + + skos:altLabel "exporting material" , + "taking material" ; + + skos:definition "Taking material is the exporting of material from a location or site. [Allotrope]" ; + + skos:prefLabel "taking" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003577 + +af-p:AFP_0003577 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003312 , + af-p:AFP_0003469 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "Pumping is a material transport of fluids by suction or pressure or both. [Allotrope]" ; + + skos:prefLabel "pumping" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003581 + +af-p:AFP_0003581 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003598 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "aggregating data" , + "collecting data" , + "data aggregation" ; + + skos:definition "A data transformation that assigns some data to a collection. [Allotrope]" ; + + skos:prefLabel "data collection" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003582 + +af-p:AFP_0003582 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003598 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "Ordering data is the process of arranging data items systematically. [Allotrope]" ; + + skos:prefLabel "ordering data" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003583 + +af-p:AFP_0003583 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003315 , + [ owl:intersectionOf ( af-p:AFP_0000307 + af-p:AFP_0003452 + ) ; + rdf:type owl:Class + ] ; + + rdfs:isDefinedBy ; + + skos:definition "Denoting is a process that assigns a symbol to an entity in order to reference it. [Allotrope]" ; + + skos:prefLabel "denoting" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003584 + +af-p:AFP_0003584 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003315 , + [ owl:intersectionOf ( af-p:AFP_0003452 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000395 ; + owl:someValuesFrom af-r:AFR_0000922 + ] + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "Describing is a process by which an account of some relevant characteristics, qualities or events of an entity are given or presented. [Allotrope]" ; + + skos:prefLabel "describing" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003585 + +af-p:AFP_0003585 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003583 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000544 ; + owl:someValuesFrom af-r:AFR_0000917 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "Identifying is recognizing an entity by some criteria and assigning an identifier to the entity. [Allotrope]" ; + + skos:prefLabel "identifying" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003586 + +af-p:AFP_0003586 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003598 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "Indexing is the process of organizing data according to a specific plan, usually to streamline data retrieval. [Allotrope]" ; + + skos:example "assigning a sequence of numbers to data items" ; + + skos:prefLabel "indexing" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003591 + +af-p:AFP_0003591 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003594 ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:altLabel "reflecting" ; + + skos:definition "Reflection is the change in direction of a wavefront at an interface between two different media so that the wavefront returns into the medium from which it originated. [Wikipedia]" ; + + skos:prefLabel "reflection" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003592 + +af-p:AFP_0003592 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003591 ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:altLabel "regular reflection" ; + + skos:definition "Specular reflection is the mirror-like reflection of waves, such as light, from a surface. In this process, each incident ray is reflected, with the reflected ray having the same angle to the surface normal as the incident ray. [Wikipedia]" ; + + skos:prefLabel "specular reflection" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003593 + +af-p:AFP_0003593 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003591 ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:definition "Diffuse reflection is the reflection of light or other waves or particles from a surface such that a ray incident on the surface is scattered at many angles rather than at just one angle as in the case of specular reflection. An ideal diffuse reflecting surface is said to exhibit Lambertian reflection, meaning that there is equal luminance when viewed from all directions lying in the half-space adjacent to the surface. [Wikipedia]" ; + + skos:prefLabel "diffuse reflection" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003594 + +af-p:AFP_0003594 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003374 ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:definition "Scattering is a general physical process where some forms of radiation, such as light, sound, or moving particles, are forced to deviate from a straight trajectory by one or more paths due to localized non-uniformities in the medium through which they pass. [Wikipedia]" ; + + skos:prefLabel "scattering" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003595 + +af-p:AFP_0003595 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003464 ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:altLabel "deflection" ; + + skos:definition "A deflection, in physics, refers to the change in an objects' acceleration as a consequence of contact (collision) with a surface or the influence of a field. [Wikipedia]" ; + + skos:prefLabel "deflecting" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003596 + +af-p:AFP_0003596 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003424 ; + + rdfs:isDefinedBy ; + + skos:definition "Significantly restraining a flow, though a portion of the flow continues to be transferred. [NIST]" ; + + skos:example "The structures of space vehicles inhibits the flow of radiation to protect crew and cargo." ; + + skos:prefLabel "inhibiting" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003597 + +af-p:AFP_0003597 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003424 ; + + rdfs:isDefinedBy ; + + skos:definition "Keeping a flow from happening. [NIST]" ; + + skos:example "A submerged gate on a dam wall prevents water from flowing to the other side. [NIST]" ; + + skos:prefLabel "preventing" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003598 + +af-p:AFP_0003598 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003565 , + [ owl:intersectionOf ( af-p:AFP_0000307 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000395 ; + owl:someValuesFrom iao:_0000030 + ] + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000399 ; + owl:someValuesFrom iao:_0000030 + ] + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "data processing" ; + + skos:changeNote "2019-09-09 Add alt label 'data processing'. [Allotrope]" ; + + skos:definition "A converting process that converts the signals from one form into another by changing its content. [Allotrope]" ; + + skos:prefLabel "data transformation" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003599 + +af-p:AFP_0003599 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003315 , + [ owl:intersectionOf ( af-p:AFP_0000307 + af-p:AFP_0003452 + ) ; + rdf:type owl:Class + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "comparison" ; + + skos:definition "The observation or assessment of the similarities or dissimilarities between two things. [Allotrope]" ; + + skos:prefLabel "comparing" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003603 + +af-p:AFP_0003603 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003315 , + [ owl:intersectionOf ( af-p:AFP_0000307 + af-p:AFP_0003452 + ) ; + rdf:type owl:Class + ] ; + + rdfs:isDefinedBy ; + + skos:definition "Assigning is the producing of an assignment that asserts some relation between entities. [Allotrope]" ; + + skos:prefLabel "assigning" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003618 + +af-p:AFP_0003618 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003603 ; + + rdfs:isDefinedBy ; + + skos:altLabel "peak assigning" , + "peak assignment" ; + + skos:changeNote "2018-08-01 Changed label and definition" ; + + skos:definition "Peak identification is an assigning of a peak to an analyte or portion of an analyte of interest. [Allotrope]" ; + + skos:prefLabel "peak identification" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003619 + +af-p:AFP_0003619 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003598 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "Peak detection is a data transformation that finds peaks in a data distribution function. [Allotrope]" ; + + skos:prefLabel "peak detection" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003620 + +af-p:AFP_0003620 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000015 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "An activity is a process that is cumulative but not homomeric. [Allotrope, DOLCE]" ; + + skos:editorialNote "Same as process in DOLCE. [Allotrope]" ; + + skos:prefLabel "activity" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003623 + +af-p:AFP_0003623 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003374 ; + + rdfs:isDefinedBy ; + + skos:definition "Containing is the state of keeping an object in the inside of a cavity. [Allotrope]" ; + + skos:prefLabel "containing" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003627 + +af-p:AFP_0003627 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( af-p:AFP_0002294 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002750 ; + owl:someValuesFrom af-q:AFQ_0000180 + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:subClassOf af-p:AFP_0002294 ; + + rdfs:isDefinedBy ; + + skos:definition "A measuring that targets the number density. [Allotrope]" ; + + skos:prefLabel "number density measurement" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003628 + +af-p:AFP_0003628 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( af-p:AFP_0003627 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002750 ; + owl:someValuesFrom af-q:AFQ_0000181 + ] + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "Cell density measurement is a measurement of the number density of cells. [Allotrope]" ; + + skos:prefLabel "cell density measurement" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003629 + +af-p:AFP_0003629 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( af-p:AFP_0001645 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002750 ; + owl:someValuesFrom af-q:AFQ_0000184 + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:subClassOf af-p:AFP_0001645 ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "Cell counting is the counting of cells. [Allotrope]" ; + + skos:prefLabel "cell counting" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003634 + +af-p:AFP_0003634 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003332 , + [ owl:intersectionOf ( [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000542 ; + owl:someValuesFrom af-r:AFR_0001209 + ] + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000544 ; + owl:someValuesFrom af-r:AFR_0001210 + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:isDefinedBy ; + + skos:definition "Sampling is the process of taking parts or partitions of an object aggregate or data set for the interest for studying it. [Allotrope]" ; + + skos:prefLabel "sampling" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003635 + +af-p:AFP_0003635 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003634 ; + + rdfs:isDefinedBy ; + + skos:definition "Sampling data is sampling on a set of data items. [Allotrope]" ; + + skos:prefLabel "sampling data" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003636 + +af-p:AFP_0003636 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003584 ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:definition "Descriptive statistics is the process of using and analyzing descriptive statistics. A descriptive statistic is a summary statistic that quantitatively describes or summarizes features of a collection of information. [Wikipedia]" ; + + skos:prefLabel "descriptive statistics" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003637 + +af-p:AFP_0003637 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003315 , + [ owl:intersectionOf ( af-p:AFP_0000307 + af-p:AFP_0003452 + ) ; + rdf:type owl:Class + ] ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:altLabel "inference" ; + + skos:definition "Inferring is a process that produces logical consequences by steps of reasoning, moving from premises. [Wikipedia]" ; + + skos:prefLabel "inferring" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003638 + +af-p:AFP_0003638 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003637 ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:definition "Statistical inference is the process of using data analysis to deduce properties of an underlying probability distribution. [Wikipedia]" ; + + skos:prefLabel "statistical inference" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003639 + +af-p:AFP_0003639 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003565 ; + + rdfs:isDefinedBy ; + + skos:altLabel "labeling" ; + + skos:definition "Marking is changing some quality of a material so that it concretizes a symbol. [Allotrope]" ; + + skos:example "marking a square on the board" , + "modifying a sample to be a marker" ; + + skos:prefLabel "marking" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003640 + +af-p:AFP_0003640 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003374 ; + + rdfs:isDefinedBy ; + + skos:definition "Dispersed state is a state of a system in which discrete particles of one material are dispersed in a continuous phase of another material. [Allotrope]" ; + + skos:prefLabel "dispersed state" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003641 + +af-p:AFP_0003641 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003374 ; + + rdfs:isDefinedBy ; + + skos:definition "Degradation is the state of changing in the qualities of a material under the influence of one or more environmental factors such as heat, light or chemicals such as acids, alkalies and some salts to a lower level of quality. [Allotrope]" ; + + skos:prefLabel "degradation" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003643 + +af-p:AFP_0003643 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003644 ; + + rdfs:isDefinedBy ; + + skos:altLabel "approval" , + "approval process" ; + + skos:definition "Approving is agreeing to a proposition or accepting something as satisfactory towards an set objective. [Allotrope]" ; + + skos:prefLabel "approving" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003644 + +af-p:AFP_0003644 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003315 , + [ owl:intersectionOf ( af-p:AFP_0000307 + af-p:AFP_0003452 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000395 ; + owl:someValuesFrom af-r:AFR_0001494 + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:isDefinedBy ; + + skos:definition "Deciding is making a choice from a set of alternatives. [Allotrope]" ; + + skos:prefLabel "deciding" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003645 + +af-p:AFP_0003645 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003315 ; + + rdfs:isDefinedBy ; + + skos:definition "A signing is attaching a signature to an information content entity. The signature is an identifier for the agent doing the signing. [Allotrope]" ; + + skos:prefLabel "signing" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003646 + +af-p:AFP_0003646 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003312 ; + + rdfs:isDefinedBy ; + + skos:altLabel "submission" ; + + skos:definition "Submitting is the transferring of a material or information from a sender (the submitter) to a receiver with the intent that the receiver acts on the transferred entity towards an objective stated by the submitter. [Allotrope]" ; + + skos:example "the submitting of a report for approval" , + "the submitting of a sample for analysis" ; + + skos:prefLabel "submitting" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003654 + +af-p:AFP_0003654 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003598 ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:definition "Shortening a passage or a write-up without changing its meaning but by using different words and sentences. [Wikipedia]" ; + + skos:prefLabel "summarizing" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003655 + +af-p:AFP_0003655 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003598 ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:altLabel "reducing data" ; + + skos:definition "Data reduction is the transformation of numerical or alphabetical digital information derived empirically or experimentally into a corrected, ordered, and/or simplified form. [Wikipedia]" ; + + skos:prefLabel "data reduction" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003656 + +af-p:AFP_0003656 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003655 ; + + rdfs:isDefinedBy ; + + skos:definition "Data aggregation is a data reduction that applies an aggregating function on the data to produce an aggregated (summary) datum from a collection of data items. [Allotrope]" ; + + skos:example "averaging" , + "totaling a sum" ; + + skos:prefLabel "data aggregation" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003657 + +af-p:AFP_0003657 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003282 , + af-p:AFP_0003655 ; + + rdfs:isDefinedBy ; + + skos:definition "Averaging is the calculation of a mean statistic or a temporal average value. [Allotrope]" ; + + skos:prefLabel "averaging" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003660 + +af-p:AFP_0003660 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003663 , + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000063 ; + owl:someValuesFrom af-p:AFP_0003666 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "Post injection needle washing is an injection needle washing that is done before using the needle for an injection. [Allotrope]" ; + + skos:prefLabel "pre injection needle washing" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003661 + +af-p:AFP_0003661 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003663 , + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000062 ; + owl:someValuesFrom af-p:AFP_0003666 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "Post injection needle washing is an injection needle washing that is done after using the needle for an injection. [Allotrope]" ; + + skos:prefLabel "post injection needle washing" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003663 + +af-p:AFP_0003663 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0001878 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000057 ; + owl:someValuesFrom [ owl:intersectionOf ( af-e:AFE_0002102 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000087 ; + owl:someValuesFrom af-rl:AFRL_0000020 + ] + ) ; + rdf:type owl:Class + ] + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "needle washing" ; + + skos:definition "Injection needle washing is the washing of an injection needle. [Allotrope]" ; + + skos:prefLabel "injection needle washing" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003664 + +af-p:AFP_0003664 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003433 ; + + rdfs:isDefinedBy ; + + skos:altLabel "detecting" , + "is detecting" ; + + skos:definition "A detecting state is a state that occurs when a detector detects its detection target. [Allotrope]" ; + + skos:prefLabel "detecting state" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003665 + +af-p:AFP_0003665 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003673 ; + + rdfs:isDefinedBy ; + + skos:altLabel "executing" , + "executing state" , + "is executing" , + "is running" , + "running" ; + + skos:definition "A running state is a state during which a device or service performs its specified function in normal operation. [Allotrope]" ; + + skos:prefLabel "running state" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003666 + +af-p:AFP_0003666 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0000708 ; + + rdfs:isDefinedBy ; + + skos:altLabel "injection" ; + + skos:definition "Injecting is the forceful loading of a fluid into the interior of some other object. [Allotrope]" ; + + skos:prefLabel "injecting" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003667 + +af-p:AFP_0003667 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003673 ; + + rdfs:isDefinedBy ; + + skos:altLabel "idle" , + "is idle" ; + + skos:definition "An idle state is a state during which a device or service waits for being started to execute a planned process. [Allotrope]" ; + + skos:prefLabel "idle state" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003668 + +af-p:AFP_0003668 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003673 ; + + rdfs:isDefinedBy ; + + skos:altLabel "completed" , + "is completed" ; + + skos:definition "A completed state is a state during which a planned process has run to completion and the device or service is waiting for a reset that cause the state to change to an idle state. [Allotrope]" ; + + skos:prefLabel "completed state" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003669 + +af-p:AFP_0003669 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003673 ; + + rdfs:isDefinedBy ; + + skos:altLabel "is paused" , + "paused" ; + + skos:definition "A paused state is a state during which a device or service waits for being resumed to continue a planned process. [Allotrope]" ; + + skos:prefLabel "paused state" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003670 + +af-p:AFP_0003670 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003673 ; + + rdfs:isDefinedBy ; + + skos:altLabel "aborted" , + "is aborted" ; + + skos:definition "An aborted state is a state during which a planned process has run to completion in an abnormal way and the device or service is waiting for a reset that cause the state to change to an idle state. [Allotrope]" ; + + skos:prefLabel "aborted state" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003671 + +af-p:AFP_0003671 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003673 ; + + rdfs:isDefinedBy ; + + skos:altLabel "is stopped" , + "stopped" ; + + skos:definition "A completed state is a state during which a planned process has run to an end and the device or service is waiting for a reset that cause the state to change to an idle state. [Allotrope]" ; + + skos:prefLabel "stopped state" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003672 + +af-p:AFP_0003672 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003673 ; + + rdfs:isDefinedBy ; + + skos:altLabel "held" , + "is held" ; + + skos:definition "A held state is a state during which a device or service waits for a longer time e.g. for maintenance. [Allotrope]" ; + + skos:prefLabel "held state" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003673 + +af-p:AFP_0003673 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003374 ; + + rdfs:isDefinedBy ; + + skos:definition "A process state is a state where a device or service is executing a planned process or is in a specific configuration. [Allotrope]" ; + + skos:note "The subclasses follow the model of ISA-S88. [Allotrope]" , + "These classes are mainly used in procedure specifications or conditions. [Allotrope]" ; + + skos:prefLabel "process state" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003674 + +af-p:AFP_0003674 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003726 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000057 ; + owl:someValuesFrom af-e:AFE_0000090 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "DAD process" ; + + skos:definition "A process executed by a diode array detector. [Allotrope]" ; + + skos:prefLabel "diode array detector process" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003677 + +af-p:AFP_0003677 rdf:type owl:Class ; + + rdfs:subClassOf [ owl:intersectionOf ( af-p:AFP_0003726 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000057 ; + owl:someValuesFrom af-e:AFE_0002177 + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "pumping system process" ; + + skos:definition "A process executed by a pump system. [Allotrope]" ; + + skos:prefLabel "pump system process" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003678 + +af-p:AFP_0003678 rdf:type owl:Class ; + + rdfs:subClassOf [ owl:intersectionOf ( bfo:_0000015 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000057 ; + owl:someValuesFrom af-e:AFE_0000073 + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A process executed by an autosampler. [Allotrope]" ; + + skos:prefLabel "autosampler process" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003679 + +af-p:AFP_0003679 rdf:type owl:Class ; + + rdfs:subClassOf obi:_0000011 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000057 ; + owl:someValuesFrom af-e:AFE_0002144 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A process that is executed by an LC-UV system. [Allotrope]" ; + + skos:prefLabel "LC-UV system process" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003681 + +af-p:AFP_0003681 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003305 ; + + rdfs:isDefinedBy ; + + skos:definition "Monitoring is an observing of a quality important for the successful and/or safe operation of a controlled process. [Allotrope]" ; + + skos:prefLabel "monitoring" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003682 + +af-p:AFP_0003682 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003598 ; + + rdfs:isDefinedBy ; + + skos:altLabel "time domain zero filling" , + "zero filling" , + "zero padding" ; + + skos:definition "Time domain zero padding is a data transformation used in Fourier transformation by padding the time domain with zero values. [Allotrope]" ; + + skos:prefLabel "time domain zero padding" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003683 + +af-p:AFP_0003683 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0001611 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "GC injection" , + "GC sample introduction" , + "gas chromatography sample introduction" ; + + skos:definition "Gas chromatography injection is the process of loading a sample into a gas chromatography system. [Allotrope]" ; + + skos:prefLabel "gas chromatography injection" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003684 + +af-p:AFP_0003684 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003683 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "Splitless injection is a GC injection whereby the carrier gas sweeps the volatilized sample onto the GC column for a specified period of time before diverting the remaining sample to waste. [Allotrope]" ; + + skos:prefLabel "splitless injection" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003685 + +af-p:AFP_0003685 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003683 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "Split injection is a GC injection whereby a fraction of the volatilized sample is swept onto the GC column with the remaining split/swept to waste. [Allotrope]" ; + + skos:prefLabel "split injection" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003686 + +af-p:AFP_0003686 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003683 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "Packed injection is a GC injection type whereby all of the volatilized sample is swept onto the GC column. [Allotrope]" ; + + skos:prefLabel "packed injection" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003687 + +af-p:AFP_0003687 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003745 ; + + rdfs:isDefinedBy ; + + skos:altLabel "being coated" , + "is coated" ; + + skos:changeNote "2020-06-18 Changed definition and subclassing. [Allotrope]" ; + + skos:definition "Coated state is the covering state when a substance covers the surface of another substance firmly. [Allotrope]" ; + + skos:prefLabel "coated state" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003691 + +af-p:AFP_0003691 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000015 ; + + rdfs:isDefinedBy ; + + skos:altLabel "sequence" ; + + skos:definition "A sequential process is a composite process that has sequential subprocesses as occurrent parts. The starts of all subprocesses occur in sequential order. The ends of all subprocesses occur at the end of the sequential process at the latest. [Allotrope]" ; + + skos:prefLabel "sequential process" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003692 + +af-p:AFP_0003692 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003691 , + obi:_0000011 ; + + rdfs:isDefinedBy ; + + skos:altLabel "analysis sequence" ; + + skos:definition "A sequential analysis process is a planned sequential process that has analytical subprocesses as sequential occurrent parts. [Allotrope]" ; + + skos:prefLabel "sequential analysis process" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003693 + +af-p:AFP_0003693 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003695 ; + + rdfs:isDefinedBy ; + + skos:definition "A linear calibration is an analyte calibration that applies curve fitting of the calibration curve to a linear function. [Allotrope]" ; + + skos:prefLabel "linear calibration" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003694 + +af-p:AFP_0003694 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003706 ; + + rdfs:isDefinedBy ; + + skos:altLabel "power calibration" ; + + skos:definition "An exponential calibration is an analyte calibration that applies curve fitting of the calibration curve to an exponential function. [Allotrope]" ; + + skos:prefLabel "exponential calibration" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003695 + +af-p:AFP_0003695 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003706 ; + + rdfs:isDefinedBy ; + + skos:definition "A polynomial calibration is an analyte calibration that applies curve fitting of the calibration curve to a polynomial function. [Allotrope]" ; + + skos:prefLabel "polynomial calibration" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003700 + +af-p:AFP_0003700 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0002294 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000544 ; + owl:someValuesFrom af-r:AFR_0000951 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "duration measurement" , + "duration measuring" , + "time measuring" ; + + skos:definition "A time measurement is a measurement of the duration of some process which is a quantification of the magnitude of the time region between the start and the end of the process in relation to some recurring process involving a clock. [Allotrope]" ; + + skos:prefLabel "time measurement" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003701 + +af-p:AFP_0003701 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000144 ; + + rdfs:isDefinedBy ; + + skos:altLabel "reference profile" ; + + skos:definition "A calibration reference profile is a process profile with a known, repeatable temporal pattern, that is a reference for calibration of a time or rate measurement device. [Allotrope]" ; + + skos:prefLabel "calibration reference profile" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003703 + +af-p:AFP_0003703 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003486 ; + + rdfs:isDefinedBy ; + + skos:altLabel "adjustment" ; + + skos:definition "Adjusting is a process of slightly changing something with the purpose to achieve an agreement with a set of specifications. [Allotrope]" ; + + skos:prefLabel "adjusting" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003704 + +af-p:AFP_0003704 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003275 , + obi:_0000011 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000546 ; + owl:someValuesFrom [ owl:intersectionOf ( af-m:AFM_0000275 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000087 ; + owl:someValuesFrom af-rl:AFRL_0000411 + ] + ) ; + rdf:type owl:Class + ] + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "standard processing" ; + + skos:definition "A sample preparation process is a planned process that prepares a portion of material for being used in a calibration standard role. [Allotrope]" ; + + skos:prefLabel "standard preparation" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003706 + +af-p:AFP_0003706 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003315 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000544 ; + owl:someValuesFrom af-r:AFR_0000788 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "calibration" ; + + skos:definition "Analyte calibration is producing a calibration curve from measurements of known amounts of analyte that will be used as measurement function for the measurement of unknown amounts of analytes. [Allotrope]" ; + + skos:prefLabel "analyte calibration" ; + + skos:scopeNote "This is not to be confused with calibration [AFP_0002389], which is the calibration of a measurement device. [Allotrope]" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003710 + +af-p:AFP_0003710 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003335 ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:altLabel "mass analysis" , + "mass selection" ; + + skos:definition "Ion selection is dividing ions according to their mass to charge ratio in a mass analyzer. [Allotrope]" ; + + skos:prefLabel "ion selection" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003711 + +af-p:AFP_0003711 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000015 ; + + dct:license ; + + dct:rights ; + + rdfs:isDefinedBy ; + + skos:altLabel "2020-12-11 Changed labels. [Allotrope]" , + "chemical reaction" , + "reaction" ; + + skos:definition "A chemical reaction is a process that results in the interconversion of chemical species. [IUPAC]" ; + + skos:prefLabel "chemical reaction (molecular)" ; + + skos:scopeNote "Chemical reactions may be elementary reactions or stepwise reactions. (It should be noted that this definition includes experimentally observable interconversions of conformers.) Detectable chemical reactions normally involve sets of molecular entities as indicated by this definition, but it is often conceptually convenient to use the term also for changes involving single molecular entities (i.e. 'microscopic chemical events'). [IUPAC]" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003712 + +af-p:AFP_0003712 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( af-p:AFP_0003711 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000057 ; + owl:someValuesFrom af-m:AFM_0000077 + ] + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "An ion reaction is a chemical reaction that has ion participants. [Allotrope]" ; + + skos:prefLabel "ion reaction" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003713 + +af-p:AFP_0003713 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003598 ; + + rdfs:isDefinedBy ; + + skos:altLabel "LC/MS reaction monitoring data processing" ; + + skos:definition "LC-MS reaction monitoring data processing is a data processing for analyzing samples using MRM technologies. [Allotrope]" ; + + skos:prefLabel "LC-MS reaction monitoring data processing" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003715 + +af-p:AFP_0003715 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003289 ; + + rdfs:isDefinedBy ; + + skos:definition "Constant pressure mobile phase delivery is a mobile phase delivery process whereby the mobile phase is delivered by maintaining a constant pressure of the mobile phase. [Allotrope]" ; + + skos:prefLabel "constant pressure mobile phase delivery" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003716 + +af-p:AFP_0003716 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003275 , + [ owl:intersectionOf ( af-p:AFP_0003475 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000395 ; + owl:someValuesFrom af-m:AFM_0000275 + ] + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000399 ; + owl:someValuesFrom af-m:AFM_0000275 + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "material combination" ; + + skos:definition "Combining material is a combing process that combines two or more materials in to a new material. [Allotrope]" ; + + skos:prefLabel "combining material" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003717 + +af-p:AFP_0003717 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003282 ; + + rdfs:isDefinedBy ; + + skos:altLabel "interpolation" ; + + skos:definition "Interpolation is a calculation that calculates a calculated measure from a primary measure by applying a measurement function that is derived from a calibration curve. [Allotrope]" ; + + skos:prefLabel "interpolation (calibration)" ; + + skos:scopeNote "The measurement function of a calibration curve can be got by curve fitting a function to a set of calibration points. Applying the function at abscissa coordinates that are part of the discrete calibration points, can be interpreted as interpolation. [Allotrope]" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003719 + +af-p:AFP_0003719 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003566 ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:definition "Nebulizing is converting by of breaking up solutions and suspensions into small aerosol droplets. [Wikipedia]" ; + + skos:prefLabel "nebulizing" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003721 + +af-p:AFP_0003721 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003598 ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:definition "Background correction is a data transformation designed to remove irrelevant contributions from the measured signal, e.g. those due to instrument noise or sample preparation. [BAO]" ; + + skos:prefLabel "background correction" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003722 + +af-p:AFP_0003722 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003598 ; + + af-x:AFX_0002808 ; + + rdfs:isDefinedBy ; + + skos:definition "Data extraction is a data transformation process whereby specific data is taken out of a larger set of data and presented in a usable format. [Allotrope]" ; + + skos:prefLabel "data extraction" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003725 + +af-p:AFP_0003725 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003726 ; + + rdfs:isDefinedBy ; + + skos:altLabel "HPLC system process" ; + + skos:definition "A high performance liquid chromatography system process is a process that is executed on a high performance liquid chromatography system. [Allotrope]" ; + + skos:prefLabel "high performance liquid chromatography system process" ; + + skos:scopeNote "The process is the technical implementation process on the HPLC system that implements the separation by HPLC. [Allotrope]" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003726 + +af-p:AFP_0003726 rdf:type owl:Class ; + + rdfs:subClassOf [ owl:intersectionOf ( obi:_0000011 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000057 ; + owl:someValuesFrom [ rdf:type owl:Class ; + owl:unionOf ( af-e:AFE_0000074 + af-e:AFE_0000354 + ) + ] + ] + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "instrument process" ; + + skos:definition "A device process is a planned process that realizes a function by a device or device system. [Allotrope]" ; + + skos:prefLabel "device process" ; + + skos:scopeNote "A device process focuses on an implementation perspective." . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003727 + +af-p:AFP_0003727 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000015 ; + + rdfs:isDefinedBy ; + + skos:altLabel "repetition" ; + + skos:definition "A repeated process is a composite process that has occurrent parts of subprocesses following the same plan. [Allotrope]" ; + + skos:prefLabel "repeated process" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003729 + +af-p:AFP_0003729 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0000307 , + af-p:AFP_0003315 , + obi:_0000011 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000544 ; + owl:someValuesFrom iao:_0000088 + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "Reporting is an information process that produces a report. [Allotrope]" ; + + skos:prefLabel "reporting" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003730 + +af-p:AFP_0003730 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003620 , + obi:_0000011 ; + + af-x:AFX_0002808 ; + + rdfs:isDefinedBy ; + + skos:definition "A project is a planned process that is undertaken or attempted to meet some requirement. [Allotrope]" ; + + skos:prefLabel "project" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003735 + +af-p:AFP_0003735 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003315 , + obi:_0000011 ; + + af-x:AFX_0002808 ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:definition "An experiment is a planned process that has the goal of verifying, falsifying, or establishing the validity of a hypothesis. [SIO]" ; + + skos:prefLabel "experiment" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003736 + +af-p:AFP_0003736 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003737 ; + + rdfs:isDefinedBy ; + + skos:definition "A thermal event is an event where a significant change of some material quality occurs at a temperature of that material or that of its environment. [Allotrope]" ; + + skos:prefLabel "thermal event" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003737 + +af-p:AFP_0003737 rdf:type owl:Class ; + + owl:equivalentClass [ rdf:type owl:Class ; + owl:unionOf ( af-p:AFP_0003370 + af-p:AFP_0003371 + ) + ] ; + + rdfs:subClassOf bfo:_0000015 ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "An event is an occurrent that is an accomplishment or an achievement. [Allotrope]" ; + + skos:prefLabel "event" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003738 + +af-p:AFP_0003738 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0001916 ; + + rdfs:isDefinedBy ; + + skos:definition "A precipitation titration is a titration in which the analyte is precipitated by the titrant. [Allotrope]" ; + + skos:prefLabel "precipitation titration" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003739 + +af-p:AFP_0003739 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003331 ; + + rdfs:isDefinedBy ; + + skos:definition "Preventative maintenance is a proactive maintenance of a device involving inspection, testing and preemptive replacement of parts likely to fail before the preventative maintenance activity. [Allotrope]" ; + + skos:prefLabel "preventative maintenance" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003740 + +af-p:AFP_0003740 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0002800 ; + + rdfs:isDefinedBy ; + + skos:definition "Titrant standardization is the accurate and precise determination of the concentration of a titrant. [Allotrope]" ; + + skos:prefLabel "titrant standardization" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003741 + +af-p:AFP_0003741 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003454 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0002012 ; + owl:someValuesFrom af-p:AFP_0003743 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "addition rate profile" ; + + skos:definition "An addition rate process profile is a rate process profile that is an occurrent part of an material addition process. [Allotrope]" ; + + skos:prefLabel "addition rate process profile" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003742 + +af-p:AFP_0003742 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003281 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002682 ; + owl:someValuesFrom pato:_0000918 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "volume profile" ; + + skos:definition "A volume process profile is a quality process profile that tracks some volume. [Allotrope]" ; + + skos:prefLabel "volume process profile" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003743 + +af-p:AFP_0003743 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0000708 , + af-p:AFP_0003475 ; + + rdfs:isDefinedBy ; + + skos:altLabel "adding" , + "addition" , + "addition (material)" , + "material addition" ; + + skos:definition "Adding is loading material into a container where it is combined with existing material. [Allotrope]" ; + + skos:prefLabel "adding (material)" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003744 + +af-p:AFP_0003744 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003454 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0002012 ; + owl:someValuesFrom af-p:AFP_0003469 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "flow rate profile" ; + + skos:definition "A material flow rate process profile is a rate process profile that is the change of amount of material being transferred through an area. [Allotrope]" ; + + skos:prefLabel "material flow rate process profile" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003745 + +af-p:AFP_0003745 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003457 ; + + rdfs:isDefinedBy ; + + skos:altLabel "is covered" ; + + skos:definition "Covered state is a connected state where something is located on the surface of another thing and prevents some kind of material or energy flow through that surface. [Allotrope]" ; + + skos:prefLabel "covered state" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003746 + +af-p:AFP_0003746 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003357 ; + + rdfs:isDefinedBy ; + + skos:definition "Covering is a joining process where the joining is on to the surface in such way that it is preventing some kind of material or energy flow through that surface. [Allotrope]" ; + + skos:prefLabel "covering" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003747 + +af-p:AFP_0003747 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0001109 ; + + rdfs:isDefinedBy ; + + skos:altLabel "SQDMS" ; + + skos:definition "Single quadrupole mass spectrometry is a quadrupole mass spectrometry using a single quadrupole mass analyzer. [Allotrope]" ; + + skos:prefLabel "single quadrupole mass spectrometry" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003748 + +af-p:AFP_0003748 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003289 ; + + rdfs:isDefinedBy ; + + skos:definition "Constant flow rate mobile phase delivery is a mobile phase delivery process whereby the mobile phase is delivered by maintaining a constant flow rate of the mobile phase. [Allotrope]" ; + + skos:prefLabel "constant flow rate mobile phase delivery" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003749 + +af-p:AFP_0003749 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0001698 ; + + rdfs:isDefinedBy ; + + skos:definition "Overhead stirring is stirring that is achieved by rotating a stirring rod with a paddle, anchor or propeller end by an overhead motor in a solution. [Allotrope]" ; + + skos:prefLabel "overhead stirring" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003750 + +af-p:AFP_0003750 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003455 ; + + rdfs:isDefinedBy ; + + skos:definition "A stirring rate process profile is a cyclic rate process profile of the changing rotation speed of the stirrer in the liquid. [Allotrope]" ; + + skos:prefLabel "stirring rate process profile" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003751 + +af-p:AFP_0003751 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003454 ; + + rdfs:isDefinedBy ; + + skos:altLabel "heat transfer coefficient profile" ; + + skos:definition "A heat transfer coefficient process profile is a rate process profile of the ratio of the heat flux and the thermodynamic driving force for the flow of heat. [Allotrope]" ; + + skos:prefLabel "heat transfer coefficient process profile" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003752 + +af-p:AFP_0003752 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003281 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002682 ; + owl:someValuesFrom pato:_0001413 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "angular velocity profile" ; + + skos:definition "An angular velocity process profile is a quality process profile of how fast an object rotates or revolves relative to another point. [Wikipedia]" ; + + skos:prefLabel "angular velocity process profile" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003753 + +af-p:AFP_0003753 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003281 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002682 ; + owl:someValuesFrom pato:_0001323 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "area profile" ; + + skos:definition "A volume process profile is a quality process profile that tracks some area. [Allotrope]" ; + + skos:prefLabel "area process profile" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003755 + +af-p:AFP_0003755 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003454 ; + + rdfs:isDefinedBy ; + + skos:altLabel "cooling rate process profile" , + "cooling rate profile" , + "heating (cooling) rate process profile" , + "heating (cooling) rate profile" , + "heating or cooling rate profile" , + "heating rate process profile" , + "heating rate profile" ; + + skos:definition "A heating or cooling rate process profile is a rate process profile of the heating/cooling rate of an object. [Allotrope]" ; + + skos:prefLabel "heating or cooling rate process profile" ; + + skos:scopeNote "The temperature process profile tracks the temperature change. This tracks the change of the change in temperature (2nd derivative)." . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003757 + +af-p:AFP_0003757 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003374 ; + + rdfs:isDefinedBy ; + + skos:definition "An approval state is a state where information content such as a specification is allowed or is suitable by an authority for a purpose or in a context. [Allotrope]" ; + + skos:prefLabel "approval state" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003758 + +af-p:AFP_0003758 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003757 ; + + rdfs:isDefinedBy ; + + skos:altLabel "approved" , + "approved state" ; + + skos:definition "Is approved is an approval state where information content such as a specification is approved by an authority for a purpose or in a context. [Allotrope]" ; + + skos:prefLabel "is approved" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003759 + +af-p:AFP_0003759 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003757 ; + + rdfs:isDefinedBy ; + + skos:altLabel "denied" , + "denied state" ; + + skos:definition "Is denied is an approval state where information content such as a specification is denied by an authority for a purpose or in a context. [Allotrope]" ; + + skos:prefLabel "is denied" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003761 + +af-p:AFP_0003761 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0002294 ; + + rdfs:isDefinedBy ; + + skos:definition "A BET analysis is a measuring process for calculating surface area based on the Brunauer–Emmett–Teller (BET) theory of multiple adsorption layers. [Allotrope]" ; + + skos:prefLabel "BET analysis" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003762 + +af-p:AFP_0003762 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0002294 ; + + rdfs:isDefinedBy ; + + skos:definition "Nephelometry is a measuring of suspended particulates in a liquid or gas colloid usually by employing a light beam (source beam) and a light detector set to one side (often 90°) of the source beam. [Allotrope]" ; + + skos:prefLabel "nephelometry" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003763 + +af-p:AFP_0003763 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0002124 , + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000132 ; + owl:someValuesFrom af-p:AFP_0002124 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "DSC cycle" , + "cycle for DSC" ; + + skos:definition "A cycle in differential scanning calorimetry is a segment of the calorimetry run with its own specific heating ramp. [Allotrope]" ; + + skos:prefLabel "differential scanning calorimetry cycle" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003764 + +af-p:AFP_0003764 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003374 , + [ rdf:type owl:Class ; + owl:unionOf ( af-p:AFP_0003396 + af-p:AFP_0003449 + ) + ] ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:definition "Hygroscopy is the phenomenon of attracting and holding water molecules via either absorption or adsorption from the surrounding environment. [Wikipedia]" ; + + skos:prefLabel "hygroscopy" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003765 + +af-p:AFP_0003765 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0002294 ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:altLabel "DVS" ; + + skos:definition "Dynamic vapor sorption is a gravimetric technique that measures how quickly and how much of a solvent is absorbed by a sample. It does this by varying the vapor concentration surrounding the sample and measuring the change in mass which this produces. [Wikipedia]" ; + + skos:prefLabel "dynamic vapor sorption" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003766 + +af-p:AFP_0003766 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0002294 ; + + rdfs:isDefinedBy ; + + skos:altLabel "electrolytic conductivity detection" ; + + skos:definition "An electrolytic conductivity measurement is a measurement of the electrolytic conductivity of a material. [Allotrope]" ; + + skos:prefLabel "electrolytic conductivity measurement" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003767 + +af-p:AFP_0003767 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0000326 , + af-p:AFP_0001185 ; + + rdfs:isDefinedBy ; + + skos:altLabel "qNMR" ; + + skos:definition "Quantitative NMR spectroscopy is an analytic assay that applies nuclear magnetic resonance spectroscopy for quantity analysis. [Allotrope]" ; + + skos:prefLabel "quantitative nuclear magnetic resonance spectroscopy" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003769 + +af-p:AFP_0003769 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0001185 ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:altLabel "qPCR" , + "real-time PCR" , + "real-time polymerase chain reaction" ; + + skos:definition "Quantitative polymerase chain reaction (qPCR) is a quantitative analytical assay based on the polymerase chain reaction (PCR). It monitors the amplification of a targeted DNA molecule during the PCR. [Allotrope]" ; + + skos:prefLabel "quantitative polymerase chain reaction" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003770 + +af-p:AFP_0003770 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0001348 ; + + dct:license ; + + dct:rights ; + + dct:source , + "PAC, 1997, 69, 1251. (Glossary of terms used in bioinorganic chemistry (IUPAC Recommendations 1997))" ; + + rdfs:isDefinedBy ; + + skos:altLabel "PCR" ; + + skos:definition "Polymerase chain reaction is a synthesis to rapidly amplify pre-determined regions of double-stranded DNA. Generally involves the use of a heat-stable DNA polymerase. [IUPAC]" ; + + skos:prefLabel "polymerase chain reaction" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003771 + +af-p:AFP_0003771 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003566 ; + + rdfs:isDefinedBy ; + + skos:altLabel "coloring" ; + + skos:definition "Dyeing is the changing of the color of some material. [Allotrope]" ; + + skos:prefLabel "dyeing" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003772 + +af-p:AFP_0003772 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003598 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000544 ; + owl:someValuesFrom af-r:AFR_0001219 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "Baseline determination is a data transformation that calculates or assigns a baseline to a curve. [Allotrope]" ; + + skos:prefLabel "baseline determination" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003774 + +af-p:AFP_0003774 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0000307 , + af-p:AFP_0003315 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000544 ; + owl:someValuesFrom iao:_0000101 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "Imaging is a process that produces an image of something. [Allotrope]" ; + + skos:prefLabel "imaging" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003775 + +af-p:AFP_0003775 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003784 ; + + rdfs:isDefinedBy ; + + skos:altLabel "standard curve" , + "standard curve experiment" ; + + skos:definition "A standard curve qPCR experiment is an experiment using qPCR that measures prepared samples and standards to determine absolute DNA target quantity in samples. [Allotrope]" ; + + skos:prefLabel "standard curve qPCR experiment" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003776 + +af-p:AFP_0003776 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003784 ; + + rdfs:isDefinedBy ; + + skos:altLabel "relative standard curve" , + "relative standard curve experiment" ; + + skos:definition "A relative standard curve qPCR experiment is an experiment using qPCR that measures relative quantity by comparison of diluted samples and known target DNA. [Allotrope]" ; + + skos:prefLabel "relative standard curve qPCR experiment" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003777 + +af-p:AFP_0003777 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003784 ; + + rdfs:isDefinedBy ; + + skos:altLabel "comparative CT experiment" , + "comparative cycle threshold qPCR experiment" , + "∆∆CT" ; + + skos:definition "A comparative CT experiment is an experiment using qPCR that determines relative target quantity in samples. Samples are compared to a normalized target quantity to determine relative quantity of the sample. [Allotrope]" ; + + skos:prefLabel "comparative CT qPCR experiment" ; + + skos:scopeNote "comparative CT" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003778 + +af-p:AFP_0003778 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003784 ; + + rdfs:isDefinedBy ; + + skos:altLabel "melt curve" , + "melt curve experiment" ; + + skos:definition "A melt curve qPCR experiment is an experiment using qPCR that identifies non-specific PCR amplification by evaluating the melting temperature of the DNA target. [Allotrope]" ; + + skos:prefLabel "melt curve qPCR experiment" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003779 + +af-p:AFP_0003779 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003784 ; + + rdfs:isDefinedBy ; + + skos:altLabel "genotyping" , + "genotyping experiment" ; + + skos:definition "A genotyping qPCR experiment is an experiment using qPCR that identifies known mutations in a DNA Sample. DNA primers are used to target and identify specific alleles in a sample. [Allotrope]" ; + + skos:prefLabel "genotyping qPCR experiment" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003780 + +af-p:AFP_0003780 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003784 ; + + rdfs:isDefinedBy ; + + skos:altLabel "presence/absence" , + "presence/absence experiment" ; + + skos:definition "A presence/absence qPCR experiment is an experiment using qPCR that identifies if DNA targets are present in samples. [Allotrope]" ; + + skos:prefLabel "presence/absence qPCR experiment" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003781 + +af-p:AFP_0003781 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0001666 . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003782 + +af-p:AFP_0003782 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003781 ; + + af-x:AFX_0002808 ; + + rdfs:isDefinedBy ; + + skos:definition "A bulk density obtained by mechanically tapping a cylinder containing the powder sample until no more change in volume occurs. [NCI]" ; + + skos:prefLabel "powder tap density" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003783 + +af-p:AFP_0003783 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003781 ; + + af-x:AFX_0002808 ; + + rdfs:isDefinedBy ; + + skos:definition "A bulk density for untapped powder sample. [Allotrope]" ; + + skos:prefLabel "powder bulk density" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003784 + +af-p:AFP_0003784 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003735 ; + + rdfs:isDefinedBy ; + + skos:definition "A qPCR experiment is an experiment that uses qPCR to achieve its goals. [Allotrope]" ; + + skos:prefLabel "qPCR experiment" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003785 + +af-p:AFP_0003785 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003473 ; + + rdfs:isDefinedBy ; + + skos:altLabel "evacuating" ; + + skos:definition "Evacuating is the removing of gasses from a container to create a vacuum. [Allotrope]" ; + + skos:prefLabel "evacuating (chem)" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003787 + +af-p:AFP_0003787 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0000780 ; + + rdfs:isDefinedBy ; + + skos:altLabel "NIR" , + "NIR spectrometry" , + "NIR spectrophotometry" , + "NIR spectroscopy" , + "NIR transmission spectrometry" , + "NIR transmission spectroscopy" , + "near infra-red spectrometry" , + "near infra-red spectrophotometry" , + "near infra-red transmission spectrometry" , + "near infra-red transmission spectroscopy" , + "near infrared (NIR) spectroscopy" , + "near infrared spectrometry" , + "near infrared spectrophotometry" , + "near infrared spectroscopy" , + "near infrared transmission spectrometry" ; + + skos:definition "Near infrared transmission spectroscopy is a type of vibrational spectroscopy where the transmission of near infrared radiation (0.8-2 µm) through a sample is detected. [CHMO]" ; + + skos:prefLabel "near infrared transmission spectroscopy" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003788 + +af-p:AFP_0003788 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0002294 ; + + rdfs:isDefinedBy ; + + skos:altLabel "FBRM" , + "fbrm" ; + + skos:definition "Focused beam reflectance measurement is a measuring process using a focused laser beam at a fixed speed of rotation to calculate particle chord lengths via detection of the backscattered light pulses. [Allotrope]" ; + + skos:prefLabel "focused beam reflectance measurement" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003795 + +af-p:AFP_0003795 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003454 ; + + rdfs:isDefinedBy ; + + skos:definition "A heat flow process profile is a rate process profile that is the change in heat flow through a material entity. [Allotrope]" ; + + skos:prefLabel "heat flow process profile" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003796 + +af-p:AFP_0003796 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003281 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002682 ; + owl:someValuesFrom pato:_0000125 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "mass profile" ; + + skos:definition "A mass process profile is a quality process profile that tracks some mass. [Allotrope]" ; + + skos:prefLabel "mass process profile" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003797 + +af-p:AFP_0003797 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003281 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002682 ; + owl:someValuesFrom pato:_0000033 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "concentration profile" ; + + skos:definition "A concentration process profile is a quality process profile that tracks some concentration. [Allotrope]" ; + + skos:prefLabel "concentration process profile" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003798 + +af-p:AFP_0003798 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003281 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002682 ; + owl:someValuesFrom pato:_0001842 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "pH profile" ; + + skos:definition "A pH process profile is a quality process profile that tracks some pH. [Allotrope]" ; + + skos:prefLabel "pH process profile" . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003801 + +af-p:AFP_0003801 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003281 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002682 ; + owl:someValuesFrom af-q:AFQ_0000036 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A configuration process profile is a quality process profile that tracks the configuration of a system or device. [Allotrope]" ; + + skos:prefLabel "configuration process profile" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000005 + +af-q:AFQ_0000005 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000145 ; + + af-x:AFX_0002811 af-x:AFX_0000245 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "factor" , + "fraction" , + "proportion" , + "relative amount" ; + + skos:definition "A ratio is a relational quality that is the proportion of the magnitude of two qualities of the same kind. [Allotrope]" ; + + skos:prefLabel "ratio" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000014 + +af-q:AFQ_0000014 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( af-q:AFQ_0000020 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000080 ; + owl:someValuesFrom af-e:AFE_0000217 + ] + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + af-x:AFX_0002811 af-x:AFX_0000904 ; + + rdfs:isDefinedBy ; + + skos:altLabel "chromatography column length" ; + + skos:changeNote "2020-06-22 Changed labels. [Allotrope]" ; + + skos:definition "The length of a chromatography column bed. [Allotrope]" ; + + skos:prefLabel "chromatography column length (quality)" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000016 + +af-q:AFQ_0000016 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( af-q:AFQ_0000018 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000080 ; + owl:someValuesFrom af-e:AFE_0000217 + ] + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "column inner diameter" , + "dc" , + "inner diameter" ; + + skos:changeNote "2020-06-22 Changed labels and definition. [Allotrope]" ; + + skos:definition "Column inner diameter is the inner diameter of a column. [Allotrope]" ; + + skos:prefLabel "column inner diameter (quality)" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000018 + +af-q:AFQ_0000018 rdf:type owl:Class ; + + rdfs:subClassOf pato:_0001334 ; + + af-x:AFX_0002811 af-x:AFX_0000916 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "inner diameter" ; + + skos:changeNote "2020-06-22 Changed definition. [Allotrope]" , + "2020-06-22 Changed labels. [Allotrope]" ; + + skos:definition "The inner diameter is the diameter at the inside. [Allotrope]" ; + + skos:example "opening of the soller slit" ; + + skos:prefLabel "inner diameter (quality)" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000019 + +af-q:AFQ_0000019 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000005 ; + + af-x:AFX_0002811 af-x:AFX_0001180 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + dct:source "Orange Book: IUPAC Compendium of Analytical Nomenclature. Second Edition, Blackwell Scientific Publications, Oxford, 1987." , + "PAC, 1993, 65, 819. Nomenclature for chromatography (IUPAC Recommendations 1993)" ; + + rdfs:isDefinedBy ; + + skos:altLabel "relative retention" , + "relative retention time" ; + + skos:definition "Relative retention time is a ratio quality of the adjusted or net retention time of a component relative to that of a standard, obtained under identical conditions. [Allotrope]" ; + + skos:prefLabel "relative retention time (quality)" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000020 + +af-q:AFQ_0000020 rdf:type owl:Class ; + + rdfs:subClassOf pato:_0000122 ; + + af-x:AFX_0002811 af-x:AFX_0002676 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy , + ; + + skos:changeNote "2020-06-22 Changed labels. [Allotrope]" ; + + skos:definition "Quality of a material entity of cylindrical or tubular shape which describes its length along its main (non-circular) dimension. [Allotrope]" ; + + skos:prefLabel "cylinder length" , + "cylinder length (quality)" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000026 + +af-q:AFQ_0000026 rdf:type owl:Class ; + + rdfs:subClassOf pato:_0000117 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000080 ; + owl:someValuesFrom af-m:AFM_0000435 + ] ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "granularity (material)" , + "particle size" ; + + skos:changeNote "2020-06-22 Changed labels. [Allotrope]" , + "2020-12-07 Moved to AFO. [Allotrope]" ; + + skos:definition "Quality of an independent continuant which describes the dimensions of an individual particle. [Allotrope]" ; + + skos:prefLabel "particle size (quality)" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000029 + +af-q:AFQ_0000029 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000199 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000080 ; + owl:someValuesFrom af-e:AFE_0000317 + ] ; + + af-x:AFX_0002808 af-x:AFX_0000027 ; + + rdfs:isDefinedBy ; + + skos:definition "A detection wavelength quality is a device setting which determines the wavelength range that a detector of electromagnetic radiation detects. [Allotrope]" ; + + skos:prefLabel "detection wavelength" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000032 + +af-q:AFQ_0000032 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000145 ; + + af-x:AFX_0002808 pato:_0000040 ; + + rdfs:isDefinedBy ; + + skos:definition "A quality that is the extent of space between two entities. [PATO]" ; + + skos:prefLabel "distance" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000036 + +af-q:AFQ_0000036 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000019 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000080 ; + owl:someValuesFrom [ rdf:type owl:Class ; + owl:unionOf ( af-e:AFE_0000354 + ro:_0002577 + ) + ] + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "configuration" , + "device configuration" , + "device setting" , + "setting" , + "system setting" ; + + skos:changeNote "2018-12-05 Changed pref label [Allotrope]" , + "2020-03-24 Generalized configuration quality to include systems. [Allotrope]" ; + + skos:definition "A configuration is a range of determinate quality or combination of qualities that are present in some part of a device or system that influence participants in some of the functions of the device or system including the device or system itself. [Allotrope]" ; + + skos:example "detector wavelength is a device configuration of a specific detector assembly, e.g. optical filters or of a controller in the detector to detect certain ranges of wavelength of the electromagnetic spectrum" ; + + skos:prefLabel "system configuration" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000042 + +af-q:AFQ_0000042 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000056 ; + + rdfs:isDefinedBy ; + + skos:definition "Quality of a bearer which describes the bearer's efficiency in terms of useful output energy. [Allotrope]" ; + + skos:prefLabel "heat rate" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000043 + +af-q:AFQ_0000043 rdf:type owl:Class ; + + rdfs:subClassOf pato:_0002242 ; + + rdfs:isDefinedBy ; + + skos:altLabel "linear velocity" ; + + skos:changeNote "2020-06-22 Changed labels. [Allotrope]" ; + + skos:definition "Quality of velocity inhering in a bearer which is traveling in a straight line, meaning its direction is not changing. [Allotrope]" ; + + skos:prefLabel "linear velocity (quality)" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000045 + +af-q:AFQ_0000045 rdf:type owl:Class ; + + rdfs:subClassOf pato:_0001035 ; + + rdfs:isDefinedBy ; + + skos:definition "A physical quality that inheres in a bearer by virtue of its rotational force. [Allotrope]" ; + + skos:prefLabel "torque" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000048 + +af-q:AFQ_0000048 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000065 ; + + rdfs:isDefinedBy ; + + skos:altLabel "voltage" ; + + skos:changeNote "2019-09-20 Changed pref label for uniqueness. [Allotrope]" ; + + skos:definition "A quality which inheres in an independent continuant which has a difference in electric potential energy between two points per unit electric charge. [Wikipedia]" ; + + skos:prefLabel "voltage (quality)" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000049 + +af-q:AFQ_0000049 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000065 ; + + rdfs:isDefinedBy ; + + skos:altLabel "current" , + "current (quality)" , + "electric current" ; + + skos:changeNote "2019-09-20 Changed pref label for uniqueness. [Allotrope]" , + "2020-07-27 Changed pref label. [Allotrope]" ; + + skos:definition "A quality inhering in a bearer by virtue of the bearer's ability to conduct an electrical charge. [Allotrope]" ; + + skos:prefLabel "electric current (quality)" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000056 + +af-q:AFQ_0000056 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000019 ; + + rdfs:isDefinedBy ; + + skos:definition "A physical quality that inheres in a bearer by virtue of its material properties pertaining to temperature. [Allotrope]" ; + + skos:prefLabel "thermal quality" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000057 + +af-q:AFQ_0000057 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000056 , + pato:_0001585 ; + + af-x:AFX_0002808 , + pato:_0001756 ; + + rdfs:isDefinedBy ; + + skos:altLabel "thermal conductivity" ; + + skos:definition "A conductivity quality inhering in a bearer by virtue of the bearer's disposition to spontaneous transfer of thermal energy from a region of higher temperature to a region of lower temperature. [Wikipedia]" ; + + skos:prefLabel "thermal conductivity (quality)" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000058 + +af-q:AFQ_0000058 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000056 ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:altLabel "heat capacity" , + "thermal capacity" ; + + skos:changeNote "2020-03-23 Changed pref label and definition. [Allotrope]" ; + + skos:definition "Heat capacity is a thermal quality that inheres in a bearer by virtue of its resistance or ability to change its temperature based on a change to the heat added or removed from said object (ratio of head added or removed from an object to the resulting temperature change). [Wikipedia]" ; + + skos:prefLabel "heat capacity (quality)" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000059 + +af-q:AFQ_0000059 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000056 ; + + rdfs:isDefinedBy ; + + skos:definition "A physical quality that inheres in a bearer by virtue of its emissivity, which is defined as a material's effectiveness in emitting energy as thermal radiation. [Wikipedia]" ; + + skos:prefLabel "radiative emissivity" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000061 + +af-q:AFQ_0000061 rdf:type owl:Class ; + + rdfs:subClassOf pato:_0001300 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + dct:source "PAC, 1990, 62, 2167 (Glossary of atmospheric chemistry terms (Recommendations 1990))" , + "PAC, 1996, 68, 2223 (Glossary of terms used in photochemistry (IUPAC Recommendations 1996))" ; + + rdfs:isDefinedBy ; + + skos:altLabel "absorbance" ; + + skos:definition "Absorbance is the logarithm of the ratio of intensities of electromagnetic radiation on both sides of a medium that the radiation passes through. Lambert-Beer's law states that absorbance is equal to the product of molar coefficient of absorbance of an absorbing compound in a medium times its concentration in the medium times path length of the electromagnetic radiation passing through the medium. [Allotrope]" ; + + skos:prefLabel "absorbance (quality)" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000062 + +af-q:AFQ_0000062 rdf:type owl:Class ; + + rdfs:subClassOf pato:_0001300 ; + + rdfs:isDefinedBy ; + + skos:altLabel "focal distance" ; + + skos:definition "A physical quality that inheres in a bearer by virtue of how strongly the bearer converges or diverges light. [Wikipedia]" ; + + skos:prefLabel "focal length" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000064 + +af-q:AFQ_0000064 rdf:type owl:Class ; + + rdfs:subClassOf pato:_0001300 ; + + dct:license ; + + dct:rights ; + + dct:source "PAC, 2007, 79, 293 (Glossary of terms used in photochemistry, 3rd edition (IUPAC Recommendations 2006))" ; + + rdfs:isDefinedBy ; + + skos:altLabel "reflectance factor" , + "reflectivity" ; + + skos:definition "Reflectance is an optical quality that is the fraction of incident radiation reflected by a surface or discontinuity. [IUPAC]" ; + + skos:prefLabel "reflectance (quality)" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000065 + +af-q:AFQ_0000065 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000019 ; + + af-x:AFX_0002808 pato:_0001291 ; + + rdfs:isDefinedBy ; + + skos:altLabel "electromagnetic radiation quality" ; + + skos:definition "A physical quality that inheres in an bearer by virtue of how that bearer interacts with electromagnetic radiation. [Wikipedia]" ; + + skos:prefLabel "electrical and magnetic quality" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000067 + +af-q:AFQ_0000067 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000065 ; + + dct:license ; + + dct:rights ; + + dct:source , + "PAC, 1996, 68, 957. (Glossary of terms in quantities and units in Clinical Chemistry (IUPAC-IFCC Recommendations 1996))" ; + + rdfs:isDefinedBy ; + + skos:altLabel "electric resistance" , + "resistance" , + "resistance (quality)" ; + + skos:changeNote "2019-09-20 Changed pref label for uniqueness. [Allotrope]" , + "2020-01-23 Changed definition to IUPAC. [Allotrope]" ; + + skos:definition "Electric resistance is the quality inhered in a conductor that is the electric potential difference divided by the electric current when there is no electromotive force in the conductor. [IUPAC]" ; + + skos:prefLabel "electric resistance (quality)" ; + + skos:scopeNote "Quality of a object or substance with the property of resisting opposing the flow of an electrical current. [NCI]" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000111 + +af-q:AFQ_0000111 rdf:type owl:Class ; + + rdfs:subClassOf pato:_0000051 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "material state" ; + + skos:definition "A state of matter is a quality of material that is one of the distinct forms in which matter can exist. Four states of matter are observable in everyday life: solid, liquid, gas, and plasma. Many other states are known to exist only in extreme situations, such as Bose-Einstein condensates, neutron-degenerate matter, and quark-gluon plasma, which only occur in situations of extreme cold, extreme density, and extremely high-energy color-charged matter respectively. [Wikipedia]" ; + + skos:prefLabel "state of matter" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000112 + +af-q:AFQ_0000112 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000111 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "solid state of matter" ; + + skos:definition "A state of matter, in which particles are closely packed together. The forces between particles are strong so that the particles cannot move freely but can only vibrate. As a result, a solid has a stable, definite shape, and a definite volume. Solids can only change their shape by force, as when broken or cut. [Wikipedia]" ; + + skos:prefLabel "solid" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000113 + +af-q:AFQ_0000113 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000111 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "liquid state of matter" ; + + skos:definition "A state of matter that is a nearly incompressible fluid that conforms to the shape of its container but retains a (nearly) constant volume independent of pressure. [Wikipedia]" ; + + skos:prefLabel "liquid" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000114 + +af-q:AFQ_0000114 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000111 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "gaseous" , + "gaseous state of matter" ; + + skos:definition "A state of matter that is a compressible fluid. Not only will a gas conform to the shape of its container but it will also expand to fill the container. In a gas, the molecules have enough kinetic energy so that the effect of intermolecular forces is small (or zero for an ideal gas), and the typical distance between neighboring molecules is much greater than the molecular size. A gas has no definite shape or volume, but occupies the entire container in which it is confined. [Wikipedia]" ; + + skos:prefLabel "gas" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000115 + +af-q:AFQ_0000115 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000111 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "plasma state of matter" ; + + skos:definition "A physical quality that inheres in a bearer by virtue of its plasma is a state of matter, that is, it does not have definite shape or volume. Unlike gases, plasmas are electrically conductive, produce magnetic fields and electric currents, and respond strongly to electromagnetic forces. Positively charged nuclei swim in a \"sea\" of freely-moving disassociated electrons, similar to the way such charges exist in conductive metal. [Wikipedia]" ; + + skos:prefLabel "plasma" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000116 + +af-q:AFQ_0000116 rdf:type owl:Class ; + + rdfs:subClassOf [ owl:intersectionOf ( af-q:AFQ_0000005 + af-q:AFQ_0000210 + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:definition "Shear modulus is a ratio of shear stress to the shear strain. It is a quantity for measuring the stiffness of materials. The shear modulus is concerned with the deformation of a material. [Wikipedia]" ; + + skos:prefLabel "shear modulus" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000118 + +af-q:AFQ_0000118 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000116 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "zero shear modulus" ; + + skos:definition "A zero shear modulus is a determinate shear modulus with zero magnitude. [Allotrope]" ; + + skos:prefLabel "shear modulus of zero magnitude" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000119 + +af-q:AFQ_0000119 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000114 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "supercritical fluid state of matter" ; + + skos:definition "A gaseous state of matter in which temperature and pressure are above the critical temperature and critical pressure. In this state, the distinction between liquid and gas disappears. [Wikipedia]" ; + + skos:prefLabel "supercritical fluid" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000120 + +af-q:AFQ_0000120 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000112 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "gel state of matter" ; + + skos:definition "A gel is a solid state of matter of jelly-like material that can have properties ranging from soft and weak to hard and tough. Gels are defined as a substantially dilute cross-linked system, which exhibits no flow when in the steady-state. By weight, gels are mostly liquid, yet they behave like solids due to a three-dimensional cross-linked network within the liquid. [Wikipedia]" ; + + skos:prefLabel "gel" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000121 + +af-q:AFQ_0000121 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000026 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:changeNote "2020-12-07 Moved to AFO. [Allotrope]" ; + + skos:definition "A particle size above one micrometer is a determinate quality of particle size that has a determinate magnitude of greater that one micrometer. Magnitude of particle size can be measured in different ways such as based on diameter of spherical objects. [Allotrope]" ; + + skos:prefLabel "particle size above one micrometer" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000123 + +af-q:AFQ_0000123 rdf:type owl:Class ; + + rdfs:subClassOf pato:_0000125 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "Exact mass is a quality of mass of an isotopic species that is obtained by summing the masses of the individual isotopes of the molecule. [Wikipedia]" ; + + skos:prefLabel "exact mass" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000129 + +af-q:AFQ_0000129 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000056 ; + + rdfs:isDefinedBy ; + + skos:definition "Thermodynamic property of a real gas that, if substituted for the pressure or partial pressure in the equations for an ideal gas, gives equations applicable to the real gas. [Wikipedia]" ; + + skos:prefLabel "fugacity" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000138 + +af-q:AFQ_0000138 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000019 ; + + af-x:AFX_0002808 ; + + rdfs:isDefinedBy ; + + skos:definition "Property that inheres in an independent continuant having to do with sound or hearing. [NCI]" ; + + skos:prefLabel "acoustic quality" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000139 + +af-q:AFQ_0000139 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000138 ; + + rdfs:isDefinedBy ; + + skos:definition "Frequency response is the quantitative measure of the output spectrum of a system or device in response to a stimulus, and is used to characterize the dynamics of the system. It is a measure of magnitude and phase of the output as a function of frequency, in comparison to the input. [Wikipedia]" ; + + skos:prefLabel "frequency response" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000141 + +af-q:AFQ_0000141 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000138 ; + + af-x:AFX_0002809 ; + + rdfs:isDefinedBy ; + + skos:definition "An unintended or unpleasant sound that emanates from a device. [NCI]" ; + + skos:prefLabel "audible device noise" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000142 + +af-q:AFQ_0000142 rdf:type owl:Class ; + + rdfs:subClassOf pato:_0001300 ; + + rdfs:isDefinedBy ; + + skos:definition "A physical quality that inheres in a bearer by virtue of the geometrical orientation of the oscillations of a transverse wave. [Allotrope]" ; + + skos:prefLabel "polarization" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000144 + +af-q:AFQ_0000144 rdf:type owl:Class ; + + rdfs:subClassOf pato:_0001906 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + dct:source "D. Schulze: Powders and Bulk Solids, Springer-Verlag, Heidelberg (2008)." ; + + rdfs:isDefinedBy ; + + skos:definition "Flowability is the quality of material to move by flow. [Allotrope]" ; + + skos:prefLabel "flowability" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000145 + +af-q:AFQ_0000145 rdf:type owl:Class ; + + rdfs:subClassOf pato:_0001035 ; + + rdfs:isDefinedBy ; + + skos:definition "Friction is a quality of an object which is resisting the force the relative motion of solid surfaces, fluid layers, and material elements produce when sliding against each other. [Wikipedia]" ; + + skos:prefLabel "friction" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000149 + +af-q:AFQ_0000149 rdf:type owl:Class ; + + owl:equivalentClass [ rdf:type owl:Class ; + owl:unionOf ( af-q:AFQ_0000150 + af-q:AFQ_0000151 + af-q:AFQ_0000152 + ) + ] ; + + rdfs:subClassOf af-q:AFQ_0000036 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000080 ; + owl:someValuesFrom af-e:AFE_0000004 + ] ; + + af-x:AFX_0002811 af-p:AFP_0001138 ; + + rdfs:isDefinedBy ; + + skos:definition "Ionization polarity is a device configuration of a ionization source whether the ions charge is negative or positive. [Allotrope]" ; + + skos:prefLabel "ionization polarity" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000150 + +af-q:AFQ_0000150 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000149 ; + + af-x:AFX_0002811 af-p:AFP_0000055 ; + + rdfs:isDefinedBy ; + + skos:altLabel "negative polarity" ; + + skos:definition "Polarity of the ionization is negative. [Allotrope]" ; + + skos:prefLabel "negative ionization polarity" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000151 + +af-q:AFQ_0000151 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000149 ; + + af-x:AFX_0002811 af-p:AFP_0000585 ; + + rdfs:isDefinedBy ; + + skos:altLabel "positive polarity" ; + + skos:definition "Polarity of the ionization is positive. [Allotrope]" ; + + skos:prefLabel "positive ionization polarity" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000152 + +af-q:AFQ_0000152 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000149 ; + + af-x:AFX_0002811 af-p:AFP_0002512 ; + + rdfs:isDefinedBy ; + + skos:altLabel "alternating polarity" ; + + skos:definition "Polarity of the ionization is alternating between positive and negative. [Allotrope]" ; + + skos:prefLabel "alternating ionization polarity" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000166 + +af-q:AFQ_0000166 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000179 ; + + rdfs:isDefinedBy ; + + skos:definition "Amount of substance is a quality inhered in a portion of material that is a size that is proportional to the number of elementary entities present. [Allotrope]" ; + + skos:prefLabel "amount of substance" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000167 + +af-q:AFQ_0000167 rdf:type owl:Class ; + + rdfs:subClassOf pato:_0000033 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + dct:license ; + + dct:rights ; + + dct:source "Green Book, 2nd ed.: IUPAC Quantities, Units and Symbols in Physical Chemistry. Second Edition, Blackwell Scientific Publications, Oxford, 1993." , + "IUPAC, Compendium of Chemical Terminology, 2nd ed. (the \"Gold Book\") (1997). Online corrected version: (2006–) \"mass concentration\". doi:10.1351/goldbook.M03713" ; + + rdfs:isDefinedBy ; + + skos:altLabel "mass concentration" ; + + skos:changeNote "2018-12-17 Changed pref label. [Allotrope]" ; + + skos:definition "Mass concentration is a concentration that is defined as the mass of a constituent divided by the volume of the mixture. [IUPAC]" ; + + skos:prefLabel "mass concentration (quality)" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000168 + +af-q:AFQ_0000168 rdf:type owl:Class ; + + rdfs:subClassOf pato:_0000033 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + dct:source "Green Book, 2nd ed.: IUPAC Quantities, Units and Symbols in Physical Chemistry. Second Edition, Blackwell Scientific Publications, Oxford, 1993." ; + + rdfs:isDefinedBy ; + + skos:altLabel "amount concentration" , + "amount concentration (quality)" , + "amount of substance concentration" , + "molar concentration" , + "molarity" , + "molarity (quality)" , + "substance concentration" , + "substance concentration (quality)" ; + + skos:changeNote "2019-08-19 Changed pref label. [Allotrope]" , + "2020-05-11 Changed pref label to molar concentration. [Allotrope]" , + "2020-06-18 Added alt labels. [Allotrope]" ; + + skos:definition "Molar concentration is the ratio of molar amount of a substance divided by volume of mixture containing the amount of substance. [Allotrope]" ; + + skos:prefLabel "molar concentration (quality)" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000169 + +af-q:AFQ_0000169 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000172 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + dct:source "Green Book, 2nd ed.: IUPAC Quantities, Units and Symbols in Physical Chemistry. Second Edition, Blackwell Scientific Publications, Oxford, 1993." , + "PAC, 1996, 68, 957 (Glossary of terms in quantities and units in Clinical Chemistry (IUPAC-IFCC Recommendations 1996))" ; + + rdfs:isDefinedBy ; + + skos:altLabel "volume fraction" ; + + skos:changeNote "2020-06-22 Changed labels. [Allotrope]" ; + + skos:definition "The volume fraction is a fraction pertaining the volume of a constituent divided by the total volume of all constituents in the mixture. [Allotrope]" ; + + skos:prefLabel "volume fraction (quality)" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000170 + +af-q:AFQ_0000170 rdf:type owl:Class ; + + rdfs:subClassOf pato:_0000918 ; + + dct:license ; + + dct:rights ; + + dct:source "PAC, 1993, 65, 819 (Nomenclature for chromatography (IUPAC Recommendations 1993)) on page 841" ; + + rdfs:isDefinedBy ; + + skos:altLabel "dead volume" ; + + skos:definition "The hold-up volume is the volume of the mobile phase required to elute a component the concentration of which in the stationary phase is negligible compared to that in the mobile phase. In other words, this component is not retained at all by the stationary phase. Thus, the hold-up volume is equal to the retention volume of an unretained compound. [IUPAC]" ; + + skos:prefLabel "hold-up volume" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000172 + +af-q:AFQ_0000172 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000005 , + pato:_0000025 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + dct:source "Green Book, 2nd ed.: IUPAC Quantities, Units and Symbols in Physical Chemistry. Second Edition, Blackwell Scientific Publications, Oxford, 1993." ; + + rdfs:isDefinedBy ; + + skos:altLabel "fraction" ; + + skos:changeNote "2020-06-22 Changed labels. [Allotrope]" ; + + skos:definition "A fraction is the ratio of one constitutent (part) to all constituents of a mixture. [Allotrope]" ; + + skos:prefLabel "fraction (quality)" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000173 + +af-q:AFQ_0000173 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000172 ; + + dct:source "Green Book, 2nd ed.: IUPAC Quantities, Units and Symbols in Physical Chemistry. Second Edition, Blackwell Scientific Publications, Oxford, 1993." , + "PAC, 1996, 68, 957 (Glossary of terms in quantities and units in Clinical Chemistry (IUPAC-IFCC Recommendations 1996))" ; + + rdfs:isDefinedBy ; + + skos:altLabel "mass fraction" ; + + skos:changeNote "2020-06-22 Changed labels. [Allotrope]" ; + + skos:definition "The mass fraction is a fraction pertaining the mass of a constituent divided by the total mass of all constituents in the mixture. [Allotrope]" ; + + skos:prefLabel "mass fraction (quality)" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000174 + +af-q:AFQ_0000174 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000172 ; + + dct:source "Green Book, 2nd ed.: IUPAC Quantities, Units and Symbols in Physical Chemistry. Second Edition, Blackwell Scientific Publications, Oxford, 1993." , + "PAC, 1996, 68, 957 (Glossary of terms in quantities and units in Clinical Chemistry (IUPAC-IFCC Recommendations 1996))" ; + + rdfs:isDefinedBy ; + + skos:altLabel "amount fraction" , + "mole fraction" , + "mole fraction (quality)" ; + + skos:changeNote "2020-06-22 Changed labels. [Allotrope]" ; + + skos:definition "The amount fraction is the ratio of the amount of a constituent divided by the total amount of all constituents in the mixture. [Allotrope]" ; + + skos:prefLabel "amount fraction (quality)" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000175 + +af-q:AFQ_0000175 rdf:type owl:Class ; + + rdfs:subClassOf pato:_0000033 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + dct:source "Green Book, 2nd ed.: IUPAC Quantities, Units and Symbols in Physical Chemistry. Second Edition, Blackwell Scientific Publications, Oxford, 1993." ; + + rdfs:isDefinedBy ; + + skos:altLabel "volume concentration" ; + + skos:changeNote "2019-08-19 Changed pref label. [Allotrope]" ; + + skos:definition "Volume concentration is a concentration that is defined as the volume of a constituent divided by the volume of the mixture. [Allotrope]" ; + + skos:prefLabel "volume concentration (quality)" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000176 + +af-q:AFQ_0000176 rdf:type owl:Class ; + + rdfs:subClassOf pato:_0000033 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + dct:license ; + + dct:rights ; + + dct:source "Green Book, 2nd ed.: IUPAC Quantities, Units and Symbols in Physical Chemistry. Second Edition, Blackwell Scientific Publications, Oxford, 1993." , + "PAC, 1996, 68, 957 (Glossary of terms in quantities and units in Clinical Chemistry (IUPAC-IFCC Recommendations 1996))" ; + + rdfs:isDefinedBy ; + + skos:altLabel "number concentration" ; + + skos:changeNote "2019-08-19 Changed pref label. [Allotrope]" ; + + skos:definition "Number concentration is a concentration defined by number of entities of a constituent in a mixture divided by the volume of the mixture. [IUPAC]" ; + + skos:prefLabel "number concentration (quality)" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000177 + +af-q:AFQ_0000177 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000005 , + af-q:AFQ_0000224 ; + + af-x:AFX_0002808 af-x:AFX_0000443 ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:definition "The dilution ratio is the ratio of solute to solvent. [Wikipedia]" ; + + skos:prefLabel "dilution ratio" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000178 + +af-q:AFQ_0000178 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000005 , + af-q:AFQ_0000224 ; + + af-x:AFX_0002808 af-x:AFX_0000443 ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:altLabel "DF" ; + + skos:definition "Dilution factor is the ratio of the aliquot volume to the final volume. [Wikipedia]" ; + + skos:prefLabel "dilution factor" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000179 + +af-q:AFQ_0000179 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000019 ; + + rdfs:isDefinedBy ; + + skos:altLabel "count" , + "size" ; + + skos:definition "The amount is the quality of a whole that is the number of entities that are part of the whole. [Allotrope]" ; + + skos:prefLabel "amount" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000180 + +af-q:AFQ_0000180 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000019 ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:definition "Number density is a quality of the amount of countable objects per units size. [Allotrope]" ; + + skos:prefLabel "number density" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000181 + +af-q:AFQ_0000181 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000180 ; + + rdfs:isDefinedBy ; + + skos:definition "Cell density is the number density of a population of cells. [Allotrope]" ; + + skos:prefLabel "cell density" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000182 + +af-q:AFQ_0000182 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000181 ; + + rdfs:isDefinedBy ; + + skos:altLabel "viable cell density" ; + + skos:definition "Viable cell count is the cell density of the partition of viable cells. [Allotrope]" ; + + skos:prefLabel "viable cell density (quality)" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000183 + +af-q:AFQ_0000183 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000181 ; + + rdfs:isDefinedBy ; + + skos:altLabel "total cell density" ; + + skos:definition "Total cell density is the cell density of the total partition of cells. [Allotrope]" ; + + skos:prefLabel "total cell density (quality)" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000184 + +af-q:AFQ_0000184 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000179 , + [ owl:intersectionOf ( [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000051 ; + owl:someValuesFrom af-m:AFM_0000341 + ] + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000080 ; + owl:someValuesFrom af-m:AFM_0000275 + ] + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "amount of cells" ; + + skos:definition "Cell count is the amount of cells within a whole. [Allotrope]" ; + + skos:prefLabel "cell count" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000185 + +af-q:AFQ_0000185 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000184 ; + + af-x:AFX_0002808 af-x:AFX_0000609 ; + + rdfs:isDefinedBy ; + + skos:altLabel "viable cell count" ; + + skos:definition "Viable cell count is the cell count of the partition of viable cells. [Allotrope]" ; + + skos:prefLabel "viable cell count (quality)" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000186 + +af-q:AFQ_0000186 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000184 ; + + af-x:AFX_0002808 af-x:AFX_0000608 ; + + rdfs:isDefinedBy ; + + skos:altLabel "total cell count" ; + + skos:definition "Total cell count is the cell count over a mereological sum of a partitioned aggregate of cells. [Allotrope]" ; + + skos:prefLabel "total cell count (quality)" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000187 + +af-q:AFQ_0000187 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000184 ; + + af-x:AFX_0002808 af-x:AFX_0000606 ; + + rdfs:isDefinedBy ; + + skos:altLabel "dead cell count" ; + + skos:definition "Dead cell count is the cell count of the partition of dead cells. [Allotrope]" ; + + skos:prefLabel "dead cell count (quality)" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000188 + +af-q:AFQ_0000188 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000036 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000080 ; + owl:someValuesFrom af-e:AFE_0000524 + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "cell counter setting" ; + + skos:definition "A cell counter configuration is a device configuration of a cell counter device. [Allotrope]" ; + + skos:prefLabel "cell counter configuration" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000189 + +af-q:AFQ_0000189 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( pato:_0001334 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000080 ; + owl:someValuesFrom af-m:AFM_0000341 + ] + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A cell diameter is the diameter of a cell. [Allotrope]" ; + + skos:prefLabel "cell diameter" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000195 + +af-q:AFQ_0000195 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000208 ; + + rdfs:isDefinedBy ; + + skos:altLabel "partial pressure of oxygen" ; + + skos:definition "pO2 is the partial pressure of oxygen gas dissolved in a solution. [Allotrope]" ; + + skos:prefLabel "pO2" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000196 + +af-q:AFQ_0000196 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000208 ; + + rdfs:isDefinedBy ; + + skos:altLabel "partial pressure of carbon dioxide" ; + + skos:definition "pCO2 is the partial pressure of carbon dioxide dissolved in a solution. [Allotrope]" ; + + skos:prefLabel "pCO2" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000197 + +af-q:AFQ_0000197 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000029 ; + + rdfs:isDefinedBy ; + + skos:definition "The electronic absorbance detection wavelength is the detection wavelength setting of an electronic absorbance detector. [Allotrope]" ; + + skos:prefLabel "electronic absorbance detection wavelength" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000198 + +af-q:AFQ_0000198 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000199 ; + + rdfs:isDefinedBy ; + + skos:definition "Detection bandwidth is a device setting of a detector controlling the bandwidth of the detection wavelength. [Allotrope]" ; + + skos:prefLabel "detection bandwidth" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000199 + +af-q:AFQ_0000199 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000036 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000080 ; + owl:someValuesFrom af-e:AFE_0000317 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "detector setting" ; + + skos:definition "A detector configuration is a device configuration of a detector. [Allotrope]" ; + + skos:prefLabel "detector configuration" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000200 + +af-q:AFQ_0000200 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000204 ; + + rdfs:isDefinedBy ; + + skos:altLabel "signal setting" ; + + skos:definition "A signal configuration is a device configuration of a device producing or consuming signals, that controls the processing of a signal. [Allotrope]" ; + + skos:prefLabel "signal configuration" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000201 + +af-q:AFQ_0000201 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000200 ; + + rdfs:isDefinedBy ; + + skos:altLabel "amplification" , + "amplification configuration" , + "amplification setting" , + "gain" , + "gain configuration" , + "gain setting" , + "signal amplification setting" , + "signal gain setting" ; + + skos:definition "A gain setting is a signal configuration, that controls the amplification of an incoming or outgoing signal. [Allotrope]" ; + + skos:prefLabel "signal gain configuration" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000202 + +af-q:AFQ_0000202 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000200 ; + + rdfs:isDefinedBy ; + + skos:altLabel "signal offset setting" ; + + skos:definition "A signal offset configuration is a signal processing configuration, that adds/subtracts a fixed amount of magnitude to the signal strength or amplitude to move the zero reference. [Allotrope]" ; + + skos:prefLabel "signal offset configuration" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000203 + +af-q:AFQ_0000203 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000036 , + [ rdf:type owl:Class ; + owl:unionOf ( [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002722 ; + owl:someValuesFrom pato:_0000146 + ] + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002723 ; + owl:someValuesFrom pato:_0000146 + ] + ) + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "temperature setting" ; + + skos:changeNote "2018-12-10 Changed alt label to temperature setting. [Allotrope]" , + "2018-12-10 Changed definition to include alerting [Allotrope]" , + "2018-12-10 Moved to AFO. [Allotrope]" , + "2019-07-01 Added relation to the temperature being controlled or observed. [Allotrope]" ; + + skos:definition "A temperature configuration is a device configuration of a temperature controlling or monitoring device, that controls or monitors the target temperature at the site of some system component. [Allotrope]" ; + + skos:example "An oven thermostat has a temperature configuration that controls the heating." ; + + skos:prefLabel "temperature configuration" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000204 + +af-q:AFQ_0000204 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000036 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002723 ; + owl:someValuesFrom bfo:_0000019 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "control setting" , + "controller setting" ; + + skos:definition "A controller configuration is a device configuration of a controller, that directly influences the controlling process done by the controller towards a goal. [Allotrope]" ; + + skos:prefLabel "controller configuration" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000205 + +af-q:AFQ_0000205 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000036 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002722 ; + owl:someValuesFrom bfo:_0000019 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "trigger setting" ; + + skos:definition "A trigger configuration is a device configuration for a system with a sensor and an actor component, that directly influences when the sensor sends an activating signal to the actor based on an observation. [Allotrope]" ; + + skos:prefLabel "trigger configuration" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000206 + +af-q:AFQ_0000206 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000205 ; + + rdfs:isDefinedBy ; + + skos:altLabel "alert configuration" , + "alert setting" , + "notification setting" , + "signaling configuration" , + "signaling setting" ; + + skos:definition "A notification setting is a trigger setting in a system that has a notification component, that controls when the component send out a notification signal. [Allotrope]" ; + + skos:example "A pressure sensor measures the pressure of the liquid in the plumbing an if the notification setting on the pressure is above a maximum, it triggers the notification of a signaling device, such as a warning lamp." ; + + skos:prefLabel "notification configuration" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000208 + +af-q:AFQ_0000208 rdf:type owl:Class ; + + rdfs:subClassOf pato:_0001025 ; + + dct:source , + "Green Book, 2nd ed.: IUPAC Quantities, Units and Symbols in Physical Chemistry. Second Edition, Blackwell Scientific Publications, Oxford, 1993." , + "PAC, 1994, 66, 533 (Standard quantities in chemical thermodynamics. Fugacities, activities and equilibrium constants for pure and mixed phases (IUPAC Recommendations 1994))" ; + + rdfs:isDefinedBy ; + + skos:altLabel "partial pressure" ; + + skos:definition "Partial pressure is the notional pressure of a gas in a mixture of gases, if it alone occupied the entire volume of the original mixture at the same temperature. [Wikipedia]" ; + + skos:prefLabel "partial pressure (quality)" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000209 + +af-q:AFQ_0000209 rdf:type owl:Class ; + + rdfs:subClassOf pato:_0000025 ; + + rdfs:isDefinedBy ; + + skos:altLabel "purity" ; + + skos:definition "Purity is a composition quality inhering in an bearer by virtue of the bearer lacking undesired components. [Allotrope]" ; + + skos:note "It is generally quantified by the sum of the mass fractions of the impurities subtracted from a theoretically pure value of 100%." ; + + skos:prefLabel "purity (quality)" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000210 + +af-q:AFQ_0000210 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000019 ; + + rdfs:isDefinedBy ; + + skos:altLabel "mechanics quality" ; + + skos:definition "A physical quality that inheres in an bearer by virtue of how that bearer behaves when subjected to forces or displacements and the effect of their bodies on their environment. [Wikipedia]" ; + + skos:prefLabel "mechanical quality" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000211 + +af-q:AFQ_0000211 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000210 ; + + dct:subject ; + + rdfs:isDefinedBy ; + + skos:altLabel "deformation" ; + + skos:definition "Strain is a quality of deformation representing the displacement between particles in the body relative to a reference length. [Wikipedia]" ; + + skos:note "A general deformation of a body can be expressed in the form x = F(X) where X is the reference position of material points in the body." ; + + skos:prefLabel "strain" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000212 + +af-q:AFQ_0000212 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000210 ; + + dct:subject ; + + rdfs:isDefinedBy ; + + skos:altLabel "τ" ; + + skos:definition "A shearing force is applied to the top of the rectangle while the bottom is held in place. The resulting shear stress deforms the rectangle into a parallelogram. The area involved would be the top of the parallelogram. A shear stress is the component of stress coplanar with a material cross section. [Wikipedia]" ; + + skos:prefLabel "shear stress" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000213 + +af-q:AFQ_0000213 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000211 ; + + dct:subject ; + + rdfs:isDefinedBy ; + + skos:definition "A normal strain is strain perpendicular to the face of an element. [Wikipedia]" ; + + skos:prefLabel "normal strain" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000214 + +af-q:AFQ_0000214 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000211 ; + + dct:subject ; + + rdfs:isDefinedBy ; + + skos:definition "A shear strain is parallel to the face of an element. [Wikipedia]" ; + + skos:prefLabel "shear strain" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000215 + +af-q:AFQ_0000215 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000222 ; + + rdfs:isDefinedBy ; + + skos:altLabel "total mass of impurities" ; + + skos:definition "Total impurities is a composition quality that is the sum of the mass of all impurities in a material. [Allotrope]" ; + + skos:prefLabel "total impurities" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000216 + +af-q:AFQ_0000216 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000209 ; + + rdfs:isDefinedBy ; + + skos:definition "A purity quality of a material with respect to its stereoisomers. [Allotrope]" ; + + skos:prefLabel "stereochemical purity" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000217 + +af-q:AFQ_0000217 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000221 , + af-q:AFQ_0000223 ; + + af-x:AFX_0002808 chmo:_0002860 ; + + rdfs:isDefinedBy ; + + skos:definition "The absolute value of the mole fraction for one diastereomer in a mixture minus the mole fraction for the other. [CHMO]" ; + + skos:prefLabel "diastereomeric excess" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000218 + +af-q:AFQ_0000218 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000005 , + af-q:AFQ_0000223 ; + + af-x:AFX_0002808 chmo:_0002858 ; + + dct:source "doi:10.1359/goldbook.D01681" ; + + rdfs:isDefinedBy ; + + skos:definition "The ratio of the percentage of one diastereomer in a mixture to that of the other. [CHMO]" ; + + skos:prefLabel "diastereomeric ratio" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000219 + +af-q:AFQ_0000219 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000005 , + af-q:AFQ_0000223 ; + + af-x:AFX_0002808 chmo:_0002859 ; + + rdfs:isDefinedBy ; + + skos:definition "The ratio of the percentage of one enantiomer in a mixture to that of the other. [CHMO]" ; + + skos:prefLabel "enantiomeric ratio" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000220 + +af-q:AFQ_0000220 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000221 , + af-q:AFQ_0000223 ; + + af-x:AFX_0002808 chmo:_0002856 ; + + dct:source "doi:10.1359/goldbook.E02070" ; + + rdfs:isDefinedBy ; + + skos:definition "The absolute value of the mole fraction for one enantiomer in a mixture minus the mole fraction for the other enantiomer. [CHMO]" ; + + skos:prefLabel "enantiomeric excess" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000221 + +af-q:AFQ_0000221 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000145 ; + + rdfs:isDefinedBy ; + + skos:altLabel "difference" ; + + skos:definition "An excess is a relational quality that is the difference in magnitude of two qualities of the same kind. [Allotrope]" ; + + skos:prefLabel "excess" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000222 + +af-q:AFQ_0000222 rdf:type owl:Class ; + + rdfs:subClassOf pato:_0000025 ; + + rdfs:isDefinedBy ; + + skos:altLabel "impurity" ; + + skos:definition "Impurity is a composition quality inhering in an bearer by virtue of the bearer having undesired components. [Allotrope]" ; + + skos:prefLabel "impurity (quality)" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000223 + +af-q:AFQ_0000223 rdf:type owl:Class ; + + rdfs:subClassOf pato:_0000025 ; + + rdfs:isDefinedBy ; + + skos:definition "Stereochemical composition is a composition quality based on the stereochemistry of its components. [Allotrope]" ; + + skos:prefLabel "stereochemical composition" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000224 + +af-q:AFQ_0000224 rdf:type owl:Class ; + + rdfs:subClassOf pato:_0000025 ; + + rdfs:isDefinedBy ; + + skos:definition "A dilution composition is a composition quality of a dilution. [Allotrope]" ; + + skos:prefLabel "dilution composition" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000225 + +af-q:AFQ_0000225 rdf:type owl:Class ; + + rdfs:subClassOf pato:_0000025 ; + + rdfs:isDefinedBy ; + + skos:definition "Reaction composition is a composition quality of a reaction mixture. [Allotrope]" ; + + skos:prefLabel "reaction composition" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000226 + +af-q:AFQ_0000226 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000005 , + af-q:AFQ_0000225 ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:altLabel "conversion" ; + + skos:definition "Conversion is a reaction composition quality dependent on the fraction of reactant remaining. [Allotrope]" ; + + skos:prefLabel "conversion (quality)" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000227 + +af-q:AFQ_0000227 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000005 , + af-q:AFQ_0000225 ; + + af-x:AFX_0002808 chmo:_0002855 ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:altLabel "percentage yield" , + "yield" ; + + skos:definition "Reaction yield is a reaction composition quality expressed as a percentage of the theoretical maximum mass of the product given the masses of the reactants. [CHMO, Allotrope]" ; + + skos:note "Often there is an assumption that the product and starting materials have the same relative response in the analytical method being used." ; + + skos:prefLabel "yield (quality)" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000228 + +af-q:AFQ_0000228 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000005 , + af-q:AFQ_0000225 ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:altLabel "selectivity" ; + + skos:definition "Reaction selectivity is a reaction composition that is expressed as the number of moles of desired product per the number of moles of undesired product. [Wikipedia]" ; + + skos:prefLabel "reaction selectivity" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000231 + +af-q:AFQ_0000231 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000145 ; + + af-x:AFX_0002808 org:Membership ; + + rdfs:isDefinedBy ; + + skos:definition "Membership is the relational quality between a group or organization and its members. [Allotrope]" ; + + skos:editorialNote "This is the structural aspect of membership. There is also a temporal aspect of being member of (membership state)." ; + + skos:prefLabel "membership" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000232 + +af-q:AFQ_0000232 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( af-q:AFQ_0000036 + [ rdf:type owl:Class ; + owl:unionOf ( [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000080 ; + owl:someValuesFrom af-e:AFE_0000014 + ] + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000080 ; + owl:someValuesFrom af-e:AFE_0002153 + ] + ) + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "plumbing setting" ; + + skos:definition "A plumbing configuration is a device configuration of a plumbing system or plumbing equipment. [Allotrope]" ; + + skos:prefLabel "plumbing configuration" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000233 + +af-q:AFQ_0000233 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( af-q:AFQ_0000036 + [ rdf:type owl:Class ; + owl:unionOf ( [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000080 ; + owl:someValuesFrom af-e:AFE_0000266 + ] + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000080 ; + owl:someValuesFrom af-e:AFE_0002186 + ] + ) + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "injection configuration" , + "injection device setting" , + "injection setting" , + "injector setting" ; + + skos:definition "An injection device configuration is a device configuration of an injection device or its components. [Allotrope]" ; + + skos:prefLabel "injection device configuration" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000235 + +af-q:AFQ_0000235 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000019 , + [ rdf:type owl:Class ; + owl:unionOf ( af-q:AFQ_0000065 + af-q:AFQ_0000138 + pato:_0001291 + ) + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "wavenumber" ; + + skos:definition "Wavenumber is a physical quality that inheres in a wave by virtue of the number of wave patterns per unit length along the direction of propagation. It is reciprocal to wavelength. [Allotrope]" ; + + skos:editorialNote "2019-07-04 Quality can be either acoustic. electromagnetic or radiation. [Allotrope]" ; + + skos:prefLabel "wavenumber (quality)" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000236 + +af-q:AFQ_0000236 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000036 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000080 ; + owl:someValuesFrom af-e:AFE_0000551 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "Raman spectrometer setting" ; + + skos:definition "Raman spectrometer configuration is a device configuration of a Raman spectrometer. [Allotrope]" ; + + skos:prefLabel "Raman spectrometer configuration" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000237 + +af-q:AFQ_0000237 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000019 ; + + dct:source "International Vocabulary of Metrology – Basic and General Concepts and Associated Terms (VIM 3rd edition) JCGM 200:2012" ; + + rdfs:isDefinedBy ; + + skos:altLabel "resolution" ; + + skos:definition "Resolution is the quality of a sensor (measurement instrument, detector) to be able to measure the smallest change in a qualities that causes a perceptible change in the corresponding indication. [Allotrope]" ; + + skos:prefLabel "resolution (quality)" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000238 + +af-q:AFQ_0000238 rdf:type owl:Class ; + + rdfs:subClassOf pato:_0000146 ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + dct:replaces af-x:AFX_0000316 ; + + rdfs:isDefinedBy ; + + skos:altLabel "melt temperature" , + "melting temperature" ; + + skos:definition "The melting point is the temperature where a material changes from the solid phase to the liquid phase. [Allotrope]" ; + + skos:prefLabel "melting point" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000239 + +af-q:AFQ_0000239 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000036 , + [ rdf:type owl:Class ; + owl:unionOf ( [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002722 ; + owl:someValuesFrom pato:_0001574 + ] + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002723 ; + owl:someValuesFrom pato:_0001574 + ] + ) + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:changeNote "2019-07-01 Added relation to the flow rate being controlled. [Allotrope]" ; + + skos:definition "A flow rate configuration is a device configuration of a fluid controlling or monitoring device, that controls or monitors the flow rate at the site of some system component. [Allotrope]" ; + + skos:prefLabel "flow rate configuration" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000240 + +af-q:AFQ_0000240 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000036 , + [ rdf:type owl:Class ; + owl:unionOf ( [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002722 ; + owl:someValuesFrom af-q:AFQ_0000005 + ] + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002723 ; + owl:someValuesFrom af-q:AFQ_0000005 + ] + ) + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "concentration ratio setting" ; + + skos:changeNote "2019-07-01 Added relation to the ratio being controlled or observed. [Allotrope]" ; + + skos:definition "A concentration ratio configuration is a device configuration of a fluid controlling or monitoring device, that controls or monitors the concentration ratio of a mixture at the site of some system component. [Allotrope]" ; + + skos:prefLabel "concentration ratio configuration" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000241 + +af-q:AFQ_0000241 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000036 , + [ rdf:type owl:Class ; + owl:unionOf ( [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002722 ; + owl:someValuesFrom pato:_0000918 + ] + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002723 ; + owl:someValuesFrom pato:_0000918 + ] + ) + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "volume setting" ; + + skos:changeNote "2019-07-01 Added relation to the volume being controlled or observed. [Allotrope]" ; + + skos:definition "A volume configuration is a device configuration of a controlling or monitoring device, that controls or monitors the volume of some material at the site of some system component. [Allotrope]" ; + + skos:prefLabel "volume configuration" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000242 + +af-q:AFQ_0000242 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000019 , + [ rdf:type owl:Class ; + owl:unionOf ( af-q:AFQ_0000065 + af-q:AFQ_0000138 + pato:_0001291 + ) + ] ; + + af-x:AFX_0002808 ; + + rdfs:isDefinedBy ; + + skos:altLabel "polarity" ; + + skos:definition "Polarity is the quality inhered in an energy that is the positive or negative direction of an electrical, acoustical, or magnetic force relative to a reference state. [Allotrope, NCI]" ; + + skos:editorialNote "2019-07-04 Quality can be either acoustic, electro magnetic or radiation. [Allotrope]" ; + + skos:prefLabel "polarity (quality)" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000243 + +af-q:AFQ_0000243 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000036 , + [ rdf:type owl:Class ; + owl:unionOf ( [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002722 ; + owl:someValuesFrom af-q:AFQ_0000242 + ] + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002723 ; + owl:someValuesFrom af-q:AFQ_0000242 + ] + ) + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "polarity setting" ; + + skos:changeNote "2019-07-01 Added relation to the polarity being controlled or observed. [Allotrope]" ; + + skos:definition "Polarity configuration is a device configuration that sets a specific detector or sensor response to be positive or negative to a reference state. [Allotrope]" ; + + skos:prefLabel "polarity configuration" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000244 + +af-q:AFQ_0000244 rdf:type owl:Class ; + + rdfs:subClassOf pato:_0002390 ; + + af-x:AFX_0002808 af-x:AFX_0001135 , + ; + + rdfs:isDefinedBy ; + + skos:definition "The average radius of the pores within the solid particles. [Allotrope]" ; + + skos:prefLabel "pore size" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000245 + +af-q:AFQ_0000245 rdf:type owl:Class ; + + rdfs:subClassOf pato:_0000973 ; + + rdfs:isDefinedBy ; + + skos:definition "A porosity quality inhering in a bearer by virtue of the bearer's being only capable of admitting the passage of gas or liquid through pores or interstices in outer layer of the solid and not its solid impermeable core. [Allotrope]" ; + + skos:prefLabel "fused core" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000247 + +af-q:AFQ_0000247 rdf:type owl:Class ; + + rdfs:subClassOf pato:_0000141 ; + + rdfs:isDefinedBy ; + + skos:definition "A bonded phase is the structure quality of a material that is covalently bonded to a substrate. [Allotrope]" ; + + skos:prefLabel "bonded phase" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000250 + +af-q:AFQ_0000250 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000019 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000052 ; + owl:someValuesFrom af-m:AFM_0001097 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A chemical substance quality is a quality that inheres in some portion of chemical substance. [Allotrope]" ; + + skos:prefLabel "chemical substance quality" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000252 + +af-q:AFQ_0000252 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000019 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000080 ; + owl:someValuesFrom chebi:_23367 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "molecular quality" ; + + skos:definition "A molecular quality is a chemical quality which inheres in a molecular entity, a single molecule, atom, ion, radical etc. [Allotrope]" ; + + skos:prefLabel "molecular entity quality" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000253 + +af-q:AFQ_0000253 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000019 ; + + rdfs:isDefinedBy ; + + skos:altLabel "energy" ; + + skos:definition "Energy (quality) is the amount of energy that a material entity contains. [Allotrope]" ; + + skos:prefLabel "energy (quality)" ; + + skos:scopeNote "Energy is in BFO considered a material entity." . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000254 + +af-q:AFQ_0000254 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000036 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000080 ; + owl:someValuesFrom af-e:AFE_0002205 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A mass spectrometry system configuration is a device configuration of a mass spectrometry system, that influences the operation of the system. [Allotrope]" ; + + skos:prefLabel "mass spectrometry system configuration" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000256 + +af-q:AFQ_0000256 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000252 , + pato:_0000125 ; + + rdfs:isDefinedBy ; + + skos:altLabel "atomic mass" , + "molecular mass" ; + + skos:changeNote "2020-03-16 Changed pref label. [Allotrope]" , + "2020-03-16 Subclassed under pato:mass. [Allotrope]" ; + + skos:definition "Molecular mass is a molecular quality inhered in a molecular entity that expresses its mass relative to 1/12 of the mass of an unbound neutral atom of carbon-12 in its nuclear and electronic ground state and at rest. [Allotrope]" ; + + skos:prefLabel "molecular mass (molecular quality)" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000257 + +af-q:AFQ_0000257 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000252 ; + + rdfs:isDefinedBy ; + + skos:altLabel "m/z" , + "m/z (molecular quality)" , + "m/z ratio" , + "mass-to-charge ratio" ; + + skos:definition "Mass-to-charge ratio is a molecular quality that expresses the ratio of the molecular mass to the charge number of a molecular entity. [Allotrope]" ; + + skos:prefLabel "mass-to-charge ratio (molecular quality)" ; + + skos:scopeNote "This quality is itself a ratio of relative qualities, the molecular mass is relative to the unified atomic mass unit and the electric charge to the elementary charge. [Allotrope]" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000263 + +af-q:AFQ_0000263 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000252 ; + + af-x:AFX_0002808 ; + + rdfs:isDefinedBy ; + + skos:altLabel "molecular formula" ; + + skos:definition "A molecular formula is a molecular quality that inheres in a molecular entity by the relative amount of component atoms. [Allotrope]" ; + + skos:prefLabel "molecular formula (molecular quality)" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000264 + +af-q:AFQ_0000264 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000253 , + bfo:_0000019 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000080 ; + owl:someValuesFrom af-m:AFM_0000418 + ] ; + + dct:license ; + + dct:rights ; + + dct:source "IUPAC. Analytical Division. Compendium of Analytical Nomenclature (the Orange Book). Definitive Rules, 1979. Compiled by J. Inczédy, T. Lengyel, A. M. Ure. Blackwell Scientific Publications, Oxford (1997)." , + "IUPAC. Compendium of Chemical Terminology, 2nd ed. (the Gold Book). Compiled by A. D. McNaught and A.Wilkinson. Blackwell Scientific Publications, Oxford (1997)." , + "K. K. Murray, R. K. Boyd, M. N. Eberlin, G. J. Langley, L. Li and Y. Naito, Pure Appl. Chem., 2013, 85, 1515-1609" ; + + rdfs:isDefinedBy ; + + skos:definition "Electron energy is the translational energy that electrons acquire when accelerated in an electric field. [IUPAC]" ; + + skos:prefLabel "electron energy" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000265 + +af-q:AFQ_0000265 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000252 ; + + rdfs:isDefinedBy ; + + skos:altLabel "isotopic distribution" ; + + skos:definition "Isotopic distribution is a molecular quality inhered in a molecule by the distribution of different isotopes in the molecule. [Allotrope]" ; + + skos:prefLabel "isotopic distribution (molecular quality)" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000266 + +af-q:AFQ_0000266 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000065 ; + + dct:license ; + + dct:rights ; + + dct:source "PAC, 1996, 68, 957. (Glossary of terms in quantities and units in Clinical Chemistry (IUPAC-IFCC Recommendations 1996))" ; + + rdfs:isDefinedBy ; + + skos:altLabel "electric resistivity" , + "resistivity" , + "resistivity (quality)" ; + + skos:definition "Electric resistivity is the quality of the electric field strength divided by the current density when there is no electromotive force in a conductor. [IUPAC]" ; + + skos:prefLabel "electric resistivity (quality)" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000267 + +af-q:AFQ_0000267 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000065 ; + + dct:license ; + + dct:rights ; + + dct:source , + "PAC, 1996, 68, 957. (Glossary of terms in quantities and units in Clinical Chemistry (IUPAC-IFCC Recommendations 1996))" ; + + rdfs:isDefinedBy ; + + skos:altLabel "conductance" , + "conductance (quality)" , + "electric conductance" ; + + skos:definition "Electric conductance is the quality inhered in a conductor that is the reciprocal of a the electric resistance. [IUPAC]" ; + + skos:prefLabel "electric conductance (quality)" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000268 + +af-q:AFQ_0000268 rdf:type owl:Class ; + + rdfs:subClassOf pato:_0000122 ; + + dct:license ; + + dct:rights ; + + rdfs:isDefinedBy ; + + skos:altLabel "cell path length" , + "path length" , + "path length (quality)" ; + + skos:definition "The cell path length is the length of the radiation path through the absorbing medium in a single-pass cell. [IUPAC]" ; + + skos:prefLabel "cell path length (quality)" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000269 + +af-q:AFQ_0000269 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000019 ; + + dct:license ; + + dct:rights ; + + rdfs:isDefinedBy ; + + skos:altLabel "enthalpy" ; + + skos:definition "Enthalpy (quality) is the quality of a system that is the internal energy of the system plus the product of pressure and volume. Its change in a system is equal to the heat brought to the system at constant pressure. [IUPAC]" ; + + skos:prefLabel "enthalpy (quality)" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000271 + +af-q:AFQ_0000271 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000058 ; + + rdfs:isDefinedBy ; + + skos:altLabel "specific heat capacity" ; + + skos:definition "A specific heat capacity (quality) is a heat capacity of a pure substance by virtue of the amount of heat necessary to raise the temperature per amount of mass. [Allotrope]" ; + + skos:prefLabel "specific heat capacity (quality)" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000273 + +af-q:AFQ_0000273 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000065 ; + + rdfs:isDefinedBy ; + + skos:altLabel "charge" , + "electric charge" ; + + skos:definition "Electric charge is the electrical quality of matter that causes it to experience a force when placed in an electromagnetic field. [Wikipedia]" ; + + skos:prefLabel "electric charge (quality)" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000275 + +af-q:AFQ_0000275 rdf:type owl:Class ; + + rdfs:subClassOf pato:_0001025 ; + + dct:license ; + + dct:rights ; + + dct:source "PAC, 1990, 62, 2167. (Glossary of atmospheric chemistry terms (Recommendations 1990)) on page 2212" ; + + rdfs:isDefinedBy ; + + skos:altLabel "saturation vapor pressure" ; + + skos:definition "The pressure exerted by a pure substance (at a given temperature) in a system containing only the vapor and condensed phase (liquid or solid) of the substance. [IUPAC]" ; + + skos:prefLabel "saturation vapor pressure (quality)" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000276 + +af-q:AFQ_0000276 rdf:type owl:Class ; + + rdfs:subClassOf pato:_0001574 ; + + rdfs:isDefinedBy ; + + skos:definition "An evacuation rate is a flow rate indicating the rate at which gas is removed from a chamber. [Allotrope]" ; + + skos:prefLabel "evacuation rate (quality)" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000277 + +af-q:AFQ_0000277 rdf:type owl:Class ; + + rdfs:subClassOf pato:_0000918 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000080 ; + owl:someValuesFrom af-e:AFE_0000646 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "free space" , + "measurement chamber free space" , + "measurement chamber free space (quality)" , + "measurement chamber free space volume" ; + + skos:definition "A measurement chamber free space volume (quality) is the volume within a sample measurement chamber that is not occupied by the sample. [Allotrope]" ; + + skos:prefLabel "measurement chamber free space volume (quality)" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000279 + +af-q:AFQ_0000279 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000250 ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:definition "Hygroscopicity is a quality inhered in a compound by virtue of its ability to readily take up and retain water, especially from the atmosphere. [Wikipedia]" ; + + skos:prefLabel "hygroscopicity" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000280 + +af-q:AFQ_0000280 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000056 ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:altLabel "enthalpy of fusion" , + "enthalpy of melting" , + "enthalpy of melting (quality)" , + "heat of fusion" , + "latent heat of fusion" ; + + skos:definition "The enthalpy of fusion is a quality inhered in of a solid substance that is the change in its enthalpy resulting from providing energy, typically heat, to a specific quantity of the substance to change its state from a solid to a liquid, at constant pressure. [Wikipedia]" ; + + skos:prefLabel "enthalpy of fusion (quality)" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000281 + +af-q:AFQ_0000281 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000056 ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:altLabel "enthalpy of vaporization" , + "heat of evaporation" , + "heat of vaporization" , + "latent heat of vaporization" ; + + skos:definition "The enthalpy of vaporization is a quality inhered in a liquid substance that is the amount of energy (enthalpy) that must be added to the liquid substance, to transform a quantity of that substance into a gas. [Wikipedia]" ; + + skos:prefLabel "enthalpy of vaporization (quality)" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000282 + +af-q:AFQ_0000282 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000281 ; + + rdfs:isDefinedBy ; + + skos:altLabel "specific heat of evaporation" , + "specific heat of vaporization" , + "specific latent heat of vaporization" ; + + skos:definition "The specific enthalpy of vaporization is the enthalpy of vaporization referenced to a unit mass of substance. [Allotrope]" ; + + skos:prefLabel "specific enthalpy of vaporization (quality)" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000283 + +af-q:AFQ_0000283 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000281 ; + + rdfs:isDefinedBy ; + + skos:altLabel "molar enthalpy of vaporization" , + "molar heat of evaporation" , + "molar heat of vaporization" , + "molar latent heat of vaporization" ; + + skos:definition "The molar enthalpy of vaporization is the enthalpy of vaporization referenced to a unit amount of substance. [Allotrope]" ; + + skos:prefLabel "molar enthalpy of vaporization (quality)" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000284 + +af-q:AFQ_0000284 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000280 ; + + rdfs:isDefinedBy ; + + skos:altLabel "molar enthalpy of fusion" , + "molar enthalpy of melting" , + "molar enthalpy of melting (quality)" , + "molar heat of fusion" , + "molar latent heat of fusion" ; + + skos:definition "The molar enthalpy of fusion is the enthalpy of fusion referenced to a unit amount of substance. [Allotrope]" ; + + skos:prefLabel "molar enthalpy of fusion (quality)" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000285 + +af-q:AFQ_0000285 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000280 ; + + rdfs:isDefinedBy ; + + skos:altLabel "specific enthalpy of fusion" , + "specific enthalpy of melting" , + "specific enthalpy of melting (quality)" , + "specific heat of melting" , + "specific latent heat of melting" ; + + skos:definition "The specific enthalpy of fusion is the enthalpy of fusion referenced to a unit mass of substance. [Allotrope]" ; + + skos:prefLabel "specific enthalpy of fusion (quality)" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000286 + +af-q:AFQ_0000286 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000056 ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:altLabel "enthalpy of sublimation" , + "heat of sublimation" ; + + skos:definition "The enthalpy of sublimation is a quality inhered in a solid substance that is the amount of energy (enthalpy) that must be added to the solid substance, to transform a quantity of that substance into a gas. [Wikipedia]" ; + + skos:prefLabel "enthalpy of sublimation (quality)" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000287 + +af-q:AFQ_0000287 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000286 ; + + rdfs:isDefinedBy ; + + skos:altLabel "specific enthalpy of sublimation" , + "specific heat of sublimation" ; + + skos:definition "The specific enthalpy of sublimation is the enthalpy of sublimation referenced to a unit mass of substance. [Allotrope]" ; + + skos:prefLabel "specific enthalpy of sublimation (quality)" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000288 + +af-q:AFQ_0000288 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000286 ; + + rdfs:isDefinedBy ; + + skos:altLabel "molar enthalpy of sublimation" , + "molar heat of sublimation" ; + + skos:definition "The specific enthalpy of sublimation is the enthalpy of sublimation referenced to a unit amount of substance. [Allotrope]" ; + + skos:prefLabel "molar enthalpy of sublimation (quality)" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000290 + +af-q:AFQ_0000290 rdf:type owl:Class ; + + rdfs:subClassOf pato:_0001300 ; + + dct:license ; + + dct:rights ; + + dct:source "IUPAC, Compendium of Chemical Terminology, 2nd ed. (the \"Gold Book\"). Compiled by A. D. McNaught and A. Wilkinson. Blackwell Scientific Publications, Oxford (1997). Online version (2019-) created by S. J. Chalk." , + "IUPAC, Compendium of Macromolecular Nomenclature, The Purple Book, 1st ed., p. 66" ; + + rdfs:isDefinedBy ; + + skos:altLabel "turbidity" ; + + skos:definition "Turbidity is an optical quality that is the apparent absorbance of the incident radiation due to scattering. For small particles, direct proportionality exists between turbidity and the Rayleigh ratio. [IUPAC]" ; + + skos:prefLabel "turbidity (quality)" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000291 + +af-q:AFQ_0000291 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000172 ; + + rdfs:isDefinedBy ; + + skos:definition "The count fraction is a quality pertaining the number of particles of a constituent divided by the total number of particles of all constituents in the mixture. [Allotrope]" ; + + skos:prefLabel "count fraction (quality)" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000292 + +af-q:AFQ_0000292 rdf:type owl:Class ; + + rdfs:subClassOf pato:_0001300 ; + + rdfs:isDefinedBy ; + + skos:definition "The refractive index is an optical quality inhered in a material by virtue of how fast light travels through the material. [Allotrope]" ; + + skos:prefLabel "refractive index (quality)" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000293 + +af-q:AFQ_0000293 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000199 , + af-q:AFQ_0000297 ; + + rdfs:isDefinedBy ; + + skos:definition "The detector gain is a (relative) amount by which a detector to increases the magnitude of a signal from the input to the output port by adding energy to the signal. [Allotrope]" ; + + skos:prefLabel "detector gain" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000295 + +af-q:AFQ_0000295 rdf:type owl:Class ; + + rdfs:subClassOf pato:_0001300 ; + + af-x:AFX_0002808 ; + + rdfs:isDefinedBy ; + + skos:altLabel "birefringence" ; + + skos:definition "An optical quality of anisotropic material that has a refractive index which depends on the properties of light. [Allotrope]" ; + + skos:prefLabel "birefringence (quality)" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000297 + +af-q:AFQ_0000297 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000005 ; + + rdfs:isDefinedBy ; + + skos:definition "Signal gain is the ratio of magnitude of a quality between a flow of energy incoming to a system (input signal) and the outgoing flow of energy (output signal) used for signaling. [Allotrope]" ; + + skos:example "detector gain" ; + + skos:prefLabel "gain" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000298 + +af-q:AFQ_0000298 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000311 ; + + af-x:AFX_0002808 "USP 30(6) Harmonization: <776> OPTICAL MICROSCOPY" ; + + rdfs:isDefinedBy ; + + skos:altLabel "acicular" , + "needle" , + "needle particle shape" ; + + skos:definition "An acicular particle shape is a shape of particle with similar small height and width and large length. [Allotrope]" ; + + skos:prefLabel "acicular particle shape" ; + + skos:scopeNote "Acicular particles are needle-like." . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000299 + +af-q:AFQ_0000299 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000311 ; + + af-x:AFX_0002808 "USP 30(6) Harmonization: <776> OPTICAL MICROSCOPY" ; + + rdfs:isDefinedBy ; + + skos:altLabel "columnar" ; + + skos:definition "A columnar particle shape is a shape of particle with similar moderate height and width and large length. [Allotrope]" ; + + skos:prefLabel "columnar particle shape" ; + + skos:scopeNote "Columnar particles are similar in shape to poster tubes or wood joists." . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000300 + +af-q:AFQ_0000300 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000311 ; + + af-x:AFX_0002808 "USP 30(6) Harmonization: <776> OPTICAL MICROSCOPY" ; + + rdfs:isDefinedBy ; + + skos:altLabel "flake" ; + + skos:definition "A flake particle shape is a shape of particle with small width and similar height and length. [Allotrope]" ; + + skos:prefLabel "flake particle shape" ; + + skos:scopeNote "Flake particles are similar in shape to beer mats." . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000301 + +af-q:AFQ_0000301 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000311 ; + + af-x:AFX_0002808 "USP 30(6) Harmonization: <776> OPTICAL MICROSCOPY" ; + + rdfs:isDefinedBy ; + + skos:altLabel "plate" ; + + skos:definition "A plate particle shape is a shape of particle with moderate width and similar height and length. [Allotrope]" ; + + skos:prefLabel "plate particle shape" ; + + skos:scopeNote "Plate particles are similar in shape to dinner plates." . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000302 + +af-q:AFQ_0000302 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000311 ; + + af-x:AFX_0002808 "USP 30(6) Harmonization: <776> OPTICAL MICROSCOPY" ; + + rdfs:isDefinedBy ; + + skos:altLabel "lath" ; + + skos:definition "A lath particle shape is a shape of particle with small width, moderate height, and large length. [Allotrope]" ; + + skos:prefLabel "lath particle shape" ; + + skos:scopeNote "Lath particles are similar in shape to A4 paper sheets." . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000303 + +af-q:AFQ_0000303 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000311 ; + + af-x:AFX_0002808 "USP 30(6) Harmonization: <776> OPTICAL MICROSCOPY" ; + + rdfs:isDefinedBy ; + + skos:altLabel "equant" ; + + skos:definition "An equant particle shape is a shape of particle with similar height, width, and length. [Allotrope]" ; + + skos:prefLabel "equant particle shape" ; + + skos:scopeNote "Equant particles may be spherical or cuboid." . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000304 + +af-q:AFQ_0000304 rdf:type owl:Class ; + + rdfs:subClassOf pato:_0000141 ; + + rdfs:isDefinedBy ; + + skos:altLabel "association state" ; + + skos:definition "An association state is a structure of an association of primary particles in a material. [Allotrope]" ; + + skos:prefLabel "association state (quality)" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000305 + +af-q:AFQ_0000305 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000304 ; + + af-x:AFX_0002808 "USP 30(6) Harmonization: <776> OPTICAL MICROSCOPY" ; + + rdfs:isDefinedBy ; + + skos:altLabel "lamellar" ; + + skos:definition "A lamellar association state is an association state where the primary particles associate as a collection of plate particles in a stack. [Allotrope]" ; + + skos:prefLabel "lamellar association state" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000306 + +af-q:AFQ_0000306 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000304 ; + + af-x:AFX_0002808 "USP 30(6) Harmonization: <776> OPTICAL MICROSCOPY" ; + + rdfs:isDefinedBy ; + + skos:altLabel "aggregate" ; + + skos:definition "An aggregate association state is an association state where the primary particles associate as a collection of particles loosely coupled together. [Allotrope]" ; + + skos:prefLabel "aggregate association state" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000307 + +af-q:AFQ_0000307 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000304 ; + + af-x:AFX_0002808 "USP 30(6) Harmonization: <776> OPTICAL MICROSCOPY" ; + + rdfs:isDefinedBy ; + + skos:altLabel "agglomerate" ; + + skos:definition "An agglomerate association state is an association state where the primary particles associate as a collection of particles tightly coupled together. [Allotrope]" ; + + skos:prefLabel "agglomerate association state" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000308 + +af-q:AFQ_0000308 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000304 ; + + af-x:AFX_0002808 "USP 30(6) Harmonization: <776> OPTICAL MICROSCOPY" ; + + rdfs:isDefinedBy ; + + skos:altLabel "conglomerate" ; + + skos:definition "A conglomerate association state is an association state where the primary particles associate as a collection of different types of particle. [Allotrope]" ; + + skos:prefLabel "conglomerate association state" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000309 + +af-q:AFQ_0000309 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000304 ; + + af-x:AFX_0002808 "USP 30(6) Harmonization: <776> OPTICAL MICROSCOPY" ; + + rdfs:isDefinedBy ; + + skos:altLabel "spherulite" ; + + skos:definition "A spherulite association state is an association state where the primary particles associate as a collection of particles grouped radially about a central point. [Allotrope]" ; + + skos:prefLabel "spherulite association state" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000310 + +af-q:AFQ_0000310 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000304 ; + + af-x:AFX_0002808 "USP 30(6) Harmonization: <776> OPTICAL MICROSCOPY" ; + + rdfs:isDefinedBy ; + + skos:altLabel "drusy" ; + + skos:definition "A drusy association state is an association state where the primary particles associate as a collection of large particle covered by smaller particles. [Allotrope]" ; + + skos:prefLabel "drusy association state" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000311 + +af-q:AFQ_0000311 rdf:type owl:Class ; + + rdfs:subClassOf pato:_0000052 ; + + rdfs:isDefinedBy ; + + skos:altLabel "particle shape" ; + + skos:definition "A particle shape is a shape quality of a particle. [Allotrope]" ; + + skos:prefLabel "particle shape (quality)" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000313 + +af-q:AFQ_0000313 rdf:type owl:Class ; + + rdfs:subClassOf pato:_0000122 ; + + rdfs:isDefinedBy ; + + skos:definition "A chord length is the length between any two points on the edge of a particle, with an upper bound of the diameter of the particle. [Allotrope]" ; + + skos:prefLabel "chord length (quality)" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000314 + +af-q:AFQ_0000314 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000036 , + [ rdf:type owl:Class ; + owl:unionOf ( [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002722 ; + owl:someValuesFrom af-q:AFQ_0000049 + ] + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002723 ; + owl:someValuesFrom af-q:AFQ_0000049 + ] + ) + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A current configuration is a device configuration of a current controlling or monitoring device, that controls or monitors the target electric current at the site of some system component. [Allotrope]" ; + + skos:prefLabel "current configuration" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000315 + +af-q:AFQ_0000315 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000036 , + [ rdf:type owl:Class ; + owl:unionOf ( [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002722 ; + owl:someValuesFrom af-q:AFQ_0000048 + ] + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002723 ; + owl:someValuesFrom af-q:AFQ_0000048 + ] + ) + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A voltage configuration is a device configuration of a voltage controlling or monitoring device, that controls or monitors the target voltage at the site of some system component. [Allotrope]" ; + + skos:prefLabel "voltage configuration" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000316 + +af-q:AFQ_0000316 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000295 ; + + dct:license ; + + dct:rights ; + + dct:source "IUPAC Quantities, Units and Symbols in Physical Chemistry, 1993" ; + + rdfs:isDefinedBy ; + + skos:altLabel "angle of optical rotation" , + "polarization rotation" ; + + skos:definition "Circular birefringence is the angle through which plane polarized light is rotated clockwise, as seen when facing the light source, in passing through an optically active medium. [IUPAC]" ; + + skos:prefLabel "circular birefringence (quality)" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000317 + +af-q:AFQ_0000317 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000295 ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:definition "Specific rotation is the change in orientation of monochromatic plane-polarized light, per unit distance–concentration product, as the light passes through a sample of a compound in solution. [Wikipedia]" ; + + skos:prefLabel "specific rotation (quality)" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000318 + +af-q:AFQ_0000318 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000056 ; + + rdfs:isDefinedBy ; + + skos:altLabel "temperature rate" ; + + skos:definition "A temperature rate is a thermal quality which describes the change in temperature over time in some material bearer. [Allotrope]" ; + + skos:prefLabel "temperature rate (quality)" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000319 + +af-q:AFQ_0000319 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000252 ; + + dct:license ; + + dct:rights ; + + rdfs:isDefinedBy ; + + skos:altLabel "chemical shift" ; + + skos:definition "The fractional variation of the resonance frequency of a nucleus in nuclear magnetic resonance (NMR) spectroscopy in consequence of its magnetic environment. [IUPAC]" ; + + skos:prefLabel "chemical shift (molecular quality)" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000321 + +af-q:AFQ_0000321 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000065 ; + + dct:license ; + + dct:rights ; + + dct:source "IUPAC Green Book, 2nd ed., p. 14" ; + + rdfs:isDefinedBy ; + + skos:altLabel "dielectric constant" , + "relative permittivity" , + "εr" ; + + skos:definition "Relative permittivity is an electrical and magnetic quality inhered in a medium that is the ratio of the electric field strength in vacuum to that in the medium. [IUPAC]" ; + + skos:prefLabel "relative permittivity (quality)" . + + + +### http://purl.allotrope.org/ontologies/quality#AFQ_0000323 + +af-q:AFQ_0000323 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000056 ; + + dct:license ; + + dct:rights ; + + dct:source "IUPAC. Compendium of Chemical Terminology, 2nd ed. (the \"Gold Book\"). Compiled by A. D. McNaught and A. Wilkinson. Blackwell Scientific Publications, Oxford (1997)" ; + + rdfs:isDefinedBy ; + + skos:altLabel "conductance" , + "conductance (quality)" , + "thermal conductance" ; + + skos:definition "Thermal conductance is the quality inhered in a conductor that is the reciprocal of the thermal resistance. [IUPAC]" ; + + skos:prefLabel "thermal conductance (quality)" . + + + +### http://purl.allotrope.org/ontologies/realizable#AFRE_0000001 + +af-re:AFRE_0000001 rdf:type owl:Class ; + + rdfs:subClassOf obi:_0000260 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "task" ; + + skos:definition "An action is a unit element in a procedure and is a concretization of an action specification. [Allotrope]" ; + + skos:prefLabel "action" . + + + +### http://purl.allotrope.org/ontologies/realizable#AFRE_0000002 + +af-re:AFRE_0000002 rdf:type owl:Class ; + + rdfs:subClassOf obi:_0000260 ; + + rdfs:isDefinedBy ; + + skos:definition "A procedure is plan containing multiple activities that are intended to be executed in an order following a procedure specification. [Allotrope]" ; + + skos:prefLabel "procedure" . + + + +### http://purl.allotrope.org/ontologies/realizable#AFRE_0000003 + +af-re:AFRE_0000003 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000017 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "Portion of reality that is realized in some process. [Allotrope]" ; + + skos:prefLabel "situation" . + + + +### http://purl.allotrope.org/ontologies/realizable#AFRE_0000004 + +af-re:AFRE_0000004 rdf:type owl:Class ; + + rdfs:subClassOf af-re:AFRE_0000003 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "constitution" , + "physique" , + "structure" ; + + skos:definition "A specific combination of qualities that the bearer realizes at some time. [Allotrope]" ; + + skos:prefLabel "configuration" . + + + +### http://purl.allotrope.org/ontologies/realizable#AFRE_0000005 + +af-re:AFRE_0000005 rdf:type owl:Class ; + + rdfs:subClassOf af-re:AFRE_0000003 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "environment" ; + + skos:definition "A situation that is realized in a processes outside the system boundary of an operation situation of a device. [Allotrope]" ; + + skos:example "example: humid conditions" ; + + skos:prefLabel "environmental situation" . + + + +### http://purl.allotrope.org/ontologies/realizable#AFRE_0000006 + +af-re:AFRE_0000006 rdf:type owl:Class ; + + rdfs:subClassOf af-re:AFRE_0000003 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "operation" ; + + skos:changeNote "2019-09-20 Moved, an operational situation is not necessarily an environmental situation. [Allotrope]" ; + + skos:definition "The situation when a device is performing its intended function. [Allotrope]" ; + + skos:prefLabel "operational situation" . + + + +### http://purl.allotrope.org/ontologies/realizable#AFRE_0000007 + +af-re:AFRE_0000007 rdf:type owl:Class ; + + rdfs:subClassOf af-re:AFRE_0000003 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A transition is a situation that is realized when one or more preceding processes end and the one or more succeeding processes begin. [Allotrope]" ; + + skos:prefLabel "transition" . + + + +### http://purl.allotrope.org/ontologies/realizable#AFRE_0000008 + +af-re:AFRE_0000008 rdf:type owl:Class ; + + rdfs:subClassOf af-re:AFRE_0000003 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A realizable entity that when realized coincides with the start of some intended or causally dependent process. [Allotrope]" ; + + skos:prefLabel "trigger" . + + + +### http://purl.allotrope.org/ontologies/realizable#AFRE_0000011 + +af-re:AFRE_0000011 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000016 ; + + rdfs:isDefinedBy ; + + skos:altLabel "chemical agent" ; + + skos:definition "A disposition of a portion of material to react with other materials in a specific way by nature of its chemical composition. [Allotrope]" ; + + skos:prefLabel "chemical disposition" . + + + +### http://purl.allotrope.org/ontologies/realizable#AFRE_0000012 + +af-re:AFRE_0000012 rdf:type owl:Class ; + + rdfs:subClassOf af-re:AFRE_0000013 ; + + af-x:AFX_0002808 chebi:_27780 , + ; + + rdfs:isDefinedBy ; + + skos:definition "A surfactant (or a mixture containing one or more surfactants) disposed to having cleaning properties in dilute solutions. [ChEBI]" ; + + skos:prefLabel "detergent" . + + + +### http://purl.allotrope.org/ontologies/realizable#AFRE_0000013 + +af-re:AFRE_0000013 rdf:type owl:Class ; + + rdfs:subClassOf af-re:AFRE_0000014 ; + + af-x:AFX_0002808 chebi:_35195 ; + + rdfs:isDefinedBy ; + + skos:definition "The disposition to lower the surface tension of the medium in which the material is dissolved, and/or the interfacial tension with other phases, and, accordingly, is positively adsorbed at the liquid/vapor and/or at other interfaces. [ChEBI]" ; + + skos:prefLabel "surfactant" . + + + +### http://purl.allotrope.org/ontologies/realizable#AFRE_0000014 + +af-re:AFRE_0000014 rdf:type owl:Class ; + + rdfs:subClassOf af-re:AFRE_0000011 ; + + rdfs:isDefinedBy ; + + skos:altLabel "surface-active agent" ; + + skos:definition "A surface-active agent is a disposition of a portion of material to react or interact with the surface of other materials. [Allotrope]" ; + + skos:prefLabel "surface-active disposition" . + + + +### http://purl.allotrope.org/ontologies/realizable#AFRE_0000015 + +af-re:AFRE_0000015 rdf:type owl:Class ; + + rdfs:subClassOf af-re:AFRE_0000011 ; + + rdfs:isDefinedBy ; + + skos:definition "A chemical reaction disposition is a disposition inhered in a reaction mixture. [Allotrope]" ; + + skos:prefLabel "chemical reaction disposition" . + + + +### http://purl.allotrope.org/ontologies/realizable#AFRE_0000016 + +af-re:AFRE_0000016 rdf:type owl:Class ; + + rdfs:subClassOf af-re:AFRE_0000015 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000092 ; + owl:someValuesFrom [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000086 ; + owl:someValuesFrom af-q:AFQ_0000228 + ] + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A reaction selectivity disposition is a disposition of a reaction mixture to have a reaction selectivity. [Allotrope]" ; + + skos:prefLabel "reaction selectivity disposition" . + + + +### http://purl.allotrope.org/ontologies/realizable#AFRE_0000019 + +af-re:AFRE_0000019 rdf:type owl:Class ; + + rdfs:subClassOf af-re:AFRE_0000004 , + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000054 ; + owl:someValuesFrom bfo:_0000182 + ] ; + + dct:source ; + + rdfs:isDefinedBy , + ; + + skos:definition "Hysteresis is the time-based dependence of a system's output on present and past inputs. The dependence arises because the history affects the value of an internal state. To predict its future outputs, either its internal state or its history must be known. [Wikipedia]" ; + + skos:prefLabel "hysteresis" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000001 + +af-r:AFR_0000001 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001060 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A plot of intensity vs. kinetic energy obtained when a high energy photon ionizes a core electron and an electron from a higher energy level descends to take its place, releasing sufficient energy to eject a second so-called 'Auger' electron. [CHMO]" ; + + skos:prefLabel "Auger spectrum" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000007 + +af-r:AFR_0000007 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001060 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "DSC curve" , + "DSC heating curve" , + "DSC plot" , + "DSC thermogram" , + "DSC thermograms" ; + + skos:definition "A plot of enthalpy vs. temperature obtained by measuring the enthalpy required to increase the temperature of a sample as a function of temperature. [CHMO]" ; + + skos:prefLabel "differential scanning calorimetry curve" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000015 + +af-r:AFR_0000015 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000413 ; + + rdfs:isDefinedBy ; + + skos:definition "A chromatography peak is a peak that results from a detector's response to the presence of an analyte in the mobile phase eluting from a column in chromatography. [Allotrope]" ; + + skos:prefLabel "chromatography peak" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000020 + +af-r:AFR_0000020 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001060 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "microwave spectra" ; + + skos:definition "A plot of emission vs. wavelength obtained through a Fourier transform of the time series of the radiation emitted by a sample of gas phase molecules that have been excited by a microwave-frequency pulse. [CHMO]" ; + + skos:prefLabel "microwave spectrum" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000023 + +af-r:AFR_0000023 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000490 ; + + rdfs:isDefinedBy ; + + skos:altLabel "Karl Fischer titration curve" ; + + skos:definition "A Karl-Fischer titration curve is a titration curve of mass of water over time. [Allotrope]" ; + + skos:prefLabel "Karl-Fischer titration curve" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000024 + +af-r:AFR_0000024 rdf:type owl:Class ; + + rdfs:subClassOf [ owl:intersectionOf ( af-r:AFR_0000207 + af-r:AFR_0000922 + ) ; + rdf:type owl:Class + ] ; + + rdfs:isDefinedBy ; + + skos:definition "The description of a chemical moiety or material that is assigned to a peak. [Allotrope]" ; + + skos:prefLabel "peak assignment target" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000035 + +af-r:AFR_0000035 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000160 ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:altLabel "SIM chromatogram" , + "SIM spectrum" ; + + skos:definition "A selected-ion monitoring (SIM) chromatogram is similar to an XIC, with the exception that the mass spectrometer is operated in SIM mode, such that only preselected m/z values are detected in the analysis. [Wikipedia]" ; + + skos:prefLabel "selected ion monitoring chromatogram" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000044 + +af-r:AFR_0000044 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001060 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "conversion spectra" ; + + skos:definition "A plot of a quantity related to the absorption, for example absorbance or cross section, multiplied by the quantum yield for the process considered against a measure of photon energy such as frequency, wavenumber or wavelength. [CHMO]" ; + + skos:prefLabel "conversion spectrum" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000046 + +af-r:AFR_0000046 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001060 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "photoelectron spectra" ; + + skos:definition "A plot of photoelectron count vs. kinetic energy. [CHMO]" ; + + skos:prefLabel "photoelectron spectrum" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000053 + +af-r:AFR_0000053 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001060 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "CD spectra" , + "CD spectrum" , + "circular dichroic spectra" , + "circular dichroic spectrum" , + "circular dichroism (CD) spectra" , + "circular dichroism spectra" ; + + skos:definition "A plot of ellipticity vs. wavelength obtained by measuring the differential absorption of left- and right-handed circularly polarized photon radiation as a function of wavelength. [CHMO]" ; + + skos:prefLabel "circular dichroism spectrum" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000057 + +af-r:AFR_0000057 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001060 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "alpha particle spectra" , + "alpha particle spectrum" , + "alpha-particle spectra" , + "α-particle spectra" , + "α-particle spectrum" ; + + skos:definition "A plot of alpha-particle count vs. energy obtained by measuring the number and kinetic energies of alpha-particles emitted by a sample. [CHMO]" ; + + skos:prefLabel "alpha-particle spectrum" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000062 + +af-r:AFR_0000062 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000207 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002734 ; + owl:someValuesFrom af-p:AFP_0000503 + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "The weighing result is the result of a weighing process. [Allotrope]" ; + + skos:prefLabel "weighing result" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000064 + +af-r:AFR_0000064 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000922 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "Data obtained from a structure determination method. [CHMO]" ; + + skos:prefLabel "structure data" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000066 + +af-r:AFR_0000066 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000514 ; + + rdfs:isDefinedBy ; + + skos:altLabel "UV-Vis-NIR absorption spectrum" , + "UV-Vis-NIR spectra" , + "UV-Vis-NIR spectrum" , + "UV-vis-NIR absorption spectra" , + "UV-vis-NIR spectra" , + "UV-vis-near IR spectra" , + "UV-vis-near IR spectrum" , + "UV-visible-near IR spectrum" ; + + skos:definition "A plot of absorbance vs. wavelength obtained by measuring the amount of radiation absorbed by a sample as a function of the wavelength of incident radiation in the ultraviolet to near-infrared (190-2000 nm) range. [CHMO]" ; + + skos:prefLabel "ultraviolet-visible-near infrared spectrum" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000068 + +af-r:AFR_0000068 rdf:type owl:Class ; + + rdfs:subClassOf [ owl:intersectionOf ( af-r:AFR_0000754 + af-r:AFR_0001060 + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "spectra" , + "spectrum plot" ; + + skos:changeNote "2020-12-10 Changed definition. [Allotrope]" ; + + skos:definition "A spectrum is a data distribution function of a measured quantity in a spectroscopy against some experimental parameter. [Allotrope]" ; + + skos:prefLabel "spectrum" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000070 + +af-r:AFR_0000070 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001060 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "voltammetric profile" ; + + skos:definition "A plot of cell current vs. the potential between the indicator and reference electrodes obtained from a voltammetry experiment. [CHMO]" ; + + skos:prefLabel "voltammogram" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000090 + +af-r:AFR_0000090 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000207 , + af-r:AFR_0000922 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A data set derived from chemical imaging consisting of a three-dimensional image where two axes describe the x and y spatial dimensions and the third dimension represents spectral wavelength. The image is obtained by stacking one image per spectral wavelength sequentially. [CHMO]" ; + + skos:prefLabel "chemical map" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000091 + +af-r:AFR_0000091 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001060 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "ITC curve" , + "ITC curves" , + "ITC-curve" , + "isothermal titration calorimetric curve" ; + + skos:definition "A plot of energy vs. time obtained from the measurement of the heat evolved during a chemical or biochemical reaction (such as protein--receptor binding). [CHMO]" ; + + skos:prefLabel "isothermal titration calorimetry curve" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000110 + +af-r:AFR_0000110 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001060 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "\\gamma-ray spectra" , + "\\gamma-ray spectrum" , + "gamma ray spectra" , + "gamma ray spectrum" , + "gamma-ray spectra" ; + + skos:definition "A plot of gamma-ray count vs. energy spectrum obtained by measuring the number and energy of gamma-rays emitted or absorbed by a sample. [CHMO]" ; + + skos:prefLabel "gamma-ray spectrum" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000120 + +af-r:AFR_0000120 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000207 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002734 ; + owl:someValuesFrom af-p:AFP_0003541 + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A temperature measurement result is an assay result that is the output of a temperature measurement. [Allotrope]" ; + + skos:prefLabel "temperature measurement result" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000132 + +af-r:AFR_0000132 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000236 ; + + rdfs:isDefinedBy ; + + skos:altLabel "GC chromatogram" ; + + skos:definition "A plot of detector signal (e.g. ion count or absorbance) vs. retention time obtained from a column chromatography experiment where the mobile phase is a gas. [CHMO]" ; + + skos:prefLabel "gas chromatogram" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000133 + +af-r:AFR_0000133 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000236 , + af-r:AFR_0000576 , + af-r:AFR_0001060 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "An electropherogram is the outcome of a capillary electrophoresis that reports the response of a detector as a function of time. [Allotrope]" ; + + skos:prefLabel "electropherogram" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000142 + +af-r:AFR_0000142 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001060 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "EELS spectra" , + "EELS spectrum" , + "electron energy loss spectroscopy (EELS) spectra" , + "electron energy loss spectroscopy (EELS) spectrum" , + "electron energy-loss spectra" ; + + skos:definition "A plot of intensity vs. energy loss obtained by measuring the energy lost by electrons on interacting with a surface. [CHMO]" ; + + skos:prefLabel "electron energy-loss spectrum" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000155 + +af-r:AFR_0000155 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000207 ; + + rdfs:isDefinedBy ; + + skos:altLabel "BGA result" , + "blood gas measurement result" ; + + skos:definition "The measurement result of analysis from a blood gas analyzer. [Allotrope]" ; + + skos:prefLabel "blood gas analysis result" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000160 + +af-r:AFR_0000160 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000236 ; + + rdfs:isDefinedBy ; + + skos:definition "A mass chromatogram is a distribution function of a mass detector signal versus time of acquisition or versus volume of analyte. [Allotrope]" ; + + skos:prefLabel "mass chromatogram" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000164 + +af-r:AFR_0000164 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001060 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "photoacoustic spectra" ; + + skos:definition "A plot of intensity vs. wavelength obtained by measuring the sound emitted when a gaseous sample is exposed to an intense laser beam, which is rapidly interrupted by a rotating slotted disk. [CHMO]" ; + + skos:prefLabel "photoacoustic spectrum" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000166 + +af-r:AFR_0000166 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001060 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "adsorption-desorption isotherm" , + "adsorption/desorption isotherm" ; + + skos:definition "A plot of relative pressure vs. volume adsorbed obtained by measuring the amount of an inert gaseous or liquid substance (the 'sorbent', usually H2 or N2) which adsorbs onto the surface of interest (the 'sorbate'), and the subsequent amount that desorbs at a constant temperature. [CHMO]" ; + + skos:prefLabel "adsorption-desorption isotherm" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000186 + +af-r:AFR_0000186 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000922 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002737 ; + owl:someValuesFrom af-r:AFR_0001046 + ] ; + + af-x:AFX_0002808 qb:Observation ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A data point is the single point in a coordinate space. [Allotrope]" ; + + skos:prefLabel "data point" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000207 + +af-r:AFR_0000207 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000922 , + af-r:AFR_0002020 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002734 ; + owl:someValuesFrom af-p:AFP_0002680 + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + af-x:AFX_0002808 chmo:_0000793 ; + + dct:license ; + + dct:rights ; + + rdfs:isDefinedBy ; + + skos:altLabel "assay output" , + "experimental result" , + "result" ; + + skos:changeNote "2020-03-20 Changed equivalent class to subclass. [Allotrope]" ; + + skos:definition "The final outcome reported for a measured or computed quantity, after performing a measuring procedure including all sub procedures and evaluations. [IUPAC, Allotrope]" ; + + skos:prefLabel "assay result" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000222 + +af-r:AFR_0000222 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000068 ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:altLabel "absorbance spectra" , + "absorbance spectrum" , + "absorption spectra" ; + + skos:definition "An absorption spectrum is a data distribution function that plots the absorption of radiance as the function of frequency or wavelength. [Wikipedia]" ; + + skos:prefLabel "absorption spectrum" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000231 + +af-r:AFR_0000231 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000432 , + [ owl:intersectionOf ( af-r:AFR_0000432 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0002351 ; + owl:allValuesFrom af-r:AFR_0000413 + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:isDefinedBy ; + + skos:changeNote "2018-07-19 Changed definition, relaxed restriction. [Allotrope]" ; + + skos:definition "A peak group is a user defined set of peaks for which summed peak facet data is expected. [Allotrope]" ; + + skos:example "A common example is for alkanes such as heptanes. Often all of the isomers (C7H16, CH3CH2(CH3)C4H10, C2H5CH2(CH3)C3H8, CH3CH2(CH2CH3)C3H8, etc) are reported as a single value." , + "Sum of all peak areas in the group." ; + + skos:prefLabel "peak group" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000236 + +af-r:AFR_0000236 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000523 , + af-r:AFR_0000576 , + af-r:AFR_0001060 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:changeNote "2020-11-12 Subclassed under chromatography result. [Allotrope]" ; + + skos:definition "A chromatogram is a distribution function of a detector signal (such as ion count or absorbance) versus time of acquisition or versus volume of analyte. [Allotrope]" ; + + skos:prefLabel "chromatogram" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000246 + +af-r:AFR_0000246 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000514 ; + + rdfs:isDefinedBy ; + + skos:altLabel "2D UV spectrum" , + "2D UV spectrum (abs. over wavelength)" , + "UV spectra" , + "UV spectrum" , + "two dimensional ultraviolet spectrum" , + "two-dimensional ultraviolet spectrum" , + "ultra-violet spectra" , + "ultra-violet spectrum" , + "ultraviolet spectra" , + "ultraviolet spectrum" ; + + skos:definition "A plot of absorbance vs. wavelength obtained by measuring the amount of radiation absorbed by a sample as a function of the wavelength of incident radiation from the ultraviolet region (190-400 nm) range. [CHMO]" ; + + skos:prefLabel "ultraviolet spectrum" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000251 + +af-r:AFR_0000251 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000068 , + af-r:AFR_0001060 , + af-r:AFR_0002105 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "IR spectra" , + "IR spectrum" , + "infra-red spectra" , + "infra-red spectrum" , + "infrared (IR) spectra" , + "infrared (IR) spectrum" , + "infrared spectra" ; + + skos:definition "A plot of absorbance or transmittance vs. wavelength/wavenumber/frequency obtained by measuring the absorption or transmission of infrared radiation by a sample. [CHMO]" ; + + skos:prefLabel "infrared spectrum" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000263 + +af-r:AFR_0000263 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001060 , + af-r:AFR_0002255 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "NMR spectra" , + "NMR spectrum" , + "nuclear magnetic resonance spectra" ; + + skos:definition "Any spectrum that shows the response of spin-active nuclei to radio frequency radiation in an applied magnetic field. [CHMO]" ; + + skos:prefLabel "nuclear magnetic resonance spectrum" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000284 + +af-r:AFR_0000284 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001060 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "optical transmission spectrum" ; + + skos:definition "A plot of extinction (or transmittance) vs. wavelength (or wavenumber) obtained by measuring the amount of radiation transmitted through a sample as a function of the wavelength of the incident radiation. Optical extinction spectra can also be derived theoretically. [CHMO]" ; + + skos:prefLabel "optical extinction spectrum" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000289 + +af-r:AFR_0000289 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001060 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "atomic spectra" ; + + skos:definition "A plot of absorption or emission radiation vs. frequency that reflects the internal degrees of freedom of an atom, obtained in an experiment where the sample is vaporized and then atomized. [CHMO]" ; + + skos:prefLabel "atomic spectrum" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000294 + +af-r:AFR_0000294 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001060 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "IET spectra" , + "IET spectrum" , + "inelastic tunneling spectra" , + "inelastic tunnelling spectra" , + "inelastic tunnelling spectrum" ; + + skos:definition "A plot of current (or a first or higher derivative of current with respect to voltage) vs. voltage obtained by measuring the tunneling current through a metal-oxide-metal sandwich. Molecules are adsorbed onto the oxide and these molecules can affect the tunneling via the excitation of vibrational states. [CHMO]" ; + + skos:prefLabel "inelastic tunneling spectrum" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000297 + +af-r:AFR_0000297 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001060 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:definition "A melting curve is the data distribution function over temperature that is the output of a melting curve analysis. Melting curve analysis is an assessment of the dissociation characteristics of double-stranded DNA during heating. As the temperature is raised, the double strand begins to dissociate leading to a rise in the absorbance intensity, hyperchromicity. [Wikipedia]" ; + + skos:prefLabel "melting curve" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000300 + +af-r:AFR_0000300 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001060 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "GEMMA spectra" , + "GEMMA spectrum" ; + + skos:definition "A plot of electrophoretic mobility diameter vs. particle count generated by separating singly-charged complexes in air under the influence of an electric field. [CHMO]" ; + + skos:prefLabel "gas-phase electrophoretic mobility molecular analysis spectrum" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000304 + +af-r:AFR_0000304 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000922 ; + + rdfs:isDefinedBy ; + + skos:definition "A certificate refers to the confirmation of certain characteristics of an object, person or organization. This confirmation is often, but not always, provided by some form of external review, education, assessment, or audit. Accreditation is a specific organization's process of certification. [Wikipedia]" ; + + skos:prefLabel "certificate" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000308 + +af-r:AFR_0000308 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000236 ; + + rdfs:isDefinedBy ; + + skos:altLabel "EMR chromatogram" ; + + skos:definition "An electromagnetic radiation chromatogram is a distribution function of a electromagnetic radiation detector signal versus time of acquisition or versus volume of analyte. [Allotrope]" ; + + skos:prefLabel "electromagnetic radiation chromatogram" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000317 + +af-r:AFR_0000317 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000514 ; + + rdfs:isDefinedBy ; + + skos:altLabel "VIS spectra" , + "VIS spectrum" , + "optical absorption spectra" , + "optical absorption spectrum" , + "visible spectra" ; + + skos:definition "A plot of absorbance vs. wavelength obtained by measuring the amount of radiation absorbed by a sample as a function of the wavelength of incident radiation from the visible region (380-800 nm) range. [CHMO]" ; + + skos:prefLabel "visible spectrum" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000319 + +af-r:AFR_0000319 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001060 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "action spectra" ; + + skos:definition "A plot of a relative biological or chemical photoresponse per number of incident photons against wavelength or energy of radiation under the same radiant power of light. [CHMO]" ; + + skos:prefLabel "action spectrum" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000323 + +af-r:AFR_0000323 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001060 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "oximetric data" , + "oximetry data" , + "oximetry spectra" ; + + skos:definition "A plot of % oxygen vs. time, measured during a process where oxygen is consumed or evolved. [CHMO]" ; + + skos:prefLabel "oximetry spectrum" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000325 + +af-r:AFR_0000325 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001060 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "acoustic emission spectra" ; + + skos:definition "A plot of decibels vs. frequency obtained by measuring the amount of noise generated by a sample as a function of frequency of incident radiation. [CHMO]" ; + + skos:prefLabel "acoustic emission spectrum" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000336 + +af-r:AFR_0000336 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001060 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A plot of stress vs. flow rate obtained from rheological measurements. [CHMO]" ; + + skos:prefLabel "flow curve" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000341 + +af-r:AFR_0000341 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001060 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "X-ray spectra" ; + + skos:definition "A plot of intensity vs. energy obtained by measuring the number and energy of X-rays absorbed or emitted by a sample. [CHMO]" ; + + skos:prefLabel "X-ray spectrum" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000345 + +af-r:AFR_0000345 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001060 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "beta particle spectra" , + "beta particle spectrum" , + "beta-particle spectra" , + "β-particle spectra" , + "β-particle spectrum" ; + + skos:definition "A plot of beta-particle count vs. energy obtained by measuring the number and energy of beta-particles emitted by a sample. [CHMO]" ; + + skos:prefLabel "beta-particle spectrum" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000360 + +af-r:AFR_0000360 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000514 ; + + rdfs:isDefinedBy ; + + skos:altLabel "UV-VIS absorption spectra" , + "UV-Vis spectra" , + "UV-Vis spectrum" , + "UV-vis absorption spectra" , + "UV-vis absorption spectrum" , + "UV-vis spectra" , + "UV-vis spectrum" , + "UV-visible spectra" , + "UV-visible spectrum" , + "UV/VIS absorption spectra" , + "UV/VIS spectra" , + "UV/vis spectra" , + "UV/vis spectrum" , + "UV/visible spectra" , + "UV/visible spectrum" , + "spectrophotometric data" , + "ultraviolet-visible spectra" , + "ultraviolet-visible spectrum" ; + + skos:definition "A plot of absorbance vs. wavelength obtained by measuring the amount of radiation absorbed by a sample as a function of the wavelength of incident radiation in the ultraviolet to visible (190-800 nm) range. [CHMO]" ; + + skos:prefLabel "ultraviolet-visible spectrum" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000369 + +af-r:AFR_0000369 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000068 ; + + rdfs:isDefinedBy ; + + skos:altLabel "dielectric spectrum" , + "impedance spectra" ; + + skos:definition "A plot of impedance vs. frequency that reflects the change in impedance of a sample during excitation. [CHMO]" ; + + skos:prefLabel "impedance spectrum" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000373 + +af-r:AFR_0000373 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001060 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A plot of e vs hv where e is the molar extinction coefficient, that is used to determine the optical gap (or 'Tauc gap') in amorphous thin film materials. [CHMO]" ; + + skos:prefLabel "Tauc plot" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000386 + +af-r:AFR_0000386 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000439 ; + + rdfs:isDefinedBy ; + + skos:altLabel "MIM spectrum" , + "multiple ion monitoring spectrum" , + "selected ion monitoring spectrum" ; + + skos:definition "Spectrum obtained with the operation of a mass spectrometer in which the abundances of one ion or several ions of specific m/z values are recorded rather than the entire mass spectrum (Selected Ion Monitoring). [PSI/MS]" ; + + skos:prefLabel "SIM spectrum" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000410 + +af-r:AFR_0000410 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000236 ; + + rdfs:isDefinedBy ; + + skos:altLabel "SEC chromatogram" , + "SEC elugram" , + "SEC profile" , + "SEC trace" , + "size exclusion chromatogram" ; + + skos:definition "A plot of detector signal (e.g. ion count or absorbance) vs. retention time obtained from a chromatography experiment where the separation is caused by exclusion effects within the stationary phase and where the stationary phase is a swollen gel. [CHMO]" ; + + skos:prefLabel "size-exclusion chromatogram" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000412 + +af-r:AFR_0000412 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001060 ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "excitation-emission spectra" , + "excitation-emission spectrum" ; + + skos:definition "A three-dimensional spectrum generated by scanning the emission spectrum at incremental steps of excitation wavelength. [CHMO]" ; + + skos:prefLabel "excitation-emission spectrum" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000413 + +af-r:AFR_0000413 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000922 , + [ owl:intersectionOf ( [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000050 ; + owl:someValuesFrom af-r:AFR_0001060 + ] + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0002351 ; + owl:someValuesFrom af-r:AFR_0001186 + ] + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A peak describes a part of a data distribution function at a definite range of the experimental parameter (independent variable) of the distribution function. This definition includes a single data point of the distribution function. [Allotrope]" ; + + skos:prefLabel "peak" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000417 + +af-r:AFR_0000417 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001060 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:altLabel "EMR spectrum" , + "electromagnetic spectrum" ; + + skos:definition "The electromagnetic radiation spectrum is the range of frequencies (the spectrum) of electromagnetic radiation and their respective wavelengths and photon energies. [Wikipedia]" ; + + skos:prefLabel "electromagnetic radiation spectrum" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000432 + +af-r:AFR_0000432 rdf:type owl:Class ; + + rdfs:subClassOf af-c:AFC_0000166 , + af-r:AFR_0000922 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0002351 ; + owl:someValuesFrom [ rdf:type owl:Class ; + owl:unionOf ( af-r:AFR_0000231 + af-r:AFR_0000413 + ) + ] + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "Collection of peaks or peak groups for a specific purpose. [Allotrope]" ; + + skos:prefLabel "peak list" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000438 + +af-r:AFR_0000438 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001060 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "IPCE spectrum" , + "incident photon conversion efficiency spectra" , + "incident photon to collected electron (IPCE) spectra" , + "incident photon to collected electron (IPCE) spectrum" , + "incident photon to collected electron spectra" , + "incident photon to current collection efficiency spectrum" , + "incident photon-to-electron conversion efficiency spectrum" , + "incident-photon-to-current conversion efficiency (IPCE) spectrum" , + "incident-photon-to-current conversion efficiency spectrum" ; + + skos:definition "A plot of incident photon-to-current conversion efficiency (IPCE) vs. wavelength obtained from a solar or photovoltaic cell. [CHMO]" ; + + skos:prefLabel "incident photon conversion efficiency spectrum" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000439 + +af-r:AFR_0000439 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000068 , + af-r:AFR_0001060 , + af-r:AFR_0002256 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + dct:license ; + + dct:rights ; + + dct:source "Pure Appl. Chem., Vol. 85, No. 7, pp. 1515–1609, 2013. http://dx.doi.org/10.1351/PAC-REC-06-04-06" ; + + rdfs:isDefinedBy ; + + skos:altLabel "mass spectra" ; + + skos:definition "A mass spectrum is a data distribution function that plots the relative abundances of ions forming a beam or other collection as a function of their m/z values. [IUPAC]" ; + + skos:note "The term is a misnomer because it is m/z rather than mass that is the independent variable in a mass spectrum. [IUPAC]" ; + + skos:prefLabel "mass spectrum" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000443 + +af-r:AFR_0000443 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000160 ; + + rdfs:isDefinedBy ; + + skos:definition "A ion chromatogram is a distribution function of a ion current signal of a mass detector versus time of acquisition or versus volume of analyte. [Allotrope]" ; + + skos:prefLabel "ion chromatogram" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000468 + +af-r:AFR_0000468 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000504 ; + + rdfs:isDefinedBy ; + + skos:altLabel "Karl Fischer titration result" ; + + skos:definition "A Karl-Fischer titration result is the result of a Karl-Fischer titration run. [Allotrope]" ; + + skos:prefLabel "Karl-Fischer titration result" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000471 + +af-r:AFR_0000471 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( af-r:AFR_0000207 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002734 ; + owl:someValuesFrom af-p:AFP_0000032 + ] + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "cell counter analysis result" , + "cell counter measurement result" ; + + skos:changeNote "2018-03-09 Added to cell counting domain [OSTHUS]" ; + + skos:definition "A cell counter result is an assay result that is the result of a cell counter assay. [Allotrope]" ; + + skos:prefLabel "cell counter result" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000490 + +af-r:AFR_0000490 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000504 , + af-r:AFR_0001060 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000353 ; + owl:someValuesFrom af-p:AFP_0001916 + ] ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "titration data" , + "titration plot" ; + + skos:definition "A plot of volume of titrant vs. an independent variable (e.g., pH or enthalpy) obtained from a titration experiment. [CHMO]" ; + + skos:prefLabel "titration curve" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000491 + +af-r:AFR_0000491 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001060 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A plot of intensity against wavelength obtained by measuring the amount of radiation emitted by a sample through luminescence against the frequency of the incident radiation. [CHMO]" ; + + skos:prefLabel "luminescence spectrum" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000496 + +af-r:AFR_0000496 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001060 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "M\\ossbauer spectra" , + "M\\ossbauer spectrum" , + "Moessbauer spectra" , + "Moessbauer spectrum" , + "Mossbauer spectra" ; + + skos:definition "A plot of intensity vs. velocity obtained by measuring the intensity and kinetic energy of a beam of gamma-rays transmitted through a solid sample. [CHMO]" ; + + skos:prefLabel "Mossbauer spectrum" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000504 + +af-r:AFR_0000504 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000207 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002734 ; + owl:someValuesFrom af-p:AFP_0001916 + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A titration result is the result of a titration. [Allotrope]" ; + + skos:prefLabel "titration result" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000507 + +af-r:AFR_0000507 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000236 ; + + rdfs:isDefinedBy ; + + skos:altLabel "GPC elugram" , + "GPC profile" , + "GPC profiles" , + "GPC trace" , + "GPC traces" , + "gel permeation chromatogram" , + "gel permeation chromatographic traces" ; + + skos:definition "A plot of detector signal (e.g. ion count or absorbance) vs. retention time obtained from a chromatography experiment where the separation is caused by differences in molecular size. [CHMO]" ; + + skos:prefLabel "gel filtration chromatogram" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000514 + +af-r:AFR_0000514 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000222 , + af-r:AFR_0001060 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A plot of absorbance vs. wavelength, obtained by measuring the amount of radiation absorbed by a sample as a function of the wavelength of incident radiation, which reflects the electronic degrees of freedom of an atom or molecule. [CHMO]" ; + + skos:prefLabel "electronic absorption spectrum" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000519 + +af-r:AFR_0000519 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000068 , + af-r:AFR_0001060 , + af-r:AFR_0002104 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "Raman spectra" ; + + skos:definition "A plot of intensity vs. Raman shift (cm-1) obtained by measuring the Raman scattering of monochromatic light from a sample. [CHMO]" ; + + skos:prefLabel "Raman spectrum" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000523 + +af-r:AFR_0000523 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( af-r:AFR_0000207 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002734 ; + owl:someValuesFrom af-p:AFP_0001321 + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:isDefinedBy ; + + skos:changeNote "2020-11-12 Moved from chromatography domain to AFO. [Allotrope]" ; + + skos:definition "A chromatography result is a result of a chromatography run. [Allotrope]" ; + + skos:prefLabel "chromatography result" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000525 + +af-r:AFR_0000525 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( af-r:AFR_0000207 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002734 ; + owl:someValuesFrom af-p:AFP_0000474 + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:subClassOf af-r:AFR_0000207 ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "The capillary electrophoresis result is the result of a process of capillary electrophoresis. [Allotrope]" ; + + skos:prefLabel "capillary electrophoresis result" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000570 + +af-r:AFR_0000570 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000231 ; + + dct:license ; + + dct:rights ; + + dct:source "K. K. Murray, R. K. Boyd, M. N. Eberlin, G. J. Langley, L. Li and Y. Naito, Pure Appl. Chem., 2013, 85, 1515-1609" ; + + rdfs:isDefinedBy ; + + skos:definition "Group of peaks representing ions of the same elemental composition, but different isotopic compositions. [IUPAC]" ; + + skos:prefLabel "isotope cluster" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000576 + +af-r:AFR_0000576 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001060 ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "time series" ; + + skos:definition "A profile is a data distribution function that is a function of time. [Allotrope]" ; + + skos:prefLabel "profile" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000580 + +af-r:AFR_0000580 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000576 , + af-r:AFR_0001060 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + dct:source "Murray, K., Boyd, R., Eberlin, M., et al. (2013). Definitions of terms relating to mass spectrometry (IUPAC Recommendations 2013). Pure and Applied Chemistry, 85(7), pp. 1515-1609. Retrieved 9 May. 2019, from doi:10.1351/PAC-REC-06-04-06" ; + + rdfs:isDefinedBy ; + + skos:definition "A total ion current profile is a data distribution function of the total ion current recorded as function of time or time dependent sampling. [Allotrope]" ; + + skos:prefLabel "total ion current profile" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000628 + +af-r:AFR_0000628 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000207 ; + + rdfs:isDefinedBy ; + + skos:definition "The readout from a microplate reader measurement. [Allotrope]" ; + + skos:prefLabel "microplate reader measurement result" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000632 + +af-r:AFR_0000632 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000633 ; + + rdfs:isDefinedBy ; + + skos:definition "A melting peak results from energy transfer due to the transition from the solid to the liquid phase. [Allotrope]" ; + + skos:prefLabel "melting peak" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000633 + +af-r:AFR_0000633 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000647 ; + + rdfs:isDefinedBy ; + + skos:definition "A transition peak is a peak in the differential scanning calorimetry curve that results from a structural transition of the sample. [Allotrope]" ; + + skos:prefLabel "transition peak" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000634 + +af-r:AFR_0000634 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000207 ; + + rdfs:isDefinedBy ; + + skos:altLabel "trending result" ; + + skos:definition "A trend is the result of a process of trending. [Allotrope]" ; + + skos:example "In Raman spectroscopy a trend a result based on a collection of spectra. [Allotrope]" , + "In infrared spectroscopy the intensities of peaks over time can be used to monitor compound concentration increase/decrease of a chemical reaction over time." ; + + skos:prefLabel "trend" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000639 + +af-r:AFR_0000639 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000992 ; + + rdfs:isDefinedBy ; + + skos:changeNote "2020-05-11 Moved from taxonomy to AFO, different perspective than iao:Document" ; + + skos:definition "A file is a resource for storing information, which is available to a computer program and is usually based on some kind of durable storage. [Wikipedia]" ; + + skos:prefLabel "file" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000647 + +af-r:AFR_0000647 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0002013 , + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000050 ; + owl:someValuesFrom af-r:AFR_0000007 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A differential scanning calorimetry peak is a peak that is the result of a differential scanning calorimetry (DSC) and part of a DSC curve. [Allotrope]" ; + + skos:prefLabel "differential scanning calorimetry peak" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000682 + +af-r:AFR_0000682 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000207 ; + + rdfs:isDefinedBy ; + + skos:altLabel "DSC result" ; + + skos:definition "The differential scanning calorimetry result is the result of a DSC measurement. [Allotrope]" ; + + skos:prefLabel "differential scanning calorimetry result" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000694 + +af-r:AFR_0000694 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000991 ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:altLabel "forecast" ; + + skos:changeNote "2019-05-10 Generalized term. [Allotrope]" ; + + skos:definition "A prediction or forecast is a proposition about a future event. [Wikipedia]" ; + + skos:prefLabel "prediction" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000700 + +af-r:AFR_0000700 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000207 ; + + rdfs:isDefinedBy ; + + skos:altLabel "fingerprinting" ; + + skos:definition "A fingerprint is a type of or portion of spectrum that has a characteristic structure. It can be used as a fingerprint for comparison to reference spectra. [Allotrope]" ; + + skos:example "Infrared spectra are fingerprints. The fingerprint region of an IR spectrum lies between 1500 and 500 cm-1 while a complete IR spectrum normally has a range from 4000 to 500 cm-1. Note that the overlay is synonym for the same activity (fingerprinting)." ; + + skos:prefLabel "fingerprint" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000733 + +af-r:AFR_0000733 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000207 ; + + rdfs:isDefinedBy ; + + skos:definition "A distribution is a collection of frequencies of results of a sample. Each frequency is number of occurrences within a given interval. The distribution can be expressed relatively to the width of the interval. [Allotrope]" ; + + skos:prefLabel "distribution" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000745 + +af-r:AFR_0000745 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000207 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002734 ; + owl:someValuesFrom af-p:AFP_0002716 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A particle sizing result is the outcome of a process of particle sizing. [Allotrope]" ; + + skos:prefLabel "particle sizing result" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000754 + +af-r:AFR_0000754 rdf:type owl:Class ; + + rdfs:subClassOf [ owl:intersectionOf ( af-r:AFR_0000207 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002734 ; + owl:someValuesFrom af-p:AFP_0000527 + ] + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "Result of a spectroscopical measurement. [Allotrope]" ; + + skos:prefLabel "spectroscopy result" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000761 + +af-r:AFR_0000761 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000633 ; + + rdfs:isDefinedBy ; + + skos:definition "A glass transition peak is a peak of the differential scanning calorimetry curve that results from the glass transition of a sample. [Allotrope]" ; + + skos:prefLabel "glass transition peak" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000774 + +af-r:AFR_0000774 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000207 ; + + rdfs:isDefinedBy ; + + skos:definition "An overlay of scans is a graphic overlay of generated spectra for comparison. [Allotrope]" ; + + skos:prefLabel "overlay of scans" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000776 + +af-r:AFR_0000776 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000647 ; + + rdfs:isDefinedBy ; + + skos:changeNote "2020-03-23 Changed definition. [Allotrope]" ; + + skos:definition "An exothermic peak is a differential scanning calorimetry peak resulting from energy transfer from the sample heating cell to the surrounding. [Allotrope]" ; + + skos:prefLabel "exothermic peak" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000780 + +af-r:AFR_0000780 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000647 ; + + rdfs:isDefinedBy ; + + skos:changeNote "2020-03-23 Changed definition. [Allotrope]" ; + + skos:definition "An endothermic peak is a differential scanning calorimetry peak peak resulting from energy transfer to the sample heating cell. [Allotrope]" ; + + skos:prefLabel "endothermic peak" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000788 + +af-r:AFR_0000788 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000207 , + af-r:AFR_0001060 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:changeNote "2019-08-19 Moved under data distribution function. [Allotrope]" ; + + skos:definition "The calibration curve is a data distribution function of the instrumental response, the so-called analytical signal, changed with the concentration of the analyte (the substance to be measured). [Wikipedia]" ; + + skos:prefLabel "calibration curve" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000894 + +af-r:AFR_0000894 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001263 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "Linear procedure specification that specifies analysis. [Allotrope]" ; + + skos:prefLabel "analysis sequence" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000895 + +af-r:AFR_0000895 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001501 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002704 ; + owl:someValuesFrom af-p:AFP_0003491 + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "An analysis method is a plan specification that specifies an analysis. [Allotrope]" ; + + skos:prefLabel "analytical method" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000896 + +af-r:AFR_0000896 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000939 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "An interpolation algorithm using cubic polynomials. [Allotrope]" ; + + skos:prefLabel "cubic interpolation algorithm" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000898 + +af-r:AFR_0000898 rdf:type owl:Class ; + + rdfs:subClassOf iao:_0000064 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "Interpolation is a method of constructing new data points within the range of a discrete set of known data points. [Wikipedia]" ; + + skos:prefLabel "interpolation algorithm" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000899 + +af-r:AFR_0000899 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000939 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "Linear interpolation is a method of curve fitting using linear polynomials to construct new data points within the range of a discrete set of known data points. [Wikipedia]" ; + + skos:prefLabel "linear interpolation algorithm" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000900 + +af-r:AFR_0000900 rdf:type owl:Class ; + + rdfs:subClassOf af-c:AFC_0000160 , + af-r:AFR_0000922 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0002351 ; + owl:someValuesFrom af-r:AFR_0000901 + ] ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "event log" , + "event protocol" , + "protocol" ; + + skos:changeNote "2020-06-23 Changed definition. [Allotrope]" ; + + skos:definition "A log is a list of related log entries. [Allotrope]" ; + + skos:prefLabel "log" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000901 + +af-r:AFR_0000901 rdf:type owl:Class ; + + rdfs:subClassOf af-c:AFC_0000161 , + af-r:AFR_0000922 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0002350 ; + owl:someValuesFrom af-r:AFR_0000900 + ] ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "protocol entry" ; + + skos:changeNote "2020-06-23 Changed definition. [Allotrope]" ; + + skos:definition "A log entry is a list item representing a recorded event. [Allotrope]" ; + + skos:prefLabel "log entry" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000902 + +af-r:AFR_0000902 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000941 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A quality profile control command is an action specification about a quality process profile. [Allotrope]" ; + + skos:prefLabel "quality profile control command" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000905 + +af-r:AFR_0000905 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000413 ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "An unretained peak is a peak which represents the detection result of a material entity which was not retained by a chromatography column. [Allotrope]" ; + + skos:prefLabel "unretained peak" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000908 + +af-r:AFR_0000908 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000916 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:altLabel "measurement scale" ; + + skos:definition "Level of measurement is a classification that describes the nature of information within the values assigned to variables. [Wikipedia]" ; + + skos:prefLabel "level of measurement" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000909 + +af-r:AFR_0000909 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000908 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A classification that only introduces categorical values. [Allotrope]" ; + + skos:prefLabel "nominal scale" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000910 + +af-r:AFR_0000910 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000908 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A classification of measurement that introduces equality and rank-ordering. [Allotrope]" ; + + skos:prefLabel "ordinal scale" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000911 + +af-r:AFR_0000911 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000908 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A scale that is based on equal quantitative intervals. [Allotrope]" ; + + skos:prefLabel "interval scale" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000912 + +af-r:AFR_0000912 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000908 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A scale that introduces a zero as origin and allows equality, rank-ordering, equality of intervals and equality of ratios. [Allotrope]" ; + + skos:prefLabel "ratio scale" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000913 + +af-r:AFR_0000913 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000908 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A log-interval scale is a type of measurement scale that classifies values based on logarithmic intervals. [Allotrope]" ; + + skos:prefLabel "log-interval scale" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000914 + +af-r:AFR_0000914 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000908 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A cyclic scale is a type of measurement scale that classifies values based on recurring intervals. [Allotrope]" ; + + skos:example "angle" , + "orientation" , + "weekday" ; + + skos:prefLabel "cyclic scale" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000915 + +af-r:AFR_0000915 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000908 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "Counts are like ratio scale that they have a zero point but there are no meaningful fractional units. [Allotrope]" ; + + skos:prefLabel "counts" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000916 + +af-r:AFR_0000916 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000991 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A classification is a proposition that categorizes things into classes or collections of things differentiated by some criteria. [Allotrope]" ; + + skos:prefLabel "classification" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000917 + +af-r:AFR_0000917 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000923 , + [ owl:intersectionOf ( [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002717 ; + owl:someValuesFrom bfo:_0000001 + ] + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002730 ; + owl:someValuesFrom af-rl:AFRL_0000007 + ] + [ rdf:type owl:Restriction ; + owl:onProperty iao:_0000219 ; + owl:someValuesFrom bfo:_0000001 + ] + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "ID" ; + + skos:definition "An identifier is a name that identifies (that is, labels the identity of) either a unique object or a unique class of objects, where the \"object\" or class may be an idea, physical [countable] object (or class thereof), or physical [uncountable] substance (or class thereof). [Wikipedia]" ; + + skos:prefLabel "identifier" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000918 + +af-r:AFR_0000918 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000917 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A globally unique identifier is an identifier whose uniqueness is guaranteed in a decentralized way by following a certain algorithm in its creation. [Allotrope]" ; + + skos:example "a UUID" ; + + skos:prefLabel "globally unique identifier" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000919 + +af-r:AFR_0000919 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000917 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "An identifier that uniquely denotes objects only within the scope of a specific object aggregate and that is not registered in an identifier registry. [Allotrope]" ; + + skos:prefLabel "local identifier" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000920 + +af-r:AFR_0000920 rdf:type owl:Class ; + + rdfs:subClassOf af-c:AFC_0000021 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A range that describes a range of quantity values using the same unit. [Allotrope]" ; + + skos:prefLabel "quantity range" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000921 + +af-r:AFR_0000921 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000928 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002800 ; + owl:someValuesFrom af-c:AFC_0000161 + ] ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A list index is a type of index that is related to a list item in a collection. [Allotrope]" ; + + skos:prefLabel "list index" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000922 + +af-r:AFR_0000922 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000991 , + [ owl:intersectionOf ( [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002699 ; + owl:someValuesFrom owl:Thing + ] + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002730 ; + owl:someValuesFrom af-rl:AFRL_0000053 + ] + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A description is a proposition about an existing entity. [Allotrope]" ; + + skos:prefLabel "description" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000923 + +af-r:AFR_0000923 rdf:type owl:Class ; + + rdfs:subClassOf iao:_0000030 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy , + , + ; + + skos:definition "A facet is a partial information that contains an aspect of some information content entity or parts of it when participating in some process. The facet abstracts of the concrete representation of this aspect of information. [Allotrope]" ; + + skos:prefLabel "facet" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000924 + +af-r:AFR_0000924 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001100 ; + + af-x:AFX_0002808 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A multiplicand in a mathematical product expression. [Allotrope]" ; + + skos:prefLabel "factor" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000925 + +af-r:AFR_0000925 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000924 ; + + af-x:AFX_0002808 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A factor with a complex number as value. [Allotrope]" ; + + skos:prefLabel "complex factor" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000926 + +af-r:AFR_0000926 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000924 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A factor with a integer number as value. [Allotrope]" ; + + skos:prefLabel "integer factor" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000927 + +af-r:AFR_0000927 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000924 ; + + af-x:AFX_0002808 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A factor with a real number as value. [Allotrope]" ; + + skos:prefLabel "real factor" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000928 + +af-r:AFR_0000928 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000923 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A facet that represents some strictly ordered key in an associative array or the position of a member in a list. [Allotrope]" ; + + skos:prefLabel "index" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000929 + +af-r:AFR_0000929 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000928 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "An index that denotes some matrix component. [Allotrope]" ; + + skos:prefLabel "matrix index" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000930 + +af-r:AFR_0000930 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000928 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "An index that denotes some tensor component. [Allotrope]" ; + + skos:prefLabel "tensor index" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000931 + +af-r:AFR_0000931 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000928 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "An index that denotes some vector component. [Allotrope]" ; + + skos:prefLabel "vector index" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000932 + +af-r:AFR_0000932 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000923 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "An order facet adds information of the ordering of some information in an aggregation of information. [Allotrope]" ; + + skos:prefLabel "order" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000933 + +af-r:AFR_0000933 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000932 , + [ rdf:type owl:Restriction ; + owl:onProperty iao:_0000219 ; + owl:someValuesFrom af-c:AFC_0000161 + ] ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A predecessor is an order facet of an information content entity that refers to the information content entity immediately before it in a containing list. [Allotrope]" ; + + skos:prefLabel "predecessor" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000934 + +af-r:AFR_0000934 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000932 , + [ rdf:type owl:Restriction ; + owl:onProperty iao:_0000219 ; + owl:someValuesFrom af-c:AFC_0000161 + ] ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A successor is an order facet of an information content entity that refers to the information content entity immediately after it in a containing list. [Allotrope]" ; + + skos:prefLabel "successor" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000935 + +af-r:AFR_0000935 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001100 ; + + af-x:AFX_0002808 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "base" ; + + skos:definition "In mathematical numeral systems, the radix or base is the number of unique digits, including zero, used to represent numbers in a positional numeral system. [Wikipedia]" ; + + skos:prefLabel "radix" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000936 + +af-r:AFR_0000936 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000923 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000690 ; + owl:qualifiedCardinality "1"^^xsd:nonNegativeInteger ; + owl:onDataRange [ rdf:type rdfs:Datatype ; + owl:onDatatype xsd:integer ; + owl:withRestrictions ( [ xsd:minInclusive 0 + ] + ) + ] + ] ; + + af-x:AFX_0002808 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "Size is the number of members of some collection of data. [Allotrope]" ; + + skos:prefLabel "size" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000937 + +af-r:AFR_0000937 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000923 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002730 ; + owl:someValuesFrom af-rl:AFRL_0000073 + ] ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "timestamp" ; + + skos:changeNote "2018-10-29 Changed pref label to time, timestamp is alt label [Allotrope]" ; + + skos:definition "A time is a facet that adds temporal information to an information content entity about the point in time when the information content entity it is participating in the some process. [Allotrope]" ; + + skos:note "Duration is a close match, but is about a time interval." , + "This facet can have multiple representational forms, e.g. XML dateTime or QUDT time quantity values." ; + + skos:prefLabel "time" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000938 + +af-r:AFR_0000938 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000957 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "flow specification" , + "protocol" , + "workflow specification" ; + + skos:definition "A specification on the order, transitions and trigger of multiple action specifications that are part of some aggregate action specification. [Allotrope]" ; + + skos:prefLabel "procedure specification" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000939 + +af-r:AFR_0000939 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000898 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "An interpolation algorithm using polynomials. [Allotrope]" ; + + skos:prefLabel "polynomial interpolation algorithm" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000940 + +af-r:AFR_0000940 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000939 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "An interpolation algorithm using cubic polynomials. [Allotrope]" ; + + skos:prefLabel "quadratic interpolation algorithm" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000941 + +af-r:AFR_0000941 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( af-r:AFR_0000957 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002704 ; + owl:someValuesFrom af-p:AFP_0003620 + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:subClassOf af-r:AFR_0000957 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + dct:replaces af-p:AFP_0002822 ; + + rdfs:isDefinedBy ; + + skos:altLabel "command" , + "instruction" ; + + skos:definition "A directive information entity that describes an action the bearer will take. [IAO]" ; + + skos:prefLabel "action specification" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000942 + +af-r:AFR_0000942 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000941 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + dct:replaces af-p:AFP_0001765 ; + + rdfs:isDefinedBy ; + + skos:definition "An action specification that specifies an event within a process when the specified activity is realized. [Allotrope]" ; + + skos:note "The events are modeled after the ISA-S88 process commands. [Allotrope]" ; + + skos:prefLabel "process command" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000944 + +af-r:AFR_0000944 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( af-r:AFR_0001005 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002704 ; + owl:someValuesFrom bfo:_0000034 + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:subClassOf af-r:AFR_0001005 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A specification that specifies a participant in a process by the function it bears in it. [Allotrope]" ; + + skos:prefLabel "function specification" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000945 + +af-r:AFR_0000945 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000938 , + af-r:AFR_0001262 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "event table" , + "linear procedure specification" , + "sequence specification" ; + + skos:changeNote "2018-10-19 Changed pref label [Allotrope]" ; + + skos:definition "A procedure specification with a linear ordered collection of action specifications. [Allotrope]" ; + + skos:prefLabel "sequential procedure specification" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000947 + +af-r:AFR_0000947 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000923 , + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000050 ; + owl:someValuesFrom af-r:AFR_0000413 + ] ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A facet that is part of a peak. [Allotrope]" ; + + skos:prefLabel "peak facet" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000948 + +af-r:AFR_0000948 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000947 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002730 ; + owl:someValuesFrom [ owl:intersectionOf ( af-rl:AFRL_0000279 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000388 ; + owl:someValuesFrom af-r:AFR_0001202 + ] + ) ; + rdf:type owl:Class + ] + ] ; + + af-x:AFX_0002811 af-x:AFX_0000287 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A peak facet that denotes the ordinate value of the peak apex offset by the baseline ascribed to the peak. [Allotrope]" ; + + skos:prefLabel "peak height" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000949 + +af-r:AFR_0000949 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000947 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002730 ; + owl:someValuesFrom af-rl:AFRL_0000248 + ] ; + + af-x:AFX_0002811 af-x:AFX_0000828 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "peak height (relative)" ; + + skos:changeNote "2018-07-19 Changed definition. [Allotrope]" ; + + skos:definition "A peak facet that denotes the height of the peak relative to some other peak or summation of peaks. [Allotrope]" ; + + skos:prefLabel "relative peak height" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000950 + +af-r:AFR_0000950 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000923 ; + + af-x:AFX_0002811 af-x:AFX_0000180 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "increment" ; + + skos:definition "The difference between two discrete points next to each other in a range of discrete values. [Allotrope]" ; + + skos:example "A device property can be set between a minimum and maximum value but only in steps of the increment value. [Allotrope]" , + "Step size of sweeping over 2Theta, unit ° [Allotrope]" ; + + skos:prefLabel "step size" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000951 + +af-r:AFR_0000951 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000953 , + af-r:AFR_0001816 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "time" ; + + skos:changeNote "2019-07-04 Moved under process quantification facet in taxonomy. [Allotrope]" ; + + skos:definition "A measure of the magnitude of the time region in which the process occurs. [Allotrope]" ; + + skos:prefLabel "duration" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000952 + +af-r:AFR_0000952 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000937 , + [ rdf:type owl:Restriction ; + owl:onProperty iao:_0000136 ; + owl:someValuesFrom af-p:AFP_0002294 + ] ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "The date/time of the measurement. [Allotrope]" ; + + skos:prefLabel "measurement time" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000953 + +af-r:AFR_0000953 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000922 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A description of a fundamental characteristic of a process. [Allotrope]" ; + + skos:prefLabel "process property" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000954 + +af-r:AFR_0000954 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000953 , + af-r:AFR_0001816 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:changeNote "2019-07-04 Moved under process quantification facet in taxonomy. [Allotrope]" ; + + skos:definition "A measure of the magnitude of change of some participating entity per amount of time relative to other processes having similar changes. [Allotrope]" ; + + skos:prefLabel "rate" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000955 + +af-r:AFR_0000955 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000922 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "An observation is a description of a portion of reality that has been observed during an observing process. [Allotrope]" ; + + skos:prefLabel "observation" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000956 + +af-r:AFR_0000956 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000936 ; + + af-x:AFX_0002811 af-x:AFX_0000663 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "The number of points is the total number of points sampled during a measurement. [Allotrope]" ; + + skos:example "In a spectrum, the number of points is the total number of peak positions." , + "number of quick slope points in UV/VIS" ; + + skos:prefLabel "number of sampled points" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000957 + +af-r:AFR_0000957 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000991 , + [ owl:intersectionOf ( [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002704 ; + owl:someValuesFrom owl:Thing + ] + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002730 ; + owl:someValuesFrom af-rl:AFRL_0000064 + ] + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "directive information entity" ; + + skos:definition "A specification is a proposition about the intended purpose or design of an entity. [Allotrope]" ; + + skos:prefLabel "specification" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000958 + +af-r:AFR_0000958 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001054 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0002351 ; + owl:allValuesFrom af-r:AFR_0000961 + ] ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:altLabel "tensor" , + "tensor value" ; + + skos:definition "In mathematics, tensors are geometric objects that describe linear relations between geometric vectors, scalars, and other tensors. Elementary examples of such relations include the dot product, the cross product, and linear maps. The tensor datum is a facet that uses a tensor as an abstract mathematical description. [Wikipedia]" ; + + skos:prefLabel "tensor datum" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000959 + +af-r:AFR_0000959 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000958 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "higher-order tensor" , + "higher-order tensor value" ; + + skos:definition "A tensor with order greater than 2. [Allotrope]" ; + + skos:prefLabel "higher-order tensor datum" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000960 + +af-r:AFR_0000960 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000958 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002705 ; + owl:hasValue 2 + ] ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:altLabel "matrix" , + "matrix value" ; + + skos:definition "In mathematics, a matrix (plural matrices) is a rectangular array of numbers, symbols, or expressions, arranged in rows and columns. [Wikipedia]" ; + + skos:prefLabel "matrix datum" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000961 + +af-r:AFR_0000961 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000958 , + [ owl:intersectionOf ( [ rdf:type owl:Restriction ; + owl:onProperty ro:_0002351 ; + owl:qualifiedCardinality "0"^^xsd:nonNegativeInteger ; + owl:onClass af-r:AFR_0000958 + ] + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002705 ; + owl:hasValue 0 + ] + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:altLabel "scalar" , + "scalar value" ; + + skos:definition "A scalar is an element of a field which is used to define a vector space. [Wikipedia]" ; + + skos:editorialNote "review of definition needed" ; + + skos:prefLabel "scalar datum" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000962 + +af-r:AFR_0000962 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000958 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002705 ; + owl:hasValue 1 + ] ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:altLabel "Euclidean vector" , + "geometric vector" , + "vector" , + "vector value" ; + + skos:definition "In mathematics, physics, and engineering, a Euclidean vector (sometimes called a geometric or spatial vector, or—as here—simply a vector) is a geometric object that has magnitude (or length) and direction. [Wikipedia]" ; + + skos:prefLabel "vector datum" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000963 + +af-r:AFR_0000963 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000964 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0002351 ; + owl:allValuesFrom af-r:AFR_0000983 + ] ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "integer vector" , + "integer vector datum" ; + + skos:definition "A number vector datum is a vector datum that has only integer scalar components. [Allotrope]" ; + + skos:prefLabel "vector integer datum" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000964 + +af-r:AFR_0000964 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000962 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0002351 ; + owl:allValuesFrom af-r:AFR_0000988 + ] ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "number vector" , + "number vector datum" , + "number vector value" ; + + skos:definition "A vector number datum is a vector datum that has only numeric scalar components. [Allotrope]" ; + + skos:prefLabel "vector number datum" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000965 + +af-r:AFR_0000965 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000962 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0002351 ; + owl:allValuesFrom [ rdf:type owl:Class ; + owl:unionOf ( af-r:AFR_0000988 + af-r:AFR_0000989 + ) + ] + ] ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "quantity vector" , + "quantity vector datum" , + "quantity vector value" ; + + skos:definition "A vector quantity datum is a vector datum that has only quantity value scalar components. [Allotrope]" ; + + skos:prefLabel "vector quantity datum" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000966 + +af-r:AFR_0000966 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000989 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "time" , + "time interval" , + "time value" ; + + skos:definition "A time datum is a type of datum that quantifies a duration of time or is about a time interval. [Allotrope]" ; + + skos:prefLabel "time datum" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000967 + +af-r:AFR_0000967 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000961 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002696 ; + owl:allValuesFrom af-c:AFC_0000021 + ] ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "scalar range" , + "scalar range value" ; + + skos:definition "A scalar range datum is a type of datum that is about range quantified by a scalar value. [Allotrope]" ; + + skos:prefLabel "scalar range datum" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000974 + +af-r:AFR_0000974 rdf:type owl:Class ; + + rdfs:subClassOf [ owl:intersectionOf ( af-r:AFR_0000944 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002704 ; + owl:someValuesFrom [ owl:intersectionOf ( bfo:_0000034 + [ rdf:type owl:Restriction ; + owl:onProperty [ owl:inverseOf af-x:AFX_0002677 + ] ; + owl:someValuesFrom bfo:_0000034 + ] + ) ; + rdf:type owl:Class + ] + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A function specification that specifies the ways of achievement. [Allotrope]" ; + + skos:prefLabel "method function specification" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000975 + +af-r:AFR_0000975 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( af-r:AFR_0001005 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002704 ; + owl:someValuesFrom af-re:AFRE_0000004 + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:subClassOf af-r:AFR_0001005 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A specification that specifies the determinate range of some quality. [Allotrope]" ; + + skos:prefLabel "quality specification" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000976 + +af-r:AFR_0000976 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000944 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A capability specification specifies some function that the target of the specification inheres. This capability can be restricted to a specific situation. [Allotrope]" ; + + skos:prefLabel "capability specification" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000977 + +af-r:AFR_0000977 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( af-r:AFR_0001005 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002704 ; + owl:someValuesFrom af-rl:AFRL_0000019 + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:subClassOf af-r:AFR_0001005 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A participant specification which specifies an information object that has the contextual role of a parameter in the realized process. [Allotrope]" ; + + skos:example "A parameter specification can include a formal name, a datatype, a shape or range of values if the parameter is a datum." ; + + skos:note "A parameter specification is about a parameter. It is a parameter itself only in the context of a specification process." ; + + skos:prefLabel "parameter specification" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000978 + +af-r:AFR_0000978 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001005 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A participant specification that specifies a information objects that have the contextual role of a result in the realized process. [Allotrope]" ; + + skos:prefLabel "result specification" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000979 + +af-r:AFR_0000979 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( af-r:AFR_0001005 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002704 ; + owl:someValuesFrom [ rdf:type owl:Class ; + owl:unionOf ( af-rl:AFRL_0000166 + bfo:_0000023 + ) + ] + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:subClassOf af-r:AFR_0001005 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:changeNote "2018-11-16 Allow contextual roles to be referenced as well has normal roles in role specifications. [Allotrope]" ; + + skos:definition "A specification that specifies a participant in a process by the general role it plays in it. [Allotrope]" ; + + skos:prefLabel "role specification" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000980 + +af-r:AFR_0000980 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( af-r:AFR_0000982 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002704 ; + owl:someValuesFrom af-re:AFRE_0000007 + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:subClassOf af-r:AFR_0000982 , + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000050 ; + owl:someValuesFrom af-r:AFR_0000938 + ] ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A specification about the transition between two or more actions. [Allotrope]" ; + + skos:prefLabel "transition specification" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000981 + +af-r:AFR_0000981 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000982 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A trigger specification is a situation specification that specifies a trigger. [Allotrope]" ; + + skos:prefLabel "trigger specification" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000982 + +af-r:AFR_0000982 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( af-r:AFR_0000957 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002704 ; + owl:someValuesFrom af-re:AFRE_0000003 + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:subClassOf af-r:AFR_0000957 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A specification of a circumstances (process). [Allotrope]" ; + + skos:prefLabel "situation specification" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000983 + +af-r:AFR_0000983 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000988 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000690 ; + owl:allValuesFrom xsd:integer + ] ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "scalar integer value" ; + + skos:definition "A datum that is an integer value. [Allotrope]" ; + + skos:prefLabel "scalar integer datum" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000984 + +af-r:AFR_0000984 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000983 , + af-r:AFR_0001101 ; + + rdfs:isDefinedBy ; + + skos:altLabel "count (datum)" , + "count datum" , + "count facet" ; + + skos:changeNote "2020-12-01 Changed labels. [Allotrope]" , + "2020-12-01 Moved to AFO. [Allotrope]" ; + + skos:definition "A datum that has non-negative integer values that is about the number of discrete things. [Allotrope]" ; + + skos:prefLabel "count" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000985 + +af-r:AFR_0000985 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000988 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000690 ; + owl:allValuesFrom xsd:decimal + ] ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A datum that is a decimal value. [Allotrope]" ; + + skos:prefLabel "scalar decimal datum" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000986 + +af-r:AFR_0000986 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000988 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000690 ; + owl:allValuesFrom [ rdf:type rdfs:Datatype ; + owl:unionOf ( xsd:double + xsd:float + ) + ] + ] ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A datum that is a IEEE floating point value. [Allotrope]" ; + + skos:prefLabel "scalar floating point number datum" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000987 + +af-r:AFR_0000987 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000961 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "scalar nominal datum" ; + + skos:definition "A scalar categorical datum is a type of datum that describes something based on a scalar value for a kind of category. [Allotrope]" ; + + skos:prefLabel "scalar categorical datum" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000988 + +af-r:AFR_0000988 rdf:type owl:Class ; + + owl:equivalentClass [ rdf:type owl:Class ; + owl:unionOf ( af-r:AFR_0000983 + af-r:AFR_0000985 + af-r:AFR_0000986 + ) + ] ; + + rdfs:subClassOf af-r:AFR_0000961 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A scalar datum that has a numeric value. [Allotrope]" ; + + skos:prefLabel "scalar number datum" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000989 + +af-r:AFR_0000989 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000961 , + [ rdf:type owl:Restriction ; + owl:onProperty qudt:numericValue ; + owl:allValuesFrom xsd:double + ] ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "scalar quantity" , + "scalar quantity value" ; + + skos:definition "A scalar quantity datum is a type of datum that is about a quantity and quantifies by a scalar value. [Allotrope]" ; + + skos:prefLabel "scalar quantity datum" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000991 + +af-r:AFR_0000991 rdf:type owl:Class ; + + rdfs:subClassOf iao:_0000030 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:altLabel "assertion" , + "content" , + "statement" ; + + skos:definition "A proposition is an information content entity that is statement or assertion that has a truth value. [Allotrope]" ; + + skos:prefLabel "proposition" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000992 + +af-r:AFR_0000992 rdf:type owl:Class ; + + rdfs:subClassOf iao:_0000030 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:definition "A representation form is a type of information content entity that represents an entity in a certain way. [Allotrope]" ; + + skos:example "plot as representation form of a temperature profile" ; + + skos:prefLabel "representation form" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000993 + +af-r:AFR_0000993 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000922 ; + + af-x:AFX_0002808 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A model is a purposeful simplified description of a part of reality that focuses on specific aspects. [Allotrope]" ; + + skos:prefLabel "model" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000994 + +af-r:AFR_0000994 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000922 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A model that explains some principle rules about something. [Allotrope]" ; + + skos:prefLabel "theory" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0000995 + +af-r:AFR_0000995 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000922 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A physical domain is a type of description that covers physical objects. [Allotrope]" ; + + skos:prefLabel "physical domain" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001004 + +af-r:AFR_0001004 rdf:type owl:Class ; + + rdfs:subClassOf iao:_0000030 ; + + dct:source "https://en.wikipedia.org/wiki/Signal" ; + + rdfs:isDefinedBy ; + + skos:definition "An information content entity that is an input or output in a process at the boundary of a system. The signal is sent or received via ports of the system. The signal conveys information about the behavior or attributes of some phenomenon. [Allotrope]" ; + + skos:prefLabel "signal" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001005 + +af-r:AFR_0001005 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000957 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002704 ; + owl:someValuesFrom [ owl:intersectionOf ( bfo:_0000002 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000056 ; + owl:someValuesFrom bfo:_0000015 + ] + ) ; + rdf:type owl:Class + ] + ] ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A specification that is part of some action specification that specifies some continuant that when the concretized action is realized becomes a participant playing some (contextual) role in the process. [Allotrope]" ; + + skos:prefLabel "participant specification" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001043 + +af-r:AFR_0001043 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000923 , + af-r:AFR_0001277 ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:altLabel "isobar" ; + + skos:changeNote "2019-05-09 Moved under classification datum. [Allotrope]" ; + + skos:definition "Isobar is a classification facet that classifies atoms (nuclides) of different chemical elements that have the same number of nucleons. Correspondingly, isobars differ in atomic number (or number of protons) but have the same mass number. [Wikipedia]" ; + + skos:prefLabel "isobar (nuclide)" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001046 + +af-r:AFR_0001046 rdf:type owl:Class ; + + rdfs:subClassOf af-c:AFC_0000160 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002803 ; + owl:someValuesFrom [ owl:intersectionOf ( af-r:AFR_0000936 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000690 ; + owl:qualifiedCardinality "1"^^xsd:nonNegativeInteger ; + owl:onDataRange [ rdf:type rdfs:Datatype ; + owl:onDatatype xsd:integer ; + owl:withRestrictions ( [ xsd:minInclusive 0 + ] + ) + ] + ] + ) ; + rdf:type owl:Class + ] + ] ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A tuple is a finite ordered list (sequence) of elements. [Wikipedia]" ; + + skos:prefLabel "tuple" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001054 + +af-r:AFR_0001054 rdf:type owl:Class ; + + rdfs:subClassOf iao:_0000030 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:altLabel "abstract object" ; + + skos:definition "A mathematical object is an information content entity that is an abstraction in the area of mathematics. It has a formal definition that allows for deductive reasoning and mathematical proofs. [Allotrope]" ; + + skos:prefLabel "mathematical object" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001055 + +af-r:AFR_0001055 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001046 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A 1-tuple is a tuple that is a singleton. [Wikipedia]" ; + + skos:prefLabel "1-tuple" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001056 + +af-r:AFR_0001056 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001046 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002803 ; + owl:someValuesFrom [ owl:intersectionOf ( af-r:AFR_0000936 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000690 ; + owl:hasValue 2 + ] + ) ; + rdf:type owl:Class + ] + ] ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A 2-tuple is a tuple that is an ordered pair. [Wikipedia]" ; + + skos:prefLabel "2-tuple" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001057 + +af-r:AFR_0001057 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001046 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A 3-tuple is a tuple that is a triple or triplet. [Wikipedia]" ; + + skos:prefLabel "3-tuple" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001058 + +af-r:AFR_0001058 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( af-r:AFR_0000957 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002704 ; + owl:someValuesFrom af-re:AFRE_0000004 + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:subClassOf af-r:AFR_0000982 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "2020-03-24 Moved under situation specification. [Allotrope]" ; + + skos:definition "A configuration specification is a situation specification that is about a realized configuration inhered in a specification target. [Allotrope]" ; + + skos:prefLabel "configuration specification" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001059 + +af-r:AFR_0001059 rdf:type owl:Class ; + + rdfs:subClassOf iao:_0000030 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:changeNote "2019-05-10 Moved up in hierarchy [Allotrope]" ; + + skos:definition "A registry is information content entity that is an aggregate of designations. [Allotrope]" ; + + skos:prefLabel "registry" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001060 + +af-r:AFR_0001060 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000922 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0002351 ; + owl:someValuesFrom af-r:AFR_0000186 + ] ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A description of distribution of a quantity with respect to a set of parameters. [Allotrope]" ; + + skos:note "This can be the result of a measurement, simulation or prediction. [Allotrope]" ; + + skos:prefLabel "data distribution function" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001061 + +af-r:AFR_0001061 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001682 , + iao:_0000590 , + [ rdf:type owl:Restriction ; + owl:onProperty iao:_0000219 ; + owl:someValuesFrom af-m:AFM_0001083 + ] ; + + af-x:AFX_0002808 foaf:familyName , + ; + + dct:source "https://en.wikipedia.org/wiki/Surname" ; + + rdfs:isDefinedBy ; + + skos:altLabel "last name" , + "surname" ; + + skos:changeNote "2019-05-10 Moved under written name [Allotrope]" ; + + skos:definition "A family name is a name that is the portion (in some cultures) of a personal name that indicates a person's family (or tribe or community, depending on the culture). [Wikipedia]" ; + + skos:editorialNote "The family name is provided (alongside given name) for use when describing parts of people's names. Although these concepts do not capture the full range of personal naming styles found world-wide, they are commonly used and have some value. [FoaF]" ; + + skos:prefLabel "family name" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001062 + +af-r:AFR_0001062 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001682 , + iao:_0000590 , + [ rdf:type owl:Restriction ; + owl:onProperty iao:_0000219 ; + owl:someValuesFrom af-m:AFM_0001083 + ] ; + + af-x:AFX_0002808 foaf:givenName , + ; + + dct:source "https://en.wikipedia.org/wiki/Given_name" ; + + rdfs:isDefinedBy ; + + skos:altLabel "Christian name" , + "first name" , + "forename" ; + + skos:changeNote "2019-05-10 Moved under written name [Allotrope]" ; + + skos:definition "A given name is a name that is a part of a person's personal name. [Wikipedia]" ; + + skos:editorialNote "The given name is provided (alongside family name) for use when describing parts of people's names. Although these concepts do not capture the full range of personal naming styles found world-wide, they are commonly used and have some value. [FoaF]" ; + + skos:prefLabel "given name" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001063 + +af-r:AFR_0001063 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001682 , + iao:_0000590 , + [ rdf:type owl:Restriction ; + owl:onProperty iao:_0000219 ; + owl:someValuesFrom af-m:AFM_0001083 + ] ; + + dct:source "https://en.wikipedia.org/wiki/Personal_name" ; + + rdfs:isDefinedBy ; + + skos:altLabel "full name" , + "name" , + "person name" ; + + skos:changeNote "2019-05-10 Moved under written name [Allotrope]" ; + + skos:definition "A personal name is a name that is composed of a set of names by which an individual is known. [Allotrope]" ; + + skos:prefLabel "personal name" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001064 + +af-r:AFR_0001064 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001065 , + iao:_0000590 ; + + af-x:AFX_0002808 ; + + rdfs:isDefinedBy ; + + skos:definition "A country name is a location facet that denotes a country. [Allotrope]" ; + + skos:prefLabel "country name" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001065 + +af-r:AFR_0001065 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000923 , + [ owl:intersectionOf ( [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002730 ; + owl:someValuesFrom af-rl:AFRL_0000373 + ] + [ rdf:type owl:Restriction ; + owl:onProperty iao:_0000136 ; + owl:someValuesFrom [ rdf:type owl:Class ; + owl:unionOf ( bfo:_0000006 + bfo:_0000029 + ) + ] + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A facet that is about some spatial region or site. [Allotrope]" ; + + skos:example "the facets of an address" ; + + skos:prefLabel "location facet" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001066 + +af-r:AFR_0001066 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001067 ; + + af-x:AFX_0002808 foaf:homepage ; + + rdfs:isDefinedBy ; + + skos:definition "A homepage hyperlink is a web page hyperlink that is a reference to home page of a person or organization. [Allotrope]" ; + + skos:prefLabel "homepage hyperlink" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001067 + +af-r:AFR_0001067 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001068 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002803 ; + owl:someValuesFrom af-r:AFR_0001068 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A web page hyperlink is a URL that is a reference to web page. [Allotrope]" ; + + skos:prefLabel "web page hyperlink" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001068 + +af-r:AFR_0001068 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000917 , + af-r:AFR_0001082 ; + + af-x:AFX_0002808 ; + + rdfs:isDefinedBy ; + + skos:definition "A Uniform Resource Locator (URL), colloquially termed a web address, is a reference to a web resource that specifies its location on a computer network and a mechanism for retrieving it. [Wikipedia]" ; + + skos:prefLabel "URL" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001069 + +af-r:AFR_0001069 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001484 ; + + rdfs:isDefinedBy ; + + skos:altLabel "LDAP ID" , + "ldap id" ; + + skos:changeNote "2020-03-20 Changed pref label, added alt labels. [Allotrope]" ; + + skos:definition "An LDAP identifier is an online account managed by an LDAP server and follows the LDAP specification. [Allotrope]" ; + + skos:prefLabel "ldap identifier" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001070 + +af-r:AFR_0001070 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000919 , + af-r:AFR_0001483 ; + + rdfs:isDefinedBy ; + + skos:definition "An account to a local computer. [Allotrope]" ; + + skos:prefLabel "local system account ID" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001071 + +af-r:AFR_0001071 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001065 , + iao:_0000590 ; + + af-x:AFX_0002808 ; + + rdfs:isDefinedBy ; + + skos:definition "A written name denoting a locality (e.g. city) as part a postal address. [Allotrope]" ; + + skos:prefLabel "locality" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001072 + +af-r:AFR_0001072 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000922 ; + + rdfs:isDefinedBy ; + + skos:definition "A molecular structure is a description of the type and arrangement of the atoms and the direction of bonds linking atoms that constitute a molecule. [Allotrope]" ; + + skos:prefLabel "molecular structure" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001073 + +af-r:AFR_0001073 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000947 ; + + rdfs:isDefinedBy ; + + skos:changeNote "2018-07-19 Definition changed. [Allotrope]" ; + + skos:definition "A peak facet that quantitates the area enclosed by a peak and the selected baseline. [Allotrope]" ; + + skos:prefLabel "peak area" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001074 + +af-r:AFR_0001074 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000947 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002730 ; + owl:someValuesFrom [ owl:intersectionOf ( af-rl:AFRL_0000278 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000388 ; + owl:someValuesFrom af-r:AFR_0001202 + ] + ) ; + rdf:type owl:Class + ] + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A peak facet that denotes the abscissa value of the extrema (maxima or minima) attributed to the peak in a data description function. The extrema is often determined through a mathematical fitting of measurement signals to eliminate spurious extrema due to noise. [Allotrope]" ; + + skos:prefLabel "peak position" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001075 + +af-r:AFR_0001075 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000947 ; + + af-x:AFX_0002811 af-x:AFX_0000276 ; + + rdfs:isDefinedBy ; + + skos:changeNote "2018-08-01 Changed definition [Allotrope]" ; + + skos:definition "A peak facet denoting its width at a specified peak height or variance. [Allotrope]" ; + + skos:prefLabel "peak width" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001078 + +af-r:AFR_0001078 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001065 , + iao:_0000590 ; + + af-x:AFX_0002808 ; + + rdfs:isDefinedBy ; + + skos:definition "The street address is a location facet of a postal address, that denotes a street. [Allotrope]" ; + + skos:prefLabel "street address" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001079 + +af-r:AFR_0001079 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000917 , + af-r:AFR_0001082 ; + + af-x:AFX_0002808 ; + + rdfs:isDefinedBy ; + + skos:altLabel "telephone" ; + + skos:definition "A number for calling a telephone. [Allotrope]" ; + + skos:prefLabel "telephone number" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001080 + +af-r:AFR_0001080 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001682 ; + + af-x:AFX_0002808 foaf:title ; + + dct:source "https://en.wikipedia.org/wiki/Title_(disambiguation)" ; + + rdfs:isDefinedBy ; + + skos:definition "A title is a prefix or suffix added to a personal name. A title can be a title of honor, that is a title bestowed as an award, a honorary title (academic), that is a recognition of contributions by a non-employee or employee, a hereditary title, that is a title that remains in a family or a job title, that is a designation of a person's position in an organization. [Wikipedia]" ; + + skos:example "Mr, Mrs, Ms, Dr." ; + + skos:prefLabel "title" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001081 + +af-r:AFR_0001081 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001682 ; + + af-x:AFX_0002808 ; + + rdfs:isDefinedBy ; + + skos:definition "An honorific prefix is a facet that is part of a prefix to a person's name. [Allotrope]" ; + + skos:prefLabel "honorific prefix" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001082 + +af-r:AFR_0001082 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000923 ; + + rdfs:isDefinedBy ; + + skos:definition "A facet that is about communication channels. [Allotrope]" ; + + skos:prefLabel "communication facet" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001083 + +af-r:AFR_0001083 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001065 , + iao:_0000590 ; + + af-x:AFX_0002808 ; + + rdfs:isDefinedBy ; + + skos:definition "A location name is a location facet that denotes a geographical place. [Allotrope]" ; + + skos:prefLabel "location name" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001087 + +af-r:AFR_0001087 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000917 , + af-r:AFR_0001082 ; + + af-x:AFX_0002808 ; + + rdfs:isDefinedBy ; + + skos:definition "A postal code of a postal address. [Allotrope]" ; + + skos:example "ZIP code" ; + + skos:prefLabel "postal code" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001088 + +af-r:AFR_0001088 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000947 ; + + rdfs:isDefinedBy ; + + skos:changeNote "2018-07-19 Definition changed. [Allotrope]" ; + + skos:definition "A peak facet that describes the deviation of the peak's distribution from symmetry about its mean. [Allotrope]" ; + + skos:prefLabel "peak asymmetry" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001089 + +af-r:AFR_0001089 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001101 , + af-r:AFR_0001177 ; + + rdfs:isDefinedBy ; + + skos:changeNote "2020-03-20 Added quantification facet superclass. [Allotrope]" ; + + skos:definition "Retention time is a chromatography peak facet that indicates the elapsed time between the injection of the sample and the maximum detector response attributed to the peak (analyte band). [Allotrope]" ; + + skos:prefLabel "retention time" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001090 + +af-r:AFR_0001090 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001100 ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:definition "Slope is a mathematical facet of a line that describes both the direction and the steepness of the line. [Wikipedia]" ; + + skos:prefLabel "slope" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001092 + +af-r:AFR_0001092 rdf:type owl:Class ; + + rdfs:subClassOf iao:_0000038 ; + + rdfs:isDefinedBy ; + + skos:altLabel "dot" , + "two-dimensional point" ; + + skos:definition "A point is a two-dimensional figure that represents a zero-dimensional spacial region. [Allotrope]" ; + + skos:prefLabel "point" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001093 + +af-r:AFR_0001093 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000923 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A figure facet is a facet that is part of a figure. [Allotrope]" ; + + skos:prefLabel "figure facet" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001094 + +af-r:AFR_0001094 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000991 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002734 ; + owl:someValuesFrom af-p:AFP_0003603 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "An assignment is a proposition that is an assertion of some relation between entities. [Allotrope]" ; + + skos:prefLabel "assignment" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001095 + +af-r:AFR_0001095 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000922 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A timebase is a description that is about a point in time (process boundary or zero dimensional temporal region) that has the role of a temporal reference. [Allotrope]" ; + + skos:prefLabel "timebase" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001100 + +af-r:AFR_0001100 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000923 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A facet that is part of a mathematical expression, formula or equation. [Allotrope]" ; + + skos:prefLabel "mathematical facet" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001101 + +af-r:AFR_0001101 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000923 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000056 ; + owl:someValuesFrom af-p:AFP_0002849 + ] ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "quantity facet" ; + + skos:changeNote "2019-07-04 Changed pref label to be more precise. [Allotrope]" , + "2020-12-01 Changed definition. [Allotrope]" , + "2021-03-16 Fixed quantifies some mass. [Allotrope]" ; + + skos:definition "A facet that is part of a quantification of a quality, aggregate or process. [Allotrope]" ; + + skos:note "A quantification facet is usually a quantity value or a categorization into some group. It is described by a numeric value together with a unit or a categorical value. [Allotrope]" ; + + skos:prefLabel "quantification facet" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001103 + +af-r:AFR_0001103 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000991 , + [ rdf:type owl:Restriction ; + owl:onProperty iao:_0000136 ; + owl:someValuesFrom [ rdf:type owl:Class ; + owl:unionOf ( bfo:_0000019 + bfo:_0000023 + bfo:_0000034 + ) + ] + ] ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "capability (proposition)" ; + + skos:changeNote "2020-12-01 Changed label and definition. [Allotrope]" ; + + skos:definition "A capability is a proposition that is about a function, role or quality realized under given conditions. [Allotrope]" ; + + skos:note "A capability can be in a description or specification role." ; + + skos:prefLabel "capability" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001104 + +af-r:AFR_0001104 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000986 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000690 ; + owl:allValuesFrom xsd:double + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A scalar double datum is a scalar floating point number datum having a IEEE double precision datum (xsd:double). [Allotrope]" ; + + skos:prefLabel "scalar double datum" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001106 + +af-r:AFR_0001106 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000923 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002730 ; + owl:someValuesFrom [ owl:intersectionOf ( af-rl:AFRL_0000299 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002731 ; + owl:someValuesFrom af-p:AFP_0000032 + ] + ) ; + rdf:type owl:Class + ] + ] , + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000050 ; + owl:someValuesFrom af-r:AFR_0000471 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "cell counter result facet" ; + + skos:definition "A cell counter result data is a facet of a document about a cell counting assay that is about a some result of the cell counting assay. [Allotrope]" ; + + skos:prefLabel "cell counter result datum" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001107 + +af-r:AFR_0001107 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001505 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000354 ; + owl:someValuesFrom af-p:AFP_0000032 + ] , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002730 ; + owl:someValuesFrom [ owl:intersectionOf ( af-rl:AFRL_0000019 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002731 ; + owl:someValuesFrom af-p:AFP_0000032 + ] + ) ; + rdf:type owl:Class + ] + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "cell counter parameter" ; + + skos:definition "A cell counter parameter datum is a facet of a document about a cell counting assay that is about a some parameter of the cell counting assay. [Allotrope]" ; + + skos:prefLabel "cell counter setting" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001108 + +af-r:AFR_0001108 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000989 , + af-r:AFR_0001106 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002816 ; + owl:someValuesFrom af-q:AFQ_0000182 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "viable cell density" , + "viable density" ; + + skos:definition "Viable cell density is a cell counter result data that quantifies the number density of the viable cells in the sample in the cell counting assay. [Allotrope]" ; + + skos:prefLabel "viable cell density (cell counter)" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001109 + +af-r:AFR_0001109 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000989 , + af-r:AFR_0001107 , + af-r:AFR_0001243 ; + + rdfs:isDefinedBy ; + + skos:altLabel "dilution ratio" ; + + skos:definition "Cell density dilution factor is a cell counter parameter data that describes the dilution factor of the solution prepared for the cell counting assay. [Allotrope]" ; + + skos:prefLabel "cell density dilution factor" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001110 + +af-r:AFR_0001110 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001107 , + af-r:AFR_0001243 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002730 ; + owl:someValuesFrom af-rl:AFRL_0000368 + ] , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002806 ; + owl:someValuesFrom af-m:AFM_0000341 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "cell type" ; + + skos:definition "Cell type is cell counter parameter data that describes the type of cells analyzed in the cell counting assay. [Allotrope]" ; + + skos:prefLabel "cell type (cell counter)" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001111 + +af-r:AFR_0001111 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000989 , + af-r:AFR_0001106 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002816 ; + owl:someValuesFrom pato:_0000169 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "viability" ; + + skos:definition "Viability is a cell counter result data that quantifies the viability of the cells analyzed. [Allotrope]" ; + + skos:prefLabel "viability (cell counter)" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001112 + +af-r:AFR_0001112 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000989 , + af-r:AFR_0001106 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002816 ; + owl:someValuesFrom af-q:AFQ_0000183 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "total cell density" , + "total density" ; + + skos:definition "Total cell density is a cell counter result data that quantifies the number density of the cells in the sample in the cell counting assay. [Allotrope]" ; + + skos:prefLabel "total cell density (cell counter)" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001113 + +af-r:AFR_0001113 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000989 , + af-r:AFR_0001106 , + [ owl:intersectionOf ( af-r:AFR_0001213 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002730 ; + owl:someValuesFrom af-rl:AFRL_0000320 + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "average live diameter" , + "live cell diameter" ; + + skos:definition "Average live cell diameter is a cell counter result data that states the average diameter of the living cells measured. [Allotrope]" ; + + skos:prefLabel "average live cell diameter (cell counter)" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001114 + +af-r:AFR_0001114 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000984 , + af-r:AFR_0001106 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002816 ; + owl:someValuesFrom af-q:AFQ_0000186 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "Total cell count is a cell counter result data that states the total number of cells that were counted in the cell counting measurement. [Allotrope]" ; + + skos:prefLabel "total cell count" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001115 + +af-r:AFR_0001115 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000984 , + af-r:AFR_0001106 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002816 ; + owl:someValuesFrom af-q:AFQ_0000185 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "live cell count" , + "live count" , + "total live count" , + "viable count" ; + + skos:definition "Viable cell count is a cell counter result data that states the number of viable cells that were counted in the cell counting assay. [Allotrope]" ; + + skos:prefLabel "viable cell count" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001116 + +af-r:AFR_0001116 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000917 , + af-r:AFR_0001117 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002717 ; + owl:someValuesFrom [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000087 ; + owl:someValuesFrom af-rl:AFRL_0000003 + ] + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "analyst ID" , + "analyst id" , + "analyst identifier" , + "operator" ; + + skos:changeNote "2020-03-09 Moved to AFO as defined class. [Allotrope]" ; + + skos:definition "Analyst is measurement metadata about the name or identifier of a person that has the role of an analyst in the measurement. [Allotrope]" ; + + skos:prefLabel "analyst" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001117 + +af-r:AFR_0001117 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000923 , + [ owl:intersectionOf ( [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002730 ; + owl:someValuesFrom [ owl:intersectionOf ( af-rl:AFRL_0000450 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002731 ; + owl:someValuesFrom af-p:AFP_0002294 + ] + ) ; + rdf:type owl:Class + ] + ] + [ rdf:type owl:Restriction ; + owl:onProperty iao:_0000136 ; + owl:someValuesFrom af-p:AFP_0002294 + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:isDefinedBy ; + + skos:definition "Measurement metadata is a facet that is part of a information content entity about a measurement that is about the context of the measurement, but not directly about the measurement result or a measurement parameter. [Allotrope]" ; + + skos:prefLabel "measurement metadata" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001118 + +af-r:AFR_0001118 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001117 , + af-r:AFR_0001745 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002717 ; + owl:someValuesFrom [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000087 ; + owl:someValuesFrom af-rl:AFRL_0000035 + ] + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "sample ID" , + "sample id" ; + + skos:definition "Sample id is a measurement metadata that identifies a sample being measured. [Allotrope]" ; + + skos:prefLabel "sample identifier" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001119 + +af-r:AFR_0001119 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0002018 , + iao:_0000131 ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "device serial number" , + "instrument serial number" , + "machine serial number" ; + + skos:changeNote "2020-03-23 Add alt labels. [Allotrope]" , + "2020-03-23 Subclassed under device identifier. [Allotrope]" ; + + skos:definition "Equipment serial number is a serial number that identifies an equipment used in the measuring by its serial number. [Allotrope]" ; + + skos:prefLabel "equipment serial number" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001120 + +af-r:AFR_0001120 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001745 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002717 ; + owl:someValuesFrom [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000087 ; + owl:someValuesFrom af-rl:AFRL_0000361 + ] + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "batch ID" , + "batch id" , + "lot ID" , + "lot id" , + "lot identifier" ; + + skos:changeNote "2020-06-15 Removed measurement metadata superclass and generalized the definition. [Allotrope]" ; + + skos:definition "A batch identifier is an identifier that identifies a batch. [Allotrope]" ; + + skos:example "A batch identifier is used to reference the batch where a sample is taken from for being measured. In this case it is a measurement metadata. [Allotrope]" ; + + skos:prefLabel "batch identifier" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001121 + +af-r:AFR_0001121 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000917 , + af-r:AFR_0001117 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002717 ; + owl:someValuesFrom af-p:AFP_0002294 + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "measurement id" , + "run id" , + "run identifier" ; + + skos:definition "Measurement id is measurement metadata that identifies the measuring run. [Allotrope]" ; + + skos:prefLabel "measurement identifier" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001124 + +af-r:AFR_0001124 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( af-r:AFR_0000941 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002704 ; + owl:someValuesFrom [ owl:intersectionOf ( af-re:AFRE_0000001 + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000054 ; + owl:someValuesFrom af-p:AFP_0001319 + ] + ) ; + rdf:type owl:Class + ] + ] + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A sampling specification is an action specification of the way a sampling is done. [Allotrope]" ; + + skos:prefLabel "sampling specification" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001140 + +af-r:AFR_0001140 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000989 , + af-r:AFR_0001284 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002816 ; + owl:someValuesFrom af-q:AFQ_0000196 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "pCO2" , + "partial pressure of carbon dioxide" ; + + skos:definition "pCO2 is a blood gas result datum that quantifies the partial pressure of carbon dioxide dissolved in solution. [Allotrope]" ; + + skos:prefLabel "pCO2 (bga)" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001141 + +af-r:AFR_0001141 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000989 , + af-r:AFR_0001284 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002816 ; + owl:someValuesFrom af-q:AFQ_0000195 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "pO2" , + "partial pressure of oxygen" ; + + skos:definition "pO2 is a blood gas result datum that quantifies the partial pressure of oxygen gas dissolved in the blood. [Allotrope]" ; + + skos:prefLabel "pO2 (bga)" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001142 + +af-r:AFR_0001142 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001583 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002816 ; + owl:someValuesFrom pato:_0001842 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "pH (datum)" , + "pondus hydrogenii" ; + + skos:definition "pH (datum) is a quantity facet that quantifies the acidity or basicity of an aqueous solution, defined as the decadic logarithm of the reciprocal activity of hydrogen ions. [Allotrope]" ; + + skos:prefLabel "pH" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001157 + +af-r:AFR_0001157 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001583 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002816 ; + owl:someValuesFrom af-q:AFQ_0000061 + ] ; + + dct:license ; + + dct:rights ; + + dct:source "PAC, 1990, 62, 2167 (Glossary of atmospheric chemistry terms (Recommendations 1990))" , + "PAC, 1996, 68, 2223 (Glossary of terms used in photochemistry (IUPAC Recommendations 1996))" ; + + rdfs:isDefinedBy ; + + skos:altLabel "absorbance (datum)" ; + + skos:definition "Absorbance is a quantity facet that quantifies the absorbance as logarithm to the base 10 (linear absorbance) of the incident (prior to absorption) spectral radiant power, divided by the transmitted spectral radiant power. [IUPAC]" ; + + skos:prefLabel "absorbance" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001158 + +af-r:AFR_0001158 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000937 , + [ rdf:type owl:Restriction ; + owl:onProperty iao:_0000136 ; + owl:someValuesFrom af-p:AFP_0003095 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "The acquisition time is the time when a signal is captured. [Allotrope]" ; + + skos:prefLabel "acquisition time" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001159 + +af-r:AFR_0001159 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001583 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002816 ; + owl:someValuesFrom pato:_0001242 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "wavelength (datum)" ; + + skos:definition "A wavelength is a facet that quantifies a wavelength of electromagnetic radiation. [Allotrope]" ; + + skos:prefLabel "wavelength" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001164 + +af-r:AFR_0001164 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000917 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002717 ; + owl:someValuesFrom af-r:AFR_0000413 + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "peak ID" , + "peak id" ; + + skos:changeNote "2020-03-09 Moved to AFO as defined class. [Allotrope]" ; + + skos:definition "A peak identifier is an identifier that identifies a peak. [Allotrope]" ; + + skos:prefLabel "peak identifier" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001165 + +af-r:AFR_0001165 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000947 ; + + rdfs:isDefinedBy ; + + skos:altLabel "peak area (relative)" ; + + skos:definition "A peak facet that denotes the area of the peak relative to some other peak or summation of peaks. [Allotrope]" ; + + skos:prefLabel "relative peak area" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001167 + +af-r:AFR_0001167 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000947 , + iao:_0000590 , + [ rdf:type owl:Restriction ; + owl:onProperty iao:_0000219 ; + owl:someValuesFrom af-r:AFR_0000413 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A peak name is a written name that denotes some peak. [Allotrope]" ; + + skos:prefLabel "peak name" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001168 + +af-r:AFR_0001168 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000928 ; + + rdfs:isDefinedBy ; + + skos:definition "A peak index is an index that denotes a peak in a list of peaks. [Allotrope]" ; + + skos:prefLabel "peak index" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001170 + +af-r:AFR_0001170 rdf:type owl:Class ; + + rdfs:subClassOf iao:_0000030 ; + + dct:source "https://en.wikipedia.org/wiki/Noise_(electronics)" , + "https://en.wikipedia.org/wiki/Signal" ; + + rdfs:isDefinedBy ; + + skos:definition "An information content entity that describes the unwanted random and systematic fluctuations to the signal that limit the ability to detect a signal contribution of interest. [Allotrope]" ; + + skos:prefLabel "noise" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001171 + +af-r:AFR_0001171 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000947 , + af-r:AFR_0001583 ; + + rdfs:isDefinedBy ; + + skos:changeNote "2020-03-20 Added superclass quality quantification facet. [Allotrope]" ; + + skos:definition "A peak facet that quantitates the amount of analyte attributed to the peak based on a calibration curve, response factor or other quantitative formula. [Allotrope]" ; + + skos:prefLabel "peak analyte amount" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001172 + +af-r:AFR_0001172 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000947 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002730 ; + owl:someValuesFrom af-rl:AFRL_0000248 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A peak facet that denotes the amount of analyte ascribed to a the peak relative to the amount of some other analyte or summation of analytes. [Allotrope]" ; + + skos:prefLabel "relative peak analyte amount" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001173 + +af-r:AFR_0001173 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000947 ; + + rdfs:isDefinedBy ; + + skos:definition "A peak facet that indicates whether the response curve of the peak is above or below the signal baseline. [Allotrope]" ; + + skos:prefLabel "peak polarity" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001174 + +af-r:AFR_0001174 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001101 , + [ owl:intersectionOf ( af-r:AFR_0001177 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002730 ; + owl:someValuesFrom af-rl:AFRL_0000248 + ] + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002816 ; + owl:someValuesFrom af-q:AFQ_0000019 + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:isDefinedBy ; + + skos:changeNote "2020-03-20 Added quantification facet superclass. [Allotrope]" ; + + skos:definition "A chromatography peak facet that denotes the retention time of the peak relative to some other specified reference peak. [Allotrope]" ; + + skos:prefLabel "relative retention time" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001175 + +af-r:AFR_0001175 rdf:type owl:Class ; + + rdfs:subClassOf [ owl:intersectionOf ( af-r:AFR_0001174 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002730 ; + owl:someValuesFrom af-rl:AFRL_0000248 + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A relative retention time that quantitates the ratio of the retention time of the peak relative to some other specified reference peak. [Allotrope]" ; + + skos:prefLabel "unadjusted relative retention" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001176 + +af-r:AFR_0001176 rdf:type owl:Class ; + + rdfs:subClassOf [ owl:intersectionOf ( af-r:AFR_0001174 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002730 ; + owl:someValuesFrom af-rl:AFRL_0000248 + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A relative retention time that quantitates the ratio of the adjusted retention time (corrected for hold-up time) of the peak relative to the adjusted retention time of some reference peak. [Allotrope]" ; + + skos:prefLabel "adjusted relative retention" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001177 + +af-r:AFR_0001177 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( af-r:AFR_0000947 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002800 ; + owl:someValuesFrom af-r:AFR_0000015 + ] + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A chromatography peak facet is a facet of a chromatography peak. [Allotrope]" ; + + skos:prefLabel "chromatography peak facet" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001178 + +af-r:AFR_0001178 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000947 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002730 ; + owl:someValuesFrom [ owl:intersectionOf ( af-rl:AFRL_0000278 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000388 ; + owl:someValuesFrom af-r:AFR_0001189 + ] + ) ; + rdf:type owl:Class + ] + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A peak facet that denotes the first value of the abscissa that belongs to the peak. [Allotrope]" ; + + skos:prefLabel "peak start" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001179 + +af-r:AFR_0001179 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000947 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002730 ; + owl:someValuesFrom [ owl:intersectionOf ( af-rl:AFRL_0000279 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000388 ; + owl:someValuesFrom af-r:AFR_0001189 + ] + ) ; + rdf:type owl:Class + ] + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A peak facet that denotes the first value of the ordinate that belongs to the peak. [Allotrope]" ; + + skos:prefLabel "peak value at start" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001180 + +af-r:AFR_0001180 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000947 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002730 ; + owl:someValuesFrom [ owl:intersectionOf ( af-rl:AFRL_0000278 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000388 ; + owl:someValuesFrom af-r:AFR_0001190 + ] + ) ; + rdf:type owl:Class + ] + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A peak facet that denotes the last value of the abscissa that belongs to the peak. [Allotrope]" ; + + skos:prefLabel "peak end" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001181 + +af-r:AFR_0001181 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000947 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002730 ; + owl:someValuesFrom [ owl:intersectionOf ( af-rl:AFRL_0000279 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000388 ; + owl:someValuesFrom af-r:AFR_0001190 + ] + ) ; + rdf:type owl:Class + ] + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A peak facet that denotes the last value of the ordinate that belongs to the peak. [Allotrope]" ; + + skos:prefLabel "peak value at end" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001182 + +af-r:AFR_0001182 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000947 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002730 ; + owl:someValuesFrom af-rl:AFRL_0000316 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A peak facet that describes the peak start boundary with respect to the signal, integration determined signal baseline or a neighboring peak. [Allotrope]" ; + + skos:prefLabel "peak baseline start code" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001183 + +af-r:AFR_0001183 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000947 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002730 ; + owl:someValuesFrom af-rl:AFRL_0000317 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A peak facet that describes the peak end boundary with respect to the signal, integration determined signal baseline or a neighboring peak. [Allotrope]" ; + + skos:prefLabel "peak baseline end code" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001184 + +af-r:AFR_0001184 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000947 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002730 ; + owl:someValuesFrom [ owl:intersectionOf ( af-rl:AFRL_0000279 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000388 ; + owl:someValuesFrom af-r:AFR_0001518 + ] + ) ; + rdf:type owl:Class + ] + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A peak facet that denotes the ordinate value of the baseline of a peak at the peak start time. [Allotrope]" ; + + skos:prefLabel "baseline value at start of peak" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001185 + +af-r:AFR_0001185 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000947 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002730 ; + owl:someValuesFrom [ owl:intersectionOf ( af-rl:AFRL_0000279 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000388 ; + owl:someValuesFrom af-r:AFR_0001518 + ] + ) ; + rdf:type owl:Class + ] + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A peak facet that denotes the ordinate value of the baseline of a peak at the peak end time. [Allotrope]" ; + + skos:prefLabel "baseline value at end of peak" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001186 + +af-r:AFR_0001186 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( af-r:AFR_0000186 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0002350 ; + owl:someValuesFrom af-r:AFR_0001219 + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:subClassOf af-r:AFR_0000186 ; + + rdfs:isDefinedBy ; + + skos:definition "A peak point is a data point that is a member of a peak. [Allotrope]" ; + + skos:prefLabel "peak point" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001187 + +af-r:AFR_0001187 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000186 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002737 ; + owl:someValuesFrom af-r:AFR_0001056 + ] ; + + rdfs:isDefinedBy ; + + skos:changeNote "2020-04-28 Moved to AFO for single inheritence in AFT. [Allotrope]" ; + + skos:definition "A 2D-data point is a data point in 2-dimensional space. [Allotrope]" ; + + skos:prefLabel "2D-data point" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001188 + +af-r:AFR_0001188 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000186 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002737 ; + owl:someValuesFrom af-r:AFR_0001057 + ] ; + + rdfs:isDefinedBy ; + + skos:changeNote "2020-04-28 Moved to AFO for single inheritence in AFT. [Allotrope]" ; + + skos:definition "A 3D-data point is a data point in 3-dimensional space. [Allotrope]" ; + + skos:prefLabel "3D-data point" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001189 + +af-r:AFR_0001189 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001186 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002730 ; + owl:someValuesFrom [ owl:intersectionOf ( af-rl:AFRL_0000316 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000388 ; + owl:someValuesFrom af-r:AFR_0000413 + ] + ) ; + rdf:type owl:Class + ] + ] ; + + rdfs:isDefinedBy ; + + skos:definition "The peak start point is the data point of the peak with the smallest abscissa value. [Allotrope]" ; + + skos:prefLabel "peak start point" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001190 + +af-r:AFR_0001190 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001186 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002730 ; + owl:someValuesFrom [ owl:intersectionOf ( af-rl:AFRL_0000317 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000388 ; + owl:someValuesFrom af-r:AFR_0000413 + ] + ) ; + rdf:type owl:Class + ] + ] ; + + rdfs:isDefinedBy ; + + skos:definition "The peak start point is the data point of the peak with the largest abscissa value. [Allotrope]" ; + + skos:prefLabel "peak end point" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001191 + +af-r:AFR_0001191 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001202 ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy , + ; + + skos:definition "The peak maximum point is the data point of the peak with the largest ordinate value. [Allotrope]" ; + + skos:prefLabel "peak maximum point" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001192 + +af-r:AFR_0001192 rdf:type owl:Class ; + + owl:equivalentClass [ rdf:type owl:Restriction ; + owl:onProperty ro:_0002350 ; + owl:someValuesFrom af-r:AFR_0001046 + ] ; + + rdfs:subClassOf af-c:AFC_0000161 ; + + rdfs:isDefinedBy ; + + skos:altLabel "tuple element" , + "tuple object" ; + + skos:definition "A tuple item is an object in a tuple. [Allotrope]" ; + + skos:prefLabel "tuple item" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001195 + +af-r:AFR_0001195 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000947 ; + + rdfs:isDefinedBy ; + + skos:definition "A peak facet that ratios the peak height value with background level of noise. It is an indication of the sensitivity of a particular method toward the analyte that the peak represents. [Allotrope]" ; + + skos:prefLabel "signal-to-noise ratio" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001196 + +af-r:AFR_0001196 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001195 ; + + rdfs:isDefinedBy ; + + skos:definition "A signal-to-noise ratio calculated using the Root Mean Square noise method. [Allotrope]" ; + + skos:prefLabel "signal-to-noise ratio (RMS)" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001197 + +af-r:AFR_0001197 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001195 ; + + rdfs:isDefinedBy ; + + skos:altLabel "signal-to-noise (peak-to-peak, EP 2.2.46)" , + "signal-to-noise (peak-to-peak, JP-G20)" , + "signal-to-noise (peak-to-peak, USP 621)" ; + + skos:changeNote "2019-09-26 Removed alt labels, now their own subclasses. [Allotrope]" ; + + skos:definition "A signal-to-noise ratio calculated using the peak-to-peak noise method. This includes JP-G20 (measured over optimally 20 X peak width at half height but at least 5 times the peak width at half height), EP 2.2.46 (measured over at least 5 times the peak width at half height), USP 621 (measured over at least 5 times the peak width at half height). [Allotrope]" ; + + skos:prefLabel "signal-to-noise ratio (peak-to-peak)" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001198 + +af-r:AFR_0001198 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001195 ; + + rdfs:isDefinedBy ; + + skos:definition "A signal-to-noise ratio calculated using the ASTM E1657-98 method. [Allotrope]" ; + + skos:prefLabel "signal-to-noise ratio (ASTM E1657-98)" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001199 + +af-r:AFR_0001199 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000947 ; + + rdfs:isDefinedBy ; + + skos:definition "A peak facet that measures the degree of separation between the peak and another specified peak. [Allotrope]" ; + + skos:prefLabel "peak resolution" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001201 + +af-r:AFR_0001201 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001202 ; + + rdfs:isDefinedBy ; + + skos:definition "The peak minimum point is the data point of the peak with the smallest ordinate value. [Allotrope]" ; + + skos:prefLabel "peak minimum point" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001202 + +af-r:AFR_0001202 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001186 ; + + rdfs:isDefinedBy ; + + skos:definition "The peak extremum point is the data point of the peak with the largest or smallest ordinate value. [Allotrope]" ; + + skos:prefLabel "peak extremum point" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001209 + +af-r:AFR_0001209 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000922 , + af-r:AFR_0001852 , + [ owl:intersectionOf ( af-c:AFC_0000168 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002730 ; + owl:someValuesFrom af-rl:AFRL_0000325 + ] + ) ; + rdf:type owl:Class + ] ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:altLabel "population" , + "population (statistics)" ; + + skos:changeNote "2019-08-19 Moved under statistical facet. [Allotrope]" ; + + skos:definition "In statistics, a population is a set of similar items or events which is of interest for some question or experiment. A statistical population can be a group of existing objects or a hypothetical and potentially infinite group of objects conceived as a generalization from experience. [Wikipedia]" ; + + skos:prefLabel "statistical population" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001210 + +af-r:AFR_0001210 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000922 , + af-r:AFR_0001852 , + [ owl:intersectionOf ( af-c:AFC_0000168 + af-r:AFR_0001211 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002730 ; + owl:someValuesFrom af-rl:AFRL_0000324 + ] + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000050 ; + owl:someValuesFrom af-r:AFR_0001209 + ] + ) ; + rdf:type owl:Class + ] ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:altLabel "statistical sample" ; + + skos:changeNote "2019-08-19 Moved under statistical facet. [Allotrope]" ; + + skos:definition "A statistical sample set is a description of a subset of the statistical population, that is chosen to represent the population in a statistical analysis. [Wikipedia]" ; + + skos:prefLabel "statistical sample set" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001211 + +af-r:AFR_0001211 rdf:type owl:Class ; + + rdfs:subClassOf af-c:AFC_0000166 , + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000050 ; + owl:someValuesFrom af-c:AFC_0000166 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A partition is a collection that is an aggregate part of a larger collection. Each member of the partition is also a member of the larger collection. [Allotrope]" ; + + skos:prefLabel "partition" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001212 + +af-r:AFR_0001212 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000922 , + af-r:AFR_0001852 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002730 ; + owl:someValuesFrom af-rl:AFRL_0000328 + ] ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:changeNote "2019-08-19 Moved under statistical facet. [Allotrope]" ; + + skos:definition "A descriptive statistic is a summary statistic that quantitatively describes or summarizes features of a collection of information. [Wikipedia]" ; + + skos:prefLabel "descriptive statistic" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001213 + +af-r:AFR_0001213 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000923 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002800 ; + owl:someValuesFrom af-c:AFC_0000166 + ] ; + + dct:subject ; + + rdfs:isDefinedBy ; + + skos:altLabel "aggregate facet" , + "summary facet" ; + + skos:definition "A summary datum is a facet of a collection that is about summary information about features of the members of the collection, such as descriptive statistics in order to communicate the largest amount of information as simply as possible. [Allotrope]" ; + + skos:example "maximum height of a peak - peak is a collection of peak points, peak height is a facet of each peak point." ; + + skos:prefLabel "summary datum" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001216 + +af-r:AFR_0001216 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000923 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + dct:replaces af-e:AFE_0001866 ; + + rdfs:isDefinedBy ; + + skos:definition "The position is the location of a physical entity. [Allotrope]" ; + + skos:example "Geolocation expressed as geographic coordinates" , + "Position expressed with respect to a given coordinate system at some time t." , + "Position of a vial on a tray expressed as indexed number." ; + + skos:prefLabel "position" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001217 + +af-r:AFR_0001217 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000186 , + af-r:AFR_0001839 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:changeNote "2018-07-23 Replaced deprecated af-p:AFP_0001083" , + "2019-08-19 Changed definition. [Allotrope]" , + "2019-08-19 Moved under data point. [Allotrope]" , + "2020-04-28 Add subclass of calibration result." ; + + skos:definition "A calibration point is a single calibration result at a specific test point (one or more reference values). [Allotrope]" ; + + skos:example "In pH calibration a point with a set pH and buffer solution." ; + + skos:prefLabel "calibration point" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001218 + +af-r:AFR_0001218 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000922 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "composition" , + "formulation" ; + + skos:definition "The formulation of a material is a data object that describes its composition of ingredients. [Allotrope]" ; + + skos:prefLabel "formulation description" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001219 + +af-r:AFR_0001219 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000922 ; + + rdfs:isDefinedBy ; + + skos:altLabel "blank reading" ; + + skos:changeNote "2020-12-11 Add label. [Allotrope]" ; + + skos:definition "An information content entity that describes the background (offset) component of a signal not due to the analyte (peak) of interest. [Allotrope]" ; + + skos:prefLabel "baseline" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001220 + +af-r:AFR_0001220 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001219 ; + + dct:license ; + + dct:rights ; + + dct:source "PAC, 1990, 62, 2167 (Glossary of atmospheric chemistry terms (Recommendations 1990))" , + "PAC, 1993, 65, 819 (Nomenclature for chromatography (IUPAC Recommendations 1993))" ; + + rdfs:isDefinedBy ; + + skos:altLabel "baseline" ; + + skos:definition "The portion of the chromatogram recording the detector response when only the mobile phase emerges from the column. [IUPAC]" ; + + skos:prefLabel "baseline (chromatography)" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001221 + +af-r:AFR_0001221 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000923 ; + + rdfs:isDefinedBy ; + + skos:definition "Term granularity relates an entity to an instance of granularity that describes the level of granularity that a term belongs to. [Allotrope]" ; + + skos:example "A vial is a container that exists in macroscopic scale." ; + + skos:prefLabel "term granularity" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001230 + +af-r:AFR_0001230 rdf:type owl:Class ; + + rdfs:subClassOf [ owl:intersectionOf ( af-r:AFR_0001177 + af-r:AFR_0001199 + ) ; + rdf:type owl:Class + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A chromatographic peak facet that quantitates the degree of separation between two peaks of a chromatogram. [Allotrope]" ; + + skos:prefLabel "chromatographic peak resolution" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001231 + +af-r:AFR_0001231 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001230 ; + + rdfs:isDefinedBy ; + + skos:altLabel "chromatographic peak resolution by USP <621> using widths at baseline" , + "chromatographic peak resolution calculated by the ASTM method" ; + + skos:definition "Chromatographic peak resolution that is calculated by the USP <621> method using peak widths measured at the baseline. [Allotrope]" ; + + skos:prefLabel "chromatographic peak resolution using baseline peak widths" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001232 + +af-r:AFR_0001232 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001230 ; + + rdfs:isDefinedBy ; + + skos:altLabel "chromatographic peak resolution by USP using widths at half-height" , + "chromatographic peak resolution calculated by EP" , + "chromatographic peak resolution calculated by JP-27" ; + + skos:definition "Chromatographic peak resolution that is calculated using peak widths measured at the half height. [Allotrope]" ; + + skos:prefLabel "chromatographic peak resolution using peak width at half-height" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001233 + +af-r:AFR_0001233 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001230 ; + + rdfs:isDefinedBy ; + + skos:definition "Chromatographic peak resolution that is calculated based on peak widths derived from the second statistical moment (peak variance). [Allotrope]" ; + + skos:prefLabel "chromatographic peak resolution using statistical moments" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001234 + +af-r:AFR_0001234 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001177 ; + + dct:license ; + + dct:rights ; + + rdfs:isDefinedBy ; + + skos:altLabel "capacity ratio" , + "mass distribution ratio" , + "partition ratio" , + "retention factor" ; + + skos:definition "The capacity factor is a chromatography peak facet that is a measure of the time the sample component resides in the stationary phase relative to the time it resides in the mobile phase: it expresses how much longer a sample component is retarded by the stationary phase than it would take to travel through the column with the velocity of the mobile phase. [IUPAC]" ; + + skos:prefLabel "capacity factor (chromatography)" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001235 + +af-r:AFR_0001235 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001177 ; + + rdfs:isDefinedBy ; + + skos:altLabel "peak selectivity" ; + + skos:definition "A chromatography peak facet that denotes the ratio of the peak's capacity factor to that of another specified peak. [Allotrope]" ; + + skos:prefLabel "peak selectivity (chromatography)" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001236 + +af-r:AFR_0001236 rdf:type owl:Class ; + + rdfs:subClassOf [ owl:intersectionOf ( af-r:AFR_0001088 + af-r:AFR_0001177 + ) ; + rdf:type owl:Class + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "tailing factor" ; + + skos:definition "A chromatography peak facet that denotes the ratio of the peak's capacity factor to that of another specified peak. [Allotrope]" ; + + skos:prefLabel "chromatographic peak asymmetry factor" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001237 + +af-r:AFR_0001237 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001236 ; + + rdfs:isDefinedBy ; + + skos:altLabel "asymmetry factor by EP" , + "asymmetry factor by JP-27" , + "tailing factor by USP <621> method" ; + + skos:definition "A quantitative asymmetry factor using 5% peak height. [Allotrope]" ; + + skos:prefLabel "asymmetry factor measured at 5 percent height" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001238 + +af-r:AFR_0001238 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001236 ; + + rdfs:isDefinedBy ; + + skos:altLabel "statistical skew" ; + + skos:definition "A quantitative asymmetry factor using the third statistical moment calculated from the peak. [Allotrope]" ; + + skos:prefLabel "statistical skew (chromatography)" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001239 + +af-r:AFR_0001239 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001177 ; + + rdfs:isDefinedBy ; + + skos:altLabel "number of theoretical plates" ; + + skos:definition "A chromatography peak facet that measures the amount of band broadening that occurs during the separation and thus the efficiency of the chromatographic system. [Allotrope]" ; + + skos:prefLabel "number of theoretical plates (chromatography)" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001240 + +af-r:AFR_0001240 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001239 ; + + rdfs:isDefinedBy ; + + skos:altLabel "number of theoretical plates by ASTM" , + "number of theoretical plates by USP method" ; + + skos:definition "The number of theoretical plates calculated based on the peak width measured at the baseline. [Allotrope]" ; + + skos:prefLabel "number of theoretical plates by tangent method" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001241 + +af-r:AFR_0001241 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001239 ; + + rdfs:isDefinedBy ; + + skos:altLabel "number of theoretical plates by EP method" , + "number of theoretical plates by JP method" ; + + skos:definition "The number of theoretical plates calculated based on the peak width measured at half height. [Allotrope]" ; + + skos:prefLabel "number of theoretical plates by peak width at half height" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001242 + +af-r:AFR_0001242 rdf:type owl:Class ; + + rdfs:subClassOf [ owl:intersectionOf ( af-r:AFR_0001575 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002704 ; + owl:someValuesFrom [ owl:intersectionOf ( af-q:AFQ_0000036 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000080 ; + owl:someValuesFrom af-e:AFE_0001711 + ] + ) ; + rdf:type owl:Class + ] + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "autosampler setting" ; + + skos:changeNote "2019-07-01 Changed specification target to be a device configuration. [Allotrope]" ; + + skos:definition "A parameter specification specific to the sampler device in the chromatography system. [Allotrope]" ; + + skos:prefLabel "autosampler setting (chromatography)" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001243 + +af-r:AFR_0001243 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001505 ; + + rdfs:isDefinedBy ; + + skos:altLabel "control parameter" ; + + skos:definition "A control setting is a setting that controls how a process is executed by some system. [Allotrope]" ; + + skos:prefLabel "control setting" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001245 + +af-r:AFR_0001245 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001505 ; + + rdfs:isDefinedBy ; + + skos:altLabel "alert parameter" ; + + skos:definition "An alert setting is a setting that specifies conditions and situations that trigger alerts during the operation of a device. [Allotrope]" ; + + skos:example "maximum environment humidity" , + "maximum pressure of the fluid for a plumbing system" , + "minimum environment temperature for operation" ; + + skos:prefLabel "alert setting" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001247 + +af-r:AFR_0001247 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001505 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002704 ; + owl:someValuesFrom af-q:AFQ_0000199 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A detector setting is a setting that specifies a detector configuration. [Allotrope]" ; + + skos:prefLabel "detector setting" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001248 + +af-r:AFR_0001248 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001247 ; + + rdfs:isDefinedBy ; + + skos:definition "An electronic absorbance detector setting is a setting that specifies a device configuration of an electronic absorbance detector. [Allotrope]" ; + + skos:prefLabel "electronic absorbance detector setting" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001249 + +af-r:AFR_0001249 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001243 , + af-r:AFR_0001247 ; + + rdfs:isDefinedBy ; + + skos:definition "A detector offset setting is a detector setting parameter that adds the specified value to its output signal. It is often used to avoid negative signal values. [Allotrope]" ; + + skos:prefLabel "detector offset setting" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001250 + +af-r:AFR_0001250 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001243 , + af-r:AFR_0001247 ; + + rdfs:isDefinedBy ; + + skos:altLabel "acquisition rate" , + "detection sampling rate" , + "detector rate setting" , + "sampling frequency" , + "sampling rate" , + "sampling rate setting" ; + + skos:definition "A detector sampling rate setting is a detector setting parameter that specifies the rate at which the detector changes its output signal. It is limited by the actual physical/chemical process of detection and the detector electronics. Often the sample rate is set lower than the maximum sampling rate so that adjacent data points can be averaged to provide better signal to noise. [Allotrope]" ; + + skos:prefLabel "detector sampling rate setting" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001251 + +af-r:AFR_0001251 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001243 , + af-r:AFR_0001248 ; + + rdfs:isDefinedBy ; + + skos:altLabel "detector reference bandwidth setting" ; + + skos:definition "An electronic absorbance reference bandwidth setting is an electronic absorbance detector setting parameter that specifies the bandwidth of the reference signal that is subtracted from a particular signal of the device in order to compensate for background signal and noise. [Allotrope]" ; + + skos:prefLabel "electronic absorbance reference bandwidth setting" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001252 + +af-r:AFR_0001252 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001243 , + af-r:AFR_0001248 ; + + rdfs:isDefinedBy ; + + skos:altLabel "detector reference wavelength setting" ; + + skos:definition "An electronic absorbance reference wavelength setting is an electronic absorbance detector setting parameter that specifies the nominal reference wavelength of the reference signal that is subtracted from a particular signal of the device in order to compensate for background signal and noise. [Allotrope]" ; + + skos:prefLabel "electronic absorbance reference wavelength setting" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001253 + +af-r:AFR_0001253 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001243 , + af-r:AFR_0001248 ; + + rdfs:isDefinedBy ; + + skos:altLabel "detector bandwidth setting" ; + + skos:definition "An electronic absorbance bandwidth setting is an electronic absorbance detector setting parameter that specifies the bandwidth of a particular signal to be measured by the device. [Allotrope]" ; + + skos:prefLabel "electronic absorbance bandwidth setting" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001254 + +af-r:AFR_0001254 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001243 , + af-r:AFR_0001248 ; + + rdfs:isDefinedBy ; + + skos:altLabel "detector wavelength setting" ; + + skos:definition "An electronic absorbance wavelength setting that is an electronic absorbance detector setting parameter that specifies the nominal wavelength of a particular signal to be measured by the device. [Allotrope]" ; + + skos:prefLabel "electronic absorbance wavelength setting" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001255 + +af-r:AFR_0001255 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( af-r:AFR_0001505 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002704 ; + owl:someValuesFrom af-q:AFQ_0000203 + ] + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "temperature parameter" ; + + skos:changeNote "2018-12-10 Changed definition. [Allotrope]" , + "2018-12-10 Make a defined class. [Allotrope]" , + "2018-12-10 Move from AFT to AFO. [Allotrope]" , + "2019-07-04 Changed to more verbose definition. [Allotrope]" ; + + skos:definition "A temperature setting is a setting that specifies some temperature configuration of a temperature controlling or monitoring device, that controls or monitors the target temperature at the site of some system component. [Allotrope]" ; + + skos:prefLabel "temperature setting" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001257 + +af-r:AFR_0001257 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001054 , + iao:_0000064 ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:altLabel "formula" , + "function" , + "function (mathematics)" ; + + skos:changeNote "2018-12-19 Added alt label. [Allotrope]" ; + + skos:definition "A function is a process or a relation that associates each element x of a set X, the domain of the function, to a single element y of another set Y (possibly the same set), the codomain of the function. [Wikipedia]" ; + + skos:prefLabel "function (math)" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001258 + +af-r:AFR_0001258 rdf:type owl:Class ; + + rdfs:subClassOf iao:_0000028 , + [ rdf:type owl:Restriction ; + owl:onProperty iao:_0000219 ; + owl:someValuesFrom [ owl:intersectionOf ( af-m:AFM_0001090 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000087 ; + owl:someValuesFrom obi:_0000571 + ] + ) ; + rdf:type owl:Class + ] + ] ; + + af-x:AFX_0002811 af-x:AFX_0000333 ; + + rdfs:isDefinedBy ; + + skos:altLabel "equipment manufacturer" , + "manufacturer" ; + + skos:definition "A product manufacturer is a symbol that denotes the organizational entity manufacturing some entity with a product role (economic). [Allotrope]" ; + + skos:prefLabel "product manufacturer" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001259 + +af-r:AFR_0001259 rdf:type owl:Class ; + + rdfs:subClassOf iao:_0000129 ; + + rdfs:isDefinedBy ; + + skos:definition "A firmware version is a version number that identifies the firmware of a device. [Allotrope]" ; + + skos:prefLabel "firmware version" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001260 + +af-r:AFR_0001260 rdf:type owl:Class ; + + rdfs:subClassOf iao:_0000010 ; + + rdfs:isDefinedBy ; + + skos:definition "In electronic systems and computing, firmware is \"the combination of a hardware device, e.g. an integrated circuit, and computer instructions and data that reside as read only software on that device\". As a result, firmware usually cannot be modified during normal operation of the device. Typical examples of devices containing firmware are embedded systems (such as traffic lights, consumer appliances, and digital watches), computers, computer peripherals, mobile phones, and digital cameras. The firmware contained in these devices provides the control program for the device. [Wikipedia]" ; + + skos:prefLabel "firmware" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001262 + +af-r:AFR_0001262 rdf:type owl:Class ; + + rdfs:subClassOf af-c:AFC_0000160 ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:definition "In computer science, a queue is a particular kind of abstract data type or collection in which the entities in the collection are kept in order and the principal (or only) operations on the collection are the addition of entities to the rear terminal position, known as enqueue, and removal of entities from the front terminal position, known as dequeue. [Wikipedia]" ; + + skos:prefLabel "queue" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001263 + +af-r:AFR_0001263 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000945 ; + + rdfs:isDefinedBy ; + + skos:altLabel "measurement queue" ; + + skos:definition "A list used to sequence objects and to line up requests for a resource. [NCI]" ; + + skos:prefLabel "request queue" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001264 + +af-r:AFR_0001264 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001075 ; + + rdfs:isDefinedBy ; + + skos:definition "The peak width determined at the baseline level. The peak tangents are drawn from the turning points of the leading and trailing edges. Then the points of intersection with the baseline are calculated. The distance between the two points of intersection is the baseline level width. [Allotrope]" ; + + skos:prefLabel "peak width at baseline" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001265 + +af-r:AFR_0001265 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001075 ; + + af-x:AFX_0002811 af-x:AFX_0000577 ; + + rdfs:isDefinedBy ; + + skos:definition "The peak width calculated at five percent of its peak height. [Allotrope]" ; + + skos:prefLabel "peak width at 5% of height" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001266 + +af-r:AFR_0001266 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001075 ; + + af-x:AFX_0002811 af-x:AFX_0000578 ; + + rdfs:isDefinedBy ; + + skos:definition "The peak width calculated at half of the peak height. [Allotrope]" ; + + skos:prefLabel "peak width at half height" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001267 + +af-r:AFR_0001267 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001242 , + af-r:AFR_0001577 ; + + rdfs:isDefinedBy ; + + skos:altLabel "autosampler injection volume setting" , + "injection volume" , + "injection volume setting" ; + + skos:definition "An autosampler parameter specification that specifies the volume of sample the autosampler is to inject into the mobile phase for separation. [Allotrope]" ; + + skos:prefLabel "autosampler injection volume setting (chromatography)" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001268 + +af-r:AFR_0001268 rdf:type owl:Class ; + + rdfs:subClassOf [ owl:intersectionOf ( af-r:AFR_0001575 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002704 ; + owl:someValuesFrom [ owl:intersectionOf ( af-q:AFQ_0000036 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000080 ; + owl:someValuesFrom af-e:AFE_0000499 + ] + ) ; + rdf:type owl:Class + ] + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "pump parameter setting" ; + + skos:changeNote "2019-07-01 Changed specification target to be a device configuration. [Allotrope]" ; + + skos:definition "A parameter specification specific to the pump device in the chromatography system. [Allotrope]" ; + + skos:prefLabel "pump setting (chromatography)" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001269 + +af-r:AFR_0001269 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001659 , + [ owl:intersectionOf ( af-r:AFR_0001243 + af-r:AFR_0001268 + ) ; + rdf:type owl:Class + ] ; + + rdfs:isDefinedBy ; + + skos:changeNote "2019-07-01 Changed specification target to be a device configuration. [Allotrope]" ; + + skos:definition "A pump parameter specification that specifies the mobile phase ratio in the eluent. [Allotrope]" ; + + skos:prefLabel "pump mobile phase ratio setting (chromatography)" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001270 + +af-r:AFR_0001270 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001660 , + [ owl:intersectionOf ( af-r:AFR_0001243 + af-r:AFR_0001268 + ) ; + rdf:type owl:Class + ] ; + + rdfs:isDefinedBy ; + + skos:changeNote "2019-07-01 Changed specification target to be a device configuration. [Allotrope]" ; + + skos:definition "A pump parameter specification that specifies the total flow rate of the combined mobile phases (eluent). [Allotrope]" ; + + skos:prefLabel "pump flow rate setting (chromatography)" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001276 + +af-r:AFR_0001276 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000957 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "norm" ; + + skos:definition "A standard is a norm or requirement that is established for technical systems. [Wikipedia]" ; + + skos:prefLabel "standard" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001277 + +af-r:AFR_0001277 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000923 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002806 ; + owl:someValuesFrom owl:Thing + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "classification facet" , + "type datum" , + "type facet" ; + + skos:changeNote "2020-12-01 Add alt labels. [Allotrope]" ; + + skos:definition "A classification datum is a facet that classifies some entity. [Allotrope]" ; + + skos:prefLabel "classification datum" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001278 + +af-r:AFR_0001278 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001277 ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "class facet" ; + + skos:changeNote "2020-12-01 Moved to AFO as defined class. [Allotrope]" ; + + skos:definition "A type datum is a classification datum that classifies a thing as an instance of an RDFS class. [Allotrope]" ; + + skos:editorialNote "2020-12-01 Moved to AFO. [Allotrope]" , + "Textual definition only to avoid owl:full." ; + + skos:prefLabel "class datum" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001279 + +af-r:AFR_0001279 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001277 ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "concept facet" ; + + skos:changeNote "2020-12-01 Moved to AFO as defined class. [Allotrope]" ; + + skos:definition "A concept datum is a classification datum that classifies a thing by a SKOS concept. [Allotrope]" ; + + skos:editorialNote "2020-12-01 Moved to AFO. [Allotrope]" ; + + skos:prefLabel "concept datum" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001280 + +af-r:AFR_0001280 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001277 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002801 ; + owl:someValuesFrom af-c:AFC_0000050 + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "code datum" ; + + skos:changeNote "2020-12-01 Moved to AFO as defined class. [Allotrope]" ; + + skos:definition "A classification datum that classifies things by a code in a codelist. [Allotrope]" ; + + skos:prefLabel "code classification datum" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001284 + +af-r:AFR_0001284 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000923 ; + + rdfs:isDefinedBy ; + + skos:altLabel "bga result datum" , + "bga result facet" , + "blood gas analysis result facet" , + "blood gas measurement datum" , + "blood gas measurement facet" ; + + skos:definition "A blood gas analysis result datum is a facet that is part a blood gas analysis result. [Allotrope]" ; + + skos:prefLabel "blood gas analysis result datum" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001285 + +af-r:AFR_0001285 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000957 ; + + rdfs:isDefinedBy ; + + skos:definition "A type specification is a specification of a collection of things by the members of that collection being classified as instance of a class or concept, often with additional constraints. [Allotrope]" ; + + skos:example "a SHACL node shape." , + "the humans that live in Berlin." ; + + skos:prefLabel "type specification" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001286 + +af-r:AFR_0001286 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000957 ; + + rdfs:isDefinedBy ; + + skos:altLabel "attribute specification" , + "characteristic specification" , + "feature specification" ; + + skos:definition "A property specification is a specification about a feature, property, attribute or characteristic. The specification defines constraints on it, such as being an instance of a specific class. [Allotrope]" ; + + skos:example "a SHACL property shape" ; + + skos:prefLabel "property specification" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001288 + +af-r:AFR_0001288 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000986 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000690 ; + owl:allValuesFrom xsd:float + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A scalar double datum is a scalar floating point number datum having a IEEE single precision datum (xsd:float). [Allotrope]" ; + + skos:prefLabel "scalar float datum" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001480 + +af-r:AFR_0001480 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000917 , + af-r:AFR_0001082 ; + + rdfs:isDefinedBy ; + + skos:altLabel "fax" ; + + skos:definition "A number for calling a fax system. [Allotrope]" ; + + skos:prefLabel "fax number" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001481 + +af-r:AFR_0001481 rdf:type owl:Class ; + + rdfs:subClassOf [ owl:intersectionOf ( af-r:AFR_0001082 + af-r:AFR_0001484 + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002808 foaf:skypeID ; + + rdfs:isDefinedBy ; + + skos:altLabel "Skype ID" , + "Skype id" ; + + skos:changeNote "2020-03-20 Changed pref label, added alt labels. [Allotrope]" ; + + skos:definition "A Skype ID is an online account on the Skype system. [Allotrope]" ; + + skos:prefLabel "Skype identifier" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001482 + +af-r:AFR_0001482 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001682 ; + + af-x:AFX_0002808 ; + + rdfs:isDefinedBy ; + + skos:definition "An honorific prefix is a facet that is part of a suffix to a person's name. [Allotrope]" ; + + skos:prefLabel "honorific suffix" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001483 + +af-r:AFR_0001483 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000923 ; + + rdfs:isDefinedBy ; + + skos:definition "An account describes authority and authorization to access resources on a system. [Allotrope]" ; + + skos:prefLabel "account" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001484 + +af-r:AFR_0001484 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000917 , + af-r:AFR_0001483 ; + + af-x:AFX_0002808 foaf:OnlineAccount ; + + rdfs:isDefinedBy ; + + skos:altLabel "online account ID" , + "online account id" ; + + skos:changeNote "2020-03-20 Changed pref label, added alt labels. [Allotrope]" ; + + skos:definition "An account that is accessible via remote access. [Allotrope]" ; + + skos:prefLabel "online account identifier" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001485 + +af-r:AFR_0001485 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001484 ; + + af-x:AFX_0002808 foaf:openid ; + + rdfs:isDefinedBy ; + + skos:altLabel "OpenID" , + "OpenID id" ; + + skos:changeNote "2020-03-20 Changed pref label, added alt labels. [Allotrope]" ; + + skos:definition "OpenID is an identifier following the OpenID specification. [Allotrope]" ; + + skos:prefLabel "OpenID identifier" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001486 + +af-r:AFR_0001486 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000923 ; + + af-x:AFX_0002808 foaf:gender , + ; + + rdfs:isDefinedBy ; + + skos:definition "The gender facet relates a human to a string representing its gender. [Allotrope]" ; + + skos:note "In most cases the value will be the string 'female' or 'male' (in lowercase without surrounding quotes or spaces). Like all FOAF properties, there is in general no requirement to use gender in any particular document or description. Values other than 'male' and 'female' may be used, but are not enumerated here. The gender mechanism is not intended to capture the full variety of biological, social and sexual concepts associated with the word 'gender'. [FoaF]" ; + + skos:prefLabel "gender" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001488 + +af-r:AFR_0001488 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001065 ; + + af-x:AFX_0002808 ; + + rdfs:isDefinedBy ; + + skos:altLabel "global positioning" ; + + skos:definition "A facet denoting a geographic position. [Allotrope]" ; + + skos:prefLabel "geolocation" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001489 + +af-r:AFR_0001489 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001065 , + iao:_0000590 ; + + af-x:AFX_0002808 ; + + rdfs:isDefinedBy ; + + skos:definition "A region name is a location facet that denotes a geographic region (state, province). [Allotrope]" ; + + skos:prefLabel "region name" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001490 + +af-r:AFR_0001490 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000923 , + af-r:AFR_0000937 ; + + af-x:AFX_0002808 foaf:birthday , + ; + + rdfs:isDefinedBy ; + + skos:altLabel "birth date" ; + + skos:definition "A birthday is a facet indicating the day of birth of a person. [Allotrope]" ; + + skos:prefLabel "birthday" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001494 + +af-r:AFR_0001494 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000991 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000353 ; + owl:someValuesFrom af-p:AFP_0003644 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A decision is a proposition that is a choice made from a set of alternative propositions. [Allotrope]" ; + + skos:prefLabel "decision" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001495 + +af-r:AFR_0001495 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000964 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0002351 ; + owl:allValuesFrom af-r:AFR_0000985 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "decimal vector" ; + + skos:definition "A number vector datum is a vector datum that has only decimal scalar components. [Allotrope]" ; + + skos:prefLabel "vector decimal datum" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001496 + +af-r:AFR_0001496 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000964 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0002351 ; + owl:allValuesFrom af-r:AFR_0000986 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "floating point vector" ; + + skos:definition "A number vector datum is a vector datum that has only floating point scalar components. [Allotrope]" ; + + skos:prefLabel "vector floating point number datum" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001497 + +af-r:AFR_0001497 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001496 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0002351 ; + owl:allValuesFrom af-r:AFR_0001288 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "float vector" ; + + skos:definition "A number vector datum is a vector datum that has only IEEE single precision floating point scalar components. [Allotrope]" ; + + skos:prefLabel "vector float datum" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001498 + +af-r:AFR_0001498 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001496 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0002351 ; + owl:allValuesFrom af-r:AFR_0001104 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "double vector" ; + + skos:definition "A number vector datum is a vector datum that has only IEEE double precision floating point scalar components. [Allotrope]" ; + + skos:prefLabel "vector double datum" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001499 + +af-r:AFR_0001499 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001245 , + af-r:AFR_0001581 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002704 ; + owl:someValuesFrom pato:_0001025 + ] , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002730 ; + owl:someValuesFrom af-rl:AFRL_0000042 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "maximum pressure" , + "plumbing pressure upper limit" , + "pressure upper limit" ; + + skos:changeNote "2019-09-20 Changed pref label. [Allotrope]" , + "2020-09-24 Changed alt labels. [Allotrope]" ; + + skos:definition "The pressure limit is a specification of the maximum pressure that the plumbing system can operate with. [Allotrope]" ; + + skos:prefLabel "plumbing maximum pressure" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001501 + +af-r:AFR_0001501 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000957 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "method" , + "plan" , + "procedure" , + "recipe" ; + + skos:changeNote "2020-05-11 Added alt labels method and procedure. [Allotrope]" ; + + skos:definition "A directive information entity with action specifications and objective specifications as parts that, when concretized, is realized in a process in which the bearer tries to achieve the objectives by taking the actions specified. [IAO]" ; + + skos:example "To lose weight, go running daily for at least 30 minutes. To isolate plasma from blood, centrifuge tubes at 1100-1300 rpm for 15 minutes. [IAO]" ; + + skos:prefLabel "plan specification" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001503 + +af-r:AFR_0001503 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000942 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + dct:replaces af-p:AFP_0002613 ; + + rdfs:isDefinedBy ; + + skos:altLabel "begin" , + "begin command" , + "start" ; + + skos:definition "A start command is a process command that orders the procedural element to begin executing the normal RUNNING logic. This command is only valid when the procedural element is in the IDLE state. [Allotrope]" ; + + skos:prefLabel "start command" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001505 + +af-r:AFR_0001505 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000957 ; + + rdfs:isDefinedBy ; + + skos:definition "A setting is a specification about a configuration of some controllable system or a situation occurring in a system that triggers a reaction. [Allotrope]" ; + + skos:example "A maximum pressure in a plumbing system that triggers a warning." , + "A temperature that is that target temperature setting of a thermostat." ; + + skos:prefLabel "setting" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001507 + +af-r:AFR_0001507 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001682 , + iao:_0000590 , + [ rdf:type owl:Restriction ; + owl:onProperty iao:_0000219 ; + owl:someValuesFrom af-m:AFM_0001083 + ] ; + + af-x:AFX_0002808 ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:changeNote "2019-05-10 Moved under written name [Allotrope]" ; + + skos:definition "The nick name is a written name of person that is a substitute for the proper name of a familiar person, place, or thing - commonly used for affection. [Wikipedia]" ; + + skos:prefLabel "nick name" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001508 + +af-r:AFR_0001508 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001501 ; + + rdfs:isDefinedBy ; + + skos:altLabel "sampling method" , + "statistical specification" ; + + skos:definition "A statistics method is a specification (method) for sampling a population, quantification of qualities of the samples and applying statistics on the quantified qualities to produce summary information on the population. [Allotrope]" ; + + skos:prefLabel "statistical method" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001509 + +af-r:AFR_0001509 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001277 , + [ rdf:type owl:Class ; + owl:unionOf ( [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002806 ; + owl:someValuesFrom [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002730 ; + owl:someValuesFrom af-rl:AFRL_0000166 + ] + ] + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002806 ; + owl:someValuesFrom [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000087 ; + owl:someValuesFrom bfo:_0000023 + ] + ] + ) + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "role datum" ; + + skos:changeNote "2020-12-01 Moved to AFO as defined class. [Allotrope]" ; + + skos:definition "A role class datum is a classification datum that classifies an entity by the role or contextual role class it plays in the context of the classification datum. [Allotrope]" ; + + skos:prefLabel "role class datum" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001510 + +af-r:AFR_0001510 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000961 ; + + rdfs:isDefinedBy ; + + skos:altLabel "boolean" , + "boolean datum" , + "boolean value" ; + + skos:definition "A scalar datum that has a boolean value. [Allotrope]" ; + + skos:prefLabel "scalar boolean datum" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001511 + +af-r:AFR_0001511 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000961 ; + + rdfs:isDefinedBy ; + + skos:altLabel "scalar text datum" , + "string" , + "string datum" , + "string value" ; + + skos:definition "A scalar datum that has a textual value. [Allotrope]" ; + + skos:prefLabel "scalar string datum" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001512 + +af-r:AFR_0001512 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000961 ; + + rdfs:isDefinedBy ; + + skos:altLabel "scalar datetime datum" , + "timestamp" , + "timestamp datum" , + "timestamp value" ; + + skos:definition "A scalar datum that has a timestamp (xsd:dateTime) literal value. [Allotrope]" ; + + skos:prefLabel "scalar timestamp datum" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001513 + +af-r:AFR_0001513 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000961 ; + + rdfs:isDefinedBy ; + + skos:altLabel "URI" , + "URI datum" , + "URI value" ; + + skos:definition "A scalar datum that has a URI as value. [Allotrope]" ; + + skos:note "The URI value is here a literal represented by xsd:anyURI datatype. It is not an RDF resource reference. [Allotrope]" ; + + skos:prefLabel "scalar URI datum" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001514 + +af-r:AFR_0001514 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000962 ; + + rdfs:isDefinedBy ; + + skos:altLabel "boolean vector" , + "boolean vector datum" , + "boolean vector value" ; + + skos:definition "A vector boolean datum is a vector datum that has only boolean scalar components. [Allotrope]" ; + + skos:prefLabel "vector boolean datum" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001515 + +af-r:AFR_0001515 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000962 ; + + rdfs:isDefinedBy ; + + skos:altLabel "string vector" , + "string vector datum" ; + + skos:definition "A vector boolean datum is a vector datum that has only string scalar components. [Allotrope]" ; + + skos:prefLabel "vector string datum" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001516 + +af-r:AFR_0001516 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000962 ; + + rdfs:isDefinedBy ; + + skos:altLabel "datetime vector" , + "datetime vector datum" , + "timestamp vector" , + "timestamp vector datum" , + "vector datetime datum" ; + + skos:definition "A vector boolean datum is a vector datum that has only timestamp scalar components. [Allotrope]" ; + + skos:prefLabel "vector timestamp datum" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001517 + +af-r:AFR_0001517 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000962 ; + + rdfs:isDefinedBy ; + + skos:altLabel "URI vector" , + "URI vector datum" ; + + skos:definition "A vector URI datum is a vector datum that has only URI scalar components. [Allotrope]" ; + + skos:prefLabel "vector URI datum" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001518 + +af-r:AFR_0001518 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( af-r:AFR_0000186 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0002350 ; + owl:someValuesFrom af-r:AFR_0001219 + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:subClassOf af-r:AFR_0000186 ; + + rdfs:isDefinedBy ; + + skos:altLabel "baseline data point" ; + + skos:definition "A baseline point is a data point that is member of a baseline. [Allotrope]" ; + + skos:prefLabel "baseline point" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001519 + +af-r:AFR_0001519 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001518 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002730 ; + owl:someValuesFrom [ owl:intersectionOf ( af-rl:AFRL_0000316 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000388 ; + owl:someValuesFrom af-r:AFR_0001219 + ] + ) ; + rdf:type owl:Class + ] + ] ; + + rdfs:isDefinedBy ; + + skos:definition "The baseline start point is the data point of the baseline with the smallest abscissa value. [Allotrope]" ; + + skos:prefLabel "baseline start point" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001520 + +af-r:AFR_0001520 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001518 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002730 ; + owl:someValuesFrom [ owl:intersectionOf ( af-rl:AFRL_0000317 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000388 ; + owl:someValuesFrom af-r:AFR_0001219 + ] + ) ; + rdf:type owl:Class + ] + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "The baseline start point is the data point of the baseline with the largest abscissa value. [Allotrope]" ; + + skos:prefLabel "baseline end point" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001521 + +af-r:AFR_0001521 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000923 ; + + rdfs:isDefinedBy ; + + skos:definition "A baseline facet is a facet that is part of a baseline. [Allotrope]" ; + + skos:prefLabel "baseline facet" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001522 + +af-r:AFR_0001522 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001521 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002730 ; + owl:someValuesFrom [ owl:intersectionOf ( af-rl:AFRL_0000278 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000388 ; + owl:someValuesFrom af-r:AFR_0001519 + ] + ) ; + rdf:type owl:Class + ] + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A baseline facet that denotes the first value of the abscissa that belongs to the baseline. [Allotrope]" ; + + skos:prefLabel "baseline start" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001523 + +af-r:AFR_0001523 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001521 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002730 ; + owl:someValuesFrom [ owl:intersectionOf ( af-rl:AFRL_0000278 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000388 ; + owl:someValuesFrom af-r:AFR_0001520 + ] + ) ; + rdf:type owl:Class + ] + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A baseline facet that denotes the last value of the abscissa that belongs to the baseline. [Allotrope]" ; + + skos:prefLabel "baseline end" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001524 + +af-r:AFR_0001524 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001521 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002730 ; + owl:someValuesFrom [ owl:intersectionOf ( af-rl:AFRL_0000279 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000388 ; + owl:someValuesFrom af-r:AFR_0001519 + ] + ) ; + rdf:type owl:Class + ] + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A baseline facet that denotes the first value of the ordinate that belongs to the baseline. [Allotrope]" ; + + skos:prefLabel "baseline value at start" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001525 + +af-r:AFR_0001525 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001521 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002730 ; + owl:someValuesFrom [ owl:intersectionOf ( af-rl:AFRL_0000279 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000388 ; + owl:someValuesFrom af-r:AFR_0001520 + ] + ) ; + rdf:type owl:Class + ] + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A baseline facet that denotes the last value of the ordinate that belongs to the baseline. [Allotrope]" ; + + skos:prefLabel "baseline value at end" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001526 + +af-r:AFR_0001526 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( af-r:AFR_0001505 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002730 ; + owl:someValuesFrom af-rl:AFRL_0000029 + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:subClassOf af-r:AFR_0001505 ; + + rdfs:isDefinedBy ; + + skos:changeNote "2020-12-04 Moved to AFO. [Allotrope]" ; + + skos:definition "A setting snapshot is a setting for a specific point in time. [Allotrope]" ; + + skos:note "The setting can be a collection of subsettings." ; + + skos:prefLabel "setting snapshot" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001527 + +af-r:AFR_0001527 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001060 ; + + rdfs:isDefinedBy ; + + skos:altLabel "3D UV spectrum" , + "3D UV spectrum (abs. over wavelength and time)" , + "UV spectra" , + "UV spectrum" , + "three dimensional ultraviolet spectrum" , + "ultra-violet spectra" , + "ultra-violet spectrum" , + "ultraviolet spectra" , + "ultraviolet spectrum" ; + + skos:definition "A plot of absorbance versus wavelength and versus time obtained by measuring the amount of radiation absorbed by a sample as a function of the wavelength of incident radiation from the ultraviolet region (190-400 nm) and as a function of time. [Allotrope]" ; + + skos:prefLabel "three-dimensional ultraviolet spectrum" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001528 + +af-r:AFR_0001528 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001556 ; + + rdfs:isDefinedBy ; + + skos:definition "A high-performance liquid chromatography system method is a device method that specifies how an HPLC system should be operated. [Allotrope]" ; + + skos:prefLabel "high-performance liquid chromatography system method" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001532 + +af-r:AFR_0001532 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000957 ; + + rdfs:isDefinedBy ; + + skos:definition "A value specification is a specification about constraints on the values of parameters or properties. [Allotrope]" ; + + skos:note "The value can be an explicit value, a range of allowed values and the specification can have also pre conditions when the value specification applies. [Allotrope]" ; + + skos:prefLabel "value specification" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001534 + +af-r:AFR_0001534 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001242 , + af-r:AFR_0001243 , + af-r:AFR_0001678 ; + + rdfs:isDefinedBy ; + + skos:changeNote "2020-01-06 Moved to chromatography domain. [Allotrope]" , + "2020-05-11 Fixed definition. [Allotrope]" ; + + skos:definition "Washing repetition setting is a setting that sets the number of repetitions of the washing. [Allotrope]" ; + + skos:prefLabel "washing repetition setting" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001535 + +af-r:AFR_0001535 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001242 , + af-r:AFR_0001243 , + af-r:AFR_0001815 ; + + rdfs:isDefinedBy ; + + skos:changeNote "2020-01-06 Moved to chromatography domain. [Allotrope]" ; + + skos:definition "Washing duration setting is a setting that sets the duration of the washing. [Allotrope]" ; + + skos:prefLabel "washing duration setting" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001536 + +af-r:AFR_0001536 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001242 , + af-r:AFR_0001243 , + af-r:AFR_0001973 ; + + rdfs:isDefinedBy ; + + skos:changeNote "2020-01-06 Moved to chromatography domain. [Allotrope]" ; + + skos:definition "Washing vial position setting is a setting that sets the position of the washing vial. [Allotrope]" ; + + skos:prefLabel "washing vial position setting" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001537 + +af-r:AFR_0001537 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001242 , + af-r:AFR_0001243 , + af-r:AFR_0001277 ; + + rdfs:isDefinedBy ; + + skos:changeNote "2020-01-06 Moved to chromatography domain. [Allotrope]" ; + + skos:definition "Washing solvent type is a setting that sets the type of washing solvent to use. [Allotrope]" ; + + skos:prefLabel "washing solvent type" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001538 + +af-r:AFR_0001538 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001242 , + af-r:AFR_0001243 , + af-r:AFR_0001255 ; + + rdfs:isDefinedBy ; + + skos:changeNote "2020-01-06 Moved to chromatography domain. [Allotrope]" ; + + skos:definition "An autosampler temperature setting is a setting that sets the temperature within the autosampler. [Allotrope]" ; + + skos:prefLabel "autosampler temperature setting" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001542 + +af-r:AFR_0001542 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001243 , + af-r:AFR_0001247 ; + + rdfs:isDefinedBy ; + + skos:altLabel "scan range setting" ; + + skos:definition "A detector scan range setting is a detector setting that sets the wavelength range of scans as well as the increment between different scans. [Allotrope]" ; + + skos:example "A scan range from 280 to 700 nm with an increment of 2 nm from one scan to the next." ; + + skos:prefLabel "detector scan range setting" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001544 + +af-r:AFR_0001544 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000957 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002704 ; + owl:someValuesFrom af-p:AFP_0003374 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "status specification" ; + + skos:definition "A state specification is a specification about a state that will be realized in some possible future occurrence. [Allotrope]" ; + + skos:example "A specification about a device running, or pausing." ; + + skos:prefLabel "state specification" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001546 + +af-r:AFR_0001546 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000981 ; + + rdfs:isDefinedBy ; + + skos:definition "A trigger specification that specifies a trigger that triggers after a certain period of time. [Allotrope]" ; + + skos:prefLabel "time trigger specification" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001547 + +af-r:AFR_0001547 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000957 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002704 ; + owl:someValuesFrom bfo:_0000035 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "An event specification is a specification about a point in time when a specific situation is realized or at process boundary. [Allotrope]" ; + + skos:prefLabel "event specification" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001548 + +af-r:AFR_0001548 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001243 ; + + rdfs:isDefinedBy ; + + skos:altLabel "maximum flow gradient" , + "pump maximum flow rate change setting" ; + + skos:definition "Maximum flow rate change setting is a control setting that sets the maximum rate at which the pump is allowed to change the % of solvents being flowed. [Allotrope]" ; + + skos:prefLabel "maximum flow rate change setting" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001552 + +af-r:AFR_0001552 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000923 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002730 ; + owl:someValuesFrom af-rl:AFRL_0000466 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "concept coordination" , + "coordination" , + "term coordination" ; + + skos:definition "A class coordination is a facet of a definition of a class that expresses some differentia. [Allotrope]" ; + + skos:prefLabel "class coordination" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001553 + +af-r:AFR_0001553 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001552 ; + + rdfs:isDefinedBy ; + + skos:definition "A label coordination is a class coordination that coordinates a class of individuals that are denoted by a common label. [Allotrope]" ; + + skos:example "Channel A is a channel that has a label coordination with value 'A'." ; + + skos:prefLabel "label coordination" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001554 + +af-r:AFR_0001554 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001547 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002704 ; + owl:someValuesFrom af-p:AFP_0003286 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "An end event specification is an event specification that is about the end of some process. [Allotrope]" ; + + skos:prefLabel "end event specification" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001555 + +af-r:AFR_0001555 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001547 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002704 ; + owl:someValuesFrom af-p:AFP_0003328 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A start event specification is an event specification that is about the start of some process. [Allotrope]" ; + + skos:prefLabel "start event specification" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001556 + +af-r:AFR_0001556 rdf:type owl:Class ; + + rdfs:subClassOf [ owl:intersectionOf ( af-r:AFR_0001501 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002704 ; + owl:someValuesFrom af-p:AFP_0003726 + ] + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "instrument method" ; + + skos:definition "A device method is a plan specification that specifies how some process is to be executed on a device. [Allotrope]" ; + + skos:prefLabel "device method" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001557 + +af-r:AFR_0001557 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000938 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A parallel procedure specification is a procedure specification having a set of activity specifications, that are to be realized in parallel. [Allotrope]" ; + + skos:prefLabel "parallel procedure specification" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001558 + +af-r:AFR_0001558 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000957 ; + + rdfs:isDefinedBy ; + + skos:definition "A flow specification is a specification on how material or information is transferred or exchanged between subsequent activities. It links activity specifications using the direction contextual roles 'to role' and 'from role'. [Allotrope]" ; + + skos:prefLabel "flow specification" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001559 + +af-r:AFR_0001559 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001558 ; + + rdfs:isDefinedBy ; + + skos:definition "A material flow specification is a flow specification about material transfers between processes. [Allotrope]" ; + + skos:example "A material produced in a preparation activity is consumed in the next step. A procedure specification of this process contains a material flow specification linking the preparation activity with the consumption activity. [Allotrope]" ; + + skos:prefLabel "material flow specification" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001560 + +af-r:AFR_0001560 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001558 ; + + rdfs:isDefinedBy ; + + skos:altLabel "information flow specification" ; + + skos:definition "A data flow specification is a flow specification about how information is exchanged between processes. [Allotrope]" ; + + skos:prefLabel "data flow specification" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001561 + +af-r:AFR_0001561 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000991 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002842 ; + owl:someValuesFrom owl:Thing + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A definition is a proposition that succinctly characterizes an entity. [Allotrope]" ; + + skos:prefLabel "definition" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001562 + +af-r:AFR_0001562 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001552 ; + + rdfs:isDefinedBy ; + + skos:altLabel "aboutness coordination" ; + + skos:definition "A subject coordination is a class coordination of a subclass of information content entity with the subject the class is about. [Allotrope]" ; + + skos:prefLabel "subject coordination" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001564 + +af-r:AFR_0001564 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001552 ; + + rdfs:isDefinedBy ; + + skos:definition "A role coordination is a class coordination of a class with the class of general role its instances have. [Allotrope]" ; + + skos:example "A reference column is a class of columns that have an reference role. [Allotrope]" ; + + skos:prefLabel "role coordination" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001565 + +af-r:AFR_0001565 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001552 ; + + rdfs:isDefinedBy ; + + skos:definition "A material coordination is a class coordination of a subclass of af-m:material. [Allotrope]" ; + + skos:prefLabel "material coordination" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001566 + +af-r:AFR_0001566 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001565 ; + + rdfs:isDefinedBy ; + + skos:altLabel "component coordination" ; + + skos:definition "A component coordination is an ingredient that coordinates a material class with its components (of the same level of granularity). [Allotrope]" ; + + skos:example "Hydrochloric acid solution is a solution coordinated with its component compounds water and hydrochloric acid. [Allotrope]" , + "material component coordination" ; + + skos:prefLabel "ingredient coordination" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001567 + +af-r:AFR_0001567 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001565 ; + + rdfs:isDefinedBy ; + + skos:definition "A substance coordination is a material coordination that coordinates the material class with the class of its granular parts of molecular scope. [Allotrope]" ; + + skos:example "Potion of water is a af-m:compound with a substance coordination to chebi:water. [Allotrope]" ; + + skos:prefLabel "substance coordination" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001568 + +af-r:AFR_0001568 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001552 ; + + rdfs:isDefinedBy ; + + skos:definition "An index coordination is a class coordination that coordinates a class of individuals that are denoted by a common index. [Allotrope]" ; + + skos:example "Column 1" ; + + skos:prefLabel "index coordination" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001569 + +af-r:AFR_0001569 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001552 ; + + rdfs:isDefinedBy ; + + skos:altLabel "inherence coordination" ; + + skos:definition "A bearer coordination is a class coordination that coordinates a specifically dependent continuant class of individuals with the bearer that inheres it. [Allotrope]" ; + + skos:example "Column temperature is a coordination of the quality temperature with column." ; + + skos:prefLabel "bearer coordination" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001570 + +af-r:AFR_0001570 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001562 ; + + rdfs:isDefinedBy ; + + skos:definition "A specification coordination is a subject coordination of a subclass of directive information class. [Allotrope]" ; + + skos:example "Volume concentration setting is a setting that specifies the volume concentration." ; + + skos:prefLabel "specification coordination" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001571 + +af-r:AFR_0001571 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001552 ; + + rdfs:isDefinedBy ; + + skos:definition "A statistic coordination is a class coordination that coordinates a class with a statistic contextual role. [Allotrope]" ; + + skos:prefLabel "statistic coordination" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001572 + +af-r:AFR_0001572 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001552 ; + + rdfs:isDefinedBy ; + + skos:definition "A member coordination is a class coordination that coordinates a collection class with the class of its members. [Allotrope]" ; + + skos:prefLabel "member coordination" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001573 + +af-r:AFR_0001573 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001552 ; + + rdfs:isDefinedBy ; + + skos:definition "A feature coordination is a class coordination that coordinates with a quality or facet class that exists in all members of a collection. [Allotrope]" ; + + skos:example "Average cell diameter is a coordination of 'cell' which is the member class of the population, the feature 'diameter' and the statistic 'arithmetic mean'." ; + + skos:prefLabel "feature coordination" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001575 + +af-r:AFR_0001575 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001505 ; + + rdfs:isDefinedBy ; + + skos:definition "A parameter specification specific to a chromatography system. [Allotrope]" ; + + skos:prefLabel "chromatography system setting" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001577 + +af-r:AFR_0001577 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001243 , + af-r:AFR_0001580 , + af-r:AFR_0001658 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002704 ; + owl:someValuesFrom [ owl:intersectionOf ( pato:_0000918 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000080 ; + owl:someValuesFrom [ owl:intersectionOf ( af-m:AFM_0000394 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000056 ; + owl:someValuesFrom af-p:AFP_0003666 + ] + ) ; + rdf:type owl:Class + ] + ] + ) ; + rdf:type owl:Class + ] + ] ; + + rdfs:isDefinedBy ; + + skos:definition "The injection volume setting is an injection setting that specifies the volume of the liquid to be injected. [Allotrope]" ; + + skos:prefLabel "injection volume setting" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001578 + +af-r:AFR_0001578 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( af-r:AFR_0001505 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002704 ; + owl:someValuesFrom [ owl:intersectionOf ( af-q:AFQ_0000036 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000080 ; + owl:someValuesFrom af-e:AFE_0000499 + ] + ) ; + rdf:type owl:Class + ] + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:subClassOf af-r:AFR_0001505 ; + + rdfs:isDefinedBy ; + + skos:definition "A pump setting is a setting that specifies some configuration of a pump. [Allotrope]" ; + + skos:prefLabel "pump setting" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001580 + +af-r:AFR_0001580 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( af-r:AFR_0001505 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002704 ; + owl:someValuesFrom af-q:AFQ_0000233 + ] + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "injection setting datum" , + "injector setting" , + "injector setting datum" ; + + skos:definition "An injection setting is a setting that specifies an injection setting configuration of an injection device. [Allotrope]" ; + + skos:prefLabel "injection setting" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001581 + +af-r:AFR_0001581 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( af-r:AFR_0001505 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002704 ; + owl:someValuesFrom [ owl:intersectionOf ( af-q:AFQ_0000036 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000080 ; + owl:someValuesFrom af-e:AFE_0002153 + ] + ) ; + rdf:type owl:Class + ] + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:subClassOf af-r:AFR_0001505 ; + + rdfs:isDefinedBy ; + + skos:definition "A plumbing setting is a setting that specifies a configuration of a plumbing system. [Allotrope]" ; + + skos:prefLabel "plumbing setting" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001582 + +af-r:AFR_0001582 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001243 , + af-r:AFR_0001581 , + af-r:AFR_0001660 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002704 ; + owl:someValuesFrom pato:_0001574 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "flow rate setting" ; + + skos:changeNote "2019-09-20 Changed pref label. [Allotrope]" ; + + skos:definition "A flow rate setting is a plumbing setting that specifies the flow rate through the plumbing. [Allotrope]" ; + + skos:prefLabel "plumbing flow rate setting" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001583 + +af-r:AFR_0001583 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( af-r:AFR_0001101 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002816 ; + owl:someValuesFrom bfo:_0000019 + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:subClassOf af-r:AFR_0001101 ; + + rdfs:isDefinedBy ; + + skos:definition "A quality quantification facet is a quantification facet that is a data output of some measurement and quantifies some measured quality. [Allotrope]" ; + + skos:prefLabel "quality quantification facet" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001584 + +af-r:AFR_0001584 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001583 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002816 ; + owl:someValuesFrom pato:_0000146 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "temperature (datum)" ; + + skos:definition "A temperature (datum) is a quantity facet that quantifies some temperature. [Allotrope]" ; + + skos:prefLabel "temperature" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001586 + +af-r:AFR_0001586 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001583 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002816 ; + owl:someValuesFrom pato:_0002027 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "osmolality (datum)" ; + + skos:definition "A osmolality (datum) is a quantity facet that quantifies some osmolality. [Allotrope]" ; + + skos:prefLabel "osmolality" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001587 + +af-r:AFR_0001587 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001583 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002816 ; + owl:someValuesFrom pato:_0001757 + ] ; + + dct:license ; + + dct:rights ; + + dct:source "PAC, 1996, 68, 957. (Glossary of terms in quantities and units in Clinical Chemistry (IUPAC-IFCC Recommendations 1996))" ; + + rdfs:isDefinedBy ; + + skos:altLabel "conductivity" , + "conductivity (datum)" , + "electric conductivity (datum)" ; + + skos:definition "Electrical conductivity is a quality quantification facet that quantifies the reciprocal of resistivity in a conductor. [IUPAC]" ; + + skos:prefLabel "electric conductivity" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001588 + +af-r:AFR_0001588 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001583 ; + + rdfs:isDefinedBy ; + + skos:altLabel "intensity (datum)" , + "relative response function" , + "signal intensity" ; + + skos:definition "Intensity (datum) is a quantity facet that quantifies the relative magnitude of a signal. [Allotrope]" ; + + skos:prefLabel "intensity" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001589 + +af-r:AFR_0001589 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001588 ; + + dct:source "PAC, 1981, 53, (Presentation of raman spectra in data collections (Recommendations 1981))" ; + + rdfs:isDefinedBy ; + + skos:altLabel "intensity" ; + + skos:definition "Raman intensity is the intensity of a Raman signal. [Allotrope]" ; + + skos:prefLabel "Raman intensity" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001590 + +af-r:AFR_0001590 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001588 ; + + dct:source "PAC, 1981, 53, (Presentation of raman spectra in data collections (Recommendations 1981))" ; + + rdfs:isDefinedBy ; + + skos:altLabel "intensity" , + "interferogram intensity" ; + + skos:definition "Raman interferogram intensity is the intensity of the Raman interferogram signal. [Allotrope]" ; + + skos:prefLabel "Raman interferogram intensity" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001591 + +af-r:AFR_0001591 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001592 ; + + dct:source "PAC, 1981, 53, (Presentation of raman spectra in data collections (Recommendations 1981))" , + "https://en.wikipedia.org/wiki/Raman_spectroscopy" ; + + rdfs:isDefinedBy ; + + skos:definition "Raman shift is the difference in wavenumbers between the observed Raman radiation and that of the excitation source. [Allotrope]" ; + + skos:prefLabel "Raman wavenumber shift" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001592 + +af-r:AFR_0001592 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001159 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002816 ; + owl:someValuesFrom af-q:AFQ_0000235 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "wavenumber datum" ; + + skos:definition "Wavenumber (datum) is a quantity facet that is the reciprocal of the wavelength or the number of waves per unit length along the direction of propagation. [Allotrope]" ; + + skos:prefLabel "wavenumber" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001593 + +af-r:AFR_0001593 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001505 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002704 ; + owl:someValuesFrom af-q:AFQ_0000236 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A Raman spectrometer setting is a setting for a Raman spectrometer or its components. [Allotrope]" ; + + skos:prefLabel "Raman spectrometer setting" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001594 + +af-r:AFR_0001594 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001243 , + af-r:AFR_0001593 ; + + dct:source "PAC, 1981, 53, (Presentation of raman spectra in data collections (Recommendations 1981))" ; + + rdfs:isDefinedBy ; + + skos:altLabel "excitation laser wavelength" , + "laser wavelength" ; + + skos:definition "The excitation laser wavelength setting is the wavelength of the laser beam used for the Raman excitation of the sample. [Allotrope]" ; + + skos:prefLabel "excitation laser wavelength setting" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001595 + +af-r:AFR_0001595 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001243 , + af-r:AFR_0001593 ; + + dct:source "PAC, 1981, 53, (Presentation of raman spectra in data collections (Recommendations 1981))" ; + + rdfs:isDefinedBy ; + + skos:altLabel "excitation laser power" , + "laser power" ; + + skos:definition "The excitation laser power setting is the power of the laser beam used for exciting the sample. [Allotrope]" ; + + skos:prefLabel "excitation laser power setting" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001596 + +af-r:AFR_0001596 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001247 , + af-r:AFR_0001593 ; + + rdfs:isDefinedBy ; + + skos:altLabel "dark background correction (primary)" ; + + skos:definition "Dark background correction enabled is a setting for a Raman detector that controls whether compensation for background signals without illumination is active. [Allotrope]" ; + + skos:prefLabel "dark background correction active" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001597 + +af-r:AFR_0001597 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000992 , + af-r:AFR_0002104 , + qb:DataSet , + [ rdf:type owl:Restriction ; + owl:onProperty [ owl:inverseOf af-x:AFX_0002737 + ] ; + owl:someValuesFrom af-r:AFR_0000519 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "Raman spectrum data cube is a data cube that is a representation of an Raman spectrum. [Allotrope]" ; + + skos:prefLabel "Raman spectrum data cube" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001598 + +af-r:AFR_0001598 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000992 , + af-r:AFR_0002104 , + qb:DataSet , + [ rdf:type owl:Restriction ; + owl:onProperty [ owl:inverseOf af-x:AFX_0002737 + ] ; + owl:someValuesFrom af-r:AFR_0001600 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "Raman interferogram data cube is a data cube that is a representation of an Raman interferogram. [Allotrope]" ; + + skos:prefLabel "Raman interferogram data cube" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001599 + +af-r:AFR_0001599 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001060 ; + + rdfs:isDefinedBy ; + + skos:definition "An interferogram is a data distribution function of interference between a reference wave and an experimental wave produced by an interferometer. [Allotrope]" ; + + skos:prefLabel "interferogram" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001600 + +af-r:AFR_0001600 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001599 , + af-r:AFR_0002104 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002734 ; + owl:someValuesFrom af-p:AFP_0001062 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A Raman interferogram is an interferogram produced by FT Raman spectroscopy. [Allotrope]" ; + + skos:prefLabel "Raman interferogram" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001601 + +af-r:AFR_0001601 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000937 ; + + rdfs:isDefinedBy ; + + skos:altLabel "interferogram time" , + "time" ; + + skos:definition "Raman interferogram time is time used as abscissa of an Raman interferogram. [Allotrope]" ; + + skos:prefLabel "Raman interferogram time" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001602 + +af-r:AFR_0001602 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( af-r:AFR_0000207 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002734 ; + owl:someValuesFrom af-p:AFP_0003491 + ] + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "The analysis assay result is the assay result of an analysis assay. [Allotrope]" ; + + skos:prefLabel "analysis assay result" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001603 + +af-r:AFR_0001603 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( af-r:AFR_0000923 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002800 ; + owl:someValuesFrom af-r:AFR_0001602 + ] + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "An analysis assay result facet is a facet of an analysis assay result. [Allotrope]" ; + + skos:prefLabel "analysis assay result facet" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001604 + +af-r:AFR_0001604 rdf:type owl:Class ; + + rdfs:subClassOf iao:_0000590 , + [ rdf:type owl:Restriction ; + owl:onProperty iao:_0000219 ; + owl:someValuesFrom [ owl:intersectionOf ( af-m:AFM_0000275 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000087 ; + owl:someValuesFrom af-rl:AFRL_0000127 + ] + ) ; + rdf:type owl:Class + ] + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "substance name" ; + + skos:definition "The analyte name is a name of a material that has the role of an analyte in an analysis assay. [Allotrope]" ; + + skos:prefLabel "analyte name" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001606 + +af-r:AFR_0001606 rdf:type owl:Class ; + + rdfs:subClassOf iao:_0000590 , + [ rdf:type owl:Restriction ; + owl:onProperty iao:_0000219 ; + owl:someValuesFrom af-r:AFR_0001501 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "plan specification name" , + "recipe name" ; + + skos:definition "A method name is a name that denotes a plan specification (method). [Allotrope]" ; + + skos:prefLabel "method name" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001607 + +af-r:AFR_0001607 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001609 ; + + rdfs:isDefinedBy ; + + skos:definition "The top identified substance is an analysis assay result facet that denotes the substance (class of materials) that has been identified by the analysis and ranked top in some measure of hit quality. [Allotrope]" ; + + skos:prefLabel "top identified substance" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001608 + +af-r:AFR_0001608 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001609 ; + + rdfs:isDefinedBy ; + + skos:altLabel "HQI" ; + + skos:definition "The hit quality index is a measure how well the spectrum measured compares against a reference spectra of a search database. [Allotrope]" ; + + skos:prefLabel "hit quality index" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001609 + +af-r:AFR_0001609 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000923 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002734 ; + owl:someValuesFrom af-p:AFP_0002691 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A fingerprinting result facet is a facet that is the result of a fingerprinting process. [Allotrope]" ; + + skos:prefLabel "fingerprinting result facet" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001610 + +af-r:AFR_0001610 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001505 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000553 ; + owl:someValuesFrom af-p:AFP_0002691 + ] , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002730 ; + owl:someValuesFrom [ owl:intersectionOf ( af-rl:AFRL_0000019 + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000054 ; + owl:someValuesFrom af-p:AFP_0002691 + ] + ) ; + rdf:type owl:Class + ] + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A fingerprinting parameter is a datum that is has a parameter role in some fingerprinting process. [Allotrope]" ; + + skos:prefLabel "fingerprinting parameter" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001611 + +af-r:AFR_0001611 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001610 ; + + rdfs:isDefinedBy ; + + skos:altLabel "HQI margin" ; + + skos:definition "The hit quality index margin is a permitted hit quality index margin in either way (+/-) to account for noise and error. [Allotrope]" ; + + skos:prefLabel "hit quality index margin" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001612 + +af-r:AFR_0001612 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001610 ; + + rdfs:isDefinedBy ; + + skos:altLabel "HQI threshold" ; + + skos:definition "The hit quality index threshold is a specification of a minimal hit quality index value for accepting positive match of the matched spectrum against the library spectrum. [Allotrope]" ; + + skos:prefLabel "hit quality index threshold" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001613 + +af-r:AFR_0001613 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001608 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002699 ; + owl:someValuesFrom [ owl:intersectionOf ( af-m:AFM_0000275 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000087 ; + owl:someValuesFrom af-rl:AFRL_0000127 + ] + ) ; + rdf:type owl:Class + ] + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "analyte HQI" , + "substance HQI" , + "substance hit quality index" ; + + skos:definition "The analyte hit quality index is hit quality index of the measured spectrum of the analyte against a spectrum library. [Allotrope]" ; + + skos:prefLabel "analyte hit quality index" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001614 + +af-r:AFR_0001614 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001610 , + iao:_0000590 ; + + rdfs:isDefinedBy ; + + skos:definition "A spectrum library name is a name that denotes a library of spectra used for substance identification by fingerprinting. [Allotrope]" ; + + skos:prefLabel "spectrum library name" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001615 + +af-r:AFR_0001615 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001610 ; + + rdfs:isDefinedBy ; + + skos:definition "The library search upper limit is an upper limit on the abscissa values of spectra to be searched. [Allotrope]" ; + + skos:prefLabel "library search upper limit" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001616 + +af-r:AFR_0001616 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001610 ; + + rdfs:isDefinedBy ; + + skos:definition "The library search lower limit is a lower limit on the abscissa values of spectra to be searched. [Allotrope]" ; + + skos:prefLabel "library search lower limit" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001617 + +af-r:AFR_0001617 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001616 ; + + rdfs:isDefinedBy ; + + skos:altLabel "library search lower wavenumber limit" ; + + skos:definition "The library search start wavenumber is a lower limit on the wavenumber values of spectra to be searched. [Allotrope]" ; + + skos:prefLabel "library search start wavenumber" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001618 + +af-r:AFR_0001618 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001615 ; + + rdfs:isDefinedBy ; + + skos:altLabel "library search upper wavenumber limit" ; + + skos:definition "The library search stop wavenumber is an upper limit on the wavenumber values of spectra to be searched. [Allotrope]" ; + + skos:prefLabel "library search stop wavenumber" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001619 + +af-r:AFR_0001619 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000922 ; + + dct:source "International Vocabulary of Metrology – Basic and General Concepts and Associated Terms (VIM 3rd edition) JCGM 200:2012" ; + + rdfs:isDefinedBy ; + + skos:definition "Resolution is a description of the smallest change in a quality being measured by a sensor (measurement instrument, detector) that causes a perceptible change in the corresponding indication. [Allotrope]" ; + + skos:prefLabel "resolution" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001620 + +af-r:AFR_0001620 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000937 ; + + rdfs:isDefinedBy ; + + skos:altLabel "calibration date" ; + + skos:definition "A calibration time is a time that indicates when a calibration is done. [Allotrope]" ; + + skos:prefLabel "calibration time" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001622 + +af-r:AFR_0001622 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000980 ; + + rdfs:isDefinedBy ; + + skos:definition "An inclusive gateway is a transition specification that has multiple activity successors. The process forks into each succeeding activity of the inclusive gateway where the guard condition is true. [Allotrope]" ; + + skos:prefLabel "inclusive gateway" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001623 + +af-r:AFR_0001623 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000980 ; + + rdfs:isDefinedBy ; + + skos:definition "An exclusive gateway is a transition specification that has multiple conditional activity successors and an optional default transition. The guard conditions on the successors are checked and at most one of them must be true at the runtime. If no guard condition is met then the optional default transition is done or the process terminates. [Allotrope]" ; + + skos:prefLabel "exclusive gateway" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001625 + +af-r:AFR_0001625 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000953 ; + + rdfs:isDefinedBy ; + + skos:altLabel "time offset" ; + + skos:definition "A delay is a process property that describes a difference in time between a process boundary and some other point in time. [Allotrope]" ; + + skos:prefLabel "delay" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001626 + +af-r:AFR_0001626 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000942 ; + + dct:replaces af-p:AFP_0001299 ; + + rdfs:isDefinedBy ; + + skos:altLabel "end" , + "end command" , + "stop" ; + + skos:definition "A stop command is a process command that orders the procedural element to execute the stopping logic. [Allotrope]" ; + + skos:note "This command is valid when the procedural element is in the running, pausing, paused, holding, held, or restarting state. [ISA-88]" ; + + skos:prefLabel "stop command" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001627 + +af-r:AFR_0001627 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000942 ; + + dct:replaces af-p:AFP_0002013 ; + + rdfs:isDefinedBy ; + + skos:altLabel "pause" , + "wait" , + "wait command" ; + + skos:definition "A pause command is a process command that orders the procedural element to pause at the next programmed pause transition within its sequencing logic and await a resume command before proceeding. [Allotrope]" ; + + skos:note "This command is only valid in the running state. [ISA-88]" ; + + skos:prefLabel "pause command" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001628 + +af-r:AFR_0001628 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000942 ; + + dct:replaces af-p:AFP_0002614 ; + + rdfs:isDefinedBy ; + + skos:altLabel "restart" ; + + skos:definition "A restart command is a process command that orders the procedural element to execute the restarting logic to safely return to the running state. [Allotrope]" ; + + skos:note "This command is only valid when the procedural element is in the held state. [ISA-88]" ; + + skos:prefLabel "restart command" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001629 + +af-r:AFR_0001629 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000942 ; + + dct:replaces af-p:AFP_0002615 ; + + rdfs:isDefinedBy ; + + skos:altLabel "abort" ; + + skos:definition "An abort command is a process command that orders the procedural element to execute an aborting logic. [Allotrope]" ; + + skos:note "The command is valid in every state except for idle, completed, aborting and aborted. [ISA-88]" ; + + skos:prefLabel "abort command" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001630 + +af-r:AFR_0001630 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000942 ; + + dct:replaces af-p:AFP_0002617 ; + + rdfs:isDefinedBy ; + + skos:altLabel "hold" ; + + skos:definition "A hold command is a process command that orders the procedural element to execute the holding logic. [Allotrope]" ; + + skos:note "This command is valid when the procedural element is in the running, pausing, paused or restarting state. [ISA-88]" ; + + skos:prefLabel "hold command" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001631 + +af-r:AFR_0001631 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000942 ; + + dct:replaces af-p:AFP_0002616 ; + + rdfs:isDefinedBy ; + + skos:altLabel "reset" ; + + skos:definition "A reset command is a process command that causes a transition to the idle state. [Allotrope]" ; + + skos:note "This command is valid from the complete, aborted, and stopped states. [ISA-88]" ; + + skos:prefLabel "reset command" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001632 + +af-r:AFR_0001632 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000942 ; + + dct:replaces af-p:AFP_0002618 ; + + rdfs:isDefinedBy ; + + skos:altLabel "resume" ; + + skos:definition "A resume command is a process command that orders a procedural element that has paused at a programmed transition as the result of either a pause command or a single step mode to resume execution. [Allotrope]" ; + + skos:note "This command is only valid when the procedural element is in the paused state. [ISA-88]" ; + + skos:prefLabel "resume command" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001633 + +af-r:AFR_0001633 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001552 ; + + rdfs:isDefinedBy ; + + skos:definition "A temporal coordination is a class coordination that coordinates a class with a temporal aspect. [Allotrope]" ; + + skos:prefLabel "temporal coordination" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001634 + +af-r:AFR_0001634 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001552 ; + + rdfs:isDefinedBy ; + + skos:definition "A topological coordination is a class coordination that coordinates a class with a topological aspect. [Allotrope]" ; + + skos:example "left, right, top, bottom" ; + + skos:prefLabel "topological coordination" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001635 + +af-r:AFR_0001635 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000941 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002704 ; + owl:someValuesFrom [ owl:intersectionOf ( af-p:AFP_0003359 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000542 ; + owl:someValuesFrom af-r:AFR_0001505 + ] + ) ; + rdf:type owl:Class + ] + ] ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "set command" ; + + skos:definition "A control command is an action specification that specifies a setting to be set by a controlling process. [Allotrope]" ; + + skos:prefLabel "control command" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001636 + +af-r:AFR_0001636 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( af-r:AFR_0000957 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002704 ; + owl:someValuesFrom [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000050 ; + owl:someValuesFrom bfo:_0000001 + ] + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:subClassOf af-r:AFR_0000957 ; + + rdfs:isDefinedBy ; + + skos:definition "A part specification is a specification about parthood. Targets of this specifications are parts of some whole. [Allotrope]" ; + + skos:prefLabel "part specification" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001637 + +af-r:AFR_0001637 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( af-r:AFR_0001636 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002704 ; + owl:someValuesFrom [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002845 ; + owl:someValuesFrom af-m:AFM_0001038 + ] + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:subClassOf af-r:AFR_0001636 ; + + dct:replaces af-r:AFR_0002032 ; + + rdfs:isDefinedBy ; + + skos:definition "An ingredient specification is a part specification about ingredients in a portion of mixed materials. [Allotrope]" ; + + skos:prefLabel "ingredient specification" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001638 + +af-r:AFR_0001638 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( af-r:AFR_0001636 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002704 ; + owl:someValuesFrom [ rdf:type owl:Restriction ; + owl:onProperty ro:_0002350 ; + owl:someValuesFrom bfo:_0000001 + ] + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:subClassOf af-r:AFR_0001636 ; + + rdfs:isDefinedBy ; + + skos:altLabel "item specification" ; + + skos:definition "A member specification is a part specification about members of a collection or an object aggregate. [Allotrope]" ; + + skos:prefLabel "member specification" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001639 + +af-r:AFR_0001639 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( af-r:AFR_0001636 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002704 ; + owl:someValuesFrom [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000939 ; + owl:someValuesFrom ro:_0002577 + ] + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:subClassOf af-r:AFR_0001636 ; + + rdfs:isDefinedBy ; + + skos:definition "A component specification is a part specification about the components of a system. [Allotrope]" ; + + skos:prefLabel "component specification" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001640 + +af-r:AFR_0001640 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( af-r:AFR_0001636 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002704 ; + owl:someValuesFrom [ rdf:type owl:Restriction ; + owl:onProperty [ owl:inverseOf obi:_0000643 + ] ; + owl:someValuesFrom chmo:_0000993 + ] + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:subClassOf af-r:AFR_0001636 ; + + rdfs:isDefinedBy ; + + skos:definition "A grain specification is a part specification about the granular parts of a whole. [Allotrope]" ; + + skos:prefLabel "grain specification" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001641 + +af-r:AFR_0001641 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( af-r:AFR_0001636 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002704 ; + owl:someValuesFrom [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002800 ; + owl:someValuesFrom iao:_0000030 + ] + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:subClassOf af-r:AFR_0001636 ; + + rdfs:isDefinedBy ; + + skos:definition "A facet specification is a part specifications about some facet of an information content entity. [Allotrope]" ; + + skos:prefLabel "facet specification" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001643 + +af-r:AFR_0001643 rdf:type owl:Class ; + + rdfs:subClassOf af-c:AFC_0000090 ; + + rdfs:isDefinedBy ; + + skos:definition "A condition that is fulfilled if a given value falls into a given range of values. [Allotrope]" ; + + skos:prefLabel "value in range condition" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001644 + +af-r:AFR_0001644 rdf:type owl:Class ; + + rdfs:subClassOf af-c:AFC_0000090 ; + + rdfs:isDefinedBy ; + + skos:altLabel "flag" , + "flag (condition)" , + "switch" ; + + skos:changeNote "2020-12-04 Changed pref label and definition. [Allotrope]" ; + + skos:definition "A condition that is fulfilled if a given boolean value is equal to the specified boolean value. [Allotrope]" ; + + skos:prefLabel "boolean condition" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001645 + +af-r:AFR_0001645 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001242 , + af-r:AFR_0002280 ; + + rdfs:isDefinedBy ; + + skos:altLabel "analysis enable" , + "cooler with range enable" ; + + skos:definition "Autosampler injection trigger enable setting is a setting that activates or deactivates triggering of injection based on a specified temperature range. [Allotrope]" ; + + skos:example "Cooler (with range) can be enabled in order to trigger injection once autosampler temperature has reached a certain value. Enabling the setting also involves activation of the cooler." ; + + skos:prefLabel "autosampler injection trigger enable setting" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001646 + +af-r:AFR_0001646 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001242 ; + + rdfs:isDefinedBy ; + + skos:definition "Autosampler injection trigger temperature setting is a setting that specifies the temperature range for triggering injection. [Allotrope]" ; + + skos:prefLabel "autosampler injection trigger temperature setting" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001647 + +af-r:AFR_0001647 rdf:type owl:Class ; + + rdfs:subClassOf af-c:AFC_0000021 ; + + rdfs:isDefinedBy ; + + skos:altLabel "accepted deviation" , + "allowed deviation" , + "tolerance" ; + + skos:definition "Range of values of allowed deviation for a given value. [Allotrope]" ; + + skos:example "Tolerance range of +/- 1 °C of a temperature value." ; + + skos:prefLabel "tolerance range" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001648 + +af-r:AFR_0001648 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001243 , + af-r:AFR_0001247 ; + + rdfs:isDefinedBy ; + + skos:definition "A detection duration setting is a setting specifies the total duration of a detection process. [Allotrope]" ; + + skos:prefLabel "detection duration setting" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001650 + +af-r:AFR_0001650 rdf:type owl:Class ; + + rdfs:subClassOf [ owl:intersectionOf ( af-r:AFR_0001556 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002704 ; + owl:someValuesFrom af-p:AFP_0003677 + ] + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:changeNote "2020-03-10 Changed definition. [Allotrope]" ; + + skos:definition "A pump system method is a device method that specifies how pumping should be executed in a pump system. [Allotrope]" ; + + skos:prefLabel "pump system method" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001651 + +af-r:AFR_0001651 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001556 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002704 ; + owl:someValuesFrom af-p:AFP_0003674 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "DAD method" ; + + skos:definition "A diode array detector method is a device method specifies how a detection is executed on a diode array detector. [Allotrope]" ; + + skos:prefLabel "diode array detector method" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001652 + +af-r:AFR_0001652 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001556 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002704 ; + owl:someValuesFrom af-p:AFP_0003678 + ] ; + + rdfs:isDefinedBy ; + + skos:changeNote "2020-01-06 Changed definition. [Allotrope]" , + "2020-03-04 Subclassed under device method. [Allotrope]" ; + + skos:definition "An autosampler method is a device method that specifies how a sampling process should be executed on an autosampler. [Allotrope]" ; + + skos:prefLabel "autosampler method" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001653 + +af-r:AFR_0001653 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001556 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002704 ; + owl:someValuesFrom af-p:AFP_0003679 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "instrument method" ; + + skos:definition "A plan specification that specifies an LC-UV system process. [Allotrope]" ; + + skos:prefLabel "LC-UV system method" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001654 + +af-r:AFR_0001654 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001575 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000553 ; + owl:someValuesFrom af-p:AFP_0003289 + ] , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002704 ; + owl:someValuesFrom af-r:AFR_0000966 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "Mobile phase delivery duration setting is a chromatography system setting that sets the total duration of mobile phase delivery. [Allotrope]" ; + + skos:prefLabel "mobile phase delivery duration setting" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001655 + +af-r:AFR_0001655 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001242 , + af-r:AFR_0001243 , + af-r:AFR_0001815 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000553 ; + owl:someValuesFrom af-p:AFP_0003678 + ] , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002704 ; + owl:someValuesFrom af-r:AFR_0000966 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "Autosampler duration setting is a setting that sets the total duration of an autosampler process. [Allotrope]" ; + + skos:prefLabel "autosampler duration setting" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001657 + +af-r:AFR_0001657 rdf:type owl:Class ; + + rdfs:subClassOf af-c:AFC_0000090 ; + + rdfs:isDefinedBy ; + + skos:altLabel "status condition" ; + + skos:definition "A condition that is fulfilled if a specified situation occurs. [Allotrope]" ; + + skos:prefLabel "state condition" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001658 + +af-r:AFR_0001658 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( af-r:AFR_0001505 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002704 ; + owl:someValuesFrom af-q:AFQ_0000241 + ] + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A volume setting is a setting that specifies some volume configuration of a controlling or monitoring device, that controls or monitors the volume of some material at the site of some system component. [Allotrope]" ; + + skos:prefLabel "volume setting" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001659 + +af-r:AFR_0001659 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( af-r:AFR_0001505 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002704 ; + owl:someValuesFrom af-q:AFQ_0000240 + ] + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A concentration ratio setting is a setting that specifies some concentration ratio configuration of a fluid controlling or monitoring device, that controls or monitors the concentration ratio of a mixture at the site of some system component. [Allotrope]" ; + + skos:prefLabel "concentration ratio setting" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001660 + +af-r:AFR_0001660 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( af-r:AFR_0001505 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002704 ; + owl:someValuesFrom af-q:AFQ_0000239 + ] + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A flow rate setting is a setting that specifies some flow rate configuration of a fluid controlling or monitoring device, that controls or monitors the flow rate at the site of some system component. [Allotrope]" ; + + skos:prefLabel "flow rate setting" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001661 + +af-r:AFR_0001661 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0002036 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002816 ; + owl:someValuesFrom af-q:AFQ_0000167 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "density" , + "mass concentration (datum)" ; + + skos:changeNote "2020-05-11 Changed definition. [Allotrope]" ; + + skos:definition "A mass concentration (datum) is a quantification facet that quantifies a concentration defined as the mass of a constituent divided by the volume of the mixture. [Allotrope]" ; + + skos:prefLabel "mass concentration" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001663 + +af-r:AFR_0001663 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001054 ; + + rdfs:isDefinedBy ; + + skos:altLabel "formula" , + "formula (mathematics)" ; + + skos:definition "A formula is a notation of a term, fact, rule or function expressed in terms of mathematical symbols. [Allotrope]" ; + + skos:prefLabel "formula (math)" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001664 + +af-r:AFR_0001664 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000576 , + af-r:AFR_0001060 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002734 ; + owl:someValuesFrom af-p:AFP_0003681 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "diagnostic profile" ; + + skos:definition "A diagnostic trace is a data distribution function that records the output of some diagnostic monitoring process over time. [Allotrope]" ; + + skos:prefLabel "diagnostic trace" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001665 + +af-r:AFR_0001665 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001583 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002730 ; + owl:someValuesFrom af-rl:AFRL_0000248 + ] , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002801 ; + owl:someValuesFrom af-r:AFR_0001669 + ] , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002816 ; + owl:someValuesFrom af-q:AFQ_0000242 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "polarity (datum)" ; + + skos:definition "Polarity is a quality quantification facet that describes the positive or negative direction of an electrical, acoustical or magnetic force relative to a reference state. [Allotrope]" ; + + skos:prefLabel "polarity" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001669 + +af-r:AFR_0001669 rdf:type owl:Class ; + + rdfs:subClassOf af-c:AFC_0000050 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002806 ; + owl:someValuesFrom af-q:AFQ_0000242 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A polarity code is a code that indicates a polarity. [Allotrope]" ; + + skos:prefLabel "polarity code" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001671 + +af-r:AFR_0001671 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000937 , + [ rdf:type owl:Restriction ; + owl:onProperty iao:_0000136 ; + owl:someValuesFrom af-p:AFP_0000970 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "The integration time is the time when the integration of signals is done in a measurement system. [Allotrope]" ; + + skos:prefLabel "integration time" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001672 + +af-r:AFR_0001672 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001100 ; + + rdfs:isDefinedBy ; + + skos:definition "The number of averages is the number of individual values taken for calculating a mean value. [Allotrope]" ; + + skos:prefLabel "number of averages" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001673 + +af-r:AFR_0001673 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001117 , + af-r:AFR_0001672 ; + + rdfs:isDefinedBy ; + + skos:definition "The number of measurement averages is the number of averages of sub measurement results taken to produce an average measurement result. [Allotrope]" ; + + skos:prefLabel "number of measurement averages" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001674 + +af-r:AFR_0001674 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001675 , + af-r:AFR_0002410 ; + + rdfs:isDefinedBy ; + + skos:altLabel "apodization" , + "apodization filter" , + "apodization method" ; + + skos:definition "Apodization (Raman) is the name of a filter method used in the data apodization of FT Raman spectra. [Allotrope]" ; + + skos:prefLabel "apodization (Raman)" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001675 + +af-r:AFR_0001675 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000923 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000553 ; + owl:someValuesFrom af-p:AFP_0000047 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "Raman parameter" ; + + skos:definition "A Raman spectroscopy parameter is a parameter that controls a Raman spectroscopy. [Allotrope]" ; + + skos:prefLabel "Raman spectroscopy parameter" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001676 + +af-r:AFR_0001676 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001675 , + af-r:AFR_0002411 ; + + rdfs:isDefinedBy ; + + skos:altLabel "number of zero filling" , + "zero filling factor" ; + + skos:definition "The factor of the size increase by time domain zero padding the Fourier transformation of a Raman spectrum. [Allotrope]" ; + + skos:prefLabel "zero filling factor (Raman)" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001677 + +af-r:AFR_0001677 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001675 , + af-r:AFR_0002412 ; + + rdfs:isDefinedBy ; + + skos:altLabel "phase correction" ; + + skos:definition "Phase correction (Raman) is the name of a method for phase correction used to adjust FT Raman spectra. [Allotrope]" ; + + skos:prefLabel "phase correction (Raman)" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001678 + +af-r:AFR_0001678 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001243 ; + + rdfs:isDefinedBy ; + + skos:definition "A repetition setting is a control setting that specifies the number of times an action is to be repeated. [Allotrope]" ; + + skos:prefLabel "repetition setting" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001679 + +af-r:AFR_0001679 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001286 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002704 ; + owl:someValuesFrom af-q:AFQ_0000244 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "Frit size is a column specification that indicates the nominal size of pores in a frit designed to exclude particles larger than the specified size. [Allotrope]" ; + + skos:prefLabel "frit size" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001680 + +af-r:AFR_0001680 rdf:type owl:Class ; + + rdfs:subClassOf iao:_0000590 ; + + rdfs:isDefinedBy ; + + skos:definition "A brand name is a marketed name given by a maker of a product to a product or class of products, especially a trademark. [Allotrope]" ; + + skos:prefLabel "brand name" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001681 + +af-r:AFR_0001681 rdf:type owl:Class ; + + rdfs:subClassOf iao:_0000017 ; + + rdfs:isDefinedBy ; + + skos:definition "The part number is a model number of a class of device parts, specified by the device manufacturer. [Allotrope]" ; + + skos:prefLabel "part number" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001682 + +af-r:AFR_0001682 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000923 , + [ rdf:type owl:Restriction ; + owl:onProperty iao:_0000136 ; + owl:someValuesFrom af-m:AFM_0001083 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A person facet is a facet that describes of a person's name or parts of it. [Allotrope]" ; + + skos:prefLabel "person facet" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001685 + +af-r:AFR_0001685 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001505 ; + + rdfs:isDefinedBy ; + + skos:altLabel "activation switch" , + "boolean setting" , + "flag" , + "switch" , + "switch setting" ; + + skos:definition "A flag is a setting that allows switching a configuration on or off. [Allotrope]" ; + + skos:prefLabel "flag (setting)" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001686 + +af-r:AFR_0001686 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001644 , + af-r:AFR_0001696 ; + + rdfs:isDefinedBy ; + + skos:altLabel "baseline at start of integration setting" , + "baseline now" , + "force baseline" ; + + skos:definition "Baseline at start of integration setting is a data processing setting that sets the ordinate value at the start of the integration baseline to the the value of the signal at the time indicated. [Allotrope]" ; + + skos:prefLabel "baseline at start of integration setting (chromatography)" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001687 + +af-r:AFR_0001687 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001644 , + af-r:AFR_0001696 ; + + rdfs:isDefinedBy ; + + skos:altLabel "force split peak" , + "peak end setting" , + "split peak" ; + + skos:definition "Peak end setting is a data processing setting that sets the peak end to the value of the abscissa at the time indicated. [Allotrope]" ; + + skos:prefLabel "peak end setting (chromatography)" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001688 + +af-r:AFR_0001688 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001644 , + af-r:AFR_0001696 ; + + rdfs:isDefinedBy ; + + skos:altLabel "baseline boundary setting" , + "force valley baselines" ; + + skos:definition "Baseline boundary setting is a data processing setting that sets the ordinate values at the boundaries of the baseline of integration to the actual signal values at the peak start and peak end. [Allotrope]" ; + + skos:prefLabel "baseline boundary setting (chromatography)" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001689 + +af-r:AFR_0001689 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001685 , + af-r:AFR_0001696 , + af-r:AFR_0002280 ; + + rdfs:isDefinedBy ; + + skos:altLabel "2020-12-04 Fixed flag parent. [Allotrope]" , + "enable integration" , + "integration on/off" , + "integration with peak detection enabled setting" ; + + skos:definition "Integration with peak detection enabled setting is a data processing setting that allows the integration process to detect peaks for the time period specified. [Allotrope]" ; + + skos:prefLabel "integration with peak detection enabled setting (chromatography)" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001690 + +af-r:AFR_0001690 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001685 , + af-r:AFR_0001696 , + af-r:AFR_0002280 ; + + rdfs:isDefinedBy ; + + skos:altLabel "2020-12-04 Fixed flag parent. [Allotrope]" , + "enable negative peak detection" , + "negative peak detection enabled setting" , + "negative peaks on/off" ; + + skos:definition "Negative peak detection enabled is a data processing setting that allows peaks to be detected below the baseline for the time specified. [Allotrope]" ; + + skos:prefLabel "negative peak detection enabled setting (chromatography)" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001691 + +af-r:AFR_0001691 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001696 ; + + rdfs:isDefinedBy ; + + skos:altLabel "area reject" , + "area threshold for peak integration setting" , + "set minimum area" ; + + skos:definition "Area threshold for peak integration setting is a data processing setting that sets a minimum or maximum area for a peak to be included in the integrated peak list. [Allotrope]" ; + + skos:prefLabel "area threshold for peak integration setting (chromatography)" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001692 + +af-r:AFR_0001692 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001696 ; + + rdfs:isDefinedBy ; + + skos:altLabel "height reject" , + "height threshold for peak integration setting" , + "set minimum height" ; + + skos:definition "Height threshold for peak integration setting is a data processing setting that sets a minimum or maximum height for a peak to be included in the integrated peak list. [Allotrope]" ; + + skos:prefLabel "height threshold for peak integration setting (chromatography)" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001693 + +af-r:AFR_0001693 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001696 ; + + rdfs:isDefinedBy ; + + skos:altLabel "expected average peak width setting" , + "peak width" , + "set peak width" ; + + skos:definition "Expected average peak width setting is a data processing setting that indicates a typical peak width for the time period specified. [Allotrope]" ; + + skos:prefLabel "expected average peak width setting (chromatography)" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001694 + +af-r:AFR_0001694 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001685 , + af-r:AFR_0001696 , + af-r:AFR_0002280 ; + + rdfs:isDefinedBy ; + + skos:altLabel "2020-12-04 Fixed flag parent. [Allotrope]" , + "detect shoulders on/off" , + "enable shoulder detection" , + "shoulder detection enabled setting" ; + + skos:definition "Shoulder detection enabled setting is a data processing setting that allows the integration process to interpolate a baseline for the smaller peak of overlapping peaks for the time period specified. [Allotrope]" ; + + skos:prefLabel "shoulder detection enabled setting (chromatography)" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001695 + +af-r:AFR_0001695 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000898 ; + + rdfs:isDefinedBy ; + + skos:definition "A step interpolation algorithm is an interpolation algorithm where two subsequent points are interpolated by a step function that switches from the first ordinate value to the second ordinate value at the center of the abscissa values. [Allotrope]" ; + + skos:prefLabel "step interpolation algorithm" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001696 + +af-r:AFR_0001696 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001243 ; + + rdfs:isDefinedBy ; + + skos:definition "A data processing setting is a setting that controls how a data processing process is executed by some system. [Allotrope]" ; + + skos:prefLabel "data processing setting" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001700 + +af-r:AFR_0001700 rdf:type owl:Class ; + + rdfs:subClassOf iao:_0000129 ; + + rdfs:isDefinedBy ; + + skos:altLabel "firmware version" ; + + skos:definition "A version number that identifies software. [Allotrope]" ; + + skos:prefLabel "software version" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001732 + +af-r:AFR_0001732 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000954 ; + + rdfs:isDefinedBy ; + + skos:definition "A frequency is a rate that quantifies the number of occurrences of some discrete event in a given amount of time. [Allotrope]" ; + + skos:prefLabel "frequency" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001745 + +af-r:AFR_0001745 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000917 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002717 ; + owl:someValuesFrom af-m:AFM_0000275 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "material id" , + "material-id" , + "product name" ; + + skos:definition "A material identifier is a identifier that identifies a material. [Allotrope]" ; + + skos:prefLabel "material identifier" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001811 + +af-r:AFR_0001811 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001583 ; + + rdfs:isDefinedBy ; + + skos:altLabel "voltage" ; + + skos:definition "A voltage range is a quality quantification facet that describes operational range of a voltage measuring device. [Allotrope]" ; + + skos:prefLabel "voltage range" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001815 + +af-r:AFR_0001815 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001505 ; + + rdfs:isDefinedBy ; + + skos:changeNote "2020-12-10 Changed definition. [Allotrope]" ; + + skos:definition "A duration setting is a setting that specifies the duration of a planned process or the duration after which a situation should trigger. [Allotrope]" ; + + skos:prefLabel "duration setting" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001816 + +af-r:AFR_0001816 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( af-r:AFR_0001101 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002816 ; + owl:someValuesFrom [ rdf:type owl:Class ; + owl:unionOf ( bfo:_0000008 + bfo:_0000015 + ) + ] + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:subClassOf af-r:AFR_0001101 ; + + rdfs:isDefinedBy ; + + skos:definition "A process quantification facet is a quantification facet that is the output of some measurement over a process or temporal region. [Allotrope]" ; + + skos:prefLabel "process quantification facet" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001817 + +af-r:AFR_0001817 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0002109 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002816 ; + owl:someValuesFrom pato:_0000122 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "Length is a quality quantification facet the quantifies the distance between two points in space. [Allotrope]" ; + + skos:prefLabel "length" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001818 + +af-r:AFR_0001818 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000922 , + af-r:AFR_0001852 ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:definition "A correlation coefficient is a numerical measure of some type of correlation, meaning a statistical relationship between two variables. [Wikipedia]" ; + + skos:prefLabel "correlation coefficient" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001825 + +af-r:AFR_0001825 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000922 ; + + rdfs:isDefinedBy ; + + skos:definition "A calibration report is a description of the outcome of calibration and subsequent assessments and adjustments. [Allotrope]" ; + + skos:prefLabel "calibration report" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001826 + +af-r:AFR_0001826 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001836 , + [ rdf:type owl:Restriction ; + owl:onProperty iao:_0000136 ; + owl:someValuesFrom af-e:AFE_0000354 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "The calibration assessment is an assessment about the calibrated instrument whether it is within the specification of the calibration method. [Allotrope]" ; + + skos:prefLabel "calibration assessment" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001828 + +af-r:AFR_0001828 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000304 ; + + rdfs:isDefinedBy ; + + skos:definition "A calibration certificate is a certificate that states that a specific item has been calibrated by some organization. [Allotrope]" ; + + skos:prefLabel "calibration certificate" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001829 + +af-r:AFR_0001829 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000937 ; + + rdfs:isDefinedBy ; + + skos:altLabel "due date" ; + + skos:definition "The due date is a time that specifies when the next calibration run is due. [Allotrope]" ; + + skos:prefLabel "due date (calibration)" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001830 + +af-r:AFR_0001830 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000951 ; + + rdfs:isDefinedBy ; + + skos:definition "The calibration interval is the duration between two consecutive calibrations. [Allotrope]" ; + + skos:prefLabel "calibration interval" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001831 + +af-r:AFR_0001831 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001732 ; + + rdfs:isDefinedBy ; + + skos:definition "The calibration frequency is the frequency of how often calibrations are done in a time interval. [Allotrope]" ; + + skos:prefLabel "calibration frequency" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001835 + +af-r:AFR_0001835 rdf:type owl:Class ; + + rdfs:subClassOf af-c:AFC_0000050 ; + + rdfs:isDefinedBy ; + + skos:definition "A calibration assessment code is a code indicating a calibration assessment about the performance of an instrument. [Allotrope]" ; + + skos:prefLabel "calibration assessment code" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001836 + +af-r:AFR_0001836 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000991 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002734 ; + owl:someValuesFrom af-p:AFP_0003538 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "evaluation" , + "rating" ; + + skos:definition "An assessment is a proposition about the judgment on a situation after considering the information known about it. [Allotrope]" ; + + skos:prefLabel "assessment" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001839 + +af-r:AFR_0001839 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000922 ; + + rdfs:isDefinedBy ; + + skos:definition "A calibration result is a relation between a nominal reference quantity or quantity distribution over time or a sample population and the measure of that quantity or distribution as it is found in the calibration of the instrument. [Allotrope]" ; + + skos:prefLabel "calibration result" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001843 + +af-r:AFR_0001843 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001583 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002816 ; + owl:someValuesFrom pato:_0000918 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "volume (datum)" ; + + skos:definition "A volume datum is a quality quantification facet that quantifies some amount of 3-dimensional space an entity occupies. [Allotrope]" ; + + skos:prefLabel "volume" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001844 + +af-r:AFR_0001844 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001583 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002816 ; + owl:someValuesFrom pato:_0000125 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "mass (datum)" ; + + skos:changeNote "2020-12-10 Changed restriction. [Allotrope]" ; + + skos:definition "A mass datum is a quality quantification facet that quantifies some amount of matter. [Allotrope]" ; + + skos:prefLabel "mass" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001845 + +af-r:AFR_0001845 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001583 , + af-r:AFR_0002408 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002816 ; + owl:someValuesFrom af-q:AFQ_0000169 + ] ; + + dct:license ; + + dct:rights ; + + dct:source , + "PAC, 1996, 68, 957. (Glossary of terms in quantities and units in Clinical Chemistry (IUPAC-IFCC Recommendations 1996)) on page 998" ; + + rdfs:isDefinedBy ; + + skos:definition "A volume fraction datum is a quality quantification facet that quantifies the volume of a constituent of a mixture divided by the sum of volumes of all constituents prior to mixing. [IUPAC]" ; + + skos:prefLabel "volume fraction" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001847 + +af-r:AFR_0001847 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000957 , + af-r:AFR_0001257 ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:definition "A measurement function is a mathematical function of quantities yielding for one or more input quantity value a corresponding unique output quantity value. [Allotrope]" ; + + skos:prefLabel "measurement function" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001849 + +af-r:AFR_0001849 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000936 ; + + rdfs:isDefinedBy ; + + skos:definition "The calibration level is number of calibration points used to fit a function to a calibration curve. [Allotrope]" ; + + skos:prefLabel "calibration level" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001852 + +af-r:AFR_0001852 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001100 ; + + rdfs:isDefinedBy ; + + skos:definition "A statistical facet is a mathematical facet that is part of some statistics. [Allotrope]" ; + + skos:prefLabel "statistical facet" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001855 + +af-r:AFR_0001855 rdf:type owl:Class ; + + rdfs:subClassOf iao:_0000088 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002734 ; + owl:someValuesFrom af-p:AFP_0002535 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "MRM transition report" ; + + skos:definition "A multiple reaction monitoring (MRM) transition report is a report that is summarizing the analysis of a MRM experiment. [Allotrope]" ; + + skos:prefLabel "multiple reaction monitoring transition report" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001856 + +af-r:AFR_0001856 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001583 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002816 ; + owl:someValuesFrom af-q:AFQ_0000049 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "2020-07-27 Changed pref label. [Allotrope]" , + "current" , + "current (datum)" , + "electric current (datum)" ; + + skos:definition "Current is a quality quantification datum that quantifies the ability to conduct an electrical charge. [PATO]" ; + + skos:prefLabel "electric current" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001857 + +af-r:AFR_0001857 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001951 , + [ rdf:type owl:Restriction ; + owl:onProperty iao:_0000136 ; + owl:someValuesFrom af-m:AFM_0000077 + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + af-x:AFX_0002808 ; + + rdfs:isDefinedBy ; + + skos:altLabel "ion attribute" , + "ion property" ; + + skos:changeNote "2020-05-11 Changed definition and moved under molecular entity facet. [Allotrope]" ; + + skos:definition "An ion facet is a molecular facet that is about some ion. [Allotrope]" ; + + skos:prefLabel "ion facet" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001859 + +af-r:AFR_0001859 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001857 , + [ rdf:type owl:Restriction ; + owl:onProperty iao:_0000136 ; + owl:someValuesFrom pato:_0002193 + ] ; + + af-x:AFX_0002808 ; + + rdfs:isDefinedBy ; + + skos:definition "Charge state is a facet that is about the electrical charge of an ion. It is single or multiple and positive or negatively charged. [Allotrope]" ; + + skos:prefLabel "charge state" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001861 + +af-r:AFR_0001861 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000922 ; + + af-x:AFX_0002808 ; + + rdfs:isDefinedBy ; + + skos:altLabel "multiple reaction monitoring transition" , + "transition" ; + + skos:definition "An ion transition is a description of the transition from precursor ion to product ions. [Allotrope]" ; + + skos:prefLabel "ion transition" ; + + skos:scopeNote "A set of two m/z values corresponding to the precursor m/z and a fragment m/z that in combination can be used to identify or quantify a specific ion, although not necessarily uniquely. [PSI/MS]" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001863 + +af-r:AFR_0001863 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000922 , + [ owl:intersectionOf ( af-c:AFC_0000166 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0002351 ; + owl:someValuesFrom af-r:AFR_0001861 + ] + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "transition list" ; + + skos:definition "A ion transition list is a collection of ion transitions. [Allotrope]" ; + + skos:prefLabel "ion transition list" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001865 + +af-r:AFR_0001865 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001619 ; + + af-x:AFX_0002808 ; + + dct:license ; + + dct:rights ; + + dct:source "G. L. Glish, D. J. Burinsky. J. Am. Soc. Mass Spectrom. 19, 161 (2008)." , + "IUPAC. Analytical Division. Compendium of Analytical Nomenclature (the Orange Book). Definitive Rules, 1979. Compiled by J. Inczédy, T. Lengyel, A. M. Ure. Blackwell Scientific Publications, Oxford (1997)" , + "IUPAC. Compendium of Chemical Terminology, 2nd ed. (the Gold Book). Compiled by A. D. McNaught and A.Wilkinson. Blackwell Scientific Publications, Oxford (1997)." , + "J. Laskin, J. H. Futrell. Mass Spectrom. Rev. 24, 135 (2005)." , + "K. K. Murray, R. K. Boyd, M. N. Eberlin, G. J. Langley, L. Li and Y. Naito, Pure Appl. Chem., 2013, 85, 1515-1609" ; + + rdfs:isDefinedBy ; + + skos:definition "Mass resolution is a resolution in a mass spectrum, the observed m/z value divided by the smallest difference Δ(m/z) for two ions that can be separated: (m/z)/Δ(m/z). [IUPAC]" ; + + skos:prefLabel "mass resolution" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001866 + +af-r:AFR_0001866 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001505 ; + + rdfs:isDefinedBy ; + + skos:definition "A mass spectrometry system setting is a setting that specifies the operation of a mass spectrometry system. [Allotrope]" ; + + skos:prefLabel "mass spectrometry system setting" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001867 + +af-r:AFR_0001867 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001866 ; + + af-x:AFX_0002808 ; + + rdfs:isDefinedBy ; + + skos:definition "The dwell time is a mass spectrometry system setting that specifies the time spent gathering data across a peak. [Allotrope]" ; + + skos:prefLabel "dwell time" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001868 + +af-r:AFR_0001868 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001583 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002816 ; + owl:someValuesFrom af-q:AFQ_0000257 + ] ; + + af-x:AFX_0002808 ; + + dct:license ; + + dct:rights ; + + rdfs:isDefinedBy ; + + skos:altLabel "mass-to-charge ratio" ; + + skos:definition "A quantification facet that quantifies the quantity formed by dividing the mass of an ion in unified atomic mass units by its charge number (regardless of sign). [IUPAC]" ; + + skos:prefLabel "m/z" ; + + skos:scopeNote "Mass-to-charge ratio is deprecated. Mass-to-charge ratio has been used occasionally for the horizontal axis in a plot of a mass spectrum, although the quantity measured is not the ion's mass divided by its electric charge (SI units kg C-1). [IUPAC]" , + "m/z is recommended as an abbreviation to represent the dimensionless quantity that is used almost universally as the independent variable in a mass spectrum. [IUPAC]" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001871 + +af-r:AFR_0001871 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000991 ; + + rdfs:isDefinedBy ; + + skos:definition "A qualification is a proposition that an entity meets the requirements of a specific right or objective. [Allotrope]" ; + + skos:prefLabel "qualification" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001872 + +af-r:AFR_0001872 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000991 ; + + rdfs:isDefinedBy ; + + skos:definition "A requirement is a proposition that states a set of conditions that have to be fulfilled to achieve some specific objective. [Allotrope]" ; + + skos:prefLabel "requirement" ; + + skos:scopeNote "The goal can be stated in a prescriptive (laws) or directive (plans) way. [Allotrope]" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001873 + +af-r:AFR_0001873 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001101 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002730 ; + owl:someValuesFrom af-rl:AFRL_0000312 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A qualifier transition ratio is a ratio of the magnitudes of the qualifier transition signal to the quantifier transition signal. [Allotrope]" ; + + skos:prefLabel "qualifier transition ratio" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001874 + +af-r:AFR_0001874 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001873 , + af-rl:AFRL_0000157 ; + + rdfs:isDefinedBy ; + + skos:definition "A measured qualifier transition ratio is a qualifier transition ratio that has the contextual role of a measure. [Allotrope]" ; + + skos:prefLabel "measured qualifier transition ratio" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001875 + +af-r:AFR_0001875 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001873 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002730 ; + owl:someValuesFrom af-rl:AFRL_0000474 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "An expected qualifier transition ratio is a qualifier transition ratio that has the contextual role of an expected datum. [Allotrope]" ; + + skos:prefLabel "expected qualifier transition ratio" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001876 + +af-r:AFR_0001876 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001873 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002730 ; + owl:someValuesFrom af-rl:AFRL_0000064 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A minimum qualifier transition ratio is a qualifier transition ratio that species a minimum allowed qualified transition ratio. [Allotrope]" ; + + skos:prefLabel "minimum qualifier transition ratio" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001877 + +af-r:AFR_0001877 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001873 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002730 ; + owl:someValuesFrom af-rl:AFRL_0000064 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A maximum qualifier transition ratio is a qualifier transition ratio that species a maximum allowed qualified transition ratio. [Allotrope]" ; + + skos:prefLabel "maximum qualifier transition ratio" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001878 + +af-r:AFR_0001878 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001871 ; + + rdfs:isDefinedBy ; + + skos:definition "A transition qualification is a qualification that a measured transition ratio that is consistent with the expected transition ratio. [Allotrope]" ; + + skos:prefLabel "transition qualification" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001879 + +af-r:AFR_0001879 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001583 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002816 ; + owl:someValuesFrom [ owl:intersectionOf ( af-q:AFQ_0000253 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000080 ; + owl:someValuesFrom af-m:AFM_0001101 + ] + ) ; + rdf:type owl:Class + ] + ] ; + + rdfs:isDefinedBy ; + + skos:definition "Collision energy is a quality quantification facet that quantifies the energy for an ion experiencing collision with a stationary gas particle resulting in dissociation of the ion. [PSI/MS]" ; + + skos:prefLabel "collision energy" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001880 + +af-r:AFR_0001880 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001583 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002816 ; + owl:someValuesFrom [ rdf:type owl:Class ; + owl:unionOf ( af-q:AFQ_0000253 + [ owl:intersectionOf ( af-q:AFQ_0000179 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000080 ; + owl:someValuesFrom af-m:AFM_0000880 + ] + ) ; + rdf:type owl:Class + ] + ) + ] + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "energy" ; + + skos:changeNote "2020-12-17 Added scope to prefLabel in order to separate from existing duplicate label. [Allotrope]" ; + + skos:definition "Energy amount is a quantification of the energy quality of a material or the amount of energy. [Allotrope]" ; + + skos:prefLabel "energy (datum)" ; + + skos:scopeNote "Energy is a material entity in BFO, so the energy quantification is about is amount quality. Material (matter) can bear energy, in this case it is the quantification of the energy quality." . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001881 + +af-r:AFR_0001881 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001583 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002816 ; + owl:someValuesFrom pato:_0001574 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "flow rate (datum)" ; + + skos:definition "Flow rate is a quality quantification facet that quantifies the motion of material through a surface per time. [Allotrope]" ; + + skos:prefLabel "flow rate" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001906 + +af-r:AFR_0001906 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001927 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002805 ; + owl:someValuesFrom af-r:AFR_0001907 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "uniform naming convention path" , + "universal naming convention path" ; + + skos:definition "An UNC path is a file path for a file location in a network that is specified by the universal naming convention. [Allotrope]" ; + + skos:example "\\\\\\\\ComputerName\\\\SharedFolder\\\\Resource" ; + + skos:prefLabel "UNC path" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001907 + +af-r:AFR_0001907 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001276 ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:altLabel "UNC" , + "uniform naming convention" ; + + skos:definition "The universal naming convention is a specification for the syntax of an identifier for a location of a network resource, such as a shared file, directory or printer in Microsoft Windows. [Allotrope]" ; + + skos:prefLabel "universal naming convention" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001916 + +af-r:AFR_0001916 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001583 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002816 ; + owl:someValuesFrom af-q:AFQ_0000048 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "voltage (datum)" ; + + skos:definition "Voltage is a quality quantification facet which quantifies the difference in electric potential energy between two points per unit electric charge. [Wikipedia]" ; + + skos:prefLabel "voltage" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001917 + +af-r:AFR_0001917 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001583 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002816 ; + owl:someValuesFrom pato:_0001024 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "power (datum)" ; + + skos:definition "Power is a quality quantification facet that quantifies the rate of doing work. [PATO]" ; + + skos:prefLabel "power" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001918 + +af-r:AFR_0001918 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001583 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002816 ; + owl:someValuesFrom pato:_0001025 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "pressure (datum)" ; + + skos:definition "Pressure is a quality quantification facet that quantifies the mount of force exerted per unit area. [PATO]" ; + + skos:prefLabel "pressure" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001919 + +af-r:AFR_0001919 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001245 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002704 ; + owl:someValuesFrom pato:_0000146 + ] , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002730 ; + owl:someValuesFrom af-rl:AFRL_0000016 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "upper temperature limit" ; + + skos:definition "An upper temperature limit is a temperature alert setting that specifies the maximum temperature the system can operate with. [Allotrope]" ; + + skos:prefLabel "maximum operating temperature" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001920 + +af-r:AFR_0001920 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001245 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002704 ; + owl:someValuesFrom pato:_0000146 + ] , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002730 ; + owl:someValuesFrom af-rl:AFRL_0000504 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "lower temperature limit" ; + + skos:definition "A lower temperature limit is a temperature alert setting that specifies the minimum temperature the system can operate with. [Allotrope]" ; + + skos:prefLabel "minimum operating temperature" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001921 + +af-r:AFR_0001921 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001243 , + af-r:AFR_0001255 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002704 ; + owl:someValuesFrom pato:_0000146 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "An instrument setting indicating at what temperature the control system should engage a cryogenic coolant for cooling. [Allotrope]" ; + + skos:prefLabel "cryogenic coolant cut-over setting" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001922 + +af-r:AFR_0001922 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001243 ; + + rdfs:isDefinedBy ; + + skos:altLabel "flow ratio" , + "split ratio" , + "split ratio setting" ; + + skos:definition "The flow ratio setting is a control setting that specifies the ratio of the flow going though the plumbing part (port of a divert valve, solvent channel) as part of a total flow. [Allotrope]" ; + + skos:prefLabel "flow ratio setting" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001923 + +af-r:AFR_0001923 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001583 , + af-r:AFR_0002408 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002730 ; + owl:someValuesFrom af-rl:AFRL_0000312 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "split ratio" ; + + skos:definition "Flow rate is a quality quantification facet that quantifies the ratio of the flow going though the plumbing part (port of a divert valve, solvent channel) as part of a total flow. [Allotrope]" ; + + skos:prefLabel "flow ratio" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001924 + +af-r:AFR_0001924 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001197 ; + + rdfs:isDefinedBy ; + + skos:altLabel "signal-to-noise (USP621)" ; + + skos:definition "Signal-to-noise ratio (USP621) is a signal-to-noise ratio (peak-to-peak) where the noise is calculated over a period that is a minimum of 5 times the peak width. [Allotrope]" ; + + skos:prefLabel "signal-to-noise ratio (USP621)" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001925 + +af-r:AFR_0001925 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001197 ; + + rdfs:isDefinedBy ; + + skos:altLabel "signal-to-noise (EP2.2.46)" , + "signal-to-noise (JP-G20)" , + "signal-to-noise ratio (JP-G20)" ; + + skos:definition "Signal-to-noise ratio (EP2.2.46) is a signal-to-noise ratio (peak-to-peak) where the noise is calculated over a period that is a minimum of 20 times the peak width. [Allotrope]" ; + + skos:prefLabel "signal-to-noise ratio (EP2.2.46)" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001926 + +af-r:AFR_0001926 rdf:type owl:Class ; + + rdfs:subClassOf iao:_0000590 ; + + rdfs:isDefinedBy ; + + skos:definition "A file name is a name that denotes a file in a file system. It is a local identifier in the scope of the folder the file is located. [Allotrope]" ; + + skos:prefLabel "file name" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001927 + +af-r:AFR_0001927 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000917 ; + + rdfs:isDefinedBy ; + + skos:changeNote "2020-12-02 Moved to AFO. [Allotrope]" ; + + skos:definition "A file path is an identifier for a file in a file system or network. [Allotrope]" ; + + skos:prefLabel "file path" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001928 + +af-r:AFR_0001928 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001927 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002805 ; + owl:someValuesFrom af-r:AFR_0001929 + ] ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:altLabel "Portable Operating System Interface path" ; + + skos:changeNote "2020-12-02 Moved to AFO. [Allotrope]" ; + + skos:definition "A POSIX path is a file path for a file location that is specified by the POSIX standard. [Allotrope]" ; + + skos:prefLabel "POSIX path" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001929 + +af-r:AFR_0001929 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001276 ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:altLabel "POSIX" , + "Portable Operating System Interface" ; + + skos:definition "POSIX is a family of standards specified by the IEEE Computer Society for maintaining compatibility between operating systems. [Wikipedia]" ; + + skos:prefLabel "POSIX standard" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001930 + +af-r:AFR_0001930 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001243 , + af-r:AFR_0001255 ; + + rdfs:isDefinedBy ; + + skos:definition "A drying temperature setting is a temperature setting that specifies the intended temperature of a drying process. [Allotrope]" ; + + skos:prefLabel "drying temperature setting" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001931 + +af-r:AFR_0001931 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001982 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002816 ; + owl:someValuesFrom [ owl:intersectionOf ( pato:_0000125 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000080 ; + owl:someValuesFrom [ owl:intersectionOf ( af-m:AFM_0000275 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000087 ; + owl:someValuesFrom [ owl:intersectionOf ( af-rl:AFRL_0000035 + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000054 ; + owl:someValuesFrom [ owl:intersectionOf ( af-p:AFP_0001876 + af-p:AFP_0003328 + ) ; + rdf:type owl:Class + ] + ] + ) ; + rdf:type owl:Class + ] + ] + ) ; + rdf:type owl:Class + ] + ] + ) ; + rdf:type owl:Class + ] + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "The sample weight before drying is a mass facet that quantifies the mass of a sample before the sample is dried. [Allotrope]" ; + + skos:prefLabel "sample weight before drying" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001932 + +af-r:AFR_0001932 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001982 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002816 ; + owl:someValuesFrom [ owl:intersectionOf ( pato:_0000125 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000080 ; + owl:someValuesFrom [ owl:intersectionOf ( af-m:AFM_0000275 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000087 ; + owl:someValuesFrom [ owl:intersectionOf ( af-rl:AFRL_0000035 + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000054 ; + owl:someValuesFrom [ owl:intersectionOf ( af-p:AFP_0001876 + af-p:AFP_0003286 + ) ; + rdf:type owl:Class + ] + ] + ) ; + rdf:type owl:Class + ] + ] + ) ; + rdf:type owl:Class + ] + ] + ) ; + rdf:type owl:Class + ] + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "dry weight" ; + + skos:definition "A dry sample weight is a mass facet about the final weight of a sample after some drying process is complete. [Allotrope]" ; + + skos:prefLabel "dry sample weight" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001933 + +af-r:AFR_0001933 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0002099 ; + + rdfs:isDefinedBy ; + + skos:definition "A relative weight loss on drying is a mass fraction that quantifies the relative value of moisture content lost from a material after a drying process. [Allotrope]" ; + + skos:prefLabel "relative weight loss on drying" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001934 + +af-r:AFR_0001934 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000694 , + af-r:AFR_0002099 ; + + rdfs:isDefinedBy ; + + skos:definition "An extrapolated moisture content is a prediction about the moisture content percentage of a material entity based on results of a partial drying process. [Allotrope]" ; + + skos:prefLabel "extrapolated moisture content" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001938 + +af-r:AFR_0001938 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000923 , + [ rdf:type owl:Restriction ; + owl:onProperty iao:_0000136 ; + owl:someValuesFrom af-p:AFP_0002389 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A calibration facet is a facet that is information about a calibration. [Allotrope]" ; + + skos:prefLabel "calibration facet" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001939 + +af-r:AFR_0001939 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001938 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002730 ; + owl:someValuesFrom af-rl:AFRL_0000478 + ] , + [ rdf:type owl:Restriction ; + owl:onProperty iao:_0000136 ; + owl:someValuesFrom af-r:AFR_0000788 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A calibration facet that is about a parameter for calibration. [Allotrope]" ; + + skos:prefLabel "calibration curve parameter" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001940 + +af-r:AFR_0001940 rdf:type owl:Class ; + + rdfs:subClassOf iao:_0000064 ; + + rdfs:isDefinedBy ; + + skos:altLabel "calibration curve type" ; + + skos:definition "A calibration algorithm is an algorithm about calibration that specifies the way a calibration curve is generated. [Allotrope]" ; + + skos:prefLabel "calibration algorithm" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001941 + +af-r:AFR_0001941 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001939 ; + + rdfs:isDefinedBy ; + + skos:definition "Order zero parameter is a calibration curve parameter that specifies the zeroth order algorithmic parameter for defining calibration regression. [Allotrope]" ; + + skos:prefLabel "order zero parameter" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001942 + +af-r:AFR_0001942 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001939 ; + + rdfs:isDefinedBy ; + + skos:definition "Order one parameter is a calibration curve parameter that specifies the first order algorithmic parameter for defining calibration regression. [Allotrope]" ; + + skos:prefLabel "order one parameter" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001943 + +af-r:AFR_0001943 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001939 ; + + rdfs:isDefinedBy ; + + skos:definition "Order two parameter is a calibration curve parameter that specifies the second order algorithmic parameter for defining calibration regression. [Allotrope]" ; + + skos:prefLabel "order two parameter" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001944 + +af-r:AFR_0001944 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001939 ; + + rdfs:isDefinedBy ; + + skos:definition "Order three parameter is a calibration curve parameter that specifies the third order algorithmic parameter for defining calibration regression. [Allotrope]" ; + + skos:prefLabel "order three parameter" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001945 + +af-r:AFR_0001945 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001866 ; + + rdfs:isDefinedBy ; + + skos:definition "Pause time is a mass spectrometry system setting that specifies the time in between different ms event's measurement time to allow the instrument to equilibrate. [Allotrope]" ; + + skos:prefLabel "pause time" ; + + skos:scopeNote "Pause time applies to MRM or SIM events and does not apply to polarity switching time. [Allotrope]" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001946 + +af-r:AFR_0001946 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001177 ; + + rdfs:isDefinedBy ; + + skos:definition "The retention time window lower offset is the extent of the retention time window in time units below the target retention time. [PSI/MS]" ; + + skos:prefLabel "retention time window lower offset" ; + + skos:scopeNote "The lower and upper offsets may be asymmetric about the target time. [PSI/MS]" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001947 + +af-r:AFR_0001947 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001177 ; + + rdfs:isDefinedBy ; + + skos:definition "The retention time window upper offset is the extent of the retention time window in time units above the target retention time. [PSI/MS]" ; + + skos:prefLabel "retention time window upper offset" ; + + skos:scopeNote "The lower and upper offsets may be asymmetric about the target time. [PSI/MS]" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001948 + +af-r:AFR_0001948 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001177 ; + + rdfs:isDefinedBy ; + + skos:definition "The retention time window width it the full width of a retention time window for a chromatographic peak. [PSI/MS]" ; + + skos:prefLabel "retention time window width" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001950 + +af-r:AFR_0001950 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001060 ; + + rdfs:isDefinedBy ; + + skos:altLabel "3-dimensional mass spectra" , + "3-dimensional mass spectrum" , + "3D mass spectra" , + "3D mass spectrum" , + "three dimensional mass spectra" , + "three dimensional mass spectrum" , + "three-dimensional mass spectra" ; + + skos:definition "A three-dimensional mass spectrum is a data distribution function of counts versus m/z and versus time obtained by counting the ions produced by a sample as a function of their mass-to-charge ratio and as a function of time. [Allotrope]" ; + + skos:prefLabel "three-dimensional mass spectrum" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001951 + +af-r:AFR_0001951 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000923 , + [ rdf:type owl:Restriction ; + owl:onProperty iao:_0000136 ; + owl:someValuesFrom [ rdf:type owl:Class ; + owl:unionOf ( af-q:AFQ_0000252 + chebi:_23367 + ) + ] + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "chemical descriptor" , + "molecular descriptor" , + "molecular facet" ; + + skos:changeNote "2020-05-11 Changed definition and moved to AFO. [Allotrope]" ; + + skos:definition "A molecular entity facet is a facet that is about some molecular entity such as atoms, ions or molecules. [Allotrope]" ; + + skos:prefLabel "molecular entity facet" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001952 + +af-r:AFR_0001952 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001951 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002699 ; + owl:someValuesFrom af-q:AFQ_0000263 + ] ; + + af-x:AFX_0002808 ; + + rdfs:isDefinedBy ; + + skos:altLabel "chemical formula" ; + + skos:definition "A molecular formula is a molecular entity facet which identifies each constituent element by its chemical symbol and indicates the number of atoms of each element found in each discrete molecular entity of that compound. [CHEMINF]" ; + + skos:prefLabel "molecular formula" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001953 + +af-r:AFR_0001953 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000922 ; + + rdfs:isDefinedBy ; + + skos:altLabel "library search report" , + "library search result" ; + + skos:definition "A spectral library search result is a report that lists the hits on search in a spectral library database. [Allotrope]" ; + + skos:prefLabel "spectral library search result" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001954 + +af-r:AFR_0001954 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000922 ; + + rdfs:isDefinedBy ; + + skos:altLabel "hit" , + "library search hit" , + "search hit" ; + + skos:definition "A spectral library search hit is a result of a library search where a record matches some search criteria. [Allotrope]" ; + + skos:prefLabel "spectral library search hit" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001957 + +af-r:AFR_0001957 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001243 , + af-r:AFR_0001247 ; + + dct:replaces af-x:AFX_0001032 ; + + rdfs:isDefinedBy ; + + skos:altLabel "detection scan rate" , + "detector scan rate" ; + + skos:definition "A detector setting that sets the frequency of scans per time unit. [Allotrope]" ; + + skos:prefLabel "detector scan rate setting" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001958 + +af-r:AFR_0001958 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001243 , + af-r:AFR_0001866 , + af-r:AFR_0001967 ; + + rdfs:isDefinedBy ; + + skos:altLabel "ionization switch delay" ; + + skos:changeNote "2020-01-06 Fix super class. [Allotrope]" ; + + skos:definition "A setting that controls the duration of time after which an ion source switches polarity of ionization. [Allotrope]" ; + + skos:prefLabel "ionization switch delay setting" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001959 + +af-r:AFR_0001959 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001243 , + af-r:AFR_0001866 , + af-r:AFR_0001967 ; + + rdfs:isDefinedBy ; + + skos:altLabel "polarity switch delay" ; + + skos:changeNote "2020-01-06 Fix super class. [Allotrope]" ; + + skos:definition "A setting that controls the duration of time after which polarity of a scan switches. [Allotrope]" ; + + skos:prefLabel "polarity switch delay setting" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001960 + +af-r:AFR_0001960 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001243 , + af-r:AFR_0001866 ; + + rdfs:isDefinedBy ; + + skos:altLabel "SIM mass setting" , + "mass per charge setting" , + "mass setting" , + "mass to charge setting" , + "selected ion monitoring mass" ; + + skos:definition "A m/z is a setting that controls the mass per charge ratio of a scan. [Allotrope]" ; + + skos:prefLabel "m/z setting" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001961 + +af-r:AFR_0001961 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000966 ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "pre-peak background time measurement range" ; + + skos:definition "Pre-peak background time measurement datum is a time datum that describes the period of time for background correction before a peak is detected. [Allotrope]" ; + + skos:prefLabel "pre-peak background time measurement datum" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001962 + +af-r:AFR_0001962 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000966 ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "post-peak background time measurement range" ; + + skos:definition "Post-peak background time measurement datum is a time datum that describes the period of time for background correction after a peak is detected. [Allotrope]" ; + + skos:prefLabel "post-peak background time measurement datum" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001963 + +af-r:AFR_0001963 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000923 , + [ owl:intersectionOf ( [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002730 ; + owl:someValuesFrom af-rl:AFRL_0000438 + ] + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002734 ; + owl:someValuesFrom af-p:AFP_0003645 + ] + ) ; + rdf:type owl:Class + ] ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:definition "A signature is facet that is a proof of identity and intent of a signer towards some information. [Allotrope]" ; + + skos:prefLabel "signature" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001964 + +af-r:AFR_0001964 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001004 ; + + dct:replaces af-e:AFE_0001830 ; + + rdfs:isDefinedBy ; + + skos:altLabel "signal" ; + + skos:changeNote "2018-07-24 Replaces af-e:AFE_0001830 [Allotrope]" ; + + skos:definition "A signal is information transported over an communication channel. [Allotrope]" ; + + skos:prefLabel "signal (communication)" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001967 + +af-r:AFR_0001967 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( af-r:AFR_0001243 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002704 ; + owl:someValuesFrom af-q:AFQ_0000243 + ] + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:changeNote "2020-01-06 Changed IRI, conflicts with repetition setting. [Allotrope]" , + "2020-01-06 Changed definition. [Allotrope]" ; + + skos:definition "Polarity setting is a control setting that specifies a polarity configuration of a specific detector or sensor response to be positive or negative to a reference state. [Allotrope]" ; + + skos:prefLabel "polarity setting" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001968 + +af-r:AFR_0001968 rdf:type owl:Class ; + + rdfs:subClassOf af-c:AFC_0000090 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002730 ; + owl:someValuesFrom af-rl:AFRL_0000519 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "default" , + "fallback" , + "fallback condition" ; + + skos:definition "A default condition is a condition that is member of a set of conditions that is always true if all others conditions in the collections are false. [Allotrope]" ; + + skos:example "A default value in a conditional parameter specification. [Allotrope]" ; + + skos:prefLabel "default condition" ; + + skos:scopeNote "There must be no more than one default condition in any collection of conditions." . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001969 + +af-r:AFR_0001969 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001583 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002816 ; + owl:someValuesFrom af-q:AFQ_0000267 + ] ; + + dct:license ; + + dct:rights ; + + dct:source , + "PAC, 1996, 68, 957. (Glossary of terms in quantities and units in Clinical Chemistry (IUPAC-IFCC Recommendations 1996))" ; + + rdfs:isDefinedBy ; + + skos:altLabel "electric conductance (datum)" ; + + skos:definition "Electric conductance is the quality quantification facet that quantifies the reciprocal of a the resistance in a conductor. [IUPAC]" ; + + skos:prefLabel "electric conductance" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001970 + +af-r:AFR_0001970 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001583 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002816 ; + owl:someValuesFrom af-q:AFQ_0000266 + ] ; + + dct:license ; + + dct:rights ; + + dct:source "PAC, 1996, 68, 957. (Glossary of terms in quantities and units in Clinical Chemistry (IUPAC-IFCC Recommendations 1996))" ; + + rdfs:isDefinedBy ; + + skos:altLabel "electric resistivity (datum)" , + "resistivity" , + "resistivity (datum)" ; + + skos:definition "Electric resistivity is the is the quality quantification facet that quantifies the electric field strength divided by the current density when there is no electromotive force in a conductor. [IUPAC]" ; + + skos:prefLabel "electric resistivity" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001971 + +af-r:AFR_0001971 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001583 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002816 ; + owl:someValuesFrom af-q:AFQ_0000067 + ] ; + + dct:license ; + + dct:rights ; + + dct:source , + "PAC, 1996, 68, 957. (Glossary of terms in quantities and units in Clinical Chemistry (IUPAC-IFCC Recommendations 1996))" ; + + rdfs:isDefinedBy ; + + skos:altLabel "electric resistance (datum)" , + "resistance" , + "resistance (datum)" ; + + skos:definition "Electric resistance is the quality quantification facet that quantifies the electric potential difference divided by the electric current when there is no electromotive force in a conductor. [IUPAC]" ; + + skos:prefLabel "electric resistance" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001972 + +af-r:AFR_0001972 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000941 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002704 ; + owl:someValuesFrom af-p:AFP_0003727 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "repetition specification" ; + + skos:definition "An repeated action specification is an action specification that specifies a repeated activity. [Allotrope]" ; + + skos:prefLabel "repeated action specification" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001973 + +af-r:AFR_0001973 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000957 ; + + rdfs:isDefinedBy ; + + skos:definition "A location specification is a specification that specifies the location of something. [Allotrope]" ; + + skos:prefLabel "location specification" ; + + skos:scopeNote "A location can be a site, a spatial region or a container, anything that is the object of 'ro:located in'. [Allotrope]" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001974 + +af-r:AFR_0001974 rdf:type owl:Class ; + + rdfs:subClassOf iao:_0000010 , + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000050 ; + owl:someValuesFrom af-e:AFE_0002234 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "LIMS" ; + + skos:definition "A laboratory information management software is a software that is used for data management in laboratories. [Allotrope]" ; + + skos:prefLabel "laboratory information management software" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001976 + +af-r:AFR_0001976 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000917 ; + + rdfs:isDefinedBy ; + + skos:altLabel "asset management ID" , + "asset management id" ; + + skos:definition "An asset management identifier is an identifier that is registered within an asset / inventory management system that identifies an equipment. [Allotrope]" ; + + skos:prefLabel "asset management identifier" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001977 + +af-r:AFR_0001977 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000917 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002717 ; + owl:someValuesFrom af-r:AFR_0002010 + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "experiment data id" , + "experiment data indentifier" , + "experiment data source" ; + + skos:definition "An experiment data identifier is an identifier that identifies some experiment data. [Allotrope]" ; + + skos:example "a filename of a file containing the experiment data" ; + + skos:prefLabel "experimental data identifier" ; + + skos:scopeNote "Experimental data identifier is different from experiment identifier. The first identifies the data about the experiment, the later the experiment itself. There can be many experimental data about the same experiment. [Allotrope]" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001978 + +af-r:AFR_0001978 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001117 , + af-r:AFR_0002034 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002717 ; + owl:someValuesFrom af-r:AFR_0000895 + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "analytical method id" ; + + skos:definition "An analytical method identifier is an identifier that identifies the analytical method used in a measurement. [Allotrope]" ; + + skos:prefLabel "analytical method identifier" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001979 + +af-r:AFR_0001979 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000917 , + af-r:AFR_0001117 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002717 ; + owl:someValuesFrom af-p:AFP_0002680 + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "analysis id" , + "analysis identifier" , + "analysis reference" , + "assay id" ; + + skos:definition "An assay identifier is an identifier that identifies some assay (analysis). [Allotrope]" ; + + skos:prefLabel "assay identifier" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001980 + +af-r:AFR_0001980 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0002017 , + [ rdf:type owl:Restriction ; + owl:onProperty iao:_0000136 ; + owl:someValuesFrom af-p:AFP_0002680 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "analysis comment" , + "analysis comments" ; + + skos:definition "An assay comment is a comment about some aspect of an assay. [Allotrope]" ; + + skos:prefLabel "assay comment" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001982 + +af-r:AFR_0001982 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001844 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002816 ; + owl:someValuesFrom [ owl:intersectionOf ( pato:_0000125 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000080 ; + owl:someValuesFrom [ owl:intersectionOf ( af-m:AFM_0000275 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000087 ; + owl:someValuesFrom [ owl:intersectionOf ( af-rl:AFRL_0000035 + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000054 ; + owl:someValuesFrom af-p:AFP_0002680 + ] + ) ; + rdf:type owl:Class + ] + ] + ) ; + rdf:type owl:Class + ] + ] + ) ; + rdf:type owl:Class + ] + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "sample mass" ; + + skos:changeNote "2020-05-11 Changed definition. [Allotrope]" ; + + skos:definition "Sample weight is a quantification facet that quantifies the mass of a sample in an analysis. [Allotrope]" ; + + skos:prefLabel "sample weight" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001983 + +af-r:AFR_0001983 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001178 , + af-r:AFR_0001584 , + af-r:AFR_0002014 ; + + rdfs:isDefinedBy ; + + skos:altLabel "onset temperature" , + "peak start temperature" ; + + skos:definition "Peak onset temperature is a thermal analysis peak facet that quantifies some temperature at the start of a thermal analysis peak. [Allotrope]" ; + + skos:prefLabel "peak onset temperature" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001984 + +af-r:AFR_0001984 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001074 , + af-r:AFR_0001584 , + af-r:AFR_0002014 ; + + rdfs:isDefinedBy ; + + skos:definition "A peak temperature is a thermal analysis peak facet that quantifies some temperature indicating the position of the thermal analysis peak. [Allotrope]" ; + + skos:prefLabel "peak temperature" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001985 + +af-r:AFR_0001985 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0002150 ; + + rdfs:isDefinedBy ; + + skos:definition "Weight loss is a mass facet that quantifies the difference in weight of a material before and after heating or drying. [Allotrope]" ; + + skos:prefLabel "weight loss" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001986 + +af-r:AFR_0001986 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0002002 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002717 ; + owl:someValuesFrom af-e:AFE_0000693 + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "balance id" ; + + skos:definition "A balance identifier is a measurement device identifier that identifies some balance. [Allotrope]" ; + + skos:prefLabel "balance identifier" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001987 + +af-r:AFR_0001987 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001277 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002806 ; + owl:someValuesFrom af-e:AFE_0000407 + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "Container type is a classification datum that classifies the type of container used. [Allotrope]" ; + + skos:prefLabel "container type" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001988 + +af-r:AFR_0001988 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001584 ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:definition "A glass transition temperature (datum) is a quantity facet that quantifies the temperature at which a glass transition occurs. The glass transition, is the gradual and reversible transition in amorphous materials (or in amorphous regions within semicrystalline materials) from a hard and relatively brittle \"glassy\" state into a viscous or rubbery state as the temperature is increased. [Wikipedia]" ; + + skos:prefLabel "glass transition temperature" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001989 + +af-r:AFR_0001989 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0002022 ; + + rdfs:isDefinedBy ; + + skos:altLabel "heat capacity" ; + + skos:definition "A heat capacity (dsc) is a quantity facet that quantifies the difference in heat capacity of a material before and after its glass transition. [Allotrope]" ; + + skos:prefLabel "heat capacity (dsc)" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001990 + +af-r:AFR_0001990 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0002021 ; + + rdfs:isDefinedBy ; + + skos:definition "Transition enthalpy is a quantity facet that quantifies some calorimetric enthalpy change from the area of the differential scanning calorimetry peak. [Allotrope]" ; + + skos:prefLabel "transition enthalpy" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001991 + +af-r:AFR_0001991 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001836 ; + + rdfs:isDefinedBy ; + + skos:definition "A conformance assessment is an assessment about whether two sources of data conform. [Allotrope]" ; + + skos:prefLabel "conformance assessment" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001992 + +af-r:AFR_0001992 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000917 , + af-r:AFR_0001117 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002717 ; + owl:someValuesFrom af-r:AFR_0002008 + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "reference data source" , + "reference id" ; + + skos:definition "A reference identifier is an identifier that identifies some reference data that is being used as a comparator. [Allotrope]" ; + + skos:prefLabel "reference identifier" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001993 + +af-r:AFR_0001993 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000922 , + af-r:AFR_0002023 ; + + rdfs:isDefinedBy ; + + skos:definition "Container state description is a state facet that describes the state of the container used in the measurement run. [Allotrope]" ; + + skos:example "A container state can be opened or closed. [Allotrope]" ; + + skos:prefLabel "container state description" ; + + skos:scopeNote "The container's material is not a container state. [Allotrope]" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001995 + +af-r:AFR_0001995 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001094 ; + + rdfs:isDefinedBy ; + + skos:definition "A transition assignment is a description of the cause of a thermal event occurring in a thermal analysis. [Allotrope]" ; + + skos:prefLabel "transition assignment" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001997 + +af-r:AFR_0001997 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001817 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002816 ; + owl:someValuesFrom af-q:AFQ_0000268 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "cell path length (datum)" , + "path length" , + "path length (datum)" ; + + skos:definition "A cell path length is a quality quantification facet that quantifies the length of the radiation path through the absorbing medium in a single-pass cell. [Allotrope]" ; + + skos:prefLabel "cell path length" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002001 + +af-r:AFR_0002001 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001501 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002704 ; + owl:someValuesFrom [ owl:intersectionOf ( bfo:_0000015 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000057 ; + owl:someValuesFrom af-e:AFE_0002233 + ] + ) ; + rdf:type owl:Class + ] + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "CDS method" , + "CDS project" , + "chromatography data system project" ; + + skos:definition "A chromatography data system method is a plan specification that specifies how a process is to be executed on a chromatography data system. [Allotrope]" ; + + skos:prefLabel "chromatography data system method" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002002 + +af-r:AFR_0002002 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0002018 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002717 ; + owl:someValuesFrom af-e:AFE_0002145 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "instrument id" , + "instrument identifier" , + "machine id" , + "machine identifier" , + "measurement device id" , + "measurement equipment id" , + "measurement equipment identifier" ; + + skos:definition "A measurement device identifier is an identifier that identifies some device designed for measurements. [Allotrope]" ; + + skos:prefLabel "measurement device identifier" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002003 + +af-r:AFR_0002003 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0002034 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002717 ; + owl:someValuesFrom af-r:AFR_0002035 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "measurement method id" , + "measurement procedure id" , + "measurement procedure identifier" , + "method number" , + "procedure id" , + "procedure identifier" ; + + skos:definition "A measurement method identifier is a method identifier that identifies some plan specification of a measurement. [Allotrope]" ; + + skos:prefLabel "measurement method identifier" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002006 + +af-r:AFR_0002006 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0002036 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002816 ; + owl:someValuesFrom af-q:AFQ_0000168 + ] ; + + dct:source , + "Green Book, 2nd ed.: IUPAC Quantities, Units and Symbols in Physical Chemistry. Second Edition, Blackwell Scientific Publications, Oxford, 1993." ; + + rdfs:isDefinedBy ; + + skos:altLabel "amount concentration" , + "amount concentration (datum)" , + "molar concentration (datum)" , + "molar concentration result" , + "molarity" , + "molarity (datum)" , + "substance concentration" , + "substance concentration (datum)" ; + + skos:definition "A molar concentration (datum) is a quantification facet that quantifies a concentration defined as the amount of substance of a constituent divided by the volume of the mixture. [Allotrope]" ; + + skos:prefLabel "molar concentration" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002008 + +af-r:AFR_0002008 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( iao:_0000030 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002730 ; + owl:someValuesFrom af-rl:AFRL_0000285 + ] + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "reference data" ; + + skos:definition "A reference is an information content entity that is referred to in another information content entity for the purpose of comparison. [Allotrope]" ; + + skos:example "reference data used to compare to with experimental data" ; + + skos:prefLabel "reference" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002009 + +af-r:AFR_0002009 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000917 , + af-r:AFR_0001117 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002717 ; + owl:someValuesFrom af-p:AFP_0003735 + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "An experiment identifier is an identifier that identifies an experiment. [Allotrope]" ; + + skos:prefLabel "experiment identifier" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002010 + +af-r:AFR_0002010 rdf:type owl:Class ; + + rdfs:subClassOf [ owl:intersectionOf ( af-r:AFR_0000922 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002699 ; + owl:someValuesFrom af-p:AFP_0003735 + ] + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "experiment data" , + "experiment information" , + "experimental information" ; + + skos:definition "Experiment data is a description of an experiment containing parameters and results of the experiment and metadata about the experiment. [Allotrope]" ; + + skos:prefLabel "experimental data" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002011 + +af-r:AFR_0002011 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000922 , + af-r:AFR_0002010 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002734 ; + owl:someValuesFrom af-p:AFP_0003735 + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "experiment report" , + "experimental result" , + "result" ; + + skos:definition "An experiment result is description, that is the data output of an experiment regarding its hypothesis. [Allotrope]" ; + + skos:prefLabel "experiment result" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002013 + +af-r:AFR_0002013 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000413 ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A thermal analysis peak is a peak that results from a thermal analysis. [Allotrope]" ; + + skos:prefLabel "thermal analysis peak" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002014 + +af-r:AFR_0002014 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( af-r:AFR_0000947 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002800 ; + owl:someValuesFrom af-r:AFR_0002013 + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:subClassOf af-r:AFR_0000947 ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A thermal analysis peak facet is a facet of a thermal analysis peak. [Allotrope]" ; + + skos:prefLabel "thermal analysis peak facet" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002016 + +af-r:AFR_0002016 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001117 , + af-r:AFR_0002034 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002717 ; + owl:someValuesFrom af-r:AFR_0001556 + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "device id" , + "instrument id" , + "instrument method identifier" ; + + skos:changeNote "2020-05-11 Generalized definition to match semantics. [Allotrope]" ; + + skos:definition "A device method identifier is an identifier that identifies the device method used in a process. [Allotrope]" ; + + skos:prefLabel "device method identifier" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002017 + +af-r:AFR_0002017 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000991 ; + + af-x:AFX_0002808 ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:altLabel "remark" ; + + skos:definition "A comment is a remark often related to an added piece of information, or an observation or statement. [SIO]" ; + + skos:prefLabel "comment" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002018 + +af-r:AFR_0002018 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000917 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002717 ; + owl:someValuesFrom af-e:AFE_0000354 + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "device id" , + "equipment id" , + "equipment identifier" , + "instrument id" , + "instrument identifier" , + "machine id" , + "machine identifier" ; + + skos:changeNote "2020-06-15 Removed measurement metadata superclass. [Allotrope]" ; + + skos:definition "A device identifier is an identifier that identifies some device. [Allotrope]" ; + + skos:prefLabel "device identifier" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002019 + +af-r:AFR_0002019 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000917 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002717 ; + owl:someValuesFrom af-r:AFR_0002020 + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "analysis data id" , + "analysis data identifier" , + "assay data id" ; + + skos:definition "An assay data identifier is an identifier that identifies some assay data. Assay data is a description of an assay containing parameters and results of the assay and metadata about the assay. [Allotrope]" ; + + skos:prefLabel "assay data identifier" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002020 + +af-r:AFR_0002020 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000922 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002699 ; + owl:someValuesFrom af-p:AFP_0002680 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "analysis data" , + "analysis information" , + "assay information" ; + + skos:definition "Assay data is a description of an assay containing parameters and results of the assay and metadata about the assay. [Allotrope]" ; + + skos:prefLabel "assay data" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002021 + +af-r:AFR_0002021 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001583 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002816 ; + owl:someValuesFrom af-q:AFQ_0000269 + ] ; + + dct:license ; + + dct:rights ; + + dct:source "Green Book, 2nd ed., p. 48" , + "PAC, 1990, 62, 2167. (Glossary of atmospheric chemistry terms (Recommendations 1990)) on page 2187" , + "PAC, 1996, 68, 957. (Glossary of terms in quantities and units in Clinical Chemistry (IUPAC-IFCC Recommendations 1996)) on page 972" ; + + rdfs:isDefinedBy ; + + skos:altLabel "enthalpy (datum)" ; + + skos:definition "Enthalpy (datum) is a quantification datum that quantifies the internal energy of a system plus the product of pressure and volume. Its change in a system is equal to the heat brought to the system at constant pressure. [IUPAC]" ; + + skos:prefLabel "enthalpy" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002022 + +af-r:AFR_0002022 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001583 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002816 ; + owl:someValuesFrom af-q:AFQ_0000058 + ] ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:altLabel "heat capacity (datum)" ; + + skos:definition "Heat capacity is a quantification facet that quantifies the amount of heat to be supplied to a given mass of a material to produce a unit change in its temperature. [Wikipedia]" ; + + skos:prefLabel "heat capacity" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002023 + +af-r:AFR_0002023 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000923 , + [ rdf:type owl:Restriction ; + owl:onProperty iao:_0000136 ; + owl:someValuesFrom af-p:AFP_0003374 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A state facet is a facet that is about some state at a certain time. A state is a process during which some characteristic remains constant. [Allotrope]" ; + + skos:example "opening state with states opened or closed" ; + + skos:prefLabel "state facet" ; + + skos:scopeNote "States that are not likely to change such as qualities are not described by state facets. Being of a certain mass is a state, but a facet that describes this would usually be usually considered a quantification facet instead of a state facet. [Allotrope]" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002024 + +af-r:AFR_0002024 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001680 ; + + rdfs:isDefinedBy ; + + skos:definition "A column brand name is a brand name of a chromatography column that can be based on the brand name of the substrate and its chemistry modification. [Allotrope]" ; + + skos:prefLabel "column brand name" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002026 + +af-r:AFR_0002026 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001277 ; + + rdfs:isDefinedBy ; + + skos:altLabel "chromatography column chemistry classification (datum)" ; + + skos:definition "A chromatography column classification is a classification datum that classifies a chromatography column by the stationary phase and chromatographic packing used. [Allotrope]" ; + + skos:prefLabel "chromatography column chemistry classification" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002027 + +af-r:AFR_0002027 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0002109 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002816 ; + owl:someValuesFrom af-q:AFQ_0000026 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "particle size (datum)" ; + + skos:definition "Particle size (datum) is a size datum that quantifies the dimensions of an individual particle. [Allotrope]" ; + + skos:prefLabel "particle size" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002029 + +af-r:AFR_0002029 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001817 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002816 ; + owl:someValuesFrom af-q:AFQ_0000014 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "chromatography column length (datum)" ; + + skos:definition "A chromatography column length (datum) is a length datum that quantifies the length of a chromatography column. [Allotrope]" ; + + skos:prefLabel "chromatography column length" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002030 + +af-r:AFR_0002030 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0002108 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002816 ; + owl:someValuesFrom af-q:AFQ_0000016 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "column inner diameter (datum)" ; + + skos:definition "A column inner diameter (datum) is an inner diameter quantifies the inner diameter of a column. [Allotrope]" ; + + skos:prefLabel "column inner diameter" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002031 + +af-r:AFR_0002031 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001636 ; + + rdfs:isDefinedBy ; + + skos:definition "A content specification is a part specification that specifies a contained portion of material of a container. [Allotrope]" ; + + skos:prefLabel "content specification" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002033 + +af-r:AFR_0002033 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000928 ; + + rdfs:isDefinedBy ; + + skos:definition "A temporal index is an index that follows temporal order of the list items or the processes that the items are about. [Allotrope]" ; + + skos:prefLabel "temporal index" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002034 + +af-r:AFR_0002034 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000917 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002717 ; + owl:someValuesFrom af-r:AFR_0001501 + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "method id" , + "plan specification id" , + "plan specification identifier" , + "procedure id" , + "procedure identifier" ; + + skos:definition "A method identifier is an identifier that identifies some plan specification (method, procedure) about some planned process. [Allotrope]" ; + + skos:prefLabel "method identifier" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002035 + +af-r:AFR_0002035 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001501 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002704 ; + owl:someValuesFrom af-p:AFP_0002294 + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "measurement plan" , + "measurement plan specfication" , + "measurement procedure" ; + + skos:definition "A measurement method is a plan specification that specifies a measurement. [Allotrope]" ; + + skos:prefLabel "measurement method" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002036 + +af-r:AFR_0002036 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001583 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002816 ; + owl:someValuesFrom pato:_0000033 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "concentration (datum)" ; + + skos:definition "A concentration (datum) is a quantification facet that quantifies a quality inhering in a substance by virtue of the amount of the bearer's there is mixed with another substance. [Allotrope]" ; + + skos:prefLabel "concentration" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002038 + +af-r:AFR_0002038 rdf:type owl:Class ; + + rdfs:subClassOf iao:_0000310 ; + + rdfs:isDefinedBy ; + + skos:definition "Electronic record is a document (any combination of text, graphics, data, audio, pictorial, or other information representation) in digital form that is created, modified, maintained, archived, retrieved, or distributed by a computer system. [FDA]" ; + + skos:prefLabel "electronic record" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002039 + +af-r:AFR_0002039 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0002038 ; + + rdfs:isDefinedBy ; + + skos:definition "A database record is an electronic record that is stored in a database. [Allotrope]" ; + + skos:prefLabel "database record" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002040 + +af-r:AFR_0002040 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000992 ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:definition "A database is an organized collection of data, generally stored and accessed electronically from a computer system. Where databases are more complex they are often developed using formal design and modeling techniques. [Wikipedia]" ; + + skos:prefLabel "database" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002041 + +af-r:AFR_0002041 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000917 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002717 ; + owl:someValuesFrom af-r:AFR_0002039 + ] ; + + af-x:AFX_0002808 ; + + rdfs:isDefinedBy ; + + skos:altLabel "primary key" ; + + skos:definition "A database primary key is an identifier of a database record. [Allotrope]" ; + + skos:prefLabel "database primary key" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002045 + +af-r:AFR_0002045 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001556 ; + + rdfs:isDefinedBy ; + + skos:altLabel "acquisition method" , + "device method" , + "instrument acquisition method" , + "instrument method" ; + + skos:definition "A device acquisition method is a machine readable plan specification that specifies how the acquisition software of an instrument is to execute the instrument's portion of an analysis. [Allotrope]" ; + + skos:prefLabel "device acquisition method" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002046 + +af-r:AFR_0002046 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000504 ; + + rdfs:isDefinedBy ; + + skos:altLabel "equivalence point" ; + + skos:definition "The equivalence point volume is the volume added in a titration which contains a chemically equivalent quantity of titrant to the analyte in the sample. [Allotrope]" ; + + skos:prefLabel "equivalence point volume" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002048 + +af-r:AFR_0002048 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000984 , + af-r:AFR_0001106 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002816 ; + owl:someValuesFrom af-q:AFQ_0000187 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "dead count" ; + + skos:definition "Dead cell count is a cell counter result data that states the number of dead cells that were counted in the cell counting assay. [Allotrope]" ; + + skos:prefLabel "dead cell count" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002050 + +af-r:AFR_0002050 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000951 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0001550 ; + owl:someValuesFrom [ rdf:type owl:Class ; + owl:unionOf ( af-r:AFR_0000937 + af-r:AFR_0001095 + ) + ] + ] ; + + rdfs:isDefinedBy ; + + skos:definition "Elapsed time is a duration measured from a specific reference time point or timebase. [Allotrope]" ; + + skos:prefLabel "elapsed time" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002051 + +af-r:AFR_0002051 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000576 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002816 ; + owl:someValuesFrom af-p:AFP_0003744 + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "flow rate profile result" ; + + skos:definition "A flow rate profile is a profile that quantifies the flow rate of a material entity over time. [Allotrope]" ; + + skos:prefLabel "flow rate profile" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002052 + +af-r:AFR_0002052 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000576 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002816 ; + owl:someValuesFrom af-p:AFP_0003742 + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "volume profile result" ; + + skos:definition "A volume profile is a profile that quantifies the volume of a material entity over time. [Allotrope]" ; + + skos:prefLabel "volume profile" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002053 + +af-r:AFR_0002053 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0002056 ; + + rdfs:isDefinedBy ; + + skos:altLabel "reaction temperature profile result" ; + + skos:definition "A reaction temperature profile is a profile that quantifies the temperature of the reaction solution over time in a synthesis. [Allotrope]" ; + + skos:prefLabel "reaction temperature profile" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002054 + +af-r:AFR_0002054 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0002056 ; + + rdfs:isDefinedBy ; + + skos:altLabel "jacket temperature profile result" ; + + skos:definition "A jacket temperature profile is a profile that quantifies the temperature profile of the reactor jacket over time. [Allotrope]" ; + + skos:prefLabel "jacket temperature profile" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002055 + +af-r:AFR_0002055 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0002060 ; + + rdfs:isDefinedBy ; + + skos:altLabel "overhead stirring rate profile result" ; + + skos:definition "An overhead stirring rate profile is a profile that quantifies the stirring rate of the stirring process using an overhead stirrer. [Allotrope]" ; + + skos:prefLabel "overhead stirring rate profile" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002056 + +af-r:AFR_0002056 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000576 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002816 ; + owl:someValuesFrom af-p:AFP_0003300 + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "temperature profile result" ; + + skos:definition "A temperature profile is a profile that quantifies the temperature of a material entity over time. [Allotrope]" ; + + skos:prefLabel "temperature profile" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002057 + +af-r:AFR_0002057 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000992 , + af-r:AFR_0002105 , + qb:DataSet , + [ rdf:type owl:Restriction ; + owl:onProperty [ owl:inverseOf af-x:AFX_0002737 + ] ; + owl:someValuesFrom af-r:AFR_0002103 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "An infrared interferogram data cube is a data cube that is a representation of an infrared interferogram. [Allotrope]" ; + + skos:prefLabel "infrared interferogram data cube" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002058 + +af-r:AFR_0002058 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000992 , + af-r:AFR_0002105 , + qb:DataSet , + [ rdf:type owl:Restriction ; + owl:onProperty [ owl:inverseOf af-x:AFX_0002737 + ] ; + owl:someValuesFrom af-r:AFR_0000251 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "An infrared spectrum data cube is a data cube that is a representation of an infrared spectrum. [Allotrope]" ; + + skos:prefLabel "infrared spectrum data cube" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002059 + +af-r:AFR_0002059 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000917 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002717 ; + owl:someValuesFrom qb:DataSet + ] ; + + rdfs:isDefinedBy ; + + rdfs:seeAlso ; + + skos:definition "A data cube identifier is an identifier for a data cube. A data cube is a multi-dimensional dataset conforming to the W3C DataCube specification (https://www.w3.org/TR/vocab-data-cube/). [Allotrope]" ; + + skos:prefLabel "data cube identifier" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002060 + +af-r:AFR_0002060 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000576 ; + + rdfs:isDefinedBy ; + + skos:altLabel "stirring rate profile result" ; + + skos:definition "An overhead stirring rate profile is a profile that quantifies the stirring rate of the stirring process. [Allotrope]" ; + + skos:prefLabel "stirring rate profile" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002061 + +af-r:AFR_0002061 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0002060 ; + + rdfs:isDefinedBy ; + + skos:altLabel "stir bar stirring rate profile result" ; + + skos:definition "A stir bar stirring rate profile is a profile that quantifies the rate of the stirring process using a magnetic stirrer. [Allotrope]" ; + + skos:prefLabel "stir bar stirring rate profile" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002062 + +af-r:AFR_0002062 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0002006 ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:altLabel "titer value" ; + + skos:definition "A titer is a calibrated result assigned as the molarity of the titrant solution in a titration. [Allotrope]" ; + + skos:prefLabel "titer" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002063 + +af-r:AFR_0002063 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000917 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002717 ; + owl:someValuesFrom af-r:AFR_0002069 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "calibration certificate id" ; + + skos:definition "A calibration certificate identifier is an identifier that identifies the calibration certificate for the piece of equipment used in a measurement. [Allotrope]" ; + + skos:prefLabel "calibration certificate identifier" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002065 + +af-r:AFR_0002065 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001844 ; + + rdfs:isDefinedBy ; + + skos:definition "A gross weight is a facet that quantifies the total mass of the objects on the platform of the weighing instrument i.e. the sample plus any container or packaging. [Allotrope]" ; + + skos:prefLabel "gross weight" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002067 + +af-r:AFR_0002067 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001844 ; + + rdfs:isDefinedBy ; + + skos:definition "A tare weight is a facet that quantifies the mass of a container or packing material to be deducted from a gross weight measurement to compute the sample weight measurement. [Allotrope]" ; + + skos:prefLabel "tare weight" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002069 + +af-r:AFR_0002069 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000304 , + [ rdf:type owl:Restriction ; + owl:onProperty iao:_0000136 ; + owl:someValuesFrom [ owl:intersectionOf ( af-e:AFE_0000354 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000056 ; + owl:someValuesFrom af-p:AFP_0002294 + ] + ) ; + rdf:type owl:Class + ] + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A calibration certificate is a certificate about a piece of equipment used in a measurement. [Allotrope]" ; + + skos:prefLabel "calibration certificate" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002070 + +af-r:AFR_0002070 rdf:type owl:Class ; + + rdfs:subClassOf iao:_0000310 , + [ rdf:type owl:Restriction ; + owl:onProperty iao:_0000136 ; + owl:someValuesFrom af-p:AFP_0001787 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "FTIR document" , + "FTIR result" , + "Fourier transform infrared result" ; + + skos:definition "A FTIR document is a document that encompasses the information associated with a Fourier Transform Infrared Spectroscopic run. [Allotrope]" ; + + skos:prefLabel "Fourier transform infrared document" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002071 + +af-r:AFR_0002071 rdf:type owl:Class ; + + rdfs:subClassOf iao:_0000310 , + [ rdf:type owl:Restriction ; + owl:onProperty iao:_0000136 ; + owl:someValuesFrom af-p:AFP_0000047 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "Raman result" ; + + skos:definition "A Raman document is a document that encompasses the information associated with a Raman spectroscopic run. [Allotrope]" ; + + skos:prefLabel "Raman document" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002072 + +af-r:AFR_0002072 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001583 ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:altLabel "heat transfer coefficient (datum)" , + "heat transfer coefficient result" ; + + skos:definition "A heat transfer coefficient is a quality quantification facet that quantifies the proportionality constant between the heat flux and the thermodynamic driving force for the flow of heat. [Wikipedia]" ; + + skos:prefLabel "heat transfer coefficient" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002073 + +af-r:AFR_0002073 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000576 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002816 ; + owl:someValuesFrom af-p:AFP_0003751 + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:altLabel "heat transfer coefficient profile result" ; + + skos:definition "A heat transfer coefficient profile is a profile that quantifies over time the proportionality constant between the heat flux and the thermodynamic driving force for the flow of heat. [Wikipedia]" ; + + skos:prefLabel "heat transfer coefficient profile" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002074 + +af-r:AFR_0002074 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001583 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002816 ; + owl:someValuesFrom pato:_0001413 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "angular velocity (datum)" , + "angular velocity result" ; + + skos:definition "A angular velocity datum is quality quantification facet that quantifies how fast an object rotates or revolves relative to another point. [Wikipedia]" ; + + skos:prefLabel "angular velocity" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002075 + +af-r:AFR_0002075 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000576 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002816 ; + owl:someValuesFrom af-p:AFP_0003752 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "angular velocity profile result" ; + + skos:definition "An angular velocity profile is a profile that quantifies over time how fast an object rotates or revolves relative to another point. [Wikipedia]" ; + + skos:prefLabel "angular velocity profile" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002076 + +af-r:AFR_0002076 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001583 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002816 ; + owl:someValuesFrom pato:_0001323 + ] ; + + af-x:AFX_0002808 , + ; + + rdfs:isDefinedBy ; + + skos:altLabel "area (datum)" , + "area result" ; + + skos:definition "An area (datum) is a quality quantification facet that quantifies the two-dimensional extend of an object. [Allotrope]" ; + + skos:prefLabel "area" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002077 + +af-r:AFR_0002077 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000576 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002816 ; + owl:someValuesFrom af-p:AFP_0003753 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "area profile result" ; + + skos:definition "An area profile is a profile that quantifies over time the area of an object. [Allotrope]" ; + + skos:prefLabel "area profile" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002079 + +af-r:AFR_0002079 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0002022 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002816 ; + owl:someValuesFrom af-q:AFQ_0000271 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "specific heat capacity (datum)" , + "specific heat capacity result" ; + + skos:definition "A specific heat capacity (datum) is a quality quantification facet that quantifies the amount of heat necessary to raise the temperature of one gram of a pure substance by one degree K. [Wikipedia]" ; + + skos:prefLabel "specific heat capacity" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002081 + +af-r:AFR_0002081 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000576 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002816 ; + owl:someValuesFrom af-p:AFP_0003755 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "cooling rate profile" , + "cooling rate profile result" , + "heating (cooling) rate profile" , + "heating (cooling) rate profile result" , + "heating or cooling rate profile result" , + "heating rate profile" , + "heating rate profile result" ; + + skos:definition "A heating or cooling rate profile is a profile that quantifies the heating/cooling rate of an object over time. [Allotrope]" ; + + skos:prefLabel "heating or cooling rate profile" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002082 + +af-r:AFR_0002082 rdf:type owl:Class ; + + rdfs:subClassOf af-c:AFC_0000160 , + iao:_0000310 , + [ rdf:type owl:Restriction ; + owl:onProperty iao:_0000136 ; + owl:someValuesFrom [ owl:intersectionOf ( bfo:_0000027 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0002351 ; + owl:someValuesFrom [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000087 ; + owl:someValuesFrom af-rl:AFRL_0000035 + ] + ] + ) ; + rdf:type owl:Class + ] + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "sample aggregate result" ; + + skos:definition "A sample aggregate document is a document that is about an ordered collection of samples. [Allotrope]" ; + + skos:prefLabel "sample aggregate document" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002083 + +af-r:AFR_0002083 rdf:type owl:Class ; + + rdfs:subClassOf iao:_0000310 , + [ rdf:type owl:Restriction ; + owl:onProperty iao:_0000136 ; + owl:someValuesFrom af-rl:AFRL_0000035 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "sample result" ; + + skos:definition "A sample document is a document about a particular sample. [Allotrope]" ; + + skos:prefLabel "sample document" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002085 + +af-r:AFR_0002085 rdf:type owl:Class ; + + rdfs:subClassOf iao:_0000310 ; + + rdfs:isDefinedBy ; + + skos:definition "A glutamate analysis document (cell-culture) is a document that encompasses the information associated with glutamate. [Allotrope]" ; + + skos:prefLabel "glutamate analysis document (cell-culture)" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002086 + +af-r:AFR_0002086 rdf:type owl:Class ; + + rdfs:subClassOf iao:_0000310 ; + + rdfs:isDefinedBy ; + + skos:definition "A glutamine analysis document (cell-culture) is a document that encompasses the information associated with glutamine. [Allotrope]" ; + + skos:prefLabel "glutamine analysis document (cell-culture)" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002087 + +af-r:AFR_0002087 rdf:type owl:Class ; + + rdfs:subClassOf iao:_0000310 ; + + rdfs:isDefinedBy ; + + skos:definition "A glucose analysis document (cell-culture) is a document that encompasses the information associated with glucose. [Allotrope]" ; + + skos:prefLabel "glucose analysis document (cell-culture)" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002088 + +af-r:AFR_0002088 rdf:type owl:Class ; + + rdfs:subClassOf iao:_0000310 ; + + rdfs:isDefinedBy ; + + skos:definition "A lactate analysis document (cell-culture) is a document that encompasses the information associated with lactate. [Allotrope]" ; + + skos:prefLabel "lactate analysis document (cell-culture)" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002089 + +af-r:AFR_0002089 rdf:type owl:Class ; + + rdfs:subClassOf iao:_0000310 ; + + rdfs:isDefinedBy ; + + skos:definition "An ammonium analysis document (cell-culture) is a document that encompasses the information associated with ammonium. [Allotrope]" ; + + skos:prefLabel "ammonium analysis document (cell-culture)" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002090 + +af-r:AFR_0002090 rdf:type owl:Class ; + + rdfs:subClassOf iao:_0000310 ; + + rdfs:isDefinedBy ; + + skos:definition "A sodium analysis document (cell-culture) is a document that encompasses the information associated with sodium. [Allotrope]" ; + + skos:prefLabel "sodium analysis document (cell-culture)" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002091 + +af-r:AFR_0002091 rdf:type owl:Class ; + + rdfs:subClassOf iao:_0000310 ; + + rdfs:isDefinedBy ; + + skos:definition "A potassium analysis document (cell-culture) is a document that encompasses the information associated with potassium. [Allotrope]" ; + + skos:prefLabel "potassium analysis document (cell-culture)" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002092 + +af-r:AFR_0002092 rdf:type owl:Class ; + + rdfs:subClassOf iao:_0000310 ; + + rdfs:isDefinedBy ; + + skos:definition "A phosphate analysis document (cell-culture) is a document that encompasses the information associated with phosphate. [Allotrope]" ; + + skos:prefLabel "phosphate analysis document (cell-culture)" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002093 + +af-r:AFR_0002093 rdf:type owl:Class ; + + rdfs:subClassOf iao:_0000310 ; + + rdfs:isDefinedBy ; + + skos:definition "A calcium analysis document (cell-culture) is a document that encompasses the information associated with calcium. [Allotrope]" ; + + skos:prefLabel "calcium analysis document (cell-culture)" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002094 + +af-r:AFR_0002094 rdf:type owl:Class ; + + rdfs:subClassOf iao:_0000310 ; + + rdfs:isDefinedBy ; + + skos:definition "A lactase dehydrogenate analysis document (cell-culture) is a document that encompasses the information associated with lactase dehydrogenate. [Allotrope]" ; + + skos:prefLabel "lactase dehydrogenate analysis document (cell-culture)" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002095 + +af-r:AFR_0002095 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000937 , + [ rdf:type owl:Restriction ; + owl:onProperty iao:_0000136 ; + owl:someValuesFrom af-p:AFP_0003598 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "Data processing time is the time when a data processing starts. [Allotrope]" ; + + skos:prefLabel "data processing time" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002099 + +af-r:AFR_0002099 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001583 , + af-r:AFR_0002408 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002816 ; + owl:someValuesFrom af-q:AFQ_0000173 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "mass fraction (datum)" , + "mass fraction result" , + "w/w %" , + "w/w%" , + "weight-weight %" ; + + skos:definition "The mass fraction (datum) is a quality quantification facet that quantifies the fraction pertaining the mass of a constituent divided by the total mass of all constituents in the mixture. [Allotrope]" ; + + skos:prefLabel "mass fraction" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002101 + +af-r:AFR_0002101 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0002074 ; + + rdfs:isDefinedBy ; + + skos:definition "Stirring rate is an angular velocity of the rotating, agitating component in stirrer. [Allotrope]" ; + + skos:prefLabel "stirring rate" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002103 + +af-r:AFR_0002103 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001599 , + af-r:AFR_0002105 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002734 ; + owl:someValuesFrom af-p:AFP_0001787 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "IR interferogram" ; + + skos:definition "An infrared interferogram is an interferogram produced by FT infrared spectroscopy. [Allotrope]" ; + + skos:prefLabel "infrared interferogram" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002104 + +af-r:AFR_0002104 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( af-r:AFR_0000754 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002734 ; + owl:someValuesFrom af-p:AFP_0000047 + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:subClassOf af-r:AFR_0000754 ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "Raman result" ; + + skos:definition "A Raman spectroscopy result is the result of a Raman spectroscopy. [Allotrope]" ; + + skos:prefLabel "Raman spectroscopy result" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002105 + +af-r:AFR_0002105 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( af-r:AFR_0000754 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002734 ; + owl:someValuesFrom [ rdf:type owl:Class ; + owl:unionOf ( af-p:AFP_0002016 + af-p:AFP_0002276 + ) + ] + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:subClassOf af-r:AFR_0000754 ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "IR result" , + "IR spectroscopy result" ; + + skos:definition "An infrared spectroscopy result is the result of an infrared absorption or transmission spectroscopy. [Allotrope]" ; + + skos:prefLabel "infrared spectroscopy result" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002107 + +af-r:AFR_0002107 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001817 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002816 ; + owl:someValuesFrom pato:_0001334 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "diameter (datum)" ; + + skos:definition "Diameter is a length which is equal to the length of any straight line segment that passes through the center of a circle and whose endpoints are on the circular boundary. [PATO]" ; + + skos:prefLabel "diameter" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002108 + +af-r:AFR_0002108 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0002107 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002816 ; + owl:someValuesFrom af-q:AFQ_0000018 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "inner diameter (datum)" ; + + skos:definition "Inner diameter is the diameter quantified at the inside. [Allotrope]" ; + + skos:prefLabel "inner diameter" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002109 + +af-r:AFR_0002109 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001583 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002816 ; + owl:someValuesFrom pato:_0000117 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "size" ; + + skos:definition "Size is a quality quantification facet that quantifies the spatial extend of an entity. [Allotrope]" ; + + skos:prefLabel "size (datum)" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002110 + +af-r:AFR_0002110 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0002036 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002816 ; + owl:someValuesFrom af-q:AFQ_0000175 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A volume concentration (datum) is a quantification facet that quantifies a concentration defined as the volume of a constituent divided by the volume of the mixture. [Allotrope]" ; + + skos:prefLabel "volume concentration" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002111 + +af-r:AFR_0002111 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001583 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002816 ; + owl:someValuesFrom af-q:AFQ_0000273 + ] ; + + dct:source "\"Glossary of terms in quantities and units in Clinical Chemistry (IUPAC-IFCC Recommendations 1996)\", Lehmann, H.P.;Fuentes-arderiu, X.;Bertello, L.F., Pure and Applied Chemistry 1996, 68(4), 957" , + "IUPAC. Compendium of Chemical Terminology, 2nd ed. (the \"Gold Book\"). Compiled by A. D. McNaught and A. Wilkinson. Blackwell Scientific Publications, Oxford (1997)" ; + + rdfs:isDefinedBy ; + + skos:altLabel "charge" ; + + skos:definition "Electric charge is the quality quantification facet that quantifies the integral of electric current over time. [Allotrope]" ; + + skos:prefLabel "electric charge" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002112 + +af-r:AFR_0002112 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001982 ; + + rdfs:isDefinedBy ; + + skos:definition "A degassed sample weight is the sample weight of a sample after it has gone through a degassing process. [Allotrope]" ; + + skos:prefLabel "degassed sample weight" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002114 + +af-r:AFR_0002114 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000917 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002717 ; + owl:someValuesFrom [ owl:intersectionOf ( af-m:AFM_0000275 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000087 ; + owl:someValuesFrom af-rl:AFRL_0000411 + ] + ) ; + rdf:type owl:Class + ] + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A reference material is an identifier that identifies some material with the role of reference material. [Allotrope]" ; + + skos:prefLabel "reference material identifier" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002115 + +af-r:AFR_0002115 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001844 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002816 ; + owl:someValuesFrom [ owl:intersectionOf ( pato:_0000125 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000080 ; + owl:someValuesFrom [ owl:intersectionOf ( af-m:AFM_0000275 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000087 ; + owl:someValuesFrom af-rl:AFRL_0000411 + ] + ) ; + rdf:type owl:Class + ] + ] + ) ; + rdf:type owl:Class + ] + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A reference material weight is a quality quantification facet that quantifies the mass of a material with the role of reference material in the analysis. [Allotrope]" ; + + skos:prefLabel "reference material weight" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002116 + +af-r:AFR_0002116 rdf:type owl:Class ; + + rdfs:subClassOf iao:_0000310 ; + + rdfs:isDefinedBy ; + + skos:definition "A BET point document is a document that encompasses the information associated with a single BET measurement point. [Allotrope]" ; + + skos:prefLabel "BET point document" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002117 + +af-r:AFR_0002117 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001583 ; + + rdfs:isDefinedBy ; + + skos:altLabel "relative pressure" ; + + skos:definition "A relative pressure is a quality quantification facet that quantifies the pressure of a pure substance in a chamber relative to its saturation pressure. [Allotrope]" ; + + skos:prefLabel "relative pressure (BET)" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002118 + +af-r:AFR_0002118 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001843 ; + + rdfs:isDefinedBy ; + + skos:definition "An adsorbed volume is a quality quantification facet that denotes the quantity of absorbant calculated to be adsorbed at STP. [Allotrope]" ; + + skos:prefLabel "adsorbed volume at STP" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002119 + +af-r:AFR_0002119 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001918 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002816 ; + owl:someValuesFrom af-q:AFQ_0000275 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "saturation pressure" , + "saturation pressure result" , + "saturation vapor pressure (datum)" , + "saturation vapor pressure result" ; + + skos:definition "A saturation pressure (datum) is a quality quantification facet that quantifies the saturation vapor pressure of a substance. [Allotrope]" ; + + skos:prefLabel "saturation vapor pressure" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002120 + +af-r:AFR_0002120 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001583 ; + + dct:license ; + + dct:rights ; + + dct:source "PAC, 1972, 31, 577. (Manual of Symbols and Terminology for Physicochemical Quantities and Units, Appendix II: Definitions, Terminology and Symbols in Colloid and Surface Chemistry)" ; + + rdfs:isDefinedBy ; + + skos:definition "When the area of the interface between two phases is proportional to the mass of one of the phases (e.g. for a solid adsorbent, for an emulsion or for an aerosol), the specific surface area (a, s or preferably as) is defined as the surface area divided by the mass of the relevant phase. [IUPAC]" ; + + skos:prefLabel "specific surface area" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002121 + +af-r:AFR_0002121 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001100 ; + + rdfs:isDefinedBy ; + + skos:definition "A y-intercept is the point where the graph of a function or relation intersects the y-axis of a coordinate system. [Wikipedia]" ; + + skos:prefLabel "y-intercept" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002122 + +af-r:AFR_0002122 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001583 ; + + rdfs:isDefinedBy ; + + skos:definition "A BET C constant is a calculated constant from a BET analysis equal to Exp(E1−EL) where E1 is heat of adsorption for the first layer and EL is the heat of vaporization for layers beyond the first layer. [Allotrope]" ; + + skos:prefLabel "BET C constant" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002123 + +af-r:AFR_0002123 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001583 ; + + rdfs:isDefinedBy ; + + skos:definition "A monolayer quantity is a volume of a monolayer based on the cross-sectional area of the adsorbent gas. [Allotrope]" ; + + skos:prefLabel "monolayer quantity" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002124 + +af-r:AFR_0002124 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000937 ; + + rdfs:isDefinedBy ; + + skos:definition "A measurement end time is the date/time of the end of the measurement process. [Allotrope]" ; + + skos:prefLabel "measurement end time" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002125 + +af-r:AFR_0002125 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001243 , + af-r:AFR_0001660 ; + + rdfs:isDefinedBy ; + + skos:definition "An evacuation rate setting is a control setting that controls the evacuation rate. [Allotrope]" ; + + skos:prefLabel "evacuation rate setting" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002126 + +af-r:AFR_0002126 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001243 , + af-r:AFR_0002288 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002704 ; + owl:someValuesFrom [ owl:intersectionOf ( af-p:AFP_0003328 + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000132 ; + owl:someValuesFrom af-p:AFP_0003785 + ] + ) ; + rdf:type owl:Class + ] + ] ; + + rdfs:isDefinedBy ; + + skos:definition "An evacuation time setting is a control setting that controls the time when a chamber is to be evacuated. [Allotrope]" ; + + skos:prefLabel "evacuation time setting" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002127 + +af-r:AFR_0002127 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001843 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002816 ; + owl:someValuesFrom af-q:AFQ_0000277 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "free space" , + "free space result" , + "free space volume" , + "measurement chamber free space" , + "measurement chamber free space (datum)" , + "measurement chamber free space volume (datum)" ; + + skos:definition "A measurement chamber free space result is a quality quantification facet that quantifies the volume of a sample chamber not occupied by the sample. [Allotrope]" ; + + skos:prefLabel "measurement chamber free space volume" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002128 + +af-r:AFR_0002128 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0002050 ; + + rdfs:isDefinedBy ; + + skos:definition "An equilibration time is an elapsed time required to reach an equilibrium state after a perturbation. [Allotrope]" ; + + skos:prefLabel "equilibration time" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002129 + +af-r:AFR_0002129 rdf:type owl:Class ; + + rdfs:subClassOf iao:_0000310 ; + + rdfs:isDefinedBy ; + + skos:definition "A loose density document is a document that encompasses the information associated with a loose density result. [Allotrope]" ; + + skos:prefLabel "loose density document" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002130 + +af-r:AFR_0002130 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001602 ; + + rdfs:isDefinedBy ; + + skos:definition "A loose density result is an analysis assay result that quantifies the volumetric density of a sample as-is without packing the sample to minimize interstitial volume. [Allotrope]" ; + + skos:prefLabel "loose density result" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002131 + +af-r:AFR_0002131 rdf:type owl:Class ; + + rdfs:subClassOf iao:_0000310 ; + + rdfs:isDefinedBy ; + + skos:definition "An intermediate tapped density aggregate document is a document is a document that is about an ordered collection of intermediate tapped density documents. [Allotrope]" ; + + skos:prefLabel "intermediate tapped density aggregate document" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002132 + +af-r:AFR_0002132 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000984 ; + + rdfs:isDefinedBy ; + + skos:altLabel "cumulative count (datum)" , + "cumulative count datum" ; + + skos:definition "A cumulative count (datum) is a count that has non-negative integer values that is about the cumulative number of discrete things. [Allotrope]" ; + + skos:prefLabel "cumulative count" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002133 + +af-r:AFR_0002133 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001583 ; + + rdfs:isDefinedBy ; + + skos:altLabel "birefringence (datum)" , + "birefringence result" ; + + skos:definition "A birefringence (datum) is a quality quantification facet indicating if the observed material exhibits birefringence. [Allotrope]" ; + + skos:prefLabel "birefringence" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002134 + +af-r:AFR_0002134 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001277 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002806 ; + owl:someValuesFrom af-q:AFQ_0000311 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "particle shape" ; + + skos:definition "A particle shape characterization is a classification datum that classifies the shape of particles. [Allotrope]" ; + + skos:prefLabel "particle shape characterization" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002135 + +af-r:AFR_0002135 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001277 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002806 ; + owl:someValuesFrom af-q:AFQ_0000304 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "An association state is a classification datum that classifies associations of primary particles (the smallest discrete unit). [Allotrope]" ; + + skos:prefLabel "association state" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002137 + +af-r:AFR_0002137 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001277 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002806 ; + owl:someValuesFrom [ owl:intersectionOf ( af-m:AFM_0000226 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002863 ; + owl:someValuesFrom af-p:AFP_0000326 + ] + ) ; + rdf:type owl:Class + ] + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A nucleus scan type is a classification datum classifying the nucleus/nuclei used in the magnetic resonance method. [Allotrope]" ; + + skos:prefLabel "nucleus scan type" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002138 + +af-r:AFR_0002138 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001843 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002816 ; + owl:someValuesFrom [ owl:intersectionOf ( pato:_0000918 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000080 ; + owl:someValuesFrom [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000087 ; + owl:someValuesFrom af-rl:AFRL_0000224 + ] + ] + ) ; + rdf:type owl:Class + ] + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A dilution volume is a volume of diluent used in a dilution. [Allotrope]" ; + + skos:prefLabel "dilution volume" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002139 + +af-r:AFR_0002139 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001243 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002704 ; + owl:someValuesFrom af-r:AFR_0002142 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "An inter scan relaxation delay setting is a setting that specifies the inter scan relaxation delay. [Allotrope]" ; + + skos:prefLabel "inter scan relaxation delay setting" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002140 + +af-r:AFR_0002140 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001603 , + af-r:AFR_0002371 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002699 ; + owl:someValuesFrom af-q:AFQ_0000209 + ] , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002734 ; + owl:someValuesFrom af-p:AFP_0003767 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A qNMR purity result is an analysis assay result facet quantifying the purity of a substance by quantitative NMR. [Allotrope]" ; + + skos:prefLabel "qNMR purity result" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002141 + +af-r:AFR_0002141 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000922 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002699 ; + owl:someValuesFrom af-p:AFP_0003282 + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A calculation description is a description that describes how a calculation was done. [Allotrope]" ; + + skos:prefLabel "calculation description" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002142 + +af-r:AFR_0002142 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001625 ; + + rdfs:isDefinedBy ; + + skos:definition "An inter scan relaxation delay is a time period which ensures that entire signal from spins is detectable. [Allotrope]" ; + + skos:prefLabel "inter scan relaxation delay" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002143 + +af-r:AFR_0002143 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001277 ; + + rdfs:isDefinedBy ; + + skos:altLabel "hygroscopicity per E.U" ; + + skos:definition "A hygroscopicity type is a classification datum that classifies the hygroscopicity of a material due to moisture sorption at 25°C and 80% relative humidity. [Allotrope]" ; + + skos:prefLabel "hygroscopicity type" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002144 + +af-r:AFR_0002144 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001836 ; + + rdfs:isDefinedBy ; + + skos:definition "A hysteresis assessment is an assessment about the hysteresis observed in a cyclic experiment. [Allotrope]" ; + + skos:prefLabel "hysteresis assessment" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002145 + +af-r:AFR_0002145 rdf:type owl:Class ; + + rdfs:subClassOf qb:DataSet ; + + rdfs:isDefinedBy ; + + skos:definition "A vapor sorption data cube is a data cube that is a representation of a vapor sorption experimental result. [Allotrope]" ; + + skos:prefLabel "vapor sorption data cube" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002146 + +af-r:AFR_0002146 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001505 ; + + rdfs:isDefinedBy ; + + skos:definition "A target P/P0 setting is a setting to set the relative pressure of a vapor. [Allotrope]" ; + + skos:prefLabel "target P/P0 setting" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002147 + +af-r:AFR_0002147 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001583 ; + + rdfs:isDefinedBy ; + + skos:definition "An actual P/P0 result is a quality quantification facet that quantifies the relative pressure of the sample. [Allotrope]" ; + + skos:prefLabel "actual P/P0 result" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002148 + +af-r:AFR_0002148 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001243 , + af-r:AFR_0001255 ; + + rdfs:isDefinedBy ; + + skos:definition "A sample temperature setting is a temperature control setting to set the target temperature of the sample. [Allotrope]" ; + + skos:prefLabel "sample temperature setting" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002149 + +af-r:AFR_0002149 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001584 ; + + rdfs:isDefinedBy ; + + skos:altLabel "2020-12-01 Changed labels. [Allotrope]" , + "2020-12-01 Moved under temperature datum. [Allotrope]" , + "sample temperature (datum)" , + "sample temperature result" ; + + skos:definition "A sample temperature result is a quality quantification facet that quantifies the temperature of the sample. [Allotrope]" ; + + skos:prefLabel "sample temperature" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002150 + +af-r:AFR_0002150 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001844 ; + + rdfs:isDefinedBy ; + + skos:definition "A mass change is a mass facet that quantifies the change in initial mass. [Allotrope]" ; + + skos:prefLabel "mass change" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002151 + +af-r:AFR_0002151 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000954 ; + + rdfs:isDefinedBy ; + + skos:definition "A mass change rate is a rate that quantifies the change in initial mass per unit time. [Allotrope]" ; + + skos:prefLabel "mass change rate" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002152 + +af-r:AFR_0002152 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001881 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002816 ; + owl:someValuesFrom [ owl:intersectionOf ( [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002730 ; + owl:someValuesFrom af-rl:AFRL_0000250 + ] + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002803 ; + owl:someValuesFrom [ owl:intersectionOf ( af-r:AFR_0002154 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002730 ; + owl:someValuesFrom af-rl:AFRL_0000478 + ] + ) ; + rdf:type owl:Class + ] + ] + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002803 ; + owl:someValuesFrom [ owl:intersectionOf ( af-r:AFR_0002156 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002730 ; + owl:someValuesFrom af-rl:AFRL_0000478 + ] + ) ; + rdf:type owl:Class + ] + ] + ) ; + rdf:type owl:Class + ] + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A total gas flow rate is a flow rate that quantifies the motion of the sum of the dry and saturated gas over time. [Allotrope]" ; + + skos:prefLabel "total gas flow rate" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002153 + +af-r:AFR_0002153 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001243 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002704 ; + owl:someValuesFrom [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000087 ; + owl:someValuesFrom af-rl:AFRL_0000531 + ] + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A saturated gas flow rate setting is a setting that specifies the target saturated gas flow rate. [Allotrope]" ; + + skos:prefLabel "saturated gas flow rate setting" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002154 + +af-r:AFR_0002154 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001881 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002816 ; + owl:someValuesFrom [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000087 ; + owl:someValuesFrom af-rl:AFRL_0000531 + ] + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A saturated gas flow rate is a flow rate that quantifies the motion of the saturated gas over time. [Allotrope]" ; + + skos:prefLabel "saturated gas flow rate" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002155 + +af-r:AFR_0002155 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001243 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002704 ; + owl:someValuesFrom [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000087 ; + owl:someValuesFrom af-rl:AFRL_0000530 + ] + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A dry gas flow rate setting is a setting that specifies the target dry gas flow rate. [Allotrope]" ; + + skos:prefLabel "dry gas flow rate setting" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002156 + +af-r:AFR_0002156 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001881 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002816 ; + owl:someValuesFrom [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000087 ; + owl:someValuesFrom af-rl:AFRL_0000530 + ] + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A dry gas flow rate is a flow rate that quantifies the motion of the dry gas over time. [Allotrope]" ; + + skos:prefLabel "dry gas flow rate" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002157 + +af-r:AFR_0002157 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001584 ; + + rdfs:isDefinedBy ; + + skos:definition "An ambient temperature is a quantity facet that quantifies the temperature of the surrounding atmosphere. [Allotrope]" ; + + skos:prefLabel "ambient temperature" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002158 + +af-r:AFR_0002158 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001918 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002816 ; + owl:someValuesFrom [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000087 ; + owl:someValuesFrom af-rl:AFRL_0000532 + ] + ] ; + + rdfs:isDefinedBy ; + + skos:definition "An inlet gas pressure is a quality qualification facet that quantifies the pressure of the inlet gas. [Allotrope]" ; + + skos:prefLabel "inlet gas pressure" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002159 + +af-r:AFR_0002159 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001881 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002816 ; + owl:someValuesFrom [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000087 ; + owl:someValuesFrom af-rl:AFRL_0000529 + ] + ] ; + + rdfs:isDefinedBy ; + + skos:definition "An exhaust gas flow rate is a flow rate that quantifies the flow rate of the exhaust gas. [Allotrope]" ; + + skos:prefLabel "exhaust gas flow rate" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002160 + +af-r:AFR_0002160 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001584 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002816 ; + owl:someValuesFrom [ owl:intersectionOf ( pato:_0000146 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000080 ; + owl:someValuesFrom [ owl:intersectionOf ( [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0001049 ; + owl:someValuesFrom af-e:AFE_0000378 + ] + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000087 ; + owl:someValuesFrom af-rl:AFRL_0000269 + ] + ) ; + rdf:type owl:Class + ] + ] + ) ; + rdf:type owl:Class + ] + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A solvent reservoir temperature is a quantity facet that quantifies the temperature of the solvent reservoir. [Allotrope]" ; + + skos:prefLabel "solvent reservoir temperature" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002161 + +af-r:AFR_0002161 rdf:type owl:Class ; + + rdfs:subClassOf iao:_0000310 ; + + rdfs:isDefinedBy ; + + skos:definition "A tapped density document is a document that encompasses the information associated with a tapped density result. [Allotrope]" ; + + skos:prefLabel "tapped density document" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002162 + +af-r:AFR_0002162 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001602 ; + + rdfs:isDefinedBy ; + + skos:definition "A tapped density result is an analysis assay result that quantifies the volumetric density of a sample after packing to minimize interstitial volume. [Allotrope]" ; + + skos:prefLabel "tapped density result" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002163 + +af-r:AFR_0002163 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001583 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002816 ; + owl:someValuesFrom af-q:AFQ_0000280 + ] ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:altLabel "enthalpy of fusion (datum)" , + "enthalpy of melting" , + "enthalpy of melting (datum)" , + "heat of fusion" ; + + skos:definition "The enthalpy of fusion datum is quantification of the amount of energy (enthalpy) that must be added to a solid substance, to transform a quantity of that substance into a liquid. [Wikipedia]" ; + + skos:prefLabel "enthalpy of fusion" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002164 + +af-r:AFR_0002164 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0002163 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002816 ; + owl:someValuesFrom af-q:AFQ_0000282 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "specific entropy of fusion (datum)" , + "specific heat of fusion" ; + + skos:definition "The specific enthalpy of fusion datum is the enthalpy of fusion referenced to a unit mass of substance. [Allotrope]" ; + + skos:prefLabel "specific enthalpy of fusion" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002165 + +af-r:AFR_0002165 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0002163 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002816 ; + owl:someValuesFrom af-q:AFQ_0000284 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "molar entropy of fusion (datum)" , + "molar heat of fusion" ; + + skos:definition "The specific enthalpy of fusion datum is the enthalpy of fusion referenced to a unit amount of substance. [Allotrope]" ; + + skos:prefLabel "molar enthalpy of fusion" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002166 + +af-r:AFR_0002166 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001583 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002816 ; + owl:someValuesFrom af-q:AFQ_0000281 + ] ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:altLabel "enthalpy of vaporization (datum)" , + "heat of vaporization" ; + + skos:definition "The enthalpy of vaporization datum is quantification of the amount of energy (enthalpy) that must be added to a liquid substance, to transform a quantity of that substance into a gas. [Wikipedia]" ; + + skos:prefLabel "enthalpy of vaporization" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002167 + +af-r:AFR_0002167 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0002166 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002816 ; + owl:someValuesFrom af-q:AFQ_0000283 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "specific enthalpy of vaporization (datum)" , + "specific heat of vaporization" ; + + skos:definition "The specific enthalpy of vaporization datum is the enthalpy of vaporization referenced to a unit mass of substance. [Allotrope]" ; + + skos:prefLabel "specific enthalpy of vaporization" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002168 + +af-r:AFR_0002168 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0002166 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002816 ; + owl:someValuesFrom af-q:AFQ_0000283 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "molar enthalpy of vaporization (datum)" , + "molar heat of vaporization" ; + + skos:definition "The molar enthalpy of vaporization datum is the enthalpy of vaporization referenced to a unit amount of substance. [Allotrope]" ; + + skos:prefLabel "molar enthalpy of vaporization" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002169 + +af-r:AFR_0002169 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001583 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002816 ; + owl:someValuesFrom af-q:AFQ_0000286 + ] ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:altLabel "enthalpy of sublimation (datum)" , + "heat of sublimation" ; + + skos:definition "The enthalpy of sublimation datum is quantification of the amount of energy (enthalpy) that must be added to a solid substance, to transform a quantity of that substance into a gas. [Wikipedia]" ; + + skos:prefLabel "enthalpy of sublimation" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002170 + +af-r:AFR_0002170 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0002169 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002816 ; + owl:someValuesFrom af-q:AFQ_0000287 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "specific enthalpy of sublimation (datum)" , + "specific heat of sublimation" ; + + skos:definition "The specific enthalpy of sublimation datum is the enthalpy of sublimation referenced to a unit mass of substance. [Allotrope]" ; + + skos:prefLabel "specific enthalpy of sublimation" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002171 + +af-r:AFR_0002171 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0002169 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002816 ; + owl:someValuesFrom af-q:AFQ_0000288 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "molar enthalpy of sublimation (datum)" , + "molar heat of sublimation" ; + + skos:definition "The molar enthalpy of sublimation datum is the enthalpy of sublimation referenced to a unit amount of substance. [Allotrope]" ; + + skos:prefLabel "molar enthalpy of sublimation" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002175 + +af-r:AFR_0002175 rdf:type owl:Class ; + + rdfs:subClassOf [ owl:intersectionOf ( af-r:AFR_0001501 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002704 ; + owl:someValuesFrom af-p:AFP_0003598 + ] + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A data processing method is a plan specification that specifies how data processing process is to be executed. [Allotrope]" ; + + skos:prefLabel "data processing method" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002176 + +af-r:AFR_0002176 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001917 ; + + rdfs:isDefinedBy ; + + skos:definition "Heat flow is a quantification of the heat transferred per time. [Allotrope]" ; + + skos:prefLabel "heat flow" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002177 + +af-r:AFR_0002177 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001745 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002717 ; + owl:someValuesFrom [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000087 ; + owl:someValuesFrom af-rl:AFRL_0000269 + ] + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "solvent id" ; + + skos:definition "A solvent identifier is an identifier denoting the solvent used in the experiment. [Allotrope]" ; + + skos:prefLabel "solvent identifier" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002178 + +af-r:AFR_0002178 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0002203 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002730 ; + owl:someValuesFrom af-rl:AFRL_0000013 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A standard nominal value is a nominal value for a measurement assigned to a standard material. [Allotrope]" ; + + skos:prefLabel "standard nominal value" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002179 + +af-r:AFR_0002179 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000207 , + af-r:AFR_0002203 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002730 ; + owl:someValuesFrom af-rl:AFRL_0000157 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A standard measured value is an assay result that is a measure of the standard material. [Allotrope]" ; + + skos:prefLabel "standard measured value" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002180 + +af-r:AFR_0002180 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001839 , + af-r:AFR_0002204 ; + + rdfs:isDefinedBy ; + + skos:definition "A calibration result deviation is a calibration result representing the deviation between the nominal and measured values for the standard as a percentage. [Allotrope]" ; + + skos:prefLabel "calibration result deviation" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002181 + +af-r:AFR_0002181 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001583 ; + + rdfs:isDefinedBy ; + + skos:altLabel "turbidity (datum)" , + "turbidity result" ; + + skos:definition "A turbidity (datum) is a quality quantification facet that quantifies the turbidity of a solution. [Allotrope]" ; + + skos:prefLabel "turbidity" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002182 + +af-r:AFR_0002182 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0002181 ; + + rdfs:isDefinedBy ; + + skos:altLabel "background corrected turbidity (datum)" , + "background corrected turbidity result" ; + + skos:definition "A background corrected turbidity (datum) is a turbidity (datum) that quantifies the turbidity in a solution corrected for background of the solvent. [Allotrope]" ; + + skos:prefLabel "background corrected turbidity" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002183 + +af-r:AFR_0002183 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000922 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002699 ; + owl:someValuesFrom af-m:AFM_0000442 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "Instrument suspension media is a description describing the suspension media used in the instrument during the experiment. [Allotrope]" ; + + skos:prefLabel "instrument suspension media" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002184 + +af-r:AFR_0002184 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000922 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002699 ; + owl:someValuesFrom af-m:AFM_0000442 + ] , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002699 ; + owl:someValuesFrom [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000087 ; + owl:someValuesFrom af-rl:AFRL_0000508 + ] + ] ; + + rdfs:isDefinedBy ; + + skos:definition "Sample suspension media is a description that describes the suspension media used in preparation of the sample. [Allotrope]" ; + + skos:prefLabel "sample suspension media" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002185 + +af-r:AFR_0002185 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001815 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002704 ; + owl:someValuesFrom af-p:AFP_0002293 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A sonication duration setting is a duration setting that specifies the duration of a sonication process before analysis. [Allotrope]" ; + + skos:prefLabel "sonication duration setting" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002186 + +af-r:AFR_0002186 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001243 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002704 ; + owl:someValuesFrom af-p:AFP_0002293 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A sonication power setting is a setting that specifies the power of a sonication process. [Allotrope]" ; + + skos:prefLabel "sonication power setting" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002187 + +af-r:AFR_0002187 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001243 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002704 ; + owl:someValuesFrom [ owl:intersectionOf ( af-q:AFQ_0000292 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000080 ; + owl:someValuesFrom af-m:AFM_0000394 + ] + ) ; + rdf:type owl:Class + ] + ] , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002730 ; + owl:someValuesFrom af-rl:AFRL_0000478 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "fluid refractive index parameter" ; + + skos:definition "A fluid refractive index setting is a setting that specifies the refractive index of the fluid used in calculating the particle size. [Allotrope]" ; + + skos:prefLabel "fluid refractive index setting" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002188 + +af-r:AFR_0002188 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001243 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002704 ; + owl:someValuesFrom [ owl:intersectionOf ( af-q:AFQ_0000292 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000080 ; + owl:someValuesFrom af-m:AFM_0000386 + ] + ) ; + rdf:type owl:Class + ] + ] , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002730 ; + owl:someValuesFrom af-rl:AFRL_0000478 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "particle refractive index parameter" ; + + skos:definition "A particle refractive index setting is a setting that specifies the refractive index of a particle used in calculating the particle size. [Allotrope]" ; + + skos:prefLabel "particle refractive index setting" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002189 + +af-r:AFR_0002189 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001243 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002704 ; + owl:someValuesFrom [ owl:intersectionOf ( pato:_0000052 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000080 ; + owl:someValuesFrom af-m:AFM_0000386 + ] + ) ; + rdf:type owl:Class + ] + ] , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002730 ; + owl:someValuesFrom af-rl:AFRL_0000478 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "particle shape setting" ; + + skos:definition "A particle shape setting is a setting that specifies the particle shape used in calculating the particle size. [Allotrope]" ; + + skos:prefLabel "particle shape setting" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002190 + +af-r:AFR_0002190 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001583 , + af-r:AFR_0002208 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002699 ; + owl:someValuesFrom [ owl:intersectionOf ( bfo:_0000027 + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000051 ; + owl:someValuesFrom af-m:AFM_0000435 + ] + ) ; + rdf:type owl:Class + ] + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "mean particle size" ; + + skos:definition "The average particle size is a quality quantification facet that quantifies the arithmetic mean of particle size of a population of particles. [Allotrope]" ; + + skos:prefLabel "average particle size" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002192 + +af-r:AFR_0002192 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001212 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002730 ; + owl:someValuesFrom af-rl:AFRL_0000527 + ] ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:definition "The standard deviation is a measure of the amount of variation or dispersion of a set of values. [Wikipedia]" ; + + skos:prefLabel "standard deviation" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002193 + +af-r:AFR_0002193 rdf:type owl:Class ; + + rdfs:subClassOf iao:_0000310 ; + + rdfs:isDefinedBy ; + + skos:changeNote "2020-12-08 Moved to AFO." ; + + skos:definition "A distribution document is a document that encompasses the information associated with a distribution. [Allotrope]" ; + + skos:prefLabel "distribution document" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002194 + +af-r:AFR_0002194 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001852 ; + + rdfs:isDefinedBy ; + + skos:definition "A cumulative distribution percentage is a statistical facet that describes the percentage of population members meeting a given condition. [Allotrope]" ; + + skos:prefLabel "cumulative distribution percentage" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002195 + +af-r:AFR_0002195 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001212 ; + + rdfs:isDefinedBy ; + + skos:definition "A bin upper limit is a statistical facet that quantifies the upper limit that population members meet within a distribution. [Allotrope]" ; + + skos:prefLabel "bin upper limit" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002196 + +af-r:AFR_0002196 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001277 , + af-r:AFR_0001852 ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:definition "A distribution modality is a classification datum that indicates the number of peaks contained in the classified distribution. [Allotrope]" ; + + skos:prefLabel "distribution modality" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002197 + +af-r:AFR_0002197 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0002408 ; + + rdfs:isDefinedBy ; + + skos:altLabel "count fraction (datum)" ; + + skos:changeNote "2020-12-01 Changed labels and generalized definition. [Allotrope]" , + "2020-12-01 Moved to AFO. [Allotrope]" ; + + skos:definition "The count fraction (datum) is a quality quantification facet that quantifies the fraction pertaining the number of object of a constituent divided by the total number of objects of all constituents in the object aggregate. [Allotrope]" ; + + skos:prefLabel "count fraction" ; + + skos:scopeNote "Definition is generalized to cover any count fraction, but usually it applies to particles in a mixture. [Allotrope]" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002198 + +af-r:AFR_0002198 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001918 ; + + rdfs:isDefinedBy ; + + skos:altLabel "partial pressure (datum)" , + "partial pressure result" ; + + skos:changeNote "2020-12-01 Changed labels and definition. [Allotrope]" , + "2020-12-01 Moved under pressure (datum). [Allotrope]" ; + + skos:definition "A partial pressure (datum) is a quality quantification facet that quantifies the notional pressure of a gas in a mixture of gases, if it alone occupied the entire volume of the original mixture at the same temperature. [Allotrope]" ; + + skos:prefLabel "partial pressure" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002202 + +af-r:AFR_0002202 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( af-r:AFR_0000922 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002842 ; + owl:someValuesFrom af-p:AFP_0001159 + ] + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A sample preparation description is a description of the sample preparation process. [Allotrope]" ; + + skos:prefLabel "sample preparation description" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002203 + +af-r:AFR_0002203 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000923 , + [ rdf:type owl:Class ; + owl:unionOf ( [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002800 ; + owl:someValuesFrom af-r:AFR_0001276 + ] + [ rdf:type owl:Restriction ; + owl:onProperty iao:_0000136 ; + owl:someValuesFrom af-rl:AFRL_0000233 + ] + ) + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A standard facet is a facet that part of some standard or is about some standard material. [Allotrope]" ; + + skos:prefLabel "standard facet" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002204 + +af-r:AFR_0002204 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001101 ; + + rdfs:isDefinedBy ; + + skos:definition "A deviation is a quantification facet that quantifies the absolute or relative difference of an observed value from another value. [Allotrope]" ; + + skos:prefLabel "deviation" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002205 + +af-r:AFR_0002205 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001277 , + af-r:AFR_0001852 ; + + rdfs:isDefinedBy ; + + skos:definition "A distribution type is a classification datum for distributions where the ordinate is expressed based on selected category. [Allotrope]" ; + + skos:prefLabel "distribution type" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002207 + +af-r:AFR_0002207 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001583 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002816 ; + owl:someValuesFrom af-q:AFQ_0000292 + ] ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:altLabel "index of refraction" , + "refraction index" , + "refractive index (datum)" ; + + skos:definition "Refraction index is a quality quantification facet, that quantifies how fast light travels through a material. It is defined as n = c/v, where c is the speed of light in vacuum and v is the phase velocity of light in the medium. [Wikipedia]" ; + + skos:prefLabel "refractive index" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002208 + +af-r:AFR_0002208 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001212 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002730 ; + owl:someValuesFrom af-rl:AFRL_0000320 + ] ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:altLabel "mean" ; + + skos:definition "The arithmetic mean is a descriptive statistic that is the sum of a collection of numbers divided by the number of numbers in the collection. [Wikipedia]" ; + + skos:prefLabel "arithmetic mean" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002209 + +af-r:AFR_0002209 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001212 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002730 ; + owl:someValuesFrom af-rl:AFRL_0000321 + ] ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:definition "The median is a descriptive statistic that denotes the value separating the higher half of a data sample, a population, or a probability distribution, from the lower half. [Wikipedia]" ; + + skos:prefLabel "median" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002210 + +af-r:AFR_0002210 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001212 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002730 ; + owl:someValuesFrom af-rl:AFRL_0000323 + ] ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:definition "The variance is a descriptive statistic that denotes the expectation of the squared deviation of a random variable from its mean. [Wikipedia]" ; + + skos:prefLabel "variance" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002211 + +af-r:AFR_0002211 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001212 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002730 ; + owl:someValuesFrom af-rl:AFRL_0000322 + ] ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:definition "Skewness is a descriptive statistic that is a measure of the asymmetry of the probability distribution of a real-valued random variable about its mean. The skewness value can be positive or negative, or undefined. [Wikipedia]" ; + + skos:prefLabel "skewness" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002212 + +af-r:AFR_0002212 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001245 , + af-r:AFR_0001581 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002704 ; + owl:someValuesFrom pato:_0001025 + ] , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002730 ; + owl:someValuesFrom af-rl:AFRL_0000041 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "minimum pressure" , + "plumbing pressure lower limit" , + "pressure lower limit" ; + + skos:definition "The plumbing minimum pressure is a specification of the minimum pressure that the plumbing system can operate with. [Allotrope]" ; + + skos:prefLabel "plumbing minimum pressure" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002226 + +af-r:AFR_0002226 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001243 ; + + rdfs:isDefinedBy ; + + skos:definition "A magnification setting is a setting that specifies the multiplicative optical apparent size manipulation being applied by an imaging device. [Allotrope]" ; + + skos:prefLabel "magnification setting" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002227 + +af-r:AFR_0002227 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0002280 ; + + rdfs:isDefinedBy ; + + skos:altLabel "polarized light enabled" ; + + skos:definition "A polarized light enabled setting is a setting that specifies whether polarized light is used in an image capture process. [Allotrope]" ; + + skos:prefLabel "polarized light enabled setting" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002228 + +af-r:AFR_0002228 rdf:type owl:Class ; + + rdfs:subClassOf iao:_0000310 , + [ rdf:type owl:Restriction ; + owl:onProperty iao:_0000136 ; + owl:someValuesFrom af-r:AFR_0001276 + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A standard document is a document about a particular standard. [Allotrope]" ; + + skos:prefLabel "standard document" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002229 + +af-r:AFR_0002229 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( af-r:AFR_0001277 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002806 ; + owl:someValuesFrom af-p:AFP_0003735 + ] + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "An experiment type is a classification datum that classifies the type of experiment performed. [Allotrope]" ; + + skos:prefLabel "experiment type" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002231 + +af-r:AFR_0002231 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001103 , + af-r:AFR_0002274 ; + + rdfs:isDefinedBy ; + + skos:definition "A plate well count is a count that quantifies the number of plate well positions present on a well plate. [Allotrope]" ; + + skos:prefLabel "plate well count" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002232 + +af-r:AFR_0002232 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001103 , + af-r:AFR_0001843 ; + + rdfs:isDefinedBy ; + + skos:definition "A well volume is a volume (datum) that quantifies how much volume of material that can be put into each well in a well plate. [Allotrope]" ; + + skos:prefLabel "well volume" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002233 + +af-r:AFR_0002233 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001277 ; + + rdfs:isDefinedBy ; + + skos:definition "A qPCR detection chemistry is a classification datum that classifies a qPCR detection based on the fluorescent agent used and the specificity of detection. [Allotrope]" ; + + skos:prefLabel "qPCR detection chemistry" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002234 + +af-r:AFR_0002234 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001243 , + af-r:AFR_0001277 , + af-r:AFR_0002278 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002704 ; + owl:someValuesFrom [ owl:intersectionOf ( af-m:AFM_0000085 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000087 ; + owl:someValuesFrom af-rl:AFRL_0000537 + ] + ) ; + rdf:type owl:Class + ] + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "passive reference dye" ; + + skos:definition "A passive reference dye setting is a setting that classifies the passive reference dye used in the qPCR experiment. [Allotrope]" ; + + skos:prefLabel "passive reference dye setting" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002235 + +af-r:AFR_0002235 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0002277 , + af-r:AFR_0002278 ; + + rdfs:isDefinedBy ; + + skos:definition "An automatic cycle threshold enabled setting is a control setting that sets whether the cycle threshold determination is automated or manual. [Allotrope]" ; + + skos:prefLabel "automatic cycle threshold enabled setting" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002236 + +af-r:AFR_0002236 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001243 , + af-r:AFR_0002278 ; + + rdfs:isDefinedBy ; + + skos:altLabel "cycle threshold value setting" ; + + skos:definition "A cycle threshold value setting is a setting that sets the threshold value used for automatic qPCR cycle threshold determination. [Allotrope]" ; + + skos:prefLabel "cycle threshold value setting (qPCR)" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002237 + +af-r:AFR_0002237 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0002277 , + af-r:AFR_0002278 ; + + rdfs:isDefinedBy ; + + skos:altLabel "automatic baseline determination enabled" ; + + skos:definition "An automatic baseline determination enabled setting is an automation flag that controls whether baseline determination is automated or manual. [Allotrope]" ; + + skos:prefLabel "automatic baseline determination enabled setting" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002238 + +af-r:AFR_0002238 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0002278 ; + + rdfs:isDefinedBy ; + + skos:definition "A baseline determination start cycle setting is a qPCR setting that specifies the start cycle for baseline determination. [Allotrope]" ; + + skos:prefLabel "baseline determination start cycle setting" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002239 + +af-r:AFR_0002239 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0002278 ; + + rdfs:isDefinedBy ; + + skos:definition "A baseline determination end cycle setting is a qPCR setting that specifies the end cycle for baseline determination. [Allotrope]" ; + + skos:prefLabel "baseline determination end cycle setting" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002240 + +af-r:AFR_0002240 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000919 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000388 ; + owl:someValuesFrom af-e:AFE_0000407 + ] , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002717 ; + owl:someValuesFrom af-e:AFE_0002241 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A well location identifier is a local identifier that identifies the location of a well on the container submitted to the experiment in the scope of the container. [Allotrope]" ; + + skos:prefLabel "well location identifier" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002241 + +af-r:AFR_0002241 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000922 ; + + rdfs:isDefinedBy ; + + skos:definition "A target DNA description is a description that describes the intended DNA target of the qPCR experiment. [Allotrope]" ; + + skos:prefLabel "target DNA description" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002242 + +af-r:AFR_0002242 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001277 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002806 ; + owl:someValuesFrom [ owl:intersectionOf ( af-m:AFM_0000275 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000087 ; + owl:someValuesFrom af-rl:AFRL_0000035 + ] + ) ; + rdf:type owl:Class + ] + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "sample type" ; + + skos:definition "A sample role type is a classification datum that classifies samples by the type of sample role in the experiment. [Allotrope]" ; + + skos:prefLabel "sample role type" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002243 + +af-r:AFR_0002243 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001243 , + af-r:AFR_0001277 , + af-r:AFR_0002278 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002704 ; + owl:someValuesFrom [ owl:intersectionOf ( af-m:AFM_0000085 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000087 ; + owl:someValuesFrom af-rl:AFRL_0000536 + ] + ) ; + rdf:type owl:Class + ] + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "reporter dye" ; + + skos:definition "A reporter dye setting is a setting that classifies the reporter dye used in the qPCR experiment. [Allotrope]" ; + + skos:prefLabel "reporter dye setting" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002244 + +af-r:AFR_0002244 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001243 , + af-r:AFR_0001277 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002704 ; + owl:someValuesFrom [ owl:intersectionOf ( af-m:AFM_0000085 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000087 ; + owl:someValuesFrom af-rl:AFRL_0000538 + ] + ) ; + rdf:type owl:Class + ] + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "quencher dye" ; + + skos:definition "A quencher dye setting is a setting that classifies the quencher dye used in the qPCR experiment. [Allotrope]" ; + + skos:prefLabel "quencher dye setting" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002246 + +af-r:AFR_0002246 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0002279 ; + + rdfs:isDefinedBy ; + + skos:altLabel "cycle threshold result" ; + + skos:definition "A cycle threshold result is an qPCR assay result that records the cycle at which the threshold was passed. [Allotrope]" ; + + skos:prefLabel "cycle threshold result (qPCR)" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002247 + +af-r:AFR_0002247 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0002279 ; + + rdfs:isDefinedBy ; + + skos:definition "A normalized reporter result is a qPCR assay result that specifies the fluorescent signal of the reporter dye normalized to the signal of the passive reference dye. [Allotrope]" ; + + skos:prefLabel "normalized reporter result" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002248 + +af-r:AFR_0002248 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0002279 ; + + rdfs:isDefinedBy ; + + skos:definition "A baseline corrected reporter result is a qPCR assay result that specifies the normalized reporter result minus the baseline signal of the instrument. [Allotrope]" ; + + skos:prefLabel "baseline corrected reporter result" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002249 + +af-r:AFR_0002249 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( af-r:AFR_0000207 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002734 ; + owl:someValuesFrom af-p:AFP_0000759 + ] + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "NMR assay result" , + "NMR result" , + "nuclear magnetic resonance result" ; + + skos:definition "An nuclear magnetic resonance result is a result of an nuclear magnetic resonance assay. [Allotrope]" ; + + skos:prefLabel "nuclear magnetic resonance result" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002250 + +af-r:AFR_0002250 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001243 , + af-r:AFR_0001247 ; + + rdfs:isDefinedBy ; + + skos:definition "A detector gain setting is setting that specifies the gain of the detector. [Allotrope]" ; + + skos:prefLabel "detector gain setting" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002251 + +af-r:AFR_0002251 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001505 ; + + rdfs:isDefinedBy ; + + skos:definition "An optical velocity setting is a setting that specifies the velocity of the moving mirror during the run. [Allotrope]" ; + + skos:prefLabel "optical velocity setting" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002252 + +af-r:AFR_0002252 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001243 ; + + rdfs:isDefinedBy ; + + skos:definition "A slit width setting is a setting that specifies the width of the opening of the slit. [Allotrope]" ; + + skos:prefLabel "slit width setting" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002253 + +af-r:AFR_0002253 rdf:type owl:Class ; + + rdfs:subClassOf [ owl:intersectionOf ( af-r:AFR_0001277 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002806 ; + owl:someValuesFrom af-e:AFE_0000317 + ] + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A detector type is a classification datum that describes the detector type. [Allotrope]" ; + + skos:prefLabel "detector type" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002254 + +af-r:AFR_0002254 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001277 ; + + rdfs:isDefinedBy ; + + skos:definition "A beamsplitter type is a classification datum that describes the beamsplitter type based on the compound used to split the light beam. [Allotrope]" ; + + skos:prefLabel "beamsplitter type" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002255 + +af-r:AFR_0002255 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( af-r:AFR_0000754 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002734 ; + owl:someValuesFrom af-p:AFP_0000326 + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:subClassOf af-r:AFR_0002249 ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "NMR spectrometry result" , + "NMR spectroscopy result" , + "nuclear magnetic resonance spectrometry result" ; + + skos:definition "An NMR spectroscopy result is a result of an NMR spectroscopy. [Allotrope]" ; + + skos:prefLabel "nuclear magnetic resonance spectroscopy result" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002256 + +af-r:AFR_0002256 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( af-r:AFR_0000754 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002734 ; + owl:someValuesFrom af-p:AFP_0001427 + ] + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "MS result" ; + + skos:definition "A mass spectrometry result is a result of a mass spectrometry. [Allotrope]" ; + + skos:prefLabel "mass spectrometry result" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002259 + +af-r:AFR_0002259 rdf:type owl:Class ; + + rdfs:subClassOf iao:_0000310 ; + + rdfs:isDefinedBy ; + + skos:definition "An intermediate tapped density document is a document that encompasses the information associated with a single intermediate tapped density result. [Allotrope]" ; + + skos:prefLabel "intermediate tapped density document" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002260 + +af-r:AFR_0002260 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001583 ; + + dct:license ; + + dct:rights ; + + rdfs:isDefinedBy ; + + skos:definition "A reflectance is a quality quantification facet that quantifies the fraction of incident radiation reflected by a surface or discontinuity. [IUPAC]" ; + + skos:prefLabel "reflectance" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002261 + +af-r:AFR_0002261 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001583 ; + + dct:license ; + + dct:rights ; + + dct:source "PAC, 1996, 68, 2223 (Glossary of terms used in photochemistry (IUPAC Recommendations 1996))" , + "PAC, 1996, 68, 957 (Glossary of terms in quantities and units in Clinical Chemistry (IUPAC-IFCC Recommendations 1996))" ; + + rdfs:isDefinedBy ; + + skos:definition "A transmittance is a quality quantification facet that quantifies the ratio of the transmitted radiant power (P_λ) to that incident on the sample (P0_λ): T = P_λ/ P0_λ. [IUPAC]" ; + + skos:prefLabel "transmittance" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002274 + +af-r:AFR_0002274 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000984 , + af-r:AFR_0001583 ; + + rdfs:isDefinedBy ; + + skos:definition "A position count is a spatial quantification facet that quantifies the number of distinct spatial locations. The spatial locations are defined by some pattern or morphology. [Allotrope]" ; + + skos:prefLabel "position count" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002277 + +af-r:AFR_0002277 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001243 , + af-r:AFR_0001685 ; + + rdfs:isDefinedBy ; + + skos:altLabel "automation enabled" , + "automation enabled setting" , + "automation flag" , + "automation switch" ; + + skos:definition "An automation flag is a flag that controls whether a process involves an automation system (true) participant alone or involves a human participant (false). [Allotrope]" ; + + skos:example "manual vs. automatic baseline determination [Allotrope]" ; + + skos:prefLabel "automation setting" ; + + skos:scopeNote "The automation can refer to subprocesses such as consuming of input, or the production of output or full automation. [Allotrope]" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002278 + +af-r:AFR_0002278 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001505 ; + + rdfs:isDefinedBy ; + + skos:definition "A qPCR setting is a setting for a qPCR experiment. [Allotrope]" ; + + skos:prefLabel "qPCR setting" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002279 + +af-r:AFR_0002279 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000207 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000353 ; + owl:someValuesFrom af-p:AFP_0003769 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A qPCR result is an assay result that is output of a qPCR experiment. [Allotrope]" ; + + skos:prefLabel "qPCR result" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002280 + +af-r:AFR_0002280 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001243 , + af-r:AFR_0001685 ; + + rdfs:isDefinedBy ; + + skos:altLabel "enabled flag" , + "enabled flag setting" ; + + skos:definition "An enabled flag setting is control setting that controls whether a process is running in a specific situation controlled by the setting. [Allotrope]" ; + + skos:prefLabel "enabled setting" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002281 + +af-r:AFR_0002281 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000068 ; + + rdfs:isDefinedBy ; + + skos:definition "A reflectance spectrum is a spectrum that plots the reflectance of radiance as the function of frequency or wavelength. [Allotrope]" ; + + skos:prefLabel "reflectance spectrum" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002282 + +af-r:AFR_0002282 rdf:type owl:Class ; + + rdfs:subClassOf qb:DataSet , + [ rdf:type owl:Restriction ; + owl:onProperty [ owl:inverseOf af-x:AFX_0002737 + ] ; + owl:someValuesFrom af-r:AFR_0002281 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A reflectance spectrum data cube is a data cube that represents a reflectance spectrum. [Allotrope]" ; + + skos:prefLabel "reflectance spectrum data cube" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002283 + +af-r:AFR_0002283 rdf:type owl:Class ; + + rdfs:subClassOf qb:DataSet , + [ rdf:type owl:Restriction ; + owl:onProperty [ owl:inverseOf af-x:AFX_0002737 + ] ; + owl:someValuesFrom af-r:AFR_0000222 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "An absorption spectrum data cube is a data cube that represents an absorption spectrum. [Allotrope]" ; + + skos:prefLabel "absorption spectrum data cube" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002284 + +af-r:AFR_0002284 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000068 ; + + rdfs:isDefinedBy ; + + skos:definition "A transmittance spectrum is a spectrum that plots the transmittance of radiance as the function of frequency or wavelength. [Allotrope]" ; + + skos:prefLabel "transmittance spectrum" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002285 + +af-r:AFR_0002285 rdf:type owl:Class ; + + rdfs:subClassOf qb:DataSet , + [ rdf:type owl:Restriction ; + owl:onProperty [ owl:inverseOf af-x:AFX_0002737 + ] ; + owl:someValuesFrom af-r:AFR_0002284 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A transmittance spectrum data cube is a data cube that represents a transmittance spectrum. [Allotrope]" ; + + skos:prefLabel "transmittance spectrum data cube" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002286 + +af-r:AFR_0002286 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001060 ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:altLabel "Brunauer–Emmett–Teller plot" ; + + skos:definition "A BET plot is a data distribution function of an adsorption isotherm with 1/v[(p0/p)-1] on the y-axis and p/p0 on the x-axis, where p is equilibrium pressure and p0 saturation pressure of adsorbates at the temperature of adsorption, and v is the adsorbed gas quantity. [Wikipedia]" ; + + skos:prefLabel "BET plot" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002287 + +af-r:AFR_0002287 rdf:type owl:Class ; + + rdfs:subClassOf qb:DataSet , + [ rdf:type owl:Restriction ; + owl:onProperty [ owl:inverseOf af-x:AFX_0002737 + ] ; + owl:someValuesFrom af-r:AFR_0002286 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "Brunauer–Emmett–Teller plot data cube" ; + + skos:definition "A BET plot data cube is a data cube that represents a BET plot. [Allotrope]" ; + + skos:prefLabel "BET plot data cube" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002288 + +af-r:AFR_0002288 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000966 , + af-r:AFR_0001505 ; + + rdfs:isDefinedBy ; + + skos:altLabel "timer" ; + + skos:definition "A time setting is a setting the specifies a point in time when a process starts or ends. [Allotrope]" ; + + skos:prefLabel "time setting" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002290 + +af-r:AFR_0002290 rdf:type owl:Class ; + + rdfs:subClassOf af-c:AFC_0000160 , + iao:_0000310 , + [ rdf:type owl:Restriction ; + owl:onProperty iao:_0000136 ; + owl:someValuesFrom [ owl:intersectionOf ( bfo:_0000027 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0002351 ; + owl:someValuesFrom [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000087 ; + owl:someValuesFrom af-rl:AFRL_0000344 + ] + ] + ) ; + rdf:type owl:Class + ] + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "reaction component aggregate document" ; + + skos:definition "A reaction component list is a document about an ordered collection of material entities with roles in a chemical reaction. [Allotrope]" ; + + skos:prefLabel "reaction component list" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002291 + +af-r:AFR_0002291 rdf:type owl:Class ; + + rdfs:subClassOf iao:_0000310 , + [ rdf:type owl:Restriction ; + owl:onProperty iao:_0000136 ; + owl:someValuesFrom af-m:AFM_0000275 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A chemical document is a document that is about some chemical substance. [Allotrope]" ; + + skos:prefLabel "chemical document" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002292 + +af-r:AFR_0002292 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001951 , + iao:_0000590 ; + + rdfs:isDefinedBy ; + + skos:definition "A chemical name is the written name of a chemical substance that shows the names of each of its elements or subcompounds. [Allotrope]" ; + + skos:prefLabel "chemical name" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002293 + +af-r:AFR_0002293 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001277 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002806 ; + owl:someValuesFrom [ owl:intersectionOf ( af-m:AFM_0001097 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000087 ; + owl:someValuesFrom af-rl:AFRL_0000344 + ] + ) ; + rdf:type owl:Class + ] + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A reaction component role type is a classification datum that classifies the role of a chemical substance in a reaction. [Allotrope]" ; + + skos:prefLabel "reaction component role type" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002294 + +af-r:AFR_0002294 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001844 , + af-r:AFR_0001951 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002816 ; + owl:someValuesFrom af-q:AFQ_0000256 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "molecular mass (datum)" , + "molecular mass result" ; + + skos:definition "A molecular mass is a quality quantification facet that quantifies the mass of a molecule. [Allotrope]" ; + + skos:prefLabel "molecular mass" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002295 + +af-r:AFR_0002295 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001072 ; + + af-x:AFX_0002808 ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:definition "A SMILES molecular structure is a molecular structure specified in Simplified Molecular Input Line Entry System (SMILES) line notation. [edamontology.org]" ; + + skos:prefLabel "SMILES molecular structure" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002296 + +af-r:AFR_0002296 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001072 ; + + af-x:AFX_0002808 ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:definition "An InChI molecular structure is a molecular structure specified in IUPAC International Chemical Identifier (InChI) line notation. [edamontology.org]" ; + + skos:prefLabel "InChI molecular structure" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002297 + +af-r:AFR_0002297 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001072 ; + + af-x:AFX_0002808 ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:definition "An InChIKey molecular structure is a molecular structure specified as an InChIKey (hashed InChI), which is a fixed length (25 character) condensed digital representation of an InChI chemical structure specification. It uniquely identifies a chemical compound. An InChIKey identifier is not human- nor machine-readable but is more suitable for web searches than an InChI chemical structure specification. [edamontology.org]" ; + + skos:prefLabel "InChIKey molecular structure" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002298 + +af-r:AFR_0002298 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( af-r:AFR_0000922 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002699 ; + owl:someValuesFrom af-p:AFP_0003743 + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:isDefinedBy ; + + skos:definition "An addition description is a description about the process of adding a reaction component to a reaction. [Allotrope]" ; + + skos:prefLabel "addition description" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002299 + +af-r:AFR_0002299 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001277 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002806 ; + owl:someValuesFrom af-e:AFE_0002248 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A probe type is a classification datum that describes the type of probe used in a process. [Allotrope]" ; + + skos:prefLabel "probe type" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002300 + +af-r:AFR_0002300 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0002002 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002717 ; + owl:someValuesFrom af-e:AFE_0002248 + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "probe id" ; + + skos:definition "A probe identifier is a measurement device identifier that identifies some probe. [Allotrope]" ; + + skos:prefLabel "probe identifier" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002301 + +af-r:AFR_0002301 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001583 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002816 ; + owl:someValuesFrom af-q:AFQ_0000321 + ] ; + + af-x:AFX_0002808 , + ; + + rdfs:isDefinedBy ; + + skos:altLabel "relative permittivity (datum)" , + "relative permittivity result" ; + + skos:definition "A relative permittivity result is a quality quantification facet that quantifies the the ability of a medium composed of molecules of a given type to transmit an electric field. [CHEMINF]" ; + + skos:note "Relative permittivity is a chemical substance quality that reflects the ability of a medium composed of molecules of a given type to transmit an electric field." ; + + skos:prefLabel "relative permittivity" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002302 + +af-r:AFR_0002302 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000576 ; + + rdfs:isDefinedBy ; + + skos:definition "An impedance scan profile is a profile that quantifies the impedance spectrum of a material over time. [Allotrope]" ; + + skos:prefLabel "impedance scan profile" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002303 + +af-r:AFR_0002303 rdf:type owl:Class ; + + rdfs:subClassOf qb:DataSet , + [ rdf:type owl:Restriction ; + owl:onProperty [ owl:inverseOf af-x:AFX_0002737 + ] ; + owl:someValuesFrom af-r:AFR_0002307 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "An impedance scan data cube is a data cube that is a representation of an impedance scan result. [Allotrope]" ; + + skos:prefLabel "impedance scan data cube" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002304 + +af-r:AFR_0002304 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0002307 ; + + rdfs:isDefinedBy ; + + skos:altLabel "Δεmax" ; + + skos:definition "An impedance scan permittivity range is an impedance scan result that quantitates the difference in heights of low and high frequency in an impedance spectrum which correlates with the viable cell density. [Allotrope]" ; + + skos:prefLabel "impedance scan permittivity range" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002305 + +af-r:AFR_0002305 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0002307 ; + + rdfs:isDefinedBy ; + + skos:definition "An impedance scan slope is an impedance scan result that quantitates the slope (α) of the beta-dispersion at the characteristic frequency fc and is indicative of the cell diameter distribution. The steeper the slope , the more homogeneous the distribution. [Allotrope]" ; + + skos:prefLabel "impedance scan slope" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002306 + +af-r:AFR_0002306 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001732 , + af-r:AFR_0002307 ; + + rdfs:isDefinedBy ; + + skos:definition "An impedance scan characteristic frequency is an impedance scan result datum obtained from the infliction point of the impedance spectrum that provides an indication of the average cell diameter. The larger the cell diameter, the smaller the fc and vice-versa. [Allotrope]" ; + + skos:prefLabel "impedance scan characteristic frequency" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002307 + +af-r:AFR_0002307 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000207 ; + + rdfs:isDefinedBy ; + + skos:definition "An impedance scan result is an assay result that is the output of processing an impedance spectrum. [Allotrope]" ; + + skos:prefLabel "impedance scan result" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002308 + +af-r:AFR_0002308 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001072 ; + + af-x:AFX_0002808 ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:definition "A Molfile molecular structure is a molecular structure specified as an MDL Molfile. [edamontology.org]" ; + + skos:prefLabel "Molfile molecular structure" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002309 + +af-r:AFR_0002309 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000992 , + af-r:AFR_0002279 , + qb:DataSet , + [ rdf:type owl:Restriction ; + owl:onProperty [ owl:inverseOf af-x:AFX_0002737 + ] ; + owl:someValuesFrom af-r:AFR_0002247 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "Rn data cube" ; + + skos:definition "A normalized reporter data cube is a data cube that represents a plot of normalized reporter result against cycle. [Allotrope]" ; + + skos:prefLabel "normalized reporter data cube" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002310 + +af-r:AFR_0002310 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000992 , + af-r:AFR_0002279 , + qb:DataSet , + [ rdf:type owl:Restriction ; + owl:onProperty [ owl:inverseOf af-x:AFX_0002737 + ] ; + owl:someValuesFrom af-r:AFR_0002248 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "ΔRn data cube" ; + + skos:definition "A baseline corrected reporter data cube is a data cube that represents a plot of baseline corrected reporter result against cycle. [Allotrope]" ; + + skos:prefLabel "baseline corrected reporter data cube" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002311 + +af-r:AFR_0002311 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000984 ; + + rdfs:isDefinedBy ; + + skos:definition "A cycle count is a count of the number of iterations of a repeated process. [Allotrope]" ; + + skos:prefLabel "cycle count" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002312 + +af-r:AFR_0002312 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000576 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002816 ; + owl:someValuesFrom af-p:AFP_0003795 + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:definition "A heat flow profile is a profile that quantifies the heat flow through a material entity over time. [Allotrope]" ; + + skos:prefLabel "heat flow profile" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002313 + +af-r:AFR_0002313 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0002312 ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A total system heat flow profile is a profile that quantifies the heat flow through a system over time. [Allotrope]" ; + + skos:prefLabel "total system heat flow profile" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002314 + +af-r:AFR_0002314 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0002312 ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A reaction heat flow profile is a profile that quantifies the heat flow through a material entity with the reaction mixture role over time. [Allotrope]" ; + + skos:prefLabel "reaction heat flow profile" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002315 + +af-r:AFR_0002315 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001243 , + af-r:AFR_0002316 ; + + rdfs:isDefinedBy ; + + skos:altLabel "filament current setting" ; + + skos:definition "A source current setting is a current setting controlling the current supplied to a radiation source. [Allotrope]" ; + + skos:prefLabel "source current setting" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002316 + +af-r:AFR_0002316 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( af-r:AFR_0001505 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002704 ; + owl:someValuesFrom af-q:AFQ_0000314 + ] + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A current setting is a setting that specifies some current configuration of a current controlling or monitoring device, that controls or monitors the target electric current at the site of some system component. [Allotrope]" ; + + skos:prefLabel "current setting" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002317 + +af-r:AFR_0002317 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001243 , + af-r:AFR_0002318 ; + + rdfs:isDefinedBy ; + + skos:definition "An electron energy setting is a voltage setting controlling the voltage in a source to accelerate electrons to the specified eV kinetic energy. [Allotrope]" ; + + skos:prefLabel "electron energy setting" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002318 + +af-r:AFR_0002318 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( af-r:AFR_0001505 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002704 ; + owl:someValuesFrom af-q:AFQ_0000315 + ] + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A voltage setting is a setting that specifies some current configuration of a voltage controlling or monitoring device, that controls or monitors the target voltage at the site of some system component. [Allotrope]" ; + + skos:prefLabel "voltage setting" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002319 + +af-r:AFR_0002319 rdf:type owl:Class ; + + rdfs:subClassOf af-c:AFC_0000160 , + iao:_0000310 , + [ rdf:type owl:Restriction ; + owl:onProperty iao:_0000136 ; + owl:someValuesFrom [ owl:intersectionOf ( bfo:_0000027 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0002351 ; + owl:someValuesFrom [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000087 ; + owl:someValuesFrom af-rl:AFRL_0000127 + ] + ] + ) ; + rdf:type owl:Class + ] + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "analyte aggregation document" ; + + skos:definition "An analyte aggregate document is a document about an ordered collection of analytes. [Allotrope]" ; + + skos:prefLabel "analyte aggregate document" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002320 + +af-r:AFR_0002320 rdf:type owl:Class ; + + rdfs:subClassOf iao:_0000310 , + [ rdf:type owl:Restriction ; + owl:onProperty iao:_0000136 ; + owl:someValuesFrom [ owl:intersectionOf ( af-m:AFM_0000275 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000087 ; + owl:someValuesFrom af-rl:AFRL_0000127 + ] + ) ; + rdf:type owl:Class + ] + ] ; + + rdfs:isDefinedBy ; + + skos:definition "An analyte document is a document that is about some analyte. [Allotrope]" ; + + skos:prefLabel "analyte document" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002324 + +af-r:AFR_0002324 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001277 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002806 ; + owl:someValuesFrom af-e:AFE_0002250 + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A radiation source type is a classification datum that classifies the type of radiation source used in a process. [Allotrope]" ; + + skos:prefLabel "radiation source type" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002326 + +af-r:AFR_0002326 rdf:type owl:Class ; + + rdfs:subClassOf iao:_0000310 , + [ rdf:type owl:Restriction ; + owl:onProperty iao:_0000136 ; + owl:someValuesFrom af-p:AFP_0001787 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "NIR document" , + "near infra-red document" , + "near-infrared document" ; + + skos:definition "A near infrared document is a document that encompasses the information associated with a near-infrared spectroscopy process. [Allotrope]" ; + + skos:prefLabel "near infrared document" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002327 + +af-r:AFR_0002327 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001060 ; + + rdfs:isDefinedBy ; + + skos:altLabel "3-dimensional FTIR spectra" , + "3-dimensional FTIR spectrum" , + "3D FTIR spectra" , + "3D FTIR spectrum" , + "three dimensional FTIR spectra" , + "three dimensional FTIR spectrum" , + "three-dimensional FTIR spectra" ; + + skos:definition "A three-dimensional FTIR spectrum is a data distribution function that is a plot of absorbance or transmittance versus wavelength and versus time obtained by measuring the amount of radiation absorbed by a sample as a function of the wavelength of incident radiation from the infrared region (2.5–25 μm) and as a function of time. [Allotrope]" ; + + skos:prefLabel "three-dimensional FTIR spectrum" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002328 + +af-r:AFR_0002328 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001060 ; + + rdfs:isDefinedBy ; + + skos:altLabel "3-dimensional Raman spectra" , + "3-dimensional Raman spectrum" , + "3D Raman spectra" , + "3D Raman spectrum" , + "three dimensional Raman spectra" , + "three dimensional Raman spectrum" , + "three-dimensional Raman spectra" ; + + skos:definition "A three-dimensional Raman spectrum is a data distribution function that is a plot of Raman intensity versus wavelength and versus time obtained by the inelastic scattering of photons from a monochromatic light source by a sample as a function of time. [Allotrope]" ; + + skos:prefLabel "three-dimensional Raman spectrum" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002329 + +af-r:AFR_0002329 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001060 ; + + rdfs:isDefinedBy ; + + skos:altLabel "3-dimensional NIR spectra" , + "3-dimensional NIR spectrum" , + "3-dimensional near infra-red spectra" , + "3-dimensional near infra-red spectrum" , + "3-dimensional near infrared (NIR) spectra" , + "3-dimensional near infrared (NIR) spectrum" , + "3-dimensional near infrared spectra" , + "3D NIR spectra" , + "3D NIR spectrum" , + "3D near infra-red spectra" , + "3D near infra-red spectrum" , + "3D near infrared (NIR) spectra" , + "3D near infrared (NIR) spectrum" , + "3D near infrared spectra" , + "three dimensional NIR spectra" , + "three dimensional NIR spectrum" , + "three dimensional near infra-red spectra" , + "three dimensional near infra-red spectrum" , + "three dimensional near infrared (NIR) spectra" , + "three dimensional near infrared (NIR) spectrum" , + "three dimensional near infrared spectra" , + "three-dimensional NIR spectra" , + "three-dimensional NIR spectrum" , + "three-dimensional near infra-red spectra" , + "three-dimensional near infra-red spectrum" , + "three-dimensional near infrared (NIR) spectra" , + "three-dimensional near infrared (NIR) spectrum" , + "three-dimensional near infrared spectra" ; + + skos:definition "A three-dimensional near infrared spectrum is a data distribution function that is a plot of absorbance or transmittance versus wavelength and versus time obtained by measuring the amount of radiation absorbed by a sample as a function of the wavelength of incident radiation from the near infrared region (0.8-2 µm) and as a function of time. [Allotrope]" ; + + skos:prefLabel "three-dimensional near infrared spectrum" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002330 + +af-r:AFR_0002330 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001060 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "NIR spectra" , + "NIR spectrum" , + "near infra-red spectra" , + "near infra-red spectrum" , + "near infrared (NIR) spectra" , + "near infrared (NIR) spectrum" , + "near infrared spectra" ; + + skos:definition "A plot of absorbance or transmittance versus wavelength obtained by measuring the amount of radiation absorbed by a sample as a function of the wavelength of incident radiation from the near infrared region (0.8-2 µm). [Allotrope]" ; + + skos:prefLabel "near infrared spectrum" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002337 + +af-r:AFR_0002337 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000576 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002816 ; + owl:someValuesFrom af-p:AFP_0003798 + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "pH profile result" ; + + skos:definition "A pH profile is a profile that quantifies the pH of a material entity over time. [Allotrope]" ; + + skos:prefLabel "pH profile" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002338 + +af-r:AFR_0002338 rdf:type owl:Class ; + + rdfs:subClassOf af-c:AFC_0000160 , + iao:_0000310 , + [ rdf:type owl:Restriction ; + owl:onProperty iao:_0000136 ; + owl:someValuesFrom [ owl:intersectionOf ( bfo:_0000027 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0002351 ; + owl:someValuesFrom [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000087 ; + owl:someValuesFrom af-rl:AFRL_0000255 + ] + ] + ) ; + rdf:type owl:Class + ] + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "standard aggregate result" ; + + skos:definition "A standard aggregate document is a document that is about an ordered collection of standards. [Allotrope]" ; + + skos:prefLabel "standard aggregate document" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002339 + +af-r:AFR_0002339 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000207 ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A pH calibration slope is an assay result determined by the ratio of the slope of a pH calibration to the theoretical maximum, expressed as a percentage. [Allotrope]" ; + + skos:prefLabel "pH calibration slope" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002340 + +af-r:AFR_0002340 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000992 , + qb:DataSet , + [ rdf:type owl:Restriction ; + owl:onProperty [ owl:inverseOf af-x:AFX_0002737 + ] ; + owl:someValuesFrom af-r:AFR_0002337 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A pH data cube is a data cube that represents the pH of a material over time. [Allotrope]" ; + + skos:prefLabel "pH data cube" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002341 + +af-r:AFR_0002341 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000992 , + qb:DataSet , + [ rdf:type owl:Restriction ; + owl:onProperty [ owl:inverseOf af-x:AFX_0002737 + ] ; + owl:someValuesFrom af-r:AFR_0002053 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A reaction temperature data cube is a data cube that represents the reaction temperature over time. [Allotrope]" ; + + skos:prefLabel "reaction temperature data cube" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002342 + +af-r:AFR_0002342 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000992 , + qb:DataSet , + [ rdf:type owl:Restriction ; + owl:onProperty [ owl:inverseOf af-x:AFX_0002737 + ] ; + owl:someValuesFrom af-r:AFR_0002054 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A jacket temperature data cube is a data cube that represents the jacket temperature over time. [Allotrope]" ; + + skos:prefLabel "jacket temperature data cube" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002343 + +af-r:AFR_0002343 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000992 , + qb:DataSet , + [ rdf:type owl:Restriction ; + owl:onProperty [ owl:inverseOf af-x:AFX_0002737 + ] ; + owl:someValuesFrom af-r:AFR_0002060 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A stirring rate data cube is a data cube that represents the stirring rate over time. [Allotrope]" ; + + skos:prefLabel "stirring rate data cube" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002344 + +af-r:AFR_0002344 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000576 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002816 ; + owl:someValuesFrom af-p:AFP_0003796 + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "mass profile result" ; + + skos:definition "A mass profile is a profile that quantifies the mass of a material entity over time. [Allotrope]" ; + + skos:prefLabel "mass profile" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002345 + +af-r:AFR_0002345 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0002051 ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "purge gas flow rate profile result" ; + + skos:definition "A purge gas flow rate profile is a flow rate profile that quantifies the flow rate of gas with the role of purge gas being added to inert equipment over time. [Allotrope]" ; + + skos:prefLabel "purge gas flow rate profile" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002346 + +af-r:AFR_0002346 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001277 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002806 ; + owl:someValuesFrom [ owl:intersectionOf ( af-m:AFM_0000154 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000087 ; + owl:someValuesFrom af-rl:AFRL_0000542 + ] + ) ; + rdf:type owl:Class + ] + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A purge gas type is a classification datum that classifies the gas with the role of purge gas used in a rinsing process. [Allotrope]" ; + + skos:prefLabel "purge gas type" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002347 + +af-r:AFR_0002347 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000992 , + qb:DataSet , + [ rdf:type owl:Restriction ; + owl:onProperty [ owl:inverseOf af-x:AFX_0002737 + ] ; + owl:someValuesFrom af-r:AFR_0002345 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A purge gas flow rate data cube is a data cube that represents the flow rate of gas with the role of purge gas over time. [Allotrope]" ; + + skos:prefLabel "purge gas flow rate data cube" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002350 + +af-r:AFR_0002350 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000576 ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A chord length distribution profile is a profile of the distribution of chord lengths of particles over time. [Allotrope]" ; + + skos:prefLabel "chord length distribution profile" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002351 + +af-r:AFR_0002351 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000992 , + qb:DataSet , + [ rdf:type owl:Restriction ; + owl:onProperty [ owl:inverseOf af-x:AFX_0002737 + ] ; + owl:someValuesFrom af-r:AFR_0002350 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A chord length distribution data cube is a data cube that represents particle count binned by chord length over time. [Allotrope]" ; + + skos:prefLabel "chord length distribution data cube" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002352 + +af-r:AFR_0002352 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000207 ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A measured chord length result is an assay result quantitating a chord length of the observed particles before correcting for the refractive index of the solution and particle, backscattering, etc. [Allotrope]" ; + + skos:prefLabel "measured chord length result" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002353 + +af-r:AFR_0002353 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001243 ; + + rdfs:isDefinedBy ; + + skos:definition "A laser rotation speed setting is a control setting that specifies the angular velocity of the laser in a FBRM run over time. [Allotrope]" ; + + skos:prefLabel "laser rotation speed setting" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002354 + +af-r:AFR_0002354 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001243 ; + + rdfs:isDefinedBy ; + + skos:definition "A chord selection setting is a control setting for a FBRM run that optimizes the analysis for small primary particles or larger agglomerates. [Allotrope]" ; + + skos:prefLabel "chord selection setting" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002355 + +af-r:AFR_0002355 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001243 , + af-r:AFR_0002280 ; + + rdfs:isDefinedBy ; + + skos:definition "A stuck particle correction enabled setting is a control setting for a FBRM run that controls whether or not data analysis ignores stuck particles (those present in the same location of the laser path even as the laser rotates), which can correct for up to 10% of the particles being stuck. [Allotrope]" ; + + skos:prefLabel "stuck particle correction enabled setting" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002356 + +af-r:AFR_0002356 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000992 , + qb:DataSet , + [ rdf:type owl:Restriction ; + owl:onProperty [ owl:inverseOf af-x:AFX_0002737 + ] ; + owl:someValuesFrom af-r:AFR_0002075 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A laser rotation speed data cube is a data cube that represents the measured angular velocity of the laser in a FBRM run over time. [Allotrope]" ; + + skos:prefLabel "laser rotation speed data cube" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002357 + +af-r:AFR_0002357 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000576 ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "FTIR profile result" ; + + skos:definition "An FTIR profile is a profile that quantifies the absorbance by or transmittance through a material entity over time and by frequency in the infrared range. [Allotrope]" ; + + skos:prefLabel "FTIR profile" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002358 + +af-r:AFR_0002358 rdf:type owl:Class ; + + rdfs:subClassOf iao:_0000310 , + [ rdf:type owl:Restriction ; + owl:onProperty iao:_0000136 ; + owl:someValuesFrom af-p:AFP_0002666 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A background document is a document that encompasses the information associated with a background measurement. [Allotrope]" ; + + skos:prefLabel "background document" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002359 + +af-r:AFR_0002359 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000576 ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "Raman profile result" ; + + skos:definition "A Raman profile is a profile that quantifies the intensity of Raman scattering vs. Raman shift (cm-1) over time. [Allotrope]" ; + + skos:prefLabel "Raman profile" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002360 + +af-r:AFR_0002360 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000576 ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "NIR profile" , + "NIR profile result" , + "near infra-red profile" , + "near infra-red profile result" , + "near infrared profile result" , + "near-infrared profile" , + "near-infrared profile result" ; + + skos:definition "A near infrared profile is a profile that quantifies absorbed or transmitted radiation over time in the near infrared region (0.8-2 µm). [Allotrope]" ; + + skos:prefLabel "near infrared profile" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002362 + +af-r:AFR_0002362 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000576 ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "UV-VIS profile" , + "UV-VIS profile result" , + "UV-VIS spectroscopy profile" , + "UV-VIS spectroscopy profile result" , + "UV-Vis profile" , + "UV-Vis profile result" , + "UV-Vis spectroscopy profile" , + "UV-Vis spectroscopy profile result" , + "UV-vis profile" , + "UV-vis profile result" , + "UV-vis spectroscopy profile" , + "UV-vis spectroscopy profile result" , + "ultraviolet-visible profile result" , + "ultraviolet-visible spectroscopy profile result" , + "uv-vis profile" , + "uv-vis profile result" , + "uv-vis spectroscopy profile" , + "uv-vis spectroscopy profile result" ; + + skos:definition "An ultraviolet-visible spectroscopy profile is a profile that quantifies absorbed or transmitted radiation over time in the ultraviolet-visible region. [Allotrope]" ; + + skos:prefLabel "ultraviolet-visible spectroscopy profile" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002363 + +af-r:AFR_0002363 rdf:type owl:Class ; + + rdfs:subClassOf iao:_0000310 , + [ rdf:type owl:Restriction ; + owl:onProperty iao:_0000136 ; + owl:someValuesFrom af-p:AFP_0000955 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "UV-VIS document" , + "UV-VIS spectroscopy document" , + "UV-Vis document" , + "UV-Vis spectroscopy document" , + "UV-vis document" , + "UV-vis spectroscopy document" , + "ultraviolet-visible document" , + "uv-vis document" , + "uv-vis spectroscopy document" ; + + skos:definition "A ultraviolet-visible spectroscopy document is a document that encompasses the information associated with a UV-Vis spectroscopic run. [Allotrope]" ; + + skos:prefLabel "ultraviolet-visible spectroscopy document" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002364 + +af-r:AFR_0002364 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001277 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002806 ; + owl:someValuesFrom af-e:AFE_0000857 + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A spectrometer type is a classification datum that classifies the type of spectrometer used in a process. [Allotrope]" ; + + skos:prefLabel "spectrometer type" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002365 + +af-r:AFR_0002365 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000576 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002816 ; + owl:someValuesFrom af-p:AFP_0003797 + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "concentration profile result" ; + + skos:definition "A concentration profile is a profile that quantifies the concentration of a material entity over time. [Allotrope]" ; + + skos:prefLabel "concentration profile" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002366 + +af-r:AFR_0002366 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001583 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002816 ; + owl:someValuesFrom af-q:AFQ_0000319 + ] ; + + dct:license ; + + dct:rights ; + + dct:source "IUPAC. Compendium of Chemical Terminology, 2nd ed. (the \"Gold Book\"). Compiled by A. D. McNaught and A. Wilkinson. Blackwell Scientific Publications, Oxford (1997)" ; + + rdfs:isDefinedBy ; + + skos:definition "A chemical shift is a quality quantification facet quantifying the fractional variation of the resonance frequency of a nucleus in nuclear magnetic resonance (NMR) spectroscopy in consequence of its magnetic environment of a nucleus. The chemical shift of a nucleus, δ, is expressed as a ratio involving its frequency, ν_cpd, relative to that of a standard, ν_ref, and defined as: δ = (ν_cpd - ν_ref)/ν_ref. [IUPAC]" ; + + skos:prefLabel "chemical shift" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002367 + +af-r:AFR_0002367 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001277 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002806 ; + owl:someValuesFrom [ owl:intersectionOf ( chmo:_0000993 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000087 ; + owl:someValuesFrom af-rl:AFRL_0000344 + ] + ) ; + rdf:type owl:Class + ] + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "synthesis material role type" ; + + skos:definition "An analysis material role type is a classification datum that classifies the role of a portion of material in a reaction. [Allotrope]" ; + + skos:prefLabel "analysis material role type" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002368 + +af-r:AFR_0002368 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0002408 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002730 ; + owl:someValuesFrom af-rl:AFRL_0000312 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "molar ratio" ; + + skos:definition "An analyte molar ratio is a ratio quantification datum that quantifies the relative molar amount of an analyte to a reference entity. [Allotrope]" ; + + skos:prefLabel "analyte molar ratio" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002369 + +af-r:AFR_0002369 rdf:type owl:Class ; + + rdfs:subClassOf af-c:AFC_0000160 , + iao:_0000310 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0002351 ; + owl:someValuesFrom af-r:AFR_0002370 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A sample preparation aggregate document is a document that aggregates sample preparation documents. [Allotrope]" ; + + skos:prefLabel "sample preparation aggregate document" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002370 + +af-r:AFR_0002370 rdf:type owl:Class ; + + rdfs:subClassOf iao:_0000310 , + [ rdf:type owl:Restriction ; + owl:onProperty iao:_0000136 ; + owl:someValuesFrom af-p:AFP_0001159 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A sample preparation document is a document about a sample preparation process. [Allotrope]" ; + + skos:prefLabel "sample preparation document" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002371 + +af-r:AFR_0002371 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001583 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002816 ; + owl:someValuesFrom af-q:AFQ_0000209 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "purity (datum)" , + "purity result" ; + + skos:definition "A purity (datum) is a quality quantification facet that quantifies the purity of a portion of material. [Allotrope]" ; + + skos:prefLabel "purity" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002372 + +af-r:AFR_0002372 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000231 ; + + rdfs:isDefinedBy ; + + skos:definition "An NMR multiplet is a peak group in a NMR spectrum, all of which are associated with a single nuclei but for which the signal has been split due to interactions with neighboring nuclei. [Allotrope]" ; + + skos:prefLabel "NMR multiplet" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002373 + +af-r:AFR_0002373 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000984 ; + + rdfs:isDefinedBy ; + + skos:definition "An associated nuclei count is a count that indicates the number of nuclei associated with a NMR multiplet. [Allotrope]" ; + + skos:prefLabel "associated nuclei count" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002374 + +af-r:AFR_0002374 rdf:type owl:Class ; + + rdfs:subClassOf af-c:AFC_0000160 , + iao:_0000310 ; + + rdfs:isDefinedBy ; + + skos:altLabel "measurement aggregate result" ; + + skos:definition "A measurement aggregate document is a document about a collection of measurement documents. [Allotrope]" ; + + skos:prefLabel "measurement aggregate document" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002375 + +af-r:AFR_0002375 rdf:type owl:Class ; + + rdfs:subClassOf iao:_0000310 , + [ rdf:type owl:Restriction ; + owl:onProperty iao:_0000136 ; + owl:someValuesFrom af-p:AFP_0002294 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A measurement document is a document that encompasses the information associated with a measurement. [Allotrope]" ; + + skos:prefLabel "measurement document" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002389 + +af-r:AFR_0002389 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001243 ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "An aperture size setting temperature setting is a control setting that specifies the size of the aperture opening. [Allotrope]" ; + + skos:prefLabel "aperture size setting" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002390 + +af-r:AFR_0002390 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001243 ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A michelson interferometer acquisition mode setting is a control setting that specifies whether the interferogram measurement is single or double-sided and whether one or both scan directions are used in the measurement. [Allotrope]" ; + + skos:prefLabel "michelson interferometer acquisition mode setting" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002391 + +af-r:AFR_0002391 rdf:type owl:Class ; + + rdfs:subClassOf [ owl:intersectionOf ( af-r:AFR_0001277 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002806 ; + owl:someValuesFrom af-e:AFE_0002253 + ] + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A sample measurement interface type is a classification datum that classifies the sample measurement interface used by a measuring process. [Allotrope]" ; + + skos:prefLabel "sample measurement interface type" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002392 + +af-r:AFR_0002392 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001583 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002816 ; + owl:someValuesFrom af-q:AFQ_0000057 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A thermal conductivity is a quality quantification facet that quantifies the disposition to spontaneous transfer of thermal energy from a region of higher temperature to a region of lower temperature. [Allotrope]" ; + + skos:prefLabel "thermal conductivity" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002393 + +af-r:AFR_0002393 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001583 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002816 ; + owl:someValuesFrom af-q:AFQ_0000318 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A temperature rate is a quality quantification facet that quantifies the change in temperature over time in some material. [Allotrope]" ; + + skos:prefLabel "temperature rate" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002394 + +af-r:AFR_0002394 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001583 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002816 ; + owl:someValuesFrom af-q:AFQ_0000316 + ] ; + + dct:license ; + + dct:rights ; + + dct:source "IUPAC Quantities, Units and Symbols in Physical Chemistry, 1993" ; + + rdfs:isDefinedBy ; + + skos:altLabel "angle of optical rotation (datum)" , + "angle of optical rotation result" , + "circular birefringence (datum)" , + "circular birefringence result" , + "polarization rotation (datum)" , + "polarization rotation result" ; + + skos:definition "An angle of optical rotation result is a quality quantification facet quantifying the angle through which plane polarized light is rotated clockwise, as seen when facing the light source, in passing through an optically active medium. [IUPAC]" ; + + skos:prefLabel "angle of optical rotation" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002395 + +af-r:AFR_0002395 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001583 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002816 ; + owl:someValuesFrom af-q:AFQ_0000317 + ] ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:altLabel "specific optical rotation" , + "specific rotation result" ; + + skos:definition "A specific rotation result is is a quality quantification facet quantifying the change in orientation of monochromatic plane-polarized light, per unit distance–concentration product, as the light passes through a sample of a compound in solution. [Wikipedia]" ; + + skos:prefLabel "specific rotation" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002397 + +af-r:AFR_0002397 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001243 ; + + rdfs:isDefinedBy ; + + skos:definition "An end point determination setting is a control setting that specifies the end point of an analysis. [Allotrope]" ; + + skos:prefLabel "end point determination setting" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002398 + +af-r:AFR_0002398 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0002397 ; + + rdfs:isDefinedBy ; + + skos:definition "A maximum run time setting is an end point determination setting that specifies the maximum time of analysis. [Allotrope]" ; + + skos:prefLabel "maximum run time setting" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002399 + +af-r:AFR_0002399 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0002397 ; + + rdfs:isDefinedBy ; + + skos:definition "A change rate end point setting is an end point determination setting that specifies the maximum change in weight per unit time. [Allotrope]" ; + + skos:prefLabel "change rate end point setting" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002400 + +af-r:AFR_0002400 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0002397 ; + + rdfs:isDefinedBy ; + + skos:definition "An extrapolated weight end point setting is an end point determination setting based on extrapolating initial weight loss to a predicted final dry weight. [Allotrope]" ; + + skos:prefLabel "extrapolated weight end point setting" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002401 + +af-r:AFR_0002401 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0002415 ; + + rdfs:isDefinedBy ; + + skos:altLabel "heating profile setting" , + "temperature program setting" ; + + skos:definition "A temperature program setting is a control setting that specifies the heating profile to use to achieve the desired temperature. [Allotrope]" ; + + skos:prefLabel "temperature profile setting" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002408 + +af-r:AFR_0002408 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001101 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002730 ; + owl:someValuesFrom af-rl:AFRL_0000312 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "ratio quantification datum" ; + + skos:definition "A ratio quantification datum is a quantification datum that quantifies the relative magnitude as a ratio of the magnitude of the subject to that of the reference entity. [Allotrope]" ; + + skos:prefLabel "ratio quantification facet" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002409 + +af-r:AFR_0002409 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001844 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002816 ; + owl:someValuesFrom pato:_0001681 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "molar mass (datum)" , + "molar mass result" ; + + skos:definition "Molar mass is a mass that quantifies the mass of a homogeneous substance containing 6.02 x 10^23 atoms or molecules. [Allotrope]" ; + + skos:prefLabel "molar mass" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002410 + +af-r:AFR_0002410 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001606 , + [ rdf:type owl:Restriction ; + owl:onProperty iao:_0000219 ; + owl:someValuesFrom af-p:AFP_0002296 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "apodization filter" , + "apodization method" ; + + skos:definition "Apodization is the name of a filter method used in some data apodization. [Allotrope]" ; + + skos:prefLabel "apodization" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002411 + +af-r:AFR_0002411 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000923 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000553 ; + owl:someValuesFrom af-p:AFP_0003682 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "number of zero filling" ; + + skos:definition "The factor of the size increase by time domain zero padding the Fourier transformation. [Allotrope]" ; + + skos:prefLabel "zero filling factor" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002412 + +af-r:AFR_0002412 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001606 ; + + rdfs:isDefinedBy ; + + skos:definition "Phase correction is the name of a method for phase correction used to adjust FT spectra. [Allotrope]" ; + + skos:prefLabel "phase correction" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002413 + +af-r:AFR_0002413 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001583 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002816 ; + owl:someValuesFrom af-q:AFQ_0000323 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A thermal conductance is a quality quantification facet that quantifies the heat flow over time through a material of specific area and thickness. [Allotrope]" ; + + skos:prefLabel "thermal conductance" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002414 + +af-r:AFR_0002414 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001505 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002704 ; + owl:someValuesFrom bfo:_0000144 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A profile setting is a setting the specifies the change of a configuration of a system over time or a reaction to a change of a situation over time. [Allotrope]" ; + + skos:prefLabel "profile setting" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002415 + +af-r:AFR_0002415 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001243 , + af-r:AFR_0002414 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002704 ; + owl:someValuesFrom af-p:AFP_0003801 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A control profile setting is a profile setting that specifies how a system's configuration is controlled over time. [Allotrope]" ; + + skos:prefLabel "control profile setting" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002416 + +af-r:AFR_0002416 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000992 , + af-r:AFR_0002255 , + qb:DataSet , + [ rdf:type owl:Restriction ; + owl:onProperty [ owl:inverseOf af-x:AFX_0002737 + ] ; + owl:someValuesFrom af-r:AFR_0000263 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "NMR spectrum data cube" ; + + skos:definition "Nuclear magnetic resonance spectrum data cube is a data cube that is a representation of a nuclear magnetic resonance spectrum. [Allotrope]" ; + + skos:prefLabel "nuclear magnetic resonance spectrum data cube" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002417 + +af-r:AFR_0002417 rdf:type owl:Class ; + + rdfs:subClassOf iao:_0000310 , + [ rdf:type owl:Restriction ; + owl:onProperty iao:_0000136 ; + owl:someValuesFrom af-p:AFP_0001427 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "mass spectrometry result" ; + + skos:definition "A mass spectrometry document is a document that encompasses the information associated with a mass spectrometry run. [Allotrope]" ; + + skos:prefLabel "mass spectrometry document" . + + + +### http://purl.allotrope.org/ontologies/result#IAO_0000310 + +af-r:IAO_0000310 rdf:type owl:Class ; + + rdfs:subClassOf iao:_0000310 , + [ rdf:type owl:Restriction ; + owl:onProperty iao:_0000136 ; + owl:someValuesFrom [ owl:intersectionOf ( af-m:AFM_0000275 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000087 ; + owl:someValuesFrom af-rl:AFRL_0000411 + ] + ) ; + rdf:type owl:Class + ] + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A reference material document is a document that encompasses the information associated with the reference material in an analysis. [Allotrope]" ; + + skos:prefLabel "reference material document" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000003 + +af-rl:AFRL_0000003 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000095 , + af-rl:AFRL_0000293 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "analyst" ; + + skos:definition "Analyst is the role of a person which is an agent in the process of examination. [Allotrope]" ; + + skos:prefLabel "analyst role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000004 + +af-rl:AFRL_0000004 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000166 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "conditional role" ; + + skos:definition "Condition role is a contextual role of an information object that specifies a prerequisite. [Allotrope]" ; + + skos:prefLabel "condition role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000005 + +af-rl:AFRL_0000005 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000095 , + af-rl:AFRL_0000296 ; + + rdfs:isDefinedBy ; + + skos:altLabel "controller" ; + + skos:definition "Controller role is a controlling role of some material entity that is controlling some other object or a process. [Allotrope]" ; + + skos:prefLabel "controller role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000006 + +af-rl:AFRL_0000006 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000264 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "Denominator is the conceptual role of a scalar that indicates the number of equal parts into which the unit is divided. [Allotrope]" ; + + skos:prefLabel "denominator" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000007 + +af-rl:AFRL_0000007 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000060 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "An identifier role is the contextual role of an information content entity that identifies another entity. [Allotrope]" ; + + skos:prefLabel "identifier role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000008 + +af-rl:AFRL_0000008 rdf:type owl:Class ; + + owl:equivalentClass [ rdf:type owl:Class ; + owl:unionOf ( af-rl:AFRL_0000044 + af-rl:AFRL_0000160 + ) + ] ; + + rdfs:subClassOf [ owl:intersectionOf ( af-rl:AFRL_0000091 + [ rdf:type owl:Class ; + owl:unionOf ( af-rl:AFRL_0000166 + bfo:_0000023 + ) + ] + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + dct:source "Sowa, Knowledge Representation, Brooks Cole Publishing Co., 2000" , + "http://www.jfsowa.com/ontology/thematic.htm" ; + + rdfs:isDefinedBy ; + + skos:altLabel "input" ; + + skos:changeNote "2018-07-23 Removed parent class, same as this. [Allotrope]" ; + + skos:definition "A general role if its bearer is the input of the process that realizes the role. The bearer exists at the beginning of the process but not necessarily at its end. [Allotrope]" ; + + skos:editorialNote "formal definition needs FOL" ; + + skos:prefLabel "input role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000009 + +af-rl:AFRL_0000009 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000264 , + [ owl:intersectionOf ( af-rl:AFRL_0000264 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002734 ; + owl:someValuesFrom af-p:AFP_0003568 + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "interpolation" ; + + skos:definition "An interpolation is the contextual role of a quantity or number that has been the result of an interpolation. [Allotrope]" ; + + skos:prefLabel "interpolation role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000010 + +af-rl:AFRL_0000010 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( af-rl:AFRL_0000160 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000081 ; + owl:someValuesFrom [ owl:intersectionOf ( af-m:AFM_0000275 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000354 ; + owl:someValuesFrom bfo:_0000015 + ] + ) ; + rdf:type owl:Class + ] + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:subClassOf [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000052 ; + owl:someValuesFrom af-m:AFM_0000275 + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "material input" ; + + skos:definition "Material input is a role of a material that is an input in a process. [Allotrope]" ; + + skos:prefLabel "material input role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000011 + +af-rl:AFRL_0000011 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000126 ; + + rdfs:isDefinedBy ; + + skos:altLabel "mobile phase role" ; + + skos:definition "Mobile phase is the chromatographic phase role of a fluid material entity in a chromatography process to act as the fluid that percolates through or along the stationary bed in chromatography. [Allotrope, CHMO]" ; + + skos:prefLabel "mobile phase" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000012 + +af-rl:AFRL_0000012 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000060 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "Name role is a contextual role of an information content entity that refers to an entity by a non-identifying designation. [Allotrope]" ; + + skos:prefLabel "name role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000013 + +af-rl:AFRL_0000013 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000053 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "nominal value" ; + + skos:changeNote "2018-07-19 Changed pref label. [Allotrope]" ; + + skos:definition "A nominal value is a contextual role of an information content entity that states an asserted value, that is assumed to be true. [Allotrope]" ; + + skos:prefLabel "nominal datum" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000014 + +af-rl:AFRL_0000014 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000264 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "Numerator is the conceptual role of a scalar that indicates the number which is to be divided into equal parts. [Allotrope]" ; + + skos:prefLabel "numerator" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000015 + +af-rl:AFRL_0000015 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000064 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "objective" ; + + skos:definition "Objective role is the contextual role of an information object that describes an intent or purpose which is a situation at the process end point. [Allotrope]" ; + + skos:prefLabel "objective role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000016 + +af-rl:AFRL_0000016 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000017 , + af-rl:AFRL_0000042 ; + + rdfs:isDefinedBy ; + + skos:altLabel "upper operating limit" ; + + skos:changeNote "2018-07-31 Changed pref label. [Allotrope]" , + "2019-09-20 Added alt label. [Allotrope]" ; + + skos:definition "An operating maximum is the contextual role of a description or specification of an upper bound of quality of a system or environment during the operation of the system. [Allotrope]" ; + + skos:prefLabel "operating maximum" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000017 + +af-rl:AFRL_0000017 rdf:type owl:Class ; + + rdfs:subClassOf [ owl:intersectionOf ( af-rl:AFRL_0000166 + [ rdf:type owl:Restriction ; + owl:onProperty iao:_0000136 ; + owl:someValuesFrom af-re:AFRE_0000006 + ] + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + af-x:AFX_0002808 "http://purl.oclc.org/NET/ssnx/ssn#OperatingRange" ; + + rdfs:isDefinedBy ; + + skos:changeNote "2018-07-31 Changed pref label and definition, and moved to AFO. [Allotrope]" ; + + skos:definition "An operating range is the contextual role of a description or specification about a operating situation (qualities of a system or its environment) during the normal operation of the system. [Allotrope]" ; + + skos:prefLabel "operating range" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000018 + +af-rl:AFRL_0000018 rdf:type owl:Class ; + + owl:equivalentClass [ rdf:type owl:Class ; + owl:unionOf ( af-rl:AFRL_0000043 + af-rl:AFRL_0000161 + ) + ] ; + + rdfs:subClassOf [ owl:intersectionOf ( af-rl:AFRL_0000091 + [ rdf:type owl:Class ; + owl:unionOf ( af-rl:AFRL_0000166 + bfo:_0000023 + ) + ] + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + dct:source "Sowa, Knowledge Representation, Brooks Cole Publishing Co., 2000" , + "http://www.jfsowa.com/ontology/thematic.htm" ; + + rdfs:isDefinedBy ; + + skos:altLabel "output" , + "product" , + "product role" ; + + skos:changeNote "2018-07-23 Removed parent class, same as this. [Allotrope]" ; + + skos:definition "A general role if its bearer is the output of the process that realizes the role. The bearer exists at the end of the process but not necessarily at its beginning. [Allotrope]" ; + + skos:editorialNote "formal definition needs FOL" ; + + skos:prefLabel "output role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000019 + +af-rl:AFRL_0000019 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000044 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:altLabel "parameter" , + "parameter (process)" , + "process parameter" ; + + skos:changeNote "2018-12-19 Added alt labels. [Allotrope]" ; + + skos:definition "Parameter role is a data input role that is about some useful or critical characteristic of a particular system, for the purpose of identification, controlling, or evaluating the performance, status or conditions in the process. [Allotrope]" ; + + skos:prefLabel "parameter role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000020 + +af-rl:AFRL_0000020 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000167 , + af-rl:AFRL_0000289 ; + + rdfs:isDefinedBy ; + + skos:altLabel "material cleaned" , + "part cleaned" , + "part cleaned role" ; + + skos:changeNote "2019-10-02 Changed pref label. [Allotrope]" ; + + skos:definition "Material that is undergoing a cleaning process. [Allotrope]" ; + + skos:prefLabel "material cleaned role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000022 + +af-rl:AFRL_0000022 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000023 ; + + rdfs:isDefinedBy ; + + skos:altLabel "reference" ; + + skos:definition "A role inhered by a participant that is a reference for qualitative or quantitative comparison in relation to other entities. [Allotrope]" ; + + skos:example "measuring standard" ; + + skos:prefLabel "reference role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000026 + +af-rl:AFRL_0000026 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000288 ; + + rdfs:isDefinedBy ; + + skos:altLabel "selected object" , + "selected component" ; + + skos:changeNote "2018-07-23 Changed pref label. [Allotrope]" ; + + skos:definition "A selected object is the selection role of the object that is selected from the selection target. [Allotrope]" ; + + skos:prefLabel "selected object role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000027 + +af-rl:AFRL_0000027 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( af-rl:AFRL_0000026 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000081 ; + owl:someValuesFrom af-e:AFE_0000354 + ] + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:changeNote "2018-07-23 Made a defined class and moved to AFO. [Allotrope]" ; + + skos:definition "A device that is selected to perform a specific function in a process. [Allotrope]" ; + + skos:prefLabel "selected device" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000028 + +af-rl:AFRL_0000028 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000064 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "setting role" , + "setting value" ; + + skos:changeNote "2018-07-31 Changed definition and pref label. [Allotrope]" ; + + skos:definition "Setting datum is the contextual role of an information object that specifies some device or process setting. [Allotrope]" ; + + skos:prefLabel "setting datum" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000029 + +af-rl:AFRL_0000029 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000073 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A snapshot is the contextual role of an information object that is about a point in time within the bounds of a process. [Allotrope]" ; + + skos:prefLabel "snapshot" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000030 + +af-rl:AFRL_0000030 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000290 , + [ owl:intersectionOf ( af-rl:AFRL_0000167 + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000054 ; + owl:someValuesFrom af-p:AFP_0003299 + ] + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "specification subject" , + "specification target" ; + + skos:definition "A specification target is the role of a material entity that participates in a specifying process and is what the resulting specification is about. [Allotrope]" ; + + skos:prefLabel "specification target role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000032 + +af-rl:AFRL_0000032 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000126 ; + + rdfs:isDefinedBy ; + + skos:definition "A stationary phase is the chromatographic phase role of a solid, gel or liquid material that is the stationary component in chromatography. [Allotrope]" ; + + skos:prefLabel "stationary phase" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000033 + +af-rl:AFRL_0000033 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000073 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "Temporal mean is the contextual role of a quantity (quantity value or count) that describes a arithmetic mean of a quantity over time. [Allotrope]" ; + + skos:prefLabel "temporal mean" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000034 + +af-rl:AFRL_0000034 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000073 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "Time segment is a contextual role of some information object that is about a temporal part in the context of representation of a process. [Allotrope]" ; + + skos:prefLabel "time segment" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000035 + +af-rl:AFRL_0000035 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000369 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000081 ; + owl:someValuesFrom [ owl:intersectionOf ( af-m:AFM_0000275 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000353 ; + owl:someValuesFrom af-p:AFP_0003634 + ] + ) ; + rdf:type owl:Class + ] + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "sample" ; + + skos:definition "A sample role is a type of role whose bearer is a material entity that is the output of a sampling. [Allotrope]" ; + + skos:prefLabel "sample role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000039 + +af-rl:AFRL_0000039 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000166 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A contextual role that describes the way information is participating in some process from a causal dependency perspective. [Allotrope]" ; + + skos:prefLabel "processing role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000040 + +af-rl:AFRL_0000040 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000166 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "The role of some datum forming the maximum or minimum value in a range or collection of values. [Allotrope]" ; + + skos:prefLabel "bound role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000041 + +af-rl:AFRL_0000041 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000040 ; + + rdfs:isDefinedBy ; + + skos:definition "The role of a datum that is smaller than all data in an ordered range or collection. [Allotrope]" ; + + skos:prefLabel "lower bound" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000042 + +af-rl:AFRL_0000042 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000040 ; + + rdfs:isDefinedBy ; + + skos:definition "The role of a datum that is greater than all data in an ordered range or collection. [Allotrope]" ; + + skos:prefLabel "upper bound" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000043 + +af-rl:AFRL_0000043 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000018 , + af-rl:AFRL_0000039 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "data output" , + "result" ; + + skos:definition "Data output role is a type of contextual role of an information artifact that is the output of a process. [Allotrope]" ; + + skos:prefLabel "data output role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000044 + +af-rl:AFRL_0000044 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000008 , + af-rl:AFRL_0000039 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "data input" ; + + skos:definition "Data input role is a type of contextual role of an information artifact that is the input of a process. [Allotrope]" ; + + skos:prefLabel "data input role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000047 + +af-rl:AFRL_0000047 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000166 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "An aggregation role is a contextual role of an information entity that is participant of an aggregation process. [Allotrope]" ; + + skos:prefLabel "aggregation role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000048 + +af-rl:AFRL_0000048 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000047 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002726 ; + owl:someValuesFrom af-c:AFC_0000166 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "Aggregate role is the contextual role of an information content entity that is a collection of others. [Allotrope]" ; + + skos:prefLabel "aggregate role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000049 + +af-rl:AFRL_0000049 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000047 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002726 ; + owl:someValuesFrom af-c:AFC_0000167 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "Member role is the contextual role of an information object that is member of some collection. [Allotrope]" ; + + skos:prefLabel "member role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000053 + +af-rl:AFRL_0000053 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000166 , + [ owl:intersectionOf ( [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002726 ; + owl:someValuesFrom [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002699 ; + owl:someValuesFrom owl:Thing + ] + ] + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002731 ; + owl:someValuesFrom af-p:AFP_0003584 + ] + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "description" , + "description role" ; + + skos:definition "A role of an information content entity that is meant to describe an object. [Allotrope]" ; + + skos:prefLabel "descriptive purpose" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000054 + +af-rl:AFRL_0000054 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000053 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A description of the cause-consequence relation of processes. [Allotrope]" ; + + skos:prefLabel "causal role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000055 + +af-rl:AFRL_0000055 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000054 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "Cause is the causal role of an information content entity that is about something causally dependent for another thing. [Allotrope]" ; + + skos:prefLabel "cause" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000056 + +af-rl:AFRL_0000056 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000054 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "effect" ; + + skos:definition "Consequence is the causal role of an information content entity that is about something causally resultant from another thing. [Allotrope]" ; + + skos:prefLabel "consequence" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000057 + +af-rl:AFRL_0000057 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000004 , + af-rl:AFRL_0000094 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "An invariant is the contextual role of an information object that is about a situation that does not change during the whole process. [Allotrope]" ; + + skos:prefLabel "invariant" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000058 + +af-rl:AFRL_0000058 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000092 , + [ owl:intersectionOf ( af-rl:AFRL_0000004 + af-rl:AFRL_0000092 + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A post condition is the temporal contextual role of an information content entity that is about the situation, that is a condition so that a process can end or achieve its goal. [Allotrope]" ; + + skos:prefLabel "post condition" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000059 + +af-rl:AFRL_0000059 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000093 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A precondition is the temporal contextual role of an information content entity that is about the situation, that is a condition so that a process can start. [Allotrope]" ; + + skos:prefLabel "precondition" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000060 + +af-rl:AFRL_0000060 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000166 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002726 ; + owl:someValuesFrom [ rdf:type owl:Restriction ; + owl:onProperty iao:_0000219 ; + owl:someValuesFrom owl:Thing + ] + ] ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "designative role" ; + + skos:definition "A designative purpose is a type of contextual role of information artifacts that denote an entity in order to describe its characteristics. [Allotrope]" ; + + skos:prefLabel "designative purpose" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000062 + +af-rl:AFRL_0000062 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000060 ; + + rdfs:isDefinedBy ; + + skos:definition "An index role is a contextual role of an information object that denotes to another object that is part of an aggregation and it is the data output of some indexing process. [Allotrope]" ; + + skos:prefLabel "index role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000064 + +af-rl:AFRL_0000064 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000166 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002726 ; + owl:someValuesFrom [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002704 ; + owl:someValuesFrom owl:Thing + ] + ] ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "directive" , + "directive role" , + "specification" , + "specification datum" , + "specification role" , + "specified datum" , + "specified value" ; + + skos:changeNote "2018-07-31 Changed definition and pref label. [Allotrope]" ; + + skos:definition "A directive purpose or specification role is a type of contextual role of information content entities that are about an entity with a purpose to give directions. [Allotrope]" ; + + skos:prefLabel "directive purpose" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000066 + +af-rl:AFRL_0000066 rdf:type owl:Class ; + + rdfs:subClassOf [ owl:intersectionOf ( af-rl:AFRL_0000064 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002704 ; + owl:someValuesFrom af-re:AFRE_0000001 + ] + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "Specified action is the role of information object that specifies an activity. [Allotrope]" ; + + skos:prefLabel "specified action" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000067 + +af-rl:AFRL_0000067 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000064 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "Specified capability is the contextual role of an information object that specifies a capability. [Allotrope]" ; + + skos:prefLabel "specified capability" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000068 + +af-rl:AFRL_0000068 rdf:type owl:Class ; + + rdfs:subClassOf [ owl:intersectionOf ( af-rl:AFRL_0000064 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002704 ; + owl:someValuesFrom bfo:_0000019 + ] + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A specified quality is the contextual role of an information object that describes a quality as part of an specification. [Allotrope]" ; + + skos:prefLabel "specified quality" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000069 + +af-rl:AFRL_0000069 rdf:type owl:Class ; + + rdfs:subClassOf [ owl:intersectionOf ( af-rl:AFRL_0000064 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002704 ; + owl:someValuesFrom af-re:AFRE_0000003 + ] + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A specified situation is the contextual role of an information object that describes a portion of reality as part of a specification. [Allotrope]" ; + + skos:prefLabel "specified situation" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000071 + +af-rl:AFRL_0000071 rdf:type owl:Class ; + + rdfs:subClassOf [ owl:intersectionOf ( af-rl:AFRL_0000064 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002704 ; + owl:someValuesFrom af-re:AFRE_0000002 + ] + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "specified flow" , + "specified workflow" ; + + skos:definition "Specified procedure is the contextual role of an information object that specifies a flow of activities. [Allotrope]" ; + + skos:prefLabel "specified procedure" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000072 + +af-rl:AFRL_0000072 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000166 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A contextual role of information that describes some social rules that are imposed on the use of some entity, that a member of the social community has to follow. [Allotrope]" ; + + skos:prefLabel "prescriptive purpose" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000073 + +af-rl:AFRL_0000073 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000166 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A contextual role of information that is dependent on some temporal region or process boundary. [Allotrope]" ; + + skos:prefLabel "temporal role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000074 + +af-rl:AFRL_0000074 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000053 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "exception" ; + + skos:definition "A contextual role of information the describes an unexpected, unusual or unintended situation. [Allotrope]" ; + + skos:prefLabel "exception role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000075 + +af-rl:AFRL_0000075 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000277 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:changeNote "2018-12-19 Changed definition. [Allotrope]" ; + + skos:definition "A variable is the contextual role of some data that is part of some other data that is varied in a mathematical function or during data processing. [Allotrope]" ; + + skos:prefLabel "variable" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000077 + +af-rl:AFRL_0000077 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000075 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:definition "A dependent variable is a contextual role of an information artifact that represents the outputs or outcomes whose variation is being studied. [Wikipedia]" ; + + skos:prefLabel "dependent variable" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000078 + +af-rl:AFRL_0000078 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000075 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:definition "An independent variable is a contextual role of an information artifact that represents inputs or causes for variation of a dependent variable. In the experimental setting, the independent variable is controlled by the experimenter. Models and experiments test or determine the effects that the independent variables have on the dependent variables. [Wikipedia]" ; + + skos:prefLabel "independent variable" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000079 + +af-rl:AFRL_0000079 rdf:type owl:Class ; + + rdfs:subClassOf [ owl:intersectionOf ( af-rl:AFRL_0000064 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002704 ; + owl:someValuesFrom bfo:_0000144 + ] + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "Specified profile is the contextual role of an information object that specifies a process profile. [Allotrope]" ; + + skos:prefLabel "specified profile" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000080 + +af-rl:AFRL_0000080 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000053 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002726 ; + owl:someValuesFrom [ owl:intersectionOf ( iao:_0000030 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000353 ; + owl:someValuesFrom af-p:AFP_0003305 + ] + ) ; + rdf:type owl:Class + ] + ] ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "actual value" , + "observed value" ; + + skos:changeNote "2018-07-19 Changed pref label and definition. [Allotrope]" ; + + skos:definition "A actual value is the contextual role of an information content entity that is the direct or indirect output of some observation and describes some quality. [Allotrope]" ; + + skos:prefLabel "actual datum" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000083 + +af-rl:AFRL_0000083 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000023 ; + + rdfs:isDefinedBy ; + + skos:altLabel "port" ; + + skos:definition "A site that is part of a system has the port role if a component is connected to other components or systems at the site and material or energy can flow at the site. [Allotrope]" ; + + skos:prefLabel "port role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000085 + +af-rl:AFRL_0000085 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000023 ; + + rdfs:isDefinedBy ; + + skos:definition "A support role is a type of role whose bearer participates in a process in order to support the process so that it proceeds towards a secondary objective. [Allotrope]" ; + + skos:editorialNote "2018-12-05 Moved to AFO to maintain single inheritence [Allotrope]" ; + + skos:prefLabel "support role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000087 + +af-rl:AFRL_0000087 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000119 , + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000054 ; + owl:someValuesFrom [ rdf:type owl:Restriction ; + owl:onProperty ro:_0002224 ; + owl:someValuesFrom af-p:AFP_0003312 + ] + ] , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000081 ; + owl:someValuesFrom bfo:_0000040 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "The role inhered in a material entity that sends the transferred object in a transfer process. [Allotrope]" ; + + skos:prefLabel "sender role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000088 + +af-rl:AFRL_0000088 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000119 , + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000054 ; + owl:someValuesFrom [ rdf:type owl:Restriction ; + owl:onProperty ro:_0002230 ; + owl:someValuesFrom af-p:AFP_0003312 + ] + ] , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000081 ; + owl:someValuesFrom bfo:_0000040 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "The role inhered in a material entity that receives the transferred object in a transfer process. [Allotrope]" ; + + skos:prefLabel "receiver role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000090 + +af-rl:AFRL_0000090 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000119 ; + + rdfs:isDefinedBy ; + + skos:altLabel "medium" ; + + skos:definition "A transfer medium is the role of a material that carries the transferred flow. [Allotrope]" ; + + skos:prefLabel "transfer medium role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000091 + +af-rl:AFRL_0000091 rdf:type owl:Class ; + + owl:equivalentClass [ rdf:type owl:Class ; + owl:unionOf ( af-rl:AFRL_0000166 + bfo:_0000023 + ) + ] ; + + rdfs:subClassOf bfo:_0000002 ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "abstract role" ; + + skos:changeNote "2019-05-13 Moved under continuant. [Allotrope]" ; + + skos:definition "A general role is either a role that is realized in a process or a contextual role in that process. [Allotrope]" ; + + skos:editorialNote "This defined class covers roles as abstractions that can be borne by material and information entities." ; + + skos:prefLabel "general role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000092 + +af-rl:AFRL_0000092 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000029 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "At end is the contextual role of an information content entity that is about the end of a process. [Allotrope]" ; + + skos:prefLabel "at end" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000093 + +af-rl:AFRL_0000093 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000029 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "At start is the contextual role of an information content entity that is about the start of a process. [Allotrope]" ; + + skos:prefLabel "at start" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000094 + +af-rl:AFRL_0000094 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000073 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "During is the contextual role of an information object that is about something within a temporal range of a process. [Allotrope]" ; + + skos:prefLabel "during" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000095 + +af-rl:AFRL_0000095 rdf:type owl:Class ; + + rdfs:subClassOf [ owl:intersectionOf ( af-rl:AFRL_0000448 + bfo:_0000023 + ) ; + rdf:type owl:Class + ] ; + + dct:source "http://deseng.ryerson.ca/DesignScience/7a.html" ; + + rdfs:isDefinedBy ; + + skos:altLabel "agent" ; + + skos:changeNote "2018-12-05 Moved to AFO to maintain single inheritence [Allotrope]" ; + + skos:definition "The role of a participant that delivers the necessary effects as active participant in the process to the operand. [Allotrope]" ; + + skos:prefLabel "agent role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000096 + +af-rl:AFRL_0000096 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000023 ; + + rdfs:isDefinedBy ; + + skos:altLabel "component" ; + + skos:definition "An granular part of an object aggregate that plays the role of a system. [Allotrope]" ; + + skos:prefLabel "component role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000097 + +af-rl:AFRL_0000097 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000291 ; + + rdfs:isDefinedBy ; + + skos:altLabel "detection stimulant" ; + + skos:definition "A role inhered when the presence of the bearer indicates the presence of the detection target in a detection process. [Allotrope]" ; + + skos:prefLabel "detection stimulant role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000100 + +af-rl:AFRL_0000100 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( af-rl:AFRL_0000161 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000081 ; + owl:someValuesFrom [ owl:intersectionOf ( af-m:AFM_0000275 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000353 ; + owl:someValuesFrom bfo:_0000015 + ] + ) ; + rdf:type owl:Class + ] + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:subClassOf [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000052 ; + owl:someValuesFrom bfo:_0000040 + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "material output" ; + + skos:definition "Material output role is a role of a material that is participant at the end of a process. [Allotrope]" ; + + skos:prefLabel "material output role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000101 + +af-rl:AFRL_0000101 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000023 ; + + rdfs:isDefinedBy ; + + skos:altLabel "system" ; + + skos:definition "A role of an object aggregate that consists of multiple components that are causally integrated. [Allotrope]" ; + + skos:prefLabel "system role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000102 + +af-rl:AFRL_0000102 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000101 ; + + rdfs:isDefinedBy ; + + skos:definition "Parts of a system that are a building a system on its own. [Allotrope]" ; + + skos:prefLabel "subsystem role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000119 + +af-rl:AFRL_0000119 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000023 , + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000054 ; + owl:someValuesFrom af-p:AFP_0003312 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "transfer role" ; + + skos:definition "A role that is realized in some transfer process. [Allotrope]" ; + + skos:prefLabel "transferring role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000120 + +af-rl:AFRL_0000120 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000121 ; + + rdfs:isDefinedBy ; + + skos:definition "Storage medium is the role of a material or site where something is stored. [Allotrope]" ; + + skos:prefLabel "storage medium role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000121 + +af-rl:AFRL_0000121 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000023 , + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000054 ; + owl:someValuesFrom af-p:AFP_0003551 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A role that is realized in some storing process. [Allotrope]" ; + + skos:prefLabel "storage role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000124 + +af-rl:AFRL_0000124 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000288 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000354 ; + owl:someValuesFrom af-p:AFP_0003329 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "selection population" , + "selection set" , + "selection target" ; + + skos:definition "The selection target is the role of a participant in a selection process from which partitions are selected. [Allotrope]" ; + + skos:prefLabel "selection target role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000126 + +af-rl:AFRL_0000126 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000023 ; + + rdfs:isDefinedBy ; + + skos:definition "One of the portions of material between which the components to be separated are distributed in chromatography. [CHMO]" ; + + skos:prefLabel "chromatographic phase" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000127 + +af-rl:AFRL_0000127 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000293 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "analyte" ; + + skos:definition "The component of a system to be analyzed. [CHMO]" ; + + skos:prefLabel "analyte role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000146 + +af-rl:AFRL_0000146 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000023 ; + + rdfs:isDefinedBy ; + + skos:altLabel "bond" ; + + skos:definition "A system bond is the role of a site where two components are connected via their ports. At this site energy or material can flow. [Allotrope]" ; + + skos:prefLabel "system bond role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000147 + +af-rl:AFRL_0000147 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000083 ; + + rdfs:isDefinedBy ; + + skos:altLabel "source" ; + + skos:definition "A role of a site where material or energy is outgoing from the component. [Allotrope]" ; + + skos:prefLabel "out-port role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000148 + +af-rl:AFRL_0000148 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000083 ; + + rdfs:isDefinedBy ; + + skos:altLabel "target" ; + + skos:definition "A role of a site where material or energy is incoming into the component. [Allotrope]" ; + + skos:prefLabel "in-port role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000149 + +af-rl:AFRL_0000149 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000295 ; + + rdfs:isDefinedBy ; + + skos:definition "The role of a material that is the flow by which means a linking process is established. [Allotrope]" ; + + skos:prefLabel "linking medium role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000154 + +af-rl:AFRL_0000154 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( af-rl:AFRL_0000043 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002734 ; + owl:someValuesFrom af-p:AFP_0003282 + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:subClassOf af-rl:AFRL_0000053 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "calculated value" ; + + skos:changeNote "2018-07-19 Changed pref label. [Allotrope]" ; + + skos:definition "A datum that is the result of some calculation. [Allotrope]" ; + + skos:prefLabel "calculated datum" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000155 + +af-rl:AFRL_0000155 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000157 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A derived measure is a measure that is the outcome of some indirect measurement. The derived value is derived from base measures by calculations following a formula or algorithm. [Allotrope]" ; + + skos:prefLabel "derived measure" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000156 + +af-rl:AFRL_0000156 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000157 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A base measure is a measure that is the direct output of some measurement process. [Allotrope]" ; + + skos:prefLabel "base measure" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000157 + +af-rl:AFRL_0000157 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000080 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "measured value" ; + + skos:definition "A measure is an actual value that is the direct or indirect outcome of some measurement and refers to some metric. [Allotrope]" ; + + skos:prefLabel "measure" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000159 + +af-rl:AFRL_0000159 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000023 , + [ owl:intersectionOf ( bfo:_0000023 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000081 ; + owl:someValuesFrom [ owl:intersectionOf ( bfo:_0000040 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000086 ; + owl:someValuesFrom [ owl:intersectionOf ( bfo:_0000019 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000059 ; + owl:someValuesFrom af-r:AFR_0001004 + ] + ) ; + rdf:type owl:Class + ] + ] + ) ; + rdf:type owl:Class + ] + ] + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy , + ; + + skos:altLabel "signal role" ; + + skos:definition "A signal is a role of some material entity that disposed to provide information. In the physical world, any quantity exhibiting variation in time or variation in space (such as an image) is potentially a signal that might provide information on the status of a physical system, or convey a message between observers, among other possibilities. [Allotrope, Wikipedia]" ; + + skos:prefLabel "physical signal role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000160 + +af-rl:AFRL_0000160 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( bfo:_0000023 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000081 ; + owl:someValuesFrom [ owl:intersectionOf ( bfo:_0000040 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000354 ; + owl:someValuesFrom bfo:_0000015 + ] + ) ; + rdf:type owl:Class + ] + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:subClassOf af-rl:AFRL_0000008 ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "physical input" ; + + skos:definition "\"Physical input\" is a role of a material or energy that is input in a process. [Allotrope]" ; + + skos:prefLabel "physical input role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000161 + +af-rl:AFRL_0000161 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( bfo:_0000023 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000081 ; + owl:someValuesFrom [ owl:intersectionOf ( bfo:_0000040 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000353 ; + owl:someValuesFrom bfo:_0000015 + ] + ) ; + rdf:type owl:Class + ] + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:subClassOf af-rl:AFRL_0000018 ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "physical output" ; + + skos:definition "\"Physical input\" is a role of a material or energy that is input in a process. [Allotrope]" ; + + skos:prefLabel "physical output role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000164 + +af-rl:AFRL_0000164 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( af-rl:AFRL_0000011 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000081 ; + owl:someValuesFrom af-m:AFM_0000154 + ] + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "gaseous mobile phase role" ; + + skos:definition "Gaseous mobile phase is the mobile phase role of a gaseous material. [Allotrope]" ; + + skos:prefLabel "gaseous mobile phase" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000165 + +af-rl:AFRL_0000165 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( af-rl:AFRL_0000011 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000081 ; + owl:someValuesFrom af-m:AFM_0000401 + ] + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "Supercritical mobile phase is the mobile phase role of a supercritical fluid material. [Allotrope]" ; + + skos:prefLabel "supercritical mobile phase" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000166 + +af-rl:AFRL_0000166 rdf:type owl:Class ; + + rdfs:subClassOf iao:_0000030 , + [ owl:intersectionOf ( [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002726 ; + owl:someValuesFrom iao:_0000030 + ] + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002731 ; + owl:someValuesFrom bfo:_0000015 + ] + ) ; + rdf:type owl:Class + ] ; + + owl:disjointWith bfo:_0000023 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A contextual role is a representation of a specific interpretation of the information content object or of the circumstances that the information content object is referencing to. [Allotrope]" ; + + skos:example "objective of a specification" , + "parameter of a calculation" , + "result of a measurement" ; + + skos:prefLabel "contextual role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000167 + +af-rl:AFRL_0000167 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000023 ; + + dct:source "Hubka, Eder, Ernst, Design Science, Springer, 1996" ; + + rdfs:isDefinedBy ; + + skos:altLabel "operand" ; + + skos:definition "The role of a participant that is being changed in the process (passive participant) from an input state to an output state. [Allotrope]" ; + + skos:prefLabel "operand role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000169 + +af-rl:AFRL_0000169 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000049 ; + + rdfs:isDefinedBy ; + + skos:definition "Indexed member is the member role that has an index facet. [Allotrope]" ; + + skos:prefLabel "indexed member" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000170 + +af-rl:AFRL_0000170 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000049 ; + + rdfs:isDefinedBy ; + + skos:definition "Ordered member is a member role that has an ordering within the collection. [Allotrope]" ; + + skos:prefLabel "ordered member" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000171 + +af-rl:AFRL_0000171 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000035 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000081 ; + owl:someValuesFrom [ owl:intersectionOf ( af-m:AFM_0000275 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000354 ; + owl:someValuesFrom af-p:AFP_0002680 + ] + ) ; + rdf:type owl:Class + ] + ] ; + + af-x:AFX_0002808 ; + + rdfs:isDefinedBy ; + + skos:altLabel "experiment sample" ; + + skos:definition "An experiment sample is a role that is played by a material object of interest in an assay used to obtain generalizable information about the sample source. [Allotrope]" ; + + skos:prefLabel "experiment sample role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000211 + +af-rl:AFRL_0000211 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000484 ; + + rdfs:isDefinedBy ; + + skos:altLabel "coated material" , + "substrate" , + "substrate role" ; + + skos:definition "A coated material is a coating role of a material whose surface is being coated by another material which it covers. [Allotrope]" ; + + skos:prefLabel "coated material role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000212 + +af-rl:AFRL_0000212 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000484 ; + + rdfs:isDefinedBy ; + + skos:altLabel "coating" , + "coating medium" , + "coating medium role" ; + + skos:definition "A coating role is the role of a material that coats another material (the substrate). [Allotrope]" ; + + skos:prefLabel "coating role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000213 + +af-rl:AFRL_0000213 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000294 ; + + rdfs:isDefinedBy ; + + skos:altLabel "measurand" ; + + skos:definition "A measurand role is a measurement role of a material entity that is being measured. [Allotrope]" ; + + skos:prefLabel "measurand role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000216 + +af-rl:AFRL_0000216 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000085 , + af-rl:AFRL_0000344 ; + + rdfs:isDefinedBy ; + + skos:altLabel "additive" ; + + skos:definition "Additive is a role of material that is added to a mixture in order to achieve a supportive purpose. [Allotrope]" ; + + skos:prefLabel "additive role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000217 + +af-rl:AFRL_0000217 rdf:type owl:Class ; + + rdfs:subClassOf obi:_0000086 ; + + af-x:AFX_0002798 "false"^^xsd:boolean ; + + af-x:AFX_0002809 chebi:_35223 ; + + dct:license ; + + dct:rights ; + + dct:source "PAC, 1996, 68, 155 (Glossary of terms used in chemical kinetics, including reaction dynamics.)" ; + + rdfs:isDefinedBy ; + + skos:altLabel "catalyst" ; + + skos:definition "A catalyst role is a reagent role of a substance that increases the rate of a reaction without modifying the overall standard Gibbs energy change in the reaction; the process is called catalysis. The catalyst is both a reactant and product of the reaction. [IUPAC]" ; + + skos:prefLabel "catalyst role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000218 + +af-rl:AFRL_0000218 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000011 ; + + rdfs:isDefinedBy ; + + skos:definition "Effluent is a mobile phase eluting from a column. [Allotrope]" ; + + skos:prefLabel "effluent" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000219 + +af-rl:AFRL_0000219 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000011 ; + + rdfs:isDefinedBy ; + + skos:changeNote "2020-12-16 Rephrased definition [Allotrope]" ; + + skos:definition "A mobile phase that is analyte material coming from the chromatograph. [Allotrope]" ; + + skos:prefLabel "eluate" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000220 + +af-rl:AFRL_0000220 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000011 ; + + rdfs:isDefinedBy ; + + skos:definition "Eluent is a mobile phase entering a column to perform a separation of material. [Allotrope]" ; + + skos:prefLabel "eluent" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000221 + +af-rl:AFRL_0000221 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000023 ; + + rdfs:isDefinedBy ; + + skos:altLabel "debris" ; + + skos:definition "Debris is a role of material to be waste. [Allotrope]" ; + + skos:prefLabel "debris role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000223 + +af-rl:AFRL_0000223 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000289 ; + + dct:license ; + + dct:rights ; + + dct:source "PAC, 1972, 31, 577 (Manual of Symbols and Terminology for Physicochemical Quantities and Units, Appendix II: Definitions, Terminology and Symbols in Colloid and Surface Chemistry) on page 612" ; + + rdfs:isDefinedBy ; + + skos:altLabel "detergent" ; + + skos:definition "A detergent role is a cleaning role of a surface active agent (or a mixture containing one of more surface active agents) having cleaning properties in dilute solution. [IUPAC]" ; + + skos:prefLabel "detergent role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000224 + +af-rl:AFRL_0000224 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000298 ; + + rdfs:isDefinedBy ; + + skos:altLabel "diluent" ; + + skos:definition "Diluent is a role of material used to lessen the strength or flavor of a solution or mixture of another ingredient. [NCI]" ; + + skos:prefLabel "diluent role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000225 + +af-rl:AFRL_0000225 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000273 ; + + rdfs:isDefinedBy ; + + skos:altLabel "dispersant" ; + + skos:definition "A dispersant is either a non-surface active polymer or a surface-active substance added to a suspension, usually a colloid, to improve the separation of particles and to prevent settling or clumping. [Wikipedia]" ; + + skos:prefLabel "dispersant role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000226 + +af-rl:AFRL_0000226 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000345 ; + + af-x:AFX_0002809 chebi:_75324 ; + + rdfs:isDefinedBy ; + + skos:altLabel "excipient" ; + + skos:definition "Excipient is a role of a generally pharmacologically inactive substance that is formulated with the active ingredient of a medication. [ChEBI]" ; + + skos:prefLabel "excipient role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000228 + +af-rl:AFRL_0000228 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000362 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "filtrate" ; + + skos:definition "Filtrate is a role of liquid outcome of a filtration process that is commonly the mechanical or physical operation which is used for the separation of solids from fluids (liquids or gases) by interposing a medium through which only the fluid can pass. [Wikipedia]" ; + + skos:prefLabel "filtrate role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000229 + +af-rl:AFRL_0000229 rdf:type owl:Class ; + + rdfs:subClassOf obi:_0000086 ; + + rdfs:isDefinedBy ; + + skos:altLabel "intermedate reagent role" , + "intermediate" , + "intermediate reagent role" , + "intermediate role" , + "reaction intermediate" ; + + skos:definition "Intermediate role is a role of material that is formed from reactants (or preceding intermediates) and reacts further to give the directly observed products of a chemical reaction. [Wikipedia]" ; + + skos:prefLabel "reaction intermediate role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000230 + +af-rl:AFRL_0000230 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000023 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000081 ; + owl:someValuesFrom [ owl:intersectionOf ( af-m:AFM_0000275 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000353 ; + owl:someValuesFrom af-p:AFP_0003639 + ] + ) ; + rdf:type owl:Class + ] + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "marker" ; + + skos:definition "A marker is a role of material to allow for identification of an object of interest. [Allotrope]" ; + + skos:prefLabel "marker role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000231 + +af-rl:AFRL_0000231 rdf:type owl:Class ; + + rdfs:subClassOf obi:_0000086 ; + + rdfs:isDefinedBy ; + + skos:altLabel "reactant" , + "starting material" ; + + skos:definition "Reactant role is a role of a chemical entity that is present at the start of a reaction. [Allotrope]" ; + + skos:prefLabel "reactant role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000232 + +af-rl:AFRL_0000232 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000362 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + dct:license ; + + dct:rights ; + + dct:source "PAC, 1972, 31, 577 (Manual of Symbols and Terminology for Physicochemical Quantities and Units, Appendix II: Definitions, Terminology and Symbols in Colloid and Surface Chemistry) on page 608" ; + + rdfs:isDefinedBy ; + + skos:altLabel "retentate" ; + + skos:definition "The retentate role is the role of the material that is retained by a filtration process. [Allotrope]" ; + + skos:prefLabel "retentate role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000233 + +af-rl:AFRL_0000233 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000022 ; + + rdfs:isDefinedBy ; + + skos:altLabel "standard" , + "standard role" ; + + skos:definition "Standard material role is a role of material that is set up and established by authority as a reference material for the measure of quantity, weight, extent, value, or quality. [Allotrope]" ; + + skos:prefLabel "standard material role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000234 + +af-rl:AFRL_0000234 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000023 , + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000054 ; + owl:someValuesFrom af-p:AFP_0001916 + ] , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000081 ; + owl:someValuesFrom af-m:AFM_0000012 + ] ; + + dct:license ; + + dct:rights ; + + dct:source "IUPAC Compendium on Analytical Nomenclature, Definitive Rules 1997, 3rd Edition, IUPAC Orange Book, prepared for publication by J. Inczedy, T. Lengyel, and A.M. Ure, Blackwell Science, 1998" ; + + rdfs:isDefinedBy ; + + skos:altLabel "titrant" ; + + skos:definition "Titrant is a role of a solution containing the active agent with which a titration is made. [IUPAC]" ; + + skos:prefLabel "titrant role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000244 + +af-rl:AFRL_0000244 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000289 ; + + rdfs:isDefinedBy ; + + skos:altLabel "detergent" , + "detergent role" , + "washing agent" , + "washing agent role" ; + + skos:definition "Cleaning agent role is a role of material used for cleaning something. [Allotrope]" ; + + skos:prefLabel "cleaning agent role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000247 + +af-rl:AFRL_0000247 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000262 ; + + rdfs:isDefinedBy ; + + skos:altLabel "origin" , + "origin role" ; + + skos:changeNote "2018-08-10 Changed labels [Allotrope]" ; + + skos:definition "Origin is the contextual role of an information object that is about the spatio-temporal location at the beginning of a process that changes it. [Allotrope]" ; + + skos:prefLabel "origin datum" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000248 + +af-rl:AFRL_0000248 rdf:type owl:Class ; + + rdfs:subClassOf [ owl:intersectionOf ( af-rl:AFRL_0000166 + af-rl:AFRL_0000314 + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "relative datum" , + "relative value" ; + + skos:changeNote "2020-03-16 Changed pref label and definition. [Allotrope]" ; + + skos:definition "A relative datum role is the contextual role of a datum that is about a quantity or number that is the result of a ratio or difference calculation or an assertion of magnitude relative to a reference entity. [Allotrope]" ; + + skos:prefLabel "relative datum role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000249 + +af-rl:AFRL_0000249 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000344 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000081 ; + owl:someValuesFrom [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000354 ; + owl:someValuesFrom af-p:AFP_0001348 + ] + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "ingredient" ; + + skos:definition "Ingredient is a role of material that is used in a material combining process to produce a new material. [Allotrope]" ; + + skos:prefLabel "ingredient role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000250 + +af-rl:AFRL_0000250 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000264 , + af-rl:AFRL_0000442 ; + + rdfs:isDefinedBy ; + + skos:definition "The sum is the contextual role of numerical data that results from the addition of two or more numbers, amounts, or items. [Allotrope]" ; + + skos:prefLabel "sum" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000251 + +af-rl:AFRL_0000251 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000060 ; + + rdfs:isDefinedBy ; + + skos:definition "A version role is the contextual role of an information content entity that denotes a specific variant in the history. [Allotrope]" ; + + skos:prefLabel "version role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000252 + +af-rl:AFRL_0000252 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000035 ; + + rdfs:isDefinedBy ; + + skos:altLabel "validation" , + "validation sample" ; + + skos:definition "An validation sample role is a sample role of a material sample that is used for validation purposes. [Allotrope]" ; + + skos:prefLabel "validation sample role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000253 + +af-rl:AFRL_0000253 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000035 ; + + rdfs:isDefinedBy ; + + skos:altLabel "control" , + "control sample" ; + + skos:definition "An control sample role is a sample role of a material that does contain a known amount of analyte for control purposes. [Allotrope]" ; + + skos:prefLabel "control sample role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000254 + +af-rl:AFRL_0000254 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000035 , + af-rl:AFRL_0000493 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000081 ; + owl:someValuesFrom [ owl:intersectionOf ( af-m:AFM_0000275 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000056 ; + owl:someValuesFrom af-p:AFP_0002389 + ] + ) ; + rdf:type owl:Class + ] + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "calibration sample" ; + + skos:definition "An calibration sample role is a sample role of a material that does contain a known amount of substance for calibration purposes. [Allotrope]" ; + + skos:prefLabel "calibration sample role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000255 + +af-rl:AFRL_0000255 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000035 ; + + rdfs:isDefinedBy ; + + skos:altLabel "standard" , + "standard sample" ; + + skos:changeNote "2020-09-16 Changed definition. [Allotrope]" ; + + skos:definition "An standard sample role is a sample role of a material sample that does contain a known amount of standard material. [Allotrope]" ; + + skos:prefLabel "standard sample role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000256 + +af-rl:AFRL_0000256 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000035 ; + + rdfs:isDefinedBy ; + + skos:altLabel "unknown" , + "unknown sample" ; + + skos:definition "An unknown sample role is a sample role of a material of an unknown substance, or that does contain an unknown amount of analyte. [Allotrope]" ; + + skos:prefLabel "unknown sample role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000257 + +af-rl:AFRL_0000257 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000253 ; + + rdfs:isDefinedBy ; + + skos:altLabel "quality control" , + "quality control sample" ; + + skos:definition "An quality control sample role is a control sample role of a material that is used for purposes of quality control. [Allotrope]" ; + + skos:prefLabel "quality control sample role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000258 + +af-rl:AFRL_0000258 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000035 ; + + rdfs:isDefinedBy ; + + skos:altLabel "reference" , + "reference sample" ; + + skos:definition "An reference sample role is a sample role of a material that does contain a known amount of analyte. [Allotrope]" ; + + skos:prefLabel "reference sample role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000259 + +af-rl:AFRL_0000259 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000035 ; + + rdfs:isDefinedBy ; + + skos:altLabel "blank" , + "blank sample" , + "blank sample role" ; + + skos:definition "An blank role is a sample role of a material that does not contain any analyte. [Allotrope]" ; + + skos:prefLabel "blank role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000260 + +af-rl:AFRL_0000260 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000035 ; + + rdfs:isDefinedBy ; + + skos:altLabel "spike" , + "spike role" , + "spike sample" ; + + skos:definition "A spiked sample role is a sample role of a material that does contain a spike substance. [Allotrope]" ; + + skos:prefLabel "spiked sample role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000261 + +af-rl:AFRL_0000261 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000035 ; + + rdfs:isDefinedBy ; + + skos:altLabel "unspiked" , + "unspiked sample" ; + + skos:definition "An unspiked sample role is a sample role of a material sample that does not contain a spike substance. [Allotrope]" ; + + skos:prefLabel "unspiked sample role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000262 + +af-rl:AFRL_0000262 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000166 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "Spatio-temporal role is a type of contextual role of an information artifact that denotes an entity in a spatio-temporal context. [Allotrope]" ; + + skos:prefLabel "spatio-temporal role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000263 + +af-rl:AFRL_0000263 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000262 ; + + rdfs:isDefinedBy ; + + skos:altLabel "destination" , + "destination role" ; + + skos:changeNote "2018-08-10 Changed labels [Allotrope]" ; + + skos:definition "Destination is the contextual role of an information object that is about the spatio-temporal location at the end of a process that changes it. [Allotrope]" ; + + skos:prefLabel "destination datum" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000264 + +af-rl:AFRL_0000264 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000277 , + [ owl:intersectionOf ( af-rl:AFRL_0000166 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002731 ; + owl:someValuesFrom af-p:AFP_0003282 + ] + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "expression role" , + "term" , + "term role" ; + + skos:definition "A role of a mathematical information object as component of a mathematical formula. [Allotrope]" ; + + skos:prefLabel "term mathematical role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000269 + +af-rl:AFRL_0000269 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000274 ; + + rdfs:isDefinedBy ; + + skos:altLabel "solvent" ; + + skos:definition "Solvent is the role of a potion of liquid material when it dissolves a solute in order to produce a solution. [Allotrope]" ; + + skos:prefLabel "solvent role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000270 + +af-rl:AFRL_0000270 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000274 ; + + rdfs:isDefinedBy ; + + skos:altLabel "dissolved compound" , + "dissolved substance" , + "solute" , + "solvated compound" ; + + skos:definition "Solute is the role a portion of material when it is dissolved within a solution. [Allotrope]" ; + + skos:prefLabel "solute role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000271 + +af-rl:AFRL_0000271 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000273 ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:altLabel "discontinuous phase" , + "dispersed phase" ; + + skos:definition """The dispersed phase role is the dispersion role of a portion of material in a dispersion, that is distributed in the form of discrete discontinuities +(particles, droplets or bubbles), in a second immiscible phase that is +continuous. [NIST]""" ; + + skos:prefLabel "dispersed phase role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000272 + +af-rl:AFRL_0000272 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000273 ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:altLabel "continuous medium" , + "continuous medium role" , + "continuous phase" ; + + skos:definition """The continuous phase role is the dispersion role of a portion of material constituting the medium, a phase that exhibits continuity throughout the +dispersion. [NIST]""" ; + + skos:prefLabel "continuous phase role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000273 + +af-rl:AFRL_0000273 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000023 , + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000054 ; + owl:someValuesFrom af-p:AFP_0003640 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "The role of a portion of material that participates in a dispersion process to form a colloid. [Allotrope]" ; + + skos:prefLabel "dispersion role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000274 + +af-rl:AFRL_0000274 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000023 , + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000054 ; + owl:someValuesFrom af-p:AFP_0000112 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "The role of a portion of material that participates in a dissolution process to form a solution. [Allotrope]" ; + + skos:prefLabel "dissolution role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000275 + +af-rl:AFRL_0000275 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000159 ; + + rdfs:isDefinedBy ; + + skos:definition "The initial response is the role of an outgoing signal as it was generated raw without signal processing from a processing component. [Allotrope]" ; + + skos:prefLabel "initial response" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000276 + +af-rl:AFRL_0000276 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000159 ; + + rdfs:isDefinedBy ; + + skos:definition "The primary response is the role of an outgoing signal that serves the intended main function of the system. [Allotrope]" ; + + skos:prefLabel "primary response" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000277 + +af-rl:AFRL_0000277 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000166 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A contextual role that describes an interpretation in a mathematical model. [Allotrope]" ; + + skos:example "coordinate" , + "variable" ; + + skos:prefLabel "mathematical role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000278 + +af-rl:AFRL_0000278 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000281 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "abscissa" ; + + skos:definition "The x-coordinate is the Cartesian coordinate in the first dimension of a 2- or 3-dimensional Cartesian coordinate system. [Allotrope]" ; + + skos:prefLabel "x-coordinate" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000279 + +af-rl:AFRL_0000279 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000281 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "ordinate" ; + + skos:definition "The y-coordinate is the Cartesian coordinate in the second dimension of a 2- or 3-dimensional Cartesian coordinate system. [Allotrope]" ; + + skos:prefLabel "y-coordinate" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000280 + +af-rl:AFRL_0000280 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000277 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "The contextual role of a scalar as component of a vector or tuple in a coordinate system specifying a point in space. [Allotrope]" ; + + skos:prefLabel "coordinate" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000281 + +af-rl:AFRL_0000281 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000280 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:definition "A Cartesian coordinate is a coordinate in a Cartesian coordinate system, that specifies each point uniquely in an n-dimensional Euclidean space . These coordinates are equal, up to sign, to distances from the point to n mutually perpendicular hyperplanes. [Allotrope, Wikipedia]" ; + + skos:prefLabel "Cartesian coordinate" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000285 + +af-rl:AFRL_0000285 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000314 ; + + rdfs:isDefinedBy ; + + skos:altLabel "reference purpose" , + "reference role" ; + + skos:definition "A reference datum is the contextual role of some information content entity that is referenced in the context of another information content entity for the purpose of comparison. It describes or denotes an object that has the role of a reference role. [Allotrope]" ; + + skos:prefLabel "reference datum" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000286 + +af-rl:AFRL_0000286 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000073 , + af-rl:AFRL_0000285 ; + + rdfs:isDefinedBy ; + + skos:altLabel "temporal reference" ; + + skos:definition "The role of some data piece of information that acts as reference for stating relative time. [Allotrope]" ; + + skos:prefLabel "temporal reference role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000287 + +af-rl:AFRL_0000287 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000095 , + bfo:_0000023 ; + + rdfs:isDefinedBy ; + + skos:altLabel "operator" ; + + skos:definition "Operator is the role of a person which controls or uses a device in an agent role. [Allotrope]" ; + + skos:prefLabel "operator role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000288 + +af-rl:AFRL_0000288 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000023 , + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000054 ; + owl:someValuesFrom af-p:AFP_0003329 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A role which is played by a participant in a selection process. [Allotrope]" ; + + skos:prefLabel "selection role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000289 + +af-rl:AFRL_0000289 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( bfo:_0000023 + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000054 ; + owl:someValuesFrom af-p:AFP_0000161 + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:subClassOf bfo:_0000023 ; + + rdfs:isDefinedBy ; + + skos:definition "The role of a participant of a cleaning process. [Allotrope]" ; + + skos:prefLabel "cleaning role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000290 + +af-rl:AFRL_0000290 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000023 , + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000054 ; + owl:someValuesFrom af-p:AFP_0003299 + ] ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "about role" , + "information subject role" , + "information target role" ; + + skos:changeNote "2018-08-03 Change labels [Allotrope]" ; + + skos:definition "A role of an entity in some information producing process that produces information about this entity. [Allotrope]" ; + + skos:prefLabel "subject role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000291 + +af-rl:AFRL_0000291 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000023 , + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000054 ; + owl:someValuesFrom af-p:AFP_0000925 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "The role of a participant in a detecting process. [Allotrope]" ; + + skos:prefLabel "detection role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000292 + +af-rl:AFRL_0000292 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000291 ; + + rdfs:isDefinedBy ; + + skos:altLabel "detection target" ; + + skos:definition "The role inhered by being the objective of a detecting activity. [Allotrope]" ; + + skos:prefLabel "detection target role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000293 + +af-rl:AFRL_0000293 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000023 , + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000054 ; + owl:someValuesFrom af-p:AFP_0003491 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A role of a participant in an analysis assay. [Allotrope]" ; + + skos:prefLabel "analysis role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000294 + +af-rl:AFRL_0000294 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000023 , + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000054 ; + owl:someValuesFrom af-p:AFP_0002294 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A role of a participant in a measurement. [Allotrope]" ; + + skos:prefLabel "measurement role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000295 + +af-rl:AFRL_0000295 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000023 , + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000054 ; + owl:someValuesFrom af-p:AFP_0003358 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A role of a participant in a linking process. [Allotrope]" ; + + skos:prefLabel "linking role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000296 + +af-rl:AFRL_0000296 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000023 , + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000054 ; + owl:someValuesFrom af-p:AFP_0003359 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A role of a participant in a controlling process. [Allotrope]" ; + + skos:prefLabel "controlling role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000297 + +af-rl:AFRL_0000297 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000296 ; + + rdfs:isDefinedBy ; + + skos:altLabel "control target" , + "control target role" , + "controlled object" ; + + skos:definition "Controlled object is the role of a material entity that is being controlled by a controller in a controlling process. [Allotrope]" ; + + skos:prefLabel "controlled object role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000298 + +af-rl:AFRL_0000298 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000023 , + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000054 ; + owl:someValuesFrom af-p:AFP_0000785 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "The role of a portion of material that participates in a dilution process. [Allotrope]" ; + + skos:prefLabel "dilution role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000299 + +af-rl:AFRL_0000299 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000043 ; + + rdfs:isDefinedBy ; + + skos:altLabel "result" ; + + skos:definition "Result role is a data output role that applies to new information produced by a process. [Allotrope]" ; + + skos:prefLabel "result role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000312 + +af-rl:AFRL_0000312 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000248 ; + + rdfs:isDefinedBy ; + + skos:altLabel "ratio datum" , + "ratio value" ; + + skos:changeNote "2020-03-16 Changed pref label and definition. [Allotrope]" ; + + skos:definition "A ratio datum role is a relative datum role that expresses the relative magnitude as a ratio of the magnitude of the subject to that of the reference entity. [Allotrope]" ; + + skos:prefLabel "ratio datum role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000313 + +af-rl:AFRL_0000313 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000248 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "difference datum" , + "difference value" ; + + skos:changeNote "2020-03-16 Changed pref label and definition. [Allotrope]" ; + + skos:definition "A difference datum role is a relative datum role that expresses the relative magnitude as a difference or interval of the magnitude of the subject to that of the reference entity. [Allotrope]" ; + + skos:prefLabel "difference datum role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000314 + +af-rl:AFRL_0000314 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000166 ; + + rdfs:isDefinedBy ; + + skos:definition "A relation role is a contextual role of an information content entity that is about a relation of the subject of the information content entity to another entity. [Allotrope]" ; + + skos:prefLabel "relation role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000316 + +af-rl:AFRL_0000316 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000170 ; + + rdfs:isDefinedBy ; + + skos:altLabel "first" ; + + skos:definition "A first member is an ordered member that has no predecessor in the aggregate. [Allotrope]" ; + + skos:prefLabel "first member" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000317 + +af-rl:AFRL_0000317 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000170 ; + + rdfs:isDefinedBy ; + + skos:altLabel "last" ; + + skos:definition "A last member is an ordered member that has no successor in the aggregate. [Allotrope]" ; + + skos:prefLabel "last member" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000319 + +af-rl:AFRL_0000319 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000277 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002726 ; + owl:someValuesFrom [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002734 ; + owl:someValuesFrom af-p:AFP_0003634 + ] + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A statistical role is a contextual role of data in statistics. [Allotrope]" ; + + skos:prefLabel "statistical role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000320 + +af-rl:AFRL_0000320 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000328 ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:altLabel "arithmetic mean" , + "average" , + "average role" , + "mean" , + "mean role" ; + + skos:changeNote "2020-09-18 Changed pref label. [Allotrope]" ; + + skos:definition "The arithmetic mean is a statistical datum role of a datum that is the sum of a collection of numbers divided by the number of numbers in the collection. [Wikipedia]" ; + + skos:prefLabel "arithmetic mean role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000321 + +af-rl:AFRL_0000321 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000328 ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:altLabel "median" ; + + skos:changeNote "2020-09-18 Changed pref label. [Allotrope]" ; + + skos:definition "The median role is a statistical datum role that denotes the value separating the higher half of a data sample, a population, or a probability distribution, from the lower half. [Wikipedia]" ; + + skos:prefLabel "median role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000322 + +af-rl:AFRL_0000322 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000328 ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:altLabel "skewness" ; + + skos:changeNote "2020-09-18 Changed pref label. [Allotrope]" ; + + skos:definition "Skewness role is a statistical datum role of a datum that is a measure of the asymmetry of the probability distribution of a real-valued random variable about its mean. The skewness value can be positive or negative, or undefined. [Wikipedia]" ; + + skos:prefLabel "skewness role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000323 + +af-rl:AFRL_0000323 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000328 ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:altLabel "variance" ; + + skos:changeNote "2020-09-18 Changed pref label. [Allotrope]" ; + + skos:definition "The variance role is a statistical datum role of a datum that denotes the expectation of the squared deviation of a random variable from its mean. [Wikipedia]" ; + + skos:prefLabel "variance role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000324 + +af-rl:AFRL_0000324 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000319 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002726 ; + owl:someValuesFrom af-c:AFC_0000166 + ] ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:definition "A statistical sample role is the contextual role of a subset of a statistical population that is chosen to represent the population in a statistical analysis. [Wikipedia]" ; + + skos:prefLabel "statistical sample role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000325 + +af-rl:AFRL_0000325 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000319 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002726 ; + owl:someValuesFrom af-c:AFC_0000166 + ] ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:altLabel "population" , + "population role" , + "statistical population" ; + + skos:definition "A statistical population role is the statistical role of a set of similar items or events which is of interest for some question or experiment (the statistical population). A statistical population can be a group of existing entities or a hypothetical and potentially infinite group of entities conceived as a generalization from experience. [Wikipedia]" ; + + skos:example "the class of living cells is the population role in the 'average living cell diameter' result datum of a cell counter result" ; + + skos:prefLabel "statistical population role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000326 + +af-rl:AFRL_0000326 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000319 ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:altLabel "aleatory variable" , + "random quantity" , + "stochastic variable" ; + + skos:definition "In probability and statistics, a random variable, random quantity, aleatory variable, or stochastic variable is a variable whose possible values are outcomes of a random phenomenon. [Wikipedia]" ; + + skos:prefLabel "random variable" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000328 + +af-rl:AFRL_0000328 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000319 , + af-rl:AFRL_0000442 ; + + rdfs:isDefinedBy ; + + skos:altLabel "statistic" , + "statistic datum" , + "statistical result" ; + + skos:changeNote "2020-09-18 Changed pref label. [Allotrope]" ; + + skos:definition "A statistic datum is the summary output of descriptive statistics on a statistical population. [Allotrope]" ; + + skos:prefLabel "statistic datum role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000330 + +af-rl:AFRL_0000330 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000064 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002704 ; + owl:someValuesFrom af-re:AFRE_0000008 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "trigger value" ; + + skos:definition "An trigger datum is the role of a datum that specifies some situation about a system or environment participating in a process that should trigger the start of another process. [Allotrope]" ; + + skos:prefLabel "trigger datum" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000332 + +af-rl:AFRL_0000332 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000166 , + [ rdf:type owl:Restriction ; + owl:onProperty iao:_0000136 ; + owl:someValuesFrom af-re:AFRE_0000005 + ] ; + + af-x:AFX_0002808 ; + + rdfs:isDefinedBy ; + + skos:definition "An survival range is the contextual role of an description or specification of about an environment in which the operation of a system can or should operate without damaging the system. [Allotrope]" ; + + skos:prefLabel "survival range" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000333 + +af-rl:AFRL_0000333 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000330 ; + + rdfs:isDefinedBy ; + + skos:altLabel "alert value" ; + + skos:definition "An alert datum is a trigger datum that specifies a trigger that initiates a notification process that warns about an unintended situation. [Allotrope]" ; + + skos:prefLabel "alert datum" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000335 + +af-rl:AFRL_0000335 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000159 ; + + rdfs:isDefinedBy ; + + skos:definition "Reference signal is the role of a signal that relates to another signal as reference for comparison. [Allotrope]" ; + + skos:prefLabel "reference signal" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000336 + +af-rl:AFRL_0000336 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000277 ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:altLabel "domain" , + "domain (mathematics)" ; + + skos:changeNote "2018-12-19 Changed pref label. [Allotrope]" ; + + skos:definition "A domain is the mathematical role of the set a function is applied on. [Allotrope]" ; + + skos:prefLabel "domain (math)" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000337 + +af-rl:AFRL_0000337 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000277 ; + + rdfs:isDefinedBy ; + + skos:altLabel "codomain" , + "codomain (mathematics)" ; + + skos:changeNote "2018-12-19 Changed pref label. [Allotrope]" ; + + skos:definition "A codomain is the mathematical role of the set a function maps to. [Allotrope]" ; + + skos:prefLabel "codomain (math)" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000339 + +af-rl:AFRL_0000339 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000011 ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "The liquid mobile phase is a role of a liquid material that percolates through the stationary bed in chromatography. [Allotrope, CHMO]" ; + + skos:prefLabel "liquid mobile phase" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000340 + +af-rl:AFRL_0000340 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000095 , + af-rl:AFRL_0000291 ; + + rdfs:isDefinedBy ; + + skos:altLabel "detector" ; + + skos:definition "The detector role is a detection role of a material entity that is detecting some other entity. [Allotrope]" ; + + skos:prefLabel "detector role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000344 + +af-rl:AFRL_0000344 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000023 , + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000054 ; + owl:someValuesFrom af-p:AFP_0001348 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A synthesis role is a role of a material that is participating in a synthesis (material conversion) process. [Allotrope]" ; + + skos:prefLabel "synthesis role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000345 + +af-rl:AFRL_0000345 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000344 ; + + rdfs:isDefinedBy ; + + skos:definition "A formulation role is a role of a material that is participating in a formulation process. [Allotrope]" ; + + skos:prefLabel "formulation role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000347 + +af-rl:AFRL_0000347 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000271 ; + + rdfs:isDefinedBy ; + + skos:definition "Particulate phase role is the role of the particles dispersed in a gel, sol or aerosol. [NIST, Allotrope]" ; + + skos:prefLabel "particulate phase" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000351 + +af-rl:AFRL_0000351 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000345 ; + + rdfs:isDefinedBy ; + + skos:altLabel "API" , + "active pharmaceutical ingredient" , + "drug substance" , + "drug substance role" ; + + skos:changeNote "2020-06-22 Add alt labels. [Allotrope]" ; + + skos:definition "The role of a material in a drug product that is biologically active when interacting with other components of the drug product, other potential drug products, or the chemistry of the body into which the drug will be applied. [Allotrope]" ; + + skos:prefLabel "active pharmaceutical ingredient role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000352 + +af-rl:AFRL_0000352 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000035 ; + + rdfs:isDefinedBy ; + + skos:altLabel "specimen" ; + + skos:definition "Specimen role is the sample role of a prepared fraction of a portion of material that is analyzed in a particular experiment. [Allotrope]" ; + + skos:prefLabel "specimen role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000359 + +af-rl:AFRL_0000359 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000344 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000081 ; + owl:someValuesFrom [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000353 ; + owl:someValuesFrom af-p:AFP_0001348 + ] + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "by-product" ; + + skos:definition "A material role of an expected but not desired product of a synthesis. [Allotrope]" ; + + skos:example "the leaving group in a de-protection step." ; + + skos:prefLabel "by-product role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000360 + +af-rl:AFRL_0000360 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000344 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000081 ; + owl:someValuesFrom [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000353 ; + owl:someValuesFrom af-p:AFP_0001348 + ] + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "chemical product" , + "product" ; + + skos:definition "A role of a material that is intended and desired to be produced in a synthesis. [Allotrope]" ; + + skos:prefLabel "product role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000361 + +af-rl:AFRL_0000361 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000360 ; + + rdfs:isDefinedBy ; + + skos:altLabel "batch" , + "lot" , + "lot role" ; + + skos:definition "Batch role is a product role of a portion of material that is intended to have uniform character and quality, within specified limits, and is produced according to a single manufacturing order during the same cycle of manufacture. [Allotrope, CFR21]" ; + + skos:prefLabel "batch role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000362 + +af-rl:AFRL_0000362 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000023 , + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000054 ; + owl:someValuesFrom af-p:AFP_0001530 + ] ; + + rdfs:isDefinedBy ; + + skos:changeNote "2019-08-27 Fixed OWL definition, bug #694. [Allotrope]" ; + + skos:definition "A filtration role is a role of a material in a filtration process. [Allotrope]" ; + + skos:prefLabel "filtration role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000363 + +af-rl:AFRL_0000363 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000244 ; + + rdfs:isDefinedBy ; + + skos:altLabel "flush" , + "rinse" , + "rinse solution" , + "rinsing agent" , + "rinsing role" , + "rinsing solution" ; + + skos:changeNote "2019-09-20 Changed definition. [Allotrope]" ; + + skos:definition "The rinse solution role is a cleaning agent role of a fluid used to flush something in order to remove contaminants. [Allotrope]" ; + + skos:prefLabel "rinse solution role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000364 + +af-rl:AFRL_0000364 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000344 ; + + rdfs:isDefinedBy ; + + skos:altLabel "impurity" ; + + skos:definition "A material role for any component of material that is not part of the defined product at the particular stage of manufacture or storage. [Allotrope]" ; + + skos:example "For example a starting material is not an impurity at the start of a reaction but it is an impurity after the final purification step." ; + + skos:prefLabel "impurity role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000365 + +af-rl:AFRL_0000365 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000364 , + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000054 ; + owl:someValuesFrom af-p:AFP_0003641 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "degradation product" ; + + skos:definition "A degradation product is an impurity resulting from a chemical change in the drug substance brought about during manufacture and/or storage of the new drug product by the effect of, for example, light, temperature, pH, water, or by reaction with an excipient and/or the immediate container closure system. [ICH-Q3B]" ; + + skos:prefLabel "degradation product role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000366 + +af-rl:AFRL_0000366 rdf:type owl:Class ; + + rdfs:subClassOf [ owl:intersectionOf ( af-rl:AFRL_0000365 + af-rl:AFRL_0000427 + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "unidentified degradation product" ; + + skos:definition "A degradation product role for which a structural characterization has not been achieved and that is defined solely by qualitative analytical properties (e.g., chromatographic retention time). [ICH-Q3A]" ; + + skos:prefLabel "unidentified degradation product role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000367 + +af-rl:AFRL_0000367 rdf:type owl:Class ; + + rdfs:subClassOf [ owl:intersectionOf ( af-rl:AFRL_0000365 + af-rl:AFRL_0000428 + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "unspecified degradation product" ; + + skos:definition "A degradation product role that is limited by a general acceptance criterion, but not individually listed with its own specific acceptance criterion, in the new drug product specification. [ICH-Q3A]" ; + + skos:prefLabel "unspecified degradation product role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000368 + +af-rl:AFRL_0000368 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000166 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002726 ; + owl:someValuesFrom [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002806 ; + owl:someValuesFrom owl:Thing + ] + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "classification role" ; + + skos:definition "A contextual role of information that classifies some of some entity into a category, class or schema. [Allotrope]" ; + + skos:prefLabel "classification purpose" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000369 + +af-rl:AFRL_0000369 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000023 , + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000054 ; + owl:someValuesFrom af-p:AFP_0003634 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A sampling role is a role of an object aggregate or a member of that aggregate that participates in a sampling process on the aggregate. [Allotrope]" ; + + skos:prefLabel "sampling role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000370 + +af-rl:AFRL_0000370 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000369 ; + + rdfs:isDefinedBy ; + + skos:altLabel "population" ; + + skos:definition "The population role is the sampling role of the object aggregate that is object of the sampling. [Allotrope]" ; + + skos:note "The statistical population contextual role is the related contextual role of an information object describing the population." ; + + skos:prefLabel "population role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000371 + +af-rl:AFRL_0000371 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000369 ; + + rdfs:isDefinedBy ; + + skos:altLabel "sample set" ; + + skos:definition "The sample set role is the role of the partition of the population object aggregate that was selected in the sampling process. [Allotrope]" ; + + skos:prefLabel "sample set role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000373 + +af-rl:AFRL_0000373 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000166 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A spatial role is the contextual role of some information context object that is about spatial location, orientation, or relative positioning. [Allotrope]" ; + + skos:example "left, right, above, below, inside, outside, parallel" ; + + skos:prefLabel "spatial role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000402 + +af-rl:AFRL_0000402 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000023 ; + + rdfs:isDefinedBy ; + + skos:definition "Role that a organizational entity plays leader or formal head of the organization. [W3C ORG]" ; + + skos:prefLabel "head" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000403 + +af-rl:AFRL_0000403 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000023 ; + + af-x:AFX_0002808 org:Post ; + + rdfs:isDefinedBy ; + + skos:definition "A post is some position within an organization that exists independently of the person or persons filling it. Posts may be used to represent situations where a person is a member of an organization ex officio. [W3C ORG]" ; + + skos:example "the Secretary of State for Scotland is part of UK Cabinet by virtue of being Secretary of State for Scotland, not as an individual person [W3C ORG]" ; + + skos:note "A post can be held by multiple people and hence can be treated as a organization in its own right. [W3C ORG]" ; + + skos:prefLabel "post" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000404 + +af-rl:AFRL_0000404 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000095 , + af-rl:AFRL_0000434 ; + + af-x:AFX_0002808 ; + + rdfs:isDefinedBy ; + + skos:definition "An approver is the role of an organizational entity that approves something. [Allotrope]" ; + + skos:prefLabel "approver" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000405 + +af-rl:AFRL_0000405 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000095 , + bfo:_0000023 ; + + af-x:AFX_0002808 , + ; + + rdfs:isDefinedBy ; + + skos:definition "A researcher is the role of an organizational entity that researches something. [Allotrope]" ; + + skos:prefLabel "researcher" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000406 + +af-rl:AFRL_0000406 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000405 ; + + af-x:AFX_0002808 ; + + rdfs:isDefinedBy ; + + skos:definition "An investigator is a researcher that is doing an investigation. [Allotrope]" ; + + skos:prefLabel "investigator" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000407 + +af-rl:AFRL_0000407 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000095 , + bfo:_0000023 ; + + af-x:AFX_0002808 ; + + rdfs:isDefinedBy ; + + skos:definition "A reviewer is the role of an agent that reviews some information. [Allotrope]" ; + + skos:prefLabel "reviewer" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000409 + +af-rl:AFRL_0000409 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000095 , + af-rl:AFRL_0000435 ; + + af-x:AFX_0002808 ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:altLabel "signatory" ; + + skos:definition "A signer is the role of the agent in a signing process. [Allotrope]" ; + + skos:prefLabel "signer" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000410 + +af-rl:AFRL_0000410 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( bfo:_0000023 + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000054 ; + owl:someValuesFrom af-p:AFP_0002389 + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:subClassOf bfo:_0000023 , + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000054 ; + owl:someValuesFrom af-p:AFP_0002389 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A calibration role is role of a material entity that participates in a calibration process. [Allotrope]" ; + + skos:prefLabel "calibration role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000411 + +af-rl:AFRL_0000411 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000410 ; + + dct:source , + "ISO Guide 30" , + "http://www.citac.cc/CITAC_EURACHEM_GUIDE.pdf" ; + + rdfs:isDefinedBy ; + + skos:altLabel "calibration material" , + "calibration material role" , + "reference material" , + "standard" , + "standard material" , + "standard material role" ; + + skos:definition "A reference material role is the role of a material used in a calibration whose qualities are sufficiently homogenous and well established to be used as reference. [Allotrope]" ; + + skos:prefLabel "reference material role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000420 + +af-rl:AFRL_0000420 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000231 ; + + rdfs:isDefinedBy ; + + skos:definition "A role for a material used in the synthesis of a new drug substance that is incorporated as an element into the structure of an intermediate and/or of the new drug substance. [ICH-Q3A]" ; + + skos:note "Starting materials are normally commercially available and of defined chemical and physical properties and structure. [ICH-Q3A]" ; + + skos:prefLabel "starting material role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000421 + +af-rl:AFRL_0000421 rdf:type owl:Class ; + + rdfs:subClassOf obi:_0000086 ; + + rdfs:isDefinedBy ; + + skos:definition "A reagent role of the material with the least mole quantity in a chemical process and as such limits the amount of product that can be formed. [Allotrope]" ; + + skos:prefLabel "limiting reagent role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000422 + +af-rl:AFRL_0000422 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000364 ; + + rdfs:isDefinedBy ; + + skos:altLabel "enantiomere" , + "enantiomeric impurity" ; + + skos:definition "An enantiomeric impurity is the impurity role of a compound with the same molecular formula as the drug substance that differs in the spatial arrangement of atoms within the molecule and is a non-superimposable mirror image. [ICH-Q3A]" ; + + skos:prefLabel "enantiomeric impurity role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000423 + +af-rl:AFRL_0000423 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000364 ; + + rdfs:isDefinedBy ; + + skos:altLabel "contaminant" , + "contaminant role" , + "extraneous contaminant" ; + + skos:definition "An extraneous contaminant role is an impurity role arising from any source extraneous to the manufacturing process. [ICH-Q3A]" ; + + skos:prefLabel "extraneous contaminant role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000424 + +af-rl:AFRL_0000424 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000364 ; + + rdfs:isDefinedBy ; + + skos:altLabel "identified impurity" ; + + skos:definition "An impurity for which a structural characterization has been achieved. [ICH-Q3A]" ; + + skos:prefLabel "identified impurity role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000425 + +af-rl:AFRL_0000425 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000364 ; + + rdfs:isDefinedBy ; + + skos:altLabel "potential impurity" ; + + skos:definition "An impurity role for a material that theoretically can arise during manufacture or storage. It may or may not actually appear in the new drug substance. [ICH-Q3A]" ; + + skos:prefLabel "potential impurity role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000426 + +af-rl:AFRL_0000426 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000364 ; + + rdfs:isDefinedBy ; + + skos:altLabel "specified impurity" ; + + skos:definition "An impurity that is individually listed and limited with aspecific acceptance criterion in the new drug substance specification. A specified impurity can be either identified or unidentified. [ICH-Q3A]" ; + + skos:prefLabel "specified impurity role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000427 + +af-rl:AFRL_0000427 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000364 ; + + rdfs:isDefinedBy ; + + skos:altLabel "unidentified impurity" ; + + skos:definition "An impurity for which a structural characterization has not been achieved and that is defined solely by qualitative analytical properties (e.g., chromatographic retention time). [ICH-Q3A]" ; + + skos:prefLabel "unidentified impurity role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000428 + +af-rl:AFRL_0000428 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000364 ; + + rdfs:isDefinedBy ; + + skos:altLabel "unspecified impurity" ; + + skos:definition "An impurity role that is limited by a general acceptance criterion, but not individually listed with its own specific acceptance criterion, in the new drug substance specification. [ICH-Q3A]" ; + + skos:prefLabel "unspecified impurity role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000429 + +af-rl:AFRL_0000429 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000365 ; + + rdfs:isDefinedBy ; + + skos:altLabel "identified degradation product" ; + + skos:definition "A degradation product role for which a structural characterization has been achieved. [ICH-Q3A]" ; + + skos:prefLabel "identified degradation product role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000430 + +af-rl:AFRL_0000430 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000365 ; + + rdfs:isDefinedBy ; + + skos:altLabel "specified degradation product" ; + + skos:definition "A degradation product role that is individually listed and limited with a specific acceptance criterion in the new drug product specification. A specified degradation product can be either identified or unidentified. [ICH-Q3A]" ; + + skos:prefLabel "specified degradation product role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000432 + +af-rl:AFRL_0000432 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000293 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:altLabel "internal standard" , + "surrogate internal standard" ; + + skos:definition "Internal standard role is the analysis role of a chemical substance that is added in a constant amount to samples, the blank and calibration standards in a chemical analysis. [Wikipedia]" ; + + skos:prefLabel "internal standard role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000434 + +af-rl:AFRL_0000434 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000023 , + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000054 ; + owl:someValuesFrom af-p:AFP_0003643 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "An approving role is a role that is realized in some approving process. [Allotrope]" ; + + skos:prefLabel "approving role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000435 + +af-rl:AFRL_0000435 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000023 , + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000054 ; + owl:someValuesFrom af-p:AFP_0003645 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A signing role is a role that is realized in some signing activity. [Allotrope]" ; + + skos:prefLabel "signing role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000436 + +af-rl:AFRL_0000436 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000167 , + af-rl:AFRL_0000435 ; + + rdfs:isDefinedBy ; + + skos:definition "The signed object is the bearer of the information content entity that is signed. [Allotrope]" ; + + skos:example "The paper where the signature was written on." ; + + skos:prefLabel "signed object" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000437 + +af-rl:AFRL_0000437 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000166 ; + + rdfs:isDefinedBy ; + + skos:definition "A signing contextual role is a contextual role of information content entities that are participants in a signing process. [Allotrope]" ; + + skos:prefLabel "signing contextual role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000438 + +af-rl:AFRL_0000438 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000060 , + af-rl:AFRL_0000437 ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:altLabel "signature" ; + + skos:definition "A signature role is the role of an information object that is associated with some information and provides a proof of identity and intent of the signer. [Allotrope]" ; + + skos:prefLabel "signature role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000439 + +af-rl:AFRL_0000439 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000437 ; + + rdfs:isDefinedBy ; + + skos:altLabel "signed content" ; + + skos:definition "Signed content role is the signing contextual role of the information content entity that is being signed. [Allotrope]" ; + + skos:example "A contract signed." , + "An approval signed." ; + + skos:note "The signed content role is the role of the information. The physical bearer of that information has the role of a signed object." ; + + skos:prefLabel "signed content role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000441 + +af-rl:AFRL_0000441 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000449 , + [ owl:intersectionOf ( af-rl:AFRL_0000087 + af-rl:AFRL_0000095 + ) ; + rdf:type owl:Class + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A submitter role is the role of a material entity that plays the sender of the submitted entity in a submitting process. [Allotrope]" ; + + skos:prefLabel "submitter" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000442 + +af-rl:AFRL_0000442 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000047 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002726 ; + owl:someValuesFrom [ rdf:type owl:Restriction ; + owl:onProperty iao:_0000136 ; + owl:someValuesFrom [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002730 ; + owl:someValuesFrom af-rl:AFRL_0000048 + ] + ] + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "summary datum" ; + + skos:definition "An aggregated datum is the role of an information object that is about aggregated or summary information on the aggregate, such as statistics, count or sums of member data. [Allotrope]" ; + + skos:prefLabel "aggregated datum" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000443 + +af-rl:AFRL_0000443 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000264 , + af-rl:AFRL_0000442 ; + + rdfs:isDefinedBy ; + + skos:altLabel "product" , + "product (mathematics)" ; + + skos:definition "The product is the contextual role of numerical data that results from the multiplication of two or more numbers, amounts, or items. [Allotrope]" ; + + skos:prefLabel "product (math)" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000444 + +af-rl:AFRL_0000444 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000047 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002726 ; + owl:someValuesFrom af-r:AFR_0001286 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "aggregated feature role" ; + + skos:definition "The aggregated feature is the role of a description or classification of a property, characteristic or facet of the members of the aggregate that is common to each member and is used to make aggregated data about the aggregate. [Allotrope]" ; + + skos:example "the diameter quality is the aggregated feature in the 'average living cell diameter' result datum of a cell counter result" ; + + skos:note "If the members of the aggregates are proxies for other information objects, then the aggregated feature is a feature of the information objects the proxies point to." ; + + skos:prefLabel "aggregated feature" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000446 + +af-rl:AFRL_0000446 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000039 , + af-rl:AFRL_0000448 ; + + rdfs:isDefinedBy ; + + skos:altLabel "software agent" ; + + skos:definition "A software agent is the contextual role of software in the context of a process where a system executes that software and causally is an agent in the process. [Allotrope]" ; + + skos:prefLabel "software agent role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000448 + +af-rl:AFRL_0000448 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000091 ; + + rdfs:isDefinedBy ; + + skos:altLabel "agent" , + "agent role" ; + + skos:definition "Agentive role is a general role of a material entity or software that influences the behavior of a process in an active way. If a material entity it is an agent role, if its is a software that is executed by a computer system, it is a software agent role. [Allotrope]" ; + + skos:prefLabel "general agent role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000449 + +af-rl:AFRL_0000449 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000023 , + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000054 ; + owl:someValuesFrom af-p:AFP_0003646 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A submission role is a role that is realized in a submitting process. [Allotrope]" ; + + skos:prefLabel "submission role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000450 + +af-rl:AFRL_0000450 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000166 ; + + rdfs:isDefinedBy ; + + skos:definition "A metadata role is a contextual role of an information content entity that is not a parameter or result of a process but describes the context of the process. [Allotrope]" ; + + skos:prefLabel "metadata role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000451 + +af-rl:AFRL_0000451 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000119 , + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000054 ; + owl:someValuesFrom [ rdf:type owl:Restriction ; + owl:onProperty ro:_0002230 ; + owl:someValuesFrom af-p:AFP_0003312 + ] + ] , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000081 ; + owl:someValuesFrom bfo:_0000029 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "destination" , + "destination site" ; + + skos:definition "Destination role is the transferring role of a site of the transferred object at the end of the transferring process. [Allotrope]" ; + + skos:prefLabel "destination role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000452 + +af-rl:AFRL_0000452 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000119 , + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000054 ; + owl:someValuesFrom [ rdf:type owl:Restriction ; + owl:onProperty ro:_0002224 ; + owl:someValuesFrom af-p:AFP_0003312 + ] + ] , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000081 ; + owl:someValuesFrom bfo:_0000029 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "origin" , + "origin site" ; + + skos:definition "Origin role is the transferring role of a site of the transferred object at the start of the transferring process. [Allotrope]" ; + + skos:prefLabel "origin role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000453 + +af-rl:AFRL_0000453 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000119 , + af-rl:AFRL_0000167 ; + + rdfs:isDefinedBy ; + + skos:definition "Transferred object is the role of a material that is being transferred from the sender to the receiver. [Allotrope]" ; + + skos:prefLabel "transferred object" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000454 + +af-rl:AFRL_0000454 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000453 , + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000054 ; + owl:someValuesFrom [ rdf:type owl:Restriction ; + owl:onProperty ro:_0002230 ; + owl:someValuesFrom af-p:AFP_0003312 + ] + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "received object" ; + + skos:definition "Sent object is the role of a transferred object at the start of the transferring process. [Allotrope]" ; + + skos:prefLabel "received object role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000455 + +af-rl:AFRL_0000455 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000453 , + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000054 ; + owl:someValuesFrom [ rdf:type owl:Restriction ; + owl:onProperty ro:_0002224 ; + owl:someValuesFrom af-p:AFP_0003312 + ] + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "sent object" ; + + skos:definition "Sent object is the role of a transferred object at the start of the transferring process. [Allotrope]" ; + + skos:prefLabel "sent object role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000457 + +af-rl:AFRL_0000457 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000471 ; + + rdfs:isDefinedBy ; + + skos:definition "A predecessor role is an ordering role that applies if the information object or the entity it is about is before another one in a sequence. [Allotrope]" ; + + skos:prefLabel "predecessor role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000458 + +af-rl:AFRL_0000458 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000471 ; + + rdfs:isDefinedBy ; + + skos:definition "A successor role is an ordering role that applies if the information object or the entity it is about is after another one in a sequence. [Allotrope]" ; + + skos:prefLabel "successor role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000461 + +af-rl:AFRL_0000461 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000472 ; + + rdfs:isDefinedBy ; + + skos:definition "A triggered event is a contextual role of an event specification that when realized is the cause of a trigger. [Allotrope]" ; + + skos:prefLabel "triggering event" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000462 + +af-rl:AFRL_0000462 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000472 ; + + rdfs:isDefinedBy ; + + skos:definition "A triggered event is a contextual role of an event specification that when realized is the consequence of a trigger. [Allotrope]" ; + + skos:prefLabel "triggered event" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000463 + +af-rl:AFRL_0000463 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000166 ; + + rdfs:isDefinedBy ; + + skos:definition "A direction role is a contextual role of some information content entity indicating a direction in a relation. [Allotrope]" ; + + skos:prefLabel "direction role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000464 + +af-rl:AFRL_0000464 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000463 ; + + rdfs:isDefinedBy ; + + skos:altLabel "destination" , + "destination role" , + "target" , + "target role" , + "to" ; + + skos:definition "A to role is a direction role indicating that something is going into an target direction. [Allotrope]" ; + + skos:editorialNote "This is an abstraction of direction, for spatio-temporal role use af-rl:destination datum. [Allotrope]" ; + + skos:prefLabel "to role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000465 + +af-rl:AFRL_0000465 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000463 ; + + rdfs:isDefinedBy ; + + skos:altLabel "from" , + "origin" , + "origin role" , + "source" , + "source role" ; + + skos:definition "A from role is a direction role indicating that something is coming from a source. [Allotrope]" ; + + skos:editorialNote "This is an abstraction of direction, for spatio-temporal role use af-rl:origin datum. [Allotrope]" ; + + skos:example "A specification of a material that is a material output of a process has the contextual role of from role in the material flow specification. [Allotrope]" ; + + skos:prefLabel "from role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000466 + +af-rl:AFRL_0000466 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000166 ; + + rdfs:isDefinedBy ; + + skos:altLabel "defining role" , + "definition role" ; + + skos:definition "Defining purpose is the contextual role of some information that has the purpose to define an entity. [Allotrope]" ; + + skos:prefLabel "defining purpose" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000471 + +af-rl:AFRL_0000471 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000166 ; + + rdfs:isDefinedBy ; + + skos:definition "An ordering role is a contextual role of an information content entity in the scope of some sequence. [Allotrope]" ; + + skos:prefLabel "ordering role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000472 + +af-rl:AFRL_0000472 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000166 ; + + rdfs:isDefinedBy ; + + skos:definition "A workflow role is a contextual role of a part of a procedure specification. [Allotrope]" ; + + skos:prefLabel "workflow role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000473 + +af-rl:AFRL_0000473 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000458 ; + + rdfs:isDefinedBy ; + + skos:definition "An default transition is a successor role in the scope of an exclusive gateway that specifies the succeeding activity if no guard conditions on the gateway are met. [Allotrope]" ; + + skos:prefLabel "default transition" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000474 + +af-rl:AFRL_0000474 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000053 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "An expected datum is a descriptive datum that describes a information that was predicted or assumed to be the outcome of some process . [Allotrope]" ; + + skos:prefLabel "expected datum" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000475 + +af-rl:AFRL_0000475 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000472 ; + + rdfs:isDefinedBy ; + + skos:altLabel "sequential role" ; + + skos:definition "A workflow role of a single step in a sequentially executed procedure. [Allotrope]" ; + + skos:example "A single data acquisition of a data acquisition profile." ; + + skos:prefLabel "sequential" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000476 + +af-rl:AFRL_0000476 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000472 ; + + rdfs:isDefinedBy ; + + skos:altLabel "loop" , + "recurring" ; + + skos:definition "A single step that can be repeated multiple times during a procedure. [Allotrope]" ; + + skos:example "A single data acquisition that is repeated multiple times with the same settings during a data acquisition profile." ; + + skos:prefLabel "repeatable" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000477 + +af-rl:AFRL_0000477 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000053 ; + + rdfs:isDefinedBy ; + + skos:altLabel "calibrated result" ; + + skos:definition "A calibrated datum is the contextual role of a datum that is the output of some process that applies a calibration function to a measured datum. [Allotrope]" ; + + skos:prefLabel "calibrated datum" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000478 + +af-rl:AFRL_0000478 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000277 ; + + rdfs:isDefinedBy ; + + skos:altLabel "parameter" , + "parameter (mathematics)" ; + + skos:definition "A parameter is the contextual role of a datum that is not explicitly varied in a mathematical function or during data processing. [Allotrope]" ; + + skos:prefLabel "parameter (math)" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000479 + +af-rl:AFRL_0000479 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000231 ; + + af-x:AFX_0002808 chebi:_63248 ; + + rdfs:isDefinedBy ; + + skos:altLabel "oxidant" , + "oxidizer" , + "oxidizer role" , + "oxidizing agent" ; + + skos:definition "An oxidant role is a chemical reactant role whereby the substance removes electrons from another reactant in a redox reaction. [Allotrope]" ; + + skos:prefLabel "oxidant role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000480 + +af-rl:AFRL_0000480 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000231 ; + + af-x:AFX_0002808 chebi:_33292 ; + + rdfs:isDefinedBy ; + + skos:altLabel "fuel" ; + + skos:definition "A fuel role is a chemical reactant role whereby an energy-rich substance is transformed with release of usable energy. [Allotrope]" ; + + skos:prefLabel "fuel role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000481 + +af-rl:AFRL_0000481 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000216 ; + + rdfs:isDefinedBy ; + + skos:altLabel "make-up" ; + + skos:definition "A make-up role is a the additive role of a fluid to adjust total flow rate into a device in order to maximize its efficiency. [Allotrope]" ; + + skos:prefLabel "make-up role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000484 + +af-rl:AFRL_0000484 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( bfo:_0000023 + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000054 ; + owl:someValuesFrom [ rdf:type owl:Class ; + owl:unionOf ( af-p:AFP_0001986 + af-p:AFP_0003687 + ) + ] + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:subClassOf bfo:_0000023 ; + + rdfs:isDefinedBy ; + + skos:altLabel "coating role" ; + + skos:definition "A coating process role is a role of a material that participates in a coating activity or the state of being coated. [Allotrope]" ; + + skos:prefLabel "coating process role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000485 + +af-rl:AFRL_0000485 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000212 ; + + rdfs:isDefinedBy ; + + skos:altLabel "capillary inner coating" ; + + skos:definition "A capillary inner coating role is a coating role of a material that is a coating within a chromatography column. [Allotrope]" ; + + skos:prefLabel "capillary inner coating role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000486 + +af-rl:AFRL_0000486 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000085 ; + + rdfs:isDefinedBy ; + + skos:altLabel "endcapping" ; + + skos:definition "An endcapping role is a supporting material role with the purpose of preventing chromatographic analytes from interacting with the substrate of the stationary phase. [Allotrope]" ; + + skos:prefLabel "endcapping role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000487 + +af-rl:AFRL_0000487 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000121 ; + + rdfs:isDefinedBy ; + + skos:altLabel "stored object" ; + + skos:definition "A stored object is the storage role of an material entity that is being stored in a storage medium. [Allotrope]" ; + + skos:prefLabel "stored object role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000488 + +af-rl:AFRL_0000488 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000410 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000081 ; + owl:someValuesFrom af-e:AFE_0000354 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "calibrated instrument" , + "unit under test" , + "unit under test role" ; + + skos:definition "A calibrated instrument role is the role of a measurement device that is the target of a calibration. [Allotrope]" ; + + skos:prefLabel "calibrated instrument role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000489 + +af-rl:AFRL_0000489 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000298 ; + + rdfs:isDefinedBy ; + + skos:definition "Diluted material is the dilution role of a material that is being diluted in the dilution process. [Allotrope]" ; + + skos:prefLabel "diluted material role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000493 + +af-rl:AFRL_0000493 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000410 ; + + rdfs:isDefinedBy ; + + skos:altLabel "calibration item" ; + + skos:definition "The calibration item role is the role of a material that is used in calibration for testing a measurement device. [Allotrope]" ; + + skos:prefLabel "calibration item role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000495 + +af-rl:AFRL_0000495 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( bfo:_0000023 + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000054 ; + owl:someValuesFrom af-p:AFP_0001427 + ] + ) ; + rdf:type owl:Class + ] ; + + rdfs:subClassOf af-rl:AFRL_0000499 ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A mass spectrometry role is a role that is realized in mass spectrometry. [Allotrope]" ; + + skos:prefLabel "mass spectrometry role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000496 + +af-rl:AFRL_0000496 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000495 , + af-rl:AFRL_0000499 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000081 ; + owl:someValuesFrom [ owl:intersectionOf ( af-m:AFM_0000077 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002735 ; + owl:someValuesFrom [ owl:intersectionOf ( bfo:_0000015 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000696 ; + owl:someValuesFrom [ owl:intersectionOf ( af-m:AFM_0000077 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000087 ; + owl:someValuesFrom af-rl:AFRL_0000497 + ] + ) ; + rdf:type owl:Class + ] + ] + ) ; + rdf:type owl:Class + ] + ] + ) ; + rdf:type owl:Class + ] + ] ; + + dct:license ; + + dct:rights ; + + dct:source "K. K. Murray, R. K. Boyd, M. N. Eberlin, G. J. Langley, L. Li and Y. Naito, Pure Appl. Chem., 2013, 85, 1515-1609" ; + + rdfs:isDefinedBy ; + + skos:altLabel "product" , + "product ion" ; + + skos:definition "Ion formed as the product of a reaction involving a particular precursor ion. [IUPAC]" ; + + skos:prefLabel "product ion role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000497 + +af-rl:AFRL_0000497 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000495 , + af-rl:AFRL_0000499 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000081 ; + owl:someValuesFrom [ owl:intersectionOf ( af-m:AFM_0000077 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000554 ; + owl:someValuesFrom [ owl:intersectionOf ( bfo:_0000015 + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000546 ; + owl:someValuesFrom [ owl:intersectionOf ( af-m:AFM_0000077 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000087 ; + owl:someValuesFrom af-rl:AFRL_0000496 + ] + ) ; + rdf:type owl:Class + ] + ] + ) ; + rdf:type owl:Class + ] + ] + ) ; + rdf:type owl:Class + ] + ] ; + + dct:license ; + + dct:rights ; + + dct:source "K. K. Murray, R. K. Boyd, M. N. Eberlin, G. J. Langley, L. Li and Y. Naito, Pure Appl. Chem., 2013, 85, 1515-1609" ; + + rdfs:isDefinedBy ; + + skos:altLabel "precursor" , + "precursor ion" , + "precursor role" , + "progenitor" , + "progenitor ion" , + "progenitor ion role" ; + + skos:definition "Precursor ion role is a role in mass spectrometry inhered in an ion that reacts to form particular product ions or undergoes specified neutral losses. The reaction can be of different types including unimolecular dissociation, ion/molecule reaction, change in charge state, possibly preceded by isomerization. [IUPAC]" ; + + skos:prefLabel "precursor ion role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000499 + +af-rl:AFRL_0000499 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( bfo:_0000023 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000081 ; + owl:someValuesFrom af-m:AFM_0000077 + ] + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "An ion role is a role inhered in an ion. [Allotrope]" ; + + skos:prefLabel "ion role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000500 + +af-rl:AFRL_0000500 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000166 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002726 ; + owl:someValuesFrom af-r:AFR_0001861 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "qualifier transition" ; + + skos:definition "A qualifier transition is the contextual role of an ion transition which when compared to the quantifier transition is used to determine the validity of the result. [Allotrope]" ; + + skos:prefLabel "qualifier transition role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000501 + +af-rl:AFRL_0000501 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000166 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002726 ; + owl:someValuesFrom af-r:AFR_0001861 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "quantifier transition" ; + + skos:definition "A quantifier transition is the contextual of an ion transition, that is used to calculate the measured result. [Allotrope]" ; + + skos:prefLabel "quantifier transition role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000502 + +af-rl:AFRL_0000502 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000166 ; + + rdfs:isDefinedBy ; + + skos:altLabel "qualified transition" ; + + skos:definition "Qualified transition role is the contextual role of an ion transition that asserts that the transition meets some qualification requirements. [Allotrope]" ; + + skos:prefLabel "qualified transition role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000504 + +af-rl:AFRL_0000504 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000017 , + af-rl:AFRL_0000041 ; + + rdfs:isDefinedBy ; + + skos:altLabel "lower operating limit" ; + + skos:definition "An operating minimum is the contextual role of a description or specification of a lower bound of quality of a system or environment during the operation of the system. [Allotrope]" ; + + skos:prefLabel "operating minimum" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000505 + +af-rl:AFRL_0000505 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000023 , + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000054 ; + owl:someValuesFrom af-p:AFP_0001478 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A changing role is a role realized in some cooling process. [Allotrope]" ; + + skos:prefLabel "cooling role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000506 + +af-rl:AFRL_0000506 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000505 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000081 ; + owl:someValuesFrom af-m:AFM_0000275 + ] ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:altLabel "coolant" , + "cooling medium" , + "heat transfer fluid" ; + + skos:definition "A role of a material that acts as a heat sink as it undergoes a phase change. [Allotrope]" ; + + skos:prefLabel "coolant role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000508 + +af-rl:AFRL_0000508 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000023 , + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000054 ; + owl:someValuesFrom af-p:AFP_0001159 + ] , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0001001 ; + owl:someValuesFrom [ owl:intersectionOf ( af-m:AFM_0000275 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000087 ; + owl:someValuesFrom af-rl:AFRL_0000035 + ] + ) ; + rdf:type owl:Class + ] + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "sample" , + "sample (preparation)" , + "sample role" ; + + skos:definition "A sample role (preparation) is a role of a material that is prepared for a bearing the sample role in an experiment. [Allotrope]" ; + + skos:prefLabel "sample role (preparation)" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000509 + +af-rl:AFRL_0000509 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000085 , + bfo:_0000023 , + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000054 ; + owl:someValuesFrom af-p:AFP_0003719 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "nebulizer support" , + "nebulizing support" , + "nebulizing support role" ; + + skos:definition "Nebulizer support role is a support role in converting liquid into aerosol mist. [Allotrope]" ; + + skos:prefLabel "nebulizer support role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000510 + +af-rl:AFRL_0000510 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000216 , + af-rl:AFRL_0000511 ; + + rdfs:isDefinedBy ; + + skos:altLabel "drying additive" ; + + skos:definition "A drying additive role is the role of a material in a drying process that supports the drying process. [Allotrope]" ; + + skos:prefLabel "drying additive role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000511 + +af-rl:AFRL_0000511 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000023 , + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000054 ; + owl:someValuesFrom af-p:AFP_0001876 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A drying role role is a role realized in some drying process. [Allotrope]" ; + + skos:prefLabel "drying role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000512 + +af-rl:AFRL_0000512 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000511 ; + + rdfs:isDefinedBy ; + + skos:altLabel "drying agent" , + "drying agent role" , + "drying medium" ; + + skos:definition "A drying medium role is a drying role of a material that takes or transports the solvent from the material being dried. [Allotrope]" ; + + skos:prefLabel "drying medium role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000513 + +af-rl:AFRL_0000513 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000511 ; + + rdfs:isDefinedBy ; + + skos:altLabel "dried material" , + "dried material role" , + "material dried" ; + + skos:definition "Material dried role is the drying role of the material being dried. [Allotrope]" ; + + skos:prefLabel "material dried role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000516 + +af-rl:AFRL_0000516 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000085 , + af-rl:AFRL_0000495 ; + + dct:license ; + + dct:rights ; + + dct:source "K. K. Murray, R. K. Boyd, M. N. Eberlin, G. J. Langley, L. Li and Y. Naito, Pure Appl. Chem., 2013, 85, 1515-1609" ; + + rdfs:isDefinedBy ; + + skos:altLabel "chemical ionization reagent gas" , + "reagent role" ; + + skos:definition "Reagent role is the role of a gas that reacts with ions to produce product ions through ion/molecule reactions; for example, a gas such as methane, ammonia, or isobutane used in chemical ionization to create reagent ions or a gas used in ion traps or collision cells to perform gas-phase ion/molecule reactions. [IUPAC]" ; + + skos:prefLabel "reagent role (ms)" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000517 + +af-rl:AFRL_0000517 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000495 ; + + dct:license ; + + dct:rights ; + + dct:source "K. K. Murray, R. K. Boyd, M. N. Eberlin, G. J. Langley, L. Li and Y. Naito, Pure Appl. Chem., 2013, 85, 1515-1609" ; + + rdfs:isDefinedBy ; + + skos:altLabel "adduct" , + "adduct ion" , + "adduct role" ; + + skos:definition "Adduct ion role is the role of an ion formed by the interaction of a precursor ion with one or more atoms or molecules to form an ion containing all the constituent atoms of the precursor ion as well as the additional atoms from the associated atoms or molecules. [IUPAC]" ; + + skos:example "For example, a Na+ adduct of a molecule (M) that is represented as [M + Na]+." ; + + skos:prefLabel "adduct ion role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000518 + +af-rl:AFRL_0000518 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000496 ; + + dct:license ; + + dct:rights ; + + dct:source "K. K. Murray, R. K. Boyd, M. N. Eberlin, G. J. Langley, L. Li and Y. Naito, Pure Appl. Chem., 2013, 85, 1515-1609" ; + + rdfs:isDefinedBy ; + + skos:altLabel "fragment" , + "fragment ion" ; + + skos:definition "A fragment ion role is a product ion role of an ion that results from the dissociation of a precursor ion. [IUPAC]" ; + + skos:prefLabel "fragment ion role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000519 + +af-rl:AFRL_0000519 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000004 ; + + rdfs:isDefinedBy ; + + skos:altLabel "default" , + "default condition" , + "default role" , + "fallback" , + "fallback condition" , + "fallback condition role" , + "fallback role" ; + + skos:definition "A default condition role is the condition role of an item in a collection of information content entities that applies (is true) if no other items apply (are false). [Allotrope]" ; + + skos:prefLabel "default condition role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000520 + +af-rl:AFRL_0000520 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000064 ; + + rdfs:isDefinedBy ; + + skos:altLabel "default" , + "fallback" , + "fallback role" ; + + skos:definition "A default role is a directive purpose that assigns a specification to be applied to a context if no other specification is asserted in that context. [Allotrope]" ; + + skos:prefLabel "default role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000521 + +af-rl:AFRL_0000521 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000064 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002726 ; + owl:someValuesFrom af-r:AFR_0000941 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "repeated action" , + "repetition role" ; + + skos:definition "A repeated action role is a contextual role of an action specification that specifies the repeated action in a repeated action specification. [Allotrope]" ; + + skos:prefLabel "repeated action role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000524 + +af-rl:AFRL_0000524 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000022 , + af-rl:AFRL_0000526 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000081 ; + owl:someValuesFrom af-e:AFE_0001622 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "reference pan" ; + + skos:definition "A reference pan role is the role of the measurement pan realized in a DSC measurement that is without sample content. [Allotrope]" ; + + skos:prefLabel "reference pan role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000525 + +af-rl:AFRL_0000525 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000526 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000081 ; + owl:someValuesFrom af-e:AFE_0001622 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "sample pan" ; + + skos:definition "A sample pan role is the role of the measurement pan realized in a DSC measurement that contains the sample. [Allotrope]" ; + + skos:prefLabel "sample pan role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000526 + +af-rl:AFRL_0000526 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( bfo:_0000023 + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000054 ; + owl:someValuesFrom af-p:AFP_0002124 + ] + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "DSC role" ; + + skos:definition "A differential calorimetry role is a role of a material entity realized in a differential scanning calorimetry process. [Allotrope]" ; + + skos:prefLabel "differential scanning calorimetry role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000527 + +af-rl:AFRL_0000527 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000328 ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:altLabel "standard deviation" ; + + skos:definition "Standard deviation role is a statistical datum role of a datum that is a measure of the amount of variation or dispersion of a set of values. [Wikipedia]" ; + + skos:prefLabel "standard deviation role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000528 + +af-rl:AFRL_0000528 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000023 , + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000054 ; + owl:someValuesFrom af-p:AFP_0003765 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "A dynamic vapor sorption role is a role that is realized in some dynamic vapor sorption process. [Allotrope]" ; + + skos:prefLabel "dynamic vapor sorption role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000529 + +af-rl:AFRL_0000529 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000528 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000081 ; + owl:someValuesFrom af-m:AFM_0000154 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "exhaust gas" , + "exhaust gas role" ; + + skos:definition "An exhaust gas role is the role of the waste gas exhausted from the system in the dynamic vapor sorption process. [Allotrope]" ; + + skos:prefLabel "exhaust gas role (DVS)" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000530 + +af-rl:AFRL_0000530 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000528 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000081 ; + owl:someValuesFrom af-m:AFM_0000154 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "dry gas" , + "dry gas role" ; + + skos:definition "A dry gas role is the role of the gas devoid of the vapor in the dynamic vapor sorption process. [Allotrope]" ; + + skos:prefLabel "dry gas role (DVS)" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000531 + +af-rl:AFRL_0000531 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000528 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000081 ; + owl:someValuesFrom af-m:AFM_0000154 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "saturated gas" , + "saturated gas role" ; + + skos:definition "A saturated gas role is the role of the gas saturated with the vapor in a dynamic vapor sorption process. [Allotrope]" ; + + skos:prefLabel "saturated gas role (DVS)" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000532 + +af-rl:AFRL_0000532 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000528 ; + + rdfs:isDefinedBy ; + + skos:altLabel "inlet gas" , + "inlet gas role" ; + + skos:definition "An inlet gas role is the role of the gas led into the system in the dynamic vapor sorption process. [Allotrope]" ; + + skos:prefLabel "inlet gas role (DVS)" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000533 + +af-rl:AFRL_0000533 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000231 , + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000054 ; + owl:someValuesFrom af-p:AFP_0003711 + ] , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000081 ; + owl:someValuesFrom af-m:AFM_0001099 + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "reaction mixture" ; + + skos:definition "A reaction mixture role is a role of a chemical mixture undergoing some chemical reaction. [Allotrope]" ; + + skos:prefLabel "reaction mixture role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000535 + +af-rl:AFRL_0000535 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000023 , + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000054 ; + owl:someValuesFrom af-p:AFP_0003769 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "quantitative polymerase chain reaction role" ; + + skos:definition "A qPCR role is a role of a material used in a qPCR experiment. [Allotrope]" ; + + skos:prefLabel "qPCR role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000536 + +af-rl:AFRL_0000536 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000535 ; + + rdfs:isDefinedBy ; + + skos:altLabel "reporter dye" ; + + skos:definition "Reporter dye role is the role of a dye in a qPCR experiment that binds to target DNA molecules and is detected via fluorescence when it is cleaved free. The fluorescence signal is proportional to DNA concentration. [Allotrope]" ; + + skos:prefLabel "reporter dye role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000537 + +af-rl:AFRL_0000537 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000022 , + af-rl:AFRL_0000535 ; + + rdfs:isDefinedBy ; + + skos:altLabel "passive reference dye" ; + + skos:definition "Passive reference dye role of a dye in a qPCR experiment to provide a baseline for normalization of the fluorescence signal. [Allotrope]" ; + + skos:prefLabel "passive reference dye role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000538 + +af-rl:AFRL_0000538 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000535 ; + + rdfs:isDefinedBy ; + + skos:altLabel "quencher dye" ; + + skos:definition "Quencher dye role is the role of a dye in a qPCR experiment that acts to suppress the fluorescence of a reporter dye in proximity. [Allotrope]" ; + + skos:prefLabel "quencher dye role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000539 + +af-rl:AFRL_0000539 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000328 ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:altLabel "coefficient of variation" ; + + skos:definition "Relative standard deviation role is a statistical datum role of a datum that is a standardized measure of dispersion of a probability distribution or frequency distribution. [Wikipedia]" ; + + skos:prefLabel "relative standard deviation role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000542 + +af-rl:AFRL_0000542 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000244 ; + + rdfs:isDefinedBy ; + + skos:definition "A purge gas role is a cleaning agent role of a gas used to remove or replace an existing gas. [Allotrope]" ; + + skos:prefLabel "purge gas role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000543 + +af-rl:AFRL_0000543 rdf:type owl:Class ; + + owl:equivalentClass [ rdf:type owl:Class ; + owl:unionOf ( af-rl:AFRL_0000544 + af-rl:AFRL_0000545 + ) + ] ; + + rdfs:subClassOf [ owl:intersectionOf ( af-rl:AFRL_0000091 + [ rdf:type owl:Class ; + owl:unionOf ( af-rl:AFRL_0000166 + bfo:_0000023 + ) + ] + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "product role" ; + + skos:definition "A product role (economic) is a general role of some continuant that is produced for the purpose of sale. [Allotrope]" ; + + skos:prefLabel "product role (economic)" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000544 + +af-rl:AFRL_0000544 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000166 , + af-rl:AFRL_0000543 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:altLabel "data product" , + "information product" ; + + skos:definition "An information product role is a contextual role of some information content entity that is produced for the purpose of sale. [Allotrope]" ; + + skos:prefLabel "information product role" . + + + +### http://purl.allotrope.org/ontologies/role#AFRL_0000545 + +af-rl:AFRL_0000545 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000543 , + bfo:_0000023 ; + + rdfs:isDefinedBy ; + + skos:altLabel "material product" , + "material product role" , + "physical product" ; + + skos:definition "A physical product role is a role of some artifact that is produced for the purpose of sale. [Allotrope]" ; + + skos:prefLabel "physical product role" . + + + +### http://purl.allotrope.org/ontologies/spatial#AFSP_0000001 + +af-sp:AFSP_0000001 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000029 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0001015 ; + owl:someValuesFrom af-m:AFM_0001090 + ] ; + + af-x:AFX_0002808 org:Site ; + + rdfs:isDefinedBy ; + + skos:altLabel "site" ; + + skos:changeNote "2019-09-04 Added restriction. [Allotrope]" , + "2019-09-04 Changed pref label and definition. [Allotrope]" ; + + skos:definition "A site (organization) is a site where organizational entities are located such as an office or premise. [Allotrope]" ; + + skos:prefLabel "site (organization)" ; + + skos:scopeNote "An office or other premise at which the organization is located. Many organizations are spread across multiple sites and many sites will host multiple locations. [W3C ORG]" . + + + +### http://purl.allotrope.org/ontologies/spatial#AFSP_0000002 + +af-sp:AFSP_0000002 rdf:type owl:Class ; + + rdfs:subClassOf af-sp:AFSP_0000005 , + bfo:_0000029 ; + + rdfs:isDefinedBy ; + + skos:altLabel "bench" ; + + skos:definition "A bench (site) is site in a workspace or laboratory where work is being done. [Allotrope]" ; + + skos:prefLabel "bench (site)" . + + + +### http://purl.allotrope.org/ontologies/spatial#AFSP_0000003 + +af-sp:AFSP_0000003 rdf:type owl:Class ; + + rdfs:subClassOf af-sp:AFSP_0000005 , + bfo:_0000029 ; + + rdfs:isDefinedBy ; + + skos:altLabel "building" , + "building site" ; + + skos:definition "A building (site) is a site located in a structure with a roof and walls. [Allotrope]" ; + + skos:prefLabel "building (site)" . + + + +### http://purl.allotrope.org/ontologies/spatial#AFSP_0000004 + +af-sp:AFSP_0000004 rdf:type owl:Class ; + + rdfs:subClassOf af-sp:AFSP_0000005 , + bfo:_0000029 ; + + rdfs:isDefinedBy ; + + skos:definition "A room is a site that is a part or division of a building enclosed by walls, floor, and ceiling. [Allotrope]" ; + + skos:prefLabel "room" . + + + +### http://purl.allotrope.org/ontologies/spatial#AFSP_0000005 + +af-sp:AFSP_0000005 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000029 ; + + rdfs:isDefinedBy ; + + skos:altLabel "free space" , + "room" ; + + skos:definition "A space is a site that can be occupied or where something can be done. [Allotrope]" ; + + skos:prefLabel "space" ; + + skos:scopeNote "Space is especially viewed in terms of whether there is enough. [Allotrope]" . + + + +### http://purl.allotrope.org/ontologies/spatial#AFSP_0000006 + +af-sp:AFSP_0000006 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000029 ; + + rdfs:isDefinedBy ; + + skos:definition "A campus is a site that is the grounds of a school, hospital, or other institution. [Allotrope]" ; + + skos:prefLabel "campus" . + + + +### http://purl.allotrope.org/ontologies/spatial#AFSP_0000007 + +af-sp:AFSP_0000007 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000029 , + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000050 ; + owl:someValuesFrom bfo:_0000029 + ] ; + + rdfs:isDefinedBy ; + + skos:altLabel "section" ; + + skos:changeNote "2020-12-01 Moved to AFO. [Allotrope]" ; + + skos:definition "A section is a site that is a more or less distinct part of a site into which the site is divided. [Allotrope]" ; + + skos:prefLabel "section (site)" . + + + +### http://purl.allotrope.org/ontologies/spatial#AFSP_0000009 + +af-sp:AFSP_0000009 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000029 ; + + rdfs:isDefinedBy ; + + skos:altLabel "hole" ; + + skos:definition "A well is a site that is a cavity in a surface open at the top. [Allotrope]" ; + + skos:prefLabel "well" . + + + +### http://purl.obolibrary.org/obo/BFO_0000001 + +bfo:_0000001 rdf:type owl:Class ; + + rdfs:subClassOf [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000108 ; + owl:someValuesFrom bfo:_0000008 + ] ; + + bfo:_0000179 "entity" ; + + bfo:_0000180 "Entity" ; + + iao:_0000112 "Julius Caesar"@en , + "Verdi’s Requiem"@en , + "the Second World War"@en , + "your body mass index" ; + + iao:_0000116 "BFO 2 Reference: In all areas of empirical inquiry we encounter general terms of two sorts. First are general terms which refer to universals or types:animaltuberculosissurgical procedurediseaseSecond, are general terms used to refer to groups of entities which instantiate a given universal but do not correspond to the extension of any subuniversal of that universal because there is nothing intrinsic to the entities in question by virtue of which they – and only they – are counted as belonging to the given group. Examples are: animal purchased by the Emperortuberculosis diagnosed on a Wednesdaysurgical procedure performed on a patient from Stockholmperson identified as candidate for clinical trial #2056-555person who is signatory of Form 656-PPVpainting by Leonardo da VinciSuch terms, which represent what are called ‘specializations’ in [81"@en , + "Entity doesn't have a closure axiom because the subclasses don't necessarily exhaust all possibilites. For example Werner Ceusters 'portions of reality' include 4 sorts, entities (as BFO construes them), universals, configurations, and relations. It is an open question as to whether entities as construed in BFO will at some point also include these other portions of reality. See, for example, 'How to track absolutely everything' at http://www.referent-tracking.com/_RTU/papers/CeustersICbookRevised.pdf" ; + + iao:_0000600 "An entity is anything that exists or has existed or will exist. (axiom label in BFO2 Reference: [001-001])" ; + + rdfs:isDefinedBy , + ; + + rdfs:label "entity" ; + + skos:definition "An entity is anything that exists or has existed or will exist. [BFO]" ; + + skos:prefLabel "entity" . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000001 ; + owl:annotatedProperty iao:_0000116 ; + owl:annotatedTarget "Entity doesn't have a closure axiom because the subclasses don't necessarily exhaust all possibilites. For example Werner Ceusters 'portions of reality' include 4 sorts, entities (as BFO construes them), universals, configurations, and relations. It is an open question as to whether entities as construed in BFO will at some point also include these other portions of reality. See, for example, 'How to track absolutely everything' at http://www.referent-tracking.com/_RTU/papers/CeustersICbookRevised.pdf" ; + iao:_0010000 ; + rdfs:comment "per discussion with Barry Smith" ; + rdfs:seeAlso +] . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000001 ; + owl:annotatedProperty iao:_0000600 ; + owl:annotatedTarget "An entity is anything that exists or has existed or will exist. (axiom label in BFO2 Reference: [001-001])" ; + iao:_0010000 +] . + + + +### http://purl.obolibrary.org/obo/BFO_0000002 + +bfo:_0000002 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000001 ; + + owl:disjointWith bfo:_0000003 ; + + bfo:_0000179 "continuant" ; + + bfo:_0000180 "Continuant" ; + + iao:_0000116 "BFO 2 Reference: Continuant entities are entities which can be sliced to yield parts only along the spatial dimension, yielding for example the parts of your table which we call its legs, its top, its nails. ‘My desk stretches from the window to the door. It has spatial parts, and can be sliced (in space) in two. With respect to time, however, a thing is a continuant.’ [60, p. 240"@en , + "Continuant doesn't have a closure axiom because the subclasses don't necessarily exhaust all possibilites. For example, in an expansion involving bringing in some of Ceuster's other portions of reality, questions are raised as to whether universals are continuants" ; + + iao:_0000600 "A continuant is an entity that persists, endures, or continues to exist through time while maintaining its identity. (axiom label in BFO2 Reference: [008-002])" ; + + iao:_0000601 "if b is a continuant and if, for some t, c has_continuant_part b at t, then c is a continuant. (axiom label in BFO2 Reference: [126-001])" , + "if b is a continuant and if, for some t, c has_continuant_part b at t, then c is a continuant. (axiom label in BFO2 Reference: [126-001])"@en , + "if b is a continuant and if, for some t, cis continuant_part of b at t, then c is a continuant. (axiom label in BFO2 Reference: [009-002])" , + "if b is a continuant and if, for some t, cis continuant_part of b at t, then c is a continuant. (axiom label in BFO2 Reference: [009-002])"@en , + "if b is a material entity, then there is some temporal interval (referred to below as a one-dimensional temporal region) during which b exists. (axiom label in BFO2 Reference: [011-002])" ; + + iao:_0000602 "(forall (x y) (if (and (Continuant x) (exists (t) (continuantPartOfAt y x t))) (Continuant y))) // axiom label in BFO2 CLIF: [009-002] " , + "(forall (x y) (if (and (Continuant x) (exists (t) (hasContinuantPartOfAt y x t))) (Continuant y))) // axiom label in BFO2 CLIF: [126-001] " , + "(forall (x) (if (Continuant x) (Entity x))) // axiom label in BFO2 CLIF: [008-002] " , + "(forall (x) (if (Material Entity x) (exists (t) (and (TemporalRegion t) (existsAt x t))))) // axiom label in BFO2 CLIF: [011-002] " ; + + rdfs:isDefinedBy , + ; + + rdfs:label "continuant" ; + + skos:definition "A continuant is an entity that persists, endures, or continues to exist through time while maintaining its identity. [BFO]" ; + + skos:prefLabel "continuant" . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000002 ; + owl:annotatedProperty iao:_0000116 ; + owl:annotatedTarget "Continuant doesn't have a closure axiom because the subclasses don't necessarily exhaust all possibilites. For example, in an expansion involving bringing in some of Ceuster's other portions of reality, questions are raised as to whether universals are continuants" ; + iao:_0010000 +] . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000002 ; + owl:annotatedProperty iao:_0000600 ; + owl:annotatedTarget "A continuant is an entity that persists, endures, or continues to exist through time while maintaining its identity. (axiom label in BFO2 Reference: [008-002])" ; + iao:_0010000 +] . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000002 ; + owl:annotatedProperty iao:_0000601 ; + owl:annotatedTarget "if b is a continuant and if, for some t, c has_continuant_part b at t, then c is a continuant. (axiom label in BFO2 Reference: [126-001])" ; + iao:_0010000 +] . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000002 ; + owl:annotatedProperty iao:_0000601 ; + owl:annotatedTarget "if b is a continuant and if, for some t, cis continuant_part of b at t, then c is a continuant. (axiom label in BFO2 Reference: [009-002])" ; + iao:_0010000 +] . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000002 ; + owl:annotatedProperty iao:_0000601 ; + owl:annotatedTarget "if b is a material entity, then there is some temporal interval (referred to below as a one-dimensional temporal region) during which b exists. (axiom label in BFO2 Reference: [011-002])" ; + iao:_0010000 +] . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000002 ; + owl:annotatedProperty iao:_0000602 ; + owl:annotatedTarget "(forall (x y) (if (and (Continuant x) (exists (t) (continuantPartOfAt y x t))) (Continuant y))) // axiom label in BFO2 CLIF: [009-002] " ; + iao:_0010000 +] . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000002 ; + owl:annotatedProperty iao:_0000602 ; + owl:annotatedTarget "(forall (x y) (if (and (Continuant x) (exists (t) (hasContinuantPartOfAt y x t))) (Continuant y))) // axiom label in BFO2 CLIF: [126-001] " ; + iao:_0010000 +] . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000002 ; + owl:annotatedProperty iao:_0000602 ; + owl:annotatedTarget "(forall (x) (if (Continuant x) (Entity x))) // axiom label in BFO2 CLIF: [008-002] " ; + iao:_0010000 +] . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000002 ; + owl:annotatedProperty iao:_0000602 ; + owl:annotatedTarget "(forall (x) (if (Material Entity x) (exists (t) (and (TemporalRegion t) (existsAt x t))))) // axiom label in BFO2 CLIF: [011-002] " ; + iao:_0010000 +] . + + + +### http://purl.obolibrary.org/obo/BFO_0000003 + +bfo:_0000003 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000001 ; + + bfo:_0000179 "occurrent" ; + + bfo:_0000180 "Occurrent" ; + + iao:_0000116 "BFO 2 Reference: every occurrent that is not a temporal or spatiotemporal region is s-dependent on some independent continuant that is not a spatial region"@en , + "BFO 2 Reference: s-dependence obtains between every process and its participants in the sense that, as a matter of necessity, this process could not have existed unless these or those participants existed also. A process may have a succession of participants at different phases of its unfolding. Thus there may be different players on the field at different times during the course of a football game; but the process which is the entire game s-depends_on all of these players nonetheless. Some temporal parts of this process will s-depend_on on only some of the players."@en , + "Occurrent doesn't have a closure axiom because the subclasses don't necessarily exhaust all possibilites. An example would be the sum of a process and the process boundary of another process." , + "Occurrent doesn't have a closure axiom because the subclasses don't necessarily exhaust all possibilites. An example would be the sum of a process and the process boundary of another process."@en , + "Simons uses different terminology for relations of occurrents to regions: Denote the spatio-temporal location of a given occurrent e by 'spn[e]' and call this region its span. We may say an occurrent is at its span, in any larger region, and covers any smaller region. Now suppose we have fixed a frame of reference so that we can speak not merely of spatio-temporal but also of spatial regions (places) and temporal regions (times). The spread of an occurrent, (relative to a frame of reference) is the space it exactly occupies, and its spell is likewise the time it exactly occupies. We write 'spr[e]' and `spl[e]' respectively for the spread and spell of e, omitting mention of the frame." ; + + iao:_0000600 "An occurrent is an entity that unfolds itself in time or it is the instantaneous boundary of such an entity (for example a beginning or an ending) or it is a temporal or spatiotemporal region which such an entity occupies_temporal_region or occupies_spatiotemporal_region. (axiom label in BFO2 Reference: [077-002])" ; + + iao:_0000601 "Every occurrent occupies_spatiotemporal_region some spatiotemporal region. (axiom label in BFO2 Reference: [108-001])" , + "Every occurrent occupies_spatiotemporal_region some spatiotemporal region. (axiom label in BFO2 Reference: [108-001])"@en , + "b is an occurrent entity iff b is an entity that has temporal parts. (axiom label in BFO2 Reference: [079-001])" ; + + iao:_0000602 "(forall (x) (if (Occurrent x) (exists (r) (and (SpatioTemporalRegion r) (occupiesSpatioTemporalRegion x r))))) // axiom label in BFO2 CLIF: [108-001] " , + "(forall (x) (iff (Occurrent x) (and (Entity x) (exists (y) (temporalPartOf y x))))) // axiom label in BFO2 CLIF: [079-001] " ; + + rdfs:isDefinedBy , + ; + + rdfs:label "occurrent" ; + + skos:definition "An occurrent is an entity that unfolds itself in time or it is the instantaneous boundary of such an entity (for example a beginning or an ending) or it is a temporal or spatiotemporal region which such an entity occupies a temporal region or occupies a spatiotemporal region. [BFO]" ; + + skos:prefLabel "occurrent" . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000003 ; + owl:annotatedProperty iao:_0000116 ; + owl:annotatedTarget "Occurrent doesn't have a closure axiom because the subclasses don't necessarily exhaust all possibilites. An example would be the sum of a process and the process boundary of another process." ; + iao:_0010000 ; + rdfs:comment "per discussion with Barry Smith" +] . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000003 ; + owl:annotatedProperty iao:_0000116 ; + owl:annotatedTarget "Simons uses different terminology for relations of occurrents to regions: Denote the spatio-temporal location of a given occurrent e by 'spn[e]' and call this region its span. We may say an occurrent is at its span, in any larger region, and covers any smaller region. Now suppose we have fixed a frame of reference so that we can speak not merely of spatio-temporal but also of spatial regions (places) and temporal regions (times). The spread of an occurrent, (relative to a frame of reference) is the space it exactly occupies, and its spell is likewise the time it exactly occupies. We write 'spr[e]' and `spl[e]' respectively for the spread and spell of e, omitting mention of the frame." ; + iao:_0010000 +] . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000003 ; + owl:annotatedProperty iao:_0000600 ; + owl:annotatedTarget "An occurrent is an entity that unfolds itself in time or it is the instantaneous boundary of such an entity (for example a beginning or an ending) or it is a temporal or spatiotemporal region which such an entity occupies_temporal_region or occupies_spatiotemporal_region. (axiom label in BFO2 Reference: [077-002])" ; + iao:_0010000 +] . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000003 ; + owl:annotatedProperty iao:_0000601 ; + owl:annotatedTarget "Every occurrent occupies_spatiotemporal_region some spatiotemporal region. (axiom label in BFO2 Reference: [108-001])" ; + iao:_0010000 +] . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000003 ; + owl:annotatedProperty iao:_0000601 ; + owl:annotatedTarget "b is an occurrent entity iff b is an entity that has temporal parts. (axiom label in BFO2 Reference: [079-001])" ; + iao:_0010000 +] . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000003 ; + owl:annotatedProperty iao:_0000602 ; + owl:annotatedTarget "(forall (x) (if (Occurrent x) (exists (r) (and (SpatioTemporalRegion r) (occupiesSpatioTemporalRegion x r))))) // axiom label in BFO2 CLIF: [108-001] " ; + iao:_0010000 +] . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000003 ; + owl:annotatedProperty iao:_0000602 ; + owl:annotatedTarget "(forall (x) (iff (Occurrent x) (and (Entity x) (exists (y) (temporalPartOf y x))))) // axiom label in BFO2 CLIF: [079-001] " ; + iao:_0010000 +] . + + + +### http://purl.obolibrary.org/obo/BFO_0000004 + +bfo:_0000004 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000002 ; + + owl:disjointWith bfo:_0000020 , + bfo:_0000031 ; + + bfo:_0000179 "ic" ; + + bfo:_0000180 "IndependentContinuant" ; + + iao:_0000112 "a chair"@en , + "a heart"@en , + "a leg"@en , + "a molecule"@en , + "a spatial region"@en , + "an atom"@en , + "an orchestra."@en , + "an organism"@en , + "the bottom right portion of a human torso"@en , + "the interior of your mouth" ; + + iao:_0000115 "b is an independent continuant = Def. b is a continuant which is such that there is no c and no t such that b s-depends_on c at t. (axiom label in BFO2 Reference: [017-002])" ; + + iao:_0000601 "For any independent continuant b and any time t there is some spatial region r such that b is located_in r at t. (axiom label in BFO2 Reference: [134-001])" , + "For any independent continuant b and any time t there is some spatial region r such that b is located_in r at t. (axiom label in BFO2 Reference: [134-001])"@en , + "For every independent continuant b and time t during the region of time spanned by its life, there are entities which s-depends_on b during t. (axiom label in BFO2 Reference: [018-002])" ; + + iao:_0000602 "(forall (x t) (if (IndependentContinuant x) (exists (r) (and (SpatialRegion r) (locatedInAt x r t))))) // axiom label in BFO2 CLIF: [134-001] " , + "(forall (x t) (if (and (IndependentContinuant x) (existsAt x t)) (exists (y) (and (Entity y) (specificallyDependsOnAt y x t))))) // axiom label in BFO2 CLIF: [018-002] " , + "(iff (IndependentContinuant a) (and (Continuant a) (not (exists (b t) (specificallyDependsOnAt a b t))))) // axiom label in BFO2 CLIF: [017-002] " ; + + rdfs:isDefinedBy , + ; + + rdfs:label "independent continuant" ; + + skos:definition "b is an independent continuant if b is a continuant which is such that there is no c and no t such that b s-depends_on c at t. [BFO]" ; + + skos:prefLabel "independent continuant" . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000004 ; + owl:annotatedProperty iao:_0000115 ; + owl:annotatedTarget "b is an independent continuant = Def. b is a continuant which is such that there is no c and no t such that b s-depends_on c at t. (axiom label in BFO2 Reference: [017-002])" ; + iao:_0010000 +] . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000004 ; + owl:annotatedProperty iao:_0000601 ; + owl:annotatedTarget "For any independent continuant b and any time t there is some spatial region r such that b is located_in r at t. (axiom label in BFO2 Reference: [134-001])" ; + iao:_0010000 +] . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000004 ; + owl:annotatedProperty iao:_0000601 ; + owl:annotatedTarget "For every independent continuant b and time t during the region of time spanned by its life, there are entities which s-depends_on b during t. (axiom label in BFO2 Reference: [018-002])" ; + iao:_0010000 +] . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000004 ; + owl:annotatedProperty iao:_0000602 ; + owl:annotatedTarget "(forall (x t) (if (IndependentContinuant x) (exists (r) (and (SpatialRegion r) (locatedInAt x r t))))) // axiom label in BFO2 CLIF: [134-001] " ; + iao:_0010000 +] . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000004 ; + owl:annotatedProperty iao:_0000602 ; + owl:annotatedTarget "(forall (x t) (if (and (IndependentContinuant x) (existsAt x t)) (exists (y) (and (Entity y) (specificallyDependsOnAt y x t))))) // axiom label in BFO2 CLIF: [018-002] " ; + iao:_0010000 +] . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000004 ; + owl:annotatedProperty iao:_0000602 ; + owl:annotatedTarget "(iff (IndependentContinuant a) (and (Continuant a) (not (exists (b t) (specificallyDependsOnAt a b t))))) // axiom label in BFO2 CLIF: [017-002] " ; + iao:_0010000 +] . + + + +### http://purl.obolibrary.org/obo/BFO_0000006 + +bfo:_0000006 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000141 ; + + owl:disjointWith bfo:_0000029 , + bfo:_0000140 ; + + bfo:_0000179 "s-region" ; + + bfo:_0000180 "SpatialRegion" ; + + iao:_0000116 "BFO 2 Reference: Spatial regions do not participate in processes."@en , + "Spatial region doesn't have a closure axiom because the subclasses don't exhaust all possibilites. An example would be the union of a spatial point and a spatial line that doesn't overlap the point, or two spatial lines that intersect at a single point. In both cases the resultant spatial region is neither 0-dimensional, 1-dimensional, 2-dimensional, or 3-dimensional." ; + + iao:_0000600 "A spatial region is a continuant entity that is a continuant_part_of spaceR as defined relative to some frame R. (axiom label in BFO2 Reference: [035-001])" ; + + iao:_0000601 "All continuant parts of spatial regions are spatial regions. (axiom label in BFO2 Reference: [036-001])" ; + + iao:_0000602 "(forall (x y t) (if (and (SpatialRegion x) (continuantPartOfAt y x t)) (SpatialRegion y))) // axiom label in BFO2 CLIF: [036-001] " , + "(forall (x) (if (SpatialRegion x) (Continuant x))) // axiom label in BFO2 CLIF: [035-001] " ; + + rdfs:isDefinedBy , + ; + + rdfs:label "spatial region" ; + + skos:definition "A spatial region is a continuant entity that is a continuant part of space R as defined relative to some frame R. [BFO]" ; + + skos:prefLabel "spatial region" . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000006 ; + owl:annotatedProperty iao:_0000116 ; + owl:annotatedTarget "Spatial region doesn't have a closure axiom because the subclasses don't exhaust all possibilites. An example would be the union of a spatial point and a spatial line that doesn't overlap the point, or two spatial lines that intersect at a single point. In both cases the resultant spatial region is neither 0-dimensional, 1-dimensional, 2-dimensional, or 3-dimensional." ; + iao:_0010000 ; + rdfs:comment "per discussion with Barry Smith" +] . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000006 ; + owl:annotatedProperty iao:_0000600 ; + owl:annotatedTarget "A spatial region is a continuant entity that is a continuant_part_of spaceR as defined relative to some frame R. (axiom label in BFO2 Reference: [035-001])" ; + iao:_0010000 +] . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000006 ; + owl:annotatedProperty iao:_0000601 ; + owl:annotatedTarget "All continuant parts of spatial regions are spatial regions. (axiom label in BFO2 Reference: [036-001])" ; + iao:_0010000 +] . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000006 ; + owl:annotatedProperty iao:_0000602 ; + owl:annotatedTarget "(forall (x y t) (if (and (SpatialRegion x) (continuantPartOfAt y x t)) (SpatialRegion y))) // axiom label in BFO2 CLIF: [036-001] " ; + iao:_0010000 +] . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000006 ; + owl:annotatedProperty iao:_0000602 ; + owl:annotatedTarget "(forall (x) (if (SpatialRegion x) (Continuant x))) // axiom label in BFO2 CLIF: [035-001] " ; + iao:_0010000 +] . + + + +### http://purl.obolibrary.org/obo/BFO_0000008 + +bfo:_0000008 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000003 , + [ owl:intersectionOf ( [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000117 ; + owl:allValuesFrom bfo:_0000008 + ] + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000132 ; + owl:allValuesFrom bfo:_0000008 + ] + ) ; + rdf:type owl:Class + ] ; + + owl:disjointWith bfo:_0000011 , + bfo:_0000015 , + bfo:_0000035 ; + + bfo:_0000179 "t-region" ; + + bfo:_0000180 "TemporalRegion" ; + + iao:_0000116 "Temporal region doesn't have a closure axiom because the subclasses don't exhaust all possibilites. An example would be the mereological sum of a temporal instant and a temporal interval that doesn't overlap the instant. In this case the resultant temporal region is neither 0-dimensional nor 1-dimensional" ; + + iao:_0000600 "A temporal region is an occurrent entity that is part of time as defined relative to some reference frame. (axiom label in BFO2 Reference: [100-001])" ; + + iao:_0000601 "All parts of temporal regions are temporal regions. (axiom label in BFO2 Reference: [101-001])" , + "All parts of temporal regions are temporal regions. (axiom label in BFO2 Reference: [101-001])"@en , + "Every temporal region t is such that t occupies_temporal_region t. (axiom label in BFO2 Reference: [119-002])" ; + + iao:_0000602 "(forall (r) (if (TemporalRegion r) (occupiesTemporalRegion r r))) // axiom label in BFO2 CLIF: [119-002] " , + "(forall (x y) (if (and (TemporalRegion x) (occurrentPartOf y x)) (TemporalRegion y))) // axiom label in BFO2 CLIF: [101-001] " , + "(forall (x) (if (TemporalRegion x) (Occurrent x))) // axiom label in BFO2 CLIF: [100-001] " ; + + rdfs:isDefinedBy , + ; + + rdfs:label "temporal region" ; + + skos:definition "A temporal region is an occurrent entity that is part of time as defined relative to some reference frame. [BFO]" ; + + skos:prefLabel "temporal region" . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000008 ; + owl:annotatedProperty iao:_0000116 ; + owl:annotatedTarget "Temporal region doesn't have a closure axiom because the subclasses don't exhaust all possibilites. An example would be the mereological sum of a temporal instant and a temporal interval that doesn't overlap the instant. In this case the resultant temporal region is neither 0-dimensional nor 1-dimensional" ; + iao:_0010000 ; + rdfs:comment "per discussion with Barry Smith" +] . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000008 ; + owl:annotatedProperty iao:_0000600 ; + owl:annotatedTarget "A temporal region is an occurrent entity that is part of time as defined relative to some reference frame. (axiom label in BFO2 Reference: [100-001])" ; + iao:_0010000 +] . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000008 ; + owl:annotatedProperty iao:_0000601 ; + owl:annotatedTarget "All parts of temporal regions are temporal regions. (axiom label in BFO2 Reference: [101-001])" ; + iao:_0010000 +] . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000008 ; + owl:annotatedProperty iao:_0000601 ; + owl:annotatedTarget "Every temporal region t is such that t occupies_temporal_region t. (axiom label in BFO2 Reference: [119-002])" ; + iao:_0010000 +] . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000008 ; + owl:annotatedProperty iao:_0000602 ; + owl:annotatedTarget "(forall (r) (if (TemporalRegion r) (occupiesTemporalRegion r r))) // axiom label in BFO2 CLIF: [119-002] " ; + iao:_0010000 +] . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000008 ; + owl:annotatedProperty iao:_0000602 ; + owl:annotatedTarget "(forall (x y) (if (and (TemporalRegion x) (occurrentPartOf y x)) (TemporalRegion y))) // axiom label in BFO2 CLIF: [101-001] " ; + iao:_0010000 +] . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000008 ; + owl:annotatedProperty iao:_0000602 ; + owl:annotatedTarget "(forall (x) (if (TemporalRegion x) (Occurrent x))) // axiom label in BFO2 CLIF: [100-001] " ; + iao:_0010000 +] . + + + +### http://purl.obolibrary.org/obo/BFO_0000009 + +bfo:_0000009 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000006 ; + + owl:disjointWith bfo:_0000028 ; + + bfo:_0000179 "2d-s-region" ; + + bfo:_0000180 "TwoDimensionalSpatialRegion" ; + + iao:_0000112 "an infinitely thin plane in space."@en , + "the surface of a sphere-shaped part of space" ; + + iao:_0000600 "A two-dimensional spatial region is a spatial region that is of two dimensions. (axiom label in BFO2 Reference: [039-001])" ; + + iao:_0000602 "(forall (x) (if (TwoDimensionalSpatialRegion x) (SpatialRegion x))) // axiom label in BFO2 CLIF: [039-001] " ; + + rdfs:isDefinedBy , + ; + + rdfs:label "two-dimensional spatial region" ; + + skos:altLabel "2D spatial region" ; + + skos:definition "A two-dimensional spatial region is a spatial region that is of two dimensions. [BFO]" ; + + skos:prefLabel "two-dimensional spatial region" . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000009 ; + owl:annotatedProperty iao:_0000600 ; + owl:annotatedTarget "A two-dimensional spatial region is a spatial region that is of two dimensions. (axiom label in BFO2 Reference: [039-001])" ; + iao:_0010000 +] . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000009 ; + owl:annotatedProperty iao:_0000602 ; + owl:annotatedTarget "(forall (x) (if (TwoDimensionalSpatialRegion x) (SpatialRegion x))) // axiom label in BFO2 CLIF: [039-001] " ; + iao:_0010000 +] . + + + +### http://purl.obolibrary.org/obo/BFO_0000011 + +bfo:_0000011 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000003 , + [ owl:intersectionOf ( [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000117 ; + owl:allValuesFrom bfo:_0000011 + ] + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000132 ; + owl:allValuesFrom bfo:_0000011 + ] + ) ; + rdf:type owl:Class + ] ; + + bfo:_0000179 "st-region" ; + + bfo:_0000180 "SpatiotemporalRegion" ; + + iao:_0000112 "the spatiotemporal region occupied by a human life"@en , + "the spatiotemporal region occupied by a process of cellular meiosis."@en , + "the spatiotemporal region occupied by the development of a cancer tumor" ; + + iao:_0000600 "A spatiotemporal region is an occurrent entity that is part of spacetime. (axiom label in BFO2 Reference: [095-001])" ; + + iao:_0000601 "All parts of spatiotemporal regions are spatiotemporal regions. (axiom label in BFO2 Reference: [096-001])" , + "All parts of spatiotemporal regions are spatiotemporal regions. (axiom label in BFO2 Reference: [096-001])"@en , + "Each spatiotemporal region at any time t projects_onto some spatial region at t. (axiom label in BFO2 Reference: [099-001])" , + "Each spatiotemporal region at any time t projects_onto some spatial region at t. (axiom label in BFO2 Reference: [099-001])"@en , + "Each spatiotemporal region projects_onto some temporal region. (axiom label in BFO2 Reference: [098-001])" , + "Each spatiotemporal region projects_onto some temporal region. (axiom label in BFO2 Reference: [098-001])"@en , + "Every spatiotemporal region occupies_spatiotemporal_region itself."@en , + "Every spatiotemporal region s is such that s occupies_spatiotemporal_region s. (axiom label in BFO2 Reference: [107-002])" ; + + iao:_0000602 "(forall (r) (if (SpatioTemporalRegion r) (occupiesSpatioTemporalRegion r r))) // axiom label in BFO2 CLIF: [107-002] " , + "(forall (x t) (if (SpatioTemporalRegion x) (exists (y) (and (SpatialRegion y) (spatiallyProjectsOntoAt x y t))))) // axiom label in BFO2 CLIF: [099-001] " , + "(forall (x y) (if (and (SpatioTemporalRegion x) (occurrentPartOf y x)) (SpatioTemporalRegion y))) // axiom label in BFO2 CLIF: [096-001] " , + "(forall (x) (if (SpatioTemporalRegion x) (Occurrent x))) // axiom label in BFO2 CLIF: [095-001] " , + "(forall (x) (if (SpatioTemporalRegion x) (exists (y) (and (TemporalRegion y) (temporallyProjectsOnto x y))))) // axiom label in BFO2 CLIF: [098-001] " ; + + rdfs:isDefinedBy , + ; + + rdfs:label "spatiotemporal region" ; + + skos:definition "A spatiotemporal region is an occurrent entity that is part of spacetime. [BFO]" ; + + skos:prefLabel "spatiotemporal region" . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000011 ; + owl:annotatedProperty iao:_0000600 ; + owl:annotatedTarget "A spatiotemporal region is an occurrent entity that is part of spacetime. (axiom label in BFO2 Reference: [095-001])" ; + iao:_0010000 +] . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000011 ; + owl:annotatedProperty iao:_0000601 ; + owl:annotatedTarget "All parts of spatiotemporal regions are spatiotemporal regions. (axiom label in BFO2 Reference: [096-001])" ; + iao:_0010000 +] . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000011 ; + owl:annotatedProperty iao:_0000601 ; + owl:annotatedTarget "Each spatiotemporal region at any time t projects_onto some spatial region at t. (axiom label in BFO2 Reference: [099-001])" ; + iao:_0010000 +] . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000011 ; + owl:annotatedProperty iao:_0000601 ; + owl:annotatedTarget "Each spatiotemporal region projects_onto some temporal region. (axiom label in BFO2 Reference: [098-001])" ; + iao:_0010000 +] . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000011 ; + owl:annotatedProperty iao:_0000601 ; + owl:annotatedTarget "Every spatiotemporal region s is such that s occupies_spatiotemporal_region s. (axiom label in BFO2 Reference: [107-002])" ; + iao:_0010000 +] . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000011 ; + owl:annotatedProperty iao:_0000602 ; + owl:annotatedTarget "(forall (r) (if (SpatioTemporalRegion r) (occupiesSpatioTemporalRegion r r))) // axiom label in BFO2 CLIF: [107-002] " ; + iao:_0010000 +] . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000011 ; + owl:annotatedProperty iao:_0000602 ; + owl:annotatedTarget "(forall (x t) (if (SpatioTemporalRegion x) (exists (y) (and (SpatialRegion y) (spatiallyProjectsOntoAt x y t))))) // axiom label in BFO2 CLIF: [099-001] " ; + iao:_0010000 +] . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000011 ; + owl:annotatedProperty iao:_0000602 ; + owl:annotatedTarget "(forall (x y) (if (and (SpatioTemporalRegion x) (occurrentPartOf y x)) (SpatioTemporalRegion y))) // axiom label in BFO2 CLIF: [096-001] " ; + iao:_0010000 +] . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000011 ; + owl:annotatedProperty iao:_0000602 ; + owl:annotatedTarget "(forall (x) (if (SpatioTemporalRegion x) (Occurrent x))) // axiom label in BFO2 CLIF: [095-001] " ; + iao:_0010000 +] . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000011 ; + owl:annotatedProperty iao:_0000602 ; + owl:annotatedTarget "(forall (x) (if (SpatioTemporalRegion x) (exists (y) (and (TemporalRegion y) (temporallyProjectsOnto x y))))) // axiom label in BFO2 CLIF: [098-001] " ; + iao:_0010000 +] . + + + +### http://purl.obolibrary.org/obo/BFO_0000015 + +bfo:_0000015 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000003 , + [ owl:intersectionOf ( [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000117 ; + owl:allValuesFrom [ rdf:type owl:Class ; + owl:unionOf ( bfo:_0000015 + bfo:_0000035 + ) + ] + ] + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000132 ; + owl:allValuesFrom bfo:_0000015 + ] + ) ; + rdf:type owl:Class + ] ; + + bfo:_0000179 "process" ; + + bfo:_0000180 "Process" ; + + iao:_0000112 "a process of cell-division, \\ a beating of the heart"@en , + "a process of meiosis"@en , + "a process of sleeping"@en , + "the course of a disease"@en , + "the flight of a bird"@en , + "the life of an organism"@en , + "your process of aging." ; + + iao:_0000115 "p is a process = Def. p is an occurrent that has temporal proper parts and for some time t, p s-depends_on some material entity at t. (axiom label in BFO2 Reference: [083-003])" ; + + iao:_0000116 "BFO 2 Reference: The realm of occurrents is less pervasively marked by the presence of natural units than is the case in the realm of independent continuants. Thus there is here no counterpart of ‘object’. In BFO 1.0 ‘process’ served as such a counterpart. In BFO 2.0 ‘process’ is, rather, the occurrent counterpart of ‘material entity’. Those natural – as contrasted with engineered, which here means: deliberately executed – units which do exist in the realm of occurrents are typically either parasitic on the existence of natural units on the continuant side, or they are fiat in nature. Thus we can count lives; we can count football games; we can count chemical reactions performed in experiments or in chemical manufacturing. We cannot count the processes taking place, for instance, in an episode of insect mating behavior.Even where natural units are identifiable, for example cycles in a cyclical process such as the beating of a heart or an organism’s sleep/wake cycle, the processes in question form a sequence with no discontinuities (temporal gaps) of the sort that we find for instance where billiard balls or zebrafish or planets are separated by clear spatial gaps. Lives of organisms are process units, but they too unfold in a continuous series from other, prior processes such as fertilization, and they unfold in turn in continuous series of post-life processes such as post-mortem decay. Clear examples of boundaries of processes are almost always of the fiat sort (midnight, a time of death as declared in an operating theater or on a death certificate, the initiation of a state of war)" ; + + iao:_0000602 "(iff (Process a) (and (Occurrent a) (exists (b) (properTemporalPartOf b a)) (exists (c t) (and (MaterialEntity c) (specificallyDependsOnAt a c t))))) // axiom label in BFO2 CLIF: [083-003] " ; + + rdfs:isDefinedBy , + ; + + rdfs:label "process" ; + + skos:definition "p is a process if p is an occurrent that has temporal proper parts and for some time t, p specifically depends on some material entity at t. [BFO]" ; + + skos:prefLabel "process" . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000015 ; + owl:annotatedProperty iao:_0000115 ; + owl:annotatedTarget "p is a process = Def. p is an occurrent that has temporal proper parts and for some time t, p s-depends_on some material entity at t. (axiom label in BFO2 Reference: [083-003])" ; + iao:_0010000 +] . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000015 ; + owl:annotatedProperty iao:_0000602 ; + owl:annotatedTarget "(iff (Process a) (and (Occurrent a) (exists (b) (properTemporalPartOf b a)) (exists (c t) (and (MaterialEntity c) (specificallyDependsOnAt a c t))))) // axiom label in BFO2 CLIF: [083-003] " ; + iao:_0010000 +] . + + + +### http://purl.obolibrary.org/obo/BFO_0000016 + +bfo:_0000016 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000017 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000052 ; + owl:someValuesFrom bfo:_0000040 + ] ; + + owl:disjointWith bfo:_0000023 ; + + bfo:_0000179 "disposition" ; + + bfo:_0000180 "Disposition" ; + + iao:_0000112 "an atom of element X has the disposition to decay to an atom of element Y"@en , + "certain people have a predisposition to colon cancer"@en , + "children are innately disposed to categorize objects in certain ways."@en , + "the cell wall is disposed to filter chemicals in endocytosis and exocytosis" ; + + iao:_0000116 "BFO 2 Reference: Dispositions exist along a strength continuum. Weaker forms of disposition are realized in only a fraction of triggering cases. These forms occur in a significant number of cases of a similar type." ; + + iao:_0000600 "b is a disposition means: b is a realizable entity & b’s bearer is some material entity & b is such that if it ceases to exist, then its bearer is physically changed, & b’s realization occurs when and because this bearer is in some special physical circumstances, & this realization occurs in virtue of the bearer’s physical make-up. (axiom label in BFO2 Reference: [062-002])" ; + + iao:_0000601 "If b is a realizable entity then for all t at which b exists, b s-depends_on some material entity at t. (axiom label in BFO2 Reference: [063-002])" ; + + iao:_0000602 "(forall (x t) (if (and (RealizableEntity x) (existsAt x t)) (exists (y) (and (MaterialEntity y) (specificallyDepends x y t))))) // axiom label in BFO2 CLIF: [063-002] " , + "(forall (x) (if (Disposition x) (and (RealizableEntity x) (exists (y) (and (MaterialEntity y) (bearerOfAt x y t)))))) // axiom label in BFO2 CLIF: [062-002] " ; + + rdfs:isDefinedBy , + ; + + rdfs:label "disposition" ; + + skos:definition "B is a disposition means: b is a realizable entity and b’s bearer is some material entity and b is such that if it ceases to exist, then its bearer is physically changed, and b’s realization occurs when and because this bearer is in some special physical circumstances, and this realization occurs in virtue of the bearer’s physical make-up. [BFO]" ; + + skos:prefLabel "disposition" . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000016 ; + owl:annotatedProperty iao:_0000600 ; + owl:annotatedTarget "b is a disposition means: b is a realizable entity & b’s bearer is some material entity & b is such that if it ceases to exist, then its bearer is physically changed, & b’s realization occurs when and because this bearer is in some special physical circumstances, & this realization occurs in virtue of the bearer’s physical make-up. (axiom label in BFO2 Reference: [062-002])" ; + iao:_0010000 +] . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000016 ; + owl:annotatedProperty iao:_0000601 ; + owl:annotatedTarget "If b is a realizable entity then for all t at which b exists, b s-depends_on some material entity at t. (axiom label in BFO2 Reference: [063-002])" ; + iao:_0010000 +] . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000016 ; + owl:annotatedProperty iao:_0000602 ; + owl:annotatedTarget "(forall (x t) (if (and (RealizableEntity x) (existsAt x t)) (exists (y) (and (MaterialEntity y) (specificallyDepends x y t))))) // axiom label in BFO2 CLIF: [063-002] " ; + iao:_0010000 +] . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000016 ; + owl:annotatedProperty iao:_0000602 ; + owl:annotatedTarget "(forall (x) (if (Disposition x) (and (RealizableEntity x) (exists (y) (and (MaterialEntity y) (bearerOfAt x y t)))))) // axiom label in BFO2 CLIF: [062-002] " ; + iao:_0010000 +] . + + + +### http://purl.obolibrary.org/obo/BFO_0000017 + +bfo:_0000017 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000020 , + [ owl:intersectionOf ( [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000054 ; + owl:someValuesFrom bfo:_0000015 + ] + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000052 ; + owl:someValuesFrom [ owl:intersectionOf ( bfo:_0000004 + [ rdf:type owl:Class ; + owl:complementOf bfo:_0000006 + ] + ) ; + rdf:type owl:Class + ] + ] + ) ; + rdf:type owl:Class + ] ; + + owl:disjointWith bfo:_0000019 ; + + bfo:_0000179 "realizable" ; + + bfo:_0000180 "RealizableEntity" ; + + iao:_0000112 "the disposition of this piece of metal to conduct electricity."@en , + "the disposition of your blood to coagulate"@en , + "the function of your reproductive organs"@en , + "the role of being a doctor"@en , + "the role of this boundary to delineate where Utah and Colorado meet" ; + + iao:_0000600 "To say that b is a realizable entity is to say that b is a specifically dependent continuant that inheres in some independent continuant which is not a spatial region and is of a type instances of which are realized in processes of a correlated type. (axiom label in BFO2 Reference: [058-002])" ; + + iao:_0000601 "All realizable dependent continuants have independent continuants that are not spatial regions as their bearers. (axiom label in BFO2 Reference: [060-002])" ; + + iao:_0000602 "(forall (x t) (if (RealizableEntity x) (exists (y) (and (IndependentContinuant y) (not (SpatialRegion y)) (bearerOfAt y x t))))) // axiom label in BFO2 CLIF: [060-002] " , + "(forall (x) (if (RealizableEntity x) (and (SpecificallyDependentContinuant x) (exists (y) (and (IndependentContinuant y) (not (SpatialRegion y)) (inheresIn x y)))))) // axiom label in BFO2 CLIF: [058-002] " ; + + rdfs:isDefinedBy , + ; + + rdfs:label "realizable entity" ; + + skos:definition "To say that b is a realizable entity is to say that b is a specifically dependent continuant that inheres in some independent continuant which is not a spatial region and is of a type instances of which are realized in processes of a correlated type.´[BFO]" ; + + skos:prefLabel "realizable entity" . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000017 ; + owl:annotatedProperty iao:_0000600 ; + owl:annotatedTarget "To say that b is a realizable entity is to say that b is a specifically dependent continuant that inheres in some independent continuant which is not a spatial region and is of a type instances of which are realized in processes of a correlated type. (axiom label in BFO2 Reference: [058-002])" ; + iao:_0010000 +] . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000017 ; + owl:annotatedProperty iao:_0000601 ; + owl:annotatedTarget "All realizable dependent continuants have independent continuants that are not spatial regions as their bearers. (axiom label in BFO2 Reference: [060-002])" ; + iao:_0010000 +] . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000017 ; + owl:annotatedProperty iao:_0000602 ; + owl:annotatedTarget "(forall (x t) (if (RealizableEntity x) (exists (y) (and (IndependentContinuant y) (not (SpatialRegion y)) (bearerOfAt y x t))))) // axiom label in BFO2 CLIF: [060-002] " ; + iao:_0010000 +] . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000017 ; + owl:annotatedProperty iao:_0000602 ; + owl:annotatedTarget "(forall (x) (if (RealizableEntity x) (and (SpecificallyDependentContinuant x) (exists (y) (and (IndependentContinuant y) (not (SpatialRegion y)) (inheresIn x y)))))) // axiom label in BFO2 CLIF: [058-002] " ; + iao:_0010000 +] . + + + +### http://purl.obolibrary.org/obo/BFO_0000018 + +bfo:_0000018 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000006 ; + + owl:disjointWith bfo:_0000028 ; + + bfo:_0000179 "0d-s-region" ; + + bfo:_0000180 "ZeroDimensionalSpatialRegion" ; + + iao:_0000600 "A zero-dimensional spatial region is a point in space. (axiom label in BFO2 Reference: [037-001])" ; + + iao:_0000602 "(forall (x) (if (ZeroDimensionalSpatialRegion x) (SpatialRegion x))) // axiom label in BFO2 CLIF: [037-001] " ; + + rdfs:isDefinedBy , + ; + + rdfs:label "zero-dimensional spatial region" ; + + skos:altLabel "0D spatial region" ; + + skos:definition "A zero-dimensional spatial region is a point in space. [BFO]" ; + + skos:prefLabel "zero-dimensional spatial region" . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000018 ; + owl:annotatedProperty iao:_0000600 ; + owl:annotatedTarget "A zero-dimensional spatial region is a point in space. (axiom label in BFO2 Reference: [037-001])" ; + iao:_0010000 +] . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000018 ; + owl:annotatedProperty iao:_0000602 ; + owl:annotatedTarget "(forall (x) (if (ZeroDimensionalSpatialRegion x) (SpatialRegion x))) // axiom label in BFO2 CLIF: [037-001] " ; + iao:_0010000 +] . + + + +### http://purl.obolibrary.org/obo/BFO_0000019 + +bfo:_0000019 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000020 ; + + bfo:_0000179 "quality" ; + + bfo:_0000180 "Quality" ; + + iao:_0000112 "the ambient temperature of this portion of air"@en , + "the color of a tomato"@en , + "the length of the circumference of your waist"@en , + "the mass of this piece of gold."@en , + "the shape of your nose"@en , + "the shape of your nostril" ; + + iao:_0000600 "a quality is a specifically dependent continuant that, in contrast to roles and dispositions, does not require any further process in order to be realized. (axiom label in BFO2 Reference: [055-001])" ; + + iao:_0000601 "If an entity is a quality at any time that it exists, then it is a quality at every time that it exists. (axiom label in BFO2 Reference: [105-001])" ; + + iao:_0000602 "(forall (x) (if (Quality x) (SpecificallyDependentContinuant x))) // axiom label in BFO2 CLIF: [055-001] " , + "(forall (x) (if (exists (t) (and (existsAt x t) (Quality x))) (forall (t_1) (if (existsAt x t_1) (Quality x))))) // axiom label in BFO2 CLIF: [105-001] " ; + + rdfs:isDefinedBy , + ; + + rdfs:label "quality" ; + + skos:definition "A quality is a specifically dependent continuant that, in contrast to roles and dispositions, does not require any further process in order to be realized. [BFO]" ; + + skos:prefLabel "quality" . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000019 ; + owl:annotatedProperty iao:_0000600 ; + owl:annotatedTarget "a quality is a specifically dependent continuant that, in contrast to roles and dispositions, does not require any further process in order to be realized. (axiom label in BFO2 Reference: [055-001])" ; + iao:_0010000 +] . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000019 ; + owl:annotatedProperty iao:_0000601 ; + owl:annotatedTarget "If an entity is a quality at any time that it exists, then it is a quality at every time that it exists. (axiom label in BFO2 Reference: [105-001])" ; + iao:_0010000 +] . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000019 ; + owl:annotatedProperty iao:_0000602 ; + owl:annotatedTarget "(forall (x) (if (Quality x) (SpecificallyDependentContinuant x))) // axiom label in BFO2 CLIF: [055-001] " ; + iao:_0010000 +] . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000019 ; + owl:annotatedProperty iao:_0000602 ; + owl:annotatedTarget "(forall (x) (if (exists (t) (and (existsAt x t) (Quality x))) (forall (t_1) (if (existsAt x t_1) (Quality x))))) // axiom label in BFO2 CLIF: [105-001] " ; + iao:_0010000 +] . + + + +### http://purl.obolibrary.org/obo/BFO_0000020 + +bfo:_0000020 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000002 , + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000050 ; + owl:allValuesFrom [ rdf:type owl:Class ; + owl:complementOf [ rdf:type owl:Class ; + owl:unionOf ( bfo:_0000004 + bfo:_0000031 + ) + ] + ] + ] ; + + bfo:_0000179 "sdc" ; + + bfo:_0000180 "SpecificallyDependentContinuant" ; + + iao:_0000112 "Reciprocal specifically dependent continuants: the function of this key to open this lock and the mutually dependent disposition of this lock: to be opened by this key"@en , + "of one-sided specifically dependent continuants: the mass of this tomato"@en , + "of relational dependent continuants (multiple bearers): John’s love for Mary, the ownership relation between John and this statue, the relation of authority between John and his subordinates."@en , + "the disposition of this fish to decay"@en , + "the function of this heart: to pump blood"@en , + "the mutual dependence of proton donors and acceptors in chemical reactions [79"@en , + "the mutual dependence of the role predator and the role prey as played by two organisms in a given interaction"@en , + "the pink color of a medium rare piece of grilled filet mignon at its center"@en , + "the role of being a doctor"@en , + "the shape of this hole."@en , + "the smell of this portion of mozzarella" ; + + iao:_0000115 "b is a specifically dependent continuant = Def. b is a continuant & there is some independent continuant c which is not a spatial region and which is such that b s-depends_on c at every time t during the course of b’s existence. (axiom label in BFO2 Reference: [050-003])" ; + + iao:_0000116 "Specifically dependent continuant doesn't have a closure axiom because the subclasses don't necessarily exhaust all possibilites. We're not sure what else will develop here, but for example there are questions such as what are promises, obligation, etc." ; + + iao:_0000602 "(iff (SpecificallyDependentContinuant a) (and (Continuant a) (forall (t) (if (existsAt a t) (exists (b) (and (IndependentContinuant b) (not (SpatialRegion b)) (specificallyDependsOnAt a b t))))))) // axiom label in BFO2 CLIF: [050-003] " ; + + rdfs:isDefinedBy , + ; + + rdfs:label "specifically dependent continuant" ; + + skos:definition "b is a specifically dependent continuant if b is a continuant and there is some independent continuant c which is not a spatial region and which is such that b specifically depends on c at every time t during the course of b’s existence. [BFO]" ; + + skos:prefLabel "specifically dependent continuant" . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000020 ; + owl:annotatedProperty iao:_0000115 ; + owl:annotatedTarget "b is a specifically dependent continuant = Def. b is a continuant & there is some independent continuant c which is not a spatial region and which is such that b s-depends_on c at every time t during the course of b’s existence. (axiom label in BFO2 Reference: [050-003])" ; + iao:_0010000 +] . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000020 ; + owl:annotatedProperty iao:_0000116 ; + owl:annotatedTarget "Specifically dependent continuant doesn't have a closure axiom because the subclasses don't necessarily exhaust all possibilites. We're not sure what else will develop here, but for example there are questions such as what are promises, obligation, etc." ; + iao:_0010000 ; + rdfs:comment "per discussion with Barry Smith" +] . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000020 ; + owl:annotatedProperty iao:_0000602 ; + owl:annotatedTarget "(iff (SpecificallyDependentContinuant a) (and (Continuant a) (forall (t) (if (existsAt a t) (exists (b) (and (IndependentContinuant b) (not (SpatialRegion b)) (specificallyDependsOnAt a b t))))))) // axiom label in BFO2 CLIF: [050-003] " ; + iao:_0010000 +] . + + + +### http://purl.obolibrary.org/obo/BFO_0000023 + +bfo:_0000023 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000017 ; + + bfo:_0000179 "role" ; + + bfo:_0000180 "Role" ; + + iao:_0000112 "John’s role of husband to Mary is dependent on Mary’s role of wife to John, and both are dependent on the object aggregate comprising John and Mary as member parts joined together through the relational quality of being married."@en , + "the priest role"@en , + "the role of a boundary to demarcate two neighboring administrative territories"@en , + "the role of a building in serving as a military target"@en , + "the role of a stone in marking a property boundary"@en , + "the role of subject in a clinical trial"@en , + "the student role" ; + + iao:_0000116 "BFO 2 Reference: One major family of examples of non-rigid universals involves roles, and ontologies developed for corresponding administrative purposes may consist entirely of representatives of entities of this sort. Thus ‘professor’, defined as follows,b instance_of professor at t =Def. there is some c, c instance_of professor role & c inheres_in b at t.denotes a non-rigid universal and so also do ‘nurse’, ‘student’, ‘colonel’, ‘taxpayer’, and so forth. (These terms are all, in the jargon of philosophy, phase sortals.) By using role terms in definitions, we can create a BFO conformant treatment of such entities drawing on the fact that, while an instance of professor may be simultaneously an instance of trade union member, no instance of the type professor role is also (at any time) an instance of the type trade union member role (any more than any instance of the type color is at any time an instance of the type length).If an ontology of employment positions should be defined in terms of roles following the above pattern, this enables the ontology to do justice to the fact that individuals instantiate the corresponding universals – professor, sergeant, nurse – only during certain phases in their lives." ; + + iao:_0000600 "b is a role means: b is a realizable entity & b exists because there is some single bearer that is in some special physical, social, or institutional set of circumstances in which this bearer does not have to be& b is not such that, if it ceases to exist, then the physical make-up of the bearer is thereby changed. (axiom label in BFO2 Reference: [061-001])" ; + + iao:_0000602 "(forall (x) (if (Role x) (RealizableEntity x))) // axiom label in BFO2 CLIF: [061-001] " ; + + rdfs:isDefinedBy , + ; + + rdfs:label "role" ; + + skos:definition "B is a role means: b is a realizable entity and b exists because there is some single bearer that is in some special physical, social, or institutional set of circumstances in which this bearer does not have to be and b is not such that, if it ceases to exist, then the physical make-up of the bearer is thereby changed. [BFO]" ; + + skos:prefLabel "role" . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000023 ; + owl:annotatedProperty iao:_0000600 ; + owl:annotatedTarget "b is a role means: b is a realizable entity & b exists because there is some single bearer that is in some special physical, social, or institutional set of circumstances in which this bearer does not have to be& b is not such that, if it ceases to exist, then the physical make-up of the bearer is thereby changed. (axiom label in BFO2 Reference: [061-001])" ; + iao:_0010000 +] . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000023 ; + owl:annotatedProperty iao:_0000602 ; + owl:annotatedTarget "(forall (x) (if (Role x) (RealizableEntity x))) // axiom label in BFO2 CLIF: [061-001] " ; + iao:_0010000 +] . + + + +### http://purl.obolibrary.org/obo/BFO_0000024 + +bfo:_0000024 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000040 ; + + bfo:_0000179 "fiat-object-part" ; + + bfo:_0000180 "FiatObjectPart" ; + + iao:_0000112 "or with divisions drawn by cognitive subjects for practical reasons, such as the division of a cake (before slicing) into (what will become) slices (and thus member parts of an object aggregate). However, this does not mean that fiat object parts are dependent for their existence on divisions or delineations effected by cognitive subjects. If, for example, it is correct to conceive geological layers of the Earth as fiat object parts of the Earth, then even though these layers were first delineated in recent times, still existed long before such delineation and what holds of these layers (for example that the oldest layers are also the lowest layers) did not begin to hold because of our acts of delineation.Treatment of material entity in BFOExamples viewed by some as problematic cases for the trichotomy of fiat object part, object, and object aggregate include: a mussel on (and attached to) a rock, a slime mold, a pizza, a cloud, a galaxy, a railway train with engine and multiple carriages, a clonal stand of quaking aspen, a bacterial community (biofilm), a broken femur. Note that, as Aristotle already clearly recognized, such problematic cases – which lie at or near the penumbra of instances defined by the categories in question – need not invalidate these categories. The existence of grey objects does not prove that there are not objects which are black and objects which are white; the existence of mules does not prove that there are not objects which are donkeys and objects which are horses. It does, however, show that the examples in question need to be addressed carefully in order to show how they can be fitted into the proposed scheme, for example by recognizing additional subdivisions [29"@en , + "the FMA:regional parts of an intact human body."@en , + "the Western hemisphere of the Earth"@en , + "the division of the brain into regions"@en , + "the division of the planet into hemispheres"@en , + "the dorsal and ventral surfaces of the body"@en , + "the upper and lower lobes of the left lung" ; + + iao:_0000116 "BFO 2 Reference: Most examples of fiat object parts are associated with theoretically drawn divisions" ; + + iao:_0000600 "b is a fiat object part = Def. b is a material entity which is such that for all times t, if b exists at t then there is some object c such that b proper continuant_part of c at t and c is demarcated from the remainder of c by a two-dimensional continuant fiat boundary. (axiom label in BFO2 Reference: [027-004])" ; + + iao:_0000602 "(forall (x) (if (FiatObjectPart x) (and (MaterialEntity x) (forall (t) (if (existsAt x t) (exists (y) (and (Object y) (properContinuantPartOfAt x y t)))))))) // axiom label in BFO2 CLIF: [027-004] " ; + + rdfs:isDefinedBy , + ; + + rdfs:label "fiat object part" ; + + skos:definition "B is a fiat object part if b is a material entity which is such that for all times t, if b exists at t then there is some object c such that b is a proper continuant part of c at t and c is demarcated from the remainder of c by a two-dimensional continuant fiat boundary. [BFO]" ; + + skos:prefLabel "fiat object part" . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000024 ; + owl:annotatedProperty iao:_0000600 ; + owl:annotatedTarget "b is a fiat object part = Def. b is a material entity which is such that for all times t, if b exists at t then there is some object c such that b proper continuant_part of c at t and c is demarcated from the remainder of c by a two-dimensional continuant fiat boundary. (axiom label in BFO2 Reference: [027-004])" ; + iao:_0010000 +] . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000024 ; + owl:annotatedProperty iao:_0000602 ; + owl:annotatedTarget "(forall (x) (if (FiatObjectPart x) (and (MaterialEntity x) (forall (t) (if (existsAt x t) (exists (y) (and (Object y) (properContinuantPartOfAt x y t)))))))) // axiom label in BFO2 CLIF: [027-004] " ; + iao:_0010000 +] . + + + +### http://purl.obolibrary.org/obo/BFO_0000026 + +bfo:_0000026 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000006 ; + + owl:disjointWith bfo:_0000028 ; + + bfo:_0000179 "1d-s-region" ; + + bfo:_0000180 "OneDimensionalSpatialRegion" ; + + iao:_0000112 "an edge of a cube-shaped portion of space." ; + + iao:_0000600 "A one-dimensional spatial region is a line or aggregate of lines stretching from one point in space to another. (axiom label in BFO2 Reference: [038-001])" ; + + iao:_0000602 "(forall (x) (if (OneDimensionalSpatialRegion x) (SpatialRegion x))) // axiom label in BFO2 CLIF: [038-001] " ; + + rdfs:isDefinedBy , + ; + + rdfs:label "one-dimensional spatial region" ; + + skos:altLabel "1D spatial region" ; + + skos:definition "A one-dimensional spatial region is a line or aggregate of lines stretching from one point in space to another. [BFO]" ; + + skos:prefLabel "one-dimensional spatial region" . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000026 ; + owl:annotatedProperty iao:_0000600 ; + owl:annotatedTarget "A one-dimensional spatial region is a line or aggregate of lines stretching from one point in space to another. (axiom label in BFO2 Reference: [038-001])" ; + iao:_0010000 +] . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000026 ; + owl:annotatedProperty iao:_0000602 ; + owl:annotatedTarget "(forall (x) (if (OneDimensionalSpatialRegion x) (SpatialRegion x))) // axiom label in BFO2 CLIF: [038-001] " ; + iao:_0010000 +] . + + + +### http://purl.obolibrary.org/obo/BFO_0000027 + +bfo:_0000027 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000040 ; + + bfo:_0000179 "object-aggregate" ; + + bfo:_0000180 "ObjectAggregate" ; + + iao:_0000112 "a collection of cells in a blood biobank."@en , + "a swarm of bees is an aggregate of members who are linked together through natural bonds"@en , + "a symphony orchestra"@en , + "an organization is an aggregate whose member parts have roles of specific types (for example in a jazz band, a chess club, a football team)"@en , + "defined by fiat: the aggregate of members of an organization"@en , + "defined through physical attachment: the aggregate of atoms in a lump of granite"@en , + "defined through physical containment: the aggregate of molecules of carbon dioxide in a sealed container"@en , + "defined via attributive delimitations such as: the patients in this hospital"@en , + "the aggregate of bearings in a constant velocity axle joint"@en , + "the aggregate of blood cells in your body"@en , + "the nitrogen atoms in the atmosphere"@en , + "the restaurants in Palo Alto"@en , + "your collection of Meissen ceramic plates." ; + + iao:_0000116 "An entity a is an object aggregate if and only if there is a mutually exhaustive and pairwise disjoint partition of a into objects " , + "BFO 2 Reference: object aggregates may gain and lose parts while remaining numerically identical (one and the same individual) over time. This holds both for aggregates whose membership is determined naturally (the aggregate of cells in your body) and aggregates determined by fiat (a baseball team, a congressional committee)." ; + + iao:_0000119 "ISBN:978-3-938793-98-5pp124-158#Thomas Bittner and Barry Smith, 'A Theory of Granular Partitions', in K. Munn and B. Smith (eds.), Applied Ontology: An Introduction, Frankfurt/Lancaster: ontos, 2008, 125-158." ; + + iao:_0000600 "b is an object aggregate means: b is a material entity consisting exactly of a plurality of objects as member_parts at all times at which b exists. (axiom label in BFO2 Reference: [025-004])" ; + + iao:_0000602 "(forall (x) (if (ObjectAggregate x) (and (MaterialEntity x) (forall (t) (if (existsAt x t) (exists (y z) (and (Object y) (Object z) (memberPartOfAt y x t) (memberPartOfAt z x t) (not (= y z)))))) (not (exists (w t_1) (and (memberPartOfAt w x t_1) (not (Object w)))))))) // axiom label in BFO2 CLIF: [025-004] " ; + + rdfs:isDefinedBy , + ; + + rdfs:label "object aggregate" ; + + skos:definition "B is an object aggregate means: b is a material entity consisting exactly of a plurality of objects as member parts at all times at which b exists. [BFO]" ; + + skos:prefLabel "object aggregate" . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000027 ; + owl:annotatedProperty iao:_0000116 ; + owl:annotatedTarget "An entity a is an object aggregate if and only if there is a mutually exhaustive and pairwise disjoint partition of a into objects " ; + iao:_0010000 +] . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000027 ; + owl:annotatedProperty iao:_0000116 ; + owl:annotatedTarget "An entity a is an object aggregate if and only if there is a mutually exhaustive and pairwise disjoint partition of a into objects " ; + iao:_0010000 +] . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000027 ; + owl:annotatedProperty iao:_0000119 ; + owl:annotatedTarget "ISBN:978-3-938793-98-5pp124-158#Thomas Bittner and Barry Smith, 'A Theory of Granular Partitions', in K. Munn and B. Smith (eds.), Applied Ontology: An Introduction, Frankfurt/Lancaster: ontos, 2008, 125-158." ; + iao:_0010000 +] . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000027 ; + owl:annotatedProperty iao:_0000600 ; + owl:annotatedTarget "b is an object aggregate means: b is a material entity consisting exactly of a plurality of objects as member_parts at all times at which b exists. (axiom label in BFO2 Reference: [025-004])" ; + iao:_0010000 +] . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000027 ; + owl:annotatedProperty iao:_0000602 ; + owl:annotatedTarget "(forall (x) (if (ObjectAggregate x) (and (MaterialEntity x) (forall (t) (if (existsAt x t) (exists (y z) (and (Object y) (Object z) (memberPartOfAt y x t) (memberPartOfAt z x t) (not (= y z)))))) (not (exists (w t_1) (and (memberPartOfAt w x t_1) (not (Object w)))))))) // axiom label in BFO2 CLIF: [025-004] " ; + iao:_0010000 +] . + + + +### http://purl.obolibrary.org/obo/BFO_0000028 + +bfo:_0000028 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000006 ; + + bfo:_0000179 "3d-s-region" ; + + bfo:_0000180 "ThreeDimensionalSpatialRegion" ; + + iao:_0000112 "a cube-shaped region of space"@en , + "a sphere-shaped region of space," ; + + iao:_0000600 "A three-dimensional spatial region is a spatial region that is of three dimensions. (axiom label in BFO2 Reference: [040-001])" ; + + iao:_0000602 "(forall (x) (if (ThreeDimensionalSpatialRegion x) (SpatialRegion x))) // axiom label in BFO2 CLIF: [040-001] " ; + + rdfs:isDefinedBy , + ; + + rdfs:label "three-dimensional spatial region" ; + + skos:altLabel "3D spatial region" ; + + skos:definition "A three-dimensional spatial region is a spatial region that is of three dimensions. [BFO]" ; + + skos:prefLabel "three-dimensional spatial region" . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000028 ; + owl:annotatedProperty iao:_0000600 ; + owl:annotatedTarget "A three-dimensional spatial region is a spatial region that is of three dimensions. (axiom label in BFO2 Reference: [040-001])" ; + iao:_0010000 +] . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000028 ; + owl:annotatedProperty iao:_0000602 ; + owl:annotatedTarget "(forall (x) (if (ThreeDimensionalSpatialRegion x) (SpatialRegion x))) // axiom label in BFO2 CLIF: [040-001] " ; + iao:_0010000 +] . + + + +### http://purl.obolibrary.org/obo/BFO_0000029 + +bfo:_0000029 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000141 ; + + bfo:_0000179 "site" ; + + bfo:_0000180 "Site" ; + + iao:_0000112 "Manhattan Canyon)"@en , + "a hole in the interior of a portion of cheese"@en , + "a rabbit hole"@en , + "an air traffic control region defined in the airspace above an airport"@en , + "the Grand Canyon"@en , + "the Piazza San Marco"@en , + "the cockpit of an aircraft"@en , + "the hold of a ship"@en , + "the interior of a kangaroo pouch"@en , + "the interior of the trunk of your car"@en , + "the interior of your bedroom"@en , + "the interior of your office"@en , + "the interior of your refrigerator"@en , + "the lumen of your gut"@en , + "your left nostril (a fiat part – the opening – of your left nasal cavity)" ; + + iao:_0000600 "b is a site means: b is a three-dimensional immaterial entity that is (partially or wholly) bounded by a material entity or it is a three-dimensional immaterial part thereof. (axiom label in BFO2 Reference: [034-002])" ; + + iao:_0000602 "(forall (x) (if (Site x) (ImmaterialEntity x))) // axiom label in BFO2 CLIF: [034-002] " ; + + rdfs:isDefinedBy , + ; + + rdfs:label "site" ; + + skos:definition "B is a site means: b is a three-dimensional immaterial entity that is (partially or wholly) bounded by a material entity or it is a three-dimensional immaterial part thereof. [BFO]" ; + + skos:prefLabel "site" . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000029 ; + owl:annotatedProperty iao:_0000600 ; + owl:annotatedTarget "b is a site means: b is a three-dimensional immaterial entity that is (partially or wholly) bounded by a material entity or it is a three-dimensional immaterial part thereof. (axiom label in BFO2 Reference: [034-002])" ; + iao:_0010000 +] . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000029 ; + owl:annotatedProperty iao:_0000602 ; + owl:annotatedTarget "(forall (x) (if (Site x) (ImmaterialEntity x))) // axiom label in BFO2 CLIF: [034-002] " ; + iao:_0010000 +] . + + + +### http://purl.obolibrary.org/obo/BFO_0000030 + +bfo:_0000030 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000040 ; + + bfo:_0000179 "object" ; + + bfo:_0000180 "Object" ; + + iao:_0000112 "atom"@en , + "cell"@en , + "cells and organisms"@en , + "engineered artifacts"@en , + "grain of sand"@en , + "molecule"@en , + "organelle"@en , + "organism"@en , + "planet"@en , + "solid portions of matter"@en , + "star" ; + + iao:_0000116 "BFO 2 Reference: BFO rests on the presupposition that at multiple micro-, meso- and macroscopic scales reality exhibits certain stable, spatially separated or separable material units, combined or combinable into aggregates of various sorts (for example organisms into what are called ‘populations’). Such units play a central role in almost all domains of natural science from particle physics to cosmology. Many scientific laws govern the units in question, employing general terms (such as ‘molecule’ or ‘planet’) referring to the types and subtypes of units, and also to the types and subtypes of the processes through which such units develop and interact. The division of reality into such natural units is at the heart of biological science, as also is the fact that these units may form higher-level units (as cells form multicellular organisms) and that they may also form aggregates of units, for example as cells form portions of tissue and organs form families, herds, breeds, species, and so on. At the same time, the division of certain portions of reality into engineered units (manufactured artifacts) is the basis of modern industrial technology, which rests on the distributed mass production of engineered parts through division of labor and on their assembly into larger, compound units such as cars and laptops. The division of portions of reality into units is one starting point for the phenomenon of counting."@en , + "BFO 2 Reference: Each object is such that there are entities of which we can assert unproblematically that they lie in its interior, and other entities of which we can assert unproblematically that they lie in its exterior. This may not be so for entities lying at or near the boundary between the interior and exterior. This means that two objects – for example the two cells depicted in Figure 3 – may be such that there are material entities crossing their boundaries which belong determinately to neither cell. Something similar obtains in certain cases of conjoined twins (see below)."@en , + "BFO 2 Reference: To say that b is causally unified means: b is a material entity which is such that its material parts are tied together in such a way that, in environments typical for entities of the type in question,if c, a continuant part of b that is in the interior of b at t, is larger than a certain threshold size (which will be determined differently from case to case, depending on factors such as porosity of external cover) and is moved in space to be at t at a location on the exterior of the spatial region that had been occupied by b at t, then either b’s other parts will be moved in coordinated fashion or b will be damaged (be affected, for example, by breakage or tearing) in the interval between t and t.causal changes in one part of b can have consequences for other parts of b without the mediation of any entity that lies on the exterior of b. Material entities with no proper material parts would satisfy these conditions trivially. Candidate examples of types of causal unity for material entities of more complex sorts are as follows (this is not intended to be an exhaustive list):CU1: Causal unity via physical coveringHere the parts in the interior of the unified entity are combined together causally through a common membrane or other physical covering\\. The latter points outwards toward and may serve a protective function in relation to what lies on the exterior of the entity [13, 47"@en , + "BFO 2 Reference: an object is a maximal causally unified material entity"@en , + "BFO 2 Reference: ‘objects’ are sometimes referred to as ‘grains’ [74" ; + + iao:_0000600 "b is an object means: b is a material entity which manifests causal unity of one or other of the types CUn listed above & is of a type (a material universal) instances of which are maximal relative to this criterion of causal unity. (axiom label in BFO2 Reference: [024-001])" ; + + rdfs:isDefinedBy , + ; + + rdfs:label "object" ; + + skos:definition """B is an object means: b is a material entity which manifests causal unity of one or other of the types causal unities and is of a type (a material universal) instances of which are maximal relative to this criterion of causal unity. + +To say that b is causally unified means: b is a material entity which is such that its material parts are tied together in such a way that, in environments typical for entities of the type in question,if c, a continuant part of b that is in the interior of b at t, is larger than a certain threshold size (which will be determined differently from case to case, depending on factors such as porosity of external cover) and is moved in space to be at t at a location on the exterior of the spatial region that had been occupied by b at t, then either b’s other parts will be moved in coordinated fashion or b will be damaged (be affected, for example, by breakage or tearing) in the interval between t and t. [BFO]""" ; + + skos:prefLabel "object" . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000030 ; + owl:annotatedProperty iao:_0000600 ; + owl:annotatedTarget "b is an object means: b is a material entity which manifests causal unity of one or other of the types CUn listed above & is of a type (a material universal) instances of which are maximal relative to this criterion of causal unity. (axiom label in BFO2 Reference: [024-001])" ; + iao:_0010000 +] . + + + +### http://purl.obolibrary.org/obo/BFO_0000031 + +bfo:_0000031 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000002 , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000058 ; + owl:someValuesFrom bfo:_0000020 + ] ; + + bfo:_0000179 "gdc" ; + + bfo:_0000180 "GenericallyDependentContinuant" ; + + iao:_0000112 "The entries in your database are patterns instantiated as quality instances in your hard drive. The database itself is an aggregate of such patterns. When you create the database you create a particular instance of the generically dependent continuant type database. Each entry in the database is an instance of the generically dependent continuant type IAO: information content entity."@en , + "the pdf file on your laptop, the pdf file that is a copy thereof on my laptop"@en , + "the sequence of this protein molecule; the sequence that is a copy thereof in that protein molecule." ; + + iao:_0000115 "b is a generically dependent continuant = Def. b is a continuant that g-depends_on one or more other entities. (axiom label in BFO2 Reference: [074-001])" ; + + iao:_0000602 "(iff (GenericallyDependentContinuant a) (and (Continuant a) (exists (b t) (genericallyDependsOnAt a b t)))) // axiom label in BFO2 CLIF: [074-001] " ; + + rdfs:isDefinedBy , + ; + + rdfs:label "generically dependent continuant" ; + + skos:definition "b is a generically dependent continuant if b is a continuant that generically depends on one or more other entities. [BFO]" ; + + skos:prefLabel "generically dependent continuant" . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000031 ; + owl:annotatedProperty iao:_0000115 ; + owl:annotatedTarget "b is a generically dependent continuant = Def. b is a continuant that g-depends_on one or more other entities. (axiom label in BFO2 Reference: [074-001])" ; + iao:_0010000 +] . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000031 ; + owl:annotatedProperty iao:_0000602 ; + owl:annotatedTarget "(iff (GenericallyDependentContinuant a) (and (Continuant a) (exists (b t) (genericallyDependsOnAt a b t)))) // axiom label in BFO2 CLIF: [074-001] " ; + iao:_0010000 +] . + + + +### http://purl.obolibrary.org/obo/BFO_0000034 + +bfo:_0000034 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000016 ; + + bfo:_0000179 "function" ; + + bfo:_0000180 "Function" ; + + iao:_0000112 "the function of a hammer to drive in nails"@en , + "the function of a heart pacemaker to regulate the beating of a heart through electricity"@en , + "the function of amylase in saliva to break down starch into sugar" ; + + iao:_0000116 "BFO 2 Reference: In the past, we have distinguished two varieties of function, artifactual function and biological function. These are not asserted subtypes of BFO:function however, since the same function – for example: to pump, to transport – can exist both in artifacts and in biological entities. The asserted subtypes of function that would be needed in order to yield a separate monoheirarchy are not artifactual function, biological function, etc., but rather transporting function, pumping function, etc." ; + + iao:_0000600 "A function is a disposition that exists in virtue of the bearer’s physical make-up and this physical make-up is something the bearer possesses because it came into being, either through evolution (in the case of natural biological entities) or through intentional design (in the case of artifacts), in order to realize processes of a certain sort. (axiom label in BFO2 Reference: [064-001])" ; + + iao:_0000602 "(forall (x) (if (Function x) (Disposition x))) // axiom label in BFO2 CLIF: [064-001] " ; + + rdfs:isDefinedBy , + ; + + rdfs:label "function" ; + + skos:definition "A function is a disposition that exists in virtue of the bearer’s physical make-up and this physical make-up is something the bearer possesses because it came into being, either through evolution (in the case of natural biological entities) or through intentional design (in the case of artifacts), in order to realize processes of a certain sort. [BFO]" ; + + skos:prefLabel "function" . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000034 ; + owl:annotatedProperty iao:_0000600 ; + owl:annotatedTarget "A function is a disposition that exists in virtue of the bearer’s physical make-up and this physical make-up is something the bearer possesses because it came into being, either through evolution (in the case of natural biological entities) or through intentional design (in the case of artifacts), in order to realize processes of a certain sort. (axiom label in BFO2 Reference: [064-001])" ; + iao:_0010000 +] . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000034 ; + owl:annotatedProperty iao:_0000602 ; + owl:annotatedTarget "(forall (x) (if (Function x) (Disposition x))) // axiom label in BFO2 CLIF: [064-001] " ; + iao:_0010000 +] . + + + +### http://purl.obolibrary.org/obo/BFO_0000035 + +bfo:_0000035 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000003 , + [ owl:intersectionOf ( [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000108 ; + owl:allValuesFrom bfo:_0000148 + ] + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000117 ; + owl:allValuesFrom bfo:_0000035 + ] + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000130 ; + owl:allValuesFrom [ owl:intersectionOf ( bfo:_0000011 + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000139 ; + owl:someValuesFrom bfo:_0000011 + ] + ) ; + rdf:type owl:Class + ] + ] + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000132 ; + owl:allValuesFrom [ rdf:type owl:Class ; + owl:unionOf ( bfo:_0000015 + bfo:_0000035 + ) + ] + ] + ) ; + rdf:type owl:Class + ] ; + + bfo:_0000179 "p-boundary" ; + + bfo:_0000180 "ProcessBoundary" ; + + iao:_0000112 "the boundary between the 2nd and 3rd year of your life." ; + + iao:_0000115 "p is a process boundary =Def. p is a temporal part of a process & p has no proper temporal parts. (axiom label in BFO2 Reference: [084-001])" ; + + iao:_0000601 "Every process boundary occupies_temporal_region a zero-dimensional temporal region. (axiom label in BFO2 Reference: [085-002])" ; + + iao:_0000602 "(forall (x) (if (ProcessBoundary x) (exists (y) (and (ZeroDimensionalTemporalRegion y) (occupiesTemporalRegion x y))))) // axiom label in BFO2 CLIF: [085-002] " , + "(iff (ProcessBoundary a) (exists (p) (and (Process p) (temporalPartOf a p) (not (exists (b) (properTemporalPartOf b a)))))) // axiom label in BFO2 CLIF: [084-001] " ; + + rdfs:isDefinedBy , + ; + + rdfs:label "process boundary" ; + + skos:definition "p is a process boundary if p is a temporal part of a process and p has no proper temporal parts. [BFO]" ; + + skos:prefLabel "process boundary" . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000035 ; + owl:annotatedProperty iao:_0000115 ; + owl:annotatedTarget "p is a process boundary =Def. p is a temporal part of a process & p has no proper temporal parts. (axiom label in BFO2 Reference: [084-001])" ; + iao:_0010000 +] . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000035 ; + owl:annotatedProperty iao:_0000601 ; + owl:annotatedTarget "Every process boundary occupies_temporal_region a zero-dimensional temporal region. (axiom label in BFO2 Reference: [085-002])" ; + iao:_0010000 +] . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000035 ; + owl:annotatedProperty iao:_0000602 ; + owl:annotatedTarget "(forall (x) (if (ProcessBoundary x) (exists (y) (and (ZeroDimensionalTemporalRegion y) (occupiesTemporalRegion x y))))) // axiom label in BFO2 CLIF: [085-002] " ; + iao:_0010000 +] . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000035 ; + owl:annotatedProperty iao:_0000602 ; + owl:annotatedTarget "(iff (ProcessBoundary a) (exists (p) (and (Process p) (temporalPartOf a p) (not (exists (b) (properTemporalPartOf b a)))))) // axiom label in BFO2 CLIF: [084-001] " ; + iao:_0010000 +] . + + + +### http://purl.obolibrary.org/obo/BFO_0000038 + +bfo:_0000038 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000008 ; + + owl:disjointWith bfo:_0000148 ; + + bfo:_0000179 "1d-t-region" ; + + bfo:_0000180 "OneDimensionalTemporalRegion" ; + + iao:_0000112 "the temporal region during which a process occurs." ; + + iao:_0000116 "BFO 2 Reference: A temporal interval is a special kind of one-dimensional temporal region, namely one that is self-connected (is without gaps or breaks)." ; + + iao:_0000600 "A one-dimensional temporal region is a temporal region that is extended. (axiom label in BFO2 Reference: [103-001])" ; + + iao:_0000602 "(forall (x) (if (OneDimensionalTemporalRegion x) (TemporalRegion x))) // axiom label in BFO2 CLIF: [103-001] " ; + + rdfs:isDefinedBy , + ; + + rdfs:label "one-dimensional temporal region" ; + + skos:altLabel "1D-temporal region" ; + + skos:definition "A one-dimensional temporal region is a temporal region that is extended. [BFO]" ; + + skos:prefLabel "one-dimensional temporal region" . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000038 ; + owl:annotatedProperty iao:_0000600 ; + owl:annotatedTarget "A one-dimensional temporal region is a temporal region that is extended. (axiom label in BFO2 Reference: [103-001])" ; + iao:_0010000 +] . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000038 ; + owl:annotatedProperty iao:_0000602 ; + owl:annotatedTarget "(forall (x) (if (OneDimensionalTemporalRegion x) (TemporalRegion x))) // axiom label in BFO2 CLIF: [103-001] " ; + iao:_0010000 +] . + + + +### http://purl.obolibrary.org/obo/BFO_0000040 + +bfo:_0000040 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000004 ; + + owl:disjointWith bfo:_0000141 ; + + bfo:_0000179 "material" ; + + bfo:_0000180 "MaterialEntity" ; + + iao:_0000112 "a flame"@en , + "a forest fire"@en , + "a human being"@en , + "a hurricane"@en , + "a photon"@en , + "a puff of smoke"@en , + "a sea wave"@en , + "a tornado"@en , + "an aggregate of human beings."@en , + "an energy wave"@en , + "an epidemic"@en , + "the undetached arm of a human being" ; + + iao:_0000116 "BFO 2 Reference: Material entities (continuants) can preserve their identity even while gaining and losing material parts. Continuants are contrasted with occurrents, which unfold themselves in successive temporal parts or phases [60"@en , + "BFO 2 Reference: Object, Fiat Object Part and Object Aggregate are not intended to be exhaustive of Material Entity. Users are invited to propose new subcategories of Material Entity."@en , + "BFO 2 Reference: ‘Matter’ is intended to encompass both mass and energy (we will address the ontological treatment of portions of energy in a later version of BFO). A portion of matter is anything that includes elementary particles among its proper or improper parts: quarks and leptons, including electrons, as the smallest particles thus far discovered; baryons (including protons and neutrons) at a higher level of granularity; atoms and molecules at still higher levels, forming the cells, organs, organisms and other material entities studied by biologists, the portions of rock studied by geologists, the fossils studied by paleontologists, and so on.Material entities are three-dimensional entities (entities extended in three spatial dimensions), as contrasted with the processes in which they participate, which are four-dimensional entities (entities extended also along the dimension of time).According to the FMA, material entities may have immaterial entities as parts – including the entities identified below as sites; for example the interior (or ‘lumen’) of your small intestine is a part of your body. BFO 2.0 embodies a decision to follow the FMA here." ; + + iao:_0000600 "A material entity is an independent continuant that has some portion of matter as proper or improper continuant part. (axiom label in BFO2 Reference: [019-002])" ; + + iao:_0000601 "Every entity which has a material entity as continuant part is a material entity. (axiom label in BFO2 Reference: [020-002])" , + "Every entity which has a material entity as continuant part is a material entity. (axiom label in BFO2 Reference: [020-002])"@en , + "every entity of which a material entity is continuant part is also a material entity. (axiom label in BFO2 Reference: [021-002])" ; + + iao:_0000602 "(forall (x) (if (MaterialEntity x) (IndependentContinuant x))) // axiom label in BFO2 CLIF: [019-002] " , + "(forall (x) (if (and (Entity x) (exists (y t) (and (MaterialEntity y) (continuantPartOfAt x y t)))) (MaterialEntity x))) // axiom label in BFO2 CLIF: [021-002] " , + "(forall (x) (if (and (Entity x) (exists (y t) (and (MaterialEntity y) (continuantPartOfAt y x t)))) (MaterialEntity x))) // axiom label in BFO2 CLIF: [020-002] " ; + + rdfs:isDefinedBy , + ; + + rdfs:label "material entity" ; + + skos:definition "A material entity is an independent continuant that has some portion of matter as proper or improper continuant part. [BFO]" ; + + skos:prefLabel "material entity" . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000040 ; + owl:annotatedProperty iao:_0000600 ; + owl:annotatedTarget "A material entity is an independent continuant that has some portion of matter as proper or improper continuant part. (axiom label in BFO2 Reference: [019-002])" ; + iao:_0010000 +] . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000040 ; + owl:annotatedProperty iao:_0000601 ; + owl:annotatedTarget "Every entity which has a material entity as continuant part is a material entity. (axiom label in BFO2 Reference: [020-002])" ; + iao:_0010000 +] . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000040 ; + owl:annotatedProperty iao:_0000601 ; + owl:annotatedTarget "every entity of which a material entity is continuant part is also a material entity. (axiom label in BFO2 Reference: [021-002])" ; + iao:_0010000 +] . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000040 ; + owl:annotatedProperty iao:_0000602 ; + owl:annotatedTarget "(forall (x) (if (MaterialEntity x) (IndependentContinuant x))) // axiom label in BFO2 CLIF: [019-002] " ; + iao:_0010000 +] . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000040 ; + owl:annotatedProperty iao:_0000602 ; + owl:annotatedTarget "(forall (x) (if (and (Entity x) (exists (y t) (and (MaterialEntity y) (continuantPartOfAt x y t)))) (MaterialEntity x))) // axiom label in BFO2 CLIF: [021-002] " ; + iao:_0010000 +] . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000040 ; + owl:annotatedProperty iao:_0000602 ; + owl:annotatedTarget "(forall (x) (if (and (Entity x) (exists (y t) (and (MaterialEntity y) (continuantPartOfAt y x t)))) (MaterialEntity x))) // axiom label in BFO2 CLIF: [020-002] " ; + iao:_0010000 +] . + + + +### http://purl.obolibrary.org/obo/BFO_0000140 + +bfo:_0000140 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000141 ; + + bfo:_0000179 "cf-boundary" ; + + bfo:_0000180 "ContinuantFiatBoundary" ; + + iao:_0000115 "b is a continuant fiat boundary = Def. b is an immaterial entity that is of zero, one or two dimensions and does not include a spatial region as part. (axiom label in BFO2 Reference: [029-001])" ; + + iao:_0000116 "BFO 2 Reference: In BFO 1.1 the assumption was made that the external surface of a material entity such as a cell could be treated as if it were a boundary in the mathematical sense. The new document propounds the view that when we talk about external surfaces of material objects in this way then we are talking about something fiat. To be dealt with in a future version: fiat boundaries at different levels of granularity.More generally, the focus in discussion of boundaries in BFO 2.0 is now on fiat boundaries, which means: boundaries for which there is no assumption that they coincide with physical discontinuities. The ontology of boundaries becomes more closely allied with the ontology of regions."@en , + "BFO 2 Reference: a continuant fiat boundary is a boundary of some material entity (for example: the plane separating the Northern and Southern hemispheres; the North Pole), or it is a boundary of some immaterial entity (for example of some portion of airspace). Three basic kinds of continuant fiat boundary can be distinguished (together with various combination kinds [29"@en , + "Continuant fiat boundary doesn't have a closure axiom because the subclasses don't necessarily exhaust all possibilites. An example would be the mereological sum of two-dimensional continuant fiat boundary and a one dimensional continuant fiat boundary that doesn't overlap it. The situation is analogous to temporal and spatial regions." ; + + iao:_0000601 "Every continuant fiat boundary is located at some spatial region at every time at which it exists" ; + + iao:_0000602 "(iff (ContinuantFiatBoundary a) (and (ImmaterialEntity a) (exists (b) (and (or (ZeroDimensionalSpatialRegion b) (OneDimensionalSpatialRegion b) (TwoDimensionalSpatialRegion b)) (forall (t) (locatedInAt a b t)))) (not (exists (c t) (and (SpatialRegion c) (continuantPartOfAt c a t)))))) // axiom label in BFO2 CLIF: [029-001] " ; + + rdfs:isDefinedBy , + ; + + rdfs:label "continuant fiat boundary" ; + + skos:definition "B is a continuant fiat boundary if b is an immaterial entity that is of zero, one or two dimensions and does not include a spatial region as part. [BFO]" ; + + skos:prefLabel "continuant fiat boundary" . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000140 ; + owl:annotatedProperty iao:_0000115 ; + owl:annotatedTarget "b is a continuant fiat boundary = Def. b is an immaterial entity that is of zero, one or two dimensions and does not include a spatial region as part. (axiom label in BFO2 Reference: [029-001])" ; + iao:_0010000 +] . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000140 ; + owl:annotatedProperty iao:_0000116 ; + owl:annotatedTarget "Continuant fiat boundary doesn't have a closure axiom because the subclasses don't necessarily exhaust all possibilites. An example would be the mereological sum of two-dimensional continuant fiat boundary and a one dimensional continuant fiat boundary that doesn't overlap it. The situation is analogous to temporal and spatial regions." ; + iao:_0010000 +] . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000140 ; + owl:annotatedProperty iao:_0000602 ; + owl:annotatedTarget "(iff (ContinuantFiatBoundary a) (and (ImmaterialEntity a) (exists (b) (and (or (ZeroDimensionalSpatialRegion b) (OneDimensionalSpatialRegion b) (TwoDimensionalSpatialRegion b)) (forall (t) (locatedInAt a b t)))) (not (exists (c t) (and (SpatialRegion c) (continuantPartOfAt c a t)))))) // axiom label in BFO2 CLIF: [029-001] " ; + iao:_0010000 +] . + + + +### http://purl.obolibrary.org/obo/BFO_0000141 + +bfo:_0000141 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000004 ; + + bfo:_0000179 "immaterial" ; + + bfo:_0000180 "ImmaterialEntity" ; + + iao:_0000116 "BFO 2 Reference: Immaterial entities are divided into two subgroups:boundaries and sites, which bound, or are demarcated in relation, to material entities, and which can thus change location, shape and size and as their material hosts move or change shape or size (for example: your nasal passage; the hold of a ship; the boundary of Wales (which moves with the rotation of the Earth) [38, 7, 10" ; + + rdfs:isDefinedBy , + ; + + rdfs:label "immaterial entity" ; + + skos:prefLabel "immaterial entity" . + + + +### http://purl.obolibrary.org/obo/BFO_0000142 + +bfo:_0000142 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000140 ; + + owl:disjointWith bfo:_0000146 , + bfo:_0000147 ; + + bfo:_0000179 "1d-cf-boundary" ; + + bfo:_0000180 "OneDimensionalContinuantFiatBoundary" ; + + iao:_0000112 "The Equator"@en , + "all geopolitical boundaries"@en , + "all lines of latitude and longitude"@en , + "the line separating the outer surface of the mucosa of the lower lip from the outer surface of the skin of the chin."@en , + "the median sulcus of your tongue" ; + + iao:_0000600 "a one-dimensional continuant fiat boundary is a continuous fiat line whose location is defined in relation to some material entity. (axiom label in BFO2 Reference: [032-001])" ; + + iao:_0000602 "(iff (OneDimensionalContinuantFiatBoundary a) (and (ContinuantFiatBoundary a) (exists (b) (and (OneDimensionalSpatialRegion b) (forall (t) (locatedInAt a b t)))))) // axiom label in BFO2 CLIF: [032-001] " ; + + rdfs:isDefinedBy , + ; + + rdfs:label "one-dimensional continuant fiat boundary" ; + + skos:altLabel "1D continuant fiat boundary" ; + + skos:definition "A one-dimensional continuant fiat boundary is a continuous fiat line whose location is defined in relation to some material entity. [BFO]" ; + + skos:prefLabel "one-dimensional continuant fiat boundary" . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000142 ; + owl:annotatedProperty iao:_0000600 ; + owl:annotatedTarget "a one-dimensional continuant fiat boundary is a continuous fiat line whose location is defined in relation to some material entity. (axiom label in BFO2 Reference: [032-001])" ; + iao:_0010000 +] . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000142 ; + owl:annotatedProperty iao:_0000602 ; + owl:annotatedTarget "(iff (OneDimensionalContinuantFiatBoundary a) (and (ContinuantFiatBoundary a) (exists (b) (and (OneDimensionalSpatialRegion b) (forall (t) (locatedInAt a b t)))))) // axiom label in BFO2 CLIF: [032-001] " ; + iao:_0010000 +] . + + + +### http://purl.obolibrary.org/obo/BFO_0000144 + +bfo:_0000144 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000015 ; + + owl:disjointWith bfo:_0000182 ; + + bfo:_0000179 "process-profile" ; + + bfo:_0000180 "ProcessProfile" ; + + iao:_0000112 "On a somewhat higher level of complexity are what we shall call rate process profiles, which are the targets of selective abstraction focused not on determinate quality magnitudes plotted over time, but rather on certain ratios between these magnitudes and elapsed times. A speed process profile, for example, is represented by a graph plotting against time the ratio of distance covered per unit of time. Since rates may change, and since such changes, too, may have rates of change, we have to deal here with a hierarchy of process profile universals at successive levels"@en , + "One important sub-family of rate process profiles is illustrated by the beat or frequency profiles of cyclical processes, illustrated by the 60 beats per minute beating process of John’s heart, or the 120 beats per minute drumming process involved in one of John’s performances in a rock band, and so on. Each such process includes what we shall call a beat process profile instance as part, a subtype of rate process profile in which the salient ratio is not distance covered but rather number of beat cycles per unit of time. Each beat process profile instance instantiates the determinable universal beat process profile. But it also instantiates multiple more specialized universals at lower levels of generality, selected from rate process profilebeat process profileregular beat process profile3 bpm beat process profile4 bpm beat process profileirregular beat process profileincreasing beat process profileand so on.In the case of a regular beat process profile, a rate can be assigned in the simplest possible fashion by dividing the number of cycles by the length of the temporal region occupied by the beating process profile as a whole. Irregular process profiles of this sort, for example as identified in the clinic, or in the readings on an aircraft instrument panel, are often of diagnostic significance."@en , + "The simplest type of process profiles are what we shall call ‘quality process profiles’, which are the process profiles which serve as the foci of the sort of selective abstraction that is involved when measurements are made of changes in single qualities, as illustrated, for example, by process profiles of mass, temperature, aortic pressure, and so on." ; + + iao:_0000115 "b is a process_profile =Def. there is some process c such that b process_profile_of c (axiom label in BFO2 Reference: [093-002])" ; + + iao:_0000600 "b process_profile_of c holds when b proper_occurrent_part_of c& there is some proper_occurrent_part d of c which has no parts in common with b & is mutually dependent on b& is such that b, c and d occupy the same temporal region (axiom label in BFO2 Reference: [094-005])" ; + + iao:_0000602 "(forall (x y) (if (processProfileOf x y) (and (properContinuantPartOf x y) (exists (z t) (and (properOccurrentPartOf z y) (TemporalRegion t) (occupiesSpatioTemporalRegion x t) (occupiesSpatioTemporalRegion y t) (occupiesSpatioTemporalRegion z t) (not (exists (w) (and (occurrentPartOf w x) (occurrentPartOf w z))))))))) // axiom label in BFO2 CLIF: [094-005] " , + "(iff (ProcessProfile a) (exists (b) (and (Process b) (processProfileOf a b)))) // axiom label in BFO2 CLIF: [093-002] " ; + + rdfs:isDefinedBy , + ; + + rdfs:label "process profile" ; + + skos:definition "B is a process profile if there is some process c such that b is process profile of c. B is process profile of c holds when b is a proper occurrent part of c and there is some proper occurrent part d of c which has no parts in common with b and is mutually dependent on b and is such that b, c and d occupy the same temporal region. [BFO]" ; + + skos:prefLabel "process profile" . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000144 ; + owl:annotatedProperty iao:_0000115 ; + owl:annotatedTarget "b is a process_profile =Def. there is some process c such that b process_profile_of c (axiom label in BFO2 Reference: [093-002])" ; + iao:_0010000 +] . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000144 ; + owl:annotatedProperty iao:_0000600 ; + owl:annotatedTarget "b process_profile_of c holds when b proper_occurrent_part_of c& there is some proper_occurrent_part d of c which has no parts in common with b & is mutually dependent on b& is such that b, c and d occupy the same temporal region (axiom label in BFO2 Reference: [094-005])" ; + iao:_0010000 +] . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000144 ; + owl:annotatedProperty iao:_0000602 ; + owl:annotatedTarget "(forall (x y) (if (processProfileOf x y) (and (properContinuantPartOf x y) (exists (z t) (and (properOccurrentPartOf z y) (TemporalRegion t) (occupiesSpatioTemporalRegion x t) (occupiesSpatioTemporalRegion y t) (occupiesSpatioTemporalRegion z t) (not (exists (w) (and (occurrentPartOf w x) (occurrentPartOf w z))))))))) // axiom label in BFO2 CLIF: [094-005] " ; + iao:_0010000 +] . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000144 ; + owl:annotatedProperty iao:_0000602 ; + owl:annotatedTarget "(iff (ProcessProfile a) (exists (b) (and (Process b) (processProfileOf a b)))) // axiom label in BFO2 CLIF: [093-002] " ; + iao:_0010000 +] . + + + +### http://purl.obolibrary.org/obo/BFO_0000145 + +bfo:_0000145 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000019 ; + + bfo:_0000179 "r-quality" ; + + bfo:_0000180 "RelationalQuality" ; + + iao:_0000112 "John’s role of husband to Mary is dependent on Mary’s role of wife to John, and both are dependent on the object aggregate comprising John and Mary as member parts joined together through the relational quality of being married."@en , + "a marriage bond, an instance of love, an obligation between one person and another." ; + + iao:_0000115 "b is a relational quality = Def. for some independent continuants c, d and for some time t: b quality_of c at t & b quality_of d at t. (axiom label in BFO2 Reference: [057-001])" ; + + iao:_0000602 "(iff (RelationalQuality a) (exists (b c t) (and (IndependentContinuant b) (IndependentContinuant c) (qualityOfAt a b t) (qualityOfAt a c t)))) // axiom label in BFO2 CLIF: [057-001] " ; + + rdfs:isDefinedBy , + ; + + rdfs:label "relational quality" ; + + skos:definition "B is a relational quality if for some independent continuants c, d and for some time t: b is quality of c at t and b is quality of d at t. [BFO]" ; + + skos:example "a marriage bond [BFO]" , + "an instance of love [BFO]" , + "an obligation between one person and another [BFO]" ; + + skos:prefLabel "relational quality" . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000145 ; + owl:annotatedProperty iao:_0000115 ; + owl:annotatedTarget "b is a relational quality = Def. for some independent continuants c, d and for some time t: b quality_of c at t & b quality_of d at t. (axiom label in BFO2 Reference: [057-001])" ; + iao:_0010000 +] . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000145 ; + owl:annotatedProperty iao:_0000602 ; + owl:annotatedTarget "(iff (RelationalQuality a) (exists (b c t) (and (IndependentContinuant b) (IndependentContinuant c) (qualityOfAt a b t) (qualityOfAt a c t)))) // axiom label in BFO2 CLIF: [057-001] " ; + iao:_0010000 +] . + + + +### http://purl.obolibrary.org/obo/BFO_0000146 + +bfo:_0000146 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000140 ; + + bfo:_0000179 "2d-cf-boundary" ; + + bfo:_0000180 "TwoDimensionalContinuantFiatBoundary" ; + + iao:_0000600 "a two-dimensional continuant fiat boundary (surface) is a self-connected fiat surface whose location is defined in relation to some material entity. (axiom label in BFO2 Reference: [033-001])" ; + + iao:_0000602 "(iff (TwoDimensionalContinuantFiatBoundary a) (and (ContinuantFiatBoundary a) (exists (b) (and (TwoDimensionalSpatialRegion b) (forall (t) (locatedInAt a b t)))))) // axiom label in BFO2 CLIF: [033-001] " ; + + rdfs:isDefinedBy , + ; + + rdfs:label "two-dimensional continuant fiat boundary" ; + + skos:altLabel "2D continuant fiat boundary" ; + + skos:definition "A two-dimensional continuant fiat boundary (surface) is a self-connected fiat surface whose location is defined in relation to some material entity. [BFO]" ; + + skos:prefLabel "two-dimensional continuant fiat boundary" . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000146 ; + owl:annotatedProperty iao:_0000600 ; + owl:annotatedTarget "a two-dimensional continuant fiat boundary (surface) is a self-connected fiat surface whose location is defined in relation to some material entity. (axiom label in BFO2 Reference: [033-001])" ; + iao:_0010000 +] . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000146 ; + owl:annotatedProperty iao:_0000602 ; + owl:annotatedTarget "(iff (TwoDimensionalContinuantFiatBoundary a) (and (ContinuantFiatBoundary a) (exists (b) (and (TwoDimensionalSpatialRegion b) (forall (t) (locatedInAt a b t)))))) // axiom label in BFO2 CLIF: [033-001] " ; + iao:_0010000 +] . + + + +### http://purl.obolibrary.org/obo/BFO_0000147 + +bfo:_0000147 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000140 ; + + bfo:_0000179 "0d-cf-boundary" ; + + bfo:_0000180 "ZeroDimensionalContinuantFiatBoundary" ; + + iao:_0000112 "the geographic North Pole"@en , + "the point of origin of some spatial coordinate system."@en , + "the quadripoint where the boundaries of Colorado, Utah, New Mexico, and Arizona meet" ; + + iao:_0000116 "zero dimension continuant fiat boundaries are not spatial points. Considering the example 'the quadripoint where the boundaries of Colorado, Utah, New Mexico, and Arizona meet' : There are many frames in which that point is zooming through many points in space. Whereas, no matter what the frame, the quadripoint is always in the same relation to the boundaries of Colorado, Utah, New Mexico, and Arizona." ; + + iao:_0000600 "a zero-dimensional continuant fiat boundary is a fiat point whose location is defined in relation to some material entity. (axiom label in BFO2 Reference: [031-001])" ; + + iao:_0000602 "(iff (ZeroDimensionalContinuantFiatBoundary a) (and (ContinuantFiatBoundary a) (exists (b) (and (ZeroDimensionalSpatialRegion b) (forall (t) (locatedInAt a b t)))))) // axiom label in BFO2 CLIF: [031-001] " ; + + rdfs:isDefinedBy , + ; + + rdfs:label "zero-dimensional continuant fiat boundary" ; + + skos:altLabel "0D continuant fiat boundary" ; + + skos:definition "A zero-dimensional continuant fiat boundary is a fiat point whose location is defined in relation to some material entity. [BFO]" ; + + skos:prefLabel "zero-dimensional continuant fiat boundary" . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000147 ; + owl:annotatedProperty iao:_0000116 ; + owl:annotatedTarget "zero dimension continuant fiat boundaries are not spatial points. Considering the example 'the quadripoint where the boundaries of Colorado, Utah, New Mexico, and Arizona meet' : There are many frames in which that point is zooming through many points in space. Whereas, no matter what the frame, the quadripoint is always in the same relation to the boundaries of Colorado, Utah, New Mexico, and Arizona." ; + iao:_0010000 ; + rdfs:comment "requested by Melanie Courtot" ; + rdfs:seeAlso +] . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000147 ; + owl:annotatedProperty iao:_0000600 ; + owl:annotatedTarget "a zero-dimensional continuant fiat boundary is a fiat point whose location is defined in relation to some material entity. (axiom label in BFO2 Reference: [031-001])" ; + iao:_0010000 +] . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000147 ; + owl:annotatedProperty iao:_0000602 ; + owl:annotatedTarget "(iff (ZeroDimensionalContinuantFiatBoundary a) (and (ContinuantFiatBoundary a) (exists (b) (and (ZeroDimensionalSpatialRegion b) (forall (t) (locatedInAt a b t)))))) // axiom label in BFO2 CLIF: [031-001] " ; + iao:_0010000 +] . + + + +### http://purl.obolibrary.org/obo/BFO_0000148 + +bfo:_0000148 rdf:type owl:Class ; + + owl:equivalentClass time:Instant ; + + rdfs:subClassOf bfo:_0000008 ; + + bfo:_0000179 "0d-t-region" ; + + bfo:_0000180 "ZeroDimensionalTemporalRegion" ; + + iao:_0000112 "a temporal region that is occupied by a process boundary"@en , + "right now"@en , + "the moment at which a child is born"@en , + "the moment at which a finger is detached in an industrial accident"@en , + "the moment of death." ; + + iao:_0000118 "temporal instant." ; + + iao:_0000600 "A zero-dimensional temporal region is a temporal region that is without extent. (axiom label in BFO2 Reference: [102-001])" ; + + iao:_0000602 "(forall (x) (if (ZeroDimensionalTemporalRegion x) (TemporalRegion x))) // axiom label in BFO2 CLIF: [102-001] " ; + + rdfs:isDefinedBy , + ; + + rdfs:label "zero-dimensional temporal region" ; + + skos:altLabel "0D-temporal region" , + "temporal instant" ; + + skos:definition "A zero-dimensional temporal region is a temporal region that is without extent. [BFO]" ; + + skos:prefLabel "zero-dimensional temporal region" . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000148 ; + owl:annotatedProperty iao:_0000600 ; + owl:annotatedTarget "A zero-dimensional temporal region is a temporal region that is without extent. (axiom label in BFO2 Reference: [102-001])" ; + iao:_0010000 +] . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000148 ; + owl:annotatedProperty iao:_0000602 ; + owl:annotatedTarget "(forall (x) (if (ZeroDimensionalTemporalRegion x) (TemporalRegion x))) // axiom label in BFO2 CLIF: [102-001] " ; + iao:_0010000 +] . + + + +### http://purl.obolibrary.org/obo/BFO_0000182 + +bfo:_0000182 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000015 , + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000184 ; + owl:someValuesFrom bfo:_0000002 + ] ; + + bfo:_0000179 "history" ; + + bfo:_0000180 "History" ; + + iao:_0000600 "A history is a process that is the sum of the totality of processes taking place in the spatiotemporal region occupied by a material entity or site, including processes on the surface of the entity or within the cavities to which it serves as host. (axiom label in BFO2 Reference: [138-001])" ; + + rdfs:isDefinedBy , + ; + + rdfs:label "history" ; + + skos:definition "A history is a process that is the sum of the totality of processes taking place in the spatiotemporal region occupied by a material entity or site, including processes on the surface of the entity or within the cavities to which it serves as host. [BFO]" ; + + skos:prefLabel "history" . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000182 ; + owl:annotatedProperty iao:_0000600 ; + owl:annotatedTarget "A history is a process that is the sum of the totality of processes taking place in the spatiotemporal region occupied by a material entity or site, including processes on the surface of the entity or within the cavities to which it serves as host. (axiom label in BFO2 Reference: [138-001])" ; + iao:_0010000 +] . + + + +### http://purl.obolibrary.org/obo/CARO_0000006 + +caro:_0000006 rdf:type owl:Class ; + + rdfs:subClassOf af-m:AFM_0000877 ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + skos:definition "A part of a multicellular organism that is a material with granularity above the level of a protein complex. Or, a substance produced by a multicellular organism with granularity above the level of a protein complex. [Allotrope, CARO]" ; + + skos:prefLabel "material anatomical entity" . + + + +### http://purl.obolibrary.org/obo/CHEBI_15377 + +chebi:_15377 rdf:type owl:Class ; + + rdfs:subClassOf chebi:_25367 ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + skos:altLabel "water" ; + + skos:definition "An oxygen hydride consisting of an oxygen atom that is covalently bonded to two hydrogen atoms. [CHEBI]" ; + + skos:prefLabel "water (molecule)" . + + + +### http://purl.obolibrary.org/obo/CHEBI_15379 + +chebi:_15379 rdf:type owl:Class ; + + rdfs:subClassOf chebi:_25367 ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + skos:definition "An elemental molecule consisting of two bivalently-bonded oxygen atoms. [Allotrope]" ; + + skos:prefLabel "dioxygen (molecule)" . + + + +### http://purl.obolibrary.org/obo/CHEBI_16134 + +chebi:_16134 rdf:type owl:Class ; + + rdfs:subClassOf chebi:_25367 ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + skos:definition "An azane that consists of a single nitrogen atom covelently bonded to three hydrogen atoms. [CHEBI]" ; + + skos:prefLabel "ammonia (molecule)" . + + + +### http://purl.obolibrary.org/obo/CHEBI_16183 + +chebi:_16183 rdf:type owl:Class ; + + rdfs:subClassOf chebi:_25367 ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + skos:definition "A one-carbon compound in which the carbon is attached by single bonds to four hydrogen atoms. [CHEBI]" ; + + skos:prefLabel "methane (molecule)" . + + + +### http://purl.obolibrary.org/obo/CHEBI_16526 + +chebi:_16526 rdf:type owl:Class ; + + rdfs:subClassOf chebi:_25367 ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + skos:definition "A one-carbon compound with formula CO2 in which the carbon is attached to each oxygen atom by a double bond. [CHEBI]" ; + + skos:prefLabel "carbon dioxide (molecule)" . + + + +### http://purl.obolibrary.org/obo/CHEBI_17632 + +chebi:_17632 rdf:type owl:Class ; + + rdfs:subClassOf af-m:AFM_0000161 ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + skos:altLabel "nitrate" ; + + skos:definition "A nitrogen oxoanion formed by loss of a proton from nitric acid. [CHEBI]" ; + + skos:prefLabel "nitrate ion" . + + + +### http://purl.obolibrary.org/obo/CHEBI_17997 + +chebi:_17997 rdf:type owl:Class ; + + rdfs:subClassOf chebi:_25367 ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + skos:definition "An elemental molecule consisting of two trivalently-bonded nitrogen atoms. [CHEBI]" ; + + skos:prefLabel "dinitrogen (molecule)" . + + + +### http://purl.obolibrary.org/obo/CHEBI_18276 + +chebi:_18276 rdf:type owl:Class ; + + rdfs:subClassOf chebi:_25367 ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + skos:definition "An elemental molecule consisting of two hydrogens joined by a single bond. [CHEBI]" ; + + skos:prefLabel "dihydrogen (molecule)" . + + + +### http://purl.obolibrary.org/obo/CHEBI_23367 + +chebi:_23367 rdf:type owl:Class ; + + rdfs:subClassOf af-m:AFM_0000275 , + bfo:_0000040 , + [ rdf:type owl:Restriction ; + owl:onProperty obi:_0000643 ; + owl:someValuesFrom chebi:_36342 + ] ; + + af-x:AFX_0002796 af-r:AFR_0001222 ; + + af-x:AFX_0002865 ; + + dct:license ; + + dct:rights ; + + dct:source "PAC, 1994, 66, 1077. (Glossary of terms used in physical organic chemistry (IUPAC Recommendations 1994)) on page 1142" ; + + rdfs:isDefinedBy ; + + skos:definition "Any constitutionally or isotopically distinct atom, molecule, ion, ion pair, radical, radical ion, complex, conformer etc., identifiable as a separately distinguishable entity. [IUPAC]" ; + + skos:prefLabel "molecular entity" . + + + +### http://purl.obolibrary.org/obo/CHEBI_25367 + +chebi:_25367 rdf:type owl:Class ; + + rdfs:subClassOf chebi:_23367 ; + + af-x:AFX_0002796 af-r:AFR_0001222 ; + + af-x:AFX_0002865 ; + + dct:license ; + + dct:rights ; + + dct:source "PAC, 1994, 66, 1077. (Glossary of terms used in physical organic chemistry (IUPAC Recommendations 1994)) on page 1143" ; + + rdfs:isDefinedBy ; + + skos:definition "A molecule is a polyatomic molecular entity that is an electrically neutral entity consisting of more than one atom. [Allotrope]" ; + + skos:prefLabel "molecule" . + + + +### http://purl.obolibrary.org/obo/CHEBI_30212 + +chebi:_30212 rdf:type owl:Class ; + + rdfs:subClassOf chebi:_36341 ; + + af-x:AFX_0002796 af-r:AFR_0001492 ; + + dct:license ; + + dct:rights ; + + dct:source "Green Book, 2nd ed., p. 93" , + "PAC, 1996, 68, 2223. 'Glossary of terms used in photochemistry (IUPAC Recommendations 1996)' on page 2262" ; + + rdfs:isDefinedBy ; + + skos:definition "A photon is a particle of zero charge, zero rest mass, spin quantum number 1, energy hν and momentum hν/c (h is the Planck constant, ν the frequency of radiation and c the speed of light), carrier of electromagnetic force. [IUPAC]" ; + + skos:prefLabel "photon" . + + + +### http://purl.obolibrary.org/obo/CHEBI_33253 + +chebi:_33253 rdf:type owl:Class ; + + owl:equivalentClass [ rdf:type owl:Class ; + owl:unionOf ( af-m:AFM_0001027 + af-m:AFM_0001028 + ) + ] ; + + rdfs:subClassOf chebi:_36339 ; + + af-x:AFX_0002796 af-r:AFR_0001492 ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:definition "A nucleon is either a proton or a neutron. [Wikipedia]" ; + + skos:prefLabel "nucleon" . + + + +### http://purl.obolibrary.org/obo/CHEBI_33681 + +chebi:_33681 rdf:type owl:Class ; + + rdfs:subClassOf af-m:AFM_0001028 ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + skos:definition "An atom of the chemical element Helium. [Allotrope]" ; + + skos:prefLabel "helium (atom)" . + + + +### http://purl.obolibrary.org/obo/CHEBI_36338 + +chebi:_36338 rdf:type owl:Class ; + + rdfs:subClassOf chebi:_36340 ; + + af-x:AFX_0002796 af-r:AFR_0001492 ; + + rdfs:isDefinedBy ; + + skos:definition "Lepton is a fermion that does not experience the strong force (strong interaction). [CHEBI]" ; + + skos:prefLabel "lepton" . + + + +### http://purl.obolibrary.org/obo/CHEBI_36339 + +chebi:_36339 rdf:type owl:Class ; + + rdfs:subClassOf chebi:_36340 ; + + af-x:AFX_0002796 af-r:AFR_0001492 ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:definition "Baryon is a fermion that does experience the strong force (strong interaction). [CHEBI]" ; + + skos:prefLabel "baryon" . + + + +### http://purl.obolibrary.org/obo/CHEBI_36340 + +chebi:_36340 rdf:type owl:Class ; + + rdfs:subClassOf chebi:_36342 ; + + af-x:AFX_0002796 af-r:AFR_0001492 ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:definition "Particle of half-integer spin quantum number following Fermi-Dirac statistics. [CHEBI]" ; + + skos:prefLabel "fermion" . + + + +### http://purl.obolibrary.org/obo/CHEBI_36341 + +chebi:_36341 rdf:type owl:Class ; + + rdfs:subClassOf chebi:_36342 ; + + af-x:AFX_0002796 af-r:AFR_0001492 ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:definition "A boson is a particle that follows Bose–Einstein statistics. [Wikipedia]" ; + + skos:prefLabel "boson" . + + + +### http://purl.obolibrary.org/obo/CHEBI_36342 + +chebi:_36342 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000040 ; + + af-x:AFX_0002796 af-r:AFR_0001492 ; + + rdfs:isDefinedBy ; + + skos:definition "A subatomic particle is a material that is below the scale of an atom. [Allotrope]" ; + + skos:prefLabel "subatomic particle" . + + + +### http://purl.obolibrary.org/obo/CHEBI_36347 + +chebi:_36347 rdf:type owl:Class ; + + rdfs:subClassOf chebi:_36342 ; + + af-x:AFX_0002796 af-r:AFR_0001492 ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + rdfs:isDefinedBy ; + + skos:definition "A nuclear particle is a nucleus or any of its constituents in any of their energy states. [CHEBI]" ; + + skos:prefLabel "nuclear particle" . + + + +### http://purl.obolibrary.org/obo/CHEBI_49468 + +chebi:_49468 rdf:type owl:Class ; + + rdfs:subClassOf af-m:AFM_0000189 ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + skos:altLabel "silver(1+)" ; + + skos:definition "An silver(1+) ion is a +1 charged silver cation. [Allotrope]" ; + + skos:prefLabel "silver(1+) ion" . + + + +### http://purl.obolibrary.org/obo/CHMO_0000993 + +chmo:_0000993 rdf:type owl:Class ; + + rdfs:subClassOf af-m:AFM_0000275 , + [ rdf:type owl:Restriction ; + owl:onProperty obi:_0000643 ; + owl:someValuesFrom chebi:_23367 + ] ; + + rdfs:isDefinedBy ; + + skos:definition "An independent material continuant that is self-connected and retains its identity over time. [CHMO]" ; + + skos:prefLabel "portion of material" . + + + +### http://purl.obolibrary.org/obo/ENVO_00002005 + +envo:_00002005 rdf:type owl:Class ; + + rdfs:subClassOf af-m:AFM_0000154 , + af-m:AFM_0000877 , + af-m:AFM_0001065 , + envo:_00010483 ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + skos:definition "The mixture of gases (roughly (by molar content/volume: 78% nitrogen, 20.95% oxygen, 0.93% argon, 0.038% carbon dioxide, trace amounts of other gases, and a variable amount (average around 1%) of water vapor) that surrounds the planet Earth. [ENVO]" ; + + skos:prefLabel "air" . + + + +### http://purl.obolibrary.org/obo/ENVO_00010483 + +envo:_00010483 rdf:type owl:Class ; + + rdfs:subClassOf af-m:AFM_0000275 , + bfo:_0000024 , + [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0000939 ; + owl:someValuesFrom envo:_01000254 + ] ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + skos:definition "An environmental material is a fiat object which forms the medium or part of the medium of an environmental system. [ENVO]" ; + + skos:prefLabel "environmental material" . + + + +### http://purl.obolibrary.org/obo/ENVO_01000254 + +envo:_01000254 rdf:type owl:Class ; + + rdfs:subClassOf ro:_0002577 ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + skos:definition "A system which has the disposition to environ one or more material entities. [ENVO]" ; + + skos:prefLabel "environmental system" . + + + +### http://purl.obolibrary.org/obo/IAO_0000005 + +iao:_0000005 rdf:type owl:Class ; + + owl:equivalentClass [ rdf:type owl:Restriction ; + owl:onProperty af-x:AFX_0002730 ; + owl:someValuesFrom af-rl:AFRL_0000015 + ] ; + + rdfs:subClassOf af-r:AFR_0000957 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + skos:altLabel "goal specification" ; + + skos:definition "A directive information entity that describes an intended process endpoint. When part of a plan specification the concretization is realized in a planned process in which the bearer tries to effect the world so that the process endpoint is achieved. [IAO]" ; + + skos:example "In the protocol of a ChIP assay the objective specification says to identify protein and DNA interaction." ; + + skos:prefLabel "objective specification" . + + + +### http://purl.obolibrary.org/obo/IAO_0000009 + +iao:_0000009 rdf:type owl:Class ; + + rdfs:subClassOf iao:_0000028 ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + skos:definition "A label is a symbol that is part of some other datum and is used to either partially define the denotation of that datum or to provide a means for identifying the datum as a member of the set of data with the same label [IAO]" ; + + skos:prefLabel "datum label" . + + + +### http://purl.obolibrary.org/obo/IAO_0000010 + +iao:_0000010 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001501 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + skos:definition "Software is a plan specification composed of a series of instructions that can be interpreted by or directly executed by a processing unit. [IAO]" ; + + skos:prefLabel "software" . + + + +### http://purl.obolibrary.org/obo/IAO_0000017 + +iao:_0000017 rdf:type owl:Class ; + + rdfs:subClassOf iao:_0000028 ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + skos:altLabel "equipment model number" , + "instrument model number" , + "part number" ; + + skos:changeNote "2019-09-19 Add alt label part number. [Allotrope]" ; + + skos:definition "A model number is an information content entity specifically borne by catalogs, design specifications, advertising materials, inventory systems and similar that is about manufactured objects of the same class. The model number is an alternative term for the class. [IAO]" ; + + skos:prefLabel "model number" . + + + +### http://purl.obolibrary.org/obo/IAO_0000028 + +iao:_0000028 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000923 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + skos:definition "An information content entity that is a mark(s) or character(s) used as a conventional representation of another entity. [IAO]" ; + + skos:example "a serial number such as \"12324X\"" , + "a stop sign" , + "a written proper name such as \"OBI\"" ; + + skos:prefLabel "symbol" . + + + +### http://purl.obolibrary.org/obo/IAO_0000030 + +iao:_0000030 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000031 ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy , + ; + + skos:altLabel "information object" ; + + skos:prefLabel "information content entity" . + + + +### http://purl.obolibrary.org/obo/IAO_0000037 + +iao:_0000037 rdf:type owl:Class ; + + rdfs:subClassOf iao:_0000038 ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + rdfs:label "dot plot" ; + + skos:definition "A dot plot is a report graph which is a graphical representation of data where each data point is represented by a single dot placed on coordinates corresponding to data point values in particular dimensions. [IAO]" ; + + skos:example "Dot plot of SSC-H and FSC-H." ; + + skos:prefLabel "dot plot" . + + + +### http://purl.obolibrary.org/obo/IAO_0000038 + +iao:_0000038 rdf:type owl:Class ; + + rdfs:subClassOf iao:_0000309 ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + skos:altLabel "two-dimensional graph" ; + + skos:definition "A diagram that presents one or more tuples of information by mapping those tuples in to a two dimensional space in a non arbitrary way. [IAO]" ; + + skos:prefLabel "graph" . + + + +### http://purl.obolibrary.org/obo/IAO_0000064 + +iao:_0000064 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001501 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + skos:definition "A plan specification which describes the inputs and output of mathematical functions as well as workflow of execution for achieving an predefined objective. Algorithms are realized usually by means of implementation as computer programs for execution by automata. [IAO]" ; + + skos:prefLabel "algorithm" . + + + +### http://purl.obolibrary.org/obo/IAO_0000088 + +iao:_0000088 rdf:type owl:Class ; + + rdfs:subClassOf iao:_0000310 ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + skos:definition "A report is a document assembled by an author for the purpose of providing information for the audience. A report is the output of a documenting process and has the objective to be consumed by a specific audience. Topic of the report is on something that has completed. A report is not a single figure. [IAO]" ; + + skos:example "case report (not patient record)" , + "grant progress report" , + "journal article" , + "patent application" ; + + skos:prefLabel "report" . + + + +### http://purl.obolibrary.org/obo/IAO_0000098 + +iao:_0000098 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000957 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + skos:definition "A data format specification is the information content borne by the document published defining the specification. [IAO]" ; + + skos:example "The ISO document specifying what encompasses an XML document; The instructions in a XSD file [IAO]" ; + + skos:prefLabel "data format specification" . + + + +### http://purl.obolibrary.org/obo/IAO_0000101 + +iao:_0000101 rdf:type owl:Class ; + + rdfs:subClassOf iao:_0000308 ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + skos:definition "An image is an affine projection to a two dimensional surface, of measurements of some quality of an entity or entities repeated at regular intervals across a spatial range, where the measurements are represented as color and luminosity on the projected on surface. [IAO]" ; + + skos:prefLabel "image" . + + + +### http://purl.obolibrary.org/obo/IAO_0000129 + +iao:_0000129 rdf:type owl:Class ; + + rdfs:subClassOf iao:_0000028 ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + skos:definition "A version number is an information content entity which is a sequence of characters borne by part of each of a class of manufactured products or its packaging and indicates its order within a set of other products having the same name. [IAO]" ; + + skos:prefLabel "version number" . + + + +### http://purl.obolibrary.org/obo/IAO_0000131 + +iao:_0000131 rdf:type owl:Class ; + + rdfs:subClassOf iao:_0000028 ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + skos:definition "A serial number is an information content entity which is a unique sequence of characters borne by part of manufactured product or its packaging that is assigned to each individual in some class of products, and so can serve as a way to identify an individual product within the class. Serial numbers can be encoded in a variety of other information objects, such as bar codes, numerals, or patterns of dots. [IAO]" ; + + skos:prefLabel "serial number" . + + + +### http://purl.obolibrary.org/obo/IAO_0000132 + +iao:_0000132 rdf:type owl:Class ; + + rdfs:subClassOf iao:_0000028 ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + skos:altLabel "batch number" ; + + skos:definition "A lot number is an information content entity which is an identical sequence of character borne by part of manufactured product or its packaging for each instances of a product class in a discrete batch of an item. [IAO]" ; + + skos:prefLabel "lot number" . + + + +### http://purl.obolibrary.org/obo/IAO_0000178 + +iao:_0000178 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( bfo:_0000040 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000053 ; + owl:someValuesFrom [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000059 ; + owl:someValuesFrom iao:_0000030 + ] + ] + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + skos:definition "A material entity in which a concretization of an information content entity inheres. [IAO]" ; + + skos:example "a brain" , + "a hard drive" , + "a page of a paperback novel with writing on it." ; + + skos:prefLabel "material information bearer" . + + + +### http://purl.obolibrary.org/obo/IAO_0000300 + +iao:_0000300 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000992 ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + skos:definition "A textual entity is a part of a manifestation (FRBR sense), a generically dependent continuant whose concretizations are patterns of glyphs intended to be interpreted as words, formulas, etc." ; + + skos:prefLabel "textual entity" . + + + +### http://purl.obolibrary.org/obo/IAO_0000304 + +iao:_0000304 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000923 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + skos:definition "A textual entity that describes a figure [IAO]" ; + + skos:example "Figure 1: A system diagram describing the modules of the Hanalyzer. Reading methods (green) take external sources of knowledge (blue) and extract information from them, either by parsing structured data or biomedical language processing to extract information from unstructured data. Reading modules are responsible for tracking the provenance of all knowledge. Reasoning methods (yellow) enrich the knowledge that results from reading by, for example, noting two genes that are annotated to the same ontology term or database entry. All knowledge sources, read or reasoned, are assigned a reliability score, and all are combined using that score into a knowledge network (orange) that represents the integration of all sorts of relationship between a pair of genes and a combined reliability score. A data network (also orange) is created from experimental results to be analyzed. The reporting modules (pink) integrate the data and knowledge networks, producing visualizations that can be queried with the associated drill-down tool." ; + + skos:prefLabel "caption" . + + + +### http://purl.obolibrary.org/obo/IAO_0000306 + +iao:_0000306 rdf:type owl:Class ; + + rdfs:subClassOf iao:_0000300 ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + skos:definition "A textual entity that contains a two-dimensional arrangement of texts repeated at regular intervals across a spatial range, such that the spatial relationships among the constituent texts expresses propositions [IAO]" ; + + skos:prefLabel "table" . + + + +### http://purl.obolibrary.org/obo/IAO_0000308 + +iao:_0000308 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000992 ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + skos:definition "An information content entity consisting of a two dimensional arrangement of information content entities such that the arrangement itself is about something. [IAO]" ; + + skos:example "Any picture, diagram or table" ; + + skos:prefLabel "figure" . + + + +### http://purl.obolibrary.org/obo/IAO_0000309 + +iao:_0000309 rdf:type owl:Class ; + + rdfs:subClassOf iao:_0000308 ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + skos:definition "A figure that expresses one or more propositions. [IAO]" ; + + skos:example "A molecular structure ribbon cartoon showing helices, turns and sheets and their relations to each other in space." ; + + skos:prefLabel "diagram" . + + + +### http://purl.obolibrary.org/obo/IAO_0000310 + +iao:_0000310 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000992 ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + skos:definition "A collection of information content entities intended to be understood together as a whole [IAO]" ; + + skos:example "A journal article, patent application, laboratory notebook, or a book" ; + + skos:prefLabel "document" . + + + +### http://purl.obolibrary.org/obo/IAO_0000422 + +iao:_0000422 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001082 ; + + rdfs:isDefinedBy ; + + skos:definition "A textual entity that is used as directive to deliver something to a person, or organization. [IAO]" ; + + skos:prefLabel "postal address" . + + + +### http://purl.obolibrary.org/obo/IAO_0000429 + +iao:_0000429 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001082 ; + + dct:source "RFC 5322" , + "https://en.wikipedia.org/wiki/Email_address" ; + + rdfs:isDefinedBy ; + + skos:definition "An email address identifies an email box to which email messages are delivered. [Wikipedia]" ; + + skos:prefLabel "email address" . + + + +### http://purl.obolibrary.org/obo/IAO_0000573 + +iao:_0000573 rdf:type owl:Class ; + + rdfs:subClassOf iao:_0000038 ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + skos:definition "A line graph is a type of graph created by connecting a series of data points together with a line. [IAO]" ; + + skos:prefLabel "line graph" . + + + +### http://purl.obolibrary.org/obo/IAO_0000577 + +iao:_0000577 rdf:type owl:Class ; + + rdfs:subClassOf iao:_0000028 ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + skos:definition "A symbol that is part of a CRID and that is sufficient to look up a record from the CRID's registry. [IAO]" ; + + skos:prefLabel "centrally registered identifier symbol" . + + + +### http://purl.obolibrary.org/obo/IAO_0000578 + +iao:_0000578 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000917 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + skos:definition "An information content entity that consists of a CRID symbol and additional information about the CRID registry to which it belongs. [IAO]" ; + + skos:example "The sentence \"The article has Pubmed ID 12345.\" contains a CRID that has two parts: one part is the CRID symbol, which is '12345'; the other part denotes the CRID registry, which is Pubmed." ; + + skos:prefLabel "centrally registered identifier" . + + + +### http://purl.obolibrary.org/obo/IAO_0000579 + +iao:_0000579 rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001059 ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + skos:definition "A CRID registry is a dataset of CRID records, each consisting of a CRID symbol and additional information which was recorded in the dataset through a assigning a centrally registered identifier process. [IAO]" ; + + skos:example "PubMed is a CRID registry. It has a dataset of PubMed identifiers associated with journal articles. " ; + + skos:prefLabel "centrally registered identifier registry" . + + + +### http://purl.obolibrary.org/obo/IAO_0000590 + +iao:_0000590 rdf:type owl:Class ; + + rdfs:subClassOf iao:_0000028 ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + skos:definition "A textual entity that denotes a particular in reality. [IAO]" ; + + skos:prefLabel "written name" . + + + +### http://purl.obolibrary.org/obo/NCBITaxon_9606 + +ncbi:_9606 rdf:type owl:Class ; + + rdfs:subClassOf obi:_0100026 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + skos:altLabel "homo sapiens" , + "human being" , + "man" ; + + skos:definition "A member of the the species Homo sapiens. [Allotrope]" ; + + skos:prefLabel "human" . + + + +### http://purl.obolibrary.org/obo/NCIT_C42636 + + rdf:type owl:Class ; + + rdfs:subClassOf af-e:AFE_0002099 ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + skos:altLabel "dosage form" , + "dose form" , + "drug dose form" , + "pharmaceutical dose form" , + "pharmaceutical formulation" ; + + skos:definition "The form in which active and/or inert ingredient(s) are physically presented. [NCI]" ; + + skos:prefLabel "pharmaceutical dosage form" . + + + +### http://purl.obolibrary.org/obo/NCIT_C42998 + + rdf:type owl:Class ; + + rdfs:subClassOf ; + + pav:importedFrom ; + + rdfs:isDefinedBy ; + + skos:altLabel "tab" , + "tablet" , + "tablet dose form" ; + + skos:definition "A table dosage form is a pharmaceutical dosage form that is a solid composed of a mixture of that active and/or inert ingredient(s) are pressed or compacted together, usually in the form of a relatively flat and round, square or oval shape. [NCI]" ; + + skos:prefLabel "tablet dosage form" . + + + +### http://purl.obolibrary.org/obo/NCIT_C45235 + + rdf:type owl:Class ; + + rdfs:subClassOf af-m:AFM_0000386 , + ; + + pav:importedFrom ; + + rdfs:isDefinedBy ; + + skos:altLabel "solid" , + "solid dose form" ; + + skos:definition "A substance having definite shape and volume manufactured for the administration of active and/or inert ingredient(s). Solids include tablets, capsules, powders, granules and certain suppositories. [NCI]" ; + + skos:prefLabel "solid dosage form" . + + + +### http://purl.obolibrary.org/obo/OBI_0000011 + +obi:_0000011 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( bfo:_0000015 + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000055 ; + owl:someValuesFrom obi:_0000260 + ] + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + skos:definition "A processual entity that realizes a plan which is the concretization of a plan specification. [IAO]" ; + + skos:example "Injecting mice with a vaccine in order to test its efficacy" ; + + skos:prefLabel "planned process" . + + + +### http://purl.obolibrary.org/obo/OBI_0000047 + +obi:_0000047 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000040 ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + skos:definition "Is a material entity that is created or changed during material processing. [OBI]" ; + + skos:example "Examples include gel matrices, filter paper, parafilm and buffer solutions, mass spectrometer, tissue samples" ; + + skos:prefLabel "processed material" . + + + +### http://purl.obolibrary.org/obo/OBI_0000086 + +obi:_0000086 rdf:type owl:Class ; + + rdfs:subClassOf af-rl:AFRL_0000249 ; + + af-x:AFX_0002809 chebi:_33893 ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + skos:altLabel "reagent" ; + + skos:definition "A role inhering in a biological or chemical entity that is intended to be applied in a scientific technique to participate (or have molecular components that participate) in a chemical reaction that facilitates the generation of data about some entity distinct from the bearer, or the generation of some specified material output distinct from the bearer. [OBI]" ; + + skos:prefLabel "reagent role" . + + + +### http://purl.obolibrary.org/obo/OBI_0000094 + +obi:_0000094 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003275 , + obi:_0000011 , + [ rdf:type owl:Class ; + owl:unionOf ( af-p:AFP_0003362 + af-p:AFP_0003566 + af-p:AFP_0003716 + ) + ] ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + skos:definition "Material processing is a planned material process which results in physical changes in a specified input material. [OBI]" ; + + skos:prefLabel "material processing" . + + + +### http://purl.obolibrary.org/obo/OBI_0000260 + +obi:_0000260 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000017 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + skos:definition "A plan is a realizable entity that is the inheres in a bearer who is committed to realizing it as a planned process. [OBI]" ; + + skos:prefLabel "plan" . + + + +### http://purl.obolibrary.org/obo/OBI_0000457 + +obi:_0000457 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003275 , + af-p:AFP_0003315 , + obi:_0000011 ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + skos:definition "Manufacturing is a producing with the intent to produce a processed material which will have a function for future use. [OBI]" ; + + skos:prefLabel "manufacturing" . + + + +### http://purl.obolibrary.org/obo/OBI_0000571 + +obi:_0000571 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000023 , + [ rdf:type owl:Restriction ; + owl:onProperty bfo:_0000054 ; + owl:someValuesFrom obi:_0000457 + ] , + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000081 ; + owl:someValuesFrom af-m:AFM_0001090 + ] ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + skos:altLabel "manufacturer" ; + + skos:definition "Manufacturer role is a role which inheres in a person or organization and which is realized by a manufacturing process. [OBI]" ; + + skos:example "With respect to The Accuri C6 Flow Cytometer System, the organization Accuri bears the role manufacturer role. [OBI]" , + "With respect to a specific antibody produced by an individual scientist, the scientist who purifies, characterizes and distributes the anitbody bears the role manufacturer role. [OBI]" , + "With respect to a transformed line of tissue culture cells derived by a specific lab, the lab whose personnel isolated the cll line bears the role manufacturer role. [OBI]" ; + + skos:prefLabel "manufacturer role" . + + + +### http://purl.obolibrary.org/obo/OBI_0000835 + +obi:_0000835 rdf:type owl:Class ; + + owl:equivalentClass [ owl:intersectionOf ( af-m:AFM_0001090 + [ rdf:type owl:Restriction ; + owl:onProperty ro:_0000087 ; + owl:someValuesFrom obi:_0000571 + ] + ) ; + rdf:type owl:Class + ] ; + + af-x:AFX_0002798 "true"^^xsd:boolean ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + skos:definition "A manufacturer is an organizational entity that has a manufacturer role. [Allotrope]" ; + + skos:prefLabel "manufacturer" . + + + +### http://purl.obolibrary.org/obo/OBI_0100026 + +obi:_0100026 rdf:type owl:Class ; + + rdfs:subClassOf af-m:AFM_0000877 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + skos:definition "A material entity that is an individual living system, such as animal, plant, bacteria or virus, that is capable of replicating or reproducing, growth and maintenance in the right environment. An organism may be unicellular or made up, like humans, of many billions of cells divided into specialized tissues and organs. [OBI]" ; + + skos:editorialNote "OBI doesn't take position as to when an organism starts or ends being an organism - e.g. sperm, foetus. This issue is outside the scope of OBI [OBI]" , + "subclasses should be imported from the NCBI taxonomy [Allotrope]" ; + + skos:prefLabel "organism" . + + + +### http://purl.obolibrary.org/obo/OBI_0200072 + +obi:_0200072 rdf:type owl:Class ; + + rdfs:subClassOf af-p:AFP_0003598 ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + skos:definition "Curve fitting is a data transformation that is the process of constructing a curve, or mathematical function, that has the best fit to a series of data points, possibly subject to constraints. [Wikipedia]" ; + + skos:prefLabel "curve fitting" . + + + +### http://purl.obolibrary.org/obo/PATO_0000008 + +pato:_0000008 rdf:type owl:Class ; + + rdfs:subClassOf pato:_0001906 ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + skos:altLabel "velocity" ; + + skos:definition "A physical quality inhering in a bearer by virtue of the bearer's scalar absolute value of the rate of change of the bearer's position. [PATO]" ; + + skos:prefLabel "speed" . + + + +### http://purl.obolibrary.org/obo/PATO_0000018 + +pato:_0000018 rdf:type owl:Class ; + + rdfs:subClassOf pato:_0001300 ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + skos:definition "A luminous flux quality inhering in a bearer by virtue of the bearer's emitting longer wavelength light following the absorption of shorter wavelength radiation; fluorescence is common with aromatic compounds with several rings joined together. [PATO]" ; + + skos:prefLabel "fluorescence" . + + + +### http://purl.obolibrary.org/obo/PATO_0000025 + +pato:_0000025 rdf:type owl:Class ; + + rdfs:subClassOf pato:_0000141 ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + skos:altLabel "compositionality" , + "content" , + "structure" ; + + skos:definition "A single physical entity inhering in an bearer by virtue of the bearer's quantities or relative ratios of subparts. [PATO]" ; + + skos:example "calcium composition (which may inhere in bone)" , + "haemoglobin composition (which may inhere in blood)." ; + + skos:prefLabel "composition" . + + + +### http://purl.obolibrary.org/obo/PATO_0000033 + +pato:_0000033 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000250 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + af-x:AFX_0002865 ; + + dct:source "Green Book, 2nd ed.: IUPAC Quantities, Units and Symbols in Physical Chemistry. Second Edition, Blackwell Scientific Publications, Oxford, 1993." ; + + rdfs:isDefinedBy ; + + skos:changeNote "2019-08-19 Changed pref label. [Allotrope]" , + "2019-08-29 Changed definition. [Allotrope]" ; + + skos:definition "Concentration is a molecular quality inhering in a substance by virtue of the amount of the bearer's there is mixed with another substance. [PATO]" ; + + skos:prefLabel "concentration (quality)" . + + + +### http://purl.obolibrary.org/obo/PATO_0000051 + +pato:_0000051 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000019 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + skos:definition "A quality of a single physical entity inhering in the bearer by virtue of the bearer's size or shape or structure. [PATO]" ; + + skos:prefLabel "morphology" . + + + +### http://purl.obolibrary.org/obo/PATO_0000052 + +pato:_0000052 rdf:type owl:Class ; + + rdfs:subClassOf pato:_0000051 ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + skos:altLabel "shape" ; + + skos:changeNote "2019-08-19 Changed pref label. [Allotrope]" ; + + skos:definition "A morphological quality inhering in a bearer by virtue of the bearer's ratios of distances between its features (points, edges, surfaces and also holes etc). [PATO]" ; + + skos:prefLabel "shape (quality)" . + + + +### http://purl.obolibrary.org/obo/PATO_0000117 + +pato:_0000117 rdf:type owl:Class ; + + rdfs:subClassOf pato:_0000051 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + skos:altLabel "dimension" , + "extend" , + "size" ; + + skos:changeNote "2019-08-19 Changed pref label. [Allotrope]" ; + + skos:definition "A morphology quality inhering in a bearer by virtue of the bearer's physical magnitude. [PATO]" ; + + skos:prefLabel "size (quality)" . + + + +### http://purl.obolibrary.org/obo/PATO_0000122 + +pato:_0000122 rdf:type owl:Class ; + + rdfs:subClassOf pato:_0001708 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + skos:altLabel "length" ; + + skos:changeNote "2019-08-19 Changed pref label. [Allotrope]" ; + + skos:definition "A 1-D extent quality which is equal to the distance between two points. [PATO]" ; + + skos:prefLabel "length (quality)" . + + + +### http://purl.obolibrary.org/obo/PATO_0000125 + +pato:_0000125 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000210 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy , + ; + + skos:altLabel "mass" ; + + skos:changeNote "2019-08-19 Changed pref label. [Allotrope]" , + "2019-09-09 Changed pref label for uniqueness. [Allotrope]" ; + + skos:definition "A physical quality that inheres in a bearer by virtue of the proportion of the bearer's amount of matter. [PATO]" ; + + skos:prefLabel "mass (quality)" . + + + +### http://purl.obolibrary.org/obo/PATO_0000141 + +pato:_0000141 rdf:type owl:Class ; + + rdfs:subClassOf pato:_0000051 ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + skos:altLabel "conformation" , + "relational structural quality" ; + + skos:changeNote "2018-12-05 Generalized definition [Allotrope]" ; + + skos:definition "A morphology quality inhering in a bearer by virtue of the bearer's relative position, shape, arrangements and connectivity of an material entity's various parts; the pattern underlying its form. [PATO]" ; + + skos:prefLabel "structure" . + + + +### http://purl.obolibrary.org/obo/PATO_0000146 + +pato:_0000146 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000056 ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + skos:altLabel "temperature" ; + + skos:changeNote "2019-08-19 Changed pref label. [Allotrope]" ; + + skos:definition "A physical quality of the thermal energy of a system. [PATO]" ; + + skos:prefLabel "temperature (quality)" . + + + +### http://purl.obolibrary.org/obo/PATO_0000169 + +pato:_0000169 rdf:type owl:Class ; + + rdfs:subClassOf pato:_0001995 ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + skos:altLabel "viability" ; + + skos:changeNote "2019-08-19 Changed pref label. [Allotrope]" ; + + skos:definition "An organismal quality inhering in a bearer or a population by virtue of the bearer's disposition to survive and develop normally or the number of surviving individuals in a given population. [PATO]" ; + + skos:prefLabel "viability (quality)" . + + + +### http://purl.obolibrary.org/obo/PATO_0000719 + +pato:_0000719 rdf:type owl:Class ; + + rdfs:subClassOf pato:_0000169 ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + skos:definition "A viability quality inhering in a bearer or a population by virtue of the bearer's ability to survive or the long term survival ability of a given population. [PATO]" ; + + skos:prefLabel "viable" . + + + +### http://purl.obolibrary.org/obo/PATO_0000915 + +pato:_0000915 rdf:type owl:Class ; + + rdfs:subClassOf pato:_0001708 ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + skos:altLabel "thickness" ; + + skos:changeNote "2019-08-19 Changed pref label. [Allotrope]" ; + + skos:definition "A 1-D extent quality which is equal to the dimension through an object as opposed to its length or width. [PATO]" ; + + skos:prefLabel "thickness (quality)" . + + + +### http://purl.obolibrary.org/obo/PATO_0000918 + +pato:_0000918 rdf:type owl:Class ; + + rdfs:subClassOf pato:_0001710 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + skos:altLabel "volume" ; + + skos:changeNote "2019-08-19 Changed pref label. [Allotrope]" ; + + skos:definition "A 3-D extent quality inhering in a bearer by virtue of the bearer's amount of 3-dimensional space it occupies." ; + + skos:prefLabel "volume (quality)" . + + + +### http://purl.obolibrary.org/obo/PATO_0000970 + +pato:_0000970 rdf:type owl:Class ; + + rdfs:subClassOf pato:_0000141 ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + skos:definition "A structural quality inhering in a bearer by virtue of the bearer's disposition to being permeated or pervaded by a gas or liquid (as by osmosis or diffusion). [PATO]" ; + + skos:prefLabel "permeability" . + + + +### http://purl.obolibrary.org/obo/PATO_0000973 + +pato:_0000973 rdf:type owl:Class ; + + rdfs:subClassOf pato:_0000970 ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + skos:definition "A permeability quality inhering in a bearer by virtue of the bearer's disposition to admit the passage of gas or liquid through pores or interstices. [PATO]" ; + + skos:prefLabel "porosity" . + + + +### http://purl.obolibrary.org/obo/PATO_0000984 + +pato:_0000984 rdf:type owl:Class ; + + rdfs:subClassOf pato:_0000973 ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + skos:altLabel "porous" ; + + skos:definition "A porosity quality inhering in a bearer by virtue of the bearer's being capable of admitting the passage of gas or liquid through pores or interstices. [PATO]" ; + + skos:prefLabel "fully porous" . + + + +### http://purl.obolibrary.org/obo/PATO_0000985 + +pato:_0000985 rdf:type owl:Class ; + + rdfs:subClassOf pato:_0000973 ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + skos:definition "A porosity quality inhering in a bearer by virtue of the bearer's being incapable of admitting the passage of gas or liquid through pores or interstices. [PATO]" ; + + skos:prefLabel "non-porous" . + + + +### http://purl.obolibrary.org/obo/PATO_0001019 + +pato:_0001019 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000210 ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + skos:altLabel "density" ; + + skos:definition "A physical quality which inheres in a bearer by virtue of some influence is exerted by the bearer's mass per unit size." ; + + skos:prefLabel "mass density" . + + + +### http://purl.obolibrary.org/obo/PATO_0001024 + +pato:_0001024 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000019 ; + + rdfs:isDefinedBy ; + + skos:altLabel "Power is a physical quality inhering in a bearer by virtue of the bearer's rate of doing work. [PATO]" , + "power" ; + + skos:prefLabel "power (quality)" . + + + +### http://purl.obolibrary.org/obo/PATO_0001025 + +pato:_0001025 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000210 ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + skos:altLabel "pressure" ; + + skos:changeNote "2019-09-20 Changed pref label for uniqueness. [Allotrope]" ; + + skos:definition "A physical quality that inheres in a bearer by virtue of the bearer's amount of force per unit area it exerts." ; + + skos:prefLabel "pressure (quality)" . + + + +### http://purl.obolibrary.org/obo/PATO_0001035 + +pato:_0001035 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000210 ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + skos:altLabel "force amplitude" ; + + skos:definition "A physical quality inhering in a bearer by virtue of the bearer's rate of change of momentum. [PATO]" ; + + skos:prefLabel "force" . + + + +### http://purl.obolibrary.org/obo/PATO_0001159 + +pato:_0001159 rdf:type owl:Class ; + + rdfs:subClassOf pato:_0000033 ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + skos:definition "A concentration that is relatively high. [Allotrope]" ; + + skos:prefLabel "concentrated" . + + + +### http://purl.obolibrary.org/obo/PATO_0001161 + +pato:_0001161 rdf:type owl:Class ; + + rdfs:subClassOf pato:_0000033 ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + skos:definition "A concentration which is relatively low. [PATO]" ; + + skos:prefLabel "diluted" . + + + +### http://purl.obolibrary.org/obo/PATO_0001230 + +pato:_0001230 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000210 ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + skos:definition "A quality inhering in a bearer by virtue of the bearer's power or force." ; + + skos:prefLabel "strength" . + + + +### http://purl.obolibrary.org/obo/PATO_0001242 + +pato:_0001242 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000019 , + [ rdf:type owl:Class ; + owl:unionOf ( af-q:AFQ_0000065 + af-q:AFQ_0000138 + pato:_0001291 + ) + ] ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + skos:altLabel "wavelength" ; + + skos:changeNote "2019-08-19 Changed pref label. [Allotrope]" ; + + skos:definition "A physical quality which is equal to the distance between repeating units of a wave pattern. [PATO]" ; + + skos:editorialNote "2019-07-04 Quality can be either acoustic. electromagnetic or radiation. [Allotrope]" ; + + skos:prefLabel "wavelength (quality)" . + + + +### http://purl.obolibrary.org/obo/PATO_0001291 + +pato:_0001291 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000019 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + skos:altLabel "EM radiation quality" ; + + skos:definition "A physical quality that inheres in an bearer by virtue of how that bearer interacts with electromagnetic radiation. [PATO]" ; + + skos:prefLabel "electromagnetic radiation quality" . + + + +### http://purl.obolibrary.org/obo/PATO_0001300 + +pato:_0001300 rdf:type owl:Class ; + + rdfs:subClassOf pato:_0001291 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + skos:definition "An EM radiation quality in which the EM radiation is within the fiat range of the spectrum visible deemed to be light. [PATO]" ; + + skos:prefLabel "optical quality" . + + + +### http://purl.obolibrary.org/obo/PATO_0001323 + +pato:_0001323 rdf:type owl:Class ; + + rdfs:subClassOf pato:_0001709 ; + + rdfs:isDefinedBy ; + + skos:altLabel "area" ; + + skos:definition "An area is a 2-D extent quality inhering in a bearer by virtue of the bearer's two dimensional extent. [PATO]" ; + + skos:prefLabel "area (quality)" . + + + +### http://purl.obolibrary.org/obo/PATO_0001334 + +pato:_0001334 rdf:type owl:Class ; + + rdfs:subClassOf pato:_0000122 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + skos:altLabel "diameter" ; + + skos:changeNote "2019-08-19 Changed pref label. [Allotrope]" ; + + skos:definition "A length quality which is equal to the length of any straight line segment that passes through the center of a circle and whose endpoints are on the circular boundary. [PATO]" ; + + skos:prefLabel "diameter (quality)" . + + + +### http://purl.obolibrary.org/obo/PATO_0001413 + +pato:_0001413 rdf:type owl:Class ; + + rdfs:subClassOf pato:_0002242 ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + skos:altLabel "angular velocity" ; + + skos:changeNote "2020-06-22 Changed labels. [Allotrope]" ; + + skos:definition "A physical quality inhering in a bearer by virtue of the rate of the bearer's angular movement about an axis; the angle rotated in a given time. [PATO]" ; + + skos:prefLabel "angular velocity (quality)" . + + + +### http://purl.obolibrary.org/obo/PATO_0001421 + +pato:_0001421 rdf:type owl:Class ; + + rdfs:subClassOf pato:_0000169 ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + skos:definition "A viability quality inhering in a bearer by virtue of the bearer's condition before death. [PATO]" ; + + skos:prefLabel "alive" . + + + +### http://purl.obolibrary.org/obo/PATO_0001422 + +pato:_0001422 rdf:type owl:Class ; + + rdfs:subClassOf pato:_0000169 ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + skos:definition "A viability quality inhering in a bearer by virtue of the cessation of the bearer's life. [PATO]" ; + + skos:prefLabel "dead" . + + + +### http://purl.obolibrary.org/obo/PATO_0001574 + +pato:_0001574 rdf:type owl:Class ; + + rdfs:subClassOf pato:_0001906 ; + + af-x:AFX_0002865 ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:altLabel "flow rate" ; + + skos:changeNote "2019-09-20 Changed definition. [Allotrope]" , + "2019-09-20 Changed pref label for uniqueness. [Allotrope]" ; + + skos:definition "A physical quality inhering in a bearer by virtue of the bearer's motion through a surface per time. [Allotrope]" ; + + skos:prefLabel "flow rate (quality)" . + + + +### http://purl.obolibrary.org/obo/PATO_0001585 + +pato:_0001585 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000019 ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + skos:definition "A physical quality inhering in a bearer by virtue of the bearer's disposition to transmit of an entity through a medium. [PATO]" ; + + skos:example "Examples could be heat or electricity or sound." ; + + skos:prefLabel "conductivity" . + + + +### http://purl.obolibrary.org/obo/PATO_0001595 + +pato:_0001595 rdf:type owl:Class ; + + rdfs:subClassOf pato:_0001708 ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + skos:altLabel "depth" ; + + skos:changeNote "2019-08-19 Changed pref label. [Allotrope]" ; + + skos:definition "A 1-D extent quality inhering in a bearer by virtue of the bearer's downward or backward or inward dimenision. [PATO]" ; + + skos:prefLabel "depth (quality)" . + + + +### http://purl.obolibrary.org/obo/PATO_0001681 + +pato:_0001681 rdf:type owl:Class ; + + rdfs:subClassOf pato:_0000125 ; + + af-x:AFX_0002865 ; + + dct:source ; + + rdfs:isDefinedBy ; + + skos:altLabel "molar mass" ; + + skos:definition "A physical quality that inheres in a homogeneous substance containing 6.02 x 10^23 atoms or molecules. [PATO]" ; + + skos:prefLabel "molar mass (quality)" . + + + +### http://purl.obolibrary.org/obo/PATO_0001708 + +pato:_0001708 rdf:type owl:Class ; + + rdfs:subClassOf pato:_0000117 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + skos:altLabel "1-D size" ; + + skos:definition "A size quality inhering in an bearer by virtue of the bearer's extension in one dimension. [PATO]" ; + + skos:prefLabel "1-D extent" . + + + +### http://purl.obolibrary.org/obo/PATO_0001709 + +pato:_0001709 rdf:type owl:Class ; + + rdfs:subClassOf pato:_0000117 ; + + rdfs:isDefinedBy ; + + skos:altLabel "2-D size" ; + + skos:definition "A 2-D extend is a size quality inhering in an bearer by virtue of the bearer's extension in two dimensions. [PATO]" ; + + skos:prefLabel "2-D extent" . + + + +### http://purl.obolibrary.org/obo/PATO_0001710 + +pato:_0001710 rdf:type owl:Class ; + + rdfs:subClassOf pato:_0000117 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + skos:altLabel "3D size" ; + + skos:definition "A size quality inhering in an bearer by virtue of the bearer's extension in three dimensions. [PATO]" ; + + skos:prefLabel "3-D extent" . + + + +### http://purl.obolibrary.org/obo/PATO_0001757 + +pato:_0001757 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000065 , + pato:_0001585 ; + + af-x:AFX_0002865 ; + + dct:license ; + + dct:rights ; + + dct:source "PAC, 1996, 68, 957. (Glossary of terms in quantities and units in Clinical Chemistry (IUPAC-IFCC Recommendations 1996))" ; + + rdfs:isDefinedBy ; + + skos:altLabel "conductivity" , + "conductivty (quality)" , + "electrical conductivity" ; + + skos:changeNote "2019-09-20 Changed pref label for uniqueness. [Allotrope]" , + "2020-01-23 Moved under electical quality and changed definition to IUPAC. [Allotrope]" ; + + skos:definition "Electrical conductivity is the quality inhered in a conductor that is the reciprocal of resistivity. [IUPAC]" ; + + skos:prefLabel "electrical conductivity (quality)" . + + + +### http://purl.obolibrary.org/obo/PATO_0001770 + +pato:_0001770 rdf:type owl:Class ; + + rdfs:subClassOf pato:_0000169 ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + skos:definition "A viability quality inhering in a population by virtue of some of it's members' ability to survive. [PATO]" ; + + skos:prefLabel "semi-viable" . + + + +### http://purl.obolibrary.org/obo/PATO_0001842 + +pato:_0001842 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000250 ; + + af-x:AFX_0002808 ; + + af-x:AFX_0002818 "true"^^xsd:boolean ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + skos:altLabel "pH" ; + + skos:changeNote "2019-08-19 Changed pref label. [Allotrope]" , + "2019-08-29 Changed definition. [Allotrope]" ; + + skos:definition "A concentration quality inhering in a bearer by virtue of the bearer's containing acid (hydrogen ions). [PATO]" ; + + skos:prefLabel "pH (quality)" . + + + +### http://purl.obolibrary.org/obo/PATO_0001906 + +pato:_0001906 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000210 ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + skos:definition "A physical quality inhering in a bearer by virtue of the bearer's participation in movement. [PATO]" ; + + skos:prefLabel "movement quality" . + + + +### http://purl.obolibrary.org/obo/PATO_0001995 + +pato:_0001995 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000019 ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + skos:definition "A quality that inheres in an entire organism or part of an organism. [PATO]" ; + + skos:prefLabel "organismal quality" . + + + +### http://purl.obolibrary.org/obo/PATO_0002027 + +pato:_0002027 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000250 ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + skos:altLabel "osmolality" ; + + skos:changeNote "2019-08-19 Changed pref label. [Allotrope]" , + "2019-08-29 Changed definition. [Allotrope]" ; + + skos:definition "A concentration quality inhering in a bearer by virtue of the bearer's amount of osmoles of solute per kilogram of solvent. [PATO]" ; + + skos:prefLabel "osmolality (quality)" . + + + +### http://purl.obolibrary.org/obo/PATO_0002070 + +pato:_0002070 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000252 ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + skos:definition "Affinity is a molecular quality that arises from the molecular attraction exerted between two atoms or compounds. [PATO]" ; + + skos:prefLabel "affinity" . + + + +### http://purl.obolibrary.org/obo/PATO_0002186 + +pato:_0002186 rdf:type owl:Class ; + + rdfs:subClassOf af-q:AFQ_0000252 ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + skos:altLabel "polarity" ; + + skos:definition "Polarity is a molecular quality that inheres in a molecular entity by virtue of whether or not the molecular entity has a separation of electric charge which leads to the molecule having an electric dipole. [PATO]" ; + + skos:prefLabel "polarity (molecular quality)" . + + + +### http://purl.obolibrary.org/obo/PATO_0002193 + +pato:_0002193 rdf:type owl:Class ; + + owl:equivalentClass [ rdf:type owl:Class ; + owl:unionOf ( pato:_0002194 + pato:_0002195 + pato:_0002196 + ) + ] ; + + rdfs:subClassOf af-q:AFQ_0000252 ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + skos:altLabel "charge" , + "electric charge" ; + + skos:definition "Electric charge is a molecular quality that inheres in a molecular entity by virtue of the overall electric charge of the molecule, which is due to a comparison between the total number of electrons and the total number of protons. [PATO]" ; + + skos:prefLabel "electric charge (molecular quality)" . + + + +### http://purl.obolibrary.org/obo/PATO_0002194 + +pato:_0002194 rdf:type owl:Class ; + + rdfs:subClassOf pato:_0002193 ; + + owl:disjointWith pato:_0002195 , + pato:_0002196 ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + skos:altLabel "neutral" ; + + skos:definition "Neutral charge is a quality which inheres in a molecular entity by virtue of the molecular entity possessing the same amount of electrons overall as protons, thus having an overall neutral charge. [PATO]" ; + + skos:prefLabel "neutral charge" . + + + +### http://purl.obolibrary.org/obo/PATO_0002195 + +pato:_0002195 rdf:type owl:Class ; + + rdfs:subClassOf pato:_0002193 ; + + owl:disjointWith pato:_0002196 ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + skos:altLabel "positive" ; + + skos:definition "Positive charge is a quality which inheres in a molecular entity by virtue of the molecular entity possessing more protons overall than electrons, thus having an overall positive charge. [PATO]" ; + + skos:prefLabel "positive charge" . + + + +### http://purl.obolibrary.org/obo/PATO_0002196 + +pato:_0002196 rdf:type owl:Class ; + + rdfs:subClassOf pato:_0002193 ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + skos:altLabel "negative" ; + + skos:definition "Negative charge is a quality which inheres in a molecular entity by virtue of the molecular entity possessing more electrons overall than protons, thus having an overall negative charge. [PATO]" ; + + skos:prefLabel "negative charge" . + + + +### http://purl.obolibrary.org/obo/PATO_0002242 + +pato:_0002242 rdf:type owl:Class ; + + rdfs:subClassOf pato:_0001906 ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + skos:definition "A physical quality inhering in a bearer by virtue of the bearer's rate of change of the position. [PATO]" ; + + skos:prefLabel "velocity" . + + + +### http://purl.obolibrary.org/obo/PATO_0002243 + +pato:_0002243 rdf:type owl:Class ; + + rdfs:subClassOf pato:_0001574 ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + skos:altLabel "fluid flow rate" , + "volume flow rate" , + "volumetric flow rate" ; + + skos:changeNote "2019-09-20 Changed pref label for uniqueness. [Allotrope]" ; + + skos:definition "A physical quality inhering in a fluid (liquid or gas) by virtue of the amount of fluid which passes through a given surface per unit time. [PATO]" ; + + skos:prefLabel "fluid flow rate (quality)" . + + + +### http://purl.obolibrary.org/obo/PATO_0002244 + +pato:_0002244 rdf:type owl:Class ; + + rdfs:subClassOf pato:_0001574 ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + skos:altLabel "mass flow rate" ; + + skos:changeNote "2019-09-20 Changed pref label for uniqueness. [Allotrope]" ; + + skos:definition "A flow rate quality inhering in a substance by virtue of the mass of substance which passes through a given surface per unit time. [PATO]" ; + + skos:prefLabel "mass flow rate (quality)" . + + + +### http://purl.obolibrary.org/obo/PATO_0002390 + +pato:_0002390 rdf:type owl:Class ; + + rdfs:subClassOf pato:_0000122 ; + + af-x:AFX_0002865 ; + + rdfs:isDefinedBy ; + + skos:altLabel "radius" ; + + skos:changeNote "2019-08-19 Changed pref label. [Allotrope]" ; + + skos:definition "A length quality which is equal to the length of any straight line segment that passes from the center of a circle to any endpoint on the circular boundary. The radius is half of the diameter. [PATO]" ; + + skos:prefLabel "radius (quality)" . + + + +### http://purl.obolibrary.org/obo/RO_0002577 + +ro:_0002577 rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000040 ; + + rdfs:isDefinedBy , + ; + + skos:definition "A material entity consisting of multiple components that are causally integrated. [RO]" ; + + skos:prefLabel "system" . + + + +### http://purl.org/NET/scovo#Dataset + + rdf:type owl:Class ; + + owl:equivalentClass qb:DataSet . + + + +### http://purl.org/NET/scovo#Item + + rdf:type owl:Class ; + + owl:equivalentClass qb:Observation . + + + +### http://purl.org/dc/terms/LicenseDocument + +dct:LicenseDocument rdf:type owl:Class . + + + +### http://purl.org/dc/terms/RightsStatement + +dct:RightsStatement rdf:type owl:Class . + + + +### http://purl.org/linked-data/cube#Attachable + +qb:Attachable rdf:type owl:Class ; + + rdfs:comment "Abstract superclass for everything that can have attributes and dimensions"@en ; + + rdfs:isDefinedBy ; + + rdfs:label "Attachable (abstract)"@en . + + + +### http://purl.org/linked-data/cube#AttributeProperty + +qb:AttributeProperty rdf:type owl:Class ; + + rdfs:subClassOf qb:ComponentProperty ; + + owl:disjointWith qb:MeasureProperty ; + + rdfs:comment "The class of components which represent attributes of observations in the cube, e.g. unit of measurement"@en ; + + rdfs:isDefinedBy ; + + rdfs:label "Attribute property"@en . + + + +### http://purl.org/linked-data/cube#CodedProperty + +qb:CodedProperty rdf:type owl:Class ; + + rdfs:subClassOf qb:ComponentProperty ; + + rdfs:comment "Superclass of all coded ComponentProperties"@en ; + + rdfs:isDefinedBy ; + + rdfs:label "Coded property"@en . + + + +### http://purl.org/linked-data/cube#ComponentProperty + +qb:ComponentProperty rdf:type owl:Class ; + + rdfs:subClassOf rdf:Property ; + + rdfs:comment "Abstract super-property of all properties representing dimensions, attributes or measures"@en ; + + rdfs:isDefinedBy ; + + rdfs:label "Component property (abstract)"@en . + + + +### http://purl.org/linked-data/cube#ComponentSet + +qb:ComponentSet rdf:type owl:Class ; + + rdfs:comment "Abstract class of things which reference one or more ComponentProperties"@en ; + + rdfs:isDefinedBy ; + + rdfs:label "Component set"@en . + + + +### http://purl.org/linked-data/cube#ComponentSpecification + +qb:ComponentSpecification rdf:type owl:Class ; + + rdfs:subClassOf qb:ComponentSet ; + + rdfs:comment "Used to define properties of a component (attribute, dimension etc) which are specific to its usage in a DSD."@en ; + + rdfs:isDefinedBy ; + + rdfs:label "Component specification"@en . + + + +### http://purl.org/linked-data/cube#DataSet + +qb:DataSet rdf:type owl:Class ; + + rdfs:subClassOf af-c:AFC_0000166 , + iao:_0000030 , + qb:Attachable ; + + af-x:AFX_0002865 ; + + rdfs:comment "Represents a collection of observations, possibly organized into various slices, conforming to some common dimensional structure."@en ; + + rdfs:isDefinedBy , + ; + + rdfs:label "Data set"@en ; + + skos:altLabel "DataSet" , + "data set" , + "dataset" ; + + skos:definition "Represents a collection of observations, possibly organized into various slices, conforming to some common dimensional structure. [QB]" ; + + skos:prefLabel "data cube" . + + + +### http://purl.org/linked-data/cube#DataStructureDefinition + +qb:DataStructureDefinition rdf:type owl:Class ; + + rdfs:subClassOf qb:ComponentSet ; + + rdfs:comment "Defines the structure of a DataSet or slice"@en ; + + rdfs:isDefinedBy ; + + rdfs:label "Data structure definition"@en . + + + +### http://purl.org/linked-data/cube#DimensionProperty + +qb:DimensionProperty rdf:type owl:Class ; + + rdfs:subClassOf qb:CodedProperty , + qb:ComponentProperty ; + + owl:disjointWith qb:MeasureProperty ; + + rdfs:comment "The class of components which represent the dimensions of the cube"@en ; + + rdfs:isDefinedBy ; + + rdfs:label "Dimension property"@en . + + + +### http://purl.org/linked-data/cube#HierarchicalCodeList + +qb:HierarchicalCodeList rdf:type owl:Class ; + + rdfs:comment "Represents a generalized hierarchy of concepts which can be used for coding. The hierarchy is defined by one or more roots together with a property which relates concepts in the hierarchy to thier child concept . The same concepts may be members of multiple hierarchies provided that different qb:parentChildProperty values are used for each hierarchy."@en ; + + rdfs:isDefinedBy ; + + rdfs:label "Hierarchical Code List"@en . + + + +### http://purl.org/linked-data/cube#MeasureProperty + +qb:MeasureProperty rdf:type owl:Class ; + + rdfs:subClassOf qb:ComponentProperty ; + + rdfs:comment "The class of components which represent the measured value of the phenomenon being observed"@en ; + + rdfs:isDefinedBy ; + + rdfs:label "Measure property"@en . + + + +### http://purl.org/linked-data/cube#Observation + +qb:Observation rdf:type owl:Class ; + + rdfs:subClassOf qb:Attachable ; + + rdfs:comment "A single observation in the cube, may have one or more associated measured values"@en ; + + rdfs:isDefinedBy ; + + rdfs:label "Observation"@en . + + + +### http://purl.org/linked-data/cube#ObservationGroup + +qb:ObservationGroup rdf:type owl:Class ; + + rdfs:comment "A, possibly arbitrary, group of observations."@en ; + + rdfs:isDefinedBy ; + + rdfs:label "Observation Group"@en . + + + +### http://purl.org/linked-data/cube#Slice + +qb:Slice rdf:type owl:Class ; + + rdfs:subClassOf qb:Attachable , + qb:ObservationGroup ; + + rdfs:comment "Denotes a subset of a DataSet defined by fixing a subset of the dimensional values, component properties on the Slice"@en ; + + rdfs:isDefinedBy ; + + rdfs:label "Slice"@en . + + + +### http://purl.org/linked-data/cube#SliceKey + +qb:SliceKey rdf:type owl:Class ; + + rdfs:subClassOf qb:ComponentSet ; + + rdfs:comment "Denotes a subset of the component properties of a DataSet which are fixed in the corresponding slices"@en ; + + rdfs:isDefinedBy ; + + rdfs:label "Slice key"@en . + + + +### http://qudt.org/schema/qudt#QuantityKind + +qudt:QuantityKind rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0000916 ; + + rdfs:isDefinedBy ; + + skos:prefLabel "quantity kind" . + + + +### http://qudt.org/schema/qudt#QuantityValue + +qudt:QuantityValue rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001101 ; + + rdfs:isDefinedBy ; + + skos:prefLabel "quantity value" . + + + +### http://qudt.org/schema/qudt#Unit + +qudt:Unit rdf:type owl:Class ; + + rdfs:subClassOf af-r:AFR_0001101 ; + + rdfs:isDefinedBy ; + + skos:prefLabel "unit" . + + + +### http://www.w3.org/1999/02/22-rdf-syntax-ns#Property + +rdf:Property rdf:type owl:Class . + + + +### http://www.w3.org/2000/01/rdf-schema#Class + +rdfs:Class rdf:type owl:Class . + + + +### http://www.w3.org/2004/02/skos/core#Collection + +skos:Collection rdf:type owl:Class ; + + owl:disjointWith skos:Concept , + skos:ConceptScheme ; + + rdfs:isDefinedBy ; + + rdfs:label "Collection" ; + + skos:definition "A meaningful collection of concepts." ; + + skos:scopeNote "Labelled collections can be used where you would like a set of concepts to be displayed under a 'node label' in the hierarchy." . + + + +### http://www.w3.org/2004/02/skos/core#Concept + +skos:Concept rdf:type owl:Class ; + + owl:disjointWith skos:ConceptScheme ; + + rdfs:isDefinedBy ; + + rdfs:label "Concept" ; + + skos:definition "An idea or notion; a unit of thought." . + + + +### http://www.w3.org/2004/02/skos/core#ConceptScheme + +skos:ConceptScheme rdf:type owl:Class ; + + rdfs:isDefinedBy ; + + rdfs:label "Concept Scheme" ; + + skos:definition "A set of concepts, optionally including statements about semantic relationships between those concepts." ; + + skos:example "Thesauri, classification schemes, subject heading lists, taxonomies, 'folksonomies', and other types of controlled vocabulary are all examples of concept schemes. Concept schemes are also embedded in glossaries and terminologies." ; + + skos:scopeNote "A concept scheme may be defined to include concepts from different sources." . + + + +### http://www.w3.org/2004/02/skos/core#OrderedCollection + +skos:OrderedCollection rdf:type owl:Class ; + + rdfs:subClassOf skos:Collection ; + + rdfs:isDefinedBy ; + + rdfs:label "Ordered Collection" ; + + skos:definition "An ordered collection of concepts, where both the grouping and the ordering are meaningful." ; + + skos:scopeNote "Ordered collections can be used where you would like a set of concepts to be displayed in a specific order, and optionally under a 'node label'." . + + + +### http://www.w3.org/2006/time#Instant + +time:Instant rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000008 ; + + rdfs:isDefinedBy ; + + skos:prefLabel "instant" . + + + +### http://www.w3.org/2006/time#Interval + +time:Interval rdf:type owl:Class ; + + rdfs:subClassOf bfo:_0000038 ; + + rdfs:isDefinedBy ; + + skos:prefLabel "interval" . + + + +### http://xmlns.com/foaf/0.1/Organization + +foaf:Organization rdf:type owl:Class . + + + + + +################################################################# +# +# Individuals +# +################################################################# + + +### http://www.allotrope.org + + rdf:type owl:NamedIndividual , + foaf:Organization ; + + foaf:name "Allotrope Foundation" . + + + +### http://www.rsc.org + + rdf:type owl:NamedIndividual , + foaf:Organization ; + + foaf:name "Royal Society of Chemistry" . + + + +### http://code.google.com/p/bfo/ + + rdf:type owl:NamedIndividual . + + + +### http://ifomis.org/bfo + + rdf:type owl:NamedIndividual . + + + +### http://purl.allotrope.org/ontologies/afo + + rdf:type owl:NamedIndividual . + + + +### http://purl.allotrope.org/ontologies/equipment#AFE_0002248 + +af-e:AFE_0002248 rdf:type owl:NamedIndividual ; + + skos:closeMatch . + + + +### http://purl.allotrope.org/ontologies/process#AFP_0003781 + +af-p:AFP_0003781 rdf:type owl:NamedIndividual . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001222 + +af-r:AFR_0001222 rdf:type owl:NamedIndividual , + af-r:AFR_0001221 ; + + rdfs:isDefinedBy ; + + skos:altLabel "quantum scale" ; + + skos:definition "Atomic scale refers to the distance between the nuclei of atoms in a material. This space is extremely large compared to the size of the atomic nucleus, and is related to the chemical bonds which bind atoms together. The spacing between atoms in most ordered solids is on the order of a few ångströms (a few tenths of a nanometer). [Wikipedia]" ; + + skos:note "atomic scale is smaller than mesoscopic scale" ; + + skos:prefLabel "atomic scale" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001223 + +af-r:AFR_0001223 rdf:type owl:NamedIndividual , + af-r:AFR_0001221 ; + + rdfs:isDefinedBy ; + + skos:definition "The macroscopic scale is the length scale on which objects or phenomena are large enough to be visible almost practically with the naked eye, without magnifying optical instruments. When applied to physical phenomena and bodies, the macroscopic scale describes things as a person can directly perceive them, without the aid of magnifying devices. This is in contrast to observations (microscopy) or theories (microphysics, statistical physics) of objects of geometric lengths smaller than perhaps some hundreds of micrometers. [Wikipedia]" ; + + skos:prefLabel "macroscopic scale" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001224 + +af-r:AFR_0001224 rdf:type owl:NamedIndividual , + af-r:AFR_0001221 ; + + rdfs:isDefinedBy ; + + skos:definition "Mesoscopic physics is a sub-discipline of condensed matter physics that deals with materials of an intermediate length. The scale of these materials can be described as being between the size of a quantity of atoms (such as a molecule) and of materials measuring micrometers. [Wikipedia]" ; + + skos:note "mesoscopic is smaller than microscopic" ; + + skos:prefLabel "mesoscopic scale" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001225 + +af-r:AFR_0001225 rdf:type owl:NamedIndividual , + af-r:AFR_0001221 ; + + rdfs:isDefinedBy ; + + skos:definition "In physics, the microscopic scale is sometimes considered the scale between the macroscopic and the quantum realm. Microscopic units and measurements are used to classify and describe very small objects. One common microscopic length scale unit is the Micrometer (μm) - one millionth of 1 meter. [Wikipedia]" ; + + skos:note "microscopic is smaller than macroscopic" ; + + skos:prefLabel "microscopic scale" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001492 + +af-r:AFR_0001492 rdf:type owl:NamedIndividual , + af-r:AFR_0001221 ; + + rdfs:isDefinedBy ; + + skos:definition "The subatomic scale is is the scale of the subatomic particles, such as electrons, protons, photons. [Wikipedia]" ; + + skos:note "subatomic is smaller than atomic" ; + + skos:prefLabel "subatomic scale" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001667 + +af-r:AFR_0001667 rdf:type owl:NamedIndividual , + af-r:AFR_0001669 ; + + skos:notation "positive" ; + + rdfs:isDefinedBy ; + + skos:altLabel "positive" ; + + skos:definition "Positive polarity is the code that indicates a positive direction of polarity. [Allotrope]" ; + + skos:prefLabel "positive polarity" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001668 + +af-r:AFR_0001668 rdf:type owl:NamedIndividual , + af-r:AFR_0001669 ; + + skos:notation "negative" ; + + rdfs:isDefinedBy ; + + skos:altLabel "negative" ; + + skos:definition "Negative polarity is the code that indicates a negative direction of polarity. [Allotrope]" ; + + skos:prefLabel "negative polarity" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001832 + +af-r:AFR_0001832 rdf:type owl:NamedIndividual , + af-r:AFR_0001835 ; + + rdfs:isDefinedBy ; + + skos:altLabel "pass" ; + + skos:definition "Pass is the calibration assessment code, that indicates that the calibrated instrument measures within the specification of the calibration method. [Allotrope]" ; + + skos:prefLabel "pass (calibration)" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001833 + +af-r:AFR_0001833 rdf:type owl:NamedIndividual , + af-r:AFR_0001835 ; + + rdfs:isDefinedBy ; + + skos:altLabel "fail" ; + + skos:definition "Fail is the calibration assessment code, that indicates the calibrated instrument does not measure within the specification of the calibration method. [Allotrope]" ; + + skos:prefLabel "fail (calibration)" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0001834 + +af-r:AFR_0001834 rdf:type owl:NamedIndividual , + af-r:AFR_0001835 ; + + rdfs:isDefinedBy ; + + skos:altLabel "indeterminate" ; + + skos:definition "Indeterminate is the calibration assessment code, that indicates it cannot be clearly stated whether the calibrated instrument does measure within the specification of the calibration method or not. [Allotrope]" ; + + skos:prefLabel "indeterminate (calibration)" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002172 + +af-r:AFR_0002172 rdf:type owl:NamedIndividual , + af-r:AFR_0002143 ; + + rdfs:isDefinedBy ; + + skos:definition "Hygroscopic is a hygroscopicity type that denotes the increase in mass as equal to or greater than 2% and less than 15%. [Allotrope]" ; + + skos:prefLabel "hygroscopic" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002173 + +af-r:AFR_0002173 rdf:type owl:NamedIndividual , + af-r:AFR_0002143 ; + + rdfs:isDefinedBy ; + + skos:definition "Slightly hygroscopic is a hygroscopicity type that denotes the increase in mass as equal to or greater than 0.2% and less than 2%. [Allotrope]" ; + + skos:prefLabel "slightly hygroscopic" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002174 + +af-r:AFR_0002174 rdf:type owl:NamedIndividual , + af-r:AFR_0002143 ; + + rdfs:isDefinedBy ; + + skos:definition "Non-hygroscopic is a hygroscopicity type that denotes the increase in mass as no greater than 0.2%. [Allotrope]" ; + + skos:prefLabel "non-hygroscopic" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002200 + +af-r:AFR_0002200 rdf:type owl:NamedIndividual , + af-r:AFR_0002143 ; + + rdfs:isDefinedBy ; + + skos:definition "Deliquescent is a hygroscopicity type that denotes the substance as sufficiently absorbant to form a liquid. [Allotrope]" ; + + skos:prefLabel "deliquescent" . + + + +### http://purl.allotrope.org/ontologies/result#AFR_0002201 + +af-r:AFR_0002201 rdf:type owl:NamedIndividual , + af-r:AFR_0002143 ; + + rdfs:isDefinedBy ; + + skos:definition "Very hygroscopic is a hygroscopicity type that denotes the increase in mass as equal to or greater than 15%. [Allotrope]" ; + + skos:prefLabel "very hygroscopic" . + + + +### http://purl.allotrope.org/voc/attribution + + rdf:type owl:NamedIndividual , + dct:RightsStatement ; + + dct:description """ +These taxonomies contain material or may constitute derivative works of material which may be subject to copyright by one of the following organizations. By using these taxonomies, you agree to the following terms and conditions applicable to its contents: +****************************************************************************** +Attribution Notice for National Center for Biomedical Ontology materials. + +This work contains material from the Cell Ontology and Clinical Measurement Ontology, available here: http://bioportal.bioontology.org/. +****************************************************************************** +Attribution Notice for ChEBI +This work contains material from the European Bioinformatics Institute’s ChEBI database. +****************************************************************************** +Attribution Notice for Quantities Units Dimensions Data Types (http://www.qudt.org/) +This work contains content from www.qudt.org and is used pursuant to a Creative Commons License available here: http://creativecommons.org/licenses/by-sa/3.0/us/legalcode. The original work may have been modified. +****************************************************************************** +Copyright and Attribution Notice for Dublin Core Metadata Initiative Document +This work contains material from the following DCMI document used pursuant to a creative commons license available here: https://creativecommons.org/licenses/by/4.0/legalcode. This material may have been modified or changed. +Timestamped URL: http://dublincore.org/documents/2012/06/14/dcmi-terms/ +Date Issued: 2012-06-14 +Document Status: This is a DCMI Recommendation. +Copyright © 1995-2015 DCMI. All Rights Reserved. DCMI liability, trademark/service mark, document use and software licensing rules apply. +****************************************************************************** + +""" , + """ +These taxonomies contain material or may constitute derivative works of material which may be subject to copyright by one of the following organizations. By using these taxonomies, you agree to the following terms and conditions applicable to its contents: +****************************************************************************** +Copyright Notice and Terms for IUPAC Gold Book +______________________________________________________________________________ +Copyright © 1998, Regents of the University of California +All rights reserved. +Redistribution and use in source and binary forms, with or without modification, are permitted provided that the following conditions are met: +1. Redistributions of source code must retain the above copyright notice, this list of conditions and the following disclaimer. +2. Redistributions in binary form must reproduce the above copyright notice, this list of conditions and the following disclaimer in the documentation and/or other materials provided with the distribution. +THIS SOFTWARE IS PROVIDED BY THE COPYRIGHT HOLDERS AND CONTRIBUTORS \"AS IS\" AND ANY EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, THE IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE ARE DISCLAIMED. IN NO EVENT SHALL THE COPYRIGHT HOLDER OR CONTRIBUTORS BE LIABLE FOR ANY DIRECT, INDIRECT, INCIDENTAL, SPECIAL, EXEMPLARY, OR CONSEQUENTIAL DAMAGES (INCLUDING, BUT NOT LIMITED TO, PROCUREMENT OF SUBSTITUTE GOODS OR SERVICES; LOSS OF USE, DATA, OR PROFITS; OR BUSINESS INTERRUPTION) HOWEVER CAUSED AND ON ANY THEORY OF LIABILITY, WHETHER IN CONTRACT, STRICT LIABILITY, OR TORT (INCLUDING NEGLIGENCE OR OTHERWISE) ARISING IN ANY WAY OUT OF THE USE OF THIS SOFTWARE, EVEN IF ADVISED OF THE POSSIBILITY OF SUCH DAMAGE. +****************************************************************************** +Copyright Notice and Terms for PSI-MS (Proteomics Standards Initiative - Mass Spectrometry) Mass spectrometer output files and spectra interpretation +_____________________________________________________________________________ +Created by Matt Chambers, Andreas Bertsch, Marius Kallhardt, Eric Deutsch Fredrik Levander, Pierre-Alain Binz, and Gerhard Mayer. Publisher: HUPO Proteomics Standards Initiative Mass Spectrometry Standards Working Group and HUPO Proteomics Standards Initiative Proteomics Informatics Working Group. This work is used pursuant to a Creative Commons license available here: http://creativecommons.org/licenses/by/3.0/legalcode + +****************************************************************************** +Attribution Notice for National Center for Biomedical Ontology materials. + +This work contains material from the Cell Ontology and Clinical Measurement Ontology, available here: http://bioportal.bioontology.org/. +****************************************************************************** +Attribution Notice for ChEBI +This work contains material from the European Bioinformatics Institute’s ChEBI database. +****************************************************************************** +Attribution Notice for Quantities Units Dimensions Data Types (http://www.qudt.org/) +This work contains content from www.qudt.org and is used pursuant to a Creative Commons License available here: http://creativecommons.org/licenses/by-sa/3.0/us/legalcode. The original work may have been modified. +****************************************************************************** +Copyright and Attribution Notice for Dublin Core Metadata Initiative Document +This work contains material from the following DCMI document used pursuant to a creative commons license available here: https://creativecommons.org/licenses/by/4.0/legalcode. This material may have been modified or changed. +Timestamped URL: http://dublincore.org/documents/2012/06/14/dcmi-terms/ +Date Issued: 2012-06-14 +Document Status: This is a DCMI Recommendation. +Copyright © 1995-2015 DCMI. All Rights Reserved. DCMI liability, trademark/service mark, document use and software licensing rules apply. +****************************************************************************** + +""" , + """ +These taxonomies contain material or may constitute derivative works of material which may be subject to copyright by one of the following organizations. By using these taxonomies, you agree to the following terms and conditions applicable to its contents: +****************************************************************************** +Copyright Notice and Terms for IUPAC Gold Book +______________________________________________________________________________ +Copyright © 1998, Regents of the University of California +All rights reserved. +Redistribution and use in source and binary forms, with or without modification, are permitted provided that the following conditions are met: +1. Redistributions of source code must retain the above copyright notice, this list of conditions and the following disclaimer. +2. Redistributions in binary form must reproduce the above copyright notice, this list of conditions and the following disclaimer in the documentation and/or other materials provided with the distribution. +THIS SOFTWARE IS PROVIDED BY THE COPYRIGHT HOLDERS AND CONTRIBUTORS \"AS IS\" AND ANY EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, THE IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE ARE DISCLAIMED. IN NO EVENT SHALL THE COPYRIGHT HOLDER OR CONTRIBUTORS BE LIABLE FOR ANY DIRECT, INDIRECT, INCIDENTAL, SPECIAL, EXEMPLARY, OR CONSEQUENTIAL DAMAGES (INCLUDING, BUT NOT LIMITED TO, PROCUREMENT OF SUBSTITUTE GOODS OR SERVICES; LOSS OF USE, DATA, OR PROFITS; OR BUSINESS INTERRUPTION) HOWEVER CAUSED AND ON ANY THEORY OF LIABILITY, WHETHER IN CONTRACT, STRICT LIABILITY, OR TORT (INCLUDING NEGLIGENCE OR OTHERWISE) ARISING IN ANY WAY OUT OF THE USE OF THIS SOFTWARE, EVEN IF ADVISED OF THE POSSIBILITY OF SUCH DAMAGE. +****************************************************************************** +Copyright Notice and Terms for PSI-MS (Proteomics Standards Initiative - Mass Spectrometry) Mass spectrometer output files and spectra interpretation +_____________________________________________________________________________ +Created by Matt Chambers, Andreas Bertsch, Marius Kallhardt, Eric Deutsch Fredrik Levander, Pierre-Alain Binz, and Gerhard Mayer. Publisher: HUPO Proteomics Standards Initiative Mass Spectrometry Standards Working Group and HUPO Proteomics Standards Initiative Proteomics Informatics Working Group. This work is used pursuant to a Creative Commons license available here: http://creativecommons.org/licenses/by/3.0/legalcode + +****************************************************************************** +Attribution Notice for National Center for Biomedical Ontology materials. + +This work contains material from the Cell Ontology and Clinical Measurement Ontology, available here: http://bioportal.bioontology.org/. +****************************************************************************** +Attribution Notice for ChEBI +This work contains material from the European Bioinformatics Institute’s ChEBI database. +****************************************************************************** +Attribution Notice for Quantities Units Dimensions Data Types (http://www.qudt.org/) +This work contains content from www.qudt.org and is used pursuant to a Creative Commons License available here: http://creativecommons.org/licenses/by-sa/3.0/us/legalcode. The original work may have been modified. +****************************************************************************** +Copyright and Attribution Notice for Dublin Core Metadata Initiative Document +This work contains material from the following DCMI document used pursuant to a creative commons license available here: https://creativecommons.org/licenses/by/4.0/legalcode. This material may have been modified or changed. +Timestamped URL: http://dublincore.org/documents/2012/06/14/dcmi-terms/ +Date Issued: 2012-06-14 +Document Status: This is a DCMI Recommendation. +Copyright © 1995-2015 DCMI. All Rights Reserved. DCMI liability, trademark/service mark, document use and software licensing rules apply. +****************************************************************************** + +""" ; + + dct:rightsHolder ; + + dct:title "Derivative works attribution" . + + + +### http://purl.allotrope.org/voc/copyright + + rdf:type owl:NamedIndividual , + dct:RightsStatement ; + + dct:description "(c) 2019 Allotrope Foundation" , + "Copyright © 2015-2020 Allotrope Foundation" ; + + dct:rightsHolder ; + + dct:title "(c) 2019 Allotrope Foundation" , + "Copyright © 2015-2020 Allotrope Foundation" . + + + +### http://purl.allotrope.org/voc/creative-commons-attribution-license + + rdf:type owl:NamedIndividual , + dct:LicenseDocument ; + + dct:description """This work is licensed under a Creative Commons Attribution 4.0 International License http://creativecommons.org/licenses/by/4.0/. + +THESE MATERIALS ARE PROVIDED \"AS IS\" AND ALLOTROPE EXPRESSLY DISCLAIMS ALL WARRANTIES, EXPRESS, IMPLIED OR STATUTORY, INCLUDING, WITHOUT LIMITATION, THE WARRANTIES OF NON-INFRINGEMENT, TITLE, MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. + +Copyright © 2015-2020 Allotrope Foundation +""" ; + + dct:rightsHolder ; + + dct:title "Creative Commons Attribution 4.0 International Public License" . + + + +### http://purl.allotrope.org/voc/iupac-copyright + + rdf:type owl:NamedIndividual , + dct:RightsStatement ; + + dct:description "Copyright (c) 2019 International Union of Pure Applied Chemistry" . + + + +### http://purl.allotrope.org/voc/iupac-license + + rdf:type owl:NamedIndividual , + dct:LicenseDocument ; + + dct:description "Reproduced by permission of International Union of Pure and Applied Chemistry" . + + + +### http://purl.allotrope.org/voc/afo/domain/CR/2018/04/lc-uv + + rdf:type owl:NamedIndividual ; + + dct:rightsHolder . + + + +### http://purl.allotrope.org/voc/afo/domain/WD/2020/12/electric-engineering + + rdf:type owl:NamedIndividual . + + + +### http://purl.obolibrary.org/obo/NCIT_C50121 + + rdf:type owl:NamedIndividual . + + + +### http://purl.obolibrary.org/obo/bfo-2-0 + + rdf:type owl:NamedIndividual ; + + foaf:homepage , + ; + + foaf:mbox . + + + +### http://purl.org/linked-data/cube#measureType + +qb:measureType rdf:type owl:NamedIndividual , + qb:DimensionProperty . + + + +### https://goldbook.iupac.org/terms/view/R05273 + + rdf:type owl:NamedIndividual . + + + +### https://semanticscience.org/resource/CHEMINF_000248 + + rdf:type owl:NamedIndividual . + + + +### mailto:arofan.gregory@earthlink.net + + rdf:type owl:NamedIndividual . + + + +### mailto:bfo-owl-devel@googlegroups.com + + rdf:type owl:NamedIndividual . + + + +### mailto:dave@epimorphics.com + + rdf:type owl:NamedIndividual . + + + +### mailto:ian@epimorphics.com + + rdf:type owl:NamedIndividual . + + + +### mailto:jeni@jenitennison.com + + rdf:type owl:NamedIndividual . + + + +### mailto:richard@cyganiak.de + + rdf:type owl:NamedIndividual . + + + +[ foaf:mbox +] . +[ foaf:mbox +] . +[ foaf:mbox +] . +[ foaf:mbox +] . +[ foaf:mbox +] . +[ foaf:mbox +] . +[ foaf:mbox +] . +[ foaf:mbox +] . +[ foaf:mbox +] . +[ foaf:mbox +] . +[ foaf:mbox +] . +[ foaf:mbox +] . +[ foaf:mbox +] . +[ foaf:mbox +] . +[ foaf:mbox +] . +[ foaf:mbox +] . +[ foaf:mbox +] . +[ foaf:mbox +] . +[ foaf:mbox +] . +[ foaf:mbox +] . +[ foaf:mbox +] . +[ foaf:mbox +] . +[ foaf:mbox +] . +[ foaf:mbox +] . +[ foaf:mbox +] . +[ foaf:mbox +] . +[ foaf:mbox +] . +[ foaf:mbox +] . +[ foaf:mbox +] . +[ foaf:mbox +] . + + +################################################################# +# +# Annotations +# +################################################################# + + + iao:_0000119 "Person:Alan Ruttenberg" . + + + +af-e:AFE_0002248 rdfs:isDefinedBy ; + + af-x:AFX_0002808 ; + + skos:definition "A probe is a device designed to reach into a location for remote manipulating or sensing. [NCI]" ; + + skos:prefLabel "probe" . + + + +af-p:AFP_0003781 skos:definition "A densitometry of bulk material that includes the contribution of the interparticulate void volume. [Allotrope]" ; + + skos:prefLabel "bulk density" ; + + af-x:AFX_0002808 ; + + rdfs:isDefinedBy . + + + +bfo:_0000134 iao:_0000600 "To say that each spatiotemporal region s temporally_projects_onto some temporal region t is to say that t is the temporal extension of s. (axiom label in BFO2 Reference: [080-003])" , + "To say that each spatiotemporal region s temporally_projects_onto some temporal region t is to say that t is the temporal extension of s. (axiom label in BFO2 Reference: [080-003])"@en , + "To say that spatiotemporal region s spatially_projects_onto spatial region r at t is to say that r is the spatial extent of s at t. (axiom label in BFO2 Reference: [081-003])" . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000134 ; + owl:annotatedProperty iao:_0000600 ; + owl:annotatedTarget "To say that each spatiotemporal region s temporally_projects_onto some temporal region t is to say that t is the temporal extension of s. (axiom label in BFO2 Reference: [080-003])" ; + iao:_0010000 +] . +[ rdf:type owl:Axiom ; + owl:annotatedSource bfo:_0000134 ; + owl:annotatedProperty iao:_0000600 ; + owl:annotatedTarget "To say that spatiotemporal region s spatially_projects_onto spatial region r at t is to say that r is the spatial extent of s at t. (axiom label in BFO2 Reference: [081-003])" ; + iao:_0010000 +] . + + + +qb:measureType rdfs:label "measure type"@en ; + + rdfs:comment "Generic measure dimension, the value of this dimension indicates which measure (from the set of measures in the DSD) is being given by the obsValue (or other primary measure)"@en ; + + rdfs:isDefinedBy . + + + + +### Generated by the OWL API (version 4.1.3) https://github.com/owlcs/owlapi + diff --git a/src/test/resources/repo/input/cidit/CIDIT_V1.2.owl b/src/test/resources/repo/input/cidit/CIDIT_V1.2.owl new file mode 100644 index 0000000..7b57c58 --- /dev/null +++ b/src/test/resources/repo/input/cidit/CIDIT_V1.2.owl @@ -0,0 +1,199995 @@ + + + + Barry Smith + Brian Athey + Gil Omenn + Anthony Huffman + Asiyah Yu Lin + Edison Ong + Hong Yu + Hsin-Hui Huang + Yang Wang + Yang Wang + Yingtong Liu + Yongqun "Oliver" He (YOH) + 05-22-2020 + The Ontology of Coronavirus Infectious Disease (CIDO) is a community-driven open-source biomedical ontology in the area of coronavirus infectious disease. The CIDO is developed to provide standardized human- and computer-interpretable annotation and representation of various coronavirus infectious diseases, including their etiology, transmission, pathogenesis, diagnosis, prevention, and treatment. + OWL-DL + CIDO: A biomedical ontology in the area of coronavirus infectious disease. + CIDO: Ontology of Coronavirus Infectious Disease + http://creativecommons.org/licenses/by/4.0/ + Vision Release: 1.0.105 + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + BFO OWL specification label + Relates an entity in the ontology to the name of the variable that is used to represent it in the code that generates the BFO OWL file from the lispy specification. + Really of interest to developers only + BFO OWL specification label + BFO OWL specification label + + + + + + + + + BFO CLIF specification label + Relates an entity in the ontology to the term that is used to represent it in the the CLIF specification of BFO2 + Person:Alan Ruttenberg + Really of interest to developers only + BFO CLIF specification label + BFO CLIF specification label + + + + + + + + + Chinese label + + + + + + + + An annotation property that represents a laboratory authorized by FDA emergency use authorization (EUA) to perform an assay such as a SARS-CoV-2 RT-PCR assay. + Asiyah Yu Lin, Oliver He + https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization + FDA EUA laboratory + + + + + + + + has_RxCUI + + + + + + + + editor preferred label + editor preferred label + editor preferred term + editor preferred term + editor preferred term~editor preferred label + + The concise, meaningful, and human-friendly name for a class or property preferred by the ontology developers. (US-English) + PERSON:Daniel Schober + GROUP:OBI:<http://purl.obolibrary.org/obo/obi> + + editor preferred label + editor preferred label + editor preferred term + editor preferred term + editor preferred term~editor preferred label + + + + + + + + example + example of usage + + A phrase describing how a class name should be used. May also include other kinds of examples that facilitate immediate understanding of a class semantics, such as widely known prototypical subclasses or instances of the class. Although essential for high level terms, examples for low level terms (e.g., Affymetrix HU133 array) are not + A phrase describing how a term should be used and/or a citation to a work which uses it. May also include other kinds of examples that facilitate immediate understanding, such as widely know prototypes or instances of a class, or cases where a relation is said to hold. + PERSON:Daniel Schober + GROUP:OBI:<http://purl.obolibrary.org/obo/obi> + + example of usage + example of usage + + + + + + + + has curation status + PERSON:Alan Ruttenberg + PERSON:Bill Bug + PERSON:Melanie Courtot + OBI_0000281 + has curation status + has curation status + + + + + + + + definition + definition + textual definition + + English language definitions of what NCI means by the concept. These are limited to 1024 characters. They may also include information about the definition's source and attribution in a form that can easily be interpreted by software. + The official OBI definition, explaining the meaning of a class or property. Shall be Aristotelian, formalized and normalized. Can be augmented with colloquial definitions. + The official definition, explaining the meaning of a class or property. Shall be Aristotelian, formalized and normalized. Can be augmented with colloquial definitions. + The official definition, explaining the meaning of a class or property. Shall be Aristotelian, formalized and normalized. Can be augmented with colloquial definitions. + 2012-04-05: +Barry Smith + +The official OBI definition, explaining the meaning of a class or property: 'Shall be Aristotelian, formalized and normalized. Can be augmented with colloquial definitions' is terrible. + +Can you fix to something like: + +A statement of necessary and sufficient conditions explaining the meaning of an expression referring to a class or property. + +Alan Ruttenberg + +Your proposed definition is a reasonable candidate, except that it is very common that necessary and sufficient conditions are not given. Mostly they are necessary, occasionally they are necessary and sufficient or just sufficient. Often they use terms that are not themselves defined and so they effectively can't be evaluated by those criteria. + +On the specifics of the proposed definition: + +We don't have definitions of 'meaning' or 'expression' or 'property'. For 'reference' in the intended sense I think we use the term 'denotation'. For 'expression', I think we you mean symbol, or identifier. For 'meaning' it differs for class and property. For class we want documentation that let's the intended reader determine whether an entity is instance of the class, or not. For property we want documentation that let's the intended reader determine, given a pair of potential relata, whether the assertion that the relation holds is true. The 'intended reader' part suggests that we also specify who, we expect, would be able to understand the definition, and also generalizes over human and computer reader to include textual and logical definition. + +Personally, I am more comfortable weakening definition to documentation, with instructions as to what is desirable. + +We also have the outstanding issue of how to aim different definitions to different audiences. A clinical audience reading chebi wants a different sort of definition documentation/definition from a chemistry trained audience, and similarly there is a need for a definition that is adequate for an ontologist to work with. + PERSON:Daniel Schober + GROUP:OBI:<http://purl.obolibrary.org/obo/obi> + DEFINITION + + definition + definition + textual definition + + + + + + + + editor note + + An administrative note intended for its editor. It may not be included in the publication version of the ontology, so it should contain nothing necessary for end users to understand the ontology. + PERSON:Daniel Schober + GROUP:OBI:<http://purl.obfoundry.org/obo/obi> + IAO:0000116 + uberon + editor_note + 1 + true + editor_note + + editor note + editor note + + + + + + + + definition editor + term editor + + Name of editor entering the definition in the file. The definition editor is a point of contact for information regarding the term. The definition editor may be, but is not always, the author of the definition, which may have been worked upon by several people + Name of editor entering the term in the file. The term editor is a point of contact for information regarding the term. The term editor may be, but is not always, the author of the definition, which may have been worked upon by several people + 20110707, MC: label update to term editor and definition modified accordingly. See http://code.google.com/p/information-artifact-ontology/issues/detail?id=115. + 20110707, MC: label update to term editor and definition modified accordingly. See https://github.com/information-artifact-ontology/IAO/issues/115. + PERSON:Daniel Schober + GROUP:OBI:<http://purl.obolibrary.org/obo/obi> + + definition editor + definition editor + term editor + term editor + + + + + + + + alternative term + + An alternative name for a class or property which means the same thing as the preferred name (semantically equivalent) + PERSON:Daniel Schober + GROUP:OBI:<http://purl.obolibrary.org/obo/obi> + + alternative term + alternative term + + + + + + + + definition source + + formal citation, e.g. identifier in external database to indicate / attribute source(s) for the definition. Free text indicate / attribute source(s) for the definition. EXAMPLE: Author Name, URI, MeSH Term C04, PUBMED ID, Wiki uri on 31.01.2007 + PERSON:Daniel Schober + Discussion on obo-discuss mailing-list, see http://bit.ly/hgm99w + GROUP:OBI:<http://purl.obolibrary.org/obo/obi> + + definition source + definition source + + + + + + + + has obsolescence reason + Relates an annotation property to an obsolescence reason. The values of obsolescence reasons come from a list of predefined terms, instances of the class obsolescence reason specification. + PERSON:Alan Ruttenberg + PERSON:Melanie Courtot + has obsolescence reason + + + + + + + + curator note + + An administrative note of use for a curator but of no use for a user + PERSON:Alan Ruttenberg + IAO:0000232 + uberon + curator_notes + 1 + true + curator_notes + + curator note + curator note + curator notes + + + + + + + + imported from + + For external terms/classes, the ontology from which the term was imported + PERSON:Alan Ruttenberg + PERSON:Melanie Courtot + GROUP:OBI:<http://purl.obolibrary.org/obo/obi> + + imported from + imported from + + + + + + + + expand expression to + + + + + + + + expand assertion to + + + + + + + + OBO foundry unique label + + An alternative name for a class or property which is unique across the OBO Foundry. + The intended usage of that property is as follow: OBO foundry unique labels are automatically generated based on regular expressions provided by each ontology, so that SO could specify unique label = 'sequence ' + [label], etc. , MA could specify 'mouse + [label]' etc. Upon importing terms, ontology developers can choose to use the 'OBO foundry unique label' for an imported term or not. The same applies to tools . + PERSON:Alan Ruttenberg + PERSON:Bjoern Peters + PERSON:Chris Mungall + PERSON:Melanie Courtot + GROUP:OBO Foundry <http://obofoundry.org/> + OBO foundry unique label + + + + + + + + elucidation + person:Alan Ruttenberg + Person:Barry Smith + Primitive terms in a highest-level ontology such as BFO are terms which are so basic to our understanding of reality that there is no way of defining them in a non-circular fashion. For these, therefore, we can provide only elucidations, supplemented by examples and by axioms + + elucidation + elucidation + + + + + + + + has associated axiom(nl) + Person:Alan Ruttenberg + Person:Alan Ruttenberg + An axiom associated with a term expressed using natural language + + has associated axiom(nl) + has associated axiom(nl) + + + + + + + + has associated axiom(fol) + Person:Alan Ruttenberg + Person:Alan Ruttenberg + An axiom expressed in first order logic using CLIF syntax + + has associated axiom(fol) + has associated axiom(fol) + + + + + + + + has_MedDRA_id + + + + + + + + ISA alternative term + + An alternative term used by the ISA tools project (http://isa-tools.org). + Requested by Alejandra Gonzalez-Beltran +https://sourceforge.net/tracker/?func=detail&aid=3603413&group_id=177891&atid=886178 + Person: Alejandra Gonzalez-Beltran + Person: Philippe Rocca-Serra + ISA tools project (http://isa-tools.org) + ISA alternative term + + + + + + + + + IEDB alternative term + + An alternative term used by the IEDB. + PERSON:Randi Vita, Jason Greenbaum, Bjoern Peters + IEDB + IEDB alternative term + + + + + + + + + temporal interpretation + An assertion that holds between an OWL Object Property and a temporal interpretation that elucidates how OWL Class Axioms that use this property are to be interpreted in a temporal context. + temporal interpretation + https://code.google.com/p/obo-relations/wiki/ROAndTime + https://github.com/oborel/obo-relations/wiki/ROAndTime + + + + + + + + + tooth SubClassOf 'never in taxon' value 'Aves' + x never in taxon T if and only if T is a class, and x does not instantiate the class expression "in taxon some T". Note that this is a shortcut relation, and should be used as a hasValue restriction in OWL. + Chris Mungall + + + ?X DisjointWith RO_0002162 some ?Y + never in taxon + + + + + + + + + + An assertion that holds between an ontology class and an organism taxon class, which is intepreted to yield some relationship between instances of the ontology class and the taxon. + taxonomic class assertion + + + + + + + + + + S dubious_for_taxon T if it is probably the case that no instances of S can be found in any instance of T. + RO:0002174 + uberon + dubious_for_taxon + 1 + 1 + dubious_for_taxon + this relation lacks a strong logical interpretation, but can be used in place of never_in_taxon where it is desirable to state that the definition of the class is too strict for the taxon under consideration, but placing a never_in_taxon link would result in a chain of inconsistencies that will take time to resolve. Example: metencephalon in teleost + dubious_for_taxon + + + + + + + + S present_in_taxon T if some instance of T has some S. This does not means that all instances of T have an S - it may only be certain life stages or sexes that have S + RO:0002175 + applicable for taxon + uberon + present_in_taxon + 1 + 1 + present_in_taxon + present_in_taxon + + + + + + + + An assertion that involves at least one OWL object that is intended to be expanded into one or more logical axioms. The logical expansion can yield axioms expressed using any formal logical system, including, but not limited to OWL2-DL. + logical macro assertion + https://github.com/oborel/obo-relations/wiki/ShortcutRelations + + + + + + + + A logical macro assertion whose domain is an IRI for a class + The domain for this class can be considered to be owl:Class, but we cannot assert this in OWL2-DL + logical macro assertion on a class + + + + + + + + + A logical macro assertion whose domain is an IRI for a property + logical macro assertion on a property + + + + + + + + + Used to annotate object properties to describe a logical meta-property or characteristic of the object property. + logical macro assertion on an object property + + + + + + + + + logical macro assertion on an annotation property + + + + + + + + + relation p is the direct form of relation q iff p is a subPropertyOf q, p does not have the Transitive characteristic, q does have the Transitive characteristic, and for all x, y: x q y -> exists z1, z2, ..., zn such that x p z1 ... z2n y + If we have the annotation P is-direct-form-of Q, and we have inverses P' and Q', then it follows that P' is-direct-form-of Q' + Chris Mungall + is direct form of + + + + + + + + + An alternate textual definition for a class taken unmodified from an external source. This definition may have been used to derive a generalized definition for the new class. + UBPROP:0000001 + uberon + external_definition + 1 + true + external_definition + This annotation property may be replaced with an annotation property from an external ontology such as IAO + external_definition + + + + + + + + A textual description of an axiom loss in this ontology compared to an external ontology. + UBPROP:0000002 + uberon + axiom_lost_from_external_ontology + 1 + true + axiom_lost_from_external_ontology + This annotation property may be replaced with an annotation property from an external ontology such as IAO + axiom_lost_from_external_ontology + + + + + + + + Notes on the homology status of this class. + UBPROP:0000003 + uberon + homology_notes + 1 + true + homology_notes + This annotation property may be replaced with an annotation property from an external ontology such as IAO + homology_notes + + + + + + + + UBPROP:0000006 + uberon + implements_design_pattern + true + implements_design_pattern + implements_design_pattern + + + + + + + + Used to connect a class to an adjectival form of its label. For example, a class with label 'intestine' may have a relational adjective 'intestinal'. + UBPROP:0000007 + uberon + has_relational_adjective + 1 + true + has_relational_adjective + has_relational_adjective + + + + + + + + Notes on the how instances of this class vary across species. + UBPROP:0000008 + uberon + taxon_notes + 1 + true + taxon_notes + taxon_notes + + + + + + + + Notes on the structure, composition or histology of instances of this class. + This annotation property may be replaced with an annotation property from an external ontology such as IAO + UBPROP:0000010 + uberon + structure_notes + 1 + structure_notes + structure_notes + + + + + + + + Notes on the ontogenic development of instances of this class. + This annotation property may be replaced with an annotation property from an external ontology such as IAO + UBPROP:0000011 + uberon + development_notes + 1 + true + development_notes + development_notes + + + + + + + + Notes on how similar or equivalent classes are represented in other ontologies. + This annotation property may be replaced with an annotation property from an external ontology such as IAO + UBPROP:0000012 + uberon + external_ontology_notes + 1 + true + external_ontology_notes + external_ontology_notes + + + + + + + + Notes on how lexical conventions regarding this class, in particular any issues that may arise due to homonyny or synonymy. + This annotation property may be replaced with an annotation property from an external ontology such as IAO + UBPROP:0000013 + uberon + terminology_notes + 1 + terminology_notes + terminology_notes + + + + + + + + FMA has terms like 'set of X'. In general we do not include set-of terms in uberon, but provide a mapping between the singular form and the FMA set term + UBPROP:0000202 + uberon + fma_set_term + true + fma_set_term + fma_set_term + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A metadata relation between a class and its taxonomic rank (eg species, family) + ncbi_taxonomy + This is an abstract class for use with the NCBI taxonomy to name the depth of the node within the tree. The link between the node term and the rank is only visible if you are using an obo 1.3 aware browser/editor; otherwise this can be ignored + has_rank + + + + + + + + + + + + + + + + + + + + Examples of a Contributor include a person, an + organisation, or a service. Typically, the name of a + Contributor should be used to indicate the entity. + + uberon + dc-contributor + 1 + true + dc-contributor + An entity responsible for making contributions to the + content of the resource. + + Contributor + Contributor + contributor + + + + + + + + Examples of a Creator include a person, an organisation, + or a service. Typically, the name of a Creator should + be used to indicate the entity. + An entity primarily responsible for making the content + of the resource. + + Creator + Creator + creator + + + + + + + + Typically, Date will be associated with the creation or + availability of the resource. Recommended best practice + for encoding the date value is defined in a profile of + ISO 8601 [W3CDTF] and follows the YYYY-MM-DD format. + A date associated with an event in the life cycle of the + resource. + + Date + Date + + + + + + + + Description may include but is not limited to: an abstract, + table of contents, reference to a graphical representation + of content or a free-text account of the content. + An account of the content of the resource. + + Description + Description + description + + + + + + + + Typically, Format may include the media-type or dimensions of + the resource. Format may be used to determine the software, + hardware or other equipment needed to display or operate the + resource. Examples of dimensions include size and duration. + Recommended best practice is to select a value from a + controlled vocabulary (for example, the list of Internet Media + Types [MIME] defining computer media formats). + The physical or digital manifestation of the resource. + + Format + Format + + + + + + + + + + + + + + The present resource may be derived from the Source resource + in whole or in part. Recommended best practice is to reference + the resource by means of a string or number conforming to a + formal identification system. + A reference to a resource from which the present resource + is derived. + + Source + Source + + + + + + + + Typically, a Subject will be expressed as keywords, + key phrases or classification codes that describe a topic + of the resource. Recommended best practice is to select + a value from a controlled vocabulary or formal + classification scheme. + The topic of the content of the resource. + + Subject and Keywords + Subject and Keywords + + + + + + + + + title + + + + + + + + Mark Miller + 2018-05-11T13:47:29Z + license + + + + + + + + + + + + + + + + + + + + + + + + + + date + + + + + + + + has_alternative_id + + + + + + + + has_broad_synonym + + + + + + + + database_cross_reference + + + + + + + + + + + + + + Fully qualified synonym, contains the string, term type, source, and an optional source code if appropriate. Each subfield is deliniated to facilitate interpretation by software. + FULL_SYN + Synonym with Source Data + has exact synonym + has_exact_synonym + + + + + + + + has_narrow_synonym + + + + + + + + has_obo_format_version + + + + + + + + disease_ontology + has_obo_namespace + + + + + + + + has_related_synonym + + + + + + + + + + + + + + id + + + + + + + + in_subset + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + shorthand + + + + + + + + + + + + + + + + + + + + + + + + + + label + label + label + + + + + + + + + uberon + seeAlso + true + seeAlso + see also + + + + + + + + + + + + + + + uberon + depicted_by + foaf-depicted_by + 1 + true + depicted_by + foaf-depicted_by + depicted by + depicted_by + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + C24 + + has_Ingredient + + + + + + + + + + C28 + + has_MoA + + + + + + + + + + C20 + + has_PE + + + + + + + + + + C32 + + has_PK + + + + + + + + + + C38 + + may_prevent + + + + + + + + + + C34 + + may_treat + + + + + + + + + + C50 + + site_of_metabolism + + + + + + + + + + + + + + + + + + + is part of + my brain is part of my body (continuant parthood, two material entities) + my stomach cavity is part of my stomach (continuant parthood, immaterial entity is part of material entity) + this day is part of this year (occurrent parthood) + a core relation that holds between a part and its whole + Everything is part of itself. Any part of any part of a thing is itself part of that thing. Two distinct things cannot be part of each other. + Occurrents are not subject to change and so parthood between occurrents holds for all the times that the part exists. Many continuants are subject to change, so parthood between continuants will only hold at certain times, but this is difficult to specify in OWL. See https://code.google.com/p/obo-relations/wiki/ROAndTime + Parthood requires the part and the whole to have compatible classes: only an occurrent can be part of an occurrent; only a process can be part of a process; only a continuant can be part of a continuant; only an independent continuant can be part of an independent continuant; only an immaterial entity can be part of an immaterial entity; only a specifically dependent continuant can be part of a specifically dependent continuant; only a generically dependent continuant can be part of a generically dependent continuant. (This list is not exhaustive.) + +A continuant cannot be part of an occurrent: use 'participates in'. An occurrent cannot be part of a continuant: use 'has participant'. A material entity cannot be part of an immaterial entity: use 'has location'. A specifically dependent continuant cannot be part of an independent continuant: use 'inheres in'. An independent continuant cannot be part of a specifically dependent continuant: use 'bearer of'. + part of + part_of + + + + + + + + + + + + BFO:0000050 + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + protein + uberon + part_of + part_of + is part of + part of + part of + part_of + + + http://www.obofoundry.org/ro/#OBO_REL:part_of + + + + + + + + + + + + + + + + + has part + my body has part my brain (continuant parthood, two material entities) + my stomach has part my stomach cavity (continuant parthood, material entity has part immaterial entity) + this year has part this day (occurrent parthood) + a core relation that holds between a whole and its part + Everything has itself as a part. Any part of any part of a thing is itself part of that thing. Two distinct things cannot have each other as a part. + Occurrents are not subject to change and so parthood between occurrents holds for all the times that the part exists. Many continuants are subject to change, so parthood between continuants will only hold at certain times, but this is difficult to specify in OWL. See https://code.google.com/p/obo-relations/wiki/ROAndTime + Parthood requires the part and the whole to have compatible classes: only an occurrent have an occurrent as part; only a process can have a process as part; only a continuant can have a continuant as part; only an independent continuant can have an independent continuant as part; only a specifically dependent continuant can have a specifically dependent continuant as part; only a generically dependent continuant can have a generically dependent continuant as part. (This list is not exhaustive.) + +A continuant cannot have an occurrent as part: use 'participates in'. An occurrent cannot have a continuant as part: use 'has participant'. An immaterial entity cannot have a material entity as part: use 'location of'. An independent continuant cannot have a specifically dependent continuant as part: use 'bearer of'. A specifically dependent continuant cannot have an independent continuant as part: use 'inheres in'. + has_part + + + + + + + + + + + + + + BFO:0000051 + chebi_ontology + protein + uberon + has_part + false + has_part + has part + has part + has_part + + + + + + + + + + bearer of + bearer_of + + http://purl.obolibrary.org/obo/omrse.owl + is bearer of + is_bearer_of + + + + + + + + + + + + + + + + + realized in + this disease is realized in this disease course + this fragility is realized in this shattering + this investigator role is realized in this investigation + is realized by + realized_in + + + + + + http://purl.obolibrary.org/obo/ro.owl + [copied from inverse property 'realizes'] to say that b realizes c at t is to assert that there is some material entity d & b is a process which has participant d at t & c is a disposition or role of which d is bearer_of at t& the type instantiated by b is correlated with the type instantiated by c. (axiom label in BFO2 Reference: [059-003]) + Paraphrase of elucidation: a relation between a realizable entity and a process, where there is some material entity that is bearer of the realizable entity and participates in the process, and the realizable entity comes to be realized in the course of the process + + realized in + + + + + + + + + + + + + + + realizes + this disease course realizes this disease + this investigation realizes this investigator role + this shattering realizes this fragility + + + + + + to say that b realizes c at t is to assert that there is some material entity d & b is a process which has participant d at t & c is a disposition or role of which d is bearer_of at t& the type instantiated by b is correlated with the type instantiated by c. (axiom label in BFO2 Reference: [059-003]) + Paraphrase of elucidation: a relation between a process and a realizable entity, where there is some material entity that is bearer of the realizable entity and participates in the process, and the realizable entity comes to be realized in the course of the process + + + realizes + + + + + + + + + + + + + + + + + + + + + + + + + preceded by + X preceded_by Y iff: end(Y) before_or_simultaneous_with start(X) + x is preceded by y if and only if the time point at which y ends is before or equivalent to the time point at which x starts. Formally: x preceded by y iff ω(y) <= α(x), where α is a function that maps a process to a start point, and ω is a function that maps a process to an end point. + An example is: translation preceded_by transcription; aging preceded_by development (not however death preceded_by aging). Where derives_from links classes of continuants, preceded_by links classes of processes. Clearly, however, these two relations are not independent of each other. Thus if cells of type C1 derive_from cells of type C, then any cell division involving an instance of C1 in a given lineage is preceded_by cellular processes involving an instance of C. The assertion P preceded_by P1 tells us something about Ps in general: that is, it tells us something about what happened earlier, given what we know about what happened later. Thus it does not provide information pointing in the opposite direction, concerning instances of P1 in general; that is, that each is such as to be succeeded by some instance of P. Note that an assertion to the effect that P preceded_by P1 is rather weak; it tells us little about the relations between the underlying instances in virtue of which the preceded_by relation obtains. Typically we will be interested in stronger relations, for example in the relation immediately_preceded_by, or in relations which combine preceded_by with a condition to the effect that the corresponding instances of P and P1 share participants, or that their participants are connected by relations of derivation, or (as a first step along the road to a treatment of causality) that the one process in some way affects (for example, initiates or regulates) the other. + is preceded by + preceded_by + + + + + http://www.obofoundry.org/ro/#OBO_REL:preceded_by + BFO:0000062 + is preceded by + takes place after + uberon + preceded_by + + preceded_by + preceded by + preceded_by + + + + + + + + + + + + + + + + + + + + precedes + x precedes y if and only if the time point at which x ends is before or equivalent to the time point at which y starts. Formally: x precedes y iff ω(x) <= α(y), where α is a function that maps a process to a start point, and ω is a function that maps a process to an end point. + + + + + BFO:0000063 + uberon + precedes + + precedes + precedes + precedes + + + + + + + + + + + + + + + + + + + occurs in + b occurs_in c =def b is a process and c is a material entity or immaterial entity& there exists a spatiotemporal region r and b occupies_spatiotemporal_region r.& forall(t) if b exists_at t then c exists_at t & there exist spatial regions s and s’ where & b spatially_projects_onto s at t& c is occupies_spatial_region s’ at t& s is a proper_continuant_part_of s’ at t + occurs_in + unfolds in + unfolds_in + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + Paraphrase of definition: a relation between a process and an independent continuant, in which the process takes place entirely within the independent continuant + + occurs in + + + + + + + + site of + [copied from inverse property 'occurs in'] b occurs_in c =def b is a process and c is a material entity or immaterial entity& there exists a spatiotemporal region r and b occupies_spatiotemporal_region r.& forall(t) if b exists_at t then c exists_at t & there exist spatial regions s and s’ where & b spatially_projects_onto s at t& c is occupies_spatial_region s’ at t& s is a proper_continuant_part_of s’ at t + + + + Paraphrase of definition: a relation between an independent continuant and a process, in which the process takes place entirely within the independent continuant + + contains process + + + + + + + + + + has_granular_part + + has granular part + + + + + + + + + + + granular part of + granular_part_of + + is granular part of + + + + + + + + + x anterior_to y iff x is further along the antero-posterior axis than y, towards the head. An antero-posterior axis is an axis that bisects an organism from head end to opposite end of body or tail: bearer + + + cjm + 2009-07-31T02:15:46Z + BSPO:0000096 + uberon + anterior_to + anterior_to + anterior_to + + + + + + + + + + x dorsal_to y iff x is further along the dorso-ventral axis than y, towards the back. A dorso-ventral axis is an axis that bisects an organism from back (e.g. spinal column) to front (e.g. belly). + + + BSPO:0000098 + uberon + dorsal_to + dorsal_to + dorsal_to + + + + + + + + + x ventral_to y iff x is further along the dorso-ventral axis than y, towards the front. A dorso-ventral axis is an axis that bisects an organism from back (e.g. spinal column) to front (e.g. belly). + + + BSPO:0000102 + uberon + ventral_to + ventral_to + ventral_to + + + + + + + + + Further away from the surface of the organism. Thus, the muscular layer is deep to the skin, but superficial to the intestines. + + + BSPO:0000107 + uberon + deep_to + deep_to + deep_to + + + + + + + + Near the outer surface of the organism. Thus, skin is superficial to the muscle layer. + + + BSPO:0000108 + uberon + superficial_to + superficial_to + superficial_to + + + + + + + + + + X proximal_side_of Y <=> if Y is subdivided into distal and proximal portions, X is part_of the proximal portion. + + + BSPO:0000124 + uberon + in_proximal_side_of + in_proximal_side_of + in_proximal_side_of + + + + + + + + + X distal_side_of Y <=> if Y is subdivided into distal and proximal portions, X is part_of the distal portion. + + + BSPO:0000125 + uberon + in_distal_side_of + in_distal_side_of + in_distal_side_of + + + + + + + + + + X in_lateral_side_of Y <=> if X is in_left_side_of Y or X is in_right_side_of Y. X is often, but not always a paired structure + + + BSPO:0000126 + uberon + in_lateral_side_of + in_lateral_side_of + in_lateral_side_of + https://github.com/obophenotype/uberon/wiki/Modeling-paired-structures-Design-Pattern + + + + + + + + + X proximalmost_part_of Y <=> X is part_of Y and X is adjacent_to the proximal boundary of Y + + + BSPO:0001106 + uberon + proximalmost_part_of + proximalmost_part_of + proximalmost_part_of + + + + + + + + is host of + + + + + + + + An object property that represents a relation between a drug and a disease process where a drug is effective in treating a host against the disease process. + Oliver He + treatment for + + + + + + + + An object property that represents a relation between a drug and a chemical entity that is the active ingredient of the drug + Oliver He, Yingtong Liu + has active ingredient + + + + + + + + + + + Oliver He, Asiyah Lin + An object property that represents a relation between an assay and an organization and the assay is authorized to use at the organization such as a company or hospital + EUA-authorized use at + + + + + + + + A short-cut relation that represents a direct relationship between a PCR test and the target gene (or gene region) that the test is designed to amplify and detect the targeted gene or gene region. + Asiyah Yu Lin, Oliver He + PCR detects + + + + + + + + An object property that represents a relation between a material entity (such as a drug or chemical or vaccine) and an adverse event (AE) where the administration of the material entity is susceptible for the presence of the adverse event. + Note: This term needs to be moved to the OAE ontology. + Oliver He, Yingtong Liu + This term needs to be transferred to OAE + susceptible for adverse event + + + + + + + + An object property that represents a relation between an assay and an organization and the assay is performed at the organization such as a company or hospital + Asiyah Yu Lin, Oliver He + performed at + assay performed at + + + + + + + + We can use the following axiom to represent the relation between a camel and MERS-CoV: +MERS-COV: ‘has susceptible host’ some Camelus + An object property that represents a relation between a microbe and an organism that serves as the host role and can host the survival of the microbe. + Oliver He, Yang Wang + has susceptible host + + + + + + + + An object property that represents the relation between a disease process and a pathogen where the disease process is caused by the infection with the pathogen. + Oliver He + caused by infection with + + + + + + + + + has measurement unit label + A relation between a value specification and its unit of measurement. + + http://purl.obolibrary.org/obo/obi.owl + has measurement unit label + + + + + + + + + is about + This document is about information artifacts and their representations + + is_about is a (currently) primitive relation that relates an information artifact to an entity. + 7/6/2009 Alan Ruttenberg. Following discussion with Jonathan Rees, and introduction of "mentions" relation. Weaken the is_about relationship to be primitive. + +We will try to build it back up by elaborating the various subproperties that are more precisely defined. + +Some currently missing phenomena that should be considered "about" are predications - "The only person who knows the answer is sitting beside me" , Allegory, Satire, and other literary forms that can be topical without explicitly mentioning the topic. + person:Alan Ruttenberg + Smith, Ceusters, Ruttenberg, 2000 years of philosophy + + + + + + + is about + + + + + + + + + results_in + + + + + + + + + + + has material basis in + has_material_basis_in + + + + + + + + An adverse event has a participant quality, such as a hyperkalemia AE has a participatn quality blood potassium increased. + an object property that represents a relation between a process and a quality, in which the process has a participant that has the quality. + This is a shortcut relation of the following full version: +'has participant' some (participant 'has quality' ) +in: process 'has participant' some (participant 'has quality' some quality) + Yongqun He + + has participant quality + + + + + + + + + a 'occurs in' relation that is applied at the adverse event setting and indicates where an adverse event occurs in. + Yongqun He + adverse event occurs in + + AE occurs in + + + + + + + + + + + + + + + + has_specified_input + has_specified_input + see is_input_of example_of_usage + + A relation between a planned process and a continuant participating in that process that is not created during the process. The presence of the continuant during the process is explicitly specified in the plan specification which the process realizes the concretization of. + 8/17/09: specified inputs of one process are not necessarily specified inputs of a larger process that it is part of. This is in contrast to how 'has participant' works. + PERSON: Alan Ruttenberg + PERSON: Bjoern Peters + PERSON: Larry Hunter + PERSON: Melanie Coutot + + + + has_specified_input + + + + + + + + + + + + + + + is_specified_input_of + is_specified_input_of + some Autologous EBV(Epstein-Barr virus)-transformed B-LCL (B lymphocyte cell line) is_input_for instance of Chromum Release Assay described at https://wiki.cbil.upenn.edu/obiwiki/index.php/Chromium_Release_assay + + A relation between a planned process and a continuant participating in that process that is not created during the process. The presence of the continuant during the process is explicitly specified in the plan specification which the process realizes the concretization of. + Alan Ruttenberg + PERSON:Bjoern Peters + + + + is_specified_input_of + + + + + + + + + + + + + + + + has_specified_output + has_specified_output + + A relation between a planned process and a continuant participating in that process. The presence of the continuant at the end of the process is explicitly specified in the objective specification which the process realizes the concretization of. + PERSON: Alan Ruttenberg + PERSON: Bjoern Peters + PERSON: Larry Hunter + PERSON: Melanie Courtot + + + + has_specified_output + + + + + + + + + + + + + + + + + is_manufactured_by + http://www.affymetrix.com/products/arrays/specific/hgu133.affx is_manufactered_by http://www.affymetrix.com/ (if we decide to use these URIs for the actual entities) + + c is_manufactured_by o means that there was a process p in which c was built in which a person, or set of people or machines did the work(bore the "Manufacturer Role", and those people/and or machines were members or of directed by the organization to do this. + Alan Ruttenberg + Liju Fan + has_make + has_manufacturer + + + is_manufactured_by + + + + + + + + + + + + + + + is_specified_output_of + is_specified_output_of + + A relation between a planned process and a continuant participating in that process. The presence of the continuant at the end of the process is explicitly specified in the objective specification which the process realizes the concretization of. + Alan Ruttenberg + PERSON:Bjoern Peters + + + + is_specified_output_of + + + + + + + + + has_role + + A relation between a continuant C and a role R. The reciprocal relation of role_of. + replaced by: http://purl.obolibrary.org/obo/BFO_0000087 + GROUP:OBI:<http://obi.sourceforge.net> + PERSON:Chris Mungal + + + obsolete_has_role + true + + + + + + + + + + + achieves_planned_objective + A cell sorting process achieves the objective specification 'material separation objective' + + This relation obtains between a planned process and a objective specification when the criteria specified in the objective specification are met at the end of the planned process. + BP, AR, PPPB branch + PPPB branch derived + modified according to email thread from 1/23/09 in accordince with DT and PPPB branch + + + + achieves_planned_objective + + + + + + + + + + objective_achieved_by + + This relation obtains between an objective specification and a planned process when the criteria specified in the objective specification are met at the end of the planned process. + OBI + OBI + + + objective_achieved_by + + + + + + + + + + + has value specification + + A relation between an information content entity and a value specification that specifies its value. + PERSON: James A. Overton + OBI + + has value specification + + + + + + + + + + + + + + + + inheres in + this fragility inheres in this vase + this red color inheres in this apple + a relation between a specifically dependent continuant (the dependent) and an independent continuant (the bearer), in which the dependent specifically depends on the bearer for its existence + A dependent inheres in its bearer at all times for which the dependent exists. + inheres_in + + + + + + http://purl.obolibrary.org/obo/ro.owl + + inheres in + + + + + + + + + + + + + + bearer of + this apple is bearer of this red color + this vase is bearer of this fragility + a relation between an independent continuant (the bearer) and a specifically dependent continuant (the dependent), in which the dependent specifically depends on the bearer for its existence + A bearer can have many dependents, and its dependents can exist for different periods of time, but none of its dependents can exist when the bearer does not exist. + bearer_of + is bearer of + + + + + + bearer of + + + + + + + + + + + + + + + + participates in + this blood clot participates in this blood coagulation + this input material (or this output material) participates in this process + this investigator participates in this investigation + a relation between a continuant and a process, in which the continuant is somehow involved in the process + participates_in + + + + participates in + + + + + + + + + + + + + + + + has participant + this blood coagulation has participant this blood clot + this investigation has participant this investigator + this process has participant this input material (or this output material) + a relation between a process and a continuant, in which the continuant is somehow involved in the process + Has_participant is a primitive instance-level relation between a process, a continuant, and a time at which the continuant participates in some way in the process. The relation obtains, for example, when this particular process of oxygen exchange across this particular alveolar membrane has_participant this particular sample of hemoglobin at this particular time. + has_participant + + + + + http://purl.obolibrary.org/obo/ro.owl + http://www.obofoundry.org/ro/#OBO_REL:has_participant + has participant + + + + + + + + + + + + + + + + A journal article is an information artifact that inheres in some number of printed journals. For each copy of the printed journal there is some quality that carries the journal article, such as a pattern of ink. The journal article (a generically dependent continuant) is concretized as the quality (a specifically dependent continuant), and both depend on that copy of the printed journal (an independent continuant). + An investigator reads a protocol and forms a plan to carry out an assay. The plan is a realizable entity (a specifically dependent continuant) that concretizes the protocol (a generically dependent continuant), and both depend on the investigator (an independent continuant). The plan is then realized by the assay (a process). + A relationship between a generically dependent continuant and a specifically dependent continuant, in which the generically dependent continuant depends on some independent continuant in virtue of the fact that the specifically dependent continuant also depends on that same independent continuant. A generically dependent continuant may be concretized as multiple specifically dependent continuants. + + + is concretized as + + + + + + + + + + + + + + + concretizes + A journal article is an information artifact that inheres in some number of printed journals. For each copy of the printed journal there is some quality that carries the journal article, such as a pattern of ink. The quality (a specifically dependent continuant) concretizes the journal article (a generically dependent continuant), and both depend on that copy of the printed journal (an independent continuant). + An investigator reads a protocol and forms a plan to carry out an assay. The plan is a realizable entity (a specifically dependent continuant) that concretizes the protocol (a generically dependent continuant), and both depend on the investigator (an independent continuant). The plan is then realized by the assay (a process). + A relationship between a specifically dependent continuant and a generically dependent continuant, in which the generically dependent continuant depends on some independent continuant in virtue of the fact that the specifically dependent continuant also depends on that same independent continuant. Multiple specifically dependent continuants can concretize the same generically dependent continuant. + + + + + concretizes + + + + + + + + + + + + + + + + this catalysis function is a function of this enzyme + a relation between a function and an independent continuant (the bearer), in which the function specifically depends on the bearer for its existence + A function inheres in its bearer at all times for which the function exists, however the function need not be realized at all the times that the function exists. + function_of + is function of + + + + function of + + + + + + + + + + + + + + + this investigator role is a role of this person + a relation between a role and an independent continuant (the bearer), in which the role specifically depends on the bearer for its existence + A role inheres in its bearer at all times for which the role exists, however the role need not be realized at all the times that the role exists. + is role of + role_of + + + + role of + + + + + + + + + + + + + + + + this enzyme has function this catalysis function (more colloquially: this enzyme has this catalysis function) + a relation between an independent continuant (the bearer) and a function, in which the function specifically depends on the bearer for its existence + A bearer can have many functions, and its functions can exist for different periods of time, but none of its functions can exist when the bearer does not exist. A function need not be realized at all the times that the function exists. + has_function + + + + has function + + + + + + + + this apple has quality this red color + a relation between an independent continuant (the bearer) and a quality, in which the quality specifically depends on the bearer for its existence + A bearer can have many qualities, and its qualities can exist for different periods of time, but none of its qualities can exist when the bearer does not exist. + has_quality + + + + RO:0000086 + protein + has_quality + false + has_quality + has quality + has_quality + + + + + + + + + + + + + + + + this person has role this investigator role (more colloquially: this person has this role of investigator) + a relation between an independent continuant (the bearer) and a role, in which the role specifically depends on the bearer for its existence + A bearer can have many roles, and its roles can exist for different periods of time, but none of its roles can exist when the bearer does not exist. A role need not be realized at all the times that the role exists. + has_role + + + + + + RO:0000087 + chebi_ontology + has_role + false + false + has_role + has role + has role + + + + + + + + + + + + a relation between an independent continuant (the bearer) and a disposition, in which the disposition specifically depends on the bearer for its existence + + has disposition + + + + + + + + + + disposition of + + + + + + + + + + + + + + + + + derives from + this cell derives from this parent cell (cell division) + this nucleus derives from this parent nucleus (nuclear division) + + a relation between two distinct material entities, the new entity and the old entity, in which the new entity begins to exist when the old entity ceases to exist, and the new entity inherits the significant portion of the matter of the old entity + This is a very general relation. More specific relations are preferred when applicable, such as 'directly develops from'. + derives_from + + + derives from + + + + + + + + + + + + + this parent cell derives into this cell (cell division) + this parent nucleus derives into this nucleus (nuclear division) + + a relation between two distinct material entities, the old entity and the new entity, in which the new entity begins to exist when the old entity ceases to exist, and the new entity inherits the significant portion of the matter of the old entity + This is a very general relation. More specific relations are preferred when applicable, such as 'directly develops into'. To avoid making statements about a future that may not come to pass, it is often better to use the backward-looking 'derives from' rather than the forward-looking 'derives into'. + derives_into + + derives into + + + + + + + + + + + + + + + is location of + my head is the location of my brain + this cage is the location of this rat + a relation between two independent continuants, the location and the target, in which the target is entirely within the location + Most location relations will only hold at certain times, but this is difficult to specify in OWL. See https://code.google.com/p/obo-relations/wiki/ROAndTime + location_of + + + + + + RO:0001015 + uberon + location_of + location_of + location of + location_of + + + + + + + + + + + + + + located in + my brain is located in my head + this rat is located in this cage + a relation between two independent continuants, the target and the location, in which the target is entirely within the location + Location as a relation between instances: The primitive instance-level relation c located_in r at t reflects the fact that each continuant is at any given time associated with exactly one spatial region, namely its exact location. Following we can use this relation to define a further instance-level location relation - not between a continuant and the region which it exactly occupies, but rather between one continuant and another. c is located in c1, in this sense, whenever the spatial region occupied by c is part_of the spatial region occupied by c1. Note that this relation comprehends both the relation of exact location between one continuant and another which obtains when r and r1 are identical (for example, when a portion of fluid exactly fills a cavity), as well as those sorts of inexact location relations which obtain, for example, between brain and head or between ovum and uterus + Most location relations will only hold at certain times, but this is difficult to specify in OWL. See https://code.google.com/p/obo-relations/wiki/ROAndTime + located_in + + + + + + + http://www.obofoundry.org/ro/#OBO_REL:located_in + RO:0001025 + uberon + located_in + located_in + located in + located_in + + + + + + + + + + RO:0002002 + uberon + has_boundary + has_boundary + has boundary + + + + + + + + + + + RO:0002007 + uberon + bounding_layer_of + bounding_layer_of + A relationship that applies between a continuant and its outer, bounding layer. Examples include the relationship between a multicellular organism and its integument, between an animal cell and its plasma membrane, and between a membrane bound organelle and its outer/bounding membrane. + bounding layer of + + + + + + + + + David Osumi-Sutherland + <= + + + + Primitive instance level timing relation between events + before or simultaneous with + + + + + + + + + + + + Relation between occurrents, shares start and end boundaries. + David Osumi-Sutherland + + + + RO:0002082 + coincides_with + is_equal_to + uberon + simultaneous_with + + simultaneous_with + t1 simultaneous_with t2 iff:= t1 before_or_simultaneous_with t2 and not (t1 before t2) + simultaneous with + simultaneous_with + + + + + + + + + + + + + + David Osumi-Sutherland + + + + X ends_after Y iff: end(Y) before_or_simultaneous_with end(X) + ends after + + + + + + + + + + + + + + X immediately_preceded_by Y iff: end(X) simultaneous_with start(Y) + David Osumi-Sutherland + starts_at_end_of + + + + + A non-transitive temporal relation in which one process immediately precedes another process, such that there is no interval of time between the two processes[SIO:000251]. + RO:0002087 + directly preceded by + is directly preceded by + is immediately preceded by + starts_at_end_of + uberon + immediately_preceded_by + immediately_preceded_by + X immediately_preceded_by Y iff: end(X) simultaneous_with start(Y) + immediately preceded by + immediately_preceded_by + + + + + + + + + + + + + + David Osumi-Sutherland + ends_at_start_of + meets + + + + + + X immediately_precedes_Y iff: end(X) simultaneous_with start(Y) + immediately precedes + + + + + + + + + + + David Osumi-Sutherland + io + + + + X starts_during Y iff: (start(Y) before_or_simultaneous_with start(X)) AND (start(X) before_or_simultaneous_with end(Y)) + starts during + + + + + + + + + + David Osumi-Sutherland + d + during + + + + X happens_during Y iff: (start(Y) before_or_simultaneous_with start(X)) AND (end(X) before_or_simultaneous_with end(Y)) + happens during + + + + + + + + + David Osumi-Sutherland + o + overlaps + + + + X ends_during Y iff: ((start(Y) before_or_simultaneous_with end(X)) AND end(X) before_or_simultaneous_with end(Y). + ends during + + + + + + + + + + + + + + + + + + + + + + x overlaps y if and only if there exists some z such that x has part z and z part of y + + + + http://purl.obolibrary.org/obo/BFO_0000051 some (http://purl.obolibrary.org/obo/BFO_0000050 some ?Y) + + + overlaps + + + + + + + + U only_in_taxon T: U is a feature found in only in organisms of species of taxon T. The feature cannot be found in an organism of any species outside of (not subsumed by) that taxon. Down-propagates in U hierarchy, up-propagates in T hierarchy (species taxonomy). Implies applicable_to_taxon. + + RO:0002160 + never_outside_taxon + specific_to + specific_to_taxon + protein + only_in_taxon + false + only_in_taxon + Down-propagates. The original name for this in the paper is 'specific_to'. Applicable to genes because some genes are lost in sub-species (strains) of a species. + only_in_taxon + + + + + + + + Binary relationship: z connects x if and only if there exists some y such that z connects x and y in a ternary connected_to(x,y,z) relationship. + this is currently used for both structural relationships (such as between a valve and the chamber it connects) and abstract relationships (anatomical lines and the entities they connect) + + + RO:0002176 + uberon + connects + connects + connects + + + + + + + + + + + + + + + + + + + + + + RO:0002202 + uberon + develops_from + develops_from + develops_from + + + + + + + + + + + RO:0002203 + uberon + develops_into + develops_into + develops_into + + + + + + + + + x surrounded_by y iff: x is adjacent to y and for every region r adjacent to x, r overlaps y + + + RO:0002219 + uberon + surrounded_by + surrounded_by + surrounded_by + + + + + + + + + x adjacent_to y iff: x and y share a boundary + + + RO:0002220 + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + uberon + adjacent_to + adjacent_to + adjacent_to + + + + + + + + inverse of surrounded_by + + + RO:0002221 + uberon + surrounds + surrounds + surrounds + + + + + + + + + + + move to BFO? + Chris Mungall + + Allen + Do not use this relation directly. It is ended as a grouping for relations between occurrents involving the relative timing of their starts and ends. + + + + https://docs.google.com/document/d/1kBv1ep_9g3sTR-SD3jqzFqhuwo9TPNF-l-9fUDbO6rM/edit?pli=1 + + A relation that holds between two occurrents. This is a grouping relation that collects together all the Allen relations. + temporal relation + temporally related to + + + + + + + + + + Relation between occurrents, shares a start boundary with. + + + RO:0002223 + uberon + starts + starts + starts + + + + + + + + + + + Every insulin receptor signaling pathway starts with the binding of a ligand to the insulin receptor + + x starts with y if and only if x has part y and the time point at which x starts is equivalent to the time point at which y starts. Formally: α(y) = α(x) ∧ ω(y) < ω(x), where α is a function that maps a process to a start point, and ω is a function that maps a process to an end point. + Chris Mungall + started by + + + + RO:0002224 + uberon + starts_with + + starts_with + starts with + starts with + + + + + + + + + Relation between occurrents, shares an end boundary with. + + + RO:0002229 + finishes + uberon + ends + ends + ends + + + + + + + + + + + + x ends with y if and only if x has part y and the time point at which x ends is equivalent to the time point at which y ends. Formally: α(y) > α(x) ∧ ω(y) = ω(x), where α is a function that maps a process to a start point, and ω is a function that maps a process to an end point. + Chris Mungall + finished by + + + + RO:0002230 + uberon + ends_with + + ends_with + ends with + ends with + + + + + + + + + + + + + + + + RO:0002254 + uberon + has_developmental_contribution_from + has_developmental_contribution_from + has developmental contribution from + + + + + + + + t1 developmentally_induced_by t2 if there is a process of organ induction (GO:0001759) with t1 and t2 as interacting participants. t2 causes t1 to change its fate from a precursor tissue type T to T', where T' develops_from T. + + + RO:0002256 + uberon + developmentally_induced_by + developmentally_induced_by + sources for developmentally_induced_by relationships in Uberon: Developmental Biology, Gilbert, 8th edition, figure 6.5(F) + developmentally_induced_by + + + + + + + + + + RO:0002258 + uberon + developmentally_preceded_by + developmentally_preceded_by + developmentally preceded by + + + + + + + + + + RO:0002285 + uberon + developmentally_replaces + developmentally_replaces + developmentally_replaces + + + + + + + + + an annotation of gene X to anatomical structure formation with results_in_formation_of UBERON:0000007 (pituitary gland) means that at the beginning of the process a pituitary gland does not exist and at the end of the process a pituitary gland exists. + every "endocardial cushion formation" (GO:0003272) results_in_formation_of some "endocardial cushion" (UBERON:0002062) + + Chris Mungall + GOC:mtg_berkeley_2013 + + results_in_formation_of + results in formation of + + + + + + + + + q inheres in part of w if and only if there exists some p such that q inheres in p and p part of w. + Because part_of is transitive, inheres in is a sub-relation of inheres in part of + Chris Mungall + + + + + inheres in part of + + + + + + + + A mereological relationship or a topological relationship + Chris Mungall + Do not use this relation directly. It is ended as a grouping for a diverse set of relations, all involving parthood or connectivity relationships + + + + mereotopologically related to + + + + + + + + + + has member is a mereological relation between a collection and an item. + + + + + RO:0002351 + uberon + has_member + has_member + has member + has member + + + + + + + + + RO:0002353 + protein + output_of + false + output_of + output_of + + + + + + + + x has the potential to develop into y iff x develops into y or if x is capable of developing into y + + + RO:0002387 + uberon + has_potential_to_develop_into + has_potential_to_develop_into + has potential to develop into + + + + + + + + + + RO:0002433 + uberon + contributes_to_morphology_of + contributes_to_morphology_of + contributes to morphology of + + + + + + + + + x composed_primarily_of y iff: more than half of the mass of x is made from parts of y + + + UBREL:0000002 + RO:0002473 + uberon + composed_primarily_of + composed_primarily_of + composed primarily of + + + + + + + + + + + + + Relation between continuant c and occurrent s, such that every instance of c comes into existing during some s. + + + BFO:0000068 + RO:0002488 + begins_to_exist_during + uberon + existence_starts_during + existence_starts_during + existence starts during + + + + + + + + + Relation between continuant and occurrent, such that c comes into existence at the start of p. + + + RO:0002489 + uberon + existence_starts_with + existence_starts_with + existence starts with + + + + + + + + + + + + + Relation between continuant c and occurrent s, such that every instance of c ceases to exist during some s, if it does not die prematurely. + + + BFO:0000069 + RO:0002492 + ceases_to_exist_during + uberon + existence_ends_during + existence_ends_during + existence ends during + + + + + + + + + Relation between continuant and occurrent, such that c ceases to exist at the end of p. + + + RO:0002493 + uberon + existence_ends_with + existence_ends_with + existence ends with + + + + + + + + + + + + RO:0002494 + transforms from + uberon + transformation_of + transformation_of + transformation of + + + + + + + + + + + + RO:0002495 + direct_transformation_of + immediately transforms from + uberon + immediate_transformation_of + immediate_transformation_of + immediate transformation of + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + RO:0002496 + uberon + existence_starts_during_or_after + existence_starts_during_or_after + existence starts during or after + + + + + + + + + + + + + + + + + + + + + + + + + + RO:0002497 + uberon + existence_ends_during_or_before + existence_ends_during_or_before + existence ends during or before + + + + + + + + Chris Mungall + + + depends on + + + + + + + + + + + + + + + RO:0002507 + uberon + has_material_contribution_from + has_material_contribution_from + has material contribution from + + + + + + + + + + A relation between a subdivision of an organism and the single subdivision of skeleton that provides structural support for that subdivision. + + + RO:0002551 + uberon + has sekeletal support + has supporting framework + has_skeleton + has_skeleton + has skeleton + + + + + + + + + + + RO:0002572 + uberon + luminal_space_of + luminal_space_of + luminal space of + + + + + + + + + + + RO:0002576 + uberon + skeleton_of + skeleton_of + skeleton of + + + + + + + + + + RO:0003000 + uberon + produces + produces + produces + + + + + + + + + + RO:0003001 + uberon + produced_by + produced_by + produced_by + + + + + + + + + an object property that defines a relation between a vaccine and its component + YL, YH + + has vaccine component + + + + + + + + + an object property that specifies a vaccine antigen + YL, YH + + This relation only works for those vaccine antigen that is physically part of a vaccine preparation. It does not include those antigens that are not part of vaccine. For example, a protein antigen expressed in a DNA vaccine is not a part of vaccine pe ser. In this case, the vaccine expresses the protein, but the gene is part of the vaccine, not the protein. For the case, we can use the relation 'DNA vaccine expresses protein antigen' under the relation 'expresses'. + has vaccine antigen + + + + + + + + + a type of 'has vaccine component' relation that is specifically for vaccine adjuvant component + YL, YH + + has vaccine adjuvant + + + + + + + + + + a shortcut relation that equals to: +'processed material' and (is_specified_output_of some 'vaccine preparation') and ('has function' some ('vaccine function' and ('is realized by' only ('vaccine immunization' and (realizes some ('vaccine host role' and (role_of some 'organism')))))))). +The domain of this relation is a vaccine. +The range of this relation is a organism. + YL + Yongqun He + vaccine immunization for host + + immunization for host + + + + + + + + a shortcut relation that equals to: + +processed material and (is_specified_output_of some vaccine preparation) and (has function some (vaccine function and (is realized by only (vaccine immunization and (realizes some ('immunization target role' and (role_of some 'MICROBE')))))))) + +The domain of this relation is a vaccine. +The range of this relation is a microbe (a bacterium, a virus, a fungus, and a parasite) + Yongqun He + vaccine immunization against microbe + + immunization against microbe + + + + + + + + immunizes against disease process + + + + + + + + + chebi_ontology + has_functional_parent + false + false + has functional parent + + + + + + + + + chebi_ontology + has_parent_hydride + false + false + has parent hydride + + + + + + + + + + chebi_ontology + is_conjugate_acid_of + true + false + is conjugate acid of + + + + + + + + + chebi_ontology + is_conjugate_base_of + true + false + is conjugate base of + + + + + + + + + chebi_ontology + is_enantiomer_of + true + false + is enantiomer of + + + + + + + + + chebi_ontology + is_substituent_group_from + false + false + is substituent group from + + + + + + + + + + chebi_ontology + is_tautomer_of + true + is tautomer of + + + + + + + + + protein + has_gene_template + false + has_gene_template + + + + + + + + + protein + lacks_part + false + lacks_part + + + + + + + + + + carries + uberon + channel_for + channel for + + + + + + + + x is a conduit for y iff y passes through the lumen of x. + + + uberon + conduit_for + conduit for + + + + + + + + + + + + uberon + existence_starts_and_ends_during + existence starts and ends during + + + + + + + + + X in_central_side Y <=> if Y is subdivided into left and right portions around some median divisor, all parts of X are closer to the median divisor than the outermost lateral sides. + + + uberon + in_central_side_of + in_central_side_of + + https://github.com/obophenotype/uberon/wiki/Modeling-paired-structures-Design-Pattern + + + + + + + + + + uberon + subdivision_of + placeholder relation. X = 'subdivision of A' and subdivision_of some B means that X is the mereological sum of A and B + subdivision of + + + + + + + + + + + + + + + + + + + http://purl.org/obo/owl/relationship + OBO_REL:0000007 + relationship + has_proper_part + has_proper_part + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + Ingredient + + + + Ingredient Strength + + + + Packaged Product + + + + VA Class + + + + VA Product + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + Active + + + + Inactive + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + has specified value + + A relation between a value specification and a number that quantifies it. + A range of 'real' might be better than 'float'. For now we follow 'has measurement value' until we can consider technical issues with SPARQL queries and reasoning. + PERSON: James A. Overton + OBI + + has specified value + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + Mental Disorders and Manifestations + N0000000006 + 984721 + C2916796 + C190 + + Mental Disorders and Manifestations [Disease/Finding] + + + + + + + + + Infectious Diseases + N0000000007 + 1023583 + 189822004 + 190563008 + 191415002 + 40733004 + C0009450 + C192 + + Infectious Diseases [Disease/Finding] + + + + + + + + + Elimination + N0000000022 + 986944 + C0221102 + C222 + + Elimination [PK] + + + + + + + + + Metabolism + N0000000023 + 1023904 + C0025519 + C224 + + Metabolism [PK] + + + + + + + + + Site of Metabolism + N0000000024 + 988808 + C1373176 + C226 + + Site of Metabolism [PK] + + + + + + + + + + + + + + + + + + + + + + + + + Route of Excretion + N0000000041 + 987962 + C1373186 + C260 + + Route of Excretion [PK] + + + + + + + + + + + + + + + + + Hepatic Excretion + N0000000043 + 989209 + C1373188 + C264 + + Hepatic Excretion [PK] + + + + + + + + + + + + + + + + + Small Ion Transport Pump Interactions + N0000000066 + 986087 + C1373107 + C310 + + Small Ion Transport Pump Interactions [MoA] + + + + + + + + + Active Transporter Interactions + N0000000072 + 1031287 + C1373104 + C322 + + Active Transporter Interactions [MoA] + + + + + + + + + Protease Inhibitors + D011480 + Protease Inhibitors + N0000000076 + 992709 + C2756997 + C330 + + Protease Inhibitors [MoA] + + + + + + + + + Immunologic Factors + D007155 + Immunologic Factors + N0000000082 + 993127 + C2757006 + C342 + + Immunologic Factors [MoA] + + + + + + + + + Receptor Interactions + N0000000085 + 988560 + C1372999 + C348 + + Receptor Interactions [MoA] + + + + + + + + + Adrenergic Antagonists + D018674 + Adrenergic Antagonists + N0000000092 + 993129 + C2757018 + C362 + + Adrenergic Antagonists [MoA] + + + + + + + + + + Cholinergic Muscarinic Receptor Interactions + N0000000097 + 986244 + C1373009 + C372 + + Cholinergic Muscarinic Receptor Interactions [MoA] + + + + + + + + + + + + + + + + + + + + + + + + + Neurotransmitter Transporter Interactions + N0000000105 + 985066 + C1373006 + C388 + + Neurotransmitter Transporter Interactions [MoA] + + + + + + + + + Serotonin Uptake Inhibitors + D017367 + Serotonin Uptake Inhibitors + N0000000109 + 992711 + C2757053 + C396 + + Serotonin Uptake Inhibitors [MoA] + + + + + + + + + + Cholinergic Muscarinic Antagonists + N0000000125 + 984609 + C1373102 + C428 + + Cholinergic Muscarinic Antagonists [MoA] + + + + + + + + + + + + + + + + + + + + + + + + + Lipoxygenase Inhibitors + D016859 + Lipoxygenase Inhibitors + N0000000134 + 1031400 + C2757064 + C446 + + Lipoxygenase Inhibitors [MoA] + + + + + + + + + Immunologic Adjuvants + D000276 + Adjuvants, Immunologic + N0000000135 + 989878 + Adjuvants, Immunologic + C1383096 + C448 + + Immunologic Adjuvants [MoA] + + + + + + + + + Hormone Receptor Agonists + N0000000149 + 985200 + C1373095 + C476 + + Hormone Receptor Agonists [MoA] + + + + + + + + + Protein Synthesis Inhibitors + D011500 + Protein Synthesis Inhibitors + N0000000150 + 993158 + C2757051 + C478 + + Protein Synthesis Inhibitors [MoA] + + + + + + + + + G-Protein-linked Receptor Interactions + N0000000152 + 984725 + G-Protein-linked Receptor-Effector Interactions + C2916797 + C482 + + G-Protein-linked Receptor Interactions [MoA] + + + + + + + + + Adrenergic Receptor Interactions + N0000000153 + 987972 + C1373072 + C484 + + Adrenergic Receptor Interactions [MoA] + + + + + + + + + Uncouplers + N0000000155 + 986674 + C1373071 + C488 + + Uncouplers [MoA] + + + + + + + + + Chloride Channel Interactions + N0000000156 + 987326 + C1373070 + C490 + + Chloride Channel Interactions [MoA] + + + + + + + + + Glucocorticoid Receptor Agonists + N0000000159 + 989879 + C1373068 + C496 + + Glucocorticoid Receptor Agonists [MoA] + + + + + + + + + Enzyme Interactions + N0000000163 + 988200 + C1373066 + C504 + + Enzyme Interactions [MoA] + + + + + + + + + Serotonin Transporter Interactions + N0000000167 + 987204 + C1373063 + C512 + + Serotonin Transporter Interactions [MoA] + + + + + + + + + Selective Estrogen Receptor Modulators + D020845 + Selective Estrogen Receptor Modulators + N0000000168 + 993164 + C2757056 + C514 + + Selective Estrogen Receptor Modulators [MoA] + + + + + + + + + Steroid Receptor Modulators + N0000000172 + 987671 + C1373061 + C522 + + Steroid Receptor Modulators [MoA] + + + + + + + + + Steroid Hormone Receptor Agonists + N0000000182 + 990907 + C1373054 + C542 + + Steroid Hormone Receptor Agonists [MoA] + + + + + + + + + + + + + + + + + Progestational Hormone Receptor Agonists + N0000000185 + 986818 + C1373052 + C548 + + Progestational Hormone Receptor Agonists [MoA] + + + + + + + + + Histamine H1 Receptor Antagonists + D006634 + Histamine H1 Antagonists + N0000000190 + 992695 + H1 Receptor Antagonists + H1 Receptor Blockers + Histamine H1 Antagonists + Histamine H1 Blockers + C2757048 + C558 + + Histamine H1 Receptor Antagonists [MoA] + + + + + + + + + + + + + + + + + Serotonin Receptor Interactions + N0000000198 + 988082 + C1373043 + C574 + + Serotonin Receptor Interactions [MoA] + + + + + + + + + + + + + + + + + Histamine Receptor Antagonists + D006633 + Histamine Antagonists + N0000000207 + 989667 + Histamine Antagonists + C1383092 + C592 + + Histamine Receptor Antagonists [MoA] + + + + + + + + + Sex Hormone Receptor Agonists + N0000000214 + 990080 + C1373033 + C606 + + Sex Hormone Receptor Agonists [MoA] + + + + + + + + + Histamine Receptor Interactions + N0000000216 + 989394 + C1373031 + C610 + + Histamine Receptor Interactions [MoA] + + + + + + + + + + + + + + + + + Dopamine Antagonists + D018492 + Dopamine Antagonists + N0000000230 + 1032050 + C2757008 + C638 + + Dopamine Antagonists [MoA] + + + + + + + + + + + + + + + + + Norepinephrine Transporter Interactions + N0000000234 + 988817 + C2267223 + C646 + + Norepinephrine Transporter Interactions [MoA] + + + + + + + + + + + + + + + + + Transcription Factor Activity + N0000000242 + 1028825 + C1148759 + C662 + + Transcription Factor Activity [MoA] + + + + + + + + + HIV Protease Inhibitors + D017320 + HIV Protease Inhibitors + N0000000246 + 993149 + Human Immunodeficiency Virus Protease Inhibitors + C2756991 + C670 + + HIV Protease Inhibitors [MoA] + + + + + + + + + Biological Response Modifiers + D015545 + Biological Response Modifiers + N0000000247 + 993132 + C2757019 + C672 + + Biological Response Modifiers [MoA] + + + + + + + + + Immunologic and Biological Factors + D007151 + Immunologic and Biological Factors + N0000000254 + 1032698 + C0021048 + C686 + + Immunologic and Biological Factors [MoA] + + + + + + + + + Hormone Receptor Modulators + N0000000255 + 989214 + C1373075 + C688 + + Hormone Receptor Modulators [MoA] + + + + + + + + + Hormone Receptor Interactions + N0000000257 + 986361 + C1373074 + C692 + + Hormone Receptor Interactions [MoA] + + + + + + + + + + + + + + + + + Abnormalities, Drug-Induced + M0000014 + D000014 + Congenital abnormalities caused by medicinal substances or drugs of abuse given to or taken by the mother, or to which she is inadvertently exposed during the manufacture of such substances. The concept excludes abnormalities resulting from exposure to non-medicinal chemicals in the environment. + Abnormalities, Drug-Induced + N0000000265 + 989962 + Drug-Induced Abnormalities + C0000771 + C708 + + Abnormalities, Drug-Induced [Disease/Finding] + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + Actinomycetales Infections + M0000289 + D000193 + Infections with bacteria of the order ACTINOMYCETALES. + Actinomycetales Infections + N0000000299 + 1024017 + Actinomycete Infections + Infections, Actinomycetales + Infections, Actinomycete + C0001255 + C776 + + Actinomycetales Infections [Disease/Finding] + + + + + + + + + Adenocarcinoma + M0000355 + D000230 + A malignant epithelial tumor with a glandular organization. + Adenocarcinoma + N0000000306 + 1023834 + 35917007 + Adenoma, Malignant + C0001418 + C790 + + Adenocarcinoma [Disease/Finding] + + + + + + + + + Adenoviridae Infections + M0000404 + D000257 + Virus diseases caused by the ADENOVIRIDAE. + Adenoviridae Infections + N0000000314 + 1025703 + 25225006 + Adenovirus Infections + Infections, Adenoviridae + Infections, Adenovirus + C0001486 + C806 + + Adenoviridae Infections [Disease/Finding] + + + + + + + + + Adenovirus Infections, Human + M0000405 + D000258 + Respiratory and conjunctival infections caused by 33 identified serotypes of human adenoviruses. + Adenovirus Infections, Human + N0000000315 + 1022278 + Human Adenovirus Infections + Infections, Human Adenovirus + C0001487 + C808 + + Adenovirus Infections, Human [Disease/Finding] + + + + + + + + + + + + + + + + + + + + + + + + + Amino Acid Metabolism, Inborn Errors + M0000918 + D000592 + Disorders affecting amino acid metabolism. The majority of these disorders are inherited and present in the neonatal period with metabolic disturbances (e.g., ACIDOSIS) and neurologic manifestations. They are present at birth, although they may not become symptomatic until later in life. + Amino Acid Metabolism, Inborn Errors + N0000000369 + 1022859 + 190680002 + 42930003 + 44779003 + Amino Acid Metabolism Disorders, Inborn + Amino Acid Metabolism, Inborn Error + Amino Acidopathies, Congenital + Amino Acidopathies, Inborn + Congenital Amino Acidopathies + Inborn Errors, Amino Acid Metabolism + C0002514 + C916 + + Amino Acid Metabolism, Inborn Errors [Disease/Finding] + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + Aortic Stenosis, Subvalvular + M0001552 + D001020 + A pathological constriction occurring in the region below the AORTIC VALVE. It is characterized by restricted outflow from the LEFT VENTRICLE into the AORTA. + Aortic Stenosis, Subvalvular + N0000000442 + 1025918 + Aortic Subvalvular Stenosis + Subvalvular Aortic Stenosis + C0003500 + C1062 + + Aortic Stenosis, Subvalvular [Disease/Finding] + + + + + + + + + + Aortic Valve Stenosis + M0001557 + D001024 + A pathological constriction that can occur above (supravalvular stenosis), below (subvalvular stenosis), or at the AORTIC VALVE. It is characterized by restricted outflow from the LEFT VENTRICLE into the AORTA. + Aortic Valve Stenosis + N0000000445 + 1021926 + 60573004 + Aortic Stenosis + C0003507 + C1068 + + Aortic Valve Stenosis [Disease/Finding] + + + + + + + + + Arbovirus Infections + M0001658 + D001102 + Infections caused by arthropod-borne viruses, general or unspecified. + Arbovirus Infections + N0000000462 + 1023709 + 40610006 + C0003723 + C1102 + + Arbovirus Infections [Disease/Finding] + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + Bacterial Infections and Mycoses + M0002125 + D001423 + Infections caused by bacteria and fungi, general, specified, or unspecified. + Bacterial Infections and Mycoses + N0000000523 + 986958 + C0004615 + C1224 + + Bacterial Infections and Mycoses [Disease/Finding] + + + + + + + + + + + + + + + + + Basal Ganglia Diseases + M0002198 + D001480 + Diseases of the BASAL GANGLIA including the PUTAMEN; GLOBUS PALLIDUS; claustrum; AMYGDALA; and CAUDATE NUCLEUS. DYSKINESIAS (most notably involuntary movements and alterations of the rate of movement) represent the primary clinical manifestations of these disorders. Common etiologies include CEREBROVASCULAR DISORDERS; NEURODEGENERATIVE DISEASES; and CRANIOCEREBRAL TRAUMA. + Basal Ganglia Diseases + N0000000536 + 1030459 + 70835005 + Basal Ganglia Disorders + C0004782 + C1250 + + Basal Ganglia Diseases [Disease/Finding] + + + + + + + + + + + + + + + + + Urinary Bladder Diseases + M0002630 + D001745 + Pathological processes of the URINARY BLADDER. + Urinary Bladder Diseases + N0000000560 + 1022750 + 42643001 + Bladder Diseases + C0005686 + C1298 + + Urinary Bladder Diseases [Disease/Finding] + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + Blood Protein Disorders + M0002708 + D001796 + Blood Protein Disorders + N0000000578 + 1027678 + C0005830 + C1334 + + Blood Protein Disorders [Disease/Finding] + + + + + + + + + Bone Marrow Diseases + M0002788 + D001855 + Bone Marrow Diseases + N0000000589 + 1023913 + 127035006 + C0005956 + C1356 + + Bone Marrow Diseases [Disease/Finding] + + + + + + + + + + + + + + + + + + + + + + + + + + Brain Diseases, Metabolic + M0002875 + D001928 + Acquired or inborn metabolic diseases that produce brain dysfunction or damage. These include primary (i.e., disorders intrinsic to the brain) and secondary (i.e., extracranial) metabolic conditions that adversely affect cerebral function. + Brain Diseases, Metabolic + N0000000606 + 1024852 + 50122000 + Brain Disorders, Metabolic + Brain Syndrome, Metabolic + Encephalopathies, Metabolic + Metabolic Brain Diseases + Metabolic Brain Syndrome + Metabolic Brain Syndromes + Metabolic Disorders, Brain + Metabolic Encephalopathies + C0006112 + C1390 + + Brain Diseases, Metabolic [Disease/Finding] + + + + + + + + + + + + + + + + + + Breast Diseases + M0002906 + D001941 + Pathological processes of the BREAST. + Breast Diseases + N0000000611 + 1025046 + 79604008 + C0006145 + C1400 + + Breast Diseases [Disease/Finding] + + + + + + + + + + + + + + + + + + Candidiasis + M0003258 + D002177 + Infection with a fungus of the genus CANDIDA. It is usually a superficial infection of the moist areas of the body and is generally caused by CANDIDA ALBICANS. (Dorland, 27th ed) + Candidiasis + N0000000650 + 1022538 + 78048006 + Moniliasis + C0006840 + C1478 + + Candidiasis [Disease/Finding] + + + + + + + + + + + + + + + + + + Carcinoma + M0003424 + D002277 + A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm but is often wrongly used as a synonym for "cancer." (From Dorland, 27th ed) + Carcinoma + N0000000664 + 1024578 + 68453008 + Epithelial Neoplasms, Malignant + Epithelial Tumors, Malignant + Epithelioma + Malignant Epithelial Neoplasms + Neoplasms, Malignant Epithelial + C0007097 + C1506 + + Carcinoma [Disease/Finding] + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + Cell Transformation, Neoplastic + M0003771 + D002471 + Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill. + Cell Transformation, Neoplastic + N0000000705 + 990924 + Neoplastic Cell Transformation + Neoplastic Transformation, Cell + Transformation, Neoplastic Cell + C0007621 + C1588 + + Cell Transformation, Neoplastic [Disease/Finding] + + + + + + + + + Central Nervous System Diseases + M0003805 + D002493 + Diseases of any component of the brain (including the cerebral hemispheres, diencephalon, brain stem, and cerebellum) or the spinal cord. + Central Nervous System Diseases + N0000000709 + 1023588 + 23853001 + CNS Diseases + Central Nervous System Disorders + C0007682 + C1596 + + Central Nervous System Diseases [Disease/Finding] + + + + + + + + + + Central Nervous System Infections + M0003806 + D002494 + Pathogenic infections of the brain, spinal cord, and meninges. DNA VIRUS INFECTIONS; RNA VIRUS INFECTIONS; BACTERIAL INFECTIONS; MYCOPLASMA INFECTIONS; SPIROCHAETALES INFECTIONS; fungal infections; PROTOZOAN INFECTIONS; HELMINTHIASIS; and PRION DISEASES may involve the central nervous system as a primary or secondary process. + Central Nervous System Infections + N0000000710 + 1026115 + 128117002 + Central Nervous System Infection + Infections, Central Nervous System + C0007684 + C1598 + + Central Nervous System Infections [Disease/Finding] + + + + + + + + + + + + + + + + + + Cerebrovascular Disorders + M0003914 + D002561 + A spectrum of pathological conditions of impaired blood flow in the brain. They can involve vessels (ARTERIES; or VEINS) in the CEREBRUM, the CEREBELLUM, and the BRAIN STEM. Major categories include INTRACRANIAL ARTERIOVENOUS MALFORMATIONS; BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; and others. + Cerebrovascular Disorders + N0000000730 + 1022010 + 62914000 + Brain Vascular Disorders + Intracranial Vascular Disorders + Vascular Diseases, Intracranial + C0007820 + C1638 + + Cerebrovascular Disorders [Disease/Finding] + + + + + + + + + + + + + + + + + + Chlamydiaceae Infections + M0004111 + D002694 + Infections with bacteria of the family CHLAMYDIACEAE. + Chlamydiaceae Infections + N0000000755 + 987383 + C0008153 + C1688 + + Chlamydiaceae Infections [Disease/Finding] + + + + + + + + + + + + + + + + + Coccidiosis + M0004678 + D003048 + Protozoan infection found in animals and man. It is caused by several different genera of COCCIDIA. + Coccidiosis + N0000000801 + 1023852 + 62005008 + C0009187 + C1780 + + Coccidiosis [Disease/Finding] + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + Colonic Diseases, Functional + M0004815 + D003109 + Chronic or recurrent colonic disorders without an identifiable structural or biochemical explanation. The widely recognized IRRITABLE BOWEL SYNDROME falls into this category. + Colonic Diseases, Functional + N0000000812 + 1026889 + Functional Colonic Diseases + C0009374 + C1802 + + Colonic Diseases, Functional [Disease/Finding] + + + + + + + + + + + + + + + + + Conjunctival Diseases + M0005013 + D003229 + Conjunctival Diseases + N0000000831 + 1024252 + 59698003 + C0009759 + C1840 + + Conjunctival Diseases [Disease/Finding] + + + + + + + + + Conjunctivitis + M0005015 + D003231 + Conjunctivitis + N0000000833 + 1026151 + 193875009 + 9826008 + C0009763 + C1844 + + Conjunctivitis [Disease/Finding] + + + + + + + + + + + + + + + + + + + + + + + + + + + Consciousness Disorders + M0005031 + D003244 + Organic mental disorders in which there is impairment of the ability to maintain awareness of self and environment and to respond to environmental stimuli. Dysfunction of the cerebral hemispheres or brain stem RETICULAR FORMATION may result in this condition. + Consciousness Disorders + N0000000840 + 1031236 + C0009792 + C1858 + + Consciousness Disorders [Disease/Finding] + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + Deglutition Disorders + M0005756 + D003680 + Difficulty in SWALLOWING which may result from neuromuscular disorder or mechanical obstruction. Dysphagia is classified into two distinct types: oropharyngeal dysphagia due to malfunction of the PHARYNX and UPPER ESOPHAGEAL SPHINCTER; and esophageal dysphagia due to malfunction of the ESOPHAGUS. + Deglutition Disorders + N0000000910 + 1023938 + 40739000 + Dysphagia + Swallowing Disorders + C0011168 + C1998 + + Deglutition Disorders [Disease/Finding] + + + + + + + + + + Hepatitis D + M0005790 + D003699 + INFLAMMATION of the LIVER in humans caused by HEPATITIS DELTA VIRUS, a defective RNA virus that can only infect HEPATITIS B patients. For its viral coating, hepatitis delta virus requires the HEPATITIS B SURFACE ANTIGENS produced by these patients. Hepatitis D can occur either concomitantly with (coinfection) or subsequent to (superinfection) hepatitis B infection. Similar to hepatitis B, it is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact. + Hepatitis D + N0000000913 + 1023265 + Delta Hepatitis + Delta Infection + Hepatitis, Delta + Infection, Delta + C0011226 + C2004 + + Hepatitis D [Disease/Finding] + + + + + + + + + Demyelinating Diseases + M0005825 + D003711 + Diseases characterized by loss or dysfunction of myelin in the central or peripheral nervous system. + Demyelinating Diseases + N0000000915 + 1026682 + Demyelinating Disorders + C0011303 + C2008 + + Demyelinating Diseases [Disease/Finding] + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + Digestive System Neoplasms + M0006375 + D004067 + Tumors or cancer of the DIGESTIVE SYSTEM. + Digestive System Neoplasms + N0000000974 + 1027801 + 128348002 + 128415001 + 189527000 + Neoplasms, Digestive System + C0012243 + C2126 + + Digestive System Neoplasms [Disease/Finding] + + + + + + + + + DNA Virus Infections + M0006675 + D004266 + DNA Virus Infections + N0000000993 + 1027612 + Infections, DNA Virus + C0012922 + C2164 + + DNA Virus Infections [Disease/Finding] + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + Dysentery + M0006913 + D004403 + Acute inflammation of the intestine associated with infectious DIARRHEA of various etiologies, generally acquired by eating contaminated food containing TOXINS, BIOLOGICAL derived from BACTERIA or other microorganisms. Dysentery is characterized initially by watery FECES then by bloody mucoid stools. It is often associated with ABDOMINAL PAIN; FEVER; and DEHYDRATION. + Dysentery + N0000001016 + 1022956 + 111939009 + 19213003 + 236076004 + Infectious Diarrheal Disease + C0013369 + C2210 + + Dysentery [Disease/Finding] + + + + + + + + + + + + + + + + + + Ear Diseases + M0006941 + D004427 + Pathological processes of the ear, the hearing, and the equilibrium system of the body. + Ear Diseases + N0000001036 + 986705 + 25906001 + Otologic Diseases + Otological Diseases + C0013447 + C2250 + + Ear Diseases [Disease/Finding] + + + + + + + + + Ectoparasitic Infestations + M0007037 + D004478 + Infestations by PARASITES which live on, or burrow into, the surface of their host's EPIDERMIS. Most ectoparasites are ARTHROPODS. + Ectoparasitic Infestations + N0000001051 + 1029036 + C0013578 + C2280 + + Ectoparasitic Infestations [Disease/Finding] + + + + + + + + + + + + + + + + + + Encephalitis + M0007337 + D004660 + Inflammation of the BRAIN due to infection, autoimmune processes, toxins, and other conditions. Viral infections (see ENCEPHALITIS, VIRAL) are a relatively frequent cause of this condition. + Encephalitis + N0000001076 + 1022474 + 45170000 + Brain Inflammation + Inflammation, Brain + C0014038 + C2330 + + Encephalitis [Disease/Finding] + + + + + + + + + + + Encephalitis, Arbovirus + M0007356 + D004671 + Infections of the brain caused by arthropod-borne viruses (i.e., arboviruses) primarily from the families TOGAVIRIDAE; FLAVIVIRIDAE; BUNYAVIRIDAE; REOVIRIDAE; and RHABDOVIRIDAE. Life cycles of these viruses are characterized by ZOONOSES, with birds and lower mammals serving as intermediate hosts. The virus is transmitted to humans by the bite of mosquitoes (CULICIDAE) or TICKS. Clinical manifestations include fever, headache, alterations of mentation, focal neurologic deficits, and COMA. (From Clin Microbiol Rev 1994 Jan;7(1):89-116; Walton, Brain's Diseases of the Nervous System, 10th ed, p321) + Encephalitis, Arbovirus + N0000001078 + 1021779 + 186498004 + 192687008 + 285756005 + Arthropod-Borne Encephalitis + Arthropod-Borne Viral Encephalitis + Encephalitis, Arthropod-Borne + Encephalitis, Epidemic + Epidemic Encephalitis + Viral Encephalitis, Arthropod-Borne + C0014055 + C2334 + + Encephalitis, Arbovirus [Disease/Finding] + + + + + + + + + Endocarditis + M0007392 + D004696 + Inflammation of the inner lining of the heart (ENDOCARDIUM), the continuous membrane lining the four chambers and HEART VALVES. It is often caused by microorganisms including bacteria, viruses, fungi, and rickettsiae. Left untreated, endocarditis can damage heart valves and become life-threatening. + Endocarditis + N0000001096 + 1027251 + 56819008 + C0014118 + C2370 + + Endocarditis [Disease/Finding] + + + + + + + + + + + + + + + + + + + Endocrine System Diseases + M0007396 + D004700 + Pathological processes of the ENDOCRINE GLANDS, and diseases resulting from abnormal level of available HORMONES. + Endocrine System Diseases + N0000001099 + 1022080 + 362969004 + Diseases of Endocrine System + Endocrine Diseases + C0014130 + C2376 + + Endocrine System Diseases [Disease/Finding] + + + + + + + + + + Endocrine Gland Neoplasms + M0007397 + D004701 + Tumors or cancer of the ENDOCRINE GLANDS. + Endocrine Gland Neoplasms + N0000001100 + 1022324 + 387922007 + 387927001 + Neoplasms, Endocrine Gland + C0014132 + C2378 + + Endocrine Gland Neoplasms [Disease/Finding] + + + + + + + + + + + + + + + + + Enterobacteriaceae Infections + M0007472 + D004756 + Infections with bacteria of the family ENTEROBACTERIACEAE. + Enterobacteriaceae Infections + N0000001108 + 1024436 + Enterobacterial Infections + Infections, Enterobacteriaceae + Infections, Enterobacterial + C0014347 + C2394 + + Enterobacteriaceae Infections [Disease/Finding] + + + + + + + + + + + + + + + + + + + + + + + + + + + Eosinophilia + M0007532 + D004802 + Abnormal increase of EOSINOPHILS in the blood, tissues or organs. + Eosinophilia + N0000001115 + 1021800 + 191363000 + C0014457 + C2408 + + Eosinophilia [Disease/Finding] + + + + + + + + + + + + + + + + + + + + + + + + + Esophageal Diseases + M0007747 + D004935 + Pathological processes in the ESOPHAGUS. + Esophageal Diseases + N0000001159 + 990942 + 37657006 + C0014852 + C2496 + + Esophageal Diseases [Disease/Finding] + + + + + + + + + + + + + + + + + Facial Dermatoses + M0008112 + D005148 + Facial Dermatoses + N0000001190 + 1028247 + Facial Dermatosis + C0015456 + C2558 + + Facial Dermatoses [Disease/Finding] + + + + + + + + + + Fascioloidiasis + M0008246 + D005213 + Infection of cattle and other herbivores with the giant liver fluke Fascioloides magna. It is characterized by extensive destruction of the liver parenchyma. + Fascioloidiasis + N0000001214 + 1026508 + C0015655 + C2606 + + Fascioloidiasis [Disease/Finding] + + + + + + + + + Fatty Liver + M0008275 + D005234 + Lipid infiltration of the hepatic parenchymal cells resulting in a yellow-colored liver. The abnormal lipid accumulation is usually in the form of TRIGLYCERIDES, either as a single large droplet or multiple small droplets. Fatty liver is caused by an imbalance in the metabolism of FATTY ACIDS. + Fatty Liver + N0000001217 + 1022768 + 197321007 + 371330000 + C0015695 + C2612 + + Fatty Liver [Disease/Finding] + + + + + + + + + Female Urogenital Diseases and Pregnancy Complications + M0008309 + D005261 + Pathological processes of the female URINARY TRACT, the reproductive system (GENITALIA, FEMALE), and disorders related to PREGNANCY. + Female Urogenital Diseases and Pregnancy Complications + N0000001224 + 985609 + C1720765 + C2626 + + Female Urogenital Diseases and Pregnancy Complications [Disease/Finding] + + + + + + + + + Filariasis + M0008468 + D005368 + Infections with nematodes of the superfamily FILARIOIDEA. The presence of living worms in the body is mainly asymptomatic but the death of adult worms leads to granulomatous inflammation and permanent fibrosis. Organisms of the genus Elaeophora infect wild elk and domestic sheep causing ischemic necrosis of the brain, blindness, and dermatosis of the face. + Filariasis + N0000001254 + 1023733 + 105706003 + Filarioidea Infections + Infections, Filarioidea + C0016085 + C2686 + + Filariasis [Disease/Finding] + + + + + + + + + Gastroenteritis + M0009018 + D005759 + INFLAMMATION of any segment of the GASTROINTESTINAL TRACT from ESOPHAGUS to RECTUM. Causes of gastroenteritis are many including genetic, infection, HYPERSENSITIVITY, drug effects, and CANCER. + Gastroenteritis + N0000001317 + 1024672 + 25374005 + C0017160 + C2812 + + Gastroenteritis [Disease/Finding] + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + Genital Diseases, Male + M0009155 + D005832 + Pathological processes involving the male reproductive tract (GENITALIA, MALE). + Genital Diseases, Male + N0000001324 + 1021837 + 64557000 + Male Genital Diseases + C0017412 + C2826 + + Genital Diseases, Male [Disease/Finding] + + + + + + + + + Genital Neoplasms, Female + M0009156 + D005833 + Tumor or cancer of the female reproductive tract (GENITALIA, FEMALE). + Genital Neoplasms, Female + N0000001325 + 1024023 + 126907002 + Female Genital Neoplasms + Gynecologic Neoplasms + Neoplasms, Female Genital + Neoplasms, Gynecologic + C0017416 + C2828 + + Genital Neoplasms, Female [Disease/Finding] + + + + + + + + + + + + + + + + + + Glomerulonephritis + M0009300 + D005921 + Inflammation of the renal glomeruli (KIDNEY GLOMERULUS) that can be classified by the type of glomerular injuries including antibody deposition, complement activation, cellular proliferation, and glomerulosclerosis. These structural and functional abnormalities usually lead to HEMATURIA; PROTEINURIA; HYPERTENSION; and RENAL INSUFFICIENCY. + Glomerulonephritis + N0000001351 + 1021985 + 236391006 + 36171008 + C0017658 + C2880 + + Glomerulonephritis [Disease/Finding] + + + + + + + + + + + + + + + + + Gonadal Disorders + M0009536 + D006058 + Pathological processes of the OVARIES or the TESTES. + Gonadal Disorders + N0000001376 + 986338 + C0018050 + C2930 + + Gonadal Disorders [Disease/Finding] + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + Heart Valve Diseases + M0009972 + D006349 + Pathological conditions involving any of the various HEART VALVES and the associated structures (PAPILLARY MUSCLES and CHORDAE TENDINEAE). + Heart Valve Diseases + N0000001443 + 989613 + 368009 + Valvular Heart Diseases + C0018824 + C3064 + + Heart Valve Diseases [Disease/Finding] + + + + + + + + + + + + + + + + + + Helminthiasis, Animal + M0010009 + D006374 + Infestation of animals with parasitic worms of the helminth class. The infestation may be experimental or veterinary. + Helminthiasis, Animal + N0000001449 + 1028354 + C0018891 + C3076 + + Helminthiasis, Animal [Disease/Finding] + + + + + + + + + + + + + + + + + + + + + + + + + Hemic and Lymphatic Diseases + M0010072 + D006425 + Hematologic diseases and diseases of the lymphatic system collectively. Hemic diseases include disorders involving the formed elements (e.g., ERYTHROCYTE AGGREGATION, INTRAVASCULAR) and chemical components (e.g., BLOOD PROTEIN DISORDERS); lymphatic diseases include disorders relating to lymph, lymph nodes, and lymphocytes. + Hemic and Lymphatic Diseases + N0000001466 + 1026878 + C0018981 + C3110 + + Hemic and Lymphatic Diseases [Disease/Finding] + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + Hepatitis + M0010205 + D006505 + INFLAMMATION of the LIVER. + Hepatitis + N0000001499 + 989819 + 128241005 + 197351001 + C0019158 + C3176 + + Hepatitis [Disease/Finding] + + + + + + + + + Hepatitis, Chronic + M0010227 + D006521 + INFLAMMATION of the LIVER with ongoing hepatocellular injury for 6 months or more, characterized by NECROSIS of HEPATOCYTES and inflammatory cell (LEUKOCYTES) infiltration. Chronic hepatitis can be caused by viruses, medications, autoimmune diseases, and other unknown factors. + Hepatitis, Chronic + N0000001504 + 989540 + 197286002 + 197288001 + 76783007 + Chronic Hepatitis + C0019189 + C3186 + + Hepatitis, Chronic [Disease/Finding] + + + + + + + + + + Hepatitis, Viral, Human + M0010233 + D006525 + INFLAMMATION of the LIVER in humans due to infection by VIRUSES. There are several significant types of human viral hepatitis with infection caused by enteric-transmission (HEPATITIS A; HEPATITIS E) or blood transfusion (HEPATITIS B; HEPATITIS C; and HEPATITIS D). + Hepatitis, Viral, Human + N0000001508 + 990781 + C0019195 + C3194 + + Hepatitis, Viral, Human [Disease/Finding] + + + + + + + + + + Hepatitis C + M0010234 + D006526 + INFLAMMATION of the LIVER in humans caused by HEPATITIS C VIRUS, a single-stranded RNA virus. Its incubation period is 30-90 days. Hepatitis C is transmitted primarily by contaminated blood parenterally, and is often associated with transfusion and intravenous drug abuse. However, in a significant number of cases, the source of hepatitis C infection is unknown. + Hepatitis C + N0000001509 + 1024879 + 186634008 + 50711007 + Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted + PT-NANBH + Parenterally-Transmitted Non-A, Non-B Hepatitis + C0019196 + C3196 + + Hepatitis C [Disease/Finding] + + + + + + + + + + + + + + + + + + + + + + + + + + + + Herpes Simplex + M0010279 + D006561 + A group of acute infections caused by herpes simplex virus type 1 or type 2 that is characterized by the development of one or more small fluid-filled vesicles with a raised erythematous base on the skin or mucous membrane. It occurs as a primary infection or recurs due to a reactivation of a latent infection. (Dorland, 27th ed.) + Herpes Simplex + N0000001530 + 1023866 + 88594005 + C0019348 + C3238 + + Herpes Simplex [Disease/Finding] + + + + + + + + + Herpesviridae Infections + M0010285 + D006566 + Virus diseases caused by the HERPESVIRIDAE. + Herpesviridae Infections + N0000001533 + 1024733 + 23513009 + Herpesvirus Infections + Infections, Herpesviridae + Infections, Herpesvirus + C0019372 + C3244 + + Herpesviridae Infections [Disease/Finding] + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + Ileal Diseases + M0011023 + D007077 + Pathological development in the ILEUM including the ILEOCECAL VALVE. + Ileal Diseases + N0000001660 + 1025763 + C0020875 + C3498 + + Ileal Diseases [Disease/Finding] + + + + + + + + + + + + + + + + + + Immunologic Deficiency Syndromes + M0011155 + D007153 + Syndromes in which there is a deficiency or defect in the mechanisms of immunity, either cellular or humoral. + Immunologic Deficiency Syndromes + N0000001667 + 1022772 + 191005003 + 234532001 + Deficiency Syndrome, Immunologic + Deficiency Syndromes, Immunologic + Immunologic Deficiency Syndrome + Immunological Deficiency Syndromes + C0021051 + C3512 + + Immunologic Deficiency Syndromes [Disease/Finding] + + + + + + + + + + + + + + + + + Immunoproliferative Disorders + M0011164 + D007160 + Disorders characterized by abnormal proliferation of primary cells of the immune system or by excessive production of immunoglobulins. + Immunoproliferative Disorders + N0000001669 + 1028023 + 127071007 + C0021070 + C3516 + + Immunoproliferative Disorders [Disease/Finding] + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + Intestinal Diseases, Parasitic + M0011570 + D007411 + Infections of the INTESTINES with PARASITES, commonly involving PARASITIC WORMS. Infections with roundworms (NEMATODE INFECTIONS) and tapeworms (CESTODE INFECTIONS) are also known as HELMINTHIASIS. + Intestinal Diseases, Parasitic + N0000001699 + 1021992 + 87282003 + Parasitic Intestinal Diseases + C0021832 + C3576 + + Intestinal Diseases, Parasitic [Disease/Finding] + + + + + + + + + + Intestinal Neoplasms + M0011574 + D007414 + Tumors or cancer of the INTESTINES. + Intestinal Neoplasms + N0000001701 + 1023921 + 126769007 + Intestines Neoplasms + Neoplasms, Intestinal + C0021841 + C3580 + + Intestinal Neoplasms [Disease/Finding] + + + + + + + + + + + + + + + + + Joint Diseases + M0011860 + D007592 + Joint Diseases + N0000001727 + 1022553 + 399269003 + C0022408 + C3632 + + Joint Diseases [Disease/Finding] + + + + + + + + + + + + + + + + + + Kidney Neoplasms + M0012021 + D007680 + Tumors or cancers of the KIDNEY. + Kidney Neoplasms + N0000001751 + 1026062 + 126880001 + Neoplasms, Kidney + Renal Neoplasms + C0022665 + C3680 + + Kidney Neoplasms [Disease/Finding] + + + + + + + + + Labyrinth Diseases + M0012125 + D007759 + Pathological processes of the inner ear (LABYRINTH) which contains the essential apparatus of hearing (COCHLEA) and balance (SEMICIRCULAR CANALS). + Labyrinth Diseases + N0000001772 + 1025984 + 20425006 + Inner Ear Disease + C0022890 + C3722 + + Labyrinth Diseases [Disease/Finding] + + + + + + + + + Leukemia + M0012382 + D007938 + A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006) + Leukemia + N0000001815 + 1021987 + 188762002 + 93143009 + C0023418 + C3808 + + Leukemia [Disease/Finding] + + + + + + + + + + + + + + + + + + Leukemia, Myeloid + M0012396 + D007951 + Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites. + Leukemia, Myeloid + N0000001826 + 1023661 + 188732008 + Granulocytic Leukemia + Leukemia, Granulocytic + Leukemia, Myelocytic + Leukemia, Myelogenous + Myelocytic Leukemia + Myelogenous Leukemia + Myeloid Leukemia + C0023470 + C3830 + + Leukemia, Myeloid [Disease/Finding] + + + + + + + + + Leukocyte Disorders + M0012409 + D007960 + Disordered formation of various types of leukocytes or an abnormal accumulation or deficiency of these cells. + Leukocyte Disorders + N0000001831 + 1025909 + 54097007 + C0023510 + C3840 + + Leukocyte Disorders [Disease/Finding] + + + + + + + + + Lip Diseases + M0012537 + D008047 + Lip Diseases + N0000001846 + 1022975 + 90678009 + C0023760 + C3870 + + Lip Diseases [Disease/Finding] + + + + + + + + + + + + + + + + + + Liver Neoplasms + M0012652 + D008113 + Tumors or cancer of the LIVER. + Liver Neoplasms + N0000001869 + 1025382 + 126851005 + Hepatic Neoplasms + Neoplasms, Hepatic + Neoplasms, Liver + C0023903 + C3916 + + Liver Neoplasms [Disease/Finding] + + + + + + + + + + + + + + + + + + Lupus Erythematosus, Cutaneous + M0012754 + D008178 + A form of lupus erythematosus in which the skin may be the only organ involved or in which skin involvement precedes the spread into other body systems. It has been classified into three forms - acute (= LUPUS ERYTHEMATOSUS, SYSTEMIC with skin lesions), subacute, and chronic (= LUPUS ERYTHEMATOSUS, DISCOID). + Lupus Erythematosus, Cutaneous + N0000001885 + 1027393 + 7119001 + C0024137 + C3948 + + Lupus Erythematosus, Cutaneous [Disease/Finding] + + + + + + + + + + + + + + + + + + + + + + + + + + Lymphatic Diseases + M0012792 + D008206 + Diseases of LYMPH; LYMPH NODES; or LYMPHATIC VESSELS. + Lymphatic Diseases + N0000001898 + 1024043 + 111590001 + 234087005 + 362971004 + C0024228 + C3974 + + Lymphatic Diseases [Disease/Finding] + + + + + + + + + Lymphedema + M0012800 + D008209 + Edema due to obstruction of lymph vessels or disorders of the lymph nodes. + Lymphedema + N0000001900 + 1023978 + 234097001 + C0024236 + C3978 + + Lymphedema [Disease/Finding] + + + + + + + + + + Lymphoma + M0012817 + D008223 + A general term for various neoplastic diseases of the lymphoid tissue. + Lymphoma + N0000001905 + 1024259 + 118600007 + Germinoblastoma + Lymphoma, Malignant + Reticulolymphosarcoma + Sarcoma, Germinoblastic + C0024299 + C3988 + + Lymphoma [Disease/Finding] + + + + + + + + + Lymphoma, Non-Hodgkin + M0012822 + D008228 + Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease. + Lymphoma, Non-Hodgkin + N0000001910 + 1024301 + 118601006 + Diffuse Small Cleaved-Cell Lymphoma + Lymphoma, Atypical Diffuse Small Lymphoid + Lymphoma, Non-Hodgkin's + Lymphoma, Non-Hodgkins + Lymphoma, Nonhodgkin's + Lymphoma, Nonhodgkins + Lymphoma, Small Cleaved Cell, Diffuse + Lymphoma, Small Cleaved-Cell, Diffuse + Non-Hodgkin Lymphoma + Non-Hodgkin's Lymphoma + Small Cleaved-Cell Lymphoma, Diffuse + C0024305 + C3998 + + Lymphoma, Non-Hodgkin [Disease/Finding] + + + + + + + + + + Lymphoproliferative Disorders + M0012826 + D008232 + Disorders characterized by proliferation of lymphoid tissue, general or unspecified. + Lymphoproliferative Disorders + N0000001914 + 987016 + 277466009 + Duncan's Syndrome + C0024314 + C4006 + + Lymphoproliferative Disorders [Disease/Finding] + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + Metabolic Diseases + M0013493 + D008659 + Generic term for diseases caused by an abnormal metabolic process. It can be congenital due to inherited enzyme abnormality (METABOLISM, INBORN ERRORS) or acquired due to disease of an endocrine organ or failure of a metabolically important organ such as the liver. (Stedman, 26th ed) + Metabolic Diseases + N0000002004 + 1022778 + 30390004 + 75934005 + Diseases, Metabolic + Thesaurismosis + C0025517 + C4186 + + Metabolic Diseases [Disease/Finding] + + + + + + + + + + Metabolism, Inborn Errors + M0013496 + D008661 + Errors in metabolic processes resulting from inborn genetic mutations that are inherited or acquired in utero. + Metabolism, Inborn Errors + N0000002005 + 1024978 + 86095007 + Inborn Errors of Metabolism + Metabolism Errors, Inborn + C0025521 + C4188 + + Metabolism, Inborn Errors [Disease/Finding] + + + + + + + + + Mite Infestations + M0013932 + D008924 + Infestations with arthropods of the subclass ACARI, superorder Acariformes. + Mite Infestations + N0000002018 + 1022195 + 187214007 + 240885009 + Acariasis + C0026229 + C4214 + + Mite Infestations [Disease/Finding] + + + + + + + + + + + + + + + + + Stomatognathic Diseases + M0014128 + D009057 + General or unspecified diseases of the stomatognathic system, comprising the mouth, teeth, jaws, and pharynx. + Stomatognathic Diseases + N0000002034 + 1027350 + Mouth and Tooth Diseases + C0038368 + C4246 + + Stomatognathic Diseases [Disease/Finding] + + + + + + + + + Mouth Diseases + M0014130 + D009059 + Mouth Diseases + N0000002036 + 1027441 + 118938008 + C0026636 + C4250 + + Mouth Diseases [Disease/Finding] + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + Musculoskeletal Diseases + M0014259 + D009140 + Diseases of the muscles and their associated ligaments and other connective tissue and of the bones and cartilage viewed collectively. + Musculoskeletal Diseases + N0000002067 + 1022076 + 928000 + C0026857 + C4312 + + Musculoskeletal Diseases [Disease/Finding] + + + + + + + + + + + + + + + + + + Mycobacterium Infections + M0014287 + D009164 + Infections with bacteria of the genus MYCOBACTERIUM. + Mycobacterium Infections + N0000002071 + 1022908 + 88415009 + Infections, Mycobacterium + C0026918 + C4320 + + Mycobacterium Infections [Disease/Finding] + + + + + + + + + + + + + + + + + Mycoplasma Infections + M0014307 + D009175 + Infections with species of the genus MYCOPLASMA. + Mycoplasma Infections + N0000002073 + 1023539 + 186462007 + 186464008 + Infections, Mycoplasma + C0026936 + C4324 + + Mycoplasma Infections [Disease/Finding] + + + + + + + + + Mycoplasmatales Infections + M0014312 + D009180 + Infections with bacteria of the order MYCOPLASMATALES. + Mycoplasmatales Infections + N0000002074 + 1030047 + Infections, Mycoplasmatales + C0026945 + C4326 + + Mycoplasmatales Infections [Disease/Finding] + + + + + + + + + Mycoses + M0014313 + D009181 + Mycoses + N0000002075 + 1024676 + 3218000 + Fungus Diseases + C0026946 + C4328 + + Mycoses [Disease/Finding] + + + + + + + + + + + + + + + + + Myeloproliferative Disorders + M0014332 + D009196 + Conditions which cause proliferation of hemopoietically active tissue or of tissue which has embryonic hemopoietic potential. They all involve dysregulation of multipotent MYELOID PROGENITOR CELLS, most often caused by a mutation in the JAK2 PROTEIN TYROSINE KINASE. + Myeloproliferative Disorders + N0000002082 + 1022355 + 128925001 + 414792005 + 414794006 + C0027022 + C4342 + + Myeloproliferative Disorders [Disease/Finding] + + + + + + + + + + + + + + + + + + + + + + + + + Nematode Infections + M0014560 + D009349 + Infections by nematodes, general or unspecified. + Nematode Infections + N0000002119 + 990406 + 84706005 + Infections, Nematode + C0027583 + C4416 + + Nematode Infections [Disease/Finding] + + + + + + + + + Congenital, Hereditary, and Neonatal Diseases and Abnormalities + M0014570 + D009358 + Diseases existing at birth and often before birth, or that develop during the first month of life (INFANT, NEWBORN, DISEASES), regardless of causation. Of these diseases, those characterized by structural deformities are termed CONGENITAL ABNORMALITIES. + Congenital, Hereditary, and Neonatal Diseases and Abnormalities + N0000002121 + 989203 + C0027612 + C4420 + + Congenital, Hereditary, and Neonatal Diseases and Abnormalities [Disease/Finding] + + + + + + + + + + + + + + + + + Neoplasms by Histologic Type + M0014588 + D009370 + A collective term for the various histological types of NEOPLASMS. It is more likely to be used by searchers than by indexers and catalogers. + Neoplasms by Histologic Type + N0000002129 + 986146 + Histological Type of Neoplasm + Histological Types of Neoplasms + Neoplasms by Histological Type + C0027652 + C4436 + + Neoplasms by Histologic Type [Disease/Finding] + + + + + + + + + Neoplasms by Site + M0014589 + D009371 + A collective term for precoordinated organ/neoplasm headings locating neoplasms by organ, as BRAIN NEOPLASMS; DUODENAL NEOPLASMS; LIVER NEOPLASMS; etc. + Neoplasms by Site + N0000002130 + 1026659 + Neoplasms by Sites + Site, Neoplasm + Sites, Neoplasm + C0027653 + C4438 + + Neoplasms by Site [Disease/Finding] + + + + + + + + + Neoplasms, Germ Cell and Embryonal + M0014592 + D009373 + Neoplasms composed of primordial GERM CELLS of embryonic GONADS or of elements of the germ layers of the EMBRYO, MAMMALIAN. The concept does not refer to neoplasms located in the gonads or present in an embryo or FETUS. + Neoplasms, Germ Cell and Embryonal + N0000002132 + 1026873 + Germ Cell and Embryonal Neoplasms + Germ Cell and Embryonic Neoplasms + Neoplasms, Germ Cell and Embryonic + C0027658 + C4442 + + Neoplasms, Germ Cell and Embryonal [Disease/Finding] + + + + + + + + + Neoplasms, Experimental + M0014595 + D009374 + Experimentally induced new abnormal growth of TISSUES in animals to provide models for studying human neoplasms. + Neoplasms, Experimental + N0000002133 + 1025199 + Experimental Neoplasms + C0027659 + C4444 + + Neoplasms, Experimental [Disease/Finding] + + + + + + + + + Neoplasms, Glandular and Epithelial + M0014596 + D009375 + Neoplasms composed of glandular tissue, an aggregation of epithelial cells that elaborate secretions, and of any type of epithelium itself. The concept does not refer to neoplasms located in the various glands or in epithelial tissue. + Neoplasms, Glandular and Epithelial + N0000002134 + 1028442 + Glandular and Epithelial Neoplasms + Neoplasms, Glandular Epithelial + C0027660 + C4446 + + Neoplasms, Glandular and Epithelial [Disease/Finding] + + + + + + + + + Neoplasms, Hormone-Dependent + M0014599 + D009376 + Certain tumors that 1, arise in organs that are normally dependent on specific hormones and 2, are stimulated or caused to regress by manipulation of the endocrine environment. + Neoplasms, Hormone-Dependent + N0000002135 + 1023294 + Hormone-Dependent Neoplasms + C0027661 + C4448 + + Neoplasms, Hormone-Dependent [Disease/Finding] + + + + + + + + + Neoplasms, Nerve Tissue + M0014605 + D009380 + Neoplasms composed of nerve tissue. This concept does not refer to neoplasms located in the nervous system or its component nerves. + Neoplasms, Nerve Tissue + N0000002139 + 985772 + Neoplasms, Nervous Tissue + Nerve Tissue Neoplasms + Nervous Tissue Neoplasms + C0027665 + C4456 + + Neoplasms, Nerve Tissue [Disease/Finding] + + + + + + + + + Neoplasms, Vascular Tissue + M0014610 + D009383 + Neoplasms composed of vascular tissue. This concept does not refer to neoplasms located in blood vessels. + Neoplasms, Vascular Tissue + N0000002142 + 1023689 + Blood Vessel Tumors + Vascular Tissue Neoplasms + C0282607 + C4462 + + Neoplasms, Vascular Tissue [Disease/Finding] + + + + + + + + + + Neoplastic Processes + M0014612 + D009385 + The pathological mechanisms and forms taken by tissue during degeneration into a neoplasm and its subsequent activity. + Neoplastic Processes + N0000002144 + 1026939 + Processes, Neoplastic + C0027671 + C4466 + + Neoplastic Processes [Disease/Finding] + + + + + + + + + Nephritis + M0014626 + D009393 + Inflammation of any part of the KIDNEY. + Nephritis + N0000002147 + 1022904 + 52845002 + C0027697 + C4472 + + Nephritis [Disease/Finding] + + + + + + + + + + + + + + + + + + Nervous System Neoplasms + M0014668 + D009423 + Benign and malignant neoplastic processes arising from or involving components of the central, peripheral, and autonomic nervous systems, cranial nerves, and meninges. Included in this category are primary and metastatic nervous system neoplasms. + Nervous System Neoplasms + N0000002160 + 1024871 + 126950007 + Neoplasms, Nervous System + Nervous System Tumors + Tumors of the Nervous System + C0027766 + C4498 + + Nervous System Neoplasms [Disease/Finding] + + + + + + + + + + + + + + + + + + Neuromuscular Diseases + M0014726 + D009468 + A general term encompassing lower MOTOR NEURON DISEASE; PERIPHERAL NERVOUS SYSTEM DISEASES; and certain MUSCULAR DISEASES. Manifestations include MUSCLE WEAKNESS; FASCICULATION; muscle ATROPHY; SPASM; MYOKYMIA; MUSCLE HYPERTONIA, myalgias, and MUSCLE HYPOTONIA. + Neuromuscular Diseases + N0000002176 + 1026561 + 255522009 + 257277002 + C0027868 + C4530 + + Neuromuscular Diseases [Disease/Finding] + + + + + + + + + + Nose Diseases + M0015012 + D009668 + Disorders of the nose, general or unspecified. + Nose Diseases + N0000002194 + 1024498 + 89488007 + Nasal Diseases + Nasal Disorders + C0028432 + C4566 + + Nose Diseases [Disease/Finding] + + + + + + + + + Nutritional and Metabolic Diseases + M0015124 + D009750 + A collective term for nutritional disorders resulting from poor absorption or nutritional imbalance, and metabolic disorders resulting from defects in biosynthesis (ANABOLISM) or breakdown (CATABOLISM) of endogenous substances. + Nutritional and Metabolic Diseases + N0000002197 + 1026553 + C0028715 + C4572 + + Nutritional and Metabolic Diseases [Disease/Finding] + + + + + + + + + + + + + + + + + + + + + + + + + + Otitis + M0015561 + D010031 + Inflammation of the ear, which may be marked by pain (EARACHE), fever, HEARING DISORDERS, and VERTIGO. Inflammation of the external ear is OTITIS EXTERNA; of the middle ear, OTITIS MEDIA; of the inner ear, LABYRINTHITIS. + Otitis + N0000002264 + 1022127 + 43275000 + Ear Inflammation + C0029877 + C4706 + + Otitis [Disease/Finding] + + + + + + + + + + + + + + + + + Otorhinolaryngologic Diseases + M0015572 + D010038 + Pathological processes of the ear, the nose, and the throat, also known as the ENT diseases. + Otorhinolaryngologic Diseases + N0000002269 + 985940 + ENT Diseases + Otolaryngologic Diseases + Otolaryngological Diseases + Otorhinolaryngologic Disease + Otorhinolaryngological Disease + C0029896 + C4716 + + Otorhinolaryngologic Diseases [Disease/Finding] + + + + + + + + + Oxyuriasis + M0015707 + D010123 + Infection with nematodes of the superfamily OXYUROIDEA. + Oxyuriasis + N0000002275 + 1024080 + 266162007 + C0030100 + C4728 + + Oxyuriasis [Disease/Finding] + + + + + + + + + + + + + + + + + Pancreatic Diseases + M0015794 + D010182 + Pathological processes of the PANCREAS. + Pancreatic Diseases + N0000002285 + 1022020 + 3855007 + C0030286 + C4748 + + Pancreatic Diseases [Disease/Finding] + + + + + + + + + + + + + + + + + + + + Paraproteinemias + M0015905 + D010265 + A group of related diseases characterized by an unbalanced or disproportionate proliferation of immunoglobulin-producing cells, usually from a single clone. These cells frequently secrete a structurally homogeneous immunoglobulin (M-component) and/or an abnormal immunoglobulin. + Paraproteinemias + N0000002317 + 1022681 + 190816000 + Paraimmunoglobulinemias + C0030489 + C4812 + + Paraproteinemias [Disease/Finding] + + + + + + + + + Parasitic Diseases + M0015919 + D010272 + Infections or infestations with parasitic organisms. They are often contracted through contact with an intermediate vector, but may occur as the result of direct exposure. + Parasitic Diseases + N0000002319 + 987316 + 17322007 + C0030499 + C4816 + + Parasitic Diseases [Disease/Finding] + + + + + + + + + Parasitic Diseases, Animal + M0015920 + D010273 + Infections or infestations with parasitic organisms. The infestation may be experimental or veterinary. + Parasitic Diseases, Animal + N0000002320 + 1027455 + C0030500 + C4818 + + Parasitic Diseases, Animal [Disease/Finding] + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + Pharyngeal Diseases + M0016479 + D010608 + Pathological processes involving the PHARYNX. + Pharyngeal Diseases + N0000002385 + 1024885 + 195832000 + 75860007 + Diseases of Pharynx + Pharynx Diseases + C0031345 + C4948 + + Pharyngeal Diseases [Disease/Finding] + + + + + + + + + + Pharyngitis + M0016483 + D010612 + Inflammation of the throat (PHARYNX). + Pharyngitis + N0000002387 + 1024296 + 405737000 + C0031350 + C4952 + + Pharyngitis [Disease/Finding] + + + + + + + + + + Phenylketonurias + M0016567 + D010661 + A group of autosomal recessive disorders marked by a deficiency of the hepatic enzyme PHENYLALANINE HYDROXYLASE or less frequently by reduced activity of DIHYDROPTERIDINE REDUCTASE (i.e., atypical phenylketonuria). Classical phenylketonuria is caused by a severe deficiency of phenylalanine hydroxylase and presents in infancy with developmental delay; SEIZURES; skin HYPOPIGMENTATION; ECZEMA; and demyelination in the central nervous system. (From Adams et al., Principles of Neurology, 6th ed, p952). + Phenylketonurias + N0000002389 + 1023735 + Phenylketonuria + C0031485 + C4956 + + Phenylketonurias [Disease/Finding] + + + + + + + + + + Phlebitis + M0016608 + D010689 + Inflammation of a vein, often a vein in the leg. Phlebitis associated with a blood clot is called (THROMBOPHLEBITIS). + Phlebitis + N0000002393 + 986358 + 61599003 + C0031542 + C4964 + + Phlebitis [Disease/Finding] + + + + + + + + + + + + + + + + + + Pneumonia + M0017064 + D011014 + Inflammation of any part, segment or lobe, of the lung parenchyma. + Pneumonia + N0000002432 + 1022757 + 205237003 + 233604007 + Lung Inflammation + Pneumonitis + Pulmonary Inflammation + C0032285 + C5042 + + Pneumonia [Disease/Finding] + + + + + + + + + + + + + + + + + + + + + + + + + + + Porphyrias + M0017334 + D011164 + A diverse group of metabolic diseases characterized by errors in the biosynthetic pathway of HEME in the LIVER, the BONE MARROW, or both. They are classified by the deficiency of specific enzymes, the tissue site of enzyme defect, or the clinical features that include neurological (acute) or cutaneous (skin lesions). Porphyrias can be hereditary or acquired as a result of toxicity to the hepatic or erythropoietic marrow tissues. + Porphyrias + N0000002464 + 1022410 + 29094004 + 371628009 + 418470004 + Porphyria + C0032708 + C5106 + + Porphyrias [Disease/Finding] + + + + + + + + + + + + + + + + + Pre-Excitation Syndromes + M0017444 + D011226 + A group of conditions in which HEART VENTRICLE activation by the atrial impulse is faster than the normal impulse conduction from the SINOATRIAL NODE. In these pre-excitation syndromes, atrial impulses often bypass the ATRIOVENTRICULAR NODE delay and travel via ACCESSORY CONDUCTING PATHWAYS connecting the atrium directly to the BUNDLE OF HIS. + Pre-Excitation Syndromes + N0000002474 + 1026072 + Preexcitation Syndrome + C0032915 + C5126 + + Pre-Excitation Syndromes [Disease/Finding] + + + + + + + + + + + + + + + + + Protozoan Infections + M0017926 + D011528 + Infections with unicellular organisms formerly members of the subkingdom Protozoa. + Protozoan Infections + N0000002508 + 1021795 + 95896000 + Infections, Protozoan + C0033740 + C5194 + + Protozoan Infections [Disease/Finding] + + + + + + + + + + Protozoan Infections, Animal + M0017927 + D011529 + Infections with unicellular organisms formerly members of the subkingdom Protozoa. The infections may be experimental or veterinary. + Protozoan Infections, Animal + N0000002509 + 1031669 + C0033741 + C5196 + + Protozoan Infections, Animal [Disease/Finding] + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + Respiration Disorders + M0018879 + D012120 + Diseases of the respiratory system in general or unspecified or for a specific respiratory disease not available. + Respiration Disorders + N0000002595 + 1022107 + 50043002 + C0035204 + C5368 + + Respiration Disorders [Disease/Finding] + + + + + + + + + + + + + + + + + + + Respiratory Hypersensitivity + M0018896 + D012130 + A form of hypersensitivity affecting the respiratory tract. It includes ASTHMA and RHINITIS, ALLERGIC, SEASONAL. + Respiratory Hypersensitivity + N0000002598 + 1025923 + Hypersensitivity, Respiratory + C0035228 + C5374 + + Respiratory Hypersensitivity [Disease/Finding] + + + + + + + + + Respiratory Tract Diseases + M0018918 + D012140 + Respiratory Tract Diseases + N0000002602 + 1024163 + C0035242 + C5382 + + Respiratory Tract Diseases [Disease/Finding] + + + + + + + + + + Respiratory Tract Infections + M0018919 + D012141 + Invasion of the host RESPIRATORY SYSTEM by microorganisms, usually leading to pathological processes or diseases. + Respiratory Tract Infections + N0000002603 + 1025855 + 275498002 + Infections, Respiratory + Infections, Respiratory Tract + Respiratory Infections + C0035243 + C5384 + + Respiratory Tract Infections [Disease/Finding] + + + + + + + + + Retinal Degeneration + M0018942 + D012162 + A retrogressive pathological change in the retina, focal or generalized, caused by genetic defects, inflammation, trauma, vascular disease, or aging. Degeneration affecting predominantly the macula lutea of the retina is MACULAR DEGENERATION. (Newell, Ophthalmology: Principles and Concepts, 7th ed, p304) + Retinal Degeneration + N0000002607 + 1026317 + 95695004 + C0035304 + C5392 + + Retinal Degeneration [Disease/Finding] + + + + + + + + + + + + + + + + + Retroviridae Infections + M0018986 + D012192 + Virus diseases caused by the RETROVIRIDAE. + Retroviridae Infections + N0000002623 + 1025440 + 105635000 + Infections, Retroviridae + Infections, Retrovirus + Retrovirus Infections + C0035369 + C5424 + + Retroviridae Infections [Disease/Finding] + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + RNA Virus Infections + M0019160 + D012327 + RNA Virus Infections + N0000002650 + 1027571 + Infections, RNA Virus + C0035690 + C5478 + + RNA Virus Infections [Disease/Finding] + + + + + + + + + + + + + + + + + Sarcoma + M0019428 + D012509 + A connective tissue neoplasm formed by proliferation of mesodermal cells; it is usually highly malignant. + Sarcoma + N0000002671 + 1021824 + 269469005 + Sarcoma, Soft Tissue + C1261473 + C5520 + + Sarcoma [Disease/Finding] + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + Sebaceous Gland Diseases + M0019581 + D012625 + Diseases of the sebaceous glands such as sebaceous hyperplasia and sebaceous cell carcinoma (SEBACEOUS GLAND NEOPLASMS). + Sebaceous Gland Diseases + N0000002710 + 1021910 + 3441005 + C0036502 + C5598 + + Sebaceous Gland Diseases [Disease/Finding] + + + + + + + + + Sensation Disorders + M0019651 + D012678 + Disorders of the special senses (i.e., VISION; HEARING; TASTE; and SMELL) or somatosensory system (i.e., afferent components of the PERIPHERAL NERVOUS SYSTEM). + Sensation Disorders + N0000002715 + 1030029 + C0036659 + C5608 + + Sensation Disorders [Disease/Finding] + + + + + + + + + + + + Sexually Transmitted Diseases + M0019758 + D012749 + Diseases due to or propagated by sexual contact. + Sexually Transmitted Diseases + N0000002724 + 1023328 + 8098009 + STDs + Venereal Diseases + C0036916 + C5626 + + Sexually Transmitted Diseases [Disease/Finding] + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + Signs and Symptoms + M0019845 + D012816 + Clinical manifestations that can be either objective when observed by a physician, or subjective when perceived by the patient. + Signs and Symptoms + N0000002748 + 1024593 + C0037088 + C5674 + + Signs and Symptoms [Disease/Finding] + + + + + + + + + Signs and Symptoms, Digestive + M0019846 + D012817 + Digestive system manifestations of diseases of the gastrointestinal system or of other organs. + Signs and Symptoms, Digestive + N0000002749 + 1029901 + C0037089 + C5676 + + Signs and Symptoms, Digestive [Disease/Finding] + + + + + + + + + + + + + + + + + Skin Diseases, Vesiculobullous + M0019930 + D012872 + Skin diseases characterized by local or general distributions of blisters. They are classified according to the site and mode of blister formation. Lesions can appear spontaneously or be precipitated by infection, trauma, or sunlight. Etiologies include immunologic and genetic factors. (From Scientific American Medicine, 1990) + Skin Diseases, Vesiculobullous + N0000002762 + 1027633 + Vesiculobullous Dermatoses + Vesiculobullous Skin Diseases + C0037275 + C5702 + + Skin Diseases, Vesiculobullous [Disease/Finding] + + + + + + + + + + Skin Diseases, Genetic + M0019934 + D012873 + Diseases of the skin with a genetic component, usually the result of various inborn errors of metabolism. + Skin Diseases, Genetic + N0000002763 + 986094 + 239001006 + Genetic Skin Diseases + C0037277 + C5704 + + Skin Diseases, Genetic [Disease/Finding] + + + + + + + + + + + + + + + + + + + Skin Diseases, Metabolic + M0019936 + D012875 + Diseases of the skin associated with underlying metabolic disorders. + Skin Diseases, Metabolic + N0000002765 + 1027237 + Metabolic Skin Diseases + C0037279 + C5708 + + Skin Diseases, Metabolic [Disease/Finding] + + + + + + + + + + Skin Diseases, Parasitic + M0019937 + D012876 + Skin diseases caused by ARTHROPODS; HELMINTHS; or other parasites. + Skin Diseases, Parasitic + N0000002766 + 1023415 + 128938009 + 33042004 + Parasitic Skin Diseases + C0037280 + C5710 + + Skin Diseases, Parasitic [Disease/Finding] + + + + + + + + + + + + + + + + + + + + + + + + + + Slow Virus Diseases + M0019974 + D012897 + Diseases of viral origin, characterized by incubation periods of months to years, insidious onset of clinical manifestations, and protracted clinical course. Though the disease process is protracted, viral multiplication may not be unusually slow. Conventional viruses produce slow virus diseases such as SUBACUTE SCLEROSING PANENCEPHALITIS, progressive multifocal leukoencephalopathy (LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL), and AIDS. Diseases produced by unconventional agents were originally considered part of this group. They are now called PRION DISEASES. + Slow Virus Diseases + N0000002775 + 1030191 + C0037341 + C5728 + + Slow Virus Diseases [Disease/Finding] + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + Pathological Conditions, Signs and Symptoms + M0020949 + D013568 + Abnormal anatomical or physiological conditions and objective or subjective manifestations of disease, not classified as disease or syndrome. + Pathological Conditions, Signs and Symptoms + N0000002872 + 984268 + Symptoms and General Pathology + C0039058 + C5922 + + Pathological Conditions, Signs and Symptoms [Disease/Finding] + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + Thrombocytosis + M0021429 + D013922 + Increased numbers of platelets in the peripheral blood. (Dorland, 27th ed) + Thrombocytosis + N0000002933 + 1022830 + 6631009 + Thrombocythemia + C0836924 + C6044 + + Thrombocytosis [Disease/Finding] + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + Trematode Infections + M0021868 + D014201 + Infections caused by infestation with worms of the class Trematoda. + Trematode Infections + N0000003004 + 1023326 + 26089000 + Infections, Trematode + C0040820 + C6186 + + Trematode Infections [Disease/Finding] + + + + + + + + + + + + + + + + + + Tumor Virus Infections + M0022156 + D014412 + Infections produced by oncogenic viruses. The infections caused by DNA viruses are less numerous but more diverse than those caused by the RNA oncogenic viruses. + Tumor Virus Infections + N0000003056 + 988538 + Infections, Tumor Virus + C0041374 + C6290 + + Tumor Virus Infections [Disease/Finding] + + + + + + + + + + + + + + + + + Urethral Diseases + M0022332 + D014522 + Pathological processes involving the URETHRA. + Urethral Diseases + N0000003072 + 1022102 + 4985009 + C0041969 + C6322 + + Urethral Diseases [Disease/Finding] + + + + + + + + + Urethral Obstruction + M0022334 + D014524 + Partial or complete blockage in any part of the URETHRA that can lead to difficulty or inability to empty the URINARY BLADDER. It is characterized by an enlarged, often damaged, bladder with frequent urges to void. + Urethral Obstruction + N0000003074 + 985086 + 95588004 + C0041972 + C6326 + + Urethral Obstruction [Disease/Finding] + + + + + + + + + + + + + + + + + + + Urogenital Neoplasms + M0022391 + D014565 + Tumors or cancer of the UROGENITAL SYSTEM in either the male or the female. + Urogenital Neoplasms + N0000003084 + 1025116 + Genito-urinary Neoplasm + Genitourinary Neoplasms + Neoplasms, Genitourinary + Neoplasms, Urogenital + C0042065 + C6346 + + Urogenital Neoplasms [Disease/Finding] + + + + + + + + + Male Urogenital Diseases + M0489510 + D052801 + Pathological processes of the male URINARY TRACT and the reproductive system (GENITALIA, MALE). + Male Urogenital Diseases + N0000003085 + 1027597 + Male Genitourinary Diseases + C1720894 + CMSHM0489510 + + Male Urogenital Diseases [Disease/Finding] + + + + + + + + + + + + + + + + + + Urologic Neoplasms + M0022401 + D014571 + Tumors or cancer of the URINARY TRACT in either the male or the female. + Urologic Neoplasms + N0000003087 + 1023305 + 126879004 + 254913005 + Neoplasms, Urologic + Urinary Tract Neoplasms + Urological Neoplasms + C0042076 + C6352 + + Urologic Neoplasms [Disease/Finding] + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + Vaginal Diseases + M0022482 + D014623 + Pathological processes of the VAGINA. + Vaginal Diseases + N0000003104 + 1026314 + 25658005 + C0042251 + C6386 + + Vaginal Diseases [Disease/Finding] + + + + + + + + + Vaginitis + M0022488 + D014627 + Inflammation of the vagina characterized by pain and a purulent discharge. + Vaginitis + N0000003107 + 1021851 + 198213001 + 30800001 + C0042267 + C6392 + + Vaginitis [Disease/Finding] + + + + + + + + + + + + + + + + + Vasculitis + M0022540 + D014657 + Inflammation of any one of the blood vessels, including the ARTERIES; VEINS; and rest of the vasculature system in the body. + Vasculitis + N0000003113 + 1026759 + 31996006 + Angiitis + C0042384 + C6404 + + Vasculitis [Disease/Finding] + + + + + + + + + + + + + + + + + Ventricular Outflow Obstruction + M0022598 + D014694 + Occlusion of the outflow tract in either the LEFT VENTRICLE or the RIGHT VENTRICLE of the heart. This may result from CONGENITAL HEART DEFECTS, predisposing heart diseases, complications of surgery, or HEART NEOPLASMS. + Ventricular Outflow Obstruction + N0000003119 + 1028258 + C0042512 + C6416 + + Ventricular Outflow Obstruction [Disease/Finding] + + + + + + + + + + + + + + + + + + Virus Diseases + M0022758 + D014777 + A general term for diseases produced by viruses. + Virus Diseases + N0000003128 + 1022696 + 34014006 + Viral Diseases + C0042769 + C6434 + + Virus Diseases [Disease/Finding] + + + + + + + + + + + + + + + + + + + + + + + + + + Vulvar Diseases + M0022856 + D014845 + Pathological processes of the VULVA. + Vulvar Diseases + N0000003145 + 1024723 + 5089007 + C0042994 + C6468 + + Vulvar Diseases [Disease/Finding] + + + + + + + + + Vulvitis + M0022858 + D014847 + Inflammation of the VULVA. It is characterized by PRURITUS and painful urination. + Vulvitis + N0000003147 + 1023099 + 266586003 + 63144007 + C0042996 + C6472 + + Vulvitis [Disease/Finding] + + + + + + + + + + Vulvovaginitis + M0022859 + D014848 + Inflammation of the VULVA and the VAGINA, characterized by discharge, burning, and PRURITUS. + Vulvovaginitis + N0000003148 + 1025805 + 198215008 + 53277000 + C0042998 + C6474 + + Vulvovaginitis [Disease/Finding] + + + + + + + + + + + + + + + + + + + West Nile Fever + M0022928 + D014901 + A mosquito-borne viral illness caused by the WEST NILE VIRUS, a FLAVIVIRUS and endemic to regions of Africa, Asia, and Europe. Common clinical features include HEADACHE; FEVER; maculopapular rash; gastrointestinal symptoms; and lymphadenopathy. MENINGITIS; ENCEPHALITIS; and MYELITIS may also occur. The disease may occasionally be fatal or leave survivors with residual neurologic deficits. (From Joynt, Clinical Neurology, 1996, Ch26, p13; Lancet 1998 Sep 5;352(9130):767-71) + West Nile Fever + N0000003161 + 1024531 + C0043124 + C6500 + + West Nile Fever [Disease/Finding] + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + Sexually Transmitted Diseases, Viral + M0023402 + D015229 + Viral diseases which are transmitted or propagated by sexual conduct. + Sexually Transmitted Diseases, Viral + N0000003211 + 1027279 + Sexually Transmitted Disease, Viral + Venereal Diseases, Viral + Viral Sexually Transmitted Disease + Viral Sexually Transmitted Diseases + Viral Venereal Diseases + C0036918 + C6600 + + Sexually Transmitted Diseases, Viral [Disease/Finding] + + + + + + + + + + Sexually Transmitted Diseases, Bacterial + M0023404 + D015231 + Bacterial diseases transmitted or propagated by sexual conduct. + Sexually Transmitted Diseases, Bacterial + N0000003212 + 1027541 + Bacterial Sexually Transmitted Disease + Bacterial Sexually Transmitted Diseases + Bacterial Venereal Diseases + Sexually Transmitted Disease, Bacterial + Venereal Diseases, Bacterial + C0036917 + C6602 + + Sexually Transmitted Diseases, Bacterial [Disease/Finding] + + + + + + + + + + Leukemia, Myelogenous, Chronic, BCR-ABL Positive + M0023821 + D015464 + Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS. + Leukemia, Myelogenous, Chronic, BCR-ABL Positive + N0000003261 + 1021752 + 92818009 + Granulocytic Leukemia, Chronic + Leukemia, Granulocytic, Chronic + Leukemia, Myelocytic, Chronic + Leukemia, Myelogenous, Chronic + Leukemia, Myelogenous, Ph1 Positive + Leukemia, Myelogenous, Ph1-Positive + Leukemia, Myeloid, Chronic + Leukemia, Myeloid, Ph1 Positive + Leukemia, Myeloid, Ph1-Positive + Leukemia, Myeloid, Philadelphia Positive + Leukemia, Myeloid, Philadelphia-Positive + Myelocytic Leukemia, Chronic + Myelogenous Leukemia, Chronic + Myelogenous Leukemia, Ph1-Positive + Myeloid Leukemia, Chronic + Myeloid Leukemia, Ph1-Positive + Myeloid Leukemia, Philadelphia-Positive + C0023473 + C6700 + + Leukemia, Myelogenous, Chronic, BCR-ABL Positive [Disease/Finding] + + + + + + + + + + + + + + + + + + + HIV Infections + M0023997 + D015658 + Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). + HIV Infections + N0000003302 + 1022756 + 86406008 + HTLV-III Infections + HTLV-III-LAV Infections + T-Lymphotropic Virus Type III Infections, Human + C0019693 + C6782 + + HIV Infections [Disease/Finding] + + + + + + + + + Vestibular Diseases + M0024253 + D015837 + Pathological processes of the VESTIBULAR LABYRINTH which contains part of the balancing apparatus. Patients with vestibular diseases show instability and are at risk of frequent falls. + Vestibular Diseases + N0000003336 + 1026474 + 20425006 + C0042594 + C6850 + + Vestibular Diseases [Disease/Finding] + + + + + + + + + Lentivirus Infections + M0024697 + D016180 + Virus diseases caused by the Lentivirus genus. They are multi-organ diseases characterized by long incubation periods and persistent infection. + Lentivirus Infections + N0000003384 + 1024090 + 24907000 + Infections, Lentivirus + C0079680 + C6946 + + Lentivirus Infections [Disease/Finding] + + + + + + + + + Lymphoma, T-Cell + M0025079 + D016399 + A group of heterogeneous lymphoid tumors representing malignant transformations of T-lymphocytes. + Lymphoma, T-Cell + N0000003398 + 1023910 + 109978004 + T-Cell Lymphoma + C0079772 + C6974 + + Lymphoma, T-Cell [Disease/Finding] + + + + + + + + + Lymphoma, T-Cell, Cutaneous + M0025093 + D016410 + A group of lymphomas exhibiting clonal expansion of malignant T-lymphocytes arrested at varying stages of differentiation as well as malignant infiltration of the skin. MYCOSIS FUNGOIDES; SEZARY SYNDROME; LYMPHOMATOID PAPULOSIS; and PRIMARY CUTANEOUS ANAPLASTIC LARGE CELL LYMPHOMA are the best characterized of these disorders. + Lymphoma, T-Cell, Cutaneous + N0000003409 + 1025184 + 400122007 + Cutaneous T-Cell Lymphoma + Lymphoma, T Cell, Cutaneous + T-Cell Lymphoma, Cutaneous + C0079773 + C6996 + + Lymphoma, T-Cell, Cutaneous [Disease/Finding] + + + + + + + + + Peripheral Vascular Diseases + M0025176 + D016491 + Pathological processes involving any one of the BLOOD VESSELS in the vasculature outside the HEART. + Peripheral Vascular Diseases + N0000003422 + 1022504 + 400047006 + Diseases, Peripheral Vascular + Peripheral Angiopathies + Vascular Diseases, Peripheral + C0085096 + C7022 + + Peripheral Vascular Diseases [Disease/Finding] + + + + + + + + + Central Nervous System Neoplasms + M0025244 + D016543 + Benign and malignant neoplastic processes that arise from or secondarily involve the brain, spinal cord, or meninges. + Central Nervous System Neoplasms + N0000003434 + 1025007 + 126951006 + Central Nervous System Tumors + Neoplasms, Central Nervous System + Tumors, Central Nervous System + C0085136 + C7046 + + Central Nervous System Neoplasms [Disease/Finding] + + + + + + + + + + + + + + + + + Embolism and Thrombosis + M0025559 + D016769 + A collective term for pathological conditions which are caused by the formation of a blood clot (THROMBUS) in a blood vessel, or by blocking of a blood vessel with an EMBOLUS, undissolved materials in the blood stream. + Embolism and Thrombosis + N0000003473 + 1031715 + 195440003 + C0085307 + C7124 + + Embolism and Thrombosis [Disease/Finding] + + + + + + + + + + + + + + + + + + + + + + + + + Neisseriaceae Infections + M0025673 + D016870 + Infections with bacteria of the family NEISSERIACEAE. + Neisseriaceae Infections + N0000003493 + 1025935 + Infections, Neisseriaceae + C0085396 + C7164 + + Neisseriaceae Infections [Disease/Finding] + + + + + + + + + Pasteurellaceae Infections + M0025674 + D016871 + Infections with bacteria of the family PASTEURELLACEAE. + Pasteurellaceae Infections + N0000003494 + 985866 + Infections, Pasteurellaceae + C0085397 + C7166 + + Pasteurellaceae Infections [Disease/Finding] + + + + + + + + + Gram-Negative Bacterial Infections + M0025725 + D016905 + Infections caused by bacteria that show up as pink (negative) when treated by the gram-staining method. + Gram-Negative Bacterial Infections + N0000003506 + 1023284 + Bacterial Infections, Gram-Negative + Infections, Gram-Negative Bacterial + C0085423 + C7190 + + Gram-Negative Bacterial Infections [Disease/Finding] + + + + + + + + + Gram-Positive Bacterial Infections + M0025728 + D016908 + Infections caused by bacteria that retain the crystal violet stain (positive) when treated by the gram-staining method. + Gram-Positive Bacterial Infections + N0000003507 + 1022700 + Bacterial Infections, Gram-Positive + Infections, Gram-Positive Bacterial + C0085426 + C7192 + + Gram-Positive Bacterial Infections [Disease/Finding] + + + + + + + + + + + Porphyrias, Hepatic + M0025973 + D017094 + A group of metabolic diseases due to deficiency of one of a number of LIVER enzymes in the biosynthetic pathway of HEME. They are characterized by the accumulation and increased excretion of PORPHYRINS or its precursors. Clinical features include neurological symptoms (PORPHYRIA, ACUTE INTERMITTENT), cutaneous lesions due to photosensitivity (PORPHYRIA CUTANEA TARDA), or both (HEREDITARY COPROPORPHYRIA). Hepatic porphyrias can be hereditary or acquired as a result of toxicity to the hepatic tissues. + Porphyrias, Hepatic + N0000003528 + 1024983 + 55056006 + Hepatic Porphyria + Porphyria, Hepatic + C0162533 + C7234 + + Porphyrias, Hepatic [Disease/Finding] + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + Adenophorea Infections + M0026092 + D017188 + Infections with nematodes of the subclass ADENOPHOREA. + Adenophorea Infections + N0000003542 + 1023621 + Aphasmidia Infections + Infections, Adenophorea + Infections, Aphasmidia + C0162623 + C7262 + + Adenophorea Infections [Disease/Finding] + + + + + + + + + Enoplida Infections + M0026094 + D017189 + Infections with nematodes of the order ENOPLIDA. + Enoplida Infections + N0000003543 + 1022471 + Infections, Enoplida + C0162624 + C7264 + + Enoplida Infections [Disease/Finding] + + + + + + + + + Secernentea Infections + M0026095 + D017190 + Infections with nematodes of the subclass SECERNENTEA. + Secernentea Infections + N0000003544 + 1026460 + Infections, Phasmidia + Infections, Secernentea + Phasmidia Infections + C0162625 + C7266 + + Secernentea Infections [Disease/Finding] + + + + + + + + + Ascaridida Infections + M0026096 + D017191 + Infections with nematodes of the order ASCARIDIDA. + Ascaridida Infections + N0000003545 + 1028907 + Infections, Ascaridida + C0162626 + C7268 + + Ascaridida Infections [Disease/Finding] + + + + + + + + + + Skin Diseases, Bacterial + M0026097 + D017192 + Skin diseases caused by bacteria. + Skin Diseases, Bacterial + N0000003546 + 984383 + 128936008 + Bacterial Skin Diseases + C0162627 + C7270 + + Skin Diseases, Bacterial [Disease/Finding] + + + + + + + + + + Skin Diseases, Viral + M0026098 + D017193 + Skin diseases caused by viruses. + Skin Diseases, Viral + N0000003547 + 1029386 + 128937004 + Viral Skin Diseases + C0162628 + C7272 + + Skin Diseases, Viral [Disease/Finding] + + + + + + + + + Oxyurida Infections + M0026099 + D017194 + Infections with nematodes of the order OXYURIDA. + Oxyurida Infections + N0000003548 + 986714 + Infections, Oxyurida + C0162629 + C7274 + + Oxyurida Infections [Disease/Finding] + + + + + + + + + Rhabditida Infections + M0026101 + D017196 + Infections with nematodes of the order RHABDITIDA. + Rhabditida Infections + N0000003549 + 1025888 + Infections, Rhabditida + C0162631 + C7276 + + Rhabditida Infections [Disease/Finding] + + + + + + + + + + + + + + + + + + Spirurida Infections + M0026109 + D017205 + Infections with nematodes of the order SPIRURIDA. + Spirurida Infections + N0000003552 + 1021997 + Infections, Spirurida + C0162636 + C7282 + + Spirurida Infections [Disease/Finding] + + + + + + + + + + + + + + + + + Skin and Connective Tissue Diseases + M0026454 + D017437 + A collective term for diseases of the skin and its appendages and of connective tissue. + Skin and Connective Tissue Diseases + N0000003573 + 1027511 + C0175166 + C7324 + + Skin and Connective Tissue Diseases [Disease/Finding] + + + + + + + + + Skin Diseases, Papulosquamous + M0026467 + D017444 + A group of dermatoses with distinct morphologic features. The primary lesion is most commonly a papule, usually erythematous, with a variable degree of scaling on the surface. Plaques form through the coalescing of primary lesions. + Skin Diseases, Papulosquamous + N0000003577 + 1024350 + 22585003 + Papulosquamous Disorders + Papulosquamous Skin Diseases + C0162818 + C7332 + + Skin Diseases, Papulosquamous [Disease/Finding] + + + + + + + + + + + + + + + + + Acneiform Eruptions + M0026528 + D017486 + Visible efflorescent lesions of the skin caused by acne or resembling acne. (Dorland, 28th ed, p18, 575) + Acneiform Eruptions + N0000003583 + 1027471 + 402644006 + C0175167 + C7344 + + Acneiform Eruptions [Disease/Finding] + + + + + + + + + + Neuroectodermal Tumors + M0026668 + D017599 + Malignant neoplasms arising in the neuroectoderm, the portion of the ectoderm of the early embryo that gives rise to the central and peripheral nervous systems, including some glial cells. + Neuroectodermal Tumors + N0000003613 + 1022212 + 253096008 + 73676002 + C0206093 + C7404 + + Neuroectodermal Tumors [Disease/Finding] + + + + + + + + + + + + + + + + + Flavivirus Infections + M0027404 + D018177 + Infections with viruses of the genus FLAVIVIRUS, family FLAVIVIRIDAE. + Flavivirus Infections + N0000003657 + 1027981 + Infections, Flavivirus + C0206608 + C7492 + + Flavivirus Infections [Disease/Finding] + + + + + + + + + Flaviviridae Infections + M0027405 + D018178 + Infections with viruses of the family FLAVIVIRIDAE. + Flaviviridae Infections + N0000003658 + 1027902 + Infections, Flaviviridae + C0206609 + C7494 + + Flaviviridae Infections [Disease/Finding] + + + + + + + + + Paramyxoviridae Infections + M0027412 + D018184 + Infections with viruses of the family PARAMYXOVIRIDAE. This includes MORBILLIVIRUS INFECTIONS; RESPIROVIRUS INFECTIONS; PNEUMOVIRUS INFECTIONS; HENIPAVIRUS INFECTIONS; AVULAVIRUS INFECTIONS; and RUBULAVIRUS INFECTIONS. + Paramyxoviridae Infections + N0000003660 + 1028342 + Infections, Paramyxoviridae + C0206613 + C7498 + + Paramyxoviridae Infections [Disease/Finding] + + + + + + + + + Pneumovirus Infections + M0027415 + D018186 + Infections with viruses of the genus PNEUMOVIRUS, family PARAMYXOVIRIDAE. This includes RESPIRATORY SYNCYTIAL VIRUS INFECTIONS, an important cause of respiratory disease in humans. + Pneumovirus Infections + N0000003662 + 1023009 + Infections, Pneumovirus + C0206615 + C7502 + + Pneumovirus Infections [Disease/Finding] + + + + + + + + + Neoplasms, Connective and Soft Tissue + M0027433 + D018204 + Neoplasms developing from some structure of the connective and subcutaneous tissue. The concept does not refer to neoplasms located in connective or soft tissue. + Neoplasms, Connective and Soft Tissue + N0000003678 + 1028165 + Connective and Soft Tissue Neoplasms + C0206765 + C7534 + + Neoplasms, Connective and Soft Tissue [Disease/Finding] + + + + + + + + + Neoplasms, Ductal, Lobular, and Medullary + M0027533 + D018299 + Neoplasms, usually carcinoma, located within the center of an organ or within small lobes, and in the case of the breast, intraductally. The emphasis of the name is on the location of the neoplastic tissue rather than on its histological type. Most cancers of this type are located in the breast. + Neoplasms, Ductal, Lobular, and Medullary + N0000003763 + 1023140 + 189704005 + Ductal, Lobular, and Medullary Neoplasms + C0206768 + C7704 + + Neoplasms, Ductal, Lobular, and Medullary [Disease/Finding] + + + + + + + + + Nevi and Melanomas + M0027561 + D018326 + A collective term for the various types of nevi and melanomas. + Nevi and Melanomas + N0000003787 + 1027690 + 189747005 + Melanomas and Nevi + C0206769 + C7752 + + Nevi and Melanomas [Disease/Finding] + + + + + + + + + + + + + + + + + + + + + + + + + + Cardiovascular Abnormalities + M0027602 + D018376 + Congenital, inherited, or acquired anomalies of the CARDIOVASCULAR SYSTEM, including the HEART and BLOOD VESSELS. + Cardiovascular Abnormalities + N0000003808 + 1026475 + 9904008 + Abnormalities, Cardiovascular + C0243050 + C7794 + + Cardiovascular Abnormalities [Disease/Finding] + + + + + + + + + + Pneumonia, Bacterial + M0027639 + D018410 + Inflammation of the lung parenchyma that is caused by bacterial infections. + Pneumonia, Bacterial + N0000003812 + 1025309 + 53084003 + Bacterial Pneumonia + C0004626 + C7802 + + Pneumonia, Bacterial [Disease/Finding] + + + + + + + + + Mononegavirales Infections + M0028015 + D018701 + Infections with viruses of the order MONONEGAVIRALES. The concept includes FILOVIRIDAE INFECTIONS; PARAMYXOVIRIDAE INFECTIONS; and RHABDOVIRIDAE INFECTIONS. + Mononegavirales Infections + N0000003845 + 1023194 + Infections, Mononegavirales + C0242916 + C7868 + + Mononegavirales Infections [Disease/Finding] + + + + + + + + + Encephalitis, Viral + M0028131 + D018792 + Inflammation of brain parenchymal tissue as a result of viral infection. Encephalitis may occur as primary or secondary manifestation of TOGAVIRIDAE INFECTIONS; HERPESVIRIDAE INFECTIONS; ADENOVIRIDAE INFECTIONS; FLAVIVIRIDAE INFECTIONS; BUNYAVIRIDAE INFECTIONS; PICORNAVIRIDAE INFECTIONS; PARAMYXOVIRIDAE INFECTIONS; ORTHOMYXOVIRIDAE INFECTIONS; RETROVIRIDAE INFECTIONS; and ARENAVIRIDAE INFECTIONS. + Encephalitis, Viral + N0000003858 + 1025326 + 34476008 + Encephalomyelitis, Infectious, Viral + Infectious Encephalomyelitis, Viral + Viral Encephalitis + C0243010 + C7894 + + Encephalitis, Viral [Disease/Finding] + + + + + + + + + Neurodegenerative Diseases + M0029135 + D019636 + Hereditary and sporadic conditions which are characterized by progressive nervous system dysfunction. These disorders are often associated with atrophy of the affected central or peripheral nervous system structures. + Neurodegenerative Diseases + N0000003949 + 1022112 + Degenerative Diseases, Nervous System + Degenerative Diseases, Neurologic + Degenerative Neurologic Diseases + Degenerative Neurologic Disorders + Nervous System Degenerative Diseases + Neurodegenerative Disorders + Neurologic Degenerative Conditions + Neurologic Degenerative Diseases + Neurologic Diseases, Degenerative + C0524851 + C8076 + + Neurodegenerative Diseases [Disease/Finding] + + + + + + + + + + + + + + + + + + + + + + + + + + + Mental Disorders Diagnosed in Childhood + M0029626 + D019952 + Those psychiatric disorders usually first diagnosed in infancy, childhood, or adolescence. These disorders can also be first diagnosed during other life stages. + Mental Disorders Diagnosed in Childhood + N0000003966 + 987008 + Disorders Usually Diagnosed in Infancy, Childhood or Adolescence + C0525040 + C8110 + + Mental Disorders Diagnosed in Childhood [Disease/Finding] + + + + + + + + + + Neurobehavioral Manifestations + M0333801 + D019954 + Signs and symptoms of higher cortical dysfunction caused by organic conditions. These include certain behavioral alterations and impairments of skills involved in the acquisition, processing, and utilization of knowledge or information. + Neurobehavioral Manifestations + N0000003967 + 1025867 + Cognitive Manifestations + Cognitive Symptoms + Neurobehavioral Signs and Symptoms + Signs and Symptoms, Neurobehavioral + C0525041 + C8112 + + Neurobehavioral Manifestations [Disease/Finding] + + + + + + + + + + + + + + + + + + + + + + + + + Delirium, Dementia, Amnestic, Cognitive Disorders + M0029645 + D019965 + Cognitive disorders including delirium, dementia, and other cognitive disorders. These may be the result of substance use, trauma, or other causes. + Delirium, Dementia, Amnestic, Cognitive Disorders + N0000003976 + 1022574 + 106014008 + 111479008 + Mental Disorders, Organic + Organic Mental Disorders + C0029227 + C8130 + + Delirium, Dementia, Amnestic, Cognitive Disorders [Disease/Finding] + + + + + + + + + Substance-Related Disorders + M0029657 + D019966 + Disorders related to substance abuse, the side effects of a medication, or toxin exposure. + Substance-Related Disorders + N0000003977 + 1027904 + C0236969 + C8132 + + Substance-Related Disorders [Disease/Finding] + + + + + + + + + Schizophrenia and Disorders with Psychotic Features + M0029660 + D019967 + Marked disorders of thought (delusions, hallucinations, or other thought disorder accompanied by disordered affect or behavior), and deterioration from a previous level of functioning. + Schizophrenia and Disorders with Psychotic Features + N0000003978 + 984843 + C0525046 + C8134 + + Schizophrenia and Disorders with Psychotic Features [Disease/Finding] + + + + + + + + + + + + + + + + + + + Hemostatic Disorders + M0029879 + D020141 + Pathological processes involving the integrity of blood circulation. Hemostasis depends on the integrity of BLOOD VESSELS, blood fluidity, and BLOOD COAGULATION. Majority of the hemostatic disorders are caused by disruption of the normal interaction between the VASCULAR ENDOTHELIUM, the plasma proteins (including BLOOD COAGULATION FACTORS), and PLATELETS. + Hemostatic Disorders + N0000003999 + 1023569 + 21112004 + Hemostatic Disorders, Vascular + Vascular Hemostatic Disorders + C0600502 + C8176 + + Hemostatic Disorders [Disease/Finding] + + + + + + + + + + + + + + + + + + Autoimmune Diseases of the Nervous System + M0328129 + D020274 + Disorders caused by cellular or humoral immune responses primarily directed towards nervous system autoantigens. The immune response may be directed towards specific tissue components (e.g., myelin) and may be limited to the central nervous system (e.g., MULTIPLE SCLEROSIS) or the peripheral nervous system (e.g., GUILLAIN-BARRE SYNDROME). + Autoimmune Diseases of the Nervous System + N0000004092 + 1025977 + Autoimmune Diseases, Nervous System + Autoimmune Diseases, Neurologic + Autoimmune Disorders of the Nervous System + Autoimmune Disorders, Nervous System + Autoimmune Nervous System Diseases + Nervous System Autoimmune Diseases + Neurologic Autoimmune Diseases + C0751871 + C8362 + + Autoimmune Diseases of the Nervous System [Disease/Finding] + + + + + + + + + + + Demyelinating Autoimmune Diseases, CNS + M0328372 + D020278 + Conditions characterized by loss or dysfunction of myelin (see MYELIN SHEATH) in the brain, spinal cord, or optic nerves secondary to autoimmune mediated processes. This may take the form of a humoral or cellular immune response directed toward myelin or OLIGODENDROGLIA associated autoantigens. + Demyelinating Autoimmune Diseases, CNS + N0000004095 + 989466 + Autoimmune Demyelinating Diseases, CNS + Autoimmune Demyelinating Diseases, Central Nervous System + Autoimmune Demyelinating Disorders, CNS + CNS Autoimmune Demyelinating Disorders + CNS Demyelinating Autoimmune Diseases + Demyelinating Autoimmune Diseases, Central Nervous System + Demyelinating Autoimmune Disorders, CNS + Demyelinating Disease, Autoimmune, CNS + C0751873 + C8368 + + Demyelinating Autoimmune Diseases, CNS [Disease/Finding] + + + + + + + + + + + + + + + + + + Neuromuscular Junction Diseases + M0328288 + D020511 + Conditions characterized by impaired transmission of impulses at the NEUROMUSCULAR JUNCTION. This may result from disorders that affect receptor function, pre- or postsynaptic membrane function, or ACETYLCHOLINESTERASE activity. The majority of diseases in this category are associated with autoimmune, toxic, or inherited conditions. + Neuromuscular Junction Diseases + N0000004153 + 984412 + 128213006 + Neuromuscular Junction Disorders + Neuromuscular Transmission Disorders + C0751950 + C8484 + + Neuromuscular Junction Diseases [Disease/Finding] + + + + + + + + + + Parkinsonian Disorders + M0328250 + D020734 + A group of disorders which feature impaired motor control characterized by bradykinesia, MUSCLE RIGIDITY; TREMOR; and postural instability. Parkinsonian diseases are generally divided into primary parkinsonism (see PARKINSON DISEASE), secondary parkinsonism (see PARKINSON DISEASE, SECONDARY) and inherited forms. These conditions are associated with dysfunction of dopaminergic or closely related motor integration neuronal pathways in the BASAL GANGLIA. + Parkinsonian Disorders + N0000004168 + 987649 + 32798002 + Parkinsonian Diseases + Parkinsonian Syndrome + Parkinsonian Syndromes + Parkinsonism + C0242422 + C8514 + + Parkinsonian Disorders [Disease/Finding] + + + + + + + + + + Brain Diseases, Metabolic, Inborn + M0328165 + D020739 + Brain disorders resulting from inborn metabolic errors, primarily from enzymatic defects which lead to substrate accumulation, product reduction, or increase in toxic metabolites through alternate pathways. The majority of these conditions are familial, however spontaneous mutation may also occur in utero. + Brain Diseases, Metabolic, Inborn + N0000004169 + 1022797 + Brain Syndrome, Metabolic, Inborn + Encephalopathies, Metabolic, Inborn + Inborn Errors of Metabolism, Brain + Inborn Metabolic Brain Diseases + Inborn Metabolic Brain Disorders + Inborn Metabolic Disorders, Brain + Metabolic Brain Diseases, Inborn + Metabolic Brain Syndrome, Inborn + Metabolic Diseases, Inborn, Brain + C0752109 + C8516 + + Brain Diseases, Metabolic, Inborn [Disease/Finding] + + + + + + + + + + Central Nervous System Viral Diseases + M0328064 + D020805 + Viral infections of the brain, spinal cord, meninges, or perimeningeal spaces. + Central Nervous System Viral Diseases + N0000004195 + 1025144 + 302810003 + Central Nervous System Viral Infections + Infections, CNS, Viral + Infections, Viral CNS + Viral Diseases, Central Nervous System + Viral Infections, Central Nervous System + C0348165 + C8568 + + Central Nervous System Viral Diseases [Disease/Finding] + + + + + + + + + + + + + + + + + + Urological Manifestations + M0328644 + D020924 + Clinical disturbances of the urinary system. + Urological Manifestations + N0000004224 + 988624 + C0752303 + C8626 + + Urological Manifestations [Disease/Finding] + + + + + + + + + + Carcinoma, Pancreatic Ductal + M0352972 + D021441 + Carcinoma that arises from the PANCREATIC DUCTS. It accounts for the majority of cancers derived from the PANCREAS. + Carcinoma, Pancreatic Ductal + N0000004241 + 985550 + Carcinoma, Ductal, Pancreatic + Duct-Cell Carcinoma of the Pancreas + Duct-Cell Carcinoma, Pancreas + Ductal Carcinoma of the Pancreas + Pancreatic Duct Cell Carcinoma + Pancreatic Ductal Carcinoma + C0887833 + C8660 + + Carcinoma, Pancreatic Ductal [Disease/Finding] + + + + + + + + + mycophenolate mofetil + M0174120 + C063008 + mycophenolate mofetil + N0000005137 + 68149 + mycophenolate mofetil + mycophenolic acid morpholinoethyl ester + C0209368 + C17504 + + mycophenolate mofetil [Chemical/Ingredient] + + + + + + + + + Methylprednisolone + M0013662 + D008775 + A PREDNISOLONE derivative with similar anti-inflammatory action. + Methylprednisolone + N0000005719 + 6902 + Methylprednisolone + 6-Methylprednisolone + Metipred + Pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-6-methyl-, (6alpha,11beta)- + C0025815 + C21782 + + Methylprednisolone [Chemical/Ingredient] + + + + + + + + + + + + + + + + + + + + + + + + + Proteins + M0017890 + D011506 + Linear POLYPEPTIDES that are synthesized on RIBOSOMES and may be further modified, crosslinked, cleaved, or assembled into complex proteins with several subunits. The specific sequence of AMINO ACIDS determines the shape the polypeptide will take, during PROTEIN FOLDING, and the function of the protein. + Proteins + N0000005817 + 8859 + Proteins + C0033684 + C21978 + + Proteins [Chemical/Ingredient] + + + + + + + + + Amodiaquine + M0001005 + D000655 + A 4-aminoquinoline compound with anti-inflammatory properties. + Amodiaquine + N0000005832 + 720 + Amodiaquine + Amodiachin + Amodiaquin + Phenol, 4-((7-chloro-4-quinolinyl)amino)-2-((diethylamino)methyl)- + C0002641 + C22008 + + Amodiaquine [Chemical/Ingredient] + + + + + + + + + + + + + + + + + Phenazopyridine + M0016493 + D010621 + A local anesthetic that has been used in urinary tract disorders. Its use is limited by problems with toxicity (primarily blood disorders) and potential carcinogenicity. + Phenazopyridine + N0000005854 + 8120 + Phenazopyridine + 2,6-Pyridinediamine, 3-(phenylazo)- + C0031379 + C22052 + + Phenazopyridine [Chemical/Ingredient] + + + + + + + + + Ribavirin + M0019062 + D012254 + A nucleoside antimetabolite antiviral agent that blocks nucleic acid synthesis and is used against both RNA and DNA viruses. + Ribavirin + N0000005892 + 9344 + Ribavirin + 1H-1,2,4-Triazole-3-carboxamide, 1-beta-D-ribofuranosyl- + Ribovirin + Tribavirin + C0035525 + C22128 + + Ribavirin [Chemical/Ingredient] + + + + + + + + + Digitoxin + M0006383 + D004074 + A cardiac glycoside sometimes used in place of DIGOXIN. It has a longer half-life than digoxin; toxic effects, which are similar to those of digoxin, are longer lasting. (From Martindale, The Extra Pharmacopoeia, 30th ed, p665) + Digitoxin + N0000005895 + 3403 + Digitoxin + Card-20(22)-enolide, 3-((O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy)-14-hydroxy-, (3beta,5beta)- + C0012258 + C22134 + + Digitoxin [Chemical/Ingredient] + + + + + + + + + + + + + + + + + + + Progesterone + M0017672 + D011374 + The major progestational steroid that is secreted primarily by the CORPUS LUTEUM and the PLACENTA. Progesterone acts on the UTERUS, the MAMMARY GLANDS and the BRAIN. It is required in EMBRYO IMPLANTATION; PREGNANCY maintenance, and the development of mammary tissue for MILK production. Progesterone, converted from PREGNENOLONE, also serves as an intermediate in the biosynthesis of GONADAL STEROID HORMONES and adrenal CORTICOSTEROIDS. + Progesterone + N0000005934 + 8727 + Progesterone + Pregn-4-ene-3,20-dione + Pregnenedione + C0033308 + C22212 + + Progesterone [Chemical/Ingredient] + + + + + + + + + Dihydroergotamine + M0006401 + D004087 + A 9,10alpha-dihydro derivative of ERGOTAMINE. It is used as a vasoconstrictor, specifically for the therapy of MIGRAINE DISORDERS. + Dihydroergotamine + N0000005941 + 3418 + Dihydroergotamine + Ergotaman-3',6',18-trione, 9,10-dihydro-12'-hydroxy-2'-methyl-5'-(phenylmethyl)-, (5'alpha,10alpha)- + C0012291 + C22226 + + Dihydroergotamine [Chemical/Ingredient] + + + + + + + + + Triazolam + M0021910 + D014229 + A short-acting benzodiazepine used in the treatment of insomnia. Some countries temporarily withdrew triazolam from the market because of concerns about adverse reactions, mostly psychological, associated with higher dose ranges. Its use at lower doses with appropriate care and labeling has been reaffirmed by the FDA and most other countries. + Triazolam + N0000006001 + 10767 + Triazolam + 4H-(1,2,4)Triazolo(4,3-a)(1,4)benzodiazepine, 8-chloro-6-(2-chlorophenyl)-1-methyl- + C0040879 + C22346 + + Triazolam [Chemical/Ingredient] + + + + + + + + + + Promethazine + M0017706 + D011398 + A phenothiazine derivative with histamine H1-blocking, antimuscarinic, and sedative properties. It is used as an antiallergic, in pruritus, for motion sickness and sedation, and also in animals. + Promethazine + N0000006007 + 8745 + Promethazine + 10H-Phenothiazine-10-ethanamine, N,N,alpha-trimethyl- + Proazamine + Prometazin + C0033405 + C22358 + + Promethazine [Chemical/Ingredient] + + + + + + + + + + + + + + + + + + Rimantadine + M0019119 + D012299 + An RNA synthesis inhibitor that is used as an antiviral agent in the prophylaxis and treatment of influenza. + Rimantadine + N0000006040 + 9386 + Rimantadine + Remantadine + Riamantadine + Tricyclo(3.3.1.13,7)decane-1-methanamine, alpha-methyl- + C0035629 + C22424 + + Rimantadine [Chemical/Ingredient] + + + + + + + + + + + + + + + + + Pimozide + M0016871 + D010868 + A diphenylbutylpiperidine that is effective as an antipsychotic agent and as an alternative to HALOPERIDOL for the suppression of vocal and motor tics in patients with Tourette syndrome. Although the precise mechanism of action is unknown, blockade of postsynaptic dopamine receptors has been postulated. (From AMA Drug Evaluations Annual, 1994, p403) + Pimozide + N0000006115 + 8331 + Pimozide + 2H-Benzimidazol-2-one, 1-(1-(4,4-bis(4-fluorophenyl)butyl)-4-piperidinyl)-1,3-dihydro- + C0031935 + C22574 + + Pimozide [Chemical/Ingredient] + + + + + + + + + Triflupromazine + M0021962 + D014273 + A phenothiazine used as an antipsychotic agent and as an antiemetic. + Triflupromazine + N0000006126 + 10805 + Triflupromazine + 10H-Phenothiazine-10-propanamine, N,N-dimethyl-2-(trifluoromethyl)- + Fluopromazine + Trifluopromazine + C0040989 + C22596 + + Triflupromazine [Chemical/Ingredient] + + + + + + + + + + Emetine + M0007281 + D004640 + The principal alkaloid of ipecac, from the ground roots of Uragoga (or Cephaelis) ipecacuanha or U. acuminata, of the Rubiaceae. It is used as an amebicide in many different preparations and may cause serious cardiac, hepatic, or renal damage and violent diarrhea and vomiting. Emetine inhibits protein synthesis in EUKARYOTIC CELLS but not PROKARYOTIC CELLS. + Emetine + N0000006145 + 3820 + Emetine + Emetan, 6',7',10,11-tetramethoxy- + Ipecine + Methylcephaeline + C0013974 + C22634 + + Emetine [Chemical/Ingredient] + + + + + + + + + Lipids + M0012553 + D008055 + A generic term for fats and lipoids, the alcohol-ether-soluble constituents of protoplasm, which are insoluble in water. They comprise the fats, fatty oils, essential oils, waxes, phospholipids, glycolipids, sulfolipids, aminolipids, chromolipids (lipochromes), and fatty acids. (Grant & Hackh's Chemical Dictionary, 5th ed) + Lipids + N0000006185 + 6411 + C0023779 + C22714 + + Lipids [Chemical/Ingredient] + + + + + + + + + interferon beta-1b + M0129586 + C044327 + interferon beta-1b + N0000006215 + 72257 + interferon beta-1b + IFN-beta ser + Ser(17) IFN-beta + beta-IFN-1b + interferon beta, Ser(17)- + interferon beta, serine(17)- + serine(17) interferon beta + C0244713 + C22776 + + interferon beta-1b [Chemical/Ingredient] + + + + + + + + + Toremifene + M0026287 + D017312 + A first generation selective estrogen receptor modulator (SERM). Like TAMOXIFEN, it is an estrogen agonist for bone tissue and cholesterol metabolism but is antagonistic on mammary and uterine tissue. + Toremifene + N0000006270 + 38409 + Toremifene + Ethanamine, 2-(4-(4-chloro-1,2-diphenyl-1-butenyl)phenoxy)-N,N-dimethyl-, (Z)- + C0076836 + C22886 + + Toremifene [Chemical/Ingredient] + + + + + + + + + + Interferon Alfa-2a + M0023693 + D015380 + A recombinant alfa interferon consisting of 165 amino acids with lysine at position 23 and histidine at position 34. It is used extensively as an antiviral and antineoplastic agent. + Interferon Alfa-2a + N0000006291 + 5879 + Interferon Alfa-2a + Recombinant Interferon Alfa-2a + Recombinant Interferon alpha-2a + C0021734 + C22928 + + Interferon Alfa-2a [Chemical/Ingredient] + + + + + + + + + Ergotamine + M0007662 + D004878 + A vasoconstrictor found in ergot of Central Europe. It is a serotonin agonist that has been used as an oxytocic agent and in the treatment of MIGRAINE DISORDERS. + Ergotamine + N0000006354 + 4025 + Ergotamine + Ergotaman-3',6',18-trione, 12'-hydroxy-2'-methyl-5'-(phenylmethyl)-, (5'alpha)- + C0014710 + C23056 + + Ergotamine [Chemical/Ingredient] + + + + + + + + + Ivermectin + M0011815 + D007559 + A mixture of mostly avermectin H2B1a (RN 71827-03-7) with some avermectin H2B1b (RN 70209-81-3), which are macrolides from STREPTOMYCES avermitilis. It binds glutamate-gated chloride channel to cause increased permeability and hyperpolarization of nerve and muscle cells. It also interacts with other CHLORIDE CHANNELS. It is a broad spectrum antiparasitic that is active against microfilariae of ONCHOCERCA VOLVULUS but not the adult form. + Ivermectin + N0000006374 + 6069 + Ivermectin + C0022322 + C23096 + + Ivermectin [Chemical/Ingredient] + + + + + + + + + famciclovir + M0168276 + C060590 + famciclovir + N0000006388 + 68099 + famciclovir + 9-(4-acetoxy-3-(acetoxymethyl)but-1-yl)-2-aminopurine + C0209227 + C23124 + + famciclovir [Chemical/Ingredient] + + + + + + + + + Warfarin + M0022871 + D014859 + An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide. + Warfarin + N0000006403 + 11289 + Warfarin + 2H-1-Benzopyran-2-one, 4-hydroxy-3-(3-oxo-1-phenylbutyl)- + 4-Hydroxy-3-(3-oxo-1-phenylbutyl)-2H-1-benzopyran-2-one + C0043031 + C23154 + + Warfarin [Chemical/Ingredient] + + + + + + + + + + + + + + + + + Mefloquine + M0024162 + D015767 + A phospholipid-interacting antimalarial drug (ANTIMALARIALS). It is very effective against PLASMODIUM FALCIPARUM with very few side effects. + Mefloquine + N0000006467 + 6694 + Mefloquine + 4-Quinolinemethanol, alpha-2-piperidinyl-2,8-bis(trifluoromethyl)-, (R*,S*)-(+-)- + Mephloquine + C0025153 + C23282 + + Mefloquine [Chemical/Ingredient] + + + + + + + + + Niclosamide + M0014827 + D009534 + An antihelmintic that is active against most tapeworms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p48) + Niclosamide + N0000006489 + 7402 + Niclosamide + Benzamide, 5-chloro-N-(2-chloro-4-nitrophenyl)-2-hydroxy- + C0028017 + C23326 + + Niclosamide [Chemical/Ingredient] + + + + + + + + + gemcitabine + M0158478 + C056507 + gemcitabine + N0000006563 + 12574 + gemcitabine + 2',2'-DFDC + 2',2'-difluoro-2'-deoxycytidine + 2',2'-difluorodeoxycytidine + 2'-deoxy-2'-difluorocytidine + dFdCyd + C0045093 + C23474 + + gemcitabine [Chemical/Ingredient] + + + + + + + + + Hydroxychloroquine + M0010751 + D006886 + A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970) + Hydroxychloroquine + N0000006573 + 5521 + Hydroxychloroquine + Hydroxychlorochin + Oxychlorochin + Oxychloroquine + ethanol, 2-((4-((7-chloro-4-quinolinyl)amino)pentyl)ethylamino)- + C0020336 + C23494 + + Hydroxychloroquine [Chemical/Ingredient] + + + + + + + + + + + + + + + + + + terconazole + M0114183 + C037815 + terconazole + N0000006622 + 37806 + terconazole + 1-(4-((2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl)methoxy)phenyl)-4-(1-methylethyl)piperazine + C0076115 + C23592 + + terconazole [Chemical/Ingredient] + + + + + + + + + + + + + + + + + Prednisolone + M0017460 + D011239 + A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. + Prednisolone + N0000006669 + 8638 + prednisolone + Pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-, (11beta)- + C0032950 + C23686 + + Prednisolone [Chemical/Ingredient] + + + + + + + + + + + + + + + + + Midazolam + M0013843 + D008874 + A short-acting hypnotic-sedative drug with anxiolytic and amnestic properties. It is used in dentistry, cardiac surgery, endoscopic procedures, as preanesthetic medication, and as an adjunct to local anesthesia. The short duration and cardiorespiratory stability makes it useful in poor-risk, elderly, and cardiac patients. It is water-soluble at pH less than 4 and lipid-soluble at physiological pH. + Midazolam + N0000006704 + 6960 + Midazolam + 4H-Imidazo(1,5-a)(1,4)benzodiazepine, 8-chloro-6-(2-fluorophenyl)-1-methyl- + C0026056 + C23756 + + Midazolam [Chemical/Ingredient] + + + + + + + + + Interferon-alpha + M0025711 + D016898 + One of the type I interferons produced by peripheral blood leukocytes or lymphoblastoid cells. In addition to antiviral activity, it activates NATURAL KILLER CELLS and B-LYMPHOCYTES, and down-regulates VASCULAR ENDOTHELIAL GROWTH FACTOR expression through PI-3 KINASE and MAPK KINASES signaling pathways. + Interferon-alpha + N0000006710 + 541 + Interferon-alpha + Interferon Alfa + Interferon, Leukocyte + Interferon, Lymphoblast + Interferon, Lymphoblastoid + Interferon, alpha + alpha-Interferon + C0002199 + C23768 + + Interferon-alpha [Chemical/Ingredient] + + + + + + + + + Azithromycin + M0027129 + D017963 + A semi-synthetic macrolide antibiotic structurally related to ERYTHROMYCIN. It has been used in the treatment of Mycobacterium avium intracellulare infections, toxoplasmosis, and cryptosporidiosis. + Azithromycin + N0000006752 + 18631 + Azithromycin + 1-Oxa-6-azacyclopentadecan-15-one, 13-((2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl)oxy)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-((3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl)oxy)-, (2R-(2R*,3S*,4R*,5R*,8R + Azythromycin + C0052796 + C23854 + + Azithromycin [Chemical/Ingredient] + + + + + + + + + Yohimbine + M0023104 + D015016 + A plant alkaloid with alpha-2-adrenergic blocking activity. Yohimbine has been used as a mydriatic in the treatment of ERECTILE DYSFUNCTION. + Yohimbine + N0000006817 + 220982 + Yohimbe Preparation + Yohimban-16-carboxylic acid, 17-hydroxy-, methyl ester, (16alpha,17alpha)- + C0724441 + C23984 + + Yohimbine [Chemical/Ingredient] + + + + + + + + + Fatty Acids + M0008265 + D005227 + Organic, monobasic acids derived from hydrocarbons by the equivalent of oxidation of a methyl group to an alcohol, aldehyde, and then acid. Fatty acids are saturated and unsaturated (FATTY ACIDS, UNSATURATED). (Grant & Hackh's Chemical Dictionary, 5th ed) + Fatty Acids + N0000006847 + 4297 + C0015684 + C24044 + + Fatty Acids [Chemical/Ingredient] + + + + + + + + + Chlorpromazine + M0004198 + D002746 + The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking DOPAMINE RECEPTORS. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup. + Chlorpromazine + N0000006947 + 2403 + Chlorpromazine + 10H-Phenothiazine-10-propanamine, 2-chloro-N,N-dimethyl- + C0008286 + C24244 + + Chlorpromazine [Chemical/Ingredient] + + + + + + + + + Flecainide + M0008556 + D005424 + A potent anti-arrhythmia agent, effective in a wide range of ventricular and atrial arrhythmias and tachycardias. Paradoxically, however, in myocardial infarct patients with either symptomatic or asymptomatic arrhythmia, flecainide exacerbates the arrhythmia and is not recommended for use in these patients. + Flecainide + N0000006966 + 4441 + Flecainide + Benzamide, N-(2-piperidinylmethyl)-2,5-bis(2,2,2-trifluoroethoxy)- + C0016229 + C24282 + + Flecainide [Chemical/Ingredient] + + + + + + + + + Cetylpyridinium + M0003973 + D002594 + Cationic bactericidal surfactant used as a topical antiseptic for skin, wounds, mucous membranes, instruments, etc.; and also as a component in mouthwash and lozenges. + Cetylpyridinium + N0000006978 + 2286 + Cetylpyridinium + Cetylpyridium + Hexadecylpyridinium + Pyridinium, 1-hexadecyl- + C0007906 + C24306 + + Cetylpyridinium [Chemical/Ingredient] + + + + + + + + + Tamoxifen + M0021024 + D013629 + One of the SELECTIVE ESTROGEN RECEPTOR MODULATORS with tissue-specific activities. Tamoxifen acts as an anti-estrogen (inhibiting agent) in the mammary tissue, but as an estrogen (stimulating agent) in cholesterol metabolism, bone density, and cell proliferation in the ENDOMETRIUM. + Tamoxifen + N0000007041 + 10324 + Tamoxifen + Ethanamine, 2-(4-(1,2-diphenyl-1-butenyl)phenoxy)-N,N-dimethyl-, (Z)- + C0039286 + C24432 + + Tamoxifen [Chemical/Ingredient] + + + + + + + + + Loperamide + M0012692 + D008139 + One of the long-acting synthetic ANTIDIARRHEALS; it is not significantly absorbed from the gut, and has no effect on the adrenergic system or central nervous system, but may antagonize histamine and interfere with acetylcholine release locally. + Loperamide + N0000007084 + 6468 + Loperamide + 1-Piperidinebutanamide, 4-(4-chlorophenyl)-4-hydroxy-N,N-dimethyl-alpha,alpha-diphenyl- + C0023992 + C24520 + + Loperamide [Chemical/Ingredient] + + + + + + + + + Lovastatin + M0012707 + D008148 + A fungal metabolite isolated from cultures of Aspergillus terreus. The compound is a potent anticholesteremic agent. It inhibits 3-hydroxy-3-methylglutaryl coenzyme A reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES), which is the rate-limiting enzyme in cholesterol biosynthesis. It also stimulates the production of low-density lipoprotein receptors in the liver. + Lovastatin + N0000007106 + 6472 + Lovastatin + 6-Methylcompactin + Butanoic acid, 2-methyl-, 1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester, (1S-(1alpha(R*),3alpha,7beta,8beta(2S*,4S*),8abeta))- + Mevinolin + Monacolin K + C0024027 + C24564 + + Lovastatin [Chemical/Ingredient] + + + + + + + + + Fluphenazine + M0008641 + D005476 + A phenothiazine used in the treatment of PSYCHOSES. Its properties and uses are generally similar to those of CHLORPROMAZINE. + Fluphenazine + N0000007109 + 4496 + Fluphenazine + 1-Piperazineethanol, 4-(3-(2-(trifluoromethyl)-10H-phenothiazin-10-yl)propyl)- + Flufenazin + C0016368 + C24570 + + Fluphenazine [Chemical/Ingredient] + + + + + + + + + Erythromycin + M0007715 + D004917 + A bacteriostatic antibiotic macrolide produced by Streptomyces erythreus. Erythromycin A is considered its major active component. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins. + Erythromycin + N0000007133 + 4053 + Erythromycin + Erythromycin A + C0014806 + C24618 + + Erythromycin [Chemical/Ingredient] + + + + + + + + + + Thiethylperazine + M0021336 + D013847 + A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. This piperazine phenothiazine does not prevent vertigo or motion sickness. (From AMA Drug Evaluations Annual, 1994, p457) + Thiethylperazine + N0000007176 + 10471 + Thiethylperazine + 10H-Phenothiazine, 2-(ethylthio)-10-(3-(4-methyl-1-piperazinyl)propyl)- + Novartis Brand of Thiethlperazine + C0039865 + C24704 + + Thiethylperazine [Chemical/Ingredient] + + + + + + + + + Clomipramine + M0004598 + D002997 + A tricyclic antidepressant similar to IMIPRAMINE that selectively inhibits the uptake of serotonin in the brain. It is readily absorbed from the gastrointestinal tract and demethylated in the liver to form its primary active metabolite, desmethylclomipramine. + Clomipramine + N0000007182 + 2597 + Clomipramine + 5H-Dibenz(b,f)azepine-5-propanamine, 3-chloro-10,11-dihydro-N,N-dimethyl- + Chlomipramine + Chlorimipramine + C0009010 + C24716 + + Clomipramine [Chemical/Ingredient] + + + + + + + + + Hexachlorophene + M0010306 + D006582 + A chlorinated bisphenol antiseptic with a bacteriostatic action against Gram-positive organisms, but much less effective against Gram-negative organisms. It is mainly used in soaps and creams and is an ingredient of various preparations used for skin disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p797) + Hexachlorophene + N0000007260 + 5293 + Hexachlorophene + Hexachlorophane + Phenol, 2,2'-methylenebis(3,4,6-trichloro)- + C0019435 + C24872 + + Hexachlorophene [Chemical/Ingredient] + + + + + + + + + penciclovir + M0151646 + C053539 + penciclovir + N0000007265 + 59839 + penciclovir + 9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine + C0164815 + C24882 + + penciclovir [Chemical/Ingredient] + + + + + + + + + Acyclovir + M0000326 + D000212 + A GUANOSINE analog that acts as an antimetabolite. Viruses are especially susceptible. Used especially against herpes. + Acyclovir + N0000007269 + 281 + Acyclovir + 6H-Purin-6-one, 2-amino-1,9-dihydro-9-((2-hydroxyethoxy)methyl)- + 9-((2-Hydroxyethoxy)methyl)guanine + Aciclovir + Acycloguanosine + C0001367 + C24890 + + Acyclovir [Chemical/Ingredient] + + + + + + + + + Thiothixene + M0021384 + D013888 + A thioxanthine used as an antipsychotic agent. Its effects are similar to the phenothiazine antipsychotics. + Thiothixene + N0000007308 + 10510 + Thiothixene + 9H-Thioxanthene-2-sulfonamide, N,N-dimethyl-9-(3-(4-methyl-1-piperazinyl)propylidene)- + Tiotixene + C0039955 + C24968 + + Thiothixene [Chemical/Ingredient] + + + + + + + + + Adenine + M0000347 + D000225 + A purine base and a fundamental unit of ADENINE NUCLEOTIDES. + Adenine + N0000007309 + 290 + Adenine + 1H-Purin-6-amine + Vitamin B 4 + C0001407 + C24970 + + Adenine [Chemical/Ingredient] + + + + + + + + + Cyclosporine + M0025279 + D016572 + A cyclic undecapeptide from an extract of soil fungi. It is a powerful immunosupressant with a specific action on T-lymphocytes. It is used for the prophylaxis of graft rejection in organ and tissue transplantation. (From Martindale, The Extra Pharmacopoeia, 30th ed). + Cyclosporine + N0000007346 + 3008 + Cyclosporine + Ciclosporin + Cyclosporin + Cyclosporin A + Cyclosporine A + C0010592 + C25044 + + Cyclosporine [Chemical/Ingredient] + + + + + + + + + Astemizole + M0025303 + D016589 + A long-acting, non-sedative antihistaminic used in the treatment of seasonal allergic rhinitis, asthma, allergic conjunctivitis, and chronic idiopathic urticaria. The drug is well tolerated and has no anticholinergic side effects. + Astemizole + N0000007383 + 42328 + Astemizole + 1H-Benzimidazol-2-amine, 1-((4-fluorophenyl)methyl)-N-(1-(2-(4-methoxyphenyl)ethyl)-4-piperidinyl)- + C0085170 + C25118 + + Astemizole [Chemical/Ingredient] + + + + + + + + + + Terfenadine + M0025307 + D016593 + A selective histamine H1-receptor antagonist devoid of central nervous system depressant activity. The drug was used for ALLERGY but withdrawn due to causing LONG QT SYNDROME. + Terfenadine + N0000007398 + 42330 + Terfenadine + 1-Piperidinebutanol, alpha-(4-(1,1-dimethylethyl)phenyl)-4-(hydroxydiphenylmethyl)- + Terfenidine + alpha-(4-(1,1-Dimethylethyl)phenyl)-4-(hydroxydiphenylmethyl)-1-piperdinebutanol + C0085173 + C25148 + + Terfenadine [Chemical/Ingredient] + + + + + + + + + + + + + + + + + Methylergonovine + M0013636 + D008755 + A homolog of ERGONOVINE containing one more CH2 group. (Merck Index, 11th ed) + Methylergonovine + N0000007462 + 6883 + Methylergonovine + Ergoline-8-carboxamide, 9,10-didehydro-N-(1-(hydroxymethyl)propyl)-6-methyl-, (8beta(S))- + Methylergobasin + Methylergometrin + Methylergometrine + C0025760 + C25276 + + Methylergonovine [Chemical/Ingredient] + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + Benzamides + M0002327 + D001549 + BENZOIC ACID amides. + Benzamides + N0000007520 + 1381 + C0005029 + C25396 + + Benzamides [Chemical/Ingredient] + + + + + + + + + Benzazepines + M0002330 + D001552 + Compounds with BENZENE fused to AZEPINES. + Benzazepines + N0000007524 + 1384 + C0005034 + C25404 + + Benzazepines [Chemical/Ingredient] + + + + + + + + + + + + + + + + + Benzhydryl Compounds + M0002345 + D001559 + Compounds which contain the methyl radical substituted with two benzene rings. Permitted are any substituents, but ring fusion to any of the benzene rings is not allowed. + Benzhydryl Compounds + N0000007528 + 1392 + Diphenylmethyl Compounds + C0005046 + C25412 + + Benzhydryl Compounds [Chemical/Ingredient] + + + + + + + + + + + + + + + + + + + + + + + + + + + Digitalis Glycosides + M0006379 + D004071 + Glycosides from plants of the genus DIGITALIS. Some of these are useful as cardiotonic and anti-arrhythmia agents. Included also are semi-synthetic derivatives of the naturally occurring glycosides. The term has sometimes been used more broadly to include all CARDIAC GLYCOSIDES, but here is restricted to those related to Digitalis. + Digitalis Glycosides + N0000007534 + 3400 + C0012253 + C25424 + + Digitalis Glycosides [Chemical/Ingredient] + + + + + + + + + + + + + + + + + Phenols + M0016520 + D010636 + Phenols + N0000007540 + 8140 + Carbol + C0031428 + C25436 + + Phenols [Chemical/Ingredient] + + + + + + + + + Benzodiazepines + M0002356 + D001569 + A group of two-ring heterocyclic compounds consisting of a benzene ring fused to a diazepine ring. + Benzodiazepines + N0000007542 + 1402 + Benzodiazepine + Benzodiazepine Compounds + C0005064 + C25440 + + Benzodiazepines [Chemical/Ingredient] + + + + + + + + + Cardenolides + M0003448 + D002298 + C(23)-steroids with methyl groups at C-10 and C-13 and a five-membered lactone at C-17. They are aglycone constituents of CARDIAC GLYCOSIDES and must have at least one double bond in the molecule. The class includes cardadienolides and cardatrienolides. Members include DIGITOXIN and DIGOXIN and their derivatives and the STROPHANTHINS. + Cardenolides + N0000007543 + 2078 + C0007143 + C25442 + + Cardenolides [Chemical/Ingredient] + + + + + + + + + + Phenothiazines + M0016525 + D010640 + Compounds containing dibenzo-1,4-thiazine. Some of them are neuroactive. + Phenothiazines + N0000007544 + 8146 + C0031436 + C25444 + + Phenothiazines [Chemical/Ingredient] + + + + + + + + + Benzofurans + M0002359 + D001572 + Compounds that contain a BENZENE ring fused to a furan ring. + Benzofurans + N0000007548 + 1405 + Coumarones + C0005068 + C25452 + + Benzofurans [Chemical/Ingredient] + + + + + + + + + + Benzopyrans + M0002367 + D001578 + Compounds with a core of fused benzo-pyran rings. + Benzopyrans + N0000007553 + 1411 + Chromenes + C0005078 + C25462 + + Benzopyrans [Chemical/Ingredient] + + + + + + + + + Benztropine + M0002383 + D001590 + A centrally active muscarinic antagonist that has been used in the symptomatic treatment of PARKINSON DISEASE. Benztropine also inhibits the uptake of dopamine. + Benztropine + N0000007558 + 1424 + Benztropine + 8-Azabicyclo(3.2.1)octane, 3-(diphenylmethoxy)-8-methyl-, endo- + Benzatropine + C0005098 + C25472 + + Benztropine [Chemical/Ingredient] + + + + + + + + + Triazoles + M0021911 + D014230 + Triazoles + N0000007567 + 10768 + C0040880 + C25490 + + Triazoles [Chemical/Ingredient] + + + + + + + + + Pyrazoles + M0018226 + D011720 + Azoles of two nitrogens at the 1,2 positions, next to each other, in contrast with IMIDAZOLES in which they are at the 1,3 positions. + Pyrazoles + N0000007569 + 8989 + C0034242 + C25494 + + Pyrazoles [Chemical/Ingredient] + + + + + + + + + + + + + + + + + Pyridinium Compounds + M0018234 + D011726 + Pyridinium Compounds + N0000007571 + 8996 + C0034256 + C25498 + + Pyridinium Compounds [Chemical/Ingredient] + + + + + + + + + + + + + + + + + + + + + + + + + + Pyrimidines + M0018260 + D011743 + A family of 6-membered heterocyclic compounds occurring in nature in a wide variety of forms. They include several nucleic acid constituents (CYTOSINE; THYMINE; and URACIL) and form the basic structure of the barbiturates. + Pyrimidines + N0000007587 + 9015 + C0034289 + C25530 + + Pyrimidines [Chemical/Ingredient] + + + + + + + + + Pyrimidinones + M0018261 + D011744 + Pyrimidinones + N0000007588 + 9016 + C0034290 + C25532 + + Pyrimidinones [Chemical/Ingredient] + + + + + + + + + + + + + + + + + + Interferon Type I, Recombinant + M0023692 + D015379 + A type I interferon with antiviral and antineoplastic activity produced by recombinant DNA technology. It can be a mixture of alpha and beta interferons. + Interferon Type I, Recombinant + N0000007612 + 5878 + C0021733 + C25584 + + Interferon Type I, Recombinant [Chemical/Ingredient] + + + + + + + + + Interferon Type I + M0011489 + D007370 + Interferon secreted by leukocytes, fibroblasts, or lymphoblasts in response to viruses or interferon inducers other than mitogens, antigens, or allo-antigens. They include alpha- and beta-interferons (INTERFERON-ALPHA and INTERFERON-BETA). + Interferon Type I + N0000007614 + 5884 + Interferons Type I + Type I Interferon + Type I Interferons + C0021743 + C25588 + + Interferon Type I [Chemical/Ingredient] + + + + + + + + + + Ergolines + M0007652 + D004873 + A series of structurally-related alkaloids that contain the ergoline backbone structure. + Ergolines + N0000007618 + 4020 + C0014699 + C25596 + + Ergolines [Chemical/Ingredient] + + + + + + + + + Ergonovine + M0007653 + D004874 + An ergot alkaloid (ERGOT ALKALOIDS) with uterine and VASCULAR SMOOTH MUSCLE contractile properties. + Ergonovine + N0000007619 + 4021 + Ergonovine + Ergobasin + Ergoline-8-carboxamide, 9,10-didehydro-N-(2-hydroxy-1-methylethyl)-6-methyl-, (8beta(S))- + Ergometrin + Ergometrine + C0014704 + C25598 + + Ergonovine [Chemical/Ingredient] + + + + + + + + + Ergot Alkaloids + M0007656 + D004876 + Alkaloids originally isolated from the ergot fungus Claviceps purpurea (Hypocreaceae). They include compounds that are structurally related to ergoline (ERGOLINES) and ergotamine (ERGOTAMINES). Many of the ergot alkaloids act as alpha-adrenergic antagonists. + Ergot Alkaloids + N0000007620 + 4023 + Ergot Alkaloids + Clavine Alkaloids + Ergots + C0014707 + C25600 + + Ergot Alkaloids [Chemical/Ingredient] + + + + + + + + + + + + + + + + + + Mycophenolic Acid + M0014304 + D009173 + An antibiotic substance derived from Penicillium stoloniferum, and related species. It blocks de novo biosynthesis of purine nucleotides by inhibition of the enzyme inosine monophosphate dehydrogenase. Mycophenolic acid is important because of its selective effects on the immune system. It prevents the proliferation of T-cells, lymphocytes, and the formation of antibodies from B-cells. It also may inhibit recruitment of leukocytes to inflammatory sites. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1301) + Mycophenolic Acid + N0000007622 + 7145 + Mycophenolic Acid + -Hexenoic acid, 6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-, (E)- + C0026933 + C25604 + + Mycophenolic Acid [Chemical/Ingredient] + + + + + + + + + Acids, Acyclic + M0000221 + D000144 + Carboxylic acids that have open-chain molecular structures as opposed to ring-shaped structures. + Acids, Acyclic + N0000007627 + 231 + Acyclic Acids + C0001129 + C25614 + + Acids, Acyclic [Chemical/Ingredient] + + + + + + + + + + + + + + + + + + + + + + + + + Interferon-beta + M0025715 + D016899 + One of the type I interferons produced by fibroblasts in response to stimulation by live or inactivated virus or by double-stranded RNA. It is a cytokine with antiviral, antiproliferative, and immunomodulating activity. + Interferon-beta + N0000007668 + 4381 + Interferon-beta + Interferon, Fibroblast + Interferon, beta + beta-Interferon + C0015980 + C25696 + + Interferon-beta [Chemical/Ingredient] + + + + + + + + + + + + + + + + + Propiophenones + M0017764 + D011427 + Propiophenones + N0000007679 + 8780 + C0033483 + C25718 + + Propiophenones [Chemical/Ingredient] + + + + + + + + + + + + + + + + + Propylamines + M0017781 + D011437 + Propylamines + N0000007691 + 8790 + C0033504 + C25742 + + Propylamines [Chemical/Ingredient] + + + + + + + + + Benzoic Acids + M0029896 + D020185 + Acids, salts, and derivatives of BENZOIC ACID. + Benzoic Acids + N0000007692 + 155099 + C0600423 + C25744 + + Benzoic Acids [Chemical/Ingredient] + + + + + + + + + + + + + + + + + + + + + + + + + + + Quinolines + M0018350 + D011804 + Quinolines + N0000007731 + 9077 + C0034424 + C25822 + + Quinolines [Chemical/Ingredient] + + + + + + + + + + Chlorophenols + M0004174 + D002733 + Phenols substituted with one or more chlorine atoms in any position. + Chlorophenols + N0000007732 + 2387 + Hydroxychlorobenzenes + C0008257 + C25824 + + Chlorophenols [Chemical/Ingredient] + + + + + + + + + Stilbenes + M0020537 + D013267 + Organic compounds that contain 1,2-diphenylethylene as a functional group. + Stilbenes + N0000007736 + 10081 + C0038333 + C25832 + + Stilbenes [Chemical/Ingredient] + + + + + + + + + Chloroquine + M0004182 + D002738 + The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses. + Chloroquine + N0000007737 + 2393 + Chloroquine + 1,4-Pentanediamine, N4-(7-chloro-4-quinolinyl)-N1,N1-diethyl- + Chingamin + Chlorochin + Khingamin + C0008269 + C25834 + + Chloroquine [Chemical/Ingredient] + + + + + + + + + Quinuclidines + M0018359 + D011812 + Quinuclidines + N0000007740 + 9086 + C0034439 + C25840 + + Quinuclidines [Chemical/Ingredient] + + + + + + + + + + Tropanes + M0022031 + D014326 + N-methyl-8-azabicyclo[3.2.1]octanes best known for the ones found in PLANTS. + Tropanes + N0000007744 + 10866 + C0041177 + C25848 + + Tropanes [Chemical/Ingredient] + + + + + + + + + 2-Aminopurine + M0023189 + D015075 + A purine that is an isomer of ADENINE (6-aminopurine). + 2-Aminopurine + N0000007749 + 37 + 1H-Purin-2-amine + C0000263 + C25858 + + 2-Aminopurine [Chemical/Ingredient] + + + + + + + + + + Deoxycytidine + M0005997 + D003841 + Deoxycytidine + N0000007762 + 3195 + CDR + Cytidine, 2'-deoxy- + Cytosine Deoxyribonucleoside + Cytosine Deoxyriboside + C0011485 + C25884 + + Deoxycytidine [Chemical/Ingredient] + + + + + + + + + Deoxyribonucleosides + M0006016 + D003853 + A purine or pyrimidine base bonded to DEOXYRIBOSE. + Deoxyribonucleosides + N0000007768 + 3215 + C0011528 + C25896 + + Deoxyribonucleosides [Chemical/Ingredient] + + + + + + + + + + + + + + + + + + + + + + + + + + Adamantane + M0000336 + D000218 + A tricyclo bridged hydrocarbon. + Adamantane + N0000007793 + 287 + Diamantane + Tricyclo(3.3.1.1(3,7))decane + C0001392 + C25946 + + Adamantane [Chemical/Ingredient] + + + + + + + + + Naphthalenes + M0014459 + D009281 + Two-ring crystalline hydrocarbons isolated from coal tar. They are used as intermediates in chemical synthesis, as insect repellents, fungicides, lubricants, preservatives, and, formerly, as topical antiseptics. + Naphthalenes + N0000007809 + 7251 + C0027378 + C25978 + + Naphthalenes [Chemical/Ingredient] + + + + + + + + + + + Bicyclo Compounds, Heterocyclic + M0028488 + D019086 + A class of saturated compounds consisting of two rings only, having two or more atoms in common, containing at least one hetero atom, and that take the name of an open chain hydrocarbon containing the same total number of atoms. (From Riguady et al., Nomenclature of Organic Chemistry, 1979, p31) + Bicyclo Compounds, Heterocyclic + N0000007813 + 82186 + Bicyclic Heterocyclic Compounds + Heterocyclic Bicyclo Compounds + Heterocyclic Cpds, Bicyclic + C0282650 + C25986 + + Bicyclo Compounds, Heterocyclic [Chemical/Ingredient] + + + + + + + + + + + + + + + + + + Aminopyridines + M0000964 + D000631 + Pyridines substituted in any position with an amino group. May be hydrogenated, but must retain at least one double bond. + Aminopyridines + N0000007862 + 694 + C0002585 + C26084 + + Aminopyridines [Chemical/Ingredient] + + + + + + + + + Aminoquinolines + M0000967 + D000634 + Quinolines substituted in any position by one or more amino groups. + Aminoquinolines + N0000007864 + 697 + C0002588 + C26088 + + Aminoquinolines [Chemical/Ingredient] + + + + + + + + + + + + + + + + + + + + + + + + + + + Glycopeptides + M0009481 + D006020 + Proteins which contain carbohydrate groups attached covalently to the polypeptide chain. The protein moiety is the predominant group with the carbohydrate making up only a small percentage of the total weight. + Glycopeptides + N0000007889 + 4944 + C0017953 + C26138 + + Glycopeptides [Chemical/Ingredient] + + + + + + + + + Ribonucleosides + M0019074 + D012263 + Nucleosides in which the purine or pyrimidine base is combined with ribose. (Dorland, 28th ed) + Ribonucleosides + N0000007894 + 9356 + C0035546 + C26148 + + Ribonucleosides [Chemical/Ingredient] + + + + + + + + + + Cycloparaffins + M0005477 + D003516 + Alicyclic hydrocarbons in which three or more of the carbon atoms in each molecule are united in a ring structure and each of the ring carbon atoms is joined to two hydrogen atoms or alkyl groups. The simplest members are cyclopropane (C3H6), cyclobutane (C4H8), cyclohexane (C6H12), and derivatives of these such as methylcyclohexane (C6H11CH3). (From Sax, et al., Hawley's Condensed Chemical Dictionary, 11th ed) + Cycloparaffins + N0000007896 + 2997 + Cyclic Olefins + Cycloalkanes + C0010578 + C26152 + + Cycloparaffins [Chemical/Ingredient] + + + + + + + + + + + + + + + + + Cyclosporins + M0005493 + D003524 + A group of closely related cyclic undecapeptides from the fungi Trichoderma polysporum and Cylindocarpon lucidum. They have some antineoplastic and antifungal action and significant immunosuppressive effects. Cyclosporins have been proposed as adjuvants in tissue and organ transplantation to suppress graft rejection. + Cyclosporins + N0000007903 + 3009 + Cyclosporines + C0010594 + C26166 + + Cyclosporins [Chemical/Ingredient] + + + + + + + + + 4-Hydroxycoumarins + M0023241 + D015110 + Substances found in many plants, containing the 4-hydroxycoumarin radical. They interfere with vitamin K and the blood clotting mechanism, are tightly protein-bound, inhibit mitochondrial and microsomal enzymes, and are used as oral anticoagulants. + 4-Hydroxycoumarins + N0000007905 + 82 + C0000506 + C26170 + + 4-Hydroxycoumarins [Chemical/Ingredient] + + + + + + + + + + Cytidine + M0005567 + D003562 + A pyrimidine nucleoside that is composed of the base CYTOSINE linked to the five-carbon sugar D-RIBOSE. + Cytidine + N0000007916 + 3042 + Cytosine Ribonucleoside + Cytosine Riboside + C0010715 + C26194 + + Cytidine [Chemical/Ingredient] + + + + + + + + + Piperazines + M0016884 + D010879 + Piperazines + N0000007927 + 8341 + C0031958 + C26216 + + Piperazines [Chemical/Ingredient] + + + + + + + + + + + + + + + + + + + + + + + + + Recombinant Proteins + M0018641 + D011994 + Proteins prepared by recombinant DNA technology. + Recombinant Proteins + N0000007956 + 9218 + Biosynthetic Proteins + Proteins, Biosynthetic + C0034861 + C26276 + + Recombinant Proteins [Chemical/Ingredient] + + + + + + + + + Isoquinolines + M0011785 + D007546 + A group of compounds with the heterocyclic ring structure of benzo(c)pyridine. The ring structure is characteristic of the group of opium alkaloids such as papaverine. (From Stedman, 25th ed) + Isoquinolines + N0000007960 + 6056 + C0022248 + C26284 + + Isoquinolines [Chemical/Ingredient] + + + + + + + + + Dibenzazepines + M0006249 + D003984 + Compounds with two BENZENE rings fused to AZEPINES. + Dibenzazepines + N0000007962 + 3331 + C0012029 + C26288 + + Dibenzazepines [Chemical/Ingredient] + + + + + + + + + Hydrazines + M0010683 + D006834 + Hydrazines + N0000007972 + 5473 + C0020233 + C26308 + + Hydrazines [Chemical/Ingredient] + + + + + + + + + + + + + + + + + Hydrocarbons, Chlorinated + M0010693 + D006843 + Hydrocarbon compounds with one or more of the hydrogens replaced by CHLORINE. + Hydrocarbons, Chlorinated + N0000007975 + 5481 + Chlorinated Hydrocarbons + Chlorine Compounds, Organic + Organochlorine Compounds + C0020247 + C26314 + + Hydrocarbons, Chlorinated [Chemical/Ingredient] + + + + + + + + + Hydrocarbons, Halogenated + M0010696 + D006846 + Hydrocarbons, Halogenated + N0000007977 + 5484 + Halogenated Hydrocarbons + C0020250 + C26318 + + Hydrocarbons, Halogenated [Chemical/Ingredient] + + + + + + + + + Pregnadienes + M0017468 + D011245 + Pregnane derivatives containing two double bonds anywhere within the ring structures. + Pregnadienes + N0000008001 + 8642 + C0032959 + C26366 + + Pregnadienes [Chemical/Ingredient] + + + + + + + + + Pregnadienetriols + M0017469 + D011246 + Doubly unsaturated pregnane derivatives substituted with three hydroxy groups anywhere within the ring structure or side chains. + Pregnadienetriols + N0000008002 + 8643 + Trihydroxypregnadienes + C0032960 + C26368 + + Pregnadienetriols [Chemical/Ingredient] + + + + + + + + + Pregnenediones + M0017514 + D011282 + Unsaturated pregnane derivatives containing two keto groups on side chains or ring structures. + Pregnenediones + N0000008024 + 8665 + Diketopregnenes + Dioxopregnenes + C0033013 + C26412 + + Pregnenediones [Chemical/Ingredient] + + + + + + + + + Pregnenes + M0017515 + D011283 + Unsaturated derivatives of PREGNANES. + Pregnenes + N0000008025 + 8666 + C0033014 + C26414 + + Pregnenes [Chemical/Ingredient] + + + + + + + + + Guanine + M0009679 + D006147 + Guanine + N0000008039 + 5039 + 6H-Purin-6-one, 2-amino-1,7-dihydro- + C0018321 + C26442 + + Guanine [Chemical/Ingredient] + + + + + + + + + + + + + + + + + + + + + + + + + Cinchona Alkaloids + M0004487 + D002930 + Alkaloids extracted from various species of Cinchona. + Cinchona Alkaloids + N0000008058 + 2545 + C0008792 + C26480 + + Cinchona Alkaloids [Chemical/Ingredient] + + + + + + + + + + + + + + + + + + + + + + + + + + Thiazoles + M0021333 + D013844 + Thiazoles + N0000008087 + 10468 + C0039859 + C26538 + + Thiazoles [Chemical/Ingredient] + + + + + + + + + + + + + + + + + + + + + + + + + Hydroxyprogesterones + M0010776 + D006908 + Metabolites or derivatives of PROGESTERONE with hydroxyl group substitution at various sites. + Hydroxyprogesterones + N0000008102 + 5542 + Hydroxyprogesterone + C0020387 + C26568 + + Hydroxyprogesterones [Chemical/Ingredient] + + + + + + + + + + Thioxanthenes + M0021388 + D013892 + Compounds with three aromatic rings in linear arrangement with a SULFUR in the center ring. + Thioxanthenes + N0000008107 + 10516 + C0039961 + C26578 + + Thioxanthenes [Chemical/Ingredient] + + + + + + + + + Ketones + M0011995 + D007659 + Ketones + N0000008109 + 6141 + C0022634 + C26582 + + Ketones [Chemical/Ingredient] + + + + + + + + + Xanthenes + M0023042 + D014966 + Compounds with three aromatic rings in linear arrangement with an OXYGEN in the center ring. + Xanthenes + N0000008115 + 11352 + C0043313 + C26594 + + Xanthenes [Chemical/Ingredient] + + + + + + + + + + Caproates + M0003305 + D002208 + Caproates + N0000008121 + 1988 + Hexanoates + C0006924 + C26606 + + Caproates [Chemical/Ingredient] + + + + + + + + + + + + + + + + + + + + + + + + + Pyrans + M0018220 + D011714 + Pyrans + N0000008141 + 8983 + C0034234 + C26646 + + Pyrans [Chemical/Ingredient] + + + + + + + + + Coumarins + M0005258 + D003374 + Synthetic or naturally occurring substances related to coumarin, the delta-lactone of coumarinic acid. The various coumarins have a wide range of proposed actions and uses including as ANTICOAGULANTS, pharmaceutical aids, indicators and reagents, photoreactive substances, and ANTINEOPLASTIC AGENTS. + Coumarins + N0000008142 + 2899 + 1,2-Benzo-Pyrones + 1,2-Benzopyrones + Benzopyran-2-ones + Coumarines + C0010207 + C26648 + + Coumarins [Chemical/Ingredient] + + + + + + + + + Benzylidene Compounds + M0002394 + D001597 + Compounds containing the PhCH= radical. + Benzylidene Compounds + N0000008143 + 1432 + C0005107 + C26650 + + Benzylidene Compounds [Chemical/Ingredient] + + + + + + + + + + Pyrimidine Nucleosides + M0018258 + D011741 + Pyrimidines with a RIBOSE attached that can be phosphorylated to PYRIMIDINE NUCLEOTIDES. + Pyrimidine Nucleosides + N0000008147 + 9013 + C0034287 + C26658 + + Pyrimidine Nucleosides [Chemical/Ingredient] + + + + + + + + + + Bridged Compounds + M0002922 + D001952 + Cyclic hydrocarbons that contain multiple rings and share one or more atoms. + Bridged Compounds + N0000008149 + 1740 + C0006174 + C26662 + + Bridged Compounds [Chemical/Ingredient] + + + + + + + + + Interferons + M0011491 + D007372 + Proteins secreted by vertebrate cells in response to a wide variety of inducers. They confer resistance against many different viruses, inhibit proliferation of normal and malignant cells, impede multiplication of intracellular parasites, enhance macrophage and granulocyte phagocytosis, augment natural killer cell activity, and show several other immunomodulatory functions. + Interferons + N0000008154 + 5886 + Interferon + C0021747 + C26672 + + Interferons [Chemical/Ingredient] + + + + + + + + + + + + + + + + + + + + + + + + + + + Amines + M0000913 + D000588 + A group of compounds derived from ammonia by substituting organic radicals for the hydrogens. (From Grant & Hackh's Chemical Dictionary, 5th ed) + Amines + N0000008168 + 823705 + C0002508 + C26700 + + Amines [Chemical/Ingredient] + + + + + + + + + Bicyclo Compounds + M0002469 + D001643 + Bicyclo Compounds + N0000008171 + 1530 + C0005378 + C26706 + + Bicyclo Compounds [Chemical/Ingredient] + + + + + + + + + Fatty Acids, Volatile + M0008273 + D005232 + Short-chain fatty acids of up to six carbon atoms in length. They are the major end products of microbial fermentation in the ruminant digestive tract and have also been implicated in the causation of neurological diseases in humans. + Fatty Acids, Volatile + N0000008176 + 4303 + Fatty Acids, Short-Chain + C0015691 + C26716 + + Fatty Acids, Volatile [Chemical/Ingredient] + + + + + + + + + + Chlorobenzenes + M0004161 + D002722 + Chlorobenzenes + N0000008177 + 2376 + C0008230 + C26718 + + Chlorobenzenes [Chemical/Ingredient] + + + + + + + + + Hypoxanthines + M0010953 + D007042 + Purine bases related to hypoxanthine, an intermediate product of uric acid synthesis and a breakdown product of adenine catabolism. + Hypoxanthines + N0000008183 + 5625 + C0020691 + C26730 + + Hypoxanthines [Chemical/Ingredient] + + + + + + + + + Glycoconjugates + M0009456 + D006001 + Carbohydrates covalently linked to a nonsugar moiety (lipids or proteins). The major glycoconjugates are glycoproteins, glycopeptides, peptidoglycans, glycolipids, and lipopolysaccharides. (From Biochemical Nomenclature and Related Documents, 2d ed; From Principles of Biochemistry, 2d ed) + Glycoconjugates + N0000008215 + 4924 + C0017906 + C26794 + + Glycoconjugates [Chemical/Ingredient] + + + + + + + + + + + + + + + + + Hydrocarbons, Alicyclic + M0010689 + D006840 + Organic compounds composed exclusively of carbon and hydrogen. Three or more carbon atoms are arranged in a cyclic structure and they possess aliphatic properties. + Hydrocarbons, Alicyclic + N0000008228 + 5478 + Alicyclic Hydrocarbons + C0020244 + C26820 + + Hydrocarbons, Alicyclic [Chemical/Ingredient] + + + + + + + + + + + + + + + + + + Nucleosides + M0015066 + D009705 + Purine or pyrimidine bases attached to a ribose or deoxyribose. (From King & Stansfield, A Dictionary of Genetics, 4th ed) + Nucleosides + N0000008235 + 7578 + C0028621 + C26834 + + Nucleosides [Chemical/Ingredient] + + + + + + + + + Pregnanes + M0017507 + D011278 + Saturated derivatives of the steroid pregnane. The 5-beta series includes PROGESTERONE and related hormones; the 5-alpha series includes forms generally excreted in the urine. + Pregnanes + N0000008242 + 8661 + C0033006 + C26848 + + Pregnanes [Chemical/Ingredient] + + + + + + + + + + + + + + + + + + Purinones + M0018170 + D011688 + Purinones + N0000008251 + 8953 + Oxopurines + C0034142 + C26866 + + Purinones [Chemical/Ingredient] + + + + + + + + + + + + + + + + + Heterocyclic Compounds, Bridged-Ring + M0010291 + D006572 + A class of organic compounds which contain two rings that share a pair of bridgehead carbon atoms. + Heterocyclic Compounds, Bridged-Ring + N0000008258 + 5288 + Bridged-Ring Heterocyclic Compounds + C0019403 + C26880 + + Heterocyclic Compounds, Bridged-Ring [Chemical/Ingredient] + + + + + + + + + + + + + + + + + + + + + + + + + Heterocyclic Compounds with 4 or More Rings + M0010295 + D006576 + A class of organic compounds containing four or more ring structures, one of which is made up of more than one kind of atom, usually carbon plus another atom. The heterocycle may be either aromatic or nonaromatic. + Heterocyclic Compounds with 4 or More Rings + N0000008261 + 5287 + Heterocyclic Cpds, 4 or More Rings + C0019402 + C26886 + + Heterocyclic Compounds with 4 or More Rings [Chemical/Ingredient] + + + + + + + + + + + + + + + + + Nucleic Acids, Nucleotides, and Nucleosides + M0015067 + D009706 + Complex compounds of high molecular weight occurring in living cells. These are basically of two types, ribonucleic (RNA) and deoxyribonucleic (DNA) acids, both of which consist of nucleotides (nucleoside phosphates linked together by phosphate bridges). + Nucleic Acids, Nucleotides, and Nucleosides + N0000008282 + 7579 + C0028622 + C26930 + + Nucleic Acids, Nucleotides, and Nucleosides [Chemical/Ingredient] + + + + + + + + + Acetylcholine Activity Alteration + N0000008290 + 988978 + C1371273 + C26946 + + Acetylcholine Activity Alteration [PE] + + + + + + + + + Adrenal Cortical Activity Alteration + N0000008291 + 985815 + C1371274 + C26948 + + Adrenal Cortical Activity Alteration [PE] + + + + + + + + + Breast Function Alteration + N0000008316 + 990630 + C1371304 + C26998 + + Breast Function Alteration [PE] + + + + + + + + + Breast Glandular Development Alteration + N0000008317 + 989277 + C1371303 + C27000 + + Breast Glandular Development Alteration [PE] + + + + + + + + + Carbohydrate Metabolism Alteration + N0000008327 + 1033881 + C1371294 + C27020 + + Carbohydrate Metabolism Alteration [PE] + + + + + + + + + Cardiac Contractility Alteration + N0000008328 + 986415 + C1371293 + C27022 + + Cardiac Contractility Alteration [PE] + + + + + + + + + Cardiac Rate Alteration + N0000008329 + 985479 + C2825066 + C27024 + + Cardiac Rate Alteration [PE] + + + + + + + + + Cardiac Rhythm Alteration + N0000008330 + 988420 + C1371292 + C27026 + + Cardiac Rhythm Alteration [PE] + + + + + + + + + Cardiovascular Activity Alteration + N0000008331 + 988145 + C1371291 + C27028 + + Cardiovascular Activity Alteration [PE] + + + + + + + + + Cell Membrane Alteration + N0000008334 + 1031394 + C0544958 + C27034 + + Cell Membrane Alteration [PE] + + + + + + + + + Cellular Activity Alteration + N0000008337 + 985006 + C1371483 + C27040 + + Cellular Activity Alteration [PE] + + + + + + + + + Cellular Cycle Alteration + N0000008339 + 990947 + C1371481 + C27044 + + Cellular Cycle Alteration [PE] + + + + + + + + + Cellular Degradation/Digestion Alteration + N0000008341 + 990545 + C1371479 + C27048 + + Cellular Degradation/Digestion Alteration [PE] + + + + + + + + + Cellular Growth Phase Alteration + N0000008343 + 987428 + C1371477 + C27052 + + Cellular Growth Phase Alteration [PE] + + + + + + + + + Cellular Growth Phase Arrest + N0000008344 + 986074 + C1371476 + C27054 + + Cellular Growth Phase Arrest [PE] + + + + + + + + + Cellular Motion Alteration + N0000008345 + 988013 + C1371475 + C27056 + + Cellular Motion Alteration [PE] + + + + + + + + + Cellular Structure Alteration + N0000008346 + 990421 + C1371474 + C27058 + + Cellular Structure Alteration [PE] + + + + + + + + + Cellular Synthetic Activity Alteration + N0000008347 + 989470 + C1371473 + C27060 + + Cellular Synthetic Activity Alteration [PE] + + + + + + + + + Cellular Transport Alteration + N0000008350 + 985278 + C1371312 + C27066 + + Cellular Transport Alteration [PE] + + + + + + + + + + + + + + + + + Connective Tissue Alteration + N0000008373 + 987429 + C1371315 + C27112 + + Connective Tissue Alteration [PE] + + + + + + + + + DNA Integrity Alteration + N0000008379 + 984969 + C1371459 + C27124 + + DNA Integrity Alteration [PE] + + + + + + + + + DNA Replication Alteration + N0000008380 + 985410 + C1371458 + C27126 + + DNA Replication Alteration [PE] + + + + + + + + + Decreased Acetylcholine Activity + N0000008383 + 985411 + C1371330 + C27132 + + Decreased Acetylcholine Activity [PE] + + + + + + + + + Decreased Autonomic Nervous System Acetylcholine Activity + N0000008394 + 985008 + C1371453 + C27154 + + Decreased Autonomic Nervous System Acetylcholine Activity [PE] + + + + + + + + + Decreased Autonomic Nervous System Norepinephrine Activity + N0000008412 + 989573 + C2267191 + C27190 + + Decreased Autonomic Nervous System Norepinephrine Activity [PE] + + + + + + + + + Decreased Cell Membrane Integrity + N0000008476 + 989770 + C1371353 + C27318 + + Decreased Cell Membrane Integrity [PE] + + + + + + + + + Decreased Central Nervous System Dopamine Activity + N0000008487 + 990956 + C1371342 + C27340 + + Decreased Central Nervous System Dopamine Activity [PE] + + + + + + + + + Decreased Central Nervous System Norepinephrine Activity + N0000008500 + 990153 + C2267194 + C27366 + + Decreased Central Nervous System Norepinephrine Activity [PE] + + + + + + + + + Decreased Central Nervous System Organized Electrical Activity + N0000008501 + 987431 + C1371428 + C27368 + + Decreased Central Nervous System Organized Electrical Activity [PE] + + + + + + + + + Decreased Cytokine Activity + N0000008571 + 989703 + C1371548 + C27508 + + Decreased Cytokine Activity [PE] + + + + + + + + + Decreased Cytokine Production + N0000008573 + 984977 + C1371550 + C27512 + + Decreased Cytokine Production [PE] + + + + + + + + + Decreased DNA Integrity + N0000008576 + 990547 + C1371553 + C27518 + + Decreased DNA Integrity [PE] + + + + + + + + + Decreased DNA Replication + N0000008577 + 989476 + C1371554 + C27520 + + Decreased DNA Replication [PE] + + + + + + + + + + + + + + + + + Decreased Dopamine Activity + N0000008588 + 988292 + C1371565 + C27542 + + Decreased Dopamine Activity [PE] + + + + + + + + + Decreased Eicosanoid Activity + N0000008590 + 984625 + C1371567 + C27546 + + Decreased Eicosanoid Activity [PE] + + + + + + + + + Decreased Endocytosis + N0000008596 + 985823 + C1371573 + C27558 + + Decreased Endocytosis [PE] + + + + + + + + + Decreased GI Motility + N0000008635 + 984546 + C1371645 + C27636 + + Decreased GI Motility [PE] + + + + + + + + + Decreased Glucocorticoid Secretion + N0000008645 + 988098 + C1371655 + C27656 + + Decreased Glucocorticoid Secretion [PE] + + + + + + + + + Decreased Hematopoiesis + N0000008656 + 989826 + C2825067 + C27678 + + Decreased Hematopoiesis [PE] + + + + + + + + + + Decreased Histamine Activity + N0000008657 + 990635 + C1371666 + C27680 + + Decreased Histamine Activity [PE] + + + + + + + + + Decreased Immunologically Active Biogenic Amine Activity + N0000008660 + 986941 + C1371669 + C27686 + + Decreased Immunologically Active Biogenic Amine Activity [PE] + + + + + + + + + Decreased Immunologically Active Biogenic Amine Degradation + N0000008661 + 986196 + C1371670 + C27688 + + Decreased Immunologically Active Biogenic Amine Degradation [PE] + + + + + + + + + + Decreased Immunologically Active Molecule Activity + N0000008663 + 988758 + C1371672 + C27692 + + Decreased Immunologically Active Molecule Activity [PE] + + + + + + + + + + Decreased Immunologically Active Molecule Degradation + N0000008664 + 986197 + C1371673 + C27694 + + Decreased Immunologically Active Molecule Degradation [PE] + + + + + + + + + + Decreased Immunologically Active Molecule Production + N0000008665 + 987036 + C1371674 + C27696 + + Decreased Immunologically Active Molecule Production [PE] + + + + + + + + + Decreased Leukotriene Activity + N0000008681 + 987436 + C1371689 + C27728 + + Decreased Leukotriene Activity [PE] + + + + + + + + + Decreased Lipid Derived Immunologically Active Molecule Activity + N0000008684 + 988099 + C1371692 + C27734 + + Decreased Lipid Derived Immunologically Active Molecule Activity [PE] + + + + + + + + + Decreased Lymphocyte Cell Production + N0000008699 + 990429 + C1371707 + C27764 + + Decreased Lymphocyte Cell Production [PE] + + + + + + + + + Decreased Metabolic Rate + N0000008707 + 989776 + C1371715 + C27780 + + Decreased Metabolic Rate [PE] + + + + + + + + + + + + + + + + + Decreased Organized Electrical Activity + N0000008768 + 987290 + C1371776 + C27902 + + Decreased Organized Electrical Activity [PE] + + + + + + + + + Decreased Ovarian Estrogen Secretion + N0000008769 + 985018 + C1371777 + C27904 + + Decreased Ovarian Estrogen Secretion [PE] + + + + + + + + + + Decreased Parasympathetic Acetylcholine Activity + N0000008779 + 985834 + C1371787 + C27924 + + Decreased Parasympathetic Acetylcholine Activity [PE] + + + + + + + + + Decreased Peripheral Nervous System Acetylcholine Activity + N0000008802 + 985671 + C1371810 + C27970 + + Decreased Peripheral Nervous System Acetylcholine Activity [PE] + + + + + + + + + Decreased Peripheral Nervous System Norepinephrine Activity + N0000008820 + 987038 + C2267202 + C28006 + + Decreased Peripheral Nervous System Norepinephrine Activity [PE] + + + + + + + + + Decreased Prostaglandin Activity + N0000008834 + 984465 + C1371841 + C28034 + + Decreased Prostaglandin Activity [PE] + + + + + + + + + + Decreased Protein Synthesis + N0000008841 + 987293 + C1371848 + C28048 + + Decreased Protein Synthesis [PE] + + + + + + + + + Decreased RNA Replication + N0000008853 + 985312 + C1371860 + C28072 + + Decreased RNA Replication [PE] + + + + + + + + + + + + + + + + + + Decreased Serotonin Activity + N0000008893 + 990122 + C1371900 + C28152 + + Decreased Serotonin Activity [PE] + + + + + + + + + Decreased Serotonin Degradation + N0000008894 + 989582 + C1371901 + C28154 + + Decreased Serotonin Degradation [PE] + + + + + + + + + + + + + + + + + + Decreased T Lymphocyte Production + N0000008998 + 986572 + C1372004 + C28362 + + Decreased T Lymphocyte Production [PE] + + + + + + + + + Decreased Thromboxane Activity + N0000009004 + 986734 + C1372010 + C28374 + + Decreased Thromboxane Activity [PE] + + + + + + + + + Decreased Uterine Smooth Muscle Contraction or Tone + N0000009014 + 987238 + C1372020 + C28394 + + Decreased Uterine Smooth Muscle Contraction or Tone [PE] + + + + + + + + + Digestive/GI System Activity Alteration + N0000009022 + 990045 + C1372028 + C28410 + + Digestive/GI System Activity Alteration [PE] + + + + + + + + + Disorganized Electrical Activity Alteration + N0000009024 + 987926 + C1372030 + C28414 + + Disorganized Electrical Activity Alteration [PE] + + + + + + + + + Dopamine Activity Alteration + N0000009025 + 986437 + C1372031 + C28416 + + Dopamine Activity Alteration [PE] + + + + + + + + + + + + + + + + + + Emesis Suppression + N0000009034 + 987062 + C1372039 + C28434 + + Emesis Suppression [PE] + + + + + + + + + Endocrine Activity Alteration + N0000009036 + 990694 + C1372041 + C28438 + + Endocrine Activity Alteration [PE] + + + + + + + + + Endocytosis Alteration + N0000009037 + 990695 + C1372042 + C28440 + + Endocytosis Alteration [PE] + + + + + + + + + Female Reproductive System Activity Alteration + N0000009044 + 985744 + C1372049 + C28454 + + Female Reproductive System Activity Alteration [PE] + + + + + + + + + GI Motility Alteration + N0000009048 + 990046 + C1372053 + C28462 + + GI Motility Alteration [PE] + + + + + + + + + Generalized Systemic Effects + N0000009057 + 990172 + C1372062 + C28480 + + Generalized Systemic Effects [PE] + + + + + + + + + Hematologic Activity Alteration + N0000009065 + 986633 + C1372069 + C28496 + + Hematologic Activity Alteration [PE] + + + + + + + + + Hematological Cell Destruction Alteration + N0000009066 + 987239 + C1372070 + C28498 + + Hematological Cell Destruction Alteration [PE] + + + + + + + + + Hematological Cell Quantity Alteration + N0000009067 + 989409 + C1372071 + C28500 + + Hematological Cell Quantity Alteration [PE] + + + + + + + + + Hematopoiesis Alteration + N0000009068 + 988943 + C1372072 + C28502 + + Hematopoiesis Alteration [PE] + + + + + + + + + Hemic/Lymphatic Activity Alteration + N0000009069 + 990696 + C1372073 + C28504 + + Hemic/Lymphatic Activity Alteration [PE] + + + + + + + + + Histamine Activity Alteration + N0000009071 + 989587 + C1372075 + C28508 + + Histamine Activity Alteration [PE] + + + + + + + + + Hypothalamic Endocrine Activity Alteration + N0000009072 + 989001 + C1372076 + C28510 + + Hypothalamic Endocrine Activity Alteration [PE] + + + + + + + + + Immunologic Activity Alteration + N0000009073 + 990814 + C1372077 + C28512 + + Immunologic Activity Alteration [PE] + + + + + + + + + Immunologically Active Molecule Activity Alteration + N0000009074 + 985286 + C1372078 + C28514 + + Immunologically Active Molecule Activity Alteration [PE] + + + + + + + + + Immunologically Active Molecule Degradation Alteration + N0000009075 + 989847 + C1372079 + C28516 + + Immunologically Active Molecule Degradation Alteration [PE] + + + + + + + + + Immunologically Active Molecule Production Alteration + N0000009076 + 989133 + C1372080 + C28518 + + Immunologically Active Molecule Production Alteration [PE] + + + + + + + + + Increased Central Nervous System Norepinephrine Activity + N0000009196 + 990469 + C1372200 + C28758 + + Increased Central Nervous System Norepinephrine Activity [PE] + + + + + + + + + Increased Cytokine Activity + N0000009267 + 984447 + C1372271 + C28900 + + Increased Cytokine Activity [PE] + + + + + + + + + Increased Hematological Cell Destruction + N0000009349 + 985291 + C1372350 + C29064 + + Increased Hematological Cell Destruction [PE] + + + + + + + + + + Increased Immunologically Active Molecule Activity + N0000009357 + 989011 + C1372357 + C29080 + + Increased Immunologically Active Molecule Activity [PE] + + + + + + + + + Increased Lymphocyte Cell Destruction + N0000009390 + 985905 + C1372389 + C29146 + + Increased Lymphocyte Cell Destruction [PE] + + + + + + + + + Increased Norepinephrine Activity + N0000009456 + 985294 + C1372455 + C29278 + + Increased Norepinephrine Activity [PE] + + + + + + + + + Increased T Lymphocyte Destruction + N0000009689 + 990657 + C1372687 + C29744 + + Increased T Lymphocyte Destruction [PE] + + + + + + + + + Inhibit Ovarian Follicular Phase + N0000009715 + 985705 + C1372713 + C29796 + + Inhibit Ovarian Follicular Phase [PE] + + + + + + + + + Inhibit Ovulation + N0000009717 + 986227 + C0542129 + C29800 + + Inhibit Ovulation [PE] + + + + + + + + + Large Intestine Fluid/Electrolyte Absorption Alteration + N0000009736 + 986030 + C1372733 + C29838 + + Large Intestine Fluid/Electrolyte Absorption Alteration [PE] + + + + + + + + + Large Intestine Fluid/Electrolyte Alteration + N0000009737 + 988364 + C1372734 + C29840 + + Large Intestine Fluid/Electrolyte Alteration [PE] + + + + + + + + + + + + + + + + + Lysosomal Function Alteration + N0000009741 + 988749 + C1372737 + C29848 + + Lysosomal Function Alteration [PE] + + + + + + + + + Metabolic Activity Alteration + N0000009748 + 990190 + C1372744 + C29862 + + Metabolic Activity Alteration [PE] + + + + + + + + + Metabolic Rate Alteration + N0000009749 + 986653 + C1372745 + C29864 + + Metabolic Rate Alteration [PE] + + + + + + + + + Musculoskeletal Activity Alteration + N0000009755 + 985711 + C1372751 + C29876 + + Musculoskeletal Activity Alteration [PE] + + + + + + + + + + + + + + + + + + + + + + + + + Neurotransmitter & Neuromuscular Transmitter Activity Alteration + N0000009761 + 989639 + C1372757 + C29888 + + Neurotransmitter & Neuromuscular Transmitter Activity Alteration [PE] + + + + + + + + + + + + + + + + + Norepinephrine Activity Alteration + N0000009765 + 985713 + C1372761 + C29896 + + Norepinephrine Activity Alteration [PE] + + + + + + + + + Nucleic Acid Replication Alteration + N0000009766 + 989424 + C1372762 + C29898 + + Nucleic Acid Replication Alteration [PE] + + + + + + + + + Ocular Smooth Muscle Activity Alteration + N0000009768 + 988502 + C1372764 + C29902 + + Ocular Smooth Muscle Activity Alteration [PE] + + + + + + + + + Organ System Specific Effects + N0000009770 + 985923 + C1372766 + C29906 + + Organ System Specific Effects [PE] + + + + + + + + + Organized Electrical Activity Alteration + N0000009774 + 988792 + C1372770 + C29914 + + Organized Electrical Activity Alteration [PE] + + + + + + + + + Ovarian Endocrine Activity Alteration + N0000009777 + 985043 + C1372773 + C29920 + + Ovarian Endocrine Activity Alteration [PE] + + + + + + + + + Ovarian Follicular Phase Alteration + N0000009778 + 986186 + C1372774 + C29922 + + Ovarian Follicular Phase Alteration [PE] + + + + + + + + + Ovarian Function Alteration + N0000009779 + 986398 + C1372775 + C29924 + + Ovarian Function Alteration [PE] + + + + + + + + + Ovulation Alteration + N0000009781 + 990274 + C1372777 + C29928 + + Ovulation Alteration [PE] + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + Pupillary Dilation + N0000009820 + 989596 + C1383072 + C30006 + + Pupillary Dilation [PE] + + + + + + + + + RNA Replication Alteration + N0000009822 + 985505 + C1372853 + C30010 + + RNA Replication Alteration [PE] + + + + + + + + + + + + + + + + + Reproductive System Activity Alteration + N0000009833 + 990488 + C1372864 + C30032 + + Reproductive System Activity Alteration [PE] + + + + + + + + + Respiratory Secretion Alteration + N0000009836 + 984707 + C1372867 + C30038 + + Respiratory Secretion Alteration [PE] + + + + + + + + + Respiratory/Pulmonary Activity Alteration + N0000009839 + 987910 + C1372870 + C30044 + + Respiratory/Pulmonary Activity Alteration [PE] + + + + + + + + + Saliva Production Alteration + N0000009841 + 986450 + C1372872 + C30048 + + Saliva Production Alteration [PE] + + + + + + + + + Salivation Inhibition + N0000009842 + 989642 + C1372873 + C30050 + + Salivation Inhibition [PE] + + + + + + + + + Serotonin Activity Alteration + N0000009844 + 986797 + C1372875 + C30054 + + Serotonin Activity Alteration [PE] + + + + + + + + + Small Intestine Fluid/Electrolyte Absorption Alteration + N0000009845 + 985050 + C1372876 + C30056 + + Small Intestine Fluid/Electrolyte Absorption Alteration [PE] + + + + + + + + + Small Intestine Fluid/Electrolyte Alteration + N0000009846 + 988322 + C1372877 + C30058 + + Small Intestine Fluid/Electrolyte Alteration [PE] + + + + + + + + + Special Sensory Systems Activity Alteration + N0000009851 + 990845 + C1372882 + C30068 + + Special Sensory Systems Activity Alteration [PE] + + + + + + + + + Stimulate Breast Glandular Development + N0000009857 + 985051 + C1372888 + C30080 + + Stimulate Breast Glandular Development [PE] + + + + + + + + + Stimulate Ovulation + N0000009863 + 988583 + C1372894 + C30092 + + Stimulate Ovulation [PE] + + + + + + + + + Stimulate Uterine Secretory Phase + N0000009867 + 986656 + C1372898 + C30100 + + Stimulate Uterine Secretory Phase [PE] + + + + + + + + + Stimulation Large Intestine Fluid/Electrolyte Absorption + N0000009870 + 988965 + C1372901 + C30106 + + Stimulation Large Intestine Fluid/Electrolyte Absorption [PE] + + + + + + + + + Stimulation Small Intestine Fluid/Electrolyte Absorption + N0000009874 + 989426 + C1372905 + C30114 + + Stimulation Small Intestine Fluid/Electrolyte Absorption [PE] + + + + + + + + + Striated Muscle Metabolic Alteration + N0000009876 + 984454 + C2916793 + C30118 + + Striated Muscle Metabolic Alteration [PE] + + + + + + + + + Striated Muscle Anabolism Alteration + N0000009877 + 989427 + C1372908 + C30120 + + Striated Muscle Anabolism Alteration [PE] + + + + + + + + + Translation Alteration + N0000009894 + 984492 + C1372925 + C30154 + + Translation Alteration [PE] + + + + + + + + + Uterine Function Alteration + N0000009897 + 1030550 + C1372928 + C30160 + + Uterine Function Alteration [PE] + + + + + + + + + Uterine Secretory Phase Alteration + N0000009900 + 988125 + C1372931 + C30166 + + Uterine Secretory Phase Alteration [PE] + + + + + + + + + + Uterine Smooth Muscle Contraction or Tone + N0000009901 + 989645 + C1372932 + C30168 + + Uterine Smooth Muscle Contraction or Tone [PE] + + + + + + + + + + + + + + + + + Decreased Cellular Migration + N0000009928 + 989196 + C1372848 + C30224 + + Decreased Cellular Migration [PE] + + + + + + + + + nitazoxanide + M0123653 + C041747 + nitazoxanide + N0000010148 + 31819 + nitazoxanide + 2-(Acetolyloxy)-N-(5-nitro-2-thiazolyl)benzamide + C0068788 + C31486 + + nitazoxanide [Chemical/Ingredient] + + + + + + + + + + + + + + + + + Physiologic States + N0000010197 + 989040 + C2916830 + C31750 + + Physiologic States [Disease/Finding] + + + + + + + + + Demographic States + N0000010198 + 985726 + C2916805 + C31754 + + Demographic States [Disease/Finding] + + + + + + + + + Age Categories + N0000010202 + 989345 + C2916832 + C31762 + + Age Categories [Disease/Finding] + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + Decreased Polymorphonuclear Leukocyte Migration + N0000010246 + 990417 + C1371595 + C31850 + + Decreased Polymorphonuclear Leukocyte Migration [PE] + + + + + + + + + Decreased Fibroblast Migration + N0000010248 + 987533 + C1371593 + C31854 + + Decreased Fibroblast Migration [PE] + + + + + + + + + Vascular Permeability Alteration + N0000010250 + 1025930 + C1371588 + C31858 + + Vascular Permeability Alteration [PE] + + + + + + + + + Decreased Vascular Permeability + N0000010252 + 984932 + C2825069 + C31862 + + Decreased Vascular Permeability [PE] + + + + + + + + + Decreased Capillary Permeability + N0000010253 + 985585 + C0232378 + C31864 + + Decreased Capillary Permeability [PE] + + + + + + + + + + Smooth Muscle Tone Alteration + N0000010268 + 985732 + C1371604 + C31894 + + Smooth Muscle Tone Alteration [PE] + + + + + + + + + + imatinib + M0424454 + C097613 + imatinib + N0000010347 + 282388 + imatinib + C0935989 + C53878 + + imatinib [Chemical/Ingredient] + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + Papillomavirus Infections + M0387084 + D030361 + Neoplasms of the skin and mucous membranes caused by papillomaviruses. They are usually benign but some have a high risk for malignant progression. + Papillomavirus Infections + N0000011003 + 1027658 + C0950124 + C291356 + + Papillomavirus Infections [Disease/Finding] + + + + + + + + + + Carcinoma, Ductal + M0445446 + D044584 + Malignant neoplasms involving the ductal systems of any of a number of organs, such as the MAMMARY GLANDS, the PANCREAS, the PROSTATE, or the LACRIMAL GLAND. + Carcinoma, Ductal + N0000011087 + 1025416 + 82711006 + Ductal Carcinoma + C1176475 + C291440 + + Carcinoma, Ductal [Disease/Finding] + + + + + + + + + Genetic Diseases, Inborn + M0385531 + D030342 + Diseases that are caused by genetic mutations present during embryo or fetal development, although they may be observed later in life. The mutations may be inherited from a parent's genome or they may be acquired in utero. + Genetic Diseases, Inborn + N0000011105 + 1025368 + Inborn Genetic Diseases + C0950123 + C291458 + + Genetic Diseases, Inborn [Disease/Finding] + + + + + + + + + + + + + + + + + Hormones + M0010538 + D006728 + Chemical substances having a specific regulatory effect on the activity of a certain organ or organs. The term was originally applied to substances secreted by various ENDOCRINE GLANDS and transported in the bloodstream to the target organs. It is sometimes extended to include those substances that are not produced by the endocrine glands but that have similar effects. + Hormones + N0000011172 + 5436 + Hormone + C0019932 + C291528 + + Hormones [Chemical/Ingredient] + + + + + + + + + Hormones, Hormone Substitutes, and Hormone Antagonists + M0010540 + D006730 + A collective grouping for both naturally occurring and synthetic hormones, substitutes, and antagonists. + Hormones, Hormone Substitutes, and Hormone Antagonists + N0000011173 + 5438 + Hormones, Substitutes, Antagonists + C0019934 + C291529 + + Hormones, Hormone Substitutes, and Hormone Antagonists [Chemical/Ingredient] + + + + + + + + + Secologanin Tryptamine Alkaloids + M0456000 + D046948 + Compounds formed by condensation of secologanin with tryptamine resulting in a tetrahydro-beta-carboline which is processed further to a number of bioactive compounds. These are especially found in plants of the APOCYNACEAE; LOGANIACEAE; and RUBIACEAE families. + Secologanin Tryptamine Alkaloids + N0000011187 + 469968 + Monoterpenoid Indole Alkaloids + Secologanin Indole Alkaloids + Terpenoid Indole Alkaloids + C1449663 + C291543 + + Secologanin Tryptamine Alkaloids [Chemical/Ingredient] + + + + + + + + + + + + + + + + + + Biological Factors + M0002530 + D001685 + Endogenously-synthesized compounds that may influence biological phenomena or represent quantifiable biomarkers. Biological factors are a variety of extracellular substances that are not otherwise classified under ENZYMES; HORMONES or HORMONE ANTAGONISTS + Biological Factors + N0000011290 + 1570 + Biologic Factors + Biological Factor + Factor, Biologic + Factor, Biological + Factors, Biological + C0005515 + C291646 + + Biological Factors [Chemical/Ingredient] + + + + + + + + + Cytokines + M0024747 + D016207 + Non-antibody proteins secreted by inflammatory leukocytes and some non-leukocytic cells, that act as intercellular mediators. They differ from classical hormones in that they are produced by a number of tissue or cell types rather than by specialized glands. They generally act locally in a paracrine or autocrine rather than endocrine manner. + Cytokines + N0000011291 + 40065 + C0079189 + C291647 + + Cytokines [Chemical/Ingredient] + + + + + + + + + Corpus Luteum Hormones + M0005208 + D003339 + Corpus Luteum Hormones + N0000011299 + 2871 + C0010094 + C291655 + + Corpus Luteum Hormones [Chemical/Ingredient] + + + + + + + + + Gonadal Hormones + M0441053 + D042341 + Hormones produced by the GONADS, including both steroid and peptide hormones. The major steroid hormones include ESTRADIOL and PROGESTERONE from the OVARY, and TESTOSTERONE from the TESTIS. The major peptide hormones include ACTIVINS and INHIBINS. + Gonadal Hormones + N0000011300 + 90006 + C0301819 + C291656 + + Gonadal Hormones [Chemical/Ingredient] + + + + + + + + + Progesterone Congeners + M0447349 + D045167 + Steroidal compounds related to PROGESTERONE, the major mammalian progestational hormone. Progesterone congeners include important progesterone precursors in the biosynthetic pathways, metabolites, derivatives, and synthetic steroids with progestational activities. + Progesterone Congeners + N0000011301 + 382321 + C1257993 + C291657 + + Progesterone Congeners [Chemical/Ingredient] + + + + + + + + + Gonadal Steroid Hormones + M0019744 + D012739 + Steroid hormones produced by the GONADS. They stimulate reproductive organs, germ cell maturation, and the secondary sex characteristics in the males and the females. The major sex steroid hormones include ESTRADIOL; PROGESTERONE; and TESTOSTERONE. + Gonadal Steroid Hormones + N0000011302 + 9730 + Sex Hormones + Sex Steroid Hormones + C0036884 + C291658 + + Gonadal Steroid Hormones [Chemical/Ingredient] + + + + + + + + + Aza Compounds + M0002056 + D001372 + Aza Compounds + N0000011324 + 1249 + C0004471 + C291680 + + Aza Compounds [Chemical/Ingredient] + + + + + + + + + + + + + + + + + + + + + + + + + + + Intercellular Signaling Peptides and Proteins + M0409590 + D036341 + Regulatory proteins and peptides that are signaling molecules involved in the process of PARACRINE COMMUNICATION. They are generally considered factors that are expressed by one cell and are responded to by receptors on another nearby cell. They are distinguished from HORMONES in that their actions are local rather than distal. + Intercellular Signaling Peptides and Proteins + N0000011384 + 337799 + C1136108 + C291740 + + Intercellular Signaling Peptides and Proteins [Chemical/Ingredient] + + + + + + + + + Receptor Tyrosine Kinase Inhibitors + N0000020000 + 987029 + C2267115 + C300385 + + Receptor Tyrosine Kinase Inhibitors [MoA] + + + + + + + + + Tyrosine Kinase Inhibitors + N0000020001 + 1028392 + C2757011 + C300386 + + Tyrosine Kinase Inhibitors [MoA] + + + + + + + + + Vascular Alterations + N0000020002 + 984378 + C2267116 + C300387 + + Vascular Alterations [PE] + + + + + + + + + Bcr-Abl Tyrosine Kinase Inhibitors + N0000020009 + 984994 + Bcr-Abl Tyrosine Kinase Inhibitor + C2267122 + C300394 + + Bcr-Abl Tyrosine Kinase Inhibitors [MoA] + + + + + + + + + Cellular Growth Phase Reduction + N0000020013 + 986120 + C2267126 + C300398 + + Cellular Growth Phase Reduction [PE] + + + + + + + + + 14-alpha Demethylase Inhibitors + N0000020025 + 989952 + C2267137 + C300411 + + 14-alpha Demethylase Inhibitors [MoA] + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + Teicoplanin + M0026325 + D017334 + Glycopeptide antibiotic complex from Actinoplanes teichomyceticus active against gram-positive bacteria. It consists of five major components each with a different fatty acid moiety. + Teicoplanin + N0000170298 + 57021 + Teicoplanin + Teichomycin + C0145106 + C7761627916676 + + Teicoplanin [Chemical/Ingredient] + + + + + + + + + + + + + + + + + + + + + + + + + Renal Insufficiency + M0480487 + D051437 + Conditions in which the KIDNEYS perform below the normal level in the ability to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism. Renal insufficiency can be classified by the degree of kidney damage (as measured by the level of PROTEINURIA) and reduction in GLOMERULAR FILTRATION RATE. + Renal Insufficiency + N0000171642 + 1026620 + Kidney Insufficiency + C1565489 + C7769506319378 + + Renal Insufficiency [Disease/Finding] + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + Protein Kinase Inhibitors + N0000175076 + 993161 + C2757016 + C634438 + + Protein Kinase Inhibitors [MoA] + + + + + + + + + Kinase Inhibitors + N0000175082 + 1025684 + C1152564 + C634444 + + Kinase Inhibitors [MoA] + + + + + + + + + anidulafungin + M0436249 + C102786 + anidulafungin + N0000175344 + 341018 + anidulafungin + C1142738 + C25703935168855 + + anidulafungin [Chemical/Ingredient] + + + + + + + + + Cholinergic Interactions + N0000175368 + 987379 + C2266879 + C634751 + + Cholinergic Interactions [MoA] + + + + + + + + + Cholinergic Antagonists + N0000175370 + 1030384 + C2757022 + C634753 + + Cholinergic Antagonists [MoA] + + + + + + + + + Corticosteroid Hormone Receptor Agonists + N0000175450 + 988660 + C2266939 + C634830 + + Corticosteroid Hormone Receptor Agonists [MoA] + + + + + + + + + Decreased Immunologic Activity + N0000175550 + 989722 + Immune Suppression + Immune System Suppression + Immunologic Suppression + Immunosuppression + C1373218 + C634943 + + Decreased Immunologic Activity [PE] + + + + + + + + + Increased Immunologic Activity + N0000175551 + 990348 + Immune Stimulation + Immune System Stimulation + Immunologic Stimulation + Immunostimulation + C2267003 + C634944 + + Increased Immunologic Activity [PE] + + + + + + + + + Autonomic Nervous System Activity Alteration + N0000175642 + 990764 + C2267060 + C635035 + + Autonomic Nervous System Activity Alteration [PE] + + + + + + + + + Parasympathetic Activity Alteration + N0000175646 + 986849 + C2267064 + C635039 + + Parasympathetic Activity Alteration [PE] + + + + + + + + + Sympathetic Activity Alteration + N0000175647 + 987557 + C2267065 + C635040 + + Sympathetic Activity Alteration [PE] + + + + + + + + + Decreased Parasympathetic Activity + N0000175648 + 984223 + Parasympatholytic Activity + C2267066 + C635041 + + Decreased Parasympathetic Activity [PE] + + + + + + + + + Decreased Sympathetic Activity + N0000175650 + 986974 + Sympatholytic Activity + C2267068 + C635043 + + Decreased Sympathetic Activity [PE] + + + + + + + + + Central Nervous System Activity Alteration + N0000175724 + 991694 + C2917136 + C635130 + + Central Nervous System Activity Alteration [PE] + + + + + + + + + Peripheral Nervous System Activity Alteration + N0000175725 + 992027 + C2917266 + C635131 + + Peripheral Nervous System Activity Alteration [PE] + + + + + + + + + Central Nervous System Depression + N0000175728 + 991695 + C2917137 + C635134 + + Central Nervous System Depression [PE] + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + Blood Pressure Alteration + N0000178476 + 991626 + C2917124 + C637932 + + Blood Pressure Alteration [PE] + + + + + + + + + + + + + + + + + Echinocandins + M0507131 + D054714 + Cyclic hexapeptides of proline-ornithine-threonine-proline-threonine-serine. The cyclization with a single non-peptide bond can lead them to be incorrectly called DEPSIPEPTIDES, but the echinocandins lack ester links. Antifungal activity is via inhibition of 1,3-beta-glucan synthase production of BETA-GLUCANS. + Echinocandins + N0000178715 + 386841 + C1268551 + CMSHM0507131 + + Echinocandins [Chemical/Ingredient] + + + + + + + + + + Azabicyclo Compounds + M0499252 + D053961 + Bicyclic bridged compounds that contain a nitrogen which has three bonds. The nomenclature indicates the number of atoms in each path around the rings, such as [2.2.2] for three equal length paths. Some members are TROPANES and BETA LACTAMS. + Azabicyclo Compounds + N0000178749 + 737880 + C1955840 + CMSHM0499252 + + Azabicyclo Compounds [Chemical/Ingredient] + + + + + + + + + Cetylpyridinium Chloride + M0003974 + D002594 + Cetylpyridinium Chloride + N0000178899 + 2287 + Cetylpyridinium Chloride + C0007907 + CMSHM0003974 + + Cetylpyridinium Chloride [Chemical/Ingredient] + + + + + + + + + 17-alpha-hydroxy-progesterone caproate + M0074009 + C020365 + 17-alpha-hydroxy-progesterone caproate + N0000179012 + 12488 + hydroxyprogesterone caproate (USP) + 17 alpha-hydroxyprogesterone caproate + 17 alpha-hydroxyprogesterone capronate + 17 alpha-oxyprogesterone capronate + 17-((1-oxohexyl)oxy)pregn-4-ene-3,20-dione + 17-hydroxyprogesterone capronate + hydroxyprogesterone caproate + hydroxyprogesterone hexanoate + oxyprogesterone caproate + C0044971 + CMSHM0074009 + + 17-alpha-hydroxy-progesterone caproate [Chemical/Ingredient] + + + + + + + + + Benzatropine Methanesulfonate + M0045522 + D001590 + Benzatropine Methanesulfonate + N0000179048 + 18927 + benztropine mesylate + Benzatropine Mesylate + Benztropine Mesylate + C0053156 + CMSHM0045522 + + Benzatropine Methanesulfonate [Chemical/Ingredient] + + + + + + + + + chloroquine diphosphate + M0081184 + C023676 + chloroquine diphosphate + N0000179079 + 20863 + chloroquine phosphate + N(4)-(7-chloro-4-quinolinyl)-N(1),N(1)-diethyl-1,4-pentanediamine, phosphate (1:2) + arechin + chingamin phosphate + chloroquine phosphate + delagil + khingamin phosphate + unspecified phosphate of chloroquine diphosphate + C0055447 + CMSHM0081184 + + chloroquine diphosphate [Chemical/Ingredient] + + + + + + + + + Tamoxifen Citrate + M0373246 + D013629 + Tamoxifen Citrate + N0000179289 + 40137 + Tamoxifen Citrate + C0079589 + CMSHM0373246 + + Tamoxifen Citrate [Chemical/Ingredient] + + + + + + + + + Toremifene Citrate + M0026288 + D017312 + Toremifene Citrate + N0000179327 + 49953 + Toremifene Citrate + Toremifene Citrate (1:1) + C0117339 + CMSHM0026288 + + Toremifene Citrate [Chemical/Ingredient] + + + + + + + + + Thiethylperazine Malate + M0021337 + D013847 + Thiethylperazine Malate + N0000179374 + 71529 + Thiethylperazine Malate + C0242518 + CMSHM0021337 + + Thiethylperazine Malate [Chemical/Ingredient] + + + + + + + + + Clomipramine Hydrochloride + M0004600 + D002997 + Clomipramine Hydrochloride + N0000179401 + 81984 + Clomipramine Hydrochloride + C0282107 + CMSHM0004600 + + Clomipramine Hydrochloride [Chemical/Ingredient] + + + + + + + + + Chlorpromazine Hydrochloride + M0363614 + D002746 + Chlorpromazine Hydrochloride + N0000179496 + 104728 + Chlorpromazine hydrochloride + C0355077 + CMSHM0363614 + + Chlorpromazine Hydrochloride [Chemical/Ingredient] + + + + + + + + + Hydroxychloroquine Sulfate + M0330264 + D006886 + Hydroxychloroquine Sulfate + N0000179552 + 153972 + Hydroxychloroquine Sulfate + Hydroxychloroquine Sulfate (1:1) Salt + C0596007 + CMSHM0330264 + + Hydroxychloroquine Sulfate [Chemical/Ingredient] + + + + + + + + + lopinavir + M0406972 + C112035 + lopinavir + N0000179581 + 195088 + lopinavir + N-(4-(((2,6-dimethylphenoxy)acetyl)amino)-3-hydroxy-5-phenyl-1-(phenylmethyl)pentyl)tetrahydro-alpha-(1-methylethyl)-2-oxo-1(2H)-pydrimidineacetamide + C0674432 + CMSHM0406972 + + lopinavir [Chemical/Ingredient] + + + + + + + + + Fluphenazine Hydrochloride + M0354107 + D005476 + Fluphenazine Hydrochloride + N0000179649 + 203207 + Fluphenazine Hydrochloride + C0700567 + CMSHM0354107 + + Fluphenazine Hydrochloride [Chemical/Ingredient] + + + + + + + + + Nelfinavir Mesylate + M0329047 + D019888 + Nelfinavir Mesylate + N0000179715 + 266565 + Nelfinavir Mesylate + Nelfinavir Monomethane Sulfonate + C0886530 + CMSHM0329047 + + Nelfinavir Mesylate [Chemical/Ingredient] + + + + + + + + + ciclesonide + M0332803 + C120481 + ciclesonide + N0000179737 + 274964 + ciclesonide + (R)-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with cyclohexanecarboxaldehyde, 21-isobutyrate + C0907850 + CMSHM0332803 + + ciclesonide [Chemical/Ingredient] + + + + + + + + + dalbavancin + M0443425 + C469289 + dalbavancin + N0000179772 + 354674 + C1172636 + CMSHM0443425 + + dalbavancin [Chemical/Ingredient] + + + + + + + + + + dasatinib + M0470497 + C488369 + dasatinib + N0000179780 + 475342 + dasatinib + N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide + C1455147 + CMSHM0470497 + + dasatinib [Chemical/Ingredient] + + + + + + + + + + + eltrombopag + M0511065 + C520809 + eltrombopag + N0000179799 + 711942 + eltrombopag + C1831905 + CMSHM0511065 + + eltrombopag [Chemical/Ingredient] + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + Leukoencephalopathies + M0529130 + D056784 + Any of various diseases affecting the white matter of the central nervous system. + Leukoencephalopathies + N0000181110 + 1023470 + Leukoencephalopathy + White Matter Diseases + C0270612 + CMSHM0529130 + + Leukoencephalopathies [Disease/Finding] + + + + + + + + + + Cardiovascular Infections + M0496690 + D053821 + Pathological conditions of the CARDIOVASCULAR SYSTEM caused by infections. + Cardiovascular Infections + N0000181166 + 1021827 + Infections, Cardiovascular + C0596270 + CMSHM0496690 + + Cardiovascular Infections [Disease/Finding] + + + + + + + + + Female Urogenital Diseases + M0489295 + D052776 + Pathological processes of the female URINARY TRACT and the reproductive system (GENITALIA, FEMALE). + Female Urogenital Diseases + N0000181236 + 1024696 + Female Genitourinary Diseases + C1720887 + CMSHM0489295 + + Female Urogenital Diseases [Disease/Finding] + + + + + + + + + Neoplasms, Plasma Cell + M0502872 + D054219 + Neoplasms associated with a proliferation of a single clone of PLASMA CELLS and characterized by the secretion of PARAPROTEINS. + Neoplasms, Plasma Cell + N0000181264 + 1005768 + Plasma Cell Neoplasms + C1959632 + CMSHM0502872 + + Neoplasms, Plasma Cell [Disease/Finding] + + + + + + + + + Proteostasis Deficiencies + M0534903 + D057165 + Disorders caused by imbalances in the protein homeostasis network - synthesis, folding, and transport of proteins; post-translational modifications; and degradation or clearance of misfolded proteins. + Proteostasis Deficiencies + N0000181302 + 1002154 + Proteostasis Dysfunctions + C2718000 + CMSHM0534903 + + Proteostasis Deficiencies [Disease/Finding] + + + + + + + + + entity + Entity + entity + Julius Caesar + Verdi’s Requiem + the Second World War + your body mass index + BFO 2 Reference: In all areas of empirical inquiry we encounter general terms of two sorts. First are general terms which refer to universals or types:animaltuberculosissurgical procedurediseaseSecond, are general terms used to refer to groups of entities which instantiate a given universal but do not correspond to the extension of any subuniversal of that universal because there is nothing intrinsic to the entities in question by virtue of which they – and only they – are counted as belonging to the given group. Examples are: animal purchased by the Emperortuberculosis diagnosed on a Wednesdaysurgical procedure performed on a patient from Stockholmperson identified as candidate for clinical trial #2056-555person who is signatory of Form 656-PPVpainting by Leonardo da VinciSuch terms, which represent what are called ‘specializations’ in [81 + Entity doesn't have a closure axiom because the subclasses don't necessarily exhaust all possibilites. For example Werner Ceusters 'portions of reality' include 4 sorts, entities (as BFO construes them), universals, configurations, and relations. It is an open question as to whether entities as construed in BFO will at some point also include these other portions of reality. See, for example, 'How to track absolutely everything' at http://www.referent-tracking.com/_RTU/papers/CeustersICbookRevised.pdf + + + + + + + + + + + + + + + + + + An entity is anything that exists or has existed or will exist. (axiom label in BFO2 Reference: [001-001]) + + entity + entity + + + + + + + + + continuant + Continuant + continuant + An entity that exists in full at any time in which it exists at all, persists through time while maintaining its identity and has no temporal parts. + An entity that exists in full at any time in which it exists at all, persists through time while maintaining its identity and has no temporal parts. + BFO 2 Reference: Continuant entities are entities which can be sliced to yield parts only along the spatial dimension, yielding for example the parts of your table which we call its legs, its top, its nails. ‘My desk stretches from the window to the door. It has spatial parts, and can be sliced (in space) in two. With respect to time, however, a thing is a continuant.’ [60, p. 240 + Continuant doesn't have a closure axiom because the subclasses don't necessarily exhaust all possibilites. For example, in an expansion involving bringing in some of Ceuster's other portions of reality, questions are raised as to whether universals are continuants + + + + + + + + + + + + + + + + + A continuant is an entity that persists, endures, or continues to exist through time while maintaining its identity. (axiom label in BFO2 Reference: [008-002]) + if b is a continuant and if, for some t, c has_continuant_part b at t, then c is a continuant. (axiom label in BFO2 Reference: [126-001]) + if b is a continuant and if, for some t, cis continuant_part of b at t, then c is a continuant. (axiom label in BFO2 Reference: [009-002]) + if b is a material entity, then there is some temporal interval (referred to below as a one-dimensional temporal region) during which b exists. (axiom label in BFO2 Reference: [011-002]) + (forall (x y) (if (and (Continuant x) (exists (t) (continuantPartOfAt y x t))) (Continuant y))) // axiom label in BFO2 CLIF: [009-002] + (forall (x y) (if (and (Continuant x) (exists (t) (hasContinuantPartOfAt y x t))) (Continuant y))) // axiom label in BFO2 CLIF: [126-001] + (forall (x) (if (Continuant x) (Entity x))) // axiom label in BFO2 CLIF: [008-002] + (forall (x) (if (Material Entity x) (exists (t) (and (TemporalRegion t) (existsAt x t))))) // axiom label in BFO2 CLIF: [011-002] + + continuant + continuant + + + + + + + + + occurrent + Occurrent + occurrent + An entity that has temporal parts and that happens, unfolds or develops through time. + BFO 2 Reference: every occurrent that is not a temporal or spatiotemporal region is s-dependent on some independent continuant that is not a spatial region + BFO 2 Reference: s-dependence obtains between every process and its participants in the sense that, as a matter of necessity, this process could not have existed unless these or those participants existed also. A process may have a succession of participants at different phases of its unfolding. Thus there may be different players on the field at different times during the course of a football game; but the process which is the entire game s-depends_on all of these players nonetheless. Some temporal parts of this process will s-depend_on on only some of the players. + Occurrent doesn't have a closure axiom because the subclasses don't necessarily exhaust all possibilites. An example would be the sum of a process and the process boundary of another process. + Simons uses different terminology for relations of occurrents to regions: Denote the spatio-temporal location of a given occurrent e by 'spn[e]' and call this region its span. We may say an occurrent is at its span, in any larger region, and covers any smaller region. Now suppose we have fixed a frame of reference so that we can speak not merely of spatio-temporal but also of spatial regions (places) and temporal regions (times). The spread of an occurrent, (relative to a frame of reference) is the space it exactly occupies, and its spell is likewise the time it exactly occupies. We write 'spr[e]' and `spl[e]' respectively for the spread and spell of e, omitting mention of the frame. + + + + + + + + + + + + + + + + + + An occurrent is an entity that unfolds itself in time or it is the instantaneous boundary of such an entity (for example a beginning or an ending) or it is a temporal or spatiotemporal region which such an entity occupies_temporal_region or occupies_spatiotemporal_region. (axiom label in BFO2 Reference: [077-002]) + Every occurrent occupies_spatiotemporal_region some spatiotemporal region. (axiom label in BFO2 Reference: [108-001]) + b is an occurrent entity iff b is an entity that has temporal parts. (axiom label in BFO2 Reference: [079-001]) + (forall (x) (if (Occurrent x) (exists (r) (and (SpatioTemporalRegion r) (occupiesSpatioTemporalRegion x r))))) // axiom label in BFO2 CLIF: [108-001] + (forall (x) (iff (Occurrent x) (and (Entity x) (exists (y) (temporalPartOf y x))))) // axiom label in BFO2 CLIF: [079-001] + + occurrent + + + + + + + + + ic + IndependentContinuant + a chair + a heart + a leg + a molecule + a spatial region + an atom + an orchestra. + an organism + the bottom right portion of a human torso + the interior of your mouth + A continuant that is a bearer of quality and realizable entity entities, in which other entities inhere and which itself cannot inhere in anything. + b is an independent continuant = Def. b is a continuant which is such that there is no c and no t such that b s-depends_on c at t. (axiom label in BFO2 Reference: [017-002]) + + + + + + + + + + + For any independent continuant b and any time t there is some spatial region r such that b is located_in r at t. (axiom label in BFO2 Reference: [134-001]) + For every independent continuant b and time t during the region of time spanned by its life, there are entities which s-depends_on b during t. (axiom label in BFO2 Reference: [018-002]) + (forall (x t) (if (IndependentContinuant x) (exists (r) (and (SpatialRegion r) (locatedInAt x r t))))) // axiom label in BFO2 CLIF: [134-001] + (forall (x t) (if (and (IndependentContinuant x) (existsAt x t)) (exists (y) (and (Entity y) (specificallyDependsOnAt y x t))))) // axiom label in BFO2 CLIF: [018-002] + (iff (IndependentContinuant a) (and (Continuant a) (not (exists (b t) (specificallyDependsOnAt a b t))))) // axiom label in BFO2 CLIF: [017-002] + + independent continuant + + + + + + + + + process + Process + process + a process of cell-division, \ a beating of the heart + a process of meiosis + a process of sleeping + the course of a disease + the flight of a bird + the life of an organism + your process of aging. + An occurrent that has temporal proper parts and for some time t, p s-depends_on some material entity at t. + p is a process = Def. p is an occurrent that has temporal proper parts and for some time t, p s-depends_on some material entity at t. (axiom label in BFO2 Reference: [083-003]) + BFO 2 Reference: The realm of occurrents is less pervasively marked by the presence of natural units than is the case in the realm of independent continuants. Thus there is here no counterpart of ‘object’. In BFO 1.0 ‘process’ served as such a counterpart. In BFO 2.0 ‘process’ is, rather, the occurrent counterpart of ‘material entity’. Those natural – as contrasted with engineered, which here means: deliberately executed – units which do exist in the realm of occurrents are typically either parasitic on the existence of natural units on the continuant side, or they are fiat in nature. Thus we can count lives; we can count football games; we can count chemical reactions performed in experiments or in chemical manufacturing. We cannot count the processes taking place, for instance, in an episode of insect mating behavior.Even where natural units are identifiable, for example cycles in a cyclical process such as the beating of a heart or an organism’s sleep/wake cycle, the processes in question form a sequence with no discontinuities (temporal gaps) of the sort that we find for instance where billiard balls or zebrafish or planets are separated by clear spatial gaps. Lives of organisms are process units, but they too unfold in a continuous series from other, prior processes such as fertilization, and they unfold in turn in continuous series of post-life processes such as post-mortem decay. Clear examples of boundaries of processes are almost always of the fiat sort (midnight, a time of death as declared in an operating theater or on a death certificate, the initiation of a state of war) + + + + + + + + + + + + + + + + + + + (iff (Process a) (and (Occurrent a) (exists (b) (properTemporalPartOf b a)) (exists (c t) (and (MaterialEntity c) (specificallyDependsOnAt a c t))))) // axiom label in BFO2 CLIF: [083-003] + bfo + BFO:0000015 + + process + process + + + + + + + + + disposition + Disposition + disposition + an atom of element X has the disposition to decay to an atom of element Y + certain people have a predisposition to colon cancer + children are innately disposed to categorize objects in certain ways. + the cell wall is disposed to filter chemicals in endocytosis and exocytosis + BFO 2 Reference: Dispositions exist along a strength continuum. Weaker forms of disposition are realized in only a fraction of triggering cases. These forms occur in a significant number of cases of a similar type. + + + + + + + + b is a disposition means: b is a realizable entity & b’s bearer is some material entity & b is such that if it ceases to exist, then its bearer is physically changed, & b’s realization occurs when and because this bearer is in some special physical circumstances, & this realization occurs in virtue of the bearer’s physical make-up. (axiom label in BFO2 Reference: [062-002]) + If b is a realizable entity then for all t at which b exists, b s-depends_on some material entity at t. (axiom label in BFO2 Reference: [063-002]) + (forall (x t) (if (and (RealizableEntity x) (existsAt x t)) (exists (y) (and (MaterialEntity y) (specificallyDepends x y t))))) // axiom label in BFO2 CLIF: [063-002] + (forall (x) (if (Disposition x) (and (RealizableEntity x) (exists (y) (and (MaterialEntity y) (bearerOfAt x y t)))))) // axiom label in BFO2 CLIF: [062-002] + + disposition + + + + + + + + + realizable + RealizableEntity + realizable entity + the disposition of this piece of metal to conduct electricity. + the disposition of your blood to coagulate + the function of your reproductive organs + the role of being a doctor + the role of this boundary to delineate where Utah and Colorado meet + A specifically dependent continuant that inheres in continuant entities and are not exhibited in full at every time in which it inheres in an entity or group of entities. The exhibition or actualization of a realizable entity is a particular manifestation, functioning or process that occurs under certain circumstances. + + + + + + + + To say that b is a realizable entity is to say that b is a specifically dependent continuant that inheres in some independent continuant which is not a spatial region and is of a type instances of which are realized in processes of a correlated type. (axiom label in BFO2 Reference: [058-002]) + All realizable dependent continuants have independent continuants that are not spatial regions as their bearers. (axiom label in BFO2 Reference: [060-002]) + (forall (x t) (if (RealizableEntity x) (exists (y) (and (IndependentContinuant y) (not (SpatialRegion y)) (bearerOfAt y x t))))) // axiom label in BFO2 CLIF: [060-002] + (forall (x) (if (RealizableEntity x) (and (SpecificallyDependentContinuant x) (exists (y) (and (IndependentContinuant y) (not (SpatialRegion y)) (inheresIn x y)))))) // axiom label in BFO2 CLIF: [058-002] + + realizable entity + + + + + + + + + quality + Quality + the ambient temperature of this portion of air + the color of a tomato + the length of the circumference of your waist + the mass of this piece of gold. + the shape of your nose + the shape of your nostril + + + + + + + + + a quality is a specifically dependent continuant that, in contrast to roles and dispositions, does not require any further process in order to be realized. (axiom label in BFO2 Reference: [055-001]) + If an entity is a quality at any time that it exists, then it is a quality at every time that it exists. (axiom label in BFO2 Reference: [105-001]) + (forall (x) (if (Quality x) (SpecificallyDependentContinuant x))) // axiom label in BFO2 CLIF: [055-001] + (forall (x) (if (exists (t) (and (existsAt x t) (Quality x))) (forall (t_1) (if (existsAt x t_1) (Quality x))))) // axiom label in BFO2 CLIF: [105-001] + bfo + BFO:0000019 + + quality + quality + + + + + + + + + sdc + SpecificallyDependentContinuant + specifically dependent continuant + Reciprocal specifically dependent continuants: the function of this key to open this lock and the mutually dependent disposition of this lock: to be opened by this key + of one-sided specifically dependent continuants: the mass of this tomato + of relational dependent continuants (multiple bearers): John’s love for Mary, the ownership relation between John and this statue, the relation of authority between John and his subordinates. + the disposition of this fish to decay + the function of this heart: to pump blood + the mutual dependence of proton donors and acceptors in chemical reactions [79 + the mutual dependence of the role predator and the role prey as played by two organisms in a given interaction + the pink color of a medium rare piece of grilled filet mignon at its center + the role of being a doctor + the shape of this hole. + the smell of this portion of mozzarella + A continuant that inheres in or is borne by other entities. Every instance of A requires some specific instance of B which must always be the same. + A continuant that inheres in or is borne by other entities. Every instance of A requires some specific instance of B which must always be the same. + b is a relational specifically dependent continuant = Def. b is a specifically dependent continuant and there are n &gt; 1 independent continuants c1, … cn which are not spatial regions are such that for all 1 i &lt; j n, ci and cj share no common parts, are such that for each 1 i n, b s-depends_on ci at every time t during the course of b’s existence (axiom label in BFO2 Reference: [131-004]) + b is a specifically dependent continuant = Def. b is a continuant & there is some independent continuant c which is not a spatial region and which is such that b s-depends_on c at every time t during the course of b’s existence. (axiom label in BFO2 Reference: [050-003]) + Specifically dependent continuant doesn't have a closure axiom because the subclasses don't necessarily exhaust all possibilites. We're not sure what else will develop here, but for example there are questions such as what are promises, obligation, etc. + + + + + + + + + + (iff (RelationalSpecificallyDependentContinuant a) (and (SpecificallyDependentContinuant a) (forall (t) (exists (b c) (and (not (SpatialRegion b)) (not (SpatialRegion c)) (not (= b c)) (not (exists (d) (and (continuantPartOfAt d b t) (continuantPartOfAt d c t)))) (specificallyDependsOnAt a b t) (specificallyDependsOnAt a c t)))))) // axiom label in BFO2 CLIF: [131-004] + (iff (SpecificallyDependentContinuant a) (and (Continuant a) (forall (t) (if (existsAt a t) (exists (b) (and (IndependentContinuant b) (not (SpatialRegion b)) (specificallyDependsOnAt a b t))))))) // axiom label in BFO2 CLIF: [050-003] + + specifically dependent continuant + + + + + + + + + role + Role + John’s role of husband to Mary is dependent on Mary’s role of wife to John, and both are dependent on the object aggregate comprising John and Mary as member parts joined together through the relational quality of being married. + the priest role + the role of a boundary to demarcate two neighboring administrative territories + the role of a building in serving as a military target + the role of a stone in marking a property boundary + the role of subject in a clinical trial + the student role + A realizable entity the manifestation of which brings about some result or end that is not essential to a continuant in virtue of the kind of thing that it is but that can be served or participated in by that kind of continuant in some kinds of natural, social or institutional contexts. + BFO 2 Reference: One major family of examples of non-rigid universals involves roles, and ontologies developed for corresponding administrative purposes may consist entirely of representatives of entities of this sort. Thus ‘professor’, defined as follows,b instance_of professor at t =Def. there is some c, c instance_of professor role & c inheres_in b at t.denotes a non-rigid universal and so also do ‘nurse’, ‘student’, ‘colonel’, ‘taxpayer’, and so forth. (These terms are all, in the jargon of philosophy, phase sortals.) By using role terms in definitions, we can create a BFO conformant treatment of such entities drawing on the fact that, while an instance of professor may be simultaneously an instance of trade union member, no instance of the type professor role is also (at any time) an instance of the type trade union member role (any more than any instance of the type color is at any time an instance of the type length).If an ontology of employment positions should be defined in terms of roles following the above pattern, this enables the ontology to do justice to the fact that individuals instantiate the corresponding universals – professor, sergeant, nurse – only during certain phases in their lives. + + + + + + b is a role means: b is a realizable entity & b exists because there is some single bearer that is in some special physical, social, or institutional set of circumstances in which this bearer does not have to be& b is not such that, if it ceases to exist, then the physical make-up of the bearer is thereby changed. (axiom label in BFO2 Reference: [061-001]) + (forall (x) (if (Role x) (RealizableEntity x))) // axiom label in BFO2 CLIF: [061-001] + + role + + + + + + + + + + bfo + BFO:0000024 + fiat object part + + + + + + + + + object-aggregate + ObjectAggregate + a collection of cells in a blood biobank. + a swarm of bees is an aggregate of members who are linked together through natural bonds + a symphony orchestra + an organization is an aggregate whose member parts have roles of specific types (for example in a jazz band, a chess club, a football team) + defined by fiat: the aggregate of members of an organization + defined through physical attachment: the aggregate of atoms in a lump of granite + defined through physical containment: the aggregate of molecules of carbon dioxide in a sealed container + defined via attributive delimitations such as: the patients in this hospital + the aggregate of bearings in a constant velocity axle joint + the aggregate of blood cells in your body + the nitrogen atoms in the atmosphere + the restaurants in Palo Alto + your collection of Meissen ceramic plates. + An entity a is an object aggregate if and only if there is a mutually exhaustive and pairwise disjoint partition of a into objects + BFO 2 Reference: object aggregates may gain and lose parts while remaining numerically identical (one and the same individual) over time. This holds both for aggregates whose membership is determined naturally (the aggregate of cells in your body) and aggregates determined by fiat (a baseball team, a congressional committee). + ISBN:978-3-938793-98-5pp124-158#Thomas Bittner and Barry Smith, 'A Theory of Granular Partitions', in K. Munn and B. Smith (eds.), Applied Ontology: An Introduction, Frankfurt/Lancaster: ontos, 2008, 125-158. + + + b is an object aggregate means: b is a material entity consisting exactly of a plurality of objects as member_parts at all times at which b exists. (axiom label in BFO2 Reference: [025-004]) + (forall (x) (if (ObjectAggregate x) (and (MaterialEntity x) (forall (t) (if (existsAt x t) (exists (y z) (and (Object y) (Object z) (memberPartOfAt y x t) (memberPartOfAt z x t) (not (= y z)))))) (not (exists (w t_1) (and (memberPartOfAt w x t_1) (not (Object w)))))))) // axiom label in BFO2 CLIF: [025-004] + + object aggregate + + + + + + + + + object + Object + atom + cell + cells and organisms + engineered artifacts + grain of sand + molecule + organelle + organism + planet + solid portions of matter + star + BFO 2 Reference: BFO rests on the presupposition that at multiple micro-, meso- and macroscopic scales reality exhibits certain stable, spatially separated or separable material units, combined or combinable into aggregates of various sorts (for example organisms into what are called ‘populations’). Such units play a central role in almost all domains of natural science from particle physics to cosmology. Many scientific laws govern the units in question, employing general terms (such as ‘molecule’ or ‘planet’) referring to the types and subtypes of units, and also to the types and subtypes of the processes through which such units develop and interact. The division of reality into such natural units is at the heart of biological science, as also is the fact that these units may form higher-level units (as cells form multicellular organisms) and that they may also form aggregates of units, for example as cells form portions of tissue and organs form families, herds, breeds, species, and so on. At the same time, the division of certain portions of reality into engineered units (manufactured artifacts) is the basis of modern industrial technology, which rests on the distributed mass production of engineered parts through division of labor and on their assembly into larger, compound units such as cars and laptops. The division of portions of reality into units is one starting point for the phenomenon of counting. + BFO 2 Reference: Each object is such that there are entities of which we can assert unproblematically that they lie in its interior, and other entities of which we can assert unproblematically that they lie in its exterior. This may not be so for entities lying at or near the boundary between the interior and exterior. This means that two objects – for example the two cells depicted in Figure 3 – may be such that there are material entities crossing their boundaries which belong determinately to neither cell. Something similar obtains in certain cases of conjoined twins (see below). + BFO 2 Reference: To say that b is causally unified means: b is a material entity which is such that its material parts are tied together in such a way that, in environments typical for entities of the type in question,if c, a continuant part of b that is in the interior of b at t, is larger than a certain threshold size (which will be determined differently from case to case, depending on factors such as porosity of external cover) and is moved in space to be at t at a location on the exterior of the spatial region that had been occupied by b at t, then either b’s other parts will be moved in coordinated fashion or b will be damaged (be affected, for example, by breakage or tearing) in the interval between t and t.causal changes in one part of b can have consequences for other parts of b without the mediation of any entity that lies on the exterior of b. Material entities with no proper material parts would satisfy these conditions trivially. Candidate examples of types of causal unity for material entities of more complex sorts are as follows (this is not intended to be an exhaustive list):CU1: Causal unity via physical coveringHere the parts in the interior of the unified entity are combined together causally through a common membrane or other physical covering\. The latter points outwards toward and may serve a protective function in relation to what lies on the exterior of the entity [13, 47 + BFO 2 Reference: an object is a maximal causally unified material entity + BFO 2 Reference: ‘objects’ are sometimes referred to as ‘grains’ [74 + + + b is an object means: b is a material entity which manifests causal unity of one or other of the types CUn listed above & is of a type (a material universal) instances of which are maximal relative to this criterion of causal unity. (axiom label in BFO2 Reference: [024-001]) + bfo + BFO:0000030 + + object + object + + + + + + + + + gdc + GenericallyDependentContinuant + generically dependent continuant + The entries in your database are patterns instantiated as quality instances in your hard drive. The database itself is an aggregate of such patterns. When you create the database you create a particular instance of the generically dependent continuant type database. Each entry in the database is an instance of the generically dependent continuant type IAO: information content entity. + the pdf file on your laptop, the pdf file that is a copy thereof on my laptop + the sequence of this protein molecule; the sequence that is a copy thereof in that protein molecule. + A continuant that is dependent on one or other independent continuant bearers. For every instance of A requires some instance of (an independent continuant type) B but which instance of B serves can change from time to time. + b is a generically dependent continuant = Def. b is a continuant that g-depends_on one or more other entities. (axiom label in BFO2 Reference: [074-001]) + + + + + + + + + + + (iff (GenericallyDependentContinuant a) (and (Continuant a) (exists (b t) (genericallyDependsOnAt a b t)))) // axiom label in BFO2 CLIF: [074-001] + + generically dependent continuant + + + + + + + + + function + Function + the function of a hammer to drive in nails + the function of a heart pacemaker to regulate the beating of a heart through electricity + the function of amylase in saliva to break down starch into sugar + BFO 2 Reference: In the past, we have distinguished two varieties of function, artifactual function and biological function. These are not asserted subtypes of BFO:function however, since the same function – for example: to pump, to transport – can exist both in artifacts and in biological entities. The asserted subtypes of function that would be needed in order to yield a separate monoheirarchy are not artifactual function, biological function, etc., but rather transporting function, pumping function, etc. + + + + A function is a disposition that exists in virtue of the bearer’s physical make-up and this physical make-up is something the bearer possesses because it came into being, either through evolution (in the case of natural biological entities) or through intentional design (in the case of artifacts), in order to realize processes of a certain sort. (axiom label in BFO2 Reference: [064-001]) + (forall (x) (if (Function x) (Disposition x))) // axiom label in BFO2 CLIF: [064-001] + + function + + + + + + + + + material + MaterialEntity + a flame + a forest fire + a human being + a hurricane + a photon + a puff of smoke + a sea wave + a tornado + an aggregate of human beings. + an energy wave + an epidemic + the undetached arm of a human being + An independent continuant that is spatially extended whose identity is independent of that of other entities and can be maintained through time. + BFO 2 Reference: Material entities (continuants) can preserve their identity even while gaining and losing material parts. Continuants are contrasted with occurrents, which unfold themselves in successive temporal parts or phases [60 + BFO 2 Reference: Object, Fiat Object Part and Object Aggregate are not intended to be exhaustive of Material Entity. Users are invited to propose new subcategories of Material Entity. + BFO 2 Reference: ‘Matter’ is intended to encompass both mass and energy (we will address the ontological treatment of portions of energy in a later version of BFO). A portion of matter is anything that includes elementary particles among its proper or improper parts: quarks and leptons, including electrons, as the smallest particles thus far discovered; baryons (including protons and neutrons) at a higher level of granularity; atoms and molecules at still higher levels, forming the cells, organs, organisms and other material entities studied by biologists, the portions of rock studied by geologists, the fossils studied by paleontologists, and so on.Material entities are three-dimensional entities (entities extended in three spatial dimensions), as contrasted with the processes in which they participate, which are four-dimensional entities (entities extended also along the dimension of time).According to the FMA, material entities may have immaterial entities as parts – including the entities identified below as sites; for example the interior (or ‘lumen’) of your small intestine is a part of your body. BFO 2.0 embodies a decision to follow the FMA here. + + + + + + + + + + + A material entity is an independent continuant that has some portion of matter as proper or improper continuant part. (axiom label in BFO2 Reference: [019-002]) + Every entity which has a material entity as continuant part is a material entity. (axiom label in BFO2 Reference: [020-002]) + every entity of which a material entity is continuant part is also a material entity. (axiom label in BFO2 Reference: [021-002]) + (forall (x) (if (MaterialEntity x) (IndependentContinuant x))) // axiom label in BFO2 CLIF: [019-002] + (forall (x) (if (and (Entity x) (exists (y t) (and (MaterialEntity y) (continuantPartOfAt x y t)))) (MaterialEntity x))) // axiom label in BFO2 CLIF: [021-002] + (forall (x) (if (and (Entity x) (exists (y t) (and (MaterialEntity y) (continuantPartOfAt y x t)))) (MaterialEntity x))) // axiom label in BFO2 CLIF: [020-002] + bfo + BFO:0000040 + + material entity + material entity + + + + + + + + + + + + + + + + + + + + + + + + An L-leucine derivative that is the amide obtained by formal condensation of the carboxy group of (2S,3S)-3-(ethoxycarbonyl)oxirane-2-carboxylic acid with the amino group of N-(3-methylbutyl)-L-leucinamide. + + 0 + C17H30N2O5 + InChI=1S/C17H30N2O5/c1-6-23-17(22)14-13(24-14)16(21)19-12(9-11(4)5)15(20)18-8-7-10(2)3/h10-14H,6-9H2,1-5H3,(H,18,20)(H,19,21)/t12-,13-,14-/m0/s1 + SRVFFFJZQVENJC-IHRRRGAJSA-N + 342.431 + 342.21547 + O1[C@@H]([C@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C)C(=O)OCC + Beilstein:5354546 + CAS:88321-09-9 + PMID:26388830 + Reaxys:5354546 + ethyl (2S,3S)-3-({(2S)-4-methyl-1-[(3-methylbutyl)amino]-1-oxopentan-2-yl}carbamoyl)oxirane-2-carboxylate + chebi_ontology + E 64d + E-64d + E64d + Ethyl (+)-(2S,3S)-2,3-epoxy-N-((S)-1-(isopentylcarbamoyl)-3-methylbutyl)succinamate + Loxistatin + aloxistatin + aloxistatina + aloxistatine + aloxistatinum + CHEBI:101381 + + aloxistatin + + + + + + + + + Elementary particle not affected by the strong force having a spin 1/2, a negative elementary charge and a rest mass of 0.000548579903(13) u, or 0.51099906(15) MeV. + + -1 + 0.000548579903 + 0.0 + KEGG:C05359 + PMID:21614077 + Wikipedia:Electron + electron + chebi_ontology + Elektron + beta + beta(-) + beta-particle + e + e(-) + e- + negatron + CHEBI:10545 + + electron + + + + + + + + + An EC 2.1.1.* (methyltransferases) inhibitor that interferes with the action of histamine N-methyltransferase (EC 2.1.1.8). + + chebi_ontology + EC 2.1.1.8 (histamine N-methyltransferase) inhibitors + EC 2.1.1.8 inhibitor + EC 2.1.1.8 inhibitors + S-adenosyl-L-methionine:histamine N-tele-methyltransferase inhibitor + S-adenosyl-L-methionine:histamine N-tele-methyltransferase inhibitors + S-adenosylmethionine-histamine N-methyltransferase inhibitor + S-adenosylmethionine-histamine N-methyltransferase inhibitors + histamine 1-methyltransferase inhibitor + histamine 1-methyltransferase inhibitors + histamine methyltransferase inhibitor + histamine methyltransferase inhibitors + histamine-methylating enzyme inhibitor + histamine-methylating enzyme inhibitors + imidazolemethyltransferase inhibitor + imidazolemethyltransferase inhibitors + CHEBI:110725 + + EC 2.1.1.8 (histamine N-methyltransferase) inhibitor + + + + + + + + + + + + + + + + An organic cation obtained by protonation of the tertiary amino group of amodiaquine; major species at pH 7.3. + + +1 + C20H23ClN3O + InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23)/p+1 + OVCDSSHSILBFBN-UHFFFAOYSA-O + 356.870 + 356.15242 + C12=CC(=CC=C1C(=CC=N2)NC3=CC(=C(C=C3)O)C[NH+](CC)CC)Cl + PMID:26427316 + chebi_ontology + amodiaquine + amodiaquine cation + CHEBI:131327 + + amodiaquine(1+) + + + + + + + + + Any bacterial metabolite produced during a metabolic reaction in Mycoplasma genitalium. + + chebi_ontology + Mycoplasma genitalium metabolites + CHEBI:131604 + + Mycoplasma genitalium metabolite + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A bisbenzylisoquinoline alkaloid that is (1beta)- berbaman which has been substituted by methyl groups at the 2 and 2' positions, by methoxy groups at the 6, 6', and 12 positions, and by a hydroxy group at position 7. Isolated from Stephania tetrandra, it has been found to possess neuroprotective and anti-tumour activity. + + 0 + C37H40N2O6 + InChI=1S/C37H40N2O6/c1-38-14-12-24-19-31(42-4)33-21-27(24)28(38)16-22-6-9-26(10-7-22)44-32-18-23(8-11-30(32)41-3)17-29-35-25(13-15-39(29)2)20-34(43-5)36(40)37(35)45-33/h6-11,18-21,28-29,40H,12-17H2,1-5H3/t28-,29-/m0/s1 + IIQSJHUEZBTSAT-VMPREFPWSA-N + 608.725 + 608.28864 + O1C=2C=C3C(=CC2OC)CCN([C@H]3CC4=CC=C(OC=5C=C(C[C@@]6(N(CCC=7C6=C1C(O)=C(OC)C7)C)[H])C=CC5OC)C=C4)C + CAS:436-77-1 + PMID:18161288 + PMID:19428795 + PMID:19764054 + PMID:20030508 + PMID:20208355 + PMID:21418191 + PMID:22130369 + PMID:22720080 + PMID:23112944 + PMID:23401195 + PMID:23452799 + PMID:23596478 + PMID:24568493 + PMID:24856768 + PMID:25539072 + PMID:25645647 + PMID:25754692 + PMID:25872479 + PMID:26408176 + PMID:26512898 + PMID:26893655 + Reaxys:78975 + Wikipedia:Fangchinoline + (1beta)-6,6',12-trimethoxy-2,2'-dimethylberbaman-7-ol + chebi_ontology + (+)-fangchinoline + (+)-limacine + (1beta)-2,2'-dimethyl-6,6',12-trimethoxyberbaman-7-ol + 7-O-demethyltetrandrine + CHEBI:132893 + + fangchinoline + + + + + + + + + A drug that makes increases the sensitivity of tumour cells to radiation therapy. + + PMID:12520460 + Wikipedia:Radiosensitizer + chebi_ontology + radiosensitiser + radiosensitisers + radiosensitising agent + radiosensitising agents + radiosensitizer + radiosensitizers + radiosensitizing agents + CHEBI:132992 + + radiosensitizing agent + + + + + + + + + A type of benzylisoquinoline alkaloid whose structures are built up of two benzylisoquinoline units linked by ether bridges. Various structural patterns resulting from additional bridging between the two units by direct carbon-carbon bridging or by methylenedioxy groups are common. + + PMID:1955879 + PMID:2191354 + PMID:3323421 + chebi_ontology + bis(benzylisoquinoline) alkaloid + bis(benzylisoquinoline) alkaloids + bis-benzylisoquinoline alkaloid + bis-benzylisoquinoline alkaloids + bisbenzylisoquinoline alkaloids + CHEBI:133004 + + bisbenzylisoquinoline alkaloid + + + + + + + + + Any organic compound having an initial boiling point less than or equal to 250 degreeC (482 degreeF) measured at a standard atmospheric pressure of 101.3 kPa. + + Wikipedia:Volatile_organic_compound + chebi_ontology + VOC + VOCs + volatile organic compounds + CHEBI:134179 + + volatile organic compound + + + + + + + + + An alkanesulfonate in which the carbon at position 1 is attached to R, which can represent hydrogens, a carbon chain, or other groups. + + -1 + CH2O3SR + 94.091 + 93.97246 + C(S([O-])(=O)=O)* + CHEBI:22318 + MetaCyc:Alkanesulfonates + chebi_ontology + alkanesulfonate oxoanions + alkanesulfonates + an alkanesulfonate + CHEBI:134249 + + alkanesulfonate oxoanion + + + + + + + + + + + 0 + C5H4FN3O2 + InChI=1S/C5H4FN3O2/c6-2-1-8-5(11)3(9-2)4(7)10/h1H,(H2,7,10)(H,8,11) + ZCGNOVWYSGBHAU-UHFFFAOYSA-N + 157.103 + 157.02875 + N=1C(=CN=C(C1C(=O)N)O)F + CAS:259793-96-9 + Drug_Central:4887 + chebi_ontology + T-705 + avigan + CHEBI:134722 + + favipiravir + + + + + + + + + + 0 + C22H25BrN2O3S + InChI=1S/C22H25BrN2O3S/c1-5-28-22(27)20-18(13-29-14-9-7-6-8-10-14)25(4)17-11-16(23)21(26)15(19(17)20)12-24(2)3/h6-11,26H,5,12-13H2,1-4H3 + KCFYEAOKVJSACF-UHFFFAOYSA-N + 477.416 + 476.07693 + C(OCC)(=O)C=1C=2C(N(C)C1CSC3=CC=CC=C3)=CC(Br)=C(O)C2CN(C)C + CAS:131707-25-0 + Drug_Central:4868 + chebi_ontology + arbidol + arbidole + CHEBI:134730 + + umifenovir + + + + + + + + + + + + + + + + 0 + C18H22ClNO + InChI=1S/C18H22ClNO/c1-18(21-14-13-20(2)3,15-7-5-4-6-8-15)16-9-11-17(19)12-10-16/h4-12H,13-14H2,1-3H3 + KKHPNPMTPORSQE-UHFFFAOYSA-N + 303.827 + 303.13899 + C(OCCN(C)C)(C)(C1=CC=C(C=C1)Cl)C2=CC=CC=C2 + CAS:77-38-3 + Drug_Central:617 + HMDB:HMDB0240223 + chebi_ontology + chlorphenoxamine hydrochloride + CHEBI:135288 + + chlorphenoxamine + + + + + + + + + + + 0 + C19H17N5O2 + InChI=1S/C19H17N5O2/c20-17(21)14-2-1-13-10-16(8-5-12(13)9-14)26-18(25)11-3-6-15(7-4-11)24-19(22)23/h1-10H,(H3,20,21)(H4,22,23,24) + MQQNFDZXWVTQEH-UHFFFAOYSA-N + 347.371 + 347.13822 + C(=N)(N)C1=CC=2C(C=C1)=CC(=CC2)OC(=O)C3=CC=C(C=C3)NC(=N)N + CAS:81525-10-2 + Drug_Central:1867 + chebi_ontology + FUT-175 + nafamostat HCl + nafamostat dihydrochloride + nafamostat hydrochloride + nafamostat mesilate + nafamostat mesylate + nafamstat + ronastat + CHEBI:135466 + + nafamostat + + + + + + + + + + + + + + + + 0 + C20H22N4O5 + InChI=1S/C20H22N4O5/c1-24(2)17(25)12-28-18(26)11-13-3-9-16(10-4-13)29-19(27)14-5-7-15(8-6-14)23-20(21)22/h3-10H,11-12H2,1-2H3,(H4,21,22,23) + XASIMHXSUQUHLV-UHFFFAOYSA-N + 398.413 + 398.15902 + C(OC1=CC=C(C=C1)CC(OCC(N(C)C)=O)=O)(=O)C2=CC=C(C=C2)NC(=N)N + CAS:59721-28-7 + Drug_Central:471 + chebi_ontology + camostat mesilate + camostat mesylate + CHEBI:135632 + + camostat + + + + + + + + + + + + + + + + 0 + C27H32ClNO2 + InChI=1S/C27H32ClNO2/c1-4-29(5-2)18-19-31-26-16-12-24(13-17-26)27(30,23-10-6-21(3)7-11-23)20-22-8-14-25(28)15-9-22/h6-17,30H,4-5,18-20H2,1-3H3 + SYHDSBBKRLVLFF-UHFFFAOYSA-N + 438.002 + 437.21216 + C(CC1=CC=C(C=C1)Cl)(O)(C2=CC=C(C=C2)OCCN(CC)CC)C3=CC=C(C=C3)C + CAS:78-41-1 + Drug_Central:2761 + chebi_ontology + clotrox + metasclene + metasqualene + trianel + triparin + tropalin + CHEBI:135714 + + triparanol + + + + + + + + + + 0 + C30H34N2O3 + InChI=1S/C30H34N2O3/c1-22-28-20-26(34)12-15-29(28)32(30(22)24-8-10-25(33)11-9-24)21-23-6-13-27(14-7-23)35-19-18-31-16-4-2-3-5-17-31/h6-15,20,33-34H,2-5,16-19,21H2,1H3 + UCJGJABZCDBEDK-UHFFFAOYSA-N + 470.604 + 470.25694 + C(N1C(=C(C2=C1C=CC(=C2)O)C)C3=CC=C(C=C3)O)C4=CC=C(C=C4)OCCN5CCCCCC5 + CAS:198481-32-2 + Drug_Central:4334 + chebi_ontology + TSE-424 + TSE424 + bazedoxifene acetate + conbriza + CHEBI:135947 + + bazedoxifene + + + + + + + + + A diol in which the two hydroxy groups are on different carbon atoms, usually but not necessarily adjacent. + + glycols + chebi_ontology + Glykol + CHEBI:13643 + + glycol + + + + + + + + + An organic group derived from any 3-oxo-Delta(4)-steroid. + + 0 + C6H6O + 94.111 + 94.04186 + C1=C(C*)*C(CC1=O)* + chebi_ontology + a 3-oxo-Delta4-steroid group + CHEBI:136849 + + 3-oxo-Delta(4)-steroid group + + + + + + + + + A compound that, on administration, undergoes conversion by biochemical (enzymatic), chemical (possibly following an enzymatic step), or physical (e.g. photochemical) activation processes before becoming the active agent for which it is a pro-agent. + + PMID:26449612 + chebi_ontology + pro-agents + proagent + proagents + CHEBI:136859 + + pro-agent + + + + + + + + + Any steroid that has beta-configuration at position 5. + + chebi_ontology + 5beta steroids + 5beta-steroid + 5beta-steroids + CHEBI:136889 + + 5beta steroid + + + + + + + + + + + + + + + Any primary amine in which the substituent attached to nitrogen is an alkyl group. + + 0 + H2NR + 16.023 + 16.01872 + N[*] + CHEBI:2587 + KEGG:C01664 + Alkylamine + chebi_ontology + CHEBI:13759 + + alkylamine + + + + + + + + + + + + + + + An organic cation obtained by protonation of the amino group of any tertiary amino compound. + + +1 + HNR3 + 15.015 + 15.01090 + [NH+](*)(*)* + chebi_ontology + a tertiary amine + tertiary amine(1+) + tertiary ammonium ions + CHEBI:137982 + + tertiary ammonium ion + + + + + + + + + A Bronsted acid derived from one or more inorganic compounds. Inorganic acids (also known as mineral acids) form hydrons and conjugate base ions when dissolved in water. + + Wikipedia:Mineral_acid + chebi_ontology + inorganic acids + mineral acid + mineral acids + CHEBI:138103 + + inorganic acid + + + + + + + + + Any main group molecular entity that is gaseous at standard temperature and pressure (STP; 0degreeC and 100 kPa). + + Wikipedia:https://en.wikipedia.org/wiki/Gas + chebi_ontology + gas molecular entities + gaseous molecular entities + gaseous molecular entity + CHEBI:138675 + + gas molecular entity + + + + + + + + + + + + + + + + -1 + CH2NO2 + InChI=1S/CH3NO2/c2-1(3)4/h2H2,(H,3,4)/p-1 + KXDHJXZQYSOELW-UHFFFAOYSA-M + 60.03212 + 60.00910 + NC([O-])=O + Beilstein:3903503 + CAS:302-11-4 + Gmelin:239604 + carbamate + chebi_ontology + Carbamat + Karbamat + carbamate ion + carbamic acid, ion(1-) + CHEBI:13941 + + carbamate + + + + + + + + + + An alpha-oxyketone that has a hydroxy group as the alpha-oxy moiety. + + PMID:15326516 + PMID:19908854 + PMID:20382022 + PMID:23295224 + chebi_ontology + alpha-hydroxy ketones + alpha-hydroxy-ketone + alpha-hydroxy-ketones + alpha-hydroxyketone + alpha-hydroxyketones + CHEBI:139588 + + alpha-hydroxy ketone + + + + + + + + + + An alpha-hydroxy ketone in which the carbonyl group and the hydroxy group are linked by a -CH2 (methylene) group. + + 0 + C2H3O2R + 59.044 + 59.01330 + *C(C(O)([H])[H])=O + chebi_ontology + primary alpha-hydroxy ketones + primary alpha-hydroxy-ketone + primary alpha-hydroxy-ketones + primary alpha-hydroxyketone + primary alpha-hydroxyketones + CHEBI:139590 + + primary alpha-hydroxy ketone + + + + + + + + + + An alpha-hydroxy ketone in which the carbonyl group and the hydroxy group are linked by a carbon bearing two organyl groups. + + 0 + C2HO2R3 + 57.028 + 56.99765 + C(C(=O)*)(O)(*)* + chebi_ontology + tertiary alpha-hydroxy ketones + tertiary alpha-hydroxy-ketone + tertiary alpha-hydroxy-ketones + tertiary alpha-hydroxyketone + tertiary alpha-hydroxyketones + CHEBI:139592 + + tertiary alpha-hydroxy ketone + + + + + + + + + A carboxamide resulting from the formal condensation of a carboxylic acid with ammonia; formula RC(=O)NH2. + + 0 + CH2NOR + 44.033 + 44.01364 + N(C(*)=O)([H])[H] + chebi_ontology + primary carboxamides + CHEBI:140324 + + primary carboxamide + + + + + + + + + A carboxamide resulting from the formal condensation of a carboxylic acid with a primary amine; formula RC(=O)NHR(1). + + 0 + CHNOR2 + 43.025 + 43.00581 + N(C(*)=O)(*)[H] + chebi_ontology + secondary carboxamides + CHEBI:140325 + + secondary carboxamide + + + + + + + + + + + + + + + A D-alpha-amino acid zwitterion arising from the transfer of a proton from the carboxy to the amino group of D-leucine; major species at pH 7.3. + + 0 + C6H13NO2 + InChI=1S/C6H13NO2/c1-4(2)3-5(7)6(8)9/h4-5H,3,7H2,1-2H3,(H,8,9)/t5-/m1/s1 + ROHFNLRQFUQHCH-RXMQYKEDSA-N + 131.173 + 131.09463 + [O-]C([C@@H](CC(C)C)[NH3+])=O + MetaCyc:CPD-12150 + PMID:24419381 + (2R)-2-azaniumyl-4-methylpentanoate + chebi_ontology + D-leu + D-leucine + CHEBI:143079 + + D-leucine zwitterion + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A member of the class of pyrazines that is pyrazine-2-carboxamide which is substituted by {3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}nitrilo, (oxan-4-yl)nitrilo and ethyl groups at positions 3,5 and 6, respectively. It is a potent inhibitor of FLT3 and AXL tyrosine kinase receptors (IC50 = 0.29 nM and 0.73 nM, respectively). Approved by the FDA for the treatment of acute myeloid leukemia in patients who have a FLT3 gene mutation. + + 0 + C29H44N8O3 + InChI=1S/C29H44N8O3/c1-4-23-28(31-20-9-17-40-18-10-20)34-29(26(33-23)27(30)38)32-21-5-6-24(25(19-21)39-3)37-11-7-22(8-12-37)36-15-13-35(2)14-16-36/h5-6,19-20,22H,4,7-18H2,1-3H3,(H2,30,38)(H2,31,32,34) + GYQYAJJFPNQOOW-UHFFFAOYSA-N + 552.724 + 552.35364 + CCC1=NC(C(=O)N)=C(NC2=CC=C(N3CCC(CC3)N4CCN(C)CC4)C(OC)=C2)N=C1NC5CCOCC5 + CAS:1254053-43-4 + DrugBank:DB12141 + KEGG:D10709 + PMCID:PMC6817455 + PMID:26279055 + PMID:27908881 + PMID:28516360 + PMID:28645776 + PMID:29498296 + PMID:30039554 + PMID:30514344 + PMID:30721452 + PMID:30936061 + PMID:31069015 + PMID:31122910 + PMID:31203997 + PMID:31320594 + PMID:31454267 + PMID:31469903 + PMID:31528345 + PMID:31665578 + PMID:31692922 + Wikipedia:Gilteritinib + 6-ethyl-3-{3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino}-5-(tetrahydro-2H-pyran-4-ylamino)pyrazine-2-carboxamide + chebi_ontology + 6-ethyl-3-((3-methoxy-4-(4-(4-methyl-1-piperazinyl)-1-piperidinyl)phenyl)amino)-5-((tetrahydro-2H-pyran-4-yl)amino)-2-pyrazinecarboxamide + 6-ethyl-3-{3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino}-5-[(oxan-4-yl)amino]pyrazine-2-carboxamide + ASP 2215 + ASP-2215 + ASP2215 + Xospata + gilteritinib + gilteritinibum + CHEBI:145372 + + gilteritinib + + + + + + + + + + A macrolide in which the macrocyclic lactone ring includes an amide group. + + PMID:11678663 + PMID:12227772 + PMID:15248618 + PMID:17378533 + PMID:31226284 + chebi_ontology + macrolide lactams + CHEBI:145565 + + macrolide lactam + + + + + + + + + + + + + + + Conjugate base of digoxin; major species at pH 7.3. + + -1 + C41H63O14 + InChI=1S/C41H63O14/c1-19-36(47)28(42)15-34(50-19)54-38-21(3)52-35(17-30(38)44)55-37-20(2)51-33(16-29(37)43)53-24-8-10-39(4)23(13-24)6-7-26-27(39)14-31(45)40(5)25(9-11-41(26,40)48)22-12-32(46)49-18-22/h12,18-21,23-31,33-38,42-45,47-48H,6-11,13-17H2,1-5H3/q-1/t19-,20-,21-,23-,24+,25-,26-,27+,28+,29+,30+,31-,33+,34+,35+,36-,37-,38-,39+,40+,41+/m1/s1 + MOAVUYWYFFCBNM-PUGKRICDSA-N + 779.942 + 779.42233 + O([C@@H]1C[C@@]2([C@](CC1)([C@@]3([C@@](CC2)([C@@]4([C@]([C@@H](C3)O)([C@H](CC4)C5=CC(O[CH-]5)=O)C)O)[H])[H])C)[H])[C@@H]6O[C@@H]([C@H]([C@H](C6)O)O[C@@H]7O[C@@H]([C@H]([C@H](C7)O)O[C@@H]8O[C@@H]([C@H]([C@H](C8)O)O)C)C)C + chebi_ontology + digoxin + CHEBI:145795 + + digoxin(1-) + + + + + + + + + + + + + + + An organic anion that is the conjugate base of digitoxin resulting from the deprotonation of furanone moiety; major species at pH 7.3. + + -1 + C41H63O13 + InChI=1S/C41H63O13/c1-20-36(46)29(42)16-34(49-20)53-38-22(3)51-35(18-31(38)44)54-37-21(2)50-33(17-30(37)43)52-25-8-11-39(4)24(15-25)6-7-28-27(39)9-12-40(5)26(10-13-41(28,40)47)23-14-32(45)48-19-23/h14,19-22,24-31,33-38,42-44,46-47H,6-13,15-18H2,1-5H3/q-1/t20-,21-,22-,24-,25+,26-,27+,28-,29+,30+,31+,33+,34+,35+,36-,37-,38-,39+,40-,41+/m1/s1 + YQICPRLGRXWDHI-XUDUSOBPSA-N + 763.943 + 763.42742 + C1C[C@@H](C[C@@]2([C@]1([C@@]3([C@@](CC2)([C@@]4([C@](CC3)([C@](CC4)(C=5[CH-]OC(C5)=O)[H])C)O)[H])[H])C)[H])O[C@H]6C[C@@H]([C@@H]([C@H](O6)C)O[C@@H]7O[C@@H]([C@H]([C@H](C7)O)O[C@H]8C[C@@H]([C@@H]([C@H](O8)C)O)O)C)O + chebi_ontology + digitoxin + digitoxin anion + CHEBI:145796 + + digitoxin(1-) + + + + + + + + + + + + + + + + + + Conjugate base of ouabain; major species at pH 7.3. + + -1 + C29H43O12 + InChI=1S/C29H43O12/c1-13-22(34)23(35)24(36)25(40-13)41-15-8-19(32)28(12-30)21-17(3-5-27(28,37)9-15)29(38)6-4-16(14-7-20(33)39-11-14)26(29,2)10-18(21)31/h7,11,13,15-19,21-25,30-32,34-38H,3-6,8-10,12H2,1-2H3/q-1/t13-,15-,16+,17+,18+,19+,21+,22-,23+,24+,25-,26+,27-,28+,29-/m0/s1 + MPLJNVZJPLASQC-HBYQJFLCSA-N + 583.652 + 583.27600 + O1[C@H]([C@@H]([C@H]([C@H]([C@@H]1O[C@H]2C[C@H]([C@]3([C@@](C2)(CC[C@]4([C@]5(CC[C@@H]([C@]5(C[C@H]([C@]34[H])O)C)C=6[CH-]OC(C6)=O)O)[H])O)CO)O)O)O)O)C + chebi_ontology + ouabain + CHEBI:145798 + + ouabain(1-) + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A carboxylic ester resulting from the formal condensation of the carboxy group of N-[(S)-{[(2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl]methoxy}(phenoxy)phosphoryl]-L-alanine with the hydroxy group of 2-ethylbutan-1-ol. A broad-spectrum antiviral prodrug with potent in vitro antiviral activity against a diverse panel of RNA viruses such as Ebola virus, MERS-CoV and SARS-CoV. It is currently in Phase III clinical trials for the treatment of Covid-19 in adults. + + 0 + C27H35N6O8P + InChI=1S/C27H35N6O8P/c1-4-18(5-2)13-38-26(36)17(3)32-42(37,41-19-9-7-6-8-10-19)39-14-21-23(34)24(35)27(15-28,40-21)22-12-11-20-25(29)30-16-31-33(20)22/h6-12,16-18,21,23-24,34-35H,4-5,13-14H2,1-3H3,(H,32,37)(H2,29,30,31)/t17-,21+,23+,24+,27-,42-/m0/s1 + RWWYLEGWBNMMLJ-YSOARWBDSA-N + 602.585 + 602.22540 + [C@]1(O[C@@H]([C@H]([C@H]1O)O)CO[P@@](N[C@H](C(OCC(CC)CC)=O)C)(OC=2C=CC=CC2)=O)(C#N)C=3N4N=CN=C(C4=CC3)N + CAS:1809249-37-3 + DrugBank:DB14761 + KEGG:D11472 + PMCID:PMC5630887 + PMID:26934220 + PMID:28124907 + PMID:28262699 + PMID:28659436 + PMID:29511076 + PMID:30275474 + PMID:30987343 + PMID:31142680 + PMID:31233808 + PMID:31924756 + PMID:32020029 + PMID:32054787 + PMID:32094225 + PMID:32145386 + PMID:32147516 + PMID:32152082 + Wikipedia:Remdesivir + 2-ethylbutyl N-[(S)-{[(2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl]methoxy}(phenoxy)phosphoryl]-L-alaninate + chebi_ontology + (2S)-2-{(2R,3S,4R,5R)-[5-(4-Aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxy-tetrahydro-furan-2-ylmethoxy]phenoxy-(S)-phosphorylamino}propionic acid 2-ethyl-butyl ester + 2-ethylbutyl (2S)-2-{[(S)-{[(2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2-yl]methoxy}(phenoxy)phosphoryl]amino}propanoate + GS 5734 + GS-5734 + GS5734 + remdesivir + remdesivirum + CHEBI:145994 + + remdesivir + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A hydrate that is the monohydrate of the dihydrochloride salt of emetine. + + 0 + C29H40N2O4.H2O.ClH.ClH + InChI=1S/C29H40N2O4.2ClH.H2O/c1-6-18-17-31-10-8-20-14-27(33-3)29(35-5)16-23(20)25(31)12-21(18)11-24-22-15-28(34-4)26(32-2)13-19(22)7-9-30-24;;;/h13-16,18,21,24-25,30H,6-12,17H2,1-5H3;2*1H;1H2/t18-,21-,24+,25-;;;/m0.../s1 + IZTPMTAWOCEKKM-VXMYZLRESA-N + 571.580 + 570.26273 + Cl.Cl.C=1C(=C(C=C2C1CCN3C[C@@H]([C@@](C[C@@]23[H])([H])C[C@@]4([H])NCCC=5C4=CC(=C(C5)OC)OC)CC)OC)OC.O + CAS:7083-71-8 + PMID:24107123 + PMID:28257497 + Reaxys:5216794 + (2S)-6',7',10,11-tetramethoxyemetan dihydrochloride--water (1/1) + chebi_ontology + (2S)-6',7',10,11-tetramethoxyemetan dihydrochloride hydrate + (2S)-6',7',10,11-tetramethoxyemetan-2',5-diium dichloride--water (1/1) + emetine dihydrochloride monohydrate + emetine hydrochloride hydrate + CHEBI:146000 + + emetine dihydrochloride hydrate + + + + + + + + + Any substance that produces or enhances dream-like states of consciousness. + + Wikipedia:Oneirogen + chebi_ontology + oneirogens + CHEBI:146270 + + oneirogen + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A C-nucleoside analog that is (2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-carbonitrile substituted by a 4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl group at position 2. It is the active metabolite of remdesivir and exhibits a broad range of inhibitory activity against various RNA viruses including HCV, parainfluenza and SARS-Cov. + + 0 + C12H13N5O4 + InChI=1S/C12H13N5O4/c13-4-12(10(20)9(19)7(3-18)21-12)8-2-1-6-11(14)15-5-16-17(6)8/h1-2,5,7,9-10,18-20H,3H2,(H2,14,15,16)/t7-,9-,10-,12+/m1/s1 + BRDWIEOJOWJCLU-LTGWCKQJSA-N + 291.267 + 291.09675 + [C@]1(O[C@@H]([C@H]([C@H]1O)O)CO)(C#N)C=2N3N=CN=C(C3=CC2)N + CAS:1191237-69-0 + PMID:22446091 + PMID:28124907 + PMID:29778200 + PMID:30755068 + (2R,3R,4S,5R)-2-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-carbonitrile + chebi_ontology + EVO 984 + EVO-984 + EVO984 + GS 441524 + GS441524 + CHEBI:147281 + + GS-441524 + + + + + + + + + An EC 3.4.22.* (cysteine endopeptidase) inhibitor that interferes with the action of SARS coronavirus main proteinase (EC 3.4.22.69). + + Wikipedia:C30_Endopeptidase + chebi_ontology + 3C-like protease inhibitor + 3C-like protease inhibitors + 3cLpro inhibitor + 3cLpro inhibitors + EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitors + EC 3.4.22.69 inhibitor + EC 3.4.22.69 inhibitors + Mpro inhibitor + Mpro inhibitors + SARS 3C-like protease inhibitor + SARS 3C-like protease inhibitors + SARS coronavirus 3CL protease inhibitor + SARS coronavirus 3CL protease inhibitors + SARS coronavirus main peptidase inhibitor + SARS coronavirus main peptidase inhibitors + SARS coronavirus main protease inhibitor + SARS coronavirus main protease inhibitors + SARS coronavirus main proteinase inhibitor + SARS coronavirus main proteinase inhibitors + SARS-CoV 3CLpro enzyme inhibitor + SARS-CoV 3CLpro enzyme inhibitors + SARS-CoV Mpro inhibitor + SARS-CoV Mpro inhibitors + SARS-CoV main protease inhibitor + SARS-CoV main protease inhibitors + coronavirus 3C-like protease inhibitor + coronavirus 3C-like protease inhibitors + severe acute respiratory syndrome coronavirus main protease inhibitor + severe acute respiratory syndrome coronavirus main protease inhibitors + CHEBI:147285 + + EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A secondary carboxamide resulting from the formal condensation of the carboxy group of N-[(benzyloxy)carbonyl]-O-tert-butyl-L-serine with the primary amino group of ethyl (2E,4S)-5-[(3S)-2-oxopyrrolidin-3-yl]-4-(L-phenylalanylamino)pent-2-enoate. It is a potent enterovirus 3C protease inhibitor with EC50 of 180 nM against enterovirus 71 (EV71) and 60 nM against human rhinovirus 14 in a live virus-cell-based assay. + + 0 + C35H46N4O8 + InChI=1S/C35H46N4O8/c1-5-45-30(40)17-16-27(21-26-18-19-36-31(26)41)37-32(42)28(20-24-12-8-6-9-13-24)38-33(43)29(23-47-35(2,3)4)39-34(44)46-22-25-14-10-7-11-15-25/h6-17,26-29H,5,18-23H2,1-4H3,(H,36,41)(H,37,42)(H,38,43)(H,39,44)/b17-16+/t26-,27+,28-,29-/m0/s1 + CTAXDRJNQQBEIB-VCJIVHKYSA-N + 650.773 + 650.33156 + C=1C(=CC=CC1)COC(N[C@H](C(N[C@H](C(N[C@H](/C=C/C(OCC)=O)C[C@H]2C(NCC2)=O)=O)CC=3C=CC=CC3)=O)COC(C)(C)C)=O + CAS:1575662-24-6 + PMID:23388726 + PMID:25039866 + PMID:25199773 + PMID:26055377 + PMID:27668727 + N-[(benzyloxy)carbonyl]-O-tert-butyl-L-seryl-N-{(2S,3E)-5-ethoxy-5-oxo-1-[(3S)-2-oxopyrrolidin-3-yl]pent-3-en-2-yl}-L-phenylalaninamide + chebi_ontology + SG 85 + SG-85 + CHEBI:147346 + + SG85 + + + + + + + + + + + + + + + + A quinolinium ion obtained by protonation of the quinoline nitrogen and tertiary amino group of the antimalarial drug chloroquine. It is the major species at pH 7.3. + + +2 + C18H28ClN3 + InChI=1S/C18H26ClN3/c1-4-22(5-2)12-6-7-14(3)21-17-10-11-20-18-13-15(19)8-9-16(17)18/h8-11,13-14H,4-7,12H2,1-3H3,(H,20,21)/p+2 + WHTVZRBIWZFKQO-UHFFFAOYSA-P + 321.890 + 321.19608 + [NH+]1=CC=C(C=2C1=CC(Cl)=CC2)NC(CCC[NH+](CC)CC)C + PMID:25693996 + 7-chloro-4-{[5-(diethylazaniumyl)pentan-2-yl]amino}quinolinium + chebi_ontology + chloroquine dication + di-protonated chloroquine + CHEBI:149484 + + chloroquine(2+) + + + + + + + + + + + + + + + An ammonium ion derivative obtained from protonation of the nitrogens of emetine. It is the major species at pH 7.3. + + +2 + C29H42N2O4 + InChI=1S/C29H40N2O4/c1-6-18-17-31-10-8-20-14-27(33-3)29(35-5)16-23(20)25(31)12-21(18)11-24-22-15-28(34-4)26(32-2)13-19(22)7-9-30-24/h13-16,18,21,24-25,30H,6-12,17H2,1-5H3/p+2/t18-,21-,24+,25-/m0/s1 + AUVVAXYIELKVAI-CKBKHPSWSA-P + 482.664 + 482.31336 + C=1C(=C(C=C2C1CC[NH+]3C[C@@H]([C@@](C[C@@]23[H])([H])C[C@@]4([H])[NH2+]CCC=5C4=CC(=C(C5)OC)OC)CC)OC)OC + MetaCyc:CPD-14817 + PMID:5985282 + (2S)-6',7',10,11-tetramethoxyemetan-2',5-diium + chebi_ontology + emetine dication + CHEBI:149548 + + emetine(2+) + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + The dihydrochloride salt of emetine. + + 0 + C29H40N2O4.ClH.ClH + InChI=1S/C29H40N2O4.2ClH/c1-6-18-17-31-10-8-20-14-27(33-3)29(35-5)16-23(20)25(31)12-21(18)11-24-22-15-28(34-4)26(32-2)13-19(22)7-9-30-24;;/h13-16,18,21,24-25,30H,6-12,17H2,1-5H3;2*1H/t18-,21-,24+,25-;;/m0../s1 + JROGBPMEKVAPEH-GXGBFOEMSA-N + 553.570 + 552.25216 + C=1C(=C(C=C2C1CCN3C[C@@H]([C@@](C[C@@]23[H])([H])C[C@@]4([H])NCCC=5C4=CC(=C(C5)OC)OC)CC)OC)OC.Cl.Cl + CAS:316-42-7 + KEGG:D03985 + PMID:11294031 + PMID:13904259 + PMID:14266439 + PMID:14852643 + PMID:24045224 + PMID:24107123 + PMID:28257497 + PMID:31964796 + PMID:3668005 + PMID:4042936 + PMID:4204205 + PMID:4245434 + PMID:4399461 + PMID:4705155 + PMID:4929936 + PMID:5495495 + PMID:5538625 + PMID:5642979 + PMID:5862615 + PMID:5957731 + PMID:616384 + PMID:8789394 + PMID:891868 + PMID:9388036 + PMID:94222 + (2S)-6',7',10,11-tetramethoxyemetan dihydrochloride + chebi_ontology + emetine HCl + emetine dihydrochloride anhydrous + emetine hydrochloride + CHEBI:149551 + + emetine dihydrochloride + + + + + + + + + Any agent that induces nausea and vomiting. + + chebi_ontology + emetics + CHEBI:149552 + + emetic + + + + + + + + + Any antiviral agent which inhibits the activity of coronaviruses. + + Wikipedia:Coronavirus + anticoronaviral agent + chebi_ontology + anti-coronaviral agent + anti-coronaviral agents + anti-coronavirus agent + anti-coronavirus agents + anticoronaviral agents + anticoronaviral drug + anticoronaviral drugs + anticoronavirus agent + anticoronavirus agents + CHEBI:149553 + + anticoronaviral agent + + + + + + + + + + + + + + + + A quinolinium ion obtained by protonation of the quinoline nitrogen and tertiary amino group of the antimalarial drug hydroxychloroquine. It is the major species at pH 7.3. + + +2 + C18H28ClN3O + InChI=1S/C18H26ClN3O/c1-3-22(11-12-23)10-4-5-14(2)21-17-8-9-20-18-13-15(19)6-7-16(17)18/h6-9,13-14,23H,3-5,10-12H2,1-2H3,(H,20,21)/p+2 + XXSMGPRMXLTPCZ-UHFFFAOYSA-P + 337.890 + 337.19099 + C=12C(NC(CCC[NH+](CCO)CC)C)=CC=[NH+]C1C=C(C=C2)Cl + PMID:25693996 + 7-chloro-4-({5-[ethyl(2-hydroxyethyl)azaniumyl]pentan-2-yl}amino)quinolinium + chebi_ontology + hydroxychloroquine dication + CHEBI:149564 + + hydroxychloroquine(2+) + + + + + + + + + + + + + + + A divalent inorganic anion obtained by removal of both protons from hydrogen sulfide. + + -2 + S + InChI=1S/S/q-2 + UCKMPCXJQFINFW-UHFFFAOYSA-N + 32.06600 + 31.97317 + [S--] + CAS:18496-25-8 + UM-BBD_compID:c0569 + sulfanediide + sulfide(2-) + chebi_ontology + S(2-) + Sulfide + sulphide + CHEBI:15138 + + sulfide(2-) + + + + + + + + + A molecular entity that can accept an electron, a pair of electrons, an atom or a group from another molecular entity. + + CHEBI:13699 + CHEBI:2377 + KEGG:C00028 + KEGG:C16722 + Acceptor + chebi_ontology + A + Akzeptor + Hydrogen-acceptor + Oxidized donor + accepteur + CHEBI:15339 + + acceptor + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + An oxygen hydride consisting of an oxygen atom that is covalently bonded to two hydrogen atoms. + + 0 + H2O + InChI=1S/H2O/h1H2 + XLYOFNOQVPJJNP-UHFFFAOYSA-N + 18.01530 + 18.01056 + [H]O[H] + CHEBI:10743 + CHEBI:13352 + CHEBI:27313 + CHEBI:42043 + CHEBI:42857 + CHEBI:43228 + CHEBI:44292 + CHEBI:44701 + CHEBI:44819 + CHEBI:5585 + Beilstein:3587155 + CAS:7732-18-5 + Gmelin:117 + HMDB:HMDB0002111 + KEGG:C00001 + KEGG:D00001 + MetaCyc:WATER + MolBase:1 + PDBeChem:HOH + Reaxys:3587155 + Wikipedia:Water + WATER + Water + oxidane + water + chebi_ontology + BOUND WATER + H2O + HOH + Wasser + [OH2] + acqua + agua + aqua + dihydridooxygen + dihydrogen oxide + eau + hydrogen hydroxide + CHEBI:15377 + + water + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + The L-enantiomer of leucine. + + 0 + C6H13NO2 + InChI=1S/C6H13NO2/c1-4(2)3-5(7)6(8)9/h4-5H,3,7H2,1-2H3,(H,8,9)/t5-/m0/s1 + ROHFNLRQFUQHCH-YFKPBYRVSA-N + 131.17296 + 131.09463 + CC(C)C[C@H](N)C(O)=O + CHEBI:10866 + CHEBI:13131 + CHEBI:21348 + CHEBI:43646 + CHEBI:43695 + CHEBI:43733 + CHEBI:43814 + CHEBI:6260 + Beilstein:1721722 + CAS:61-90-5 + DrugBank:DB00149 + Drug_Central:1557 + ECMDB:ECMDB00687 + Gmelin:50204 + HMDB:HMDB0000687 + KEGG:C00123 + KEGG:D00030 + KNApSAcK:C00001377 + MetaCyc:LEU + PDBeChem:LEU_LFOH + PMID:17609475 + PMID:22735334 + PMID:24206068 + PMID:24333966 + PMID:8798704 + Reaxys:1721722 + Wikipedia:Leucine + YMDB:YMDB00387 + L-Leucine + L-leucine + chebi_ontology + (2S)-2-amino-4-methylpentanoic acid + (2S)-alpha-2-Amino-4-methylvaleric acid + (2S)-alpha-Leucine + (S)-(+)-leucine + (S)-leucine + 2-Amino-4-methylvaleric acid + L + L-Leucin + L-Leuzin + LEUCINE + Leu + CHEBI:15603 + + L-leucine + + + + + + + + + + + + + + + + + + + + + + + + + + + Any alpha-amino acid having L-configuration at the alpha-carbon. + + 0 + C2H4NO2R + 74.05870 + 74.02420 + N[C@@H]([*])C(O)=O + CHEBI:13072 + CHEBI:13243 + CHEBI:13797 + CHEBI:21224 + CHEBI:6175 + KEGG:C00151 + L-alpha-amino acid + L-alpha-amino acids + chebi_ontology + L-2-Amino acid + L-Amino acid + L-alpha-amino acids + CHEBI:15705 + + L-alpha-amino acid + + + + + + + + + A primary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has either three hydrogen atoms attached to it or only one other carbon atom and two hydrogen atoms attached to it. + + 0 + CH3OR + 31.034 + 31.01839 + *C(O)([H])[H] + CHEBI:13676 + CHEBI:14887 + CHEBI:26262 + CHEBI:57489 + CHEBI:8406 + KEGG:C00226 + Primary alcohol + chebi_ontology + 1-Alcohol + a primary alcohol + primary alcohols + CHEBI:15734 + + primary alcohol + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A triterpenoid saponin that is the glucosiduronide derivative of 3beta-hydroxy-11-oxoolean-12-en-30-oic acid. + + 0 + C42H62O16 + InChI=1S/C42H62O16/c1-37(2)21-8-11-42(7)31(20(43)16-18-19-17-39(4,36(53)54)13-12-38(19,3)14-15-41(18,42)6)40(21,5)10-9-22(37)55-35-30(26(47)25(46)29(57-35)33(51)52)58-34-27(48)23(44)24(45)28(56-34)32(49)50/h16,19,21-31,34-35,44-48H,8-15,17H2,1-7H3,(H,49,50)(H,51,52)(H,53,54)/t19-,21-,22-,23-,24-,25-,26-,27+,28-,29-,30+,31+,34-,35-,38+,39-,40-,41+,42+/m0/s1 + LPLVUJXQOOQHMX-QWBHMCJMSA-N + 822.93210 + 822.40379 + [H][C@@]12C[C@](C)(CC[C@]1(C)CC[C@]1(C)C2=CC(=O)[C@]2([H])[C@@]3(C)CC[C@H](O[C@H]4O[C@@H]([C@@H](O)[C@H](O)[C@H]4O[C@@H]4O[C@@H]([C@@H](O)[C@H](O)[C@H]4O)C(O)=O)C(O)=O)C(C)(C)[C@]3([H])CC[C@@]12C)C(O)=O + CHEBI:24418 + CHEBI:5508 + Beilstein:77922 + CAS:1405-86-3 + Drug_Central:1325 + HMDB:HMDB0029843 + KEGG:C02284 + LIPID_MAPS_instance:LMPR0106150013 + MetaCyc:GLYCYRRHIZINATE + PMID:11282481 + PMID:15013279 + PMID:24497916 + Reaxys:77922 + Wikipedia:Glycyrrhizin + 30-hydroxy-11,30-dioxoolean-12-en-3beta-yl (2-O-beta-D-glucopyranosyluronic acid)-alpha-D-glucopyranosiduronic acid + chebi_ontology + (3beta,20beta)-20-carboxy-11-oxo-30-norolean-12-en-3-yl-2-O-beta-D-glucopyranuronosyl-alpha-D-glucopyranosiduronic acid + Glycyrrhizic acid + Glycyrrhizin + glycyrrhizic acid + CHEBI:15939 + + glycyrrhizinic acid + + + + + + + + + + A monoatomic monoanion resulting from the addition of an electron to any halogen atom. + + -1 + X + 0.0 + 0.0 + [*-] + CHEBI:14384 + CHEBI:5605 + KEGG:C00462 + halide ions + chebi_ontology + HX + Halide + a halide anion + halide anions + halide(1-) + halides + halogen anion + CHEBI:16042 + + halide anion + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + An azane that consists of a single nitrogen atom covelently bonded to three hydrogen atoms. + + 0 + H3N + InChI=1S/H3N/h1H3 + QGZKDVFQNNGYKY-UHFFFAOYSA-N + 17.03056 + 17.02655 + [H]N([H])[H] + CHEBI:13405 + CHEBI:13406 + CHEBI:13407 + CHEBI:13771 + CHEBI:22533 + CHEBI:44269 + CHEBI:44284 + CHEBI:44404 + CHEBI:7434 + Beilstein:3587154 + CAS:7664-41-7 + Drug_Central:4625 + Gmelin:79 + HMDB:HMDB0000051 + KEGG:C00014 + KEGG:D02916 + KNApSAcK:C00007267 + MetaCyc:AMMONIA + MolBase:930 + PDBeChem:NH3 + PMID:110589 + PMID:11139349 + PMID:11540049 + PMID:11746427 + PMID:11783653 + PMID:13753780 + PMID:14663195 + PMID:15092448 + PMID:15094021 + PMID:15554424 + PMID:15969015 + PMID:16008360 + PMID:16050680 + PMID:16348008 + PMID:16349403 + PMID:16614889 + PMID:16664306 + PMID:16842901 + PMID:17025297 + PMID:17439666 + PMID:17569513 + PMID:17737668 + PMID:18670398 + PMID:22002069 + PMID:22081570 + PMID:22088435 + PMID:22100291 + PMID:22130175 + PMID:22150211 + PMID:22240068 + PMID:22290316 + PMID:22342082 + PMID:22385337 + PMID:22443779 + PMID:22560242 + Reaxys:3587154 + Wikipedia:Ammonia + AMMONIA + Ammonia + ammonia + azane + chebi_ontology + Ammoniak + NH3 + R-717 + [NH3] + ammoniac + amoniaco + spirit of hartshorn + CHEBI:16134 + + ammonia + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A sulfur hydride consisting of a single sulfur atom bonded to two hydrogen atoms. A highly poisonous, flammable gas with a characteristic odour of rotten eggs, it is often produced by bacterial decomposition of organic matter in the absence of oxygen. + + 0 + H2S + InChI=1S/H2S/h1H2 + RWSOTUBLDIXVET-UHFFFAOYSA-N + 34.08188 + 33.98772 + [H]S[H] + CHEBI:13356 + CHEBI:14414 + CHEBI:24639 + CHEBI:43058 + CHEBI:45489 + CHEBI:5787 + Beilstein:3535004 + CAS:7783-06-4 + Drug_Central:4260 + Gmelin:303 + KEGG:C00283 + KNApSAcK:C00007266 + MolBase:1709 + PDBeChem:H2S + PMID:11788560 + PMID:14654297 + PMID:15003943 + PMID:15607739 + PMID:16446402 + PMID:18098324 + PMID:18524810 + PMID:18948540 + PMID:19695225 + PMID:22004989 + PMID:22378060 + PMID:22448627 + PMID:22473176 + PMID:22486842 + PMID:22520971 + PMID:22787557 + UM-BBD_compID:c0239 + Wikipedia:Hydrogen_sulfide + Hydrogen sulfide + dihydridosulfur + dihydrogen(sulfide) + hydrogen sulfide + sulfane + chebi_ontology + H2S + HYDROSULFURIC ACID + Hydrogen-sulfide + Schwefelwasserstoff + Sulfide + [SH2] + acide sulfhydrique + dihydrogen monosulfide + dihydrogen sulfide + hydrogen monosulfide + hydrogen sulphide + hydrogene sulfure + sulfure d'hydrogene + CHEBI:16136 + + hydrogen sulfide + + + + + + + + + + + + + + + + + + + + + + + + + + + The simplest member of the class of benzoates that is the conjugate base of benzoic acid, comprising a benzoic acid core with a proton missing to give a charge of -1. + + -1 + C7H5O2 + InChI=1S/C7H6O2/c8-7(9)6-4-2-1-3-5-6/h1-5H,(H,8,9)/p-1 + WPYMKLBDIGXBTP-UHFFFAOYSA-M + 121.11340 + 121.02950 + [O-]C(=O)c1ccccc1 + CHEBI:13879 + CHEBI:22717 + Beilstein:1862486 + CAS:766-76-7 + Gmelin:2945 + HMDB:HMDB0001870 + KEGG:C00180 + MetaCyc:BENZOATE + Reaxys:1862486 + UM-BBD_compID:c0121 + benzoate + chebi_ontology + Benzenecarboxylate + Benzeneformate + Benzenemethanoate + Phenylcarboxylate + Phenylformate + benzoate anion + benzoic acid, ion(1-) + CHEBI:16150 + + benzoate + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A one-carbon compound in which the carbon is attached by single bonds to four hydrogen atoms. It is a colourless, odourless, non-toxic but flammable gas (b.p. -161degreeC). + + 0 + CH4 + InChI=1S/CH4/h1H4 + VNWKTOKETHGBQD-UHFFFAOYSA-N + 16.04246 + 16.03130 + [H]C([H])([H])[H] + CHEBI:14585 + CHEBI:25220 + CHEBI:6811 + Beilstein:1718732 + CAS:74-82-8 + Gmelin:59 + HMDB:HMDB0002714 + KEGG:C01438 + MetaCyc:CH4 + PMID:17791569 + PMID:23104415 + PMID:23353606 + PMID:23376302 + PMID:23397538 + PMID:23718889 + PMID:23739479 + PMID:23742231 + PMID:23756351 + PMID:24132456 + PMID:24161402 + PMID:24259373 + Patent:FR994032 + Patent:US2583090 + Reaxys:1718732 + UM-BBD_compID:c0095 + Wikipedia:Methane + Methane + methane + tetrahydridocarbon + chebi_ontology + CH4 + Methan + marsh gas + metano + methyl hydride + CHEBI:16183 + + methane + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A carbonyl group with two C-bound amine groups. + + 0 + CH4N2O + InChI=1S/CH4N2O/c2-1(3)4/h(H4,2,3,4) + XSQUKJJJFZCRTK-UHFFFAOYSA-N + 60.05534 + 60.03236 + NC(N)=O + CHEBI:15292 + CHEBI:27218 + CHEBI:46379 + CHEBI:9888 + Beilstein:635724 + CAS:57-13-6 + DrugBank:DB03904 + Drug_Central:4264 + ECMDB:ECMDB04172 + Gmelin:1378 + HMDB:HMDB0000294 + KEGG:C00086 + KEGG:D00023 + KNApSAcK:C00007314 + MetaCyc:UREA + PDBeChem:URE + PMID:18037357 + PMID:22770225 + PPDB:1728 + Reaxys:635724 + UM-BBD_compID:c0165 + Wikipedia:Urea + YMDB:YMDB00003 + UREA + Urea + urea + chebi_ontology + 1728 + Carbamide + E927b + H2NC(O)NH2 + Harnstoff + Karbamid + carbamide + carbonyldiamide + ur + uree + CHEBI:16199 + + urea + + + + + + + + + + + + + + + + + + + + + + -1 + HO + InChI=1S/H2O/h1H2/p-1 + XLYOFNOQVPJJNP-UHFFFAOYSA-M + 17.00734 + 17.00329 + [O-][H] + CHEBI:13365 + CHEBI:13419 + CHEBI:44641 + CHEBI:5594 + CAS:14280-30-9 + Gmelin:24714 + KEGG:C01328 + PDBeChem:OH + hydridooxygenate(1-) + hydroxide + oxidanide + chebi_ontology + HO- + HYDROXIDE ION + Hydroxide ion + OH(-) + OH- + CHEBI:16234 + + hydroxide + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A 2-aminopurine carrying a 6-oxo substituent. + + 0 + C5H5N5O + InChI=1S/C5H5N5O/c6-5-9-3-2(4(11)10-5)7-1-8-3/h1H,(H4,6,7,8,9,10,11) + UYTPUPDQBNUYGX-UHFFFAOYSA-N + 151.126 + 151.04941 + C12=C(N=C(NC1=O)N)NC=N2 + CHEBI:14371 + CHEBI:14372 + CHEBI:24443 + CHEBI:42948 + CHEBI:5563 + Beilstein:147911 + CAS:73-40-5 + DrugBank:DB02377 + Gmelin:431879 + HMDB:HMDB0000132 + KEGG:C00242 + KNApSAcK:C00001501 + MetaCyc:GUANINE + PDBeChem:GUN + PMID:22770225 + PMID:8070089 + Reaxys:147911 + Wikipedia:Guanine + 2-amino-1,9-dihydro-6H-purin-6-one + GUANINE + Guanine + guanine + chebi_ontology + 2-Amino-6-hydroxypurine + 2-amino-6-oxopurine + G + Gua + CHEBI:16235 + + guanine + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A primary alcohol that is ethane in which one of the hydrogens is substituted by a hydroxy group. + + 0 + C2H6O + InChI=1S/C2H6O/c1-2-3/h3H,2H2,1H3 + LFQSCWFLJHTTHZ-UHFFFAOYSA-N + 46.06844 + 46.04186 + CCO + CHEBI:14222 + CHEBI:23978 + CHEBI:30878 + CHEBI:30880 + CHEBI:42377 + CHEBI:44594 + CHEBI:4879 + Beilstein:1718733 + CAS:64-17-5 + DrugBank:DB00898 + Drug_Central:1076 + Gmelin:787 + HMDB:HMDB0000108 + KEGG:C00469 + KEGG:D00068 + KEGG:D06542 + KNApSAcK:C00019560 + MetaCyc:ETOH + MolBase:858 + MolBase:859 + PDBeChem:EOH + PMID:11046114 + PMID:11090978 + PMID:11198720 + PMID:11200745 + PMID:11262320 + PMID:11303910 + PMID:11333032 + PMID:11505026 + PMID:11590970 + PMID:11728426 + PMID:11750186 + PMID:11754521 + PMID:11810019 + PMID:11826039 + PMID:11981228 + PMID:12824058 + PMID:12829422 + PMID:12888778 + PMID:12946583 + PMID:14674846 + PMID:15019421 + PMID:15239123 + PMID:15285839 + PMID:15464411 + PMID:15465973 + PMID:15749123 + PMID:15900217 + PMID:15902919 + PMID:16084479 + PMID:16133132 + PMID:16352430 + PMID:16390872 + PMID:16737463 + PMID:16891664 + PMID:16934862 + PMID:17043811 + PMID:17190852 + PMID:17663926 + PMID:17687877 + PMID:18095657 + PMID:18249266 + PMID:18320157 + PMID:18347649 + PMID:18408978 + PMID:18411066 + PMID:18456322 + PMID:18513832 + PMID:18922656 + PMID:18925476 + PMID:19280886 + PMID:19359288 + PMID:19384566 + PMID:19458312 + PMID:19851413 + PMID:19901811 + PMID:21600756 + PMID:21762181 + PMID:21881875 + PMID:21967628 + PMID:22019193 + PMID:22222864 + PMID:22261437 + PMID:22286266 + PMID:22306018 + PMID:22331491 + PMID:22336593 + PPDB:1373 + Reaxys:1718733 + UM-BBD_compID:c0038 + Wikipedia:Ethanol + ETHANOL + Ethanol + ethanol + chebi_ontology + 1-hydroxyethane + Aethanol + Aethylalkohol + Alkohol + C2H5OH + Dehydrated ethanol + EtOH + Ethyl alcohol + Methylcarbinol + [CH2Me(OH)] + [OEtH] + alcohol + alcohol etilico + alcool ethylique + etanol + hydroxyethane + spiritus vini + CHEBI:16236 + + ethanol + + + + + + + + + + Compounds having the structure RSR (R =/= H). Such compounds were once called thioethers. + + 0 + SR2 + 32.066 + 31.97207 + CHEBI:13694 + CHEBI:26960 + CHEBI:9340 + KEGG:C00297 + sulfides + chebi_ontology + RSR + Sulfide + Thioether + organic sulfides + thioethers + CHEBI:16385 + + organic sulfide + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + The L-enantiomer of valine. + + 0 + C5H11NO2 + InChI=1S/C5H11NO2/c1-3(2)4(6)5(7)8/h3-4H,6H2,1-2H3,(H,7,8)/t4-/m0/s1 + KZSNJWFQEVHDMF-BYPYZUCNSA-N + 117.14638 + 117.07898 + CC(C)[C@H](N)C(O)=O + CHEBI:13186 + CHEBI:21417 + CHEBI:46282 + CHEBI:46376 + CHEBI:46418 + CHEBI:46484 + CHEBI:6321 + Beilstein:1721136 + CAS:72-18-4 + DrugBank:DB00161 + Drug_Central:4128 + Gmelin:2827 + HMDB:HMDB0000883 + KEGG:C00183 + KEGG:D00039 + KNApSAcK:C00001398 + MetaCyc:VAL + PDBeChem:VAL + PMID:14608070 + PMID:17670823 + PMID:21706252 + PMID:22138982 + PMID:22287678 + PMID:22585822 + Reaxys:1721136 + Wikipedia:L-valine + L-Valine + L-valine + chebi_ontology + (2S)-2-amino-3-methylbutanoic acid + (S)-valine + 2-Amino-3-methylbutyric acid + L-(+)-alpha-Aminoisovaleric acid + L-Valin + L-alpha-Amino-beta-methylbutyric acid + V + VALINE + Val + CHEBI:16414 + + L-valine + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + The R-enantiomer of serine. + + 0 + C3H7NO3 + InChI=1S/C3H7NO3/c4-2(1-5)3(6)7/h2,5H,1,4H2,(H,6,7)/t2-/m1/s1 + MTCFGRXMJLQNBG-UWTATZPHSA-N + 105.09262 + 105.04259 + N[C@H](CO)C(O)=O + CHEBI:13019 + CHEBI:143888 + CHEBI:21090 + CHEBI:42262 + CHEBI:4245 + Beilstein:1721403 + CAS:312-84-5 + DrugBank:DB03929 + ECMDB:ECMDB03406 + Gmelin:1041392 + HMDB:HMDB0003406 + KEGG:C00740 + MetaCyc:D-SERINE + PDBeChem:DSN + PMID:11864625 + PMID:12850593 + PMID:19212759 + PMID:19217074 + PMID:21295046 + PMID:21914633 + PMID:21956571 + PMID:22117694 + PMID:22128843 + PMID:22266400 + PMID:22280157 + PMID:22362148 + PMID:22369458 + PMID:22445805 + PMID:22465696 + PMID:22486999 + Reaxys:1721403 + YMDB:YMDB00284 + D-SERINE + D-Serine + D-serine + chebi_ontology + (2R)-2-amino-3-hydroxypropanoic acid + (R)-2-Amino-3-hydroxy-propionic acid + (R)-2-amino-3-hydroxypropanoic acid + D-Serin + DSN + CHEBI:16523 + + D-serine + + + + + + + + + Any member of the class of organooxygen compounds that is a polyhydroxy-aldehyde or -ketone or a lactol resulting from their intramolecular condensation (monosaccharides); substances derived from these by reduction of the carbonyl group (alditols), by oxidation of one or more hydroxy groups to afford the corresponding aldehydes, ketones, or carboxylic acids, or by replacement of one or more hydroxy group(s) by a hydrogen atom; and polymeric products arising by intermolecular acetal formation between two or more such molecules (disaccharides, polysaccharides and oligosaccharides). Carbohydrates contain only carbon, hydrogen and oxygen atoms; prior to any oxidation or reduction, most have the empirical formula Cm(H2O)n. Compounds obtained from carbohydrates by substitution, etc., are known as carbohydrate derivatives and may contain other elements. Cyclitols are generally not regarded as carbohydrates. + + CHEBI:15131 + CHEBI:23008 + CHEBI:9318 + Wikipedia:Carbohydrate + carbohydrate + carbohydrates + chebi_ontology + Kohlenhydrat + Kohlenhydrate + carbohidrato + carbohidratos + glucide + glucides + glucido + glucidos + hydrates de carbone + saccharide + saccharides + saccharidum + CHEBI:16646 + + carbohydrate + + + + + + + + + + + + + + + + + + + + + + + peptide + Amide derived from two or more amino carboxylic acid molecules (the same or different) by formation of a covalent bond from the carbonyl carbon of one to the nitrogen atom of another with formal loss of water. The term is usually applied to structures formed from alpha-amino acids, but it includes those derived from any amino carboxylic acid. + Amide derived from two or more amino carboxylic acid molecules (the same or different) by formation of a covalent bond from the carbonyl carbon of one to the nitrogen atom of another with formal loss of water. The term is usually applied to structures formed from alpha-amino acids, but it includes those derived from any amino carboxylic acid. X = OH, OR, NH2, NHR, etc. + + + + 0 + (C2H2NOR)nC2H3NOR + CHEBI:14753 + CHEBI:25906 + CHEBI:7990 + KEGG COMPOUND:C00012 + KEGG:C00012 + Peptide + peptides + chebi_ontology + C2H4NO2R(C2H2NOR)n + Peptid + peptido + peptidos + CHEBI:16670 + + peptide + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A six-carbon aromatic annulene in which each carbon atom donates one of its two 2p electrons into a delocalised pi system. A toxic, flammable liquid byproduct of coal distillation, it is used as an industrial solvent. Benzene is a carcinogen that also damages bone marrow and the central nervous system. + + 0 + C6H6 + InChI=1S/C6H6/c1-2-4-6-5-3-1/h1-6H + UHOVQNZJYSORNB-UHFFFAOYSA-N + 78.11184 + 78.04695 + c1ccccc1 + CHEBI:13876 + CHEBI:22703 + CHEBI:3025 + CHEBI:41187 + Beilstein:969212 + CAS:71-43-2 + Gmelin:1671 + HMDB:HMDB0001505 + KEGG:C01407 + PDBeChem:BNZ + PMID:11684179 + PMID:11993966 + PMID:12857942 + PMID:14677922 + PMID:15468289 + PMID:15935818 + PMID:16161967 + PMID:17373369 + PMID:18072742 + PMID:18407866 + PMID:18409691 + PMID:18836923 + PMID:19228219 + PMID:21325737 + PMID:23088855 + PMID:23222815 + PMID:23534829 + PMID:6353911 + PMID:8124204 + Reaxys:969212 + UM-BBD_compID:c0142 + Wikipedia:Benzene + BENZENE + Benzene + benzene + chebi_ontology + Benzen + Benzine + Benzol + Bicarburet of hydrogen + Coal naphtha + Mineral naphtha + Phene + Pyrobenzol + Pyrobenzole + [6]annulene + benzole + cyclohexatriene + phenyl hydride + CHEBI:16716 + + benzene + + + + + + + + + + + + + + + + + + + + + + 0 + C2H4NO2R + 74.05870 + 74.02420 + N[C@H]([*])C(O)=O + CHEBI:12909 + CHEBI:13625 + CHEBI:20906 + CHEBI:4097 + KEGG:C00405 + D-alpha-amino acid + D-alpha-amino acids + chebi_ontology + D-Amino acid + D-alpha-amino acids + CHEBI:16733 + + D-alpha-amino acid + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A member of the class of 2-benzofurans that is 2-benzofuran-1(3H)-one which is substituted at positions 4, 5, 6, and 7 by methyl, methoxy, (2E)-5-carboxy-3-methylpent-2-en-1-yl, and hydroxy groups, respectively. It is an antibiotic produced by Penicillium brevi-compactum, P. stoloniferum, P. echinulatum and related species. An immunosuppressant, it is widely used (partiularly as its sodium salt and as the 2-(morpholin-4-yl)ethyl ester prodrug, mycophenolate mofetil) to prevent tissue rejection following organ transplants and for the treatment of certain autoimmune diseases. + + 0 + C17H20O6 + InChI=1S/C17H20O6/c1-9(5-7-13(18)19)4-6-11-15(20)14-12(8-23-17(14)21)10(2)16(11)22-3/h4,20H,5-8H2,1-3H3,(H,18,19)/b9-4+ + HPNSFSBZBAHARI-RUDMXATFSA-N + 320.33710 + 320.12599 + COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(O)=O + CHEBI:43973 + Beilstein:318158 + CAS:24280-93-1 + DrugBank:DB01024 + Drug_Central:1860 + KEGG:D05096 + PDBeChem:MOA + PMID:11272311 + PMID:15470161 + PMID:16629948 + PMID:16640327 + PMID:17482154 + PMID:17498396 + PMID:18194117 + PMID:18611107 + PMID:18996104 + PMID:19689217 + Patent:US4753935 + Reaxys:318158 + Wikipedia:Mycophenolic_acid + (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enoic acid + chebi_ontology + (E)-6-(4-Hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoic acid + Micofenolico acido + Mycophenolate + Mycophenolsaeure + acide mycophenolique + acido micofenolico + acidum mycophenolicum + mycophenolic acid + CHEBI:168396 + + mycophenolic acid + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A monohydroxybenzoic acid that is benzoic acid with a hydroxy group at the ortho position. It is obtained from the bark of the white willow and wintergreen leaves. + + 0 + C7H6O3 + InChI=1S/C7H6O3/c8-6-4-2-1-3-5(6)7(9)10/h1-4,8H,(H,9,10) + YGSDEFSMJLZEOE-UHFFFAOYSA-N + 138.12070 + 138.03169 + OC(=O)c1ccccc1O + CHEBI:26597 + CHEBI:45521 + CHEBI:9006 + Beilstein:774890 + CAS:69-72-7 + DrugBank:DB00936 + Drug_Central:2416 + Gmelin:3418 + HMDB:HMDB0001895 + KEGG:C00805 + KEGG:D00097 + KNApSAcK:C00000206 + LINCS:LSM-4763 + MetaCyc:CPD-110 + PDBeChem:SAL + PMID:11016405 + PMID:12865403 + PMID:1650428 + PMID:19400653 + PMID:19816125 + PMID:22770225 + PMID:29079364 + PMID:3425858 + Reaxys:774890 + Wikipedia:Salicylic_Acid + 2-hydroxybenzoic acid + Salicylic acid + chebi_ontology + 2-HYDROXYBENZOIC ACID + 2-carboxyphenol + o-Hydroxybenzoic acid + o-carboxyphenol + o-hydroxybenzoic acid + CHEBI:16914 + + salicylic acid + + + + + + + + + deoxyribonucleic acid + High molecular weight, linear polymers, composed of nucleotides containing deoxyribose and linked by phosphodiester bonds; DNA contain the genetic information of organisms. + + + deoxyribonucleic acid + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + The D-enantiomer of phenylalanine. + + 0 + C9H11NO2 + InChI=1S/C9H11NO2/c10-8(9(11)12)6-7-4-2-1-3-5-7/h1-5,8H,6,10H2,(H,11,12)/t8-/m1/s1 + COLNVLDHVKWLRT-MRVPVSSYSA-N + 165.18918 + 165.07898 + N[C@H](Cc1ccccc1)C(O)=O + CHEBI:13007 + CHEBI:21067 + CHEBI:42207 + CHEBI:4224 + Beilstein:2804068 + CAS:673-06-3 + DrugBank:DB02556 + ECMDB:ECMDB20144 + Gmelin:83219 + KEGG:C02265 + MetaCyc:CPD-216 + PDBeChem:DPN + PMID:22382026 + PMID:22397264 + PMID:24464217 + PMID:7114516 + Reaxys:2804068 + YMDB:YMDB00995 + (2R)-2-amino-3-phenylpropanoic acid + D-PHENYLALANINE + D-Phenylalanine + D-phenylalanine + chebi_ontology + D-Phe + D-alpha-Amino-beta-phenylpropionic acid + DPN + phenylalanine D-form + CHEBI:16998 + + D-phenylalanine + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A C21-steroid hormone in which a pregnane skeleton carries oxo substituents at positions 3 and 20 and is unsaturated at C(4)-C(5). As a hormone, it is involved in the female menstrual cycle, pregnancy and embryogenesis of humans and other species. + + 0 + C21H30O2 + InChI=1S/C21H30O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h12,16-19H,4-11H2,1-3H3/t16-,17+,18-,19-,20-,21+/m0/s1 + RJKFOVLPORLFTN-LEKSSAKUSA-N + 314.46170 + 314.22458 + [H][C@@]12CCC3=CC(=O)CC[C@]3(C)[C@@]1([H])CC[C@]1(C)[C@H](CC[C@@]21[H])C(C)=O + CHEBI:14896 + CHEBI:18798 + CHEBI:26269 + CHEBI:439 + CHEBI:45786 + CHEBI:8453 + Beilstein:1915950 + CAS:57-83-0 + DrugBank:DB00396 + Drug_Central:2279 + Gmelin:708590 + HMDB:HMDB0001830 + KEGG:C00410 + KEGG:D00066 + MetaCyc:PROGESTERONE + PDBeChem:STR + PMID:10438974 + PMID:9506942 + Reaxys:1915950 + Wikipedia:Progesterone + PROGESTERONE + Progesterone + pregn-4-ene-3,20-dione + progesterone + chebi_ontology + (S)-4-Pregnene-3,20-dione + (S)-Pregn-4-en-3,20-dione + (S)-Progesterone + 17alpha-progesterone + 4-Pregnene-3,20-dione + Agolutin + Akrolutin + Crinone + Delta(4)-pregnene-3,20-dione + Gelbkoerperhormon + Progesteron + corpus luteum hormone + luteohormone + CHEBI:17026 + + progesterone + + + + + + + + + A compound in which a carbonyl group is bonded to two carbon atoms: R2C=O (neither R may be H). + + + 0 + COR2 + 28.010 + 27.99491 + [*]C([*])=O + CHEBI:13427 + CHEBI:13646 + CHEBI:24974 + CHEBI:6127 + CHEBI:8742 + KEGG COMPOUND:C00709 + KEGG COMPOUND:C01450 + KEGG:C01450 + Wikipedia:Ketone + Ketone + ketones + chebi_ontology + COR2 + Keton + R-CO-R' + [*]C([*])=O + a ketone + cetone + ketones + CHEBI:17087 + + ketone + + + + + + + + + + + + + + + A compound in which one or more of the OH groups of phosphoric acid have been replaced with an amino or substituted amino group. The term is commonly confined to the phosphoric triamides, P(=O)(NR2)3, since replacement of one or two OH groups produces phosphoramidic acids: P(=O)(OH)(NR2)2 , P(=O)(OH)2(NR2). + + CHEBI:14827 + CHEBI:26076 + CHEBI:8162 + chebi_ontology + phosphamide + phosphamides + phosphoramides + CHEBI:17102 + + phosphoramide + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + The L-enantiomer of serine. + + 0 + C3H7NO3 + InChI=1S/C3H7NO3/c4-2(1-5)3(6)7/h2,5H,1,4H2,(H,6,7)/t2-/m0/s1 + MTCFGRXMJLQNBG-REOHCLBHSA-N + 105.09262 + 105.04259 + N[C@@H](CO)C(O)=O + CHEBI:13167 + CHEBI:21387 + CHEBI:45440 + CHEBI:45451 + CHEBI:45590 + CHEBI:45597 + CHEBI:45677 + CHEBI:6301 + Beilstein:1721404 + CAS:56-45-1 + DrugBank:DB00133 + Drug_Central:4127 + ECMDB:ECMDB00187 + Gmelin:2570 + HMDB:HMDB0000187 + KEGG:C00065 + KEGG:D00016 + KNApSAcK:C00001393 + MetaCyc:SER + PDBeChem:SER + PMID:1650428 + PMID:17439666 + PMID:19062365 + PMID:21956576 + PMID:22265470 + PMID:22393170 + PMID:22547037 + PMID:22566084 + PMID:22566694 + Reaxys:1721404 + Wikipedia:L-serine + YMDB:YMDB00112 + L-Serine + L-serine + chebi_ontology + (2S)-2-amino-3-hydroxypropanoic acid + (S)-(-)-serine + (S)-2-amino-3-hydroxypropanoic acid + (S)-alpha-Amino-beta-hydroxypropionic acid + (S)-serine + L-(-)-serine + L-2-Amino-3-hydroxypropionic acid + L-3-Hydroxy-2-aminopropionic acid + L-3-Hydroxy-alanine + L-Ser + L-Serin + S + SERINE + Ser + Serine + beta-Hydroxy-L-alanine + beta-Hydroxyalanine + CHEBI:17115 + + L-serine + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + -1 + HO3S + InChI=1S/H2O3S/c1-4(2)3/h(H2,1,2,3)/p-1 + LSNNMFCWUKXFEE-UHFFFAOYSA-M + 81.07214 + 80.96519 + OS([O-])=O + CHEBI:13367 + CHEBI:5598 + CAS:15181-46-1 + Gmelin:1455 + KEGG:C11481 + PDBeChem:SO3 + hydrogen(trioxidosulfate)(1-) + hydrogensulfite(1-) + hydrogentrioxosulfate(1-) + hydrogentrioxosulfate(IV) + hydroxidodioxidosulfate(1-) + monohydrogentrioxosulfate + chebi_ontology + Bisulfite + HSO3(-) + HSO3- + Hydrogen sulfite + [SO2(OH)](-) + bisulfite + bisulphite + hydrogen sulfite(1-) + hydrosulfite anion + CHEBI:17137 + + hydrogensulfite + + + + + + + + + + + + + + + + + + + + + + + + + + + The 7H-tautomer of purine. + + 0 + C5H4N4 + InChI=1S/C5H4N4/c1-4-5(8-2-6-1)9-3-7-4/h1-3H,(H,6,7,8,9) + KDCGOANMDULRCW-UHFFFAOYSA-N + 120.11222 + 120.04360 + c1ncc2[nH]cnc2n1 + CHEBI:14968 + CHEBI:8639 + Beilstein:3200 + Gmelin:601779 + HMDB:HMDB0001366 + KEGG:C15587 + Reaxys:3200 + 7H-purine + chebi_ontology + Purine + Purine base + CHEBI:17258 + + 7H-purine + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + The L-enantiomer of phenylalanine. + + 0 + C9H11NO2 + InChI=1S/C9H11NO2/c10-8(9(11)12)6-7-4-2-1-3-5-7/h1-5,8H,6,10H2,(H,11,12)/t8-/m0/s1 + COLNVLDHVKWLRT-QMMMGPOBSA-N + 165.18918 + 165.07898 + N[C@@H](Cc1ccccc1)C(O)=O + CHEBI:13151 + CHEBI:21370 + CHEBI:44851 + CHEBI:44885 + CHEBI:45079 + CHEBI:6282 + Beilstein:1910408 + CAS:63-91-2 + DrugBank:DB00120 + Drug_Central:2144 + ECMDB:ECMDB00159 + Gmelin:50837 + HMDB:HMDB0000159 + KEGG:C00079 + KEGG:D00021 + KNApSAcK:C00001386 + MetaCyc:PHE + PDBeChem:PHE + PMID:13945318 + PMID:16893175 + PMID:17784858 + PMID:21203787 + PMID:21956539 + PMID:22081386 + PMID:22112574 + PMID:22143120 + PMID:22209218 + PMID:22494897 + PMID:23836015 + PMID:24464217 + PMID:24733517 + PMID:24966042 + Reaxys:1910408 + Wikipedia:Phenylalanine + YMDB:YMDB00304 + (2S)-2-amino-3-phenylpropanoic acid + L-Phenylalanine + L-phenylalanine + chebi_ontology + (S)-2-Amino-3-phenylpropionic acid + (S)-alpha-Amino-beta-phenylpropionic acid + 3-phenyl-L-alanine + F + PHENYLALANINE + Phe + beta-phenyl-L-alanine + CHEBI:17295 + + L-phenylalanine + + + + + + + + + + + + + + + + + A sulfur oxoanion that is the conjugate base of hydrogen sulfite (H2SO3). + + -2 + O3S + InChI=1S/H2O3S/c1-4(2)3/h(H2,1,2,3)/p-2 + LSNNMFCWUKXFEE-UHFFFAOYSA-L + 80.06420 + 79.95791 + [O-]S([O-])=O + CHEBI:15139 + CHEBI:45548 + CAS:14265-45-3 + Gmelin:1449 + PDBeChem:SO3 + sulfite + trioxidosulfate(2-) + trioxosulfate(2-) + trioxosulfate(IV) + chebi_ontology + SO3 + SO3(2-) + SULFITE ION + [SO3](2-) + sulphite + CHEBI:17359 + + sulfite + + + + + + + + + + + + + + + + + + + + + + + + + + + A pseudohalide anion that is the conjugate base of hydrogen cyanide. + + -1 + CN + InChI=1S/CN/c1-2/q-1 + XFXPMWWXUTWYJX-UHFFFAOYSA-N + 26.01740 + 26.00362 + [C-]#N + CHEBI:14038 + CHEBI:3969 + CHEBI:41780 + Beilstein:1900509 + CAS:57-12-5 + Gmelin:89 + HMDB:HMDB0002084 + KEGG:C00177 + MetaCyc:CPD-13584 + PDBeChem:CYN + PMID:11386635 + PMID:14871577 + PMID:17554165 + PMID:7839575 + Reaxys:1900509 + Wikipedia:Cyanide + Cyanide + cyanide + nitridocarbonate(1-) + chebi_ontology + CN(-) + CN- + CYANIDE ION + Prussiate + Zyanid + CHEBI:17514 + + cyanide + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + The carbon oxoanion resulting from the removal of a proton from carbonic acid. + + -1 + CHO3 + InChI=1S/CH2O3/c2-1(3)4/h(H2,2,3,4)/p-1 + BVKZGUZCCUSVTD-UHFFFAOYSA-M + 61.01684 + 60.99312 + OC([O-])=O + CHEBI:13363 + CHEBI:22863 + CHEBI:40961 + CHEBI:5589 + Beilstein:3903504 + CAS:71-52-3 + Gmelin:49249 + HMDB:HMDB0000595 + KEGG:C00288 + MetaCyc:HCO3 + PDBeChem:BCT + PMID:17215880 + PMID:17505962 + PMID:18439416 + PMID:28732801 + PMID:29150416 + PMID:29460248 + PMID:29466234 + PMID:4208463 + Wikipedia:Bicarbonate + Hydrogencarbonate + hydrogen(trioxidocarbonate)(1-) + hydrogencarbonate + hydrogencarbonate(1-) + hydrogentrioxocarbonate(1-) + hydrogentrioxocarbonate(IV) + hydroxidodioxidocarbonate(1-) + chebi_ontology + Acid carbonate + BICARBONATE ION + Bicarbonate + HCO3(-) + HCO3- + [CO2(OH)](-) + hydrogen carbonate + CHEBI:17544 + + hydrogencarbonate + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + The simplest member of the class toluenes consisting of a benzene core which bears a single methyl substituent. + + 0 + C7H8 + InChI=1S/C7H8/c1-7-5-3-2-4-6-7/h2-6H,1H3 + YXFVVABEGXRONW-UHFFFAOYSA-N + 92.13842 + 92.06260 + Cc1ccccc1 + CHEBI:15248 + CHEBI:27022 + CHEBI:44023 + CHEBI:9624 + Beilstein:635760 + CAS:108-88-3 + DrugBank:DB01900 + Gmelin:2456 + KEGG:C01455 + PDBeChem:MBN + PMID:11182169 + PMID:11314682 + PMID:11846266 + PMID:11991009 + PMID:12062755 + PMID:12213539 + PMID:12237258 + PMID:12784113 + PMID:12876426 + PMID:14512097 + PMID:14559343 + PMID:14605898 + PMID:15015825 + PMID:15019953 + PMID:15119846 + PMID:15193425 + PMID:15542760 + PMID:15567510 + PMID:15695158 + PMID:15796064 + PMID:16316648 + PMID:16348226 + PMID:16601996 + PMID:17145141 + PMID:17175136 + PMID:17497535 + PMID:17725881 + PMID:18397809 + PMID:18832024 + PMID:19261054 + PMID:19384711 + PMID:19429395 + PMID:19635754 + PMID:19765629 + PMID:19825861 + PMID:19928203 + PMID:19969016 + PMID:20347282 + PMID:20837561 + PMID:21430649 + PMID:21655021 + PMID:21731073 + PMID:21802510 + PMID:21840036 + Reaxys:635760 + UM-BBD_compID:c0114 + Wikipedia:Toluene + TOLUENE + Toluene + toluene + chebi_ontology + Toluen + Toluol + methylbenzene + phenylmethane + CHEBI:17578 + + toluene + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A 2'-deoxycytidine having geminal fluoro substituents in the 2'-position. An inhibitor of ribonucleotide reductase, gemcitabine is used in the treatment of various carcinomas, particularly non-small cell lung cancer, pancreatic cancer, bladder cancer and breast cancer. + + 0 + C9H11F2N3O4 + InChI=1S/C9H11F2N3O4/c10-9(11)6(16)4(3-15)18-7(9)14-2-1-5(12)13-8(14)17/h1-2,4,6-7,15-16H,3H2,(H2,12,13,17)/t4-,6-,7-/m1/s1 + SDUQYLNIPVEERB-QPPQHZFASA-N + 263.19810 + 263.07176 + Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1 + CHEBI:42752 + CHEBI:5295 + Beilstein:5382060 + CAS:95058-81-4 + DrugBank:DB00441 + Drug_Central:1283 + KEGG:C07650 + KEGG:D02368 + LINCS:LSM-5333 + PDBeChem:GEO + PMID:11034044 + PMID:11061612 + PMID:11088063 + PMID:11122828 + PMID:11132538 + PMID:11142482 + PMID:11221019 + PMID:11356111 + PMID:11374818 + PMID:11489002 + PMID:11504793 + PMID:11510027 + PMID:11585734 + PMID:11595724 + PMID:11807603 + PMID:11859947 + PMID:11901308 + PMID:12057041 + PMID:12057046 + PMID:12057157 + PMID:12115355 + PMID:12142097 + PMID:12520460 + PMID:12571808 + PMID:12722678 + PMID:12722691 + PMID:12743987 + PMID:12761494 + PMID:12798170 + PMID:12917815 + PMID:12954073 + PMID:14606642 + PMID:14653877 + PMID:14720338 + PMID:15131028 + PMID:15160243 + PMID:15221904 + PMID:15282439 + PMID:15297392 + PMID:15542781 + PMID:15637766 + PMID:15744590 + PMID:16001951 + PMID:16041610 + PMID:16080557 + PMID:16143373 + PMID:16149285 + PMID:16317298 + PMID:16500746 + PMID:16555971 + PMID:16584929 + PMID:16807461 + PMID:16807463 + PMID:16894289 + PMID:16905983 + PMID:17101674 + PMID:17296311 + PMID:17296587 + PMID:17347561 + PMID:17429628 + PMID:17460420 + PMID:17602464 + PMID:17639396 + PMID:17887663 + PMID:17939651 + PMID:17941128 + PMID:17987263 + PMID:18035967 + PMID:18050344 + PMID:18086345 + PMID:18166944 + PMID:18186604 + PMID:18257544 + PMID:18348652 + PMID:18773046 + PMID:18789834 + PMID:18819792 + PMID:18981552 + PMID:19034448 + PMID:19177022 + PMID:19399788 + PMID:19839926 + PMID:19879060 + PMID:22763439 + PMID:28594276 + PMID:28608357 + PMID:28912244 + Patent:EP1939198 + Patent:EP2108368 + Patent:EP2275135 + Patent:GB2136425 + Patent:US2009124797 + Patent:US2010111852 + Patent:US4808614 + Reaxys:5382060 + Wikipedia:Gemcitabine + 2'-deoxy-2',2'-difluorocytidine + chebi_ontology + 2',2'-Difluorodeoxycytidine + 2'-Deoxy-2',2'-difluorocytidine + 4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one + gemcitabina + gemcitabine + gemcitabinum + CHEBI:175901 + + gemcitabine + + + + + + + + + + + + + + + A primary ammonium ion obtained by protonation of the amino goup of any alkylamine; major species at pH 7.3. + + +1 + H3NR + 17.031 + 17.02655 + [NH3+][*] + CHEBI:66885 + MetaCyc:Alkylamines + PMID:9989229 + chebi_ontology + alkylamine cation + alkylaminium cation + alkylaminium(1+) + an alkylamine + CHEBI:17664 + + alkylaminium + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + The primary alcohol that is the simplest aliphatic alcohol, comprising a methyl and an alcohol group. + + 0 + CH4O + InChI=1S/CH4O/c1-2/h2H,1H3 + OKKJLVBELUTLKV-UHFFFAOYSA-N + 32.04186 + 32.02621 + CO + CHEBI:14588 + CHEBI:25227 + CHEBI:44080 + CHEBI:44553 + CHEBI:6816 + Beilstein:1098229 + CAS:67-56-1 + Gmelin:449 + HMDB:HMDB0001875 + KEGG:C00132 + KEGG:D02309 + MetaCyc:METOH + PDBeChem:MOH + PMID:11141607 + PMID:11430978 + PMID:11489599 + PMID:11680737 + PMID:11684179 + PMID:14012711 + PMID:14678513 + PMID:14760634 + PMID:15172721 + PMID:15906011 + PMID:16705261 + PMID:17451998 + PMID:17733096 + PMID:19064074 + PMID:19850112 + PMID:20314698 + Reaxys:1098229 + UM-BBD_compID:c0132 + Wikipedia:Methanol + METHANOL + Methanol + methanol + chebi_ontology + CH3OH + MeOH + Methyl alcohol + Methylalkohol + carbinol + spirit of wood + wood alcohol + wood naphtha + wood spirit + CHEBI:17790 + + methanol + + + + + + + + + + A compound containing at least one carbon-halogen bond (where X is a halogen atom). + + 0 + RX + ** + CHEBI:13444 + CHEBI:36684 + CHEBI:8767 + KEGG:C01322 + MetaCyc:Organohalogen-Compounds + chebi_ontology + RX + organic halide + organic halides + organohalogen compounds + CHEBI:17792 + + organohalogen compound + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + An alpha-amino acid that is alanine substituted at position 3 by a hydroxy group. + + 0 + C3H7NO3 + InChI=1S/C3H7NO3/c4-2(1-5)3(6)7/h2,5H,1,4H2,(H,6,7) + MTCFGRXMJLQNBG-UHFFFAOYSA-N + 105.09262 + 105.04259 + NC(CO)C(O)=O + CHEBI:15081 + CHEBI:26648 + CHEBI:9116 + Beilstein:1721402 + CAS:302-84-1 + Gmelin:26429 + KEGG:C00716 + KNApSAcK:C00001393 + Reaxys:1721402 + Wikipedia:Serine + Serine + serine + chebi_ontology + 2-Amino-3-hydroxypropionic acid + 2-amino-3-hydroxypropanoic acid + 3-Hydroxyalanine + Serin + CHEBI:17822 + + serine + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A mononuclear parent hydride consisting of covalently bonded hydrogen and chlorine atoms. + + 0 + ClH + HCl + InChI=1S/ClH/h1H + VEXZGXHMUGYJMC-UHFFFAOYSA-N + 36.46064 + 35.97668 + Cl[H] + CHEBI:13364 + CHEBI:24635 + CHEBI:5590 + CAS:7647-01-0 + Drug_Central:4568 + Gmelin:322 + HMDB:HMDB0002306 + KEGG:C01327 + KEGG:D02057 + MetaCyc:HCL + PMID:15823700 + PMID:17492841 + PMID:22804993 + Reaxys:1098214 + Wikipedia:HCl + Wikipedia:Hydrochloric_acid + Hydrogen chloride + chlorane + chloridohydrogen + hydrogen chloride + chebi_ontology + Chlorwasserstoff + HCl + Hydrochloride + Hydrogenchlorid + Wasserstoffchlorid + [HCl] + chlorure d'hydrogene + cloruro de hidrogeno + hydrochloric acid + CHEBI:17883 + + hydrogen chloride + + + + + + + + + A molecular entity that can transfer ("donate") an electron, a pair of electrons, an atom or a group to another molecular entity. + + CHEBI:14202 + CHEBI:4697 + KEGG:C01351 + Donor + chebi_ontology + Donator + donneur + CHEBI:17891 + + donor + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + An aromatic alcohol that consists of benzene bearing a single hydroxymethyl substituent. + + 0 + C7H8O + InChI=1S/C7H8O/c8-6-7-4-2-1-3-5-7/h1-5,8H,6H2 + WVDDGKGOMKODPV-UHFFFAOYSA-N + 108.13782 + 108.05751 + OCc1ccccc1 + CHEBI:13888 + CHEBI:22742 + CHEBI:3053 + Beilstein:878307 + CAS:100-51-6 + Drug_Central:334 + Gmelin:26514 + HMDB:HMDB0003119 + KEGG:C00556 + KEGG:C03485 + KEGG:D00077 + KNApSAcK:C00029811 + MetaCyc:BENZYL-ALCOHOL + PMID:11766131 + PMID:21557223 + PMID:22036973 + Reaxys:878307 + UM-BBD_compID:c0278 + Wikipedia:Benzyl_Alcohol + Benzyl alcohol + benzyl alcohol + phenylmethanol + chebi_ontology + (hydroxymethyl)benzene + Aromatic alcohol + Benzenemethanol + Benzylalkohol + Hydroxymethylbenzene + Phenylcarbinol + Phenylmethanol + alcoholum benzylicum + alcool benzylique + alpha-Hydroxytoluene + alpha-toluenol + benzenecarbinol + benzylic alcohol + phenylmethyl alcohol + CHEBI:17987 + + benzyl alcohol + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A halide anion formed when chlorine picks up an electron to form an an anion. + + -1 + Cl + InChI=1S/ClH/h1H/p-1 + VEXZGXHMUGYJMC-UHFFFAOYSA-M + 35.45270 + 34.96940 + [Cl-] + CHEBI:13291 + CHEBI:13970 + CHEBI:3616 + CHEBI:3731 + CHEBI:48804 + Beilstein:3587171 + CAS:16887-00-6 + Gmelin:14910 + KEGG:C00115 + KEGG:C00698 + PDBeChem:CL + UM-BBD_compID:c0884 + Chloride + chloride + chloride(1-) + chebi_ontology + CHLORIDE ION + Chloride ion + Chloride(1-) + Chlorine anion + Cl(-) + Cl- + CHEBI:17996 + + chloride + + + + + + + + + 'Lipids' is a loosely defined term for substances of biological origin that are soluble in nonpolar solvents. They consist of saponifiable lipids, such as glycerides (fats and oils) and phospholipids, as well as nonsaponifiable lipids, principally steroids. + + CHEBI:14517 + CHEBI:25054 + CHEBI:6486 + KEGG:C01356 + Lipid + lipids + chebi_ontology + CHEBI:18059 + + lipid + + + + + + + + + + + + + + + + 0 + HX + 1.008 + 1.00783 + [F,Cl,Br,I] + CHEBI:13368 + CHEBI:37140 + CHEBI:5599 + hydrogen halide + hydrogen halides + chebi_ontology + HX + hydrogen halides + CHEBI:18140 + + hydrogen halide + + + + + + + + + + + 0 + C5H9O3R + 117.123 + 117.05517 + OC[C@H]1O[C@@H]([*])C[C@@H]1O + CHEBI:1083 + CHEBI:11394 + CHEBI:11567 + CHEBI:11568 + CHEBI:19259 + CHEBI:19560 + CHEBI:4421 + KEGG:C02269 + KEGG:C03216 + chebi_ontology + 2'-Deoxynucleoside + 2'-deoxyribonucleosides + 2-Deoxy-D-ribosyl-base + Deoxynucleoside + a 2'-deoxyribonucleoside + CHEBI:18274 + + 2'-deoxyribonucleoside + + + + + + + + + That part of DNA or RNA that may be involved in pairing. + + CHEBI:13873 + CHEBI:25598 + CHEBI:2995 + KEGG:C00701 + Wikipedia:Nucleobase + chebi_ontology + Base + nucleobases + CHEBI:18282 + + nucleobase + + + + + + + + + + An acyclic branched or unbranched hydrocarbon having the general formula CnH2n+2, and therefore consisting entirely of hydrogen atoms and saturated carbon atoms. + + 0 + CH3R + 15.035 + 15.02348 + C[*] + CHEBI:13435 + CHEBI:22317 + CHEBI:2576 + KEGG:C01371 + Alkane + alkane + alkanes + chebi_ontology + Alkan + RH + alcane + alcanes + alcano + alcanos + an alkane + CHEBI:18310 + + alkane + + + + + + + + + + + + + + + + A phosphate ion that is the conjugate base of hydrogenphosphate. + + -3 + O4P + InChI=1S/H3O4P/c1-5(2,3)4/h(H3,1,2,3,4)/p-3 + NBIIXXVUZAFLBC-UHFFFAOYSA-K + 94.97136 + 94.95507 + [O-]P([O-])([O-])=O + CHEBI:14791 + CHEBI:45024 + CHEBI:7793 + Beilstein:3903772 + CAS:14265-44-2 + Gmelin:1997 + KEGG:C00009 + PDBeChem:PO4 + Reaxys:3903772 + phosphate + tetraoxidophosphate(3-) + tetraoxophosphate(3-) + tetraoxophosphate(V) + chebi_ontology + Orthophosphate + PHOSPHATE ION + PO4(3-) + Phosphate + [PO4](3-) + CHEBI:18367 + + phosphate(3-) + + + + + + + + + + + + + + + A compound having the structure RC#N; thus a C-substituted derivative of hydrocyanic acid, HC#N. In systematic nomenclature, the suffix nitrile denotes the triply bound #N atom, not the carbon atom attached to it. + + 0 + CNR + 26.01740 + 26.00307 + [*]C#N + CHEBI:13212 + CHEBI:13426 + CHEBI:13660 + CHEBI:25547 + CHEBI:7584 + KEGG:C00726 + Nitrile + nitrile + nitriles + chebi_ontology + Nitril + R-CN + a nitrile + nitrilos + CHEBI:18379 + + nitrile + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A one-carbon compound consisting of a methine group triple bonded to a nitrogen atom + + 0 + CHN + InChI=1S/CHN/c1-2/h1H + LELOWRISYMNNSU-UHFFFAOYSA-N + 27.02530 + 27.01090 + C#N + CHEBI:13362 + CHEBI:5786 + CAS:74-90-8 + HMDB:HMDB0060292 + KEGG:C01326 + KNApSAcK:C00007569 + MetaCyc:HCN + PMID:19849830 + PMID:26700190 + PMID:26778429 + PMID:26823582 + PMID:26940198 + PMID:27123778 + Reaxys:1718793 + Wikipedia:Hydrogen_cyanide + Hydrogen cyanide + hydridonitridocarbon + hydrogen cyanide + hydrogen(nitridocarbonate) + methanenitrile + chebi_ontology + Blausaeure + Cyanwasserstoff + HCN + [CHN] + formonitrile + hydrocyanic acid + CHEBI:18407 + + hydrogen cyanide + + + + + + + + + + chebi_ontology + 11alpha-hydroxy steroids + CHEBI:19129 + + 11alpha-hydroxy steroid + + + + + + + + + + + chebi_ontology + pyrimidine 2'-deoxyribonucleosides + CHEBI:19255 + + pyrimidine 2'-deoxyribonucleoside + + + + + + + + + + Any 3-oxo steroid that contains a double bond between positions 1 and 2. + + 0 + C19H27OR + 271.418 + 271.20619 + C12C(C3C(C(CC3)*)(C)CC1)CCC4C2(C=CC(C4)=O)C + CHEBI:13603 + CHEBI:1625 + KEGG:C02941 + MetaCyc:3-Oxo-Delta-1-Steroids + 3-oxo-Delta(1) steroid + chebi_ontology + 3-keto-Delta(1) steroid + 3-keto-Delta(1) steroids + 3-oxo Delta(1)-steroid + 3-oxo Delta(1)-steroids + 3-oxo-Delta(1) steroids + 3-oxo-Delta(1)-steroids + 3-oxo-Delta1-steroid + 3-oxo-Delta1-steroids + a 3-oxo-Delta(1)-steroid + CHEBI:20156 + + 3-oxo-Delta(1) steroid + + + + + + + + + Any aminopurine having the amino substituent at the 2-position. + + 2-aminopurines + chebi_ontology + CHEBI:20702 + + 2-aminopurines + + + + + + + + + + A mitochondrial respiratory-chain inhibitor that interferes with the action of ATP synthase. + + chebi_ontology + CHEBI:20854 + + ATP synthase inhibitor + + + + + + + + + + A glycosyl compound arising formally from the elimination of water from a glycosidic hydroxy group and an H atom bound to a carbon atom, thus creating a C-C bond. + + chebi_ontology + C-glycoside + C-glycosides + C-glycosyl compounds + CHEBI:20857 + + C-glycosyl compound + + + + + + + + + + + A glycosyl compound arising formally from the elimination of water from a glycosidic hydroxy group and an H atom bound to a nitrogen atom, thus creating a C-N bond. + + + glycosylamine + chebi_ontology + N-glycoside + N-glycosides + N-glycosyl compounds + glycosylamines + CHEBI:21731 + + N-glycosyl compound + + + + + + + + + An organosulfur compound having the structure R2S=O or R2C=S=O (R =/= H). + + CHEBI:35813 + sulfoxide + chebi_ontology + S-oxides + sulfoxides + CHEBI:22063 + + sulfoxide + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A thiol that is the tautomer of mercaptopurine. + + 0 + C5H4N4S + InChI=1S/C5H4N4S/c10-5-3-4(7-1-6-3)8-2-9-5/h1-2H,(H2,6,7,8,9,10) + GLVAUDGFNGKCSF-UHFFFAOYSA-N + 152.17822 + 152.01567 + Sc1ncnc2nc[nH]c12 + CAS:50-44-2 + DrugBank:DB01033 + KEGG:C01756 + KEGG:C02380 + PDBeChem:PM6 + PMID:24211998 + PMID:24651962 + PMID:24670805 + PMID:24774509 + Reaxys:608595 + 7H-purine-6-thiol + chebi_ontology + 1,7-Dihydro-6H-purine-6-thione + 3H-Purine-6-thiol + 6-MP + 6-Thiohypoxanthine + CHEBI:2208 + + purine-6-thiol + + + + + + + + + A substance used to destroy pests of the subclass Acari (mites and ticks). + + Wikipedia:Acaricide + chebi_ontology + Akarizid + Akarizide + acaricides + miticide + CHEBI:22153 + + acaricide + + + + + + + + + Compounds with the general formula RNHC(=O)CH3. + + chebi_ontology + CHEBI:22160 + + acetamides + + + + + + + + + An organic group formed by removing one or more hydroxy groups from an oxoacid that has the general structure RkE(=O)l(OH)m (l =/= 0). Although the term is almost always applied to organic compounds, with carboxylic acid as the oxoacid, acyl groups can in principle be derived from other types of acids such as sulfonic acids or phosphonic acids. + + acyl group + alkanoyl + chebi_ontology + acyl groups + alkanoyl group + groupe acyle + CHEBI:22221 + + acyl group + + + + + + + + + + + + + + + Any of basic nitrogen compounds (mostly heterocyclic) occurring mostly in the plant kingdom (but not excluding those of animal origin). Amino acids, peptides, proteins, nucleotides, nucleic acids, amino sugars and antibiotics are not normally regarded as alkaloids. By extension, certain neutral compounds biogenetically related to basic alkaloids are included. + Any of the naturally occurring, basic nitrogen compounds (mostly heterocyclic) occurring mostly in the plant kingdom, but also found in bacteria, fungi, and animals. By extension, certain neutral compounds biogenetically related to basic alkaloids are also classed as alkaloids. Amino acids, peptides, proteins, nucleotides, nucleic acids, amino sugars and antibiotics are not normally regarded as alkaloids. Compounds in which the nitrogen is exocyclic (dopamine, mescaline, serotonin, etc.) are usually classed as amines rather than alkaloids. + + + Wikipedia:Alkaloid + Alkaloid + alkaloids + chebi_ontology + Alkaloide + alcaloide + alcaloides + CHEBI:22315 + + alkaloid + + + + + + + + + + + + + + + A univalent group -CnH2n+1 derived from an alkane by removal of a hydrogen atom from any carbon atom. + + alkyl group + alkyl groups + chebi_ontology + groupe alkyle + grupo alquilo + grupos alquilo + CHEBI:22323 + + alkyl group + + + + + + + + + Highly reactive chemical that introduces alkyl radicals into biologically active molecules and thereby prevents their proper functioning. It could be used as an antineoplastic agent, but it might be very toxic, with carcinogenic, mutagenic, teratogenic, and immunosuppressant actions. It could also be used as a component of poison gases. + + chebi_ontology + CHEBI:22333 + + alkylating agent + + + + + + + + + + An alcohol containing an amino functional group in addition to the alcohol-defining hydroxy group. + + chebi_ontology + amino alcohols + aminoalcohol + aminoalcohols + CHEBI:22478 + + amino alcohol + + + + + + + + + Any purine having at least one amino substituent. + + chebi_ontology + aminopurines + CHEBI:22527 + + aminopurine + + + + + + + + + A monoatomic or polyatomic species having one or more elementary charges of the electron. + + Anion + anion + chebi_ontology + Anionen + aniones + anions + CHEBI:22563 + + anion + + + + + + + + + A substance that opposes oxidation or inhibits reactions brought about by dioxygen or peroxides. + + chebi_ontology + antioxidants + antioxydant + antoxidant + CHEBI:22586 + + antioxidant + + + + + + + + + A substance that destroys or inhibits replication of viruses. + + chebi_ontology + anti-viral agent + anti-viral agents + antiviral + antiviral agents + antivirals + CHEBI:22587 + + antiviral agent + + + + + + + + + + A monocarboxylic acid amide in which the amide linkage is bonded directly to an arene ring system. + + chebi_ontology + arenecarboxamides + CHEBI:22645 + + arenecarboxamide + + + + + + + + + A molecular entity having an available pair of electrons capable of forming a covalent bond with a hydron (Bronsted base) or with the vacant orbital of some other molecular entity (Lewis base). + + KEGG:C00701 + Base + base + chebi_ontology + Base1 + Base2 + Basen + Nucleobase + bases + CHEBI:22695 + + base + + + + + + + + + + chebi_ontology + CHEBI:22702 + + benzamides + + + + + + + + + Any benzenoid aromatic compound consisting of the benzene skeleton and its substituted derivatives. + + chebi_ontology + CHEBI:22712 + + benzenes + + + + + + + + + + An organic heterocyclic compound containing a benzene ring fused to an imidazole ring. + + chebi_ontology + CHEBI:22715 + + benzimidazoles + + + + + + + + + A monocarboxylic acid anion obtained by deprotonation of the carboxy group of any benzoic acid. + + chebi_ontology + benzoate anion + CHEBI:22718 + + benzoates + + + + + + + + + + Any aromatic carboxylic acid that consists of benzene in which at least a single hydrogen has been substituted by a carboxy group. + + chebi_ontology + CHEBI:22723 + + benzoic acids + + + + + + + + + + + Wikipedia:Benzopyran + chebi_ontology + benzopyrans + CHEBI:22727 + + benzopyran + + + + + + + + + + + + + chebi_ontology + benzopyrroles + CHEBI:22728 + + benzopyrrole + + + + + + + + + Compounds containing a phenylmethanol skeleton. + + chebi_ontology + benzylic alcohol + benzylic alcohols + CHEBI:22743 + + benzyl alcohols + + + + + + + + + + + + + + + + + 0 + C7H7 + 91.13048 + 91.05478 + C1=C(C=CC=C1)C* + benzyl + chebi_ontology + Bn + C6H5-CH2- + phenylalanine side-chain + phenylmethyl + CHEBI:22744 + + benzyl group + + + + + + + + + Any isoquinoline alkaloid based on a benzylisoquinoline skeleton. + + chebi_ontology + benzylisoquinoline alkaloids + CHEBI:22750 + + benzylisoquinoline alkaloid + + + + + + + + + + + + + + + Any amino acid in which the parent hydrocarbon chain has one or more alkyl substituents + + chebi_ontology + branched chain amino acids + CHEBI:22918 + + branched-chain amino acid + + + + + + + + + + + + + + + + 0 + Br + InChI=1S/Br + WKBOTKDWSSQWDR-UHFFFAOYSA-N + 79.90400 + 78.91834 + [Br] + WebElements:Br + bromine + chebi_ontology + 35Br + Br + Brom + brome + bromine + bromo + bromum + CHEBI:22927 + + bromine atom + + + + + + + + + + + + + + + + bromine molecular entity + chebi_ontology + bromine compounds + bromine molecular entities + CHEBI:22928 + + bromine molecular entity + + + + + + + + + + + 0 + C24H38O2 + InChI=1S/C24H38O2/c1-23-13-4-3-5-17(23)7-8-18-20-10-9-19(16-6-11-22(25)26-15-16)24(20,2)14-12-21(18)23/h16-21H,3-15H2,1-2H3/t16-,17?,18-,19+,20+,21-,23-,24+/m0/s1 + PXOHOSHERMSUCD-YQMMVUDVSA-N + 358.55732 + 358.28718 + [H][C@@]1(CCC(=O)OC1)[C@@]1([H])CC[C@]2([H])[C@]3([H])CCC4CCCC[C@]4(C)[C@@]3([H])CC[C@]12C + bufanolide + chebi_ontology + CHEBI:22934 + + bufanolide + + + + + + + + + + + + + + + Any ester of carbamic acid or its N-substituted derivatives. + + Wikipedia:Carbamate + chebi_ontology + carbamate esters + carbamates + CHEBI:23003 + + carbamate ester + + + + + + + + + + + + + + + The univalent carboacyl group formed by loss of -OH from the carboxy group of carbamic acid. + + 0 + CH2NO + 44.03272 + 44.01364 + *C(N)=O + PMID:24168430 + carbamoyl + chebi_ontology + -C(O)NH2 + -CONH2 + aminocarbonyl + carbamyl + carbamyl group + carboxamide + CHEBI:23004 + + carbamoyl group + + + + + + + + + + 0 + CO + 28.01010 + 27.99491 + O=C(*)* + carbonyl + carbonyl group + chebi_ontology + >C=O + CHEBI:23019 + + carbonyl group + + + + + + + + + + + + + + + + + + chebi_ontology + chloride salts + chlorides + CHEBI:23114 + + chloride salt + + + + + + + + + + + + + + + + 0 + Cl + InChI=1S/Cl + ZAMOUSCENKQFHK-UHFFFAOYSA-N + 35.45270 + 34.96885 + [Cl] + WebElements:Cl + chlorine + chebi_ontology + 17Cl + Chlor + Cl + chlore + chlorine + chlorum + cloro + CHEBI:23116 + + chlorine atom + + + + + + + + + + + + + + + A halogen molecular entity containing one or more atoms of chlorine. + + + chebi_ontology + CHEBI:23117 + + chlorine molecular entity + + + + + + + + + + Any organochlorine compound containing a benzene ring which is substituted by one or more chlorines. + + chebi_ontology + CHEBI:23132 + + chlorobenzenes + + + + + + + + + An organic molecule or ion (usually a metal ion) that is required by an enzyme for its activity. It may be attached either loosely (coenzyme) or tightly (prosthetic group). + + Wikipedia:Cofactor_(biochemistry) + cofactor + cofactors + chebi_ontology + CHEBI:23357 + + cofactor + + + + + + + + + + + molecular entity + Any constitutionally or isotopically distinct atom, molecule, ion, ion pair, radical, radical ion, complex, conformer etc., identifiable as a separately distinguishable entity. + We are assuming that every molecular entity has to be completely connected by chemical bonds. This excludes protein complexes, which are comprised of minimally two separate molecular entities. We will follow up with Chebi to ensure this is their understanding as well + + + + + + molecular entity + chebi_ontology + . + entidad molecular + entidades moleculares + entite moleculaire + molecular entities + molekulare Entitaet + CHEBI:23367 + + molecular entity + + + + + + + + + + + + + + + Salts and C-organyl derivatives of hydrogen cyanide, HC#N. + + cyanides + chebi_ontology + CHEBI:23424 + + cyanides + + + + + + + + + + CHEBI:3990 + cyclic amide + chebi_ontology + cyclic amides + CHEBI:23443 + + cyclic amide + + + + + + + + + + + chebi_ontology + Cyclopeptid + Zyklopeptid + cyclic peptides + peptide cyclique + peptido ciclico + CHEBI:23449 + + cyclic peptide + + + + + + + + + + chebi_ontology + deoxyribonucleosides + CHEBI:23636 + + deoxyribonucleoside + + + + + + + + + A natural or synthetic compound having a sequence of amino and hydroxy carboxylic acid residues (usually alpha-amino and alpha-hydroxy acids), commonly but not necessarily regularly alternating. + + depsipeptides + chebi_ontology + Depsipeptid + CHEBI:23643 + + depsipeptide + + + + + + + + + An azole that is either one of a pair of heterocyclic organic compounds comprising three carbon atoms and two nitrogen atoms arranged in a ring. + + chebi_ontology + diazoles + CHEBI:23677 + + diazole + + + + + + + + + + chebi_ontology + dicarboxylic acid amides + CHEBI:23690 + + dicarboxylic acid amide + + + + + + + + + Any member of the class of chlorobenzenes carrying two chloro groups at unspecified positions. + + 0 + C6H4Cl2 + 147.002 + 145.96901 + dichlorobenzene + chebi_ontology + Dichlorbenzol + dichlorobenzenes + CHEBI:23697 + + dichlorobenzene + + + + + + + + + + chebi_ontology + quinolones + CHEBI:23765 + + quinolone + + + + + + + + + A compound that contains two hydroxy groups, generally assumed to be, but not necessarily, alcoholic. Aliphatic diols are also called glycols. + + Wikipedia:Diol + diols + chebi_ontology + CHEBI:23824 + + diol + + + + + + + + + Any substance which when absorbed into a living organism may modify one or more of its functions. The term is generally accepted for a substance taken for a therapeutic purpose, but is also commonly used for abused substances. + + chebi_ontology + drugs + medicine + CHEBI:23888 + + drug + + + + + + + + + + + chebi_ontology + monoatomic anions + CHEBI:23905 + + monoatomic anion + + + + + + + + + + A compound or agent that combines with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. + + enzyme inhibitor + chebi_ontology + enzyme inhibitors + inhibidor enzimatico + inhibidores enzimaticos + inhibiteur enzymatique + inhibiteurs enzymatiques + CHEBI:23924 + + enzyme inhibitor + + + + + + + + + + chebi_ontology + ethanolamine + CHEBI:23981 + + ethanolamines + + + + + + + + + Any primary alcohol based on an ethanol skeleton. + + chebi_ontology + CHEBI:23982 + + ethanols + + + + + + + + + + + + + + + + + + + + + Any carboxylic ester resulting from the formal condensation of the carboxy group of a carboxylic acid with ethanol. + + 0 + C3H5O2R + 73.07060 + 73.02895 + CCOC([*])=O + CHEBI:85056 + chebi_ontology + carboxylic acid ethyl ester + carboxylic acid ethyl esters + ethyl carboxylate + ethyl carboxylates + ethyl esters + CHEBI:23990 + + ethyl ester + + + + + + + + + A member of the class of flavonoid with a 2-aryl-1-benzopyran-4-one (2-arylchromen-4-one) skeleton and its substituted derivatives. + + 0 + C15O2R10 + 212.160 + 211.98983 + O1C2=C(C(C(=C1C3=C(C(=C(C(=C3*)*)*)*)*)*)=O)C(=C(C(=C2*)*)*)* + MetaCyc:Flavones + Wikipedia:Flavone + chebi_ontology + 2-aryl-1-benzopyran-4-one + 2-aryl-1-benzopyran-4-ones + 2-arylchromen-4-one + 2-arylchromen-4-ones + a flavone + CHEBI:24043 + + flavones + + + + + + + + + + + + + + + + 0 + F + InChI=1S/F + YCKRFDGAMUMZLT-UHFFFAOYSA-N + 18.99840 + 18.99840 + [F] + CAS:7782-41-4 + WebElements:F + fluorine + chebi_ontology + 9F + F + Fluor + fluor + fluorine + fluorum + CHEBI:24061 + + fluorine atom + + + + + + + + + + + + + + + + + fluorine molecular entity + chebi_ontology + fluorine compounds + fluorine molecular entities + CHEBI:24062 + + fluorine molecular entity + + + + + + + + + + A haloalkane that is an alkane in which at least one hydrogen atom has been replaced by a fluorine atom. + + fluoroalkane + chebi_ontology + fluoroalkanes + CHEBI:24067 + + fluoroalkane + + + + + + + + + + A substance used to destroy fungal pests. + + chebi_ontology + fungicides + CHEBI:24127 + + fungicide + + + + + + + + + + Compounds containing at least one furan ring. + + chebi_ontology + oxacyclopenta-2,4-dienes + CHEBI:24129 + + furans + + + + + + + + + + 0 + C20H33 + 273.47602 + 273.25823 + CC(=CCC/C(=C/CC/C(=C/CC/C(=C/C*)/C)/C)/C)C + (2E,6E,10E)-3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraen-1-yl + chebi_ontology + (2E,6E,10E)-3,7,11,15-tetramethyl-2,6,10,14-hexadecatetraen-1-yl group + CHEBI:24231 + + geranylgeranyl group + + + + + + + + + Glucocorticoids are a class of steroid hormones that regulate a variety of physiological processes, in particular control of the concentration of glucose in blood. + + chebi_ontology + glucocorticoids + CHEBI:24261 + + glucocorticoid + + + + + + + + + + Any substance produced by linking glucuronic acid to another substance via a glycosidic bond. + + chebi_ontology + glucosiduronic acids + glucuronide + CHEBI:24302 + + glucosiduronic acid + + + + + + + + + + Any carbohydrate derivative that consists of glycan moieties covalently attached to the side chains of the amino acid residues that constitute the peptide. + + CHEBI:24395 + CHEBI:5478 + glycopeptides + chebi_ontology + CHEBI:24396 + + glycopeptide + + + + + + + + + A glycosyl compound resulting from the attachment of a glycosyl group to a non-acyl group RO-, RS-, RSe-, etc. The bond between the glycosyl group and the non-acyl group is called a glycosidic bond. By extension, the terms N-glycosides and C-glycosides are used as class names for glycosylamines and for compounds having a glycosyl group attached to a hydrocarbyl group respectively. These terms are misnomers and should not be used. The preferred terms are glycosylamines and C-glycosyl compounds, respectively. + + glycosides + chebi_ontology + O-glycoside + O-glycosides + glycosides + CHEBI:24400 + + glycoside + + + + + + + + + + A chemical entity is a physical entity of interest in chemistry including molecular entities, parts thereof, and chemical substances. + + + + + chemical entity + chebi_ontology + . + grouped_by_chemistry + CHEBI:24431 + + chemical entity + + + + + + + + + A role played by the molecular entity or part thereof within a biological context. + + chebi_ontology + biological function + CHEBI:24432 + + biological role + + + + + + + + + + + + + + + A defined linked collection of atoms or a single atom within a molecular entity. + + group + chebi_ontology + Gruppe + Rest + groupe + grupo + grupos + CHEBI:24433 + + group + + + + + + + + + Any organonitrogen compound containing a carbamimidamido (guanidino) group. Guanidines have the general structure (R(1)R(2)N)(R(3)R(4)N)C=N-R(5) and are related structurally to amidines and ureas. + + chebi_ontology + CHEBI:24436 + + guanidines + + + + + + + + + An organohalogen compound that is an alkane in which at least one hydrogen atom has been replaced by with a halogen atom. + + chebi_ontology + alkyl halide + alkyl halides + haloalkanes + CHEBI:24469 + + haloalkane + + + + + + + + + + + + + + + + + halogen molecular entity + chebi_ontology + halogen compounds + halogen molecular entities + CHEBI:24471 + + halogen molecular entity + + + + + + + + + + + halogen + halogens + chebi_ontology + Halogene + group 17 elements + group VII elements + halogene + halogenes + halogeno + halogenos + CHEBI:24473 + + halogen + + + + + + + + + + + + + + + + chebi_ontology + CHEBI:24531 + + heterocyclic antibiotic + + + + + + + + + + + A cyclic compound having as ring members atoms of carbon and at least of one other element. + + + chebi_ontology + organic heterocycle + organic heterocyclic compounds + CHEBI:24532 + + organic heterocyclic compound + + + + + + + + + A heterodetic cyclic peptide is a peptide consisting only of amino-acid residues, but in which the linkages forming the ring are not solely peptide bonds; one or more is an isopeptide, disulfide, ester, or other bond. + + heterodetic cyclic peptide + chebi_ontology + heterodetic cyclic peptides + peptide cyclique heterodetique + peptido ciclico heterodetico + CHEBI:24533 + + heterodetic cyclic peptide + + + + + + + + + + A C6, medium-chain fatty acid carrying a double bond at any position along the main chain. + + 0 + C6H10O2 + 114.143 + 114.06808 + hexenoic acid + chebi_ontology + hexenoic acids + CHEBI:24580 + + hexenoic acid + + + + + + + + + A homodetic cyclic peptide is a cyclic peptide in which the ring consists solely of amino-acid residues in peptide linkages. + + + homodetic cyclic peptide + chebi_ontology + homodetic cyclic peptides + peptide cyclique homodetique + peptido ciclico homodetico + CHEBI:24613 + + homodetic cyclic peptide + + + + + + + + + + Originally referring to an endogenous compound that is formed in specialized organ or group of cells and carried to another organ or group of cells, in the same organism, upon which it has a specific regulatory function, the term is now commonly used to include non-endogenous, semi-synthetic and fully synthetic analogues of such compounds. + + chebi_ontology + endocrine + hormones + CHEBI:24621 + + hormone + + + + + + + + + Hydrazine (diazane) and its substituted derivatives. + + hydrazines + chebi_ontology + CHEBI:24631 + + hydrazines + + + + + + + + + A compound consisting of carbon and hydrogen only. + + hydrocarbon + hydrocarbons + chebi_ontology + Kohlenwasserstoff + Kohlenwasserstoffe + hidrocarburo + hidrocarburos + hydrocarbure + CHEBI:24632 + + hydrocarbon + + + + + + + + + + + + + + + + An oxoanion resulting from the removal of a proton from the hydroxy group of any hydroxamic acid. + + chebi_ontology + hydroxamate + hydroxamates + hydroxamic acid anions + hydroxamic anion + hydroxamic anions + CHEBI:24648 + + hydroxamic acid anion + + + + + + + + + + + + + + + A compound, RkE(=O)lNHOH, derived from an oxoacid RkE(=O)l(OH) (l =/= 0) by replacing -OH with -NHOH, and derivatives thereof. Specific examples of hydroxamic acids are preferably named as N-hydroxy amides. + + hydroxamic acids + chebi_ontology + N-hydroxy amide + N-hydroxy amides + N-hydroxy-amide + N-hydroxy-amides + N-hydroxyamide + N-hydroxyamides + hydroxamic acids + CHEBI:24650 + + hydroxamic acid + + + + + + + + + + + + + + + + + Hydroxides are chemical compounds containing a hydroxy group or salts containing hydroxide (OH(-)). + + + chebi_ontology + CHEBI:24651 + + hydroxides + + + + + + + + + + + + + + + + Any benzoate derivative carrying a single carboxylate group and at least one hydroxy substituent. + + chebi_ontology + hydroxybenzoates + CHEBI:24675 + + hydroxybenzoate + + + + + + + + + + + + + + + + + + + + + + Any benzoic acid carrying one or more phenolic hydroxy groups on the benzene ring. + + 0 + C7H6O3 + 138.121 + 138.03169 + CHEBI:50778 + hydroxybenzoic acid + chebi_ontology + hydroxybenzoic acids + CHEBI:24676 + + hydroxybenzoic acid + + + + + + + + + + Any flavone in which one or more ring hydrogens are replaced by hydroxy groups. + + chebi_ontology + hydroxyflavones + CHEBI:24698 + + hydroxyflavone + + + + + + + + + + + + + + + + 0 + CH3O + 31.03392 + 31.01839 + C(*)O + hydroxymethyl + chebi_ontology + -CH3-OH + serine side-chain + CHEBI:24712 + + hydroxymethyl group + + + + + + + + + A five-membered organic heterocycle containing two nitrogen atoms at positions 1 and 3, or any of its derivatives; compounds containing an imidazole skeleton. + + chebi_ontology + CHEBI:24780 + + imidazoles + + + + + + + + + + imide + chebi_ontology + imides + CHEBI:24782 + + imide + + + + + + + + + Any compound containing an indole skeleton. + + + chebi_ontology + CHEBI:24828 + + indoles + + + + + + + + + + + + + + + A compound which contains oxygen, at least one other element, and at least one hydrogen bound to oxygen, and which produces a conjugate base by loss of positive hydrogen ion(s) (hydrons). + + + oxoacid + oxoacids + chebi_ontology + oxacids + oxiacids + oxo acid + oxy-acids + oxyacids + CHEBI:24833 + + oxoacid + + + + + + + + + + + chebi_ontology + inorganic anions + CHEBI:24834 + + inorganic anion + + + + + + + + + A molecular entity that contains no carbon. + + + chebi_ontology + anorganische Verbindungen + inorganic compounds + inorganic entity + inorganic molecular entities + inorganics + CHEBI:24835 + + inorganic molecular entity + + + + + + + + + + + chebi_ontology + inorganic oxides + CHEBI:24836 + + inorganic oxide + + + + + + + + + + + anorganisches Salz + inorganic salts + CHEBI:24839 + inorganic salt + + + + + + + + + Strictly, a substance intended to kill members of the class Insecta. In common usage, any substance used for preventing, destroying, repelling or controlling insects. + + Wikipedia:Insecticide + chebi_ontology + insecticides + CHEBI:24852 + + insecticide + + + + + + + + + + + + + + + + + + + + + Chemical element with atomic number 53. + + 0 + I + InChI=1S/I + ZCYVEMRRCGMTRW-UHFFFAOYSA-N + 126.90447 + 126.90447 + [I] + WebElements:I + iodine + chebi_ontology + 53I + I + Iod + J + Jod + iode + iodine + iodium + yodo + CHEBI:24859 + + iodine atom + + + + + + + + + + + + + + + + iodine molecular entity + chebi_ontology + iodine compounds + iodine molecular entities + CHEBI:24860 + + iodine molecular entity + + + + + + + + + + + + + + + + + + + + + A salt is an assembly of cations and anions. + + + salt + chebi_ontology + Salz + Salze + ionic compound + ionic compounds + sal + sales + salts + sel + sels + CHEBI:24866 + + salt + + + + + + + + + + + chebi_ontology + monoatomic ions + CHEBI:24867 + + monoatomic ion + + + + + + + + + + chebi_ontology + organic salts + organisches Salz + CHEBI:24868 + + organic salt + + + + + + + + + A compound which can carry specific ions through membranes of cells or organelles. + + Wikipedia:Ionophore + ionophore + chebi_ontology + ionophores + CHEBI:24869 + + ionophore + + + + + + + + + A molecular entity having a net electric charge. + + + Ion + ion + chebi_ontology + Ionen + iones + ions + CHEBI:24870 + + ion + + + + + + + + + + Any lipid formally derived from isoprene (2-methylbuta-1,3-diene), the skeleton of which can generally be discerned in repeated occurrence in the molecule. The skeleton of isoprenoids may differ from strict additivity of isoprene units by loss or shift of a fragment, commonly a methyl group. The class includes both hydrocarbons and oxygenated derivatives. + + LIPID_MAPS_class:LMPR01 + PMID:12769708 + PMID:19219049 + isoprenoid + isoprenoids + chebi_ontology + isoprenoids + CHEBI:24913 + + isoprenoid + + + + + + + + + Any alkaloid that has a structure based on an isoquinoline nucleus. They are derived from the amino acids like tyrosine and phenylalanine. + + chebi_ontology + isoquinoline alkaloids + CHEBI:24921 + + isoquinoline alkaloid + + + + + + + + + + A class of organic heteropolycyclic compound consisting of isoquinoline and its substitution derivatives. + + chebi_ontology + CHEBI:24922 + + isoquinolines + + + + + + + + + + + Cyclic amides of amino carboxylic acids, having a 1-azacycloalkan-2-one structure, or analogues having unsaturation or heteroatoms replacing one or more carbon atoms of the ring. + + lactam + lactams + chebi_ontology + Laktam + Laktame + lactams + CHEBI:24995 + + lactam + + + + + + + + + + 0 + C55H86O24 + InChI=1S/C55H86O24/c1-10-23(2)46(71)79-43-44(72-24(3)60)55(22-59)26(17-50(43,4)5)25-11-12-30-51(6)15-14-32(52(7,21-58)29(51)13-16-53(30,8)54(25,9)18-31(55)61)75-49-41(77-48-38(67)36(65)34(63)28(20-57)74-48)39(68)40(42(78-49)45(69)70)76-47-37(66)35(64)33(62)27(19-56)73-47/h10-11,26-44,47-49,56-59,61-68H,12-22H2,1-9H3,(H,69,70)/b23-10-/t26-,27+,28+,29+,30+,31+,32-,33+,34+,35-,36-,37+,38+,39-,40-,41+,42-,43-,44-,47-,48-,49+,51-,52+,53+,54+,55-/m0/s1 + AXNVHPCVMSNXNP-OXPBSUTMSA-N + 1131.259 + 1130.55090 + C\C=C(\C)C(=O)O[C@H]1[C@H](OC(C)=O)[C@]2(CO)[C@H](O)C[C@]3(C)C(=CC[C@@H]4[C@@]5(C)CC[C@H](O[C@@H]6O[C@@H]([C@@H](O[C@@H]7O[C@H](CO)[C@@H](O)[C@H](O)[C@H]7O)[C@H](O)[C@H]6O[C@@H]6O[C@H](CO)[C@@H](O)[C@H](O)[C@H]6O)C(O)=O)[C@](C)(CO)[C@@H]5CC[C@@]34C)[C@@H]2CC1(C)C + CAS:6805-41-0 + KEGG:C08921 + KEGG:D07912 + KNApSAcK:C00003497 + Aescin + chebi_ontology + Escin + CHEBI:2500 + + Aescin + + + + + + + + + + + Any cyclic carboxylic ester containing a 1-oxacycloalkan-2-one structure, or an analogue having unsaturation or heteroatoms replacing one or more carbon atoms of the ring. + + + lactone + lactones + chebi_ontology + Lacton + Lakton + Laktone + lactona + lactonas + CHEBI:25000 + + lactone + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A branched-chain amino acid that consists of glycine in which one of the hydrogens attached to the alpha-carbon is substituted by an isobutyl group. + + 0 + C6H13NO2 + InChI=1S/C6H13NO2/c1-4(2)3-5(7)6(8)9/h4-5H,3,7H2,1-2H3,(H,8,9) + ROHFNLRQFUQHCH-UHFFFAOYSA-N + 131.17296 + 131.09463 + CC(C)CC(N)C(O)=O + Beilstein:636005 + CAS:328-39-2 + Gmelin:50203 + KEGG:C16439 + LIPID_MAPS_instance:LMFA01100048 + PMID:17439666 + Reaxys:636005 + Wikipedia:Leucine + leucine + chebi_ontology + (+-)-Leucine + (RS)-Leucine + 2-amino-4-methylpentanoic acid + DL-Leucine + Hleu + L + Leu + Leucin + Leuzin + CHEBI:25017 + + leucine + + + + + + + + + + + + + + + + A proteinogenic amino acid derivative resulting from reaction of L-leucine at the amino group or the carboxy group, or from the replacement of any hydrogen of L-leucine by a heteroatom. + + chebi_ontology + CHEBI:25018 + + L-leucine derivative + + + + + + + + + + + + + + + A macrocyclic lactone with a ring of twelve or more members which exhibits antibiotic activity. + + + chebi_ontology + Makrolidantibiotika + macrolide antibiotics + CHEBI:25105 + + macrolide antibiotic + + + + + + + + + + A macrocyclic lactone with a ring of twelve or more members derived from a polyketide. + + + Wikipedia:Macrolide + macrolide + macrolides + chebi_ontology + Makrolid + macrolides + CHEBI:25106 + + macrolide + + + + + + + + + Any intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites. + + CHEBI:26619 + CHEBI:35220 + metabolite + chebi_ontology + metabolites + primary metabolites + secondary metabolites + CHEBI:25212 + + metabolite + + + + + + + + + + + + + + + A 1,1-diunsubstituted alkanesulfonate that is the conjugate base of methanesulfonic acid. + + -1 + CH3O3S + InChI=1S/CH4O3S/c1-5(2,3)4/h1H3,(H,2,3,4)/p-1 + AFVFQIVMOAPDHO-UHFFFAOYSA-M + 95.09872 + 94.98084 + CS([O-])(=O)=O + MetaCyc:CPD-3746 + UM-BBD_compID:c0347 + methanesulfonate + chebi_ontology + methylsulfonate + CHEBI:25224 + + methanesulfonate + + + + + + + + + Compounds containing a benzene skeleton substituted with one methoxy group. + + chebi_ontology + monomethoxybenzenes + CHEBI:25235 + + monomethoxybenzene + + + + + + + + + + + + + + + Any carboxylic ester resulting from the formal condensation of a carboxy group with methanol. + + 0 + C2H3O2R + 59.044 + 59.01330 + COC([*])=O + chebi_ontology + carboxylic acid methyl ester + carboxylic acid methyl esters + CHEBI:25248 + + methyl ester + + + + + + + + + + chebi_ontology + mitochondrial electron transport chain inhibitors + mitochondrial electron-transport chain inhibitor + mitochondrial respiratory chain inhibitors + CHEBI:25355 + + mitochondrial respiratory-chain inhibitor + + + + + + + + + + CHEBI:25359 + modified amino acid + + + + + + + + + Any polyatomic entity that is an electrically neutral entity consisting of more than one atom. + + molecule + chebi_ontology + Molekuel + molecula + molecules + neutral molecular compounds + CHEBI:25367 + + molecule + + + + + + + + + + + + + + + An oxoacid containing a single carboxy group. + + chebi_ontology + monocarboxylic acids + CHEBI:25384 + + monocarboxylic acid + + + + + + + + + A hydroxybenzoate carrying a single hydroxy substituent at unspecified position. + + chebi_ontology + monohydroxybenzoates + CHEBI:25388 + + monohydroxybenzoate + + + + + + + + + Any hydroxybenzoic acid having a single phenolic hydroxy substituent on the benzene ring. + + chebi_ontology + monohydroxybenzoic acids + CHEBI:25389 + + monohydroxybenzoic acid + + + + + + + + + + + + + + + Any fatty acid with one double or triple bond in the fatty acid chain and singly bonded carbon atoms in the rest of the chain. MUFAs have positive effects on the cardiovascular system, and in diabetes treatment. + + PMID:10584045 + PMID:12936956 + chebi_ontology + MUFA + MUFAs + monounsaturated fatty acids + CHEBI:25413 + + monounsaturated fatty acid + + + + + + + + + An agent that increases the frequency of mutations above the normal background level, usually by interacting directly with DNA and causing it damage, including base substitution. + + Wikipedia:Mutagen + chebi_ontology + mutagene + mutagenes + mutagenic agent + mutageno + mutagenos + mutagens + CHEBI:25435 + + mutagen + + + + + + + + + + Poisonous substance produced by fungi. + + chebi_ontology + fungal toxins + mycotoxins + CHEBI:25442 + + mycotoxin + + + + + + + + + + Any benzenoid aromatic compound having a skeleton composed of two ortho-fused benzene rings. + + chebi_ontology + CHEBI:25477 + + naphthalenes + + + + + + + + + + + + + + + + 0 + C11H7O2 + 171.172 + 171.04460 + naphthalenecarboxylate + chebi_ontology + CHEBI:25482 + + naphthoate + + + + + + + + + + + + + + + + An aromatic carboxylic acid that consists of a naphthalene skeleton substituted by one or more carboxy groups. + + 0 + C11H8O2 + 172.180 + 172.05243 + naphthalenecarboxylic acid + chebi_ontology + CHEBI:25483 + + naphthoic acid + + + + + + + + + A substance used to destroy pests of the phylum Nematoda (roundworms). + + Wikipedia:Nematicide + chebi_ontology + nematicides + nematocide + nematocides + CHEBI:25491 + + nematicide + + + + + + + + + + + + + + + + + 0 + N + 14.007 + 14.00307 + WebElements:N + nitrogen + chebi_ontology + 7N + N + Stickstoff + azote + nitrogen + nitrogeno + CHEBI:25555 + + nitrogen atom + + + + + + + + + + + chebi_ontology + organonitrogen heterocyclic antibiotics + CHEBI:25558 + + organonitrogen heterocyclic antibiotic + + + + + + + + + + nonmetal + chebi_ontology + Nichtmetall + Nichtmetalle + no metal + no metales + non-metal + non-metaux + nonmetal + nonmetals + CHEBI:25585 + + nonmetal atom + + + + + + + + + + + + + + + + + + + + + + + + + + + + + Any of the 26-membered ring macrolides produced by Streptomyces species that can be toxic to other organisms through their ability to inhibit mitochondrial membrane-bound ATP synthases. + + 0 + C43H64O10R5 + 740.964 + 740.44995 + [C@@H]1([C@H](CC([C@]2(O1)C([C@@H]3OC(C=C[C@H](C)[C@@H](O)[C@H](C)C(=O)[C@H](C)[C@@H](O)[C@H](C)C([C@@]([C@@H](O)[C@H](C)CC=CC=C[C@@H](CC[C@@H]([C@H]3C)O2)CC)(*)C)=O)=O)(*)*)=*)C)C[C@H](O)* + Wikipedia:Oligomycin + chebi_ontology + oligomycins + CHEBI:25675 + + oligomycin + + + + + + + + + + + + chebi_ontology + organic heteromonocyclic compounds + CHEBI:25693 + + organic heteromonocyclic compound + + + + + + + + + + Any organic ion with a net negative charge. + + chebi_ontology + organic anions + CHEBI:25696 + + organic anion + + + + + + + + + + Any organic ion with a net positive charge. + + + chebi_ontology + organic cations + CHEBI:25697 + + organic cation + + + + + + + + + An organooxygen compound with formula ROR, where R is not hydrogen. + + 0 + OR2 + 15.99940 + 15.99491 + [*]O[*] + ether + ethers + chebi_ontology + ethers + CHEBI:25698 + + ether + + + + + + + + + + + + chebi_ontology + organic ions + CHEBI:25699 + + organic ion + + + + + + + + + An alcohol derived from an aliphatic compound. + + 0 + HOR + 17.007 + 17.00274 + O* + KEGG:C02525 + Aliphatic alcohol + chebi_ontology + aliphatic alcohols + an aliphatic alcohol + CHEBI:2571 + + aliphatic alcohol + + + + + + + + + + An oxide is a chemical compound of oxygen with other chemical elements. + + oxide + chebi_ontology + oxides + CHEBI:25741 + + oxide + + + + + + + + + + + + + + + Any fatty acid anion containing at least one C-C unsaturated bond; formed by deprotonation of the carboxylic acid moiety. + + chebi_ontology + CHEBI:2580 + + unsaturated fatty acid anion + + + + + + + + + + + + + + + + + 0 + O + InChI=1S/O + QVGXLLKOCUKJST-UHFFFAOYSA-N + 15.99940 + 15.99491 + [O] + KEGG:C00007 + WebElements:O + oxygen + chebi_ontology + 8O + O + Sauerstoff + oxigeno + oxygen + oxygene + CHEBI:25805 + + oxygen atom + + + + + + + + + + + + + + + + + oxygen molecular entity + chebi_ontology + oxygen molecular entities + CHEBI:25806 + + oxygen molecular entity + + + + + + + + + + chebi_ontology + CHEBI:25807 + + organooxygen heterocyclic antibiotic + + + + + + + + + + chebi_ontology + oxopurines + CHEBI:25810 + + oxopurine + + + + + + + + + + + chebi_ontology + pentacyclic triterpenoids + CHEBI:25872 + + pentacyclic triterpenoid + + + + + + + + + + + + + + + + chebi_ontology + CHEBI:25903 + + peptide antibiotic + + + + + + + + + Strictly, a substance intended to kill pests. In common usage, any substance used for controlling, preventing, or destroying animal, microbiological or plant pests. + + Wikipedia:Pesticide + pesticide + chebi_ontology + Pestizid + Pestizide + pesticides + CHEBI:25944 + + pesticide + + + + + + + + + + + + + + + An amino acid derivative resulting from reaction of alanine at the amino group or the carboxy group, or from the replacement of any hydrogen of phenylalanine by a heteroatom. The definition normally excludes peptides containing phenylalanine residues. + + chebi_ontology + CHEBI:25985 + + phenylalanine derivative + + + + + + + + + Any organic aromatic compound with a structure based on a phenylpropane skeleton. The class includes naturally occurring phenylpropanoid esters, flavonoids, anthocyanins, coumarins and many small phenolic molecules as well as their semi-synthetic and synthetic analogues. Phenylpropanoids are also precursors of lignin. + + Wikipedia:Phenylpropanoid + chebi_ontology + phenylpropanoids + CHEBI:26004 + + phenylpropanoid + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A phosphorus oxoacid that consists of one oxo and three hydroxy groups joined covalently to a central phosphorus atom. + + 0 + H3O4P + InChI=1S/H3O4P/c1-5(2,3)4/h(H3,1,2,3,4) + NBIIXXVUZAFLBC-UHFFFAOYSA-N + 97.99520 + 97.97690 + [H]OP(=O)(O[H])O[H] + Beilstein:1921286 + CAS:7664-38-2 + Drug_Central:4478 + Gmelin:2000 + HMDB:HMDB0002142 + KEGG:C00009 + KEGG:D05467 + KNApSAcK:C00007408 + PMID:11455380 + PMID:15630224 + PMID:17439666 + PMID:17518491 + PMID:22282755 + PMID:22333268 + PMID:22381614 + PMID:22401268 + Reaxys:1921286 + Wikipedia:Phosphoric_Acid + Phosphoric acid + phosphoric acid + tetraoxophosphoric acid + trihydrogen tetraoxophosphate(3-) + trihydroxidooxidophosphorus + chebi_ontology + H3PO4 + Orthophosphoric acid + Phosphate + Phosphorsaeure + Phosphorsaeureloesungen + [PO(OH)3] + acide phosphorique + acidum phosphoricum + orthophosphoric acid + CHEBI:26078 + + phosphoric acid + + + + + + + + + + + + + + + + chebi_ontology + CHEBI:26079 + + phosphoric acid derivative + + + + + + + + + + + + + + + + chebi_ontology + phosphorus molecular entities + CHEBI:26082 + + phosphorus molecular entity + + + + + + + + + + + + chebi_ontology + CHEBI:26144 + + piperazines + + + + + + + + + + + + chebi_ontology + CHEBI:26151 + + piperidines + + + + + + + + + A chemical, natural or artificial, that can affect the rate of growth of a plant. + + chebi_ontology + plant growth regulators + CHEBI:26155 + + plant growth regulator + + + + + + + + + + + + + + + Any amino acid whose side chain is capable of forming one or more hydrogen bonds. + + 0 + C2H4NO2R + 74.059 + 74.02420 + OC(C(*)N)=O + CHEBI:8283 + MetaCyc:Polar-amino-acids + PMID:12016058 + polar amino acid + chebi_ontology + polar amino acids + polar amino-acid + polar amino-acids + CHEBI:26167 + + polar amino acid + + + + + + + + + + chebi_ontology + CHEBI:26179 + + polyether antibiotic + + + + + + + + + + Natural and synthetic compounds containing alternating carbonyl and methylene groups ('beta-polyketones'), biogenetically derived from repeated condensation of acetyl coenzyme A (via malonyl coenzyme A), and usually the compounds derived from them by further condensations, etc. Considered by many to be synonymous with the less frequently used terms acetogenins and ketides. + Natural compounds containing alternating carbonyl and methylene groups ('beta-polyketones'), biogenetically derived from repeated condensation of acetyl coenzyme A (via malonyl coenzyme A), and usually the compounds derived from them by further condensations. Considered by many to be synonymous with the less frequently used terms acetogenins and ketides. + + + polyketide + chebi_ontology + polyketides + CHEBI:26188 + + polyketide + + + + + + + + + A compound that contains two or more hydroxy groups. + + chebi_ontology + polyols + CHEBI:26191 + + polyol + + + + + + + + + Members of the class of phenols that contain 2 or more benzene rings each of which is substituted by at least one hydroxy group. + + Wikipedia:Polyphenol + chebi_ontology + polyphenols + CHEBI:26195 + + polyphenol + + + + + + + + + + chebi_ontology + CHEBI:26201 + + polyprenyl group + + + + + + + + + + chebi_ontology + CHEBI:26249 + + prenyl groups + + + + + + + + + Any propanediol bearing hydroxy groups at positions 1 and 3. + + chebi_ontology + CHEBI:26287 + + propane-1,3-diols + + + + + + + + + + chebi_ontology + CHEBI:26288 + + propanediol + + + + + + + + + + A nucleobase whose skeleton is derived from purine. + + 0 + C5H3N4R2 + 119.104 + 119.03577 + C1(NC(=NC=2NC=NC12)*)=* + KEGG:C15587 + purine nucleobase + chebi_ontology + a purine nucleobase + purine bases + purine nucleobases + CHEBI:26386 + + purine nucleobase + + + + + + + + + A class of imidazopyrimidines that consists of purine and its substituted derivatives. + + 0 + C5N4R7 + 116.080 + 116.01230 + CHEBI:13678 + chebi_ontology + CHEBI:26401 + + purines + + + + + + + + + + chebi_ontology + CHEBI:26410 + + pyrazoles + + + + + + + + + + Any organonitrogen heterocyclic compound based on a pyridine skeleton and its substituted derivatives. + + + chebi_ontology + CHEBI:26421 + + pyridines + + + + + + + + + + + KEGG:C03169 + chebi_ontology + N-D-Ribosylpyrimidine + pyrimidine nucleosides + CHEBI:26440 + + pyrimidine nucleoside + + + + + + + + + + An L-alpha-amino acid which is biosynthesised from pyruvate (i.e. alanine, valine, and leucine). A closed class. + + chebi_ontology + pyruvate family amino acids + CHEBI:26463 + + pyruvate family amino acid + + + + + + + + + + + quinoline alkaloids + CHEBI:26509 + quinoline alkaloid + + + + + + + + + + + A class of aromatic heterocyclic compounds each of which contains a benzene ring ortho fused to carbons 2 and 3 of a pyridine ring. + + + chebi_ontology + CHEBI:26513 + + quinolines + + + + + + + + + + rhamnoside + chebi_ontology + rhamnosides + CHEBI:26547 + + rhamnoside + + + + + + + + + + + + + + + + + + + + + A glycoside that is a compound containing one or more hydrophilic glycoside moieties combined with a lipophilic triterpenoid or steroid derivative. Found in particular abundance in plant species. + + CHEBI:60583 + chebi_ontology + sapogenin glycoside + sapogenin glycosides + saponins + CHEBI:26605 + + saponin + + + + + + + + + Any organic polycyclic compound that is the aglycon moiety of a saponin; sapogenins may be steroids or triterpenoids. + + sapogenin + chebi_ontology + sapogenins + CHEBI:26606 + + sapogenin + + + + + + + + + + + + + + + An amino acid derivative resulting from reaction of serine at the amino group or the carboxy group, or from the replacement of any hydrogen of serine by a heteroatom. The definition normally excludes peptides containing serine residues. + + chebi_ontology + serine derivatives + CHEBI:26649 + + serine derivative + + + + + + + + + + An L-alpha-amino acid which is biosynthesised from 3-phosphoglycerate (i.e. serine, glycine, cysteine and homocysteine). A closed class. + + PMID:20709681 + chebi_ontology + 3-phosphoglycerate family amino acid + 3-phosphoglycerate family amino acids + serine family amino acids + CHEBI:26650 + + serine family amino acid + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A quinoline having a chloro group at the 7-position and an aryl amino group at the 4-position. + + 0 + C20H22ClN3O + InChI=1S/C20H22ClN3O/c1-3-24(4-2)13-14-11-16(6-8-20(14)25)23-18-9-10-22-19-12-15(21)5-7-17(18)19/h5-12,25H,3-4,13H2,1-2H3,(H,22,23) + OVCDSSHSILBFBN-UHFFFAOYSA-N + 355.86100 + 355.14514 + CCN(CC)Cc1cc(Nc2ccnc3cc(Cl)ccc23)ccc1O + Beilstein:300962 + CAS:86-42-0 + DrugBank:DB00613 + Drug_Central:186 + KEGG:C07626 + KEGG:D02922 + LINCS:LSM-4042 + PDBeChem:CQA + PMID:11044276 + PMID:11971651 + PMID:17046445 + PMID:17222819 + PMID:18419816 + PMID:18855526 + PMID:19024339 + PMID:19245687 + PMID:26206402 + PMID:26597254 + PMID:26647924 + PMID:26735991 + PMID:26851641 + PMID:26900802 + PMID:26930583 + PMID:27031231 + PMID:8885219 + Patent:US2474821 + Reaxys:300962 + Wikipedia:Amodiaquine + 4-[(7-chloroquinolin-4-yl)amino]-2-[(diethylamino)methyl]phenol + Amodiaquine + chebi_ontology + amodiaquina + amodiaquine + amodiaquinum + CHEBI:2674 + + amodiaquine + + + + + + + + + + + + + + + Any steroid that acts as hormone. + + chebi_ontology + Steroidhormon + Steroidhormone + hormona esteroide + hormonas esteroideas + hormone steroide + hormones steroides + steroid hormones + CHEBI:26764 + + steroid hormone + + + + + + + + + + + KEGG:C15507 + chebi_ontology + steroid lactones + CHEBI:26766 + + steroid lactone + + + + + + + + + + + chebi_ontology + steroidal alkaloids + CHEBI:26767 + + steroid alkaloid + + + + + + + + + + + 0 + C14H12 + InChI=1S/C14H12/c1-3-7-13(8-4-1)11-12-14-9-5-2-6-10-14/h1-12H + PJANXHGTPQOBST-UHFFFAOYSA-N + 180.24508 + 180.09390 + [H]C(=C([H])c1ccccc1)c1ccccc1 + Beilstein:1904445 + CAS:588-59-0 + Gmelin:67845 + 1,1'-(ethene-1,2-diyl)dibenzene + stilbene + chebi_ontology + 1,1'-(1,2-ethenediyl)bis[benzene] + 1,1'-(1,2-ethenediyl)bisbenzene + 1,1'-(1,2-ethenediyl)dibenzene + 1,1'-ethene-1,2-diyldibenzene + 1,2-diphenylethylene + alpha,beta-diphenylethylene + CHEBI:26775 + + stilbene + + + + + + + + + + Any olefinic compound characterised by a 1,2-diphenylethylene backbone. + + chebi_ontology + stilbenes + stilbenoids + CHEBI:26776 + + stilbenoid + + + + + + + + + Any sulfur molecular entity that involves either covalently bonded or anionic sulfur. + + chebi_ontology + sulphides + CHEBI:26822 + + sulfide + + + + + + + + + + chebi_ontology + CHEBI:26830 + + sulfonium compound + + + + + + + + + + + + + + + + + 0 + S + InChI=1S/S + NINIDFKCEFEMDL-UHFFFAOYSA-N + 32.06600 + 31.97207 + [S] + CAS:7704-34-9 + KEGG:C00087 + KEGG:D06527 + PPDB:605 + WebElements:S + sulfur + chebi_ontology + 16S + Elemental sulfur + S + Schwefel + azufre + soufre + sulfur + sulphur + theion + CHEBI:26833 + + sulfur atom + + + + + + + + + + + + + + + + + sulfur molecular entity + chebi_ontology + sulfur molecular entities + CHEBI:26835 + + sulfur molecular entity + + + + + + + + + + Any terpenoid which contains a keto group. + + chebi_ontology + CHEBI:26872 + + terpene ketone + + + + + + + + + + + + + + + Any isoprenoid that is a natural product or related compound formally derived from isoprene units. Terpenoids may contain oxygen in various functional groups. This class is subdivided according to the number of carbon atoms in the parent terpene. The skeleton of terpenoids may differ from strict additivity of isoprene units by the loss or shift of a fragment, generally a methyl group. + + Wikipedia:Terpenoid + Terpenoid + terpenoids + chebi_ontology + terpenoide + terpenoides + CHEBI:26873 + + terpenoid + + + + + + + + + A tertiary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has three other carbon atoms attached to it. + + 0 + C4H7OR3 + 71.09780 + 71.04969 + OC(C[*])(C[*])C[*] + tertiary alcohol + chebi_ontology + tertiary alcohols + CHEBI:26878 + + tertiary alcohol + + + + + + + + + + Any oxacycle having an oxolane (tetrahydrofuran) skeleton. + + chebi_ontology + CHEBI:26912 + + oxolanes + + + + + + + + + Compounds containing at least one thiophene ring. + + chebi_ontology + CHEBI:26961 + + thiophenes + + + + + + + + + + + An organic tricyclic compound in which at least one of the rings of the tricyclic skeleton contains one or more heteroatoms. + + + chebi_ontology + heterotricyclic compounds + organic heterotricyclic compounds + CHEBI:26979 + + organic heterotricyclic compound + + + + + + + + + Any member of the class of benzenes that is a substituted benzene in which the substituents include one (and only one) methyl group. + + chebi_ontology + CHEBI:27024 + + toluenes + + + + + + + + + + Poisonous substance produced by a biological organism such as a microbe, animal or plant. + + Wikipedia:Toxin + toxin + chebi_ontology + toxins + CHEBI:27026 + + toxin + + + + + + + + + Any nutrient required in small quantities by organisms throughout their life in order to orchestrate a range of physiological functions. + + Wikipedia:Micronutrient + chebi_ontology + micronutrients + trace elements + CHEBI:27027 + + micronutrient + + + + + + + + + + + chebi_ontology + tricarboxylate + tricarboxylates + tricarboxylic acid trianions + CHEBI:27092 + + tricarboxylic acid trianion + + + + + + + + + + + + + + + An oxoacid containing three carboxy groups. + + 0 + C3H3O6R + 135.052 + 134.99296 + Wikipedia:Tricarboxylic_acid + chebi_ontology + Tricarbonsaeure + Trikarbonsaeure + tricarboxylic acids + CHEBI:27093 + + tricarboxylic acid + + + + + + + + + Any member of the class of chlorobenzenes carrying three chloro substituents at unspecified positions. + + 0 + C6H3Cl3 + 181.447 + 179.93003 + Wikipedia:Trichlorobenzene + trichlorobenzene + chebi_ontology + Trichlorbenzol + CHEBI:27096 + + trichlorobenzene + + + + + + + + + Any hydroxyflavone carrying three hydroxy groups at unspecified positions. + + chebi_ontology + trihydroxyflavones + CHEBI:27116 + + trihydroxyflavone + + + + + + + + + + + + + chebi_ontology + heterobicyclic compounds + organic heterobicyclic compounds + CHEBI:27171 + + organic heterobicyclic compound + + + + + + + + + A univalent carboacyl group is a group formed by loss of OH from the carboxy group of a carboxylic acid. + + chebi_ontology + univalent acyl group + univalent carboacyl groups + univalent carboxylic acyl groups + CHEBI:27207 + + univalent carboacyl group + + + + + + + + + + + + + + + Any fatty acid containing at least one C=C or C#C bond. + + LIPID_MAPS_class:LMFA0103 + PMID:5322381 + chebi_ontology + alkene acid + olefinic acid + unsaturated fatty acids + CHEBI:27208 + + unsaturated fatty acid + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A branched-chain amino acid that consists of glycine in which one of the hydrogens attached to the alpha-carbon is substituted by an isopropyl group. + + 0 + C5H11NO2 + InChI=1S/C5H11NO2/c1-3(2)4(6)5(7)8/h3-4H,6H2,1-2H3,(H,7,8) + KZSNJWFQEVHDMF-UHFFFAOYSA-N + 117.14638 + 117.07898 + CC(C)C(N)C(O)=O + Beilstein:506689 + CAS:516-06-3 + Gmelin:49877 + KEGG:C16436 + PMID:17190852 + PMID:22770225 + Reaxys:506689 + Wikipedia:Valine + valine + chebi_ontology + 2-amino-3-methylbutanoic acid + DL-valine + Hval + Valin + valina + CHEBI:27266 + + valine + + + + + + + + + + + + + + + + An amino acid derivative resulting from reaction of valine at the amino group or the carboxy group, or from the replacement of any hydrogen of valine by a heteroatom. The definition normally excludes peptides containing valine residues. + + + chebi_ontology + CHEBI:27267 + + valine derivative + + + + + + + + + + + + chebi_ontology + CHEBI:27358 + + yohimban alkaloid + + + + + + + + + + zinc compounds + zinc molecular entities + CHEBI:27364 + zinc molecular entity + + + + + + + + + A neutral compound having formal unit electrical charges of opposite sign on non-adjacent atoms. Sometimes referred to as inner salts, dipolar ions (a misnomer). + + zwitterion + zwitterions + chebi_ontology + compose zwitterionique + compuestos zwitterionicos + zwitteriones + zwitterionic compounds + CHEBI:27369 + + zwitterion + + + + + + + + + + + + + + + + + + + + + + An alkanesulfonic acid in which the alkyl group directly linked to the sulfo functionality is methyl. + + 0 + CH4O3S + InChI=1S/CH4O3S/c1-5(2,3)4/h1H3,(H,2,3,4) + AFVFQIVMOAPDHO-UHFFFAOYSA-N + 96.10666 + 95.98812 + CS(O)(=O)=O + CHEBI:6813 + Beilstein:1446024 + CAS:75-75-2 + Gmelin:1681 + KEGG:C11145 + MetaCyc:CPD-3746 + PMID:24304088 + PMID:24593036 + Reaxys:1446024 + Wikipedia:Methanesulfonic_acid + Methanesulfonic acid + methanesulfonic acid + chebi_ontology + Methansulfonsaeure + methylsulfonic acid + CHEBI:27376 + + methanesulfonic acid + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + The D-enantiomer of valine. + + 0 + C5H11NO2 + InChI=1S/C5H11NO2/c1-3(2)4(6)5(7)8/h3-4H,6H2,1-2H3,(H,7,8)/t4-/m1/s1 + KZSNJWFQEVHDMF-SCSAIBSYSA-N + 117.14638 + 117.07898 + CC(C)[C@@H](N)C(O)=O + CHEBI:21112 + CHEBI:4261 + Beilstein:1721135 + CAS:640-68-6 + Gmelin:82413 + KEGG:C06417 + MetaCyc:CPD-3642 + PDBeChem:DVA + PMID:13465080 + PMID:23085840 + PMID:236834 + PMID:7118128 + Reaxys:1721135 + D-Valine + D-valine + chebi_ontology + (2R)-2-amino-3-methylbutanoic acid + (R)-2-Amino-3-methylbutyric acid + (R)-valine + D-Valin + DVA + CHEBI:27477 + + D-valine + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A saturated organic heteromonocyclic parent that is a three-membered heterocycle of two carbon atoms and one oxygen atom. + + 0 + C2H4O + InChI=1S/C2H4O/c1-2-3-1/h1-2H2 + IAYPIBMASNFSPL-UHFFFAOYSA-N + 44.05256 + 44.02621 + C1CO1 + CHEBI:24001 + CHEBI:4900 + Beilstein:102378 + CAS:75-21-8 + Gmelin:676 + HMDB:HMDB0031305 + KEGG:C06548 + KEGG:D03474 + PMID:11437638 + PMID:24313866 + PMID:24882394 + PMID:25005741 + PMID:3932500 + Reaxys:102378 + UM-BBD_compID:c0527 + Wikipedia:Oxirane + oxirane + chebi_ontology + 1,2-Epoxyaethan + 1,2-epoxyethane + Aethylenoxid + Amprolene + Anprolene + Anproline + Dihydrooxirene + Dimethylene oxide + ETO + Ethylene oxide + Oxacyclopropane + Oxane + Oxidoethane + Oxyfume + epoxyethane + ethene oxide + oxyde d'ethylene + CHEBI:27561 + + oxirane + + + + + + + + + + A phosphoric ester (phosphate) that has an NR2 instead of an OH group. + + CHEBI:26050 + CHEBI:37718 + CHEBI:8144 + KEGG:C01976 + chebi_ontology + Phosphoamide + phosphoramidate esters + CHEBI:27577 + + phosphoramidate ester + + + + + + + + + + + + + + + + + 0 + C + InChI=1S/C + OKTJSMMVPCPJKN-UHFFFAOYSA-N + 12.01070 + 12.00000 + [C] + CHEBI:23009 + CHEBI:3399 + CAS:7440-44-0 + KEGG:C06265 + WebElements:C + carbon + chebi_ontology + 6C + C + Carbon + Kohlenstoff + carbon + carbone + carbonium + carbono + CHEBI:27594 + + carbon atom + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A spiroketal, monensin A is the major component of monensin, a mixture of antibiotic substances produced by Streptomyces cinnamonensis. An antiprotozoal, it is used as the sodium salt as a feed additive for the prevention of coccidiosis in poultry and as a growth promoter in cattle. + + 0 + C36H62O11 + InChI=1S/C36H62O11/c1-10-34(31-20(3)16-26(43-31)28-19(2)15-21(4)36(41,18-37)46-28)12-11-27(44-34)33(8)13-14-35(47-33)17-25(38)22(5)30(45-35)23(6)29(42-9)24(7)32(39)40/h19-31,37-38,41H,10-18H2,1-9H3,(H,39,40)/t19-,20-,21+,22+,23-,24-,25-,26+,27+,28-,29+,30-,31+,33-,34-,35+,36-/m0/s1 + GAOZTHIDHYLHMS-KEOBGNEYSA-N + 670.87090 + 670.42921 + [H][C@@]1(C[C@H](C)[C@@]([H])(O1)[C@]1(CC)CC[C@@]([H])(O1)[C@]1(C)CC[C@]2(C[C@H](O)[C@@H](C)[C@]([H])(O2)[C@@H](C)[C@@H](OC)[C@H](C)C(O)=O)O1)[C@@]1([H])O[C@@](O)(CO)[C@H](C)C[C@@H]1C + CHEBI:25376 + CHEBI:6973 + CAS:17090-79-8 + KEGG:C06693 + KEGG:D08228 + LINCS:LSM-5659 + PMID:21215424 + Reaxys:1633130 + (2S,3R,4S)-4-[(2S,5R,7S,8R,9S)-2-{(2S,2'R,3'S,5R,5'R)-2-ethyl-5'-[(2S,3S,5R,6R)-6-hydroxy-6-(hydroxymethyl)-3,5-dimethyltetrahydro-2H-pyran-2-yl]-3'-methyloctahydro-2,2'-bifuran-5-yl}-9-hydroxy-2,8-dimethyl-1,6-dioxaspiro[4.5]dec-7-yl]-3-methoxy-2-methylpentanoic acid + Monensin A + chebi_ontology + Monensin + monensic acid + monensin + monensina + monensinum + CHEBI:27617 + + monensin A + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A dicarboximide that is 4-(2-hydroxyethyl)piperidine-2,6-dione in which one of the hydrogens attached to the carbon bearing the hydroxy group is replaced by a 3,5-dimethyl-2-oxocyclohexyl group. It is an antibiotic produced by the bacterium Streptomyces griseus. + + 0 + C15H23NO4 + InChI=1S/C15H23NO4/c1-8-3-9(2)15(20)11(4-8)12(17)5-10-6-13(18)16-14(19)7-10/h8-12,17H,3-7H2,1-2H3,(H,16,18,19)/t8-,9-,11-,12+/m0/s1 + YPHMISFOHDHNIV-FSZOTQKASA-N + 281.34740 + 281.16271 + C[C@H]1C[C@H](C)C(=O)[C@@H](C1)[C@H](O)CC1CC(=O)NC(=O)C1 + CHEBI:23484 + CHEBI:4015 + Beilstein:88868 + CAS:66-81-9 + KEGG:C06685 + KEGG:D03625 + KNApSAcK:C00047211 + LINCS:LSM-2791 + PDBeChem:3HE + PMID:11972861 + PPDB:1680 + Reaxys:88868 + Wikipedia:Cycloheximide + 4-{(2R)-2-[(1S,3S,5S)-3,5-dimethyl-2-oxocyclohexyl]-2-hydroxyethyl}piperidine-2,6-dione + Cycloheximide + cycloheximide + chebi_ontology + 3-((R)-2-((1S,3S,5S)-3,5-dimethyl-2-oxocyclohexyl)-2-hydroxyethyl)glutarimide + Cycloheximid + Zykloheximid + cicloheximida + cicloheximide + cicloheximidum + naramycin + naramycin A + CHEBI:27641 + + cycloheximide + + + + + + + + + + 0 + C6H11O5R + 163.14850 + 163.06065 + C[C@@H]1O[C@@H](O[*])[C@H](O)[C@H](O)[C@H]1O + CHEBI:10294 + CHEBI:22426 + KEGG:C02757 + 6-deoxy-alpha-L-mannopyranoside + alpha-L-Rhamnoside + chebi_ontology + alpha-L-rhamnosides + CHEBI:27848 + + alpha-L-rhamnoside + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A steroid alkaloid that is con-5-enine substituted by a N,N-dimethylamino group at position 3. It has been isolated from the plant species of the family Apocynaceae. + + 0 + C24H40N2 + InChI=1S/C24H40N2/c1-16-20-8-9-22-19-7-6-17-14-18(25(3)4)10-12-23(17,2)21(19)11-13-24(20,22)15-26(16)5/h6,16,18-22H,7-15H2,1-5H3/t16-,18-,19+,20+,21-,22-,23-,24-/m0/s1 + GPLGAQQQNWMVMM-MYAJQUOBSA-N + 356.58780 + 356.31915 + C[C@H]1[C@H]2CC[C@H]3[C@@H]4CC=C5C[C@H](CC[C@]5(C)[C@H]4CC[C@]23CN1C)N(C)C + CHEBI:23369 + CHEBI:3853 + Beilstein:4702160 + CAS:546-06-5 + KEGG:C06545 + KNApSAcK:C00002243 + PMID:15413865 + PMID:18683917 + PMID:20161899 + PMID:21834632 + PMID:23758861 + Reaxys:4702160 + Wikipedia:Conessine + Conessine + N,N-dimethylcon-5-enin-3beta-amine + chebi_ontology + Conessinum + Neriine + Roquessine + CHEBI:27965 + + conessine + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A complex glycopeptide from Streptomyces orientalis. It inhibits a specific step in the synthesis of the peptidoglycan layer in the Gram-positive bacteria Staphylococcus aureus and Clostridium difficile. + + 0 + C66H75Cl2N9O24 + InChI=1S/C66H75Cl2N9O24/c1-23(2)12-34(71-5)58(88)76-49-51(83)26-7-10-38(32(67)14-26)97-40-16-28-17-41(55(40)101-65-56(54(86)53(85)42(22-78)99-65)100-44-21-66(4,70)57(87)24(3)96-44)98-39-11-8-27(15-33(39)68)52(84)50-63(93)75-48(64(94)95)31-18-29(79)19-37(81)45(31)30-13-25(6-9-36(30)80)46(60(90)77-50)74-61(91)47(28)73-59(89)35(20-43(69)82)72-62(49)92/h6-11,13-19,23-24,34-35,42,44,46-54,56-57,65,71,78-81,83-87H,12,20-22,70H2,1-5H3,(H2,69,82)(H,72,92)(H,73,89)(H,74,91)(H,75,93)(H,76,88)(H,77,90)(H,94,95)/t24-,34+,35-,42+,44-,46+,47+,48-,49+,50-,51+,52+,53+,54-,56+,57+,65-,66-/m0/s1 + MYPYJXKWCTUITO-LYRMYLQWSA-N + 1449.25336 + 1447.43020 + CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)c2ccc(Oc3cc4cc(Oc5ccc(cc5Cl)[C@@H](O)[C@@H]5NC(=O)[C@H](NC(=O)[C@@H]4NC(=O)[C@H](CC(N)=O)NC1=O)c1ccc(O)c(c1)-c1c(O)cc(O)cc1[C@H](NC5=O)C(O)=O)c3O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1)c(Cl)c2 + CHEBI:27276 + CHEBI:49941 + CHEBI:9931 + Beilstein:3132 + CAS:1404-90-6 + DrugBank:DB00512 + Drug_Central:2807 + KEGG:C06689 + KEGG:D00212 + KNApSAcK:C00016052 + MetaCyc:CPD-12245 + PDBeChem:VAN + PMID:11028184 + PMID:11408222 + PMID:11688538 + PMID:11864951 + PMID:11886013 + PMID:11980329 + PMID:12019070 + PMID:12541895 + PMID:12852813 + PMID:13370625 + PMID:13521912 + PMID:14605050 + PMID:14702667 + PMID:15047516 + PMID:15081082 + PMID:15465645 + PMID:15590714 + PMID:15792257 + PMID:16183423 + PMID:16184232 + PMID:16420976 + PMID:16596002 + PMID:16720708 + PMID:17027219 + PMID:17184835 + PMID:17299012 + PMID:17594206 + PMID:18030187 + PMID:18159039 + PMID:18162343 + PMID:18260149 + PMID:18361944 + PMID:18462092 + PMID:18582342 + PMID:18817166 + PMID:18983037 + PMID:19107100 + PMID:19830166 + PMID:20956604 + PMID:21109901 + PMID:21458937 + PMID:21466775 + PMID:21664803 + PMID:21719238 + PMID:21951032 + PMID:22011388 + PMID:22015328 + PMID:22027450 + PMID:22124537 + Patent:US3067099 + Reaxys:3132 + Wikipedia:Vancomycin + (3S,6R,7R,11R,23S,26S,30aS,36R,38aR)-44-[2-O-(3-amino-2,3,6-trideoxy-3-C-methyl-alpha-L-lyxo-hexopyranosyl)-beta-D-glucopyranosyloxy]-3-(carbamoylmethyl)-10,19-dichloro-2,3,4,5,6,7,23,25,26,36,37,38,38a-tetradecahydro-7,22,28,30,32-pentahydroxy-6-(N-methyl-D-leucyl)-2,5,24,38,39-pentaoxo-1H,22H-23,36-(epiminomethano)-8,11:18,21-dietheno-13,16:31,35-di(metheno)[1,6,9]oxadiazacyclohexadecino[4,5-m][10,2,16]benzoxadiazacyclotetracosine-26-carboxylic acid + VANCOMYCIN + Vancomycin + chebi_ontology + (1S,2R,18R,22S,25R,28R,40S)-22-(2-amino-2-oxoethyl)-48-[2-O-(3-amino-2,3,6-trideoxy-3-methyl-alpha-L-lyxo-hexopyranosyl)-beta-D-glucopyranosyloxy]-5,15-dichloro-2,18,32,35,37-pentahydroxy-19-[(N-methyl-D-leucyl)amino]-20,23,26,42,44-pentaoxo-7,13-dioxa-21,24,27,41,43-pentaazaoctacyclo[26.14.2.2(3,6).2(14,17).1(8,12).1(29,33).0(10,25).0(34,39)]pentaconta-3,5,8(48),9,11,14,16,29(45),30,32,34,36,38,46,49-pentadecaene-40-carboxylic acid + (2.2Sp,3.5Sa,2.6Sp)-O(4.2),C(3.4):C(5.4),O(4.6):C(3.5),C(2.7)-tricyclo[N-methyl-D-leucyl-3-chloro-(R)-beta-hydroxy-D-tyrosyl-L-asparaginyl-D-2-(4-{[2-O-(3-amino-2,3,6-trideoxy-3-C-methyl-alpha-L-lyxo-hexopyranosyl)-beta-D-glucopyranosyl]oxy}phenyl)glycyl-D-2-(4-hydroxyphenyl)glycyl-3-chloro-(R)-beta-hydroxy-L-tyrosyl-L-2-(3,5-dihydroxyphenyl)glycine] + Vancocin + vancomicin + vancomicina + vancomycin + vancomycine + vancomycinum + CHEBI:28001 + + vancomycin + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + An aromatic amino acid that is alanine in which one of the methyl hydrogens is substituted by a phenyl group. + + 0 + C9H11NO2 + InChI=1S/C9H11NO2/c10-8(9(11)12)6-7-4-2-1-3-5-7/h1-5,8H,6,10H2,(H,11,12) + COLNVLDHVKWLRT-UHFFFAOYSA-N + 165.18918 + 165.07898 + NC(Cc1ccccc1)C(O)=O + CHEBI:25984 + CHEBI:8089 + Beilstein:1910407 + CAS:150-30-1 + Gmelin:50836 + KEGG:C02057 + PMID:17439666 + PMID:22264337 + Reaxys:1910407 + Wikipedia:Phenylalanine + 2-amino-3-phenylpropanoic acid + Phenylalanine + phenylalanine + chebi_ontology + DL-Phenylalanine + F + PHE + Phenylalanin + alpha-Amino-beta-phenylpropionic acid + fenilalanina + CHEBI:28044 + + phenylalanine + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A harmala alkaloid in which the harman skeleton is methoxy-substituted at C-7. + + 0 + C13H12N2O + InChI=1S/C13H12N2O/c1-8-13-11(5-6-14-8)10-4-3-9(16-2)7-12(10)15-13/h3-7,15H,1-2H3 + BXNJHAXVSOCGBA-UHFFFAOYSA-N + 212.24720 + 212.09496 + COc1ccc2c(c1)[nH]c1c(C)nccc21 + CHEBI:24477 + CHEBI:5624 + Beilstein:178813 + CAS:442-51-3 + DrugBank:DB07919 + KEGG:C06538 + KNApSAcK:C00001737 + LINCS:LSM-5451 + PDBeChem:HRM + PMID:11473435 + PMID:22877698 + Reaxys:178813 + Wikipedia:Harmine + 7-methoxy-1-methyl-9H-pyrido[3,4-b]indole + Harmine + chebi_ontology + 6-Methoxyharman + 7-methoxy-1-methyl-9H-beta-carboline + Banisterine + Leucoharmine + Telepathine + Yageine + Yajeine + CHEBI:28121 + + harmine + + + + + + + + + An aromatic amide that consists of benzene bearing a single carboxamido substituent. The parent of the class of benzamides. + + 0 + C7H7NO + InChI=1S/C7H7NO/c8-7(9)6-4-2-1-3-5-6/h1-5H,(H2,8,9) + KXDAEFPNCMNJSK-UHFFFAOYSA-N + 121.13662 + 121.05276 + NC(=O)c1ccccc1 + CHEBI:22701 + CHEBI:3021 + CHEBI:46351 + Beilstein:385876 + CAS:55-21-0 + HMDB:HMDB0004461 + KEGG:C09815 + PMID:20133863 + Reaxys:385876 + UM-BBD_compID:c0368 + Wikipedia:Benzamide + Benzamide + benzamide + chebi_ontology + Benzenecarboxamide + Benzoic acid amide + Benzoylamide + PhC(=O)NH2 + PhC(O)NH2 + Phenylcarboxamide + Phenylcarboxyamide + CHEBI:28179 + + benzamide + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + The D-enantiomer of leucine. + + 0 + C6H13NO2 + InChI=1S/C6H13NO2/c1-4(2)3-5(7)6(8)9/h4-5H,3,7H2,1-2H3,(H,8,9)/t5-/m1/s1 + ROHFNLRQFUQHCH-RXMQYKEDSA-N + 131.17296 + 131.09463 + CC(C)C[C@@H](N)C(O)=O + CHEBI:21045 + CHEBI:41908 + CHEBI:4202 + Beilstein:1721721 + CAS:328-38-1 + DrugBank:DB01746 + Gmelin:82675 + HMDB:HMDB0013773 + KEGG:C01570 + PDBeChem:DLE + PMID:15375647 + PMID:21941889 + PMID:24097941 + Reaxys:1721721 + YMDB:YMDB00997 + D-LEUCINE + D-Leucine + D-leucine + chebi_ontology + (2R)-2-amino-4-methylpentanoic acid + (R)-(-)-leucine + (R)-leucine + D-2-Amino-4-methylvaleric acid + D-Leucin + D-Leuzin + DLE + CHEBI:28225 + + D-leucine + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A 2-carbon sulfoxide in which the sulfur atom has two methyl substituents. + + 0 + C2H6OS + InChI=1S/C2H6OS/c1-4(2)3/h1-2H3 + IAZDPXIOMUYVGZ-UHFFFAOYSA-N + 78.13444 + 78.01394 + CS(C)=O + CHEBI:23801 + CHEBI:42138 + CHEBI:4612 + Beilstein:506008 + CAS:67-68-5 + DrugBank:DB01093 + Drug_Central:906 + Gmelin:1556 + HMDB:HMDB0002151 + KEGG:C11143 + KEGG:D01043 + LINCS:LSM-36361 + PDBeChem:DMS + PMID:11162043 + PMID:11350866 + PMID:15237653 + PMID:15588915 + PMID:15868171 + PMID:16434015 + PMID:19096138 + PMID:19382398 + PMID:21426213 + PMID:22030943 + PMID:22722716 + PMID:22768202 + PMID:22814967 + Reaxys:506008 + UM-BBD_compID:c0236 + Wikipedia:Dimethyl_Sulfoxide + (methanesulfinyl)methane + DIMETHYL SULFOXIDE + Dimethyl sulfoxide + dimethyl sulfoxide + chebi_ontology + (CH3)2SO + DMSO + Dimethylsulfoxid + S(O)Me2 + dimethyl sulfoxide + dimethyl sulfur oxide + dimethyl sulphoxide + dimethyli sulfoxidum + dimethylsulfoxyde + dimetil sulfoxido + dmso + methylsulfinylmethane + sulfinylbis(methane) + CHEBI:28262 + + dimethyl sulfoxide + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + 9260 + An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria. + + + 0 + C33H40N2O9 + InChI=1S/C33H40N2O9/c1-38-19-7-8-20-21-9-10-35-16-18-13-27(44-32(36)17-11-25(39-2)30(41-4)26(12-17)40-3)31(42-5)28(33(37)43-6)22(18)15-24(35)29(21)34-23(20)14-19/h7-8,11-12,14,18,22,24,27-28,31,34H,9-10,13,15-16H2,1-6H3/t18-,22+,24-,27-,28+,31+/m1/s1 + QEVHRUUCFGRFIF-MDEJGZGSSA-N + 608.67870 + 608.27338 + [H][C@]12C[C@@H](OC(=O)c3cc(OC)c(OC)c(OC)c3)[C@H](OC)[C@@H](C(=O)OC)[C@@]1([H])C[C@@]1([H])N(CCc3c1[nH]c1cc(OC)ccc31)C2 + CHEBI:26531 + CHEBI:8808 + Beilstein:102014 + Beilstein:5326088 + CAS:50-55-5 + ChemIDplus:50-55-5 + DrugBank:DB00206 + Drug_Central:2370 + HMDB:HMDB0014351 + KEGG COMPOUND:50-55-5 + KEGG COMPOUND:C06539 + KEGG DRUG:D00197 + KEGG:C06539 + KEGG:D00197 + KNApSAcK:C00001763 + LINCS:LSM-4162 + NIST Chemistry WebBook:50-55-5 + PMID:20701244 + PMID:20825390 + PMID:24603678 + Reaxys:102014 + Wikipedia:Reserpine + Reserpine + methyl (3beta,16beta,17alpha,18beta,20alpha)-11,17-dimethoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]yohimban-16-carboxylate + chebi_ontology + (-)-reserpine + (3beta,16beta,17alpha,18beta,20alpha)-11,17-dimethoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]yohimban-16-carboxylic acid methyl ester + 3,4,5-trimethoxybenzoyl methyl reserpate + Apoplon + C33H40N2O9 + InChI=1S/C33H40N2O9/c1-38-19-7-8-20-21-9-10-35-16-18-13-27(44-32(36)17-11-25(39-2)30(41-4)26(12-17)40-3)31(42-5)28(33(37)43-6)22(18)15-24(35)29(21)34-23(20)14-19/h7-8,11-12,14,18,22,24,27-28,31,34H,9-10,13,15-16H2,1-6H3/t18-,22+,24-,27-,28+,31+/m1/s1 + InChIKey=QEVHRUUCFGRFIF-MDEJGZGSSA-N + Reserpin + Serpalan + [H][C@]12C[C@@H](OC(=O)c3cc(OC)c(OC)c(OC)c3)[C@H](OC)[C@@H](C(=O)OC)[C@@]1([H])C[C@@]1([H])N(CCc3c1[nH]c1cc(OC)ccc31)C2 + CHEBI:28487 + + Reserpine + reserpine + + + + + + + + + + + + + + + + + + + + + + + + + + + A cardenolide glycoside in which the 3beta-hydroxy group of digitoxigenin carries a 2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl trisaccharide chain. + + 0 + C41H64O13 + InChI=1S/C41H64O13/c1-20-36(46)29(42)16-34(49-20)53-38-22(3)51-35(18-31(38)44)54-37-21(2)50-33(17-30(37)43)52-25-8-11-39(4)24(15-25)6-7-28-27(39)9-12-40(5)26(10-13-41(28,40)47)23-14-32(45)48-19-23/h14,20-22,24-31,33-38,42-44,46-47H,6-13,15-19H2,1-5H3/t20-,21-,22-,24-,25+,26-,27+,28-,29+,30+,31+,33+,34+,35+,36-,37-,38-,39+,40-,41+/m1/s1 + WDJUZGPOPHTGOT-XUDUSOBPSA-N + 764.93910 + 764.43469 + [H][C@]12CC[C@]3([H])[C@]([H])(CC[C@]4(C)[C@]([H])(CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1 + CHEBI:23728 + CHEBI:4549 + Beilstein:76678 + CAS:71-63-6 + DrugBank:DB01396 + Drug_Central:881 + KEGG:C06955 + KEGG:D00297 + KNApSAcK:C00003617 + PMID:10438974 + PMID:10687899 + PMID:26573786 + Reaxys:76678 + Wikipedia:Digitoxin + 3beta-[2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyloxy]-14-hydroxy-5beta-card-20(22)-enolide + Digitoxin + chebi_ontology + Crystodigin (TN) + Digitoxoside + CHEBI:28544 + + digitoxin + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A twelve-membered cyclodepsipeptide composed of three repeating D-alpha-hydroxyisovaleryl-D-valyl-L-lactoyl-L-valyl units joined in sequence. An antibiotic found in several Streptomyces strains. + + 0 + C54H90N6O18 + InChI=1S/C54H90N6O18/c1-22(2)34-49(67)73-31(19)43(61)55-38(26(9)10)53(71)77-41(29(15)16)47(65)59-36(24(5)6)51(69)75-33(21)45(63)57-39(27(11)12)54(72)78-42(30(17)18)48(66)60-35(23(3)4)50(68)74-32(20)44(62)56-37(25(7)8)52(70)76-40(28(13)14)46(64)58-34/h22-42H,1-21H3,(H,55,61)(H,56,62)(H,57,63)(H,58,64)(H,59,65)(H,60,66)/t31-,32-,33-,34+,35+,36+,37-,38-,39-,40+,41+,42+/m0/s1 + FCFNRCROJUBPLU-DNDCDFAISA-N + 1111.32180 + 1110.63116 + CC(C)[C@@H]1NC(=O)[C@H](C)OC(=O)[C@H](NC(=O)[C@H](OC(=O)[C@@H](NC(=O)[C@H](C)OC(=O)[C@H](NC(=O)[C@H](OC(=O)[C@@H](NC(=O)[C@H](C)OC(=O)[C@H](NC(=O)[C@H](OC1=O)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C + CHEBI:27269 + CHEBI:66347 + CHEBI:9924 + Beilstein:78657 + CAS:2001-95-8 + KEGG:C06684 + PMID:10603383 + PMID:18633285 + PMID:19347893 + PMID:22683555 + PMID:7590182 + Reaxys:78657 + Wikipedia:Valinomycin + (3R,6R,9S,12S,15R,18R,21S,24S,27R,30R,33S,36S)-3,6,9,15,18,21,27,30,33-nonaisopropyl-12,24,36-trimethyl-1,7,13,19,25,31-hexaoxa-4,10,16,22,28,34-hexaazacyclohexatriacontane-2,5,8,11,14,17,20,23,26,29,32,35-dodecone + Valinomycin + chebi_ontology + Cyclic(D-alpha-hydroxyisovaleryl-D-valyl-L-lactoyl-L-valyl-D-alpha-hydroxyisovaleryl-D-valyl-L-lactoyl-L-valyl-D-alpha-hydroxyisovaleryl-D-valyl-L-lactoyl-L-valyl) + cyclo[-D-O-Val-D-Val-L-O-Ala-L-Val]3 + CHEBI:28545 + + valinomycin + + + + + + + + + + + + + + + + + + + + + + + A one-carbon compound that is ammonia in which one of the hydrogens is replaced by a carboxy group. Although carbamic acid derivatives are common, carbamic acid itself has never been synthesised. + + 0 + CH3NO2 + InChI=1S/CH3NO2/c2-1(3)4/h2H2,(H,3,4) + KXDHJXZQYSOELW-UHFFFAOYSA-N + 61.04006 + 61.01638 + NC(O)=O + CHEBI:22504 + CHEBI:23002 + CHEBI:3386 + CHEBI:44573 + Beilstein:1734754 + CAS:463-77-4 + DrugBank:DB04261 + Gmelin:130345 + KEGG:C01563 + PDBeChem:OUT + Wikipedia:Carbamic_acid + CARBAMIC ACID + Carbamic acid + carbamic acid + chebi_ontology + Aminoameisensaeure + Aminoformic acid + Carbamate + Carbamidsaeure + CHEBI:28616 + + carbamic acid + + + + + + + + + + + + + + + + + 0 + P + InChI=1S/P + OAICVXFJPJFONN-UHFFFAOYSA-N + 30.97376 + 30.97376 + [P] + CHEBI:26080 + CHEBI:8168 + CAS:7723-14-0 + Gmelin:16235 + KEGG:C06262 + WebElements:P + phosphorus + chebi_ontology + 15P + P + Phosphor + Phosphorus + fosforo + phosphore + phosphorus + CHEBI:28659 + + phosphorus atom + + + + + + + + + + + + + + + + The conjugate base of a fatty acid, arising from deprotonation of the carboxylic acid group of the corresponding fatty acid. + + -1 + CO2R + 44.00950 + 43.98983 + [O-]C([*])=O + CHEBI:13634 + CHEBI:24022 + CHEBI:4985 + KEGG:C02403 + PMID:18628202 + Fatty acid anion + chebi_ontology + Alkanate + Fettsaeureanion + Fettsaeureanionen + a fatty acid + acido graso anionico + acidos grasos anionicos + anion de l'acide gras + fatty acid anions + CHEBI:28868 + + fatty acid anion + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + An onium cation obtained by protonation of ammonia. + + +1 + H4N + InChI=1S/H3N/h1H3/p+1 + QGZKDVFQNNGYKY-UHFFFAOYSA-O + 18.03850 + 18.03383 + [H][N+]([H])([H])[H] + CHEBI:22534 + CHEBI:49783 + CHEBI:7435 + CAS:14798-03-9 + Gmelin:84 + KEGG:C01342 + MetaCyc:AMMONIUM + MolBase:929 + PDBeChem:NH4 + PMID:11319011 + PMID:11341317 + PMID:12096804 + PMID:14512268 + PMID:14879753 + PMID:16345391 + PMID:16903292 + PMID:17392693 + PMID:18515490 + PMID:19199063 + PMID:19596600 + PMID:19682559 + PMID:19716251 + PMID:21993530 + PMID:22265469 + PMID:22524020 + PMID:22562341 + PMID:22631217 + Reaxys:16093784 + Wikipedia:Ammonium + ammonium + azanium + chebi_ontology + Ammonium(1+) + NH4(+) + NH4+ + [NH4](+) + ammonium cation + ammonium ion + CHEBI:28938 + + ammonium + + + + + + + + + + + + + + + + + + + + + + + + + + + + A piperidine compound having a 2-(4-methoxyphenyl)ethyl group at the 1-position and an N-[(4-fluorobenzyl)benzimidazol-2-yl]amino group at the 4-position. + + 0 + C28H31FN4O + InChI=1S/C28H31FN4O/c1-34-25-12-8-21(9-13-25)14-17-32-18-15-24(16-19-32)30-28-31-26-4-2-3-5-27(26)33(28)20-22-6-10-23(29)11-7-22/h2-13,24H,14-20H2,1H3,(H,30,31) + GXDALQBWZGODGZ-UHFFFAOYSA-N + 458.57030 + 458.24819 + COc1ccc(CCN2CCC(CC2)Nc2nc3ccccc3n2Cc2ccc(F)cc2)cc1 + Beilstein:4830190 + CAS:68844-77-9 + DrugBank:DB00637 + Drug_Central:249 + KEGG:C06832 + KEGG:D00234 + LINCS:LSM-5502 + Patent:EP5318 + Patent:US4219559 + 1-(4-fluorobenzyl)-N-{1-[2-(4-methoxyphenyl)ethyl]piperidin-4-yl}-1H-benzimidazol-2-amine + chebi_ontology + 1-(p-Fluorobenzyl)-2-((1-(2-(p-methoxyphenyl)ethyl)piperid-4-yl)amino)benzimidazole + 1-(p-Fluorobenzyl)-2-((1-(p-methoxyphenethyl)-4-piperidyl)amino)benzimidazole + Astemison + astemizol + astemizole + astemizolum + CHEBI:2896 + + astemizole + + + + + + + + + + + + + + + + + + + + + + + 0 + CH2O3 + InChI=1S/CH2O3/c2-1(3)4/h(H2,2,3,4) + BVKZGUZCCUSVTD-UHFFFAOYSA-N + 62.02478 + 62.00039 + OC(O)=O + CHEBI:13351 + CHEBI:23017 + CHEBI:23744 + CHEBI:3401 + CAS:463-79-6 + Gmelin:25554 + KEGG:C01353 + PDBeChem:CO3 + Carbonic acid + carbonic acid + dihydroxidooxidocarbon + chebi_ontology + Dihydrogen carbonate + H2CO3 + Koehlensaeure + [CO(OH)2] + CHEBI:28976 + + carbonic acid + + + + + + + + + + + + + + + + The conjugate base formed when the carboxy group of a carboxylic acid is deprotonated. + + -1 + CO2R + 44.00950 + 43.98983 + [O-]C([*])=O + CHEBI:13626 + CHEBI:13945 + CHEBI:23026 + CHEBI:58657 + chebi_ontology + a carboxylate + carboxylic acid anions + carboxylic anions + CHEBI:29067 + + carboxylic acid anion + + + + + + + + + + + + + + + + + + + + + + 0 + H2O3S + InChI=1S/H2O3S/c1-4(2)3/h4H,(H,1,2,3) + BDHFUVZGWQCTTF-UHFFFAOYSA-N + 82.08008 + 81.97247 + [H]S(O)(=O)=O + Gmelin:1404640 + hydridohydroxidodioxidosulfur + sulfonic acid + chebi_ontology + HSHO3 + Sulfonsaeure + [SHO2(OH)] + acide sulfonique + sulphonic acid + CHEBI:29214 + + sulfonic acid + + + + + + + + + + + + + + + An organosulfur compound in which a thiol group, -SH, is attached to a carbon atom of any aliphatic or aromatic moiety. + + 0 + HSR + 33.07300 + 32.97990 + S[*] + CHEBI:13443 + CHEBI:13696 + CHEBI:17366 + CHEBI:26969 + CHEBI:8766 + CHEBI:9556 + KEGG:C00145 + Wikipedia:Thiol + Thiol + thiols + chebi_ontology + Mercaptan + Merkaptan + RSH + a thiol + mercaptans + thiols + CHEBI:29256 + + thiol + + + + + + + + + + + + + + + + -2 + N2 + InChI=1S/N2/c1-2/q-2 + BZZJUZUZJRQHLZ-UHFFFAOYSA-N + 28.01348 + 28.00725 + [N-]=[N-] + Gmelin:1565041 + diazenediide + dinitride(2-) + chebi_ontology + N2(2-) + CHEBI:29277 + + dinitride(2-) + + + + + + + + + + + + + + + + + + + + + + + -1 + H2N + InChI=1S/H2N/h1H2/q-1 + HYGWNUKOUCZBND-UHFFFAOYSA-N + 16.02262 + 16.01927 + [H][N-][H] + amide + azanide + dihydridonitrate(1-) + chebi_ontology + NH2(-) + CHEBI:29337 + + azanide + + + + + + + + + + + + + + + + A divalent inorganic anion resulting from the removal of two protons from ammonia. + + -2 + HN + InChI=1S/HN/h1H/q-2 + DZQYTNGKSBCIOE-UHFFFAOYSA-N + 15.01468 + 15.01200 + [N--][H] + azanediide + hydridonitrate(2-) + chebi_ontology + NH(2-) + imide + CHEBI:29340 + + hydridonitrate(2-) + + + + + + + + + A carboxamide derived from a monocarboxylic acid. + + 0 + CNOR3 + 42.01680 + 41.99799 + [*]N([*])C([*])=O + CHEBI:13211 + CHEBI:22207 + CHEBI:25383 + CHEBI:6977 + chebi_ontology + monocarboxylic acid amides + CHEBI:29347 + + monocarboxylic acid amide + + + + + + + + + + + + + + + + -2 + CH2 + InChI=1S/CH2/h1H2/q-2 + PZPOWPOFQLSNJO-UHFFFAOYSA-N + 14.02658 + 14.01675 + [H][C--][H] + Beilstein:5915711 + Gmelin:322698 + dihydridocarbonate(2-) + methanediide + chebi_ontology + CH2(2-) + [CH2](2-) + CHEBI:29360 + + methanediide + + + + + + + + + + + + + + + + + +1 + H3O + InChI=1S/H2O/h1H2/p+1 + XLYOFNOQVPJJNP-UHFFFAOYSA-O + 19.02322 + 19.01784 + [H][O+]([H])[H] + CAS:13968-08-6 + Gmelin:141 + MolBase:1646 + aquahydrogen(1+) + oxidanium + oxonium + trihydridooxygen(1+) + chebi_ontology + H3O(+) + Hydronium cation + Hydronium ion + [OH3](+) + CHEBI:29412 + + oxonium + + + + + + + + + + + + + + + + + + + + + + -1 + CH3 + InChI=1S/CH3/h1H3/q-1 + LGRLWUINFJPLSH-UHFFFAOYSA-N + 15.03452 + 15.02402 + [H][C-]([H])[H] + Beilstein:1813938 + CAS:15194-58-8 + Gmelin:259263 + methanide + trihydridocarbonate(1-) + chebi_ontology + CH3(-) + [CH3](-) + lambda(2)-methanuide + methyl anion + CHEBI:29438 + + methanide + + + + + + + + + + 0 + C48H72O14 + InChI=1S/C48H72O14/c1-11-25(2)43-28(5)17-18-47(62-43)23-34-20-33(61-47)16-15-27(4)42(26(3)13-12-14-32-24-55-45-40(49)29(6)19-35(46(51)58-34)48(32,45)52)59-39-22-37(54-10)44(31(8)57-39)60-38-21-36(53-9)41(50)30(7)56-38/h12-15,17-19,25-26,28,30-31,33-45,49-50,52H,11,16,20-24H2,1-10H3/b13-12+,27-15+,32-14+/t25-,26-,28-,30-,31-,33+,34-,35-,36-,37-,38-,39-,40+,41-,42-,43+,44-,45+,47+,48+/m0/s1 + RRZXIRBKKLTSOM-XPNPUAGNSA-N + 873.07690 + 872.49221 + CC[C@H](C)[C@H]1O[C@@]2(C[C@@H]3C[C@@H](C\C=C(C)\[C@@H](O[C@H]4C[C@H](OC)[C@@H](O[C@H]5C[C@H](OC)[C@@H](O)[C@H](C)O5)[C@H](C)O4)[C@@H](C)\C=C\C=C4/CO[C@@H]5[C@H](O)C(C)=C[C@@H](C(=O)O3)[C@]45O)O2)C=C[C@@H]1C + BPDB:8 + Beilstein:3645625 + CAS:65195-55-3 + KEGG:C11983 + LIPID_MAPS_instance:LMPK04000024 + MetaCyc:CPD-12963 + VSDB:8 + (2aE,4E,5'S,6S,6'R,7S,8E,11R,13S,15S,17aR,20R,20aR,20bS)-20,20b-dihydroxy-5',6,8,19-tetramethyl-6'-[(1S)-1-methylpropyl]-17-oxo-5',6,6',10,11,14,15,17,17a,20,20a,20b-dodecahydro-2H,7H-spiro[11,15-methanofuro[4,3,2-pq][2,6]benzodioxacyclooctadecine-13,2'-pyran]-7-yl 2,6-dideoxy-4-O-(2,6-dideoxy-3-O-methyl-alpha-L-arabino-hexopyranosyl)-3-O-methyl-alpha-L-arabino-hexopyranoside + Avermectin B1a + chebi_ontology + abamectin component B1a + CHEBI:29534 + + avermectin B1a + + + + + + + + + + 0 + C47H70O14 + InChI=1S/C47H70O14/c1-24(2)41-27(5)16-17-46(61-41)22-33-19-32(60-46)15-14-26(4)42(25(3)12-11-13-31-23-54-44-39(48)28(6)18-34(45(50)57-33)47(31,44)51)58-38-21-36(53-10)43(30(8)56-38)59-37-20-35(52-9)40(49)29(7)55-37/h11-14,16-18,24-25,27,29-30,32-44,48-49,51H,15,19-23H2,1-10H3/b12-11+,26-14+,31-13+/t25-,27-,29-,30-,32+,33-,34-,35-,36-,37-,38-,39+,40-,41+,42-,43-,44+,46+,47+/m0/s1 + ZFUKERYTFURFGA-PVVXTEPVSA-N + 859.05030 + 858.47656 + [H][C@@]12C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@]4([H])[C@H](O)C(C)=C[C@@]([H])(C(=O)O[C@@H](C1)C[C@]1(O2)O[C@]([H])(C(C)C)[C@@H](C)C=C1)[C@]34O + Beilstein:8399072 + CAS:65195-56-4 + KEGG:C11967 + LIPID_MAPS_instance:LMPK04000020 + MetaCyc:CPD-12964 + (2aE,4E,5'S,6S,6'R,7S,8E,11R,13S,15S,17aR,20R,20aR,20bS)-20,20b-dihydroxy-5',6,8,19-tetramethyl-17-oxo-6'-(propan-2-yl)-5',6,6',10,11,14,15,17,17a,20,20a,20b-dodecahydro-2H,7H-spiro[11,15-methanofuro[4,3,2-pq][2,6]benzodioxacyclooctadecine-13,2'-pyran]-7-yl 2,6-dideoxy-4-O-(2,6-dideoxy-3-O-methyl-alpha-L-arabino-hexopyranosyl)-3-O-methyl-alpha-L-arabino-hexopyranoside + Avermectin B1b + chebi_ontology + (2aE,4E,5'S,6S,6'R,7S,8E,11R,13S,15S,17aR,20R,20aR,20bS)-20,20b-dihydroxy-6'-isopropyl-5',6,8,19-tetramethyl-17-oxo-5',6,6',10,11,14,15,17,17a,20,20a,20b-dodecahydro-2H,7H-spiro[11,15-methanofuro[4,3,2-pq][2,6]benzodioxacyclooctadecine-13,2'-pyran]-7-yl 2,6-dideoxy-4-O-(2,6-dideoxy-3-O-methyl-alpha-L-arabino-hexopyranosyl)-3-O-methyl-alpha-L-arabino-hexopyranoside + abamectin component B1b + CHEBI:29537 + + avermectin B1b + + + + + + + + + + + + + + + + + + + + + + + + + + + 18631 + A macrolide antibiotic that has formula C38H72N2O12. + A macrolide antibiotic useful for the treatment of bacterial infections. + + + 0 + C38H72N2O12 + InChI=1S/C38H72N2O12/c1-15-27-38(10,46)31(42)24(6)40(13)19-20(2)17-36(8,45)33(52-35-29(41)26(39(11)12)16-21(3)48-35)22(4)30(23(5)34(44)50-27)51-28-18-37(9,47-14)32(43)25(7)49-28/h20-33,35,41-43,45-46H,15-19H2,1-14H3/t20-,21-,22+,23-,24-,25+,26+,27-,28+,29-,30+,31-,32+,33-,35+,36-,37-,38-/m1/s1 + MQTOSJVFKKJCRP-BICOPXKESA-N + 748.98450 + 748.50853 + CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O + CHEBI:46596 + Beilstein:5387583 + CAS:83905-01-5 + ChemIDplus:83905-01-5 + DrugBank:DB00207 + Drug_Central:276 + HMDB:HMDB0014352 + KEGG COMPOUND:C06838 + KEGG DRUG:D07486 + KEGG:C06838 + KEGG:D07486 + LINCS:LSM-5821 + PDBeChem:ZIT + PMID:15143799 + PMID:18253999 + Patent:BE892357 + Patent:US4517359 + Reaxys:5387583 + Reaxys:8820027 + Wikipedia:Azithromycin + (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-15-oxo-11-{[3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl]oxy}-1-oxa-6-azacyclopentadecan-13-yl 2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranoside + chebi_ontology + (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)13-((2,6-Dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl)oxy)-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-((3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl)oxy)-1-oxa-6-azacyclopentadecan-15-one + Azenil + Azifast + Azigram + Azimakrol + Azitromin + C38H72N2O12 + CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@@H]([C@H]2O)N(C)C)[C@](C)(O)C[C@@H](C)CN(C)[C@H](C)[C@@H](O)[C@]1(C)O + Hemomycin + InChI=1S/C38H72N2O12/c1-15-27-38(10,46)31(42)24(6)40(13)19-20(2)17-36(8,45)33(52-35-29(41)26(39(11)12)16-21(3)48-35)22(4)30(23(5)34(44)50-27)51-28-18-37(9,47-14)32(43)25(7)49-28/h20-33,35,41-43,45-46H,15-19H2,1-14H3/t20-,21-,22+,23-,24-,25+,26+,27-,28+,29-,30+,31-,32+,33-,35+,36-,37-,38-/m1/s1 + InChIKey=MQTOSJVFKKJCRP-BICOPXKESA-N + Zithromax + Zmax + azithromycine + azithromycinum + azitromicina + CHEBI:2955 + + Azithromycin + azithromycin + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A trihydroxyflavone with the hydroxy groups at positions C-5, -6 and -7. + + 0 + C15H10O5 + InChI=1S/C15H10O5/c16-9-6-11(8-4-2-1-3-5-8)20-12-7-10(17)14(18)15(19)13(9)12/h1-7,17-19H + FXNFHKRTJBSTCS-UHFFFAOYSA-N + 270.23690 + 270.05282 + Oc1cc2oc(cc(=O)c2c(O)c1O)-c1ccccc1 + Beilstein:272683 + CAS:491-67-8 + KEGG:C10023 + KNApSAcK:C00001022 + LINCS:LSM-6355 + LIPID_MAPS_instance:LMPK12111095 + MetaCyc:CPD-12724 + PMID:10724177 + PMID:15853750 + PMID:22891631 + PMID:23098745 + PMID:28166217 + Patent:CN102429899 + Reaxys:272683 + Wikipedia:Baicalein + 5,6,7-trihydroxy-2-phenyl-4H-chromen-4-one + Baicalein + chebi_ontology + 5,6,7-Trihydroxyflavone + CHEBI:2979 + + baicalein + + + + + + + + + + + + + + + A tricarboxylic acid trianion that is the conjugate base of glycyrrhizinic acid. + + -3 + C42H59O16 + InChI=1S/C42H62O16/c1-37(2)21-8-11-42(7)31(20(43)16-18-19-17-39(4,36(53)54)13-12-38(19,3)14-15-41(18,42)6)40(21,5)10-9-22(37)55-35-30(26(47)25(46)29(57-35)33(51)52)58-34-27(48)23(44)24(45)28(56-34)32(49)50/h16,19,21-31,34-35,44-48H,8-15,17H2,1-7H3,(H,49,50)(H,51,52)(H,53,54)/p-3/t19-,21-,22-,23-,24-,25-,26-,27+,28-,29-,30+,31+,34-,35-,38+,39-,40-,41+,42+/m0/s1 + LPLVUJXQOOQHMX-QWBHMCJMSA-K + 819.90826 + 819.38196 + [H][C@@]12C[C@](C)(CC[C@]1(C)CC[C@]1(C)C2=CC(=O)[C@]2([H])[C@@]3(C)CC[C@H](O[C@H]4O[C@@H]([C@@H](O)[C@H](O)[C@H]4O[C@@H]4O[C@@H]([C@@H](O)[C@H](O)[C@H]4O)C([O-])=O)C([O-])=O)C(C)(C)[C@]3([H])CC[C@@]12C)C([O-])=O + CHEBI:14367 + CHEBI:24419 + KEGG:C02284 + KEGG:D00157 + KNApSAcK:C00003522 + MetaCyc:GLYCYRRHIZINATE + chebi_ontology + (3beta,20beta)-20-Carboxy-11-oxo-30-norolean-12-en-3-yl-2-O-beta-D-glucuronosyl-beta-D-glucosiduronic acid + Glycyrrhizic acid + Glycyrrhizin + Glycyrrhizinate + glycyrrhizin + CHEBI:29807 + + glycyrrhizinate(3-) + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + The glycosyloxyflavone which is the 7-O-glucuronide of baicalein. + + 0 + C21H18O11 + InChI=1S/C21H18O11/c22-9-6-10(8-4-2-1-3-5-8)30-11-7-12(14(23)15(24)13(9)11)31-21-18(27)16(25)17(26)19(32-21)20(28)29/h1-7,16-19,21,23-27H,(H,28,29)/t16-,17-,18+,19-,21+/m0/s1 + IKIIZLYTISPENI-ZFORQUDYSA-N + 446.36100 + 446.08491 + O[C@H]1[C@@H](O[C@@H]([C@@H](O)[C@@H]1O)C(O)=O)Oc1cc2oc(cc(=O)c2c(O)c1O)-c1ccccc1 + Beilstein:70480 + CAS:21967-41-9 + Drug_Central:4055 + HMDB:HMDB0041832 + KEGG:C10025 + KNApSAcK:C00001024 + LIPID_MAPS_instance:LMPK12111081 + MetaCyc:CPD-12725 + PMID:10724177 + PMID:18650094 + PMID:21087019 + PMID:22467027 + PMID:23302221 + PMID:23354080 + PMID:23523628 + Patent:CN102584918 + Patent:WO2012119458 + Reaxys:70480 + Wikipedia:Baicalin + 5,6-dihydroxy-4-oxo-2-phenyl-4H-chromen-7-yl beta-D-glucopyranosiduronic acid + Baicalin + chebi_ontology + 5,6,7-trihydroxyflavone 7-O-beta-D-glucuronide + 5,6-dihydroxy-4-oxo-2-phenyl-4H-1-benzopyran-7-yl beta-D-glucopyranosiduronic acid + 7-D-glucuronic acid-5,6-dihydroxyflavone + Baicalein 7-O-glucuronide + CHEBI:2981 + + baicalin + + + + + + + + + + + + + + + + 0 + HS + 33.074 + 32.97990 + *S[H] + CHEBI:26821 + CHEBI:29916 + sulfanyl + thiol + thiol group + chebi_ontology + -SH + HS- + Mercaptogruppe + Merkaptogruppe + Sulfhydrylgruppe + Thiolgruppe + mercapto group + sulfhydryl group + sulphydryl group + CHEBI:29917 + + thiol group + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + -1 + HS + InChI=1S/H2S/h1H2/p-1 + RWSOTUBLDIXVET-UHFFFAOYSA-M + 33.07394 + 32.98044 + [S-][H] + CAS:15035-72-0 + Gmelin:24766 + hydrogen(sulfide)(1-) + hydrosulfide + sulfanide + chebi_ontology + HS anion + HS(-) + hydrogen sulfide + CHEBI:29919 + + hydrosulfide + + + + + + + + + + + + + + + + 0 + HO3S + 81.07214 + 80.96464 + S(=O)(O)(*)=O + PDBeChem:SFO + SULFO GROUP + hydroxydioxo-lambda(6)-sulfanyl + hydroxysulfonyl + sulfo + chebi_ontology + -S(O)2(OH) + CHEBI:29922 + + sulfo group + + + + + + + + + + + + + + + + 0 + H2N2 + InChI=1S/H2N2/c1-2/h1-2H + RAABOESOVLLHRU-UHFFFAOYSA-N + 30.02936 + 30.02180 + N=N + CAS:3618-05-1 + KEGG:C05360 + diazene + chebi_ontology + Diimide + HN=NH + CHEBI:30096 + + diazene + + + + + + + + + + + + + + + + + + + + + + -1 + HN2 + InChI=1S/HN2/c1-2/h1H/q-1 + XSCXGOPPNHTWEF-UHFFFAOYSA-N + 29.02142 + 29.01452 + N=[N-] + diazenide + chebi_ontology + N=NH(-) + CHEBI:30103 + + diazenide + + + + + + + + + + + + + + + + 0 + N2 + 28.01348 + 28.00615 + N(=N/*)\* + diazenediyl + chebi_ontology + -N=N- + azo + diazene-1,2-diyl + CHEBI:30106 + + azo group + + + + + + + + + + + + + + + + + 0 + C3H7 + 43.08768 + 43.05478 + CC(*)C + isopropyl + propan-2-yl + chebi_ontology + (CH3)2CH- + -CH(CH3)2 + 1-methylethyl + iPr + valine side-chain + CHEBI:30353 + + isopropyl group + + + + + + + + + + + + + + + + + 0 + C4H9 + 57.11426 + 57.07043 + CC(C)C* + 2-methylpropan-1-ido + 2-methylpropyl + isobutyl + chebi_ontology + (CH3)2CH-CH2- + -CH2-CH(CH3)2 + iBu + leucine side-chain + CHEBI:30356 + + isobutyl group + + + + + + + + + + + + + + + + + + + + + + An alkane that is propane substituted by a methyl group at position 2. + + 0 + C4H10 + InChI=1S/C4H10/c1-4(2)3/h4H,1-3H3 + NNPPMTNAJDCUHE-UHFFFAOYSA-N + 58.12220 + 58.07825 + CC(C)C + Beilstein:1730720 + CAS:75-28-5 + Gmelin:1301 + KEGG:D04623 + PMID:24179026 + PMID:24464945 + Reaxys:1730720 + Wikipedia:Isobutane + 2-methylpropane + isobutane + chebi_ontology + (CH3)2CH-CH3 + E943b + R-600a + CHEBI:30363 + + isobutane + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + 1424 + Tropane in which a hydrogen at position 3 is substituted by a diphenylmethoxy group (endo-isomer). An acetylcholine receptor antagonist, it is used (particularly as its methanesulphonate salt) in the treatment of Parkinson's disease, and to reduce parkinsonism and akathisia side effects of antipsychotic treatments. + + + 0 + C21H25NO + InChI=1S/C21H25NO/c1-22-18-12-13-19(22)15-20(14-18)23-21(16-8-4-2-5-9-16)17-10-6-3-7-11-17/h2-11,18-21H,12-15H2,1H3/t18-,19+,20+ + GIJXKZJWITVLHI-PMOLBWCYSA-N + 307.42930 + 307.19361 + [H][C@]1(C[C@]2([H])CC[C@]([H])(C1)N2C)OC(c1ccccc1)c1ccccc1 + CHEBI:661238 + Beilstein:90688 + CAS:86-13-5 + ChEMBL:661238 + ChemIDplus:86-13-5 + DrugBank:DB00245 + Drug_Central:333 + KEGG COMPOUND:86-13-5 + KEGG COMPOUND:C06846 + KEGG DRUG:D07511 + KEGG:C06846 + KEGG:D07511 + NIST Chemistry WebBook:86-13-5 + Patent:US2595405 + Wikipedia:Benzatropine + (3-endo)-3-(diphenylmethoxy)-8-methyl-8-azabicyclo[3.2.1]octane + Benzatropine + chebi_ontology + 3alpha-(diphenylmethoxy)-1alphaH,5alphaH-tropane + 3alpha-(diphenylmethoxy)tropane + 3alpha-benzhydryloxy-8-methyl-8-azabicyclo[3.2.1]octane + 3endo-benzhydryloxytropane + Benztropine + C21H25NO + InChI=1S/C21H25NO/c1-22-18-12-13-19(22)15-20(14-18)23-21(16-8-4-2-5-9-16)17-10-6-3-7-11-17/h2-11,18-21H,12-15H2,1H3/t18-,19+,20+ + InChIKey=GIJXKZJWITVLHI-PMOLBWCYSA-N + [H][C@]1(C[C@]2([H])CC[C@]([H])(C1)N2C)OC(c1ccccc1)c1ccccc1 + benzatropina + benzatropine + benzatropinum + benzhydryl 8-methyl-8-azabicyclo[3.2.1]oct-3-yl ether + tropine benzohydryl ether + CHEBI:3048 + + Benztropine + benzatropine + + + + + + + + + + + + + + + + + + +1 + H3S + InChI=1S/H2S/h1H2/p+1 + RWSOTUBLDIXVET-UHFFFAOYSA-O + 35.08982 + 34.99500 + [H][S+]([H])[H] + CAS:18155-21-0 + Gmelin:307 + sulfanium + sulfonium + trihydridosulfur(1+) + chebi_ontology + H3S(+) + H3S+ + [SH3](+) + sulphonium + CHEBI:30488 + + sulfonium + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + The methanesulfonate salt of benzatropine. An acetylcholine receptor antagonist, it is used in the treatment of Parkinson's disease, and to reduce parkinsonism and akathisia side effects of antipsychotic treatments. + + 0 + C22H29NO4S + InChI=1S/C21H25NO.CH4O3S/c1-22-18-12-13-19(22)15-20(14-18)23-21(16-8-4-2-5-9-16)17-10-6-3-7-11-17;1-5(2,3)4/h2-11,18-21H,12-15H2,1H3;1H3,(H,2,3,4)/t18-,19+,20+; + CPFJLLXFNPCTDW-BWSPSPBFSA-N + 403.53500 + 403.18173 + CS([O-])(=O)=O.[H][C@]1(C[C@]2([H])CC[C@]([H])(C1)[NH+]2C)OC(c1ccccc1)c1ccccc1 + Beilstein:3826475 + CAS:132-17-2 + DrugBank:DB00245 + KEGG:D00778 + Patent:US2595405 + (3-endo)-3-(diphenylmethoxy)-8-methyl-8-azabicyclo[3.2.1]octane methanesulfonate + chebi_ontology + (3-endo)-3-(diphenylmethoxy)-8-methyl-8-azoniabicyclo[3.2.1]octane methanesulfonate + 3-diphenylmethoxytropane mesylate + 3-diphenylmethoxytropane methanesulfonate + 3alpha-(diphenylmethoxy)-1alphaH,5alphaH-tropane mesylate + 3alpha-(diphenylmethoxy)-1alphaH,5alphaH-tropane methanesulfonate + 3alpha-(diphenylmethoxy)tropane mesylate + 3alpha-(diphenylmethoxy)tropane methanesulfonate + 3endo-benzhydryloxytropane mesylate + 3endo-benzhydryloxytropane methanesulphonate + benzatropine methanesulfonate + benztropine mesilate + benztropine mesylate + benztropine methanesulfonate + tropine benzohydryl ether mesylate + tropine benzohydryl ether methanesulphonate + CHEBI:3049 + + benzatropine mesylate + + + + + + + + + + + 0 + C37H40N2O6 + InChI=1S/C37H40N2O6/c1-38-14-12-24-19-32(41-3)33-21-27(24)28(38)16-22-6-9-26(10-7-22)44-31-18-23(8-11-30(31)40)17-29-35-25(13-15-39(29)2)20-34(42-4)36(43-5)37(35)45-33/h6-11,18-21,28-29,40H,12-17H2,1-5H3/t28-,29+/m0/s1 + DFOCUWZXJBAUSQ-URLMMPGGSA-N + 608.725 + 608.28864 + COc1cc2CCN(C)[C@H]3Cc4ccc(Oc5cc(C[C@H]6N(C)CCc7cc(OC)c(OC)c(Oc1cc23)c67)ccc5O)cc4 + CAS:478-61-5 + KEGG:C09357 + KNApSAcK:C00001817 + Berbamine + chebi_ontology + CHEBI:3063 + + Berbamine + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A compound comprising a benzene ring core carrying a carboxylic acid substituent. + + 0 + C7H6O2 + InChI=1S/C7H6O2/c8-7(9)6-4-2-1-3-5-6/h1-5H,(H,8,9) + WPYMKLBDIGXBTP-UHFFFAOYSA-N + 122.12130 + 122.03678 + OC(=O)c1ccccc1 + CHEBI:22722 + CHEBI:3029 + CHEBI:41051 + Beilstein:636131 + CAS:65-85-0 + DrugBank:DB03793 + Drug_Central:4664 + Gmelin:2946 + HMDB:HMDB0001870 + KEGG:C00180 + KEGG:C00539 + KEGG:D00038 + KNApSAcK:C00000207 + LINCS:LSM-37118 + MetaCyc:BENZOATE + PDBeChem:BEZ + PMID:16728954 + PMID:17439666 + PMID:18314336 + PPDB:1475 + Reaxys:636131 + Wikipedia:Benzoic_Acid + YMDB:YMDB02301 + BENZOIC ACID + Benzoic acid + benzoic acid + chebi_ontology + Aromatic carboxylic acid + Benzenecarboxylic acid + Benzeneformic acid + Benzenemethanoic acid + Benzoesaeure + Dracylic acid + E210 + Phenylcarboxylic acid + Phenylformic acid + acide benzoique + CHEBI:30746 + + benzoic acid + + + + + + + + + + + + + + + + + + + + + A monohydroxybenzoate that is the conjugate base of salicylic acid. + + -1 + C7H5O3 + InChI=1S/C7H6O3/c8-6-4-2-1-3-5(6)7(9)10/h1-4,8H,(H,9,10)/p-1 + YGSDEFSMJLZEOE-UHFFFAOYSA-M + 137.11280 + 137.02442 + Oc1ccccc1C([O-])=O + CHEBI:15061 + CHEBI:26595 + Beilstein:3605209 + CAS:63-36-5 + Gmelin:3417 + KEGG:C00805 + PMID:16669002 + PMID:16934829 + Reaxys:3605209 + UM-BBD_compID:c0043 + 2-hydroxybenzoate + Salicylate + salicylate + chebi_ontology + 2-hydroxybenzoic acid ion(1-) + o-hydroxybenzoate + sal + CHEBI:30762 + + salicylate + + + + + + + + + A compound in which a hydroxy group, -OH, is attached to a saturated carbon atom. + + 0 + HOR + 17.007 + 17.00274 + O[*] + CHEBI:13804 + CHEBI:22288 + CHEBI:2553 + KEGG:C00069 + Alcohol + alcohols + chebi_ontology + an alcohol + CHEBI:30879 + + alcohol + + + + + + + + + + 0 + C32H44O7 + InChI=1S/C32H44O7/c1-18(2)28(36)37-17-25(35)32-26(38-29(39-32)19-8-6-5-7-9-19)15-23-22-11-10-20-14-21(33)12-13-30(20,3)27(22)24(34)16-31(23,32)4/h12-14,18-19,22-24,26-27,29,34H,5-11,15-17H2,1-4H3/t22-,23-,24-,26+,27+,29+,30-,31-,32+/m0/s1 + LUKZNWIVRBCLON-GXOBDPJESA-N + 540.689 + 540.30870 + C(COC(C(C)C)=O)(=O)[C@]12[C@]3(C)[C@@](C[C@]1(O[C@H](O2)C4CCCCC4)[H])([C@]5([C@]([C@H](C3)O)([C@]6(C)C(CC5)=CC(C=C6)=O)[H])[H])[H] + CAS:126544-47-6 + Drug_Central:633 + KEGG:D01703 + Ciclesonide + chebi_ontology + alvesco + omnaris + CHEBI:31397 + + Ciclesonide + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A 2'-deoxycytidine hydrochloriode having geminal fluoro substituents in the 2'-position. An inhibitor of ribonucleotide reductase, gemcitabine hydrochloride is used in the treatment of various carcinomas, including non-small cell lung cancer, pancreatic cancer, bladder cancer and breast cancer. + + 0 + C9H11F2N3O4.HCl + C9H12ClF2N3O4 + InChI=1S/C9H11F2N3O4.ClH/c10-9(11)6(16)4(3-15)18-7(9)14-2-1-5(12)13-8(14)17;/h1-2,4,6-7,15-16H,3H2,(H2,12,13,17);1H/t4-,6-,7-;/m1./s1 + OKKDEIYWILRZIA-OSZBKLCCSA-N + 299.65900 + 299.04844 + [H+].[Cl-].Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1 + Beilstein:5386970 + CAS:122111-03-9 + DrugBank:DB00441 + KEGG:D01155 + 2'-deoxy-2',2'-difluorocytidine hydrochloride + chebi_ontology + 2',2'-Difluorodeoxycytidine monohydrochloride + 2'-Deoxy-2',2'-difluorocytidine monohydrochloride + Gemcitabine HCl + CHEBI:31647 + + gemcitabine hydrochloride + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A terpene ketone in which a (9E,13E)-geranylgernayl group is bonded to one of the alpha-methyls of acetone (it is a mixture of 5E- and 5Z-geoisomers in a 3:2 ratio). + + 0 + C23H38O + InChI=1S/C23H38O/c1-19(2)11-7-12-20(3)13-8-14-21(4)15-9-16-22(5)17-10-18-23(6)24/h11,13,15,17H,7-10,12,14,16,18H2,1-6H3/b20-13+,21-15+,22-17? + HUCXKZBETONXFO-AJDZVAQLSA-N + 330.54720 + 330.29227 + CC(C)=CCC\C(C)=C\CC\C(C)=C\CCC(C)=CCCC(C)=O + CAS:6809-52-5 + Drug_Central:2596 + KEGG:C13297 + KEGG:D01827 + PMID:21645219 + PMID:22004457 + PMID:22548767 + PMID:23229517 + PMID:23289389 + PMID:23684147 + PMID:23792203 + PMID:23942364 + PMID:24008351 + PMID:24098472 + PMID:24531083 + PMID:24573719 + PMID:24582814 + PMID:24631258 + PMID:24633659 + PMID:24695789 + PMID:24737026 + Reaxys:8717724 + (9E,13E)-6,10,14,18-tetramethylnonadeca-5,9,13,17-tetraen-2-one + chebi_ontology + Geranylgeranylacetone + Selbex + teprenona + teprenone + teprenonum + CHEBI:31649 + + teprenone + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A methanesulfonate (mesylate) salt that is the monomesylate salt of imatinib. Used for treatment of chronic myelogenous leukemia and gastrointestinal stromal tumours. + + 0 + C29H31N7O.CH4O3S + C30H35N7O4S + InChI=1S/C29H31N7O.CH4O3S/c1-21-5-10-25(18-27(21)34-29-31-13-11-26(33-29)24-4-3-12-30-19-24)32-28(37)23-8-6-22(7-9-23)20-36-16-14-35(2)15-17-36;1-5(2,3)4/h3-13,18-19H,14-17,20H2,1-2H3,(H,32,37)(H,31,33,34);1H3,(H,2,3,4) + YLMAHDNUQAMNNX-UHFFFAOYSA-N + 589.70968 + 589.24712 + CS(O)(=O)=O.CN1CCN(CC1)Cc1ccc(cc1)C(=O)Nc1ccc(C)c(Nc2nccc(n2)-c2cccnc2)c1 + Beilstein:10229624 + CAS:220127-57-1 + DrugBank:DB00619 + HMDB:HMDB0014757 + KEGG:D01441 + PMID:12047970 + PMID:12616857 + PMID:12669406 + PMID:12975485 + PMID:14760091 + PMID:15059881 + PMID:15161340 + PMID:15206509 + PMID:15250677 + PMID:15601563 + PMID:15727903 + PMID:16570351 + PMID:16805961 + PMID:16835496 + PMID:17212133 + PMID:18422477 + PMID:19073506 + PMID:19258052 + PMID:19508953 + PMID:19542718 + PMID:19568828 + PMID:21084823 + PMID:21333826 + PMID:23462796 + Patent:RU2365587 + Patent:WO2004106326 + Patent:WO2011161689 + Patent:WO9903854 + Reaxys:10229624 + 4-[(4-methylpiperazin-1-yl)methyl]-N-{4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl}benzamide methanesulfonate + chebi_ontology + Gleevec + Glivec + imatinib mesilate + imatinib mesylate + imatinib methansulfonate + imatinib monomesylate + CHEBI:31690 + + imatinib methanesulfonate + + + + + + + + + + + + + + + + + + + + + + + + + + + + A dicarboxylic acid diamide that is amphetamine is substituted on nitrogen by a (2,6-dimethylphenoxy)acetyl group and on the carbon alpha- to nitrogen by a (1S,3S)-1-hydroxy-3-{[(2S)-3-methyl-2-(2-oxotetrahydropyrimidin-1-yl)butanoyl]amino}-4-phenylbutyl group. An antiretroviral of the protease inhibitor class, it is used against HIV infections as a fixed-dose combination with another protease inhibitor, ritonavir. + + 0 + C37H48N4O5 + InChI=1S/C37H48N4O5/c1-25(2)34(41-20-12-19-38-37(41)45)36(44)39-30(21-28-15-7-5-8-16-28)23-32(42)31(22-29-17-9-6-10-18-29)40-33(43)24-46-35-26(3)13-11-14-27(35)4/h5-11,13-18,25,30-32,34,42H,12,19-24H2,1-4H3,(H,38,45)(H,39,44)(H,40,43)/t30-,31-,32-,34-/m0/s1 + KJHKTHWMRKYKJE-SUGCFTRWSA-N + 628.80080 + 628.36247 + CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](Cc1ccccc1)NC(=O)COc1c(C)cccc1C)Cc1ccccc1 + CAS:192725-17-0 + DrugBank:DB01601 + Drug_Central:1601 + HMDB:HMDB0015539 + KEGG:C12871 + KEGG:D01425 + LINCS:LSM-6027 + PDBeChem:AB1 + PMID:24014186 + PMID:24518130 + PMID:24566184 + PMID:24805184 + PMID:24906762 + PMID:24958908 + PMID:25120613 + Reaxys:9309881 + (2S)-N-[(2S,4S,5S)-5-{[(2,6-dimethylphenoxy)acetyl]amino}-4-hydroxy-1,6-diphenylhexan-2-yl]-3-methyl-2-(2-oxotetrahydropyrimidin-1(2H)-yl)butanamide + Lopinavir + chebi_ontology + CHEBI:31781 + + lopinavir + + + + + + + + + + + + 0 + C19H19N5O2.2CH3O3S + 539.585 + 539.11445 + KEGG:D01670 + chebi_ontology + 6-Amidino-2-naphthyl 4-guanidinobenzoate dimethanesulfonate + Futhan + Nafamostat mesilate + Nafamostat mesylate (TN) + CHEBI:31890 + + nafamostat methanesulfonate + + + + + + + + + + 0 + C30H42O8 + InChI=1S/C30H42O8/c1-16-24(32)25(33)26(34)27(37-16)38-19-8-11-28(2)18(14-19)5-6-22-21(28)9-12-29(3)20(10-13-30(22,29)35)17-4-7-23(31)36-15-17/h4,7,14-16,19-22,24-27,32-35H,5-6,8-13H2,1-3H3/t16-,19-,20+,21-,22+,24-,25+,26+,27-,28-,29+,30-/m0/s1 + MYEJFUXQJGHEQK-ALRJYLEOSA-N + 530.651 + 530.28797 + C[C@@H]1O[C@@H](O[C@H]2CC[C@]3(C)[C@H]4CC[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CCC3=C2)C6=COC(=O)C=C6)[C@H](O)[C@H](O)[C@H]1O + CAS:466-06-8 + Drug_Central:2313 + KEGG:D01379 + Proscillaridin + chebi_ontology + caradrin + cardiovite + desglucotransvaaline + procardin + proscillaridin A + scillacrist + CHEBI:32065 + + Proscillaridin + + + + + + + + + + + + + + + + + + + + + + The simplest member of the class of salicylamides derived from salicylic acid. + + 0 + C7H7NO2 + InChI=1S/C7H7NO2/c8-7(10)5-3-1-2-4-6(5)9/h1-4,9H,(H2,8,10) + SKZKKFZAGNVIMN-UHFFFAOYSA-N + 137.13600 + 137.04768 + NC(=O)c1ccccc1O + Beilstein:742439 + CAS:65-45-2 + DrugBank:DB08797 + Drug_Central:2415 + Gmelin:142521 + KEGG:D01811 + PDBeChem:OHB + PMID:14729655 + PMID:1650428 + PMID:22530891 + Reaxys:742439 + Wikipedia:Salicylamide + 2-hydroxybenzamide + chebi_ontology + 2-Carbamoylphenol + 2-Carboxamidophenol + 2-Hydroxybenzamide + OHB + Salicylic Acid amide + o-Hydroxybenzamide + salicilamida + salicylamide + salicylamidum + CHEBI:32114 + + salicylamide + + + + + + + + + + + + + + + + + + + + + + 0 + C22H29N3S2.(C4H4O4)2 + C22H29N3S2.C8H8O8 + C30H37N3O8S2 + InChI=1S/C22H29N3S2.2C4H4O4/c1-3-26-18-9-10-22-20(17-18)25(19-7-4-5-8-21(19)27-22)12-6-11-24-15-13-23(2)14-16-24;2*5-3(6)1-2-4(7)8/h4-5,7-10,17H,3,6,11-16H2,1-2H3;2*1-2H,(H,5,6)(H,7,8)/b;2*2-1- + RVBRTNPNFYFDMZ-SPIKMXEPSA-N + 631.76220 + 631.20221 + [H+].[H+].[H+].[H+].[O-]C(=O)\C=C/C([O-])=O.[O-]C(=O)\C=C/C([O-])=O.CCSc1ccc2Sc3ccccc3N(CCCN3CCN(C)CC3)c2c1 + Beilstein:3864479 + CAS:1179-69-7 + DrugBank:DB00372 + KEGG:D01130 + 2-(ethylsulfanyl)-10-[3-(4-methylpiperazin-1-yl)propyl]-10H-phenothiazine di[(2Z)-but-2-enedioate] + chebi_ontology + 10H-Phenothiazine, 2-(ethylthio)-10-(3-(4-methyl-1-piperazinyl)propyl)-, (Z)-2-butenedioate (1:2) + 2-(Ethylthio)-10-(3-(4-methyl-1-piperazinyl)propyl)phenothiazine dimaleate + 2-Ethylmercapto-10-(3-(1-methyl-4-piperazinyl)propyl)phenothiazine dimaleate + Thiethylperazine dimaleate + Tietylperazine maleate + Torecan + CHEBI:32216 + + thiethylperazine maleate + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + An optically active form of phenylalaninate having L-configuration. + + -1 + C9H10NO2 + InChI=1S/C9H11NO2/c10-8(9(11)12)6-7-4-2-1-3-5-7/h1-5,8H,6,10H2,(H,11,12)/p-1/t8-/m0/s1 + COLNVLDHVKWLRT-QMMMGPOBSA-M + 164.18120 + 164.07170 + N[C@@H](Cc1ccccc1)C([O-])=O + Beilstein:4136718 + Gmelin:329084 + PMID:21956539 + Reaxys:4136718 + L-phenylalaninate + chebi_ontology + (2S)-2-amino-3-phenylpropanoate + L-phenylalanine anion + CHEBI:32486 + + L-phenylalaninate + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + An optically active form of phenylalaninium having L-configuration. + + +1 + C9H12NO2 + InChI=1S/C9H11NO2/c10-8(9(11)12)6-7-4-2-1-3-5-7/h1-5,8H,6,10H2,(H,11,12)/p+1/t8-/m0/s1 + COLNVLDHVKWLRT-QMMMGPOBSA-O + 166.19710 + 166.08626 + [NH3+][C@@H](Cc1ccccc1)C(O)=O + PMID:21956539 + L-phenylalaninium + chebi_ontology + (1S)-1-carboxy-2-phenylethanaminium + L-phenylalanine cation + CHEBI:32487 + + L-phenylalaninium + + + + + + + + + + + + + + + + + + + + + The D-enantiomer of phenylalaninate. + + -1 + C9H10NO2 + InChI=1S/C9H11NO2/c10-8(9(11)12)6-7-4-2-1-3-5-7/h1-5,8H,6,10H2,(H,11,12)/p-1/t8-/m1/s1 + COLNVLDHVKWLRT-MRVPVSSYSA-M + 164.18120 + 164.07170 + N[C@H](Cc1ccccc1)C([O-])=O + Beilstein:5740552 + Gmelin:746993 + D-phenylalaninate + chebi_ontology + (2R)-2-amino-3-phenylpropanoate + D-phenylalanine anion + CHEBI:32494 + + D-phenylalaninate + + + + + + + + + + + + + + + + + + + + + An optically active form of phenylalaninium having D-configuration. + + +1 + C9H12NO2 + InChI=1S/C9H11NO2/c10-8(9(11)12)6-7-4-2-1-3-5-7/h1-5,8H,6,10H2,(H,11,12)/p+1/t8-/m1/s1 + COLNVLDHVKWLRT-MRVPVSSYSA-O + 166.19710 + 166.08626 + [NH3+][C@H](Cc1ccccc1)C(O)=O + D-phenylalaninium + chebi_ontology + (1R)-1-carboxy-2-phenylethanaminium + D-phenylalanine cation + CHEBI:32495 + + D-phenylalaninium + + + + + + + + + + + + + + + + An aromatic amino-acid anion that is the conjugate base of phenylalanine, arising from deprotonation of the carboxy group. + + -1 + C9H10NO2 + InChI=1S/C9H11NO2/c10-8(9(11)12)6-7-4-2-1-3-5-7/h1-5,8H,6,10H2,(H,11,12)/p-1 + COLNVLDHVKWLRT-UHFFFAOYSA-M + 164.18120 + 164.07170 + NC(Cc1ccccc1)C([O-])=O + Gmelin:329083 + phenylalaninate + chebi_ontology + 2-amino-3-phenylpropanoate + phenylalanine anion + CHEBI:32504 + + phenylalaninate + + + + + + + + + + + + + + + An alpha-amino-acid cation that is the conjugate acid of phenylalanine, arising from protonation of the amino group. + + +1 + C9H12NO2 + InChI=1S/C9H11NO2/c10-8(9(11)12)6-7-4-2-1-3-5-7/h1-5,8H,6,10H2,(H,11,12)/p+1 + COLNVLDHVKWLRT-UHFFFAOYSA-O + 166.19710 + 166.08626 + [NH3+]C(Cc1ccccc1)C(O)=O + phenylalaninium + chebi_ontology + 1-carboxy-2-phenylethanaminium + phenylalanine cation + CHEBI:32505 + + phenylalaninium + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + The L-enantiomer of leucinate. + + -1 + C6H12NO2 + InChI=1S/C6H13NO2/c1-4(2)3-5(7)6(8)9/h4-5H,3,7H2,1-2H3,(H,8,9)/p-1/t5-/m0/s1 + ROHFNLRQFUQHCH-YFKPBYRVSA-M + 130.16502 + 130.08735 + CC(C)C[C@H](N)C([O-])=O + Beilstein:3537983 + Gmelin:326784 + L-leucinate + chebi_ontology + (2S)-2-amino-4-methylpentanoate + L-leucine anion + CHEBI:32619 + + L-leucinate + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + The L-enantiomer of leucinium. + + +1 + C6H14NO2 + InChI=1S/C6H13NO2/c1-4(2)3-5(7)6(8)9/h4-5H,3,7H2,1-2H3,(H,8,9)/p+1/t5-/m0/s1 + ROHFNLRQFUQHCH-YFKPBYRVSA-O + 132.18090 + 132.10191 + CC(C)C[C@H]([NH3+])C(O)=O + L-leucinium + chebi_ontology + (1S)-1-carboxy-3-methylbutan-1-aminium + L-leucine cation + CHEBI:32620 + + L-leucinium + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + The D-enantiomer of leucinate. + + -1 + C6H12NO2 + InChI=1S/C6H13NO2/c1-4(2)3-5(7)6(8)9/h4-5H,3,7H2,1-2H3,(H,8,9)/p-1/t5-/m1/s1 + ROHFNLRQFUQHCH-RXMQYKEDSA-M + 130.16502 + 130.08735 + CC(C)C[C@@H](N)C([O-])=O + Gmelin:533394 + D-leucinate + chebi_ontology + (2R)-2-amino-4-methylpentanoate + D-leucine anion + CHEBI:32623 + + D-leucinate + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + The D-enantiomer of leucinium. + + +1 + C6H14NO2 + InChI=1S/C6H13NO2/c1-4(2)3-5(7)6(8)9/h4-5H,3,7H2,1-2H3,(H,8,9)/p+1/t5-/m1/s1 + ROHFNLRQFUQHCH-RXMQYKEDSA-O + 132.18090 + 132.10191 + CC(C)C[C@@H]([NH3+])C(O)=O + Gmelin:363610 + D-leucinium + chebi_ontology + (1R)-1-carboxy-3-methylbutan-1-aminium + D-leucine cation + CHEBI:32624 + + D-leucinium + + + + + + + + + + + + + + + + An alpha-amino-acid anion that is the conjugate base of leucine, arising from deprotonation of the carboxy group. + + -1 + C6H12NO2 + InChI=1S/C6H13NO2/c1-4(2)3-5(7)6(8)9/h4-5H,3,7H2,1-2H3,(H,8,9)/p-1 + ROHFNLRQFUQHCH-UHFFFAOYSA-M + 130.16502 + 130.08735 + CC(C)CC(N)C([O-])=O + Reaxys:5245805 + leucinate + chebi_ontology + 2-amino-4-methylpentanoate + leu(-) + leucine anion + CHEBI:32627 + + leucinate + + + + + + + + + + + + + + + An alpha-amino-acid cation that is the conjugate acid of leucine, arising from protonation of the amino group. + + +1 + C6H14NO2 + InChI=1S/C6H13NO2/c1-4(2)3-5(7)6(8)9/h4-5H,3,7H2,1-2H3,(H,8,9)/p+1 + ROHFNLRQFUQHCH-UHFFFAOYSA-O + 132.18090 + 132.10191 + CC(C)CC([NH3+])C(O)=O + Gmelin:1651836 + leucinium + chebi_ontology + 1-carboxy-3-methylbutan-1-aminium + H2leu(+) + leucine cation + CHEBI:32628 + + leucinium + + + + + + + + + + + + + + + + + + + + + + A serinate that is the conjugate base of L-serine, obtained by deprotonation of the carboxy group. + + -1 + C3H6NO3 + InChI=1S/C3H7NO3/c4-2(1-5)3(6)7/h2,5H,1,4H2,(H,6,7)/p-1/t2-/m0/s1 + MTCFGRXMJLQNBG-REOHCLBHSA-M + 104.08468 + 104.03532 + N[C@@H](CO)C([O-])=O + Beilstein:4372751 + Gmelin:324693 + L-serinate + chebi_ontology + (2S)-2-amino-3-hydroxypropanoate + L-serine anion + CHEBI:32836 + + L-serinate + + + + + + + + + + + + + + + + + + + + + A serinium that is the conjugate acid of L-serine, obtained by protonation of the amino group. + + +1 + C3H8NO3 + InChI=1S/C3H7NO3/c4-2(1-5)3(6)7/h2,5H,1,4H2,(H,6,7)/p+1/t2-/m0/s1 + MTCFGRXMJLQNBG-REOHCLBHSA-O + 106.10056 + 106.04987 + [NH3+][C@@H](CO)C(O)=O + L-serinium + chebi_ontology + (1S)-1-carboxy-2-hydroxyethanaminium + L-serine cation + CHEBI:32837 + + L-serinium + + + + + + + + + + + + + + + + + + + + + The D-enantiomer of serinate. + + -1 + C3H6NO3 + InChI=1S/C3H7NO3/c4-2(1-5)3(6)7/h2,5H,1,4H2,(H,6,7)/p-1/t2-/m1/s1 + MTCFGRXMJLQNBG-UWTATZPHSA-M + 104.08468 + 104.03532 + N[C@H](CO)C([O-])=O + Gmelin:745975 + D-serinate + chebi_ontology + (2R)-2-amino-3-hydroxypropanoate + D-serine anion + CHEBI:32840 + + D-serinate + + + + + + + + + + + + + + + + + + + + + The D-enantiomer of serinium. + + +1 + C3H8NO3 + InChI=1S/C3H7NO3/c4-2(1-5)3(6)7/h2,5H,1,4H2,(H,6,7)/p+1/t2-/m1/s1 + MTCFGRXMJLQNBG-UWTATZPHSA-O + 106.10056 + 106.04987 + [NH3+][C@H](CO)C(O)=O + D-serinium + chebi_ontology + (1R)-1-carboxy-2-hydroxyethanaminium + D-serine cation + CHEBI:32841 + + D-serinium + + + + + + + + + + + + + + + + + + + + + An alpha-amino-acid anion that is the conjugate base of serine. + + -1 + C3H6NO3 + InChI=1S/C3H7NO3/c4-2(1-5)3(6)7/h2,5H,1,4H2,(H,6,7)/p-1 + MTCFGRXMJLQNBG-UHFFFAOYSA-M + 104.08468 + 104.03532 + NC(CO)C([O-])=O + Gmelin:324692 + serinate + chebi_ontology + 2-amino-3-hydroxypropanoate + serine anion + CHEBI:32845 + + serinate + + + + + + + + + + + + + + + + + + + + + An alpha-amino-acid cation that is the conjugate acid of serine. + + +1 + C3H8NO3 + InChI=1S/C3H7NO3/c4-2(1-5)3(6)7/h2,5H,1,4H2,(H,6,7)/p+1 + MTCFGRXMJLQNBG-UHFFFAOYSA-O + 106.10056 + 106.04987 + [NH3+]C(CO)C(O)=O + Gmelin:1925675 + serinium + chebi_ontology + 1-carboxy-2-hydroxyethanaminium + serine cation + CHEBI:32846 + + serinium + + + + + + + + + + + + + + + + + + + + + + + + + + + + The L-enantiomer of valinate. + + -1 + C5H10NO2 + InChI=1S/C5H11NO2/c1-3(2)4(6)5(7)8/h3-4H,6H2,1-2H3,(H,7,8)/p-1/t4-/m0/s1 + KZSNJWFQEVHDMF-BYPYZUCNSA-M + 116.13844 + 116.07170 + CC(C)[C@H](N)C([O-])=O + Beilstein:3933569 + Gmelin:325409 + L-valinate + chebi_ontology + (2S)-2-amino-3-methylbutanoate + L-valine anion + CHEBI:32851 + + L-valinate + + + + + + + + + + + + + + + + + + + + + + + + + + + The L-enantiomer of valinium. + + +1 + C5H12NO2 + InChI=1S/C5H11NO2/c1-3(2)4(6)5(7)8/h3-4H,6H2,1-2H3,(H,7,8)/p+1/t4-/m0/s1 + KZSNJWFQEVHDMF-BYPYZUCNSA-O + 118.15432 + 118.08626 + CC(C)[C@H]([NH3+])C(O)=O + L-valinium + chebi_ontology + (1S)-1-carboxy-2-methylpropan-1-aminium + L-valine cation + CHEBI:32852 + + L-valinium + + + + + + + + + + + + + + + + + + + + + + + + + + + The D-enantiomer of valinate. + + -1 + C5H10NO2 + InChI=1S/C5H11NO2/c1-3(2)4(6)5(7)8/h3-4H,6H2,1-2H3,(H,7,8)/p-1/t4-/m1/s1 + KZSNJWFQEVHDMF-SCSAIBSYSA-M + 116.13844 + 116.07170 + CC(C)[C@@H](N)C([O-])=O + Gmelin:325408 + D-valinate + chebi_ontology + (2R)-2-amino-3-methylbutanoate + D-valine anion + CHEBI:32855 + + D-valinate + + + + + + + + + + + + + + + + + + + + + + + + + + + The D-enantiomer of valinium. + + +1 + C5H12NO2 + InChI=1S/C5H11NO2/c1-3(2)4(6)5(7)8/h3-4H,6H2,1-2H3,(H,7,8)/p+1/t4-/m1/s1 + KZSNJWFQEVHDMF-SCSAIBSYSA-O + 118.15432 + 118.08626 + CC(C)[C@@H]([NH3+])C(O)=O + D-valinium + chebi_ontology + (1R)-1-carboxy-2-methylpropan-1-aminium + D-valine cation + CHEBI:32856 + + D-valinium + + + + + + + + + + + + + + + + + -1 + C5H10NO2 + InChI=1S/C5H11NO2/c1-3(2)4(6)5(7)8/h3-4H,6H2,1-2H3,(H,7,8)/p-1 + KZSNJWFQEVHDMF-UHFFFAOYSA-M + 116.13844 + 116.07170 + CC(C)C(N)C([O-])=O + Gmelin:49876 + valinate + chebi_ontology + 2-amino-3-methylbutanoate + val(-) + valine anion + CHEBI:32859 + + valinate + + + + + + + + + + + + + + + + +1 + C5H12NO2 + InChI=1S/C5H11NO2/c1-3(2)4(6)5(7)8/h3-4H,6H2,1-2H3,(H,7,8)/p+1 + KZSNJWFQEVHDMF-UHFFFAOYSA-O + 118.15432 + 118.08626 + CC(C)C([NH3+])C(O)=O + Gmelin:1651060 + valinium + chebi_ontology + 1-carboxy-2-methylpropan-1-aminium + H2val(+) + valine cation + CHEBI:32860 + + valinium + + + + + + + + + + A compound formally derived from ammonia by replacing three hydrogen atoms by hydrocarbyl groups. + + + 0 + NR3 + 14.00670 + 14.00307 + [*]N([*])[*] + CHEBI:26879 + CHEBI:9458 + KEGG COMPOUND:C02196 + KEGG:C02196 + Tertiary amine + tertiary amines + chebi_ontology + NR3 + R3N + [*]N([*])[*] + tertiaeres Amin + CHEBI:32876 + + tertiary amine + + + + + + + + + + A compound formally derived from ammonia by replacing one hydrogen atom by a hydrocarbyl group. + + 0 + H2NR + 16.02260 + 16.01872 + N[*] + CHEBI:26263 + CHEBI:26265 + CHEBI:8407 + CHEBI:8409 + KEGG:C00375 + KEGG:C00893 + KEGG:C02580 + Primary amine + primary amines + chebi_ontology + Primary monoamine + R-NH2 + RCH2NH2 + primaeres Amin + CHEBI:32877 + + primary amine + + + + + + + + + + + + + + + + + 0 + C3H8 + InChI=1S/C3H8/c1-3-2/h3H2,1-2H3 + ATUOYWHBWRKTHZ-UHFFFAOYSA-N + 44.09562 + 44.06260 + CCC + Beilstein:1730718 + CAS:74-98-6 + Gmelin:25044 + propane + chebi_ontology + CH3-CH2-CH3 + E944 + Propan + CHEBI:32879 + + propane + + + + + + + + + 2286 + A pyridinium ion that has formula C21H38N. + + + +1 + C21H38N + InChI=1S/C21H38N/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-16-19-22-20-17-15-18-21-22/h15,17-18,20-21H,2-14,16,19H2,1H3/q+1 + NEUSVAOJNUQRTM-UHFFFAOYSA-N + 304.53316 + 304.29988 + CCCCCCCCCCCCCCCC[n+]1ccccc1 + Beilstein:1431415 + CAS:7773-52-6 + ChemIDplus:1431415 + ChemIDplus:7773-52-6 + Drug_Central:3083 + Gmelin:342398 + 1-hexadecylpyridinium + chebi_ontology + C21H38N + CCCCCCCCCCCCCCCC[n+]1ccccc1 + InChI=1S/C21H38N/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-16-19-22-20-17-15-18-21-22/h15,17-18,20-21H,2-14,16,19H2,1H3/q+1 + InChIKey=NEUSVAOJNUQRTM-UHFFFAOYSA-N + N-hexadecylpyridinium + CHEBI:32914 + + Cetylpyridinium + cetylpyridinium + + + + + + + + + + + + + + + + + + + + + + + + + + + + A pyridinium salt that has N-hexadecylpyridinium as the cation and chloride as the anion. It has antiseptic properties and is used in solutions or lozenges for the treatment of minor infections of the mouth and throat. + + 0 + C21H38ClN + InChI=1S/C21H38N.ClH/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-16-19-22-20-17-15-18-21-22;/h15,17-18,20-21H,2-14,16,19H2,1H3;1H/q+1;/p-1 + YMKDRGPMQRFJGP-UHFFFAOYSA-M + 339.98600 + 339.26928 + [Cl-].CCCCCCCCCCCCCCCC[n+]1ccccc1 + Beilstein:3578606 + CAS:123-03-5 + Gmelin:33016 + Wikipedia:Cetylpyridinium_Chloride + 1-hexadecylpyridinium chloride + chebi_ontology + 1-cetylpyridinium chloride + 1-palmitylpyridinium chloride + N-cetylpyridinium chloride + N-hexadecylpyridinium chloride + cetylpyridinii chloridum + cetylpyridinium chloride + cetylpyridinium chloride anhydrous + chlorure de cetylpyridinium + cloruro de cetilpiridinio + hexadecylpyridinium chloride + CHEBI:32915 + + cetylpyridinium chloride + + + + + + + + + A compound formally derived from ammonia by replacing one, two or three hydrogen atoms by hydrocarbyl groups. + + + CHEBI:13814 + CHEBI:22474 + CHEBI:2641 + KEGG COMPOUND:C00706 + KEGG:C00706 + Amine + amines + chebi_ontology + Amin + Substituted amine + an amine + CHEBI:32952 + + amine + + + + + + + + + + + + + + + Any cyclic ether in which the oxygen atom forms part of a 3-membered ring. + + 0 + C2OR4 + 40.02080 + 39.99491 + [*]C1([*])OC1([*])[*] + CHEBI:13828 + CHEBI:23930 + CHEBI:4812 + KEGG:C00722 + PMID:10891060 + Wikipedia:Epoxide + Epoxide + epoxides + chebi_ontology + Alkene oxide + Olefin oxide + an epoxide + epoxides + CHEBI:32955 + + epoxide + + + + + + + + + An amide is a derivative of an oxoacid RkE(=O)l(OH)m (l =/= 0) in which an acidic hydroxy group has been replaced by an amino or substituted amino group. + + + CHEBI:22473 + CHEBI:2633 + KEGG COMPOUND:C00241 + KEGG:C00241 + Amide + amides + chebi_ontology + CHEBI:32988 + + amide + + + + + + + + + Intended use of the molecular entity or part thereof by humans. + + chebi_ontology + CHEBI:33232 + + application + + + + + + + + + A particle not known to have substructure. + + elementary particle + chebi_ontology + elementary particles + CHEBI:33233 + + fundamental particle + + + + + + + + + A monoatomic entity is a molecular entity consisting of a single atom. + + chebi_ontology + atomic entity + monoatomic entities + CHEBI:33238 + + monoatomic entity + + + + + + + + + + + + + + + + chebi_ontology + oxoacid derivatives + CHEBI:33241 + + oxoacid derivative + + + + + + + + + + + chebi_ontology + inorganic hydrides + CHEBI:33242 + + inorganic hydride + + + + + + + + + + An organic fundamental parent is a structure used as a basis for substitutive names in organic nomenclature, containing, in addition to one or more hydrogen atoms, a single atom of an element, a number of atoms (alike or different) linked together to form an unbranched chain, a monocyclic or polycyclic ring system, or a ring assembly or ring/chain system. + + chebi_ontology + organic fundamental parents + organic parent hydrides + CHEBI:33245 + + organic fundamental parent + + + + + + + + + Any substituent group which does not contain carbon. + + chebi_ontology + inorganic groups + CHEBI:33246 + + inorganic group + + + + + + + + + + + + + + + + Any substituent group or skeleton containing carbon. + + + chebi_ontology + organic groups + CHEBI:33247 + + organic group + + + + + + + + + + + + + + + A univalent group formed by removing a hydrogen atom from a hydrocarbon. + + hydrocarbyl group + hydrocarbyl groups + chebi_ontology + groupe hydrocarbyle + grupo hidrocarbilo + grupos hidrocarbilo + CHEBI:33248 + + hydrocarbyl group + + + + + + + + + Any organic substituent group, regardless of functional type, having one free valence at a carbon atom. + + organyl group + organyl groups + chebi_ontology + groupe organyle + grupo organilo + grupos organilo + CHEBI:33249 + + organyl group + + + + + + + + + + + + + + + + + + + + + A chemical entity constituting the smallest component of an element having the chemical properties of the element. + + CHEBI:22671 + CHEBI:23907 + atom + chebi_ontology + atome + atomo + atoms + atomus + element + elements + CHEBI:33250 + + atom + + + + + + + + + + + + + + + A nucleus is the positively charged central portion of an atom, excluding the orbital electrons. + + nucleus + chebi_ontology + Atomkern + Kern + noyau + noyau atomique + nuclei + nucleo + nucleo atomico + nucleus atomi + CHEBI:33252 + + atomic nucleus + + + + + + + + + + Heavy nuclear particle: proton or neutron. + + nucleon + chebi_ontology + Nukleon + Nukleonen + nucleons + CHEBI:33253 + + nucleon + + + + + + + + + A derivative of an oxoacid RkE(=O)l(OH)m (l =/= 0) in which an acidic hydroxy group has been replaced by an amino or substituted amino group. + + + primary amide + primary amides + chebi_ontology + CHEBI:33256 + + primary amide + + + + + + + + + A derivative of two oxoacids RkE(=O)l(OH)m (l =/= 0) in which two acyl groups are attached to the amino or substituted amino group. + + secondary amide + secondary amides + chebi_ontology + CHEBI:33257 + + secondary amide + + + + + + + + + A molecular entity all atoms of which have the same atomic number. + + chebi_ontology + homoatomic entity + homoatomic molecular entities + homoatomic molecular entity + CHEBI:33259 + + elemental molecular entity + + + + + + + + + + An organosulfur compound is a compound containing at least one carbon-sulfur bond. + + + CHEBI:23010 + CHEBI:25714 + Wikipedia:Organosulfur_compounds + organosulfur compound + chebi_ontology + organosulfur compounds + CHEBI:33261 + + organosulfur compound + + + + + + + + + + 0 + N2 + 28.013 + 28.00615 + chebi_ontology + CHEBI:33266 + + diatomic nitrogen + + + + + + + + + + + chebi_ontology + CHEBI:33267 + + elemental nitrogen + + + + + + + + + + An anion consisting of more than one atom. + + chebi_ontology + polyatomic anions + CHEBI:33273 + + polyatomic anion + + + + + + + + + + chebi_ontology + chemical messenger + CHEBI:33280 + + molecular messenger + + + + + + + + + A substance that kills or slows the growth of microorganisms, including bacteria, viruses, fungi and protozoans. + + CHEBI:22582 + PMID:12964249 + PMID:22117953 + PMID:22439833 + PMID:22849268 + PMID:22849276 + PMID:22958833 + chebi_ontology + Antibiotika + Antibiotikum + antibiotic + antibiotics + antibiotique + antimicrobial + antimicrobial agents + antimicrobials + microbicide + microbicides + CHEBI:33281 + + antimicrobial agent + + + + + + + + + A substance (or active part thereof) that kills or slows the growth of bacteria. + + chebi_ontology + antibacterial agents + antibacterials + bactericide + bactericides + CHEBI:33282 + + antibacterial agent + + + + + + + + + A nutrient is a food component that an organism uses to survive and grow. + + chebi_ontology + nutrients + CHEBI:33284 + + nutrient + + + + + + + + + A heteroorganic entity is an organic molecular entity in which carbon atoms or organic groups are bonded directly to one or more heteroatoms. + + + chebi_ontology + heteroorganic entities + organoelement compounds + CHEBI:33285 + + heteroorganic entity + + + + + + + + + An agrochemical is a substance that is used in agriculture or horticulture. + + Wikipedia:Agrochemical + chebi_ontology + agrichemical + agrichemicals + agricultural chemicals + agrochemicals + CHEBI:33286 + + agrochemical + + + + + + + + + A fertilizer is any substance that is added to soil or water to assist the growth of plants. + + chebi_ontology + fertiliser + fertilizers + CHEBI:33287 + + fertilizer + + + + + + + + + An energy-rich substance that can be transformed with release of usable energy. + + chebi_ontology + CHEBI:33292 + + fuel + + + + + + + + + A substance administered to aid diagnosis of a disease. + + chebi_ontology + diagnostic aid + CHEBI:33295 + + diagnostic agent + + + + + + + + + Any p-block element atom that is in group 15 of the periodic table: nitrogen, phosphorus, arsenic, antimony and bismuth. + + pnictogens + chebi_ontology + group 15 elements + group V elements + nitrogenoideos + nitrogenoides + pnictogene + pnictogenes + CHEBI:33300 + + pnictogen + + + + + + + + + + + + + + + A p-block molecular entity containing any pnictogen. + + + pnictogen molecular entity + chebi_ontology + pnictogen molecular entities + CHEBI:33302 + + pnictogen molecular entity + + + + + + + + + Any p-block element belonging to the group 16 family of the periodic table. + + PMID:17084588 + chalcogen + chalcogens + chebi_ontology + Chalkogen + Chalkogene + anfigeno + anfigenos + calcogeno + calcogenos + chalcogene + chalcogenes + group 16 elements + group VI elements + CHEBI:33303 + + chalcogen + + + + + + + + + + + + + + + Any p-block molecular entity containing a chalcogen. + + + chalcogen molecular entity + chebi_ontology + chalcogen compounds + chalcogen molecular entities + CHEBI:33304 + + chalcogen molecular entity + + + + + + + + + + group 14 elements + chebi_ontology + carbon group element + carbon group elements + carbonoides + cristallogene + cristallogenes + group IV elements + CHEBI:33306 + + carbon group element atom + + + + + + + + + + An ester of a carboxylic acid, R(1)C(=O)OR(2), where R(1) = H or organyl and R(2) = organyl. + An ester of a carboxylic acid. + + + 0 + CO2R2 + 44.010 + 43.98983 + [*]C(=O)O[*] + CHEBI:13204 + CHEBI:23028 + CHEBI:3408 + KEGG COMPOUND:C02391 + KEGG:C02391 + Wikipedia:Ester + Carboxylic ester + carboxylic ester + carboxylic esters + chebi_ontology + CO2R2 + a carboxylic ester + carboxylic acid esters + CHEBI:33308 + + carboxylic ester + + + + + + + + + An atom belonging to one of the main groups (found in the s- and p- blocks) of the periodic table. + + main group elements + chebi_ontology + Hauptgruppenelement + Hauptgruppenelemente + main group element + CHEBI:33318 + + main group element atom + + + + + + + + + + + + + + + + + + + + + A serine zwitterion obtained by transfer of a proton from the carboxy to the amino group of L-serine. + + 0 + C3H7NO3 + InChI=1S/C3H7NO3/c4-2(1-5)3(6)7/h2,5H,1,4H2,(H,6,7)/t2-/m0/s1 + MTCFGRXMJLQNBG-REOHCLBHSA-N + 105.09262 + 105.04259 + [NH3+][C@@H](CO)C([O-])=O + MetaCyc:SER + (2S)-2-ammonio-3-hydroxypropanoate + L-serine zwitterion + chebi_ontology + L-serine + CHEBI:33384 + + L-serine zwitterion + + + + + + + + + + + chebi_ontology + oxoacids of sulfur + sulfur oxoacids + CHEBI:33402 + + sulfur oxoacid + + + + + + + + + + + + + + + A hydracid is a compound which contains hydrogen that is not bound to oxygen, and which produces a conjugate base by loss of positive hydrogen ion(s) (hydrons). + + hydracid + chebi_ontology + hydracids + CHEBI:33405 + + hydracid + + + + + + + + + + + + + + + + + chebi_ontology + pnictogen oxoacids + CHEBI:33408 + + pnictogen oxoacid + + + + + + + + + + + sulfur oxoacid derivative + chebi_ontology + sulfur oxoacid derivatives + CHEBI:33424 + + sulfur oxoacid derivative + + + + + + + + + + + -1 + 0.00000 + [*-] + chebi_ontology + monoatomic monoanions + CHEBI:33429 + + monoatomic monoanion + + + + + + + + + + + chebi_ontology + CHEBI:33431 + + elemental chlorine + + + + + + + + + + + 0 + Cl + 35.453 + 34.96885 + chebi_ontology + atomic chlorine + CHEBI:33432 + + monoatomic chlorine + + + + + + + + + + chebi_ontology + monoatomic halogens + CHEBI:33433 + + monoatomic halogen + + + + + + + + + + elemental halogen + chebi_ontology + elemental halogens + CHEBI:33434 + + elemental halogen + + + + + + + + + Arylmethyl groups and derivatives formed by substitution: ArCR2-. + + benzylic group + benzylic groups + chebi_ontology + benzylic groups + groupe benzylique + CHEBI:33452 + + benzylic group + + + + + + + + + + A pnictogen oxoacid which contains phosphorus and oxygen, at least one hydrogen atom bound to oxygen, and forms an ion by the loss of one or more protons. + + phosphorus oxoacid + chebi_ontology + Oxosaeure des Phosphors + oxoacids of phosphorus + phosphorus oxoacids + CHEBI:33457 + + phosphorus oxoacid + + + + + + + + + + + pnictogen oxoanion + chebi_ontology + pnictogen oxoanions + CHEBI:33459 + + pnictogen oxoanion + + + + + + + + + + + + phosphorus oxoanion + chebi_ontology + oxoanions of phosphorus + phosphorus oxoanions + CHEBI:33461 + + phosphorus oxoanion + + + + + + + + + + + + elemental pnictogen + chebi_ontology + elemental pnictogens + CHEBI:33465 + + elemental pnictogen + + + + + + + + + + + sulfur oxoanion + chebi_ontology + oxoanions of sulfur + sulfur oxoanions + CHEBI:33482 + + sulfur oxoanion + + + + + + + + + + + + + + + + + chalcogen oxoacid + chebi_ontology + chalcogen oxoacids + CHEBI:33484 + + chalcogen oxoacid + + + + + + + + + + + chalcogen oxoanion + chebi_ontology + chalcogen oxoanions + CHEBI:33485 + + chalcogen oxoanion + + + + + + + + + A molecular entity containing one or more atoms of a transition element. + + transition element molecular entities + transition metal molecular entity + CHEBI:33497 + transition element molecular entity + + + + + + + + + + + sulfur hydride + chebi_ontology + hydrides of sulfur + sulfur hydrides + sulphur hydrides + CHEBI:33535 + + sulfur hydride + + + + + + + + + + + + + + + The sulfur oxoanion formed by deprotonation of sulfonic acid. + + -1 + HO3S + InChI=1S/H2O3S/c1-4(2)3/h4H,(H,1,2,3)/p-1 + BDHFUVZGWQCTTF-UHFFFAOYSA-M + 81.07214 + 80.96519 + [H]S([O-])(=O)=O + Gmelin:971569 + hydridotrioxidosulfate(1-) + chebi_ontology + SHO3(-) + [SHO3](-) + sulfonates + CHEBI:33543 + + sulfonate + + + + + + + + + + + + + + + + + + + + + + + + + + + + + An organic derivative of sulfonic acid in which the sulfo group is linked directly to carbon. + + 0 + HO3SR + 81.07100 + 80.96464 + OS([*])(=O)=O + chebi_ontology + organosulfonic acids + sulfonic acids + CHEBI:33551 + + organosulfonic acid + + + + + + + + + + + + + + + + sulfonic acid derivative + chebi_ontology + derivatives of sulfonic acid + sulfonic acid derivatives + CHEBI:33552 + + sulfonic acid derivative + + + + + + + + + + + + + + + + + + + + + An organic anion obtained by deprotonation of the sufonate group(s) of any organosulfonic acid. + + -1 + O3SR + 80.064 + 79.95681 + *S([O-])(=O)=O + chebi_ontology + organosulfonate + organosulfonate oxoanions + organosulfonates + CHEBI:33554 + + organosulfonate oxoanion + + + + + + + + + + + + + + + An amino-acid anion obtained by deprotonation of any alpha-amino acid. + + alpha-amino-acid anion + chebi_ontology + alpha-amino acid anions + alpha-amino-acid anions + CHEBI:33558 + + alpha-amino-acid anion + + + + + + + + + + chebi_ontology + s-block element + s-block elements + CHEBI:33559 + + s-block element atom + + + + + + + + + Any main group element atom belonging to the p-block of the periodic table. + + chebi_ontology + p-block element + p-block elements + CHEBI:33560 + + p-block element atom + + + + + + + + + + + + + + + + + + + + + + + + + A carbon oxoacid acid carrying at least one -C(=O)OH group and having the structure RC(=O)OH, where R is any any monovalent functional group. Carboxylic acids are the most common type of organic acid. + An oxoacid acid carrying at least one -C(=O)OH group and having the structure RC(=O)OH, where R is any any monovalent functional group. Carboxylic acids are the most common type of organic acid. + + + 0 + CHO2R + 45.01740 + 44.99765 + OC([*])=O + CHEBI:13428 + CHEBI:13627 + CHEBI:23027 + CiteXplore:17147560 + CiteXplore:18433345 + PMID:17147560 + PMID:18433345 + Wikipedia:Carboxylic_acid + carboxylic acid + carboxylic acids + chebi_ontology + CHO2R + Carbonsaeure + Carbonsaeuren + Karbonsaeure + OC([*])=O + RC(=O)OH + acide carboxylique + acides carboxyliques + acido carboxilico + acidos carboxilicos + CHEBI:33575 + + carboxylic acid + + + + + + + + + + + + + + + A molecular entity containing one or more atoms from any of groups 1, 2, 13, 14, 15, 16, 17, and 18 of the periodic table. + + + chebi_ontology + main group compounds + main group molecular entities + CHEBI:33579 + + main group molecular entity + + + + + + + + + + + + + + + + + carbon group molecular entity + chebi_ontology + carbon group molecular entities + CHEBI:33582 + + carbon group molecular entity + + + + + + + + + + Any molecule that consists of a series of atoms joined together to form a ring. + + + Wikipedia:Cyclic_compound + chebi_ontology + cyclic compounds + CHEBI:33595 + + cyclic compound + + + + + + + + + A cyclic compound having as ring members atoms of the same element only. + + homocyclic compound + homocyclic compounds + chebi_ontology + isocyclic compounds + CHEBI:33597 + + homocyclic compound + + + + + + + + + + A homocyclic compound in which all of the ring members are carbon atoms. + + carbocyclic compound + carbocyclic compounds + chebi_ontology + carbocycle + CHEBI:33598 + + carbocyclic compound + + + + + + + + + A compound having one atom as the only common member of two rings. + + spiro compound + spiro compounds + chebi_ontology + spiro-fused compounds + spirocycle + spirocycles + spirocyclic compound + spirocyclic compounds + spirofused compounds + CHEBI:33599 + + spiro compound + + + + + + + + + + + + + + + + + chebi_ontology + hydrogen compounds + hydrogen molecular entities + CHEBI:33608 + + hydrogen molecular entity + + + + + + + + + + + chebi_ontology + polycyclic compounds + CHEBI:33635 + + polycyclic compound + + + + + + + + + A molecule that features two fused rings. + + + chebi_ontology + bicyclic compounds + CHEBI:33636 + + bicyclic compound + + + + + + + + + + Acyclic and cyclic hydrocarbons having one or more carbon-carbon double bonds, apart from the formal ones in aromatic compounds. The class olefins subsumes alkenes and cycloalkenes and the corresponding polyenes. + + olefin + olefins + chebi_ontology + olefins + CHEBI:33641 + + olefin + + + + + + + + + Acyclic branched or unbranched hydrocarbons having one or more carbon-carbon double bond. + + chebi_ontology + acyclic olefins + CHEBI:33645 + + acyclic olefin + + + + + + + + + Any acyclic or cyclic, saturated or unsaturated carbon compound, excluding aromatic compounds. + + aliphatic compounds + chebi_ontology + CHEBI:33653 + + aliphatic compound + + + + + + + + + A cyclically conjugated molecular entity with a stability (due to delocalization) significantly greater than that of a hypothetical localized structure (e.g. Kekule structure) is said to possess aromatic character. + + + aromatic compounds + aromatic molecular entity + chebi_ontology + aromatics + aromatische Verbindungen + CHEBI:33655 + + aromatic compound + + + + + + + + + + Any monocyclic or polycyclic aromatic hydrocarbon. + + arene + arenes + chebi_ontology + aromatic hydrocarbons + CHEBI:33658 + + arene + + + + + + + + + + + + chebi_ontology + organic aromatic compounds + CHEBI:33659 + + organic aromatic compound + + + + + + + + + + + chebi_ontology + monocyclic compounds + CHEBI:33661 + + monocyclic compound + + + + + + + + + A mancude monocyclic hydrocarbon without side chains of the general formula CnHn (n is an even number) or CnHn+1 (n is an odd number). In systematic nomenclature an annulene with seven or more carbon atoms may be named [n]annulene, where n is the number of carbon atoms. + + annulene + annulenes + chebi_ontology + CHEBI:33662 + + annulene + + + + + + + + + + + cyclic hydrocarbon + chebi_ontology + cyclic hydrocarbons + CHEBI:33663 + + cyclic hydrocarbon + + + + + + + + + + monocyclic hydrocarbon + monocyclic hydrocarbons + chebi_ontology + monocyclic hydrocarbons + CHEBI:33664 + + monocyclic hydrocarbon + + + + + + + + + + + + heteromonocyclic compound + heteromonocyclic compounds + chebi_ontology + CHEBI:33670 + + heteromonocyclic compound + + + + + + + + + + A polycyclic compound in which at least one of the rings contains at least one non-carbon atom. + + + heteropolycyclic compounds + chebi_ontology + polyheterocyclic compounds + CHEBI:33671 + + heteropolycyclic compound + + + + + + + + + + A bicyclic compound in which at least one of the rings contains at least one skeletal heteroatom. + + + heterobicyclic compounds + chebi_ontology + CHEBI:33672 + + heterobicyclic compound + + + + + + + + + + zinc group molecular entities + CHEBI:33673 + zinc group molecular entity + + + + + + + + + + + + + + + An s-block molecular entity is a molecular entity containing one or more atoms of an s-block element. + + + s-block molecular entity + chebi_ontology + s-block compounds + s-block molecular entities + CHEBI:33674 + + s-block molecular entity + + + + + + + + + + + + + + + A main group molecular entity that contains one or more atoms of a p-block element. + A p-block molecular entity is a molecular entity containing one or more atoms of a p-block element. + + + chebi_ontology + p-block compounds + p-block molecular entities + p-block molecular entitiy + CHEBI:33675 + + p-block molecular entity + + + + + + + + + A d-block molecular entity is a molecular entity containing one or more atoms of a d-block element. + + d-block molecular entity + d-block compounds + d-block molecular entities + CHEBI:33676 + d-block molecular entity + + + + + + + + + + Hydrides are chemical compounds of hydrogen with other chemical elements. + + chebi_ontology + CHEBI:33692 + + hydrides + + + + + + + + + + oxygen hydride + chebi_ontology + hydrides of oxygen + oxygen hydrides + CHEBI:33693 + + oxygen hydride + + + + + + + + + nucleic acid + A macromolecule made up of nucleotide units and hydrolysable into certain pyrimidine or purine bases (usually adenine, cytosine, guanine, thymine, uracil), D-ribose or 2-deoxy-D-ribose and phosphoric acid. + + + nucleic acid + + + + + + + + + ribonucleic acid + High molecular weight, linear polymers, composed of nucleotides containing ribose and linked by phosphodiester bonds; RNA is central to the synthesis of proteins. + + + ribonucleic acid + + + + + + + + + + A cation consisting of more than one atom. + + chebi_ontology + polyatomic cations + CHEBI:33702 + + polyatomic cation + + + + + + + + + + amino-acid cation + chebi_ontology + amino acid cation + amino-acid cations + CHEBI:33703 + + amino-acid cation + + + + + + + + + + + + + + + + + + + + + An amino acid in which the amino group is located on the carbon atom at the position alpha to the carboxy group. + + 0 + C2H4NO2R + 74.05870 + 74.02420 + NC([*])C(O)=O + CHEBI:10208 + CHEBI:13779 + CHEBI:22442 + CHEBI:2642 + KEGG:C00045 + KEGG:C05167 + alpha-amino acid + chebi_ontology + Amino acid + Amino acids + alpha-amino acids + alpha-amino carboxylic acids + CHEBI:33704 + + alpha-amino acid + + + + + + + + + + + + + + + When two or more amino acids combine to form a peptide, the elements of water are removed, and what remains of each amino acid is called an amino-acid residue. + + + amino acid residue + amino-acid residue + protein residue + chebi_ontology + amino acid residue + amino-acid residues + CHEBI:33708 + + amino-acid residue + + + + + + + + + + + + + + + + A carboxylic acid containing one or more amino groups. + + + CHEBI:13815 + CHEBI:22477 + Wikipedia:Amino_acid + chebi_ontology + Aminocarbonsaeure + Aminokarbonsaeure + Aminosaeure + amino acids + CHEBI:33709 + + amino acid + + + + + + + + + + alpha-amino-acid cation + chebi_ontology + alpha-amino acid cations + alpha-amino-acid cations + CHEBI:33719 + + alpha-amino-acid cation + + + + + + + + + + + + + + + + + carbohydrate acid + chebi_ontology + carbohydrate acids + CHEBI:33720 + + carbohydrate acid + + + + + + + + + + + + + + + + carbohydrate acid anion + chebi_ontology + carbohydrate acid anions + CHEBI:33721 + + carbohydrate acid anion + + + + + + + + + + An organic compound having at least one hydroxy group attached to a carbon atom. + + CHEBI:64710 + hydroxy compounds + chebi_ontology + organic alcohol + organic hydroxy compounds + CHEBI:33822 + + organic hydroxy compound + + + + + + + + + + + Any organic molecule that consists of atoms connected in the form of a ring. + + + chebi_ontology + organic cyclic compounds + CHEBI:33832 + + organic cyclic compound + + + + + + + + + + A heterocyclic compound formally derived from an arene by replacement of one or more methine (-C=) and/or vinylene (-CH=CH-) groups by trivalent or divalent heteroatoms, respectively, in such a way as to maintain the continuous pi-electron system characteristic of aromatic systems and a number of out-of-plane pi-electrons corresponding to the Hueckel rule (4n+2). + + + heteroarenes + chebi_ontology + hetarenes + CHEBI:33833 + + heteroarene + + + + + + + + + + + chebi_ontology + benzenoid aromatic compounds + benzenoid compound + CHEBI:33836 + + benzenoid aromatic compound + + + + + + + + + + + + + + + + + An N-glycosyl compound that has both a nucleobase, normally adenine, guanine, xanthine, thymine, cytosine or uracil, and either a ribose or deoxyribose as functional parents. + + 0 + C5H8O3R2 + 116.115 + 116.04734 + [C@H]1([C@H]([C@@H](*)[C@@H](O1)*)O)CO + CHEBI:13661 + CHEBI:25611 + CHEBI:7647 + KEGG:C00801 + Nucleoside + nucleosides + chebi_ontology + a nucleoside + nucleosides + CHEBI:33838 + + nucleoside + + + + + + + + + + macromolecule + A macromolecule is a molecule of high relative molecular mass, the structure of which essentially comprises the multiple repetition of units derived, actually or conceptually, from molecules of low relative molecular mass. + polymer + + + + macromolecule + macromolecules + polymer + polymer molecule + polymers + CHEBI:33839 + macromolecule + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + An antibiotic isolated from various Streptomyces species. It interferes with protein and DNA synthesis by inhibiting peptidyl transferase or the 80S ribosome system. + + 0 + C14H19NO4 + InChI=1S/C14H19NO4/c1-9(16)19-14-12(15-8-13(14)17)7-10-3-5-11(18-2)6-4-10/h3-6,12-15,17H,7-8H2,1-2H3/t12-,13+,14+/m1/s1 + YKJYKKNCCRKFSL-RDBSUJKOSA-N + 265.30500 + 265.13141 + COc1ccc(C[C@H]2NC[C@H](O)[C@H]2OC(C)=O)cc1 + CHEBI:2737 + CHEBI:40748 + Beilstein:20705 + CAS:22862-76-6 + DrugBank:DB07374 + KEGG:C11281 + LINCS:LSM-4047 + PDBeChem:ANM + PMID:16005213 + PMID:22004851 + PMID:23192275 + PMID:23525555 + PMID:23582782 + PMID:24333448 + PMID:6834379 + Reaxys:20705 + Wikipedia:Anisomycin + (2R,3S,4S)-4-hydroxy-2-(4-methoxybenzyl)pyrrolidin-3-yl acetate + chebi_ontology + 1,4,5-Trideoxy-1,4-imino-5-(p-methoxyphenyl)-D-xylo-pentitol 3-acetate + 2-(p-Methoxybenzyl)-3,4-pyrrolidinediol 3-acetate + 2-p-Methoxyphenylmethyl-3-acetoxy-4-hydroxypyrrolidine + Anisomycin + CHEBI:338412 + + (-)-anisomycin + + + + + + + + + + + chebi_ontology + aromatic annulenes + CHEBI:33842 + + aromatic annulene + + + + + + + + + A monocyclic aromatic hydrocarbon. + + chebi_ontology + monocyclic arenes + CHEBI:33847 + + monocyclic arene + + + + + + + + + + Organic aromatic compounds having one or more hydroxy groups attached to a benzene or other arene ring. + + 0 + C6HOR5 + 89.072 + 89.00274 + C1(=C(C(=C(C(=C1*)*)*)*)*)O + CHEBI:13664 + CHEBI:13825 + CHEBI:25969 + CHEBI:2857 + KEGG:C15584 + MetaCyc:Phenols + Wikipedia:Phenols + phenols + chebi_ontology + Aryl alcohol + a phenol + arenols + CHEBI:33853 + + phenols + + + + + + + + + + Any alcohol in which the alcoholic hydroxy group is attached to a carbon which is itself bonded to an aromatic ring. + + 0 + HOR + 17.007 + 17.00274 + *O + CHEBI:13818 + CHEBI:22620 + CHEBI:22640 + CHEBI:2831 + chebi_ontology + an aromatic alcohol + aromatic alcohols + aryl alcohol + aryl alcohols + CHEBI:33854 + + aromatic alcohol + + + + + + + + + + + + + + + + + + + + + + An amino acid whose structure includes an aromatic ring. + + 0 + C2H4NO2R + 88.085 + 74.02420 + CHEBI:13820 + CHEBI:22623 + CHEBI:2835 + KEGG:C01021 + Wikipedia:Aromatic_amino_acid + Aromatic amino acid + chebi_ontology + aromatic amino acids + CHEBI:33856 + + aromatic amino acid + + + + + + + + + + + + + + + + Any carboxylic acid in which the carboxy group is directly bonded to an aromatic ring. + + CHEBI:13817 + CHEBI:13821 + CHEBI:2830 + chebi_ontology + aromatic carboxylic acids + CHEBI:33859 + + aromatic carboxylic acid + + + + + + + + + + An amino compound in which the amino group is linked directly to an aromatic system. + + CHEBI:13827 + CHEBI:22622 + CHEBI:22646 + CHEBI:2834 + CHEBI:2863 + chebi_ontology + aromatic amines + aryl amine + aryl amines + arylamine + arylamines + CHEBI:33860 + + aromatic amine + + + + + + + + + A substance used in a chemical reaction to detect, measure, examine, or produce other substances. + + reagent + chebi_ontology + reactif + reactivo + reagents + CHEBI:33893 + + reagent + + + + + + + + + + chebi_ontology + CHEBI:33937 + + macronutrient + + + + + + + + + + + + + + + + + + chebi_ontology + halide salts + halides + CHEBI:33958 + + halide salt + + + + + + + + + + + + + + + + + + + + + + A 3-oxo Delta(4)-steroid that is progesterone which has been oxidised to introduce a double bond between positions 1 and 2. + + 0 + C21H28O2 + InChI=1S/C21H28O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h8,10,12,16-19H,4-7,9,11H2,1-3H3/t16-,17+,18-,19-,20-,21+/m0/s1 + QIEPWCSVQYUPIY-LEKSSAKUSA-N + 312.44582 + 312.20893 + [H][C@@]12CCC3=CC(=O)C=C[C@]3(C)[C@@]1([H])CC[C@]1(C)[C@H](CC[C@@]21[H])C(C)=O + Beilstein:1999508 + CAS:1162-54-5 + KEGG:C14677 + Reaxys:1999508 + pregna-1,4-diene-3,20-dione + chebi_ontology + 1,2-dehydroprogesterone + 1,2-didehydroprogesterone + 1-Dehydroprogesterone + 3,20-dioxo-1,4-pregnadiene + 3,20-dioxo-pregna-1,4-diene + Pregna-1,4-diene-3,20-dione + delta1-Progesterone + CHEBI:34073 + + Delta(1)-progesterone + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A member of the class of benzimidazoles that is benzimidalole which is substituted at position 2 by a (methoxycarbonyl)amino group and at position 5 by a 2-thienoyl group. It is an antineoplastic agent that exerts its effect by depolymerising microtubules. + + 0 + C14H11N3O3S + InChI=1S/C14H11N3O3S/c1-20-14(19)17-13-15-9-5-4-8(7-10(9)16-13)12(18)11-3-2-6-21-11/h2-7H,1H3,(H2,15,16,17,19) + KYRVNWMVYQXFEU-UHFFFAOYSA-N + 301.32000 + 301.05211 + COC(=O)Nc1nc2cc(ccc2[nH]1)C(=O)c1cccs1 + Beilstein:1085978 + CAS:31430-18-9 + DrugBank:DB08313 + KEGG:C13719 + KEGG:D05197 + LINCS:LSM-2260 + PDBeChem:NZO + PMID:11679255 + PMID:20399776 + PMID:22002881 + PMID:23869451 + PMID:518692 + PMID:6384770 + PMID:7199049 + PMID:7284368 + PMID:7344613 + Reaxys:1085978 + Wikipedia:Nocodazole + methyl [5-(2-thienylcarbonyl)-1H-benzimidazol-2-yl]carbamate + chebi_ontology + (5-(2-thienylcarbonyl)-1H-benzimidazol-2-yl)-carbamic acid methyl ester + N-(5-(2-thenoyl)-2-benzimidazolyl)carbamic acid methyl ester + N-(5-(2-thienoyl)-2-benzimidazolyl)carbamic acid methyl ester + R 17934 + R-17934 + R17,934 + methyl (5-(2-thienylcarbonyl))-1H-benzimidazole-2-ylcarbamate + methyl N-(5-thenoyl-2-benzimidazolyl)carbamate + nocodazol + nocodazole + nocodazolum + oncodazole + CHEBI:34892 + + nocodazole + + + + + + + + + + + chebi_ontology + nitrogen hydrides + CHEBI:35106 + + nitrogen hydride + + + + + + + + + Saturated acyclic nitrogen hydrides having the general formula NnHn+2. + + chebi_ontology + azanes + CHEBI:35107 + + azane + + + + + + + + + + A hydrocarbon of biological origin having carbon skeleton formally derived from isoprene [CH2=C(CH3)CH=CH2]. + + terpene + terpenes + chebi_ontology + Terpen + terpenes + terpeno + terpenos + CHEBI:35186 + + terpene + + + + + + + + + A C30 terpene. + + triterpenes + chebi_ontology + Triterpen + triterpenes + triterpeno + triterpenos + CHEBI:35191 + + triterpene + + + + + + + + + A substance which lowers the surface tension of the medium in which it is dissolved, and/or the interfacial tension with other phases, and, accordingly, is positively adsorbed at the liquid/vapour and/or at other interfaces. + + surfactant + chebi_ontology + surface active agent + surfactants + CHEBI:35195 + + surfactant + + + + + + + + + + A depsipeptide in which the amino and hydroxy carboxylic acid residues are connected in a ring. + + cyclodepsipeptides + chebi_ontology + Cyclodepsipeptid + Zyklodepsipeptid + CHEBI:35213 + + cyclodepsipeptide + + + + + + + + + A substance which is structurally similar to a metabolite but which competes with it or replaces it, and so prevents or reduces its normal utilization. + + Wikipedia:Antimetabolite + antimetabolite + chebi_ontology + antimetabolites + CHEBI:35221 + + antimetabolite + + + + + + + + + A substance that diminishes the rate of a chemical reaction. + + inhibitor + chebi_ontology + inhibidor + inhibiteur + inhibitors + CHEBI:35222 + + inhibitor + + + + + + + + + A small molecule which increases (activator) or decreases (inhibitor) the activity of an (allosteric) enzyme by binding to the enzyme at the regulatory site (which is different from the substrate-binding catalytic site). + + Wikipedia:Effector_(biology) + effector + chebi_ontology + enzyme modulator + CHEBI:35224 + + effector + + + + + + + + + A fuel such as coal, oil and natural gas which has formed over many years through the decomposition of deposited vegetation which was under extreme pressure of an overburden of earth. + + fossil fuel + chebi_ontology + CHEBI:35230 + + fossil fuel + + + + + + + + + The zwitterionic form of an amino acid having a negatively charged carboxyl group and a positively charged amino group. + + amino acid zwitterion + chebi_ontology + CHEBI:35238 + + amino acid zwitterion + + + + + + + + + + + + + + + An amino acid zwitterion obtained by transfer of a proton from the carboxy to the amnio group of serine. + + 0 + C3H7NO3 + InChI=1S/C3H7NO3/c4-2(1-5)3(6)7/h2,5H,1,4H2,(H,6,7) + MTCFGRXMJLQNBG-UHFFFAOYSA-N + 105.09262 + 105.04259 + [NH3+]C(CO)C([O-])=O + Beilstein:3935647 + Gmelin:2060272 + 2-ammonio-3-hydroxypropanoate + serine zwitterion + chebi_ontology + CHEBI:35243 + + serine zwitterion + + + + + + + + + + + + + + + + + + + + + A serine zwitterion obtained by transfer of a proton from the carboxy to the amino group of D-serine. + + 0 + C3H7NO3 + InChI=1S/C3H7NO3/c4-2(1-5)3(6)7/h2,5H,1,4H2,(H,6,7)/t2-/m1/s1 + MTCFGRXMJLQNBG-UWTATZPHSA-N + 105.09262 + 105.04259 + [NH3+][C@H](CO)C([O-])=O + MetaCyc:D-SERINE + (2R)-2-ammonio-3-hydroxypropanoate + D-serine zwitterion + chebi_ontology + D-serine + CHEBI:35247 + + D-serine zwitterion + + + + + + + + + + + CHEBI:22721 + chebi_ontology + CHEBI:35259 + + benzofurans + + + + + + + + + + + + + + + + A derivative of ammonium, NH4(+), in which one (or more) of the hydrogens bonded to the nitrogen have been replaced with univalent organyl groups. The substituting carbon of the organyl group must not itself be directly attached to a heteroatom (thereby excluding protonated amides, hemiaminals, etc). + + chebi_ontology + ammonium ion derivatives + azanium ion derivative + azanium ion derivatives + CHEBI:35274 + + ammonium ion derivative + + + + + + + + + + A polyclic compound in which all of the ring members are carbon atoms. + + chebi_ontology + carbopolycyclic compounds + CHEBI:35294 + + carbopolycyclic compound + + + + + + + + + + + chebi_ontology + homopolycyclic compounds + CHEBI:35295 + + homopolycyclic compound + + + + + + + + + + glycosiduronic acid + chebi_ontology + glycosiduronic acids + CHEBI:35314 + + glycosiduronic acid + + + + + + + + + + deoxy hexoside + chebi_ontology + deoxy hexosides + CHEBI:35315 + + deoxy hexoside + + + + + + + + + + + + + + + A pyridoisoquinoline comprising emetam having a hydroxy group at the 6'-position and methoxy substituents at the 7'-, 10- and 11-positions. + + 0 + C28H38N2O4 + InChI=1S/C28H38N2O4/c1-5-17-16-30-9-7-19-13-27(33-3)28(34-4)15-22(19)24(30)11-20(17)10-23-21-14-26(32-2)25(31)12-18(21)6-8-29-23/h12-15,17,20,23-24,29,31H,5-11,16H2,1-4H3/t17-,20-,23+,24-/m0/s1 + DTGZHCFJNDAHEN-OZEXIGSWSA-N + 466.61240 + 466.28316 + [H][C@]1(C[C@@]2([H])NCCc3cc(O)c(OC)cc23)C[C@]2([H])N(CCc3cc(OC)c(OC)cc23)C[C@@H]1CC + Beilstein:100615 + CAS:483-17-0 + KEGG:C09390 + KNApSAcK:C00001835 + LINCS:LSM-3808 + PMID:11411558 + PMID:11913711 + PMID:11996324 + PMID:12880315 + PMID:13437707 + PMID:18327911 + PMID:20061395 + PMID:20495341 + PMID:21228475 + PMID:2715231 + PMID:6716976 + Reaxys:100615 + 7',10,11-trimethoxyemetan-6'-ol + Cephaeline + chebi_ontology + Cephaelin + CHEBI:3533 + + cephaeline + + + + + + + + + Any drug that enhances the activity of the central nervous system. + + Wikipedia:Central_nervous_system_stimulants + central nervous system stimulant + chebi_ontology + CNS stimulant + analeptic + analeptic agent + analeptic drug + analeptics + central stimulant + CHEBI:35337 + + central nervous system stimulant + + + + + + + + + + + + + + + Amines that constitute a class of central nervous system stimulants based on the structure of the parent amphetamine 1-phenylpropan-2-amine. + + chebi_ontology + amphetamine drug + CHEBI:35338 + + amphetamines + + + + + + + + + + Any of naturally occurring compounds and synthetic analogues, based on the cyclopenta[a]phenanthrene carbon skeleton, partially or completely hydrogenated; there are usually methyl groups at C-10 and C-13, and often an alkyl group at C-17. By extension, one or more bond scissions, ring expansions and/or ring contractions of the skeleton may have occurred. Natural steroids are derived biogenetically from squalene, so may be considered as triterpenoids. + + 0 + C19H31R + 259.450 + 259.24258 + C12C(C3C(C(CC3)*)(C)CC1)CCC4C2(CCCC4)C + CHEBI:13687 + CHEBI:26768 + CHEBI:9263 + KEGG:C00377 + MetaCyc:Steroids + Steroid + steroids + chebi_ontology + a steroid + CHEBI:35341 + + steroid + + + + + + + + + The alpha-stereoisomer of 17-hydroxy steroid. + + CHEBI:13585 + CHEBI:19174 + CHEBI:782 + KEGG:C03336 + chebi_ontology + 17-alpha-Hydroxysteroid + 17alpha-hydroxy steroids + CHEBI:35342 + + 17alpha-hydroxy steroid + + + + + + + + + + CHEBI:1300 + CHEBI:13596 + CHEBI:19803 + KEGG:C02506 + chebi_ontology + 21-Hydroxysteroid + 21-hydroxy steroids + 21-hydroxysteroids + CHEBI:35344 + + 21-hydroxy steroid + + + + + + + + + Any 11-hydroxy steroid in which the hydroxy group at position 11 has beta- configuration. + + 0 + C19H31OR + 275.450 + 275.23749 + C12(CCCCC1CCC3C2[C@H](CC4(C3CCC4*)C)O)C + CHEBI:13774 + CHEBI:19134 + CHEBI:738 + KEGG:C01058 + chebi_ontology + 11beta-Hydroxysteroid + 11beta-hydroxy steroids + 11beta-hydroxysteroids + an 11beta-hydroxysteroid + CHEBI:35346 + + 11beta-hydroxy steroid + + + + + + + + + + + CHEBI:24748 + CHEBI:5814 + KEGG:C02159 + chebi_ontology + Hydroxysteroid + hydroxy steroids + hydroxysteroids + CHEBI:35350 + + hydroxy steroid + + + + + + + + + + Any heteroorganic entity containing at least one carbon-nitrogen bond. + + + organonitrogen compounds + chebi_ontology + organonitrogens + CHEBI:35352 + + organonitrogen compound + + + + + + + + + An imide in which the two acyl substituents on nitrogen are carboacyl groups. + + 0 + C2NO2R3 + 70.027 + 69.99290 + [*]N(C([*])=O)C([*])=O + chebi_ontology + dicarboximides + CHEBI:35356 + + dicarboximide + + + + + + + + + + + + + + + + Any aliphatic monocarboxylic acid derived from or contained in esterified form in an animal or vegetable fat, oil or wax. + + 0 + CHO2R + 45.01740 + 44.99765 + OC([*])=O + CHEBI:13633 + CHEBI:24024 + CHEBI:4984 + KEGG:C00162 + PMID:14287444 + PMID:14300208 + PMID:14328676 + Wikipedia:Fatty_acid + Fatty acid + fatty acids + chebi_ontology + Fettsaeure + Fettsaeuren + acide gras + acides gras + acido graso + acidos grasos + fatty acids + CHEBI:35366 + + fatty acid + + + + + + + + + Parent monosaccharides are polyhydroxy aldehydes H[CH(OH)]nC(=O)H or polyhydroxy ketones H-[CHOH]n-C(=O)[CHOH]m-H with three or more carbon atoms. The generic term 'monosaccharide' (as opposed to oligosaccharide or polysaccharide) denotes a single unit, without glycosidic connection to other such units. It includes aldoses, dialdoses, aldoketoses, ketoses and diketoses, as well as deoxy sugars, provided that the parent compound has a (potential) carbonyl group. + + CHEBI:25407 + CHEBI:6984 + KEGG:C06698 + Monosaccharide + monosaccharides + chebi_ontology + Monosaccharid + Monosacharid + monosacarido + monosacaridos + CHEBI:35381 + + monosaccharide + + + + + + + + + + + + + + + A benzazepine alkaloid isolated from Cephalotaxus harringtonia. + + 0 + C18H21NO4 + InChI=1S/C18H21NO4/c1-21-15-9-18-4-2-5-19(18)6-3-11-7-13-14(23-10-22-13)8-12(11)16(18)17(15)20/h7-9,16-17,20H,2-6,10H2,1H3/t16-,17-,18+/m1/s1 + YMNCVRSYJBNGLD-KURKYZTESA-N + 315.36368 + 315.14706 + [H][C@@]12[C@H](O)C(OC)=C[C@@]11CCCN1CCc1cc3OCOc3cc21 + Beilstein:628324 + CAS:24316-19-6 + KEGG:C10580 + KNApSAcK:C00002324 + KNApSAcK:C00027319 + Reaxys:628324 + Cephalotaxine + cephalotaxine + chebi_ontology + (-)-Cephalotaxine + (1S,3aR,14bS)-2-methoxy-1,5,6,8,9,14b-hexahydro-4H-cyclopenta[a][1,3]dioxolo[4,5-h]pyrrolo[2,1-b][3]benzazepin-1-ol + CHEBI:3540 + + cephalotaxine + + + + + + + + + + An oxoanion is an anion derived from an oxoacid by loss of hydron(s) bound to oxygen. + + CHEBI:33274 + CHEBI:33436 + oxoanion + chebi_ontology + oxoacid anions + oxoanions + CHEBI:35406 + + oxoanion + + + + + + + + + A substance used in the prophylaxis or therapy of infectious diseases. + + chebi_ontology + anti-infective agents + anti-infective drugs + antiinfective agents + antiinfective drug + CHEBI:35441 + + antiinfective agent + + + + + + + + + A substance used to treat or prevent parasitic infections. + + Wikipedia:Antiparasitic + chebi_ontology + antiparasitic drugs + antiparasitics + parasiticides + CHEBI:35442 + + antiparasitic agent + + + + + + + + + Substance intended to kill parasitic worms (helminths). + + anthelminthic + chebi_ontology + anthelminthics + anthelmintic + anthelmintics + antihelminth + antihelmintico + vermifuge + CHEBI:35443 + + anthelminthic drug + + + + + + + + + + A substance used in the treatment or control of nematode infestations. + + chebi_ontology + antinematodal agent + antinematodal drugs + antinematodals + CHEBI:35444 + + antinematodal drug + + + + + + + + + + A bisbenzylisoquinoline alkaloid from tubers of Stephania; stimulates recovery of immunologic function in lymphatic system after administration of antineoplastic agents or x-irradiation. + + 0 + C37H38N2O6 + InChI=1S/C37H38N2O6/c1-38-13-11-24-18-31(41-4)33-20-27(24)28(38)16-23-7-10-30(40-3)32(17-23)44-26-8-5-22(6-9-26)15-29-35-25(12-14-39(29)2)19-34-36(37(35)45-33)43-21-42-34/h5-10,17-20,28-29H,11-16,21H2,1-4H3/t28-,29+/m1/s1 + YVPXVXANRNDGTA-WDYNHAJCSA-N + 606.709 + 606.27299 + C12=C3C=4[C@@H](N(CCC4C=C1OCO2)C)CC=5C=CC(=CC5)OC=6C(=CC=C(C6)C[C@H]7N(CCC8=C7C=C(C(=C8)OC)O3)C)OC + Beilstein:75231 + CAS:481-49-2 + KEGG:C09391 + KEGG:D01035 + KNApSAcK:C00001836 + PMID:26703475 + Reaxys:75231 + (14S,27R)-22,33-dimethoxy-13,28-dimethyl-2,5,7,20-tetraoxa-13,28-diazaoctacyclo[25.6.2.2(16,19).1(3,10).1(21,25).0(4,8).0(14,39).0(31,35)]nonatriaconta-1(33),3,8,10(39),16,18,21(36),22,24,31,34,37-dodecaene + Cepharanthine + chebi_ontology + (+)-Cepharanthine + 6',12'-Dimethoxy-2,2'-dimethyl-6,7-(methylenebis(oxy))oxyacanthan + CHEBI:3546 + + cepharanthine + + + + + + + + + Antidepressants are mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions. + + chebi_ontology + antidepressant drugs + antidepressants + thymoanaleptics + thymoleptic drugs + thymoleptics + CHEBI:35469 + + antidepressant + + + + + + + + + A class of drugs producing both physiological and psychological effects through a variety of mechanisms involving the central nervous system. + + chebi_ontology + CNS agent + CNS drugs + central nervous system agents + CHEBI:35470 + + central nervous system drug + + + + + + + + + A loosely defined grouping of drugs that have effects on psychological function. + + Wikipedia:Psychotropic_drug + chebi_ontology + psychoactive agent + psychoactive drugs + psychopharmaceuticals + psychotropic drugs + CHEBI:35471 + + psychotropic drug + + + + + + + + + + A substance that reduces or suppresses inflammation. + + chebi_ontology + anti-inflammatory drugs + antiinflammatory agent + antiinflammatory drug + antiinflammatory drugs + CHEBI:35472 + + anti-inflammatory drug + + + + + + + + + + A traditional grouping of drugs said to have a soothing or calming effect on mood, thought or behaviour. + + chebi_ontology + ataractics + tranquilising drug + tranquilizing drugs + tranquillising agent + tranquillizing agents + CHEBI:35473 + + tranquilizing drug + + + + + + + + + + An anti-inflammatory drug that is not a steroid. In addition to anti-inflammatory actions, non-steroidal anti-inflammatory drugs have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. + + Wikipedia:Non-steroidal_anti-inflammatory_drug + chebi_ontology + NSAID + NSAIDs + non-steroidal anti-inflammatory agent + non-steroidal anti-inflammatory drugs + CHEBI:35475 + + non-steroidal anti-inflammatory drug + + + + + + + + + Antipsychotic drugs are agents that control agitated psychotic behaviour, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. + + chebi_ontology + Neuroleptikum + antipsychotic agents + antipsychotic drug + antipsychotic drugs + antipsychotics + antipsychotiques + grosser Tranquilizer + major tranquilizers + major tranquilizing agents + neuroleptic + neuroleptic agents + neuroleptics + neuroleptique + neuroleptiques + CHEBI:35476 + + antipsychotic agent + + + + + + + + + + An agent capable of relieving pain without the loss of consciousness or without producing anaesthesia. In addition, analgesic is a role played by a compound which is exhibited by a capability to cause a reduction of pain symptoms. + + chebi_ontology + CHEBI:35480 + + analgesic + + + + + + + + + A drug that has principally analgesic, antipyretic and anti-inflammatory actions. Non-narcotic analgesics do not bind to opioid receptors. + + chebi_ontology + CHEBI:35481 + + non-narcotic analgesic + + + + + + + + + A loosely defined group of drugs that tend to reduce the activity of the central nervous system. + + chebi_ontology + CNS depressants + central nervous system depressants + CHEBI:35488 + + central nervous system depressant + + + + + + + + + + Any fluoroarene that is a benzene or a substituted benzene carrying at least one fluoro group. + + chebi_ontology + CHEBI:35496 + + fluorobenzenes + + + + + + + + + An addition compound contains two or more simpler compounds that can be packed in a definite ratio into a crystal. The term covers donor-acceptor complexes (adducts) and a variety of lattice compounds. + + chebi_ontology + addition compounds + CHEBI:35504 + + addition compound + + + + + + + + + + + + + + + An addition compound that contains water in weak chemical combination with another compound. + + chebi_ontology + Hydrat + hidrato + hidratos + hydrates + CHEBI:35505 + + hydrate + + + + + + + + + + chebi_ontology + alkaloid fundamental parents + CHEBI:35506 + + alkaloid fundamental parent + + + + + + + + + + natural product fundamental parents + chebi_ontology + CHEBI:35507 + + natural product fundamental parent + + + + + + + + + + + chebi_ontology + steroid fundamental parents + CHEBI:35508 + + steroid fundamental parent + + + + + + + + + + 0 + C23H36O2 + InChI=1S/C23H36O2/c1-22-11-4-3-5-16(22)6-7-17-19-9-8-18(15-13-21(24)25-14-15)23(19,2)12-10-20(17)22/h15-20H,3-14H2,1-2H3/t15-,16-,17-,18+,19+,20-,22-,23+/m0/s1 + AQARKTASOBROAE-KPSWSRIPSA-N + 344.53074 + 344.27153 + [H][C@]1(COC(=O)C1)[C@@]1([H])CC[C@]2([H])[C@]3([H])CC[C@]4([H])CCCC[C@]4(C)[C@@]3([H])CC[C@]12C + 5beta-cardanolide + chebi_ontology + CHEBI:35542 + + 5beta-cardanolide + + + + + + + + + + + 0 + C23H36O2 + InChI=1S/C23H36O2/c1-22-11-4-3-5-16(22)6-7-17-19-9-8-18(15-13-21(24)25-14-15)23(19,2)12-10-20(17)22/h15-20H,3-14H2,1-2H3/t15-,16?,17-,18+,19+,20-,22-,23+/m0/s1 + AQARKTASOBROAE-OCYOQFCJSA-N + 344.53074 + 344.27153 + [H][C@]1(COC(=O)C1)[C@@]1([H])CC[C@]2([H])[C@]3([H])CCC4CCCC[C@]4(C)[C@@]3([H])CC[C@]12C + cardanolide + chebi_ontology + CHEBI:35543 + + cardanolide + + + + + + + + + + heterocyclic parent hydrides + chebi_ontology + heterocyclic fundamental parent + heterocyclic organic fundamental parents + organic heterocyclic fundamental parents + CHEBI:35552 + + heterocyclic organic fundamental parent + + + + + + + + + A drug that affects the rate or intensity of cardiac contraction, blood vessel diameter or blood volume. + + chebi_ontology + cardiovascular agent + cardiovascular drugs + CHEBI:35554 + + cardiovascular drug + + + + + + + + + Any molecular entity that consists of a ring having (formally) the maximum number of noncumulative double bonds. + + mancude-ring systems + chebi_ontology + mancude rings + mancunide-ring systems + CHEBI:35568 + + mancude ring + + + + + + + + + + + chebi_ontology + mancude organic heterobicyclic parents + mancude-ring organic heterobicyclic parents + CHEBI:35570 + + mancude organic heterobicyclic parent + + + + + + + + + + + chebi_ontology + mancude organic heterocyclic parents + mancude-ring organic heterocyclic parents + CHEBI:35571 + + mancude organic heterocyclic parent + + + + + + + + + + + chebi_ontology + organic mancude parents + organic mancude-ring parents + CHEBI:35573 + + organic mancude parent + + + + + + + + + + + + + + + + A heterobicyclic aromatic organic compound comprising a pyrimidine ring fused to an imidazole ring; the parent compound of the purines. + + 0 + C5H4N4 + 120.112 + 120.04360 + HMDB:HMDB0001366 + KEGG:C15587 + MetaCyc:PURINE + PMID:12865945 + PMID:24088627 + purine + chebi_ontology + CHEBI:35584 + + purine + + + + + + + + + + + + + + + + + + + + + + + + + + + The 1H-tautomer of purine. + + 0 + C5H4N4 + InChI=1S/C5H4N4/c1-4-5(8-2-6-1)9-3-7-4/h1-3H,(H,6,7,8,9) + KDCGOANMDULRCW-UHFFFAOYSA-N + 120.11210 + 120.04360 + c1nc2c[nH]cnc2n1 + Gmelin:2379911 + 1H-purine + chebi_ontology + CHEBI:35586 + + 1H-purine + + + + + + + + + + + + + + + + + + + + + + + + + + + The 3H-tautomer of purine. + + 0 + C5H4N4 + InChI=1S/C5H4N4/c1-4-5(8-2-6-1)9-3-7-4/h1-3H,(H,6,7,8,9) + KDCGOANMDULRCW-UHFFFAOYSA-N + 120.11222 + 120.04360 + c1nc2cnc[nH]c2n1 + PMID:6149478 + PMID:7178185 + PMID:7296170 + Reaxys:1210196 + 3H-purine + chebi_ontology + CHEBI:35588 + + 3H-purine + + + + + + + + + + + + + + + + + + + + + + + + + + + The 9H-tautomer of purine. + + 0 + C5H4N4 + InChI=1S/C5H4N4/c1-4-5(8-2-6-1)9-3-7-4/h1-3H,(H,6,7,8,9) + KDCGOANMDULRCW-UHFFFAOYSA-N + 120.11222 + 120.04360 + c1ncc2nc[nH]c2n1 + Beilstein:606899 + CAS:120-73-0 + Gmelin:3120 + Wikipedia:Purine + 9H-purine + chebi_ontology + CHEBI:35589 + + 9H-purine + + + + + + + + + + + A negative ion consisting solely of carbon and oxygen atoms, and therefore having the general formula CxOy(n-) for some integers x, y and n. + + carbon oxoanion + chebi_ontology + carbon oxoanions + oxocarbon anion + oxocarbon anions + CHEBI:35604 + + carbon oxoanion + + + + + + + + + + + chebi_ontology + carbon oxoacids + oxoacids of carbon + CHEBI:35605 + + carbon oxoacid + + + + + + + + + A substance that inhibits or prevents the proliferation of neoplasms. + + chebi_ontology + anticancer agent + anticancer agents + antineoplastic + antineoplastic agents + cytostatic + CHEBI:35610 + + antineoplastic agent + + + + + + + + + + Any ether in which the oxygen is attached to at least one aryl substituent. + + chebi_ontology + CHEBI:35618 + + aromatic ether + + + + + + + + + A drug used to cause dilation of the blood vessels. + + chebi_ontology + vasodilator + vasodilator agents + CHEBI:35620 + + vasodilator agent + + + + + + + + + Adrenergic uptake inhibitors are drugs that block the transport of adrenergic transmitters into axon terminals or into storage vesicles within terminals. The tricyclic antidepressants and amphetamines are among the therapeutically important drugs that may act via inhibition of adrenergic transport. Many of these drugs also block transport of serotonin. + + chebi_ontology + ARI + NERI + NRI + adrenergic reuptake inhibitor + adrenergic reuptake inhibitors + adrenergic uptake inhibitors + norepinephrine reuptake inhibitor + norepinephrine reuptake inhibitors + CHEBI:35640 + + adrenergic uptake inhibitor + + + + + + + + + + + 0 + C15H19N + InChI=1S/C15H19N/c1-2-6-13-12(4-1)10-16-9-8-11-5-3-7-14(13)15(11)16/h1-2,4,6,11,14-15H,3,5,7-10H2/t11-,14-,15+/m0/s1 + CDIONMUWHFYLPO-TUKIKUTGSA-N + 213.31810 + 213.15175 + [H][C@]12CCC[C@@]3([H])c4ccccc4CN(CC1)[C@]23[H] + Beilstein:8326915 + galanthan + chebi_ontology + CHEBI:35646 + + galanthan + + + + + + + + + + + 0 + C22H37N + InChI=1S/C22H37N/c1-15-18-9-10-20-17-8-7-16-6-4-5-12-21(16,2)19(17)11-13-22(18,20)14-23(15)3/h15-20H,4-14H2,1-3H3/t15-,16?,17+,18+,19-,20-,21-,22-/m0/s1 + ICKQFGPZAUSMPE-PFKVMXGZSA-N + 315.53592 + 315.29260 + [H][C@]12CC[C@@]3([H])[C@]4([H])CCC5CCCC[C@]5(C)[C@@]4([H])CC[C@]13CN(C)[C@H]2C + conanine + chebi_ontology + CHEBI:35655 + + conanine + + + + + + + + + + An inhibitor of HIV protease, an enzyme required for production of proteins needed for viral assembly. + + Wikipedia:Protease_inhibitor_(pharmacology) + chebi_ontology + HIV protease inhibitors + CHEBI:35660 + + HIV protease inhibitor + + + + + + + + + Any drug used in the treatment of acute or chronic vascular hypertension regardless of pharmacological mechanism. + + Wikipedia:Antihypertensive_drug + chebi_ontology + antihypertensive + antihypertensive agents + antihypertensive drug + antihypertensive drugs + CHEBI:35674 + + antihypertensive agent + + + + + + + + + + A group of two-ring heterocyclic compounds consisting of a benzene ring fused to an azepine ring. + + benzazepine + chebi_ontology + benzazepines + benzoazepines + CHEBI:35676 + + benzazepine + + + + + + + + + A secondary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has two other carbon atoms attached to it. + + 0 + CH2OR2 + 30.026 + 30.01056 + *C(*)O + CHEBI:13425 + CHEBI:13686 + CHEBI:26617 + CHEBI:58662 + CHEBI:8741 + CHEBI:9077 + KEGG:C00432 + KEGG:C01612 + Secondary alcohol + chebi_ontology + R-CHOH-R' + a secondary alcohol + secondary alcohols + CHEBI:35681 + + secondary alcohol + + + + + + + + + Any organic sulfide in which the sulfur is attached to at least one aromatic group. + + aryl sulfide + chebi_ontology + aryl sulfides + CHEBI:35683 + + aryl sulfide + + + + + + + + + + A compound formally derived from an oxoacid RkE(=O)l(OH)m (l > 0) and an alcohol, phenol, heteroarenol, or enol by linking with formal loss of water from an acidic hydroxy group of the former and a hydroxy group of the latter. + + + CHEBI:23960 + CHEBI:4859 + KEGG COMPOUND:C00287 + KEGG:C00287 + Wikipedia:Ester + Ester + chebi_ontology + esters + CHEBI:35701 + + ester + + + + + + + + + A xenobiotic (Greek, xenos "foreign"; bios "life") is a compound that is foreign to a living organism. Principal xenobiotics include: drugs, carcinogens and various compounds that have been introduced into the environment by artificial means. + + CHEBI:10074 + CHEBI:27333 + KEGG:C06708 + Wikipedia:Xenobiotic + Xenobiotic + xenobiotic + xenobiotics + chebi_ontology + xenobiotic compounds + CHEBI:35703 + + xenobiotic + + + + + + + + + An agent that suppresses immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-cells or by inhibiting the activation of helper cells. In addition, an immunosuppressive agent is a role played by a compound which is exhibited by a capability to diminish the extent and/or voracity of an immune response. + + chebi_ontology + immunosuppressant + immunosuppressive agents + inmunosupresor + CHEBI:35705 + + immunosuppressive agent + + + + + + + + + A central nervous system depressant used to induce drowsiness or sleep or to reduce psychological excitement or anxiety. + + chebi_ontology + hypnotics + hypnotics and sedatives + sedative drug + sedatives + sedatives and hypnotics + CHEBI:35717 + + sedative + + + + + + + + + An antimicrobial agent that destroys fungi by suppressing their ability to grow or reproduce. + + chebi_ontology + antifungal + antifungal agents + antifungal drug + antifungal drugs + antifungals + CHEBI:35718 + + antifungal agent + + + + + + + + + + + An azole in which the five-membered heterocyclic aromatic skeleton contains three N atoms and two C atoms. + + + chebi_ontology + triazole compounds + CHEBI:35727 + + triazoles + + + + + + + + + + + + + + + Any anion of a tricarboxylic acid formed by deprotonation of at least one carboxy group. + + tricarboxylic acid anion + chebi_ontology + tricarboxylic acid anions + CHEBI:35753 + + tricarboxylic acid anion + + + + + + + + + + + + + + + A carboxylic acid anion formed when the carboxy group of a monocarboxylic acid is deprotonated. + + -1 + CO2R + 44.01000 + 43.98983 + [O-]C([*])=O + CHEBI:13657 + CHEBI:25382 + CHEBI:3407 + KEGG:C00060 + chebi_ontology + Carboxylate + Monocarboxylate + a monocarboxylate + monocarboxylates + monocarboxylic acid anions + CHEBI:35757 + + monocarboxylic acid anion + + + + + + + + + + dicarboxylic acid diamide + chebi_ontology + dicarboxylic acid diamides + CHEBI:35779 + + dicarboxylic acid diamide + + + + + + + + + + + + + + + + + + + + + A phosphorus oxoanion that is the conjugate base of phosphoric acid. + + chebi_ontology + Pi + phosphate + phosphate ions + CHEBI:35780 + + phosphate ion + + + + + + + + + + + CHEBI:24979 + CHEBI:25804 + chebi_ontology + keto steroids + ketosteroids + oxo steroids + oxosteroids + CHEBI:35789 + + oxo steroid + + + + + + + + + An agent useful in the treatment or prevention of coccidiosis in man or animals. + + chebi_ontology + anticoccidial agent + coccidiostats + CHEBI:35818 + + coccidiostat + + + + + + + + + + Any antimicrobial drug which is used to treat or prevent protozoal infections. + + Wikipedia:Antiprotozoal_agent + chebi_ontology + antiprotozoal agent + antiprotozoal agents + antiprotozoal drugs + CHEBI:35820 + + antiprotozoal drug + + + + + + + + + A drug used to treat rheumatoid arthritis. + + chebi_ontology + anti-rheumatic drugs + antirheumatic agent + antirheumatic drugs + CHEBI:35842 + + antirheumatic drug + + + + + + + + + A compound or agent that combines with lipoxygenase and thereby prevents its substrate-enzyme combination with arachidonic acid and the formation of the icosanoid products hydroxyicosatetraenoic acid and various leukotrienes. + + chebi_ontology + lipooxygenase inhibitor + lipoxygenase inhibitors + CHEBI:35856 + + lipoxygenase inhibitor + + + + + + + + + + + + chebi_ontology + imidazopyrimidines + CHEBI:35875 + + imidazopyrimidine + + + + + + + + + + + pnictogen hydride + chebi_ontology + pnictogen hydrides + CHEBI:35881 + + pnictogen hydride + + + + + + + + + + A substance used for its pharmacological action on any aspect of neurotransmitter systems. Neurotransmitter agents include agonists, antagonists, degradation inhibitors, uptake inhibitors, depleters, precursors, and modulators of receptor function. + + chebi_ontology + neurotransmitter agents + CHEBI:35942 + + neurotransmitter agent + + + + + + + + + + A drug used to treat or prevent microbial infections. + + chebi_ontology + antimicrobial drugs + CHEBI:36043 + + antimicrobial drug + + + + + + + + + + A substance used in the prophylaxis or therapy of virus diseases. + + chebi_ontology + anti-viral drug + anti-virus drug + antiviral drugs + CHEBI:36044 + + antiviral drug + + + + + + + + + + A drug used to treat or prevent bacterial infections. + + Wikipedia:Antibacterial + chebi_ontology + antibacterial drugs + CHEBI:36047 + + antibacterial drug + + + + + + + + + + + + + + + + Esters of benzoic acid or substituted benzoic acids. + + benzoate ester + chebi_ontology + benzoate esters + benzoic acid esters + CHEBI:36054 + + benzoate ester + + + + + + + + + Any monocarboxylic acid anion carrying at least one hydroxy substituent. + + chebi_ontology + hydroxy monocarboxylic acid anions + hydroxymonocarboxylic acid anion + hydroxymonocarboxylic acid anions + CHEBI:36059 + + hydroxy monocarboxylic acid anion + + + + + + + + + + + inorganic chloride salts + CHEBI:36093 + inorganic chloride salt + + + + + + + + + + + chebi_ontology + organic chloride salts + CHEBI:36094 + + organic chloride salt + + + + + + + + + A compound in which two monosaccharides are joined by a glycosidic bond. + + CHEBI:23844 + CHEBI:4654 + KEGG:C01911 + Disaccharide + disaccharides + chebi_ontology + Disaccharid + Disacharid + disacarido + disacaridos + CHEBI:36233 + + disaccharide + + + + + + + + + Any member of a group of drugs that reversibly inhibit the propagation of signals along nerves. Wide variations in potency, stability, toxicity, water-solubility and duration of action determine the route used for administration, e.g. topical, intravenous, epidural or spinal block. + + local anaesthetic + chebi_ontology + Lokalanaesthetikum + anesthesique local + local anaesthetics + local anesthetics + CHEBI:36333 + + local anaesthetic + + + + + + + + + + Lepton is a fermion that does not experience the strong force (strong interaction). The term is derived from the Greek lambdaepsilonpitauomicronsigma (small, thin). + + chebi_ontology + leptons + CHEBI:36338 + + lepton + + + + + + + + + + Baryon is a fermion that does experience the strong force (strong interaction). The term is derived from the Greek betaalpharhoupsilonsigma (heavy). + + chebi_ontology + baryons + CHEBI:36339 + + baryon + + + + + + + + + Particle of half-integer spin quantum number following Fermi-Dirac statistics. Fermions are named after Enrico Fermi. + + fermion + chebi_ontology + fermions + CHEBI:36340 + + fermion + + + + + + + + + A particle smaller than an atom. + + chebi_ontology + subatomic particles + CHEBI:36342 + + subatomic particle + + + + + + + + + A subatomic particle known to have substructure (i.e. consisting of smaller particles). + + chebi_ontology + composite particles + CHEBI:36343 + + composite particle + + + + + + + + + Hadron is a subatomic particle which experiences the strong force. + + chebi_ontology + hadrons + CHEBI:36344 + + hadron + + + + + + + + + A nucleus or any of its constituents in any of their energy states. + + nuclear particle + chebi_ontology + CHEBI:36347 + + nuclear particle + + + + + + + + + + + + + + + Any molecular entity consisting of more than one atom. + + + chebi_ontology + polyatomic entities + CHEBI:36357 + + polyatomic entity + + + + + + + + + + An ion consisting of more than one atom. + + chebi_ontology + polyatomic ions + CHEBI:36358 + + polyatomic ion + + + + + + + + + + + + + + + + + phosphorus oxoacid derivative + chebi_ontology + CHEBI:36359 + + phosphorus oxoacid derivative + + + + + + + + + + chebi_ontology + CHEBI:36360 + + phosphorus oxoacids and derivatives + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + 2393 + A quinoline alkaloid that has formula C18H26ClN3. + An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis. + + + 0 + C18H26ClN3 + InChI=1S/C18H26ClN3/c1-4-22(5-2)12-6-7-14(3)21-17-10-11-20-18-13-15(19)8-9-16(17)18/h8-11,13-14H,4-7,12H2,1-3H3,(H,20,21) + WHTVZRBIWZFKQO-UHFFFAOYSA-N + 319.87200 + 319.18153 + CCN(CC)CCCC(C)Nc1ccnc2cc(Cl)ccc12 + Beilstein:482809 + CAS:54-05-7 + ChemIDplus:54-05-7 + DrugBank:DB00608 + Drug_Central:607 + Gmelin:781126 + HMDB:HMDB0014746 + KEGG COMPOUND:54-05-7 + KEGG COMPOUND:C07625 + KEGG DRUG:D02366 + KEGG:C07625 + KEGG:D02366 + LINCS:LSM-1901 + NIST Chemistry WebBook:54-05-7 + PDBeChem:CLQ + PMID:11198399 + PMID:17594118 + PMID:18052874 + PMID:19426658 + PMID:23288916 + PMID:23580861 + PMID:23635029 + PMID:23644906 + PMID:23706562 + PMID:23852712 + PMID:23891850 + PMID:25285162 + Patent:DE683692 + Patent:US2233970 + Reaxys:482809 + Wikipedia:Chloroquine + Chloroquine + N(4)-(7-chloroquinolin-4-yl)-N(1),N(1)-diethylpentane-1,4-diamine + chebi_ontology + Aralen + Artrichin + Bemaphate + C18H26ClN3 + CCN(CC)CCCC(C)Nc1ccnc2cc(Cl)ccc12 + Capquin + Chlorochin + InChI=1S/C18H26ClN3/c1-4-22(5-2)12-6-7-14(3)21-17-10-11-20-18-13-15(19)8-9-16(17)18/h8-11,13-14H,4-7,12H2,1-3H3,(H,20,21) + InChIKey=WHTVZRBIWZFKQO-UHFFFAOYSA-N + N(4)-(7-chloro-4-quinolinyl)-N(1),N(1)-diethyl-1,4-pentanediamine + Nivaquine B + Resoquine + Reumachlor + Sanoquin + chloroquine + chloroquinum + cloroquina + CHEBI:3638 + + Chloroquine + chloroquine + + + + + + + + + + + + 0 + C25H32N2 + InChI=1S/C25H32N2/c1-2-18-17-27-14-12-20-8-4-6-10-23(20)25(27)16-21(18)15-24-22-9-5-3-7-19(22)11-13-26-24/h3-10,18,21,24-26H,2,11-17H2,1H3/t18-,21-,24+,25-/m0/s1 + KSQYVPHTTWSOHG-CKBKHPSWSA-N + 360.53506 + 360.25655 + [H][C@]1(C[C@@]2([H])NCCc3ccccc23)C[C@]2([H])N(CCc3ccccc23)C[C@@H]1CC + emetan + chebi_ontology + CHEBI:36380 + + emetan + + + + + + + + + + chebi_ontology + saturated heterocyclic parent hydride + saturated heterocyclic parent hydrides + saturated organic heterocyclic parents + CHEBI:36388 + + saturated organic heterocyclic parent + + + + + + + + + + + chebi_ontology + saturated heteromonocyclic parent hydride + saturated heteromonocyclic parent hydrides + saturated organic heteromonocyclic parents + CHEBI:36389 + + saturated organic heteromonocyclic parent + + + + + + + + + + + chebi_ontology + mancude organic heterotricyclic parents + mancude-ring organic heterotricyclic parents + CHEBI:36416 + + mancude organic heterotricyclic parent + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + 2403 + A substituted phenothiazine in which the ring nitrogen at position 10 is attached to C-3 of an N,N-dimethylpropanamine moiety. + + + 0 + C17H19ClN2S + InChI=1S/C17H19ClN2S/c1-19(2)10-5-11-20-14-6-3-4-7-16(14)21-17-9-8-13(18)12-15(17)20/h3-4,6-9,12H,5,10-11H2,1-2H3 + ZPEIMTDSQAKGNT-UHFFFAOYSA-N + 318.86400 + 318.09575 + CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc12 + Beilstein:289793 + CAS:50-53-3 + ChemIDplus:50-53-3 + CiteXplore:1650428 + CiteXplore:2427628 + DrugBank:DB00477 + Drug_Central:621 + HMDB:HMDB0014620 + KEGG COMPOUND:50-53-3 + KEGG COMPOUND:C06906 + KEGG DRUG:D00270 + KEGG:C06906 + KEGG:D00270 + LINCS:LSM-4017 + NIST Chemistry WebBook:50-53-3 + PDBeChem:Z80 + PMID:14354584 + PMID:14404586 + PMID:15170372 + PMID:1650428 + PMID:16653219 + PMID:20825390 + PMID:2427628 + PMID:7192992 + Patent:US2645640 + Reaxys:289793 + Wikipedia:Chlorpromazine + 3-(2-chloro-10H-phenothiazin-10-yl)-N,N-dimethylpropan-1-amine + Chlorpromazine + chebi_ontology + 3-(2-chloro-10H-phenothiazin-10-yl)-N,N-dimethyl-1-propanamine + 3-(2-chlorophenothiazin-10-yl)-N,N-dimethyl-propan-1-amine + Aminazine + C17H19ClN2S + CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc12 + CPZ + Chlorderazin + Chloropromazine + Chlorpromados + Contomin + InChI=1S/C17H19ClN2S/c1-19(2)10-5-11-20-14-6-3-4-7-16(14)21-17-9-8-13(18)12-15(17)20/h3-4,6-9,12H,5,10-11H2,1-2H3 + InChIKey=ZPEIMTDSQAKGNT-UHFFFAOYSA-N + Largactil + N-(3-dimethylaminopropyl)-3-chlorophenothiazine + Thorazine + chlorpromazine + chlorpromazinum + clorpromazina + CHEBI:3647 + + Chlorpromazine + chlorpromazine + + + + + + + + + + + + + + + + + + + + + + + + + + + + The hydrochloride salt of chlorpromazine. + + 0 + C17H19ClN2S.HCl + InChI=1S/C17H19ClN2S.ClH/c1-19(2)10-5-11-20-14-6-3-4-7-16(14)21-17-9-8-13(18)12-15(17)20;/h3-4,6-9,12H,5,10-11H2,1-2H3;1H + FBSMERQALIEGJT-UHFFFAOYSA-N + 355.32558 + 354.07243 + [H+].[Cl-].CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc12 + Beilstein:3779989 + CAS:69-09-0 + DrugBank:DB00477 + KEGG:C07952 + KEGG:D00789 + PMID:18968700 + PMID:18969944 + PMID:20541454 + PMID:22527301 + PMID:24521912 + PMID:6196640 + Reaxys:3779989 + 3-(2-chloro-10H-phenothiazin-10-yl)-N,N-dimethylpropan-1-amine hydrochloride + Chlorpromazine hydrochloride + chebi_ontology + 2-chloro-10-(3-(dimethylamino)propyl)phenothiazine monohydrochloride + 2-chloro-N,N-dimethyl-10H-phenothiazine-10-propanamine monohydrochloride + Aminazin + Ampliactil + Chlorazin + Chloropromazine monohydrochloride + Hibernal + Largactil + Plegomazin + Propaphenin + Thorazine + chlorpromazinium chloride + CHEBI:3649 + + chlorpromazine hydrochloride + + + + + + + + + + + + + + + + Any compound containing the carbonyl group, C=O. The term is commonly used in the restricted sense of aldehydes and ketones, although it actually includes carboxylic acids and derivatives. + + + carbonyl compounds + chebi_ontology + CHEBI:36586 + + carbonyl compound + + + + + + + + + + + + + + + + Organic compounds containing an oxygen atom, =O, doubly bonded to carbon or another element. + + + oxo compounds + chebi_ontology + organic oxo compounds + CHEBI:36587 + + organic oxo compound + + + + + + + + + + + + + + + Any terpenoid derived from a triterpene. The term includes compounds in which the C30 skeleton of the parent triterpene has been rearranged or modified by the removal of one or more skeletal atoms (generally methyl groups). + + CHEBI:27151 + CHEBI:9748 + KEGG:C06085 + Triterpenoid + chebi_ontology + triterpenoides + triterpenoids + CHEBI:36615 + + triterpenoid + + + + + + + + + + + An organochlorine compound is a compound containing at least one carbon-chlorine bond. + + + 0 + ClR + 35.453 + 34.96885 + *Cl + MetaCyc:Chlorides + Wikipedia:Organochloride + organochlorine compound + chebi_ontology + an organochlorine molecule + chloroorganic compounds + chlororganische Verbindungen + organochloride + organochloride compound + organochloride compounds + organochlorides + organochlorine compounds + CHEBI:36683 + + organochlorine compound + + + + + + + + + + A compound containing at least one carbon-halogen bond. + + organohalogen compounds + CHEBI:36684 + organohalogen compound + + + + + + + + + + + heterotricyclic compound + heterotricyclic compounds + chebi_ontology + heterotricyclic compounds + CHEBI:36688 + + heterotricyclic compound + + + + + + + + + + Any of a class of steroid hormones that are produced in the adrenal cortex. + + chebi_ontology + adrenal cortex hormones + corticosteroid hormones + CHEBI:36699 + + corticosteroid hormone + + + + + + + + + + Any member of the class of quinolines in which the quinoline skeleton is substituted by one or more amino or substituted-amino groups. + + aminoquinoline + chebi_ontology + aminoquinolines + CHEBI:36709 + + aminoquinoline + + + + + + + + + + A bicyclic compound in which all the ring atoms are carbon. + + chebi_ontology + carbobicyclic compounds + CHEBI:36785 + + carbobicyclic compound + + + + + + + + + A salt formally resulting from the reaction of hydrochloric acid with an organic base. + + chebi_ontology + Hydrochlorid + hydrochloride salts + hydrochlorides + CHEBI:36807 + + hydrochloride + + + + + + + + + + antidepresivo triciclico + antidepresivos triciclicos + tricyclic antidepressant drugs + tricyclic antidepressants + tricyclic antidepressive agents + CHEBI:36809 + tricyclic antidepressant + + + + + + + + + Two or more cyclic systems (single rings or fused systems) which are directly joined to each other by double or single bonds are named ring assemblies when the number of such direct ring junctions is one less than the number of cyclic systems involved. + + ring assemblies + ring assembly + chebi_ontology + CHEBI:36820 + + ring assembly + + + + + + + + + + pseudohalide group + chebi_ontology + halogenoid group + pseudohalido group + pseudohalo groups + pseudohalogen group + CHEBI:36823 + + pseudohalo group + + + + + + + + + + pseudohalide ions + chebi_ontology + pseudohalide anions + pseudohalides + pseudohalogen anion + pseudohalogen ion + CHEBI:36828 + + pseudohalide anion + + + + + + + + + + + chebi_ontology + polyatomic monoanions + CHEBI:36829 + + polyatomic monoanion + + + + + + + + + + -1 + chebi_ontology + monoanions + CHEBI:36830 + + monoanion + + + + + + + + + Any hydroxy steroid carrying a hydroxy group at position 3. + + chebi_ontology + 3-hydroxy steroids + CHEBI:36834 + + 3-hydroxy steroid + + + + + + + + + + A 3-hydroxy steroid in which the 3-hydroxy substituent is in the beta-position. + + 0 + C19H31OR + 275.450 + 275.23749 + C12C(C3C(C(CC3)*)(C)CC1)CCC4C2(CC[C@@H](C4)O)C + CHEBI:71195 + KEGG:C02945 + MetaCyc:3-Beta-Hydroxysterols + PMID:10535978 + PMID:12829805 + chebi_ontology + 3beta-hydroxy steroids + a 3beta-hydroxysteroid + CHEBI:36836 + + 3beta-hydroxy steroid + + + + + + + + + A hydroxy steroid carrying a hydroxy group at position 17. + + chebi_ontology + 17-hydroxy steroids + CHEBI:36838 + + 17-hydroxy steroid + + + + + + + + + + chebi_ontology + 11-hydroxy steroids + CHEBI:36841 + + 11-hydroxy steroid + + + + + + + + + + chebi_ontology + 5-hydroxy steroids + CHEBI:36848 + + 5-hydroxy steroid + + + + + + + + + + + + + + + + + + + + + + 0 + CHN + InChI=1S/CHN/c1-2/h2H + QIUBLANJVAOHHY-UHFFFAOYSA-N + 27.02538 + 27.01090 + [C-]#[NH+] + Beilstein:2069401 + CAS:6914-07-4 + Gmelin:113 + hydrogen isocyanide + nitriliomethanide + chebi_ontology + CNH + HN(+)#C(-) + HNC + hydroisocyanic acid + CHEBI:36856 + + hydrogen isocyanide + + + + + + + + + + chebi_ontology + 14-hydroxy steroids + CHEBI:36860 + + 14-hydroxy steroid + + + + + + + + + A 14-hydroxy steroid in which the hydroxy group has a beta-configuration. + + chebi_ontology + 14beta-hydroxy steroids + CHEBI:36862 + + 14beta-hydroxy steroid + + + + + + + + + An oxo steroid carrying an oxo group at position 20. + + chebi_ontology + 20-oxo steroids + CHEBI:36885 + + 20-oxo steroid + + + + + + + + + + + chalcogen hydride + chebi_ontology + chalcogen hydrides + CHEBI:36902 + + chalcogen hydride + + + + + + + + + + + chebi_ontology + inorganic ions + CHEBI:36914 + + inorganic ion + + + + + + + + + + + chebi_ontology + inorganic cations + CHEBI:36915 + + inorganic cation + + + + + + + + + A monoatomic or polyatomic species having one or more elementary charges of the proton. + + + CHEBI:23058 + CHEBI:3473 + KEGG COMPOUND:C01373 + KEGG:C01373 + Cation + cation + chebi_ontology + Kation + Kationen + cationes + cations + CHEBI:36916 + + cation + + + + + + + + + + chalcocarbonic acid + chalcocarbonic acids + chebi_ontology + chalcocarbonic acids + CHEBI:36961 + + chalcocarbonic acid + + + + + + + + + + An organochalcogen compound is a compound containing at least one carbon-chalcogen bond. + + + organochalcogen compound + chebi_ontology + organochalcogen compounds + CHEBI:36962 + + organochalcogen compound + + + + + + + + + + An organochalcogen compound containing at least one carbon-oxygen bond. + + + CiteXplore:17586126 + PMID:17586126 + organooxygen compound + chebi_ontology + organooxygen compounds + CHEBI:36963 + + organooxygen compound + + + + + + + + + + + + + + + + + amino-acid anion + chebi_ontology + amino acid anions + amino-acid anions + CHEBI:37022 + + amino-acid anion + + + + + + + + + + chebi_ontology + CHEBI:37086 + + C-nucleoside + + + + + + + + + + A compound containing at least one carbon-bromine bond. + + 0 + BrR + 79.904 + 78.91834 + *Br + MetaCyc:Bromide + Wikipedia:Organobromine_compound + organobromine compound + chebi_ontology + an organobromine molecule + bromoorganic compound + organobromide + organobromide compound + organobromide compounds + organobromides + organobromine compounds + CHEBI:37141 + + organobromine compound + + + + + + + + + + An organoiodine compound is a compound containing at least one carbon-iodine bond. + + 0 + IR + 126.904 + 126.90447 + *I + MetaCyc:Organoiodine-Compounds + Wikipedia:Organoiodine_compound + organoiodine compound + chebi_ontology + organoiodine compounds + CHEBI:37142 + + organoiodine compound + + + + + + + + + + + An organofluorine compound is a compound containing at least one carbon-fluorine bond. + + + 0 + FR + 18.998 + 18.99840 + *F + MetaCyc:Fluorides + organofluorine compound + chebi_ontology + fluoroorganic compound + fluoroorganic compounds + fluoroorganics + fluororganische Verbindungen + organofluorine compounds + CHEBI:37143 + + organofluorine compound + + + + + + + + + + A member of the class of benzenes that is benzene substituted by at least one bromo group. + + chebi_ontology + CHEBI:37149 + + bromobenzenes + + + + + + + + + Any EC 3.1.3.* (phosphoric monoester hydrolase) inhibitor that interferes with the action of phosphoprotein phosphatase (EC 3.1.3.16). + + CHEBI:62670 + Wikipedia:Phosphoprotein_phosphatase + Wikipedia:Protein_serine/threonine_phosphatase + chebi_ontology + 3-hydroxy 3-methylglutaryl coenzymeA reductase phosphatase inhibitor + 3-hydroxy 3-methylglutaryl coenzymeA reductase phosphatase inhibitors + Aspergillus awamori acid protein phosphatase inhibitor + Aspergillus awamori acid protein phosphatase inhibitors + BCKDH phosphatase inhibitor + BCKDH phosphatase inhibitors + EC 3.1.3.16 (protein serine/threonine phosphatase) inhibitors + EC 3.1.3.16 inhibitor + EC 3.1.3.16 inhibitors + HMG-CoA reductase phosphatase inhibitor + HMG-CoA reductase phosphatase inhibitors + branched-chain alpha-keto acid dehydrogenase phosphatase inhibitor + branched-chain alpha-keto acid dehydrogenase phosphatase inhibitors + calcineurin inhibitor + calcineurin inhibitors + casein phosphatase inhibitor + casein phosphatase inhibitors + phosphatase 2A inhibitor + phosphatase 2A inhibitors + phosphatase 2B inhibitor + phosphatase 2B inhibitors + phosphatase C-II inhibitor + phosphatase C-II inhibitors + phosphatase H-II inhibitor + phosphatase H-II inhibitors + phosphatase I inhibitor + phosphatase I inhibitors + phosphatase IB inhibitor + phosphatase IB inhibitors + phosphatase II inhibitor + phosphatase II inhibitors + phosphatase III inhibitor + phosphatase III inhibitors + phosphatase IV inhibitor + phosphatase IV inhibitors + phosphatase SP inhibitor + phosphatase SP inhibitors + phosphoprotein phosphatase (EC 3.1.3.16) inhibitor + phosphoprotein phosphatase (EC 3.1.3.16) inhibitors + phosphoprotein phosphatase inhibitor + phosphoprotein phosphatase inhibitors + phosphoprotein phosphohydrolase inhibitor + phosphoprotein phosphohydrolase inhibitors + phosphopyruvate dehydrogenase phosphatase inhibitor + phosphopyruvate dehydrogenase phosphatase inhibitors + phosphospectrin phosphatase inhibitor + phosphospectrin phosphatase inhibitors + polycation modulated (PCM-) phosphatase inhibitor + polycation modulated (PCM-) phosphatase inhibitors + protein D phosphatase inhibitor + protein D phosphatase inhibitors + protein phosphatase inhibitor + protein phosphatase inhibitors + protein phosphatase-1 inhibitor + protein phosphatase-1 inhibitors + protein phosphatase-2A inhibitor + protein phosphatase-2A inhibitors + protein phosphatase-2B inhibitor + protein phosphatase-2B inhibitors + protein phosphatase-2C inhibitor + protein phosphatase-2C inhibitors + protein serine/threonine phosphatase (EC 3.1.3.16) inhibitors + protein serine/threonine phosphatase inhibitor + protein serine/threonine phosphatase inhibitors + serine/threonine specific protein phosphatase inhibitor + serine/threonine specific protein phosphatase inhibitors + CHEBI:37153 + + EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor + + + + + + + + + + chebi_ontology + organic hydrides + CHEBI:37175 + + organic hydride + + + + + + + + + + mononuclear parent hydrides + chebi_ontology + mononuclear hydride + mononuclear hydrides + CHEBI:37176 + + mononuclear parent hydride + + + + + + + + + A substance administered to enhance contrast in images of the inside of the body obtained using X-rays, gamma-rays, sound waves, radio waves (MRI), or radioactive particles in order to diagnose disease. + + chebi_ontology + CHEBI:37334 + + diagnostic imaging agent + + + + + + + + + + chebi_ontology + CHEBI:37335 + + MRI contrast agent + + + + + + + + + + Any ether in which the oxygen atom forms part of a ring. + + CHEBI:37406 + cyclic ether + cyclic ethers + epoxy compounds + chebi_ontology + cyclic ethers + epoxy compounds + CHEBI:37407 + + cyclic ether + + + + + + + + + An acid is a molecular entity capable of donating a hydron (Bronsted acid) or capable of forming a covalent bond with an electron pair (Lewis acid). + + CHEBI:13800 + CHEBI:13801 + CHEBI:22209 + CHEBI:2426 + KEGG:C00174 + Acid + acid + chebi_ontology + Saeure + Saeuren + acide + acido + acids + CHEBI:37527 + + acid + + + + + + + + + + + + + + + + + + + + + Derivatives of diazene with the general structure R-N=N-R'. + + azo compounds + chebi_ontology + azo compounds + CHEBI:37533 + + azo compound + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A hydrochloride resulting from the reaction of equimolar amounts of clomipramine and hydrogen chloride. One of the more sedating tricyclic antidepressants, it is used for the treatment of depression as well as obsessive-compulsive disorder and phobias. + + 0 + C19H24Cl2N2 + InChI=1S/C19H23ClN2.ClH/c1-21(2)12-5-13-22-18-7-4-3-6-15(18)8-9-16-10-11-17(20)14-19(16)22;/h3-4,6-7,10-11,14H,5,8-9,12-13H2,1-2H3;1H + WIMWMKZEIBHDTH-UHFFFAOYSA-N + 351.31300 + 350.13165 + Cl.CN(C)CCCN1c2ccccc2CCc2ccc(Cl)cc12 + CAS:17321-77-6 + DrugBank:DB01242 + KEGG:D00811 + Reaxys:4168494 + VSDB:1812 + 3-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethylpropan-1-amine hydrochloride + chebi_ontology + 3-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethylpropan-1-aminium chloride + 3-chloroimipramine hydrochloride + Anafranil + chloroimipramine monohydrochloride + clomipramine HCl + clomipramine monohydrochloride + CHEBI:3755 + + clomipramine hydrochloride + + + + + + + + + A molecular entity consisting of two or more chemical elements. + + + chebi_ontology + chemical compound + heteroatomic molecular entities + CHEBI:37577 + + heteroatomic molecular entity + + + + + + + + + + Any heteroatomic molecular entity that is a chemical compound of halogen with other chemical elements. + + + Wikipedia:Halide + chebi_ontology + halides + CHEBI:37578 + + halide + + + + + + + + + A lactone having a five-membered lactone ring. + + 0 + C4H3O2R3 + 83.066 + 83.01330 + O1C(C(C(C1=O)*)*)* + CHEBI:13194 + CHEBI:18937 + CHEBI:22971 + CHEBI:541 + PMID:18789684 + chebi_ontology + 1,4-Lactone + 1,4-lactones + a 1,4-lactone + butyrolactones + gamma-Laktone + gamma-lactona + gamma-lactonas + gamma-lactones + CHEBI:37581 + + gamma-lactone + + + + + + + + + + + + + + + + + An amide of a carboxylic acid, having the structure RC(=O)NR2. The term is used as a suffix in systematic name formation to denote the -C(=O)NH2 group including its carbon atom. + + + 0 + CNOR3 + 42.01680 + 41.99799 + [*]C(=O)N([*])[*] + CHEBI:35354 + CHEBI:35355 + carboxamides + chebi_ontology + CNOR3 + [*]C(=O)N([*])[*] + carboxamides + primary carboxamide + CHEBI:37622 + + carboxamide + + + + + + + + + A compound which inhibits or antagonizes the biosynthesis or actions of proteases (endopeptidases). + + Wikipedia:Protease_inhibitor_(biology) + chebi_ontology + protease inhibitors + CHEBI:37670 + + protease inhibitor + + + + + + + + + An EC 2.7.* (P-containing group transferase) inhibitor that interferes with the action of protein kinases. + + chebi_ontology + protein kinase inhibitors + CHEBI:37699 + + protein kinase inhibitor + + + + + + + + + An EC 2.7.11.* (protein-serine/threonine kinase) inhibitor that interferes with the action of protein kinase C (EC 2.7.11.13). + + chebi_ontology + ATP:protein phosphotransferase (diacylglycerol-dependent) inhibitor + ATP:protein phosphotransferase (diacylglycerol-dependent) inhibitors + EC 2.7.11.13 (protein kinase C) inhibitors + EC 2.7.11.13 inhibitor + EC 2.7.11.13 inhibitors + PKC inhibitor + PKC inhibitors + PKCalpha inhibitor + PKCalpha inhibitors + PKCbeta inhibitor + PKCbeta inhibitors + PKCdelta inhibitor + PKCdelta inhibitors + PKCepsilon inhibitor + PKCepsilon inhibitors + PKCgamma inhibitor + PKCgamma inhibitors + PKCzeta inhibitor + PKCzeta inhibitors + PKN3 inhibitor + PKN3 inhibitors + Pkc1p inhibitor + Pkc1p inhibitors + STK24 inhibitor + STK24 inhibitors + cPKC inhibitor + cPKC inhibitors + cPKCalpha inhibitor + cPKCalpha inhibitors + cPKCbeta inhibitor + cPKCbeta inhibitors + cPKCgamma inhibitor + cPKCgamma inhibitors + calcium-dependent protein kinase C inhibitor + calcium-dependent protein kinase C inhibitors + calcium-independent protein kinase C inhibitor + calcium-independent protein kinase C inhibitors + calcium/phospholipid dependent protein kinase inhibitor + calcium/phospholipid dependent protein kinase inhibitors + nPKC inhibitor + nPKC inhibitors + nPKCdelta inhibitor + nPKCdelta inhibitors + nPKCepsilon inhibitor + nPKCepsilon inhibitors + nPKCeta inhibitor + nPKCeta inhibitors + nPKCtheta inhibitor + nPKCtheta inhibitors + protein kinase C (EC 2.7.11.13) inhibitor + protein kinase C (EC 2.7.11.13) inhibitors + protein kinase C inhibitor + protein kinase C inhibitors + protein kinase Cepsilon inhibitor + protein kinase Cepsilon inhibitors + CHEBI:37700 + + EC 2.7.11.13 (protein kinase C) inhibitor + + + + + + + + + + + CHEBI:26019 + chebi_ontology + CHEBI:37734 + + phosphoric ester + + + + + + + + + + + + + + + A carboacyl group is a group formed by loss of at least one OH from the carboxy group of a carboxylic acid. + + carboacyl groups + carboxylic acyl group + chebi_ontology + carboxylic acyl groups + CHEBI:37838 + + carboacyl group + + + + + + + + + + A plant growth regulator that modulates the formation of stems, leaves and flowers, as well as the development and ripening of fruit. The term includes endogenous and non-endogenous compounds (e.g. active compounds produced by bacteria on the leaf surface) as well as semi-synthetic and fully synthetic compounds. + + CHEBI:26158 + Wikipedia:Phytohormone + chebi_ontology + phytohormone + phytohormones + plant growth factor + plant growth factors + plant growth hormone + plant growth hormones + plant hormones + CHEBI:37848 + + plant hormone + + + + + + + + + + chebi_ontology + phenothiazine antipsychotic drugs + phenothiazine antipsychotics + phenothiazine neuroleptics + CHEBI:37930 + + phenothiazine antipsychotic drug + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + The 10H-tautomer of phenothiazine. + + 0 + C12H9NS + InChI=1S/C12H9NS/c1-3-7-11-9(5-1)13-10-6-2-4-8-12(10)14-11/h1-8,13H + WJFKNYWRSNBZNX-UHFFFAOYSA-N + 199.27260 + 199.04557 + N1c2ccccc2Sc2ccccc12 + Beilstein:143237 + CAS:92-84-2 + LINCS:LSM-3324 + PMID:25382702 + PMID:26661932 + Reaxys:143237 + Wikipedia:Phenothiazine + 10H-phenothiazine + chebi_ontology + 10H-Phenothiazin + dibenzo-1,4-thiazine + phenothiazine + CHEBI:37931 + + 10H-phenothiazine + + + + + + + + + + + 0 + C12H9NS + 199.273 + 199.04557 + phenothiazine + chebi_ontology + Phenothiazin + CHEBI:37932 + + phenothiazine + + + + + + + + + + + + + + + + + + + + + + + + + + + + 0 + C12H9NS + InChI=1S/C12H9NS/c1-3-7-11-9(5-1)13-10-6-2-4-8-12(10)14-11/h1-8,11H + UTOHXUCINHSOMQ-UHFFFAOYSA-N + 199.27260 + 199.04557 + S1C2C=CC=CC2=Nc2ccccc12 + Beilstein:1211644 + 4aH-phenothiazine + chebi_ontology + CHEBI:37933 + + 4aH-phenothiazine + + + + + + + + + + + + + + + + + + + + + + + + + + + + 0 + C12H9NS + InChI=1S/C12H9NS/c1-3-7-11-9(5-1)13-10-6-2-4-8-12(10)14-11/h1-5,7-8H,6H2 + QWXDTDWOYQPERX-UHFFFAOYSA-N + 199.27260 + 199.04557 + C1C=CC=C2Sc3ccccc3N=C12 + 1H-phenothiazine + chebi_ontology + CHEBI:37934 + + 1H-phenothiazine + + + + + + + + + + + + + + + + + + + + + + + + + + + + 0 + C12H9NS + InChI=1S/C12H9NS/c1-3-7-11-9(5-1)13-10-6-2-4-8-12(10)14-11/h1-3,5-8H,4H2 + FIICCGOYRVMEPV-UHFFFAOYSA-N + 199.27260 + 199.04557 + C1C=CC2=Nc3ccccc3SC2=C1 + 3H-phenothiazine + chebi_ontology + CHEBI:37935 + + 3H-phenothiazine + + + + + + + + + A spiro compound in which at least one of the cyclic components is an oxygen heterocyle. + + chebi_ontology + oxaspiro compounds + CHEBI:37948 + + oxaspiro compound + + + + + + + + + H1-receptor antagonists are the drugs that selectively bind to but do not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine. + + PMID:22035879 + chebi_ontology + H1 antihistaminics + H1 receptor antagonists + H1 receptor blockaders + H1-receptor antagonists + H1-receptor blocker + H1-receptor blockers + classical antihistamines + classical antihistaminics + CHEBI:37955 + + H1-receptor antagonist + + + + + + + + + + Histamine antagonists are the drugs that bind to but do not activate histamine receptors, thereby blocking the actions of histamine or histamine agonists. + + PMID:22035879 + Wikipedia:Antihistamines + chebi_ontology + antihistamine + antihistamines + antihistaminico + antihistaminics + histamine receptor blocker + histamine receptor blockers + CHEBI:37956 + + histamine antagonist + + + + + + + + + Drugs used for their actions on histaminergic systems. + + chebi_ontology + histamine agents + histamine drugs + histaminergic agent + histaminergic agents + histaminergic drugs + CHEBI:37957 + + histaminergic drug + + + + + + + + + Any agent that acts on an adrenergic receptor or affects the life cycle of an adrenergic transmitter. + + chebi_ontology + adrenergic agents + adrenergic drug + adrenergic drugs + adrenergic neuron agents + adrenergics + CHEBI:37962 + + adrenergic agent + + + + + + + + + + + chebi_ontology + mesylate salt + mesylate salts + methanesulfonate salts + CHEBI:38037 + + methanesulfonate salt + + + + + + + + + A drug used in the treatment of malaria. Antimalarials are usually classified on the basis of their action against Plasmodia at different stages in their life cycle in the human. + + chebi_ontology + antimalarials + CHEBI:38068 + + antimalarial + + + + + + + + + A drug used for the treatment or prevention of cardiac arrhythmias. Anti-arrhythmia drugs may affect the polarisation-repolarisation phase of the action potential, its excitability or refractoriness, or impulse conduction or membrane responsiveness within cardiac fibres. + + chebi_ontology + anti-arrhythmia agent + antiarrhythmic agent + CHEBI:38070 + + anti-arrhythmia drug + + + + + + + + + + Any member of the class of cardenolides with glycosyl residues attached to position 3. + + CHEBI:23035 + CHEBI:38080 + CHEBI:38082 + chebi_ontology + 5alpha-cardenolide glycoside + 5beta-cardenolide glycoside + CHEBI:38092 + + cardenolide glycoside + + + + + + + + + + + chebi_ontology + CHEBI:38093 + + phenothiazines + + + + + + + + + + Any organonitrogen compound containing a cyclic component with nitrogen and at least one other element as ring member atoms. + + + chebi_ontology + heterocyclic organonitrogen compounds + organonitrogen heterocyclic compounds + CHEBI:38101 + + organonitrogen heterocyclic compound + + + + + + + + + + Any organic heterocyclic compound containing at least one ring oxygen atom. + + + CiteXplore:17134300 + PMID:17134300 + chebi_ontology + heterocyclic organooxygen compounds + organooxygen heterocyclic compounds + oxacycles + CHEBI:38104 + + oxacycle + + + + + + + + + + + + chebi_ontology + heterocyclic organosulfur compounds + organosulfur heterocyclic compounds + CHEBI:38106 + + organosulfur heterocyclic compound + + + + + + + + + Cyclic hemiacetals formed by intramolecular addition of a hydroxy group to an aldehydic or ketonic carbonyl group. They are thus 1-oxacycloalkan-2-ols or unsaturated analogues. + + Wikipedia:Lactol + lactol + lactols + chebi_ontology + lactols + CHEBI:38131 + + lactol + + + + + + + + + A drug that has a strengthening effect on the heart or that can increase cardiac output. + + chebi_ontology + cardiotonic drugs + CHEBI:38147 + + cardiotonic drug + + + + + + + + + + chebi_ontology + organic heteropentacyclic compounds + CHEBI:38164 + + organic heteropentacyclic compound + + + + + + + + + + + + CHEBI:25429 + CHEBI:38075 + chebi_ontology + organic heteropolycyclic compounds + CHEBI:38166 + + organic heteropolycyclic compound + + + + + + + + + + + chebi_ontology + monocyclic heteroarenes + CHEBI:38179 + + monocyclic heteroarene + + + + + + + + + + + chebi_ontology + polycyclic heteroarenes + CHEBI:38180 + + polycyclic heteroarene + + + + + + + + + + + chebi_ontology + 5beta-hydroxy steroids + CHEBI:38195 + + 5beta-hydroxy steroid + + + + + + + + + + Compounds containing a pyridine skeleton substituted by one or more amine groups. + + chebi_ontology + aminopyridines + CHEBI:38207 + + aminopyridine + + + + + + + + + + chebi_ontology + CHEBI:38222 + + hydrocarbyl anion + + + + + + + + + Any inhibitor of a DNA polymerase. + + chebi_ontology + CHEBI:38234 + + DNA polymerase inhibitor + + + + + + + + + + Any of a class of heterocyclic amines having a saturated five-membered ring. + + CHEBI:26922 + CHEBI:38191 + chebi_ontology + CHEBI:38260 + + pyrrolidines + + + + + + + + + + chebi_ontology + pyrrolidinones + CHEBI:38275 + + pyrrolidinone + + + + + + + + + + Any organic heterocyclic compound containing a benzene ring in which two of the C-H fragments have been replaced by isolobal nitrogens (the diazine parent structure). + + chebi_ontology + CHEBI:38313 + + diazines + + + + + + + + + + chebi_ontology + CHEBI:38314 + + pyrazines + + + + + + + + + Any drug used for its actions on cholinergic systems. Included here are agonists and antagonists, drugs that affect the life cycle of acetylcholine, and drugs that affect the survival of cholinergic neurons. + + chebi_ontology + cholinergic agent + cholinergic drugs + cholinomimetic + CHEBI:38323 + + cholinergic drug + + + + + + + + + + A member of the class of pyrimidines that is pyrimidine substituted by at least one amino group and its derivatives. + + chebi_ontology + aminopyrimidines + CHEBI:38338 + + aminopyrimidine + + + + + + + + + A hexenoic acid with the double bond at position 4. + + 0 + C6H10O2 + InChI=1S/C6H10O2/c1-2-3-4-5-6(7)8/h2-3H,4-5H2,1H3,(H,7,8) + NIDHFQDUBOVBKZ-UHFFFAOYSA-N + 114.14240 + 114.06808 + [H]C(C)=CCCC(O)=O + Beilstein:1720995 + LIPID_MAPS_instance:LMFA01030010 + hex-4-enoic acid + chebi_ontology + 4-hexenoic acid + 4-hexenoic acids + gamma-hexenoic acid + gamma-hexenoic acids + hex-4-enoic acids + CHEBI:38355 + + hex-4-enoic acid + + + + + + + + + + + CHEBI:26949 + CHEBI:38417 + 1,3-thiazoles + chebi_ontology + 1,3-thiazoles + CHEBI:38418 + + 1,3-thiazole + 1,3-thiazoles + + + + + + + + + + chebi_ontology + 1-benzopyrans + CHEBI:38443 + + 1-benzopyran + + + + + + + + + + + + chebi_ontology + alkaloid esters + CHEBI:38481 + + alkaloid ester + + + + + + + + + + chebi_ontology + indole alkaloid fundamental parents + CHEBI:38482 + + indole alkaloid fundamental parent + + + + + + + + + + + chebi_ontology + CHEBI:38485 + + indolizines + + + + + + + + + + chebi_ontology + CHEBI:38496 + + electron-transport chain inhibitor + + + + + + + + + + chebi_ontology + CHEBI:38497 + + respiratory-chain inhibitor + + + + + + + + + + An EC 1.9.3.* (oxidoreductase acting on donor heme group, oxygen as acceptor) inhibitor that interferes with the action of cytochrome c oxidase (EC 1.9.3.1). + + CHEBI:38501 + CHEBI:62966 + PMID:12969439 + Wikipedia:Cytochrome_c_oxidase + chebi_ontology + CcO inhibitor + EC 1.9.3.1 (cytochrome c oxidase) inhibitors + EC 1.9.3.1 inhibitor + EC 1.9.3.1 inhibitors + NADH cytochrome c oxidase inhibitor + NADH cytochrome c oxidase inhibitors + Warburg's respiratory enzyme inhibitor + Warburg's respiratory enzyme inhibitors + complex IV (mitochondrial electron transport) inhibitor + complex IV (mitochondrial electron transport) inhibitors + cytochrome a3 inhibitor + cytochrome a3 inhibitors + cytochrome aa3 inhibitor + cytochrome aa3 inhibitors + cytochrome c oxidase (EC 1.9.3.1) inhibitor + cytochrome c oxidase (EC 1.9.3.1) inhibitors + cytochrome c oxidase inhibitor + cytochrome c oxidase inhibitors + cytochrome oxidase inhibitor + cytochrome oxidase inhibitors + cytochrome-c oxidase inhibitor + cytochrome-c oxidase inhibitors + ferrocytochrome c oxidase inhibitor + ferrocytochrome c oxidase inhibitors + ferrocytochrome-c:oxygen oxidoreductase inhibitor + ferrocytochrome-c:oxygen oxidoreductase inhibitors + indophenol oxidase inhibitor + indophenol oxidase inhibitors + indophenolase inhibitor + indophenolase inhibitors + mitochondrial complex IV inhibitor + mitochondrial complex IV inhibitors + mitochondrial cytochrome-c oxidase inhibitors + CHEBI:38500 + + EC 1.9.3.1 (cytochrome c oxidase) inhibitor + + + + + + + + + + + Patent:WO9106547 + chebi_ontology + indolizidine alkaloids + indolizine alkaloids + CHEBI:38511 + + indolizidine alkaloid + + + + + + + + + + chebi_ontology + indolizine alkaloid fundamental parents + CHEBI:38513 + + indolizine alkaloid fundamental parent + + + + + + + + + + chebi_ontology + isoquinoline alkaloid fundamental parents + CHEBI:38515 + + isoquinoline alkaloid fundamental parent + + + + + + + + + + chebi_ontology + steroid alkaloid fundamental parents + CHEBI:38516 + + steroid alkaloid fundamental parent + + + + + + + + + + + chebi_ontology + benzazepine alkaloids + CHEBI:38523 + + benzazepine alkaloid + + + + + + + + + + chebi_ontology + benzazepine alkaloid fundamental parents + CHEBI:38527 + + benzazepine alkaloid fundamental parent + + + + + + + + + An EC 1.4.3.* (oxidoreductase acting on donor CH-NH2 group, oxygen as acceptor) inhibitor that interferes with the action of monoamine oxidase (EC 1.4.3.4). + + Wikipedia:Monoamine_oxidase_inhibitor + chebi_ontology + EC 1.4.3.4 (monoamine oxidase) inhibitors + EC 1.4.3.4 inhibitor + EC 1.4.3.4 inhibitors + MAO A inhibitor + MAO A inhibitors + MAO B inhibitor + MAO B inhibitors + MAO inhibitor + MAO inhibitors + MAO-A inhibitor + MAO-A inhibitors + MAO-B inhibitor + MAO-B inhibitors + adrenalin oxidase inhibitor + adrenalin oxidase inhibitors + adrenaline oxidase inhibitor + adrenaline oxidase inhibitors + amine oxidase (flavin-containing) inhibitor + amine oxidase (flavin-containing) inhibitors + amine:oxygen oxidoreductase (deaminating) (flavin-containing) inhibitor + amine:oxygen oxidoreductase (deaminating) (flavin-containing) inhibitors + amine:oxygen oxidoreductase (deaminating) inhibitor + amine:oxygen oxidoreductase (deaminating) inhibitors + epinephrine oxidase inhibitor + epinephrine oxidase inhibitors + monoamine oxidase (EC 1.4.3.4) inhibitor + monoamine oxidase (EC 1.4.3.4) inhibitors + monoamine oxidase A inhibitor + monoamine oxidase A inhibitors + monoamine oxidase B inhibitor + monoamine oxidase B inhibitors + monoamine oxidase inhibitor + monoamine oxidase inhibitors + monoamine:O2 oxidoreductase (deaminating) inhibitor + monoamine:O2 oxidoreductase (deaminating) inhibitors + serotonin deaminase inhibitor + serotonin deaminase inhibitors + tyraminase inhibitor + tyraminase inhibitors + tyramine oxidase inhibitor + tyramine oxidase inhibitors + CHEBI:38623 + + EC 1.4.3.4 (monoamine oxidase) inhibitor + + + + + + + + + Any agent that affects the transport of molecular entities across a biological membrane. + + chebi_ontology + membrane transport modulators + CHEBI:38632 + + membrane transport modulator + + + + + + + + + Any protein kinase inhibitor that interferes with the action of tyrosine kinase. + + Wikipedia:Tyrosine-kinase_inhibitor + chebi_ontology + TKI inhibitor + TKI inhibitors + protein tyrosine kinase inhibitor + protein tyrosine kinase inhibitors + tyrosine kinase inhibitors + tyrphostin + tyrphostins + CHEBI:38637 + + tyrosine kinase inhibitor + + + + + + + + + Any hydroxyflavone in which two ring hydrogens are replaced by hydroxy substituents. + + CHEBI:23779 + CHEBI:25390 + chebi_ontology + dihydroxyflavones + CHEBI:38686 + + dihydroxyflavone + + + + + + + + + A trianion containing at least one carboxy group. + + carboxylic acid trianion + chebi_ontology + carboxylic acid trianions + CHEBI:38717 + + carboxylic acid trianion + + + + + + + + + Any compound containing morpholine as part of its structure. + + chebi_ontology + CHEBI:38785 + + morpholines + + + + + + + + + Compounds consisting wholly of fluorine and carbon. + + fluorocarbon + fluorocarbons + chebi_ontology + fluorocarbons + CHEBI:38824 + + fluorocarbon + + + + + + + + + + + + + + + + + 0 + CF4 + InChI=1S/CF4/c2-1(3,4)5 + TXEYQDLBPFQVAA-UHFFFAOYSA-N + 88.00431 + 87.99361 + FC(F)(F)F + Beilstein:1697288 + CAS:75-73-0 + Gmelin:2016 + tetrafluoromethane + chebi_ontology + CF4 + Freon 14 + Halon 14 + Tetrafluorkohlenstoff + Tetrafluormethan + carbon tetrafluoride + perfluoromethane + tetrafluoridocarbon + tetrafluorocarbon + CHEBI:38825 + + tetrafluoromethane + + + + + + + + + + chebi_ontology + CHEBI:38831 + + 2-benzofurans + + + + + + + + + Substance which produces loss of feeling or sensation. + + anaesthetic + chebi_ontology + Anaesthetika + Anaesthetikum + anaesthetics + anesthetic agent + anesthetic drug + anesthetics + CHEBI:38867 + + anaesthetic + + + + + + + + + Any organic heterobicyclic compound consisting of a pyridine ring ortho-fused at any position to a pyrimidine ring. + + pyridopyrimidine + chebi_ontology + pyridopyrimidines + CHEBI:38932 + + pyridopyrimidine + + + + + + + + + + + + + + + + An alkaloid containing an indole skeleton. + + + CHEBI:24795 + CHEBI:5901 + KEGG COMPOUND:C06073 + KEGG:C06073 + Wikipedia:Indole_alkaloid + Indole alkaloid + chebi_ontology + indole alkaloids + CHEBI:38958 + + indole alkaloid + + + + + + + + + Any alkylbenzene that is benzene substituted with one or more methyl groups. + + chebi_ontology + methylbenzenes + CHEBI:38975 + + methylbenzene + + + + + + + + + + + + + + + + A monocyclic arene that is benzene substituted with one or more alkyl groups. + + alkylbenzene + chebi_ontology + Alkylbenzol + alkylbenzenes + CHEBI:38976 + + alkylbenzene + + + + + + + + + + A molecular entity capable of donating a hydron to an acceptor (Bronsted base). + + Bronsted acid + chebi_ontology + Bronsted-Saeure + acide de Bronsted + donneur d'hydron + hydron donor + CHEBI:39141 + + Bronsted acid + + + + + + + + + + A molecular entity capable of accepting a hydron from a donor (Bronsted acid). + + Bronsted base + chebi_ontology + Bronsted-Base + accepteur d'hydron + base de Bronsted + hydron acceptor + CHEBI:39142 + + Bronsted base + + + + + + + + + + A molecular entity able to provide a pair of electrons and thus capable of forming a covalent bond with an electron-pair acceptor (Lewis acid), thereby producing a Lewis adduct. + + Lewis base + chebi_ontology + Lewis-Base + base de Lewis + donneur d'une paire d'electrons + electron donor + CHEBI:39144 + + Lewis base + + + + + + + + + + + + + + + + A haloalkane that is methane in which one (or more) of the hydrogens have been replaced by a halogen atom/halogen atoms. + + halomethane + chebi_ontology + halomethanes + CHEBI:39279 + + halomethane + + + + + + + + + + A halomethane that is methane in which one or more hydrogens has been replaced by fluorine. + + chebi_ontology + CHEBI:39281 + + fluoromethanes + + + + + + + + + Any chemical substance that inhibits the life-cycle of an organism. + + chebi_ontology + growth regulators + CHEBI:39317 + + growth regulator + + + + + + + + + + + chebi_ontology + dioxolanes + CHEBI:39430 + + dioxolane + + + + + + + + + Any compound having a pyrimidine as part of its structure. + + CHEBI:13681 + CHEBI:26448 + chebi_ontology + CHEBI:39447 + + pyrimidines + + + + + + + + + + + + + + + + + + + + + + A monovalent inorganic anion that consists of phosphoric acid in which one of the three OH groups has been deprotonated. + + -1 + H2O4P + InChI=1S/H3O4P/c1-5(2,3)4/h(H3,1,2,3,4)/p-1 + NBIIXXVUZAFLBC-UHFFFAOYSA-M + 96.98724 + 96.96962 + [H]OP([O-])(=O)O[H] + CHEBI:29137 + CHEBI:39739 + DrugBank:DB02831 + Gmelin:1999 + PDBeChem:2HP + dihydrogen(tetraoxidophosphate)(1-) + dihydrogenphosphate + dihydrogentetraoxophosphate(1-) + dihydrogentetraoxophosphate(V) + dihydroxidodioxidophosphate(1-) + chebi_ontology + DIHYDROGENPHOSPHATE ION + H2PO4(-) + [PO2(OH)2](-) + CHEBI:39745 + + dihydrogenphosphate + + + + + + + + + + KEGG:C02019 + Cyclic ketone + cyclic ketones + chebi_ontology + CHEBI:3992 + + cyclic ketone + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + 3008 + A cyclic nonribosomal peptide of eleven amino acids; an immunosuppressant drug widely used in post-allogeneic organ transplant to reduce the activity of the patient's immune system, and therefore the risk of organ rejection. Also causes reversible inhibition of immunocompetent lymphocytes in the G0- and G1-phase of the cell cycle. + + + 0 + C62H111N11O12 + InChI=1S/C62H111N11O12/c1-25-27-28-40(15)52(75)51-56(79)65-43(26-2)58(81)67(18)33-48(74)68(19)44(29-34(3)4)55(78)66-49(38(11)12)61(84)69(20)45(30-35(5)6)54(77)63-41(16)53(76)64-42(17)57(80)70(21)46(31-36(7)8)59(82)71(22)47(32-37(9)10)60(83)72(23)50(39(13)14)62(85)73(51)24/h25,27,34-47,49-52,75H,26,28-33H2,1-24H3,(H,63,77)(H,64,76)(H,65,79)(H,66,78)/b27-25+/t40-,41+,42-,43+,44+,45+,46+,47+,49+,50+,51+,52-/m1/s1 + PMATZTZNYRCHOR-CGLBZJNRSA-N + 1202.61120 + 1201.84137 + CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C + CHEBI:63586 + CHEBI:91802 + Beilstein:3647785 + CAS:59865-13-3 + ChemIDplus:59865-13-3 + CiteXplore:11058832 + CiteXplore:11069928 + CiteXplore:11079273 + CiteXplore:11080188 + CiteXplore:11238591 + CiteXplore:11256490 + CiteXplore:11278005 + CiteXplore:11315347 + CiteXplore:11370709 + CiteXplore:11406057 + CiteXplore:11426833 + CiteXplore:11442023 + CiteXplore:11481617 + CiteXplore:11493684 + CiteXplore:11529914 + CiteXplore:11557554 + CiteXplore:11564166 + CiteXplore:11676831 + CiteXplore:11870366 + CiteXplore:12021257 + CiteXplore:12050171 + CiteXplore:12603598 + CiteXplore:12761440 + CiteXplore:12929192 + CiteXplore:12950728 + CiteXplore:14521916 + CiteXplore:14621732 + CiteXplore:14638917 + CiteXplore:14672695 + CiteXplore:14682659 + CiteXplore:14743390 + CiteXplore:15030555 + CiteXplore:15175101 + CiteXplore:15210365 + CiteXplore:15306697 + CiteXplore:15383526 + CiteXplore:15541012 + CiteXplore:15613074 + CiteXplore:15626898 + CiteXplore:15657176 + CiteXplore:1566062 + CiteXplore:15711594 + CiteXplore:15811524 + CiteXplore:15962181 + CiteXplore:16372476 + CiteXplore:16404634 + CiteXplore:16724420 + CiteXplore:16801218 + CiteXplore:16898534 + CiteXplore:17032751 + CiteXplore:17083576 + CiteXplore:17117422 + CiteXplore:17192032 + CiteXplore:17220244 + CiteXplore:17229932 + CiteXplore:17265451 + CiteXplore:17446460 + CiteXplore:17603747 + CiteXplore:18076075 + CiteXplore:18171316 + CiteXplore:18191430 + CiteXplore:18217899 + CiteXplore:18259730 + CiteXplore:18299432 + CiteXplore:18359899 + CiteXplore:18583716 + CiteXplore:18597363 + CiteXplore:18790203 + CiteXplore:18818682 + CiteXplore:18931077 + CiteXplore:18975184 + CiteXplore:19282398 + CiteXplore:19589783 + DrugBank:DB00091 + Drug_Central:760 + KEGG COMPOUND:59865-13-3 + KEGG COMPOUND:C05086 + KEGG DRUG:D00184 + KEGG:C05086 + KEGG:D00184 + KNApSAcK:C00001517 + LINCS:LSM-1703 + PMID:11058832 + PMID:11069928 + PMID:11079273 + PMID:11080188 + PMID:11238591 + PMID:11256490 + PMID:11278005 + PMID:11315347 + PMID:11370709 + PMID:11406057 + PMID:11426833 + PMID:11442023 + PMID:11481617 + PMID:11493684 + PMID:11529914 + PMID:11557554 + PMID:11564166 + PMID:11676831 + PMID:11870366 + PMID:12021257 + PMID:12050171 + PMID:12603598 + PMID:12761440 + PMID:12929192 + PMID:12950728 + PMID:14521916 + PMID:14621732 + PMID:14638917 + PMID:14672695 + PMID:14682659 + PMID:14743390 + PMID:15030555 + PMID:15175101 + PMID:15210365 + PMID:15306697 + PMID:15383526 + PMID:15541012 + PMID:15613074 + PMID:15626898 + PMID:15657176 + PMID:1566062 + PMID:15711594 + PMID:15811524 + PMID:15962181 + PMID:16372476 + PMID:16404634 + PMID:16724420 + PMID:16801218 + PMID:16898534 + PMID:17032751 + PMID:17083576 + PMID:17117422 + PMID:17192032 + PMID:17220244 + PMID:17229932 + PMID:17265451 + PMID:17446460 + PMID:17603747 + PMID:18076075 + PMID:18171316 + PMID:18191430 + PMID:18217899 + PMID:18259730 + PMID:18299432 + PMID:18359899 + PMID:18583716 + PMID:18597363 + PMID:18790203 + PMID:18818682 + PMID:18931077 + PMID:18975184 + PMID:19282398 + PMID:19589783 + PMID:21752960 + PMID:23620378 + Patent:US4117118 + Reaxys:3647785 + VSDB:1765 + Wikipedia:Ciclosporin + 30-ethyl-33-[(4E)-1-hydroxy-2-methylhex-4-en-1-yl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-bis(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone + Cyclosporin A + chebi_ontology + (R-[R*,R*-(E)])-Cyclic(L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl-3-hydroxy-N,4-dimethyl-L-2-amino-6-octenoyl-L-alpha-aminobutyryl-N-methylglycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucyl) + 1,11-cyclo[L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl-(E)-(2S,3R,4R)-2-amino-3-hydroxy-N,4-dimethyloct-6-enoyl-L-2-aminobutanoyl-N-methylglycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucine] + 30-ethyl-33-[(4E)-1-hydroxy-2-methylhex-4-en-1-yl]-6,9,18,24-tetraisobutyl-3,21-diisopropyl-1,4,7,10,12,15,19,25,28-nonamethyl-1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone + Antibiotic S 7481F1 + C62H111N11O12 + CC[C@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C + Ciclosporin + Cyclo(L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl-((3R,4R,6E)-6,7-didehydro-3-hydroxy-N,4-dimethyl-L-2-aminooctanoyl)-L-2-aminobutanoyl-N-methylglycyl-N-methyl-L-leucyl-L-valyl-N-methylleucyl) + Cyclosporine + Gengraf + InChI=1S/C62H111N11O12/c1-25-27-28-40(15)52(75)51-56(79)65-43(26-2)58(81)67(18)33-48(74)68(19)44(29-34(3)4)55(78)66-49(38(11)12)61(84)69(20)45(30-35(5)6)54(77)63-41(16)53(76)64-42(17)57(80)70(21)46(31-36(7)8)59(82)71(22)47(32-37(9)10)60(83)72(23)50(39(13)14)62(85)73(51)24/h25,27,34-47,49-52,75H,26,28-33H2,1-24H3,(H,63,77)(H,64,76)(H,65,79)(H,66,78)/b27-25+/t40-,41+,42+,43-,44+,45-,46+,47+,49+,50-,51+,52-/m1/s1 + InChIKey=PMATZTZNYRCHOR-VJRYSDSKSA-N + Neoral + Sandimmune + ciclosporin + ciclosporina + ciclosporine + ciclosporinum + CHEBI:4031 + + Cyclosporine + cyclosporin A + + + + + + + + + + + + + + + + 0 + CHF3 + InChI=1S/CHF3/c2-1(3)4/h1H + XPDWGBQVDMORPB-UHFFFAOYSA-N + 70.01385 + 70.00303 + [H]C(F)(F)F + CHEBI:24073 + CHEBI:41543 + Beilstein:1731035 + CAS:75-46-7 + Gmelin:1543 + PDBeChem:CFT + UM-BBD_compID:c0802 + fluoroform + chebi_ontology + CHF3 + Freon 23 + Freon F-23 + TRIFLUOROMETHANE + carbon trifluoride + methyl trifluoride + CHEBI:41550 + + fluoroform + + + + + + + + + + + + + + + + -2 + CO3 + InChI=1S/CH2O3/c2-1(3)4/h(H2,2,3,4)/p-2 + BVKZGUZCCUSVTD-UHFFFAOYSA-L + 60.00890 + 59.98584 + [O-]C([O-])=O + CHEBI:29201 + CHEBI:41605 + Beilstein:3600898 + CAS:3812-32-6 + Gmelin:1559 + PDBeChem:CO3 + carbonate + trioxidocarbonate(2-) + chebi_ontology + CARBONATE ION + CO3(2-) + Karbonat + [CO3](2-) + CHEBI:41609 + + carbonate + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + 10324 + A tertiary amino compound that has formula C26H29NO. + + + 0 + C26H29NO + InChI=1S/C26H29NO/c1-4-25(21-11-7-5-8-12-21)26(22-13-9-6-10-14-22)23-15-17-24(18-16-23)28-20-19-27(2)3/h5-18H,4,19-20H2,1-3H3/b26-25- + NKANXQFJJICGDU-QPLCGJKRSA-N + 371.51460 + 371.22491 + CC\C(c1ccccc1)=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1 + CHEBI:41767 + CHEBI:9396 + Beilstein:2062020 + CAS:10540-29-1 + ChemIDplus:10540-29-1 + DrugBank:DB00675 + Drug_Central:2561 + HMDB:HMDB0014813 + KEGG COMPOUND:10540-29-1 + KEGG COMPOUND:C07108 + KEGG:C07108 + KEGG:D08559 + PMID:14681337 + PMID:14709804 + PMID:18348622 + PMID:7688593 + Patent:BE637389 + Patent:BE678807 + Patent:US4536516 + Wikipedia:Tamoxifen + 2-{4-[(1Z)-1,2-diphenylbut-1-en-1-yl]phenoxy}-N,N-dimethylethanamine + Tamoxifen + chebi_ontology + (Z)-2-(4-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylethanamine + (Z)-2-(para-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylamine + 1-p-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene + 1-para-beta-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene + Apo-Tamox + C26H29NO + CC\C(c1ccccc1)=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1 + Crisafeno + Diemon + InChI=1S/C26H29NO/c1-4-25(21-11-7-5-8-12-21)26(22-13-9-6-10-14-22)23-15-17-24(18-16-23)28-20-19-27(2)3/h5-18H,4,19-20H2,1-3H3/b26-25- + InChIKey=NKANXQFJJICGDU-QPLCGJKRSA-N + tamoxifen + tamoxifene + tamoxifeno + tamoxifenum + trans-Tamoxifen + CHEBI:41774 + + Tamoxifen + tamoxifen + + + + + + + + + + + + + + + + A 5beta-cardenolide that is 5beta-cardanolide with hydroxy substituents at the 3beta- and 14beta-positions and double bond unsaturation at C(20)-C(22). + + 0 + C23H34O4 + InChI=1S/C23H34O4/c1-21-8-5-16(24)12-15(21)3-4-19-18(21)6-9-22(2)17(7-10-23(19,22)26)14-11-20(25)27-13-14/h11,15-19,24,26H,3-10,12-13H2,1-2H3/t15-,16+,17-,18+,19-,21+,22-,23+/m1/s1 + XZTUSOXSLKTKJQ-CESUGQOBSA-N + 374.51366 + 374.24571 + [H][C@]12CC[C@]3([H])[C@]([H])(CC[C@]4(C)[C@]([H])(CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@H](O)C2 + CHEBI:38073 + CHEBI:42214 + Beilstein:95448 + CAS:143-62-4 + LIPID_MAPS_instance:LMST01120001 + PDBeChem:DTX + PMID:10438974 + Wikipedia:Digitoxigenin + 3beta,14-dihydroxy-5beta-card-20(22)-enolide + chebi_ontology + Cerberigenin + Echujetin + Evonogenin + Thevetigenin + CHEBI:42219 + + digitoxigenin + + + + + + + + + + 0 + HO + 17.00734 + 17.00274 + *O[H] + CHEBI:24706 + CHEBI:43171 + PDBeChem:OH + HYDROXY GROUP + hydroxy + hydroxy group + chebi_ontology + -OH + hydroxyl + hydroxyl group + CHEBI:43176 + + hydroxy group + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A phosphate ion that is the conjugate base of dihydrogenphosphate. + + -2 + HO4P + InChI=1S/H3O4P/c1-5(2,3)4/h(H3,1,2,3,4)/p-2 + NBIIXXVUZAFLBC-UHFFFAOYSA-L + 95.97930 + 95.96234 + OP([O-])([O-])=O + CHEBI:29139 + CHEBI:43470 + Gmelin:1998 + MolBase:1628 + PDBeChem:PI + PDBeChem:PO4 + hydrogen(tetraoxidophosphate)(2-) + hydrogenphosphate + hydrogentetraoxophosphate(2-) + hydrogentetraoxophosphate(V) + hydroxidotrioxidophosphate(2-) + chebi_ontology + HPO4(2-) + HYDROGENPHOSPHATE ION + INORGANIC PHOSPHATE GROUP + [P(OH)O3](2-) + [PO3(OH)](2-) + hydrogen phosphate + phosphate + CHEBI:43474 + + hydrogenphosphate + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + 85762 + An L-valine derivative that is L-valinamide in which alpha-amino group has been acylated by a [(2-isopropyl-1,3-thiazol-4-yl)methyl]methylcarbamoyl group and in which a hydrogen of the carboxamide amino group has been replaced by a (2R,4S,5S)-4-hydroxy-1,6-diphenyl-5-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}hexan-2-yl group. A CYP3A inhibitor and antiretroviral drug from the protease inhibitor class used to treat HIV infection and AIDS, it is often used as a fixed-dose combination with another protease inhibitor, lopinavir. Also used in combination with dasabuvir sodium hydrate, ombitasvir and paritaprevir (under the trade name Viekira Pak) for treatment of chronic hepatitis C virus genotype 1 infection as well as cirrhosis of the liver. + + + 0 + C37H48N6O5S2 + InChI=1S/C37H48N6O5S2/c1-24(2)33(42-36(46)43(5)20-29-22-49-35(40-29)25(3)4)34(45)39-28(16-26-12-8-6-9-13-26)18-32(44)31(17-27-14-10-7-11-15-27)41-37(47)48-21-30-19-38-23-50-30/h6-15,19,22-25,28,31-33,44H,16-18,20-21H2,1-5H3,(H,39,45)(H,41,47)(H,42,46)/t28-,31-,32-,33-/m0/s1 + NCDNCNXCDXHOMX-XGKFQTDJSA-N + 720.94400 + 720.31276 + CC(C)[C@H](NC(=O)N(C)Cc1csc(n1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](Cc1ccccc1)NC(=O)OCc1cncs1)Cc1ccccc1 + CHEBI:8873 + CAS:155213-67-5 + Drug_Central:2391 + HMDB:HMDB0014646 + KEGG:C07240 + KEGG:D00427 + LINCS:LSM-5623 + PDBeChem:RIT + PMID:11363086 + PMID:11363184 + PMID:11363300 + PMID:11363329 + PMID:11363397 + PMID:11363517 + PMID:11996889 + PMID:24202050 + PMID:8568292 + PMID:9140265 + PMID:9278209 + PMID:9585800 + Reaxys:768009 + Wikipedia:Ritonavir + N-[(2S,4S,5S)-4-hydroxy-1,6-diphenyl-5-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}hexan-2-yl]-N(2)-(methyl{[2-(propan-2-yl)-1,3-thiazol-4-yl]methyl}carbamoyl)-L-valinamide + chebi_ontology + ritonavir + CHEBI:45409 + + Ritonavir + ritonavir + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cardenolide glycoside that is digitoxin beta-hydroxylated at C-12. A cardiac glycoside extracted from the foxglove plant, Digitalis lanata, it is used to control ventricular rate in atrial fibrillation and in the management of congestive heart failure with atrial fibrillation, but the margin between toxic and therapeutic doses is small. + + 0 + C41H64O14 + InChI=1S/C41H64O14/c1-19-36(47)28(42)15-34(50-19)54-38-21(3)52-35(17-30(38)44)55-37-20(2)51-33(16-29(37)43)53-24-8-10-39(4)23(13-24)6-7-26-27(39)14-31(45)40(5)25(9-11-41(26,40)48)22-12-32(46)49-18-22/h12,19-21,23-31,33-38,42-45,47-48H,6-11,13-18H2,1-5H3/t19-,20-,21-,23-,24+,25-,26-,27+,28+,29+,30+,31-,33+,34+,35+,36-,37-,38-,39+,40+,41+/m1/s1 + LTMHDMANZUZIPE-PUGKRICDSA-N + 780.93850 + 780.42961 + [H][C@]12CC[C@]3([H])[C@]([H])(C[C@@H](O)[C@]4(C)[C@H](CC[C@]34O)C3=CC(=O)OC3)[C@@]1(C)CC[C@@H](C2)O[C@H]1C[C@H](O)[C@H](O[C@H]2C[C@H](O)[C@H](O[C@H]3C[C@H](O)[C@H](O)[C@@H](C)O3)[C@@H](C)O2)[C@@H](C)O1 + CHEBI:41856 + CHEBI:569365 + CHEBI:616935 + Beilstein:77011 + CAS:20830-75-5 + DrugBank:DB00390 + Drug_Central:882 + KEGG:C06956 + KEGG:D00298 + KNApSAcK:C00003618 + PDB:1IGJ + PDBeChem:DGX + PMID:10438974 + PMID:16970134 + PMID:7739045 + PMID:8234291 + Reaxys:77011 + Wikipedia:Digoxin + (3beta,5beta,12beta)-3-{[2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl]oxy}-12,14-dihydroxycard-20(22)-enolide + chebi_ontology + 12beta-hydroxydigitoxin + digoxin + CHEBI:4551 + + digoxin + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A benzamide obtained by formal condensation of the carboxy group of 4-[(4-methylpiperazin-1-yl)methyl]benzoic acid with the primary aromatic amino group of 4-methyl-N(3)-[4-(pyridin-3-yl)pyrimidin-2-yl]benzene-1,3-diamine. Used (as its mesylate salt) for treatment of chronic myelogenous leukemia and gastrointestinal stromal tumours. + + 0 + C29H31N7O + InChI=1S/C29H31N7O/c1-21-5-10-25(18-27(21)34-29-31-13-11-26(33-29)24-4-3-12-30-19-24)32-28(37)23-8-6-22(7-9-23)20-36-16-14-35(2)15-17-36/h3-13,18-19H,14-17,20H2,1-2H3,(H,32,37)(H,31,33,34) + KTUFNOKKBVMGRW-UHFFFAOYSA-N + 493.60270 + 493.25901 + CN1CCN(Cc2ccc(cc2)C(=O)Nc2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)CC1 + CHEBI:305376 + CHEBI:38918 + CHEBI:45781 + Beilstein:7671333 + CAS:152459-95-5 + DrugBank:DB00619 + Drug_Central:1423 + HMDB:HMDB0014757 + KEGG:D08066 + LINCS:LSM-1023 + PDBeChem:STI + PMID:14660054 + PMID:14715630 + PMID:15073101 + PMID:15170967 + PMID:15722647 + PMID:15794712 + PMID:15966213 + PMID:16122278 + PMID:16826359 + PMID:16983347 + PMID:17190842 + PMID:17410337 + PMID:17457302 + PMID:17717205 + PMID:18193246 + PMID:18216472 + PMID:18337118 + PMID:18344535 + PMID:18376233 + PMID:18407734 + PMID:18420270 + PMID:18423008 + PMID:18548219 + PMID:18623899 + PMID:18780518 + PMID:18809244 + PMID:19020005 + PMID:19052981 + PMID:19077095 + PMID:19097599 + PMID:19182535 + PMID:19242505 + PMID:19415889 + PMID:19527930 + PMID:19591692 + PMID:19693287 + PMID:19749465 + PMID:19810774 + PMID:19853594 + PMID:19920908 + PMID:22891806 + PMID:23075630 + PMID:23183914 + PMID:23313020 + PMID:23394269 + PMID:23480638 + PMID:23503753 + PMID:23536338 + PMID:23574742 + PMID:23580311 + PMID:23587588 + Patent:EP564409 + Patent:US5521184 + Reaxys:7671333 + Wikipedia:Imatinib + 4-[(4-methylpiperazin-1-yl)methyl]-N-{4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl}benzamide + chebi_ontology + 4-(4-METHYL-PIPERAZIN-1-YLMETHYL)-N-[4-METHYL-3-(4-PYRIDIN-3-YL-PYRIMIDIN-2-YLAMINO)-PHENYL]-BENZAMIDE + STI 571 + alpha-(4-methyl-1-piperazinyl)-3'-((4-(3-pyridyl)-2-pyrimidinyl)amino)-p-toluidide + imatinib + CHEBI:45783 + + imatinib + + + + + + + + + + 0 + O + 15.99940 + 15.99491 + O=* + CHEBI:29353 + CHEBI:44607 + PDBeChem:O + OXO GROUP + oxo + chebi_ontology + =O + CHEBI:46629 + + oxo group + + + + + + + + + + 0 + C22H28N2O5 + InChI=1S/C22H28N2O5/c1-28-12-3-4-13-14-5-6-24-10-11-7-18(25)21(29-2)19(22(26)27)15(11)9-17(24)20(14)23-16(13)8-12/h3-4,8,11,15,17-19,21,23,25H,5-7,9-10H2,1-2H3,(H,26,27)/t11-,15+,17-,18-,19+,21+/m1/s1 + JVHNBFFHWQQPLL-WOXROFTLSA-N + 400.46820 + 400.19982 + [H][C@]12C[C@@H](O)[C@H](OC)[C@@H](C(O)=O)[C@@]1([H])C[C@@]1([H])N(CCc3c1[nH]c1cc(OC)ccc31)C2 + Beilstein:98529 + CAS:83-60-3 + LINCS:LSM-2712 + (3beta,16beta,17alpha,18beta,20alpha)-18-hydroxy-11,17-dimethoxyyohimban-16-carboxylic acid + reserpic acid + chebi_ontology + 18beta-hydroxy-11,17alpha-dimethoxy-3beta,20alpha-yohimban-16beta-carboxylic acid + reserpinolic acid + CHEBI:46690 + + reserpic acid + + + + + + + + + + chebi_ontology + hydroxypyrrolidines + CHEBI:46773 + + hydroxypyrrolidine + + + + + + + + + + chebi_ontology + monohydroxypyrrolidines + CHEBI:46777 + + monohydroxypyrrolidine + + + + + + + + + + A liquid that can dissolve other substances (solutes) without any change in their chemical composition. + + Wikipedia:Solvent + chebi_ontology + Loesungsmittel + solvant + solvents + CHEBI:46787 + + solvent + + + + + + + + + + + + chebi_ontology + N-alkylpiperazines + CHEBI:46845 + + N-alkylpiperazine + + + + + + + + + + + + chebi_ontology + N-arylpiperazines + CHEBI:46848 + + N-arylpiperazine + + + + + + + + + + + chebi_ontology + N-(2-hydroxyethyl)piperazines + CHEBI:46851 + + N-(2-hydroxyethyl)piperazine + + + + + + + + + + + chebi_ontology + indolyl carboxylic acids + CHEBI:46867 + + indolyl carboxylic acid + + + + + + + + + + 0 + CHO2 + 45.01744 + 44.99765 + *C(=O)O + CHEBI:23025 + CHEBI:41420 + PDBeChem:FMT + CARBOXY GROUP + carboxy + chebi_ontology + -C(O)OH + -CO2H + -COOH + carboxyl group + CHEBI:46883 + + carboxy group + + + + + + + + + + A compound consisting of a peptide with attached lipid. + + PMID:19889045 + PMID:20545290 + PMID:23131643 + PMID:23318669 + Wikipedia:Lipopeptide + chebi_ontology + LP + lipopeptides + CHEBI:46895 + + lipopeptide + + + + + + + + + + + chebi_ontology + N-methylpiperazines + CHEBI:46920 + + N-methylpiperazine + + + + + + + + + + + chebi_ontology + CHEBI:46926 + + dioxanes + + + + + + + + + + Any organic heteromonocyclic compoundthat is oxane or its substituted derivatives. + + chebi_ontology + tetrahydropyrans + CHEBI:46942 + + oxanes + + + + + + + + + + + + chebi_ontology + oxazinanes + CHEBI:46952 + + oxazinane + + + + + + + + + An amino acid derivative resulting from reaction of leucine at the amino group or the carboxy group, or from the replacement of any hydrogen of leucine by a heteroatom. The definition normally excludes peptides containing leucine residues. + + chebi_ontology + CHEBI:47003 + + leucine derivative + + + + + + + + + + chebi_ontology + tetrahydrofuranols + CHEBI:47017 + + tetrahydrofuranol + + + + + + + + + + chebi_ontology + monohydroxytetrahydrofurans + CHEBI:47018 + + monohydroxytetrahydrofuran + + + + + + + + + double-stranded DNA + + + double-stranded DNA + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A steroid hormone that is a multi-hydroxylated alpha-L-rhamnosyl cardenoloide. It binds to and inhibits the plasma membrane Na(+)/K(+)-ATPase (sodium pump). It has been isolated naturally from Strophanthus gratus. + + 0 + C29H44O12 + InChI=1S/C29H44O12/c1-13-22(34)23(35)24(36)25(40-13)41-15-8-19(32)28(12-30)21-17(3-5-27(28,37)9-15)29(38)6-4-16(14-7-20(33)39-11-14)26(29,2)10-18(21)31/h7,13,15-19,21-25,30-32,34-38H,3-6,8-12H2,1-2H3/t13-,15-,16+,17+,18+,19+,21+,22-,23+,24+,25-,26+,27-,28+,29-/m0/s1 + LPMXVESGRSUGHW-HBYQJFLCSA-N + 584.65250 + 584.28328 + [H][C@@]12CC[C@]3(O)C[C@H](C[C@@H](O)[C@]3(CO)[C@@]1([H])[C@H](O)C[C@]1(C)[C@H](CC[C@]21O)C1=CC(=O)OC1)O[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O + CHEBI:44461 + CHEBI:7805 + Beilstein:101712 + CAS:630-60-4 + DrugBank:DB01092 + Drug_Central:2004 + HMDB:HMDB0015224 + KEGG:C01443 + KEGG:D00112 + KNApSAcK:C00003633 + LINCS:LSM-2781 + LIPID_MAPS_instance:LMST01120022 + PDBeChem:OBN + PMID:10438974 + PMID:1316269 + PMID:16529963 + PMID:20372980 + PMID:9872395 + Reaxys:101712 + Wikipedia:Ouabain + 3-(6-deoxy-alpha-L-mannopyranosyloxy)-1beta,5beta,11alpha,14,19-pentahydroxy-5beta-card-20(22)-enolide + Ouabain + chebi_ontology + 3-(alpha-L-rhamnopyranosyloxy)-1beta,5beta,11alpha,14,19-pentahydroxy-5beta-card-20(22)-enolide + G-Strophanthin + Ouabagenin L-Rhamnoside + Ouabagenin-L-rhamnosid + Ouabain anhydrous + Ouabaine + Oubain + Strodival + CHEBI:472805 + + ouabain + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A dibenzoazepine that is 5H-dibenzo[b,f]azepine substituted by a 3-(dimethylamino)propyl group at the nitrogen atom. + + 0 + C19H24N2 + InChI=1S/C19H24N2/c1-20(2)14-7-15-21-18-10-5-3-8-16(18)12-13-17-9-4-6-11-19(17)21/h3-6,8-11H,7,12-15H2,1-2H3 + BCGWQEUPMDMJNV-UHFFFAOYSA-N + 280.40734 + 280.19395 + CN(C)CCCN1c2ccccc2CCc2ccccc12 + CHEBI:47498 + CHEBI:5881 + Beilstein:256892 + CAS:50-49-7 + DrugBank:DB00458 + Drug_Central:1427 + Gmelin:1572523 + HMDB:HMDB0001848 + KEGG:C07049 + KEGG:D08070 + LINCS:LSM-2852 + PDBeChem:IXX + PMID:20825390 + Patent:US2554736 + Reaxys:256892 + Wikipedia:Imipramine + 3-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethylpropan-1-amine + Imipramine + chebi_ontology + 10,11-dihydro-N,N-dimethyl-5H-dibenz[b,f]azepine-5-propanamine + 3-(5H-DIBENZO[B,F]AZEPIN-5-YL)-N,N-DIMETHYLPROPAN-1-AMINE + 5-[3-(dimethylamino)propyl]-10,11-dihydro-5H-dibenz[b,f]azepine + Antideprin + Imipramin + Irmin + Melipramine + N-(gamma-dimethylaminopropyl)iminodibenzyl + imipramine + imipraminum + imizine + CHEBI:47499 + + imipramine + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A peptide antibiotic that is vancomycin lacking the disaccharide moiety. + + 0 + C53H52Cl2N8O17 + InChI=1S/C53H52Cl2N8O17/c1-19(2)10-29(57-3)47(71)62-42-44(68)21-5-8-33(27(54)12-21)79-35-14-23-15-36(46(35)70)80-34-9-6-22(13-28(34)55)45(69)43-52(76)61-41(53(77)78)26-16-24(64)17-32(66)38(26)25-11-20(4-7-31(25)65)39(49(73)63-43)60-50(74)40(23)59-48(72)30(18-37(56)67)58-51(42)75/h4-9,11-17,19,29-30,39-45,57,64-66,68-70H,10,18H2,1-3H3,(H2,56,67)(H,58,75)(H,59,72)(H,60,74)(H,61,76)(H,62,71)(H,63,73)(H,77,78)/t29-,30+,39-,40-,41+,42-,43+,44-,45-/m1/s1 + JHIKFOISFAQTJQ-YZANBJIASA-N + 1143.92900 + 1142.28275 + CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)c2ccc(Oc3cc4cc(Oc5ccc(cc5Cl)[C@@H](O)[C@@H]5NC(=O)[C@H](NC(=O)[C@@H]4NC(=O)[C@H](CC(N)=O)NC1=O)c1ccc(O)c(c1)-c1c(O)cc(O)cc1[C@H](NC5=O)C(O)=O)c3O)c(Cl)c2 + CAS:82198-76-3 + MetaCyc:CPD-15745 + PMID:11470430 + PMID:14649827 + PMID:15785812 + PMID:22177724 + Reaxys:6049255 + (1S,2R,18R,19R,22S,25R,28R,40S)-22-(2-amino-2-oxoethyl)-5,15-dichloro-2,18,32,35,37,48-hexahydroxy-19-{[(2R)-4-methyl-2-(methylamino)pentanoyl]amino}-20,23,26,42,44-pentaoxo-7,13-dioxa-21,24,27,41,43-pentaazaoctacyclo[26.14.2.2(3,6).2(14,17).1(8,12).1(29,33).0(10,25).0(34,39)]pentaconta-3,5,8(48),9,11,14,16,29(45),30,32,34,36,38,46,49-pentadecaene-40-carboxylic acid + chebi_ontology + Aglucovancomycin B + Balhimycin aglycon + CHEBI:47724 + + vancomycin aglycone + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + 2597 + A dibenzoazepine that is 10,11-dihydro-5H-dibenzo[b,f]azepine which is substituted by chlorine at position 3 and in which the hydrogen attached to the nitrogen is replaced by a 3-(dimethylamino)propyl group. One of the more sedating tricyclic antidepressants, it is used as the hydrochloride salt for the treatment of depression as well as obsessive-compulsive disorder and phobias. + + + 0 + C19H23ClN2 + InChI=1S/C19H23ClN2/c1-21(2)12-5-13-22-18-7-4-3-6-15(18)8-9-16-10-11-17(20)14-19(16)22/h3-4,6-7,10-11,14H,5,8-9,12-13H2,1-2H3 + GDLIGKIOYRNHDA-UHFFFAOYSA-N + 314.85210 + 314.15498 + CN(C)CCCN1c2ccccc2CCc2ccc(Cl)cc12 + CHEBI:3754 + CHEBI:47359 + Beilstein:1323477 + CAS:303-49-1 + ChemIDplus:1323477 + ChemIDplus:303-49-1 + CiteXplore:12007764 + CiteXplore:12084414 + CiteXplore:16085036 + CiteXplore:17471183 + CiteXplore:19810911 + DrugBank:DB01242 + Drug_Central:701 + KEGG COMPOUND:303-49-1 + KEGG COMPOUND:C06918 + KEGG:C06918 + KEGG:D07727 + LINCS:LSM-3171 + NIST Chemistry WebBook:303-49-1 + PDBeChem:CXX + PMID:12007764 + PMID:12084414 + PMID:16085036 + PMID:17471183 + PMID:19747949 + PMID:19810911 + Patent:CH371799 + Patent:US3467650 + Reaxys:1323477 + Wikipedia:Clomipramine + 3-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethylpropan-1-amine + Clomipramine + chebi_ontology + 3-(3-CHLORO-5H-DIBENZO[B,F]AZEPIN-5-YL)-N,N-DIMETHYLPROPAN-1-AMINE + 3-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethyl-1-propanamine + 3-chloroimipramine + C19H23ClN2 + CN(C)CCCN1c2ccccc2CCc2ccc(Cl)cc12 + G 34586 + InChI=1S/C19H23ClN2/c1-21(2)12-5-13-22-18-7-4-3-6-15(18)8-9-16-10-11-17(20)14-19(16)22/h3-4,6-7,10-11,14H,5,8-9,12-13H2,1-2H3 + InChIKey=GDLIGKIOYRNHDA-UHFFFAOYSA-N + chlorimipramine + monochlorimipramine + CHEBI:47780 + + Clomipramine + clomipramine + + + + + + + + + + Any oxo steroid where an oxo substituent is located at position 3. + + 0 + C19H29OR + 273.434 + 273.22184 + C12C(C3C(C(CC3)*)(C)CC1)CCC4C2(CCC(C4)=O)C + CHEBI:13607 + CHEBI:1653 + CHEBI:20182 + CHEBI:71186 + KEGG:C01876 + MetaCyc:3-Oxosteroids + PMID:9811880 + chebi_ontology + 3-Oxosteroid + 3-oxo steroids + 3-oxosteroids + a 3-oxosteroid + CHEBI:47788 + + 3-oxo steroid + + + + + + + + + + + + + + + + A mancude organic heterotricyclic parent that consists of a seven-membered nitrogen hetrocycle fused with two benzene rings. + + 0 + C14H11N + InChI=1S/C14H11N/c1-3-7-13-11(5-1)9-10-12-6-2-4-8-14(12)15-13/h1-10,15H + LCGTWRLJTMHIQZ-UHFFFAOYSA-N + 193.24388 + 193.08915 + N1c2ccccc2C=Cc2ccccc12 + Beilstein:1343358 + CAS:256-96-2 + PMID:22322005 + PMID:24358274 + Reaxys:1343358 + Wikipedia:Dibenzazepine + 5H-dibenzo[b,f]azepine + chebi_ontology + 2,2'-iminostilbene + 2,3,6,7-dibenzazepine + 5H-Dibenz[b,f]azepin + 5H-dibenz[b,f]azepine + 5H-dibenzazepine + dibenz(b,f)azepine + dibenzazepine + iminostilbene + o,o'-iminostilbene + CHEBI:47802 + + 5H-dibenzo[b,f]azepine + + + + + + + + + + + + dibenzoazepine + chebi_ontology + dibenzazepine + dibenzoazepines + CHEBI:47804 + + dibenzoazepine + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A pyridoisoquinoline comprising emetam having methoxy substituents at the 6'-, 7'-, 10- and 11-positions. It is an antiprotozoal agent and emetic. It inhibits SARS-CoV2, Zika and Ebola virus replication and displays antimalarial, antineoplastic and antiamoebic properties. + + 0 + C29H40N2O4 + InChI=1S/C29H40N2O4/c1-6-18-17-31-10-8-20-14-27(33-3)29(35-5)16-23(20)25(31)12-21(18)11-24-22-15-28(34-4)26(32-2)13-19(22)7-9-30-24/h13-16,18,21,24-25,30H,6-12,17H2,1-5H3/t18-,21-,24+,25-/m0/s1 + AUVVAXYIELKVAI-CKBKHPSWSA-N + 480.63898 + 480.29881 + [H][C@]1(C[C@@]2([H])NCCc3cc(OC)c(OC)cc23)C[C@]2([H])N(CCc3cc(OC)c(OC)cc23)C[C@@H]1CC + Beilstein:100834 + Beilstein:6253162 + CAS:483-18-1 + DrugBank:DB13393 + Drug_Central:1001 + KEGG:C09421 + KNApSAcK:C00001849 + LINCS:LSM-2041 + MetaCyc:CPD-14817 + PMID:14119536 + PMID:16109351 + PMID:17094176 + PMID:19227966 + PMID:29872540 + PMID:31436297 + PMID:31533472 + PMID:31734270 + PMID:31775307 + PMID:31964796 + PMID:32245264 + PMID:32251767 + Reaxys:100834 + Wikipedia:Emetine + 6',7',10,11-tetramethoxyemetan + Emetine + chebi_ontology + Emetan + Emetin + cephaeline methyl ether + cephaline-O-methyl ether + methyl cephaeline + CHEBI:4781 + + emetine + + + + + + + + + + + + + + + + CHEBI:27220 + CHEBI:36947 + chebi_ontology + urea derivatives + CHEBI:47857 + + ureas + + + + + + + + + A chemical compound that can be excited by light of a specific wavelength and subsequently transfer energy to a chosen reactant. This is commonly molecular oxygen within a cancer tissue, which is converted to (highly rective) singlet state oxygen. This rapidly reacts with any nearby biomolecules, ultimately killing the cancer cells. + + chebi_ontology + photosensitising agent + CHEBI:47868 + + photosensitizing agent + + + + + + + + + + + + + + + Organic derivatives of sulfonic acid in which the sulfo group is linked directly to carbon of an alkyl group. + + CHEBI:13809 + CHEBI:33553 + chebi_ontology + alkanesulfonic acids + alkylsulfonic acids + CHEBI:47901 + + alkanesulfonic acid + + + + + + + + + + + + + + + + A 3-oxo steroid conjugated to a C=C double bond at the alpha,beta position. + + 0 + C19H27OR + 271.418 + 271.20619 + C12C(C3C(C(CC3)*)(C)CC1)CCC=4C2(CCC(C4)=O)C + CHEBI:13604 + CHEBI:1626 + CHEBI:20157 + KEGG:C00619 + MetaCyc:3-Oxo-Delta-4-Steroids + chebi_ontology + 3-Oxo-delta4-steroid + 3-oxo Delta(4)-steroid + 3-oxo Delta(4)-steroids + 3-oxo-Delta(4) steroids + a 3-oxo-Delta(4)-steroid + CHEBI:47909 + + 3-oxo-Delta(4) steroid + + + + + + + + + + + + + + + + + + + + + Any member of the 'superclass' flavonoids whose skeleton is based on 1-benzopyran with an aryl substituent at position 2. The term was originally restricted to natural products, but is now also used to describe semi-synthetic and fully synthetic compounds. + + CHEBI:13638 + CHEBI:24044 + CHEBI:5077 + KEGG:C01579 + Wikipedia:Flavonoid + Flavonoid + chebi_ontology + 2-aryl-1-benzopyran + 2-aryl-1-benzopyrans + flavonoids + CHEBI:47916 + + flavonoid + + + + + + + + + + Ethers ROR' where R has a double bond adjacent to the oxygen of the ether linkage. + + 0 + C2OR4 + 40.02080 + 39.99491 + [*]\C([*])=C(\[*])O[*] + enol ether + chebi_ontology + enol ethers + CHEBI:47985 + + enol ether + + + + + + + + + A compound, usually an anti-bacterial agent or a toxin, which inhibits the synthesis of a protein. + + chebi_ontology + protein synthesis antagonist + protein synthesis antagonists + protein synthesis inhibitors + CHEBI:48001 + + protein synthesis inhibitor + + + + + + + + + + + chebi_ontology + Schwefeloxide + oxides of sulfur + sulfur oxides + CHEBI:48154 + + sulfur oxide + + + + + + + + + A substance used locally on humans and other animals to destroy harmful microorganisms or to inhibit their activity (cf. disinfectants, which destroy microorganisms found on non-living objects, and antibiotics, which can be transported through the lymphatic system to destroy bacteria within the body). + + Wikipedia:Antiseptic + chebi_ontology + antiseptic + antiseptic agent + antiseptic agents + antiseptics + local antiinfective agents + local microbicides + topical antiinfective agents + topical microbicides + CHEBI:48218 + + antiseptic drug + + + + + + + + + An antimicrobial agent that is applied to non-living objects to destroy harmful microorganisms or to inhibit their activity. + + chebi_ontology + Desinfektionsmittel + desinfectant + disinfectants + disinfecting agent + CHEBI:48219 + + disinfectant + + + + + + + + + + chebi_ontology + serotonergic agents + serotonergic drugs + serotonin drugs + CHEBI:48278 + + serotonergic drug + + + + + + + + + Drugs that bind to but do not activate serotonin receptors, thereby blocking the actions of serotonin or serotonergic agonists. + + chebi_ontology + 5-HT antagonists + 5-hydroxytryptamine antagonists + antiserotonergic agents + serotonin antagonists + serotonin blockaders + CHEBI:48279 + + serotonergic antagonist + + + + + + + + + A substance, extract, or preparation for diffusing or imparting an agreeable or attractive smell. + + chebi_ontology + Parfuem + aroma + arome + essence + parfum + perfume + scent + CHEBI:48318 + + fragrance + + + + + + + + + A solvent that is composed of polar molecules. Polar solvents can dissolve ionic compounds or ionisable covalent compounds. + + polar solvent + chebi_ontology + polar solvents + CHEBI:48354 + + polar solvent + + + + + + + + + + chebi_ontology + CHEBI:48355 + + non-polar solvent + + + + + + + + + + A polar solvent that is capable of acting as a hydron (proton) donor. + + protogenic solvent + chebi_ontology + CHEBI:48356 + + protic solvent + + + + + + + + + + chebi_ontology + CHEBI:48357 + + aprotic solvent + + + + + + + + + + A solvent with a comparatively high relative permittivity (or dielectric constant), greater than ca. 15, and a sizable permanent dipole moment, that cannot donate suitably labile hydrogen atoms to form strong hydrogen bonds. + + dipolar aprotic solvent + chebi_ontology + CHEBI:48358 + + polar aprotic solvent + + + + + + + + + + + chebi_ontology + CHEBI:48359 + + protophilic solvent + + + + + + + + + + + chebi_ontology + CHEBI:48360 + + amphiprotic solvent + + + + + + + + + + + + + + + + + 0 + CH4N2O + InChI=1S/CH4N2O/c2-1(3)4/h(H4,2,3,4) + XSQUKJJJFZCRTK-UHFFFAOYSA-N + 60.05534 + 60.03236 + NC(O)=N + Beilstein:773698 + CAS:4744-36-9 + carbamimidic acid + chebi_ontology + H2N-C(=NH)-OH + H2N-C(OH)=NH + HO-C(=NH)-NH2 + Isoharnstoff + carbamimic acid + carbonamidimidic acid + isourea + pseudourea + CHEBI:48376 + + carbamimidic acid + + + + + + + + + + Compounds derived from oxoacids RkE(=O)l(OH)m (l =/= 0) by replacing =O by =NR; thus tautomers of amides. In organic chemistry an unspecified imidic acid is generally a carboximidic acid, RC(=NR)(OH). + + imidic acid + imidic acids + chebi_ontology + imidic acids + imino acids + CHEBI:48377 + + imidic acid + + + + + + + + + + + carboximidic acid + carboximidic acids + chebi_ontology + carboximidic acids + CHEBI:48378 + + carboximidic acid + + + + + + + + + A carboximidic acid that is the imidic acid tautomer of urea, H2NC(=NH)OH, and its hydrocarbyl derivatives. + + isoureas + chebi_ontology + isoureas + CHEBI:48379 + + isourea + + + + + + + + + A drug used in the treatment of Parkinson's disease. + + Wikipedia:Antiparkinson + chebi_ontology + antiparkinson agent + CHEBI:48407 + + antiparkinson drug + + + + + + + + + An agent and endogenous substances that antagonize or inhibit the development of new blood vessels. + + CHEBI:67170 + Wikipedia:Angiogenesis_inhibitor + chebi_ontology + angiogenesis antagonist + angiostatic agents + anti-angiogenic agent + CHEBI:48422 + + angiogenesis inhibitor + + + + + + + + + + + + + + + Esters or salts of methanesulfonic acid. + + chebi_ontology + CHEBI:48544 + + methanesulfonates + + + + + + + + + + phenylindole + chebi_ontology + phenylindoles + CHEBI:48559 + + phenylindole + + + + + + + + + A drug used for its effects on dopamine receptors, on the life cycle of dopamine, or on the survival of dopaminergic neurons. + + chebi_ontology + dopamine agent + dopamine agents + dopamine drug + dopamine drugs + dopaminergic agents + CHEBI:48560 + + dopaminergic agent + + + + + + + + + A drug that binds to but does not activate dopamine receptors, thereby blocking the actions of dopamine or exogenous agonists. + + chebi_ontology + dopamine antagonist + dopamine blocker + dopamine receptor antagonist + dopaminergic antagonists + CHEBI:48561 + + dopaminergic antagonist + + + + + + + + + A role played by a substance that can react readily with, and thereby eliminate, radicals. + + chebi_ontology + free radical scavengers + free-radical scavenger + CHEBI:48578 + + radical scavenger + + + + + + + + + + + chebi_ontology + piperidone + CHEBI:48589 + + piperidones + + + + + + + + + Substance which binds to cell receptors normally responding to naturally occurring substances and which produces a response of its own. + + agonist + chebi_ontology + agonista + agoniste + agonists + CHEBI:48705 + + agonist + + + + + + + + + Substance that attaches to and blocks cell receptors that normally bind naturally occurring substances. + + antagonist + chebi_ontology + antagonista + antagoniste + antagonists + CHEBI:48706 + + antagonist + + + + + + + + + + + + + + + + 0 + CN + 26.017 + 26.00307 + C(#N)* + CHEBI:36824 + CHEBI:48818 + PDBeChem:CYN + cyanido + cyano + chebi_ontology + -C#N + -CN + CYANIDE GROUP + NC- + carbonitrile group + CHEBI:48819 + + cyano group + + + + + + + + + + + + + + + + + + + + + + 0 + H2O3S + InChI=1S/H2O3S/c1-4(2)3/h(H2,1,2,3) + LSNNMFCWUKXFEE-UHFFFAOYSA-N + 82.08008 + 81.97247 + OS(O)=O + CHEBI:26837 + CHEBI:9344 + CAS:7782-99-2 + Gmelin:1458 + KEGG:C00094 + KNApSAcK:C00019662 + PDBeChem:SO3 + UM-BBD_compID:c0348 + Sulfurous acid + dihydrogen trioxosulfate + dihydroxidooxidosulfur + sulfurous acid + trioxosulfuric acid + chebi_ontology + H2SO3 + S(O)(OH)2 + Sulfite + [SO(OH)2] + acide sulfureux + acido sulfuroso + schweflige Saeure + sulphurous acid + CHEBI:48854 + + sulfurous acid + + + + + + + + + Any drug that binds to but does not activate cholinergic receptors, thereby blocking the actions of acetylcholine or cholinergic agonists. + + chebi_ontology + Anticholinergika + Anticholinergikum + acetylcholine antagonists + acetylcholine receptor antagonist + agent anticholinergique + agente anticolinergico + agentes anticolinergicos + anticholinergic agents + anticholinergics + anticholinergiques + anticolinergicos + cholinergic-blocking agents + CHEBI:48873 + + cholinergic antagonist + + + + + + + + + A drug that binds to but does not activate muscarinic cholinergic receptors, thereby blocking the actions of endogenous acetylcholine or exogenous agonists. + + chebi_ontology + Antimuskarinika + Antimuskarinikum + agente antimuscarinico + agentes antimuscarinicos + agents antimuscariniques + antimuscarinic agents + antimuscarinicos + muscarinic acetylcholine receptor antagonist + muscarinic antagonists + CHEBI:48876 + + muscarinic antagonist + + + + + + + + + + + chebi_ontology + pyridoindoles + CHEBI:48888 + + pyridoindole + + + + + + + + + + + + + An azole in which the five-membered heterocyclic aromatic skeleton contains a N atom and one S atom. + + + chebi_ontology + thiazole + CHEBI:48901 + + thiazoles + + + + + + + + + + + 0 + C38H42N2O6 + InChI=1S/C38H42N2O6/c1-39-15-13-25-20-32(42-4)34-22-28(25)29(39)17-23-7-10-27(11-8-23)45-33-19-24(9-12-31(33)41-3)18-30-36-26(14-16-40(30)2)21-35(43-5)37(44-6)38(36)46-34/h7-12,19-22,29-30H,13-18H2,1-6H3/t29-,30-/m0/s1 + WVTKBKWTSCPRNU-KYJUHHDHSA-N + 622.751 + 622.30429 + COc1ccc2C[C@@H]3N(C)CCc4cc(OC)c(OC)c(Oc5cc6[C@H](Cc7ccc(Oc1c2)cc7)N(C)CCc6cc5OC)c34 + CAS:518-34-3 + KEGG:C09654 + KNApSAcK:C00001919 + KNApSAcK:C00025278 + LINCS:LSM-6539 + (+)-Tetrandrine + chebi_ontology + Tetrandrine + CHEBI:49 + + (+)-Tetrandrine + + + + + + + + + + A chemical substance which inhibits the function of the endocrine glands, the biosynthesis of their secreted hormones, or the action of hormones upon their specific sites. + + chebi_ontology + hormone antagonists + CHEBI:49020 + + hormone antagonist + + + + + + + + + A compound that inhibits the action of prostaglandins. + + Wikipedia:Prostaglandin_antagonist + chebi_ontology + prostaglandin inhibitor + CHEBI:49023 + + prostaglandin antagonist + + + + + + + + + + chebi_ontology + drug metabolites + CHEBI:49103 + + drug metabolite + + + + + + + + + + A drug used to treat asthma. + + chebi_ontology + anti-asthmatic agent + anti-asthmatic agents + anti-asthmatic drugs + CHEBI:49167 + + anti-asthmatic drug + + + + + + + + + An EC 3.6.3.* (acid anhydride hydrolase catalysing transmembrane movement of substances) inhibitor that inhibits H(+)/K(+)-exchanging ATPase, EC 3.6.3.10. Such compounds are also known as proton pump inhibitors. + + Wikipedia:Proton_pump_inhibitor + chebi_ontology + (K(+) + H(+))-ATPase inhibitor + (K(+) + H(+))-ATPase inhibitors + ATP phosphohydrolase (H(+)/K(+)-exchanging) inhibitor + ATP phosphohydrolase (H(+)/K(+)-exchanging) inhibitors + EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitors + EC 3.6.3.10 inhibitor + EC 3.6.3.10 inhibitors + H(+)-K(+)-ATPase inhibitor + H(+)-K(+)-ATPase inhibitors + H(+)/K(+)-ATPase inhibitor + H(+)/K(+)-ATPase inhibitors + H(+)/K(+)-exchanging ATPase inhibitor + H(+)/K(+)-exchanging ATPase inhibitors + H,K-ATPase inhibitor + H,K-ATPase inhibitors + proton pump inhibitor + proton pump inhibitors + CHEBI:49200 + + EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor + + + + + + + + + One of various classes of drugs with different action mechanisms used to treat or ameliorate peptic ulcer or irritation of the gastrointestinal tract. + + chebi_ontology + anti-ulcer agent + anti-ulcer agents + anti-ulcer drugs + CHEBI:49201 + + anti-ulcer drug + + + + + + + + + + + chebi_ontology + CHEBI:49318 + + piperidine antibiotic + + + + + + + + + A chemical substance that prevents or reduces the probability of conception. + + chebi_ontology + contraceptive agent + contraceptive drugs + CHEBI:49323 + + contraceptive drug + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + An aminopyrimidine that is 2-methylpyrimidine which is substituted at position 4 by the primary amino group of 2-amino-1,3-thiazole-5-carboxylic acid and at position 6 by a 4-(2-hydroxyethyl)piperazin-1-yl group, and in which the carboxylic acid group has been formally condensed with 2-chloro-6-methylaniline to afford the corresponding amide. A multi-targeted kinase inhibitor, it is used, particularly as the monohydrate, for the treatment of chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia. Note that the name 'dasatinib' is used to refer to the monohydrate (USAN) as well as to anhydrous dasatinib (INN). + + 0 + C22H26ClN7O2S + InChI=1S/C22H26ClN7O2S/c1-14-4-3-5-16(23)20(14)28-21(32)17-13-24-22(33-17)27-18-12-19(26-15(2)25-18)30-8-6-29(7-9-30)10-11-31/h3-5,12-13,31H,6-11H2,1-2H3,(H,28,32)(H,24,25,26,27) + ZBNZXTGUTAYRHI-UHFFFAOYSA-N + 488.00652 + 487.15572 + Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1 + CHEBI:38943 + CHEBI:49372 + CAS:302962-49-8 + DrugBank:DB01254 + Drug_Central:785 + HMDB:HMDB0015384 + KEGG:D03658 + LINCS:LSM-1020 + PDBeChem:1N1 + PMID:16775234 + PMID:17154512 + PMID:18020922 + PMID:18784745 + PMID:18797457 + PMID:18823558 + PMID:19494352 + PMID:19502192 + PMID:19640584 + PMID:21226671 + PMID:22411867 + PMID:22740998 + PMID:22992064 + PMID:23065516 + Patent:US7125875 + Patent:US7941725 + Patent:WO2010067374 + Patent:WO2010139979 + Reaxys:9966762 + Wikipedia:Dasatinib + N-(2-chloro-6-methylphenyl)-2-({6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl}amino)-1,3-thiazole-5-carboxamide + chebi_ontology + BMS Dasatinib + BMS-354825 + N-(2-CHLORO-6-METHYLPHENYL)-2-({6-[4-(2-HYDROXYETHYL)PIPERAZIN-1-YL]-2-METHYLPYRIMIDIN-4-YL}AMINO)-1,3-THIAZOLE-5-CARBOXAMIDE + anh. dasatinib + anhydrous dasatinib + dasatinib + dasatinib (anh.) + dasatinibum + CHEBI:49375 + + dasatinib (anhydrous) + + + + + + + + + + + + + + + + + + 0 + H + InChI=1S/H + YZCKVEUIGOORGS-UHFFFAOYSA-N + 1.00794 + 1.00783 + [H] + CHEBI:24634 + CHEBI:49636 + WebElements:H + hydrogen + chebi_ontology + 1H + H + Wasserstoff + hidrogeno + hydrogen + hydrogene + CHEBI:49637 + + hydrogen atom + + + + + + + + + + CHEBI:8864 + chebi_ontology + CHEBI:49886 + + rimantadine + + + + + + + + + + 39937 + A compound of zinc and chloride ions in the ratio 1:2. It exists in four crystalline forms, in each of which the Zn(2+) ions are trigonal planar coordinated to four chloride ions. + + ChemIDplus:7646-85-7 + CiteXplore:7615984 + Gmelin:430396 + KEGG DRUG:D02058 + MolBase:1125 + NIST Chemistry WebBook:7646-85-7 + Wikipedia:Zinc_Chloride + zinc dichloride + zinc(2+) chloride + zinc(II) chloride + Cl2Zn + InChI=1S/2ClH.Zn/h2*1H;/q;;+2/p-2 + InChIKey=JIAARYAFYJHUJI-UHFFFAOYSA-L + Zinkchlorid + ZnCl2 + [Cl-].[Cl-].[Zn++] + butter of zinc + chlorure de zinc + dichlorozinc + zinc chloride + zinc chloride, anhydrous + CHEBI:49976 + zinc chloride + zinc dichloride + + + + + + + + + + A member of the class of flavones having one or more glycosyl residues attached at unspecified positions. + + glycosyloxyflavone + chebi_ontology + flavone glycoside + flavone glycosides + glycosyloxyflavones + CHEBI:50018 + + glycosyloxyflavone + + + + + + + + + + + + + + + + + + + + + + + A compound formally derived from ammonia by replacing one, two or three hydrogen atoms by organyl groups. + + + + chebi_ontology + organic amino compounds + CHEBI:50047 + + organic amino compound + + + + + + + + + An agent that binds to and activates excitatory amino acid receptors. + + chebi_ontology + excitatory amino acid agonists + excitatory amino acid receptor agonist + excitatory amino acid receptor agonists + CHEBI:50103 + + excitatory amino acid agonist + + + + + + + + + Any hormone that is responsible for controlling sexual characteristics and reproductive function. + + chebi_ontology + Geschlechtshormon + Geschlechtshormone + Sexualhormon + Sexualhormone + hormone sexuelle + hormones sexuelles + sex hormones + CHEBI:50112 + + sex hormone + + + + + + + + + + + + + + + + + + + + + + 0 + CF3 + 69.00591 + 68.99521 + C(F)(*)(F)F + trifluoromethyl + chebi_ontology + -CF3 + CHEBI:50127 + + trifluoromethyl group + + + + + + + + + A drug that softens, separates, and causes desquamation of the cornified epithelium or horny layer of skin. Keratolytic drugs are used to expose mycelia of infecting fungi or to treat corns, warts, and certain other skin diseases. + + chebi_ontology + desquamating agent + keratolytic agent + keratolytic drugs + skin-peeling agent + CHEBI:50176 + + keratolytic drug + + + + + + + + + A drug used to treat or prevent skin disorders or for the routine care of skin. + + chebi_ontology + dermatologic agent + dermatologic drugs + dermatological agent + CHEBI:50177 + + dermatologic drug + + + + + + + + + A compound which inhibits the movement of an ion across an energy-transducing cell membrane. + + chebi_ontology + ion transport inhibitors + ion-transport inhibitor + ion-transport inhibitors + CHEBI:50184 + + ion transport inhibitor + + + + + + + + + Salts from maleic acid. + + maleate salt + chebi_ontology + maleate salts + CHEBI:50221 + + maleate salt + + + + + + + + + Any protective agent counteracting or neutralizing the action of poisons. + + chebi_ontology + antidotes + CHEBI:50247 + + antidote + + + + + + + + + + A compound that, on administration, must undergo chemical conversion by metabolic processes before becoming the pharmacologically active drug for which it is a prodrug. + + PMID:23993918 + PMID:23998799 + PMID:24329110 + PMID:24628402 + PMID:24709544 + PMID:25144792 + PMID:25157234 + PMID:25269430 + PMID:25391982 + PMID:25591121 + PMID:25620096 + PMID:25795057 + PMID:26028253 + PMID:26184144 + PMID:28070577 + PMID:28215138 + PMID:28219047 + PMID:28259775 + PMID:28319647 + PMID:28329729 + PMID:28334528 + Wikipedia:Prodrug + chebi_ontology + Prodrugs + CHEBI:50266 + + prodrug + + + + + + + + + Synthetic or natural substance which is given to prevent a disease or disorder or are used in the process of treating a disease or injury due to a poisonous agent. + + chebi_ontology + chemoprotectant + chemoprotectants + chemoprotective agent + chemoprotective agents + protective agents + CHEBI:50267 + + protective agent + + + + + + + + + + chebi_ontology + CHEBI:50312 + + onium compound + + + + + + + + + Mononuclear cations derived by addition of a hydron to a mononuclear parent hydride of the pnictogen, chalcogen and halogen families. + + onium cations + chebi_ontology + onium cations + onium ion + onium ions + CHEBI:50313 + + onium cation + + + + + + + + + + + + + + + + +1 + ClH2 + InChI=1S/ClH2/h1H2/q+1 + IGJWHVUMEJASKV-UHFFFAOYSA-N + 37.46858 + 36.98395 + [H][Cl+][H] + Gmelin:331 + chloranium + chloronium + chebi_ontology + H2Cl(+) + [ClH2](+) + CHEBI:50315 + + chloronium + + + + + + + + + A univalent organyl group obtained by cleaving the bond from C-2 to the side chain of a proteinogenic amino-acid. + + chebi_ontology + canonical amino-acid side-chain + canonical amino-acid side-chains + proteinogenic amino-acid side-chain + proteinogenic amino-acid side-chain groups + proteinogenic amino-acid side-chains + CHEBI:50325 + + proteinogenic amino-acid side-chain group + + + + + + + + + + + + chebi_ontology + pyridinium ions + CHEBI:50334 + + pyridinium ion + + + + + + + + + + + + + + + + Any of the macrolides obtained as fermentation products from the bacterium Streptomyces avermitilis and consisting of a 16-membered macrocyclic backbone that is fused both benzofuran and spiroketal functions and contains a disaccharide substituent. They have significant anthelmintic and insecticidal properties. + + PMID:22039784 + PMID:22039799 + PMID:22542398 + PMID:23165468 + PMID:8688633 + Wikipedia:Avermectin + avermectin + chebi_ontology + avermectins + CHEBI:50344 + + avermectin + + + + + + + + + + + + + + + + + + + + + + 0 + C22H30O5 + InChI=1S/C22H30O5/c1-12-8-14-15-5-7-22(27,18(26)11-23)21(15,3)10-17(25)19(14)20(2)6-4-13(24)9-16(12)20/h4,6,9,12,14-15,17,19,23,25,27H,5,7-8,10-11H2,1-3H3/t12?,14-,15-,17-,19+,20-,21-,22-/m0/s1 + VHRSUDSXCMQTMA-UWKORSIYSA-N + 374.47060 + 374.20932 + CC1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12 + Beilstein:7113955 + 11beta,17,21-trihydroxy-6-methylpregna-1,4-diene-3,20-dione + chebi_ontology + (11beta)-11,17,21-trihydroxy-6-methylpregna-1,4-diene-3,20-dione + CHEBI:50366 + + 6-methylprednisolone + + + + + + + + + Any cholinergic antagonist that inhibits the actions of the parasympathetic nervous system. The major group of drugs used therapeutically for this purpose is the muscarinic antagonists. + + chebi_ontology + parasympatholytics + CHEBI:50370 + + parasympatholytic + + + + + + + + + A group derived from a haloalkane by removal of a hydrogen atom. + + chebi_ontology + haloalkyl groups + CHEBI:50491 + + haloalkyl group + + + + + + + + + + A gamma-lactone that consists of a 2-furanone skeleton and its substituted derivatives. + + 0 + C4H4O2 + 84.074 + 84.02113 + CHEBI:22960 + CHEBI:38121 + Wikipedia:Butenolide + furan-2-one + chebi_ontology + 2-furanone + butenolides + CHEBI:50523 + + butenolide + + + + + + + + + An organic anion arising from deprotonation of the OH function of a phenol compound. + + chebi_ontology + phenolate anions + CHEBI:50525 + + phenolate anion + + + + + + + + + An aliphatic alcohol in which the aliphatic alkane chain is substituted by a hydroxy group at unspecified position. + + CHEBI:22937 + CHEBI:50581 + chebi_ontology + alkyl alcohols + hydroxyalkane + hydroxyalkanes + CHEBI:50584 + + alkyl alcohol + + + + + + + + + An agent that inhibits bone resorption and/or favor bone mineralization and bone regeneration. Used to heal bone fractures and to treat bone diseases such as osteopenia and osteoporosis. + + CHEBI:72497 + Wikipedia:Osteoporosis + chebi_ontology + anti-osteopenia agent + anti-osteopenia agents + anti-osteopenia drug + anti-osteopenia drugs + anti-osteoporosis agent + anti-osteoporosis agents + anti-osteoporosis drug + anti-osteoporosis drugs + anti-osteoporotic + anti-osteoporotic agent + anti-osteoporotic agents + anti-osteoporotic drug + anti-osteoporotic drugs + anti-osteoporotics + antiosteoporotic + antiosteoporotics + bone density conservation agents + bone density conservation drug + bone density conservation drugs + CHEBI:50646 + + bone density conservation agent + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A member of the class of purines that is 6,7-dihydro-1H-purine carrying a thione group at position 6. An adenine analogue, it is used in the treatment of acute lymphocytic leukemia (ALL), chronic myeloid leukemia (CML), Crohn's disease, and ulcerative colitis. + + 0 + C5H4N4S + InChI=1S/C5H4N4S/c10-5-3-4(7-1-6-3)8-2-9-5/h1-2H,(H2,6,7,8,9,10) + GLVAUDGFNGKCSF-UHFFFAOYSA-N + 152.17822 + 152.01567 + S=c1[nH]cnc2nc[nH]c12 + Beilstein:132916 + CAS:50-44-2 + DrugBank:DB01033 + KEGG:C02380 + KEGG:D04931 + PDBeChem:PM6 + PMID:16267626 + PMID:28011186 + PMID:28166217 + PMID:28212467 + PMID:28295989 + PMID:28301625 + PMID:28406092 + PMID:28418010 + PMID:28484608 + PMID:28574837 + Patent:US2697709 + Patent:US2721866 + Reaxys:132916 + 1,7-dihydro-6H-purine-6-thione + Mercaptopurine + mercaptopurine + chebi_ontology + 6 MP + 6-MP + 6-Mercaptopurine + 6-Thiohypoxanthine + 6-Thioxopurine + Mercaptopurina + Mercapurin + Puri-Nethol + Purinethol + mercaptopurine + mercaptopurinum + CHEBI:50667 + + mercaptopurine + + + + + + + + + A substance used either in the prevention or facilitation of pregnancy. + + chebi_ontology + reproductive control agent + reproductive control drugs + CHEBI:50689 + + reproductive control drug + + + + + + + + + A compound in which monosaccharide units are joined by glycosidic linkages. The term is commonly used to refer to a defined structure as opposed to a polymer of unspecified length or a homologous mixture. When the linkages are of other types the compounds are regarded as oligosaccharide analogues. + + CHEBI:25679 + CHEBI:35319 + CHEBI:7758 + KEGG:C00930 + Oligosaccharide + oligosaccharides + chebi_ontology + O-glycosylglycoside + O-glycosylglycosides + oligosacarido + oligosacaridos + CHEBI:50699 + + oligosaccharide + + + + + + + + + A product in capsule, tablet or liquid form that provide essential nutrients, such as a vitamin, an essential mineral, a protein, an herb, or similar nutritional substance. + + chebi_ontology + Dietary Supplement + Food Supplementation + Nutritional supplement + CHEBI:50733 + + nutraceutical + + + + + + + + + A substance that possess antiestrogenic actions but can also produce estrogenic effects as well. It acts as complete or partial agonist or as antagonist. It can be either steroidal or nonsteroidal in structure. + + chebi_ontology + CHEBI:50739 + + estrogen receptor modulator + + + + + + + + + A salt of citric acid. + + chebi_ontology + citrate + citrate salts + citrates + CHEBI:50744 + + citrate salt + + + + + + + + + A compound that interacts with progesterone receptors in target tissues to bring about effects similar to those of progesterone. + + chebi_ontology + gestagen + gestagens + progestagen + progestagens + progestogens + CHEBI:50745 + + progestogen + + + + + + + + + + An antagonist at the estrogen receptor. + + chebi_ontology + estrogen receptor antagonists + CHEBI:50792 + + estrogen receptor antagonist + + + + + + + + + A compound which inhibits or antagonises the biosynthesis or actions of estrogens. + + chebi_ontology + oestrogen antagonist + CHEBI:50837 + + estrogen antagonist + + + + + + + + + + Biologically active substance whose activity affects or plays a role in the functioning of the immune system. + + Wikipedia:Immunotherapy + chebi_ontology + Biomodulator + Immune factor + Immunologic factor + Immunological factor + immunomodulators + CHEBI:50846 + + immunomodulator + + + + + + + + + A drug used to treat allergic reactions. + + chebi_ontology + anti-allergic agents + anti-allergic drug + anti-allergic drugs + CHEBI:50857 + + anti-allergic agent + + + + + + + + + A natural or synthetic analogue of the hormones secreted by the adrenal gland. + + chebi_ontology + corticoides + corticosteroides + corticosteroids + CHEBI:50858 + + corticosteroid + + + + + + + + + + + + + + + Any molecular entity that contains carbon. + + + CHEBI:25700 + CHEBI:33244 + chebi_ontology + organic compounds + organic entity + organic molecular entities + CHEBI:50860 + + organic molecular entity + + + + + + + + + A role played by a chemical compound to induce direct or indirect DNA damage. Such damage can potentially lead to the formation of a malignant tumour, but DNA damage does not lead inevitably to the creation of cancerous cells. + + Wikipedia:Genotoxicity + chebi_ontology + genotoxic agent + genotoxic agents + genotoxins + CHEBI:50902 + + genotoxin + + + + + + + + + A role played by a chemical compound which is known to induce a process of carcinogenesis by corrupting normal cellular pathways, leading to the acquistion of tumoral capabilities. + + chebi_ontology + agente carcinogeno + cancerigene + cancerogene + carcinogen + carcinogene + carcinogenic agents + carcinogeno + carcinogens + CHEBI:50903 + + carcinogenic agent + + + + + + + + + A chemical compound, or part thereof, which causes the onset of an allergic reaction by interacting with any of the molecular pathways involved in an allergy. + + Wikipedia:Allergen + chebi_ontology + alergeno + allergene + allergenic agent + CHEBI:50904 + + allergen + + + + + + + + + A role played by a chemical compound in biological systems with adverse consequences in embryo developments, leading to birth defects, embryo death or altered development, growth retardation and functional defect. + + chebi_ontology + agent teratogene + teratogen + teratogeno + CHEBI:50905 + + teratogenic agent + + + + + + + + + A role is particular behaviour which a material entity may exhibit. + + chebi_ontology + CHEBI:50906 + + role + + + + + + + + + + A poison that interferes with the functions of the nervous system. + + CHEBI:50911 + Wikipedia:Neurotoxin + chebi_ontology + agente neurotoxico + nerve poison + nerve poisons + neurotoxic agent + neurotoxic agents + neurotoxicant + neurotoxins + CHEBI:50910 + + neurotoxin + + + + + + + + + A drug used to prevent nausea or vomiting. An antiemetic may act by a wide range of mechanisms: it might affect the medullary control centres (the vomiting centre and the chemoreceptive trigger zone) or affect the peripheral receptors. + + Wikipedia:Antiemetic + chebi_ontology + anti-emetic + anti-emetics + antiemetico + antiemetics + CHEBI:50919 + + antiemetic + + + + + + + + + An EC 2.7.11.* (protein-serine/threonine kinase) inhibitor that interferes with the action of non-specific serine/threonine protein kinase (EC 2.7.11.1), a kinase enzyme involved in phosphorylation of hydroxy group of serine or threonine. + + CHEBI:75764 + chebi_ontology + A-kinase inhibitor + A-kinase inhibitors + AP50 kinase inhibitor + AP50 kinase inhibitors + ATP-protein transphosphorylase inhibitor + ATP-protein transphosphorylase inhibitors + ATP:protein phosphotransferase (non-specific) inhibitor + ATP:protein phosphotransferase (non-specific) inhibitors + BR serine/threonine-protein kinase 2 inhibitor + BR serine/threonine-protein kinase 2 inhibitors + CK-2 inhibitor + CK-2 inhibitors + CKI inhibitor + CKI inhibitors + CKII inhibitor + CKII inhibitors + EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitors + EC 2.7.11.1 inhibitor + EC 2.7.11.1 inhibitors + HIPK2 inhibitor + HIPK2 inhibitors + Hpr kinase inhibitor + Hpr kinase inhibitors + M phase-specific cdc2 kinase inhibitor + M phase-specific cdc2 kinase inhibitors + MKNK2 inhibitor + MKNK2 inhibitors + PAK-1 inhibitor + PAK-1 inhibitors + PAK1 inhibitor + PAK1 inhibitors + PKA inhibitor + PKA inhibitors + Prp4 protein kinase inhibitor + Prp4 protein kinase inhibitors + Raf kinase inhibitor + Raf kinase inhibitors + Raf-1 inhibitor + Raf-1 inhibitors + STK32 inhibitor + STK32 inhibitors + T-antigen kinase inhibitor + T-antigen kinase inhibitors + WEE1Hu inhibitor + WEE1Hu inhibitors + Wee 1-like kinase inhibitor + Wee 1-like kinase inhibitors + Wee-kinase inhibitor + Wee-kinase inhibitors + betaIIPKC inhibitor + betaIIPKC inhibitors + cAMP-dependent protein kinase A inhibitor + cAMP-dependent protein kinase A inhibitors + cAMP-dependent protein kinase inhibitor + cAMP-dependent protein kinase inhibitors + cGMP-dependent protein kinase inhibitor + cGMP-dependent protein kinase inhibitors + calcium-dependent protein kinase C inhibitor + calcium-dependent protein kinase C inhibitors + calcium/phospholipid-dependent protein kinase inhibitor + calcium/phospholipid-dependent protein kinase inhibitors + casein kinase (phosphorylating) inhibitor + casein kinase (phosphorylating) inhibitors + casein kinase 2 inhibitor + casein kinase 2 inhibitors + casein kinase I inhibitor + casein kinase I inhibitors + casein kinase II inhibitor + casein kinase II inhibitors + casein kinase inhibitor + casein kinase inhibitors + cyclic AMP-dependent protein kinase A inhibitor + cyclic AMP-dependent protein kinase A inhibitors + cyclic AMP-dependent protein kinase inhibitor + cyclic AMP-dependent protein kinase inhibitors + cyclic monophosphate-dependent protein kinase inhibitor + cyclic monophosphate-dependent protein kinase inhibitors + cyclic nucleotide-dependent protein kinase inhibitor + cyclic nucleotide-dependent protein kinase inhibitors + cyclin-dependent kinase inhibitor + cyclin-dependent kinase inhibitors + dsk1 inhibitor + dsk1 inhibitors + epsilon PKC inhibitor + epsilon PKC inhibitors + glycogen synthase a kinase inhibitor + glycogen synthase a kinase inhibitors + glycogen synthase kinase inhibitor + glycogen synthase kinase inhibitors + hydroxyalkyl-protein kinase inhibitor + hydroxyalkyl-protein kinase inhibitors + mitogen-activated S6 kinase inhibitor + mitogen-activated S6 kinase inhibitors + non-specific serine/threonine protein kinase (EC 2.7.11.1) inhibitor + non-specific serine/threonine protein kinase (EC 2.7.11.1) inhibitors + non-specific serine/threonine protein kinase inhibitor + non-specific serine/threonine protein kinase inhibitors + p21 activated kinase-1 inhibitor + p21 activated kinase-1 inhibitors + p82 kinase inhibitor + p82 kinase inhibitors + phosphorylase b kinase kinase inhibitor + phosphorylase b kinase kinase inhibitors + protein glutamyl kinase inhibitor + protein glutamyl kinase inhibitors + protein kinase (phosphorylating) inhibitor + protein kinase (phosphorylating) inhibitors + protein kinase A inhibitor + protein kinase A inhibitors + protein kinase CK2 inhibitor + protein kinase CK2 inhibitors + protein kinase p58 inhibitor + protein kinase p58 inhibitors + protein phosphokinase inhibitor + protein phosphokinase inhibitors + protein serine kinase inhibitor + protein serine kinase inhibitors + protein serine-threonine kinase inhibitor + protein serine-threonine kinase inhibitors + protein-aspartyl kinase inhibitor + protein-aspartyl kinase inhibitors + protein-cysteine kinase inhibitor + protein-cysteine kinase inhibitors + protein-serine kinase inhibitor + protein-serine kinase inhibitors + protein-serine/threonine kinase inhibitors + ribosomal S6 protein kinase inhibitor + ribosomal S6 protein kinase inhibitors + ribosomal protein S6 kinase II inhibitor + ribosomal protein S6 kinase II inhibitors + serine kinase inhibitor + serine kinase inhibitors + serine protein kinase inhibitor + serine protein kinase inhibitors + serine(threonine) protein kinase inhibitor + serine(threonine) protein kinase inhibitors + serine-specific protein kinase inhibitor + serine-specific protein kinase inhibitors + serine/threonine protein kinase inhibitor + serine/threonine protein kinase inhibitors + threonine-specific protein kinase inhibitor + threonine-specific protein kinase inhibitors + twitchin kinase inhibitor + twitchin kinase inhibitors + type-2 casein kinase inhibitor + type-2 casein kinase inhibitors + CHEBI:50925 + + EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor + + + + + + + + + A compound that specifically inhibits the reuptake of serotonin in the brain. This increases the serotonin concentration in the synaptic cleft which then activates serotonin receptors to a greater extent. + + Wikipedia:Selective_serotonin_reuptake_inhibitor + chebi_ontology + SSRI + serotonin reuptake inhibitor + CHEBI:50949 + + serotonin uptake inhibitor + + + + + + + + + + + + + + + A compound formally derived from ammonia by replacing one hydrogen atom by an organyl group. + + chebi_ontology + primary amino compounds + CHEBI:50994 + + primary amino compound + + + + + + + + + A compound formally derived from ammonia by replacing two hydrogen atoms by organyl groups. + + chebi_ontology + secondary amino compounds + CHEBI:50995 + + secondary amino compound + + + + + + + + + + + + + + + A compound formally derived from ammonia by replacing three hydrogen atoms by organyl groups. + + + chebi_ontology + tertiary amino compounds + CHEBI:50996 + + tertiary amino compound + + + + + + + + + + A cyclic compound containing nine or more atoms as part of the cyclic system. + A cyclic macromolecule. + + + Wikipedia:Macrocycle + macrocycle + chebi_ontology + Makrocyclen + Makrozyklen + macrocycles + makrocyclische Verbindungen + makrozyklische Verbindungen + CHEBI:51026 + + macrocycle + + + + + + + + + + A chemical substance which binds to specific hormone receptors activating the function of the endocrine glands, the biosynthesis of their secreted hormones, or the action of hormones upon their specific sites. + + chebi_ontology + CHEBI:51060 + + hormone agonist + + + + + + + + + + A drug that modulates the function of the endocrine glands, the biosynthesis of their secreted hormones, or the action of hormones upon their specific sites. + + chebi_ontology + hormone receptor modulators + CHEBI:51061 + + hormone receptor modulator + + + + + + + + + + chebi_ontology + organic halide salts + CHEBI:51069 + + organic halide salt + + + + + + + + + A role played by the molecular entity or part thereof within a chemical context. + + chebi_ontology + CHEBI:51086 + + chemical role + + + + + + + + + + + + + + + + + CHEBI:25556 + CHEBI:7594 + KEGG COMPOUND:C06061 + KEGG:C06061 + chebi_ontology + Nitrogenous compounds + nitrogen compounds + nitrogen molecular entities + CHEBI:51143 + + nitrogen molecular entity + + + + + + + + + An organic molecule that is electrically neutral carrying a positive and a negative charge in one of its major canonical descriptions. In most dipolar compounds the charges are delocalized; however the term is also applied to species where this is not the case. + + chebi_ontology + dipolar compounds + CHEBI:51151 + + dipolar compound + + + + + + + + + + + 4496 + A phenothiazine derivative having a trifluoromethyl subsitituent at the 2-position and a 3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl group at the N-10 position. + + Beilstein:1189506 + Beilstein:61643 + ChemIDplus:69-23-8 + CiteXplore:1650428 + CiteXplore:5128930 + DrugBank:DB00623 + Gmelin:1231182 + KEGG COMPOUND:69-23-8 + KEGG COMPOUND:C07010 + KEGG DRUG:D07977 + NIST Chemistry WebBook:69-23-8 + Patent:GB829246 + Patent:GB833474 + Patent:US3058979 + Patent:US3194733 + Wikipedia:Fluphenazine + 2-(4-{3-[2-(trifluoromethyl)-10H-phenothiazin-10-yl]propyl}piperazin-1-yl)ethanol + Fluphenazine + 1-(2-hydroxyethyl)-4-(3-(trifluoromethyl-10-phenothiazinyl)propyl)-piperazine + 10-(3'-(4''-(beta-hydroxyethyl)-1''-piperazinyl)-propyl)-3-trifluoromethylphenothiazine + 10-(3-(2-hydroxyethyl)piperazinopropyl)-2-(trifluoromethyl)phenothiazine + 2-(4-(3-[2-(trifluoromethyl)-10H-phenothiazin-10-yl]propyl)-1-piperazinyl)ethanol + 2-(trifluoromethyl)-10-(3-(1-(beta-hydroxyethyl)-4-piperazinyl)propyl)phenothiazine + 4-(3-(-trifluoromethyl-10-phenothiazyl)-propyl)-1-piperazineethanol + 4-(3-(2-(trifluoromethyl)-10H-phenothiazin-10-yl)propyl)-1-piperazineethanol + 4-(3-(2-trifluoromethyl-10-phenothiazyl)-propyl)-1-piperazineethanol + C22H26F3N3OS + Fluorfenazine + Fluorophenazine + Fluorphenazine + InChI=1S/C22H26F3N3OS/c23-22(24,25)17-6-7-21-19(16-17)28(18-4-1-2-5-20(18)30-21)9-3-8-26-10-12-27(13-11-26)14-15-29/h1-2,4-7,16,29H,3,8-15H2 + InChIKey=PLDUPXSUYLZYBN-UHFFFAOYSA-N + OCCN1CCN(CCCN2c3ccccc3Sc3ccc(cc23)C(F)(F)F)CC1 + Triflumethazine + flufenazina + fluphenazine + fluphenazinum + CHEBI:5123 + Fluphenazine + fluphenazine + + + + + + + + + + + + + + + + 0 + C22H26F3N3OS.2HCl + C22H28Cl2F3N3OS + InChI=1S/C22H26F3N3OS.2ClH/c23-22(24,25)17-6-7-21-19(16-17)28(18-4-1-2-5-20(18)30-21)9-3-8-26-10-12-27(13-11-26)14-15-29;;/h1-2,4-7,16,29H,3,8-15H2;2*1H + MBHNWCYEGXQEIT-UHFFFAOYSA-N + 510.445 + 509.12822 + C=12N(C3=C(SC1C=CC=C2)C=CC(=C3)C(F)(F)F)CCCN4CCN(CCO)CC4.Cl.Cl + CAS:146-56-5 + KEGG:D00791 + Fluphenazine hydrochloride + chebi_ontology + Permitil + Prolixin + CHEBI:5126 + + Fluphenazine hydrochloride + + + + + + + + + Any organic substituent group, regardless of functional type, having two free valences at carbon atom(s). + + chebi_ontology + organodiyl groups + CHEBI:51422 + + organodiyl group + + + + + + + + + + chebi_ontology + CHEBI:51446 + + organic divalent group + + + + + + + + + + chebi_ontology + CHEBI:51447 + + organic univalent group + + + + + + + + + Cyclopropane and its derivatives formed by substitution. + + chebi_ontology + CHEBI:51454 + + cyclopropanes + + + + + + + + + Compounds containing a pyridine skeleton substituted by two amino groups. + + chebi_ontology + diaminopyridines + CHEBI:51598 + + diaminopyridine + + + + + + + + + Any compound containing two aryl groups connected by a single C atom. + + chebi_ontology + diarylmethanes + CHEBI:51614 + + diarylmethane + + + + + + + + + + Any aromatic ether that consists of a benzene skeleton substituted with one or more methoxy groups. + + chebi_ontology + methoxybenzene + CHEBI:51683 + + methoxybenzenes + + + + + + + + + + An alpha,beta-unsaturated ketone of general formula R(1)R(2)C=CR(3)-C(=O)R(4) (R(4) =/= H) in which the C=O function is conjugated to a C=C double bond at the alpha,beta position. + + 0 + C3OR4 + 52.03150 + 51.99491 + [*]\C([*])=C(\[*])C([*])=O + Wikipedia:Enone + chebi_ontology + enones + CHEBI:51689 + + enone + + + + + + + + + + An alpha,beta-unsaturated carboxylic ester of general formula R(1)R(2)C=CR(3)-C(=O)OR(4) (R(4) =/= H) in which the ester C=O function is conjugated to a C=C double bond at the alpha,beta position. + + 0 + C3O2R4 + 68.03090 + 67.98983 + [*]\C([*])=C(\[*])C(=O)O[*] + chebi_ontology + enoate + enoate esters + enoates + CHEBI:51702 + + enoate ester + + + + + + + + + A ketone of general formula R(1)R(2)C=CR(3)-C(=O)R(4) (R(4) =/= H) or R(1)C#C-C(=O)R(2) (R(2) =/= H) in which the ketonic C=O function is conjugated to an unsaturated C-C bond at the alpha,beta position. + + chebi_ontology + alpha,beta-unsaturated ketones + CHEBI:51721 + + alpha,beta-unsaturated ketone + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A 14beta-hydroxy steroid that is bufan-20,22-dienolide having hydroxy substituents at the 5beta- and 14beta-positions. It has been isolated from the skin of the toad Bufo bufo. + + 0 + C24H34O4 + InChI=1S/C24H34O4/c1-22-10-7-17(25)13-16(22)4-5-20-19(22)8-11-23(2)18(9-12-24(20,23)27)15-3-6-21(26)28-14-15/h3,6,14,16-20,25,27H,4-5,7-13H2,1-2H3/t16-,17+,18-,19+,20-,22+,23-,24+/m1/s1 + QEEBRPGZBVVINN-BMPKRDENSA-N + 386.52440 + 386.24571 + [H][C@]12CC[C@]3([H])[C@]([H])(CC[C@]4(C)[C@]([H])(CC[C@]34O)c3ccc(=O)oc3)[C@@]1(C)CC[C@H](O)C2 + Beilstein:96550 + CAS:465-21-4 + KEGG:C16922 + LIPID_MAPS_instance:LMST01130001 + PMID:10438974 + PMID:21185919 + PMID:23949904 + PMID:24484199 + PMID:24515724 + PMID:24719521 + PMID:26111756 + PMID:26133118 + PMID:26381511 + PMID:26446205 + PMID:8282340 + Reaxys:96550 + (3beta,5beta)-3,14-dihydroxybufa-20,22-dienolide + chebi_ontology + 3,14-Dihydroxy-bufa-20,22-dienolide + 3-beta,14-Dihydroxy-5-beta-bufa-20,22-dienolide + 3beta,14beta-dihydroxy-5beta-bufa-20,22-dienolide + CHEBI:517248 + + bufalin + + + + + + + + + A carboxylic ester of general formula R(1)R(2)C=CR(3)-C(=O)OR(4) (R(4) =/= H) or R(1)C#C-C(=O)OR(2) (R(2) =/= H) in which the ester C=O function is conjugated to an unsaturated C-C bond at the alpha,beta position. + + chebi_ontology + alpha,beta-unsaturated carboxylic esters + CHEBI:51737 + + alpha,beta-unsaturated carboxylic ester + + + + + + + + + A ketone of formula RC(=O)CH3 (R =/= H). + + chebi_ontology + methyl ketones + CHEBI:51867 + + methyl ketone + + + + + + + + + + + + chebi_ontology + organic polycyclic compounds + CHEBI:51958 + + organic polycyclic compound + + + + + + + + + + + chebi_ontology + organic tricyclic compounds + CHEBI:51959 + + organic tricyclic compound + + + + + + + + + + + + + + + + + + + + + An organic anion that is the conjugate base of methanol. + + -1 + CH3O + InChI=1S/CH3O/c1-2/h1H3/q-1 + NBTOZLQBSIZIKS-UHFFFAOYSA-N + 31.03390 + 31.01894 + C[O-] + Reaxys:1839368 + chebi_ontology + methoxide ion + CHEBI:52090 + + methoxide + + + + + + + + + + + + + + + + + + + + + + + + + + + An organic anion that is the conjugate base of ethanol. + + -1 + C2H5O + InChI=1S/C2H5O/c1-2-3/h2H2,1H3/q-1 + HHFAWKCIHAUFRX-UHFFFAOYSA-N + 45.06050 + 45.03459 + CC[O-] + Beilstein:1839415 + Reaxys:1839415 + chebi_ontology + ethoxy anion + CHEBI:52092 + + ethoxide + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + 0 + C28H22F3N7O + InChI=1S/C28H22F3N7O/c1-17-5-6-19(10-25(17)37-27-33-9-7-24(36-27)20-4-3-8-32-14-20)26(39)35-22-11-21(28(29,30)31)12-23(13-22)38-15-18(2)34-16-38/h3-16H,1-2H3,(H,35,39)(H,33,36,37) + HHZIURLSWUIHRB-UHFFFAOYSA-N + 529.51580 + 529.18379 + Cc1cn(cn1)-c1cc(NC(=O)c2ccc(C)c(Nc3nccc(n3)-c3cccnc3)c2)cc(c1)C(F)(F)F + CAS:641571-10-0 + DrugBank:DB04868 + Drug_Central:1932 + KEGG:D08953 + LINCS:LSM-1099 + Wikipedia:Nilotinib + 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]benzamide + chebi_ontology + AMN 107 + AMN107 + nilotinib + nilotinibum + CHEBI:52172 + + nilotinib + + + + + + + + + A biological role played by the molecular entity or part thereof within a biochemical context. + + chebi_ontology + CHEBI:52206 + + biochemical role + + + + + + + + + + chebi_ontology + CHEBI:52208 + + biophysical role + + + + + + + + + A role played by the molecular entity or part thereof which causes the development of a pathological process. + + chebi_ontology + etiopathogenetic agent + etiopathogenetic role + CHEBI:52209 + + aetiopathogenetic role + + + + + + + + + A biological role which describes how a drug interacts within a biological system and how the interactions affect its medicinal properties. + + chebi_ontology + CHEBI:52210 + + pharmacological role + + + + + + + + + + chebi_ontology + CHEBI:52211 + + physiological role + + + + + + + + + Any substance introduced into a living organism with therapeutic or diagnostic purpose. + + CHEBI:33293 + CHEBI:33294 + chebi_ontology + farmaco + medicament + pharmaceuticals + CHEBI:52217 + + pharmaceutical + + + + + + + + + A compound with the general formula R2C=O (R=/=H) where one or more of the R groups contains an oxy (-O-) group. + + chebi_ontology + oxyketones + CHEBI:52395 + + oxyketone + + + + + + + + + An oxyketone with the general formula R2C(=O) (R=/=H) where one or more of the R groups contains an oxy (-O-) group and the oxy and carbonyl groups are bonded to the same carbon atom. + + chebi_ontology + alpha-oxyketones + CHEBI:52396 + + alpha-oxyketone + + + + + + + + + + + chebi_ontology + inorganic hydroxides + CHEBI:52625 + + inorganic hydroxy compound + + + + + + + + + + quinolinium ion + chebi_ontology + quinolinium ions + CHEBI:52837 + + quinolinium ion + + + + + + + + + An organic group that consists of a closed ring. It may be a substituent or a skeleton. + + chebi_ontology + cyclic organic groups + CHEBI:52845 + + cyclic organic group + + + + + + + + + A cyclic macromolecule containing one or more nitrogen atoms in place of carbon either as the divalent group NH for the group CH2 or a single trivalent nitrogen atom for the group CH. + + chebi_ontology + aza macrocycle + aza macrocyclic compound + aza-macrocycle + azamacrocycles + CHEBI:52898 + + azamacrocycle + + + + + + + + + The biological role played by a material entity when bound by a receptor of the adaptive immune system. Specific site on an antigen to which an antibody binds. + + chebi_ontology + antigenic determinant + epitope function + epitope role + CHEBI:53000 + + epitope + + + + + + + + + + + + + + + + chebi_ontology + CHEBI:53443 + + salicylamides + + + + + + + + + An EC 1.1.1.* (oxidoreductase acting on donor CH-OH group, NAD(+) or NADP(+) acceptor) inhibitor that interferes with the action of IMP dehydrogenase (EC 1.1.1.205), so blocking de novo biosynthesis of purine nucleotides. + + chebi_ontology + EC 1.1.1.205 (IMP dehydrogenase) inhibitors + EC 1.1.1.205 inhibitor + EC 1.1.1.205 inhibitors + IMP dehydrogenase (EC 1.1.1.205) inhibitor + IMP dehydrogenase (EC 1.1.1.205) inhibitors + IMP dehydrogenase inhibitor + IMP dehydrogenase inhibitors + IMP oxidoreductase inhibitor + IMP oxidoreductase inhibitors + IMP:NAD(+) oxidoreductase inhibitor + IMP:NAD(+) oxidoreductase inhibitors + inosinate dehydrogenase inhibitor + inosinate dehydrogenase inhibitors + inosine 5'-monophosphate dehydrogenase inhibitors + inosine monophosphate dehydrogenase inhibitor + inosine monophosphate dehydrogenase inhibitors + inosine monophosphate oxidoreductase inhibitor + inosine monophosphate oxidoreductase inhibitors + inosinic acid dehydrogenase inhibitor + inosinic acid dehydrogenase inhibitors + CHEBI:53746 + + EC 1.1.1.205 (IMP dehydrogenase) inhibitor + + + + + + + + + + A dicarboximide that is piperidine which is substituted by oxo groups at positions 2 and 6. + + 0 + C5H7NO2 + InChI=1S/C5H7NO2/c7-4-2-1-3-5(8)6-4/h1-3H2,(H,6,7,8) + KNCYXPMJDCCGSJ-UHFFFAOYSA-N + 113.11460 + 113.04768 + O=C1CCCC(=O)N1 + Beilstein:110052 + CAS:1121-89-7 + Gmelin:971891 + KEGG:C07275 + PMID:10783491 + Reaxys:110052 + Piperidine-2,6-dione + piperidine-2,6-dione + chebi_ontology + 2,6-Diketopiperidine + 2,6-piperidinedione + Glutarimide + CHEBI:5435 + + piperidine-2,6-dione + + + + + + + + + + A compound that exhibits agonist activity at the mu-opioid receptor. + + CHEBI:50136 + chebi_ontology + mu opioid agonist + mu-opioid agonists + mu-opioid receptor agonists + CHEBI:55322 + + mu-opioid receptor agonist + + + + + + + + + Any drug found useful in the symptomatic treatment of diarrhoea. + + chebi_ontology + antidiarrheal + antidiarrheal agent + antidiarrheal agents + antidiarrheal drug + antidiarrheal drugs + antidiarrheals + antidiarrhoeal + antidiarrhoeal agent + antidiarrhoeal agents + antidiarrhoeal drugs + antidiarrhoeals + antiperistaltic + antiperistaltic agent + antiperistaltic agents + antiperistaltic drug + antiperistaltic drugs + antiperistaltics + CHEBI:55323 + + antidiarrhoeal drug + + + + + + + + + A drug used for its effects on the gastrointestinal system, e.g. controlling gastric acidity, regulating gastrointestinal motility and water flow, and improving digestion. + + chebi_ontology + gastrointestinal agent + gastrointestinal agents + gastrointestinal drugs + CHEBI:55324 + + gastrointestinal drug + + + + + + + + + + + + + A semisynthetic echinocandin anti-fungal drug. It is active against Aspergillus and Candida species and is used for the treatment of invasive candidiasis. + + 0 + C58H73N7O17 + InChI=1S/C58H73N7O17/c1-5-6-7-24-82-40-22-18-35(19-23-40)33-10-8-32(9-11-33)34-12-14-37(15-13-34)51(74)59-41-26-43(70)54(77)63-56(79)47-48(71)29(2)27-65(47)58(81)45(31(4)67)61-55(78)46(50(73)49(72)36-16-20-38(68)21-17-36)62-53(76)42-25-39(69)28-64(42)57(80)44(30(3)66)60-52(41)75/h8-23,29-31,39,41-50,54,66-73,77H,5-7,24-28H2,1-4H3,(H,59,74)(H,60,75)(H,61,78)(H,62,76)(H,63,79)/t29-,30+,31+,39+,41-,42-,43+,44-,45-,46-,47-,48-,49-,50-,54+/m0/s1 + JHVAMHSQVVQIOT-MFAJLEFUSA-N + 1140.23690 + 1139.50629 + CCCCCOc1ccc(cc1)-c1ccc(cc1)-c1ccc(cc1)C(=O)N[C@H]1C[C@@H](O)[C@@H](O)NC(=O)[C@@H]2[C@@H](O)[C@@H](C)CN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)c1ccc(O)cc1)[C@@H](C)O + Beilstein:7408417 + CAS:166663-25-8 + DrugBank:DB00362 + KEGG:D03211 + PMID:15482216 + PMID:16770294 + PMID:17316149 + PMID:19072176 + PMID:19113794 + PMID:19877739 + PMID:19877740 + PMID:19877741 + PMID:19877742 + PMID:24165173 + PMID:24955796 + PMID:25473029 + Reaxys:7408417 + Wikipedia:Anidulafungin + N-{(2R,6S,9S,11R,12R,14aS,15S,16S,20S,23S,25aS)-23-[(1S,2S)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-2,11,12,15-tetrahydroxy-6,20-bis[(1R)-1-hydroxyethyl]-16-methyl-5,8,14,19,22,25-hexaoxotetracosahydro-1H-dipyrrolo[2,1-c:2',1'-l][1,4,7,10,13,16]hexaazacyclohenicosin-9-yl}-4''-(pentyloxy)-1,1':4',1''-terphenyl-4-carboxamide + chebi_ontology + Eraxis + anidulafungin + anidulafungina + anidulafungine + anidulafunginum + CHEBI:55346 + + anidulafungin + + + + + + + + + + + + + + + + + + + + + + + + + + + + + An indole alkaloid fundamental parent with a structure of 9H-beta-carboline carrying a methyl substituent at C-1. It has been isolated from the bark of Sickingia rubra, Symplocus racemosa, Passiflora incarnata, Peganum harmala, Banisteriopsis caapi and Tribulus terrestris, as well as from tobacco smoke. It is a specific, reversible inhibitor of monoamine oxidase A. + + 0 + C12H10N2 + InChI=1S/C12H10N2/c1-8-12-10(6-7-13-8)9-4-2-3-5-11(9)14-12/h2-7,14H,1H3 + PSFDQSOCUJVVGF-UHFFFAOYSA-N + 182.22120 + 182.08440 + Cc1nccc2c3ccccc3[nH]c12 + Beilstein:143898 + CAS:486-84-0 + KEGG:C09209 + KNApSAcK:C00001736 + LINCS:LSM-19989 + PMID:11473435 + PMID:19645722 + PMID:20732341 + PMID:22757671 + PMID:22981972 + PMID:23544153 + PMID:24103378 + PMID:24300779 + PMID:24486683 + Reaxys:143898 + 1-methyl-9H-pyrido[3,4-b]indole + Harman + chebi_ontology + 1-methyl-2-carboline + 1-methyl-9H-beta-carboline + 1-methyl-beta-carboline + 1-methylnorharman + L-methylpyridobindole + aribin + aribine + harmane + locuturin + locuturine + loturine + passiflorin + CHEBI:5623 + + harman + + + + + + + + + A compound having the general formula RR'C(OH)OR'' (R'' =/= H). + + 0 + CH2O2R2 + 46.025 + 46.00548 + Hemiacetal + hemiacetals + chebi_ontology + hemiacetals + CHEBI:5653 + + hemiacetal + + + + + + + + + A cyclic compound having as ring members atoms of at least two different elements. + + + Heterocyclic compound + chebi_ontology + compuesto heterociclico + compuestos heterociclicos + heterocycle + heterocyclic compounds + CHEBI:5686 + + heterocyclic compound + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + An organochlorine compound that is diphenylmethane in which each of the phenyl groups is substituted by chlorines at positions 2, 3, and 5, and by a hydroxy group at position 6. An antiseptic that is effective against Gram-positive organisms, it is used in soaps and creams for the treatment of various skin disorders. It is also used in agriculture as an acaricide and fungicide, but is not approved for such use within the European Union. + + 0 + C13H6Cl6O2 + InChI=1S/C13H6Cl6O2/c14-6-2-8(16)12(20)4(10(6)18)1-5-11(19)7(15)3-9(17)13(5)21/h2-3,20-21H,1H2 + ACGUYXCXAPNIKK-UHFFFAOYSA-N + 406.90400 + 403.84990 + Oc1c(Cl)cc(Cl)c(Cl)c1Cc1c(O)c(Cl)cc(Cl)c1Cl + CAS:70-30-4 + DrugBank:DB00756 + Drug_Central:1364 + HMDB:HMDB0014894 + KEGG:C08039 + KEGG:D00859 + LINCS:LSM-6032 + PDBeChem:H3P + PMID:1133685 + PMID:22313968 + PMID:23251633 + PMID:397166 + PMID:894425 + PMID:952574 + PPDB:381 + Patent:US2250480 + Patent:US2435593 + Patent:US2812365 + Reaxys:2064407 + Wikipedia:Hexachlorophene + 2,2'-methylenebis(3,4,6-trichlorophenol) + chebi_ontology + 2,2',3,3',5,5'-hexachloro-6,6'-dihydroxydiphenylmethane + 2,2'-dihydroxy-3,3',5,5',6,6'-hexachlorodiphenylmethane + 2,2'-dihydroxy-3,5,6,3',5',6'-hexachlorodiphenylmethane + 2,2'-methanediylbis(3,4,6-trichlorophenol) + Acigena + Almederm + Armohex + Distodin + Esaclorofene + Exofene + Gamophen + Gamophene + Germa-medica + Hexa-Germ + Hexabalm + Hexafen + Hexascrub + Hexide + Nabac + Phiso-Scrub + Phisodan + Septi-Soft + Septisol + Septofen + Solu-Heks + Soy-Dome + Staphene O + Ster-Zac + Steral + Steraskin + Surgi-Cen + Surgi-cin + Surofene + Tersaseptic + Turgex + bis(2-hydroxy-3,5,6-trichlorophenyl)methane + bis(3,5,6-trichloro-2-hydroxyphenyl)methane + hexachlorophene + hexachlorophenum + hexaclorofeno + CHEBI:5693 + + hexachlorophene + + + + + + + + + + Any one of a family of large lipopeptides that are inhibitors of the enzyme 1,3-beta-glucan synthase, thus damaging fungal cell walls. Echinocandins are fungicidal against most Candida spp and fungistatic against Aspergillus spp. + + chebi_ontology + echinocandins + CHEBI:57248 + + echinocandin + + + + + + + + + + + + + + + Zwitterionic form of L-leucine. + + 0 + C6H13NO2 + InChI=1S/C6H13NO2/c1-4(2)3-5(7)6(8)9/h4-5H,3,7H2,1-2H3,(H,8,9)/t5-/m0/s1 + ROHFNLRQFUQHCH-YFKPBYRVSA-N + 131.17290 + 131.09463 + CC(C)C[C@H]([NH3+])C([O-])=O + Gmelin:363609 + (2S)-2-azaniumyl-4-methylpentanoate + chebi_ontology + L-leucine + leucine zwitterion + CHEBI:57427 + + L-leucine zwitterion + + + + + + + + + + + + + + + An L-alpha-amino acid zwitterion obtained by transfer of a proton from the carboxy to the amino group of L-valine; major species at pH 7.3. + + 0 + C5H11NO2 + InChI=1S/C5H11NO2/c1-3(2)4(6)5(7)8/h3-4H,6H2,1-2H3,(H,7,8)/t4-/m0/s1 + KZSNJWFQEVHDMF-BYPYZUCNSA-N + 117.14630 + 117.07898 + CC(C)[C@H]([NH3+])C([O-])=O + Gmelin:2826 + (2S)-2-azaniumyl-3-methylbutanoate + chebi_ontology + (2S)-2-ammonio-3-methylbutanoate + L-valine + CHEBI:57762 + + L-valine zwitterion + + + + + + + + + + + + + + + + + + + + + A D-alpha-amino acid zwitterion that is D-phenylalanine in which a proton has been transferred from the carboxy group to the amino group. It is the major species at pH 7.3. + + 0 + C9H11NO2 + InChI=1S/C9H11NO2/c10-8(9(11)12)6-7-4-2-1-3-5-7/h1-5,8H,6,10H2,(H,11,12)/t8-/m1/s1 + COLNVLDHVKWLRT-MRVPVSSYSA-N + 165.18910 + 165.07898 + [NH3+][C@H](Cc1ccccc1)C([O-])=O + MetaCyc:CPD-216 + (2R)-2-azaniumyl-3-phenylpropanoate + chebi_ontology + (2R)-2-ammonio-3-phenylpropanoate + D-phenylalanine + CHEBI:57981 + + D-phenylalanine zwitterion + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions. + + 0 + C18H26ClN3O + InChI=1S/C18H26ClN3O/c1-3-22(11-12-23)10-4-5-14(2)21-17-8-9-20-18-13-15(19)6-7-16(17)18/h6-9,13-14,23H,3-5,10-12H2,1-2H3,(H,20,21) + XXSMGPRMXLTPCZ-UHFFFAOYSA-N + 335.87200 + 335.17644 + CCN(CCO)CCCC(C)Nc1ccnc2cc(Cl)ccc12 + CAS:118-42-3 + DrugBank:DB01611 + Drug_Central:1395 + HMDB:HMDB0015549 + KEGG:C07043 + KEGG:D08050 + LINCS:LSM-5193 + PMID:23216212 + PMID:23218706 + PMID:23481418 + PMID:23485647 + PMID:23581274 + PMID:23778483 + PMID:23887202 + PMID:23902281 + Patent:US2546658 + Reaxys:253894 + Wikipedia:Hydroxychloroquine + 2-[{4-[(7-chloroquinolin-4-yl)amino]pentyl}(ethyl)amino]ethanol + chebi_ontology + (+-)-hydroxychloroquine + 2-((4-((7-chloro-4-quinolyl)amino)pentyl)ethylamino)ethanol + 2-(N-(4-(7-chlor-4-chinolylamino)-4-methylbutyl)ethylamino)ethanol + 7-chloro-4-(4-(N-ethyl-N-beta-hydroxyethylamino)-1-methylbutylamino)quinoline + 7-chloro-4-(4-(ethyl(2-hydroxyethyl)amino)-1-methylbutylamino)quinoline + 7-chloro-4-[4-(N-ethyl-N-beta-hydroxyethylamino)-1-methylbutylamino]quinoline + 7-chloro-4-[5-(N-ethyl-N-2-hydroxyethylamino)-2-pentyl]aminoquinoline + NSC4375 + Polirreumin + hidroxicloroquina + hydroxychloroquine + hydroxychloroquinum + oxichlorochine + oxichloroquine + CHEBI:5801 + + hydroxychloroquine + + + + + + + + + + + + + + + + + + + + + An amino acid zwitterion arising from transfer of a proton from the carboxy to the amino group of L-phenylalanine; major species at pH 7.3. + + 0 + C9H11NO2 + InChI=1S/C9H11NO2/c10-8(9(11)12)6-7-4-2-1-3-5-7/h1-5,8H,6,10H2,(H,11,12)/t8-/m0/s1 + COLNVLDHVKWLRT-QMMMGPOBSA-N + 165.18910 + 165.07898 + [NH3+][C@@H](Cc1ccccc1)C([O-])=O + MetaCyc:PHE + PMID:21956539 + (2S)-2-azaniumyl-3-phenylpropanoate + chebi_ontology + (2S)-2-ammonio-3-phenylpropanoate + L-phenylalanine + phenylalanine + CHEBI:58095 + + L-phenylalanine zwitterion + + + + + + + + + + 0 + C27H40O4 + InChI=1S/C27H40O4/c1-5-6-7-8-24(30)31-27(18(2)28)16-13-23-21-10-9-19-17-20(29)11-14-25(19,3)22(21)12-15-26(23,27)4/h17,21-23H,5-16H2,1-4H3/t21-,22+,23+,25+,26+,27+/m1/s1 + DOMWKUIIPQCAJU-LJHIYBGHSA-N + 428.605 + 428.29266 + CCCCCC(=O)O[C@@]1(CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)=O + CAS:630-56-8 + Drug_Central:4189 + KEGG:C08148 + KEGG:D00949 + Hydroxyprogesterone caproate + chebi_ontology + 17-alpha-hydroxy-progesterone caproate + 17alpha-Caproyloxypregn-4-ene-3,20-dione + 17alpha-Hydroxyprogesterone hexanoate + 17alpha-hydroxyprogesterone + Primolut depot + delalutin + gestageno + hydroxyprogesterone hexanoate + makena + oxyprogesterone caproate + progesterone caproate + CHEBI:5812 + + Hydroxyprogesterone caproate + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A phenothiazine derivative in which 10H-phenothiazinecarries a 3-(4-methylpiperazin-1-yl)propyl substituent at the N-10 position. + + 0 + C20H25N3S + InChI=1S/C20H25N3S/c1-21-13-15-22(16-14-21)11-6-12-23-17-7-2-4-9-19(17)24-20-10-5-3-8-18(20)23/h2-5,7-10H,6,11-16H2,1H3 + WEYVCQFUGFRXOM-UHFFFAOYSA-N + 339.49800 + 339.17692 + CN1CCN(CCCN2c3ccccc3Sc3ccccc23)CC1 + Beilstein:39009 + CAS:84-97-9 + Drug_Central:2100 + Gmelin:298041 + KEGG:C16903 + PMID:1650428 + PMID:19904008 + PMID:23479940 + PMID:24425538 + Patent:GB780193 + Reaxys:39009 + Wikipedia:Perazine + 10-[3-(4-methylpiperazin-1-yl)propyl]-10H-phenothiazine + chebi_ontology + 10-(3-(4-Methyl-1-piperazinyl)propyl)-10H-phenothiazine + N-(3-(4-Methyl-1-piperazinyl)propyl)phenothiazine + N-Methyl-piperazinyl-N'-propyl-phenothiazin + N-Methyl-piperazinylpropyl-phenothiazine + Pernazine + CHEBI:59118 + + perazine + + + + + + + + + Any EC 3.4.* (hydrolases acting on peptide bond) inhibitor that inhibits the activity of a serine endopeptidase (EC 3.4.21.*). + + chebi_ontology + EC 3.4.21.* (serine endopeptidase) inhibitors + EC 3.4.21.* inhibitor + EC 3.4.21.* inhibitors + inhibitor of serine endopeptidase (EC 3.4.21.*) + inhibitor of serine endopeptidase (EC 3.4.21.*)s + serine endopeptidase inhibitor + serine endopeptidase inhibitors + CHEBI:5924 + + EC 3.4.21.* (serine endopeptidase) inhibitor + + + + + + + + + + CAS:76543-88-9 + KEGG:C07900 + KEGG:D00745 + Interferon alfa-2a + chebi_ontology + Interferon alpha-2A + CHEBI:5937 + + Interferon alfa-2a + + + + + + + + + + CAS:145155-23-3 + KEGG:C07901 + KEGG:D00746 + Interferon beta-1b + chebi_ontology + CHEBI:5938 + + Interferon beta-1b + + + + + + + + + Any substance that inhibits the synthesis of DNA. + + chebi_ontology + DNA synthesis inhibitors + CHEBI:59517 + + DNA synthesis inhibitor + + + + + + + + + + + + + + + Any fatty acid with a chain length of between C6 and C12. + + 0 + CHO2R + 45.01740 + 44.99765 + OC([*])=O + chebi_ontology + MCFA + MCFAs + medium-chain fatty acids + CHEBI:59554 + + medium-chain fatty acid + + + + + + + + + + + + + + + A fatty acid anion resulting from the deprotonation of the carboxylic acid moiety of a medium-chain fatty acid. + + -1 + CO2R + 44.010 + 43.98983 + [O-]C([*])=O + chebi_ontology + MCFA anion + MCFA anions + a medium chain fatty acid + medium-chain FA anion + medium-chain FA anions + medium-chain fatty acid anions + CHEBI:59558 + + medium-chain fatty acid anion + + + + + + + + + A drug, usually applied topically, that relieves pruritus (itching). + + chebi_ontology + anti-itching drug + anti-itching drugs + antipruritic agent + antipruritic agents + antipruritic drugs + CHEBI:59683 + + antipruritic drug + + + + + + + + + Compounds containing one or more phosphoric acid units. + + chebi_ontology + CHEBI:59698 + + phosphoric acids + + + + + + + + + + A reagent that forms a bond to its reaction partner (the electrophile) by donating both bonding electrons. + + chebi_ontology + nucleophile + nucleophiles + nucleophilic reagents + CHEBI:59740 + + nucleophilic reagent + + + + + + + + + An organooxygen compound having the structure RR'C(OR'')(OR''') (R'', R''' =/= H). Mixed acetals have R'' and R''' groups which differ. + + chebi_ontology + acetals + CHEBI:59769 + + acetal + + + + + + + + + + An acetal in the molecule of which the acetal carbon and one or both oxygen atoms thereon are members of a ring. + + chebi_ontology + cyclic acetals + CHEBI:59770 + + cyclic acetal + + + + + + + + + A hemiacetal having the structure RR(1)C(OH)OR(2) (R, R(1), R(2) =/= H), derived from a ketone by formal addition of an alcohol to the carbonyl group. + + 0 + CHO2R3 + 45.017 + 44.99765 + C(*)(O)(O*)* + chebi_ontology + hemiketals + CHEBI:59772 + + hemiketal + + + + + + + + + An acetal of formula R2C(OR)2 (R =/= H) derived from a ketone by replacement of the oxo group by two hydrocarbyloxy groups. The class name 'ketals', once abandoned by IUPAC, has been reinstated as a subclass of acetals. + + chebi_ontology + ketals + CHEBI:59777 + + ketal + + + + + + + + + + A ketal in the molecule of which the ketal carbon and one or both oxygen atoms thereon are members of a ring. + + chebi_ontology + cyclic ketals + CHEBI:59779 + + cyclic ketal + + + + + + + + + + A hemiacetal having the structure R2C(OH)OR (R =/= H), derived from a ketone by formal addition of an alcohol to the carbonyl group. The term 'cyclic hemiketals', once abandoned by IUPAC, has been reinstated as a subclass of hemiacetals. + + chebi_ontology + cyclic hemiketals + CHEBI:59780 + + cyclic hemiketal + + + + + + + + + + + + + + + Conjugate base of an L-alpha-amino acid arising from deprotonation of the C-1 carboxy group. + + -1 + C2H3NO2R + 73.051 + 73.01638 + [C@H](C(=O)[O-])(N)* + chebi_ontology + L-alpha-amino carboxylate + CHEBI:59814 + + L-alpha-amino acid anion + + + + + + + + + A synthetic progestogen. + + Wikipedia:Progestin + chebi_ontology + progestins + CHEBI:59826 + + progestin + + + + + + + + + + + + + + + Zwitterionic form of an L-alpha-amino acid having an anionic carboxy group and a protonated amino group. + + 0 + C2H4NO2R + 74.059 + 74.02420 + [NH3+][C@@H]([*])C([O-])=O + chebi_ontology + L-alpha-amino acid zwitterions + an L-alpha-amino acid + CHEBI:59869 + + L-alpha-amino acid zwitterion + + + + + + + + + + + + + + + Zwitterionic form of a D-alpha-amino acid having an anionic carboxy group and a protonated amino group. + + 0 + C2H4NO2R + 74.059 + 74.02420 + [NH3+][C@H]([*])C([O-])=O + chebi_ontology + D-alpha-amino acid zwitterions + a D-alpha-amino acid + CHEBI:59871 + + D-alpha-amino acid zwitterion + + + + + + + + + + A DNA polymerase inhibitor that interferes with the activity of reverse transcriptase, EC 2.7.7.49, a viral DNA polymerase enzyme that retroviruses need in order to reproduce. + + Wikipedia:Reverse-transcriptase_inhibitor + chebi_ontology + DNA nucleotidyltransferase (RNA-directed) inhibitor + DNA nucleotidyltransferase (RNA-directed) inhibitors + EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitors + EC 2.7.7.49 inhibitor + EC 2.7.7.49 inhibitors + RNA revertase inhibitor + RNA revertase inhibitors + RNA-dependent DNA polymerase inhibitor + RNA-dependent DNA polymerase inhibitors + RNA-dependent deoxyribonucleate nucleotidyltransferase inhibitor + RNA-dependent deoxyribonucleate nucleotidyltransferase inhibitors + RNA-directed DNA polymerase (EC 2.7.7.49) inhibitor + RNA-directed DNA polymerase (EC 2.7.7.49) inhibitors + RNA-directed DNA polymerase inhibitor + RNA-directed DNA polymerase inhibitors + RNA-instructed DNA polymerase inhibitor + RNA-instructed DNA polymerase inhibitors + RT inhibitor + RT inhibitors + deoxynucleoside-triphosphate:DNA deoxynucleotidyltransferase (RNA-directed) inhibitor + deoxynucleoside-triphosphate:DNA deoxynucleotidyltransferase (RNA-directed) inhibitors + reverse transcriptase inhibitor + reverse transcriptase inhibitors + revertase inhibitor + revertase inhibitors + telomerase inhibitor + telomerase inhibitors + CHEBI:59897 + + EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor + + + + + + + + + + A chemical substance is a portion of matter of constant composition, composed of molecular entities of the same type or of different types. + + + chebi_ontology + Chemische Substanz + CHEBI:59999 + + chemical substance + + + + + + + + + A mixture is a chemical substance composed of multiple molecules, at least two of which are of a different kind. + + + chebi_ontology + Mischung + CHEBI:60004 + + mixture + + + + + + + + + Any anion arising from deprotonation of at least one OH group in a flavonoid compound. + + chebi_ontology + flavonoid oxoanions + CHEBI:60038 + + flavonoid oxoanion + + + + + + + + + An atom or small molecule with a positive charge that does not contain carbon in covalent linkage, with a valency of one. + + chebi_ontology + a monovalent cation + CHEBI:60242 + + monovalent inorganic cation + + + + + + + + + A hydrolase inhibitor that interferes with the action of any hydrolase acting on peptide bonds (peptidase), EC 3.4.*.*). + + CHEBI:76763 + chebi_ontology + EC 3.4.* (hydrolase acting on peptide bond) inhibitor + EC 3.4.* (hydrolase acting on peptide bonds) inhibitors + EC 3.4.* (hydrolases acting on peptide bond) inhibitors + EC 3.4.* (peptidase) inhibitor + EC 3.4.* (peptidase) inhibitors + EC 3.4.* inhibitor + EC 3.4.* inhibitors + inhibitor of hydrolases acting on peptide bond (EC 3.4.*) + inhibitors of hydrolases acting on peptide bond (EC 3.4.*) + peptidase inhibitors + protease inhibitor + protease inhibitors + CHEBI:60258 + + EC 3.4.* (hydrolases acting on peptide bond) inhibitor + + + + + + + + + An anion formed by deprotonation of at least one peptide carboxy group. + + chebi_ontology + peptide anions + CHEBI:60334 + + peptide anion + + + + + + + + + + + + + + + Zwitterionic form of any peptide where, in general, the amino terminus is positively charged and the carboxy terminus is negatively charged. + + 0 + C2H4NO2R(C2H2NOR)n + chebi_ontology + peptide zwitterions + CHEBI:60466 + + peptide zwitterion + + + + + + + + + Any agent that acts on an opioid receptor or affects the life cycle of an opioid transmitter. + + chebi_ontology + opioid agents + CHEBI:60598 + + opioid agent + + + + + + + + + Any agent that acts on a mu-opioid receptor. + + chebi_ontology + mu-opioid agents + CHEBI:60599 + + mu-opioid agent + + + + + + + + + + An agent that selectively binds to and activates an opioid receptor. + + chebi_ontology + opiate agonist + opiate agonists + opioid agonist + opioid agonists + opioid receptor agonists + CHEBI:60606 + + opioid receptor agonist + + + + + + + + + Any substance that inhibits the action of N-methyl-D-aspartate (NMDA) receptors. They tend to induce a state known as dissociative anesthesia, marked by catalepsy, amnesia, and analgesia, while side effects can include hallucinations, nightmares, and confusion. Due to their psychotomimetic effects, many NMDA receptor antagonists are used as recreational drugs. + + CHEBI:60797 + chebi_ontology + N-methyl-D-aspartate receptor antagonist + N-methyl-D-aspartate receptor antagonists + NMDA receptor antagonists + NMDAR antagonist + NMDAR antagonists + CHEBI:60643 + + NMDA receptor antagonist + + + + + + + + + + + + + + + Any organic aromatic compound containing two phenyl (or substituted phenyl) groups attached to a single carbon or heteroatom and which has significant antifungal properties. + + chebi_ontology + bridged diphenyl antifungal agents + CHEBI:60644 + + bridged diphenyl antifungal agent + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + 6069 + A mixture consisting of >= 80% 22,23-dihydroavermectin B1a and <= 20% 22,23-dihydroavermectin B1b. It is a semi-synthetic derivative of abamectin. A broad-spectrum antiparasite medication, particularly against worms (except tapeworms) but also effective againstmost mites and some lice + A mixture consisting of >= 90% 22,23-dihydroavermectin B1a (R = Me) and <= 10% 22,23-dihydroavermectin B1b (R = H). A semi-synthetic derivative of abamectin, it is used as a broad-spectrum antiparasite medication, particularly against worms (except tapeworms), although it is also effective against most mites and some lice. + + + 0 + C47H71O14R + 860.060 + 859.48438 + [H][C@@]12C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@]4([H])[C@H](O)C(C)=C[C@@]([H])(C(=O)O[C@@H](C1)C[C@]1(CC[C@H](C)[C@]([H])(O1)[C@@H](C)C[*])O2)[C@]34O + CAS:70288-86-7 + ChemIDplus:70288-86-7 + CiteXplore:15078277 + CiteXplore:18718154 + CiteXplore:21824728 + CiteXplore:21831526 + CiteXplore:22039801 + CiteXplore:22047763 + DrugBank:DB00602 + HMDB:HMDB0014740 + KEGG COMPOUND:70288-86-7 + KEGG COMPOUND:C07970 + KEGG DRUG:D00804 + KEGG:D00804 + PMID:15078277 + PMID:18718154 + PMID:21824728 + PMID:21831526 + PMID:22039784 + PMID:22039801 + PMID:22047763 + Patent:US4199569 + Wikipedia:Ivermectin + chebi_ontology + Ivermax + Ivomec + Mectizan + Noromectin + Privermectin + Sklice + Stromectol + Vetrimec + Zimecterin + ivermectin + ivermectine + ivermectino + ivermectinum + CHEBI:6078 + + Ivermectin + ivermectin + + + + + + + + + Any substance which inhibits the action of receptors for excitatory amino acids. + + chebi_ontology + EAA receptor antagonist + EAA receptor antagonists + excitatory amino acid antagonists + excitatory amino acid receptor antagonist + excitatory amino acid receptor antagonists + CHEBI:60798 + + excitatory amino acid antagonist + + + + + + + + + Any substance that interacts with tubulin to inhibit or promote polymerisation of microtubules. + + chebi_ontology + tubulin modulators + CHEBI:60832 + + tubulin modulator + + + + + + + + + Any pyridoindole containing a beta-carboline skeleton and their hydrogenated derivatives + + PMID:1967844 + chebi_ontology + 9H-pyrido[3,4-b]indoles + CHEBI:60834 + + beta-carbolines + + + + + + + + + + + + + + + Any alpha-amino acid anion in which the parent amino acid has D-configuration. + + -1 + C2H3NO2R + 73.051 + 73.01638 + [C@@H](C(=O)[O-])(N)* + chebi_ontology + D-alpha-amino acid anions + D-alpha-amino carboxylate + CHEBI:60895 + + D-alpha-amino acid anion + + + + + + + + + A racemate is an equimolar mixture of a pair of enantiomers. + + + chebi_ontology + melange racemique + racemates + racemic mixture + CHEBI:60911 + + racemate + + + + + + + + + + + + + + + + Any compound that has a nucleobase as a part. + + chebi_ontology + nucleobase-containing compound + nucleobase-containing compounds + nucleobase-containing molecular entities + CHEBI:61120 + + nucleobase-containing molecular entity + + + + + + + + + + + + + + + An ammonium ion that results from the protonation of the dimethyl-substituted nitrogen of promethazine. + + +1 + C17H21N2S + InChI=1S/C17H20N2S/c1-13(18(2)3)12-19-14-8-4-6-10-16(14)20-17-11-7-5-9-15(17)19/h4-11,13H,12H2,1-3H3/p+1 + PWWVAXIEGOYWEE-UHFFFAOYSA-O + 285.42700 + 285.14200 + CC(CN1c2ccccc2Sc2ccccc12)[NH+](C)C + Reaxys:4263748 + N,N-dimethyl-1-(10H-phenothiazin-10-yl)propan-2-aminium + chebi_ontology + promethazine cation + promethazinium + CHEBI:61214 + + promethazine(1+) + + + + + + + + + + + + + + + + The carbohydrate acid derivative anion that is the conjugate base of baicalin. + + -1 + C21H17O11 + InChI=1S/C21H18O11/c22-9-6-10(8-4-2-1-3-5-8)30-11-7-12(14(23)15(24)13(9)11)31-21-18(27)16(25)17(26)19(32-21)20(28)29/h1-7,16-19,21,23-27H,(H,28,29)/p-1/t16-,17-,18+,19-,21+/m0/s1 + IKIIZLYTISPENI-ZFORQUDYSA-M + 445.35310 + 445.07763 + O[C@H]1[C@@H](O[C@@H]([C@@H](O)[C@@H]1O)C([O-])=O)Oc1cc2oc(cc(=O)c2c(O)c1O)-c1ccccc1 + MetaCyc:CPD-12725 + PMID:10724177 + 5,6-dihydroxy-4-oxo-2-phenyl-4H-chromen-7-yl beta-D-glucopyranosiduronate + chebi_ontology + 5,6,7-trihydroxyflavone 7-O-beta-D-glucuronate + 5,6,7-trihydroxyflavone-7-O-beta-D-glucuronate + baicalein 7-O-beta-D-glucuronate + baicalin + CHEBI:61283 + + baicalin(1-) + + + + + + + + + A steroid that has a structure based on a 21-carbon (pregnane) skeleton. Note that individual examples may have ring substituents at other positions and/or contain double bonds, aromatic A-rings, expanded/contracted rings etc., so the formula and mass may vary from that given for the generic structure. + + 0 + C21H36 + InChI=1S/C21H36/c1-4-15-9-11-18-17-10-8-16-7-5-6-13-20(16,2)19(17)12-14-21(15,18)3/h15-19H,4-14H2,1-3H3 + JWMFYGXQPXQEEM-UHFFFAOYSA-N + 288.511 + 288.28170 + C1CCCC2C1(C3C(CC2)C4C(CC3)(C(CC4)CC)C)C + chebi_ontology + a C21-steroid + CHEBI:61313 + + C21-steroid + + + + + + + + + + Any member of a class of naturally occurring alkaloids based on a 1-methyl-9H-beta-carboline skeleton. + + chebi_ontology + harmala alkaloids + CHEBI:61379 + + harmala alkaloid + + + + + + + + + + Any saponin derived from a hydroxysteroid. + + PMID:18486659 + PMID:20346608 + PMID:20846658 + chebi_ontology + glycosteroid + glycosteroids + glycosyl steroid + glycosyl steroids + steroid glycoside + steroid glycosides + steroid saponins + steroidal glycoside + steroidal glycosides + sterol glycoside + sterol glycosides + steryl glycoside + steryl glycosides + CHEBI:61655 + + steroid saponin + + + + + + + + + An organic heterotricyclic compound with a skeleton derived from a pyridine ring fused to an isoquinoline. + + chebi_ontology + pyridoisoquinolines + CHEBI:61692 + + pyridoisoquinoline + + + + + + + + + + A terpenoid in which one or more hydroxy functions are glycosylated. + + chebi_ontology + terpene glycosides + CHEBI:61777 + + terpene glycoside + + + + + + + + + + A terpene glycoside in which the terpene moiety is a triterpenoid. + + Wikipedia:Triterpenoid_saponin + chebi_ontology + triterpene glycoside + triterpene glycosides + triterpenoid saponins + CHEBI:61778 + + triterpenoid saponin + + + + + + + + + + Any substance that interacts with tubulin to inhibit polymerisation of microtubules. + + PMID:17099073 + chebi_ontology + microtubule destabilising agent + microtubule destabilising agents + microtubule destabilising role + microtubule destabilizing role + microtubule-destabilising agents + microtubule-destabilizing agent + microtubule-destabilizing agents + CHEBI:61951 + + microtubule-destabilising agent + + + + + + + + + + + + + + + Zwitterionic form of a polar amino acid having an anionic carboxy group and a protonated amino group. + + 0 + C2H4NO2R + 74.059 + 74.02420 + C(C([O-])=O)(*)[NH3+] + MetaCyc:Polar-amino-acids + chebi_ontology + a polar amino acid + CHEBI:62031 + + polar amino acid zwitterion + + + + + + + + + + + + + + + + An alkanesulfonate in which the carbon at position 1 is attached to at least two hydrogens. + + -1 + CH2O3SR + 94.09000 + 93.97246 + [H]C([H])([*])S([O-])(=O)=O + KEGG:C15521 + MetaCyc:Alkanesulfonates + chebi_ontology + 1,1-di-unsubstituted alkanesulfonate + 1,1-di-unsubstituted alkanesulfonates + 1,1-diunsubstituted alkanesulfonates + CHEBI:62081 + + 1,1-diunsubstituted alkanesulfonate + + + + + + + + + + An EC 2.7.10.* (protein-tyrosine kinase) inhibitor that interferes with the action of receptor protein-tyrosine kinase (EC 2.7.10.1). + + Wikipedia:Anaplastic_lymphoma_kinase + chebi_ontology + AATK inhibitor + AATYK inhibitor + AATYK2 inhibitor + AATYK3 inhibitor + ACH inhibitor + ALK inhibitor + ALK inhibitors + ARK inhibitor + ATP:[protein]-L-tyrosine O-phosphotransferase (receptor-type) inhibitor + ATP:[protein]-L-tyrosine O-phosphotransferase (receptor-type) inhibitors + AXL inhibitor + BRT inhibitor + Bek inhibitor + Bfgfr inhibitor + Bsk inhibitor + C-FMS inhibitor + CAK inhibitor + CCK4 inhibitor + CD115 inhibitor + CD135 inhibitor + CDw135 inhibitor + CFD1 inhibitor + CKIT inhibitor + CSF1R inhibitor + Cek1 inhibitor + Cek10 inhibitor + Cek11 inhibitor + Cek2 inhibitor + Cek3 inhibitor + Cek5 inhibitor + Cek6 inhibitor + Cek7 inhibitor + DAlk inhibitor + DDR1 inhibitor + DDR2 inhibitor + DKFZp434C1418 inhibitor + DRT inhibitor + DTK inhibitor + Dek inhibitor + Drosophila Eph kinase inhibitor + EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitors + EC 2.7.10.1 inhibitor + EC 2.7.10.1 inhibitors + ECK inhibitor + EDDR1 inhibitor + EGFR inhibitor + EPH inhibitor + EPHA1 inhibitor + EPHA2 inhibitor + EPHA6 inhibitor + EPHA7 inhibitor + EPHA8 inhibitor + EPHB1 inhibitor + EPHB2 inhibitor + EPHB3 inhibitor + EPHB4 inhibitor + EPHT inhibitor + EPHT2 inhibitor + EPHT3 inhibitor + EPHX inhibitor + ERBB inhibitor + ERBB1 inhibitor + ERBB2 inhibitor + ERBB3 inhibitor + ERBB4 inhibitor + ERK inhibitor + Ebk inhibitor + Eek inhibitor + Ehk2 inhibitor + Ehk3 inhibitor + Elk inhibitor + EphB5 inhibitor + Eyk inhibitor + FGFR1 inhibitor + FGFR2 inhibitor + FGFR3 inhibitor + FGFR4 inhibitor + FLG inhibitor + FLK1 inhibitor + FLK2 inhibitor + FLT1 inhibitor + FLT2 inhibitor + FLT3 inhibitor + FLT4 inhibitor + FMS inhibitor + Fv2 inhibitor + HBGFR inhibitor + HEK11 inhibitor + HEK2 inhibitor + HEK3 inhibitor + HEK5 inhibitor + HEK6 inhibitor + HEP inhibitor + HER2 inhibitor + HER3 inhibitor + HER4 inhibitor + HGFR inhibitor + HSCR1 inhibitor + HTK inhibitor + IGF1R inhibitor + INSR inhibitor + INSRR inhibitor + IR inhibitor + IRR inhibitor + JTK12 inhibitor + JTK13 inhibitor + JTK14 inhibitor + JWS inhibitor + K-SAM inhibitor + KDR inhibitor + KGFR inhibitor + KIA0641 inhibitor + KIAA1079 inhibitor + KIAA1459 inhibitor + KIT inhibitor + KLG inhibitor + Kil inhibitor + Kin15 inhibitor + Kin16 inhibitor + LTK inhibitor + MCF3 inhibitor + MEN2A/B inhibitor + MER inhibitor + MERTK inhibitor + MEhk1 inhibitor + MST1R inhibitor + MTC1 inhibitor + MUSK inhibitor + Mdk1 inhibitor + Mdk2 inhibitor + Mdk5 inhibitor + Mep inhibitor + Mlk1 inhibitor + Mlk2 inhibitor + Mrk inhibitor + Myk1 inhibitor + N-SAM inhibitor + NEP inhibitor + NET inhibitor + NGL inhibitor + NOK inhibitor + NTRK1 inhibitor + NTRK2 inhibitor + NTRK3 inhibitor + NTRK4 inhibitor + NTRKR1 inhibitor + NTRKR2 inhibitor + NTRKR3 inhibitor + NYK inhibitor + Neu inhibitor + Nsk2 inhibitor + Nuk inhibitor + PCL inhibitor + PDGFR inhibitor + PDGFRA inhibitor + PDGFRB inhibitor + PHB6 inhibitor + PTK inhibitor + PTK3 inhibitor + PTK7 inhibitor + RET inhibitor + RON inhibitor + ROR1 inhibitor + ROR2 inhibitor + ROS1 inhibitor + RSE inhibitor + RTK inhibitor + RYK inhibitor + SEA inhibitor + SKY inhibitor + STK inhibitor + STK1 inhibitor + Sek2 inhibitor + Sek3 inhibitor + Sek4 inhibitor + Sfr inhibitor + TEK inhibitor + TIE inhibitor + TIE1 inhibitor + TIE2 inhibitor + TIF inhibitor + TKT inhibitor + TRK inhibitor + TRKA inhibitor + TRKB inhibitor + TRKC inhibitor + TRKE inhibitor + TYK1 inhibitor + TYRO10 inhibitor + TYRO3 inhibitor + TYRO7 inhibitor + Tyro11 inhibitor + Tyro5 inhibitor + Tyro6 inhibitor + UFO inhibitor + VEGFR1 inhibitor + VEGFR2 inhibitor + VEGFR3 inhibitor + Vik inhibitor + YK1 inhibitor + Yrk inhibitor + anaplastic lymphoma kinase inhibitor + anaplastic lymphoma kinase inhibitors + ephrin-B3 receptor tyrosine kinase inhibitor + insulin receptor protein-tyrosine kinase inhibitor + neurite outgrowth regulating kinase inhibitor + nork inhibitor + novel oncogene with kinase-domain inhibitor + receptor protein tyrosine kinase inhibitor + receptor protein-tyrosine kinase (EC 2.7.10.1) inhibitor + receptor protein-tyrosine kinase (EC 2.7.10.1) inhibitors + receptor protein-tyrosine kinase inhibitor + receptor protein-tyrosine kinase inhibitors + CHEBI:62434 + + EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor + + + + + + + + + A molecular messenger in which the molecule is specifically involved in transmitting information between cells. Such molecules are released from the cell sending the signal, cross over the gap between cells by diffusion, and interact with specific receptors in another cell, triggering a response in that cell by activating a series of enzyme controlled reactions which lead to changes inside the cell. + + chebi_ontology + signal molecule + signal molecules + signaling molecule + signaling molecules + signalling molecules + CHEBI:62488 + + signalling molecule + + + + + + + + + + An ester where the ester linkage is bonded directly to an aromatic system. + + chebi_ontology + aromatic esters + CHEBI:62732 + + aromatic ester + + + + + + + + + + An amide in which the amide linkage is bonded directly to an aromatic system. + + chebi_ontology + aromatic amides + CHEBI:62733 + + aromatic amide + + + + + + + + + Any additive that enhances the efficiency of fuel. + + chebi_ontology + fuel additives + fuel enhancer + CHEBI:62803 + + fuel additive + + + + + + + + + Any compound that is able to prevent damage to the liver. + + chebi_ontology + antihepatotoxic agent + hepatoprotective agents + CHEBI:62868 + + hepatoprotective agent + + + + + + + + + An EC 1.2.3.* (oxidoreductase acting on donor aldehyde/oxo group with oxygen as acceptor) inhibitor which interferes with the action of aldehyde oxidase (EC 1.2.3.1). + + Wikipedia:Aldehyde_oxidase + chebi_ontology + EC 1.2.3.1 (aldehyde oxidase) inhibitors + EC 1.2.3.1 inhibitor + EC 1.2.3.1 inhibitors + aldehyde oxidase (EC 1.2.3.1) inhibitor + aldehyde oxidase (EC 1.2.3.1) inhibitors + aldehyde oxidase inhibitor + aldehyde oxidase inhibitors + aldehyde:oxygen oxidoreductase inhibitor + aldehyde:oxygen oxidoreductase inhibitors + quinoline oxidase inhibitor + quinoline oxidase inhibitors + retinal oxidase inhibitor + retinal oxidase inhibitors + retinoic acid synthase inhibitor + retinoic acid synthase inhibitors + CHEBI:62872 + + EC 1.2.3.1 (aldehyde oxidase) inhibitor + + + + + + + + + + + + + + + A monocarboxylic acid anion resulting from the removal of a proton from the carboxy group of mycophenolic acid. + + -1 + C17H19O6 + InChI=1S/C17H20O6/c1-9(5-7-13(18)19)4-6-11-15(20)14-12(8-23-17(14)21)10(2)16(11)22-3/h4,20H,5-8H2,1-3H3,(H,18,19)/p-1/b9-4+ + HPNSFSBZBAHARI-RUDMXATFSA-M + 319.32920 + 319.11871 + COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC([O-])=O + (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enoate + mycophenolate + chebi_ontology + CHEBI:62932 + + mycophenolate + + + + + + + + + The chemical role played by a substance that stabilizes an emulsion by increasing its kinetic stability. + + chebi_ontology + emulgent + emulgents + emulsifiers + CHEBI:63046 + + emulsifier + + + + + + + + + A carbohydrate derivative arising formally from the elimination of water from a glycosidic hydroxy group and an H atom bound to an oxygen, carbon, nitrogen or sulfur atom of a separate entity. + + + chebi_ontology + glycosyl compounds + CHEBI:63161 + + glycosyl compound + + + + + + + + + + + + + + + + Any organooxygen compound derived from a carbohydrate by replacement of one or more hydroxy group(s) by an amino group, a thiol group or similar heteroatomic groups. The term also includes derivatives of these compounds. + + + chebi_ontology + carbohydrate derivatives + derivatised carbohydrate + derivatised carbohydrates + derivatized carbohydrate + derivatized carbohydrates + CHEBI:63299 + + carbohydrate derivative + + + + + + + + + An EC 3.1.3.* (phosphoric monoester hydrolase) inhibitor that interferes with the action of alkaline phosphatase (EC 3.1.3.1). + + Wikipedia:Alkaline_phosphatase + chebi_ontology + EC 3.1.3.1 (alkaline phosphatase) inhibitors + EC 3.1.3.1 inhibitor + EC 3.1.3.1 inhibitors + alkaline phenyl phosphatase inhibitor + alkaline phenyl phosphatase inhibitors + alkaline phosphatase (EC 3.1.3.1) inhibitor + alkaline phosphatase (EC 3.1.3.1) inhibitors + alkaline phosphatase inhibitor + alkaline phosphatase inhibitors + alkaline phosphohydrolase inhibitor + alkaline phosphohydrolase inhibitors + alkaline phosphomonoesterase inhibitor + alkaline phosphomonoesterase inhibitors + glycerophosphatase inhibitor + glycerophosphatase inhibitors + orthophosphoric-monoester phosphohydrolase (alkaline optimum) inhibitor + orthophosphoric-monoester phosphohydrolase (alkaline optimum) inhibitors + phosphate-monoester phosphohydrolase (alkaline optimum) inhibitor + phosphate-monoester phosphohydrolase (alkaline optimum) inhibitors + phosphomonoesterase inhibitor + phosphomonoesterase inhibitors + CHEBI:63332 + + EC 3.1.3.1 (alkaline phosphatase) inhibitor + + + + + + + + + + + + + + + A carbohydrate derivative that is formally obtained from a disaccharide. + + chebi_ontology + disaccharide derivatives + CHEBI:63353 + + disaccharide derivative + + + + + + + + + + + + + + + A carbohydrate derivative that is formally obtained from a monosaccharide. + + chebi_ontology + monosaccharide derivatives + CHEBI:63367 + + monosaccharide derivative + + + + + + + + + + + + + + + + + + + + + A carbohydrate derivative that is formally obtained from a carbohydrate acid. + + chebi_ontology + carbohydrate acid derivatives + CHEBI:63436 + + carbohydrate acid derivative + + + + + + + + + + + + + + + A branched-chain amino acid whose alpha-carboxylic acid group is ionized (not protonated). + + chebi_ontology + branched-chain amino-acid anions + CHEBI:63471 + + branched-chain amino-acid anion + + + + + + + + + + + + + + + An aromatic amino acid whose alpha-carboxylic acid group is ionized (non-protonated). + + chebi_ontology + aromatic amino-acid anions + CHEBI:63473 + + aromatic amino-acid anion + + + + + + + + + An EC 3.6.3.* (acid anhydride hydrolase catalysing transmembrane movement of substances) inhibitor that interferes with the action of Na(+)/K(+)-transporting ATPase (EC 3.6.3.9). + + Wikipedia:Sodium-potassium_ATPase + chebi_ontology + EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitors + EC 3.6.3.9 inhibitor + EC 3.6.3.9 inhibitors + Na(+)/K(+)-ATPase inhibitor + Na(+)/K(+)-ATPase inhibitors + Na(+)/K(+)-pump inhibitor + Na(+)/K(+)-pump inhibitors + Na(+)/K(+)-transporting ATPase (EC 3.6.3.9) inhibitor + Na(+)/K(+)-transporting ATPase (EC 3.6.3.9) inhibitors + Na(+)/K(+)-transporting ATPase inhibitor + Na(+)/K(+)-transporting ATPase inhibitors + sodium pump inhibitor + sodium pump inhibitors + sodium-potassium adenosine triphosphatase inhibitor + sodium-potassium adenosine triphosphatase inhibitors + sodium-potassium pump inhibitor + sodium-potassium pump inhibitors + CHEBI:63510 + + EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor + + + + + + + + + + + + + + + + + + + + + A carboxylic acid anion resulting from the deprotonation of the carboxy group of a carbohydrate acid derivative. + + chebi_ontology + carbohydrate acid anion derivative + carbohydrate acid anion derivatives + carbohydrate acid derivative anions + CHEBI:63551 + + carbohydrate acid derivative anion + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + 9344 + A 1-ribosyltriazole that is the 1-ribofuranosyl derivative of 1,2,4-triazole-3-carboxamide. A synthetic guanosine analogue, it is an inhibitor of HCV polymerase and possesses a broad spectrum of activity against DNA and RNA viruses. + A 1-ribosyltriazole that is the 1-ribofuranosyl derivative of 1,2,4-triazole-3-carboxamide. An inhibitor of HCV polymerase. + + + 0 + C8H12N4O5 + InChI=1S/C8H12N4O5/c9-6(16)7-10-2-12(11-7)8-5(15)4(14)3(1-13)17-8/h2-5,8,13-15H,1H2,(H2,9,16)/t3-,4-,5-,8-/m1/s1 + IWUCXVSUMQZMFG-AFCXAGJDSA-N + 244.20470 + 244.08077 + NC(=O)c1ncn(n1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O + CHEBI:8840 + Beilstein:892462 + CAS:36791-04-5 + ChemIDplus:36791-04-5 + ChemIDplus:892462 + CiteXplore:21827730 + CiteXplore:22052088 + CiteXplore:22052220 + CiteXplore:22156853 + CiteXplore:22158703 + CiteXplore:22212566 + CiteXplore:22212568 + CiteXplore:22212569 + CiteXplore:22212572 + CiteXplore:22212576 + CiteXplore:22212579 + CiteXplore:22220723 + CiteXplore:22239498 + CiteXplore:22239511 + DrugBank:DB00811 + Drug_Central:2373 + KEGG DRUG:36791-04-5 + KEGG DRUG:D00423 + KEGG:D00423 + LINCS:LSM-5701 + PMID:21827730 + PMID:22052088 + PMID:22052220 + PMID:22156853 + PMID:22158703 + PMID:22212566 + PMID:22212568 + PMID:22212569 + PMID:22212572 + PMID:22212576 + PMID:22212579 + PMID:22220723 + PMID:22239498 + PMID:22239511 + PMID:29438107 + Reaxys:892462 + Wikipedia:Ribavirin + 1-(beta-D-ribofuranosyl)-1H-1,2,4-triazole-3-carboxamide + chebi_ontology + 1-beta-D-Ribofuranosyl-1,2,4-triazole-3-carboxamide + 1-beta-D-Ribofuranosyl-1H-1,2,4-triazole-3-carboxamide + C8H12N4O5 + InChI=1S/C8H12N4O5/c9-6(16)7-10-2-12(11-7)8-5(15)4(14)3(1-13)17-8/h2-5,8,13-15H,1H2,(H2,9,16)/t3-,4-,5-,8-/m1/s1 + InChIKey=IWUCXVSUMQZMFG-AFCXAGJDSA-N + NC(=O)c1ncn(n1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O + RBV + ribavirin + ribavirina + ribavirine + ribavirinum + CHEBI:63580 + + Ribavirin + ribavirin + + + + + + + + + + An N-glycosyl compound that consists of any triazole having a glycosyl residue attached at position 1. + + + chebi_ontology + 1-glycosyltriazoles + CHEBI:63593 + + 1-glycosyltriazole + + + + + + + + + A 1-glycosyltriazole in which the glycosyl residue is specified as ribosyl. + + + chebi_ontology + 1-ribosyltriazoles + CHEBI:63594 + + 1-ribosyltriazole + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + 6694 + A racemate composed of (+)-(11R,2'S)- and (-)-(11S,2'R)-enantiomers of mefloquine. An antimalarial agent which acts as a blood schizonticide; its mechanism of action is unknown. + + + CHEBI:6718 + CAS:53230-10-7 + ChemIDplus:53230-10-7 + CiteXplore:21118921 + CiteXplore:21853223 + CiteXplore:21861987 + CiteXplore:22006004 + CiteXplore:22217970 + CiteXplore:22223333 + CiteXplore:22232280 + CiteXplore:22233563 + CiteXplore:22236373 + CiteXplore:22245668 + CiteXplore:22246492 + DrugBank:DB00358 + KEGG COMPOUND:53230-10-7 + KEGG COMPOUND:C07633 + KEGG DRUG:D04895 + KEGG:C07633 + KEGG:D04895 + PMID:21118921 + PMID:21853223 + PMID:21861987 + PMID:22006004 + PMID:22217970 + PMID:22223333 + PMID:22232280 + PMID:22233563 + PMID:22236373 + PMID:22245668 + PMID:22246492 + Reaxys:5306591 + Wikipedia:Mefloquine + rac--(R)-[2,8-bis(trifluoromethyl)quinolin-4-yl][(2S)-piperidin-2-yl]methanol + chebi_ontology + Racemic mefloquine + [(R*,S*)-2,8-bis(trifluoromethyl)quinolin-4-yl]-(2-piperidyl)methanol + [DL-erythro-alpha-2-Piperidyl-2,8-bis(trifluoromethyl)]-4-quinolinemethanol + mefloquina + mefloquine + mefloquinum + CHEBI:63609 + + Mefloquine + mefloquine + + + + + + + + + + + + An organofluorine compound that consists of quinoline bearing trifluoromethyl substituents at positions 2 and 8 as well as a (2-piperidinyl)hydroxymethyl substituent at position 4. + + 0 + C17H16F6N2O + InChI=1S/C17H16F6N2O/c18-16(19,20)11-5-3-4-9-10(15(26)12-6-1-2-7-24-12)8-13(17(21,22)23)25-14(9)11/h3-5,8,12,15,24,26H,1-2,6-7H2 + XEEQGYMUWCZPDN-UHFFFAOYSA-N + 378.31220 + 378.11668 + OC(C1CCCCN1)c1cc(nc2c(cccc12)C(F)(F)F)C(F)(F)F + CAS:49752-90-1 + CAS:53230-10-7 + KEGG:C07633 + KEGG:D04895 + LINCS:LSM-5180 + Reaxys:766168 + [2,8-bis(trifluoromethyl)quinolin-4-yl](piperidin-2-yl)methanol + chebi_ontology + alpha-2-Piperidinyl-2,8-bis(trifluoromethyl)-4-quinolinemethanol + alpha-2-piperidinyl-2,8-bis(trifluoromethyl)-4-quinolinemethanol + CHEBI:63681 + + [2,8-bis(trifluoromethyl)quinolin-4-yl]-(2-piperidyl)methanol + + + + + + + + + + + + + + + + + + + + + An optically active form of [2,8-bis(trifluoromethyl)quinolin-4-yl]-(2-piperidyl)methanol having (+)-(11R,2'S)-erythro-configuration. An antimalarial agent, used in racemic form, which acts as a blood schizonticide; its mechanism of action is unknown. + + 0 + C17H16F6N2O + InChI=1S/C17H16F6N2O/c18-16(19,20)11-5-3-4-9-10(15(26)12-6-1-2-7-24-12)8-13(17(21,22)23)25-14(9)11/h3-5,8,12,15,24,26H,1-2,6-7H2/t12-,15+/m0/s1 + XEEQGYMUWCZPDN-SWLSCSKDSA-N + 378.31220 + 378.11668 + O[C@@H]([C@@H]1CCCCN1)c1cc(nc2c(cccc12)C(F)(F)F)C(F)(F)F + CAS:51688-68-7 + Reaxys:766169 + (R)-[2,8-bis(trifluoromethyl)quinolin-4-yl][(2S)-piperidin-2-yl]methanol + chebi_ontology + (+)-mefloquine + [(11R,2'S)-2,8-bis(trifluoromethyl)quinolin-4-yl]-(2-piperidyl)methanol + CHEBI:63684 + + (+)-(11R,2'S)-erythro-mefloquine + + + + + + + + + + + + + + + + + + + + + An optically active form of [2,8-bis(trifluoromethyl)quinolin-4-yl]-(2-piperidyl)methanol having (-)-(11S,2'R)-erythro-configuration. An antimalarial agent, used in racemic form, which acts as a blood schizonticide; its mechanism of action is unknown. + + 0 + C17H16F6N2O + InChI=1S/C17H16F6N2O/c18-16(19,20)11-5-3-4-9-10(15(26)12-6-1-2-7-24-12)8-13(17(21,22)23)25-14(9)11/h3-5,8,12,15,24,26H,1-2,6-7H2/t12-,15+/m1/s1 + XEEQGYMUWCZPDN-DOMZBBRYSA-N + 378.31220 + 378.11668 + O[C@H]([C@H]1CCCCN1)c1cc(nc2c(cccc12)C(F)(F)F)C(F)(F)F + CAS:51742-87-1 + LINCS:LSM-5525 + Reaxys:5629059 + (S)-[2,8-bis(trifluoromethyl)quinolin-4-yl][(2R)-piperidin-2-yl]methanol + chebi_ontology + (-)-Mefloquine + [(11S,2'R)-2,8-bis(trifluoromethyl)quinolin-4-yl]-(2-piperidyl)methanol + CHEBI:63687 + + (-)-(11S,2'R)-erythro-mefloquine + + + + + + + + + Any compound that can be used for the treatment of neurodegenerative disorders. + + chebi_ontology + neuroprotectant + neuroprotectants + neuroprotective agents + CHEBI:63726 + + neuroprotective agent + + + + + + + + + + + + + + + + A macrocyclic lactone that is avermectin B1a in which the double bond present in the spirocyclic ring system has been reduced to a single bond. It is the major component of ivermectin. + + 0 + C48H74O14 + InChI=1S/C48H74O14/c1-11-25(2)43-28(5)17-18-47(62-43)23-34-20-33(61-47)16-15-27(4)42(26(3)13-12-14-32-24-55-45-40(49)29(6)19-35(46(51)58-34)48(32,45)52)59-39-22-37(54-10)44(31(8)57-39)60-38-21-36(53-9)41(50)30(7)56-38/h12-15,19,25-26,28,30-31,33-45,49-50,52H,11,16-18,20-24H2,1-10H3/b13-12+,27-15+,32-14+/t25-,26-,28-,30-,31-,33+,34-,35-,36-,37-,38-,39-,40+,41-,42-,43+,44-,45+,47+,48+/m0/s1 + AZSNMRSAGSSBNP-XPNPUAGNSA-N + 875.09280 + 874.50786 + [H][C@@]12C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@]4([H])[C@H](O)C(C)=C[C@@]([H])(C(=O)O[C@@H](C1)C[C@]1(CC[C@H](C)[C@]([H])(O1)[C@@H](C)CC)O2)[C@]34O + CAS:71827-03-7 + PDBeChem:IVM + PMID:2411323 + PMID:6125361 + PMID:6148214 + PMID:6547280 + Reaxys:4643153 + VSDB:1455 + (2aE,4E,5'S,6S,6'R,7S,8E,11R,13R,15S,17aR,20R,20aR,20bS)-6'-[(2S)-butan-2-yl]-20,20b-dihydroxy-5',6,8,19-tetramethyl-17-oxo-3',4',5',6,6',10,11,14,15,17,17a,20,20a,20b-tetradecahydro-2H,7H-spiro[11,15-methanofuro[4,3,2-pq][2,6]benzodioxacyclooctadecine-13,2'-pyran]-7-yl 2,6-dideoxy-4-O-(2,6-dideoxy-3-O-methyl-alpha-L-arabino-hexopyranosyl)-3-O-methyl-alpha-L-arabino-hexopyranoside + chebi_ontology + 5-O-demethyl-22,23-dihydroavermectin A1a + H2B1a + avermectin H2B1a + dihydroavermectin B1a + ivermectin B1a + CHEBI:63941 + + 22,23-dihydroavermectin B1a + + + + + + + + + + + + + + + + A macrocyclic lactone that is avermectin B1b in which the double bond present in the spirocyclic ring system has been reduced to a single bond. It is the minor component of ivermectin. + + 0 + C47H72O14 + InChI=1S/C47H72O14/c1-24(2)41-27(5)16-17-46(61-41)22-33-19-32(60-46)15-14-26(4)42(25(3)12-11-13-31-23-54-44-39(48)28(6)18-34(45(50)57-33)47(31,44)51)58-38-21-36(53-10)43(30(8)56-38)59-37-20-35(52-9)40(49)29(7)55-37/h11-14,18,24-25,27,29-30,32-44,48-49,51H,15-17,19-23H2,1-10H3/b12-11+,26-14+,31-13+/t25-,27-,29-,30-,32+,33-,34-,35-,36-,37-,38-,39+,40-,41+,42-,43-,44+,46+,47+/m0/s1 + VARHUCVRRNANBD-PVVXTEPVSA-N + 861.06620 + 860.49221 + [H][C@@]12C\C=C(C)\[C@@H](O[C@H]3C[C@H](OC)[C@@H](O[C@H]4C[C@H](OC)[C@@H](O)[C@H](C)O4)[C@H](C)O3)[C@@H](C)\C=C\C=C3/CO[C@]4([H])[C@H](O)C(C)=C[C@@]([H])(C(=O)O[C@@H](C1)C[C@]1(CC[C@H](C)[C@]([H])(O1)C(C)C)O2)[C@]34O + CAS:70209-81-3 + PMID:6125361 + PMID:6148214 + PMID:6895285 + PMID:6896121 + Reaxys:8183665 + (2aE,4E,5'S,6S,6'R,7S,8E,11R,13R,15S,17aR,20R,20aR,20bS)-20,20b-dihydroxy-5',6,8,19-tetramethyl-17-oxo-6'-(propan-2-yl)-3',4',5',6,6',10,11,14,15,17,17a,20,20a,20b-tetradecahydro-2H,7H-spiro[11,15-methanofuro[4,3,2-pq][2,6]benzodioxacyclooctadecine-13,2'-pyran]-7-yl 2,6-dideoxy-4-O-(2,6-dideoxy-3-O-methyl-alpha-L-arabino-hexopyranosyl)-3-O-methyl-alpha-L-arabino-hexopyranoside + chebi_ontology + H2B1b + avermectin H2B1b + dihydroavermectin B1b + ivermectin B1b + ivermectin component b1b + CHEBI:63943 + + 22,23-dihydroavermectin B1b + + + + + + + + + + Any lactone in which the cyclic carboxylic ester group forms a part of a cyclic macromolecule. + + + CHEBI:50333 + chebi_ontology + macrocyclic lactones + CHEBI:63944 + + macrocyclic lactone + + + + + + + + + An EC 3.6.4.10 (non-chaperonin molecular chaperone ATPase) inhibitor that blocks the action of heat shock protein 90. + + PMID:19860732 + PMID:19946660 + PMID:22035754 + PMID:22920907 + PMID:22959035 + PMID:23160336 + PMID:23312026 + Wikipedia:Hsp90_inhibitors + chebi_ontology + Hsp90 inhibitors + heat shock protein 90 inhibitor + heat shock protein 90 inhibitors + CHEBI:63962 + + Hsp90 inhibitor + + + + + + + + + An agonist that selectively binds to and activates a protein kinase C receptor + + chebi_ontology + protein kinase C agonists + CHEBI:64018 + + protein kinase C agonist + + + + + + + + + + Any substance which is added to food to preserve or enhance its flavour and/or appearance. + + Wikipedia:Food_additive + chebi_ontology + food additives + CHEBI:64047 + + food additive + + + + + + + + + An agonist that selectively binds to and activates a protein kinase receptor. + + chebi_ontology + protein kinase agonists + CHEBI:64106 + + protein kinase agonist + + + + + + + + + + Any protease inhibitor that restricts the action of a cysteine protease. + + chebi_ontology + cysteine protease inhibitors + cysteine proteinase inhibitor + cysteine proteinase inhibitors + CHEBI:64152 + + cysteine protease inhibitor + + + + + + + + + A histamine antagonist that selectively binds to but does not activate histamine H3 receptors, thereby blocking the actions of endogenous histamine. + + chebi_ontology + H3-receptor antagonists + histamine H3-receptor antagonist + histamine H3-receptor antagonists + CHEBI:64176 + + H3-receptor antagonist + + + + + + + + + + + + + + + + An ammonium ion resulting from the protonation of the dimethyl-substituted amino group of clomipramine. + + +1 + C19H24ClN2 + InChI=1S/C19H23ClN2/c1-21(2)12-5-13-22-18-7-4-3-6-15(18)8-9-16-10-11-17(20)14-19(16)22/h3-4,6-7,10-11,14H,5,8-9,12-13H2,1-2H3/p+1 + GDLIGKIOYRNHDA-UHFFFAOYSA-O + 315.86000 + 315.16225 + C[NH+](C)CCCN1c2ccccc2CCc2ccc(Cl)cc12 + 3-(3-chloro-10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethylpropan-1-aminium + chebi_ontology + CHEBI:64209 + + clomipramine(1+) + + + + + + + + + + Any organic salt prepared using an organosulfonic acid as the acid component. + + chebi_ontology + organosulfonate salts + organosulphonate salt + organosulphonate salts + CHEBI:64382 + + organosulfonate salt + + + + + + + + + An excitatory amino acid agonist which binds to NMDA receptors and triggers a response. + + chebi_ontology + N-methyl-D-aspartate receptor agonist + N-methyl-D-aspartate receptor agonists + NMDA receptor agonists + NMDAR agonist + NMDAR agonists + CHEBI:64571 + + NMDA receptor agonist + + + + + + + + + A food additive which is added to flour or dough to improve baking quality and/or colour. + + Wikipedia:Flour_treatment_agent + flour treatment agent + chebi_ontology + dough improver + dough improvers + improving agent + improving agents + CHEBI:64577 + + flour treatment agent + + + + + + + + + + A steroid compound with a structure based on a 21-carbon (pregnane) skeleton that acts as a hormone. + + chebi_ontology + C21-steroid hormones + CHEBI:64600 + + C21-steroid hormone + + + + + + + + + An organic molecular entity containing a single carbon atom (C1). + + chebi_ontology + one-carbon compounds + CHEBI:64708 + + one-carbon compound + + + + + + + + + Any organic molecular entity that is acidic and contains carbon in covalent linkage. + + chebi_ontology + organic acids + CHEBI:64709 + + organic acid + + + + + + + + + Any substance that causes disturbance to organisms by chemical reaction or other activity on the molecular scale, when a sufficient quantity is absorbed by the organism. + + Wikipedia:Poison + chebi_ontology + poisonous agent + poisonous agents + poisonous substance + poisonous substances + poisons + toxic agent + toxic agents + toxic substance + toxic substances + CHEBI:64909 + + poison + + + + + + + + + Any compound that inhibits cell division (mitosis). + + Wikipedia:Mitotic_inhibitor + chebi_ontology + antimitotics + mitosis inhibitor + mitosis inhibitors + mitotic inhibitor + mitotic inhibitors + CHEBI:64911 + + antimitotic + + + + + + + + + + An antiparasitic drug which is effective against Apicomplexan parasites in the genus Plasmodium. The genus contains over 200 species and includes those responsible for malaria. + + chebi_ontology + antiplasmodial agent + antiplasmodial agents + antiplasmodial drugs + antiplasmodium agent + antiplasmodium agents + antiplasmodium drug + antiplasmodium drugs + CHEBI:64915 + + antiplasmodial drug + + + + + + + + + A cysteine protease inhibitor which inhibits cathepsin B (EC 3.4.22.1). + + chebi_ontology + EC 3.4.22.1 inhibitor + EC 3.4.22.1 inhibitors + cathepsin B inhibitors + cathepsin B1 inhibitor + cathepsin B1 inhibitors + cathepsin II inhibitor + cathepsin II inhibitors + CHEBI:64932 + + cathepsin B inhibitor + + + + + + + + + An antiviral agent that destroys or inhibits the replication of the human immunodeficiency virus. + + chebi_ontology + anti-AIDS agent + anti-AIDS agents + anti-HIV agents + CHEBI:64946 + + anti-HIV agent + + + + + + + + + An anti-HIV agent that destroys or inhibits the replication of HIV-1, the more infective and more virulent of the two types of HIV virus. + + chebi_ontology + anti-HIV-1 agents + anti-HTLV-III agent + anti-HTLV-III agents + anti-LAV agent + anti-LAV agents + CHEBI:64947 + + anti-HIV-1 agent + + + + + + + + + A lipoxygenase inhibitor that interferes with the action of arachidonate 12-lipoxygenase (EC 1.13.11.31). + + chebi_ontology + 12-LOX inhibitor + 12-LOX inhibitors + 12-lipoxygenase inhibitor + 12-lipoxygenase inhibitors + 12S-lipoxygenase inhibitor + 12S-lipoxygenase inhibitors + 5delta-lipoxygenase inhibitor + 5delta-lipoxygenase inhibitors + C-5-lipoxygenase inhibitor + C-5-lipoxygenase inhibitors + EC 1.13.11.31 (arachidonate 12-lipoxygenase) inhibitors + EC 1.13.11.31 inhibitor + EC 1.13.11.31 inhibitors + LTA4 synthase inhibitor + LTA4 synthase inhibitors + arachidonate 12-lipoxygenase (EC 1.13.11.31) inhibitor + arachidonate 12-lipoxygenase (EC 1.13.11.31) inhibitors + arachidonate 12-lipoxygenase inhibitor + arachidonate 12-lipoxygenase inhibitors + delta(12)-lipoxygenase inhibitor + delta(12)-lipoxygenase inhibitors + leukotriene A4 synthase inhibitor + leukotriene A4 synthase inhibitors + CHEBI:64995 + + EC 1.13.11.31 (arachidonate 12-lipoxygenase) inhibitor + + + + + + + + + + A lipoxygenase inhibitor that interferes with the action of arachidonate 15-lipoxygenase (EC 1.13.11.33). + + chebi_ontology + 15-LOX inhibitor + 15-LOX inhibitors + 15-lipoxygenase inhibitor + 15-lipoxygenase inhibitors + EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitors + EC 1.13.11.33 inhibitor + EC 1.13.11.33 inhibitors + arachidonate 15-lipoxygenase (EC 1.13.11.33) inhibitor + arachidonate 15-lipoxygenase (EC 1.13.11.33) inhibitors + arachidonate 15-lipoxygenase inhibitor + arachidonate 15-lipoxygenase inhibitors + arachidonate:oxygen 15-oxidoreductase inhibitor + arachidonate:oxygen 15-oxidoreductase inhibitors + linoleic acid omega(6)-lipoxygenase inhibitor + linoleic acid omega(6)-lipoxygenase inhibitors + omega(6) lipoxygenase inhibitor + omega(6) lipoxygenase inhibitors + CHEBI:64996 + + EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor + + + + + + + + + Any EC 3.1.1.* (carboxylic ester hydrolase) inhibitor that inhibits the action of triacylglycerol lipase (EC 3.1.1.3). + + chebi_ontology + EC 3.1.1.3 (triacylglycerol lipase) inhibitors + EC 3.1.1.3 inhibitor + EC 3.1.1.3 inhibitors + GEH inhibitor + GEH inhibitors + PPL inhibitor + PPL inhibitors + Tween hydrolase inhibitor + Tween hydrolase inhibitors + Tweenase inhibitor + Tweenase inhibitors + Tweenesterase inhibitor + Tweenesterase inhibitors + butyrinase inhibitor + butyrinase inhibitors + cacordase inhibitor + cacordase inhibitors + capalase L inhibitor + capalase L inhibitors + glycerol ester hydrolase inhibitor + glycerol ester hydrolase inhibitors + glycerol-ester hydrolase inhibitor + glycerol-ester hydrolase inhibitors + heparin releasable hepatic lipase inhibitor + heparin releasable hepatic lipase inhibitors + hepatic lipase inhibitor + hepatic lipase inhibitors + hepatic monoacylglycerol acyltransferase inhibitor + hepatic monoacylglycerol acyltransferase inhibitors + lipase inhibitor + lipase inhibitors + lipazin inhibitor + lipazin inhibitors + liver lipase inhibitor + liver lipase inhibitors + pancreatic lipase inhibitor + pancreatic lipase inhibitors + pancreatic triacylglycerol lipase inhibitor + pancreatic triacylglycerol lipase inhibitors + post-heparin plasma protamine-resistant lipase inhibitor + post-heparin plasma protamine-resistant lipase inhibitors + salt-resistant post-heparin lipase inhibitor + salt-resistant post-heparin lipase inhibitors + steapsin inhibitor + steapsin inhibitors + triacetinase inhibitor + triacetinase inhibitors + triacylglycerol ester hydrolase inhibitor + triacylglycerol ester hydrolase inhibitors + triacylglycerol lipase (EC 3.1.1.3) inhibitor + triacylglycerol lipase (EC 3.1.1.3) inhibitors + triacylglycerol lipase inhibitor + triacylglycerol lipase inhibitors + tributyrase inhibitor + tributyrase inhibitors + tributyrin esterase inhibitor + tributyrin esterase inhibitors + tributyrinase inhibitor + tributyrinase inhibitors + triglyceridase inhibitor + triglyceridase inhibitors + triglyceride hydrolase inhibitor + triglyceride hydrolase inhibitors + triglyceride lipase inhibitor + triglyceride lipase inhibitors + triolein hydrolase inhibitor + triolein hydrolase inhibitors + tween-hydrolysing esterase inhibitor + tween-hydrolyzing esterase inhibitors + CHEBI:65001 + + EC 3.1.1.3 (triacylglycerol lipase) inhibitor + + + + + + + + + Any compound that has anti-asthmatic effects. + + chebi_ontology + anti-asthmatic agents + antiasthmatic agent + antiasthmatic agents + CHEBI:65023 + + anti-asthmatic agent + + + + + + + + + Antipsychotic drugs which can have different modes of action but which tend to be more likely than second generation antipsychotics to cause extrapyramidal motor control disabilities such as body rigidity or Parkinson's disease-type movements; such body movements can become permanent even after treatment has ceased. + + Wikipedia:Typical_antipsychotic + chebi_ontology + first generation antipsychotic agent + first generation antipsychotic agents + first generation antipsychotic drug + first generation antipsychotic drugs + first generation antipsychotics + typical antipsychotic + typical antipsychotic agent + typical antipsychotic agents + typical antipsychotic drug + typical antipsychotic drugs + typical antipsychotics + CHEBI:65190 + + first generation antipsychotic + + + + + + + + + An EC 3.4.21.* (serine endopeptidase) inhibitor that interferes with the action of thrombin (EC 3.4.21.5). + + chebi_ontology + E thrombin inhibitor + E thrombin inhibitors + EC 3.4.21.5 (thrombin) inhibitors + EC 3.4.21.5 inhibitor + EC 3.4.21.5 inhibitors + activated blood-coagulation factor II inhibitor + activated blood-coagulation factor II inhibitors + beta-thrombin inhibitor + beta-thrombin inhibitors + blood-coagulation factor IIa inhibitor + blood-coagulation factor IIa inhibitors + factor IIa inhibitor + factor IIa inhibitors + fibrinogenase inhibitor + fibrinogenase inhibitors + gamma-thrombin inhibitor + gamma-thrombin inhibitors + thrombase inhibitor + thrombase inhibitors + thrombin (EC 3.4.21.5) inhibitor + thrombin (EC 3.4.21.5) inhibitors + thrombin inhibitor + thrombin inhibitors + thrombin-C inhibitor + thrombin-C inhibitors + thrombofort inhibitor + thrombofort inhibitors + tropostasin inhibitor + tropostasin inhibitors + CHEBI:65232 + + EC 3.4.21.5 (thrombin) inhibitor + + + + + + + + + Substances which are added to food in order to prevent decomposition caused by microbial growth or by undesirable chemical changes. + + chebi_ontology + food preservatives + CHEBI:65255 + + food preservative + + + + + + + + + + A food preservative which prevents decomposition of food by preventing the growth of fungi or bacteria. In European countries, E-numbers for permitted food preservatives are from E200 to E299, divided into sorbates (E200-209), benzoates (E210-219), sulfites (E220-229), phenols and formates (E230-239), nitrates (E240-259), acetates (E260-269), lactates (E270-279), propionates (E280-289) and others (E290-299). + + chebi_ontology + antimicrobial food preservatives + antimicrobial preservative + antimicrobial preservatives + CHEBI:65256 + + antimicrobial food preservative + + + + + + + + + + + + + + + + An ammonium ion derivative resulting from the protonation of the nitrogen atom of a primary amino compound. Major species at pH 7.3. + + +1 + H3NR + 17.031 + 17.02655 + [NH3+][*] + chebi_ontology + a primary amine + substituted ammonium + CHEBI:65296 + + primary ammonium ion + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + 6468 + A synthetic piperidine derivative, effective against diarrhoea resulting from gastroenteritis or inflammatory bowel disease. + + + 0 + C29H33ClN2O2 + InChI=1S/C29H33ClN2O2/c1-31(2)27(33)29(24-9-5-3-6-10-24,25-11-7-4-8-12-25)19-22-32-20-17-28(34,18-21-32)23-13-15-26(30)16-14-23/h3-16,34H,17-22H2,1-2H3 + RDOIQAHITMMDAJ-UHFFFAOYSA-N + 477.03800 + 476.22306 + CN(C)C(=O)C(CCN1CCC(O)(CC1)c1ccc(Cl)cc1)(c1ccccc1)c1ccccc1 + Beilstein:1558273 + CAS:53179-11-6 + ChemIDplus:53179-11-6 + DrugBank:DB00836 + Drug_Central:1599 + HMDB:HMDB0004999 + KEGG COMPOUND:53179-11-6 + KEGG COMPOUND:C07080 + KEGG:C07080 + KEGG:D08144 + LINCS:LSM-3365 + PMID:15900907 + PMID:19034106 + PMID:24398461 + Patent:FR2100711 + Patent:US3714159 + Reaxys:1558273 + Wikipedia:Loperamide + 4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-N,N-dimethyl-2,2-diphenylbutanamide + Loperamide + loperamide + chebi_ontology + C29H33ClN2O2 + CN(C)C(=O)C(CCN1CCC(O)(CC1)c1ccc(Cl)cc1)(c1ccccc1)c1ccccc1 + InChI=1S/C29H33ClN2O2/c1-31(2)27(33)29(24-9-5-3-6-10-24,25-11-7-4-8-12-25)19-22-32-20-17-28(34,18-21-32)23-13-15-26(30)16-14-23/h3-16,34H,17-22H2,1-2H3 + InChIKey=RDOIQAHITMMDAJ-UHFFFAOYSA-N + loperamida + loperamide + loperamidum + CHEBI:6532 + + Loperamide + loperamide + + + + + + + + + An indole alkaloid which is biosynthesised from L-tryptophan and isoprenoid building blocks. + + chebi_ontology + terpenoid indole alkaloids + CHEBI:65321 + + terpenoid indole alkaloid + + + + + + + + + A terpenoid indole alkaloid which is biosynthesised from L-tryptophan and diisoprenoid (usually secolaganin) building blocks. + + PMID:18280746 + PMID:20717879 + PMID:21425787 + PMID:22679912 + chebi_ontology + monoterpenoid indole alkaloids + CHEBI:65323 + + monoterpenoid indole alkaloid + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + An indolizidine alkaloid that is 3,12-didehydrogalanthan substituted by hydroxy groups at positions and 2 and a methylenedioxy group across positions 9 and 10. Isolated from Crinum asiaticum, it has been shown to exhibit antimalarial activity. + + 0 + C16H17NO4 + InChI=1S/C16H17NO4/c18-11-3-8-1-2-17-6-9-4-12-13(21-7-20-12)5-10(9)14(15(8)17)16(11)19/h3-5,11,14-16,18-19H,1-2,6-7H2/t11-,14-,15+,16+/m0/s1 + XGVJWXAYKUHDOO-DANNLKNASA-N + 287.31050 + 287.11576 + [H][C@]12[C@H](O)[C@@H](O)C=C3CCN(Cc4cc5OCOc5cc14)[C@@]23[H] + Beilstein:93605 + CAS:476-28-8 + KEGG:C08532 + KNApSAcK:C00001576 + PDBeChem:3KD + PMID:12232602 + PMID:14669261 + PMID:15386196 + PMID:19788245 + Reaxys:93605 + 9,10-(methylenedioxy)-3,12-didehydrogalanthan-1alpha,2beta-diol + Lycorine + chebi_ontology + (-)-lycorine + Amarylline + Galanthidine + Licorine + Narcissine + CHEBI:6601 + + lycorine + + + + + + + + + + + + + + + + + + + + + + + + An organic heterotricyclic compound that consists of a 2,3,3a,8b-tetrahydro-H-benzo[b]cyclopenta[d]furan framework substituted by hydroxy groups at positions C-1 and C-8b, a methoxycarbonyl group at C-2, a phenyl group at C-3, a 4-methoxyphenyl group at C-3a, a methoxy group at C-8 and a 1,4-dioxan-2-yloxy group at position C-6 which in turn is substituted by a methoxy group at position 3 and a 1,2-dihydroxyethyl group at position 6. Isolated from Aglaia silvestris, it exhibits antineoplastic activity. + + 0 + C34H38O13 + InChI=1S/C34H38O13/c1-40-20-12-10-19(11-13-20)34-27(18-8-6-5-7-9-18)26(30(38)42-3)29(37)33(34,39)28-23(41-2)14-21(15-24(28)47-34)45-32-31(43-4)44-17-25(46-32)22(36)16-35/h5-15,22,25-27,29,31-32,35-37,39H,16-17H2,1-4H3/t22-,25-,26-,27-,29-,31-,32-,33+,34+/m1/s1 + GVKXFVCXBFGBCD-QKDMMWSPSA-N + 654.65770 + 654.23124 + [H][C@@]1(CO[C@@H](OC)[C@H](Oc2cc(OC)c3c(O[C@]4([C@@H]([C@H]([C@@H](O)[C@@]34O)C(=O)OC)c3ccccc3)c3ccc(OC)cc3)c2)O1)[C@H](O)CO + PMID:15132542 + PMID:17695501 + PMID:19401772 + PMID:19412536 + PMID:20939540 + PMID:23025805 + PMID:23497456 + Patent:US2009186839 + Patent:WO2013016658 + Reaxys:9977230 + methyl (1R,2R,3S,3aR,8bS)-6-({(2S,3R,6R)-6-[(1R)-1,2-dihydroxyethyl]-3-methoxy-1,4-dioxan-2-yl}oxy)-1,8b-dihydroxy-8-methoxy-3a-(4-methoxyphenyl)-3-phenyl-2,3,3a,8b-tetrahydro-1H-benzo[b]cyclopenta[d]furan-2-carboxylate + chebi_ontology + (-)-silvestrol + CHEBI:66484 + + silvestrol + + + + + + + + + + + + + + + + + + + + + + + + An aromatic amide obtained by formal condensation of the carboxy group of 4-oxo-1,4-dihydroquinoline-3-carboxylic acid with the amino group of 5-amino-2,4-di-tert-butylphenol. Used for the treatment of cystic fibrosis. + + 0 + C24H28N2O3 + InChI=1S/C24H28N2O3/c1-23(2,3)16-11-17(24(4,5)6)20(27)12-19(16)26-22(29)15-13-25-18-10-8-7-9-14(18)21(15)28/h7-13,27H,1-6H3,(H,25,28)(H,26,29) + PURKAOJPTOLRMP-UHFFFAOYSA-N + 392.49070 + 392.20999 + CC(C)(C)c1cc(c(NC(=O)c2c[nH]c3ccccc3c2=O)cc1O)C(C)(C)C + CAS:873054-44-5 + Drug_Central:4228 + KEGG:D09916 + PMID:22047557 + PMID:22293084 + PMID:22383668 + PMID:22499233 + PMID:22508750 + PMID:22543461 + PMID:22618984 + PMID:22698459 + PMID:22723294 + PMID:22739718 + PMID:22768130 + Reaxys:11821038 + Wikipedia:Ivacaftor + N-(2,4-di-tert-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide + chebi_ontology + Kalydeco + VX-770 + ivacaftor + ivacaftorum + CHEBI:66901 + + ivacaftor + + + + + + + + + A membrane transport modulator that restores the chloride ion transport ability of defective cystic fibrosis transmembrane conductance regulator (CFTR) genes. + + Wikipedia:Cystic_fibrosis_transmembrane_conductance_regulator + chebi_ontology + CFTR potentiators + cystic fibrosis transmembrane conductance regulator potentiator + cystic fibrosis transmembrane conductance regulator potentiators + CHEBI:66902 + + CFTR potentiator + + + + + + + + + Any compound which can be used to treat or alleviate the symptoms of dyskinesia. + + chebi_ontology + antidyskinesia agents + antidyskinesia drug + antidyskinesia drugs + antidyskinetic agent + antidyskinetic agents + antidyskinetic drug + antidyskinetic drugs + CHEBI:66956 + + antidyskinesia agent + + + + + + + + + Any compound that has anti-inflammatory effects. + + chebi_ontology + anti-inflammatory agents + antiinflammatory agent + antiinflammatory agents + CHEBI:67079 + + anti-inflammatory agent + + + + + + + + + + + A primary alcohol that is ethanol in which one of the methyl hydrogens is replaced by a morpholin-4-yl group. + + 0 + C6H13NO2 + InChI=1S/C6H13NO2/c8-4-1-7-2-5-9-6-3-7/h8H,1-6H2 + KKFDCBRMNNSAAW-UHFFFAOYSA-N + 131.17290 + 131.09463 + OCCN1CCOCC1 + CAS:622-40-2 + Reaxys:104375 + chebi_ontology + 2-(4-morpholinyl)ethanol + 4-(2-hydroxyethyl)morpholine + 4-morpholineethanol + N(2-hydroxyethyl)morpholine + N-beta-hydroxyethylmorpholine + hydroxyethylmorpholine + morpholine ethanol + CHEBI:67144 + + 2-(morpholin-4-yl)ethanol + + + + + + + + + + Any monocyclic heteroarene consisting of a five-membered ring containing nitrogen. Azoles can also contain one or more other non-carbon atoms, such as nitrogen, sulfur or oxygen. + + Wikipedia:Azole + chebi_ontology + azoles + CHEBI:68452 + + azole + + + + + + + + + + A deoxyribonucleoside containing a pyrimidine base. + + MetaCyc:Pyrimidine-Deoxyribonucleosides + chebi_ontology + pyrimidine deoxyribonucleosides + CHEBI:68472 + + pyrimidine deoxyribonucleoside + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A macrocyclic lactone that is rapamycin in which the hydroxy group attached to the cyclohexyl moiety has been converted to the corresponding 2-hydroxyethyl ether. It is an immunosuppressant and antineoplastic agent. + + 0 + C53H83NO14 + InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1 + HKVAMNSJSFKALM-GKUWKFKPSA-N + 958.22440 + 957.58136 + [H][C@]1(CC[C@@H](OCCO)[C@@H](C1)OC)C[C@@H](C)[C@]1([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]2([H])CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@@]2([H])C(=O)O1)OC + CAS:159351-69-6 + DrugBank:DB01590 + Drug_Central:1118 + HMDB:HMDB0015529 + KEGG:D02714 + PMID:22404500 + PMID:22461124 + PMID:22683823 + PMID:22967800 + PMID:22969095 + PMID:22983698 + PMID:22986894 + Patent:CN102138903 + Patent:RU2008143550 + Patent:WO2012066502 + Wikipedia:Everolimus + (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-{(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone + Everolimus + chebi_ontology + (1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,35R)-1,18-dihydroxy-12-{(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl}-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.0(4,9)]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone + 40-O-(2-hydroxyethyl)-rapamycin + 42-O-(2-Hydroxyethyl)rapamycin + Afinitor + everolimus + everolimusum + CHEBI:68478 + + everolimus + + + + + + + + + A protein kinase inhibitor of the mammalian target of rapamycin (mTOR), a protein that regulates cell growth, cell proliferation, cell motility, cell survival, protein synthesis and transcription. mTOR inhibitors are used to prevent transplant rejection and in treatment of cancer. + + Wikipedia:MTOR_inhibitors + chebi_ontology + mTOR inhibitors + mammalian target of rapamycin inhibitor + mammalian target of rapamycin inhibitors + CHEBI:68481 + + mTOR inhibitor + + + + + + + + + Any substance that induces the process of apoptosis (programmed cell death) in multi-celled organisms. + + chebi_ontology + Type I cell-death inducer + Type I cell-death inducers + Type I programmed cell-death inducer + Type I programmed cell-death inducers + apoptosis inducers + CHEBI:68495 + + apoptosis inducer + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + The 6alpha-stereoisomer of 6-methylprednisolone. + + 0 + C22H30O5 + InChI=1S/C22H30O5/c1-12-8-14-15-5-7-22(27,18(26)11-23)21(15,3)10-17(25)19(14)20(2)6-4-13(24)9-16(12)20/h4,6,9,12,14-15,17,19,23,25,27H,5,7-8,10-11H2,1-3H3/t12-,14-,15-,17-,19+,20-,21-,22-/m0/s1 + VHRSUDSXCMQTMA-PJHHCJLFSA-N + 374.47060 + 374.20932 + C[C@H]1C[C@H]2[C@@H]3CC[C@](O)(C(=O)CO)[C@@]3(C)C[C@H](O)[C@@H]2[C@@]2(C)C=CC(=O)C=C12 + Beilstein:2340300 + CAS:83-43-2 + DrugBank:DB00959 + Drug_Central:1768 + HMDB:HMDB0015094 + KEGG:D00407 + PMID:25232411 + Patent:US2897218 + Patent:US3053832 + Reaxys:2340300 + VSDB:1936 + Wikipedia:Methylprednisolone + 11beta,17,21-trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione + chebi_ontology + (6alpha,11beta)-11,17,21-trihydroxy-6-methylpregna-1,4-diene-3,20-dione + 1-dehydro-6alpha-methylhydrocortisone + 6alpha-methyl-11beta,17alpha,21-triol-1,4-pregnadiene-3,20-dione + Delta(1)-6alpha-methylhydrocortisone + Medrate + Medrol + Medrone + Methylprednisolon + Solomet + Urbason + methylprednisolone + methylprednisolonum + metilprednisolona + CHEBI:6888 + + 6alpha-methylprednisolone + + + + + + + + + A hormone agonist that binds to and activates progesterone receptors. + + chebi_ontology + PR agonist + PR agonists + progesterone receptor agonists + CHEBI:70709 + + progesterone receptor agonist + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A cephalotaxine-derived alkaloid ester obtained from Cephalotaxus harringtonia; used for the treatment of chronic or accelerated phase chronic myeloid leukaemia. + + 0 + C29H39NO9 + InChI=1S/C29H39NO9/c1-27(2,33)8-5-10-29(34,16-23(31)36-4)26(32)39-25-22(35-3)15-28-9-6-11-30(28)12-7-18-13-20-21(38-17-37-20)14-19(18)24(25)28/h13-15,24-25,33-34H,5-12,16-17H2,1-4H3/t24-,25-,28+,29-/m1/s1 + HYFHYPWGAURHIV-JFIAXGOJSA-N + 545.62130 + 545.26248 + [H][C@@]12[C@H](OC(=O)[C@@](O)(CCCC(C)(C)O)CC(=O)OC)C(OC)=C[C@@]11CCCN1CCc1cc3OCOc3cc21 + Beilstein:5687925 + CAS:26833-87-4 + Drug_Central:4677 + KEGG:D08956 + LINCS:LSM-3716 + PDBeChem:HMT + PMID:20971952 + PMID:21152934 + PMID:21258877 + PMID:21294709 + PMID:21415308 + PMID:21418889 + PMID:21468038 + PMID:21509439 + PMID:21845438 + PMID:21916787 + PMID:22040954 + PMID:22054289 + PMID:22075327 + PMID:22289991 + PMID:22391162 + PMID:22580751 + PMID:22714632 + PMID:22896000 + PMID:22898909 + PMID:22917222 + PMID:22967374 + PMID:23053254 + PMID:23059828 + PMID:23086639 + PMID:23109844 + PMID:23456623 + Patent:US2010240887 + Patent:WO2007089878 + Reaxys:5687925 + Wikipedia:Omacetaxine_mepesuccinate + chebi_ontology + (-)-homoharringtonine + (2'R,3S,4S,5R)-(-)-homoharringtonine + CGX-635 + Homoharringtonine + Synribo + mepesuccinate d'omacetaxine + mepesuccinato de omacetaxina + omacetaxine mepesuccinate + omacetaxini mepesuccinas + CHEBI:71019 + + omacetaxine mepesuccinate + + + + + + + + + Any drug that has been developed specifically for treatment of a rare medical condition, the condition itself being known as an orphan disease. + + PMID:20036435 + PMID:20800761 + PMID:21180460 + PMID:21682893 + PMID:21947805 + PMID:22363762 + PMID:22366309 + PMID:22371464 + PMID:22731105 + PMID:22739138 + PMID:22747423 + PMID:22814659 + PMID:22814660 + PMID:22973866 + PMID:22981668 + PMID:22989856 + PMID:23013790 + PMID:23090701 + PMID:23109143 + PMID:23129684 + Wikipedia:Orphan_drug + chebi_ontology + orphan drugs + CHEBI:71031 + + orphan drug + + + + + + + + + + + + + + + + + + + + + + + + + + + A glycopeptide that is vancomycin substituted at position N-3'' by a 2-(decylamino)ethyl group and at position C-29 by a (phosphonomethyl)aminomethyl group. Used as its hydrochloride salt for treatment of adults with complicated skin and skin structure infections caused by bacteria. + + 0 + C80H106Cl2N11O27P + InChI=1S/C80H106Cl2N11O27P/c1-7-8-9-10-11-12-13-14-21-85-22-23-87-80(5)32-57(115-37(4)71(80)103)119-70-68(102)67(101)55(34-94)118-79(70)120-69-53-28-41-29-54(69)117-52-20-17-40(27-46(52)82)65(99)63-77(109)91-61(78(110)111)43-30-50(96)44(33-86-35-121(112,113)114)66(100)58(43)42-25-38(15-18-49(42)95)59(74(106)93-63)90-75(107)60(41)89-73(105)48(31-56(83)97)88-76(108)62(92-72(104)47(84-6)24-36(2)3)64(98)39-16-19-51(116-53)45(81)26-39/h15-20,25-30,36-37,47-48,55,57,59-65,67-68,70-71,79,84-87,94-96,98-103H,7-14,21-24,31-35H2,1-6H3,(H2,83,97)(H,88,108)(H,89,105)(H,90,107)(H,91,109)(H,92,104)(H,93,106)(H,110,111)(H2,112,113,114)/t37-,47+,48-,55+,57-,59+,60+,61-,62+,63-,64+,65+,67+,68-,70+,71+,79-,80-/m0/s1 + ONUMZHGUFYIKPM-MXNFEBESSA-N + 1755.63500 + 1753.63743 + CCCCCCCCCCNCCN[C@@]1(C)C[C@@H](O[C@@H](C)[C@H]1O)O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1Oc1c2Oc3ccc(cc3Cl)[C@@H](O)[C@@H](NC(=O)[C@@H](CC(C)C)NC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]4C(=O)N[C@@H]([C@H](O)c5ccc(Oc1cc3c2)c(Cl)c5)C(=O)N[C@H](C(O)=O)c1cc(O)c(CNCP(O)(O)=O)c(O)c1-c1cc4ccc1O + CAS:372151-71-8 + Drug_Central:4116 + PMID:18443115 + PMID:21740298 + PMID:22078909 + PMID:22123693 + PMID:22174040 + PMID:22248980 + PMID:22252798 + PMID:22252799 + PMID:22411615 + PMID:22416054 + PMID:22491686 + PMID:22508304 + PMID:22547931 + PMID:22575272 + PMID:22619476 + PMID:22668202 + PMID:22687502 + PMID:22855107 + PMID:22867688 + PMID:22890759 + PMID:22916113 + PMID:23030322 + PMID:23083812 + PMID:23129464 + Patent:WO2008085913 + Reaxys:9988046 + Wikipedia:Telavancin + chebi_ontology + N(3'')-[2-(decylamino)ethyl]-29-{[(phosphonomethyl)amino]methyl}vancomycin + telavancin + telavancina + telavancine + telavancinum + CHEBI:71229 + + telavancin + + + + + + + + + An enzyme inhibitor that inhibits the action of a transferase (EC 2.*) + + Wikipedia:Transferase + chebi_ontology + EC 2 inhibitor + EC 2 inhibitors + EC 2.* (transferase) inhibitors + EC 2.* inhibitor + EC 2.* inhibitors + transferase inhibitor + transferase inhibitors + CHEBI:71300 + + EC 2.* (transferase) inhibitor + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A diaminopyridine that is 2,6-diaminopyridine substituted at position 3 by a phenylazo group. A local anesthetic that has topical analgesic effect on mucosa lining of the urinary tract. Its use is limited by problems with toxicity (primarily blood disorders) and potential carcinogenicity. + + 0 + C11H11N5 + InChI=1S/C11H11N5/c12-10-7-6-9(11(13)14-10)16-15-8-4-2-1-3-5-8/h1-7H,(H4,12,13,14) + QPFYXYFORQJZEC-UHFFFAOYSA-N + 213.23850 + 213.10145 + Nc1ccc(N=Nc2ccccc2)c(N)n1 + CHEBI:8057 + Beilstein:184497 + CAS:94-78-0 + DrugBank:DB01438 + HMDB:HMDB0015506 + KEGG:C07429 + KEGG:D08346 + LINCS:LSM-3705 + PMID:19300288 + PMID:19744778 + PMID:20196783 + PMID:20467292 + PMID:20636989 + PMID:20976818 + PMID:21147318 + PMID:21376167 + PMID:21681956 + PMID:21789523 + PMID:21856805 + PMID:22110938 + PMID:22987905 + PMID:23030327 + PMID:28166217 + Patent:US2009247628 + Patent:WO2008033466 + Patent:WO2010071878 + Reaxys:184497 + Wikipedia:Phenazopyridine + 3-(phenyldiazenyl)pyridine-2,6-diamine + chebi_ontology + 2,6-Diamino-3-(phenylazo)pyridine + 2,6-Diamino-3-phenylazopyridine + 3-(Phenylazo)-2,6-pyridinediamine + fenazopiridina + phenazopyridine + phenazopyridinum + CHEBI:71416 + + phenazopyridine + + + + + + + + + + + + + + + + An organic cation that is the conjugate acid of phenazopyridine. + + +1 + C11H12N5 + InChI=1S/C11H11N5/c12-10-7-6-9(11(13)14-10)16-15-8-4-2-1-3-5-8/h1-7H,(H4,12,13,14)/p+1/b16-15+ + QPFYXYFORQJZEC-FOCLMDBBSA-O + 214.24650 + 214.10872 + [H+].Nc1ccc(\N=N\c2ccccc2)c(N)n1 + chebi_ontology + phenazopyridine cation + CHEBI:71420 + + phenazopyridine(1+) + + + + + + + + + + Any organic molecular entity whose stucture is based on derivatives of a phenyl-substituted 1-phenylpropane possessing a C15 or C16 skeleton, or such a structure which is condensed with a C6-C3 lignan precursors. The term is a 'superclass' comprising all members of the classes of flavonoid, isoflavonoid, neoflavonoid, chalcones, dihydrochalcones, aurones, pterocarpan, coumestans, rotenoid, flavonolignan, homoflavonoid and flavonoid oligomers. Originally restricted to natural products, the term is also applied to synthetic compounds related to them. + + Wikipedia:Flavonoids + chebi_ontology + flavonoid + CHEBI:72544 + + flavonoids + + + + + + + + + Any organic molecular entity derived from a natural product by partial chemical synthesis. + + Wikipedia:Semisynthesis + chebi_ontology + semi-synthetic compound + semi-synthetic compounds + semi-synthetic derivative + semi-synthetic derivatives + semisynthetic compound + semisynthetic compounds + semisynthetic derivatives + CHEBI:72588 + + semisynthetic derivative + + + + + + + + + + A cyclic ketal in which the ketal carbon is the only common atom of two rings. + + PMID:19262920 + PMID:20024126 + PMID:21076755 + PMID:21604735 + PMID:21860857 + PMID:22421755 + chebi_ontology + spiroacetal + spiroacetals + spiroketals + CHEBI:72600 + + spiroketal + + + + + + + + + + Any molecule that consists of at least one carbon atom as part of the electrically neutral entity. + + chebi_ontology + organic compound + organic compounds + organic molecules + CHEBI:72695 + + organic molecule + + + + + + + + + An EC 1.11.1.* (peroxidases) inhibitor that inhibits the action of L-ascorbate peroxidase (EC 1.11.1.11). + + Wikipedia:L-ascorbate_peroxidase + chebi_ontology + EC 1.11.1.11 (L-ascorbate peroxidase) inhibitors + EC 1.11.1.11 inhibitor + EC 1.11.1.11 inhibitors + L-ascorbate peroxidase (EC 1.11.1.11) inhibitor + L-ascorbate peroxidase (EC 1.11.1.11) inhibitors + L-ascorbate peroxidase inhibitor + L-ascorbate peroxidase inhibitors + L-ascorbate:hydrogen-peroxide oxidoreductase inhibitor + L-ascorbate:hydrogen-peroxide oxidoreductase inhibitors + L-ascorbic acid peroxidase inhibitor + L-ascorbic acid peroxidase inhibitors + L-ascorbic acid-specific peroxidase inhibitor + L-ascorbic acid-specific peroxidase inhibitors + ascorbate peroxidase inhibitor + ascorbate peroxidase inhibitors + ascorbic acid peroxidase inhibitor + ascorbic acid peroxidase inhibitors + CHEBI:73181 + + EC 1.11.1.11 (L-ascorbate peroxidase) inhibitor + + + + + + + + + Any hydrolase inhibitor that interferes with the action of a hydrolase which acts on acid anhydrides (EC 3.6.*.*). + + CHEBI:76765 + chebi_ontology + EC 3.6 inhibitor + EC 3.6 inhibitors + EC 3.6.* (hydrolases acting on acid anhydrides) inhibitors + EC 3.6.* inhibitor + EC 3.6.* inhibitors + EC 3.6.*.* inhibitor + EC 3.6.*.* inhibitors + acid anhydride hydrolase inhibitor + acid anhydride hydrolase inhibitors + inhibitor of hydrolase acting on acid anhydride (EC 3.6.*) + inhibitors of hydrolase acting on acid anhydride (EC 3.6.*) + CHEBI:73216 + + EC 3.6.* (hydrolases acting on acid anhydrides) inhibitor + + + + + + + + + An acaricide that kills mites of the genus Sarcoptes. + + Wikipedia:Scabicide + chebi_ontology + scabicides + CHEBI:73333 + + scabicide + + + + + + + + + A mancude heterobicyclic organic group consisting of a benzene ring fused to a pyrrole ring. + + 0 + C8N + 110.09230 + 110.00307 + C1(=C(C(=C2C(=C1*)N(C(=C2*)*)*)*)*)* + chebi_ontology + CHEBI:73398 + + indole skeleton + + + + + + + + + A bicyclic organic group that contains both carbon and hetero atoms. + + chebi_ontology + organic heterobicyclic rings + CHEBI:73541 + + organic heterobicyclic ring + + + + + + + + + + An L-alpha-amino acid which is biosynthesised from erythrose 4-phosphate and phosphoenolpyruvate (i.e. phenylalanine, tyrosine, and tryptophan). A closed class. + + chebi_ontology + erythrose 4-phosphate and phosphoenolpyruvate family amino acid + erythrose 4-phosphate and phosphoenolpyruvate family amino acids + erythrose 4-phosphate family amino acid + erythrose 4-phosphate family amino acids + erythrose 4-phosphate/phosphoenolpyruvate family amino acids + phosphoenolpyruvate family amino acid + phosphoenolpyruvate family amino acids + CHEBI:73690 + + erythrose 4-phosphate/phosphoenolpyruvate family amino acid + + + + + + + + + An EC 1.17.* (oxidoreductase acting on CH or CH2) inhibitor that inhibits the action of ribonucleoside-diphosphate reductase (EC 1.17.4.1). + + Wikipedia:Ribonucleoside-diphosphate_reductase + chebi_ontology + 2'-deoxyribonucleoside-diphosphate:thioredoxin-disulfide 2'-oxidoreductase inhibitor + 2'-deoxyribonucleoside-diphosphate:thioredoxin-disulfide 2'-oxidoreductase inhibitors + ADP reductase inhibitor + ADP reductase inhibitors + CDP reductase inhibitor + CDP reductase inhibitors + EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitors + EC 1.17.4.1 inhibitor + EC 1.17.4.1 inhibitors + RR inhibitor + RR inhibitors + UDP reductase inhibitor + UDP reductase inhibitors + nucleoside diphosphate reductase inhibitor + nucleoside diphosphate reductase inhibitors + ribonucleoside diphosphate reductase inhibitor + ribonucleoside diphosphate reductase inhibitors + ribonucleoside-diphosphate reductase (EC 1.17.4.1) inhibitor + ribonucleoside-diphosphate reductase (EC 1.17.4.1) inhibitors + ribonucleoside-diphosphate reductase inhibitor + ribonucleoside-diphosphate reductase inhibitors + ribonucleotide diphosphate reductase inhibitor + ribonucleotide diphosphate reductase inhibitors + ribonucleotide reductase inhibitor + ribonucleotide reductase inhibitors + CHEBI:74213 + + EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor + + + + + + + + + A lactam in which the amide bond is contained within a five-membered ring, which includes the amide nitrogen and the carbonyl carbon. + + chebi_ontology + gamma-lactams + CHEBI:74222 + + gamma-lactam + + + + + + + + + + A pyrrolidinone in which the oxo group is at position 2 of the pyrrolidine ring. + + 0 + C4NOR7 + 78.04890 + 77.99799 + [*]N1C(=O)C([*])([*])C([*])([*])C1([*])[*] + chebi_ontology + 2-pyrrolidinones + 2-pyrrolidones + pyrrolidine-2-ones + CHEBI:74223 + + pyrrolidin-2-ones + + + + + + + + + + + + + + + A D-alpha-amino acid zwitterion that is D-valine in which a proton has been transferred from the carboxy group to the amino group. It is the major species at pH 7.3. + + 0 + C5H11NO2 + InChI=1S/C5H11NO2/c1-3(2)4(6)5(7)8/h3-4H,6H2,1-2H3,(H,7,8)/t4-/m1/s1 + KZSNJWFQEVHDMF-SCSAIBSYSA-N + 117.14630 + 117.07898 + CC(C)[C@@H]([NH3+])C([O-])=O + MetaCyc:CPD-3642 + (2R)-2-ammonio-3-methylbutanoate + chebi_ontology + D-valine + CHEBI:74338 + + D-valine zwitterion + + + + + + + + + + Any steroid lactone that is a C23 steroid with a five-membered lactone ring at C-17 and its substituted derivatives. They form the aglycone constituents of cardiac glycosides. + + chebi_ontology + CHEBI:74634 + + cardenolides + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + An aryl sulfide that is used (as its mesylate salt) for treatment of HIV and also exhibits some anticancer properties. + + 0 + C32H45N3O4S + InChI=1S/C32H45N3O4S/c1-21-25(15-10-16-28(21)36)30(38)33-26(20-40-24-13-6-5-7-14-24)29(37)19-35-18-23-12-9-8-11-22(23)17-27(35)31(39)34-32(2,3)4/h5-7,10,13-16,22-23,26-27,29,36-37H,8-9,11-12,17-20H2,1-4H3,(H,33,38)(H,34,39)/t22-,23+,26-,27-,29+/m0/s1 + QAGYKUNXZHXKMR-HKWSIXNMSA-N + 567.78200 + 567.31308 + Cc1c(O)cccc1C(=O)N[C@@H](CSc1ccccc1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C + CAS:159989-64-7 + DrugBank:DB00220 + Drug_Central:1893 + HMDB:HMDB0014365 + KEGG:C07257 + KEGG:D08259 + LINCS:LSM-5819 + PDBeChem:1UN + PMID:23109184 + PMID:23386514 + PMID:23454896 + PMID:23647753 + PMID:23872785 + PMID:23916134 + PMID:24194293 + PMID:24418752 + PMID:24483157 + PMID:24498124 + PMID:24574416 + PMID:24596143 + PMID:24719428 + Reaxys:7419619 + Wikipedia:Nelfinavir + (3S,4aS,8aS)-N-tert-butyl-2-[(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-(phenylsulfanyl)butyl]decahydroisoquinoline-3-carboxamide + chebi_ontology + nelfinavir + CHEBI:7496 + + nelfinavir + + + + + + + + + + + + + + + + + + + + + + + + + + + A methanesulfonate (mesylate) salt prepared from equimolar amounts of nelfinavir and methanesulfonic acid. It is used for treatment of HIV and also exhibits some anticancer properties. + + 0 + C32H45N3O4S.CH4O3S + C33H49N3O7S2 + InChI=1S/C32H45N3O4S.CH4O3S/c1-21-25(15-10-16-28(21)36)30(38)33-26(20-40-24-13-6-5-7-14-24)29(37)19-35-18-23-12-9-8-11-22(23)17-27(35)31(39)34-32(2,3)4;1-5(2,3)4/h5-7,10,13-16,22-23,26-27,29,36-37H,8-9,11-12,17-20H2,1-4H3,(H,33,38)(H,34,39);1H3,(H,2,3,4)/t22-,23+,26-,27-,29+;/m0./s1 + NQHXCOAXSHGTIA-SKXNDZRYSA-N + 663.88800 + 663.30119 + CS(O)(=O)=O.Cc1c(O)cccc1C(=O)N[C@@H](CSc1ccccc1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C + CAS:159989-65-8 + DrugBank:DB00220 + KEGG:C08091 + KEGG:D00899 + PMID:10452644 + PMID:10698844 + PMID:11106345 + PMID:16189129 + PMID:16545536 + PMID:17046010 + PMID:18430402 + PMID:19443141 + PMID:19660105 + PMID:20399586 + PMID:21392920 + PMID:23385634 + PMID:9397180 + PMID:9607830 + Reaxys:7407090 + Wikipedia:Nelfinavir + (3S,4aS,8aS)-3-(tert-butylcarbamoyl)-2-[(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-(phenylsulfanyl)butyl]decahydroisoquinolinium methanesulfonate + (3S,4aS,8aS)-N-tert-butyl-2-[(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-(phenylsulfanyl)butyl]decahydroisoquinoline-3-carboxamide methanesulfonate + chebi_ontology + Nelfinavir mesilate + Viracept + nelfinavir mesylate + CHEBI:7497 + + nelfinavir mesylate + + + + + + + + + Any compound that inhibits one or more steps in the pathway leading to the synthesis of ergosterol. + + PMID:12604527 + PMID:19835945 + chebi_ontology + ergosterol biosynthesis inhibitors + CHEBI:75282 + + ergosterol biosynthesis inhibitor + + + + + + + + + An EC 1.11.* (oxidoreductase acting on peroxide as donors) inhibitor that interferes with the action of any of the peroxidases (EC 1.11.1.*). + + Wikipedia:Peroxidases + chebi_ontology + EC 1.11.1 inhibitor + EC 1.11.1 inhibitors + EC 1.11.1.* (peroxidase) inhibitor + EC 1.11.1.* (peroxidase) inhibitors + EC 1.11.1.* (peroxidases) inhibitors + EC 1.11.1.* inhibitor + EC 1.11.1.* inhibitors + inhibitor of peroxidases + inhibitors of peroxidases + peroxidases inhibitors + CHEBI:75381 + + EC 1.11.1.* (peroxidases) inhibitor + + + + + + + + + + 0 + C13H8Cl2N2O4 + InChI=1S/C13H8Cl2N2O4/c14-7-1-4-12(18)9(5-7)13(19)16-11-3-2-8(17(20)21)6-10(11)15/h1-6,18H,(H,16,19) + RJMUSRYZPJIFPJ-UHFFFAOYSA-N + 327.120 + 325.98611 + C1=CC(=C(C=C1[N+](=O)[O-])Cl)NC(=O)C2=C(C=CC(=C2)Cl)O + CHEBI:92630 + CAS:50-65-7 + Drug_Central:1912 + HMDB:HMDB0015679 + KEGG:D00436 + LINCS:LSM-2787 + PPDB:1929 + VSDB:1929 + Niclosamide + chebi_ontology + NICLOCIDE (TN) + cestocide + clonitralide + niclocide + CHEBI:7553 + + Niclosamide + + + + + + + + + + + + + + + A carboxamide that is a hydroxamic acid in which the hydrogen of the hydroxy group is replaced by an organyl group. + + 0 + CHNO2R2 + 59.02410 + 59.00073 + [*]C(=O)NO[*] + chebi_ontology + RC(O)NHOR' + RCONHOR' + hydroxamate ester + hydroxamate esters + hydroxamic acid esters + CHEBI:75606 + + hydroxamic acid ester + + + + + + + + + Any metabolite produced during a metabolic reaction in eukaryotes, the taxon that include members of the fungi, plantae and animalia kingdoms. + + chebi_ontology + eukaryotic metabolites + CHEBI:75763 + + eukaryotic metabolite + + + + + + + + + Any eukaryotic metabolite produced during a metabolic reaction in animals that include diverse creatures from sponges, insects to mammals. + + CHEBI:77721 + CHEBI:77743 + chebi_ontology + animal metabolites + CHEBI:75767 + + animal metabolite + + + + + + + + + Any animal metabolite produced during a metabolic reaction in mammals. + + CHEBI:77464 + CHEBI:77744 + chebi_ontology + mammalian metabolites + CHEBI:75768 + + mammalian metabolite + + + + + + + + + Any mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus). + + chebi_ontology + Mus musculus metabolite + Mus musculus metabolites + mouse metabolites + CHEBI:75771 + + mouse metabolite + + + + + + + + + Any fungal metabolite produced during a metabolic reaction in Baker's yeast (Saccharomyces cerevisiae). + + CHEBI:76949 + CHEBI:76951 + chebi_ontology + S. cerevisiae metabolite + S. cerevisiae metabolites + S. cerevisiae secondary metabolite + S. cerevisiae secondary metabolites + Saccharomyces cerevisiae metabolites + Saccharomyces cerevisiae secondary metabolites + baker's yeast metabolite + baker's yeast metabolites + baker's yeast secondary metabolite + baker's yeast secondary metabolites + CHEBI:75772 + + Saccharomyces cerevisiae metabolite + + + + + + + + + Any metabolite produced during a metabolic reaction in prokaryotes, the taxon that include members of domains such as the bacteria and archaea. + + chebi_ontology + prokaryotic metabolites + CHEBI:75787 + + prokaryotic metabolite + + + + + + + + + + + + + + + + + + + + + A peptide zwitterion obtained by transfer of a proton from the carboxy to the amino group of vancomycin aglycone. + + 0 + C53H52Cl2N8O17 + InChI=1S/C53H52Cl2N8O17/c1-19(2)10-29(57-3)47(71)62-42-44(68)21-5-8-33(27(54)12-21)79-35-14-23-15-36(46(35)70)80-34-9-6-22(13-28(34)55)45(69)43-52(76)61-41(53(77)78)26-16-24(64)17-32(66)38(26)25-11-20(4-7-31(25)65)39(49(73)63-43)60-50(74)40(23)59-48(72)30(18-37(56)67)58-51(42)75/h4-9,11-17,19,29-30,39-45,57,64-66,68-70H,10,18H2,1-3H3,(H2,56,67)(H,58,75)(H,59,72)(H,60,74)(H,61,76)(H,62,71)(H,63,73)(H,77,78)/t29-,30+,39-,40-,41+,42-,43+,44-,45-/m1/s1 + JHIKFOISFAQTJQ-YZANBJIASA-N + 1143.92900 + 1142.28275 + C[NH2+][C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)c2ccc(Oc3cc4cc(Oc5ccc(cc5Cl)[C@@H](O)[C@@H]5NC(=O)[C@H](NC(=O)[C@@H]4NC(=O)[C@H](CC(N)=O)NC1=O)c1ccc(O)c(c1)-c1c(O)cc(O)cc1[C@H](NC5=O)C([O-])=O)c3O)c(Cl)c2 + MetaCyc:CPD-15745 + PMID:11470430 + chebi_ontology + CHEBI:75954 + + vancomycin aglycone zwitterion + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + An addition compound obtained by combining equimolar amounts of trametinib and dimethyl sulfoxide. Used for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, and who have not received prior BRAF inhibitor treatment. + + 0 + C26H23FIN5O4.C2H6OS + C28H29FIN5O5S + InChI=1S/C26H23FIN5O4.C2H6OS/c1-13-22-21(23(31(3)24(13)35)30-20-10-7-15(28)11-19(20)27)25(36)33(17-8-9-17)26(37)32(22)18-6-4-5-16(12-18)29-14(2)34;1-4(2)3/h4-7,10-12,17,30H,8-9H2,1-3H3,(H,29,34);1-2H3 + OQUFJVRYDFIQBW-UHFFFAOYSA-N + 693.52800 + 693.09181 + CS(C)=O.CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O + CAS:1187431-43-1 + DrugBank:DB08911 + KEGG:D10176 + PMID:21245089 + PMID:22169769 + PMID:22389471 + PMID:22507781 + PMID:23248257 + PMID:23432625 + PMID:23848983 + PMID:24025354 + PMID:24030134 + Patent:WO2005121142 + Reaxys:12497280 + Wikipedia:Trametinib + N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide--(methylsulfinyl)methane (1/1) + chebi_ontology + GSK1120212 + GSK1120212B + JTP 74057 + Mekinist + Trametinib DMSO + CHEBI:75991 + + trametinib dimethyl sulfoxide + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A pyridopyrimidine that is used (as its dimethyl sulfoxide addition compound) for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations, and who have not received prior BRAF inhibitor treatment. + + 0 + C26H23FIN5O4 + InChI=1S/C26H23FIN5O4/c1-13-22-21(23(31(3)24(13)35)30-20-10-7-15(28)11-19(20)27)25(36)33(17-8-9-17)26(37)32(22)18-6-4-5-16(12-18)29-14(2)34/h4-7,10-12,17,30H,8-9H2,1-3H3,(H,29,34) + LIRYPHYGHXZJBZ-UHFFFAOYSA-N + 615.39480 + 615.07788 + CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O + CAS:871700-17-3 + DrugBank:DB08911 + Drug_Central:4802 + KEGG:D10175 + LINCS:LSM-1143 + PMID:21523318 + PMID:22245957 + PMID:23035153 + PMID:23237773 + PMID:23248257 + PMID:23290787 + PMID:23432625 + PMID:23438367 + PMID:23441129 + PMID:23533766 + PMID:23583440 + PMID:23587417 + PMID:23649971 + PMID:23658559 + PMID:23709751 + PMID:23807941 + PMID:23844038 + PMID:23846731 + PMID:23893461 + PMID:23971497 + PMID:23977666 + PMID:24055054 + Patent:WO2005121142 + Patent:WO2011038082 + Patent:WO2011038085 + Patent:WO2011047238 + Reaxys:12497153 + Wikipedia:Trametinib + N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide + chebi_ontology + GSK 1120212 + JTP 74057 + trametinib + trametinibum + CHEBI:75998 + + trametinib + + + + + + + + + + + + + + + An amino acid zwitterion obtained by transfer of a proton from the carboxy to the amino group of any aromatic amino-acid. + + 0 + C2H4NO2R + 74.059 + 74.02420 + [NH3+]C([*])C([O-])=O + MetaCyc:Aromatic-Amino-Acids + chebi_ontology + an aromatic amino-acid + aromatic amino-acid zwitterions + CHEBI:76042 + + aromatic amino-acid zwitterion + + + + + + + + + Any metabolite produced by metabolism of a xenobiotic compound. + + chebi_ontology + xenobiotic metabolites + CHEBI:76206 + + xenobiotic metabolite + + + + + + + + + A ketone in which the carbonyl group is attached to an aromatic ring. + + chebi_ontology + aromatic ketones + aryl ketone + aryl ketones + CHEBI:76224 + + aromatic ketone + + + + + + + + + + + + + + + 7531 + A tricyclic antidepressant that has formula C19H21N. + + ChemIDplus:2216786 + ChemIDplus:72-69-5 + KEGG COMPOUND:72-69-5 + KEGG COMPOUND:C07274 + NIST Chemistry WebBook:72-69-5 + Wikipedia:Nortriptyline + 3-(10,11-dihydro-5H-dibenzo[a,d][7]annulen-5-ylidene)-N-methylpropan-1-amine + Nortriptyline + 10,11-dihydro-N-methyl-5H-dibenzo[a,d]cycloheptene-Delta(5,gamma)-propylamine + 3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine + Ateben + Avantyl + Aventyl + C19H21N + CNCCC=C1c2ccccc2CCc2ccccc12 + InChI=1S/C19H21N/c1-20-14-6-11-19-17-9-4-2-7-15(17)12-13-16-8-3-5-10-18(16)19/h2-5,7-11,20H,6,12-14H2,1H3 + InChIKey=PHVGLTMQBUFIQQ-UHFFFAOYSA-N + Noritren + Psychostyl + Sensaval + demethylamitriptyline + desmethylamitriptyline + CHEBI:7640 + Nortriptyline + nortriptyline + + + + + + + + + A gas in an atmosphere that absorbs and emits radiation within the thermal infrared range, so contributing to the 'greenhouse effect'. + + Wikipedia:Greenhouse_gas + chebi_ontology + greenhouse gases + CHEBI:76413 + + greenhouse gas + + + + + + + + + A compressed gas or liquid with a boiling point lower than room temperature which to used to propel and dispense liquids such as deodorants, insecticides, paints, etc. from aerosol cans. + + PMID:22519407 + PMID:24001847 + chebi_ontology + propellants + CHEBI:76414 + + propellant + + + + + + + + + Any metabolite produced during a metabolic reaction in marine macro- and microorganisms. + + CHEBI:77078 + chebi_ontology + marine metabolites + CHEBI:76507 + + marine metabolite + + + + + + + + + Any protective agent that is able to prevent damage to the kidney. + + chebi_ontology + nephroprotective agents + CHEBI:76595 + + nephroprotective agent + + + + + + + + + A transferase inhibitor inhibiting the action of transferase of a one-carbon-containing group (EC 2.1.*.*). + + chebi_ontology + C1-transferase (EC 2.1.*) inhibitor + C1-transferase (EC 2.1.*) inhibitors + C1-transferase inhibitor + C1-transferase inhibitors + EC 2.1.* (C1-transferase) inhibitors + EC 2.1.* inhibitor + EC 2.1.* inhibitors + one-carbon-containing group transferase inhibitor + one-carbon-containing group transferase inhibitors + CHEBI:76655 + + EC 2.1.* (C1-transferase) inhibitor + + + + + + + + + A transferase inhibitor that interferes with the action of an acyltransferase (EC 2.3.*.*). + + chebi_ontology + EC 2.3.* (acyltransferase) inhibitors + EC 2.3.* inhibitor + EC 2.3.* inhibitors + acyltransferase inhibitor + acyltransferase inhibitors + CHEBI:76661 + + EC 2.3.* (acyltransferase) inhibitor + + + + + + + + + A transferase inhibitor that inhibits the action of a phosphorus-containing group transferase (EC 2.7.*.*). + + chebi_ontology + EC 2.7.* (P-containing group transferase) inhibitors + EC 2.7.* (phosphorus-containing group transferase) inhibitor + EC 2.7.* (phosphorus-containing group transferase) inhibitors + EC 2.7.* inhibitor + EC 2.7.* inhibitors + phosphorus-containing group transferase (EC 2.7.*) inhibitor + phosphorus-containing group transferase (EC 2.7.*) inhibitors + phosphorus-containing group transferase inhibitor + phosphorus-containing group transferase inhibitors + CHEBI:76668 + + EC 2.7.* (P-containing group transferase) inhibitor + + + + + + + + + An enzyme inhibitor which interferes with the action of an oxidoreductase (EC 1.*.*.*). + + Wikipedia:Oxidoreductase + chebi_ontology + EC 1.* (oxidoreductase) inhibitors + EC 1.* inhibitor + EC 1.* inhibitors + oxidoreductase (EC 1.*) inhibitor + oxidoreductase (EC 1.*) inhibitors + oxidoreductase inhibitor + oxidoreductase inhibitors + CHEBI:76725 + + EC 1.* (oxidoreductase) inhibitor + + + + + + + + + An oxidoreductase inhibitor which interferes with the action of an oxidoreductase acting on the CH-OH group of donors (EC 1.1.*.*). + + chebi_ontology + EC 1.1.* (oxidoreductase acting on donor CH-OH group) inhibitors + EC 1.1.* inhibitor + EC 1.1.* inhibitors + inhibitor of oxidoreductase acting on CH-OH group of donor + inhibitor of oxidoreductase acting on CH-OH group of donors + inhibitors of oxidoreductase acting on CH-OH group of donor + inhibitors of oxidoreductase acting on CH-OH group of donors + oxidoreductase acting on donor CH-OH group (EC 1.1.*) inhibitor + oxidoreductase acting on donor CH-OH group (EC 1.1.*) inhibitors + oxidoreductase acting on donor CH-OH group inhibitor + oxidoreductase acting on donor CH-OH group inhibitors + CHEBI:76726 + + EC 1.1.* (oxidoreductase acting on donor CH-OH group) inhibitor + + + + + + + + + An oxidoreductase inhibitor which interferes with the action of an oxidoreductase acting on the aldehyde or oxo group of donors (EC 1.2.*.*). + + chebi_ontology + EC 1.2.* (oxidoreductase acting on donor aldehyde or oxo group) inhibitor + EC 1.2.* (oxidoreductase acting on donor aldehyde or oxo group) inhibitors + EC 1.2.* (oxidoreductase acting on donor aldehyde/oxo group) inhibitors + EC 1.2.* inhibitor + EC 1.2.* inhibitors + inhibitor of oxidoreductase acting on aldehyde or oxo group of donor + inhibitor of oxidoreductase acting on aldehyde or oxo group of donors + inhibitor of oxidoreductase acting on aldehyde/oxo group of donor + inhibitor of oxidoreductase acting on aldehyde/oxo group of donors + inhibitors of oxidoreductase acting on aldehyde or oxo group of donor + inhibitors of oxidoreductase acting on aldehyde or oxo group of donors + inhibitors of oxidoreductase acting on aldehyde/oxo group of donor + inhibitors of oxidoreductase acting on aldehyde/oxo group of donors + oxidoreductase acting on donor aldehyde or oxo group (EC 1.2.*) inhibitor + oxidoreductase acting on donor aldehyde or oxo group (EC 1.2.*) inhibitors + oxidoreductase acting on donor aldehyde or oxo group inhibitor + oxidoreductase acting on donor aldehyde or oxo group inhibitors + oxidoreductase acting on donor aldehyde/oxo group (EC 1.2.*) inhibitor + oxidoreductase acting on donor aldehyde/oxo group (EC 1.2.*) inhibitors + oxidoreductase acting on donor aldehyde/oxo group inhibitor + oxidoreductase acting on donor aldehyde/oxo group inhibitors + CHEBI:76727 + + EC 1.2.* (oxidoreductase acting on donor aldehyde/oxo group) inhibitor + + + + + + + + + An oxidoreductase inhibitor which interferes with the action of an oxidoreductase acting on the CH-NH2 group of donors (EC 1.4.*.*). + + EC 1.4.* (oxidoreductase acting on donor CH-NH2 group) inhibitor + chebi_ontology + EC 1.4.* (oxidoreductase acting on donor CH-NH2 group) inhibitors + EC 1.4.* inhibitor + EC 1.4.* inhibitors + inhibitor of oxidoreductase acting on CH-NH2 group of donor + inhibitor of oxidoreductase acting on CH-NH2 group of donors + inhibitors of oxidoreductase acting on CH-NH2 group of donor + inhibitors of oxidoreductase acting on CH-NH2 group of donors + oxidoreductase acting on CH-NH2 group of donor inhibitor + oxidoreductase acting on CH-NH2 group of donor inhibitors + oxidoreductase acting on CH-NH2 group of donors (EC 1.4.*) inhibitor + oxidoreductase acting on CH-NH2 group of donors (EC 1.4.*) inhibitors + CHEBI:76730 + + EC 1.4.* (oxidoreductase acting on donor CH-NH2 group) inhibitor + + + + + + + + + An oxidoreductase inhibitor which interferes with the action of an oxidoreductase of class EC 1.8.*.* (acting on a sulfur group of donors). + + chebi_ontology + EC 1.8.* (oxidoreductase acting on sulfur group of donors) inhibitors + EC 1.8.* inhibitor + EC 1.8.* inhibitors + oxidoreductase acting on a sulfur group of donors (EC 1.8.*) inhibitor + oxidoreductase acting on a sulfur group of donors (EC 1.8.*) inhibitors + CHEBI:76735 + + EC 1.8.* (oxidoreductase acting on sulfur group of donors) inhibitor + + + + + + + + + An oxidoreductase inhibitor which interferes with the action of an oxidoreductase acting on a heme group of donors (EC 1.9.*.*). + + chebi_ontology + EC 1.9.* (oxidoreductase acting on a heme group of donors) inhibitor + EC 1.9.* (oxidoreductase acting on a heme group of donors) inhibitors + EC 1.9.* (oxidoreductase acting on donor heme group) inhibitors + EC 1.9.* inhibitor + EC 1.9.* inhibitors + oxidoreductase acting on a heme group of donors (EC 1.9.*) inhibitor + oxidoreductase acting on a heme group of donors (EC 1.9.*) inhibitors + CHEBI:76736 + + EC 1.9.* (oxidoreductase acting on donor heme group) inhibitor + + + + + + + + + An oxidoreductase inhibitor which interferes with the action of an oxidoreductase acting on peroxide as donors (EC 1.11.*.*). + + chebi_ontology + EC 1.11.* (oxidoreductase acting on peroxide as donors) inhibitors + EC 1.11.* (oxidoreductases acting on peroxide as donors) inhibitor + EC 1.11.* (oxidoreductases acting on peroxide as donors) inhibitors + EC 1.11.* inhibitor + EC 1.11.* inhibitors + oxidoreductase acting on peroxide as donors (EC 1.11.*) inhibitor + oxidoreductase acting on peroxide as donors (EC 1.11.*) inhibitors + oxidoreductases acting on peroxide as donors (EC 1.11.*) inhibitor + oxidoreductases acting on peroxide as donors (EC 1.11.*) inhibitors + CHEBI:76738 + + EC 1.11.* (oxidoreductase acting on peroxide as donors) inhibitor + + + + + + + + + An oxidoreductase inhibitor which interferes with the action of an oxidoreductase acting on single donors with incorporation of molecular oxygen (oxygenases), EC 1.13.*.*. + + chebi_ontology + EC 1.13.* [oxidoreductase acting on single donors with incorporation of molecular oxygen (oxygenases)] inhibitors + EC 1.13.* inhibitor + EC 1.13.* inhibitors + oxidoreductase acting on single donors with incorporation of molecular oxygen (oxygenases) (EC 1.13.*) inhibitor + oxidoreductase acting on single donors with incorporation of molecular oxygen (oxygenases) (EC 1.13.*) inhibitors + oxidoreductase acting on single donors with incorporation of molecular oxygen (oxygenases) inhibitor + oxidoreductase acting on single donors with incorporation of molecular oxygen (oxygenases) inhibitors + CHEBI:76740 + + EC 1.13.* [oxidoreductase acting on single donors with incorporation of molecular oxygen (oxygenases)] inhibitor + + + + + + + + + An oxidoreductase inhibitor which interferes with the action of an oxidoreductase acting on CH or CH2 (EC 1.17.*.*). + + chebi_ontology + EC 1.17.* (oxidoreductase acting on CH or CH2) inhibitors + EC 1.17.* inhibitor + EC 1.17.* inhibitors + oxidoreductase acting on CH or CH2 (EC 1.17.*) inhibitor + oxidoreductase acting on CH or CH2 (EC 1.17.*) inhibitors + oxidoreductase acting on CH or CH2 inhibitor + oxidoreductase acting on CH or CH2 inhibitors + CHEBI:76744 + + EC 1.17.* (oxidoreductase acting on CH or CH2) inhibitor + + + + + + + + + Any enzyme inhibitor that interferes with the action of a hydrolase (EC 3.*.*.*). + + Wikipedia:Hydrolase + chebi_ontology + EC 3.* (hydrolase) inhibitors + EC 3.* inhibitor + EC 3.* inhibitors + EC 3.*.*.* inhibitor + EC 3.*.*.* inhibitors + hydrolase (EC 3.*) inhibitor + hydrolase (EC 3.*) inhibitors + hydrolase inhibitor + hydrolase inhibitors + CHEBI:76759 + + EC 3.* (hydrolase) inhibitor + + + + + + + + + A hydrolase inhibitor that interferes with the action of any ester hydrolase (EC 3.1.*.*). + + chebi_ontology + EC 3.1.* (ester hydrolase) inhibitors + EC 3.1.* inhibitor + EC 3.1.* inhibitors + ester hydrolase (EC 3.1.*) inhibitor + ester hydrolase (EC 3.1.*) inhibitors + ester hydrolase inhibitor + ester hydrolase inhibitors + CHEBI:76760 + + EC 3.1.* (ester hydrolase) inhibitor + + + + + + + + + Any hydrolase inhibitor that interferes with the action of a hydrolase acting on C-N bonds, other than peptide bonds (EC 3.5.*.*). + + chebi_ontology + EC 3.5.* (hydrolase acting on non-peptide C-N bond) inhibitor + EC 3.5.* (hydrolase acting on non-peptide C-N bond) inhibitors + EC 3.5.* (hydrolases acting on C-N bonds, other than peptide bonds) inhibitor + EC 3.5.* (hydrolases acting on C-N bonds, other than peptide bonds) inhibitors + EC 3.5.* (hydrolases acting on non-peptide C-N bonds) inhibitors + EC 3.5.* inhibitor + EC 3.5.* inhibitors + CHEBI:76764 + + EC 3.5.* (hydrolases acting on non-peptide C-N bonds) inhibitor + + + + + + + + + An EC 3.1.* (ester hydrolase) inhibitor that interferes with the action of a carboxylic ester hydrolase (EC 3.1.1.*). + + chebi_ontology + EC 3.1.1.* (carboxylic ester hydrolase) inhibitors + EC 3.1.1.* inhibitor + EC 3.1.1.* inhibitors + carboxylic ester hydrolase (EC 3.1.1.*) inhibitor + carboxylic ester hydrolase (EC 3.1.1.*) inhibitors + CHEBI:76773 + + EC 3.1.1.* (carboxylic ester hydrolase) inhibitor + + + + + + + + + An EC 3.1.* (ester hydrolase) inhibitor that interferes with the action of any phosphoric monoester hydrolase (EC 3.1.3.*). + + chebi_ontology + EC 3.1.3.* (phosphoric monoester hydrolase) inhibitors + EC 3.1.3.* inhibitor + EC 3.1.3.* inhibitors + inhibitor of phosphoric monoester hydrolase + inhibitor of phosphoric monoester hydrolase (EC 3.1.3.*) + inhibitors of phosphoric monoester hydrolase + inhibitors of phosphoric monoester hydrolase (EC 3.1.3.*) + phosphoric monoester hydrolase (EC 3.1.3.*) inhibitor + phosphoric monoester hydrolase (EC 3.1.3.*) inhibitors + phosphoric monoester hydrolase inhibitor + phosphoric monoester hydrolase inhibitors + CHEBI:76775 + + EC 3.1.3.* (phosphoric monoester hydrolase) inhibitor + + + + + + + + + Any EC 3.4.21.* (serine endopeptidase) inhibitor that interferes with the action of prolyl oligopeptidase (EC 3.4.21.26). + + chebi_ontology + EC 3.4.21.26 (prolyl oligopeptidase) inhibitors + EC 3.4.21.26 inhibitor + EC 3.4.21.26 inhibitors + endoprolylpeptidase inhibitor + endoprolylpeptidase inhibitors + post-proline cleaving enzyme inhibitor + post-proline cleaving enzyme inhibitors + post-proline endopeptidase inhibitor + post-proline endopeptidase inhibitors + proline endopeptidase inhibitor + proline endopeptidase inhibitors + proline-specific endopeptidase inhibitor + proline-specific endopeptidase inhibitors + prolyl endopeptidase inhibitor + prolyl endopeptidase inhibitors + prolyl oligopeptidase (EC 3.4.21.26) inhibitor + prolyl oligopeptidase (EC 3.4.21.26) inhibitors + prolyl oligopeptidase inhibitor + CHEBI:76779 + + EC 3.4.21.26 (prolyl oligopeptidase) inhibitor + + + + + + + + + An EC 3.4.* (hydrolases acting on peptide bond) inhibitor that interferes with the action of any cysteine endopeptidase (EC 3.4.22.*). + + chebi_ontology + EC 3.4.22.* (cysteine endopeptidase) inhibitors + EC 3.4.22.* inhibitor + EC 3.4.22.* inhibitors + cysteine endopeptidase (EC 3.4.22.*) inhibitor + cysteine endopeptidase (EC 3.4.22.*) inhibitors + cysteine endopeptidase inhibitor + cysteine endopeptidase inhibitors + CHEBI:76796 + + EC 3.4.22.* (cysteine endopeptidase) inhibitor + + + + + + + + + An EC 3.5.* (hydrolases acting on non-peptide C-N bonds) inhibitor that interferes with the action of any non-peptide linear amide C-N hydrolase (EC 3.5.1.*). + + chebi_ontology + EC 3.5.1.* (non-peptide linear amide C-N hydrolase) inhibitors + EC 3.5.1.* inhibitor + EC 3.5.1.* inhibitors + non-peptide linear amide C-N hydrolase (EC 3.5.1.*) inhibitor + non-peptide linear amide C-N hydrolase (EC 3.5.1.*) inhibitors + CHEBI:76807 + + EC 3.5.1.* (non-peptide linear amide C-N hydrolase) inhibitor + + + + + + + + + + An EC 2.7.* (P-containing group transferase) inhibitor that interferes with the action of any protein-serine/threonine kinase (EC 2.7.11.*). + + chebi_ontology + EC 2.7.11.* (protein-serine/threonine kinase) inhibitors + EC 2.7.11.* inhibitor + EC 2.7.11.* inhibitors + protein-serine/threonine kinase (EC 2.7.11.*) inhibitor + protein-serine/threonine kinase (EC 2.7.11.*) inhibitors + protein-serine/threonine kinase inhibitor + protein-serine/threonine kinase inhibitors + CHEBI:76812 + + EC 2.7.11.* (protein-serine/threonine kinase) inhibitor + + + + + + + + + An EC 2.7.* (P-containing group transferase) inhibitor that interferes with the action of any nucleotidyltransferase (EC 2.7.7.*). + + chebi_ontology + EC 2.7.7.* (nucleotidyltransferase) inhibitors + inhibitor of nucleotidyltransferases + inhibitor of nucleotidyltransferases (EC 2.7.7.*) + inhibitors of nucleotidyltransferases + inhibitors of nucleotidyltransferases (EC 2.7.7.*) + nucleotidyltransferase (EC 2.7.7.*) inhibitor + nucleotidyltransferase (EC 2.7.7.*) inhibitors + nucleotidyltransferase inhibitor + nucleotidyltransferase inhibitors + CHEBI:76815 + + EC 2.7.7.* (nucleotidyltransferase) inhibitor + + + + + + + + + + An EC 2.7.* (P-containing group transferase) inhibitor that interferes with the action of any protein-tyrosine kinase (EC 2.7.10.*). + + chebi_ontology + EC 2.7.10.* (protein-tyrosine kinase) inhibitors + EC 2.7.10.* inhibitor + EC 2.7.10.* inhibitors + protein-tyrosine kinase (EC 2.7.10.*) inhibitor + protein-tyrosine kinase (EC 2.7.10.*) inhibitors + protein-tyrosine kinase inhibitor + protein-tyrosine kinase inhibitors + CHEBI:76817 + + EC 2.7.10.* (protein-tyrosine kinase) inhibitor + + + + + + + + + An EC 1.1.* (oxidoreductase acting on donor CH-OH group) inhibitor that uses NAD(+) or NADP(+) as acceptor (EC 1.1.1.*). + + chebi_ontology + EC 1.1.1.* (oxidoreductase acting on donor CH-OH group, NAD(+) or NADP(+)acceptor) inhibitors + EC 1.1.1.* inhibitor + EC 1.1.1.* inhibitors + oxidoreductase acting on donor CH-OH group, NAD(+) or NADP(+) acceptor (EC 1.1.1.*) inhibitor + oxidoreductase acting on donor CH-OH group, NAD(+) or NADP(+) acceptor (EC 1.1.1.*) inhibitors + CHEBI:76835 + + EC 1.1.1.* (oxidoreductase acting on donor CH-OH group, NAD(+) or NADP(+) acceptor) inhibitor + + + + + + + + + An EC 1.13.* [oxidoreductase acting on single donors with incorporation of molecular oxygen (oxygenases)] inhibitor that inhibits the action of any oxidoreductase incorporating 2 atoms of oxygen (EC 1.13.11.*). + + chebi_ontology + EC 1.13.11.* (oxidoreductase acting on single donors and incorporating 2 O atoms) inhibitors + EC 1.13.11.* (oxidoreductase acting on single donors and incorporating 2 atoms of oxygen) inhibitor + EC 1.13.11.* (oxidoreductase acting on single donors and incorporating 2 atoms of oxygen) inhibitors + EC 1.13.11.* inhibitor + EC 1.13.11.* inhibitors + oxidoreductase acting on single donors and incorporating 2 atoms of oxygen (EC 1.13.11.*) inhibitor + oxidoreductase acting on single donors and incorporating 2 atoms of oxygen (EC 1.13.11.*) inhibitors + CHEBI:76837 + + EC 1.13.11.* (oxidoreductase acting on single donors and incorporating 2 O atoms) inhibitor + + + + + + + + + + + + + + + An organic cation that is the conjugate acid of vancomycin, obtained by deprotonation of the carboxy group and protonation of the two amino functions; major species at pH 7.3. + + +1 + C66H76Cl2N9O24 + InChI=1S/C66H75Cl2N9O24/c1-23(2)12-34(71-5)58(88)76-49-51(83)26-7-10-38(32(67)14-26)97-40-16-28-17-41(55(40)101-65-56(54(86)53(85)42(22-78)99-65)100-44-21-66(4,70)57(87)24(3)96-44)98-39-11-8-27(15-33(39)68)52(84)50-63(93)75-48(64(94)95)31-18-29(79)19-37(81)45(31)30-13-25(6-9-36(30)80)46(60(90)77-50)74-61(91)47(28)73-59(89)35(20-43(69)82)72-62(49)92/h6-11,13-19,23-24,34-35,42,44,46-54,56-57,65,71,78-81,83-87H,12,20-22,70H2,1-5H3,(H2,69,82)(H,72,92)(H,73,89)(H,74,91)(H,75,93)(H,76,88)(H,77,90)(H,94,95)/p+1/t24-,34+,35-,42+,44-,46+,47+,48-,49+,50-,51+,52+,53+,54-,56+,57+,65-,66-/m0/s1 + MYPYJXKWCTUITO-LYRMYLQWSA-O + 1450.26100 + 1448.43748 + C[NH2+][C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)c2ccc(Oc3cc4cc(Oc5ccc(cc5Cl)[C@@H](O)[C@@H]5NC(=O)[C@H](NC(=O)[C@@H]4NC(=O)[C@H](CC(N)=O)NC1=O)c1ccc(O)c(c1)-c1c(O)cc(O)cc1[C@H](NC5=O)C([O-])=O)c3O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1)c(Cl)c2 + MetaCyc:CPD-12245 + chebi_ontology + vancomycin + CHEBI:76842 + + vancomycin(1+) + + + + + + + + + An EC 1.17.* (oxidoreductase acting on CH or CH2) inhibitor that interferes with the activity of any such enzyme that uses a disulfide as acceptor (EC 1.17.4.*). + + chebi_ontology + EC 1.17.4.* (oxidoreductase acting on CH or CH2 with a disulfide as acceptor) inhibitors + EC 1.17.4.* inhibitor + EC 1.17.4.* inhibitors + oxidoreductase acting on CH or CH2 with a disulfide as acceptor (EC 1.17.4.*) inhibitor + oxidoreductase acting on CH or CH2 with a disulfide as acceptor (EC 1.17.4.*) inhibitors + CHEBI:76848 + + EC 1.17.4.* (oxidoreductase acting on CH or CH2 with a disulfide as acceptor) inhibitor + + + + + + + + + An EC 1.2.* (oxidoreductase acting on donor aldehyde/oxo group) inhibitor that interferes with the action of any such enzyme using oxygen as acceptor (EC 1.2.3.*). + + chebi_ontology + EC 1.2.3.* (oxidoreductase acting on donor aldehyde/oxo group with oxygen as acceptor) inhibitors + EC 1.2.3.* inhibitor + EC 1.2.3.* inhibitors + oxidoreductase acting on donor aldehyde/oxo group with oxygen as acceptor (EC 1.2.3.*) inhibitor + oxidoreductase acting on donor aldehyde/oxo group with oxygen as acceptor (EC 1.2.3.*) inhibitors + CHEBI:76853 + + EC 1.2.3.* (oxidoreductase acting on donor aldehyde/oxo group with oxygen as acceptor) inhibitor + + + + + + + + + An EC 1.4.* (oxidoreductase acting on donor CH-NH2 group) inhibitor that interferes with the action of any such enzyme using oxygen as acceptor (EC 1.4.3.*). + + chebi_ontology + EC 1.4.3.* (oxidoreductase acting on donor CH-NH2 group, oxygen as acceptor) inhibitors + EC 1.4.3.* inhibitor + EC 1.4.3.* inhibitors + oxidoreductase acting on donor CH-NH2 group, oxygen as acceptor (EC 1.4.3.*) inhibitor + oxidoreductase acting on donor CH-NH2 group, oxygen as acceptor (EC 1.4.3.*) inhibitors + CHEBI:76861 + + EC 1.4.3.* (oxidoreductase acting on donor CH-NH2 group, oxygen as acceptor) inhibitor + + + + + + + + + An EC 1.8.* (oxidoreductase acting on sulfur group of donors) inhibitor that interferes with the action of any such enzyme using NAD(+) or NADP(+) as acceptor (EC 1.8.1.*). + + chebi_ontology + EC 1.8.1.* (oxidoreductase acting on sulfur group of donors, NAD(+) or NADP(+) as acceptor) inhibitors + EC 1.8.1.* inhibitor + EC 1.8.1.* inhibitors + oxidoreductase acting on sulfur group of donors, NAD(+) or NADP(+) as acceptor (EC 1.8.1.*) inhibitor + oxidoreductase acting on sulfur group of donors, NAD(+) or NADP(+) as acceptor (EC 1.8.1.*) inhibitors + CHEBI:76869 + + EC 1.8.1.* (oxidoreductase acting on sulfur group of donors, NAD(+) or NADP(+) as acceptor) inhibitor + + + + + + + + + An EC 1.9.* (oxidoreductase acting on donor heme group) inhibitor that interferes with the action of any such enzyme using oxygen as acceptor (EC 1.9.3.*). + + chebi_ontology + EC 1.9.3.* (oxidoreductase acting on donor heme group, oxygen as acceptor) inhibitors + EC 1.9.3.* inhibitor + EC 1.9.3.* inhibitors + oxidoreductase acting on donor heme group, oxygen as acceptor (EC 1.9.3.*) inhibitor + oxidoreductase acting on donor heme group, oxygen as acceptor (EC 1.9.3.*) inhibitors + CHEBI:76870 + + EC 1.9.3.* (oxidoreductase acting on donor heme group, oxygen as acceptor) inhibitor + + + + + + + + + An EC 2.1.* (C1-transferase) inhibitor that interferes with the action of any methyltransferase (EC 2.1.1.*). + + chebi_ontology + EC 2.1.1.* (methyltransferase) inhibitor + EC 2.1.1.* (methyltransferase) inhibitors + EC 2.1.1.* (methyltransferases) inhibitors + EC 2.1.1.* inhibitor + EC 2.1.1.* inhibitors + methyltransferase (EC 2.1.1.*) inhibitor + methyltransferase (EC 2.1.1.*) inhibitors + CHEBI:76871 + + EC 2.1.1.* (methyltransferases) inhibitor + + + + + + + + + An EC 3.6.* (hydrolases acting on acid anhydrides) inhibitor that interferes with the action of any such enzyme that catalyses transmembrane movement of substances (EC 3.6.3.*). + + chebi_ontology + EC 3.6.3.* (acid anhydride hydrolase catalysing transmembrane movement of substances) inhibitors + EC 3.6.3.* inhibitor + EC 3.6.3.* inhibitors + acid anhydride hydrolase catalysing transmembrane movement of substances (EC 3.6.3.*) inhibitor + acid anhydride hydrolase catalysing transmembrane movement of substances (EC 3.6.3.*) inhibitors + CHEBI:76895 + + EC 3.6.3.* (acid anhydride hydrolase catalysing transmembrane movement of substances) inhibitor + + + + + + + + + Any eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms. + + CHEBI:75766 + CHEBI:76925 + chebi_ontology + plant metabolites + plant secondary metabolites + CHEBI:76924 + + plant metabolite + + + + + + + + + An enzyme inhibitor that interferes with one or more steps in a metabolic pathway. + + chebi_ontology + metabolic pathway inhibitor + metabolic pathway inhibitors + pathway inhibitors + CHEBI:76932 + + pathway inhibitor + + + + + + + + + An EC 3.6.* (hydrolases acting on acid anhydrides) inhibitor that interferes with the action of any such enzyme acting on ATP and involved in cellular and subcellular movement (EC 3.6.4.*). + + chebi_ontology + EC 3.6.4.* (hydrolase acting on ATP; involved in cellular and subcellular movement) inhibitor + EC 3.6.4.* (hydrolase acting on ATP; involved in cellular and subcellular movement) inhibitors + EC 3.6.4.* (hydrolases acting on ATP; involved in cellular and subcellular movement) inhibitors + EC 3.6.4.* inhibitor + EC 3.6.4.* inhibitors + hydrolases acting on ATP; involved in cellular and subcellular movement (EC 3.6.4.*) inhibitor + hydrolases acting on ATP; involved in cellular and subcellular movement (EC 3.6.4.*) inhibitors + CHEBI:76938 + + EC 3.6.4.* (hydrolases acting on ATP; involved in cellular and subcellular movement) inhibitor + + + + + + + + + An EC 3.6.4.* (hydrolases acting on ATP; involved in cellular and subcellular movement) inhibitor that interferes with the action of a non-chaperonin molecular chaperone ATPase (EC 3.6.4.10). + + Wikipedia:Non-chaperonin_molecular_chaperone_ATPase + chebi_ontology + ATP phosphohydrolase (polypeptide-polymerising) inhibitor + ATP phosphohydrolase (polypeptide-polymerising) inhibitors + ATP phosphohydrolase (polypeptide-polymerizing) inhibitor + ATP phosphohydrolase (polypeptide-polymerizing) inhibitors + EC 3.6.4.10 (non-chaperonin molecular chaperone ATPase) inhibitors + EC 3.6.4.10 inhibitor + EC 3.6.4.10 inhibitors + molecular chaperone Hsc70 ATPase inhibitor + molecular chaperone Hsc70 ATPase inhibitors + non-chaperonin molecular chaperone ATPase (EC 3.6.4.10) inhibitor + non-chaperonin molecular chaperone ATPase (EC 3.6.4.10) inhibitors + CHEBI:76939 + + EC 3.6.4.10 (non-chaperonin molecular chaperone ATPase) inhibitor + + + + + + + + + Any eukaryotic metabolite produced during a metabolic reaction in fungi, the kingdom that includes microorganisms such as the yeasts and moulds. + + CHEBI:75765 + CHEBI:76947 + chebi_ontology + fungal metabolites + CHEBI:76946 + + fungal metabolite + + + + + + + + + Any fungal metabolite produced during a metabolic reaction in Penicillium. + + CHEBI:76205 + CHEBI:76963 + chebi_ontology + Penicillium metabolites + CHEBI:76964 + + Penicillium metabolite + + + + + + + + + + Any human metabolite produced by metabolism of a xenobiotic compound in humans. + + chebi_ontology + human xenobiotic metabolites + CHEBI:76967 + + human xenobiotic metabolite + + + + + + + + + Any prokaryotic metabolite produced during a metabolic reaction in bacteria. + + CHEBI:75760 + CHEBI:76970 + chebi_ontology + CHEBI:76969 + + bacterial metabolite + + + + + + + + + Any bacterial metabolite produced during a metabolic reaction in Escherichia coli. + + chebi_ontology + E.coli metabolite + E.coli metabolites + Escherichia coli metabolites + CHEBI:76971 + + Escherichia coli metabolite + + + + + + + + + An EC 2.3.* (acyltransferase) inhibitor that interferes with the action of an acyltransferase which converts the acyl group to an alkyl group on transfer (EC 2.3.3.*). + + chebi_ontology + EC 2.3.3.* (acyltransferase converting acyl to alkyl group on transfer) inhibitors + EC 2.3.3.* inhibitor + EC 2.3.3.* inhibitors + acyltransferase converting acyl to alkyl group on transfer (EC 2.3.3.*) inhibitor + acyltransferase converting acyl to alkyl group on transfer (EC 2.3.3.*) inhibitors + CHEBI:77022 + + EC 2.3.3.* (acyltransferase converting acyl to alkyl group on transfer) inhibitor + + + + + + + + + An EC 2.3.3.* (acyltransferase converting acyl to alkyl group on transfer) inhibitor that interferes with the action of citrate (Si)-synthase, EC 2.3.3.1. + + Wikipedia:Citrate_synthase + chebi_ontology + (R)-citrate synthase inhibitor + (R)-citrate synthase inhibitors + EC 2.3.3.1 (citrate (Si)-synthase) inhibitor + EC 2.3.3.1 (citrate (Si)-synthase) inhibitors + EC 2.3.3.1 [citrate (Si)-synthase] inhibitors + EC 2.3.3.1 inhibitor + EC 2.3.3.1 inhibitors + acetyl-CoA:oxaloacetate C-acetyltransferase [thioester-hydrolysing, (pro-S)-carboxymethyl forming] inhibitor + acetyl-CoA:oxaloacetate C-acetyltransferase [thioester-hydrolysing, (pro-S)-carboxymethyl forming] inhibitors + citrate (Si)-synthase (EC 2.3.3.1) inhibitor + citrate (Si)-synthase (EC 2.3.3.1) inhibitors + citrate condensing enzyme inhibitor + citrate condensing enzyme inhibitors + citrate oxaloacetate-lyase [(pro-3S)-CH2COO->acetyl-CoA] inhibitor + citrate oxaloacetate-lyase [(pro-3S)-CH2COO->acetyl-CoA] inhibitors + citrate oxaloacetate-lyase, CoA-acetylating inhibitor + citrate oxaloacetate-lyase, CoA-acetylating inhibitors + citrate synthase inhibitor + citrate synthase inhibitors + citrate synthetase inhibitor + citrate synthetase inhibitors + citric synthase inhibitor + citric synthase inhibitors + citric-condensing enzyme inhibitor + citric-condensing enzyme inhibitors + citrogenase inhibitor + citrogenase inhibitors + condensing enzyme inhibitor + condensing enzyme inhibitors + oxalacetic transacetase inhibitor + oxalacetic transacetase inhibitors + oxaloacetate transacetase inhibitor + oxaloacetate transacetase inhibitors + CHEBI:77023 + + EC 2.3.3.1 [citrate (Si)-synthase] inhibitor + + + + + + + + + An EC 3.1.3.* (phosphoric monoester hydrolase) inhibitor that interferes with the action of 4-nitrophenylphosphatase (EC 3.1.3.41). + + Wikipedia:4-nitrophenylphosphatase + chebi_ontology + 4-nitrophenylphosphatase (EC 3.1.3.41) inhibitor + 4-nitrophenylphosphatase (EC 3.1.3.41) inhibitors + 4-nitrophenylphosphate phosphohydrolase inhibitor + 4-nitrophenylphosphate phosphohydrolase inhibitors + EC 3.1.3.41 (4-nitrophenylphosphatase) inhibitors + EC 3.1.3.41 inhibitor + EC 3.1.3.41 inhibitors + Ecto-p-nitrophenyl phosphatase inhibitor + Ecto-p-nitrophenyl phosphatase inhibitors + K-pNPPase inhibitor + K-pNPPase inhibitors + NPPase inhibitor + NPPase inhibitors + PNPPase inhibitor + PNPPase inhibitors + nitrophenyl phosphatase inhibitor + nitrophenyl phosphatase inhibitors + p-nitrophenylphosphatase inhibitor + p-nitrophenylphosphatase inhibitors + p-nitrophenylphosphate phosphohydrolase inhibitor + p-nitrophenylphosphate phosphohydrolase inhibitors + para-nitrophenyl phosphatase inhibitor + para-nitrophenyl phosphatase inhibitors + xK-pNPPase inhibitors + CHEBI:77024 + + EC 3.1.3.41 (4-nitrophenylphosphatase) inhibitor + + + + + + + + + Compounds that are considered to increase the volume of secretions in the respiratory tract, so facilitating their removal by ciliary action and coughing. Compare with mucolytics, which decrease the viscosity of mucus, facilitating its removal by ciliary action and expectoration, and antitussives, which suppress the cough reflex. + + PMID:17594730 + chebi_ontology + expectorants + CHEBI:77035 + + expectorant + + + + + + + + + + A 3-oxo-Delta(1) steroid containing an additional double bond between positions 4 and 5. + + 0 + C19H25OR + 269.402 + 269.19054 + C12(C=CC(C=C1CCC3C2CCC4(C3CCC4*)C)=O)C + chebi_ontology + 3-oxo Delta(1),Delta(4)-steroid + 3-oxo Delta(1),Delta(4)-steroids + 3-oxo-Delta(1),Delta(4)-steroids + 3-oxo-Delta(1,4)-steroid + 3-oxo-Delta(1,4)-steroids + a 3-oxo-Delta(1,4)-steroid + CHEBI:77166 + + 3-oxo-Delta(1),Delta(4)-steroid + + + + + + + + + Any protective agent that is able to prevent damage to the heart. + + chebi_ontology + cardioprotective agents + CHEBI:77307 + + cardioprotective agent + + + + + + + + + An EC 1.8.1.* (oxidoreductase acting on sulfur group of donors, NAD+ or NADP+ as acceptor) inhibitor that interferes with the action of trypanothione-disulfide reductase (EC 1.8.1.12). + + Wikipedia:Trypanothione-disulfide_reductase + chebi_ontology + EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitors + EC 1.8.1.12 inhibitor + EC 1.8.1.12 inhibitors + N(1),N(8)-bis(glutathionyl)spermidine reductase inhibitor + N(1),N(8)-bis(glutathionyl)spermidine reductase inhibitors + NADPH2:trypanothione oxidoreductase inhibitor + NADPH2:trypanothione oxidoreductase inhibitors + NADPH:trypanothione oxidoreductase inhibitor + NADPH:trypanothione oxidoreductase inhibitors + trypanothione reductase inhibitor + trypanothione reductase inhibitors + trypanothione-disulfide reductase (EC 1.8.1.12) inhibitor + trypanothione-disulfide reductase (EC 1.8.1.12) inhibitors + trypanothione:NADP(+) oxidoreductase inhibitor + trypanothione:NADP(+) oxidoreductase inhibitors + CHEBI:77402 + + EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor + + + + + + + + + Any mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens). + + CHEBI:75770 + CHEBI:77123 + chebi_ontology + H. sapiens metabolite + H. sapiens metabolites + Homo sapiens metabolite + Homo sapiens metabolites + CHEBI:77746 + + human metabolite + + + + + + + + + An EC 3.5.1.* (non-peptide linear amide C-N hydrolase) inhibitor that interferes with the action of amidase (EC 3.5.1.4). + + Wikipedia:Amidase + chebi_ontology + EC 3.5.1.4 (amidase) inhibitors + EC 3.5.1.4 inhibitor + EC 3.5.1.4 inhibitors + N-acetylaminohydrolase inhibitor + N-acetylaminohydrolase inhibitors + acylamidase inhibitor + acylamidase inhibitors + acylamide amidohydrolase inhibitor + acylamide amidohydrolase inhibitors + amidase (EC 3.5.1.4) inhibitor + amidase (EC 3.5.1.4) inhibitors + amidase inhibitor + amidase inhibitors + amidohydrolase inhibitor + amidohydrolase inhibitors + deaminase inhibitor + deaminase inhibitors + fatty acylamidase inhibitor + fatty acylamidase inhibitors + CHEBI:77941 + + EC 3.5.1.4 (amidase) inhibitor + + + + + + + + + + + + + + + + + + + + + + A peptide anion that is the conjugate base of vancomycin aglycone and the major microspecies at pH 7.3 (according to Marvin v 6.2.0.). + + -1 + C53H51Cl2N8O17 + InChI=1S/C53H52Cl2N8O17/c1-19(2)10-29(57-3)47(71)62-42-44(68)21-5-8-33(27(54)12-21)79-35-14-23-15-36(46(35)70)80-34-9-6-22(13-28(34)55)45(69)43-52(76)61-41(53(77)78)26-16-24(64)17-32(66)38(26)25-11-20(4-7-31(25)65)39(49(73)63-43)60-50(74)40(23)59-48(72)30(18-37(56)67)58-51(42)75/h4-9,11-17,19,29-30,39-45,57,64-66,68-70H,10,18H2,1-3H3,(H2,56,67)(H,58,75)(H,59,72)(H,60,74)(H,61,76)(H,62,71)(H,63,73)(H,77,78)/p-1/t29-,30+,39-,40-,41+,42-,43+,44-,45-/m1/s1 + JHIKFOISFAQTJQ-YZANBJIASA-M + 1142.92200 + 1141.27547 + C[NH2+][C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)c2ccc(Oc3cc4cc(Oc5ccc(cc5Cl)[C@@H](O)[C@@H]5NC(=O)[C@H](NC(=O)[C@@H]4NC(=O)[C@H](CC(N)=O)NC1=O)c1ccc(O)c(c1)-c1c(O)cc(O)cc1[C@H](NC5=O)C([O-])=O)c3[O-])c(Cl)c2 + (1S,2R,18R,19R,22S,25R,28R,40S)-22-(2-amino-2-oxoethyl)-5,15-dichloro-2,18,32,35,37-pentahydroxy-19-{[(2R)-4-methyl-2-(methylazaniumyl)pentanoyl]amino}-48-oxido-20,23,26,42,44-pentaoxo-7,13-dioxa-21,24,27,41,43-pentaazaoctacyclo[26.14.2.2(3,6).2(14,17).1(8,12).1(29,33).0(10,25).0(34,39)]pentaconta-3,5,8(48),9,11,14,16,29(45),30,32,34,36,38,46,49-pentadecaene-40-carboxylate + chebi_ontology + vancomycin aglycone + CHEBI:77981 + + vancomycin aglycone(1-) + + + + + + + + + + A propellant that is used to expel foods from an aerosol container. + + chebi_ontology + food propellants + CHEBI:78017 + + food propellant + + + + + + + + + Any substance that is distributed in foodstuffs. It includes materials derived from plants or animals, such as vitamins or minerals, as well as environmental contaminants. + + chebi_ontology + dietary component + dietary components + food components + CHEBI:78295 + + food component + + + + + + + + + Any minor or unwanted substance introduced into the environment that can have undesired effects. + + chebi_ontology + environmental contaminants + CHEBI:78298 + + environmental contaminant + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A flavonoid oxoanion obtained by deprotonation of the hydroxy group at position 7 of baicalein. It is the major microspecies at pH 7.3 (according to Marvin v 6.2.0.). + + -1 + C15H9O5 + InChI=1S/C15H10O5/c16-9-6-11(8-4-2-1-3-5-8)20-12-7-10(17)14(18)15(19)13(9)12/h1-7,17-19H/p-1 + FXNFHKRTJBSTCS-UHFFFAOYSA-M + 269.22950 + 269.04555 + Oc1c([O-])cc2oc(cc(=O)c2c1O)-c1ccccc1 + PMID:10724177 + PMID:15853750 + PMID:22891631 + PMID:23098745 + 5,6-dihydroxy-4-oxo-2-phenyl-4H-chromen-7-olate + chebi_ontology + baicalein + CHEBI:78324 + + baicalein(1-) + + + + + + + + + A substance used in a thermodynamic heat pump cycle or refrigeration cycle that undergoes a phase change from a gas to a liquid and back. Refrigerants are used in air-conditioning systems and freezers or refrigerators and are assigned a "R" number (by ASHRAE - formerly the American Society of Heating, Refrigerating and Air Conditioning Engineers), which is determined systematically according to their molecular structure. + + Wikipedia:Refrigerant + chebi_ontology + refrigerants + CHEBI:78433 + + refrigerant + + + + + + + + + + Any inducer of heat shock protein 70. + + Wikipedia:Hsp70 + chebi_ontology + Hsp70 activator + Hsp70 activators + Hsp70 inducers + heat shock protein 70 activator + heat shock protein 70 activators + heat shock protein 70 inducer + heat shock protein 70 inducers + CHEBI:78606 + + Hsp70 inducer + + + + + + + + + + + + + + + An amino acid zwitterion obtained by transfer of a proton from the carboxy to the amino group of any alpha-amino acid; major species at pH 7.3. + + 0 + C2H4NO2R + 74.059 + 74.02420 + [NH3+]C([*])C([O-])=O + CHEBI:83409 + MetaCyc:Alpha-Amino-Acids + chebi_ontology + an alpha-amino acid + CHEBI:78608 + + alpha-amino acid zwitterion + + + + + + + + + Any organooxygen compound that is a polyhydroxy-aldehyde or -ketone, or a compound derived from one. Carbohydrates contain only carbon, hydrogen and oxygen and usually have an empirical formula Cm(H2O)n; carbohydrate derivatives may contain other elements by substitution or condensation. + + chebi_ontology + carbohydrates and derivatives + carbohydrates and their derivatives + CHEBI:78616 + + carbohydrates and carbohydrate derivatives + + + + + + + + + Any metabolite produced by all living cells. + + chebi_ontology + essential metabolite + essential metabolites + fundamental metabolites + CHEBI:78675 + + fundamental metabolite + + + + + + + + + + + + + + + + An organic cation obtained by protonation of the tertiary amino group of nelfinavir. + + +1 + C32H46N3O4S + InChI=1S/C32H45N3O4S/c1-21-25(15-10-16-28(21)36)30(38)33-26(20-40-24-13-6-5-7-14-24)29(37)19-35-18-23-12-9-8-11-22(23)17-27(35)31(39)34-32(2,3)4/h5-7,10,13-16,22-23,26-27,29,36-37H,8-9,11-12,17-20H2,1-4H3,(H,33,38)(H,34,39)/p+1/t22-,23+,26-,27-,29+/m0/s1 + QAGYKUNXZHXKMR-HKWSIXNMSA-O + 568.79000 + 568.32035 + Cc1c(O)cccc1C(=O)N[C@@H](CSc1ccccc1)[C@H](O)C[NH+]1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C + (3S,4aS,8aS)-3-(tert-butylcarbamoyl)-2-[(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-(phenylsulfanyl)butyl]decahydroisoquinolinium + chebi_ontology + nelfinavir cation + CHEBI:78767 + + nelfinavir(1+) + + + + + + + + + Any organic molecular entity that contains at least one C=C bond. + + chebi_ontology + olefinic compounds + CHEBI:78840 + + olefinic compound + + + + + + + + + + An EC 2.7.11.* (protein-serine/threonine kinase) inhibitor that interferes with the action of mitogen-activated protein kinase (EC 2.7.11.24). + + CHEBI:75997 + Wikipedia:MEK_inhibitor + Wikipedia:Mitogen-activated_protein_kinase + chebi_ontology + ATP:protein phosphotransferase (MAPKK-activated) inhibitor + ATP:protein phosphotransferase (MAPKK-activated) inhibitors + Dp38 inhibitor + Dp38 inhibitors + EC 2.7.11.24 (mitogen-activated protein kinase) inhibitors + EC 2.7.11.24 inhibitor + EC 2.7.11.24 inhibitors + ERK inhibitor + ERK inhibitors + ERK1 inhibitor + ERK1 inhibitors + ERK2 inhibitor + ERK2 inhibitors + JNK inhibitor + JNK inhibitors + JNK3alpha1 inhibitor + JNK3alpha1 inhibitors + LeMPK3 inhibitor + LeMPK3 inhibitors + MAP kinase inhibitor + MAP kinase inhibitors + MAP-2 kinase inhibitor + MAP-2 kinase inhibitors + MAPK inhibitor + MAPK inhibitors + MBP kinase I inhibitor + MBP kinase I inhibitors + MBP kinase II inhibitor + MBP kinase II inhibitors + MEK inhibitor + MEK inhibitors + PMK-1 inhibitor + PMK-1 inhibitors + PMK-2 inhibitor + PMK-2 inhibitors + PMK-3 inhibitor + PMK-3 inhibitors + SAPK inhibitor + SAPK inhibitors + STK26 inhibitor + STK26 inhibitors + c-Jun N-terminal kinase inhibitor + c-Jun N-terminal kinase inhibitors + extracellular signal-regulated kinase inhibitor + extracellular signal-regulated kinase inhibitors + microtubule-associated protein 2 kinase inhibitor + microtubule-associated protein 2 kinase inhibitors + microtubule-associated protein kinase inhibitor + microtubule-associated protein kinase inhibitors + mitogen-activated protein kinase (EC 2.7.11.24) inhibitor + mitogen-activated protein kinase (EC 2.7.11.24) inhibitors + mitogen-activated protein kinase inhibitor + mitogen-activated protein kinase inhibitors + myelin basic protein kinase inhibitor + myelin basic protein kinase inhibitors + p38-2 inhibitor + p38-2 inhibitors + p38delta inhibitor + p38delta inhibitors + p42 mitogen-activated protein kinase inhibitor + p42 mitogen-activated protein kinase inhibitors + p42(mapk) inhibitor + p42(mapk) inhibitors + p44mpk inhibitor + p44mpk inhibitors + pp42 inhibitor + pp42 inhibitors + pp44(mapk) inhibitor + pp44(mapk) inhibitors + stress-activated protein kinase inhibitor + stress-activated protein kinase inhibitors + CHEBI:79091 + + EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor + + + + + + + + + Any inorganic anion with a valency of three. + + chebi_ontology + trivalent inorganic anions + CHEBI:79387 + + trivalent inorganic anion + + + + + + + + + Any inorganic anion with a valency of two. + + chebi_ontology + divalent inorganic anions + CHEBI:79388 + + divalent inorganic anion + + + + + + + + + Any inorganic anion with a valency of one. + + chebi_ontology + monovalent inorganic anions + CHEBI:79389 + + monovalent inorganic anion + + + + + + + + + + + + + + + + + + + + + + A member of the class of 2-aminopurines that is guanine in which the hydrogen at position 9 is substituted by a 4-hydroxy-3-(hydroxymethyl)but-1-yl group. An antiviral drug, it is administered topically for treatment of herpes labialis. A prodrug, famciclovir, is used for oral administration. + + 0 + C10H15N5O3 + InChI=1S/C10H15N5O3/c11-10-13-8-7(9(18)14-10)12-5-15(8)2-1-6(3-16)4-17/h5-6,16-17H,1-4H2,(H3,11,13,14,18) + JNTOCHDNEULJHD-UHFFFAOYSA-N + 253.25780 + 253.11749 + Nc1nc2n(CCC(CO)CO)cnc2c(=O)[nH]1 + CHEBI:44870 + CAS:39809-25-1 + DrugBank:DB00299 + Drug_Central:2079 + HMDB:HMDB0014444 + KEGG:C07417 + KEGG:D05407 + LINCS:LSM-5587 + PDBeChem:PE2 + PMID:3040998 + Patent:US5075445 + Reaxys:4501039 + Wikipedia:Penciclovir + 2-amino-9-[4-hydroxy-3-(hydroxymethyl)butyl]-1,9-dihydro-6H-purin-6-one + chebi_ontology + 9-(4-hydroxy-3-(hydroxymethyl)butyl)guanine + 9-(4-hydroxy-3-hydroxymethylbut-1-yl)-guanine + 9-[2-hydroxy-1-(hydroxymethyl)-ethoxymethyl]guanine + 9-[4-hydroxy-3-(hydroxymethyl)but-1-yl]guanine + PCV + PE2 + penciclovir + penciclovirum + CHEBI:7956 + + penciclovir + + + + + + + + + + + + + + + + + + + + + + + 0 + C42H70O11 + InChI=1S/C42H70O11/c1-11-29(38(46)47)31-15-14-23(4)36(50-31)27(8)34(44)26(7)35(45)30(12-2)37-24(5)22-25(6)41(51-37)19-16-32(43)42(53-41)21-20-39(10,52-42)33-17-18-40(48,13-3)28(9)49-33/h16,19,23-34,36-37,43-44,48H,11-15,17-18,20-22H2,1-10H3,(H,46,47)/t23-,24-,25+,26-,27-,28-,29+,30-,31+,32+,33+,34+,36+,37-,39-,40+,41-,42-/m0/s1 + KQXDHUJYNAXLNZ-XQSDOZFQSA-N + 750.99860 + 750.49181 + CC[C@H]([C@H]1CC[C@H](C)[C@@H](O1)[C@@H](C)[C@H](O)[C@H](C)C(=O)[C@H](CC)[C@H]1O[C@@]2(O[C@@]3(CC[C@](C)(O3)C3CC[C@](O)(CC)[C@H](C)O3)[C@H](O)C=C2)[C@H](C)C[C@@H]1C)C(O)=O + CAS:53003-10-4 + KEGG:C15690 + KEGG:D08502 + KNApSAcK:C00018019 + Wikipedia:Salinomycin + chebi_ontology + CHEBI:80025 + + Salinomycin + + + + + + + + + Substances that are administered to farmed animals to improve productivity by promoting weight gain, increasing muscle mass, limiting fat deposition, reducing feed consumption, and reducing waste production. + + PMID:22444918 + PMID:2745641 + PMID:6226938 + chebi_ontology + animal growth promotants + animal growth promoter + animal growth promoters + CHEBI:82655 + + animal growth promotant + + + + + + + + + + + + + + + Any unsaturated fatty acid anion with one double or triple bond in the fatty acid chain. + + -1 + CO2R + 44.010 + 43.98983 + [O-]C([*])=O + chebi_ontology + monounsaturated fatty acid anions + CHEBI:82680 + + monounsaturated fatty acid anion + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A semisynthetic glycopeptide used (as its bisphosphate salt) for the treatment of acute bacterial skin and skin structure infections caused or suspected to be caused by susceptible isolates of designated Gram-positive microorganisms including MRSA. + + 0 + C86H97Cl3N10O26 + InChI=1S/C86H97Cl3N10O26/c1-35(2)22-51(92-7)77(110)98-67-69(105)42-15-20-55(49(88)24-42)120-57-26-44-27-58(73(57)125-84-74(71(107)70(106)59(34-100)122-84)124-62-32-86(6,76(109)37(4)119-62)93-33-38-8-10-39(11-9-38)40-12-17-45(87)18-13-40)121-56-21-16-43(25-50(56)89)72(123-61-31-85(5,91)75(108)36(3)118-61)68-82(115)97-66(83(116)117)48-28-46(101)29-54(103)63(48)47-23-41(14-19-53(47)102)64(79(112)99-68)96-80(113)65(44)95-78(111)52(30-60(90)104)94-81(67)114/h8-21,23-29,35-37,51-52,59,61-62,64-72,74-76,84,92-93,100-103,105-109H,22,30-34,91H2,1-7H3,(H2,90,104)(H,94,114)(H,95,111)(H,96,113)(H,97,115)(H,98,110)(H,99,112)(H,116,117)/t36-,37-,51+,52-,59+,61-,62-,64+,65+,66-,67+,68-,69+,70+,71-,72+,74+,75-,76-,84-,85-,86-/m0/s1 + VHFGEBVPHAGQPI-LXKZPTCJSA-N + 1793.10100 + 1790.56411 + CN[C@H](CC(C)C)C(=O)N[C@@H]1[C@H](O)c2ccc(Oc3cc4cc(Oc5ccc(cc5Cl)[C@@H](O[C@H]5C[C@](C)(N)[C@@H](O)[C@H](C)O5)[C@@H]5NC(=O)[C@H](NC(=O)[C@@H]4NC(=O)[C@H](CC(N)=O)NC1=O)c1ccc(O)c(c1)-c1c(O)cc(O)cc1[C@H](NC5=O)C(O)=O)c3O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O[C@H]1C[C@](C)(NCc3ccc(cc3)-c3ccc(Cl)cc3)[C@@H](O)[C@H](C)O1)c(Cl)c2 + CHEBI:29553 + CAS:171099-57-3 + Drug_Central:4678 + KEGG:C12034 + PMID:22941898 + PMID:23089749 + PMID:23261897 + PMID:23759507 + PMID:24035967 + PMID:24449768 + PMID:24505091 + PMID:24550323 + PMID:24897083 + PMID:24906505 + PMID:25022588 + PMID:25058176 + PMID:25118105 + PMID:25239268 + PMID:25294250 + PMID:25294303 + Reaxys:7608605 + Wikipedia:Oritavancin + chebi_ontology + (4''R)-22-O-(3-Amino-2,3,6-trideoxy-3-C-methyl-alpha-L-arabinohexopyranosyl)-N3''-(p-(p-chlorophenyl)benzyl)vancomycin + (4''R)-22-O-(3-amino-2,3,6-trideoxy-3-C-methyl-alpha-L-arabino-hexopyranosyl)-N(3'')-((4'-chloro(1,1'-biphenyl)-4-yl)methyl)vancomycin + Chlorobiphenyl-chloroeremomycin + LY333328 + CHEBI:82699 + + oritavancin + + + + + + + + + An aryl thiol is a thiol in which a sulfanyl group, SH, is attached to an aryl group. + + 0 + HSR + 33.074 + 32.97990 + S[*] + KEGG:C01336 + chebi_ontology + an aryl thiol + CHEBI:82711 + + aryl thiol + + + + + + + + + + + + + + + + + + + + + + + + A semisynthetic glycopeptide used for the treatment of acute bacterial skin and skin structure infections caused or suspected to be caused by susceptible isolates of designated Gram-positive microorganisms including MRSA. + + 0 + C88H100Cl2N10O28 + InChI=1S/C88H100Cl2N10O28/c1-38(2)13-10-8-6-7-9-11-14-61(106)94-70-73(109)75(111)78(86(120)121)128-87(70)127-77-58-31-43-32-59(77)124-55-24-19-42(29-50(55)89)71(107)69-85(119)98-67(80(114)92-25-12-26-100(4)5)48-33-44(102)34-57(125-88-76(112)74(110)72(108)60(37-101)126-88)62(48)47-28-40(17-22-52(47)103)65(82(116)99-69)95-83(117)66(43)96-84(118)68-49-35-46(36-54(105)63(49)90)123-56-30-41(18-23-53(56)104)64(91-3)81(115)93-51(79(113)97-68)27-39-15-20-45(122-58)21-16-39/h15-24,28-36,38,51,60,64-76,78,87-88,91,101-105,107-112H,6-14,25-27,37H2,1-5H3,(H,92,114)(H,93,115)(H,94,106)(H,95,117)(H,96,118)(H,97,113)(H,98,119)(H,99,116)(H,120,121)/t51-,60-,64-,65-,66-,67+,68+,69+,70-,71-,72-,73-,74+,75+,76+,78+,87-,88+/m1/s1 + KGPGQDLTDHGEGT-SZUNQUCBSA-N + 1816.69200 + 1814.60856 + CN[C@@H]1c2ccc(O)c(Oc3cc(O)c(Cl)c(c3)[C@@H]3NC(=O)[C@@H](Cc4ccc(Oc5cc6cc(Oc7ccc(cc7Cl)[C@@H](O)[C@@H]7NC(=O)[C@H](NC(=O)[C@@H]6NC3=O)c3ccc(O)c(c3)-c3c(O[C@H]6O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]6O)cc(O)cc3[C@H](NC7=O)C(=O)NCCCN(C)C)c5O[C@@H]3O[C@@H]([C@@H](O)[C@H](O)[C@H]3NC(=O)CCCCCCCCC(C)C)C(O)=O)cc4)NC1=O)c2 + CAS:171500-79-1 + Drug_Central:777 + KEGG:D03640 + PMID:22951648 + PMID:23357293 + PMID:23414746 + PMID:23880168 + PMID:24341387 + PMID:24343828 + PMID:24608916 + PMID:24897082 + PMID:24939490 + PMID:24972854 + PMID:25118105 + PMID:25136251 + PMID:25211361 + PMID:25229922 + PMID:25229923 + PMID:25229924 + PMID:25229925 + PMID:25243251 + Reaxys:9839185 + Wikipedia:Dalbavancin + chebi_ontology + BI 397 + BI397 + dalbavancin + dalbavancin B0 + CHEBI:82721 + + dalbavancin + + + + + + + + + + + + + + + A dioxolane that is 1,3-dioxolane which is substituted at positions 2, 2, and 4 by 2,4-dichlorophenyl, 1H-1,2,4-triazol-1-ylmethyl, and [4-(4-isopropylpiperazin-1-yl)phenoxy]methyl groups, respectively. + + 0 + C26H31Cl2N5O3 + InChI=1S/C26H31Cl2N5O3/c1-19(2)31-9-11-32(12-10-31)21-4-6-22(7-5-21)34-14-23-15-35-26(36-23,16-33-18-29-17-30-33)24-8-3-20(27)13-25(24)28/h3-8,13,17-19,23H,9-12,14-16H2,1-2H3 + BLSQLHNBWJLIBQ-UHFFFAOYSA-N + 532.46200 + 531.18040 + CC(C)N1CCN(CC1)c1ccc(OCC2COC(Cn3cncn3)(O2)c2ccc(Cl)cc2Cl)cc1 + 1-(4-{[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)-4-isopropylpiperazine + chebi_ontology + CHEBI:82979 + + 1-(4-{[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)-4-isopropylpiperazine + + + + + + + + + + + + + + + A 1-(4-{[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)-4-isopropylpiperazine in which positions 2 and 4 of the 1,3-dioxolane moiety have R and S configuration, respectively. + + 0 + C26H31Cl2N5O3 + InChI=1S/C26H31Cl2N5O3/c1-19(2)31-9-11-32(12-10-31)21-4-6-22(7-5-21)34-14-23-15-35-26(36-23,16-33-18-29-17-30-33)24-8-3-20(27)13-25(24)28/h3-8,13,17-19,23H,9-12,14-16H2,1-2H3/t23-,26-/m0/s1 + BLSQLHNBWJLIBQ-OZXSUGGESA-N + 532.46200 + 531.18040 + CC(C)N1CCN(CC1)c1ccc(OC[C@H]2CO[C@@](Cn3cncn3)(O2)c2ccc(Cl)cc2Cl)cc1 + LINCS:LSM-3923 + PMID:16217826 + PMID:17607804 + PMID:19650049 + 1-(4-{[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)-4-isopropylpiperazine + chebi_ontology + CHEBI:82980 + + (2R,4S)-terconazole + + + + + + + + + + + + + + + A 1-(4-{[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)-4-isopropylpiperazine in which positions 2 and 4 of the 1,3-dioxolane moiety have S and R configuration, respectively. + + 0 + C26H31Cl2N5O3 + InChI=1S/C26H31Cl2N5O3/c1-19(2)31-9-11-32(12-10-31)21-4-6-22(7-5-21)34-14-23-15-35-26(36-23,16-33-18-29-17-30-33)24-8-3-20(27)13-25(24)28/h3-8,13,17-19,23H,9-12,14-16H2,1-2H3/t23-,26-/m1/s1 + BLSQLHNBWJLIBQ-ZEQKJWHPSA-N + 532.46200 + 531.18040 + CC(C)N1CCN(CC1)c1ccc(OC[C@@H]2CO[C@](Cn3cncn3)(O2)c2ccc(Cl)cc2Cl)cc1 + LINCS:LSM-6538 + PMID:16217826 + PMID:17607804 + PMID:19650049 + Reaxys:7471104 + 1-(4-{[(2S,4R)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)-4-isopropylpiperazine + chebi_ontology + (2S,4R)-(-)-terconazole + CHEBI:82981 + + (2S,4R)-terconazole + + + + + + + + + An animal metabolite produced by arthropods such as crabs, lobsters, crayfish, shrimps and krill. + + chebi_ontology + crustacean metabolites + CHEBI:83039 + + crustacean metabolite + + + + + + + + + A Daphnia metabolite produced by the species Daphnia magna. + + chebi_ontology + Daphnia magna metabolites + CHEBI:83056 + + Daphnia magna metabolite + + + + + + + + + A crustacean metabolite produced by the genus of small planktonic arthropods, Daphnia + + Wikipedia:Daphnia + chebi_ontology + Daphnia metabolites + CHEBI:83057 + + Daphnia metabolite + + + + + + + + + + Any compound that inhibits the biosynthesis of any sterol. + + chebi_ontology + sterol biosynthesis inhibitors + CHEBI:83317 + + sterol biosynthesis inhibitor + + + + + + + + + + Any metabolite produced by metabolism of a xenobiotic compound in marine macro- and microorganisms. + + chebi_ontology + marine xenobiotic metabolites + CHEBI:83399 + + marine xenobiotic metabolite + + + + + + + + + Any member of the class of chlorobenzenes containing a mono- or poly-substituted benzene ring in which only one substituent is chlorine. + + chebi_ontology + CHEBI:83403 + + monochlorobenzenes + + + + + + + + + + + + + + + + An organofluorine compound that is (trifluoromethyl)benzene and derivatives arising from substitution of one or more of the phenyl hydrogens. + + chebi_ontology + CHEBI:83565 + + (trifluoromethyl)benzenes + + + + + + + + + Any member of the class of fluorobenzenes containing a mono- or poly-substituted benzene ring carrying a single fluorine substitutent. + + monofluorobenzenes + chebi_ontology + CHEBI:83575 + + monofluorobenzenes + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A glucocorticoid that is prednisone in which the oxo group at position 11 has been reduced to the corresponding beta-hydroxy group. It is a drug metabolite of prednisone. + + 0 + C21H28O5 + InChI=1S/C21H28O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h5,7,9,14-16,18,22,24,26H,3-4,6,8,10-11H2,1-2H3/t14-,15-,16-,18+,19-,20-,21-/m0/s1 + OIGNJSKKLXVSLS-VWUMJDOOSA-N + 360.44400 + 360.19367 + [H][C@@]12CCC3=CC(=O)C=C[C@]3(C)[C@@]1([H])[C@@H](O)C[C@@]1(C)[C@@]2([H])CC[C@]1(O)C(=O)CO + Beilstein:1354103 + CAS:50-24-8 + DrugBank:DB00860 + Drug_Central:2245 + HMDB:HMDB0014998 + KEGG:C07369 + KEGG:D00472 + PMID:11294518 + PMID:23625982 + PMID:24392764 + Reaxys:1354103 + VSDB:1848 + Wikipedia:Prednisolone + 11beta,17,21-trihydroxypregna-1,4-diene-3,20-dione + chebi_ontology + (11beta)-11,17,21-trihydroxypregna-1,4-diene-3,20-dione + 1,4-pregnadiene-11beta,17alpha,21-triol-3,20-dione + 1,4-pregnadiene-3,20-dione-11beta,17alpha,21-triol + 3,20-dioxo-11beta,17alpha,21-trihydroxy-1,4-pregnadiene + Delta(1)-dehydrocortisol + Delta(1)-dehydrohydrocortisone + Delta(1)-hydrocortisone + hydroretrocortine + metacortandralone + prednisolona + prednisolone + prednisolonum + CHEBI:8378 + + prednisolone + + + + + + + + + + + + + + + Any derivative of a proteinogenic amino acid resulting from reaction at an amino group, carboxy group, or a side-chain functional group, or from the replacement of any hydrogen by a heteroatom. + + chebi_ontology + canonical amino acid derivative + canonical amino acid derivatives + canonical amino-acid derivative + canonical amino-acid derivatives + proteinogenic amino acid derivatives + proteinogenic amino-acid derivative + proteinogenic amino-acid derivatives + CHEBI:83811 + + proteinogenic amino acid derivative + + + + + + + + + + Any of the 23 alpha-amino acids that are precursors to proteins, and are incorporated into proteins during translation. The group includes the 20 amino acids encoded by the nuclear genes of eukaryotes together with selenocysteine, pyrrolysine, and N-formylmethionine. Apart from glycine, which is non-chiral, all have L configuration. + + Wikipedia:Proteinogenic_amino_acid + chebi_ontology + canonical amino acid + canonical amino acids + proteinogenic amino acids + CHEBI:83813 + + proteinogenic amino acid + + + + + + + + + Any amino-acid that is not naturally encoded in the genetic code of any organism. + + Wikipedia:Non-proteinogenic_amino_acids + chebi_ontology + non-canonical amino acid + non-canonical amino acids + non-canonical amino-acid + non-canonical amino-acids + non-coded amino acid + non-coded amino acids + non-coded amino-acid + non-coded amino-acids + non-proteinogenic amino acids + non-proteinogenic amino-acid + non-proteinogenic amino-acids + CHEBI:83820 + + non-proteinogenic amino acid + + + + + + + + + Any derivative of an amino acid resulting from reaction at an amino group, carboxy group, side-chain functional group, or from the replacement of any hydrogen by a heteroatom. The definition normally excludes peptides containing amino acid residues. + + CHEBI:25359 + chebi_ontology + amino acid derivatives + modified amino acids + CHEBI:83821 + + amino acid derivative + + + + + + + + + + 0 + C21H36 + InChI=1S/C21H36/c1-4-15-9-11-18-17-10-8-16-7-5-6-13-20(16,2)19(17)12-14-21(15,18)3/h15-19H,4-14H2,1-3H3/t15-,16?,17-,18-,19-,20-,21+/m0/s1 + JWMFYGXQPXQEEM-WZBAXQLOSA-N + 288.51054 + 288.28170 + [H][C@]1(CC)CC[C@@]2([H])[C@]3([H])CCC4([H])CCCC[C@]4(C)[C@@]3([H])CC[C@]12C + LIPID_MAPS_instance:LMST02030000 + Wikipedia:Pregnane + pregnane + chebi_ontology + CHEBI:8386 + + pregnane + + + + + + + + + + Any alpha-amino acid which is not a member of the group of 23 proteinogenic amino acids. + + chebi_ontology + non-proteinogenic alpha-amino acids + non-proteinogenic alpha-amino-acid + non-proteinogenic alpha-amino-acids + CHEBI:83925 + + non-proteinogenic alpha-amino acid + + + + + + + + + + + + + + + + Steroid lactones containing sugar residues that act on the contractile force of the cardiac muscles. + + Wikipedia:Cardiac_glycoside + chebi_ontology + cardiac glycosides + CHEBI:83970 + + cardiac glycoside + + + + + + + + + + + + + + + + A proteinogenic amino acid derivative resulting from reaction of L-valine at the amino group or the carboxy group, or from the replacement of any hydrogen of L-valine by a heteroatom. + + chebi_ontology + L-valine derivatives + CHEBI:84129 + + L-valine derivative + + + + + + + + + + + + + + + + A proteinogenic amino acid derivative resulting from reaction of L-serine at the amino group or the carboxy group, or from the replacement of any hydrogen of L-serine by a heteroatom. + + chebi_ontology + L-serine derivatives + CHEBI:84135 + + L-serine derivative + + + + + + + + + + + + + + + + A proteinogenic amino acid derivative resulting from reaction of L-phenylalanine at the amino group or the carboxy group, or from the replacement of any hydrogen of L-phenylalanine by a heteroatom. + + chebi_ontology + L-phenylalanine derivatives + CHEBI:84144 + + L-phenylalanine derivative + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + 8745 + A tertiary amine that is a substituted phenothiazine in which the ring nitrogen at position 10 is attached to C-3 of an N,N-dimethylpropan-2-amine moiety. + A substituted phenothiazine in which the ring nitrogen at position 10 is attached to C-3 of an N,N-dimethylpropan-2-amine moiety. + + + 0 + C17H20N2S + InChI=1S/C17H20N2S/c1-13(18(2)3)12-19-14-8-4-6-10-16(14)20-17-11-7-5-9-15(17)19/h4-11,13H,12H2,1-3H3 + PWWVAXIEGOYWEE-UHFFFAOYSA-N + 284.42018 + 284.13472 + CC(CN1c2ccccc2Sc2ccccc12)N(C)C + Beilstein:88554 + CAS:60-87-7 + ChemIDplus:60-87-7 + DrugBank:DB01069 + Drug_Central:2286 + Gmelin:337077 + HMDB:HMDB0015202 + KEGG COMPOUND:60-87-7 + KEGG COMPOUND:C07404 + KEGG DRUG:D00494 + KEGG:C07404 + KEGG:D00494 + LINCS:LSM-4440 + NIST Chemistry WebBook:60-87-7 + Patent:US2530451 + Patent:US2607773 + Reaxys:88554 + Wikipedia:Promethazine + N,N-dimethyl-1-(10H-phenothiazin-10-yl)propan-2-amine + Promethazine + chebi_ontology + (2-dimethylamino-2-methyl)ethyl-N-dibenzoparathiazine + 10-(2-Dimethylaminopropyl)phenothiazine + 10-[2-(dimethylamino)propyl]phenothiazine + C17H20N2S + CC(CN1c2ccccc2Sc2ccccc12)N(C)C + InChI=1S/C17H20N2S/c1-13(18(2)3)12-19-14-8-4-6-10-16(14)20-17-11-7-5-9-15(17)19/h4-11,13H,12H2,1-3H3 + InChIKey=PWWVAXIEGOYWEE-UHFFFAOYSA-N + N,N,alpha-trimethyl-10H-phenothiazine-10-ethanamine + N-(2'-dimethylamino-2'-methyl)ethylphenothiazine + proazamine + prometazina + promethazine + promethazinum + CHEBI:8461 + + Promethazine + promethazine + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + The hydrochloride salt of promethazine. + + 0 + C17H20N2S.HCl + C17H21ClN2S + InChI=1S/C17H20N2S.ClH/c1-13(18(2)3)12-19-14-8-4-6-10-16(14)20-17-11-7-5-9-15(17)19;/h4-11,13H,12H2,1-3H3;1H + XXPDBLUZJRXNNZ-UHFFFAOYSA-N + 320.88000 + 320.11140 + Cl.CC(CN1c2ccccc2Sc2ccccc12)N(C)C + Beilstein:4166397 + CAS:58-33-3 + DrugBank:DB01069 + KEGG:D00480 + PMID:20541454 + PMID:21125640 + PMID:21134682 + PMID:21788155 + PMID:21871787 + PMID:22119804 + PMID:22346617 + PMID:6196640 + Reaxys:4166397 + N,N-dimethyl-1-(10H-phenothiazin-10-yl)propan-2-amine hydrochloride + chebi_ontology + (+-)-10-(2-(Dimethylamino)propyl)phenothiazine monohydrochloride + 10-(2-Dimethylamino-1-propyl)phenothiazine hydrochloride + 10-(3-Dimethylaminoisopropyl)phenothiazine hydrochloride + Fenergan + N-(2'-dimethylamino-2'-methyl)ethylphenothiazine hydrochloride + N-(2-dimethylaminopropyl-1)phenothiazine hydrochloride + Phenergan + promethazine HCl + CHEBI:8462 + + promethazine hydrochloride + + + + + + + + + Any eukaryotic metabolite produced during a metabolic reaction in algae including unicellular organisms like chlorella and diatoms to multicellular organisms like giant kelps and brown algae. + + chebi_ontology + algal metabolites + CHEBI:84735 + + algal metabolite + + + + + + + + + + + + + + + + + + + + + + + A hydrazine in which each nitrogen atom is substituted, one by a 3'-carboxy-2-hydroxy[1,1'-biphenyl]-3-yl group and the other by a 1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydro-4H-pyrazol-4-ylidene group. A small molecule agonist of the c-mpl (TpoR) receptor (the physiological target of the hormone thrombopoietin), it has been developed as a medication for conditions that lead to thrombocytopenia (abnormally low platelet counts). + + 0 + C25H22N4O4 + InChI=1S/C25H22N4O4/c1-14-10-11-19(12-15(14)2)29-24(31)22(16(3)28-29)27-26-21-9-5-8-20(23(21)30)17-6-4-7-18(13-17)25(32)33/h4-13,26,30H,1-3H3,(H,32,33)/b27-22- + XDXWLKQMMKQXPV-QYQHSDTDSA-N + 442.46660 + 442.16411 + CC1=NN(C(=O)\C1=N/Nc1cccc(-c2cccc(c2)C(O)=O)c1O)c1ccc(C)c(C)c1 + CAS:496775-61-2 + Drug_Central:4399 + PMID:24433306 + PMID:25063763 + PMID:25170628 + PMID:25400215 + PMID:25578417 + PMID:25700916 + Wikipedia:Eltrombopag + 3'-{(2Z)-2-[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydro-4H-pyrazol-4-ylidene]hydrazinyl}-2'-hydroxy[1,1'-biphenyl]-3-carboxylic acid + chebi_ontology + 3'-{(2Z)-2-[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydro-4H-pyrazol-4-ylidene]hydrazino}-2'-hydroxybiphenyl-3-carboxylic acid + CHEBI:85010 + + eltrombopag + + + + + + + + + An agonist that selectively binds to and activates the thrombopoietin receptor [myeloproliferative leukemia protein or CD110 (Cluster of Differentiation 110)]. + + chebi_ontology + TPO receptor agonist + TPO receptor agonists + thrombopoietin receptor agonists + CHEBI:85012 + + thrombopoietin receptor agonist + + + + + + + + + + + + + + + + + + + + + A compound that has a structure that is related to miconazole, contains an azole (imidazole or triazole) moiety, and has significant systemic antifungal properties. They inhibit cytochrome P450-dependent enzymes (particularly C14-demethylase) involved in the biosynthesis of ergosterol, which is required for fungal cell membrane structure and function. + + CHEBI:60593 + chebi_ontology + azole antibiotic + azole antibiotics + conazole antifungal agents + CHEBI:86323 + + conazole antifungal agent + + + + + + + + + + + Any antifungal agent used to prevent or treat fungal infections in humans or animals. + + Wikipedia:Antifungal + chebi_ontology + anti-fungal drug + anti-fungal drugs + anti-fungal medication + anti-fungal medications + antifungal drugs + antifungal medication + antifungal medications + pharmaceutical fungicide + pharmaceutical fungicides + CHEBI:86327 + + antifungal drug + + + + + + + + + + + Any substance used in acriculture, horticulture, forestry, etc. for its fungicidal properties. + + chebi_ontology + agrichemical fungicide + agrichemical fungicides + agrochemical fungicide + agrochemical fungicides + anti-fungal agrichemical + anti-fungal agrichemicals + anti-fungal agrochemical + anti-fungal agrochemicals + antifungal agrichemical + antifungal agrichemicals + antifungal agrochemicals + CHEBI:86328 + + antifungal agrochemical + + + + + + + + + + + + + + + A member of the class of triazole that has significant antifungal properties. + + chebi_ontology + triazole antifungal agents + CHEBI:86426 + + triazole antifungal agent + + + + + + + + + + + + + + + Heteroorganic entities that are microbial metabolites (or compounds derived from them) which have significant antifungal properties. + + chebi_ontology + antibiotic antifungal agents + CHEBI:86478 + + antibiotic antifungal agent + + + + + + + + + + + + + + + + 0 + 2C26H28N3.C23H14O6 + C75H70N6O6 + InChI=1S/2C26H28N3.C23H16O6/c2*1-19-17-21(20(2)29(19)24-9-7-6-8-10-24)11-13-23-14-12-22-18-25(27(3)4)15-16-26(22)28(23)5;24-20-16(14-7-3-1-5-12(14)9-18(20)22(26)27)11-17-15-8-4-2-6-13(15)10-19(21(17)25)23(28)29/h2*6-18H,1-5H3;1-10,24-25H,11H2,(H,26,27)(H,28,29)/q2*+1;/p-2 + OOPDAHSJBRZRPH-UHFFFAOYSA-L + 1151.398 + 1150.53568 + N1(C2=CC=CC=C2)C(=C(/C=C/C3=[N+](C4=C(C=C(N(C)C)C=C4)C=C3)C)C=C1C)C.C1=CC=CC2=C1C=C(C(=C2CC=3C4=C(C=C(C3O)C(=O)[O-])C=CC=C4)O)C(=O)[O-].N1(C2=CC=CC=C2)C(=C(/C=C/C3=[N+](C4=C(C=C3)C=C(C=C4)N(C)C)C)C=C1C)C + CAS:3546-41-6 + KEGG:D00489 + Pyrvinium pamoate + chebi_ontology + Povan + CHEBI:8688 + + Pyrvinium pamoate + + + + + + + + + + + + + + + + An organic cation obtained by protonation of the tertiary amino function of loperamide. + + +1 + C29H34ClN2O2 + InChI=1S/C29H33ClN2O2/c1-31(2)27(33)29(24-9-5-3-6-10-24,25-11-7-4-8-12-25)19-22-32-20-17-28(34,18-21-32)23-13-15-26(30)16-14-23/h3-16,34H,17-22H2,1-2H3/p+1 + RDOIQAHITMMDAJ-UHFFFAOYSA-O + 478.04500 + 477.23033 + CN(C)C(=O)C(CC[NH+]1CCC(O)(CC1)c1ccc(Cl)cc1)(c1ccccc1)c1ccccc1 + 4-(4-chlorophenyl)-1-[4-(dimethylamino)-4-oxo-3,3-diphenylbutyl]-4-hydroxypiperidin-1-ium + chebi_ontology + loperamide cation + CHEBI:86969 + + loperamide(1+) + + + + + + + + + + + + + + + + Any organic aromatic compound containing two phenyl (or substituted phenyl) groups attached to a single carbon or heteroatom and which has been used as a fungicide. + + chebi_ontology + bridged diphenyl fungicides + CHEBI:87039 + + bridged diphenyl fungicide + + + + + + + + + + + + + + + + Any conazole antifungal agent that has been used for the treatment of fungal infections in animals or humans. + + chebi_ontology + conazole antifungal drugs + CHEBI:87071 + + conazole antifungal drug + + + + + + + + + + + + + + + Any triazole antifungal agent that has been used for the treatment of fungal infections in humans or animals. + + chebi_ontology + triazole antifungal drugs + CHEBI:87101 + + triazole antifungal drug + + + + + + + + + + + + + + + Any antibiotic antifungal agent used to treat fungal infections in humans or animals. + + chebi_ontology + antibiotic antifungal drugs + CHEBI:87113 + + antibiotic antifungal drug + + + + + + + + + + + + + + + Any antibiotic antifungal agent that has been used as a fungicide. + + chebi_ontology + antibiotic fungicides + CHEBI:87114 + + antibiotic fungicide + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A carboxylic ester resulting from the formal condensation between the carboxylic acid group of mycophenolic acid and the hydroxy group of 2-(morpholin-4-yl)ethanol. In the liver, it is metabolised to mycophenolic acid, an immunosuppressant for which it is a prodrug. It is widely used to prevent tissue rejection following organ transplants as well as for the treatment of certain autoimmune diseases. + + 0 + C23H31NO7 + InChI=1S/C23H31NO7/c1-15(5-7-19(25)30-13-10-24-8-11-29-12-9-24)4-6-17-21(26)20-18(14-31-23(20)27)16(2)22(17)28-3/h4,26H,5-14H2,1-3H3/b15-4+ + RTGDFNSFWBGLEC-SYZQJQIISA-N + 433.49470 + 433.21005 + COc1c(C)c2COC(=O)c2c(O)c1C\C=C(/C)CCC(=O)OCCN1CCOCC1 + CAS:128794-94-5 + DrugBank:DB00688 + Drug_Central:1859 + HMDB:HMDB0014826 + KEGG:C07908 + KEGG:D00752 + PMID:11099793 + PMID:11490743 + PMID:15572389 + PMID:15992049 + PMID:16979992 + PMID:19858585 + PMID:21180633 + PMID:21710356 + PMID:22081165 + PMID:22294686 + PMID:22310598 + PMID:22417996 + PMID:22460418 + PMID:22560143 + PMID:8826401 + PMID:9274835 + Reaxys:7500599 + Wikipedia:Mycophenolate_mofetil + 2-(morpholin-4-yl)ethyl (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enoate + chebi_ontology + 2-morpholinoethyl (E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-5-phthalanyl)-4-methyl-4-hexenoate + Cellcept + MMF + RS 61443 + mycophenolic acid morpholinoethyl ester + CHEBI:8764 + + mycophenolate mofetil + + + + + + + + + + Any drug which causes the onset of an allergic reaction. + + chebi_ontology + allergenic drug + CHEBI:88188 + + drug allergen + + + + + + + + + Any ionophore capable of transportation of potassium ions across membranes. + + PMID:11841304 + chebi_ontology + potassium ionophores + CHEBI:88227 + + potassium ionophore + + + + + + + + + + Any compound that inhibits the process of autophagy (the self-digestion of one or more components of a cell through the action of enzymes originating within the same cell). + + PMID:24830781 + PMID:25727221 + PMID:25793774 + PMID:25896709 + Wikipedia:Autophagy + chebi_ontology + autophagocytosis inhibitor + autophagocytosis inhibitors + autophagy inhibitors + CHEBI:88230 + + autophagy inhibitor + + + + + + + + + + Any organic heterobicyclic compound containing ortho-fused pyrrolidine and triazine rings. + + chebi_ontology + pyrrolotriazines + CHEBI:88341 + + pyrrolotriazine + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A member of the class of benzimidazoles that is 1-methyl-1H-benzimidazole which is substituted at positions 4, 5, and 6 by fluorine, (4-bromo-2-chlorophenyl)amino, and N-(2-hydroxyethoxy)aminocarbonyl groups, respectively. It is a MEK1 and MEK2 inhibitor. + + 0 + C17H15BrClFN4O3 + InChI=1S/C17H15BrClFN4O3/c1-24-8-21-16-13(24)7-10(17(26)23-27-5-4-25)15(14(16)20)22-12-3-2-9(18)6-11(12)19/h2-3,6-8,22,25H,4-5H2,1H3,(H,23,26) + CYOHGALHFOKKQC-UHFFFAOYSA-N + 457.682 + 456.00001 + N1(C=NC2=C1C=C(C(=C2F)NC3=CC=C(C=C3Cl)Br)C(=O)NOCCO)C + CAS:606143-52-6 + KEGG:D09666 + LINCS:LSM-1056 + PDBeChem:3EW + PMID:20407895 + PMID:20978926 + PMID:21594619 + PMID:22241789 + PMID:22343622 + PMID:22394161 + PMID:22565394 + PMID:22972589 + PMID:23372439 + PMID:23444215 + PMID:23942066 + PMID:25322874 + PMID:25342139 + PMID:25379021 + PMID:25385055 + PMID:25498501 + PMID:25637165 + PMID:25887099 + PMID:26059332 + PMID:26384399 + PMID:26446942 + Reaxys:11099648 + Wikipedia:Selumetinib + 5-[(4-bromo-2-chlorophenyl)amino]-4-fluoro-N-(2-hydroxyethoxy)-1-methyl-1H-benzimidazole-6-carboxamide + chebi_ontology + ARRY 142886 + ARRY-142886 + ARRY142886 + AZD 6244 + AZD-6244 + AZD6244 + selumetinib + selumetinibum + CHEBI:90227 + + selumetinib + + + + + + + + + + + + + + + + + + + + + + chebi_ontology + CHEBI:90628 + + benzyl ester + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A member of the class of imidazoles carrying 4-methylsulfinylphenyl, 4-pyridyl and 4-fluorophenyl substituents at positions 2, 4 and 5 respectively. An inhibitor of mitogen-activated protein kinase. + + 0 + C21H16FN3OS + InChI=1S/C21H16FN3OS/c1-27(26)18-8-4-16(5-9-18)21-24-19(14-2-6-17(22)7-3-14)20(25-21)15-10-12-23-13-11-15/h2-13H,1H3,(H,24,25) + CDMGBJANTYXAIV-UHFFFAOYSA-N + 377.437 + 377.09981 + S(C=1C=CC(C2=NC(C=3C=CN=CC3)=C(N2)C4=CC=C(C=C4)F)=CC1)(C)=O + CAS:152121-47-6 + LINCS:LSM-1168 + PMID:11457647 + PMID:24563432 + PMID:25172309 + PMID:25242011 + PMID:25366607 + PMID:25465717 + PMID:25496832 + PMID:25500336 + PMID:25593217 + PMID:25655298 + PMID:25676262 + PMID:25724654 + PMID:25727011 + PMID:25744405 + PMID:25924425 + PMID:26277520 + PMID:26350014 + PMID:26423029 + PMID:26537343 + Reaxys:8078222 + 4-{4-(4-fluorophenyl)-2-[4-(methanesulfinyl)phenyl]-1H-imidazol-5-yl}pyridine + chebi_ontology + 4-(4-Fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)-1H-imidazole + SB-203580 + SB203580 + CHEBI:90705 + + SB 203580 + + + + + + + + + A drug that acts as an antagonist, agonist, reverse agonist, or in some other fashion when interacting with cellular receptors. + + chebi_ontology + receptor modulators + CHEBI:90710 + + receptor modulator + + + + + + + + + + + + + + + A carboxylic acic anion obtained by deprotonation of the carboxy group of any aromatic carboxylic acid. Major species at pH 7.3. + + -1 + CO2R + 44.010 + 43.98983 + *C([O-])=O + chebi_ontology + an aromatic carboxylate + CHEBI:91007 + + aromatic carboxylate + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A macrolide lactam isolated from Streptomyces hygroscopicus consisting of a 29-membered ring containing 4 trans double bonds, three of which are conjugated. It is an antibiotic, immunosupressive and antineoplastic agent. + + 0 + C51H79NO13 + InChI=1S/C51H79NO13/c1-30-16-12-11-13-17-31(2)42(61-8)28-38-21-19-36(7)51(60,65-38)48(57)49(58)52-23-15-14-18-39(52)50(59)64-43(33(4)26-37-20-22-40(53)44(27-37)62-9)29-41(54)32(3)25-35(6)46(56)47(63-10)45(55)34(5)24-30/h11-13,16-17,25,30,32-34,36-40,42-44,46-47,53,56,60H,14-15,18-24,26-29H2,1-10H3/b13-11+,16-12+,31-17+,35-25+/t30-,32-,33-,34-,36-,37+,38+,39+,40-,42+,43+,44-,46-,47+,51-/m1/s1 + QFJCIRLUMZQUOT-HPLJOQBZSA-N + 914.17190 + 913.55514 + [H][C@]1(CC[C@@H](O)[C@@H](C1)OC)C[C@@H](C)[C@]1([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]2([H])CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@@]2([H])C(=O)O1)OC + CHEBI:45276 + CHEBI:67812 + CAS:53123-88-9 + DrugBank:DB00877 + Drug_Central:2446 + HMDB:HMDB0015015 + KEGG:C07909 + KEGG:D00753 + KNApSAcK:C00018055 + LIPID_MAPS_instance:LMPK06000003 + PDBeChem:RAP + PMID:22960739 + PMID:22981852 + PMID:22984623 + Reaxys:5848501 + Wikipedia:Rapamycin + (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-{(2R)-1-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]propan-2-yl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone + Sirolimus + chebi_ontology + (-)-Rapamycin + (1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-{(2S)-1-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]propan-2-yl}-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.0(4,9)]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone + Antibiotic AY 22989 + Rapamune + rapamycin + sirolimus + sirolimusum + CHEBI:9168 + + sirolimus + + + + + + + + + + + + + + + + + + + + + + + + + + + + 0 + C26H29NO.C6H8O7 + InChI=1S/C26H29NO.C6H8O7/c1-4-25(21-11-7-5-8-12-21)26(22-13-9-6-10-14-22)23-15-17-24(18-16-23)28-20-19-27(2)3;7-3(8)1-6(13,5(11)12)2-4(9)10/h5-18H,4,19-20H2,1-3H3;13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)/b26-25-; + FQZYTYWMLGAPFJ-OQKDUQJOSA-N + 563.63812 + 563.25192 + [H+].[H+].[H+].OC(CC([O-])=O)(CC([O-])=O)C([O-])=O.CC\C(c1ccccc1)=C(/c1ccccc1)c1ccc(OCCN(C)C)cc1 + Beilstein:5723042 + CAS:54965-24-1 + DrugBank:DB00675 + KEGG:D00966 + 2-{4-[(1Z)-1,2-diphenylbut-1-en-1-yl]phenoxy}-N,N-dimethylethanamine 2-hydroxypropane-1,2,3-tricarboxylate + chebi_ontology + (Z)-2-(p-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylethylamine citrate (1:1) + Ethanamine, 2-(4-(1,2-diphenyl-1-butenyl)phenoxy)-N,N-dimethyl, (Z)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) + Kessar + Nolvadex + Tamox + Tamoxan + Tamoxene + Tamoxin + trans-1-(p-beta-Dimethylaminoethoxyphenyl)-1,2-diphenylbut-1-ene citrate + CHEBI:9397 + + tamoxifen citrate + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A racemate consisting of equimolar amounts of (2R,4S)- and (2S,4R)-terconazole. It has broad-spectrum antifungal activitiy and is used for the treatment of vaginal yeast infections (Candida). + + CAS:67915-31-5 + DrugBank:DB00251 + HMDB:HMDB0014396 + KEGG:C08080 + KEGG:D00888 + PMID:1941796 + PMID:20801303 + PMID:2099320 + PMID:2277372 + PMID:2381618 + PMID:2677363 + PMID:2677364 + PMID:2677365 + PMID:2680088 + PMID:2696620 + PMID:2817662 + PMID:2902415 + PMID:2903397 + PMID:3129389 + PMID:3520601 + PMID:3729366 + PMID:4007621 + PMID:6617296 + PMID:6834396 + PMID:8023214 + PMID:8987951 + Reaxys:7471103 + Wikipedia:Terconazole + rac-1-(4-{[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)-4-isopropylpiperazine + chebi_ontology + R 42,470 + R-42,470 + R-42470 + Terazol 3 + Terazol 7 + cis-1-(p-{[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)-4-isopropylpiperazine + terconazol + terconazole + terconazolum + CHEBI:9451 + + terconazole + + + + + + + + + + + + + + + + + 0 + C12H9N3O5S + InChI=1S/C12H9N3O5S/c1-7(16)20-9-5-3-2-4-8(9)11(17)14-12-13-6-10(21-12)15(18)19/h2-6H,1H3,(H,13,14,17) + YQNQNVDNTFHQSW-UHFFFAOYSA-N + 307.284 + 307.02629 + CC(=O)OC1=CC=CC=C1C(=O)NC2=NC=C(S2)[N+](=O)[O-] + CAS:55981-09-4 + Drug_Central:1943 + HMDB:HMDB0014649 + LINCS:LSM-6002 + chebi_ontology + nitazode + nitazoxanida + nizonide + CHEBI:94807 + + acetic acid [2-[[(5-nitro-2-thiazolyl)amino]-oxomethyl]phenyl] ester + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A member of the class of phenothiazines that is perazine substituted by a ethylsulfanyl group at position 2. + + 0 + C22H29N3S2 + InChI=1S/C22H29N3S2/c1-3-26-18-9-10-22-20(17-18)25(19-7-4-5-8-21(19)27-22)12-6-11-24-15-13-23(2)14-16-24/h4-5,7-10,17H,3,6,11-16H2,1-2H3 + XCTYLCDETUVOIP-UHFFFAOYSA-N + 399.61788 + 399.18029 + CCSc1ccc2Sc3ccccc3N(CCCN3CCN(C)CC3)c2c1 + Beilstein:52127 + CAS:1420-55-9 + DrugBank:DB00372 + Drug_Central:2630 + HMDB:HMDB0014516 + KEGG:C07132 + KEGG:D02354 + LINCS:LSM-3556 + PMID:15469457 + PMID:23243946 + Reaxys:52127 + Wikipedia:Thiethylperazine + 2-(ethylsulfanyl)-10-[3-(4-methylpiperazin-1-yl)propyl]-10H-phenothiazine + Thiethylperazine + chebi_ontology + 2-(ethylthio)-10-[3-(4-methylpiperazin-1-yl)propyl]-10H-phenothiazine + 3-Ethylmercapto-10-(1'-methylpiperazinyl-4'-propyl)phenothiazine + Ethylthioperazine + thiethylperazine + thiethylperazinum + tietilperazina + CHEBI:9544 + + thiethylperazine + + + + + + + + + + + + + + + + + + + + + + + + + + + A 2-aminopurine that is the 6-thiono derivative of 2-amino-1,9-dihydro-6H-purine. Incorporates into DNA and inhibits synthesis. Used in the treatment of leukaemia. + + 0 + C5H5N5S + InChI=1S/C5H5N5S/c6-5-9-3-2(4(11)10-5)7-1-8-3/h1H,(H4,6,7,8,9,10,11) + WYWHKKSPHMUBEB-UHFFFAOYSA-N + 167.19200 + 167.02657 + Nc1nc2[nH]cnc2c(=S)[nH]1 + CAS:154-42-7 + DrugBank:DB00352 + Drug_Central:2632 + KEGG:C07648 + KEGG:D08603 + KNApSAcK:C00018807 + LINCS:LSM-6723 + MetaCyc:CPD-5721 + PDBeChem:DX4 + PMID:21803983 + PMID:22178190 + PMID:22245861 + PMID:22261533 + PMID:22280519 + PMID:22563779 + PMID:22646133 + PMID:22822082 + PMID:22983983 + PMID:23259153 + PMID:23261807 + PMID:23377192 + PMID:23377281 + PMID:23393198 + PMID:25542975 + PMID:28166217 + Reaxys:1074099 + Wikipedia:Thioguanine + 2-amino-1,9-dihydro-6H-purine-6-thione + chebi_ontology + 2-Amino 6MP + 2-Amino-1,7-dihydro-6H-purine-6-thione + 2-Amino-6-mercaptopurine + 2-Amino-6-merkaptopurin + 2-Amino-6-purinethiol + 2-Aminopurin-6-thiol + 2-Aminopurine-6(1H)-thione + 2-Aminopurine-6-thiol + 2-amino-1,9-dihydropurine-6-thione + 6-Mercapto-2-aminopurine + 6-Mercaptoguanine + 6-TG + 6-Thioguanine + 6-thioguanine + TG + ThG + Thioguanine + Tioguanin + tioguanina + tioguanine + tioguaninum + CHEBI:9555 + + tioguanine + + + + + + + + + + + + + + + + 0 + C23H29N3O2S2 + InChI=1S/C23H29N3O2S2/c1-24(2)30(27,28)18-10-11-23-21(17-18)19(20-7-4-5-9-22(20)29-23)8-6-12-26-15-13-25(3)14-16-26/h4-5,7-11,17H,6,12-16H2,1-3H3/b19-8- + GFBKORZTTCHDGY-UWVJOHFNSA-N + 443.628 + 443.17012 + CN(C)S(=O)(=O)C1=CC\2=C(SC3=CC=CC=C3/C2=C/CCN4CCN(C)CC4)C=C1 + CAS:3313-26-6 + CAS:5591-45-7 + Drug_Central:2639 + HMDB:HMDB0015560 + KEGG:D00374 + Thiothixene + chebi_ontology + Navane (TN) + Tiotixene + cis-Thiothixene + thiothixene HCl + thiothixene hydrochloride + CHEBI:9571 + + Thiothixene + + + + + + + + + + + + + + + + 0 + C26H28ClNO.C6H8O7 + C32H36ClNO8 + InChI=1S/C26H28ClNO.C6H8O7/c1-28(2)19-20-29-24-15-13-23(14-16-24)26(22-11-7-4-8-12-22)25(17-18-27)21-9-5-3-6-10-21;7-3(8)1-6(13,5(11)12)2-4(9)10/h3-16H,17-20H2,1-2H3;13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)/b26-25-; + IWEQQRMGNVVKQW-OQKDUQJOSA-N + 598.084 + 597.21294 + C(CC(O)=O)(CC(O)=O)(C(O)=O)O.C1=CC=CC(=C1)\C(\C=2C=CC(=CC2)OCCN(C)C)=C(\C3=CC=CC=C3)/CCCl + CAS:89778-27-8 + KEGG:D00967 + Toremifene citrate + chebi_ontology + Fareston (TN) + CHEBI:9636 + + Toremifene citrate + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A member of the class of phenothiazines that is 10H-phenothiazine having a trifluoromethyl subsitituent at the 2-position and a 3-(dimethylamino)propyl group at the N-10 position. + + 0 + C18H19F3N2S + InChI=1S/C18H19F3N2S/c1-22(2)10-5-11-23-14-6-3-4-7-16(14)24-17-9-8-13(12-15(17)23)18(19,20)21/h3-4,6-9,12H,5,10-11H2,1-2H3 + XSCGXQMFQXDFCW-UHFFFAOYSA-N + 352.41700 + 352.12210 + CN(C)CCCN1c2ccccc2Sc2ccc(cc12)C(F)(F)F + Beilstein:335308 + CAS:146-54-3 + DrugBank:DB00508 + Drug_Central:2742 + HMDB:HMDB0014650 + KEGG:D00390 + LINCS:LSM-3421 + PMID:1650428 + PMID:24959397 + Patent:GB813861 + Reaxys:335308 + Wikipedia:Triflupromazine + N,N-dimethyl-3-[2-(trifluoromethyl)-10H-phenothiazin-10-yl]propan-1-amine + chebi_ontology + 10-(3-(Dimethylamino)propyl)-2-(trifluoromethyl)phenothiazine + 2-(Trifluoromethyl)promazine + 2-Trifluoromethyl-10-(gamma-dimethylaminopropyl)phenothiazine + trifluopromazine + triflupromazina + triflupromazine + triflupromazinum + CHEBI:9711 + + triflupromazine + + + + + + + + + + + + + + + + + + + + + + 0 + C18H19F3N2S.HCl + InChI=1S/C18H19F3N2S.ClH/c1-22(2)10-5-11-23-14-6-3-4-7-16(14)24-17-9-8-13(12-15(17)23)18(19,20)21;/h3-4,6-9,12H,5,10-11H2,1-2H3;1H + FTNWXGFYRHWUKG-UHFFFAOYSA-N + 388.87879 + 388.09878 + [H+].[Cl-].CN(C)CCCN1c2ccccc2Sc2ccc(cc12)C(F)(F)F + Beilstein:3801519 + CAS:1098-60-8 + DrugBank:DB00508 + KEGG:D00800 + N,N-dimethyl-3-[2-(trifluoromethyl)-10H-phenothiazin-10-yl]propan-1-amine hydrochloride + Triflupromazine hydrochloride + chebi_ontology + 10-(3-(Dimethylamino)propyl)-2-(trifluoromethyl)phenothiazine monohydrochloride + 10-(3-Dimethylaminopropyl)-2-(trifluoromethyl)phenothiazine hydrochloride + Fluopromazine monohydrochloride + Trifluopromazine hydrochloride + Triflupromazine HCl + Triflupromazine monohydrochloride + CHEBI:9712 + + triflupromazine hydrochloride + + + + + + + + + + + + + + + + + + + + + A disease process that is induced by coronavirus infection + Oliver He, Yu Hong + https://en.wikipedia.org/wiki/Coronavirus + coronavirus infectious disease process + + + + + + + + + + + + + + + + + + + + + + + + + + + Oliver He, Yu Hong + SARS coronavirus disease process + Severe Acute Respiratory Syndrome + https://en.wikipedia.org/wiki/Severe_acute_respiratory_syndrome + https://www.who.int/ith/diseases/sars/en/ + SARS was a relatively rare disease; at the end of the epidemic in June 2003, the incidence was 8422 cases with a case-fatality rate of 11%. The case-fatality ratio ranges from 0% to 50% depending on the age group of the patient. Patients under 24 were least likely to die; those 65 and older were most likely to die. +Reference: https://en.wikipedia.org/wiki/Severe_acute_respiratory_syndrome + SARS-CoV disease process + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + a coronavirus disease process that is induced by SARS-CoV-2 + Oliver He, Yu Hong + 2019 novel coronavirus disease process + 2019-nCoV disease process + https://en.wikipedia.org/wiki/Severe_acute_respiratory_syndrome + https://www.who.int/ith/diseases/sars/en/ + COVID-19 disease process + + + + + + + + + + + + + + + + + + + + + + + + + + + Oliver He, Yu Hong + Middle East respiratory syndrome DP + https://en.wikipedia.org/wiki/Middle_East_respiratory_syndrome-related_coronavirus + MERS-CoV disease process + + + + + + + + + + + + + + + + + + + + + Oliver He, Yu Hong + https://en.wikipedia.org/wiki/Human_coronavirus_229E + Human coronavirus 229E disease process + + + + + + + + + + + + + + + + + + + + + Oliver He, Yu Hong + https://en.wikipedia.org/wiki/Human_coronavirus_OC43 + Human coronavirus OC43 disease process + + + + + + + + + + + + + + + + + + + + + Oliver He, Yu Hong + https://en.wikipedia.org/wiki/Human_coronavirus_NL63 + Human coronavirus NL63 disease process + + + + + + + + + + + + + + + + + + + + + Oliver He, Yu Hong + https://en.wikipedia.org/wiki/Human_coronavirus_HKU1 + Human coronavirus HKU1 disease process + + + + + + + + + + + + + + + A drug that is used to treat for COVID-19 + COVID-19 drug + + + + + + + + + A COVID-19 drug that is experinentallly proven to be effective against SARS-CoV-2 infection, where the experiment can be done either in vivo or in vitro. The in vitro study is typically conducted using cell line cells. + Asiyah Yu Lin, Oliver He + https://www.preprints.org/manuscript/202003.0413/v1 + COVID-19 experimental drug + + + + + + + + + A COVID-19 experimental drug that is under clinical trial testing. + Asiyah Yu Lin, Oliver He + COVID-19 experimental drug in clinical trial + + + + + + + + + diagnostic objective + + + + + + + + + COVID-19 diagnostic objective + + + + + + + + + A COVID-19 diagnostic process that uses a computed tomography (CT). + Hong Yu, Oliver He, Asiyah Yu Lin + https://www.ncbi.nlm.nih.gov/pubmed/32245835 + COVID-19 diagnostic process by CT scanning + + + + + + + + + + + + + + + A COVID-19 diagnostic process that uses a serological assay that tests the serum from the blood specimen + Hong Yu, Oliver He, Asiyah Yu Lin + https://www.ncbi.nlm.nih.gov/pubmed/32245835 + COVID-19 diagnostic process by serological assay + + + + + + + + + Oliver He, Asiyah Yu Lin + https://www.fda.gov/medical-devices/emergency-situations-medical-devices/emergency-use-authorizations#covid19ivd + https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7170415/ + COVID-19 RT-PCR assay + + + + + + + + + + + + + + + + + + + + + Yale New Haven Hospital, Clinical Virology Laboratory + Asiyah Yu Lin, Oliver He + https://www.fda.gov/media/136602/download + Under this Emergency Use Authorization (EUA), this test is authorized for use in the single laboratory that developed the authorized test and that is certified under Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a to perform high complexity tests. URL: https://www.fda.gov/medical-devices/emergency-situations-medical-devices/emergency-use-authorizations#covid19ivd + Yale New Haven Hospital SARS-CoV-2 assay + + + + + + + + + Altru Diagnostics, Inc. + Asiyah Yu Lin, Oliver He + SARS-CoV-2 test by Altru Diagnostics, Inc + https://www.fda.gov/media/137546/download + Altru Dx SARS-CoV-2 RT-PCR assay + + + + + + + + + An organization that has members to perform COVID-19 test for patients who drive through to a specifc location + Oliver He, Asiyah Lin + drive-thru COVID-19 testing site + drive-thru COVID-19 testing entity + + + + + + + + + A COVID-19 diagnostic process by viral culturing in cells and identification of the isolated viruses + Oliver He, Asiyah Yu Lin, Hong Yu + https://www.ncbi.nlm.nih.gov/pubmed/32245835 + COVID-19 diagnostic process by viral culture and isolation + + + + + + + + + A COVID-19 diagnostic process by viral genome sequencing and identification of the SARS-CoV-2 based on the genome sequence. + Oliver He, Asiyah Yu Lin, Hong Yu + https://www.ncbi.nlm.nih.gov/pubmed/32245835 + COVID-19 diagnostic process by viral genome sequencing + + + + + + + + + A COVID-19 diagnostic process that identifies typical phenotypes (symptoms) of a patient and makes a diagnostic conclusion. + Oliver He, Hong Yu, Asiyah Yu Lin + https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html + https://www.ncbi.nlm.nih.gov/pubmed/32245835 + Symptoms may appear 2-14 days after exposure to the virus. People with these symptoms or combinations of symptoms may have COVID-19: +Cough, and Shortness of breath or difficulty breathing. CDC also defines at least two of these symptoms: Fever, Chills, Repeated shaking with chills, Muscle pain, Headache, Sore throat, New loss of taste or smell. +Reference: https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html + COVID-19 diagnostic process based on symptoms + + + + + + + + + An organization that is authorized by US FDA according to a FDA Emergency Use Authorization (EUA). + Asiyah Yu Lin, Oliver He + https://www.fda.gov/medical-devices/emergency-situations-medical-devices/emergency-use-authorizations + FDA EUA-authorized organization + + + + + + + + + A COVID-19 diagnostic process that is performed by chest imaging. Thoracic imaging with chest radiography (CXR) and computed tomography (CT) are key tools for pulmonary disease diagnosis and management. + COVID-19 diagnostic process by thoracic imaging + Hong Yu, Oliver He, Asiyah Yu Lin + https://www.ncbi.nlm.nih.gov/pubmed/32245835 + COVID-19 diagnostic process by chest imaging + + + + + + + + + A COVID-19 diagnostic process that is performed by chest radiography (CXR) + COVID-19 diagnostic process by thoracic imaging + Hong Yu, Oliver He, Asiyah Yu Lin + https://www.ncbi.nlm.nih.gov/pubmed/32245835 + COVID-19 diagnostic process by chest radiography + + + + + + + + + A COVID-19 diagnostic process that uses an serological assay that tests the serum from the blood specimen by an Enzyme Linked Immunosorbent Assay (ELISA) screening test + Hong Yu, Oliver He, Asiyah Yu Lin + https://www.ncbi.nlm.nih.gov/pubmed/32245835 + COVID-19 diagnostic process by ELISA serological assay + + + + + + + + + A COVID-19 diagnostic process that uses an serological assay that tests the serum from the blood specimen by an Immunofluorescence assay (IFA) + Hong Yu, Oliver He, Asiyah Yu Lin + https://www.ncbi.nlm.nih.gov/pubmed/32245835 + COVID-19 diagnostic process by immunofluorescence serological assay + + + + + + + + + A COVID-19 diagnostic process that uses a real time RT-PCR test + Oliver He, Hong Yu, Asiyah Yu Lin + https://www.ncbi.nlm.nih.gov/pubmed/32245835 + COVID-19 diagnostic process using real time RT-PCR + + + + + + + + + A COVID-19 diagnostic process that detects SARS-CoV-2 by amplification and identification of nucleic acids of SARS-CoV-2. + Oliver He, Hong Yu, Asiyah Yu Lin + https://www.ncbi.nlm.nih.gov/pubmed/32245835 + COVID-19 diagnostic process using nucleic acid detection + + + + + + + + + A COVID-19 diagnostic process that detects SARS-CoV-2 by loop mediated isothermal amplification ((LAMP) assay + Hong Yu, Oliver He + https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7182526/ + COVID-19 diagnostic process using LAMP assay + + + + + + + + + Biocerna + Asiyah Lin, Oliver He + https://www.fda.gov/media/137450/download + Biocerna SARS-CoV-2 Test + + + + + + + + + Nationwide Children’s Hospital + Asiyah Lin, Oliver He + https://www.fda.gov/media/137423/download + Nationwide Children’s Hospital SARS-CoV-2 Assay + + + + + + + + + AIT Laboratories + Asiyah Lin, Oliver He + https://www.fda.gov/media/137374/download + AIT Laboratories SARS-CoV-2 Assay + + + + + + + + + Ultimate Dx Laboratory + Asiyah Lin, Oliver He + https://www.fda.gov/media/137372/download + UDX SARS-CoV-2 Molecular Assay + + + + + + + + + Southwest Regional PCR Laboratory LLC. dba MicroGen DX + Asiyah Lin, Oliver He + https://www.fda.gov/media/137370/download + MicroGen DX COVID-19 Key + + + + + + + + + Diatherix Eurofins Laboratory + Asiyah Lin, Oliver He + https://www.fda.gov/media/137255/download + Diatherix Eurofins SARS-CoV-2 PCR Test + + + + + + + + + Mayo Clinic Laboratories, Rochester, MN + Asiyah Lin, Oliver He + https://www.fda.gov/media/137163/download + Mayo Clinic SARS-CoV-2 Molecular Detection Assay + + + + + + + + + CirrusDx Laboratories + Asiyah Lin, Oliver He + https://www.fda.gov/media/137034/download + CirrusDx SARS-CoV-2 Assay + + + + + + + + + Hackensack University Medical Center (HUMC) Molecular Pathology Laboratory + Asiyah Lin, Oliver He + https://www.fda.gov/media/137036/download + CDI Enhanced COVID-19 Test + + + + + + + + + Exact Sciences Laboratories + Asiyah Lin, Oliver He + https://www.fda.gov/media/137095/download + Exact Sciences Laboratory SARS-CoV-2 Test + + + + + + + + + Pathology/Laboratory Medicine Lab of Baptist Hospital Miami + Asiyah Lin, Oliver He + https://www.fda.gov/media/136944/download + Baptist Health Care COVID-19 RT-PCR Test + + + + + + + + + Integrity Laboratories + Asiyah Lin, Oliver He + https://www.fda.gov/media/136942/download + Integrity Laboratories SARS-CoV-2 Assay + + + + + + + + + Specialty Diagnostic (SDI) Laboratories + Asiyah Lin, Oliver He + https://www.fda.gov/media/136877/download + SDI SARS-CoV-2 AssayLetter Granting Inclusion + + + + + + + + + Rutgers Clinical Genomics Laboratory-Rutgers University + Asiyah Lin, Oliver He + https://www.fda.gov/media/136875/download + ThermoFisher - Applied Biosystems TaqPath COVID-19 Combo Kit + + + + + + + + + Orig3n, Inc. + Asiyah Lin, Oliver He + https://www.fda.gov/media/136873/download + Orig3n 2019 Novel Coronavirus (COVID-19) Test + + + + + + + + + University of North Carolina Medical Center + Asiyah Lin, Oliver He + https://www.fda.gov/media/136880/download + UNC Health SARS-CoV-2 real-time RT-PCR test + + + + + + + + + Stanford Health Care Clinical Virology Laboratory + Asiyah Lin, Oliver He + https://www.fda.gov/media/136818/download + Stanford SARS-CoV-2 assay + + + + + + + + + Viracor Eurofins Clinical Diagnostics + Asiyah Lin, Oliver He + https://www.fda.gov/media/136740/download + Viracor SARS-CoV-2 assay + + + + + + + + + Massachusetts General Hospital + Asiyah Lin, Oliver He + https://www.fda.gov/media/136699/download + MGH COVID-19 qPCR assay + + + + + + + + + Infectious Disease Diagnostics Laboratory - Children's Hospital of Philadelphia + Asiyah Lin, Oliver He + https://www.fda.gov/media/136656/download + CHOP SARS-CoV-2 RT-PCR test + + + + + + + + + Diagnostic Molecular Laboratory - Northwestern Medicine + Asiyah Lin, Oliver He + https://www.fda.gov/media/136669/download + Northwestern Medicine SARS-Cov-2 Assay + + + + + + + + + Infectious Diseases Diagnostics Laboratory (IDDL), Boston Children's Hospital + Asiyah Lin, Oliver He + https://www.fda.gov/media/136971/download + Childrens-Altona-SARS-CoV-2 Assay + + + + + + + + + Hong Yu, Oliver He + a human patient who is infected with coronavirus + human coronavirus patient + + + + + + + + + Hong Yu, Oliver He + a human patient who is infected with SARS coronavirus + SARS patient + human SARS patient + + + + + + + + + Hong Yu, Oliver He + a human patient who is infected with MERS coronavirus + MERS patient + human MERS patient + + + + + + + + + Hong Yu, Oliver He + a human patient who is infected with SARS-CoV-2 coronavirus or has the disease of COVID-19 + COVID-19 patient + human COVID-19 patient + + + + + + + + + A diagnostic process for detecting coronavirus disease from a patient + Oliver He, Hong Yu + coronavirus diagnostic process + coronavirus disease diagnostic process + + + + + + + + + + + + + + + A diagnostic process for detecting coronavirus from a patient + Oliver He, Hong Yu + COVID-19 diagnostic process + + + + + + + + + A diagnostic process for detecting SARS from a patient + Oliver He, Hong Yu + SARS diagnostic process + + + + + + + + + A diagnostic process for detecting MERS from a patient + Oliver He, Hong Yu + MERS diagnostic process + + + + + + + + + The representation of a conclusion of a diagnostic process for a coronavirus disease. + Oliver He, Hong Yu + coronavirus disease diagnosis + + + + + + + + + The representation of a conclusion of a diagnostic process for the SARS coronavirus disease. + Oliver He, Hong Yu + SARS diagnosis + + + + + + + + + The representation of a conclusion of a diagnostic process for the MERS coronavirus disease. + Oliver He, Hong Yu + MERS diagnosis + + + + + + + + + The representation of a conclusion of a diagnostic process for the COVID-19 coronavirus disease. + Oliver He, Hong Yu + COVID-19 diagnosis + + + + + + + + + The representation of a negative conclusion of a diagnostic process for the COVID-19 coronavirus disease. + Oliver He, Hong Yu + negative COVID-19 diagnosis + + + + + + + + + The representation of a presumptive positive conclusion of a diagnostic process for the COVID-19 coronavirus disease. + Oliver He, Hong Yu + presumptive positive COVID-19 diagnosis + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A COVID-19 diagnostic process that uses a reverse transcription polymerase chain reaction (rRT -PCR) test + Oliver He, Hong Yu, Asiyah Yu Lin + https://www.ncbi.nlm.nih.gov/pubmed/32245835 + COVID-19 diagnostic process using RT-PCR + + + + + + + + + A viral infectious disease that has_material_basis_in Coronavirus. + + disease_ontology + DOID:0080599 + Coronavirus infection + + + + + + + + + A Coronavirus infection that is characterized by fever, cough and shortness of breath and that has_material_basis_in SARS-CoV-2. + + 2019 Novel Coronavirus (2019-nCoV) + 2019-nCoV infection + Wuhan coronavirus infection + Wuhan seafood market pneumonia virus infection + disease_ontology + DOID:0080600 + COVID-19 + + + + + + + + + A Coronavirus infection that is characterized by severe respiratory illness, including fever, cough, and shortness of breath and that has_material_basis_in MERS-CoV. + + disease_ontology + DOID:0080642 + Middle East respiratory syndrome + + + + + + + + + + + + + + + A Coronavirus infection that results_in infection located_in respiratory tract, has_material_basis_in SARS coronavirus (SARS-CoV), which is transmitted_by droplet spread of respiratory secretions, transmitted_by ingestion of contaminated food, or transmitted_by fomites. The infection has_symptom fever, has_symptom headache, has_symptom body aches, has_symptom dry cough, and has_symptom hypoxia. + + GARD:9237 + ICD10CM:J12.81 + ICD9CM:079.82 + MESH:D045169 + NCI:C85064 + SNOMEDCT_US_2019_09_01:398447004 + UMLS_CUI:C1175175 + SARS + SARS-CoV infection + disease_ontology + DOID:2945 + + + severe acute respiratory syndrome + + + + + + + + + A disease by infectious agent that results in infection, has_material_basis_in Viruses. + + DOID:1329 + ICD10CM:A94 + ICD10CM:B34.9 + ICD9CM:060-066.99 + MESH:D001102 + MESH:D014777 + NCI:C3439 + NCI:C34396 + SNOMEDCT_US_2019_09_01:34014006 + SNOMEDCT_US_2019_09_01:40610006 + UMLS_CUI:C0003723 + UMLS_CUI:C0042769 + Viral Infection + Viral disease + virus infection + disease_ontology + DOID:934 + + + + viral infectious disease + + + + + + + + + the role of a material entity to prevent, diagnose, treat, or study disease and/or its effects + William Hogan + + William Hogan + clinical drug role + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + a material entity (1) containing at least one scattered molecular aggregate as part that is the bearer of an active ingredient role and (2) that is itself the bearer of a clinical drug role + William Hogan + + William Hogan + drug product + + + + + + + + + a material entity that contains two or more scattered object aggregates as its only parts, where the grains of each object aggregate are of different types and evenly distributed throughout, such that any two parts of the entity, each of which is spatially contiguous and of the same size, contain nearly equal numbers of grains of the aggregates + William Hogan + + William Hogan + Examples: saline solution, a suspension of dust particles in air, milk. + Typically, the grains of the object aggregates are molecules (as in a solution of salt in water), but a mate- rial entity made of gravel mixed in a heap of soil also meets the definition, where the grains are individual rocks (gravel) and particles of soil. + portion of mixture + + + + + + + + + a portion of mixture of two or more portions of pure substances whereby one or more of its pure substance parts called solute(s) is (are) dispersed evenly in another pure substance part called the solvent, whereby (1) the grains of the solvent and solute(s) are of size ≤10^-9m, and (2) the solvent typically has a much greater mass and volume than the solute(s) + William Hogan + + William Hogan + The phase (solid, liquid, gas) of the solution is usually the phase of the solvent. + portion of solution + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + a portion of solution that is the bearer of a clinical drug role + William Hogan + + William Hogan + drug solution + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + a solid object typically of discoid, spheroid, or elliptic-cylindrical shape or approximations thereof, that bears a clinical drug role. + William Hogan + + William Hogan + drug tablet + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + an object that is the bearer of a drug role and is comprised of a solid shell of elliptical-cylindrical shape and another object contained in the shell that has a scattered molecular aggregate as a proper part + William Hogan + + William Hogan + drug capsule + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + active ingredient role + a role of a scattered molecular aggregate that is part of a drug product that is realized by (1) administration of the drug to an organism followed by (2) some change in the structure or functioning of some part of the organism + William R. Hogan + + active ingredient + + + + + + + + + + + + + + + + + + + + role of a scattered molecular aggregate + a role borne by a scattered molecular aggregate and realized by its grains participating in one or more processes + William R. Hogan + + role of scattered molecular aggregate + + + + + + + + + + + + + + + + + + + + + + + + administration of a drug product to an organism + a treatment that has as participants an extended organism and a drug product and that results in part of the drug product being located in the extended organism + William R. Hogan + + drug administration + + + + + + + + + + + + + + + + + + + + therapeutic function of a drug product + a function inhering in a drug product that when realized, is realized by a process that either (1) negatively regulates symptom processes, processes leading to symptoms, and/or the realization of a disease, (2) has specified output some entity useful in the diagnosis of disease, or (3) negatively regulates or blocks etiological processes. + William R. Hogan + indication of drug product + + drug product therapeutic function + + + + + + + + + anti-malarial function of a drug product + a therapeutic function of a drug product that is realized by administration of the drug product resulting in creation of a material basis of a resistance to malaria infection disposition + William R. Hogan + anti-malarial + anti-malarial indication + + anti-malarial function + anti-malarial function of a drug product + + + + + + + + + anti-hypertensive function of a drug product + a therapeutic function of a drug product that is realized by administration of the drug product resulting in a decrease of systemic arterial pressure + Tim Modzelewski + anti-hypertensive + + anti-hypertensive function + anti-hypertensive function of a drug product + + + + + + + + + function-activating mu opioid receptor binding disposition + a disposition of a molecule to bind an instance of a mu opioid receptor in a manner that activates the realization of a biological function of the receptor instance​ + Amanda Hicks + Baxter Bramblett + Josh Hanna + Matthew Diller + Mirela Vasconcelos + Rodel Enderez + Samria Amirova + Tim Modzelewski + William R. Hogan + mu agonist + + function-activating mu receptor binding disposition + function-activating mu receptor binding disposition + + + + + + + + + function-inhibiting sodium-chloride cotransporter binding disposition + + + + + + + + + + A disposition to bind to a glucocorticoid steroid receptor in such a way as to prevent the realization of the function of the receptor. + ciara lusnia + + This is the mechanism of action for all common corticosteroids such as prednisone, hydrocortisone, etc. + function-inhibiting glucocorticoid steroid receptor binding disposition + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + Rodel Enderez + loperamide tablet + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + Mirela L Vasconcelos + Chloroquine solution + + + + + + + + + + Mirela L Vasconcelos + Chloroquine injectable solution + + + + + + + + + 5521 + + Hydroxychloroquine + + + + + + + + + 8795 + + Proscillaridin + + + + + + + + + 10510 + + Thiothixene + + + + + + + + + 720 + + Amodiaquine + + + + + + + + + 57021 + + Teicoplanin + + + + + + + + + 203223 + + digoxin antibodies Fab fragments + + + + + + + + + 59839 + + penciclovir + + + + + + + + + 114289 + + Indinavir + + + + + + + + + 202912 + + Interferon Alfa-n1 + + + + + + + + + 68149 + + mycophenolate mofetil + + + + + + + + + 72257 + + interferon beta-1b + + + + + + + + + 37806 + + terconazole + + + + + + + + + 4507 + + Fluspirilene + + + + + + + + + + + + + + + 10772 + + Trichlormethiazide + + + + + + + + + 5293 + + Hexachlorophene + + + + + + + + + 31819 + + nitazoxanide + + + + + + + + + 7762 + + Ouabain + + + + + + + + + 7402 + + Niclosamide + + + + + + + + + 3403 + + Digitoxin + + + + + + + + + 195088 + + lopinavir + + + + + + + + + 8120 + + Phenazopyridine + + + + + + + + + 7145 + + Mycophenolic Acid + + + + + + + + + 5879 + + Interferon Alfa-2a + + + + + + + + + 9386 + + Rimantadine + + + + + + + + + 42328 + + Astemizole + + + + + + + + + 3820 + + Emetine + + + + + + + + + 3523 + + Dipyrone + + + + + + + + + 141704 + + everolimus + + + + + + + + + 282388 + + imatinib + + + + + + + + + 341018 + + anidulafungin + + + + + + + + + 475342 + + dasatinib + + + + + + + + + 662281 + + nilotinib + + + + + + + + + + + + + + + 274964 + + ciclesonide + + + + + + + + + 711942 + + eltrombopag + + + + + + + + + 473837 + + telavancin + + + + + + + + + 612865 + + tocilizumab + + + + + + + + + 1243041 + + ivacaftor + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + 370656 + https://www.fda.gov/media/136537/download + https://www.fda.gov/safety/medical-product-safety-information/hydroxychloroquine-or-chloroquine-covid-19-drug-safety-communication-fda-cautions-against-use + + Hydroxychloroquine Oral Tablet + + + + + + + + + + + + + + + + + + + + + + + + + + + + + 370726 + + Ivermectin Oral Tablet + + + + + + + + + + + + + + + + + + + + + + + + + + + + + 371038 + + Benztropine Oral Tablet + + + + + + + + + + + + + + + + + + + + + + + + + + + + + 371459 + + Chlorpromazine Extended Release Capsule + + + + + + + + + + + + + + + + + + + + + + + + + + + + + 371576 + + Clomipramine Extended Release Tablet + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + 371926 + + Chlorpromazine / Dipyrone Oral Solution + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + 372241 + + Fluphenazine / Nortriptyline Oral Tablet + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + 372745 + + Mefloquine Oral Tablet + + + + + + + + + + + + + + + + + + + + + + + + + + + + + 373631 + + Promethazine Injectable Solution + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + 373767 + + Reserpine / Trichlormethiazide Oral Tablet + + + + + + + + + + + + + + + + + + + + + + + + + + + + + 373795 + + Ritonavir Oral Capsule + + + + + + + + + + + + + + + + + + + + + + + + + + + + + 374020 + + Tamoxifen Oral Tablet + + + + + + + + + + + + + + + + + + + + + + + + + + + + + 374573 + + Cyclosporine Injectable Solution + + + + + + + + + + + + + + + + + + + + + + + + + + + + + 375766 + + Azithromycin Injectable Solution + + + + + + + + + + + + + + + + + + + + + + + + + + + + + 376293 + + Ribavirin Injectable Solution + + + + + + + + + + + + + + + + + + + + + + + + + + + + + 379181 + + interferon beta-1b Injectable Solution + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + 637705 + + Cetylpyridinium / zinc chloride Mouthwash + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + 20.0 + + + + + + + + + + + + + + + 313195 + + Tamoxifen 20 MG Oral Tablet + + + + + + + + + 425194 + + Cetylpyridinium Chloride 1 MG/ML / zinc chloride 0.5 MG/ML Mouthwash + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + 75.0 + + + + + + + + + + + + + + + 857326 + + Clomipramine Hydrochloride 75 MG Extended Release Tablet + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + 1.5 + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + 30.0 + + + + + + + + + + + + + + + 865146 + + Fluphenazine Hydrochloride 1.5 MG / Nortriptyline 30 MG Oral Tablet + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + 0.5 + + + + + + + + + + + + + + + 885219 + + benztropine mesylate 0.5 MG Oral Tablet + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + 200.0 + + + + + + + + + + + + + + + 979092 + + Hydroxychloroquine Sulfate 200 MG Oral Tablet + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + 200.0 + + + + + + + + + + + + + + + 991346 + + Chlorpromazine hydrochloride 200 MG Extended Release Capsule + + + + + + + + + 992460 + + Promethazine Hydrochloride 25 MG/ML Injectable Solution + + + + + + + + + 351710 + + Tamoxifen 20 MG Oral Tablet [Barr - Tamoxifen Citrate] + + + + + + + + + 1311505 + + Glycyrrhizin, Ammoniated + + + + + + + + + + function-inhibiting cytochrome P450 2D6 (CYP2D6) binding disposition + + + + + + + + + + cytochrome P450 isoenzyme 2C19 (CYP2C19) substrate disposition + + + + + + + + + ciara lusnia + + cytochrome P450 isoenzyme 2D6 (CYP2D6) substrate disposition + + + + + + + + + 1425099 + + trametinib + + + + + + + + + 1441386 + + bazedoxifene + + + + + + + + + 1539239 + + dalbavancin + + + + + + + + + 1547611 + + oritavancin + + + + + + + + + 1946825 + + abemaciclib + + + + + + + + + 2105806 + + gilteritinib + + + + + + + + + molecular_function + A molecular process that can be carried out by the action of a single macromolecular machine, usually via direct physical interactions with other molecular entities. Function in this sense denotes an action, or activity, that a gene product (or a complex) performs. These actions are described from two distinct but related perspectives: (1) biochemical activity, and (2) role as a component in a larger system/process. + + + molecular_function + + + + + + + + + catalytic activity + Catalysis of a biochemical reaction at physiological temperatures. In biologically catalyzed reactions, the reactants are known as substrates, and the catalysts are naturally occurring macromolecular substances known as enzymes. Enzymes possess specific binding sites for substrates, and are usually composed wholly or largely of protein, but RNA that has catalytic activity (ribozyme) is often also regarded as enzymatic. + + + catalytic activity + + + + + + + + + RNA-directed DNA polymerase activity + Catalysis of the reaction: deoxynucleoside triphosphate + DNA(n) = diphosphate + DNA(n+1). Catalyzes RNA-template-directed extension of the 3'- end of a DNA strand by one deoxynucleotide at a time. + + + RNA-directed DNA polymerase activity + + + + + + + + + The cellular metabolic process in which a protein is formed, using the sequence of a mature mRNA or circRNA molecule to specify the sequence of amino acids in a polypeptide chain. Translation is mediated by the ribosome, and begins with the formation of a ternary complex between aminoacylated initiator methionine tRNA, GTP, and initiation factor 2, which subsequently associates with the small subunit of the ribosome and an mRNA or circRNA. Translation ends with the release of a polypeptide chain from the ribosome. + + protein anabolism + biological_process + GO:0006412 + translation + + + + + + + + + + immune response + Any immune system process that functions in the calibrated response of an organism to a potential internal or invasive threat. + + + + + biological_process + GO:0006955 + This term was improved by GO_REF:0000022. It was redefined and moved. + immune response + + + + + + + + + biological_process + A biological process represents a specific objective that the organism is genetically programmed to achieve. Biological processes are often described by their outcome or ending state, e.g., the biological process of cell division results in the creation of two daughter cells (a divided cell) from a single parent cell. A biological process is accomplished by a particular set of molecular functions carried out by specific gene products (or macromolecular complexes), often in a highly regulated manner and in a particular temporal sequence. + Any process specifically pertinent to the functioning of integrated living units: cells, tissues, organs, and organisms. A process is a collection of molecular events with a defined beginning and end. + + + + + + biological_process + GO:0008150 + biological_process + + + + + + + + + Any protein maturation process achieved by the cleavage of a peptide bond or bonds within a protein. Protein maturation is the process leading to the attainment of the full functional capacity of a protein. + + biological_process + peptidolysis during protein maturation + GO:0016485 + protein processing + + + + + + + + + + + + + + + protein-containing complex + A ribosome is a protein complex. + A stable assembly of two or more macromolecules, i.e. proteins, nucleic acids, carbohydrates or lipids, in which at least one component is a protein and the constituent parts function together. + protein complex + + + protein-containing complex + + + + + + + + + DNA polymerase activity + Catalysis of the reaction: deoxynucleoside triphosphate + DNA(n) = diphosphate + DNA(n+1); the synthesis of DNA from deoxyribonucleotide triphosphates in the presence of a nucleic acid template and a 3'hydroxyl group. + + + DNA polymerase activity + + + + + + + + + + + + + + + + + + + + + DNA polymerase complex + A protein complex that possesses DNA polymerase activity and is involved in template directed synthesis of DNA. + + + DNA polymerase complex + + + + + + + + + response to stimulus + Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus. The process begins with detection of the stimulus and ends with a change in state or activity or the cell or organism. + + + + response to stimulus + + + + + + + + + Any process that localizes a substance or cellular component. This may occur via movement, tethering or selective degradation. + + + Gene Ontology: http://purl.obolibrary.org/obo/go.owl + establishment of localization + + + + + + + + + A phenotypic abnormality. + + UMLS:C4021819 + Organ abnormality + human_phenotype + HP:0000118 + This is the root of the phenotypic abnormality subontology of the HPO. + Phenotypic abnormality + + + + + + + + + + + UMLS:C4025879 + Abnormality of taste sensation + human_phenotype + HP:0000223 + Abnormality of taste sensation + + + + + + + + + An abnormality of the head. + + UMLS:C4021812 + Abnormal head + Abnormality of the head + Head abnormality + human_phenotype + HP:0000234 + Abnormality of the head + + + + + + + + + An abnormality of the face. + + Abnormality of the countenance + Abnormality of the physiognomy + Abnormality of the visage + Disorder of face + SNOMEDCT_US:118930001 + SNOMEDCT_US:32003007 + SNOMEDCT_US:398206004 + SNOMEDCT_US:398302004 + UMLS:C0266617 + UMLS:C1290857 + UMLS:C4025871 + Abnormal face + Abnormality of the face + Facial abnormality + Disorder of the face + human_phenotype + Anomaly of face + Anomaly of the face + Facial anomaly + HP:0000271 + + Abnormality of the face + + + + + + + + + An abnormality of the nose. + + SNOMEDCT_US:128274005 + SNOMEDCT_US:72089000 + UMLS:C0240547 + UMLS:C0265736 + UMLS:C2235909 + Abnormality of the nose + Anomaly of the nose + Nasal abnormality + Nasal anomaly + Deformity of the nose + Malformation of the nose + Nasal deformity + Nasal malformation + human_phenotype + HP:0000366 + + Abnormality of the nose + + + + + + + + + An inability to perceive odors. This is a general term describing inability to smell arising in any part of the process of smelling from absorption of odorants into the nasal mucous overlying the olfactory epithelium, diffusion to the cilia, binding to olfactory receptor sites, generation of action potentials in olfactory neurons, and perception of a smell. + + MSH:D000857 + SNOMEDCT_US:44169009 + UMLS:C0003126 + Loss of smell + Lost smell + human_phenotype + HP:0000458 + + Anosmia + + + + + + + + + An anomaly of the pharynx, i.e., of the tubular structure extending from the base of the skull superiorly to the esophageal inlet inferiorly. + + UMLS:C4025838 + human_phenotype + HP:0000600 + The pharynx is tubular structure extending from base of skull superiorly +to esophageal inlet inferiorly, and is composed of three distinct areas: the nasopharynx, the oropharynx, and the hypopharynx, with the pharyngeal walls being composed of the superior, middle, and inferior pharyngeal constrictor muscles. It is part of the digestive system and of the conducting zone of the respiratory system. + Abnormality of the pharynx + + + + + + + + + An abnormality of the nervous system. + + HP:0001333 + HP:0006987 + Brain and/or spinal cord issue + MSH:D009421 + SNOMEDCT_US:88425004 + UMLS:C0497552 + Abnormality of the nervous system + Neurologic abnormalities + Neurological abnormality + human_phenotype + HP:0000707 + The nervous system comprises the neuraxis (brain, spinal cord, and ventricles), the autonomic nervous system, the enteric nervous system, and the peripheral nervous system. + Abnormality of the nervous system + + + + + + + + + An abnormality of the endocrine system. + + MSH:D004700 + SNOMEDCT_US:362969004 + UMLS:C0014130 + UMLS:C4025823 + human_phenotype + Endocrine system disease + HP:0000818 + The endocrine system is composed of glands that secrete hormones directly into the bloodstream and includes the following glands: thyroid, parathyroids, adrenals, pancreas, gonads (testicles and ovaries), and pituitary. Many other organs, such as the kidney, liver, and heart, have secondary endocrine functions. + Abnormality of the endocrine system + + + + + + + + + + A group of abnormalities characterized by hyperglycemia and glucose intolerance. + + HP:0004908 + HP:0008217 + HP:0008234 + HP:0008260 + MSH:D003920 + SNOMEDCT_US:73211009 + UMLS:C0011849 + human_phenotype + HP:0000819 + Diabetes mellitus + + + + + + + + + 甲状腺功能减退 + Deficiency of thyroid hormone. + + HP:0003222 + HP:0008203 + MSH:D007037 + SNOMEDCT_US:40930008 + UMLS:C0020676 + Low T4 + Underactive thyroid + human_phenotype + HP:0000821 + Hypothyroidism + + + + + + + + + 高血压 + The presence of chronic increased pressure in the systemic arterial system. + + HP:0004949 + HP:0005126 + MSH:D006973 + SNOMEDCT_US:24184005 + SNOMEDCT_US:38341003 + UMLS:C0020538 + UMLS:C0497247 + Systemic hypertension + human_phenotype + High blood pressure + HP:0000822 + Hypertension is sustained elevation of resting systolic BP (140 mm Hg or higher), diastolic BP (90 mm Hg or higher), or both. + Hypertension + + + + + + + + + An abnormality of the skeletal system. + + UMLS:C4021790 + Abnormality of the skeletal system + Skeletal abnormalities + Skeletal anomalies + human_phenotype + HP:0000924 + Abnormality of the skeletal system + + + + + + + + + 嗜睡 + A state of disinterestedness, listlessness, and indifference, resulting in difficulty performing simple tasks or concentrating. + + MSH:D053609 + SNOMEDCT_US:214264003 + UMLS:C0023380 + Lethargy + human_phenotype + HP:0001254 + Lethargy + + + + + + + + + 昏迷 + Complete absence of wakefulness and content of conscience, which manifests itself as a lack of response to any kind of external stimuli. + + ICD-10:R40.2 + MSH:D003128 + SNOMEDCT_US:371632003 + UMLS:C0009421 + Coma + human_phenotype + HP:0001259 + Coma is generally a result of diffuse or extensive involvement of both hemispheres of the brain or lesions in the brainstem. + Coma + + + + + + + + + + 体位性低血压病 + A form of hypotension characterized by a sudden fall in blood pressure that occurs when a person assumes a standing position. + + HP:0004932 + HP:0006700 + MSH:D007024 + SNOMEDCT_US:28651003 + UMLS:C0020651 + Decrease in blood pressure upon standing up + Postural hypotension + human_phenotype + HP:0001278 + Orthostatic hypotension + + + + + + + + + 帕金森氏病 + Characteristic neurologic anomaly resulting form degeneration of dopamine-generating cells in the substantia nigra, a region of the midbrain, characterized clinically by shaking, rigidity, slowness of movement and difficulty with walking and gait. + + MSH:D020734 + SNOMEDCT_US:32798002 + UMLS:C0242422 + human_phenotype + Parkinsonian disease + HP:0001300 + Parkinsonism + + + + + + + + + 肝硬化 + A chronic disorder of the liver in which liver tissue becomes scarred and is partially replaced by regenerative nodules and fibrotic tissue resulting in loss of liver function. + + MSH:D008103 + SNOMEDCT_US:19943007 + UMLS:C0023890 + Hepatic cirrhosis + Scar tissue replaces healthy tissue in the liver + human_phenotype + Liver cirrhosis + HP:0001394 + Cirrhosis is caused by chronic liver disease as a result of viral infections (hepatitis), alcohol abuse, certain medications, certain metabolic disorders of iron and copper, and many others. Cirrhosis may lead to a number of abnormalities including hepatomegaly, jaundice, abnormal liver function tests, ascites, dilatation of veins in the abdominal wall, anemia, and clotting deficiencies. + Cirrhosis + + + + + + + + + Any abnormality of the cardiovascular system. + + MSH:D002318 + MSH:D018376 + SNOMEDCT_US:49601007 + UMLS:C0007222 + UMLS:C0243050 + Abnormality of the cardiovascular system + Cardiovascular abnormality + human_phenotype + Cardiovascular disease + HP:0001626 + The cardiovascular system consists of the heart, vasculature, and the lymphatic system. + Abnormality of the cardiovascular system + + + + + + + + + + 冠心病 + Reduction of the diameter of the coronary arteries as the result of an accumulation of atheromatous plaques within the walls of the coronary arteries, which increases the risk of myocardial ischemia. + + HP:0004929 + HP:0005138 + MSH:D003324 + SNOMEDCT_US:414024009 + SNOMEDCT_US:53741008 + UMLS:C1956346 + Coronary atherosclerosis + Coronary disease + Plaque build-up in arteries supplying blood to heart + human_phenotype + HP:0001677 + Coronary artery disease, also called atherosclerotic heart disease, is the result of atheromatous plaques within the coronary arteries leading to myocardial ischemia and infarction. + Coronary artery atherosclerosis + + + + + + + + + 心绞痛 + Paroxysmal chest pain that occurs with exertion or stress and is related to myocardial ischemia. + + MSH:D000787 + SNOMEDCT_US:194828000 + SNOMEDCT_US:225566008 + UMLS:C0002962 + human_phenotype + HP:0001681 + Angina pectoris + + + + + + + + + 心脏骤停 + An abrupt loss of heart function. + + MSH:D006323 + SNOMEDCT_US:397829000 + SNOMEDCT_US:410429000 + UMLS:C0018790 + Heart stops beating + human_phenotype + HP:0001695 + Cardiac arrest + + + + + + + + + + + UMLS:C4025750 + human_phenotype + HP:0001739 + The nasopharynx (nasal part of the pharynx) lies behind the nose and above the level of the soft palate. + Abnormality of the nasopharynx + + + + + + + + + Reduced ability to pass air through the nasal cavity often leading to mouth breathing. + + MSH:D015508 + SNOMEDCT_US:232209000 + SNOMEDCT_US:267100006 + SNOMEDCT_US:68235000 + UMLS:C0027424 + UMLS:C0027429 + Blockage of nose + Nasal blockage + Nasal obstruction + Obstruction of nose + Stuffy nose + Congestion of nose + Nasal congestion + human_phenotype + HP:0001742 + Nasal obstruction + + + + + + + + + An abnormality of the hematopoietic system. + + HP:0003135 + MSH:D006402 + SNOMEDCT_US:191124002 + SNOMEDCT_US:34093004 + UMLS:C0018939 + UMLS:C0850715 + UMLS:C4020864 + Abnormality of blood and blood-forming tissues + Abnormality of the hematopoietic system + Hematological abnormality + human_phenotype + Abnormality of the haematopoietic system + Hematologic disease + HP:0001871 + The hematopoietic system comprises the organs that are involved in the production of blood, primarily the bone marrow, spleen, tonsils, and lymph nodes. + Abnormality of blood and blood-forming tissues + + + + + + + + + + HP:0002146 + HP:0004355 + HP:0004367 + UMLS:C4021768 + Laboratory abnormality + Metabolism abnormality + human_phenotype + HP:0001939 + Abnormality of metabolism/homeostasis + + + + + + + + + 发热 + Elevated body temperature due to failed thermoregulation. + + MSH:D005334 + SNOMEDCT_US:386661006 + SNOMEDCT_US:50177009 + UMLS:C0015967 + Fever + Hyperthermia + Pyrexia + human_phenotype + HP:0001945 + Hyperthermia is defined as a temperature greater than 37.5-38.3 degree celsius (100-101 degree Fahrenheit). + Fever + + + + + + + + + 心悸 + A sensation that the heart is pounding or racing, which is a non-specific sign but may be a manifestation of arrhythmia. + + HP:0001676 + SNOMEDCT_US:80313002 + UMLS:C0030252 + Heart palpitations + Missed heart beat + Palpitations + Skipped heart beat + human_phenotype + HP:0001962 + Palpitations + + + + + + + + + 呕吐 + Forceful ejection of the contents of the stomach through the mouth by means of a series of involuntary spasmic contractions. + + MEDDRA:10047700 + MSH:D014839 + SNOMEDCT_US:249497008 + SNOMEDCT_US:300359004 + SNOMEDCT_US:422400008 + UMLS:C0042963 + Emesis + Throwing up + Vomiting + human_phenotype + HP:0002013 + + Vomiting + + + + + + + + + 腹泻 + Abnormally increased frequency of loose or watery bowel movements. + + MSH:D003967 + SNOMEDCT_US:267060006 + SNOMEDCT_US:62315008 + UMLS:C0011991 + Diarrhea + Diarrhoea + Watery stool + human_phenotype + HP:0002014 + Diarrhea + + + + + + + + + + SNOMEDCT_US:16932000 + UMLS:C0027498 + Nausea and vomiting + human_phenotype + HP:0002017 + Nausea and vomiting + + + + + + + + + A sensation of unease in the stomach together with an urge to vomit. + + MEDDRA:10028813 + MSH:D009325 + SNOMEDCT_US:422587007 + UMLS:C0027497 + Nausea + human_phenotype + HP:0002018 + + Nausea + + + + + + + + + + An unpleasant sensation characterized by physical discomfort (such as pricking, throbbing, or aching) and perceived to originate in the abdomen. + + Gastro pain + Gastrointestinal pain + MEDDRA:10000081 + MSH:D015746 + SNOMEDCT_US:21522001 + UMLS:C0000737 + Abdominal pain + Pain in stomach + Stomach pain + human_phenotype + Abdominal discomfort + Upset stomach + HP:0002027 + + Abdominal pain can be crampy, achy, dull, intermittent or sharp. The terms stomach ache and stomach cramps are nonmedical terms often used to describe pain in the mid- or upper abdominal area, even though it is not the case that the (smooth) muscles of the stomach or the abdomen have cramps. Stomach pain is another layperson term commonly used to refer to abdominal pain. + Abdominal pain + + + + + + + + + An abnormality of the respiratory system, which include the airways, lungs, and the respiratory muscles. + + UMLS:C4018871 + Respiratory abnormality + human_phenotype + HP:0002086 + Abnormality of the respiratory system + + + + + + + + + 呼吸困难 + Difficult or labored breathing. + + MSH:D004417 + SNOMEDCT_US:230145002 + SNOMEDCT_US:267036007 + UMLS:C0013404 + Abnormal breathing + Breathing difficulty + Difficult to breathe + Trouble breathing + human_phenotype + HP:0002094 + Dyspnea + + + + + + + + + + 脑梗塞 + + SNOMEDCT_US:422504002 + UMLS:C0948008 + human_phenotype + HP:0002140 + Ischemic stroke + + + + + + + + + + 高尿酸血症 + An abnormally high level of uric acid in the blood. + + MSH:D033461 + SNOMEDCT_US:35885006 + UMLS:C0740394 + High blood uric acid level + Hyperuricaemia + human_phenotype + HP:0002149 + Hyperuricemia + + + + + + + + + + An increased susceptibility to respiratory infections as manifested by a history of recurrent respiratory infections. + + HP:0002782 + HP:0002873 + UMLS:C3806482 + Frequent respiratory infections + Multiple respiratory infections + Recurrent respiratory infections + Susceptibility to respiratory infections + respiratory infections, recurrent + human_phenotype + HP:0002205 + Recurrent respiratory infections + + + + + + + + + + 消化道出血 + Hemorrhage affecting the gastrointestinal tract. + + MSH:D006471 + SNOMEDCT_US:74474003 + UMLS:C0017181 + GI hemorrhage + Gastrointestinal bleeding + Gastrointestinal haemorrhage + human_phenotype + HP:0002239 + Gastrointestinal hemorrhage + + + + + + + + + 头痛 + Cephalgia, or pain sensed in various parts of the head, not confined to the area of distribution of any nerve. + + HP:0000266 + HP:0001354 + MSH:D006261 + SNOMEDCT_US:25064002 + UMLS:C0018681 + Headache + Headaches + human_phenotype + HP:0002315 + Headache is one of the most common types of recurrent pain as well as one of the most frequent symptoms in neurology. In addition to occasional headaches, there are well-defined headache disorders that vary in incidence, prevalence and duration and can be divided into two broad categories. In secondary headache disorders, headaches are attributed to another condition, such as brain tumour or head injury; for the primary disorders the headache is not due to another condition. + Headache + + + + + + + + + An abnormality of the vasculature. + + UMLS:C0241657 + Abnormality of blood vessels + Abnormality of the vasculature + Vascular abnormalities + human_phenotype + HP:0002597 + Abnormality of the vasculature + + + + + + + + + + + MSH:D002545 + SNOMEDCT_US:287731003 + SNOMEDCT_US:389100007 + UMLS:C0007786 + UMLS:C0917798 + Brain ischemia + Cerebrovascular ischemia + Disruption of blood oxygen supply to brain + human_phenotype + HP:0002637 + Cerebral ischemia + + + + + + + + + 骨关节炎 + Degeneration (wear and tear) of articular cartilage, i.e., of the joint surface. Joint degeneration may be accompanied by osteophytes (bone overgrowth), narrowing of the joint space, regions of sclerosis at the joint surface, or joint deformity. + + HP:0001379 + HP:0002824 + HP:0005762 + MSH:D010003 + SNOMEDCT_US:225655006 + SNOMEDCT_US:396275006 + UMLS:C0029408 + Degenerative joint disease + human_phenotype + HP:0002758 + Osteoarthritis + + + + + + + + + + An increased susceptibility to upper respiratory tract infections as manifested by a history of recurrent upper respiratory tract infections (running ears - otitis, sinusitis, pharyngitis, tonsillitis). + + HP:0001740 + HP:0002784 + SNOMEDCT_US:195708003 + UMLS:C0581381 + Frequent upper respiratory infections + Frequent upper respiratory tract infections + Recurrent URI + Recurrent colds + Recurrent upper respiratory and lower respiratory infections + Recurrent upper respiratory infection + Recurrent upper respiratory infections + Upper respiratory tract infections + Upper respiratory tract infections, recurrent + human_phenotype + HP:0002788 + Recurrent upper respiratory tract infections + + + + + + + + + + Fyler:4200 + UMLS:C4025677 + Abnormal respiration + Functional respiratory abnormality + human_phenotype + Respiratory problem + HP:0002795 + This category describes not-primarily structural lesions. + Functional respiratory abnormality + + + + + + + + + + Any abnormality of bones of the arms or legs. + + UMLS:C4082761 + Abnormal shape of limb bone + Arm and/or leg bone differences + Limb abnormality + human_phenotype + HP:0002813 + Abnormality of limb bone morphology + + + + + + + + + An abnormality of the leg. + + SNOMEDCT_US:449715001 + UMLS:C1096086 + Abnormality of the leg + Abnormality of the lower limb + Lower limb deformities + human_phenotype + HP:0002814 + + Abnormality of the lower limb + + + + + + + + + Any anomaly of the structure of the femur. + + HP:0001439 + UMLS:C4021750 + Abnormality of the femora + Abnormality of the thighbone + human_phenotype + HP:0002823 + The femur (plural: femora) is the thigh bone. + Abnormality of femur morphology + + + + + + + + + 呼吸衰竭 + A severe form of respiratory insufficiency characterized by inadequate gas exchange such that the levels of oxygen or carbon dioxide cannot be maintained within normal limits. + + HP:0004877 + MSH:D012131 + SNOMEDCT_US:409622000 + UMLS:C1145670 + Respiratory failure + human_phenotype + HP:0002878 + Respiratory failure is classified as type 1 with hypoxemia (arterial partial pressure of oxygen less than 60 mmHg) without hypercapnea, and type 2 with hypoxemia in the present of hypercapnea (partial pressure of carbon dioxide over 50 mmHg). + Respiratory failure + + + + + + + + + 结肠癌 + + HP:0006718 + MSH:D003110 + SNOMEDCT_US:363406005 + UMLS:C0007102 + Colon cancer + human_phenotype + HP:0003003 + Colon cancer + + + + + + + + + 低蛋白血症 + A decreased concentration of protein in the blood. + + MSH:D007019 + SNOMEDCT_US:8900005 + UMLS:C0020639 + Decreased protein levels in blood + human_phenotype + HP:0003075 + Hypoproteinemia + + + + + + + + + 高脂血症 + An elevated lipid concentration in the blood. + + HP:0008159 + HP:0008356 + MSH:D006949 + SNOMEDCT_US:55822004 + UMLS:C0020473 + Elevated lipids in blood + human_phenotype + HP:0003077 + Hyperlipidemia is an elevation of the blood levels of lipids including primarily cholesterol, phospholipids and triglycerides and cholesterol esters. The lipids are transported on lipoproteins some of which are commonly used for clinical measurements, including chylomicrons, very-low density lipoproteins (VLDL), intermediate-density lipoproteins (IDL), low-density lipoproteins, and high-density lipoproteins (HDL). + Hyperlipidemia + + + + + + + + + 肌肉酸痛 + Pain in muscle. + + HP:0003718 + MSH:D063806 + SNOMEDCT_US:68962001 + UMLS:C0231528 + Muscle ache + Muscle pain + human_phenotype + Myalgias + HP:0003326 + Myalgia + + + + + + + + + 室性心律失常 + + peter + 2008-02-20T01:28:00Z + SNOMEDCT_US:44103008 + UMLS:C0085612 + Ventricular arrhythmias + human_phenotype + HP:0004308 + Ventricular arrhythmia + + + + + + + + + + peter + 2008-03-18T07:12:00Z + SNOMEDCT_US:3006004 + UMLS:C0234428 + Disturbances of consciousness + Lowered consciousness + Reduced consciousness/confusion + human_phenotype + HP:0004372 + Reduced consciousness/confusion + + + + + + + + + + An anomaly in the ability to perceive and distinguish scents (odors). + + peter + 2008-03-18T09:21:00Z + HP:0004410 + UMLS:C4021655 + Abnormal sense of smell + Abnormality of olfaction + Abnormality of the sense of smell + Smell defect + human_phenotype + HP:0004408 + + Abnormality of the sense of smell + + + + + + + + + 慢性支气管炎 + Chronic inflammation of the bronchi. + + MSH:D029481 + SNOMEDCT_US:63480004 + UMLS:C0008677 + human_phenotype + HP:0004469 + Chronic bronchitis + + + + + + + + + + 股骨头缺血性坏死 + Avascular necrosis of the proximal epiphysis of the femur occurring in growing children and caused by an interruption of the blood supply to the head of the femur close to the hip joint. The necrosis is characteristically associated with flattening of the femoral head, for which reason the term coxa plana has been used to refer to this feature in the medical literature. + + HP:0003280 + HP:0006448 + HP:0010887 + ICD-10:M91.1 + MSH:D007873 + SNOMEDCT_US:111255008 + SNOMEDCT_US:240241003 + UMLS:C0023234 + Osteochondrosis of the femoral head + Osteonecrosis of the femoral head + Perthes-like femoral head changes + human_phenotype + Coxa plana + Legg-Calve-Perthes syndrome + Legg-Perthes disease + Morbus Legg-Calve-Perthes + HP:0005743 + In medical parlance, this is often referred to as Legg Calve Perthes disease. Here, the name 'Avascular necrosis of the capital femoral epiphysis' is preferred to emphasize that the term refers to a phenotypic feature rather than a disease entity. Avascular necrosis of the femoral head may result in pain in the hip, limp, stiffness and reduced range of motion, and some degree of atrophy of the affected leg. The phrase Legg Perthes syndrome or Legg Calve Perthes disease is also used to refer to a number of diseases, including the idiopathic form and a form that is related to mutation in the COL2A1 gene (MIM 150600). Legg-Calve-Perthes disease usually occurs in boys 4 to 10 years old, and is clinically characterized by limping, hip stiffness, limited range of motion, and can result in restriction of growth of the affected leg and wasting of the muscles of the upper thigh. + Avascular necrosis of the capital femoral epiphysis + + + + + + + + + 2型糖尿病 + A type of diabetes mellitus initially characterized by insulin resistance and hyperinsulinemia and subsequently by glucose interolerance and hyperglycemia. + + HP:0005965 + HP:0100652 + MSH:D003924 + SNOMEDCT_US:44054006 + UMLS:C0011860 + Diabetes mellitus Type II + Diabetes mellitus, noninsulin-dependent + NIDDM + NIDDM diabetes mellitus + Non-insulin dependent diabetes + Noninsulin dependent diabetes mellitus + Noninsulin-dependent diabetes + Type 2 diabetes + Type II diabetes + human_phenotype + Diabetes mellitus type 2 + Noninsulin-dependent diabetes mellitus + HP:0005978 + Persons with type II diabetes mellitus rarely develop ketoacidosis. + Type II diabetes mellitus + + + + + + + + + + An anomaly of a growth plate of a femur. + + peter + 2008-03-28T06:28:00Z + HP:0006412 + HP:0008811 + UMLS:C4025034 + Abnormality of thighbone end part + human_phenotype + HP:0006499 + Abnormality of femoral epiphysis + + + + + + + + + + An anomaly of one or more epiphyses of one or both legs. + + peter + 2008-03-28T06:31:00Z + UMLS:C4021595 + Abnormal shape of end part of lower limb end bone + Abnormality involving the epiphyses of the lower limbs + human_phenotype + HP:0006500 + Abnormality of lower limb epiphysis morphology + + + + + + + + + + An anomaly of one or more epiphyses of a limb. + + peter + 2008-03-28T06:48:00Z + UMLS:C4021593 + Abnormal shape of end part of limb bones + Abnormality involving the epiphyses of the limbs + human_phenotype + HP:0006505 + An epiphysis is the expanded articular end of a long bone that developes from a secondary ossification center, and which during the period of growth is either entirely cartilaginous or is separated from the shaft by a cartilaginous disk. + Abnormality of limb epiphysis morphology + + + + + + + + + 慢阻肺 + An anomaly that is characterized progressive airflow obstruction that is only partly reversible, inflammation in the airways, and systemic effects or comorbities. + + MSH:D029424 + SNOMEDCT_US:13645005 + UMLS:C0024117 + COPD + human_phenotype + HP:0006510 + COPD is usually conceptualized as a disease entity. It is heterogeneous histologically and pathogenically, and conventionally includes emphysema and chronic bronchitis, It is included as a phenotype term as COPD is often annotated as a feature of other diseases. + Chronic obstructive pulmonary disease + + + + + + + + + 神志不清 + + MSH:D014474 + SNOMEDCT_US:418107008 + SNOMEDCT_US:419045004 + UMLS:C0041657 + Loss of consciousness + Passing out + human_phenotype + HP:0007185 + Loss of consciousness + + + + + + + + + + A tumor (abnormal growth of tissue) of the gastrointestinal tract. + + peter + 2008-04-01T11:55:00Z + MSH:D005770 + NCIT:C3262 + SNOMEDCT_US:126768004 + UMLS:C0017185 + GI tract tumor + Gastrointestinal tract neoplasia + Gastrointestinal tract neoplasm + Gastrointestinal tract tumor + Neoplasm of the GI tract + human_phenotype + HP:0007378 + Neoplasm of the gastrointestinal tract + + + + + + + + + + Any structural anomaly of a cerebral artery. The cerebral arteries comprise three main pairs of arteries and their branches, which supply the cerebrum of the brain. These are the anterior cerebral artery, the middle cerebral artery, and the posterior cerebral artery. + + peter + 2008-05-02T01:39:00Z + UMLS:C4021520 + Abnormality of cerebral artery + Abnormality of the cerebral arteries + human_phenotype + HP:0009145 + Abnormal cerebral artery morphology + + + + + + + + + + Any abnormality of the proximal epiphysis of the femur. + + sandra1 + 2009-10-21T01:28:23Z + HP:0010589 + UMLS:C4021252 + Abnormality of the end part of the innermost thighbone + Abnormality of the proximal femoral epiphysis + human_phenotype + HP:0010574 + Note that the proximal epiphysis of the femur is often referred to as the capital femoral epiphysis from the Latin word caput for head. + Abnormality of the epiphysis of the femoral head + + + + + + + + + An abnormality of the systemic arterial tree, which consists of the aorta and other systemic arteries. + + peter + 2011-02-16T08:46:49Z + HP:0002620 + HP:0005114 + Fyler:2600 + SNOMEDCT_US:234119001 + UMLS:C0151489 + UMLS:C4021205 + Abnormal systemic artery morphology + Abnormality of the systemic arterial tree + Systemic artery abnormality + human_phenotype + Arterial abnormalities + HP:0011004 + Abnormal systemic arterial morphology + + + + + + + + + An abnormality of the gastrointestinal tract. + + peter + 2011-03-01T07:52:06Z + MSH:D004066 + MSH:D005767 + SNOMEDCT_US:119292006 + SNOMEDCT_US:25374005 + SNOMEDCT_US:53619000 + UMLS:C0012242 + UMLS:C0017178 + UMLS:C4023588 + Abnormality of the GI tract + Abnormality of the gastrointestinal tract + human_phenotype + Digestive system disease + Gastrointestinal disease + HP:0011024 + Abnormality of the gastrointestinal tract + + + + + + + + + Abnormal functionality of the cardiovascular system. + + peter + 2011-03-03T10:23:19Z + UMLS:C4023587 + Abnormality of cardiovascular system physiology + human_phenotype + HP:0011025 + Abnormal cardiovascular system physiology + + + + + + + + + + The presence of hemorrhage within the body. + + peter + 2011-03-03T10:26:26Z + UMLS:C1390214 + Internal bleeding + Internal haemorrhage + human_phenotype + HP:0011029 + Internal hemorrhage + + + + + + + + + + peter + 2012-03-25T05:35:45Z + UMLS:C0740651 + human_phenotype + HP:0011458 + Abdominal symptom + + + + + + + + + Any cardiac rhythm other than the normal sinus rhythm. Such a rhythm may be either of sinus or ectopic origin and either regular or irregular. An arrhythmia may be due to a disturbance in impulse formation or conduction or both. + + peter + 2012-04-09T12:47:32Z + HP:0001656 + HP:0001661 + HP:0001665 + HP:0001666 + HP:0001675 + HP:0001687 + HP:0001721 + HP:0004351 + HP:0005158 + MSH:C562490 + MSH:D001145 + SNOMEDCT_US:102594003 + SNOMEDCT_US:44808001 + SNOMEDCT_US:698247007 + UMLS:C0003811 + UMLS:C0264886 + UMLS:C0522055 + UMLS:C0855329 + UMLS:C1832603 + UMLS:C1842820 + Abnormal heart rate + Arrhythmias + Cardiac arrhythmia + Cardiac arrhythmias + Cardiac rhythm disturbances + Heart rhythm disorders + Irregular heart beat + Irregular heartbeat + human_phenotype + HP:0011675 + Arrhythmia + + + + + + + + + An abnormality of the form, structure, or size of the skeletal system. + + peter + 2012-05-07T08:08:37Z + UMLS:C4023165 + Abnormally shaped skeletal + human_phenotype + HP:0011842 + Abnormality of skeletal morphology + + + + + + + + + An abnormality of the appendicular skeletal system, consisting of the of the limbs, shoulder and pelvic girdles. + + peter + 2012-05-07T08:12:26Z + UMLS:C4023163 + human_phenotype + HP:0011844 + Abnormal appendicular skeleton morphology + + + + + + + + + An infection of the upper or lower respiratory tract. + + peter + 2012-06-21T08:26:36Z + MSH:D012141 + SNOMEDCT_US:275498002 + UMLS:C0035243 + Respiratory infection + Respiratory tract infection + human_phenotype + Respiratory infections + HP:0011947 + Respiratory tract infection + + + + + + + + + 骨髓纤维化 + Replacement of bone marrow by fibrous tissue. + + peter + 2012-07-18T08:51:57Z + SNOMEDCT_US:52967002 + UMLS:C0026987 + human_phenotype + HP:0011974 + Myelofibrosis + + + + + + + + + An anomaly in the processes involved in the maintenance of an internal equilibrium. + + peter + 2013-09-13T09:23:23Z + MP:0001764 + UMLS:C4022950 + human_phenotype + HP:0012337 + Abnormal homeostasis + + + + + + + + + 乏力 + A subjective feeling of tiredness characterized by a lack of energy and motivation. + + peter + 2013-10-15T08:52:04Z + MSH:D005221 + SNOMEDCT_US:248274002 + SNOMEDCT_US:84229001 + UMLS:C0015672 + Fatigue + Tired + Tiredness + human_phenotype + Malaise + HP:0012378 + Fatigue is distinct from muscle weakness. + Fatigue + + + + + + + + + A structural abnormality of the brain, which has as its parts the forebrain, midbrain, and hindbrain. + + peter + 2013-11-23T02:38:00Z + UMLS:C4021085 + Abnormal shape of brain + Abnormality of the brain + human_phenotype + HP:0012443 + Abnormality of brain morphology + + + + + + + + + An unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage. + + peter + 2013-12-15T09:38:08Z + MSH:D010146 + SNOMEDCT_US:22253000 + UMLS:C0030193 + Pain + human_phenotype + HP:0012531 + Pain + + + + + + + + + 慢性肾疾病 + Functional anomaly of the kidney persisting for at least three months. + + peter + 2014-01-17T01:14:52Z + HP:0000106 + HP:0001918 + HP:0008671 + MSH:D051436 + SNOMEDCT_US:709044004 + UMLS:C0748318 + UMLS:C1561643 + Chronic kidney disease + human_phenotype + Loss of renal function + Progressive renal failure + Progressive renal insufficiency + Renal failure, progressive + Renal insufficiency, progressive + HP:0012622 + Chronic kidney disease + + + + + + + + + A functional anomaly of the nervous system. + + peter + 2014-01-19T08:02:46Z + UMLS:C4022811 + Abnormality of nervous system physiology + human_phenotype + HP:0012638 + Abnormal nervous system physiology + + + + + + + + + + Abnormal structure of the gastrointestinal tract. + + peter + 2014-03-23T01:09:02Z + UMLS:C4021073 + Abnormal shape of the digestive system + Morphological abnormality of the GI tract + Morphological anomaly of the digestive system + human_phenotype + HP:0012718 + Morphological abnormality of the gastrointestinal tract + + + + + + + + + + Abnormal functionality of the gastrointestinal tract. + + peter + 2014-03-23T01:10:47Z + UMLS:C4022755 + Functional abnormality of the GI tract + GI dysfunction + human_phenotype + HP:0012719 + Functional abnormality of the gastrointestinal tract + + + + + + + + + HP_0012735 + A sudden, audible expulsion of air from the lungs through a partially closed glottis, preceded by inhalation. + + peter + 2014-03-23T03:19:50Z + MSH:D003371 + SNOMEDCT_US:263731006 + SNOMEDCT_US:272039006 + SNOMEDCT_US:49727002 + UMLS:C0010200 + Cough + Coughing + human_phenotype + HP:0012735 + The European Respiratory Society Task Force recommended two possible definitions of cough: (1) A three-phase expulsive motor act characterized by an inspiratory effort (inspiratory phase) followed by a forced expiratory effort against a closed glottis (compressive phase) and then by opening of the glottis and rapid expiratory airflow (expulsive phase);and (2) A forced expiratory manoeuvre, usually against a closed glottis and associated with a characteristic sound. The term Cough or any of its more specific descendents can be modified by the terms Acute (HP:0011009), Subacute (HP:0011011), and Chronic (HP:0011010). There is agreement that an actue cough lasts less than 3 weeks, a subacute cough from 3 to 8 weeks, and a chronic cough longer than 8 weeks. + Cough + + + + + + + + + + + 2016-08-12T11:24:56Z + HPO:probinson + Abnormal vascular morphology + + + + + + + + + + 2016-08-27T13:44:32Z + HPO:probinson + Any anomaly of the digestive system, a collection of organs that is made up of the gastrointestinal tract and the liver, pancreas, and gallbladder. The gastrointestinal tract is a series of hollow organs joined in a long, twisting tube from the mouth to the anus, including the mouth, esophagus, stomach, small intestine, large intestine and anus. + Abnormality of the digestive system + + + + + + + + + A functional anomaly of the digestive system. + + 2016-08-27T13:58:05Z + HPO:probinson + Abnormality of digestive system physiology + + + + + + + + + A symptom or manifestation indicating a systemic or general effect of a disease and that may affect the general well-being or status of an individual. + + 2016-11-29T11:02:54Z + HPO:probinson + Note that we use the preferred term label constitutional symptom because this reflects common usage, but we do not restrict the term or its descendents to the narrow meaning of symptom, i.e., a complaint related by a patient to a physician. There is no generally accepted classification of what defines a constitutional symptom, but examples include weight loss, fatigue, general weakness, night sweats, shaking, chills, fever, and vomiting. + Constitutional symptom + + + + + + + + + A sudden sensation of feeling cold. + + 2016-11-29T11:10:01Z + HPO:probinson + Chills + The word chills can also refer to an episode of shivering, accompanied by paleness and feeling cold. + Chills + + + + + + + + + A chronic deviation from normal pressure in the systemic arterial system. + + 2017-04-18T13:55:40Z + robinp + Abnormal systemic BP + Abnormal systemic blood pressure + + + + + + + + + A distortion of the sense of taste, often characterized by the sensation of a metallic taste. + + 2017-08-12T13:35:52Z + peter + Dysgeusia + Metallic taste + Metallic taste in mouth + Parageusia + + + + + + + + + 休克 + The state in which profound and widespread reduction of effective tissue perfusion leads first to reversible, and then if prolonged, to irreversible cellular injury. + + 2017-08-12T20:50:38Z + peter + Shock + + + + + + + + + Increased discharge of mucus from the nose. + + 2017-09-12T02:06:56Z + peter + Nasal Discharge + Runny Nose + Rhinorrhea + + + + + + + + + A type of infection that is regarded as a sign of a pathological susceptibility to infection. There are five general subtypes. (i) Opportunistic infection, meaning infection by a pathogen that is not normally able to cause infection in a healthy host (e.g., pneumonia by Pneumocystis jirovecii or CMV); (ii) Unusual location (focus) of an infection (e.g., an aspergillus brain abscess); (iii) a protracted course or lack of adequate response to treatment (e.g., chronic rhinosinusitis); (iv) Unusual severity or intensity of an infection; and (v) unusual recurrence of infections. + + 2018-11-04T22:23:03Z + peter + Unusual infection + + + + + + + + + An abnormal level of an analyte measured in the blood. + + 2019-01-12T13:45:59Z + peter + Abnormal circulating metabolite concentration + + + + + + + + + 肺结核 + A lung infection by Mycobacterium tuberculosis a slightly curved non-motile, aerobic, non-capsulated and non-spore forming strains of mycobacteria. + + 2019-01-27T19:04:54Z + peter + Pulmonary TB + Predisposing factors include poverty, social disruption, malnutrition, different causes of immune suppression, human immunodeficiency virus (HIV) infection, HIV-TB co-infection and increasing drug resistance. + Pulmonary tuberculosis + + + + + + + + + 腔隙性脑梗死 + A stroke related to a small infarct (2-20 mm in diameter) in the deep cerebral white matter, basal ganglia, or pons, that is presumed to result from the occlusion of a single small perforating artery supplying the subcortical areas of the brain. + + 2019-02-14T11:57:13Z + peter + Lacunar stroke + + + + + + + + + + HPO:skoehler + SNOMEDCT_US:445144002 + UMLS:C0239337 + UMLS:C4073131 + Abnormal limbs + Abnormality of limbs + Limb anomaly + Dysmelia + Abnormality of limbs + + + + + + + + + + + HPO:skoehler + UMLS:C4022456 + Abnormality of limb bone + Abnormality of limb bone + + + + + + + + + + + HPO:skoehler + HP:0040066 + UMLS:C4022455 + UMLS:C4022457 + Abnormal morphology of bones of the lower limbs + Abnormal shape of bones of the lower limbs + Abnormality of lower limb bone + Abnormal lower limb bone morphology + + + + + + + + + 脑软化 + Encephalomalacia is the softening or loss of brain tissue after cerebral infarction, cerebral ischemia, infection, craniocerebral trauma, or other injury. + + PhenoTips:CHum + MSH:D004678 + SNOMEDCT_US:58762006 + UMLS:C0014068 + Cerebral softening + Encephalomalacia + + + + + + + + + Narrowing or constriction of the inner surface (lumen) of an artery. + + doelkens + 2010-12-21T01:30:07Z + SNOMEDCT_US:68109007 + UMLS:C0038449 + Narrowing of an artery + human_phenotype + HP:0100545 + Arterial stenosis + + + + + + + + + + + doelkens + 2010-12-30T11:39:15Z + UMLS:C4022001 + Abnormality of the cerebral blood vessels + human_phenotype + HP:0100659 + Abnormality of the cerebral vasculature + + + + + + + + + 精神分裂症 + A mental disorder characterized by a disintegration of thought processes and of emotional responsiveness. It most commonly manifests as auditory hallucinations, paranoid or bizarre delusions, or disorganized speech and thinking, and it is accompanied by significant social or occupational dysfunction. The onset of symptoms typically occurs in young adulthood, with a global lifetime prevalence of about 0.3-0.7%. + + doelkens + 2011-06-07T09:53:08Z + MSH:D012559 + SNOMEDCT_US:191526005 + SNOMEDCT_US:58214004 + UMLS:C0036341 + human_phenotype + HP:0100753 + Positive symptoms, such as delusions and hallucinations (especially of voices), are common, and any Schneiderian first-rank symptoms are particularly indicative of the illness. Negative symptoms include social withdrawal, impairment of ego boundaries, and loss of energy and initiative. Schizophrenia is diagnosed only if symptoms persist for at least one month. The illness can spontaneously remit, run a course with infrequent or frequent relapses, or become chronic. The prognosis has improved with antipsychotic drugs and with vigorous psychological and social management and rehabilitation. The many causes include genetic factors, environmental stress, and various triggering factors. + Schizophrenia + + + + + + + + + + An increased susceptibility to pharyngitis as manifested by a history of recurrent pharyngitis. + + doelkens + 2011-06-07T05:28:27Z + UMLS:C0747556 + Pharyngitis, recurrent + Recurrent sore throat + human_phenotype + HP:0100776 + Recurrent pharyngitis + + + + + + + + + + The presence of a neoplasm of the large intestine. + + doelkens + 2011-06-09T06:03:45Z + MSH:D015179 + NCIT:C3262 + SNOMEDCT_US:126837005 + UMLS:C0009404 + Large intestine tumor + human_phenotype + HP:0100834 + Neoplasm of the large intestine + + + + + + + + + measurement unit label + Examples of measurement unit labels are liters, inches, weight per volume. + + A data item label that denotes a unit of measure. + 2009-03-16: provenance: a term measurement unit was +proposed for OBI (OBI_0000176) , edited by Chris Stoeckert and +Cristian Cocos, and subsequently moved to IAO where the objective for +which the original term was defined was satisfied with the definition +of this, different, term. + 2009-03-16: review of this term done during during the OBI workshop winter 2009 and the current definition was considered acceptable for use in OBI. If there is a need to modify this definition please notify OBI. + PERSON: Alan Ruttenberg + PERSON: Melanie Courtot + + http://purl.obolibrary.org/obo/obi.owl + measurement unit label + + + + + + + + + objective specification + In the protocol of a ChIP assay the objective specification says to identify protein and DNA interaction. + + + a directive information entity that describes an intended process endpoint. When part of a plan specification the concretization is realized in a planned process in which the bearer tries to effect the world so that the process endpoint is achieved. + 2009-03-16: original definition when imported from OBI read: "objective is an non realizable information entity which can serve as that proper part of a plan towards which the realization of the plan is directed." + 2014-03-31: In the example of usage ("In the protocol of a ChIP assay the objective specification says to identify protein and DNA interaction") there is a protocol which is the ChIP assay protocol. In addition to being concretized on paper, the protocol can be concretized as a realizable entity, such as a plan that inheres in a person. The objective specification is the part that says that some protein and DNA interactions are identified. This is a specification of a process endpoint: the boundary in the process before which they are not identified and after which they are. During the realization of the plan, the goal is to get to the point of having the interactions, and participants in the realization of the plan try to do that. + Answers the question, why did you do this experiment? + PERSON: Alan Ruttenberg + PERSON: Barry Smith + PERSON: Bjoern Peters + PERSON: Jennifer Fostel + goal specification + OBI Plan and Planned Process/Roles Branch + OBI_0000217 + + + + objective specification + + + + + + + + + action specification + Pour the contents of flask 1 into flask 2 + + a directive information entity that describes an action the bearer will take + Alan Ruttenberg + OBI Plan and Planned Process branch + + + + action specification + + + + + + + + + data item label + + An information content entity that is part of some data item and is used to partially define the denotation of that data item. + http://www.golovchenko.org/cgi-bin/wnsearch?q=label#4n + GROUP: IAO + datum label + 9/22/11 BP: changed the rdfs:label for this class from 'label' to 'datum label' to convey that this class is not intended to cover all kinds of labels (stickers, radiolabels, etc.), and not even all kind of textual labels, but rather the kind of labels occuring in a datum. + + + http://purl.obolibrary.org/obo/obi.owl + data item label + + + + + + + + + data item + Data items include counts of things, analyte concentrations, and statistical summaries. + + a data item is an information content entity that is intended to be a truthful statement about something (modulo, e.g., measurement precision or other systematic errors) and is constructed/acquired by a method which reliably tends to produce (approximately) truthful statements. + 2/2/2009 Alan and Bjoern discussing FACS run output data. This is a data item because it is about the cell population. Each element records an event and is typically further composed a set of measurment data items that record the fluorescent intensity stimulated by one of the lasers. + 2009-03-16: data item deliberatly ambiguous: we merged data set and datum to be one entity, not knowing how to define singular versus plural. So data item is more general than datum. + 2009-03-16: removed datum as alternative term as datum specifically refers to singular form, and is thus not an exact synonym. + 2014-03-31: See discussion at http://odontomachus.wordpress.com/2014/03/30/aboutness-objects-propositions/ + JAR: datum -- well, this will be very tricky to define, but maybe some +information-like stuff that might be put into a computer and that is +meant, by someone, to denote and/or to be interpreted by some +process... I would include lists, tables, sentences... I think I might +defer to Barry, or to Brian Cantwell Smith + +JAR: A data item is an approximately justified approximately true approximate belief + PERSON: Alan Ruttenberg + PERSON: Chris Stoeckert + PERSON: Jonathan Rees + data + + + + + + + + + + + data item + + + + + + + + + + + + + + + information content entity + Examples of information content entites include journal articles, data, graphical layouts, and graphs. + + + A generically dependent continuant that is about some thing. + An information content entity is an entity that is generically dependent on some artifact and stands in relation of aboutness to some entity + 2014-03-10: The use of "thing" is intended to be general enough to include universals and configurations (see https://groups.google.com/d/msg/information-ontology/GBxvYZCk1oc/-L6B5fSBBTQJ). + information_content_entity 'is_encoded_in' some digital_entity in obi before split (040907). information_content_entity 'is_encoded_in' some physical_document in obi before split (040907). + +Previous. An information content entity is a non-realizable information entity that 'is encoded in' some digital or physical entity. + PERSON: Chris Stoeckert + OBI_0000142 + + + + + + + + + + + + information content entity + information content entity + + + + + + + + + + + + + + + directive information entity + + + An information content entity whose concretizations indicate to their bearer how to realize them in a process. + 2009-03-16: provenance: a term realizable information entity was proposed for OBI (OBI_0000337) , edited by the PlanAndPlannedProcess branch. Original definition was "is the specification of a process that can be concretized and realized by an actor" with alternative term "instruction".It has been subsequently moved to IAO where the objective for which the original term was defined was satisfied with the definitionof this, different, term. + 2013-05-30 Alan Ruttenberg: What differentiates a directive information entity from an information concretization is that it can have concretizations that are either qualities or realizable entities. The concretizations that are realizable entities are created when an individual chooses to take up the direction, i.e. has the intention to (try to) realize it. + 8/6/2009 Alan Ruttenberg: Changed label from "information entity about a realizable" after discussions at ICBO + Werner pushed back on calling it realizable information entity as it isn't realizable. However this name isn't right either. An example would be a recipe. The realizable entity would be a plan, but the information entity isn't about the plan, it, once concretized, *is* the plan. -Alan + PERSON: Alan Ruttenberg + PERSON: Bjoern Peters + + + + + directive information entity + + + + + + + + + algorithm + PMID: 18378114.Genomics. 2008 Mar 28. LINKGEN: A new algorithm to process data in genetic linkage studies. + + A plan specification which describes the inputs and output of mathematical functions as well as workflow of execution for achieving an predefined objective. Algorithms are realized usually by means of implementation as computer programs for execution by automata. + Philippe Rocca-Serra + PlanAndPlannedProcess Branch + OBI_0000270 + adapted from discussion on OBI list (Matthew Pocock, Christian Cocos, Alan Ruttenberg) + + algorithm + + + + + + + + + + + + + + + + + + + + + + + + curation status specification + + The curation status of the term. The allowed values come from an enumerated list of predefined terms. See the specification of these instances for more detailed definitions of each enumerated value. + Better to represent curation as a process with parts and then relate labels to that process (in IAO meeting) + PERSON:Bill Bug + GROUP:OBI:<http://purl.obolibrary.org/obo/obi> + OBI_0000266 + + + + + + + + + + + curation status specification + + + + + + + + + + + + + + + data set + Intensity values in a CEL file or from multiple CEL files comprise a data set (as opposed to the CEL files themselves). + + A data item that is an aggregate of other data items of the same type that have something in common. Averages and distributions can be determined for data sets. + 2009/10/23 Alan Ruttenberg. The intention is that this term represent collections of like data. So this isn't for, e.g. the whole contents of a cel file, which includes parameters, metadata etc. This is more like java arrays of a certain rather specific type + 2014-05-05: Data sets are aggregates and thus must include two or more data items. We have chosen not to add logical axioms to make this restriction. + person:Allyson Lister + person:Chris Stoeckert + data list + OBI_0000042 + group:OBI + + data set + + + + + + + + + data about an ontology part + data about an ontology part is a data item about a part of an ontology, for example a term + Person:Alan Ruttenberg + + + + + + + + + + + data about an ontology part + + + + + + + + + + + + + + + + + + + + + plan specification + PMID: 18323827.Nat Med. 2008 Mar;14(3):226.New plan proposed to help resolve conflicting medical advice. + + + A directive information entity with action specifications and objective specifications as parts that, when concretized, is realized in a process in which the bearer tries to achieve the objectives by taking the actions specified. + 2009-03-16: provenance: a term a plan was proposed for OBI (OBI_0000344) , edited by the PlanAndPlannedProcess branch. Original definition was " a plan is a specification of a process that is realized by an actor to achieve the objective specified as part of the plan". It has been subsequently moved to IAO where the objective for which the original term was defined was satisfied with the definitionof this, different, term. + 2014-03-31: A plan specification can have other parts, such as conditional specifications. + Alternative previous definition: a plan is a set of instructions that specify how an objective should be achieved + Alan Ruttenberg + OBI Plan and Planned Process branch + OBI_0000344 + + + + 2/3/2009 Comment from OBI review. + +Action specification not well enough specified. +Conditional specification not well enough specified. +Question whether all plan specifications have objective specifications. + +Request that IAO either clarify these or change definitions not to use them + plan specification + + + + + + + + + + + + + + + measurement datum + Examples of measurement data are the recoding of the weight of a mouse as {40,mass,"grams"}, the recording of an observation of the behavior of the mouse {,process,"agitated"}, the recording of the expression level of a gene as measured through the process of microarray experiment {3.4,luminosity,}. + + A measurement datum is an information content entity that is a recording of the output of a measurement such as produced by a device. + 2/2/2009 is_specified_output of some assay? + person:Chris Stoeckert + OBI_0000305 + group:OBI + + measurement datum + + + + + + + + + + + + + + + + + + + + obsolescence reason specification + + The reason for which a term has been deprecated. The allowed values come from an enumerated list of predefined terms. See the specification of these instances for more detailed definitions of each enumerated value. + The creation of this class has been inspired in part by Werner Ceusters' paper, Applying evolutionary terminology auditing to the Gene Ontology. + PERSON: Alan Ruttenberg + PERSON: Melanie Courtot + + obsolescence reason specification + + + + + + + + + Disease process is the progression disease in an individual over time. The process begins with the appropriate exposure to or accumulation of factors sufficient for the disease process to begin in a susceptible host. For an infectious disease, the exposure is a microorganism. For cancer, the exposure may be a factor that initiates the process, such as asbestos fibers or components in tobacco smoke (for lung cancer), or one that promotes the process, such as estrogen (for endometrial cancer). + https://www.cdc.gov/ophss/csels/dsepd/ss1978/lesson1/section9.html + + disease process + 疾病过程 + + + + + + + + + + pathological anatomical entity + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A disease whose physical basis is an infectious disorder. + Albert Goldfain + Alexander Diehl + Lindsay Cowell + tranmissible disease + + The disposition is realized in an infectious disease course. + infectious disease + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A disposition to initiate processes that result in a disorder. + Albert Goldfain + Alexander Diehl + Lindsay Cowell + pathogenicity + + A pathogenic disposition is realized in processes that create a disorder. + The use of 'initiates' is intended to convey that a pathogenic disposition is realized when processes resulting in a disorder begin because of some action on the part of the bearer of the disposition. By this interpretation of 'initiates', disorder-causing entities such as glass, UV light, and toxins do not have a pathogenic disposition. + pathogenic disposition + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A pathogenic disposition that inheres in an organism and is a disposition for that organism (1) to be transmitted to a host, (2) to establish itself in the host, (3) to initiate processes that result in a disorder in the host, and (4) to become part of that disorder. + Albert Goldfain + Alexander Diehl + Lindsay Cowell + + The disposition is realized in a process that has as part a transmission process, an establishment in host process, a process that results in a disorder, and a process in which the bearer of the disposition becomes part of that disorder. The infectious disposition has a complementary disposition that inheres in an organism and is the capability to be host to an organism with an infectious disposition and to undergo processes initiated by that infectious organism that result in a disorder. + infectious disposition + + + + + + + + + + + + + + + + + + + + A disease course that is the realization of an infectious disease. + Albert Goldfain + Alexander Diehl + Lindsay Cowell + + infectious disease course + + + + + + + + + + + + + + + + + + An infection that is clinically abnormal. + Albert Goldfain + Alexander Diehl + Lindsay Cowell + + infectious disorder + + + + + + + + + + + + + + + + + + + + A material entity with a pathogenic disposition. + Albert Goldfain + Alexander Diehl + Lindsay Cowell + + pathogen + + + + + + + + + + + + + + + + + + + + An organism bearing a host role. + Albert Goldfain + Alexander Diehl + Lindsay Cowell + + host + + + + + + + + + + + + + + + + + + + + + + + A part of an extended organism that itself has as part a population of one or more infectious agents and that (1) exists as a result of processes initiated by members of the infectious agent population and is (2) clinically abnormal in virtue of the presence of this infectious agent population, or (3) has a disposition to bring clinical abnormality to immunocompetent organisms of the same Species as the host (the organism corresponding to the extended organism) through transmission of a member or offspring of a member of the infectious agent population. + Albert Goldfain + Alexander Diehl + Lindsay Cowell + + The organism corresponding to the extended organism is host to the infectious agents. By this definition, parts of the host can be considered part of the infection. + infection + + + + + + + + + + + + + + + + + + + + + An organism that has an infectious disposition. + Albert Goldfain + Alexander Diehl + Lindsay Cowell + + infectious agent + + + + + + + + + + + + + + + An establishment of localization process in which a material entity reaches a site in an organism in which it can survive, grow, multiply, or mature. + Requested addition of this term to the GO. + Albert Goldfain + Alexander Diehl + Lindsay Cowell + + An organism begins bearing a particular host role as soon as the extended organism contains the relevant material entity, regardless of that entity's location in the extended organism. An establishment process is any process by which the entity reaches a location in the extended organism in which it can persist and continue its lifecycle. For example, an organism is host to a virus as soon as any part of the extended organism is occupied by virus particles. During an establishment process, virus particles enter host cells of the relevant type, and viral DNA is integrated into host DNA. + establishment of localization in host + + + + + + + + + + + + + + + A process by which a disorder comes into existence. + Albert Goldfain + Alexander Diehl + Lindsay Cowell + + appearance of disorder + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A role borne by an organism in virtue of the fact that it's extended organism contains a material entity other than the organism. + Albert Goldfain + Alexander Diehl + Lindsay Cowell + + host role + + + + + + + + + 粘液瘤 + Neoplasms resembling primitive mesenchymal tissue with a soft mucous matrix. + + mouse_pathology.ontology + MPATH:429 + myxomatous tumor + + + + + + + + + Anatomically located instance of pathological response or entity. + + mouse_pathology.ontology + MPATH:603 + pathological anatomical entity + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Rocky Mountain bat coronavirus 61/2007/EF + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Rocky Mountain bat coronavirus 15/2006/ML + + + + + + + + + + + GC_ID:1 + PMID:15371245 + ncbi_taxonomy + Muridae + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Helictidinae + + + + + + + + + + + GC_ID:1 + Mus + mice + mouse + ncbi_taxonomy + Mus <genus> + + + + + + + + + + + GC_ID:1 + mice + ncbi_taxonomy + Mus sp. + + + + + + + + + + + GC_ID:1 + rat + rats + ncbi_taxonomy + Rattus + + + + + + + + + + + NCBITaxon:2042702 + GC_ID:1 + ncbi_taxonomy + Bat coronavirus Hipposideros/Ractcha-67/THA/2007 + Bat coronavirus Hipposideros/Ratcha-67/THA/2007 + + + + + + + + + + Viruses + + + + + + + + GC_ID:1 + Viruses + ncbi_taxonomy + Vira + Viridae + viral- + viruses + NCBITaxon:10239 + Viruses + virus + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Rm-Bat-CoV 429/2007/MV + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Rm-Bat-CoV 453/2007/EF + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Rm-Bat-CoV 09-07/2009/MV + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Feline coronavirus UU47 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Feline coronavirus UU54 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus M.ful/Japan/03/2009 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus M.ful/Japan/04/2010 + + + + + + + + + + + FRCoV-511c + GC_ID:1 + ncbi_taxonomy + Ferret coronavirus 511c + + + + + + + + + + + FRCoV-4E98 + GC_ID:1 + ncbi_taxonomy + Ferret coronavirus 4E98 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Betacoronavirus M.sch/A/Spain/2004 + Alphacoronavirus M.sch/A/Spain/2004 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Betacoronavirus M.bly/B/Spain/2004 + Alphacoronavirus M.bly/B/Spain/2004 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Betacoronavirus N.las/C/Spain/2007 + Alphacoronavirus N.las/C/Spain/2007 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Betacoronavirus N.las/D/Spain/2007 + Alphacoronavirus N.las/D/Spain/2007 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Betacoronavirus N.las/E/Spain/2007 + Alphacoronavirus N.las/E/Spain/2007 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Betacoronavirus N.las/F/Spain/2007 + Alphacoronavirus N.las/F/Spain/2007 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Betacoronavirus N.las/G/Spain/2007 + Alphacoronavirus N.las/G/Spain/2007 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Betacoronavirus M.dau/H/Spain/2007 + Alphacoronavirus M.dau/H/Spain/2007 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Betacoronavirus M.myo/I/Spain/2007 + Alphacoronavirus M.myo/I/Spain/2007 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Betacoronavirus P.kuh/Iprima/Spain/2007 + Alphacoronavirus P.kuh/Iprima/Spain/2007 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Betacoronavirus P.sp/K/Spain/2007 + Alphacoronavirus P.sp/K/Spain/2007 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Betacoronavirus H.sav/L/Spain/2007 + Alphacoronavirus H.sav/L/Spain/2007 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Alphacoronavirus H.sav/J/Spain/2007 + Betacoronavirus H.sav/J/Spain/2007 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Alphacoronavirus E.isa/M/Spain/2007 + Betacoronavirus E.isa/M/Spain/2007 + + + + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronaviridae + + + + + + + + + + IBV + GC_ID:1 + ncbi_taxonomy + Avian infectious bronchitis virus + avian infectious bronchitis coronavirus IBV + avian infectious bronchitis virus IBV + avian infectious bronchitis virus, IBV + infectious bronchitis virus IBV + Infectious bronchitis virus + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Avian infectious bronchitis virus (strain 6/82) + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Avian infectious bronchitis virus (strain Beaudette) + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Avian infectious bronchitis virus (strain Beaudette M42) + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Avian infectious bronchitis virus (strain D274) + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Avian infectious bronchitis virus (strain D3896) + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Avian infectious bronchitis virus (strain KB8523) + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Avian infectious bronchitis virus (strain M41) + + + + + + + + + + + + BCV + BECV + GC_ID:1 + ncbi_taxonomy + Bovine enteritic coronavirus + Bovine enteritic coronavirus BECV + bovine coronavirus BCV + bovine enteric coronavirus + calf diarrheal coronavirus + neonatal calf diarrhea virus + Bovine coronavirus + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bovine coronavirus (STRAIN F15) + Bovine coronavirus strain F15 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bovine coronavirus (STRAIN L9) + Bovine coronavirus strain L9 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bovine coronavirus (STRAIN LY-138) + Bovine coronavirus LY-138 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bovine coronavirus (STRAIN MEBUS) + Bovine coronavirus strain Mebus + Bovine coronavirus Mebus + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bovine coronavirus (STRAIN QUEBEC) + Bovine coronavirus strain Quebec + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bovine coronavirus (STRAIN VACCINE) + Bovine coronavirus strain vaccine + + + + + + + + + + FIPV + GC_ID:1 + ncbi_taxonomy + Feline infectious peritonitis virus + + + + + + + + + + + HCoV-229E + GC_ID:1 + ncbi_taxonomy + Coronavirus 229E + Human coronavirus (STRAIN 229E) + Human coronavirus serogroup 229E + Human coronavirus strain 229E + Human coronavirus 229E + + + + + + + + + + MHV + GC_ID:1 + ncbi_taxonomy + mouse hepatitis virus + mouse hepatitis virus MHV + murine hepatitis virus MHV + murine hepatitis virus, MHV + Murine hepatitis virus + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Murine coronavirus mhv (STRAIN 1) + Murine hepatitis virus (strain 1) + Murine hepatitis virus strain 1 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Murine coronavirus mhv (STRAIN 3) + Murine hepatitis virus (strain 3) + Murine hepatitis virus strain 3 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Murine coronavirus mhv (STRAIN A59) + Murine hepatitis virus (strain A59) + Murine hepatitis virus strain A59 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Murine coronavirus mhv (STRAIN DEFECTIVE JHM) + Murine hepatitis virus (strain defective JHM) + Murine hepatitis virus strain defective JHM + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Murine coronavirus mhv (STRAIN JHM) + Murine hepatitis virus (strain JHM) + Murine hepatitis virus strain JHM + + + + + + + + + + MHV-S + GC_ID:1 + ncbi_taxonomy + Murine coronavirus mhv (STRAIN S) + Murine hepatitis virus (strain S) + murine hepatitis virus MHV-S + Murine hepatitis virus strain S + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + porcine respiratory coronavirus PRCV + porcine respiratory virus + Porcine respiratory coronavirus + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Porcine respiratory coronavirus (STRAIN RM4) + + + + + + + + + + NCBITaxon:12859 + TGEV + GC_ID:1 + ncbi_taxonomy + Porcine transmissable gastroenteritis coronavirus + Porcine transmissible gastroenteritis coronavirus + porcine transmissible gastroenteritis virus + transmissible gastroenteritis coronavirus + transmissible gastroenteritis virus TGEV + Transmissible gastroenteritis virus + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Porcine transmissible gastroenteritis coronavirus (STRAIN FS772/70) + Porcine transmissible gastroenteritis coronavirus strain FS772/70 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Porcine transmissible gastroenteritis coronavirus (STRAIN PURDUE) + Porcine transmissible gastroenteritis coronavirus strain Purdue + + + + + + + + + + TCV + GC_ID:1 + ncbi_taxonomy + Turkey enteric coronavirus + Turkey coronavirus + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Canine enteric coronavirus + canine coronavirus CCV + Canine coronavirus + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus Philippines/Laguna2265/2010 + BtCoV 2265/Philippines/2010 + Bat coronavirus 2265/Philippines/2010 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus Philippines/Laguna2231/2010 + BtCoV 2231/Philippines/2010 + Bat coronavirus 2231/Philippines/2010 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus M.daubentonii/UK/Wyt/962A + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus M.daubentonii/UK/Wyt/964Co + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus M.daubentonii/UK/Wyt/971Co + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus M.daubentonii/UK/Wyt/972A + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus M.daubentonii/UK/Wyt/991C + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus M.nattereri/UK/Sav/1088A + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus M.nattereri/UK/Sav/1089B + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus M.nattereri/UK/Sav/1091C + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus M.nattereri/UK/Sav/1092B + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus M.nattereri/UK/Sav/1095A + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus M.nattereri/UK/Sav/1106A + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus M.nattereri/UK/Sav/1108A + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus M.nattereri/UK/Wyt/1011A + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus M.nattereri/UK/Wyt/1012B + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus M.nattereri/UK/Wyt/1018A + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus M.nattereri/UK/Wyt/1019A + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus M.nattereri/UK/Wyt/1020A + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus M.nattereri/UK/Wyt/1023A + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Deltacoronavirus + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Common-moorhen coronavirus HKU21 + Common moorhen coronavirus HKU21 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Magpie-robin coronavirus HKU18 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Night-heron coronavirus HKU19 + Night heron coronavirus HKU19 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Porcine coronavirus HKU15 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Sparrow coronavirus HKU17 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + White-eye coronavirus HKU16 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Wigeon coronavirus HKU20 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Rabbit coronavirus HKU14 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Betacoronavirus MHV/S/3239-17 + Murine hepatitis virus strain S/3239-17 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Teleostomi + + + + + + + + + + Euteleostomi + bony vertebrates + + + + NCBITaxon:40673 + GC_ID:1 + bony vertebrates + ncbi_taxonomy + Euteleostomi + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Alpaca respiratory coronavirus + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus Gabon/292/2009 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus Gabon/390/2009 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus Gabon/391/2009 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus CAR/P 25/2009 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus CAR/P 31/2009 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + unclassified Deltacoronavirus + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Alphacoronavirus Eptesicus fuscus + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Alphacoronavirus Perimyotis subflavus + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Murine hepatitis virus strain ML-11 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + human betacoronavirus 2c EMC + Human betacoronavirus 2c EMC/2012 + + + + + + + + + + BtCoV_HKU10 + GC_ID:1 + ncbi_taxonomy + Hipposideros bat coronavirus HKU10 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Rousettus bat coronavirus HKU10 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus HKU10 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Guinea fowl coronavirus GfCoV/FR/2011 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Miniopterus bat coronavirus/South Africa/Irene/2009 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Mops bat coronavirus/South Africa/1364/2011 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Neoromicia bat coronavirus/South Africa/167/2007 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Rhinolophus bat coronavirus/Rwanda/441/2008 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Rhinolophus bat coronavirus/Rwanda/445/2008 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Betacoronavirus England 1 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Ferret coronavirus + + + + + + + + + + FECV + GC_ID:1 + ncbi_taxonomy + Feline enteric coronavirus + Feline enteric coronavirus FECV + Feline coronavirus + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus BCoV/PB675/Art_lit/PAN/2011 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus BtCoV/BRA100/Car_per/BRA/2009 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus BtCoV/BRA114/Car_bre/BRA/2009 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus BtCoV/BRA118/Car_per/BRA/2009 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus BtCoV/BRA119/Car_per/BRA/2009 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus BtCoV/BRA182/Mol_ruf/BRA/2009 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus BtCoV/BRA344/Car_bre/BRA/2009 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus BtCoV/BRAP103/Mol_cur/BRA/2009 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus BtCoV/KCR216/Car_per/CRC/2010 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus BtCoV/KCR230/Pte_par/CRC/2010 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus BtCoV/KCR24/Ano_geo/CRC/2010 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus BtCoV/KCR252/Car_per/CRC/2010 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus BtCoV/KCR253/Car_per/CRC/2010 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus BtCoV/KCR289/Ano_geo/CRC/2010 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus BtCoV/KCR291/Ano_geo/CRC/2010 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus BtCoV/KCR293/Ano_geo/CRC/2010 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus BtCoV/KCR370/Pte_par/CRC/2011 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus BtCoV/KCR372/Car_per/CRC/2010 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus BtCoV/KCR90/Car_per/CRC/2010 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus BtCoV/KCR91/Car_per/CRC/2010 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus BtCoV/KP256/Art_jam/PAN/2010 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus BtCoV/KP524/Art_jam/PAN/2010 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus BtCoV/KP534/Art_lit/PAN/2010 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus BtCoV/KP565/Art_jam/PAN/2010 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus BtCoV/KP816/Phy_dis/PAN/2011 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus BtCoV/KP817/Phy_dis/PAN/2011 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus BtCoV/OCR11/Pte_par/CRC/2011 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Betacoronavirus BtCoV/KW2E-F53/Nyc_spec/GHA/2011 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Betacoronavirus BtCoV/KW2E-F82/Nyc_spec/GHA/2011 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Betacoronavirus BtCoV/KW2E-F93/Nyc_spec/GHA/2010 + + + + + + + + + + NCBITaxon:11141 + MHV-4 + GC_ID:1 + ncbi_taxonomy + Murine coronavirus mhv (STRAIN WILD TYPE 4) + Murine coronavirus mhv (strain 4) + Murine hepatitis virus (strain 4) + murine hepatitis virus MHV 4 + murine hepatitis virus MHV-4 + Murine hepatitis virus strain 4 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat Rp-coronavirus/Shaanxi2011 + Bat coronavirus Rp/Shaanxi2011 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat Cp-coronavirus/Yunnan2011 + Bat coronavirus Cp/Yunnan2011 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus BtCoV/8-691/Pip_nat/ROU/2009 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus BtCoV/8-724/Pip_pyg/ROU/2009 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus BtCoV/UKR-G17/Pip_nat/UKR/2011 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat Mr-coronavirus/Shanxi2011 + Bat coronavirus Mr/Shanxi2011 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus POA/2012/105 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus POA/2012/127 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus POA/2012/132 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus POA/2012/143 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus POA/2012/144 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus POA/2012/44 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus POA/2012/94 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus POA/2012/96 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus POA/2012/B01 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus POA/2012/D09 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus POA/2012/E05 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus POA/2012/E07 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus POA/2012/E11 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus POA/2012/E9 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus POA/2012/G01 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus POA/2012/G03 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus Mex_CoV-1 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus Mex_CoV-10 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus Mex_CoV-11a + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus Mex_CoV-2 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus Mex_CoV-3 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus Mex_CoV-4 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus Mex_CoV-5a + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus Mex_CoV-5b + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus Mex_CoV-6 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus Mex_CoV-7 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus Mex_CoV-8 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus Mex_CoV-9 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + coronavirus Mex_CoV-11b + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Munia coronavirus HKU13 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Thrush coronavirus HKU12 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Human betacoronavirus 2c England-Qatar/2012 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Human betacoronavirus 2c strain Jordan-N3/2012 + Human betacoronavirus 2c Jordan-N3/2012 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus isolate Susurluk10 + Coronavirus Susurluk10 + + + + + + + + + + GC_ID:1 + PMID:16286089 + PMID:19281946 + PMID:22982760 + ncbi_taxonomy + Toxicofera + + + + + + + + + + GC_ID:1 + PMID:16286089 + PMID:22982760 + ncbi_taxonomy + Episquamata + + + + + + + + + + GC_ID:1 + PMID:22982760 + ncbi_taxonomy + Unidentata + + + + + + + + + + GC_ID:1 + PMID:22982760 + split-tongued squamates + ncbi_taxonomy + Bifurcata + + + + + + + + + + + + + + + + + + + MERS + MERS-CoV + GC_ID:1 + ncbi_taxonomy + MERS coronavirus + MERS virus + Middle East Respiratory Syndrome Coronavirus (MERS-CoV) + Middle East respiratory syndrome coronavirus + Middle East respiratory syndrome-related coronavirus + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Dipnotetrapodomorpha + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + shorebird coronavirus + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Betacoronavirus BtCoV/KCR15/Pte_par/CRC/2012 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Betacoronavirus BtCoV/KCR155/Pte_par/CRC/2012 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Betacoronavirus BtCoV/KCR180/Pte_par/CRC/2012 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Betacoronavirus BtCoV/KCR22/Pte_par/CRC/2012 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Betacoronavirus BtCoV/KCR260/Car_per/CRC/2012 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Betacoronavirus BtCoV/Rhi_bla/BB98-22/BGR/2008 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Betacoronavirus BtCoV/Rhi_eur/BB98-92/BGR/2008 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Betacoronavirus BtCoV/Rhi_eur/BB98-98/BGR/2008 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Betacoronavirus BtCoV/Rhi_eur/BB99-04/BGR/2009 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Betacoronavirus BtCoV/Rhi_fer/FR0711-B11/FRA/2011 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Betacoronavirus BtCoV/Rhi_fer/FR0711-B3/FRA/2011 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Betacoronavirus BtCoV/Rhi_fer/It1/ITA/2009 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Betacoronavirus BtCoV/Rhi_fer/It13/ITA/2009 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Betacoronavirus BtCoV/Rhi_fer/It15/ITA/2009 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Betacoronavirus BtCoV/Rhi_fer/It17/ITA/2009 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Betacoronavirus BtCoV/Rhi_fer/It2/ITA/2009 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Betacoronavirus BtCoV/Rhi_hip/R07-09/SPA/2010 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Betacoronavirus BtCoV/Rhi_hip/R13-08/SPA/2010 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Betacoronavirus BtCoV/Rhi_hip/R46-03/SPA/2010 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Betacoronavirus BtCoV/Rhi_hip/R7-08/SPA/2010 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Betacoronavirus BtCoV/Rhi_hip/R77-02/SPA/2010 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Betacoronavirus BtCoV/Rhi_hip/R8-09/SPA/2010 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Betacoronavirus BtCoV/Rhi_hip/Slo48/SLO/2009 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Betacoronavirus BtCoV/Rhi_hip/Slo52/SLO/2009 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Betacoronavirus BtCoV/Rhi_hip/Slo53/SLO/2009 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Betacoronavirus BtCoV/Rhi_hip/Slo54/SLO/2009 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Betacoronavirus BtCoV/Rhi_hip/Slo57/SLO/2009 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Betacoronavirus BtCoV/Rhi_hip/Slo69/SLO/2009 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Equine coronavirus + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus Neoromicia/GrNC5/RSA/2012 + Coronavirus Neoromicia/PML-PHE1/RSA/2011 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + BatCoV-M.rufus28/Brazil/2010 + Bat coronavirus M.rufus28/Brazil/2010 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + BatCoV-P.davyi49/Mexico/2012 + Bat coronavirus P.davyi49/Mexico/2012 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat Coronavirus Rhhar/CII_KSA_004/Bisha/Saudi Arabia/2013 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat Coronavirus Taper/CII_KSA_287/Bisha/Saudi Arabia/2012 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus Pikuh/CII_KSA_001/Riyadh/Saudi Arabia/2013 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus Rhhar/CII_KSA_002/Bisha/Saudi Arabia/2013 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus Rhhar/CII_KSA_003/Bisha/Saudi Arabia/2013 + + + + + + + + + + BtCoV_CDPHE15 + GC_ID:1 + ncbi_taxonomy + Bat coronavirus CDPHE15/USA/2006 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Betacoronavirus Erinaceus/VMC/DEU/2012 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus Costa Rica + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus PgCoV-1 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus PgCoV-2 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus PgCoV-3 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus PgCoV-4 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat SARS-like coronavirus Rs3262-1 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat SARS-like coronavirus Rs3262-2 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat SARS-like coronavirus Rs3267-1 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat SARS-like coronavirus Rs3267-2 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat SARS-like coronavirus Rs3367 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat SARS-like coronavirus Rs3369 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat SARS-like coronavirus Rs4075 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat SARS-like coronavirus Rs4079 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat SARS-like coronavirus Rs4080 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat SARS-like coronavirus Rs4081 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat SARS-like coronavirus Rs4084 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat SARS-like coronavirus Rs4085 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat SARS-like coronavirus Rs4087-1 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat SARS-like coronavirus Rs4087-2 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat SARS-like coronavirus Rs4090 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat SARS-like coronavirus Rs4092 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat SARS-like coronavirus Rs4096 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat SARS-like coronavirus Rs4097 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat SARS-like coronavirus Rs4105 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat SARS-like coronavirus Rs4108 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat SARS-like coronavirus Rs4110 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat SARS-like coronavirus RsSHC014 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat SARS-like coronavirus WIV1 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Human coronavirus Feline-like Hu142 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Alphacoronavirus Pipistrellus kuhlii/Italy/206645-41/2010 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Alphacoronavirus Pipistrellus kuhlii/Italy/206679-3/2010 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Betacoronavirus Nyctalus noctula/Italy/206679-5/2010 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Betacoronavirus Pipistrellus kuhlii/Italy/206645-27/2011 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Betacoronavirus Pipistrellus kuhlii/Italy/206645-29/2011 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Betacoronavirus Pipistrellus kuhlii/Italy/206645-3/2011 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Betacoronavirus Pipistrellus kuhlii/Italy/206645-53/2011 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Betacoronavirus Pipistrellus kuhlii/Italy/206645-54/2011 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Betacoronavirus Pipistrellus kuhlii/Italy/206645-63/2011 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Betacoronavirus Pipistrellus kuhlii/Italy/330375-15/2012 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Betacoronavirus Pipistrellus spp/Italy/49967-19/2010 + Betacoronavirus Pipistrellus/Italy/49967-19/2010 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Betacoronavirus Rhinolophus hipposideros/Italy/187632-2/2012 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Betacoronavirus Rhinolophus hipposideros/Italy/196814/2011 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Betacoronavirus Rhinolophus hipposideros/Italy/243585/2012 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Betacoronavirus H.sav/Italy/206645-40/2011 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat SARS coronavirus + SARS bat coronavirus + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + unclassified Gammacoronavirus + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bottlenose dolphin coronavirus HKU22 + + + + + + + + + + + + GC_ID:1 + PMID:11743200 + PMID:11791233 + ncbi_taxonomy + Boreotheria + Boreoeutheria + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Haematopus ostralegus coronavirus + Eurasian oystercatcher coronavirus + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Betacoronavirus Eptesicus/13RS384_26/Italy/2012 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Alphacoronavirus Myotis/13rs384_31/Italy/2012 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Deltacoronavirus swine/USA/Illinois121/2014 + Deltacoronavirus PDCoV/USA/Illinois121/2014 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Alphacoronavirus 2 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Porcine deltacoronavirus 8734/USA-IA/2014 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus IFB2012-13F + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus IFB2012-17F + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus IFB2012-8F + + + + + + + + + + GC_ID:1 + Deltacoronavirus SDCV/USA/Illinois133/2014 + ncbi_taxonomy + Deltacoronavirus PDCoV/USA/Illinois133/2014 + + + + + + + + + + GC_ID:1 + Deltacoronavirus SDCV/USA/Illinois134/2014 + ncbi_taxonomy + Deltacoronavirus PDCoV/USA/Illinois134/2014 + + + + + + + + + + GC_ID:1 + Deltacoronavirus SDCV/USA/Illinois136/2014 + ncbi_taxonomy + Deltacoronavirus PDCoV/USA/Illinois136/2014 + + + + + + + + + + GC_ID:1 + Deltacoronavirus SDCV/USA/Ohio137/2014 + ncbi_taxonomy + Deltacoronavirus PDCoV/USA/Ohio137/2014 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Dromedary camel coronavirus HKU23 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Mystacina bat CoV/New Zealand/2013 + Mystacina coronavirus New Zealand/2013 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Myotis daubentonii coronavirus + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Myotis davidii coronavirus + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Rhinolophus affinis coronavirus + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Rhinolophus ferrumequinum coronavirus + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Rhinolophus hipposideros coronavirus + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Betacoronavirus SC2013 + BtVs-BetaCoV/SC2013 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Betacoronavirus JMH-2014 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + BtMf-AlphaCoV/AH2011 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + BtMf-AlphaCoV/FJ2012 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + BtMf-AlphaCoV/GD2012 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + BtMf-AlphaCoV/GD2012-a + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + BtMf-AlphaCoV/GD2012-b + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + BtMf-AlphaCoV/HeN2013 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + BtMf-AlphaCoV/HeN2013-a + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + BtMf-AlphaCoV/HeN2013-b + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + BtMf-AlphaCoV/HuB2013 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + BtMf-AlphaCoV/HuB2013-a + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + BtMf-AlphaCoV/JX2012 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + BtMr-AlphaCoV/SAX2011 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + BtMs-AlphaCoV/GS2013 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + BtNv-AlphaCoV/SC2013 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + BtRf-AlphaCoV/HuB2013 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + BtRf-AlphaCoV/YN2012 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + BtMd-BetaCoV/HuB2013 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + BtPa-BetaCoV/GD2013 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + BtRf-BetaCoV/HeB2013 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + BtRf-BetaCoV/HeN2013 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + BtRf-BetaCoV/HuB2013 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + BtRf-BetaCoV/JL2012 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + BtRf-BetaCoV/SX2013 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + BtRs-BetaCoV/GX2013 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + BtRs-BetaCoV/HuB2013 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + BtRs-BetaCoV/YN2013 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + BtTp-BetaCoV/GX2012 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Anlong Ms bat coronavirus + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Longquan Aa mouse coronavirus + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Longquan Rl rat coronavirus + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Lucheng Rn rat coronavirus + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Lushi Ml bat coronavirus + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Neixiang Md bat coronavirus + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat Betacoronavirus SARS related virus + Bat SARS-related coronavirus + SARS-related bat coronavirus + Bat SARS-like coronavirus + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Wencheng Sm shrew coronavirus + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus BtCoV/B85/HUN/2013 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus BtCoV/BS49/HUN/2013 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus BtCoV/E63/HUN/2013 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus BtCoV/M67/HUN/2013 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus BtCoV/M8/HUN/2013 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus BtCoV/M9/HUN/2013 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus BtCoV/V16/HUN/2013 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Mallard coronavirus + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bean goose coronavirus + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Porcine epidemic diarrhea virus (strain GER/L00721/2014) + Porcine epidemic diarrhea virus L00721/GER/2014 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SdCV/USA/OhioCVM1/2014 + Swine deltacoronavirus OhioCVM1/2014 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Alphacoronavirus BtCoV/GrNC1/Neo_cap/RSA/2012 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Alphacoronavirus BtCoV/GrNC2/Neo_cap/RSA/2012 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Alphacoronavirus BtCoV/GrNC3/Neo_cap/RSA/2012 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Alphacoronavirus BtCoV/GrNC4/Neo_cap/RSA/2012 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Alphacoronavirus BtCoV/GrNC5/Neo_cap/RSA/2012 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Alphacoronavirus BtCoV/GrNC6/Neo_cap/RSA/2012 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Alphacoronavirus BtCoV/GrNC7/Neo_cap/RSA/2012 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Alphacoronavirus BtCoV/GrNC8/Neo_cap/RSA/2012 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Alphacoronavirus BtCoV/MSTM2/Min_nat/RSA/2010 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Alphacoronavirus BtCoV/MSTM6/Min_nat/RSA/2010 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Alphacoronavirus BtCoV/NCL_MCO1/Mop_con/RSA/2012 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Alphacoronavirus BtCoV/VH_NC2/Neo_cap/RSA/2012 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat Hp-betacoronavirus/Zhejiang2013 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat Hp-betacoronavirus/Zhejiang2013-1 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat Hp-betacoronavirus/Zhejiang2013-2 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat Hp-betacoronavirus/Zhejiang2013-3 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat Hp-betacoronavirus/Zhejiang2013-4 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat Hp-betacoronavirus/Zhejiang2013-5 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Porcine deltacoronavirus KNU14-04 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Alphacoronavirus TadaridaM4 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Porcine deltacoronavirus + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Betacoronavirus HKU24 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Infectious bronchitis virus (strain Beaudette CK) + Avian infectious bronchitis virus (strain Beaudette CK) + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Avian infectious bronchitis virus (strain Beaudette US) + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Suncus coronavirus + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus BEM001F + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus ANK036F + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus ANK047F + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus BEM073F + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus BEM074F + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus BEM077F + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus ANK081F + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus BEM003F + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus ANK011F + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus ANK045F + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus MAH051F + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus MAH056F + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus MAH058F + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus BEM070F + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Goose-dominant Coronavirus + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Pigeon-dominant Coronavirus + + + + + + + + + + + NCBITaxon:1562771 + GC_ID:1 + ncbi_taxonomy + Duck-dominant coronavirus + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Human enteric coronavirus 4408 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus Hare_CoV/La06_377/Lep_gra/ESP/2006 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus Hare_CoV/La06_378/Lep_gra/ESP/2006 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus Hare_CoV/La06_379/Lep_gra/ESP/2006 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus Hare_CoV/La06_380/Lep_gra/ESP/2006 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus Hare_CoV/La06_382/Lep_gra/ESP/2006 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus Hare_CoV/La06_383/Lep_gra/ESP/2006 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus Hare_CoV/La08_60/Lep_gra/ESP/2008 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus Hare_CoV/La08_96/Lep_gra/ESP/2008 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus Hare_CoV/La08_99/Lep_gra/ESP/2008 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus RCoV/Bor473/Rat_rat/MYS/2012 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus RCoV/D_RMU10_1055/Myo_gla/GER/2010 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus RCoV/D_RMU10_1087/Apo_fla/GER/2010 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus RCoV/D_RMU10_1182/Mic_agr/GER/2010 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus RCoV/D_RMU10_1222/Mus_dom/GER/2010 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus RCoV/D_RMU10_1226/Myo_gla/GER/2010 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus RCoV/D_RMU10_1228/Mus_dom/GER/2010 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus RCoV/D_RMU10_1919/Myo_gla/GER/2010 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus RCoV/D_RMU10_1940/Myo_gla/GER/2010 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus RCoV/D_RMU10_1972/Myo_gla/GER/2010 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus RCoV/D_RMU10_1974/Myo_gla/GER/2010 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus RCoV/D_RMU10_1985/Myo_gla/GER/2010 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus RCoV/D_RMU10_1989/Myo_gla/GER/2010 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus RCoV/D_RMU10_1993/Myo_gla/GER/2010 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus RCoV/D_RMU10_2065/Myo_gla/GER/2010 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus RCoV/D_RMU10_2066/Myo_gla/GER/2010 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus RCoV/D_RMU10_2070/Myo_gla/GER/2010 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus RCoV/D_RMU10_2089/Myo_gla/GER/2010 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus RCoV/D_RMU10_590/Mic_arv/GER/2010 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus RCoV/D_RMU10_592/Mic_arv/GER/2010 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus RCoV/D_RMU10_974/Myo_gla/GER/2010 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus RCoV/D_RMU10_986/Myo_gla/GER/2010 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus RCoV/KS10_2636/Mic_arv/GER/2010 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus RCoV/KS10_2743/Mic_arv/GER/2010 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus RCoV/KS10_2810/Mic_arv/GER/2010 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus RCoV/KS10_2864/Myo_glar/GER/2010 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus RCoV/KS11_0514/Mic_arv/GER/2011 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus RCoV/KS11_0997/Apo_agr/GER/2011 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus RCoV/LEO/Rat_sik/CHN/2007 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus RCoV/Lmg115/Sig_spec/MEX/2011 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus RCoV/NL_69/Mic_arv/NED/2007 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus RCoV/NSP32/Rha_pum/RSA/2008 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus RCoV/NSP63/Rha_pum/RSA/2008 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus RCoV/NSP65/Rha_pum/RSA/2008 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus RCoV/RMU10_2010/Myo_gla/GER/2010 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus RCoV/RMU10_3052/Apo_fla/GER/2010 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus RCoV/RMU10_3147/Apo_fla/GER/2010 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus RCoV/RMU10_3212/Myo_gla/GER/2010 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus RCoV/RMU10_620/Apo_agr/GER/2010 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus RCoV/SPB40/Liomys_spec/MEX/2011 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus RCoV/TP3_22/Ban_ind/THA/2005 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus RCoV/TP3_26/Rat_rat/THA/2005 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus Rabbit_CoV/La06_256/Ory_cun/ESP/2006 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus Rabbit_CoV/La09_24/Ory_cun/ESP/2009 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus Rabbit_CoV/La09_31/Ory_cun/ESP/2009 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus Rabbit_CoV/La09_32/Ory_cun/ESP/2009 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus Rabbit_CoV/La09_48/Ory_cun/ESP/2009 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Mustelinae + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Alphacoronavirus Pip1_Cr_FR_2014 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Alphacoronavirus Pip2_Cr_FR_2014 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Alphacoronavirus Pip3_M_FR_2014 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Deltacoronavirus B07 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Deltacoronavirus isolate B04 + Deltacoronavirus B04 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Colubrinae + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Camel alphacoronavirus + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Camel coronavirus HKU23 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Myotis Bat Alphacoronavirus strain MJ_26C + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Myotis Bat Alphacoronavirus strain MJ_27C + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Myotis Bat Alphacoronavirus strain MJ_2C + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Myotis Bat Alphacoronavirus strain MJ_51C + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Myotis Bat Alphacoronavirus strain YNXY_10C + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Myotis Bat Alphacoronavirus strain YNXY_11C + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Myotis Bat Alphacoronavirus strain YNXY_12C + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Myotis Bat Alphacoronavirus strain YNXY_13C + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Myotis Bat Alphacoronavirus strain YNXY_15C + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Myotis Bat Alphacoronavirus strain YNXY_16C + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Myotis Bat Alphacoronavirus strain YNXY_17C + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Myotis Bat Alphacoronavirus strain YNXY_18C + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Myotis Bat Alphacoronavirus strain YNXY_19C + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Myotis Bat Alphacoronavirus strain YNXY_20C + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Myotis Bat Alphacoronavirus strain YNXY_21C + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Myotis Bat Alphacoronavirus strain YNXY_31C + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Myotis Bat Alphacoronavirus strain YNXY_33C + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Myotis Bat Alphacoronavirus strain YNXY_34C + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Myotis Bat Alphacoronavirus strain YNXY_39C + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Myotis Bat Alphacoronavirus strain YNXY_3C + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Myotis Bat Alphacoronavirus strain YNXY_41C + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Myotis Bat Alphacoronavirus strain YNXY_42C + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Myotis Bat Alphacoronavirus strain YNXY_44C + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Myotis Bat Alphacoronavirus strain YNXY_45C + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Myotis Bat Alphacoronavirus strain YNXY_46C + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Myotis Bat Alphacoronavirus strain YNXY_47C + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Myotis Bat Alphacoronavirus strain YNXY_48C + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Myotis Bat Alphacoronavirus strain YNXY_50C + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Myotis Bat Alphacoronavirus strain YNXY_54C + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Myotis Bat Alphacoronavirus strain YNXY_5C + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Myotis Bat Alphacoronavirus strain YNXY_7C + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Myotis Bat Alphacoronavirus strain YNXY_8C + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Rhinolophus Bat Alphacoronavirus strain MJ_69C + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Rousettus Bat Alphacoronavirus strain ML_32I + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Rousettus Bat Betacoronavirus ML_56I + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Rousettus Bat Betacoronavirus strain ML_101I + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Rousettus Bat Betacoronavirus strain ML_3I + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Rousettus Bat Betacoronavirus strain ML_44I + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Rousettus Bat Betacoronavirus strain ML_70I + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Rousettus Bat Betacoronavirus strain ML_7I + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Rousettus Bat Betacoronavirus strain ML_83I + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Hipposideros Bat Alphacoronavirus strain MJ_55C + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Hipposideros Bat Alphacoronavirus strain MJ_67C + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat SARS-like coronavirus YNLF_31C + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat SARS-like coronavirus YNLF_34C + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus PREDICT_CoV-49 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus PREDICT_CoV-50 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS-like coronavirus strain BatCoV/BB9904/BGR/2008 + SARS-like coronavirus BatCoV/BB9904/BGR/2008 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat Alphacoronavirus 229E related virus + Human coronavirus 229E -related bat coronavirus + 229E-related bat coronavirus + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS-like coronavirus WIV16 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus M.bech/GER/8355/2014 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus M.nat/GER/3856/2014 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus M.nat/GER/533A/2014 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus M.nat/GER/F0BF/2014 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus P.nat/GER/1048/2013 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus P.pyg/GER/9848/2014 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + European turkey coronavirus 080385d + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Swine enteric coronavirus + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Alpaca coronavirus + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coroanvirus HpBtCoV/3740-1 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coroanvirus MfulBtCoV/3709 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coroanvirus MsBtCoV/4001-1 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coroanvirus MsBtCoV/4001-2 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coroanvirus RaBtCoV/4307-2 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus HpBtCoV/3723 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus HpBtCoV/3740-2 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus MfulBtCoV/3709 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus MfulBtCoV/3736-1 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus MfulBtCoV/3759-1 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus MfusBtCoV 4040 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus MfusBtCoV/4023-2 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus MsBtCoV/3710 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus MsBtCoV/4039 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus MsBtCoV/4056 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus MsBtCoV/4068 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus RaBtCoV/3750 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus RaBtCoV/4307-1 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus RsBtCoV/3716 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Hipposideros bat coronavirus BtCoV/3723 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Hipposideros bat coronavirus BtCoV/3740-1 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Hipposideros bat coronavirus BtCoV/3740-2 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Miniopterus bat coronavirus BtCoV/3709 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Miniopterus bat coronavirus BtCoV/3728-1 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Miniopterus bat coronavirus BtCoV/3728-2 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Miniopterus bat coronavirus BtCoV/3736-1 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Miniopterus bat coronavirus BtCoV/3736-2 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Miniopterus bat coronavirus BtCoV/3759-1 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Miniopterus bat coronavirus BtCoV/3759-2 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Miniopterus bat coronavirus BtCoV/3760-1 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Miniopterus bat coronavirus BtCoV/3760-2 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Miniopterus bat coronavirus BtCoV/3767 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Miniopterus bat coronavirus BtCoV/3983 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Miniopterus bat coronavirus BtCoV/4001-1 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Miniopterus bat coronavirus BtCoV/4001-2 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Miniopterus bat coronavirus BtCoV/4023-1 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Miniopterus bat coronavirus BtCoV/4023-2 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Miniopterus bat coronavirus BtCoV/4036-1 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Miniopterus bat coronavirus BtCoV/4036-2 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Miniopterus bat coronavirus BtCoV/4039 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Miniopterus bat coronavirus BtCoV/4040 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Miniopterus bat coronavirus BtCoV/4056-1 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Miniopterus bat coronavirus BtCoV/4056-2 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Miniopterus bat coronavirus BtCoV/4068-1 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Miniopterus bat coronavirus BtCoV/4068-2 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Miniopterus bat coronavirus BtCov/3710 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Rhinolophus bat coronavirus BtCoV/3716 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Rhinolophus bat coronavirus BtCoV/3750 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Rhinolophus bat coronavirus BtCoV/3772 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Rhinolophus bat coronavirus BtCoV/3992-1 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Rhinolophus bat coronavirus BtCoV/3992-2 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Rhinolophus bat coronavirus BtCoV/3994 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Rhinolophus bat coronavirus BtCoV/4017-1 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Rhinolophus bat coronavirus BtCoV/4017-2 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Rhinolophus bat coronavirus BtCoV/4030-1 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Rhinolophus bat coronavirus BtCoV/4030-2 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Rhinolophus bat coronavirus BtCoV/4060 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Rhinolophus bat coronavirus BtCoV/4307-1 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Rhinolophus bat coronavirus BtCoV/4307-2 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Rhinolophus bat coronavirus BtCoV/4991 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Rhinolophus bat coronavirus BtCov/3990 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat betacoronavirus + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Alphacoronavirus TT-2016a + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus/2173/2014/Cynomops planirostris/Brazil + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus/2218/2014/Cynomops planirostris/Brazil + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus/4292/2013/Desmodus rotundus/Brazil + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus/4539/2013/Cynomops planirostris/Brazil + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus/4620/2014/Glossophaga soricina/Brazil + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus/4702/2013/Cynomops abrasus/Brazil + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus/4705/2013/Cynomops abrasus/Brazil + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus/5026/2013/Cynomops abrasus/Brazil + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Rhinolophinae + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Scotophilus kuhlii bat coronavirus + Scotophilus kuhlii coronavirus + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Kerivoula titania coronavirus + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Miniopterus fuliginosus coronavirus + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Myotis latirostis coronavirus + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Rhinolophus monoceros coronavirus + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Rousettus bat coronavirus + + + + + + + + + + Camel229E-CoV + GC_ID:1 + ncbi_taxonomy + Camel alphacoronavirus Camel229E + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus Art.lit/1816/BRA/2010 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus Art.lit/2064/BRA/2011 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus Art.lit/2294/BRA/2012 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus Car.per/1514/BRA/2011 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus Car.per/1516/BRA/2011 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus Car.per/1599/BRA/2012 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus Eum.gla/242/BRA/2013 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus Glo.sor/100/BRA/2014 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus Mol.ruf/63/BRA/2014 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus Mol.ruf/92/BRA/2013 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus Myo.nig/117/BRA/2013 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus Myo.rip/259/BRA/2013 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus Stu.lil/1573/BRA/2012 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus Stu.lil/1613/BRA/2012 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus Stu.lil/1617/BRA/2012 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Rabbit coronavirus + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Alphacoronavirus sp. + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Deltacoronavirus sp. + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Mink coronavirus 1 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus CDPHE15 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + NL63-related bat coronavirus + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat alphacoronavirus/UF-FWC/2016/3 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Betacoronavirus sp. + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Calidris alba coronavirus + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Rynchops niger coronavirus + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Calidris fuscicollis coronavirus + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Anser cygnoides coronavirus + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Dromedary camel coronavirus + + + + + + + + + + + GC_ID:1 + mice and others + ncbi_taxonomy + Sciurognathi + Myomorpha + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus AcCoV-JC34 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus JC02 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus JC30 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus JC54 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus JC66 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus JC81 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus HKU15 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Hedgehog coronavirus 1 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + unclassified Coronaviridae + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronaviridae sp. + + + + + + + + + Bacteria + eubacteria + + + + + + + GC_ID:11 + PMID:10425795 + PMID:10425796 + PMID:10425797 + PMID:10490293 + PMID:10843050 + PMID:10939651 + PMID:10939673 + PMID:10939677 + PMID:11211268 + PMID:11321083 + PMID:11321113 + PMID:11411719 + PMID:11540071 + PMID:11542017 + PMID:11542087 + PMID:11760965 + PMID:12054223 + PMID:2112744 + PMID:270744 + PMID:8123559 + PMID:8590690 + PMID:9103655 + PMID:9336922 + eubacteria + ncbi_taxonomy + Monera + Procaryotae + Prokaryota + Prokaryotae + bacteria + prokaryote + prokaryotes + Bacteria + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Pantherophis + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Porcine enteric alphacoronavirus + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Hypsugo bat coronavirus HKU25 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Myotis lucifugus bat coronavirus + Myotis lucifugus coronavirus + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Pipistrellus bat alphacoronavirus + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Tylonycteris bat alphacoronavirus + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Equine coronavirus strain NC99 + Equine coronavirus NC99 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Porcine enteric alphacoronavirus GDS04 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus HKU23 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Swine acute diarrhea syndrome coronavirus + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus PREDICT CoV-10 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus PREDICT CoV-11 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus PREDICT CoV-12 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus PREDICT CoV-13 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus PREDICT CoV-14 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus PREDICT CoV-15 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus PREDICT CoV-17 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus PREDICT CoV-18 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus PREDICT CoV-19 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus PREDICT CoV-2 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus PREDICT CoV-20 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus PREDICT CoV-21 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus PREDICT CoV-22 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus PREDICT CoV-23 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus PREDICT CoV-24 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus PREDICT CoV-25 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus PREDICT CoV-27 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus PREDICT CoV-28 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus PREDICT CoV-29 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus PREDICT CoV-30 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus PREDICT CoV-32 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus PREDICT CoV-33 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus PREDICT CoV-34 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus PREDICT CoV-35 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus PREDICT CoV-36 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus PREDICT CoV-37 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus PREDICT CoV-38 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus PREDICT CoV-39 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus PREDICT CoV-4 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus PREDICT CoV-40 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus PREDICT CoV-41 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus PREDICT CoV-42 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus PREDICT CoV-43 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus PREDICT CoV-44 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus PREDICT CoV-45 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus PREDICT CoV-46 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus PREDICT CoV-47 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus PREDICT CoV-48 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus PREDICT CoV-51 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus PREDICT CoV-52 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus PREDICT CoV-53 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus PREDICT CoV-54 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus PREDICT CoV-55 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus PREDICT CoV-56 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus PREDICT CoV-57 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus PREDICT CoV-58 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus PREDICT CoV-59 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus PREDICT CoV-60 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus PREDICT CoV-61 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus PREDICT CoV-62 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus PREDICT CoV-63 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus PREDICT CoV-64 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus PREDICT CoV-65 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus PREDICT CoV-66 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus PREDICT CoV-67 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus PREDICT CoV-68 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus PREDICT CoV-70 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus PREDICT CoV-71 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Kenya bat coronavirus/BtKY56/BtKY55 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Kenya bat coronavirus BtKY33/2006 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Kenya bat coronavirus/KY33/2006 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Alphacoronavirus Trinidad/1FY2BA/2007 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Melogale + + + + + + + + + + + GC_ID:1 + Chinese ferret-badger + ncbi_taxonomy + Melogale moschata + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus 1 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS-related bat coronavirus RsSHC014 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS-related betacoronavirus Rp3/2004 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Myotis alphacoronavirus + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus A977/A970 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Vespertilionid betacoronavirus + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Swine enteric alphacoronavirus + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Rodent coronavirus + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Shrew coronavirus + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Homo/Pan/Gorilla group + Homininae + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Falcon coronavirus UAE-HKU27 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Houbara coronavirus UAE-HKU28 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Quail coronavirus UAE-HKU30 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Pigeon coronavirus UAE-HKU29 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Porcine deltacoronavirus Sichuan + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Neotropic cormorant coronavirus + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Rhinolophus pusillus coronavirus + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Swine acute diarrhea syndrome related coronavirus + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Guangdong chinese water skink coronavirus + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus GCCDC1 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Water deer coronavirus + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Canine respiratory coronavirus + + + + + + + + + Archaea + + + + + + GC_ID:11 + PMID:10425795 + PMID:10425796 + PMID:10425797 + PMID:10490293 + PMID:10843050 + PMID:10939651 + PMID:10939673 + PMID:10939677 + PMID:11211268 + PMID:11321083 + PMID:11321113 + PMID:11411719 + PMID:11540071 + PMID:11541975 + PMID:11542064 + PMID:11542149 + PMID:11760965 + PMID:12054223 + PMID:2112744 + PMID:25527841 + PMID:270744 + PMID:8123559 + PMID:8590690 + PMID:9103655 + PMID:9336922 + ncbi_taxonomy + Archaebacteria + Mendosicutes + Metabacteria + Monera + Procaryotae + Prokaryota + Prokaryotae + archaea + prokaryote + prokaryotes + Archaea + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Gammacoronavirus sp. + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Alphacoronavirus strain Mink/China/1/2016 + Alphacoronavirus Mink/China/1/2016 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Paradoxurinae + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Sparrow deltacoronavirus + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Quail deltacoronavirus + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus Vietnam + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus Taiwan + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus Tor2 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus Hong Kong/03/2003 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus strain Urbani + SARS-CoV (Urbani strain) + SARS coronavirus Urbani + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus HKU-39849 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus BJ02 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus BJ01 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus BJ03 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus CUHK-W1 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus BJ04 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Porcine epidemic diarrhea virus (strain CV777) + Porcine epidemic diarrhea virus CV777 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Porcine epidemic diarrhea virus (strain Br1/87) + Porcine epidemic diarrhea virus Br1/87 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Chicken enteric coronavirus + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus CUHK-Su10 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus Frankfurt 1 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus TW1 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bovine coronavirus (strain G95) + Bovine coronavirus G95 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Porcine hemagglutinating encephalomyelitis virus (strain IAF-404) + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Porcine hemagglutinating encephalomyelitis virus (strain 67N) + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus ZJ01 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus Taiwan JC-2003 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bovine coronavirus (strain LSU) + Bovine coronavirus LSU + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bovine coronavirus (strain OK) + Bovine coronavirus strain OK + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bovine coronavirus (strain Ontario) + Bovine coronavirus strain Ontario + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Murine coronavirus (strain DVIM) + Murine coronavirus strain DVIM + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Avian infectious bronchitis virus (strain H120) + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Avian infectious bronchitis virus (strain H52) + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Avian infectious bronchitis virus (strain SAIB20) + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Avian infectious bronchitis virus (strain V18/91) + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Avian infectious bronchitis virus (strain Vic S) + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Turkey coronavirus (strain Indiana) + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Turkey coronavirus (strain Minnesota) + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Turkey coronavirus (strain NC95) + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bovine coronavirus (strain OK-0514-3) + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Rat coronavirus (strain NJ) + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Avian infectious bronchitis virus (strain Arkansas 99) + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Avian infectious bronchitis virus (strain D1466) + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Civet SARS-CoV/SZ3/2003 + SARS coronavirus SZ3 + Civet SARS CoV SZ3/2003 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus SZ13 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Civet SARS-CoV/SZ16/2003 + SARS coronavirus SZ16 + Civet SARS CoV SZ16/2003 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus SZ1 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus GZ43 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus GZ60 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus HKU-36871 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus HKU-65806 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus HKU-66078 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus GZ50 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus GD01 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bovine coronavirus (strain LSU-94LSS-051) + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bovine enteric coronavirus (strain 98TXSF-110-ENT) + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bovine respiratory coronavirus (strain 98TXSF-110-LUN) + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Avian infectious bronchitis virus (strain DE072) + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus TWC + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Guinea fowl coronavirus + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus HSR 1 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus Hong Kong ZY-2003 + SARS coronavirus Shanhgai LY + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus Sin2774 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus Sin2748 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus Sin2679 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus Sin2677 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus Sin2500 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Avian infectious bronchitis virus (strain D41) + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus TC1 + SARS coronavirus Taiwan TC1 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus TC2 + SARS coronavirus Taiwan TC2 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus CUHK-AG01 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus CUHK-AG02 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus CUHK-AG03 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus Taiwan TC3 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus ZMY 1 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus TWH + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus TWJ + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus TWK + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus TWS + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus TWY + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus BJ2232 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus TWC2 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus TWC3 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat alphacoronavirus + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Feline alphacoronavirus 1 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus FRA + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus HPZ-2003 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus WHU + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus AS + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus SarBatCoV1 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus GZ-A + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus GZ-B + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus GZ-C + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus GZ-D + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus HGZ8L1-A + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus HGZ8L1-B + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus HSZ2-A + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus HSZ-A + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus HSZ-Bb + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus HSZ-Cb + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus HZS2-Fb + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus JMD + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus HZS2-D + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus HZS2-E + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus HZS2-Fc + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus HZS2-C + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus HGZ8L2 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus HSZ-Bc + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus HSZ-Cc + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus ZS-B + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus ZS-A + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus LC1 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus LC2 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus LC3 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus LC4 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus LC5 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus ZS-C + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus HZS2-Bb + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Alphacoronavirus Bat-CoV/P.kuhlii/Italy/206645-41/2011 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Alphacoronavirus Bat-CoV/P.kuhlii/Italy/206679-3/2010 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Alphacoronavirus Bat-CoV/P.kuhlii/Italy/3398-19/2015 + + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Cornidovirineae + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Yak coronavirus + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Rhinolophus ferrumequinum alphacoronavirus HuB-2013 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Myotis ricketti alphacoronavirus Sax-2011 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Nyctalus velutinus alphacoronavirus SC-2013 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + NL63-related bat coronavirus strain BtKYNL63-9b + + + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Orthocoronavirinae + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + China Rattus coronavirus HKU24 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat Hp-betacoronavirus Zhejiang2013 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Rousettus bat coronavirus GCCDC1 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Andecovirus + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Buldecovirus + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Cegacovirus + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Colacovirus + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Decacovirus + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Duvinacovirus + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Embecovirus + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Herdecovirus + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Hibecovirus + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Igacovirus + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Luchacovirus + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Merbecovirus + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Minacovirus + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Minunacovirus + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Moordecovirus + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Myotacovirus + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Nobecovirus + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Nyctacovirus + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Pedacovirus + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Rhinacovirus + + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Sarbecovirus + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Setracovirus + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Tegacovirus + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Alphacoronavirus L232 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Alphacoronavirus PLMg1 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Alphacoronavirus UKMa1 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Alphacoronavirus UKRn3 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus BJ302 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus PUMC01 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus PUMC02 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus PUMC03 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus HB + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus SoD + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus Sino3-11 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus Sino1-11 + + + + + + + + + + + + GC_ID:1 + RNA viruses + RNA viruses and viroids + ncbi_taxonomy + Riboviria + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus GZ02 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Canada goose coronavirus + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus GD69 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus ShanghaiQXC1 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus ShanghaiQXC2 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Rhinolophus bat coronavirus HKU32 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Tylonycteris bat coronavirus HKU33 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Pheasant coronavirus + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus TW10 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus TW11 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus TW2 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus TW3 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus TW4 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus TW5 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus TW6 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus TW7 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus TW8 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus TW9 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus BtSk-AlphaCoV/GX2018A + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus BtSk-AlphaCoV/GX2018B + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus BtSk-AlphaCoV/GX2018C + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus BtSk-AlphaCoV/GX2018D + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus BtRs-AlphaCoV/YN2018 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus BtRl-BetaCoV/SC2018 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus BtRs-BetaCoV/YN2018A + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus BtRs-BetaCoV/YN2018B + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus BtRs-BetaCoV/YN2018C + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus BtRs-BetaCoV/YN2018D + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus BtRt-BetaCoV/GX2018 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus SZ61 + SARS coronavirus HC/SZ/61/03 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Betacoronavirus BtCoV22/29 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Gull coronavirus + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus CUHK-L2 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus strain NS-1 + SARS coronavirus NS-1 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus GD03T0013 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Acinonyx jubatus coronavirus + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus TW + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus TW-HP1 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus TW-HP2 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus TW-HP3 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus TW-HP4 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus TW-JC2 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus TW-KC1 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus TW-KC3 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus TW-GD1 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus TW-GD2 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus TW-GD3 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus TW-GD4 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus TW-GD5 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus TW-YM1 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus TW-YM2 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus TW-YM3 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus TW-YM4 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus TW-PH1 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus TW-PH2 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus sf099 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus cw049 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus sf098 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus cw037 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus xw002 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus Sin0409 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus Sin_WNV + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + unclassified Merbecovirus + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Erinaceus hedgehog coronavirus HKU31 + + + + + + + + + + NCBITaxon:233263 + GC_ID:1 + ncbi_taxonomy + unclassified coronaviruses + unclassified Coronavirinae + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus Sin842 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus Sin852 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus Sin3408 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus Sin3765V + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus Sin848 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus Sin849 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus Sin3725V + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus SinP1 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus SinP2 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus SinP3 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus SinP4 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus SinP5 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus Sin845 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus Sin846 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus Sin847 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus Sin850 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus Sin3408L + + + + + + + + + Wuhan coronavirus + Wuhan seafood market pneumonia virus + https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id=2697049 + + 2019-nCoV + ncbi_taxonomy + NCBITaxon:2697049 + SARS-CoV-2 + severe acute respiratory syndrome coronavirus 2 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Human group 1 coronavirus associated with pneumonia + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Human group 1 coronavirus HCoV-NL isolate 3363 + Human coronavirus 3363/2000/NL + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Human group 1 coronavirus HCoV-NL isolate 1196 + Human coronavirus 1196/2001/NL + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus LLJ-2004 + + + + + + + + + Eukaryota + eucaryotes + eukaryotes + + + + + + GC_ID:1 + PMID:23020233 + PMID:30257078 + eucaryotes + eukaryotes + ncbi_taxonomy + Eucarya + Eucaryotae + Eukarya + Eukaryotae + eukaryotes + Eukaryota + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bovinae + + + + + + + + + + + NCBITaxon:266092 + HCoV-NL63 + GC_ID:1 + ncbi_taxonomy + Coronavirus NL63 + Human coronavirus NL + Human coronavirus NL63 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus GZ0401 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Enteric coronavirus + + + + + + + + + + + PEDV + GC_ID:1 + ncbi_taxonomy + porcine epidemic diarrhoea virus + Porcine epidemic diarrhea virus + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Avian infectious bronchitis virus partridge/GD/S14/2003 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus TJF + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus HHS-2004 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Civet SARS-CoV/007/2004 + SARS coronavirus civet007 + Civet SARS CoV 007/2004 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus civet010 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus civet014 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus civet019 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus civet020 + + + + + + + + + + + HCoV-HKU1 + GC_ID:1 + ncbi_taxonomy + CoV-HKU1 + Human CoV/HKU1 + Human coronavirus HKU1 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus GD322 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS Coronavirus CDC#200301157 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus PC4-127 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus PC4-205 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus GZ0403 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus GZ0402 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus PC4-13 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus PC4-136 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus PC4-227 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus PC4-115 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus PC4-137 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus PC4-145 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus PC4-199 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus PC4-241 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus B039 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Goose coronavirus + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Duck coronavirus + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Pigeon coronavirus + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bird droppings coronavirus + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Canine coronavirus 1-71 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus A022 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus A001 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus A013 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus A021 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus A030 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus A031 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus B012 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus B024 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus B029 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus B033 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus B040 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus C013 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus C014 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus C017 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus C018 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus C019 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus C025 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus C028 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus C029 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Microchiroptera + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Human coronavirus type 5 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus WH20 + + + + + + + + + + + + GC_ID:1 + PMID:11214318 + PMID:11214319 + PMID:12878460 + ncbi_taxonomy + Laurasiatheria + + + + + + + + + + Euarchontoglires + + + + + GC_ID:1 + PMID:11214319 + PMID:12082125 + PMID:12878460 + PMID:15522813 + ncbi_taxonomy + Euarchontoglires + + + + + + + + + + GC_ID:1 + PMID:11214319 + PMID:12082125 + PMID:15522813 + Rodents and rabbits + ncbi_taxonomy + Glires + + + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Anthropoidea + Simiiformes + + + + + + + + + + + GC_ID:1 + ape + apes + ncbi_taxonomy + Hominoidea + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Avian infectious bronchitis virus (strain GRAY) + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Avian infectious bronchitis virus (strain PORTUGAL/322/82) + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Avian infectious bronchitis virus (strain UK/123/82) + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Avian infectious bronchitis virus (strain UK/142/86) + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Avian infectious bronchitis virus (strain UK/167/84) + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Avian infectious bronchitis virus (strain UK/183/66) + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Avian infectious bronchitis virus (strain UK/68/84) + + + + + + + + + + HCoV-OC43 + GC_ID:1 + ncbi_taxonomy + Human coronavirus (strain OC43) + Human coronavirus strain OC43 + Human coronavirus OC43 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Rat coronavirus + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus BJ162 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus BJ202 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Canine coronavirus isolate NJ17 + + + + + + + + + + Tetrapoda + tetrapods + + + + GC_ID:1 + tetrapods + ncbi_taxonomy + Tetrapoda + + + + + + + + + + Amniota + amniotes + + + + GC_ID:1 + amniotes + ncbi_taxonomy + Amniota + + + + + + + + + + GC_ID:1 + Theria + ncbi_taxonomy + Theria <mammals> + + + + + + + + + + GC_ID:1 + diapsids + ncbi_taxonomy + Diapsida + Sauria + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus ZS-2005 + + + + + + + + + Opisthokonta + + + + GC_ID:1 + ncbi_taxonomy + Fungi/Metazoa group + opisthokonts + Opisthokonta + + + + + + + + + + + GC_ID:1 + metazoans + multicellular animals + ncbi_taxonomy + Animalia + animals + Metazoa + + + + + + + + + + Bilateria + + + + GC_ID:1 + ncbi_taxonomy + Bilateria + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS-CoV HKU3-1 + Bat SARS coronavirus HKU3-1 + + + + + + + + + + GC_ID:1 + deuterostomes + ncbi_taxonomy + Deuterostomia + + + + + + + + + + + + GC_ID:1 + carnivores + ncbi_taxonomy + carnivores + Carnivora + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Canine enteric coronavirus (strain K378) + Canine enteric coronavirus K378 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Feline enteric coronavirus (strain 79-1683) + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Feline infectious peritonitis virus (strain 79-1146) + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Murine coronavirus mhv (strain JHMV / variant CL-2) + Murine hepatitis virus (strain JHMV / variant CL-2) + Murine hepatitis virus strain JHMV / variant CL-2 + + + + + + + + + + NCBITaxon:11147 + GC_ID:1 + ncbi_taxonomy + Porcine respiratory coronavirus (STRAIN PRCV 86/137004 / BRITISH ISOLATE) + Porcine respiratory coronavirus (strain 86/137004 / British isolate) + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Porcine transmissible gastroenteritis coronavirus (strain Miller) + Porcine transmissible gastroenteritis coronavirus strain Miller + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Porcine transmissible gastroenteritis coronavirus (strain Neb72-RT) + Porcine transmissible gastroenteritis coronavirus strain Neb72-RT + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Rat coronavirus (strain 681) + + + + + + + + + + GC_ID:1 + PMID:15019624 + PMID:15371245 + ncbi_taxonomy + Muroidea + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Felinae + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat SARS coronavirus HKU3-2 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat SARS coronavirus HKU3-3 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus ZJ0301 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat SARS coronavirus Rm1 + Bat SARS-CoV/Rm1/2004 + Bat SARS CoV Rm1/2004 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat SARS coronavirus Rf1 + Bat SARS-CoV/Rf1/2004 + Bat SARS CoV Rf1/2004 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Nyctereutes + + + + + + + + + + + GC_ID:1 + raccoon dog + ncbi_taxonomy + Canis procyonoides + Nycteruetes procyonoides + Nyctereutes procyonoides + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat SARS coronavirus Rp1 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat SARS coronavirus Rp2 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat SARS coronavirus Rp3 + Bat SARS-CoV/Rp3/2004 + Bat SARS CoV Rp3/2004 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Xenophidia + Colubroidea + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Parrot coronavirus AV71/99 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus ZJ02 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Pecora + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Spotted hyena coronavirus + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Canine enteric coronavirus (strain INSAVC-1) + Canine enteric coronavirus INSAVC-1 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + unclassified Group 1 species + unclassified Alphacoronavirus + + + + + + + + + + + FECV-MSU1 + GC_ID:1 + ncbi_taxonomy + Ferret enteric coronavirus MSU1 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Ictailurus + Prionailurus + + + + + + + + + + + GC_ID:1 + leopard cat + ncbi_taxonomy + Felis bengalensis + Prionailurus bengalensis + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Haplorrhini + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Feliformia + + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Caniformia + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Human coronavirus NO + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Human coronavirus NO/1055/04 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Human coronavirus NO/0003/05 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Human coronavirus NO/0749/04 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Human coronavirus NO/0848/04 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Human coronavirus NO/1917/04 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Human coronavirus NO/0835/04 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Human coronavirus NO/0341/04 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Human coronavirus NO/0053/04 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Human coronavirus NO/0398/05 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Human coronavirus NO/0023/05 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Human coronavirus NO/0193/05 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Human coronavirus NO/2708/04 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Human coronavirus NO/0733/05 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Human coronavirus NO/0643/05 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Human coronavirus NO/0867/04 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus CS21 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus CS24 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus ES191 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus ES260 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus WF188 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus GDH-BJH01 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus China 2005 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus (BtCoV/A504/2005) + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus (BtCoV/A535/2005) + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus (BtCoV/A604/2005) + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus (BtCoV/A613/2005) + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus (BtCoV/A619/2005) + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus (BtCoV/A620/2005) + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus (BtCoV/A629/2005) + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus (BtCoV/A632/2005) + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus (BtCoV/A633/2005) + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus (BtCoV/A634/2005) + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus (BtCoV/A754/2005) + + + + + + + + + + + NCBITaxon:434616 + GC_ID:1 + ncbi_taxonomy + Bat coronavirus (BtCoV/A773/2005) + Bat coronavirus A773/2005 + Bat coronavirus Fujian/773/2005 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus (BtCoV/A819/2005) + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus (BtCoV/A821/2005) + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus (BtCoV/860/2005) + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus (BtCoV/A893/2005) + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus (BtCoV/A894/2005) + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus (BtCoV/A895/2005) + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus (BtCoV/A897/2005) + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus (BtCoV/A898/2005) + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus (BtCoV/A900/2005) + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus (BtCoV/A905/2005) + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus (BtCoV/A906/2005) + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus (BtCoV/908/2005) + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus (BtCoV/A909/2005) + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus (BtCoV/A910/2005) + + + + + + + + + + + NCBITaxon:434617 + GC_ID:1 + ncbi_taxonomy + Bat coronavirus (BtCoV/A911/2005) + Bat coronavirus A911/2005 + Bat coronavirus Anhui/911/2005 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus (BtCoV/A912/2005) + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus (BtCoV/A914/2005) + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus (BtCoV/A957/2005) + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus (BtCoV/A970/2005) + + + + + + + + + + + NCBITaxon:434618 + GC_ID:1 + ncbi_taxonomy + Bat coronavirus (BtCoV/A977/2005) + BtCov Shandong/977/2006 + Bat coronavirus Shandong/977/2006 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus (BtCoV/273/2005) + BtCoV/273/2005 + Bat CoV 273/2005 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus (BtCoV/279/2005) + Bat CoV 279/2005 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus (BtCoV/ A1074/2005) + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus (BtCoV/ A1201/2005) + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus (BtCoV/133/2005) + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus (BtCoV/242/2005) + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus (BtCoV/301/2005) + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus (BtCoV/303/2005) + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus (BtCoV/309/2005) + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus (BtCoV/310A /2005) + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus (BtCoV/311A /2005) + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus (BtCoV/355A/2005) + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus (BtCoV/359A/2005) + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus (BtCoV/363A/2005) + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus (BtCoV/364A/2005) + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus (BtCoV/365A/2005) + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus (BtCoV/367A/2005) + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus (BtCoV/427/2005) + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus (BtCoV/A1018/2005) + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus (BtCoV/A1116/2005) + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus (BtCoV/A1196/2005) + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus (BtCoV/A1203/2005) + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus (BtCoV/A1206/2005) + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus (BtCoV/A421/2005) + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus (BtCoV/A429/2005) + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus (BtCoV/A433/2005) + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus (BtCoV/A434/2005) + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus (BtCoV/A437/2005) + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus (BtCoV/A515/2005) + Bat coronavirus A515/2005 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus (BtCoV/A527/2005) + Bat coronavirus A527/2005 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus (BtCoV/A701/2005) + Bat coronavirus A701/2005 + + + + + + + + + + + + + + + + + GC_ID:1 + Western rat snake + rat snake + ncbi_taxonomy + Coluber obsoletus Say 1823 + Elaphe obsoleta + Pantherophis obsoletus + + + + + + + + + + + NCBITaxon:109679 + GC_ID:1 + ncbi_taxonomy + Murinae + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus Frankfurt1-v01 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus HKU6 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus HKU7 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus 1A + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus 1B + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bovine coronavirus DB2 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Transmissible gastroenteritis virus Miller M6 + TGEV Miller M6 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Transmissible gastroenteritis virus Miller M60 + TGEV Miller M60 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Transmissible gastroenteritis virus strain Purdue P115 + TGEV Purdue P115 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + TGEV virulent Purdue + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Porcine respiratory coronavirus ISU-1 + PRCV ISU-1 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bovine coronavirus isolate Alpaca + + + + + + + + + Mammalia + mammals + + + + + GC_ID:1 + mammals + ncbi_taxonomy + mammals + Mammalia + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Infectious bronchitis virus PRT/L-898/2004 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Infectious bronchitis virus AZE/L-1582/2004 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Infectious bronchitis virus RUS/L-1777/2005 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Infectious bronchitis virus YEM/L-2865/2005 + + + + + + + + + + HEV + PHEV + GC_ID:1 + ncbi_taxonomy + Hemagglutinating encephalomyelitis virus + Porcine hemagglutinating encephalomyelitis coronavirus + porcine hemagglutinating encephalomyelitis virus HEV + Porcine hemagglutinating encephalomyelitis virus + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus strain TJ01 + SARS coronavirus TJ01 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Sambar deer coronavirus US/OH-WD388/1994 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Sambar deer coronavirus US/OH-WD388-TC/1994 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + White-tailed deer coronavirus US/OH-WD470/1994 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Waterbuck antelope coronavirus US/OH-WD358/1994 + Waterbuck coronavirus US/OH-WD358/1994 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Waterbuck antelope coronavirus US/OH-WD358-TC/1994 + Waterbuck coronavirus US/OH-WD358-TC/1994 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Antelope coronavirus US/OH1/2003 + Sable antelope coronavirus US/OH1/2003 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Giraffe coronavirus US/OH3/2003 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Calf-giraffe coronavirus US/OH3/2006 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Giraffe coronavirus US/OH3-TC/2006 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bovine coronavirus R-AH65 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bovine coronavirus R-AH65-TC + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bovine coronavirus E-DB2-TC + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bovine coronavirus E-AH65 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bovine coronavirus E-AH65-TC + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bovine coronavirus R-AH187 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bovine coronavirus E-AH187 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus HKU4-1 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus HKU4-2 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus HKU4-3 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus HKU4-4 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus HKU5-1 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus HKU5-2 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus HKU5-3 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus HKU5-5 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus HKU9-1 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus HKU9-2 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus HKU9-3 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus HKU9-4 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bovine coronaviurus KV0501 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bovine coronaviurus KV0516 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus group 2c + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Murine coronavirus repJHM/RA59 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Murine coronavirus repA59/RJHM + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Murine coronavirus SA59/RJHM + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Quail coronavirus Italy/Elvia/2005 + + + + + + + + + + RDCoV/GZ43/03 + GC_ID:1 + ncbi_taxonomy + Raccoon dog coronavirus GZ43/2003 + + + + + + + + + + CFBCoV/DM95/03 + GC_ID:1 + ncbi_taxonomy + Chinese ferret badger coronavirus DM95/2003 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Canine coronavirus (strain BGF10) + Canine coronavirus BGF10 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Asian leopard cat coronavirus Guangxi/F230/2006 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Chinese bamboo rat coronavirus Guangxi/B305/2005 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Chinese ferret badger coronavirus Guangxi/F247/2006 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Chinese ferret badger coronavirus Guangxi/F250/2006 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Flying squirrel coronavirus Guangxi/E001/2006 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Lesser Indian civet coronavirus Guangxi/D690/2005 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Masked palm civet coronavirus Guangxi/D728/2005 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Siberian weasel coronavirus Guangxi/D1000/2006 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Yellow-bellied weasel coronavirus Guangxi/D726/2005 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Guangxi coronaviridae + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus HKU3 + SARS-related bat coronavirus HKU3 + Bat SARS coronavirus HKU3 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Human coronavirus HKU1 (isolate N1) + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Human coronavirus HKU1 (isolate N2) + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Human coronavirus HKU1 (isolate N5) + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus group 2b + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Feline coronavirus strain UU3 + Feline coronavirus UU3 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Feline coronavirus strain UU4 + Feline coronavirus UU4 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Feline coronavirus strain UU5 + Feline coronavirus UU5 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Feline coronavirus strain UU7 + Feline coronavirus UU7 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bovine enteric coronavirus-AH187-TC + Bovine coronavirus E-AH187-TC + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + unclassified Coronavirus group 2b + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Rocky Mountain Bat Coronavirus 11 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Rocky Mountain Bat Coronavirus 27 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Rocky Mountain Bat Coronavirus 3 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Rocky Mountain Bat Coronavirus 48 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Rocky Mountain Bat Coronavirus 6 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Rocky Mountain Bat Coronavirus 65 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bovine coronavirus Bubalus/Italy/179/07-11 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus DR/2007 + + + + + + + + + + + GC_ID:1 + horseshoe bats + ncbi_taxonomy + Rhinolophus + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus M.das/Germany/D2.2/2007 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus M.das/Germany/D3.3/2007 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus M.das/Germany/D3.4/2007 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus M.das/Germany/D3.15/2007 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus M.das/Germany/D3.5/2007 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus M.das/Germany/D3.6/2007 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus M.das/Germany/D3.28/2007 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus M.das/Germany/D3.10/2007 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus M.das/Germany/D5.17/2007 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus M.das/Germany/D3.33/2007 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus M.das/Germany/D3.38/2007 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus P.nat/Germany/D5.16/2007 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus M.bec/Germany/D6.6/2007 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus M.dau/Germany/D7.3/2007 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus P.pyg/Germany/D5.70/2007 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus P.pyg/Germany/D5.71/2007 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus P.nat/Germany/D5.73/2007 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus P.pyg/Germany/D5.85/2007 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus M.dau/Germany/D8.46/2007 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus M.dau/Germany/D8.45/2007 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus M.dau/Germany/D8.42/2007 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus M.dau/Germany/D8.38/2007 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus M.dau/Germany/D8.32/2007 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Waterbuck coronavirus US/OH-WD358-GnC/1994 + + + + + + + + + + NCBITaxon:454949 + GC_ID:1 + ncbi_taxonomy + Feline coronavirus strain RM + Feline coronavirus RM + + + + + + + + + + NCBITaxon:454950 + GC_ID:1 + ncbi_taxonomy + Feline coronavirus strain UU2 + Feline coronavirus UU2 + + + + + + + + + + NCBITaxon:454961 + GC_ID:1 + ncbi_taxonomy + Rat coronavirus strain Parker + Rat coronavirus Parker + + + + + + + + + + NCBITaxon:429333 + GC_ID:1 + ncbi_taxonomy + Murine coronavirus strain MHV-3 + Murine coronavirus MHV-3 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bovine respiratory coronavirus bovine/US/OH-440-TC/1996 + + + + + + + + + + NCBITaxon:429332 + GC_ID:1 + ncbi_taxonomy + Murine coronavirus strain MHV-1 + Murine coronavirus MHV-1 + + + + + + + + + + NCBITaxon:430471 + GC_ID:1 + ncbi_taxonomy + Murine coronavirus SJHM/RA59 + Murine coronavirus RA59/SJHM + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bovine respiratory coronavirus AH187 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus BJ182-12 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus BJ182-4 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus BJ182-8 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus BJ182a + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus BJ182b + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bovine coronavirus UP1/PRT/2005 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bovine coronavirus UP2/PRT/2005 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus R.aur/Australia/CoV000/2006 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus M.mac/Australia/CoV034/2008 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus M.aus/Australia/CoV088/2007 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus R.meg/Australia/CoV100/2007 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus M.aus/Australia/CoV132/2007 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus M.sch/Australia/CoV146/2007 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus M.aus/Australia/CoV180/1996 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Tai Forest coronavirus + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + BtCoV/Trinidad/1FY2BA/2007 + Bat coronavirus Trinidad/1FY2BA/2007 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + BtCoV/Trinidad/1CO7BA/2007 + Bat coronavirus Trinidad/1CO7BA/2007 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bulbul coronavirus HKU11-796 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bulbul coronavirus HKU11-934 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Munia coronavirus HKU13-3514 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Thrush coronavirus HKU12-600 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bulbul coronavirus HKU11 + + + + + + + + + + + GC_ID:1 + Old World leaf-nosed bats + ncbi_taxonomy + Rhinolophidae + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Murine coronavirus MHV-JHM.IA + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Murine coronavirus RA59/R13 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Murine coronavirus RJHM/A + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Murine coronavirus inf-MHV-A59 + + + + + + + + + + + NCBITaxon:177187 + GC_ID:1 + greater horseshoe bat + ncbi_taxonomy + Rhinolophus ferrumquinum + Rhinolophus ferrumequinum + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Eumetazoa + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus Hipposideros/GhanaBoo/344/2008 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus Hipposideros/GhanaBoo/348/2008 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus Hipposideros/GhanaKwam/10/2008 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus Hipposideros/GhanaKwam/13/2008 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus Hipposideros/GhanaKwam/19/2008 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus Hipposideros/GhanaKwam/20/2008 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus Hipposideros/GhanaKwam/22/2008 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus Hipposideros/GhanaKwam/24/2008 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus Hipposideros/GhanaKwam/26/2008 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus Hipposideros/GhanaKwam/27/2008 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus Hipposideros/GhanaKwam/31/2008 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus Hipposideros/GhanaKwam/8/2008 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Feline coronavirus UU10 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Feline coronavirus UU11 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Feline coronavirus UU15 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Feline coronavirus UU16 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Feline coronavirus UU8 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Feline coronavirus UU9 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Human enteric coronavirus strain 4408 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus ExoN1 + + + + + + + + + + NCBITaxon:633141 + GC_ID:1 + ncbi_taxonomy + SARS coronavirus strain P2 + SARS coronavirus P2 + + + + + + + + + + NCBITaxon:627441 + GC_ID:1 + Urbani derived + ncbi_taxonomy + SARS coronavirus strain MA15 + SARS coronavirus MA15 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus strain MA15 ExoN1 + SARS coronavirus MA15 ExoN1 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Infectious bronchitis virus CK/CH/LHLJ/04V + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus Anas/p71/2005/GBR + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus red knot/p60/2006/GBR + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus oystercatcher/p17/2006/GBR + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus Anas/p42/2005/GBR + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Infectious bronchitis virus ITA/90254/2005 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Infectious bronchitis virus NGA/A116E7/2006 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat SARS coronavirus Rs_806/2006 + Bat SARS Cov Rs806/2006 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Alpaca coronavirus CA08-1/2008 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus SLO1A0050/2008/SVN + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus SLO1A0066/2008/SVN + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus SLO1A0082/2008/SVN + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Harbor seal coronavirus 1 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Kenya bat coronavirus BtKY01 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Kenya bat coronavirus BtKY02 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Kenya bat coronavirus BtKY03 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Kenya bat coronavirus BtKY04 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Kenya bat coronavirus BtKY05 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Kenya bat coronavirus BtKY07 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Kenya bat coronavirus BtKY08 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Kenya bat coronavirus BtKY09 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Kenya bat coronavirus BtKY10 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Kenya bat coronavirus BtKY11 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Kenya bat coronavirus BtKY12 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Kenya bat coronavirus BtKY13 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Kenya bat coronavirus BtKY14 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Kenya bat coronavirus BtKY15 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Kenya bat coronavirus BtKY17 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Kenya bat coronavirus BtKY18 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Kenya bat coronavirus BtKY19 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Kenya bat coronavirus BtKY20 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Kenya bat coronavirus BtKY21 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Kenya bat coronavirus BtKY23 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Kenya bat coronavirus BtKY24 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Kenya bat coronavirus BtKY25 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Kenya bat coronavirus BtKY28 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Kenya bat coronavirus BtKY29 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Kenya bat coronavirus BtKY30 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Kenya bat coronavirus BtKY31 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Kenya bat coronavirus BtKY34 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Kenya bat coronavirus BtKY35 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Kenya bat coronavirus BtKY36 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Kenya bat coronavirus BtKY37 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Kenya bat coronavirus BtKY39 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Kenya bat coronavirus BtKY40 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Kenya bat coronavirus BtKY42 + + + + + + + + + + + GC_ID:1 + PMID:22073158 + lesser rice-field rat + ncbi_taxonomy + Rattus losea + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirinae + + + + + + + + + + + NCBITaxon:156438 + NCBITaxon:446038 + GC_ID:1 + ncbi_taxonomy + Coronavirus + Coronavirus group 1 + Group 1 species + Alphacoronavirus + + + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Alphacoronavirus-1 + Alphacoronavirus 1 + + + + + + + + + + + NCBITaxon:285711 + GC_ID:1 + ncbi_taxonomy + Bat coronavirus HKU2 + Rhinolophus bat coronavirus HKU2 + + + + + + + + + + + NCBITaxon:389168 + GC_ID:1 + ncbi_taxonomy + Bat coronavirus (BtCoV/512/2005) + Bat coronavirus 512/2005 + BtCoV/512/2005 + Scotophilus bat coronavirus 512/05 + Scotophilus bat coronavirus 512 + + + + + + + + + + + NCBITaxon:311558 + GC_ID:1 + ncbi_taxonomy + Bat coronavirus strain 61 + Miniopterus bat coronavirus 1 + + + + + + + + + + + NCBITaxon:393047 + GC_ID:1 + ncbi_taxonomy + Bat coronavirus HKU8 + Miniopterus bat coronavirus HKU8 + + + + + + + + + + + + + NCBITaxon:156439 + GC_ID:1 + ncbi_taxonomy + Coronavirus + Coronavirus group 2 + Group 2 species + Betacoronavirus + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Betacoronavirus 1 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Murine coronavirus + + + + + + + + + + + NCBITaxon:393048 + Bat CoV HKU9 + GC_ID:1 + ncbi_taxonomy + Bat coronavirus HKU9 + Rousettus bat coronavirus HKU9 + + + + + + + + + + + NCBITaxon:393043 + GC_ID:1 + ncbi_taxonomy + Bat coronavirus HKU4 + Tylonycteris bat coronavirus HKU4 + + + + + + + + + + + NCBITaxon:393044 + GC_ID:1 + ncbi_taxonomy + Bat coronavirus HKU5 + Pipistrellus bat coronavirus HKU5 + + + + + + + + + + + + + + NCBITaxon:227859 + NCBITaxon:311178 + HCoV-SARS + SARS + SARSr-CoV + GC_ID:1 + ncbi_taxonomy + Human coronavirus (strain SARS) + SARS coronavirus + SARS virus + SARS-like coronavirus + SARS-related coronavirus + Severe acute respiratory syndrome coronavirus + Severe acute respiratory syndrome-related coronavirus + + + + + + + + + + + NCBITaxon:156440 + GC_ID:1 + ncbi_taxonomy + Coronavirus + Coronavirus group 3 + Group 3 species + Gammacoronavirus + + + + + + + + + + + ACoV + GC_ID:1 + ncbi_taxonomy + Avian coronavirus + + + + + + + + + + + NCBITaxon:480629 + GC_ID:1 + ncbi_taxonomy + Coronavirus SW1 + Beluga whale coronavirus SW1 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + unidentified coronavirus + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + human coronavirus + unidentified human coronavirus + + + + + + + + + + NCBITaxon:363808 + GC_ID:1 + ncbi_taxonomy + unclassified group 2 species + unclassified Betacoronavirus + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + recombinant SARSr-CoV + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + SARS coronavirus wtic-MB + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bovine coronavirus Bubalus/339/ITA/2007 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bovine coronavirus Bubalus/82/ITA/2008 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bovine coronavirus Bubalus/153/ITA/2008 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bovine coronavirus Bubalus/155/ITA/2008 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus Philippines/Diliman1552G1/2008 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus Philippines/Diliman1525G2/2008 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Feline coronavirus UU22 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Feline coronavirus UU23 + + + + + + + + + + NCBITaxon:663564 + GC_ID:1 + ncbi_taxonomy + Bat SARS CoV Rs672/2006 + Bat SARS coronavirus Rs_672/2006 + SARS coronavirus Rs_672/2006 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Ferret enteric coronavirus 1202 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Ferret systemic coronavirus MSU-S + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Ferret systemic coronavirus WADL + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Ferret enteric coronavirus + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat SARS coronavirus HKU3-10 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat SARS coronavirus HKU3-11 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat SARS coronavirus HKU3-12 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat SARS coronavirus HKU3-13 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat SARS coronavirus HKU3-4 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat SARS coronavirus HKU3-5 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat SARS coronavirus HKU3-6 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat SARS coronavirus HKU3-7 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat SARS coronavirus HKU3-8 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat SARS coronavirus HKU3-9 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Ferret systemic coronavirus + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus N.noc/VM182/2007/NLD + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus N.noc/VM176/2007/NLD + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus N.noc/VM366/2008/NLD + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus N.noc/VM199/2007/NLD + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus P.pipi/VM312/2008/NLD + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus M.das/VM3/2007/NLD + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus M.das/VM34/2006/NLD + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus M.das/VM84/2007/NLD + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus M.das/VM105/2006/NLD + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus M.das/VM62/2007/NLD + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus M.das/VM73/2007/NLD + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus M.dau/VM222/2007/NLD + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus M.dau/VM303/2008/NLD + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus M.dau/VM361/2008/NLD + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus M.das/VM7/2007/NLD + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus M.das/VM284/2008/NLD + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus M.das/VM2/2007/NLD + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Coronavirus P.pipi/VM314/2008/NLD + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + unclassified Avian coronavirus + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Black-headed gull coronavirus CIR-66144 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Black-headed gull coronavirus CIR-66146 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Black-headed gull coronavirus CIR-66152 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Black-headed gull coronavirus CIR-66183 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Black-headed gull coronavirus CIR-66185 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Black-headed gull coronavirus CIR-66187 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Brent goose coronavirus KR-69 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Brent goose coronavirus KR-70 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Brent goose coronavirus KR-88 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Glaucous-winged gull CIR-66002 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Glaucus-gull coronavirus PBA-173 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Pintail coronavirus PBA-10 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Pintail coronavirus PBA-124 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Pintail coronavirus PBA-15 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Pintail coronavirus PBA-16 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Pintail coronavirus PBA-25 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Pintail coronavirus PBA-37 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Rock sandpiper coronavirus CIR-65824 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Rock sandpiper coronavirus CIR-65828 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Rock sandpiper coronavirus CIR-65885 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Rock sandpiper coronavirus CIR-665821 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Snow goose coronavirus WIR-159 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Western sandpiper coronavirus KR-28 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Infectious bronchitis virus 4/91 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bovine coronavirus cow/WDBR-96/BRA/2003 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bovine coronavirus cow/WDBR-729/BRA/2003 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bovine coronavirus cow/WDBR-841/BRA/2003 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bovine coronavirus cow/WDBR-887/BRA/2003 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bovine coronavirus cow/WDBR-923/BRA/2003 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bovine coronavirus cow/WDBR-978/BRA/2003 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bovine coronavirus cow/WDBR-1005/BRA/2003 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bovine coronavirus cow/WDBR-1275/BRA/2003 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bovine coronavirus cow/WDBR-9146/BRA/2003 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bovine coronavirus cow/WDBR-9215/BRA/2003 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bovine coronavirus cow/WDBR-9224/BRA/2003 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bovine coronavirus cow/WDBR-54/BRA/2003 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Murine hepatitis virus strain 2 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Puffinosis virus + Puffinosis coronavirus + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Mink coronavirus strain WD1127 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Mink coronavirus strain WD1133 + + + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Nidovirales + + + + + + + + + + + GC_ID:1 + chordates + ncbi_taxonomy + chordates + Chordata + + + + + + + + + + Vertebrata <Metazoa> + Vertebrata + vertebrates + + + + GC_ID:1 + Vertebrata + vertebrates + ncbi_taxonomy + vertebrates + Vertebrata <Metazoa> + Vertebrata <vertebrates> + + + + + + + + + + GC_ID:1 + Gnathostomata + jawed vertebrates + ncbi_taxonomy + Gnathostomata <vertebrates> + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus TM5 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Sarcopterygii + + + + + + + + + + GC_ID:1 + sauropsids + ncbi_taxonomy + Sauropsida + + + + + + + + + + + GC_ID:1 + PMID:22982760 + lepidosaurs + ncbi_taxonomy + Reptilia + lizards + reptiles + Lepidosauria + + + + + + + + + + + GC_ID:1 + PMID:16286089 + PMID:22982760 + PMID:23627680 + squamates + ncbi_taxonomy + Squamata + + + + + + + + + + + GC_ID:1 + PMID:19281946 + snakes + ncbi_taxonomy + Ophidia + snakes + Serpentes + + + + + + + + + + + GC_ID:1 + colubrid snakes + ncbi_taxonomy + Colubridae + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus BB98-15/BGR/2008 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus BB98-16/BGR/2008 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus BB98-18/BGR/2008 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus BB98-41/BGR/2008 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus BB98-43/BGR/2008 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus BM48-12/BGR/2008 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus BM48-28/BGR/2008 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus BM48-31/BGR/2008 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus BM48-32/BGR/2008 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus BM48-34/BGR/2008 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus BM48-35/BGR/2008 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus BM48-39/BGR/2008 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus BM48-48/BGR/2008 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus BM98-01/BGR/2008 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus BM98-05/BGR/2008 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus BM98-07/BGR/2008 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus BM98-13/BGR/2008 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus BM98-65/BGR/2008 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus BNM98-29/BGR/2008 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus BNM98-30/BGR/2008 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus BR98-12/BGR/2008 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus BR98-14/BGR/2008 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus BR98-18/BGR/2008 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus BR98-30/BGR/2008 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus BR98-31/BGR/2008 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus BR98-37/BGR/2008 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus BR98-40/BGR/2008 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus BR98-52/BGR/2008 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus BR98-53/BGR/2008 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus BR98-55/BGR/2008 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus NM98-62/GER/2008 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus 1B BR98-19/BGR/2008 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus 2B BR98-19/BGR/2008 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Feline coronavirus UU17 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Feline coronavirus UU18 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Feline coronavirus UU21 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Feline coronavirus UU24 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Feline coronavirus UU31 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Feline coronavirus UU34 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus HKU9-10-1 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus HKU9-10-2 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus HKU9-5-1 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus HKU9-5-2 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus Hipposideros/KT/Thailand/2007 + + + + + + + + + + + GC_ID:1 + Chinese rufous horseshoe bat + ncbi_taxonomy + Rhinolophus rouxii sinicus + Rhinolophus sinicus + + + + + + + + + + + GC_ID:1 + Craniata + ncbi_taxonomy + Craniata <chordates> + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Kenya bat coronavirus BtKY100 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Kenya bat coronavirus BtKY101 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Kenya bat coronavirus BtKY102 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Kenya bat coronavirus BtKY103 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Kenya bat coronavirus BtKY104 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Kenya bat coronavirus BtKY105 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Kenya bat coronavirus BtKY106 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Kenya bat coronavirus BtKY107 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Kenya bat coronavirus BtKY108 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Kenya bat coronavirus BtKY109 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Kenya bat coronavirus BtKY110 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Kenya bat coronavirus BtKY111 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Kenya bat coronavirus BtKY112 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Kenya bat coronavirus BtKY113 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Kenya bat coronavirus BtKY44 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Kenya bat coronavirus BtKY45 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Kenya bat coronavirus BtKY46 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Kenya bat coronavirus BtKY47 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Kenya bat coronavirus BtKY48 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Kenya bat coronavirus BtKY49 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Kenya bat coronavirus BtKY50 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Kenya bat coronavirus BtKY51 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Kenya bat coronavirus BtKY52 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Kenya bat coronavirus BtKY53 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Kenya bat coronavirus BtKY54 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Kenya bat coronavirus BtKY55 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Kenya bat coronavirus BtKY56 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Kenya bat coronavirus BtKY57 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Kenya bat coronavirus BtKY58 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Kenya bat coronavirus BtKY59 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Kenya bat coronavirus BtKY60 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Kenya bat coronavirus BtKY61 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Kenya bat coronavirus BtKY62 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Kenya bat coronavirus BtKY63 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Kenya bat coronavirus BtKY64 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Kenya bat coronavirus BtKY65 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Kenya bat coronavirus BtKY66 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Kenya bat coronavirus BtKY67 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Kenya bat coronavirus BtKY68 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Kenya bat coronavirus BtKY69 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Kenya bat coronavirus BtKY70 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Kenya bat coronavirus BtKY71 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Kenya bat coronavirus BtKY72 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Kenya bat coronavirus BtKY73 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Kenya bat coronavirus BtKY74 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Kenya bat coronavirus BtKY75 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Kenya bat coronavirus BtKY76 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Kenya bat coronavirus BtKY77 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Kenya bat coronavirus BtKY78 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Kenya bat coronavirus BtKY79 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Kenya bat coronavirus BtKY80 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Kenya bat coronavirus BtKY81 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Kenya bat coronavirus BtKY82 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Kenya bat coronavirus BtKY83 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Kenya bat coronavirus BtKY84 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Kenya bat coronavirus BtKY85 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Kenya bat coronavirus BtKY86 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Kenya bat coronavirus BtKY87 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Kenya bat coronavirus BtKY88 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Kenya bat coronavirus BtKY89 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Kenya bat coronavirus BtKY90 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Kenya bat coronavirus BtKY91 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Kenya bat coronavirus BtKY92 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Kenya bat coronavirus BtKY93 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Kenya bat coronavirus BtKY94 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Kenya bat coronavirus BtKY95 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Kenya bat coronavirus BtKY96 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Kenya bat coronavirus BtKY97 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Kenya bat coronavirus BtKY98 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Kenya bat coronavirus BtKY99 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Feline coronavirus UU19 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Feline coronavirus UU20 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Feline coronavirus UU30 + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Feline coronavirus UU40 + + + + + + + + + + + GC_ID:1 + whales, hippos, ruminants, pigs, camels etc. + ncbi_taxonomy + Cetartiodactyla + even-toed ungulates + Artiodactyla + + + + + + + + + + NCBITaxon:28296 + SDAV + GC_ID:1 + ncbi_taxonomy + Sialodacaryoadenitis virus + sialodacryoadenitis virus + sialodacryoadenitis virus SDAV + Rat sialodacryoadenitis coronavirus + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Alphacoronavirus Eptesicus fuscus/Appalachian Ridge/P1-C1148/IT/USA/2009 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Alphacoronavirus Eptesicus fuscus/Appalachian Ridge/P1-C837/IT/USA/2009 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Alphacoronavirus Eptesicus fuscus/Appalachian Ridge/P3-C766/IT/USA/2009 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Alphacoronavirus Eptesicus fuscus/Appalachian Ridge/P3-C450/IT/USA/2009 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Alphacoronavirus Eptesicus fuscus/Appalachian Ridge/P1-287740/IT/USA/2009 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Alphacoronavirus Eptesicus fuscus/Appalachian Ridge/P1-replicase/IT/USA/2009 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Alphacoronavirus Eptesicus fuscus/Appalachian Ridge/P1-C676/IT/USA/2009 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Alphacoronavirus Eptesicus fuscus/Appalachian Ridge/P1-C454/IT/USA/2009 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Alphacoronavirus Eptesicus fuscus/Appalachian Ridge/P1-239577/IT/USA/2009 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Alphacoronavirus Eptesicus fuscus/Appalachian Ridge/P1-C414//IT/USA/2009 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Alphacoronavirus Eptesicus fuscus/Appalachian Ridge/P1-C412/IT/USA/2009 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Alphacoronavirus Eptesicus fuscus/Appalachian Ridge/P1-C368/IT/USA/2009 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Alphacoronavirus Eptesicus fuscus/Appalachian Ridge/P1-C362/IT/USA/2009 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Alphacoronavirus Eptesicus fuscus/Appalachian Ridge/P1-C348/IT/USA/2009 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Alphacoronavirus Eptesicus fuscus/Appalachian Ridge/P2-C344/IT/USA/2009 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Alphacoronavirus Eptesicus fuscus/Appalachian Ridge/P1-C328/IT/USA/2009 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Alphacoronavirus Eptesicus fuscus/Appalachian Ridge/P1-293985/IT/USA/2009 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Alphacoronavirus Eptesicus fuscus/Appalachian Ridge/P1-5088/IT/USA/2009 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Alphacoronavirus Eptesicus fuscus/Appalachian Ridge/P1-66604/IT/USA/2009 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Alphacoronavirus Eptesicus fuscus/Appalachian Ridge/P1-C265/IT/USA/2009 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Alphacoronavirus Eptesicus fuscus/Appalachian Ridge/P1-C264/IT/USA/2009 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Alphacoronavirus Eptesicus fuscus/Appalachian Ridge/P2-21252/IT/USA/2009 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Alphacoronavirus Eptesicus fuscus/Appalachian Ridge/P1-265225/IT/USA/2009 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Alphacoronavirus Eptesicus fuscus/Appalachian Ridge/P1-C149/IT/USA/2009 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Alphacoronavirus Eptesicus fuscus/Appalachian Ridge/P1-C146/IT/USA/2009 + + + + + + + + + + GC_ID:1 + eutherian mammals + placental mammals + placentals + ncbi_taxonomy + Placentalia + placentals + Eutheria + + + + + + + + + + + GC_ID:1 + bats + ncbi_taxonomy + bats + Chiroptera + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + unclassified Mus + + + + + + + + + + + GC_ID:1 + primate + ncbi_taxonomy + Primata + primates + Primates + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Catarrhini + + + + + + + + + + + GC_ID:1 + great apes + ncbi_taxonomy + Pongidae + Hominidae + + + + + + + + + + + GC_ID:1 + humans + ncbi_taxonomy + Homo + + + + + + + + + + + Homo sapiens + human + human being + man + + + + + GC_ID:1 + human + man + ncbi_taxonomy + Home sapiens + Homo sampiens + Homo sapeins + Homo sapian + Homo sapians + Homo sapien + Homo sapience + Homo sapiense + Homo sapients + Homo sapines + Homo spaiens + Homo spiens + Humo sapiens + Homo sapiens + + + + + + + + + + + + GC_ID:1 + dog, coyote, wolf, fox + ncbi_taxonomy + Canidae + + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Canis + + + + + + + + + + + + GC_ID:1 + gray wolf + grey wolf + ncbi_taxonomy + Canis lupus + + + + + + + + + + + + GC_ID:1 + dog + dogs + ncbi_taxonomy + Canis canis + Canis domesticus + Canis familiaris + Canis lupus familiaris + + + + + + + + + + + NCBITaxon:68731 + NCBITaxon:9609 + GC_ID:1 + ncbi_taxonomy + Fennecus + Vulpes + + + + + + + + + + + NCBITaxon:9628 + GC_ID:1 + red fox + silver fox + ncbi_taxonomy + Canis vulpes + Vulpes vulpes + + + + + + + + + + + GC_ID:1 + PMID:14745111 + PMID:18275614 + weasel, mink, badger, martens and others + ncbi_taxonomy + Mustelidae + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Mustela + + + + + + + + + + + GC_ID:1 + European mink + mink + ncbi_taxonomy + Mustela lutreola + + + + + + + + + + + GC_ID:1 + civets + ncbi_taxonomy + Viverridae + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Paguma + + + + + + + + + + + GC_ID:1 + masked palm civet + ncbi_taxonomy + Paguma larvata + + + + + + + + + + + GC_ID:1 + cat family + ncbi_taxonomy + Felidae + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Felis + + + + + + + + + + + NCBITaxon:36475 + GC_ID:1 + PMID:17600185 + PMID:8581300 + PMID:8603894 + cat + cats + domestic cat + ncbi_taxonomy + Felis domesticus + Felis silvestris catus + Felis catus + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Tylopoda + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Camelidae + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Camelus + + + + + + + + + + + GC_ID:1 + Bactrian camel + camel + domestic Bactrian camel + two-humped camel + ncbi_taxonomy + Camelus bactrianus + + + + + + + + + + + GC_ID:1 + Arabian camel + camel + dromedaries + dromedary + dromedary camel + one-humped camel + ncbi_taxonomy + Camelus dromedarius + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus BtKY43/Kenya/2006 + Cardioderma coronavirus/Kenya/KY43/2006 + Cardioderma bat coronavirus/Kenya/KY43/2006 + + + + + + + + + + + NCBITaxon:681884 + GC_ID:1 + ncbi_taxonomy + Bat coronavirus BtKY41/Chaerephon pumilus/Kenya/2006 + Chaerephon coronavirus/Kenya/KY41/2006 + Kenya bat coronavirus BtKY41 + Chaerephon bat coronavirus/Kenya/KY41/2006 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus BtKY24/Eidolon helvum/Kenya/2006 + Eidonlon coronavirus/Kenya/KY24/2006 + Eidolon bat coronavirus/Kenya/KY24/2006 + + + + + + + + + + + NCBITaxon:681853 + GC_ID:1 + ncbi_taxonomy + Bat coronavirus BtKY06/Rousettus aegyptiacus/Kenya/2006 + Kenya bat coronavirus BtKY06 + Rousettus coronavirus/Kenya/KY06/2006 + Rousettus bat coronavirus/Kenya/KY06/2006 + + + + + + + + + + + NCBITaxon:681872 + GC_ID:1 + ncbi_taxonomy + Bat coronavirus BtKY27/Miniopterus natalensis/Kenya/2006 + Kenya bat coronavirus BtKY27 + Miniopterus coronavirus/Kenya/KY27/2006 + Miniopterus bat coronavirus/Kenya/KY27/2006 + + + + + + + + + + + NCBITaxon:681877 + GC_ID:1 + ncbi_taxonomy + Bat coronavirus BtKY33/Miniopterus inflatus/Kenya/2006 + Kenya bat coronavirus BtKY33 + Miniopterus coronavirus/Kenya/KY33/2006 + Miniopterus bat coronavirus/Kenya/KY33/2006 + + + + + + + + + + + NCBITaxon:681868 + GC_ID:1 + ncbi_taxonomy + Bat coronavirus BtKY22/Chaerephon sp./Kenya/2006 + Chaerephon coronavirus/Kenya/KY22/2006 + Kenya bat coronavirus BtKY22 + Chaerephon bat coronavirus/Kenya/KY22/2006 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Ruminantia + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Zaria bat coronavirus + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bovidae + + + + + + + + + + + GC_ID:1 + oxen, cattle + ncbi_taxonomy + Bos + + + + + + + + + + + NCBITaxon:272461 + GC_ID:1 + bovine + cattle + cow + dairy cow + domestic cattle + domestic cow + ncbi_taxonomy + Bos Tauurus + Bos bovis + Bos primigenius taurus + Bos taurus + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus N78-10/Germany/2008 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus M.ful/Japan/01/2009 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus M.ful/Japan/02/2009 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus M.ful/Japan/01/2010 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus M.ful/Japan/02/2010 + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Bat coronavirus M.ful/Japan/03/2010 + + + + + + + + + + + GC_ID:1 + Pholidota + pangolins + ncbi_taxonomy + Edentata + Pholidota <placentals> + + + + + + + + + + + GC_ID:1 + pangolins + scaly anteaters + ncbi_taxonomy + Manidae + + + + + + + + + + + GC_ID:1 + ncbi_taxonomy + Smutsia + Manis + + + + + + + + + + + GC_ID:1 + Malayan pangolin + ncbi_taxonomy + Manis javanica + + + + + + + + + + + GC_ID:1 + rodent + ncbi_taxonomy + rodents + Rodentia + + + + + + + + + + ncbi_taxonomy + class + + + + + + + + + + ncbi_taxonomy + family + + + + + + + + + + ncbi_taxonomy + genus + + + + + + + + + + ncbi_taxonomy + infraorder + + + + + + + + + + ncbi_taxonomy + kingdom + + + + + + + + + + ncbi_taxonomy + order + + + + + + + + + + ncbi_taxonomy + parvorder + + + + + + + + + + ncbi_taxonomy + phylum + + + + + + + + + + ncbi_taxonomy + species + + + + + + + + + + ncbi_taxonomy + subfamily + + + + + + + + + + ncbi_taxonomy + subgenus + + + + + + + + + + ncbi_taxonomy + suborder + + + + + + + + + + ncbi_taxonomy + subphylum + + + + + + + + + + ncbi_taxonomy + superclass + + + + + + + + + + ncbi_taxonomy + superfamily + + + + + + + + + + ncbi_taxonomy + superkingdom + + + + + + + + + + ncbi_taxonomy + superorder + + + + + + + + + + + + + + + a pathological bodily process that occurs after a medical intervention. An adverse event is likely caused by the medical intervention; however, such a causal association is not required to be an adverse event. + Melanie Courtot and YH: More work is needed on how to restrict the scope of a term to be an 'adverse event', notably regarding temporal association. When is an appropirate time interval between a medical intervention and an adverse event observed? One week, one month, one year, or a lifetime? For some well-studied medical interventions (e.g., administration of many vaccines or drugs), we probably have a general idea. For many new interventions, we don't know much. In OAE, this issue is associated with defining the 'adverse event incubation time'. + YH: An adverse event is a process that has specified output of some adverse medical outcome (e.g., symptom, sign or accident) after a medical intervention (or process) (e.g., administration of drug or vaccine). The medical intervention can be an administration of a drug, a vaccine (i.e., vaccination), or a special nutritional product (for example, dietary supplement, infant formula, medical food), surgery, or usage of a medical device. + YH: An adverse event is possibly induced by the medical intervention. It can be caused by the medical intervention, or may not be caused by the medical intervention. One ultimate goal (or the goal in clinics) of study adverse events is to assess if the adverse event outcome is due to the medical intervention. + YH: In development of OAE, we initially use vaccine adverse event as our use case. A vaccine adverse event is associated with a vaccination (i.e. a medical intervention), regardless of whether it is considered vaccine-related, and includes any side effect, injury, toxicity, or sensitivity reaction or significant failure of immunization (i.e., a pharmacologic action). +Ref: Baylor NW and Midthum K. Regulation and testing of vaccines. In: Vaccines (Editors: Plotkin S, Orenstein W, and Offit P). 2008. p1623. + YH: The current term 'adverse event' is different from the term definition shown in our paper: He Y, Xiang Z, Sarntivijai S, Toldo L, Ceusters W. OAE: a realism-based biomedical ontology for the representation of adverse events. Adverse Event Representation Workshop, International Conference on Biomedical Ontologies (ICBO), University at Buffalo, NY, July 26-30, 2011. Full lenghth conference proceeding paper. + +We made the name changing in order to make OAE cover the broader sense of the 'adverse event' which does not assume definite causal effect between an adverse event and a medical intervention. In current definition, the adverse event emphasizes the time association and assumes a likelihood of such a causal association. This term 'adverse event' is stil under the OGMS:pathological bodily process. + +The 'adverse event' defined in the above paper has now been changed to a new term: 'causal adverse event'. See more information in the new publication: Yongqun He Y, Sirarat Sarntivijai, Yu Lin, Zuoshuang Xiang, Abra Guo, Shelley Zhang, Desikan Jagannathan, Luca Toldo, Cui Tao and Barry Smith. OAE: The Ontology of Adverse Events. Journal of Biomedical Semantics. 2014, 5:29 doi:10.1186/2041-1480-5-29. PMID: 25093068.PMCID: PMC4120740. + YH: The main scope of OAE includes: (1) represent terms and relations in the area of adverse events, (2) assess possible associations between an adverse event and a medical intervention, particularly, identify any causal effect of a medical intervention to an adverse event; and (2) understand the mechanism (including molecular mechanisms) of causal adverse events. + YH: There has been discussion regarding whether the term 'side effect' is an alternative term for 'adverse event'. In AERO, the term 'AERO:adverse event' represents a subset of those adverse events for which causality has been established. In OAE, an adverse event for which causality has been established is called 'causal adverse event'. + Yongqun He + AE + adverse reaction + WEB: http://en.wikipedia.org/wiki/Adverse_event + WEB: http://www.fda.gov/Safety/MedWatch/HowToReport/ucm053087.htm + WEB: http://www.ncbi.nlm.nih.gov/pubmed/25093068 + + The OAE official website is: http://www.oae-ontology.org/. + adverse event + + + + + + + + + medical intervention is a planned process that has the goal of diagnosing, preventing or relieving illness or injury. + The act of intervening, interfering or interceding with the intent of modifying the outcome. In medicine, an intervention is usually undertaken to help treat or cure a condition. For example, "Acupuncture as a therapeutic intervention is widely practiced in the United States," +Reference: +http://www.medterms.com/script/main/art.asp?articlekey=34214 . Some interventions can be used for diagnosis. + YH + WEB: http://wiki.answers.com/Q/What_is_medical_intervention + + medical intervention + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + a cardiovascular disorder AE that has a cardiac disorder outcome. + SS, YH + WEB: Primary Source: http://medical-dictionary.thefreedictionary.com/heart+disease Secondary Source: http://www.ncbi.nlm.nih.gov/pubmed/23091623 + + 10007541 + 10061024 + cardiac disorder AE + HPO: HP_0001627 + SIDER: C0018799 + + + + + + + + + + + + + + + + + + + + an AE that occurs in cardiovascular system. + YH + cardiovascular disorder AE + + 10007649 + cardiovascular AE + HPO: HP_0001626 + SIDER: C0007222 + + + + + + + + + a cardiac disorder AE which has an outcome of abnormal heart rhythm + SS, YH + abnormal heartbeat AE + cardiac arrhythmia AE + WEB: http://www.nhlbi.nih.gov/health/health-topics/topics/arr/ + + 10003119 + arrhythmia AE + HPO: HP_0011675 + MP: MP_0004085 + SIDER: C0003811 + + + + + + + + + a process quality that represents the level of severity of an adverse event. + YH, SS + AE severity + + severity of adverse event + + + + + + + + + a severity of AE that shows asymptomatic, or involves mild or minor symptoms, or is of marginal clinical relevance, or consists of clinical or diagnostic observations alone, or where intervention is not indicated, or where only non-prescription intervention is indicated. + YH, SS + AE severity Grade 1 + Web: http://ncicb.nci.nih.gov/xml/owl/EVS/ctcae.owl#Grade_1_Adverse_Event + + Note the AE severity Grade 1 equals to CTCAE G1 AE severity. + AE severity G1 + CTCAE4: E10005 (Grade 1 Adverse Event) + + + + + + + + + a severity of AE for which only minimal, local, or noninvasive intervention (e.g. packing, cautery) is indicated, or that limits instrumental activities of daily living (ADLs, e.g., shopping, laundry, transportation, or ability to conduct finances). + YH, SS + AE severity Grade 2 + Web: http://ncicb.nci.nih.gov/xml/owl/EVS/ctcae.owl#Grade_2_Adverse_Event + + Note the AE severity Grade 2 equals to CTCAE G2 AE severity. + AE severity G2 + CTCAE4: E10006 (Grade 2 Adverse Event) + + + + + + + + + a severity of AE that shows an outcome which is medically significant but not life-threatening; or for which inpatient care or prolongation of hospitalization are indicated; or that is an important medical event that does not result in hospitalization, but may jeopardize the patient or may require intervention either to prevent hospitalization, to prevent the AE from becoming life-threatening or causing death; or that is disabling; or that results in persistent or significant disability, incapacity, or limitation of self care activities of daily living (ADLs, getting in and out of bed, dressing, eating, getting around inside, bathing, or using the toilet). + YH, SS + AE severity Grade 3 + Web: http://ncicb.nci.nih.gov/xml/owl/EVS/ctcae.owl#Grade_3_Adverse_Event + + Note the AE severity Grade 3 equals to CTCAE G3 AE severity. + AE severity G3 + CTCAE4: E10007 (Grade 3 Adverse Event) + + + + + + + + + a severity of AE that has life-threatening consequences, for which urgent intervention is indicated, that puts the patient is at risk of death at the time of the event if immediate intervention is not undertaken, or that causes blindness or deafness (need to decide if unilateral or bilateral). + YH, SS + AE severity Grade 4 + Web: http://ncicb.nci.nih.gov/xml/owl/EVS/ctcae.owl#Grade_4_Adverse_Event + + Note the AE severity Grade 4 equals to CTCAE G4 AE severity. + AE severity G4 + CTCAE4: E10008 (Grade 4 Adverse Event) + + + + + + + + + a severity of AE that results in death. + YH, SS + AE severity Grade 5 + Web: http://ncicb.nci.nih.gov/xml/owl/EVS/ctcae.owl#Grade_5_Adverse_Event + + Note the AE severity Grade 5 equals to CTCAE G5 AE severity. + AE severity G5 + CTCAE4: E10009 (Grade 5 Adverse Event) + + + + + + + + + + + + + + + + + + + + + + a data transformation that has input of mulitple data and report overall trend of the data. + Jie Zheng, Oliver He + WEB: https://en.wikipedia.org/wiki/Statistics + + statistical data analysis + + + + + + + + + + + + + + + + + + + + + A data item that measures the proportion of actual positives which are correctly identified as such (e.g. the percentage of sick people who are correctly identified as having the condition). + Yongqun He + sensitivity estimate + true positive rate, recall + WEB: http://en.wikipedia.org/wiki/Sensitivity_and_specificity + + STATO_0000233 + sensitivity + + + + + + + + + + + + + + + A data item that refers to the proportion of negatives in a binary classification test which are correctly identified + Yongqun He + true negative rate + WEB: http://en.wikipedia.org/wiki/Sensitivity_and_specificity + + STATO_0000134 + specificity + + + + + + + + + A sensitivity that refers to the number of patients with a positive test who have a disease divided by all patients who have the disease. A test with high sensitivity will not miss many patients who have the disease (i.e., few false negative results). + Yongqun He + WEB: http://www.uptodate.com/contents/glossary-of-common-biostatistical-and-epidemiological-terms + + disease test sensitivity + + + + + + + + + A specificity that refers to the number of patients who have a negative test and do not have the disease divided by the number of patients who do not have the disease. A test with high specificity will infrequently identify patients as having a disease when they do not (i.e., few false positive results). + Yongqun He + WEB: http://www.uptodate.com/contents/glossary-of-common-biostatistical-and-epidemiological-terms + + disease test specificity + + + + + + + + + + + + + + + + + + + + + A statistical data analysis that uses patterns in the sample data to draw inferences about the population represented, accounting for randomness. + Jie Zheng, Oliver He + significantly statistical data analysis + + WEB: http://en.wikipedia.org/wiki/Statistics + + inferential statistical data analysis + + + + + + + + + A statistical data analysis objective where the aim is to make inference using population sample data. + Jie Zheng, Oliver He + + inferential statistical data analysis objective + + + + + + + + + A disposition that inheres in a population of continuant and is realized in a test process (e.g., disease diagnosis). + https://jbiomedsem.biomedcentral.com/articles/10.1186/s13326-016-0099-4 + + AB, JZ, JFE, YH + This term is generated in OBCS based on BIPO: https://github.com/OpenLHS/BIPO. See more from OBCS track issue: https://github.com/obcs/obcs/issues/9 + Traditionally, sensitivity inheres in a population of material entity like human. However, it raises a concern in the existance of such sensitivity disposition in the context of machine learning using syntheti data generated with mathematical formula. In this case, the population of disposition bearer are not population of organisms or material entities. Here the bearer of the disposition is not independent continuant. + sensitivity disposition + + + + + + + + + + + + + + + + + + + + A data item that is derived from a statistical data analysis. + Jie Zheng, Yongqun He, Marcy Harris, Asiyah Yu Lin + statistic + WEB: http://en.wikipedia.org/wiki/Statistic + WEB: http://www.ask.com/question/what-is-numerical-data + + derived data from statistical analysis + + + + + + + + + + + + + + + + + + + + A data item that is derived from an inferential statistical data analysis. + Jie Zheng, Yongqun He + inferential statistic + WEB: http://psc.dss.ucdavis.edu/sommerb/sommerdemo/stat_inf/intro.htm + WEB: http://www.ask.com/question/what-is-numerical-data + + derived data from inferential statistical analysis + + + + + + + + + + + + + + + + + + + + A data item that is produced as the output of a data transformation. + Person: Jie Zheng, Oliver He + + transformed data item + + + + + + + + + + + + + + + + + + + + planned process + planned process + Injecting mice with a vaccine in order to test its efficacy + + A processual entity that realizes a plan which is the concretization of a plan specification. + 'Plan' includes a future direction sense. That can be problematic if plans are changed during their execution. There are however implicit contingencies for protocols that an agent has in his mind that can be considered part of the plan, even if the agent didn't have them in mind before. Therefore, a planned process can diverge from what the agent would have said the plan was before executing it, by adjusting to problems encountered during execution (e.g. choosing another reagent with equivalent properties, if the originally planned one has run out.) + We are only considering successfully completed planned processes. A plan may be modified, and details added during execution. For a given planned process, the associated realized plan specification is the one encompassing all changes made during execution. This means that all processes in which an agent acts towards achieving some +objectives is a planned process. + Bjoern Peters + branch derived + 6/11/9: Edited at workshop. Used to include: is initiated by an agent + This class merges the previously separated objective driven process and planned process, as they the separation proved hard to maintain. (1/22/09, branch call) + + + + + + http://purl.obolibrary.org/obo/obi.owl + planned process + + + + + + + + + + + + + + + reference substance role + Calibration standard, positive control substance, vehicle Good Laboratory Practices: Questions and Answers - Test Control and Reference Substance Characterization http://www.epa.gov/enforcement/monitoring/programs/fifra/glpqanda-character.html + + a role inhering in a material entity that is realized when characteristics or responses elicited by the substance are used for comparison or reference. + Person:Jennifer Fostel + reference substance + OBI + + reference substance role + + + + + + + + + + + + + + + + + + + + processed material + Examples include gel matrices, filter paper, parafilm and buffer solutions, mass spectrometer, tissue samples + + Is a material entity that is created or changed during material processing. + PERSON: Alan Ruttenberg + + + + http://purl.obolibrary.org/obo/obi.owl + processed material + + + + + + + + + + + + + + + + + + + + + evaluant role + When a specimen of blood is assayed for glucose concentration, the blood has the evaluant role. When measuring the mass of a mouse, the evaluant is the mouse. When measuring the time of DNA replication, the evaluant is the DNA. When measuring the intensity of light on a surface, the evaluant is the light source. + + a role that inheres in a material entity that is realized in an assay in which data is generated about the bearer of the evaluant role + Role call - 17nov-08: JF and MC think an evaluant role is always specified input of a process. Even in the case where we have an assay taking blood as evaluant and outputting blood, the blood is not the specified output at the end of the assay (the concentration of glucose in the blood is) + examples of features that could be described in an evaluant: quality.... e.g. "contains 10 pg/ml IL2", or "no glucose detected") + GROUP: Role Branch + OBI + Feb 10, 2009. changes after discussion at OBI Consortium Workshop Feb 2-6, 2009. accepted as core term. + + evaluant role + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + assay + Assay the wavelength of light emitted by excited Neon atoms. Count of geese flying over a house. + + A planned process with the objective to produce information about the material entity that is the evaluant, by physically examining it or its proxies. + 12/3/12: BP: the reference to the 'physical examination' is included to point out that a prediction is not an assay, as that does not require physical examiniation. + PlanAndPlannedProcess Branch + measuring + scientific observation + OBI branch derived + + study assay + any method + assay + + + + + + + + + reagent role + Buffer, dye, a catalyst, a solvating agent. + + A role inhering in a biological or chemical entity that is intended to be applied in a scientific technique to participate (or have molecular components that participate) in a chemical reaction that facilitates the generation of data about some entity distinct from the bearer, or the generation of some specified material output distinct from the bearer. + PERSON:Matthew Brush + reagent + PERSON:Matthew Brush + Feb 10, 2009. changes after discussion at OBI Consortium Workshop Feb 2-6, 2009. accepted as core term. + +May 28 2013. Updated definition taken from ReO based on discussions initiated in Philly 2011 workshop. Former defnition described a narrower view of reagents in chemistry that restricts bearers of the role to be chemical entities ("a role played by a molecular entity used to produce a chemical reaction to detect, measure, or produce other substances"). Updated definition allows for broader view of reagents in the domain of biomedical research to include larger materials that have parts that participate chemically in a molecular reaction or interaction. + + + (copied from ReO) +Reagents are distinguished from instruments or devices that also participate in scientific techniques by the fact that reagents are chemical or biological in nature and necessarily participate in or have parts that participate in some chemical interaction or reaction during their intended participation in some technique. By contrast, instruments do not participate in a chemical reaction/interaction during the technique. + +Reagents are distinguished from study subjects/evaluants in that study subjects and evaluants are that about which conclusions are drawn and knowledge is sought in an investigation - while reagents, by definition, are not. It should be noted, however, that reagent and study subject/evaluant roles can be borne by instances of the same type of material entity - but a given instance will realize only one of these roles in the execution of a given assay or technique. For example, taq polymerase can bear a reagent role or an evaluant role. In a DNA sequencing assay aimed at generating sequence data about some plasmid, the reagent role of the taq polymerase is realized. In an assay to evaluate the quality of the taq polymerase itself, the evaluant/study subject role of the taq is realized, but not the reagent role since the taq is the subject about which data is generated. + +In regard to the statement that reagents are 'distinct' from the specified outputs of a technique, note that a reagent may be incorporated into a material output of a technique, as long as the IDENTITY of this output is distinct from that of the bearer of the reagent role. For example, dNTPs input into a PCR are reagents that become part of the material output of this technique, but this output has a new identity (ie that of a 'nucleic acid molecule') that is distinct from the identity of the dNTPs that comprise it. Similarly, a biotin molecule input into a cell labeling technique are reagents that become part of the specified output, but the identity of the output is that of some modified cell specimen which shares identity with the input unmodified cell specimen, and not with the biotin label. Thus, we see that an important criteria of 'reagent-ness' is that it is a facilitator, and not the primary focus of an investigation or material processing technique (ie not the specified subject/evaluant about which knowledge is sought, or the specified output material of the technique). + reagent role + + + + + + + + + + + + + + + + + + + + + + + + + + + material processing + A cell lysis, production of a cloning vector, creating a buffer. + + A planned process which results in physical changes in a specified input material + PERSON: Bjoern Peters + PERSON: Frank Gibson + PERSON: Jennifer Fostel + PERSON: Melanie Courtot + PERSON: Philippe Rocca Serra + material transformation + OBI branch derived + + + material processing + + + + + + + + + + + + + + + + + + + + + + + + + specimen role + liver section; a portion of a culture of cells; a nemotode or other animal once no longer a subject (generally killed); portion of blood from a patient. + + a role borne by a material entity that is gained during a specimen collection process and that can be realized by use of the specimen in an investigation + 22Jun09. The definition includes whole organisms, and can include a human. The link between specimen role and study subject role has been removed. A specimen taken as part of a case study is not considered to be a population representative, while a specimen taken as representing a population, e.g. person taken from a cohort, blood specimen taken from an animal) would be considered a population representative and would also bear material sample role. + Note: definition is in specimen creation objective which is defined as an objective to obtain and store a material entity for potential use as an input during an investigation. + blood taken from animal: animal continues in study, whereas blood has role specimen. +something taken from study subject, leaves the study and becomes the specimen. + parasite example +- when parasite in people we study people, people are subjects and parasites are specimen +- when parasite extracted, they become subject in the following study +specimen can later be subject. + GROUP: Role Branch + OBI + + specimen role + + + + + + + + + + + + + + + filter paper + + A device manufacture with the intent to provide a porous unsized paper used for filtering. + Frank Gibson + sep:00107 + + filter paper + + + + + + + + + + + + + + + antigen role + + Antigen is a role played by material which when introduced into an immune-competent organism causes an immune response + a role that inheres in a vaccine component and plays an antigen role, i.e., it is introducd into an immune-competent organism to cause an immune response + An antigen is a substance that prompts the generation of antibodies and can cause an immune response. Wikipedia http://en.wikipedia.org/wiki/Antigen. In the strict sense, immunogens are those substances that elicit a response from the immune system, whereas antigens are defined as substances that bind to specific antibodies. Not all antigens produce an immunogenic response, but all immunogens are antigens + Role Branch + OBI + 9Mar09 waiting for discussion with immunology terms + + + antigen role + + + + + + + + + organization + PMID: 16353909.AAPS J. 2005 Sep 22;7(2):E274-80. Review. The joint food and agriculture organization of the United Nations/World Health Organization Expert Committee on Food Additives and its role in the evaluation of the safety of veterinary drug residues in foods. + + An entity that can bear roles, has members, and has a set of organization rules. Members of organizations are either organizations themselves or individual people. Members can bear specific organization member roles that are determined in the organization rules. The organization rules also determine how decisions are made on behalf of the organization by the organization members. + BP: The definition summarizes long email discussions on the OBI developer, roles, biomaterial and denrie branches. It leaves open if an organization is a material entity or a dependent continuant, as no consensus was reached on that. The current placement as material is therefore temporary, in order to move forward with development. Here is the entire email summary, on which the definition is based: + +1) there are organization_member_roles (president, treasurer, branch +editor), with individual persons as bearers + +2) there are organization_roles (employer, owner, vendor, patent holder) + +3) an organization has a charter / rules / bylaws, which specify what roles +there are, how they should be realized, and how to modify the +charter/rules/bylaws themselves. + +It is debatable what the organization itself is (some kind of dependent +continuant or an aggregate of people). This also determines who/what the +bearer of organization_roles' are. My personal favorite is still to define +organization as a kind of 'legal entity', but thinking it through leads to +all kinds of questions that are clearly outside the scope of OBI. + +Interestingly enough, it does not seem to matter much where we place +organization itself, as long as we can subclass it (University, Corporation, +Government Agency, Hospital), instantiate it (Affymetrix, NCBI, NIH, ISO, +W3C, University of Oklahoma), and have it play roles. + +This leads to my proposal: We define organization through the statements 1 - +3 above, but without an 'is a' statement for now. We can leave it in its +current place in the is_a hierarchy (material entity) or move it up to +'continuant'. We leave further clarifications to BFO, and close this issue +for now. + PERSON: Alan Ruttenberg + PERSON: Bjoern Peters + PERSON: Philippe Rocca-Serra + PERSON: Susanna Sansone + GROUP: OBI + + + organization + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + adding a material entity into a target + Injecting a drug into a mouse. Adding IL-2 to a cell culture. Adding NaCl into water. + + is a process with the objective to place a material entity bearing the 'material to be added role' into a material bearing the 'target of material addition role'. + Class was renamed from 'administering substance', as this is commonly used only for additions into organisms. + BP + branch derived + + + adding a material entity into a target + + + + + + + + + material to be added role + drug added to a buffer contained in a tube; substance injected into an animal; + + material to be added role is a protocol participant role realized by a material which is added into a material bearing the target of material addition role in a material addition process + Role Branch + OBI + 9 March 09 from discussion with PA branch + + + material to be added role + + + + + + + + + contain function + A syringe, a beaker + + A contain function is a function to constrain a material entities location in space + Bill Bug + Daniel Schober + Frank Gibson + Melanie Courtot + + contain function + + + + + + + + + material separation function + + A material separation function is a function that increases the resolution between two or more material entities. The to distinction between the entities is usually based on some associated physical quality. + Bill Bug + Daniel Schober + Frank Gibson + Melanie Courtot + + material separation function + + + + + + + + + synthesizing function + + A synthesizing function is a function to assemble new output materials from distinct input materials. The output materials typically consist of chemically distinct monomeric objects or object aggregate polymers. + Bill Bug + Daniel Schober + Frank Gibson + Melanie Courtot + + synthesizing function + + + + + + + + + filter function + + A filter function is a function to prevent the flow of certain entities based on a quality or qualities of the entity while allowing entities which have different qualities to pass through + Frank Gibson + + filter function + + + + + + + + + + + + + + + primer role + + a complementary nucleotide probe role which inheres in nucleic acid molecular entity and is realized by the use of the entity bearing the role to initiate chain elongation. + (cell and molecular biology) A short strand of RNA that is synthesized along single-stranded DNA during replication, initiating DNA polymerase-catalyzed synthesis of the complementary strand. http://www.answers.com/topic/rna-primer + + primer role + + + + + + + + + + + + + + + + + + + + + PCR product + PCR products are the results of amplifcation process. Detection of a PCR products is used to detect DNA and RNA. + + is double stranded DNA that is the specified output of a polymerase chain reaction + We are using PCR and not the written out words, as this is the most common used. + GROUP: OBI BIomaterial Branch + GROUP: OBI BIomaterial Branch + + PCR product + + + + + + + + + + + + + + + + + + + + + nucleic acid template role + a model or standard for making comparisons; wordnet.princeton.edu/perl/webwn 19 feb 2009 + + a reference substance role which inheres in nucleic acid material entity and is realized in the process of using the nucleic acid bearing the template role as a reference during synthesis of a reverse copy. + + nucleic acid template role + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + polymerase chain reaction + Opisthorchis viverrini: Detection by polymerase chain reaction (PCR) in human stool samples. Exp Parasitol. 2008 Sep 9. PMID: 18805413 + + PCR is the process in which a DNA polymerase is used to amplify a piece of DNA by in vitro enzymatic replication. As PCR progresses, the DNA thus generated is itself used as a template for replication. This sets in motion a chain reaction in which the DNA template is exponentially amplified. + OBI Plan + PCR + adapted from wikipedai + + polymerase chain reaction + + + + + + + + + + + + + + + + + + + + + + + + + reverse transcriptase + + enzyme and has_function some GO:0003964 (RNA-directed DNA polymerase +activity) + person:Melanie Courtot + group:OBI + + reverse transcriptase + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + enzyme + + (protein or rna) or has_part (protein or rna) and +has_function some GO:0003824 (catalytic activity) + MC: known issue: enzyme doesn't classify under material entity for now as it isn't stated that anything +that has_part some material entity is a material entity. If we add as equivalent classes to material entity has_part some material entity and part_of some material entity (each one in his own necessary and sufficient block) Pellet in P3 doesn't classify any more. + person: Melanie Courtot + GROUP:OBI + + enzyme + + + + + + + + + adding material objective + creating a mouse infected with LCM virus + + is the specification of an objective to add a material into a target material. The adding is asymmetric in the sense that the target material largely retains its identity + BP + + + adding material objective + + + + + + + + + assay objective + the objective to determine the weight of a mouse. + + an objective specification to determine a specified type of information about an evaluated entity (the material entity bearing evaluant role) + PPPB branch + PPPB branch + + assay objective + + + + + + + + + + + + + + + + + + + + + target of material addition role + peritoneum of an animal receiving an interperitoneal injection; solution in a tube receiving additional material; location of absorbed material following a dermal application. + + target of material addition role is a role realized by an entity into which a material is added in a material addition process + From Branch discussion with BP, AR, MC -- there is a need for the recipient to interact with the administered material. for example, a tooth receiving a filling was not considered to be a target role. + GROUP: Role Branch + OBI + + + target of material addition role + + + + + + + + + + + + + + + + + + + + + + + + + + measure function + A glucometer measures blood glucose concentration, the glucometer has a measure function. + + Measure function is a function that is borne by a processed material and realized in a process in which information about some entity is expressed relative to some reference. + PERSON: Daniel Schober + PERSON: Helen Parkinson + PERSON: Melanie Courtot + PERSON:Frank Gibson + + measure function + + + + + + + + + material transformation objective + The objective to create a mouse infected with LCM virus. The objective to create a defined solution of PBS. + + an objective specifiction that creates an specific output object from input materials. + PERSON: Bjoern Peters + PERSON: Frank Gibson + PERSON: Jennifer Fostel + PERSON: Melanie Courtot + PERSON: Philippe Rocca-Serra + artifact creation objective + GROUP: OBI PlanAndPlannedProcess Branch + + + material transformation objective + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + reverse transcribed polymerase chain reaction + Harmonisation of multi-centre real-time reverse-transcribed PCR results of a candidate prognostic marker in breast cancer: an EU-FP6 supported study of members of the EORTC - PathoBiology Group. + +Span PN, Sieuwerts AM, Heuvel JJ, Spyratos F, Duffy MJ, Eppenberger-Castori S, Vacher S, O'Brien K, McKiernan E, Pierce A, Vuaroqueaux V, Foekens JA, Sweep FC, Martens JW. +Eur J Cancer. 2009 Jan;45(1):74-81. PMID: 19008094 + + reverse transcribe pcr is a process which allow amplification of cDNA during a pcr reaction while the cDNA results from a retrotranscription of messenger RNA isolated from a material entity. + 3/21/10, BP:Modified definition to clarify that this is not the assay, but the material transformation + Philippe Rocca-Serra + RT-PCR + reverse transcription polymerase chain reaction + + reverse transcribed polymerase chain reaction + + + + + + + + + scattered molecular aggregate + the sodium and chloride ions in a glass of salt water + + A scattered molecular aggregate is a material entity that consists of all the molecules of a specific type that are located in some bounded region and which is part of a more massive material entity that has parts that are other such aggregates + PERSON: Alan Ruttenberg + Collective + Discussion in Karslruhe with, among others, Alan Rector, Stefan Schulz, Marijke Keet, Melanie Courtot, and Alan Ruttenberg. With inspiration from the paper Granularity, scale and collectivity: When size does and does not matter, Alan Recto, Jeremy Rogers, Thomas Bittner, Journal of Biomedical Informatics 39 (2006) 333-349 + + scattered molecular aggregate + + + + + + + + + + + + + + + + + material separation objective + The objective to obtain multiple aliquots of an enzyme preparation. The objective to obtain cells contained in a sample of blood. + + is an objective to transform a material entity into spatially separated components. + PPPB branch + PPPB branch + + material separation objective + + + + + + + + + + + + + + + + + + + + + + + + + + + material combination + Mixing two fluids. Adding salt into water. Injecting a mouse with PBS. + + is a material processing with the objective to combine two or more material entities as input into a single material entity as output. + created at workshop as parent class for 'adding material into target', which is asymmetric, while combination encompasses all addition processes. + bp + bp + + + material combination + + + + + + + + + + + + + + + + + + + + + + + + + + + blood specimen + blood drawn from a human for glucose assay + + a material entity derived from a portion of blood collected from an organism + Bjoern Peters + Bjoern Peters + + blood specimen + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + specimen collection process + drawing blood from a patient for analysis, collecting a piece of a plant for depositing in a herbarium, buying meat from a butcher in order to measure its protein content in an investigation + + A planned process with the objective of collecting a specimen. + Note: definition is in specimen creation objective which is defined as an objective to obtain and store a material entity for potential use as an input during an investigation. + Philly2013: A specimen collection can have as part a material entity acquisition, such as ordering from a bank. The distinction is that specimen collection necessarily involves the creation of a specimen role. However ordering cell lines cells from ATCC for use in an investigation is NOT a specimen collection, because the cell lines already have a specimen role. + Philly2013: The specimen_role for the specimen is created during the specimen collection process. + label changed to 'specimen collection process' on 10/27/2014, details see tracker: +http://sourceforge.net/p/obi/obi-terms/716/ + Bjoern Peters + specimen collection + 5/31/2012: This process is not necessarily an acquisition, as specimens may be collected from materials already in posession + 6/9/09: used at workshop + + specimen collection process + + + + + + + + + portioning objective + The objective to obtain multiple aliquots of an enzyme preparation. + + A material separation objective aiming to separate material into multiple portions, each of which contains a similar composition of the input material. + + portioning objective + + + + + + + + + separation into different composition objective + The objective to obtain cells contained in a sample of blood. + + A material separation objective aiming to separate a material entity that has parts of different types, and end with at least one output that is a material with parts of fewer types (modulo impurities). + We should be using has the grain relations or concentrations to distinguish the portioning and other sub-objectives + + separation into different composition objective + + + + + + + + + specimen collection objective + The objective to collect bits of excrement in the rainforest. The objective to obtain a blood sample from a patient. + + A objective specification to obtain a material entity for potential use as an input during an investigation. + Bjoern Peters + Bjoern Peters + + specimen collection objective + + + + + + + + + material combination objective + + is an objective to obtain an output material that contains several input materials. + PPPB branch + bp + + + material combination objective + + + + + + + + + + + + + + + host role + In biology, a host is an organism that harbors a virus or parasite, or a mutual or commensal symbiont, typically providing nourishment and shelter. http://en.wikipedia.org/wiki/Host_(biology) 30 March 09 + + host role is a role played by an organism and realized by providing nourishment, shelter or a means of reproduction to another organism within the organism playing the host role + 30Mar09 virus reproducing inside a cell; bacteria causing a disease, host can be harmed or not. we want to avoid a cat sitting on my lap and an animal care technician; these are not examples or hosts; dental cares = on tooth, but part of outer layer of tooth, so covered by "within" in the definition + GROUP: Role Branch + 30 Mar09 submitted by vaccine community + OBI + http://en.wikipedia.org/wiki/Host_(biology) + + + host role + + + + + + + + + + + + + + + + + + + + + amplified DNA + Amplied DNA created by PCR + + DNA that has been produced in an enzymatic amplification process + PERSON: Alan Ruttenberg + Alan Ruttenberg + + amplified DNA + + + + + + + + + + + + + + + + + + + + measurement device + A ruler, a microarray scanner, a Geiger counter. + + A device in which a measure function inheres. + GROUP:OBI Philly workshop + OBI + + measurement device + + + + + + + + + + + + + + + complementary nucleotide probe role + A primer in a PCR reaction. A probe on an Affymetrix chip. + + A role played by a nucleic acid molecule that is used in a planned process for its ability to bind a nucleic acid molecules with complementary nucleotide sequence + PERSON:Bjoern Peters + + complementary nucleotide probe role + + + + + + + + + + + + + + + + + + + + material separation device + flow cytometer + + A device with a separation function realized in a planed process + + material separation device + + + + + + + + + + + + + + + + + + processed specimen + A tissue sample that has been sliced and stained for a histology study. +A blood specimen that has been centrifuged to obtain the white blood cells. + + A specimen that has been intentionally physically modified. + Bjoern Peters + Bjoern Peters + + A tissue sample that has been sliced and stained for a histology study. + processed specimen + + + + + + + + + + + + + + + + + + + + + device + A voltmeter is a measurement device which is intended to perform some measure function. + An autoclave is a device that sterlizes instruments or contaminated waste by applying high temperature and pressure. + + A material entity that is designed to perform a function in a scientific investigation, but is not a reagent. + 2012-12-17 JAO: In common lab usage, there is a distinction made between devices and reagents that is difficult to model. Therefore we have chosen to specifically exclude reagents from the definition of "device", and are enumerating the types of roles that a reagent can perform. + +2013-6-5 MHB: The following clarifications are outcomes of the May 2013 Philly Workshop. Reagents are distinguished from devices that also participate in scientific techniques by the fact that reagents are chemical or biological in nature and necessarily participate in some chemical interaction or reaction during the realization of their experimental role. By contrast, devices do not participate in such chemical reactions/interactions. Note that there are cases where devices use reagent components during their operation, where the reagent-device distinction is less clear. For example: + +(1) An HPLC machine is considered a device, but has a column that holds a stationary phase resin as an operational component. This resin qualifies as a device if it participates purely in size exclusion, but bears a reagent role that is realized in the running of a column if it interacts electrostatically or chemically with the evaluant. The container the resin is in (“the column”) considered alone is a device. So the entire column as well as the entire HPLC machine are devices that have a reagent as an operating part. + +(2) A pH meter is a device, but its electrode component bears a reagent role in virtue of its interacting directly with the evaluant in execution of an assay. + +(3) A gel running box is a device that has a metallic lead as a component that participates in a chemical reaction with the running buffer when a charge is passed through it. This metallic lead is considered to have a reagent role as a component of this device realized in the running of a gel. + +In the examples above, a reagent is an operational component of a device, but the device itself does not realize a reagent role (as bearing a reagent role is not transitive across the part_of relation). In this way, the asserted disjointness between a reagent and device holds, as both roles are never realized in the same bearer during execution of an assay. + PERSON: Helen Parkinson + instrument + OBI development call 2012-12-17. + + device + + + + + + + + + + + + + + + + + + + + sequence data + example of usage: the representation of a nucleotide sequence in FASTA format used for a sequence similarity search. + + A measurement datum that representing the primary structure of a macromolecule(it's sequence) sometimes associated with an indicator of confidence of that measurement. + + Person:Chris Stoeckert + GROUP: OBI + + sequence data + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + specimen from organism + + A specimen that derives from an anatomical part or substance arising from an organism. Examples of tissue specimen include tissue, organ, physiological system, blood, or body location (arm). + PERSON: Chris Stoeckert, Jie Zheng + tissue specimen + MO_954 organism_part + + specimen from organism + + + + + + + + + value specification + The value of 'positive' in a classification scheme of "positive or negative"; the value of '20g' on the quantitative scale of mass. + + An information content entity that specifies a value within a classification scheme or on a quantitative scale. + This term is currently a descendant of 'information content entity', which requires that it 'is about' something. A value specification of '20g' for a measurement data item of the mass of a particular mouse 'is about' the mass of that mouse. However there are cases where a value specification is not clearly about any particular. In the future we may change 'value specification' to remove the 'is about' requirement. + PERSON:Bjoern Peters + + value specification + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + blood serum specimen + PMID: 18229666.Adv Med Sci. 2007;52 Suppl 1:204-6.Antioxidant activity of blood serum and saliva in patients with periodontal disease treated due to epilepsy. + + A material entity which derives from blood and corresponds to blood plasma without fibrinogen or the other clotting factors. + PERSON: Maura Gasparetto + PERSON: Melanie Courtot + PERSON: Philippe Rocca-Serra + WEB: http://en.wikipedia.org/wiki/Blood_plasma + + blood serum specimen + + + + + + + + + + + + + + + + + + + + organism + animal + fungus + plant + virus + + + A material entity that is an individual living system, such as animal, plant, bacteria or virus, that is capable of replicating or reproducing, growth and maintenance in the right environment. An organism may be unicellular or made up, like humans, of many billions of cells divided into specialized tissues and organs. + 10/21/09: This is a placeholder term, that should ideally be imported from the NCBI taxonomy, but the high level hierarchy there does not suit our needs (includes plasmids and 'other organisms') + 13-02-2009: +OBI doesn't take position as to when an organism starts or ends being an organism - e.g. sperm, foetus. +This issue is outside the scope of OBI. + GROUP: OBI Biomaterial Branch + WEB: http://en.wikipedia.org/wiki/Organism + + + + + + + http://purl.obolibrary.org/obo/obi.owl + obi + OBI:0100026 + organism + organism + + + + + + + + + + + + + + + + + + + + specimen + Biobanking of blood taken and stored in a freezer for potential future investigations stores specimen. + + A material entity that has the specimen role. + Note: definition is in specimen creation objective which is defined as an objective to obtain and store a material entity for potential use as an input during an investigation. + PERSON: James Malone + PERSON: Philippe Rocca-Serra + GROUP: OBI Biomaterial Branch + + specimen + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + data transformation + The application of a clustering protocol to microarray data or the application of a statistical testing method on a primary data set to determine a p-value. + + A planned process that produces output data from input data. + Elisabetta Manduchi + Helen Parkinson + James Malone + Melanie Courtot + Philippe Rocca-Serra + Richard Scheuermann + Ryan Brinkman + Tina Hernandez-Boussard + data analysis + data operation + data processing + Branch editors + + data transformation + + + + + + + + + descriptive statistical calculation objective + + A descriptive statistical calculation objective is a data transformation objective which concerns any calculation intended to describe a feature of a data set, for example, its center or its variability. + Elisabetta Manduchi + James Malone + Melanie Courtot + Monnie McGee + PERSON: Elisabetta Manduchi + PERSON: James Malone + PERSON: Melanie Courtot + PERSON: Monnie McGee + + descriptive statistical calculation objective + + + + + + + + + data transformation objective + normalize objective + + An objective specification to transformation input data into output data + Modified definition in 2013 Philly OBI workshop + James Malone + PERSON: James Malone + + data transformation objective + + + + + + + + + + + + + + + + + + + + + filtration + PMID: 18524968.Filtration of CSF improves isolation of Mycobacteria.J Clin Microbiol. 2008 Jun 4. + + filtration is a process which separates components suspended in a fluid based on granularity properties relying on a filter device + Philippe Rocca-Serra + OBI-Branch: adapted from wikipedia and wordnet + + filtration + + + + + + + + + + + + + + + + + + + + + centrifugation + PMID: 18428461.Purification of oligodendrocytes and their progenitors using immunomagnetic separation and Percoll gradient centrifugation. Curr Protoc Neurosci. 2001 May;Chapter 3:Unit 3.12. + + centrifugation is a process separating molecules by size or density using centrifugal forces generated by a spinning rotor. G-forces of several hundred thousand times gravity are generated in ultracentrifugation + Philippe Rocca-Serra + adapted from http://www.fao.org/DOCREP/003/X3910E/X3910E06.htm + + centrifugation + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + centrifuge + + A device with a rapidly rotating container that applies centrifugal force to its contents + Melanie Courtot + Person: Jennifer Fostel + Trish Whetzel + http://en.wikipedia.org/wiki/Centrifuge + + centrifuge + + + + + + + + + + + + + + + + + + + + + + + + + + + collecting specimen from organism + taking a sputum sample from a cancer patient, taking the spleen from a killed mouse, collecting a urine sample from a patient + + a process with the objective to obtain a material entity that was part of an organism for potential future use in an investigation + PERSON:Bjoern Peters + IEDB + + collecting specimen from organism + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + administering substance in vivo + Balb/c mice received an intracameral or subconjunctival injection of trinitrophenylated spleen cells + injecting mice with 10 ug morphine intranasally, a patient taking two pills of 1 mg aspirin orally + + A process by which a substance is intentionally given to an organism resulting in exposure of the organism to that substance. + 2009-11-10. Tracker: https://sourceforge.net/tracker/?func=detail&aid=2893050&group_id=177891&atid=886178 + Different routes and means of administration should go as children underneath this + Update the definition based on the discussion. Details see the tracker: +https://sourceforge.net/p/obi/obi-terms/738/ + needs roles such as perturber and perturbee (children of input role). Perturb is too strong. Host might be the name for one role. Others considered: Doner, Donated, Acceptor. + Bjoern Peters + Person:Bjoern Peters + IEDB + + + administering substance in vivo + + + + + + + + + + + + + + + + + + + + + + + + + + + material component separation + Using a cell sorter to separate a mixture of T cells into two fractions; one with surface receptor CD8 and the other lacking the receptor, or purification + + a material processing in which components of an input material become segregated in space + Bjoern Peters + IEDB + + material component separation + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + artificially induced reverse transcription + The use of M-MLV reverse transcriptase from the Moloney murine leukemia virus to transcribe an RNA sample into cDNA + + a protocol with the objective to transcribe single-stranded RNA into complementary DNA (cDNA) + It could also be added that the reverse transcriptase is bearer of a GO:0003964 RNA-directed DNA polymerase activity, which is realized in this process. + We need to indicate the relationship between the cDNA generated and the RNA that was used as a template. This may be outside of the OBI scope + PERSON:Kevin Clancy + OBI branch derived + + artificially induced reverse transcription + + + + + + + + + + + + + + + dialysis + the use of a dialysis bag of select pore size to remove salt from collagen isolated from mouse cartilage + + a protocol application that uses diffusion through a semi-permeable membrane to separate an input material into two fractions of different composition + PERSON:Kevin Clancy + OBI branch derived + + dialysis + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + enzymatic amplification + the use of a polymerase chain reaction to amplify a fragment of DNA + + the use of enzymes to increase the number of molecules of a biomaterial + PERSON:Kevin Clancy + OBI branch derived + + enzymatic amplification + + + + + + + + + + + + + + + antigen + + is a material entity that has the antigen role + IEDB + IEDB + + antigen + + + + + + + + + + + + + + + assay antigen role + + Any molecule recognized by the adaptive immune receptors? Recognized means bound with a certain affinity? From GO ag binding:Interacting selectively with an antigen, any substance which is capable of inducing a specific immune response and of reacting with the products of that response, the specific antibody or specifically sensitized T-lymphocytes, or both. Binding may counteract the biological activity of the antigen. see OBI_1110120 below + IEDB + IEDB + + assay antigen role + + + + + + + + + A disposition (i) to undergo pathological processes that (ii) exists in an organism because of one or more disorders in that organism. + + + disease + + + + + + + + + A material entity which is clinically abnormal and part of an extended organism. Disorders are the physical basis of disease. + + + disorder + + + + + + + + + Albert Goldfain + creation date: 2009-06-23T11:53:49Z + + + + bodily process + + + + + + + + + A bodily process that is clinically abnormal. + Albert Goldfain + http://ontology.buffalo.edu/medo/Disease_and_Diagnosis.pdf + creation date: 2009-06-23T11:54:29Z + + + + pathological bodily process + + + + + + + + + The totality of all processes through which a given disease instance is realized. + + + disease course + + + + + + + + + The representation of a conclusion of a diagnostic process. + Albert Goldfain + http://ontology.buffalo.edu/medo/Disease_and_Diagnosis.pdf + creation date: 2009-06-23T12:42:23Z + + + diagnosis + + + + + + + + + An object aggregate consisting of an organism and all material entities located within the organism, overlapping the organism, or occupying sites formed in part by the organism. + + + extended organism + + + + + + + + + A processual entity whose completion is hypothesized (by a healthcare provider) to alleviate the signs and symptoms associated with a disorder + Albert Goldfain + http://code.google.com/p/ogms/issues/detail?id=35 + creation date: 2010-03-31T04:51:11Z + + http://purl.obolibrary.org/obo/ogms.owl + treatment + + + + + + + + + An interpretive process that has as input a clinical picture of a given patient and as output an assertion to the effect that the patient has a disease, disorder, or syndrome of a certain type, or none of these. + Albert Goldfain + http://groups.google.com/group/ogms-discuss/browse_thread/thread/2a7008f311fac766/e7de486c94dfd82e + creation date: 2011-09-20T09:57:44Z + + + diagnostic process + + + + + + + + + human patient + + + + + + + + + The representation of a positive conclusion of a diagnostic process for the COVID-19 coronavirus disease. + Oliver He, Hong Yu + positive COVID-19 diagnosis + + + + + + + + + A physical quality that inheres in a bearer by virtue of the proportion of the bearer's amount of matter. + + http://purl.obolibrary.org/obo/pato.owl + quality + PATO:0000125 + + + + mass + + + + + + + + + viability + An organismal quality inhering in a bearer or a population by virtue of the bearer's ability or inability to survive and develop normally or the number of surviving individuals in a given population. + + + viability + + + + + + + + + A quality which inheres in an process. + + + PATO:0001239 + PATO:0001240 + quality of a process + quality of occurrent + quality of process + relational quality of occurrent + quality + PATO:0001236 + See comments of relational quality of a physical entity. + process quality + + + + + + + + + quality of a single physical entity + A physical object quality which inheres in a single-bearer. + + + quality of a single physical entity + + + + + + + + + physical object quality + A quality which inheres in a continuant. + + + physical object quality + + + + + + + + + organismal quality + A quality that inheres in an entire organism or part of an organism. + + + organismal quality + + + + + + + + + virulence + A quality inhering in a bearer by virtue of the bearer's pathogenicity. + + + virulence + + + + + + + + + protein + A biological macromolecule that is composed of amino acids linked in a linear sequence (a polypeptide chain) and is genetically encoded. Proteins descended from a common ancestor can be classified into families and superfamilies composed of products of evolutionarily-related genes. The domain architecture of a protein is described by the order of its constituent domains. Proteins with the same domains in the same order are defined as homeomorphic. + + + protein + + + + + + + + + + + + + + + + + + + + protein + antithrombin III is a protein + An amino acid chain that is produced de novo by ribosome-mediated translation of a genetically-encoded mRNA, and any derivatives thereof. + + + protein + PR:000000001 + The definition above excludes protein complexes, which some also consider a protein. Those who wish to refer to a class representing both senses of the word are directed to CHEBI:36080. Proteins (in the sense defined here) that descended from a common ancestor can be classified into families and superfamilies composed of products of evolutionarily-related genes. The domain architecture of a protein is described by the order of its constituent domains. Proteins with the same domains in the same order are defined as homeomorphic [PRO:WCB]. + protein + + + + + + + + + + + + + + + An organic amino compound that consists of amino acid residues (unmodified amino-acid residues and/or modified amino-acid residues) linked by peptide bonds or derivatives of such bonds. + + peptide + polypeptide + protein + PR:000018263 + Category=external. + amino acid chain + + + + + + + + + + + + + + + + + + + + + + + + + + A protein that is produced as the result of proteolytic processing of a longer protein. + + ClvPrd + peptide + polypeptide + protein + PR:000018264 + proteolytic cleavage product + + + + + + + + + + + + + + + A part of a protein that is removed during the protein maturation process. + + cleaved_peptide_region + protein + PR:000021935 + immature protein part + + + + + + + + + + + + + + + + + + + + + + + + + + A protein that is encoded in the genome of some virus. + + virus protein + protein + PR:000036197 + viral protein + + + + + + + + + + + + + + + + + + + + + + + + + + A protein that is encoded in the genome of severe acute respiratory syndrome coronavirus 2. + + 2019-nCoV protein + SARS-CoV-2 protein + SARS2 protein + protein + PR:000050262 + severe acute respiratory syndrome coronavirus 2 protein + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A protein that is a translation product of the rep gene in SARS-CoV-2. + + rep (SARS2) + protein + GU280_gp01 + ORF1a-1b + ORF1ab + rep + PR:000050263 + Category=organism-gene. Note: The rep gene produces two translation products, one with (ORF1ab) and one without (ORF1a) -1 ribosomal frameshifting. Both products are further processed by proteolytic cleavage to yield 10 identical chains, while 1 additional chain is unique to ORF1a and 5 additional chains are unique to ORF1ab. + rep gene translation product (SARS-CoV-2) + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + An ORF8 protein (SARS-CoV-2) that has had the signal peptide removed. UniProtKB:P0DTC8, 16-121. + + ORF8/SigPep- (SARS2) + PRO_0000449655 + UniProtKB:P0DTC8, 16-121 + protein + PR:000050264 + Category=organism-modification. + ORF8 protein, signal peptide removed form (SARS-CoV-2) + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A protein 7a (SARS-CoV-2) that has had the signal peptide removed. UniProtKB:P0DTC7, 16-121. + + 7a/SigPep- (SARS2) + PRO_0000449654 + UniProtKB:P0DTC7, 16-121 + protein + PR:000050265 + Category=organism-modification. + protein 7a, signal peptide removed form (SARS-CoV-2) + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A spike glycoprotein (SARS-CoV-2) that has had the signal peptide removed. UniProtKB:P0DTC2, 13-1273. + + PRO_0000449646 + S/SigPep- (SARS2) + UniProtKB:P0DTC2, 13-1273 + protein + PR:000050266 + Category=organism-modification. + spike glycoprotein, signal peptide removed form (SARS-CoV-2) + + + + + + + + + + + + + + + + + + + + + + A spike glycoprotein, signal peptide removed form (SARS-CoV-2) that has been processed by proteolytic cleavage to yield the N-terminal portion. UniProtKB:P0DTC2, 13-685. + + PRO_0000449647 + S1 (SARS2) + UniProtKB:P0DTC2, 13-685 + protein + PR:000050267 + Category=organism-modification. + spike protein S1 (SARS-CoV-2) + + + + + + + + + + + + + + + + + + + + + + A spike glycoprotein, signal peptide removed form (SARS-CoV-2) that has been processed by proteolytic cleavage to yield the C-terminal portion. UniProtKB:P0DTC2, 686-1273. + + PRO_0000449648 + S2 (SARS2) + UniProtKB:P0DTC2, 686-1273 + protein + PR:000050268 + Category=organism-modification. + spike protein S2 (SARS-CoV-2) + + + + + + + + + + + + + + + + + + + + + A spike protein S2 (SARS-CoV-2) that has been further processed by proteolytic cleavage to yield the C-terminal portion. UniProtKB:P0DTC2, 816-1273. + + PRO_0000449649 + S2' (SARS2) + UniProtKB:P0DTC2, 816-1273 + protein + PR:000050269 + Category=organism-modification. + spike protein S2' (SARS-CoV-2) + + + + + + + + + + + + + + + A rep gene proteolytic cleavage product (SARS-CoV-2) that is the portion produced by the enzymatic action of PL-PRO proteinase (nsp3) when it cleaves the precursor between residues 180-181. + + GenPept:YP_009725297 + PRO_0000449619 + PRO_0000449635 + UniProtKB:P0DTC1, 1-180 + UniProtKB:P0DTD1, 1-180 + leader protein (SARS2) + non-structural protein 1 (SARS2) + nsp1 (SARS2) + rep/Clv:nsp1 (SARS2) + protein + PR:000050270 + Category=organism-modification. Note: 180 aa protein. Proteinase inferred from PMID:15564471. + host translation inhibitor nsp1 (SARS-CoV-2) + + + + + + + + + + + + + + + A rep gene proteolytic cleavage product (SARS-CoV-2) that is the portion produced by the enzymatic action of PL-PRO proteinase (nsp3) when it cleaves the precursor between residues 180-181 and 818-819. + + GenPept:YP_009725298 + PRO_0000449620 + PRO_0000449636 + UniProtKB:P0DTC1, 181-818 + UniProtKB:P0DTD1, 181-818 + nsp2 (SARS2) + p65 homolog (SARS2) + rep/Clv:nsp2 (SARS2) + protein + PR:000050271 + Category=organism-modification. Note: 638 aa protein. + non-structural protein 2 (SARS-CoV-2) + + + + + + + + + + + + + + + A rep gene proteolytic cleavage product (SARS-CoV-2) that is the portion produced by the autocatalytic action of PL-PRO proteinase (nsp3) when it cleaves the precursor between residues 818-819 and 2763-2764. + + GenPept:YP_009725299 + PLpro (SARS2) + PRO_0000449621 + PRO_0000449637 + UniProtKB:P0DTC1, 819-2763 + UniProtKB:P0DTD1, 819-2763 + main proteinase (SARS2) + nsp3 (SARS2) + papain-like proteinase (SARS2) + rep/Clv:nsp3 (SARS2) + protein + PL2-PRO (SARS2) + PR:000050272 + Category=organism-modification. Note: 1945 aa protein. Unlike some other coronaviruses, SARS coronaviruses only encode a single papain-like proteinase, PLpro. [PMID:15564471] + non-structural protein 3 (SARS-CoV-2) + + + + + + + + + + + + + + + A rep gene proteolytic cleavage product (SARS-CoV-2) that is the portion produced by the combined actions of PL-PRO proteinase (nsp3) when it cleaves the precursor between residues 2763-2764, and 3CL-PRO (nsp5) when it cleaves the precursor between residues 3263-3264. + + GenPept:YP_009725300 + PRO_0000449622 + PRO_0000449638 + UniProtKB:P0DTC1, 2764-3263 + UniProtKB:P0DTD1, 2764-3263 + nsp4 (SARS2) + rep/Clv:nsp4 (SARS2) + protein + PR:000050273 + Category=organism-modification. Note: 500 aa protein. + non-structural protein 4 (SARS-CoV-2) + + + + + + + + + + + + + + + A rep gene proteolytic cleavage product (SARS-CoV-2) that is the portion produced by the autocatalytic action of 3CL-PRO proteinase (nsp5) when it cleaves the precursor between residues 3263-3264 and 3569-3570. + + GenPept:YP_009725301 + 3CL-PRO (SARS2) + 3CLp (SARS2) + 3CLpro (SARS2) + PRO_0000449623 + PRO_0000449639 + UniProtKB:P0DTC1, 3264-3569 + UniProtKB:P0DTD1, 3264-3569 + nsp5 (SARS2) + picornavirus 3C-like protease (SARS2) + rep/Clv:nsp5 (SARS2) + protein + PR:000050274 + Category=organism-modification. Note: 306 aa protein. + 3C-like proteinase (SARS-CoV-2) + + + + + + + + + + + + + + + A rep gene proteolytic cleavage product (SARS-CoV-2) that is the portion produced by the enzymatic action of 3CL-PRO proteinase (nsp5) when it cleaves the precursor between residues 3569-3570 and 3859-3860. + + GenPept:YP_009725302 + PRO_0000449624 + PRO_0000449640 + UniProtKB:P0DTC1, 3570-3859 + UniProtKB:P0DTD1, 3570-3859 + nsp6 (SARS2) + rep/Clv:nsp6 (SARS2) + protein + PR:000050275 + Category=organism-modification. Note: 290 aa protein. + non-structural protein 6 (SARS-CoV-2) + + + + + + + + + + + + + + + A rep gene proteolytic cleavage product (SARS-CoV-2) that is the portion produced by the enzymatic action of 3CL-PRO proteinase (nsp5) when it cleaves the precursor between residues 3859-3860 and 3942-3943. + + GenPept:YP_009725303 + PRO_0000449625 + PRO_0000449641 + UniProtKB:P0DTC1, 3860-3942 + UniProtKB:P0DTD1, 3860-3942 + nsp7 (SARS2) + rep/Clv:nsp7 (SARS2) + protein + PR:000050276 + Category=organism-modification. Note: 83 aa protein. + non-structural protein 7 (SARS-CoV-2) + + + + + + + + + + + + + + + A rep gene proteolytic cleavage product (SARS-CoV-2) that is the portion produced by the enzymatic action of 3CL-PRO proteinase (nsp5) when it cleaves the precursor between residues 3942-3943 and 4140-4141. + + GenPept:YP_009725304 + PRO_0000449626 + PRO_0000449642 + UniProtKB:P0DTC1, 3943-4140 + UniProtKB:P0DTD1, 3943-4140 + nsp8 (SARS2) + rep/Clv:nsp8 (SARS2) + protein + PR:000050277 + Category=organism-modification. Note: 198 aa protein. + non-structural protein 8 (SARS-CoV-2) + + + + + + + + + + + + + + + A rep gene proteolytic cleavage product (SARS-CoV-2) that is the portion produced by the enzymatic action of 3CL-PRO proteinase (nsp5) when it cleaves the precursor between residues 4140-4141 and 4253-4254. + + GenPept:YP_009725305 + PRO_0000449627 + PRO_0000449643 + UniProtKB:P0DTC1, 4141-4253 + UniProtKB:P0DTD1, 4141-4253 + nsp9 (SARS2) + rep/Clv:nsp9 (SARS2) + protein + PR:000050278 + Category=organism-modification. Note: 113 aa protein. + non-structural protein 9 (SARS-CoV-2) + + + + + + + + + + + + + + + A rep gene proteolytic cleavage product (SARS-CoV-2) that is the portion produced by the enzymatic action of 3CL-PRO proteinase (nsp5) when it cleaves the precursor between residues 4253-4254 and 4392-4393. + + GenPept:YP_009725306 + GFL (SARS2) + PRO_0000449628 + PRO_0000449644 + UniProtKB:P0DTC1, 4254-4392 + UniProtKB:P0DTD1, 4254-4392 + growth factor-like peptide (SARS2) + nsp10 (SARS2) + rep/Clv:nsp10 (SARS2) + protein + PR:000050279 + Category=organism-modification. Note: 139 aa protein. + non-structural protein 10 (SARS-CoV-2) + + + + + + + + + + + + + + + An ORF1a proteolytic cleavage product (SARS-CoV-2) that is the portion produced by the enzymatic action of 3CL-PRO proteinase (nsp5) when it cleaves the precursor between residues 4392-4393 and 4405-4406. UniProtKB:P0DTC1, 4393-4405. + + GenPept:YP_009725312 + PRO_0000449645 + UniProtKB:P0DTC1, 4393-4405 + nsp11 (SARS2) + rep/Clv:nsp11 (SARS2) + protein + PR:000050280 + Category=organism-modification. Note: 13 aa protein. + non-structural protein 11 (SARS-CoV-2) + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A rep gene translation product (SARS-CoV-2) that has been processed by proteolytic cleavage. + + rep/ClvPrd (SARS2) + protein + PR:000050281 + Category=organism-modification. + rep gene proteolytic cleavage product (SARS-CoV-2) + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A replicase polyprotein 1a (SARS-CoV-2) that has been processed by proteolytic cleavage. + + ORF1a/ClvPrd (SARS2) + protein + PR:000050282 + Category=organism-modification. + ORF1a proteolytic cleavage product (SARS-CoV-2) + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A replicase polyprotein 1ab (SARS-CoV-2) that has been processed by proteolytic cleavage. + + ORF1ab/ClvPrd (SARS2) + protein + PR:000050283 + Category=organism-modification. + ORF1ab proteolytic cleavage product (SARS-CoV-2) + + + + + + + + + + + + + + + An ORF1ab proteolytic cleavage product (SARS-CoV-2) that is the portion produced by the enzymatic action of 3CL-PRO proteinase (nsp5) when it cleaves the precursor between residues 4392-4393 and 5324-5325. + + GenPept:YP_009725307 + ORF1ab/Clv:nsp12 (SARS2) + PRO_0000449629 + Pol (SARS2) + RdRp (SARS2) + UniProtKB:P0DTD1, 4393-5324 + nsp12 (SARS2) + protein + PR:000050284 + Category=organism-modification. Note: 932 aa protein. + RNA-directed RNA polymerase (SARS-CoV-2) + + + + + + + + + + + + + + + An ORF1ab proteolytic cleavage product (SARS-CoV-2) that is the portion produced by the enzymatic action of 3CL-PRO proteinase (nsp5) when it cleaves the precursor between residues 5324-5325 and 5925-5926. + + GenPept:YP_009725308 + Hel (SARS2) + ORF1ab/Clv:nsp13 (SARS2) + PRO_0000449630 + UniProtKB:P0DTD1, 5325-5925 + nsp13 (SARS2) + protein + PR:000050285 + Category=organism-modification. Note: 601 aa protein. + helicase (SARS-CoV-2) + + + + + + + + + + + + + + + An ORF1ab proteolytic cleavage product (SARS-CoV-2) that is the portion produced by the enzymatic action of 3CL-PRO proteinase (nsp5) when it cleaves the precursor between residues 5925-5926 and 6452-6453. + + GenPept:YP_009725309 + ExoN (SARS2) + ORF1ab/Clv:nsp14 (SARS2) + PRO_0000449631 + UniProtKB:P0DTD1, 5926-6452 + nsp14 (SARS2) + 3'-to-5' exonuclease (SARS2) + guanine-N7 methyltransferase (SARS2) + protein + PR:000050286 + Category=organism-modification. Note: 527 aa protein. + bifunctional exonuclease/methyltransferase (SARS-CoV-2) + + + + + + + + + + + + + + + An ORF1ab proteolytic cleavage product (SARS-CoV-2) that is the portion produced by the enzymatic action of 3CL-PRO proteinase (nsp5) when it cleaves the precursor between residues 6452-6453 and 6798-6799. + + GenPept:YP_009725310 + NendoU (SARS2) + ORF1ab/Clv:nsp15 (SARS2) + PRO_0000449632 + UniProtKB:P0DTD1, 6453-6798 + endoRNAse (SARS2) + nsp15 (SARS2) + protein + PR:000050287 + Category=organism-modification. Note: 346 aa protein. + uridylate-specific endoribonuclease (SARS-CoV-2) + + + + + + + + + + + + + + + An ORF1ab proteolytic cleavage product (SARS-CoV-2) that is the portion produced by the enzymatic action of 3CL-PRO proteinase (nsp5) when it cleaves the precursor between residues 6798-6799. + + GenPept:YP_009725311 + 2'-O-ribose methyltransferase (SARS2) + ORF1ab/Clv:nsp16 (SARS2) + PRO_0000449633 + UniProtKB:P0DTD1, 6799-7096 + nsp16 (SARS2) + protein + PR:000050288 + Category=organism-modification. Note: 298 aa protein. + 2'-O-methyltransferase (SARS-CoV-2) + + + + + + + + + + + + + + + A rep gene proteolytic cleavage product (SARS-CoV-2) that is the portion produced by the enzymatic action of PL-PRO proteinase (nsp3) when it cleaves the precursor between residues 180-181 and 2763-2764. + + UniProtKB:P0DTC1, 181-2763 + UniProtKB:P0DTD1, 181-2763 + nsp2-nsp3 (SARS2) + rep/Clv:nsp2-3 (SARS2) + protein + PR:000050289 + Category=organism-modification. Note: Inferred from PMID:15564471. + NSP2-3 intermediate (SARS-CoV-2) + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A protein that is a translation product of the ORF10 gene in SARS-CoV-2. + + GenPept:YP_009725255 + UniProtKB:A0A663DJA2 + ORF10 (SARS2) + protein + GU280_gp11 + ORF10 + PR:A0A663DJA2 + Category=organism-gene. Note: 38 aa protein. + ORF10 protein (SARS-CoV-2) + + + + + + + + + + + + + + + A rep gene translation product (SARS-CoV-2) that is a translation product of some mRNA giving rise to a protein with the amino acid sequence represented by UniProtKB:P0DTC1-1. + + PR:P0DTC1 + GenPept:YP_009725295 + UniProtKB:P0DTC1 + ORF1a polyprotein (SARS2) + PRO_0000449634 + pp1a (SARS2) + rep/iso:ORF1a (SARS2) + protein + PR:P0DTC1-1 + Category=organism-sequence. Note: 4405 aa protein. Undergoes additional processing by proteolytic cleavage. + replicase polyprotein 1a (SARS-CoV-2) + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A protein that is a translation product of the S gene in SARS-CoV-2. + + GenPept:YP_009724390 + UniProtKB:P0DTC2 + E2 (SARS2) + S (SARS2) + S glycoprotein (SARS2) + peplomer protein (SARS2) + surface glycoprotein (SARS2) + protein + GU280_gp02 + S + PR:P0DTC2 + Category=organism-gene. Note: 1273 aa protein. Undergoes additional processing by proteolytic cleavage. + spike glycoprotein (SARS-CoV-2) + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A protein that is a translation product of the ORF3a gene in SARS-CoV-2. + + GenPept:YP_009724391 + UniProtKB:P0DTC3 + ORF3a (SARS2) + PRO_0000449650 + accessory protein 3a (SARS2) + protein U274 (SARS2) + protein X1 (SARS2) + protein + GU280_gp03 + ORF3a + PR:P0DTC3 + Category=organism-gene. Note: 275 aa protein. + protein 3a (SARS-CoV-2) + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A protein that is a translation product of the E gene in SARS-CoV-2. + + GenPept:YP_009724392 + UniProtKB:P0DTC4 + E (SARS2) + E protein (SARS2) + PRO_0000449651 + envelope protein (SARS2) + sM protein (SARS2) + protein + E + GU280_gp04 + ORF4 + PR:P0DTC4 + Category=organism-gene. Note: 75 aa protein. + envelope small membrane protein (SARS-CoV-2) + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A protein that is a translation product of the M gene in SARS-CoV-2. + + GenPept:YP_009724393 + UniProtKB:P0DTC5 + E1 glycoprotein (SARS2) + M (SARS2) + M protein (SARS2) + PRO_0000449652 + matrix glycoprotein (SARS2) + membrane glycoprotein (SARS2) + protein + GU280_gp05 + M + ORF5 + PR:P0DTC5 + Category=organism-gene. Note: 222 aa protein. + membrane protein (SARS-CoV-2) + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A protein that is a translation product of the ORF6 gene in SARS-CoV-2. + + GenPept:YP_009724394 + UniProtKB:P0DTC6 + ORF6 (SARS2) + PRO_0000449653 + accessory protein 6 (SARS2) + ns6 (SARS2) + protein X3 (SARS2) + protein + GU280_gp06 + ORF6 + non-structural protein 6 (SARS2) + PR:P0DTC6 + Category=organism-gene. Note: 61 aa protein. + ORF6 protein (SARS-CoV-2) + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A protein that is a translation product of the ORF7a gene in SARS-CoV-2. + + GenPept:YP_009724395 + UniProtKB:P0DTC7 + ORF7a (SARS2) + accessory protein 7a (SARS2) + protein U122 (SARS2) + protein X4 (SARS2) + protein + GU280_gp07 + ORF7a + PR:P0DTC7 + Category=organism-gene. Note: 121 aa protein. + protein 7a (SARS-CoV-2) + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A protein that is a translation product of the ORF8 gene in SARS-CoV-2. + + GenPept:YP_009724396 + UniProtKB:P0DTC8 + ORF8 (SARS2) + ns8 (SARS2) + protein + GU280_gp09 + ORF8 + non-structural protein 8 (SARS2) + PR:P0DTC8 + Category=organism-gene. Note: 121 aa protein. + ORF8 protein (SARS-CoV-2) + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A protein that is a translation product of the N gene in SARS-CoV-2. + + GenPept:YP_009724397 + UniProtKB:P0DTC9 + N (SARS2) + NC (SARS2) + PRO_0000449656 + nucleocapsid protein (SARS2) + protein N (SARS2) + protein + GU280_gp10 + N + ORF9 + PR:P0DTC9 + Category=organism-gene. Note: 419 aa protein. + nucleoprotein (SARS-CoV-2) + + + + + + + + + + + + + + + A rep gene translation product (SARS-CoV-2) that is a translation product of some mRNA giving rise to a protein with the amino acid sequence represented by UniProtKB:P0DTD1-1. Requires ribosomal frameshifting. + + PR:P0DTD1 + GenPept:YP_009724389 + UniProtKB:P0DTD1 + ORF1ab polyprotein (SARS2) + PRO_0000449618 + pp1ab (SARS2) + rep/iso:ORF1ab (SARS2) + protein + PR:P0DTD1-1 + Category=organism-sequence. Note: 7096 aa protein. Undergoes additional processing by proteolytic cleavage. + replicase polyprotein 1ab (SARS-CoV-2) + + + + + + + + + + + + + + + A protein that is a translation product of the ORF9b gene in SARS-CoV-2. + + UniProtKB:P0DTD2 + ORF-9b (SARS2) + ORF9b (SARS2) + PRO_0000449657 + accessory protein 9b (SARS2) + protein + ORF9b + PR:P0DTD2 + Category=organism-gene. Note: 97 aa protein. + protein 9b (SARS-CoV-2) + + + + + + + + + + + + + + + A protein that is a translation product of the ORF14 gene in SARS-CoV-2. + + UniProtKB:P0DTD3 + ORF14 (SARS2) + PRO_0000449658 + protein + ORF14 + PR:P0DTD3 + Category=organism-gene. Note: 73 aa protein. + uncharacterized protein 14 (SARS-CoV-2) + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A protein that is a translation product of the ORF7b gene in SARS-CoV-2. + + GenPept:YP_009725318 + UniProtKB:P0DTD8 + ORF7b (SARS2) + PRO_0000449799 + accessory protein 7b (SARS2) + non-structural protein 7b (SARS2) + ns7b (SARS2) + protein + GU280_gp08 + ORF7b + PR:P0DTD8 + Category=organism-gene. Note: 43 aa protein. + protein 7b (SARS-CoV-2) + + + + + + + + + region + A sequence_feature with an extent greater than zero. A nucleotide region is composed of bases and a polypeptide region is composed of amino acids. + primary structure of sequence macromolecule + sequence + + + region + + + + + + + + + + protein-coding + sequence + SO:0000010 + protein_coding + + + + + + + + An extent of biological sequence. + + located_sequence_feature + sequence feature + sequence + located sequence feature + SO:0000110 + sequence_feature + + + + + + + + + + signal peptide + sequence + signal + SO:0000418 + The signal peptide can be cleaved either co- or post-translationally. For this reason, we do not use the derives_from relation when defining protein forms lacking the signal peptide (because the precursor form might not yet exist at the time of removal). + signal_peptide + + + + + + + + + A region (or regions) that includes all of the sequence elements necessary to encode a functional transcript. A gene may include regulatory regions, transcribed regions and/or other functional sequence regions. + + sequence + SO:0000704 + gene + + + + + + + + + + + + + + + + protein coding gene + sequence + SO:0001217 + protein_coding_gene + + + + + + + + + A process that is the means during which the pathogen is transmitted directly or indirectly from its natural reservoir, a susceptible host or source to a new host. + Suggested definition: A process by which a pathogen passes from one host organism to a second host organism of the same Species. + Suggested label: pathogen transmission process + + + Transmission Ontology: http://purl.obolibrary.org/obo/trans.owl + transmission process + + + + + + + + + + + + The olfactory organ of vertebrates, consisting of nares, olfactory epithelia and the structures and skeletal framework of the nasal cavity. + + Organ that is the specialized structure of the face that contains olfactory neurons. The peripheral olfactory organ is paired[ZFA:0000047]. + a protuberance in vertebrates that houses the nostrils, or nares, which admit and expel air for respiration in conjunction with the mouth. Behind the nose are the olfactory mucosa and the sinuses. Behind the nasal cavity, air next passes through the pharynx, shared with the digestive system, and then into the rest of the respiratory system. In humans, the nose is located centrally on the face; on most other mammals, it is on the upper tip of the snout[WP]. GO: The nose is the specialized structure of the face that serves as the organ of the sense of smell and as part of the respiratory system. Includes the nasi externus (external nose) and cavitas nasi (nasal cavity)[Wikipedia:Nose]. + the organ that is specialized for smell and is part of the respiratory system + the structure of the nose varies across vertebrates. In tetrapods the nose is part of the respiratory system.[PMID:25312359] + + + + BTO:0000840 + CALOHA:TS-2037 + EHDAA2:0001274 + EHDAA:1502 + EMAPA:16542 + EV:0100037 + EV:0100370 + FMA:46472 + GAID:77 + MA:0000281 + MAT:0000139 + MESH:D009666 + MIAA:0000139 + NCIT:C12756 + OpenCyc:Mx4rvViCbJwpEbGdrcN5Y29ycA + TAO:0000047 + UMLS:C0028429 + ZFA:0000047 + galen:Nose + nasal sac + nose + peripheral olfactory organ + uberon + nasus + olfactory apparatus + proboInOwlscis + UBERON:0000004 + + + + + + nose + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + Any portion of the organ that covers that body and consists of a layer of epidermis and a layer of dermis. + Note the distinction between the entire skin of the body, of which there is only 1 in an organism, and zones of skin, of which there can be many. Examples: skin of knee + + + (...) it is well-established that neural crest cells contribute to both the dermal skeleton (craniofacial bone, teeth, and the caudal fin rays of teleosts) and the integument, including craniofacial dermis and all pigment cells outside the retina (...).[well established][VHOG] + we assume that mouse, HOG and GAID all mean zone of skin when they say skin. We also choose skin as an exact synonym, as it is more intuitive + + + EHDAA2:0001844 + EHDAA:6530 + EMAPA:17525 + EV:0100152 + FMA:86166 + GAID:933 + MA:0000151 + MAT:0000284 + MESH:D012867 + MIAA:0000284 + OpenCyc:Mx4rvVjX3ZwpEbGdrcN5Y29ycA + VHOG:0000860 + portion of skin + region of skin + skin + skin region + skin zone + uberon + UBERON:0000014 + + zone of skin + + + + + + + + + + + A non-material anatomical entity of two dimensions. Anatomical boundaries are contiguous structures. + + + AEO:0000192 + CARO:0000010 + FMA:50705 + uberon + UBERON:0000015 + + + Except in the case of abstracted fiat boundaries such as the midline plane of an organism, all 2D anatomical entities have a 3 dimensional projection. For example, the surface of the shell of a muscle has a distinct shape that projects into the third dimension. Note that boundaries are 2D structures. They have no thickness - and so can not be sites of gene expression or gene product localisation. For this, use boundary region terms. + anatomical boundary + + + + + + + + + + + + + + + Any hollow cylindrical anatomical structure containing a lumen through which substances are transported. + not every anatomical conduit is a tube - for example, a bone foramen is an opening in the bone, and there is no distinct separate tube structure. Tubes may transport large mixed objects (for example, a bolus of food in the digestive tube) or they may transport the secretions of a single gland (for example, gland ducts) + + + tubular + galen:Tube + anatomical tube + duct + uberon + UBERON:0000025 + tube + + + + + + + + + Major subdivision of an organism that protrudes from the body[DOS, CARO]. + + + An appendage is an external body part, or natural prolongation, that protrudes from an organism's body, such as a vertebrate's limbs[BILA][BILA:0000018]. + Organ or organ part that is attached to the body of an organism. For example a limb[GO, modified][GO:0048736]. + appendicular + this is currently a subtype of organism subdivision - which would exclude feathers + + + + + AEO:0000193 + BILA:0000018 + BTO:0001492 + CARO:0010003 + EFO:0000799 + EHDAA2:0003193 + EV:0100155 + FBbt:00007000 + HAO:0000144 + MAT:0000023 + MESH:D005121 + MIAA:0000023 + OpenCyc:Mx4rvViC-JwpEbGdrcN5Y29ycA + UMLS:C0598782 + VSAO:0000075 + XAO:0000218 + uberon + appendages + extremitaet + extremity + limbs/digits/tail + UBERON:0000026 + + + + + appendage + + + + + + + + + + + + + + + + + + + + + The head is the anterior-most division of the body [GO]. + + + Organism subdivision that is the part of the body consisting of the cranial and pharyngeal regions.[AAO] + Organism subdivision which is the part of the body which consists of the cranial and pharygeal regions.[TAO] + Vertebrate evolution has been characterized by a fresh and vast array of cranial structures that collectively form the head.[well established][VHOG] + + + + + + + AAO:0010335 + AEO:0000106 + BILA:0000115 + BTO:0000282 + CALOHA:TS-0436 + EFO:0000964 + EHDAA2:0003106 + EMAPA:31858 + FBbt:00000004 + FMA:7154 + GAID:61 + HAO:0000397 + MA:0000023 + MAT:0000294 + MESH:D006257 + MIAA:0000294 + OpenCyc:Mx4rEOLm4rgPEdmAAAACs6hRjg + OpenCyc:Mx4rvVi6YJwpEbGdrcN5Y29ycA + SPD:0000016 + TAO:0001114 + TGMA:0000002 + UMLS:C0018670 + VHOG:0001644 + WBbt:0005739 + XAO:0003024 + ZFA:0001114 + galen:Head + head (volume) + adult head + uberon + cephalic area + UBERON:0000033 + + + + + + + head + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + multi-tissue structure that is comprised of a secretory epithelial layer (mesothelium) and a connective tissue layer. + + + A multi-tissue structure that is comprised of a secretory epithelial layer and a connective tissue layer.[TAO] + a smooth membrane consisting of a thin layer of cells which excrete serous fluid. Serous membranes line and enclose several body cavities, known as serous cavities, where they secrete a lubricating fluid which reduces friction from muscle movement. Serosa is not to be confused with adventitia, a connective tissue layer which binds together structures rather than reducing friction between them. Each serous membrane is composed of a secretory epithelial layer and a connective tissue layer underneath. The epithelial layer, known as mesothelium, consists of a single layer of avascular flat nucleated cells (cuboidal epithelium) which produce the lubricating serous fluid. This fluid has a consistency similar to thin mucus. These cells are bound tightly to the underlying connective tissue. The connective tissue layer provides the blood vessels and nerves for the overlying secretory cells, and also serves as the binding layer which allows the whole serous membrane to adhere to organs and other structures.[WP] + in FMA, SM = mesothelium + connective tissue. It excludes the cavity. Serous sac = SM + cavity. Note that the SM is a subtype of wall in FMA. + + + + + + FMA:9581 + GAID:19 + MESH:D012704 + TAO:0005425 + UMLS:C0036760 + ZFA:0005425 + tunica serosa + wall of serous sac + uberon + serosa + UBERON:0000042 + + + serous membrane + + + + + + + + + + + + + + + + + A tubular structure that contains, conveys body fluid, such as blood or lymph. + + + uberon + UBERON:0000055 + + + + vessel + + + + + + + + + + + + + + + + + + + + + + + + + + + A tubular structure that transports secreted or excreted substances. + + + A tube shaped portion of tissue lined with epithelial cells that collects secretions and routes them to their destination[ZFA:0005171]. + Most ducts, but not all, are exocrine gland ducts. Some ontologies classify structures such as the oviduct here. + + + + + AAO:0011123 + FBbt:00100314 + FMA:30320 + TAO:0005171 + UMLS:C0687028 + XAO:0004000 + ZFA:0005171 + galen:Duct + anatomical duct + exocrine duct + exocrine gland duct + uberon + ducts + UBERON:0000058 + + + duct + + + + + + + + + + + + + + + + + + + + + Organ component adjacent to an organ cavity and which consists of a maximal aggregate of organ component layers. + + + in FMA, serosa is a wall + UBERON:0009915 + wall + EMAPA:25036 + FMA:82482 + galen:Wall + wall of organ + uberon + organ wall + UBERON:0000060 + + + anatomical wall + + + + + + + + + + + + + + + + + + + + + Material anatomical entity that is a single connected structure with inherent 3D shape generated by coordinated expression of the organism's own genome. + + + + + AAO:0010825 + AEO:0000003 + BILA:0000003 + CARO:0000003 + EHDAA2:0003003 + EMAPA:0 + FBbt:00007001 + FMA:305751 + FMA:67135 + GAID:781 + HAO:0000003 + MA:0003000 + MESH:D000825 + TAO:0000037 + TGMA:0001823 + VHOG:0001759 + WBbt:0000100 + XAO:0003000 + ZFA:0000037 + biological structure + connected biological structure + uberon + UBERON:0000061 + + + anatomical structure + + + + + + + + + + + + + + + + + + + + + + + + + + + Anatomical structure that performs a specific function or group of functions [WP]. + + + + Organs are commonly observed as visibly distinct structures, but may also exist as loosely associated clusters of cells that work together to perform a specific function or functions. + CARO v1 does not include a generic 'organ' class, only simple and compound organ. CARO v2 may include organ, see https://github.com/obophenotype/caro/issues/4 + + + + + + BIRNLEX:4 + CARO:0020004 + EFO:0000634 + EMAPA:35949 + ENVO:01000162 + FMA:67498 + MA:0003001 + NCIT:C13018 + OpenCyc:Mx4rv5XMb5wpEbGdrcN5Y29ycA + OpenCyc:Mx4rwP3iWpwpEbGdrcN5Y29ycA + UMLS:C0178784 + WBbt:0003760 + uberon + anatomical unit + body organ + element + UBERON:0000062 + + + organ + + + + + + + + + A part of an organ that constitutes a distinct modular sub-unit. In some cases, the organ may also contain other sub-units of identical or similar types, in other cases this may be a distinct entity. + FMA distinguishes segment from zone by whether the fiat boundaries are fixed/anchored (segments) or floating (zone). It's not completely clear how to apply this distinction + + + Organ region with one or more anchored fiat boundaries. Examples: artery, trunk of nerve, cervical part of esophagus, pelvic part of vagina, horn of thyroid cartilage, anterior segment of eyeball. + Organ region with one or more fixed or anchored fiat boundaries. Examples: artery, trunk of nerve, cervical part of esophagus, pelvic part of vagina, horn of thyroid cartilage, anterior segment of eyebal. + FMA:86140 + uberon + organ region with fixed fiat boundary + organ segment + segment of organ + UBERON:0000063 + + + organ subunit + + + + + + + + + + + + + + + A multicellular structure that is a part of an organ. + currently defined in a very broad sense, may be replaced by more specific classes in the future + + + + + + AAO:0011124 + BIRNLEX:16 + EFO:0000635 + FMA:82472 + cardinal organ part + uberon + regional part of organ + UBERON:0000064 + + + + + + organ part + + + + + + + + + + + + + + + + + + + + + + + + + + + The stage of development at which the animal is fully formed, including immaturity and maturity. Includes both sexually immature stage, and adult stage. + + + adult stage + BTO:0001043 + BilaDO:0000004 + EFO:0001272 + FBdv:00005369 + WBls:0000041 + XtroDO:0000084 + fully formed animal stage + juvenile-adult stage + uberon + UBERON:0000066 + + fully formed stage + + + + + + + + + + + + + + + + + + + + + + + + + + + A stage that is part of the embryo stage. + + + embryonic stage part + uberon + UBERON:0000067 + + + embryo stage part + + + + + + + + + + + + + + + + + + + + + + + + + + + A life cycle stage that starts with fertilization and ends with the fully formed embryo. + + + + BilaDO:0000002 + EV:0300001 + FBdv:00005289 + FMA:72652 + HsapDv:0000002 + MmusDv:0000002 + OGES:000000 + OGES:000022 + WBls:0000003 + WBls:0000092 + WBls:0000102 + XAO:1000012 + embryonic stage + uberon + embryogenesis + UBERON:0000068 + embryo stage + + + + + + + + + + + + + + + + + + + + + End of the life of an organism. + + + ncit:Death is an outcome + XAO:0000437 + XtroDO:0000085 + uberon + death + UBERON:0000071 + death stage + + + + + + + + + + + + + + + + + + + + + Anatomical cluster consisting of the skeletal elements and articular elements that are part of an individual subdivision of the organism. + + + UBERON:0010322 + + + + FMA:85544 + UMLS:C1519343 + galen:ComplexSkeletalStructure + skeletal system subdivision + uberon + skeletal system part + UBERON:0000075 + + + subdivision of skeletal system + + + + + + + + + + + + + + + + + + + + + + The surface (external) layer of ectoderm which begins to proliferate shortly after separation from the neuroectoderm. + merge with non-neural. In vertebrates, the ectoderm has three parts: external ectoderm (also known as surface ectoderm), the neurectoderm (neural crest, and neural tube) + + + (or external ectoderm) forms the following structures: Skin Epithelium of the mouth and nasal cavity saliavary glands, and glands of mouth and nasal cavity Enamel - as a side note dentin and dental pulp are formed from ectomesenchyme which is derived from ectoderm Epithelium of pineal and pituitary glands Lens and cornea of the eye Apical ectodermal ridge inducing development of the limb buds of the embryo. Sensory receptors in epidermis + + + + EHDAA2:0001968 + EHDAA:1494 + EHDAA:350 + EHDAA:4784 + EHDAA:4790 + EHDAA:4796 + EHDAA:7860 + EMAPA:16096 + FMA:87656 + UMLS:C1515087 + surface (external) ectoderm + surface ectoderm + uberon + UBERON:0000076 + + external ectoderm + + + + + + + + + + + + + + + + + + + + + + stage succeeding embryo, including mature structure + + + In birds, the postnatal stage begins when the beak penetrates the shell (i.e., external pipping) (Brown et al. 1997) + BilaDO:0000003 + OGES:000010 + OGES:000014 + OGES:000024 + WBls:0000022 + WBls:0000093 + WBls:0000103 + postembryonic stage + post-hatching stage + uberon + postembryonic + UBERON:0000092 + post-embryonic stage + + + + + + + + + + + + + + + + Nonparenchymatous organ that primarily consists of dense connective tissue organized into a sheet which interconnects two or more organs, separates two or more body spaces from one another, or surrounds an organ or body part. Examples: interosseous membrane of forearm, obturator membrane, tympanic membrane, fibrous pericardium, fascia lata, dura mater. [FMA] + + + cjm + 2009-07-30T05:19:13Z + membrane + FMA:7145 + membrane of organ + uberon + UBERON:0000094 + membrane organ + + + + + + + + + + + + + + + + + + + + + + + + + + + An entire span of an organism's life, commencing with the zygote stage and ending in the death of the organism. + + + FBdv:00000000 + HsapDv:0000001 + MmusDv:0000001 + OGES:000011 + ncithesaurus:Life + entire life cycle + entire lifespan + life + lifespan + uberon + UBERON:0000104 + + life cycle + + + + + + + + + + + + + + + + A spatiotemporal region encompassing some part of the life cycle of an organism. + this class represents a proper part of the life cycle of an organism. The class 'life cycle' should not be placed here + + + the WBls class 'all stages' belongs here as it is the superclass of other WBls stages + we map the ZFS unknown stage here as it is logically equivalent to saying *some* life cycle stage + BILS:0000105 + EFO:0000399 + FBdv:00007012 + FMA:24120 + HsapDv:0000000 + MmusDv:0000000 + OlatDv:0000010 + PdumDv:0000090 + WBls:0000002 + XAO:1000000 + ZFS:0000000 + ZFS:0100000 + ncithesaurus:Developmental_Stage + developmental stage + stage + uberon + UBERON:0000105 + + + + life cycle stage + + + + + + + + + + + + + + + + + + + + + A stage at which the organism is a single cell produced by means of sexual reproduction. + + + As in all metazoans, eumetazoan development begins with a fertilized egg, or zygote.[well established][VHOG] + + + BILS:0000106 + BilaDO:0000005 + EFO:0001322 + EHDAA:27 + EMAPA:16033 + FBdv:00005288 + PdumDv:0000100 + VHOG:0000745 + XAO:1000001 + ZFS:0000001 + 1-cell stage + fertilized egg stage + one cell stage + uberon + fertilized egg stage + one-cell stage + zygote + zygotum + UBERON:0000106 + + zygote stage + + + + + + + + + + + + + + + + + + + + + The first few specialized divisions of an activated animal egg; Stage consisting of division of cells in the early embryo. The zygotes of many species undergo rapid cell cycles with no significant growth, producing a cluster of cells the same size as the original zygote. The different cells derived from cleavage are called blastomeres and form a compact mass called the morula. Cleavage ends with the formation of the blastula. + + + + BILS:0000107 + BilaDO:0000006 + EFO:0001290 + FBdv:00000054 + MESH:A16.254.270 + MmusDv:0000004 + OGES:000015 + OGES:000020 + PdumDv:0000200 + XAO:1000004 + ZFS:0000046 + uberon + UBERON:0000107 + + cleavage stage + + + + + + + + + + + + + + + + + + + + + An early stage of embryonic development in animals. It is produced by cleavage of a fertilized ovum and consists of a spherical layer of around 128 cells surrounding a central fluid-filled cavity called the blastocoel. The blastula follows the morula and precedes the gastrula in the developmental sequence. + consider adding a preceding stage 'morula stage' as part of cleavage + + + + BILS:0000108 + BilaDO:0000007 + EFO:0001282 + HsapDv:0000006 + MmusDv:0000007 + OGES:000003 + OGES:000016 + OGES:000021 + OpenCyc:Mx4rEetFnKP2EdqAAAACs4vPlg + WBls:0000005 + XAO:1000003 + ZFS:0000045 + uberon + UBERON:0000108 + + blastula stage + + + + + + + + + + + + + + + + + + + + + + A stage defined by complex and coordinated series of cellular movements that occurs at the end of cleavage during embryonic development of most animals. The details of gastrulation vary from species to species, but usually result in the formation of the three primary germ layers, ectoderm, mesoderm and endoderm. + + + BILS:0000109 + BilaDO:0000008 + EFO:0001296 + FBdv:00005317 + HsapDv:0000010 + MmusDv:0000013 + OGES:000004 + OGES:000019 + WBls:0000010 + XAO:1000005 + ZFS:0000047 + uberon + blastocystis trilaminaris stage + trilaminar blastocyst stage + trilaminar blastoderm stage + trilaminar disk stage + trilaminar germ stage + trilaminar stage + UBERON:0000109 + + gastrula stage + + + + + + + + + + + + + + + + + + + + + Staged defined by the formation of a tube from the flat layer of ectodermal cells known as the neural plate. This will give rise to the central nervous system. + + + BILS:0000110 + BilaDO:0000009 + HsapDv:0000012 + MmusDv:0000017 + XAO:1000006 + uberon + UBERON:0000110 + neurula stage + + + + + + + + + + + + + + + + + + + + + + A stage at which the ectoderm, endoderm, and mesoderm develop into the internal organs of the organism. + + + + BILS:0000111 + BilaDO:0000010 + HsapDv:0000015 + MmusDv:0000018 + OGES:000005 + OGES:000032 + uberon + segmentation stage + UBERON:0000111 + organogenesis stage + + + + + + + + + + + A tube in the respiratory system. Examples: bronchus, bronchiole, trachea. + + in GO lung development is part of respiratory tube development. This can lead to inconsistencies with other ontologies, e.g. VT. The GO structure may be better represented by a tree of tubes (see the FMA class) + EMAPA:37946 + FMA:12224 + segment of tracheobronchial tree + respiratory conducting tube + segment of tracheobronchial tree + tracheobronchial tree segment + uberon + airway + UBERON:0000117 + respiratory tube + + + + + + + + + + + + + + + + + uberon + UBERON:0000153 + anterior region of body + + + + + + + + + + + uberon + UBERON:0000154 + posterior region of body + + + + + + + + + Segment of the alimentary canal extending from the stomach to the anus and, in humans and other mammals, consists of two segments, the small intestine and the large intestine. + This class is probably too inclusive + + Portion of the alimentary canal bounded anteriorly by the pyloric sphincter and posteriorly by the cloacal sphincter.[AAO] + The tract of the alimentary canal. [Dorian_AF, Elsevier's_encyclopaedic_dictionary_of_medicine, Part_B:_Anatomy_(1988)_Amsterdam_etc.:_Elsevier][VHOG] + intestinal + In zebrafish, No stomach, small intestine, or large intestine can be distinguished. However, differences can be found in the morphology of the mucosa columnar epithelial cells and the number of goblet cells, suggesting functional differentiation. The intestine has numerous folds that become progressively shorter in a rostral-to-caudal direction. Proportionally, these folds are significantly larger than the finger-like intestinal villi of mammals and other amniotes (Wallace et al. 2005). Columnar-shaped absorptive enterocytes are the most numerous in the zebrafish intestinal epithelium. Goblet cells are the second most populous epithelial cell type. + + + + AAO:0000246 + ANISEED:1235303 + BSA:0000093 + BTO:0000648 + CALOHA:TS-0490 + EFO:0000834 + EMAPA:32874 + EV:0100071 + FMA:7199 + GAID:295 + MA:0000328 + MA:0001524 + MESH:A03.492.411 + MIAA:0000043 + NCIT:C12736 + TAO:0001338 + UMLS:C0021853 + VHOG:0000056 + WBbt:0005772 + XAO:0000129 + ZFA:0001338 + galen:Intestine + bowel + uberon + intestinal tract + UBERON:0000160 + + + + + intestine + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + The proximal portion of the digestive tract, containing the oral cavity and bounded by the oral opening. In vertebrates, this extends to the pharynx and includes gums, lips, tongue and parts of the palate. Typically also includes the teeth, except where these occur elsewhere (e.g. pharyngeal jaws) or protrude from the mouth (tusks). + + + Cavity in which food is initially ingested and generally contains teeth, tongue and glands.[AAO] + Molecular and developmental cell lineage data suggest that the acoel mouth opening is homologous to the mouth of protostomes and deuterostomes and that the last common ancestor of the Bilateria (the 'urbilaterian') had only this single digestive opening.[well established][VHOG] + oral + some AOs place this as developing from the stomodeum but we weaken this to developmental contribution, as the mouth includes non-ectodermal derivatives + in FMA, the tongue, palate etc are part of the mouth which is itself a subdivision of the face. ZFA includes a separate class 'oral region' which is part of the mouth, but excludes tongue and lips + + + + AAO:0010355 + BTO:0001090 + BTO:0004698 + CALOHA:TS-1315 + EFO:0000825 + EHDAA2:0001326 + EHDAA:542 + EMAPA:16262 + FBbt:00003126 + FMA:49184 + GAID:75 + MA:0000341 + MA:0002474 + MAT:0000038 + MESH:D009055 + MIAA:0000038 + OpenCyc:Mx4rvVidh5wpEbGdrcN5Y29ycA + TADS:0000040 + TAO:0000547 + TAO:0000590 + TGMA:0000131 + VHOG:0000280 + VHOG:0000812 + XAO:0003029 + ZFA:0000547 + ZFA:0000590 + galen:Mouth + regio oralis + adult mouth + uberon + cavital oralis + cavitas oris + cavum oris + mouth cavity + oral region + oral vestibule + rima oris + stoma + stomatodaeum + trophic apparatus + vestibule of mouth + vestibulum oris + UBERON:0000165 + + + + + + + + + mouth + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + blood + A fluid that is composed of blood plasma and erythrocytes. + This class excludes blood analogues, such as the insect analog of blood. See UBERON:0000179 haemolymphatic fluid. + + + + A complex mixture of cells suspended in a liquid matrix that delivers nutrients to cells and removes wastes. (Source: BioGlossary, www.Biology-Text.com)[TAO] + Highly specialized circulating tissue consisting of several types of cells suspended in a fluid medium known as plasma.[AAO] + relationship loss: subclass specialized connective tissue (AAO:0000571)[AAO] + Recent findings strongly suggest that the molecular pathways involved in the development and function of blood cells are highly conserved among vertebrates and various invertebrates phyla. (...) There is now good reason to believe that, in vertebrates and invertebrates alike, blood cell lineages diverge from a common type of progenitor cell, the hemocytoblast.[well established][VHOG] + + + + + + AAO:0000046 + BTO:0000089 + CALOHA:TS-0079 + EFO:0000296 + EHDAA2:0000176 + EHDAA:418 + EMAPA:16332 + ENVO:02000027 + EV:0100047 + FMA:9670 + GAID:965 + MA:0000059 + MESH:D001769 + MIAA:0000315 + OpenCyc:Mx4rvVjI8JwpEbGdrcN5Y29ycA + TAO:0000007 + UMLS:C0005767 + VHOG:0000224 + XAO:0000124 + ZFA:0000007 + galen:Blood + portion of blood + vertebrate blood + uberon + whole blood + UBERON:0000178 + + + + + + + blood + + + + + + + + + + + + + + + + + + + + + + + + + + Circulating fluid that is part of the hemolymphoid system. Blood, lymph, interstitial fluid or its analogs. + + + cjm + 2009-04-08T04:38:19Z + CARO:0000081 + uberon + blood or blood analog + circulating fluid + UBERON:0000179 + haemolymphatic fluid + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + Organism at the blastula stage - an early stage of embryonic development in animals. It is produced by cleavage of a fertilized ovum and consists of a spherical layer of around 128 cells surrounding a central fluid-filled cavity called the blastocoel. The blastula follows the morula and precedes the gastrula in the developmental sequence. + TODO - check relationship with epiblast. Note in FMA this is not a subclass of embryo, but in uberon embryo is the whole organism from zygote onwards and thus includes the blastula + + + UBERON:0007011 + + BILA:0000059 + BTO:0000128 + GAID:1294 + MESH:A16.254.270.274 + OGEM:000006 + OpenCyc:Mx4rEetFnKP2EdqAAAACs4vPlg + blastula embryo + uberon + blastosphere + UBERON:0000307 + + + blastula + + + + + + + + + + In anatomy, the throat is the anterior part of the neck, in front of the vertebral column. It consists of the pharynx and larynx. An important feature of the throat is the epiglottis, a flap which separates the esophagus from the trachea and prevents inhalation of food or drink. The throat contains various blood vessels, various pharyngeal muscles, the trachea (windpipe) and the esophagus. The hyoid bone and the clavicle are the only bones located in the throat of mammals. It is sometimes considered a synonym for fauces. [WP,unvetted]. + + gular + The hyoid bone and the clavicle are the only bones located in the throat of mammals. + + + BTO:0000828 + EMAPA:37973 + FMA:228738 + NCIT:C54272 + OpenCyc:Mx4rwQtO_JwpEbGdrcN5Y29ycA + UMLS:C0230069 + uberon + gula + UBERON:0000341 + + throat + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + The subdivision of the musculoskeletal system that consists of all the muscles of the body[VSAO, modified]. + consider whether this should be restricted to skeletal musculature. See https://github.com/obophenotype/uberon/issues/77 + + + + Anatomical system that consists of the muscles of the body.[VSAO] + we place the MA term musculature here, rather than under uberon:musculature, as this seems more appropriate given the structure of MA + AAO:0000307 + BILA:0000088 + BTO:0001369 + BTO:0001485 + EFO:0000801 + EMAPA:35578 + FBbt:00005069 + FMA:72954 + MA:0002888 + MAT:0000025 + MIAA:0000025 + VSAO:0000033 + XAO:0004042 + muscle system + muscle system of body + muscular system + musculature system + set of all muscles + set of muscles of body + vertebrate muscular system + uberon + muskelsystem + UBERON:0000383 + + + musculature of body + + + + + + + + + + + + + + + + + + + + + A gland in which the principal secretory cells are serous secreting cells. + + + glands that secrete watery albuminous material that often contains enzymes[MP:0008052]. + + BTO:0001837 + FMA:62889 + uberon + UBERON:0000409 + + + serous gland + + + + + + + + + + + + + + + + + + + + + + + + + + + A portion of organism substance that is produced by exocrine glands. + + + BTO has two distunct classes, with exocrine glandular secretion a subtype of secretion - however, all examples in BTO directly under secretion appear to be exocrine gland secretions + UBERON:0006540 + secretion + + + AEO:0001005 + BTO:0002977 + BTO:0002979 + EMAPA:36535 + FMA:9675 + MA:0002504 + MESH:D012634 + UMLS:C1516992 + galen:Secretion + exocrine gland fluid/secretion + secreted substance + uberon + exocrine gland fluid + exocrine gland fluid or secretion + exocrine gland secretion + external secretion + UBERON:0000456 + bodily secretion + + + + + + + + + + + + + + + organism substance + Material anatomical entity in a gaseous, liquid, semisolid or solid state; produced by anatomical structures or derived from inhaled and ingested substances that have been modified by anatomical structures as they pass through the body. + + + + + AAO:0010839 + AEO:0000004 + BILA:0000004 + CALOHA:TS-2101 + CARO:0000004 + EHDAA2:0003004 + EMAPA:35178 + FBbt:00007019 + FMA:9669 + HAO:0000004 + MA:0002450 + SPD:0000008 + TAO:0001487 + TGMA:0001824 + VHOG:0001726 + XAO:0004001 + ZFA:0001487 + galen:BodySubstance + body fluid or substance + body substance + organism substance + portion of body substance + portion of organism substance + uberon + UBERON:0000463 + + + + organism substance + + + + + + + + + + + + + + + Non-material anatomical entity of three dimensions, that is generated by morphogenetic or other physiologic processes; is surrounded by one or more anatomical structures; contains one or more organism substances or anatomical structures. + + + lumen + space + + + AAO:0010110 + AEO:0000005 + BILA:0000005 + CARO:0000005 + EHDAA2:0003005 + FBbt:00007017 + FMA:5897 + HAO:0000005 + TAO:0001668 + TGMA:0001825 + UMLS:C0524461 + VHOG:0001728 + XAO:0003190 + ZFA:0001643 + lumen space + uberon + anatomical spaces + UBERON:0000464 + + + anatomical space + + + + + + + + + + material anatomical entity + Anatomical entity that has mass. + + + + + AAO:0010264 + AEO:0000006 + BILA:0000006 + CARO:0000006 + EHDAA2:0003006 + FBbt:00007016 + FMA:67165 + HAO:0000006 + TAO:0001836 + TGMA:0001826 + VHOG:0001721 + uberon + UBERON:0000465 + + + material anatomical entity + + + + + + + + + Anatomical entity that has no mass. + + + AAO:0010265 + AEO:0000007 + BILA:0000007 + CARO:0000007 + EHDAA2:0003007 + FBbt:00007015 + FMA:67112 + HAO:0000007 + TAO:0001835 + TGMA:0001827 + VHOG:0001727 + immaterial physical anatomical entity + uberon + UBERON:0000466 + + + + immaterial anatomical entity + + + + + + + + + + + + + + + + + + + + + + + + + + + Multicellular, connected anatomical structure that has multiple organs as parts and whose parts work together to achieve some shared function. + + + system + + + + + + AAO:0000007 + AEO:0000011 + BILA:0000011 + BSA:0000049 + CALOHA:TS-2088 + CARO:0000011 + EHDAA2:0003011 + EHDAA:392 + EMAPA:16103 + EV:0100000 + FBbt:00004856 + FMA:7149 + HAO:0000011 + MA:0000003 + OpenCyc:Mx4rCWM0QCtDEdyAAADggVbxzQ + TAO:0001439 + TGMA:0001831 + UMLS:C0460002 + VHOG:0001725 + WBbt:0005746 + WBbt:0005763 + XAO:0003002 + ZFA:0001439 + galen:AnatomicalSystem + body system + connected anatomical system + organ system + uberon + anatomical systems + UBERON:0000467 + + + + + + anatomical system + + + + + + + + + + Anatomical structure that is an individual member of a species and consists of more than one cell. + TODO - split body and mc organism? body continues after death stage + + + organismal + + + + + AAO:0010026 + AEO:0000191 + BILA:0000012 + BSA:0000038 + BTO:0000042 + CARO:0000012 + EFO:0002906 + EHDAA2:0003103 + EHDAA2:0003191 + EHDAA:1 + EHDAA:9178 + EMAPA:25765 + EV:0100016 + FBbt:00000001 + FMA:256135 + HAO:0000012 + TADS:0000001 + TAO:0001094 + TGMA:0001832 + VHOG:0000671 + WBbt:0007833 + XAO:0003004 + ZFA:0001094 + galen:Organism + ncithesaurus:Whole_Organism + multi-cellular organism + organism + whole organism + animal + uberon + Koerper + body + whole body + UBERON:0000468 + + + + + + + multicellular organism + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + Anatomical structure which is a subdivision of a whole organism, consisting of components of multiple anatomical systems, largely surrounded by a contiguous region of integument. + Reflects CARO2. todo - check the inclusion of FMA 'cardinal body part here', and check child terms for consistency + + + + + + + AAO:0010053 + AEO:0000032 + BILA:0000032 + CALOHA:TS-2084 + CARO:0000032 + EFO:0000808 + EHDAA2:0003032 + EMAPA:36031 + FBbt:00007009 + FMA:7153 + HAO:0000032 + MA:0002433 + MAT:0000293 + MESH:D001829 + MIAA:0000293 + OpenCyc:Mx4rvViAHJwpEbGdrcN5Y29ycA + TAO:0001308 + TGMA:0001840 + UMLS:C0229962 + VHOG:0001758 + XAO:0003013 + ZFA:0001308 + galen:BodyPart + anatomic region + uberon + body part + body region + cardinal body part + UBERON:0000475 + + + + + + + organism subdivision + + + + + + + + + Anatomical structure that consists of cell parts and cell substances and together does not constitute a cell or a tissue. + + + AAO:0010268 + AEO:0000040 + BILA:0000040 + CARO:0000040 + EHDAA2:0003040 + FBbt:00007013 + FMA:63863 + HAO:0000040 + TAO:0000382 + TGMA:0001841 + XAO:0003162 + ZFA:0000382 + uberon + acellular anatomical structures + UBERON:0000476 + + + acellular anatomical structure + + + + + + + + + + anatomical cluster + Anatomical group that has its parts adjacent to one another. + Will be obsoleted in CARO v2 [https://github.com/obophenotype/caro/issues/3] + + + + AAO:0010009 + AEO:0000041 + BILA:0000041 + CARO:0000041 + EHDAA2:0003041 + FBbt:00007277 + FMA:49443 + HAO:0000041 + TADS:0000605 + TAO:0001478 + TGMA:0001842 + VHOG:0001737 + XAO:0003160 + ZFA:0001478 + uberon + UBERON:0000477 + + + + anatomical cluster + + + + + + + + + + + + + + + Multicellular anatomical structure that consists of many cells of one or a few types, arranged in an extracellular matrix such that their long-range organisation is at least partly a repetition of their short-range organisation. + changed label and definition to reflect CARO2 + + + + + + AAO:0000607 + AAO:0010054 + AEO:0000043 + BILA:0000043 + BIRNLEX:19 + CALOHA:TS-2090 + CARO:0000043 + EHDAA2:0003043 + EMAPA:35868 + FBbt:00007003 + FMA:9637 + HAO:0000043 + MA:0003002 + MESH:D014024 + NCIT:C12801 + TAO:0001477 + TGMA:0001844 + UMLS:C0040300 + VHOG:0001757 + WBbt:0005729 + XAO:0003040 + ZFA:0001477 + galen:Tissue + portion of tissue + tissue portion + simple tissue + uberon + UBERON:0000479 + + + + tissue + + + + + + + + + + + + + + + Anatomical structure that has as its parts two or more portions of tissue of at least two different types and which through specific morphogenetic processes forms a single distinct structural unit demarcated by bona-fide boundaries from other distinct structural units of different types. + + + AAO:0010048 + AEO:0000055 + BILA:0000055 + CARO:0000055 + EHDAA2:0003055 + FBbt:00007010 + HAO:0000055 + TAO:0001488 + TGMA:0001847 + VHOG:0001762 + XAO:0003037 + ZFA:0001488 + uberon + multi-tissue structures + UBERON:0000481 + + + multi-tissue structure + + + + + + + + + + + + + + + + + + + + + + + Portion of tissue, that consists of one or more layers of epithelial cells connected to each other by cell junctions and which is underlain by a basal lamina. Examples: simple squamous epithelium, glandular cuboidal epithelium, transitional epithelium, myoepithelium[CARO]. + + + The two basic types of metazoan tissue are epithelial and connective. The simplest metazoans, and developmental stages of many primitive invertebrates, consist solely of these two layers. Thus, epithelial and connective tissues may be the primary (original) tissues of metazoans, and both are important in the functional organization of animals.[well established][VHOG] + epithelial + + + + + AAO:0000144 + AAO:0010055 + AEO:0000066 + BILA:0000066 + BTO:0000416 + CALOHA:TS-0288 + CARO:0000066 + EHDAA2:0003066 + EMAPA:32738 + FBbt:00007005 + FMA:9639 + GAID:402 + HAO:0000066 + MA:0003060 + MESH:D004848 + TAO:0001486 + UMLS:C0014609 + VHOG:0000387 + XAO:0003045 + ZFA:0001486 + epithelial tissue + portion of epithelium + uberon + UBERON:0000483 + + + + + + epithelium + + + + + + + + + + Epithelium which consists of more than one layer of epithelial cells that may or may not be in contact with a basement membrane. Examples: keratinized stratified squamous epithelium, ciliated stratified columnar epithelium.[FMA] + + + Epithelium that consists of more than one layer of epithelial cells.[CARO] + + + + + AAO:0010059 + AEO:0000069 + BILA:0000069 + BTO:0002074 + CARO:0000069 + EHDAA2:0003069 + FMA:45562 + HAO:0000069 + TAO:0001494 + UMLS:C0682575 + XAO:0004006 + ZFA:0001494 + stratified epithelium + uberon + laminated epithelium + UBERON:0000486 + + + + + multilaminar epithelium + + + + + + + + + + Unilaminar epithelium which consists of a single layer of squamous cells. Examples: pulmonary alveolar epithelium, endothelium.[FMA] + + + Unilaminar epithelium that consists of a single layer of squamous cells.[CARO] + + + + AAO:0010066 + AEO:0000070 + BILA:0000070 + BTO:0002073 + CARO:0000070 + EHDAA2:0003070 + FMA:45565 + HAO:0000070 + TAO:0001498 + UMLS:C0836133 + XAO:0004010 + ZFA:0001498 + epithelium simplex squamosum + uberon + simple squamous epithelia + UBERON:0000487 + + + + + simple squamous epithelium + + + + + + + + + + Epithelium which consists of a single layer of epithelial cells. Examples: endothelium, mesothelium, glandular squamous epithelium.[FMA] + consider adding disjointness axiom between unilaminar and multilaminar - but note that this will render EHDAA2:0003244 (chorionic trophoblast) unsatisfiable + + + Epithelium that consists of a single layer of epithelial cells.[CARO] + + + + AAO:0010062 + AEO:0000073 + BILA:0000073 + BTO:0002073 + CARO:0000073 + EHDAA2:0003073 + FMA:45561 + HAO:0000073 + TAO:0001495 + UMLS:C0682574 + XAO:0004007 + ZFA:0001495 + simple epithelium + uberon + unilaminar epithelia + UBERON:0000490 + + + unilaminar epithelium + + + + + + + + + + + + + + + + + + + + + + + + + + + Subdivision of trunk that lies between the head and the abdomen. + note that we use the slightly verbose term 'thoracic segment of trunk' to avoid confusuon with insect thorax. todo - taxonomic constraints. Also, in FMA 'thorax' is a synonym for chest + + + + + + + + EMAPA:35862 + FMA:259209 + MA:0000022 + thorax + uberon + anterior subdivision of trunk + upper body + upper trunk + UBERON:0000915 + + + thoracic segment of trunk + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + Anatomical entity that comprises the organism in the early stages of growth and differentiation that are characterized by cleavage, the laying down of fundamental tissues, and the formation of primitive organs and organ systems. For example, for mammals, the process would begin with zygote formation and end with birth. For insects, the process would begin at zygote formation and end with larval hatching. For plant zygotic embryos, this would be from zygote formation to the end of seed dormancy. For plant vegetative embryos, this would be from the initial determination of the cell or group of cells to form an embryo until the point when the embryo becomes independent of the parent plant. + + + embryonic + Obsoleted in ZFA. Note that embryo is not classified as an embryonic structure - an embryonic structure is only the parts of an embryo + + + + + + AAO:0011035 + AEO:0000169 + BILA:0000056 + BSA:0000039 + BTO:0000379 + CALOHA:TS-0229 + EFO:0001367 + EHDAA2:0000002 + EHDAA2_RETIRED:0003236 + EHDAA:38 + EMAPA:16039 + FBbt:00000052 + FMA:69068 + GAID:963 + MAT:0000226 + MESH:D004622 + MIAA:0000019 + OGEM:000001 + OpenCyc:Mx4rwP1ceZwpEbGdrcN5Y29ycA + UMLS:C0013935 + VHOG:0001766 + XAO:0000113 + ZFA:0000103 + embryonic organism + uberon + developing organism + developmental tissue + UBERON:0000922 + + + + + + + embryo + + + + + + + + + + + + + + + + + + + + + + + A layer of cells produced during the process of gastrulation during the early development of the animal embryo, which is distinct from other such layers of cells, as an early step of cell differentiation. The three types of germ layers are the endoderm, ectoderm, and mesoderm. + + + The Bilateria are triploblastic (with true endoderm, mesoderm, and ectoderm) (...).[well established][VHOG] + embryonic tissue + + + + + + AAO:0000480 + BILA:0000035 + BTO:0000556 + EMAPA:36033 + FBbt:00000110 + FMA:69069 + GAID:1303 + MESH:A16.254.425 + TAO:0001122 + UMLS:C0920502 + UMLS:C1708239 + VHOG:0001223 + XAO:0003011 + ZFA:0001122 + germinal layer + primary germ layer + uberon + embryonic germ layer + embryonic germ layers + UBERON:0000923 + + + + + Classically the germ layers are ectoderm, mesoderm and endoderm. Alternatively: primary = ectoderm, endoderm; secondary=mesoderm; tertiary=dorsal mesoderm, NC[https://github.com/obophenotype/uberon/wiki/The-neural-crest] + germ layer + + + + + + + + + + + + + + + Primary germ layer that is the outer of the embryo's three germ layers and gives rise to epidermis and neural tissue. + + + Primary germ layer that is the outer of the embryonic germ layers and gives rise to epidermis and neural tissue.[AAO] + The Bilateria are triploblastic (with true endoderm, mesoderm, and ectoderm) (...).[well established][VHOG] + ectodermal + + + + + AAO:0000137 + BILA:0000036 + BTO:0000315 + CALOHA:TS-0216 + EFO:0000414 + EHDAA2:0000428 + EMAPA:16069 + EV:0100003 + FBbt:00000111 + FMA:69070 + GAID:1304 + MAT:0000155 + MAT:0000173 + MESH:A16.254.425.273 + MIAA:0000173 + TAO:0000016 + UMLS:C0013574 + VHOG:0000153 + XAO:0000001 + ZFA:0000016 + embryonic ectoderm + uberon + UBERON:0000924 + + + + + + + ectoderm + + + + + + + + + + + + + + + + Primary germ layer that lies remote from the surface of the embryo and gives rise to internal tissues such as gut. + + + The Bilateria are triploblastic (with true endoderm, mesoderm, and ectoderm) (...).[well established][VHOG] + endodermal + + + + + AAO:0000139 + BILA:0000038 + BTO:0000800 + CALOHA:TS-0273 + EFO:0002545 + EHDAA2:0000436 + EMAPA:16062 + EV:0100005 + FBbt:00000125 + FMA:69071 + GAID:1305 + MAT:0000175 + MESH:A16.254.425.407 + MIAA:0000175 + TAO:0000017 + UMLS:C0014144 + VHOG:0000154 + XAO:0000090 + ZFA:0000017 + uberon + entoderm + UBERON:0000925 + + + + + + + endoderm + + + + + + + + + + + + + + + + + The middle germ layer of the embryo, between the endoderm and ectoderm. + + + + Primary germ layer that is the middle of the embryonic germ layers.[AAO] + The Bilateria are triploblastic (with true endoderm, mesoderm, and ectoderm) (...).[well established][VHOG] + mesodermal + sponges do not seem to have a mesoderm and accordingly Amphimedon lacks transcription factors involved in mesoderm development (Fkh, Gsc, Twist, Snail)[http://www.nature.com/nature/journal/v466/n7307/full/nature09201.html]. Mesoderm may not be homologous across verteberates + UBERON:0003263 + + + + + AAO:0000304 + BILA:0000037 + BTO:0000839 + CALOHA:TS-0623 + EFO:0001981 + EHDAA2:0001128 + EHDAA:124 + EHDAA:160 + EHDAA:168 + EHDAA:183 + EMAPA:16083 + EV:0100006 + FBbt:00000126 + FMA:69072 + GAID:522 + MAT:0000174 + MESH:A16.254.425.660 + MIAA:0000174 + TAO:0000041 + UMLS:C0025485 + VHOG:0000152 + XAO:0000050 + ZFA:0000041 + uberon + embryonic mesoderm + entire mesoderm + mesodermal mantle + UBERON:0000926 + + + + + + + mesoderm + + + + + + + + + + + + + + + + + + + + + + + Anterior part of the embryonic digestive tract that develops into a mouth. The stomodeum includes as parts an invagination of the ectoderm and the stomodeal cavity. + consider indicating location. e.g. anterior. Note some AOs place this as part of oral opening, but it's not clear when this structure comes into existence + + + Anterior part of the embryonic alimentary canal formed as an invagination of the ectoderm; the future mouth.[TAO] + the primordial mouth region of the developing head, initially a midline ectodermal depression between the forebrain bulge (cranially) and the heart bulge (caudally) and between the maxillary and mandibular components of the first pharyngeal arch; the stomodeum is separated from the anterior end of the foregut by the buccopharyngeal membrane; the mouth is developed partly from the stomodeum, and partly from the floor of the anterior portion of the foregut; the lips, teeth, and gums are formed from the walls of the stomodeum, but the tongue is developed in the floor of the pharynx + stomodeal + This class groups together disparate structures as all being the anterior part of the early metazoan digestive tract and precursor of the mouth. However, the developmental processes vary, so this class may be split in future. E.g. in mammals it is a rostral depression surrounded by prominences. Outgrowth of the prominences produces a stomodeal cavity. + stomodeal-hypophyseal primordium + + + + BTO:0004224 + EHDAA2:0001929 + EMAPA:16263 + FBbt:00000439 + FMA:295846 + TAO:0001290 + TGMA:0000135 + UMLS:C1514977 + XAO:0000269 + ZFA:0001290 + mouth primordium + primitive oral cavity + stomatodeum + stomodaeum + uberon + mouth pit + oral ectoderm + oral pit + UBERON:0000930 + + + + + + + + stomodeum + + + + + + + + + + + An expanded region of the vertebrate alimentary tract that serves as a food storage compartment and digestive organ. A stomach is lined, in whole or in part by a glandular epithelium. + + Portion of alimentary canal with increased circular and longitudinal smooth muscle. Bounded posteriorly by the pyloric sphincter. Mucosal lining has increased folding.[AAO] + It appears that the stomach has an ancient origin. The stomach first appears in the fish lineage. The prevertebrate chordates do not have a true stomach, whereas the cartilaginous and bony fish do. Although most fish do have a true stomach, some fish species appear to have lost the stomach secondarily. The remaining vertebrate lineages do have a true stomach (at least in the adult animal), although there is great variation in the size and shape of the stomach.[well established][VHOG] + We restrict this to the vertebrate specific structure - see the grouping class 'food storage organ' for analogous structures in other species. Teleosts: Zebrafish is functionally stomach-less, but may retain ontogenic footprint. Although the precise shape and size of the stomach varies widely among different vertebrates, the relative positions of the oesophageal and duodenal openings remain relatively constant. As a result, the organ always curves somewhat to the left before curving back to meet the pyloric sphincter. However, lampreys, hagfishes, chimaeras, lungfishes, and some teleost fish have no stomach at all, with the oesophagus opening directly into the intestine. The gastric lining is usually divided into two regions, an anterior portion lined by fundic glands, and a posterior with pyloric glands. Cardiac glands are unique to mammals, and even then are absent in a number of species. The distributions of these glands vary between species, and do not always correspond with the same regions as in man. Furthermore, in many non-human mammals, a portion of the stomach anterior to the cardiac glands is lined with epithelium essentially identical to that of the oesophagus. Ruminants, in particular, have a complex stomach, the first three chambers of which are all lined with oesophageal mucosa + + + + AAO:0000579 + ANISEED:1235297 + BTO:0001307 + CALOHA:TS-0980 + EFO:0000837 + EHDAA2:0001915 + EHDAA:2993 + EMAPA:17021 + EV:0100070 + FMA:7148 + GAID:293 + MA:0000353 + MAT:0000051 + MESH:A03.492.766 + MIAA:0000051 + NCIT:C12391 + OpenCyc:Mx4rvVjlqpwpEbGdrcN5Y29ycA + TAO:0002121 + UMLS:C0038351 + VHOG:0000408 + XAO:0000128 + galen:Stomach + stomach chamber + uberon + anterior intestine + gaster + mesenteron + ventriculus + UBERON:0000945 + + + + + + + stomach + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A myogenic muscular circulatory organ found in the vertebrate cardiovascular system composed of chambers of cardiac muscle. It is the primary circulatory organ. + + + Blood pumping organ composed of four chambers: sinus venosus, atrium, cardiac ventricle and bulbus arteriosus.[TAO] + Part of the circulatory system responsible for pumping blood; composed of three chambers--two atria and one ventricle.[AAO] + relationship type change: differentiates_from lateral plate mesoderm (AAO:0010574) CHANGED TO: develops_from lateral plate mesoderm (UBERON:0003081)[AAO] + As noted, the hearts of birds and mammals have four chambers that arises from the two chambers (atrium and ventricle) of the fish heart.[well established][VHOG] + cardiac + + + + + AAO:0010210 + BILA:0000020 + BTO:0000562 + CALOHA:TS-0445 + EFO:0000815 + EHDAA2:0000738 + EHDAA:420 + EMAPA:16105 + EV:0100018 + FMA:7088 + GAID:174 + MA:0000072 + MAT:0000036 + MESH:D006321 + MIAA:0000036 + NCIT:C12727 + OpenCyc:Mx4rvVjvDpwpEbGdrcN5Y29ycA + TAO:0000114 + UMLS:C0018787 + VHOG:0000276 + XAO:0000064 + ZFA:0000114 + galen:Heart + chambered heart + vertebrate heart + branchial heart + uberon + Herz@de + cardium + UBERON:0000948 + + + + + + + + + + + Taxon notes:" the ascidian tube-like heart lacks chambers....The ascidian heart is formed after metamorphosis as a simple tube-like structure with a single-layered myoepithelium that is continuous with a single-layered pericar- dial wall. It lacks chambers and endocardium.... The innovation of the chambered heart was a key event in vertebrate evolution, because the chambered heart generates one-way blood flow with high pressure, a critical requirement for the efficient blood supply of large-body vertebrates... all extant vertebrates have hearts with two or more chambers (Moorman and Christoffels 2003)" DOI:10.1101/gad.1485706 + Taxon notes:" the ascidian tube-like heart lacks chambers....The ascidian heart is formed after metamorphosis as a simple tube-like structure with a single-layered myoepithelium that is continuous with a single-layered pericar- dial wall. It lacks chambers and endocardium.... The innovation of the chambered heart was a key event in vertebrate evolution, because the chambered heart generates one-way blood flow with high pressure, a critical requirement for the efficient blood supply of large-body vertebrates... all extant vertebrates have hearts with two or more chambers (Moorman and Christoffels 2003)" http://dx.doi.org/10.1101/gad.1485706 + heart + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + Anatomical cluster that consists of two or more adjacent skeletal structures, which may be interconnected by various types of tissue[VSAO]. + + + Anatomical cluster that consists of two or more adjacent bones or cartilages, which may be interconnected by various types of tissue.[VSAO] + Anatomical cluster which consists of two or more adjacent bones or cartilages, which may be interconnected by various types of tissue.[TAO] + articulation + joint + + + + + AEO:0000182 + BTO:0001686 + CALOHA:TS-2023 + EFO:0000948 + EMAPA:35456 + FMA:7490 + GAID:102 + MA:0000319 + MAT:0000188 + MESH:D007596 + MIAA:0000188 + OpenCyc:Mx4rvVjjdpwpEbGdrcN5Y29ycA + RETIRED_EHDAA2:0003182 + TAO:0000367 + UMLS:C0022417 + VHOG:0001276 + VSAO:0000101 + XAO:0000171 + ZFA:0001596 + galen:Joint + uberon + articular joint + joints + UBERON:0000982 + + + + + + + + + skeletal joint + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + The outer epithelial layer of the skin that is superficial to the dermis. + + + A cellular, multilayered epithelium derived from the ectoderm. Zebrafish epidermis consists only of living cells unlike terrestrial vertebrates in which dead, keratinized cells are present. Le Guellec et al, 2004.[TAO] + The outer epithelial layer of the external integument of the body that is derived from the embryonic epiblast.[AAO] + relationship loss: subclass external integument structures (AAO:0000961)[AAO] + (...) outer epithelia in all metazoan animals are homologous. (...) The ancestor of all metazoans likely had an epidermis with a basal extracellular matrix (ECM), an apical extracellular glycocalyx, and one cilium with a striated rootlet per cell.[well established][VHOG] + epidermal + Zebrafish epidermis consists only of living cells unlike terrestrial vertebrates in which dead, keratinized cells are present. In terrestrial vertebrates the epidermis often forms an outer keratinized or cornified layer, the stratum corneum. Interaction between the epideris and dermis gives rise to feathers (birds), hair and mammary glands (mammals), teeth and scales (placoid: chondrichthyans; cosmoids, ganoid, cycloid in bony fishes). + epidermis + skin + + + + + AAO:0000143 + BTO:0000404 + CALOHA:TS-0283 + EFO:0000954 + EMAPA:17528 + EV:0100153 + FMA:70596 + GAID:932 + MA:0000153 + MAT:0000154 + MESH:D004817 + MIAA:0000154 + TAO:0000105 + UMLS:C0014520 + VHOG:0000077 + XAO:0000028 + ZFA:0000105 + vertebrate epidermis + uberon + UBERON:0001003 + + + + + + + skin epidermis + + + + + + + + + + + + + + + Functional system which consists of structures involved in respiration. + + + + The anatomical system in which the exchange of oxygen and carbon dioxide between the organism and its environment.[AAO] + There is no doubt that the primitive pattern of vertebrate air-breathing is the buccal pulse pump found in actinopterygian fishes.[well established][VHOG] + + + + + AAO:0000541 + BTO:0000203 + CALOHA:TS-1319 + EFO:0000804 + EHDAA2:0001604 + EHDAA:2203 + EMAPA:16727 + EV:0100036 + FMA:7158 + GAID:78 + MA:0000327 + MAT:0000030 + MESH:D012137 + MIAA:0000030 + OpenCyc:Mx4rvVjzFJwpEbGdrcN5Y29ycA + TAO:0000272 + UMLS:C0035237 + VHOG:0000202 + XAO:0000117 + ZFA:0000272 + apparatus respiratorius + respiratory system + uberon + Atmungssystem + apparatus respiratorius + systema respiratorium + UBERON:0001004 + + + + + + + + + respiratory system + + + + + + + + + + + + + + + + Anatomical system that has as its parts the organs devoted to the ingestion, digestion, and assimilation of food and the discharge of residual wastes. + + + An anatomical system consisting of the alimentary canal and digestive glands responsible for intake, absorption, digestion and excretion of food.[AAO] + digestive + many anatomy ontologies consider gastrointestinal system synonymous with digestive system. here we follow MA in dividing digestive system into gastrointestinal and hepatobiliary. hepatobiliary includes the liver and biliary tract. species-specific AO classes are categorized according to whether liver is included. For example, XAO includes liver as part of XAO:0000125 alimentary system, so we assume this class is the more generic class + + + AAO:0000129 + BILA:0000082 + BTO:0000058 + CALOHA:TS-1293 + EFO:0000793 + EV:0100056 + FBbt:00005055 + FMA:7152 + GAID:278 + MA:0002431 + MAT:0000018 + MESH:D004064 + MIAA:0000018 + TADS:0000170 + TAO:0000339 + WBbt:0005748 + XAO:0000125 + ZFA:0000339 + galen:DigestiveSystem + ncithesaurus:Digestive_System + uberon + alimentary system + alimentary tract + gastrointestinal system + gut + UBERON:0001007 + + + + + + + digestive system + + + + + + + + + + + + + + + organ system that passes nutrients (such as amino acids and electrolytes), gases, hormones, blood cells, etc. to and from cells in the body to help fight diseases and help stabilize body temperature and pH to maintain homeostasis[WP]. + the cardiovascular system and the lymphatic system are parts of the circulatory system + + + + + + + Anatomical system of ion binding, a pumping mechanism, and an efficient vascular system; consisting of the blood, heart, and blood and lymph vessels, respectively.[AAO] + We should divest ourselves of the view that earlier vertebrate groups were 'on their way' to becoming mammals, as clearly they were not such visionaries. Neither were their systems 'imperfect' as earlier anatomists thought. Instead, their circulatory systems served them well to address the ecological demands arising from their lifestyles.[well established][VHOG] + + AAO:0000959 + CALOHA:TS-2103 + FBbt:00005057 + OpenCyc:Mx4rvVjzG5wpEbGdrcN5Y29ycA + VHOG:0001248 + uberon + systema cardiovasculare + UBERON:0001009 + + + circulatory system + + + + + + + + + + Portion of connective tissue composed of adipocytes enmeshed in areolar tissue + + + Connective tissue in which fat is stored.[TAO] + Tissue that contains adipocytes, used for cushioning, thermal insulation, lubrication (primarily in the pericardium) and energy storage.[AAO] + relationship loss: subclass connective tissue proper (AAO:0000099)[AAO] + Adipose tissue is unique to vertebrates. It is found in mostmammals, birds, reptiles and amphibians, and a variety is found in some species of fish. Furthermore, in insects the fat body found in larvae as well as in adults shares some homology with adipose tissue.[well established][VHOG] + adipose + In humans, adipose tissue is located beneath the skin (subcutaneous fat), around internal organs (visceral fat), in bone marrow (yellow bone marrow) and in breast tissue. Adipose tissue is found in specific locations, which are referred to as adipose depots. Adipose tissue contains several cell types, with the highest percentage of cells being adipocytes, which contain fat droplets. Other cell types include fibroblasts, macrophages, and endothelial cells. Adipose tissue contains many small blood vessels.; Mice have eight major adipose depots, four of which are within the abdominal cavity. The paired gonadal depots are attached to the uterus and ovaries in females and the epididymis and testes in males; the paired retroperitoneal depots are found along the dorsal wall of the abdomen, surrounding the kidney, and, when massive, extend into the pelvis. The mesenteric depot forms a glue-like web that supports the intestines, and the omental depot, which originates near the stomach and spleen, and, when massive, extends into the ventral abdomen. + in FMA this is dense irregular connective tissue + + + + + AAO:0000001 + AEO:000020 + BTO:0001487 + CALOHA:TS-0013 + EFO:0000790 + EHDAA2:0003120 + EMAPA:35112 + EV:0100381 + FMA:20110 + GAID:920 + MA:0000009 + MAT:0000015 + MESH:D000273 + MIAA:0000015 + OpenCyc:Mx4rvVjc_ZwpEbGdrcN5Y29ycA + TAO:0002134 + UMLS:C0001527 + VHOG:0001284 + XAO:0003049 + ZFA:0005345 + galen:FattyTissue + fat + fat tissue + fatty tissue + uberon + adipose + bodyfat + fatty depot + UBERON:0001013 + + + + + adipose tissue + + + + + + + + + + + + + + + + + + + + + A subdivision of the muscular system corresponding to a subdisivision of an organism. + + + In FMA this is classified as a set of organs. ZFA musculature system has subtypes, so it is classified here. WBbt muscular system has subtypes so it goes here. Note that we use the MA term set of skeletal muscles here as it seems most appropriate (*not* MA:musculature). AAO is generally confused here. + + + + + AAO:0011066 + BTO:0000887 + EFO:0001949 + EMAPA:32715 + EMAPA:35577 + FMA:32558 + MA:0000165 + OpenCyc:Mx4rvVjmr5wpEbGdrcN5Y29ycA + TAO:0000548 + UMLS:C0026845 + VSAO:0005038 + WBbt:0005737 + ZFA:0000548 + muscle group + muscles set + musculature + musculi + set of muscles + set of skeletal muscles + uberon + muscle system + muscles + musculature system + UBERON:0001015 + + + + + + + musculature + + + + + + + + + + + + + + + + + + + + + + The nervous system is an organ system containing predominantly neuron and glial cells. In bilaterally symmetrical organism, it is arranged in a network of tree-like structures connected to a central body. The main functions of the nervous system are to regulate and control body functions, and to receive sensory input, process this information, and generate behavior [CUMBO]. + + + A regulatory system of the body that consists of neurons and neuroglial cells. The nervous system is divided into two parts, the central nervous system (CNS) and the peripheral nervous system (PNS). (Source: BioGlossary, www.Biology-Text.com)[TAO] + Anatomical system consisting of nerve bodies and nerve fibers which regulate the response of the body to external and internal stimuli.[AAO] + Nervous systems evolved in the ancestor of Eumetazoa.[well established][VHOG] + nervous + neural + + + + + + + AAO:0000324 + BILA:0000079 + BTO:0001484 + CALOHA:TS-1313 + EFO:0000802 + EHDAA2:0001246 + EHDAA:826 + EMAPA:16469 + EV:0100162 + FBbt:00005093 + FMA:7157 + GAID:466 + MA:0000016 + MAT:0000026 + MESH:D009420 + MIAA:0000026 + OpenCyc:Mx4rvViT_pwpEbGdrcN5Y29ycA + TAO:0000396 + UMLS:C0027763 + VHOG:0000402 + WBbt:0005735 + XAO:0000177 + ZFA:0000396 + neurological system + nerve net + uberon + systema nervosum + UBERON:0001016 + + + + + + + + nervous system + + + + + + + + + + + + + + + + + + + + + + + + The central nervous system is the core nervous system that serves an integrating and coordinating function. In vertebrates it consists of the neural tube derivatives: the brain and spinal cord. In invertebrates it includes central ganglia plus nerve cord. + + + + Part of the nervous system which includes the brain and spinal cord.[AAO] + The brain and spinal cord. Kimmel et al, 1995.[TAO] + The central nervous system (CNS) is the part of the nervous system which includes the brain, spinal cord, and nerve cell layer of the retina (CUMBO). + (...) at some stage of its development, every chordate exhibits five uniquely derived characters or synapomorphies of the group: (...) (4) a single, tubular nerve cord that is located dorsal to the notochord (...) (reference 1); The neural tube is destined to differentiate into the brain and spinal cord (the central nervous system) (reference 2); Taken together, our data make a very strong case that the complex molecular mediolateral architecture of the developing trunk CNS (central nervous system), as shared between Platynereis and vertebrates, was already present in their last common ancestor, Urbilateria. The concept of bilaterian nervous system centralization implies that neuron types concentrate on one side of the trunk, as is the case in vertebrates and many invertebrates including Platynereis, where they segregate and become spatially organized (as opposed to a diffuse nerve net). Our data reveal that a large part of the spatial organization of the annelid and vertebrate CNS was already present in their last common ancestor, which implies that Urbilateria had already possessed a CNS (reference 3).[well established][VHOG] + + + + + + + AAO:0000090 + BAMS:CNS + BILA:0000080 + BTO:0000227 + CALOHA:TS-0150 + EFO:0000908 + EHDAA2:0000225 + EHDAA:828 + EMAPA:16470 + EMAPA:16754 + EV:0100163 + FBbt:00005094 + FMA:55675 + GAID:570 + MA:0000167 + MAT:0000457 + MESH:D002490 + OpenCyc:Mx4rvzYt3pwpEbGdrcN5Y29ycA + TAO:0000012 + UMLS:C0927232 + VHOG:0000293 + XAO:0000215 + ZFA:0000012 + CNS + systema nervosum centrale + cerebrospinal axis + uberon + neuraxis + UBERON:0001017 + + + + + + + + central nervous system + + + + + + + + + + + + + + + Primordia are populations of contiguous cells that are morphologically distinct and already correspond in extent to a later organ/tissue[FBbt, Hartenstein, V. (2004)]. + + + + + + AEO:0000171 + BTO:0001886 + EFO:0001652 + EHDAA2:0003171 + FBbt:00005495 + FMA:86589 + MAT:0000482 + UMLS:C0678727 + XAO:0003043 + uberon + bud + future organ + placode + primordia + rudiment + UBERON:0001048 + + + + + primordium + + + + + + + + + + + + + + + + + + In the developing vertebrate, the neural tube is the embryo's precursor to the central nervous system, which comprises the brain and spinal cord. The neural groove gradually deepens as the neural folds become elevated, and ultimately the folds meet and coalesce in the middle line and convert the groove into a closed tube, the neural tube or neural canal (which strictly speaking is the center of the neural tube), the ectodermal wall of which forms the rudiment of the nervous system. [WP,unvetted]. + + + Hollow epithelial tube on dorsal side of the embryo that develops into the central nervous system.[AAO] + The dorsal tubular structure in the vertebrate embryo that develops into the brain and spinal cord. [TFD][VHOG] + (...) at some stage of its development, every chordate exhibits five uniquely derived characters or synapomorphies of the group: (...) (4) a single, tubular nerve cord that is located dorsal to the notochord (...).[well established][VHOG] + The mature structure of the neural tube exists when the tube has been segmented into the forebrain, midbrain, hindbrain and spinal cord regions. In addition neural crest has budded away from the epithelium + + + + + + AAO:0010617 + BTO:0001057 + CALOHA:TS-2371 + DHBA:10154 + EHDAA2:0001254 + EHDAA:2869 + EHDAA:908 + EMAPA:16164 + EMAPA:16530 + EMAPA:16757 + FMA:293882 + MAT:0000069 + MIAA:0000069 + TAO:0001135 + UMLS:C0231024 + VHOG:0000307 + XAO:0003204 + ZFA:0001135 + uberon + neural primordium + presumptive central nervous system + tubus neuralis + UBERON:0001049 + + + + + + neural tube + + + + + + + + + + Biological entity that is either an individual member of a biological species or constitutes the structural organization of an individual member of a biological species. + + + + + + + AAO:0010841 + AEO:0000000 + BILA:0000000 + BIRNLEX:6 + CARO:0000000 + EHDAA2:0002229 + FBbt:10000000 + FBbt_root:00000000 + FMA:62955 + HAO:0000000 + MA:0000001 + NCIT:C12219 + TAO:0100000 + TGMA:0001822 + UMLS:C1515976 + WBbt:0000100 + XAO:0000000 + ZFA:0100000 + uberon + UBERON:0001062 + + + + anatomical entity + + + + + + + + + + + + + + + + + + + + + + + + + + Transudate contained in the synovial cavity of joints, and in the cavity of tendon sheaths and bursae. + + + Portion of organism substance that is a clear fluid that occupies the space in synovial joints.[TAO] + + + + BTO:0001339 + CALOHA:TS-0996 + ENVO:02000039 + FMA:12277 + GAID:265 + MA:0002544 + MESH:D013582 + TAO:0005154 + UMLS:C0039097 + ZFA:0005154 + galen:SynovialFluid + joint fluid + uberon + UBERON:0001090 + + + synovial fluid + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + Simple squamous epithelium of mesodermal origin which lines serous membranes. Examples: mesothelium of pleura, mesothelium of peritoneum[FMA]. http://en.wikipedia.org/wiki/ The mesothelium is a membrane that forms the lining of several body cavities: the pleura (thoracal cavity), peritoneum (abdominal cavity including the mesentery) and pericardium (heart sac). Mesothelial tissue also surrounds the male internal reproductive organs (the tunica vaginalis testis) and covers the internal reproductive organs of women (the tunica serosa uteri). + + + + + + + AEO:0000111 + BTO:0002422 + CALOHA:TS-1183 + EHDAA2_RETIRED:0003111 + EHDAA:2331 + EHDAA:2349 + EHDAA:295 + EHDAA:6073 + EHDAA:640 + EHDAA:646 + EMAPA:32856 + FMA:14074 + MA:0000565 + UMLS:C0086610 + uberon + UBERON:0001136 + + mesothelium + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + Anatomical system that is a multi-element, multi-tissue anatomical cluster that consists of the skeleton and the articular system. + + + Anatomical system consisting of multiple elements and tissues that provides physical support.[TAO] + Anatomical system that is a multi-element, multi-tissue anatomical cluster that consists of the skeleton and the articular system.[VSAO] + System that provides physical support to the organism.[AAO] + By taking a holistic approach, integration of the evidence from molecular and developmental features of model organisms, the phylogenetic distribution in the 'new animal phylogeny' and the earliest fossilized remains of mineralized animal skeletons suggests independent origins of the skeleton at the phylum level.[debated][VHOG] + skeletal + GO defines skeletal system very generically: The skeleton is the bony framework of the body in vertebrates (endoskeleton) or the hard outer envelope of insects (exoskeleton or dermoskeleton) GO:0001501; however, all annotations are to vertebrates + + + + AAO:0000566 + BTO:0001486 + CALOHA:TS-1320 + EFO:0000806 + EHDAA2:0003168 + EMAPA:35773 + FMA:23881 + MA:0000018 + OpenCyc:Mx4rvVi1rpwpEbGdrcN5Y29ycA + TAO:0000434 + UMLS:C0037253 + VHOG:0001254 + VSAO:0000027 + XAO:0003060 + ZFA:0000434 + skeleton system + set of all bones and joints + uberon + Skelettsystem + UBERON:0001434 + + + + + + + skeletal system + https://github.com/obophenotype/uberon/wiki/The-skeletal-system + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + Skeletal element that is composed of bone tissue. + + + Also called osseous tissue, (Latin: os). Is a type of hard endoskeletal connective tissue found in many vertebrate animals. Bone is the main tissue of body organs that support body structures, protect internal organs, (in conjunction with muscles) facilitate movement; and are involved with cell formation, calcium metabolism, and mineral storage.[AAO] + Portion of tissue which is calcified connective tissue making up the structural elements of the skeletal system.[TAO] + Skeletal element that is composed of bone tissue.[VSAO] + relationship loss: subclass specialized connective tissue (AAO:0000571)[AAO] + The 'new animal phylogeny' reveals that many of the groups known to biomineralize sit among close relatives that do not, and it favours an interpretation of convergent or parallel evolution for biomineralization in animals. (...) Whether this 'biomineralization toolkit'of genes reflects a parallel co-option of a common suite of genes or the inheritance of a skeletogenic gene regulatory network from a biomineralizing common ancestor remains an open debate.[debated][VHOG] + + + + + + + + AAO:0000047 + AEO:0000082 + BTO:0000140 + CALOHA:TS-0088 + EFO:0000298 + EHDAA2:0003082 + EMAPA:32782 + ENVO:00002039 + EV:0100140 + FMA:30317 + FMA:5018 + GAID:92 + MA:0001459 + MAT:0000299 + MIAA:0000299 + OpenCyc:Mx4rvViDlpwpEbGdrcN5Y29ycA + OpenCyc:Mx4rvVkCG5wpEbGdrcN5Y29ycA + TAO:0001514 + UMLS:C0262950 + VHOG:0001190 + VSAO:0000057 + XAO:0000169 + ZFA:0001514 + galen:Bone + bone element + bone organ + uberon + bone + bones + UBERON:0001474 + + + + + + + + + + + bone element + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + An articular capsule (or joint capsule) is an envelope surrounding a synovial joint. [WP,unvetted]. + + + check ncita + + + + + + FMA:34836 + GAID:263 + MA:0001519 + MESH:D017746 + UMLS:C0206207 + galen:JointCapsule + capsula articularis + fibrous capsule of joint + joint capsule + joint fibrous capsule + uberon + capsulae articulares + UBERON:0001484 + + + articular capsule + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A tube extending from the mouth to the anus. + + + + + The alimentary or digestive tract, and associated organs.[TAO] + The bilaterian gut is typically a complete tube that opens to the exterior at both ends. It consists of mouth, foregut, midgut, hindgut, and anus (reference 1); Although all vertebrates have a digestive tract and accessory glands, various parts of this system are not necessarily homologous, analogous, or even present in all species. Therefore, broad comparisons can be best made under the listings of headgut, foregut, midgut, pancreas and biliary system, hindgut (reference 2).[well established][VHOG] + FMA also has a term 'gastrointestinal tract', but this includes the liver. + we place the MA and EMAPA class here, although the intent is probably a smaller region. See https://github.com/obophenotype/uberon/issues/509 + we following Kardong in naming the entire tube from mouth to anus the alimentary canal. Kardong calls the portion of this tract that excludes buccal cavity and pharynx the 'alimentary canal', consider adding an extra class for this + gut + + + AAO:0010023 + BILA:0000083 + BTO:0000511 + BTO:0000545 + EHDAA2:0000726 + EHDAA:518 + EMAPA:16247 + FBbt:00003125 + FMA:45615 + MA:0000917 + OpenCyc:Mx4rvVi0GpwpEbGdrcN5Y29ycA + TAO:0000112 + TGMA:0001819 + UMLS:C0017189 + VHOG:0000309 + WBbt:0005743 + ZFA:0000112 + galen:AlimentaryTract + digestive tube + enteric tract + alimentary canal + alimentary tract + uberon + digestive canal + gut tube + UBERON:0001555 + + + + + digestive tract + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + Organ consisting of a tissue made up of various elongated cells that are specialized to contract and thus to produce movement and mechanical work[GO]. + + + Portion of tissue composed of contractile fibers.[TAO] + It seems clear that the metazoan ancestor inherited from its unicellular descendants an actin cytoskeleton and motor-proteins of the myosin superfamily. Within metazoans, these two molecules were arranged into effective contractile units, the muscles. The basic trends for muscle evolution are already expressed in the diploblastic taxa.[well established][VHOG] + muscular + muscle + + AAO:0011066 + EMAPA:32715 + EV:0100146 + FMA:5022 + GAID:131 + MA:0000015 + OpenCyc:Mx4rv2kf-5wpEbGdrcN5Y29ycA + TAO:0005145 + VHOG:0001245 + XAO:0000172 + ZFA:0005145 + galen:Muscle + uberon + UBERON:0001630 + + + + + + + + muscle organ + + + + + + + + + + + + + + + The liquid component of blood, in which erythrocytes are suspended. + + + plasma + portion of plasma + + + + BTO:0000131 + CALOHA:TS-0800 + EFO:0001905 + EMAPA:35690 + FMA:62970 + GAID:1178 + MA:0002501 + MAT:0000052 + MESH:D010949 + MIAA:0000052 + OpenCyc:Mx4rEg4ZYrIbEduAAAAOpmP6tw + UMLS:C0032105 + blood plasm + portion of blood plasma + uberon + UBERON:0001969 + + + + blood plasma + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A vessel through which blood circulates in the body. + consider adopting the EMAPA superclass 'vascular element', which includes microvasculature (e.g. capillaries), vascular plexus + + + Any of the vessels through which blood circulates in the body. [XAO:0001011_][VHOG] + Any of the vessels through which blood circulates in the body.[AAO] + The appearance of Chordata and subsequently the vertebrates is accompanied by a rapid structural diversification of this primitive linear heart: looping, unidirectional circulation, an enclosed vasculature, and the conduction system.[well established][VHOG] + annelids have blood vessels, but this class is not applicable to annelids. + FMA:63183 Blood vessel is categorized as 'general anatomical term'. Suggestion to map to region of vascular tree from Terry H at JAX + vascular element + + + + + + AAO:0011004 + AEO:0000207 + BTO:0001102 + CALOHA:TS-0080 + EFO:0000817 + EHDAA2:0003252 + EHDAA:240 + EMAPA:32743 + EMAPA:35993 + FMA:50722 + FMA:63183 + GAID:169 + MA:0000060 + MAT:0000393 + MESH:D001808 + OpenCyc:Mx4rvVjxlpwpEbGdrcN5Y29ycA + TAO:0002137 + UMLS:C0005847 + VHOG:0001250 + XAO:0001011 + ZFA:0005314 + region of vascular tree organ + vascular tree organ region + uberon + vas sanguineum + UBERON:0001981 + + + + + + + blood vessel + + + + + + + + + + Portion of semisolid bodily waste discharged through the anus[MW,modified] + + Excretion in semisolid state processed by the intestine.[FMA] + fecal + excreta + + + BTO:0000440 + CALOHA:TS-2345 + ENVO:00002003 + FMA:64183 + GAID:1199 + MA:0002509 + MAT:0000053 + MESH:D005243 + MIAA:0000053 + NCIT:C13234 + OpenCyc:Mx4rvVjJMZwpEbGdrcN5Y29ycA + UMLS:C0015733 + galen:Feces + faeces + fecal material + fecal matter + matières fécales@fr + merde@fr + partie de la merde@fr + piece of shit + porción de mierda@es + portion of excrement + portion of faeces + portion of fecal material + portion of fecal matter + portion of feces + portionem cacas + stool + teil der fäkalien@de + cow dung + cow pat + dung + fewmet + frass + guano + portion of dung + portion of guano + portion of scat + scat + spraint + uberon + droppings + excrement + ordure + spoor + UBERON:0001988 + + + feces + + + + + + + + + + + + Respiration organ that develops as an oupocketing of the esophagus. + + Either of two organs which allow gas exchange absorbing oxygen from inhaled air and releasing carbon dioxide with exhaled air.[AAO] + Lungs had already developed as paired ventral pockets from the intestine in the ancestor of Osteognathostomata. (...) In actinopterygian fishes, apart from Cladistia, the ventral intestinal pocket migrates dorsally and becomes the swim-bladder, a mainly hydrostatical organ (reference 1); Comparative transcriptome analyses indicate molecular homology of zebrafish swimbladder and Mammalian lung (reference 2).[well established][VHOG] + pulmonary + respiration organ in all air-breathing animals, including most tetrapods, a few fish and a few snails. In mammals and the more complex life forms, the two lungs are located in the chest on either side of the heart. Their principal function is to transport oxygen from the atmosphere into the bloodstream, and to release carbon dioxide from the bloodstream into the atmosphere. This exchange of gases is accomplished in the mosaic of specialized cells that form millions of tiny, exceptionally thin-walled air sacs called alveoli. // Avian lungs do not have alveoli as mammalian lungs do, they have Faveolar lungs. They contain millions of tiny passages known as para-bronchi, connected at both ends by the dorsobronchi + + + + AAO:0000275 + AAO:0010567 + BTO:0000763 + CALOHA:TS-0568 + EFO:0000934 + EHDAA2:0001042 + EHDAA:1554 + EHDAA:2205 + EMAPA:16728 + EV:0100042 + FMA:7195 + GAID:345 + MA:0000415 + MAT:0000135 + MESH:D008168 + MIAA:0000135 + NCIT:C12468 + OpenCyc:Mx4rvVjKy5wpEbGdrcN5Y29ycA + UMLS:C0024109 + VHOG:0000310 + XAO:0000119 + galen:Lung + pulmo + uberon + UBERON:0002048 + + + + + + Snakes and limbless lizards typically possess only the right lung as a major respiratory organ; the left lung is greatly reduced, or even absent. Amphisbaenians, however, have the opposite arrangement, with a major left lung, and a reduced or absent right lung [WP] + lung + + + + + + + + + + + + + + + + + + + + + + + + + + + + An interconnected tubular multi-tissue structure contains fluid that is actively transported around the organism[ZFA]. Examples: vasculature of lung, vasculature of face. + see also: vascular system. Consider merging? + + + vascular + BTO:0003718 + FMA:69050 + TAO:0005249 + ZFA:0005249 + vascular network + uberon + UBERON:0002049 + + + + + + vasculature + + + + + + + + + + + + + + + + + + + + + + + + + + + + Anatomical structure that is part of an embryo. + + + Anatomical structure that is part of the embryo and is comprised of portions of tissue or cells.[AAO] + Anatomical structure that is part of the embryo and is comprised of portions of tissue or cells.[TAO] + Anatomical structure that is part of the embryo and is comprised of portions of tissue or cells.[VSAO] + in FMA embryo is_a embryonic structure + + + + AAO:0000138 + BILA:0000034 + BTO:0000174 + CALOHA:TS-2110 + EFO:0000461 + FBbt:00004208 + FMA:69067 + GAID:407 + MESH:D004628 + RETIRED_EHDAA2:0003169 + TAO:0001105 + UMLS:C0013948 + VSAO:0000178 + XAO:0003042 + ZFA:0001105 + developing embryonic structure + embryonic anatomical structure + uberon + developing structure + embryonale Struktur + embryonic structures + UBERON:0002050 + + + + + + embryonic structure + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + The dermis is a layer of skin between the epidermis (with which it makes up the skin) and subcutaneous tissues, and is composed of two layers, the papillary and reticular dermis[WP]. + Consider adding a layer-of-skin grouping class for all skin layers + + + A collagenous layer of the skin subjacent to the epidermis and covering the hypodermis. It contains various types of cells (e.g. fibroblasts, pigment cells, nerve, blood vessels and scales. Le Guellec et al, 2004.[TAO] + When approaching controversies surrounding skin evolution, we need to remember that the skin consists of two layers, an epidermis and a dermis, not a single evolving structure. (...) It is little wonder that controversies about homology exist. If we think of the epidermis, the dermis, and their interactions as an evolving unit, then their specialized products (hair, feathers, and reptilian scales) are broadly homologous.[well established][VHOG] + dermal + + + + + AAO:0000128 + BTO:0000294 + CALOHA:TS-2076 + EFO:0000953 + EMAPA:17527 + EV:0100154 + FMA:70323 + GAID:1321 + MA:0000152 + MAT:0000153 + MESH:D020405 + MIAA:0000153 + TAO:0001119 + UMLS:C0011646 + VHOG:0000108 + XAO:0000217 + ZFA:0001119 + vertebrate dermis + uberon + corium + cutis + UBERON:0002067 + + + + + + + dermis + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + Lowermost layer of the integumentary system in vertebrates. Types of cells that are found in the hypodermis are fibroblasts, adipose cells, and macrophages. It is derived from the mesoderm, but unlike the dermis, it is not derived from the dermatome region of the mesoderm. The hypodermis is used mainly for fat storage[WP]. + + + A layer separating the inner face of the dermis from the subjacent muscle cells. It is covered on both sides by a basement membrane. It contains pigment cells. Le Guellec et al, 2004.[TAO] + A layer separating the inner face of the dermis from the subjacent muscle cells. It is covered on both sides by a basement membrane. It contains pigment cells[FMA:70544]. + hypodermal + subcutaneous + subcutaneus + BTO has 'subcutis', as part of dermis. We follow FMA in having distinct classes for hypodermis and superficial fascia, and including these as part of the non-skin intgeument. + + + + BTO:0001314 + CALOHA:TS-2366 + FMA:70544 + TAO:0001136 + UMLS:C0278403 + ZFA:0001136 + hypoderm + vertebrate hypodermis + uberon + sub-tegumental tissue + subcutaneous tissue + subcutis + subtegumental tissue + superficial fascia + tela subcutanea + UBERON:0002072 + + + + + + hypodermis + + + + + + + + + + + + + + + + + + + + + + + + + + + + + The post-cranial subdivision of skeleton structural components forming the long axis of the vertebrate body; in Danio, consisting of the notochord, vertebrae, ribs, supraneurals, intermuscular bones, and unpaired median fins; in human consists of the bones of the vertebral column, the thoracic cage and the pelvis[ZFA+FMA]. + + + Skeletal subdivision of the central body axis including vertebrae, notochord, ribs, and sternum.[VSAO] + The axial skeleton is formed by the vertebral column, a metameric, semi-flexible, arched bar located in the dorsal part of the trunk, and is formed by a series of cartilaginous or bony vertebrae. It provides suspension for the appendicular skeleton and protection for the spinal nerve cord.[AAO] + The post-cranial structural components forming the long axis of the vertebrate body; usually consists of the notochord, vertebrae, ribs, supraneurals, intermuscular bones, and unpaired median fins.[TAO] + The axial musculoskeletal system represents the plesiomorphic locomotor engine of the vertebrate body, playing a central role in locomotion. In craniates, the evolution of the postcranial skeleton is characterized by two major transformations. First, the axial skeleton became increasingly functionally and morphologically regionalized. Second, the axial-based locomotion plesiomorphic for craniates became progressively appendage-based with the evolution of extremities in tetrapods.[well established][VHOG] + axial skeleton + AAO:0000034 + EFO:0000942 + EHDAA2:0000161 + EHDAA:5049 + EMAPA:17214 + FMA:71221 + MA:0002986 + MAT:0000148 + MIAA:0000148 + TAO:0000317 + VHOG:0000317 + VSAO:0000093 + XAO:0003073 + ZFA:0000317 + post-cranial axial skeleton + uberon + UBERON:0002090 + + + + + previous some AOs had used the term 'axial skeleton' to include the skull. This is being resolved (see tracker items above). Status: MA - fixed. + postcranial axial skeleton + http://purl.obolibrary.org/obo/uberon/docs/The-axial-skeleton + + + + + + + + + + + + + + + + + + + + + + + + + + + + The organ covering the body that consists of the dermis and epidermis. + consider 'integumentary system' for invertebrates + + + MA uses the term skin to refer to what is called here: zone of skin + + + + + BTO:0001253 + CALOHA:TS-0934 + EFO:0000962 + EHDAA2:0001844 + EMAPA:17525 + FMA:7163 + MESH:D012867 + MFMO:0000099 + OpenCyc:Mx4rvVjX3ZwpEbGdrcN5Y29ycA + UMLS:C1123023 + XAO:0000023 + galen:Skin + entire skin + skin organ + uberon + entire integument + integument + integumental organ + pelt + skin + UBERON:0002097 + + + + + + + skin of body + + + + + + + + + + + + + + + + Organism subdivision which is the part of the body posterior to the cervical region (or head, when cervical region not present) and anterior to the caudal region. Includes the sacrum when present. + + + Organism subdivision that is the part of the body posterior to the head and anterior to the tail.[AAO] + Organism subdivision which is the part of the body posterior to the head and anterior to the tail.[TAO] + + + + + + + AAO:0010339 + BILA:0000116 + BTO:0001493 + CALOHA:TS-1071 + EFO:0000966 + EMAPA:31857 + FMA:7181 + MA:0000004 + MAT:0000296 + MIAA:0000296 + OpenCyc:Mx4rvVkJjpwpEbGdrcN5Y29ycA + TAO:0001115 + UMLS:C0460005 + XAO:0000054 + XAO:0003025 + ZFA:0001115 + galen:Trunk + thoracolumbar region + torso + trunk region + uberon + Rumpf + UBERON:0002100 + + + + + + + trunk + + + + + + + + + + + A paired organ of the urinary tract which has the production of urine as its primary function. + + One of either of a pair of structures lying on either side of the dorsal aorta in which fluid balance is regulated and waste is excreted out in the form of urine.[AAO] + renal + + + + + AAO:0000250 + BTO:0000671 + CALOHA:TS-0510 + EFO:0000929 + EMAPA:17373 + EV:0100096 + FMA:7203 + GAID:423 + MA:0000368 + MAT:0000119 + MESH:D007668 + MIAA:0000119 + NCIT:C12415 + OpenCyc:Mx4rvVjlYpwpEbGdrcN5Y29ycA + UMLS:C0022646 + XAO:0003267 + galen:Kidney + reniculate kidney + uberon + UBERON:0002113 + + + + + + + kidney + + + + + + + + + Lung which consists of the right upper lobe, middle lobe and right lower lobe.[FMA] + + Lungs had already developed as paired ventral pockets from the intestine in the ancestor of Osteognathostomata.[well established][VHOG] + https://github.com/obophenotype/uberon/wiki/Modeling-paired-structures-Design-Pattern + + + + EHDAA2:0001730 + EHDAA:4969 + EMAPA:17661 + FMA:7309 + MA:0000426 + NCIT:C33483 + OpenCyc:Mx8Ngh4rvgHsHZwpEbGdrcN5Y29ycB4rvVjKy5wpEbGdrcN5Y29ycA + UMLS:C0225706 + VHOG:0000301 + uberon + UBERON:0002167 + + + right lung + + + + + + + + + + Lung which consists of the left upper lobe and left lower lobe.[FMA] + + Lungs had already developed as paired ventral pockets from the intestine in the ancestor of Osteognathostomata.[well established][VHOG] + https://github.com/obophenotype/uberon/wiki/Modeling-paired-structures-Design-Pattern + + + + EHDAA2:0000943 + EHDAA:4947 + EMAPA:17653 + FMA:7310 + MA:0000425 + NCIT:C32967 + OpenCyc:Mx8Ngh4rvgIFoJwpEbGdrcN5Y29ycB4rvVjKy5wpEbGdrcN5Y29ycA + UMLS:C0225730 + VHOG:0000618 + uberon + UBERON:0002168 + + + left lung + + + + + + + + + + the upper conducting airways of the lung; these airways arise from the terminus of the trachea + + Each of the two primary divisions of the trachea leading respectively into the right and the left lung. [Dorian_AF, Elsevier's_encyclopaedic_dictionary_of_medicine, Part_B:_Anatomy_(1988)_Amsterdam_etc.:_Elsevier][VHOG] + bronchial + In humans, the main bronchus is histologically identical to trachea; 2ary and 3ary bronchi are not; epithelium becomes simple columnar, goblet cell number decreases, elastic fibers in lamina propria increases, distribution more uniform. Muscular layer between mucosa and submucosa appears. cartilage rings become discontinuous plates connected by fibrous connective tissue + + + + BTO:0001340 + CALOHA:TS-1229 + EFO:0000932 + EMAPA:32689 + EV:0100041 + FMA:7409 + GAID:346 + MA:0000436 + MAT:0000133 + MESH:D001980 + MIAA:0000133 + NCIT:C12683 + UMLS:C0006255 + VHOG:0000262 + XAO:0000121 + bronchi + bronchial trunk + uberon + bronchial tissue + UBERON:0002185 + + + + + bronchus + + + + + + + + + + Anatomical cluster consisting of the hematopoietic system and the lymphoid system, or its analogs. + + + CALOHA:TS-2018 + EHDAA2:0004615 + EMAPA:18765 + FMA:74562 + MA:0000013 + hematolymphoid system + lymphomyeloid complex + uberon + haemolymphoid system + UBERON:0002193 + hemolymphoid system + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + The dermis, epidermis and hypodermis. + in FMA intergument = skin+superficial fascia(hypodermis), skin=dermis+epidermis+hair_nail. Note that the definition provided here excludes the more general sense of the term 'integument' used in invertebrates; consider 'integumental system'. Note that the VSAO class appears to include adnexa by its definition. + + + Anatomical system that protects the body from damage, comprising the skin and its appendages.[AAO] + Surface structure that is the outer protective covering of the body.[VSAO] + The outer protective barrier that separates the animal from its aquatic environment. Le Guellec et al, 2004.[TAO] + integumental + integumentary + + AAO:0000239 + BTO:0000634 + FMA:74657 + TAO:0000368 + VSAO:0000029 + ZFA:0000368 + galen:Integument + dermis plus epidermis plus hypodermis + integumentum commune + skin and subcutaneous tissue + skin plus hypodermis + the integument + uberon + Hautsystem@de + dermal system + dermoid system + skin + tegument + vertebrate integument + UBERON:0002199 + + + + + + integument + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + Anatomical system that consists of the muscular and skeletal systems. + + + Anatomical system that provides locomotion and physical support to the organism.[AAO] + There are more than 50,000 extant vertebrate species, representing over 500 million years of evolution. During that time, the vertebrate musculoskeletal systems have adapted to aquatic, terrestrial, fossorial, and arboreal lifestyles, while simultaneously retaining functionally integrated axial and appendicular skeletal systems.[well established][VHOG] + musculoskeletal + + + + + + AAO:0010546 + CALOHA:TS-1311 + EMAPA:32714 + EV:0100139 + FMA:7482 + GAID:98 + MA:0002418 + MESH:D009141 + OpenCyc:Mx4rQRpVNgAKEdyHxgDggVfs8g + UMLS:C0026860 + VHOG:0001275 + VSAO:0000031 + XAO:0000168 + musculo-skeletal system + uberon + UBERON:0002204 + + + musculoskeletal system + + + + + + + + + + + + + + + + + + + + + + + + + + Joint in which the articulating bones or cartilages are connected by an articular capsule which encloses a synovial membrane and a synovial cavity. Examples: Temporomandibular joint, knee joint.[FMA] + + + Is a joint that is located at the point of contact of articulating bones allowing movement. The joint has a capsule containing synovial fluid surrounding the articulating bone surfaces.[TAO] + + + + AEO:0000183 + CALOHA:TS-2138 + EHDAA2:0003183 + FMA:7501 + MA:0000322 + OpenCyc:Mx4rv2bBV5wpEbGdrcN5Y29ycA + TAO:0005153 + ZFA:0005153 + galen:SynovialJoint + articulatio synoviale + diarthroses + diarthrosis + diarthrosis joint + uberon + diarthrodial joints + UBERON:0002217 + + + + + + synovial joint + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + The part of the coelemic cavity lumen that is enclosed by the walls of the thorax. + + + In many species, the diaphragm separates thoracic and abdominal cavities + + + + + EMAPA:36497 + FMA:7565 + GAID:93 + MA:0000032 + MESH:A01.911.800 + OpenCyc:Mx4rmvyleLfEEduAAAACs6hRXg + OpenCyc:Mx4rvhU_TpwpEbGdrcN5Y29ycA + UMLS:C0230139 + cavitas thoracis + cavity of chest + cavity of thorax + chest cavity + pectoral cavity + space of thoracic compartment + thoracic lumen + uberon + UBERON:0002224 + + + + thoracic cavity + + + + + + + + + + + + + + + + + + + + + + + The cavity within the body of all animals higher than the coelenterates and certain primitive worms, formed by the splitting of the embryonic mesoderm into two layers. In mammals it forms the peritoneal, pleural, and pericardial cavities. + check the FMA placement here; ncit placement of body cavity here probably not correct + + + Anatomical space, part of the trunk that contains the pericardial and pleuroperitoneal cavities[ZFA]. + The cavity within the body of all animals higher than the coelenterates and certain primitive worms, formed by the splitting of the embryonic mesoderm into two layers. In mammals it forms the peritoneal, pleural, and pericardial cavities[BTO]. + In mammals it forms the peritoneal, pleural, and pericardial cavities + UBERON:0000169 + body cavity + + + + AEO:0000186 + BTO:0001707 + EHDAA2:0000267 + FBbt:00005060 + FMA:85006 + RETIRED_EHDAA2:0003186 + TAO:0001438 + UMLS:C0333343 + ZFA:0001438 + galen:BodyCavity + coelomic cavity + coelomic cavity lumen + main body cavity + space of body compartment + ventral body cavity + uberon + celom + coelom + coelome + hemocoel + UBERON:0002323 + + + + + coelemic cavity lumen + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A flexible rod-shaped body found in embryos of all chordates. It is composed of cells derived from the mesoderm and defines the primitive axis of the embryo. In some chordates, it persists throughout life as the main axial support of the body, while in most vertebrates it becomes the nucleus pulposus of the intervertebral disc. The notochord is found ventral to the neural tube. + + + Avascular multi-tissue structure composed of large vacuolated epithelial cells (chordablasts) and perichordal fibrous tissue.[VSAO] + Rod-like principal supportive element of the embryo and larva, present in the midline just ventral to the neural tube, and differentiating during the segmentation period to form large vacuolated epithelial cells and a surrounding a sheath of fibrous and elastic layers. Layering of the sheath may differ in structure, thickness and development among groups; in cypriniforms there are actually three very thin layers to the sheath. A functional, well developed notochord is present throughout life in certain basal fish groups but not in cypriniforms. Kimmel et al, 1995.[TAO] + Slender rod of fibrous connective tissue surrounding a core of fluid-filled cells of mesodermal origin; it lies above the gut and directly beneath the spinal cord. The notochord is present during early development and in a few cases it is retained through life; however, usually the notochord is replaced by the vertebral column.[AAO] + relationship type change: differentiates_from mesoderm (AAO:0000304) CHANGED TO: develops_from mesoderm (UBERON:0000926)[AAO] + (...) at some stage of its development, every chordate exhibits five uniquely derived characters or synapomorphies of the group: (...) (3) a stiff, longitudinal rod of turgid cells along the dorsal part of the body that is called a notochord (...).[well established][VHOG] + notochordal + In between vertebra the notochord becomes the nucleus pulposus, under it degenerates, and at anterior end in some species its tissue merges with some of the cranial bones.. Some organisms retain a post-embryonic notochord. + + + + + + + + AAO:0000327 + BTO:0001768 + CALOHA:TS-0690 + EHDAA2:0001277 + EHDAA:1241 + EHDAA:6021 + EMAPA:16191 + EV:0100002 + FMA:85521 + GAID:1311 + MAT:0000281 + MESH:A16.254.610 + TAO:0000135 + UMLS:C0028439 + VHOG:0000199 + VSAO:0000032 + XAO:0000055 + ZFA:0000135 + embryonic notocord + notocord + uberon + notochorda + UBERON:0002328 + + + + + + The notochord appears early in embryogeny and plays an important role in promoting or organizing the embryonic development of nearby structures. In most adult chordates the notochord disappears or becomes highly modified. In some non-vertebrate chordates and fishes the notochord persists as a laterally flexible but incompressible skeletal rod that prevents telescopic collapse of the body during swimming[TOLWEB] + notochord + + + + + + + + + + + + + + + + + + Somites are spheres of epithelial cells that form sequentially along the anterior-posterior axis of the embryo through mesenchymal to epithelial transition of the presomitic mesoderm. + currently classified as an epithelial vesicle, consistent with EHDAA2 and https://github.com/obophenotype/uberon/wiki/The-neural-crest. Consider making 'somitic mesoderm' a separate term and correlate with regionalization processes. Consider moving ZFA term to 'trunk somite' as it is part of the trunk + + + + Post-cranial axial segments which form sclerotome and dermomyotome.[AAO] + Undifferentiated mesodermal components of early trunk or tail segments or metameres, derived from paraxial mesoderm; forms myotomes, sclerotomes and perhaps dermatomes. Kimmel et al, 1995.[TAO] + relationship loss: develops_from paraxial mesenchyme (TAO:0000942)[TAO] + relationship type change: OBO_REL:part_of trunk (TAO:0001115) CHANGED TO: develops_from trunk (UBERON:0002100)[TAO] + relationship type change: part_of paraxial mesoderm (AAO:0010568) CHANGED TO: develops_from paraxial mesoderm (UBERON:0003077)[AAO] + (...) cephalocordates and craniates belong to a group known as Somitichordata. Somitichordate synapomorphies include (1) somites (...) (reference 1); The idea that the last common ancestor of bilaterian animals (Urbilateria) was segmented has been raised recently on evidence coming from comparative molecular embryology (reference 2).[well established][VHOG] + somitic + mesodermal cluster + + + + AAO:0010569 + AEO:0001015 + BTO:0001558 + EHDAA2:0003436 + EHDAA:366 + EHDAA:699 + EMAPA:31169 + FMA:85522 + GAID:1306 + MAT:0000068 + MESH:A16.254.425.660.750 + MIAA:0000068 + TAO:0000155 + UMLS:C0376449 + VHOG:0000191 + XAO:0000058 + ZFA:0000155 + uberon + epimere + epimere mesoderm + epithelial somite + somites + somitic mesoderm + somitus + UBERON:0002329 + + + + + + When the somite becomes segmented from the segmental plate, it is composed of an epithelial sac enclosing mesenchymal somitocoel cells. Thereafter the somite differentiates into two parts, the ventro-medial mesenchymal sclerotome and the dorso-lateral epithelial dermomyotome. This change in the epithelial somite depends on surrounding tissue [PMID:15906248] + somite + + + + + + + + + + + + + + + + + + + + + + Anatomical system that consists of the glands and parts of glands that produce exocrine secretions and help to integrate and control bodily metabolic activity. Exocrine glands are glands that secrete their products (hormones) into ducts (duct glands). They are the counterparts to endocrine glands, which secrete their products (hormones) directly into the bloodstream (ductless glands) or release hormones (paracrines) that affect only target cells nearby the release site. [Wikipedia]. + + + + + + CALOHA:TS-2057 + EHDAA2:0002225 + EMAPA:35329 + FMA:85539 + MA:0002411 + UMLS:C1516995 + WikipediaCategory:Exocrine_system + exocrine glandular system + uberon + UBERON:0002330 + + + + exocrine system + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A specialized region of ectoderm found between the neural ectoderm (neural plate) and non-neural ectoderm and composed of highly migratory pluripotent cells that delaminate in early embryonic development from the dorsal neural tube and give rise to an astounding variety of differentiated cell types[MP]. + consider including subclasses for pre- and post- migratory (e.g. sheets/paths/streams). + + + + A cell population arising from the dorsolateral aspect of the central nervous system primordium during the segmentation period, and later migrating along stereotyped pathways to give rise to a diverse and well-defined set of cell types including pigment cells, peripheral neurons and glia, and head cartilage. Kimmel et al, 1995.[TAO] + Migratory cell population which delaminates from neural tube, borders surface ectoderm and neural ectoderm, and gives rise to many different tissue types.[AAO] + A well developed neural crest population is present in lampreys (Horigome et al. 1999 ; Tomsa & Langeland, 1999) and gnathostomes. chordate fossils from the early Cambrian (Yunnanozoan and Haikouella) with apparent neural-crest derived structures (pharyngeal denticles and pharyngeal skeletons resembling the striped mucocartilage of the branchial bars in lamprey ammocoete larvae), suggests that neural crest arose very early in vertebrate evolution (Chen et al. 1999; Holland & Chen, 2001). The invertebrate chordates apparently lack defini- tive neural crest. One marker of migrating neural crest in some vertebrates, the antibody HNK1, does not recognize any cells in amphioxus embryos (Holland, unpublished). Even so, in both amphioxus and tunicates, cells at the edges of the neural plate and adjacent nonneural ectoderm share some properties of neural crest[PMID:11523831] + We conclude that the neural crest is a vertebrate novelty, but that neural crest cells and their derivatives evolved and diversified in a step-wise fashion - first by elaboration of neural plate border cells, then by the innovation or co-option of new or ancient metazoan cell fates.[well established][VHOG] + + + + + + AAO:0010578 + BTO:0001764 + CALOHA:TS-0676 + EHDAA2:0004419 + EMAPA:32737 + FMA:86666 + GAID:1310 + MAT:0000066 + MESH:A16.254.600 + MIAA:0000066 + TAO:0000045 + UMLS:C0027789 + VHOG:0000057 + XAO:0000048 + ZFA:0000045 + NC + uberon + crista neuralis + neural crest material + UBERON:0002342 + + + + + + Gene notes: Many factors and genes, such as Pax3 (Tremblay et al., 1995), slug (Nieto et al., 1994), AP-2 (Zhang et al., 1996; Schorle et al., 1996), and Wnt-1/3a (Ikeya et al., 1997) are expressed in the dorsal most region of the neural tube, and have been shown to be involved in the generation of neural crest cells. + neural crest + + + + + + + + + + + + + + + + + + Embryonic ectoderm that gives rise to nervous tissue. + + + (...) the ability of ectoderm to produce neuronal cells is a general metazoan feature.[well established][VHOG] + neurectodermal + we prefer neurectoderm to neural ectoderm since placodal ectoderm is not classified here + + + + AAO:0011074 + BILA:0000039 + CALOHA:TS-1212 + EHDAA2:0001248 + EHDAA:1498 + EHDAA:255 + EMAPA:16073 + EV:0100004 + FBbt:00001061 + FMA:87657 + MAT:0000176 + MIAA:0000176 + TAO:0001120 + UMLS:C1518271 + VHOG:0000150 + XAO:0000042 + ZFA:0001120 + neural ectoderm + neuroectoderm + uberon + epithelium tubi neuralis; neuroectoderma + neuaral ectoderm + presumptive central nervous system + ventral neurogenic region + UBERON:0002346 + + + + + neurectoderm + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A gland that secretes products (excluding hormones and other chemical messengers) into ducts (duct glands) which lead directly into the external environment[WP]. Typical exocrine glands include sweat glands, salivary glands, mammary glands, stomach, liver, pancreas + Currently this is logically defined by the system it belongs to, but a better system may be base this on presence/absence of ducts. However, the dual nature of the liver should be taken into consideration here. Consider adding subclasses + + + + + + + AEO:0000097 + BTO:0000765 + CALOHA:TS-2012 + EHDAA2:0003097 + EMAPA:35327 + FMA:9596 + GAID:34 + MA:0002564 + MESH:D005088 + UMLS:C0015282 + ducted gland + glandula exocrina + uberon + UBERON:0002365 + + + + + + exocrine gland + + + + + + + + + Tissue with cells that deposit non-polarized extracellular matrix including connective tissue fibers and ground substance. + + + One of the four types of tissue in traditional classifications. It is largely a category of exclusion rather than one with a precise definition, but there are certain characteristics shared by all or most tissues in this category, such as involvement in structure and support, derived from mesoderm, and characterized largely by the traits of non-living tissue.[AAO] + Portion of tissue that consists of mesodermally derived cells and intercellular matrix comprised of protein fibers and carbohydrates, which supports, ensheathes and binds together other tissues.[TAO] + Tissue with cells that deposit non-polarized extracellular matrix including connective tissue fibers and ground substance.[VSAO] + MA also has set of connective tissues + + + + + + AAO:0000098 + BTO:0000421 + CALOHA:TS-2009 + EFO:0000952 + EMAPA:35251 + FMA:9640 + GAID:100 + MA:0000011 + MAT:0000301 + MESH:D003238 + MIAA:0000301 + OpenCyc:Mx4rv-aBgZwpEbGdrcN5Y29ycA + TAO:0001641 + UMLS:C0009780 + VSAO:0000017 + XAO:0001017 + ZFA:0001632 + galen:ConnectiveTissue + portion of connective tissue + textus connectivus + uberon + Bindegewebe + UBERON:0002384 + + + + + + connective tissue + + + + + + + + + + + + + + + + + + + + + + Muscle tissue is a contractile tissue made up of actin and myosin fibers[GO]. + + + One of the four types of tissue in traditional classifications. Tissue that contains cells with contractile filaments that move past each other and change the size of the cell. Muscle tissue also is separated into three distinct categories.[AAO] + + + + + + AAO:0000306 + AEO:0000122 + CALOHA:TS-0642 + EHDAA2:0003122 + EMAPA:32715 + FMA:9641 + MA:0002437 + MESH:D009132 + UMLS:C2328219 + galen:MuscleTissue + muscular tissue + portion of muscle tissue + textus muscularis + uberon + UBERON:0002385 + + + Vertebrate muscle is categorized into three major muscle types defined by their structural and functional properties: skeletal, cardiac and smooth. In Dmel the counterparts are somatic, heart/cardiac and visceral. Here we take a cell type based approach. + muscle tissue + + + + + + + + + + + + + + + + + + + + + + Anatomical system that is involved in the production of hematopoietic cells. + + + Anatomical system that consists of the blood and blood forming tissues.[AAO] + Zebrafish developmental hematopoiesis shows close correspondence to the development of the mammalian hematopoietic system and is regulated by conserved molecular pathways.[well established][VHOG] + hematopoietic + In humans this is primarily the bone marrow, spleen, tonsils, and lymph nodes + + + + + AAO:0011002 + BTO:0000570 + CALOHA:TS-0449 + EFO:0000798 + EMAPA:35402 + EV:0100045 + FMA:9667 + GAID:1008 + MA:0002434 + MAT:0000022 + MESH:D006413 + MIAA:0000022 + TAO:0005023 + UMLS:C0018957 + VHOG:0001624 + XAO:0000122 + ZFA:0005023 + haematological system + haemopoietic system + organa haemopoietica + uberon + Blutbildungssystem + haematopoietic system + hematological system + hematolymphoid system + hemopoietic system + UBERON:0002390 + + + + + + + hematopoietic system + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + Connected anatomical system that forms a barrier between an animal and its environment. In vertebrates, the integumental system consists of the epidermis, dermis plus associated glands and adnexa such as hair and scales. In invertebrates, the integumental system may include cuticle. + + + (...) the integument of many tetrapods is reinforced by a morphologically and structurally diverse assemblage of skeletal elements. These elements are widely understood to be derivatives of the once all-encompassing dermal skeleton of stem-gnathostomes (...).[well established][VHOG] + + + UBERON:0007029 + + + + + AEO:0000154 + BILA:0000118 + CALOHA:TS-1299 + CARO:0002001 + EFO:0000807 + EHDAA2:0000836 + EHDAA2_RETIRED:0003154 + EHDAA:6520 + EMAPA:17524 + EV:0100151 + FBbt:00004969 + FMA:72979 + HAO:0000421 + MA:0000014 + MAT:0000033 + MESH:D034582 + MIAA:0000033 + TADS:0000108 + UMLS:C0037267 + VHOG:0000403 + XAO:0000176 + galen:Surface + integumentary system + uberon + body surface + dermal system + external covering of organism + integumentum commune + organism surface + surface + UBERON:0002416 + + + + + integumental system + + + + + + + + + + The abdominal segment of the torso. + + + + + EMAPA:35104 + FMA:259211 + MA:0000021 + uberon + abdomen/pelvis/perineum + lower body + lower trunk + lumbar region + UBERON:0002417 + abdominal segment of trunk + + + + + + + + + + + + + + + Skeletal tissue with a collagen-rich extracellular matrix vascularized, mineralized with hydroxyapatite and typically including osteocytes located in lacunae that communicate with one another by cell processes (in canaliculi). Bone is deposited by osteoblasts. + see https://github.com/obophenotype/uberon/issues/27 + + + Skeletal tissue with a collagen-rich extracellular matrix vascularized, mineralized with hydroxyapatite and typically including osteocytes located in lacunae that communicate with one another by cell processes (in canaliculi). Bone is deposited by osteoblasts.[VSAO] + + + + CALOHA:TS-2011 + EMAPA:35179 + FMA:224804 + MA:0002780 + MESH:D001842 + UMLS:C0391978 + VSAO:0000047 + XAO:0004040 + ZFA:0005621 + galen:BoneTissue + calcium tissue + osseous tissue + osteogenic tissue + mineralized bone tissue + uberon + bone + portion of bone tissue + UBERON:0002481 + + + + bone tissue + + + + + + + + + + + + + + + an organ that functions as a secretory or excretory organ + + + glandular + UBERON:MIAA_0000021 + + + + + AAO:0000212 + AEO:0000096 + BTO:0000522 + EFO:0000797 + EHDAA2:0003096 + EHDAA:2161 + EHDAA:4475 + EHDAA:6522 + EMAPA:18425 + FBbt:00100317 + FMA:7146 + FMA:86294 + HAO:0000375 + MA:0003038 + MAT:0000021 + MIAA:0000021 + OpenCyc:Mx4rwP3vyJwpEbGdrcN5Y29ycA + UMLS:C1285092 + WikipediaCategory:Glands + galen:Gland + glandular organ + uberon + Druese + glandula + UBERON:0002530 + + + + + gland + + + + + + + + + + In amniote animal embryology, the epiblast is a tissue type derived either from the inner cell mass in mammals or the blastodisc in birds and reptiles. It lies above the hypoblast. In mammalian embryogenesis, the columnar cells of the epiblast are adjacent to the trophoblast, while the cuboidal cells of the hypoblast are closer to the blastocoele. The epiblast, whilst referred to as the primary ectoderm, differentiates to form all three layers of the trilaminar germ disc in a process called gastrulation[WP]. The outer of the two layers of the blastoderm that form during gastrulation, corresponding to primitive ectoderm during gastrulation and to the definitive ectoderm after gastrulation[ZFA] + MP says - tissue that gives rise to the ectoderm, endoderm and mesoderm of the embryo proper. In HOG, epiblast is part of primitive streak/blastpore, which is inconsistent with the MP definition of primitive streak as a ridge of the epiblast. Note that these terms, epiblast and hypoblast, are also used to describe layers of the avian embryonic blastoderm, but the layers so-named seem to be altogether different in these two kinds of vertebrate embryos(CVS). Consider obsoleting this as a grouping class + + + In pregastrula zebrafish embryos, the epiblast is an inverted cup of cells that sits on top of a large yolk cell. (...) In amniote embryos (mammals and birds), gastrulation initiates in an epithelial layer called the epiblast. Cells in the epiblast undergo an epithelial to mesenchymal transition (EMT), migrate through the primitive streak (PS), and incorporate in the middle (mesoderm) or outer (endoderm) layer. The presumptive definitive endoderm (DE) cells invade and displace an outer layer of extraembryonic tissue cells, the hypoblast in chick and the visceral endoderm (VE) in mouse, which form supporting structures such as the yolk sac.[uncertain][VHOG] + + BTO:0004593 + FMA:296704 + MAT:0000067 + MIAA:0000067 + VHOG:0000243 + epiblast + uberon + blastocyst + ectoblast + epiblastus + primitive ectoderm + UBERON:0002532 + + + + + + + + + epiblast (generic) + + + + + + + + + + + + + + + + Anatomical space which contains portions of one or more body substances and is bounded by the internal surface of one maximally connected anatomical structure. Examples: cranial cavity, pharyngeal recess space, nasal cavity, tooth socket, cavity of serous sac, lumen of stomach, lumen of artery, fornix of vagina. + + + cavity + + + FMA:67552 + MA:0002447 + galen:Cavity + uberon + UBERON:0002553 + + + anatomical cavity + + + + + + + + + + + + + + + + + + + + + + + + + + + + A temporary epithelium that derives from the outer layer of the ectdoerm and is shed once the inner layer differentiates to form a true epidermis. + + + The outermost epidermal layer covering the fish at embryonic stages; derived from the EVL and thought to eventually be replaced by the superficial stratum of the epidermis. Sometimes used synonymously with EVL. Le Guellec et al, 2004.[TAO] + relationship type change: OBO_REL:part_of ectoderm (TAO:0000016) CHANGED TO: develops_from ectoderm (UBERON:0000924)[TAO] + In mice, the first non-basal layer formed at ~E9.5; it is a temporary structure composed of simple squamous epithelium that serves as the first barrier to the embryo's physical environment, exists throughout the entire keratinocyte stratification process, and sheds off at ~E17, when it is replaced by corneocytes[MP] + In some mammals, Eyelid Fusion is thought to be driven by a population of cells which are derived from the periderm, the outermost layer of the developing epidermis + Originally the epidermis is one layer thick, in most vertebrates it soon becomes a two-layered structure. The outer layer gives rise to the periderm. The periderm goes through distinct developmental phases and is ultimately sloughed into the amniotic fluid when differentiation of the underlying epidermal layers is complete. The function of the periderm is not known, but is thought to be related to transport/exchange between the fetus and the amniotic fluid (http://courses.washington.edu/hubio567/devbio/periderm.html) + + + EHDAA2:0001846 + EHDAA:6538 + FMA:295662 + TAO:0001185 + UMLS:C1518973 + VHOG:0001680 + XAO:0000029 + ZFA:0001185 + skin periderm + uberon + EVL + epidermis epithelial layer + epidermis outer layer + epitrichium + periderm + UBERON:0003055 + + + + periderm + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + Unsegmented field of paraxial mesoderm present posterior to the most recently formed somite pair, from which somites will form. + + + Unsegmented field of paraxial mesoderm present posterior to the most recently formed somite pair, from which somites will form. Kimmel et al, 1995.[TAO] + It is reasonable to assume that the proximate invertebrate ancestor of the vertebrates had an amphioxus-like tail bud in its larval stage. This archetypal tail bud would have (...) (3) lacked any component of mesenchyme cells, (4) budded off new mesodermal segments directly, without any intervening zone of presomitic mesoderm (...). Then, early in vertebrate evolution, epithelium-to-mesenchyme interconversions (and the gene networks for effecting them) became prominent features of development. (...) In any case, conspicuous mesenchymal components tended to be added to the vertebrate tail bud itself. In addition, a mesenchymatous presomitic mesoderm (not a part of the tail bud proper) came to intervene between the tail bud and the forming somites.[well established][VHOG] + AAO:0011086 + EFO:0001982 + EMAPA:16189 + EMAPA:16752 + TAO:0000279 + VHOG:0000559 + XAO:0000057 + ZFA:0000279 + segmental plate + unsegmented paraxial mesoderm + uberon + PSM + presumptive somite mesoderm + somitogenic mesoderm + somitomeric mesoderm + unsegmented mesenchyme + UBERON:0003059 + + + presomitic mesoderm + + + + + + + + + + + + + + + + + + + + + + + + + + + Blood islands are structures in the developing embryo which lead to many different parts of the circulatory system. They primarily derive from plexuses formed from angioblasts. Within them, vacuoles appear through liquefaction of the central part of the syncytium into plasma. The lumen of the blood vessels thus formed is probably intracellular. The flattened cells at the periphery form the endothelium. The nucleated red blood corpuscles develop either from small masses of the original angioblast left attached to the inner wall of the lumen or directly from the flat endothelial cells. In either case the syncytial mass thus formed projects from and is attached to the wall of the vessel. Such a mass is known as a blood island and hemoglobin gradually accumulates within it. Later the cells on the surface round up, giving the mass a mulberry-like appearance. Then the red blood cells break loose and are carried away in the plasma. Such free blood cells continue to divide. Blood islands have been seen in the area vasculosa in the omphalomesenteric vein and arteries, and in the dorsal aorta[WP, unvetted]. + + + Nests of developing blood cells arising late in the segmentation period from the intermediate mass, and located in the anterior-ventral tail, just posterior to the yolk extension. Kimmel et al, 1995.[TAO] + Region located on the ventral surface of the developing embryo that is a site of hematopoiesis and that is analogous to the yolk sac blood islands of higher vertebrates.[AAO] + relationship loss: part_of intermediate cell mass of mesoderm (TAO:0000033)[TAO] + Small clusters of mesodermal cells called blood islands mark the embryonic debut of the cardiovascular system (in vertebrates) (reference 1); In birds and mammals, primitive hemangioblasts are extraembryonic, populating the yolk sac as the so-called blood islands (reference 2).[well established][VHOG] + EHDAA2 distinguishes 3 types, but does not have a superclass. The VHOG class may refer to yolk sac + ventral lateral plate mesoderm + + + + AAO:0011006 + EFO:0003489 + EHDAA:207 + TAO:0000094 + TE:E5.11.2.0.0.0.4 + UMLS:C1511224 + VHOG:0000085 + XAO:0000067 + ZFA:0000094 + blood islands + uberon + VBI + caudal hematopoietic tissue + posterior ICM + posterior blood island + ventral blood island + UBERON:0003061 + + + + + + + blood island + + + + + + + + + + + + + + + + + + + + + + + + + + + The axial mesoderm includes the prechordal mesoderm and the chordamesoderm. It gives rise to the prechordal plate and to the notochord. + + + The portion of the mesoderm underlying the midline of the embryo. [Gastrulation:_From_cells_to_embryo_(2004)_Cold_Spring_Harbor, Glossary_XV, New_York:_Cold_Spring_Harbor_Laboratory_Press, Stern_CD][VHOG] + + AAO:0011017 + EFO:0003647 + TAO:0001204 + VHOG:0000107 + XAO:0000205 + ZFA:0001204 + uberon + chordamesoderm + UBERON:0003068 + + + + axial mesoderm + + + + + + + + + + + + + + + + + + + + + + + + A region of embryonic ectodermal cells that lie directly above the notochord. During neurulation, they change shape and produce an infolding of the neural plate (the neural fold) that then seals to form the neural tube[XAO]. The earliest recognizable dorsal ectodermal primordium of the central nervous system present near the end of gastrulation before infolding to form the neural keel; consists of a thickened pseudostratified epithelium[ZFA] + + + The earliest recognizable dorsal ectodermal primordium of the central nervous system present near the end of gastrulation before infolding to form the neural keel; consists of a thickened pseudostratified epithelium. Kimmel et al, 1995.[TAO] + (...) at some stage of its development, every chordate exhibits five uniquely derived characters or synapomorphies of the group: (...) (4) a single, tubular nerve cord that is located dorsal to the notochord (...).[well established][VHOG] + + + + + AAO:0011072 + BTO:0001765 + DHBA:10153 + DMBA:15565 + EHDAA:346 + EHDAA:902 + EMAPA:35593 + FMA:293879 + RETIRED_EHDAA2:0001252 + TAO:0000132 + UMLS:C0920623 + VHOG:0000068 + XAO:0000249 + ZFA:0000132 + uberon + lamina neuralis + presumptive central nervous system + UBERON:0003075 + + + + + + neural plate + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + The paraxial mesoderm is the mesoderm located bilaterally adjacent to the notochord and neural tube[GO] + + + Mesoderm lateral to the neural tube and notochord that is divided into cranial and post-cranial portions. The trunk portions further segment into somites.[AAO] + Presently, Cephalochordata, Urochordata, and Vertebrata are placed as subphyla of the phylum Chordata, in which the overall organization of embryonic tissues (dorsal hollow nerve cord, ventral digestive tract, axial notochord, and bilateral paraxial mesoderm) is largely conserved. In contrast, the echinoderms and hemichordates are sister groups of the chordates and they lack the notochord and paraxial mesoderm. Thus, the basic mesodermal organization of vertebrates must have appeared first in the common ancestor of the chordates.[well established][VHOG] + note that all AOs differ in the relationship between this structure and the mesoderm; in ZFA it is a subclass (and this is implied by the GO definition and GO relationships), in AAO it is part of, and in EHDAA2 it develops from the mesoderm (but in EHDAA2 the naming convention is to use 'paraxial mesenchyme', rather than 'paraxial mesoderm'). Also in ZFA it is part of the trunk whereas this conflicts with the division into head and trunk in ehdaa2 (which we follow here) + + + + + AAO:0010568 + EFO:0003515 + EMAPA:16183 + EMAPA:16751 + FMA:293145 + TAO:0000255 + UMLS:C1284009 + VHOG:0000114 + XAO:0000259 + ZFA:0000255 + paraxial mesenchyme + somitic mesoderm + uberon + mesoderma paraxiale + UBERON:0003077 + + + + + + paraxial mesoderm + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + Portion of the middle of the three primary germ layers of the embryo that resides on the periphery of the embryo, is continuous with the extra-embryonic mesoderm, splits into two layers enclosing the intra-embryonic coelom, and gives rise to body wall structures[MP]. + + + Portion of mesoderm traditionally thought to give rise to limb bones and parts of the girdles.[AAO] + The portion of the mesoderm of the trunk of vertebrate embryos lying lateral to the intermediate mesoderm. [...] [It] subdivides into two plates: one dorsal, called the somatopleure, and one ventral, called the splanchnopleure. [Gastrulation:_From_cells_to_embryo_(2004)_Cold_Spring_Harbor, Glossary_XV, New_York:_Cold_Spring_Harbor_Laboratory_Press, Stern_CD][VHOG] + A ventrolateral zone of amphioxus mesoderm grows down to surround the gut. Homology of this zone to the lateral plate mesoderm of vertebrates is supported by site of origin and fate.[well established][VHOG] + subclass of mesoderm in ZFA. + UBERON:0006258 + + + + + AAO:0010574 + EHDAA2:0000919 + EHDAA:379 + EMAPA:16179 + FMA:293149 + TAO:0000121 + UMLS:C1517749 + VHOG:0000118 + XAO:0000311 + ZFA:0000121 + LPM + lateral mesoderm + uberon + lateral plate + lateral plate mesenchyme + mesoderma laminae lateralis + UBERON:0003081 + + + + lateral plate mesoderm + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + Bilateral groups of cells consisting of three rows: one row of endocardial precursors medially and two rows of myocardical precursors laterally. The two populations fuse at the midline to form the heart rudiment or cone. + should probably be merged with heart rudiment. + + + Bilateral groups of cells consisting of three rows: one row of endocardial precursors medially and two rows of myocardical precursors laterally. The two populations fuse at the midline between 21 and 26 somites to form the heart rudiment or cone. Stainier 2001.[TAO] + The fused aspects of ventral mesoderm, which have migrated from either side of the prechordal plate, and fused ventrally, just behind the cement gland. They will give rise to the endocardium at NF stage 27&28.[AAO] + relationship loss: develops_from lateral mesoderm (TAO:0001065)[TAO] + + + AAO:0011044 + BTO:0001887 + TAO:0000028 + UMLS:C1514450 + XAO:0000336 + ZFA:0000028 + uberon + cardiac field + fused heart primordium + UBERON:0003084 + + + heart primordium + + + + + + + + + + + + + + + + + Ventral somitic compartment that is a precursor of the axial skeleton[XAO]. Sclerotomes eventually differentiate into the vertebrae and most of the skull. The caudal (posterior) half of one sclerotome fuses with the rostral (anterior) half of the adjacent one to form each vertebra. From their initial location within the somite, the sclerotome cells migrate medially towards the notochord. These cells meet the sclerotome cells from the other side to form the vertebral body. From this vertebral body, sclerotome cells move dorsally and surround the developing spinal cord, forming the vertebral arch[WP]. + + + Skeletogenic portion of somites.[AAO] + The vertebrate sclerotome has no equivalent in amphioxus and is a novelty linked with the evolution of the axial skeleton.[well established][VHOG] + part_of somite in XAO + + + + AAO:0010571 + AEO:0000212 + EHDAA2:0003439 + EMAPA:31159 + FMA:295652 + TAO:0001080 + UMLS:C0183176 + VHOG:0000680 + XAO:0000397 + ZFA:0001080 + sclerotomes + uberon + sclerotomus + UBERON:0003089 + + + + + + sclerotome + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + Anatomical structure that overlaps the outer epithelial layer and is adjacent to the space surrounding the organism. + + + Organism subdivision which is the collection of anatomical structures on the body surface.[ZFA] + + + + AAO:0010337 + AEO_RETIRED:0000010 + EHDAA2_RETIRED:0003010 + TAO:0000292 + VSAO:0000001 + XAO:0003028 + ZFA:0000292 + galen:SurfaceRegion + anatomical surface feature + uberon + surface feature + surface region + surface structures + UBERON:0003102 + + + surface structure + + + + + + + + + Anatomical structure that has as its parts two or more multi-tissue structures of at least two different types and which through specific morphogenetic processes forms a single distinct structural unit demarcated by bona fide boundaries from other distinct anatomical structures of different types. + this class was introduced for consistency with CARO. However, in this ontology we typically classify organs directly under 'organ' rather than subdividing into compound and simple organs + + + AAO:0010015 + AEO:0000024 + BILA:0000024 + CARO:0000024 + EHDAA2:0003024 + HAO:0000024 + TADS:0000598 + TAO:0000496 + TGMA:0001837 + VHOG:0001723 + XAO:0003041 + ZFA:0000496 + uberon + organ + UBERON:0003103 + + + + + compound organ + + + + + + + + + + + + + + + Portion of tissue consisting of loosely organized undifferentiated mesodermal cells that give rise to such structures as connective tissues, blood, lymphatics, bone, and cartilage[XAO]. A mesh-like cell arrangement, less compact than an epithelium[ZFA]. The part of the embryonic mesoderm, consisting of loosely packed, unspecialized cells set in a gelatinous ground substance, from which connective tissue, bone, cartilage, and the circulatory and lymphatic systems develop[BTO]. + the relationship to mesoderm is weaker than develops_from in order to have classes such as 'head mesenchyme from mesoderm' make sense + + + A mesh-like cell arrangement, less compact than an epithelium. Kimmel et al, 1995.[TAO] + Portion of tissue consisting of loosely organized undifferentiated mesodermal cells that give rise to such structures as connective tissues, blood, lymphatics, bone, and cartilage.[AAO] + mesenchymal + + + + AAO:0010427 + AEO:0000145 + BTO:0001393 + CALOHA:TS-0620 + EHDAA2:0003145 + EV:0100007 + TAO:0000393 + UMLS:C0162415 + VHOG:0000170 + XAO:0003046 + ZFA:0000393 + mesenchymal tissue + mesenchyme tissue + portion of mesenchymal tissue + portion of mesenchyme tissue + uberon + mesenchyma + UBERON:0003104 + + + + + + mesenchyme + + + + + + + + + + + + + + + + Portion of tissue in the nervous system which consists of neurons and glial cells, and may also contain parts of the vasculature. + + + One of the four types of tissue in traditional classifications. Cells forming the brain, spinal cord and peripheral nervous system.[AAO] + FMA definition includes vasculature + + + + AAO:0000325 + AEO:0000123 + EHDAA2:0003123 + FMA:9642 + GAID:609 + MESH:D009417 + OpenCyc:Mx4rVmfYCsQ_QdeM_bFAeS8NRQ + UMLS:C0027757 + nerve tissue + nervous tissue + portion of neural tissue + uberon + UBERON:0003714 + neural tissue + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + An anatomical cavity that has the potential to develop into a coelemic cavity lumen. + + + uberon + body cavity precursor + UBERON:0003886 + + + + + future coelemic cavity lumen + + + + + + + + + + + + + + + + + + + + + + The part of the coelom in the embryo between the somatopleuric and splanchnopleuric mesoderm; the principal body cavities of the trunk (thoracic, abdominal, and pelvic) arise from this embryonic part of the coelom + consider merging with coelom. TODO - add spatial relationships to halves of LPM. Note the OG places XAO and ZFA coelem terms here. editor note: TODO check ZFA, which appears to be a structure present in adults + + + (...) I regard it unlikely that coeloms of all bilaterian animals are comparable and evolved very early. Considering all these questions, few convincing characters concerning the evolution of body cavities remain to be named. (...) A segmental coelom appears to have evolved at least two times, in Annelida and in Myomerata (Acrania and Craniota).[well established][VHOG] + + + + EHDAA:251 + EMAPA:16088 + UMLS:C1512940 + VHOG:0000316 + somatic coelom + uberon + UBERON:0003887 + + intraembryonic coelom + + + + + + + + + + Epithelial tubes transport gases, liquids and cells from one site to another and form the basic structure of many organs and tissues, with tube shape and organization varying from the single-celled excretory organ in Caenorhabditis elegans to the branching trees of the mammalian kidney and insect tracheal system. + contrast with a multi-tissue tube, which has as parts both epithelium, connective tissue, possibly muscle layers + + + AEO:0000114 + EHDAA2:0003114 + FBbt:00007474 + epithelial or endothelial tube + uberon + UBERON:0003914 + epithelial tube + + + + + + + + + + + + + + + + + + + + + A transitional population of migrating mesenchymal cells that derive from somites and that will become dermal cells. + + + Not to be confused with 'dermatome segment of skin'. + + + + AAO:0011028 + AEO:0001017 + EHDAA2_RETIRED:0003428 + EHDAA:1719 + EHDAA:1725 + EHDAA:1731 + EHDAA:1737 + EMAPA:32838 + FMA:295656 + UMLS:C0180383 + XAO:0000220 + cutis plate + dermatomal mesenchyme + uberon + epimere mesoderm + mesenchyma dermatomiale + UBERON:0004016 + + dermatome + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + 2 + + + + + 2 + + + + + + + + + + + + + + + + + + Any tube, opening or passage that connects two distinct anatomical spaces. + + + FMA has both conduit and conduit space. In EHDAA2 this is a surface feature + + + AEO:0000080 + EHDAA2:0003080 + FMA:242873 + foramen + foramina + uberon + opening + ostia + ostium + UBERON:0004111 + anatomical conduit + + + + + + + + + An anatomical structure that develops (entirely or partially) from the endoderm. + Grouping term for query purposes + + uberon + UBERON:0004119 + + endoderm-derived structure + + + + + + + + + + + + + + + + + + + + + + + + + + An anatomical structure that develops (entirely or partially) from the mesoderm. + Grouping term for query purposes + + + uberon + UBERON:0004120 + + + mesoderm-derived structure + + + + + + + + + + + + + + + + + + + + + + + + + + An anatomical structure that develops (entirely or partially) from the ectoderm. + Grouping term for query purposes + + + FBbt:00025990 + ectodermal deriviative + uberon + UBERON:0004121 + + + ectoderm-derived structure + + + + + + + + + + + + + + + + + + + + + The first recognizable structure derived from the heart field + TODO - check plate vs rudiment vs primordium vs endocardial tube. See XAO + + + (In vertebrates) The embryonic mesoderm is the source of both the cardiogenic plate, giving rise to the future myocardium as well as the endocardium that will line the system on the inner side.[well established][VHOG] + EHDAA2:0000215 + EMAPA:16106 + VHOG:0000975 + myocardial plate + uberon + cardiac crescent + cardiogenic crescent + heart rudiment + UBERON:0004139 + + cardiogenic plate + + + + + + + + + + + + + + + + + A specific region of the lateral mesoderm that will form the primary beating heart tube. In mammals the primary heart field gives rise to the left ventricle. + + + this term denotes the primary heart field; GO:0003128 denotes the superclass of primary and secondary: specific region of the lateral mesoderm into the area which will form the primary beating heart tube[GO:0003138] + XAO:0004185 + first heart field + primary heart field + uberon + FHF + PHF + heart field + UBERON:0004140 + primary heart field + + + + + + + + + + + + + + + + + + + + + + + An epithelial tube that will give rise to the mature heart. + + + the paired, longitudinal, endothelial-lined channels formed from the cardiogenic mesoderm in embryonic development; angiogenic cell clusters (aka angioblastic cords) located in a horse-shoe shape configuration in the cardiogenic plate coalesce to form the right and left endocardial heart tubes which then fuse in cephalo-caudal direction to form a single primitive heart tube. + + AAO:0010411 + EFO:0003526 + EMAPA:32685 + TAO:0000360 + XAO:0000337 + ZFA:0000360 + embryonic heart tube + endocardial heart tube + endocardial tube + uberon + UBERON:0004141 + + + + + heart tube + + + + + + + + + + + + + + + + A cardiac chamber surrounds an enclosed cavity within the heart + + + + FMA:7095 + OpenCyc:Mx4rmexpjPdAEduAAAAOpmP6tw + chamber of heart + heart chamber + uberon + UBERON:0004151 + generic enough to cover FBbt:00003156 heart chamber but this is a cavity. GO defines it as the cavity. TODO - move subclasses. Note this also includes sinus venosus + cardiac chamber + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + Anatomical cluster that consists of all the skeletal elements (eg., bone, cartilage, and teeth) of the body. + + + Anatomical cluster that consists of all the skeletal elements (eg., bone, cartilage, and teeth) of the body.[VSAO] + skeletal + + + AEO:0000168 + EHDAA2:0001843 + EHDAA:5047 + EMAPA:17213 + FMA:23875 + GAID:177 + MA:0003006 + MAT:0000032 + MESH:D012863 + MIAA:0000032 + OpenCyc:Mx4rvVi1rpwpEbGdrcN5Y29ycA + VSAO:0000026 + XAO:0004053 + galen:Skeleton + set of all bones + set of bones of body + uberon + UBERON:0004288 + + + + + skeleton + https://github.com/obophenotype/uberon/wiki/The-skeletal-system + + + + + + + + + + + + + + + + + The bilaminar epithelium formed from the myotome and dermatome. + + + Epithelial sheet on the external surface of the somite that gives rise to trunk, muscle and dermis. Within the dermomyotome there is also a medio-lateral difference. The central region makes dermis, the mesenchymal connective tissue of the back skin. The medial region (closest to neural tube) makes epaxial muscle, and the lateral region (furthest from neural tube) makes hypaxial muscle[http://www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=eurekah&part=A66768]. + Epithelial sheet on the external surface of the somite that gives rise to trunk, muscle and dermis.[TAO] + Portion of somites that gives rise to dermis and muscles.[AAO] + all but the sclerotome of a mesodermal somite; the primordium of skeletal muscle and, perhaps, of the dermis. + Thus, representatives of the agnathan vertebrates, chondrichthyans, and sarcopterygians all have a layer of undifferentiated cells external to the embryonic myotome. In the amniotes, this external cell layer is the dermomyotome. The simplest interpretation of the similar position, morphology, and lack of myosin labeling is that a dermomyotome epithelium is a shared, ancestral vertebrate characteristic.[well established][VHOG] + + + AAO:0010572 + AEO:0000214 + EHDAA2:0003259 + EMAPA:31109 + FMA:295654 + TAO:0001513 + UMLS:C1511786 + VHOG:0000676 + ZFA:0001513 + uberon + dermamyotome + dermomyotomes + UBERON:0004290 + dermomyotome + + + + + + + + + + + + + + + + + + + + + A cone-like structure that is formed when myocardial progenitor cells of the heart field fuse at the midline. The heart rudiment is the first structure of the heart tube. + + + The migrating myocardial precursors of the heart rudiment form a cone like structure between 19.5hpf and 22hpf, and eventually telescope out into the primitive heart tube at 24hpf. Stainier 2001.[TAO] + TAO:0000115 + ZFA:0000115 + heart cone + rudimentary heart + uberon + UBERON:0004291 + heart rudiment + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + Anatomical system that has as its parts the heart and blood vessels. + we treat cardiovascular as part of circulatory system, with the latter including other kinds of circulation, including lymph. + + + The vessels of the cardiovascular system are as varied as the diverse organs they supply. However, these variations are based on modifications of a fundamental plan of organization common to vertebrates.[well established][VHOG] + + + + AAO:0011001 + BILA:0000016 + BTO:0000088 + CALOHA:TS-1297 + EFO:0000791 + EHDAA2:0000216 + EHDAA:394 + EMAPA:16104 + EMAPA:16370 + EV:0100017 + FMA:7161 + GAID:467 + MA:0000010 + MAT:0000016 + MESH:D002319 + MIAA:0000016 + OpenCyc:Mx4rvVjzG5wpEbGdrcN5Y29ycA + TAO:0000010 + UMLS:C0007226 + VHOG:0000302 + WikipediaCategory:Cardiovascular_system + XAO:0000100 + XAO:0001010 + ZFA:0000010 + uberon + CV system + Herz und Gefaesssystem + UBERON:0004535 + + + + + + + cardiovascular system + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A vascular network consisting of blood vessels. + + + TAO:0001079 + ZFA:0001079 + blood vascular network + set of blood vessels + uberon + blood system + blood vessel system + blood vessels + UBERON:0004537 + blood vasculature + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + The embryo and its adnexa (appendages or adjunct parts) or associated membranes (i.e. the products of conception) The conceptus includes all structures that develop from the zygote, both embryonic and extraembryonic. It includes the embryo as well as the embryonic part of the placenta and its associated membranes - amnion, chorion (gestational sac), and yolk sac[WP]. + EHDAA2 places this as a subtype of organism. This leads to the inference that a conceptus is an embryo (if an embryo is defined as an organism at embryo stage), which eliminates the embryonic + extra-embryonic = conceptus + + + + + + AEO:0000194 + BTO:0003834 + EHDAA2:0000001 + EHDAA2:0003235 + EMAPA:36040 + UMLS:C1516779 + embryo plus adnexa + uberon + UBERON:0004716 + conceptus + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + Organism at the gastrula stage. + + + We explicitly merge the NCITA terms here + UBERON:0007012 + + + + + + + BILA:0000060 + BTO:0001403 + FBbt:00005317 + FMA:293108 + GAID:1302 + MESH:A16.254.412 + MIAA:0000179 + UMLS:C0017199 + UMLS:C1284022 + gastrula embryo + uberon + blastocystis trilaminaris + tri-laminar disc + tri-laminar disk + trilaminar blastocyst + trilaminar blastoderm + trilaminar disc + trilaminar disk + trilaminar germ + UBERON:0004734 + + gastrula + + + + + + + + + + + + + + + A specialized form of connective tissue in which the extracellular matrix is firm, providing the tissue with resilience, and/or mineralized and that functions in mechanical and structural support.[VSAO] + + + A specialized form of connective tissue in which the extracellular matrix is firm, providing the tissue with resilience, and/or mineralized and that functions in mechanical and structural support.[VSAO] + + MA:0003047 + VSAO:0000015 + XAO:0004038 + ZFA:0005619 + uberon + UBERON:0004755 + Four classes of mineralized tissues are found in vertebrates: bone, cartilage, dentine, and enamel. We think of cartilage and bone as skeletal tissues and of enamel and dentine as dental tissues, but enamel and dentine arose evolutionarily together with bone as skeletal tissues in the dermal skeleton (exoskeleton) of early vertebrates. Scales and teeth of sharks are examples of dermal skeletal elements that are still composed of the three ancient components-enamel, dentine, and bone. Cartilage, on the other hand, provided the basis for the second vertebrate skeletal system, the endoskeleton (Smith and Hall, 1990; Hall, 1998a,b). some invertebrate skeletal tissues have surprisingly bone-like features. Examples include chondrocytes interconnected by cell processes in cephalopod cartilages (Cole and Hall, 2004a,b), and the calcium phosphate layer in the shells of brachiopods (Rodland et al., 2003). However, neither bone nor mineralized cartilage have been found in invertebrates. Editors notes: TODO - develops_from + skeletal tissue + + + + + + + + + + + + + + + Organ consisting of skeletal tissue. Encompasses whole bones, fused bones, cartilaginious elements, teeth, dermal denticles. + + + Organ entity that is typically involved in mechanical support and may have different skeletal tissue compositions at different stages.[VSAO] + Organ entity that may have different tissue compositions at different stages and is typically involved in mechanical support.[TAO] + AAO:0011129 + TAO:0001890 + VSAO:0000128 + XAO:0004012 + ZFA:0005494 + galen:SkeletalStructure + uberon + UBERON:0004765 + + + + + skeletal element + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + Anatomical system that consists of all the joints of the body. + + + + EMAPA:35150 + FMA:23878 + MA:0003007 + VSAO:0000181 + joint system + set of all joints of body + uberon + set of all joints + set of joints of body + UBERON:0004770 + articular system + + + + + + + + + + + + + + + + + + + + + Layer of lateral plate mesoderm that forms the circulatory system and future gut wall - overlies endoderm[WP]. + + + We group the BILA class here. Considering adding more general class for metazoa grouping cardiogenic successors + visceral mesoderm + + AAO:0011102 + BILA:0000044 + FMA:295568 + XAO:0000276 + inner layer of lateral plate mesoderm + uberon + splanchnic mesoderm + UBERON:0004872 + + splanchnic layer of lateral plate mesoderm + + + + + + + + + + + + + + + + + + + + + The central region of trunk mesoderm. This tissue forms the notochord + + + Notochord rudiment[ZFIN:ZDB-PUB-961014-576]. + WP treats this as synonym of axial mesoderm. Induces neural tube. Gilbert: contains an anterior head process and the notochord. + AAO:0000478 + EFO:0003426 + TAO:0000091 + ZFA:0000091 + axial chorda mesoderm + chorda mesoderm + dorsal mesoderm + presumptive notochord + uberon + UBERON:0004880 + + + chordamesoderm + + + + + + + + + + + + + + + Anatomical cluster that connects two or more adjacent skeletal elements or hardened body parts. + + + FBbt:00005811 + joint + uberon + UBERON:0004905 + + + articulation + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A proximal-distal subdivision of the digestive tract. + intended to denote both embryonic and adult structures. Note the FMA grouping here is not quite correct. + + + FBbt:00100315 + FMA:71131 + uberon + alimentary system subdivision + intestinal tract + segment of intestinal tract + subdivision of alimentary system + UBERON:0004921 + + + subdivision of digestive tract + + + + + + + + + + + + + + + A part of a wall of an organ that forms a layer. + + + FMA:82485 + uberon + UBERON:0004923 + + + organ component layer + + + + + + + + + + + + + + + The median dorsal longitudinal groove formed in the embryo by the neural plate after the appearance of the neural folds. + + + The neural groove is a shallow median groove between the neural folds of an embryo. The neural folds are two longitudinal ridges that are caused by a folding up of the ectoderm in front of the primitive streak of the developing embryo. The groove gradually deepens as the neural folds become elevated, and ultimately the folds meet and coalesce in the middle line and convert the groove into a closed tube, the neural tube or canal, the ectodermal wall of which forms the rudiment of the nervous system. After the coalescence of the neural folds over the anterior end of the primitive streak, the blastopore no longer opens on the surface but into the closed canal of the neural tube, and thus a transitory communication, the neurenteric canal, is established between the neural tube and the primitive digestive tube. The coalescence of the neural folds occurs first in the region of the hind-brain, and from there extends forward and backward; toward the end of the third week the front opening (anterior neuropore) of the tube finally closes at the anterior end of the future brain, and forms a recess which is in contact, for a time, with the overlying ectoderm; the hinder part of the neural groove presents for a time a rhomboidal shape, and to this expanded portion the term sinus rhomboidalis has been applied. Before the neural groove is closed a ridge of ectodermal cells appears along the prominent margin of each neural fold; this is termed the neural crest or ganglion ridge, and from it the spinal and cranial nerve ganglia and the ganglia of the sympathetic nervous system are developed. By the upward growth of the mesoderm the neural tube is ultimately separated from the overlying ectoderm. The cephalic end of the neural groove exhibits several dilatations, which, when the tube is closed, assume the form of three vesicles; these constitute the three primary cerebral vesicles, and correspond respectively to the future fore-brain (prosencephalon), mid-brain (mesencephalon), and hind-brain (rhombencephalon). The walls of the vesicles are developed into the nervous tissue and neuroglia of the brain, and their cavities are modified to form its ventricles. The remainder of the tube forms the medulla spinalis or spinal cord; from its ectodermal wall the nervous and neuroglial elements of the medulla spinalis are developed while the cavity persists as the central canal[Wikipedia:Neural_groove]. + + + + + + AAO:0011071 + EMAPA:35594 + FMA:295624 + UMLS:C0814992 + XAO:0000248 + uberon + UBERON:0005061 + neural groove + + + + + + + + + + + + + + + + + + + + + + + + One of the two elevated edges of the neural groove[GO,MP]. + + + In front of the primitive streak two longitudinal ridges, caused by a folding up of the ectoderm, make their appearance, one on either side of the middle line. These are named the neural folds; they commence some little distance behind the anterior end of the embryonic disk, where they are continuous with each other, and from there gradually extend backward, one on either side of the anterior end of the primitive streak. Also, after differentiation it turns into the neural tubes[Wikipedia:Neural_fold]. + + + + + + EHDAA2:0001249 + EMAPA:16142 + EMAPA:16146 + EMAPA:16151 + EMAPA:16155 + EMAPA:16159 + EMAPA:16162 + EMAPA:16288 + EMAPA:16292 + EMAPA:16295 + EMAPA:16299 + EMAPA:16303 + EMAPA:16307 + EMAPA:16528 + FMA:295618 + UMLS:C0814993 + XAO:0004087 + medullary fold + uberon + UBERON:0005062 + + neural fold + + + + + + + + + + + + + + + + + + + + + A solid rod of neurectoderm derived from the neural keel. The neural rod is roughly circular in cross section. Neural rod formation occurs during primary neurulation in teleosts[GO]. An intermediate stage in the development of the central nervous system present during the segmentation period; the neural rod is roughly cylindrical in shape, forms from the neural keel, and is not yet hollowed out into the neural tube[ZFIN]. + + + An intermediate stage in the development of the central nervous system present during the segmentation period; the neural rod is roughly cylindrical in shape, forms from the neural keel, and is not yet hollowed out into the neural tube. Kimmel et al, 1995.[TAO] + EFO:0003498 + TAO:0000133 + ZFA:0000133 + uberon + neural tube rod + UBERON:0005068 + + neural rod + + + + + + + + + Muscle structures are contractile cells, tissues or organs that are found in multicellular organisms[GO]. + in some organisms such as drosophila, muscles can be single cells. This class groups together all discrete muscle elements, from multicellular muscle organs in vertebrates, to individual single-cell muscles in drisophila + + + EMAPA:32715 + FBbt:00005073 + FMA:30316 + musculus + uberon + muscle + muscle element + UBERON:0005090 + muscle structure + + + + + + + + + An epithelial sheet bent on a linear axis. + + + uberon + UBERON:0005157 + epithelial fold + + + + + + + + + + + + + + + + + + + + + + + + + + An organ or element that part of the trunk region. The trunk region can be further subdividied into thoracic (including chest and thoracic cavity) and abdominal (including abdomen and pelbis) regions. + + + EMAPA:37270 + MA:0000516 + trunk organ + uberon + UBERON:0005177 + + + + + trunk region element + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + An organ or element that is in the thoracic cavity. Examples: lung, heart, longus colli. + + + MA:0000557 + thoracic cavity organ + uberon + UBERON:0005178 + + + + thoracic cavity element + + + + + + + + + + + + + + + + + + + + + + + + + + An organ that part of the thoracic segment region. This region can be further subdividied chest and thoracic cavity regions. + + + EMAPA:37271 + MA:0000563 + uberon + upper body organ + UBERON:0005181 + + + thoracic segment organ + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + Mesenchyme that is part of a developing trunk. + + + EFO:0003485 + EHDAA2:0002092 + EHDAA:377 + EMAPA:16177 + TAO:0000081 + VHOG:0000281 + ZFA:0000081 + uberon + trunk and cervical mesenchyme + UBERON:0005256 + + + + trunk mesenchyme + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A portion of tissue that is part of an embryo. + + + CALOHA:TS-2100 + portion of embryonic tissue + uberon + developing tissue + UBERON:0005291 + + + + embryonic tissue + + + + + + + + + + + AEO:0000125 + CALOHA:TS-2122 + EHDAA2:0003125 + FBbt:00007006 + FMA:292313 + MIAA:0000019 + uberon + developing structure + developmental structure + developmental tissue + UBERON:0005423 + developing anatomical structure + + + + + + + + + + + + + + + + + + + + + + + Multi-tissue structure that arises from the heart rudiment and will become the heart tube. + + + + + EHDAA2:0001512 + EHDAA:424 + EHDAA:436 + EMAPA:16208 + EMAPA:16215 + FMA:321916 + TAO:0000149 + ZFA:0000149 + primitive heart tube + early primitive heart tube + uberon + UBERON:0005498 + + + primitive heart tube + + + + + + + + + + + + + + + + + + + + + + + + + + A acellular anatomical structure that is the bounding layer of a anatomical structure. + + + FMA:63871 + uberon + UBERON:0005764 + acellular membrane + + + + + + + + + + + + + + + An acellular membrane that is part of the epithelium, lies adjacent to the epithelial cells, and is the fusion of the the basal lamina and the reticular lamina. + this class represents a continuous sheet of basement membrane which can underlie multiple epithelial cells over large regions. In contrast, the GO class 'basal membrane' represents a portion of substance on the scale of a single cell. + + + + + + + + AAO:0010596 + FMA:63872 + GAID:915 + UMLS:C0004799 + basement membrane of connective tissue + membrana basalis + uberon + basement membrane + UBERON:0005769 + basement membrane of epithelium + + + + + + + + + + A delimited region of dense mesenchyme within looser mesenchyme. + + + AEO:0000148 + EHDAA2_RETIRED:0003148 + EHDAA:8979 + mesenchyme condensation + uberon + UBERON:0005856 + developing mesenchymal condensation + + + + + + + + + + + + + + + + + + + + + Organ with organ cavity, which has as parts a serous membrane and a serous cavity . Examples: pleural sac, pericardial sac, tendon sheath, bursa.[FMA] + + + + + EMAPA:16060 + FMA:9689 + MA:0000005 + uberon + UBERON:0005906 + See notes for serous membrane + serous sac + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + Subdivision of skeleton which consists of cranial skeleton, set of all vertebrae, set of all ribs and sternum[FMA, modified]. + + + Skeletal subdivision of the central body axis including the cranium, vertebrae, notochord, ribs, and sternum.[VSAO] + + + + + + AAO:0000963 + EMAPA:17214 + EMAPA:18043 + MA:0000308 + UMLS:C0222645 + VSAO:0000056 + XAO:0004011 + uberon + skeleton axiale + UBERON:0005944 + + + axial skeleton plus cranial skeleton + http://purl.obolibrary.org/obo/uberon/docs/The-axial-skeleton + + + + + + + + + + + + + + + + + + + + + + + + The notochordal plate is the dorsal part of the notochordal process when the ventral portion breaks down. It is continuous laterally with the endoderm that composes the roof of the primitive foregut and is in contact dorsally with the neural tube. The folding off of the notochordal plate gives rise to the notochord. + TODO - check ordering; awaiting confirmation from JB + + + The notochordal plate is the dorsal part of the notochordal process when the ventral portion breaks down. It is continuous laterally with the endoderm that composes the roof of the primitive foregut and is in contact dorsally with the neural tube. The folding off of the notochordal plate gives rise to the notochord. [Carson_JL, Dehart_DB, Developmental_Dynamics_(1994)_201:_260-278, Gesteland_K_and_Schoenwolf_GC, Inagaki_T, Morphogenesis_of_the_murine_node_and_notochordal_plate, The_prechordal_plate, Vrablic_T, see_Mueller_F_and_O'Rahilly_R, the_rostral_end_of_the_notochord_and_nearby_median_features_in_staged_human_embryos._Cells_Tissues_Organs_(2003)_173:_1-20_and_Sulik_K][VHOG] + + + EHDAA2:0001278 + EHDAA:264 + EMAPA:16101 + UMLS:C1518429 + VHOG:0001212 + uberon + UBERON:0006267 + + + notochordal plate + + + + + + + + + + + + + + + A midline cellular cord formed from the migration of mesenchymal cells from the primitive knot + + + + + EHDAA2:0001279 + EHDAA:224 + EMAPA:16102 + FMA:293135 + UMLS:C1518430 + VHOG:0001213 + uberon + chordamesoderm + presumptive notochord + UBERON:0006268 + + + The notochordal process grows cranially until it reaches the prechordal plate, the future site of the mouth. In this area the ectoderm is attached directly to the endoderm without intervening mesoderm. This area is known as the oropharyngeal membrane, and it will break down to become the mouth. At the other end of the primitive streak the ectoderm is also fused directly to the endoderm; this is known as the cloacal membrane (proctodeum), or primordial anus. + notochordal process + + + + + + + + + Liquid components of living organisms. includes fluids that are excreted or secreted from the body as well as body water that normally is not. + + + fluid + + + FMA:280556 + GAID:266 + MESH:D001826 + galen:BodyFluid + body fluid + uberon + UBERON:0006314 + + bodily fluid + + + + + + + + + The pharynx is the part of the digestive system immediately posterior to the mouth[GO]. + currently this is an extremely generic class, encompassing both protostomes and deuterostomes. + + + branchial + pharyngeal + FBbt:00005380 + MAT:0000049 + MIAA:0000049 + uberon + anterior part of foregut + pharyngeal tube + UBERON:0006562 + + + + + pharynx + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + Presumptive structure of the blastula that will develop into endoderm. + + + AAO:0000471 + EFO:0003437 + TAO:0000416 + ZFA:0000416 + uberon + UBERON:0006595 + + presumptive endoderm + + + + + + + + + + + + + + + + + + + + + + + + + + + + AAO:0000468 + EFO:0003439 + TAO:0000568 + ZFA:0000568 + future blood + uberon + UBERON:0006596 + + presumptive blood + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + Portion of embryonic tissue determined by fate mapping to become a structure. + Consider merging with anlage + + + AAO:0000479 + TAO:0001116 + ZFA:0001116 + future structure + presumptive structures + uberon + UBERON:0006598 + presumptive structure + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + Presumptive structure of the blastula that will develop into ectoderm. + + + AAO:0000470 + EFO:0003466 + TAO:0001376 + XAO:0004132 + ZFA:0001376 + uberon + presumptive epidermis + UBERON:0006601 + + presumptive ectoderm + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + Presumptive structure of the blastula that will develop into mesoderm. + + + AAO:0000476 + EFO:0003467 + TAO:0001377 + ZFA:0001377 + uberon + UBERON:0006603 + + presumptive mesoderm + + + + + + + + + An epithelium characterised by its most superficial layer consisting of squamous epithelial cells. + + + FBbt:00007028 (squamous epithelium) A type of epithelium that is made up of flattened cells which are arranged with their long axes in the plane of the epithelium + + + + + BTO:0002072 + UMLS:C0221909 + uberon + UBERON:0006914 + squamous epithelium + + + + + + + + + + + + + + + The vascular cord is the primordial vasculature that will develop into blood vessels by the process of tubulogenesis[GO]. The vascular cord is composed of angioblast or vascular endothelial cells in a solid linear mass called a cord. The cord then undergoes tubulogenesis to form the lumen of the vessels[ZFA]. + + + EFO:0003709 + TAO:0005077 + ZFA:0005077 + uberon + UBERON:0006965 + + vascular cord + + + + + + + + + A two dimensional anatomical structure that is the boundary between an anatomical structure and an anatomical substance, an anatomical space or the organism's environment. Examples include the surface of your skin, the surface of the lining of your gut; the surface of the endothelium of you aorta that is in contact with blood.n + + + + + AAO:0010270 + BILA:0000010 + CARO:0001002 + EHDAA2:0003192 + FMA:24137 + ID:0000000 + UMLS:C1515977 + ZFA:0005594 + uberon + UBERON:0006984 + + Old definition: 'Non-material anatomical entity of two dimensions, that is demarcated by anatomical lines or points on the external or internal surfaces of anatomical structures.' Note, in the new definition, the space referred to is not necessarily an anatomical space. It may be the outside of an organism. + anatomical surface + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + The splanchnic mesoderm in the cardiogenic region where the heart develops; it gives rise to endocardial heart tubes that fuse to form the primordial cardiac tube, the heart primordium[web]. Two migratory heart primordia that move ventrally during the course of neurulation, and then fuse[XAO]. + consider FBbt:00005541 ! cardiogenic mesoderm + review EHDAA2 placement + + + + AAO:0011021 + BILA:0000051 + EFO:0000315 + EHDAA2:0000214 + EHDAA:385 + FMA:293143 + VHOG:0001641 + XAO:0000235 + uberon + cardiogenic mesoderm + cardiogenic region + heart primordia + UBERON:0007005 + + + cardiac mesoderm + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + Organism at the cleavage stage. + + + BILA:0000058 + uberon + UBERON:0007010 + cleaving embryo + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + The endodermal cells generate only the lining of the digestive tube and its glands; mesodermal mesenchyme cells will surround this tube to provide the muscles for peristalsis + + + + BILA:0000084 + UMLS:C1514442 + future digestive tract + future digestive tube + future gut + primitive gut + uberon + embryonic digestive tube + primordial digestive tube + primordial gut + UBERON:0007026 + presumptive gut + + + + + + + + + A hollow, muscular organ, which, by contracting rhythmically, keeps up the circulation of the blood or analogs[GO,modified]. + + + note we reserve the subclass 'heart' from the vertebrate multi-chambered heart. 'The first heart-like organ is believed to have appeared 500my ago in an ancestral bilaterian'. Amniotes: four-chambered heart. Amphibians: two atria, one ventricle, pulmonary; fish: single atrium and ventricle; amphioxus: tubular, non-striated, closed, unidirectional; ascidians: tubular, striated, open, bidirectional; arthropods: tubular, open; C elegans: contractile pharynx; Cnideria: striated muscle cells associated with gastrodermis + + + FBbt:00003154 + SPD:0000130 + TADS:0000147 + dorsal tube + heart + uberon + adult heart + UBERON:0007100 + + + Gene notes: Bmp, Nkx, Gata + primary circulatory organ + + + + + + + + + + + + + + + An intermediate stage (between the neural plate and neural rod) during the early segmentation period in the morphogenesis of the central nervous system primordium; the keel is roughly triangular shaped in cross section. + + + An intermediate stage (between the neural plate and neural rod) during the early segmentation period in the morphogenesis of the central nervous system primordium; the keel is roughly triangular shaped in cross section. Kimmel et al, 1995.[TAO] + EFO:0003497 + TAO:0000131 + ZFA:0000131 + uberon + presumptive central nervous system + UBERON:0007135 + + neural keel + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A presumptive structure that has the potential to develop into a presomitic mesoderm. + + + EFO:0003421 + TAO:0000053 + ZFA:0000053 + uberon + presumptive segmental plates + UBERON:0007282 + + presumptive segmental plate + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A presumptive structure that has the potential to develop into a neural plate. + consider merging + + + Region of the gastrula which gives rise to the neural plate.[TAO] + EFO:0003424 + TAO:0000063 + ZFA:0000063 + prospective neuroectoderm + prospective vegetal ectoderm + uberon + UBERON:0007284 + + presumptive neural plate + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A presumptive structure that has the potential to develop into a paraxial mesoderm. + + + EFO:0003443 + TAO:0000591 + XAO:0004134 + ZFA:0000591 + future paraxial mesoderm + uberon + UBERON:0007285 + + presumptive paraxial mesoderm + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + The epidermis is the entire outer epithelial layer of an animal, it may be a single layer that produces an extracellular material (e.g. the cuticle of arthropods) or a complex stratified squamous epithelium, as in the case of many vertebrate species[GO]. + this grouping class exists primarily to align with GO - see GO:0008544. + + + + BSA:0000073 + BTO:0000313 + FBbt:00004993 + HAO:0000298 + TADS:0000109 + WBbt:0005733 + epidermis + epidermis (sensu Metazoa) + outer epidermal layer + outer epithelial layer + uberon + hypoderm + hypodermis + UBERON:0007376 + + + outer epithelium + + + + + + + + + + + + + + + + + Portion of the dermis characterized by a well-arranged, plywood-like, collagenous network. + + + Portion of the dermis characterized by a well-arranged, plywood-like, collagenous network. Le Guellec et al, 2004.[TAO] + relationship loss: develops_from collagenous dermal stroma (TAO:0001186)[TAO] + connective tissue in the skin is usually diffuse and irregular, although in some species collagen bundles are arranged in a distinct ordered layer in the dermis + AAO:0010600 + TAO:0001182 + ZFA:0001182 + dermal deep region + uberon + UBERON:0007377 + stratum compactum + + + + + + + + + + + + + + + + + + + + + + + Outermost layer of cells surrounding the embryo. + + + Outermost monolayer of cells surrounding the embryo that become very flattened in the blastula and give rise to the periderm. Sometimes used synonymously with periderm. Kimmel et al, 1995.[TAO] + relationship loss: develops_from superficial blastomere (TAO:0001484)[TAO] + Originally this tissue is one cell layer thick but in most vertebrates it soon becomes a two layered structure. The outer layer gives rise to the periderm. + EFO:0003425 + TAO:0000086 + ZFA:0000086 + EVL + enveloping layer + uberon + UBERON:0007383 + + enveloping layer of ectoderm + + + + + + + + + An epithelial tube open at both ends that allows fluid flow. + + + AEO_RETIRED:0000116 + RETIRED_EHDAA2:0003116 + uberon + UBERON:0007500 + epithelial tube open at both ends + + + + + + + + + A closed epithelium with a lumen. + + + EHDAA2:0003119 + AEO:0000119 + EHDAA2:0003119 + uberon + UBERON:0007503 + epithelial vesicle + + + + + + + + + Mesenchyme with little extracellular matrix. + + + EHDAA2:0003146 + AEO:0000146 + EHDAA2:0003146 + uberon + UBERON:0007524 + dense mesenchyme tissue + + + + + + + + + Mesenchymal cells that are migrating. + this class will be an important part of the NC reorganization + + + EHDAA2:0003152 + AEO:0000152 + EHDAA2:0003152 + uberon + UBERON:0007530 + migrating mesenchyme population + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A thin, loose vascular connective tissue that makes up the membranes surrounding joints and the sheaths protecting tendons (particularly flexor tendons in the hands and feet) where they pass over bony prominences. Synovial tissue contains synovial cells, which secrete a viscous liquid called synovial fluid; this liquid contains protein and hyaluronic acid and serves as a lubricant and nutrient for the joint cartilage surfaces[BTO]. Synovial tissue can be found in tendons (tissues that connect muscle to bone), bursae (fluid-filled, cushioning sacs found in spaces between tendons, ligaments, and bones), and the cavity (hollow enclosed area) that separates the bones of a freely movable joint, such as the knee or elbow[BTO]. + + + BTO:0001338 + CALOHA:TS-0998 + FMA:66762 + synovium + stratum synoviale + synovial layer + synovial membrane + uberon + synovial tissue + UBERON:0007616 + layer of synovial tissue + + + + + + + + + + + + + + + + + + + + + + + + + + An anatomical cavity that surrounded_by a synovial joint. + + + FMA:11356 + articular cavity (synovial joint) + cavitas articularis (junctura synovialis) + cavity of synovial joint + uberon + joint cavity + synovial cavity + UBERON:0007617 + synovial cavity of joint + + + + + + + + + + + + + + + + Anlagen are populations of contiguous cells, typically arranged in one plane, that are morphologically indistinct, but that already correspond in extent to a later organ/tissue. + + + field + + AEO:0000170 + EFO:0001649 + EHDAA2:0003170 + FBbt:00005426 + developmental field + uberon + future organ + organ field + UBERON:0007688 + + anlage + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + Any fluid produced by a serous gland. + + + the FMA def is Transudate contained in a serous sac + + FMA:20932 + serous gland fluid + uberon + UBERON:0007794 + serous fluid + + + + + + + + + + + + + + + Anatomical system that consists of all blood and lymph vessels. + consider merging with vasculature + + + The cardiovascular and lymphatic systems, collectively[ncithesaurus:Vascular_System]. + in both MA and BTO, the arterial system and venous sytem are subtypes of the vascular system + + + BTO:0001085 + CALOHA:TS-2053 + EHDAA2:0004520 + EMAPA:35905 + MA:0002718 + UMLS:C0489903 + uberon + Gefaesssystem@ge + UBERON:0007798 + + vascular system + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + The anteriormost subdivision of the body that includes the head, jaws, pharyngeal region and the neck (if present). In vertebrates this is the subdivision that includes the cervical vertebrae. + + + + + + CALOHA:TS-2356 + EV:0100009 + FMA:280881 + MA:0000006 + UMLS:C0460004 + WikipediaCategory:Head_and_neck + galen:HeadAndNeck + uberon + cephalic area + cephalic part of animal + cephalic region + head and neck + head or neck + UBERON:0007811 + + craniocervical region + + + + + + + + + + + + + + + + + + + + + + + + + + + Sum total of mesenchyme in the embryo. + consider adding new class (EMAPA:16097) for mesenchyme of embryo (some mesenchyme is extraembryonic - e.g. amnion mesoderm) + + + UBERON:0003313 + EHDAA2:0001113 + EHDAA:177 + EMAPA:16097 + uberon + UBERON:0009142 + entire embryonic mesenchyme + + + + + + + + + + + + + + + + + + FMA:25054 + region of trunk + trunk subdivision + uberon + UBERON:0009569 + + + subdivision of trunk + + + + + + + + + + + + + + + + + + + + + + + + EHDAA2:0002094 + trunk and cervical paraxial mesenchyme + uberon + trunk paraxial mesenchyme + UBERON:0009618 + trunk paraxial mesoderm + + + + + + + + + + + + + + + The many-lobed berry cluster of cells that is the terminous of a gland where the secretion is produced is acinar in form. + + + acinar + acinus + + FMA:55588 + uberon + acini + UBERON:0009842 + glandular acinus + + + + + + + + + + + + + + + + + + + EFO:0003704 + TAO:0005041 + ZFA:0005041 + ALPM + uberon + UBERON:0009881 + + anterior lateral plate mesoderm + + + + + + + + + An anatomical structure that has more than one cell as a part. + + + CARO:0010000 + FBbt:00100313 + multicellular structure + uberon + UBERON:0010000 + + multicellular anatomical structure + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + Mesenchyme that has the potential to develop into a dermis. + check development + + + EHDAA2:0000598 + uberon + UBERON:0010083 + future dermis + + + + + + + + + + + + + + + + + + + + + + + + + + An anatomical structure that has some part that develops from the neural crest. + Grouping term for query purposes + + + uberon + UBERON:0010314 + + + structure with developmental contribution from neural crest + + + + + + + + + + + + + + + + + uberon + UBERON:0010316 + germ layer / neural crest + + + + + + + + + + + + + + + + + + + + + + + + + + + Epithelium composed of cells that develops from the ectoderm[FMA,modified]. + + + FMA:69064 + ectoderm-derived epithelium + uberon + UBERON:0010371 + ecto-epithelium + + + + + + + + + + + + + + + + + + + + + Anatomical cluster consisting of the skeletal elements (i.e. bone elements, cartilage elements, cartilage condensations) that are part of an individual subdivision of the organism. Excludes joints. + + + Anatomical cluster consisting of the skeletal elements that are part of the skeleton.[VSAO] + + FMA:23879 + VSAO:0000042 + skeletal subdivision + uberon + subdivision of skeleton (in vivo) + UBERON:0010912 + + + subdivision of skeleton + + + + + + + + + Joint in which the articulating bones or cartilages are connected by ligaments or fibrocartilage without an intervening synovial cavity. Examples: sagittal suture, inferior tibiofibular syndesmosis, costochondral joint, pubic symphysis. + + + FMA:7491 + solid joint + uberon + UBERON:0011134 + nonsynovial joint + + + + + + + + + + + + + + + + + + + + + Subdivision of the skeletal system which consists of the axial skeleton plus associated joints. + + + FMA:7483 + uberon + UBERON:0011137 + axial skeletal system + http://purl.obolibrary.org/obo/uberon/docs/The-axial-skeleton + + + + + + + + + + + + + + + + Subdivision of the skeletal system which consists of the post-cranial axial skeleton plus associated joints. + + + + axial skeletal system + FMA:302077 + uberon + UBERON:0011138 + post-cranial axial skeletal system + http://purl.obolibrary.org/obo/uberon/docs/The-axial-skeleton + + + + + + + + + + + + + + + A subdivision of an anatomical system. + + + + FBbt:00007330 + FMA:67509 + uberon + UBERON:0011216 + + + organ system subdivision + + + + + + + + + + + + + + + + + + + + + + compare with 'stratum basale of epidermis'. This class is the source for many adult structures - see WP2062. See also: 'enveloping layer of ectoderm' + + + EHDAA2:0001845 + uberon + basal cell layer of skin + outer epithelium of body + UBERON:0011272 + embryonic skin basal layer + + + + + + + + + Anatomical structure that is an aggregation of similar cells from which cartilages and bones form, and from which chondrogenesis and osteogenesis are initiated during repair and/or regeneration. (Hall and Miyake 1995). + consider obsoleting, coordinate with VSAO + + + VSAO:0000006 + XAO:0004021 + uberon + UBERON:0011585 + cell condensation + + + + + + + + + + + + + + + A major subdivision of an organism that divides an organism along its main body axis (typically anterio-posterior axis). In vertebrates, this is based on the vertebral column. + Ideally this would be disjoint with analagous class for appendicular axes, but currently 'appendages' like antennae, horns cause a problem + + + axial subdivision of organism + uberon + body segment + main body segment + UBERON:0011676 + + + subdivision of organism along main body axis + + + + + + + + + + + + + + + + + + + + + + + + + + A cardiovascular system that is part of a conceptus. + + + + EHDAA2:0000216 + FMA:305965 + conceptus cardiovascular system + uberon + embryonic circulatory system + fetal circulatory system + UBERON:0011695 + embryonic cardiovascular system + + + + + + + + + Connective tissue, which consists of a population of connective tissue cells, the intercellular matrix of which contains an irregular network of collagen and elastic fiber bundles. Examples: areolar tissue, mucoid tissue, connective tissue of peritoneum, connective tissue of fibrous pericardium. + + + FMA:20107 + uberon + UBERON:0011821 + irregular connective tissue + + + + + + + + + + + + + + + + + + + + + + + + + + + Irregular connective tissue is an irregular connective tissue, the intercellular matrix of which contains a dense irregular network of collagen and elastic fiber bundles. Examples: connective tissue of peritoneum, connective tissue of fibrous pericardium. + + + Tissue characterized by a thick, random arrangement of collagen and elastin fibers with very few cells. The majority of the cells are fibroblasts, but mast cells and macrophages may also be seen. It is found in the dermis, periosteum, perichondrium, capsules of organs and sheaths of nerves and muscles[NCIT] + + + + FMA:20109 + UMLS:C0738366 + irregular dense connective tissue + typus irregularis (textus connectivus collagenosus compactus) + uberon + UBERON:0011822 + dense irregular connective tissue + + + + + + + + + + + + + + + + + + + + + + + + + + Dense connective tissue is mainly composed of collagen type I. Crowded between the collagen fibers are rows of fibroblasts, fiber-forming cells, that manufacture the fibers. Dense connective tissue forms strong, rope-like structures such as tendons and ligaments. Tendons attach skeletal muscles to bones; ligaments connect bones to bones at joints. Ligaments are more stretchy and contain more elastic fibers than tendons. Dense connective tissue also make up the lower layers of the skin (dermis), where it is arranged in sheets + our OWL definition states that this is differentiated from other connective tissue types by virtue of the fact that the collage fiber component predominates, as opposed to cells and fluid. + + + Connective tissue in which the fibrous component predominates. The cells, ground substance, and tissue fluid represent a minor component[NCIT] + + + + AAO:0000121 + UMLS:C1511770 + uberon + UBERON:0011823 + dense connective tissue + + + + + + + + + Irregular connective tissue, the intercellular matrix of which contains a sparse irregular network of collagen and elastic fiber bundles. Examples: areolar tissue, neuroglial tissue, mucoid tissue. + + + + + + FMA:19783 + UMLS:C1253917 + textus connectivus collagenosus laxus + textus connectivus laxus + uberon + UBERON:0011825 + loose connective tissue + + + + + + + + + + + + + + + + + + + + + + + + + + An acinus that is part of a exocrine gland. + + + exocrine gland acinus + uberon + UBERON:0011858 + acinus of exocrine gland + + + + + + + + + + + the FMA class specifically refers to ureter + + FMA:63212 + MESH:D024022 + NIF_Subcellular:sao7547390221 + uberon + UBERON:0011860 + collection of collagen fibrils + + + + + + + + + + The aggregate of the coelemic cavity lumen plus the membranes that line the lumen. + EHDAA2 distingsuishes between the lumen, the lining, and the 'coelomic cavity', which despire it's name, is not a space - it is the aggregate of space plus lining. + + + coelomic + + EHDAA2:0004731 + enterocoelom + haemocoelom + schizocoelom + uberon + coelem + coelomic cavity + UBERON:0011997 + coelom + + + + + + + + + + + + + + + + + + + + + + + + + + + Epithelium that derives from the mesoderm. [Automatically generated definition]. + + + FMA:86452 + mesoderm-derived epithelium + mesoepithelium + uberon + UBERON:0012275 + meso-epithelium + + + + + + + + + + + + + + + + + + + + + + + + + + The secretory unit of a serous gland. The acinar portion is composed of serous secreting cells. + + + FMA:86279 + acinus of serous gland + uberon + UBERON:0013232 + serous acinus + + + + + + + + + + + + + + + + + + + + + + + + + + The space that surrounds an organism. + + + external to organism + outside of body + uberon + UBERON:0013514 + space surrounding organism + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + uberon + UBERON:0013522 + subdivision of tube + + + + + + + + + + + + + + 2 + + + + + 2 + + + + + + + + + + + + An anatomical space which is the lumen of some anatomical conduit and connects two or more spaces together[FMA,modified]. + + + FMA:9338 + foramen space + uberon + UBERON:0013686 + anatomical conduit space + + + + + + + + + A principle subdivision of an organism that includes all structures along the primary axis, typically the anterior-posterior axis, from head to tail, including structures of the body proper where present (for example, ribs), but excluding appendages. + + + uberon + UBERON:0013701 + + main body axis + + + + + + + + + + + + + + + The region of the organism associated with the visceral organs. + + + Cardinal body part, which consists of a maximal set of diverse subclasses of organ and organ part spatially associated with the vertebral column and ribcage. Examples: There is only one body proper[FMA:231424]. + + AEO:0000103 + BTO:0001489 + EMAPA:36031 + FMA:231424 + uberon + body + whole body + UBERON:0013702 + + body proper + + + + + + + + + + + + + + + + + + + + + + + + + + A organ component layer that is part of a integumental system. + + + + layer of skin + skin layer + uberon + UBERON:0013754 + + integumentary system layer + + + + + + + + + + + + + + + + + + + + + + Subdivision of skeletal system that consists of all skeletal elements in the thoracic region of the trunk. In most vertebrates this is the rib cage and sternum. + + + + EHDAA2:0002013 + FMA:77169 + skeleton of thorax + thoracic part of axial skeleton + thoracic skeleton + uberon + UBERON:0014477 + + thoracic skeleton + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A portion of tissue that will develop into vasculature. + + + EFO:0003708 + TAO:0005076 + ZFA:0005076 + uberon + UBERON:0014903 + primordial vasculature + + + + + + + + + + + + + + + + + + + + + + + + + + Any structure that is placed on one side of the left-right axis of a bilaterian. + This class is primarily to implement taxon constraints. It may be removed in the future. + + + uberon + UBERON:0015212 + + + lateral structure + + + + + + + + + + + + + + + A hollow, muscular organ, which, by contracting rhythmically, contributes to the circulation of lymph, blood or analogs. Examples: a chambered vertebrate heart; the tubular peristaltic heart of ascidians; the dorsal vessel of an insect; the lymoh heart of a reptile. + + + heart + SPD:0000130 + cardiac pump + heart or heart like organ + circulatory vessel + uberon + cardiac structure + UBERON:0015228 + + circulatory organ + + + + + + + + + + + + + + + + + MA:0002449 + heart/pericardium + uberon + UBERON:0015410 + heart plus pericardium + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + Primordium that develops into the central nervous system + + + UBERON:3000469 + future CNS + presumptive central nervous system + uberon + UBERON:0016879 + future central nervous system + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + Primordium that develops into the nervous system + + + UBERON:3000477 + AAO:0000477 + presumptive nervous system + uberon + UBERON:0016880 + future nervous system + + + + + + + + + + + + + + + + + + + + + + + + + + + The part of the conceptus that may be lost before birth or will be discarded at birth, or when the embryo becomes an independent organism. + + + AEO:0000195 + EHDAA2:0000003 + EMAPA:16042 + extra-embryonic component + extraembryonic component + uberon + UBERON:0016887 + entire extraembryonic component + + + + + + + + + An embryonic anatomical entity that will turn into one or more other anatomical entities, perhaps with other anatomical entities, later in development. + + + AEO:0000132 + uberon + UBERON:0016888 + transitional anatomical structure + + + + + + + + + + + + + + + + + + + + + + + + + + A mesenchyme-derived anatomical entity undergoing a transtion to become another structure. + + + AEO:0001016 + uberon + UBERON:0017650 + developing mesenchymal structure + + + + + + + + + + + + + + + An multicellular anatomical structure that has subparts of multiple organs as a part. + + + CARO:0020001 + uberon + anatomical cluster + UBERON:0034921 + multi organ part structure + + + + + + + + + + + + + + + A cluster of cells, largely surrounded by a morphological boundary. + + + CARO:0020002 + FMA:62807 + uberon + UBERON:0034922 + cell cluster + + + + + + + + + + + + + + + A collection of anatomical structures that are alike in terms of their morphology or developmental origin. + resolve if this should be a subclass of disconnected anatomical group. Some collections (e.g. the skeleton or skull) are arguably connected + + + uberon + UBERON:0034925 + anatomical collection + + + + + + + + + + + FMA:55268 + organ sector + organ zonal region + organ zone + uberon + organ region with floating fiat boundary + UBERON:0034944 + zone of organ + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + uberon + duct epithelium + ductal epithelium + UBERON:0034969 + epithelial layer of duct + + + + + + + + + + + + + + + + + + + + + + + + + + + + The primordial mouth region of the developing head. + + + FMA:293105 + primitive mouth + primordial mouth + uberon + UBERON:0035804 + future mouth + + + + + + + + + + + + + + + + + + + + + + + + + + Structures of the dermis, epidermis, glands and pigment cells recognizable on the external surfaces of the integument. + + + This class was sourced from an external ontology (amphibian_anatomy). Its definitions, naming conventions and relationships may need to be checked for compatibility with uberon + amphibian_anatomy_curators + uberon/phenoscape-anatomy + external integument structure + + + + + + + + + mass unit + A unit which is a standard measure of the amount of matter/energy of a physical object. + + http://purl.obolibrary.org/obo/obi.owl + mass unit + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + A vaccine is a processed material with the function that when administered, it prevents or ameliorates a disorder in a target organism by inducing or modifying adaptive immune responses specific to the antigens in the vaccine. + Many vaccines are developed to protect against infectious pathogens that causes infectious diseases. Many vaccines are also being developed against other diseases such as cancer, allergy, and autoimmune diseases. + YH, BP, BS, MC, LC, XZ, RS + a role that inheres in a prepared material entity that is designed to induce protection or treament for a diease or infection in vivo. + + vaccine + MeSH: D014612 + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + a process of administering substance in vivo that involves in adding a vaccine into a host (e.g., human) in vivo with the intent to invoke a protective or therapeutic adaptive immune response. + YH, BP + vaccine administration + + vaccination + + + + + + + + + a vaccine adjuvant that is formed as a mineral salt. + SGS, YH + + mineral salt vaccine adjuvant + CVX: 119 + + + + + + + + + YH, SGS + a vaccine adjuvant that contains microbial derived material. + + microbial derivative vaccine adjuvant + CVX: 52 + CVX: 83 + + + + + + + + + an adjuvant role that inheres in a vaccine component which is added as part of a vaccine and induces enhanced adaptive immune response to the vaccine antigen. + YH + + The Latin "adjuvans" means to help, particularly to reach a goal. + +Adjuvant therapy for cancer is surgery followed by chemotherapy or radiation to help decrease the risk of the cancer recurring (coming back). + +An adjuvant is a substance that helps and enhances the pharmacological effect of a drug or increases the ability of an antigen to stimulate the immune system. + vaccine adjuvant role + + + + + + + + + a virulence of vaccine organism that shows an attenuated pheontype of the organism as the major component of a vaccine. + YH + + vaccine organism live attenuated + + + + + + + + + + + + + + + + + + + a processed material that is output of the vaccine preparation and part of a vaccine. + YH + cardinal part of vaccine + vaccine ingredient + + vaccine component + + + + + + + + + an organismal quality of a whole organism vaccine where the whole organism is inactivated/killed and lacks the capability of replication. + YH + vaccine organism killed + + vaccine organism inactivated + + + + + + + + + + + + + + + + + vaccine function is a function that inheres in a vaccine that induces protective immune response against a disease. It is realized in the immunization process in the host. + PERSPN: Oliver He: There has been hot discussion about whether we use 'vaccine function' or 'vaccine role'. Vaccine role may not be the good term to use. Vaccine is designed to be 'vaccine', so it should be vaccine function. One special case is cowpox virus. The cowpox virus can be mixed with some liquid like water and used as a smallpox vaccine. In this case, people often say: the cowpox virus has a 'vaccine role'. However, the cowpox virus vaccine is a processed material of a mix of the virus with water. The virus is a virus, it is not a vaccine per se. Therefore, vaccine role may not be an accurate term. + YH, MC, XZ, and AR + + vaccine function + + + + + + + + + YH + + company + + + + + + + + + YL,YH + Page 73, Chapter 6, Vaccine, 5th Edition. EXPERT CONSULT by Plotkin SA., et. al. 2008 + a role inheres in a material entity, that has been added into a vaccine's formulation by the manufacture for a specific purpose. For example: adjuvant to enhance the effect of immunogen, perservatives, stablizers and those materials added for affecting PH and isotonicity. + + vaccine additive role + + + + + + + + + + + + + + + + + + + + + + + + + + + preventive vaccine function is a vaccine function realized by the process of vaccination and leading to induction of an adaptive immune response to the antigens in a vaccine, which protects against a specific disorder. + YH + prophylactic vaccine function + + preventive vaccine function + + + + + + + + + Protective antigen is an antigen that stimulates protective immunity when used in vivo. + YH + + protective antigen role + + + + + + + + + immunization is a processual entity that primes or modifies an adaptivie immune response to some antigens. + YH, XZ, BP + WEB: http://en.wikipedia.org/wiki/Immunization + + immunization + + + + + + + + + Active immunization is an immunization process that entails the introduction of a foreign molecule into the body, which causes the body itself to generate adaptive immunity against the target. + YH, XZ + WEB: http://en.wikipedia.org/wiki/Immunization + + Active immunization entails the introduction of a foreign molecule into the body, which causes the body itself to generate immunity against the target. This immunity comes from the T cells and the B cells with their antibodies. +Active immunization can occur naturally when a person comes in contact with, for example, a microbe. If the person has not yet come into contact with the microbe and has no pre-made antibodies for defense (like in passive immunization), the person becomes immunized. The immune system will eventually create antibodies and other defenses against the microbe. The next time, the immune response against this microbe can be very efficient; this is the case in many of the childhood infections that a person only contracts once, but then is immune. +Artificial active immunization is where the microbe, or parts of it, are injected into the person before they are able to take it in naturally. If whole microbes are used, they are pre-treated, Attenuated vaccine. (Wikipedia) + active immunization + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + artificial active immunization is an active immunization that occurs when a person or animal is vaccinated with a specific vaccine. + YH, XZ + artificial active immunization + WEB: http://en.wikipedia.org/wiki/Immunization + + vaccine immunization + + + + + + + + + induction of adaptive immune response to antigen is an active immunization process that results in induction of adaptive immune response to some antigens, for example, in a vaccine. + YH, XZ + + induction of adaptive immune response to antigen + + + + + + + + + disorder prevention is a processual entity that prevents a disorder that is the physical basis of a disease. + YH, XZ + + disorder prevention + + + + + + + + + disorder treatment is a processual entity that leads to treat a disorder that is the physical basis of a disease. + YH, XZ + + disorder treatment + + + + + + + + + modification of adaptive immune response to antigen is an active immunization process that results in modification of an adaptive immune response to some antigens, for example, in a therapeutic vaccine. + YH, XZ + + modification of adaptive immune response to antigen + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + The therapeutic vaccine function is a function realized by the process of vaccination and leading to induction of an adaptive immune response to the antigens in a vaccine, which ameliorates a specific disorder. + YH + + therapeutic vaccine function + + + + + + + + + + + + + + + + + + + a vaccine component that is chemical substance added to vaccine and enhance and direct immune response to protective antigen. Many of vaccine adjuvants cause a range of serious side-effects. + YH + + vaccine adjuvant + + + + + + + + + immunization objective is the specification of an objective to achieve immunization. + YH, XZ + WEB: http://en.wikipedia.org/wiki/Immunization + + immunization objective + + + + + + + + + + + + + + + + + + + + + + + + + + vaccine preparation is a manufacturing process to produce a vaccine. + YH, BP + vaccine generation + vaccine production + + vaccine preparation + + + + + + + + + + + + + + + + + + + + + A vaccine that targets against a viral disease. + YH + + viral vaccine + MeSH: D014765 + + + + + + + + + YH + a role that inheres in a prepared material entity that is designed to induce protection or treatment for a disease or infection. + + vaccine role + + + + + + + + + + + + + + + + + + + + YH + a role that inheres in a material entity that becomes an ingredient of a vaccine. + + vaccine component role + + + + + + + + + licensed vaccine role is a regulation-assigned role that indicates that a vaccine obtains official approval for commercial production and selling on the market. + YH + + licensed vaccine role + + + + + + + + + a licensed vaccine role that indicates the vaccine occurs in USA. + YH + + USA licensed vaccine role + + + + + + + + + a mineral salt vaccine adjuvant that is composed of aluminum salt. + Aluminum vaccine adjuvant is a vaccine adjuvant that is composed of some aluminum compound. + YH + + aluminum vaccine adjuvant + + + + + + + + + + + + + + + + + + + + + Modified live virus + YH + + RECOMBITEK Corona MLV + + + + + + + + + + + + + + + YH + + canine coronavirus vaccine + + + + + + + + + vaccine viability is a viability of a vaccine organism. + YH, ZX + + vaccine organism viability + + + + + + + + + A microbial derivative vaccine adjuvant compsed of CpG DNA. + YH + PMID: 12899580 + + CpG DNA vaccine adjuvant + + + + + + + + + + + + + + + + + + + + + a role of host that contains vaccine. It is a role that inheres in an organism that is the target of a vaccine administration (vaccination process). + YH, ZX + + vaccine host role + + + + + + + + + The objective that intends to produce vaccine via the vaccine preparation process. + + YH + vaccine target specification + + + + + + + + + + + + + + + viral vaccine that is used to protect against Bovine coronavirus infection + generated using OntoRat + YL + + bovine coronavirus vaccine + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + generated using OntoRat + YL + + Canine Coronavirus Killed Virus Vaccine (USDA: 14P5.20) + USDA: 14P5.20 + violinID:1562 + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + generated using OntoRat + YL + + Canine Coronavirus Killed Virus Vaccine (USDA: 14P5.21) + USDA: 14P5.21 + violinID:1563 + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + generated using OntoRat + YL + + Canine Coronavirus Modified Live Virus Vaccine (USDA: 14P1.20) + USDA: 14P1.20 + violinID:1561 + + + + + + + + + Rebecca Racz, Yongqun He + + An E mutant is attenuated in hamsters and induces significant protection from challenge with wild type SARS + SARS-CoV E gene mutant vaccine + + + + + + + + + + + + + + + RS, NF, YH + + RBD-rAAV-SARS-CoV + violinID: 4160 + + + + + + + + + + + + + + + RS, NF, YH + + RBD-rAAV-SARS-CoV-02 + violinID: 4161 + + + + + + + + + + + + + + + RS, NF, YH + + rMV- SARS-CoV -S/Ssol + violinID: 4196 + + + + + + + + + + + + + + + + + + + + + A vaccine against coronavirus infection + Hong Yu, Oliver He + + coronavirus vaccine + + + + + + + + + + + + + + + + + + + + + MERS-CoV vaccine + + MERS vaccine + + + + + + + + + + + + + + + + + + + + + + + + + + + + https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5884803/ + + MERS-CoV S protein with alum and CpG adjuvants + + + + + + + + + + MERS-CoV protein + + + + + + + + + + MERS-CoV S protein + + + + + + + + + + + + + + + SARS-CoV-2 vaccine + + COVID-19 vaccine + + + + + + + + + a protein from a virus + YH, ZX + + virus protein + + + + + + + + + YH, ZX + + SARS-CoV protein + + + + + + + + + + + + + + + YH, ZX + + The receptor-binding domain (RBD) of SARS-CoV spike (S) protein is an important target in developing safe and effective SARS vaccines. A previous study has demonstrated that vaccination with adeno-associated virus encoding RBD (RBD-rAAV) induces high titer of neutralizing antibodies. The immune responses and protective effect of the immunization with RBD-rAAV prime/RBD-specific T cell peptide boost were assessed. Compared with the RBD-rAAV prime/boost vaccination, RBD-rAAV prime/RBD-peptide (RBD-Pep) boost induced similar levels of Th1 and neutralizing antibody responses that protected the vaccinated mice from subsequent SARS-CoV challenge, but stronger Th2 and CTL responses. No significant immune responses and protective effects were detected in mice vaccinated with RBD-Pep or blank AAV alone [PubMed: 18289745]. + S protein + Protegen ID: 789; NCBI Gene GI: 1489668; NCBI Protein GI: 29836496; NCBI Protein Accession: NP_828851; NCBITaxon: 694009 + + + + + + + + + + + + + + + YH, ZX + + SARS Subunit Spike Protein Vaccine + VIOLIN Vaccine ID: 842 + + + + + + + + + + + + + + + + + + + + + A vaccine that protects against SARS-CoV. + YH, ZX + SARS-CoV vaccine + + SARS vaccine + + + + + + + + + ncbi_taxonomy + This is an abstract class for use with the NCBI taxonomy to name the depth of the node within the tree. The link between the node term and the rank is only visible if you are using an obo 1.3 aware browser/editor; otherwise this can be ignored. + taxonomic rank + + + + + + + + + + + + + + + A protein coding gene S in severe acute respiratory syndrome coronavirus 2. + + gene + NCBIGene:43740568 + Category=external. + S (severe acute respiratory syndrome coronavirus 2) + + + + + + + + + + + + + + + A protein coding gene 3a in severe acute respiratory syndrome coronavirus 2. + + gene + NCBIGene:43740569 + Category=external. + 3a (severe acute respiratory syndrome coronavirus 2) + + + + + + + + + + + + + + + A protein coding gene E in severe acute respiratory syndrome coronavirus 2. + + gene + NCBIGene:43740570 + Category=external. + E (severe acute respiratory syndrome coronavirus 2) + + + + + + + + + + + + + + + A protein coding gene M in severe acute respiratory syndrome coronavirus 2. + + gene + NCBIGene:43740571 + Category=external. + M (severe acute respiratory syndrome coronavirus 2) + + + + + + + + + + + + + + + A protein coding gene 6 in severe acute respiratory syndrome coronavirus 2. + + gene + NCBIGene:43740572 + Category=external. + 6 (severe acute respiratory syndrome coronavirus 2) + + + + + + + + + + + + + + + A protein coding gene 7a in severe acute respiratory syndrome coronavirus 2. + + gene + NCBIGene:43740573 + Category=external. + 7a (severe acute respiratory syndrome coronavirus 2) + + + + + + + + + + + + + + + A protein coding gene 7b in severe acute respiratory syndrome coronavirus 2. + + gene + NCBIGene:43740574 + Category=external. + 7b (severe acute respiratory syndrome coronavirus 2) + + + + + + + + + + + + + + + A protein coding gene N in severe acute respiratory syndrome coronavirus 2. + + gene + NCBIGene:43740575 + Category=external. + N (severe acute respiratory syndrome coronavirus 2) + + + + + + + + + + + + + + + A protein coding gene ORF10 in severe acute respiratory syndrome coronavirus 2. + + gene + NCBIGene:43740576 + Category=external. + ORF10 (severe acute respiratory syndrome coronavirus 2) + + + + + + + + + + + + + + + A protein coding gene ORF8 in severe acute respiratory syndrome coronavirus 2. + + gene + NCBIGene:43740577 + Category=external. + ORF8 (severe acute respiratory syndrome coronavirus 2) + + + + + + + + + + + + + + + A protein coding gene ORF1ab in severe acute respiratory syndrome coronavirus 2. + + gene + NCBIGene:43740578 + Category=external. + ORF1ab (severe acute respiratory syndrome coronavirus 2) + + + + + + + + + + + + + + + + + + + + COVID19 ontology concepts + + + + + + + + + R-Naught + R0 + basic reproduction rate + multiplicity of infection + reproduction number + basic reproduction number + + + + + + + + + infectious disease control strategy + + + + + + + + + epidemic + + + + + + + + + endemic + + + + + + + + + Community Spread + infection in population + + + + + + + + + contact tracing + + + + + + + + + spatial region + + + + + + + + + temporal region + + + + + + + + + two-dimensional spatial region + + + + + + + + + spatiotemporal region + + + + + + + + + zero-dimensional spatial region + + + + + + + + + one-dimensional spatial region + + + + + + + + + three-dimensional spatial region + + + + + + + + + site + + + + + + + + + process boundary + + + + + + + + + one-dimensional temporal region + + + + + + + + + continuant fiat boundary + + + + + + + + + immaterial entity + + + + + + + + + one-dimensional continuant fiat boundary + + + + + + + + + process profile + + + + + + + + + relational quality + + + + + + + + + two-dimensional continuant fiat boundary + + + + + + + + + zero-dimensional continuant fiat boundary + + + + + + + + + zero-dimensional temporal region + + + + + + + + + history + + + + + + + + + zafirlukast + cyclopentyl 3-[2-methoxy-4-(2-methylphenylsulfonylcarbamoyl)benzyl]-1-methyl-1H-indol-5-ylcarbamate + + + + + + + + + erlotinib + N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine + + + + + + + + + Efavirenz + efavirenz + (4S)-6-chloro-4-(cyclopropylethynyl)-4-(trifluoromethyl)-1,4-dihydro-2H-3,1-benzoxazin-2-one + + + + + + + + + grazoprevir + (1aR,5S,8S,10R,22aR)-5-tert-butyl-N-{(1R,2S)-1-[(cyclopropanesulfonyl)carbamoyl]-2-ethenylcyclopropyl}-14-methoxy-3,6-dioxo-1,1a,3,4,5,6,9,10,18,19,20,21,22,22a-tetradecahydro-8H-7,10-methanocyclopropa[18,19][1,10,3,6]dioxadiazacyclononadecino[11,12-b]quinoxaline-8-carboxamide + + + + + + + + + velpatasvir + methyl {(2S)-1-[(2S,5S)-2-(9-{2-[(2S,4S)-1-{(2R)-2-[(methoxycarbonyl)amino]-2-phenylacetyl}-4-(methoxymethyl)pyrrolidin-2-yl]-1H-imidazol-4-yl}-1,11-dihydro[2]benzopyrano[4',3':6,7]naphtho[1,2-d]imidazol-2-yl)-5-methylpyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl}carbamate + + + + + + + + + tenofovir(1-) + hydrogen ({[(2R)-1-(6-amino-9H-purin-9-yl)propan-2-yl]oxy}methyl)phosphonate + + + + + + + + + ceftolozane + 7-{[(2Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-{[(2-carboxypropan-2-yl)oxy]imino}acetyl]amino}-3-[ (5-amino-4-{[(2-aminoethyl)carbamoyl]amino}-1-methyl-1H-pyrazol-2-ium-2-yl)methyl]-3,4-didehydrocepham-4-carboxylate + + + + + + + + + simeprevir + + + + + + + + + ethoheptazine + + + + + + + + + gemeprost + + + + + + + + + thymopentin + + + + + + + + + valrubicin + + + + + + + + + pralmorelin + + + + + + + + + pevonedistat + [(1S,2S,4R)-4-{4-[(1S)-2,3-dihydro-1H-inden-1-ylamino]-7H-pyrrolo[2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl]methyl sulfamate + + + + + + + + + cinanserin + (2E)-N-(2-{[3-(dimethylamino)propyl]sulfanyl}phenyl)-3-phenylprop-2-enamide + + + + + + + + + TDZD-8 + 4-Benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione + 4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione + + + + + + + + + tigecycline + (4S,4aS,5aR,12aS)-9-[(N-tert-butylglycyl)amino]-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide + + + + + + + + + Prostaglandin I2 + prostaglandin I2 + (5Z,13E,15S)-6,9alpha-epoxy-11alpha,15-dihydroxyprosta-5,13-dienoic acid + + + + + + + + + Hydrogen peroxide + bis(hydridooxygen)(O--O) + dihydrogen peroxide + dihydrogen(peroxide) + dioxidane + hydrogen peroxide + hydrogen peroxide + HYDROGEN PEROXIDE + + + + + + + + + Adenosine + adenosine + adenosine + ADENOSINE + + + + + + + + + nitric oxide + oxidonitrogen(.) + oxoazanyl + nitric oxide + Nitric oxide + + + + + + + + + Creatinine + creatinine + creatinine + 2-imino-1-methylimidazolidin-4-one + + + + + + + + + N-[2-(5-methoxy-1H-indol-3-yl)ethyl]acetamide + melatonin + melatonin + Melatonin + + + + + + + + + Nicotinamide + nicotinamide + pyridine-3-carboxamide + nicotinamide + NICOTINAMIDE + + + + + + + + + 4-methylumbelliferone + 7-hydroxy-4-methyl-2H-chromen-2-one + 4-methylumbelliferone + 4-Methylumbelliferone + + + + + + + + + CHLORAMPHENICOL + Chloramphenicol + chloramphenicol + chloramphenicol + 2,2-dichloro-N-[(1R,2R)-2-hydroxy-1-(hydroxymethyl)-2-(4-nitrophenyl)ethyl]acetamide + + + + + + + + + Benzylpenicillin + benzylpenicillin + 2,2-dimethyl-6beta-(phenylacetamido)penam-3alpha-carboxylic acid + + + + + + + + + dihydroartemisinin + (3R,5aS,6R,8aS,9R,12R,12aR)-3,6,9-trimethyldecahydro-3,12-epoxypyrano[4,3-j][1,2]benzodioxepin-10-ol + + + + + + + + + vitamin C + Vitamin C + + + + + + + + + acetylcysteine + + + + + + + + + bafilomycin A1 + (3Z,5E,7R,8S,9S,11E,13E,15S,16R)-16-{(2S,3R,4S)-4-[(2R,4R,5S,6R)-2,4-dihydroxy-6-isopropyl-5-methyltetrahydro-2H-pyran-2-yl]-3-hydroxypentan-2-yl}-8-hydroxy-3,15-dimethoxy-5,7,9,11-tetramethyloxacyclohexadeca-3,5,11,13-tetraen-2-one + + + + + + + + + bleomycin + + + + + + + + + cephalosporin + Cephalosporin + + + + + + + + + colchicine + N-(1,2,3,10-tetramethoxy-9-oxo-5,6,7,9-tetrahydrobenzo[a]heptalen-7-yl)acetamide + + + + + + + + + CINCHOCAINE + cinchocaine + 2-butoxy-N-[2-(diethylamino)ethyl]quinoline-4-carboxamide + + + + + + + + + porphyrins + porphyrins + + + + + + + + + Amitriptyline + amitriptyline + 3-(10,11-dihydro-5H-dibenzo[a,d][7]annulen-5-ylidene)-N,N-dimethylpropan-1-amine + + + + + + + + + Chalcone + chalcone + 1,3-diphenylprop-2-en-1-one + + + + + + + + + CAFFEINE + Caffeine + caffeine + caffeine + 1,3,7-trimethyl-3,7-dihydro-1H-purine-2,6-dione + + + + + + + + + Eriodictyol + eriodictyol + (2S)-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-2,3-dihydro-4H-chromen-4-one + + + + + + + + + Tetryzoline + tetryzoline + 2-(1,2,3,4-tetrahydronaphthalen-1-yl)-4,5-dihydro-1H-imidazole + + + + + + + + + 3,3',5'-triiodothyronine + 3,3',5'-triiodothyronine + 3,3',5'-Triiodothyronine + + + + + + + + + Hesperidin + hesperidin + hesperidin + (2S)-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-4-oxo-3,4-dihydro-2H-chromen-7-yl 6-O-(6-deoxy-alpha-L-mannopyranosyl)-beta-D-glucopyranoside + + + + + + + + + Ampicillin + ampicillin + 6beta-[(2R)-2-amino-2-phenylacetamido]-2,2-dimethylpenam-3alpha-carboxylic acid + + + + + + + + + monohydrogen + hydrogen(.) + hydrogen + hydrogen(.) + + + + + + + + + teicoplanin + + + + + + + + + bromhexine hydrochloride + 2,4-dibromo-6-{[cyclohexyl(methyl)amino]methyl}aniline hydrochloride + + + + + + + + + camostat methanesulfonate + + + + + + + + + Carmofur + Carmofur + + + + + + + + + Ebastine + Ebastine + + + + + + + + + EMTRICITABINE + Emtricitabine + emtricitabine + 4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2(1H)-one + + + + + + + + + Eplerenone + eplerenone + 7alpha-methoxycarbonyl-3-oxo-9,11alpha-epoxy-17alpha-pregn-4-ene-21,17-carbolactone + + + + + + + + + pantethine + Bis(N-pantothenylamidoethyl) disulfide + (2R,2'R)-N,N'-{disulfanediylbis[ethane-2,1-diylimino(3-oxopropane-3,1-diyl)]}bis(2,4-dihydroxy-3,3-dimethylbutanamide) + + + + + + + + + pirfenidone + 5-methyl-1-phenylpyridin-2(1H)-one + + + + + + + + + sodium hypochlorite + sodium hypochlorite + + + + + + + + + captopril + 1-[(2S)-2-methyl-3-sulfanylpropanoyl]-L-proline + + + + + + + + + Carvedilol + carvedilol + 1-(9H-carbazol-4-yloxy)-3-{[2-(2-methoxyphenoxy)ethyl]amino}propan-2-ol + + + + + + + + + diuretic + + + + + + + + + Chlorothiazide + chlorothiazide + 6-chloro-4H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide + + + + + + + + + Darunavir + darunavir + (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl [(2S,3R)-4-{[(4-aminophenyl)sulfonyl](2-methylpropyl)amino}-3-hydroxy-1-phenylbutan-2-yl]carbamate + + + + + + + + + Camphor + bornan-2-one + camphor + camphor + 1,7,7-trimethylbicyclo[2.2.1]heptan-2-one + + + + + + + + + adrenergic antagonist + + + + + + + + + atazanavir + dimethyl (3S,8S,9S,12S)-9-benzyl-3,12-di-tert-butyl-8-hydroxy-4,11-dioxo-6-[4-(2-pyridyl)benzyl]-2,5,6,10,13-pentaazatetradecanedioate + + + + + + + + + colistin + Colistin + + + + + + + + + calcium channel blocker + + + + + + + + + Atorvastatin + atorvastatin + (3R,5R)-7-[3-(anilinocarbonyl)-5-(4-fluorophenyl)-4-phenyl-2-(propan-2-yl)-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid + + + + + + + + + VALPROIC ACID + valproic acid + 2-propylpentanoic acid + + + + + + + + + Dexamethasone + dexamethasone + dexamethasone + 9-fluoro-11beta,17,21-trihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione + + + + + + + + + Daunorubicin + daunorubicin + (1S,3S)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside + + + + + + + + + {(1S,4R)-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]cyclopent-2-en-1-yl}methanol + abacavir + Abacavir + + + + + + + + + Emodin + emodin + 1,3,8-trihydroxy-6-methylanthra-9,10-quinone + + + + + + + + + EQUILIN + Equilin + equilin + 3-hydroxyestra-1,3,5(10),7-tetraen-17-one + + + + + + + + + desferrioxamine B + N'-{5-[acetyl(hydroxy)amino]pentyl}-N-(5-{4-[(5-aminopentyl)(hydroxy)amino]-4-oxobutanamido}pentyl)-N-hydroxybutanediamide + + + + + + + + + lisinopril + N(2)-[(1S)-1-carboxy-3-phenylpropyl]-L-lysyl-L-proline + + + + + + + + + 2-benzyl-5-[(2S)-2-(tert-butylcarbamoyl)-4-(pyridin-3-ylmethyl)piperazin-1-yl]-2,3,5-trideoxy-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-D-erythro-pentonamide + Indinavir + indinavir + (2S)-1-[(2S,4R)-4-benzyl-2-hydroxy-5-{[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]amino}-5-oxopentyl]-N-tert-butyl-4-(pyridin-3-ylmethyl)piperazine-2-carboxamide + + + + + + + + + Pentamidine + pentamidine + 4,4'-[pentane-1,5-diylbis(oxy)]dibenzenecarboximidamide + + + + + + + + + praziquantel + + + + + + + + + Ganciclovir + ganciclovir + 2-amino-9-{[(1,3-dihydroxypropan-2-yl)oxy]methyl}-1,9-dihydro-6H-purin-6-one + + + + + + + + + dipyridamole + 2,2',2'',2'''-[(4,8-dipiperidin-1-ylpyrimido[5,4-d]pyrimidine-2,6-diyl)dinitrilo]tetraethanol + + + + + + + + + Disulfiram + disulfiram + 1,1',1'',1'''-[disulfanediylbis(carbonothioylnitrilo)]tetraethane + + + + + + + + + Caspofungin + caspofungin + (10R,12S)-N-{(2R,6S,9S,11R,12S,14aS,15S,20S,23S,25aS)-12-[(2-aminoethyl)amino]-20-[(1R)-3-amino-1-hydroxypropyl]-23-[(1S,2S)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-2,11,15-trihydroxy-6-[(1R)-1-hydroxyethyl]-5,8,14,19,22,25-hexaoxotetracosahydro-1H-dipyrrolo[2,1-c:2',1'-l][1,4,7,10,13,16]hexaazacyclohenicosin-9-yl}-10,12-dimethyltetradecanamide + + + + + + + + + Entacapone + entacapone + (2E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethylprop-2-enamide + + + + + + + + + cinacalcet + N-[(1R)-1-(1-naphthyl)ethyl]-3-[3-(trifluoromethyl)phenyl]propan-1-amine + + + + + + + + + olmesartan + olmesartan + 4-(1-hydroxy-1-methylethyl)-2-propyl-1-{[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl}-1H-imidazole-5-carboxylic acid + + + + + + + + + angiotensin II + + + + + + + + + Indomethacin + [1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl]acetic acid + Indomethacin + indomethacin + INDOMETHACIN + + + + + + + + + aprepitant + 5-{[(2R,3S)-2-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy}-3-(4-fluorophenyl)morpholin-4-yl]methyl}-2,4-dihydro-3H-1,2,4-triazol-3-one + + + + + + + + + propan-2-yl 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoate + fenofibrate + Fenofibrate + + + + + + + + + 5-aza-2'-deoxycytidine + 4-amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)-1,3,5-triazin-2(1H)-one + + + + + + + + + Montelukast + {1-[({(1R)-1-{3-[(E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl}-3-[2-(2-hydroxypropan-2-yl)phenyl]propyl}sulfanyl)methyl]cyclopropyl}acetic acid + montelukast + MONTELUKAST + + + + + + + + + 3-sulfanylvaline + penicillamine + 2-amino-3-methyl-3-sulfanylbutanoic acid + + + + + + + + + sorafenib + 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide + + + + + + + + + thiazolidinediones + + + + + + + + + Pseudoephedrine + pseudoephedrine + (1S,2S)-2-(methylamino)-1-phenylpropan-1-ol + + + + + + + + + formoterol + rac-N-{2-hydroxy-5-[(1R)-1-hydroxy-2-{[(2R)-1-(4-methoxyphenyl)propan-2-yl]amino}ethyl]phenyl}formamide + + + + + + + + + [(1R)-3-methyl-1-({(2S)-3-phenyl-2-[(pyrazin-2-ylcarbonyl)amino]propanoyl}amino)butyl]boronic acid + bortezomib + N-[(1R)-1-(dihydroxyboranyl)-3-methylbutyl]-N(alpha)-(pyrazin-2-ylcarbonyl)-L-phenylalaninamide + + + + + + + + + Ile(5)-angiotensin II (1-7) + L-alpha-aspartyl-L-arginyl-L-valyl-L-tyrosyl-L-isoleucyl-L-histidyl-L-proline + + + + + + + + + haloperidol + 4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-1-(4-fluorophenyl)butan-1-one + + + + + + + + + Hypericin + hypericin + 1,3,4,6,8,13-hexahydroxy-10,11-dimethylphenanthro[1,10,9,8-opqra]perylene-7,14-dione + + + + + + + + + Ibuprofen + ibuprofen + 2-[4-(2-methylpropyl)phenyl]propanoic acid + + + + + + + + + Irbesartan + irbesartan + 2-butyl-3-{[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl}-1,3-diazaspiro[4.4]non-1-en-4-one + + + + + + + + + ACE2 inhibitor + angiotensin receptor antagonist + + + + + + + + + fingolimod + 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol + + + + + + + + + Labetalol + labetalol + 2-hydroxy-5-{1-hydroxy-2-[(1-methyl-3-phenylpropyl)amino]ethyl}benzamide + + + + + + + + + midostaurin + N-[(5S,6R,7R,9R)-6-methoxy-5-methyl-14-oxo-6,7,8,9,15,16-hexahydro-5H,14H-5,9-epoxy-4b,9a,15-triazadibenzo[b,h]cyclonona[1,2,3,4-jkl]cyclopenta[e]-as-indacen-7-yl]-N-methylbenzamide + + + + + + + + + N-({(5S)-3-[3-fluoro-4-(morpholin-4-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl}methyl)acetamide + linezolid + Linezolid + + + + + + + + + Moxifloxacin + moxifloxacin + 1-cyclopropyl-6-fluoro-8-methoxy-7-[(4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic acid + + + + + + + + + saquinavir + N(1)-{(2S,3R)-4-[(3S,4aS,8aS)-3-(tert-butylcarbamoyl)octahydroisoquinolin-2(1H)-yl]-3-hydroxy-1-phenylbutan-2-yl}-N(2)-(quinolin-2-ylcarbonyl)-L-aspartamide + + + + + + + + + tipranavir + N-(3-{(1R)-1-[(6R)-4-hydroxy-2-oxo-6-(2-phenylethyl)-6-propyl-5,6-dihydro-2H-pyran-3-yl]propyl}phenyl)-5-(trifluoromethyl)pyridine-2-sulfonamide + + + + + + + + + Leflunomide + leflunomide + 5-methyl-N-[4-(trifluoromethyl)phenyl]-1,2-oxazole-4-carboxamide + + + + + + + + + levamisole + (6S)-6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazole + + + + + + + + + carfilzomib + N-{(2S)-2-[(morpholin-4-ylacetyl)amino]-4-phenylbutanoyl}-L-leucyl-N-{(2S)-4-methyl-1-[(2R)-2-methyloxiran-2-yl]-1-oxopentan-2-yl}-L-phenylalaninamide + + + + + + + + + andrographolide + (3E,4S)-4-hydroxy-3-{2-[(1R,4aS,5R,6R,8aS)-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylidenedecahydronaphthalen-1-yl]ethylidene}dihydrofuran-2(3H)-one + + + + + + + + + Losartan + losartan + (2-butyl-4-chloro-1-{[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl}-1H-imidazol-5-yl)methanol + + + + + + + + + ruxolitinib + (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile + + + + + + + + + meperidine + Meperidine + Meperidine + + + + + + + + + mesalamine + 5-amino-2-hydroxybenzoic acid + + + + + + + + + N,N-dimethylimidodicarbonimidic diamide + metformin + Metformin + + + + + + + + + Methicillin + methicillin + 6beta-(2,6-dimethoxybenzamido)-2,2-dimethylpenam-3alpha-carboxylic acid + + + + + + + + + icatibant + (2S)-2-({[(2S,3aS,7aS)-1-({(3R)-2-[(2S)-2-{[(2S)-2-[2-({[(2S,4R)-1-({(2S)-1-[(2S)-2-{[(2R)-2-amino-5-carbamimidamidopentanoyl]amino}-5-carbamimidamidopentanoyl]pyrrolidin-2-yl}carbonyl)-4-hydroxypyrrolidin-2-yl]carbonyl}amino)acetamido]-3-(thiophen-2-yl)propanoyl]amino}-3-hydroxypropanoyl]-1,2,3,4-tetrahydroisoquinolin-3-yl}carbonyl)octahydro-1H-indol-2-yl]carbonyl}amino)-5-carbamimidamidopentanoic acid + + + + + + + + + ticagrelor + (1S,2S,3R,5S)-3-[7-{[(1R,2S)-2-(3,4-difluorophenyl)cyclopropyl]amino}-5-(propylsulfanyl)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)cyclopentane-1,2-diol + + + + + + + + + telaprevir + (1S,3aR,6aS)-2-[(2S)-2-({(2S)-2-cyclohexyl-2-[(pyrazin-2-ylcarbonyl)amino]acetyl}amino)-3,3-dimethylbutanoyl]-N-[(3S)-1-(cyclopropylamino)-1,2-dioxohexan-3-yl]octahydrocyclopenta[c]pyrrole-1-carboxamide + + + + + + + + + rilpivirine + 4-{[4-({4-[(E)-2-cyanoethenyl]-2,6-dimethylphenyl}amino)pyrimidin-2-yl]amino}benzonitrile + + + + + + + + + boceprevir + (1R,2S,5S)-N-(4-amino-1-cyclobutyl-3,4-dioxobutan-2-yl)-3-[N-(tert-butylcarbamoyl)-3-methyl-L-valyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide + + + + + + + + + bepotastine + + + + + + + + + nitrofurantoin + 1-{[(5-nitro-2-furyl)methylene]amino}imidazolidine-2,4-dione + + + + + + + + + elvitegravir + 6-(3-chloro-2-fluorobenzyl)-1-[(2S)-1-hydroxy-3-methylbutan-2-yl]-7-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid + + + + + + + + + cobicistat + 1,3-thiazol-5-ylmethyl [(2R,5R)-5-{[(2S)-2-({[(2-isopropyl-1,3-thiazol-4-yl)methyl](methyl)carbamoyl}amino)-4-(morpholin-4-yl)butanoyl]amino}-1,6-diphenylhexan-2-yl]carbamate + + + + + + + + + Naphazoline + + + + + + + + + dabrafenib + N-{3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide + + + + + + + + + dolutegravir + (4R,12aS)-N-(2,4-difluorobenzyl)-7-hydroxy-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide + + + + + + + + + ebselen + 2-phenyl-1,2-benzoselenazol-3(2H)-one + + + + + + + + + tranilast + 2-{[(2E)-3-(3,4-dimethoxyphenyl)prop-2-enoyl]amino}benzoic acid + + + + + + + + + Ranitidine bismuth citrate + + + + + + + + + omeprazole + rac-5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole + + + + + + + + + (S)-verapamil + (2S)-2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile + + + + + + + + + ethyl (3R,4R,5S)-4-acetamido-5-amino-3-(pentan-3-yloxy)cyclohex-1-ene-1-carboxylate + oseltamivir + Oseltamivir + + + + + + + + + ponatinib + 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide + + + + + + + + + oxymetholone + 17beta-hydroxy-2-(hydroxymethylidene)-17-methyl-5alpha-androstan-3-one + + + + + + + + + Paroxetine + paroxetine + (3S,4R)-3-[(1,3-benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine + + + + + + + + + Perphenazine + perphenazine + 2-{4-[3-(2-chloro-10H-phenothiazin-10-yl)propyl]piperazin-1-yl}ethanol + + + + + + + + + Isoniazid pyruvate + + + + + + + + + Shikonin + + + + + + + + + thyroid stimulating hormone + + + + + + + + + trans-piceid + 3-hydroxy-5-[(E)-2-(4-hydroxyphenyl)ethenyl]phenyl beta-D-glucopyranoside + + + + + + + + + fosamprenavir + (3S)-tetrahydrofuran-3-yl [(2S,3R)-4-{[(4-aminophenyl)sulfonyl](2-methylpropyl)amino}-1-phenyl-3-(phosphonooxy)butan-2-yl]carbamate + + + + + + + + + raltegravir + + + + + + + + + daclatasvir + methyl [(2S)-1-{(2S)-2-[4-(4'-{2-[(2S)-1-{(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl}pyrrolidin-2-yl]-1H-imidazol-4-yl}biphenyl-4-yl)-1H-imidazol-2-yl]pyrrolidin-1-yl}-3-methyl-1-oxobutan-2-yl]carbamate + + + + + + + + + Procainamide + procainamide + 4-amino-N-[2-(diethylamino)ethyl]benzamide + + + + + + + + + ledipasvir + methyl [(2S)-1-{(6S)-6-[4-(9,9-difluoro-7-{2-[(1R,3S,4S)-2-{(2S)-2-[(methoxycarbonyl)amino]-3-methylbutanoyl}-2-azabicyclo[2.2.1]hept-3-yl]-1H-benzimidazol-5-yl}-9H-fluoren-2-yl)-1H-imidazol-2-yl]-5-azaspiro[2.4]hept-5-yl}-3-methyl-1-oxobutan-2-yl]carbamate + + + + + + + + + fluoroquinolones + fluoroquinolone antibiotic + + + + + + + + + tenofovir alafenamide + propan-2-yl N-[(S)-({[(2R)-1-(6-amino-9H-purin-9-yl)propan-2-yl]oxy}methyl)(phenoxy)phosphoryl]-L-alaninate + + + + + + + + + piperaquine + 7-chloro-4-(4-{3-[4-(7-chloroquinolin-4-yl)piperazin-1-yl]propyl}piperazin-1-yl)quinoline + + + + + + + + + Suramin sodium + Suramin sodium + + + + + + + + + Tamsulosin + tamsulosin + 5-[(2R)-2-{[2-(2-ethoxyphenoxy)ethyl]amino}propyl]-2-methoxybenzenesulfonamide + + + + + + + + + Telmisartan + telmisartan + 4'-[(1,7'-dimethyl-2'-propyl-1H,3'H-2,5'-bibenzimidazol-3'-yl)methyl][1,1'-biphenyl]-2-carboxylic acid + + + + + + + + + terbinafine + terbinafine + (2E)-N,6,6-trimethyl-N-(1-naphthylmethyl)hept-2-en-4-yn-1-amine + + + + + + + + + 1-phenyl-1-cyclopentanecarboxylic acid 2-[2-(diethylamino)ethoxy]ethyl ester + + + + + + + + + rac-2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione + thalidomide + Thalidomide + + + + + + + + + ticlopidine + 5-(2-chlorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine + + + + + + + + + tolazamide + N-(azepan-1-ylcarbamoyl)-4-methylbenzenesulfonamide + + + + + + + + + toremifene + 2-{4-[(1Z)-4-chloro-1,2-diphenylbut-1-en-1-yl]phenoxy}-N,N-dimethylethanamine + + + + + + + + + magnetic-bead extraction + magnetic bead extraction + automated magnetic bead-purification procedure + magnetic separation + + + + + + + + + cell + cell + + + + + + + + + T-cell + T-lymphocyte + T cell + T lymphocyte + + + + + + + + + macrophage + histiocyte + + + + + + + + + B-cell + B-lymphocyte + B cell + B lymphocyte + + + + + + + + + pneumonocyte + pneumocyte + alveolar epithelial cells + alveolar epithelial cell + + + + + + + + + CD4-positive helper T lymphocyte + CD4-positive helper T-cell + CD4-positive helper T-lymphocyte + CD4-positive helper T cell + CD4-positive T-helper cell + + + + + + + + + natural killer cell + natural killer (NK) cell + NK cell + + + + + + + + + CD4-positive, alpha-beta T-cell + CD4-positive, alpha-beta T-lymphocyte + CD4-positive, alpha-beta T cell + CD4-positive, alpha-beta T lymphocyte + + + + + + + + + foreign body giant cell + macrophage polykaryon + multinucleate giant cell + syncytial giant cell + multinucleated giant cell + Langerhans giant cell + + + + + + + + + neutrophil leucocyte + neutrophil leukocyte + neutrophilic leucocyte + neutrophilic leukocyte + neutrophil + neutrocyte + + + + + + + + + alpha-beta T-cell + alpha-beta T-lymphocyte + alpha-beta T cell + alpha-beta T lymphocyte + + + + + + + + + mature alpha-beta T-cell + mature alpha-beta T-lymphocyte + mature alpha-beta T cell + mature alpha-beta T lymphocyte + + + + + + + + + CD4-positive, CD25-positive, alpha-beta regulatory T-cell + CD4-positive, CD25-positive, alpha-beta regulatory T-lymphocyte + CD4-positive, CD25-positive, alpha-beta regulatory T cell + regulatory T cells (Tregs) (CD4+CD25+) + CD4-positive, CD25-positive, alpha-beta regulatory T lymphocyte + + + + + + + + + regulatory T lymphocyte + regulatory T-cell + regulatory T-lymphocyte + regulatory T cell + Treg + + + + + + + + + Tfh + T follicular helper cell + T(FH) + + + + + + + + + mature T-cell + mature T cell + CD3e-positive T cell + + + + + + + + + clinical measurement + + + + + + + + + cardiovascular measurement + + + + + + + + + heart rate + + + + + + + + + systolic blood pressure + mean arterial blood pressure + + + + + + + + + blood chemistry measurement + + + + + + + + + leukocyte numbers + white blood cell count + + + + + + + + + platelet count + + + + + + + + + blood lymphocyte count + + + + + + + + + blood measurement + + + + + + + + + blood cell measurement + + + + + + + + + prothrombin time + + + + + + + + + cell measurement + + + + + + + + + pulse + + + + + + + + + oxygen saturation + + + + + + + + + disease of metabolism + metabolic disease + + + + + + + + + bacterial sepsis + + + + + + + + + carbohydrate metabolism disease + + + + + + + + + disease by infectious agent + infectious disease + + + + + + + + + lower respiratory tract disease + + + + + + + + + respiratory system benign neoplasm + + + + + + + + + cardiomyopathy + Cardiomyopathies + + + + + + + + + artery disease + + + + + + + + + CD45 deficiency + + + + + + + + + autoimmune disease of cardiovascular system + + + + + + + + + hypersensitivity reaction disease + + + + + + + + + benign neoplasm + + + + + + + + + organ system benign neoplasm + + + + + + + + + acquired metabolic disease + + + + + + + + + bacterial infectious disease + + + + + + + + + viral pneumonia + + + + + + + + + kidney failure + renal failure + + + + + + + + + High blood pressure + hyperpiesia + vascular hypertensive disorder + hypertension + HTN + + + + + + + + + acute respiratory Failure + acute-on-chronic respiratory failure + chronic respiratory failure + respiratory insufficiency/failure + respiratory failure + acute and chronic respiratory failure + + + + + + + + + Defibrination syndrome + Diffuse or disseminated intravascular coagulation + disseminated intravascular coagulation + DIC + + + + + + + + + Non-cardiogenic pulmonary edema + Shock lung + adult RDS + adult respiratory distress syndrome + acute respiratory distress syndrome + ARDS + + + + + + + + + pulmonary edema + + + + + + + + + heart disease + + + + + + + + + acquired agammaglobulinemia + acquired hypogammaglobulinemia + common variable agammaglobulinemia + sporadic hypogammaglobulinemia + common variable immunodeficiency + CVID + + + + + + + + + neutropenia + + + + + + + + + postpartum coagulation defect with delivery + blood coagulation disease + Coagulation disorders + postpartum coagulation defect + + + + + + + + + respiratory syncytial virus infection + respiratory syncytial virus infectious disease + + + + + + + + + cardiovascular system disease + Cardiovascular Disease + disease of subdivision of hemolymphoid system + + + + + + + + + Granulopenia + granulocytopenia + agranulocytosis + Granulocytopenic disorder + + + + + + + + + neoplasm + disease of cellular proliferation + cell process disease + + + + + + + + + respiratory system disease + + + + + + + + + malignant tumor + primary cancer + cancer + malignant neoplasm + + + + + + + + + musculoskeletal system disease + + + + + + + + + vascular disease + vascular tissue disease + + + + + + + + + urinary tract disease + urinary system disease + Non-neoplastic urinary tract disease + + + + + + + + + atherosclerosis + + + + + + + + + hepatitis B infection + hepatitis B + chronic hepatitis B + + + + + + + + + constipation + + + + + + + + + Immunoglobulin heavy chain deficiency + immunoglobulin heavy chain deletion + B cell deficiency + B cell (antibody) deficiencies + + + + + + + + + syndrome + + + + + + + + + obstructive lung disease + respiratory airway obstruction + + + + + + + + + arteriosclerotic cardiovascular disease + Cardiovascular arteriosclerosis + + + + + + + + + Arteriosclerotic vascular disease + arteriosclerosis + Arteriosclerosis + + + + + + + + + thrombophilia + hypercoagulability state + + + + + + + + + hypogammaglobulinemia + mu heavy chain deficiency + agammaglobulinemia + IGHM + + + + + + + + + immune system disease + + + + + + + + + antiphospholipid antibody syndrome + antiphospholipid syndrome + Antiphospholipid syndrome + + + + + + + + + interstitial lung disease + Interstitial lung abnormalities + ILD + + + + + + + + + COPD + chronic obstructive airway disease + chronic obstructive lung disease + chronic obstructive pulmonary disease + COLD + + + + + + + + + hepatobiliary disease + liver and biliary tract disease + + + + + + + + + central nervous system disease + + + + + + + + + Coronary disease + coronary arteriosclerosis + coronary heart disease + coronary artery disease + CHD + + + + + + + + + lung benign neoplasm + Benign Lung Neoplasm + tumor of the lung + + + + + + + + + pulmonary fibrosis + Fibrosis of lung + + + + + + + + + hepatic disorder + liver disease + disorder of liver + + + + + + + + + hypersensitivity reaction type II disease + autoimmune hypersensitivity disease + autoimmune disease + + + + + + + + + glucose metabolism disease + disorder of glucose metabolism + + + + + + + + + intestinal disease + + + + + + + + + Heck's disease + Multifocal epithelial hyperplasia + focal epithelial hyperplasia + Heck disease + + + + + + + + + Coin lesion of lung + pulmonary coin lesion + Coin lesion lung + + + + + + + + + pneumonia + acute pneumonia + + + + + + + + + nephropathy + kidney disease + impaired renal function disease + + + + + + + + + proteinuria + + + + + + + + + heart attack + myocardial infarction + heart attack + Myocardial infarct + + + + + + + + + immune deficiency disorder + immunodeficiency syndrome + primary immunodeficiency disease + hypoimmunity + + + + + + + + + lymphopenia + Lymphocytopenia + + + + + + + + + leukopenia + Leucopenia + + + + + + + + + combined T and B cell inborn immunodeficiency + severe combined immunodeficiency + SCID + + + + + + + + + combined immunodeficiency + combined T cell and B cell immunodeficiency + Congenital Combined Immunodeficiency + + + + + + + + + disorder of connective tissue + connective tissue disease + connective tissue disorder + + + + + + + + + Cerebrovascular accident + cerebrovascular accident + cerebrovascular disorder + stroke + cerebrovascular disease + CVA + + + + + + + + + disease of anatomical entity + + + + + + + + + Blood dyscrasia + DISEASE OF THE BLOOD AND BLOOD-FORMING ORGANS + Hematological disease + blood disorder + disease of haematopoietic system + disease of hematopoietic system + haematopoietic system disease + hematopoietic system disease + Blood disease + + + + + + + + + Gastroenteropathy + alimentary system disease + digestive system disorder + gastrointestinal disease + gastrointestinal disorder + gastrointestinal system disease + GIT disease + + + + + + + + + CRF + chronic kidney failure + chronic renal disease + chronic renal failure syndrome + renal failure - chronic + chronic kidney disease + CKD + + + + + + + + + Influenza with other manifestations + flu + influenza with non-respiratory manifestation + influenza + Influenza with non-respiratory manifestation + + + + + + + + + lung disease + + + + + + + + + measles + morbilli + + + + + + + + + nervous system disease + + + + + + + + + diabetes mellitus + + + + + + + + + non-insulin-dependent diabetes mellitus + type 2 diabetes + type II diabetes mellitus + type 2 diabetes mellitus + NIDDM + + + + + + + + + brain disease + encephalopathy + + + + + + + + + leukocyte disease + + + + + + + + + upper respiratory tract disease + + + + + + + + + bowel dysfunction + + + + + + + + + bevacizumab + + + + + + + + + peginterferon alfa-2a + + + + + + + + + Interferon Alfa-2b + + + + + + + + + eculizumab + + + + + + + + + adalimumab + + + + + + + + + sarilumab + + + + + + + + + baricitinib + + + + + + + + + Baloxavir marboxil + + + + + + + + + Fedratinib + + + + + + + + + technique + + + + + + + + + intervention + + + + + + + + + prevention intervention + prevention and control intervention + + + + + + + + + population screening + patient screening + + + + + + + + + molecular assay + + + + + + + + + organismal assay + + + + + + + + + clinical assay + + + + + + + + + imaging technique + + + + + + + + + data processing operation + + + + + + + + + data analysis operation + + + + + + + + + graph-based models + graph-based analysis operation + + + + + + + + + computational model + computational + + + + + + + + + Neuraminidase inhibitor + neuraminidase inhibitor drug + + + + + + + + + Immunoglobulin + Antibody + + + + + + + + + Immunoglobulin G + IgG + + + + + + + + + Immunoglobulin M + IgM + + + + + + + + + Immunoglobulin E + IgE + + + + + + + + + travel history evaluation + travel history item + + + + + + + + + ribosomal large subunit assembly + + + + + + + + + ribosomal small subunit assembly + + + + + + + + + mitotic sister chromatid segregation + mitotic chromosome segregation + + + + + + + + + cell cycle checkpoint + + + + + + + + + DNA replication checkpoint + + + + + + + + + regulation of cyclin-dependent protein serine/threonine kinase activity + regulation of CDK activity + + + + + + + + + G1/S transition of mitotic cell cycle + + + + + + + + + regulation of transcription involved in G1/S transition of mitotic cell cycle + + + + + + + + + G2/M transition of mitotic cell cycle + mitotic G2/M transition + + + + + + + + + cytoplasmic ubiquitin ligase complex + + + + + + + + + MAP kinase kinase kinase cascade + MAPK signal transduction + MAPKKK cascade + mitogen-activated protein kinase cascade + MAPK cascade + MAP kinase cascade + + + + + + + + + mRNA catabolic process, nonsense-mediated + mRNA catabolism, nonsense-mediated + mRNA degradation, nonsense-mediated decay + nonsense-mediated mRNA decay + nuclear mRNA catabolic process, nonsense-mediated decay + nuclear-transcribed mRNA catabolic process, nonsense-mediated decay + mRNA breakdown, nonsense-mediated decay + + + + + + + + + spindle organization during meiosis + meiotic spindle organization + meiotic spindle organisation + + + + + + + + + spliceosomal complex assembly + + + + + + + + + nuclear division + + + + + + + + + mitotic cytokinesis + cytokinesis after mitosis + + + + + + + + + response to ROI + response to ROS + response to active oxygen species + response to reactive oxidative species + response to reactive oxygen intermediate + response to reactive oxygen species + response to AOS + + + + + + + + + nuclear mRNA 5'-splice site recognition + mRNA 5'-splice site recognition + nuclear mRNA 5' splice site recognition + + + + + + + + + chromosome, centric region + chromosome, centromeric region + centromere complex + + + + + + + + + kinetochore + + + + + + + + + condensed chromosome kinetochore + + + + + + + + + condensed nuclear chromosome kinetochore + + + + + + + + + condensed chromosome, centromeric region + condensed chromosome, centric region + + + + + + + + + condensed nuclear chromosome, centromeric region + condensed nuclear chromosome, centric region + + + + + + + + + condensed chromosome + + + + + + + + + condensed nuclear chromosome + + + + + + + + + sister chromatid segregation + + + + + + + + + cytokinesis involved in cell cycle + cytokinesis + cell cycle cytokinesis + + + + + + + + + spindle pole + + + + + + + + + condensed chromosome outer kinetochore + outer kinetochore of condensed chromosome + + + + + + + + + nuclear mRNA catabolism + nuclear mRNA degradation + nuclear-transcribed mRNA catabolic process + nuclear mRNA breakdown + + + + + + + + + regulation of neurotransmitter levels + + + + + + + + + cornified envelope + + + + + + + + + oocyte maturation + + + + + + + + + virus receptor activity + viral receptor activity + + + + + + + + + urogenital system development + + + + + + + + + ureteric bud development + + + + + + + + + immunological synapse + supramolecular activation cluster + + + + + + + + + kidney development + + + + + + + + + mesonephros development + Wolffian body development + + + + + + + + + liver development + + + + + + + + + uropod + uropodium + + + + + + + + + renin-angiotensin pathway + brain renin-angiotensin system + + + + + + + + + cytoplasmic translation + + + + + + + + + stimulatory C-type lectin receptor signaling pathway + stimulatory C-type lectin receptor signalling pathway + + + + + + + + + immune memory response + adaptive immune response + acquired immune response + + + + + + + + + neutrophil activation involved in immune response + + + + + + + + + lymphocyte activation involved in immune response + + + + + + + + + T cell activation involved in immune response + + + + + + + + + alpha-beta T cell activation involved in immune response + + + + + + + + + T cell differentiation involved in immune response + + + + + + + + + alpha-beta T cell differentiation involved in immune response + + + + + + + + + CD4-positive, alpha-beta T cell differentiation involved in immune response + + + + + + + + + immunoglobulin production + antibody production + + + + + + + + + immune response-activating cell surface receptor signalling pathway + immune response-activating cell surface receptor signaling pathway + activation of immune response by cell surface receptor signaling pathway + + + + + + + + + Fc-receptor mediated stimulatory signaling pathway + Fc receptor mediated stimulatory signaling pathway + Fc receptor mediated stimulatory signalling pathway + + + + + + + + + phagocytosis triggered by activation of immune response cell surface activating receptor + immune response-regulating cell surface receptor signaling pathway involved in phagocytosis + immune response-regulating cell surface receptor signalling pathway involved in phagocytosis + + + + + + + + + production of molecular mediator of immune response + + + + + + + + + neutrophil mediated immunity + + + + + + + + + lymphocyte mediated immunity + + + + + + + + + circulating immunoglobulin mediated immune response + humoral immune response mediated by circulating antibody + humoral immune response mediated by circulating immunoglobulin + circulating antibody mediated immune response + + + + + + + + + adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains + + + + + + + + + antigen processing and presentation of exogenous peptide antigen + exogenous peptide antigen processing and presentation + + + + + + + + + antigen processing and presentation of peptide antigen via MHC class II + peptide antigen processing and presentation via MHC class II + + + + + + + + + antigen processing and presentation of peptide or polysaccharide antigen via MHC class II + peptide or polysaccharide antigen processing and presentation of via MHC class II + + + + + + + + + acute inflammatory response + + + + + + + + + production of molecular mediator involved in inflammatory response + + + + + + + + + cytokine production involved in inflammatory response + + + + + + + + + regulation of acute inflammatory response + + + + + + + + + respiratory burst involved in defense response + + + + + + + + + down-regulation of immune system process + downregulation of immune system process + negative regulation of immune system process + down regulation of immune system process + + + + + + + + + positive regulation of leucocyte activation + up regulation of leukocyte activation + up-regulation of leukocyte activation + upregulation of leukocyte activation + positive regulation of leukocyte activation + positive regulation of immune cell activation + + + + + + + + + regulation of immune effector process + + + + + + + + + down-regulation of immune effector process + downregulation of immune effector process + negative regulation of immune effector process + down regulation of immune effector process + + + + + + + + + inhibitory C-type lectin receptor signaling pathway + inhibitory C-type lectin receptor signalling pathway + + + + + + + + + regulation of myeloid leukocyte mediated immunity + + + + + + + + + regulation of humoral immune response + + + + + + + + + glomerular filtration + + + + + + + + + cardiac chamber morphogenesis + heart chamber morphogenesis + + + + + + + + + signaling receptor binding + + + + + + + + + cellular component + cellular_component + cell or subcellular entity + + + + + + + + + nuclear envelope + + + + + + + + + U1 snRNP + snRNP U1 + + + + + + + + + mitochondrial outer membrane + outer mitochondrial membrane + + + + + + + + + mitochondrial inner membrane + inner mitochondrial membrane + + + + + + + + + mitochondrial proton-transporting ATP synthase complex + mitochondrial respiratory chain complex V + + + + + + + + + mitochondrial matrix + mitochondrial lumen + + + + + + + + + lysosomal membrane + lysosome membrane + + + + + + + + + primary lysosome + + + + + + + + + early endosome + + + + + + + + + late endosome + prevacuolar compartment + + + + + + + + + vacuolar membrane + + + + + + + + + vacuolar lumen + + + + + + + + + ER lumen + cisternal lumen + endoplasmic reticulum cisterna + endoplasmic reticulum lumen + ER cisterna + + + + + + + + + ER-Golgi intermediate compartment + ER-Golgi transport container + ERGIC + VTC + endoplasmic reticulum-Golgi transport container + pre-Golgi intermediate compartment + vesicular-tubular cluster + endoplasmic reticulum-Golgi intermediate compartment + EGTC + + + + + + + + + spindle + + + + + + + + + ribosome + + + + + + + + + polysome + polyribosome + + + + + + + + + kinesin complex + + + + + + + + + microtubulus + microtubule + microtubuli + + + + + + + + + microtubule associated complex + + + + + + + + + spindle microtubule + + + + + + + + + clathrin-coated pit + coated pit + + + + + + + + + bicellular tight junction + zonula occludens + + + + + + + + + connecting hemi-adherens junction + focal contact + hemi-adherens junction + focal adhesion + HAJ + + + + + + + + + cell cortex + + + + + + + + + monosaccharide metabolic process + monosaccharide metabolism + + + + + + + + + fructose 6-phosphate metabolic process + fructose 6-phosphate metabolism + + + + + + + + + glucose metabolism + glucose metabolic process + cellular glucose metabolic process + + + + + + + + + UDP-N-acetylglucosamine metabolic process + UDP-N-acetylglucosamine metabolism + + + + + + + + + alcohol metabolic process + alcohol metabolism + + + + + + + + + alkanal metabolic process + alkanal metabolism + cellular aldehyde metabolic process + aldehyde metabolism + + + + + + + + + pyruvate metabolic process + pyruvate metabolism + + + + + + + + + oxidative phosphorylation + respiratory-chain phosphorylation + + + + + + + + + DNA replication + + + + + + + + + DNA replication initiation + DNA-dependent DNA replication initiation + + + + + + + + + mRNA splice site selection + + + + + + + + + RNA catabolism + RNA degradation + RNA catabolic process + RNA breakdown + + + + + + + + + mRNA catabolism + mRNA degradation + mRNA catabolic process + mRNA breakdown + + + + + + + + + translational initiation + translation initiation + + + + + + + + + protein deglycosylation + glycoprotein deglycosylation + + + + + + + + + protein targeting + + + + + + + + + protein-membrane targeting + protein targeting to membrane + protein membrane targeting + + + + + + + + + cotranslational protein membrane targeting + cotranslational protein-membrane targeting + cotranslational protein targeting to membrane + cotranslational membrane targeting + + + + + + + + + SRP-dependent cotranslational protein-membrane targeting + SRP-dependent cotranslational protein targeting to membrane + SRP-dependent cotranslational membrane targeting + + + + + + + + + one carbon metabolism + one-carbon metabolism + one-carbon transfer metabolic process + one-carbon transfer metabolism + one-carbon metabolic process + one carbon metabolic process + + + + + + + + + coenzyme metabolic process + coenzyme metabolism + + + + + + + + + oxidoreduction coenzyme metabolic process + oxidoreduction coenzyme metabolism + + + + + + + + + reduced NAD regeneration + reduced nicotinamide adenine dinucleotide regeneration + NADH regeneration + NAD (reduced) regeneration + + + + + + + + + NADP (oxidized) metabolism + NADP (reduced) metabolic process + NADP (reduced) metabolism + NADP metabolism + NADPH metabolic process + NADPH metabolism + nicotinamide adenine dinucleotide phosphate metabolic process + nicotinamide adenine dinucleotide phosphate metabolism + oxidized NADP metabolic process + oxidized NADP metabolism + oxidized nicotinamide adenine dinucleotide phosphate metabolic process + oxidized nicotinamide adenine dinucleotide phosphate metabolism + reduced NADP metabolic process + reduced NADP metabolism + reduced nicotinamide adenine dinucleotide phosphate metabolic process + reduced nicotinamide adenine dinucleotide phosphate metabolism + NADP metabolic process + NADP (oxidized) metabolic process + + + + + + + + + ATP biosynthesis + ATP formation + ATP synthesis + ATP biosynthetic process + ATP anabolism + + + + + + + + + folate and derivative metabolism + folate-containing compound metabolic process + folate-containing compound metabolism + folic acid and derivative metabolic process + folic acid and derivative metabolism + folic acid-containing compound metabolism + vitamin B9 and derivative metabolic process + vitamin B9 and derivative metabolism + vitamin M and derivative metabolic process + vitamin M and derivative metabolism + folic acid-containing compound metabolic process + folate and derivative metabolic process + + + + + + + + + vesicle endocytosis + endocytosis + endocytic import into cell + + + + + + + + + receptor-mediated endocytosis + receptor mediated endocytosis + + + + + + + + + phagocytosis + + + + + + + + + phagocytosis, recognition + recognition of phagocytosed substance by phagocytic cell + + + + + + + + + phagocytosis, engulfment + + + + + + + + + autophagy + + + + + + + + + apoptotic programmed cell death + programmed cell death by apoptosis + apoptotic process + apoptotic cell death + + + + + + + + + viral-induced cell-cell fusion + viral-induced host cell-cell fusion + induction by virus of host cell-cell fusion + induction by virus of cell-cell fusion in host + + + + + + + + + syncytium formation + + + + + + + + + inflammatory response + + + + + + + + + complement response + complement activation + complement cascade + + + + + + + + + complement activation, classical pathway + complement cascade, classical pathway + + + + + + + + + humoral immune response + + + + + + + + + osmotic stress response + response to osmotic stress + osmotic response + + + + + + + + + response to unfolded protein + + + + + + + + + actin filament organization + actin filament organisation + + + + + + + + + cell-substrate junction assembly + + + + + + + + + spindle organization + spindle organisation + + + + + + + + + spindle organization and biogenesis during mitosis + mitotic spindle organization + mitotic spindle organisation + + + + + + + + + chromosome segregation + chromosome division + + + + + + + + + mitotic nuclear envelope catabolism + mitotic nuclear envelope degradation + mitotic nuclear envelope disassembly + mitotic nuclear envelope breakdown + + + + + + + + + mitotic metaphase plate congression + + + + + + + + + regulation of mitotic nuclear division + regulation of mitosis + + + + + + + + + mitotic metaphase/anaphase transition + metaphase/anaphase transition of mitotic cell cycle + metaphase/anaphase transition by anaphase-promoting complex-dependent proteasomal ubiquitin-dependent protein catabolic process + + + + + + + + + mitotic cell cycle checkpoint + + + + + + + + + mitotic spindle assembly checkpoint + mitotic cell cycle spindle assembly checkpoint + + + + + + + + + female meiotic nuclear division + + + + + + + + + cell adhesion + + + + + + + + + signaling + signal transduction + + + + + + + + + integrin-mediated signaling pathway + integrin-mediated signalling pathway + + + + + + + + + receptor signaling pathway via JAK-STAT + JAK-STAT signal transduction + + + + + + + + + cell-cell signaling + cell-cell signalling + + + + + + + + + female gamete generation + + + + + + + + + neuron long process generation + axonogenesis + axon morphogenesis + + + + + + + + + axon guidance + axon pathfinding + + + + + + + + + salivary gland development + + + + + + + + + salivary gland morphogenesis + + + + + + + + + aging + ageing + + + + + + + + + blood coagulation + blood clotting + + + + + + + + + cell recognition + recognition of surroundings by cell + + + + + + + + + integrin complex + + + + + + + + + epidermis development + + + + + + + + + kinetochore-microtubule attachment + microtubule anchoring at kinetochore + spindle chromosome attachment + spindle kinetochore attachment + attachment of spindle microtubules to kinetochore + attachment of spindle microtubules to chromosome + + + + + + + + + glycoprotein metabolic process + glycoprotein metabolism + + + + + + + + + nucleoside monophosphate metabolic process + nucleoside monophosphate metabolism + + + + + + + + + nucleoside monophosphate biosynthesis + nucleoside monophosphate formation + nucleoside monophosphate synthesis + nucleoside monophosphate biosynthetic process + nucleoside monophosphate anabolism + + + + + + + + + purine nucleoside monophosphate metabolic process + purine nucleoside monophosphate metabolism + + + + + + + + + purine nucleoside monophosphate biosynthesis + purine nucleoside monophosphate formation + purine nucleoside monophosphate synthesis + purine nucleoside monophosphate biosynthetic process + purine nucleoside monophosphate anabolism + + + + + + + + + nucleoside triphosphate metabolic process + nucleoside triphosphate metabolism + + + + + + + + + nucleoside triphosphate biosynthesis + nucleoside triphosphate formation + nucleoside triphosphate synthesis + nucleoside triphosphate biosynthetic process + nucleoside triphosphate anabolism + + + + + + + + + purine nucleoside triphosphate metabolic process + purine nucleoside triphosphate metabolism + + + + + + + + + purine nucleoside triphosphate biosynthesis + purine nucleoside triphosphate formation + purine nucleoside triphosphate synthesis + purine nucleoside triphosphate biosynthetic process + purine nucleoside triphosphate anabolism + + + + + + + + + purine ribonucleotide biosynthesis + purine ribonucleotide formation + purine ribonucleotide synthesis + purine ribonucleotide biosynthetic process + purine ribonucleotide anabolism + + + + + + + + + deoxyribonucleoside monophosphate biosynthesis + deoxyribonucleoside monophosphate formation + deoxyribonucleoside monophosphate synthesis + deoxyribonucleoside monophosphate biosynthetic process + deoxyribonucleoside monophosphate anabolism + + + + + + + + + ribonucleoside monophosphate metabolic process + ribonucleoside monophosphate metabolism + + + + + + + + + deoxyribonucleoside monophosphate metabolic process + deoxyribonucleoside monophosphate metabolism + + + + + + + + + nucleotide biosynthesis + nucleotide formation + nucleotide synthesis + nucleotide biosynthetic process + nucleotide anabolism + + + + + + + + + purine ribonucleoside monophosphate metabolic process + purine ribonucleoside monophosphate metabolism + + + + + + + + + purine ribonucleoside monophosphate biosynthesis + purine ribonucleoside monophosphate formation + purine ribonucleoside monophosphate synthesis + purine ribonucleoside monophosphate biosynthetic process + purine ribonucleoside monophosphate anabolism + + + + + + + + + ribonucleoside triphosphate metabolic process + ribonucleoside triphosphate metabolism + + + + + + + + + ribonucleoside triphosphate biosynthesis + ribonucleoside triphosphate formation + ribonucleoside triphosphate synthesis + ribonucleoside triphosphate biosynthetic process + ribonucleoside triphosphate anabolism + + + + + + + + + purine ribonucleoside triphosphate metabolic process + purine ribonucleoside triphosphate metabolism + + + + + + + + + purine ribonucleoside triphosphate biosynthesis + purine ribonucleoside triphosphate formation + purine ribonucleoside triphosphate synthesis + purine ribonucleoside triphosphate biosynthetic process + purine ribonucleoside triphosphate anabolism + + + + + + + + + ribonucleotide biosynthesis + ribonucleotide formation + ribonucleotide synthesis + ribonucleotide biosynthetic process + ribonucleotide anabolism + + + + + + + + + pathogenesis + + + + + + + + + positive regulation of catabolism + positive regulation of degradation + up regulation of catabolic process + up-regulation of catabolic process + upregulation of catabolic process + positive regulation of catabolic process + positive regulation of breakdown + + + + + + + + + outer surface of cytoplasmic membrane + external side of plasma membrane + external leaflet of plasma membrane + + + + + + + + + epidermal cell differentiation + + + + + + + + + basal plasma membrane + + + + + + + + + cellular physiological process + cellular process + cell physiology + + + + + + + + + endosome membrane + endosomal membrane + + + + + + + + + membrane invagination + + + + + + + + + regulation of G2/M transition of mitotic cell cycle + regulation of mitotic entry + + + + + + + + + mesenchymal cell proliferation + + + + + + + + + regulation of mesenchymal cell proliferation + + + + + + + + + regulation of macrophage derived foam cell differentiation + + + + + + + + + positive regulation of macrophage derived foam cell differentiation + + + + + + + + + regulation of plasminogen activation + + + + + + + + + negative regulation of cell cycle process + + + + + + + + + regulation of mitotic sister chromatid separation + + + + + + + + + positive regulation of G2/M transition of mitotic cell cycle + positive regulation of mitotic entry + + + + + + + + + PI3K cascade + PI3K signal transduction + PI3K signaling + phosphatidylinositol 3-kinase signal transduction + phosphoinositide 3-kinase cascade + phosphatidylinositol 3-kinase signaling + PI 3-kinase cascade + + + + + + + + + positive regulation of PI3K cascade + positive regulation of phosphoinositide 3-kinase cascade + up regulation of phosphatidylinositol 3-kinase cascade + up-regulation of phosphatidylinositol 3-kinase cascade + upregulation of phosphatidylinositol 3-kinase cascade + positive regulation of phosphatidylinositol 3-kinase signaling + positive regulation of PI 3-kinase cascade + + + + + + + + + post synaptic density + post-synaptic density + postsynaptic density + neuronal postsynaptic density + + + + + + + + + response to purine-containing compound + + + + + + + + + large ribosomal subunit + ribosomal large subunit + + + + + + + + + small ribosomal subunit + ribosomal small subunit + + + + + + + + + nucleobase-containing small molecule interconversion + + + + + + + + + viral process + virus process + + + + + + + + + growth of cell + cell growth + cellular growth + + + + + + + + + carbohydrate catabolism + carbohydrate degradation + catabolic carbohydrate metabolic process + catabolic carbohydrate metabolism + carbohydrate catabolic process + carbohydrate breakdown + + + + + + + + + organic acid catabolism + organic acid degradation + organic acid catabolic process + organic acid breakdown + + + + + + + + + immunoglobulin mediated immune response + antibody-mediated immune response + + + + + + + + + O-glycan processing + + + + + + + + + basolateral plasma membrane + + + + + + + + + apical plasma membrane + + + + + + + + + nuclear matrix + nucleoskeleton + + + + + + + + + cell migration + + + + + + + + + histone phosphorylation + + + + + + + + + antibiotic metabolic process + antibiotic metabolism + + + + + + + + + antibiotic catabolism + antibiotic degradation + antibiotic catabolic process + antibiotic breakdown + + + + + + + + + host cellular component + host + host organism + + + + + + + + + viral nucleocapsid + nucleocapsid + + + + + + + + + capsid + viral capsid + + + + + + + + + helical + helical viral capsid + + + + + + + + + viral envelope + viral outside membrane + + + + + + + + + phage lysogeny + viral dormancy + viral latency + latent virus infection + + + + + + + + + release from viral latency + + + + + + + + + modulation by virus of host anatomy or process + viral interaction with host + viral-host process + virus-host process + modulation by virus of host process + host-virus interaction + + + + + + + + + activation by virus of host apoptotic programmed cell death + activation of apoptosis in host by virus + induction by virus of host apoptotic programmed cell death + induction of apoptosis in host by virus + induction by virus of host apoptotic process + activation by virus of host apoptosis + + + + + + + + + regulation by virus of host cellular process + regulation of cellular process in host by virus + regulation of host cellular process by virus + viral host cell process manipulation + modulation by virus of host cellular process + modification by virus of host cellular process + + + + + + + + + viral life cycle + + + + + + + + + uncoating of virus + Entry (Receptor) and uncoating + viral uncoating + + + + + + + + + virion attachment to host cell + viral absorption + + + + + + + + + viral envelope fusion with host membrane + viral envelope fusion with host plasma membrane + fusion of virus membrane with host plasma membrane + viral envelope fusion with host cell membrane + + + + + + + + + receptor mediated endocytosis of virus by host + receptor mediated endocytosis of virus particle by host + receptor-mediated endocytosis of virus by host + viral receptor mediated endocytosis + virus receptor-mediated endocytosis by host + receptor-mediated endocytosis of virus by host cell + receptor mediated endocytosis by host of virus particle + + + + + + + + + viral particle assembly + virion assembly and maintenance + virion organization + virus assembly + virus particle assembly + virion assembly + Assembly of Virus particles + viral assembly + + + + + + + + + viral genome packaging + + + + + + + + + viral RNA genome packaging + + + + + + + + + virus maturation + viral maturation + + + + + + + + + viral exit + viral release + viral shedding + virus exit from host cell + viral release from host cell + release of virus from host + + + + + + + + + Virus Replication Cycle + viral genome replication + + + + + + + + + viral gene expression + viral genome expression + + + + + + + + + viral protein biosynthesis + viral protein biosynthetic process + viral protein formation + viral protein synthesis + viral translation + viral protein anabolism + + + + + + + + + viral protein processing + + + + + + + + + viral transcription + + + + + + + + + hexose metabolic process + hexose metabolism + + + + + + + + + hexose catabolism + hexose degradation + hexose catabolic process + hexose breakdown + + + + + + + + + nicotinamide nucleotide biosynthesis + nicotinamide nucleotide formation + nicotinamide nucleotide synthesis + nicotinamide nucleotide biosynthetic process + nicotinamide nucleotide anabolism + + + + + + + + + pyridine nucleotide metabolic process + pyridine nucleotide metabolism + + + + + + + + + pyridine nucleotide biosynthesis + pyridine nucleotide formation + pyridine nucleotide synthesis + pyridine nucleotide biosynthetic process + pyridine nucleotide anabolism + + + + + + + + + calcium signaling + calcium signalling + calcium-mediated signalling + calcium-mediated signaling + calcium ion signaling + + + + + + + + + B lymphocyte mediated immunity + B-cell mediated immune effector process + B-cell mediated immunity + B-lymphocyte mediated immune effector process + B-lymphocyte mediated immunity + B cell mediated immunity + B lymphocyte mediated immune effector process + + + + + + + + + antimicrobial humoral response + + + + + + + + + immunoglobulin complex + + + + + + + + + outer membrane + + + + + + + + + antigen processing + antigen processing and presentation + antigen presentation + + + + + + + + + antigen processing and presentation of exogenous antigen + antigen presentation, exogenous antigen + + + + + + + + + antigen processing and presentation of exogenous peptide antigen via MHC class II + exogenous peptide antigen processing and presentation via MHC class II + + + + + + + + + diencephalon development + + + + + + + + + cranial nerve development + + + + + + + + + gland morphogenesis + + + + + + + + + cytosolic large ribosomal subunit + + + + + + + + + cytosolic ribosome + + + + + + + + + cytosolic small ribosomal subunit + + + + + + + + + lamellipodium + + + + + + + + + contractile actin filament bundle assembly + + + + + + + + + cell-substrate junction + cell-matrix junction + + + + + + + + + spot desmosome + desmosome + macula adherens + + + + + + + + + regulation of mitotic metaphase/anaphase transition + + + + + + + + + coated vesicle + + + + + + + + + clathrin-coated vesicle + + + + + + + + + endocytotic vesicle + endocytic vesicle + endocytotic transport vesicle + + + + + + + + + integral to ER membrane + integral component of endoplasmic reticulum membrane + ER integral membrane protein + + + + + + + + + keratinocyte differentiation + keratinocyte cell differentiation + + + + + + + + + nuclear chromosome condensation + chromosome condensation + eukaryotic chromosome condensation + + + + + + + + + membrane catabolism + membrane degradation + membrane disassembly + membrane breakdown + + + + + + + + + ER-associated ubiquitin-dependent protein catabolic process + ER-associated ubiquitin-dependent protein catabolism + ER-associated ubiquitin-dependent protein degradation + endoplasmic reticulum-associated ubiquitin-dependent protein catabolic process + endoplasmic reticulum-associated ubiqutin-dependent protein catabolism + ubiquitin-dependent proteasomal protein catabolism of ER proteins + ubiquitin-dependent ERAD pathway + ER-associated ubiquitin-dependent protein breakdown + + + + + + + + + regulation of complement activation + regulation of complement cascade + + + + + + + + + midbody + + + + + + + + + snRNP + small nuclear ribonucleoprotein complex + small nuclear ribonucleoprotein + + + + + + + + + neutrophil chemotaxis + + + + + + + + + clathrin-coated vesicle membrane + + + + + + + + + endocytic vesicle membrane + + + + + + + + + secretory granule membrane + + + + + + + + + mitigation by virus of host immune response + negative regulation by virus of extracellular antiviral response + negative regulation by virus of intracellular antiviral response + negative regulation of host extracellular antiviral response by virus + negative regulation of host intracellular antiviral response by virus + suppression by virus of host extracellular antiviral response + suppression by virus of host intracellular antiviral response + suppression of host extracellular antiviral response by virus + suppression of host intracellular antiviral response by virus + viral inhibition of intracellular antiviral response + mitigation of host immune response by virus + inhibition of extracellular antiviral response + + + + + + + + + erUPR + endoplasmic reticulum unfolded protein response + ER unfolded protein response + + + + + + + + + protein retrotranslocation, ER to cytosol + retrograde protein transport, endoplasmic reticulum to cytosol + retrograde protein transport, ER to cytosol + protein dislocation from ER + + + + + + + + + hair follicle morphogenesis + + + + + + + + + regeneration + + + + + + + + + animal organ regeneration + + + + + + + + + APC-dependent proteasomal ubiquitin-dependent protein catabolism + anaphase-promoting complex-dependent proteasomal ubiquitin-dependent protein breakdown + anaphase-promoting complex-dependent proteasomal ubiquitin-dependent protein catabolic process + anaphase-promoting complex-dependent proteasomal ubiquitin-dependent protein catabolism + anaphase-promoting complex-dependent proteasomal ubiquitin-dependent protein degradation + anaphase-promoting complex-dependent catabolic process + APC-dependent proteasomal ubiquitin-dependent protein catabolic process + + + + + + + + + intrinsic component of endoplasmic reticulum membrane + + + + + + + + + leading edge of cell + cell leading edge + front of cell + + + + + + + + + trailing edge + cell trailing edge + back of cell + + + + + + + + + positive regulation of cellular catabolism + positive regulation of cellular degradation + up regulation of cellular catabolic process + up-regulation of cellular catabolic process + upregulation of cellular catabolic process + positive regulation of cellular catabolic process + positive regulation of cellular breakdown + + + + + + + + + keratinization + + + + + + + + + actin cytoskeleton reorganisation + actin cytoskeleton reorganization + actin cytoskeleton remodeling + + + + + + + + + DNA integrity checkpoint + + + + + + + + + spindle checkpoint + + + + + + + + + cell-substrate adhesion + + + + + + + + + plasminogen activation + cleavage of plasminogen to plasmin + + + + + + + + + regulation of protein stability + + + + + + + + + nuclear membrane + + + + + + + + + organelle outer membrane + + + + + + + + + vesicle lumen + + + + + + + + + down-regulation of protein binding + downregulation of protein binding + negative regulation of protein binding + down regulation of protein binding + + + + + + + + + asymmetric synapse + Gray's type I synapse + + + + + + + + + up-regulation of intracellular transport + upregulation of intracellular transport + positive regulation of intracellular transport + up regulation of intracellular transport + + + + + + + + + regulation of cytokinesis + regulation of cell cycle cytokinesis + + + + + + + + + protein export from ER + protein export from endoplasmic reticulum + protein exit from endoplasmic reticulum + protein exit from ER + + + + + + + + + low-density lipoprotein receptor metabolic process + low-density lipoprotein receptor metabolism + low-density lipoprotein receptor particle metabolic process + LDL receptor metabolic process + + + + + + + + + LDL receptor catabolic process + LDL receptor degradation + low-density lipoprotein receptor breakdown + low-density lipoprotein receptor catabolic process + low-density lipoprotein receptor catabolism + low-density lipoprotein receptor degradation + low-density lipoprotein particle receptor catabolic process + LDL receptor breakdown + + + + + + + + + regulation of actin cytoskeleton organization + regulation of actin cytoskeleton organisation + + + + + + + + + IP3 metabolism + inositol trisphosphate metabolism + inositol trisphosphate metabolic process + IP3 metabolic process + + + + + + + + + regulation of actin filament-based process + + + + + + + + + muscle cell proliferation + myocyte proliferation + + + + + + + + + regulation of sister chromatid segregation + + + + + + + + + negative regulation of sister chromatid segregation + + + + + + + + + regulation of mitotic sister chromatid segregation + + + + + + + + + negative regulation of mitotic sister chromatid segregation + + + + + + + + + endoplasmic reticulum-Golgi intermediate compartment membrane + ER-Golgi intermediate compartment membrane + + + + + + + + + regulation of intracellular protein transport + + + + + + + + + S-M checkpoint + mitotic cell cycle DNA replication checkpoint + mitotic DNA replication checkpoint + S-M DNA replication checkpoint + + + + + + + + + cellular response to stress + + + + + + + + + adherens junction assembly + adherens junction formation + + + + + + + + + plasma lipoprotein particle + + + + + + + + + plasma lipoprotein particle clearance + lipoprotein particle clearance + + + + + + + + + low-density lipoprotein particle clearance + LDL clearance + + + + + + + + + protein localization at cell surface + protein localization to cell surface + protein localisation at cell surface + + + + + + + + + nuclear periphery + + + + + + + + + nucleobase, nucleoside and nucleotide biosynthesis + nucleobase, nucleoside and nucleotide formation + nucleobase, nucleoside and nucleotide synthesis + nucleobase-containing small molecule biosynthetic process + nucleobase, nucleoside and nucleotide anabolism + + + + + + + + + protein localization to kinetochore + protein localisation to kinetochore + + + + + + + + + protein localization to chromosome + protein localisation to chromosome + + + + + + + + + cellular response to unfolded protein + + + + + + + + + integrin alphav-beta1 complex + alphav-beta1 integrin complex + + + + + + + + + secretory granule lumen + + + + + + + + + cellular response to endoplasmic reticulum stress + response to ER stress + response to endoplasmic reticulum stress + ER stress response + + + + + + + + + up-regulation of histone acetylation + upregulation of histone acetylation + positive regulation of histone acetylation + up regulation of histone acetylation + + + + + + + + + microtubule plus end + microtubule plus-end + growing microtubule plus end + + + + + + + + + azurophil granule membrane + primary granule membrane + + + + + + + + + azurophil granule lumen + primary granule lumen + + + + + + + + + specific granule membrane + secondary granule membrane + + + + + + + + + CD4-positive, alpha-beta T cell activation + + + + + + + + + aorta development + + + + + + + + + aldosterone secretion + + + + + + + + + response to topologically incorrect protein + + + + + + + + + cellular response to topologically incorrect protein + + + + + + + + + endolysosome + + + + + + + + + viral membrane + + + + + + + + + UPR signaling by IRE1 stress sensor + endoplasmic reticulum unfolded protein response; IRE1 signaling + IRE1-mediated unfolded protein response + IRE1 branch of UPR + + + + + + + + + protein degradation by ERAD + ERAD pathway + endoplasmic reticulum-associated degradation + + + + + + + + + protein demannosylation + protein de-mannosylation + + + + + + + + + protein alpha-1,2-demannosylation + + + + + + + + + NIK/NF-kappaB signaling + NIK/NF-kappaB signal transduction + + + + + + + + + Fc receptor signaling pathway + Fc receptor signalling pathway + + + + + + + + + Fc-gamma receptor signaling pathway + Fc-gamma receptor signalling pathway + + + + + + + + + Fc-epsilon receptor signaling pathway + Fc-epsilon receptor signalling pathway + + + + + + + + + Fc-gamma receptor signalling pathway involved in phagocytosis + Fcgamma receptor-mediated phagocytosis + IgG-mediated phagocytosis + Fc-gamma receptor signaling pathway involved in phagocytosis + Fc gamma receptor-dependent phagocytosis + + + + + + + + + suppression by virus of host interferon type I production + suppression by virus of host type I IFN production + suppression by virus of host type I interferon production + negative regulation by virus of host type I interferon production + + + + + + + + + negative regulation by virus of host innate immune response + negative regulation by virus of host innate immunity + suppression by virus of host innate immunity + suppression by virus of host innate immune response + inhibition of host innate immune response by virus + + + + + + + + + regulation by virus of host catalytic activity + regulation of host catalytic activity by virus + modulation by virus of host catalytic activity + modulation of catalytic activity of host by virus + + + + + + + + + regulation by virus of host protein serine/threonine phosphatase activity + modulation by virus of host protein serine/threonine phosphatase activity + modulation by virus of protein serine/threonine phosphatase activity in host + + + + + + + + + modulation by virus of host autophagy + regulation by virus of host autophagy + + + + + + + + + induction by virus of host autophagy + activation of host autophagy by virus + + + + + + + + + inhibition of host mRNA nuclear export by virus + suppression of host mRNA nuclear export by virus + suppression by virus of host mRNA export from nucleus + inhibition by virus of host mRNA nuclear export + + + + + + + + + inhibition of host mRNA processing by virus + inhibition of host pre-mRNA processing by virus + suppression by virus of host mRNA processing + inhibition by virus of host mRNA processing + + + + + + + + + modulation of host chromatin by virus + modulation of host chromatin structure by virus + modulation by virus of host chromatin organization + modulation by virus of host chromatin organisation + + + + + + + + + modulation of host cell apoptosis by virus + regulation by virus of host apoptosis + modulation by virus of host apoptotic process + modulation by virus of host apoptosis + + + + + + + + + suppression by virus of host mitochondrial antiviral-signaling protein + suppression by virus of host MAVS activity + inhibition of host MAVS by virus + + + + + + + + + suppression by virus of host interferon regulatory factor 3 + suppression by virus of host IRF3 activity + inhibition of host IRF3 by virus + + + + + + + + + suppression by virus of host MDA-5 activity + Inhibition of host MDA5 by virus + + + + + + + + + inhibition of host interferon regulatory factor-7 by virus + suppression by virus of host interferon regulatory factor 7 activity + suppression by virus of host IRF7 activity + inhibition of host IRF7 by virus + + + + + + + + + suppression by virus of host exit from mitosis + inhibition of host mitotic exit by virus + + + + + + + + + induction of host mRNA decay + promotion of host mRNA degradation + viral induction of host mRNA decay + virus-mediated mRNA decay + induction by virus of catabolism of host mRNA + induction by virus of host mRNA catabolic process + + + + + + + + + cleavage by virus of host mRNA + host mRNA cleavage by viral endoribonuclease + + + + + + + + + viral inhibition of cellular protein synthesis + viral shutoff of host protein synthesis + suppression by virus of host translation + host translation shutoff by virus + + + + + + + + + modulation by virus of host protein phosphorylation + + + + + + + + + induction by virus of host protein phosphorylation + + + + + + + + + killing by virus of host cell + killing by virus of host cells + + + + + + + + + killing by virus of host cells involved in superinfection exclusion + killing by virus of host cell during superinfection exclusion + killing by virus of host cells during superinfection exclusion + + + + + + + + + lipopolysaccharide binding involved in viral attachment to host cell + virion attachment, binding to host lipopolysaccharide + lipopolysaccharide-mediated virion attachment to host cell + LPS binding involved in viral attachment to host cell + + + + + + + + + virion nucleoid + + + + + + + + + modulation by virus of host G0/G1 transition checkpoint + G0/G1 host cell cycle checkpoint dysregulation by virus + + + + + + + + + modulation by virus of host protein ubiquitination + + + + + + + + + modulation by virus of host ubiquitin-protein ligase activity + + + + + + + + + activation by virus of host NF-kappaB transcription factor activity + activation of host NF-kappa-B by virus + + + + + + + + + fusion of virus membrane with host endosome membrane + fusion of virus membrane with host endosomal membrane + + + + + + + + + modulation by virus of host gene expression + + + + + + + + + suppression by virus of host gene expression + host gene expression shutoff by virus + + + + + + + + + membrane fusion involved in viral entry into host cell + + + + + + + + + lysis of host organelle involved in viral entry into host cell + viral penetration via lysis of host organellar membrane + + + + + + + + + viral penetration via perforation of host organellar membrane by virus + viral penetration via permeabilization of host organellar membrane + permeabilization of host organelle membrane involved in viral entry into host cell + viral penetration via host endosomal membrane disruption by virus + + + + + + + + + evasion by virus of host natural killer cell response + protection by virus against host NK cell cytotoxicity + suppression by virus of host natural killer cell function + viral immunoevasion of host NK cell + evasion by virus of host natural killer cell activity + evasion by virus of host NK cell killing + + + + + + + + + suppression by virus of host natural killer cell activation + suppression by virus of host NK-cell activation + + + + + + + + + viral genome ejection through host cell envelope + + + + + + + + + positive stranded viral RNA replication + + + + + + + + + viral RNA genome replication + + + + + + + + + RNA-templated viral transcription + + + + + + + + + viral mRNA cap methylation + IFIT mRNA restriction evasion by virus + + + + + + + + + microtubule-dependent intracellular transport of viral material towards cell periphery + + + + + + + + + nuclear capsid assembly + + + + + + + + + cytoplasmic capsid assembly + + + + + + + + + T-helper cell differentiation + helper T cell differentiation + + + + + + + + + T-cell activation + T-lymphocyte activation + T cell activation + T lymphocyte activation + + + + + + + + + B-cell activation + B-lymphocyte activation + B cell activation + B lymphocyte activation + + + + + + + + + macrophage activation + macrophage polarization + + + + + + + + + neutrophil activation + + + + + + + + + neurotransmitter metabolic process + neurotransmitter metabolism + + + + + + + + + regulation of protein catabolism + regulation of protein degradation + regulation of protein catabolic process + regulation of protein breakdown + + + + + + + + + ribosome biogenesis + ribosome biogenesis and assembly + + + + + + + + + ribosome assembly + + + + + + + + + ribosomal large subunit biogenesis + ribosomal large subunit biogenesis and assembly + + + + + + + + + ribosomal small subunit biogenesis + ribosomal small subunit biogenesis and assembly + + + + + + + + + vasoconstriction + negative regulation of blood vessel size + + + + + + + + + vasodilatation + vasodilation + positive regulation of blood vessel size + + + + + + + + + melanosome + + + + + + + + + ear morphogenesis + hearing organ morphogenesis + + + + + + + + + inner ear morphogenesis + + + + + + + + + response to hydrogen peroxide + + + + + + + + + pteridine and derivative metabolism + pteridine-containing compound metabolism + pteridine-containing compound metabolic process + pteridine and derivative metabolic process + + + + + + + + + specific granule + secondary granule + + + + + + + + + azurophil granule + primary granule + + + + + + + + + drug catabolism + drug degradation + drug catabolic process + drug breakdown + + + + + + + + + defence response to bacterium + defense response to bacteria + defense response to bacterium + defence response to bacteria + + + + + + + + + polysomal ribosome + + + + + + + + + stress fiber assembly + + + + + + + + + lysosomal lumen + + + + + + + + + apical junction + apical junction complex + apical cell junction complex + + + + + + + + + regulation of immune cell granule exocytosis + regulation of leucocyte degranulation + regulation of leukocyte granule exocytosis + regulation of leukocyte degranulation + regulation of immune cell degranulation + + + + + + + + + neutrophil degranulation + neutrophil granule exocytosis + + + + + + + + + endothelial cell migration + + + + + + + + + ear development + hearing organ development + + + + + + + + + skin development + animal skin development + + + + + + + + + dicarboxylate metabolism + dicarboxylic acid metabolism + dicarboxylic acid metabolic process + dicarboxylate metabolic process + + + + + + + + + cellular carbohydrate metabolic process + cellular carbohydrate metabolism + + + + + + + + + small molecule catabolic process + small molecule catabolism + + + + + + + + + ERQC + endoplasmic reticulum quality control compartment + ER quality control compartment + + + + + + + + + ribosomal subunit + + + + + + + + + virion + virion part + + + + + + + + + viral exit from host cell by cytolysis + viral release by cell lysis + viral release by host cell lysis + viral release from host cell by cytolysis + lytic viral release + + + + + + + + + topo II checkpoint + topoisomerase II checkpoint + mitotic DNA integrity checkpoint + mitotic cell cycle G2/M transition decatenation checkpoint + + + + + + + + + metaphase/anaphase transition of cell cycle + + + + + + + + + mitotic G2/M transition checkpoint + + + + + + + + + modulation by virus of host cytokine production + + + + + + + + + positive regulation by virus of host cytokine production + + + + + + + + + cell cycle G2/M phase transition + + + + + + + + + cell cycle G1/S phase transition + + + + + + + + + protein-ER targeting + protein-endoplasmic reticulum targeting + protein targeting to ER + protein targeting to endoplasmic reticulum + + + + + + + + + pronucleus + + + + + + + + + membrane raft + lipid raft + + + + + + + + + meiotic chromosome segregation + + + + + + + + + apical part of cell + apical region of cell + + + + + + + + + basal part of cell + + + + + + + + + hydrogen-translocating F-type ATPase complex + hydrogen-transporting ATP synthase complex + proton-transporting ATP synthase complex + F1-F0 complex + + + + + + + + + mRNA cis splicing, via spliceosome + nuclear mRNA cis splicing, via spliceosome + + + + + + + + + clathrin-coated endocytic vesicle + + + + + + + + + phagocytic vesicle + phagosome + + + + + + + + + oxidative burst + respiratory burst + metabolic burst + + + + + + + + + positive regulation of protein catabolism + positive regulation of protein degradation + up regulation of protein catabolic process + up-regulation of protein catabolic process + upregulation of protein catabolic process + positive regulation of protein catabolic process + positive regulation of protein breakdown + + + + + + + + + up-regulation of cell adhesion + upregulation of cell adhesion + positive regulation of cell adhesion + up regulation of cell adhesion + + + + + + + + + positive regulation of progression through cell cycle + up regulation of progression through cell cycle + up-regulation of progression through cell cycle + upregulation of progression through cell cycle + positive regulation of cell cycle + positive regulation of cell cycle progression + + + + + + + + + down-regulation of mitosis + downregulation of mitosis + negative regulation of mitosis + negative regulation of mitotic nuclear division + down regulation of mitosis + + + + + + + + + down-regulation of mitotic metaphase/anaphase transition + downregulation of mitotic metaphase/anaphase transition + negative regulation of mitotic metaphase/anaphase transition + down regulation of mitotic metaphase/anaphase transition + + + + + + + + + down-regulation of progression through mitotic cell cycle + downregulation of progression through mitotic cell cycle + negative regulation of mitotic cell cycle progression + negative regulation of progression through mitotic cell cycle + negative regulation of mitotic cell cycle + down regulation of progression through mitotic cell cycle + + + + + + + + + positive regulation of progression through mitotic cell cycle + up regulation of progression through mitotic cell cycle + up-regulation of progression through mitotic cell cycle + upregulation of progression through mitotic cell cycle + positive regulation of mitotic cell cycle + positive regulation of mitotic cell cycle progression + + + + + + + + + ATP metabolic process + ATP metabolism + + + + + + + + + carboxylic acid catabolism + carboxylic acid degradation + carboxylic acid catabolic process + carboxylic acid breakdown + + + + + + + + + organophosphate catabolism + organophosphate degradation + organophosphate catabolic process + organophosphate breakdown + + + + + + + + + nicotinamide nucleotide metabolic process + nicotinamide nucleotide metabolism + + + + + + + + + gamma-delta T-cell activation + gamma-delta T-lymphocyte activation + gamma-delta T cell activation + gamma-delta T lymphocyte activation + + + + + + + + + alpha-beta T-cell activation + alpha-beta T-lymphocyte activation + alpha-beta T cell activation + alpha-beta T lymphocyte activation + + + + + + + + + regulation of alpha-beta T-cell activation + regulation of alpha-beta T-lymphocyte activation + regulation of alpha-beta T cell activation + regulation of alpha-beta T lymphocyte activation + + + + + + + + + positive regulation of alpha-beta T-cell activation + positive regulation of alpha-beta T-lymphocyte activation + up regulation of alpha-beta T cell activation + up-regulation of alpha-beta T cell activation + upregulation of alpha-beta T cell activation + positive regulation of alpha-beta T cell activation + positive regulation of alpha-beta T lymphocyte activation + + + + + + + + + tetrahydrofolate metabolic process + tetrahydrofolate metabolism + + + + + + + + + response to antibiotic + + + + + + + + + response to organophosphorus + + + + + + + + + phage translocation + viral penetration + virion penetration + virion penetration into host cell + virus entry into host cell + viral entry into host cell + entry of virus into host cell + + + + + + + + + induction of host immune response by virus + activation of host immune response by virus + + + + + + + + + induction of innate immune response in host by virus + active viral induction of innate immune response in host + + + + + + + + + intercellular virus transport + spread of virus within host, cell to cell + viral spread within host, cell to cell + transport of virus in host, cell to cell + cell tropism + cell to cell spread of virus within host + + + + + + + + + tissue to tissue spread of virus within host + viral spread within host, tissue to tissue + transport of virus in host, tissue to tissue + tissue tropism + spread of virus within host, tissue to tissue + + + + + + + + + non-lytic viral release + + + + + + + + + viral exocytosis + + + + + + + + + viral budding + + + + + + + + + virus budding from Golgi membrane + viral budding from Golgi membrane + Golgi membrane viral budding + + + + + + + + + virus budding from plasma membrane + virus budding from plasma membrane by viral capsid envelopment + viral budding from plasma membrane + plasma membrane viral budding + + + + + + + + + endoplasmic reticulum membrane viral budding + viral budding from ER membrane + virus budding from ER membrane + virus budding from ER membrane by viral capsid envelopment + viral budding from endoplasmic reticulum membrane + ER membrane viral budding + + + + + + + + + modification by virus of host polysomes + viral perturbation of polysomes + + + + + + + + + viral replication complex formation and maintenance + + + + + + + + + transport of virus + viral transport + + + + + + + + + receptor-mediated virion attachment to host cell + virion attachment, binding of host cell surface receptor + + + + + + + + + fibroblast proliferation + + + + + + + + + regulation of fibroblast proliferation + + + + + + + + + up-regulation of fibroblast proliferation + upregulation of fibroblast proliferation + positive regulation of fibroblast proliferation + up regulation of fibroblast proliferation + + + + + + + + + organelle fission + + + + + + + + + digestive tract development + + + + + + + + + post-embryonic animal organ development + post-embryonic animal organogenesis + + + + + + + + + reproductive structure development + + + + + + + + + epidermis morphogenesis + + + + + + + + + gland development + + + + + + + + + pigment granule + + + + + + + + + inner ear development + + + + + + + + + establishment and maintenance of chromosome localization + establishment and maintenance of chromosome position + chromosome localization + chromosome localisation + + + + + + + + + RNA transport + + + + + + + + + epithelial cell proliferation + + + + + + + + + regulation of epithelial cell proliferation + + + + + + + + + regulation of inflammatory response + + + + + + + + + regulation of biological process + regulation of physiological process + + + + + + + + + antigen receptor-mediated signaling pathway + antigen receptor-mediated signalling pathway + + + + + + + + + T lymphocyte receptor signalling pathway + T-cell receptor signaling pathway + T-cell receptor signalling pathway + T-lymphocyte receptor signaling pathway + T-lymphocyte receptor signalling pathway + TCR signaling pathway + T cell receptor signaling pathway + T lymphocyte receptor signaling pathway + + + + + + + + + B lymphocyte receptor signaling pathway + B lymphocyte receptor signalling pathway + B-cell receptor signaling pathway + B-cell receptor signalling pathway + B-lymphocyte receptor signaling pathway + B-lymphocyte receptor signalling pathway + B cell receptor signaling pathway + B cell receptor signalling pathway + + + + + + + + + regulation of B-cell activation + regulation of B-lymphocyte activation + regulation of B cell activation + regulation of B lymphocyte activation + + + + + + + + + up-regulation of cell activation + upregulation of cell activation + positive regulation of cell activation + up regulation of cell activation + + + + + + + + + positive regulation of B-cell activation + positive regulation of B-lymphocyte activation + up regulation of B cell activation + up-regulation of B cell activation + upregulation of B cell activation + positive regulation of B cell activation + positive regulation of B lymphocyte activation + + + + + + + + + immune cell trafficking + leucocyte migration + leucocyte trafficking + leukocyte trafficking + leukocyte migration + immune cell migration + + + + + + + + + actin filament bundle assembly + + + + + + + + + nuclear envelope catabolism + nuclear envelope degradation + nuclear envelope disassembly + nuclear envelope breakdown + + + + + + + + + glucose 6-phosphate metabolic process + glucose 6-phosphate metabolism + + + + + + + + + single organism nuclear import + substance nuclear import + import into nucleus + nuclear import + + + + + + + + + cofactor catabolism + cofactor degradation + cofactor catabolic process + cofactor breakdown + + + + + + + + + cofactor biosynthesis + cofactor formation + cofactor synthesis + cofactor biosynthetic process + cofactor anabolism + + + + + + + + + up-regulation of protein transport + upregulation of protein transport + positive regulation of protein transport + up regulation of protein transport + + + + + + + + + bipolar spindle formation + spindle biosynthesis + spindle formation + spindle assembly + bipolar spindle biosynthesis + + + + + + + + + spindle equator + spindle midzone + central spindle + + + + + + + + + maintenance of location + maintenance of localization + + + + + + + + + regulation of lymphocyte activation + + + + + + + + + up-regulation of lymphocyte activation + upregulation of lymphocyte activation + positive regulation of lymphocyte activation + up regulation of lymphocyte activation + + + + + + + + + regulation of cell division + + + + + + + + + establishment of chromosome localisation + establishment of chromosome localization + chromosome positioning + + + + + + + + + chromosome separation + + + + + + + + + sister chromatid separation during mitosis + mitotic sister chromatid separation + mitotic sister chromatid resolution + + + + + + + + + meiotic chromosome resolution + meiotic chromosome separation + chromosome separation during meiosis + + + + + + + + + metaphase plate congression + chromosome congression + + + + + + + + + meiotic cell cycle + + + + + + + + + response to 3',5'-cAMP + response to adenosine 3',5'-cyclophosphate + response to cyclic AMP + response to cAMP + response to 3',5' cAMP + + + + + + + + + protein maturation + + + + + + + + + regulation of nuclear division + + + + + + + + + down-regulation of nuclear division + downregulation of nuclear division + negative regulation of nuclear division + down regulation of nuclear division + + + + + + + + + regulation of chromosome segregation + + + + + + + + + down-regulation of chromosome segregation + downregulation of chromosome segregation + negative regulation of chromosome segregation + down regulation of chromosome segregation + + + + + + + + + regulation of attachment of spindle microtubules to kinetochore + regulation of kinetochore-microtubule attachment + + + + + + + + + pharyngeal system development + + + + + + + + + positive regulation of apoptotic process by virus + + + + + + + + + modulation by virus of syncytium formation via plasma membrane fusion + + + + + + + + + positive regulation of syncytium formation by virus + syncytium formation induced by viral infection + + + + + + + + + cytoplasmic vesicle lumen + + + + + + + + + type I interferon-mediated signalling pathway + type I interferon signaling pathway + type I interferon-activated signaling pathway + + + + + + + + + lung epithelium development + pulmonary epithelium development + + + + + + + + + respiratory system development + + + + + + + + + kidney morphogenesis + + + + + + + + + hepaticobiliary system development + hepatobiliary system development + + + + + + + + + regulation of proteasomal protein catabolic process + + + + + + + + + renal tubule development + + + + + + + + + heart trabecula morphogenesis + + + + + + + + + reproductive system development + + + + + + + + + macrophage proliferation + + + + + + + + + actin filament bundle organization + + + + + + + + + glycolytic process through fructose-6-phosphate + glycolysis through fructose-6-phosphate + + + + + + + + + glycolytic process through glucose-6-phosphate + + + + + + + + + canonical glycolysis + + + + + + + + + cytoskeleton-dependent cytokinesis + + + + + + + + + glucose catabolic process to pyruvate + glucose catabolism to pyruvate + + + + + + + + + modulation by virus of host NIK/NF-kappaB signaling + + + + + + + + + collagen-containing extracellular matrix + + + + + + + + + chemokine-mediated signaling pathway + chemokine-mediated signalling pathway + + + + + + + + + occluding junction + tight junction + occluding cell junction + + + + + + + + + cornification + + + + + + + + + response to fatty acid + + + + + + + + + regulation of protein processing + regulation of protein maturation by peptide bond cleavage + + + + + + + + + tertiary granule + gelatinase granule + + + + + + + + + tertiary granule membrane + + + + + + + + + protein localization in ER + protein localization in endoplasmic reticulum + protein localization to endoplasmic reticulum + protein localisation in endoplasmic reticulum + + + + + + + + + spindle assembly checkpoint + + + + + + + + + mitotic spindle checkpoint + mitotic cell cycle spindle checkpoint + + + + + + + + + cellular response to zinc ion + cellular response to zinc + + + + + + + + + cellular hypertonic response + cellular response to hypertonicity + cellular hyperosmotic response + cellular HOG response + + + + + + + + + otic vesicle development + + + + + + + + + otic vesicle morphogenesis + + + + + + + + + IgM immunoglobulin complex, circulating + IgM antibody + + + + + + + + + renal system development + + + + + + + + + nephron development + + + + + + + + + kidney epithelium development + + + + + + + + + nephron tubule development + + + + + + + + + mesonephric epithelium development + + + + + + + + + mesonephric tubule development + + + + + + + + + signal transduction by p53 class mediator + + + + + + + + + protein activitory cascade + protein activation cascade + protein activation pathway + + + + + + + + + purine-containing compound anabolism + purine-containing compound biosynthesis + purine-containing compound formation + purine-containing compound synthesis + purine-containing compound biosynthetic process + purine and derivative biosynthetic process + + + + + + + + + pyridine-containing compound metabolism + pyridine-containing compound metabolic process + pyridine and derivative metabolic process + + + + + + + + + pyridine-containing compound anabolism + pyridine-containing compound biosynthesis + pyridine-containing compound formation + pyridine-containing compound synthesis + pyridine-containing compound biosynthetic process + pyridine and derivative biosynthetic process + + + + + + + + + blood microparticle + cell membrane microparticle + + + + + + + + + establishment of protein localisation to endoplasmic reticulum + establishment of protein localization in endoplasmic reticulum + establishment of protein localization to ER + establishment of protein localization to endoplasmic reticulum + establishment of protein localisation to ER + + + + + + + + + neutrophil extravasation + + + + + + + + + mitotic spindle + + + + + + + + + endosome membrane permeabilization involved in viral entry into host cell + + + + + + + + + virus endocytosis by host + endocytosis involved in viral entry into host cell + viral penetration via endocytosis followed by endosome disruption + + + + + + + + + viral penetration via clathrin-mediated endocytosis + clathrin-dependent endocytosis of virus by host cell + clathrin-mediated endocytosis of virus by host cell + + + + + + + + + endosome lysis involved in viral entry into host cell + viral entry into host cell via caveolae-mediated endocytosis followed by endosome lysis + + + + + + + + + microtubule-dependent intracellular transport of viral material + + + + + + + + + actin-dependent intracellular transport of virus + actin-dependent intracellular transport of viral material + + + + + + + + + viral translational frameshifting + ribosomal frameshifting involved in viral translation + + + + + + + + + ribosomal skipping + + + + + + + + + cap snatching + cap snatching involved in viral mRNA transcription + + + + + + + + + viral RNA editing + RNA editing involved in viral mRNA transcription + + + + + + + + + modulation by virus of host immune response + regulation by virus of host immune system process + + + + + + + + + intracellular transport of viral material + movement of virus within host cell + viral genome transport in host cell + intracellular transport of virus + egress of virus within host cell + + + + + + + + + positive regulation of monocyte chemotaxis + + + + + + + + + positive regulation of cell cycle process + + + + + + + + + establishment of protein localization in membrane + establishment of protein localization to membrane + establishment of protein localisation in membrane + + + + + + + + + negative regulation of release of cytochrome c from mitochondria + + + + + + + + + mitotic spindle assembly + spindle assembly involved in mitosis + + + + + + + + + positive regulation of intracellular protein transport + + + + + + + + + sensory organ morphogenesis + + + + + + + + + response to thyroid hormone + response to thyroid hormone stimulus + + + + + + + + + vascular smooth muscle cell development + + + + + + + + + extrinsic apoptotic signalling pathway + extrinsic apoptotic signaling pathway + extrinsic apoptotic pathway + + + + + + + + + renal filtration + + + + + + + + + apical dendrite + + + + + + + + + neuron protrusion guidance + neuronal cell projection guidance + neuron projection guidance + neuron process guidance + + + + + + + + + spliceosomal snRNP complex + + + + + + + + + protein complex involved in cell adhesion + + + + + + + + + entry receptor-mediated virion attachment to host cell + viral attachment to host entry receptor + + + + + + + + + adhesion receptor-mediated virion attachment to host cell + viral attachment to host adhesion receptor + + + + + + + + + modulation of host virulence by virus + + + + + + + + + virion maturation + viral particle maturation + + + + + + + + + chromosomal region + chromosome region + + + + + + + + + mitochondrial protein complex + + + + + + + + + inner mitochondrial membrane protein complex + + + + + + + + + nuclear chromosome segregation + + + + + + + + + lytic vacuole membrane + + + + + + + + + membrane microdomain + + + + + + + + + synapse disassembly + synapse elimination + synapse removal + synapse pruning + synapse clearance + + + + + + + + + neuron to neuron synapse + + + + + + + + + disruption of host cell envelope during viral entry + + + + + + + + + degradation of host lipopolysaccharide during virus entry + disruption by virus of host envelope lipopolysaccharide during virus entry + degradation of host cell envelope lipopolysaccharide during viral entry + + + + + + + + + fusion of virus membrane with host outer membrane + viral envelope fusion with host outer membrane + + + + + + + + + viral entry via permeabilization of endosomal membrane + + + + + + + + + viral entry via permeabilization of inner membrane + + + + + + + + + plasma membrane invagination + + + + + + + + + viral extrusion + + + + + + + + + postsynaptic specialization + + + + + + + + + cell cortex region + perimembrane region + + + + + + + + + ficolin-1-rich granule + ficolin-1 rich granule + + + + + + + + + ficolin-1-rich granule membrane + + + + + + + + + Sm-like protein family complex + + + + + + + + + meiotic nuclear division + + + + + + + + + mitotic nuclear division + + + + + + + + + viral entry via permeabilization of host membrane + + + + + + + + + distal part of the axon + distal axon + distal part of axon + + + + + + + + + carbohydrate derivative catabolism + carbohydrate derivative degradation + carbohydrate derivative catabolic process + carbohydrate derivative breakdown + + + + + + + + + positive regulation of neuronal cell death + up regulation of neuron cell death + up regulation of neuron death + up regulation of neuronal cell death + up-regulation of neuron cell death + up-regulation of neuron death + up-regulation of neuronal cell death + upregulation of neuron cell death + upregulation of neuron death + upregulation of neuronal cell death + positive regulation of neuron death + positive regulation of neuron cell death + + + + + + + + + nucleoside phosphate biosynthesis + nucleoside phosphate formation + nucleoside phosphate synthesis + nucleoside phosphate biosynthetic process + nucleoside phosphate anabolism + + + + + + + + + glycosyl compound catabolism + glycosyl compound degradation + glycosyl compound catabolic process + glycosyl compound breakdown + + + + + + + + + regulation of cell cycle transition + regulation of cell cycle phase transition + cell cycle control + + + + + + + + + down regulation of cell cycle transition + down-regulation of cell cycle phase transition + down-regulation of cell cycle transition + downregulation of cell cycle phase transition + downregulation of cell cycle transition + inhibition of cell cycle transition + negative regulation of cell cycle transition + negative regulation of cell cycle phase transition + down regulation of cell cycle phase transition + + + + + + + + + positive regulation of cell cycle transition + up regulation of cell cycle phase transition + up regulation of cell cycle transition + up-regulation of cell cycle phase transition + up-regulation of cell cycle transition + upregulation of cell cycle phase transition + upregulation of cell cycle transition + positive regulation of cell cycle phase transition + activation of cell cycle transition + + + + + + + + + regulation of mitotic cell cycle phase transition + mitotic cell cycle control + + + + + + + + + down-regulation of mitotic cell cycle phase transition + downregulation of mitotic cell cycle phase transition + negative regulation of mitotic cell cycle phase transition + down regulation of mitotic cell cycle phase transition + + + + + + + + + up-regulation of mitotic cell cycle phase transition + upregulation of mitotic cell cycle phase transition + positive regulation of mitotic cell cycle phase transition + up regulation of mitotic cell cycle phase transition + + + + + + + + + regulation of metaphase/anaphase transition of cell cycle + + + + + + + + + down-regulation of metaphase/anaphase transition of cell cycle + downregulation of metaphase/anaphase transition of cell cycle + negative regulation of metaphase/anaphase transition of cell cycle + down regulation of metaphase/anaphase transition of cell cycle + + + + + + + + + serine/threonine protein kinase complex + + + + + + + + + regulation of neutrophil activation + + + + + + + + + regulation of cell cycle G2/M phase transition + + + + + + + + + down-regulation of cell cycle G2/M phase transition + downregulation of cell cycle G2/M phase transition + negative regulation of cell cycle G2/M phase transition + down regulation of cell cycle G2/M phase transition + + + + + + + + + up-regulation of cell cycle G2/M phase transition + upregulation of cell cycle G2/M phase transition + positive regulation of cell cycle G2/M phase transition + up regulation of cell cycle G2/M phase transition + + + + + + + + + microtubule dynamics involved in mitosis + microtubule cytoskeleton organization involved in mitosis + microtubule cytoskeleton organisation involved in mitosis + + + + + + + + + meiotic cell cycle process + + + + + + + + + regulation of peptidolysis involved in cellular protein catabolism + regulation of proteolysis involved in cellular protein catabolic process + regulation of peptidolysis involved in cellular protein catabolic process + + + + + + + + + regulation of protein maturation + + + + + + + + + regulation of protein folding + + + + + + + + + regulation of cellular protein catabolism + regulation of cellular protein degradation + regulation of cellular protein catabolic process + regulation of cellular protein breakdown + + + + + + + + + positive regulation of cellular protein catabolism + positive regulation of cellular protein degradation + up regulation of cellular protein breakdown + up regulation of cellular protein catabolic process + up regulation of cellular protein catabolism + up regulation of cellular protein degradation + up-regulation of cellular protein breakdown + up-regulation of cellular protein catabolic process + up-regulation of cellular protein catabolism + up-regulation of cellular protein degradation + upregulation of cellular protein breakdown + upregulation of cellular protein catabolic process + upregulation of cellular protein catabolism + upregulation of cellular protein degradation + positive regulation of cellular protein catabolic process + positive regulation of cellular protein breakdown + + + + + + + + + endoplasmic reticulum to cytosol transport + ER to cytosol transport + + + + + + + + + up regulation of cellular protein localisation + up regulation of cellular protein localization + up-regulation of cellular protein localisation + up-regulation of cellular protein localization + upregulation of cellular protein localisation + upregulation of cellular protein localization + positive regulation of cellular protein localization + positive regulation of cellular protein localisation + + + + + + + + + regulation of cyclin-dependent protein kinase activity + + + + + + + + + ER protein alpha-1,2-demannosylation + protein alpha-1,2-demannosylation in ER + protein alpha-1,2-demannosylation in ER quality control compartment + protein alpha-1,2-demannosylation in ERQC + protein alpha-1,2-demannosylation in endoplasmic reticulum + protein alpha-1,2-demannosylation in endoplasmic reticulum quality control compartment + endoplasmic reticulum mannose trimming + ER mannose trimming + + + + + + + + + regulation of ubiquitin ligase activity + regulation of ubiquitin protein ligase activity + regulation of protein ubiquitination activity + + + + + + + + + membrane-enclosed lumen of tertiary granule + tertiary granule membrane-enclosed lumen + tertiary granule lumen + membrane-enclosed lumen of gelatinase granule + + + + + + + + + vascular associated smooth muscle cell migration + vascular smooth muscle cell migration + + + + + + + + + membrane-enclosed lumen of ficolin-1 rich granule + membrane-enclosed lumen of ficolin-1-rich granule + ficolin-1-rich granule lumen + ficolin-1-rich granule membrane-enclosed lumen + + + + + + + + + positive regulation of protein positioning + positive regulation of protein recruitment + up regulation of establishment of protein localisation + up regulation of establishment of protein localization + up regulation of protein positioning + up regulation of protein recruitment + up-regulation of establishment of protein localisation + up-regulation of establishment of protein localization + up-regulation of protein positioning + up-regulation of protein recruitment + upregulation of establishment of protein localisation + upregulation of establishment of protein localization + upregulation of protein positioning + upregulation of protein recruitment + positive regulation of establishment of protein localization + positive regulation of establishment of protein localisation + + + + + + + + + regulation of chromosome separation + + + + + + + + + down-regulation of chromosome separation + downregulation of chromosome separation + negative regulation of chromosome separation + down regulation of chromosome separation + + + + + + + + + regulation of cellular response to endoplasmic reticulum stress + regulation of response to ER stress + regulation of response to endoplasmic reticulum stress + regulation of ER stress response + + + + + + + + + microtubule end + + + + + + + + + lipoprotein particle + + + + + + + + + regulation of protein activitory cascade + regulation of protein activation cascade + regulation of protein activation pathway + + + + + + + + + regulation of CD4-positive, alpha-beta T cell activation + + + + + + + + + positive regulation of peptidyl-lysine acetylation + + + + + + + + + negative regulation of sister chromatid separation during mitosis + negative regulation of mitotic sister chromatid separation + negative regulation of mitotic sister chromatid resolution + + + + + + + + + negative regulation of chromosome organization + negative regulation of chromosome organisation + + + + + + + + + Abnormality of the kidney + Renal anomalies + Renal anomaly + Abnormality of the kidney + Abnormal kidney + + + + + + + + + Urinary tract abnormality + Urinary tract anomalies + Abnormality of the urinary system + Urinary tract abnormalities + + + + + + + + + Genitourinary abnormality + Genitourinary tract anomalies + Genitourinary tract malformation + Urogenital abnormalities + Urogenital anomalies + Abnormality of the genitourinary system + Abnormality of the GU system + + + + + + + + + Head and neck abnormality + Abnormality of head or neck + Abnormality of head or neck + + + + + + + + + Hematuria + Blood in urine + + + + + + + + + RAS activation + Hyperactive renin-angiotensin system + + + + + + + + + Abnormality of renin-angiotensin system + Abnormality of the renin-aldosterone axis + + + + + + + + + Abnormality of the liver + Liver abnormality + Abnormality of the liver + Abnormal liver + + + + + + + + + Abnormality of neutrophils + Abnormality of polymorphonuclear neutrophils + Abnormality of neutrophils + Abnormality of neutrophil + + + + + + + + + Abnormal eosinophil morphology + Abnormality of eosinophils + + + + + + + + + Abnormality of leukocytes + Abnormal leukocyte morphology + Abnormal leukocyte function + + + + + + + + + Abnormal granulocyte morphology + Abnormality of granulocytes + + + + + + + + + Acute renal failure + Acute kidney injury + Acute kidney failure + + + + + + + + + Coagulation abnormalities + Coagulation abnormality + Haemorrhagic disorders + Abnormality of coagulation + Abnormal blood coagulation studies + + + + + + + + + Gastrointestinal tract defects + Abnormality of the abdominal organs + Abnormality of the abdominal organs + + + + + + + + + Abnormality of the lungs + Abnormally shaped lung + Unusal lung shape + Abnormal lung morphology + Abnormality of lung morphology + + + + + + + + + progressive respiratory failure + Respiratory insufficiency + Respiratory impairment + + + + + + + + + Difficulty breathing + Respiratory difficulties + Respiratory distress + difficulty breathing + shortness of breath + Breathing difficulties + + + + + + + + + Pulmonic infiltration + Pulmonary infiltrates + Lung infiltrates + + + + + + + + + Azotemia + Azotaemia + + + + + + + + + Neonatal respiratory distress + Newborn respiratory distress + Respiratory distress, neonatal + Neonatal respiratory distress + Infantile respiratory distress + + + + + + + + + Immunological abnormality + Abnormality of the immune system + Abnormality of the immune system + + + + + + + + + Frequent, severe infections + Increased frequency of infection + Predisposition to infections + Recurrent infections + Susceptibility to infection + infections, recurrent + Recurrent infections + Frequent infections + + + + + + + + + Abnormality of the lymph nodes + Abnormality of the lymph nodes + Abnormal lymph node histology + + + + + + + + + Lower respiratory tract infections + Recurrent chest infections + Recurrent lower respiratory tract infections + Chronic lung infections + + + + + + + + + Aspiration + + + + + + + + + Hypokalemia + Low blood potassium levels + + + + + + + + + Unregulated immune response + Immune dysregulation + Immune dysregulation + + + + + + + + + Urine issues + Abnormality of urine homeostasis + Pee issues + + + + + + + + + Electrolyte disorders + Abnormal blood ion concentration + Abnormality of ion homeostasis + + + + + + + + + Abnormal circulating hormone level + Abnormality of circulating hormone level + + + + + + + + + Increased blood urea nitrogen + Increased blood urea nitrogen + Increased BUN + + + + + + + + + Abnormality of the coagulation cascade + Coagulopathy + + + + + + + + + High ferritin level + Hyperferritinaemia + Hyperferritinemia + Increased ferritin + Increased plasma ferritin + Increased serum ferritin level + Increased serum ferritin + Elevated serum ferritin + + + + + + + + + Elevated sedimentation rate + High ESR + High erythrocyte sedimentation rate + Increased erythrocyte sedimentation rate + Raised erythrocyte sedimentation rate + Elevated erythrocyte sedimentation rate + Elevated ESR + + + + + + + + + Abnormality of cells of the lymphoid lineage + Abnormal lymphocyte morphology + Abnormal lymphocytes + + + + + + + + + Abnormal circulating nitrogen compound concentration + + + + + + + + + Poor appetite + Poor appetite + Loss of appetite + Decreased appetite + + + + + + + + + Elevated systolic blood pressure + Elevated systolic BP + + + + + + + + + Impaired lung function + Impaired pulmonary function + Decreased pulmonary function + Decreased lung function + + + + + + + + + Breathing dysregulation + + + + + + + + + Chronic lung disease + Chronic lung disease + + + + + + + + + Interstitial lung disease + Interstitial pulmonary disease + Interstitial pulmonary abnormality + Abnormality in area between air sacs in lung + + + + + + + + + Pneumonia, recurrent + Pneumonia, recurrent episodes + Pulmonary infection + Pulmonary infections + Recurrent pneumonia + Recurrent pulmonary infections + pulmonary infections, recurrent + Recurrent pneumonia + Multiple pulmonary infections + + + + + + + + + Increased international normalized ratio + Low factor II activity + Prolonged PT + Reduced factor II activity + Reduced prothrombin activity + increased international normalised ratio + Prolonged prothrombin time + Increased INR + + + + + + + + + Abnormal circulating protein level + Abnormality of circulating protein level + + + + + + + + + Abnormal blood cation concentration + Abnormality of cation homeostasis + + + + + + + + + Abnormal blood monovalent inorganic cation concentration + Abnormality of monovalent inorganic cation homeostasis + + + + + + + + + Abnormality of the upper urinary tract + Abnormality of the upper urinary tract + + + + + + + + + Abnormal myeloid leukocyte morphology + Abnormality of myeloid leukocytes + + + + + + + + + Abnormality of immune system physiology + + + + + + + + + Abnormal cellular immune system morphology + + + + + + + + + Abnormality of circulating enzyme level + + + + + + + + + Abnormality of potassium homeostasis + Abnormal blood potassium concentration + Abnormal blood K concentration + + + + + + + + + Abnormality of immune serum protein physiology + + + + + + + + + Abnormality of serum cytokine level + + + + + + + + + Elevated CRP concentraction + Elevated C-reactive protein level + + + + + + + + + Abnormality of the urinary system physiology + + + + + + + + + Abnormal leukocyte count + Abnormal white blood cell count + + + + + + + + + Neutrophilia + Increased blood neutrophil counts + + + + + + + + + Abnormal neutrophil count + Abnormal neutrophil cell number + + + + + + + + + Hepatitis + Liver inflammation + + + + + + + + + Abnormality of natural killer cells + Abnormal natural killer cell morphology + Abnormal NK cells + + + + + + + + + Abnormality of prothrombin + + + + + + + + + Abnormal renal function + Abnormality of renal physiology + Kidney function issue + Renal functional abnormality + Abnormal renal physiology + Abnormal kidney function + + + + + + + + + Abnormal respiratory system morphology + + + + + + + + + Abnormal blood gas level + Abnormal blood gas level + + + + + + + + + Hypoxemia + Low blood oxygen level + + + + + + + + + Abnormal urine cytology + + + + + + + + + Abnormal inflammatory response + Abnormal inflammatory response + + + + + + + + + Increased inflammatory response + + + + + + + + + Abnormal eosinophil count + + + + + + + + + Abnormal Westergren sedimentation rate + Abnormal erythrocyte sedimentation rate + Abnormal ESR + + + + + + + + + Ground-glass opacification on pulmonary HRCT + + + + + + + + + Centrilobular groundglass opacity + Centrilobular ground-glass opacification on pulmonary HRCT + ground-glass opacity + Centrilobular groundglass opacification + + + + + + + + + Pulmonary interstitial high-resolution computed tomography abnormality + Pulmonary interstitiatial HRCT abnormality + + + + + + + + + interlobular septal thickening + Interlobular septal thickening on pulmonary HRCT + + + + + + + + + Chest tightness + Tightness in chest + + + + + + + + + Pulmonary opacity + + + + + + + + + Severe viral infection + + + + + + + + + parainfluenza + Severe parainfluenza infection + + + + + + + + + Reduction in eosinophils + Decreased eosinophil count + + + + + + + + + Abnormal blood urea nitrogen concentration + Abnormal BUN concentration + + + + + + + + + Abnormal pulmonary thoracic imaging finding + Abnormal chest radiograph finding (lung) + + + + + + + + + Severe infection + Unusual course of infection + + + + + + + + + pulmonary parenchymal consolidation + Parenchymal consolidation + + + + + + + + + Abnormal prothrombin time + Abnormal PT + + + + + + + + + Abnormal immune system morphology + + + + + + + + + Increased blood pressure + Increased BP + + + + + + + + + elevated procalcitonin + Increased circulating procalcitonin level + + + + + + + + + Abnormal granulocyte count + + + + + + + + + Abnormal C-reactive protein level + + + + + + + + + Abnormal circulating CPK concentration + Abnormal circulation phospho-CK concentration + Abnormal levels of creatine kinase in blood + Abnormal circulating creatine kinase concentration + Abnormal circulating CK concentration + + + + + + + + + Abnormal natural killer cell count + Abnormal number of natural killer cells + Abnormality of natural killer cell count + Abnormal natural killer cell count + Abnormal NK cell count + + + + + + + + + Abnormal serum ferritin + Abnormal serum ferritin + Abnormal plasma ferritin + + + + + + + + + Reduced natural killer cell number + Reduced natural killer cell count + Lower level of natural killer cells + Reduced NK cell number + + + + + + + + + Abnormality of fibrinolysis + Abnormality of the fibrinolytic system + + + + + + + + + hyper-fibrinolysis + Hyperfibrinolysis + + + + + + + + + Abnormal Ca2+ PO4 regulating hormone level + Abnormal calcium-phosphate regulating hormone level + Abnormal Ca-PHOS regulating hormone level + + + + + + + + + Abnormality of the lymphatic system + + + + + + + + + Sepsis + Infection in blood stream + + + + + + + + + Acute hepatitis + Acute liver inflammation + + + + + + + + + Abnormal liver morphology + + + + + + + + + Abnormal blood oxygen levels + Abnromal O2 blood concentration + Abnormal blood oxygen level + Abnormal blood O2 level + + + + + + + + + time period + incubation period + + + + + + + + + Period of communicability + communicability period + + + + + + + + + secondary infection + + + + + + + + + transmission period + + + + + + + + + D-dimer measurement + D dimer level test + + + + + + + + + swab collection of rectum + rectal swab + anal swab + + + + + + + + + computed tomography + + + + + + + + + hyperplastic + hyperplasia + hyperplasia + + + + + + + + + Epstein-Barr Virus infection + Human gammaherpesvirus 4 caused disease or disorder + Human gammaherpesvirus 4 disease or disorder + Human gammaherpesvirus 4 infectious disease + Epstein-Barr virus infection + EBV infection + + + + + + + + + Herpesviridae disease or disorder + Herpesviridae infections + herpesvirus infection + Herpesviridae infectious disease + Herpesviridae caused disease or disorder + + + + + + + + + vertebral hypoplasia with lumbar kyphosis + vertebral hypoplasia with lumbar kyphosis + + + + + + + + + rare pulmonary disease + + + + + + + + + diffuse alveolar hemorrhage (disease) + diffuse alveolar hemorrhage + + + + + + + + + viral respiratory tract infection + respiratory viral infections + viral respiratory tract infection + + + + + + + + + hemorrhagic necrosis + + + + + + + + + cardiac dysplasia + abnormal heart morphology + abnormal cardiac morphology + + + + + + + + + brain inflammation + encephalitis + + + + + + + + + choroid inflammation + inflammation of the eye membrane + inflammation of the membrane that lines the front of the eye + choroiditis + + + + + + + + + carditis + heart inflammation + cardiac inflammation + + + + + + + + + cardiac fibrosis + + + + + + + + + significantly high blood levels of chemokines + abnormal circulating chemokine level + + + + + + + + + abnormal circulating cytokine level + + + + + + + + + alveolus inflammation + alveolitis + inflamed alveolus + alveolar inflammation + + + + + + + + + root + + + + + + + + + Chinese hamsters + Cricetulus aureus + Cricetulus griseus + Chinese hamster + + + + + + + + + Herpesviridae + + + + + + + + + Betaherpesvirinae + Betaherpesviruses + + + + + + + + + Cytomegalovirus + + + + + + + + + Human betaherpesvirus 5 + Human cytomegalovirus + + + + + + + + + lymphoproliferative virus group + Gammaherpesvirinae + Gammaherpesviruses + + + + + + + + + Lymphocryptovirus + + + + + + + + + Epstein-Barr virus + Human gammaherpesvirus 4 + Epstein Barr virus + + + + + + + + + Rhadinovirus + + + + + + + + + Adenoviridae + + + + + + + + + Mastadenovirus + + + + + + + + + Human adenovirus 2 + + + + + + + + + Reoviridae + + + + + + + + + Rotavirus + + + + + + + + + Mononegavirales + negative-sense genome single-stranded RNA viruses + + + + + + + + + Pneumoviridae + + + + + + + + + Picornaviridae + + + + + + + + + Enterovirus + + + + + + + + + Coxsackievirus A9 + + + + + + + + + Human mastadenovirus C + + + + + + + + + cellular organisms + + + + + + + + + Enterovirus B + + + + + + + + + Human metapneumovirus + + + + + + + + + Metapneumovirus + + + + + + + + + Negarnaviricota + + + + + + + + + Haploviricotina + + + + + + + + + Monjiviricetes + + + + + + + + + Human adenovirus 5 + + + + + + + + + Manis tricuspis + Tree pangolin + + + + + + + + + Human gammaherpesvirus 8 + + + + + + + + + single stranded RNA virus + ssRNA viruses + + + + + + + + + Picornavirales + + + + + + + + + Herpesvirales + + + + + + + + + Human herpesvirus 8 strain rKSHV.219 + + + + + + + + + Sedoreovirinae + + + + + + + + + ADEMETIONINE + Ademetionine + Methionine, S-adenosyl-, DL- + S-Adenosyl-DL-methionine + Ademetionine + (3-Amino-3-carboxypropyl)-[[(2S,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl]-methylsulfanium + (+-)-5'-((R*)-((R*)-3-Amino-3-carboxypropyl)methylsulfonio)-5'-deoxyadenosine Hydroxide, Inner Salt + + + + + + + + + High Risk + High Risk + higher risk + risky group + HIGH RISK + + + + + + + + + Diammonium Glycyrrhizinate + alpha-D-Glucopyranosiduronic acid, (3beta,20beta)-20-carboxy-11-oxo-30-norolean-12-en-3-yl 2-O-beta-D-Glucopyranuronosyl-, Diammonium Salt (9CI) + Diammonium Glycyrrhizinate + 18beta-Glycyrrhizic Acid Diammoniumsalt + + + + + + + + + Cytarabine/Homoharringtonine/Interferon Alfa + Cytarabine/Homoharringtonine/Interferon Alfa + ARA-C/HH/IFN-A + + + + + + + + + BECLABUVIR + BMS-791325 + Beclabuvir + Beclabuvir + (4bS,5aR)-12-Cyclohexyl-N-(dimethylsulfamoyl)-3-methoxy-5a-((3-methyl-3,8-diazabicyclo(3.2.1)oct-8-yl)carbonyl)-4b,5,5a,6-tetrahydrocyclopropa(d)indolo(2,1-a)(2)benzazepine-9-carboxamide + + + + + + + + + Adenoviral Infection + Adenovirus Infection + Adenovirus Infection + AdV Infection + + + + + + + + + Healthcare-Associated Infection + Hospital-Acquired Infection + Hospital-Onset Infection + Nosocomial Infection + Nosocomial Infection + nosocomial transmission + HAI + + + + + + + + + Fluid Therapy + Fluid Therapy + + + + + + + + + GS-5806 + Methanesulfonamide, N-(2-(((2S)-2-(5-((3S)-3-amino-1-pyrrolidinyl)-6-methylpyrazolo(1,5-a)pyrimidin-2-yl)-1-piperidinyl)carbonyl)-4-chlorophenyl)- + PRESATOVIR + Presatovir + Respiratory Syncytial Virus Fusion Inhibitor GS-5806 + Presatovir + GS 5806 + + + + + + + + + Camrelizumab + HR-301210 + SHR-1210 + SHR1210 + Camrelizumab + CAMRELIZUMAB + + + + + + + + + Plasma Cells + Plasmacytes + Plasmocyte + plasma cell + plasmacyte + plasmacytic + Plasma Cell + Plasma Cell + + + + + + + + + PD1 Inhibitor + Programmed Cell Death Protein 1 Inhibitor + Protein PD-1 Inhibitor + PD1 Inhibitor + PD-1 mAb + PD-1 Inhibitor + + + + + + + + + Spiro(cyclohexane-1,3'(2'H)-imidazo(1,5-a)pyridine)-1',5'-dione, 6'-((6-Amino-4-pyrimidinyl)amino)-8'-methyl- + TOMIVOSERTIB + Tomivosertib + eFT508 + Tomivosertib + EFT-508 + + + + + + + + + Lymphocyte + Lymphocytes + lymphocyte + Lymphocyte + Lymph Cell + + + + + + + + + CD8 Lymphocyte + CD8 Lymphocytes + CD8+ T Cell + CD8+ T Lymphocyte + CD8+ T Lymphocytes + CD8+ T-Lymphocyte + CD8-Positive Lymphocyte + CD8-Positive Lymphocytes + CD8-Positive T-Lymphocyte + CD8-Positive T-Lymphocytes + T8 Cell + T8 Cells + T8 Lymphocyte + T8 Lymphocytes + CD8-Positive T-Lymphocyte + CD8 T cells + CD8 Cell + + + + + + + + + Antibody-Producing Cell + Antibody-Producing Cells + Immunoglobulin-Producing Cell + Immunoglobulin-Producing Cells + Antibody-Producing Cell + antibody-secreting cells + Antibody Producing Cell + + + + + + + + + Renal Replacement Therapy + Renal Replacement Therapy + RRT + + + + + + + + + Some shortness of breath + Some Shortness of Breath + shortness of breath + Some Shortness of Breath + + + + + + + + + Mode of Transmission + infection spread + modes of transmission + transmission route + Mode of Transmission + + + + + + + + + Recombinant Granulocyte Colony-Stimulating Factor + rhG-CSF + Recombinant Granulocyte Colony-Stimulating Factor + Recombinant Colony-Stimulating Factor 3 + + + + + + + + + Fujimycin + Hecoria + Hexadecahydro-5,19-dihydroxy-3-[2-(4-hydroxy-3-methoxycyclohexyl)-1-methylethenyl]-14,16-dimethoxy-4,10,12,18-tetramethyl-8-(2-propenyl)-15,19-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclotricosine-1,7,20,21(4H,23H)-tetrone + Prograf + Protopic + TACROLIMUS + Tacrolimus + tacrolimus + Tacrolimus + FK 506 + + + + + + + + + Open Reading Frame + Open Reading Frame + ORF + + + + + + + + + Recovered Plasma + Recovered Plasma + + + + + + + + + Transmembrane Domain + Transmembrane Region + Transmembrane Domain + TM Domain + + + + + + + + + Cytoplasmic Tail + Cytosolic Domain + Cytoplasmic Domain + Cytoplasmic Domain + + + + + + + + + Leronlimab + PA14 + PRO 140 + PRO-140 + PRO140 + WHO 10751 + Leronlimab + LERONLIMAB + + + + + + + + + Immunocompromised Host + Immunocompromised Patient + Immunosuppressed + Immunosuppressed Host + Immunosuppressed Patient + immunocompromised + immunocompromised host + immunocompromised patient + immunosuppressed host + immunosuppressed patient + Immunocompromised + Immunocompromised + + + + + + + + + data capture + Data Capture + Data Capture + + + + + + + + + Docrised + RC-160 + VAPREOTIDE + Vapreotide + vapreotide + Vapreotide + BMY-41606 + + + + + + + + + Angiotensin II Acetate + Angiotensin II Acetate + ANGIOTENSIN II ACETATE + + + + + + + + + Lung infection + Lung Infection, CTCAE + Lung Infection, CTCAE + + + + + + + + + Enoxaparin + enoxaparin + Enoxaparin + ENOXAPARIN + + + + + + + + + Polyinosinic-polycytidylic Acid/Inactivated Rabies Virus Vaccine YS-ON-001 + YS ON 001 + YS-ON-001 + Polyinosinic-polycytidylic Acid/Inactivated Rabies Virus Vaccine YS-ON-001 + Poly IC/Inactivated RV-V YS-ON-001 + + + + + + + + + Clinical Trials + Clinical Trials, Unspecified + Trial + clinical trial + Clinical Trial + Clinical Trial + + + + + + + + + Verdinexor + Verdinexor + VERDINEXOR + + + + + + + + + Self-care + Selfcare + Self Care + Self Care + + + + + + + + + Oropharyngeal Swab Specimen + THRT + Throat Swab + Oropharyngeal Swab Specimen + Oropharyngeal Swab + + + + + + + + + Supportive Therapy + Symptom Management + Therapy, Supportive + supportive care + Supportive Care + Supportive Care + + + + + + + + + Drug Development + drug discovery + Drug Development + + + + + + + + + Chronic Respiratory Disease + Chronic Respiratory Disease + + + + + + + + + Animal Testing + Animal Testing + + + + + + + + + WESTERN BLOT + Western Blot + Western Blotting + Western Blotting + Blotting, Western + + + + + + + + + Cathepsins + Cathepsin + Cathepsin + + + + + + + + + Nucleic Acid Synthesis Inhibitor + Nucleic Acid Synthesis Inhibitor + Inhibitors, Nucleic Acid Synthesis + + + + + + + + + Integrin + Integrin Receptor + RGD Receptor + Integrin + Extracellular Matrix, Integrins + + + + + + + + + Interview + interview/survey + Interview + + + + + + + + + Model System + Modeling System + Models + model + Model + Model + + + + + + + + + risk factor + Risk Factor + Risk Factor + + + + + + + + + Viral Genome + Viral Genome + + + + + + + + + Experimental Models, Other + Experimental Model + Experimental models of disease + Experimental Model + + + + + + + + + oxidative stress + Oxidative Stress + Oxidative Stress + + + + + + + + + Surface Plasmon Resonance + Surface Plasmon Resonance + SURFACE PLASMON RESONANCE + + + + + + + + + Older Populations + Older Population + Older Population + + + + + + + + + In Vitro Model + In Vitro Model + + + + + + + + + In Vivo Model + In Vivo Model + + + + + + + + + Epidemiological Factors + epidemiology + Epidemiological Factors + + + + + + + + + Personal Attribute + Subject Characteristics + Personal Attribute + Personal + + + + + + + + + Co-Immunoprecipitation + Co-Immunoprecipitation + + + + + + + + + MoAB + Monoclonal Antibodies + Monoclonal Antibody + Monoclonal Antibody Therapy + monoclonal antibody + Monoclonal Antibody + monoclonal antibodies + passive antibody therapy + MAb + + + + + + + + + Human Leukocyte Interferon + Human Lymphoblastoid Interferon + IFN + Interferon + interferon + Interferon + Human Fibroblast Interferon + + + + + + + + + Lopinavir/Ritonavir + lopinavir/ritonavir + Lopinavir/Ritonavir + Lopinavir + ritonavir + Kaletra + + + + + + + + + Thymosin + Thymosin + + + + + + + + + symptomatic + Symptomatic + Symptomatic + + + + + + + + + Examination + Medical Assessment + Medical Exam + Medical Examination + Medical Inspection + Medical Examination + Exam + + + + + + + + + Isolation + isolation + Isolation + social isolation + Isolated + + + + + + + + + Antibiotic Agents + Antibiotic Drugs + Antibiotic Therapy + Antibiotics + Antimicrobial + Antimicrobial Agent + antibiotic + antimicrobial + Antibiotic + Antibiotic + + + + + + + + + Chinese Herbs + Chinese Herbs + + + + + + + + + Aspartate aminotransferase increased + Aspartate Aminotransferase Increased + elevated AST + Aspartate Aminotransferase Increased + + + + + + + + + Alanine aminotransferase increased + Alanine Aminotransferase Increased + elevated ALT + Alanine Aminotransferase Increased + + + + + + + + + (R)-9-(2-Phosphonomethoxypropyl)adenine + (R)-9-(Phosphonomethoxypropyl)adenine + GS-1275 + GS-1278 + PMPA + TENOFOVIR + Tenofovir + Tenofovir + (((1R)-2-(6-Amino-9H-purin-9-yl)-1-methylethoxy)methyl)phosphonic acid + + + + + + + + + Type II Pneumocyte + Alveolar Cell Type II + alveolar epithelial type II cells + Alveolar Cell Type II + + + + + + + + + HIE + Hypoxic Ischemic Encephalopathy + Hypoxic Ischemic Encephalopathy + hypoxic encephalopathy + Anoxic encephalopathy + + + + + + + + + negative test result + Negative Test Result + negative result + tested negative + Negative Test Result + + + + + + + + + positive test result + Positive Laboratory Test Result + positive result + positive test result + tested positive + Positive Laboratory Test Result + + + + + + + + + Chest X-ray + chest x-ray + Chest Radiography + Chest Radiography + + + + + + + + + Hypoxic + hypoxia + hypoxic + Hypoxia + Hypoxia + + + + + + + + + ACTINOMYCIN D + Actinomycin A IV + Actinomycin C1 + Actinomycin D + Actinomycin I1 + Actinomycin IV + Actinomycin X 1 + Actinomycin-[thr-val-pro-sar-meval] + Cosmegen + DACT + DACTINOMYCIN + Dactinomycin + Dactinomycine + Lyovac Cosmegen + Lyovac cosmegen + Meractinomycin + dactinomycin + Dactinomycin + 2-bis[Cyclo(N-methyl-L-valyl-sarcosyl-L-prolyl-D-valyl-L-threonyl)]-1,9 dimethyl-4,6 3H-phenoxazinone-3 + + + + + + + + + 7-Chloro-4-((4-(diethylamino)-1-methylbutyl)amino)quinoline Phosphate (1:2) + Aralen Phosphate + Avloclor + CHLOROQUINE PHOSPHATE + Chloroquine Phosphate + Tanakan + Chloroquine Phosphate + 1,4-Pentanediamine, N4-(7-chloro-4-quinolinyl)-N1,N1-diethyl-, Phosphate (1:2) + + + + + + + + + RESPRATE + Respiratory Rate + Respiratory Rate + RESP + + + + + + + + + Low Blood Oxygen Saturation + Low Oxygen Saturation + Oxygen Saturation Decreased + Oxygen Saturation, Low + Saturation, Low Oxygen + Low Blood Oxygen Saturation + decreased oxygen saturation + Desaturation + + + + + + + + + Occlusion + Occlusive + Occlusion + Occlusal + + + + + + + + + Sore throat + Throat, Sore + Sore Throat + Sore Throat + + + + + + + + + Erythrocytes + RBC + Red Blood Cell Count + Red Blood Cells + Red Cell Count + Erythrocyte Count + Erythrocyte Count + + + + + + + + + 6Alpha-Methylprednisolone + Adlone + Caberdelta M + DepMedalone + Depo Moderin + Depo-Nisolone + Duralone + Emmetipi + Esametone + Firmacort + METHYLPREDNISOLONE + Medlone 21 + Medrate + Medrol + Medrol Veriderm + Medrone + Mega-Star + Meprolone + Methylprednisolone + Methylprednisolonum + Metilbetasone Solubile + Metrocort + Metypresol + Metysolon + Predni-M-Tablinen + Prednilen + Radilem + Sieropresol + Solpredone + Summicort + Urbason + Veriderm Medrol + Wyacort + methylprednisolone + Methylprednisolone + (6alpha,11beta)-11,17,21-Trihydroxy-6-methylpregna-1,4-diene-3,20-dione + + + + + + + + + MERIMEPODIB + MMPD + Merimepodib + VI-21,497 + VX-497 + Merimepodib + Carbamic acid, ((3-((((3-methoxy-4-(5-oxazolyl)phenyl)amino)carbonyl)amino)phenyl)methyl)-, (3S)-tetrahydro-3-furanyl ester + + + + + + + + + Angiotensin II Receptor Antagonist + Angiotensin II Receptor Antagonists + Angiotensin II Receptor Blocker + Angiotensin Receptor Blockers + Angiotensin II Receptor Antagonist + ARB + + + + + + + + + Animal Model, Generic + Research Model, Animal + Animal Model + Animal Model + + + + + + + + + Antibody Titer + Antibody Titer + + + + + + + + + Quarantine + Quarantine + + + + + + + + + PX-12 + Thioredoxin-1 Inhibitor PX-12 + Thioredoxin-1 Inhibitor PX-12 + 2-(Sec-butyldisulfanyl)-1h-imidazole + 1-Methylpropyl 2-Imidazolyl Disulfide + + + + + + + + + Cytokine release syndrome + Cytokine Release Syndrome + cytokine storm syndrome + Cytokine Release Syndrome + + + + + + + + + Atrophy + Atrophy + ATROPHY + + + + + + + + + Biological Models + Model + Model System + Biological Model + Biological Model + + + + + + + + + Benzimidazol-2-amine + MARIBAVIR + Maribavir + NTBC + maribavir + Maribavir + BW 1263W94 + + + + + + + + + Ethyl (2E,4S)-4-(((2R,5S)-2-(4-fluorobenzyl)-6-methyl-5-(((5-methylisoxazol-3-yl)carbonyl)amino)-4-oxoheptanoyl)amino)-5-((3S)-2-oxopyrrolidin-3-yl)pent-2-enoate + RUPINTRIVIR + Rupintrivir + Ruprintrivir + Rupintrivir + AG7088 + + + + + + + + + Recombinant Human Angiotensin Converting Enzyme 2 APN01 + rhACE2 APN01 + Recombinant Human Angiotensin Converting Enzyme 2 APN01 + APN01 + + + + + + + + + Expectorate + Expectorate + EXPECTORATION + + + + + + + + + Mask + surgical mask + Mask + + + + + + + + + INK128 + MLN-0128 + MLN0128 + SAPANISERTIB + Sapanisertib + TAK-228 + Sapanisertib + INK-128 + + + + + + + + + Apilimod + Benzaldehyde, 3-Methyl-, (6-(4-Morpholinyl)-2-(2-(2-Pyridinyl)Ethoxy)-4-Pyrimidinyl)Hydrazone + N-(3-Methyl-Benzylidene)-N'-(6-Morpholin-4-Yl-2-(2-Pyridin-2-Yl-Ethoxy)-Pyrimidin-4-Yl)-Hydrazine + STA 5326 + Apilimod + APILIMOD + + + + + + + + + oxygen therapy + supplemental oxygen therapy + Oxygen Therapy + Oxygen Therapy + + + + + + + + + Nypta + TIDEGLUSIB + Tideglusib + Zentylor + Tideglusib + 4-Benzyl-2-(naphthalen-1-yl)-1,2,4-thiadiazolidine-3,5-dione + + + + + + + + + CX 4945 + CX-4945 + CX4945 + SILMITASERTIB + Silmitasertib + Silmitasertib + 5-((3-chlorophenyl)amino)-benzo(c)-2,6-naphthyridine-8-carboxylic Acid + + + + + + + + + artificial respiration + ventilator + mechanical ventilation + + + + + + + + + PUI + person under investigation + participant under investigation role + + + + + + + + + genotyping assay + + + + + + + + + enzyme-linked immunosorbent assay + + + + + + + + + average value + + + + + + + + + nasal swab + nasopharyngeal swab + nasal swab specimen + + + + + + + + + reverse transcription polymerase chain reaction assay + + + + + + + + + gene + + + + + + + + + gene of Eukaryota + + + + + + + + + gene of Homo sapiens + + + + + + + + + protein-coding gene of Homo sapiens + + + + + + + + + gene of Homo sapiens with other gene disposition + + + + + + + + + A2M + + + + + + + + + AGTR1 + + + + + + + + + ALB + + + + + + + + + ALPL + + + + + + + + + ANPEP + + + + + + + + + BIRC5 + + + + + + + + + FASLG + + + + + + + + + AREG + + + + + + + + + ARG1 + + + + + + + + + BDH1 + + + + + + + + + C1QBP + + + + + + + + + C3 + + + + + + + + + C4B + + + + + + + + + C5 + + + + + + + + + CALCA + + + + + + + + + CASP1 + + + + + + + + + CCNB1 + + + + + + + + + CD2 + + + + + + + + + CD3E + + + + + + + + + CD3G + + + + + + + + + CD247 + + + + + + + + + CD4 + + + + + + + + + CD8A + + + + + + + + + CD8B + + + + + + + + + CD14 + + + + + + + + + CKM + + + + + + + + + CRP + + + + + + + + + GMCSF + CSF2 + + + + + + + + + CSF3 + + + + + + + + + VCAN + + + + + + + + + CTLA4 + + + + + + + + + CTSB + + + + + + + + + CTSD + + + + + + + + + CTSL + + + + + + + + + CTSZ + + + + + + + + + DDX1 + + + + + + + + + DPP4 + + + + + + + + + GPR183 + + + + + + + + + ESR1 + + + + + + + + + FABP4 + + + + + + + + + FABP5 + + + + + + + + + FCN1 + + + + + + + + + fibrinogen + FGA + + + + + + + + + fibrinogen + FGB + + + + + + + + + FGF2 + + + + + + + + + FGG + + + + + + + + + Ferritin + FTH1 + + + + + + + + + FYN + + + + + + + + + GBP1 + + + + + + + + + GOT1 + + + + + + + + + GOT2 + + + + + + + + + GPT + + + + + + + + + GRN + + + + + + + + + CXCL1 + + + + + + + + + CXCL2 + + + + + + + + + GZMA + + + + + + + + + GZMB + + + + + + + + + GZMK + + + + + + + + + HAS2 + + + + + + + + + NRG1 + + + + + + + + + HLA-DRB1 + + + + + + + + + HLA-DRB4 + + + + + + + + + HLA-DRB5 + + + + + + + + + HNRNPA1 + + + + + + + + + HSPA5 + + + + + + + + + IFNA1 + + + + + + + + + IFNAR1 + + + + + + + + + IFNB1 + + + + + + + + + IFNG + + + + + + + + + IGFBP3 + + + + + + + + + IGHE + + + + + + + + + IGHG1 + + + + + + + + + IGHG2 + + + + + + + + + IGHG4 + + + + + + + + + IGLC2 + + + + + + + + + IGLL1 + + + + + + + + + IL1B + + + + + + + + + IL1R1 + + + + + + + + + IL1RN + + + + + + + + + IL2 + + + + + + + + + IL2RA + + + + + + + + + IL2RB + + + + + + + + + IL6R + + + + + + + + + IL7 + + + + + + + + + IL8 + + + + + + + + + IL9 + + + + + + + + + CXCR2 + + + + + + + + + IL10 + + + + + + + + + IL18 + + + + + + + + + IMPA1 + + + + + + + + + INHBA + + + + + + + + + CXCL10 + + + + + + + + + IRF1 + + + + + + + + + IRF3 + + + + + + + + + ISG20 + + + + + + + + + ITGA1 + + + + + + + + + ITGAE + + + + + + + + + JUN + + + + + + + + + KLRC1 + + + + + + + + + KLRD1 + + + + + + + + + LBP + + + + + + + + + LCK + + + + + + + + + LDHA + + + + + + + + + LDHB + + + + + + + + + LDHC + + + + + + + + + LY6E + + + + + + + + + SMAD3 + + + + + + + + + MAS1 + + + + + + + + + CXCL9 + + + + + + + + + MRC1 + + + + + + + + + MX1 + + + + + + + + + NPM1 + + + + + + + + + NPPB + + + + + + + + + NTRK1 + + + + + + + + + FURIN + + + + + + + + + PDCD1 + + + + + + + + + PDGFB + + + + + + + + + PHB + + + + + + + + + PLG + + + + + + + + + PRF1 + + + + + + + + + PRSS1 + + + + + + + + + RPL19 + + + + + + + + + RRAS + + + + + + + + + RRM2 + + + + + + + + + S100A8 + + + + + + + + + S100A9 + + + + + + + + + SAA1 + + + + + + + + + CCL2 + + + + + + + + + CCL3 + + + + + + + + + CCL3L1 + + + + + + + + + CCL4 + + + + + + + + + CCL5 + + + + + + + + + CCL8 + + + + + + + + + CCL13 + + + + + + + + + CXCL6 + + + + + + + + + CXCL11 + + + + + + + + + XCL1 + + + + + + + + + SELL + + + + + + + + + SGTA + + + + + + + + + SPP1 + + + + + + + + + STAT1 + + + + + + + + + XCL2 + + + + + + + + + TFRC + + + + + + + + + TGFB1 + + + + + + + + + TGFB2 + + + + + + + + + TIMP1 + + + + + + + + + TLR3 + + + + + + + + + TMPRSS2 + + + + + + + + + TNF + + + + + + + + + TNNI3 + + + + + + + + + TNNT1 + + + + + + + + + TNNT2 + + + + + + + + + TPO + + + + + + + + + VEGFA + + + + + + + + + XPO1 + + + + + + + + + ZAP70 + + + + + + + + + RAE1 + + + + + + + + + TNFSF10 + + + + + + + + + CCNB2 + + + + + + + + + NOG + + + + + + + + + TP53I3 + + + + + + + + + ISG15 + + + + + + + + + G3BP2 + + + + + + + + + GDF11 + + + + + + + + + PRG3 + + + + + + + + + IFITM3 + + + + + + + + + CXCR6 + + + + + + + + + PHB2 + + + + + + + + + IL37 + + + + + + + + + TRBC1 + + + + + + + + + TRAC + + + + + + + + + MACROD1 + + + + + + + + + KLRF1 + + + + + + + + + GTSE1 + + + + + + + + + TREM2 + + + + + + + + + DDIT4 + + + + + + + + + STEAP3 + + + + + + + + + NKRF + + + + + + + + + Hepcidin + HAMP + + + + + + + + + CXCL16 + + + + + + + + + ACE2 + + + + + + + + + MMP25 + + + + + + + + + HOPX + + + + + + + + + HAVCR2 + + + + + + + + + IL33 + + + + + + + + + SCGB3A1 + + + + + + + + + AMICA1 + + + + + + + + + CMTM2 + + + + + + + + + APOBEC3A + + + + + + + + + TIGIT + + + + + + + + + ZNF683 + + + + + + + + + genetic variability + genetic variation + + + + + + + + + haplotype of SARS-CoV-2 infection + haplotype + + + + + + + + + mutation + + + + + + + + + clinical finding + + + + + + + + + laboratory finding + + + + + + + + + sign + + + + + + + + + vital sign + + + + + + + + + homeostasis + + + + + + + + + dysregulation of homeostasis + abnormal homeostasis + + + + + + + + + physical examination finding + + + + + + + + + health care process + + + + + + + + + therapeutic procedure + + + + + + + + + asymptomatic + + + + + + + + + clinical data item + + + + + + + + + underlying disease + comorbidity + + + + + + + + + Personal Protective Equipment + + + + + + + + + Arrhythmias, Cardiac + + + + + + + + + Cross Infection + + + + + + + + + differential diagnosis + Diagnosis, Differential + + + + + + + + + Eosinophils + + + + + + + + + Heart Injuries + + + + + + + + + hygienic care + Hygiene + + + + + + + + + Traditional Chinese medicine + Medicine, Chinese Traditional + + + + + + + + + Case fatality rate + death rate + Mortality + + + + + + + + + Pulmonary Ventilation + + + + + + + + + CD4+ T cells + CD4-Positive T-Lymphocytes + + + + + + + + + Immunoglobulins, Intravenous + + + + + + + + + T-Lymphocytopenia, Idiopathic CD4-Positive + + + + + + + + + Cyclophilins + + + + + + + + + Pneumonia, Ventilator-Associated + + + + + + + + + Lung Injury + + + + + + + + + tropism + Viral Tropism + + + + + + + + + Chemical and Drug Induced Liver Injury + Drug-Induced Liver Injury + + + + + + + + + Endophenotypes + + + + + + + + + Drug repurposing + Drug Repositioning + + + + + + + + + pandemic + Pandemics + + + + + + + + + Molecular docking + Molecular Docking Simulation + + + + + + + + + Noninvasive Ventilation + + + + + + + + + hand washing + Hand Hygiene + + + + + + + + + Hand Sanitizers + + + + + + + + + Vascular Remodeling + + + + + + + + + morbidity + + + + + + + + + population quality + + + + + + + + + interferon alpha + fam:IFNA + + + + + + + + + interferon beta + IFNB + + + + + + + + + interferon type I + type I interferon + IFN type I + + + + + + + + + dry cough + + + + + + + + + hemorrhage + + + + + + + + + inflammation + + + + + + + + + lethargy + + + + + + + + + myocarditis + + + + + + + + + pain + + + + + + + + + pleural effusion + + + + + + + + + thrombocytopenia + + + + + + + + + seizure + seizure + + + + + + + + + conjunctivitis + + + + + + + + + feces and droppings symptom + fecal + + + + + + + + + vasculitis + + + + + + + + + weight loss + + + + + + + + + abnormal heart rhythm + dysrhythmia + heart rhythm symptom + arrhythmia + abnormal heart beat + + + + + + + + + heart failure + + + + + + + + + hyperemic + hyperemia + hyperaemia + + + + + + + + + head symptom + + + + + + + + + neurological and physiological symptom + + + + + + + + + sputum + + + + + + + + + shock + + + + + + + + + Shock, Septic + septic shock + + + + + + + + + digestive system symptom + + + + + + + + + symptom + + + + + + + + + nutrition, metabolism, and development symptom + + + + + + + + + nervous system symptom + + + + + + + + + skin and integumentary tissue symptom + + + + + + + + + headache + + + + + + + + + respiratory system and chest symptom + + + + + + + + + expectoration of blood + expectoration of blood-stained sputum + haemoptysis + hemoptysis + haemoptysis + coughing up of blood + + + + + + + + + cardiovascular system symptom + + + + + + + + + tachycardia + + + + + + + + + edema + dropsy + + + + + + + + + disturbances of sensation of smell and taste + + + + + + + + + general symptom + + + + + + + + + diarrhoea + fecal incontinence + incontinence of feces + loose bowel + loose bowels + the runs + diarrhea + diarrhoea + bacterial gastroenteritis + + + + + + + + + chest pain + + + + + + + + + head and neck symptom + + + + + + + + + respiratory abnormality + + + + + + + + + tachypnea + + + + + + + + + fever + + + + + + + + + cough + + + + + + + + + leukocytosis + + + + + + + + + plummeting blood pressure + low blood pressure + + + + + + + + + multiorgan dysfunction + multiple organ failure + + + + + + + + + brain attack + cerebral accident + cerebrovascular accident + stroke + apoplexy + + + + + + + + + VT + ventricular tachycardia + V-tach + + + + + + + + + sensation perception + + + + + + + + + cardiac fibrillation + + + + + + + + + ventricular fibrillation + v-fib + + + + + + + + + hemic and immune system symptom + + + + + + + + + immune system symptom + + + + + + + + + hemic system symptom + + + + + + + + + muscle ache + muscle pain + + + + + + + + + eye symptom + + + + + + + + + chills + rigors + + + + + + + + + malaise + + + + + + + + + fatigue + + + + + + + + + direct + + + + + + + + + direct contact + contact + + + + + + + + + Droplet transmission + droplet spread + + + + + + + + + infiltration of inflammatory cells + inflammatory cell infiltration + + + + + + + + + organ of sensory organ system + organ of sensory system + sense organ system organ + sensory organ + sensory organ system organ + sensory system organ + sense organ + organ of sense organ system + + + + + + + + + breathing organ + organ of apparatus respiratorius + organ of respiratory system + respiratory organ + respiratory system organ + respiration organ + apparatus respiratorius organ + + + + + + + + + cavitated compound organ + cavitated organ + + + + + + + + + mucus + + + + + + + + + brain + + + + + + + + + eye + + + + + + + + + liver + + + + + + + + + olfactory sense organ + olfactory sensory organ + olfactory organ + olfactory organ + + + + + + + + + glandula endocrina + endocrine gland + ductless gland + + + + + + + + + abdomen element + abdomen organ + + + + + + + + + abdominal segment element + abdominal segment organ + + + + + + + + + alveolar system + pulmonary alveolar system + + + + + + + + + digestive system gland + + + + + + + + + digestive system organ + digestive system element + digestive organ + + + + + + + + + white phlegm + phlegm + + + + + + + + + renin-angiotensin system + + + + + + + + + CD3-positive T-lymphocyte count + + + + + + + + + A1a haplotype + + + + + + + + + A2a1 haplotype + + + + + + + + + A2a2 haplotype + + + + + + + + + A2a2a haplotype + + + + + + + + + A2a3 haplotype + + + + + + + + + A2a3a haplotype + + + + + + + + + A2a haplotype + + + + + + + + + B1a1 haplotype + + + + + + + + + B1a haplotype + + + + + + + + + BEL-based approach + BEL based model + + + + + + + + + C-19 COVID symptom tracker + + + + + + + + + CD16+CD56+ + CD16 positive CD56 positive lymphocyte + + + + + + + + + Suppression of COVID-19 + COVID-19 suppression + + + + + + + + + drive-thru testing + + + + + + + + + N95 respirator + + + + + + + + + ORF3b + + + + + + + + + ORF7 + + + + + + + + + ORF8a + + + + + + + + + ORF8b + + + + + + + + + ORF9c + + + + + + + + + RNA genome + RNA viral genome + + + + + + + + + RNAaemia + + + + + + + + + SARS-CoV-1 model + + + + + + + + + SARS-CoV-2 model + + + + + + + + + SARS coronavirus genome + SARS-CoV genome + + + + + + + + + ShuFengJieDu + + + + + + + + + Wuhan + + + + + + + + + abnormal respiratory finding + + + + + + + + + Brain Injuries + acute brain injury + + + + + + + + + acute cardiac injury + + + + + + + + + air bronchogram + + + + + + + + + alpha-ketoamide inhibitor + + + + + + + + + alveolar damage + + + + + + + + + alveolar exudate + + + + + + + + + SARS-CoV-2-human protein-protein interactions + analysis of SARS-CoV-2 host interacting proteins + + + + + + + + + apex + + + + + + + + + apicidin + + + + + + + + + azvudine + + + + + + + + + bilateral involvement + + + + + + + + + bipartite viral genome + + + + + + + + + carriomycin + + + + + + + + + cell-substrate adherens junction + + + + + + + + + Chemiluminescence immunoassay + chemiluminescence-linked immunosorbent assay + + + + + + + + + clinical sign + + + + + + + + + cluster of COVID-19 + + + + + + + + + common CT finding + common computed tomography pattern + + + + + + + + + Phylogenetic analysis + computational phylogenetic analysis + + + + + + + + + convalescent plasma + + + + + + + + + cough etiquette + + + + + + + + + coughing by symptomatic patient + + + + + + + + + cytokine dysregulation + + + + + + + + + cytoplasmic budding + + + + + + + + + cytosolic part + + + + + + + + + danoprevir + + + + + + + + + degeneration of the alveolar epithelia + + + + + + + + + desoxyrhaponticin + + + + + + + + + early symptom + + + + + + + + + emergency warning sign + + + + + + + + + End Organ Damage + end-organ dysfunction + + + + + + + + + enrichment for domain families within the interacting proteins + + + + + + + + + enzaplatovir + + + + + + + + + enzyme level signalling struggling liver + + + + + + + + + ferroquine + + + + + + + + + D-dimer + fibrin fragment D + + + + + + + + + Flattening the curve + flatten the curve + + + + + + + + + fluid management + + + + + + + + + frequently washing hands with soap and water for 20 seconds + + + + + + + + + fulminant myocarditis + + + + + + + + + Gamma-glutamyltransferases + gamma-glutamyltransferase + + + + + + + + + GO enrichment analysis + gene ontology enrichment analysis + + + + + + + + + gold immunochromatographic assay + + + + + + + + + haplotype of Severe acute respiratory syndrome coronavirus 2 infection + + + + + + + + + high-flow nasal cannula oxygenation + + + + + + + + + higher sequential organ failure assessment score + + + + + + + + + inhalation of droplets + + + + + + + + + edema, interstitial + interstitial edema + + + + + + + + + fibrosis, interstitial + interstitial fibrosis + + + + + + + + + jakotinib hydrochloride + + + + + + + + + lack of personnel + + + + + + + + + lianhuaqingwen + + + + + + + + + local transmission + + + + + + + + + low-flow nasal cannula oxygenation + + + + + + + + + lumen stenosis + + + + + + + + + Clinical Aspects + medical aspect + + + + + + + + + meplazumab + + + + + + + + + mild symptom + + + + + + + + + mobile application + + + + + + + + + non-segmented viral genome + + + + + + + + + community mitigation strategies. + nonpharmaceutical Intervention + + + + + + + + + nonstructural protein + + + + + + + + + nose nerve ending cell damage + + + + + + + + + not touching face + + + + + + + + + nsp7-nsp8 heterodimer + nsp7 and nsp8 primase complex + + + + + + + + + Online Survey + online-interview + + + + + + + + + openEHR-Suspected Covid-19 assessment.v0 + + + + + + + + + outbreak + + + + + + + + + oxygen uptake diminishment + + + + + + + + + patchy consolidation + + + + + + + + + peripheral distribution + + + + + + + + + human-to-human viral transmission + person-to-person transmission + + + + + + + + + Confirmed positive case + positive COVID-19 test + + + + + + + + + positive-stranded RNA virus + positive sense viral genome + + + + + + + + + post natal transmission + + + + + + + + + posterior distribution + + + + + + + + + preprocalcitonin + + + + + + + + + presumptive positive COVID-19 test result + + + + + + + + + proelastase + + + + + + + + + RDT + Rapid diagnostic test + Rapid test + quick test + + + + + + + + + sanglifehrin A + + + + + + + + + secondary bacterial infection + + + + + + + + + self-assessment application + + + + + + + + + Self-Monitoring + self-observation + + + + + + + + + 2019-nCoV + SARS-CoV-2 + severe acute respiratory syndrome coronavirus 2 + + + + + + + + + severe symptom + + + + + + + + + Lockdown + shelter-in-place order + + + + + + + + + sneeze etiquette + + + + + + + + + sneezing by symptomatic patient + + + + + + + + + Physical Distancing + social distancing + + + + + + + + + ssRNA viral genome + + + + + + + + + super-spreader + + + + + + + + + ternatin 4 + + + + + + + + + thick pulmonary interalveolar septum + thickened alveolar septum + + + + + + + + + touching contaminated surfaces + + + + + + + + + touching eyes + + + + + + + + + touching mouth + + + + + + + + + touching nose + + + + + + + + + Asymptomatic transmission + transmission from asymptomatic people + + + + + + + + + Transmission Cycle of SARS CoV 2 + transmission of virus + + + + + + + + + transmission to healthcare workers + + + + + + + + + Travel ban + travel restriction + + + + + + + + + triazavirin + + + + + + + + + congested blood vessels of alveolar septum + vascular congestion + + + + + + + + + viral transmission by vector + + + + + + + + + virus contact + + + + + + + + + virus elimination + + + + + + + + + virus excretion + + + + + + + + + zoonotic viral transmission + + + + + + + + + zotatifin + + + + + + + + + TDZD-8 + 4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione' + + + + + + + + + N-terminal domain (SARS-CoV-2) + + + + + + + + + CD8+ T cell exhaustion + exhaustion of CD8+ T cell + + + + + + + + + fusion peptide (SARS-CoV-2) + + + + + + + + + heptad repeat 1 (SARS-CoV-2) + + + + + + + + + heptad repeat 2 (SARS-CoV-2) + + + + + + + + + receptor-binding domain (SARS-CoV-2) + + + + + + + + + signal peptide (SARS-CoV-2) + + + + + + + + WHO COVID CRF RAPID ontology concepts + + + + + + + + + A history of self-reported feverishness or measured fever of ≥ 38 degrees Celsius + + + + + + + + + Ability to self-care at discharge versus before illness + + + + + + + + + ACE Inhibitor + + + + + + + + + Acute renal injury + + + + + + + + + Admission date at this facility + + + + + + + + + Admission form + + + + + + + + + Age + + + + + + + + + Alert Verbal Painful Unresponsive Scale Clinical Classification + + + + + + + + + Altered consciousness/confusion + + + + + + + + + Anaemia + + + + + + + + + Anemia + + + + + + + + + Angiotensin converting enzyme inhibitors (ACE inhibitors) + + + + + + + + + Angiotensin II receptor blockers (ARBs) + + + + + + + + + Antifungal agent + + + + + + + + + Antimalarial agent + + + + + + + + + Antiviral list + + + + + + + + + Arthralgia + + + + + + + + + Ashtma + + + + + + + + + Asplenia + + + + + + + + + AVPU list + + + + + + + + + AVPU scale + + + + + + + + + Bacteraemia + + + + + + + + + Bacteremia + + + + + + + + + Bleeding + + + + + + + + + Bleeding (Haemorrhage) + + + + + + + + + Body Weight + + + + + + + + + BP (diastolic) + + + + + + + + + BP (systolic) + + + + + + + + + Bronchiolitis + + + + + + + + + Chest X-Ray /CT performed + + + + + + + + + chronic heart disease + + + + + + + + + Chronic liver disease + + + + + + + + + Chronic nervous system disorder + + + + + + + + + Clinical inclusion criteria + + + + + + + + + Clinical or Research Assessment Questionnaire + + + + + + + + + Clinical suspicion of ARI despite not meeting criteria above + + + + + + + + + Co-morbidities + + + + + + + + + Complication + + + + + + + + + Complications + + + + + + + + + Confusion + + + + + + + + + Coronavirus list + + + + + + + + + Corticosteroid + + + + + + + + + Corticosteroid list + + + + + + + + + Cough with haemoptysis + + + + + + + + + Cough with sputum + + + + + + + + + Curent Smoker + + + + + + + + + Current smoking + + + + + + + + + Daily clinical features + + + + + + + + + Date of Birth + + + + + + + + + Date of enrolment + + + + + + + + + Date of follow up + + + + + + + + + Date of onset and admission vital signs + + + + + + + + + Date question + + + + + + + + + datum label + + + + + + + + + Decreased liver function + + + + + + + + + Demographics + + + + + + + + + diabetes + + + + + + + + + Diagnostic/pathogen testing + + + + + + + + + Diastolic Blood Pressure + + + + + + + + + Discharge/death form + + + + + + + + + duration in days + + + + + + + + + duration in weeks + + + + + + + + + Dyspnea + + + + + + + + + Endocarditis + + + + + + + + + Experimental agent + + + + + + + + + Extracorporeal (ECMO) support + + + + + + + + + Falciparum malaria + + + + + + + + + Fatigue/Malaise + + + + + + + + + Follow-up + + + + + + + + + Gestational weeks assessment + + + + + + + + + Glasgow Coma Score (GCS /15) + + + + + + + + + Have other symptoms + + + + + + + + + Healthcare worker + + + + + + + + + Height + + + + + + + + + History of fever + + + + + + + + + HIV + + + + + + + + + HIV list + + + + + + + + + ICU or High Dependency Unit admission + + + + + + + + + if yes list + + + + + + + + + If yes specify + + + + + + + + + Inability to walk + + + + + + + + + Indrawing of ribs during respiration + + + + + + + + + Infiltrates present + + + + + + + + + Influenza virus + + + + + + + + + Influenza virus type + + + + + + + + + Inotropes/vasopressors + + + + + + + + + Interface + + + + + + + + + Intravenous fluids + + + + + + + + + Invasive ventilation + + + + + + + + + Joint pain (arthralgia) + + + + + + + + + Laboratory question + + + + + + + + + Laboratory results + + + + + + + + + Laboratory Worker + + + + + + + + + length unit + + + + + + + + + List question + + + + + + + + + Liver dysfunction + + + + + + + + + Lower chest wall indrawing + + + + + + + + + Lymphadenopathy + + + + + + + + + Malnutrition + + + + + + + + + Maximum daily corticosteroid dose + + + + + + + + + Medication + + + + + + + + + Meningitis + + + + + + + + + Meningitis/Encephalitis + + + + + + + + + Mid-upper arm circumference + + + + + + + + + Modified glasgow coma score + + + + + + + + + Muscle aches (myalgia) + + + + + + + + + Myalgia + + + + + + + + + Myocarditis/Pericarditis + + + + + + + + + Non-falciparum malaria + + + + + + + + + Non-invasive ventilation + + + + + + + + + Non-steroidal anti-inflammatory (NSAID) + + + + + + + + + Nonsteroidal Antiinflammatory Drug + + + + + + + + + Number question + + + + + + + + + O2 flow + + + + + + + + + Oral/orogastric fluids + + + + + + + + + Other complication + + + + + + + + + Other corona virus + + + + + + + + + Other respiratory pathogen + + + + + + + + + Other Risk Factor + + + + + + + + + Other signs or symptoms + + + + + + + + + Outcome + + + + + + + + + Outcome date + + + + + + + + + Outcome list + + + + + + + + + Outcome saturation list + + + + + + + + + Oxygen interface + + + + + + + + + Oxygen Saturation Measurement + + + + + + + + + Pancreatitis + + + + + + + + + Pericarditis + + + + + + + + + Pre-admission & chronic medication + + + + + + + + + Pregnant + + + + + + + + + Productive cough + + + + + + + + + Prone position + + + + + + + + + Proven or suspected infection with pathogen of Public Health Interest + + + + + + + + + Question + + + + + + + + + Question about ALT/SGPT measurement + + + + + + + + + Question about APTT/APTR measurement + + + + + + + + + Question about AST/SGOT measurement + + + + + + + + + Question about Creatine kinase measurement + + + + + + + + + Question about Creatinine measurement + + + + + + + + + Question about CRP measurement + + + + + + + + + Question about D-dimer measurement + + + + + + + + + Question about ESR measurement + + + + + + + + + Question about Ferritin measurement + + + + + + + + + Question about gestational weeks assessment + + + + + + + + + Question about Haematocrit measurement + + + + + + + + + Question about Haemoglobin measurement + + + + + + + + + Question about IL-6 measurement + + + + + + + + + Question about INR measurement + + + + + + + + + Question about Lactate measurement + + + + + + + + + Question about LDH measurement + + + + + + + + + Question about Platelets measurement + + + + + + + + + Question about Potassium measurement + + + + + + + + + Question about presence of Ashtma + + + + + + + + + Question about presence of Asplenia + + + + + + + + + Question about presence of Chronic cardiac disease (not hypertension) + + + + + + + + + Question about presence of Chronic kidney disease + + + + + + + + + Question about presence of Chronic liver disease + + + + + + + + + Question about presence of Chronic neurological disorder + + + + + + + + + Question about presence of Chronic pulmonary disease + + + + + + + + + Question about presence of cough + + + + + + + + + Question about presence of Diabetes + + + + + + + + + Question about presence of dyspnoea (shortness of breath) OR Tachypnoea + + + + + + + + + Question about presence of HIV + + + + + + + + + Question about presence of Hypertension + + + + + + + + + Question about presence of Malignant neoplasm + + + + + + + + + Question about presence of Other co-morbidities + + + + + + + + + Question about presence of Tuberculosis + + + + + + + + + Question about Procalcitonin measurement + + + + + + + + + Question about PT measurement + + + + + + + + + Question about Sodium measurement + + + + + + + + + Question about Total bilirubin measurement + + + + + + + + + Question about Troponin measurement + + + + + + + + + Question about Urea (BUN) measurement + + + + + + + + + Question about WBC count measurement + + + + + + + + + Questionnaire Subsection + + + + + + + + + Renal replacement therapy (RRT) or dialysis + + + + + + + + + Runny nose (rhinorrhoea) + + + + + + + + + Seizures + + + + + + + + + Severe dehydration + + + + + + + + + Sex at birth + + + + + + + + + sex at birth list + + + + + + + + + Signs and symptoms on admission + + + + + + + + + Site name + + + + + + + + + Site of the bleeding + + + + + + + + + Skin rash + + + + + + + + + Skin ulcers + + + + + + + + + Source of oxygen + + + + + + + + + specific response + + + + + + + + + Sternal capillary refill time >2seconds + + + + + + + + + Sternal capillary refill time >2seconds' + + + + + + + + + Symptom onset (date of first/earliest symptom) + + + + + + + + + Symptom Onset Date + + + + + + + + + Temperature + + + + + + + + + time unit + + + + + + + + + Tuberculosis + + + + + + + + + Viral haemorrhagic fever + + + + + + + + + Vomiting/Nausea + + + + + + + + + Was pathogen testing done during this illness episode + + + + + + + + + Weight + + + + + + + + + Wheezing + + + + + + + + + Which antifungal agent + + + + + + + + + Which antimalarial agent + + + + + + + + + Which antiviral + + + + + + + + + Which complication + + + + + + + + + Which coronavirus + + + + + + + + + Which corticosteroid route + + + + + + + + + Which experimental agent + + + + + + + + + Which NSAID + + + + + + + + + Which other antiviral + + + + + + + + + Which other pathogen + + + + + + + + + Which respiratory pathogen + + + + + + + + + Which sign or symptom + + + + + + + + + Which virus + + + + + + + + + WHO-COVID-19-Rapid-CRF + + + + + + + + + Concentrator + + + + + + + + + Cylinder + + + + + + + + + HF nasal cannula + + + + + + + + + Inhaled + + + + + + + + + Intravenous + + + + + + + + + Mask with reservoir + + + + + + + + + Nasal prongs + + + + + + + + + Piped + + + + + + + + + Ribavirin + + + + + + + + + Transfer to other facility + + + + + + + + + Yes-not on ART + + + + + + + + + Yes-on ART + + + + + + + + + >15 L/min + + + + + + + + + Room air + + + + + + + + + 1-5 L/min + + + + + + + + + 11-15 L/min + + + + + + + + + 6-10 L/min + + + + + + + + + CPAP/NIV mask + + + + + + + + + Discharged alive + + + + + + + + + Palliative discharge + + + + + + + + + Same as before illness + + + + + + + + + Better + + + + + + + + + Unknown + + + + + + + + + N/A + + + + + + + + + Oral + + + + + + + + + mm + + + + + + + + + kg + + + + + + + + + Not Specified + + + + + + + + + Degree Celsius + + + + + + + + + Male + + + + + + + + + Female + + + + + + + + + No + + + + + + + + + Yes + + + + + + + + + cm + + + + + + + + + mmHg + + + + + + + + + beats/min + + + + + + + + + breaths/min + + + + + + + + + Hospitalized + + + + + + + + + MERS-CoV + + + + + + + + + Negative + + + + + + + + + Not done + + + + + + + + + Positive + + + + + + + + + Worse + + + + + + + + + unknown unit + + + + + + + + + g/L + + + + + + + + + mmol/L + + + + + + + + + pg/mL + + + + + + + + + mm/hr + + + + + + + + + mg/L + + + + + + + + + μmol/L + + + + + + + + + x10 9/L + + + + + + + + + ng/mL + + + + + + + + + seconds + + + + + + + + + mEq/L + + + + + + + + + U/L + + + + + + + + + Alert + + + + + + + + + Unresponsive + + + + + + + + + Verbal + + + + + + + + COVID-19 SURVEILLANCE ontology concepts + + + + + + + + + exposure to COVID-19 + + + + + + + + + Tested for 2019-nCoV (Wuhan) infection + + + + + + + + + exposure to Wuhan 2019-nCoV (novel coronavirus) infection + + + + + + + + + 2019-nCoV (novel coronavirus) serology + + + + + + + + + serotype 2019-nCoV (novel coronavirus) + + + + + + + + + close exposure to 2019-nCoV (novel coronavirus) infection + + + + + + + + + exposure to coronavirus infection (Non specific) + + + + + + + + + definite COVID-19 + + + + + + + + + 2019-nCoV (novel coronavirus) detected + + + + + + + + + possible COVID-19 + + + + + + + + + Suspected disease caused by 2019-nCoV (novel coronavirus) + + + + + + + + + antibody to 2019-nCoV (novel coronavirus) + + + + + + + + + not detected COVID-19 + + + + + + + + + 2019-nCoV (novel coronavirus) not detected + + + + + + + + + investigation COVID-19 + + + + + + + + + Detection of 2019-nCoV (novel coronavirus) using polymerase chain reaction technique + + + + + + + + + Measurement of 2019-nCoV (novel coronavirus) antibody + + + + + + + + + Measurement of 2019-nCoV (novel coronavirus) antigen + + + + + + + + + antigen of 2019-nCoV (novel coronavirus) + + + + + + + + + ribonucleic acid of 2019-nCoV (novel coronavirus) + + + + + + + + + throat swab taken + + + + + + + + + nasal swab taken + + + + + + + + + throat swab culture positive + + + + + + + + + throat swab culture negative + + + + + + + + + nose swab culture positive + + + + + + + + + nose swab culture negative + + + + + + + + + education for COVID-19 + + + + + + + + + advice given about 2019-nCoV (novel coronavirus) by telephone + + + + + + + + + advice given about 2019-nCoV (novel coronavirus) infection + + + + + + + + + educated about 2019-nCoV (novel coronavirus) infection + + + + + + + + + education about cross infection prevention + + + + + + + + + education about isolation for infection control + + + + + + + + + isolation due to COVID-19 symptoms + + + + + + + + + Isolation of infection contact + + + + + + + + + Isolation of infection carrier + + + + + + + + + Surveillance of contact + + + + + + + + + Under care of contact tracing nurse + + + + + + + + + Seen by contact tracing nurse + + + + + + + + + Referral by contact tracing nurse + + + + + + + + + Referral to contact tracing nurse + + + + + + + + + Discharge by contact tracing nurse + + + + + + + + + Isolation of infected patient + + + + + + + + + Monitoring for signs and symptoms of infection + + + + + + + + + Isolation nursing in negative pressure isolation environment + + + + + + + + + Management of isolation for infection control + + + + + + + + + Prospective focused infection control surveillance + + + + + + + + + Absence of signs and symptoms of infection + + + + + + + + + Free of symptoms + + + + + + + + + Need for isolation and other prophylactic measures + + + + + + + + + Telephone consultation for suspected 2019-nCoV (novel coronavirus) + + + + + + + + CODO ontology concepts + + + + + + + + + Covid Testing Facility + + + + + + + + + Medical clinic + + + + + + + + + Clinical finding (finding) + + + + + + + + + Disease caused by 2019 novel coronavirus + + + + + + + + + COVID-19 dedicated facility + + + + + + + + + Close contact + + + + + + + + + Country wise statistics + + + + + + + + + Covid Care Centre (CCC) + + + + + + + + + Dedicated Covid Health Centre (DCHC) + + + + + + + + + Dedicated Covid Hospital (DCH) + + + + + + + + + Diagnosed With Covid + + + + + + + + + Disease caused by Coronaviridae + + + + + + + + + District + + + + + + + + + District wise statistics + + + + + + + + + Doctor + + + + + + + + + Gathering + + + + + + + + + Laboratory test finding + + + + + + + + + Mild and very mild COVID-19 + + + + + + + + + Moderate COVID-19 + + + + + + + + + Nurse + + + + + + + + + Severe COVID-19 + + + + + + + + + State wise statistics + + + + + + + + + Statistics + + + + + + + + + Test result + + + + + + + + + Untested for Covid + + + + + + + + + Vital signs + + + + + + + + + Woman + + + + + + + + + Agent + + + + + + + + + Person + + + + + + + + + Country + + + + + + + + + Gender type + + + + + + + + + Patient + + + + + + + + + Place + + + + + + + + + State + + + + + + + + + Generalized aches and pains (finding) + + + + + + + + + Hacking cough + + + + + + + + + Infected co-passenger + + + + + + + + + Infected family member + + + + + + + + + Nasal congestion + + + + + + + + + Pain in throat + + + + + + + + + Nasal discharge presen + + + + + + + + + Severe Pneumonia + + + + + + + + + Sneezing + + + + + + + + + Feeling tired + + + + + + + + + URTI + + + + + + + + + covid-19 + + + + + + + + ACT COVID-19 ontology concepts + + + + + + + + + {28 (ribavirin 200 mg oral tablet [moderiba]) / 28 (ribavirin 400 mg oral tablet [moderiba]) } pack [moderiba 600 dose pack] + + + + + + + + + {28 (ribavirin 200 mg oral tablet [ribasphere]) / 28 (ribavirin 400 mg oral tablet [ribasphere]) } pack [ribasphere ribapak 600] + + + + + + + + + {28 (ribavirin 200 mg oral tablet) / 28 (ribavirin 400 mg oral tablet) } pack + + + + + + + + + {28 (ribavirin 400 mg oral tablet [moderiba]) / 28 (ribavirin 600 mg oral tablet [moderiba]) } pack [moderiba 1000 dose pack] + + + + + + + + + {28 (ribavirin 400 mg oral tablet [ribasphere]) / 28 (ribavirin 600 mg oral tablet [ribasphere]) } pack [ribasphere ribapak 1000] + + + + + + + + + {28 (ribavirin 400 mg oral tablet [ribatab]) / 28 (ribavirin 600 mg oral tablet [ribatab]) } pack [ribatab 1000 mg/day compliance pack] + + + + + + + + + {28 (ribavirin 400 mg oral tablet) / 28 (ribavirin 600 mg oral tablet) } pack + + + + + + + + + {3 (azithromycin 500 mg oral tablet [zithromax]) } pack [tri-pak] + + + + + + + + + {3 (azithromycin 500 mg oral tablet) } pack + + + + + + + + + {30 (aspirin 325 mg oral tablet) / 30 (pravastatin sodium 80 mg oral tablet) } pack + + + + + + + + + {30 (aspirin 81 mg oral tablet) / 30 (pravastatin sodium 40 mg oral tablet) } pack + + + + + + + + + {42 (rivaroxaban 15 mg oral tablet [xarelto]) / 9 (rivaroxaban 20 mg oral tablet [xarelto]) } pack [xarelto kit] + + + + + + + + + {42 (rivaroxaban 15 mg oral tablet) / 9 (rivaroxaban 20 mg oral tablet) } pack + + + + + + + + + {56 (ribavirin 400 mg oral tablet [moderiba]) } pack [moderiba 800 dose pack] + + + + + + + + + {56 (ribavirin 400 mg oral tablet [ribasphere]) } pack [ribasphere ribapak 800] + + + + + + + + + {56 (ribavirin 400 mg oral tablet [ribatab]) } pack [ribatab compliance pack] + + + + + + + + + {56 (ribavirin 400 mg oral tablet) } pack + + + + + + + + + {56 (ribavirin 600 mg oral tablet [moderiba]) } pack [moderiba 1200 dose pack] + + + + + + + + + {56 (ribavirin 600 mg oral tablet [ribasphere]) } pack [ribasphere ribapak 1200] + + + + + + + + + {56 (ribavirin 600 mg oral tablet) } pack + + + + + + + + + {6 (azithromycin 250 mg oral tablet [zithromax]) } pack [z-pak] + + + + + + + + + {6 (azithromycin 250 mg oral tablet) } pack + + + + + + + + + {6 (azithromycin 500 mg oral tablet) } pack + + + + + + + + + {74 (apixaban 5 mg oral tablet [eliquis]) } pack [eliquis 30-day starter pack] + + + + + + + + + {74 (apixaban 5 mg oral tablet) } pack + + + + + + + + + 0.2 ml bemiparin sodium 12500 unt/ml prefilled syringe + + + + + + + + + 0.2 ml bemiparin sodium 17500 unt/ml prefilled syringe + + + + + + + + + 0.2 ml bemiparin sodium 25000 unt/ml prefilled syringe + + + + + + + + + 0.2 ml dalteparin sodium 12500 unt/ml prefilled syringe [fragmin] + + + + + + + + + 0.2 ml dalteparin sodium 12500 unt/ml prefilled syringe + + + + + + + + + 0.2 ml dalteparin sodium 25000 unt/ml prefilled syringe [fragmin] + + + + + + + + + 0.2 ml dalteparin sodium 25000 unt/ml prefilled syringe + + + + + + + + + 0.2 ml enoxaparin sodium 100 mg/ml prefilled syringe + + + + + + + + + 0.2 ml heparin calcium 25000 unt/ml prefilled syringe + + + + + + + + + 0.25 ml reviparin sodium 5730 unt/ml prefilled syringe + + + + + + + + + 0.25 ml tinzaparin sodium 10000 unt/ml prefilled syringe + + + + + + + + + 0.3 ml bemiparin sodium 22500 unt/ml prefilled syringe + + + + + + + + + 0.3 ml dalteparin sodium 25000 unt/ml prefilled syringe [fragmin] + + + + + + + + + 0.3 ml dalteparin sodium 25000 unt/ml prefilled syringe + + + + + + + + + 0.3 ml enoxaparin sodium 100 mg/ml prefilled syringe [lovenox] + + + + + + + + + 0.3 ml enoxaparin sodium 100 mg/ml prefilled syringe + + + + + + + + + 0.3 ml epinephrine 1 mg/ml prefilled syringe [symjepi] + + + + + + + + + 0.3 ml epinephrine 1 mg/ml prefilled syringe + + + + + + + + + 0.35 ml tinzaparin sodium 10000 unt/ml prefilled syringe + + + + + + + + + 0.4 ml bemiparin sodium 40000 unt/ml prefilled syringe + + + + + + + + + 0.4 ml dalteparin sodium 25000 unt/ml prefilled syringe [fragmin] + + + + + + + + + 0.4 ml dalteparin sodium 25000 unt/ml prefilled syringe + + + + + + + + + 0.4 ml enoxaparin sodium 100 mg/ml prefilled syringe [lovenox] + + + + + + + + + 0.4 ml enoxaparin sodium 100 mg/ml prefilled syringe + + + + + + + + + 0.4 ml fondaparinux sodium 12.5 mg/ml prefilled syringe [arixtra] + + + + + + + + + 0.4 ml fondaparinux sodium 12.5 mg/ml prefilled syringe + + + + + + + + + 0.45 ml tinzaparin sodium 10000 unt/ml prefilled syringe + + + + + + + + + 0.5 ml dalteparin sodium 25000 unt/ml prefilled syringe [fragmin] + + + + + + + + + 0.5 ml dalteparin sodium 25000 unt/ml prefilled syringe + + + + + + + + + 0.5 ml fondaparinux sodium 5 mg/ml prefilled syringe [arixtra] + + + + + + + + + 0.5 ml fondaparinux sodium 5 mg/ml prefilled syringe + + + + + + + + + 0.5 ml heparin calcium 25000 unt/ml prefilled syringe + + + + + + + + + 0.5 ml heparin sodium + + + + + + + + + 0.5 ml peginterferon alfa-2a 0.27 mg/ml auto-injector [pegasys] + + + + + + + + + 0.5 ml peginterferon alfa-2a 0.27 mg/ml auto-injector + + + + + + + + + 0.5 ml peginterferon alfa-2a 0.27 mg/ml prefilled syringe + + + + + + + + + 0.5 ml peginterferon alfa-2a 0.36 mg/ml auto-injector [pegasys] + + + + + + + + + 0.5 ml peginterferon alfa-2a 0.36 mg/ml auto-injector + + + + + + + + + 0.5 ml peginterferon alfa-2a 0.36 mg/ml prefilled syringe [pegasys] + + + + + + + + + 0.5 ml peginterferon alfa-2a 0.36 mg/ml prefilled syringe + + + + + + + + + 0.5 ml tinzaparin sodium 20000 unt/ml prefilled syringe + + + + + + + + + 0.6 ml dalteparin sodium 25000 unt/ml prefilled syringe [fragmin] + + + + + + + + + 0.6 ml dalteparin sodium 25000 unt/ml prefilled syringe + + + + + + + + + 0.6 ml enoxaparin sodium 100 mg/ml prefilled syringe [lovenox] + + + + + + + + + 0.6 ml enoxaparin sodium 100 mg/ml prefilled syringe + + + + + + + + + 0.6 ml fondaparinux sodium 12.5 mg/ml prefilled syringe [arixtra] + + + + + + + + + 0.6 ml fondaparinux sodium 12.5 mg/ml prefilled syringe + + + + + + + + + 0.67 ml anakinra 149 mg/ml prefilled syringe [kineret] + + + + + + + + + 0.67 ml anakinra 149 mg/ml prefilled syringe + + + + + + + + + 0.7 ml tinzaparin sodium 20000 unt/ml prefilled syringe + + + + + + + + + 0.72 ml dalteparin sodium 25000 unt/ml prefilled syringe [fragmin] + + + + + + + + + 0.72 ml dalteparin sodium 25000 unt/ml prefilled syringe + + + + + + + + + 0.8 ml enoxaparin sodium 100 mg/ml prefilled syringe [lovenox] + + + + + + + + + 0.8 ml enoxaparin sodium 100 mg/ml prefilled syringe + + + + + + + + + 0.8 ml enoxaparin sodium 150 mg/ml prefilled syringe [lovenox] + + + + + + + + + 0.8 ml enoxaparin sodium 150 mg/ml prefilled syringe + + + + + + + + + 0.8 ml fondaparinux sodium 12.5 mg/ml prefilled syringe [arixtra] + + + + + + + + + 0.8 ml fondaparinux sodium 12.5 mg/ml prefilled syringe + + + + + + + + + 0.9 ml tinzaparin sodium 20000 unt/ml prefilled syringe + + + + + + + + + 0.9 ml tocilizumab 180 mg/ml prefilled syringe [actemra] + + + + + + + + + 0.9 ml tocilizumab 180 mg/ml prefilled syringe + + + + + + + + + 1 ml angiotensin ii 2.5 mg/ml injection [giapreza] + + + + + + + + + 1 ml angiotensin ii 2.5 mg/ml injection + + + + + + + + + 1 ml dalteparin sodium 10000 unt/ml prefilled syringe [fragmin] + + + + + + + + + 1 ml dalteparin sodium 10000 unt/ml prefilled syringe + + + + + + + + + 1 ml diclofenac sodium 37.5 mg/ml injection [dyloject] + + + + + + + + + 1 ml diclofenac sodium 37.5 mg/ml injection + + + + + + + + + 1 ml enoxaparin sodium 100 mg/ml prefilled syringe [lovenox] + + + + + + + + + 1 ml enoxaparin sodium 100 mg/ml prefilled syringe + + + + + + + + + 1 ml enoxaparin sodium 150 mg/ml prefilled syringe [lovenox] + + + + + + + + + 1 ml enoxaparin sodium 150 mg/ml prefilled syringe + + + + + + + + + 1 ml epinephrine 1 mg/ml injection [adrenalin] + + + + + + + + + 1 ml epinephrine 1 mg/ml injection + + + + + + + + + 1 ml heparin sodium + + + + + + + + + 1 ml ketorolac tromethamine 15 mg/ml cartridge + + + + + + + + + 1 ml ketorolac tromethamine 15 mg/ml injection + + + + + + + + + 1 ml ketorolac tromethamine 15 mg/ml prefilled syringe + + + + + + + + + 1 ml ketorolac tromethamine 30 mg/ml cartridge + + + + + + + + + 1 ml ketorolac tromethamine 30 mg/ml injection + + + + + + + + + 1 ml ketorolac tromethamine 30 mg/ml prefilled syringe + + + + + + + + + 1 ml midazolam 5 mg/ml cartridge + + + + + + + + + 1 ml midazolam 5 mg/ml injection + + + + + + + + + 1 ml midazolam 5 mg/ml prefilled syringe + + + + + + + + + 1 ml peginterferon alfa-2a 0.18 mg/ml injection [pegasys] + + + + + + + + + 1 ml peginterferon alfa-2a 0.18 mg/ml injection + + + + + + + + + 1 ml phenylephrine hydrochloride 10 mg/ml injection [neo-synephrine] + + + + + + + + + 1 ml phenylephrine hydrochloride 10 mg/ml injection [vazculep] + + + + + + + + + 1 ml phenylephrine hydrochloride 10 mg/ml injection + + + + + + + + + 1.14 ml sarilumab 132 mg/ml auto-injector [kevzara] + + + + + + + + + 1.14 ml sarilumab 132 mg/ml auto-injector + + + + + + + + + 1.14 ml sarilumab 132 mg/ml prefilled syringe [kevzara] + + + + + + + + + 1.14 ml sarilumab 132 mg/ml prefilled syringe + + + + + + + + + 1.14 ml sarilumab 175 mg/ml auto-injector [kevzara] + + + + + + + + + 1.14 ml sarilumab 175 mg/ml auto-injector + + + + + + + + + 1.14 ml sarilumab 175 mg/ml prefilled syringe [kevzara] + + + + + + + + + 1.14 ml sarilumab 175 mg/ml prefilled syringe + + + + + + + + + 10 ml dipyridamole 5 mg/ml injection + + + + + + + + + 10 ml dopamine hydrochloride 40 mg/ml injection + + + + + + + + + 10 ml dopamine hydrochloride 40 mg/ml prefilled syringe + + + + + + + + + 10 ml dopamine hydrochloride 80 mg/ml injection + + + + + + + + + 10 ml epinephrine 0.1 mg/ml prefilled syringe + + + + + + + + + 10 ml eptifibatide 2 mg/ml injection [integrilin] + + + + + + + + + 10 ml eptifibatide 2 mg/ml injection + + + + + + + + + 10 ml furosemide 10 mg/ml injection + + + + + + + + + 10 ml furosemide 10 mg/ml prefilled syringe + + + + + + + + + 10 ml heparin sodium + + + + + + + + + 10 ml milrinone lactate 1 mg/ml injection + + + + + + + + + 10 ml propofol 10 mg/ml injection [diprivan] + + + + + + + + + 10 ml propofol 10 mg/ml injection + + + + + + + + + 10 ml tocilizumab 20 mg/ml injection [actemra] + + + + + + + + + 10 ml tocilizumab 20 mg/ml injection + + + + + + + + + 100 ml bivalirudin 5 mg/ml injection + + + + + + + + + 100 ml dexmedetomidine 0.004 mg/ml injection [precedex] + + + + + + + + + 100 ml dexmedetomidine 0.004 mg/ml injection + + + + + + + + + 100 ml eptifibatide 0.75 mg/ml injection [integrilin] + + + + + + + + + 100 ml eptifibatide 0.75 mg/ml injection + + + + + + + + + 100 ml eptifibatide 2 mg/ml injection [integrilin] + + + + + + + + + 100 ml eptifibatide 2 mg/ml injection + + + + + + + + + 100 ml heparin sodium + + + + + + + + + 100 ml milrinone lactate 0.2 mg/ml injection + + + + + + + + + 100 ml propofol 10 mg/ml injection [diprivan] + + + + + + + + + 100 ml propofol 10 mg/ml injection + + + + + + + + + 100 ml tirofiban 0.05 mg/ml injection [aggrastat] + + + + + + + + + 100 ml tirofiban 0.05 mg/ml injection + + + + + + + + + 100 ml vancomycin 5 mg/ml injection + + + + + + + + + 1000 ml heparin sodium + + + + + + + + + 125 actuat epinephrine 0.22 mg/actuat metered dose inhaler + + + + + + + + + 125 ml argatroban 1 mg/ml injection + + + + + + + + + 15 ml tirofiban 0.25 mg/ml injection [aggrastat] + + + + + + + + + 15 ml tirofiban 0.25 mg/ml injection + + + + + + + + + 150 ml vancomycin 5 mg/ml injection + + + + + + + + + 2 ml bumetanide 0.25 mg/ml injection + + + + + + + + + 2 ml dexmedetomidine 0.1 mg/ml injection [precedex] + + + + + + + + + 2 ml dexmedetomidine 0.1 mg/ml injection + + + + + + + + + 2 ml furosemide 10 mg/ml injection + + + + + + + + + 2 ml heparin sodium + + + + + + + + + 2 ml ibuprofen 10 mg/ml injection [neoprofen] + + + + + + + + + 2 ml ibuprofen 10 mg/ml injection + + + + + + + + + 2 ml ketorolac tromethamine 30 mg/ml cartridge + + + + + + + + + 2 ml ketorolac tromethamine 30 mg/ml injection + + + + + + + + + 2 ml ketorolac tromethamine 30 mg/ml prefilled syringe + + + + + + + + + 2 ml midazolam 1 mg/ml cartridge + + + + + + + + + 2 ml midazolam 1 mg/ml injection + + + + + + + + + 2 ml midazolam 1 mg/ml prefilled syringe + + + + + + + + + 2 ml midazolam 5 mg/ml injection + + + + + + + + + 2 ml midazolam 5 mg/ml prefilled syringe + + + + + + + + + 2 ml torsemide 10 mg/ml injection [demadex] + + + + + + + + + 2 ml torsemide 10 mg/ml injection + + + + + + + + + 2.5 ml argatroban 100 mg/ml injection + + + + + + + + + 2.5 ml heparin sodium + + + + + + + + + 20 ml cisatracurium 10 mg/ml injection [nimbex] + + + + + + + + + 20 ml cisatracurium 10 mg/ml injection + + + + + + + + + 20 ml dexmedetomidine 0.004 mg/ml injection [precedex] + + + + + + + + + 20 ml dexmedetomidine 0.004 mg/ml injection + + + + + + + + + 20 ml dobutamine 12.5 mg/ml injection + + + + + + + + + 20 ml milrinone lactate 1 mg/ml injection + + + + + + + + + 20 ml propofol 10 mg/ml injection [diprivan] + + + + + + + + + 20 ml propofol 10 mg/ml injection + + + + + + + + + 20 ml tocilizumab 20 mg/ml injection [actemra] + + + + + + + + + 20 ml tocilizumab 20 mg/ml injection + + + + + + + + + 200 ml milrinone lactate 0.2 mg/ml injection + + + + + + + + + 200 ml vancomycin 5 mg/ml injection + + + + + + + + + 2019-ncov acute respiratory disease + + + + + + + + + 24 hr aspirin 162.5 mg extended release oral capsule [durlaza] + + + + + + + + + 24 hr aspirin 162.5 mg extended release oral capsule + + + + + + + + + 24 hr diclofenac sodium 100 mg extended release oral tablet [voltaren] + + + + + + + + + 24 hr diclofenac sodium 100 mg extended release oral tablet + + + + + + + + + 24 hr etodolac 400 mg extended release oral tablet + + + + + + + + + 24 hr etodolac 500 mg extended release oral tablet + + + + + + + + + 24 hr etodolac 600 mg extended release oral tablet + + + + + + + + + 24 hr ketoprofen 200 mg extended release oral capsule + + + + + + + + + 24 hr naproxen 1000 mg extended release oral tablet + + + + + + + + + 24 hr naproxen 375 mg extended release oral tablet [naprelan] + + + + + + + + + 24 hr naproxen 375 mg extended release oral tablet + + + + + + + + + 24 hr naproxen 500 mg extended release oral tablet [naprelan] + + + + + + + + + 24 hr naproxen 500 mg extended release oral tablet + + + + + + + + + 24 hr naproxen 750 mg extended release oral tablet [naprelan] + + + + + + + + + 24 hr naproxen 750 mg extended release oral tablet + + + + + + + + + 250 ml argatroban 1 mg/ml injection + + + + + + + + + 250 ml dobutamine 1 mg/ml injection + + + + + + + + + 250 ml dobutamine 2 mg/ml injection + + + + + + + + + 250 ml dobutamine 4 mg/ml injection + + + + + + + + + 250 ml dopamine hydrochloride 0.8 mg/ml injection + + + + + + + + + 250 ml dopamine hydrochloride 1.6 mg/ml injection + + + + + + + + + 250 ml dopamine hydrochloride 3.2 mg/ml injection + + + + + + + + + 250 ml heparin sodium + + + + + + + + + 250 ml tirofiban 0.05 mg/ml injection [aggrastat] + + + + + + + + + 250 ml tirofiban 0.05 mg/ml injection + + + + + + + + + 270 actuat epinephrine 0.22 mg/actuat metered dose inhaler [primatene mist inhaler] + + + + + + + + + 270 actuat epinephrine 0.22 mg/actuat metered dose inhaler + + + + + + + + + 3 ml heparin sodium + + + + + + + + + introduction of influenza vaccine into subcutaneous tissue + + + + + + + + + introduction of other therapeutic substance into respiratory tract + + + + + + + + + 4 ml bumetanide 0.25 mg/ml injection + + + + + + + + + 4 ml furosemide 10 mg/ml injection + + + + + + + + + 4 ml furosemide 10 mg/ml prefilled syringe + + + + + + + + + 4 ml norepinephrine 1 mg/ml injection [levophed] + + + + + + + + + 4 ml norepinephrine 1 mg/ml injection + + + + + + + + + 4 ml tocilizumab 20 mg/ml injection [actemra] + + + + + + + + + 4 ml tocilizumab 20 mg/ml injection + + + + + + + + + 40 ml dobutamine 12.5 mg/ml injection + + + + + + + + + 5 ml abciximab 2 mg/ml injection [reopro] + + + + + + + + + 5 ml abciximab 2 mg/ml injection + + + + + + + + + 5 ml cisatracurium 2 mg/ml injection [nimbex] + + + + + + + + + 5 ml cisatracurium 2 mg/ml injection + + + + + + + + + 5 ml dopamine hydrochloride 160 mg/ml injection + + + + + + + + + 5 ml dopamine hydrochloride 40 mg/ml injection + + + + + + + + + 5 ml dopamine hydrochloride 40 mg/ml prefilled syringe + + + + + + + + + 5 ml dopamine hydrochloride 80 mg/ml injection + + + + + + + + + 5 ml heparin sodium + + + + + + + + + 5 ml midazolam 1 mg/ml injection + + + + + + + + + 5 ml milrinone lactate 1 mg/ml injection + + + + + + + + + 5 ml torsemide 10 mg/ml injection [demadex] + + + + + + + + + 5 ml torsemide 10 mg/ml injection + + + + + + + + + 50 ml argatroban 1 mg/ml injection + + + + + + + + + 50 ml bivalirudin 5 mg/ml injection + + + + + + + + + 50 ml dexmedetomidine 0.004 mg/ml injection [precedex] + + + + + + + + + 50 ml dexmedetomidine 0.004 mg/ml injection + + + + + + + + + 50 ml milrinone lactate 1 mg/ml injection + + + + + + + + + 50 ml propofol 10 mg/ml injection [diprivan] + + + + + + + + + 50 ml propofol 10 mg/ml injection + + + + + + + + + 500 ml dopamine hydrochloride 0.8 mg/ml injection + + + + + + + + + 500 ml dopamine hydrochloride 1.6 mg/ml injection + + + + + + + + + 500 ml heparin sodium + + + + + + + + + ventilation less than 24 consecutive hours + + + + + + + + + assistance with respiratory ventilation + + + + + + + + + ventilation 24-96 consecutive hours + + + + + + + + + respiratory ventilation + + + + + + + + + ventilation ventilation greater than 96 consecutive hours + + + + + + + + + 8 ml furosemide 10 mg/ml prefilled syringe + + + + + + + + + 8 ml ibuprofen 100 mg/ml injection [caldolor] + + + + + + + + + 8 ml ibuprofen 100 mg/ml injection + + + + + + + + + abciximab injection + + + + + + + + + abciximab + + + + + + + + + abnormal chest ct (derived) + + + + + + + + + abnormal chest ct + + + + + + + + + abnormal chest imaging (derived) + + + + + + + + + abnormal chest imaging + + + + + + + + + ace inhibitors + + + + + + + + + acenocoumarol 1 mg oral tablet + + + + + + + + + acenocoumarol 4 mg oral tablet + + + + + + + + + acenocoumarol oral tablet + + + + + + + + + acenocoumarol + + + + + + + + + acute bronchitis due to other specified organisms + + + + + + + + + acute respiratory distress + + + + + + + + + advance care planning including the explanation and discussion of advance directives such as standard forms with completion of such forms + + + + + + + + + alanine aminotransferase | bld-ser-plas + + + + + + + + + alanine aminotransferase:ccnc:pt:bld:qn + + + + + + + + + alanine aminotransferase:ccnc:pt:ser/plas:qn:no addition of p-5-p + + + + + + + + + alanine aminotransferase:ccnc:pt:ser/plas:qn:with p-5-p + + + + + + + + + alanine aminotransferase:ccnc:pt:ser/plas:qn + + + + + + + + + alanine aminotransferase:ccnc:pt:ser/plas/bld:qn + + + + + + + + + alanine aminotransferase:ccnc:stdy^max:ser/plas:qn:no addition of p-5-p + + + + + + + + + alanine aminotransferase/aspartate aminotransferase:crto:pt:ser/plas:qn + + + + + + + + + albumin | bld-ser-plas + + + + + + + + + albumin:mcnc:pt:bld:qn:bcp + + + + + + + + + albumin:mcnc:pt:ser/plas:qn:bcg + + + + + + + + + albumin:mcnc:pt:ser/plas:qn:bcp + + + + + + + + + albumin:mcnc:pt:ser/plas:qn:electrophoresis + + + + + + + + + albumin:mcnc:pt:ser/plas:qn + + + + + + + + + albumin:mcnc:pt:ser/plas/bld:qn:bcp + + + + + + + + + albumin:prthr:pt:ser/plas:ord + + + + + + + + + albumin:scnc:pt:ser/plas:qn:bcg + + + + + + + + + albumin:scnc:pt:ser/plas:qn:bcp + + + + + + + + + albumin:scnc:pt:ser/plas:qn + + + + + + + + + albumin/globulin:mrto:pt:ser/plas:qn:electrophoresis + + + + + + + + + albumin/globulin:mrto:pt:ser/plas:qn + + + + + + + + + albumin/protein.total:mfr:pt:ser/plas:qn:electrophoresis + + + + + + + + + albumin/protein.total:mfr:pt:ser/plas:qn + + + + + + + + + albumin/protein.total:mfr.df:pt:ser/plas:qn:electrophoresis + + + + + + + + + albumin^2h post peritoneal dialysis:mcnc:pt:ser/plas:qn + + + + + + + + + ambulatory + + + + + + + + + ambulatory visit + + + + + + + + + anakinra prefilled syringe + + + + + + + + + anakinra + + + + + + + + + anesthetics + + + + + + + + + angiotensin ii inhibitor + + + + + + + + + angiotensin ii injection + + + + + + + + + anticoagulants + + + + + + + + + antineoplastics + + + + + + + + + antivirals + + + + + + + + + any antibody lab test equivocal + + + + + + + + + any antibody lab test negative + + + + + + + + + any antibody lab test pending + + + + + + + + + any antibody lab test positive + + + + + + + + + any nucleic acid lab test equivocal + + + + + + + + + any nucleic acid lab test negative + + + + + + + + + any nucleic acid lab test pending + + + + + + + + + any nucleic acid lab test positive + + + + + + + + + apixaban 2.5 mg oral tablet [eliquis] + + + + + + + + + apixaban 2.5 mg oral tablet + + + + + + + + + apixaban 5 mg oral tablet [eliquis] + + + + + + + + + apixaban 5 mg oral tablet + + + + + + + + + apixaban oral tablet + + + + + + + + + apixaban + + + + + + + + + argatroban injection + + + + + + + + + argatroban + + + + + + + + + arterial catheterization or cannulation for sampling + + + + + + + + + aspartate aminotransferase | bld-ser-plas + + + + + + + + + aspartate aminotransferase:ccnc:pt:ser/plas:qn:no addition of p-5-p + + + + + + + + + aspartate aminotransferase:ccnc:pt:ser/plas:qn:with p-5-p + + + + + + + + + aspartate aminotransferase:ccnc:pt:ser/plas:qn + + + + + + + + + aspartate aminotransferase:ccnc:stdy^max:ser/plas:qn + + + + + + + + + aspartate aminotransferase:prthr:pt:ser/plas:ord + + + + + + + + + aspartate aminotransferase/alanine aminotransferase:crto:pt:ser/plas:qn + + + + + + + + + aspirin 1 mg/mg oral powder + + + + + + + + + aspirin 1.5 mg/ml oral solution + + + + + + + + + aspirin 100 mg oral tablet + + + + + + + + + aspirin 120 mg chewable tablet + + + + + + + + + aspirin 120 mg rectal suppository + + + + + + + + + aspirin 150 mg rectal suppository + + + + + + + + + aspirin 15600 mg oral tablet + + + + + + + + + aspirin 162 mg delayed release oral tablet + + + + + + + + + aspirin 165 mg delayed release oral tablet + + + + + + + + + aspirin 2.5 mg/ml oral solution + + + + + + + + + aspirin 200 mg rectal suppository + + + + + + + + + aspirin 228 mg chewing gum [aspergum] + + + + + + + + + aspirin 228 mg chewing gum + + + + + + + + + aspirin 300 mg chewable tablet + + + + + + + + + aspirin 300 mg delayed release oral tablet + + + + + + + + + aspirin 300 mg oral capsule + + + + + + + + + aspirin 300 mg oral tablet + + + + + + + + + aspirin 300 mg rectal suppository + + + + + + + + + aspirin 31200 mg oral tablet + + + + + + + + + aspirin 325 mg delayed release oral tablet [bayer aspirin] + + + + + + + + + aspirin 325 mg delayed release oral tablet [ecotrin] + + + + + + + + + aspirin 325 mg delayed release oral tablet [ecpirin] + + + + + + + + + aspirin 325 mg delayed release oral tablet + + + + + + + + + aspirin 325 mg oral capsule + + + + + + + + + aspirin 325 mg oral powder + + + + + + + + + aspirin 325 mg oral tablet [ascriptin] + + + + + + + + + aspirin 325 mg oral tablet [bayer aspirin] + + + + + + + + + aspirin 325 mg oral tablet [bufferin] + + + + + + + + + aspirin 325 mg oral tablet [norwich aspirin] + + + + + + + + + aspirin 325 mg oral tablet + + + + + + + + + aspirin 3900 mg oral tablet + + + + + + + + + aspirin 500 mg delayed release oral tablet [bayer aspirin] + + + + + + + + + aspirin 500 mg delayed release oral tablet [ecotrin] + + + + + + + + + aspirin 500 mg delayed release oral tablet + + + + + + + + + aspirin 500 mg oral tablet [ascriptin] + + + + + + + + + aspirin 500 mg oral tablet [bayer aspirin] + + + + + + + + + aspirin 500 mg oral tablet [bufferin] + + + + + + + + + aspirin 500 mg oral tablet [migralex] + + + + + + + + + aspirin 500 mg oral tablet [norwich aspirin] + + + + + + + + + aspirin 500 mg oral tablet + + + + + + + + + aspirin 60 mg chewable tablet + + + + + + + + + aspirin 600 mg rectal suppository + + + + + + + + + aspirin 650 mg delayed release oral tablet + + + + + + + + + aspirin 650 mg oral powder + + + + + + + + + aspirin 650 mg oral tablet [bayer aspirin] + + + + + + + + + aspirin 650 mg oral tablet + + + + + + + + + aspirin 75 mg delayed release oral tablet + + + + + + + + + aspirin 75 mg disintegrating oral tablet + + + + + + + + + aspirin 75 mg oral tablet + + + + + + + + + aspirin 800 mg oral tablet + + + + + + + + + aspirin 81 mg chewable tablet [bayer aspirin] + + + + + + + + + aspirin 81 mg chewable tablet [st. joseph aspirin] + + + + + + + + + aspirin 81 mg chewable tablet + + + + + + + + + aspirin 81 mg delayed release oral tablet [aspi-cor] + + + + + + + + + aspirin 81 mg delayed release oral tablet [aspir-low] + + + + + + + + + aspirin 81 mg delayed release oral tablet [bayer aspirin] + + + + + + + + + aspirin 81 mg delayed release oral tablet [bufferin] + + + + + + + + + aspirin 81 mg delayed release oral tablet [ecotrin] + + + + + + + + + aspirin 81 mg delayed release oral tablet [halfprin] + + + + + + + + + aspirin 81 mg delayed release oral tablet [miniprin] + + + + + + + + + aspirin 81 mg delayed release oral tablet [st. joseph aspirin] + + + + + + + + + aspirin 81 mg delayed release oral tablet + + + + + + + + + aspirin 81 mg disintegrating oral tablet [fasprin] + + + + + + + + + aspirin 81 mg disintegrating oral tablet + + + + + + + + + aspirin 81 mg oral strip + + + + + + + + + aspirin 81 mg oral tablet [anacin aspirin regimen] + + + + + + + + + aspirin 81 mg oral tablet [bayer aspirin] + + + + + + + + + aspirin 81 mg oral tablet [bufferin] + + + + + + + + + aspirin 81 mg oral tablet + + + + + + + + + aspirin 975 mg delayed release oral tablet + + + + + + + + + aspirin 975 mg oral tablet + + + + + + + + + aspirin chewable tablet + + + + + + + + + aspirin chewing gum + + + + + + + + + aspirin delayed release oral tablet + + + + + + + + + aspirin disintegrating oral tablet + + + + + + + + + aspirin extended release oral capsule + + + + + + + + + aspirin oral capsule + + + + + + + + + aspirin oral powder + + + + + + + + + aspirin oral solution + + + + + + + + + aspirin oral strip + + + + + + + + + aspirin oral tablet + + + + + + + + + aspirin rectal suppository + + + + + + + + + aspirin + + + + + + + + + auto-immune disease (derived) + + + + + + + + + auto-immune disease + + + + + + + + + azithromycin 10 mg/ml ophthalmic solution [azasite] + + + + + + + + + azithromycin 10 mg/ml ophthalmic solution + + + + + + + + + azithromycin 1000 mg powder for oral suspension [zithromax] + + + + + + + + + azithromycin 1000 mg powder for oral suspension + + + + + + + + + azithromycin 20 mg/ml oral suspension [zithromax] + + + + + + + + + azithromycin 20 mg/ml oral suspension + + + + + + + + + azithromycin 250 mg oral capsule + + + + + + + + + azithromycin 250 mg oral tablet [zithromax] + + + + + + + + + azithromycin 250 mg oral tablet + + + + + + + + + azithromycin 33.3 mg/ml extended release suspension [zmax] + + + + + + + + + azithromycin 33.3 mg/ml extended release suspension + + + + + + + + + azithromycin 33.3 mg/ml oral suspension + + + + + + + + + azithromycin 40 mg/ml oral suspension [zithromax] + + + + + + + + + azithromycin 40 mg/ml oral suspension + + + + + + + + + azithromycin 500 mg injection [zithromax] + + + + + + + + + azithromycin 500 mg injection + + + + + + + + + azithromycin 500 mg oral tablet [zithromax] + + + + + + + + + azithromycin 500 mg oral tablet + + + + + + + + + azithromycin 600 mg oral tablet [zithromax] + + + + + + + + + azithromycin 600 mg oral tablet + + + + + + + + + azithromycin extended release suspension + + + + + + + + + azithromycin injection + + + + + + + + + azithromycin ophthalmic solution + + + + + + + + + azithromycin oral capsule + + + + + + + + + azithromycin oral suspension + + + + + + + + + azithromycin oral tablet + + + + + + + + + azithromycin powder for oral suspension + + + + + + + + + azithromycin + + + + + + + + + b20 human immunodeficiency virus [hiv] disease + + + + + + + + + b20-b20 human immunodeficiency virus [hiv] disease (b20) + + + + + + + + + bemiparin prefilled syringe + + + + + + + + + bemiparin + + + + + + + + + benazepril hydrochloride 10 mg oral tablet [lotensin] + + + + + + + + + benazepril hydrochloride 10 mg oral tablet + + + + + + + + + benazepril hydrochloride 20 mg oral tablet [lotensin] + + + + + + + + + benazepril hydrochloride 20 mg oral tablet + + + + + + + + + benazepril hydrochloride 40 mg oral tablet [lotensin] + + + + + + + + + benazepril hydrochloride 40 mg oral tablet + + + + + + + + + benazepril hydrochloride 5 mg oral tablet [lotensin] + + + + + + + + + benazepril hydrochloride 5 mg oral tablet + + + + + + + + + benazepril oral tablet + + + + + + + + + benazepril + + + + + + + + + betrixaban 40 mg oral capsule [bevyxxa] + + + + + + + + + betrixaban 40 mg oral capsule + + + + + + + + + betrixaban 80 mg oral capsule [bevyxxa] + + + + + + + + + betrixaban 80 mg oral capsule + + + + + + + + + betrixaban oral capsule + + + + + + + + + betrixaban + + + + + + + + + bilirubin | bld-ser-plas + + + + + + + + + bilirubin:mcnc:pt:bld:qn + + + + + + + + + bilirubin:mcnc:pt:ser/plas:qn + + + + + + + + + bilirubin:mscnc:pt:ser/plas:qn + + + + + + + + + bilirubin:scnc:pt:bld:qn + + + + + + + + + bilirubin:scnc:pt:ser/plas:qn + + + + + + + + + bilirubin:scnc:pt:ser/plas/bld:qn + + + + + + + + + bivalirudin 250 mg injection [angiomax] + + + + + + + + + bivalirudin 250 mg injection + + + + + + + + + bivalirudin injection + + + + + + + + + bivalirudin + + + + + + + + + bromfenac 0.7 mg/ml ophthalmic solution [prolensa] + + + + + + + + + bromfenac 0.7 mg/ml ophthalmic solution + + + + + + + + + bromfenac 0.75 mg/ml ophthalmic solution [bromsite] + + + + + + + + + bromfenac 0.75 mg/ml ophthalmic solution + + + + + + + + + bromfenac 0.9 mg/ml ophthalmic solution [bromday] + + + + + + + + + bromfenac 0.9 mg/ml ophthalmic solution + + + + + + + + + bromfenac ophthalmic solution + + + + + + + + + bromfenac + + + + + + + + + bronchitis + + + + + + + + + bumetanide 0.2 mg/ml oral solution + + + + + + + + + bumetanide 0.25 mg/ml injectable solution + + + + + + + + + bumetanide 0.5 mg oral tablet [bumex] + + + + + + + + + bumetanide 0.5 mg oral tablet + + + + + + + + + bumetanide 1 mg oral tablet [bumex] + + + + + + + + + bumetanide 1 mg oral tablet + + + + + + + + + bumetanide 2 mg oral tablet [bumex] + + + + + + + + + bumetanide 2 mg oral tablet + + + + + + + + + bumetanide 5 mg oral tablet + + + + + + + + + bumetanide and potassium + + + + + + + + + bumetanide injectable solution + + + + + + + + + bumetanide injection + + + + + + + + + bumetanide oral solution + + + + + + + + + bumetanide oral tablet + + + + + + + + + bumetanide + + + + + + + + + c reactive protein | bld-ser-plas + + + + + + + + + c reactive protein:mcnc:pt:bld:qn:high sensitivity + + + + + + + + + c reactive protein:mcnc:pt:ser/plas:qn:high sensitivity + + + + + + + + + c reactive protein:mcnc:pt:ser/plas:qn + + + + + + + + + c reactive protein:prthr:pt:ser/plas:ord + + + + + + + + + c reactive protein:quintile:pt:ser/plas:qn:high sensitivity + + + + + + + + + c reactive protein:scnc:pt:ser/plas:qn:high sensitivity + + + + + + + + + c reactive protein:scnc:pt:ser/plas:qn + + + + + + + + + c reactive protein:titr:pt:ser/plas:qn + + + + + + + + + candesartan cilexetil 16 mg oral tablet [atacand] + + + + + + + + + candesartan cilexetil 16 mg oral tablet + + + + + + + + + candesartan cilexetil 2 mg oral tablet + + + + + + + + + candesartan cilexetil 32 mg oral tablet [atacand] + + + + + + + + + candesartan cilexetil 32 mg oral tablet + + + + + + + + + candesartan cilexetil 4 mg oral tablet [atacand] + + + + + + + + + candesartan cilexetil 4 mg oral tablet + + + + + + + + + candesartan cilexetil 8 mg oral tablet [atacand] + + + + + + + + + candesartan cilexetil 8 mg oral tablet + + + + + + + + + candesartan oral tablet + + + + + + + + + candesartan + + + + + + + + + cangrelor 50 mg injection [kengreal] + + + + + + + + + cangrelor 50 mg injection + + + + + + + + + cangrelor injection + + + + + + + + + cangrelor + + + + + + + + + caplacizumab + + + + + + + + + captopril 100 mg oral tablet + + + + + + + + + captopril 12.5 mg oral tablet + + + + + + + + + captopril 25 mg oral tablet + + + + + + + + + captopril 5 mg/ml oral solution + + + + + + + + + captopril 50 mg oral tablet + + + + + + + + + captopril 6.25 mg oral tablet + + + + + + + + + captopril oral solution + + + + + + + + + captopril oral tablet + + + + + + + + + carbon dioxide | blood arterial + + + + + + + + + carbon dioxide:ppres:pt:blda:qn + + + + + + + + + carbon dioxide:scnc:pt:blda:qn:calculated + + + + + + + + + carbon dioxide:scnc:pt:blda:qn + + + + + + + + + carbon dioxide^^adjusted to patients actual temperature:ppres:pt:blda:qn + + + + + + + + + cardiovascular agents + + + + + + + + + cdc testing laboratories to test patients for sars-cov-2 + + + + + + + + + cefepime 1000 mg injection [maxipime] + + + + + + + + + cefepime 1000 mg injection + + + + + + + + + cefepime 2000 mg injection [maxipime] + + + + + + + + + cefepime 2000 mg injection + + + + + + + + + cefepime 500 mg injection [maxipime] + + + + + + + + + cefepime 500 mg injection + + + + + + + + + cefepime injection + + + + + + + + + cefepime + + + + + + + + + ceftriaxone 100 mg/ml injectable solution + + + + + + + + + ceftriaxone 1000 mg injection + + + + + + + + + ceftriaxone 2000 mg injection + + + + + + + + + ceftriaxone 250 mg injection + + + + + + + + + ceftriaxone 500 mg injection + + + + + + + + + ceftriaxone injectable solution + + + + + + + + + ceftriaxone injection + + + + + + + + + ceftriaxone + + + + + + + + + celecoxib 100 mg oral capsule [celebrex] + + + + + + + + + celecoxib 100 mg oral capsule + + + + + + + + + celecoxib 200 mg oral capsule [celebrex] + + + + + + + + + celecoxib 200 mg oral capsule + + + + + + + + + celecoxib 400 mg oral capsule [celebrex] + + + + + + + + + celecoxib 400 mg oral capsule + + + + + + + + + celecoxib 50 mg oral capsule [celebrex] + + + + + + + + + celecoxib 50 mg oral capsule + + + + + + + + + celecoxib oral capsule + + + + + + + + + celecoxib + + + + + + + + + chemotherapy (derived) + + + + + + + + + chemotherapy administration intralesional + + + + + + + + + chemotherapy administration intravenous + + + + + + + + + chemotherapy administration + + + + + + + + + chemotherapy + + + + + + + + + chloroquine oral solution + + + + + + + + + chloroquine oral tablet + + + + + + + + + chloroquine phosphate 16 mg/ml oral solution + + + + + + + + + chloroquine phosphate 250 mg oral tablet + + + + + + + + + chloroquine phosphate 500 mg oral tablet [aralen phosphate] + + + + + + + + + chloroquine phosphate 500 mg oral tablet + + + + + + + + + chloroquine sulfate 13.6 mg/ml oral solution + + + + + + + + + chloroquine sulfate 200 mg oral tablet + + + + + + + + + cilazapril 0.5 mg oral tablet + + + + + + + + + cilazapril 1 mg oral tablet + + + + + + + + + cilazapril 2.5 mg oral tablet + + + + + + + + + cilazapril 5 mg oral tablet + + + + + + + + + cilazapril oral tablet + + + + + + + + + cilazapril + + + + + + + + + cisatracurium 2 mg/ml injectable solution [nimbex] + + + + + + + + + cisatracurium 2 mg/ml injectable solution + + + + + + + + + cisatracurium injectable solution + + + + + + + + + cisatracurium injection + + + + + + + + + cisatracurium + + + + + + + + + clopidogrel 300 mg oral tablet [plavix] + + + + + + + + + clopidogrel 300 mg oral tablet + + + + + + + + + clopidogrel 75 mg oral tablet [plavix] + + + + + + + + + clopidogrel 75 mg oral tablet + + + + + + + + + clopidogrel oral tablet + + + + + + + + + clopidogrel + + + + + + + + + coagulation tissue factor induced actual/normal:reltime:pt:ppp:qn:coag + + + + + + + + + coagulation tissue factor induced:time:pt:ppp:qn:coag.saline 1:1 + + + + + + + + + coagulation tissue factor induced:time:pt:ppp:qn:coag + + + + + + + + + coagulation tissue factor induced^1.5h post xxx challenge:time:pt:ppp:qn:coag + + + + + + + + + coagulation tissue factor induced^12h post xxx challenge:time:pt:ppp:qn:coag + + + + + + + + + coagulation tissue factor induced^1d post xxx challenge:time:pt:ppp:qn:coag + + + + + + + + + coagulation tissue factor induced^1h post xxx challenge:time:pt:ppp:qn:coag + + + + + + + + + coagulation tissue factor induced^2h post xxx challenge:time:pt:ppp:qn:coag + + + + + + + + + coagulation tissue factor induced^2h pre xxx challenge:time:pt:ppp:qn:coag + + + + + + + + + coagulation tissue factor induced^30m post xxx challenge:time:pt:ppp:qn:coag + + + + + + + + + coagulation tissue factor induced^3h post xxx challenge:time:pt:ppp:qn:coag + + + + + + + + + coagulation tissue factor induced^4h post xxx challenge:time:pt:ppp:qn:coag + + + + + + + + + coagulation tissue factor induced^6h post xxx challenge:time:pt:ppp:qn:coag + + + + + + + + + coagulation tissue factor induced^8h post xxx challenge:time:pt:ppp:qn:coag + + + + + + + + + coagulation tissue factor induced^baseline:time:pt:ppp:qn:coag + + + + + + + + + coagulation tissue factor induced^post heparin adsorption:time:pt:ppp:qn:coag + + + + + + + + + cobicistat / darunavir oral tablet + + + + + + + + + cobicistat / darunavir + + + + + + + + + cobicistat 150 mg / darunavir 800 mg oral tablet [prezcobix] + + + + + + + + + cobicistat 150 mg / darunavir 800 mg oral tablet + + + + + + + + + conditions + + + + + + + + + confirmed case + + + + + + + + + contact with and (suspected) exposure to other viral communicable diseases + + + + + + + + + continuous negative pressure ventilation (cnp) + + + + + + + + + continuous positive airway pressure ventilation (cpap) + + + + + + + + + course of illness + + + + + + + + + covid-19 related terms + + + + + + + + + cpt4 ventilation procedures + + + + + + + + + creatinine | bld-ser-plas + + + + + + + + + creatinine renal clearance.predicted:vrat:pt:ser/plas:qn:cockcroft-gault formula + + + + + + + + + creatinine renal clearance/1.73 sq m.predicted:arvrat:pt:ser/plas:qn:cockcroft-gault formula + + + + + + + + + creatinine renal clearance/1.73 sq m.predicted.female:arvrat:pt:ser/plas:qn:cockcroft-gault formula + + + + + + + + + creatinine renal clearance/1.73 sq m.predicted.male:arvrat:pt:ser/plas:qn:cockcroft-gault formula + + + + + + + + + creatinine:mcnc:pt:bld:qn + + + + + + + + + creatinine:mcnc:pt:ser/plas:qn + + + + + + + + + creatinine:mcnc:stdy^max:ser/plas:qn + + + + + + + + + creatinine:mscnc:pt:ser/plas:qn + + + + + + + + + creatinine:scnc:pt:bld:qn + + + + + + + + + creatinine:scnc:pt:ser/plas:qn + + + + + + + + + creatinine:scnc:pt:ser/plas/bld:qn + + + + + + + + + creatinine/urea nitrogen:mrto:pt:ser/plas:qn + + + + + + + + + creatinine^2h specimen:mcnc:pt:ser/plas:qn + + + + + + + + + creatinine^4h specimen:mcnc:pt:ser/plas:qn + + + + + + + + + creatinine^post dialysis:mcnc:pt:ser/plas:qn + + + + + + + + + creatinine^post dialysis:scnc:pt:ser/plas:qn + + + + + + + + + creatinine^pre contrast:mcnc:pt:ser/plas:qn + + + + + + + + + creatinine^pre dialysis:mcnc:pt:ser/plas:qn + + + + + + + + + creatinine^pre dialysis:scnc:pt:ser/plas:qn + + + + + + + + + critical care + + + + + + + + + critical care services + + + + + + + + + current smokeless tobacco user (eg) + + + + + + + + + current tobacco non-user (cad) + + + + + + + + + current tobacco smoker (cad) + + + + + + + + + cytokine release syndromes (crs/sirs) + + + + + + + + + other autoimmune hemolytic anemias + + + + + + + + + pancytopenia + + + + + + + + + antineoplastic chemotherapy induced pancytopenia + + + + + + + + + other drug-induced pancytopenia + + + + + + + + + other pancytopenia + + + + + + + + + hemophagocytic lymphohistiocytosis + + + + + + + + + hemophagocytic syndrome + + + + + + + + + immunodeficiency with predominantly antibody defects + + + + + + + + + certain disorders involving the immune mechanism + + + + + + + + + hereditary hypogammaglobulinemia + + + + + + + + + nonfamilial hypogammaglobulinemia + + + + + + + + + selective deficiency of immunoglobulin a [iga] + + + + + + + + + selective deficiency of immunoglobulin g [igg] subclasses + + + + + + + + + selective deficiency of immunoglobulin m [igm] + + + + + + + + + immunodeficiency with increased immunoglobulin m [igm] + + + + + + + + + antibody deficiency with near-normal immunoglobulins or with hyperimmunoglobulinemia + + + + + + + + + transient hypogammaglobulinemia of infancy + + + + + + + + + other immunodeficiencies with predominantly antibody defects + + + + + + + + + combined immunodeficiencies + + + + + + + + + severe combined immunodeficiency [scid] with reticular dysgenesis + + + + + + + + + severe combined immunodeficiency [scid] with low t- and b-cell numbers + + + + + + + + + severe combined immunodeficiency [scid] with low or normal b-cell numbers + + + + + + + + + adenosine deaminase [ada] deficiency + + + + + + + + + nezelofs syndrome + + + + + + + + + purine nucleoside phosphorylase [pnp] deficiency + + + + + + + + + major histocompatibility complex class i deficiency + + + + + + + + + major histocompatibility complex class ii deficiency + + + + + + + + + other combined immunodeficiencies + + + + + + + + + biotin-dependent carboxylase deficiency + + + + + + + + + biotinidase deficiency + + + + + + + + + other biotin-dependent carboxylase deficiency + + + + + + + + + immunodeficiency associated with other major defects + + + + + + + + + wiskott-aldrich syndrome + + + + + + + + + di georges syndrome + + + + + + + + + immunodeficiency with short-limbed stature + + + + + + + + + immunodeficiency following hereditary defective response to epstein-barr virus + + + + + + + + + hyperimmunoglobulin e [ige] syndrome + + + + + + + + + immunodeficiency associated with other specified major defects + + + + + + + + + immunodeficiency associated with major defect + + + + + + + + + common variable immunodeficiency with predominant abnormalities of b-cell numbers and function + + + + + + + + + common variable immunodeficiency with predominant immunoregulatory t-cell disorders + + + + + + + + + common variable immunodeficiency with autoantibodies to b- or t-cells + + + + + + + + + other common variable immunodeficiencies + + + + + + + + + other immunodeficiencies + + + + + + + + + lymphocyte function antigen-1 [lfa-1] defect + + + + + + + + + defects in the complement system + + + + + + + + + other specified immunodeficiencies + + + + + + + + + immunodeficiency + + + + + + + + + sarcoidosis + + + + + + + + + sarcoidosis of lung + + + + + + + + + sarcoidosis of lymph nodes + + + + + + + + + sarcoidosis of lung with sarcoidosis of lymph nodes + + + + + + + + + sarcoidosis of skin + + + + + + + + + sarcoidosis of other sites + + + + + + + + + sarcoid meningitis + + + + + + + + + multiple cranial nerve palsies in sarcoidosis + + + + + + + + + sarcoid iridocyclitis + + + + + + + + + sarcoid pyelonephritis + + + + + + + + + sarcoid myocarditis + + + + + + + + + sarcoid arthropathy + + + + + + + + + sarcoid myositis + + + + + + + + + other disorders involving the immune mechanism + + + + + + + + + polyclonal hypergammaglobulinemia + + + + + + + + + cryoglobulinemia + + + + + + + + + hypergammaglobulinemia + + + + + + + + + immune reconstitution syndrome + + + + + + + + + mast cell activation syndrome and related disorders + + + + + + + + + mast cell activation + + + + + + + + + monoclonal mast cell activation syndrome + + + + + + + + + idiopathic mast cell activation syndrome + + + + + + + + + secondary mast cell activation + + + + + + + + + other mast cell activation disorder + + + + + + + + + other specified disorders involving the immune mechanism + + + + + + + + + graft-versus-host disease + + + + + + + + + acute graft-versus-host disease + + + + + + + + + chronic graft-versus-host disease + + + + + + + + + acute on chronic graft-versus-host disease + + + + + + + + + autoimmune lymphoproliferative syndrome [alps] + + + + + + + + + disorder involving the immune mechanism + + + + + + + + + dabigatran etexilate 110 mg oral capsule [pradaxa] + + + + + + + + + dabigatran etexilate 110 mg oral capsule + + + + + + + + + dabigatran etexilate 150 mg oral capsule [pradaxa] + + + + + + + + + dabigatran etexilate 150 mg oral capsule + + + + + + + + + dabigatran etexilate 75 mg oral capsule [pradaxa] + + + + + + + + + dabigatran etexilate 75 mg oral capsule + + + + + + + + + dabigatran etexilate oral capsule + + + + + + + + + dabigatran etexilate + + + + + + + + + dalteparin injectable solution + + + + + + + + + dalteparin prefilled syringe + + + + + + + + + dalteparin sodium 10000 unt/ml injectable solution [fragmin] + + + + + + + + + dalteparin sodium 10000 unt/ml injectable solution + + + + + + + + + dalteparin sodium 25000 unt/ml injectable solution [fragmin] + + + + + + + + + dalteparin sodium 25000 unt/ml injectable solution + + + + + + + + + dalteparin + + + + + + + + + darunavir 100 mg/ml oral suspension [prezista] + + + + + + + + + darunavir 100 mg/ml oral suspension + + + + + + + + + darunavir 150 mg oral tablet [prezista] + + + + + + + + + darunavir 150 mg oral tablet + + + + + + + + + darunavir 300 mg oral tablet + + + + + + + + + darunavir 400 mg oral tablet [prezista] + + + + + + + + + darunavir 400 mg oral tablet + + + + + + + + + darunavir 600 mg oral tablet [prezista] + + + + + + + + + darunavir 600 mg oral tablet + + + + + + + + + darunavir 75 mg oral tablet [prezista] + + + + + + + + + darunavir 75 mg oral tablet + + + + + + + + + darunavir 800 mg oral tablet [prezista] + + + + + + + + + darunavir 800 mg oral tablet + + + + + + + + + darunavir oral suspension + + + + + + + + + darunavir oral tablet + + + + + + + + + desirudin 15 mg injection [iprivask] + + + + + + + + + desirudin 15 mg injection + + + + + + + + + desirudin injection + + + + + + + + + desirudin + + + + + + + + + dexmedetomidine 0.00009 mg/mg oral gel [sileo] + + + + + + + + + dexmedetomidine 0.00009 mg/mg oral gel + + + + + + + + + dexmedetomidine 0.1 mg/ml injectable solution + + + + + + + + + dexmedetomidine hydrochloride 0.1 mg/ml injectable solution [dexdomitor] + + + + + + + + + dexmedetomidine hydrochloride 0.1 mg/ml injectable solution + + + + + + + + + dexmedetomidine hydrochloride 0.5 mg/ml injectable solution [dexdomitor] + + + + + + + + + dexmedetomidine hydrochloride 0.5 mg/ml injectable solution + + + + + + + + + dexmedetomidine injectable solution + + + + + + + + + dexmedetomidine injection + + + + + + + + + dexmedetomidine oral gel + + + + + + + + + dexmedetomidine + + + + + + + + + diagnostic lab tests + + + + + + + + + diagnostics + + + + + + + + + diclofenac 18 mg oral capsule [zorvolex] + + + + + + + + + diclofenac 18 mg oral capsule + + + + + + + + + diclofenac 35 mg oral capsule [zorvolex] + + + + + + + + + diclofenac 35 mg oral capsule + + + + + + + + + diclofenac delayed release oral tablet + + + + + + + + + diclofenac epolamine 0.013 mg/mg medicated patch [flector] + + + + + + + + + diclofenac epolamine 0.013 mg/mg medicated patch + + + + + + + + + diclofenac extended release oral tablet + + + + + + + + + diclofenac injectable solution + + + + + + + + + diclofenac injection + + + + + + + + + diclofenac medicated patch + + + + + + + + + diclofenac ophthalmic solution + + + + + + + + + diclofenac oral capsule + + + + + + + + + diclofenac oral solution + + + + + + + + + diclofenac oral tablet + + + + + + + + + diclofenac potassium 25 mg oral capsule [zipsor] + + + + + + + + + diclofenac potassium 25 mg oral capsule + + + + + + + + + diclofenac potassium 25 mg oral tablet + + + + + + + + + diclofenac potassium 50 mg oral tablet [cataflam] + + + + + + + + + diclofenac potassium 50 mg oral tablet + + + + + + + + + diclofenac potassium 50 mg powder for oral solution [cambia] + + + + + + + + + diclofenac potassium 50 mg powder for oral solution + + + + + + + + + diclofenac powder for oral solution + + + + + + + + + diclofenac rectal suppository + + + + + + + + + diclofenac sodium 0.01 mg/mg topical gel [voltaren] + + + + + + + + + diclofenac sodium 0.01 mg/mg topical gel + + + + + + + + + diclofenac sodium 0.03 mg/mg topical gel [solaraze] + + + + + + + + + diclofenac sodium 0.03 mg/mg topical gel + + + + + + + + + diclofenac sodium 0.25 mg/ml oral solution + + + + + + + + + diclofenac sodium 1 mg/ml ophthalmic solution [voltaren] + + + + + + + + + diclofenac sodium 1 mg/ml ophthalmic solution + + + + + + + + + diclofenac sodium 10 mg/ml topical cream [surpass anti-inflammatory] + + + + + + + + + diclofenac sodium 10 mg/ml topical cream + + + + + + + + + diclofenac sodium 100 mg oral capsule + + + + + + + + + diclofenac sodium 100 mg rectal suppository + + + + + + + + + diclofenac sodium 12.5 mg rectal suppository + + + + + + + + + diclofenac sodium 15 mg/ml topical solution [pennsaid] + + + + + + + + + diclofenac sodium 15 mg/ml topical solution + + + + + + + + + diclofenac sodium 20 mg/ml topical solution [pennsaid] + + + + + + + + + diclofenac sodium 20 mg/ml topical solution + + + + + + + + + diclofenac sodium 25 mg delayed release oral tablet + + + + + + + + + diclofenac sodium 25 mg rectal suppository + + + + + + + + + diclofenac sodium 25 mg/ml injectable solution + + + + + + + + + diclofenac sodium 50 mg delayed release oral tablet + + + + + + + + + diclofenac sodium 50 mg rectal suppository + + + + + + + + + diclofenac sodium 75 mg delayed release oral tablet [voltaren] + + + + + + + + + diclofenac sodium 75 mg delayed release oral tablet + + + + + + + + + diclofenac topical cream + + + + + + + + + diclofenac topical gel + + + + + + + + + diclofenac topical solution + + + + + + + + + diclofenac + + + + + + + + + dicumarol 25 mg oral tablet + + + + + + + + + dicumarol oral tablet + + + + + + + + + dicumarol + + + + + + + + + diflunisal 250 mg oral tablet + + + + + + + + + diflunisal 500 mg oral tablet + + + + + + + + + diflunisal oral tablet + + + + + + + + + diflunisal + + + + + + + + + dipyridamole 10 mg/ml oral suspension + + + + + + + + + dipyridamole 100 mg oral tablet + + + + + + + + + dipyridamole 150 mg extended release oral tablet + + + + + + + + + dipyridamole 25 mg oral tablet [persantine] + + + + + + + + + dipyridamole 25 mg oral tablet + + + + + + + + + dipyridamole 50 mg oral tablet [persantine] + + + + + + + + + dipyridamole 50 mg oral tablet + + + + + + + + + dipyridamole 75 mg oral tablet [persantine] + + + + + + + + + dipyridamole 75 mg oral tablet + + + + + + + + + dipyridamole extended release oral tablet + + + + + + + + + dipyridamole injection + + + + + + + + + dipyridamole oral suspension + + + + + + + + + dipyridamole oral tablet + + + + + + + + + dobutamine injection + + + + + + + + + dobutamine + + + + + + + + + dopamine injection + + + + + + + + + dopamine prefilled syringe + + + + + + + + + dopamine + + + + + + + + + autoimmune thyroiditis + + + + + + + + + type 1 diabetes mellitus + + + + + + + + + type 1 diabetes mellitus with ketoacidosis + + + + + + + + + type 1 diabetes mellitus with ketoacidosis without coma + + + + + + + + + type 1 diabetes mellitus with ketoacidosis with coma + + + + + + + + + type 1 diabetes mellitus with kidney complications + + + + + + + + + type 1 diabetes mellitus with diabetic nephropathy + + + + + + + + + type 1 diabetes mellitus with diabetic chronic kidney disease + + + + + + + + + type 1 diabetes mellitus with other diabetic kidney complication + + + + + + + + + type 1 diabetes mellitus with ophthalmic complications + + + + + + + + + type 1 diabetes mellitus with unspecified diabetic retinopathy + + + + + + + + + type 1 diabetes mellitus with unspecified diabetic retinopathy with macular edema + + + + + + + + + type 1 diabetes mellitus with unspecified diabetic retinopathy without macular edema + + + + + + + + + type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy + + + + + + + + + type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema + + + + + + + + + diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema + + + + + + + + + type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye + + + + + + + + + diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, left eye + + + + + + + + + type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bi + + + + + + + + + type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, unsp + + + + + + + + + type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy + + + + + + + + + type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema + + + + + + + + + type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, right eye + + + + + + + + + type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, left eye + + + + + + + + + type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, bilateral + + + + + + + + + type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, unspecified eye + + + + + + + + + type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema + + + + + + + + + type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, right eye + + + + + + + + + type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, left eye + + + + + + + + + type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, bilateral + + + + + + + + + type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, unspecified eye + + + + + + + + + type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy + + + + + + + + + type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema + + + + + + + + + type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, right eye + + + + + + + + + type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, left eye + + + + + + + + + type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, bilateral + + + + + + + + + type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, unspecified eye + + + + + + + + + type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema + + + + + + + + + type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, right eye + + + + + + + + + type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, left eye + + + + + + + + + type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, bilateral + + + + + + + + + type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, unspecified eye + + + + + + + + + type 1 diabetes mellitus with proliferative diabetic retinopathy + + + + + + + + + type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema + + + + + + + + + type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, right eye + + + + + + + + + type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, left eye + + + + + + + + + type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, bilateral + + + + + + + + + type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, unspecified eye + + + + + + + + + type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula + + + + + + + + + type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, right eye + + + + + + + + + type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, left eye + + + + + + + + + type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, bilateral + + + + + + + + + type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, unspecified eye + + + + + + + + + type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula + + + + + + + + + type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, right eye + + + + + + + + + type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, left eye + + + + + + + + + type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, bilateral + + + + + + + + + type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, unspecified eye + + + + + + + + + type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment + + + + + + + + + type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, right eye + + + + + + + + + type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, left eye + + + + + + + + + type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, bilateral + + + + + + + + + type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, unspecified eye + + + + + + + + + type 1 diabetes mellitus with stable proliferative diabetic retinopathy + + + + + + + + + type 1 diabetes mellitus with stable proliferative diabetic retinopathy, right eye + + + + + + + + + type 1 diabetes mellitus with stable proliferative diabetic retinopathy, left eye + + + + + + + + + type 1 diabetes mellitus with stable proliferative diabetic retinopathy, bilateral + + + + + + + + + type 1 diabetes mellitus with stable proliferative diabetic retinopathy, unspecified eye + + + + + + + + + type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema + + + + + + + + + type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, right eye + + + + + + + + + type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, left eye + + + + + + + + + type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, bilateral + + + + + + + + + type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema, unspecified eye + + + + + + + + + type 1 diabetes mellitus with diabetic cataract + + + + + + + + + type 1 diabetes mellitus with diabetic macular edema + + + + + + + + + type 1 diabetes mellitus with diabetic macular edema, right eye + + + + + + + + + type 1 diabetes mellitus with diabetic macular edema, left eye + + + + + + + + + type 1 diabetes mellitus with diabetic macular edema, bilateral + + + + + + + + + type 1 diabetes mellitus with diabetic macular edema, unspecified eye + + + + + + + + + type 1 diabetes mellitus with other diabetic ophthalmic complication + + + + + + + + + type 1 diabetes mellitus with neurological complications + + + + + + + + + type 1 diabetes mellitus with diabetic neuropathy + + + + + + + + + type 1 diabetes mellitus with diabetic mononeuropathy + + + + + + + + + type 1 diabetes mellitus with diabetic polyneuropathy + + + + + + + + + type 1 diabetes mellitus with diabetic autonomic (poly)neuropathy + + + + + + + + + type 1 diabetes mellitus with diabetic amyotrophy + + + + + + + + + type 1 diabetes mellitus with other diabetic neurological complication + + + + + + + + + type 1 diabetes mellitus with circulatory complications + + + + + + + + + type 1 diabetes mellitus with diabetic peripheral angiopathy without gangrene + + + + + + + + + type 1 diabetes mellitus with diabetic peripheral angiopathy with gangrene + + + + + + + + + type 1 diabetes mellitus with other circulatory complications + + + + + + + + + type 1 diabetes mellitus with other specified complications + + + + + + + + + type 1 diabetes mellitus with diabetic arthropathy + + + + + + + + + type 1 diabetes mellitus with diabetic neuropathic arthropathy + + + + + + + + + type 1 diabetes mellitus with other diabetic arthropathy + + + + + + + + + type 1 diabetes mellitus with skin complications + + + + + + + + + type 1 diabetes mellitus with diabetic dermatitis + + + + + + + + + type 1 diabetes mellitus with foot ulcer + + + + + + + + + type 1 diabetes mellitus with other skin ulcer + + + + + + + + + type 1 diabetes mellitus with other skin complications + + + + + + + + + type 1 diabetes mellitus with oral complications + + + + + + + + + type 1 diabetes mellitus with periodontal disease + + + + + + + + + type 1 diabetes mellitus with other oral complications + + + + + + + + + type 1 diabetes mellitus with hypoglycemia + + + + + + + + + type 1 diabetes mellitus with hypoglycemia with coma + + + + + + + + + type 1 diabetes mellitus with hypoglycemia without coma + + + + + + + + + type 1 diabetes mellitus with hyperglycemia + + + + + + + + + type 1 diabetes mellitus with other specified complication + + + + + + + + + type 1 diabetes mellitus with unspecified complications + + + + + + + + + type 1 diabetes mellitus without complications + + + + + + + + + edoxaban 15 mg oral tablet [savaysa] + + + + + + + + + edoxaban 15 mg oral tablet + + + + + + + + + edoxaban 30 mg oral tablet [savaysa] + + + + + + + + + edoxaban 30 mg oral tablet + + + + + + + + + edoxaban 60 mg oral tablet [savaysa] + + + + + + + + + edoxaban 60 mg oral tablet + + + + + + + + + edoxaban oral tablet + + + + + + + + + edoxaban + + + + + + + + + emergency department services + + + + + + + + + emergency department visit admit to inpatient + + + + + + + + + emergency department visit for the evaluation and management of a patient + + + + + + + + + emergency department visit + + + + + + + + + emergency + + + + + + + + + enalapril injectable solution + + + + + + + + + enalapril maleate 1 mg/ml oral solution [epaned] + + + + + + + + + enalapril maleate 1 mg/ml oral solution + + + + + + + + + enalapril maleate 1.25 mg/ml injectable solution + + + + + + + + + enalapril maleate 10 mg oral tablet [vasotec] + + + + + + + + + enalapril maleate 10 mg oral tablet + + + + + + + + + enalapril maleate 2.5 mg oral tablet [vasotec] + + + + + + + + + enalapril maleate 2.5 mg oral tablet + + + + + + + + + enalapril maleate 20 mg oral tablet [vasotec] + + + + + + + + + enalapril maleate 20 mg oral tablet + + + + + + + + + enalapril maleate 5 mg oral tablet [vasotec] + + + + + + + + + enalapril maleate 5 mg oral tablet + + + + + + + + + enalapril oral solution + + + + + + + + + enalapril oral tablet + + + + + + + + + enalapril + + + + + + + + + enoxaparin injectable solution + + + + + + + + + enoxaparin prefilled syringe + + + + + + + + + enoxaparin sodium 100 mg/ml injectable solution [lovenox] + + + + + + + + + enoxaparin sodium 100 mg/ml injectable solution + + + + + + + + + epinephrine 0.1 mg/ml injectable solution + + + + + + + + + epinephrine 0.22 mg inhalant powder + + + + + + + + + epinephrine 0.3 mg/actuat inhalant solution [asthmahaler] + + + + + + + + + epinephrine 0.3 mg/actuat inhalant solution + + + + + + + + + epinephrine 0.5 mg/ml injectable solution + + + + + + + + + epinephrine 0.5 mg/ml ophthalmic solution + + + + + + + + + epinephrine 1 mg/ml inhalant solution + + + + + + + + + epinephrine 1 mg/ml injectable solution [adrenalin] + + + + + + + + + epinephrine 1 mg/ml injectable solution + + + + + + + + + epinephrine 1 mg/ml nasal solution + + + + + + + + + epinephrine 1 mg/ml ophthalmic solution + + + + + + + + + epinephrine 10 mg/ml ophthalmic solution + + + + + + + + + epinephrine 2.5 mg/ml ophthalmic solution + + + + + + + + + epinephrine 5 mg/ml ophthalmic solution + + + + + + + + + epinephrine auto-injector + + + + + + + + + epinephrine inhalant powder + + + + + + + + + epinephrine inhalant solution + + + + + + + + + epinephrine injectable solution + + + + + + + + + epinephrine injection + + + + + + + + + epinephrine metered dose inhaler + + + + + + + + + epinephrine nasal solution + + + + + + + + + epinephrine ophthalmic solution + + + + + + + + + epinephrine prefilled syringe + + + + + + + + + epinephrine + + + + + + + + + epoprostenol 0.5 mg injection [flolan] + + + + + + + + + epoprostenol 0.5 mg injection [veletri] + + + + + + + + + epoprostenol 0.5 mg injection + + + + + + + + + epoprostenol 1.5 mg injection [flolan] + + + + + + + + + epoprostenol 1.5 mg injection [veletri] + + + + + + + + + epoprostenol 1.5 mg injection + + + + + + + + + epoprostenol injection + + + + + + + + + epoprostenol + + + + + + + + + eprosartan 300 mg oral tablet + + + + + + + + + eprosartan 400 mg oral tablet + + + + + + + + + eprosartan 600 mg oral tablet [teveten] + + + + + + + + + eprosartan 600 mg oral tablet + + + + + + + + + eprosartan oral tablet + + + + + + + + + eprosartan + + + + + + + + + eptifibatide injection + + + + + + + + + eptifibatide + + + + + + + + + established patient office or other outpatient services + + + + + + + + + etacrynic acid + + + + + + + + + etodolac 200 mg oral capsule + + + + + + + + + etodolac 300 mg oral capsule + + + + + + + + + etodolac 400 mg oral tablet [lodine] + + + + + + + + + etodolac 400 mg oral tablet + + + + + + + + + etodolac 500 mg oral tablet + + + + + + + + + etodolac extended release oral tablet + + + + + + + + + etodolac oral capsule + + + + + + + + + etodolac oral tablet + + + + + + + + + etodolac + + + + + + + + + extracorporeal membrane oxygenation + + + + + + + + + extracorporeal membrane oxygenation (ecmo) + + + + + + + + + extracorporeal membrane oxygenation (ecmo)/extracorporeal life support (ecls) provided by physician daily management + + + + + + + + + extracorporeal membrane oxygenation (ecmo)/extracorporeal life support (ecls) provided by physician initiation + + + + + + + + + extracorporeal membrane oxygenation (ecmo)/extracorporeal life support (ecls) provided by physician insertion of central cannula(e) by sternotomy or thoracotomy + + + + + + + + + extracorporeal membrane oxygenation (ecmo)/extracorporeal life support (ecls) provided by physician insertion of peripheral (arterial and/or venous) cannula(e) + + + + + + + + + extracorporeal membrane oxygenation (ecmo)/extracorporeal life support (ecls) provided by physician removal of central cannula(e) by sternotomy or thoracotomy + + + + + + + + + extracorporeal membrane oxygenation (ecmo)/extracorporeal life support (ecls) provided by physician removal of peripheral (arterial and/or venous) cannula(e) + + + + + + + + + extracorporeal membrane oxygenation (ecmo)/extracorporeal life support (ecls) provided by physician reposition central cannula(e) by sternotomy or thoracotomy + + + + + + + + + extracorporeal membrane oxygenation (ecmo)/extracorporeal life support (ecls) provided by physician reposition of central cannula(e) by sternotomy or thoracotomy + + + + + + + + + extracorporeal membrane oxygenation (ecmo)/extracorporeal life support (ecls) provided by physician reposition peripheral (arterial and/or venous) cannula(e) + + + + + + + + + extracorporeal membrane oxygenation (ecmo)/extracorporeal life support (ecls) provided by physician + + + + + + + + + extracorporeal oxygenation + + + + + + + + + fenoprofen 200 mg oral capsule [fenortho] + + + + + + + + + fenoprofen 200 mg oral capsule [nalfon] + + + + + + + + + fenoprofen 200 mg oral capsule + + + + + + + + + fenoprofen 300 mg oral capsule + + + + + + + + + fenoprofen 300 mg oral tablet + + + + + + + + + fenoprofen 400 mg oral capsule [fenortho] + + + + + + + + + fenoprofen 400 mg oral capsule [nalfon] + + + + + + + + + fenoprofen 400 mg oral capsule + + + + + + + + + fenoprofen 600 mg oral tablet [profeno] + + + + + + + + + fenoprofen 600 mg oral tablet + + + + + + + + + fenoprofen oral capsule + + + + + + + + + fenoprofen oral tablet + + + + + + + + + fenoprofen + + + + + + + + + ferritin | bld-ser-plas + + + + + + + + + ferritin:imp:pt:bld:nom + + + + + + + + + ferritin:mcnc:pt:bld:qn + + + + + + + + + ferritin:mcnc:pt:ser/plas:qn:ia + + + + + + + + + ferritin:mcnc:pt:ser/plas:qn + + + + + + + + + ferritin:mscnc:pt:ser/plas:qn + + + + + + + + + ferritin:scnc:pt:ser/plas:qn + + + + + + + + + fibrin d-dimer ddu | platelet poor plasma + + + + + + + + + fibrin d-dimer ddu:mcnc:pt:ppp:qn:ia + + + + + + + + + fibrin d-dimer ddu:mcnc:pt:ppp:qn + + + + + + + + + fibrin d-dimer feu | platelet poor plasma + + + + + + + + + fibrin d-dimer feu:mcnc:pt:ppp:qn:ia + + + + + + + + + fibrin d-dimer feu:mcnc:pt:ppp:qn + + + + + + + + + fibrinogen | platelet poor plasma + + + + + + + + + fibrinogen ag:mcnc:pt:ppp:qn:ia + + + + + + + + + fibrinogen ag:mcnc:pt:ppp:qn:nephelometry + + + + + + + + + fibrinogen ag/fibrinogen:mrto:pt:ppp:qn + + + + + + + + + fibrinogen:imp:pt:ppp:nom + + + + + + + + + fibrinogen:mcnc:pt:ppp:qn:coag.derived + + + + + + + + + fibrinogen:mcnc:pt:ppp:qn:coag + + + + + + + + + fibrinogen:mcnc:pt:ppp:qn:heat denaturation + + + + + + + + + fibrinogen:mscnc:pt:ppp:qn:coag + + + + + + + + + fibrinogen:prthr:pt:ppp:ord + + + + + + + + + flu shot (derived) + + + + + + + + + flu shot + + + + + + + + + flurbiprofen 100 mg oral tablet [ansaid] + + + + + + + + + flurbiprofen 100 mg oral tablet + + + + + + + + + flurbiprofen 100 mg rectal suppository + + + + + + + + + flurbiprofen 200 mg extended release oral capsule + + + + + + + + + flurbiprofen 50 mg oral tablet + + + + + + + + + flurbiprofen 8.75 mg oral lozenge + + + + + + + + + flurbiprofen extended release oral capsule + + + + + + + + + flurbiprofen ophthalmic solution + + + + + + + + + flurbiprofen oral lozenge + + + + + + + + + flurbiprofen oral tablet + + + + + + + + + flurbiprofen rectal suppository + + + + + + + + + flurbiprofen sodium 0.3 mg/ml ophthalmic solution [ocufen] + + + + + + + + + flurbiprofen sodium 0.3 mg/ml ophthalmic solution + + + + + + + + + flurbiprofen + + + + + + + + + fondaparinux prefilled syringe + + + + + + + + + fondaparinux + + + + + + + + + fosinopril oral tablet + + + + + + + + + fosinopril sodium 10 mg oral tablet [monopril] + + + + + + + + + fosinopril sodium 10 mg oral tablet + + + + + + + + + fosinopril sodium 20 mg oral tablet + + + + + + + + + fosinopril sodium 40 mg oral tablet [monopril] + + + + + + + + + fosinopril sodium 40 mg oral tablet + + + + + + + + + fosinopril + + + + + + + + + furosemide 1 mg/ml oral solution + + + + + + + + + furosemide 10 mg/ml oral solution [furoquid] + + + + + + + + + furosemide 10 mg/ml oral solution + + + + + + + + + furosemide 12.5 mg oral tablet [disal] + + + + + + + + + furosemide 12.5 mg oral tablet [salix - substance] + + + + + + + + + furosemide 12.5 mg oral tablet + + + + + + + + + furosemide 20 mg oral tablet [lasix] + + + + + + + + + furosemide 20 mg oral tablet + + + + + + + + + furosemide 20 mg/ml injectable solution + + + + + + + + + furosemide 4 mg/ml oral solution + + + + + + + + + furosemide 40 mg oral tablet [lasix] + + + + + + + + + furosemide 40 mg oral tablet + + + + + + + + + furosemide 50 mg oral tablet [disal] + + + + + + + + + furosemide 50 mg oral tablet [salix - substance] + + + + + + + + + furosemide 50 mg oral tablet + + + + + + + + + furosemide 50 mg/ml injectable solution [disal] + + + + + + + + + furosemide 50 mg/ml injectable solution [salix - substance] + + + + + + + + + furosemide 50 mg/ml injectable solution + + + + + + + + + furosemide 500 mg oral tablet + + + + + + + + + furosemide 8 mg/ml oral solution + + + + + + + + + furosemide 80 mg oral tablet [lasix] + + + + + + + + + furosemide 80 mg oral tablet + + + + + + + + + furosemide and potassium + + + + + + + + + furosemide injectable solution + + + + + + + + + furosemide injection + + + + + + + + + furosemide oral solution + + + + + + + + + furosemide oral tablet + + + + + + + + + furosemide prefilled syringe + + + + + + + + + furosemide + + + + + + + + + myasthenia gravis + + + + + + + + + myasthenia gravis without (acute) exacerbation + + + + + + + + + myasthenia gravis with (acute) exacerbation + + + + + + + + + heparin cartridge + + + + + + + + + heparin injectable solution + + + + + + + + + heparin injection + + + + + + + + + heparin prefilled syringe + + + + + + + + + heparin sodium + + + + + + + + + heparin + + + + + + + + + hormones/sythetics/modifiers + + + + + + + + + hospital discharge day management 30 minutes or less + + + + + + + + + hospital discharge day management more than 30 minutes + + + + + + + + + hospital discharge day management + + + + + + + + + hospital discharge services + + + + + + + + + hospital inpatient services + + + + + + + + + hydroxychloroquine sulfate 200 mg oral tablet [plaquenil] + + + + + + + + + ia nfct ab sarscov2 covid19 + + + + + + + + + ibuprofen 0.05 mg/mg topical gel + + + + + + + + + ibuprofen 0.1 mg/mg topical gel + + + + + + + + + ibuprofen 100 mg chewable tablet [advil] + + + + + + + + + ibuprofen 100 mg chewable tablet [motrin] + + + + + + + + + ibuprofen 100 mg chewable tablet + + + + + + + + + ibuprofen 100 mg oral tablet [advil] + + + + + + + + + ibuprofen 100 mg oral tablet [motrin] + + + + + + + + + ibuprofen 100 mg oral tablet + + + + + + + + + ibuprofen 20 mg/ml oral solution + + + + + + + + + ibuprofen 20 mg/ml oral suspension [advil] + + + + + + + + + ibuprofen 20 mg/ml oral suspension [motrin] + + + + + + + + + ibuprofen 20 mg/ml oral suspension [pediacare childrens pain & fever w/ ibuprofen] + + + + + + + + + ibuprofen 20 mg/ml oral suspension + + + + + + + + + ibuprofen 200 mg oral capsule [advil] + + + + + + + + + ibuprofen 200 mg oral capsule [midol cramps & bodyaches] + + + + + + + + + ibuprofen 200 mg oral capsule [motrin] + + + + + + + + + ibuprofen 200 mg oral capsule [wal-profen] + + + + + + + + + ibuprofen 200 mg oral capsule + + + + + + + + + ibuprofen 200 mg oral tablet [addaprin] + + + + + + + + + ibuprofen 200 mg oral tablet [advil] + + + + + + + + + ibuprofen 200 mg oral tablet [counteract ib] + + + + + + + + + ibuprofen 200 mg oral tablet [dragon tabs] + + + + + + + + + ibuprofen 200 mg oral tablet [genpril] + + + + + + + + + ibuprofen 200 mg oral tablet [ibuprohm] + + + + + + + + + ibuprofen 200 mg oral tablet [ibutab] + + + + + + + + + ibuprofen 200 mg oral tablet [midol cramps & bodyaches] + + + + + + + + + ibuprofen 200 mg oral tablet [motrin] + + + + + + + + + ibuprofen 200 mg oral tablet [nuprin] + + + + + + + + + ibuprofen 200 mg oral tablet [proprinal] + + + + + + + + + ibuprofen 200 mg oral tablet [ultraprin] + + + + + + + + + ibuprofen 200 mg oral tablet [wal-profen] + + + + + + + + + ibuprofen 200 mg oral tablet + + + + + + + + + ibuprofen 3 mg/ml oral suspension + + + + + + + + + ibuprofen 40 mg/ml oral suspension [advil] + + + + + + + + + ibuprofen 40 mg/ml oral suspension [motrin] + + + + + + + + + ibuprofen 40 mg/ml oral suspension [pediacare fever] + + + + + + + + + ibuprofen 40 mg/ml oral suspension + + + + + + + + + ibuprofen 400 mg oral tablet [ibu] + + + + + + + + + ibuprofen 400 mg oral tablet + + + + + + + + + ibuprofen 50 mg chewable tablet [advil] + + + + + + + + + ibuprofen 50 mg chewable tablet + + + + + + + + + ibuprofen 50 mg/ml topical cream + + + + + + + + + ibuprofen 50 mg/ml topical foam + + + + + + + + + ibuprofen 50 mg/ml topical spray + + + + + + + + + ibuprofen 600 mg oral tablet [ibu] + + + + + + + + + ibuprofen 600 mg oral tablet + + + + + + + + + ibuprofen 800 mg oral tablet [ibu] + + + + + + + + + ibuprofen 800 mg oral tablet [motrin] + + + + + + + + + ibuprofen 800 mg oral tablet [samson 8] + + + + + + + + + ibuprofen 800 mg oral tablet + + + + + + + + + ibuprofen chewable tablet + + + + + + + + + ibuprofen injection + + + + + + + + + ibuprofen oral capsule + + + + + + + + + ibuprofen oral solution + + + + + + + + + ibuprofen oral suspension + + + + + + + + + ibuprofen oral tablet + + + + + + + + + ibuprofen topical cream + + + + + + + + + ibuprofen topical foam + + + + + + + + + ibuprofen topical gel + + + + + + + + + ibuprofen topical spray + + + + + + + + + icd10 ventilation procedures + + + + + + + + + illness severity + + + + + + + + + imidapril 10 mg oral tablet + + + + + + + + + imidapril 20 mg oral tablet + + + + + + + + + imidapril 5 mg oral tablet + + + + + + + + + imidapril oral tablet + + + + + + + + + imidapril + + + + + + + + + immunization administration through 18 years of age via any route of administration + + + + + + + + + immunodeficiency (derived) + + + + + + + + + immunosuppressants + + + + + + + + + indobufen + + + + + + + + + indomethacin 1 mg injection + + + + + + + + + indomethacin 10 mg/ml ophthalmic solution + + + + + + + + + indomethacin 100 mg rectal suppository + + + + + + + + + indomethacin 20 mg oral capsule [tivorbex] + + + + + + + + + indomethacin 20 mg oral capsule + + + + + + + + + indomethacin 25 mg oral capsule + + + + + + + + + indomethacin 40 mg oral capsule [tivorbex] + + + + + + + + + indomethacin 40 mg oral capsule + + + + + + + + + indomethacin 5 mg/ml oral suspension [indocin] + + + + + + + + + indomethacin 5 mg/ml oral suspension + + + + + + + + + indomethacin 50 mg oral capsule + + + + + + + + + indomethacin 50 mg rectal suppository [indocin] + + + + + + + + + indomethacin 50 mg rectal suppository + + + + + + + + + indomethacin 75 mg extended release oral capsule [indocin] + + + + + + + + + indomethacin 75 mg extended release oral capsule + + + + + + + + + indomethacin 75 mg oral capsule + + + + + + + + + indomethacin extended release oral capsule + + + + + + + + + indomethacin injection + + + + + + + + + indomethacin ophthalmic solution + + + + + + + + + indomethacin oral capsule + + + + + + + + + indomethacin oral suspension + + + + + + + + + indomethacin rectal suppository + + + + + + + + + infectious agent antibody + + + + + + + + + infectious agent detection by nucleic acid (dna or rna) + + + + + + + + + influenza a/b positive (derived) + + + + + + + + + influenza a/b positive + + + + + + + + + influenza virus vaccine + + + + + + + + + initial hospital care + + + + + + + + + initial hospital inpatient care services + + + + + + + + + inpatient (critical care) + + + + + + + + + inpatient (routine) + + + + + + + + + inpatient hospital stay + + + + + + + + + insertion of endotracheal airway into trachea + + + + + + + + + interferon beta-1b 0.3 mg injection [betaseron] + + + + + + + + + interferon beta-1b 0.3 mg injection [extavia] + + + + + + + + + interferon beta-1b 0.3 mg injection + + + + + + + + + interferon beta-1b injection + + + + + + + + + intubation + + + + + + + + + irbesartan 150 mg oral tablet [avapro] + + + + + + + + + irbesartan 150 mg oral tablet + + + + + + + + + irbesartan 300 mg oral tablet [avapro] + + + + + + + + + irbesartan 300 mg oral tablet + + + + + + + + + irbesartan 75 mg oral tablet [avapro] + + + + + + + + + irbesartan 75 mg oral tablet + + + + + + + + + irbesartan oral tablet + + + + + + + + + itolizumab + + + + + + + + + nfluenza due to identified novel influenza a virus + + + + + + + + + influenza due to identified novel influenza a virus with pneumonia + + + + + + + + + influenza due to identified novel influenza a virus with other respiratory manifestations + + + + + + + + + influenza due to identified novel influenza a virus with gastrointestinal manifestations + + + + + + + + + influenza due to identified novel influenza a virus with other manifestations + + + + + + + + + influenza due to other identified influenza virus + + + + + + + + + influenza due to other identified influenza virus with pneumonia + + + + + + + + + influenza due to other identified influenza virus with unspecified type of pneumonia + + + + + + + + + influenza due to other identified influenza virus with the same other identified influenza virus pneumonia + + + + + + + + + influenza due to other identified influenza virus with other specified pneumonia + + + + + + + + + influenza due to other identified influenza virus with other respiratory manifestations + + + + + + + + + influenza due to other identified influenza virus with gastrointestinal manifestations + + + + + + + + + influenza due to other identified influenza virus with other manifestations + + + + + + + + + influenza due to other identified influenza virus with encephalopathy + + + + + + + + + influenza due to other identified influenza virus with myocarditis + + + + + + + + + influenza due to other identified influenza virus with otitis media + + + + + + + + + complication of respirator [ventilator] + + + + + + + + + mechanical complication of respirator + + + + + + + + + ventilator associated pneumonia + + + + + + + + + other complication of respirator [ventilator] + + + + + + + + + ulcerative colitis + + + + + + + + + ulcerative (chronic) pancolitis + + + + + + + + + ulcerative (chronic) pancolitis without complications + + + + + + + + + ulcerative (chronic) pancolitis with complications + + + + + + + + + ulcerative (chronic) pancolitis with rectal bleeding + + + + + + + + + ulcerative (chronic) pancolitis with intestinal obstruction + + + + + + + + + ulcerative (chronic) pancolitis with fistula + + + + + + + + + ulcerative (chronic) pancolitis with abscess + + + + + + + + + ulcerative (chronic) pancolitis with other complication + + + + + + + + + ulcerative (chronic) pancolitis with unspecified complications + + + + + + + + + ulcerative (chronic) proctitis + + + + + + + + + ulcerative (chronic) proctitis without complications + + + + + + + + + ulcerative (chronic) proctitis with complications + + + + + + + + + ulcerative (chronic) proctitis with rectal bleeding + + + + + + + + + ulcerative (chronic) proctitis with intestinal obstruction + + + + + + + + + ulcerative (chronic) proctitis with fistula + + + + + + + + + ulcerative (chronic) proctitis with abscess + + + + + + + + + ulcerative (chronic) proctitis with other complication + + + + + + + + + ulcerative (chronic) proctitis with unspecified complications + + + + + + + + + ulcerative (chronic) rectosigmoiditis + + + + + + + + + ulcerative (chronic) rectosigmoiditis without complications + + + + + + + + + ulcerative (chronic) rectosigmoiditis with complications + + + + + + + + + ulcerative (chronic) rectosigmoiditis with rectal bleeding + + + + + + + + + ulcerative (chronic) rectosigmoiditis with intestinal obstruction + + + + + + + + + ulcerative (chronic) rectosigmoiditis with fistula + + + + + + + + + ulcerative (chronic) rectosigmoiditis with abscess + + + + + + + + + ulcerative (chronic) rectosigmoiditis with other complication + + + + + + + + + ulcerative (chronic) rectosigmoiditis with unspecified complications + + + + + + + + + inflammatory polyps of colon + + + + + + + + + inflammatory polyps of colon without complications + + + + + + + + + inflammatory polyps of colon with complications + + + + + + + + + inflammatory polyps of colon with rectal bleeding + + + + + + + + + inflammatory polyps of colon with intestinal obstruction + + + + + + + + + inflammatory polyps of colon with fistula + + + + + + + + + inflammatory polyps of colon with abscess + + + + + + + + + inflammatory polyps of colon with other complication + + + + + + + + + inflammatory polyps of colon with unspecified complications + + + + + + + + + left sided colitis + + + + + + + + + left sided colitis without complications + + + + + + + + + left sided colitis with complications + + + + + + + + + left sided colitis with rectal bleeding + + + + + + + + + left sided colitis with intestinal obstruction + + + + + + + + + left sided colitis with fistula + + + + + + + + + left sided colitis with abscess + + + + + + + + + left sided colitis with other complication + + + + + + + + + left sided colitis with unspecified complications + + + + + + + + + other ulcerative colitis + + + + + + + + + other ulcerative colitis without complications + + + + + + + + + other ulcerative colitis with complications + + + + + + + + + other ulcerative colitis with rectal bleeding + + + + + + + + + other ulcerative colitis with intestinal obstruction + + + + + + + + + other ulcerative colitis with fistula + + + + + + + + + other ulcerative colitis with abscess + + + + + + + + + other ulcerative colitis with other complication + + + + + + + + + other ulcerative colitis with unspecified complications + + + + + + + + + ulcerative colitis without complications + + + + + + + + + ulcerative colitis with complications + + + + + + + + + Ulcerative colitis, unspecified with rectal bleeding + + + + + + + + + Ulcerative colitis, unspecified with intestinal obstruction + + + + + + + + + Ulcerative colitis, unspecified with fistula + + + + + + + + + Ulcerative colitis, unspecified with abscess + + + + + + + + + Ulcerative colitis, unspecified with other complication + + + + + + + + + Ulcerative colitis, unspecified with unspecified complications + + + + + + + + + ketamine 10 mg/ml injectable solution [ketalar] + + + + + + + + + ketamine 10 mg/ml injectable solution + + + + + + + + + ketamine 100 mg/ml injectable solution [ketaject] + + + + + + + + + ketamine 100 mg/ml injectable solution [ketalar] + + + + + + + + + ketamine 100 mg/ml injectable solution [ketaset] + + + + + + + + + ketamine 100 mg/ml injectable solution [ketathesia] + + + + + + + + + ketamine 100 mg/ml injectable solution [ketaved] + + + + + + + + + ketamine 100 mg/ml injectable solution [vetaket] + + + + + + + + + ketamine 100 mg/ml injectable solution [zetamine] + + + + + + + + + ketamine 100 mg/ml injectable solution + + + + + + + + + ketamine 50 mg/ml injectable solution [ketalar] + + + + + + + + + ketamine 50 mg/ml injectable solution + + + + + + + + + ketamine injectable solution + + + + + + + + + ketamine + + + + + + + + + ketoprofen 0.025 mg/mg topical gel + + + + + + + + + ketoprofen 0.05 mg/mg topical powder + + + + + + + + + ketoprofen 100 mg delayed release oral tablet + + + + + + + + + ketoprofen 100 mg oral capsule + + + + + + + + + ketoprofen 100 mg oral tablet + + + + + + + + + ketoprofen 100 mg rectal suppository + + + + + + + + + ketoprofen 100 mg/ml injectable solution [ketofen] + + + + + + + + + ketoprofen 100 mg/ml injectable solution + + + + + + + + + ketoprofen 12.5 mg oral tablet + + + + + + + + + ketoprofen 150 mg extended release oral tablet + + + + + + + + + ketoprofen 25 mg oral capsule + + + + + + + + + ketoprofen 25 mg oral tablet + + + + + + + + + ketoprofen 50 mg delayed release oral tablet + + + + + + + + + ketoprofen 50 mg oral capsule + + + + + + + + + ketoprofen 50 mg rectal suppository + + + + + + + + + ketoprofen 75 mg oral capsule + + + + + + + + + ketoprofen delayed release oral tablet + + + + + + + + + ketoprofen extended release oral capsule + + + + + + + + + ketoprofen extended release oral tablet + + + + + + + + + ketoprofen injectable solution + + + + + + + + + ketoprofen oral capsule + + + + + + + + + ketoprofen oral tablet + + + + + + + + + ketoprofen rectal suppository + + + + + + + + + ketoprofen topical gel + + + + + + + + + ketoprofen topical powder + + + + + + + + + ketoprofen + + + + + + + + + ketorolac cartridge + + + + + + + + + ketorolac injectable solution + + + + + + + + + ketorolac injection + + + + + + + + + ketorolac metered dose nasal spray + + + + + + + + + ketorolac ophthalmic solution + + + + + + + + + ketorolac oral tablet + + + + + + + + + ketorolac prefilled syringe + + + + + + + + + ketorolac tromethamine 10 mg oral tablet + + + + + + + + + ketorolac tromethamine 10 mg/ml injectable solution + + + + + + + + + ketorolac tromethamine 15.8 mg/actuat metered dose nasal spray [sprix] + + + + + + + + + ketorolac tromethamine 15.8 mg/actuat metered dose nasal spray + + + + + + + + + ketorolac tromethamine 30 mg/ml injectable solution + + + + + + + + + ketorolac tromethamine 4 mg/ml ophthalmic solution [acular] + + + + + + + + + ketorolac tromethamine 4 mg/ml ophthalmic solution + + + + + + + + + ketorolac tromethamine 4.5 mg/ml ophthalmic solution [acuvail] + + + + + + + + + ketorolac tromethamine 4.5 mg/ml ophthalmic solution + + + + + + + + + ketorolac tromethamine 5 mg/ml ophthalmic solution [acular] + + + + + + + + + ketorolac tromethamine 5 mg/ml ophthalmic solution + + + + + + + + + ketorolac + + + + + + + + + known deceased + + + + + + + + + lupus erythematosus + + + + + + + + + discoid lupus erythematosus + + + + + + + + + subacute cutaneous lupus erythematosus + + + + + + + + + other local lupus erythematosus + + + + + + + + + lab orders + + + + + + + + + lactate dehydrogenase | bld-ser-plas + + + + + + + + + lactate dehydrogenase:ccnc:pt:ser/plas:qn:reaction: lactate to pyruvate + + + + + + + + + lactate dehydrogenase:ccnc:pt:ser/plas:qn:reaction: pyruvate to lactate + + + + + + + + + lactate dehydrogenase:ccnc:pt:ser/plas:qn + + + + + + + + + lepirudin + + + + + + + + + leukocytes | bld-ser-plas + + + + + + + + + leukocytes:ncnc:pt:bld:qn:automated count + + + + + + + + + leukocytes:ncnc:pt:bld:qn:estimate + + + + + + + + + leukocytes:ncnc:pt:bld:qn:manual count + + + + + + + + + leukocytes:ncnc:pt:bld:qn + + + + + + + + + leukocytes^^corrected for nucleated erythrocytes:ncnc:pt:bld:qn:automated count + + + + + + + + + leukocytes^^corrected for nucleated erythrocytes:ncnc:pt:bld:qn + + + + + + + + + level of care (setting) + + + + + + + + + lisinopril 1 mg/ml oral solution [qbrelis] + + + + + + + + + lisinopril 1 mg/ml oral solution + + + + + + + + + lisinopril 10 mg oral tablet [prinivil] + + + + + + + + + lisinopril 10 mg oral tablet [zestril] + + + + + + + + + lisinopril 10 mg oral tablet + + + + + + + + + lisinopril 2.5 mg oral tablet [zestril] + + + + + + + + + lisinopril 2.5 mg oral tablet + + + + + + + + + lisinopril 20 mg oral tablet [prinivil] + + + + + + + + + lisinopril 20 mg oral tablet [zestril] + + + + + + + + + lisinopril 20 mg oral tablet + + + + + + + + + lisinopril 30 mg oral tablet [zestril] + + + + + + + + + lisinopril 30 mg oral tablet + + + + + + + + + lisinopril 40 mg oral tablet [zestril] + + + + + + + + + lisinopril 40 mg oral tablet + + + + + + + + + lisinopril 5 mg oral tablet [prinivil] + + + + + + + + + lisinopril 5 mg oral tablet [zestril] + + + + + + + + + lisinopril 5 mg oral tablet + + + + + + + + + lisinopril oral solution + + + + + + + + + lisinopril oral tablet + + + + + + + + + equivocal + + + + + + + + + pending + + + + + + + + + loop diuretics + + + + + + + + + lopinavir / ritonavir oral capsule + + + + + + + + + lopinavir / ritonavir oral solution + + + + + + + + + lopinavir / ritonavir oral tablet + + + + + + + + + lopinavir / ritonavir + + + + + + + + + lopinavir 100 mg / ritonavir 25 mg oral tablet [kaletra] + + + + + + + + + lopinavir 100 mg / ritonavir 25 mg oral tablet + + + + + + + + + lopinavir 133 mg / ritonavir 33.3 mg oral capsule + + + + + + + + + lopinavir 200 mg / ritonavir 50 mg oral tablet [kaletra] + + + + + + + + + lopinavir 200 mg / ritonavir 50 mg oral tablet + + + + + + + + + lopinavir 80 mg/ml / ritonavir 20 mg/ml oral solution [kaletra] + + + + + + + + + lopinavir 80 mg/ml / ritonavir 20 mg/ml oral solution + + + + + + + + + losartan oral tablet + + + + + + + + + losartan potassium 100 mg oral tablet [cozaar] + + + + + + + + + losartan potassium 100 mg oral tablet + + + + + + + + + losartan potassium 25 mg oral tablet [cozaar] + + + + + + + + + losartan potassium 25 mg oral tablet + + + + + + + + + losartan potassium 50 mg oral tablet [cozaar] + + + + + + + + + losartan potassium 50 mg oral tablet + + + + + + + + + lymphocytes | bld-ser-plas + + + + + + + + + lymphocytes:ncnc:pt:bld:qn:automated count + + + + + + + + + lymphocytes:ncnc:pt:bld:qn:manual count + + + + + + + + + lymphocytes:ncnc:pt:bld:qn + + + + + + + + + lymphocytes/100 leukocytes:nfr:pt:bld:qn:automated count + + + + + + + + + lymphocytes/100 leukocytes:nfr:pt:bld:qn:manual count + + + + + + + + + lymphocytes/100 leukocytes:nfr:pt:bld:qn + + + + + + + + + lymphocytes/leukocytes:nfr.df:pt:bld:qn:automated count + + + + + + + + + lymphocytes/leukocytes:nfr.df:pt:bld:qn:manual count + + + + + + + + + rheumatoid arthritis with rheumatoid factor + + + + + + + + + feltys syndrome + + + + + + + + + feltys syndrome(unspecified site) + + + + + + + + + feltys syndrome(shoulder) + + + + + + + + + feltys syndrome(right shoulder) + + + + + + + + + feltys syndrome(left shoulder) + + + + + + + + + feltys syndrome(unspecified shoulder) + + + + + + + + + feltys syndrome(elbow) + + + + + + + + + feltys syndrome(right elbow) + + + + + + + + + feltys syndrome(left elbow) + + + + + + + + + feltys syndrome(unspecified elbow) + + + + + + + + + feltys syndrome(wrist) + + + + + + + + + feltys syndrome(right wrist) + + + + + + + + + feltys syndrome(left wrist) + + + + + + + + + feltys syndrome(unspecified wrist) + + + + + + + + + feltys syndrome(hand) + + + + + + + + + feltys syndrome(right hand) + + + + + + + + + feltys syndrome(left hand) + + + + + + + + + feltys syndrome(unspecified hand) + + + + + + + + + feltys syndrome(hip) + + + + + + + + + feltys syndrome(right hip) + + + + + + + + + feltys syndrome(left hip) + + + + + + + + + feltys syndrome(unspecified hip) + + + + + + + + + feltys syndrome(knee) + + + + + + + + + feltys syndrome(right knee) + + + + + + + + + feltys syndrome(left knee) + + + + + + + + + feltys syndrome(unspecified knee) + + + + + + + + + feltys syndrome(ankle and foot) + + + + + + + + + feltys syndrome(right ankle and foot) + + + + + + + + + feltys syndrome(left ankle and foot) + + + + + + + + + feltys syndrome(unspecified ankle and foot) + + + + + + + + + feltys syndrome(multiple sites) + + + + + + + + + rheumatoid lung disease with rheumatoid arthritis + + + + + + + + + rheumatoid lung disease with rheumatoid arthritis of unspecified site + + + + + + + + + rheumatoid lung disease with rheumatoid arthritis of shoulder + + + + + + + + + rheumatoid lung disease with rheumatoid arthritis of right shoulder + + + + + + + + + rheumatoid lung disease with rheumatoid arthritis of left shoulder + + + + + + + + + rheumatoid lung disease with rheumatoid arthritis of unspecified shoulder + + + + + + + + + rheumatoid lung disease with rheumatoid arthritis of elbow + + + + + + + + + rheumatoid lung disease with rheumatoid arthritis of right elbow + + + + + + + + + rheumatoid lung disease with rheumatoid arthritis of left elbow + + + + + + + + + rheumatoid lung disease with rheumatoid arthritis of unspecified elbow + + + + + + + + + rheumatoid lung disease with rheumatoid arthritis of wrist + + + + + + + + + rheumatoid lung disease with rheumatoid arthritis of right wrist + + + + + + + + + rheumatoid lung disease with rheumatoid arthritis of left wrist + + + + + + + + + rheumatoid lung disease with rheumatoid arthritis of unspecified wrist + + + + + + + + + rheumatoid lung disease with rheumatoid arthritis of hand + + + + + + + + + rheumatoid lung disease with rheumatoid arthritis of right hand + + + + + + + + + rheumatoid lung disease with rheumatoid arthritis of left hand + + + + + + + + + rheumatoid lung disease with rheumatoid arthritis of unspecified hand + + + + + + + + + rheumatoid lung disease with rheumatoid arthritis of hip + + + + + + + + + rheumatoid lung disease with rheumatoid arthritis of right hip + + + + + + + + + rheumatoid lung disease with rheumatoid arthritis of left hip + + + + + + + + + rheumatoid lung disease with rheumatoid arthritis of unspecified hip + + + + + + + + + rheumatoid lung disease with rheumatoid arthritis of knee + + + + + + + + + rheumatoid lung disease with rheumatoid arthritis of right knee + + + + + + + + + rheumatoid lung disease with rheumatoid arthritis of left knee + + + + + + + + + rheumatoid lung disease with rheumatoid arthritis of unspecified knee + + + + + + + + + rheumatoid lung disease with rheumatoid arthritis of ankle and foot + + + + + + + + + rheumatoid lung disease with rheumatoid arthritis of right ankle and foot + + + + + + + + + rheumatoid lung disease with rheumatoid arthritis of left ankle and foot + + + + + + + + + rheumatoid lung disease with rheumatoid arthritis of unspecified ankle and foot + + + + + + + + + rheumatoid lung disease with rheumatoid arthritis of multiple sites + + + + + + + + + rheumatoid vasculitis with rheumatoid arthritis + + + + + + + + + rheumatoid vasculitis with rheumatoid arthritis of unspecified site + + + + + + + + + rheumatoid vasculitis with rheumatoid arthritis of shoulder + + + + + + + + + rheumatoid vasculitis with rheumatoid arthritis of right shoulder + + + + + + + + + rheumatoid vasculitis with rheumatoid arthritis of left shoulder + + + + + + + + + rheumatoid vasculitis with rheumatoid arthritis of unspecified shoulder + + + + + + + + + rheumatoid vasculitis with rheumatoid arthritis of elbow + + + + + + + + + rheumatoid vasculitis with rheumatoid arthritis of right elbow + + + + + + + + + rheumatoid vasculitis with rheumatoid arthritis of left elbow + + + + + + + + + rheumatoid vasculitis with rheumatoid arthritis of unspecified elbow + + + + + + + + + rheumatoid vasculitis with rheumatoid arthritis of wrist + + + + + + + + + rheumatoid vasculitis with rheumatoid arthritis of right wrist + + + + + + + + + rheumatoid vasculitis with rheumatoid arthritis of left wrist + + + + + + + + + rheumatoid vasculitis with rheumatoid arthritis of unspecified wrist + + + + + + + + + rheumatoid vasculitis with rheumatoid arthritis of hand + + + + + + + + + rheumatoid vasculitis with rheumatoid arthritis of right hand + + + + + + + + + rheumatoid vasculitis with rheumatoid arthritis of left hand + + + + + + + + + rheumatoid vasculitis with rheumatoid arthritis of unspecified hand + + + + + + + + + rheumatoid vasculitis with rheumatoid arthritis of hip + + + + + + + + + rheumatoid vasculitis with rheumatoid arthritis of right hip + + + + + + + + + rheumatoid vasculitis with rheumatoid arthritis of left hip + + + + + + + + + rheumatoid vasculitis with rheumatoid arthritis of unspecified hip + + + + + + + + + rheumatoid vasculitis with rheumatoid arthritis of knee + + + + + + + + + rheumatoid vasculitis with rheumatoid arthritis of right knee + + + + + + + + + rheumatoid vasculitis with rheumatoid arthritis of left knee + + + + + + + + + rheumatoid vasculitis with rheumatoid arthritis of unspecified knee + + + + + + + + + rheumatoid vasculitis with rheumatoid arthritis of ankle and foot + + + + + + + + + rheumatoid vasculitis with rheumatoid arthritis of right ankle and foot + + + + + + + + + rheumatoid vasculitis with rheumatoid arthritis of left ankle and foot + + + + + + + + + rheumatoid vasculitis with rheumatoid arthritis of unspecified ankle and foot + + + + + + + + + rheumatoid vasculitis with rheumatoid arthritis of multiple sites + + + + + + + + + rheumatoid heart disease with rheumatoid arthritis + + + + + + + + + rheumatoid heart disease with rheumatoid arthritis of unspecified site + + + + + + + + + rheumatoid heart disease with rheumatoid arthritis of shoulder + + + + + + + + + rheumatoid heart disease with rheumatoid arthritis of right shoulder + + + + + + + + + rheumatoid heart disease with rheumatoid arthritis of left shoulder + + + + + + + + + rheumatoid heart disease with rheumatoid arthritis of unspecified shoulder + + + + + + + + + rheumatoid heart disease with rheumatoid arthritis of elbow + + + + + + + + + rheumatoid heart disease with rheumatoid arthritis of right elbow + + + + + + + + + rheumatoid heart disease with rheumatoid arthritis of left elbow + + + + + + + + + rheumatoid heart disease with rheumatoid arthritis of unspecified elbow + + + + + + + + + rheumatoid heart disease with rheumatoid arthritis of wrist + + + + + + + + + rheumatoid heart disease with rheumatoid arthritis of right wrist + + + + + + + + + rheumatoid heart disease with rheumatoid arthritis of left wrist + + + + + + + + + rheumatoid heart disease with rheumatoid arthritis of unspecified wrist + + + + + + + + + rheumatoid heart disease with rheumatoid arthritis of hand + + + + + + + + + rheumatoid heart disease with rheumatoid arthritis of right hand + + + + + + + + + rheumatoid heart disease with rheumatoid arthritis of left hand + + + + + + + + + rheumatoid heart disease with rheumatoid arthritis of unspecified hand + + + + + + + + + rheumatoid heart disease with rheumatoid arthritis of hip + + + + + + + + + rheumatoid heart disease with rheumatoid arthritis of right hip + + + + + + + + + rheumatoid heart disease with rheumatoid arthritis of left hip + + + + + + + + + rheumatoid heart disease with rheumatoid arthritis of unspecified hip + + + + + + + + + rheumatoid heart disease with rheumatoid arthritis of knee + + + + + + + + + rheumatoid heart disease with rheumatoid arthritis of right knee + + + + + + + + + rheumatoid heart disease with rheumatoid arthritis of left knee + + + + + + + + + rheumatoid heart disease with rheumatoid arthritis of unspecified knee + + + + + + + + + rheumatoid heart disease with rheumatoid arthritis of ankle and foot + + + + + + + + + rheumatoid heart disease with rheumatoid arthritis of right ankle and foot + + + + + + + + + rheumatoid heart disease with rheumatoid arthritis of left ankle and foot + + + + + + + + + rheumatoid heart disease with rheumatoid arthritis of unspecified ankle and foot + + + + + + + + + rheumatoid heart disease with rheumatoid arthritis of multiple sites + + + + + + + + + rheumatoid myopathy with rheumatoid arthritis + + + + + + + + + rheumatoid myopathy with rheumatoid arthritis of unspecified site + + + + + + + + + rheumatoid myopathy with rheumatoid arthritis of shoulder + + + + + + + + + rheumatoid myopathy with rheumatoid arthritis of right shoulder + + + + + + + + + rheumatoid myopathy with rheumatoid arthritis of left shoulder + + + + + + + + + rheumatoid myopathy with rheumatoid arthritis of unspecified shoulder + + + + + + + + + rheumatoid myopathy with rheumatoid arthritis of elbow + + + + + + + + + rheumatoid myopathy with rheumatoid arthritis of right elbow + + + + + + + + + rheumatoid myopathy with rheumatoid arthritis of left elbow + + + + + + + + + rheumatoid myopathy with rheumatoid arthritis of unspecified elbow + + + + + + + + + rheumatoid myopathy with rheumatoid arthritis of wrist + + + + + + + + + rheumatoid myopathy with rheumatoid arthritis of right wrist + + + + + + + + + rheumatoid myopathy with rheumatoid arthritis of left wrist + + + + + + + + + rheumatoid myopathy with rheumatoid arthritis of unspecified wrist + + + + + + + + + rheumatoid myopathy with rheumatoid arthritis of hand + + + + + + + + + rheumatoid myopathy with rheumatoid arthritis of right hand + + + + + + + + + rheumatoid myopathy with rheumatoid arthritis of left hand + + + + + + + + + rheumatoid myopathy with rheumatoid arthritis of unspecified hand + + + + + + + + + rheumatoid myopathy with rheumatoid arthritis of hip + + + + + + + + + rheumatoid myopathy with rheumatoid arthritis of right hip + + + + + + + + + rheumatoid myopathy with rheumatoid arthritis of left hip + + + + + + + + + rheumatoid myopathy with rheumatoid arthritis of unspecified hip + + + + + + + + + rheumatoid myopathy with rheumatoid arthritis of knee + + + + + + + + + rheumatoid myopathy with rheumatoid arthritis of right knee + + + + + + + + + rheumatoid myopathy with rheumatoid arthritis of left knee + + + + + + + + + rheumatoid myopathy with rheumatoid arthritis of unspecified knee + + + + + + + + + rheumatoid myopathy with rheumatoid arthritis of ankle and foot + + + + + + + + + rheumatoid myopathy with rheumatoid arthritis of right ankle and foot + + + + + + + + + rheumatoid myopathy with rheumatoid arthritis of left ankle and foot + + + + + + + + + rheumatoid myopathy with rheumatoid arthritis of unspecified ankle and foot + + + + + + + + + rheumatoid myopathy with rheumatoid arthritis of multiple sites + + + + + + + + + rheumatoid polyneuropathy with rheumatoid arthritis + + + + + + + + + rheumatoid polyneuropathy with rheumatoid arthritis of unspecified site + + + + + + + + + rheumatoid polyneuropathy with rheumatoid arthritis of shoulder + + + + + + + + + rheumatoid polyneuropathy with rheumatoid arthritis of right shoulder + + + + + + + + + rheumatoid polyneuropathy with rheumatoid arthritis of left shoulder + + + + + + + + + rheumatoid polyneuropathy with rheumatoid arthritis of unspecified shoulder + + + + + + + + + rheumatoid polyneuropathy with rheumatoid arthritis of elbow + + + + + + + + + rheumatoid polyneuropathy with rheumatoid arthritis of right elbow + + + + + + + + + rheumatoid polyneuropathy with rheumatoid arthritis of left elbow + + + + + + + + + rheumatoid polyneuropathy with rheumatoid arthritis of unspecified elbow + + + + + + + + + rheumatoid polyneuropathy with rheumatoid arthritis of wrist + + + + + + + + + rheumatoid polyneuropathy with rheumatoid arthritis of right wrist + + + + + + + + + rheumatoid polyneuropathy with rheumatoid arthritis of left wrist + + + + + + + + + rheumatoid polyneuropathy with rheumatoid arthritis of unspecified wrist + + + + + + + + + rheumatoid polyneuropathy with rheumatoid arthritis of hand + + + + + + + + + rheumatoid polyneuropathy with rheumatoid arthritis of right hand + + + + + + + + + rheumatoid polyneuropathy with rheumatoid arthritis of left hand + + + + + + + + + rheumatoid polyneuropathy with rheumatoid arthritis of unspecified hand + + + + + + + + + rheumatoid polyneuropathy with rheumatoid arthritis of hip + + + + + + + + + rheumatoid polyneuropathy with rheumatoid arthritis of right hip + + + + + + + + + rheumatoid polyneuropathy with rheumatoid arthritis of left hip + + + + + + + + + rheumatoid polyneuropathy with rheumatoid arthritis of unspecified hip + + + + + + + + + rheumatoid polyneuropathy with rheumatoid arthritis of knee + + + + + + + + + rheumatoid polyneuropathy with rheumatoid arthritis of right knee + + + + + + + + + rheumatoid polyneuropathy with rheumatoid arthritis of left knee + + + + + + + + + rheumatoid polyneuropathy with rheumatoid arthritis of unspecified knee + + + + + + + + + rheumatoid polyneuropathy with rheumatoid arthritis of ankle and foot + + + + + + + + + rheumatoid polyneuropathy with rheumatoid arthritis of right ankle and foot + + + + + + + + + rheumatoid polyneuropathy with rheumatoid arthritis of left ankle and foot + + + + + + + + + rheumatoid polyneuropathy with rheumatoid arthritis of unspecified ankle and foot + + + + + + + + + rheumatoid polyneuropathy with rheumatoid arthritis of multiple sites + + + + + + + + + rheumatoid arthritis with involvement of other organs and systems + + + + + + + + + rheumatoid arthritis of unspecified site with involvement of other organs and systems + + + + + + + + + rheumatoid arthritis of shoulder with involvement of other organs and systems + + + + + + + + + rheumatoid arthritis of right shoulder with involvement of other organs and systems + + + + + + + + + rheumatoid arthritis of left shoulder with involvement of other organs and systems + + + + + + + + + rheumatoid arthritis of unspecified shoulder with involvement of other organs and systems + + + + + + + + + rheumatoid arthritis of elbow with involvement of other organs and systems + + + + + + + + + rheumatoid arthritis of right elbow with involvement of other organs and systems + + + + + + + + + rheumatoid arthritis of left elbow with involvement of other organs and systems + + + + + + + + + rheumatoid arthritis of unspecified elbow with involvement of other organs and systems + + + + + + + + + rheumatoid arthritis of wrist with involvement of other organs and systems + + + + + + + + + rheumatoid arthritis of right wrist with involvement of other organs and systems + + + + + + + + + rheumatoid arthritis of left wrist with involvement of other organs and systems + + + + + + + + + rheumatoid arthritis of unspecified wrist with involvement of other organs and systems + + + + + + + + + rheumatoid arthritis of hand with involvement of other organs and systems + + + + + + + + + rheumatoid arthritis of right hand with involvement of other organs and systems + + + + + + + + + rheumatoid arthritis of left hand with involvement of other organs and systems + + + + + + + + + rheumatoid arthritis of unspecified hand with involvement of other organs and systems + + + + + + + + + rheumatoid arthritis of hip with involvement of other organs and systems + + + + + + + + + rheumatoid arthritis of right hip with involvement of other organs and systems + + + + + + + + + rheumatoid arthritis of left hip with involvement of other organs and systems + + + + + + + + + rheumatoid arthritis of unspecified hip with involvement of other organs and systems + + + + + + + + + rheumatoid arthritis of knee with involvement of other organs and systems + + + + + + + + + rheumatoid arthritis of right knee with involvement of other organs and systems + + + + + + + + + rheumatoid arthritis of left knee with involvement of other organs and systems + + + + + + + + + rheumatoid arthritis of unspecified knee with involvement of other organs and systems + + + + + + + + + rheumatoid arthritis of ankle and foot with involvement of other organs and systems + + + + + + + + + rheumatoid arthritis of right ankle and foot with involvement of other organs and systems + + + + + + + + + rheumatoid arthritis of left ankle and foot with involvement of other organs and systems + + + + + + + + + rheumatoid arthritis of unspecified ankle and foot with involvement of other organs and systems + + + + + + + + + rheumatoid arthritis of multiple sites with involvement of other organs and systems + + + + + + + + + rheumatoid arthritis with rheumatoid factor without organ or systems involvement + + + + + + + + + rheumatoid arthritis with rheumatoid factor of unspecified site without organ or systems involvement + + + + + + + + + rheumatoid arthritis with rheumatoid factor of shoulder without organ or systems involvement + + + + + + + + + rheumatoid arthritis with rheumatoid factor of right shoulder without organ or systems involvement + + + + + + + + + rheumatoid arthritis with rheumatoid factor of left shoulder without organ or systems involvement + + + + + + + + + rheumatoid arthritis with rheumatoid factor of unspecified shoulder without organ or systems involvement + + + + + + + + + rheumatoid arthritis with rheumatoid factor of elbow without organ or systems involvement + + + + + + + + + rheumatoid arthritis with rheumatoid factor of right elbow without organ or systems involvement + + + + + + + + + rheumatoid arthritis with rheumatoid factor of left elbow without organ or systems involvement + + + + + + + + + rheumatoid arthritis with rheumatoid factor of unspecified elbow without organ or systems involvement + + + + + + + + + rheumatoid arthritis with rheumatoid factor of wrist without organ or systems involvement + + + + + + + + + rheumatoid arthritis with rheumatoid factor of right wrist without organ or systems involvement + + + + + + + + + rheumatoid arthritis with rheumatoid factor of left wrist without organ or systems involvement + + + + + + + + + rheumatoid arthritis with rheumatoid factor of unspecified wrist without organ or systems involvement + + + + + + + + + rheumatoid arthritis with rheumatoid factor of hand without organ or systems involvement + + + + + + + + + rheumatoid arthritis with rheumatoid factor of right hand without organ or systems involvement + + + + + + + + + rheumatoid arthritis with rheumatoid factor of left hand without organ or systems involvement + + + + + + + + + rheumatoid arthritis with rheumatoid factor of unspecified hand without organ or systems involvement + + + + + + + + + rheumatoid arthritis with rheumatoid factor of hip without organ or systems involvement + + + + + + + + + rheumatoid arthritis with rheumatoid factor of right hip without organ or systems involvement + + + + + + + + + rheumatoid arthritis with rheumatoid factor of left hip without organ or systems involvement + + + + + + + + + rheumatoid arthritis with rheumatoid factor of unspecified hip without organ or systems involvement + + + + + + + + + rheumatoid arthritis with rheumatoid factor of knee without organ or systems involvement + + + + + + + + + rheumatoid arthritis with rheumatoid factor of right knee without organ or systems involvement + + + + + + + + + rheumatoid arthritis with rheumatoid factor of left knee without organ or systems involvement + + + + + + + + + rheumatoid arthritis with rheumatoid factor of unspecified knee without organ or systems involvement + + + + + + + + + rheumatoid arthritis with rheumatoid factor of ankle and foot without organ or systems involvement + + + + + + + + + rheumatoid arthritis with rheumatoid factor of right ankle and foot without organ or systems involvement + + + + + + + + + rheumatoid arthritis with rheumatoid factor of left ankle and foot without organ or systems involvement + + + + + + + + + rheumatoid arthritis with rheumatoid factor of unspecified ankle and foot without organ or systems involvement + + + + + + + + + rheumatoid arthritis with rheumatoid factor of multiple sites without organ or systems involvement + + + + + + + + + other rheumatoid arthritis with rheumatoid factor + + + + + + + + + other rheumatoid arthritis with rheumatoid factor of unspecified site + + + + + + + + + other rheumatoid arthritis with rheumatoid factor of shoulder + + + + + + + + + other rheumatoid arthritis with rheumatoid factor of right shoulder + + + + + + + + + other rheumatoid arthritis with rheumatoid factor of left shoulder + + + + + + + + + other rheumatoid arthritis with rheumatoid factor of unspecified shoulder + + + + + + + + + other rheumatoid arthritis with rheumatoid factor of elbow + + + + + + + + + other rheumatoid arthritis with rheumatoid factor of right elbow + + + + + + + + + other rheumatoid arthritis with rheumatoid factor of left elbow + + + + + + + + + other rheumatoid arthritis with rheumatoid factor of unspecified elbow + + + + + + + + + other rheumatoid arthritis with rheumatoid factor of wrist + + + + + + + + + other rheumatoid arthritis with rheumatoid factor of right wrist + + + + + + + + + other rheumatoid arthritis with rheumatoid factor of left wrist + + + + + + + + + other rheumatoid arthritis with rheumatoid factor of unspecified wrist + + + + + + + + + other rheumatoid arthritis with rheumatoid factor of hand + + + + + + + + + other rheumatoid arthritis with rheumatoid factor of right hand + + + + + + + + + other rheumatoid arthritis with rheumatoid factor of left hand + + + + + + + + + other rheumatoid arthritis with rheumatoid factor of unspecified hand + + + + + + + + + other rheumatoid arthritis with rheumatoid factor of hip + + + + + + + + + other rheumatoid arthritis with rheumatoid factor of right hip + + + + + + + + + other rheumatoid arthritis with rheumatoid factor of left hip + + + + + + + + + other rheumatoid arthritis with rheumatoid factor of unspecified hip + + + + + + + + + other rheumatoid arthritis with rheumatoid factor of knee + + + + + + + + + other rheumatoid arthritis with rheumatoid factor of right knee + + + + + + + + + other rheumatoid arthritis with rheumatoid factor of left knee + + + + + + + + + other rheumatoid arthritis with rheumatoid factor of unspecified knee + + + + + + + + + other rheumatoid arthritis with rheumatoid factor of ankle and foot + + + + + + + + + other rheumatoid arthritis with rheumatoid factor of right ankle and foot + + + + + + + + + other rheumatoid arthritis with rheumatoid factor of left ankle and foot + + + + + + + + + other rheumatoid arthritis with rheumatoid factor of unspecified ankle and foot + + + + + + + + + other rheumatoid arthritis with rheumatoid factor of multiple sites + + + + + + + + + systemic sclerosis [scleroderma] + + + + + + + + + progressive systemic sclerosis + + + + + + + + + cr(e)st syndrome + + + + + + + + + systemic sclerosis induced by drug and chemical + + + + + + + + + other forms of systemic sclerosis + + + + + + + + + systemic sclerosis with lung involvement + + + + + + + + + systemic sclerosis with myopathy + + + + + + + + + systemic sclerosis with polyneuropathy + + + + + + + + + other systemic sclerosis + + + + + + + + + systemic sclerosis + + + + + + + + + medications + + + + + + + + + mefenamate oral capsule + + + + + + + + + mefenamate oral suspension + + + + + + + + + mefenamate oral tablet + + + + + + + + + mefenamate + + + + + + + + + mefenamic acid 10 mg/ml oral suspension + + + + + + + + + mefenamic acid 250 mg oral capsule [ponstel] + + + + + + + + + mefenamic acid 250 mg oral capsule + + + + + + + + + mefenamic acid 500 mg oral tablet + + + + + + + + + meloxicam 0.5 mg/ml oral suspension [metacam] + + + + + + + + + meloxicam 0.5 mg/ml oral suspension + + + + + + + + + meloxicam 1.5 mg/ml oral suspension [eloxioral] + + + + + + + + + meloxicam 1.5 mg/ml oral suspension [loxicom] + + + + + + + + + meloxicam 1.5 mg/ml oral suspension [meloxidyl] + + + + + + + + + meloxicam 1.5 mg/ml oral suspension [metacam] + + + + + + + + + meloxicam 1.5 mg/ml oral suspension [mobic] + + + + + + + + + meloxicam 1.5 mg/ml oral suspension [ostilox] + + + + + + + + + meloxicam 1.5 mg/ml oral suspension + + + + + + + + + meloxicam 10 mg oral capsule [vivlodex] + + + + + + + + + meloxicam 10 mg oral capsule + + + + + + + + + meloxicam 15 mg oral tablet [mobic] + + + + + + + + + meloxicam 15 mg oral tablet + + + + + + + + + meloxicam 15 mg rectal suppository + + + + + + + + + meloxicam 5 mg oral capsule [vivlodex] + + + + + + + + + meloxicam 5 mg oral capsule + + + + + + + + + meloxicam 5 mg/ml injectable solution [eloxiject] + + + + + + + + + meloxicam 5 mg/ml injectable solution [loxicom] + + + + + + + + + meloxicam 5 mg/ml injectable solution [metacam] + + + + + + + + + meloxicam 5 mg/ml injectable solution [ostilox] + + + + + + + + + meloxicam 5 mg/ml injectable solution + + + + + + + + + meloxicam 7.5 mg oral tablet [mobic] + + + + + + + + + meloxicam 7.5 mg oral tablet + + + + + + + + + meloxicam 7.5 mg rectal suppository + + + + + + + + + meloxicam injectable solution + + + + + + + + + meloxicam oral capsule + + + + + + + + + meloxicam oral suspension + + + + + + + + + meloxicam oral tablet + + + + + + + + + meloxicam rectal suppository + + + + + + + + + meloxicam + + + + + + + + + midazolam 1 mg/ml injectable solution + + + + + + + + + midazolam 2 mg/ml injectable solution + + + + + + + + + midazolam 2 mg/ml oral solution + + + + + + + + + midazolam 5 mg/ml injectable solution + + + + + + + + + midazolam 7.5 mg oral tablet + + + + + + + + + midazolam cartridge + + + + + + + + + midazolam injectable solution + + + + + + + + + midazolam injection + + + + + + + + + midazolam oral solution + + + + + + + + + midazolam oral tablet + + + + + + + + + midazolam prefilled syringe + + + + + + + + + midazolam + + + + + + + + + milrinone injection + + + + + + + + + milrinone + + + + + + + + + moderate illness (derived) + + + + + + + + + moderate illness + + + + + + + + + moexipril hydrochloride 15 mg oral tablet [univasc] + + + + + + + + + moexipril hydrochloride 15 mg oral tablet + + + + + + + + + moexipril hydrochloride 7.5 mg oral tablet [univasc] + + + + + + + + + moexipril hydrochloride 7.5 mg oral tablet + + + + + + + + + moexipril oral tablet + + + + + + + + + moexipril + + + + + + + + + most recent diastolic blood pressure greater than or equal to 90 mm hg + + + + + + + + + most recent hemoglobin a1c (hba1c) level 7.0-9.0% (dm) + + + + + + + + + most recent hemoglobin a1c (hba1c) level less than 7.0% (dm) + + + + + + + + + most recent hemoglobin a1c level greater than 9.0% (dm) + + + + + + + + + most recent systolic blood pressure 130-139 mm hg (dm) + + + + + + + + + n17.9 acute kidney failure + + + + + + + + + nabumetone 100 mg/ml oral suspension + + + + + + + + + nabumetone 2.5 mg/ml oral solution + + + + + + + + + nabumetone 500 mg oral tablet + + + + + + + + + nabumetone 750 mg oral tablet + + + + + + + + + nabumetone oral solution + + + + + + + + + nabumetone oral suspension + + + + + + + + + nabumetone oral tablet + + + + + + + + + nabumetone + + + + + + + + + nadroparin 19000 unt/ml injectable solution + + + + + + + + + nadroparin 9500 unt/ml injectable solution + + + + + + + + + nadroparin injectable solution + + + + + + + + + nadroparin + + + + + + + + + naproxen 125 mg oral tablet + + + + + + + + + naproxen 200 mg oral tablet + + + + + + + + + naproxen 25 mg/ml oral suspension [naprosyn] + + + + + + + + + naproxen 25 mg/ml oral suspension + + + + + + + + + naproxen 250 mg delayed release oral tablet + + + + + + + + + naproxen 250 mg oral tablet [naprosyn] + + + + + + + + + naproxen 250 mg oral tablet + + + + + + + + + naproxen 375 mg delayed release oral tablet [naprosyn] + + + + + + + + + naproxen 375 mg delayed release oral tablet + + + + + + + + + naproxen 375 mg oral tablet [naprosyn] + + + + + + + + + naproxen 375 mg oral tablet + + + + + + + + + naproxen 500 mg delayed release oral tablet [naprosyn] + + + + + + + + + naproxen 500 mg delayed release oral tablet + + + + + + + + + naproxen 500 mg oral tablet [naprosyn] + + + + + + + + + naproxen 500 mg oral tablet + + + + + + + + + naproxen 500 mg rectal suppository + + + + + + + + + naproxen delayed release oral tablet + + + + + + + + + naproxen extended release oral tablet + + + + + + + + + naproxen oral capsule + + + + + + + + + naproxen oral suspension + + + + + + + + + naproxen oral tablet + + + + + + + + + naproxen rectal suppository + + + + + + + + + naproxen sodium 220 mg oral capsule [aleve] + + + + + + + + + naproxen sodium 220 mg oral capsule + + + + + + + + + naproxen sodium 220 mg oral tablet [aleve] + + + + + + + + + naproxen sodium 220 mg oral tablet [menstridol] + + + + + + + + + naproxen sodium 220 mg oral tablet [midol extended relief] + + + + + + + + + naproxen sodium 220 mg oral tablet [wal-proxen] + + + + + + + + + naproxen sodium 220 mg oral tablet + + + + + + + + + naproxen sodium 275 mg oral tablet [anaprox] + + + + + + + + + naproxen sodium 275 mg oral tablet + + + + + + + + + naproxen sodium 550 mg oral tablet [anaprox] + + + + + + + + + naproxen sodium 550 mg oral tablet + + + + + + + + + naproxen + + + + + + + + + 0.3 ml epinephrine 0.5 mg/ml auto-injector [epipen] + + + + + + + + + 0.3 ml epinephrine 0.5 mg/ml auto-injector + + + + + + + + + 0.3 ml epinephrine 1 mg/ml auto-injector [epipen] + + + + + + + + + 0.3 ml epinephrine 1 mg/ml auto-injector + + + + + + + + + 0.15 ml epinephrine 1 mg/ml auto-injector [adrenaclick] + + + + + + + + + 0.15 ml epinephrine 1 mg/ml auto-injector + + + + + + + + + 0.3 ml epinephrine 1 mg/ml auto-injector [adrenaclick] + + + + + + + + + 0.1 ml epinephrine 1 mg/ml auto-injector [auvi-q] + + + + + + + + + 0.1 ml epinephrine 1 mg/ml auto-injector + + + + + + + + + 0.15 ml epinephrine 1 mg/ml auto-injector [auvi-q] + + + + + + + + + 0.3 ml epinephrine 1 mg/ml auto-injector [auvi-q] + + + + + + + + + neuromuscular blocking agents + + + + + + + + + neutrophils | bld-ser-plas + + + + + + + + + neutrophils:ncnc:pt:bld:qn:automated count + + + + + + + + + neutrophils:ncnc:pt:bld:qn:manual count + + + + + + + + + neutrophils:ncnc:pt:bld:qn + + + + + + + + + neutrophils/100 leukocytes:nfr:pt:bld:qn:automated count + + + + + + + + + neutrophils/100 leukocytes:nfr:pt:bld:qn:manual count + + + + + + + + + neutrophils/100 leukocytes:nfr:pt:bld:qn + + + + + + + + + neutrophils/leukocytes:nfr.df:pt:bld:qn:automated count + + + + + + + + + neutrophils/leukocytes:nfr.df:pt:bld:qn:manual count + + + + + + + + + new or established patient emergency department services + + + + + + + + + new or established patient initial hospital inpatient care services + + + + + + + + + new patient office or other outpatient services + + + + + + + + + nitric oxide / nitrogen gas for inhalation + + + + + + + + + nitric oxide / nitrogen + + + + + + + + + nitric oxide 0.01 % / nitrogen 99.99 % gas for inhalation [inomax] + + + + + + + + + nitric oxide 0.01 % / nitrogen 99.99 % gas for inhalation + + + + + + + + + nitric oxide 0.08 % / nitrogen 99.92 % gas for inhalation [inomax] + + + + + + + + + nitric oxide 0.08 % / nitrogen 99.92 % gas for inhalation + + + + + + + + + nitric oxide 0.5 % / nitrogen 99.5 % gas for inhalation + + + + + + + + + non-cdc laboratory tests for sars-cov-2/2019-ncov (covid-19) + + + + + + + + + non-steroidal anti-inflammatory drugs (nsaids) + + + + + + + + + norepinephrine injection + + + + + + + + + norepinephrine + + + + + + + + + human immunodeficiency virus [hiv] disease complicating pregnancy + + + + + + + + + human immunodeficiency virus [hiv] disease complicating childbirth + + + + + + + + + human immunodeficiency virus [hiv] disease complicating the puerperium + + + + + + + + + observation or inpatient care services (including admission and discharge services) + + + + + + + + + observation or inpatient hospital care + + + + + + + + + office or other outpatient services + + + + + + + + + office or other outpatient visit for the evaluation and management of a new patient + + + + + + + + + office or other outpatient visit for the evaluation and management of an established patient + + + + + + + + + olmesartan medoxomil + + + + + + + + + oseltamivir 12 mg/ml oral suspension + + + + + + + + + oseltamivir 30 mg oral capsule [tamiflu] + + + + + + + + + oseltamivir 30 mg oral capsule + + + + + + + + + oseltamivir 45 mg oral capsule [tamiflu] + + + + + + + + + oseltamivir 45 mg oral capsule + + + + + + + + + oseltamivir 6 mg/ml oral suspension [tamiflu] + + + + + + + + + oseltamivir 6 mg/ml oral suspension + + + + + + + + + oseltamivir 75 mg oral capsule [tamiflu] + + + + + + + + + oseltamivir 75 mg oral capsule + + + + + + + + + oseltamivir oral capsule + + + + + + + + + oseltamivir oral suspension + + + + + + + + + other coronavirus as the cause of diseases classified elsewhere + + + + + + + + + other emergency department services + + + + + + + + + other medications + + + + + + + + + other nonspecific abnormal finding of lung field + + + + + + + + + other procedures + + + + + + + + + other specified respiratory disorders + + + + + + + + + other variables of interest + + + + + + + + + other viral pneumonia + + + + + + + + + oxygen | blood arterial + + + + + + + + + oxygen:ppres:pt:blda:qn + + + + + + + + + oxygen^^adjusted to patients actual temperature:ppres:pt:blda:qn + + + + + + + + + oxygen^^saturation adjusted to 0.5:ppres:pt:blda:qn + + + + + + + + + oxygenation + + + + + + + + + parnaparin + + + + + + + + + peginterferon alfa-2a 0.36 mg/ml injectable solution + + + + + + + + + peginterferon alfa-2a auto-injector + + + + + + + + + peginterferon alfa-2a injectable solution + + + + + + + + + peginterferon alfa-2a injection + + + + + + + + + peginterferon alfa-2a prefilled syringe + + + + + + + + + perindopril erbumine 2 mg oral tablet [aceon] + + + + + + + + + perindopril erbumine 2 mg oral tablet + + + + + + + + + perindopril erbumine 4 mg oral tablet [aceon] + + + + + + + + + perindopril erbumine 4 mg oral tablet + + + + + + + + + perindopril erbumine 8 mg oral tablet [aceon] + + + + + + + + + perindopril erbumine 8 mg oral tablet + + + + + + + + + perindopril oral tablet + + + + + + + + + perindopril + + + + + + + + + phenprocoumon + + + + + + + + + phenylephrine 0.0025 mg/mg rectal suppository [medicone hemorrhoidal] + + + + + + + + + phenylephrine 0.0025 mg/mg rectal suppository + + + + + + + + + phenylephrine 1.25 mg/ml nasal spray + + + + + + + + + phenylephrine 1.25 mg/ml ophthalmic solution + + + + + + + + + phenylephrine 1.5 mg/ml extended release suspension + + + + + + + + + phenylephrine 10 mg oral strip [sudafed pe] + + + + + + + + + phenylephrine 10 mg oral strip + + + + + + + + + phenylephrine 2.5 mg/ml oral solution + + + + + + + + + phenylephrine chewable tablet + + + + + + + + + phenylephrine disintegrating oral tablet + + + + + + + + + phenylephrine extended release suspension + + + + + + + + + phenylephrine hydrochloride 0.5 mg/ml oral solution [sudafed pe childrens nasal decongestant] + + + + + + + + + phenylephrine hydrochloride 0.5 mg/ml oral solution + + + + + + + + + phenylephrine hydrochloride 1.2 mg/ml ophthalmic solution + + + + + + + + + phenylephrine hydrochloride 1.25 mg/ml nasal solution [little noses decongestant] + + + + + + + + + phenylephrine hydrochloride 1.25 mg/ml nasal solution + + + + + + + + + phenylephrine hydrochloride 10 mg chewable tablet [nasop] + + + + + + + + + phenylephrine hydrochloride 10 mg chewable tablet + + + + + + + + + phenylephrine hydrochloride 10 mg disintegrating oral tablet [nasop] + + + + + + + + + phenylephrine hydrochloride 10 mg disintegrating oral tablet + + + + + + + + + phenylephrine hydrochloride 10 mg oral tablet [sudafed pe] + + + + + + + + + phenylephrine hydrochloride 10 mg oral tablet [sudogest pe] + + + + + + + + + phenylephrine hydrochloride 10 mg oral tablet [wal-phed pe] + + + + + + + + + phenylephrine hydrochloride 10 mg oral tablet + + + + + + + + + phenylephrine hydrochloride 10 mg/ml injectable solution [vazculep] + + + + + + + + + phenylephrine hydrochloride 10 mg/ml injectable solution + + + + + + + + + phenylephrine hydrochloride 10 mg/ml nasal solution + + + + + + + + + phenylephrine hydrochloride 10 mg/ml nasal spray [4-way] + + + + + + + + + phenylephrine hydrochloride 10 mg/ml nasal spray [neo-synephrine] + + + + + + + + + phenylephrine hydrochloride 10 mg/ml nasal spray [wal-four] + + + + + + + + + phenylephrine hydrochloride 10 mg/ml nasal spray + + + + + + + + + phenylephrine hydrochloride 100 mg/ml ophthalmic solution + + + + + + + + + phenylephrine hydrochloride 2.5 mg/ml nasal solution + + + + + + + + + phenylephrine hydrochloride 2.5 mg/ml nasal spray [neo-synephrine] + + + + + + + + + phenylephrine hydrochloride 2.5 mg/ml nasal spray [rhinall] + + + + + + + + + phenylephrine hydrochloride 2.5 mg/ml nasal spray + + + + + + + + + phenylephrine hydrochloride 25 mg/ml ophthalmic solution [mydfrin] + + + + + + + + + phenylephrine hydrochloride 25 mg/ml ophthalmic solution + + + + + + + + + phenylephrine hydrochloride 5 mg oral tablet [congestaid ii] + + + + + + + + + phenylephrine hydrochloride 5 mg oral tablet [sudo-tab] + + + + + + + + + phenylephrine hydrochloride 5 mg oral tablet + + + + + + + + + phenylephrine hydrochloride 5 mg/ml nasal solution + + + + + + + + + phenylephrine hydrochloride 5 mg/ml nasal spray [afrin nasal] + + + + + + + + + phenylephrine hydrochloride 5 mg/ml nasal spray [neo-synephrine] + + + + + + + + + phenylephrine hydrochloride 5 mg/ml nasal spray [sinex] + + + + + + + + + phenylephrine hydrochloride 5 mg/ml nasal spray + + + + + + + + + phenylephrine hydrochloride 50 mg/ml ophthalmic solution + + + + + + + + + phenylephrine injectable solution + + + + + + + + + phenylephrine injection + + + + + + + + + phenylephrine nasal solution + + + + + + + + + phenylephrine nasal spray + + + + + + + + + phenylephrine ophthalmic solution + + + + + + + + + phenylephrine oral solution + + + + + + + + + phenylephrine oral strip + + + + + + + + + phenylephrine oral suspension + + + + + + + + + phenylephrine oral tablet + + + + + + + + + phenylephrine rectal suppository + + + + + + + + + phenylephrine tannate 1 mg/ml oral suspension + + + + + + + + + phenylephrine + + + + + + + + + physician or other qualified health care professional direction of emergency medical systems (ems) emergency care + + + + + + + + + piretanide + + + + + + + + + platelet aggregation inhibitors + + + + + + + + + prasugrel 10 mg oral tablet [effient] + + + + + + + + + prasugrel 10 mg oral tablet + + + + + + + + + prasugrel 5 mg oral tablet [effient] + + + + + + + + + prasugrel 5 mg oral tablet + + + + + + + + + prasugrel oral tablet + + + + + + + + + prasugrel + + + + + + + + + pregnant (derived) + + + + + + + + + procalcitonin | bld-ser-plas + + + + + + + + + procalcitonin:mcnc:pt:ser/plas:qn:ia + + + + + + + + + procalcitonin:mcnc:pt:ser/plas:qn + + + + + + + + + prognostic lab tests + + + + + + + + + propofol 10 mg/ml injectable suspension [propoflo] + + + + + + + + + propofol 10 mg/ml injectable suspension [propothesia] + + + + + + + + + propofol 10 mg/ml injectable suspension [propovan] + + + + + + + + + propofol 10 mg/ml injectable suspension [propoven] + + + + + + + + + propofol 10 mg/ml injectable suspension + + + + + + + + + propofol injectable suspension + + + + + + + + + propofol injection + + + + + + + + + propofol + + + + + + + + + prothrombin time (pt) | platelet poor plasma + + + + + + + + + quinapril 10 mg oral tablet [accupril] + + + + + + + + + quinapril 10 mg oral tablet + + + + + + + + + quinapril 20 mg oral tablet [accupril] + + + + + + + + + quinapril 20 mg oral tablet + + + + + + + + + quinapril 40 mg oral tablet [accupril] + + + + + + + + + quinapril 40 mg oral tablet + + + + + + + + + quinapril 5 mg oral tablet [accupril] + + + + + + + + + quinapril 5 mg oral tablet + + + + + + + + + quinapril oral tablet + + + + + + + + + quinapril + + + + + + + + + hepatomegaly and splenomegaly + + + + + + + + + hepatomegaly + + + + + + + + + splenomegaly + + + + + + + + + hepatomegaly with splenomegaly + + + + + + + + + enlarged lymph nodes + + + + + + + + + symptoms and signs specifically associated with systemic inflammation and infection + + + + + + + + + systemic inflammatory response syndrome (sirs) of non-infectious origin + + + + + + + + + systemic inflammatory response syndrome (sirs) of non-infectious origin without acute organ dysfunction + + + + + + + + + systemic inflammatory response syndrome (sirs) of non-infectious origin with acute organ dysfunction + + + + + + + + + severe sepsis + + + + + + + + + severe sepsis without septic shock + + + + + + + + + severe sepsis with septic shock + + + + + + + + + ramipril 1.25 mg oral capsule [altace] + + + + + + + + + ramipril 1.25 mg oral capsule + + + + + + + + + ramipril 1.25 mg oral tablet + + + + + + + + + ramipril 10 mg oral capsule [altace] + + + + + + + + + ramipril 10 mg oral capsule + + + + + + + + + ramipril 10 mg oral tablet + + + + + + + + + ramipril 2.5 mg oral capsule [altace] + + + + + + + + + ramipril 2.5 mg oral capsule + + + + + + + + + ramipril 2.5 mg oral tablet + + + + + + + + + ramipril 5 mg oral capsule [altace] + + + + + + + + + ramipril 5 mg oral capsule + + + + + + + + + ramipril 5 mg oral tablet + + + + + + + + + ramipril oral capsule + + + + + + + + + ramipril oral tablet + + + + + + + + + ramipril + + + + + + + + + remdesivir + + + + + + + + + respiratory system diagnosis with ventilator support + + + + + + + + + respiratory system diagnosis with ventilator support < 96 hrs + + + + + + + + + respiratory therapy management + + + + + + + + + reviparin prefilled syringe + + + + + + + + + reviparin + + + + + + + + + ribavirin 100 mg oral capsule + + + + + + + + + ribavirin 100 mg/ml injectable solution [virazole] + + + + + + + + + ribavirin 100 mg/ml injectable solution + + + + + + + + + ribavirin 20 mg/ml inhalant solution [virazole] + + + + + + + + + ribavirin 20 mg/ml inhalant solution + + + + + + + + + ribavirin 200 mg oral capsule [rebetol] + + + + + + + + + ribavirin 200 mg oral capsule [ribasphere] + + + + + + + + + ribavirin 200 mg oral capsule + + + + + + + + + ribavirin 200 mg oral tablet [copegus] + + + + + + + + + ribavirin 200 mg oral tablet [moderiba] + + + + + + + + + ribavirin 200 mg oral tablet [ribasphere] + + + + + + + + + ribavirin 200 mg oral tablet + + + + + + + + + ribavirin 40 mg/ml oral solution [rebetol] + + + + + + + + + ribavirin 40 mg/ml oral solution + + + + + + + + + ribavirin 400 mg oral tablet [moderiba] + + + + + + + + + ribavirin 400 mg oral tablet [ribasphere] + + + + + + + + + ribavirin 400 mg oral tablet [ribatab] + + + + + + + + + ribavirin 400 mg oral tablet + + + + + + + + + ribavirin 500 mg oral tablet + + + + + + + + + ribavirin 600 mg oral tablet [moderiba] + + + + + + + + + ribavirin 600 mg oral tablet [ribasphere] + + + + + + + + + ribavirin 600 mg oral tablet [ribatab] + + + + + + + + + ribavirin 600 mg oral tablet + + + + + + + + + ribavirin inhalant solution + + + + + + + + + ribavirin oral capsule + + + + + + + + + ribavirin oral solution + + + + + + + + + ribavirin oral tablet + + + + + + + + + rivaroxaban 10 mg oral tablet [xarelto] + + + + + + + + + rivaroxaban 10 mg oral tablet + + + + + + + + + rivaroxaban 15 mg oral tablet [xarelto] + + + + + + + + + rivaroxaban 15 mg oral tablet + + + + + + + + + rivaroxaban 20 mg oral tablet [xarelto] + + + + + + + + + rivaroxaban 20 mg oral tablet + + + + + + + + + rivaroxaban oral tablet + + + + + + + + + rivaroxaban + + + + + + + + + rocuronium bromide 10 mg/ml injectable solution [zemuron] + + + + + + + + + rocuronium bromide 10 mg/ml injectable solution + + + + + + + + + rocuronium injectable solution + + + + + + + + + rocuronium + + + + + + + + + sarilumab auto-injector + + + + + + + + + sarilumab prefilled syringe + + + + + + + + + sars coronavirus 2 igg & igm antibody panel (qualitative results) + + + + + + + + + sars coronavirus 2 igg & igm antibody panel (quantitative results) + + + + + + + + + sars coronavirus 2 rna panel (respiratory specimens) + + + + + + + + + sars coronavirus 2 rna panel (unspecified specimens) + + + + + + + + + sars-associated coronavirus as the cause of diseases classified elsewhere + + + + + + + + + sars-cov + sars-like + sars-cov-2 (qualitative) + + + + + + + + + sars-cov + sars-like + sars-cov-2 + mers (qualitative) + + + + + + + + + sars-cov-2 (nasopharynx) + + + + + + + + + sars-cov-2 (respiratory specimen) + + + + + + + + + sars-cov-2 (serum or plasma) + + + + + + + + + sars-cov-2 (unspecified specimen) + + + + + + + + + sars-cov-2 ab qualitative(equivocal) + + + + + + + + + sars-cov-2 ab qualitative(negative) + + + + + + + + + sars-cov-2 ab qualitative(pending) + + + + + + + + + sars-cov-2 ab qualitativepositive) + + + + + + + + + sars-cov-2 ab qualitative + + + + + + + + + sars-cov-2 ag + + + + + + + + + sars-cov-2 antibody interpretation + + + + + + + + + sars-cov-2 covid-19 antibody + + + + + + + + + sars-cov-2 e gene + + + + + + + + + sars-cov-2 e gene (qualitative) + + + + + + + + + sars-cov-2 e gene (quantitative) + + + + + + + + + sars-cov-2 iga + + + + + + + + + sars-cov-2 igg + + + + + + + + + sars-cov-2 igg (qualitative) + + + + + + + + + sars-cov-2 igg (quantitative) + + + + + + + + + sars-cov-2 igg + igm + + + + + + + + + sars-cov-2 igm + + + + + + + + + sars-cov-2 igm (qualitative) + + + + + + + + + sars-cov-2 igm (quantitative) + + + + + + + + + sars-cov-2 n gene + + + + + + + + + sars-cov-2 n gene (qualitative) + + + + + + + + + sars-cov-2 n gene (quantitative) + + + + + + + + + sars-cov-2 n gene result + + + + + + + + + sars-cov-2 n overall result + + + + + + + + + sars-cov-2 orf1ab region + + + + + + + + + sars-cov-2 orf1ab region (quantitative) + + + + + + + + + sars-cov-2 rdrp gene + + + + + + + + + sars-cov-2 rdrp gene (qualitative) + + + + + + + + + sars-cov-2 rna + + + + + + + + + sars-cov-2 rna (qualitative) + + + + + + + + + sars-cov-2 s gene + + + + + + + + + sars-cov-2 whole genome(equivocal) + + + + + + + + + sars-cov-2 whole genome(negative) + + + + + + + + + sars-cov-2 whole genome(pending) + + + + + + + + + sars-cov-2 whole genome(positive) + + + + + + + + + sars-cov-2 whole genome + + + + + + + + + sars-like cov n gene (qualitative) + + + + + + + + + sars-like cov n gene (quantitative) + + + + + + + + + sars-related cov + + + + + + + + + sedatives/hypnotics + + + + + + + + + severe diagnosis and procedures + + + + + + + + + severe illness (derived) + + + + + + + + + severe illness + + + + + + + + + severe lab tests + + + + + + + + + severe medications + + + + + + + + + severe procedures + + + + + + + + + siltuximab 100 mg injection [sylvant] + + + + + + + + + siltuximab 100 mg injection + + + + + + + + + siltuximab 400 mg injection [sylvant] + + + + + + + + + siltuximab 400 mg injection + + + + + + + + + siltuximab injection + + + + + + + + + siltuximab + + + + + + + + + social determinants of health + + + + + + + + + spirapril + + + + + + + + + subsequent hospital care + + + + + + + + + subsequent hospital care services + + + + + + + + + supplemental oxygen + + + + + + + + + suspected case + + + + + + + + + sympathomimetics (adrenergics) + + + + + + + + + symptoms indicating suspected case + + + + + + + + + telmisartan 20 mg oral tablet [micardis] + + + + + + + + + telmisartan 20 mg oral tablet + + + + + + + + + telmisartan 40 mg oral tablet [micardis] + + + + + + + + + telmisartan 40 mg oral tablet + + + + + + + + + telmisartan 80 mg oral tablet [micardis] + + + + + + + + + telmisartan 80 mg oral tablet + + + + + + + + + telmisartan oral tablet + + + + + + + + + thromboplastin time + + + + + + + + + ticagrelor 60 mg oral tablet [brilinta] + + + + + + + + + ticagrelor 60 mg oral tablet + + + + + + + + + ticagrelor 90 mg oral tablet [brilinta] + + + + + + + + + ticagrelor 90 mg oral tablet + + + + + + + + + ticagrelor oral tablet + + + + + + + + + ticlopidine hydrochloride 250 mg oral tablet [ticlid] + + + + + + + + + ticlopidine hydrochloride 250 mg oral tablet + + + + + + + + + ticlopidine oral tablet + + + + + + + + + tinzaparin injectable solution + + + + + + + + + tinzaparin prefilled syringe + + + + + + + + + tinzaparin sodium 10000 unt/ml injectable solution + + + + + + + + + tinzaparin sodium 20000 unt/ml injectable solution [innohep] + + + + + + + + + tinzaparin sodium 20000 unt/ml injectable solution + + + + + + + + + tinzaparin + + + + + + + + + tioclomarol + + + + + + + + + tirofiban injection + + + + + + + + + tirofiban + + + + + + + + + tocilizumab injection + + + + + + + + + tocilizumab prefilled syringe + + + + + + + + + torsemide 10 mg oral tablet [demadex] + + + + + + + + + torsemide 10 mg oral tablet + + + + + + + + + torsemide 100 mg oral tablet [demadex] + + + + + + + + + torsemide 100 mg oral tablet + + + + + + + + + torsemide 2.5 mg oral tablet + + + + + + + + + torsemide 20 mg oral tablet [demadex] + + + + + + + + + torsemide 20 mg oral tablet + + + + + + + + + torsemide 5 mg oral tablet [demadex] + + + + + + + + + torsemide 5 mg oral tablet + + + + + + + + + torsemide injection + + + + + + + + + torsemide oral tablet + + + + + + + + + torsemide + + + + + + + + + total patient count + + + + + + + + + trandolapril 0.5 mg oral capsule + + + + + + + + + trandolapril 1 mg oral capsule + + + + + + + + + trandolapril 1 mg oral tablet [mavik] + + + + + + + + + trandolapril 1 mg oral tablet + + + + + + + + + trandolapril 2 mg oral capsule + + + + + + + + + trandolapril 2 mg oral tablet [mavik] + + + + + + + + + trandolapril 2 mg oral tablet + + + + + + + + + trandolapril 4 mg oral capsule + + + + + + + + + trandolapril 4 mg oral tablet [mavik] + + + + + + + + + trandolapril 4 mg oral tablet + + + + + + + + + trandolapril oral capsule + + + + + + + + + trandolapril oral tablet + + + + + + + + + trandolapril + + + + + + + + + transplant (derived) + + + + + + + + + transplant + + + + + + + + + troponin i.cardiac | bld-ser-plas + + + + + + + + + troponin i.cardiac:acnc:pt:ser/plas:qn + + + + + + + + + troponin i.cardiac:mcnc:pt:bld:qn + + + + + + + + + troponin i.cardiac:mcnc:pt:ser/plas:qn:detection limit <= 0.01 ng/ml + + + + + + + + + troponin i.cardiac:mcnc:pt:ser/plas:qn + + + + + + + + + troponin i.cardiac:prthr:pt:ser/plas/bld:ord:ia.rapid + + + + + + + + + troponin t.cardiac | bld-ser-plas + + + + + + + + + troponin t.cardiac:mcnc:pt:bld:qn + + + + + + + + + troponin t.cardiac:mcnc:pt:ser/plas:qn:detection limit <= 5 ng/l + + + + + + + + + troponin t.cardiac:mcnc:pt:ser/plas:qn + + + + + + + + + troponin t.cardiac:prthr:pt:bld:ord + + + + + + + + + troponin t.cardiac:prthr:pt:ser/plas:ord + + + + + + + + + umifenovir (arbidol) + + + + + + + + + unspecified acute lower respiratory infection + + + + + + + + + encounter for antineoplastic chemotherapy + + + + + + + + + vaccinations + + + + + + + + + valsartan 160 mg oral capsule + + + + + + + + + valsartan 160 mg oral tablet [diovan] + + + + + + + + + valsartan 160 mg oral tablet + + + + + + + + + valsartan 320 mg oral tablet [diovan] + + + + + + + + + valsartan 320 mg oral tablet + + + + + + + + + valsartan 4 mg/ml oral solution + + + + + + + + + valsartan 40 mg oral capsule + + + + + + + + + valsartan 40 mg oral tablet [diovan] + + + + + + + + + valsartan 40 mg oral tablet + + + + + + + + + valsartan 80 mg oral capsule + + + + + + + + + valsartan 80 mg oral tablet [diovan] + + + + + + + + + valsartan 80 mg oral tablet + + + + + + + + + valsartan oral capsule + + + + + + + + + valsartan oral solution + + + + + + + + + valsartan oral tablet + + + + + + + + + valsartan + + + + + + + + + vancomycin 100 mg/ml injectable solution + + + + + + + + + vancomycin 1000 mg injection + + + + + + + + + vancomycin 125 mg oral capsule [vancocin] + + + + + + + + + vancomycin 125 mg oral capsule + + + + + + + + + vancomycin 1250 mg injection + + + + + + + + + vancomycin 1500 mg injection + + + + + + + + + vancomycin 25 mg/ml oral solution [firvanq] + + + + + + + + + vancomycin 25 mg/ml oral solution + + + + + + + + + vancomycin 250 mg injection + + + + + + + + + vancomycin 250 mg oral capsule [vancocin] + + + + + + + + + vancomycin 250 mg oral capsule + + + + + + + + + vancomycin 50 mg/ml injectable solution + + + + + + + + + vancomycin 50 mg/ml oral solution [firvanq] + + + + + + + + + vancomycin 50 mg/ml oral solution + + + + + + + + + vancomycin 500 mg injection + + + + + + + + + vancomycin 750 mg injection + + + + + + + + + vancomycin injectable solution + + + + + + + + + vancomycin injection + + + + + + + + + vancomycin oral capsule + + + + + + + + + vancomycin oral solution + + + + + + + + + vasopressin (usp) 20 unt/ml injectable solution [vasostrict] + + + + + + + + + vasopressin (usp) 20 unt/ml injectable solution + + + + + + + + + vasopressin (usp) injectable solution + + + + + + + + + vasopressin (usp) + + + + + + + + + vecuronium bromide 1 mg/ml injectable solution + + + + + + + + + vecuronium injectable solution + + + + + + + + + vecuronium + + + + + + + + + ventilation assist and management + + + + + + + + + ventilation diagnosis + + + + + + + + + ventilation procedures + + + + + + + + + vitals + + + + + + + + + vorapaxar 2.08 mg oral tablet [zontivity] + + + + + + + + + vorapaxar 2.08 mg oral tablet + + + + + + + + + vorapaxar oral tablet + + + + + + + + + vorapaxar + + + + + + + + + warfarin injectable solution + + + + + + + + + warfarin oral tablet + + + + + + + + + warfarin sodium 0.5 mg oral tablet + + + + + + + + + warfarin sodium 1 mg oral tablet [coumadin] + + + + + + + + + warfarin sodium 1 mg oral tablet [jantoven] + + + + + + + + + warfarin sodium 1 mg oral tablet + + + + + + + + + warfarin sodium 10 mg oral tablet [coumadin] + + + + + + + + + warfarin sodium 10 mg oral tablet [jantoven] + + + + + + + + + warfarin sodium 10 mg oral tablet + + + + + + + + + warfarin sodium 2 mg oral tablet [coumadin] + + + + + + + + + warfarin sodium 2 mg oral tablet [jantoven] + + + + + + + + + warfarin sodium 2 mg oral tablet + + + + + + + + + warfarin sodium 2 mg/ml injectable solution + + + + + + + + + warfarin sodium 2.5 mg oral tablet [coumadin] + + + + + + + + + warfarin sodium 2.5 mg oral tablet [jantoven] + + + + + + + + + warfarin sodium 2.5 mg oral tablet + + + + + + + + + warfarin sodium 3 mg oral tablet [coumadin] + + + + + + + + + warfarin sodium 3 mg oral tablet [jantoven] + + + + + + + + + warfarin sodium 3 mg oral tablet + + + + + + + + + warfarin sodium 4 mg oral tablet [coumadin] + + + + + + + + + warfarin sodium 4 mg oral tablet [jantoven] + + + + + + + + + warfarin sodium 4 mg oral tablet + + + + + + + + + warfarin sodium 5 mg oral tablet [coumadin] + + + + + + + + + warfarin sodium 5 mg oral tablet [jantoven] + + + + + + + + + warfarin sodium 5 mg oral tablet + + + + + + + + + warfarin sodium 6 mg oral tablet [coumadin] + + + + + + + + + warfarin sodium 6 mg oral tablet [jantoven] + + + + + + + + + warfarin sodium 6 mg oral tablet + + + + + + + + + warfarin sodium 7.5 mg oral tablet [coumadin] + + + + + + + + + warfarin sodium 7.5 mg oral tablet [jantoven] + + + + + + + + + warfarin sodium 7.5 mg oral tablet + + + + + + + + + warfarin + + + + + + + + + encounter for other preprocedural examination + + + + + + + + + carrier of infectious disease + + + + + + + + + carrier of typhoid + + + + + + + + + carrier of other intestinal infectious diseases + + + + + + + + + carrier of diphtheria + + + + + + + + + carrier of other specified bacterial diseases + + + + + + + + + carrier of bacterial disease due to meningococci + + + + + + + + + carrier of bacterial disease due to staphylococci + + + + + + + + + carrier or suspected carrier of methicillin susceptible staphylococcus aureus + + + + + + + + + carrier or suspected carrier of methicillin resistant staphylococcus aureus + + + + + + + + + carrier of bacterial disease due to streptococci + + + + + + + + + carrier of group b streptococcus + + + + + + + + + carrier of other streptococcus + + + + + + + + + carrier of infections with a predominantly sexual mode of transmission + + + + + + + + + carrier of human t-lymphotropic virus type-1 [htlv-1] infection + + + + + + + + + carrier of other infectious diseases + + + + + + + + + encounter for immunization + + + + + + + + + encounter for supervision of normal pregnancy + + + + + + + + + encounter for supervision of normal first pregnancy + + + + + + + + + encounter for supervision of other normal pregnancy + + + + + + + + + weeks of gestation + + + + + + + + + weeks of gestation of pregnancy + + + + + + + + + weeks of gestation of pregnancy not specified + + + + + + + + + less than 8 weeks gestation of pregnancy + + + + + + + + + 8 weeks gestation of pregnancy + + + + + + + + + 9 weeks gestation of pregnancy + + + + + + + + + 10 weeks gestation of pregnancy + + + + + + + + + 11 weeks gestation of pregnancy + + + + + + + + + 12 weeks gestation of pregnancy + + + + + + + + + 13 weeks gestation of pregnancy + + + + + + + + + 14 weeks gestation of pregnancy + + + + + + + + + 15 weeks gestation of pregnancy + + + + + + + + + 16 weeks gestation of pregnancy + + + + + + + + + 17 weeks gestation of pregnancy + + + + + + + + + 18 weeks gestation of pregnancy + + + + + + + + + 19 weeks gestation of pregnancy + + + + + + + + + 20 weeks gestation of pregnancy + + + + + + + + + 21 weeks gestation of pregnancy + + + + + + + + + 22 weeks gestation of pregnancy + + + + + + + + + 23 weeks gestation of pregnancy + + + + + + + + + 24 weeks gestation of pregnancy + + + + + + + + + 25 weeks gestation of pregnancy + + + + + + + + + 26 weeks gestation of pregnancy + + + + + + + + + 27 weeks gestation of pregnancy + + + + + + + + + 28 weeks gestation of pregnancy + + + + + + + + + 29 weeks gestation of pregnancy + + + + + + + + + 30 weeks gestation of pregnancy + + + + + + + + + 31 weeks gestation of pregnancy + + + + + + + + + 32 weeks gestation of pregnancy + + + + + + + + + 33 weeks gestation of pregnancy + + + + + + + + + 34 weeks gestation of pregnancy + + + + + + + + + 35 weeks gestation of pregnancy + + + + + + + + + 36 weeks gestation of pregnancy + + + + + + + + + 37 weeks gestation of pregnancy + + + + + + + + + 38 weeks gestation of pregnancy + + + + + + + + + 39 weeks gestation of pregnancy + + + + + + + + + 40 weeks gestation of pregnancy + + + + + + + + + 41 weeks gestation of pregnancy + + + + + + + + + 42 weeks gestation of pregnancy + + + + + + + + + greater than 42 weeks gestation of pregnancy + + + + + + + + + personal history of antineoplastic chemotherapy + + + + + + + + + transplanted organ and tissue status + + + + + + + + + kidney transplant status + + + + + + + + + heart transplant status + + + + + + + + + lung transplant status + + + + + + + + + heart and lungs transplant status + + + + + + + + + liver transplant status + + + + + + + + + skin transplant status + + + + + + + + + bone transplant status + + + + + + + + + corneal transplant status + + + + + + + + + other transplanted organ and tissue status + + + + + + + + + bone marrow transplant status + + + + + + + + + intestine transplant status + + + + + + + + + pancreas transplant status + + + + + + + + + stem cells transplant status + + + + + + + + + dependence on respirator + + + + + + + + + encounter for respirator [ventilator] dependence during power failure + + + + + + + + + zofenopril + + + + + + + + IDO COVID-19 ontology concepts + + + + + + + + + infectious disease control objective specification + + + + + + + + + disease transmission model + + + + + + + + + place closure control strategy + + + + + + + + + case isolation control strategy + + + + + + + + + vector control strategy + + + + + + + + + quarantine control strategy + + + + + + + + + disease surveillance objective specification + + + + + + + + + anatomical entity + + + + + + + + + protein + + + + + + + + + developmental stage + + + + + + + + + geographical entity + + + + + + + + + geographical feature + + + + + + + + + geographical region + + + + + + + + + leukocyte mediated immunity + + + + + + + + + B cell receptor complex + + + + + + + + + developmental process + + + + + + + + + T cell receptor complex + + + + + + + + + adhesion of symbiont to host + + + + + + + + + entry into host + + + + + + + + + entry into host through host barriers + + + + + + + + + innate immune response + + + + + + + + + negative regulation of viral process + + + + + + + + + negative regulation of immune response + + + + + + + + + negative regulation of developmental process + + + + + + + + + multi-organism process + + + + + + + + + biological regulation + + + + + + + + + symbiont role + + + + + + + + + mutualist role + + + + + + + + + commensal role + + + + + + + + + parasite role + + + + + + + + + infectious agent role + + + + + + + + + pathogen role + + + + + + + + + opportunistic infectious disposition + + + + + + + + + primary infectious disposition + + + + + + + + + symbiont host role + + + + + + + + + definitive host role + + + + + + + + + intermediate host role + + + + + + + + + dead-end host role + + + + + + + + + infectious agent host role + + + + + + + + + pathogen host role + + + + + + + + + mechanical vector role + passive carrier + + + + + + + + + biological vector role + + + + + + + + + pathogen vehicle role + + + + + + + + + biological vehicle role + + + + + + + + + fomite role + + + + + + + + + reservoir of infectious agent role + + + + + + + + + virulence factor disposition + + + + + + + + + toxin disposition + + + + + + + + + exotoxin disposition + + + + + + + + + infectious agent portal of entry role + + + + + + + + + infectious agent portal of exit role + + + + + + + + + primary infection role + + + + + + + + + secondary infection role + + + + + + + + + adhesion disposition + + + + + + + + + invasion disposition + + + + + + + + + protective resistance + + + + + + + + + resistance to drug + + + + + + + + + resistance to infectious agent + + + + + + + + + herd immunity to infectious organism + + + + + + + + + immunity to infectious agent + + + + + + + + + sterilizing immunity to infectious agent + + + + + + + + + invasive disposition + + + + + + + + + zoonotic disposition + + + + + + + + + reverse zoonotic disposition + + + + + + + + + collective disposition + + + + + + + + + immunosuppressed organism + + + + + + + + + immunocompetent organism + + + + + + + + + contagiousness + + + + + + + + + colonized host + + + + + + + + + infectious agent transmissibility + + + + + + + + + infectivity + + + + + + + + + virulence + + + + + + + + + susceptibility + + + + + + + + + susceptibility to infectious agent + + + + + + + + + drug susceptibility + + + + + + + + + drug susceptibility of infectious agent + + + + + + + + + extracellular infection + + + + + + + + + intracellular infection + + + + + + + + + acute infectious disease course + + + + + + + + + infectious disease incidence + + + + + + + + + infection incidence + + + + + + + + + infectious disease incidence proportion + + + + + + + + + infection incidence proportion + + + + + + + + + infectious disease incidence rate + + + + + + + + + infection incidence rate + + + + + + + + + infectious disease prevalence + + + + + + + + + infection prevalence + + + + + + + + + infectious disease lifetime prevalence + + + + + + + + + pathogen seroprevalence + + + + + + + + + infectious disease mortality rate + + + + + + + + + infectious disease endemicity + + + + + + + + + infectious disease sporadicity + + + + + + + + + long-term non-progressing infectious disease course + + + + + + + + + immunization against infectious agent + + + + + + + + + active immunization against infectious agent + + + + + + + + + vaccination against infectious agent + + + + + + + + + variolation + + + + + + + + + passive immunization against infectious agent + + + + + + + + + infectious disease epidemic + + + + + + + + + infectious disease pandemic + + + + + + + + + organism population + + + + + + + + + infected population + + + + + + + + + diseased population + + + + + + + + + infectious agent population + + + + + + + + + susceptible population + + + + + + + + + normal resident microbiota population + + + + + + + + + incubation interval + + + + + + + + + communicability interval + + + + + + + + + symbiont + + + + + + + + + obligatory symbiont + + + + + + + + + mutualist + + + + + + + + + commensal + + + + + + + + + parasite + + + + + + + + + primary pathogen + + + + + + + + + definitive host + + + + + + + + + intermediate host + + + + + + + + + dead-end host + + + + + + + + + infectious agent host + + + + + + + + + pathogen host + + + + + + + + + asymptomatic infectious agent carrier + + + + + + + + + infectious agent vector + + + + + + + + + mechanical vector of infectious agent + + + + + + + + + biological vector of infectious agent + + + + + + + + + pathogen vehicle + + + + + + + + + fomite + + + + + + + + + infectious agent reservoir + + + + + + + + + virulence factor + + + + + + + + + invasion factor + + + + + + + + + toxin + + + + + + + + + exotoxin + + + + + + + + + enterotoxin + + + + + + + + + endotoxin + + + + + + + + + infectious agent portal of entry + + + + + + + + + infectious agent portal of exit + + + + + + + + + adhesion factor + + + + + + + + + primary infection + + + + + + + + + zoonosis + + + + + + + + + subclinical infection + + + + + + + + + resistant entity + + + + + + + + + innate immunity to infectious agent + + + + + + + + + humoral immunity to infectious agent + + + + + + + + + leukocyte-mediated immunity to infectious agent + + + + + + + + + passive immunity to infectious agent + + + + + + + + + antibiotic resistance + + + + + + + + + emerging pathogen + + + + + + + + + cytotoxin + + + + + + + + + collective pathogenic disposition + + + + + + + + + genetic resistance to infectious agent + + + + + + + + + collective resistance disposition + + + + + + + + + immunodeficient organism + + + + + + + + + chronic infectious disease course + + + + + + + + + immune population + + + + + + + + + transmission interval + + + + + + + + + potential host of infectious agent + + + + + + + + + process of establishing an infection + + + + + + + + + colonization of host + + + + + + + + + establishment of a clinically abnormal colony + + + + + + + + + production + + + + + + + + + replication + + + + + + + + + immunosuppression + + + + + + + + + physiologic immunosuppression + + + + + + + + + pathologic immunosuppression + + + + + + + + + colony + + + + + + + + + infectious agent colony + + + + + + + + + immunocompetence + + + + + + + + + immunosuppressive disposition + + + + + + + + + acquired immunity to infectious agent + + + + + + + + + communicability + + + + + + + + + acute infection + + + + + + + + + community-acquired infection + + + + + + + + + neurotoxin + + + + + + + + + source of infection role + + + + + + + + + nursing-home acquired infection + + + + + + + + + infectious human pathogen + + + + + + + + + acquired immunodeficiency + + + + + + + + + re-emerging pathogen + + + + + + + + + colonization of human + + + + + + + + + primary immunodeficiency + + + + + + + + + reverse zoonosis + + + + + + + + + opportunistic pathogen + + + + + + + + + transmissibility disposition + + + + + + + + + horizontal pathogen transmission process + + + + + + + + + process that results in death + + + + + + + + + susceptible organism + + + + + + + + + negative regulation of life-sustaining process + + + + + + + + + source of infection + + + + + + + + + transition to clinical abnormality + + + + + + + + + infection-based immunosuppression + + + + + + + + + pathologically immunosuppressed organism + + + + + + + + + immunosuppressed organism experiencing infection-based immunosuppression + + + + + + + + + immunosuppressed organism experiencing HIV-based immunosuppression + + + + + + + + + immunosuppressed human experiencing HIV-based immunosuppression + + + + + + + + + drug-based immunosuppression + + + + + + + + + immunosuppressed organism experiencing drug-based immunosuppression + + + + + + + + + immunosuppressed organism experiencing chronic systemic steroid use-based immunosuppression + + + + + + + + + immunosuppressed human experiencing chronic systemic steroid use-based immunosuppression + + + + + + + + + immunosuppressed human experiencing drug-based immunosuppression due to organ transplant + + + + + + + + + single-stranded RNA retrovirus + Baltimore Classification Group VI + + + + + + + + + single-stranded DNA virus + Baltimore Classification Group II + + + + + + + + + double-stranded DNA virus + Baltimore Classification Group I + + + + + + + + + double-stranded DNA retrovirus + Baltimore Classification Group VII + + + + + + + + + positive-sense single-stranded RNA virus + Baltimore Classification Group IV + + + + + + + + + negative-sense single-stranded RNA virus + Baltimore Classification Group V + + + + + + + + + double-stranded RNA virus + Baltimore Classification Group III + + + + + + + + + architectual structure + + + + + + + + + facility + + + + + + + + + hospital facility + + + + + + + + + healthcare facility + + + + + + + + + indirect + + + + + + + + + respiratory secretion + + + + + + + + + viremia + + + + + + + + + viricide + + + + + + + + + anatomical space + + + + + + + + + cell space + + + + + + + + + coronavirus disorder + + + + + + + + + SARS-CoV-2 disorder + + + + + + + + + coronavirus disease course + + + + + + + + + COVID-19 disease course + + + + + + + + + subclinical coronavirus infection + + + + + + + + + subclinical SARS-CoV-2 infection + + + + + + + + + coronavirus population + + + + + + + + + SARS-CoV-2 population + + + + + + + + + respiratory droplet coronavirus fomite + + + + + + + + + respiratory droplet SARS-CoV-2 fomite + + + + + + + + + coronavirus pathogenesis + + + + + + + + + SARS-CoV-2 pathogenesis + + + + + + + + + coronavirus replication + + + + + + + + + SARS-CoV-2 replication + + + + + + + + + SARS-CoV-2 attachment stage + + + + + + + + + SARS-CoV-2 penetration stage + + + + + + + + + SARS-CoV-2 release stage + + + + + + + + + SARS-CoV-2 genome replication stage + + + + + + + + + SARS-CoV-2 transcription stage + + + + + + + + + SARS-CoV-2 synthesis stage + + + + + + + + + SARS-CoV-2 uncoating stage + + + + + + + + + SARS-COV-2 adhesion susceptible cell + + + + + + + + + symbiotic process + + + + + + + + + infection incidence profile + + + + + + + + + infection incidence proportion profile + + + + + + + + + infection incidence rate profile + + + + + + + + + infection prevalence profile + + + + + + + + + negative regulation of establishment of localization + + + + + + + + + negative regulation of reproduction + + + + + + + + + negative regulation of production + + + + + + + + + negative regulation of replication + + + + + + + + + organism birth + + + + + + + + + organism death + + + + + + + + + organism death temporal boundary + + + + + + + + + organism birth temporal boundary + + + + + + + + + viricidal disposition + + + + + + + + + virostatic disposition + + + + + + + + + fungicidal disposition + + + + + + + + + fungistatic disposition + + + + + + + + + bactericidal disposition + + + + + + + + + bacteriostatic disposition + + + + + + + + + parasiticidal disposition + + + + + + + + + parasitostatic disposition + + + + + + + + + pathogen portal of entry site + + + + + + + + + pathogen portal of exit site + + + + + + + + + bacteriostatic + + + + + + + + + bactericidal + + + + + + + + + infectious structure + + + + + + + + + acellular structure population + + + + + + + + + site of infection + + + + + + + + + acellular infectious agent birth + + + + + + + + + acellular infectious agent death + + + + + + + + + acellular infectious agent birth temporal region + + + + + + + + + acellular infectious agent death temporal region + + + + + + + + + acellular structure + + + + + + + + + cidal agent + + + + + + + + + static agent + + + + + + + + + static agent disposition + + + + + + + + + cidal disposition + + + + + + + + + infectious structure host + + + + + + + + + infectious structure host role + + + + + + + + + pathogen transporter + + + + + + + + + pathogen transporter role + + + + + + + + + source of infection site + + + + + + + + + infectious agent developmental stage + + + + + + + + + infectious structure developmental stage + + + + + + + + + pathogen developmental stage + + + + + + + + + viral disease + + + + + + + + + asymptomatic carrier role + + + + + + + + + asymptomatic carrier + + + + + + + + + asymptomatic infectious structure carrier + + + + + + + + + pathogen vector role + + + + + + + + + symptomatic carrier role + + + + + + + + + symptomatic carrier + + + + + + + + + infectious structure role + + + + + + + + + coronavirus disease + + + + + + + + + infectious disposition + + + + + + + + + cytotoxin disposition + + + + + + + + + neurotoxin disposition + + + + + + + + + endotoxin disposition + + + + + + + + + enterotoxin disposition + + + + + + + + + symptomatic infectious structure carrier + + + + + + + + + symptomatic infectious agent carrier + + + + + + + + + infectious structure population + + + + + + + + + pathogen vector + + + + + + + + + biological vector + + + + + + + + + mechanical vector + + + + + + + + + biological vehicle + + + + + + + + + viral adhesion disposition + + + + + + + + + SARS-COV-2 adhesion disposition + + + + + + + + + angiotensin-converting enzyme 2 + + + + + + + + + SARS-COV-2 prevalence + + + + + + + + + COVID-19 prevalence + + + + + + + + + COVID-19 mortality rate + + + + + + + + + COVID-19 lifetime prevalence + + + + + + + + + COVID-19 incidence rate + + + + + + + + + COVID-19 disease incidence proportion + + + + + + + + + COVID-19 incidence + + + + + + + + + COVID-19 endemicity + + + + + + + + + SARS-CoV-2 transmissibility + + + + + + + + + SARS-CoV-2 seroprevalence + + + + + + + + + SARS-CoV-2 incidence rate + + + + + + + + + SARS-CoV-2 incidence proportion + + + + + + + + + SARS-CoV-2 incidence + + + + + + + + + SARS-CoV-2 infectivity + + + + + + + + + SARS-CoV-2 virulence + + + + + + + + + COVID-19 sporadicity + + + + + + + + + virostatic + + + + + + + + + virus replication + + + + + + + + + virus population + + + + + + + + + viroid population + + + + + + + + + prion population + + + + + + + + + prion replication + + + + + + + + + virus attachment stage + + + + + + + + + virus penetration stage + + + + + + + + + virus developmental stage + + + + + + + + + virus uncoating stage + + + + + + + + + virus translation stage + + + + + + + + + virus synthesis stage + + + + + + + + + virus release stage + + + + + + + + + viral disease course + + + + + + + + + virus disorder + + + + + + + + + virus host + + + + + + + + + subclinical virus infection + + + + + + + + + respiratory droplet + + + + + + + + + respiratory droplet fomite + + + + + + + + + respiratory droplet virus fomite + + + + + + + + + viral pathogenesis + + + + + + + + + process of establishing viral infection + + + + + + + + + virus transcription stage + + + + + + + + + virus adhesion susceptible cell + + + + + + + + + descriptive information content entity + + + + + + + + + designative information content entity + + + + + + + + + directive information content entity + + + + + + + + + division of geopolitical entity + + + + + + + + + geopolitical entity + + + + + + + + + geospatial location + + + + + + + + + geospatial region + + + + + + + + SNOMED CT COVID concepts + + + + + + + + + SARS-CoV-2 + Severe acute respiratory syndrome coronavirus 2 (organism) + + + + + + + + + SARS-CoV-2 vaccination + Severe acute respiratory syndrome coronavirus 2 vaccination (procedure) + + + + + + + + + Antibody to SARS-CoV-2 + Antibody to severe acute respiratory syndrome coronavirus 2 (substance) + + + + + + + + + Antigen of SARS-CoV-2 + Antigen of severe acute respiratory syndrome coronavirus 2 (substance) + + + + + + + + + COVID-19 + Disease caused by severe acute respiratory syndrome coronavirus 2 (disorder) + + + + + + + + + Suspected COVID-19 + Suspected disease caused by severe acute respiratory coronavirus 2 (situation) + + + + + + + + + Exposure to SARS-CoV-2 + Exposure to severe acute respiratory syndrome coronavirus 2 (event) + + + + + + + + + Disturbance of consciousness + Disturbance of consciousness (finding) + + + + + + + + + Polymerase chain reaction analysis + Polymerase chain reaction analysis (procedure) + + + + + + + + + Positive + Positive (qualifier value) + + + + + + + + + Loss of taste + Loss of taste (finding) + + + + + + + + + Asymptomatic + Asymptomatic (finding) + + + + + + + + + Pre-existing condition + Pre-existing condition (finding) + + + + + + + + + Associated symptom + Associated symptom (finding) + + + + + + + + + Feeling feverish + Feeling feverish (finding) + + + + + + + + + Sputum specimen + Sputum specimen (specimen) + + + + + + + + + Stool specimen + Stool specimen (specimen) + + + + + + + + + Saliva specimen + Saliva specimen (specimen) + + + + + + + + + Plasma specimen + Plasma specimen (specimen) + + + + + + + + + Serum specimen + Serum specimen (specimen) + + + + + + + + + Urine specimen + Urine specimen (specimen) + + + + + + + + + Specimen from lung obtained by biopsy + Specimen from lung obtained by biopsy (specimen) + + + + + + + + + Specimen unsatisfactory for evaluation + Specimen unsatisfactory for evaluation (finding) + + + + + + + + + Exudative pharyngitis + Exudative pharyngitis (disorder) + + + + + + + + + Chronic nervous system disorder + Chronic nervous system disorder (disorder) + + + + + + + + + Conjunctival hyperemia + Conjunctival hyperemia (finding) + + + + + + + + + Healthcare professional + Healthcare professional (occupation) + + + + + + + + + Female + Female (finding) + + + + + + + + + Male + Male (finding) + + + + + + + + + First trimester + First trimester (qualifier value) + + + + + + + + + Second trimester + Second trimester (qualifier value) + + + + + + + + + Third trimester + Third trimester (qualifier value) + + + + + + + + + Nasopharyngeal aspirate + Nasopharyngeal aspirate (specimen) + + + + + + + + + Oropharyngeal aspirate + Oropharyngeal aspirate (specimen) + + + + + + + + + Nasopharyngeal washings + Nasopharyngeal washings (specimen) + + + + + + + + + Nasopharyngeal swab + Nasopharyngeal swab (specimen) + + + + + + + + + Throat swab + Throat swab (specimen) + + + + + + + + + Whole blood sample + Whole blood sample (specimen) + + + + + + + + + Lower respiratory sample + Lower respiratory sample (specimen) + + + + + + + + + Bronchoalveolar lavage fluid sample + Bronchoalveolar lavage fluid sample (specimen) + + + + + + + + + day + day (qualifier value) + + + + + + + + + month + month (qualifier value) + + + + + + + + + year + year (qualifier value) + + + + + + + + + Negative + Negative (qualifier value) + + + + + + + + + Weakly positive + Weakly positive (qualifier value) + + + + + + + + + Able to breathe + Able to breathe (finding) + + + + + + + + + Unable to breathe + Unable to breathe (finding) + + + + + + + + + Rhabdomyoma + Rhabdomyoma (disorder) + + + + + + + + + Secondary bacterial pneumonia + Secondary bacterial pneumonia (disorder) + + + + + + + + + Upper respiratory swab sample + Upper respiratory swab sample (specimen) + + + + + + + + + Lower respiratory fluid sample + Lower respiratory fluid sample (specimen) + + + + + + + + + Isolation of infected patient + Isolation of infected patient (procedure) + + + + + + + + + Heart rate + Heart rate (observable entity) + + + + + + + + + Acute respiratory distress + Acute respiratory distress (finding) + + + + + + + + + Not done + Not done (qualifier value) + + + + + + + + + Body temperature + Body temperature (observable entity) + + + + + + + + + Action status unknown + Action status unknown (qualifier value) + + + + + + + + + Probably present + Probably present (qualifier value) + + + + + + + + + Probably NOT present + Probably NOT present (qualifier value) + + + + + + + + + Definitely NOT present + Definitely NOT present (qualifier value) + + + + + + + + + Confirmed present + Confirmed present (qualifier value) + + + + + + + + + Pleural fluid specimen + Pleural fluid specimen (specimen) + + + + + + + + + Inconclusive + Inconclusive (qualifier value) + + + + + + + + + Traumatic injury of skeletal muscle + Traumatic injury of skeletal muscle (disorder) + + + + + + + + + Peripheral oxygen saturation + Peripheral oxygen saturation (observable entity) + + + + + + + + + Swab of internal nose + Swab of internal nose (specimen) + + + + + + + + + Specimen from trachea obtained by aspiration + Specimen from trachea obtained by aspiration (specimen) + + + + + + + + + Swab from nasal sinus + Swab from nasal sinus (specimen) + + + + + + + + + Anterior nares swab + Anterior nares swab (specimen) + + + + + + + + + Cytokine release syndrome + Cytokine-associated toxicity (disorder) + + + + + + + + + Presumptive positive + Presumptive positive (qualifier value) + + + + + + + + + Plasma specimen or serum specimen or whole blood specimen + Plasma specimen or serum specimen or whole blood specimen (specimen) + + + + + + + + + Lymphocytopenia due to Severe acute respiratory syndrome coronavirus 2 + Lymphocytopenia due to Severe acute respiratory syndrome coronavirus 2 (disorder) + + + + + + + + + Thrombocytopenia due to Severe acute respiratory syndrome coronavirus 2 + Thrombocytopenia due to Severe acute respiratory syndrome coronavirus 2 (disorder) + + + + + + + + + SARS-CoV-2 IgG + Immunoglobulin G antibody to Severe acute respiratory syndrome coronavirus 2 (substance) + + + + + + + + + SARS-CoV-2 IgM + Immunoglobulin M antibody to Severe acute respiratory syndrome coronavirus 2 (substance) + + + + + + + + + At increased risk of exposure to Severe acute respiratory syndrome coronavirus 2 + At increased risk of exposure to Severe acute respiratory syndrome coronavirus 2 (finding) + + + + + + + + + Sepsis due to disease caused by Severe acute respiratory syndrome coronavirus 2 + Sepsis due to disease caused by Severe acute respiratory syndrome coronavirus 2 (disorder) + + + + + + + + + Acute kidney injury due to disease caused by Severe acute respiratory syndrome coronavirus 2 + Acute kidney injury due to disease caused by Severe acute respiratory syndrome coronavirus 2 (disorder) + + + + + + + + + Acute hypoxemic respiratory failure due to disease caused by Severe acute respiratory syndrome coronavirus 2 + Acute hypoxemic respiratory failure due to disease caused by Severe acute respiratory syndrome coronavirus 2 (disorder) + + + + + + + + + Rhabdomyolysis due to disease caused by Severe acute respiratory syndrome coronavirus 2 + Rhabdomyolysis due to disease caused by Severe acute respiratory syndrome coronavirus 2 (disorder) + + + + + + + + + Detection of Severe acute respiratory syndrome coronavirus 2 antibody + Detection of Severe acute respiratory syndrome coronavirus 2 antibody (observable entity) + + + + + + + + + Detection of Severe acute respiratory syndrome coronavirus 2 antigen + Detection of Severe acute respiratory syndrome coronavirus 2 antigen (observable entity) + + + + + + + + + Detection of ribonucleic acid of Severe acute respiratory syndrome coronavirus 2 + Detection of ribonucleic acid of Severe acute respiratory syndrome coronavirus 2 (observable entity) + + + + + + + + + Detection of ribonucleic acid of Severe acute respiratory syndrome coronavirus 2 in nasopharyngeal swab + Detection of ribonucleic acid of Severe acute respiratory syndrome coronavirus 2 in nasopharyngeal swab (observable entity) + + + + + + + + + Detection of ribonucleic acid of Severe acute respiratory syndrome coronavirus 2 in oropharyngeal swab + Detection of ribonucleic acid of Severe acute respiratory syndrome coronavirus 2 in oropharyngeal swab (observable entity) + + + + + + + + + Detection of ribonucleic acid of Severe acute respiratory syndrome coronavirus 2 in sputum + Detection of ribonucleic acid of Severe acute respiratory syndrome coronavirus 2 in sputum (observable entity) + + + + + + + + + Detection of ribonucleic acid of Severe acute respiratory syndrome coronavirus 2 in bronchoalveolar lavage fluid + Detection of ribonucleic acid of Severe acute respiratory syndrome coronavirus 2 in bronchoalveolar lavage fluid (observable entity) + + + + + + + + + Detection of ribonucleic acid of Severe acute respiratory syndrome coronavirus 2 using polymerase chain reaction + Detection of ribonucleic acid of Severe acute respiratory syndrome coronavirus 2 using polymerase chain reaction (observable entity) + + + + + + + + + Detection of Severe acute respiratory syndrome coronavirus 2 + Detection of Severe acute respiratory syndrome coronavirus 2 (observable entity) + + + + + + + + + Mid-turbinate nasal swab + Swab specimen from nasal mid-turbinate (specimen) + + + + + + + + + Cardiomyopathy due to disease caused by Severe acute respiratory syndrome coronavirus 2 + Cardiomyopathy due to disease caused by Severe acute respiratory syndrome coronavirus 2 + + + + + + + + + Conjunctivitis due to disease caused by Severe acute respiratory syndrome coronavirus 2 + Conjunctivitis due to disease caused by Severe acute respiratory syndrome coronavirus 2 (disorder) + + + + + + + + + Fever caused by Severe acute respiratory syndrome coronavirus 2 + Fever caused by Severe acute respiratory syndrome coronavirus 2 (disorder) + + + + + + + + + Dyspnea caused by Severe acute respiratory syndrome coronavirus 2 + Dyspnea caused by Severe acute respiratory syndrome coronavirus 2 (disorder) + + + + + + + + + Oropharyngeal swab + Swab specimen from oropharynx (specimen) + + + + + + + + + Insertion of fiducial marker into lung using computed tomography guidance + Insertion of fiducial marker into lung using computed tomography guidance (procedure) + + + + + + + + + Severe acute respiratory syndrome coronavirus 2 RNA + Ribonucleic acid of Severe acute respiratory syndrome coronavirus 2 (substance) + + + + + + + + + Measurement of Severe acute respiratory syndrome coronavirus 2 antibody + Measurement of Severe acute respiratory syndrome coronavirus 2 antibody (observable entity) + + + + + + + + + Measurement of Severe acute respiratory syndrome coronavirus 2 antigen + Measurement of Severe acute respiratory syndrome coronavirus 2 antigen (observable entity) + + + + + + + + + Otitis media due to disease caused by Severe acute respiratory syndrome coronavirus 2 + Otitis media due to disease caused by Severe acute respiratory syndrome coronavirus 2 (disorder) + + + + + + + + + Myocarditis due to disease caused by Severe acute respiratory syndrome coronavirus 2 + Myocarditis due to disease caused by Severe acute respiratory syndrome coronavirus 2 (disorder) + + + + + + + + + Infection of upper respiratory tract caused by Severe acute respiratory syndrome coronavirus 2 + Infection of upper respiratory tract caused by Severe acute respiratory syndrome coronavirus 2 (disorder) + + + + + + + + + Encephalopathy due to disease caused by Severe acute respiratory syndrome coronavirus 2 + Encephalopathy due to disease caused by Severe acute respiratory syndrome coronavirus 2 (disorder) + + + + + + + + + Severe acute respiratory syndrome coronavirus 2 detected + Severe acute respiratory syndrome coronavirus 2 detected (finding) + + + + + + + + + Severe acute respiratory syndrome coronavirus 2 not detected + Severe acute respiratory syndrome coronavirus 2 not detected (finding) + + + + + + + + + Acute bronchitis caused by SARS-CoV-2 + Acute bronchitis caused by Severe acute respiratory syndrome coronavirus 2 (disorder) + + + + + + + + + Asymptomatic SARS-CoV-2 + Asymptomatic Severe acute respiratory syndrome coronavirus 2 infection (finding) + + + + + + + + + History of SARS-CoV-2 + History of disease caused by Severe acute respiratory syndrome coronavirus 2 (situation) + + + + + + + + + Acute respiratory distress syndrome due to disease caused by Severe acute respiratory syndrome coronavirus 2 + Acute respiratory distress syndrome due to disease caused by Severe acute respiratory syndrome coronavirus 2 (disorder) + + + + + + + + + Disease caused by Severe acute respiratory syndrome coronavirus 2 absent + Disease caused by Severe acute respiratory syndrome coronavirus 2 absent (situation) + + + + + + + + + Lower respiratory infection caused by SARS-CoV-2 + Lower respiratory infection caused by Severe acute respiratory syndrome coronavirus 2 (disorder) + + + + + + + + + Pneumonia caused by SARS-CoV-2 + Pneumonia caused by Severe acute respiratory syndrome coronavirus 2 (disorder) + + + + + + + + LOINC concepts + + + + + + + + + SARS-related coronavirus+MERS coronavirus RNA in Respiratory specimen by NAA with probe detection + + + + + + + + + SARS-CoV+SARS-CoV-2 (COVID-19) Ag in Respiratory specimen by Rapid immunoassay + + + + + + + + + SARS-CoV-2 (COVID-19) Ab in Serum or Plasma + + + + + + + + + SARS-CoV-2 (COVID-19) Ab in Serum or Plasma by Immunoassay + + + + + + + + + SARS-CoV-2 (COVID-19) Ab panel - Serum or Plasma by Immunoassay + + + + + + + + + SARS-CoV-2 (COVID-19) Ab panel - Serum, Plasma or Blood by Rapid immunoassay + + + + + + + + + SARS-CoV-2 (COVID-19) Ag in Respiratory specimen by Rapid immunoassay + + + + + + + + + SARS-CoV-2 (COVID-19) IgA Ab in Serum or Plasma by Immunoassay + + + + + + + + + SARS-CoV-2 (COVID-19) IgA Ab in Serum, Plasma or Blood by Rapid immunoassay + + + + + + + + + SARS-CoV-2 (COVID-19) IgA+IgM in Serum or Plasma by Immunoassay + + + + + + + + + SARS-CoV-2 (COVID-19) IgG Ab in DBS by Immunoassay + + + + + + + + + SARS-CoV-2 (COVID-19) IgG Ab in Serum or Plasma by Immunoassay + + + + + + + + + SARS-CoV-2 (COVID-19) IgG Ab in Serum, Plasma or Blood by Rapid immunoassay + + + + + + + + + SARS-CoV-2 (COVID-19) IgG+IgM Ab in Serum or Plasma by Immunoassay + + + + + + + + + SARS-CoV-2 (COVID-19) IgM Ab in DBS by Immunoassay + + + + + + + + + SARS-CoV-2 (COVID-19) IgM Ab in Serum or Plasma by Immunoassay + + + + + + + + + SARS-CoV-2 (COVID-19) IgM Ab in Serum, Plasma or Blood by Rapid immunoassay + + + + + + + + + SARS-CoV-2 (COVID-19) in Unspecified specimen by Organism specific culture + + + + + + + + + SARS-CoV-2 (COVID-19) N gene in Nasopharynx by NAA with probe detection + + + + + + + + + SARS-CoV-2 (COVID-19) N gene in Nose by NAA with probe detection + + + + + + + + + SARS-CoV-2 (COVID-19) N gene in Respiratory specimen by NAA with probe detection + + + + + + + + + SARS-CoV-2 (COVID-19) N gene in Respiratory specimen by Nucleic acid amplification using CDC primer-probe set N1 + + + + + + + + + SARS-CoV-2 (COVID-19) N gene in Serum or Plasma by NAA with probe detection + + + + + + + + + SARS-CoV-2 (COVID-19) N gene in Unspecified specimen by NAA with probe detection + + + + + + + + + SARS-CoV-2 (COVID-19) N gene in Unspecified specimen by Nucleic acid amplification using CDC primer-probe set N1 + + + + + + + + + SARS-CoV-2 (COVID-19) N gene in Unspecified specimen by Nucleic acid amplification using CDC primer-probe set N2 + + + + + + + + + SARS-CoV-2 (COVID-19) neutralizing antibody in Serum by pVNT + + + + + + + + + SARS-CoV-2 (COVID-19) ORF1ab region in Respiratory specimen by NAA with probe detection + + + + + + + + + SARS-CoV-2 (COVID-19) ORF1ab region in Unspecified specimen by NAA with probe detection + + + + + + + + + SARS-CoV-2 (COVID-19) RdRp gene in Respiratory specimen by NAA with probe detection + + + + + + + + + SARS-CoV-2 (COVID-19) RdRp gene in Unspecified specimen by NAA with probe detection + + + + + + + + + SARS-CoV-2 (COVID-19) RNA (viral load) in Unspecified specimen by NAA with probe detection + + + + + + + + + SARS-CoV-2 (COVID-19) RNA in Nasopharynx by NAA with non-probe detection + + + + + + + + + SARS-CoV-2 (COVID-19) RNA in Nasopharynx by NAA with probe detection + + + + + + + + + SARS-CoV-2 (COVID-19) RNA in Nose by NAA with probe detection + + + + + + + + + SARS-CoV-2 (COVID-19) RNA in Respiratory specimen by NAA with probe detection + + + + + + + + + SARS-CoV-2 (COVID-19) RNA in Saliva (oral fluid) by NAA with probe detection + + + + + + + + + SARS-CoV-2 (COVID-19) RNA in Saliva (oral fluid) by Sequencing + + + + + + + + + SARS-CoV-2 (COVID-19) RNA in Serum or Plasma by NAA with probe detection + + + + + + + + + SARS-CoV-2 (COVID-19) RNA in Unspecified specimen by NAA with probe detection + + + + + + + + + SARS-CoV-2 (COVID-19) RNA panel - Respiratory specimen by NAA with probe detection + + + + + + + + + SARS-CoV-2 (COVID-19) RNA panel - Unspecified specimen by NAA with probe detection + + + + + + + + + SARS-CoV-2 (COVID-19) S gene in Respiratory specimen by NAA with probe detection + + + + + + + + + SARS-CoV-2 (COVID-19) S gene in Serum or Plasma by NAA with probe detection + + + + + + + + + SARS-CoV-2 (COVID-19) S gene in Unspecified specimen by NAA with probe detection + + + + + + + + + SARS-CoV-2 (COVID-19) whole genome in Isolate by Sequencing + + + + + + + + + SARS-like coronavirus N gene in Unspecified specimen by NAA with probe detection + + + + + + + + + SARS-related coronavirus E gene in Respiratory specimen by NAA with probe detection + + + + + + + + + SARS-related coronavirus E gene in Serum or Plasma by NAA with probe detection + + + + + + + + + SARS-related coronavirus E gene in Unspecified specimen by NAA with probe detection + + + + + + + + + SARS-related coronavirus RNA in Respiratory specimen by NAA with probe detection + + + + + + + + + SARS-related coronavirus RNA in Unspecified specimen by NAA with probe detection + + + + + + + + + SARS-related coronavirus+MERS coronavirus RNA + + + + + + + + + SARS coronavirus 2 + + + + + + + + + SARS coronavirus 2 Ab + + + + + + + + + SARS coronavirus 2 Ab panel + + + + + + + + + SARS coronavirus 2 Ab.IgA + + + + + + + + + SARS coronavirus 2 Ab.IgA+IgM + + + + + + + + + SARS coronavirus 2 Ab.IgG + + + + + + + + + SARS coronavirus 2 Ab.IgG+IgM + + + + + + + + + SARS coronavirus 2 Ab.IgM + + + + + + + + + SARS coronavirus 2 Ab.neut + + + + + + + + + SARS coronavirus 2 Ag + + + + + + + + + SARS coronavirus 2 N gene + + + + + + + + + SARS coronavirus 2 ORF1ab region + + + + + + + + + SARS coronavirus 2 RdRp gene + + + + + + + + + SARS coronavirus 2 RNA + + + + + + + + + SARS coronavirus 2 RNA panel + + + + + + + + + SARS coronavirus 2 S gene + + + + + + + + + SARS coronavirus 2 whole genome + + + + + + + + + SARS coronavirus+SARS coronavirus 2 Ag + + + + + + + + + SARS-like coronavirus N gene + + + + + + + + + SARS-related coronavirus E gene + + + + + + + + + SARS-related coronavirus RNA + + + + + + + + UMLS concepts + + + + + + + + + 2019 novel coronavirus infection + 2019-nCoV disease + 2019-nCoV infection + COVID-19 + COVID-19 pandemic + COVID-19 + coronavirus disease 2019 + coronavirus disease-19 + Disease caused by 2019 novel coronavirus + Disease caused by 2019 novel coronavirus (disorder) + Disease caused by 2019-nCoV + Disease caused by Wuhan coronavirus + 2019 novel coronavirus disease + + + + + + + + + 2019-nCoV + COVID-19 virus + COVID19 virus + SARS-CoV-2 + Wuhan coronavirus + Wuhan seafood market pneumonia virus + coronavirus disease 2019 virus + severe acute respiratory syndrome coronavirus 2 + 2019 novel coronavirus + 2019 novel coronavirus (organism) + 2019-nCoV + Wuhan coronavirus + SARS2 + 2019 novel coronavirus + + + + + + + + Stanford clinical observations + + + + + + + + + febrile + + + + + + + + + covid + + + + + + + + + nausea and vomiting + + + + + + + + + acetaminophen + + + + + + + + + infection + + + + + + + + + rash + + + + + + + + + abdominal pain + + + + + + + + + anxiety + + + + + + + + + mass + + + + + + + + + opacities + + + + + + + + + albuterol + + + + + + + + + congestion + + + + + + + + + weakness + + + + + + + + + hyperlipidemia + + + + + + + + + urticaria + + + + + + + + + asthma + + + + + + + + + tenderness + + + + + + + + + dizziness + + + + + + + + + oxygen + + + + + + + + + afebrile + + + + + + + + + gerd + + + + + + + + + depression + + + + + + + + + atelectasis + + + + + + + + + back pain + + + + + + + + + rales + + + + + + + + Auxiliary concepts + + + + + + + + + Old episode (qualifier value) + Old episode + Old + + + + + + + + + Positive (qualifier value) + Positive + Positive for + Ruled in + + + + + + + + + Performed (qualifier value) + Performed + + + + + + + + + day (qualifier value) + day + d - day + days + + + + + + + + + Image (foundation metadata concept) + Image + + + + + + + + + Reconstruction procedure (procedure) + Reconstruction + Reconstruction procedure + + + + + + + + + Axial (qualifier value) + Axial + + + + + + + + + Multiple (qualifier value) + Multiple + Plural + + + + + + + + + Glass (substance) + Glass + + + + + + + + + Lower (qualifier value) + Lower + + + + + + + + + Increased thickness (finding) + Increased thickness + Thickening + + + + + + + + + Appearance (observable entity) + Appearance + + + + + + + + + Black - ethnic group (ethnic group) + Black - ethnic group + Black + + + + + + + + + Linear (qualifier value) + Linear + Line + + + + + + + + + Distribution (attribute) + Distribution + + + + + + + + + Arrow, device (physical object) + Arrow + Arrow, device + + + + + + + + + Present (qualifier value) + Present + Presence of + + + + + + + + + Coronal (qualifier value) + Coronal + Frontal + + + + + + + + + Peripheral (qualifier value) + Peripheral + + + + + + + + + Red color (finding) + Red colour + Red color + Redness + Red + Rubor + + + + + + + + + Level (attribute) + Level + + + + + + + + + Medial (qualifier value) + Medial + + + + + + + + + Lateral segment (qualifier value) + Lateral segment + + + + + + + + + Median (qualifier value) + Middle + Midline + Median + + + + + + + + + Increased density (finding) + Increased density + Increased mass to volume ratio + + + + + + + + + year (qualifier value) + yr + year + years + + + + + + + + + Unable to speak (finding) + Unable to speak + No speech + Mute + Unable to talk + + + + + + + + + Remote (qualifier value) + Remote + + + + + + + + + Pathologic (qualifier value) + Pathologic + Pathological + + + + + + + + + Hospital (environment) + Hospital + + + + + + + + + Exertion, function (observable entity) + Exertion + Exertion, function + + + + + + + + + Oxygen (substance) + Oxygen + Chemical oxygen + Elemental oxygen + O>2< + O2 - oxygen + + + + + + + + + Blood gas analysis (procedure) + Blood gas analysis + BGA - Blood gas analysis + + + + + + + + + Documents (qualifier value) + Documents + + + + + + + + + Reduced (qualifier value) + Reduced + + + + + + + + + Initial (qualifier value) + Initial + Initially + + + + + + + + + Short (qualifier value) + Short + + + + + + + + + Ward (environment) + Ward + + + + + + + + + Laboratory (environment) + Laboratory + + + + + + + + + Tests (qualifier value) + Tests + + + + + + + + + Increased (qualifier value) + Increased + Augmented + Increased by + + + + + + + + + Lactate dehydrogenase (substance) + Lactate dehydrogenase + LDH - lactate dehydrogenase + LD - lactate dehydrogenase + + + + + + + + + Interleukin (substance) + Interleukin + + + + + + + + + Computerized axial tomography (procedure) + Computerized axial tomography + Computerized transaxial tomography + CAT scan + Computerised axial tomography + Computerised transaxial tomography + Computerised tomography + CAT - Computerised axial tomography + CT - Computerised tomography + Computerised tomograph scan + Computerized tomograph scan + CAT - Computerized axial tomography + CT - Computerized tomography + Computerized tomography + Computed axial tomography + + + + + + + + + Patchy (qualifier value) + Patchy + Spotty + + + + + + + + + In (attribute) + In + Of + Arising from + Found in + Located in + Within + Has location + Has setting + + + + + + + + + Lingual (qualifier value) + Lingual + + + + + + + + + Basal (qualifier value) + Basal + + + + + + + + + Left (qualifier value) + Left + Left lateral + Levo- + Left side + Lt - Left + + + + + + + + + Minimal (qualifier value) + Minimal + + + + + + + + + Right and left (qualifier value) + Right and left + Both + Both sides + Bilateral + + + + + + + + + Apical (qualifier value) + Apical + + + + + + + + + Compatible with (attribute) + Compatible with + CW + Consistent with + + + + + + + + + Swab - unit of product usage (qualifier value) + Swab + Swabs + Swab - unit of product usage + + + + + + + + + Infectious diseases department (environment) + Infectious diseases department + + + + + + + + + Treated with (attribute) + Treated with + TW + Treated by + + + + + + + + + Antiviral therapy (procedure) + Antiviral therapy + + + + + + + + + 1.5 (qualifier value) + 1.5 + One point five + + + + + + + + + min (qualifier value) + min + minute + minutes + + + + + + + + + Type 2 (qualifier value) + Type 2 + Type II + + + + + + + + + After (attribute) + After + Following + + + + + + + + + Clinical (qualifier value) + Clinical + + + + + + + + + Picture (physical object) + Picture + + + + + + + + + New (qualifier value) + New + + + + + + + + + Control (attribute) + Control + + + + + + + + + REPLACED BY (attribute) + REPLACED BY + + + + + + + + + Widespread (qualifier value) + Widespread + + + + + + + + + Reticular (qualifier value) + Reticular + + + + + + + + + Associated with (attribute) + Associated with + + + + + + + + + Small (qualifier value) + Small + Little + + + + + + + + + Strip (unit of presentation) + Strip + + + + + + + + + Localized (qualifier value) + Localized + Limited area + Localised + + + + + + + + + With distribution (attribute) + With distribution + Has distribution + + + + + + + + + Pulmonary (intended site) + Pulmonary + + + + + + + + + Affecting (qualifier value) + Affected + Affecting + + + + + + + + + Pathology (qualifier value) + Pathology + + + + + + + + + Diagnostic ultrasonography (procedure) + Ultrasonography + Diagnostic ultrasonography + Ultrasound scan + USS - Ultrasound scan + Ultrasound + Ultrasonogram + US - Ultrasound + Diagnostic sonar + Ultrasound procedure + Diagnostic echography + + + + + + + + + Right (qualifier value) + Right + Right lateral + Dextro + Rt - Right + Right side + + + + + + + + + Documented (qualifier value) + Documented + + + + + + + + + Home (environment) + Dwelling + Private home + Private dwelling + Home + + + + + + + + + Pulmonic valve stenosis (disorder) + Pulmonic valve stenosis + Pulmonary valve stenosis + PVS - Pulmonary valve stenosis + Pulmonic stenosis + PS - Pulmonary valve stenosis + Pulmonary stenosis + + + + + + + + + Area (qualifier value) + Area + + + + + + + + + Dyspnea on exertion (finding) + Exertional dyspnea + Breathlessness on exertion + Dyspnea on effort + Dyspnoea on effort + Exertional dyspnoea + Dyspnoea on exertion + Dyspnea on exertion + Short of breath on exertion + SOBOE - Shortness of breath on exertion + + + + + + + + + History of (contextual qualifier) (qualifier value) + History of + History + History of (contextual qualifier) + + + + + + + + + Contact with (contextual qualifier) (qualifier value) + Contact with + Contact with (contextual qualifier) + + + + + + + + + Child (person) + Child + + + + + + + + + Exposure to (contextual qualifier) (qualifier value) + Exposure to + Exposed to + Exposed + Exposure to (contextual qualifier) + + + + + + + + + Case - situation (qualifier value) + Case + Case - situation + Cases + + + + + + + + + High (qualifier value) + High + Elevated + + + + + + + + + Disease (disorder) + Disease + Clinical disease AND/OR syndrome + Disorder + Syndrome + Disease AND/OR syndrome present + Clinical disease AND/OR syndrome present + Disorders + Diseases + + + + + + + + + Naja haje (organism) + Naja haje + Egyptian cobra + Asp + + + + + + + + + Distance vision 3/4 (finding) + 3/4 + Distance vision 3/4 + + + + + + + + + Classic (qualifier value) + Classic + + + + + + + + + Increase (qualifier value) + Increase + + + + + + + + + Limited component (foundation metadata concept) + Limited component + Limited + + + + + + + + + Both lungs (body structure) + Both lungs + + + + + + + + + Mild (qualifier value) + Mild + + + + + + + + + Due to (attribute) + Due to + + + + + + + + + Known (qualifier value) + Known + + + + + + + + + Worsening (qualifier value) + Worsening + + + + + + + + + Dyspnea (finding) + Dyspnea + Dyspnoea + Breathless + Breathlessness + SOB - Shortness of breath + Shortness of breath + + + + + + + + + milligram (qualifier value) + mg + milligram + + + + + + + + + Sagittal (qualifier value) + Sagittal + + + + + + + + + Medium (qualifier value) + Medium + + + + + + + + + Raised (qualifier value) + Raised + + + + + + + + + Severe (severity modifier) (qualifier value) + Severe + High grade + Gravis + Severely + Severe (severity modifier) + + + + + + + + + Fatty degeneration (morphologic abnormality) + Fatty degeneration + Lipoid degeneration + Fatty change + Fatty metamorphosis + Steatosis + + + + + + + + + Second (qualifier value) + Second + Secondly + Second - ordinal + 2nd + + + + + + + + + Is a (attribute) + Is a + + + + + + + + + Suspicion (finding) + Suspicion + + + + + + + + + Extensive (qualifier value) + Extensive + + + + + + + + + Involved (qualifier value) + Involved + Involving + Involvement with + + + + + + + + + Anterior segment (qualifier value) + Anterior segment + + + + + + + + + Upper (qualifier value) + Upper + + + + + + + + + Medial segment (qualifier value) + Medial segment + + + + + + + + + Atypical (qualifier value) + Atypical + + + + + + + + + Form (attribute) + Form + + + + + + + + + Extreme (qualifier value) + Extreme + + + + + + + + + Specific (qualifier value) + Specific + Specified + + + + + + + + + Rare (qualifier value) + Rare + Seldom + Rarely + + + + + + + + + Manifestation of (qualifier value) + Manifestation of + + + + + + + + + Unilateral (qualifier value) + Unilateral + One-sided + + + + + + + + + Current (qualifier value) + Current + Currently + + + + + + + + + Therapeutic procedure (procedure) + Therapeutic procedure + Procedure - therapeutic + + + + + + + + + Cortisone (substance) + Cortisone + Compound E + + + + + + + + + Damage (morphologic abnormality) + Damage + Tissue damage + + + + + + + + + Pattern (attribute) + Pattern + + + + + + + + + Immune (qualifier value) + Immune + + + + + + + + + Induced (qualifier value) + Induced + + + + + + + + + Barotrauma mechanism (qualifier value) + Barotrauma mechanism + Barotrauma + + + + + + + + + Reversible (qualifier value) + Reversible + + + + + + + + + Thoracic structure (body structure) + Thorax + Chest + Thoracic structure + + + + + + + + + Understanding, function (observable entity) + Understanding + Understanding, function + + + + + + + + + Clinic (environment) + Clinic + + + + + + + + + Pneumonia (disorder) + Pneumonia + + + + + + + + + Suffering (finding) + Suffering + + + + + + + + + Hyperpyrexia (finding) + Hyperpyrexia + + + + + + + + + Intractable (qualifier value) + Intractable + Refractory + + + + + + + + + Confluent (qualifier value) + Confluent + + + + + + + + + England (geographic location) + England + + + + + + + + + Influenza-like illness (finding) + Influenza-like illness + Flu-like symptoms + Flu-like illness + Influenza like illness + + + + + + + + + Resuscitation (procedure) + Resuscitation + + + + + + + + + Reported (qualifier value) + Reported + + + + + + + + + 118 (qualifier value) + 118 + One hundred and eighteen + + + + + + + + + Entrance (qualifier value) + Entrance + + + + + + + + + Requested (qualifier value) + Requested + + + + + + + + + Posterior (qualifier value) + Posterior + Back of + + + + + + + + + Phase (attribute) + Phase + + + + + + + + + Juxta-posed (qualifier value) + Juxta-posed + Next to + Adjacent to + Juxta- + Adjacent + + + + + + + + + Mediastinal (qualifier value) + Mediastinal + + + + + + + + + Levofloxacin (substance) + Levofloxacin + + + + + + + + + Generalized (qualifier value) + Generalized + Global + General + Generalised + + + + + + + + + Sister (person) + Sister + Sr - Sister + + + + + + + + + Gold color (qualifier value) + Gold colour + Gold color + Gold + + + + + + + + + Onset of (contextual qualifier) (qualifier value) + Onset of + With onset + Onset of (contextual qualifier) + + + + + + + + + Tickling sensation quality (qualifier value) + Tickling + Tickling sensation quality + + + + + + + + + Significant (qualifier value) + Significant + + + + + + + + + Hyperglycemia (disorder) + Hyperglycemia + Hyperglycaemia + + + + + + + + + Related (finding) + Related + + + + + + + + + Numerous (qualifier value) + Many + Numerous + + + + + + + + + Anterior (qualifier value) + Front of + Ventral + Anterior + + + + + + + + + Posterior segment (qualifier value) + Posterior segment + + + + + + + + + Lateral (qualifier value) + Lateral + + + + + + + + + Segment (qualifier value) + Segment + + + + + + + + + Filter, device (physical object) + Filter + Filter, device + + + + + + + + + Mediastinal structure (body structure) + Mediastinum + Mediastinal structure + Structure of mediastinum + + + + + + + + + Prevascular (qualifier value) + Prevascular + + + + + + + + + Paratracheal (qualifier value) + Paratracheal + + + + + + + + + Short axis (qualifier value) + Short axis + + + + + + + + + Millimeter (qualifier value) + mm + millimetre + Millimeter + + + + + + + + + Compression - action (qualifier value) + Compression + Compression - action + + + + + + + + + Structure of parenchyma of lung (body structure) + Lung parenchyma + Structure of parenchyma of lung + + + + + + + + + Unit (qualifier value) + Unit + + + + + + + + + Severity (attribute) + Severity + + + + + + + + + Frequent (qualifier value) + Frequent + Often + Frequently + + + + + + + + + Intensive care unit (environment) + Intensive care unit + ICU - Intensive care unit + ITU + ICU + + + + + + + + + Clinical course (attribute) + Clinical course + + + + + + + + + Feeling angry (finding) + Anger + Feeling angry + Angry + + + + + + + + + 1/3 meter (finding) + 1/3 meter + Nr - Near + Near + 1/3 metre + + + + + + + + + Brother (person) + Brother + + + + + + + + + Finding of erythrocyte sedimentation rate (finding) + Erythrocyte sedimentation rate + Erythrocyte sedimentation rate - finding + Finding of erythrocyte sedimentation rate + + + + + + + + + Focal (qualifier value) + Focal + Focally + Foci of + + + + + + + + + Early stage (qualifier value) + Early stage + + + + + + + + + Absent (qualifier value) + Absent + Absence of + + + + + + + + + Urgency (qualifier value) + Urgency + Has urgency + Urgent + + + + + + + + + Recent (qualifier value) + Recent + Recently + + + + + + + + + Radical (substance) + Radical + + + + + + + + + Prostatectomy (procedure) + Prostatectomy + Prostate excision + + + + + + + + + Abdominal (qualifier value) + Abdominal + + + + + + + + + Infiltration (morphologic abnormality) + Infiltration + Tissue infiltration + Infiltrate + + + + + + + + + Cephalic (qualifier value) + Cephalic + Rostral + Cephalad + Craniad + Cranial + Toward the head + + + + + + + + + Study (environment) + Study + + + + + + + + + Evaluation - action (qualifier value) + Evaluation - action + Patient evaluation - action + Evaluation + Assessment + + + + + + + + + Interstitial pneumonia (disorder) + Interstitial pneumonia + Interstitial pneumonitis + + + + + + + + + Suspected (qualifier value) + Suspected + + + + + + + + + Preoperative (qualifier value) + Preoperative + Before surgery + + + + + + + + + At risk context (qualifier value) + At risk + At risk context + + + + + + + + + Risk of (contextual qualifier) (qualifier value) + Risk of + Risk of (contextual qualifier) + + + + + + + + + Surgery (qualifier value) + Surgery + + + + + + + + + Phobia (finding) + Phobia + Fear of + Abnormal fear + + + + + + + + + Voluntary (qualifier value) + Voluntary + + + + + + + + + Early (qualifier value) + Early + + + + + + + + + At rest (qualifier value) + At rest + + + + + + + + + Transport (physical object) + Transport + + + + + + + + + Decrease (qualifier value) + Decrease + + + + + + + + + Serum (substance) + Serum + + + + + + + + + Creatine kinase (substance) + Creatine kinase + Creatine phosphokinase + CK - Creatine kinase + CPK - Creatine phosphokinase + + + + + + + + + 0.88 (qualifier value) + 0.88 + Zero point eight eight + + + + + + + + + Myoglobin (substance) + Myoglobin + + + + + + + + + Before values (qualifier value) + Before values + Ante + Pre + + + + + + + + + Dorsal (qualifier value) + Dorsal + Dx - Dorsal + + + + + + + + + Upper segment (qualifier value) + Upper segment + + + + + + + + + Simultaneous (qualifier value) + Simultaneous + Simultaneously with + Concomitantly with + Concomitant + + + + + + + + + Substance with antiviral mechanism of action (substance) + Substance with antiviral mechanism of action + Antiviral + + + + + + + + + Fourth (qualifier value) + Fourth + Fourthly + 4th + + + + + + + + + Dyslipidemia (disorder) + Dyslipidemia + Dyslipidaemia + High blood cholesterol/triglycerides + + + + + + + + + Pharmacologic (qualifier value) + Pharmacologic + Pharmacological + + + + + + + + + Does reach (finding) + Reaches + Does reach + + + + + + + + + Paracetamol (substance) + Acetaminophen + Paracetamol + + + + + + + + + Location (attribute) + Location + + + + + + + + + Mitral valve structure (body structure) + Mitral valve + Left atrioventricular valve + Mitral valve structure + + + + + + + + + Electrocardiographic monitoring (procedure) + Electrocardiographic monitoring + Cardiovascular monitoring by ECG + ECG + EKG + ECG monitoring + Electrocardiography + + + + + + + + + Ischemia (disorder) + Ischemia + Ischaemia + + + + + + + + + Procalcitonin (substance) + Procalcitonin + Calcitonin precursor polyprotein + + + + + + + + + Projection (qualifier value) + Projection + + + + + + + + + Forced (qualifier value) + Forced + + + + + + + + + Supine body position (finding) + Supine body position + Lying on back + Supine position + Lying flat on back + Lying supine + + + + + + + + + False (qualifier value) + False + Pseudo + + + + + + + + + Nodular (qualifier value) + Nodular + + + + + + + + + Structure of half of thorax lateral to midsagittal plane (body structure) + Structure of half of thorax lateral to midsagittal plane + Hemithorax + + + + + + + + + Greater (qualifier value) + Greater + Larger + Bigger + + + + + + + + + Reinforcement (procedure) + Reinforcement + + + + + + + + + Texture (attribute) + Texture + + + + + + + + + During values (qualifier value) + Intra + Peri + During values + + + + + + + + + Bronchial (qualifier value) + Bronchial + + + + + + + + + Thickened (qualifier value) + Thickened + + + + + + + + + Scanner (physical object) + Scanner + + + + + + + + + 1.2 (qualifier value) + 1.2 + One point two + + + + + + + + + Consolidation (morphologic abnormality) + Consolidation + + + + + + + + + Tracheal structure (body structure) + Trachea + Windpipe + Tracheal structure + + + + + + + + + Patent (qualifier value) + Patent + Open + Opening + Patency of + + + + + + + + + Reactive (qualifier value) + Reactive + + + + + + + + + Structure of lymph node (body structure) + Lymph node + Lymph gland + Lymphatic gland + Lymph node structure + Structure of lymph node + + + + + + + + + No evidence of (contextual qualifier) (qualifier value) + No evidence of + NE + No evidence for + No evidence of (contextual qualifier) + + + + + + + + + Pericardial effusion (disorder) + Pericardial effusion + + + + + + + + + Order Araneae (organism) + Order Araneae + Spiders + Spider + Orthognata + + + + + + + + + Congenital webbing (morphologic abnormality) + Congenital webbing + Congenital web + Web + Webbing + Congenital membrane + + + + + + + + + Abnormally opaque structure (morphologic abnormality) + Opacity + Abnormally opaque structure + + + + + + + + + Triangular (qualifier value) + Triangular + Triangle + + + + + + + + + Angular (qualifier value) + Angular + Angle + + + + + + + + + Below (qualifier value) + Beneath + Infra- + Under + Subjacent + Sub- + Below + + + + + + + + + Pleural (qualifier value) + Pleural + + + + + + + + + Internal (qualifier value) + Inner + Inside + Internal + + + + + + + + + Pleural membrane structure (body structure) + Pleura + Pleural structure + Pleural membrane structure + + + + + + + + + Shape (attribute) + Shape + + + + + + + + + Swab from pharynx (specimen) + Swab from pharynx + Pharyngeal swab + + + + + + + + + Result (navigational concept) + Result + + + + + + + + + Entire (qualifier value) + Entire + + + + + + + + + Drug therapy (procedure) + Drug therapy + + + + + + + + + Seventh (qualifier value) + Seventh + + + + + + + + + Progressive (qualifier value) + Progressive + + + + + + + + + Moderate (severity modifier) (qualifier value) + Moderate + Midgrade + Moderate (severity modifier) + + + + + + + + + Stable (qualifier value) + Stable + Stable status + + + + + + + + + Repeat (qualifier value) + Repeat + Repeated + Repetition of + + + + + + + + + Tenth (qualifier value) + Tenth + + + + + + + + + Reduction plasty (qualifier value) + Reduction plasty + Surgical reduction + Reduction + + + + + + + + + Stretching procedure (procedure) + Stretching + Stretching procedure + + + + + + + + + Visceral pleura structure (body structure) + Visceral pleura + Visceral pleura structure + + + + + + + + + Right posterior (qualifier value) + Right posterior + + + + + + + + + Visible (qualifier value) + Visible + + + + + + + + + Slowly (qualifier value) + Slowly + + + + + + + + + Evaluation procedure (procedure) + Patient evaluation procedure + Clinical investigation + Investigations + Evaluation procedure + Assessment + Clinical evaluation + + + + + + + + + Fall (event) + Fall + + + + + + + + + week (qualifier value) + week + wk + weeks + + + + + + + + + Complete (qualifier value) + Complete + + + + + + + + + Stages (qualifier value) + Stages + + + + + + + + + Myelodysplastic syndrome (morphologic abnormality) + Myelodysplastic syndrome + Dysmyelopoietic syndrome + + + + + + + + + Arterial (qualifier value) + Arterial + + + + + + + + + Italy (geographic location) + Italy + + + + + + + + + Troponin (substance) + Troponin + + + + + + + + + Partial (qualifier value) + Partial + + + + + + + + + Obliteration (morphologic abnormality) + Obliteration + + + + + + + + + Shadow (finding) + Shadow + + + + + + + + + Aortic (qualifier value) + Aortic + + + + + + + + + Button, device (physical object) + Button + Button, device + + + + + + + + + X-ray electromagnetic radiation (physical force) + X-ray + X-radiation + X-ray electromagnetic radiation + + + + + + + + + Equipment (attribute) + Equipment + + + + + + + + + Obtained (attribute) + Obtained + + + + + + + + + Identified (qualifier value) + Identified + Identifiable + Discernible + + + + + + + + + Thoracic region (surface region of back) + Thoracic region + Thoracic region (surface region of back) (body structure) + Dorsal region + + + + + + + + + Lesser (qualifier value) + Lesser + Smaller + + + + + + + + + Observation parameter (observable entity) + Parameters + Observation parameter + + + + + + + + + Condition (attribute) + Condition + + + + + + + + + Worse (qualifier value) + Worse + Worsened + + + + + + + + + Altered (qualifier value) + Altered + Modified + + + + + + + + + 72 hours (qualifier value) + 72 hours + + + + + + + + + Involvement (attribute) + Involvement + + + + + + + + + Multifocal (qualifier value) + Multifocal + + + + + + + + + Removal by grinding (procedure) + Removal by grinding + Grinding + + + + + + + + + Density (qualifier value) + Density + Mass to volume ratio + DEN + + + + + + + + + Continuous (qualifier value) + Continuous + + + + + + + + + Airway pressure (observable entity) + Airways pressure + Airway pressure + Pmth - Mouth pressure + Pressure in patient's airways + + + + + + + + + Vital (qualifier value) + Vital + + + + + + + + + Slow (qualifier value) + Slow + + + + + + + + + Alzheimer's disease (disorder) + Alzheimer's disease + AD - Alzheimer's disease + Alzheimer disease + Alzheimer dementia + + + + + + + + + Diffuse (qualifier value) + Diffuse + + + + + + + + + Parietal (qualifier value) + Parietal + + + + + + + + + Certain (qualifier value) + Certain + Certainty + + + + + + + + + Bone plate, device (physical object) + Bone plate + Plate + Bone plate, device + + + + + + + + + Fine (qualifier value) + Fine + + + + + + + + + Enlarged (qualifier value) + Enlarged + + + + + + + + + Structure of descending thoracic aorta (body structure) + Descending thoracic aorta + Structure of descending thoracic aorta + + + + + + + + + Normal (qualifier value) + Normal + Unremarkable + + + + + + + + + Secondary immune response, function (observable entity) + Secondary immune response + Anamnestic response + Anamnesis + Secondary immune response, function + + + + + + + + + Electrolytes measurement, serum (procedure) + Electrolytes measurement, serum + Serum electrolytes + + + + + + + + + Bed (physical object) + Bed + + + + + + + + + Supine decubitus (qualifier value) + Supine decubitus + + + + + + + + + Widened structure (morphologic abnormality) + Widening + Widened structure + + + + + + + + + Method (attribute) + Method + + + + + + + + + Anatomic (qualifier value) + Anatomic + Anatomical + + + + + + + + + Difficult (qualifier value) + Difficult + With difficulty + + + + + + + + + Traditional (qualifier value) + Traditional + + + + + + + + + Student (occupation) + Student + + + + + + + + + Amoxicillin (substance) + Amoxicillin + + + + + + + + + Railway train, device (physical object) + Railway train + Train + Railway train, device + + + + + + + + + Female child (person) + Female child + Girl + + + + + + + + + Medical air (product) + Medical air + Air + Air gas + + + + + + + + + Context (attribute) + Context + + + + + + + + + Extending (qualifier value) + Extending + Extension of + Extends to + Extent of + + + + + + + + + Medical (qualifier value) + Medical + + + + + + + + + Traveling (observable entity) + Traveling + Travelling + + + + + + + + + Denied (qualifier value) + Denied + + + + + + + + + Leukocyte (cell) + Leukocyte + White blood cell + WBC - White blood cell + White blood cells + Leucocyte + + + + + + + + + Thoracic (qualifier value) + Thoracic + + + + + + + + + Diagnostic intent (qualifier value) + Diagnostic + Diagnostic intent + + + + + + + + + Imaging (procedure) + Imaging + Clinical imaging + + + + + + + + + Confirmed by (contextual qualifier) (qualifier value) + Confirmed by + Confirmed by (contextual qualifier) + + + + + + + + + Time (foundation metadata concept) + Time + + + + + + + + + Probe with target amplification technique (qualifier value) + Probe with target amplification + PCR + Probe with target amplification technique + + + + + + + + + Double (qualifier value) + Double + Duplicate + Twin + Replicate + + + + + + + + + Regression - mental defense mechanism (finding) + Regression + Regression - mental defense mechanism + Regression - mental defence mechanism + + + + + + + + + Discussion (procedure) + Discussion + + + + + + + + + Manifest (qualifier value) + Manifest + + + + + + + + + Fluoroscopic bronchography (procedure) + Fluoroscopic bronchography + + + + + + + + + Poorly defined (qualifier value) + Poorly defined + + + + + + + + + Slight (qualifier value) + Slight + + + + + + + + + Patterns (qualifier value) + Patterns + + + + + + + + + Hemagglutinating antibody (substance) + Hemagglutinin + Haemagglutinating antibody + Hemagglutinating antibody + Haemagglutinin + + + + + + + + + Type 1 (qualifier value) + Type 1 + Type I + + + + + + + + + Sialidase (substance) + Sialidase + Neuraminidase + + + + + + + + + Atypical pneumonia (disorder) + Atypical pneumonia + + + + + + + + + Genus Pan (organism) + Genus Pan + Chimpanzee + Pan + + + + + + + + + Approximate (qualifier value) + Approximate + Approximately + + + + + + + + + Sufficiently defined by necessary conditions definition status (core metadata concept) + Sufficiently defined by necessary conditions definition status + Defined + + + + + + + + + Report (record artifact) + Document type + Document type code + Report + + + + + + + + + Crisis (finding) + Crisis + + + + + + + + + 37.5 (qualifier value) + 37.5 + Thirty-seven point five + + + + + + + + + Hemoglobin (substance) + Hemoglobin + Hb + Hb - Haemoglobin + HGB - Haemoglobin + Haemoglobin + Hb - Hemoglobin + HGB - Hemoglobin + + + + + + + + + Platelet (cell structure) + Platelet + Thrombocyte + Platelets + PLT - Platelets + PLT - Platelet + + + + + + + + + Light color (qualifier value) + Light colour + Light color + Light + + + + + + + + + Request for (contextual qualifier) (qualifier value) + Request for + Request for (contextual qualifier) + + + + + + + + + hour (qualifier value) + hr + h - hour + hour + hours + + + + + + + + + Patient need for (contextual qualifier) (qualifier value) + Patient need for + Need for + Patient needs + Patient need for (contextual qualifier) + Patient dependence on (contextual qualifier) + + + + + + + + + Smoker (finding) + Smoker + Current smoker + + + + + + + + + Asthenia (finding) + Asthenia + General weakness + Debility + Lassitude + Weakness + Weakness - general + Feeling weak + + + + + + + + + Detected (qualifier value) + Detected + + + + + + + + + In progress (qualifier value) + In progress + + + + + + + + + Not significant (qualifier value) + Not significant + + + + + + + + + Indication of (contextual qualifier) (qualifier value) + Indication of + With indication + Indication of (contextual qualifier) + + + + + + + + + Internal medicine specialist (occupation) + Internal medicine specialist + Internist + + + + + + + + + Radiology - specialty (qualifier value) + Radiology - speciality + Radiology - specialty + Radiology + + + + + + + + + Outpatient (person) + Outpatient + + + + + + + + + Plain radiography (procedure) + Plain film + Skiagram + Radiogram + Roentgenogram + Radiograph + Roentgenography + X-ray + Plain x-ray + Plain radiography + + + + + + + + + Low back pain (finding) + Low back pain + LBP - Low back pain + Low back syndrome + Lumbalgia + Lumbago + Lumbar pain + Nonspecific pain in the lumbar region + + + + + + + + + Resolved (qualifier value) + Resolved + + + + + + + + + Husband (person) + Husband + + + + + + + + + Lung field (body structure) + Lung field + + + + + + + + + Computed tomography of chest (procedure) + CT of chest + CT of thorax + Chest CT + Computed tomography of chest + + + + + + + + + Consistent with (qualifier value) + Consistent with + + + + + + + + + Resistant (qualifier value) + Resistant + Resistant to + Is resistant to + + + + + + + + + Direct (qualifier value) + Direct + + + + + + + + + Does turn (finding) + Does turn + Turns + + + + + + + + + Employed (finding) + In work + In employment + Employed + + + + + + + + + Hotel (environment) + Hotel + + + + + + + + + Indicated (qualifier value) + Indicated + + + + + + + + + Travel abroad (finding) + Travel abroad + + + + + + + + + Household composition (observable entity) + Household composition + LW - Lives with + Lives with + + + + + + + + + Wife (person) + Wife + + + + + + + + + Continuity (attribute) + Continuity + + + + + + + + + Previous (qualifier value) + Previous + + + + + + + + + Colon structure (body structure) + Colon + Colon structure + + + + + + + + + Acute sinusitis (disorder) + Acute sinusitis + Acute inflammation of nasal sinus + Acute inflammation of sinus + Acute infection of sinus + + + + + + + + + 500 (qualifier value) + 500 + Five hundred + + + + + + + + + Ended (qualifier value) + Ended + Ceased + + + + + + + + + Daughter (person) + Daughter + + + + + + + + + Does not (qualifier value) + Unwilling to do + Does not + + + + + + + + + Blood culture (procedure) + Blood culture + BC - Blood culture + + + + + + + + + 12.4 (qualifier value) + 12.4 + Twelve point four + + + + + + + + + Grain (substance) + Grain + + + + + + + + + White - ethnic group (ethnic group) + White + White - ethnic group + + + + + + + + + 0.6 (qualifier value) + 0.6 + Zero point six + + + + + + + + + Glucose (substance) + Glucose + D-glucose + Dextrose + + + + + + + + + 126 (qualifier value) + 126 + One hundred and twenty-six + + + + + + + + + Hydrogen ion concentration measurement (procedure) + Hydrogen ion concentration measurement + Hydrogen ion concentration + Hydrogen ion concentration - observation + + + + + + + + + 7.4 (qualifier value) + 7.4 + Seven point four + + + + + + + + + 0.75 (qualifier value) + 0.75 + Zero point seven five + + + + + + + + + Discrepancy (finding) + Discrepancy + + + + + + + + + Probable diagnosis (contextual qualifier) (qualifier value) + Probable diagnosis + Probable + Probably + Likely + Probable diagnosis (contextual qualifier) + Presumptive diagnosis + + + + + + + + + 200 (qualifier value) + 200 + Two hundred + + + + + + + + + Clear (qualifier value) + Clear + Has clarity + + + + + + + + + Ischemic heart disease (disorder) + Ischemic heart disease + Ischaemic heart disease + IHD - Ischemic heart disease + IHD - Ischaemic heart disease + + + + + + + + + External (qualifier value) + External + Outside + Outer + + + + + + + + + Radiographic (qualifier value) + Radiographic + + + + + + + + + Volume (property) (qualifier value) + VOL + Volume + Volume (property) + + + + + + + + + Free of (attribute) + Free of + + + + + + + + + Good (qualifier value) + Good + Well + + + + + + + + + Smooth (qualifier value) + Smooth + + + + + + + + + Sudden (qualifier value) + Sudden + + + + + + + + + Exit (qualifier value) + Exit + + + + + + + + + Replacement - action (qualifier value) + Replacement - action + Replacement + + + + + + + + + Slightly (qualifier value) + Slightly + + + + + + + + + Sinus (morphologic abnormality) + Sinus + + + + + + + + + Emergency medicine (qualifier value) + Emergency medicine + + + + + + + + + Large (qualifier value) + Large + Great + Big + + + + + + + + + History of asthma (situation) + H/O: asthma + History of asthma + + + + + + + + + Accurate (qualifier value) + Accurate + + + + + + + + + Cohabiting (finding) + Cohabiting + + + + + + + + + Son (person) + Son + + + + + + + + + Case - unit of product usage (qualifier value) + Case + Case unit dose + Cases + Cases of unit dose + Case - unit of product usage + + + + + + + + + Surgical transfer - action (qualifier value) + Surgical transfer - action + Transfer - action + Transfer + Transfer procedure + + + + + + + + + Informing (procedure) + Reporting + Giving information + Informing + + + + + + + + + Congestive cardiomyopathy (disorder) + Congestive cardiomyopathy + Dilated cardiomyopathy + CCM - Congestive cardiomyopathy + COCM - Congestive cardiomyopathy + DCM - Dilated cardiomyopathy + Congestive dilated cardiomyopathy + + + + + + + + + Congestive heart failure (disorder) + Congestive heart failure + Congestive heart disease + Congestive cardiac failure + CCF - Congestive cardiac failure + CHF - Congestive heart failure + + + + + + + + + Severe obesity (disorder) + Severe obesity + + + + + + + + + Radiologist (occupation) + Radiologist + + + + + + + + + X-ray diagnosis (contextual qualifier) (qualifier value) + X-ray diagnosis + X-ray diagnosis (contextual qualifier) + + + + + + + + + Person in the family (person) + Family member + Person in the family + + + + + + + + + Airport (environment) + Airport + + + + + + + + + B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma (morphologic abnormality) + Chronic lymphocytic leukemia + Chronic lymphoid leukemia + Chronic lymphatic leukemia + Chronic lymphocytic leukemia, B-cell type + B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma + B-cell chronic lymphocytic leukaemia/small lymphocytic lymphoma + Chronic lymphatic leukaemia + Chronic lymphocytic leukaemia, B-cell type + Chronic lymphoid leukaemia + Chronic lymphocytic leukaemia + + + + + + + + + 12 hours (qualifier value) + 12 hours + + + + + + + + + Hypoxemic respiratory failure (disorder) + Hypoxemic respiratory failure + Hypoxaemic respiratory failure + + + + + + + + + Dry cough (finding) + Dry cough + Unproductive cough + Non-productive cough + + + + + + + + + Leukocytosis (disorder) + Leukocytosis + Leucocytosis + + + + + + + + + Coarse (qualifier value) + Coarse + + + + + + + + + Principal (qualifier value) + Principal + Primary + Main + + + + + + + + + Sleep apnea (disorder) + Sleep apnea + Sleep apnoea + SAS - Sleep apnea syndrome + Sleep hypopnea + Sleep apnea syndrome + SAS - Sleep apnoea syndrome + Sleep hypopnoea + Sleep apnoea syndrome + + + + + + + + + Finding of hematocrit (finding) + Hematocrit + Hematocrit - finding + Haematocrit + Haematocrit - finding + Finding of hematocrit + Finding of haematocrit + + + + + + + + + Extended (qualifier value) + Extended + + + + + + + + + Intermediate (qualifier value) + Intermediate + Inter- + In between + Between + + + + + + + + + Stationary (qualifier value) + Stationary + + + + + + + + + Size (attribute) + Size + + + + + + + + + Enlargement (morphologic abnormality) + Enlargement + + + + + + + + + Paravertebral (qualifier value) + Paravertebral + + + + + + + + + Distance vision 6/3 (finding) + 6/3 + 20/10 + Distance vision 6/3 + + + + + + + + + Access (attribute) + Access + + + + + + + + + 800 (qualifier value) + 800 + Eight hundred + + + + + + + + + 100 (qualifier value) + 100 + One hundred + + + + + + + + + 400 (qualifier value) + 400 + Four hundred + + + + + + + + + Food appetite, function (observable entity) + Food appetite + Desire for food + Appetite + Food appetite, function + + + + + + + + + Associated morphology (attribute) + Associated morphology + Morphology + + + + + + + + + Health (qualifier value) + Health + + + + + + + + + Syncope (disorder) + Syncope attack + Syncope + Fainting + Faint + Blackout + + + + + + + + + Triage (procedure) + Triage + + + + + + + + + Poor - grade (qualifier value) + Poor - grade + Poor + + + + + + + + + Movement (observable entity) + Movement + Quality of movement + + + + + + + + + Mosaic (qualifier value) + Mosaic + + + + + + + + + Central (qualifier value) + Central + Center + Centre + + + + + + + + + Radioimmunoassay (procedure) + Radioimmunoassay + RIA + + + + + + + + + Closed (qualifier value) + Closed + + + + + + + + + Trustee (person) + Trustee + + + + + + + + + Acute abdomen (disorder) + Acute abdomen + Acute abdominal pain syndrome + Surgical abdomen + + + + + + + + + Possible (qualifier value) + Possible + + + + + + + + + Perforation of intestine (disorder) + Perforation of intestine + Intestinal perforation + + + + + + + + + Needed (qualifier value) + Needed + + + + + + + + + Surgical (qualifier value) + Surgical + + + + + + + + + After values (qualifier value) + Post + After values + + + + + + + + + Structure of abdominopelvic cavity and/or content of abdominopelvic cavity and/or anterior abdominal wall (body structure) + Abdomen + Intra-abdominopelvic structure and/or anterior abdominal wall + Structure of abdominopelvic cavity and/or content of abdominopelvic cavity and/or anterior abdominal wall + + + + + + + + + Type (attribute) + Type - attribute + Type + + + + + + + + + Flap (attribute) + Flap + + + + + + + + + Peritoneal cavity structure (body structure) + Peritoneal cavity + Greater peritoneal cavity + Peritoneal cavity structure + + + + + + + + + Effusion (substance) + Effusion + + + + + + + + + Rapid (qualifier value) + Rapid + + + + + + + + + Indigestion (finding) + Indigestion + Dyspepsia + + + + + + + + + Episodes (qualifier value) + Episodes + + + + + + + + + Physical examination procedure (procedure) + Clinical examination + Physical examination procedure + Physical examination + Examination of patient + PE - Physical examination + + + + + + + + + 4.6 (qualifier value) + 4.6 + Four point six + + + + + + + + + 0.7 (qualifier value) + 0.7 + Zero point seven + + + + + + + + + 141 (qualifier value) + 141 + One hundred and forty-one + + + + + + + + + Entire lung (body structure) + Entire lung + + + + + + + + + Bad (qualifier value) + Bad + Poorly + Badly + + + + + + + + + Including (qualifier value) + Including + Inclusive + Has part + Includes + + + + + + + + + Collection of blood specimen for laboratory (procedure) + Collection of blood specimen for laboratory + Taking blood sample + Blood withdrawal for testing + Blood sampling + Blood draw + + + + + + + + + Protein C (substance) + Protein C + + + + + + + + + Sensitive (qualifier value) + Sensitive + Is sensitive to + Sensitive to + + + + + + + + + 110 (qualifier value) + 110 + One hundred and ten + + + + + + + + + Peak gastric acid output (observable entity) + Peak gastric acid output + PAO + + + + + + + + + Random (qualifier value) + Random + + + + + + + + + Degree (attribute) + Degree + + + + + + + + + Epicardial (qualifier value) + Epicardial + + + + + + + + + Coronary angiography (procedure) + Coronary angiography + Angiography of coronary arteries + Coronary arteriography + Coronary angiogram + Coronary arteriogram + + + + + + + + + Episode (attribute) + Episode of + Episode + + + + + + + + + 4.5 (qualifier value) + 4.5 + Four point five + + + + + + + + + 650 (qualifier value) + 650 + Six hundred and fifty + + + + + + + + + Deciliter (qualifier value) + decilitre + dL + Deciliter + + + + + + + + + 150 (qualifier value) + 150 + One hundred and fifty + + + + + + + + + 450 (qualifier value) + 450 + Four hundred and fifty + + + + + + + + + Evening (qualifier value) + Evening + During the evening + + + + + + + + + Regular (qualifier value) + Regular + + + + + + + + + Reactive lymphadenopathy (disorder) + Reactive lymphadenopathy + + + + + + + + + Portal (qualifier value) + Portal + Hilar + + + + + + + + + Strong (qualifier value) + Strong + + + + + + + + + Nasal (intended site) + Nasal + + + + + + + + + Responsive (qualifier value) + Responsive + + + + + + + + + Availability of (contextual qualifier) (qualifier value) + Availability of + Available + Availability of (contextual qualifier) + + + + + + + + + Cavity (morphologic abnormality) + Cavity + Cavitation + + + + + + + + + Nature (attribute) + Nature + + + + + + + + + Relative (person) + Relative + + + + + + + + + Bilateral pleural effusion (disorder) + Bilateral pleural effusion + + + + + + + + + Bilateral pneumonia (disorder) + Bilateral pneumonia + + + + + + + + + Right ventricular failure (disorder) + Right ventricular failure + Right heart failure + + + + + + + + + Hypertensive heart disease (disorder) + Hypertensive heart disease + Hypertensive cardiopathy + Hypertensive cardiomegaly + Hypertensive cardiovascular disease + HHD - Hypertensive heart disease + + + + + + + + + Afternoon (qualifier value) + Afternoon + + + + + + + + + Diuretic therapy (procedure) + Diuretic therapy + + + + + + + + + Basal crepitations (finding) + Basal crepitations + Basal creps + + + + + + + + + 160 (qualifier value) + 160 + One hundred and sixty + + + + + + + + + Blood chemistry (procedure) + Blood chemistry + + + + + + + + + 137 (qualifier value) + 137 + One hundred and thirty-seven + + + + + + + + + Lobular (qualifier value) + Lobular + + + + + + + + + 140 (qualifier value) + 140 + One hundred and forty + + + + + + + + + 326 (qualifier value) + Three hundred and twenty-six + 326 + + + + + + + + + 225 (qualifier value) + 225 + Two hundred and twenty-five + + + + + + + + + With meals (qualifier value) + With meals + Meals + + + + + + + + + Lymph (substance) + Lymph + + + + + + + + + Symmetrical (qualifier value) + Symmetrical + + + + + + + + + Centimeter (qualifier value) + centimetre + cm + Centimeter + + + + + + + + + Emphysematous (qualifier value) + Emphysematous + + + + + + + + + To the left (qualifier value) + To the left + + + + + + + + + 2.7 (qualifier value) + 2.7 + Two point seven + + + + + + + + + Travel (event) + Travel + + + + + + + + + Motor bus, device (physical object) + Motor bus + Bus + Motor bus, device + + + + + + + + + Stress (qualifier value) + Stress + Stress - value + + + + + + + + + Patient died (finding) + Patient died + + + + + + + + + Bar (basic dose form) + Bar + + + + + + + + + Monday (qualifier value) + Monday + + + + + + + + + Negative (qualifier value) + Negative + Negative for + Ruled out + + + + + + + + + Lucid (finding) + Lucid + + + + + + + + + Reservoir (environment) + Reservoir + + + + + + + + + Positioning patient (procedure) + Putting patient in a position + Positioning patient + Positions patient + Positioning + Positioning therapy + Positioning treatments and procedures + + + + + + + + + On admission (qualifier value) + On admission + + + + + + + + + Venturi mask (physical object) + Venturi mask + + + + + + + + + Affect, function (observable entity) + Affect + Affect, function + + + + + + + + + Cannula, device (physical object) + Cannula + Cannula, device + + + + + + + + + Central venous (qualifier value) + Central venous + + + + + + + + + Superior vena cava structure (body structure) + Superior vena cava + Anterior vena cava + Superior vena cava structure + + + + + + + + + Prolonged (qualifier value) + Prolonged + + + + + + + + + Non-smoker (finding) + Non-smoker + + + + + + + + + Insulin (substance) + Insulin + + + + + + + + + 11.2 (qualifier value) + 11.2 + Eleven point two + + + + + + + + + 135 (qualifier value) + 135 + One hundred and thirty-five + + + + + + + + + International normalized ratio (observable entity) + INR - Internationalised ratio + Internationalised ratio + International normalized ratio + International normalised ratio + + + + + + + + + 1.4 (qualifier value) + 1.4 + One point four + + + + + + + + + Acute pulmonary thromboembolism (disorder) + Acute pulmonary thromboembolism + + + + + + + + + Volumetric (qualifier value) + Volumetric + + + + + + + + + 0.5 (qualifier value) + 0.5 + Zero point five + + + + + + + + + Tazobactam (substance) + Tazobactam + + + + + + + + + Review of (contextual qualifier) (qualifier value) + Review of + Review of (contextual qualifier) + + + + + + + + + 4.2 (qualifier value) + 4.2 + Four point two + + + + + + + + + Concept model range (foundation metadata concept) + Concept model range + Range + + + + + + + + + 3.5 (qualifier value) + 3.5 + Three point five + + + + + + + + + month (qualifier value) + month + months + + + + + + + + + Completely - dosing instruction fragment (qualifier value) + Completely + Completely - dosing instruction fragment + + + + + + + + + Low (qualifier value) + Low + + + + + + + + + Viral load (procedure) + Viral load + + + + + + + + + Aid (attribute) + Aid + + + + + + + + + Number (attribute) + Number + + + + + + + + + Minor (qualifier value) + Minor + + + + + + + + + Purpose (attribute) + Purpose + + + + + + + + + Right cardiac ventricular structure (body structure) + Right ventricle + Right ventricular structure + Right cardiac ventricular structure + Right ventricle of heart + + + + + + + + + Lysergic acid diethylamide (substance) + Lysergic acid diethylamide + LSD + Lysergide + + + + + + + + + Massive (qualifier value) + Massive + Marked + Markedly + Massively + + + + + + + + + Language, function (observable entity) + Language + Language, function + + + + + + + + + Integral (qualifier value) + Integral + + + + + + + + + Intact (qualifier value) + Intact + Integrity of + + + + + + + + + Apartment (environment) + Residential flat + Flat + Apartment + + + + + + + + + Peristalsis, function (observable entity) + Peristalsis + Vermiculation + Peristalsis, function + + + + + + + + + Vesicular breathing (finding) + Vesicular breath sounds + Vesicular breathing + Vesicular murmur + + + + + + + + + 0.8 (qualifier value) + 0.8 + Zero point eight + + + + + + + + + 1.1 (qualifier value) + 1.1 + One point one + + + + + + + + + Steroid therapy (procedure) + Administration of steroid + Steroid therapy + + + + + + + + + Obesity (disorder) + Obesity + Adiposis + Adiposity + + + + + + + + + Administration (procedure) + Administration + + + + + + + + + Total (qualifier value) + In toto + Total + + + + + + + + + Septal (qualifier value) + Septal + + + + + + + + + Extent (attribute) + Extent + + + + + + + + + Clavulanic acid (substance) + Clavulanic acid + Clavulanate + + + + + + + + + Oral route (qualifier value) + Oral route + Per os + Oral use + Per oral route + PO - Per os + By mouth + + + + + + + + + Suggestive of (attribute) + Suggestive of + + + + + + + + + History of bariatric surgical procedure (situation) + History of bariatric operative procedure + History of bariatric surgical procedure + History of bariatric surgery + + + + + + + + + Bipolar (qualifier value) + Bipolar + + + + + + + + + 420 (qualifier value) + 420 + Four hundred and twenty + + + + + + + + + Patch - unit of product usage (qualifier value) + Patch + Patches + Patch - unit of product usage + + + + + + + + + Pulmonary embolism (disorder) + Pulmonary embolism + PE - Pulmonary embolism + + + + + + + + + Embolism (disorder) + Embolism + + + + + + + + + View (attribute) + View + + + + + + + + + Conservative therapy (regime/therapy) + Conservative therapy + Conservative management + + + + + + + + + Established (qualifier value) + Established + + + + + + + + + Traumatic abnormality (morphologic abnormality) + Injury + Trauma + Traumatic abnormality + + + + + + + + + Beclometasone (substance) + Beclomethasone + Beclometasone + + + + + + + + + Puff - unit of product usage (qualifier value) + Puff + Puffs + Puff - unit of product usage + + + + + + + + + Percent (property) (qualifier value) + PCT + Percent + % + percent + Percent (property) + + + + + + + + + 0.13 (qualifier value) + 0.13 + Zero point one three + + + + + + + + + Active (qualifier value) + Active + + + + + + + + + Intracranial (qualifier value) + Intracranial + + + + + + + + + Bone structure of rib (body structure) + Rib + Bone structure of rib + + + + + + + + + Bone structure of cranium (body structure) + Skull + Cranium + Bone structure of cranium + Bone of cranium + + + + + + + + + Linear atrophy (morphologic abnormality) + Linear atrophy + Striae + Striae gravidarum + Lineae albicantes + Striae distensae + Lineae atrophicae + Stretch marks + + + + + + + + + Started (qualifier value) + Started + + + + + + + + + Wet (qualifier value) + Wet + Moist + Humid + Damp + + + + + + + + + Hemodynamically stable (finding) + Hemodynamically stable + Haemodynamically stable + + + + + + + + + Diuresis, function (observable entity) + Diuresis + Urinary flow + Diuresis, function + + + + + + + + + Respiratory alkalosis (disorder) + Respiratory alkalosis + + + + + + + + + 7.5 (qualifier value) + 7.5 + Seven point five + + + + + + + + + 0.16 (qualifier value) + 0.16 + Zero point one six + + + + + + + + + Milliliter (qualifier value) + millilitre + cm3 + cc + mL + Milliliter + + + + + + + + + Expression (foundation metadata concept) + Expression + + + + + + + + + Substance amount (property) (qualifier value) + SUB + Substance amount + Substance amount (property) + + + + + + + + + Cyst (morphologic abnormality) + Cyst + + + + + + + + + Diameter (qualifier value) + Diameter + Calibre + Caliber + + + + + + + + + Heavy sensation quality (qualifier value) + Heavy sensation quality + Heavy + + + + + + + + + Lower third (qualifier value) + Lower third + + + + + + + + + Evidence of (contextual qualifier) (qualifier value) + Evidence of + EO + Evidence for + Evidence of (contextual qualifier) + + + + + + + + + Respiratory function (observable entity) + Respiratory function + Breathing + + + + + + + + + Silent (qualifier value) + Silent + + + + + + + + + Figs (substance) + Figs + + + + + + + + + Distance vision 3/6 (finding) + 3/6 + Distance vision 3/6 + + + + + + + + + Chronic thyroiditis (disorder) + Chronic thyroiditis + + + + + + + + + Loss of taste (finding) + Ageusia + Loss of taste + Absence of sense of taste + Gustatory alteration + Gustatory anesthesia + Gustatory anaesthesia + + + + + + + + + Chronic (qualifier value) + Chronic + Chronic course - prolonged duration + + + + + + + + + Place (environment) + Places + Place + + + + + + + + + Asthma (disorder) + Airway hyperreactivity + Asthmatic + Bronchial asthma + Bronchial hyperreactivity + BHR - Bronchial hyperreactivity + Bronchial hyperresponsiveness + Bronchial hypersensitivity + Asthma + Hyperreactive airway disease + + + + + + + + + Exclude (qualifier value) + Exclude + Rule out + + + + + + + + + Mid (qualifier value) + Mid + + + + + + + + + Local (qualifier value) + Local + + + + + + + + + Common (qualifier value) + Common + + + + + + + + + Assisted (qualifier value) + Assisted + Requires assistance + + + + + + + + + Extravasation (morphologic abnormality) + Extravasation + Leakage + Spillage + + + + + + + + + Paraseptal emphysema (disorder) + Paraseptal emphysema + Peripheral lobular emphysema + Subpleural emphysema + + + + + + + + + Ex-smoker (finding) + Ex-smoker + Cessation of smoking + + + + + + + + + Peak (qualifier value) + Peak + + + + + + + + + Singular (qualifier value) + Singular + Solitary + Single + Single - numerical descriptor + + + + + + + + + Excision of appendix (procedure) + Appendectomy + Excision of appendix + Appendicectomy + + + + + + + + + Immediate (qualifier value) + Immediate + + + + + + + + + Panlobular (qualifier value) + Panlobular + + + + + + + + + Oropharyngeal (intended site) + Oropharyngeal + + + + + + + + + Measurement procedure (procedure) + Measurement + Measurement procedure + + + + + + + + + Screening - procedure intent (qualifier value) + Screening + Screening - action + Screening intent + Screening - procedure intent + + + + + + + + + Very high (qualifier value) + Very high + + + + + + + + + Angiography (procedure) + Angiography + Angiogram + Diagnostic angiogram + Diagnostic angiography + + + + + + + + + Opacification (attribute) + Opacification + + + + + + + + + Segmental (qualifier value) + Segmental + + + + + + + + + Viral disease (disorder) + Viral disease + Viral infection + Disease caused by virus + Viral infectious disease + Viral illness + Disease due to virus + + + + + + + + + Able with difficulty (qualifier value) + Difficulty + Has difficulty doing + Able with difficulty + + + + + + + + + Feeding patient (regime/therapy) + Feeding patient + Patient feeding technique + Feeding + + + + + + + + + Polymyalgia (disorder) + Polymyalgia + + + + + + + + + Arteritis (disorder) + Arteritis + Inflammation of artery + + + + + + + + + Auscultation (procedure) + Auscultation + Auscultation - examination + Listening + + + + + + + + + Saturday (qualifier value) + Saturday + + + + + + + + + Electrolyte imbalance (disorder) + Electrolyte imbalance + + + + + + + + + Morning (qualifier value) + Morning + om - omni mane + During morning + am - ante meridiem + ante meridiem + In the morning + mane + + + + + + + + + Late (qualifier value) + Late + Tardy + + + + + + + + + Sunday (qualifier value) + Sunday + + + + + + + + + Malignant neoplasm of breast (disorder) + Malignant tumor of breast + Breast cancer + CA - Breast cancer + Malignant tumour of breast + Malignant neoplasm of breast + + + + + + + + + Simple mastectomy (procedure) + SM - Simple mastectomy + Simple mastectomy + Total mastectomy + + + + + + + + + Excision of lymph node (procedure) + Excision of lymph node + Simple lymphadenectomy + Lymphadenectomy + + + + + + + + + Habitual (qualifier value) + Habitual + + + + + + + + + Family medicine specialist (occupation) + Family medicine specialist + Family doctor + GP - General practitioner + General practitioner + + + + + + + + + Pink color (finding) + Pink color + Pink colour + Pink + + + + + + + + + Mucous (qualifier value) + Mucous + + + + + + + + + Painless (qualifier value) + Painless + + + + + + + + + Dry (qualifier value) + Dry + + + + + + + + + Roman numeral III (qualifier value) + III + Roman numeral III + + + + + + + + + Standard chest X-ray (procedure) + Standard chest X-ray + Chest X-ray - routine + Routine chest X-ray + + + + + + + + + 5.02 (qualifier value) + Five point zero two + 5.02 + + + + + + + + + Aspartate aminotransferase (substance) + Aspartate aminotransferase + Glutamic-oxaloacetic transaminase + Glutamic-aspartic transaminase + Transaminase A + SGOT + GOT + L-aspartate:2-oxoglutarate aminotransferase + ASAT - Aspartate aminotransferase + SGOT - Glutamate oxaloacetate transaminase + Glutamate oxaloacetate transaminase + AST - Aspartate transaminase + Aspartate transaminase + + + + + + + + + 136 (qualifier value) + 136 + One hundred and thirty-six + + + + + + + + + Lopinavir (substance) + Lopinavir + + + + + + + + + Ritonavir (substance) + Ritonavir + + + + + + + + + Medical therapy (procedure) + Medical therapy + + + + + + + + + Acute cholecystitis (disorder) + Acute cholecystitis + + + + + + + + + 170 (qualifier value) + 170 + One hundred and seventy + + + + + + + + + Pain (finding) + Pain + Dolor + Painful + Part hurts + Pain observations + + + + + + + + + Deep palpation (procedure) + Deep palpation + + + + + + + + + 1.7 (qualifier value) + 1.7 + One point seven + + + + + + + + + Cholecystitis (disorder) + Cholecystitis + Inflamed gallbladder + + + + + + + + + Times (qualifier value) + Times + + + + + + + + + Gallbladder structure (body structure) + Gallbladder + Gallbladder structure + Gall bladder + + + + + + + + + Chest and/or abdomen structure (body structure) + Chest and abdomen + Chest and/or abdomen structure + + + + + + + + + Localization - action (qualifier value) + Localisation + Localisation - action + Localization + Localization - action + + + + + + + + + Malignant lymphoma in remission (disorder) + Malignant lymphoma in remission + Lymphoma in remission + + + + + + + + + Oxygen saturation within reference range (finding) + Normal oxygen saturation + Oxygen saturation within reference range + + + + + + + + + Halo sign (finding) + Halo sign + + + + + + + + + Parity finding (finding) + Parity finding + Number of previous babies + Parity + Number of deliveries + Para + + + + + + + + + Dimensions (qualifier value) + Size value + Dimensions + + + + + + + + + Remission phase (qualifier value) + Remission phase + Remission + + + + + + + + + Position (attribute) + Position + + + + + + + + + Irregular (qualifier value) + Irregular + + + + + + + + + Subtotal (qualifier value) + Subtotal + ST - Subtotal + + + + + + + + + Persistence (finding) + Persistence + + + + + + + + + Mixed (qualifier value) + Mixed + + + + + + + + + Left hip region structure (body structure) + Left hip region structure + Left hip + + + + + + + + + Idiopathic pulmonary fibrosis (disorder) + Usual interstitial pneumonia + Idiopathic fibrosing alveolitis + Cryptogenic fibrosing alveolitis + Idiopathic pulmonary fibrosis + + + + + + + + + Tyrosine (substance) + Tyrosine + L-tyrosine + + + + + + + + + Kinase (disposition) + Kinase + + + + + + + + + Home oxygen therapy (procedure) + Home oxygen therapy + + + + + + + + + Excision of stomach structure (procedure) + Gastrectomy + Excision of stomach structure + + + + + + + + + Port (substance) + Port + + + + + + + + + Rhenium (substance) + Rhenium + + + + + + + + + Grade (attribute) + Grade + Has grade + With grade + + + + + + + + + Neutrophilia (finding) + Neutrophilia + Neutrophilic leukocytosis + Neutrophilic leucocytosis + Neutrophil count above reference range + + + + + + + + + Monocytopenia (finding) + Monocytopenia + + + + + + + + + Major (qualifier value) + Major + + + + + + + + + Infracardiac (qualifier value) + Infracardiac + + + + + + + + + Bone structure of femur (body structure) + Femur + Bone structure of femur + + + + + + + + + Fracture of bone (disorder) + Fracture of bone + Fracture + Broken bone + + + + + + + + + Accidental fall (event) + Accidental fall + Fall - accidental + + + + + + + + + Equal (qualifier value) + Equal + + + + + + + + + 3.7 (qualifier value) + 3.7 + Three point seven + + + + + + + + + 1000 (qualifier value) + 1000 + One thousand + + + + + + + + + 12.6 (qualifier value) + 12.6 + Twelve point six + + + + + + + + + Simple carbohydrate (substance) + Sugar + Simple carbohydrate + + + + + + + + + 0.04 (qualifier value) + 0.04 + Zero point zero four + + + + + + + + + Pitch (observable entity) + Pitch + + + + + + + + + Frontal plane (body structure) + Frontal plane + Coronal plane + + + + + + + + + No status change (qualifier value) + No status change + No change + Unchanged + Id status quo + + + + + + + + + Aunt (person) + Aunt + + + + + + + + + Patient waiting for (contextual qualifier) (qualifier value) + Patient waiting for + Waiting for + Patient waiting for (contextual qualifier) + + + + + + + + + 290 (qualifier value) + Two hundred and ninety + 290 + + + + + + + + + 5.3 (qualifier value) + Five point three + 5.3 + + + + + + + + + 640 (qualifier value) + 640 + Six hundred and forty + + + + + + + + + 11.4 (qualifier value) + 11.4 + Eleven point four + + + + + + + + + Improving (qualifier value) + Improving + + + + + + + + + Sitting position (finding) + Sitting position + Sitting + + + + + + + + + Inspiration (observable entity) + Inspiration + Inhalation + Inspiratory + Breathing in + + + + + + + + + Transverse (qualifier value) + Transverse + Transversal + + + + + + + + + Score (attribute) + Score + + + + + + + + + Origin (attribute) + Origin + + + + + + + + + Diaphragm structure (body structure) + Diaphragm + Diaphragm structure + + + + + + + + + Extension (qualifier value) + Extension + + + + + + + + + Compensation (finding) + Compensation + + + + + + + + + Partial pressure (property) (qualifier value) + PPRES + Partial pressure + Partial pressure (property) + + + + + + + + + Pressure ratio (property) (qualifier value) + Pressure ratio (property) + Pressure ratio + + + + + + + + + 300 (qualifier value) + 300 + Three hundred + + + + + + + + + Swelling (morphologic abnormality) + Swelling + + + + + + + + + Soft tissues (body structure) + Soft tissues + + + + + + + + + Supraclavicular approach (qualifier value) + Supraclavicular approach + Supraclavicular + + + + + + + + + Does carry (finding) + Carries + Does carry + + + + + + + + + Central venous catheter, device (physical object) + Central venous catheter + Central intravenous catheter + Central line + Central venous line + CVP (central venous pressure) line + Central venous catheter, device + + + + + + + + + Mediastinal emphysema (disorder) + Mediastinal emphysema + Pneumomediastinum + + + + + + + + + Interstitial emphysema (morphologic abnormality) + Interstitial emphysema + Soft tissue emphysema + + + + + + + + + Chest wall structure (body structure) + Chest wall + Thoracic wall + Chest wall structure + + + + + + + + + Neck structure (body structure) + Neck + Neck structure + + + + + + + + + Progression (attribute) + Progression + + + + + + + + + Lung volume, function (observable entity) + Lung volume + Lung volume, function + + + + + + + + + Cystic (qualifier value) + Cystic + + + + + + + + + Walls (physical object) + Walls + + + + + + + + + Relationship (attribute) + Relationship + + + + + + + + + Air cyst (morphologic abnormality) + Air cyst + Pneumatocele + Aerocele + + + + + + + + + Pneumothorax (disorder) + Pneumothorax + + + + + + + + + Cervical (qualifier value) + Cervical + Cx - Cervical + + + + + + + + + Emphysema (morphologic abnormality) + Emphysema + Pathological accumulation of air in tissues + + + + + + + + + Subcutaneous (intended site) + Subcutaneous + + + + + + + + + Upper thoracic region (surface region of back) + Upper thoracic region + Upper thoracic region (surface region of back) (body structure) + + + + + + + + + Pneumopericardium (disorder) + Pneumopericardium + + + + + + + + + Large blood vessel structure (body structure) + Large vessel + Large blood vessel structure + Large vessels + + + + + + + + + Nasogastric tube, device (physical object) + Nasogastric tube + NG - Nasogastric tube + NGT - Nasogastric tube + Nasogastric tube, device + + + + + + + + + Distal (qualifier value) + Distal + Far from + + + + + + + + + End (qualifier value) + End + + + + + + + + + Vena caval structure (body structure) + Vena cava + Vena caval structure + + + + + + + + + Superior (qualifier value) + Superior + + + + + + + + + Venous (qualifier value) + Venous + + + + + + + + + Rehabilitation - specialty (qualifier value) + Rehabilitation - speciality + Rehabilitation - specialty + Rehabilitation + + + + + + + + + Bone structure of humerus (body structure) + Humerus + Bone structure of humerus + + + + + + + + + Empirical therapy (regime/therapy) + Empirical therapy + + + + + + + + + Psoriasis (disorder) + Psoriasis + + + + + + + + + Atenolol (substance) + Atenolol + + + + + + + + + Escitalopram (substance) + Escitalopram + + + + + + + + + Lorazepam (substance) + Lorazepam + + + + + + + + + 2.5 (qualifier value) + 2.5 + Two point five + + + + + + + + + Allopurinol (substance) + Allopurinol + + + + + + + + + 250 (qualifier value) + 250 + Two hundred and fifty + + + + + + + + + Spread (attribute) + Spread + + + + + + + + + Congestion (morphologic abnormality) + Congestion + + + + + + + + + Support, device (physical object) + Support + Support, device + + + + + + + + + Pulmonary thromboembolism (disorder) + Pulmonary thromboembolism + PTE - Pulmonary thromboembolism + PE - Pulmonary thromboembolism + + + + + + + + + Iopromide (substance) + Iopromide + + + + + + + + + 370 (qualifier value) + 370 + Three hundred and seventy + + + + + + + + + Confirmation of (contextual qualifier) (qualifier value) + Confirmation of + Confirmation of (contextual qualifier) + + + + + + + + + No thrombus (situation) + No thrombus + + + + + + + + + Pulmonary artery structure (body structure) + Pulmonary artery + Pulmonary artery structure + + + + + + + + + Male child (person) + Boy + Male child + + + + + + + + + Objective observation (qualifier value) + Objective + Objective observation + + + + + + + + + Infant (person) + Infant + Baby + + + + + + + + + Systole, function (observable entity) + Systole + Systolic + Systole, function + + + + + + + + + Pressure (finding) + Pressure + + + + + + + + + Bed-ridden (finding) + Bed-ridden + Staying in bed + Bed-fast + Bedridden patient + Bedbound + Stuck in bed + + + + + + + + + Ratio (property) (qualifier value) + RATIO + Ratio + Ratios + Ratio (property) + + + + + + + + + 24 hours (qualifier value) + 24 hours + + + + + + + + + Discharge - substance (substance) + Discharge - substance + Discharge + Dx - Discharge + + + + + + + + + Site of (attribute) + Site of + + + + + + + + + Structure resulting from tissue repair process (morphologic abnormality) + Tissue repair + Healing + Healing following injury + Repair following injury + Wound healing + Structure resulting from tissue repair process + + + + + + + + + Rhinitis (disorder) + Rhinitis + Irritation of nose + + + + + + + + + Mother (person) + Mother + Maternal + + + + + + + + + Grandmother (person) + Grand-mother + Grandmother + + + + + + + + + Chemical (substance) + Chemical + + + + + + + + + Employee (person) + Employee + + + + + + + + + Neurologic (qualifier value) + Neurologic + Neurological + + + + + + + + + Ulcerative (qualifier value) + Ulcerative + + + + + + + + + Rectal (qualifier value) + Rectal + + + + + + + + + Colitis (disorder) + Colitis + Colon inflammation + + + + + + + + + Substance with antiretroviral mechanism of action (substance) + Substance with antiretroviral mechanism of action + Antiretroviral + + + + + + + + + Suspected urinary tract infection (situation) + Suspected urinary tract infection + Suspected UTI (urinary tract infection) + + + + + + + + + Urinary tract infectious disease (disorder) + Urinary tract infectious disease + Urinary tract infection + UTI - Urinary tract infection + + + + + + + + + Benign (qualifier value) + Benign + Bgn - Benign + + + + + + + + + Uncomplicated (qualifier value) + Uncomplicated + + + + + + + + + Advanced (qualifier value) + Advanced + Advanced phase + + + + + + + + + Adolescence (qualifier value) + Adolescence + Adolescence - period + + + + + + + + + Adult (person) + Adult + + + + + + + + + Scheduled - procedure status (qualifier value) + Scheduled - procedure status + Scheduled + + + + + + + + + Paraplegia (disorder) + Paraplegia + Paralysis of both lower limbs + Lower paraplegia + Paraplegia (complete or partial paralysis of legs) + + + + + + + + + Traumatic injury (disorder) + Traumatic injury + Injury - disorder + Trauma + + + + + + + + + Date property (qualifier value) + Date + DATE + Date property + + + + + + + + + Struck by (contextual qualifier) (qualifier value) + Struck by + Hit by + Struck by (contextual qualifier) + + + + + + + + + Breast structure (body structure) + Breast + Breast structure + Breast anatomy + + + + + + + + + Herniated structure (morphologic abnormality) + Hernia + Herniated structure + Herniated tissue + Herniation + + + + + + + + + Persistent cough (finding) + Persistent cough + + + + + + + + + Intolerance, function (observable entity) + Intolerance + Intolerance, function + + + + + + + + + Use of (attribute) + Use of + + + + + + + + + Helmet (physical object) + Helmet + Protective helmet + Protective headgear + + + + + + + + + Suspended (qualifier value) + Suspended + + + + + + + + + Electrolyte (substance) + Electrolyte + + + + + + + + + Positive end expiratory pressure (observable entity) + Positive end expiratory pressure + PEEP - Positive end expiratory pressure + + + + + + + + + 12.5 (qualifier value) + 12.5 + Twelve point five + + + + + + + + + 480 (qualifier value) + 480 + Four hundred and eighty + + + + + + + + + Unit dose (qualifier value) + Unit dose + Dose + + + + + + + + + 48 hours (qualifier value) + 48 hours + + + + + + + + + Definitive (qualifier value) + Definitive + + + + + + + + + Gradual (qualifier value) + Gradual + + + + + + + + + Alternating (qualifier value) + Alternating + Alternating with + + + + + + + + + 216 (qualifier value) + 216 + Two hundred and sixteen + + + + + + + + + Band, device (physical object) + Band + Band, device + + + + + + + + + Face structure (body structure) + Face + Face structure + + + + + + + + + Variant (qualifier value) + Variant + Variation + + + + + + + + + Worker (occupation) + Worker + + + + + + + + + Monocytosis (disorder) + Monocytosis + + + + + + + + + Easy (qualifier value) + Easy + Easily + + + + + + + + + Depth (attribute) + Depth + + + + + + + + + Areola structure (body structure) + Areola + Areola structure + Areolar anatomy + + + + + + + + + Mediastinal lymphadenopathy (disorder) + Mediastinal lymphadenopathy + + + + + + + + + Solid (state of matter) + Solid + + + + + + + + + Formations (qualifier value) + Formations + + + + + + + + + Father (person) + Father + + + + + + + + + Improved (qualifier value) + Improved + + + + + + + + + Prescription (procedure) + Prescription + Prescription of + + + + + + + + + Cardiologist (occupation) + Cardiologist + + + + + + + + + Myocardial necrosis (finding) + Myocardial necrosis + + + + + + + + + Percutaneous transluminal coronary angioplasty (procedure) + Percutaneous transluminal coronary angioplasty + Balloon angioplasty of coronary artery + Percutaneous transluminal coronary balloon angioplasty + PTCA - Percutaneous transluminal coronary angioplasty + Percutaneous angioplasty of coronary artery + + + + + + + + + Digital slit-beam radiograph (procedure) + Digital slit-beam radiograph + Topogram + Scanogram + Scout view + + + + + + + + + Bronchiectasis (disorder) + Bronchiectasis + + + + + + + + + Greek letter lambda (qualifier value) + Lambda + Greek letter lambda + + + + + + + + + Multiple myeloma (clinical) + Plasmacytic myeloma + Kahler's disease + Myelomatosis + Multiple myeloma + Myeloma + Multiple myeloma (disorder) + + + + + + + + + Aciclovir (substance) + Acyclovir + Aciclovir + + + + + + + + + Aspirin (substance) + Aspirin + Acetylsalicylic acid + + + + + + + + + Colecalciferol (substance) + Vitamin D>3< + Vitamin D3 + Colecalciferol + Cholecalciferol + Activated 7-dehydrocholesterol + VITD - Colecalciferol + VITD - cholecalciferol + D3 - cholecalciferol + D3 - colecalciferol + + + + + + + + + Cytopenia (finding) + Cytopenia + + + + + + + + + 540 (qualifier value) + Five hundred and forty + 540 + + + + + + + + + microgram (qualifier value) + microgram + mcg + ug + + + + + + + + + Hypoalbuminemia (disorder) + Hypoalbuminemia + Hypoalbuminaemia + Serum albumin low + + + + + + + + + 145 (qualifier value) + 145 + One hundred and forty-five + + + + + + + + + Beats/minute (qualifier value) + beats/min + beats per minute + BPM - beats per minute + Beats/minute + + + + + + + + + Deep venous thrombosis (disorder) + Deep venous thrombosis + DVT - Deep vein thrombosis + Deep vein thrombosis + + + + + + + + + Right atrial structure (body structure) + Right atrium + Right atrial structure + + + + + + + + + Heparin therapy (procedure) + Heparin therapy + + + + + + + + + Structure of left foot (body structure) + Left foot + Structure of left foot + + + + + + + + + Capillary refill (finding) + Capillary refill + + + + + + + + + Filling defect (finding) + Filling defect + + + + + + + + + Structure of left pulmonary artery (body structure) + Left pulmonary artery + Left main pulmonary artery + Structure of left pulmonary artery + + + + + + + + + Aortic structure (body structure) + Aorta + Aortic structure + + + + + + + + + Structure of left common iliac artery (body structure) + Left common iliac artery + Structure of left common iliac artery + + + + + + + + + Structure of external iliac artery (body structure) + External iliac artery + Structure of external iliac artery + + + + + + + + + Superficial femoral artery (body structure) + Superficial femoral artery + SFA - Superficial femoral artery + + + + + + + + + Filiform (qualifier value) + Filiform + + + + + + + + + Structure of profunda femoris artery (body structure) + Profunda femoris artery + Structure of profunda femoris artery + Deep femoral artery + + + + + + + + + Opaque (qualifier value) + Opaque + + + + + + + + + Structure of popliteal artery (body structure) + Popliteal artery + Structure of popliteal artery + + + + + + + + + Occluded (qualifier value) + Occluded + + + + + + + + + Structure of anterior tibial artery (body structure) + Anterior tibial artery + Structure of anterior tibial artery + + + + + + + + + Proximal (qualifier value) + Proximal + Near to + Neighbor of + Neighbour of + + + + + + + + + Lower limb structure (body structure) + Lower extremity + Lower limb + Lower limb structure + Lower extremity structure + Leg + + + + + + + + + Foot (qualifier value) + feet + ft + Foot + + + + + + + + + Asymmetry (qualifier value) + Asymmetry + Inequality of size + Asymmetrical + + + + + + + + + Splenic structure (body structure) + Spleen + Splenic structure + + + + + + + + + Removal of embolus (procedure) + Removal of embolus + Embolectomy + + + + + + + + + Bone structure of axis (body structure) + Axis + Second cervical vertebra + Bone structure of axis + Specific axis site + + + + + + + + + Fogarty catheter, device (physical object) + Fogarty catheter + Fogarty catheter, device + + + + + + + + + Surgical procedure (procedure) + Surgical procedure + Operation + Surgical procedures + Operative procedure + + + + + + + + + Gangrenous disorder (disorder) + Gangrenous disorder + Gangrene + + + + + + + + + Limb structure (body structure) + Extremity + Limb + Limb structure + + + + + + + + + Transfusion of blood product (procedure) + Transfusion of blood product + Blood product administration by intravascular infusion + Transfusing blood products + BT - Blood transfusion + Blood transfusion + + + + + + + + + Consultation (procedure) + Consultation + + + + + + + + Concatenation concepts + + + + + + + + + abdominal pain and hyperpyrexia + + + + + + + + + abdominal ultrasound + + + + + + + + + Absence of comorbidity + + + + + + + + + absence of conjunctivitis + + + + + + + + + absence of dyspnea + + + + + + + + + absence of known medical history + + + + + + + + + absence of pleural effusion + + + + + + + + + absence of significant lymphopenia + + + + + + + + + acetylsalicylic acid 100 milligram + + + + + + + + + Aciclovir 400 milligram + + + + + + + + + adjacent lung parenchyma + + + + + + + + + adjacent pleura + + + + + + + + + advanced adolescence + + + + + + + + + affecting both lungs + + + + + + + + + afternoon of Sunday + + + + + + + + + Air flap + + + + + + + + + airway infection + + + + + + + + + Allopurinol 300 milligram + + + + + + + + + altered density + + + + + + + + + ambulatory patient + + + + + + + + + amoxicillin and azithromycin + + + + + + + + + Amoxicillin and Clavulanic Acid + + + + + + + + + Amoxicillin and cortisone + + + + + + + + + anatomical conditions + + + + + + + + + angry cough + + + + + + + + + angular appearance + + + + + + + + + anterior and posterior + + + + + + + + + antibiotics and supportive care + + + + + + + + + antiretroviral and hydroxychloroquine + + + + + + + + + antiviral therapy and levofloxacin + antiviral drugs and levofloxacin + + + + + + + + + aortic button + + + + + + + + + apical and basal + + + + + + + + + apical segment + + + + + + + + + apical site + + + + + + + + + Appearance of acute sinusitis + + + + + + + + + appearance of hyperpyrexia + + + + + + + + + appearance of leukopenia + + + + + + + + + appendectomy projection + + + + + + + + + arterial access + + + + + + + + + Arterial hypertension + + + + + + + + + arterial oxygen + + + + + + + + + assessment age + + + + + + + + + asthenia treated with Ceftriaxone + + + + + + + + + Atenolol 100 milligram + + + + + + + + + atypical form + + + + + + + + + augmented lymph node + + + + + + + + + axial diameter + + + + + + + + + axial image + + + + + + + + + Azithromycin 500 milligram + + + + + + + + + Azithromycin and Paracetamol + + + + + + + + + barotrauma damage + + + + + + + + + basal center + + + + + + + + + basal conditions + + + + + + + + + basal pleural effusion + + + + + + + + + basal posterior + + + + + + + + + basal segment + + + + + + + + + basal site + + + + + + + + + base of both lungs + + + + + + + + + bilateral basal crepitations + + + + + + + + + bilateral basal pleural effusion + + + + + + + + + bilateral basal site + + + + + + + + + bilateral COVID-19 pneumonia + + + + + + + + + Bilateral interstitial pneumonia + + + + + + + + + Bilateral interstitial pneumonia picture + + + + + + + + + Bilateral medium-basal + + + + + + + + + bilateral mid-basal region + + + + + + + + + bilateral middle-basal crepitations + + + + + + + + + bilateral opacities + + + + + + + + + bilateral parenchymal consolidation + + + + + + + + + bilateral pneumothorax + + + + + + + + + bilateral pulmonary thickening + + + + + + + + + bilateral thickening + + + + + + + + + bipolar syndrome + + + + + + + + + black arrow + + + + + + + + + Blood chemistry tests + + + + + + + + + blood sugar + blood glucose + + + + + + + + + blood tests + + + + + + + + + body temperature was elevated + + + + + + + + + breast cancer in remission + + + + + + + + + bronchial thickening + + + + + + + + + cancer control + + + + + + + + + case history + + + + + + + + + case history positive for contact with Covid-19 + + + + + + + + + case history positive for contact with Covid-19 patient + + + + + + + + + case just exposed + + + + + + + + + case of acute pulmonary thromboembolism + + + + + + + + + case of discrepancy + + + + + + + + + case report + + + + + + + + + center-lobular + + + + + + + + + center-panlobular emphysematous + + + + + + + + + Central venous tube + + + + + + + + + chest pain and vomiting + + + + + + + + + chest radiogram + + + + + + + + + Chest radiograph + + + + + + + + + chest radiographic examination + + + + + + + + + Chest ultrasound + + + + + + + + + Chest ultrasound performed + + + + + + + + + chest X-ray examination + + + + + + + + + Chest x-ray on bed + chest x-ray in bed + + + + + + + + + chest x-ray was performed + Chest x-ray is performed + chest x-ray performed + + + + + + + + + Chest x-ray was worsened + + + + + + + + + chest-abdomen + + + + + + + + + cholecystitis and bilateral pleural effusion + + + + + + + + + history of chronic obstructive pulmonary disease + chronic obstructive pulmonary disease history + + + + + + + + + classic for Covid-19 + + + + + + + + + clear progression + + + + + + + + + clear reduction + + + + + + + + + clear regression + + + + + + + + + clinic and specific + + + + + + + + + clinical case + + + + + + + + + clinical condition worsened + + + + + + + + + clinical condition + clinical conditions + + + + + + + + + CLINICAL DIAGNOSTIC + + + + + + + + + Clinical healing + + + + + + + + + clinical outcome + + + + + + + + + clinical parameters + + + + + + + + + clinical phase + + + + + + + + + clinical picture + + + + + + + + + clinical-laboratory + + + + + + + + + clinical-laboratory conditions + + + + + + + + + clinical-laboratory picture + + + + + + + + + coarse air + + + + + + + + + cohabiting son + + + + + + + + + compatible with COVID-19 related pathology + + + + + + + + + compatible with interstitial pneumonia + + + + + + + + + compatible with medium-high viral pneumonia + + + + + + + + + compatible with mild viral pneumonia + + + + + + + + + compatible with pneumatocele + + + + + + + + + compatible with the early stage + + + + + + + + + compatible with unilateral interstitial pneumonia + + + + + + + + + compatible with viral pneumonia + + + + + + + + + completely asymptomatic + + + + + + + + + completely occluded + + + + + + + + + computerized tomography and nasopharyngeal swab + + + + + + + + + computerized tomography angiography + + + + + + + + + computerized tomography chest-abdomen + + + + + + + + + computerized tomography examination + computerized tomography exam + + + + + + + + + computerized tomography examination documents + + + + + + + + + computerized tomography investigations + + + + + + + + + computerized tomography involvement score + + + + + + + + + computerized tomography performed + computerized tomography are performed + computerized tomography is performed + + + + + + + + + computerized tomography is repeated + + + + + + + + + computerized tomography level + + + + + + + + + computerized tomography patterns + + + + + + + + + computerized tomography picture + + + + + + + + + computerized tomography study + + + + + + + + + concomitant appearance + + + + + + + + + concomitant area + + + + + + + + + concomitant bilateral pleural effusion + + + + + + + + + Concomitant center-panlobular emphysematous + + + + + + + + + concomitant pleural effusion + + + + + + + + + condition worsened + + + + + + + + + confluent appearance + + + + + + + + + conservative therapy is established + + + + + + + + + consolidation and thickening + + + + + + + + + contact with Covid-19 patient + + + + + + + + + Contact with family member + + + + + + + + + contact with positive Covid-19 patient + + + + + + + + + contact with relative + + + + + + + + + continuous positive airway pressure + + + + + + + + + control chest x-ray + + + + + + + + + control examination + + + + + + + + + Coronal image + + + + + + + + + Coronal reconstruction + + + + + + + + + corticosteroids and antibiotics + + + + + + + + + cough and asthenia + + + + + + + + + cough and breathing difficulties + + + + + + + + + cough and chest tightness + + + + + + + + + cough and desaturation + + + + + + + + + cough and respiratory failure + + + + + + + + + cough and wheezing + + + + + + + + + coughing or dyspnoea + + + + + + + + + covid pathology + + + + + + + + + COVID person + + + + + + + + + COVID-19 cases + + + + + + + + + Covid-19 infection + + + + + + + + + COVID-19 lung picture + + + + + + + + + Covid-19 negative + + + + + + + + + Covid-19 negative swab + + + + + + + + + Covid-19 negative swab performed + + + + + + + + + Covid-19 pathology + + + + + + + + + Covid-19 patient + + + + + + + + + Covid-19 pneumonia + + + + + + + + + Covid-19 positive + + + + + + + + + Covid-19 positive pharyngeal swab + + + + + + + + + SARS-CoV-2 swab tested positive + Covid-19 positive swab + + + + + + + + + COVID-19 related pathology + + + + + + + + + COVID-19 tested positive + + + + + + + + + COVID-19 was positive + + + + + + + + + COVID-19-related + + + + + + + + + currently asymptomatic + + + + + + + + + cytomegalovirus pneumonia + + + + + + + + + D-dimer was performed + + + + + + + + + decrease in polymerase chain reaction + + + + + + + + + decrease in serum + + + + + + + + + diabetes mellitus and hypertension + + + + + + + + + diagnosis of dyspnea + + + + + + + + + diagnosis of interstitial pneumonia + + + + + + + + + diagnosis of pulmonary embolism + + + + + + + + + diagnosis of right heart failure + + + + + + + + + diagnostic examination + + + + + + + + + difficulty feeding + + + + + + + + + Disease extension + + + + + + + + + Diseases Unit + diseases ward + + + + + + + + + disposition in isolation + + + + + + + + + documented in both lungs + + + + + + + + + documented partial regression + + + + + + + + + documents the absence of + + + + + + + + + Does not report coughing + + + + + + + + + does not report fever + + + + + + + + + dorsal striae + + + + + + + + + double projection + + + + + + + + + double swab + + + + + + + + + fever and dry cough + dry cough and fever + + + + + + + + + dry cough and pyrexia + + + + + + + + + due to the worsening + + + + + + + + + dyspnea and chest pain + + + + + + + + + dyspnea and cough + + + + + + + + + Dyspnea and hyperthermia + + + + + + + + + dyspnea or fever + + + + + + + + + dyspnea with desaturation + + + + + + + + + cough and dyspnoea + dyspnoea and cough + + + + + + + + + early stages + + + + + + + + + elevated fever + + + + + + + + + elevated polymerase chain reaction + + + + + + + + + emergency surgery + + + + + + + + + entire lung area + + + + + + + + + epicardial coronary artery disease + + + + + + + + + evaluation performed + + + + + + + + + exam is requested + + + + + + + + + examination documents + + + + + + + + + examination performed + exam performed + examination is performed + + + + + + + + + exertion and cough + + + + + + + + + extensive parenchymal consolidation + + + + + + + + + extensive patches + + + + + + + + + extensive thickening + + + + + + + + + extent of the disease + + + + + + + + + extent of the thickening + + + + + + + + + external ambulatory patient + + + + + + + + + fatigue and persistent cough + + + + + + + + + female medical patient + + + + + + + + + Female patient + + + + + + + + + femur fracture + + + + + + + + + femur fracture following accidental fall + + + + + + + + + fever and acute respiratory failure + + + + + + + + + fever and asthenia + + + + + + + + + cough and fever + fever and cough + + + + + + + + + fever and diarrhea + + + + + + + + + fever and dyspepsia + + + + + + + + + dyspnea and fever + fever and dyspnea + + + + + + + + + fever and dyspnoea + + + + + + + + + fever and exertional dyspnea + + + + + + + + + fever and malaise + + + + + + + + + Fever and non-productive cough + + + + + + + + + fever and suspected urinary tract infection + + + + + + + + + field of both lungs + + + + + + + + + filter for mediastinum + + + + + + + + + flat abdomen + + + + + + + + + flu syndrome + + + + + + + + + focal interstitial pneumonia + + + + + + + + + focal pulmonary thickening + + + + + + + + + following days + following day + + + + + + + + + following morning + + + + + + + + + following the presumptive diagnosis + + + + + + + + + forced supine position + + + + + + + + + form of viral pneumonia + + + + + + + + + fourth day + + + + + + + + + fracture following accidental fall + + + + + + + + + frequent in intensive care unit + + + + + + + + + general clinical conditions + + + + + + + + + general clinical picture + + + + + + + + + general conditions + + + + + + + + + General malaise + + + + + + + + + good clinical conditions + + + + + + + + + good condition + + + + + + + + + good general conditions + + + + + + + + + good health + + + + + + + + + greater involvement + + + + + + + + + greater level + + + + + + + + + head trauma + + + + + + + + + health worker + + + + + + + + + heart and large vessels + + + + + + + + + heart shadow + + + + + + + + + heavy smoker + + + + + + + + + hemagglutinin type 1 + + + + + + + + + hematocrit and procalcitonin + + + + + + + + + hernia surgery + + + + + + + + + Hypertension and dyslipidemia + high blood pressure and dyslipidemia + + + + + + + + + high fever + + + + + + + + + High PCR + High polymerase chain reaction + + + + + + + + + high risk myelodysplastic syndrome + + + + + + + + + high sensitivity + + + + + + + + + high viral pneumonia + + + + + + + + + hilar enlargement + + + + + + + + + history of asthma and type II diabetes + + + + + + + + + history of chronic thyroiditis + + + + + + + + + history of contact with Covid-19 + + + + + + + + + history of contact with Covid-19 patient + + + + + + + + + history of ischemic heart disease + + + + + + + + + history of pathological history positive for arterial hypertension + + + + + + + + + history positive for contact with Covid-19 patient + history of positive contact with Covid-19 patient + + + + + + + + + history positive for contact with Covid-19 + history of certain contact with known positive Covid-19 + history of positive contact with Covid-19 + + + + + + + + + history of remote pathology + + + + + + + + + history of remote pathology positive for arterial hypertension + + + + + + + + + home quarantine + home isolation + + + + + + + + + home quarantine patient + + + + + + + + + Home treatment + + + + + + + + + home trustee isolation + + + + + + + + + hospitalized in Emergency Medicine + + + + + + + + + hyperemic pharynx + + + + + + + + + cough and hyperpyrexia + hyperpyrexia and cough + + + + + + + + + hyperpyrexia refractory + + + + + + + + + improving after oxygen therapy + + + + + + + + + includes scout view + + + + + + + + + increase in body temperature + + + + + + + + + increase in fever + + + + + + + + + increase in fibrinogen + + + + + + + + + increase in lactate dehydrogenase + + + + + + + + + increase in lymphocytopenia + + + + + + + + + increased polymerase chain reaction + increased PCR + increase in polymerase chain reaction + + + + + + + + + increase in procalcitonin + + + + + + + + + increased in volume + + + + + + + + + increased lung density + + + + + + + + + indication of the internist + + + + + + + + + induced barotrauma damage + + + + + + + + + infectious disease ward + + + + + + + + + inhaled oxygen + + + + + + + + + initial phase + + + + + + + + + initial stages + + + + + + + + + initially hospitalized + + + + + + + + + intact sensitivity + + + + + + + + + COVID-19 interstitial pneumonia + interstitial pneumonia from Covid-19 + + + + + + + + + Intestinal perforation is needed + + + + + + + + + intra-abdominal effusion + + + + + + + + + intra-lobular septal thickening + + + + + + + + + intra-lobular smooth septal thickening + + + + + + + + + intravenous administration + + + + + + + + + involvement score + + + + + + + + + involving both lungs + + + + + + + + + Iopromide 370 milligram + + + + + + + + + is a rare + + + + + + + + + is a rare manifestation of + + + + + + + + + known medical history + + + + + + + + + laboratory investigations + + + + + + + + + Laboratory tests + + + + + + + + + lambda myeloma + + + + + + + + + large cavity + + + + + + + + + Late Sunday evening + + + + + + + + + lateral basal segment + + + + + + + + + left apical + + + + + + + + + left apical site + + + + + + + + + left basal site + + + + + + + + + left hemithorax + + + + + + + + + left hip trauma + + + + + + + + + left limb + + + + + + + + + left peripheral middle-upper field + + + + + + + + + left pulmonary field + + + + + + + + + left upper pulmonary field + + + + + + + + + leg and foot + + + + + + + + + lesser extent + + + + + + + + + leukopenia stable + + + + + + + + + leukopenia with neutrophilia + + + + + + + + + limited foci of + + + + + + + + + limited lymphadenopathy + + + + + + + + + limited size + + + + + + + + + Linear thickening + + + + + + + + + lingual and basal + + + + + + + + + liver and kidney + + + + + + + + + liver steatosis + + + + + + + + + Lopinavir-Ritonavir + + + + + + + + + Lorazepam 2.5 milligram + + + + + + + + + low viral load + + + + + + + + + lower density + + + + + + + + + lower left limb + + + + + + + + + lower left pulmonary field + + + + + + + + + lower lung field + + + + + + + + + lower pulmonary + + + + + + + + + lower right lung + + + + + + + + + lower right pulmonary field + + + + + + + + + Low-grade + + + + + + + + + Low-grade fever + + + + + + + + + Lung algorithm + + + + + + + + + Lung algorithm reconstruction + + + + + + + + + lung area + + + + + + + + + lung bases + + + + + + + + + lung damage + + + + + + + + + lung density + + + + + + + + + lung involvement + + + + + + + + + lung parenchyma involved + + + + + + + + + lung picture + + + + + + + + + lymphadenopathy is documented + + + + + + + + + main bronchi + + + + + + + + + malaise and loss of appetite + + + + + + + + + male infant + + + + + + + + + male patient + + + + + + + + + manifestation of Covid-19 + + + + + + + + + manifestation of Covid-19 pathology + + + + + + + + + manifestation of the distribution + + + + + + + + + massive pulmonary cyst + + + + + + + + + mechanical ventilation-induced barotrauma damage + + + + + + + + + medial and lateral segment + + + + + + + + + mediastinal area + + + + + + + + + mediastinum filter + + + + + + + + + medical history + + + + + + + + + medical patient + + + + + + + + + medium-high + + + + + + + + + medium-high viral pneumonia + + + + + + + + + Metformin 1000 milligram + + + + + + + + + mid-apical + + + + + + + + + mid-apical field + + + + + + + + + mid-basal region + + + + + + + + + middle-basal crepitations + + + + + + + + + middle-basal field + + + + + + + + + middle-basal lung + + + + + + + + + middle-basal site + + + + + + + + + middle-lower right field + + + + + + + + + middle-upper pulmonary field + + + + + + + + + Mild bilateral pleural effusion + + + + + + + + + mild dyspnea + + + + + + + + + mild fever + + + + + + + + + mild headache + + + + + + + + + Mild hypoalbuminemia + + + + + + + + + mild hypoxia + + + + + + + + + mild leukopenia + + + + + + + + + mild lymphopenia + + + + + + + + + mild phase + + + + + + + + + mild respiratory alkalosis + + + + + + + + + Mild right hilar enlargement + + + + + + + + + mild viral pneumonia + + + + + + + + + mild wheezing + + + + + + + + + Minimal and initial + + + + + + + + + minimal size + + + + + + + + + Minimal thickening + + + + + + + + + mitral valve replacement + + + + + + + + + mitral valve slightly reduced + + + + + + + + + mixed pattern + + + + + + + + + moderate concomitant pleural effusion + + + + + + + + + moderate respiratory failure + + + + + + + + + moderate size + + + + + + + + + moderate volumetric reduction + + + + + + + + + month-old + + + + + + + + + month-old baby + + + + + + + + + morphology and size + + + + + + + + + mother and grandmother + + + + + + + + + multiple COVID-19 cases + + + + + + + + + multiple focal interstitial pneumonia + + + + + + + + + Multiple opacities + + + + + + + + + multiple parenchymal consolidation patches + + + + + + + + + multiple patches + + + + + + + + + mute remote + + + + + + + + + mute remote pathological history + + + + + + + + + nasal swab for COVID-19 + + + + + + + + + nasopharyngeal swab for SARS-CoV-2 + + + + + + + + + Nasopharyngeal swab was performed + Nasopharyngeal swab is performed + + + + + + + + + nausea and loss of appetite + + + + + + + + + near mutation + + + + + + + + + near negative pathological anamnesis + + + + + + + + + near pathological anamnesis + + + + + + + + + Near positive pathological history of contact with Covid-19 + + + + + + + + + Near positive pathological history of contact with Covid-19 patient + + + + + + + + + neck and upper thoracic region + + + + + + + + + need for blood transfusion + + + + + + + + + Negative chest x-ray + + + + + + + + + Negative history of certain contact with known positive Covid-19 + + + + + + + + + negative pathological anamnesis + + + + + + + + + negative remote medical history + + + + + + + + + negative troponin + + + + + + + + + neuraminidase type 1 + + + + + + + + + neuraminidase type 1 influenza + + + + + + + + + neurological pathology + + + + + + + + + new chest X-ray + + + + + + + + + No evidence of pericardial effusion + + + + + + + + + nodular appearance + + + + + + + + + nodular formations + + + + + + + + + normal blood tests + + + + + + + + + Normal heart shadow + + + + + + + + + normal laboratory tests + + + + + + + + + normal language + + + + + + + + + normal procalcitonin + + + + + + + + + nose-pharyngeal swab + nose and throat swab + + + + + + + + + number and density + + + + + + + + + number of cases + + + + + + + + + numerous patches + + + + + + + + + objective evaluation + + + + + + + + + objective evaluation performed + + + + + + + + + old female patient + old female medical patient + + + + + + + + + old male patient + + + + + + + + + old male + old man + + + + + + + + + old patient + + + + + + + + + old female + old woman + + + + + + + + + onset of dyspnea + + + + + + + + + onset of fever + + + + + + + + + onset of moderate respiratory failure + + + + + + + + + onset of respiratory distress + + + + + + + + + oral amoxicillin + + + + + + + + + oral treatment + + + + + + + + + outbreak of COVID-19 + + + + + + + + + outside the pulmonary stenosis + + + + + + + + + oxygen and drug therapy + + + + + + + + + oxygen desaturation + + + + + + + + + painful abdomen + + + + + + + + + panlobular emphysematous + + + + + + + + + parenchymal consolidation area + + + + + + + + + parenchymal consolidation patches + + + + + + + + + parenchymal consolidation plate + + + + + + + + + partial regression + + + + + + + + + patchy appearance + + + + + + + + + patchy distribution + + + + + + + + + patent bronchi + + + + + + + + + pathological history + pathological anamnesis + + + + + + + + + Pathological case + + + + + + + + + Pathological case history + + + + + + + + + Pathological history of positive contact with Covid-19 patient + positive pathological history of contact with Covid-19 patient + Pathological case history positive for contact with Covid-19 patient + + + + + + + + + Pathological history of positive contact with Covid-19 + positive pathological history of contact with Covid-19 + Pathological history positive for contact with positive Covid-19 patient + Pathological case history positive for contact with Covid-19 + + + + + + + + + pathological history of bariatric surgery + + + + + + + + + pathological history of contact with Covid-19 + + + + + + + + + pathological history of contact with Covid-19 patient + + + + + + + + + pathological history positive for arterial hypertension + + + + + + + + + pathology positive for arterial hypertension + + + + + + + + + patient alert + + + + + + + + + patient is treated with + patient being treated with + + + + + + + + + patient examination + + + + + + + + + patient in mechanical ventilation + + + + + + + + + patient is hospitalized + + + + + + + + + patient reported + + + + + + + + + patient reported nausea + + + + + + + + + patient sitting + + + + + + + + + patient was hospitalized + + + + + + + + + patient with fever + + + + + + + + + pcr movement + + + + + + + + + performed in appendectomy + + + + + + + + + performed in urgency + + + + + + + + + Performed recent chest x-ray + + + + + + + + + peri-bronchial + + + + + + + + + peri-bronchial thickening + + + + + + + + + pericardial effusion and mediastinal lymphadenopathy + + + + + + + + + peripheral area + + + + + + + + + peripheral location + + + + + + + + + peripheral middle-upper field + + + + + + + + + Peristalsis present + + + + + + + + + persistent cough and dyspnoea + + + + + + + + + pharmacological treatment + + + + + + + + + pharyngeal swab for COVID-19 + + + + + + + + + picture compatible with viral pneumonia + + + + + + + + + pink mucous + + + + + + + + + pleural basal site + + + + + + + + + pleural distribution + + + + + + + + + pleural effusion is documented + + + + + + + + + pleural effusion on both sides + + + + + + + + + pleural or pericardial effusion + + + + + + + + + pneumomediastinum and soft tissue emphysema + + + + + + + + + lactate dehydrogenase and polymerase chain reaction + polymerase chain reaction and lactate dehydrogenase + + + + + + + + + polymerase chain reaction method + + + + + + + + + polymerase chain reaction not available + + + + + + + + + poor pcr movement + + + + + + + + + poorly productive cough + + + + + + + + + positive airway pressure + + + + + + + + + Positive anamnesis + + + + + + + + + positive for contact with Covid-19 patient + positive contact with Covid-19 patient + + + + + + + + + positive for contact with Covid-19 + positive contact with Covid-19 + + + + + + + + + positive COVID person + + + + + + + + + positive Covid-19 patient + + + + + + + + + Positive COVID-19 swab + + + + + + + + + positive for arterial hypertension + + + + + + + + + positive for SARS-CoV-2 + positive for Covid-19 infection + + + + + + + + + positive for steroid therapy + + + + + + + + + Positive swab + positive for the swab + + + + + + + + + positive nose-pharyngeal swab + + + + + + + + + positive nose-pharyngeal swab cases + + + + + + + + + Positive pharyngeal swab + + + + + + + + + positive for Covid-19 + positive Covid-19 + positive result for SARS-CoV-2 + positive SARS-CoV-2 + positive result for Covid-19 + + + + + + + + + Positive swab performed + + + + + + + + + positive thorax + + + + + + + + + possible expression + + + + + + + + + posterior left + + + + + + + + + prescription of the Cardiologist + + + + + + + + + presence of bilateral interstitial pneumonia + + + + + + + + + presence of patent bronchi + + + + + + + + + presence of SARS-CoV-2 + + + + + + + + + presence of SARS-CoV-2 coronavirus + + + + + + + + + presence of SARS-CoV-2 coronavirus ribonucleic acid + + + + + + + + + previous exam + + + + + + + + + previous history + + + + + + + + + previous lung parenchyma + + + + + + + + + previous lung parenchyma involved + + + + + + + + + previous week + + + + + + + + + procalcitonin and lactate dehydrogenase + + + + + + + + + progressive clinical phase + + + + + + + + + progressive dyspnea + + + + + + + + + progressive onset of respiratory distress + + + + + + + + + projection in supine decubitus + + + + + + + + + Protein C reactive + + + + + + + + + pseudo-nodular + + + + + + + + + pseudo-nodular appearance + + + + + + + + + pulmonary base + + + + + + + + + pulmonary cyst + + + + + + + + + Pulmonary embolism is suspected + + + + + + + + + pulmonary field + + + + + + + + + pulmonary hilar + + + + + + + + + pulmonary involvement + + + + + + + + + Pulmonary picture + + + + + + + + + pulmonary stenosis for cough + + + + + + + + + pulmonary thickening + + + + + + + + + pulmonary thickening increased + + + + + + + + + pulmonary ultrasound + + + + + + + + + pulmonary ultrasound examination + + + + + + + + + quarantine patient + + + + + + + + + radiographic examination + + + + + + + + + rare and fine + + + + + + + + + rare manifestation of Covid-19 + + + + + + + + + rare manifestation of Covid-19 pathology + + + + + + + + + reactive lymph node + + + + + + + + + Reactive Protein C + + + + + + + + + recent chest x-ray + + + + + + + + + recent medical history + + + + + + + + + recent onset of + + + + + + + + + recent onset of moderate respiratory failure + + + + + + + + + recent upper airway infection + + + + + + + + + recent worsening + + + + + + + + + rectal colitis + + + + + + + + + red area + + + + + + + + + reduced in density + + + + + + + + + reduced in size + + + + + + + + + Reduced the density + + + + + + + + + reduction in white blood cells + + + + + + + + + reduction of asthenia + + + + + + + + + Regular appearance + + + + + + + + + regular caliber + + + + + + + + + regular morphology + + + + + + + + + rehabilitation facility + + + + + + + + + related COVID-19 pathology + + + + + + + + + remote medical history + + + + + + + + + remote pathological history + + + + + + + + + remote pathology + + + + + + + + + remote pathology positive for arterial hypertension + + + + + + + + + report coughing + + + + + + + + + report fever + + + + + + + + + reported dyspnea + + + + + + + + + reported fever + + + + + + + + + reported intubation + + + + + + + + + reported nausea + + + + + + + + + reporting anosmia + + + + + + + + + resistant to antibiotic therapy + + + + + + + + + Respiratory failure on blood gas analysis + + + + + + + + + result DETECTED + + + + + + + + + result positive for COVID-19 + + + + + + + + + reticular opacities + + + + + + + + + reticular thickening + + + + + + + + + review of covid-19 + + + + + + + + + right apical + + + + + + + + + right apical site + + + + + + + + + right basal field + + + + + + + + + right basal site + + + + + + + + + right hemithorax + + + + + + + + + right hilar + + + + + + + + + right hilar enlargement + + + + + + + + + right humerus + + + + + + + + + right lung were normal + + + + + + + + + right middle-basal site + + + + + + + + + right posterior basal site + + + + + + + + + right pulmonary + + + + + + + + + right pulmonary base + + + + + + + + + right pulmonary field + + + + + + + + + right pulmonary hilar + + + + + + + + + rule out COVID-19 + rule out COVID-19 infection + + + + + + + + + SARS-CoV-2 (COVID-19) ribonucleic acid + SARS-CoV 2 coronavirus ribonucleic acid (COVID-19) + SARS-CoV-2 coronavirus ribonucleic acid + + + + + + + + + COVID 19 + SARS-CoV-2 coronavirus + + + + + + + + + SARS-CoV-2 infection + + + + + + + + + SARS-CoV-2 positive + + + + + + + + + SARS-CoV-2 positive result + + + + + + + + + SARS-CoV-2 swab infection + + + + + + + + + swab for Covid-19 + COVID-19 swab + SARS-CoV-2 swab + + + + + + + + + Saturday afternoon + + + + + + + + + second chest x-ray + + + + + + + + + second pharyngeal swab + + + + + + + + + second swab + + + + + + + + + septal thickening + + + + + + + + + serum creatine kinase + + + + + + + + + seventh day + + + + + + + + + severe congestive heart failure + + + + + + + + + severe cough + + + + + + + + + severe dyspnoea + + + + + + + + + severe general clinical conditions + + + + + + + + + Severe lymphopenia + + + + + + + + + significant pericardial effusion + + + + + + + + + Significant reduction + + + + + + + + + single appendectomy + + + + + + + + + single appendectomy projection + + + + + + + + + single projection + + + + + + + + + skull and chest + + + + + + + + + slight increase + + + + + + + + + slight pulmonary thickening + + + + + + + + + slightly reduced + slight reduction + + + + + + + + + slightly increased polymerase chain reaction + slightly elevated polymerase chain reaction + + + + + + + + + slightly increased + slightly elevated + + + + + + + + + small review of covid-19 + + + + + + + + + smooth septal thickening + + + + + + + + + solid nodular formations + + + + + + + + + specific case + + + + + + + + + spider web + spider web sign + + + + + + + + + spleen and liver + + + + + + + + + stable clinical conditions + + + + + + + + + Stable parameters + + + + + + + + + stages of consolidation + + + + + + + + + stages of diagnosis + + + + + + + + + started treatment + + + + + + + + + stationary clinical picture + + + + + + + + + Steroid and Paracetamol + + + + + + + + + steroid therapy and obesity + + + + + + + + + steroid treatment + + + + + + + + + strong clinical suspicion + + + + + + + + + sub pleural distribution + + + + + + + + + subcutaneous soft tissues + + + + + + + + + sudden worsening + + + + + + + + + suffering from Alzheimer's disease + + + + + + + + + suffering from covid-19 + + + + + + + + + suffering from fever + + + + + + + + + Suffering from high blood pressure + + + + + + + + + suggestive of CoViD-19 + + + + + + + + + suggestive of interstitial pneumonia + + + + + + + + + Sunday evening + + + + + + + + + supine decubitus position + + + + + + + + + surgical treatment + + + + + + + + + suspected close contact + + + + + + + + + suspected pneumonia + + + + + + + + + suspicion of pulmonary embolism + + + + + + + + + suspicion of pulmonary thromboembolism + + + + + + + + + swab is negative + + + + + + + + + swab performed + Swab is performed + + + + + + + + + swab is positive for + + + + + + + + + swab tested positive + + + + + + + + + swelling of soft tissues + + + + + + + + + systolic pressure + + + + + + + + + tenth day + + + + + + + + + tested positive for SARS-CoV-2 + tested positive for COVID-19 + + + + + + + + + tested positive for nasopharyngeal swab + + + + + + + + + thickened inside + + + + + + + + + thickening increased + + + + + + + + + thoracic area + + + + + + + + + thoracic imaging + + + + + + + + + thoracic picture + + + + + + + + + Thoracic ultrasound + + + + + + + + + thoracic-abdominal pain + + + + + + + + + thorax X-ray + + + + + + + + + thorax X-ray examination + + + + + + + + + tickling cough + + + + + + + + + time of diagnosis + + + + + + + + + to the left pulmonary base + + + + + + + + + Tocilizumab 480 milligram + + + + + + + + + total body + + + + + + + + + traditional X-ray + + + + + + + + + travel by bus + + + + + + + + + treated with antiviral therapy + treated by antiviral therapy + + + + + + + + + treated by continuous positive airway pressure + + + + + + + + + treated with antibiotics + treated with antibiotic + + + + + + + + + treated with metformin + + + + + + + + + treated with oxygen + + + + + + + + + treated with oxygen therapy + + + + + + + + + treated with percutaneous transluminal coronary angioplasty + + + + + + + + + treatment of urinary tract infection + + + + + + + + + treatment with Ceftriaxone + + + + + + + + + treatment with Kaletra + + + + + + + + + triangular and angular + + + + + + + + + ulcerative rectal colitis + + + + + + + + + ultrasound evaluation + + + + + + + + + ultrasound examination + + + + + + + + + ultrasound performed + + + + + + + + + understanding covid pathology + + + + + + + + + unilateral interstitial pneumonia + + + + + + + + + upper airway + + + + + + + + + upper airway infection + + + + + + + + + upper and prevascular + + + + + + + + + upper pulmonary field + + + + + + + + + vena cava superior + + + + + + + + + very high D-dimer + + + + + + + + + Vesicular murmur present + + + + + + + + + viral infection pneumonia + + + + + + + + + vital parameters + + + + + + + + + volumetric reduction + + + + + + + + + Voluntary home quarantine + + + + + + + + + Voluntary home quarantine patient + + + + + + + + + week of treatment + + + + + + + + + week-old + + + + + + + + + week-old male infant + + + + + + + + + wheezing and fever + + + + + + + + + widespread increase + + + + + + + + + widespread picture + + + + + + + + + widespread reticular thickening + + + + + + + + + Worsening chest x-ray + + + + + + + + + worsening of dyspnea + worsening dyspnea + + + + + + + + + worsening respiratory failure + worsening of respiratory failure + + + + + + + + + X-ray examination + + + + + + + + + X-ray pattern + + + + + + + + + year old boy + + + + + + + + + year-old female patient + year-old female medical patient + year old female patient + + + + + + + + + year-old male patient + year old male patient + + + + + + + + + year-old male + year-old man + year old man + year old male + + + + + + + + + year-old patient + year old patient + + + + + + + + + years old + year-old + years of age + year old + + + + + + + + + year old female + year-old woman + year old woman + year-old female + + + + + + + Anchoring concepts + + + + + + + + + 12 hours of stability + + + + + + + + + 2P radiograms + 2p radiography + 2 P radiograms + + + + + + + + + 4 stages + + + + + + + + + 64-layer scanner + + + + + + + + + 64Multislices equipment + + + + + + + + + abdominal acuities + + + + + + + + + abdominal collections + + + + + + + + + absence of angor + + + + + + + + + absence of visits + + + + + + + + + accentuation of the lung plot + + + + + + + + + accompanied by his aunt + + + + + + + + + acute dyspnea + + + + + + + + + acute dyspnea and cough + + + + + + + + + Acute ischemia + + + + + + + + + adjacent pleura was stretched + + + + + + + + + adjacent pulmonary interstitium + + + + + + + + + adjacent seat + + + + + + + + + ADK gastrectomy + + + + + + + + + admission to Resuscitation + + + + + + + + + admitted to the Infectious Diseases department + + + + + + + + + adult patients + + + + + + + + + aerial bronchogram + + + + + + + + + aerial multiple + + + + + + + + + affecting all the lobes + + + + + + + + + agreement with the clinical colleagues + + + + + + + + + bronchogram of air + air bronchograms + air brancogram + + + + + + + + + air bronchiologram + + + + + + + + + albeit + + + + + + + + + Almost all lung + + + + + + + + + almost all lung lobes + + + + + + + + + Almost all lung segments + + + + + + + + + almost complete + + + + + + + + + almost complete resolution + + + + + + + + + almost complete TDM resolution + + + + + + + + + almost complete TDM resolution of the bilateral thickenings + + + + + + + + + almost completely engage + + + + + + + + + almost completely occluded + + + + + + + + + almost completely occupied + + + + + + + + + almost unilateral + + + + + + + + + already + + + + + + + + + already had fever + + + + + + + + + already had fever and symptoms + + + + + + + + + already hospitalized + + + + + + + + + already under treatment + + + + + + + + + also present + + + + + + + + + alteration of serum electrolytes + + + + + + + + + alteration of the normal architecture + + + + + + + + + alterations for ischemia + + + + + + + + + alterations of the interstitium + + + + + + + + + alternate mechanical ventilation + + + + + + + + + alternate mechanical ventilation SIMV-CPAP + + + + + + + + + although + + + + + + + + + alveolar consolidation + + + + + + + + + alveolar interstitial pneumonia + + + + + + + + + alveolar interstitial pneumonia is observed + + + + + + + + + ambient air + + + + + + + + + Amoxicillin and cortisone therapy + + + + + + + + + angio-CT aorta + + + + + + + + + angio-CT examination + + + + + + + + + angio-CT of the chest + + + + + + + + + angio-CT pulmonary circulation + + + + + + + + + angioTC is performed + + + + + + + + + angor + + + + + + + + + another hospital + + + + + + + + + Another swab + + + + + + + + + anterior and posterior segments + anterior and posterior segment + + + + + + + + + anterior mantle + + + + + + + + + anterior segment of the LSS + + + + + + + + + anterior segments + + + + + + + + + anterior territory + + + + + + + + + antibiotic therapy with Augmentin + + + + + + + + + aorto-coronary atheromatous calcifications + + + + + + + + + apical and basal site + + + + + + + + + apical segment of the LID + + + + + + + + + apical segment of the LIS + + + + + + + + + apical segments + + + + + + + + + apico-dorsal + + + + + + + + + apico-dorsal lobe + + + + + + + + + apico-dorsal segment of the upper left lobe + + + + + + + + + apico-dorsal segments + apicodorsal segment + + + + + + + + + Apiretic patient + + + + + + + + + apiretic pulmonary stenosis + + + + + + + + + Apparently mute remote pathological history + + + + + + + + + appear reduced + + + + + + + + + appeared in the left apical site + + + + + + + + + appendectomy projection in supine decubitus + + + + + + + + + appendectomy projection in supine decubitus position + + + + + + + + + appropriate treatment + + + + + + + + + apyretic for a day + + + + + + + + + apyretic patient reported nausea + + + + + + + + + areas at risk + + + + + + + + + areas at risk of being infected + + + + + + + + + areas in both upper lobes + + + + + + + + + areas in the context + + + + + + + + + areas in the spleen and liver + + + + + + + + + areas of altered density + + + + + + + + + areas of bilateral parenchymal consolidation + + + + + + + + + areas of consolidation + + + + + + + + + Areas of extensive parenchymal consolidation + + + + + + + + + areas of increased density + + + + + + + + + areas of increased lung density + + + + + + + + + areas of parenchymal consolidation + + + + + + + + + areas with patchy distribution + + + + + + + + + arranged in patches + + + + + + + + + arranged in the peripheral location + + + + + + + + + Arrived at the pulmonary stenosis + + + + + + + + + arrives at the emergency room + + + + + + + + + arrives in pulmonary stenosis for cough + + + + + + + + + arrives in pulmonary stenosis for cough and fever + + + + + + + + + arrives in Radiology + + + + + + + + + Arrives in severe general clinical conditions + + + + + + + + + arterial branches + + + + + + + + + aspect of the thickening + + + + + + + + + aspect on both upper lobes + + + + + + + + + assigned a score + + + + + + + + + associated bilateral reticular and interstitial thickening + + + + + + + + + associated extensive areas + + + + + + + + + associated fever + + + + + + + + + associated multiple areas + + + + + + + + + associated parenchymal consolidation areas + + + + + + + + + associated pleural effusion + + + + + + + + + associated reinforcement of the interstitial texture + + + + + + + + + associated reticular opacities + + + + + + + + + associated rib fractures + + + + + + + + + associated thickening of the interlobular septa + + + + + + + + + associated thickening of the interstitial weft + + + + + + + + + asthenic state + + + + + + + + + Asymmetrical representation + + + + + + + + + asymptomatic and apiretic + + + + + + + + + asymptomatic parents + + + + + + + + + atypical form of viral pneumonia + + + + + + + + + augmented lymph node subcentimeters + + + + + + + + + Autonomous origin + + + + + + + + + average age + + + + + + + + + average age of the children + + + + + + + + + average and basal scan + average and basal scans + + + + + + + + + Axial images + + + + + + + + + axial reconstructions + + + + + + + + + B lines in the right apical site + + + + + + + + + background grinding + + + + + + + + + bariatric surgery + + + + + + + + + basal crepitation + + + + + + + + + basal crepitation on the left + + + + + + + + + basal fibrotic-disventilatory streaks + + + + + + + + + basal interstitial + + + + + + + + + basal pyramids + + + + + + + + + basal rattles + + + + + + + + + basal regions + + + + + + + + + basal scans + basal scan + + + + + + + + + basal seat + + + + + + + + + basal segments + + + + + + + + + basic conditions + + + + + + + + + basis of imaging + + + + + + + + + basis of thoracic imaging + + + + + + + + + bed in clinostasis + + + + + + + + + beginning of the disease + + + + + + + + + begins antibiotic therapy + + + + + + + + + best clinical management + + + + + + + + + best patient management + + + + + + + + + bi-basal + + + + + + + + + bi-basal pleural effusion + + + + + + + + + bi-basal rattles + + + + + + + + + bi-basal site + + + + + + + + + bilateral alveolar + + + + + + + + + bilateral and subcarinal areas + + + + + + + + + bilateral areas + + + + + + + + + bilateral disventilator + + + + + + + + + bilateral infiltrates + + + + + + + + + bilateral intercleidoilary + + + + + + + + + bilateral intercleidoilary site + + + + + + + + + bilateral interlobular septa + + + + + + + + + bilateral interstitial involvement + + + + + + + + + bilateral interstitial pneumonia + + + + + + + + + bilateral mantle + + + + + + + + + Bilateral medium-basal disventilator + + + + + + + + + bilateral opacities are evident + + + + + + + + + bilateral parenchymal patheological findings + + + + + + + + + bilateral parenchymal pathological findings + + + + + + + + + bilateral pleural effusion coexists + + + + + + + + + bilateral PNX + bilateral pneumothorax layers + + + + + + + + + bilateral rhonco + + + + + + + + + bilateral subpleural + + + + + + + + + bilateral thickenings + + + + + + + + + bilaterally present + + + + + + + + + bilaterally thickened interstitial-alveolar infiltratives + + + + + + + + + black arrows + + + + + + + + + black circle + + + + + + + + + Blood chemists + + + + + + + + + blood count + + + + + + + + + Blood gas analysis and saturation + + + + + + + + + borne by both hemithorax + + + + + + + + + both lower lobes + + + + + + + + + both lower lung fields + + + + + + + + + both lungs arranged + + + + + + + + + both lungs in subpleural location + + + + + + + + + both lungs in the subpleural + both lungs in subpleural + + + + + + + + + bpco in home treatment + + + + + + + + + bpco in home treatment with c-pap + + + + + + + + + brachiocephalic venous trunk + + + + + + + + + branch for the lower lobe + + + + + + + + + branches for both basal + + + + + + + + + branches for both basal pyramids + + + + + + + + + breach of the left hemithorax + + + + + + + + + breach of the right hemithorax + + + + + + + + + breach of the right hemithorax and fibrotic + + + + + + + + + breast ETP + + + + + + + + + bronchial asthma and NAO therapy + + + + + + + + + bronchial branches + + + + + + + + + bronchial distortions + + + + + + + + + bronchial secretions + + + + + + + + + bronchopneumonic foci + + + + + + + + + buffer for Covid + + + + + + + + + buffer for Covid-19 + SARS-CoV-2 buffer + buffer for COVID 19 + + + + + + + + + buffer for SARS-Cov-2 + buffer for Covid -19 + + + + + + + + + Buffer for Covid-19 and HRCT + + + + + + + + + Buffer for COVID-19 tested positive + + + + + + + + + buffer for SARS-Cov-2 research + + + + + + + + + calcific lymph nodes + + + + + + + + + calcific parietal atheromasia + + + + + + + + + calcifications of the aortic button + + + + + + + + + Cardiac image + + + + + + + + + Cardiac image within limits + + + + + + + + + Cardiac shadow + + + + + + + + + Cardiac transverse diameter + + + + + + + + + Cardioasa 100 milligram + + + + + + + + + Cardiomediastinal shadow + + + + + + + + + Cardiomediastinal shadow in the norm + + + + + + + + + cardio-thoracic + + + + + + + + + Cardio-vascular shadow + + + + + + + + + Carried out second swab + + + + + + + + + case just discussed + + + + + + + + + case report illustrates + + + + + + + + + case studies + + + + + + + + + case we have presented + + + + + + + + + caused by COVID-19 + + + + + + + + + causes compression + + + + + + + + + central and subpleural + + + + + + + + + cervical passage + + + + + + + + + characteristic for a related COVID-19 pathology + + + + + + + + + characteristics compatible with pneumatocele + + + + + + + + + characterize the thoracic picture + + + + + + + + + characterized by a reduction + + + + + + + + + characterized by fever + + + + + + + + + characterized by minute + + + + + + + + + characterized in heart rate + + + + + + + + + Chemical industry + + + + + + + + + Chest radiogram at onset + + + + + + + + + Chest x - ray + + + + + + + + + Chest x-ray demonstrates + + + + + + + + + chest x-ray demonstrating + + + + + + + + + chest X-ray diagnosis + + + + + + + + + Chest X-ray investigation + + + + + + + + + Chest x-ray required + Chest x-ray is required + + + + + + + + + chest x-ray shows + + + + + + + + + children had high fever + + + + + + + + + chronic obstructive pulmonary disease signs + + + + + + + + + chronic pathologies + + + + + + + + + cities with epidemic outbreaks + + + + + + + + + classic for Covid-19 infection + + + + + + + + + clavulanic acid therapy + + + + + + + + + clavulanic and paracetamol + + + + + + + + + CLINICAL CARE + + + + + + + + + clinical characteristics + + + + + + + + + clinical colleagues + + + + + + + + + clinical condition deteriorated + + + + + + + + + clinical condition worsened considerably + + + + + + + + + clinical data + + + + + + + + + CLINICAL DIAGNOSTIC PATH + + + + + + + + + clinical improvement + + + + + + + + + clinical management + + + + + + + + + clinical objectivity + + + + + + + + + clinical recovery + + + + + + + + + clinical situation + + + + + + + + + clinical symptoms + clinical symptomatology + + + + + + + + + clinical-anamnestic + + + + + + + + + clinical-laboratory setting + + + + + + + + + clinical-radiological + + + + + + + + + Cluster bronchiectasis + + + + + + + + + cohabitation with her husband + + + + + + + + + colon noeplasia + + + + + + + + + coming for cough and dyspnoea + + + + + + + + + Coming from a rehabilitation facility + + + + + + + + + commitment of the lower lobes + + + + + + + + + comorbidities at the time of diagnosis + + + + + + + + + comparable to the previous + + + + + + + + + compare the chest radiographic examination + + + + + + + + + compare the chest X-ray examination + + + + + + + + + compared to + + + + + + + + + Compared to the child + + + + + + + + + compared to the previous one + + + + + + + + + compatible with the early stage of infectious pneumonia + + + + + + + + + complaining of fever + + + + + + + + + complains of dyspnea + + + + + + + + + complete resolution + + + + + + + + + completely engage + + + + + + + + + completely occupied + + + + + + + + + computed/computerized tomography + + + + + + + + + computed/computerized tomography and nasopharyngeal swab + + + + + + + + + computed/computerized tomography and nasopharyngeal swab are required + + + + + + + + + computed/computerized tomography and RT + + + + + + + + + computed/computerized tomography angiography + + + + + + + + + computed/computerized tomography at the onset + + + + + + + + + computed/computerized tomography check + + + + + + + + + computed/computerized tomography chest-abdomen + + + + + + + + + computed/computerized tomography confirms + + + + + + + + + computed/computerized tomography exam is requested + + + + + + + + + computed/computerized tomography examination + computed/computerized tomography exam + + + + + + + + + computed/computerized tomography examination documents + + + + + + + + + computed/computerized tomography is performed + computed/computerized tomography performed + computed/computerized tomography are performed + computed/computerized tomography examination is performed + + + + + + + + + computed/computerized tomography is required + computed/computerized tomography required + computed/computerized tomography examination is required + + + + + + + + + computed/computerized tomography shows + computed/computerized tomography show + computed/computerized tomography which shows + computed/computerized tomography examination shows + + + + + + + + + computed/computerized tomography findings + computed/computerized tomography finding + + + + + + + + + computed/computerized tomography framework + + + + + + + + + computed/computerized tomography investigations + computed/computerized tomography investigation + + + + + + + + + computed/computerized tomography involvement score + + + + + + + + + computed/computerized tomography is repeated + + + + + + + + + computed/computerized tomography level + + + + + + + + + computed/computerized tomography patterns + + + + + + + + + computed/computerized tomography picture + + + + + + + + + computed/computerized tomography room + + + + + + + + + computed/computerized tomography scan + + + + + + + + + computed/computerized tomography study + + + + + + + + + computed/computerized tomography survey + + + + + + + + + Concomitant areas + + + + + + + + + Concomitant center-panlobular emphysematous changes + + + + + + + + + concomitant pathologies + + + + + + + + + Conducted in pulmonary stenosis + + + + + + + + + Confirmation with swab + + + + + + + + + confirmed positive + + + + + + + + + confirmed SARS-CoV-2 swab infection + + + + + + + + + confirmed the presence of + + + + + + + + + confirming the diagnosis of pulmonary embolism + + + + + + + + + confirms an interstitial pneumonia + + + + + + + + + confirms multiple thickenings + + + + + + + + + confirms the presence of bilateral interstitial pneumonia + + + + + + + + + confluence at the bases + + + + + + + + + confluence with consolidation + + + + + + + + + confluent aspect + + + + + + + + + confluent blotches + + + + + + + + + confluent character + + + + + + + + + confluent consolidations + + + + + + + + + confluent densities + + + + + + + + + consideration of the clinical course + + + + + + + + + consideration of the radiographic findings + + + + + + + + + consolidated morphology + + + + + + + + + consolidation aspects + + + + + + + + + consolidation phenomena + + + + + + + + + consolidations at the posterior regions + + + + + + + + + consolidations in both upper lobes + + + + + + + + + consolidations in the posterior subpleural + + + + + + + + + consolidative type + + + + + + + + + contact with people + + + + + + + + + contact with relatives + + + + + + + + + contact with subjects + + + + + + + + + contacts at risk + + + + + + + + + contacts with positive COVID-19 people + + + + + + + + + contextual pharyngeal swab for COVID-19 + + + + + + + + + contextual pharyngeal swab for COVID-19 was positive + + + + + + + + + continuation of oxygen therapy + + + + + + + + + continued to be altered + + + + + + + + + continuity care + + + + + + + + + continuous positive airway pressure at VM + + + + + + + + + continuous solutions + + + + + + + + + contrast medium + + + + + + + + + contrasted on the left + + + + + + + + + control chest x-ray is performed + + + + + + + + + control shows + + + + + + + + + cooperating alert + + + + + + + + + coronal and axial + + + + + + + + + coronal images + + + + + + + + + Coronal reconstruction MPR + + + + + + + + + coronal reconstructions + + + + + + + + + correspondence of the dorsal region of the LSS + + + + + + + + + correspondence of the lung bases + + + + + + + + + correspondence of the medial segment + + + + + + + + + correspondence with both upper lobes + + + + + + + + + costophrenic sinus + + + + + + + + + costophrenic sinus on this side + + + + + + + + + cough and asthenia treated with Ceftriaxone + + + + + + + + + Cough and fever from February + + + + + + + + + cough and hyperpyrexia refractory to anti-pyretics + + + + + + + + + course and extent of the disease in patients + + + + + + + + + course and severity of the disease + + + + + + + + + course of the descending thoracic aorta + + + + + + + + + COVID19 + Covid19 + severe acute respiratory syndrome - COVID infection 2 + Covid -19 + + + + + + + + + Covid department + + + + + + + + + Covid reference Hub + Covid Hub of reference + + + + + + + + + covid observation ward + + + + + + + + + Covid therapy + + + + + + + + + Covid-19 and HRCT + + + + + + + + + COVID-19 cases have occurred + + + + + + + + + COVID-19 patients + + + + + + + + + Covid-19 positive colleagues + + + + + + + + + COVID-19 positive patients + + + + + + + + + COVID19 positive subjects + + + + + + + + + crackling rales + + + + + + + + + cranial portion + + + + + + + + + cranial scans + + + + + + + + + crazy paving + + + + + + + + + pattern crazy paving + crazy-paving pattern + crazy-paving patterns + crazy paving appearance + + + + + + + + + creatinine and ionemia + + + + + + + + + currently apiretic + + + + + + + + + currently exceeds + + + + + + + + + currently in IOT + + + + + + + + + currently lives + + + + + + + + + cystic alteration + + + + + + + + + days after admission + + + + + + + + + days after hospitalization + + + + + + + + + days after the computed + + + + + + + + + days ago + + + + + + + + + days from hospitalization + + + + + + + + + days from the onset + + + + + + + + + days of hospitalization + + + + + + + + + days of positivity + + + + + + + + + D-Dimer and troponin values + + + + + + + + + declared as red zone + declared red zone + declared a red zone + + + + + + + + + decrease in polymerase chain reaction and lactate dehydrogenase + + + + + + + + + decrease in polymerase chain reaction and lactate dehydrogenase values + + + + + + + + + decrease in serum creatine kinase + + + + + + + + + dedicated center + + + + + + + + + dedicated to COVID-19 + + + + + + + + + dedicated to COVID-19 patients + + + + + + + + + demonstrated the presence of + + + + + + + + + demonstrates a widespread increase + + + + + + + + + demonstrates a widespread increase in the peribroncovascular interstitial texture + + + + + + + + + demonstrates the extreme variability + + + + + + + + + Denies chronic pathologies + + + + + + + + + denies coughing or dyspnoea + + + + + + + + + denoting a shape + + + + + + + + + denoting a shape similar + + + + + + + + + densities with peripheral distribution + + + + + + + + + density ground glass + + + + + + + + + Deny drug + + + + + + + + + Deny drug allergies + + + + + + + + + deny travel abroad + + + + + + + + + Department of Infectious Diseases + + + + + + + + + department of our hospital + + + + + + + + + described currently exceeds + + + + + + + + + detected in ambient + + + + + + + + + detects the presence of SARS-CoV-2 coronavirus ribonucleic acid + + + + + + + + + developing pulmonary embolism + + + + + + + + + development of pulmonary embolism + + + + + + + + + device positioned + + + + + + + + + diabetes and high blood pressure + + + + + + + + + diabetic in oral treatment + + + + + + + + + diagnostic completion + + + + + + + + + diagnostic hypothesis + + + + + + + + + diarrheal alve + + + + + + + + + diarrheal episodes + + + + + + + + + different stages of consolidation + + + + + + + + + difficulty feeding and hydrating + + + + + + + + + diffuse bronchitic + + + + + + + + + Diffuse manifestations + + + + + + + + + diffuse peribronchial + + + + + + + + + disappearance of headache + + + + + + + + + disappearance of the fever + + + + + + + + + discharged after a few days + + + + + + + + + discharged at home + + + + + + + + + discharged in good condition + + + + + + + + + discharged to the home + + + + + + + + + Discrete concomitant pleural effusion + + + + + + + + + discrete increase in the peribroncovascular interstitium + + + + + + + + + Discrete pneumomediastinum + + + + + + + + + disease stratification + + + + + + + + + distal tract + + + + + + + + + distributed in the peri-bronco-vasal + + + + + + + + + distribution bilaterally + + + + + + + + + distribution tending + + + + + + + + + disventilation of the lung bases + + + + + + + + + disventilative striae + + + + + + + + + doctors and health workers + + + + + + + + + document an increase in fibronogen + + + + + + + + + does not correspond + + + + + + + + + dorsal areas + + + + + + + + + dorsal cord + + + + + + + + + dorsal hump + + + + + + + + + dorsal region of the LSS + + + + + + + + + dorsal sectors + + + + + + + + + double orthogonal + + + + + + + + + doubtful swab + + + + + + + + + drug allergies + + + + + + + + + drug therapy and O2-therapy + + + + + + + + + dry limbs + + + + + + + + + due to + + + + + + + + + due to the worsening of symptoms + + + + + + + + + dyschromias of the left foot + + + + + + + + + Dyspnea and fever onset + + + + + + + + + Dyspnea and hyperthermia appear + + + + + + + + + dyspnea from exertion + + + + + + + + + dyspnoea arises + + + + + + + + + early March + + + + + + + + + early stages of diagnosis + + + + + + + + + ECGgraphic disorders + + + + + + + + + EGA performed + + + + + + + + + electrolyte disturbance + + + + + + + + + emergency department + + + + + + + + + emergency room + + + + + + + + + emery glass + + + + + + + + + emery glass areas + + + + + + + + + emery glass density + + + + + + + + + emphysematous bubble + + + + + + + + + empty black arrows + + + + + + + + + endoluminal filling defect + + + + + + + + + endotracheal cannula + + + + + + + + + Enlarged cardiac + + + + + + + + + enlargement of the thickenings + + + + + + + + + entered the emergency room + + + + + + + + + entering the pulmonary stenosis + + + + + + + + + enters the Emergency Department + + + + + + + + + enters the pulmonary stenosis + + + + + + + + + epidemic outbreaks + + + + + + + + + epidemiological suspicion + + + + + + + + + equal parts + + + + + + + + + especially fever + + + + + + + + + especially lymphopenia + + + + + + + + + especially the apical segments + + + + + + + + + evaluating its clinical parameters + + + + + + + + + evening he develops + + + + + + + + + evidence on the left + + + + + + + + + evident coarse air + + + + + + + + + evident dorsal hump + + + + + + + + + evident in both lower lobes + + + + + + + + + evident in the bilateral mantle + + + + + + + + + evident in the cranial scans + + + + + + + + + evident in the lingual and basal + + + + + + + + + evident in the lower lobes + + + + + + + + + evident in the right basal site + + + + + + + + + evident on the left + + + + + + + + + evident with diffuse + + + + + + + + + evident with diffuse peribronchial + + + + + + + + + evolution of the clinical picture + + + + + + + + + ex smoker + + + + + + + + + examination demonstrates + + + + + + + + + examination performed in appendectomy + + + + + + + + + examination performed in appendectomy projection + + + + + + + + + exams performed + + + + + + + + + exams performed in vision + + + + + + + + + exception of mild leukopenia + + + + + + + + + exception of monocytosis + + + + + + + + + execution of the examination + + + + + + + + + execution of the nasopharyngeal swab + + + + + + + + + execution of the traditional X-ray + + + + + + + + + execution of the traditional X-ray investigation + + + + + + + + + exertional dyspnea is less + + + + + + + + + ex-heavy smoker + + + + + + + + + exit was recorded + + + + + + + + + experienced a sudden worsening + + + + + + + + + experiencing shortness of breath + + + + + + + + + explored area + + + + + + + + + extend to the bases + + + + + + + + + extensive and nuanced + Extended and nuanced + + + + + + + + + extended widely + + + + + + + + + extensive areas + + + + + + + + + extensive parenchyma + + + + + + + + + extensive thickenings + + + + + + + + + extent of the alterations + + + + + + + + + extent of the disease in patients + + + + + + + + + external iliac artery is not contrasted + + + + + + + + + externally performed + + + + + + + + + extreme variability + + + + + + + + + fairly large + + + + + + + + + fever and cough appeared + + + + + + + + + fever indication + + + + + + + + + fever with acme + + + + + + + + + fever with shiver + + + + + + + + + feverish peak + + + + + + + + + feverish peak appears + + + + + + + + + feverish state + + + + + + + + + fibrotic-like reticular bands + + + + + + + + + fiduciary home isolation + + + + + + + + + fields and the right pulmonary base + + + + + + + + + finding for viral pneumonia + + + + + + + + + finding is compatible with + + + + + + + + + finding of extensive thickenings + + + + + + + + + Fine background + + + + + + + + + first day + + + + + + + + + first day of hospitalization + + + + + + + + + first day of hospitalization + + + + + + + + + first method + + + + + + + + + first swab is negative + + + + + + + + + Five-day + five days + + + + + + + + + Flat and manageable + + + + + + + + + floating formation in the right atrium + + + + + + + + + Focal areas + + + + + + + + + following a trip + + + + + + + + + following symptoms + + + + + + + + + Following the documentation + + + + + + + + + formation in the right atrium + + + + + + + + + forthcoming mutation + + + + + + + + + FOV is enlarged + + + + + + + + + framework compatible with unilateral interstitial pneumonia + + + + + + + + + framework for bilateral pneumonia + + + + + + + + + framework is compatible with COVID-19 related pathology + + + + + + + + + free intra-abdominal effusion + + + + + + + + + frequent in intensive care unit patients + + + + + + + + + front projection + + + + + + + + + front projection of a supine + + + + + + + + + frosted glass + + + + + + + + + frosted-glass areas + frosted glass areas + + + + + + + + + frosted glass areoles + frosted glass areolas + + + + + + + + + frosted glass aspect + + + + + + + + + frosted glass at the LSS + + + + + + + + + frosted glass character + + + + + + + + + frosted glass of the parenchyma + + + + + + + + + frosted glass superimposed + + + + + + + + + Frosted glass thickenings + + + + + + + + + full black arrow + + + + + + + + + full laboratory tests + + + + + + + + + gangrene framework + + + + + + + + + gastrointestinal complaints + + + + + + + + + gave positive result for Covid-19 + + + + + + + + + GGO opacities + ground-glass opacity + GGO + + + + + + + + + girl was subjected + + + + + + + + + giving oxygen and drug therapy + + + + + + + + + goes to the emergency department + + + + + + + + + greater magnitude + + + + + + + + + greater peribronchial + + + + + + + + + ground glass alteration + + + + + + + + + Ground glass alterations + + + + + + + + + ground glass are observed + + + + + + + + + ground-glass areas + ground glass areas + + + + + + + + + ground glass areoles + + + + + + + + + ground glass densities + + + + + + + + + ground glass thickenings + + + + + + + + + ground-glass + ground glass + + + + + + + + + ground-glass alterations + + + + + + + + + ground-glass pseudonodular + + + + + + + + + ground-glass thickenings + + + + + + + + + ground-glass with aspects + + + + + + + + + GT RANGE + + + + + + + + + haematological consultation + + + + + + + + + halo sign aspects + + + + + + + + + HCRT exam + + + + + + + + + health workers + + + + + + + + + heart tones + + + + + + + + + Hematochemical tests + + + + + + + + + hematological follow-up + + + + + + + + + hematological parameters + + + + + + + + + hematological pathology + + + + + + + + + hemicostat trauma + + + + + + + + + Heparin therapy set + + + + + + + + + hepatic steatosis + + + + + + + + + high blood pressure and diabetes + + + + + + + + + high fever and dry cough + + + + + + + + + high resolution algorithm + + + + + + + + + high-resolution + high resolution + + + + + + + + + high-flow + + + + + + + + + highlighted the spider web sign + + + + + + + + + highly suggestive of CoViD-19 + + + + + + + + + history changes + + + + + + + + + home therapy + + + + + + + + + Home treatment with Taziocin + + + + + + + + + honeycombing-like pattern + + + + + + + + + Horton's arteritis + + + + + + + + + hospital patients + + + + + + + + + hospitalization at the Intensive Care Unit + + + + + + + + + hospitalization for left hip trauma + + + + + + + + + hospitalization for treatment of urinary tract infection + + + + + + + + + hospitalization in isolation + + + + + + + + + hospitalization performed + + + + + + + + + however + + + + + + + + + HRCT control investigation + + + + + + + + + HRCT is performed + + + + + + + + + HRCT study + + + + + + + + + HRTC chest + + + + + + + + + HRTC exam + + + + + + + + + HRTC is performed + + + + + + + + + Hub Covid-19 + + + + + + + + + humid noises + + + + + + + + + hydrated skin + + + + + + + + + hydroxychloroquine is set + + + + + + + + + hyperpyrexia refractory to anti-pyretics + + + + + + + + + hypocapnic hypoxemic respiratory failure + + + + + + + + + hypocapnic respiratory failure + + + + + + + + + hypodiaphania of the middle-basal field + + + + + + + + + hypo-expanded thorax + + + + + + + + + hypo-expansion of the left lung + + + + + + + + + hypothesis COVID 19 + + + + + + + + + idiopathic pulmonary fibrosis in therapy + + + + + + + + + iliac axis + + + + + + + + + ilo-mediastinal lymphadenomegalies + + + + + + + + + ilo-mediastinal lymphadenopathies + + + + + + + + + ilo-mediastinal site + + + + + + + + + ilomediastinal + ilo-mediastinal + + + + + + + + + ilo-peri-ilar + + + + + + + + + ilo-perilary vascular congestion + + + + + + + + + images obtained were analyzed + images obtained have been analyzed + + + + + + + + + Immune-mediated + + + + + + + + + significant dyspnea + important dyspnea + + + + + + + + + important dyspnoea + + + + + + + + + important dyspnoea arises + + + + + + + + + important emphysema + + + + + + + + + important tickling cough + + + + + + + + + improvement of his clinical-laboratory conditions + + + + + + + + + improvement of the clinical picture + improvement of the clinical conditions + + + + + + + + + improvement of the clinical-laboratory picture + improvement of the clinical-laboratory conditions + + + + + + + + + improvement of the general conditions + + + + + + + + + in part with pseudo-nodular appearance + + + + + + + + + increase in fibronogen + + + + + + + + + increase in interstitial texture + + + + + + + + + increase in lactate dehydrogenase and polymerase chain reaction + + + + + + + + + increase in polymerase chain reaction and lactate dehydrogenase values + + + + + + + + + increase in polymerase chain reaction values + + + + + + + + + increase in the peribroncovascular interstitium + + + + + + + + + increase in the values + + + + + + + + + increase in transaminases + + + + + + + + + increase of neoplastic + + + + + + + + + increased after positioning Venturi + + + + + + + + + increased PRC + + + + + + + + + increased thrombophilic risk + + + + + + + + + increased values + + + + + + + + + increasin in transaminase values + + + + + + + + + index case + + + + + + + + + indexes of myocardial necrosis + + + + + + + + + indicative for direct contact + + + + + + + + + indicative of ischemia + + + + + + + + + indicative of urinary tract infection + + + + + + + + + infected with Covid-19 + + + + + + + + + infected with SARS-CoV-2 + + + + + + + + + infectious diseases + + + + + + + + + infectious diseases ward + Infectious Diseases Unit + + + + + + + + + infectious pneumonia + + + + + + + + + inflammation indexes + + + + + + + + + inflammatory damage + + + + + + + + + inflammatory lung damage + + + + + + + + + inflammatory nature + + + + + + + + + inflammatory process + + + + + + + + + inflammatory pulmonary phenomenon + + + + + + + + + inflammatory-infectious pathology + + + + + + + + + initial areas + + + + + + + + + insistent anamnesis + + + + + + + + + insulin therapy + + + + + + + + + integral and symmetric + + + + + + + + + inter- and intralobular interstices + + + + + + + + + intercleidoilary site + + + + + + + + + interleukin 6 + + + + + + + + + interstitial consolidation and thickening + + + + + + + + + interstitial Covid-19 pneumonia + + + + + + + + + interstitial disease + + + + + + + + + interstitial inflammatory infiltrate of the lung bases + + + + + + + + + interstitial peri-bronchovasal weft + + + + + + + + + interstitial reinforcement + + + + + + + + + interstitial texture + + + + + + + + + interstitial texture and peribronchial + + + + + + + + + interstitial thickening + + + + + + + + + interstitial-alveolar pneumonia + + + + + + + + + interstitial-alveolar pneumonia at onset + + + + + + + + + interstitial-vascular texture + + + + + + + + + interstitium of the left hemithorax + + + + + + + + + interstitium pneumonia + + + + + + + + + interstitium pneumonia at onset + + + + + + + + + interviewing the patient + + + + + + + + + intracranial lesions + + + + + + + + + intra-lobular smooth septal thickening at the LSS + + + + + + + + + intravenous administration of contrast medium + + + + + + + + + Introduction of antibiotic therapy + + + + + + + + + intubated and hospitalized + + + + + + + + + intubated in a shock room + + + + + + + + + irregular margins + + + + + + + + + irritating cough + + + + + + + + + jatal hernia surgery + + + + + + + + + known areas + + + + + + + + + known comorbidities + + + + + + + + + known pathologies + + + + + + + + + laboratory framework + + + + + + + + + Laboratory tests at admission + + + + + + + + + Laboratory tests during hospitalization + + + + + + + + + laboratory tests in the standard + laboratory tests in the norm + + + + + + + + + laboratory tests showing + Laboratory tests showed + + + + + + + + + lack of appetite + + + + + + + + + lack of response to antibiotic + + + + + + + + + lack of response to antibiotic therapy + + + + + + + + + procalcitonin and lactate dehydrogenase values + lactate dehydrogenase and procalcitonin values + + + + + + + + + lactate dehydrogenase and transaminases + + + + + + + + + lactate dehydrogenase values + + + + + + + + + lamellar aspect + + + + + + + + + Large areas + + + + + + + + + large branches + + + + + + + + + largest right pulmonary hilar + + + + + + + + + last administration + + + + + + + + + last days + + + + + + + + + last days of February + + + + + + + + + last week + + + + + + + + + last week of February + + + + + + + + + later date + + + + + + + + + lateral sectors + + + + + + + + + lateral side + + + + + + + + + lateral subpleural + + + + + + + + + lateral subpleural sites + + + + + + + + + latero-basal + + + + + + + + + latero-basal and postero-basal segment + + + + + + + + + latero-basal segment + + + + + + + + + laterocervical area + + + + + + + + + latter suspended + + + + + + + + + lattice-interstitial disease + + + + + + + + + led to transfer + + + + + + + + + left hemithorax is blurred + + + + + + + + + left lobe + + + + + + + + + left lung field + + + + + + + + + left paracardiac + + + + + + + + + left pulmonary artery and its subdivision + + + + + + + + + LES positive for steroid therapy + + + + + + + + + LES positive for steroid therapy and obesity + + + + + + + + + Leukopenia persists + + + + + + + + + levoflacin and lactic ferments + + + + + + + + + Levoxacin and antidiarrheal drugs + + + + + + + + + Levoxacin and oxygen therapy + + + + + + + + + limited foci of parenchymal thickening + + + + + + + + + lingula and the lower lobes + lingula and lower lobe + + + + + + + + + lingula and the middle lobe + + + + + + + + + little benefit + + + + + + + + + lives at home + + + + + + + + + lobar region + + + + + + + + + lobar site + + + + + + + + + lobe of both lungs + + + + + + + + + lobe of both lungs in the subpleural + + + + + + + + + lobe of the left lung + + + + + + + + + lobe of the right lung + + + + + + + + + lobe of the right lung subpleurally + + + + + + + + + lobes of both lungs + + + + + + + + + lobular septa + + + + + + + + + localizing interstitial pneumonia + + + + + + + + + Located in the adjacent seat + + + + + + + + + located in the mantle + + + + + + + + + Lopinavir / Ritonavir therapy + + + + + + + + + lower limbs + + + + + + + + + lower limit + + + + + + + + + lower lingular + + + + + + + + + lower lobes + lower lobe + + + + + + + + + lower paracaval site + + + + + + + + + lower pulmonary veins + + + + + + + + + lower right lung lobe + + + + + + + + + lower sectors + + + + + + + + + low-flow + + + + + + + + + LSD and LID + + + + + + + + + lung areas + + + + + + + + + lung changes + + + + + + + + + lung fields + + + + + + + + + lung lesions + + + + + + + + + lung lobes + lung lobe + + + + + + + + + lung parenchymes + + + + + + + + + lung plot + + + + + + + + + lung segments + + + + + + + + + lung segments + + + + + + + + + Lung thickenings + + + + + + + + + lymph node images + + + + + + + + + lymph nodes + + + + + + + + + lymphadenopathies in the upper and prevascular vascular paratracheal area + + + + + + + + + made a train journey + + + + + + + + + main airways + + + + + + + + + main aspect + + + + + + + + + main branches + main branch + + + + + + + + + mainly affecting + + + + + + + + + mainly involving + + + + + + + + + mainly involving the lingula + + + + + + + + + mainly located in the mantle + + + + + + + + + male aged + + + + + + + + + manage dyspnea + + + + + + + + + management and clinical outcome + + + + + + + + + manifestations of Covid-19 pathology + + + + + + + + + mantle distribution + + + + + + + + + mantle site of + + + + + + + + + mantle-subpleural distribution + + + + + + + + + marbled appearance + + + + + + + + + marked data + + + + + + + + + marked rise + + + + + + + + + mastectomy with lymphadenectomy + + + + + + + + + maximum severity + + + + + + + + + maximum short axis + + + + + + + + + may be related + + + + + + + + + mechanical ventilation SIMV-CPAP + + + + + + + + + medial portion + + + + + + + + + median seat + + + + + + + + + mediastinal adenopathies + + + + + + + + + mediastinal lymphadenomegalies + + + + + + + + + mediastinal lymphadenomegaly + + + + + + + + + mediastinal lymphadenopathies + + + + + + + + + mediastinal profile + + + + + + + + + medical colleague + + + + + + + + + medicine department + + + + + + + + + medicine for pomonitis + + + + + + + + + mediobasal segment + + + + + + + + + medium scan + + + + + + + + + mental confusion + + + + + + + + + micromolecular lambda myeloma + + + + + + + + + mid-apical field of both lungs + + + + + + + + + middle fields + + + + + + + + + middle lobes + middle lobe + + + + + + + + + middle tract + + + + + + + + + middle-basal lung fields + + + + + + + + + millimeter slice-thickness + + + + + + + + + Minimum bilateral basal pleural effusion + + + + + + + + + mitral valve and bibasal + + + + + + + + + mitral valve diffusely + + + + + + + + + moderate decrease + + + + + + + + + modest asthenia + + + + + + + + + modest bilateral pleural effusion + + + + + + + + + modest but progressive improvement + + + + + + + + + Modest liver steatosis + + + + + + + + + modest lymphopenia + + + + + + + + + modest monocytopenia + + + + + + + + + modest pericardial effusion + + + + + + + + + modest variation + + + + + + + + + modest variation of the findings + + + + + + + + + monitored at home + + + + + + + + + monolaterality of lung + + + + + + + + + monolaterality of lung changes + + + + + + + + + monovasal obstructive epicardial coronary artery disease + + + + + + + + + mosaic alteration + + + + + + + + + MRSE and port-a-cath + + + + + + + + + multi-district + + + + + + + + + multi-drug therapy + + + + + + + + + multi-drug therapy and O2-therapy + + + + + + + + + multiple areas + + + + + + + + + multiple thickenings + + + + + + + + + Multiples Lung thickenings + + + + + + + + + Municipality of the rhenium + + + + + + + + + Municipality of the rhenium Zone + + + + + + + + + nasopharyngeal swab are then arranged + + + + + + + + + nasopharyngeal swab for SARS-CoV-2 research + + + + + + + + + nasopharyngeal swab is carried + + + + + + + + + nasopharyngeal swab is prepared + + + + + + + + + NCOV positive buffer + + + + + + + + + COVID19 positive + NCOV positive + nCOV-19 positive + + + + + + + + + nCOV-19 swab + + + + + + + + + nCOV-19 swab is required + + + + + + + + + need for blood transfusion appeared + + + + + + + + + need for hospitalization + + + + + + + + + negative buffer + + + + + + + + + Negative history of certain contact with known positive Covid-19 patients + + + + + + + + + negative results + + + + + + + + + neutrophils and lymphocytes + + + + + + + + + new chest X-ray shows + + + + + + + + + next contact + + + + + + + + + next day + + + + + + + + + next hour + + + + + + + + + night desaturation + + + + + + + + + no evidence of pleuro-pericardial effusion + + + + + + + + + nodules at the anterior segments + + + + + + + + + Non focal + + + + + + + + + non-co-pathological + + + + + + + + + non-cough + + + + + + + + + nonspecific low back pain + + + + + + + + + normal architecture + + + + + + + + + normal values + + + + + + + + + noted the presence of + + + + + + + + + noteworthy pathology + + + + + + + + + nuanced bilateral alveolar + + + + + + + + + nuanced thickening + + + + + + + + + numerous doctors + + + + + + + + + Objective finding + + + + + + + + + objectivity is normal + + + + + + + + + obliteration of the costophrenic sinus + + + + + + + + + obliteration of the SCF + + + + + + + + + observation of the emergency department + + + + + + + + + Observation ward + + + + + + + + + observed in adult + + + + + + + + + observed in adult patients + + + + + + + + + obstructive epicardial coronary artery disease + + + + + + + + + occupying most of the upper lobe + + + + + + + + + occurs in pulmonary stenosis + + + + + + + + + one case + + + + + + + + + one week + + + + + + + + + onset of dyspnea with desaturation + + + + + + + + + onset of symptoms + + + + + + + + + Onset with asthenia + + + + + + + + + onset with high fever + + + + + + + + + opacification defects + + + + + + + + + oral hypoglycaemic agents + + + + + + + + + Oropharyngeal swab is tested + + + + + + + + + Orthostasis chest x-ray performed + + + + + + + + + outbreaks in progress + + + + + + + + + outbreaks of parenchymal consolidation + + + + + + + + + outpatient basis + + + + + + + + + oval lymph nodes + + + + + + + + + overall clinical picture + + + + + + + + + oxygen Hb + + + + + + + + + oxygen saturation input + + + + + + + + + oxygen therapy is administered + + + + + + + + + paracardiac site + + + + + + + + + paracardial thickening + + + + + + + + + paracaval site + + + + + + + + + para-centimetric + + + + + + + + + parascissural distribution + + + + + + + + + parascissural distribution tending + + + + + + + + + paratracheal area + + + + + + + + + parenchymal area + + + + + + + + + parenchymal band + + + + + + + + + parenchymal band aspects + + + + + + + + + parenchymal consolidation + + + + + + + + + parenchymal consolidation areas + + + + + + + + + Parenchymal consolidation bands + + + + + + + + + parenchymal consolidation rates + + + + + + + + + parenchymal density + + + + + + + + + parenchymal pathological findings + + + + + + + + + parenchymal pathological TDM + + + + + + + + + Parenchymal pleural findings + + + + + + + + + parenchymal pulmonary thickening + + + + + + + + + parenchymal pulmonary thickening increased + + + + + + + + + parenchymal thickening + + + + + + + + + parenchymal thickening and disventilative + + + + + + + + + parenchymal thickening areas + + + + + + + + + parenchymal thickening with a frosted glass appearance + + + + + + + + + Parents and grandmother + + + + + + + + + parents both hospitalized + + + + + + + + + parents Covid-19 positive + + + + + + + + + parents in their home + + + + + + + + + parietal atheromasia + + + + + + + + + parietal calcifications + + + + + + + + + part of the anterior segment + + + + + + + + + part of the medial segment + + + + + + + + + partial pressure ratio + + + + + + + + + partial re-expansion + + + + + + + + + partially confluent aspect + + + + + + + + + particular anatomical conditions + + + + + + + + + particular in the posterior segments + + + + + + + + + particular negative + + + + + + + + + particular on the right + + + + + + + + + partly confluent + + + + + + + + + partly sub pleural distribution + + + + + + + + + pathological changes + + + + + + + + + pathological findings + + + + + + + + + pathological noises + + + + + + + + + pathological TDM + + + + + + + + + patient arrives + + + + + + + + + patient at admission + + + + + + + + + patient complained + + + + + + + + + Patient discharged + + + + + + + + + patient experiences + + + + + + + + + patient has been receiving + + + + + + + + + patient has not traveled + + + + + + + + + patient is accompanied + + + + + + + + + patient is admitted + + + + + + + + + patient is discharged + + + + + + + + + patient is hospitalized in Emergency Medicine + + + + + + + + + patient is intubated + + + + + + + + + patient transferred + patient is transferred + + + + + + + + + patient is treated with oxygen therapy + + + + + + + + + patient management + + + + + + + + + patient presents + + + + + + + + + patient reports + + + + + + + + + patient was admitted + + + + + + + + + patient was discharged + + + + + + + + + patient with fever and cough + + + + + + + + + patients who have other concomitant pathologies + + + + + + + + + patients with Covid-19 + + + + + + + + + patients with COVID-19 infection + + + + + + + + + Pediatric aid + + + + + + + + + pediatric cases + + + + + + + + + pedidio pulse + + + + + + + + + people from the red zone + + + + + + + + + people with severe cough + + + + + + + + + per dose + + + + + + + + + Perform chest x-ray + + + + + + + + + perform the swab + + + + + + + + + performed in appendectomy projection + + + + + + + + + performed in standard + + + + + + + + + performed urgently + + + + + + + + + performed with high resolution + + + + + + + + + performing double swab + + + + + + + + + performing pharyngeal swab + + + + + + + + + performs a nasal swab for COVID-19 + + + + + + + + + Performs abdominal ultrasound + + + + + + + + + performs an X-ray + + + + + + + + + Performs chest x-ray + + + + + + + + + Performs chest x-ray in bed + + + + + + + + + performs ecg + + + + + + + + + performs negative chest X-ray + + + + + + + + + Performs pulmonary angio-CT + + + + + + + + + Performs standard chest x-ray + + + + + + + + + peribronchial distribution + + + + + + + + + peribronchial thickening + + + + + + + + + peri-bronco-vasal + peri-bronchovasal + + + + + + + + + peribroncovasal density + + + + + + + + + peribroncovasal pulmonary + + + + + + + + + peribroncovasal pulmonary interstitial + + + + + + + + + peribroncovasal pulmonary interstitial reinforcement + + + + + + + + + peribroncovascular distribution + + + + + + + + + peribroncovascular pulmonary + + + + + + + + + peribroncovascular pulmonary design + + + + + + + + + peri-centimetric + + + + + + + + + perilary hypodiaphany + + + + + + + + + perilary pulmonary seat + + + + + + + + + perilary region + + + + + + + + + peripheral distribution on load + + + + + + + + + peripheral disventilative branches + + + + + + + + + Peripheral thickenings + + + + + + + + + periscissural localization + + + + + + + + + peritracheo-broncho-hilar + + + + + + + + + peritracheo-broncho-hilar chains + + + + + + + + + persistence of symptoms + + + + + + + + + persistence of the symptomatology + + + + + + + + + persistent chest pain + + + + + + + + + persistent hyperpyrexia + + + + + + + + + pervades the main airways + + + + + + + + + Pervia and regular caliber + + + + + + + + + pharmacological therapies + + + + + + + + + Pharyngeal nose swab + + + + + + + + + pharyngeal swab for COVID-19 was positive + + + + + + + + + pharyngeal swab performed + + + + + + + + + pharyngeal swab test + + + + + + + + + pharyngodynia and difficulty feeding + + + + + + + + + pharyngodynia and mild dyspnea + + + + + + + + + phlogistic nature + + + + + + + + + phlogistic picture + + + + + + + + + phlogistic-infectious form + + + + + + + + + phlogistic-infectious nature + + + + + + + + + phlogistic-infectious nature is hypothesized + + + + + + + + + Physical examination shows + + + + + + + + + pink mucous membranes + + + + + + + + + placed in isolation + + + + + + + + + Plaquenil 400 milligram + + + + + + + + + Pleural effusion not recognizable + + + + + + + + + pleural effusion was no longer visible + + + + + + + + + pleural findings + + + + + + + + + pleural veiling + + + + + + + + + pleurogenic obliteration of the SCF + + + + + + + + + pleuro-lung + + + + + + + + + pleuro-lung lesions + + + + + + + + + pleuro-pericardial effusion + + + + + + + + + pneumological tests + + + + + + + + + pneumonia at onset + + + + + + + + + pocket infection + + + + + + + + + point of view + + + + + + + + + polymerase chain reaction and lactate dehydrogenase values + + + + + + + + + polymerase chain reaction and procalciton + + + + + + + + + poorly defined margins + + + + + + + + + portable device + + + + + + + + + portable device positioned + + + + + + + + + port-a-cath + + + + + + + + + positioning Venturi + + + + + + + + + Positive buffer + + + + + + + + + positive Covid19 + + + + + + + + + positive Covid-19 patients + + + + + + + + + positive COVID-19 people + + + + + + + + + positive COVID-19 was excluded + + + + + + + + + positive Murphy + + + + + + + + + positive patients + + + + + + + + + positive results + + + + + + + + + positive SARS-CoV-2 buffer + + + + + + + + + positivity for Covid-19 infection + + + + + + + + + positive for SAR-CoV-2 + positivity to COVID-19 + positive results for Covid-19 + positivity for Covid-19 + + + + + + + + + positivity of the pharyngeal swab + + + + + + + + + possibility of positive COVID-19 + + + + + + + + + possibility of positive COVID-19 was excluded + + + + + + + + + possible emphysematic + + + + + + + + + posterior regions + + + + + + + + + posterior seat + + + + + + + + + posterior segments + + + + + + + + + posterior slopes + + + + + + + + + posterior subpleural + + + + + + + + + postero-basal + + + + + + + + + postero-basal parenchyma + + + + + + + + + postero-basal segment + + + + + + + + + postero-basal site + + + + + + + + + postero-basal site of the LIS + + + + + + + + + postero-lower + + + + + + + + + postero-lower sectors + + + + + + + + + post-mortem + + + + + + + + + pouring costofrenic sinuses + + + + + + + + + Practice laboratory tests + + + + + + + + + Practice laboratory tests showing + + + + + + + + + precautionary purpose + + + + + + + + + predisposed to nasopharyngeal swab + + + + + + + + + predominantly peripheral distribution + + + + + + + + + pre-hospitalization + + + + + + + + + prepares for nasopharyngeal swab + + + + + + + + + prescribed antibiotic therapy + + + + + + + + + prescribed antibiotic therapy with Augmentin + + + + + + + + + prescription of the Cardiologist of reference + + + + + + + + + presence of different + + + + + + + + + presence of patent bronchi and ectasics + + + + + + + + + presence of people + + + + + + + + + presented with fever + + + + + + + + + presented with hyperpyrexia and cough + + + + + + + + + presenting with fever and exertional dyspnea + + + + + + + + + presents hyperpyrexia + + + + + + + + + preserved diuresis + + + + + + + + + prevailing bilateral mantle + + + + + + + + + prevalent at the bases + + + + + + + + + prevalent in the lower lobes + + + + + + + + + prevalent in the lower right lung + + + + + + + + + prevalent in the lower right lung lobe + + + + + + + + + prevalent patchy + + + + + + + + + prevalent patchy subpleural distribution + + + + + + + + + prevalent peripheral distribution + + + + + + + + + previous exams + + + + + + + + + previous one + + + + + + + + + previous ones + + + + + + + + + previous pathologies + + + + + + + + + previous therapy + + + + + + + + + previously reported to the LSS + + + + + + + + + procalcitonin indices + + + + + + + + + procalcitonin values + + + + + + + + + progressive improvement + + + + + + + + + projection in supine decubitus position + + + + + + + + + projection of a supine + + + + + + + + + prolonged enticement + + + + + + + + + pseudo-nodular densities + + + + + + + + + pseudonodular in appearance + + + + + + + + + pseudo-nodular thickenings + pseudonodular thickening + + + + + + + + + pseudonodular type + + + + + + + + + pulmonary angio-CT + + + + + + + + + pulmonary arteries + + + + + + + + + pulmonary changes + + + + + + + + + pulmonary circulation + + + + + + + + + pulmonary fields + + + + + + + + + pulmonary interstitium + + + + + + + + + pulmonary opacation + + + + + + + + + pulmonary parenchymal + pulmonary parenchymes + pulmonary parenchyma + + + + + + + + + pulmonary periphery + + + + + + + + + pulmonary phenomenon + + + + + + + + + Pulmonary picture improvement + + + + + + + + + pulmonary stenosis for cough and fever + + + + + + + + + pulmonary stenosis for syncopal episode + + + + + + + + + pulmonary stenosis radiography + + + + + + + + + pulmonary stenosis regime + + + + + + + + + pulmonary thickenings + + + + + + + + + pulmonary transparency + + + + + + + + + pulmonary ultrasound examination is performed + + + + + + + + + pure heart tones + + + + + + + + + quantify the extent of the disease + + + + + + + + + radical robotic prostatectomy + + + + + + + + + radiographic characteristics + + + + + + + + + radiographic findings + + + + + + + + + radiographic images + + + + + + + + + radiographic investigation + + + + + + + + + radiographic signs + + + + + + + + + Radiography of pulmonary stenosis + + + + + + + + + radiological diagnosis of interstitial pneumonia + + + + + + + + + radiological diagnostic hypothesis + + + + + + + + + radiological healing + + + + + + + + + radiological picture + + + + + + + + + radiological picture is then reassessed + + + + + + + + + radiological score + + + + + + + + + radiological suspicion + + + + + + + + + random arrangement + + + + + + + + + rapid exitus + + + + + + + + + rare and fine crackles + + + + + + + + + rare manifestation of the distribution + + + + + + + + + real time polymerase chain reaction + + + + + + + + + real-time + + + + + + + + + reassessment with chest x-ray + + + + + + + + + reassessment with chest x-ray shows + + + + + + + + + recent CT-scan + + + + + + + + + recent stay + + + + + + + + + recently undergoing + + + + + + + + + reconstructions are performed + + + + + + + + + reconstructions with filter for mediastinum + reconstructions with a mediastinum filter + + + + + + + + + recovered from severe pneumonia + + + + + + + + + recovery of appetite + + + + + + + + + red zone + red areas + + + + + + + + + reduced pO2 + + + + + + + + + reduction of diaphanous + + + + + + + + + re-expansion of the previous lung parenchyma involved + + + + + + + + + regions of both lower lobes + + + + + + + + + regions of the apical segments + + + + + + + + + regressed with diuretic therapy + + + + + + + + + regular morphology and size + + + + + + + + + reinforcement of the interstitial texture + + + + + + + + + relation to previous pathologies + + + + + + + + + relation to the X-ray finding + + + + + + + + + relationship with the airways + + + + + + + + + relative well-being and stability + + + + + + + + + relevant pathological findings + + + + + + + + + remain available + + + + + + + + + remain available bilaterally + + + + + + + + + remain patent + + + + + + + + + remained stable + + + + + + + + + remaining laboratory tests + + + + + + + + + remaining laboratory tests in the standard + remaining laboratory tests in the norm + + + + + + + + + remaining laboratory tests in the standard + + + + + + + + + Remote pathological history changes + + + + + + + + + reported contacts + + + + + + + + + reported dyspnea and chest pain + + + + + + + + + reported since + + + + + + + + + reported to the LSS + + + + + + + + + reports dyspnea + + + + + + + + + reports dyspnea and fever + + + + + + + + + reports fever + + + + + + + + + reports hyperpyrexia + + + + + + + + + represented by an area + + + + + + + + + represents a rare manifestation of Covid-19 pathology + + + + + + + + + required in Covid-19 + + + + + + + + + requires surgical treatment + + + + + + + + + research evaluation + + + + + + + + + resolution COVID-19 lung picture + + + + + + + + + resolution of the clinical symptomatology + + + + + + + + + resolved spontaneously + + + + + + + + + respiratory crisis + + + + + + + + + respiratory failure arose + + + + + + + + + respiratory parameters + + + + + + + + + respiratory picture + + + + + + + + + response to antibiotic therapy + + + + + + + + + result of positivity + + + + + + + + + Result of the buffer + + + + + + + + + reticular bands + + + + + + + + + revascularized in its distal tract + + + + + + + + + reverse transcription polymerase chain reaction + + + + + + + + + Reversible or irreversible + + + + + + + + + rhenium Zone + + + + + + + + + rheumatic polymyalgia + + + + + + + + + Rhino-pharyngeal swab + + + + + + + + + Rhino-pharyngeal swab performed + rhino-pharyngeal swab is performed + + + + + + + + + rib fractures + + + + + + + + + right and left side + + + + + + + + + right basal field crackling + + + + + + + + + right hemifrene + + + + + + + + + right hemithorax and fibrotic + + + + + + + + + right lobe + + + + + + + + + right lung field + + + + + + + + + right lung subpleurally + + + + + + + + + right paracardiac + + + + + + + + + right pulmonary perilary seat + + + + + + + + + rise in lactate dehydrogenase + + + + + + + + + rise in polymerase chain reaction + + + + + + + + + risk area + + + + + + + + + risk of being infected + + + + + + + + + risk of developing + + + + + + + + + robotic prostatectomy + + + + + + + + + roughly triangular and angular + + + + + + + + + roughly triangular and angular appearance + + + + + + + + + RT-PCR + + + + + + + + + safe continuous solutions + + + + + + + + + SAR-CoV2 positive + + + + + + + + + SARS-CoV-2 positive patients + SAR-CoV2 positive patients + + + + + + + + + SAR-Cov-2 viral infection pneumonia + + + + + + + + + SAR-Cov-2 viral infection pneumonia patients + + + + + + + + + SARS-CoV2 + + + + + + + + + SARS-Cov-2 research + + + + + + + + + sat oxygen + + + + + + + + + Saturation and blood gas analysis + + + + + + + + + saturation is detected + + + + + + + + + scan of the chest + + + + + + + + + scan of the pulmonary + + + + + + + + + scan of the pulmonary circulation + + + + + + + + + scan of the skull and chest + + + + + + + + + scan of the thorax + + + + + + + + + scans of the study + + + + + + + + + scarcely affected + + + + + + + + + second buffer + + + + + + + + + segment of the LIS + + + + + + + + + segment of the upper lobe + + + + + + + + + segmental-subsegmentary + + + + + + + + + segments of the LSD + + + + + + + + + segments of the upper lobes + + + + + + + + + self-isolation + + + + + + + + + Semi-sitting + + + + + + + + + sent to pulmonary stenosis + + + + + + + + + sepsis from MRSE + + + + + + + + + septa thickened inside + + + + + + + + + severe and suggestive + + + + + + + + + shaded glass + + + + + + + + + shaded glass areola + + + + + + + + + shape similar + + + + + + + + + shock room + + + + + + + + + shortly before surgery + + + + + + + + + show increased PRC + + + + + + + + + show increased values + + + + + + + + + show leukopenia with neutrophilia + + + + + + + + + show pathological findings + + + + + + + + + showed a worsening + + + + + + + + + showed a worsening of the respiratory + + + + + + + + + showed focal pulmonary thickening + + + + + + + + + showed normal values + + + + + + + + + showed up at our emergency department + + + + + + + + + shows a reduction + + + + + + + + + shows a widespread increase + + + + + + + + + shows an extensive thickening + + + + + + + + + shows an increase + + + + + + + + + shows opacification + + + + + + + + + shows opacification defects + + + + + + + + + shows significant + + + + + + + + + shows significant improvements + + + + + + + + + shows some bilateral rhonco + + + + + + + + + siblings and asymptomatic parents + + + + + + + + + significant alterations + + + + + + + + + significant images + + + + + + + + + significant improvements + + + + + + + + + Significant increase + + + + + + + + + significantly reduced + + + + + + + + + significantly thickened + + + + + + + + + significantly thickened-imbibed + + + + + + + + + signs of deep vein thrombosis + + + + + + + + + signs of heart failure + + + + + + + + + signs of hemagglutinin type 1 + + + + + + + + + signs of interstitial pneumonia + + + + + + + + + signs of pleural effusion + + + + + + + + + signs of pleural or pericardial effusion + + + + + + + + + signs of spillage + + + + + + + + + similar to that of a spider web + + + + + + + + + simultaneous sanitation + + + + + + + + + Six days + + + + + + + + + Six days after admission + + + + + + + + + slight feverish + + + + + + + + + slight increase in body temperature + + + + + + + + + slight increase in polymerase chain reaction + + + + + + + + + slight predominance + + + + + + + + + slight reduction in white blood cells + + + + + + + + + slightly dyspnoic + + + + + + + + + slightly tachypneic + + + + + + + + + sloping and symmetrical + + + + + + + + + small and nuanced + + + + + + + + + Small and subtle + + + + + + + + + Small areas + + + + + + + + + small circle + + + + + + + + + small interstice + + + + + + + + + Smaller alteration + + + + + + + + + smaller densities + + + + + + + + + Softened confluent densities + + + + + + + + + spider web in the corner + + + + + + + + + stability of the patient + + + + + + + + + Standard chest radiogram + + + + + + + + + Standard double orthogonal + + + + + + + + + Standard Radiogram + + + + + + + + + standard triage + + + + + + + + + started treatment with Amoxicillina + + + + + + + + + starts treatment with Kaletra + + + + + + + + + still present + + + + + + + + + strategic role + + + + + + + + + stretched and thickened + + + + + + + + + strip-like + + + + + + + + + strongly suspected + + + + + + + + + strongly suspected for a positivity + + + + + + + + + study shows + + + + + + + + + subject recently undergoing + + + + + + + + + subjected to a nasopharyngeal swab beforehand + + + + + + + + + subjected to nasopharyngeal swab + subjected to a nasopharyngeal swab + + + + + + + + + subjected to pharyngeal swab + subjected to a pharyngeal swab + + + + + + + + + subjected to a swab + + + + + + + + + subjected to blood sampling + + + + + + + + + subjected to home quarantine + + + + + + + + + subjected to mechanical ventilation + + + + + + + + + subjected to nasopharyngeal swab for SARS-CoV-2 + + + + + + + + + subjected to nasopharyngeal swab for SARS-CoV-2 research + + + + + + + + + subjected to swab for Covid-19 + + + + + + + + + submantellar and paravertebral + + + + + + + + + sub-mantle + + + + + + + + + subpleural location + subpleural area + + + + + + + + + subpleural distribution + + + + + + + + + subpleural dorsal striae + + + + + + + + + subpleural paraseptal emphysema + + + + + + + + + subpleural thickening + + + + + + + + + subpleurally and extensive parenchyma + + + + + + + + + subsequently confirmed by + + + + + + + + + subsequently performed + + + + + + + + + substantially normal + + + + + + + + + substantially stationary clinical picture + + + + + + + + + subtotal commitment + + + + + + + + + suffered by the patient + + + + + + + + + suffers from flu-like symptoms + + + + + + + + + suggestive alterations for ischemia + + + + + + + + + supine patient + + + + + + + + + supported by hepatomegaly + + + + + + + + + survey was repeated + + + + + + + + + suspected case of Covid19 + suspect for SARS-CoV2 + + + + + + + + + suspected finding + + + + + + + + + suspected for a positivity + + + + + + + + + suspected symptomatology + + + + + + + + + suspected symptoms + + + + + + + + + suspicious cases + + + + + + + + + suspicious for bilateral COVID-19 pneumonia + + + + + + + + + suspicious lung picture + + + + + + + + + swab is positive for Covid-19 + + + + + + + + + swabs for testing Covid-19 infection + + + + + + + + + symptomatic children + + + + + + + + + Symptomatic parents + + + + + + + + + symptomatic therapy + + + + + + + + + symptomatology for COVID + + + + + + + + + symptoms for a week + + + + + + + + + symptoms such as flu syndrome + + + + + + + + + syncopal episode + + + + + + + + + syncope after urination + + + + + + + + + tachycardic and slightly tachypnoic + + + + + + + + + tachypnoic at rest + + + + + + + + + tachypnoic pulmonary stenosis + + + + + + + + + tail of Covid-19 infection + + + + + + + + + taken to the emergency room + + + + + + + + + takes Amoxicillin + + + + + + + + + taking paracetamol + + + + + + + + + Tavanic 500 milligram + + + + + + + + + TC Chest + + + + + + + + + TC pattern + + + + + + + + + TC score + + + + + + + + + temperature in the norm + + + + + + + + + tendency + + + + + + + + + tendency to cavitation + + + + + + + + + tends to manifest + + + + + + + + + TEPA negative + + + + + + + + + tested for COVID-19 + + + + + + + + + testing Covid-19 infection + tested for Covid-19 infection + + + + + + + + + tested positive for SARS-CoV-2 infection + + + + + + + + + tested which is positive for SAR-CoV-2 + + + + + + + + + therapy with amoxicillin + + + + + + + + + therapy with amoxicillin and azithromycin + + + + + + + + + therapy with antiretroviral and hydroxychloroquine + + + + + + + + + therapy with carfilzomib + + + + + + + + + therapy with Lopinavir-Ritonavir + Therapy with Lopinavir / Ritonavir + + + + + + + + + therapy with Tocilizumab 480 milligram + + + + + + + + + therapy with tyrosine kinase inhibitor + + + + + + + + + therapy with Venturi mask + + + + + + + + + therapy-resistant + + + + + + + + + therapy-resistant hypepyrexia + + + + + + + + + therefore + + + + + + + + + thermotact of the left foot + + + + + + + + + thick walls + + + + + + + + + thickened areas + + + + + + + + + thickened interstitial-alveolar infiltratives + + + + + + + + + thickened-imbibed + + + + + + + + + thickening areas + + + + + + + + + thickening of the interlobular septa + + + + + + + + + thickening of the interstitial septa + + + + + + + + + thickening of the LSS + + + + + + + + + thickening of the peribronco-vascular interstitium + thickening of the peribroncovascular interstitium + + + + + + + + + thickenings adjacent to + + + + + + + + + thickenings at the anterior and posterior segments + + + + + + + + + thickenings at the anterior and posterior segments of the upper right lobe + + + + + + + + + thickenings in both lungs + + + + + + + + + thickenings in the lower lobes + + + + + + + + + thickenings in the right pulmonary + + + + + + + + + thickenings in the right pulmonary perilary seat + + + + + + + + + thickenings of para-centimetric + + + + + + + + + Thin bilateral pleural effusion + + + + + + + + + thin spillage + + + + + + + + + THORAX TC + + + + + + + + + three weeks + + + + + + + + + three weeks of therapy + + + + + + + + + three-day + + + + + + + + + Three-month-old baby + + + + + + + + + thrombo-embolism + + + + + + + + + thrombophilic risk + + + + + + + + + thrombus-embolic filling defects + + + + + + + + + throughout the lung area + + + + + + + + + tickling cough and asthenia + + + + + + + + + took oral amoxicillin + + + + + + + + + total points + + + + + + + + + towards consolidation + + + + + + + + + traces of effusion + + + + + + + + + traditional X-ray investigation + + + + + + + + + train journey + + + + + + + + + transferred to the Covid Department + + + + + + + + + transferred to the infectious disease ward + transferred to the infectious diseases department + + + + + + + + + transported to pulmonary stenosis + + + + + + + + + trauma occurred + + + + + + + + + traveled by train + + + + + + + + + travels to pulmonary stenosis + + + + + + + + + treat the patient + + + + + + + + + Treatable abdomen + + + + + + + + + treated at home + + + + + + + + + treated with antiviral therapy and levofloxacin + treated by antiviral therapy and levofloxacin + + + + + + + + + treated by antiviral therapy and levoxacin + + + + + + + + + treated with antibiotic and tachipirine + + + + + + + + + treated with antibiotics and supportive care + + + + + + + + + treated with Augmentin + + + + + + + + + treated with Klacid + + + + + + + + + treated with zitromax + + + + + + + + + triangular and angular appearance + + + + + + + + + trilinear cytopenia + + + + + + + + + Tropical Diseases ward + + + + + + + + + troponin values + + + + + + + + + Two days later + + + + + + + + + type 2 diabetes is diagnosed + + + + + + + + + typical for COVID-19 interstitial pneumonia + + + + + + + + + ubiquitous distribution + + + + + + + + + ubiquitous distribution bilaterally + + + + + + + + + ubiquitously localized + + + + + + + + + ultra sensitive + + + + + + + + + uncomplicated course + + + + + + + + + undergoes a pulmonary ultrasound + + + + + + + + + undergoes an ultrasound examination + + + + + + + + + underlying pathology + + + + + + + + + underwent a chest X-ray + + + + + + + + + underwent a Chest X-ray examination + + + + + + + + + uneven bilateral pulmonary thickening + + + + + + + + + unilateral and unilobal + + + + + + + + + unilateral lesions + + + + + + + + + unilobal involvement + + + + + + + + + unilobal pulmonary involvement + + + + + + + + + upon + + + + + + + + + upper airways + + + + + + + + + upper and mantle lobes + + + + + + + + + upper limits + + + + + + + + + upper lobar site + + + + + + + + + upper lobes + upper lobe + + + + + + + + + urgent URO-CT request + + + + + + + + + used outside the pulmonary stenosis + + + + + + + + + valid peristalsis + + + + + + + + + variation of the findings + + + + + + + + + veiling on the left + + + + + + + + + venous trunk + + + + + + + + + Venturi patient + + + + + + + + + verifiable contact with subjects + + + + + + + + + very high D-dimer values + + + + + + + + + very high values + + + + + + + + + viral infection pneumonia patients + + + + + + + + + viral interstitial disease + + + + + + + + + Voluntary home quarantine patient returning + + + + + + + + + vomiting and epigastralgia + + + + + + + + + Watchful patient + + + + + + + + + week ago + + + + + + + + + week before presenting + + + + + + + + + week of hospitalization + + + + + + + + + white arrows + + + + + + + + + white blood count + + + + + + + + + widespread areas + + + + + + + + + widespread background + + + + + + + + + widespread background grinding of lung density + + + + + + + + + widespread peribronchial distribution + + + + + + + + + within the large branches + + + + + + + + + without administration + + + + + + + + + without comorbidity + + + + + + + + + without evidence of + + + + + + + + + without fever + + + + + + + + + without intravenous administration + + + + + + + + + without intravenous administration of contrast medium + + + + + + + + + without parenchymal consolidation + + + + + + + + + without personal protective equipment + + + + + + + + + without pleural effusion + + + + + + + + + without significant + + + + + + + + + without significant images + + + + + + + + + works in a company + + + + + + + + + worsening respiratory exchanges + + + + + + + + + worsens its clinical conditions + + + + + + + + + Worthy of diagnostic examination + + + + + + + + + x-ray check + + + + + + + + + X-ray detection + + + + + + + + + X-ray examination is completed + + + + + + + + + X-ray examination shows + + + + + + + + + X-ray finding + + + + + + + + + X-ray investigation + + + + + + + + + year-old female cardiac + + + + + + + + + year-old male diabetic + + + + + + + + + year-old male teenager + + + + + + + + Number concepts + + + + + + + + + one + 1 + + + + + + + + + two + 2 + + + + + + + + + three + 3 + + + + + + + + + four + 4 + + + + + + + + + five + 5 + + + + + + + + + six + 6 + + + + + + + + + seven + 7 + + + + + + + + + eight + 8 + + + + + + + + + nine + 9 + + + + + + + + + ten + 10 + + + + + + + + + eleven + 11 + + + + + + + + + twelve + 12 + + + + + + + + + thirteen + 13 + + + + + + + + + fourteen + 14 + + + + + + + + + fifteen + 15 + + + + + + + + + sixteen + 16 + + + + + + + + + seventeen + 17 + + + + + + + + + eighteen + 18 + + + + + + + + + nineteen + 19 + + + + + + + + + twenty + 20 + + + + + + + + + twenty-one + 21 + + + + + + + + + twenty-two + 22 + + + + + + + + + twenty-three + 23 + + + + + + + + + twenty-four + 24 + + + + + + + + + twenty-five + 25 + + + + + + + + + twenty-six + 26 + + + + + + + + + twenty-seven + 27 + + + + + + + + + twenty-eight + 28 + + + + + + + + + twenty-nine + 29 + + + + + + + + + thirty + 30 + + + + + + + + + thirty-one + 31 + + + + + + + + + thirty-two + 32 + + + + + + + + + thirty-three + 33 + + + + + + + + + thirty-four + 34 + + + + + + + + + thirty-five + 35 + + + + + + + + + thirty-six + 36 + + + + + + + + + thirty-seven + 37 + + + + + + + + + thirty-eight + 38 + + + + + + + + + thirty-nine + 39 + + + + + + + + + forty + 40 + + + + + + + + + forty-one + 41 + + + + + + + + + forty-two + 42 + + + + + + + + + forty-three + 43 + + + + + + + + + forty-four + 44 + + + + + + + + + forty-five + 45 + + + + + + + + + forty-six + 46 + + + + + + + + + forty-seven + 47 + + + + + + + + + forty-eight + 48 + + + + + + + + + forty-nine + 49 + + + + + + + + + fifty + 50 + + + + + + + + + fifty-one + 51 + + + + + + + + + fifty-two + 52 + + + + + + + + + fifty-three + 53 + + + + + + + + + fifty-four + 54 + + + + + + + + + fifty-five + 55 + + + + + + + + + fifty-six + 56 + + + + + + + + + fifty-seven + 57 + + + + + + + + + fifty-eight + 58 + + + + + + + + + fifty-nine + 59 + + + + + + + + + sixty + 60 + + + + + + + + + sixty-one + 61 + + + + + + + + + sixty-two + 62 + + + + + + + + + sixty-three + 63 + + + + + + + + + sixty-four + 64 + + + + + + + + + sixty-five + 65 + + + + + + + + + sixty-six + 66 + + + + + + + + + sixty-seven + 67 + + + + + + + + + sixty-eight + 68 + + + + + + + + + sixty-nine + 69 + + + + + + + + + seventy + 70 + + + + + + + + + seventy-one + 71 + + + + + + + + + seventy-two + 72 + + + + + + + + + seventy-three + 73 + + + + + + + + + seventy-four + 74 + + + + + + + + + seventy-five + 75 + + + + + + + + + seventy-six + 76 + + + + + + + + + seventy-seven + 77 + + + + + + + + + seventy-eight + 78 + + + + + + + + + seventy-nine + 79 + + + + + + + + + eighty + 80 + + + + + + + + + eighty-one + 81 + + + + + + + + + eighty-two + 82 + + + + + + + + + eighty-three + 83 + + + + + + + + + eighty-four + 84 + + + + + + + + + eighty-five + 85 + + + + + + + + + eighty-six + 86 + + + + + + + + + eighty-seven + 87 + + + + + + + + + eighty-eight + 88 + + + + + + + + + eighty-nine + 89 + + + + + + + + + ninety + 90 + + + + + + + + + ninety-one + 91 + + + + + + + + + ninety-two + 92 + + + + + + + + + ninety-three + 93 + + + + + + + + + ninety-four + 94 + + + + + + + + + ninety-five + 95 + + + + + + + + + ninety-six + 96 + + + + + + + + + ninety-seven + 97 + + + + + + + + + ninety-eight + 98 + + + + + + + + + ninety-nine + 99 + + + + + + + + + one hundred + 100 + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + https://www.wikidata.org/wiki/Q12073283 + Yale New Haven Hospital + + + + + + + + + example to be eventually removed + example to be eventually removed + + + + + + + + + + The term was used in an attempt to structure part of the ontology but in retrospect failed to do a good job + Person:Alan Ruttenberg + failed exploratory term + + + + + + + + + + metadata complete + Class has all its metadata, but is either not guaranteed to be in its final location in the asserted IS_A hierarchy or refers to another class that is not complete. + metadata complete + + + + + + + + + + organizational term + term created to ease viewing/sort terms for development purpose, and will not be included in a release + PERSON:Alan Ruttenberg + organizational term + + + + + + + + + + ready for release + + Class has undergone final review, is ready for use, and will be included in the next release. Any class lacking "ready_for_release" should be considered likely to change place in hierarchy, have its definition refined, or be obsoleted in the next release. Those classes deemed "ready_for_release" will also derived from a chain of ancestor classes that are also "ready_for_release." + ready for release + + + + + + + + + + metadata incomplete + Class is being worked on; however, the metadata (including definition) are not complete or sufficiently clear to the branch editors. + metadata incomplete + + + + + + + + + + uncurated + Nothing done yet beyond assigning a unique class ID and proposing a preferred term. + uncurated + + + + + + + + + + pending final vetting + + All definitions, placement in the asserted IS_A hierarchy and required minimal metadata are complete. The class is awaiting a final review by someone other than the term editor. + pending final vetting + + + + + + + + + + placeholder removed + + + + + + + + + An editor note should explain what were the merged terms and the reason for the merge. + terms merged + + + + + + + + + This is to be used when the original term has been replaced by a term imported from an other ontology. An editor note should indicate what is the URI of the new term to use. + term imported + + + + + + + + + This is to be used when a term has been split in two or more new terms. An editor note should indicate the reason for the split and indicate the URIs of the new terms created. + term split + + + + + + + + + to be replaced with external ontology term + Terms with this status should eventually replaced with a term from another ontology. + Alan Ruttenberg + group:OBI + to be replaced with external ontology term + + + + + + + + + requires discussion + + A term that is metadata complete, has been reviewed, and problems have been identified that require discussion before release. Such a term requires editor note(s) to identify the outstanding issues. + Alan Ruttenberg + group:OBI + requires discussion + + + + + + + + axiom holds for all times + + +## Elucidation + +This is used when the statement/axiom is assumed to hold true 'eternally' + +## How to interpret (informal) + +First the "atemporal" FOL is derived from the OWL using the standard +interpretation. This axiom is temporalized by embedding the axiom +within a for-all-times quantified sentence. The t argument is added to +all instantiation predicates and predicates that use this relation. + +## Example + + Class: nucleus + SubClassOf: part_of some cell + + forall t : + forall n : + instance_of(n,Nucleus,t) + implies + exists c : + instance_of(c,Cell,t) + part_of(n,c,t) + +## Notes + +This interpretation is *not* the same as an at-all-times relation + + + axiom holds for all times + + + + + + + + + milligram + A mass unit which is equal to one thousandth of a gram or 10^[-3] g. + mg + + milligram + + + + + + + + + Intervet has merged with Schering-Plough Animal Health and become Intervet/Schering-Plough Animal Health™ (YL.) + YH + http://www.intervet.com/ + Intervet + + + + + + + + + YH + http://www.wyeth.com/ + Wyeth Pharmaceuticals Inc + + + + + + + + + YH + http://www.pfizerah.com/ + Pfizer Animal Health + + + + + + + + + YH + http://www.merial.com/ + Merial, Inc + + + + + + + + + YL + Vaccicel, Inc. has a location in Belton, TX. Active officers include Andre Menchu, Andres Menchu, Kathryn M Baker, Katheryn Becker and Andres Menches. Vaccicel, Inc. filed as a Domestic For-Profit Corporation on Tuesday, August 22, 1995 in the state of Texas and is currently active. Andres Menchu serves as the registered agent for this organization.The company's line of business includes Mfg Research & Development Veterinary Bacterial Vaccines. +(http://www.corporationwiki.com/Texas/Belton/vaccicel-inc/34296230.aspx) + VacciCel, Inc. + + + + + + + + en + + + + + + + + + + + + Adam Goldstein + Alan Ruttenberg + Albert Goldfain + Barry Smith + Bjoern Peters + Carlo Torniai + Chris Mungall + Chris Stoeckert + Christian A. Boelling + Darren Natale + David Osumi-Sutherland + Gwen Frishkoff + Holger Stenzhorn + James A. Overton + James Malone + Jennifer Fostel + Jie Zheng + Jonathan Rees + Larisa Soldatova + Lawrence Hunter + Mathias Brochhausen + Matt Brush + Melanie Courtot + Michel Dumontier + Paolo Ciccarese + Pat Hayes + Philippe Rocca-Serra + Randy Dipert + Ron Rudnicki + Satya Sahoo + Sivaram Arabandi + Werner Ceusters + William Duncan + William Hogan + Yongqun (Oliver) He + http://creativecommons.org/licenses/by/4.0/ + An information artifact is, loosely, a dependent continuant or its bearer that is created as the result of one or more intentional processes. Examples: uniprot, the english language, the contents of this document or a printout of it, the temperature measurements from a weather balloon. For more information, see the project home page at https://github.com/information-artifact-ontology/IAO + IDs allocated to related efforts: PNO: IAO_0020000-IAO_0020999, D_ACTS: IAO_0021000-IAO_0021999 + IDs allocated to subdomains of IAO. pno.owl: IAO_0020000-IAO_0020999, d-acts.owl: IAO_0021000-IAO_0021999 + The Information Artifact Ontology (IAO) is licensed under the Creative Commons Attribution License (CC-BY) version 4.0. You are free to share (copy and redistribute the material in any medium or format) and adapt (remix, transform, and build upon the material) for any purpose, even commercially. for any purpose, even commercially. The licensor cannot revoke these freedoms as long as you follow the license terms. You must give appropriate credit (by using the original ontology IRI for the whole ontology and original term IRIs for individual terms), provide a link to the license, and indicate if any changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. For more information see http://www.obofoundry.org/docs/Citation.html + This version of the ontology is the merge of all its imports and has added axioms inferred by an OWL reasoner + + + + + + + + + en + Ontology for Biomedical Investigations + Advisors for this project come from the IFOMIS group, Saarbruecken and from the Co-ODE group in Manchester + Alan Ruttenberg + Allyson Lister + Barry Smith + Bill Bug + Bjoern Peters + Carlo Torniai + Chris Mungall + Chris Stoeckert + Chris Taylor + Christian Bolling + Cristian Cocos + Daniel Rubin + Daniel Schober + Dawn Field + Dirk Derom + Elisabetta Manduchi + Eric Deutsch + Frank Gibson + Gilberto Fragoso + Helen C. Causton + Helen Parkinson + Holger Stenzhorn + James A. Overton + James Malone + Jay Greenbaum + Jeffrey Grethe + Jennifer Fostel + Jessica Turner + Jie Zheng + Joe White + John Westbrook + Kevin Clancy + Larisa Soldatova + Lawrence Hunter + Liju Fan + Luisa Montecchi + Matthew Brush + Matthew Pocock + Melanie Courtot + Melissa Haendel + Mervi Heiskanen + Monnie McGee + Norman Morrison + Philip Lord + Philippe Rocca-Serra + Pierre Grenon + Richard Bruskiewich + Richard Scheuermann + Robert Stevens + Ryan R. Brinkman + Stefan Wiemann + Susanna-Assunta Sansone + Tanya Gray + Tina Hernandez-Boussard + Trish Whetzel + Yongqun He + 2009-07-31 + The Ontology for Biomedical Investigations (OBI) is build in a collaborative, international effort and will serve as a resource for annotating biomedical investigations, including the study design, protocols and instrumentation used, the data generated and the types of analysis performed on the data. This ontology arose from the Functional Genomics Investigation Ontology (FuGO) and will contain both terms that are common to all biomedical investigations, including functional genomics investigations and those that are more domain specific. + OWL-DL + An ontology for the annotation of biomedical and functional genomics experiments. + http://creativecommons.org/licenses/by/4.0/ + Ontology for Biomedical Investigations + Please cite the OBI consortium http://purl.obolibrary.org/obo/obi where traditional citation is called for. However it is adequate that individual terms be attributed simply by use of the identifying PURL for the term, in projects that refer to them. + 2019-11-12 + 2020-04-23 + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + NDF-RT2 [Public Edition] + NDF-RT2 Public + + + + C26 + CI_ChemClass + + + C30 + CI_MoA + + + + C22 + + CI_PE + + + CI_with + + C36 + + + Display_Name + C264 + + + + FDA_UNII + + C12847068852884 + + + + Level + C98 + + + + C176 + MeSH_CUI + + + MeSH_DUI + + C134 + + + C142 + + MeSH_Definition + + + C287 + + MeSH_Name + + + 3683 + N0000000001 + C0013227 + + Pharmaceutical Preparations + C176 + Pharmaceutical Preparations + + + Chemical Ingredients [Chemical/Ingredient] + 991181 + C178 + + N0000000002 + Chemical Ingredients + + + C180 + C1373163 + Clinical Kinetics [PK] + 1030853 + N0000000003 + Clinical Kinetics + + + + Diseases, Manifestations or Physiologic States [Disease/Finding] + Diseases, Manifestations or Physiologic States + 989348 + N0000000004 + + C1373233 + C182 + + + 988640 + + Intestinal Metabolism + Intestinal Metabolism [PK] + N0000000025 + C228 + C1373177 + + + Hepatic Metabolism + Hepatic Metabolism [PK] + C230 + + C1373178 + 984512 + N0000000026 + + + N0000000042 + C1373187 + C262 + + Renal Excretion + Renal Excretion [PK] + 986666 + + + C308 + C1372991 + + Physiochemical Activity [MoA] + 989958 + Physiochemical Activity + N0000000065 + + + D000317 + Adrenergic alpha-Antagonists + Alpha-adrenergic Blocker + + C2756989 + N0000000099 + Adrenergic alpha-Antagonists [MoA] + Adrenergic alpha-Antagonists + C376 + 1023426 + + + C382 + Norepinephrine Uptake Inhibitors + 989028 + N0000000102 + Norepinephrine Uptake Inhibitors [MoA] + Adrenergic Uptake Inhibitors + D018759 + + C2757023 + + + C2757052 + Serotonin Antagonists [MoA] + D012702 + 993156 + C438 + N0000000130 + Serotonin Antagonists + Serotonin Antagonists + + + + D004791 + Enzyme Inhibitors [MoA] + C444 + N0000000133 + C2756995 + + Enzyme Inhibitors + 1032544 + Enzyme Inhibitors + + + Monoamine Oxidase Inhibitors [MoA] + Monoamine Oxidase Inhibitors + MAOI + N0000000184 + + Monoamine Oxidase Inhibitors + D008996 + 992698 + C2756978 + C546 + + + C564 + 988382 + N0000000193 + Ion Channel Interactions [MoA] + + C1373047 + Ion Channel Interactions + + + Dopamine Receptor Interactions [MoA] + N0000000203 + C1373039 + 985948 + Dopamine Receptor Interactions + + C584 + + + + N0000000223 + 986459 + Cellular or Molecular Interactions + C1373094 + C624 + Cellular or Molecular Interactions [MoA] + + + C2757009 + 993166 + N0000000233 + Nucleic Acid Synthesis Inhibitors + Nucleic Acid Synthesis Inhibitors + C644 + D019384 + Nucleic Acid Synthesis Inhibitors [MoA] + + + + Na-K ATPases Interactions [MoA] + 987976 + N0000000238 + C1373085 + Na-K ATPases Interactions + C654 + + + + C0000768 + Deformities + Congenital Defects + Birth Defects + C706 + N0000000264 + 276720006 + Congenital Abnormalities + Malformations of organs or body parts during development in utero. + Congenital Abnormalities + 1021840 + M0000013 + 276655000 + 276654001 + Abnormalities, Congenital + D000013 + + Congenital Abnormalities [Disease/Finding] + Defects, Congenital + + + Miscarriage + C714 + Spontaneous Abortion + Abortion, Spontaneous [Disease/Finding] + 17369002 + Abortion, Spontaneous + M0000024 + Expulsion of the product of FERTILIZATION before completing the term of GESTATION and without deliberate interference. + C0000786 + Abortion, Spontaneous + 198631006 + 1026142 + N0000000268 + + D000022 + + + Acne Vulgaris [Disease/Finding] + C754 + + M0000231 + C0001144 + 88616000 + Acne Vulgaris + 1024380 + D000152 + A chronic disorder of the pilosebaceous apparatus associated with an increase in sebum secretion. It is characterized by open comedones (blackheads), closed comedones (whiteheads), and pustular nodules. The cause is unknown, but heredity and age are predisposing factors. + N0000000288 + Acne Vulgaris + Acne + + + 62479008 + An acquired defect of cellular immunity associated with infection by the human immunodeficiency virus (HIV), a CD4-positive T-lymphocyte count under 200 cells/microliter or less than 14% of total lymphocytes, and increased susceptibility to opportunistic infections and malignant neoplasms. Clinical manifestations also include emaciation (wasting) and dementia. These elements reflect criteria for AIDS as defined by the CDC in 1993. + + Acquired Immune Deficiency Syndrome + C760 + Immunodeficiency Syndrome, Acquired + Immunologic Deficiency Syndrome, Acquired + Acquired Immuno-Deficiency Syndrome + D000163 + Acquired Immunodeficiency Syndrome [Disease/Finding] + N0000000291 + AIDS + C0001175 + M0000245 + Acquired Immunodeficiency Syndrome + Acquired Immunodeficiency Syndrome + 1022762 + + + 111910009 + Amebiasis + N0000000365 + 105637008 + Infection with any of various amebae. It is an asymptomatic carrier state in most individuals, but diseases ranging from chronic, mild diarrhea to fulminant dysentery may occur. + + D000562 + Amebiasis + 388759003 + Amoebiasis + 1023982 + C0002438 + M0000878 + Amebiasis [Disease/Finding] + C908 + + + 1024010 + M0000887 + N0000000368 + C0002453 + 14302001 + D000568 + Amenorrhea + C914 + Amenorrhea + Amenorrhea [Disease/Finding] + Absence of menstruation. + + + + M0001053 + 17602002 + Amyloidosis + A group of sporadic, familial and/or inherited, degenerative, and infectious disease processes, linked by the common theme of abnormal protein folding and deposition of AMYLOID. As the amyloid deposits enlarge they displace normal tissue structures, causing disruption of function. Various signs and symptoms depend on the location and size of the deposits. + 1024175 + N0000000375 + Amyloidosis + Amyloidosis [Disease/Finding] + D000686 + C928 + C0002726 + + + + C0002871 + 1024481 + A reduction in the number of circulating erythrocytes or in the quantity of hemoglobin. + Anemia [Disease/Finding] + D000740 + + M0001119 + 271737000 + N0000000384 + C946 + Anemia + 267531008 + Anemia + + + C1048 + Anxiety Disorders [Disease/Finding] + 1023219 + Anxiety Disorders + Persistent and disabling ANXIETY. + Anxiety Disorders + + M0001533 + 197480006 + N0000000435 + C0003469 + D001008 + + + Arrythmia + C1116 + C0003811 + Arrhythmias, Cardiac + Arrhythmias, Cardiac + Cardiac Arrhythmias + M0001715 + Cardiac Arrhythmia + Any disturbances of the normal rhythmic beating of the heart or MYOCARDIAL CONTRACTION. Cardiac arrhythmias can be classified by the abnormalities in HEART RATE, disorders of electrical impulse generation, or impulse conduction. + Cardiac Dysrhythmia + N0000000469 + + Arrhythmias, Cardiac [Disease/Finding] + 1023395 + D001145 + 195107004 + Arrhythmia + + + N0000000478 + Arthritis + D001168 + C1134 + 1023652 + C0003864 + Arthritis [Disease/Finding] + M0001741 + Arthritis + + 3723001 + + + Arthritis, Rheumatoid + A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated. + D001172 + Arthritis, Rheumatoid [Disease/Finding] + 69896004 + N0000000482 + C1142 + Rheumatoid Arthritis + M0001750 + + Arthritis, Rheumatoid + C0003873 + 1023050 + + + + M0001785 + Infection by nematodes of the genus ASCARIS. Ingestion of infective eggs causes diarrhea and pneumonitis. Its distribution is more prevalent in areas of poor sanitation and where human feces are used for fertilizer. + Ascariasis [Disease/Finding] + D001196 + C0003950 + Ascariasis + N0000000488 + 2435008 + C1154 + Ascariasis + 1022405 + + + C0004238 + Auricular Fibrillation + Atrial Fibrillation + Abnormal cardiac rhythm that is characterized by rapid, uncoordinated firing of electrical impulses in the upper chambers of the heart (HEART ATRIA). In such case, blood cannot be effectively pumped into the lower chambers of the heart (HEART VENTRICLES). It is caused by abnormal impulse generation. + C1192 + Atrial Fibrillation + 49436004 + D001281 + N0000000507 + M0001926 + 1023706 + + Atrial Fibrillation [Disease/Finding] + + + C0004239 + Auricular Flutter + + Atrial Flutter [Disease/Finding] + 5370000 + Rapid, irregular atrial contractions caused by a block of electrical impulse conduction in the right atrium and a reentrant wave front traveling up the inter-atrial septum and down the right atrial free wall or vice versa. Unlike ATRIAL FIBRILLATION which is caused by abnormal impulse generation, typical atrial flutter is caused by abnormal impulse conduction. As in atrial fibrillation, patients with atrial flutter cannot effectively pump blood into the lower chambers of the heart (HEART VENTRICLES). + N0000000508 + D001282 + C1194 + Atrial Flutter + Atrial Flutter + 985206 + M0001927 + + + M0001989 + N0000000514 + C0004364 + D001327 + Autoimmune Diseases + C1206 + Disorders that are characterized by the production of antibodies that react with host tissues or immune effector cells that are autoreactive to endogenous peptides. + Autoimmune Diseases [Disease/Finding] + Autoimmune Diseases + + 85828009 + 1026092 + + + 186335000 + D001424 + 301811001 + Infection, Bacterial + Bacterial Infection + Bacterial Infections + 1022614 + C0004623 + M0002126 + Bacterial Infections + 87628006 + Infections, Bacterial + C1226 + N0000000524 + + Infections by bacteria, general or unspecified. + Bacterial Infections [Disease/Finding] + + + D001523 + Mental Disorders [Disease/Finding] + Psychiatric illness or diseases manifested by breakdowns in the adaptational process expressed primarily as abnormalities of thought, feeling, and behavior producing either distress or impairment of function. + C0004936 + C1254 + N0000000538 + Mental Disorders + M0002289 + 1022308 + + 74732009 + Mental Disorders + + + M0002634 + 399072004 + Blocked urine flow through the bladder neck, the narrow internal urethral opening at the base of the URINARY BLADDER. Narrowing or strictures of the URETHRA can be congenital or acquired. It is often observed in males with enlarged PROSTATE glands. + Bladder Outlet Obstruction + D001748 + Urinary Bladder Neck Obstruction [Disease/Finding] + Urinary Bladder Neck Obstruction + C0005694 + C1304 + Bladder Neck Obstruction + + N0000000563 + 1023806 + Urinary Bladder Neck Obstruction + + + An advanced phase of chronic myelogenous leukemia, characterized by a rapid increase in the proportion of immature white blood cells (blasts) in the blood and bone marrow to greater than 30%. + Blast Crisis + Blast Crisis + 413656006 + 1024400 + C0005699 + Blast Crisis [Disease/Finding] + + D001752 + M0002638 + C1310 + N0000000566 + Blast Phase + + + Blood Coagulation Disorders + D001778 + C1328 + Blood Coagulation Disorders + N0000000575 + 1022276 + 64779008 + Coagulation Disorders, Blood + Blood Coagulation Disorders [Disease/Finding] + + C0005779 + M0002683 + Disorders, Blood Coagulation + Hemorrhagic and thrombotic disorders that occur as a consequence of abnormalities in blood coagulation due to a variety of factors such as COAGULATION PROTEIN DISORDERS; BLOOD PLATELET DISORDERS; BLOOD PROTEIN DISORDERS or nutritional conditions. + 362970003 + + + Disorders caused by abnormalities in platelet count or function. + Blood Platelet Disorders + Thrombocytopathy + D001791 + M0002703 + N0000000577 + C1332 + Blood Platelet Disorders [Disease/Finding] + 1025348 + C0005818 + 22716005 + Blood Platelet Disorders + + + + Chronic Encephalopathy + 1024348 + N0000000603 + Brain Damage, Chronic + Encephalopathy, Chronic + D001925 + M0002872 + + C0006109 + Brain Damage, Chronic [Disease/Finding] + Brain Damage, Chronic + C1384 + 78689005 + A condition characterized by long-standing brain dysfunction or damage, usually of three months duration or longer. Potential etiologies include BRAIN INFARCTION; certain NEURODEGENERATIVE DISORDERS; CRANIOCEREBRAL TRAUMA; ANOXIA, BRAIN; ENCEPHALITIS; certain NEUROTOXICITY SYNDROMES; metabolic disorders (see BRAIN DISEASES, METABOLIC); and other conditions. + + + 986258 + Intracranial CNS Disorders + N0000000605 + Brain Diseases + Brain Diseases + C0006111 + M0002874 + + Intracranial Central Nervous System Disorders + 81308009 + Pathologic conditions affecting the BRAIN, which is composed of the intracranial components of the CENTRAL NERVOUS SYSTEM. This includes (but is not limited to) the CEREBRAL CORTEX; intracranial white matter; BASAL GANGLIA; THALAMUS; HYPOTHALAMUS; BRAIN STEM; and CEREBELLUM. + D001927 + Central Nervous System Intracranial Disorders + C1388 + Brain Disorders + CNS Disorders, Intracranial + Central Nervous System Disorders, Intracranial + Encephalon Diseases + Brain Diseases [Disease/Finding] + + + C1396 + Neoplasms, Brain + D001932 + 189537005 + Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain. + C0006118 + N0000000609 + Brain Neoplasms + + Brain Neoplasms + 1025641 + 126952004 + Brain Neoplasms [Disease/Finding] + Brain Tumors + M0002885 + + + D001943 + Tumors or cancer of the human BREAST. + Breast Neoplasms + Breast Neoplasms + Breast Tumors + C1402 + Neoplasms, Breast + M0002910 + Breast Neoplasms [Disease/Finding] + Tumors, Breast + N0000000612 + + C1458155 + 1023282 + 126926005 + + + Moniliasis, Vulvovaginal + Candidiasis, Vulvovaginal + Candidiasis, Vulvovaginal + D002181 + M0003262 + 1024776 + 72605008 + + N0000000654 + Infection of the VULVA and VAGINA with a fungus of the genus CANDIDA. + Candidiasis, Vulvovaginal [Disease/Finding] + C1486 + C0700345 + + + 1025619 + Renal Cell Carcinoma + Carcinoma, Renal Cell [Disease/Finding] + C0007134 + M0003442 + Renal Cell Cancer + + 188251003 + Adenocarcinoma, Renal Cell + Carcinoma, Renal Cell + Carcinoma, Renal Cell + A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma. + D002292 + C1534 + N0000000678 + Nephroid Carcinoma + + + Cardiac Output, Low + D002303 + C0007166 + Low Cardiac Output + 1024618 + + C1544 + Cardiac Output, Low + Cardiac Output, Low [Disease/Finding] + N0000000683 + 86318000 + A state of subnormal or depressed cardiac output at rest or during stress. It is a characteristic of CARDIOVASCULAR DISEASES, including congenital, valvular, rheumatic, hypertensive, coronary, and cardiomyopathic. The serious form of low cardiac output is characterized by marked reduction in STROKE VOLUME, and systemic vasoconstriction resulting in cold, pale, and sometimes cyanotic extremities. + M0003453 + + + M0003464 + 233873004 + Cardiomyopathy, Hypertrophic [Disease/Finding] + A form of CARDIAC MUSCLE disease, characterized by left and/or right ventricular hypertrophy (HYPERTROPHY, LEFT VENTRICULAR; HYPERTROPHY, RIGHT VENTRICULAR), frequent asymmetrical involvement of the HEART SEPTUM, and normal or reduced left ventricular volume. Risk factors include HYPERTENSION; AORTIC STENOSIS; and gene MUTATION; (FAMILIAL HYPERTROPHIC CARDIOMYOPATHY). + + N0000000687 + Cardiomyopathy, Hypertrophic + D002312 + C1552 + C0007194 + 45227007 + Cardiomyopathy, Hypertrophic + 1024263 + Cardiomyopathy, Hypertrophic Obstructive + + + C1556 + 105980002 + Cardiovascular Diseases + + Cardiovascular Diseases + N0000000689 + Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM. + 49601007 + Cardiovascular Diseases [Disease/Finding] + C0007222 + D002318 + 1022075 + M0003473 + + + Hemorrhage, Cerebral + C1620 + Cerebral Parenchymal Hemorrhage + C2937358 + M0003884 + + 73020009 + Cerebral Hemorrhage [Disease/Finding] + N0000000721 + 1508000 + Cerebral Hemorrhage + Intracerebral Hemorrhage + Hemorrhage, Cerebrum + Bleeding into one or both CEREBRAL HEMISPHERES including the BASAL GANGLIA and the CEREBRAL CORTEX. It is often associated with HYPERTENSION and CRANIOCEREBRAL TRAUMA. + D002543 + Cerebral Hemorrhage + 1103691 + 274100004 + Brain Hemorrhage, Cerebral + + + Chlamydia Infections + Infections, Chlamydia + D002690 + N0000000754 + + C0008149 + Infections with bacteria of the genus CHLAMYDIA. + 105629000 + Chlamydia Infections [Disease/Finding] + C1686 + Chlamydia Infections + M0004107 + 1023626 + + + Clostridium Infections + C1770 + N0000000796 + D003015 + + Infections with bacteria of the genus CLOSTRIDIUM. + Clostridium Infections [Disease/Finding] + 989684 + C0009062 + Clostridium Infections + 56688005 + M0004637 + Infections, Clostridium + + + C0009319 + N0000000806 + + 64226004 + C1790 + D003092 + Inflammation of the COLON section of the large intestine (INTESTINE, LARGE), usually with symptoms such as DIARRHEA (often with blood and mucus), ABDOMINAL PAIN, and FEVER. + M0004770 + Colitis + Colitis [Disease/Finding] + 1024342 + Colitis + + + Ulcerative Colitis + + 64766004 + 1025158 + C0009324 + Colitis, Ulcerative [Disease/Finding] + M0004771 + N0000000807 + Inflammation of the COLON that is predominantly confined to the MUCOSA. Its major symptoms include DIARRHEA, rectal BLEEDING, the passage of MUCUS, and ABDOMINAL PAIN. + Colitis, Ulcerative + D003093 + C1792 + Colitis, Ulcerative + + + 128524007 + Colonic Diseases + + D003108 + Colonic Diseases [Disease/Finding] + Colonic Diseases + M0004814 + 1025915 + Pathological processes in the COLON region of the large intestine (INTESTINE, LARGE). + N0000000811 + C1800 + C0009373 + + + Comatose + N0000000819 + 988251 + Coma [Disease/Finding] + M0004841 + Coma + C1816 + + C0009421 + 371632003 + D003128 + A profound state of unconsciousness associated with depressed cerebral activity from which the individual cannot be aroused. Coma generally occurs when there is dysfunction or injury involving both cerebral hemispheres or the brain stem RETICULAR FORMATION. + Coma + + + Allergic Conjunctivitis + C1848 + Conjunctivitis, Allergic + M0005017 + N0000000835 + + Conjunctivitis, Allergic [Disease/Finding] + Conjunctivitis, Atopic + 984750 + D003233 + Conjunctivitis, Allergic + Conjunctivitis due to hypersensitivity to various allergens. + 231854006 + C0009766 + + + 105969002 + D003240 + M0005027 + C1856 + C0009782 + 986518 + + Connective Tissue Diseases + N0000000839 + A heterogeneous group of disorders, some hereditary, others acquired, characterized by abnormal structure or function of one or more of the elements of connective tissue, i.e., collagen, elastin, or the mucopolysaccharides. + Connective Tissue Diseases [Disease/Finding] + Connective Tissue Diseases + + + 1022104 + Constipation + Constipation + Constipation [Disease/Finding] + + 14760008 + D003248 + Infrequent or difficult evacuation of FECES. These symptoms are associated with a variety of causes, including low DIETARY FIBER intake, emotional or nervous disturbances, systemic and structural disorders, drug-induced aggravation, and infections. + C0009806 + M0005043 + C1860 + N0000000841 + + + Cryoglobulinemia + 1027021 + A condition characterized by the presence of abnormal quantities of CRYOGLOBULINS in the blood. Upon cold exposure, these abnormal proteins precipitate into the microvasculature leading to restricted blood flow in the exposed areas. + M0005376 + D003449 + 30911005 + Cryoglobulinemia [Disease/Finding] + C0010403 + Cryoglobulinemia + N0000000879 + + C1936 + + + + N0000000882 + 1026025 + Cryptosporidiosis [Disease/Finding] + Cryptosporidiosis + C1942 + M0005385 + Cryptosporidiosis + Intestinal infection with organisms of the genus CRYPTOSPORIDIUM. It occurs in both animals and humans. Symptoms include severe DIARRHEA. + D003457 + C0010418 + 240370009 + 58777003 + + + C0011581 + + Depressive Disorder + D003866 + M0006033 + 1026289 + N0000000938 + Neurosis, Depressive + Depressive Disorder + C2054 + Depressive Disorder [Disease/Finding] + 35489007 + An affective disorder manifested by either a dysphoric mood or loss of interest or pleasure in usual activities. The mood disturbance is prominent and relatively persistent. + + + C0011991 + + N0000000963 + An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight. + Diarrhea [Disease/Finding] + C2104 + 267060006 + 62315008 + 1022243 + D003967 + Diarrhea + 398032003 + Diarrhea + M0006212 + + + C0012242 + 53619000 + Diseases in any part of the GASTROINTESTINAL TRACT or the accessory organs (LIVER; BILIARY TRACT; PANCREAS). + Digestive System Diseases [Disease/Finding] + Digestive System Diseases + + Digestive System Diseases + M0006374 + C2124 + 1023342 + N0000000973 + D004066 + + + D004342 + Drug Hypersensitivity + N0000000999 + Hypersensitivity, Drug + 416093006 + 1024684 + C0013182 + Drug Allergy + Drug Hypersensitivity [Disease/Finding] + + Immunologically mediated adverse reactions to medicinal substances used legally or illegally. + Allergy, Drug + C2176 + Drug Hypersensitivity + M0006829 + 416098002 + + + 1022029 + Toxicity, Drug + D004362 + Drug Toxicity + 7895008 + C2178 + N0000001000 + Manifestations of the adverse effects of drugs administered therapeutically or in the course of diagnostic techniques. It does not include accidental or intentional poisoning for which specific headings are available. + Drug Toxicity + M0006855 + + Drug Toxicity [Disease/Finding] + C0013221 + + + N0000001005 + D004378 + + Duodenal Diseases + M0006881 + 1022796 + C0013289 + Pathological conditions in the DUODENUM region of the small intestine (INTESTINE, SMALL). + C2188 + 52182008 + Duodenal Diseases [Disease/Finding] + Duodenal Diseases + + + C1527298 + Dysentery, Bacillary + N0000001018 + D004405 + M0006916 + C2214 + DYSENTERY caused by gram-negative rod-shaped enteric bacteria (ENTEROBACTERIACEAE), most often by the genus SHIGELLA. Shigella dysentery, Shigellosis, is classified into subgroups according to syndrome severity and the infectious species. Group A: SHIGELLA DYSENTERIAE (severest); Group B: SHIGELLA FLEXNERI; Group C: SHIGELLA BOYDII; and Group D: SHIGELLA SONNEI (mildest). + Dysentery, Bacillary + Dysentery, Bacillary [Disease/Finding] + 1027736 + 274081004 + + + + C2302 + 1029275 + Elephantiasis + Elephantiasis [Disease/Finding] + C0013882 + Elephantiasis + 240820001 + D004604 + Hypertrophy and thickening of the tissues from any cause. Elephantiasis caused by filarial infection is ELEPHANTIASIS, FILARIAL. (From Dorland, 27th ed) + + N0000001062 + M0007229 + + + Endocarditides, Bacterial + Inflammation of the ENDOCARDIUM caused by BACTERIA that entered the bloodstream. The strains of bacteria vary with predisposing factors, such as CONGENITAL HEART DEFECTS; HEART VALVE DISEASES; HEART VALVE PROSTHESIS IMPLANTATION; or intravenous drug use. + Endocarditis, Bacterial + 301183007 + C2372 + D004697 + Endocarditis, Bacterial [Disease/Finding] + 1021809 + C0014121 + + N0000001097 + M0007393 + Bacterial Endocarditis + Endocarditis, Bacterial + Bacterial Endocarditides + + + 129103003 + Endometriosis + Endometriosis [Disease/Finding] + C0014175 + Endometriosis + 1024249 + C2382 + + M0007413 + A condition in which functional endometrial tissue is present outside the UTERUS. It is often confined to the PELVIS involving the OVARY, the ligaments, cul-de-sac, and the uterovesical peritoneum. + D004715 + N0000001102 + + + D004760 + 1025705 + C0014356 + 43752006 + + Enterocolitis + M0007478 + N0000001109 + Enterocolitis + Enterocolitis [Disease/Finding] + Inflammation of the MUCOSA of both the SMALL INTESTINE and the LARGE INTESTINE. Etiology includes ISCHEMIA, infections, allergic, and immune responses. + C2396 + + + Enterocolitis, Pseudomembranous + D004761 + Enterocolitis, Pseudomembranous + Enterocolitis, Pseudomembranous [Disease/Finding] + C2398 + Pseudomembranous Enterocolitis + C0014358 + N0000001110 + M0007479 + 1025680 + + An acute inflammation of the INTESTINAL MUCOSA that is characterized by the presence of pseudomembranes or plaques in the SMALL INTESTINE (pseudomembranous enteritis) and the LARGE INTESTINE (pseudomembranous colitis). It is commonly associated with antibiotic therapy and CLOSTRIDIUM DIFFICILE colonization. + 397683000 + + + Epilepsy + N0000001126 + + 1021750 + Seizure Disorder + 128613002 + D004827 + C0014544 + M0007564 + Epilepsy + Seizures, Epileptic + Epileptic Seizures + A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313) + 84757009 + C2430 + Epilepsy [Disease/Finding] + + + Cardiospasm + 45564002 + 1023001 + N0000001155 + Esophageal Achalasia + 235630008 + C0014848 + Esophageal Achalasia + C2488 + M0007740 + Achalasia + A motility disorder of the ESOPHAGUS in which the LOWER ESOPHAGEAL SPHINCTER (near the CARDIA) fails to relax resulting in functional obstruction of the esophagus, and DYSPHAGIA. Achalasia is characterized by a grossly contorted and dilated esophagus (megaesophagus). + Achalasia, Esophageal + + Esophageal Achalasia [Disease/Finding] + D004931 + + + N0000001181 + Eye Diseases + Eye Diseases [Disease/Finding] + Eye Diseases + 1023594 + D005128 + 194183009 + M0008088 + C2540 + C0015397 + + + + M0009033 + C0017178 + C2818 + Gastrointestinal Diseases + 119292006 + N0000001320 + 1022118 + Gastrointestinal Diseases [Disease/Finding] + D005767 + Gastrointestinal Diseases + Diseases in any segment of the GASTROINTESTINAL TRACT from ESOPHAGUS to RECTUM. + + + + Tumors or cancer of the GASTROINTESTINAL TRACT, from the MOUTH to the ANAL CANAL. + 1025588 + D005770 + N0000001321 + Gastrointestinal Neoplasms + Gastrointestinal Neoplasms + M0009038 + C2820 + 126768004 + Neoplasms, Gastrointestinal + + C0017185 + Gastrointestinal Neoplasms [Disease/Finding] + + + Gynecologic Diseases + Genital Diseases, Female + Genital Diseases, Female + Female Genital Diseases + 1026095 + 310789003 + 244938009 + C0017411 + Genital Diseases, Female [Disease/Finding] + Pathological processes involving the female reproductive tract (GENITALIA, FEMALE). + D005831 + M0009154 + N0000001323 + C2824 + + + + 58265007 + An infection of the SMALL INTESTINE caused by the flagellated protozoan GIARDIA LAMBLIA. It is spread via contaminated food and water and by direct person-to-person contact. + C2840 + M0009224 + Giardiasis + Giardiasis + + D005873 + Lambliasis + 10679007 + N0000001331 + C0017536 + 988685 + Giardiasis [Disease/Finding] + + + Glomerulonephritis, Focal Sclerosing + A clinicopathological syndrome or diagnostic term for a type of glomerular injury that has multiple causes, primary or secondary. Clinical features include PROTEINURIA, reduced GLOMERULAR FILTRATION RATE, and EDEMA. Kidney biopsy initially indicates focal segmental glomerular consolidation (hyalinosis) or scarring which can progress to globally sclerotic glomeruli leading to eventual KIDNEY FAILURE. + D005923 + Glomerulosclerosis, Focal Segmental [Disease/Finding] + C2884 + 25821008 + Glomerulosclerosis, Focal + + N0000001353 + Glomerulosclerosis, Focal Segmental + Glomerulosclerosis, Focal Segmental + Focal Segmental Glomerulosclerosis + M0009302 + 1026699 + C0017668 + + + Graft-Versus-Host Disease + 234646005 + M0009578 + N0000001384 + C0018133 + C2946 + Graft vs Host Disease [Disease/Finding] + + The clinical entity characterized by anorexia, diarrhea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the GRAFT VS HOST REACTION. + Runt Disease + Homologous Wasting Disease + Graft vs Host Disease + 1024721 + Graft-vs-Host Disease + Graft vs Host Disease + D006086 + + + D006177 + 1022299 + Enlargement of the BREAST in the males, caused by an excess of ESTROGENS. Physiological gynecomastia is normally observed in NEWBORNS; ADOLESCENT; and AGING males. + M0009717 + C2970 + N0000001396 + Gynecomastia [Disease/Finding] + Male Breast Enlargement + C0018418 + + 4754008 + Gynecomastia + Gynecomastia + + + 1021899 + Infections, Hemophilus + C0018482 + Haemophilus Infections + Hemophilus Infections + D006192 + Infections, Haemophilus + Infections with bacteria of the genus HAEMOPHILUS. + N0000001398 + + C2974 + Haemophilus Infections [Disease/Finding] + Haemophilus Infections + 41659003 + M0009740 + + + C3038 + Heart Block + M0009945 + Heart Block [Disease/Finding] + Heart Block + 1023276 + D006327 + Impaired conduction of cardiac impulse that can occur anywhere along the conduction pathway, such as between the SINOATRIAL NODE and the right atrium (SA block) or between atria and ventricles (AV block). Heart blocks can be classified by the duration, frequency, or completeness of conduction block. Reversibility depends on the degree of structural or functional defects. + + N0000001430 + 233916004 + C0018794 + + + Heart Defects, Congenital [Disease/Finding] + Heart Abnormalities + D006330 + Congenital Heart Defect + 1022077 + 204413006 + N0000001431 + C3040 + Developmental abnormalities involving structures of the heart. These defects are present at birth but may be discovered later in life. + Congenital Heart Defects + Abnormality, Heart + Heart Defects, Congenital + C0018798 + M0009950 + Heart Defects, Congenital + Heart Defect, Congenital + Defects, Congenital Heart + + + + Heart Diseases + 56265001 + D006331 + Heart Diseases + Pathological conditions involving the HEART including its structural and functional abnormalities. + C3042 + Cardiac Diseases + C0018799 + Heart Diseases [Disease/Finding] + 1022072 + M0009951 + N0000001432 + + + + 42343007 + D006333 + A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION. + Heart Failure + C3046 + Heart Failure + 1024953 + C0018802 + N0000001434 + M0009953 + Cardiac Failure + Heart Failure [Disease/Finding] + + + + + Helminthiasis + C3074 + M0010007 + Infestation with parasitic worms of the helminth class. + D006373 + Helminthiasis + Helminthiasis [Disease/Finding] + 1021865 + C0018889 + 27601005 + N0000001448 + + + D006391 + 189194008 + Hemangioma + Hemangioma + 400210000 + M0010031 + C3080 + N0000001451 + C0018916 + 987582 + A vascular anomaly due to proliferation of BLOOD VESSELS that forms a tumor-like mass. The common types involve CAPILLARIES and VEINS. It can occur anywhere in the body but is most frequently noticed in the SKIN and SUBCUTANEOUS TISSUE. (from Stedman, 27th ed, 2000) + Hemangioma [Disease/Finding] + + + + D006402 + C3096 + Hematologic Diseases [Disease/Finding] + 191402006 + 1021953 + Hematologic Diseases + 267573000 + M0010044 + Hematologic Diseases + C0018939 + + Disorders of the blood and blood forming tissues. + Blood Diseases + Hematological Diseases + N0000001459 + + + + Hemoglobinopathies + A group of inherited disorders characterized by structural alterations within the hemoglobin molecule. + N0000001472 + C3122 + 80141007 + Hemoglobinopathies + M0010129 + Hemoglobinopathies [Disease/Finding] + 1023547 + D006453 + C0019045 + + + C0019080 + D006470 + + Hemorrhage + M0010152 + Bleeding or escape of blood from a vessel. + N0000001481 + Hemorrhage + 195511004 + 1023287 + C3140 + Bleeding + Hemorrhage [Disease/Finding] + + + C0019087 + Hemorrhagic Diathesis + Hemorrhagic Disorders + D006474 + C3148 + M0010157 + + Hemorrhagic Disorders + Hemorrhagic Disorders [Disease/Finding] + N0000001485 + Spontaneous or near spontaneous bleeding caused by a defect in clotting mechanisms (BLOOD COAGULATION DISORDERS) or another abnormality causing a structural flaw in the blood vessels (HEMOSTATIC DISORDERS). + 191331006 + 1023732 + + + 1021881 + M0010236 + 109841003 + Liver Cancer, Adult + + Hepatoma + Carcinoma, Hepatocellular [Disease/Finding] + Hepatocellular Carcinoma + A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested. + 187769009 + C2239176 + C3200 + D006528 + Liver Cell Carcinoma, Adult + Hepatocellular Cancer + Carcinoma, Hepatocellular + N0000001511 + Carcinoma, Hepatocellular + + + M0010278 + + Herpes Labialis + 1475003 + C3236 + D006560 + Herpes Simplex, Labial + Cold Sore + 1021986 + Fever Blister + Herpes Labialis + Herpes Labialis [Disease/Finding] + C0019345 + Herpes simplex, caused by type 1 virus, primarily spread by oral secretions and usually occurring as a concomitant of fever. It may also develop in the absence of fever or prior illness. It commonly involves the facial region, especially the lips and the nares. (Dorland, 27th ed.) + N0000001529 + + + 65958008 + N0000001534 + Hiccup [Disease/Finding] + Hiccough + Hiccup + + C0019521 + D006606 + A spasm of the diaphragm that causes a sudden inhalation followed by rapid closure of the glottis which produces a sound. + Hiccup + C3246 + M0010343 + 1021801 + + + Hypersensitivity [Disease/Finding] + Hypersensitivity + C3398 + D006967 + Allergy + N0000001610 + + 106190000 + Hypersensitivity + 127072000 + C0020517 + M0010851 + 269284003 + 1022134 + Altered reactivity to an antigen, which can result in pathologic reactions upon subsequent exposure to that particular antigen. + + + + IgE-Mediated Hypersensitivity + Hypersensitivity, Atopic + M0010854 + Hypersensitivity, Immediate [Disease/Finding] + C3402 + 20671006 + N0000001612 + 1023968 + Hypersensitivity, Immediate + Hypersensitivity reactions which occur within minutes of exposure to challenging antigen due to the release of histamine which follows the antigen-antibody reaction and causes smooth muscle contraction and increased vascular permeability. + Hypersensitivity, Type I + Type I Hypersensitivity + Atopic Hypersensitivity + D006969 + Hypersensitivity, Immediate + C0020523 + + + 1023354 + Hypertension + Blood Pressure, High + N0000001616 + C0020538 + + C3410 + Hypertension [Disease/Finding] + M0010859 + 38341003 + D006973 + Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. + Hypertension + + + M0010927 + N0000001649 + Vascular Hypotension + Hypotension + Hypotension + + Abnormally low BLOOD PRESSURE that can result in inadequate blood flow to the brain and other vital organs. Common symptom is DIZZINESS but greater negative impacts on the body occur when there is prolonged depravation of oxygen and nutrients. + Hypotension, Vascular + Low Blood Pressure + C3476 + D007022 + Blood Pressure, Low + Hypotension [Disease/Finding] + 1022536 + 45007003 + C0020649 + + + Tumors or cancer in the ILEUM region of the small intestine (INTESTINE, SMALL). + N0000001661 + Ileal Neoplasms + + Ileal Neoplasms + C0020876 + Ileal Neoplasms [Disease/Finding] + 1026955 + M0011024 + 126835002 + D007078 + C3500 + + + Immune System Diseases + D007154 + 41266007 + N0000001668 + Immunologic Diseases + + Immunological Diseases + C0021053 + Disorders caused by abnormal or absent immunologic mechanisms, whether humoral, cell-mediated, or both. + Immune System Diseases [Disease/Finding] + C3514 + Immune Diseases + Immune Disorders + Immune System Diseases + M0011156 + Diseases of Immune System + 1022843 + + + M0011294 + 40733004 + + C0021311 + D007239 + Infection + N0000001681 + Infection [Disease/Finding] + Infection + 1022093 + Invasion of the host organism by microorganisms that can cause pathological conditions or diseases. + C3540 + + + C0021368 + D007249 + + 23583003 + N0000001687 + 987778 + A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function. + Inflammation + Inflammation [Disease/Finding] + M0011307 + C3552 + Inflammation + + + 85919009 + Intestinal Diseases + N0000001698 + 1023320 + D007410 + Pathological processes in any segment of the INTESTINE from DUODENUM to RECTUM. + C3574 + Intestinal Diseases [Disease/Finding] + M0011569 + Intestinal Diseases + C0021831 + + + + N0000001702 + Intestinal Obstruction + Any impairment, arrest, or reversal of the normal flow of INTESTINAL CONTENTS toward the ANAL CANAL. + 1023737 + Intestinal Obstruction [Disease/Finding] + Intestinal Obstruction + C3582 + 81060008 + + M0011575 + C0021843 + D007415 + + + C0022658 + 90708001 + + M0012014 + N0000001748 + Kidney Diseases [Disease/Finding] + 1022215 + Kidney Diseases + Pathological processes of the KIDNEY or its component tissues. + D007674 + Kidney Diseases + C3674 + + + A neoplastic disease of the lymphoreticular cells which is considered to be a rare type of chronic leukemia; it is characterized by an insidious onset, splenomegaly, anemia, granulocytopenia, thrombocytopenia, little or no lymphadenopathy, and the presence of "hairy" or "flagellated" cells in the blood and bone marrow. + D007943 + M0012387 + Leukemia, Hairy Cell + Reticuloendotheliosis, Leukemic + Leukemia, Hairy Cell + N0000001820 + 1022561 + Hairy Cell Leukemia + 118613001 + Leukemic Reticuloendotheliosis + C0023443 + + 188644003 + Leukemia, Hairy Cell [Disease/Finding] + C3818 + + + D008107 + M0012644 + Pathological processes of the LIVER. + + 1024220 + Liver Diseases [Disease/Finding] + Liver Diseases + Liver Diseases + 235856003 + C0023895 + C3910 + N0000001866 + + + M0012744 + Pathological processes involving any part of the LUNG. + Pulmonary Disease + C3936 + + D008171 + 19829001 + N0000001879 + Diseases, Pulmonary + Pulmonary Diseases + Lung Diseases + Lung Diseases + Disease, Pulmonary + 1021971 + C0024115 + Lung Diseases [Disease/Finding] + + + Lupus Erythematosus, Discoid [Disease/Finding] + C0024138 + Lupus Erythematosus, Chronic Cutaneous + 1022154 + Lupus Erythematosus, Discoid + A chronic form of cutaneous lupus erythematosus (LUPUS ERYTHEMATOSUS, CUTANEOUS) in which the skin lesions mimic those of the systemic form but in which systemic signs are rare. It is characterized by the presence of discoid skin plaques showing varying degrees of edema, erythema, scaliness, follicular plugging, and skin atrophy. Lesions are surrounded by an elevated erythematous border. The condition typically involves the face and scalp, but widespread dissemination may occur. + + Lupus Erythematosus, Discoid + M0012756 + 238927000 + 200938002 + Lupus Erythematosus, Cutaneous, Chronic + C3950 + D008179 + N0000001886 + + + Systemic Lupus Erythematosus + Lupus Erythematosus, Systemic [Disease/Finding] + A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow. + 1023595 + Lupus Erythematosus Disseminatus + Lupus Erythematosus, Systemic + + C0024141 + D008180 + Lupus Erythematosus, Systemic + M0012757 + N0000001887 + 55464009 + C3952 + + + Age-Related Maculopathy + D008268 + Age-Related Macular Degeneration + Macular Dystrophy + Age-Related Maculopathies + Degenerative changes in the RETINA usually of older adults which results in a loss of vision in the center of the visual field (the MACULA LUTEA) because of damage to the retina. It occurs in dry and wet forms. + M0012875 + 302891003 + Macular Degeneration [Disease/Finding] + C0242383 + C4014 + 987866 + Maculopathies, Age-Related + + Macular Degeneration + Macular Degeneration + N0000001918 + Maculopathy, Age-Related + + + N0000001924 + C0024530 + Malaria + Infections, Plasmodium + Remittent Fever + Malaria + 105649009 + 1025176 + 186797008 + + Paludism + C4026 + Marsh Fever + 61462000 + A protozoan disease caused in humans by four species of the PLASMODIUM genus: PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PLASMODIUM OVALE; and PLASMODIUM MALARIAE; and transmitted by the bite of an infected female mosquito of the genus ANOPHELES. Malaria is endemic in parts of Asia, Africa, Central and South America, Oceania, and certain Caribbean islands. It is characterized by extreme exhaustion associated with paroxysms of high FEVER; SWEATING; shaking CHILLS; and ANEMIA. Malaria in ANIMALS is caused by other species of plasmodia. + D008288 + Plasmodium Infections + M0012910 + Malaria [Disease/Finding] + + + 1024199 + Malaria, Avian + + Any of a group of infections of fowl caused by protozoa of the genera PLASMODIUM, Leucocytozoon, and Haemoproteus. The life cycles of these parasites and the disease produced bears strong resemblance to those observed in human malaria. + C0024533 + D008289 + 1498006 + C4028 + Malaria, Avian [Disease/Finding] + Malaria, Avian + N0000001925 + M0012911 + + + N0000001941 + C0024759 + Mansonelliasis [Disease/Finding] + Mansonellosis + + 240849009 + M0013012 + Mansonelliasis + Mansonelliasis + Infection with nematodes of the genus MANSONELLA. Symptoms include pruritus, headache, and articular swelling. + D008368 + C4060 + 1025658 + + + N0000001969 + M0013309 + Melanoma + Melanoma [Disease/Finding] + Malignant Melanoma + D008545 + A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445) + + C0025202 + C4116 + 372244006 + Melanoma + 1023577 + + + Variations of menstruation which may be indicative of disease. + 1021753 + D008599 + Menstruation Disorders + C4166 + M0013402 + Menstruation Disturbances + Menstruation Disturbances + C0025345 + N0000001994 + 386804004 + + Menstruation Disturbances [Disease/Finding] + + + Motion Sickness + 37031009 + N0000002031 + C4240 + C0026603 + M0014105 + 1022871 + Disorder caused by motion, as sea sickness, train sickness, car sickness, air sickness, or SPACE MOTION SICKNESS. It may include nausea, vomiting and dizziness. + 269278001 + Motion Sickness [Disease/Finding] + D009041 + Motion Sickness + + + + 60342002 + N0000002039 + + Movement Disorders + C0026650 + M0014141 + Movement Disorders + Movement Disorder Syndromes + Dyskinesia Syndromes + Syndromes which feature DYSKINESIAS as a cardinal manifestation of the disease process. Included in this category are degenerative, hereditary, post-infectious, medication-induced, post-inflammatory, and post-traumatic conditions. + Movement Disorders [Disease/Finding] + D009069 + 1024614 + C4256 + + + Myelomatosis + Plasma Cell Myeloma + Myeloma-Multiple + Myeloma, Plasma-Cell + N0000002050 + Multiple Myeloma + M0014195 + Kahler Disease + 1022141 + C0026764 + Multiple Myeloma + 109989006 + + A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY. + D009101 + Multiple Myeloma [Disease/Finding] + C4278 + + + MS (Multiple Sclerosis) + Multiple Sclerosis [Disease/Finding] + N0000002052 + C4282 + Multiple Sclerosis + M0014197 + Multiple Sclerosis + 1024685 + + C0026769 + D009103 + 24700007 + Sclerosis, Disseminated + An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903) + 192928003 + + + C4318 + D009157 + A disorder of neuromuscular transmission characterized by weakness of cranial and skeletal muscles. Autoantibodies directed against acetylcholine receptors damage the motor endplate portion of the NEUROMUSCULAR JUNCTION, impairing the transmission of impulses to skeletal muscles. Clinical manifestations may include diplopia, ptosis, and weakness of facial, bulbar, respiratory, and proximal limb muscles. The disease may remain limited to the ocular muscles. THYMOMA is commonly associated with this condition. (Adams et al., Principles of Neurology, 6th ed, p1459) + C0026896 + 91637004 + Myasthenia Gravis + 1024161 + + M0014279 + Myasthenia Gravis + N0000002070 + Myasthenia Gravis [Disease/Finding] + + + Infections, Atypical Mycobacterium + Infections with so called atypical mycobacteria (tuberculoid bacilli): M. kansasii, M. marinum, M. scrofulaceum, M. flavescens, M. gordonae, M. obuense, M. gilvum, M. duvali, M. szulgai, M. intracellulare (see MYCOBACTERIUM AVIUM COMPLEX;), M. xenopi (littorale), M. ulcerans, M. buruli, M. terrae, M. fortuitum (minetti, giae), M. chelonae. + 111812000 + Infections, Tuberculoid + Mycobacterium Infections, Atypical + 1026349 + Atypical Mycobacterium Infections + 111811007 + Tuberculoid Infections + + Mycobacterium Infections, Atypical [Disease/Finding] + M0014288 + N0000002072 + Mycobacterium Infections, Atypical + C0026919 + D009165 + C4322 + + + 188618003 + Mycosis Fungoides + Mycosis Fungoides + A chronic, malignant T-cell lymphoma of the skin. In the late stages, the LYMPH NODES and viscera are affected. + 118618005 + + C0026948 + D009182 + 1024347 + Mycosis Fungoides [Disease/Finding] + N0000002076 + M0014314 + C4330 + + + + Myocardial Infarction + Myocardial Infarct + 1024565 + C4348 + N0000002085 + NECROSIS of the MYOCARDIUM caused by an obstruction of the blood supply to the heart (CORONARY CIRCULATION). + 22298006 + Myocardial Infarction [Disease/Finding] + C0027051 + D009203 + M0014340 + Myocardial Infarction + + + 1023644 + C0027497 + Nausea [Disease/Finding] + Nausea + M0014528 + An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses. + N0000002114 + Nausea + + C4406 + D009325 + 73879007 + + + 55342001 + Neoplasms + Neoplasms + Tumors + 1022284 + M0014585 + 189525008 + New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. + 189526009 + C0027651 + Neoplasms [Disease/Finding] + + N0000002128 + C4434 + D009369 + + + C4496 + Neurologic Disorders + Nervous System Diseases + D009422 + Nervous System Diseases + Nervous System Disorders + N0000002159 + 1026444 + Nervous System Diseases [Disease/Finding] + M0014667 + + 118940003 + C0027765 + Diseases of the central and peripheral nervous system. This includes disorders of the brain, spinal cord, cranial nerves, peripheral nerves, nerve roots, autonomic nervous system, neuromuscular junction, and muscle. + Neurological Disorders + + + M0014716 + Neurologic Manifestations + D009461 + Neurologic Manifestation + + 1025946 + Manifestations, Neurological + C4524 + Neurologic Manifestations [Disease/Finding] + N0000002173 + Neurologic Signs and Symptoms + Neurological Manifestations + Neurologic Manifestations + Clinical signs and symptoms caused by nervous system injury or dysfunction. + C0027854 + Manifestations, Neurologic + + + + N0000002203 + Obsessive-Compulsive Disorder + C0028768 + 1022585 + Obsessive-Compulsive Disorder + Anankastic Personality + An anxiety disorder characterized by recurrent, persistent obsessions or compulsions. Obsessions are the intrusive ideas, thoughts, or images that are experienced as senseless or repugnant. Compulsions are repetitive and seemingly purposeful behavior which the individual generally recognizes as senseless and from which the individual does not derive pleasure although it may provide a release from tension. + Neurosis, Obsessive-Compulsive + M0015170 + 191736004 + D009771 + Obsessive-Compulsive Disorder [Disease/Finding] + C4584 + + + C0029001 + N0000002218 + Onchocerciasis + Onchocerciasis [Disease/Finding] + Infection with nematodes of the genus ONCHOCERCA. Characteristics include the presence of firm subcutaneous nodules filled with adult worms, PRURITUS, and ocular lesions. + 38539003 + 984320 + M0015295 + C4614 + Onchocerciasis + + D009855 + + + Middle Ear Inflammation + D010033 + C0029882 + Otitis Media + C4710 + 65363002 + Otitis Media + + N0000002266 + Otitis Media [Disease/Finding] + M0015563 + Inflammation of the MIDDLE EAR including the AUDITORY OSSICLES and the EUSTACHIAN TUBE. + 1022862 + + + N0000002278 + 1021856 + + D010146 + C4734 + 22253000 + C0030193 + M0015742 + An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS. + Pain + Pain + Pain [Disease/Finding] + + + Pancreas Neoplasms + Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA). + D010190 + Pancreatic Neoplasms + Pancreatic Neoplasms + C4754 + + N0000002288 + M0015803 + Neoplasms, Pancreatic + Pancreatic Neoplasms [Disease/Finding] + 1026434 + 126859007 + C0030297 + + + Parkinson Disease, Idiopathic + Lewy Body Parkinson's Disease + C4832 + Idiopathic Parkinson's Disease + Parkinson's Disease + 49049000 + M0015963 + Parkinson Disease [Disease/Finding] + Paralysis Agitans + C0030567 + 1022466 + Parkinson's Disease, Lewy Body + A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75) + Lewy Body Parkinson Disease + N0000002327 + + Parkinson Disease + Parkinson Disease + Idiopathic Parkinson Disease + Parkinson's Disease, Idiopathic + Primary Parkinsonism + D010300 + + + N0000002338 + The abnormal mechanisms and forms involved in the dysfunctions of tissues and organs. + C0030660 + 1025320 + Processes, Pathologic + Pathological Processes + Pathologic Processes [Disease/Finding] + + 370135005 + Pathologic Processes + D010335 + M0016012 + C4854 + Pathologic Processes + 308489006 + + + + Pemphigus + 1025707 + 65172003 + D010392 + M0016112 + N0000002347 + C0030807 + C4872 + Pemphigus [Disease/Finding] + Group of chronic blistering diseases characterized histologically by ACANTHOLYSIS and blister formation within the EPIDERMIS. + Pemphigus + + + Peptic Ulcer [Disease/Finding] + Ulcer that occurs in the regions of the GASTROINTESTINAL TRACT which come into contact with GASTRIC JUICE containing PEPSIN and GASTRIC ACID. It occurs when there are defects in the MUCOSA barrier. The common forms of peptic ulcers are associated with HELICOBACTER PYLORI and the consumption of nonsteroidal anti-inflammatory drugs (NSAIDS). + M0016211 + D010437 + + 196697002 + 266437002 + C0030920 + N0000002351 + 1024813 + 13200003 + Peptic Ulcer + Gastroduodenal Ulcer + Peptic Ulcer + C4880 + + + Pericarditis + D010493 + 1025582 + C0031046 + Pericarditis [Disease/Finding] + 3238004 + C4902 + M0016303 + Pericarditis + + Inflammation of the PERICARDIUM from various origins, such as infection, neoplasm, autoimmune process, injuries, or drug-induced. Pericarditis usually leads to PERICARDIAL EFFUSION, or CONSTRICTIVE PERICARDITIS. + N0000002362 + + + Constrictive Pericarditis + C0031048 + N0000002363 + Pericarditis, Constrictive + M0016304 + 85598007 + 1026769 + Pericarditis, Constrictive + Pericarditis, Constrictive [Disease/Finding] + Inflammation of the PERICARDIUM that is characterized by the fibrous scarring and adhesion of both serous layers, the VISCERAL PERICARDIUM and the PARIETAL PERICARDIUM leading to the loss of pericardial cavity. The thickened pericardium severely restricts cardiac filling. Clinical signs include FATIGUE, muscle wasting, and WEIGHT LOSS. + + D010494 + C4904 + + + Photosensitivity Disorders [Disease/Finding] + D010787 + C4970 + Photodermatitis + M0016756 + + C0031762 + Photosensitivity Disorders + 1026591 + N0000002396 + Photosensitivity Disorders + 22649008 + Abnormal responses to sunlight or artificial light due to extreme reactivity of light-absorbing molecules in tissues. It refers almost exclusively to skin photosensitivity, including sunburn, reactions due to repeated prolonged exposure in the absence of photosensitizing factors, and reactions requiring photosensitizing factors such as photosensitizing agents and certain diseases. With restricted reference to skin tissue, it does not include photosensitivity of the eye to light, as in photophobia or photosensitive epilepsy. + + + Pneumonia, Primary Atypical + 46970008 + Mycoplasma Pneumonia + Pneumonia, Mycoplasma [Disease/Finding] + 1023268 + Pneumonia, Mycoplasma + N0000002436 + C5050 + C0032302 + Pneumonia, Mycoplasma + + M0017072 + Interstitial pneumonia caused by extensive infection of the lungs (LUNG) and BRONCHI, particularly the lower lobes of the lungs, by MYCOPLASMA PNEUMONIAE in humans. In SHEEP, it is caused by MYCOPLASMA OVIPNEUMONIAE. In CATTLE, it may be caused by MYCOPLASMA DISPAR. + D011019 + + + Poisoning + M0017099 + N0000002447 + A condition or physical state produced by the ingestion, injection, inhalation of or exposure to a deleterious agent. + Poisoning [Disease/Finding] + Poisoning + C5072 + C0032343 + D011041 + 1026915 + + 75478009 + + + + N0000002467 + C0032787 + Complication, Postoperative + M0017367 + 385486001 + Postoperative Complications [Disease/Finding] + Postoperative Complications + D011183 + Postoperative Complications + 1022600 + Pathologic processes that affect patients after a surgical procedure. They may or may not be related to the disease for which the surgery was done, and they may or may not be direct results of the surgery. + C5112 + + + Pregnancy Complications [Disease/Finding] + 1023402 + C5134 + Pregnancy Complications + C0032962 + N0000002478 + Conditions or pathological processes associated with pregnancy. They can occur during or after pregnancy, and range from minor discomforts to serious diseases that require medical interventions. They include diseases in pregnant females, and pregnancies in females with diseases. + Complications, Pregnancy + 198881004 + 90821003 + D011248 + M0017474 + Pregnancy Complications + + + + + 9014002 + Psoriasis + Psoriasis + A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis. + N0000002526 + C5230 + D011565 + Psoriasis [Disease/Finding] + 200961000 + 1022582 + C0033860 + M0017975 + + + Psychotic Disorders + Disorders in which there is a loss of ego boundaries or a gross impairment in reality testing with delusions or prominent hallucinations. (From DSM-IV, 1994) + Psychoses + Psychotic Disorders + 1023496 + C0033975 + D011618 + Psychotic Disorders [Disease/Finding] + C5242 + M0018060 + N0000002532 + + 69322001 + + + Development of SEXUAL MATURATION in boys and girls at a chronological age that is 2.5 standard deviations below the mean age at onset of PUBERTY in the population. This early maturation of the hypothalamic-pituitary-gonadal axis results in sexual precocity, elevated serum levels of GONADOTROPINS and GONADAL STEROID HORMONES such as ESTRADIOL and TESTOSTERONE. + M0018083 + Puberty, Precocious [Disease/Finding] + 1023098 + Precocious Puberty + D011629 + 400179000 + C0034013 + Puberty, Precocious + + 123527003 + N0000002535 + Puberty, Precocious + C5248 + + + Pathological developments in the RECTUM region of the large intestine (INTESTINE, LARGE). + N0000002578 + + D012002 + Rectal Diseases [Disease/Finding] + Rectal Diseases + 1024401 + C0034882 + 5964004 + M0018654 + Rectal Diseases + C5334 + + + Respiratory Distress Syndrome, Adult + C0035222 + + Adult Respiratory Distress Syndrome + ARDS, Human + A syndrome characterized by progressive life-threatening RESPIRATORY INSUFFICIENCY in the absence of known LUNG DISEASES, usually following a systemic insult such as surgery or major TRAUMA. + M0018891 + Acute Respiratory Distress Syndrome + Respiratory Distress Syndrome, Adult + Shock Lung + D012128 + Respiratory Distress Syndrome, Acute + C5372 + Respiratory Distress Syndrome, Adult [Disease/Finding] + 67782005 + 95437004 + N0000002597 + 990085 + + + + Retinal Diseases [Disease/Finding] + C5396 + D012164 + Retinal Diseases + 1023467 + Retinal Diseases + 29555009 + N0000002609 + 399625000 + C0035309 + M0018945 + + + D012202 + Fatty Liver with Encephalopathy + Reye Syndrome + Reye Syndrome + M0018992 + 74351001 + 1026604 + N0000002624 + Reye's Syndrome + A form of encephalopathy with fatty infiltration of the LIVER, characterized by brain EDEMA and VOMITING that may rapidly progress to SEIZURES; COMA; and DEATH. It is caused by a generalized loss of mitochondrial function leading to disturbances in fatty acid and CARNITINE metabolism. + C0035400 + C5426 + Reye Syndrome [Disease/Finding] + Reye-Johnson Syndrome + + + + C0035435 + M0019014 + N0000002632 + Rheumatic Diseases + 396332003 + Rheumatic Diseases + D012216 + + Rheumatic Diseases [Disease/Finding] + 1022758 + Disorders of connective tissue, especially the joints and related structures, characterized by inflammation, degeneration, or metabolic derangement. + C5442 + Rheumatism + 203100003 + + + + N0000002634 + C0035455 + 1023076 + C5446 + Rhinitis [Disease/Finding] + D012220 + Rhinitis + Rhinitis + Nasal Catarrh + Inflammation of the NASAL MUCOSA, the mucous membrane lining the NASAL CAVITIES. + 70076002 + M0019019 + + + 1025485 + + Rhinitis, Allergic, Perennial + C0035457 + N0000002635 + Rhinitis, Allergic, Perennial + C5448 + D012221 + Rhinitis, Allergic, Nonseasonal + M0019020 + 38103000 + Rhinitis, Allergic, Perennial [Disease/Finding] + Inflammation of the mucous membrane of the nose similar to that found in hay fever except that symptoms persist throughout the year. The causes are usually air-borne allergens, particularly dusts, feathers, molds, animal fur, etc. + + + D012480 + 1025316 + 90974009 + 302231008 + Salmonellosis + Salmonella Infections [Disease/Finding] + C0036117 + Salmonella Infections + C5510 + Infections, Salmonella + M0019393 + N0000002666 + + Infections with bacteria of the genus SALMONELLA. + Salmonella Infections + + + D012514 + C0036220 + A multicentric, malignant neoplastic vascular proliferation characterized by the development of bluish-red cutaneous nodules, usually on the lower extremities, most often on the toes or feet, and slowly increasing in size and number and spreading to more proximal areas. The tumors have endothelium-lined channels and vascular spaces admixed with variably sized aggregates of spindle-shaped cells, and often remain confined to the skin and subcutaneous tissue, but widespread visceral involvement may occur. Kaposi's sarcoma occurs spontaneously in Jewish and Italian males in Europe and the United States. An aggressive variant in young children is endemic in some areas of Africa. A third form occurs in about 0.04% of kidney transplant patients. There is also a high incidence in AIDS patients. (From Dorland, 27th ed & Holland et al., Cancer Medicine, 3d ed, pp2105-7) HHV-8 is the suspected cause. + Kaposi's Sarcoma + C5530 + Kaposi Sarcoma + + Sarcoma, Kaposi [Disease/Finding] + 109385007 + N0000002676 + Sarcoma, Kaposi + Sarcoma, Kaposi + M0019437 + 1027423 + + + N0000002681 + + C5540 + 1022265 + C0036262 + D012532 + Scabies + A contagious cutaneous inflammation caused by the bite of the mite SARCOPTES SCABIEI. It is characterized by pruritic papular eruptions and burrows and affects primarily the axillae, elbows, wrists, and genitalia, although it can spread to cover the entire body. + Scabies + Scabies [Disease/Finding] + M0019458 + 128869009 + + + 1022169 + Schizophrenic Disorders + Schizophrenia + + 58214004 + 191528006 + 191526005 + D012559 + C5558 + M0019489 + Schizophrenia + N0000002690 + Dementia Praecox + C0036341 + Schizophrenia [Disease/Finding] + A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior. + + + Systemic Scleroderma + 1022426 + A chronic multi-system disorder of CONNECTIVE TISSUE. It is characterized by SCLEROSIS in the SKIN, the LUNGS, the HEART, the GASTROINTESTINAL TRACT, the KIDNEYS, and the MUSCULOSKELETAL SYSTEM. Other important features include diseased small BLOOD VESSELS and AUTOANTIBODIES. The disorder is named for its most prominent feature (hard skin), and classified into subsets by the extent of skin thickening: LIMITED SCLERODERMA and DIFFUSE SCLERODERMA. + Scleroderma, Systemic [Disease/Finding] + D012595 + C5580 + Systemic Sclerosis + M0019543 + C0036421 + Scleroderma, Systemic + + 89155008 + Scleroderma, Systemic + N0000002701 + Sclerosis, Systemic + + + Sezary Syndrome + N0000002725 + D012751 + + 188629004 + M0019760 + A form of cutaneous T-cell lymphoma manifested by generalized exfoliative ERYTHRODERMA; PRURITUS; peripheral lymphadenopathy, and abnormal hyperchromatic mononuclear (cerebriform) cells in the skin, LYMPH NODES, and peripheral blood (Sezary cells). + Sezary's Lymphoma + Sezary Syndrome [Disease/Finding] + Erythroderma, Sezary + C5628 + C0036920 + 118611004 + 1022616 + Sezary Syndrome + + + Shock [Disease/Finding] + 27942005 + Circulatory Collapse + Shock + M0019782 + N0000002728 + 274729009 + Circulatory Failure + + Shock + D012769 + C5634 + C0036974 + 1023333 + A pathological condition manifested by failure to perfuse or oxygenate vital organs. + + + + 89138009 + D012770 + C5636 + Shock, Cardiogenic [Disease/Finding] + Shock, Cardiogenic + M0019783 + 1026337 + C0036980 + Shock resulting from diminution of cardiac output in heart disease. + N0000002729 + Shock, Cardiogenic + + + C5700 + Skin Diseases + + D012871 + Dermatoses + Skin Diseases + C0037274 + Dermatosis + 95320005 + 1022858 + N0000002761 + Skin Diseases [Disease/Finding] + M0019929 + + + C0037278 + N0000002764 + D012874 + C5706 + + Skin Diseases, Infectious [Disease/Finding] + Skin Diseases, Infectious + Infectious Skin Diseases + Skin diseases caused by bacteria, fungi, parasites, or viruses. + 1025346 + Skin Diseases, Infectious + 108365000 + M0019935 + + + M0019939 + 1025991 + C5714 + Neoplasms, Skin + + N0000002768 + Skin Neoplasms [Disease/Finding] + C0037286 + D012878 + Skin Neoplasms + Tumors or cancer of the SKIN. + 126488004 + Skin Neoplasms + + + 1023651 + D012883 + Skin Ulcer + 46742003 + C0037299 + Skin Ulcer [Disease/Finding] + + Skin Ulcer + N0000002769 + C5716 + 247454005 + M0019944 + + + D013203 + C0038160 + Staphylococcal Infections + Staphylococcal Infections + M0020423 + N0000002817 + + Staphylococcal Infections [Disease/Finding] + Infections, Staphylococcal + C5812 + 56038003 + Infections with bacteria of the genus STAPHYLOCOCCUS. + 1023915 + + + Staphylococcal Skin Infections + Staphylococcal Infections, Skin + C0038166 + Staphylococcal Skin Diseases + C5816 + Infections to the skin caused by bacteria of the genus STAPHYLOCOCCUS. + Staphylococcal Skin Infections + + 1022363 + N0000002819 + 402938009 + D013207 + M0020427 + Staphylococcal Skin Infections [Disease/Finding] + Skin Diseases, Staphylococcal + Infections, Staphylococcal Skin + 371308001 + Staphylococcal Diseases, Skin + Skin Infections, Staphylococcal + + + M0020542 + Pathological processes involving the STOMACH. + + N0000002826 + D013272 + Stomach Diseases + C5830 + 988579 + Stomach Diseases + 29384001 + Stomach Diseases [Disease/Finding] + C0038354 + Gastric Diseases + + + N0000002837 + C0038395 + Streptococcal Infections [Disease/Finding] + + 1022383 + 85769006 + Infections, Streptococcal + Infections with bacteria of the genus STREPTOCOCCUS. + C5852 + Streptococcal Infections + D013290 + M0020568 + Streptococcal Infections + + + Infection with nematodes of the genus STRONGYLOIDES. The presence of larvae may produce pneumonitis and the presence of adult worms in the intestine could lead to moderate to severe diarrhea. + C5860 + C0038463 + + D013322 + 1214006 + 1024903 + Strongyloidiasis + M0020615 + Strongyloidiasis [Disease/Finding] + Strongyloidiasis + N0000002841 + + + D013610 + Abnormally rapid heartbeat, usually with a HEART RATE above 100 beats per minute for adults. Tachycardia accompanied by disturbance in the cardiac depolarization (cardiac arrhythmia) is called tachyarrhythmia. + Tachycardia + 1023558 + 86651002 + Tachycardia + N0000002888 + M0020996 + 3424008 + C5954 + Tachycardia [Disease/Finding] + C0039231 + + + + C5968 + A generic expression for any tachycardia that originates above the BUNDLE OF HIS. + Tachycardia, Supraventricular + Tachycardia, Supraventricular + Tachycardia, Supraventricular [Disease/Finding] + N0000002895 + D013617 + M0021006 + 1022287 + C0039240 + 6456007 + + + + Tetanus + N0000002915 + 76902006 + + A disease caused by tetanospasmin, a powerful protein toxin produced by CLOSTRIDIUM TETANI. Tetanus usually occurs after an acute injury, such as a puncture wound or laceration. Generalized tetanus, the most common form, is characterized by tetanic muscular contractions and hyperreflexia. Localized tetanus presents itself as a mild condition with manifestations restricted to muscles near the wound. It may progress to the generalized form. + C6008 + Tetanus [Disease/Finding] + 276202003 + D013742 + Tetanus + 1022251 + M0021200 + C0039614 + + + Thrombocythemia, Primary + Hemorrhagic Thrombocythemia + + Thrombocythemia, Hemorrhagic + A clinical syndrome characterized by repeated spontaneous hemorrhages and a remarkable increase in the number of circulating platelets. + 1022170 + D013920 + M0021427 + N0000002931 + Thrombocythemia, Essential [Disease/Finding] + C6040 + 109994006 + C0040028 + Thrombocythemia, Essential + Thrombocythemia, Idiopathic + Thrombocythemia, Essential + + + A subnormal level of BLOOD PLATELETS. + + 302215000 + M0021428 + Thrombocytopenia + N0000002932 + Thrombocytopenia + C6042 + 1024914 + D013921 + Thrombopenia + C0040034 + Thrombocytopenia [Disease/Finding] + + + Obstruction of a blood vessel (embolism) by a blood clot (THROMBUS) in the blood stream. + + C0040038 + M0021430 + C6046 + 371039008 + Thromboembolism + 1027317 + D013923 + N0000002934 + Thromboembolism [Disease/Finding] + Thromboembolism + + + C6048 + C0040046 + Thrombophlebitis [Disease/Finding] + 64156001 + + Thrombophlebitis + M0021432 + Thrombophlebitis + Inflammation of a vein associated with a blood clot (THROMBUS). + D013924 + N0000002935 + 1025289 + + + M0021435 + Thrombosis + 1022873 + N0000002936 + + D013927 + 118927008 + C6050 + Formation and development of a thrombus or blood clot in the blood vessel. + Thrombosis [Disease/Finding] + Thrombosis + C0040053 + + + D014069 + + Tonsillitis + Tonsillitis [Disease/Finding] + Inflammation of the tonsils, especially the PALATINE TONSILS but the ADENOIDS (pharyngeal tonsils) and lingual tonsils may also be involved. Tonsillitis usually is caused by bacterial infection. Tonsillitis may be acute, chronic, or recurrent. + C6116 + N0000002969 + Tonsillitis + C0040425 + M0021666 + 1023281 + 90176007 + + + 60570001 + C0040954 + 1023521 + Infection with nematodes of the genus TRICHURIS, formerly called Trichocephalus. + Trichuriasis [Disease/Finding] + N0000003014 + M0021941 + Trichuriasis + 3752003 + C6206 + + D014257 + Trichocephaliasis + Trichuriasis + + + 419045004 + 418107008 + C0041657 + Unconscious State + Unconsciousness + Consciousness, Loss of + + D014474 + N0000003064 + C6306 + M0022251 + 1026031 + Unconsciousness + Unconsciousness [Disease/Finding] + Loss of the ability to maintain awareness of self and environment combined with markedly reduced responsiveness to environmental stimuli. (From Adams et al., Principles of Neurology, 6th ed, pp344-5) + + + N0000003076 + Urethritis [Disease/Finding] + D014526 + C6330 + 1025450 + Urethritis + Inflammation involving the URETHRA. Similar to CYSTITIS, clinical symptoms range from vague discomfort to painful urination (DYSURIA), urethral discharge, or both. + 31822004 + Urethritis + M0022336 + C0041976 + + 197905005 + + + Urologic Diseases + 41368006 + M0022400 + 1022769 + + Pathological processes of the URINARY TRACT in both males and females. + D014570 + 128606002 + Urologic Diseases [Disease/Finding] + N0000003086 + Urinary Tract Diseases + C6350 + Urological Diseases + Urologic Diseases + C0042075 + 197951006 + + + A vascular reaction of the skin characterized by erythema and wheal formation due to localized increase of vascular permeability. The causative mechanism may be allergy, infection, or stress. + C0042109 + Urticaria [Disease/Finding] + C6354 + M0022414 + D014581 + Urticaria + Urticaria + N0000003088 + + 1023461 + 126485001 + Hives + + + Uterine Diseases [Disease/Finding] + Uterine Diseases + D014591 + C0042131 + C6358 + Uterine Diseases + M0022426 + 12337004 + 1025904 + N0000003090 + + Pathological processes involving any part of the UTERUS. + + + Uterine Hemorrhage [Disease/Finding] + D014592 + C6360 + Hemorrhage, Uterine + 1024627 + Uterine Hemorrhage + N0000003091 + 38280009 + C0042134 + Uterine Hemorrhage + + Uterine Bleeding + M0022428 + Bleeding from blood vessels in the UTERUS, sometimes manifested as vaginal bleeding. + + + Tumors or cancer of the UTERUS. + Uterine Neoplasms [Disease/Finding] + 126908007 + C6364 + N0000003093 + Neoplasms, Uterus + 1022983 + + M0022431 + Uterine Neoplasms + Uterine Neoplasms + C0042138 + Neoplasms, Uterine + D014594 + Uterus Neoplasms + + + 27550009 + 1024109 + N0000003111 + D014652 + + M0022535 + Vascular Diseases + Pathological processes involving any of the BLOOD VESSELS in the cardiac or peripheral circulation. They include diseases of ARTERIES; VEINS; and rest of the vasculature system in the body. + Vascular Diseases [Disease/Finding] + C6400 + C0042373 + Vascular Diseases + + + N0000003118 + C6414 + A potentially lethal cardiac arrhythmia that is characterized by uncoordinated extremely rapid firing of electrical impulses (400-600/min) in HEART VENTRICLES. Such asynchronous ventricular quivering or fibrillation prevents any effective cardiac output and results in unconsciousness (SYNCOPE). It is one of the major electrocardiographic patterns seen with CARDIAC ARREST. + C0042510 + D014693 + Ventricular Fibrillation [Disease/Finding] + Ventricular Fibrillation + 1024218 + 71908006 + M0022595 + + Ventricular Fibrillation + + + An illusion of movement, either of the external world revolving around the individual or of the individual revolving in space. Vertigo may be associated with disorders of the inner ear (EAR, INNER); VESTIBULAR NERVE; BRAINSTEM; or CEREBRAL CORTEX. Lesions in the TEMPORAL LOBE and PARIETAL LOBE may be associated with FOCAL SEIZURES that may feature vertigo as an ictal manifestation. (From Adams et al., Principles of Neurology, 6th ed, pp300-1) + N0000003121 + M0022633 + C6420 + Vertigo [Disease/Finding] + Spinning Sensation + + 271792009 + Vertigo + D014717 + C0042571 + 1023692 + Vertigo, Subjective + Vertigo + + + D014786 + Vision Disorders + C0042790 + 95677002 + + 128127008 + Vision Disorders + Vision Disorders [Disease/Finding] + M0022771 + Visual impairments limiting one or more of the basic functions of the eye: visual acuity, dark adaptation, color vision, or peripheral vision. These may result from EYE DISEASES; OPTIC NERVE DISEASES; VISUAL PATHWAY diseases; OCCIPITAL LOBE diseases; OCULAR MOTILITY DISORDERS; and other conditions. Visual disability refers to inability of the individual to perform specific visual tasks, such as reading, writing, orientation, or traveling unaided. (From Newell, Ophthalmology: Principles and Concepts, 7th ed, p132) + C6438 + N0000003130 + 1023787 + + + Emesis + C0042963 + + Vomiting + D014839 + The forcible expulsion of the contents of the STOMACH through the MOUTH. + 1025810 + N0000003141 + M0022844 + C6460 + Vomiting [Disease/Finding] + 15387003 + Vomiting + + + D014860 + C6482 + Warts [Disease/Finding] + Warts + C0043037 + + Verruca + Warts + Benign epidermal proliferations or tumors; some are viral in origin. + 57019003 + 1022255 + N0000003152 + M0022875 + + + 1023880 + C0043202 + A form of ventricular pre-excitation characterized by a short PR interval and a long QRS interval with a delta wave. In this syndrome, atrial impulses are abnormally conducted to the HEART VENTRICLES via an ACCESSORY CONDUCTING PATHWAY that is located between the wall of the right or left atria and the ventricles, also known as a BUNDLE OF KENT. The inherited form can be caused by mutation of PRKAG2 gene encoding a gamma-2 regulatory subunit of AMP-activated protein kinase. + D014927 + M0022990 + N0000003166 + Wolff-Parkinson-White Syndrome + Wolff-Parkinson-White Syndrome + Wolf-Parkinson-White Syndrome + Anomalous Ventricular Excitation Syndrome + 74390002 + Auriculoventricular Accessory Pathway Syndrome + C6510 + False Bundle-Branch Block Syndrome + WPW Syndrome + + Wolff-Parkinson-White Syndrome [Disease/Finding] + + + 266434009 + C0014858 + + N0000003189 + Esophageal Dysmotility + Esophageal Motility Disorders [Disease/Finding] + Disorders affecting the motor function of the UPPER ESOPHAGEAL SPHINCTER; LOWER ESOPHAGEAL SPHINCTER; the ESOPHAGUS body, or a combination of these parts. The failure of the sphincters to maintain a tonic pressure may result in gastric reflux of food and acid into the esophagus (GASTROESOPHAGEAL REFLUX). Other disorders include hypermotility (spastic disorders) and markedly increased amplitude in contraction (nutcracker esophagus). + M0023297 + 1022716 + C6556 + Esophageal Motility Disorders + D015154 + Esophageal Motility Disorders + + + Colorectal Neoplasms + 1022247 + C6574 + Colorectal Neoplasms [Disease/Finding] + M0023329 + D015179 + N0000003198 + C0009404 + + 126837005 + Neoplasms, Colorectal + Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI. + Colorectal Neoplasms + Colorectal Tumors + + + 1023128 + 24526004 + Bowel Diseases, Inflammatory + C6590 + Inflammatory Bowel Diseases [Disease/Finding] + M0023374 + Chronic, non-specific inflammation of the GASTROINTESTINAL TRACT. Etiology may be genetic or environmental. This term includes CROHN DISEASE and ULCERATIVE COLITIS. + Inflammatory Bowel Diseases + C0021390 + Inflammatory Bowel Diseases + + D015212 + N0000003206 + + + Myeloid Leukemia, Chronic, Accelerated Phase + The phase of chronic myeloid leukemia following the chronic phase (LEUKEMIA, MYELOID, CHRONIC-PHASE), where there are increased systemic symptoms, worsening cytopenias, and refractory LEUKOCYTOSIS. + Leukemia, Myeloid, Accelerated Phase + D015465 + Leukemia, Myeloid, Aggressive-Phase + Leukemia, Myelogenous, Aggressive-Phase + Myeloid Leukemia, Chronic, Aggressive-Phase + C0023472 + Myelogenous Leukemia, Chronic, Aggressive-Phase + M0023822 + + Myeloid Leukemia, Chronic, Accelerated-Phase + Leukemia, Myeloid, Accelerated Phase [Disease/Finding] + 413389003 + Leukemia, Myeloid, Accelerated Phase + Leukemia, Myelogenous, Aggressive Phase + 989240 + C6702 + N0000003262 + Leukemia, Myeloid, Accelerated-Phase + Myeloid Leukemia, Chronic, Aggressive Phase + Myelogenous Leukemia, Chronic, Aggressive Phase + + + Panic Disorder + Panic Disorder [Disease/Finding] + 1022562 + 371631005 + C0030319 + C7062 + Panic Disorder + M0025297 + N0000003442 + D016584 + A type of anxiety disorder characterized by unexpected panic attacks that last minutes or, rarely, hours. Panic attacks begin with intense apprehension, fear or terror and, often, a feeling of impending doom. Symptoms experienced during a panic attack include dyspnea or sensations of being smothered; dizziness, loss of balance or faintness; choking sensations; palpitations or accelerated heart rate; shakiness; sweating; nausea or other form of abdominal distress; depersonalization or derealization; paresthesias; hot flashes or chills; chest discomfort or pain; fear of dying and fear of not being in control of oneself or going crazy. Agoraphobia may also develop. Similar to other anxiety disorders, it may be inherited as an autosomal dominant trait. + + + + Plasmodium falciparum Malaria + Malaria caused by PLASMODIUM FALCIPARUM. This is the severest form of malaria and is associated with the highest levels of parasites in the blood. This disease is characterized by irregularly recurring febrile paroxysms that in extreme cases occur with acute cerebral, renal, or gastrointestinal manifestations. + N0000003481 + M0025570 + D016778 + C7140 + 1023574 + C0024535 + Malaria, Falciparum [Disease/Finding] + 62676009 + + Malaria, Falciparum + Malaria, Falciparum + + + M0025572 + 27052006 + N0000003483 + C0024537 + C7144 + Malaria, Vivax + Plasmodium vivax Malaria + D016780 + Malaria, Vivax + 1022708 + + Malaria caused by PLASMODIUM VIVAX. This form of malaria is less severe than MALARIA, FALCIPARUM, but there is a higher probability for relapses to occur. Febrile paroxysms often occur every other day. + Malaria, Vivax [Disease/Finding] + + + 42399005 + N0000003529 + 1022860 + Kidney Failure + Kidney Failure [Disease/Finding] + A severe irreversible decline in the ability of kidneys to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism. + + C0035078 + D051437 + 266553002 + Kidney Failure + Renal Failure + C7236 + M0025974 + + + D017118 + M0026010 + An autosomal dominant porphyria that is due to a deficiency of HYDROXYMETHYLBILANE SYNTHASE in the LIVER, the third enzyme in the 8-enzyme biosynthetic pathway of HEME. Clinical features are recurrent and life-threatening neurologic disturbances, ABDOMINAL PAIN, and elevated level of AMINOLEVULINIC ACID and PORPHOBILINOGEN in the urine. + 1023116 + Porphyria, Acute Intermittent [Disease/Finding] + C7250 + C0162565 + Acute Porphyria + 234422006 + N0000003536 + Porphyria, Acute Intermittent + + Porphyria, Acute Intermittent + + + D017119 + Porphyria Cutanea Tarda + 61860000 + C0162566 + N0000003537 + Porphyria Cutanea Tarda [Disease/Finding] + An autosomal dominant or acquired porphyria due to a deficiency of UROPORPHYRINOGEN DECARBOXYLASE in the LIVER. It is characterized by photosensitivity and cutaneous lesions with little or no neurologic symptoms. Type I is the acquired form and is strongly associated with liver diseases and hepatic toxicities caused by alcohol or estrogenic steroids. Type II is the familial form. + M0026011 + 1025616 + Porphyria Cutanea Tarda + + C7252 + + + Tachycardia, Ventricular + 1023929 + + Tachycardia, Ventricular + M0026083 + 25569003 + Tachycardia, Ventricular [Disease/Finding] + An abnormally rapid ventricular rhythm usually in excess of 150 beats per minute. It is generated within the ventricle below the BUNDLE OF HIS, either as autonomic impulse formation or reentrant impulse conduction. Depending on the etiology, onset of ventricular tachycardia can be paroxysmal (sudden) or nonparoxysmal, its wide QRS complexes can be uniform or polymorphic, and the ventricular beating may be independent of the atrial beating (AV dissociation). + C7260 + C0042514 + D017180 + N0000003541 + Ventricular Tachycardia + + + 414545008 + Ischemia, Myocardial + C0151744 + A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries (CORONARY ARTERY DISEASE), to obstruction by a thrombus (CORONARY THROMBOSIS), or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (MYOCARDIAL INFARCTION). + Heart Disease, Ischemic + 1022046 + N0000003550 + M0026104 + Myocardial Ischemia + 414795007 + Myocardial Ischemia + C7278 + Ischemic Heart Disease + D017202 + Myocardial Ischemia [Disease/Finding] + + + + Enterobius vermicularis Infection + C7292 + Oxyuris vermicularis Infection + Infection with nematodes of the genus ENTEROBIUS; E. vermicularis, the pinworm of man, causes a crawling sensation and pruritus. This condition results in scratching the area, occasionally causing scarification. + Infection, Enterobius vermicularis + Infection, Oxyuris vermicularis + 1023562 + 266162007 + C0086227 + Enterobiasis [Disease/Finding] + Enterobiasis + N0000003557 + M0026142 + 360419005 + D017229 + + Enterobiasis + + + Skin Diseases, Vascular + Skin diseases affecting or involving the cutaneous blood vessels and generally manifested as inflammation, swelling, erythema, or necrosis in the affected area. + M0026469 + Vascular Skin Diseases + 1024271 + Skin Diseases, Vascular + Skin Diseases, Vascular [Disease/Finding] + C7334 + N0000003578 + + C0162819 + D017445 + 11263005 + + + A heterogeneous group of disorders with the common feature of prolonged eosinophilia of unknown cause and associated organ system dysfunction, including the heart, central nervous system, kidneys, lungs, gastrointestinal tract, and skin. There is a massive increase in the number of eosinophils in the blood, mimicking leukemia, and extensive eosinophilic infiltration of the various organs. It is often referred to as idiopathic. + N0000003620 + + Hypereosinophilic Syndrome + C1540912 + Hypereosinophilic Syndrome + C7418 + D017681 + Hypereosinophilic Syndrome [Disease/Finding] + M0026741 + 1024984 + 128835008 + + + N0000003803 + Pneumovirus infections caused by the RESPIRATORY SYNCYTIAL VIRUSES. Humans and cattle are most affected but infections in goats and sheep have been reported. + + D018357 + Respiratory Syncytial Virus Infections + Respiratory Syncytial Virus Infections + C0035235 + 986730 + M0027589 + Infections, Respiratory Syncytial Virus + Respiratory Syncytial Virus Infections [Disease/Finding] + C7784 + 55735004 + + + 1024535 + N0000003804 + C0206754 + Neuroendocrine Tumors + Neuroendocrine Tumors [Disease/Finding] + Tumors whose cells possess secretory granules and originate from the neuroectoderm, i.e., the cells of the ectoblast or epiblast that program the neuroendocrine system. Common properties across most neuroendocrine tumors include ectopic hormone production (often via APUD CELLS), the presence of tumor-associated antigens, and isozyme composition. + D018358 + 255046005 + M0027590 + C7786 + Neuroendocrine Tumors + + + + Hepatitis, Autoimmune + N0000003952 + A chronic self-perpetuating hepatocellular INFLAMMATION of unknown cause, usually with HYPERGAMMAGLOBULINEMIA and serum AUTOANTIBODIES. + M0029243 + Hepatitis, Autoimmune + + Hepatitis, Autoimmune [Disease/Finding] + Autoimmune Chronic Hepatitis + C8082 + D019693 + 408335007 + 1021796 + C0241910 + Autoimmune Hepatitis + + + N0000003954 + INFLAMMATION of the LIVER in humans that is caused by HEPATITIS C VIRUS lasting six months or more. Chronic hepatitis C can lead to LIVER CIRRHOSIS. + Chronic Hepatitis C + C0524910 + Hepatitis C, Chronic [Disease/Finding] + + M0029252 + D019698 + Hepatitis C, Chronic + Hepatitis C, Chronic + 1025809 + C8086 + 128302006 + + + D019958 + Attention Deficit and Disruptive Behavior Disorders + Attention Deficit and Disruptive Behavior Disorders [Disease/Finding] + Attention Deficit and Disruptive Behavior Disorders + C0236964 + M0029636 + N0000003971 + C8120 + 1031543 + + + + M0029642 + C8128 + Mood Disorders [Disease/Finding] + C0525045 + N0000003975 + Affective Disorders + + Those disorders that have a disturbance in mood as their predominant feature. + D019964 + Mood Disorders + 46206005 + Mood Disorders + 1022464 + + + C8152 + Human Herpesvirus 4 Infections + 402121009 + Infections, EBV + Epstein-Barr Virus Infections [Disease/Finding] + EBV Infections + C0149678 + + Infection with human herpesvirus 4 (HERPESVIRUS 4, HUMAN); which may facilitate the development of various lymphoproliferative disorders. These include BURKITT LYMPHOMA (African type), INFECTIOUS MONONUCLEOSIS, and oral hairy leukoplakia (LEUKOPLAKIA, HAIRY). + 1024384 + M0029738 + Herpesvirus 4 Infections, Human + Infections, Epstein-Barr Virus + N0000003987 + Human Herpes Virus 4 Infections + Epstein-Barr Virus Infections + D020031 + Epstein-Barr Virus Infections + + + C0042487 + N0000004074 + Thrombosis, Venous + Venous Thrombosis + C8326 + M0029908 + 111293003 + Phlebothrombosis + The formation or presence of a blood clot (THROMBUS) within a vein. + Venous Thrombosis [Disease/Finding] + Venous Thrombosis + 1023173 + + 18266009 + D020246 + + + Intracranial Hemorrhages + D020300 + 1026294 + Intracranial Hemorrhages + + Bleeding within the SKULL, including hemorrhages in the brain and the three membranes of MENINGES. The escape of blood often leads to the formation of HEMATOMA in the cranial epidural, subdural, and subarachnoid spaces. + Hemorrhage, Intracranial + C0151699 + Intracranial Hemorrhages [Disease/Finding] + N0000004102 + 1386000 + C8382 + M0328611 + + + Abnormal involuntary movements which primarily affect the extremities, trunk, or jaw that occur as a manifestation of an underlying disease process. Conditions which feature recurrent or persistent episodes of dyskinesia as a primary manifestation of disease may be referred to as dyskinesia syndromes (see MOVEMENT DISORDERS). Dyskinesias are also a relatively common manifestation of BASAL GANGLIA DISEASES. + Dyskinesias [Disease/Finding] + 9748009 + C8586 + 1021897 + Abnormal Movements + Dyskinesias + D020820 + N0000004204 + M0014140 + + C0013384 + Dyskinesias + + + 2028 + C0007004 + M0003360 + Carbohydrates + The largest class of organic compounds, including STARCH; GLYCOGEN; CELLULOSE; POLYSACCHARIDES; and simple MONOSACCHARIDES. Carbohydrates are composed of carbon, hydrogen, and oxygen in a ratio of Cn(H2O)n. + + C21790 + Carbohydrates + Carbohydrates [Chemical/Ingredient] + N0000005723 + D002241 + + + C21866 + 703 + M0000973 + An antianginal and antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting Na,K-activated myocardial adenosine triphosphatase. There is a resulting decrease in heart rate and in vascular resistance. + Methanone, (2-butyl-3-benzofuranyl)(4-(2-(diethylamino)ethoxy)-3,5-diiodophenyl)- + N0000005761 + Amiodarone [Chemical/Ingredient] + + Amiodarone + C0002598 + Amiodarone + D000638 + Amiodarone + + + 36567 + C22028 + N0000005842 + C0074554 + A derivative of LOVASTATIN and potent competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES), which is the rate-limiting enzyme in cholesterol biosynthesis. It may also interfere with steroid hormone production. Due to the induction of hepatic LDL RECEPTORS, it increases breakdown of LDL CHOLESTEROL. + M0029425 + Synvinolin + Simvastatin + Simvastatin [Chemical/Ingredient] + Simvastatin + + Simvastatin + D019821 + + + Digoxin + D004077 + Digoxin [Chemical/Ingredient] + N0000005903 + Card-20(22)-enolide, 3-((O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1-4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy)-12,14-dihydroxy-, (3beta,5beta,12beta)- + + C0012265 + 3407 + M0006386 + C22150 + A cardiotonic glycoside obtained mainly from Digitalis lanata; it consists of three sugars and the aglycone DIGOXIGENIN. Digoxin has positive inotropic and negative chronotropic activity. It is used to control ventricular rate in ATRIAL FIBRILLATION and in the management of congestive heart failure with atrial fibrillation. Its use in congestive heart failure and sinus rhythm is less certain. The margin between toxic and therapeutic doses is small. (From Martindale, The Extra Pharmacopoeia, 30th ed, p666) + Digoxin + Digoxin + + + 6H-Purine-6-thione, 1,7-dihydro- + 6-Mercaptopurine + M0023263 + N0000006010 + 6-Thiohypoxanthine + 103 + mercaptopurine + Mercaptopurine + 6-Thiopurine + C22364 + + An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. + 6-Mercaptopurine + 1,7-Dihydro-6H-purine-6-thione + C0000618 + D015122 + 6-Mercaptopurine [Chemical/Ingredient] + + + A potent HIV protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children. + Nelfinavir + D019888 + Nelfinavir + M0029531 + C22438 + 134527 + Nelfinavir + Nelfinavir [Chemical/Ingredient] + C0525005 + + N0000006047 + + + Bepridil + Bepridil [Chemical/Ingredient] + D015764 + + A long-acting calcium-blocking agent with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist. + C0005116 + Bepridil + Bepridil + 1436 + N0000006461 + M0024153 + C23270 + 1-Pyrrolidineethanamine, beta-((2-methylpropoxy)methyl)-N-phenyl-N-(phenylmethyl)- + + + Cisapride [Chemical/Ingredient] + C23528 + + 35255 + Cisapride + D020117 + A substituted benzamide used for its prokinetic properties. It is used in the management of gastroesophageal reflux disease, functional dyspepsia, and other disorders associated with impaired gastrointestinal motility. (Martindale The Extra Pharmacopoeia, 31st ed) + N0000006590 + C0072916 + M0029858 + Cisapride + Cisapride + Benzamide, 4-amino-5-chloro-N-(1-(3-(4-fluorophenoxy)propyl)-3-methoxy -4-piperidinyl)-2-methoxy-, cis- + + + Reserpine [Chemical/Ingredient] + Yohimban-16-carboxylic acid, 11,17-dimethoxy-18-((3,4,5-trimethoxybenzoyl)oxy)-, methyl ester, (3beta,16beta,17alpha,18beta,20alpha)- + An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria. Reserpine inhibits the uptake of norepinephrine into storage vesicles resulting in depletion of catecholamines and serotonin from central and peripheral axon terminals. It has been used as an antihypertensive and an antipsychotic as well as a research tool, but its adverse effects limit its clinical use. + Reserpine + Reserpine + D012110 + + Reserpine + N0000006632 + C23612 + C0035179 + M0018861 + 9260 + + + M0017736 + C0033429 + + Propafenone [Chemical/Ingredient] + Propafenone + Propafenone + 8754 + Propafenone + An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity. The drug is generally well tolerated. + N0000006692 + C23732 + 1-Propanone, 1-(2-(2-hydroxy-3-(propylamino)propoxy)phenyl)-3-phenyl- + D011405 + + + + C0292818 + D019438 + Ritonavir [Chemical/Ingredient] + N0000007423 + An HIV protease inhibitor that works by interfering with the reproductive cycle of HIV. + 85762 + M0028918 + Ritonavir + Ritonavir + C25198 + Ritonavir + + + Pyrido(4,3-b)Indoles + Carbolines [Chemical/Ingredient] + D002243 + M0003364 + A group of pyrido-indole compounds. Included are any points of fusion of pyridine with the five-membered ring of indole and any derivatives of these compounds. These are similar to CARBAZOLES which are benzo-indoles. + N0000007499 + C0007007 + Carbolines + + C25354 + 2030 + Carbolines + + + C25362 + Alkaloids + D000470 + 496 + C0002062 + M0000713 + Alkaloids + N0000007503 + + Alkaloids [Chemical/Ingredient] + Organic nitrogenous bases. Many alkaloids of medical importance occur in the animal and vegetable kingdoms, and some have been synthesized. (Grant & Hackh's Chemical Dictionary, 5th ed) + + + Anilides [Chemical/Ingredient] + Anilides + C0003035 + N0000007515 + D000813 + Anilides + + C25386 + 842 + M0001214 + + + C0005037 + Benzene Derivatives + 1387 + Benzene Derivatives [Chemical/Ingredient] + C25406 + N0000007525 + D001555 + Benzene Derivatives + M0002333 + + + + A group of macrocyclic compounds formed by chain extension of multiple PROPIONATES and cyclized into a large (typically 12, 14, 16) membered lactone. They are often glycosylated. Many of them are ANTIBIOTICS. + + 586370 + C25414 + Macrolides [Chemical/Ingredient] + M0028311 + N0000007529 + Macrolides + D018942 + Macrolides + C0282563 + + + C0037968 + M0020345 + Spiro Compounds [Chemical/Ingredient] + Spiro Compounds + Spiro Compounds + D013141 + A group of compounds consisting in part of two rings sharing one carbon atom in common. + 9993 + C25420 + N0000007532 + + + + C25428 + Compounds with a BENZENE fused to IMIDAZOLES. + 1396 + Benzimidazoles + Benzimidazoles + N0000007536 + + M0002348 + C0005050 + Benzimidazoles [Chemical/Ingredient] + D001562 + + + Pyridines + M0018233 + Compounds with a six membered aromatic ring containing NITROGEN. The saturated version is PIPERIDINES. + 8995 + C0034255 + D011725 + Pyridines [Chemical/Ingredient] + Pyridines + C25496 + + N0000007570 + + + N0000007577 + Salicylamides + M0019360 + + Salicylamides + C25510 + D012457 + C0036072 + 9519 + Salicylamides [Chemical/Ingredient] + Amides of salicylic acid. + + + N0000007578 + 9521 + 2-Hydroxy-N-phenylbenzamides. N-phenyl substituted salicylamides. Derivatives have been used as fungicides, anti-mildew agents and topical antifungal agents. In concentrated form may cause irritation of skin and mucous membranes. + M0019361 + C25512 + C0036074 + + N-Phenylsalicylamides + Salicylanilides + Salicylanilides [Chemical/Ingredient] + D012458 + Salicylanilides + + + C0034326 + C25542 + + Pyrrolidines [Chemical/Ingredient] + 9034 + M0018277 + Pyrrolidines + N0000007593 + D011759 + Pyrrolidines + + + Ergotamines + M0007665 + A series of structurally-related alkaloids containing the ergotaman backbone structure. + Ergotamines [Chemical/Ingredient] + Ergotamines + + C0014711 + 4026 + N0000007621 + D004879 + C25602 + + + D000146 + Acids, Carbocyclic + Acids, Carbocyclic [Chemical/Ingredient] + Carbocyclic Acids + C25616 + 233 + N0000007628 + Acids, Carbocyclic + C0001131 + + M0000223 + Carboxylic acids that have a homocyclic ring structure in which all the ring atoms are carbon. + + + M0012175 + 6209 + Lactones + Lactones + D007783 + N0000007646 + C0022947 + Lactones [Chemical/Ingredient] + Cyclic esters of hydroxy carboxylic acids, containing a 1-oxacycloalkan-2-one structure. Large cyclic lactones of over a dozen atoms are MACROLIDES. + + C25652 + + + + C25712 + Organic Chemicals [Chemical/Ingredient] + C0029224 + 7692 + Organic Chemicals + N0000007676 + D009930 + M0015401 + Organic Chemicals + A broad class of substances containing carbon and its derivatives. Many of these chemicals will frequently contain hydrogen with or without oxygen, nitrogen, sulfur, phosphorus, and other elements. They exist in either carbon chain or carbon ring form. + + + Amides [Chemical/Ingredient] + C0002482 + N0000007681 + C25722 + D000577 + Amides + Amides + Organic compounds containing the -CO-NH2 radical. Amides are derived from acids by replacement of -OH by -NH2 or from ammonia by the replacement of H by an acyl group. (From Grant & Hackh's Chemical Dictionary, 5th ed) + M0000897 + 633 + + + + N0000007720 + 10072 + D013256 + Steroids [Chemical/Ingredient] + + C25800 + A group of polycyclic compounds closely related biochemically to TERPENES. They include cholesterol, numerous hormones, precursors of certain vitamins, bile acids, alcohols (STEROLS), and certain natural drugs and poisons. Steroids have a common nucleus, a fused, reduced 17-carbon atom ring system, cyclopentanoperhydrophenanthrene. Most steroids also have two methyl groups and an aliphatic side-chain attached to the nucleus. (From Hawley's Condensed Chemical Dictionary, 11th ed) + M0020527 + Steroids + C0038317 + Steroids + + + Cinchonan-9-ol, 6'-methoxy-, (9S)- + C25816 + 9068 + N0000007728 + Chinidin + C0034414 + + M0018341 + Quinidine + An optical isomer of quinine, extracted from the bark of the Cinchona tree and similar plant species. This alkaloid dampens the excitability of cardiac and skeletal muscles by blocking sodium and potassium currents across cellular membranes. It prolongs cellular action potential, and decreases automaticity. Quinidine also blocks muscarinic and alpha-adrenergic neurotransmission. + D011802 + Quinidine + Quinidine + Quinidine [Chemical/Ingredient] + + + Imidazoles + + 5684 + N0000007769 + Compounds containing 1,3-diazole, a five membered aromatic ring containing two nitrogen atoms separated by one of the carbons. Chemically reduced ones include IMIDAZOLINES and IMIDAZOLIDINES. Distinguish from 1,2-diazole (PYRAZOLES). + Imidazoles [Chemical/Ingredient] + C0020924 + C25898 + Imidazoles + M0011048 + D007093 + + + Furans + C25910 + Furans [Chemical/Ingredient] + M0008898 + 4600 + Furans + D005663 + + Compounds with a 5-membered ring of four carbons and an oxygen. They are aromatic heterocycles. The reduced form is tetrahydrofuran. + C0016850 + N0000007775 + + + C0002526 + + C26026 + D000602 + N0000007833 + Amino Acids, Peptides, and Proteins [Chemical/Ingredient] + Amino acids and chains of amino acids connected by peptide linkages. + Amino Acids, Peptides, and Proteins + Amino Acids, Peptides, and Proteins + 664 + M0000928 + + + C0030956 + N0000007874 + M0016238 + Peptides [Chemical/Ingredient] + + D010455 + 8036 + C26108 + Peptides + Peptides + Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are linear polypeptides that are normally synthesized on RIBOSOMES. + + + C26110 + N0000007875 + Peptides, Cyclic + M0016239 + + Cyclic Peptides + Peptides, Cyclic + Peptides, Cyclic [Chemical/Ingredient] + Peptides whose amino and carboxy ends are linked together with a peptide bond forming a circular chain. Some of them are ANTI-INFECTIVE AGENTS. Some of them are biosynthesized non-ribosomally (PEPTIDE BIOSYNTHESIS, NON-RIBOSOMAL). + D010456 + 8037 + C0030957 + + + M0009500 + 4958 + Glycosides + C26154 + C0017977 + Any compound that contains a constituent sugar, in which the hydroxyl group attached to the first carbon is substituted by an alcoholic, phenolic, or other group. They are named specifically for the sugar contained, such as glucoside (glucose), pentoside (pentose), fructoside (fructose), etc. Upon hydrolysis, a sugar and nonsugar component (aglycone) are formed. (From Dorland, 28th ed; From Miall's Dictionary of Chemistry, 5th ed) + D006027 + Glycosides + Glycosides [Chemical/Ingredient] + + N0000007897 + + + A family of hexahydropyridines. + Piperidines + 8343 + Piperidines + + D010880 + C0031960 + N0000007929 + Piperidines [Chemical/Ingredient] + C26220 + M0016885 + + + N0000007930 + 8344 + Piperidones [Chemical/Ingredient] + M0016886 + Piperidones + C26222 + C0031961 + D010881 + + Piperidones + + + C26310 + 5476 + C0020242 + + M0010687 + N0000007973 + Hydrocarbons [Chemical/Ingredient] + D006838 + Hydrocarbons + Hydrocarbons + + + M0020768 + Mercaptans + 10200 + C0038734 + Mercapto Compounds + + Thiols + C26446 + D013438 + N0000008041 + Sulfhydryl Compounds + Sulfhydryl Compounds + Compounds containing the -SH radical. + Sulfhydryl Compounds [Chemical/Ingredient] + + + N0000008052 + M0011238 + Indoles + 5779 + Benzopyrroles with the nitrogen at the number one carbon adjacent to the benzyl portion, in contrast to ISOINDOLES which have the nitrogen away from the six-membered ring. + D007211 + C0021242 + Indoles + Indoles [Chemical/Ingredient] + + C26468 + + + Cinnamates + C26484 + C0008801 + + N0000008060 + Cinnamates + D002934 + 2547 + Cinnamates [Chemical/Ingredient] + M0004490 + + + D011687 + C0034140 + Purines + Purines [Chemical/Ingredient] + N0000008065 + M0018169 + 8952 + A series of heterocyclic compounds that are variously substituted in nature and are known also as purine bases. They include ADENINE and GUANINE, constituents of nucleic acids, as well as many alkaloids such as CAFFEINE and THEOPHYLLINE. Uric acid is the metabolic end product of purine metabolism. + Purines + C26494 + + + + Heterocyclic Compounds [Chemical/Ingredient] + 5283 + D006571 + M0010290 + N0000008095 + Heterocyclic Compounds + C0019398 + + C26554 + Heterocyclic Compounds + Ring compounds having atoms other than carbon in their nuclei. (Grant & Hackh's Chemical Dictionary, 5th ed) + + + D006575 + 5286 + + C26556 + C0019401 + Heterocyclic Compounds, 3-Ring [Chemical/Ingredient] + A class of organic compounds containing three ring structures, one of which is made up of more than one kind of atom, usually carbon plus another atom. The heterocycle may be either aromatic or nonaromatic + Heterocyclic Compounds, 3-Ring + N0000008096 + Heterocyclic Cpds, 3 Ring + M0010294 + Heterocyclic Compounds, 3-Ring + + + Carboxylic Acids + C26638 + 2060 + C0007066 + Carboxylic Acids + Organic compounds containing the carboxy group (-COOH). This group of compounds includes amino acids and fatty acids. Carboxylic acids can be saturated, unsaturated, or aromatic. + D002264 + + N0000008137 + M0003405 + Carboxylic Acids [Chemical/Ingredient] + + + The aglycone constituents of CARDIAC GLYCOSIDES. The ring structure is basically a cyclopentanoperhydrophenanthrene nucleus attached to a lactone ring at the C-17 position. + Cardanolides [Chemical/Ingredient] + C0007142 + + M0003447 + 2077 + C26644 + D002297 + Cardanolides + N0000008140 + Cardanolides + + + Cardiotonic Steroids + 2079 + D002301 + + Cardiac Glycosides [Chemical/Ingredient] + Cyclopentanophenanthrenes with a 5- or 6-membered lactone ring attached at the 17-position and SUGARS attached at the 3-position. Plants they come from have long been used in congestive heart failure. They increase the force of cardiac contraction without significantly affecting other parameters, but are very toxic at larger doses. Their mechanism of action usually involves inhibition of the NA(+)-K(+)-EXCHANGING ATPASE and they are often used in cell biological studies for that purpose. + M0003451 + N0000008157 + Cardiac Glycosides + Cardiac Glycosides + C26678 + C0007158 + + + N0000008164 + A major group of unsaturated cyclic hydrocarbons containing two or more rings. The vast number of compounds of this important group, derived chiefly from petroleum and coal tar, are rather highly reactive and chemically versatile. The name is due to the strong and not unpleasant odor characteristic of most substances of this nature. (From Hawley's Condensed Chemical Dictionary, 12th ed, p96) + C26692 + Polycyclic Hydrocarbons, Aromatic [Chemical/Ingredient] + 8504 + C0032458 + Polynuclear Aromatic Hydrocarbons + D011084 + + M0017164 + Polycyclic Hydrocarbons, Aromatic + Polycyclic Hydrocarbons, Aromatic + Polycyclic Aromatic Hydrocarbons + + + + Azoles [Chemical/Ingredient] + M0002083 + N0000008217 + Five membered rings containing a NITROGEN atom. + C26798 + Azoles + 1269 + Azoles + C0004504 + D001393 + + + Hydrocarbons, Aromatic + C0020245 + N0000008229 + D006841 + Organic compounds containing carbon and hydrogen in the form of an unsaturated, usually hexagonal ring structure. The compounds can be single ring, or double, triple, or multiple fused rings. + C26822 + Hydrocarbons, Aromatic [Chemical/Ingredient] + + M0010690 + Aromatic Hydrocarbons + 5479 + Hydrocarbons, Aromatic + + + Sulfur Compounds + C0038776 + N0000008249 + + C26862 + 10225 + D013457 + Sulfur Compounds [Chemical/Ingredient] + Inorganic or organic compounds that contain sulfur as an integral part of the molecule. + Sulfur Compounds + M0020800 + + + 5824 + C26878 + A broad class of substances encompassing all those that do not include carbon and its derivatives as their principal elements. However, carbides, carbonates, cyanides, cyanates, and carbon disulfide are included in this class. + Inorganic Chemicals [Chemical/Ingredient] + N0000008257 + Inorganic Chemicals + + M0011365 + C0021521 + D007287 + Inorganic Chemicals + + + Heterocyclic Cpds, 1-Ring + M0010292 + Heterocyclic Compounds, 1-Ring + D006573 + 5284 + C0019399 + N0000008259 + Heterocyclic Compounds, 1-Ring + C26882 + + Heterocyclic Compounds, 1-Ring [Chemical/Ingredient] + A class of organic compounds containing a ring structure made up of more than one kind of atom, usually carbon plus another atom. The ring structure can be aromatic or nonaromatic. + + + M0010293 + Heterocyclic Compounds, 2-Ring + C0019400 + 5285 + + N0000008260 + C26884 + A class of organic compounds containing two ring structures, one of which is made up of more than one kind of atom, usually carbon plus another atom. The heterocycle may be either aromatic or nonaromatic. + Heterocyclic Compounds, 2-Ring + Heterocyclic Compounds, 2-Ring [Chemical/Ingredient] + D006574 + + + C0020248 + Hydrocarbons, Cyclic + + Organic compounds composed exclusively of carbon and hydrogen forming a closed ring that may be either alicyclic or aromatic. + M0010694 + Hydrocarbons, Cyclic [Chemical/Ingredient] + Cyclic Hydrocarbons + D006844 + 5482 + N0000008280 + C26926 + Hydrocarbons, Cyclic + + + N0000008369 + 985660 + C1371319 + + C27104 + Conduction System Depolarization [PE] + Conduction System Depolarization + + + C1371555 + Decreased Disorganized Electrical Activity [PE] + Decreased Disorganized Electrical Activity + N0000008578 + + 986372 + C27522 + + + N0000008764 + C27894 + C2267200 + + 989127 + Decreased Norepinephrine Activity [PE] + Decreased Norepinephrine Activity + + + Decreased Respiratory Secretions + C1371875 + 985021 + Decreased Respiratory Secretions [PE] + + N0000008868 + C28102 + + + Decreased Sympathetic Norepinephrine Activity + 986379 + C28350 + Decreased Sympathetic Norepinephrine Activity [PE] + C2267207 + N0000008992 + + + + N0000009027 + + Electrical Activity Alteration + Electrical Activity Alteration [PE] + C28420 + 985119 + C1372033 + + + Lipid Metabolism Alteration [PE] + C29844 + N0000009739 + 987514 + + Lipid Metabolism Alteration + C0548934 + + + Negative Chronotropy + + C1372752 + 986396 + Negative Chronotropy [PE] + N0000009756 + C29878 + + + C2916815 + C29884 + 987311 + N0000009759 + Nervous System Activity Alteration [PE] + + Nervous System Activity Alteration + + + + Nodal Depolarization + C29892 + C1372759 + N0000009763 + Nodal Depolarization [PE] + 987463 + + + C1372798 + N0000009802 + Physiological Effects + + Physiological Effects [PE] + 984490 + C29970 + + + + C29982 + 987259 + Positive Chronotropy + N0000009808 + Positive Chronotropy [PE] + C1372804 + + + + C29984 + Positive Inotropy + N0000009809 + 989869 + C1372805 + Positive Inotropy [PE] + + + Renal/Urological Activity Alteration + + C30030 + N0000009832 + Renal/Urological Activity Alteration [PE] + C1372863 + 988191 + + + 990716 + Unknown Cellular or Molecular Interaction + N0000009915 + Unknown Cellular or Molecular Interaction [MoA] + C1373108 + C30196 + + + + N0000010195 + Pregnancy + C31746 + Pregnancy [Disease/Finding] + + 1022794 + C0032961 + 289908002 + + + C31764 + C0021270 + N0000010203 + 1023674 + + Infant + Infant [Disease/Finding] + 133931009 + + + N0000010205 + 410601007 + C31768 + 1025000 + + Child [Disease/Finding] + C0008059 + Child + + + Young Child [Disease/Finding] + 1029003 + Young Child + C31772 + N0000010207 + 74489007 + C0728836 + + + + Lactation [Disease/Finding] + Lactation + N0000010216 + 1025167 + 169741004 + C31790 + + C0022925 + + + + N0000010582 + C288626 + 987399 + Drug Products by Generic Ingredient Combinations + C2267084 + Drug Products by Generic Ingredient Combinations + + + N0000010583 + C2267085 + + 989498 + C288627 + A [Preparations] + A [Preparations] + + + C288628 + 987472 + + B [Preparations] + C2267086 + B [Preparations] + N0000010584 + + + C288629 + + C [Preparations] + 987820 + C2267087 + N0000010585 + C [Preparations] + + + + 990856 + C2267088 + D [Preparations] + N0000010586 + C288630 + D [Preparations] + + + C288631 + E [Preparations] + + E [Preparations] + 984666 + N0000010587 + C2267089 + + + F [Preparations] + C288632 + N0000010588 + 986610 + C2267090 + + F [Preparations] + + + C288633 + G [Preparations] + G [Preparations] + N0000010589 + + C2267091 + 986405 + + + C288634 + H [Preparations] + + H [Preparations] + N0000010590 + 985945 + C2741642 + + + N0000010591 + C288635 + I [Preparations] + + C2267092 + I [Preparations] + 987875 + + + + N0000010594 + L [Preparations] + C2267094 + 984195 + C288638 + L [Preparations] + + + C288639 + M [Preparations] + C2267095 + M [Preparations] + + 989499 + N0000010595 + + + N [Preparations] + N0000010596 + N [Preparations] + + C2267096 + 984993 + C288640 + + + N0000010598 + C288642 + P [Preparations] + P [Preparations] + + C2267098 + 987400 + + + C288644 + C2267100 + + N0000010600 + R [Preparations] + R [Preparations] + 987269 + + + T [Preparations] + + C2267102 + N0000010602 + 989806 + C288646 + T [Preparations] + + + C291490 + Cardiomyopathies [Disease/Finding] + Myocardiopathies + Myocardial Diseases + D009202 + 1025008 + M0014337 + N0000011137 + 57809008 + 85898001 + Cardiomyopathies + Cardiomyopathies + A group of diseases in which the dominant feature is the involvement of the CARDIAC MUSCLE itself. Cardiomyopathies are classified according to their predominant pathophysiological features (DILATED CARDIOMYOPATHY; HYPERTROPHIC CARDIOMYOPATHY; RESTRICTIVE CARDIOMYOPATHY) or their etiological/pathological factors (CARDIOMYOPATHY, ALCOHOLIC; ENDOCARDIAL FIBROELASTOSIS). + + C0878544 + + + M0377033 + Indole Alkaloids + Group of alkaloids containing a benzylpyrrole group (derived from TRYPTOPHAN) + C0949738 + N0000011188 + Indole Alkaloids [Chemical/Ingredient] + Indole Alkaloids + + C291544 + D026121 + 287953 + + + M0456185 + D047028 + Macrocyclic Compounds + C1449665 + Macrocycle Compounds + Cyclic compounds with a ring size of approximately 1-4 dozen atoms. + 469970 + N0000011330 + Macrocyclic Compounds [Chemical/Ingredient] + C291686 + + Macrocyclic Compounds + + + Compounds consisting of two or more fused ring structures. + Polycyclic Compounds + D011083 + M0017162 + 8502 + N0000011331 + Polycyclic Compounds [Chemical/Ingredient] + + Polycyclic Compounds + C291687 + C0032456 + + + Interferon Alfa-2a + INTERFERON ALFA-2A + C0021734 + Ingredient + INTERFERON ALFA-2A + 4022121 + <VANDF_Record>50.6^183^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>183</VA_IEN> + + 5879 + Active + N0000020127 + C15918 + + + <VANDF_Record>50.6^3161^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>3161</VA_IEN> + C0035629 + RIMANTADINE + Active + N0000021902 + 9386 + RIMANTADINE + Rimantadine + + C19566 + 4023897 + Ingredient + + + 72257 + 4023900 + + Active + C0244713 + <VANDF_Record>50.6^3172^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>3172</VA_IEN> + INTERFERON BETA-1B + C15946 + N0000021905 + Ingredient + interferon beta-1b + INTERFERON BETA-1B + + + 12574 + C0045093 + Active + <VANDF_Record>50.6^3358^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>3358</VA_IEN> + gemcitabine + + GEMCITABINE + GEMCITABINE + C15022 + 4024031 + N0000022036 + Ingredient + + + 134527 + NELFINAVIR + + 4024050 + Ingredient + Active + <VANDF_Record>50.6^3394^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>3394</VA_IEN> + C17618 + C0525005 + N0000022055 + NELFINAVIR + Nelfinavir + + + Ingredient + Active + <VANDF_Record>50.6^3476^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>3476</VA_IEN> + TOREMIFENE + 4024102 + Toremifene + C0076836 + TOREMIFENE + 38409 + C21018 + + N0000022107 + + + C15024 + + C0771488 + Active + Gemcitabine hydrochloride + GEMCITABINE HYDROCHLORIDE + 236234 + <VANDF_Record>50.416^3642^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>3642</VA_IEN> + U347PV74IL + N0000022977 + 4020975 + Ingredient + GEMCITABINE HYDROCHLORIDE + + + Digitoxin + <VANDF_Record>50.416^20^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>20</VA_IEN> + Ingredient + 3403 + N0000145817 + DIGITOXIN + C13764 + DIGITOXIN + + Active + E90NZP2L9U + <VANDF_Record>50.6^9^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>9</VA_IEN> + 4017429 + C0012258 + + + <VANDF_Record>50.416^98^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>98</VA_IEN> + Ingredient + 8B1QWR724A + RESERPINE + <VANDF_Record>50.6^57^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>57</VA_IEN> + Active + C19522 + + Reserpine + 4017506 + C0035179 + N0000145891 + RESERPINE + 9260 + + + 12488 + Active + HYDROXYPROGESTERONE CAPROATE + <VANDF_Record>50.416^207^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>207</VA_IEN> + N0000145993 + C15582 + hydroxyprogesterone caproate (USP) + 276F2O42F5 + C0044971 + Ingredient + HYDROXYPROGESTERONE CAPROATE + 4017613 + + + + C14814 + Active + FLUPHENAZINE HYDROCHLORIDE + Fluphenazine Hydrochloride + N0000146092 + Ingredient + <VANDF_Record>50.416^318^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>318</VA_IEN> + 4017723 + C0700567 + 203207 + + ZOU145W1XL + FLUPHENAZINE HYDROCHLORIDE + + + Ingredient + TRIFLUPROMAZINE HYDROCHLORIDE + + 4017744 + C0304376 + <VANDF_Record>50.416^339^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>339</VA_IEN> + C21136 + 9E75N4A5HM + Active + N0000146110 + Triflupromazine hydrochloride + TRIFLUPROMAZINE HYDROCHLORIDE + 91125 + + + Ingredient + 18927 + BENZTROPINE MESYLATE + WMJ8TL7510 + N0000146182 + C0053156 + C11662 + 4017824 + + <VANDF_Record>50.416^419^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>419</VA_IEN> + benztropine mesylate + BENZTROPINE MESYLATE + Active + + + N0000146203 + + 4017846 + PROMETHAZINE HYDROCHLORIDE + Active + PROMETHAZINE HYDROCHLORIDE + 142445 + R61ZEH7I1I + Ingredient + C0546876 + Promethazine Hydrochloride + C19210 + <VANDF_Record>50.416^441^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>441</VA_IEN> + + + <VANDF_Record>50.416^455^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>455</VA_IEN> + Active + Chlorpromazine hydrochloride + CHLORPROMAZINE HYDROCHLORIDE + N0000146213 + + 104728 + 4017860 + C12754 + CHLORPROMAZINE HYDROCHLORIDE + Ingredient + C0355077 + 9WP59609J6 + + + <VANDF_Record>50.416^456^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>456</VA_IEN> + U42B7VYA4P + C0008286 + <VANDF_Record>50.6^216^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>216</VA_IEN> + CHLORPROMAZINE + N0000146214 + + Active + 2403 + CHLORPROMAZINE + Chlorpromazine + Ingredient + 4017861 + C12752 + + + Digoxin + Active + DIGOXIN + N0000146388 + <VANDF_Record>50.416^644^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>644</VA_IEN> + DIGOXIN + C0012265 + Ingredient + 73K4184T59 + 4018047 + 3407 + <VANDF_Record>50.6^372^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>372</VA_IEN> + C13772 + + + + Ingredient + 6902 + METHYLPREDNISOLONE + 4018068 + <VANDF_Record>50.416^665^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>665</VA_IEN> + Active + C0025815 + N0000146409 + Methylprednisolone + + X4W7ZR7023 + METHYLPREDNISOLONE + <VANDF_Record>50.6^394^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>394</VA_IEN> + C17198 + + + chloroquine phosphate + 20863 + Ingredient + C0055447 + 6E17K3343P + C12714 + CHLOROQUINE PHOSPHATE + 4018228 + + <VANDF_Record>50.416^826^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>826</VA_IEN> + N0000146559 + Active + CHLOROQUINE PHOSPHATE + + + 5293 + <VANDF_Record>50.6^557^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>557</VA_IEN> + <VANDF_Record>50.416^850^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>850</VA_IEN> + + HEXACHLOROPHENE + C15398 + Active + 4018252 + Hexachlorophene + IWW5FV6NK2 + C0019435 + N0000146582 + Ingredient + HEXACHLOROPHENE + + + <VANDF_Record>50.416^851^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>851</VA_IEN> + Hydroxychloroquine Sulfate + Active + C15570 + 8Q2869CNVH + 153972 + 4018253 + HYDROXYCHLOROQUINE SULFATE + + N0000146583 + Ingredient + HYDROXYCHLOROQUINE SULFATE + C0596007 + + + C0028017 + 4018264 + N0000146594 + + C17666 + 8KK8CQ2K8G + Ingredient + NICLOSAMIDE + <VANDF_Record>50.416^862^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>862</VA_IEN> + 7402 + NICLOSAMIDE + Niclosamide + Active + <VANDF_Record>50.6^573^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>573</VA_IEN> + + + C0079589 + Ingredient + N0000146786 + Active + 7FRV7310N6 + TAMOXIFEN CITRATE + 4018462 + Tamoxifen Citrate + + 40137 + C20578 + <VANDF_Record>50.416^1060^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>1060</VA_IEN> + TAMOXIFEN CITRATE + + + CYCLOSPORINE + Cyclosporine + C13348 + Active + 3008 + + 4018761 + 83HN0GTJ6D + C0010592 + CYCLOSPORINE + <VANDF_Record>50.6^1100^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>1100</VA_IEN> + Ingredient + <VANDF_Record>50.416^1363^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>1363</VA_IEN> + N0000147064 + + + 91235 + <VANDF_Record>50.416^1508^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>1508</VA_IEN> + DIGITALIS + C13756 + Active + C0304520 + <VANDF_Record>50.6^1303^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>1303</VA_IEN> + Digitalis preparation + + DIGITALIS + F1T8QT9U8B + Ingredient + 4018904 + N0000147198 + + + + THIETHYLPERAZINE MALEATE + C0242518 + C20802 + N0000147331 + <VANDF_Record>50.416^1670^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>1670</VA_IEN> + Thiethylperazine Malate + 71529 + THIETHYLPERAZINE MALEATE + RUK64CF26E + Ingredient + 4019064 + Active + + + + CETYLPYRIDINIUM CHLORIDE + Cetylpyridinium Chloride + N0000147354 + C12610 + Ingredient + C0007907 + D9OM4SK49P + 2287 + CETYLPYRIDINIUM CHLORIDE + <VANDF_Record>50.416^1702^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>1702</VA_IEN> + <VANDF_Record>50.6^2211^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>2211</VA_IEN> + 4019096 + Active + + + 49717AWG6K + <VANDF_Record>50.416^1910^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>1910</VA_IEN> + RIBAVIRIN + 9344 + RIBAVIRIN + Active + <VANDF_Record>50.6^1909^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>1909</VA_IEN> + N0000147496 + 4019299 + C19534 + + Ribavirin + Ingredient + C0035525 + + + ASTEMIZOLE + Ingredient + <VANDF_Record>50.6^1989^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>1989</VA_IEN> + C11390 + ASTEMIZOLE + 42328 + <VANDF_Record>50.416^1992^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>1992</VA_IEN> + Astemizole + + N0000147536 + Active + 4019379 + C0085170 + + + CLOMIPRAMINE HYDROCHLORIDE + C12984 + 81984 + C0282107 + <VANDF_Record>50.416^2106^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>2106</VA_IEN> + Clomipramine Hydrochloride + 2LXW0L6GWJ + Ingredient + CLOMIPRAMINE HYDROCHLORIDE + + N0000147612 + 4019492 + Active + + + 37806 + TERCONAZOLE + 0KJ2VE664U + terconazole + Ingredient + 4019521 + + C0076115 + C20680 + TERCONAZOLE + Active + N0000147638 + <VANDF_Record>50.6^2169^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>2169</VA_IEN> + <VANDF_Record>50.416^2136^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>2136</VA_IEN> + + + Ingredient + <VANDF_Record>50.6^1852^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>1852</VA_IEN> + C0002641 + AMODIAQUINE + <VANDF_Record>50.416^2229^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>2229</VA_IEN> + 720 + Active + N0000147704 + 220236ED28 + AMODIAQUINE + C11084 + 4019610 + Amodiaquine + + + + Benztropine + <VANDF_Record>50.416^2249^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>2249</VA_IEN> + BENZTROPINE + Ingredient + <VANDF_Record>50.6^190^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>190</VA_IEN> + N0000147723 + BENZTROPINE + Active + C0005098 + 4019630 + C11660 + + 1424 + 1NHL2J4X8K + + + + C0007906 + Ingredient + CETYLPYRIDINIUM + Cetylpyridinium + 2286 + N0000147763 + CETYLPYRIDINIUM + <VANDF_Record>50.416^2290^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>2290</VA_IEN> + Active + C12608 + 4019671 + + + Active + C12708 + <VANDF_Record>50.6^529^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>529</VA_IEN> + Ingredient + CHLOROQUINE + C0008269 + 886U3H6UFF + 4019675 + + CHLOROQUINE + 2393 + <VANDF_Record>50.416^2294^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>2294</VA_IEN> + N0000147767 + Chloroquine + + + CLOMIPRAMINE + <VANDF_Record>50.6^2137^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>2137</VA_IEN> + 4019687 + <VANDF_Record>50.416^2306^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>2306</VA_IEN> + C0009010 + N0000147779 + 2597 + CLOMIPRAMINE + Clomipramine + NUV44L116D + Active + + C12982 + Ingredient + + + EMETINE + <VANDF_Record>50.416^2362^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>2362</VA_IEN> + 3820 + <VANDF_Record>50.6^31^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>31</VA_IEN> + Ingredient + X8D5EPO80M + Emetine + EMETINE + Active + C0013974 + N0000147834 + 4019743 + C14188 + + + + C14804 + Fluphenazine + 4496 + <VANDF_Record>50.416^2382^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>2382</VA_IEN> + S79426A41Z + <VANDF_Record>50.6^115^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>115</VA_IEN> + C0016368 + FLUPHENAZINE + N0000147853 + Ingredient + Active + FLUPHENAZINE + 4019762 + + + + C15568 + HYDROXYCHLOROQUINE + <VANDF_Record>50.6^558^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>558</VA_IEN> + Hydroxychloroquine + 4QWG6N8QKH + N0000147871 + C0020336 + 5521 + <VANDF_Record>50.416^2403^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>2403</VA_IEN> + HYDROXYCHLOROQUINE + Ingredient + Active + 4019780 + + + + Active + C15578 + N0000147872 + C0020387 + HYDROXYPROGESTERONE + <VANDF_Record>50.6^100^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>100</VA_IEN> + <VANDF_Record>50.416^2404^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>2404</VA_IEN> + Ingredient + 5542 + HYDROXYPROGESTERONE + 4019781 + + Hydroxyprogesterone + + + LOPERAMIDE + C16610 + + C0023992 + Loperamide + N0000147893 + Ingredient + 4019804 + LOPERAMIDE + 6X9OC3H4II + <VANDF_Record>50.416^2427^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>2427</VA_IEN> + <VANDF_Record>50.6^1766^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>1766</VA_IEN> + 6468 + Active + + + TML814419R + C0025153 + 4019811 + + C16862 + <VANDF_Record>50.416^2434^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>2434</VA_IEN> + MEFLOQUINE + <VANDF_Record>50.6^2143^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>2143</VA_IEN> + Active + N0000147900 + 6694 + MEFLOQUINE + Mefloquine + Ingredient + + + <VANDF_Record>50.6^1218^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>1218</VA_IEN> + C18490 + PHENAZOPYRIDINE + Ingredient + <VANDF_Record>50.416^2509^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>2509</VA_IEN> + C0031379 + 8120 + N0000147969 + Active + Phenazopyridine + PHENAZOPYRIDINE + K2J09EMJ52 + 4019884 + + + + 8745 + Ingredient + + 4019910 + PROMETHAZINE + C19204 + FF28EJQ494 + Active + PROMETHAZINE + N0000147995 + <VANDF_Record>50.416^2535^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>2535</VA_IEN> + <VANDF_Record>50.6^214^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>214</VA_IEN> + C0033405 + Promethazine + + + N0000148024 + TAMOXIFEN + + C0039286 + Ingredient + C20576 + 4019939 + TAMOXIFEN + 10324 + Tamoxifen + <VANDF_Record>50.416^2565^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>2565</VA_IEN> + 094ZI81Y45 + <VANDF_Record>50.6^772^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>772</VA_IEN> + Active + + + N0000148028 + 4019943 + + Thiethylperazine + C20800 + Ingredient + THIETHYLPERAZINE + C0039865 + 10471 + <VANDF_Record>50.416^2569^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>2569</VA_IEN> + THIETHYLPERAZINE + 8ETK1WAF6R + Active + <VANDF_Record>50.6^1562^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>1562</VA_IEN> + + + Active + 10510 + <VANDF_Record>50.6^825^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>825</VA_IEN> + THIOTHIXENE + + Ingredient + N0000148032 + THIOTHIXENE + <VANDF_Record>50.416^2573^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>2573</VA_IEN> + Thiothixene + C0039955 + C20832 + 7318FJ13YJ + 4019947 + + + <VANDF_Record>50.6^133^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>133</VA_IEN> + RO16TQF95Y + Ingredient + <VANDF_Record>50.416^2584^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>2584</VA_IEN> + N0000148043 + Triflupromazine + TRIFLUPROMAZINE + 4019958 + C21134 + Active + + TRIFLUPROMAZINE + C0040989 + 10805 + + + + N0000148074 + AZITHROMYCIN + C0052796 + Active + <VANDF_Record>50.6^2712^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>2712</VA_IEN> + <VANDF_Record>50.416^2648^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>2648</VA_IEN> + F94OW58Y8V + 4020019 + Azithromycin + AZITHROMYCIN + Ingredient + C11448 + 18631 + + + MYCOPHENOLATE MOFETIL + + C17502 + C0209368 + N0000148406 + Active + <VANDF_Record>50.6^3295^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>3295</VA_IEN> + mycophenolate mofetil + MYCOPHENOLATE MOFETIL + 4020921 + <VANDF_Record>50.416^3581^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>3581</VA_IEN> + 9242ECW6R0 + Ingredient + 68149 + + + RITONAVIR + Active + 4020963 + 85762 + + Ingredient + C19590 + <VANDF_Record>50.416^3629^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>3629</VA_IEN> + Ritonavir + O3J8G9O825 + RITONAVIR + C0292818 + <VANDF_Record>50.6^3349^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>3349</VA_IEN> + N0000148436 + + + 4020992 + Active + + C18312 + 59839 + penciclovir + C0164815 + <VANDF_Record>50.416^3659^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>3659</VA_IEN> + 359HUE8FJC + PENCICLOVIR + <VANDF_Record>50.6^3378^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>3378</VA_IEN> + N0000148462 + PENCICLOVIR + Ingredient + + + C17620 + 266565 + Ingredient + C0886530 + + 4021010 + NELFINAVIR MESYLATE + NELFINAVIR MESYLATE + Active + 98D603VP8V + N0000148479 + <VANDF_Record>50.416^3677^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>3677</VA_IEN> + Nelfinavir Mesylate + + + Ingredient + <VANDF_Record>50.6^3436^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>3436</VA_IEN> + IVERMECTIN + + Active + C16206 + IVERMECTIN + 4021046 + Ivermectin + N0000148510 + C0022322 + 8883YP2R6D + 6069 + <VANDF_Record>50.416^3714^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>3714</VA_IEN> + + + Active + Toremifene Citrate + TOREMIFENE CITRATE + C0117339 + 4021088 + 2498Y783QT + 49953 + Ingredient + TOREMIFENE CITRATE + <VANDF_Record>50.416^3756^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>3756</VA_IEN> + C21020 + + N0000148546 + + + N0000148672 + C0674432 + Ingredient + lopinavir + 2494G1JF75 + 4021228 + <VANDF_Record>50.416^3900^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>3900</VA_IEN> + LOPINAVIR + C16616 + Active + 195088 + LOPINAVIR + + + + + N0000148698 + 282388 + C0935989 + 4021257 + IMATINIB + Ingredient + C53876 + <VANDF_Record>50.416^3929^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>3929</VA_IEN> + BKJ8M8G5HI + IMATINIB + Active + imatinib + <VANDF_Record>50.6^3696^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>3696</VA_IEN> + + + 284924 + C53880 + N0000148699 + Imatinib mesylate + + 4021258 + Ingredient + 8A1O1M485B + <VANDF_Record>50.416^3930^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>3930</VA_IEN> + C0939537 + IMATINIB MESYLATE + IMATINIB MESYLATE + Active + + + C31484 + C0068788 + Active + NITAZOXANIDE + 4021365 + N0000148784 + NITAZOXANIDE + 31819 + <VANDF_Record>50.416^4039^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>4039</VA_IEN> + <VANDF_Record>50.6^3842^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>3842</VA_IEN> + Ingredient + SOA12P041N + nitazoxanide + + + + MYCOPHENOLIC ACID + Ingredient + <VANDF_Record>50.416^4095^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>4095</VA_IEN> + HU9DX48N0T + C273300 + 7145 + N0000148832 + <VANDF_Record>50.6^3937^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>3937</VA_IEN> + Active + Mycophenolic Acid + + MYCOPHENOLIC ACID + 4021418 + C0026933 + + + Triparanol + Triparanol [Chemical/Ingredient] + C0041088 + Antilipemic agent with high ophthalmic toxicity. According to Merck Index, 11th ed, the compound was withdrawn from the market in 1962 because of its association with the formation of irreversible cataracts. + D014308 + M0022011 + Triparanol + C7757245273072 + 10846 + Benzeneethanol, 4-chloro-alpha-(4-(2-(diethylamino)ethoxy)phenyl)-alpha-(4-methylphenyl)- + + N0000166394 + + + + N0000166641 + Cinanserin [Chemical/Ingredient] + D002928 + 2543 + 2-Propenamide, N-(2-((3-(dimethylamino)propyl)thio)phenyl)-3-phenyl- + A serotonin antagonist with limited antihistaminic, anticholinergic, and immunosuppressive activity. + C7757801986565 + M0004484 + C0008788 + Cinanserin + Cinanserin + + + + M0015663 + C0030046 + Oxyclozanide + Benzamide, 2,3,5-trichloro-N-(3,5-dichloro-2-hydroxyphenyl)-6-hydroxy- + Oxyclozanide + Anthelmintic used in grazing animals for fasciola and cestode infestations. + D010097 + 7802 + Oxiclozanidum + C7758280989622 + N0000166893 + Oxyclozanide [Chemical/Ingredient] + + + C7758479301978 + Nocodazole [Chemical/Ingredient] + N0000166936 + 7497 + + Oncodazole + Nocodazole + C0028247 + D015739 + Nocodazole + Nocodazole is an antineoplastic agent which exerts its effect by depolymerizing microtubules. + Carbamic acid, (5-(2-thienylcarbonyl)-1H-benzimidazol-2-yl)-, methyl ester + M0024123 + + + Monensin [Chemical/Ingredient] + N0000167131 + C0026408 + M0014007 + + 7026 + C7758754814648 + D008985 + An antiprotozoal agent produced by Streptomyces cinnamonensis. It exerts its effect during the development of first-generation trophozoites into first-generation schizonts within the intestinal epithelial cells. It does not interfere with hosts' development of acquired immunity to the majority of coccidial species. Monensin is a sodium and proton selective ionophore and is widely used as such in biochemical studies. + Monensin + Monensin + + + C7758765830014 + 3,4-Pyrrolidinediol, 2-((4-methoxyphenyl)methyl)-, 3-acetate, (2R-(2alpha,3alpha,4beta))- + C0003082 + N0000167149 + + An antibiotic isolated from various Streptomyces species. It interferes with protein and DNA synthesis by inhibiting peptidyl transferase or the 80S ribosome system. + Anisomycin + M0001251 + Anisomycin + Anisomycin [Chemical/Ingredient] + D000841 + 857 + + + D003513 + Cycloheximide + C7758827087800 + Antibiotic substance isolated from streptomycin-producing strains of Streptomyces griseus. It acts by inhibiting elongation during protein synthesis. + 2993 + 2,6-Piperidinedione, 4-(2-(3,5-dimethyl-2-oxocyclohexyl)-2-hydroxyethyl)-, (1S-(1alpha(S*),3alpha,5beta))- + M0005473 + Cycloheximide [Chemical/Ingredient] + + Cycloheximide + N0000167211 + C0010572 + Cicloheximide + + + Banisterine + Yageine + Alkaloid isolated from seeds of Peganum harmala L., Zygophyllaceae. It is identical to banisterine, or telepathine, from Banisteria caapi and is one of the active ingredients of hallucinogenic drinks made in the western Amazon region from related plants. It has no therapeutic use, but (as banisterine) was hailed as a cure for postencephalitic Parkinson disease in the 1920's. + Harmine + D006247 + C7758364911462 + 5101 + Telepathine + Leucoharmine + Harmine + N0000167259 + M0009805 + + C0018605 + Harmine [Chemical/Ingredient] + 9H-Pyrido(3,4-b)indole, 7-methoxy-1-methyl- + + + 1,3,8-Triazaspiro(4.5)decan-4-one, 8-(4,4-bis(4-fluorophenyl)butyl)-1-phenyl- + C0016383 + M0008650 + A long-acting injectable antipsychotic agent used for chronic schizophrenia. + Fluspirilene [Chemical/Ingredient] + 4507 + D005484 + Fluspirilene + C7758700772025 + N0000167366 + + Spirodiflamine + Fluspirilene + Fluspirilene + + + N0000167413 + C0006350 + + 1795 + Bufanolides + M0003002 + C7759104670845 + Cyclopentanophenanthrenes with a 6-membered lactone ring attached at the 17-position and SUGARS attached at the 3-position. They are found in BUFONIDAE and often possess cardiotonic properties. + Bufanolides + Bufanolides [Chemical/Ingredient] + D002018 + + + A closely related group of toxic substances elaborated by various strains of Streptomyces. They are 26-membered macrolides with lactone moieties and double bonds and inhibit various ATPases, causing uncoupling of phosphorylation from mitochondrial respiration. Used as tools in cytochemistry. Some specific oligomycins are RUTAMYCIN, peliomycin, and botrycidin (formerly venturicidin X). + + N0000168432 + Oligomycins + Oligomycins + C7758210287620 + Oligomycin + C0028951 + 7636 + Oligomycins [Chemical/Ingredient] + D009840 + M0015277 + + + Proscillaridin + A cardiotonic glycoside isolated from Scilla maritima var. alba (Squill). + D011442 + Proscillaridin + Bufa-4,20,22-trienolide, 3-((6-deoxy-alpha-L-mannopyranosyl)oxy)-14-hydroxy-, (3beta)- + 8795 + Desglucotransvaaline + Proscillaridin [Chemical/Ingredient] + N0000168447 + C7759106809664 + C0033513 + Proscillaridine + + Proscillaridin + Proscillaridin A + M0017785 + Scillarenin Rhamnoside + + + Compounds consisting of chains of AMINO ACIDS alternating with CARBOXYLIC ACIDS via ester and amide linkages. They are commonly cyclized. + C0796678 + + 253508 + C7759071624466 + Depsipeptides [Chemical/Ingredient] + M0458175 + N0000170351 + D047630 + Depsipeptides + Depsipeptides + + + C0042287 + Valinomycin + + M0022498 + A cyclododecadepsipeptide ionophore antibiotic produced by Streptomyces fulvissimus and related to the enniatins. It is composed of 3 moles each of L-valine, D-alpha-hydroxyisovaleric acid, D-valine, and L-lactic acid linked alternately to form a 36-membered ring. (From Merck Index, 11th ed) Valinomycin is a potassium selective ionophore and is commonly used as a tool in biochemical studies. + C7759071830917 + D014634 + Valinomycin + 11116 + Valinomycin [Chemical/Ingredient] + N0000170352 + + + 341018 + <VANDF_Record>50.6^4117^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>4117</VA_IEN> + Ingredient + 4025092 + <VANDF_Record>50.416^4274^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>4274</VA_IEN> + anidulafungin + ANIDULAFUNGIN + 9HLM53094I + C1142738 + N0000171752 + Active + C23260279896467 + + ANIDULAFUNGIN + + + N0000171775 + C1172636 + C23283814211303 + Ingredient + 4025243 + DALBAVANCIN + DALBAVANCIN + <VANDF_Record>50.416^4301^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>4301</VA_IEN> + + 354674 + Active + + + <VANDF_Record>50.416^4401^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>4401</VA_IEN> + DASATINIB + 475342 + C50.416.4401 + <VANDF_Record>50.6^4184^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>4184</VA_IEN> + Active + 4025488 + + dasatinib + RBZ1571X5H + N0000176043 + Ingredient + C1455147 + DASATINIB + + + + MYCOPHENOLATE + C50.416.4438 + MYCOPHENOLATE + Ingredient + C0883242 + 4025608 + MYCOPHENOLATE + <VANDF_Record>50.6^4198^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>4198</VA_IEN> + 265323 + Active + <VANDF_Record>50.416^4438^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>4438</VA_IEN> + N0000176078 + + + nilotinib + 662281 + <VANDF_Record>50.416^4485^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>4485</VA_IEN> + NILOTINIB + C50.416.4485 + NILOTINIB + C1721377 + 4026964 + N0000176124 + Ingredient + Active + <VANDF_Record>50.6^4315^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>4315</VA_IEN> + F41401512X + + + + C0907850 + <VANDF_Record>50.416^4511^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>4511</VA_IEN> + Ingredient + CICLESONIDE + <VANDF_Record>50.6^4361^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>4361</VA_IEN> + Active + 274964 + + 4027427 + C50.416.4511 + CICLESONIDE + S59502J185 + N0000176150 + ciclesonide + + + ELTROMBOPAG + N0000177933 + Ingredient + 4028105 + C50.416.4547 + eltrombopag + ELTROMBOPAG + + C1831905 + Active + 711942 + <VANDF_Record>50.6^4405^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>4405</VA_IEN> + <VANDF_Record>50.416^4547^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>4547</VA_IEN> + + + <VANDF_Record>50.416^4578^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>4578</VA_IEN> + C0541315 + EVEROLIMUS + C50.416.4578 + 141704 + 4028636 + N0000178379 + Ingredient + <VANDF_Record>50.6^4453^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>4453</VA_IEN> + Active + EVEROLIMUS + + everolimus + + + Decreased Blood Pressure [PE] + Decreased Blood Pressure + N0000178477 + C2917141 + + C637933 + 991700 + + + 4028922 + BAICALIN + <VANDF_Record>50.416^4615^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>4615</VA_IEN> + C0052929 + Active + Ingredient + C50.416^4615^ + 18737 + BAICALIN + N0000179808 + + + + N0000180310 + Active + TELAVANCIN + 473837 + 4029465 + C50.416^4662^ + + Ingredient + <VANDF_Record>50.6^4531^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>4531</VA_IEN> + C1453642 + telavancin + <VANDF_Record>50.416^4662^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>4662</VA_IEN> + TELAVANCIN + + + Active + C50.416^4670^ + 4029705 + + TOCILIZUMAB + Ingredient + N0000180629 + <VANDF_Record>50.6^4548^</VANDF_Record><VA_File>50.6</VA_File><VA_IEN>4548</VA_IEN> + 612865 + TOCILIZUMAB + C1609165 + tocilizumab + <VANDF_Record>50.416^4670^</VANDF_Record><VA_File>50.416</VA_File><VA_IEN>4670</VA_IEN> + + + NUI + C10490107818172 + + + + + C818 + RxNorm_CUI + + + RxNorm_Name + C819 + + + + SNOMED_CID + C28502475289736 + + + + + C27489601424203 + Status + + + + Synonym + C136 + + + C140 + UMLS_CUI + + + + VANDF_Record + C262721 + + + + C262777 + + VUID + + + + AHC0 + true + + + + + + + + Janna Hastings + Leonard Jacuzzo + + Barry Smith + The BSD license on the BFO project site refers to code used to build BFO. + Please see the project site https://github.com/BFO-ontology/BFO, the bfo2 owl discussion group http://groups.google.com/group/bfo-owl-devel , the bfo2 discussion group http://groups.google.com/group/bfo-devel, the tracking google doc http://goo.gl/IlrEE, and the current version of the bfo2 reference http://purl.obolibrary.org/obo/bfo/dev/bfo2-reference.docx . This ontology is generated from a specification at https://github.com/BFO-ontology/BFO/tree/master/src/ontology/owl-group/specification/ and with the code that generates the OWL version in https://github.com/BFO-ontology/BFO/tree/master/src/tools/. A very early version of BFO version 2 in CLIF is at http://purl.obolibrary.org/obo/bfo/dev/bfo.clif + Pierre Grenon + David Osumi-Sutherland + + Selja Seppälä + Werner Ceusters + Jie Zheng + Thomas Bittner + Mathias Brochhausen + This BFO 2.0 version represents a major update to BFO and is not strictly backwards compatible with BFO 1.1. The previous OWL version of BFO, version 1.1.1 will remain available at http://ifomis.org/bfo/1.1 and will no longer be updated. The BFO 2.0 OWL is a classes-only specification. The incorporation of core relations has been held over for a later version. + Mauricio Almeida + Bjoern Peters + Melanie Courtot + + + Yongqun "Oliver" He + + BFO 2 Reference: For both terms and relational expressions in BFO, we distinguish between primitive and defined. ‘Entity’ is an example of a primitive term. Primitive terms in a highest-level ontology such as BFO are terms that are so basic to our understanding of reality that there is no way of defining them in a non-circular fashion. For these, therefore, we can provide only elucidations, supplemented by examples and by axioms. + James A. Overton + Jonathan Bona + Holger Stenzhorn + + Fabian Neuhaus + + + Randall Dipert + Larry Hunter + Stefan Schulz + http://creativecommons.org/licenses/by/4.0/ + Chris Mungall + + Ron Rudnicki + BFO 2 Reference: BFO does not claim to provide complete coverage of entities of all types. It seeks only to provide coverage of those entities studied by empirical science together with those entities which affect or are involved in human activities such as data processing and planning - coverage that is sufficiently broad to provide assistance to those engaged in building domain ontologies for purposes of data annotation. + Mark Ressler + BFO 2 Reference: BFO’s treatment of continuants and occurrents - as also its treatment of regions, rests on a dichotomy between space and time, and on the view that there are two perspectives on reality - earlier called the ‘SNAP’ and ‘SPAN’ perspectives, both of which are essential to the non-reductionist representation of reality as we understand it from the best available science + Albert Goldfain + Alan Ruttenberg + Bill Duncan + Ludger Jansen + + + + For any queries contact chebi-help@ebi.ac.uk + 1.2 + Author: ChEBI curation team + developed by Michael Ashburner & Pankaj Jaiswal. + 27:04:2020 18:57 + ChEBI subsumes and replaces the Chemical Ontology first + ChEBI Release version 187 + + + + 1.2 + The Disease Ontology has been developed as a standardized ontology for human disease with the purpose of providing the biomedical community with consistent, reusable and sustainable descriptions of human disease terms, phenotype characteristics and related medical vocabulary disease concepts. + The Disease Ontology content is available via the Creative Commons Public Domain Dedication CC0 1.0 Universal license (https://creativecommons.org/publicdomain/zero/1.0/). + Human Disease Ontology + 01:04:2020 16:38 + + + An ontology of drugs. + Josh Hanna + 2020-01-06 + William Hogan + This version of DrOn is current through the January, 2020 version of RxNorm. + https://creativecommons.org/licenses/by/3.0/ + DrOn contains content developed by the National Library of Medicine in RxNorm. In creating DrOn, we have used RxNorm content only with SAB = RXNORM. + https://creativecommons.org/licenses/by/3.0/ + Eric Joseph + When citing DrOn, use the permanent URL of the ontology: http://purl.obolibrary.org/obo/dron.owl. When referencing a specific component of the DrOn, such as a class, object property, annotation property, or individual, use the Uniform Resource Identifier (URI) of that component. + Mathias Brochhausen + + + http://orcid.org/0000-0002-8343-612X + Includes Ontology(OntologyID(OntologyIRI(<http://purl.obolibrary.org/obo/envo/modules/entity_attribute.owl>) VersionIRI(<null>))) [Axioms: 114 Logical Axioms: 19] + Includes Ontology(OntologyID(OntologyIRI(<http://purl.obolibrary.org/obo/envo/modules/process_attribute.owl>) VersionIRI(<null>))) [Axioms: 21 Logical Axioms: 2] + Includes Ontology(OntologyID(OntologyIRI(<http://purl.obolibrary.org/obo/envo/modules/chemical_concentration.owl>) VersionIRI(<null>))) [Axioms: 186 Logical Axioms: 30] + Includes Ontology(OntologyID(OntologyIRI(<http://purl.obolibrary.org/obo/envo/modules/entity_quality_location.owl>) VersionIRI(<null>))) [Axioms: 40 Logical Axioms: 6] + http://orcid.org/0000-0002-4366-3088 + http://orcid.org/0000-0003-1604-1512 + http://orcid.org/0000-0002-6601-2165 + Includes Ontology(OntologyID(OntologyIRI(<http://purl.obolibrary.org/obo/envo/modules/entity_attribute_location.owl>) VersionIRI(<null>))) [Axioms: 132 Logical Axioms: 23] + ENVO is an ontology which represents knowledge about environments,environmental processes, ecosystems, habitats, and related entities. It interoperates with other ontologies in the OBO Foundry and Library. + +New terms or revisions can be requested at https://github.com/EnvironmentOntology/envo/issues/ + + +Please see www.environmentontology.org for more information and citations. + https://orcid.org/0000-0002-6962-2807 + + + Oliver He + Ling Wan (Eric) + 1.0.7 + Edison Ong + 8-12-2019 + ICDO: International Classification of Diseases Ontology + + + 2017-11-03T15:13:52 + http://www.infectiousdiseaseontology.org + Albert Goldfain + Alexander Diehl + Bjoern Peters + The core Infectious Disease Ontology is an ontology of entities generally relevant to both the biomedical and clinical aspects of infectious diseases, including terms such as 'pathogen', 'host', 'vector', and 'vaccine'. The structure of IDO adheres to the Basic Formal Ontology. Terms in IDO that are within the scope of other OBO Foundry ontologies, such as the Gene Ontology, are derived from those ontologies. Other terms are defined as cross-products of terms from Foundry ontologies to the extent possible. For more information, see http://www.infectiousdiseaseontology.org/Home.html. + Alan Ruttenberg + + en + Barry Smith + 2017-11-03 + Lindsay Cowell + Jie Zheng + + + Autogenerated by OWLTools-NCBIConverter. + + + Desikan Jagannathan + An ontology for the annotation of the adverse event domain. + Vision Release; 1.2.19 + Elizabeth Blair + "Asiyah" Yu Lin + Abra Guo + Sydni Joubran + OWL-DL + Product version + Darrell R. Abernethy + Sirarat Sarntivijai + Ling Wan + Shelley Zhang + Rebecca Racz + Liwei Wang + Meiu Wong + The Ontology of Adverse Eventsy (OAE) is a biomedical ontology in the domain of adverse events. OAE aims to standardize adverse event annotation, integrate various adverse event data, and support computer-assisted reasoning. OAE is a community-based ontology. Its development follows the OBO Foundry principles. Vaccine adverse events have been used as an initial testing use case. OAE also studies adverse events associated with the administration of drug and nutritional products, the operation of surgeries, and the usage of medical devices, etc. + Kevin Mo + OAE: Ontology of Adverse Events + Yongqun "Oliver" He (YH) + Luca Toldo + Noemi Garg + Edison Ong + Keith Burkhart + Mathias Brochhausen + Izabela Birsanescu + Zuoshuang "Allen" Xiang + Barry Smith + Bingjian Yang + + Qingping Liu + Jiangan Xie + 2019-2-21 + Sydni Joubran + Kelly Yang + David Ameriguian + + + Yu Lin + Barry Smith + Jean-François Ethier + + Adrien Barton + Qingzhi Liu + OBCS stands for the Ontology of Biological and Clinical Statistics. OBCS is an ontology in the domain of biological and clinical statistics. It is aligned with the Basic Formal Ontology (BFO) and the Ontology for Biomedical Investigations (OBI). OBCS imports all possible biostatistics terms in OBI and includes many additional biostatistics terms, some of which were proposed and discussed in the OBI face-to-face workshop in Ann Arbor in 2012. + 101 + Yongqun "Oliver" He + Marcy Harris + Jie Zheng + Huan Li + + + Daniel Merico + Werner Ceusters + Bill Hogan + Albert Goldfain + This ontology is in early development. Expect it to change. + 2011-09-20 + Alan Ruttenberg + Sivaram Arabandi + Lindsay Cowell + 2009-08-07 + Cornelius Rosse + Richard Scheuermann + Anand Kumar + Barry Smith + The Ontology for General Medical Science (OGMS) is based on the papers Toward an Ontological Treatment of Disease and Diagnosis and On Carcinomas and Other Pathological Entities. The ontology attempts to address some of the issues raised at the Workshop on Ontology of Diseases (Dallas, TX). OGMS was formerly called the clinical phenotype ontology. Terms from OGMS hang from the Basic Formal Ontology. + +The latest version of OGMS is always available at http://purl.obolibrary.org/obo/ogms.owl +This is version 2011-09-20 aka '0.9' +http://purl.obolibrary.org/obo/ogms/2011-09-20/ogms.owl + +The OGMS developer site is http://code.google.com/p/ogms/ +The discussion group is http://groups.google.com/group/ogms-discuss + +If you are interested in participating in the development of OGMS, please send email to albertgoldfain@gmail.com. Be sure to include a google-account username with your request (this will be the username associated with a gmail address). + + + This ontology grew out of efforts to represent the reality underlying the demographic information required by the US federal government's "meaningful use" criteria for electronic medical records and a presentation by Dr. William Hogan at the Electronic Health Record of the Future conference in Buffalo, NY http://ontology.buffalo.edu/EHR/Demographics_Hogan_Buffalo_2010_09_22.ppt + William Hogan + Amanda Hicks + 2017-06-08 + Mathias Brochhausen + Swetha Garimalla + Daniel Welch + The Ontology of Medically Related Social Entities + Shariq Tariq + + + Asiyah Yu Lin + Yongqun "Oliver" He (YH) + Jie Zheng + Jennifer Schaub + Vision Release: 1.0.97 + OPMI subject: Precision medicine and related investigations + http://creativecommons.org/licenses/by/4.0/ + OPMI: Ontology of Precision Medicine and Investigation + Matthias Kretzler + OWL-DL + Sean Mooney + Fred Dowd + Qingliang Leon Li + OPMI is a biomedical ontology in the area of precision medicine and its related investigations. It is community-driven and developed by following the OBO Foundry ontology development principles. + Christopher Park + John F. O’Toole + 1-31-2020 + Becky Steck + Hong Yu + + + + 22:04:2020 15:22 + 1.2 + The PRotein Ontology is licensed under CC BY 4.0. Please see http://obofoundry.org/ontology/pr for details. + Use reasoner in OBO Edit to see the correct hierarchy. + + + en + Lindsay Cowell + Chris mungall + OWL-DL + Alexander D. Diehl + Ryan R. Brinkman + Samantha G. Sayers (SGS) + Kallan Roan + Hong Yu + Alan Ruttenburg + + Rebecca Racz + Yu Lin (YL) + The Vaccine Ontology (VO) is a biomedical ontology in the domain of vaccine and vaccination. VO aims to standardize vaccine annotation, integrate various vaccine data, and support computer-assisted reasoning. VO supports basic vaccine R&D and clincal vaccine usage. VO is being developed as a community-based ontology with support and collaborations from the vaccine and bio-ontology communities. + 1.1.89 + Shunzhou Deng + Ronak Sutariya + Khadeejah Khan + Thomas Todd + Ningxian Fan + Edison Ong + Zuoshuang "Allen" Xiang + Ningxian Fan + Yongqun "Oliver" He (YH) + Randi Vita + Randi Vita + Barry Smith + April 27, 2020 + Erica Marcos + Paul Fabry + Jason Hu + An ontology in the domain of vaccine and vaccination + Richard H. Scheuermann + Omar Tibi + Vaccine Ontology + Melanie Courtot + Bjoern Peters + + + + + + + + + + + + + diff --git a/src/test/resources/repo/input/dmto/DINTO adverse effects.owl b/src/test/resources/repo/input/dmto/DINTO adverse effects.owl new file mode 100644 index 0000000..c9c4bb7 --- /dev/null +++ b/src/test/resources/repo/input/dmto/DINTO adverse effects.owl @@ -0,0 +1,104612 @@ + + + + + + + +]> + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + http://bioontology.org/ontologies/BiomedicalResources.owl#Environmental_Health_and_Safety + Environmental Health and Safety Resource + + + + purl:Definition + obo2:IAO_0000122 + + + + purl:Definition + obo2:iao.owl + + + + purl:Definition + Definition + + + + obo:AHFScode + AHFScode + + + + obo:ATCCode + ATCCode + + + + obo:CASRN + CASRN + + + + obo:DBBrand + DBBrand + + + + obo:DBSalt + DBSalt + + + + obo:DBSynonym + DBSynonym + + + + obo:DBname + DBname + + + + obo:Gene + Gene + + + + obo:InChI + InChI + + + + obo:InChIKey + InChIKey + + + + obo:OrganismClass + OrganismClass + + + + obo:SMILES + SMILES + + + + obo:Synonym + Synonym + + + + obo:altId + altId + + + + obo:mapsTo + maps to + + + + obo:xref + xref + + + + obo2:BFO_0000001 + obo2:obi.owl + + + + obo2:BFO_0000001 + obo2:ogms.owl + + + + obo2:BFO_0000001 + obo2:bfo.owl + + + + obo2:BFO_0000002 + obo2:obi.owl + + + + obo2:BFO_0000002 + obo2:bfo.owl + + + + obo2:BFO_0000003 + obo2:obi.owl + + + + obo2:BFO_0000003 + obo2:bfo.owl + + + + obo2:BFO_0000004 + obo2:obi.owl + + + + obo2:BFO_0000004 + obo2:bfo.owl + + + + obo2:BFO_0000005 + obo2:obi.owl + + + + obo2:BFO_0000006 + obo2:bfo.owl + + + + obo2:BFO_0000008 + obo2:bfo.owl + + + + obo2:BFO_0000009 + obo2:bfo.owl + + + + obo2:BFO_0000011 + obo2:bfo.owl + + + + obo2:BFO_0000017 + obo2:obi.owl + + + + obo2:BFO_0000017 + obo2:bfo.owl + + + + obo2:BFO_0000018 + obo2:bfo.owl + + + + obo2:BFO_0000020 + obo2:obi.owl + + + + obo2:BFO_0000020 + obo2:bfo.owl + + + + obo2:BFO_0000024 + obo2:bfo.owl + + + + obo2:BFO_0000026 + obo2:bfo.owl + + + + obo2:BFO_0000027 + obo2:bfo.owl + + + + obo2:BFO_0000028 + obo2:bfo.owl + + + + obo2:BFO_0000030 + obo2:bfo.owl + + + + obo2:BFO_0000034 + obo2:bfo.owl + + + + obo2:BFO_0000035 + obo2:bfo.owl + + + + obo2:BFO_0000050 + obo2:go.owl + + + + obo2:BFO_0000050 + obo2:uberon.owl + + + + obo2:BFO_0000050 + + + + + obo2:BFO_0000050 + + + + + obo2:BFO_0000050 + + + + + obo2:BFO_0000050 + + + + + obo2:BFO_0000050 + + + + + obo2:BFO_0000050 + + + + + obo2:BFO_0000050 + + + + + obo2:BFO_0000050 + + + + + obo2:BFO_0000050 + + + + + obo2:BFO_0000050 + + + + + obo2:BFO_0000050 + + + + + obo2:BFO_0000050 + + + + + obo2:BFO_0000051 + obo2:uberon.owl + + + + obo2:BFO_0000052 + obo2:bfo.owl + + + + obo2:BFO_0000053 + obo2:obi.owl + + + + obo2:BFO_0000053 + obo2:bfo.owl + + + + obo2:BFO_0000054 + obo2:obi.owl + + + + obo2:BFO_0000054 + obo2:bfo.owl + + + + obo2:BFO_0000056 + obo2:bfo.owl + + + + obo2:BFO_0000057 + obo2:obi.owl + + + + obo2:BFO_0000057 + + + + + obo2:BFO_0000057 + + + + + obo2:BFO_0000057 + + + + + obo2:BFO_0000057 + + + + + obo2:BFO_0000057 + + + + + obo2:BFO_0000057 + + + + + obo2:BFO_0000057 + + + + + obo2:BFO_0000057 + + + + + obo2:BFO_0000057 + + + + + obo2:BFO_0000057 + + + + + obo2:BFO_0000057 + + + + + obo2:BFO_0000057 + + + + + obo2:BFO_0000057 + obo2:bfo.owl + + + + obo2:BFO_0000058 + obo2:bfo.owl + + + + obo2:BFO_0000059 + obo2:bfo.owl + + + + obo2:BFO_0000067 + obo2:bfo.owl + + + + obo2:BFO_0000068 + obo2:uberon.owl + + + + obo2:BFO_0000069 + obo2:uberon.owl + + + + obo2:BFO_0000070 + obo2:bfo.owl + + + + obo2:BFO_0000079 + obo2:bfo.owl + + + + obo2:BFO_0000080 + obo2:bfo.owl + + + + obo2:BFO_0000081 + obo2:bfo.owl + + + + obo2:BFO_0000083 + obo2:bfo.owl + + + + obo2:BFO_0000084 + obo2:bfo.owl + + + + obo2:BFO_0000085 + obo2:obi.owl + + + + obo2:BFO_0000085 + obo2:bfo.owl + + + + obo2:BFO_0000087 + obo2:obi.owl + + + + obo2:BFO_0000087 + obo2:bfo.owl + + + + obo2:BFO_0000101 + obo2:bfo.owl + + + + obo2:BFO_0000107 + obo2:bfo.owl + + + + obo2:BFO_0000108 + obo2:bfo.owl + + + + obo2:BFO_0000110 + obo2:bfo.owl + + + + obo2:BFO_0000111 + obo2:bfo.owl + + + + obo2:BFO_0000112 + obo2:bfo.owl + + + + obo2:BFO_0000113 + obo2:bfo.owl + + + + obo2:BFO_0000115 + obo2:bfo.owl + + + + obo2:BFO_0000117 + obo2:bfo.owl + + + + obo2:BFO_0000118 + obo2:bfo.owl + + + + obo2:BFO_0000119 + obo2:bfo.owl + + + + obo2:BFO_0000121 + obo2:bfo.owl + + + + obo2:BFO_0000123 + obo2:bfo.owl + + + + obo2:BFO_0000124 + obo2:bfo.owl + + + + obo2:BFO_0000125 + obo2:bfo.owl + + + + obo2:BFO_0000126 + obo2:bfo.owl + + + + obo2:BFO_0000127 + obo2:bfo.owl + + + + obo2:BFO_0000129 + obo2:bfo.owl + + + + obo2:BFO_0000130 + obo2:bfo.owl + + + + obo2:BFO_0000132 + obo2:bfo.owl + + + + obo2:BFO_0000133 + obo2:bfo.owl + + + + obo2:BFO_0000136 + obo2:bfo.owl + + + + obo2:BFO_0000137 + obo2:bfo.owl + + + + obo2:BFO_0000138 + obo2:bfo.owl + + + + obo2:BFO_0000139 + obo2:bfo.owl + + + + obo2:BFO_0000140 + obo2:bfo.owl + + + + obo2:BFO_0000141 + obo2:bfo.owl + + + + obo2:BFO_0000142 + obo2:bfo.owl + + + + obo2:BFO_0000144 + obo2:bfo.owl + + + + obo2:BFO_0000145 + obo2:bfo.owl + + + + obo2:BFO_0000146 + obo2:bfo.owl + + + + obo2:BFO_0000147 + obo2:bfo.owl + + + + obo2:BFO_0000151 + obo2:bfo.owl + + + + obo2:BFO_0000152 + obo2:bfo.owl + + + + obo2:BFO_0000153 + obo2:bfo.owl + + + + obo2:BFO_0000154 + obo2:bfo.owl + + + + obo2:BFO_0000155 + obo2:bfo.owl + + + + obo2:BFO_0000156 + obo2:bfo.owl + + + + obo2:BFO_0000157 + obo2:bfo.owl + + + + obo2:BFO_0000158 + obo2:bfo.owl + + + + obo2:BFO_0000159 + obo2:bfo.owl + + + + obo2:BFO_0000160 + obo2:bfo.owl + + + + obo2:BFO_0000161 + obo2:bfo.owl + + + + obo2:BFO_0000162 + obo2:bfo.owl + + + + obo2:BFO_0000163 + obo2:bfo.owl + + + + obo2:BFO_0000164 + obo2:bfo.owl + + + + obo2:BFO_0000165 + obo2:bfo.owl + + + + obo2:BFO_0000166 + obo2:bfo.owl + + + + obo2:BFO_0000167 + obo2:bfo.owl + + + + obo2:BFO_0000168 + obo2:bfo.owl + + + + obo2:BFO_0000169 + obo2:bfo.owl + + + + obo2:BFO_0000170 + obo2:bfo.owl + + + + obo2:BFO_0000171 + obo2:bfo.owl + + + + obo2:BFO_0000172 + obo2:bfo.owl + + + + obo2:BFO_0000173 + obo2:bfo.owl + + + + obo2:BFO_0000174 + obo2:bfo.owl + + + + obo2:BFO_0000175 + obo2:bfo.owl + + + + obo2:BFO_0000176 + obo2:bfo.owl + + + + obo2:BFO_0000177 + obo2:bfo.owl + + + + obo2:BFO_0000178 + obo2:bfo.owl + + + + obo2:BFO_0000179 + BFO OWL specification label + + + + obo2:BFO_0000180 + BFO CLIF specification label + + + + obo2:BFO_0000181 + obo2:bfo.owl + + + + obo2:BFO_0000182 + obo2:bfo.owl + + + + obo2:BFO_0000184 + obo2:bfo.owl + + + + obo2:BFO_0000185 + obo2:bfo.owl + + + + obo2:BFO_0000186 + obo2:bfo.owl + + + + obo2:BFO_0000187 + obo2:bfo.owl + + + + obo2:BSPO_0000096 + obo2:uberon.owl + + + + obo2:BSPO_0000097 + obo2:uberon.owl + + + + obo2:BSPO_0000098 + obo2:uberon.owl + + + + obo2:BSPO_0000099 + obo2:uberon.owl + + + + obo2:BSPO_0000100 + obo2:uberon.owl + + + + obo2:BSPO_0000102 + obo2:uberon.owl + + + + obo2:BSPO_0000120 + obo2:uberon.owl + + + + obo2:BSPO_0000121 + obo2:uberon.owl + + + + obo2:BSPO_0000124 + obo2:uberon.owl + + + + obo2:BSPO_0000125 + obo2:uberon.owl + + + + obo2:BSPO_0000126 + obo2:uberon.owl + + + + obo2:BSPO_0001106 + obo2:uberon.owl + + + + obo2:BSPO_0001108 + obo2:uberon.owl + + + + obo2:CHEBI_15841 + obo2:chebi.owl + + + + obo2:CHEBI_16385 + obo2:chebi.owl + + + + obo2:CHEBI_16670 + obo2:chebi.owl + + + + obo2:CHEBI_17087 + obo2:chebi.owl + + + + obo2:CHEBI_18059 + obo2:chebi.owl + + + + obo2:CHEBI_18254 + obo2:chebi.owl + + + + obo2:CHEBI_18274 + obo2:chebi.owl + + + + obo2:CHEBI_18379 + obo2:chebi.owl + + + + obo2:CHEBI_18946 + obo2:chebi.owl + + + + obo2:CHEBI_19255 + obo2:chebi.owl + + + + obo2:CHEBI_21731 + obo2:chebi.owl + + + + obo2:CHEBI_22315 + obo2:chebi.owl + + + + obo2:CHEBI_22475 + obo2:chebi.owl + + + + obo2:CHEBI_22478 + obo2:chebi.owl + + + + obo2:CHEBI_22563 + obo2:chebi.owl + + + + obo2:CHEBI_22682 + obo2:chebi.owl + + + + obo2:CHEBI_22712 + obo2:chebi.owl + + + + obo2:CHEBI_22723 + obo2:chebi.owl + + + + obo2:CHEBI_22728 + obo2:chebi.owl + + + + obo2:CHEBI_22888 + obo2:chebi.owl + + + + obo2:CHEBI_23003 + obo2:chebi.owl + + + + obo2:CHEBI_23367 + obo2:chebi.owl + + + + obo2:CHEBI_23449 + obo2:chebi.owl + + + + obo2:CHEBI_23636 + obo2:chebi.owl + + + + obo2:CHEBI_23666 + obo2:chebi.owl + + + + obo2:CHEBI_23677 + obo2:chebi.owl + + + + obo2:CHEBI_23765 + obo2:chebi.owl + + + + obo2:CHEBI_23849 + obo2:chebi.owl + + + + obo2:CHEBI_23981 + obo2:chebi.owl + + + + obo2:CHEBI_24129 + obo2:chebi.owl + + + + obo2:CHEBI_24400 + obo2:chebi.owl + + + + obo2:CHEBI_24471 + obo2:chebi.owl + + + + obo2:CHEBI_24532 + obo2:chebi.owl + + + + obo2:CHEBI_24651 + obo2:chebi.owl + + + + obo2:CHEBI_24669 + obo2:chebi.owl + + + + obo2:CHEBI_24780 + obo2:chebi.owl + + + + obo2:CHEBI_24782 + obo2:chebi.owl + + + + obo2:CHEBI_24828 + obo2:chebi.owl + + + + obo2:CHEBI_24866 + obo2:chebi.owl + + + + obo2:CHEBI_24868 + obo2:chebi.owl + + + + obo2:CHEBI_24870 + obo2:chebi.owl + + + + obo2:CHEBI_24897 + obo2:chebi.owl + + + + obo2:CHEBI_24913 + obo2:chebi.owl + + + + obo2:CHEBI_24995 + obo2:chebi.owl + + + + obo2:CHEBI_25000 + obo2:chebi.owl + + + + obo2:CHEBI_25106 + obo2:chebi.owl + + + + obo2:CHEBI_25359 + obo2:chebi.owl + + + + obo2:CHEBI_25384 + obo2:chebi.owl + + + + obo2:CHEBI_25477 + obo2:chebi.owl + + + + obo2:CHEBI_25608 + obo2:chebi.owl + + + + obo2:CHEBI_25676 + obo2:chebi.owl + + + + obo2:CHEBI_25693 + obo2:chebi.owl + + + + obo2:CHEBI_25696 + obo2:chebi.owl + + + + obo2:CHEBI_25698 + obo2:chebi.owl + + + + obo2:CHEBI_25699 + obo2:chebi.owl + + + + obo2:CHEBI_25703 + obo2:chebi.owl + + + + obo2:CHEBI_25710 + obo2:chebi.owl + + + + obo2:CHEBI_25741 + obo2:chebi.owl + + + + obo2:CHEBI_25806 + obo2:chebi.owl + + + + obo2:CHEBI_26069 + obo2:chebi.owl + + + + obo2:CHEBI_26079 + obo2:chebi.owl + + + + obo2:CHEBI_26082 + obo2:chebi.owl + + + + obo2:CHEBI_26144 + obo2:chebi.owl + + + + obo2:CHEBI_26151 + obo2:chebi.owl + + + + obo2:CHEBI_26188 + obo2:chebi.owl + + + + obo2:CHEBI_26373 + obo2:chebi.owl + + + + obo2:CHEBI_26394 + obo2:chebi.owl + + + + obo2:CHEBI_26401 + obo2:chebi.owl + + + + obo2:CHEBI_26421 + obo2:chebi.owl + + + + obo2:CHEBI_26440 + obo2:chebi.owl + + + + obo2:CHEBI_26455 + obo2:chebi.owl + + + + obo2:CHEBI_26512 + obo2:chebi.owl + + + + obo2:CHEBI_26513 + obo2:chebi.owl + + + + obo2:CHEBI_26714 + obo2:chebi.owl + + + + obo2:CHEBI_26835 + obo2:chebi.owl + + + + obo2:CHEBI_26912 + obo2:chebi.owl + + + + obo2:CHEBI_26979 + obo2:chebi.owl + + + + obo2:CHEBI_27171 + obo2:chebi.owl + + + + obo2:CHEBI_29067 + obo2:chebi.owl + + + + obo2:CHEBI_29347 + obo2:chebi.owl + + + + obo2:CHEBI_29348 + obo2:chebi.owl + + + + obo2:CHEBI_30879 + obo2:chebi.owl + + + + obo2:CHEBI_32863 + obo2:chebi.owl + + + + obo2:CHEBI_32876 + obo2:chebi.owl + + + + obo2:CHEBI_32952 + obo2:chebi.owl + + + + obo2:CHEBI_32988 + obo2:chebi.owl + + + + obo2:CHEBI_33241 + obo2:chebi.owl + + + + obo2:CHEBI_33245 + obo2:chebi.owl + + + + obo2:CHEBI_33256 + obo2:chebi.owl + + + + obo2:CHEBI_33261 + obo2:chebi.owl + + + + obo2:CHEBI_33273 + obo2:chebi.owl + + + + obo2:CHEBI_33285 + obo2:chebi.owl + + + + obo2:CHEBI_33296 + obo2:chebi.owl + + + + obo2:CHEBI_33302 + obo2:chebi.owl + + + + obo2:CHEBI_33304 + obo2:chebi.owl + + + + obo2:CHEBI_33308 + obo2:chebi.owl + + + + obo2:CHEBI_33424 + obo2:chebi.owl + + + + obo2:CHEBI_33497 + obo2:chebi.owl + + + + obo2:CHEBI_33575 + obo2:chebi.owl + + + + obo2:CHEBI_33576 + obo2:chebi.owl + + + + obo2:CHEBI_33579 + obo2:chebi.owl + + + + obo2:CHEBI_33595 + obo2:chebi.owl + + + + obo2:CHEBI_33597 + obo2:chebi.owl + + + + obo2:CHEBI_33598 + obo2:chebi.owl + + + + obo2:CHEBI_33608 + obo2:chebi.owl + + + + obo2:CHEBI_33635 + obo2:chebi.owl + + + + obo2:CHEBI_33636 + obo2:chebi.owl + + + + obo2:CHEBI_33654 + obo2:chebi.owl + + + + obo2:CHEBI_33659 + obo2:chebi.owl + + + + obo2:CHEBI_33670 + obo2:chebi.owl + + + + obo2:CHEBI_33671 + obo2:chebi.owl + + + + obo2:CHEBI_33672 + obo2:chebi.owl + + + + obo2:CHEBI_33674 + obo2:chebi.owl + + + + obo2:CHEBI_33675 + obo2:chebi.owl + + + + obo2:CHEBI_33692 + obo2:chebi.owl + + + + obo2:CHEBI_33709 + obo2:chebi.owl + + + + obo2:CHEBI_33822 + obo2:chebi.owl + + + + obo2:CHEBI_33832 + obo2:chebi.owl + + + + obo2:CHEBI_33833 + obo2:chebi.owl + + + + obo2:CHEBI_33836 + obo2:chebi.owl + + + + obo2:CHEBI_33838 + obo2:chebi.owl + + + + obo2:CHEBI_33839 + obo2:chebi.owl + + + + obo2:CHEBI_33860 + obo2:chebi.owl + + + + obo2:CHEBI_33861 + obo2:chebi.owl + + + + obo2:CHEBI_33862 + obo2:chebi.owl + + + + obo2:CHEBI_35259 + obo2:chebi.owl + + + + obo2:CHEBI_35294 + obo2:chebi.owl + + + + obo2:CHEBI_35295 + obo2:chebi.owl + + + + obo2:CHEBI_35341 + obo2:chebi.owl + + + + obo2:CHEBI_35350 + obo2:chebi.owl + + + + obo2:CHEBI_35352 + obo2:chebi.owl + + + + obo2:CHEBI_35356 + obo2:chebi.owl + + + + obo2:CHEBI_35358 + obo2:chebi.owl + + + + obo2:CHEBI_35363 + obo2:chebi.owl + + + + obo2:CHEBI_35406 + obo2:chebi.owl + + + + obo2:CHEBI_35479 + obo2:chebi.owl + + + + obo2:CHEBI_35505 + obo2:chebi.owl + + + + obo2:CHEBI_35555 + obo2:chebi.owl + + + + obo2:CHEBI_35570 + obo2:chebi.owl + + + + obo2:CHEBI_35571 + obo2:chebi.owl + + + + obo2:CHEBI_35573 + obo2:chebi.owl + + + + obo2:CHEBI_35618 + obo2:chebi.owl + + + + obo2:CHEBI_35624 + obo2:chebi.owl + + + + obo2:CHEBI_35681 + obo2:chebi.owl + + + + obo2:CHEBI_35689 + obo2:chebi.owl + + + + obo2:CHEBI_35701 + obo2:chebi.owl + + + + obo2:CHEBI_35727 + obo2:chebi.owl + + + + obo2:CHEBI_35748 + obo2:chebi.owl + + + + obo2:CHEBI_35789 + obo2:chebi.owl + + + + obo2:CHEBI_35790 + obo2:chebi.owl + + + + obo2:CHEBI_35850 + obo2:chebi.owl + + + + obo2:CHEBI_35868 + obo2:chebi.owl + + + + obo2:CHEBI_35871 + obo2:chebi.owl + + + + obo2:CHEBI_35875 + obo2:chebi.owl + + + + obo2:CHEBI_35972 + obo2:chebi.owl + + + + obo2:CHEBI_36141 + obo2:chebi.owl + + + + obo2:CHEBI_36357 + obo2:chebi.owl + + + + obo2:CHEBI_36358 + obo2:chebi.owl + + + + obo2:CHEBI_36359 + obo2:chebi.owl + + + + obo2:CHEBI_36360 + obo2:chebi.owl + + + + obo2:CHEBI_36468 + obo2:chebi.owl + + + + obo2:CHEBI_36585 + obo2:chebi.owl + + + + obo2:CHEBI_36586 + obo2:chebi.owl + + + + obo2:CHEBI_36588 + obo2:chebi.owl + + + + obo2:CHEBI_36624 + obo2:chebi.owl + + + + obo2:CHEBI_36683 + obo2:chebi.owl + + + + obo2:CHEBI_36684 + obo2:chebi.owl + + + + obo2:CHEBI_36785 + obo2:chebi.owl + + + + obo2:CHEBI_36962 + obo2:chebi.owl + + + + obo2:CHEBI_36963 + obo2:chebi.owl + + + + obo2:CHEBI_37141 + obo2:chebi.owl + + + + obo2:CHEBI_37142 + obo2:chebi.owl + + + + obo2:CHEBI_37143 + obo2:chebi.owl + + + + obo2:CHEBI_37406 + obo2:chebi.owl + + + + obo2:CHEBI_37577 + obo2:chebi.owl + + + + obo2:CHEBI_37578 + obo2:chebi.owl + + + + obo2:CHEBI_37598 + obo2:chebi.owl + + + + obo2:CHEBI_37622 + obo2:chebi.owl + + + + obo2:CHEBI_37734 + obo2:chebi.owl + + + + obo2:CHEBI_37947 + obo2:chebi.owl + + + + obo2:CHEBI_38101 + obo2:chebi.owl + + + + obo2:CHEBI_38104 + obo2:chebi.owl + + + + obo2:CHEBI_38106 + obo2:chebi.owl + + + + obo2:CHEBI_38166 + obo2:chebi.owl + + + + obo2:CHEBI_38179 + obo2:chebi.owl + + + + obo2:CHEBI_38180 + obo2:chebi.owl + + + + obo2:CHEBI_38260 + obo2:chebi.owl + + + + obo2:CHEBI_38261 + obo2:chebi.owl + + + + obo2:CHEBI_38295 + obo2:chebi.owl + + + + obo2:CHEBI_38296 + obo2:chebi.owl + + + + obo2:CHEBI_38298 + obo2:chebi.owl + + + + obo2:CHEBI_38304 + obo2:chebi.owl + + + + obo2:CHEBI_38313 + obo2:chebi.owl + + + + obo2:CHEBI_38315 + obo2:chebi.owl + + + + obo2:CHEBI_38329 + obo2:chebi.owl + + + + obo2:CHEBI_38338 + obo2:chebi.owl + + + + obo2:CHEBI_38418 + obo2:chebi.owl + + + + obo2:CHEBI_38597 + obo2:chebi.owl + + + + obo2:CHEBI_38669 + obo2:chebi.owl + + + + obo2:CHEBI_38670 + obo2:chebi.owl + + + + obo2:CHEBI_38700 + obo2:chebi.owl + + + + obo2:CHEBI_38785 + obo2:chebi.owl + + + + obo2:CHEBI_38958 + obo2:chebi.owl + + + + obo2:CHEBI_39430 + obo2:chebi.owl + + + + obo2:CHEBI_39446 + obo2:chebi.owl + + + + obo2:CHEBI_39447 + obo2:chebi.owl + + + + obo2:CHEBI_3992 + obo2:chebi.owl + + + + obo2:CHEBI_4356 + obo2:chebi.owl + + + + obo2:CHEBI_46754 + obo2:chebi.owl + + + + obo2:CHEBI_46771 + obo2:chebi.owl + + + + obo2:CHEBI_46844 + obo2:chebi.owl + + + + obo2:CHEBI_46845 + obo2:chebi.owl + + + + obo2:CHEBI_46848 + obo2:chebi.owl + + + + obo2:CHEBI_46851 + obo2:chebi.owl + + + + obo2:CHEBI_46867 + obo2:chebi.owl + + + + obo2:CHEBI_46895 + obo2:chebi.owl + + + + obo2:CHEBI_46906 + obo2:chebi.owl + + + + obo2:CHEBI_46908 + obo2:chebi.owl + + + + obo2:CHEBI_46918 + obo2:chebi.owl + + + + obo2:CHEBI_46921 + obo2:chebi.owl + + + + obo2:CHEBI_46952 + obo2:chebi.owl + + + + obo2:CHEBI_46969 + obo2:chebi.owl + + + + obo2:CHEBI_47017 + obo2:chebi.owl + + + + obo2:CHEBI_47788 + obo2:chebi.owl + + + + obo2:CHEBI_47804 + obo2:chebi.owl + + + + obo2:CHEBI_47909 + obo2:chebi.owl + + + + obo2:CHEBI_47945 + obo2:chebi.owl + + + + obo2:CHEBI_48337 + obo2:chebi.owl + + + + obo2:CHEBI_48420 + obo2:chebi.owl + + + + obo2:CHEBI_48441 + obo2:chebi.owl + + + + obo2:CHEBI_48442 + obo2:chebi.owl + + + + obo2:CHEBI_48589 + obo2:chebi.owl + + + + obo2:CHEBI_48626 + obo2:chebi.owl + + + + obo2:CHEBI_48684 + obo2:chebi.owl + + + + obo2:CHEBI_48864 + obo2:chebi.owl + + + + obo2:CHEBI_48888 + obo2:chebi.owl + + + + obo2:CHEBI_48901 + obo2:chebi.owl + + + + obo2:CHEBI_50047 + obo2:chebi.owl + + + + obo2:CHEBI_50860 + obo2:chebi.owl + + + + obo2:CHEBI_50893 + obo2:chebi.owl + + + + obo2:CHEBI_50995 + obo2:chebi.owl + + + + obo2:CHEBI_51026 + obo2:chebi.owl + + + + obo2:CHEBI_51143 + obo2:chebi.owl + + + + obo2:CHEBI_51958 + obo2:chebi.owl + + + + obo2:CHEBI_51959 + obo2:chebi.owl + + + + obo2:CHEBI_52362 + obo2:chebi.owl + + + + obo2:CHEBI_52557 + obo2:chebi.owl + + + + obo2:CHEBI_55370 + obo2:chebi.owl + + + + obo2:CHEBI_55373 + obo2:chebi.owl + + + + obo2:CHEBI_5686 + obo2:chebi.owl + + + + obo2:CHEBI_59230 + obo2:chebi.owl + + + + obo2:CHEBI_59779 + obo2:chebi.owl + + + + obo2:CHEBI_60004 + obo2:chebi.owl + + + + obo2:CHEBI_61120 + obo2:chebi.owl + + + + obo2:CHEBI_63161 + obo2:chebi.owl + + + + obo2:CHEBI_63299 + obo2:chebi.owl + + + + obo2:CHEBI_63593 + obo2:chebi.owl + + + + obo2:CHEBI_63667 + obo2:chebi.owl + + + + obo2:CHEBI_63697 + obo2:chebi.owl + + + + obo2:CHEBI_63944 + obo2:chebi.owl + + + + obo2:DOID_870 + obo2:doid.owl + + + + obo2:FMA_85972 + obo2:uberon.owl + + + + obo2:FMA_86003 + obo2:uberon.owl + + + + obo2:GO_0000002 + obo2:go.owl + + + + obo2:GO_0000003 + obo2:go.owl + + + + obo2:GO_0000003 + obo2:go#goslim_generic + + + + obo2:GO_0000003 + obo2:go#goslim_pir + + + + obo2:GO_0000003 + obo2:go#goslim_plant + + + + obo2:GO_0000003 + obo2:go#gosubset_prok + + + + obo2:GO_0000084 + obo2:go.owl + + + + obo2:GO_0000087 + obo2:go.owl + + + + obo2:GO_0000278 + obo2:go.owl + + + + obo2:GO_0000278 + obo2:go#goslim_yeast + + + + obo2:GO_0000279 + obo2:go.owl + + + + obo2:GO_0000280 + obo2:go.owl + + + + obo2:GO_0000280 + obo2:go#goslim_pir + + + + obo2:GO_0000320 + obo2:go.owl + + + + obo2:GO_0000975 + obo2:go.owl + + + + obo2:GO_0000976 + obo2:go.owl + + + + obo2:GO_0000977 + obo2:go.owl + + + + obo2:GO_0000981 + obo2:go.owl + + + + obo2:GO_0001012 + obo2:go.owl + + + + obo2:GO_0001067 + obo2:go.owl + + + + obo2:GO_0001071 + obo2:go.owl + + + + obo2:GO_0001071 + obo2:go#goslim_generic + + + + obo2:GO_0001071 + obo2:go#goslim_metagenomics + + + + obo2:GO_0001071 + obo2:go#goslim_yeast + + + + obo2:GO_0001071 + obo2:go#high_level_annotation_qc + + + + obo2:GO_0001503 + obo2:go.owl + + + + obo2:GO_0001504 + obo2:go.owl + + + + obo2:GO_0001505 + obo2:go.owl + + + + obo2:GO_0001508 + obo2:go.owl + + + + obo2:GO_0001562 + obo2:go.owl + + + + obo2:GO_0001568 + obo2:go.owl + + + + obo2:GO_0001664 + obo2:go.owl + + + + obo2:GO_0001775 + obo2:go.owl + + + + obo2:GO_0001775 + obo2:go#goslim_pir + + + + obo2:GO_0001820 + obo2:go.owl + + + + obo2:GO_0001932 + obo2:go.owl + + + + obo2:GO_0001932 + obo2:go#gosubset_prok + + + + obo2:GO_0001933 + obo2:go.owl + + + + obo2:GO_0001933 + obo2:go#gosubset_prok + + + + obo2:GO_0001944 + obo2:go.owl + + + + obo2:GO_0001959 + obo2:go.owl + + + + obo2:GO_0001960 + obo2:go.owl + + + + obo2:GO_0001963 + obo2:go.owl + + + + obo2:GO_0002252 + obo2:go.owl + + + + obo2:GO_0002376 + obo2:go.owl + + + + obo2:GO_0002376 + obo2:go#goslim_generic + + + + obo2:GO_0002376 + obo2:go#goslim_metagenomics + + + + obo2:GO_0002376 + obo2:go#goslim_pir + + + + obo2:GO_0002544 + obo2:go.owl + + + + obo2:GO_0002676 + obo2:go.owl + + + + obo2:GO_0002682 + obo2:go.owl + + + + obo2:GO_0002683 + obo2:go.owl + + + + obo2:GO_0002694 + obo2:go.owl + + + + obo2:GO_0002695 + obo2:go.owl + + + + obo2:GO_0002790 + obo2:go.owl + + + + obo2:GO_0002791 + obo2:go.owl + + + + obo2:GO_0002793 + obo2:go.owl + + + + obo2:GO_0003001 + obo2:go.owl + + + + obo2:GO_0003008 + obo2:go.owl + + + + obo2:GO_0003012 + obo2:go.owl + + + + obo2:GO_0003013 + obo2:go.owl + + + + obo2:GO_0003013 + obo2:go#goslim_generic + + + + obo2:GO_0003015 + obo2:go.owl + + + + obo2:GO_0003674 + obo2:go.owl + + + + obo2:GO_0003674 + obo2:go#goslim_aspergillus + + + + obo2:GO_0003674 + obo2:go#goslim_candida + + + + obo2:GO_0003674 + obo2:go#goslim_generic + + + + obo2:GO_0003674 + obo2:go#goslim_metagenomics + + + + obo2:GO_0003674 + obo2:go#goslim_pir + + + + obo2:GO_0003674 + obo2:go#goslim_plant + + + + obo2:GO_0003674 + obo2:go#goslim_yeast + + + + obo2:GO_0003674 + obo2:go#gosubset_prok + + + + obo2:GO_0003676 + obo2:go.owl + + + + obo2:GO_0003676 + obo2:go#goslim_metagenomics + + + + obo2:GO_0003676 + obo2:go#goslim_pir + + + + obo2:GO_0003676 + obo2:go#goslim_plant + + + + obo2:GO_0003676 + obo2:go#gosubset_prok + + + + obo2:GO_0003677 + obo2:go.owl + + + + obo2:GO_0003677 + obo2:go#goslim_aspergillus + + + + obo2:GO_0003677 + obo2:go#goslim_candida + + + + obo2:GO_0003677 + obo2:go#goslim_generic + + + + obo2:GO_0003677 + obo2:go#goslim_plant + + + + obo2:GO_0003677 + obo2:go#goslim_yeast + + + + obo2:GO_0003677 + obo2:go#gosubset_prok + + + + obo2:GO_0003700 + obo2:go.owl + + + + obo2:GO_0003700 + obo2:go#goslim_plant + + + + obo2:GO_0003700 + obo2:go#gosubset_prok + + + + obo2:GO_0003707 + obo2:go.owl + + + + obo2:GO_0003824 + obo2:go.owl + + + + obo2:GO_0003824 + obo2:go#goslim_metagenomics + + + + obo2:GO_0003824 + obo2:go#goslim_pir + + + + obo2:GO_0003824 + obo2:go#goslim_plant + + + + obo2:GO_0003824 + obo2:go#gosubset_prok + + + + obo2:GO_0004112 + obo2:go.owl + + + + obo2:GO_0004112 + obo2:go#gosubset_prok + + + + obo2:GO_0004420 + obo2:go.owl + + + + obo2:GO_0004420 + obo2:go#gosubset_prok + + + + obo2:GO_0004497 + obo2:go.owl + + + + obo2:GO_0004497 + obo2:go#goslim_pir + + + + obo2:GO_0004497 + obo2:go#gosubset_prok + + + + obo2:GO_0004672 + obo2:go.owl + + + + obo2:GO_0004672 + obo2:go#goslim_aspergillus + + + + obo2:GO_0004672 + obo2:go#goslim_candida + + + + obo2:GO_0004672 + obo2:go#goslim_metagenomics + + + + obo2:GO_0004672 + obo2:go#gosubset_prok + + + + obo2:GO_0004674 + obo2:go.owl + + + + obo2:GO_0004674 + obo2:go#gosubset_prok + + + + obo2:GO_0004713 + obo2:go.owl + + + + obo2:GO_0004713 + obo2:go#gosubset_prok + + + + obo2:GO_0004871 + obo2:go.owl + + + + obo2:GO_0004871 + obo2:go#goslim_aspergillus + + + + obo2:GO_0004871 + obo2:go#goslim_candida + + + + obo2:GO_0004871 + obo2:go#goslim_generic + + + + obo2:GO_0004871 + obo2:go#goslim_pir + + + + obo2:GO_0004871 + obo2:go#goslim_plant + + + + obo2:GO_0004871 + obo2:go#goslim_yeast + + + + obo2:GO_0004871 + obo2:go#gosubset_prok + + + + obo2:GO_0004872 + obo2:go.owl + + + + obo2:GO_0004872 + obo2:go#goslim_metagenomics + + + + obo2:GO_0004872 + obo2:go#goslim_plant + + + + obo2:GO_0004872 + obo2:go#gosubset_prok + + + + obo2:GO_0004879 + obo2:go.owl + + + + obo2:GO_0004882 + obo2:go.owl + + + + obo2:GO_0004888 + obo2:go.owl + + + + obo2:GO_0004888 + obo2:go#gosubset_prok + + + + obo2:GO_0004930 + obo2:go.owl + + + + obo2:GO_0004930 + obo2:go#gosubset_prok + + + + obo2:GO_0004935 + obo2:go.owl + + + + obo2:GO_0004936 + obo2:go.owl + + + + obo2:GO_0004939 + obo2:go.owl + + + + obo2:GO_0004953 + obo2:go.owl + + + + obo2:GO_0004954 + obo2:go.owl + + + + obo2:GO_0004955 + obo2:go.owl + + + + obo2:GO_0004974 + obo2:go.owl + + + + obo2:GO_0004993 + obo2:go.owl + + + + obo2:GO_0005102 + obo2:go.owl + + + + obo2:GO_0005102 + obo2:go#goslim_metagenomics + + + + obo2:GO_0005102 + obo2:go#goslim_plant + + + + obo2:GO_0005102 + obo2:go#gosubset_prok + + + + obo2:GO_0005126 + obo2:go.owl + + + + obo2:GO_0005179 + obo2:go.owl + + + + obo2:GO_0005215 + obo2:go.owl + + + + obo2:GO_0005215 + obo2:go#goslim_aspergillus + + + + obo2:GO_0005215 + obo2:go#goslim_candida + + + + obo2:GO_0005215 + obo2:go#goslim_metagenomics + + + + obo2:GO_0005215 + obo2:go#goslim_pir + + + + obo2:GO_0005215 + obo2:go#goslim_plant + + + + obo2:GO_0005215 + obo2:go#gosubset_prok + + + + obo2:GO_0005216 + obo2:go.owl + + + + obo2:GO_0005216 + obo2:go#gosubset_prok + + + + obo2:GO_0005244 + obo2:go.owl + + + + obo2:GO_0005244 + obo2:go#gosubset_prok + + + + obo2:GO_0005248 + obo2:go.owl + + + + obo2:GO_0005261 + obo2:go.owl + + + + obo2:GO_0005261 + obo2:go#gosubset_prok + + + + obo2:GO_0005272 + obo2:go.owl + + + + obo2:GO_0005488 + obo2:go.owl + + + + obo2:GO_0005488 + obo2:go#goslim_pir + + + + obo2:GO_0005488 + obo2:go#goslim_plant + + + + obo2:GO_0005488 + obo2:go#gosubset_prok + + + + obo2:GO_0005496 + obo2:go.owl + + + + obo2:GO_0005496 + obo2:go#goslim_pir + + + + obo2:GO_0005496 + obo2:go#gosubset_prok + + + + obo2:GO_0005497 + obo2:go.owl + + + + obo2:GO_0005504 + obo2:go.owl + + + + obo2:GO_0005504 + obo2:go#gosubset_prok + + + + obo2:GO_0005515 + obo2:go.owl + + + + obo2:GO_0005515 + obo2:go#goslim_aspergillus + + + + obo2:GO_0005515 + obo2:go#goslim_candida + + + + obo2:GO_0005515 + obo2:go#goslim_pir + + + + obo2:GO_0005515 + obo2:go#goslim_plant + + + + obo2:GO_0005515 + obo2:go#gosubset_prok + + + + obo2:GO_0005575 + obo2:go.owl + + + + obo2:GO_0005575 + obo2:go#goslim_aspergillus + + + + obo2:GO_0005575 + obo2:go#goslim_candida + + + + obo2:GO_0005575 + obo2:go#goslim_generic + + + + obo2:GO_0005575 + obo2:go#goslim_metagenomics + + + + obo2:GO_0005575 + obo2:go#goslim_pir + + + + obo2:GO_0005575 + obo2:go#goslim_plant + + + + obo2:GO_0005575 + obo2:go#goslim_yeast + + + + obo2:GO_0005575 + obo2:go#gosubset_prok + + + + obo2:GO_0005622 + obo2:go.owl + + + + obo2:GO_0005622 + obo2:go#goslim_generic + + + + obo2:GO_0005622 + obo2:go#goslim_pir + + + + obo2:GO_0005622 + obo2:go#goslim_plant + + + + obo2:GO_0005622 + obo2:go#gosubset_prok + + + + obo2:GO_0005623 + obo2:go.owl + + + + obo2:GO_0005623 + obo2:go#goslim_generic + + + + obo2:GO_0005623 + obo2:go#goslim_plant + + + + obo2:GO_0005623 + obo2:go#gosubset_prok + + + + obo2:GO_0005737 + obo2:go.owl + + + + obo2:GO_0005737 + obo2:go#goslim_candida + + + + obo2:GO_0005737 + obo2:go#goslim_generic + + + + obo2:GO_0005737 + obo2:go#goslim_metagenomics + + + + obo2:GO_0005737 + obo2:go#goslim_plant + + + + obo2:GO_0005737 + obo2:go#goslim_yeast + + + + obo2:GO_0005737 + obo2:go#gosubset_prok + + + + obo2:GO_0005739 + obo2:go.owl + + + + obo2:GO_0005739 + obo2:go#goslim_aspergillus + + + + obo2:GO_0005739 + obo2:go#goslim_candida + + + + obo2:GO_0005739 + obo2:go#goslim_generic + + + + obo2:GO_0005739 + obo2:go#goslim_metagenomics + + + + obo2:GO_0005739 + obo2:go#goslim_pir + + + + obo2:GO_0005739 + obo2:go#goslim_plant + + + + obo2:GO_0005739 + obo2:go#goslim_yeast + + + + obo2:GO_0006066 + obo2:go.owl + + + + obo2:GO_0006066 + obo2:go#goslim_pir + + + + obo2:GO_0006066 + obo2:go#gosubset_prok + + + + obo2:GO_0006082 + obo2:go.owl + + + + obo2:GO_0006082 + obo2:go#goslim_pir + + + + obo2:GO_0006082 + obo2:go#gosubset_prok + + + + obo2:GO_0006139 + obo2:go.owl + + + + obo2:GO_0006139 + obo2:go#goslim_pir + + + + obo2:GO_0006139 + obo2:go#goslim_plant + + + + obo2:GO_0006139 + obo2:go#gosubset_prok + + + + obo2:GO_0006144 + obo2:go.owl + + + + obo2:GO_0006144 + obo2:go#gosubset_prok + + + + obo2:GO_0006213 + obo2:go.owl + + + + obo2:GO_0006213 + obo2:go#gosubset_prok + + + + obo2:GO_0006259 + obo2:go.owl + + + + obo2:GO_0006259 + obo2:go#goslim_aspergillus + + + + obo2:GO_0006259 + obo2:go#goslim_candida + + + + obo2:GO_0006259 + obo2:go#goslim_generic + + + + obo2:GO_0006259 + obo2:go#goslim_metagenomics + + + + obo2:GO_0006259 + obo2:go#goslim_pir + + + + obo2:GO_0006259 + obo2:go#goslim_plant + + + + obo2:GO_0006259 + obo2:go#gosubset_prok + + + + obo2:GO_0006260 + obo2:go.owl + + + + obo2:GO_0006260 + obo2:go#goslim_pir + + + + obo2:GO_0006260 + obo2:go#goslim_pombe + + + + obo2:GO_0006260 + obo2:go#goslim_yeast + + + + obo2:GO_0006260 + obo2:go#gosubset_prok + + + + obo2:GO_0006261 + obo2:go.owl + + + + obo2:GO_0006261 + obo2:go#gosubset_prok + + + + obo2:GO_0006278 + obo2:go.owl + + + + obo2:GO_0006278 + obo2:go#gosubset_prok + + + + obo2:GO_0006304 + obo2:go.owl + + + + obo2:GO_0006304 + obo2:go#goslim_pir + + + + obo2:GO_0006304 + obo2:go#gosubset_prok + + + + obo2:GO_0006351 + obo2:go.owl + + + + obo2:GO_0006351 + obo2:go#goslim_aspergillus + + + + obo2:GO_0006351 + obo2:go#goslim_metagenomics + + + + obo2:GO_0006351 + obo2:go#goslim_pombe + + + + obo2:GO_0006351 + obo2:go#gosubset_prok + + + + obo2:GO_0006355 + obo2:go.owl + + + + obo2:GO_0006355 + obo2:go#goslim_pombe + + + + obo2:GO_0006355 + obo2:go#gosubset_prok + + + + obo2:GO_0006357 + obo2:go.owl + + + + obo2:GO_0006366 + obo2:go.owl + + + + obo2:GO_0006366 + obo2:go#goslim_yeast + + + + obo2:GO_0006396 + obo2:go.owl + + + + obo2:GO_0006396 + obo2:go#goslim_pir + + + + obo2:GO_0006396 + obo2:go#gosubset_prok + + + + obo2:GO_0006397 + obo2:go.owl + + + + obo2:GO_0006397 + obo2:go#goslim_generic + + + + obo2:GO_0006397 + obo2:go#goslim_yeast + + + + obo2:GO_0006397 + obo2:go#gosubset_prok + + + + obo2:GO_0006412 + obo2:go.owl + + + + obo2:GO_0006412 + obo2:go#goslim_aspergillus + + + + obo2:GO_0006412 + obo2:go#goslim_candida + + + + obo2:GO_0006412 + obo2:go#goslim_generic + + + + obo2:GO_0006412 + obo2:go#goslim_metagenomics + + + + obo2:GO_0006412 + obo2:go#goslim_pir + + + + obo2:GO_0006412 + obo2:go#goslim_plant + + + + obo2:GO_0006412 + obo2:go#gosubset_prok + + + + obo2:GO_0006417 + obo2:go.owl + + + + obo2:GO_0006417 + obo2:go#goslim_yeast + + + + obo2:GO_0006417 + obo2:go#gosubset_prok + + + + obo2:GO_0006464 + obo2:go.owl + + + + obo2:GO_0006464 + obo2:go#goslim_aspergillus + + + + obo2:GO_0006464 + obo2:go#goslim_candida + + + + obo2:GO_0006464 + obo2:go#goslim_generic + + + + obo2:GO_0006464 + obo2:go#goslim_pir + + + + obo2:GO_0006464 + obo2:go#goslim_plant + + + + obo2:GO_0006464 + obo2:go#gosubset_prok + + + + obo2:GO_0006468 + obo2:go.owl + + + + obo2:GO_0006468 + obo2:go#goslim_yeast + + + + obo2:GO_0006468 + obo2:go#gosubset_prok + + + + obo2:GO_0006469 + obo2:go.owl + + + + obo2:GO_0006469 + obo2:go#gosubset_prok + + + + obo2:GO_0006508 + obo2:go.owl + + + + obo2:GO_0006508 + obo2:go#goslim_pir + + + + obo2:GO_0006508 + obo2:go#gosubset_prok + + + + obo2:GO_0006520 + obo2:go.owl + + + + obo2:GO_0006520 + obo2:go#goslim_aspergillus + + + + obo2:GO_0006520 + obo2:go#goslim_generic + + + + obo2:GO_0006520 + obo2:go#goslim_metagenomics + + + + obo2:GO_0006520 + obo2:go#goslim_pombe + + + + obo2:GO_0006520 + obo2:go#goslim_yeast + + + + obo2:GO_0006520 + obo2:go#gosubset_prok + + + + obo2:GO_0006521 + obo2:go.owl + + + + obo2:GO_0006521 + obo2:go#gosubset_prok + + + + obo2:GO_0006575 + obo2:go.owl + + + + obo2:GO_0006575 + obo2:go#gosubset_prok + + + + obo2:GO_0006576 + obo2:go.owl + + + + obo2:GO_0006576 + obo2:go#gosubset_prok + + + + obo2:GO_0006584 + obo2:go.owl + + + + obo2:GO_0006584 + obo2:go#gosubset_prok + + + + obo2:GO_0006590 + obo2:go.owl + + + + obo2:GO_0006629 + obo2:go.owl + + + + obo2:GO_0006629 + obo2:go#goslim_aspergillus + + + + obo2:GO_0006629 + obo2:go#goslim_candida + + + + obo2:GO_0006629 + obo2:go#goslim_generic + + + + obo2:GO_0006629 + obo2:go#goslim_metagenomics + + + + obo2:GO_0006629 + obo2:go#goslim_pir + + + + obo2:GO_0006629 + obo2:go#goslim_plant + + + + obo2:GO_0006629 + obo2:go#goslim_pombe + + + + obo2:GO_0006629 + obo2:go#goslim_yeast + + + + obo2:GO_0006629 + obo2:go#gosubset_prok + + + + obo2:GO_0006643 + obo2:go.owl + + + + obo2:GO_0006643 + obo2:go#gosubset_prok + + + + obo2:GO_0006664 + obo2:go.owl + + + + obo2:GO_0006664 + obo2:go#gosubset_prok + + + + obo2:GO_0006665 + obo2:go.owl + + + + obo2:GO_0006665 + obo2:go#gosubset_prok + + + + obo2:GO_0006672 + obo2:go.owl + + + + obo2:GO_0006672 + obo2:go#gosubset_prok + + + + obo2:GO_0006677 + obo2:go.owl + + + + obo2:GO_0006677 + obo2:go#gosubset_prok + + + + obo2:GO_0006678 + obo2:go.owl + + + + obo2:GO_0006678 + obo2:go#gosubset_prok + + + + obo2:GO_0006679 + obo2:go.owl + + + + obo2:GO_0006679 + obo2:go#gosubset_prok + + + + obo2:GO_0006687 + obo2:go.owl + + + + obo2:GO_0006687 + obo2:go#gosubset_prok + + + + obo2:GO_0006688 + obo2:go.owl + + + + obo2:GO_0006688 + obo2:go#gosubset_prok + + + + obo2:GO_0006694 + obo2:go.owl + + + + obo2:GO_0006694 + obo2:go#gosubset_prok + + + + obo2:GO_0006696 + obo2:go.owl + + + + obo2:GO_0006696 + obo2:go#gosubset_prok + + + + obo2:GO_0006725 + obo2:go.owl + + + + obo2:GO_0006725 + obo2:go#goslim_pir + + + + obo2:GO_0006725 + obo2:go#gosubset_prok + + + + obo2:GO_0006793 + obo2:go.owl + + + + obo2:GO_0006793 + obo2:go#goslim_pir + + + + obo2:GO_0006793 + obo2:go#gosubset_prok + + + + obo2:GO_0006796 + obo2:go.owl + + + + obo2:GO_0006796 + obo2:go#gosubset_prok + + + + obo2:GO_0006807 + obo2:go.owl + + + + obo2:GO_0006807 + obo2:go#goslim_metagenomics + + + + obo2:GO_0006807 + obo2:go#goslim_pir + + + + obo2:GO_0006807 + obo2:go#gosubset_prok + + + + obo2:GO_0006810 + obo2:go.owl + + + + obo2:GO_0006810 + obo2:go#goslim_aspergillus + + + + obo2:GO_0006810 + obo2:go#goslim_candida + + + + obo2:GO_0006810 + obo2:go#goslim_generic + + + + obo2:GO_0006810 + obo2:go#goslim_metagenomics + + + + obo2:GO_0006810 + obo2:go#goslim_pir + + + + obo2:GO_0006810 + obo2:go#goslim_plant + + + + obo2:GO_0006810 + obo2:go#gosubset_prok + + + + obo2:GO_0006811 + obo2:go.owl + + + + obo2:GO_0006811 + obo2:go#goslim_metagenomics + + + + obo2:GO_0006811 + obo2:go#goslim_pir + + + + obo2:GO_0006811 + obo2:go#goslim_yeast + + + + obo2:GO_0006811 + obo2:go#gosubset_prok + + + + obo2:GO_0006812 + obo2:go.owl + + + + obo2:GO_0006812 + obo2:go#gosubset_prok + + + + obo2:GO_0006814 + obo2:go.owl + + + + obo2:GO_0006814 + obo2:go#gosubset_prok + + + + obo2:GO_0006816 + obo2:go.owl + + + + obo2:GO_0006816 + obo2:go#gosubset_prok + + + + obo2:GO_0006836 + obo2:go.owl + + + + obo2:GO_0006836 + obo2:go#goslim_pir + + + + obo2:GO_0006837 + obo2:go.owl + + + + obo2:GO_0006873 + obo2:go.owl + + + + obo2:GO_0006873 + obo2:go#goslim_yeast + + + + obo2:GO_0006873 + obo2:go#gosubset_prok + + + + obo2:GO_0006915 + obo2:go.owl + + + + obo2:GO_0006936 + obo2:go.owl + + + + obo2:GO_0006936 + obo2:go#goslim_pir + + + + obo2:GO_0006937 + obo2:go.owl + + + + obo2:GO_0006939 + obo2:go.owl + + + + obo2:GO_0006940 + obo2:go.owl + + + + obo2:GO_0006950 + obo2:go.owl + + + + obo2:GO_0006950 + obo2:go#goslim_aspergillus + + + + obo2:GO_0006950 + obo2:go#goslim_candida + + + + obo2:GO_0006950 + obo2:go#goslim_generic + + + + obo2:GO_0006950 + obo2:go#goslim_metagenomics + + + + obo2:GO_0006950 + obo2:go#goslim_plant + + + + obo2:GO_0006950 + obo2:go#gosubset_prok + + + + obo2:GO_0006950 + obo2:go#high_level_annotation_qc + + + + obo2:GO_0006952 + obo2:go.owl + + + + obo2:GO_0006952 + obo2:go#gosubset_prok + + + + obo2:GO_0006954 + obo2:go.owl + + + + obo2:GO_0006996 + obo2:go.owl + + + + obo2:GO_0006996 + obo2:go#goslim_aspergillus + + + + obo2:GO_0006996 + obo2:go#goslim_candida + + + + obo2:GO_0006996 + obo2:go#goslim_pir + + + + obo2:GO_0006996 + obo2:go#gosubset_prok + + + + obo2:GO_0007005 + obo2:go.owl + + + + obo2:GO_0007005 + obo2:go#goslim_generic + + + + obo2:GO_0007005 + obo2:go#goslim_pir + + + + obo2:GO_0007005 + obo2:go#goslim_pombe + + + + obo2:GO_0007005 + obo2:go#goslim_yeast + + + + obo2:GO_0007049 + obo2:go.owl + + + + obo2:GO_0007049 + obo2:go#goslim_aspergillus + + + + obo2:GO_0007049 + obo2:go#goslim_candida + + + + obo2:GO_0007049 + obo2:go#goslim_generic + + + + obo2:GO_0007049 + obo2:go#goslim_pir + + + + obo2:GO_0007049 + obo2:go#goslim_plant + + + + obo2:GO_0007049 + obo2:go#gosubset_prok + + + + obo2:GO_0007067 + obo2:go.owl + + + + obo2:GO_0007067 + obo2:go#goslim_generic + + + + obo2:GO_0007088 + obo2:go.owl + + + + obo2:GO_0007090 + obo2:go.owl + + + + obo2:GO_0007154 + obo2:go.owl + + + + obo2:GO_0007154 + obo2:go#goslim_metagenomics + + + + obo2:GO_0007154 + obo2:go#goslim_pir + + + + obo2:GO_0007154 + obo2:go#goslim_plant + + + + obo2:GO_0007154 + obo2:go#gosubset_prok + + + + obo2:GO_0007165 + obo2:go.owl + + + + obo2:GO_0007165 + obo2:go#goslim_aspergillus + + + + obo2:GO_0007165 + obo2:go#goslim_candida + + + + obo2:GO_0007165 + obo2:go#goslim_generic + + + + obo2:GO_0007165 + obo2:go#goslim_metagenomics + + + + obo2:GO_0007165 + obo2:go#goslim_plant + + + + obo2:GO_0007165 + obo2:go#gosubset_prok + + + + obo2:GO_0007166 + obo2:go.owl + + + + obo2:GO_0007166 + obo2:go#gosubset_prok + + + + obo2:GO_0007186 + obo2:go.owl + + + + obo2:GO_0007210 + obo2:go.owl + + + + obo2:GO_0007213 + obo2:go.owl + + + + obo2:GO_0007267 + obo2:go.owl + + + + obo2:GO_0007267 + obo2:go#goslim_generic + + + + obo2:GO_0007267 + obo2:go#goslim_plant + + + + obo2:GO_0007267 + obo2:go#gosubset_prok + + + + obo2:GO_0007268 + obo2:go.owl + + + + obo2:GO_0007270 + obo2:go.owl + + + + obo2:GO_0007275 + obo2:go.owl + + + + obo2:GO_0007275 + obo2:go#goslim_plant + + + + obo2:GO_0007346 + obo2:go.owl + + + + obo2:GO_0007346 + obo2:go#goslim_pombe + + + + obo2:GO_0008015 + obo2:go.owl + + + + obo2:GO_0008015 + obo2:go#goslim_pir + + + + obo2:GO_0008016 + obo2:go.owl + + + + obo2:GO_0008081 + obo2:go.owl + + + + obo2:GO_0008081 + obo2:go#gosubset_prok + + + + obo2:GO_0008152 + obo2:go.owl + + + + obo2:GO_0008152 + obo2:go#goslim_pir + + + + obo2:GO_0008152 + obo2:go#goslim_plant + + + + obo2:GO_0008152 + obo2:go#gosubset_prok + + + + obo2:GO_0008168 + obo2:go.owl + + + + obo2:GO_0008168 + obo2:go#goslim_generic + + + + obo2:GO_0008168 + obo2:go#goslim_yeast + + + + obo2:GO_0008168 + obo2:go#gosubset_prok + + + + obo2:GO_0008171 + obo2:go.owl + + + + obo2:GO_0008171 + obo2:go#gosubset_prok + + + + obo2:GO_0008202 + obo2:go.owl + + + + obo2:GO_0008202 + obo2:go#gosubset_prok + + + + obo2:GO_0008204 + obo2:go.owl + + + + obo2:GO_0008204 + obo2:go#gosubset_prok + + + + obo2:GO_0008219 + obo2:go.owl + + + + obo2:GO_0008219 + obo2:go#goslim_generic + + + + obo2:GO_0008219 + obo2:go#goslim_plant + + + + obo2:GO_0008219 + obo2:go#gosubset_prok + + + + obo2:GO_0008227 + obo2:go.owl + + + + obo2:GO_0008227 + obo2:go#gosubset_prok + + + + obo2:GO_0008233 + obo2:go.owl + + + + obo2:GO_0008233 + obo2:go#goslim_aspergillus + + + + obo2:GO_0008233 + obo2:go#goslim_candida + + + + obo2:GO_0008233 + obo2:go#goslim_generic + + + + obo2:GO_0008233 + obo2:go#goslim_metagenomics + + + + obo2:GO_0008233 + obo2:go#goslim_pir + + + + obo2:GO_0008233 + obo2:go#goslim_yeast + + + + obo2:GO_0008233 + obo2:go#gosubset_prok + + + + obo2:GO_0008238 + obo2:go.owl + + + + obo2:GO_0008238 + obo2:go#gosubset_prok + + + + obo2:GO_0008283 + obo2:go.owl + + + + obo2:GO_0008283 + obo2:go#goslim_generic + + + + obo2:GO_0008283 + obo2:go#goslim_pir + + + + obo2:GO_0008283 + obo2:go#gosubset_prok + + + + obo2:GO_0008289 + obo2:go.owl + + + + obo2:GO_0008289 + obo2:go#goslim_candida + + + + obo2:GO_0008289 + obo2:go#goslim_generic + + + + obo2:GO_0008289 + obo2:go#goslim_pir + + + + obo2:GO_0008289 + obo2:go#goslim_plant + + + + obo2:GO_0008289 + obo2:go#goslim_yeast + + + + obo2:GO_0008289 + obo2:go#gosubset_prok + + + + obo2:GO_0008324 + obo2:go.owl + + + + obo2:GO_0008324 + obo2:go#gosubset_prok + + + + obo2:GO_0008610 + obo2:go.owl + + + + obo2:GO_0008610 + obo2:go#gosubset_prok + + + + obo2:GO_0008757 + obo2:go.owl + + + + obo2:GO_0008757 + obo2:go#gosubset_prok + + + + obo2:GO_0009056 + obo2:go.owl + + + + obo2:GO_0009056 + obo2:go#goslim_generic + + + + obo2:GO_0009056 + obo2:go#goslim_metagenomics + + + + obo2:GO_0009056 + obo2:go#goslim_plant + + + + obo2:GO_0009056 + obo2:go#gosubset_prok + + + + obo2:GO_0009058 + obo2:go.owl + + + + obo2:GO_0009058 + obo2:go#goslim_generic + + + + obo2:GO_0009058 + obo2:go#goslim_metagenomics + + + + obo2:GO_0009058 + obo2:go#goslim_plant + + + + obo2:GO_0009058 + obo2:go#gosubset_prok + + + + obo2:GO_0009059 + obo2:go.owl + + + + obo2:GO_0009059 + obo2:go#gosubset_prok + + + + obo2:GO_0009063 + obo2:go.owl + + + + obo2:GO_0009063 + obo2:go#gosubset_prok + + + + obo2:GO_0009112 + obo2:go.owl + + + + obo2:GO_0009112 + obo2:go#gosubset_prok + + + + obo2:GO_0009116 + obo2:go.owl + + + + obo2:GO_0009116 + obo2:go#goslim_pir + + + + obo2:GO_0009116 + obo2:go#gosubset_prok + + + + obo2:GO_0009120 + obo2:go.owl + + + + obo2:GO_0009120 + obo2:go#gosubset_prok + + + + obo2:GO_0009163 + obo2:go.owl + + + + obo2:GO_0009163 + obo2:go#gosubset_prok + + + + obo2:GO_0009247 + obo2:go.owl + + + + obo2:GO_0009247 + obo2:go#gosubset_prok + + + + obo2:GO_0009308 + obo2:go.owl + + + + obo2:GO_0009308 + obo2:go#goslim_pir + + + + obo2:GO_0009308 + obo2:go#gosubset_prok + + + + obo2:GO_0009310 + obo2:go.owl + + + + obo2:GO_0009310 + obo2:go#gosubset_prok + + + + obo2:GO_0009448 + obo2:go.owl + + + + obo2:GO_0009448 + obo2:go#gosubset_prok + + + + obo2:GO_0009605 + obo2:go.owl + + + + obo2:GO_0009605 + obo2:go#goslim_plant + + + + obo2:GO_0009605 + obo2:go#gosubset_prok + + + + obo2:GO_0009605 + obo2:go#high_level_annotation_qc + + + + obo2:GO_0009607 + obo2:go.owl + + + + obo2:GO_0009607 + obo2:go#goslim_plant + + + + obo2:GO_0009607 + obo2:go#gosubset_prok + + + + obo2:GO_0009607 + obo2:go#high_level_annotation_qc + + + + obo2:GO_0009611 + obo2:go.owl + + + + obo2:GO_0009615 + obo2:go.owl + + + + obo2:GO_0009615 + obo2:go#gosubset_prok + + + + obo2:GO_0009617 + obo2:go.owl + + + + obo2:GO_0009617 + obo2:go#gosubset_prok + + + + obo2:GO_0009620 + obo2:go.owl + + + + obo2:GO_0009653 + obo2:go.owl + + + + obo2:GO_0009653 + obo2:go#goslim_plant + + + + obo2:GO_0009653 + obo2:go#gosubset_prok + + + + obo2:GO_0009712 + obo2:go.owl + + + + obo2:GO_0009712 + obo2:go#gosubset_prok + + + + obo2:GO_0009719 + obo2:go.owl + + + + obo2:GO_0009719 + obo2:go#goslim_plant + + + + obo2:GO_0009719 + obo2:go#gosubset_prok + + + + obo2:GO_0009719 + obo2:go#high_level_annotation_qc + + + + obo2:GO_0009725 + obo2:go.owl + + + + obo2:GO_0009755 + obo2:go.owl + + + + obo2:GO_0009889 + obo2:go.owl + + + + obo2:GO_0009889 + obo2:go#gosubset_prok + + + + obo2:GO_0009890 + obo2:go.owl + + + + obo2:GO_0009890 + obo2:go#gosubset_prok + + + + obo2:GO_0009892 + obo2:go.owl + + + + obo2:GO_0009892 + obo2:go#gosubset_prok + + + + obo2:GO_0009914 + obo2:go.owl + + + + obo2:GO_0009914 + obo2:go#goslim_pir + + + + obo2:GO_0009966 + obo2:go.owl + + + + obo2:GO_0009966 + obo2:go#gosubset_prok + + + + obo2:GO_0009968 + obo2:go.owl + + + + obo2:GO_0009968 + obo2:go#gosubset_prok + + + + obo2:GO_0009987 + obo2:go.owl + + + + obo2:GO_0009987 + obo2:go#goslim_pir + + + + obo2:GO_0009987 + obo2:go#goslim_plant + + + + obo2:GO_0009987 + obo2:go#gosubset_prok + + + + obo2:GO_0010033 + obo2:go.owl + + + + obo2:GO_0010033 + obo2:go#gosubset_prok + + + + obo2:GO_0010467 + obo2:go.owl + + + + obo2:GO_0010467 + obo2:go#gosubset_prok + + + + obo2:GO_0010468 + obo2:go.owl + + + + obo2:GO_0010468 + obo2:go#gosubset_prok + + + + obo2:GO_0010469 + obo2:go.owl + + + + obo2:GO_0010556 + obo2:go.owl + + + + obo2:GO_0010556 + obo2:go#gosubset_prok + + + + obo2:GO_0010558 + obo2:go.owl + + + + obo2:GO_0010563 + obo2:go.owl + + + + obo2:GO_0010564 + obo2:go.owl + + + + obo2:GO_0010565 + obo2:go.owl + + + + obo2:GO_0010605 + obo2:go.owl + + + + obo2:GO_0010608 + obo2:go.owl + + + + obo2:GO_0010639 + obo2:go.owl + + + + obo2:GO_0010646 + obo2:go.owl + + + + obo2:GO_0010648 + obo2:go.owl + + + + obo2:GO_0010803 + obo2:go.owl + + + + obo2:GO_0010817 + obo2:go.owl + + + + obo2:GO_0010894 + obo2:go.owl + + + + obo2:GO_0010941 + obo2:go.owl + + + + obo2:GO_0010942 + obo2:go.owl + + + + obo2:GO_0010948 + obo2:go.owl + + + + obo2:GO_0010959 + obo2:go.owl + + + + obo2:GO_0012501 + obo2:go.owl + + + + obo2:GO_0014046 + obo2:go.owl + + + + obo2:GO_0014059 + obo2:go.owl + + + + obo2:GO_0014062 + obo2:go.owl + + + + obo2:GO_0015075 + obo2:go.owl + + + + obo2:GO_0015075 + obo2:go#gosubset_prok + + + + obo2:GO_0015267 + obo2:go.owl + + + + obo2:GO_0015267 + obo2:go#gosubset_prok + + + + obo2:GO_0015464 + obo2:go.owl + + + + obo2:GO_0015672 + obo2:go.owl + + + + obo2:GO_0015672 + obo2:go#gosubset_prok + + + + obo2:GO_0015833 + obo2:go.owl + + + + obo2:GO_0015833 + obo2:go#goslim_pir + + + + obo2:GO_0015833 + obo2:go#gosubset_prok + + + + obo2:GO_0015837 + obo2:go.owl + + + + obo2:GO_0015837 + obo2:go#goslim_pir + + + + obo2:GO_0015837 + obo2:go#gosubset_prok + + + + obo2:GO_0015844 + obo2:go.owl + + + + obo2:GO_0015844 + obo2:go#gosubset_prok + + + + obo2:GO_0015850 + obo2:go.owl + + + + obo2:GO_0015850 + obo2:go#gosubset_prok + + + + obo2:GO_0015870 + obo2:go.owl + + + + obo2:GO_0015872 + obo2:go.owl + + + + obo2:GO_0015874 + obo2:go.owl + + + + obo2:GO_0016032 + obo2:go.owl + + + + obo2:GO_0016032 + obo2:go#goslim_metagenomics + + + + obo2:GO_0016032 + obo2:go#goslim_pir + + + + obo2:GO_0016043 + obo2:go.owl + + + + obo2:GO_0016043 + obo2:go#goslim_metagenomics + + + + obo2:GO_0016043 + obo2:go#goslim_pir + + + + obo2:GO_0016043 + obo2:go#goslim_plant + + + + obo2:GO_0016043 + obo2:go#gosubset_prok + + + + obo2:GO_0016054 + obo2:go.owl + + + + obo2:GO_0016054 + obo2:go#gosubset_prok + + + + obo2:GO_0016070 + obo2:go.owl + + + + obo2:GO_0016070 + obo2:go#goslim_aspergillus + + + + obo2:GO_0016070 + obo2:go#goslim_candida + + + + obo2:GO_0016070 + obo2:go#goslim_metagenomics + + + + obo2:GO_0016070 + obo2:go#goslim_pir + + + + obo2:GO_0016070 + obo2:go#gosubset_prok + + + + obo2:GO_0016071 + obo2:go.owl + + + + obo2:GO_0016071 + obo2:go#goslim_pombe + + + + obo2:GO_0016071 + obo2:go#gosubset_prok + + + + obo2:GO_0016125 + obo2:go.owl + + + + obo2:GO_0016125 + obo2:go#gosubset_prok + + + + obo2:GO_0016126 + obo2:go.owl + + + + obo2:GO_0016126 + obo2:go#gosubset_prok + + + + obo2:GO_0016128 + obo2:go.owl + + + + obo2:GO_0016128 + obo2:go#gosubset_prok + + + + obo2:GO_0016129 + obo2:go.owl + + + + obo2:GO_0016129 + obo2:go#gosubset_prok + + + + obo2:GO_0016265 + obo2:go.owl + + + + obo2:GO_0016265 + obo2:go#goslim_plant + + + + obo2:GO_0016265 + obo2:go#gosubset_prok + + + + obo2:GO_0016301 + obo2:go.owl + + + + obo2:GO_0016301 + obo2:go#goslim_generic + + + + obo2:GO_0016301 + obo2:go#goslim_metagenomics + + + + obo2:GO_0016301 + obo2:go#goslim_plant + + + + obo2:GO_0016301 + obo2:go#goslim_yeast + + + + obo2:GO_0016301 + obo2:go#gosubset_prok + + + + obo2:GO_0016310 + obo2:go.owl + + + + obo2:GO_0016310 + obo2:go#goslim_metagenomics + + + + obo2:GO_0016310 + obo2:go#gosubset_prok + + + + obo2:GO_0016462 + obo2:go.owl + + + + obo2:GO_0016462 + obo2:go#gosubset_prok + + + + obo2:GO_0016491 + obo2:go.owl + + + + obo2:GO_0016491 + obo2:go#goslim_aspergillus + + + + obo2:GO_0016491 + obo2:go#goslim_candida + + + + obo2:GO_0016491 + obo2:go#goslim_generic + + + + obo2:GO_0016491 + obo2:go#goslim_metagenomics + + + + obo2:GO_0016491 + obo2:go#goslim_pir + + + + obo2:GO_0016491 + obo2:go#goslim_yeast + + + + obo2:GO_0016491 + obo2:go#gosubset_prok + + + + obo2:GO_0016614 + obo2:go.owl + + + + obo2:GO_0016614 + obo2:go#gosubset_prok + + + + obo2:GO_0016616 + obo2:go.owl + + + + obo2:GO_0016616 + obo2:go#gosubset_prok + + + + obo2:GO_0016627 + obo2:go.owl + + + + obo2:GO_0016627 + obo2:go#gosubset_prok + + + + obo2:GO_0016635 + obo2:go.owl + + + + obo2:GO_0016635 + obo2:go#gosubset_prok + + + + obo2:GO_0016645 + obo2:go.owl + + + + obo2:GO_0016645 + obo2:go#gosubset_prok + + + + obo2:GO_0016646 + obo2:go.owl + + + + obo2:GO_0016646 + obo2:go#gosubset_prok + + + + obo2:GO_0016705 + obo2:go.owl + + + + obo2:GO_0016705 + obo2:go#gosubset_prok + + + + obo2:GO_0016712 + obo2:go.owl + + + + obo2:GO_0016712 + obo2:go#gosubset_prok + + + + obo2:GO_0016740 + obo2:go.owl + + + + obo2:GO_0016740 + obo2:go#goslim_aspergillus + + + + obo2:GO_0016740 + obo2:go#goslim_candida + + + + obo2:GO_0016740 + obo2:go#goslim_metagenomics + + + + obo2:GO_0016740 + obo2:go#goslim_pir + + + + obo2:GO_0016740 + obo2:go#goslim_plant + + + + obo2:GO_0016740 + obo2:go#gosubset_prok + + + + obo2:GO_0016741 + obo2:go.owl + + + + obo2:GO_0016741 + obo2:go#gosubset_prok + + + + obo2:GO_0016765 + obo2:go.owl + + + + obo2:GO_0016765 + obo2:go#goslim_generic + + + + obo2:GO_0016765 + obo2:go#goslim_metagenomics + + + + obo2:GO_0016765 + obo2:go#goslim_yeast + + + + obo2:GO_0016765 + obo2:go#gosubset_prok + + + + obo2:GO_0016772 + obo2:go.owl + + + + obo2:GO_0016772 + obo2:go#gosubset_prok + + + + obo2:GO_0016773 + obo2:go.owl + + + + obo2:GO_0016773 + obo2:go#gosubset_prok + + + + obo2:GO_0016787 + obo2:go.owl + + + + obo2:GO_0016787 + obo2:go#goslim_aspergillus + + + + obo2:GO_0016787 + obo2:go#goslim_candida + + + + obo2:GO_0016787 + obo2:go#goslim_metagenomics + + + + obo2:GO_0016787 + obo2:go#goslim_pir + + + + obo2:GO_0016787 + obo2:go#goslim_plant + + + + obo2:GO_0016787 + obo2:go#gosubset_prok + + + + obo2:GO_0016788 + obo2:go.owl + + + + obo2:GO_0016788 + obo2:go#goslim_metagenomics + + + + obo2:GO_0016788 + obo2:go#gosubset_prok + + + + obo2:GO_0016817 + obo2:go.owl + + + + obo2:GO_0016817 + obo2:go#gosubset_prok + + + + obo2:GO_0016818 + obo2:go.owl + + + + obo2:GO_0016818 + obo2:go#gosubset_prok + + + + obo2:GO_0017111 + obo2:go.owl + + + + obo2:GO_0017111 + obo2:go#gosubset_prok + + + + obo2:GO_0018108 + obo2:go.owl + + + + obo2:GO_0018108 + obo2:go#gosubset_prok + + + + obo2:GO_0018130 + obo2:go.owl + + + + obo2:GO_0018130 + obo2:go#gosubset_prok + + + + obo2:GO_0018193 + obo2:go.owl + + + + obo2:GO_0018193 + obo2:go#goslim_yeast + + + + obo2:GO_0018193 + obo2:go#gosubset_prok + + + + obo2:GO_0018212 + obo2:go.owl + + + + obo2:GO_0018212 + obo2:go#gosubset_prok + + + + obo2:GO_0018958 + obo2:go.owl + + + + obo2:GO_0018958 + obo2:go#gosubset_prok + + + + obo2:GO_0019058 + obo2:go.owl + + + + obo2:GO_0019067 + obo2:go.owl + + + + obo2:GO_0019216 + obo2:go.owl + + + + obo2:GO_0019216 + obo2:go#gosubset_prok + + + + obo2:GO_0019218 + obo2:go.owl + + + + obo2:GO_0019218 + obo2:go#gosubset_prok + + + + obo2:GO_0019219 + obo2:go.owl + + + + obo2:GO_0019219 + obo2:go#gosubset_prok + + + + obo2:GO_0019220 + obo2:go.owl + + + + obo2:GO_0019220 + obo2:go#gosubset_prok + + + + obo2:GO_0019221 + obo2:go.owl + + + + obo2:GO_0019222 + obo2:go.owl + + + + obo2:GO_0019222 + obo2:go#gosubset_prok + + + + obo2:GO_0019226 + obo2:go.owl + + + + obo2:GO_0019438 + obo2:go.owl + + + + obo2:GO_0019438 + obo2:go#gosubset_prok + + + + obo2:GO_0019538 + obo2:go.owl + + + + obo2:GO_0019538 + obo2:go#goslim_metagenomics + + + + obo2:GO_0019538 + obo2:go#goslim_pir + + + + obo2:GO_0019538 + obo2:go#goslim_plant + + + + obo2:GO_0019538 + obo2:go#gosubset_prok + + + + obo2:GO_0019725 + obo2:go.owl + + + + obo2:GO_0019725 + obo2:go#goslim_aspergillus + + + + obo2:GO_0019725 + obo2:go#goslim_candida + + + + obo2:GO_0019725 + obo2:go#goslim_plant + + + + obo2:GO_0019725 + obo2:go#gosubset_prok + + + + obo2:GO_0019752 + obo2:go.owl + + + + obo2:GO_0019752 + obo2:go#gosubset_prok + + + + obo2:GO_0022402 + obo2:go.owl + + + + obo2:GO_0022402 + obo2:go#gosubset_prok + + + + obo2:GO_0022403 + obo2:go.owl + + + + obo2:GO_0022414 + obo2:go.owl + + + + obo2:GO_0022414 + obo2:go#gosubset_prok + + + + obo2:GO_0022415 + obo2:go.owl + + + + obo2:GO_0022607 + obo2:go.owl + + + + obo2:GO_0022607 + obo2:go#goslim_generic + + + + obo2:GO_0022607 + obo2:go#goslim_pir + + + + obo2:GO_0022607 + obo2:go#gosubset_prok + + + + obo2:GO_0022803 + obo2:go.owl + + + + obo2:GO_0022803 + obo2:go#gosubset_prok + + + + obo2:GO_0022832 + obo2:go.owl + + + + obo2:GO_0022836 + obo2:go.owl + + + + obo2:GO_0022838 + obo2:go.owl + + + + obo2:GO_0022843 + obo2:go.owl + + + + obo2:GO_0022857 + obo2:go.owl + + + + obo2:GO_0022857 + obo2:go#goslim_generic + + + + obo2:GO_0022857 + obo2:go#goslim_yeast + + + + obo2:GO_0022857 + obo2:go#gosubset_prok + + + + obo2:GO_0022891 + obo2:go.owl + + + + obo2:GO_0022891 + obo2:go#gosubset_prok + + + + obo2:GO_0022892 + obo2:go.owl + + + + obo2:GO_0022892 + obo2:go#gosubset_prok + + + + obo2:GO_0022898 + obo2:go.owl + + + + obo2:GO_0022898 + obo2:go#gosubset_prok + + + + obo2:GO_0023051 + obo2:go.owl + + + + obo2:GO_0023052 + obo2:go.owl + + + + obo2:GO_0023052 + obo2:go#goslim_pombe + + + + obo2:GO_0023052 + obo2:go#goslim_yeast + + + + obo2:GO_0023057 + obo2:go.owl + + + + obo2:GO_0023061 + obo2:go.owl + + + + obo2:GO_0030001 + obo2:go.owl + + + + obo2:GO_0030001 + obo2:go#gosubset_prok + + + + obo2:GO_0030072 + obo2:go.owl + + + + obo2:GO_0030148 + obo2:go.owl + + + + obo2:GO_0030148 + obo2:go#gosubset_prok + + + + obo2:GO_0030154 + obo2:go.owl + + + + obo2:GO_0030154 + obo2:go#goslim_generic + + + + obo2:GO_0030154 + obo2:go#goslim_plant + + + + obo2:GO_0030154 + obo2:go#gosubset_prok + + + + obo2:GO_0030162 + obo2:go.owl + + + + obo2:GO_0030162 + obo2:go#gosubset_prok + + + + obo2:GO_0030252 + obo2:go.owl + + + + obo2:GO_0030278 + obo2:go.owl + + + + obo2:GO_0030518 + obo2:go.owl + + + + obo2:GO_0030521 + obo2:go.owl + + + + obo2:GO_0030522 + obo2:go.owl + + + + obo2:GO_0030594 + obo2:go.owl + + + + obo2:GO_0031323 + obo2:go.owl + + + + obo2:GO_0031323 + obo2:go#gosubset_prok + + + + obo2:GO_0031324 + obo2:go.owl + + + + obo2:GO_0031324 + obo2:go#gosubset_prok + + + + obo2:GO_0031326 + obo2:go.owl + + + + obo2:GO_0031326 + obo2:go#gosubset_prok + + + + obo2:GO_0031327 + obo2:go.owl + + + + obo2:GO_0031327 + obo2:go#gosubset_prok + + + + obo2:GO_0031347 + obo2:go.owl + + + + obo2:GO_0031348 + obo2:go.owl + + + + obo2:GO_0031399 + obo2:go.owl + + + + obo2:GO_0031399 + obo2:go#goslim_yeast + + + + obo2:GO_0031399 + obo2:go#gosubset_prok + + + + obo2:GO_0031400 + obo2:go.owl + + + + obo2:GO_0031406 + obo2:go.owl + + + + obo2:GO_0031406 + obo2:go#goslim_pir + + + + obo2:GO_0031406 + obo2:go#gosubset_prok + + + + obo2:GO_0031644 + obo2:go.owl + + + + obo2:GO_0031701 + obo2:go.owl + + + + obo2:GO_0031834 + obo2:go.owl + + + + obo2:GO_0031835 + obo2:go.owl + + + + obo2:GO_0031952 + obo2:go.owl + + + + obo2:GO_0031953 + obo2:go.owl + + + + obo2:GO_0032042 + obo2:go.owl + + + + obo2:GO_0032101 + obo2:go.owl + + + + obo2:GO_0032102 + obo2:go.owl + + + + obo2:GO_0032225 + obo2:go.owl + + + + obo2:GO_0032259 + obo2:go.owl + + + + obo2:GO_0032268 + obo2:go.owl + + + + obo2:GO_0032268 + obo2:go#gosubset_prok + + + + obo2:GO_0032269 + obo2:go.owl + + + + obo2:GO_0032274 + obo2:go.owl + + + + obo2:GO_0032276 + obo2:go.owl + + + + obo2:GO_0032350 + obo2:go.owl + + + + obo2:GO_0032351 + obo2:go.owl + + + + obo2:GO_0032409 + obo2:go.owl + + + + obo2:GO_0032409 + obo2:go#gosubset_prok + + + + obo2:GO_0032411 + obo2:go.owl + + + + obo2:GO_0032412 + obo2:go.owl + + + + obo2:GO_0032412 + obo2:go#gosubset_prok + + + + obo2:GO_0032414 + obo2:go.owl + + + + obo2:GO_0032443 + obo2:go.owl + + + + obo2:GO_0032501 + obo2:go.owl + + + + obo2:GO_0032501 + obo2:go#goslim_pir + + + + obo2:GO_0032502 + obo2:go.owl + + + + obo2:GO_0032502 + obo2:go#goslim_aspergillus + + + + obo2:GO_0032502 + obo2:go#goslim_pir + + + + obo2:GO_0032502 + obo2:go#gosubset_prok + + + + obo2:GO_0032870 + obo2:go.owl + + + + obo2:GO_0032879 + obo2:go.owl + + + + obo2:GO_0032879 + obo2:go#gosubset_prok + + + + obo2:GO_0032940 + obo2:go.owl + + + + obo2:GO_0033043 + obo2:go.owl + + + + obo2:GO_0033043 + obo2:go#goslim_yeast + + + + obo2:GO_0033143 + obo2:go.owl + + + + obo2:GO_0033209 + obo2:go.owl + + + + obo2:GO_0033238 + obo2:go.owl + + + + obo2:GO_0033238 + obo2:go#gosubset_prok + + + + obo2:GO_0033239 + obo2:go.owl + + + + obo2:GO_0033261 + obo2:go.owl + + + + obo2:GO_0033293 + obo2:go.owl + + + + obo2:GO_0033293 + obo2:go#gosubset_prok + + + + obo2:GO_0033604 + obo2:go.owl + + + + obo2:GO_0033605 + obo2:go.owl + + + + obo2:GO_0033673 + obo2:go.owl + + + + obo2:GO_0034097 + obo2:go.owl + + + + obo2:GO_0034220 + obo2:go.owl + + + + obo2:GO_0034311 + obo2:go.owl + + + + obo2:GO_0034311 + obo2:go#gosubset_prok + + + + obo2:GO_0034612 + obo2:go.owl + + + + obo2:GO_0034641 + obo2:go.owl + + + + obo2:GO_0034641 + obo2:go#goslim_generic + + + + obo2:GO_0034641 + obo2:go#gosubset_prok + + + + obo2:GO_0034645 + obo2:go.owl + + + + obo2:GO_0034654 + obo2:go.owl + + + + obo2:GO_0034654 + obo2:go#gosubset_prok + + + + obo2:GO_0034762 + obo2:go.owl + + + + obo2:GO_0034765 + obo2:go.owl + + + + obo2:GO_0035637 + obo2:go.owl + + + + obo2:GO_0035725 + obo2:go.owl + + + + obo2:GO_0035821 + obo2:go.owl + + + + obo2:GO_0036211 + obo2:go.owl + + + + obo2:GO_0038023 + obo2:go.owl + + + + obo2:GO_0038083 + obo2:go.owl + + + + obo2:GO_0042069 + obo2:go.owl + + + + obo2:GO_0042069 + obo2:go#gosubset_prok + + + + obo2:GO_0042083 + obo2:go.owl + + + + obo2:GO_0042083 + obo2:go#gosubset_prok + + + + obo2:GO_0042110 + obo2:go.owl + + + + obo2:GO_0042127 + obo2:go.owl + + + + obo2:GO_0042127 + obo2:go#gosubset_prok + + + + obo2:GO_0042165 + obo2:go.owl + + + + obo2:GO_0042165 + obo2:go#goslim_pir + + + + obo2:GO_0042166 + obo2:go.owl + + + + obo2:GO_0042180 + obo2:go.owl + + + + obo2:GO_0042180 + obo2:go#goslim_pir + + + + obo2:GO_0042180 + obo2:go#gosubset_prok + + + + obo2:GO_0042221 + obo2:go.owl + + + + obo2:GO_0042221 + obo2:go#goslim_aspergillus + + + + obo2:GO_0042221 + obo2:go#goslim_candida + + + + obo2:GO_0042221 + obo2:go#goslim_yeast + + + + obo2:GO_0042221 + obo2:go#gosubset_prok + + + + obo2:GO_0042221 + obo2:go#high_level_annotation_qc + + + + obo2:GO_0042278 + obo2:go.owl + + + + obo2:GO_0042278 + obo2:go#gosubset_prok + + + + obo2:GO_0042282 + obo2:go.owl + + + + obo2:GO_0042282 + obo2:go#gosubset_prok + + + + obo2:GO_0042325 + obo2:go.owl + + + + obo2:GO_0042325 + obo2:go#gosubset_prok + + + + obo2:GO_0042326 + obo2:go.owl + + + + obo2:GO_0042326 + obo2:go#gosubset_prok + + + + obo2:GO_0042379 + obo2:go.owl + + + + obo2:GO_0042391 + obo2:go.owl + + + + obo2:GO_0042391 + obo2:go#gosubset_prok + + + + obo2:GO_0042403 + obo2:go.owl + + + + obo2:GO_0042440 + obo2:go.owl + + + + obo2:GO_0042440 + obo2:go#goslim_pir + + + + obo2:GO_0042440 + obo2:go#gosubset_prok + + + + obo2:GO_0042445 + obo2:go.owl + + + + obo2:GO_0042445 + obo2:go#goslim_pir + + + + obo2:GO_0042445 + obo2:go#gosubset_prok + + + + obo2:GO_0042537 + obo2:go.owl + + + + obo2:GO_0042537 + obo2:go#gosubset_prok + + + + obo2:GO_0042562 + obo2:go.owl + + + + obo2:GO_0042562 + obo2:go#goslim_pir + + + + obo2:GO_0042578 + obo2:go.owl + + + + obo2:GO_0042578 + obo2:go#gosubset_prok + + + + obo2:GO_0042592 + obo2:go.owl + + + + obo2:GO_0042592 + obo2:go#goslim_generic + + + + obo2:GO_0042592 + obo2:go#goslim_metagenomics + + + + obo2:GO_0042592 + obo2:go#gosubset_prok + + + + obo2:GO_0042981 + obo2:go.owl + + + + obo2:GO_0043067 + obo2:go.owl + + + + obo2:GO_0043068 + obo2:go.owl + + + + obo2:GO_0043086 + obo2:go.owl + + + + obo2:GO_0043086 + obo2:go#gosubset_prok + + + + obo2:GO_0043167 + obo2:go.owl + + + + obo2:GO_0043167 + obo2:go#goslim_generic + + + + obo2:GO_0043167 + obo2:go#goslim_pir + + + + obo2:GO_0043167 + obo2:go#goslim_yeast + + + + obo2:GO_0043167 + obo2:go#gosubset_prok + + + + obo2:GO_0043169 + obo2:go.owl + + + + obo2:GO_0043169 + obo2:go#gosubset_prok + + + + obo2:GO_0043170 + obo2:go.owl + + + + obo2:GO_0043170 + obo2:go#goslim_pir + + + + obo2:GO_0043170 + obo2:go#gosubset_prok + + + + obo2:GO_0043176 + obo2:go.owl + + + + obo2:GO_0043176 + obo2:go#goslim_pir + + + + obo2:GO_0043176 + obo2:go#gosubset_prok + + + + obo2:GO_0043226 + obo2:go.owl + + + + obo2:GO_0043226 + obo2:go#goslim_generic + + + + obo2:GO_0043226 + obo2:go#goslim_pir + + + + obo2:GO_0043226 + obo2:go#gosubset_prok + + + + obo2:GO_0043227 + obo2:go.owl + + + + obo2:GO_0043227 + obo2:go#gosubset_prok + + + + obo2:GO_0043229 + obo2:go.owl + + + + obo2:GO_0043229 + obo2:go#goslim_pir + + + + obo2:GO_0043229 + obo2:go#gosubset_prok + + + + obo2:GO_0043231 + obo2:go.owl + + + + obo2:GO_0043231 + obo2:go#goslim_pir + + + + obo2:GO_0043231 + obo2:go#gosubset_prok + + + + obo2:GO_0043269 + obo2:go.owl + + + + obo2:GO_0043271 + obo2:go.owl + + + + obo2:GO_0043401 + obo2:go.owl + + + + obo2:GO_0043412 + obo2:go.owl + + + + obo2:GO_0043412 + obo2:go#goslim_pir + + + + obo2:GO_0043412 + obo2:go#gosubset_prok + + + + obo2:GO_0043436 + obo2:go.owl + + + + obo2:GO_0043436 + obo2:go#gosubset_prok + + + + obo2:GO_0043549 + obo2:go.owl + + + + obo2:GO_0043549 + obo2:go#gosubset_prok + + + + obo2:GO_0043565 + obo2:go.owl + + + + obo2:GO_0043565 + obo2:go#gosubset_prok + + + + obo2:GO_0044057 + obo2:go.owl + + + + obo2:GO_0044060 + obo2:go.owl + + + + obo2:GO_0044085 + obo2:go.owl + + + + obo2:GO_0044085 + obo2:go#gosubset_prok + + + + obo2:GO_0044087 + obo2:go.owl + + + + obo2:GO_0044092 + obo2:go.owl + + + + obo2:GO_0044093 + obo2:go.owl + + + + obo2:GO_0044106 + obo2:go.owl + + + + obo2:GO_0044107 + obo2:go.owl + + + + obo2:GO_0044108 + obo2:go.owl + + + + obo2:GO_0044212 + obo2:go.owl + + + + obo2:GO_0044237 + obo2:go.owl + + + + obo2:GO_0044237 + obo2:go#goslim_pir + + + + obo2:GO_0044237 + obo2:go#gosubset_prok + + + + obo2:GO_0044238 + obo2:go.owl + + + + obo2:GO_0044238 + obo2:go#goslim_pir + + + + obo2:GO_0044238 + obo2:go#gosubset_prok + + + + obo2:GO_0044248 + obo2:go.owl + + + + obo2:GO_0044248 + obo2:go#gosubset_prok + + + + obo2:GO_0044249 + obo2:go.owl + + + + obo2:GO_0044249 + obo2:go#gosubset_prok + + + + obo2:GO_0044255 + obo2:go.owl + + + + obo2:GO_0044255 + obo2:go#goslim_pir + + + + obo2:GO_0044255 + obo2:go#gosubset_prok + + + + obo2:GO_0044260 + obo2:go.owl + + + + obo2:GO_0044260 + obo2:go#gosubset_prok + + + + obo2:GO_0044267 + obo2:go.owl + + + + obo2:GO_0044267 + obo2:go#gosubset_prok + + + + obo2:GO_0044271 + obo2:go.owl + + + + obo2:GO_0044271 + obo2:go#gosubset_prok + + + + obo2:GO_0044281 + obo2:go.owl + + + + obo2:GO_0044281 + obo2:go#goslim_generic + + + + obo2:GO_0044281 + obo2:go#goslim_metagenomics + + + + obo2:GO_0044282 + obo2:go.owl + + + + obo2:GO_0044283 + obo2:go.owl + + + + obo2:GO_0044359 + obo2:go.owl + + + + obo2:GO_0044362 + obo2:go.owl + + + + obo2:GO_0044424 + obo2:go.owl + + + + obo2:GO_0044424 + obo2:go#gosubset_prok + + + + obo2:GO_0044444 + obo2:go.owl + + + + obo2:GO_0044444 + obo2:go#gosubset_prok + + + + obo2:GO_0044464 + obo2:go.owl + + + + obo2:GO_0044464 + obo2:go#goslim_pir + + + + obo2:GO_0044464 + obo2:go#gosubset_prok + + + + obo2:GO_0044488 + obo2:go.owl + + + + obo2:GO_0044561 + obo2:go.owl + + + + obo2:GO_0045023 + obo2:go.owl + + + + obo2:GO_0045321 + obo2:go.owl + + + + obo2:GO_0045595 + obo2:go.owl + + + + obo2:GO_0045595 + obo2:go#gosubset_prok + + + + obo2:GO_0045763 + obo2:go.owl + + + + obo2:GO_0045763 + obo2:go#gosubset_prok + + + + obo2:GO_0045786 + obo2:go.owl + + + + obo2:GO_0045833 + obo2:go.owl + + + + obo2:GO_0045833 + obo2:go#gosubset_prok + + + + obo2:GO_0045859 + obo2:go.owl + + + + obo2:GO_0045859 + obo2:go#gosubset_prok + + + + obo2:GO_0045930 + obo2:go.owl + + + + obo2:GO_0045932 + obo2:go.owl + + + + obo2:GO_0045934 + obo2:go.owl + + + + obo2:GO_0045934 + obo2:go#gosubset_prok + + + + obo2:GO_0045936 + obo2:go.owl + + + + obo2:GO_0045936 + obo2:go#gosubset_prok + + + + obo2:GO_0045939 + obo2:go.owl + + + + obo2:GO_0045939 + obo2:go#gosubset_prok + + + + obo2:GO_0046104 + obo2:go.owl + + + + obo2:GO_0046104 + obo2:go#gosubset_prok + + + + obo2:GO_0046112 + obo2:go.owl + + + + obo2:GO_0046112 + obo2:go#gosubset_prok + + + + obo2:GO_0046120 + obo2:go.owl + + + + obo2:GO_0046120 + obo2:go#gosubset_prok + + + + obo2:GO_0046122 + obo2:go.owl + + + + obo2:GO_0046122 + obo2:go#gosubset_prok + + + + obo2:GO_0046125 + obo2:go.owl + + + + obo2:GO_0046125 + obo2:go#gosubset_prok + + + + obo2:GO_0046126 + obo2:go.owl + + + + obo2:GO_0046126 + obo2:go#gosubset_prok + + + + obo2:GO_0046134 + obo2:go.owl + + + + obo2:GO_0046134 + obo2:go#gosubset_prok + + + + obo2:GO_0046148 + obo2:go.owl + + + + obo2:GO_0046148 + obo2:go#gosubset_prok + + + + obo2:GO_0046165 + obo2:go.owl + + + + obo2:GO_0046165 + obo2:go#gosubset_prok + + + + obo2:GO_0046317 + obo2:go.owl + + + + obo2:GO_0046317 + obo2:go#gosubset_prok + + + + obo2:GO_0046395 + obo2:go.owl + + + + obo2:GO_0046395 + obo2:go#gosubset_prok + + + + obo2:GO_0046467 + obo2:go.owl + + + + obo2:GO_0046467 + obo2:go#gosubset_prok + + + + obo2:GO_0046476 + obo2:go.owl + + + + obo2:GO_0046476 + obo2:go#gosubset_prok + + + + obo2:GO_0046483 + obo2:go.owl + + + + obo2:GO_0046483 + obo2:go#goslim_pir + + + + obo2:GO_0046483 + obo2:go#gosubset_prok + + + + obo2:GO_0046513 + obo2:go.owl + + + + obo2:GO_0046513 + obo2:go#gosubset_prok + + + + obo2:GO_0046519 + obo2:go.owl + + + + obo2:GO_0046519 + obo2:go#gosubset_prok + + + + obo2:GO_0046520 + obo2:go.owl + + + + obo2:GO_0046520 + obo2:go#gosubset_prok + + + + obo2:GO_0046649 + obo2:go.owl + + + + obo2:GO_0046777 + obo2:go.owl + + + + obo2:GO_0046777 + obo2:go#gosubset_prok + + + + obo2:GO_0046872 + obo2:go.owl + + + + obo2:GO_0046872 + obo2:go#goslim_metagenomics + + + + obo2:GO_0046872 + obo2:go#gosubset_prok + + + + obo2:GO_0046879 + obo2:go.owl + + + + obo2:GO_0046883 + obo2:go.owl + + + + obo2:GO_0046887 + obo2:go.owl + + + + obo2:GO_0046890 + obo2:go.owl + + + + obo2:GO_0046890 + obo2:go#gosubset_prok + + + + obo2:GO_0046903 + obo2:go.owl + + + + obo2:GO_0046903 + obo2:go#goslim_pir + + + + obo2:GO_0046903 + obo2:go#gosubset_prok + + + + obo2:GO_0048020 + obo2:go.owl + + + + obo2:GO_0048285 + obo2:go.owl + + + + obo2:GO_0048285 + obo2:go#goslim_pir + + + + obo2:GO_0048285 + obo2:go#goslim_yeast + + + + obo2:GO_0048518 + obo2:go.owl + + + + obo2:GO_0048518 + obo2:go#gosubset_prok + + + + obo2:GO_0048519 + obo2:go.owl + + + + obo2:GO_0048519 + obo2:go#gosubset_prok + + + + obo2:GO_0048522 + obo2:go.owl + + + + obo2:GO_0048522 + obo2:go#gosubset_prok + + + + obo2:GO_0048523 + obo2:go.owl + + + + obo2:GO_0048523 + obo2:go#gosubset_prok + + + + obo2:GO_0048545 + obo2:go.owl + + + + obo2:GO_0048583 + obo2:go.owl + + + + obo2:GO_0048583 + obo2:go#gosubset_prok + + + + obo2:GO_0048583 + obo2:go#high_level_annotation_qc + + + + obo2:GO_0048585 + obo2:go.owl + + + + obo2:GO_0048585 + obo2:go#high_level_annotation_qc + + + + obo2:GO_0048610 + obo2:go.owl + + + + obo2:GO_0048610 + obo2:go#gosubset_prok + + + + obo2:GO_0048731 + obo2:go.owl + + + + obo2:GO_0048856 + obo2:go.owl + + + + obo2:GO_0048856 + obo2:go#goslim_generic + + + + obo2:GO_0048869 + obo2:go.owl + + + + obo2:GO_0048869 + obo2:go#gosubset_prok + + + + obo2:GO_0048878 + obo2:go.owl + + + + obo2:GO_0048878 + obo2:go#gosubset_prok + + + + obo2:GO_0050432 + obo2:go.owl + + + + obo2:GO_0050433 + obo2:go.owl + + + + obo2:GO_0050542 + obo2:go.owl + + + + obo2:GO_0050684 + obo2:go.owl + + + + obo2:GO_0050684 + obo2:go#gosubset_prok + + + + obo2:GO_0050727 + obo2:go.owl + + + + obo2:GO_0050730 + obo2:go.owl + + + + obo2:GO_0050730 + obo2:go#gosubset_prok + + + + obo2:GO_0050732 + obo2:go.owl + + + + obo2:GO_0050732 + obo2:go#gosubset_prok + + + + obo2:GO_0050757 + obo2:go.owl + + + + obo2:GO_0050757 + obo2:go#gosubset_prok + + + + obo2:GO_0050758 + obo2:go.owl + + + + obo2:GO_0050758 + obo2:go#gosubset_prok + + + + obo2:GO_0050789 + obo2:go.owl + + + + obo2:GO_0050789 + obo2:go#goslim_aspergillus + + + + obo2:GO_0050789 + obo2:go#goslim_candida + + + + obo2:GO_0050789 + obo2:go#gosubset_prok + + + + obo2:GO_0050790 + obo2:go.owl + + + + obo2:GO_0050790 + obo2:go#gosubset_prok + + + + obo2:GO_0050793 + obo2:go.owl + + + + obo2:GO_0050793 + obo2:go#gosubset_prok + + + + obo2:GO_0050794 + obo2:go.owl + + + + obo2:GO_0050794 + obo2:go#gosubset_prok + + + + obo2:GO_0050801 + obo2:go.owl + + + + obo2:GO_0050801 + obo2:go#gosubset_prok + + + + obo2:GO_0050804 + obo2:go.owl + + + + obo2:GO_0050810 + obo2:go.owl + + + + obo2:GO_0050810 + obo2:go#gosubset_prok + + + + obo2:GO_0050863 + obo2:go.owl + + + + obo2:GO_0050865 + obo2:go.owl + + + + obo2:GO_0050866 + obo2:go.owl + + + + obo2:GO_0050877 + obo2:go.owl + + + + obo2:GO_0050877 + obo2:go#goslim_generic + + + + obo2:GO_0050877 + obo2:go#goslim_pir + + + + obo2:GO_0050886 + obo2:go.owl + + + + obo2:GO_0050886 + obo2:go#goslim_pir + + + + obo2:GO_0050896 + obo2:go.owl + + + + obo2:GO_0050896 + obo2:go#goslim_pir + + + + obo2:GO_0050896 + obo2:go#gosubset_prok + + + + obo2:GO_0050896 + obo2:go#high_level_annotation_qc + + + + obo2:GO_0051046 + obo2:go.owl + + + + obo2:GO_0051046 + obo2:go#gosubset_prok + + + + obo2:GO_0051047 + obo2:go.owl + + + + obo2:GO_0051048 + obo2:go.owl + + + + obo2:GO_0051049 + obo2:go.owl + + + + obo2:GO_0051049 + obo2:go#goslim_yeast + + + + obo2:GO_0051049 + obo2:go#gosubset_prok + + + + obo2:GO_0051050 + obo2:go.owl + + + + obo2:GO_0051050 + obo2:go#gosubset_prok + + + + obo2:GO_0051051 + obo2:go.owl + + + + obo2:GO_0051051 + obo2:go#gosubset_prok + + + + obo2:GO_0051052 + obo2:go.owl + + + + obo2:GO_0051052 + obo2:go#goslim_yeast + + + + obo2:GO_0051052 + obo2:go#gosubset_prok + + + + obo2:GO_0051055 + obo2:go.owl + + + + obo2:GO_0051055 + obo2:go#gosubset_prok + + + + obo2:GO_0051094 + obo2:go.owl + + + + obo2:GO_0051094 + obo2:go#gosubset_prok + + + + obo2:GO_0051128 + obo2:go.owl + + + + obo2:GO_0051128 + obo2:go#gosubset_prok + + + + obo2:GO_0051129 + obo2:go.owl + + + + obo2:GO_0051129 + obo2:go#gosubset_prok + + + + obo2:GO_0051171 + obo2:go.owl + + + + obo2:GO_0051171 + obo2:go#gosubset_prok + + + + obo2:GO_0051172 + obo2:go.owl + + + + obo2:GO_0051174 + obo2:go.owl + + + + obo2:GO_0051174 + obo2:go#gosubset_prok + + + + obo2:GO_0051179 + obo2:go.owl + + + + obo2:GO_0051179 + obo2:go#goslim_pir + + + + obo2:GO_0051179 + obo2:go#gosubset_prok + + + + obo2:GO_0051234 + obo2:go.owl + + + + obo2:GO_0051234 + obo2:go#goslim_pir + + + + obo2:GO_0051234 + obo2:go#gosubset_prok + + + + obo2:GO_0051239 + obo2:go.owl + + + + obo2:GO_0051241 + obo2:go.owl + + + + obo2:GO_0051246 + obo2:go.owl + + + + obo2:GO_0051246 + obo2:go#gosubset_prok + + + + obo2:GO_0051248 + obo2:go.owl + + + + obo2:GO_0051248 + obo2:go#gosubset_prok + + + + obo2:GO_0051249 + obo2:go.owl + + + + obo2:GO_0051252 + obo2:go.owl + + + + obo2:GO_0051252 + obo2:go#gosubset_prok + + + + obo2:GO_0051253 + obo2:go.owl + + + + obo2:GO_0051253 + obo2:go#gosubset_prok + + + + obo2:GO_0051320 + obo2:go.owl + + + + obo2:GO_0051325 + obo2:go.owl + + + + obo2:GO_0051329 + obo2:go.owl + + + + obo2:GO_0051336 + obo2:go.owl + + + + obo2:GO_0051336 + obo2:go#gosubset_prok + + + + obo2:GO_0051338 + obo2:go.owl + + + + obo2:GO_0051338 + obo2:go#gosubset_prok + + + + obo2:GO_0051341 + obo2:go.owl + + + + obo2:GO_0051341 + obo2:go#gosubset_prok + + + + obo2:GO_0051342 + obo2:go.owl + + + + obo2:GO_0051346 + obo2:go.owl + + + + obo2:GO_0051346 + obo2:go#gosubset_prok + + + + obo2:GO_0051348 + obo2:go.owl + + + + obo2:GO_0051348 + obo2:go#gosubset_prok + + + + obo2:GO_0051354 + obo2:go.owl + + + + obo2:GO_0051354 + obo2:go#gosubset_prok + + + + obo2:GO_0051378 + obo2:go.owl + + + + obo2:GO_0051381 + obo2:go.owl + + + + obo2:GO_0051580 + obo2:go.owl + + + + obo2:GO_0051581 + obo2:go.owl + + + + obo2:GO_0051583 + obo2:go.owl + + + + obo2:GO_0051584 + obo2:go.owl + + + + obo2:GO_0051588 + obo2:go.owl + + + + obo2:GO_0051589 + obo2:go.owl + + + + obo2:GO_0051608 + obo2:go.owl + + + + obo2:GO_0051610 + obo2:go.owl + + + + obo2:GO_0051611 + obo2:go.owl + + + + obo2:GO_0051615 + obo2:go.owl + + + + obo2:GO_0051616 + obo2:go.owl + + + + obo2:GO_0051620 + obo2:go.owl + + + + obo2:GO_0051621 + obo2:go.owl + + + + obo2:GO_0051630 + obo2:go.owl + + + + obo2:GO_0051631 + obo2:go.owl + + + + obo2:GO_0051641 + obo2:go.owl + + + + obo2:GO_0051641 + obo2:go#goslim_pir + + + + obo2:GO_0051641 + obo2:go#gosubset_prok + + + + obo2:GO_0051649 + obo2:go.owl + + + + obo2:GO_0051649 + obo2:go#gosubset_prok + + + + obo2:GO_0051704 + obo2:go.owl + + + + obo2:GO_0051704 + obo2:go#goslim_pir + + + + obo2:GO_0051704 + obo2:go#gosubset_prok + + + + obo2:GO_0051707 + obo2:go.owl + + + + obo2:GO_0051707 + obo2:go#gosubset_prok + + + + obo2:GO_0051716 + obo2:go.owl + + + + obo2:GO_0051716 + obo2:go#gosubset_prok + + + + obo2:GO_0051716 + obo2:go#high_level_annotation_qc + + + + obo2:GO_0051726 + obo2:go.owl + + + + obo2:GO_0051726 + obo2:go#goslim_yeast + + + + obo2:GO_0051726 + obo2:go#gosubset_prok + + + + obo2:GO_0051783 + obo2:go.owl + + + + obo2:GO_0051784 + obo2:go.owl + + + + obo2:GO_0051899 + obo2:go.owl + + + + obo2:GO_0051924 + obo2:go.owl + + + + obo2:GO_0051934 + obo2:go.owl + + + + obo2:GO_0051937 + obo2:go.owl + + + + obo2:GO_0051937 + obo2:go#gosubset_prok + + + + obo2:GO_0051940 + obo2:go.owl + + + + obo2:GO_0051945 + obo2:go.owl + + + + obo2:GO_0051952 + obo2:go.owl + + + + obo2:GO_0051953 + obo2:go.owl + + + + obo2:GO_0051954 + obo2:go.owl + + + + obo2:GO_0051969 + obo2:go.owl + + + + obo2:GO_0055082 + obo2:go.owl + + + + obo2:GO_0055082 + obo2:go#gosubset_prok + + + + obo2:GO_0055085 + obo2:go.owl + + + + obo2:GO_0055085 + obo2:go#goslim_generic + + + + obo2:GO_0055085 + obo2:go#goslim_pombe + + + + obo2:GO_0055085 + obo2:go#goslim_yeast + + + + obo2:GO_0055086 + obo2:go.owl + + + + obo2:GO_0055086 + obo2:go#goslim_pombe + + + + obo2:GO_0055086 + obo2:go#goslim_yeast + + + + obo2:GO_0055086 + obo2:go#gosubset_prok + + + + obo2:GO_0055114 + obo2:go.owl + + + + obo2:GO_0055114 + obo2:go#goslim_metagenomics + + + + obo2:GO_0055114 + obo2:go#gosubset_prok + + + + obo2:GO_0060047 + obo2:go.owl + + + + obo2:GO_0060089 + obo2:go.owl + + + + obo2:GO_0060089 + obo2:go#goslim_pir + + + + obo2:GO_0060089 + obo2:go#gosubset_prok + + + + obo2:GO_0060123 + obo2:go.owl + + + + obo2:GO_0060255 + obo2:go.owl + + + + obo2:GO_0060255 + obo2:go#gosubset_prok + + + + obo2:GO_0060341 + obo2:go.owl + + + + obo2:GO_0060759 + obo2:go.owl + + + + obo2:GO_0060761 + obo2:go.owl + + + + obo2:GO_0060765 + obo2:go.owl + + + + obo2:GO_0060986 + obo2:go.owl + + + + obo2:GO_0061097 + obo2:go.owl + + + + obo2:GO_0061337 + obo2:go.owl + + + + obo2:GO_0065007 + obo2:go.owl + + + + obo2:GO_0065007 + obo2:go#goslim_pir + + + + obo2:GO_0065007 + obo2:go#gosubset_prok + + + + obo2:GO_0065008 + obo2:go.owl + + + + obo2:GO_0065008 + obo2:go#gosubset_prok + + + + obo2:GO_0065009 + obo2:go.owl + + + + obo2:GO_0065009 + obo2:go#gosubset_prok + + + + obo2:GO_0070011 + obo2:go.owl + + + + obo2:GO_0070011 + obo2:go#gosubset_prok + + + + obo2:GO_0070316 + obo2:go.owl + + + + obo2:GO_0070838 + obo2:go.owl + + + + obo2:GO_0070838 + obo2:go#gosubset_prok + + + + obo2:GO_0070887 + obo2:go.owl + + + + obo2:GO_0071310 + obo2:go.owl + + + + obo2:GO_0071310 + obo2:go#gosubset_prok + + + + obo2:GO_0071345 + obo2:go.owl + + + + obo2:GO_0071356 + obo2:go.owl + + + + obo2:GO_0071383 + obo2:go.owl + + + + obo2:GO_0071495 + obo2:go.owl + + + + obo2:GO_0071495 + obo2:go#gosubset_prok + + + + obo2:GO_0071702 + obo2:go.owl + + + + obo2:GO_0071705 + obo2:go.owl + + + + obo2:GO_0071840 + obo2:go.owl + + + + obo2:GO_0071841 + obo2:go.owl + + + + obo2:GO_0071842 + obo2:go.owl + + + + obo2:GO_0071844 + obo2:go.owl + + + + obo2:GO_0071855 + obo2:go.owl + + + + obo2:GO_0071875 + obo2:go.owl + + + + obo2:GO_0071897 + obo2:go.owl + + + + obo2:GO_0071897 + obo2:go#gosubset_prok + + + + obo2:GO_0071900 + obo2:go.owl + + + + obo2:GO_0072358 + obo2:go.owl + + + + obo2:GO_0072359 + obo2:go.owl + + + + obo2:GO_0072511 + obo2:go.owl + + + + obo2:GO_0072511 + obo2:go#gosubset_prok + + + + obo2:GO_0072521 + obo2:go.owl + + + + obo2:GO_0072527 + obo2:go.owl + + + + obo2:GO_0072528 + obo2:go.owl + + + + obo2:GO_0080090 + obo2:go.owl + + + + obo2:GO_0080134 + obo2:go.owl + + + + obo2:GO_0086006 + obo2:go.owl + + + + obo2:GO_0086010 + obo2:go.owl + + + + obo2:GO_0086012 + obo2:go.owl + + + + obo2:GO_0086017 + obo2:go.owl + + + + obo2:GO_0086019 + obo2:go.owl + + + + obo2:GO_0086029 + obo2:go.owl + + + + obo2:GO_0086036 + obo2:go.owl + + + + obo2:GO_0086047 + obo2:go.owl + + + + obo2:GO_0086065 + obo2:go.owl + + + + obo2:GO_0086068 + obo2:go.owl + + + + obo2:GO_0090087 + obo2:go.owl + + + + obo2:GO_0090153 + obo2:go.owl + + + + obo2:GO_0090155 + obo2:go.owl + + + + obo2:GO_0090257 + obo2:go.owl + + + + obo2:GO_0090276 + obo2:go.owl + + + + obo2:GO_0090277 + obo2:go.owl + + + + obo2:GO_0090304 + obo2:go.owl + + + + obo2:GO_1900060 + obo2:go.owl + + + + obo2:GO_1900084 + obo2:go.owl + + + + obo2:GO_2000112 + obo2:go.owl + + + + obo2:GO_2000113 + obo2:go.owl + + + + obo2:GO_2000272 + obo2:go.owl + + + + obo2:GO_2000278 + obo2:go.owl + + + + obo2:GO_2000303 + obo2:go.owl + + + + obo2:GO_2000602 + obo2:go.owl + + + + obo2:GO_2000609 + obo2:go.owl + + + + obo2:GO_2000823 + obo2:go.owl + + + + obo2:GO_2001141 + obo2:go.owl + + + + obo2:GO_2001215 + obo2:go.owl + + + + obo2:GO_2001257 + obo2:go.owl + + + + obo2:IAO_0000028 + obo2:iao.owl + + + + obo2:IAO_0000078 + obo2:iao.owl + + + + obo2:IAO_0000102 + obo2:iao.owl + + + + obo2:IAO_0000111 + obo2:IAO_0000122 + + + + obo2:IAO_0000111 + obo2:iao.owl + + + + obo2:IAO_0000111 + editor preferred term + + + + obo2:IAO_0000112 + obo2:iao.owl + + + + obo2:IAO_0000112 + example of usage + + + + obo2:IAO_0000114 + has curation status + + + + obo2:IAO_0000116 + obo2:IAO_0000122 + + + + obo2:IAO_0000116 + obo2:iao.owl + + + + obo2:IAO_0000116 + editor note + + + + obo2:IAO_0000117 + obo2:IAO_0000122 + + + + obo2:IAO_0000117 + obo2:iao.owl + + + + obo2:IAO_0000117 + definition editor + + + + obo2:IAO_0000117 + term editor + + + + obo2:IAO_0000118 + obo2:IAO_0000125 + + + + obo2:IAO_0000118 + obo2:iao.owl + + + + obo2:IAO_0000118 + alternative term + + + + obo2:IAO_0000119 + obo2:IAO_0000122 + + + + obo2:IAO_0000119 + obo2:iao.owl + + + + obo2:IAO_0000119 + definition source + + + + obo2:IAO_0000132 + obo2:iao.owl + + + + obo2:IAO_0000136 + obo2:iao.owl + + + + obo2:IAO_0000232 + obo2:IAO_0000122 + + + + obo2:IAO_0000232 + obo2:iao.owl + + + + obo2:IAO_0000232 + curator note + + + + obo2:IAO_0000300 + obo2:iao.owl + + + + obo2:IAO_0000412 + obo2:iao.owl + + + + obo2:IAO_0000412 + imported from + + + + obo2:IAO_0000600 + obo2:iao.owl + + + + obo2:IAO_0000600 + elucidation + + + + obo2:IAO_0000601 + obo2:iao.owl + + + + obo2:IAO_0000601 + has associated axiom(nl) + + + + obo2:IAO_0000602 + obo2:iao.owl + + + + obo2:IAO_0000602 + has associated axiom(fol) + + + + obo2:IAO_0010000 + obo2:iao.owl + + + + obo2:IAO_0010000 + has axiom label + + + + obo2:NCBITaxon_10114 + obo2:uberon.owl + + + + obo2:NCBITaxon_32443 + obo2:uberon.owl + + + + obo2:NCBITaxon_32523 + obo2:uberon.owl + + + + obo2:NCBITaxon_7776 + obo2:uberon.owl + + + + obo2:NCBITaxon_7955 + obo2:uberon.owl + + + + obo2:NCBITaxon_8782 + obo2:uberon.owl + + + + obo2:OAE_0000001 + A drug adverse effect is a response to a drug that is noxious and unintended and occurs at doses normally used in man for the prophylaxis, diagnosis or therapy of disease, or for modifi-cation of physiological function. + + + + obo2:OAE_0000001 + a pathological bodily process that occurs after a medical intervention. An adverse event is likely caused by the medical intervention; however, such a causal association is not required to be an adverse event. + + + + obo2:OAE_0000001 + http://purl.obofoundry.org/obo/DINTO_000038 + + + + obo2:OAE_0000001 + Melanie Courtot and YH: More work is needed on how to restrict the scope of a term to be an 'adverse event', notably regarding temporal association. When is an appropirate time interval between a medical intervention and an adverse event observed? One week, one month, one year, or a lifetime? For some well-studied medical interventions (e.g., administration of many vaccines or drugs), we probably have a general idea. For many new interventions, we don't know much. In OAE, this issue is associated with defining the 'adverse event incubation time'. + + + + obo2:OAE_0000001 + YH: An adverse event is a process that has specified output of some adverse medical outcome (e.g., symptom, sign or accident) after a medical intervention (or process) (e.g., administration of drug or vaccine). The medical intervention can be an administration of a drug, a vaccine (i.e., vaccination), or a special nutritional product (for example, dietary supplement, infant formula, medical food), surgery, or usage of a medical device. + + + + obo2:OAE_0000001 + YH: An adverse event is possibly induced by the medical intervention. It can be caused by the medical intervention, or may not be caused by the medical intervention. One ultimate goal (or the goal in clinics) of study adverse events is to assess if the adverse event outcome is due to the medical intervention. + + + + obo2:OAE_0000001 + YH: In development of OAE, we initially use vaccine adverse event as our use case. A vaccine adverse event is associated with a vaccination (i.e. a medical intervention), regardless of whether it is considered vaccine-related, and includes any side effect, injury, toxicity, or sensitivity reaction or significant failure of immunization (i.e., a pharmacologic action). +Ref: Baylor NW and Midthum K. Regulation and testing of vaccines. In: Vaccines (Editors: Plotkin S, Orenstein W, and Offit P). 2008. p1623. + + + + obo2:OAE_0000001 + YH: The current term 'adverse event' is different from the term definition shown in our paper: He Y, Xiang Z, Sarntivijai S, Toldo L, Ceusters W. OAE: a realism-based biomedical ontology for the representation of adverse events. Adverse Event Representation Workshop, International Conference on Biomedical Ontologies (ICBO), University at Buffalo, NY, July 26-30, 2011. Full lenghth conference proceeding paper. + +We made the name changing in order to make OAE cover the broader sense of the 'adverse event' which does not assume definite causal effect between an adverse event and a medical intervention. In current definition, the adverse event emphasizes the time association and assumes a likelihood of such a causal association. This term 'adverse event' is stil under the OGMS:pathological bodily process. + +The 'adverse event' defined in the above paper has now been changed to a new term: 'causal adverse event'. See more information in the new publication: Yongqun He Y, Sirarat Sarntivijai, Yu Lin, Zuoshuang Xiang, Abra Guo, Shelley Zhang, Desikan Jagannathan, Luca Toldo, Cui Tao and Barry Smith. OAE: The Ontology of Adverse Events. Journal of Biomedical Semantics. 2014, 5:29 doi:10.1186/2041-1480-5-29. PMID: 25093068.PMCID: PMC4120740. + + + + obo2:OAE_0000001 + YH: The main scope of OAE includes: (1) represent terms and relations in the area of adverse events, (2) assess possible associations between an adverse event and a medical intervention, particularly, identify any causal effect of a medical intervention to an adverse event; and (2) understand the mechanism (including molecular mechanisms) of causal adverse events. + + + + obo2:OAE_0000001 + YH: There has been discussion regarding whether the term 'side effect' is an alternative term for 'adverse event'. In AERO, the term 'AERO:adverse event' represents a subset of those adverse events for which causality has been established. In OAE, an adverse event for which causality has been established is called 'causal adverse event'. + + + + obo2:OAE_0000001 + Yongqun He + + + + obo2:OAE_0000001 + AE + + + + obo2:OAE_0000001 + adverse reaction + + + + obo2:OAE_0000001 + WEB: http://en.wikipedia.org/wiki/Adverse_event + + + + obo2:OAE_0000001 + WEB: http://www.fda.gov/Safety/MedWatch/HowToReport/ucm053087.htm + + + + obo2:OAE_0000001 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/25093068 + + + + obo2:OAE_0000001 + WHO. (1972). International drug monitoring: the role of national centres. Thechnical Report Services WHO, no 498 + + + + obo2:OAE_0000001 + The OAE official website is: http://www.oae-ontology.org/. + + + + obo2:OAE_0000001 + adverse effect + + + + obo2:OAE_0000001 + adverse event + + + + obo2:OAE_0000003 + an adverse event which is a causal adverse event, a pathological bodily process that is induced by a medical intervention. + + + + obo2:OAE_0000003 + YH: The term 'causal adverse event' has the same meaning as we previously defined as 'adverse event'. Reference: He Y, Xiang Z, Sarntivijai S, Toldo L, Ceusters W. OAE: a realism-based biomedical ontology for the representation of adverse events. Adverse Event Representation Workshop, International Conference on Biomedical Ontologies (ICBO), University at Buffalo, NY, July 26-30, 2011. Full lenghth conference proceeding paper. + +We made the name changing as a way to make OAE cover the broader sense of the 'adverse event' which does not assume definite causal effect between an adverse event and a medical intervention. + + + + obo2:OAE_0000003 + YH + + + + obo2:OAE_0000003 + adverse effect + + + + obo2:OAE_0000003 + He Y, Xiang Z, Sarntivijai S, Toldo L, Ceusters W. OAE: a realism-based biomedical ontology for the representation of adverse events. Adverse Event Representation Workshop, International Conference on Biomedical Ontologies (ICBO), University at Buffalo, NY, July 26-30, 2011. Full lenghth conference proceeding paper. + + + + obo2:OAE_0000003 + YH: the term "adverse effect" has the same meaning of "causal adverse event". + + + + obo2:OAE_0000003 + causal adverse event + + + + obo2:OAE_0000004 + an adverse event that occurs after a vaccination. + + + + obo2:OAE_0000004 + YH + + + + obo2:OAE_0000004 + vaccine adverse event + + + + obo2:OAE_0000005 + an adverse event that occurs after a drug administration + + + + obo2:OAE_0000005 + YH + + + + obo2:OAE_0000005 + ADE + + + + obo2:OAE_0000005 + drug adverse event + + + + obo2:OAE_0000005 + adverse drug event + + + + obo2:OAE_0000006 + an adverse event that is associated with the usage of a medical device. + + + + obo2:OAE_0000006 + YH + + + + obo2:OAE_0000006 + medical device adverse event + + + + obo2:OAE_0000007 + an adverse event that is associated with eating a medical food. + + + + obo2:OAE_0000007 + YH + + + + obo2:OAE_0000007 + medical food adverse event + + + + obo2:OAE_0000008 + an adverse event that is induced by consuming a nutritional product. + + + + obo2:OAE_0000008 + YH + + + + obo2:OAE_0000008 + nutritional product adverse event + + + + obo2:OAE_0000009 + an adverse event that is associated with consuming a dietary supplement. + + + + obo2:OAE_0000009 + YH + + + + obo2:OAE_0000009 + dietary supplement adverse event + + + + obo2:OAE_0000010 + an adverse event that is associated with consuming an infant formula. + + + + obo2:OAE_0000010 + YH + + + + obo2:OAE_0000010 + infant formula adverse event + + + + obo2:OAE_0000017 + an imaging investigation result abnormal AE that is characterized by an abnormal X-ray + + + + obo2:OAE_0000017 + SS, YH, EB + + + + obo2:OAE_0000017 + X-ray result abnormal AE + + + + obo2:OAE_0000017 + MedDRA: 10048065 + + + + obo2:OAE_0000018 + an X-ray result abnormal AE that has an outcome of an abnormality in chest X-ray test + + + + obo2:OAE_0000018 + SS, YH + + + + obo2:OAE_0000018 + chest X-ray abnormal AE + + + + obo2:OAE_0000018 + MedDRA ID: 10008499 + + + + obo2:OAE_0000019 + a haematoma AE that has an outcome of contusion. + + + + obo2:OAE_0000019 + SS, YH + + + + obo2:OAE_0000019 + WEB: http://en.wikipedia.org/wiki/Bruise + + + + obo2:OAE_0000019 + Contusion is a type of relatively minor hematoma of tissue in which capillaries and sometimes venules are damaged by trauma, allowing blood to seep into the surrounding interstitial tissues. + + + + obo2:OAE_0000019 + contusion AE + + + + obo2:OAE_0000019 + MedDRA ID: 10050584 + + + + obo2:OAE_0000020 + a digestive system AE which has an outcome of dry throat, which is a sensation of dryness in the throat. + + + + obo2:OAE_0000020 + SS, YH + + + + obo2:OAE_0000020 + dry throat AE + + + + obo2:OAE_0000020 + MedDRA ID: 10013789 + + + + obo2:OAE_0000021 + a skin discoloration AE which has an outcome of flushing, a sudden reddening of the face, neck, or upper chest + + + + obo2:OAE_0000021 + SS, YH + + + + obo2:OAE_0000021 + WEB: http://www.nlm.nih.gov/medlineplus/ency/article/003241.htm + + + + obo2:OAE_0000021 + flushing AE + + + + obo2:OAE_0000021 + HPO: HP_0001033 + + + + obo2:OAE_0000021 + MedDRA ID: 10016825 + + + + obo2:OAE_0000021 + SIDER: C0016382 + + + + obo2:OAE_0000022 + a pain AE that has an outcome of extreme pain + + + + obo2:OAE_0000022 + SS, YH + + + + obo2:OAE_0000022 + pain in extremity AE + + + + obo2:OAE_0000022 + HPO: HP_0009763 + + + + obo2:OAE_0000022 + SIDER: C0030196 + + + + obo2:OAE_0000023 + a respiratory system AE which has an outcome of postnasal drip, which occurs when excessive mucus is produced by the nasal Mucosa. The excess mucus accumulates in the throat or back of the nose. + + + + obo2:OAE_0000023 + SS, YH + + + + obo2:OAE_0000023 + PDN + + + + obo2:OAE_0000023 + UACS + + + + obo2:OAE_0000023 + Upper Airway Cough Syndrome + + + + obo2:OAE_0000023 + WEB: http://en.wikipedia.org/wiki/Post-nasal_drip + + + + obo2:OAE_0000023 + postnasal drip AE + + + + obo2:OAE_0000024 + a syndrome AE that is subclassified as five defined entities which represent clinical circumstances in which both the heart and the kidney are involved in a bidirectional injury and dysfunction via a final common pathway of cell-to-cell death and accelerated apoptosis mediated by oxidative stress. Types 1 and 2 involve acute and chronic cardiovascular disease (CVD) scenarios leading to acute kidney injury or accelerated chronic kidney disease. Types 2 and 3 describe acute and chronic kidney disease leading primarily to heart failure, although it is possible that acute coronary syndromes, stroke, and arrhythmias could be CVD outcomes in these forms of CRS. Finally, CRS type 5 describes a simultaneous insult to both heart and kidneys, such as sepsis, where both organs are injured simultaneously. + + + + obo2:OAE_0000024 + SS, YH + + + + obo2:OAE_0000024 + CRS + + + + obo2:OAE_0000024 + WEB: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3030731/ + + + + obo2:OAE_0000024 + cardiorenal syndrome AE + + + + obo2:OAE_0000024 + MedDRA: 10068230 + + + + obo2:OAE_0000026 + A bursal disorder AE that has an outcome of the symptom of bursitis. + + + + obo2:OAE_0000026 + SS, YH + + + + obo2:OAE_0000026 + bursa inflammation + + + + obo2:OAE_0000026 + WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001456/ + + + + obo2:OAE_0000026 + bursitis AE + + + + obo2:OAE_0000027 + an adverse event that has an outcome of abnormal sign in musculoskeletal and connective tissue. + + + + obo2:OAE_0000027 + YH, RR + + + + obo2:OAE_0000027 + WEB: http://www.cdc.gov/niosh/programs/msd/ + + + + obo2:OAE_0000027 + A musculoskeletal disorder is an injury or disorder of the muscles, nerves, tendons, joints, cartilage, or supporting structures of the upper or lower limbs, neck, or lower back that are caused, precipitated, or exacerbated by sudden exertion or prolonged exposure to physical factors such as repetition, force, vibration, or awkward posture + + + + obo2:OAE_0000027 + musculoskeletal and connective tissue AE + + + + obo2:OAE_0000027 + MedDRA: 10028395 + + + + obo2:OAE_0000029 + a musculoskeletal system AE which has an outcome of bursal disorder + + + + obo2:OAE_0000029 + YH + + + + obo2:OAE_0000029 + bursal disorder AE + + + + obo2:OAE_0000030 + a vaccine adverse event that is induced by an influenza vaccine. + + + + obo2:OAE_0000030 + YH: This term is just used as an example of vaccine induced adverse events. Specific vaccine-associated and vaccine-induced adverse events are now represented with the Ontology of Vaccine Adverse Events (OVAE).: http://www.violinet.org/ovae/. + + + + obo2:OAE_0000030 + YH + + + + obo2:OAE_0000030 + influenza vaccine-induced adverse event + + + + obo2:OAE_0000031 + an influenza vaccine adverse event that is induced by a killed influenza vaccine (KIV). + + + + obo2:OAE_0000031 + YH + + + + obo2:OAE_0000031 + KIV-induced adverse event + + + + obo2:OAE_0000032 + A KIV-induced AE that results in a GBS. + + + + obo2:OAE_0000032 + YH + + + + obo2:OAE_0000032 + VAERS statistical data analysis + + + + obo2:OAE_0000032 + There is little evidence to support a causal association between GBS and most vaccines. The evidence for a causal association is strongest for the swine influenza vaccine that was used in 1976-77. Studies of influenza vaccines used in subsequent years, however, have found small or no increased risk of GBS. +Reference: http://www.ncbi.nlm.nih.gov/pubmed?term=19388722. + + + + obo2:OAE_0000032 + KIV-induced GBS averse event in 1976-1977 + + + + obo2:OAE_0000033 + a muscle pain AE that is induced by Afluria influenza vaccine administration + + + + obo2:OAE_0000033 + YH + + + + obo2:OAE_0000033 + WEB: http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM220730.pdf + + + + obo2:OAE_0000033 + Afluria-induced muscle ache AE + + + + obo2:OAE_0000034 + a behavior and neurological AE that has an outcome of fatigue, which is a state of awareness describing a range of afflictions, usually associated with physical and/or mental weakness, though varying from a general state of lethargy to a specific work-induced burning sensation within one's muscles. Physical fatigue is the inability to continue functioning at the level of one's normal abilities. + + + + obo2:OAE_0000034 + SS, YH + + + + obo2:OAE_0000034 + lethargy AE + + + + obo2:OAE_0000034 + WEB: http://en.wikipedia.org/wiki/Fatigue_%28medical%29 + + + + obo2:OAE_0000034 + fatigue AE + + + + obo2:OAE_0000034 + HPO: HP_0003388 + + + + obo2:OAE_0000034 + MedDRA: 10016256 + + + + obo2:OAE_0000034 + MedDRA: 10024264 + + + + obo2:OAE_0000034 + SIDER: C0015672 + + + + obo2:OAE_0000035 + a microbiology and serology investigation result abnormal AE that has an outcome of CSF culture negative + + + + obo2:OAE_0000035 + SS, YH, EB + + + + obo2:OAE_0000035 + CSF culture negative AE + + + + obo2:OAE_0000036 + a lab test abnormal AE that has an outcome of an abnormal result in a blood cell lab test + + + + obo2:OAE_0000036 + SS, YH + + + + obo2:OAE_0000036 + blood cell lab test abnormal AE + + + + obo2:OAE_0000037 + an eosinophil percentage abnormal AE that has an outcome of increased eosinophil percentage + + + + obo2:OAE_0000037 + YH, EB + + + + obo2:OAE_0000037 + eosinophil percentage increased AE + + + + obo2:OAE_0000037 + MedDRA ID: 10052222 + + + + obo2:OAE_0000038 + a cardiac disorder AE that is characterized by a necrosis of the myocardium caused by an obstruction of the blood supply to the heart + + + + obo2:OAE_0000038 + SS + + + + obo2:OAE_0000038 + WEB: http://www.ncbi.nlm.nih.gov/mesh/68009203 + + + + obo2:OAE_0000038 + 心肌梗塞 + + + + obo2:OAE_0000038 + myocardial infarction AE + + + + obo2:OAE_0000038 + HPO: HP_0001658 + + + + obo2:OAE_0000038 + MedDRA: 10028596 + + + + obo2:OAE_0000038 + SIDER: C0027051 + + + + obo2:OAE_0000039 + a neutrophil count abnormal AE that has an outcome of increased neutrophil count + + + + obo2:OAE_0000039 + YH + + + + obo2:OAE_0000039 + neutrophil count increased AE + + + + obo2:OAE_0000039 + HPO: HP_0011991 + + + + obo2:OAE_0000039 + MedDRA: 10029368 + + + + obo2:OAE_0000039 + SIDER: NA + + + + obo2:OAE_0000040 + an adverse event that has an outcome of injury and procedural complication + + + + obo2:OAE_0000040 + SS, YH + + + + obo2:OAE_0000040 + injury and procedural complication AE + + + + obo2:OAE_0000041 + an injury and procedural complication AE which has an outcome of injury + + + + obo2:OAE_0000041 + SS, YH + + + + obo2:OAE_0000041 + injury AE + + + + obo2:OAE_0000041 + MedDRA ID: 10022116 + + + + obo2:OAE_0000042 + an injury AE which has an outcome of head injury + + + + obo2:OAE_0000042 + SS, YH + + + + obo2:OAE_0000042 + head injury AE + + + + obo2:OAE_0000042 + MedDRA ID: 10019196 + + + + obo2:OAE_0000043 + a behavior and neurological AE that has an abnormal outcome in social behavior + + + + obo2:OAE_0000043 + SS, YH + + + + obo2:OAE_0000043 + social behavior AE + + + + obo2:OAE_0000044 + a social behavior AE that has an outcome of impaired work ability + + + + obo2:OAE_0000044 + SS, YH + + + + obo2:OAE_0000044 + impaired work ability AE + + + + obo2:OAE_0000045 + an allergy AE which has an outcome of injection-site allergic reaction + + + + obo2:OAE_0000045 + injection-site allergic reaction AE + + + + obo2:OAE_0000045 + MedDRA: 10022095 + + + + obo2:OAE_0000046 + a myelitis AE which has an outcome of myelitis transverse. Transverse myelitis (in Latin nomenclature: myelitis transversa) is a neurological disorder caused by an inflammatory process of the spinal cord, and can cause axonal demyelination. + + + + obo2:OAE_0000046 + SS, YH + + + + obo2:OAE_0000046 + WEB: http://en.wikipedia.org/wiki/Transverse_myelitis + + + + obo2:OAE_0000046 + myelitis transverse AE + + + + obo2:OAE_0000046 + MedDRA ID: 10028527 + + + + obo2:OAE_0000047 + a skin adverse even that has an outcome of warm skin + + + + obo2:OAE_0000047 + SS, YH + + + + obo2:OAE_0000047 + skin warm AE + + + + obo2:OAE_0000048 + Nystagmus AE is an eye AE that is a condition of involuntary eye movement, acquired in infancy or later in life, that may result in reduced or limited vision. Due to the involuntary movement of the eye, it is often called "dancing eyes". + + + + obo2:OAE_0000048 + JX, LW, YH + + + + obo2:OAE_0000048 + WEB: http://en.wikipedia.org/wiki/Nystagmus + + + + obo2:OAE_0000048 + nystagmus AE + + + + obo2:OAE_0000048 + MedDRA: 10029864 + + + + obo2:OAE_0000048 + 眼球震颤 + + + + obo2:OAE_0000049 + a dermatitis AE that has an outcome of dermatitis bullous + + + + obo2:OAE_0000049 + SS, YH + + + + obo2:OAE_0000049 + bullous pemphigoid AE + + + + obo2:OAE_0000049 + Bullous pemphigoid is a skin disorder characterized by large blisters. + + + + obo2:OAE_0000049 + dermatitis bullous AE + + + + obo2:OAE_0000049 + HPO: HP_0011123 + + + + obo2:OAE_0000049 + MedDRA ID: 10012441 + + + + obo2:OAE_0000049 + SIDER: C0085932 + + + + obo2:OAE_0000050 + a skin adverse event that has an outcome of hot flush + + + + obo2:OAE_0000050 + SS, YH + + + + obo2:OAE_0000050 + hot flush + + + + obo2:OAE_0000050 + HPO: HP_0008209 + + + + obo2:OAE_0000050 + SIDER: C0600142 + + + + obo2:OAE_0000051 + a KIV-induced adverse event that has an outcome of Afluria-induced adverse event + + + + obo2:OAE_0000051 + YH + + + + obo2:OAE_0000051 + Afluria-induced adverse event + + + + obo2:OAE_0000052 + an adverse event that results in the outcome of a tumor. + + + + obo2:OAE_0000052 + mass AE + + + + obo2:OAE_0000052 + nodule AE + + + + obo2:OAE_0000052 + YH, RR + + + + obo2:OAE_0000052 + tumor AE + + + + obo2:OAE_0000052 + MedDRA: 10026865 + + + + obo2:OAE_0000053 + a respiratory system AE which has an outcome of wheezing, a high-pitched whistling sound made while breathing. + + + + obo2:OAE_0000053 + SS, YH + + + + obo2:OAE_0000053 + WEB: http://www.mayoclinic.org/symptoms/wheezing/basics/definition/sym-20050764 + + + + obo2:OAE_0000053 + wheezing AE + + + + obo2:OAE_0000053 + MedDRA ID: 10047924 + + + + obo2:OAE_0000054 + a behavior and neurological AE that has an outcome of weight bearing difficulty + + + + obo2:OAE_0000054 + weight bearing difficulty is a behavior AE that results in difficulty in managing the amount of weight a patient puts on the leg on which surgery has been performed. In general, it is described as a percentage of the body weight, because each leg of a healthy person carries the full body weight when walking, in an alternating fashion. + + + + obo2:OAE_0000054 + SS, YH + + + + obo2:OAE_0000054 + WEB: http://en.wikipedia.org/wiki/Weight-bearing + + + + obo2:OAE_0000054 + weight bearing difficulty AE + + + + obo2:OAE_0000057 + an Afluria-induced adverse event that has an outcome of Afluria-induced fever in child + + + + obo2:OAE_0000057 + YH + + + + obo2:OAE_0000057 + WEB: http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM220730.pdf + + + + obo2:OAE_0000057 + Afluria-induced fever AE in child + + + + obo2:OAE_0000058 + an Afluria-induced adverse event that has an outcome of Afluria-induced cough in child + + + + obo2:OAE_0000058 + YH + + + + obo2:OAE_0000058 + WEB: http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM220730.pdf + + + + obo2:OAE_0000058 + Afluria-induced cough AE in child + + + + obo2:OAE_0000059 + an Afluria-induced adverse event which has an outcome of Afluria-induced injection site pain + + + + obo2:OAE_0000059 + YH + + + + obo2:OAE_0000059 + WEB: http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM220730.pdf + + + + obo2:OAE_0000059 + Afluria-induced injection site pain AE + + + + obo2:OAE_0000060 + an Afluria-induced adverse event that has an outcome of Afluria-induced injection site redness + + + + obo2:OAE_0000060 + YH + + + + obo2:OAE_0000060 + WEB: http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM220730.pdf + + + + obo2:OAE_0000060 + Afluria-induced injection site redness AE + + + + obo2:OAE_0000061 + an Afluria-induced AE that has an outcome of Afluria-induced inject site swelling + + + + obo2:OAE_0000061 + YH + + + + obo2:OAE_0000061 + WEB: http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM220730.pdf + + + + obo2:OAE_0000061 + Afluria-induced inject site swelling AE + + + + obo2:OAE_0000062 + an Afluria-induced adverse event that has an outcome of Afluria-induced headache + + + + obo2:OAE_0000062 + YH + + + + obo2:OAE_0000062 + WEB: http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM220730.pdf + + + + obo2:OAE_0000062 + Afluria-induced headache AE + + + + obo2:OAE_0000063 + an adverse event that occurs systematically in a patient's body. + + + + obo2:OAE_0000063 + YH + + + + obo2:OAE_0000063 + systematic adverse event + + + + obo2:OAE_0000064 + A pregnancy, neonatal and perinatal AE that displays a disorder associated with pregnancy. + + + + obo2:OAE_0000064 + YH + + + + obo2:OAE_0000064 + pregnancy AE + + + + obo2:OAE_0000066 + an adverse event that is induced by surgery. + + + + obo2:OAE_0000066 + YH + + + + obo2:OAE_0000066 + surgery adverse event + + + + obo2:OAE_0000068 + a sugery adverse event that has an outcome of pressure ulcer. + + + + obo2:OAE_0000068 + YH + + + + obo2:OAE_0000068 + surgery-induced bedsore AE + + + + obo2:OAE_0000068 + surgery-induced decubitus ulcer AE + + + + obo2:OAE_0000068 + surgery-induced pressure ulcer AE + + + + obo2:OAE_0000069 + an adverse event which occurs in a metabolism process (including anabolism and catabolism), endocrine system, or exocrine system. + + + + obo2:OAE_0000069 + SS, YH + + + + obo2:OAE_0000069 + metabolism, endocrine, and exocrine system AE + + + + obo2:OAE_0000069 + MP: 0005266; MedDRA: 10027433 + + + + obo2:OAE_0000070 + an adverse event that occurs in clinical trial. + + + + obo2:OAE_0000070 + YH + + + + obo2:OAE_0000070 + clinical trial adverse event + + + + obo2:OAE_0000073 + an influenza vaccine adverse event that is induced by a live attenuated influenza vaccine (LAIV). + + + + obo2:OAE_0000073 + YH + + + + obo2:OAE_0000073 + LAIV-induced adverse event + + + + obo2:OAE_0000074 + an LAIV-induced adverse event that is caused by the FluMist LAIV. + + + + obo2:OAE_0000074 + YH + + + + obo2:OAE_0000074 + WEB: http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM123743.pdf + + + + obo2:OAE_0000074 + FluMist-induced adverse event + + + + obo2:OAE_0000075 + a FluMist-induced adverse event that has an outcome of FluMist-induced runny nose + + + + obo2:OAE_0000075 + YH + + + + obo2:OAE_0000075 + FluMist-induced runny nose AE + + + + obo2:OAE_0000076 + a FluMist-induced AE that has an outcome of FluMist-induced nasal congestion + + + + obo2:OAE_0000076 + YH + + + + obo2:OAE_0000076 + FluMist-induced nasal congestion AE + + + + obo2:OAE_0000078 + A FluMist-induced AE that has an outcome of sore throat + + + + obo2:OAE_0000078 + YH + + + + obo2:OAE_0000078 + WEB: http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM123743.pdf + + + + obo2:OAE_0000078 + FluMist-induced sore throat AE in adult + + + + obo2:OAE_0000079 + a tumore AE that results in the outcome of a benign tumor. + + + + obo2:OAE_0000079 + YH + + + + obo2:OAE_0000079 + benign tumor AE + + + + obo2:OAE_0000080 + a tumore AE that results in the outcome of a malignant tumor. + + + + obo2:OAE_0000080 + YH + + + + obo2:OAE_0000080 + malignant tumor AE + + + + obo2:OAE_0000081 + a sensory capability AE that resuls in an uncomfortable feeling. + + + + obo2:OAE_0000081 + YH + + + + obo2:OAE_0000081 + discomfort AE + + + + obo2:OAE_0000081 + HPO: HP_0010832 + + + + obo2:OAE_0000081 + SIDER: C0234215 + + + + obo2:OAE_0000082 + a reproductive system AE that occurs on the female side. + + + + obo2:OAE_0000082 + YH + + + + obo2:OAE_0000082 + female reproductive system AE + + + + obo2:OAE_0000082 + MedDRA ID: 10038604 + + + + obo2:OAE_0000083 + a reproductive system AE that occurs on the male side. + + + + obo2:OAE_0000083 + YH + + + + obo2:OAE_0000083 + male reproductive system AE + + + + obo2:OAE_0000084 + a cardiovascular disorder AE that has a cardiac disorder outcome. + + + + obo2:OAE_0000084 + SS, YH + + + + obo2:OAE_0000084 + WEB: Primary Source: http://medical-dictionary.thefreedictionary.com/heart+disease Secondary Source: http://www.ncbi.nlm.nih.gov/pubmed/23091623 + + + + obo2:OAE_0000084 + cardiac disorder AE + + + + obo2:OAE_0000084 + HPO: HP_0001627 + + + + obo2:OAE_0000084 + MedDRA (PT): 10061024 + + + + obo2:OAE_0000084 + MedDRA (SOC) : 10007541 + + + + obo2:OAE_0000084 + SIDER: C0018799 + + + + obo2:OAE_0000085 + a cardiovascular disorder AE that has a vascular disorder outcome + + + + obo2:OAE_0000085 + vascular disorder AE + + + + obo2:OAE_0000085 + MedDRA: 10047065 + + + + obo2:OAE_0000086 + a skin adverse event that results in an inflammation of skin + + + + + obo2:OAE_0000086 + SS, YH + + + + obo2:OAE_0000086 + dermatitis AE + + + + obo2:OAE_0000086 + HPO: HP_0011123 + + + + obo2:OAE_0000086 + MedDRA: 10012431 + + + + obo2:OAE_0000086 + SIDER: C0011603 + + + + obo2:OAE_0000087 + a drug adverse event that is induced by aspirin. + + + + obo2:OAE_0000087 + YH + + + + obo2:OAE_0000087 + WEB: http://www.consumerreports.org/health/prescription-drugs/aspirin/while-taking.htm + + + + obo2:OAE_0000087 + aspirin-induced adverse event + + + + obo2:OAE_0000088 + an aspirin-induced adverse event that is induced by the aspirin drug Aspidrox. + + + + obo2:OAE_0000088 + Aspidrox-induced adverse event + + + + obo2:OAE_0000089 + an aspirin-induced adverse event that has an outcome of nausea + + + + obo2:OAE_0000089 + YH + + + + obo2:OAE_0000089 + WEB: http://www.consumerreports.org/health/prescription-drugs/aspirin/while-taking.htm + + + + obo2:OAE_0000089 + aspirin-induced nausea AE + + + + obo2:OAE_0000090 + an aspirin-induced adverse event that has an outcome of vomiting + + + + obo2:OAE_0000090 + YH + + + + obo2:OAE_0000090 + WEB: http://www.consumerreports.org/health/prescription-drugs/aspirin/while-taking.htm + + + + obo2:OAE_0000090 + aspirin-induced vomiting AE + + + + obo2:OAE_0000091 + an aspirin-induced adverse event that has an outcome of stomach pain + + + + obo2:OAE_0000091 + YH + + + + obo2:OAE_0000091 + WEB: http://www.consumerreports.org/health/prescription-drugs/aspirin/while-taking.htm + + + + obo2:OAE_0000091 + aspirin-induced stomach pain AE + + + + obo2:OAE_0000092 + an aspirin-induced adverse event that has an outcome of heartburn + + + + obo2:OAE_0000092 + YH + + + + obo2:OAE_0000092 + WEB: http://www.consumerreports.org/health/prescription-drugs/aspirin/while-taking.htm + + + + obo2:OAE_0000092 + aspirin-induced heartburn AE + + + + obo2:OAE_0000093 + an aspirin-induced adverse event that has an outcome of rash symptom. + + + + obo2:OAE_0000093 + YH + + + + obo2:OAE_0000093 + WEB: http://www.consumerreports.org/health/prescription-drugs/aspirin/while-taking.htm + + + + obo2:OAE_0000093 + aspirin-induced rash AE + + + + obo2:OAE_0000095 + YH + + + + obo2:OAE_0000095 + a drug adverse event that is caused by a drug adiministration. Here a causal effect is established between the drug administration and the adverse event. + + + + obo2:OAE_0000095 + causal adverse drug event + + + + obo2:OAE_0000096 + a medical device adverse event that is induced by a medical device. There is a causal relation between the adverse event and the usage of a medical device. + + + + obo2:OAE_0000096 + YH + + + + obo2:OAE_0000096 + adverse event induced by medical device + + + + obo2:OAE_0000097 + an adverse event that is induced by a vaccination. + + + + obo2:OAE_0000097 + YH + + + + obo2:OAE_0000097 + vaccine-induced adverse event + + + + obo2:OAE_0000098 + a surgery adverse event that is caused by a surgery. + + + + obo2:OAE_0000098 + YH + + + + obo2:OAE_0000098 + surgery-induced adverse event + + + + obo2:OAE_0000099 + YH + + + + obo2:OAE_0000099 + a nutritional product adverse event that has a causal assocition with the usage of the nutritional product. + + + + obo2:OAE_0000099 + nutritional product-induced adverse event + + + + obo2:OAE_0000100 + influenza like illness AE is an adverse event that has an outcome of a medical diagnosis of possible influenza or other illness causing a set of common symptoms + + + + obo2:OAE_0000100 + SS, YH + + + + obo2:OAE_0000100 + acute respiratory infection, ARI, flu-like syndrome + + + + obo2:OAE_0000100 + WEB: http://en.wikipedia.org/wiki/Influenza-like_illness + + + + obo2:OAE_0000100 + influenza like illness AE + + + + obo2:OAE_0000100 + HPO: HP_0005376 + + + + obo2:OAE_0000100 + MDR: 10022004 + + + + obo2:OAE_0000100 + SIDER: C0521839 + + + + obo2:OAE_0000103 + YH + + + + obo2:OAE_0000103 + a pathogen infection adverse event that has an outcome of a fungal infection. + + + + obo2:OAE_0000103 + fungal infection AE + + + + obo2:OAE_0000103 + HPO: HP_0002841 + + + + obo2:OAE_0000103 + MedDRA: 10017533 + + + + obo2:OAE_0000103 + SIDER: C0026946 + + + + obo2:OAE_0000162 + a peripheral neuropathy AE which has an outcome of sensory neuropathy that involves damage to nerves of the peripheral nervous system. + + + + obo2:OAE_0000162 + YH, AG + + + + obo2:OAE_0000162 + sensory neuropathy AE + + + + obo2:OAE_0000162 + sensory neuropathy AE + + + + obo2:OAE_0000163 + a sensory neuropathy AE which has an outcome of distal sensory neuropathy that involves damage to distal sensory nerves of the peripheral nervous system. + + + + obo2:OAE_0000163 + YH, AG + + + + obo2:OAE_0000163 + distal sensory neuropathy AE + + + + obo2:OAE_0000164 + a distal sensory neuropathy AE that is chronic. + + + + obo2:OAE_0000164 + YH, AG + + + + obo2:OAE_0000164 + chronic distal sensory neuropathy AE + + + + obo2:OAE_0000165 + a neuropathy AE that is induced by a drug administration + + + + obo2:OAE_0000165 + AG, YH + + + + obo2:OAE_0000165 + neurotoxicity + + + + obo2:OAE_0000165 + drug-induced neuropathy AE + + + + obo2:OAE_0000166 + Tremor AE is a behavior and neurological AE that has an outcome of an involuntary trembling or quivering, and muscle contraction and relaxation. + + + + obo2:OAE_0000166 + SS, YH + + + + obo2:OAE_0000166 + WEB: http://www.nlm.nih.gov/medlineplus/tremor.html + + + + obo2:OAE_0000166 + tremor AE + + + + obo2:OAE_0000166 + HPO: HP_0001337 + + + + obo2:OAE_0000166 + MedDRA: 10044565 + + + + obo2:OAE_0000166 + SIDER: C0040822 + + + + obo2:OAE_0000167 + a neuropathy AE which shows symptoms due to the damage to the autonomic nerves. This damage disrupts signals between the brain and portions of the autonomic nervous system, such as the heart, blood vessels and sweat glands. This can cause decreased or abnormal performance of one or more involuntary body functions. + + + + obo2:OAE_0000167 + AG, YH + + + + obo2:OAE_0000167 + WEB: http://www.mayoclinic.org/diseases-conditions/autonomic-neuropathy/basics/definition/con-20029053 + + + + obo2:OAE_0000167 + autonomic neuropathy AE + + + + obo2:OAE_0000167 + HPO: HP_0002270 + + + + obo2:OAE_0000167 + MedDRA ID: 10061666 + + + + obo2:OAE_0000167 + SIDER: C0259749 + + + + obo2:OAE_0000168 + a peripheral neuropathy AE which is caused by a damage to motor neurons + + + + obo2:OAE_0000168 + AG, YH + + + + obo2:OAE_0000168 + motor neuropathy AE + + + + obo2:OAE_0000169 + A peripheral neuropathy AE which is characterized by damage to more than one nerve + + + + obo2:OAE_0000169 + AG, YH, RR + + + + obo2:OAE_0000169 + WEB: http://www.merckmanuals.com/home/brain_spinal_cord_and_nerve_disorders/peripheral_nerve_disorders/polyneuropathy.html + + + + obo2:OAE_0000169 + polyneuropathy AE + + + + obo2:OAE_0000169 + HPO: HP_0001271 + + + + obo2:OAE_0000169 + MedDRA ID: 10036105 + + + + obo2:OAE_0000169 + SIDER: C0152025 + + + + obo2:OAE_0000170 + a neuropathy AE which is characterized by isolated damage of a single nerve + + + + obo2:OAE_0000170 + AG, YH + + + + obo2:OAE_0000170 + mononeuropathy AE + + + + obo2:OAE_0000170 + MedDRA ID: 10062203 + + + + obo2:OAE_0000171 + a peripheral neuropathy AE which affects extremities, such as, toes, fingers, hand and feet. + + + + obo2:OAE_0000171 + AG, YH + + + + obo2:OAE_0000171 + axonal neuropathy AE + + + + obo2:OAE_0000171 + WEB: http://www.livestrong.com/article/184686-distal-neuropathy-symptoms/ + + + + obo2:OAE_0000171 + distal neuropathy AE + + + + obo2:OAE_0000172 + a nervous system AE that affects the neuronal cell body + + + + obo2:OAE_0000172 + AG, YH + + + + obo2:OAE_0000172 + WEB: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922643/ + + + + obo2:OAE_0000172 + neuronopathy AE + + + + obo2:OAE_0000173 + A neuritis AE which has an outcome of mononeuritis characterized by isolated inflammation of one nerve. + + + + obo2:OAE_0000173 + AG, YH + + + + obo2:OAE_0000173 + mononeuritis AE + + + + obo2:OAE_0000173 + MedDRA ID: 10027910 + + + + obo2:OAE_0000174 + A neuritis AE which has an outcome of polyneuritis characterized by isolated inflammation of many nerves. + + + + obo2:OAE_0000174 + AG, YH + + + + obo2:OAE_0000174 + polyneuritis AE + + + + obo2:OAE_0000175 + a mononeuritis AE which has an outcome of mononeuritis multiplex which involves damage to at least two seperate unrelated nerve area. + + + + obo2:OAE_0000175 + AG, YH + + + + obo2:OAE_0000175 + mononeuritis multiplex AE + + + + obo2:OAE_0000176 + a sensory neuropathy AE which has an outcome of acute sensory neuropathy that is characterized by rapid onset + + + + obo2:OAE_0000176 + AG, YH + + + + obo2:OAE_0000176 + acute sensory neuropathy AE + + + + obo2:OAE_0000179 + a causal adverse drug event that is induced by a drug-drug interaction. + + + + obo2:OAE_0000179 + YH, LT + + + + obo2:OAE_0000179 + WEB: http://medical-dictionary.thefreedictionary.com/drug+interaction + + + + obo2:OAE_0000179 + causal adverse drug event due to drug-drug interaction + + + + obo2:OAE_0000179 + MedDRA: 10013710 + + + + obo2:OAE_0000180 + a causal adverse drug event that is induced by a food-drug interaction. + + + + obo2:OAE_0000180 + YH, LT + + + + obo2:OAE_0000180 + causal adverse drug event due to food-drug interaction + + + + obo2:OAE_0000181 + a causal adverse drug event that is induced bygenetic predisposition. + + + + obo2:OAE_0000181 + YH, LT + + + + obo2:OAE_0000181 + causal adverse drug event due to genetic predisposition + + + + obo2:OAE_0000182 + a causal adverse drug event due to genetic predisposition that is specifically induced by SNP. + + + + obo2:OAE_0000182 + YH, LT + + + + obo2:OAE_0000182 + causal adverse drug event due to SNP + + + + obo2:OAE_0000183 + a cardiovascular disorder AE that is a result of insufficient blood flow throughout the body. Shock often accompanies severe injury or illness. + + + + obo2:OAE_0000183 + physiological shock AE + + + + obo2:OAE_0000183 + shock + + + + obo2:OAE_0000183 + WEB: http://en.wikipedia.org/wiki/Shock_%28circulatory%29 + + + + obo2:OAE_0000183 + 休克 + + + + obo2:OAE_0000183 + Circulatory shock is not related to the emotional state of shock. + + + + obo2:OAE_0000183 + circulatory shock AE + + + + obo2:OAE_0000183 + MedDRA: 10040560 + + + + obo2:OAE_0000184 + a behavior and neurological AE that has an outcome of a loss of brain function. + + + + obo2:OAE_0000184 + YH + + + + obo2:OAE_0000184 + Dementia is a loss of brain function that occurs with certain diseases or pathological processes. Reference: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001748/ + + + + obo2:OAE_0000184 + dementia AE + + + + obo2:OAE_0000184 + HPO: HP_0000726 + + + + obo2:OAE_0000184 + MedDRA ID: 10012272 + + + + obo2:OAE_0000184 + SIDER: C0497327 + + + + obo2:OAE_0000185 + A vascular disorder AE that results in the presence of blood clot along the wall of a blood vessel, frequently causing vascular obstruction. Some authorities differentiate thrombus formation from simple coagulation or clot formation. + + + + obo2:OAE_0000185 + SS, YH + + + + obo2:OAE_0000185 + thrombosis AE + + + + obo2:OAE_0000185 + HPO: HP_0004419 + + + + obo2:OAE_0000185 + MedDRA: 10043607 + + + + obo2:OAE_0000185 + SIDER: C0040053 + + + + obo2:OAE_0000187 + a metabolic disorder AE that has an outcome of cell death. + + + + obo2:OAE_0000187 + SS, YH + + + + obo2:OAE_0000187 + cell death AE + + + + obo2:OAE_0000187 + HPO: HP_0010885 + + + + obo2:OAE_0000187 + MedDRA: 10057248 + + + + obo2:OAE_0000187 + SIDER: C0007587 + + + + obo2:OAE_0000188 + a respiratory system AE which has an outcome of some respiratory tract neoplasm. + + + + obo2:OAE_0000188 + YH + + + + obo2:OAE_0000188 + respiratory tract neoplasm AE + + + + obo2:OAE_0000188 + MedDRA ID: 10029107 + + + + obo2:OAE_0000194 + an inflammation AE that shows the result of an inflammation located in a vein, usually in the legs. + + + + obo2:OAE_0000194 + phlebitis AE + + + + obo2:OAE_0000194 + HPO: HP_0004419 + + + + obo2:OAE_0000194 + MedDRA: 10034879 + + + + obo2:OAE_0000194 + SIDER: C0031542 + + + + obo2:OAE_0000195 + a liver, biliary, and pancreatic AE that has an outcome of pancreatitis. + + + + obo2:OAE_0000195 + YH + + + + obo2:OAE_0000195 + pancreatitis AE + + + + obo2:OAE_0000195 + HPO: HP_0001733 + + + + obo2:OAE_0000195 + MedDRA: 10033646 + + + + obo2:OAE_0000195 + SIDER: C0030305 + + + + obo2:OAE_0000196 + a cell death AE that has an outcome of apoptosis. + + + + obo2:OAE_0000196 + SS, YH + + + + obo2:OAE_0000196 + apoptosis AE + + + + obo2:OAE_0000196 + MedDRA: 10059512 + + + + obo2:OAE_0000197 + a cell death AE that has an outcome of necrosis + + + + obo2:OAE_0000197 + SS, YH + + + + obo2:OAE_0000197 + necrosis AE + + + + obo2:OAE_0000197 + HPO: HP_0003713 + + + + obo2:OAE_0000197 + SIDER: C0027540 + + + + obo2:OAE_0000198 + A cardiovascular disorder AE that results in Insufficient blood supply for the need of a part of the body, usually as a result of a disease of the blood vessels supplying that part. + + + + obo2:OAE_0000198 + SS, YH + + + + obo2:OAE_0000198 + ischaemia AE + + + + obo2:OAE_0000198 + Note: also spelt ischemia. + + + + obo2:OAE_0000198 + ischemia AE + + + + obo2:OAE_0000198 + HPO: HP_0002597 + + + + obo2:OAE_0000198 + MedDRA: 10061255 + + + + obo2:OAE_0000198 + SIDER: C0022116 + + + + obo2:OAE_0000199 + an adverse event that occurs in hair, skin, or nail. + + + + obo2:OAE_0000199 + YH, SS + + + + obo2:OAE_0000199 + hair, skin, and nail AE + + + + obo2:OAE_0000200 + a hair, skin, and nail AE that occurs in hair. + + + + obo2:OAE_0000200 + YH, SS + + + + obo2:OAE_0000200 + hair AE + + + + obo2:OAE_0000201 + a hair, skin, and nail AE that occurs in nail. + + + + obo2:OAE_0000201 + YH, SS + + + + obo2:OAE_0000201 + nail AE + + + + obo2:OAE_0000202 + a metabolism, endocrine, and exocrine system AE that occurs in endocrine system. + + + + obo2:OAE_0000202 + YH, SS + + + + obo2:OAE_0000202 + endocrine system AE + + + + obo2:OAE_0000202 + MedDRA: 10014698 + + + + obo2:OAE_0000203 + a metabolism, endocrine, and exocrine system AE that occurs in exocrine system + + + + obo2:OAE_0000203 + YH, SS + + + + obo2:OAE_0000203 + exocrine system AE + + + + obo2:OAE_0000204 + an adverse event that displays a congential and genetic disorder. + + + + obo2:OAE_0000204 + congenital abnormality AE + + + + obo2:OAE_0000204 + YH, SS + + + + obo2:OAE_0000204 + congenital AE + + + + obo2:OAE_0000204 + MedDRA: 10010331 + + + + obo2:OAE_0000205 + a muscular weakness AE that is caused by nerve damage or disease. + + + + obo2:OAE_0000205 + paresis AE + + + + obo2:OAE_0000205 + HPO: HP_0008153 + + + + obo2:OAE_0000205 + MedDRA: 10033800 + + + + obo2:OAE_0000205 + SIDER: C0030552 + + + + obo2:OAE_0000206 + a syndrome AE that has an outcome of cystic fibrosis, an inherited disease that affects the lungs, digestive system, sweat glands, and male fertility. + + + + obo2:OAE_0000206 + YH + + + + obo2:OAE_0000206 + WEB: http://medical-dictionary.thefreedictionary.com/cystic+fibrosis + + + + obo2:OAE_0000206 + cystic fibrosis AE + + + + obo2:OAE_0000206 + HPO: HP_0006552 + + + + obo2:OAE_0000206 + MedDRA: 10011762 + + + + obo2:OAE_0000206 + SIDER: C0010674 + + + + obo2:OAE_0000207 + a tumore AE that results in the outcome of hyperplasia, an abnormal increase in the number of normal cells in normal arrangement in an organ or tissue, which increases its volume. + + + + obo2:OAE_0000207 + YH, SS + + + + obo2:OAE_0000207 + hyperplasia AE + + + + obo2:OAE_0000207 + HPO: HP_0010279 + + + + obo2:OAE_0000207 + SIDER: C0020507 + + + + obo2:OAE_0000208 + an adverse event that displays a disorder in abdomen. + + + + obo2:OAE_0000208 + YH, SS + + + + obo2:OAE_0000208 + abdominal AE + + + + obo2:OAE_0000209 + an adverse event that results in genetic disorder. + + + + obo2:OAE_0000209 + genetic disorder AE + + + + obo2:OAE_0000209 + YH, SS + + + + obo2:OAE_0000209 + genetic AE + + + + obo2:OAE_0000210 + a liver, biliary, and pancreatic AE that has an outcome of hepatitis. + + + + obo2:OAE_0000210 + YH + + + + obo2:OAE_0000210 + hepatitis AE + + + + obo2:OAE_0000210 + HPO: HP_0006562 + + + + obo2:OAE_0000210 + SIDER: C0019158 + + + + obo2:OAE_0000211 + an adverse event that displays an outcome of ulcer. + + + + obo2:OAE_0000211 + YH, SS + + + + obo2:OAE_0000211 + ulcer AE + + + + obo2:OAE_0000211 + HPO: HP_0005229 + + + + obo2:OAE_0000211 + SIDER: C0041582 + + + + obo2:OAE_0000212 + a musculoskeletal and connective tissue AE that displays an outcome of fistula, a permanent abnormal passageway between two organs in the body or between an organ and the exterior of the body. + + + + obo2:OAE_0000212 + WEB: http://medical-dictionary.thefreedictionary.com/fistula + + + + obo2:OAE_0000212 + YH, SS + + + + obo2:OAE_0000212 + fistula AE + + + + obo2:OAE_0000212 + HPO: HP_0010294 + + + + obo2:OAE_0000212 + MedDRA: 10067143 + + + + obo2:OAE_0000212 + SIDER: C0016169 + + + + obo2:OAE_0000213 + an abnormal fluid regulation AE which has an outcome of extravasation, a discharge or escape, as of blood, from a vessel into the tissues. + + + + + obo2:OAE_0000213 + YH, SS + + + + obo2:OAE_0000213 + WEB: http://medical-dictionary.thefreedictionary.com/extravasation + + + + obo2:OAE_0000213 + extravasation AE + + + + obo2:OAE_0000213 + MedDRA: 10015866 + + + + obo2:OAE_0000214 + an adverse event that displays an outcome of an sclerosis, the stiffening of a structure, usually caused by a replacement of the normal organ-specific tissue with connective tissue. + + + + obo2:OAE_0000214 + YH, SS + + + + obo2:OAE_0000214 + sclerosis AE + + + + obo2:OAE_0000215 + a crying abnormal AE that has an outcome of abnormal inconsolable crying in a patient + + + + obo2:OAE_0000215 + YH + + + + obo2:OAE_0000215 + inconsolable crying AE + + + + obo2:OAE_0000215 + MedDRA: 10065283 + + + + obo2:OAE_0000216 + a crying abnormal AE that has an outcome of abnormal unusual high-pitched crying in a patient + + + + obo2:OAE_0000216 + YH + + + + obo2:OAE_0000216 + unusual high-pitched crying AE + + + + obo2:OAE_0000217 + a crying abnormal AE that has an outcome of abnormal prolonged crying in a patient + + + + obo2:OAE_0000217 + YH + + + + obo2:OAE_0000217 + prolonged crying AE + + + + obo2:OAE_0000218 + a decreased heart rate AE that results in a resting heart rate of under 60 beats per minutes (BPM). + + + + obo2:OAE_0000218 + WEB: http://en.wikipedia.org/wiki/Bradycardia + + + + obo2:OAE_0000218 + WEB: http://medical-dictionary.thefreedictionary.com/bradycardia + + + + obo2:OAE_0000218 + bradycardia AE + + + + obo2:OAE_0000218 + HPO: HP_0001662 + + + + obo2:OAE_0000218 + MedDRA: 10006093 + + + + obo2:OAE_0000218 + SIDER: C0428977 + + + + obo2:OAE_0000219 + an adverse event that displays a disorder associated with child birth, newborn infant, or an infant. + + + + obo2:OAE_0000219 + YH + + + + obo2:OAE_0000219 + pregnancy, neonatal and perinatal AE + + + + obo2:OAE_0000219 + MedDRA: 10036585 + + + + obo2:OAE_0000222 + a bupropion-induced adverse event that is induced by aplenzin administration + + + + obo2:OAE_0000222 + YH + + + + obo2:OAE_0000222 + aplenzin-induced adverse event + + + + obo2:OAE_0000226 + an adverse event that occurs in the site of a medical intervention (e.g., vaccination injection site). + + + + obo2:OAE_0000226 + YH + + + + obo2:OAE_0000226 + application site reaction + + + + obo2:OAE_0000226 + medical intervention site AE + + + + obo2:OAE_0000226 + MedDRA: 10003055 + + + + obo2:OAE_0000231 + A pregnancy, neonatal and perinatal AE that displays a disorder associated with newborn infant or an infant. + + + + obo2:OAE_0000231 + YH + + + + obo2:OAE_0000231 + neonatal AE + + + + obo2:OAE_0000232 + A pregnancy, neonatal and perinatal AE that displays a disorder associated with childbirth + + + + obo2:OAE_0000232 + YH + + + + obo2:OAE_0000232 + perinatal AE + + + + obo2:OAE_0000236 + a vascular disorder AE that affects the artery + + + + obo2:OAE_0000236 + SS + + + + obo2:OAE_0000236 + arterial disease AE + + + + obo2:OAE_0000236 + arterial disorder AE + + + + obo2:OAE_0000236 + HPO: HP_0002620 + + + + obo2:OAE_0000236 + SIDER: C0852949 + + + + obo2:OAE_0000237 + an artery disorder AE that is characterized by a narrowing of the blood vessels outside of the heart. + + + + obo2:OAE_0000237 + SS + + + + obo2:OAE_0000237 + peripheral artery disease AE + + + + obo2:OAE_0000237 + peripheral artery disorder AE + + + + obo2:OAE_0000237 + WEB: http://vsearch.nlm.nih.gov/vivisimo/cgi-bin/query-meta?v%3Aproject=medlineplus&query=peripheral+arterial+disease + + + + obo2:OAE_0000237 + peripheral arterial disease AE + + + + obo2:OAE_0000237 + HPO: HP_0004950 + + + + obo2:OAE_0000237 + MedDRA: 10067825 + + + + obo2:OAE_0000237 + SIDER: C1704436 + + + + obo2:OAE_0000238 + a skin adverse event that shows a symptom of psoriasis, a skin disorder that shows dry red patches on the skin. + + + + obo2:OAE_0000238 + SZ, SS, YH + + + + obo2:OAE_0000238 + WEB: http://medical-dictionary.thefreedictionary.com/psoriasis + + + + obo2:OAE_0000238 + psoriasis AE + + + + obo2:OAE_0000238 + HPO: HP_0003765 + + + + obo2:OAE_0000238 + MedDRA: 10037153 + + + + obo2:OAE_0000238 + SIDER: C0033860 + + + + obo2:OAE_0000239 + a distal sensory neuropathy AE characterized by an increase in degree (cumulative) + + + + obo2:OAE_0000239 + AG, YH + + + + obo2:OAE_0000239 + cumulative distal sensory neuropathy AE + + + + obo2:OAE_0000240 + a behavior and neurological AE that has an outcome of stress in a patient + + + + obo2:OAE_0000240 + YH + + + + obo2:OAE_0000240 + stress AE + + + + obo2:OAE_0000241 + an abscess AE that has an outcome of a pocket of infected fluid and pus located inside the abdominal cavity + + + + obo2:OAE_0000241 + DJ, SS, YH + + + + obo2:OAE_0000241 + WEB: http://www.nlm.nih.gov/medlineplus/ency/article/000212.htm + + + + obo2:OAE_0000241 + abdominal abscess AE + + + + obo2:OAE_0000241 + MedDRA: 10060921 + + + + obo2:OAE_0000242 + a discomfort AE that has an outcome of a stomach ache + + + + obo2:OAE_0000242 + DJ, SS, YH + + + + obo2:OAE_0000242 + WEB: http://medical-dictionary.thefreedictionary.com/Abdominal+discomfort + + + + obo2:OAE_0000242 + abdominal discomfort AE + + + + obo2:OAE_0000242 + HPO: HP_0002027 + + + + obo2:OAE_0000242 + MedDRA: 10000059 + + + + obo2:OAE_0000242 + SIDER: C0232487 + + + + obo2:OAE_0000243 + a sensory capability AE that results in a sensation of elevated abdominal pressure and volume + + + + obo2:OAE_0000243 + DJ, SS, YH + + + + obo2:OAE_0000243 + WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0003609/ + + + + obo2:OAE_0000243 + abdominal distension AE + + + + obo2:OAE_0000243 + HPO: HP_0003270 + + + + obo2:OAE_0000243 + MedDRA: 10000060 + + + + obo2:OAE_0000243 + SIDER: C0000731 + + + + obo2:OAE_0000244 + a sepsis AE that has an outcome of sepsis in the abdominal area + + + + obo2:OAE_0000244 + DJ, SS, YH + + + + obo2:OAE_0000244 + WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001687/ + + + + obo2:OAE_0000244 + abdominal sepsis AE + + + + obo2:OAE_0000244 + MedDRA: 10058040 + + + + obo2:OAE_0000245 + an abdominal abscess AE that has an outcome of a collection of pus in the abdominal wall, causes inflammation + + + + obo2:OAE_0000245 + DJ, SS, YH + + + + obo2:OAE_0000245 + WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0002329/ + + + + obo2:OAE_0000245 + abdominal wall abscess AE + + + + obo2:OAE_0000245 + MedDRA: 10000099 + + + + obo2:OAE_0000246 + a behavioral AE that results in uncharacteristic behaviors + + + + obo2:OAE_0000246 + DJ, SS, YH + + + + obo2:OAE_0000246 + abnormal behaviour AE + + + + obo2:OAE_0000246 + abnormal behavior AE + + + + obo2:OAE_0000246 + HPO: HP_0000708 + + + + obo2:OAE_0000246 + MedDRA: 10061422 + + + + obo2:OAE_0000246 + SIDER: C0233514 + + + + obo2:OAE_0000247 + a behavioral AE that results in odd dreams + + + + obo2:OAE_0000247 + DJ, SS, YH + + + + obo2:OAE_0000247 + abnormal dreams AE + + + + obo2:OAE_0000247 + MedDRA: 10000125 + + + + obo2:OAE_0000248 + an abortion AE that has an outcome of expulsion of a fetus from the uterus brought on intentionally by medication or instrumentation + + + + obo2:OAE_0000248 + DJ, SS, YH + + + + obo2:OAE_0000248 + WEB: http://medical-dictionary.thefreedictionary.com/induced+abortion + + + + obo2:OAE_0000248 + abortion induced AE + + + + obo2:OAE_0000248 + MedDRA: 10000220 + + + + obo2:OAE_0000249 + an abortion AE that results in a miscarriage + + + + obo2:OAE_0000249 + DJ, SS, YH + + + + obo2:OAE_0000249 + WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0002458/ + + + + obo2:OAE_0000249 + abortion spontaneous AE + + + + obo2:OAE_0000249 + HPO: HP_0005268 + + + + obo2:OAE_0000249 + MedDRA: 10000234 + + + + obo2:OAE_0000249 + SIDER: C0000786 + + + + obo2:OAE_0000250 + a skin AE that is characterized by pimples generally on the face, chest and back, caused by clogging of the pores + + + + obo2:OAE_0000250 + DJ, SS, YH + + + + obo2:OAE_0000250 + WEB: http://medical-dictionary.thefreedictionary.com/acne + + + + obo2:OAE_0000250 + acne AE + + + + obo2:OAE_0000250 + HPO: HP_0001061 + + + + obo2:OAE_0000250 + MedDRA: 10000496 + + + + obo2:OAE_0000250 + SIDER: C0702166 + + + + obo2:OAE_0000251 + a immune system disorder AE that is caused by the HIV virus + + + + obo2:OAE_0000251 + DJ, SS, YH + + + + obo2:OAE_0000251 + WEB: http://www.nlm.nih.gov/medlineplus/hivaids.html + + + + obo2:OAE_0000251 + acquired immunodeficiency syndrome AE + + + + obo2:OAE_0000251 + HPO: HP_0002721 + + + + obo2:OAE_0000251 + MedDRA: 10000565 + + + + obo2:OAE_0000251 + SIDER: C0001175 + + + + obo2:OAE_0000252 + a hematopoietic system AE that has an outcome of a prolonged time taken for blood to clot. The partial thromboplastin time (PTT) is a blood test that looks at how long it takes for blood to clot. PTT measures the efficacy of the comon coagulation pathways and helps tell if bleeding or clotting problems exist. + + + + obo2:OAE_0000252 + DJ, SS, YH + + + + obo2:OAE_0000252 + WEB: http://www.nlm.nih.gov/medlineplus/ency/article/003653.htm + + + + obo2:OAE_0000252 + activated partial thromboplastin time prolonged AE + + + + obo2:OAE_0000252 + HPO: HP_0003645 + + + + obo2:OAE_0000252 + MedDRA: 10000636 + + + + obo2:OAE_0000252 + SIDER: C0853223 + + + + obo2:OAE_0000253 + a digestive system AE that has an outcome of a complication during stem cell or bone marrow transplant in which the newly transplanted donor cells in the intestine attack the transplant recipient's body + + + + obo2:OAE_0000253 + DJ, SS, YH + + + + obo2:OAE_0000253 + WEB: http://www.nlm.nih.gov/medlineplus/ency/article/001309.htm + + + + obo2:OAE_0000253 + acute graft versus host disease in intestine AE + + + + obo2:OAE_0000253 + MedDRA: 10066264 + + + + obo2:OAE_0000254 + a skin AE that has an outcome of a complication during stem cell or bone marrow transplant in which the newly transplanted donor cells in the skin attack the transplant recipient's body + + + + obo2:OAE_0000254 + DJ, SS, YH + + + + obo2:OAE_0000254 + WEB: http://www.nlm.nih.gov/medlineplus/ency/article/001309.htm + + + + obo2:OAE_0000254 + acute graft versus host disease in skin AE + + + + obo2:OAE_0000254 + MedDRA: 10066262 + + + + obo2:OAE_0000255 + a hematopoietic system AE that has an outcome of a type of acute leukemia, characterized by anemia, fatigue, weight loss, easy bruising, thrombocytopenia, granulocytopenia with bacterial infections, and bone pain + + + + obo2:OAE_0000255 + DJ, SS, YH + + + + obo2:OAE_0000255 + acute lymphocytic leukaemia AE + + + + obo2:OAE_0000255 + WEB: http://medical-dictionary.thefreedictionary.com/Blast+count + + + + obo2:OAE_0000255 + acute lymphocytic leukemia AE + + + + obo2:OAE_0000255 + HPO: HP_0006721 + + + + obo2:OAE_0000255 + MedDRA: 10000846 + + + + obo2:OAE_0000255 + SIDER: C0023449 + + + + obo2:OAE_0000256 + a hematopoietic system AE that has an outcome of the reoccurance of fast-growing cancer of the white blood cells where abnormal blasts do not fight infections after a period of remission + + + + obo2:OAE_0000256 + DJ, SS, YH + + + + obo2:OAE_0000256 + acute lymphocytic leukaemia recurrent AE + + + + obo2:OAE_0000256 + WEB: http://marrow.org/Patient/Disease_and_Treatment/About_Your_Disease/ALL/Acute_Lymphoblastic_Leukemia_(ALL).aspx + + + + obo2:OAE_0000256 + acute lymphocytic leukemia recurrent AE + + + + obo2:OAE_0000256 + MedDRA: 10063620 + + + + obo2:OAE_0000257 + a hematopoietic system AE that has an outcome of cancer in the myeloid line of blood cells, characterized by the rapid growth of abnormal white blood cells that accumulate in the bone marrow and interfere with the production of normal blood cells + + + + obo2:OAE_0000257 + DJ, SS, YH + + + + obo2:OAE_0000257 + acute myeloid leukaemia AE + + + + obo2:OAE_0000257 + WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001569/ + + + + obo2:OAE_0000257 + acute myeloid leukemia AE + + + + obo2:OAE_0000257 + HPO: HP_0004808 + + + + obo2:OAE_0000257 + MedDRA: 10000880 + + + + obo2:OAE_0000257 + SIDER: C0023467 + + + + obo2:OAE_0000258 + an acute myeloid leukemia AE that shows an recurrence of acute myeloid leukemia + + + + obo2:OAE_0000258 + DJ, SS, YH + + + + obo2:OAE_0000258 + acute myeloid leukaemia recurrent AE + + + + obo2:OAE_0000258 + WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001569/ + + + + obo2:OAE_0000258 + acute myeloid leukemia recurrent AE + + + + obo2:OAE_0000258 + MedDRA: 10059034 + + + + obo2:OAE_0000259 + a lung disorder AE that has the outcome fluid accumulation in the air spaces and parenchyma of the lungs with rapid onset + + + + obo2:OAE_0000259 + DJ, SS, YH + + + + obo2:OAE_0000259 + acute pulmonary oedema AE + + + + obo2:OAE_0000259 + WEB: http://medical-dictionary.thefreedictionary.com/Acute+pulmonary+edema + + + + obo2:OAE_0000259 + acute pulmonary edema AE + + + + obo2:OAE_0000259 + HPO: HP_0100598 + + + + obo2:OAE_0000259 + MedDRA: 10001029 + + + + obo2:OAE_0000259 + SIDER: C0155919 + + + + obo2:OAE_0000260 + a respiratory distress AE that has an outcome of a life-threatening lung condition that prevents enough oxygen from getting to the lungs and into the blood + + + + obo2:OAE_0000260 + DJ, SS, YH + + + + obo2:OAE_0000260 + WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001164/ + + + + obo2:OAE_0000260 + acute respiratory distress syndrome AE + + + + obo2:OAE_0000260 + HPO: HP_0002093 + + + + obo2:OAE_0000260 + MedDRA: 10001052 + + + + obo2:OAE_0000260 + SIDER: C0035222 + + + + obo2:OAE_0000261 + a lung disorder AE that has an outcome of a condition in which not enough oxygen passes from the lungs into the blood, with rapid onset + + + + obo2:OAE_0000261 + DJ, SS, YH + + + + obo2:OAE_0000261 + WEB: http://www.nhlbi.nih.gov/health/health-topics/topics/rf/ + + + + obo2:OAE_0000261 + acute respiratory failure AE + + + + obo2:OAE_0000261 + HPO: HP_0002093 + + + + obo2:OAE_0000261 + MedDRA: 10001053 + + + + obo2:OAE_0000261 + SIDER: C0264490 + + + + obo2:OAE_0000262 + a syncope AE that results in sudden episodes of fainting and sometimes seizures + + + + obo2:OAE_0000262 + DJ, SS, YH + + + + obo2:OAE_0000262 + WEB: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1518479/ + + + + obo2:OAE_0000262 + adams-stokes syndrome AE + + + + obo2:OAE_0000262 + MedDRA: 10001115 + + + + obo2:OAE_0000263 + a reproductive system AE that results in the thickening of the walls of the uterus. This ccurs when endometrial tissue, which normally lines the uterus, moves into the outer muscular walls of the uterus. + + + + obo2:OAE_0000263 + DJ, SS, YH + + + + obo2:OAE_0000263 + endrometriosis interma AE + + + + obo2:OAE_0000263 + WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0002481/ + + + + obo2:OAE_0000263 + adenomyosis AE + + + + obo2:OAE_0000263 + MedDRA: 10056268 + + + + obo2:OAE_0000264 + a viral infection that occurs in the respiratory system and has an outcome of viral infection by nonenveloped icosahedral viruses causing illness in the respiratory system + + + + obo2:OAE_0000264 + DJ, SS, YH + + + + obo2:OAE_0000264 + WEB: http://medical-dictionary.thefreedictionary.com/Adenovirus+Infections + + + + obo2:OAE_0000264 + adenovirus infection AE + + + + obo2:OAE_0000264 + HPO: HP_0004429 + + + + obo2:OAE_0000264 + MedDRA: 10060931 + + + + obo2:OAE_0000264 + SIDER: C0001486 + + + + obo2:OAE_0000265 + a tumor AE that results in an abnormal number of cells proliferating on the kidney(s) + + + + obo2:OAE_0000265 + DJ, SS, YH + + + + obo2:OAE_0000265 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/22486993 + + + + obo2:OAE_0000265 + adrenal neoplasm AE + + + + obo2:OAE_0000265 + MedDRA: 10061588 + + + + obo2:OAE_0000266 + an endocrine system AE that results in the suppression of the functions of the adrenal glands + + + + obo2:OAE_0000266 + DJ, SS, YH + + + + obo2:OAE_0000266 + adrenal suppression AE + + + + obo2:OAE_0000266 + MedDRA: 10001382 + + + + obo2:OAE_0000267 + a behavior and neurological AE that results in an increase in hostile behavior + + + + obo2:OAE_0000267 + DJ, SS, YH + + + + obo2:OAE_0000267 + aggression AE + + + + obo2:OAE_0000267 + HPO: HP_0000718 + + + + obo2:OAE_0000267 + MedDRA: 10001488 + + + + obo2:OAE_0000267 + SIDER: C0001807 + + + + obo2:OAE_0000268 + a hematopoietic system AE that has an outcome of acute leukopenia, or lowered white blood cell count, most commonly of neutrophils causing neutropenia in circulating blood + + + + obo2:OAE_0000268 + JX, DJ, SS, YH + + + + obo2:OAE_0000268 + WEB: http://www.nlm.nih.gov/medlineplus/ency/article/001295.htm + + + + obo2:OAE_0000268 + 粒性白血球缺乏症 + + + + obo2:OAE_0000268 + agranulocytosis AE + + + + obo2:OAE_0000268 + HPO: HP_0001913 + + + + obo2:OAE_0000268 + MedDRA: 10001507 + + + + obo2:OAE_0000268 + SIDER: C0001824 + + + + obo2:OAE_0000269 + an embolism AE that is caused by an air bubble in the vessel + + + + obo2:OAE_0000269 + DJ, SS, YH + + + + obo2:OAE_0000269 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/23295634 + + + + obo2:OAE_0000269 + air embolism AE + + + + obo2:OAE_0000269 + MedDRA: 10001526 + + + + obo2:OAE_0000270 + a liver related investigation result abnormal AE that has an outcome of an abnormal blood level of alanine aminotransferase + + + + obo2:OAE_0000270 + DJ, SS, YH + + + + obo2:OAE_0000270 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/23139615 + + + + obo2:OAE_0000270 + alanine aminotransferase level abnormal AE + + + + obo2:OAE_0000270 + MedDRA: 10001547 + + + + obo2:OAE_0000271 + an alanine aminotransferase level abnormal AE that has an outcome of a decrease in alanine aminotransferase level in body + + + + obo2:OAE_0000271 + DJ, SS, YH, EB + + + + obo2:OAE_0000271 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/23139615 + + + + obo2:OAE_0000271 + alanine aminotransferase level decreased AE + + + + obo2:OAE_0000271 + MedDRA: 10001549 + + + + obo2:OAE_0000272 + an alanine aminotransferase level abnormal AE that has an outcome of elevated levels of alanine transaminase, an enzyme most commonly found in the liver + + + + obo2:OAE_0000272 + DJ, SS, YH, EB + + + + obo2:OAE_0000272 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/23139615 + + + + obo2:OAE_0000272 + alanine aminotransferase level increased AE + + + + obo2:OAE_0000272 + MedDRA: 10001551 + + + + obo2:OAE_0000273 + a liver/biliary system AE that is characterized by liver disease caused by the patient's alcoholic activity + + + + obo2:OAE_0000273 + DJ, SS, YH + + + + obo2:OAE_0000273 + alcoholic liver disease AE + + + + obo2:OAE_0000273 + MedDRA: 10001627 + + + + obo2:OAE_0000274 + a behavior and neurological AE that has an outcome of significantly different waking beta wave state + + + + obo2:OAE_0000274 + DJ, SS, YH + + + + obo2:OAE_0000274 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/20182997 + + + + obo2:OAE_0000274 + altered state of consciousness AE + + + + obo2:OAE_0000274 + MedDRA: 10001854 + + + + obo2:OAE_0000275 + a female reproductive system AE that is characterized by the absence of menstrual period in a woman of reproductive age + + + + obo2:OAE_0000275 + DJ, SS, YH + + + + obo2:OAE_0000275 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/21942684 + + + + obo2:OAE_0000275 + amenorrhoea AE + + + + obo2:OAE_0000275 + HPO: HP_0000141 + + + + obo2:OAE_0000275 + MedDRA: 10001928 + + + + obo2:OAE_0000275 + SIDER: C0002453 + + + + obo2:OAE_0000276 + an abnormal fluid regulation AE that results in a decreased volume of amniotic fluid during pregnancy + + + + obo2:OAE_0000276 + DJ, SS, YH + + + + obo2:OAE_0000276 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/22039031 + + + + obo2:OAE_0000276 + amniotic fluid volume decreased AE + + + + obo2:OAE_0000276 + MedDRA: 10063356 + + + + obo2:OAE_0000277 + a digestive system AE that has an outcome of a split or tear in the mucosa lining the lower rectum + + + + obo2:OAE_0000277 + DJ, SS, YH + + + + obo2:OAE_0000277 + WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0002116/ + + + + obo2:OAE_0000277 + anal fissure AE + + + + obo2:OAE_0000277 + HPO: HP_0004378 + + + + obo2:OAE_0000277 + MedDRA: 10002153 + + + + obo2:OAE_0000277 + SIDER: C0016167 + + + + obo2:OAE_0000278 + an ulcer AE that has an outcome of an ulcer in the anal cavity + + + + obo2:OAE_0000278 + DJ, SS, YH + + + + obo2:OAE_0000278 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/17073250 + + + + obo2:OAE_0000278 + anal ulcer AE + + + + obo2:OAE_0000278 + MedDRA: 10002180 + + + + obo2:OAE_0000279 + a vascular disorder AE that has an outcome of a leakage at the site of the intersection of two blood vessels + + + + obo2:OAE_0000279 + DJ, SS, YH + + + + obo2:OAE_0000279 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/23122582 + + + + obo2:OAE_0000279 + anastomotic leak AE + + + + obo2:OAE_0000279 + MedDRA: 10050456 + + + + obo2:OAE_0000280 + a cardiac disorder AE that is stable and shows the symptom of a chest pain due to ischemia of the heart + + + + obo2:OAE_0000280 + DJ, SS, YH + + + + obo2:OAE_0000280 + stable angina AE + + + + obo2:OAE_0000280 + WEB: http://www.heart.org/HEARTORG/Conditions/HeartAttack/SymptomsDiagnosisofHeartAttack/Angina-Pectoris-Stable-Angina_UCM_437515_Article.jsp# + + + + obo2:OAE_0000280 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/23016723 + + + + obo2:OAE_0000280 + angina pectoris AE + + + + obo2:OAE_0000280 + HPO: HP_0001681 + + + + obo2:OAE_0000280 + MedDRA: 10002383 + + + + obo2:OAE_0000280 + SIDER: C0002962 + + + + obo2:OAE_0000281 + a angina AE that is unstable and has an outcome of a condition in which the heart doesn't get enough blood flow through the blood vessels of the heart muscle, may lead to heart attack. + + + + obo2:OAE_0000281 + DJ, SS, YH + + + + obo2:OAE_0000281 + WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001250/ + + + + obo2:OAE_0000281 + angina unstable AE + + + + obo2:OAE_0000281 + HPO: HP_0001681 + + + + obo2:OAE_0000281 + MedDRA: 10002388 + + + + obo2:OAE_0000281 + SIDER: C0002965 + + + + obo2:OAE_0000282 + an immunology and allergy investigation result abnormal AE that is characterized by antibodies present that are against cell-membrane phospholipids that provoke blood clots + + + + obo2:OAE_0000282 + DJ, SS, YH, EB + + + + obo2:OAE_0000282 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/23231732 + + + + obo2:OAE_0000282 + antiphospholipid antibodies positive AE + + + + obo2:OAE_0000282 + MedDRA: 10048678 + + + + obo2:OAE_0000283 + a urinary system AE that has an outcome of the absence of urine formation + + + + obo2:OAE_0000283 + DJ, SS, YH + + + + obo2:OAE_0000283 + WEB: http://medical-dictionary.thefreedictionary.com/anuria + + + + obo2:OAE_0000283 + anuria AE + + + + obo2:OAE_0000283 + HPO: HP_0100519 + + + + obo2:OAE_0000283 + MedDRA: 10002847 + + + + obo2:OAE_0000283 + SIDER: C0003460 + + + + obo2:OAE_0000284 + a vascular disorder AE that results in a condition affecting the aorta and aortic valves + + + + obo2:OAE_0000284 + DJ, SS, YH + + + + obo2:OAE_0000284 + WEB: http://www.rightdiagnosis.com/medical/aorta_disorder.htm + + + + obo2:OAE_0000284 + aortic disorder AE + + + + obo2:OAE_0000284 + HPO: HP_0001679 + + + + obo2:OAE_0000284 + MedDRA: 10058648 + + + + obo2:OAE_0000284 + SIDER: C0003493 + + + + obo2:OAE_0000285 + a cardiac valve disease AE that has an outcome of inability of the aortic valve to function effectively + + + + obo2:OAE_0000285 + DJ, SS, YH + + + + obo2:OAE_0000285 + WEB: http://www.rightdiagnosis.com/a/aortic_valve_incompetence/intro.htm + + + + obo2:OAE_0000285 + aortic valve incompetence AE + + + + obo2:OAE_0000285 + HPO: HP_0001659 + + + + obo2:OAE_0000285 + MedDRA: 10002915 + + + + obo2:OAE_0000285 + SIDER: C0003504 + + + + obo2:OAE_0000286 + a congenital abnormality AE with an outcome of defective development or congenital absense of an organ or tissue + + + + obo2:OAE_0000286 + DJ, SS, YH + + + + obo2:OAE_0000286 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/737831 + + + + obo2:OAE_0000286 + aplasia AE + + + + obo2:OAE_0000286 + HPO: HP_0010515 + + + + obo2:OAE_0000286 + MedDRA: 10002961 + + + + obo2:OAE_0000286 + SIDER: C0243065 + + + + obo2:OAE_0000287 + Aplastic anaemia AE is an anemia AE that occurs when the bone marrow, and the blood stem cells that reside there are damaged. This causes a deficiency of all three blood cell types (pancytopenia): red blood cells (anemia), white blood cells (leukopenia), and platelets (thrombocytopenia). + + + + obo2:OAE_0000287 + DJ, SS, JX, YH + + + + obo2:OAE_0000287 + aplastic anemia + + + + obo2:OAE_0000287 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/23292240 + + + + obo2:OAE_0000287 + 再生障碍性贫血 + + + + obo2:OAE_0000287 + aplastic anaemia AE + + + + obo2:OAE_0000287 + HPO: HP_0001915 + + + + obo2:OAE_0000287 + MedDRA: 10002967 + + + + obo2:OAE_0000287 + SIDER: C0002874 + + + + obo2:OAE_0000288 + a serious AE that has an outcome of an event that puts the patient's life at risk + + + + obo2:OAE_0000288 + DJ, SS, YH + + + + obo2:OAE_0000288 + apparent life threatening event AE + + + + obo2:OAE_0000288 + MedDRA: 10065044 + + + + obo2:OAE_0000289 + a hypersensitivity AE that occurs at the site of an application of a medical intervention (e.g., drug administration or vaccination). + + + + obo2:OAE_0000289 + DJ, SS, YH + + + + obo2:OAE_0000289 + application site hypersensitivity AE + + + + obo2:OAE_0000289 + MedDRA: 10063683 + + + + obo2:OAE_0000290 + an infection AE that occurs at the site of drug application + + + + obo2:OAE_0000290 + DJ, SS, YH + + + + obo2:OAE_0000290 + application site infection AE + + + + obo2:OAE_0000290 + MedDRA: 10049041 + + + + obo2:OAE_0000291 + a hemorrhage AE that has an outcome of bleeding in the arteries + + + + obo2:OAE_0000291 + DJ, SS, YH + + + + obo2:OAE_0000291 + arterial bleeding AE + + + + obo2:OAE_0000291 + arterial haemorrhage AE + + + + obo2:OAE_0000291 + arterial hemorrhage AE + + + + obo2:OAE_0000291 + MedDRA: 10060964 + + + + obo2:OAE_0000292 + CSF protein increased AE is an abnormal cerebrospinal fluid production that results in and increase in blood level CSF protein + + + + obo2:OAE_0000292 + SS, YH + + + + obo2:OAE_0000292 + CSF protein increased AE + + + + obo2:OAE_0000292 + MedDRA ID: 10011575 + + + + obo2:OAE_0000293 + a neurological, special senses and psychiatric investigation result abnormal AE that has an outcome of an abnormal result in the cerebrospinal fluid (CSF) collection test that examines the fluid that surrounds the brain and spinal cord + + + + obo2:OAE_0000293 + This should be inferred as a "AE: lab test abnormal". + + + + obo2:OAE_0000293 + SS, YH, EB + + + + obo2:OAE_0000293 + WEB: www.nlm.nih.gov/medlineplus/ency/article/003428.htm + + + + obo2:OAE_0000293 + CSF test result abnormal AE + + + + obo2:OAE_0000293 + MedDRA ID: 10059703 + + + + obo2:OAE_0000294 + Henoch-Schonlein purpura AE is a purpura AE, a systemic vasculitis (inflammation of blood vessels) characterized by deposition of immune complexes containing the antibody IgA in the skin and kidney. This results from some allergic response, + + + + obo2:OAE_0000294 + SS, YH + + + + obo2:OAE_0000294 + allergic purpura, anaphylactoid purpura, vascular purpura + + + + obo2:OAE_0000294 + WEB: http://en.wikipedia.org/wiki/Henoch-Schonlein_purpura + + + + obo2:OAE_0000294 + Henoch-Schonlein purpura AE + + + + obo2:OAE_0000294 + HPO: HP_0000979 + + + + obo2:OAE_0000294 + MedDRA ID: 10019617 + + + + obo2:OAE_0000294 + SIDER: C0034152 + + + + obo2:OAE_0000295 + SS, YH + + + + obo2:OAE_0000295 + WEB: http://en.wikipedia.org/wiki/Abasia + + + + obo2:OAE_0000295 + a movement disorder AE that has an outcome of abasia, a movement disorder that results in and inability to walk due to impaired muscle coordination + + + + obo2:OAE_0000295 + abasia AE + + + + obo2:OAE_0000295 + HPO: HP_0002540 + + + + obo2:OAE_0000295 + MedDRA ID: 10049460 + + + + obo2:OAE_0000295 + SIDER: C0877217 + + + + obo2:OAE_0000296 + an abdominal pain AE that is observed in upper stomach + + + + obo2:OAE_0000296 + SS, YH + + + + obo2:OAE_0000296 + abdominal pain upper AE + + + + obo2:OAE_0000296 + HPO: HP_0002027 + + + + obo2:OAE_0000296 + MedDRA ID: 10000087 + + + + obo2:OAE_0000296 + SIDER: C0232492 + + + + obo2:OAE_0000297 + a behavior and neurological AE that has an outcome of loss of taste functions of the tongue, particularly the inability to detect sweetness, sourness, bitterness, saltiness, and umami (the taste of monosodium glutamate). + + + + obo2:OAE_0000297 + SS, YH + + + + obo2:OAE_0000297 + WEB: http://en.wikipedia.org/wiki/Ageusia + + + + obo2:OAE_0000297 + ageusia AE + + + + obo2:OAE_0000297 + MedDRA ID: 10001480 + + + + obo2:OAE_0000298 + a sensory neuropathy AE that has an outcome of chronic sensory neuropathy characterized by being persistent or long-lasting in nature + + + + obo2:OAE_0000298 + AG, YH + + + + obo2:OAE_0000298 + chronic sensory neuropathy AE + + + + obo2:OAE_0000299 + a behavior and neurological AE that has an outcome of a lack of functioning olfaction, an inability to perceive odors + + + + obo2:OAE_0000299 + SS, YH + + + + obo2:OAE_0000299 + WEB: http://en.wikipedia.org/wiki/Olfaction + + + + obo2:OAE_0000299 + anosmia AE + + + + obo2:OAE_0000299 + HPO: HP_0010632 + + + + obo2:OAE_0000299 + MedDRA ID: 10002653 + + + + obo2:OAE_0000299 + SIDER: C0003126 + + + + obo2:OAE_0000300 + a behavior and neurological AE that has an outcome of a psychological and physiological state characterized by cognitive, somatic, emotional, and behavioral components. These components combine to create an unpleasant feeling that is typically associated with uneasiness, fear, or worry. + + + + obo2:OAE_0000300 + SS, YH + + + + obo2:OAE_0000300 + WEB: http://en.wikipedia.org/wiki/Anxiety + + + + obo2:OAE_0000300 + anxiety AE + + + + obo2:OAE_0000300 + HPO: HP_0000739 + + + + obo2:OAE_0000300 + MedDRA: 10029216 + + + + obo2:OAE_0000300 + SIDER: C0003467 + + + + obo2:OAE_0000301 + an arrhythmia AE that is characterized by rapid regular atrial contractions occurring usually at rates between 250 and 400 per minute and often producing saw-tooth waves in an electrocardiogram. + + + + obo2:OAE_0000301 + SS + + + + obo2:OAE_0000301 + AF + + + + obo2:OAE_0000301 + auricular flutter + + + + obo2:OAE_0000301 + WEB: http://medical-dictionary.thefreedictionary.com/atrial+flutter + + + + obo2:OAE_0000301 + atrial flutter AE + + + + obo2:OAE_0000301 + HPO: HP_0004749 + + + + obo2:OAE_0000301 + MedDRA: 10003662 + + + + obo2:OAE_0000301 + SIDER: C0004239 + + + + obo2:OAE_0000302 + a behavior and neurological AE that has an outcome of a disturbance that causes an individual to feel unsteady, giddy, woozy, or have a sensation of movement, spinning, or floating. + + + + obo2:OAE_0000302 + SS, YH + + + + obo2:OAE_0000302 + WEB: http://en.wikipedia.org/wiki/Balance_disorder + + + + obo2:OAE_0000302 + balance disorder AE + + + + obo2:OAE_0000302 + HPO: HP_0002141 + + + + obo2:OAE_0000302 + MedDRA ID: 10049848 + + + + obo2:OAE_0000302 + SIDER: C0575090 + + + + obo2:OAE_0000303 + blister AE is a skin adverse event that results in a small pocket of fluid within the upper layers of the skin + + + + obo2:OAE_0000303 + SS, YH + + + + obo2:OAE_0000303 + WEB: http://en.wikipedia.org/wiki/Blister + + + + obo2:OAE_0000303 + blister AE + + + + obo2:OAE_0000303 + HPO: HP_0008066 + + + + obo2:OAE_0000303 + MedDRA ID: 10005191 + + + + obo2:OAE_0000303 + MedDRA: 10005191 + + + + obo2:OAE_0000303 + SIDER: C0005758 + + + + obo2:OAE_0000304 + cellulitis AE is an inflammation AE that is a diffuse inflammation of connective tissue with severe inflammation of dermal and subcutaneous layers of the skin + + + + obo2:OAE_0000304 + SS, YH + + + + obo2:OAE_0000304 + WEB: http://en.wikipedia.org/wiki/Cellulitis + + + + obo2:OAE_0000304 + cellulitis AE + + + + obo2:OAE_0000304 + HPO: HP_0003553 + + + + obo2:OAE_0000304 + MedDRA: 10007882 + + + + obo2:OAE_0000304 + SIDER: C0007642 + + + + obo2:OAE_0000305 + a behavior and neurological AE that has an outcome of a type of perspiration usually associated with anxiety or fear + + + + obo2:OAE_0000305 + SS, YH + + + + obo2:OAE_0000305 + WEB: http://en.wikipedia.org/wiki/Cold_sweat + + + + obo2:OAE_0000305 + cold sweat AE + + + + obo2:OAE_0000306 + convulsion AE is a muscle adverse event that results in a medical condition where body muscles contract and relax rapidly and repeatedly, resulting in an uncontrolled shaking of the body + + + + obo2:OAE_0000306 + SS, YH + + + + obo2:OAE_0000306 + WEB: http://en.wikipedia.org/wiki/Convulsion + + + + obo2:OAE_0000306 + convulsion AE + + + + obo2:OAE_0000306 + HPO: HP_0001250 + + + + obo2:OAE_0000306 + MedDRA ID: 10010904 + + + + obo2:OAE_0000306 + SIDER: C0009951 + + + + obo2:OAE_0000307 + SS, YH + + + + obo2:OAE_0000307 + a movement disorder AE that has an outcome of difficulty in walking properly + + + + obo2:OAE_0000307 + difficulty in walking AE + + + + obo2:OAE_0000308 + a behavior and neurological AE that has an outcome of distortion of the sense of taste + + + + obo2:OAE_0000308 + SS, YH + + + + obo2:OAE_0000308 + WEB: http://en.wikipedia.org/wiki/Dysgeusia + + + + obo2:OAE_0000308 + dysgeusia AE + + + + obo2:OAE_0000308 + HPO: HP_0000223 + + + + obo2:OAE_0000308 + MedDRA ID: 10013911 + + + + obo2:OAE_0000308 + SIDER: C0013378 + + + + obo2:OAE_0000309 + a movement disorder AE that has an outcome of dyskinesia + + + + obo2:OAE_0000309 + SS, YH + + + + obo2:OAE_0000309 + WEB: http://en.wikipedia.org/wiki/Dyskinesia + + + + obo2:OAE_0000309 + dyskinesia is a movement disorder which consists of effects including diminished voluntary movements and the presence of involuntary movements + + + + obo2:OAE_0000309 + dyskinesia AE + + + + obo2:OAE_0000309 + HPO: HP_0100660 + + + + obo2:OAE_0000309 + MedDRA ID: 10013916 + + + + obo2:OAE_0000309 + SIDER: C0013384 + + + + obo2:OAE_0000310 + dyspnoea AE is an abnormal respiration AE debilitating symptom that is the experience of unpleasant or uncomfortable respiratory sensations, shortness of breath, air hunger + + + + obo2:OAE_0000310 + SS, YH + + + + obo2:OAE_0000310 + dyspnoea AE + + + + obo2:OAE_0000310 + WEB: http://en.wikipedia.org/wiki/Dyspnoea + + + + obo2:OAE_0000310 + dyspnea AE + + + + obo2:OAE_0000310 + HPO: HP_0002094 + + + + obo2:OAE_0000310 + MedDRA ID: 10013968 + + + + obo2:OAE_0000310 + SIDER: C0013404 + + + + obo2:OAE_0000311 + SS, YH, EB + + + + obo2:OAE_0000311 + WEB: http://en.wikipedia.org/wiki/Electromyography + + + + obo2:OAE_0000311 + a neurological, special senses and psychiatric investigation result abnormal AE that has an outcome of abnormal activity in skeletal muscles evaluted and measured by electromyography + + + + obo2:OAE_0000311 + electromyogram result abnormal AE + + + + obo2:OAE_0000311 + MedDRA ID: 10014431 + + + + obo2:OAE_0000312 + eye irritation AE is an eye disorder AE that results in mild eye redness, itching, or tearing + + + + obo2:OAE_0000312 + SS, YH + + + + obo2:OAE_0000312 + WEB: http://www.freemd.com/eye-irritation/ + + + + obo2:OAE_0000312 + eye irritation AE + + + + obo2:OAE_0000312 + HPO: HP_0000478 + + + + obo2:OAE_0000312 + MedDRA ID: 10015946 + + + + obo2:OAE_0000312 + SIDER: C0235266 + + + + obo2:OAE_0000313 + eye pruritus AE is a pruritus AE (an unpleasant sensation that evokes the desire or reflex to scratch) at the eye area + + + + obo2:OAE_0000313 + SS, YH + + + + obo2:OAE_0000313 + eye pruritus AE + + + + obo2:OAE_0000313 + HPO: HP_0000989 + + + + obo2:OAE_0000313 + MedDRA ID: 10052140 + + + + obo2:OAE_0000313 + SIDER: C0022281 + + + + obo2:OAE_0000314 + glomerulonephritis AE is a kidney disorder AE that results in a renal disease that is characterized by inflammation of the glomeruli, or small blood vessels in the kidneys. + + + + obo2:OAE_0000314 + SS, YH + + + + obo2:OAE_0000314 + glomerular nephritis AE + + + + obo2:OAE_0000314 + WEB: http://en.wikipedia.org/wiki/Glomerulonephritis + + + + obo2:OAE_0000314 + glomerulonephritis AE + + + + obo2:OAE_0000314 + HPO: HP_0000099 + + + + obo2:OAE_0000314 + SIDER: C0017658 + + + + obo2:OAE_0000315 + A conduction system disorder AE that is a condition in which the electrical impulse from the bundle of His to the ventricles is delayed or fails to conduct along the right bundle branch, resulting in right ventricular depolarization by cell-to-cell conduction spreading from the interventricular septum and left ventricle to the right ventricle–ie, slow and uncoordinated Natural history Surgically induced RBBB has few acute hemodynamic consequences and a generally benign course long term; rarely, progression to complete heart block and sudden death occur, especially if accompanied by major His-Purkinje system–eg, left anterior hemiblock, first-degree AV block–injury; tetralogy of Fallot repair with an RBBB and a markedly prolonged QRS duration >180 ms have an ↑ risk for ventricular arrhythmias and sudden death. + + + + obo2:OAE_0000315 + SS + + + + obo2:OAE_0000315 + RBBB + + + + obo2:OAE_0000315 + right bundle branch block + + + + obo2:OAE_0000315 + WEB: http://medical-dictionary.thefreedictionary.com/right+bundle+branch+block + + + + obo2:OAE_0000315 + bundle branch block right AE + + + + obo2:OAE_0000315 + HPO: HP_0011712 + + + + obo2:OAE_0000315 + MedDRA: 10006582 + + + + obo2:OAE_0000315 + SIDER: C0085615 + + + + obo2:OAE_0000316 + a cardiac disorder AE of the electrical conduction system that controls the heart rate, generates and conducts electrical impulses throughout the muscle of the heart, stimulating the heart to contract and pump blood. + + + + obo2:OAE_0000316 + SS + + + + obo2:OAE_0000316 + cardiac conduction disorder AE + + + + obo2:OAE_0000316 + WEB: http://www.medterms.com/script/main/art.asp?articlekey=8407 + + + + obo2:OAE_0000316 + conduction system disorder AE + + + + obo2:OAE_0000316 + MedDRA: 10000032 + + + + obo2:OAE_0000317 + a sensory capability AE that has an outcome of hypoaesthesia, meaning that skin loses some of its sensitivity to pain or touch + + + + obo2:OAE_0000317 + SS, YH + + + + obo2:OAE_0000317 + disesthesia AE + + + + obo2:OAE_0000317 + hypoaesthesia AE + + + + obo2:OAE_0000317 + WEB:http://medguides.medicines.org.uk/document.aspx?name=hypoaesthesia + + + + obo2:OAE_0000317 + hypoesthesia AE + + + + obo2:OAE_0000317 + HPO: HP_0010830 + + + + obo2:OAE_0000317 + MedDRA ID: 10020937 + + + + obo2:OAE_0000317 + SIDER: C0020580 + + + + obo2:OAE_0000318 + a thrombosis AE that has an outcome of a blood clot within an artery + + + + obo2:OAE_0000318 + [SS] Per DRA and KKB's comment, arterial thrombosis may also be characterized as an embolism. + + + + obo2:OAE_0000318 + DJ, SS, YH + + + + obo2:OAE_0000318 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/23236330 + + + + obo2:OAE_0000318 + arterial thrombosis AE + + + + obo2:OAE_0000318 + HPO: HP_0004420 + + + + obo2:OAE_0000318 + MedDRA: 10003178 + + + + obo2:OAE_0000318 + SIDER: C0151942 + + + + obo2:OAE_0000319 + a viral infection AE that demonstrates an influenza viral infection. Influenza is an infectious disease caused by RNA viruses of the family Orthomyxoviridae (the influenza viruses), that affects birds and mammals + + + + obo2:OAE_0000319 + SS, YH + + + + obo2:OAE_0000319 + WEB: http://en.wikipedia.org/wiki/Influenza + + + + obo2:OAE_0000319 + influenza AE + + + + obo2:OAE_0000319 + HPO: HP_0005376 + + + + obo2:OAE_0000319 + MDR: 10022000 + + + + obo2:OAE_0000319 + SIDER: C0021400 + + + + obo2:OAE_0000320 + a coronary artery disease AE with the outcome hardening of the coronary artery due to a build up of waxy plaque on the inside of blood vessels + + + + obo2:OAE_0000320 + DJ, SS, YH + + + + obo2:OAE_0000320 + WEB: http://medical-dictionary.thefreedictionary.com/Coronary+Arteriosclerosis + + + + obo2:OAE_0000320 + arteriosclerosis coronary artery AE + + + + obo2:OAE_0000320 + HPO: HP_0004929 + + + + obo2:OAE_0000320 + MedDRA: 10003211 + + + + obo2:OAE_0000320 + SIDER: C0010054 + + + + obo2:OAE_0000321 + injected limb mobility decreased AE is a mobility decreased AE that occurs in the limb in which injection is administered + + + + obo2:OAE_0000321 + SS, YH + + + + obo2:OAE_0000321 + injected limb mobility decreased AE + + + + obo2:OAE_0000322 + a haematoma AE that has an outcome of injection-site haematoma, which results in a collection of blood outside the blood vessels at the physical area of injection + + + + obo2:OAE_0000322 + SS, YH + + + + obo2:OAE_0000322 + injection-site haematoma AE + + + + obo2:OAE_0000322 + WEB: http://medical-dictionary.thefreedictionary.com/hematoma + + + + obo2:OAE_0000322 + http://en.wikipedia.org/wiki/Hematoma + + + + obo2:OAE_0000322 + injection-site hematoma AE + + + + obo2:OAE_0000322 + MedDRA: 10022066 + + + + obo2:OAE_0000323 + injection-site induration AE is an skin AE that results in hardening or thickening of tissue at the physical injection site + + + + obo2:OAE_0000323 + SS, YH + + + + obo2:OAE_0000323 + WEB: http://wordnetweb.princeton.edu/perl/webwn?s=induration + + + + obo2:OAE_0000323 + injection-site induration AE + + + + obo2:OAE_0000324 + injection-site pruritus AE is an pruritus AE that results in an unpleasant sensation that evokes the desire or reflex to scratch at the physical area of injection + + + + obo2:OAE_0000324 + SS, YH + + + + obo2:OAE_0000324 + WEB: http://en.wikipedia.org/wiki/Itch + + + + obo2:OAE_0000324 + WEB: http://medical-dictionary.thefreedictionary.com/pruritus + + + + obo2:OAE_0000324 + injection-site pruritus AE + + + + obo2:OAE_0000324 + MedDRA: 10022093 + + + + obo2:OAE_0000325 + injection-site rash AE is a rash AE that results in a change of the skin which affects its color, appearance or texture at the physical injection site + + + + obo2:OAE_0000325 + SS, YH + + + + obo2:OAE_0000325 + WEB: http://en.wikipedia.org/wiki/Rash + + + + obo2:OAE_0000325 + injection-site rash AE + + + + obo2:OAE_0000326 + injection-site warmth AE is a homeostasis AE that results in feeling of warmth at the physical injection site + + + + obo2:OAE_0000326 + SS, YH + + + + obo2:OAE_0000326 + injection-site warmth AE + + + + obo2:OAE_0000327 + A joint disorder AE that has an outcome of joint swelling, which is a joint disorder that results in a buildup of fluid in the soft tissue surrounding the joint + + + + obo2:OAE_0000327 + SS, YH + + + + obo2:OAE_0000327 + WEB: http://www.nlm.nih.gov/medlineplus/ency/article/003262.htm + + + + obo2:OAE_0000327 + joint swelling AE + + + + obo2:OAE_0000327 + HPO: HP_0005833 + + + + obo2:OAE_0000327 + MedDRA ID: 10023232 + + + + obo2:OAE_0000327 + SIDER: C0152031 + + + + obo2:OAE_0000328 + an adverse event that occurs in kidney. + + + + obo2:OAE_0000328 + SS, YH + + + + obo2:OAE_0000328 + kidney AE + + + + obo2:OAE_0000328 + MedDRA: 10038428 + + + + obo2:OAE_0000329 + a behavior and neurological AE that has an outcome of an increase in production, secretion, and shedding of tears + + + + obo2:OAE_0000329 + SS, YH + + + + obo2:OAE_0000329 + WEB: http://en.wikipedia.org/wiki/Tears + + + + obo2:OAE_0000329 + WEB: http://www.medterms.com/script/main/art.asp?articlekey=6199 + + + + obo2:OAE_0000329 + lacrimation increased AE + + + + obo2:OAE_0000329 + HPO: HP_0009926 + + + + obo2:OAE_0000329 + MedDRA ID: 10023644 + + + + obo2:OAE_0000329 + MedDRA: 10023644 + + + + obo2:OAE_0000329 + SIDER: C0152227 + + + + obo2:OAE_0000330 + lip swelling AE is an edema (swelling) AE that results in enlargement or protuberance in the lip + + + + obo2:OAE_0000330 + SS, YH + + + + obo2:OAE_0000330 + WEB: http://en.wikipedia.org/wiki/Swelling_%28medical%29 + + + + obo2:OAE_0000330 + lip swelling AE + + + + obo2:OAE_0000330 + HPO: HP_0000159 + + + + obo2:OAE_0000330 + MedDRA ID: 10024570 + + + + obo2:OAE_0000330 + SIDER: C0240211 + + + + obo2:OAE_0000331 + A lymphadenopathy AE that results in swollen/enlarged lymph nodes + + + + obo2:OAE_0000331 + SS, YH + + + + obo2:OAE_0000331 + WEB: http://en.wikipedia.org/wiki/Lymphadenopathy + + + + obo2:OAE_0000331 + lymphadenitis AE + + + + obo2:OAE_0000331 + HPO: HP_0002840 + + + + obo2:OAE_0000331 + SIDER: C0024205 + + + + obo2:OAE_0000332 + mobility decreased AE is a nervous system AE that results in difficulty in movement leading to less ability to move part(s) of body + + + + obo2:OAE_0000332 + SS, YH + + + + obo2:OAE_0000332 + mobility decreased AE + + + + obo2:OAE_0000332 + HPO: HP_0006217 + + + + obo2:OAE_0000332 + MedDRA ID: 10048334 + + + + obo2:OAE_0000332 + SIDER: C0700572 + + + + obo2:OAE_0000333 + a muscle AE that has an outcome of muscular weakness AE (i.e., lack of muscle strength). + + + + obo2:OAE_0000333 + SS, YH + + + + obo2:OAE_0000333 + WEB: http://en.wikipedia.org/wiki/Muscular_weakness + + + + obo2:OAE_0000333 + muscular weakness AE + + + + obo2:OAE_0000333 + HPO: HP_0001324 + + + + obo2:OAE_0000333 + MedDRA ID: 10028372 + + + + obo2:OAE_0000333 + SIDER: C0151786 + + + + obo2:OAE_0000334 + a sensory capability AE that has an outcome of a sensation of stiffness in muscles and skeleton + + + + obo2:OAE_0000334 + SS, YH + + + + obo2:OAE_0000334 + musculoskeletal stiffness AE + + + + obo2:OAE_0000334 + HPO: HP_0003552 + + + + obo2:OAE_0000334 + MedDRA ID: 10052904 + + + + obo2:OAE_0000334 + SIDER: C0948525 + + + + obo2:OAE_0000335 + nasal congestion AE is a respiratory system AE that results in a blockage of the nasal passages usually due to membranes lining the nose becoming swollen from inflamed blood vessels + + + + obo2:OAE_0000335 + SS, YH + + + + obo2:OAE_0000335 + WEB: http://en.wikipedia.org/wiki/Nasal_congestion + + + + obo2:OAE_0000335 + nasal congestion AE + + + + obo2:OAE_0000335 + HPO: HP_0001742 + + + + obo2:OAE_0000335 + SIDER: C0027424 + + + + obo2:OAE_0000336 + a respiratory system inflammation AE which has an outcome of nasopharyngitis, a respiratory system inflammation that results in common cold, a contagious, viral infectious disease of the upper respiratory system + + + + obo2:OAE_0000336 + a respiratory system inflammation AE which has an outcome of nasopharyngitis, a respiratory system inflammation that results in common cold, a contagious, viral infectious disease of the upper respiratory system + + + + obo2:OAE_0000336 + SS, YH + + + + obo2:OAE_0000336 + common cold AE + + + + obo2:OAE_0000336 + WEB: http://en.wikipedia.org/wiki/Nasopharyngitis + + + + obo2:OAE_0000336 + nasopharyngitis AE + + + + obo2:OAE_0000336 + HPO: HP_0002087 + + + + obo2:OAE_0000336 + SIDER: C0027441 + + + + obo2:OAE_0000337 + an neuropathy AE that results in a damage to the peripheral nervous system (PNS, outside the brain and spinal cord), the vast communication network that transmits information from the brain and the spinal cord (the central nervous system) to every other part of the body. + + + + obo2:OAE_0000337 + SS, YH + + + + obo2:OAE_0000337 + neuropathy peripheral AE + + + + obo2:OAE_0000337 + WEB: http://en.wikipedia.org/wiki/Peripheral_neuropathy + + + + obo2:OAE_0000337 + WEB: http://www.ninds.nih.gov/disorders/peripheralneuropathy/detail_peripheralneuropathy.htm + + + + obo2:OAE_0000337 + peripheral neuropathy AE + + + + obo2:OAE_0000337 + MedDRA: 10029331 + + + + obo2:OAE_0000338 + ocular hyperaemia AE is an eye disorder AE that results in severe redness and irritation of the eyes + + + + obo2:OAE_0000338 + SS, YH + + + + obo2:OAE_0000338 + ocular hyperaemia AE + + + + obo2:OAE_0000338 + WEB: http://www.med.miami.edu/news/view.asp?id=259 + + + + obo2:OAE_0000338 + ocular hyperemia AE + + + + obo2:OAE_0000338 + MedDRA ID: 10030041 + + + + obo2:OAE_0000339 + a pain AE that has an outcome of oropharyngeal pain + + + + obo2:OAE_0000339 + SS, YH + + + + obo2:OAE_0000339 + WEB: http://en.wikipedia.org/wiki/Oropharyngeal_airway + + + + obo2:OAE_0000339 + oropharyngeal pain is a pain in oral airway + + + + obo2:OAE_0000339 + oropharyngeal pain AE + + + + obo2:OAE_0000339 + HPO: HP_0010833 + + + + obo2:OAE_0000339 + MedDRA ID: 10068319 + + + + obo2:OAE_0000339 + SIDER: C2363731 + + + + obo2:OAE_0000340 + an ear disorder AE which has an outcome of otitis media that results in inflammation of the middle ear, or middle ear infection + + + + obo2:OAE_0000340 + SS, YH + + + + obo2:OAE_0000340 + WEB: http://en.wikipedia.org/wiki/Otitis_media + + + + obo2:OAE_0000340 + otitis media AE + + + + obo2:OAE_0000340 + HPO: HP_0008623 + + + + obo2:OAE_0000340 + SIDER: C0029882 + + + + obo2:OAE_0000341 + an inflammation AE that has an outcome of pericaditis, which is a cardiovascular disorder that results in a condition in which the sac-like covering around the heart (pericardium) becomes inflamed + + + + obo2:OAE_0000341 + SS, YH + + + + obo2:OAE_0000341 + WEB: http://www.nlm.nih.gov/medlineplus/ency/article/000182.htm + + + + obo2:OAE_0000341 + pericarditis AE + + + + obo2:OAE_0000341 + HPO: HP_0001701 + + + + obo2:OAE_0000341 + MedDRA: 10034484 + + + + obo2:OAE_0000341 + SIDER: C0031046 + + + + obo2:OAE_0000342 + pharyngeal edema AE is an edema AE that results in an bbnormal fluid accumulation in TISSUES or body cavities in pharynx (throat swelling). + + + + obo2:OAE_0000342 + SS, YH + + + + obo2:OAE_0000342 + pharyngeal oedema AE + + + + obo2:OAE_0000342 + WEB: http://www.ncbi.nlm.nih.gov/mesh/68004487?ordinalpos=1&itool=EntrezSystem2.PEntrez.Mesh.Mesh_ResultsPanel.Mesh_RVDocSum + + + + obo2:OAE_0000342 + pharyngeal edema AE + + + + obo2:OAE_0000343 + pharyngitis AE is a digestive system AE that results in an inflammation of the throat or pharynx + + + + obo2:OAE_0000343 + SS, YH + + + + obo2:OAE_0000343 + WEB: http://en.wikipedia.org/wiki/Pharyngitis + + + + obo2:OAE_0000343 + pharyngitis AE + + + + obo2:OAE_0000343 + HPO: HP_0100776 + + + + obo2:OAE_0000343 + MedDRA ID: 10034835 + + + + obo2:OAE_0000343 + SIDER: C0031350 + + + + obo2:OAE_0000344 + a pain AE that has an outcome of pharyngolaryngeal pain + + + + obo2:OAE_0000344 + pharyngolaryngeal pain is a pain in sinus and throat + + + + obo2:OAE_0000344 + SS, YH + + + + obo2:OAE_0000344 + WEB: http://www.wordinfo.info/words/index/info/view_unit/1631/ + + + + obo2:OAE_0000344 + pharyngolaryngeal pain AE + + + + obo2:OAE_0000344 + HPO: HP_0010833 + + + + obo2:OAE_0000344 + SIDER: C0858635 + + + + obo2:OAE_0000345 + rash macular AE is a rash AE that results in a skin eruption in which the lesions are flat and less than 1 cm in diameter + + + + obo2:OAE_0000345 + SS, YH + + + + obo2:OAE_0000345 + WEB: http://medical-dictionary.thefreedictionary.com/macular+rash + + + + obo2:OAE_0000345 + rash macular AE + + + + obo2:OAE_0000345 + HPO: HP_0000988 + + + + obo2:OAE_0000345 + SIDER: C0221201 + + + + obo2:OAE_0000346 + rash papular AE is a rash adverse event that results in a change of the skin which affects its color, appearance or texture to a form similar to a papule + + + + obo2:OAE_0000346 + SS, YH + + + + obo2:OAE_0000346 + WEB: http://en.wikipedia.org/wiki/Rash + + + + obo2:OAE_0000346 + rash papular AE + + + + obo2:OAE_0000346 + HPO: HP_0007432 + + + + obo2:OAE_0000346 + MedDRA: 10037876 + + + + obo2:OAE_0000346 + SIDER: C0221202 + + + + obo2:OAE_0000347 + respiratory distress AE is a respiratory system AE that results in a severe lung disease caused by a variety of direct and indirect issues. It is characterized by inflammation of the lung parenchyma leading to impaired gas exchange with concomitant systemic release of inflammatory mediators causing inflammation, hypoxemia and frequently resulting in multiple organ failure. + + + + obo2:OAE_0000347 + SS, YH + + + + obo2:OAE_0000347 + WEB: http://en.wikipedia.org/wiki/Acute_respiratory_distress_syndrome + + + + obo2:OAE_0000347 + respiratory distress AE + + + + obo2:OAE_0000347 + HPO: HP_0002747 + + + + obo2:OAE_0000347 + MedDRA ID: 10038687 + + + + obo2:OAE_0000347 + MedDRA: 10038687 + + + + obo2:OAE_0000347 + SIDER: C0476273 + + + + obo2:OAE_0000348 + respiratory tract congestion AE is a respiratory system AE that results in congestion in respiratory tract + + + + obo2:OAE_0000348 + SS, YH + + + + obo2:OAE_0000348 + respiratory tract congestion AE + + + + obo2:OAE_0000349 + retching AE is a digestive system AE that results in a process in the human body where gastric (and sometimes duodenal) contents are forced into the esophagus, but do not enter the pharynx + + + + obo2:OAE_0000349 + SS, YH + + + + obo2:OAE_0000349 + WEB: http://en.wikipedia.org/wiki/Retching + + + + obo2:OAE_0000349 + retching AE + + + + obo2:OAE_0000349 + MedDRA ID: 10038776 + + + + obo2:OAE_0000349 + MedDRA: 10038776 + + + + obo2:OAE_0000350 + rhinitis AE is a respiratory system inflammation characterized by runny nose,irritation and inflammation of some internal areas of the nose + + + + obo2:OAE_0000350 + SS, YH + + + + obo2:OAE_0000350 + runny nose + + + + obo2:OAE_0000350 + WEB: http://en.wikipedia.org/wiki/Rhinitis + + + + obo2:OAE_0000350 + WEB: http://medical-dictionary.thefreedictionary.com/rhinitis + + + + obo2:OAE_0000350 + rhinitis AE + + + + obo2:OAE_0000350 + HPO: HP_0002257 + + + + obo2:OAE_0000350 + MedDRA: 10028116 + + + + obo2:OAE_0000350 + SIDER: C0035455 + + + + obo2:OAE_0000351 + rhinorrhoea AE is a respiratory system AE that results in runny nose, an unusually significant amount of nasal fluid + + + + obo2:OAE_0000351 + SS, YH + + + + obo2:OAE_0000351 + rhinorrhoea AE + + + + obo2:OAE_0000351 + WEB: http://en.wikipedia.org/wiki/Rhinorrhoea + + + + obo2:OAE_0000351 + rhinorrhea AE + + + + obo2:OAE_0000352 + a pain AE that occurs in shoulder + + + + obo2:OAE_0000352 + shoulder pain is a pain iin or around the shoulder joint + + + + obo2:OAE_0000352 + SS, YH + + + + obo2:OAE_0000352 + WEB: http://www.nlm.nih.gov/medlineplus/ency/article/003171.htm + + + + obo2:OAE_0000352 + shoulder pain AE + + + + obo2:OAE_0000353 + sinus congestion AE is a nasal congestion AE that results in blockage of the air cavities in the cranial bones or nasal passages usually due to membranes lining the nose becoming swollen from inflamed blood vessels + + + + obo2:OAE_0000353 + SS, YH + + + + obo2:OAE_0000353 + WEB: http://en.wikipedia.org/wiki/Sinus_%28anatomy%29, http://en.wikipedia.org/wiki/Nasal_congestion + + + + obo2:OAE_0000353 + sinus congestion AE + + + + obo2:OAE_0000353 + HPO: HP_0002257 + + + + obo2:OAE_0000353 + SIDER: C0152029 + + + + obo2:OAE_0000354 + sneezing AE is a respiratory system adverse event that results in sternutation, a semi-autonomous, convulsive expulsion of air from the lungs through the nose and mouth, usually caused by foreign particles irritating the nasal mucosa + + + + obo2:OAE_0000354 + SS, YH + + + + obo2:OAE_0000354 + sternutation + + + + obo2:OAE_0000354 + WEB: http://en.wikipedia.org/wiki/Sneezing + + + + obo2:OAE_0000354 + sneezing AE + + + + obo2:OAE_0000354 + MedDRA ID: 10041232 + + + + obo2:OAE_0000355 + an increased heart rate AE that has an outcome of tachycardia, which is an increased heart rate that exceeds the normal range for a resting heartrate (heartrate in an inactive or sleeping individual) + + + + obo2:OAE_0000355 + SS, YH + + + + obo2:OAE_0000355 + WEB: http://en.wikipedia.org/wiki/Tachycardia + + + + obo2:OAE_0000355 + tachycardia AE + + + + obo2:OAE_0000355 + HPO: HP_0001649 + + + + obo2:OAE_0000355 + MedDRA ID: 10043071 + + + + obo2:OAE_0000355 + SIDER: C0039231 + + + + obo2:OAE_0000356 + a tendon disorder AE that has an outcome of tendonitis + + + + obo2:OAE_0000356 + SS, YH + + + + obo2:OAE_0000356 + tendinitis AE + + + + obo2:OAE_0000356 + WEB: http://en.wikipedia.org/wiki/Tendinitis + + + + obo2:OAE_0000356 + tendonitis is a tendon disorder that results in an inflammation of a tendon + + + + obo2:OAE_0000356 + tendonitis AE + + + + obo2:OAE_0000356 + HPO: HP_0100261 + + + + obo2:OAE_0000356 + SIDER: C0039503 + + + + obo2:OAE_0000357 + a sensory capability AE that has an outcome of a sensation of tightness in the throat + + + + obo2:OAE_0000357 + throat tightness AE + + + + obo2:OAE_0000357 + MedDRA ID: 10043528 + + + + obo2:OAE_0000358 + an infection AE is a respiratory system AE that results in illnesses caused by an acute infection which involves the upper respiratory tract: nose, sinuses, pharynx or larynx + + + + obo2:OAE_0000358 + SS, YH + + + + obo2:OAE_0000358 + URI, URTI + + + + obo2:OAE_0000358 + WEB: http://en.wikipedia.org/wiki/Upper_respiratory_tract_infection + + + + obo2:OAE_0000358 + upper respiratory tract infection AE + + + + obo2:OAE_0000358 + HPO: HP_0002788 + + + + obo2:OAE_0000358 + SIDER: C0041912 + + + + obo2:OAE_0000359 + a viral infection AE that results in an acute contagious diseased caused by herpes varicella zoster virus; causes a rash of vesicles on the face and body. + + + + obo2:OAE_0000359 + SS, YH + + + + obo2:OAE_0000359 + chicken pox AE + + + + obo2:OAE_0000359 + WEB: http://wordnetweb.princeton.edu/perl/webwn?s=varicella + + + + obo2:OAE_0000359 + varicella AE + + + + obo2:OAE_0000359 + HPO: HP_0005428 + + + + obo2:OAE_0000359 + SIDER: C0008049 + + + + obo2:OAE_0000360 + a paresthesia AE that occurs in oral area. + + + + obo2:OAE_0000360 + SS, YH + + + + obo2:OAE_0000360 + paraesthesia oral AE + + + + obo2:OAE_0000360 + http://www.answers.com/topic/oral-paresthesia + + + + obo2:OAE_0000360 + paraesthesia oral is a paresthesia that results in a numbness or tingling that occurs in the mucosa or tissues of the oral cavity. + + + + obo2:OAE_0000360 + paresthesia oral AE + + + + obo2:OAE_0000360 + HPO: HP_0003401 + + + + obo2:OAE_0000360 + MedDRA ID: 10057372 + + + + obo2:OAE_0000360 + SIDER: C0521591 + + + + obo2:OAE_0000361 + an abnormal body temperature AE which has an outcome of fever + + + + obo2:OAE_0000361 + YH, SS + + + + obo2:OAE_0000361 + body temperature increased AE + + + + obo2:OAE_0000361 + febrile response + + + + obo2:OAE_0000361 + pyrexia AE + + + + obo2:OAE_0000361 + Axelrod YK1, Diringer MN. Temperature management in acute neurologic disorders. Neurol Clin. 2008 May;26(2):585-603, xi. doi: 10.1016/j.ncl.2008.02.005. PMID: 18514828. + + + + obo2:OAE_0000361 + WEB: http://en.wikipedia.org/wiki/Pyrexia + + + + obo2:OAE_0000361 + Fever is a frequent medical sign that describes an increase in internal body temperature to levels above normal. Fever is characterized as a temporary elevation in the body's thermoregulatory set-point, usually by about 1-2 °F). + + + + obo2:OAE_0000361 + fever AE + + + + obo2:OAE_0000361 + MedDRA: 10005911 + + + + obo2:OAE_0000361 + MedDRA: 10037660 + + + + obo2:OAE_0000362 + a skin adverse event that has the outcome of rash + + + + obo2:OAE_0000362 + YH + + + + obo2:OAE_0000362 + A rash is a change of the skin which affects its color, appearance, or texture. A rash may be localized in one part of the body, or affect all the skin. Rashes may cause the skin to change color, itch, become warm, bumpy, dry, cracked or blistered, swell and may be painful. + + + + obo2:OAE_0000362 + rash AE + + + + obo2:OAE_0000362 + HPO: HP_0000988 + + + + obo2:OAE_0000362 + MDR: 10037844 + + + + obo2:OAE_0000362 + MedDRA ID: 10037844 + + + + obo2:OAE_0000362 + MedDRA: 10037844 + + + + obo2:OAE_0000362 + SIDER: C0015230 + + + + obo2:OAE_0000363 + an adverse event that displays a pathogen infection. + + + + obo2:OAE_0000363 + change of name from 'infection adverse event' to 'infectious adverse event' on 09/23/13 for a better clinical relevance, move 'infection adverse event' as an alternative term - SS + + + + obo2:OAE_0000363 + YH + + + + obo2:OAE_0000363 + infectious adverse event + + + + obo2:OAE_0000363 + WEB: http://medical-dictionary.thefreedictionary.com/infection + + + + obo2:OAE_0000363 + infection AE + + + + obo2:OAE_0000363 + MedDRA: 10021789 + + + + obo2:OAE_0000364 + An AE that has an outcome of syndrome. Syndrome is the association of several clinically recognizable features, signs (observed by a physician), symptoms (reported by the patient), phenomena or characteristics that often occur together, so that the presence of one feature alerts the physician to the presence of the others. + + + + obo2:OAE_0000364 + YH + + + + obo2:OAE_0000364 + syndrome AE + + + + obo2:OAE_0000365 + a sensory capability AE that has an outcome of emotional state of excitement or restlessness + + + + obo2:OAE_0000365 + YH + + + + obo2:OAE_0000365 + agitation AE + + + + obo2:OAE_0000365 + HPO: HP_0000711 + + + + obo2:OAE_0000365 + MedDRA ID: 10001497 + + + + obo2:OAE_0000365 + SIDER: C0085631 + + + + obo2:OAE_0000366 + injection-site AE is an AE that occurs in an injection site (e.g., during vaccination). + + + + obo2:OAE_0000366 + YH + + + + obo2:OAE_0000366 + injection-site reaction + + + + obo2:OAE_0000366 + local reaction AE + + + + obo2:OAE_0000366 + injection-site adverse event + + + + obo2:OAE_0000366 + MDR: 10022095 + + + + obo2:OAE_0000367 + a hypersensitivity AE which has an outcome of injection-site hypersensitivity + + + + obo2:OAE_0000367 + YH + + + + obo2:OAE_0000367 + injection-site hypersensitivity AE + + + + obo2:OAE_0000368 + an edema AE which occurs at the injection site. In this case, a collection of fluid at the injection site is found. + + + + obo2:OAE_0000368 + YH, RR + + + + obo2:OAE_0000368 + injection-site oedema AE + + + + obo2:OAE_0000368 + injection-site swelling AE + + + + obo2:OAE_0000368 + WEB: http://www.uptodate.com/contents/edema-swelling-beyond-the-basics + + + + obo2:OAE_0000368 + injection-site edema AE + + + + obo2:OAE_0000368 + MedDRA: 10053425 + + + + obo2:OAE_0000369 + a pain AE that occurs in an injection site of a medical intervention + + + + obo2:OAE_0000369 + YH + + + + obo2:OAE_0000369 + injection-site pain AE + + + + obo2:OAE_0000369 + MedDRA: 10022086 + + + + obo2:OAE_0000370 + an inflammation AE which has an outcome of injection-site inflammation + + + + obo2:OAE_0000370 + YH + + + + obo2:OAE_0000370 + injection-site inflammation AE + + + + obo2:OAE_0000371 + a hemorrhage AE that has an outcome of injection-site hemorrhage + + + + obo2:OAE_0000371 + YH + + + + obo2:OAE_0000371 + injection-site hemorrhage AE + + + + obo2:OAE_0000371 + MedDRA: 10022067 + + + + obo2:OAE_0000372 + an injection-site AE that display an injection-site mass + + + + obo2:OAE_0000372 + YH, SS + + + + obo2:OAE_0000372 + injection site nodule AE + + + + obo2:OAE_0000372 + injection-site mass is a mass at physical injection site + + + + obo2:OAE_0000372 + injection-site mass AE + + + + obo2:OAE_0000373 + a skin adverse event that has an outcome of pruritus + + + + obo2:OAE_0000373 + YH, SS + + + + obo2:OAE_0000373 + itch + + + + obo2:OAE_0000373 + itching + + + + obo2:OAE_0000373 + pruritus generalised AE + + + + obo2:OAE_0000373 + WEB: http://www.ncbi.nlm.nih.gov/sites/entrez?db=mesh&cmd=DetailsSearch&term=pruritus+generalised&log$=activity + + + + obo2:OAE_0000373 + Pruritus is an itch (Latin: pruritus), i.e., an unpleasant sensation that evokes the desire or reflex to scratch. + + + + obo2:OAE_0000373 + pruritus AE + + + + obo2:OAE_0000373 + HPO: HP_0000989 + + + + obo2:OAE_0000373 + MDR: 10037087 + + + + obo2:OAE_0000373 + MedDRA ID: 10037087 + + + + obo2:OAE_0000373 + SIDER: C0033774 + + + + obo2:OAE_0000374 + a sensory capability AE that has an outcome of pain in a patient + + + + obo2:OAE_0000374 + YH + + + + obo2:OAE_0000374 + pain AE + + + + obo2:OAE_0000374 + HPO: HP_0010833 + + + + obo2:OAE_0000374 + SIDER: C0030193 + + + + obo2:OAE_0000375 + a pain AE that has outcome of myalgia. Myalgia means "muscle pain" and is a symptom of many diseases and disorders. + + + + obo2:OAE_0000375 + YH + + + + obo2:OAE_0000375 + muscle pain AE + + + + obo2:OAE_0000375 + myalgia AE + + + + obo2:OAE_0000375 + HPO: HP_0003326 + + + + obo2:OAE_0000375 + MDR: 10028411 + + + + obo2:OAE_0000375 + MedDRA ID: 10028411 + + + + obo2:OAE_0000375 + SIDER: C0231528 + + + + obo2:OAE_0000376 + Urticaria AE is a rash AE notable for dark red, raised, itchy bumps. + + + + obo2:OAE_0000376 + YH + + + + obo2:OAE_0000376 + hives + + + + obo2:OAE_0000376 + urticaria AE + + + + obo2:OAE_0000376 + HPO: HP_0001025 + + + + obo2:OAE_0000376 + MedDRA ID: 10046735 + + + + obo2:OAE_0000376 + SIDER: C0042109 + + + + obo2:OAE_0000377 + a pain AE that has an outcome of headache + + + + obo2:OAE_0000377 + YH + + + + obo2:OAE_0000377 + headache AE + + + + obo2:OAE_0000377 + HPO: HP_0002315 + + + + obo2:OAE_0000377 + SIDER: C0018681 + + + + obo2:OAE_0000378 + an AE that occurs in respiratory system. + + + + obo2:OAE_0000378 + I created this term and make it to be an umbrella term for different disorder terms related to respiratory system. --Oliver He + + + + obo2:OAE_0000378 + YH + + + + obo2:OAE_0000378 + respiratory system AE + + + + obo2:OAE_0000379 + a leukocyte cell number abnormal AE that has an outcome of greater than normal number of leukocytes, or nucleated cells of the myeloid or lymphoid lineages, found in blood or other tissue + + + + obo2:OAE_0000379 + According to the Vaccine Adverse Event Reporting System (VAERS), 'leukocytosis' is an adverse event that was mentioned in 1,021 VAERS reports (0.8%) during1991-2001 (Reference: PMID: 12825543). + + + + obo2:OAE_0000379 + SS, YH, EB + + + + obo2:OAE_0000379 + increased leukocyte cell number AE + + + + + obo2:OAE_0000379 + leukocytosis AE + + + + obo2:OAE_0000379 + white blood cell count increased AE + + + + obo2:OAE_0000379 + WEB: http://en.wikipedia.org/wiki/Leukocytosis + + + + obo2:OAE_0000379 + leukocyte cell number increased AE + + + + obo2:OAE_0000379 + MP: MP_0000218 + + + + obo2:OAE_0000379 + MedDRA: 10024378 + + + + obo2:OAE_0000379 + MedDRA: 10047943 + + + + obo2:OAE_0000380 + a leukocyte cell number abnormal AE that has an outcome of reduction in the number of leukocytes, or of nucleated cells of the myeloid or lymphoid lineages, found in blood or other tissue + + + + obo2:OAE_0000380 + According to the Vaccine Adverse Event Reporting System (VAERS), 'leukopenia' is an adverse event that was mentioned in 417 VAERS reports (0.3%) during1991-2001 (Reference: PMID: 12825543). + + + + obo2:OAE_0000380 + decreased leukocyte cell number AE + + + + obo2:OAE_0000380 + white blood cell count decreased AE + + + + obo2:OAE_0000380 + leukocyte cell number decreased AE + + + + obo2:OAE_0000380 + MP: MP_0000221 + + + + obo2:OAE_0000380 + MedDRA: 10047942 + + + + obo2:OAE_0000381 + a cardiovascular disorder AE that has an outcome of abnormal blood pressure, representing altered tension of the blood within the systemic arteries + + + + obo2:OAE_0000381 + abnormal blood pressure AE + + + + obo2:OAE_0000381 + MP: MP_0000230 + + + + obo2:OAE_0000382 + a muscle adverse event which has an outcome of asthenia, which is a medical term denoting symptoms of physical weakness and loss of strength. + + + + obo2:OAE_0000382 + YH + + + + obo2:OAE_0000382 + asthenia AE + + + + obo2:OAE_0000382 + HPO: HP_0001324 + + + + obo2:OAE_0000382 + MedDRA ID: 10003549 + + + + obo2:OAE_0000382 + SIDER: C0004093 + + + + obo2:OAE_0000383 + a muscle pain AE that has an outcome of muscle ache. + + + + obo2:OAE_0000383 + YH + + + + obo2:OAE_0000383 + muscle ache AE + + + + obo2:OAE_0000384 + A rash AE that shows a flat, red area on the skin overed with small confluent bumps. + + + + obo2:OAE_0000384 + YH + + + + obo2:OAE_0000384 + WEB: http://en.wikipedia.org/wiki/Maculopapular_rash + + + + obo2:OAE_0000384 + maculopapular rash AE + + + + obo2:OAE_0000384 + MedDRA: 10037868 + + + + obo2:OAE_0000385 + An joint disorder AE that has an outcome of arthralgia. Arthralgia means joint pain. It is a symptom of injury, infection, illnesses (in particular arthritis) or an allergic reaction to medication. According to MeSH, the term "arthralgia" should only be used when the condition is non-inflammatory, and the term "arthritis" should be used when the condition is inflammatory. + + + + obo2:OAE_0000385 + YH + + + + obo2:OAE_0000385 + arthralgia AE + + + + obo2:OAE_0000385 + HPO: HP_0002829 + + + + obo2:OAE_0000385 + MDR: 10003239 + + + + obo2:OAE_0000385 + SIDER: C0003862 + + + + obo2:OAE_0000386 + vesiculobullous rash AE is a rash AE characterized by serous-fluid-filled vesicles (blisters) + + + + obo2:OAE_0000386 + YH + + + + obo2:OAE_0000386 + vesiculobullous rash AE + + + + obo2:OAE_0000386 + HPO: HP_0000988 + + + + obo2:OAE_0000386 + SIDER: C0151883 + + + + obo2:OAE_0000387 + a syndrome AE which has an outcome of screaming syndrome + + + + obo2:OAE_0000387 + YH + + + + obo2:OAE_0000387 + screaming syndrome AE + + + + obo2:OAE_0000388 + a sensory capability AE that has an outcome of dizziness + + + + obo2:OAE_0000388 + YH, SS + + + + obo2:OAE_0000388 + Dizziness describes a number of subjective symptoms, which the patient may describe as feelings of lightheadedness, floating, wooziness, giddiness, confusion, disorientation or loss of balance. Medical terms include vertigo, disequilibrium, pre-syncope or syncoptic episode. Causes may stem from a variety of failures of equilibrioception, hypotension, cerebral hypoxia or a reaction to environmental chemicals or drugs. + + + + obo2:OAE_0000388 + dizziness AE + + + + obo2:OAE_0000388 + HPO: HP_0002321 + + + + obo2:OAE_0000388 + MedDRA ID: 10013573 + + + + obo2:OAE_0000388 + SIDER: C0012833 + + + + obo2:OAE_0000389 + peripheral edema AE is an edema AE that results in swelling of tissues, usually in the lower limbs, due to the accumulation of fluids + + + + obo2:OAE_0000389 + YH, SS + + + + obo2:OAE_0000389 + edema peripheral AE + + + + obo2:OAE_0000389 + oedema peripheral AE + + + + obo2:OAE_0000389 + WEB: http://en.wikipedia.org/wiki/Peripheral_edema + + + + obo2:OAE_0000389 + peripheral edema AE + + + + obo2:OAE_0000389 + MedDRA: 10030124 + + + + obo2:OAE_0000390 + a sensory capability AE that has an outcome of malaise + + + + obo2:OAE_0000390 + YH + + + + obo2:OAE_0000390 + Malaise is a feeling of general discomfort or uneasiness, an "out of sorts" feeling. Malaise is often the first indication of an infection or other disease. Vaccination may induce malaise. + + + + obo2:OAE_0000390 + malaise AE + + + + obo2:OAE_0000390 + HPO: HP_0002321 + + + + obo2:OAE_0000390 + MDR: 10025482 + + + + obo2:OAE_0000390 + SIDER: C0231218 + + + + obo2:OAE_0000391 + a behavior and neurological AE that has an outcome of somnolence + + + + obo2:OAE_0000391 + YH, SS + + + + obo2:OAE_0000391 + drowsiness + + + + obo2:OAE_0000391 + Somnolence (or "drowsiness") is a state of near-sleep, a strong desire for sleep, or sleeping for unusually long periods (c.f. hypersomnia). + + + + obo2:OAE_0000391 + somnolence AE + + + + obo2:OAE_0000391 + HPO: HP_0001262 + + + + obo2:OAE_0000391 + MedDRA ID: 10041349 + + + + obo2:OAE_0000391 + SIDER: C2830004 + + + + obo2:OAE_0000392 + a sensory neuropathy AE that shows a sensation of tingling, pricking, or numbness of a person's skin with no apparent long-term physical effect. + + + + obo2:OAE_0000392 + YH + + + + obo2:OAE_0000392 + WEB: http://en.wikipedia.org/wiki/Paraesthesia + + + + obo2:OAE_0000392 + Paresthesia is more generally known as the feeling of "pins and needles" or of a limb being "asleep" (although this is not directly related to the phenomenon of sleep). The manifestation of paresthesia may be transient or chronic. + + + + obo2:OAE_0000392 + paresthesia AE + + + + obo2:OAE_0000392 + MedDRA: 10033775 + + + + obo2:OAE_0000393 + a behavior and neurological AE that has an outcome of abnormal crying in a patient + + + + obo2:OAE_0000393 + YH + + + + obo2:OAE_0000393 + crying abnormal AE + + + + obo2:OAE_0000393 + MedDRA: 10011469 + + + + obo2:OAE_0000394 + a sensory capability AE that has an outcome of chills + + + + obo2:OAE_0000394 + YH + + + + obo2:OAE_0000394 + feeling cold AE + + + + obo2:OAE_0000394 + Chills refers to feeling cold after an exposure to a cold environment. The word can also refer to an episode of shivering, accompanied by paleness and feeling cold. + + + + obo2:OAE_0000394 + chills AE + + + + obo2:OAE_0000394 + HPO: HP_0001945 + + + + obo2:OAE_0000394 + MedDRA: 10008531 + + + + obo2:OAE_0000394 + SIDER: C0085593 + + + + obo2:OAE_0000395 + a behavior and neurological AE that has an outcome of stupor + + + + obo2:OAE_0000395 + YH + + + + obo2:OAE_0000395 + Stupor is the lack of critical cognitive function and level of consciousness wherein a sufferer is almost entirely unresponsive and only responds to base stimuli such as pain. The word derives from the Latin stupure, meaning insensible. Being characterised by impairments of reactions to external stimuli, in this case, vaccine immunization. + + + + obo2:OAE_0000395 + stupor AE + + + + obo2:OAE_0000395 + HPO: HP_0004372 + + + + obo2:OAE_0000395 + MedDRA ID: 10042264 + + + + obo2:OAE_0000395 + SIDER: C0085628 + + + + obo2:OAE_0000396 + a gustatory system AE which has an outcome of anorexia, which is the decreased sensation of appetite. + + + + obo2:OAE_0000396 + YH + + + + obo2:OAE_0000396 + anorexia nervosa + + + + obo2:OAE_0000396 + decreased appetite AE + + + + obo2:OAE_0000396 + anorexia AE + + + + obo2:OAE_0000396 + HPO: HP_0002039 + + + + obo2:OAE_0000396 + MedDRA: 10002649 + + + + obo2:OAE_0000396 + MedDRA: 10061428 + + + + obo2:OAE_0000396 + SIDER: C0003123 + + + + obo2:OAE_0000397 + face edema AE is an edema AE that results in facial swelling, the build-up of fluid in the tissues of the face. Swelling may also affect the neck and upper arms + + + + obo2:OAE_0000397 + YH, SS + + + + obo2:OAE_0000397 + face oedema AE + + + + obo2:OAE_0000397 + WEB:http://www.nlm.nih.gov/medlineplus/ency/article/003105.htm + + + + obo2:OAE_0000397 + swelling face + + + + obo2:OAE_0000397 + face edema AE + + + + obo2:OAE_0000397 + MedDRA: 10016029 + + + + obo2:OAE_0000397 + MedDRA: 10042682 + + + + obo2:OAE_0000398 + cough increased AE is an abnormal respiration AE that results in a reflex that keeps your throat and airways clear + + + + obo2:OAE_0000398 + YH, SS + + + + obo2:OAE_0000398 + cough + + + + obo2:OAE_0000398 + WEB: http://medical-dictionary.thefreedictionary.com/cough + + + + obo2:OAE_0000398 + WEB: http://www.nlm.nih.gov/medlineplus/cough.html + + + + obo2:OAE_0000398 + cough increased AE + + + + obo2:OAE_0000398 + MedDRA: 10011224 + + + + obo2:OAE_0000399 + a syndrome AE that has an outcome of a flu syndrome AE and occurs after a medical intervention. + + + + obo2:OAE_0000399 + YH + + + + obo2:OAE_0000399 + flu-like symptom AE + + + + obo2:OAE_0000399 + flu syndrome AE + + + + obo2:OAE_0000400 + a sensory capability AE that has an outcome of loss of consciousness, fainting + + + + obo2:OAE_0000400 + YH, SS + + + + obo2:OAE_0000400 + Syncope is the medical term for fainting, a sudden, usually temporary, loss of consciousness. + + + + obo2:OAE_0000400 + fainting + + + + obo2:OAE_0000400 + WEB: http://en.wikipedia.org/wiki/Syncope_%28medicine%29 + + + + obo2:OAE_0000400 + WEB: http://en.wikipedia.org/wiki/Unconsciousness + + + + obo2:OAE_0000400 + syncope AE + + + + obo2:OAE_0000400 + HPO: HP_0001279 + + + + obo2:OAE_0000400 + MedDRA ID: 10042772 + + + + obo2:OAE_0000400 + MedDRA: 10024855 + + + + obo2:OAE_0000400 + SIDER: C0039070 + + + + obo2:OAE_0000401 + a skin adverse event that has an outcome of sweating + + + + obo2:OAE_0000401 + According to the Vaccine Adverse Event Reporting System (VAERS), 'sweating' is an adverse event that was mentioned in 2,301 VAERS reports (1.8%) during1991-2001 (Reference: PMID: 12825543). + + + + obo2:OAE_0000401 + YH + + + + obo2:OAE_0000401 + sweating AE + + + + obo2:OAE_0000401 + HPO: HP_0000975 + + + + obo2:OAE_0000401 + SIDER: C0038990 + + + + obo2:OAE_0000402 + According to the Vaccine Adverse Event Reporting System (VAERS), 'abdominal pain' is an adverse event that was mentioned in 2,254 VAERS reports (1.8%) during1991-2001 (Reference: PMID: 12825543). + + + + obo2:OAE_0000402 + YH, SS + + + + obo2:OAE_0000402 + WEB: http://en.wikipedia.org/wiki/Abdominal_pain + + + + obo2:OAE_0000402 + a pain AE that is observed in abdominal cavity + + + + obo2:OAE_0000402 + abdominal pain AE + + + + obo2:OAE_0000402 + HPO: HP_0002027 + + + + obo2:OAE_0000402 + MedDRA ID: 10000081 + + + + obo2:OAE_0000402 + SIDER: C0000737 + + + + obo2:OAE_0000403 + an abnormal blood pressure AE that has an outcome of sustained high blood pressure at a level that is likely to result in cardiovascular disease and/or other pathological states + + + + obo2:OAE_0000403 + YH, SS + + + + obo2:OAE_0000403 + blood pressure increased + + + + obo2:OAE_0000403 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/21722707 + + + + obo2:OAE_0000403 + hypertension AE + + + + obo2:OAE_0000403 + HPO: HP_0000822 + + + + obo2:OAE_0000403 + MP: MP_0000231 + + + + obo2:OAE_0000403 + MedDRA: 10005750 + + + + obo2:OAE_0000403 + MedDRA: 10020772 + + + + obo2:OAE_0000403 + SIDER: C0020538 + + + + obo2:OAE_0000404 + a cardiac valve disease AE that is characterized by a condition of the heart in which the aortic valve, located between the aorta and left ventricle of the heart, is norrower than normal size + + + + obo2:OAE_0000404 + SS + + + + obo2:OAE_0000404 + WEB: http://medical-dictionary.thefreedictionary.com/aortic+valve+stenosis + + + + obo2:OAE_0000404 + aortic valve stenosis AE + + + + obo2:OAE_0000404 + HPO: HP_0005173 + + + + obo2:OAE_0000404 + MedDRA: 10002918 + + + + obo2:OAE_0000404 + SIDER: C0003507 + + + + obo2:OAE_0000405 + a muscular weakness AE that has an outcome of myasthenia. Myasthenia represenats myasthenia gravis, a neuromuscular disease leading to fluctuating muscle weakness and fatiguability. + + + + obo2:OAE_0000405 + YH, SS + + + + obo2:OAE_0000405 + myasthenia gravis + + + + obo2:OAE_0000405 + myasthenia syndrome AE + + + + obo2:OAE_0000405 + myasthenic syndrome AE + + + + obo2:OAE_0000405 + myasthenia AE + + + + obo2:OAE_0000405 + HPO: HP_0001324 + + + + obo2:OAE_0000405 + SIDER: C0947912 + + + + obo2:OAE_0000406 + a pain AE that has an outcome of chest pain + + + + obo2:OAE_0000406 + According to the Vaccine Adverse Event Reporting System (VAERS), 'chest pain' was mentioned in 1,752 VAERS reports (1.4%) during1991-2001 (Reference: PMID: 12825543). + + + + obo2:OAE_0000406 + YH + + + + obo2:OAE_0000406 + chest pain AE + + + + obo2:OAE_0000406 + HPO: HP_0001681 + + + + obo2:OAE_0000406 + MedDRA ID: 10008479 + + + + obo2:OAE_0000406 + SIDER: C0008031 + + + + obo2:OAE_0000407 + a sensory neuropathy AE which has an outcome of sensory axonal characterized by damage to axonas of the peripheral nervous system (PNS) + + + + obo2:OAE_0000407 + AG, YH + + + + obo2:OAE_0000407 + sensory axonal AE + + + + obo2:OAE_0000408 + an abnormal vision AE characterised by leakage of fluid under the retina causing visual impairment, usually in one eye. + + + + obo2:OAE_0000408 + SJ, YH + + + + + obo2:OAE_0000408 + central serous chorioretinopathy + + + + obo2:OAE_0000408 + WEB: http://en.wikipedia.org/wiki/Central_serous_retinopathy + + + + obo2:OAE_0000408 + central serous retinopathy AE + + + + obo2:OAE_0000408 + MedDRA ID: 10063118 + + + + obo2:OAE_0000409 + a movement disorder AE that has an outcome of twitching, an involuntary sudden movement of part of the body. + + + + obo2:OAE_0000409 + According to the Vaccine Adverse Event Reporting System (VAERS), 'twitching' is an adverse event that was mentioned in 1,511 VAERS reports (1.2%) during1991-2001 (Reference: PMID: 12825543). + + + + obo2:OAE_0000409 + YH + + + + obo2:OAE_0000409 + twitching AE + + + + obo2:OAE_0000410 + a seizure AE that has an outcome of febrile seizure + + + + obo2:OAE_0000410 + YH + + + + obo2:OAE_0000410 + febrile seizure AE + + + + obo2:OAE_0000411 + a respiratory system AE which has an outcome of asthma + + + + obo2:OAE_0000411 + YH + + + + obo2:OAE_0000411 + 哮喘 + + + + obo2:OAE_0000411 + Asthma is a common chronic lung disease. It has been defined by the National Heart, Lung and Blood Institute as a common chronic disorder of the airways that is complex and characterized by variable and recurring symptoms, airflow obstruction, bronchial hyperresponsiveness (bronchospasm), and an underlying inflammation. + + + + obo2:OAE_0000411 + asthma AE + + + + obo2:OAE_0000411 + HPO: HP_0002099 + + + + obo2:OAE_0000411 + MedDRA ID: 10003553 + + + + obo2:OAE_0000411 + SIDER: C0004096 + + + + obo2:OAE_0000412 + a pain AE that has an outcome of neck pain + + + + obo2:OAE_0000412 + According to the Vaccine Adverse Event Reporting System (VAERS), 'neck pain' was mentioned in 1,323 VAERS reports (1.0%) during1991-2001 (Reference: PMID: 12825543). + + + + obo2:OAE_0000412 + YH + + + + obo2:OAE_0000412 + neck pain AE + + + + obo2:OAE_0000412 + HPO: HP_0003418 + + + + obo2:OAE_0000412 + SIDER: C0007859 + + + + obo2:OAE_0000413 + an arthritis AE that has an outcome of inflammation of a joint, resulting from infectious agents, such as bacteria and viruses + + + + obo2:OAE_0000413 + DJ, SS, YH + + + + obo2:OAE_0000413 + WEB: http://www.rightdiagnosis.com/i/infectious_arthritis/intro.htm + + + + obo2:OAE_0000413 + arthritis infective AE + + + + obo2:OAE_0000413 + HPO: HP_0003095 + + + + obo2:OAE_0000413 + MedDRA: 10060968 + + + + obo2:OAE_0000413 + SIDER: C0003869 + + + + obo2:OAE_0000414 + a pain AE that has an outcome of back pain + + + + obo2:OAE_0000414 + According to the Vaccine Adverse Event Reporting System (VAERS), 'back pain' was mentioned in 1,277 VAERS reports (1.0%) during1991-2001 (Reference: PMID: 12825543). + + + + obo2:OAE_0000414 + YH + + + + obo2:OAE_0000414 + back pain AE + + + + obo2:OAE_0000414 + HPO: HP_0003418 + + + + obo2:OAE_0000414 + MedDRA ID: 10003988 + + + + obo2:OAE_0000414 + SIDER: C0004604 + + + + obo2:OAE_0000415 + a hair AE that has an outcome of alopecia and occurs after a medical intervention. + + + + obo2:OAE_0000415 + VAE + + + + obo2:OAE_0000415 + alopecia means the absence of hair or loss of hair. It is not usually in reference to primary genetic hairlessness but may be due to dietary, stress, secondary to immune condition. + + + + obo2:OAE_0000415 + alopecia AE + + + + obo2:OAE_0000415 + HPO: HP_0001596 + + + + obo2:OAE_0000415 + MP: MP_0000414 + + + + obo2:OAE_0000415 + MedDRA: 10001760 + + + + obo2:OAE_0000415 + SIDER: C0002170 + + + + obo2:OAE_0000416 + a hemorrhage AE that has an outcome of gastrointestinal hemorrhage + + + + obo2:OAE_0000416 + gastrointestinal haemorrhage AE + + + + obo2:OAE_0000416 + WEB: http://medical-dictionary.thefreedictionary.com/gastrointestinal+hemorrhage + + + + obo2:OAE_0000416 + bleeding in the stomach and/or the intestines + + + + obo2:OAE_0000416 + gastrointestinal hemorrhage AE + + + + obo2:OAE_0000416 + MP: MP_0000465 + + + + obo2:OAE_0000416 + MedDRA: 10017955 + + + + obo2:OAE_0000417 + a movement disorder AE that has an outcome of eyes gaze upward + + + + obo2:OAE_0000417 + According to the Vaccine Adverse Event Reporting System (VAERS), 'eyes gaze upward' was mentioned in 1,249 VAERS reports (1.0%) during1991-2001 (Reference: PMID: 12825543). + + + + obo2:OAE_0000417 + YH + + + + obo2:OAE_0000417 + eyes gaze upward AE + + + + obo2:OAE_0000418 + a nervous system AE that shows a damage to or disease affecting the nerves. + + + + obo2:OAE_0000418 + YH, RR + + + + obo2:OAE_0000418 + WEB: http://www.emedicinehealth.com/neuropathy/article_em.htm + + + + obo2:OAE_0000418 + WEB: http://www.medicalnewstoday.com/articles/147963.php + + + + obo2:OAE_0000418 + WEB: http://www.neuropathy.org/ + + + + obo2:OAE_0000418 + neuropathy AE + + + + obo2:OAE_0000418 + HPO: HP_0007141 + + + + obo2:OAE_0000418 + SIDER: C0442874 + + + + obo2:OAE_0000419 + a skin adverse event that has an outcome of skin nodule + + + + obo2:OAE_0000419 + According to the Vaccine Adverse Event Reporting System (VAERS), 'skin nodule' was mentioned in 1,134 VAERS reports (0.9%) during1991-2001 (Reference: PMID: 12825543). + + + + obo2:OAE_0000419 + YH + + + + obo2:OAE_0000419 + skin nodule AE + + + + obo2:OAE_0000419 + HPO: HP_0200036 + + + + obo2:OAE_0000419 + SIDER: C0037287 + + + + obo2:OAE_0000420 + a movement disorder AE that has an outcome of arthrosis. + + + + obo2:OAE_0000420 + YH + + + + obo2:OAE_0000420 + Arthrosis is an articular illness that produces fibrosis or degeneration of the cartilage. + + + + obo2:OAE_0000420 + arthrosis AE + + + + obo2:OAE_0000421 + a muscle adverse event which has an outcome of hypokinesia, refering to slow or diminished movement of body musculature. + + + + obo2:OAE_0000421 + YH + + + + obo2:OAE_0000421 + hypokinesia AE + + + + obo2:OAE_0000421 + HPO: HP_0002375 + + + + obo2:OAE_0000421 + MedDRA ID: 10021021 + + + + obo2:OAE_0000421 + SIDER: C0086439 + + + + obo2:OAE_0000422 + Muscle twitch AE is a twitching AE that is a small, local, involuntary muscle contraction and relaxation which may be visible under the skin. + + + + obo2:OAE_0000422 + JX, YH + + + + obo2:OAE_0000422 + WEB: http://en.wikipedia.org/wiki/Fasciculation + + + + obo2:OAE_0000422 + fasciculation AE + + + + obo2:OAE_0000422 + muscle contraction AE + + + + obo2:OAE_0000422 + myokymia AE + + + + obo2:OAE_0000422 + muscle twitch AE + + + + obo2:OAE_0000422 + MedDRA: 10028346 + + + + obo2:OAE_0000423 + skin discoloration AE is a skin adverse event that results in change in color of skin or mucus membranes + + + + obo2:OAE_0000423 + According to the Vaccine Adverse Event Reporting System (VAERS), 'skin discoloration' is an adverse event that was mentioned in 909 VAERS reports (0.7%) during1991-2001 (Reference: PMID: 12825543). + + + + obo2:OAE_0000423 + YH, SS + + + + obo2:OAE_0000423 + skin discolouration AE + + + + obo2:OAE_0000423 + skin discoloration AE + + + + obo2:OAE_0000423 + MedDRA: 10040829 + + + + obo2:OAE_0000424 + a viral infection AE which has an outcome of herpes zoster + + + + obo2:OAE_0000424 + YH + + + + obo2:OAE_0000424 + shingles + + + + obo2:OAE_0000424 + zoster + + + + obo2:OAE_0000424 + Herpes zoster is a viral disease characterized by a painful skin rash with blisters in a limited area on one side of the body, often in a stripe. The initial infection with varicella zoster virus (VZV) causes the acute (short-lived) illness chickenpox, and generally occurs in children and young people. Once an episode of chickenpox has resolved, the virus is not eliminated from the body but can go on to cause shingles (an illness with very different symptoms) often many years after the initial infection. + + + + obo2:OAE_0000424 + herpes zoster AE + + + + obo2:OAE_0000424 + HPO: HP_0005353 + + + + obo2:OAE_0000424 + MedDRA: 10019974 + + + + obo2:OAE_0000424 + SIDER: C0019360 + + + + obo2:OAE_0000425 + a movement disorder AE that has an outcome of laryngismus + + + + obo2:OAE_0000425 + According to the Vaccine Adverse Event Reporting System (VAERS), 'laryngismus' is an adverse event that was mentioned in 881 VAERS reports (0.7%) during1991-2001 (Reference: PMID: 12825543). + + + + obo2:OAE_0000425 + YH + + + + obo2:OAE_0000425 + laryngospasm + + + + obo2:OAE_0000425 + sudden laryngeal spasm with crowing inhalation and cyanosis + + + + obo2:OAE_0000425 + Laryngismus is an uncontrolled/involuntary muscular contraction (spasm) of the laryngeal cords. + + + + obo2:OAE_0000425 + laryngismus AE + + + + obo2:OAE_0000426 + a behavior and neurological AE that has an outcome of disorder in speech + + + + obo2:OAE_0000426 + YH + + + + obo2:OAE_0000426 + speech disorder AE + + + + obo2:OAE_0000426 + HPO: HP_0006977 + + + + obo2:OAE_0000426 + MedDRA ID: 10041466 + + + + obo2:OAE_0000426 + SIDER: C0037822 + + + + obo2:OAE_0000427 + a cardiovascular disorder AE that has an outcome of hemorrhage + + + + obo2:OAE_0000427 + bleeding AE + + + + obo2:OAE_0000427 + haemorrhage AE + + + + obo2:OAE_0000427 + WEB: http://medical-dictionary.thefreedictionary.com/hemorrhage + + + + obo2:OAE_0000427 + loss of blood from the vascular compartment to the exterior or into nonvascular body space as a result of rupture or severance of the blood vessels + + + + obo2:OAE_0000427 + hemorrhage AE + + + + obo2:OAE_0000427 + MP: MP_0001914 + + + + obo2:OAE_0000427 + MedDRA: 10055798 + + + + obo2:OAE_0000428 + a bone disorder AE which has an outcome of neck rigidity + + + + obo2:OAE_0000428 + YH + + + + obo2:OAE_0000428 + neck rigidity AE + + + + obo2:OAE_0000429 + a nervous system AE that has the symptom of GBS. Guillain-Barre syndrome (GBS) is a disorder in which the body's immune system attacks part of the peripheral nervous system. The first symptoms of this disorder include varying degrees of weakness or tingling sensations in the legs. In many instances, the weakness and abnormal sensations spread to the arms and upper body. These symptoms can increase in intensity until the muscles cannot be used at all and the patient is almost totally paralyzed. In these cases, the disorder is life-threatening and is considered a medical emergency. Usually Guillain-Barre occurs a few days or weeks after the patient has had symptoms of a respiratory or gastrointestinal viral infection. Occasionally, surgery or vaccinations will trigger the syndrome. Reference: http://www.ninds.nih.gov/disorders/gbs/gbs.htm. + + + + obo2:OAE_0000429 + YH, SS + + + + obo2:OAE_0000429 + GBS AE + + + + obo2:OAE_0000429 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/23299621 + + + + obo2:OAE_0000429 + Guillain-Barre syndrome AE + + + + obo2:OAE_0000429 + HPO: HP_0007131 + + + + obo2:OAE_0000429 + MedDRA ID: 10018767 + + + + obo2:OAE_0000429 + MedDRA: 10018767 + + + + obo2:OAE_0000429 + SIDER: C0018378 + + + + obo2:OAE_0000430 + an abnormal digestion AE which has an outcome of nausea and vomiting + + + + obo2:OAE_0000430 + According to the Vaccine Adverse Event Reporting System (VAERS), 'nausea and vomiting' is an adverse event that was mentioned in 812 VAERS reports (0.6%) during1991-2001 (Reference: PMID: 12825543). + + + + obo2:OAE_0000430 + This term will most likely removed since it is just a combination of nausea and vomiting. + + + + obo2:OAE_0000430 + YH + + + + obo2:OAE_0000430 + nausea and vomiting AE + + + + obo2:OAE_0000431 + a perinatal AE that results in sudden death of an infant. + + + + obo2:OAE_0000431 + According to the Vaccine Adverse Event Reporting System (VAERS), 'sudden infant death' is an adverse event that was mentioned in 808 VAERS reports (0.6%) during1991-2001 (Reference: PMID: 12825543). + + + + obo2:OAE_0000431 + YH + + + + obo2:OAE_0000431 + sudden infant death AE + + + + obo2:OAE_0000432 + a fever AE that has an outcome of fever with chills, which is successive stages of chills and fever. This is a symptom of malaria. + + + + obo2:OAE_0000432 + YH + + + + obo2:OAE_0000432 + chills and fever AE + + + + obo2:OAE_0000432 + fever with chills AE + + + + obo2:OAE_0000432 + MedDRA: 10016559 + + + + obo2:OAE_0000433 + a behavior and neurological AE that has an outcome of personal disorder + + + + obo2:OAE_0000433 + YH + + + + obo2:OAE_0000433 + personality disorder AE + + + + obo2:OAE_0000433 + HPO: HP_0000751 + + + + obo2:OAE_0000433 + MedDRA ID: 10034721 + + + + obo2:OAE_0000433 + SIDER: C0031212 + + + + obo2:OAE_0000434 + a respiratory system AE which has an outcome of lung disorder + + + + obo2:OAE_0000434 + YH + + + + obo2:OAE_0000434 + lung disorder AE + + + + obo2:OAE_0000434 + lung AE + + + + obo2:OAE_0000434 + HPO: HP_0006552 + + + + obo2:OAE_0000434 + MedDRA: 10025082 + + + + obo2:OAE_0000434 + SIDER: C0024115 + + + + obo2:OAE_0000435 + a musculoskeletal system AE that occurs in muscle. + + + + obo2:OAE_0000435 + YH + + + + obo2:OAE_0000435 + muscle AE + + + + obo2:OAE_0000436 + an AE that occurs in liver, biliary, and pancreatic areas. + + + + obo2:OAE_0000436 + YH + + + + obo2:OAE_0000436 + liver, biliary, and pancreatic AE + + + + obo2:OAE_0000437 + a liver/biliary system AE which has an outcome of an enlarged liver, or larger than average size of the liver + + + + obo2:OAE_0000437 + According to the Vaccine Adverse Event Reporting System (VAERS), 'hepatomegaly' was mentioned in 106 VAERS reports (<0.1%) during1991-2001 (Reference: PMID: 12825543). + + + + obo2:OAE_0000437 + enlarged liver AE + + + + obo2:OAE_0000437 + MP: MP_0000599 + + + + obo2:OAE_0000438 + a nervous system AE which has an outcome of meningitis, a medical condition caused by inflammation of the protective membranes covering the brain and spinal cord, known collectively as the meninges. The inflammation is caused by infection with viruses, bacteria, or other microorganisms, and less commonly by certain drugs or diseases. + + + + obo2:OAE_0000438 + YH + + + + obo2:OAE_0000438 + meningitis AE + + + + obo2:OAE_0000438 + HPO: HP_0001287 + + + + obo2:OAE_0000438 + MedDRA ID: 10027199 + + + + obo2:OAE_0000438 + SIDER: C0025289 + + + + obo2:OAE_0000439 + an AE that occurs in digestive system. + + + + obo2:OAE_0000439 + YH + + + + obo2:OAE_0000439 + digestive system AE + + + + obo2:OAE_0000440 + a paralysis AE that has an outcome of paralysis in face + + + + obo2:OAE_0000440 + According to the Vaccine Adverse Event Reporting System (VAERS), 'facial paralysis' was mentioned in 580 VAERS reports (0.5%) during1991-2001 (Reference: PMID: 12825543). + + + + obo2:OAE_0000440 + YH + + + + obo2:OAE_0000440 + facial paralysis AE + + + + obo2:OAE_0000440 + HPO: HP_0007209 + + + + obo2:OAE_0000440 + SIDER: C0015469 + + + + obo2:OAE_0000441 + a behavior and neurological AE that has an outcome of confusion, which is a mild form of delirium. + + + + obo2:OAE_0000441 + YH, KM + + + + obo2:OAE_0000441 + confused state + + + + obo2:OAE_0000441 + mental confusion + + + + obo2:OAE_0000441 + WEB: http://medical-dictionary.thefreedictionary.com/mental+confusion + + + + obo2:OAE_0000441 + confusion AE + + + + obo2:OAE_0000441 + MedDRA: 10010305 + + + + obo2:OAE_0000442 + a musculoskeletal system AE which has an outcome of joint disorder + + + + obo2:OAE_0000442 + YH + + + + obo2:OAE_0000442 + joint disorder AE + + + + obo2:OAE_0000443 + an AE that occurs in eye. + + + + obo2:OAE_0000443 + YH + + + + obo2:OAE_0000443 + eye disorder AE + + + + obo2:OAE_0000443 + eye AE + + + + obo2:OAE_0000443 + HPO: HP_0000496 + + + + obo2:OAE_0000443 + MedDRA ID: 10015916 + + + + obo2:OAE_0000443 + SIDER: C0015397 + + + + obo2:OAE_0000444 + a behavior and neurological AE that has an outcome of autism + + + + obo2:OAE_0000444 + YH + + + + obo2:OAE_0000444 + Autism is a brain development disorder characterized by impaired social interaction and communication, and by restricted and repetitive behavior. + + + + obo2:OAE_0000444 + autism AE + + + + obo2:OAE_0000445 + a hematopoietic system AE which has an outcome of sedimentation rate increased + + + + obo2:OAE_0000445 + According to the Vaccine Adverse Event Reporting System (VAERS), 'sedimentation rate increased' is an adverse event that was mentioned in 530 VAERS reports (0.4%) during1991-2001 (Reference: PMID: 12825543). + + + + obo2:OAE_0000445 + This term should be inferred to lab test abnormal. + + + + obo2:OAE_0000445 + YH + + + + obo2:OAE_0000445 + ESR + + + + obo2:OAE_0000445 + erythrocyte sedimentation rate + + + + obo2:OAE_0000445 + red blood cell sedimentation rate increased AE + + + + obo2:OAE_0000445 + sedrate + + + + obo2:OAE_0000445 + Sedimentation rate is a diagnostic test for inflammation. The test measures the rate at which red blood cells fall to the bottom of a tube over time. An increased sedimentation rate corresponds to increased non-specific inflammation in the body. It is often called "sedrate" for short. + + + + obo2:OAE_0000445 + red blood cell sedimentation rate increased AE is an AE: sedimentation rate increased that has an increase in rate at which red blood cells precipitate in a period of 1 hour. + + + + obo2:OAE_0000445 + sedimentation rate increased AE + + + + obo2:OAE_0000446 + an arthritis AE that has an outcome of arthritis due to an infection in another part of the body + + + + obo2:OAE_0000446 + DJ, SS, YH + + + + obo2:OAE_0000446 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/16822921 + + + + obo2:OAE_0000446 + arthritis reactive AE + + + + obo2:OAE_0000446 + MedDRA: 10003267 + + + + obo2:OAE_0000447 + an abnormal vision AE which has an outcome of amblyopia + + + + obo2:OAE_0000447 + YH + + + + obo2:OAE_0000447 + amblyopia AE + + + + obo2:OAE_0000447 + HPO: HP_0000646 + + + + obo2:OAE_0000447 + MedDRA ID: 10001906 + + + + obo2:OAE_0000447 + SIDER: C0002418 + + + + obo2:OAE_0000448 + a mental disorder AE that has an outcome of mental retardation + + + + obo2:OAE_0000448 + YH + + + + obo2:OAE_0000448 + mental retardation AE + + + + obo2:OAE_0000448 + HPO: HP_0001249 + + + + obo2:OAE_0000448 + SIDER: C0025362 + + + + obo2:OAE_0000449 + a nervous system AE which has an outcome of erythema multiforme, which is local accumulation of fluid, plasma proteins, and leukocytes in the brain + + + + obo2:OAE_0000449 + YH + + + + obo2:OAE_0000449 + brain inflammation + + + + obo2:OAE_0000449 + erythema multiforme AE + + + + obo2:OAE_0000449 + HPO: HP_0010783 + + + + obo2:OAE_0000449 + MedDRA ID: 10015218 + + + + obo2:OAE_0000449 + SIDER: C0014742 + + + + obo2:OAE_0000450 + a lab test abnormal AE that has an outcome of SGOT increased + + + + obo2:OAE_0000450 + According to the Vaccine Adverse Event Reporting System (VAERS), 'SGOT increased' is an adverse event that was mentioned in 477 VAERS reports (0.4%) during1991-2001 (Reference: PMID: 12825543). + + + + obo2:OAE_0000450 + YH + + + + obo2:OAE_0000450 + SGOT respresents serum glutamic oxaloacetic transaminase, an enzyme that is normally present in liver and heart cells. SGOT is released into blood when the liver or heart is damaged. The blood SGOT levels are thus elevated with liver damage (for example, from viral hepatitis) or with an insult to the heart (for example, from a heart attack). Some medications can also raise SGOT levels. SGOT is also called aspartate aminotransferase (AST). + + + + obo2:OAE_0000450 + SGOT increased AE + + + + obo2:OAE_0000451 + a lab test abnormal AE that has an outcome of SGPT increased + + + + obo2:OAE_0000451 + According to the Vaccine Adverse Event Reporting System (VAERS), 'SGPT increased' is an adverse event that was mentioned in 459 VAERS reports (0.4%) during1991-2001 (Reference: PMID: 12825543). + + + + obo2:OAE_0000451 + YH + + + + obo2:OAE_0000451 + SGPT represents serum glutamic pyruvic transaminase, an enzyme that is normally present in liver and heart cells. SGPT is released into blood when the liver or heart are damaged. The blood SGPT levels are thus elevated with liver damage (for example, from viral hepatitis) or with an insult to the heart (for example, from a heart attack). Some medications can also raise SGPT levels. SGPT is also called alanine aminotransferase (ALT). + + + + obo2:OAE_0000451 + SGPT increased AE + + + + obo2:OAE_0000452 + a behavior and neurological AE that has an outcome of thinking abnormality + + + + obo2:OAE_0000452 + According to the Vaccine Adverse Event Reporting System (VAERS), 'thinking abnormality' is an adverse event that was mentioned in 457 VAERS reports (0.4%) during1991-2001 (Reference: PMID: 12825543). + + + + obo2:OAE_0000452 + YH + + + + obo2:OAE_0000452 + thinking abnormality AE + + + + obo2:OAE_0000452 + MedDRA: 10043431 + + + + obo2:OAE_0000453 + an abnormal digestion AE which has an outcome of dyspepsia + + + + obo2:OAE_0000453 + According to the Vaccine Adverse Event Reporting System (VAERS), 'dyspepsia' is an adverse event that was mentioned in 454 VAERS reports (0.4%) during1991-2001 (Reference: PMID: 12825543). + + + + obo2:OAE_0000453 + YH + + + + obo2:OAE_0000453 + Dyspepsia is popularly known as indigestion, meaning hard or difficult digestion. It is a medical condition characterized by chronic or recurrent pain in the upper abdomen, upper abdominal fullness and feeling full earlier than expected when eating. + + + + obo2:OAE_0000453 + dyspepsia AE + + + + obo2:OAE_0000453 + HPO: HP_0002577 + + + + obo2:OAE_0000453 + MedDRA ID: 10013946 + + + + obo2:OAE_0000453 + MedDRA: 10013946 + + + + obo2:OAE_0000453 + SIDER: C0013395 + + + + obo2:OAE_0000454 + an allergy AE which has an outcome of anaphylactoid reaction AE is an acute systemic (multi-system) and very severe Type I Hypersensitivity allergic reaction in humans and other mammals. Minute amounts of allergens may cause a life-threatening anaphylactic reaction. + + + + obo2:OAE_0000454 + According to the Vaccine Adverse Event Reporting System (VAERS), 'anaphylactoid reaction' was mentioned in 452 VAERS reports (0.4%) during1991-2001 (Reference: PMID: 12825543). + + + + obo2:OAE_0000454 + YH + + + + obo2:OAE_0000454 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/22293078 + + + + obo2:OAE_0000454 + anaphylactoid reaction AE + + + + obo2:OAE_0000454 + HPO: HP_0100845 + + + + obo2:OAE_0000454 + MedDRA ID: 10002216 + + + + obo2:OAE_0000454 + MedDRA: 10002198 + + + + obo2:OAE_0000454 + SIDER: C0340865 + + + + obo2:OAE_0000455 + a digestive system AE which has an outcome of a gastrointestinal disorder + + + + obo2:OAE_0000455 + According to the Vaccine Adverse Event Reporting System (VAERS), 'gastrointestinal disorder' is an adverse event that was mentioned in 449 VAERS reports (0.3%) during1991-2001 (Reference: PMID: 12825543). + + + + obo2:OAE_0000455 + YH + + + + obo2:OAE_0000455 + gastrointestinal disorder AE + + + + obo2:OAE_0000455 + HPO: HP_0011024 + + + + obo2:OAE_0000455 + SIDER: C0017178 + + + + obo2:OAE_0000456 + an edema AE that has an outcome of accumulation of fluid in the peritoneal cavity + + + + obo2:OAE_0000456 + DJ, SS, YH + + + + obo2:OAE_0000456 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/23296107 + + + + obo2:OAE_0000456 + ascites AE + + + + obo2:OAE_0000456 + HPO: HP_0001541 + + + + obo2:OAE_0000456 + MedDRA: 10003445 + + + + obo2:OAE_0000456 + SIDER: C0003962 + + + + obo2:OAE_0000457 + a hypersensitivity AE which has an outcome of serum sickness + + + + obo2:OAE_0000457 + According to the Vaccine Adverse Event Reporting System (VAERS), 'serum sickness' is an adverse event that was mentioned in 428 VAERS reports (0.3%) during1991-2001 (Reference: PMID: 12825543). + + + + obo2:OAE_0000457 + YH + + + + obo2:OAE_0000457 + Serum sickness is a reaction to proteins in antiserum derived from an animal source. It is a type of hypersensitivity, specifically immune complex hypersensitivity (type III). + + + + obo2:OAE_0000457 + serum sickness AE + + + + obo2:OAE_0000458 + an abscess AE which has an outcome of injection-site abscess + + + + obo2:OAE_0000458 + YH + + + + obo2:OAE_0000458 + injection-site abscess AE + + + + obo2:OAE_0000459 + a neurological, special senses and psychiatric investigation result abnormal AE that is the abnormal result of a procedure that uses small, flat metal discs (electrodes) attached to your scalp to detect electrical activity in your brain + + + + obo2:OAE_0000459 + According to the Vaccine Adverse Event Reporting System (VAERS), 'abnormal electroencephalogram' is an adverse event that was mentioned in 420 VAERS reports (0.3%) during1991-2001 (Reference: PMID: 12825543). + + + + obo2:OAE_0000459 + YH, EB + + + + obo2:OAE_0000459 + WEB: http://www.mayoclinic.com/health/eeg/MY00296 + + + + obo2:OAE_0000459 + abnormal electroencephalogram result AE + + + + obo2:OAE_0000459 + MedDRA: 10000130 + + + + obo2:OAE_0000460 + a dizziness AE that has an outcome of vertigo + + + + obo2:OAE_0000460 + According to the Vaccine Adverse Event Reporting System (VAERS), 'vertigo' was mentioned in 412 VAERS reports (0.3%) during1991-2001 (Reference: PMID: 12825543). + + + + obo2:OAE_0000460 + YH + + + + obo2:OAE_0000460 + Vertigo is a specific type of dizziness, a major symptom of a balance disorder. It is the sensation of spinning or swaying while the body is actually stationary with respect to the surroundings. The effects of vertigo may be slight. It can cause nausea and vomiting and, in severe cases, it may give rise to difficulties with standing and walking. + + + + obo2:OAE_0000460 + vertigo AE + + + + obo2:OAE_0000460 + HPO: HP_0002321 + + + + obo2:OAE_0000460 + MedDRA ID: 10047340 + + + + obo2:OAE_0000460 + SIDER: C0042571 + + + + obo2:OAE_0000461 + a cardiac disorder AE that has an outcome of heartarrest. Heart arrest is the abrupt cessation of normal circulation of the blood due to failure of the heart to contract effectively during systole. + + + + obo2:OAE_0000461 + YH + + + + obo2:OAE_0000461 + asystole + + + + obo2:OAE_0000461 + cardiac arrest + + + + obo2:OAE_0000461 + cardiopulmonary arrest + + + + obo2:OAE_0000461 + circulatory arrest + + + + obo2:OAE_0000461 + WEB: http://en.wikipedia.org/wiki/Myocardial_infarction + + + + obo2:OAE_0000461 + WEB: http://medical-dictionary.thefreedictionary.com/cardiac+arrest + + + + obo2:OAE_0000461 + heart arrest AE + + + + obo2:OAE_0000461 + MedDRA: 10007515 + + + + obo2:OAE_0000461 + MedDRA: 10007617 + + + + obo2:OAE_0000461 + MedDRA: 10028596 + + + + obo2:OAE_0000462 + a respiratory system inflammation AE which has an outcome of bronchitis + + + + obo2:OAE_0000462 + YH + + + + obo2:OAE_0000462 + Bronchitis is an inflammation of the air passages within the lungs. It occurs when the trachea (windpipe) and the large and small bronchi (airways) within the lungs become inflamed because of infection or other causes. + + + + obo2:OAE_0000462 + bronchitis AE + + + + obo2:OAE_0000462 + HPO: HP_0002837 + + + + obo2:OAE_0000462 + SIDER: C0006277 + + + + obo2:OAE_0000463 + a seizure AE that has an outcome of grand malconvulsion + + + + obo2:OAE_0000463 + YH + + + + obo2:OAE_0000463 + A generalized seizure disorder characterized by recurrent major motor seizures. The initial brief tonic phase is marked by trunk flexion followed by diffuse extension of the trunk and extremities. The clonic phase features rhythmic flexor contractions of the trunk and limbs, pupillary dilation, elevations of blood pressure and pulse, urinary incontinence, and tongue biting. This is followed by a profound state of depressed consciousness (post-ictal state) which gradually improves over minutes to hours. The disorder may be cryptogenic, familial, or symptomatic (caused by an identified disease process). + + + + obo2:OAE_0000463 + grand malconvulsion AE + + + + obo2:OAE_0000464 + a liver/biliary system AE which has an outcome of liver function tests abnormal, which is aberrant function of this bile-secreting exocrine gland, which is important for detoxification; for fat, carbohydrate, and protein metabolism; and for glycogen storage + + + + obo2:OAE_0000464 + According to the Vaccine Adverse Event Reporting System (VAERS), 'liver function tests abnormal' was mentioned in 717 VAERS reports (0.6%) during1991-2001 (Reference: PMID: 12825543). + + + + obo2:OAE_0000464 + WEB: http://medical-dictionary.thefreedictionary.com/hepatic+function + + + + obo2:OAE_0000464 + liver function tests abnormal AE + + + + obo2:OAE_0000464 + MP: MP_0000609 + + + + obo2:OAE_0000464 + MedDRA: 10019670 + + + + obo2:OAE_0000464 + MedDRA: 10024690 + + + + obo2:OAE_0000465 + an AE that occurs in ear. + + + + obo2:OAE_0000465 + YH + + + + obo2:OAE_0000465 + ear disorder AE + + + + obo2:OAE_0000465 + ear AE + + + + obo2:OAE_0000465 + HPO: HP_0000598 + + + + obo2:OAE_0000465 + SIDER: C0013447 + + + + obo2:OAE_0000466 + an infection AE that results in detrimental colonization of a host organism by virus + + + + obo2:OAE_0000466 + YH, SS + + + + obo2:OAE_0000466 + viral infection + + + + obo2:OAE_0000466 + WEB: http://en.wikipedia.org/wiki/Viral_infection + + + + obo2:OAE_0000466 + viral infection AE + + + + obo2:OAE_0000466 + HPO: HP_0005364 + + + + obo2:OAE_0000466 + SIDER: C0042769 + + + + obo2:OAE_0000467 + a movement disorder AE that has an outcome of lacrimation disorder + + + + obo2:OAE_0000467 + According to the Vaccine Adverse Event Reporting System (VAERS), 'lacrimation disorder' was mentioned in 334 VAERS reports (0.3%) during1991-2001 (Reference: PMID: 12825543). + + + + obo2:OAE_0000467 + YH + + + + obo2:OAE_0000467 + Lacrimation is the production, secretion, and shedding of tears. + + + + obo2:OAE_0000467 + lacrimation disorder AE + + + + obo2:OAE_0000468 + a liver/biliary system AE which has an outcome of jaundice, which is the clinical manifestation of hyperbilirubinemia, with deposition of bile pigments in the skin, resulting in yellowish staining of the skin and mucous membranes + + + + obo2:OAE_0000468 + According to the Vaccine Adverse Event Reporting System (VAERS), 'jaundice' is an adverse event that was mentioned in 317 VAERS reports (0.2%) during1991-2001 (Reference: PMID: 12825543). + + + + obo2:OAE_0000468 + SS, YH + + + + obo2:OAE_0000468 + icterus AE + + + + obo2:OAE_0000468 + WEB: http://en.wikipedia.org/wiki/Jaundice + + + + obo2:OAE_0000468 + jaundice AE + + + + obo2:OAE_0000468 + HPO: HP_0000952 + + + + obo2:OAE_0000468 + MP: MP_0000611 + + + + obo2:OAE_0000468 + MedDRA ID: 10023126 + + + + obo2:OAE_0000468 + MedDRA: 10023126 + + + + obo2:OAE_0000468 + SIDER: C0022346 + + + + obo2:OAE_0000469 + an immune system disorder AE which shows an enclosed collection of liquefied tissue, known as pus, somewhere in the body. Abscess is the result of the body's defensive reaction to foreign material. + + + + obo2:OAE_0000469 + YH + + + + obo2:OAE_0000469 + abscessus + + + + obo2:OAE_0000469 + WEB: http://medical-dictionary.thefreedictionary.com/abscess + + + + obo2:OAE_0000469 + An abscess is a collection of pus (dead neutrophils) that has accumulated in a cavity formed by the tissue on the basis of an infectious process (usually caused by bacteria or parasites) or other foreign materials (e.g. splinters, bullet wounds, or injecting needles). It is a defensive reaction of the tissue to prevent the spread of infectious materials to other parts of the body. + + + + obo2:OAE_0000469 + abscess AE + + + + obo2:OAE_0000469 + HPO: HP_0002722 + + + + obo2:OAE_0000469 + MedDRA: 10000269 + + + + obo2:OAE_0000469 + SIDER: C0000833 + + + + obo2:OAE_0000470 + a pain AE that has an outcome of eye pain + + + + obo2:OAE_0000470 + According to the Vaccine Adverse Event Reporting System (VAERS), 'eye pain' is an adverse event that was mentioned in 316 VAERS reports (0.2%) during1991-2001 (Reference: PMID: 12825543). + + + + obo2:OAE_0000470 + YH + + + + obo2:OAE_0000470 + eye pain AE + + + + obo2:OAE_0000470 + HPO: HP_0200025 + + + + obo2:OAE_0000470 + MedDRA ID: 10015958 + + + + obo2:OAE_0000470 + SIDER: C0151827 + + + + obo2:OAE_0000471 + a sensory capability AE that has an outcome of palpitation + + + + obo2:OAE_0000471 + YH + + + + obo2:OAE_0000471 + WEB: http://en.wikipedia.org/wiki/Palpitations + + + + obo2:OAE_0000471 + A palpitation is an abnormal awareness of the beating of the heart, whether it is too slow, too fast, irregular, or at its normal frequency. + + + + obo2:OAE_0000471 + palpitation AE + + + + obo2:OAE_0000471 + MedDRA: 10033557 + + + + obo2:OAE_0000472 + an edema AE which has an outcome of tongue edema + + + + obo2:OAE_0000472 + YH, RR + + + + obo2:OAE_0000472 + tongue oedema AE + + + + obo2:OAE_0000472 + tongue swelling AE + + + + obo2:OAE_0000472 + WEB: http://www.medterms.com/script/main/art.asp?articlekey=97582 + + + + obo2:OAE_0000472 + tongue edema AE + + + + obo2:OAE_0000472 + MedDRA: 10042727 + + + + obo2:OAE_0000473 + a pain AE that has an outcome of ear pain + + + + obo2:OAE_0000473 + According to the Vaccine Adverse Event Reporting System (VAERS), 'ear pain' was mentioned in 302 VAERS reports (0.2%) during1991-2001 (Reference: PMID: 12825543). + + + + obo2:OAE_0000473 + YH + + + + obo2:OAE_0000473 + ear pain AE + + + + obo2:OAE_0000473 + HPO: HP_0010833 + + + + obo2:OAE_0000473 + SIDER: C0013456 + + + + obo2:OAE_0000474 + an edema AE which has an outcome of angioedema + + + + obo2:OAE_0000474 + YH, SJ + + + + obo2:OAE_0000474 + angioneurotic edema + + + + obo2:OAE_0000474 + WEB: http://www.mayoclinic.org/diseases-conditions/hives-and-angioedema/basics/definition/con-20014815 + + + + + obo2:OAE_0000474 + Angioedema is the rapid swelling (edema) of the dermis, subcutaneous tissue, mucosa and submucosal tissues often around the eyes and lips. It is very similar to urticaria, but urticaria, commonly known as hives, occurs in the upper dermis. + + + + obo2:OAE_0000474 + angioedema AE + + + + obo2:OAE_0000474 + MedDRA: 10002473 + + + + obo2:OAE_0000475 + An arthritis AE that has the outcome of rheumatoid arthritis. Rheumatoid arthritis is an autoimmune disease that causes chronic inflammation of the joints and may also cause inflammation of the tissue around the joints, as well as other organs in the body. + + + + obo2:OAE_0000475 + YH + + + + obo2:OAE_0000475 + rheumatoid arthritis AE + + + + obo2:OAE_0000475 + HPO: HP_0005681 + + + + obo2:OAE_0000475 + SIDER: C0003873 + + + + obo2:OAE_0000476 + an AE that occurs in immune system. + + + + obo2:OAE_0000476 + According to the Vaccine Adverse Event Reporting System (VAERS), 'immune system disorder' was mentioned in 292 VAERS reports (0.2%) during1991-2001 (Reference: PMID: 12825543). + + + + obo2:OAE_0000476 + YH + + + + obo2:OAE_0000476 + immune system disorder AE + + + + obo2:OAE_0000476 + immune system AE + + + + obo2:OAE_0000476 + HPO: HP_0002715 + + + + obo2:OAE_0000476 + SIDER: C0021053 + + + + obo2:OAE_0000477 + an immune system disorder AE which has an outcome of antinuclear antibody present + + + + obo2:OAE_0000477 + According to the Vaccine Adverse Event Reporting System (VAERS), 'antinuclear antibody present'; is an adverse event that was mentioned in 288 VAERS reports (0.2%) during1991-2001 (Reference: PMID: 12825543). + + + + obo2:OAE_0000477 + YH + + + + obo2:OAE_0000477 + anti-nuclear factor present + + + + obo2:OAE_0000477 + The presence of anti-nuclear antibodies (ANAs) that are antibodies directed against contents of the cell nucleus. ANAs are present in higher than normal numbers in autoimmune disease. The ANA test measures the pattern and amount of autoantibody which can attack the body's tissues as if they were foreign material. Autoantibodies are present in low titers in the general population, but in about 5% of the population, their concentration is increased, and about half of this 5% have an autoimmune disease. + + + + obo2:OAE_0000477 + antinuclear antibody present AE + + + + obo2:OAE_0000478 + a nervous system AE which involves inflammation of the spinal cord, which disrupts central nervous system functions linking the brain and limbs. + + + + obo2:OAE_0000478 + YH + + + + obo2:OAE_0000478 + myelitis AE + + + + obo2:OAE_0000479 + a headache AE that has an outcome of migraine + + + + obo2:OAE_0000479 + According to the Vaccine Adverse Event Reporting System (VAERS), 'migraine'; is an adverse event that was mentioned in 267 VAERS reports (0.2%) during1991-2001 (Reference: PMID: 12825543). + + + + obo2:OAE_0000479 + YH + + + + obo2:OAE_0000479 + migraine headache + + + + obo2:OAE_0000479 + A migraine is a very painful type of headache. People who get migraines often describe the pain as pulsing or throbbing in one area of the head. During migraines, people are very sensitive to light and sound. They may also become nauseated and vomit. + + + + obo2:OAE_0000479 + migraine AE + + + + obo2:OAE_0000479 + HPO: HP_0002076 + + + + obo2:OAE_0000479 + SIDER: C0149931 + + + + obo2:OAE_0000480 + Thrombocytopenic purpura AE are purpura AE associated with a reduction in circulating blood platelets which can result from a variety of causes. + + + + obo2:OAE_0000480 + According to the Vaccine Adverse Event Reporting System (VAERS), 'thrombocytopenic purpura'; is an adverse event that was mentioned in 267 VAERS reports (0.2%) during1991-2001 (Reference: PMID: 12825543). + + + + obo2:OAE_0000480 + YH + + + + obo2:OAE_0000480 + thrombocytopenic purpura AE + + + + obo2:OAE_0000480 + HPO: HP_0004829 + + + + obo2:OAE_0000480 + MedDRA ID: 10043561 + + + + obo2:OAE_0000480 + SIDER: C0857305 + + + + obo2:OAE_0000481 + multiple sclerosis AE is an immune system disorder AE, or an autoimmune condition in which the immune system attacks the central nervous system, leading to demyelination. + + + + obo2:OAE_0000481 + YH + + + + obo2:OAE_0000481 + MS + + + + obo2:OAE_0000481 + disseminated sclerosis + + + + obo2:OAE_0000481 + encephalomyelitis disseminata + + + + obo2:OAE_0000481 + multiple sclerosis AE + + + + obo2:OAE_0000481 + MedDRA ID: 10028245 + + + + obo2:OAE_0000482 + a behavior and neurological AE that has an outcome of amnesia in a patient + + + + obo2:OAE_0000482 + YH + + + + obo2:OAE_0000482 + Amnesia is a short term memory condition in which memory is disturbed. In simple terms it is the loss of memory. + + + + obo2:OAE_0000482 + amnesia AE + + + + obo2:OAE_0000482 + HPO: HP_0002354 + + + + obo2:OAE_0000482 + MedDRA ID: 10001949 + + + + obo2:OAE_0000482 + SIDER: C0002622 + + + + obo2:OAE_0000483 + a movement disorder AE that has an outcome of incoordination + + + + obo2:OAE_0000483 + According to the Vaccine Adverse Event Reporting System (VAERS), 'incoordination' was mentioned in 261 VAERS reports (0.2%) during1991-2001 (Reference: PMID: 12825543). + + + + obo2:OAE_0000483 + YH + + + + obo2:OAE_0000483 + a lack of normal adjustment of muscular action so that the intended movement of the limb or other part is not made smoothly and harmoniously, and does not accurately achieve its objective. If the abnormality is hypermetric, the condition is referred to as ataxia. If it is inclined to weakness, e.g. knuckling at the turn, stumbling, failure to flex limbs properly, or to misdirection as in a proprioceptive deficit, it is called incoordination. + + + + obo2:OAE_0000483 + incoordination AE + + + + obo2:OAE_0000484 + a speech disorder that has an outcome of voice alteration + + + + obo2:OAE_0000484 + YH + + + + obo2:OAE_0000484 + voice alteration AE + + + + obo2:OAE_0000485 + a pregnancy AE that is the termination of a pregnancyby the removal or expulsion from the uterus of a fetus or embryo, resulting in or caused by its death. + + + + obo2:OAE_0000485 + According to the Vaccine Adverse Event Reporting System (VAERS), 'abortion'; is an adverse event that was mentioned in 257 VAERS reports (0.2%) during1991-2001 (Reference: PMID: 12825543). + + + + obo2:OAE_0000485 + YH, SS + + + + obo2:OAE_0000485 + WEB: http://en.wikipedia.org/wiki/Abortion + + + + obo2:OAE_0000485 + abortion AE + + + + obo2:OAE_0000485 + MedDRA ID: 10000210 + + + + obo2:OAE_0000486 + a mental disorder AE that has an outcome of shock + + + + obo2:OAE_0000486 + YH + + + + obo2:OAE_0000486 + acute stress disorder AE + + + + obo2:OAE_0000486 + acute stress reaction AE + + + + obo2:OAE_0000486 + mental shock AE + + + + obo2:OAE_0000486 + Mental shock (or shock) is a psychological condition arising in response to a terrifying event. It should not be confused with the unrelated circulatory condition of shock. + + + + obo2:OAE_0000486 + There are two types of shocks. Another is circulatory shock which is physiological with MedDRA ID of 10040560. + + + + obo2:OAE_0000486 + psychological shock AE + + + + obo2:OAE_0000486 + MedDRA ID: 10001084 + + + + obo2:OAE_0000487 + a skin discoloration AE which has an outcome of purpura + + + + obo2:OAE_0000487 + According to the Vaccine Adverse Event Reporting System (VAERS), 'purpura'; is an adverse event that was mentioned in 251 VAERS reports (0.2%) during1991-2001 (Reference: PMID: 12825543). + + + + obo2:OAE_0000487 + YH + + + + obo2:OAE_0000487 + Purpura is the appearance of red or purple discolorations on the skin that do not blanch on applying pressure. They are caused by bleeding underneath the skin. This is common with typhus and can be present with meningitis caused by meningococcal meningitis or septicaemia. Reference: http://en.wikipedia.org/wiki/Purpura. + + + + obo2:OAE_0000487 + purpura AE + + + + obo2:OAE_0000487 + HPO: HP_0000979 + + + + obo2:OAE_0000487 + MedDRA ID: 10037549 + + + + obo2:OAE_0000487 + SIDER: C0034150 + + + + obo2:OAE_0000488 + an infection AE that results in detrimental colonization of a host organism by bacteria + + + + obo2:OAE_0000488 + YH, SS + + + + obo2:OAE_0000488 + bacterial infection AE + + + + obo2:OAE_0000488 + WEB: http://en.wikipedia.org/wiki/Bacterial_infection + + + + obo2:OAE_0000488 + bacterial infection AE + + + + obo2:OAE_0000488 + HPO: HP_0002718 + + + + obo2:OAE_0000488 + MedDRA: 10060945 + + + + obo2:OAE_0000488 + SIDER: C0004623 + + + + obo2:OAE_0000489 + a skin adverse event that has an outcome of skin striae that displays irregular areas of skin that look like bands, stripes, or lines. Striae are seen when a person grows or gains weight rapidly or has certain diseases or conditions. + + + + obo2:OAE_0000489 + According to the Vaccine Adverse Event Reporting System (VAERS), 'skin striae'; is an adverse event that was mentioned in 247 VAERS reports (0.2%) during1991-2001 (Reference: PMID: 12825543). + + + + obo2:OAE_0000489 + YH + + + + obo2:OAE_0000489 + stretch marks + + + + obo2:OAE_0000489 + striae distensae + + + + obo2:OAE_0000489 + skin striae AE + + + + obo2:OAE_0000489 + HPO: HP_0001065 + + + + obo2:OAE_0000489 + SIDER: C0152459 + + + + obo2:OAE_0000490 + a syndrome AE that has an outcome of an acute brain syndrome AE and occurs after a medical intervention. + + + + obo2:OAE_0000490 + YH + + + + obo2:OAE_0000490 + acute brain syndrome AE + + + + obo2:OAE_0000491 + a sensory capability AE that has an outcome of coma + + + + obo2:OAE_0000491 + YH + + + + obo2:OAE_0000491 + Coma is a profound state of unconsciousness. A comatose person cannot be awakened, fails to respond normally to pain or light, does not have sleep-wake cycles, and does not take voluntary actions. + + + + obo2:OAE_0000491 + coma AE + + + + obo2:OAE_0000491 + HPO: HP_0001259 + + + + obo2:OAE_0000491 + MedDRA ID: 10010071 + + + + obo2:OAE_0000491 + SIDER: C0009421 + + + + obo2:OAE_0000492 + a muscle adverse event which has an outcome of hyperkinesia, an abnormal increase in muscular activity. + + + + obo2:OAE_0000492 + YH + + + + obo2:OAE_0000492 + hyperkinesia AE + + + + obo2:OAE_0000492 + HPO: HP_0002487 + + + + obo2:OAE_0000492 + MedDRA ID: 10020651 + + + + obo2:OAE_0000492 + SIDER: C0424295 + + + + obo2:OAE_0000493 + an AE that occurs in cardiovascular system. + + + + obo2:OAE_0000493 + YH + + + + obo2:OAE_0000493 + cardiovascular disorder AE + + + + obo2:OAE_0000493 + cardiovascular AE + + + + obo2:OAE_0000493 + HPO: HP_0001626 + + + + obo2:OAE_0000493 + MedDRA ID: 10007649 + + + + obo2:OAE_0000493 + SIDER: C0007222 + + + + obo2:OAE_0000494 + a nervous system AE which has an outcome of encephalopathy, which is disorder or disease of the brain. + + + + obo2:OAE_0000494 + YH + + + + obo2:OAE_0000494 + encephalopathy AE + + + + obo2:OAE_0000494 + HPO: HP_0007239 + + + + obo2:OAE_0000494 + MedDRA ID: 10014625 + + + + obo2:OAE_0000494 + SIDER: C0085584 + + + + obo2:OAE_0000495 + a urinary system AE that has an outcome of urine abnormality AE + + + + obo2:OAE_0000495 + YH + + + + obo2:OAE_0000495 + urine abnormality AE + + + + obo2:OAE_0000495 + HPO: HP_0011036 + + + + obo2:OAE_0000495 + SIDER: C0235639 + + + + obo2:OAE_0000496 + a gastrointestinal disorder AE which has an outcome of gastroenteritis, an inflammation occuring in the gastrointestinal tract that involves both the stomach and the small intestine, often results in diarrhea, vomiting and abdominal pain and cramping + + + + obo2:OAE_0000496 + According to the Vaccine Adverse Event Reporting System (VAERS), 'gastroenteritis' was mentioned in 218 VAERS reports (0.2%) during1991-2001 (Reference: PMID: 12825543). + + + + obo2:OAE_0000496 + YH + + + + obo2:OAE_0000496 + WEB: http://medical-dictionary.thefreedictionary.com/gastroenteritis + + + + obo2:OAE_0000496 + gastroenteritis AE + + + + obo2:OAE_0000496 + HPO: HP_0004386 + + + + obo2:OAE_0000496 + MedDRA: 10017888 + + + + obo2:OAE_0000496 + SIDER: C0017160 + + + + obo2:OAE_0000497 + a cardiovascular disorder AE that has an outcome of peripheral vascular disorder + + + + obo2:OAE_0000497 + YH + + + + obo2:OAE_0000497 + peripheral vascular disorder AE + + + + obo2:OAE_0000497 + HPO: HP_0005299 + + + + obo2:OAE_0000497 + SIDER: C0085096 + + + + obo2:OAE_0000498 + a urinary system AE that has an outcome of urnary tract infection AE + + + + obo2:OAE_0000498 + YH + + + + obo2:OAE_0000498 + urinary tract infection AE + + + + obo2:OAE_0000498 + HPO: HP_0000094 + + + + obo2:OAE_0000498 + SIDER: C0042029 + + + + obo2:OAE_0000499 + an abnormal salivary gland physiology AE which has an outcome of increased salivation, meaning greater than normal amounts of flowing saliva + + + + obo2:OAE_0000499 + According to the Vaccine Adverse Event Reporting System (VAERS), 'increased salivation' is an adverse event that was mentioned in 336 VAERS reports (0.3%) during1991-2001 (Reference: PMID: 12825543). + + + + obo2:OAE_0000499 + increased salivation AE + + + + obo2:OAE_0000499 + MP: MP_0000622 + + + + obo2:OAE_0000500 + a sensory capability AE that has an outcome of depression. Depression causes a persistent feeling of sadness and loss of interest. + + + + obo2:OAE_0000500 + YH + + + + obo2:OAE_0000500 + WEB: http://www.mayoclinic.org/diseases-conditions/depression/basics/definition/con-20032977 + + + + obo2:OAE_0000500 + depression AE + + + + obo2:OAE_0000500 + HPO: HP_0000716 + + + + obo2:OAE_0000500 + MedDRA ID: 10012378 + + + + obo2:OAE_0000500 + SIDER: C0011570 + + + + obo2:OAE_0000501 + a glucose homeostasis AE which has an outcome of diabetes mellitus + + + + obo2:OAE_0000501 + YH + + + + obo2:OAE_0000501 + diabetes AE + + + + obo2:OAE_0000501 + Diabetes mellitus, often referred to simply as diabetes, is a syndrome of disordered metabolism, usually due to a combination of hereditary and environmental causes, resulting in abnormally high blood sugar levels (hyperglycemia). + + + + obo2:OAE_0000501 + diabetes mellitus AE + + + + obo2:OAE_0000501 + HPO: HP_0000819 + + + + obo2:OAE_0000501 + MedDRA ID: 10012601 + + + + obo2:OAE_0000501 + SIDER: C0011849 + + + + obo2:OAE_0000502 + a respiratory system inflammation AE which has an outcome of laryngitis + + + + obo2:OAE_0000502 + According to the Vaccine Adverse Event Reporting System (VAERS), 'laryngitis'; is an adverse event that was mentioned in 190 VAERS reports (0.1%) during1991-2001 (Reference: PMID: 12825543). + + + + obo2:OAE_0000502 + YH + + + + obo2:OAE_0000502 + Laryngitis is an inflammation of the larynx. It causes hoarse voice or the complete loss of the voice because of irritation to the vocal folds (vocal cords). + + + + obo2:OAE_0000502 + laryngitis AE + + + + obo2:OAE_0000502 + HPO: HP_0001600 + + + + obo2:OAE_0000502 + SIDER: C0023067 + + + + obo2:OAE_0000503 + a muscle spasm AE which has an outcome of generalized spasm, which is an involuntary contraction of a muscle or group of muscles. Spasms may involve skeletal muscle (MUSCLE, SKELETAL) or smooth muscle (MUSCLE, SMOOTH). + + + + obo2:OAE_0000503 + YH + + + + obo2:OAE_0000503 + generalized spasm AE + + + + obo2:OAE_0000504 + According to the Vaccine Adverse Event Reporting System (VAERS), 'reflexes decreased'; is an adverse event that was mentioned in 178 VAERS reports (0.1%) during1991-2001 (Reference: PMID: 12825543). + + + + obo2:OAE_0000504 + YH + + + + obo2:OAE_0000504 + hyporeflexia AE + + + + obo2:OAE_0000504 + a movement disorder AE that has an outcome of reflexes decreased, an abnormal decrease in an involuntary response to a peripheral stimulus + + + + obo2:OAE_0000504 + reflexes decreased AE + + + + obo2:OAE_0000505 + a digestive system AE which has an outcome of dry mouth, which is dryness of the mouth resulting from reduced salivary secretion + + + + obo2:OAE_0000505 + According to the Vaccine Adverse Event Reporting System (VAERS), 'dry mouth'; is an adverse event that was mentioned in 171 VAERS reports (0.1%) during1991-2001 (Reference: PMID: 12825543). + + + + obo2:OAE_0000505 + YH + + + + obo2:OAE_0000505 + xerostomia + + + + obo2:OAE_0000505 + dry mouth AE + + + + obo2:OAE_0000505 + HPO: HP_0000217 + + + + obo2:OAE_0000505 + MedDRA ID: 10013781 + + + + obo2:OAE_0000505 + SIDER: C0043352 + + + + obo2:OAE_0000506 + a neuritis AE which has an outcome of optic neuritis + + + + obo2:OAE_0000506 + YH + + + + obo2:OAE_0000506 + optic neuritis AE + + + + obo2:OAE_0000506 + HPO: HP_0100653 + + + + obo2:OAE_0000506 + MedDRA ID: 10030942 + + + + obo2:OAE_0000506 + SIDER: C0029134 + + + + obo2:OAE_0000507 + a cardiovascular disorder AE that has an outcome of thrombocythemia + + + + obo2:OAE_0000507 + YH + + + + obo2:OAE_0000507 + Thrombocythemia (primary thrombocythemia) is a disorder in which excess platelets are produced, leading to abnormal blood clotting or bleeding. + + + + obo2:OAE_0000507 + thrombocythemia AE + + + + obo2:OAE_0000508 + a hemorrhage AE that has an outcome of epistaxis + + + + obo2:OAE_0000508 + YH + + + + obo2:OAE_0000508 + nosebleed + + + + obo2:OAE_0000508 + Epistaxis is the relatively common occurrence of hemorrhage from the nose, usually noticed when the blood drains out through the nostrils. + + + + obo2:OAE_0000508 + epistaxis AE + + + + obo2:OAE_0000508 + HPO: HP_0000421 + + + + obo2:OAE_0000508 + MedDRA ID: 10015090 + + + + obo2:OAE_0000508 + MedDRA: 10015090 + + + + obo2:OAE_0000508 + SIDER: C0014591 + + + + obo2:OAE_0000509 + a syndrome AE that displays a lupus syndrome. Lupus is an autoimmune disease where the body's immune system becomes hyperactive and attacks normal, healthy tissue. This results in symptoms such as inflammation, swelling, and damage to joints, skin, kidneys, blood, the heart, and lungs. + + + + obo2:OAE_0000509 + YH + + + + obo2:OAE_0000509 + 狼疮样综合征 + + + + obo2:OAE_0000509 + WEB: http://www.medicalnewstoday.com/info/lupus/ + + + + obo2:OAE_0000509 + lupus syndrome AE + + + + obo2:OAE_0000510 + an eye disorder AE which has an outcome of photophobia + + + + obo2:OAE_0000510 + YH + + + + obo2:OAE_0000510 + Photophobia is a symptom of excessive sensitivity to light and the aversion to sunlight or well-lit places. In medical terms it is not fear, but an experience of discomfort or pain to the eyes due to light exposure. + + + + obo2:OAE_0000510 + photophobia AE + + + + obo2:OAE_0000510 + HPO: HP_0000613 + + + + obo2:OAE_0000510 + MedDRA ID: 10034960 + + + + obo2:OAE_0000510 + SIDER: C0085636 + + + + obo2:OAE_0000511 + a digestive system AE which has an outcome of abnormal salivary gland physiology, which is any functional anomaly of any of the glands in the mouth that secrete saliva + + + + obo2:OAE_0000511 + abnormal salivary gland physiology AE + + + + obo2:OAE_0000511 + MP: MP_0005310 + + + + obo2:OAE_0000512 + a sensory capability AE that has an outcome of hallucination + + + + obo2:OAE_0000512 + YH + + + + obo2:OAE_0000512 + A hallucination, in the broadest sense, is a perception in the absence of a stimulus. In a stricter sense, hallucinations are defined as perceptions in a conscious and awake state in the absence of external stimuli which have qualities of real perception, in that they are vivid, substantial, and located in external objective space. + + + + obo2:OAE_0000512 + hallucination AE + + + + obo2:OAE_0000512 + HPO: HP_0000738 + + + + obo2:OAE_0000512 + MedDRA ID: 10019063 + + + + obo2:OAE_0000512 + SIDER: C0018524 + + + + obo2:OAE_0000513 + a digestive system AE which has an outcome of tongue disorder + + + + obo2:OAE_0000513 + According to the Vaccine Adverse Event Reporting System (VAERS), 'tongue disorder'; is an adverse event that was mentioned in 156 VAERS reports (0.1%) during1991-2001 (Reference: PMID: 12825543). + + + + obo2:OAE_0000513 + YH + + + + obo2:OAE_0000513 + tongue disorder + + + + obo2:OAE_0000513 + HPO: HP_0000157 + + + + obo2:OAE_0000513 + SIDER: C0040409 + + + + obo2:OAE_0000514 + a pain AE that has an outcome of neuralgia + + + + obo2:OAE_0000514 + According to the Vaccine Adverse Event Reporting System (VAERS), 'neuralgia'; is an adverse event that was mentioned in 155 VAERS reports (0.1%) during1991-2001 (Reference: PMID: 12825543). + + + + obo2:OAE_0000514 + YH + + + + obo2:OAE_0000514 + Neuralgia or neuropathic pain can be defined most simply as non-nociceptive pain. Neuralgia is pain produced by a change in neurological structure or function. Unlike nociceptive pain, Neuralgia exists with no continuous nociceptive input. Neuralgia falls into two categories: central Neuralgia and peripheral Neuralgia. + + + + obo2:OAE_0000514 + neuralgia AE + + + + obo2:OAE_0000514 + HPO: HP_0003489 + + + + obo2:OAE_0000514 + MedDRA ID: 10029223 + + + + obo2:OAE_0000514 + SIDER: C0027796 + + + + obo2:OAE_0000515 + an edema AE which has an outcome of lung edema + + + + obo2:OAE_0000515 + YH + + + + obo2:OAE_0000515 + lung edema AE + + + + obo2:OAE_0000516 + a paresthesia AE that occurs around the mouth. + + + + obo2:OAE_0000516 + YH + + + + obo2:OAE_0000516 + circumoral paresthesia AE + + + + obo2:OAE_0000516 + HPO: HP_0003401 + + + + obo2:OAE_0000516 + SIDER: C0151838 + + + + obo2:OAE_0000517 + an abnormal fluid regulation AE which has an outcome of thirst + + + + obo2:OAE_0000517 + YH + + + + obo2:OAE_0000517 + Thirst is the craving for liquids, resulting in the basic instinct of humans or animals to drink. It is an essential mechanism involved in fluid balance. + + + + obo2:OAE_0000517 + thirst AE + + + + obo2:OAE_0000517 + HPO: HP_0001959 + + + + obo2:OAE_0000517 + MedDRA ID: 10043458 + + + + obo2:OAE_0000517 + SIDER: C0039971 + + + + obo2:OAE_0000518 + a musculoskeletal system AE which has an outcome of bone disorder + + + + obo2:OAE_0000518 + YH + + + + obo2:OAE_0000518 + bone disorder AE + + + + obo2:OAE_0000518 + HPO: HP_0000924 + + + + obo2:OAE_0000518 + MedDRA: 10005956 + + + + obo2:OAE_0000518 + SIDER: C0005940 + + + + obo2:OAE_0000519 + a perinatal AE that displays fetal disorder. + + + + obo2:OAE_0000519 + YH + + + + obo2:OAE_0000519 + fetal disorder AE + + + + obo2:OAE_0000520 + a sensory capability AE that has an outcome of emotional liability + + + + obo2:OAE_0000520 + YH + + + + obo2:OAE_0000520 + emotional liability AE + + + + obo2:OAE_0000521 + a muscle adverse event which has an outcome of muscle spasm, which is an involuntary and often painful muscle contraction or cramps having a number of causes ranging from nutritional deficiency to serious nervous system conditions + + + + obo2:OAE_0000521 + SS, YH + + + + obo2:OAE_0000521 + WEB: http://en.wikipedia.org/wiki/Spasm + + + + obo2:OAE_0000521 + muscle spasm AE + + + + obo2:OAE_0000521 + MP: MP_0000743 + + + + obo2:OAE_0000521 + MedDRA: 10028334 + + + + obo2:OAE_0000522 + a movement disorder AE that has an outcome of tendon disorder + + + + obo2:OAE_0000522 + A tendon (or sinew) is a tough band of fibrous connective tissue that usually connects muscle to bone and is capable of withstanding tension. + + + + obo2:OAE_0000522 + According to the Vaccine Adverse Event Reporting System (VAERS), 'tendon disorder'; is an adverse event that was mentioned in 137 VAERS reports (0.1%) during1991-2001 (Reference: PMID: 12825543). + + + + obo2:OAE_0000522 + YH + + + + obo2:OAE_0000522 + Tendon disorder is a medical condition that results in a tendon not functioning normally. + + + + obo2:OAE_0000522 + tendon disorder AE + + + + obo2:OAE_0000523 + a behavior and neurological AE that has an outcome of hostility + + + + obo2:OAE_0000523 + YH + + + + obo2:OAE_0000523 + hostility AE + + + + obo2:OAE_0000523 + MedDRA ID: 10020400 + + + + obo2:OAE_0000524 + an eye disorder AE which has an outcome of visual field defect + + + + obo2:OAE_0000524 + SS, YH + + + + obo2:OAE_0000524 + visual impairment AE + + + + obo2:OAE_0000524 + WEB: http://en.wikipedia.org/wiki/Visual_impairment + + + + obo2:OAE_0000524 + visual field defect AE + + + + obo2:OAE_0000524 + MedDRA ID: 10047555 + + + + obo2:OAE_0000524 + MedDRA: 10047571 + + + + obo2:OAE_0000525 + a muscle adverse event which has an outcome of myopathy AE, an abnormal condition or disease of the skeletal muscle + + + + obo2:OAE_0000525 + myopathy AE + + + + obo2:OAE_0000525 + HPO: HP_0003198 + + + + obo2:OAE_0000525 + MP: MP_0000751 + + + + obo2:OAE_0000525 + MedDRA ID: 10028641 + + + + obo2:OAE_0000525 + MedDRA: 10028641 + + + + obo2:OAE_0000525 + SIDER: C0026848 + + + + obo2:OAE_0000526 + a behavior and neurological AE that has an outcome of apathy state + + + + obo2:OAE_0000526 + YH + + + + obo2:OAE_0000526 + impassivity + + + + obo2:OAE_0000526 + perfunctoriness + + + + obo2:OAE_0000526 + Apathy is a state of indifference, or the suppression of emotions such as concern, excitement, motivation and passion. An apathetic individual has an absence of interest or concern to emotional, social, or physical life. They may also exhibit an insensibility or sluggishness. + + + + obo2:OAE_0000526 + apathy AE + + + + obo2:OAE_0000526 + HPO: HP_0000741 + + + + obo2:OAE_0000526 + MedDRA ID: 10002942 + + + + obo2:OAE_0000526 + SIDER: C0085632 + + + + obo2:OAE_0000527 + a paralysis AE that has an outcome of hemiplegia + + + + obo2:OAE_0000527 + According to the Vaccine Adverse Event Reporting System (VAERS), 'hemiplegia'; is an adverse event that was mentioned in 129 VAERS reports (0.1%) during1991-2001 (Reference: PMID: 12825543). + + + + obo2:OAE_0000527 + YH + + + + obo2:OAE_0000527 + Hemiplegia is total paralysis of the arm, leg, and trunk on the same side of the body. Hemiplegia is more severe than hemiparesis, wherein one half of the body is weakened but not paralysed. + + + + obo2:OAE_0000527 + hemiplegia AE + + + + obo2:OAE_0000527 + HPO: HP_0002301 + + + + obo2:OAE_0000527 + MedDRA ID: 10019468 + + + + obo2:OAE_0000527 + MedDRA: 10019468 + + + + obo2:OAE_0000527 + SIDER: C0018991 + + + + obo2:OAE_0000528 + Pastular rash AE is a rash AE that is composed of pustular lesions. + + + + obo2:OAE_0000528 + According to the Vaccine Adverse Event Reporting System (VAERS), 'pustular rash'; is an adverse event that was mentioned in 128 VAERS reports (<0.1%) during1991-2001 (Reference: PMID: 12825543). + + + + obo2:OAE_0000528 + YH + + + + obo2:OAE_0000528 + pustular rash AE + + + + obo2:OAE_0000528 + MedDRA: 10037888 + + + + obo2:OAE_0000529 + a blood creatine phosphokinase level abnormal AE that is characterized by an increased level of creatine phosphokinase (CPK) or phosphocreatine kinase, an enzyme expressed by various tissue types that catalyses the conversion of creatine and consumes adenosine triphosphate (ATP) to create phosphocreatine and adenosine diphosphate (ADP) + + + + obo2:OAE_0000529 + YH, EB + + + + obo2:OAE_0000529 + elevated serum creatine phosphate kinase AE + + + + obo2:OAE_0000529 + blood creatine phosphokinase level increased AE + + + + obo2:OAE_0000529 + MedDRA: 10005470 + + + + obo2:OAE_0000530 + a hypertension AE that has an outcome of elevated pressure in the skull. + + + + obo2:OAE_0000530 + YH, SS + + + + obo2:OAE_0000530 + WEB: http://www.ihrfoundation.org/intracranial/hypertension/info/C16 + + + + obo2:OAE_0000530 + intracranial hypertension AE + + + + obo2:OAE_0000530 + MedDRA: 10049977 + + + + obo2:OAE_0000531 + a sensory neuropathy AE which shows a painful neuropathy characterized by damage to sensory and motor nerves + + + + obo2:OAE_0000531 + AG, YH + + + + obo2:OAE_0000531 + sensorimotor painful neuropathy AE + + + + obo2:OAE_0000532 + a digestive system AE which has an outcome of abnormal stool + + + + obo2:OAE_0000532 + According to the Vaccine Adverse Event Reporting System (VAERS), 'abnormal stools' was mentioned in 111 VAERS reports (<0.1%) during1991-2001 (Reference: PMID: 12825543). + + + + obo2:OAE_0000532 + YH + + + + obo2:OAE_0000532 + abnormal stool AE + + + + obo2:OAE_0000533 + a pain AE that has an outcome of bone pain + + + + obo2:OAE_0000533 + According to the Vaccine Adverse Event Reporting System (VAERS), 'bone pain' was mentioned in 109 VAERS reports (<0.1%) during1991-2001 (Reference: PMID: 12825543). + + + + obo2:OAE_0000533 + YH + + + + obo2:OAE_0000533 + bone pain AE + + + + obo2:OAE_0000533 + HPO: HP_0002653 + + + + obo2:OAE_0000533 + MedDRA ID: 10006002 + + + + obo2:OAE_0000533 + MedDRA: 10006002 + + + + obo2:OAE_0000533 + SIDER: C0151825 + + + + obo2:OAE_0000534 + a cardiovascular disorder AE that comes with cerebrovascular accident + + + + obo2:OAE_0000534 + YH + + + + obo2:OAE_0000534 + stroke + + + + obo2:OAE_0000534 + Cerebrovascular accident: The sudden death of some brain cells due to lack of oxygen when the blood flow to the brain is impaired by blockage or rupture of an artery to the brain. A CVA is also referred to as a stroke. + + + + obo2:OAE_0000534 + cerebrovascular accident AE + + + + obo2:OAE_0000534 + HPO: HP_0001297 + + + + obo2:OAE_0000534 + MedDRA ID: 10008190 + + + + obo2:OAE_0000534 + SIDER: C0038454 + + + + obo2:OAE_0000535 + a digestive system AE which has an outcome of parotid gland enlargement + + + + obo2:OAE_0000535 + According to the Vaccine Adverse Event Reporting System (VAERS), 'parotid gland enlargement' was mentioned in 103 VAERS reports (<0.1%) during1991-2001 (Reference: PMID: 12825543). + + + + obo2:OAE_0000535 + YH + + + + obo2:OAE_0000535 + parotid gland enlargement AE + + + + obo2:OAE_0000535 + MedDRA ID: 10034023 + + + + obo2:OAE_0000536 + a movement disorder AE that has an outcome of flatulence + + + + obo2:OAE_0000536 + According to the Vaccine Adverse Event Reporting System (VAERS), 'flatulence' was mentioned in 102 VAERS reports (<0.1%) during1991-2001 (Reference: PMID: 12825543). + + + + obo2:OAE_0000536 + YH + + + + obo2:OAE_0000536 + Flatulence is the production of a mixture of gases in the digestive tract of mammals or other animals that are byproducts of the digestion process. Such a mixture of gases is known as flatus, and is expelled from the rectum in a process colloquially referred to as "passing gas" or "farting". + + + + obo2:OAE_0000536 + flatulence AE + + + + obo2:OAE_0000536 + HPO: HP_0011024 + + + + obo2:OAE_0000536 + MedDRA ID: 10016766 + + + + obo2:OAE_0000536 + SIDER: C0016204 + + + + obo2:OAE_0000537 + a liver/biliary system AE which has an outcome of liver damage + + + + obo2:OAE_0000537 + According to the Vaccine Adverse Event Reporting System (VAERS), 'liver damage' was mentioned in 102 VAERS reports (<0.1%) during1991-2001 (Reference: PMID: 12825543). + + + + obo2:OAE_0000537 + YH + + + + obo2:OAE_0000537 + liver damage AE + + + + obo2:OAE_0000538 + a respiratory system AE which has an outcome of sore throat + + + + obo2:OAE_0000538 + YH + + + + obo2:OAE_0000538 + sore throat AE + + + + obo2:OAE_0000539 + a movement disorder AE that has an outcome of paralysis, the loss of power of voluntary movement in a muscle through injury or disease of its nerve supply + + + + obo2:OAE_0000539 + According to the Vaccine Adverse Event Reporting System (VAERS), 'paralysis' is an adverse event that was mentioned in 574 VAERS reports (0.4%) during1991-2001 (Reference: PMID: 12825543). + + + + obo2:OAE_0000539 + SS, YH + + + + obo2:OAE_0000539 + hemiplegia, palsy, paraplegia, quadiplegia + + + + obo2:OAE_0000539 + paralysis AE + + + + obo2:OAE_0000539 + HPO: HP_0010549 + + + + obo2:OAE_0000539 + MP: MP_0000753 + + + + obo2:OAE_0000539 + MedDRA ID: 10033799 + + + + obo2:OAE_0000539 + SIDER: C0522224 + + + + obo2:OAE_0000540 + a bone disorder AE that has an outcome of cellular death of bone components due to interupption of blood supply + + + + obo2:OAE_0000540 + DJ, SS, YH + + + + obo2:OAE_0000540 + WEB: http://medical-dictionary.thefreedictionary.com/avascular+necrosis + + + + obo2:OAE_0000540 + aseptic necrosis bone AE + + + + obo2:OAE_0000540 + MedDRA: 10003460 + + + + obo2:OAE_0000541 + a physical examination result abnormal AE that has an outcome of weight loss, which is the progressive reduction of body weight below normal average for age + + + + obo2:OAE_0000541 + weight loss AE + + + + obo2:OAE_0000541 + MP: MP_0001263 + + + + obo2:OAE_0000541 + MedDRA: 10047895 + + + + obo2:OAE_0000542 + According to the Vaccine Adverse Event Reporting System (VAERS), 'ataxia' is an adverse event that was mentioned in 555 VAERS reports (0.4%) during1991-2001 (Reference: PMID: 12825543). + + + + obo2:OAE_0000542 + a movement disorder AE that has an outcome of ataxia, inability to coordinate voluntary muscular movements + + + + obo2:OAE_0000542 + ataxia AE + + + + obo2:OAE_0000542 + HPO: HP_0001251 + + + + obo2:OAE_0000542 + MP: MP_0001393 + + + + obo2:OAE_0000542 + MedDRA ID: 10003591 + + + + obo2:OAE_0000542 + MedDRA: 10003591 + + + + obo2:OAE_0000542 + SIDER: C0004134 + + + + obo2:OAE_0000543 + a hair, skin, and nail AE that occurs in skin. + + + + obo2:OAE_0000543 + YH + + + + obo2:OAE_0000543 + WEB: http://www.thefreedictionary.com/skin+disorder + + + + obo2:OAE_0000543 + skin AE + + + + obo2:OAE_0000543 + MedDRA: 10040831 + + + + obo2:OAE_0000544 + a movement disorder AE that has an outcome of unusual or distinctive way of walking + + + + obo2:OAE_0000544 + According to the Vaccine Adverse Event Reporting System (VAERS), 'abnormal gait' is an adverse event that was mentioned in 998 VAERS reports (0.8%) during1991-2001 (Reference: PMID: 12825543). + + + + obo2:OAE_0000544 + SS, YH + + + + obo2:OAE_0000544 + gait disturbance AE + + + + obo2:OAE_0000544 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/21224774 + + + + obo2:OAE_0000544 + abnormal gait AE + + + + obo2:OAE_0000544 + MP: MP_0001406 + + + + obo2:OAE_0000544 + MedDRA: 10017577 + + + + obo2:OAE_0000545 + an abnormal fluid regulation AE which has an outcome of dehydration, which is an excessive water loss from the body or from an organ or bodily part + + + + obo2:OAE_0000545 + YH, SS + + + + obo2:OAE_0000545 + hypohydration + + + + obo2:OAE_0000545 + dehydration AE + + + + obo2:OAE_0000545 + HPO: HP_0001944 + + + + obo2:OAE_0000545 + MP: MP_0001429 + + + + obo2:OAE_0000545 + MedDRA ID: 10012174 + + + + obo2:OAE_0000545 + MedDRA: 10012174 + + + + obo2:OAE_0000545 + SIDER: C0011175 + + + + obo2:OAE_0000546 + a homeostasis AE which has an outcome of abnormal fluid regulation, which is any anomaly in the control of intracellular and/or extracellular fluid + + + + obo2:OAE_0000546 + abnormal fluid regulation AE + + + + obo2:OAE_0000546 + MP: MP_0001784 + + + + obo2:OAE_0000547 + a glucose homeostasis AE which has an outcome of hyperglycemia, which is an abnormally high concentration of glucose in the blood; generally refers to a pathological state + + + + obo2:OAE_0000547 + WEB: http://medical-dictionary.thefreedictionary.com/hyperglycemia + + + + obo2:OAE_0000547 + hyperglycemia AE + + + + obo2:OAE_0000547 + MP: MP_0001559 + + + + obo2:OAE_0000547 + MedDRA: 10020635 + + + + obo2:OAE_0000548 + a homeostasis AE which has an outcome of abnormal ciculating bilirubin level, which is aberrant concentration in the blood of this yellow heme breakdown product + + + + obo2:OAE_0000548 + According to the Vaccine Adverse Event Reporting System (VAERS), 'bilirubinemia'; is an adverse event that was mentioned in 221 VAERS reports (0.2%) during1991-2001 (Reference: PMID: 12825543). + + + + obo2:OAE_0000548 + abnormal circulating bilirubin level AE + + + + obo2:OAE_0000548 + MP: MP_0001569 + + + + obo2:OAE_0000549 + a skin adverse event that has an outcome of cyanosis, a dark bluish or purple skin discoloration resulting from deficient oxygenation of the blood + + + + obo2:OAE_0000549 + According to the Vaccine Adverse Event Reporting System (VAERS), 'cyanosis' is an adverse event that was mentioned in 1,804 VAERS reports (1.4%) during1991-2001 (Reference: PMID: 12825543). + + + + obo2:OAE_0000549 + cyanosis AE + + + + obo2:OAE_0000549 + HPO: HP_0000961 + + + + obo2:OAE_0000549 + MP: MP_0001575 + + + + obo2:OAE_0000549 + MedDRA ID: 10011703 + + + + obo2:OAE_0000549 + MedDRA: 10011703 + + + + obo2:OAE_0000549 + SIDER: C0010520 + + + + obo2:OAE_0000550 + a hematopoietic system AE which has an outcome of anemia, which is less than normal levels of red blood cells and/or hemoglobin within red blood cells, or volume of packed red blood cells in the bloodstream, resulting in insufficient oxygenation of tissues and organs + + + + obo2:OAE_0000550 + WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001586/ + + + + obo2:OAE_0000550 + anemia AE + + + + obo2:OAE_0000550 + MP: MP_0001577 + + + + obo2:OAE_0000550 + MedDRA: 10002034 + + + + obo2:OAE_0000551 + an abnormal blood pressure AE that has an outcome of sustained low blood pressure at a level that is likely to result in cardiovascular disease and/or other pathological states + + + + obo2:OAE_0000551 + blood pressure decreased, low blood pressure + + + + obo2:OAE_0000551 + hypotension AE + + + + obo2:OAE_0000551 + HPO: HP_0002615 + + + + obo2:OAE_0000551 + MP: MP_0001596 + + + + obo2:OAE_0000551 + MedDRA ID: 10021097 + + + + obo2:OAE_0000551 + MedDRA: 10005734 + + + + obo2:OAE_0000551 + MedDRA: 10021097 + + + + obo2:OAE_0000551 + SIDER: C0020649 + + + + obo2:OAE_0000552 + an arrhythmia AE that has an outcome of uneven timing of heart contraction + + + + obo2:OAE_0000552 + irregular heartbeat AE + + + + obo2:OAE_0000552 + MP: MP_0001636 + + + + obo2:OAE_0000554 + a digestive system AE which has an outcome of abnormal digestion, which is an altered ability of the mechanical, chemical, and enzymatic processes of the body to convert ingested food into material suitable for assimilation for synthesis of tissues or liberation of energy + + + + obo2:OAE_0000554 + abnormal digestion AE + + + + obo2:OAE_0000554 + MP: MP_0001664 + + + + obo2:OAE_0000555 + an AE that occurs in the homeostasis system. + + + + obo2:OAE_0000555 + anomaly in the processes involved in the maintenance of an internal equilibrium of various functions and chemical or protein composition of the fluids and tissues + + + + obo2:OAE_0000555 + homeostasis AE + + + + obo2:OAE_0000555 + MP: MP_0001764 + + + + obo2:OAE_0000556 + an abnormal fluid regulation AE which has an outcome of edema, which is an accumulation of an excessive amount of watery fluid in cells or intercellular tissues + + + + obo2:OAE_0000556 + oedema, swelling, dropsy + + + + obo2:OAE_0000556 + WEB: http://en.wikipedia.org/wiki/Oedema + + + + obo2:OAE_0000556 + WEB: http://en.wikipedia.org/wiki/Swelling_(medical) + + + + obo2:OAE_0000556 + edema AE + + + + obo2:OAE_0000556 + MP: MP_0001785 + + + + obo2:OAE_0000556 + MedDRA: 10016807 + + + + obo2:OAE_0000556 + MedDRA: 10030095 + + + + obo2:OAE_0000556 + MedDRA: 10042674 + + + + obo2:OAE_0000557 + an immune system disorder AE that results in complex biological response of vascular tissues to harmful stimuli, such as pathogens, damaged cells, or irritants. Inflammation is a protective attempt by the organism to remove the injurious stimuli as well as initiate the healing process for the tissue greater than expected response to injury, infection, or insult. + + + + obo2:OAE_0000557 + SS, YH + + + + obo2:OAE_0000557 + WEB: http://en.wikipedia.org/wiki/Inflammation + + + + obo2:OAE_0000557 + inflammation AE + + + + obo2:OAE_0000557 + HPO: HP_0007891 + + + + obo2:OAE_0000557 + MP: MP_0001846 + + + + obo2:OAE_0000557 + MedDRA: 10061218 + + + + obo2:OAE_0000557 + SIDER: C0021368 + + + + obo2:OAE_0000558 + an inflammation AE which has an outcome of brain inflammation, which is local accumulation of fluid, plasma proteins, and leukocytes in the brain + + + + obo2:OAE_0000558 + According to the Vaccine Adverse Event Reporting System (VAERS), 'encephalitis' is an adverse event that was mentioned in 480 VAERS reports (0.4%) during1991-2001 (Reference: PMID: 12825543). + + + + obo2:OAE_0000558 + brain inflammation AE + + + + obo2:OAE_0000558 + MP: MP_0001847 + + + + obo2:OAE_0000559 + an ear disorder AE which has an outcome of increased susceptibility to otitis media, which is greater likelihood of middle ear inflammation, with an accumulation of a thick, mucous-like fluid; usually associated with a viral or bacterial respiratory infection + + + + obo2:OAE_0000559 + increased susceptibility to otitis media AE + + + + obo2:OAE_0000559 + MP: MP_0001850 + + + + obo2:OAE_0000560 + an eye disorder AE which has an outcome of eye inflammation, which is local accumulation of fluid, plasma proteins, and leukocytes in the eye + + + + obo2:OAE_0000560 + eye inflammation AE + + + + obo2:OAE_0000560 + HPO: HP_0100533 + + + + obo2:OAE_0000560 + MP: MP_0001851 + + + + obo2:OAE_0000560 + MedDRA ID: 10015943 + + + + obo2:OAE_0000560 + SIDER: C0239429 + + + + obo2:OAE_0000561 + an eye inflammation AE which has an outcome of conjunctivitis, which is inflammation of the mucous membrane that lines the inner surface of the eyelids and the front of the eyeball + + + + obo2:OAE_0000561 + conjunctivitis AE + + + + obo2:OAE_0000561 + HPO: HP_0000509 + + + + obo2:OAE_0000561 + MP: MP_0001852 + + + + obo2:OAE_0000561 + MedDRA ID: 10010741 + + + + obo2:OAE_0000561 + MedDRA: 10010741 + + + + obo2:OAE_0000561 + SIDER: C0009763 + + + + obo2:OAE_0000562 + a liver/biliary system AE which has an outcome of liver inflammation, a local accumulation of fluid, plasma proteins, and leukocytes in the liver + + + + obo2:OAE_0000562 + According to the Vaccine Adverse Event Reporting System (VAERS), 'hepatitis' was mentioned in 387 VAERS reports (0.3%) during1991-2001 (Reference: PMID: 12825543). + + + + obo2:OAE_0000562 + liver inflammation AE + + + + obo2:OAE_0000562 + MP: MP_0001860 + + + + obo2:OAE_0000563 + aa inflammation AE which has an outcome of lung inflammation, a local accumulation of fluid, plasma proteins, and leukocytes in the lung + + + + obo2:OAE_0000563 + According to the Vaccine Adverse Event Reporting System (VAERS), 'pneumonia' was mentioned in 879 VAERS reports (0.7%) during1991-2001 (Reference: PMID: 12825543). + + + + obo2:OAE_0000563 + lung inflammation AE + + + + obo2:OAE_0000563 + MP: MP_0001861 + + + + obo2:OAE_0000564 + an inflammation AE which has an outcome of respiratory system inflammation, the local accumulation of fluid, plasma proteins, and leukocytes in the respiratory system + + + + obo2:OAE_0000564 + respiratory system inflammation AE + + + + obo2:OAE_0000564 + MP: MP_0002405 + + + + obo2:OAE_0000565 + an inflammation AE that has an outcome of vasculitis, which is an inflammation of a blood or lymph vessel + + + + obo2:OAE_0000565 + It's an inflammation. + + + + obo2:OAE_0000565 + vasculitis AE + + + + obo2:OAE_0000565 + HPO: HP_0002633 + + + + obo2:OAE_0000565 + MP: MP_0001864 + + + + obo2:OAE_0000565 + MedDRA ID: 10047115 + + + + obo2:OAE_0000565 + SIDER: C0042384 + + + + obo2:OAE_0000566 + an inflammation AE which has an outcome of salivary gland inflammation, which is local accumulation of fluid, plasma proteins, and leukocytes in the salivary gland + + + + obo2:OAE_0000566 + salivary gland inflammation AE + + + + obo2:OAE_0000566 + MP: MP_0001870 + + + + obo2:OAE_0000567 + a respiratory system inflammation AE which has an outcome of sinus inflammation, an inflammation of paranasal sinuses, which may be due to infection, allergy, or autoimmune issues. + + + + obo2:OAE_0000567 + According to the Vaccine Adverse Event Reporting System (VAERS), 'sinusitis'; is an adverse event that was mentioned in 298 VAERS reports (0.2%) during1991-2001 (Reference: PMID: 12825543). + + + + obo2:OAE_0000567 + SS, YH, RR + + + + obo2:OAE_0000567 + sinus inflammation AE + + + + obo2:OAE_0000567 + WEB: http://en.wikipedia.org/wiki/Sinusitis + + + + obo2:OAE_0000567 + sinusitis AE + + + + obo2:OAE_0000567 + HPO: HP_0000246 + + + + obo2:OAE_0000567 + MP: MP_0001872 + + + + obo2:OAE_0000567 + SIDER: C0037199 + + + + obo2:OAE_0000568 + a hypersensitivity AE which results in an allergic response showing a marked increase in reactivity to an antigen upon subsequent exposure. + + + + obo2:OAE_0000568 + JX, LW, YH + + + + obo2:OAE_0000568 + allergic reaction AE + + + + obo2:OAE_0000568 + allergic response AE + + + + obo2:OAE_0000568 + anaphylactic reaction AE + + + + obo2:OAE_0000568 + WEB: http://en.wikipedia.org/wiki/Allergy + + + + obo2:OAE_0000568 + 变态反应 + + + + obo2:OAE_0000568 + 过敏反应 + + + + obo2:OAE_0000568 + allergy AE + + + + obo2:OAE_0000568 + MP: MP_0001878 + + + + obo2:OAE_0000568 + MedDRA: 10001738 + + + + obo2:OAE_0000569 + a nervous system AE which has an outcome of abnormal cerebrospinal fluid production, an anomaly in the normal output of the fluid that fills the ventricles and other cavities of the brain and spinal cord + + + + obo2:OAE_0000569 + abnormal cerebrospinal fluid production AE + + + + obo2:OAE_0000569 + MP: MP_0001911 + + + + obo2:OAE_0000570 + an AE that occurs in nervous system. + + + + obo2:OAE_0000570 + YH + + + + obo2:OAE_0000570 + nervous system AE + + + + obo2:OAE_0000570 + MP: MP_0003633 + + + + obo2:OAE_0000571 + a respiratory system AE which has an outcome of abnormal respiration, an anomaly in the movement of gases into and out of the lung + + + + obo2:OAE_0000571 + According to the Vaccine Adverse Event Reporting System (VAERS), 'respiratory disorder' is an adverse event that was mentioned in 556 VAERS reports (0.4%) during1991-2001 (Reference: PMID: 12825543). + + + + obo2:OAE_0000571 + Not sure if it is same as respiratory system disorder or abnormal respiration. --Oliver He + + + + obo2:OAE_0000571 + abnormal respiration AE + + + + obo2:OAE_0000571 + MP: MP_0001943 + + + + obo2:OAE_0000572 + an abnormal respiration AE which has an outcome of apnea, temporary cessation of breathing; sometimes episodic + + + + obo2:OAE_0000572 + According to the Vaccine Adverse Event Reporting System (VAERS), 'apnea' is an adverse event that was mentioned in 1,618 VAERS reports (1.3%) during1991-2001 (Reference: PMID: 12825543). + + + + obo2:OAE_0000572 + JX, YH + + + + obo2:OAE_0000572 + respiratory arrest AE + + + + obo2:OAE_0000572 + WEB: http://medical-dictionary.thefreedictionary.com/apnea + + + + obo2:OAE_0000572 + apnea AE + + + + obo2:OAE_0000572 + MP: MP_0001957 + + + + obo2:OAE_0000572 + MedDRA: 10002974 + + + + obo2:OAE_0000573 + an ear disorder AE which has an outcome of deafness, which is an inability to hear + + + + obo2:OAE_0000573 + deafness AE + + + + obo2:OAE_0000573 + HPO: HP_0000365 + + + + obo2:OAE_0000573 + MP: MP_0001967 + + + + obo2:OAE_0000573 + MedDRA ID: 10011878 + + + + obo2:OAE_0000573 + SIDER: C0011053 + + + + obo2:OAE_0000574 + an adverse event that occurs in a gustatory system + + + + obo2:OAE_0000574 + gustatory system AE + + + + obo2:OAE_0000574 + MP: MP_0001985 + + + + obo2:OAE_0000575 + a gustatory system AE which has an outcome of taste sensitivity, or changes in the ability to perceive a particular flavor or suggestion of something imparting a flavor by the chemoreceptors of the gustatory system + + + + obo2:OAE_0000575 + taste sensitivity AE + + + + obo2:OAE_0000575 + MP: MP_0001986 + + + + obo2:OAE_0000576 + a urinary system AE that has an outcome of excessive or abnormally large production or passage of urine. + + + + obo2:OAE_0000576 + LW, ML, JX, YH + + + + obo2:OAE_0000576 + WEB: http://en.wikipedia.org/wiki/Polyuria + + + + obo2:OAE_0000576 + 多尿 + + + + obo2:OAE_0000576 + polyuria AE + + + + obo2:OAE_0000576 + MedDRA: 10036142 + + + + obo2:OAE_0000577 + an abnormal vision AE which has an outcome of blindness, which is loss of the sense of sight + + + + obo2:OAE_0000577 + blindness AE + + + + obo2:OAE_0000577 + HPO: HP_0000618 + + + + obo2:OAE_0000577 + MP: MP_0002001 + + + + obo2:OAE_0000577 + MedDRA ID: 10005169 + + + + obo2:OAE_0000577 + SIDER: C0456909 + + + + obo2:OAE_0000578 + an eye disorder AE which has an outcome of abnormal vision, which is an inability or decreased ability to see + + + + obo2:OAE_0000578 + abnormal vision AE + + + + obo2:OAE_0000578 + MP: MP_0002090 + + + + obo2:OAE_0000579 + a behavior and neurological AE that shows a sudden surge of electrical activity in the brain. + + + + obo2:OAE_0000579 + YH, JX + + + + obo2:OAE_0000579 + WEB: http://www.healthline.com/symptom/seizures + + + + obo2:OAE_0000579 + 突然发作 + + + + obo2:OAE_0000579 + seizure AE + + + + obo2:OAE_0000579 + MP: MP_0002064; MDR: 10039910 + + + + obo2:OAE_0000580 + an adverse event that has an outcome of abnormal behavior and neurological phenotype + + + + obo2:OAE_0000580 + any anomaly in the actions, reactions, or performance of an organism in response to external or internal stimuli compared to controls + + + + obo2:OAE_0000580 + behavior and neurological AE + + + + obo2:OAE_0000580 + MP: MP_0004924 + + + + obo2:OAE_0000581 + a behavior and neurological AE that has an outcome of altered ability to coordinate voluntary movement or repetitive, compulsive movements + + + + obo2:OAE_0000581 + movement disorder AE + + + + obo2:OAE_0000581 + HPO: HP_0100022 + + + + obo2:OAE_0000581 + MP: MP_0002066 + + + + obo2:OAE_0000581 + MedDRA ID: 10028035 + + + + obo2:OAE_0000581 + SIDER: C0026650 + + + + obo2:OAE_0000582 + a behavior and neurological AE that has an outcome of inability or altered ability to respond to a sensory stimulus + + + + obo2:OAE_0000582 + sensory capability AE + + + + obo2:OAE_0000582 + MP: MP_0002067 + + + + obo2:OAE_0000583 + a homeostasis AE which has an outcome of glucose homeostasis, which is an anomaly in the processes involved in the maintenance of an internal equilibrium of glucose in the fluids and tissues + + + + obo2:OAE_0000583 + glucose homeostasis AE + + + + obo2:OAE_0000583 + MP: MP_0002078 + + + + obo2:OAE_0000584 + Hypersensitivity AE is a immune system AE that is a set of undesirable reactions produced by the normal immune system, including allergies and autoimmunity. These reactions may be damaging, uncomfortable, or occasionally fatal. + + + + obo2:OAE_0000584 + JX, LW, YH + + + + obo2:OAE_0000584 + hypersensitivity reaction AE + + + + obo2:OAE_0000584 + WEB: http://en.wikipedia.org/wiki/Hypersensitivity + + + + obo2:OAE_0000584 + 超敏反应 + + + + obo2:OAE_0000584 + hypersensitivity AE + + + + obo2:OAE_0000584 + HPO: HP_0100326 + + + + obo2:OAE_0000584 + MP: MP_0002148 + + + + obo2:OAE_0000584 + MedDRA ID: 10020751 + + + + obo2:OAE_0000584 + MedDRA: 10020751 + + + + obo2:OAE_0000584 + SIDER: C0020517 + + + + obo2:OAE_0000585 + YH + + + + obo2:OAE_0000585 + Muscle atrophy is a wasting of muscle tissue resulting in a derangement of the muscle fibers; occurs with age, immobilization, weightlessness, malnutrition or denervation. + + + + obo2:OAE_0000585 + a muscle adverse event AE which has an outcome of muscular atrophy. + + + + obo2:OAE_0000585 + muscular atrophy AE + + + + obo2:OAE_0000585 + MP: MP_0002269 + + + + obo2:OAE_0000586 + an abnormal respiration AE which has an outcome of hyperventilation, i.e., increased alveolar ventilation relative to metabolic carbon dioxide production; results in carbon dioxide pressure decreasing below normal + + + + obo2:OAE_0000586 + According to the Vaccine Adverse Event Reporting System (VAERS), 'Petechiae' was mentioned in 510 VAERS reports (0.4%) during1991-2001 (Reference: PMID: 12825543). + + + + obo2:OAE_0000586 + hyperventilation AE + + + + obo2:OAE_0000586 + HPO: HP_0002883 + + + + obo2:OAE_0000586 + MP: MP_0002320 + + + + obo2:OAE_0000586 + MedDRA ID: 10020910 + + + + obo2:OAE_0000586 + SIDER: C0020578 + + + + obo2:OAE_0000587 + an abnormal respiration AE which has an outcome of hypoventilation AE is reduced alveolar ventilation relative to metabolic carbon dioxide production; results in alveolar carbon dioxide pressure increasing above normal + + + + obo2:OAE_0000587 + an abnormal respiration AE which has an outcome of hypoventilation, i.e., reduced alveolar ventilation relative to metabolic carbon dioxide production; results in alveolar carbon dioxide pressure increasing above normal + + + + obo2:OAE_0000587 + According to the Vaccine Adverse Event Reporting System (VAERS), 'hypoventilation' is an adverse event that was mentioned in 321 VAERS reports (0.2%) during1991-2001 (Reference: PMID: 12825543). + + + + obo2:OAE_0000587 + hypoventilation AE + + + + obo2:OAE_0000587 + HPO: HP_0007110 + + + + obo2:OAE_0000587 + MP: MP_0002321 + + + + obo2:OAE_0000587 + MedDRA ID: 10021133 + + + + obo2:OAE_0000587 + SIDER: C0398353 + + + + obo2:OAE_0000588 + an adverse event which occurs in a hematopoietic system, which is any structural or developmental anomaly of the blood cells or the organs associated with the development and formation of blood cells + + + + obo2:OAE_0000588 + hematopoietic system AE + + + + obo2:OAE_0000588 + MP: MP_0002396 + + + + obo2:OAE_0000589 + an eye disorder AE which has an outcome of mydriasis, which is dilation of one or both pupils regardless of light conditions + + + + obo2:OAE_0000589 + mydriasis AE + + + + obo2:OAE_0000589 + HPO: HP_0011499 + + + + obo2:OAE_0000589 + MP: MP_0002546 + + + + obo2:OAE_0000589 + MedDRA ID: 10028521 + + + + obo2:OAE_0000589 + SIDER: C0026961 + + + + obo2:OAE_0000590 + an arrhythmia AE that has an outcome of greater than average resting heart beats per minute, usually measured by the number of times the heart ventricles contract per unit of time, usually per minute + + + + obo2:OAE_0000590 + tachycardia + + + + obo2:OAE_0000590 + WEB: http://en.wikipedia.org/wiki/Tachycardia + + + + obo2:OAE_0000590 + increased heart rate AE + + + + obo2:OAE_0000590 + MP: MP_0002626 + + + + obo2:OAE_0000590 + MedDRA: 10019303 + + + + obo2:OAE_0000591 + a behavior and neurological AE that has an outcome of exaggerated reflex action + + + + obo2:OAE_0000591 + hyperresponsive to tactile stimuli AE + + + + obo2:OAE_0000591 + MP: MP_0002738 + + + + obo2:OAE_0000592 + a muscle spasm AE that has an outcome of opisthotonus + + + + obo2:OAE_0000592 + YH + + + + obo2:OAE_0000592 + opisthotonus is a form of tetanic spasm in which the head, neck and spine are bent backward and the body is bowed forward + + + + obo2:OAE_0000592 + opisthotonus AE + + + + obo2:OAE_0000592 + HPO: HP_0002179 + + + + obo2:OAE_0000592 + MP: MP_0002880 + + + + obo2:OAE_0000592 + MedDRA ID: 10030899 + + + + obo2:OAE_0000592 + SIDER: C0151818 + + + + obo2:OAE_0000593 + An joint disorder AE that has an outcome of joint inflammation, which is local accumulation of fluid, plasma proteins, and leukocytes in the joints + + + + obo2:OAE_0000593 + YH + + + + obo2:OAE_0000593 + joint inflammation AE + + + + obo2:OAE_0000593 + MP: MP_0002933 + + + + obo2:OAE_0000594 + an abnormal enzyme level AE which has an outcome of incraesed lactate dehydrogenase level, which is greater than the normal concentration of this enzyme, which catalyzes the interconversion of lactate and pyruvate + + + + obo2:OAE_0000594 + increased lactate dehydrogenase level AE + + + + obo2:OAE_0000594 + MP: MP_0002944 + + + + obo2:OAE_0000595 + an abnormal enzyme level AE which has an outcome of increased circulating alkaline phophatase level, which is an elevated activity of this enzyme, which hydrolyzes orthophosphoric monoesters, found in the blood + + + + obo2:OAE_0000595 + increased circulating alkaline phosphatase level AE + + + + obo2:OAE_0000595 + MP: MP_0002968 + + + + obo2:OAE_0000596 + A joint inflammation AE that has an outcome of arthritis, marked by changes in the synovial membranes and thickening of articular structures, widespread degeneration of the collagen fibers in connective tissues, and by atrophy and rarefaction of bony structures + + + + obo2:OAE_0000596 + YH + + + + obo2:OAE_0000596 + 关节炎 + + + + obo2:OAE_0000596 + arthritis AE + + + + obo2:OAE_0000596 + HPO: HP_0001369 + + + + obo2:OAE_0000596 + MP: MP_0002993 + + + + obo2:OAE_0000596 + MedDRA ID: 10003246 + + + + obo2:OAE_0000596 + SIDER: C0003864 + + + + obo2:OAE_0000597 + a digestive system AE which has an outcome of dysphagia, which is a behavior and neurological AE that has an outcome of difficulty in swallowing food or liquid + + + + obo2:OAE_0000597 + dysphagia AE + + + + obo2:OAE_0000597 + HPO: HP_0002015 + + + + obo2:OAE_0000597 + MP: MP_0003158 + + + + obo2:OAE_0000597 + MedDRA ID: 10013950 + + + + obo2:OAE_0000597 + MedDRA: 10013950 + + + + obo2:OAE_0000597 + SIDER: C0011168 + + + + obo2:OAE_0000598 + an ear disorder AE which has an outcome of decreased lateral semicircular canal size, which is small size of the lateral long bony tube of the labyrinth that is involved in the sense of balance + + + + obo2:OAE_0000598 + decreased lateral semicircular canal size AE + + + + obo2:OAE_0000598 + MP: MP_0003162 + + + + obo2:OAE_0000599 + a hematopoietic system AE which has an outcome of decreased platelet count, which is fewer than the normal numbers of the non-nucleated cells found in the blood and involved in blood coagulation + + + + obo2:OAE_0000599 + SS, YH + + + + obo2:OAE_0000599 + decreased platelet cell number AE + + + + obo2:OAE_0000599 + platelet count decreased AE + + + + obo2:OAE_0000599 + HPO: HP_0001873 + + + + obo2:OAE_0000599 + MP: MP_0003179 + + + + obo2:OAE_0000599 + MedDRA: 10035528 + + + + obo2:OAE_0000599 + SIDER: C0392386 + + + + obo2:OAE_0000600 + an abnormal digestion AE which has an outcome of nausea, a gastric discomfort associated with the inclination to vomit + + + + obo2:OAE_0000600 + nausea AE + + + + obo2:OAE_0000600 + HPO: HP_0002018 + + + + obo2:OAE_0000600 + MP: MP_0003259; MDR: 10028813 + + + + obo2:OAE_0000600 + MedDRA ID: 10028813 + + + + obo2:OAE_0000600 + MedDRA: 10028813 + + + + obo2:OAE_0000600 + SIDER: C0027497 + + + + obo2:OAE_0000601 + regurgitation AE + + + + obo2:OAE_0000601 + an abnormal digestion AE which has an outcome of vomiting, the retrograde expulsion of gastric contents through the oral cavity + + + + obo2:OAE_0000601 + vomiting AE + + + + obo2:OAE_0000601 + HPO: HP_0002013 + + + + obo2:OAE_0000601 + MP: MP_0003260; MDR: 10047700 + + + + obo2:OAE_0000601 + MedDRA ID: 10047700 + + + + obo2:OAE_0000601 + MedDRA: 10047700 + + + + obo2:OAE_0000601 + SIDER: C0042963 + + + + obo2:OAE_0000602 + an abnormal defecation AE that has an outcome of constipation, which is incomplete, infrequent or difficult evacuation of fecal matter + + + + obo2:OAE_0000602 + According to the Vaccine Adverse Event Reporting System (VAERS), 'constipation'; is an adverse event that was mentioned in 242 VAERS reports (0.2%) during1991-2001 (Reference: PMID: 12825543). + + + + obo2:OAE_0000602 + infrequent bowel movements AE + + + + obo2:OAE_0000602 + constipation AE + + + + obo2:OAE_0000602 + HPO: HP_0002019 + + + + obo2:OAE_0000602 + MP: MP_0003267 + + + + obo2:OAE_0000602 + MedDRA ID: 10010774 + + + + obo2:OAE_0000602 + SIDER: C0009806 + + + + obo2:OAE_0000603 + a digestive system AE that has an outcome of abnormal defecation, an anomaly in the production and excretion of feces + + + + obo2:OAE_0000603 + abnormal defecation AE + + + + obo2:OAE_0000603 + MP: MP_0003866 + + + + obo2:OAE_0000604 + a urinary system AE that has an outcome of the symptom of urinary incontinence, which is the inability to control the urinary excretory functions. + + + + obo2:OAE_0000604 + YH + + + + obo2:OAE_0000604 + WEB: http://www.nlm.nih.gov/medlineplus/urinaryincontinence.html + + + + obo2:OAE_0000604 + urinary incontinence AE + + + + obo2:OAE_0000604 + HPO: HP_0000020 + + + + obo2:OAE_0000604 + MP: MP_0003280 + + + + obo2:OAE_0000604 + SIDER: C0042024 + + + + obo2:OAE_0000605 + clonus AE is a series of involuntary, rhythmic, muscular contractions and relaxations. + + + + obo2:OAE_0000605 + SJ, YH + + + + obo2:OAE_0000605 + WEB: http://en.wikipedia.org/wiki/Clonus + + + + obo2:OAE_0000605 + clonus AE causes large motions that are usually initiated by a reflex. + + + + obo2:OAE_0000605 + clonus AE + + + + obo2:OAE_0000605 + MedDRA ID: 10009346 + + + + obo2:OAE_0000606 + a skin discoloration AE which has an outcome of pallor, an unnatural paleness to the skin, generally attributable to anemia + + + + obo2:OAE_0000606 + pallor AE + + + + obo2:OAE_0000606 + HPO: HP_0008361 + + + + obo2:OAE_0000606 + MP: MP_0003717 + + + + obo2:OAE_0000606 + MedDRA ID: 10033546 + + + + obo2:OAE_0000606 + SIDER: C0030232 + + + + obo2:OAE_0000607 + an ear disorder AE which has an outcome of tinnitus, which is a persistent sensation of buzzing, ringing, clicking, or other noises in the ear + + + + obo2:OAE_0000607 + tinnitus AE + + + + obo2:OAE_0000607 + HPO: HP_0000360 + + + + obo2:OAE_0000607 + MP: MP_0003741 + + + + obo2:OAE_0000607 + MedDRA ID: 10043882 + + + + obo2:OAE_0000607 + SIDER: C0040264 + + + + obo2:OAE_0000608 + a digestive system AE which has an outcome of stomatitis, which is an inflammation of the mucous lining of the mouth + + + + obo2:OAE_0000608 + This is a type of inflammation. + + + + obo2:OAE_0000608 + WEB: http://medical-dictionary.thefreedictionary.com/stomatitis + + + + obo2:OAE_0000608 + stomatitis AE + + + + obo2:OAE_0000608 + HPO: HP_0010280 + + + + obo2:OAE_0000608 + MP: MP_0003746 + + + + obo2:OAE_0000608 + MedDRA ID: 10042128 + + + + obo2:OAE_0000608 + MedDRA: 10042128 + + + + obo2:OAE_0000608 + SIDER: C0038362 + + + + obo2:OAE_0000609 + a digestive system AE which has an outcome of mouth mucosal ulceration, which is lesions through the mucous membrane of the mouth, usually associated with loss of tissue + + + + obo2:OAE_0000609 + According to the Vaccine Adverse Event Reporting System (VAERS), 'mouth ulceration' was mentioned in 246 VAERS reports (0.2%) during1991-2001 (Reference: PMID: 12825543). + + + + obo2:OAE_0000609 + mouth mucosal ulceration AE + + + + obo2:OAE_0000609 + MP: MP_0003747 + + + + obo2:OAE_0000610 + a muscle adverse event AE that has an outcome of abnormal muscle tone, which is an anomaly in the resting tautness or laxity of a muscle, normally somewhere in the middle of the range between total contraction and total relaxation + + + + obo2:OAE_0000610 + YH + + + + obo2:OAE_0000610 + abnormal muscle tone AE + + + + obo2:OAE_0000610 + MP: MP_0004142 + + + + obo2:OAE_0000611 + an abnormal muscle tone AE which has an outcome of hypertonia, which is increased muscle tension resulting in stiffness of the muscles in the resting state + + + + obo2:OAE_0000611 + YH + + + + obo2:OAE_0000611 + hypertonia AE + + + + obo2:OAE_0000611 + HPO: HP_0001276 + + + + obo2:OAE_0000611 + MP: MP_0004143 + + + + obo2:OAE_0000611 + MedDRA ID: 10020852 + + + + obo2:OAE_0000611 + SIDER: C0026826 + + + + obo2:OAE_0000612 + an abnormal muscle tone AE which has an outcome of hypotonia, which is decreased muscle tension resulting in limpness of the muscles in the resting state, not to be confused with weakness + + + + obo2:OAE_0000612 + YH + + + + obo2:OAE_0000612 + hypotonia AE + + + + obo2:OAE_0000612 + HPO: HP_0009062 + + + + obo2:OAE_0000612 + MP: MP_0004144 + + + + obo2:OAE_0000612 + MedDRA ID: 10021118 + + + + obo2:OAE_0000612 + SIDER: C0026827 + + + + obo2:OAE_0000613 + a muscle inflammation AE which has an outcome of myositis, which is an inflammation of skeletal muscle; local accumulation of fluid, plasma proteins, and leukocytes in the striated muscle + + + + obo2:OAE_0000613 + YH + + + + obo2:OAE_0000613 + myositis AE + + + + obo2:OAE_0000613 + HPO: HP_0009071 + + + + obo2:OAE_0000613 + MP: MP_0004510 + + + + obo2:OAE_0000613 + MedDRA ID: 10028653 + + + + obo2:OAE_0000613 + MedDRA: 10028653 + + + + obo2:OAE_0000613 + SIDER: C0027121 + + + + obo2:OAE_0000614 + a muscle adverse event which has an outcome of muscle inflammation, which is a local accumulation of fluid, plasma proteins, and leukocytes in muscle + + + + obo2:OAE_0000614 + YH + + + + obo2:OAE_0000614 + muscle inflammation AE + + + + obo2:OAE_0000614 + MP: MP_0004511 + + + + obo2:OAE_0000615 + a lymphocyte count abnormal AE that has an outcome of greater than normal number of the cells involved in adaptive immune reactions of the body in most inflammatory and autoimmune diseases, including B cells, T cells and natural killer cells + + + + obo2:OAE_0000615 + According to the Vaccine Adverse Event Reporting System (VAERS), 'lymphocytosis'; is an adverse event that was mentioned in 129 VAERS reports (0.1%) during1991-2001 (Reference: PMID: 12825543). + + + + obo2:OAE_0000615 + EB + + + + obo2:OAE_0000615 + increased lymphocyte cell number AE + + + + obo2:OAE_0000615 + lymphocyte cell number increased AE + + + + obo2:OAE_0000615 + lymphocyte count increased AE + + + + obo2:OAE_0000615 + MP: MP_0005013 + + + + obo2:OAE_0000615 + MedDRA: 10025258 + + + + obo2:OAE_0000616 + an abnormal defecation AE that has an outcome of diarrhea, which is abnormally frequent discharge of semi-solid or fluid fecal matter from the bowel + + + + obo2:OAE_0000616 + diarrhoea AE + + + + obo2:OAE_0000616 + WEB: http://medical-dictionary.thefreedictionary.com/diarrhea + + + + obo2:OAE_0000616 + diarrhea AE + + + + obo2:OAE_0000616 + MP: MP_0005036 + + + + obo2:OAE_0000616 + MedDRA: 10012735 + + + + obo2:OAE_0000617 + a homeostasis AE which has an outcome of hypoxia, which is a reduced concentration of O2 in the blood, alveoli or other tissues resulting in the decreased pressure of this component of body gases + + + + obo2:OAE_0000617 + WEB: http://medical-dictionary.thefreedictionary.com/hypoxia + + + + obo2:OAE_0000617 + hypoxia AE + + + + obo2:OAE_0000617 + HPO: HP_0002795 + + + + obo2:OAE_0000617 + MP: MP_0005039 + + + + obo2:OAE_0000617 + MedDRA ID: 10021143 + + + + obo2:OAE_0000617 + MedDRA: 10021143 + + + + obo2:OAE_0000617 + SIDER: C0242184 + + + + obo2:OAE_0000618 + an infectious adverse event which has an outcome of the presence of various pathogenic organisms, or their toxins, in the blood or tissues that results in the infections in blood stream. + + + + obo2:OAE_0000618 + According to the Vaccine Adverse Event Reporting System (VAERS), 'sepsis' was mentioned in 416 VAERS reports (0.3%) during1991-2001 (Reference: PMID: 12825543). + + + + obo2:OAE_0000618 + SS + + + + obo2:OAE_0000618 + sepsis AE + + + + obo2:OAE_0000618 + HPO: HP_0002718 + + + + obo2:OAE_0000618 + MP: MP_0005044 + + + + obo2:OAE_0000618 + MedDRA ID: 10040047 + + + + obo2:OAE_0000618 + MedDRA: 10040047 + + + + obo2:OAE_0000618 + SIDER: C0243026 + + + + obo2:OAE_0000619 + a urinary system AE that results in the presence of blood in the urine + + + + obo2:OAE_0000619 + YH, SJ + + + + obo2:OAE_0000619 + blood urine + + + + obo2:OAE_0000619 + haematuria AE + + + + obo2:OAE_0000619 + WEB: http://kidney.niddk.nih.gov/kudiseases/pubs/hematuria/ + + + + obo2:OAE_0000619 + WEB: http://medical-dictionary.thefreedictionary.com/hematuria + + + + obo2:OAE_0000619 + Hematuria AE can be caused by menstruation, vigorous exercise, sexual activity, viral illness, trauma, or infection, such as a urinary tract infection (UTI), along with more serious disorders such as cancer, disease, and clotting. + + + + obo2:OAE_0000619 + hematuria AE + + + + obo2:OAE_0000619 + MP: MP_0005161 + + + + obo2:OAE_0000619 + MedDRA: 10018867 + + + + obo2:OAE_0000619 + MedDRA: 10018870 + + + + obo2:OAE_0000620 + a homeostasis AE which has an outcome of abnormal enzyme level, which is an altered level of any enzyme or their cofactors, that act as catalysts to induce chemical changes in other substances + + + + obo2:OAE_0000620 + abnormal enzyme level AE + + + + obo2:OAE_0000620 + MP: MP_0005319 + + + + obo2:OAE_0000621 + an arrhythmia AE that has an outcome of fewer than average resting heart beats per minute, usually measured by the number of times the heart ventricles contract per unit of time, usually per minute + + + + obo2:OAE_0000621 + Added MedDRA term LB + + + + obo2:OAE_0000621 + decreased heart rate AE + + + + obo2:OAE_0000621 + MP: MP_0005333 + + + + obo2:OAE_0000621 + MedDRA: 10019301 + + + + obo2:OAE_0000622 + an adverse event that has an outcome of urinary system AE is a functional anomaly of any of the organs involved in the production or excretion of urine + + + + obo2:OAE_0000622 + YH + + + + obo2:OAE_0000622 + urinary system AE + + + + obo2:OAE_0000622 + MP: MP_0005502 + + + + obo2:OAE_0000623 + an abnormal body temperature AE which has an outcome of decreased body temperature, which is less than the level of heat natural to a living being + + + + obo2:OAE_0000623 + YH, SJ + + + + obo2:OAE_0000623 + decreased body temperature AE + + + + obo2:OAE_0000623 + Hypothermia AE is a medical emergency that occurs when your body loses heat faster than it can produce heat, causing a dangerously low body temperature. + + + + obo2:OAE_0000623 + hypothermia AE + + + + obo2:OAE_0000623 + MP: MP_0005534 + + + + obo2:OAE_0000623 + MedDRA: 10021113 + + + + obo2:OAE_0000624 + a homeostasis AE whic has an outcome of abnomal body temperature, which is a deviation in the level of heat natural to a living being + + + + obo2:OAE_0000624 + abnormal body temperature AE + + + + obo2:OAE_0000624 + MP: MP_0005535 + + + + obo2:OAE_0000625 + a peripheral neuropathy AE which has an outcome of neuritis, the local accumulation of fluid, plasma proteins, and leukocytes in the brain and/or spinal cord + + + + obo2:OAE_0000625 + neuritis AE + + + + obo2:OAE_0000625 + MP: MP_0006082 + + + + obo2:OAE_0000625 + MedDRA ID: 10029240 + + + + obo2:OAE_0000626 + diplopia AE + + + + obo2:OAE_0000626 + an abnormal vision AE which has an outcome of double vision, which is two images perceived when only a single object is present + + + + obo2:OAE_0000626 + double vision AE + + + + obo2:OAE_0000626 + MP: MP_0006150 + + + + obo2:OAE_0000626 + MedDRA: 10013036 + + + + obo2:OAE_0000627 + an anemia AE which has an outcome of hypochromic anemia, which is a hemoglobin deficiency resulting from a reduction in the concentration of hemoglobin in red cells, resulting in insufficient oxygenation of tissues and organs + + + + obo2:OAE_0000627 + hypochromic anemia AE + + + + obo2:OAE_0000627 + MP: MP_0008387 + + + + obo2:OAE_0000628 + an adverse event that is indicated by an abnormal result of an investigation that uses some laboratory equipment, device, or medical technology. + + + + obo2:OAE_0000628 + This term is used to replace 'lab test abnormal AE'. The reason for this is that some test, like X-ray test, is not considered by many physicians as a lab test. Therefore, we have used this new term to cover a broader scope. All terms asserted under this term represent the investigation results without defined conclusion of disease. + + + + obo2:OAE_0000628 + EB, SS, YH + + + + obo2:OAE_0000628 + laboratory test abnormal + + + + obo2:OAE_0000628 + investigation result abnormal AE + + + + obo2:OAE_0000628 + MedDRA: 10061253 + + + + obo2:OAE_0000629 + a movement disorder AE that has an outcome of nervous + + + + obo2:OAE_0000629 + According to the Vaccine Adverse Event Reporting System (VAERS), 'nervousness' is an adverse event that was mentioned in 583 VAERS reports (0.5%) during1991-2001 (Reference: PMID: 12825543). + + + + obo2:OAE_0000629 + increased, skittish, behavior induced by stimulation such as handling, touching or noise + + + + obo2:OAE_0000629 + nervous AE + + + + obo2:OAE_0000629 + MP: MP_0008912 + + + + obo2:OAE_0000630 + a hemorrhage AE that has an outcome of ecchymosis + + + + obo2:OAE_0000630 + an ecchymosis is a spot caused by loss of blood from a vessel; it implies a larger size than a petechiae, and has a more diffuse border than purpura; an ecchymosis can be caused by a bruise (which implies trauma), but can also be caused by bleeding diathesis + + + + obo2:OAE_0000630 + ecchymosis AE + + + + obo2:OAE_0000630 + HPO: HP_0000978 + + + + obo2:OAE_0000630 + MP: MP_0009276 + + + + obo2:OAE_0000630 + MedDRA ID: 10014080 + + + + obo2:OAE_0000630 + SIDER: C0013491 + + + + obo2:OAE_0000631 + serious adverse event is an adverse event that requires in-patient hospitalization, or prolongation of existing hospitalization, or that causes congenital malformation, or that results in persistent or significant disability or incapacity, or that is life threatening or results in death. + + + + obo2:OAE_0000631 + YH, MC + + + + obo2:OAE_0000631 + serious adverse event + + + + obo2:OAE_0000631 + WEB: http://en.wikipedia.org/wiki/Serious_adverse_event + + + + obo2:OAE_0000631 + WEB: http://www.fda.gov/Safety/MedWatch/HowToReport/ucm053087.htm + + + + obo2:OAE_0000631 + WEB: http://www.google.ca/url?sa=t&source=web&ct=res&cd=1&ved=0CA4QFjAA&url=http%3A%2F%2Fwww.irrd.ca%2Fethics%2Fimages%2FAdverse-event-definition.doc&ei=eqFMS-yFNZSoswOt6siKAQ&usg=AFQjCNGnQcwI8OXH7dqxwo4RgZEEn8X6lg&sig2=UNngkCdO5ZTFvbIB1pKuaA + + + + obo2:OAE_0000631 + severe adverse event + + + + obo2:OAE_0000632 + a serious adverse event that has an outcome of death. + + + + obo2:OAE_0000632 + YH + + + + obo2:OAE_0000632 + WEB: http://www.fda.gov/Safety/MedWatch/HowToReport/ucm053087.htm + + + + obo2:OAE_0000632 + death AE + + + + obo2:OAE_0000632 + HPO: HP_0001645 + + + + obo2:OAE_0000632 + MedDRA: 10011906 + + + + obo2:OAE_0000632 + SIDER: C1306577 + + + + obo2:OAE_0000633 + a serious adverse event that is life-threatening. This adverse event occurs when a patient was at substantial risk of dying or it is suspected that the use or continued use of the product would result in the patient's death. + + + + obo2:OAE_0000633 + YH + + + + obo2:OAE_0000633 + WEB: http://www.fda.gov/Safety/MedWatch/HowToReport/ucm053087.htm + + + + obo2:OAE_0000633 + life-threating adverse event + + + + obo2:OAE_0000634 + a serious adverse event that leads to hospitalization. + + + + obo2:OAE_0000634 + YH + + + + obo2:OAE_0000634 + WEB: http://www.fda.gov/Safety/MedWatch/HowToReport/ucm053087.htm + + + + obo2:OAE_0000634 + adverse event leading to hospitalization + + + + obo2:OAE_0000635 + a serious adverse event that leads to disability or permanent damage. + + + + obo2:OAE_0000635 + YH + + + + obo2:OAE_0000635 + WEB: http://www.fda.gov/Safety/MedWatch/HowToReport/ucm053087.htm + + + + obo2:OAE_0000635 + adverse event leading to disability + + + + obo2:OAE_0000636 + a serious adverse event that is an adverse event leading to congenital anomaly leads to suspicions that exposure to a medical product prior to conception or during pregnancy resulted in an adverse outcome in the child. + + + + obo2:OAE_0000636 + YH + + + + obo2:OAE_0000636 + WEB: http://www.fda.gov/Safety/MedWatch/HowToReport/ucm053087.htm + + + + obo2:OAE_0000636 + WEB: http://www.thefreedictionary.com/birth+defect + + + + obo2:OAE_0000636 + adverse event leading to congenital anomaly + + + + obo2:OAE_0000636 + MedDRA: 10010356 + + + + obo2:OAE_0000637 + a serious adverse event which is an adverse event that requires intervention to prevent permanent impairment or damage leads to suspicions that the use of a medical product may result in a condition which required medical or surgical intervention to preclude permanent impairment or damage to a patient. + + + + obo2:OAE_0000637 + YH + + + + obo2:OAE_0000637 + WEB: http://www.fda.gov/Safety/MedWatch/HowToReport/ucm053087.htm + + + + obo2:OAE_0000637 + adverse event that requires intervention to prevent permanent impairment or damage + + + + obo2:OAE_0000638 + an adverse event that is considered not serious. + + + + obo2:OAE_0000638 + YH, MC + + + + obo2:OAE_0000638 + WEB: http://www.google.ca/url?sa=t&source=web&ct=res&cd=1&ved=0CA4QFjAA&url=http%3A%2F%2Fwww.irrd.ca%2Fethics%2Fimages%2FAdverse-event-definition.doc&ei=eqFMS-yFNZSoswOt6siKAQ&usg=AFQjCNGnQcwI8OXH7dqxwo4RgZEEn8X6lg&sig2=UNngkCdO5ZTFvbIB1pKuaA + + + + obo2:OAE_0000638 + non-serious adverse event + + + + obo2:OAE_0000639 + low-grade fever AE is a fever adverse event with a temperature between 100° F and 102.2° F (37.8° C and 39° C). + + + + obo2:OAE_0000639 + YH + + + + obo2:OAE_0000639 + WEB: http://www.toyourhealth.com/mpacms/tyh/article.php?id=1521 + + + + obo2:OAE_0000639 + The low-grade level of fever is beneficial. With most microbes/"bugs" that a child will be exposed to, this fever will assist the body in repelling the invader. + + + + obo2:OAE_0000639 + low-grade fever AE + + + + obo2:OAE_0000640 + moderate-grade fever AE is a fever adverse event with a temperature typically between 102.2° F and 104.5° F (39° C and 40° C). + + + + obo2:OAE_0000640 + YH + + + + obo2:OAE_0000640 + WEB: http://www.toyourhealth.com/mpacms/tyh/article.php?id=1521 + + + + obo2:OAE_0000640 + This moderate-grade fever temperature is still considered beneficial. If a child's body has reached this temperature, it's what's needed to kill whatever bacteria or virus their body is attempting to fight. + + + + obo2:OAE_0000640 + moderate-grade fever AE + + + + obo2:OAE_0000641 + high-grade fever AE is a fever adverse event with a fever temperature greater than 104.5° F (40° C). + + + + obo2:OAE_0000641 + YH + + + + obo2:OAE_0000641 + WEB: http://www.toyourhealth.com/mpacms/tyh/article.php?id=1521 + + + + obo2:OAE_0000641 + This fever may cause the child some discomfort and result in crankiness. Generally indicative of a bacterial infection, this fever means that the body is fighting something more serious than the common cold. + + + + obo2:OAE_0000641 + high-grade fever AE + + + + obo2:OAE_0000642 + hyperpyrexia AE is a fever adverse event that has an outcome of an excessive and unusual elevation of set body temperature greater than or equal to 41 °C. It is an extremely high fever. Such a high temperature is considered a medical emergency as it may indicate a serious underlying condition such as sepsis. + + + + obo2:OAE_0000642 + YH + + + + obo2:OAE_0000642 + extreme pyrexia AE + + + + obo2:OAE_0000642 + Axelrod YK1, Diringer MN. Temperature management in acute neurologic disorders. Neurol Clin. 2008 May;26(2):585-603, xi. doi: 10.1016/j.ncl.2008.02.005. PMID: 18514828. + + + + obo2:OAE_0000642 + WEB: http://en.wikipedia.org/wiki/Hyperpyrexia + + + + obo2:OAE_0000642 + hyperpyrexia AE + + + + obo2:OAE_0000642 + HPO: HP_0001945 + + + + obo2:OAE_0000642 + MedDRA ID: 10020741 + + + + obo2:OAE_0000642 + SIDER: C0392676 + + + + obo2:OAE_0000643 + a pain AE that has an outcome of musculoskeletal pain + + + + obo2:OAE_0000643 + SS, YH + + + + obo2:OAE_0000643 + WEB: http://www.webmd.com/pain-management/guide/musculoskeletal-pain + + + + obo2:OAE_0000643 + Musculoskeletal pain is pain that affects the muscles, ligaments and tendons, along with the bones. + + + + obo2:OAE_0000643 + musculoskeletal pain AE + + + + obo2:OAE_0000643 + HPO: HP_0003326 + + + + obo2:OAE_0000643 + MedDRA ID: 10028391 + + + + obo2:OAE_0000643 + SIDER: C0026858 + + + + obo2:OAE_0000644 + injection-site erythema AE is an erythema AE that results in redness of skin, caused by hyperermia of the capillaries in the lower layers of the skin at the physical area of injection + + + + obo2:OAE_0000644 + SS, YH + + + + obo2:OAE_0000644 + WEB: http://en.wikipedia.org/wiki/Erythema + + + + obo2:OAE_0000644 + WEB: http://medical-dictionary.thefreedictionary.com/erythema + + + + obo2:OAE_0000644 + injection-site erythema AE + + + + obo2:OAE_0000644 + MedDRA: 10022061 + + + + obo2:OAE_0000645 + Erythema AE is a skin adverse event that showns redness of the skin caused by hyperemia of the capillaries in the lower layers of the skin. + + + + obo2:OAE_0000645 + SS, YH + + + + obo2:OAE_0000645 + reddish skin + + + + obo2:OAE_0000645 + WEB: http://en.wikipedia.org/wiki/Erythema + + + + obo2:OAE_0000645 + erythema AE + + + + obo2:OAE_0000645 + HPO: HP_0010783 + + + + obo2:OAE_0000645 + MP:0001190 + + + + obo2:OAE_0000645 + MedDRA ID: 10015150 + + + + obo2:OAE_0000645 + MedDRA: 10015150 + + + + obo2:OAE_0000645 + SIDER: C0041834 + + + + obo2:OAE_0000646 + a headache AE that has an outcome of sinus headache + + + + obo2:OAE_0000646 + YH, SS + + + + obo2:OAE_0000646 + WEB: http://american-rhinologic.org/patientinfo.headache.phtml + + + + obo2:OAE_0000646 + sinus headache is a headache located over the sinuses, (forehead, corners of the eye, and cheek areas). On occasion, the pain will be felt behind the eyes, in the back of the neck, or may extend into the upper teeth. + + + + obo2:OAE_0000646 + sinus headache AE + + + + obo2:OAE_0000646 + HPO: HP_0002315 + + + + obo2:OAE_0000646 + SIDER: C0037195 + + + + obo2:OAE_0000647 + pneumonia AE is a respiratory system AE that results in an abnormal inflammatory condition of the lung. It is often characterized as including inflammation of the parenchyma of the lung (that is, the alveoli) and abnormal alveolar filling with fluid (consolidation and exudation). + + + + obo2:OAE_0000647 + SS, YH + + + + obo2:OAE_0000647 + WEB: http://en.wikipedia.org/wiki/Pneumonia + + + + obo2:OAE_0000647 + pneumonia AE + + + + obo2:OAE_0000647 + HPO: HP_0002090 + + + + obo2:OAE_0000647 + MedDRA ID: 10035664 + + + + obo2:OAE_0000647 + MedDRA: 10035664 + + + + obo2:OAE_0000647 + SIDER: C0032285 + + + + obo2:OAE_0000648 + lobar pneumonia is pneumonia AE that affects a large and continuous area of the lobe of a lung + + + + obo2:OAE_0000648 + SS, YH + + + + obo2:OAE_0000648 + WEB: http://en.wikipedia.org/wiki/Lobar_pneumonia + + + + obo2:OAE_0000648 + lobar pneumonia AE + + + + obo2:OAE_0000648 + HPO: HP_0002090 + + + + obo2:OAE_0000648 + MedDRA: 10024738 + + + + obo2:OAE_0000648 + SIDER: C0032300 + + + + obo2:OAE_0000649 + axillary pain AE is a pain AE that occurs in the underarm (the area on the human body directly under the join where the arm connects to the shoulder) + + + + obo2:OAE_0000649 + SS, YH + + + + obo2:OAE_0000649 + axillary pain AE + + + + obo2:OAE_0000650 + an cardiovascular adverse event that is a collection of blood outside the blood vessels, generally the result of hemorrhage, or more specifically, internal bleeding. It is commonly called a bruise. + + + + obo2:OAE_0000650 + SS, YH + + + + obo2:OAE_0000650 + bruise AE + + + + obo2:OAE_0000650 + ecchymoses AE + + + + obo2:OAE_0000650 + haematoma AE + + + + obo2:OAE_0000650 + WEB: http://en.wikipedia.org/wiki/Hematoma + + + + obo2:OAE_0000650 + hematoma AE + + + + obo2:OAE_0000650 + HPO: HP_0001892 + + + + obo2:OAE_0000650 + MedDRA ID: 10018852 + + + + obo2:OAE_0000650 + SIDER: C0018944 + + + + obo2:OAE_0000651 + reproductive system AE is an AE that occurs in the reproductive system. + + + + obo2:OAE_0000651 + YH, SS + + + + obo2:OAE_0000651 + reproductive system AE + + + + obo2:OAE_0000652 + an immune system disorder AE which has an outcome of antinuclear antibody negative + + + + obo2:OAE_0000652 + SS, YH + + + + obo2:OAE_0000652 + antinuclear antibody negative AE + + + + obo2:OAE_0000653 + a CSF test result abnormal AE that has an outcome of CSF white blood cell count negative + + + + obo2:OAE_0000653 + SS, YH, EB + + + + obo2:OAE_0000653 + CSF white blood cell count negative AE + + + + obo2:OAE_0000653 + MedDRA: 10061099 + + + + obo2:OAE_0000654 + a microbiology and serology investigation result abnormal AE that has an outcome of positive influenza serology test result + + + + obo2:OAE_0000654 + SS, YH, EB + + + + obo2:OAE_0000654 + influenza serology positive AE + + + + obo2:OAE_0000654 + MedDRA: 10060078 + + + + obo2:OAE_0000655 + YH + + + + obo2:OAE_0000655 + a paralysis AE that has an outcome of VIIth nerve paralysis + + + + obo2:OAE_0000655 + VIIth nerve paralysis AE + + + + obo2:OAE_0000655 + HPO: HP_0006824 + + + + obo2:OAE_0000655 + MedDRA ID: 10050040 + + + + obo2:OAE_0000655 + SIDER: C0919980 + + + + obo2:OAE_0000656 + an aspartate aminotransferase level abnormal AE that has an outcome of an increased amount of AST, an enzyme normally present in body tissues especially of the heart and liver + + + + obo2:OAE_0000656 + DJ, SS, YH, EB + + + + obo2:OAE_0000656 + WEB: http://medical-dictionary.thefreedictionary.com/aspartate+aminotransferase + + + + obo2:OAE_0000656 + aspartate aminotransferase level increased AE + + + + obo2:OAE_0000656 + MedDRA: 10003481 + + + + obo2:OAE_0000658 + an immune system disorder AE which has an outcome of acute disseminated encephalomyelitis + + + + obo2:OAE_0000658 + SS, YH + + + + obo2:OAE_0000658 + WEB: http://en.wikipedia.org/wiki/Acute_disseminated_encephalomyelitis + + + + obo2:OAE_0000658 + Acute disseminated encephalomyelitis (ADEM) is an immune mediated disease of the brain. It usually occurs following a viral infection but may appear following vaccination, bacterial or parasitic infection, or even appear spontaneously. As it involves autoimmune demyelination, it is similar to multiple sclerosis, and is considered part of the Multiple sclerosis borderline diseases. + + + + obo2:OAE_0000658 + acute disseminated encephalomyelitis AE + + + + obo2:OAE_0000658 + MedDRA ID: 10000709 + + + + obo2:OAE_0000659 + an arrhythmia AE that involves the two upper chambers (atria) of the heart + + + + obo2:OAE_0000659 + SS, YH + + + + obo2:OAE_0000659 + AF + + + + obo2:OAE_0000659 + WEB: http://en.wikipedia.org/wiki/Atrial_fibrillation + + + + obo2:OAE_0000659 + WEB: http://medical-dictionary.thefreedictionary.com/atrial+fibrillation + + + + obo2:OAE_0000659 + Atrial fibrillation (AF or A-fib) is the most common cardiac arrhythmia (abnormal heart rhythm), and involves the two upper chambers (atria) of the heart. Its name comes from the fibrillating (i.e., quivering) of the heart muscles of the atria, instead of a coordinated contraction. + + + + obo2:OAE_0000659 + atrial fibrillation AE + + + + obo2:OAE_0000659 + HPO: HP_0005110 + + + + obo2:OAE_0000659 + MedDRA ID: 10003658 + + + + obo2:OAE_0000659 + MedDRA: 10003658 + + + + obo2:OAE_0000659 + SIDER: C0004238 + + + + obo2:OAE_0000660 + a cardiac disorder AE which has an outcome of abnormal heart rhythm + + + + obo2:OAE_0000660 + SS, YH + + + + obo2:OAE_0000660 + abnormal heartbeat AE + + + + obo2:OAE_0000660 + cardiac arrhythmia AE + + + + obo2:OAE_0000660 + WEB: http://www.nhlbi.nih.gov/health/health-topics/topics/arr/ + + + + obo2:OAE_0000660 + arrhythmia AE + + + + obo2:OAE_0000660 + HPO: HP_0011675 + + + + obo2:OAE_0000660 + MP: MP_0004085 + + + + obo2:OAE_0000660 + MedDRA: 10003119 + + + + obo2:OAE_0000660 + SIDER: C0003811 + + + + obo2:OAE_0000661 + a cardiac valve disease AE that is characterized by a condition of the heart in which one of the valve openings has become narrow and restricts the flow of blood from the upper left chamber (left atrium) to the lower left chamber (left ventricle). + + + + obo2:OAE_0000661 + SS + + + + obo2:OAE_0000661 + WEB: http://medical-dictionary.thefreedictionary.com/mitral+valve+stenosis + + + + obo2:OAE_0000661 + mitral valve stenosis AE + + + + obo2:OAE_0000661 + MedDRA: 10027733 + + + + obo2:OAE_0000662 + a blood creatinine level abnormal AE that has an outcome of decreased blood creatine + + + + obo2:OAE_0000662 + SS, YH, EB + + + + obo2:OAE_0000662 + blood creatinine level decreased AE + + + + obo2:OAE_0000662 + MedDRA: 10005482 + + + + obo2:OAE_0000663 + SS, YH, EB + + + + obo2:OAE_0000663 + carbon dioxide decreased AE + + + + obo2:OAE_0000663 + MedDRA: 10007223 + + + + obo2:OAE_0000663 + a carbon dioxide abnormal AE that has an outcome of a decreased level of carbon dioxide in the blood + + + + obo2:OAE_0000665 + an infection adverse event that has an outcome of croup infection + + + + obo2:OAE_0000665 + SS, YH + + + + obo2:OAE_0000665 + WEB: http://www.medicinenet.com/croup/article.htm + + + + obo2:OAE_0000665 + Croup is an infectious illness of the respiratory system involving the vocal cords (larynx), the windpipe (trachea), and the upper airways of the lungs (bronchial tubes). The majority of a child's symptoms reflect involvement of the larynx. Croup is usually a viral infection and maybe caused by many different viruses, including those responsible for the common cold and influenza. Rarely, croup is caused by a bacterial infection. + + + + obo2:OAE_0000665 + croup infection AE + + + + obo2:OAE_0000666 + a respiratory system AE that has an outcome of the drawing of a foreign substance into the respiratory tract during inhalation + + + + obo2:OAE_0000666 + DJ, SS, YH + + + + obo2:OAE_0000666 + WEB: http://medical-dictionary.thefreedictionary.com/aspiration + + + + obo2:OAE_0000666 + aspiration AE + + + + obo2:OAE_0000666 + HPO: HP_0002835 + + + + obo2:OAE_0000666 + MedDRA: 10003504 + + + + obo2:OAE_0000666 + SIDER: C0700198 + + + + obo2:OAE_0000667 + a respiratory system AE that has an outcome of the removal of gas or fluid from the pleural cavity of the lungs + + + + obo2:OAE_0000667 + DJ, SS, YH + + + + obo2:OAE_0000667 + WEB: http://medical-dictionary.thefreedictionary.com/aspiration + + + + obo2:OAE_0000667 + aspiration pleural cavity AE + + + + obo2:OAE_0000667 + MedDRA: 10003522 + + + + obo2:OAE_0000668 + a skin adverse event which has an outcome of excoriation AE is an injury to a surface of the body caused by trauma, such as scratching, abrasion, or a chemical or thermal burn. + + + + obo2:OAE_0000668 + SS, YH + + + + obo2:OAE_0000668 + WEB: http://medical-dictionary.thefreedictionary.com/excoriation + + + + obo2:OAE_0000668 + excoriation AE + + + + obo2:OAE_0000668 + MedDRA ID: 10049796 + + + + obo2:OAE_0000669 + a pain AE that has an outcome of facial pain + + + + obo2:OAE_0000669 + SS, YH + + + + obo2:OAE_0000669 + WEB: http://www.bettermedicine.com/article/facial-pain + + + + obo2:OAE_0000669 + facial pain is a pain in facial area (eyes, eyebrows, forehead, nose, cheeks, mouth, teeth and chin). Facial pain may include injuries to the nerves or bones that coordinate many of your face’s actions. + + + + obo2:OAE_0000669 + facial pain AE + + + + obo2:OAE_0000669 + HPO: HP_0100661 + + + + obo2:OAE_0000669 + MedDRA ID: 10016059 + + + + obo2:OAE_0000669 + SIDER: C0015468 + + + + obo2:OAE_0000670 + a hematology investigation result abnormal AE that has an outcome of abnormal full blood count + + + + obo2:OAE_0000670 + SS, YH, EB + + + + obo2:OAE_0000670 + full blood count abnormal AE + + + + obo2:OAE_0000670 + MedDRA ID: 10017412 + + + + obo2:OAE_0000670 + MedDRA: 10064198 + + + + obo2:OAE_0000671 + a reflexes decreased AE that has an outcome of hyporeflexia + + + + obo2:OAE_0000671 + SS, YH + + + + obo2:OAE_0000671 + WEB: http://en.wikipedia.org/wiki/Hyporeflexia + + + + obo2:OAE_0000671 + hyporeflexia is the condition of below normal or absent reflexes. Hyporeflexia is generally associated with a lower motor neuron deficit (at the alpha motor neurons from the spinal cord to muscle). + + + + obo2:OAE_0000671 + hyporeflexia AE + + + + obo2:OAE_0000671 + HPO: HP_0009072 + + + + obo2:OAE_0000671 + MedDRA ID: 10021089 + + + + obo2:OAE_0000671 + SIDER: C0151888 + + + + obo2:OAE_0000672 + a tumor AE that is characterized by cancer in the brain + + + + obo2:OAE_0000672 + DJ, SS, YH + + + + obo2:OAE_0000672 + WEB: http://medical-dictionary.thefreedictionary.com/astrocytoma + + + + obo2:OAE_0000672 + astrocytoma AE + + + + obo2:OAE_0000672 + HPO: HP_0009592 + + + + obo2:OAE_0000672 + MedDRA: 10003571 + + + + obo2:OAE_0000672 + SIDER: C0004114 + + + + obo2:OAE_0000674 + a lung disorder AE that has an outcome of collapse in part of or all of a lung + + + + obo2:OAE_0000674 + DJ, SS, YH + + + + obo2:OAE_0000674 + WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001130/ + + + + obo2:OAE_0000674 + atelectasis AE + + + + obo2:OAE_0000674 + HPO: HP_0001642 + + + + obo2:OAE_0000674 + MedDRA: 10003598 + + + + obo2:OAE_0000674 + SIDER: C0004144 + + + + obo2:OAE_0000675 + an influenza serology positive AE that has an outcome of positive result in an influenza virus test + + + + obo2:OAE_0000675 + SS, YH, EB + + + + obo2:OAE_0000675 + influenza virus test positive AE + + + + obo2:OAE_0000675 + MedDRA: 10070717 + + + + obo2:OAE_0000676 + joint range of motion decreased AE is a mobility decreased AE that results in limited or decreased range of joint motion + + + + obo2:OAE_0000676 + SS, YH + + + + obo2:OAE_0000676 + joint range of motion decreased AE + + + + obo2:OAE_0000677 + a muscle spasm AE which has an outcome of laryngospasm, which is an uncontrolled/involuntary muscular contraction (spasm) of the laryngeal cords. The condition typically lasts less than 60 seconds, and causes a partial blocking of breathing in, while breathing out remains easier. It may be triggered when the vocal cords or the area of the trachea below the cords detects the entry of water, mucus, blood, or other substance. It is characterized by stridor and or retractions. + + + + obo2:OAE_0000677 + SS, YH + + + + obo2:OAE_0000677 + WEB: http://en.wikipedia.org/wiki/Laryngospasm + + + + obo2:OAE_0000677 + laryngospasm AE + + + + obo2:OAE_0000677 + HPO: HP_0006511 + + + + obo2:OAE_0000677 + MedDRA ID: 10023891 + + + + obo2:OAE_0000677 + SIDER: C0023066 + + + + obo2:OAE_0000678 + a lymphocyte percentage abnormal AE that has an outcome of decreased lymphocyte percentage + + + + obo2:OAE_0000678 + SS, YH, EB + + + + obo2:OAE_0000678 + lymphocyte percentage decreased AE + + + + obo2:OAE_0000678 + MedDRA ID: 10052231 + + + + obo2:OAE_0000679 + a monocyte percentage abnormal AE that has an outcome of increased monocyte percentage + + + + obo2:OAE_0000679 + SS, YH, EB + + + + obo2:OAE_0000679 + monocyte percentage increased AE + + + + obo2:OAE_0000679 + MedDRA: 10052230 + + + + obo2:OAE_0000680 + a nuclear magnetic resonance imaging result abnormal AE that has an outcome of abnormal nuclear magnetic resonance imaging test of the brain + + + + obo2:OAE_0000680 + SS, YH + + + + obo2:OAE_0000680 + nuclear magnetic resonance imaging brain abnormal AE + + + + obo2:OAE_0000680 + MedDRA: 0000680 + + + + + obo2:OAE_0000681 + periorbial edema AE is an edema AE that has an outcome of swelling around the eye. + + + + obo2:OAE_0000681 + SS, YH + + + + obo2:OAE_0000681 + Periorbital puffiness + + + + obo2:OAE_0000681 + WEB: http://en.wikipedia.org/wiki/Periorbital_puffiness + + + + obo2:OAE_0000681 + Periorbital puffiness, also known as "puffy eyes" or swelling around the eyes, refers to the appearance of swelling in the tissues around the eyes, called the orbits. + + + + obo2:OAE_0000681 + periorbital edema AE + + + + obo2:OAE_0000681 + MedDRA: 10034545 + + + + obo2:OAE_0000682 + an injury and procedural complication AE which has an outcome of pregnancy test positive + + + + obo2:OAE_0000682 + SS, YH + + + + obo2:OAE_0000682 + pregnancy test positive AE + + + + obo2:OAE_0000682 + MedDRA ID: 10036575 + + + + obo2:OAE_0000682 + MedDRA: 10036556 + + + + obo2:OAE_0000684 + a sensory capability AE that has an outcome of a sensation feeling of foreign body + + + + obo2:OAE_0000684 + SS, YH + + + + obo2:OAE_0000684 + sensation of foreign body AE + + + + obo2:OAE_0000684 + MedDRA ID: 10061549 + + + + obo2:OAE_0000685 + a sensory capability AE that has an outcome of a sensation feeling of heaviness + + + + obo2:OAE_0000685 + SS, YH + + + + obo2:OAE_0000685 + feeling heavy AE + + + + obo2:OAE_0000685 + sensation of heaviness AE + + + + obo2:OAE_0000686 + a sensory capability AE that has an outcome of a loss of sensation + + + + obo2:OAE_0000686 + SS, YH + + + + obo2:OAE_0000686 + sensory loss AE + + + + obo2:OAE_0000686 + HPO: HP_0003474 + + + + obo2:OAE_0000686 + MedDRA ID: 10040030 + + + + obo2:OAE_0000686 + SIDER: C0278134 + + + + obo2:OAE_0000687 + a skin adverse event that has an outcome of skin exfoliation + + + + obo2:OAE_0000687 + SS, YH + + + + obo2:OAE_0000687 + skin exfoliation AE + + + + obo2:OAE_0000687 + HPO: HP_0007549 + + + + obo2:OAE_0000687 + MedDRA ID: 10040844 + + + + obo2:OAE_0000687 + MedDRA: 10040844 + + + + obo2:OAE_0000687 + SIDER: C0237849 + + + + obo2:OAE_0000688 + a digestive system AE which has an outcome of stomach discomfort + + + + obo2:OAE_0000688 + SS, YH + + + + obo2:OAE_0000688 + stomach discomfort AE + + + + obo2:OAE_0000689 + an immunology and allergy investigation result abnormal AE that has an outcome of autoantibodies present + + + + obo2:OAE_0000689 + DJ, SS, YH, EB + + + + obo2:OAE_0000689 + WEB: http://medical-dictionary.thefreedictionary.com/autoantibody + + + + obo2:OAE_0000689 + autoantibody positive AE + + + + obo2:OAE_0000689 + MedDRA: 10060973 + + + + obo2:OAE_0000690 + a wheezing AE which has an outcome of stridor, a high pitched wheezing sound resulting from turbulent air flow in the upper airway. It is primarily inspiratory. It can be indicative of serious airway obstruction from severe conditions such as epiglottitis, a foreign body lodged in the airway, or a laryngeal tumor. + + + + obo2:OAE_0000690 + SS, YH + + + + obo2:OAE_0000690 + WEB: http://en.wikipedia.org/wiki/Stridor + + + + obo2:OAE_0000690 + stridor AE + + + + obo2:OAE_0000690 + HPO: HP_0010307 + + + + obo2:OAE_0000690 + MedDRA ID: 10042241 + + + + obo2:OAE_0000690 + SIDER: C0038450 + + + + obo2:OAE_0000691 + a skin adverse event that has an outcome of skin ulcer AE results in a sore on the skin or a mucous membrane, accompanied by the disintegration of tissue. Ulcers can result in complete loss of the epidermis and often portions of the dermis and even subcutaneous fat. + + + + obo2:OAE_0000691 + SS, YH + + + + obo2:OAE_0000691 + WEB: http://en.wikipedia.org/wiki/Ulcer_%28dermatology%29 + + + + obo2:OAE_0000691 + skin ulcer AE + + + + obo2:OAE_0000691 + HPO: HP_0200042 + + + + obo2:OAE_0000691 + MedDRA: 10040943 + + + + obo2:OAE_0000691 + SIDER: C0037299 + + + + obo2:OAE_0000693 + a respiratory tract congestion AE which has an outcome of upper respiratory tract congestion + + + + obo2:OAE_0000693 + SS, YH + + + + obo2:OAE_0000693 + upper respiratory tract congestion AE + + + + obo2:OAE_0000694 + a renal and urinary tract investigation and urinalysis result abnormal AE that has an outcome of a urine analysis abnormality + + + + obo2:OAE_0000694 + SS, YH, EB + + + + obo2:OAE_0000694 + urine analysis result abnormal AE + + + + obo2:OAE_0000694 + MedDRA: 10062226 + + + + + obo2:OAE_0000695 + a renal and urinary tract investigation and urinalysis abnormal AE that has an outcome of ketone body present in urine + + + + obo2:OAE_0000695 + SS, YH, EB + + + + obo2:OAE_0000695 + urine ketone body present AE + + + + obo2:OAE_0000695 + MedDRA ID: 10057597 + + + + obo2:OAE_0000696 + a liver/biliary system AE that has an outcome of inflammation of the liver that occurs when immune cells mistake the liver's normal cells for harmful invaders and attack them + + + + obo2:OAE_0000696 + DJ, SS, YH + + + + obo2:OAE_0000696 + WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001291/ + + + + obo2:OAE_0000696 + autoimmune hepatitis AE + + + + obo2:OAE_0000696 + HPO: HP_0004787 + + + + obo2:OAE_0000696 + MedDRA: 10003827 + + + + obo2:OAE_0000696 + SIDER: C0241910 + + + + obo2:OAE_0000697 + a hemorrhage AE that has an outcome of vaginal hemorrhage + + + + obo2:OAE_0000697 + SS, YH + + + + obo2:OAE_0000697 + WEB: http://www.brooksidepress.org/Products/Military_OBGYN/Textbook/AbnormalBleeding/Bleeding.htm + + + + obo2:OAE_0000697 + vaginal hemorrhage is irregular/heavy bleeding from the vagina. Vaginal hemorrhage is more often associated with pregnancy complications such as miscarriage or placental abruption, but certainly can occur in the absence of pregnancy. + + + + obo2:OAE_0000697 + vaginal hemorrhage AE + + + + obo2:OAE_0000697 + MedDRA: 10046910 + + + + obo2:OAE_0000698 + SS, YH + + + + obo2:OAE_0000698 + WEB: http://en.wikipedia.org/wiki/Vasodilation + + + + obo2:OAE_0000698 + a cardiovascular disorder AE which has an outcome of vasodilatation, which refers to the widening of blood vessels resulting from relaxation of smooth muscle cells within the vessel walls, particularly in the large arteries, smaller arterioles and large veins. + + + + obo2:OAE_0000698 + vasodilatation AE + + + + obo2:OAE_0000698 + HPO: HP_0004927 + + + + obo2:OAE_0000698 + SIDER: C0595862 + + + + obo2:OAE_0000699 + a bacterial infection AE that has an outcome of bacteria in the blood + + + + obo2:OAE_0000699 + DJ, SS, YH + + + + obo2:OAE_0000699 + bacteraemia AE + + + + obo2:OAE_0000699 + WEB: http://medical-dictionary.thefreedictionary.com/bacteremia + + + + obo2:OAE_0000699 + bacteremia AE + + + + obo2:OAE_0000699 + MedDRA: 10003997 + + + + obo2:OAE_0000700 + a sepsis AE caused by bacterial infection in the bloodstream or body tissues + + + + obo2:OAE_0000700 + DJ, SS, YH + + + + obo2:OAE_0000700 + WEB: http://medical-dictionary.thefreedictionary.com/sepsis + + + + obo2:OAE_0000700 + bacterial sepsis AE + + + + obo2:OAE_0000700 + MedDRA: 10053840 + + + + obo2:OAE_0000701 + a skin AE that has an outcome of a slow-growing nonmelanoma skin cancer + + + + obo2:OAE_0000701 + DJ, SS, YH + + + + obo2:OAE_0000701 + WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001827/ + + + + obo2:OAE_0000701 + basal cell carcinoma AE + + + + obo2:OAE_0000701 + HPO: HP_0002671 + + + + obo2:OAE_0000701 + MedDRA: 10004146 + + + + obo2:OAE_0000701 + SIDER: C0007117 + + + + obo2:OAE_0000702 + a basophil count abnormal AE that is characterized by increase in the number of basophils in the body + + + + obo2:OAE_0000702 + DJ, SS, YH, EB + + + + obo2:OAE_0000702 + WEB: http://medical-dictionary.thefreedictionary.com/basophil+granulocyte + + + + obo2:OAE_0000702 + basophil count increased AE + + + + obo2:OAE_0000702 + MedDRA: 10004169 + + + + obo2:OAE_0000703 + an ulcer AE that is characterized by ulcers in the mouth that may decrease ocular functionality + + + + obo2:OAE_0000703 + DJ, SS, YH + + + + obo2:OAE_0000703 + WEB: http://medical-dictionary.thefreedictionary.com/behcet's+disease + + + + obo2:OAE_0000703 + behcet's syndrome AE + + + + obo2:OAE_0000703 + MedDRA: 10004213 + + + + obo2:OAE_0000704 + a musculoskeletal system AE that has an outcome of low muscle tone + + + + obo2:OAE_0000704 + DJ, SS, YH + + + + obo2:OAE_0000704 + WEB: http://medical-dictionary.thefreedictionary.com/hypotonia + + + + obo2:OAE_0000704 + benign congenital hypotonia AE + + + + obo2:OAE_0000704 + MedDRA: 10051900 + + + + obo2:OAE_0000705 + a female reproductive system AE that has an outcome of a non-fertilized egg that implants itself in the uterus and turns a normal pregnancy into an abnormal one + + + + obo2:OAE_0000705 + DJ, SS, YH + + + + obo2:OAE_0000705 + WEB: http://medical-dictionary.thefreedictionary.com/hydatidiform+mole + + + + obo2:OAE_0000705 + benign hydatidiform mole AE + + + + obo2:OAE_0000705 + MedDRA: 10004272 + + + + obo2:OAE_0000706 + a benign tumor AE that has an outcome of a benign tumor in their ovaries + + + + obo2:OAE_0000706 + DJ, SS, YH + + + + obo2:OAE_0000706 + benign ovarian tumour AE + + + + obo2:OAE_0000706 + benign ovarian tumor AE + + + + obo2:OAE_0000706 + MedDRA: 10004433 + + + + obo2:OAE_0000707 + a digestive system AE that has an outcome of a blockage in the tubes that carry bile from the liber to the gallbladder and small intestine + + + + obo2:OAE_0000707 + DJ, SS, YH + + + + obo2:OAE_0000707 + WEB: http://www.nlm.nih.gov/medlineplus/ency/article/000263.htm + + + + obo2:OAE_0000707 + bile duct obstruction AE + + + + obo2:OAE_0000707 + MedDRA: 10056375 + + + + obo2:OAE_0000708 + a liver/biliary system AE that has an outcome of dilating or stretching of the bile duct + + + + obo2:OAE_0000708 + DJ, SS, YH + + + + obo2:OAE_0000708 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/21843715 + + + + obo2:OAE_0000708 + biliary dilatation AE + + + + obo2:OAE_0000708 + MedDRA: 10057202 + + + + obo2:OAE_0000709 + an eating disorder that is characterized by episodes of uncontrollable eating. + + + + obo2:OAE_0000709 + DJ, SS, YH + + + + obo2:OAE_0000709 + WEB: http://medical-dictionary.thefreedictionary.com/binge+eating + + + + obo2:OAE_0000709 + binge eating AE + + + + obo2:OAE_0000709 + MedDRA: 10004716 + + + + obo2:OAE_0000710 + an eye disorder AE that has an outcome of binocular eye movement disorder where control and alignment of eyes are compromised + + + + obo2:OAE_0000710 + DJ, SS, YH + + + + obo2:OAE_0000710 + WEB: Primary Source: http://www.ncbi.nlm.nih.gov/pubmed/23201436 Secondary Source: http://brain.oxfordjournals.org/content/119/6/1933.full.pdf + + + + obo2:OAE_0000710 + binocular eye movement disorder AE + + + + obo2:OAE_0000710 + MedDRA: 10061010 + + + + obo2:OAE_0000711 + a digestive system AE that has an outcome of cancer that starts in the bladder, the body part that holds and releases urine in the center of the lower belly area + + + + obo2:OAE_0000711 + DJ, SS, YH + + + + obo2:OAE_0000711 + WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001517/ + + + + obo2:OAE_0000711 + bladder cancer AE + + + + obo2:OAE_0000711 + HPO: HP_0009725 + + + + obo2:OAE_0000711 + MedDRA: 10005003 + + + + obo2:OAE_0000711 + SIDER: C0005684 + + + + obo2:OAE_0000712 + a blast cell count abnormal AE that has an outcome of an increased amount of immature precursors of either lymphocytes or granulocytes that do not normally appear in peripheral blood. May indicate acute leukemia + + + + obo2:OAE_0000712 + DJ, SS, YH + + + + obo2:OAE_0000712 + WEB: http://meds.queensu.ca/medicine/deptmed/hemonc/anemia/blast.htm + + + + obo2:OAE_0000712 + blast cell count increased AE + + + + obo2:OAE_0000712 + MedDRA: 10062274 + + + + obo2:OAE_0000713 + a hematopoietic system AE that has an outcome of a sudden, severe change in the course of chronic granulocytic leukemia with an increase in the proportion of myeloblasts + + + + obo2:OAE_0000713 + DJ, SS, YH + + + + obo2:OAE_0000713 + WEB: http://medical-dictionary.thefreedictionary.com/blast+crisis + + + + obo2:OAE_0000713 + blast cell crisis AE + + + + obo2:OAE_0000713 + MedDRA: 10053747 + + + + obo2:OAE_0000714 + a hematopoietic system AE that has an outcome of myeloblasts or myeloid blasts. Presence of these abnormal blasts prevent production of adequate platelets, red blood cells and white blood cells, can be associated with leukemia + + + + obo2:OAE_0000714 + DJ, SS, YH + + + + obo2:OAE_0000714 + WEB: http://lymphoma.about.com/od/glossary/ss/Blast-Cells.htm + + + + obo2:OAE_0000714 + blast cells present AE + + + + obo2:OAE_0000714 + MedDRA: 10057107 + + + + obo2:OAE_0000715 + a hematopoietic system AE that has an outcome of the last stage of chronic myelogenous leukemia characterized by rapid progression and short survival with an increase of myeloblasts or lymphoblasts in the blood or bone marrow + + + + obo2:OAE_0000715 + DJ, SS, YH + + + + obo2:OAE_0000715 + blast crisis in myelogenous leukaemia AE + + + + obo2:OAE_0000715 + WEB: Primary Source: http://medical-dictionary.thefreedictionary.com/blast+crisis , Secondary Source: http://www.ncbi.nlm.nih.gov/pubmed/23171293 + + + + obo2:OAE_0000715 + blast crisis in myelogenous leukemia AE + + + + obo2:OAE_0000715 + MedDRA: 10050282 + + + + obo2:OAE_0000716 + an eye inflammation AE that has an outcome of swelling in the eyelids, usually where eyelash follicles are located + + + + obo2:OAE_0000716 + DJ, SS, YH + + + + obo2:OAE_0000716 + WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0002586/ + + + + obo2:OAE_0000716 + blepharitis AE + + + + obo2:OAE_0000716 + HPO: HP_0000498 + + + + obo2:OAE_0000716 + MedDRA: 10005148 + + + + obo2:OAE_0000716 + SIDER: C0005741 + + + + obo2:OAE_0000717 + a blood albumin level abnormal AE with an outcome of a decrease in the amount of albumin, a protein made by the liver + + + + obo2:OAE_0000717 + DJ, SS, YH, EB + + + + obo2:OAE_0000717 + hypoalbuminemia AE + + + + obo2:OAE_0000717 + WEB: http://www.nlm.nih.gov/medlineplus/ency/article/003480.htm + + + + obo2:OAE_0000717 + blood albumin level decreased AE + + + + obo2:OAE_0000717 + MedDRA: 10005287 + + + + obo2:OAE_0000718 + a liver related investigation result abnormal AE that has an outcome of an abnormal level of alkaline phosphatase in the blood + + + + obo2:OAE_0000718 + DJ, SS, YH, EB + + + + obo2:OAE_0000718 + blood alkaline phosphatase level abnormal AE + + + + obo2:OAE_0000718 + MedDRA: 10059571 + + + + obo2:OAE_0000719 + a blood alkaline phosphatase abnormal AE that has an outcome of a decreased level of alkaline phosphatase in the blood + + + + obo2:OAE_0000719 + DJ, SS, YH + + + + obo2:OAE_0000719 + WEB: http://medical-dictionary.thefreedictionary.com/alkaline+phosphatase + + + + obo2:OAE_0000719 + blood alkaline phosphatase decreased AE + + + + obo2:OAE_0000719 + MedDRA: 10059569 + + + + obo2:OAE_0000720 + a blood alkaline phosphatase abnormal AE that has an outcome of elevated levels of alkaline phosphatase, an enzyme responsible for removing phosphate groups. a liver/biliary system AE that has an outcome of an increased amount of ALP, an isoenzyme that removes phosphate groups commonly found in the bile ducts but also found in the bone + + + + obo2:OAE_0000720 + DJ, SS, YH + + + + obo2:OAE_0000720 + WEB: http://medical-dictionary.thefreedictionary.com/alkaline+phosphatase + + + + obo2:OAE_0000720 + blood alkaline phosphatase increased AE + + + + obo2:OAE_0000720 + HPO: HP_0003155 + + + + obo2:OAE_0000720 + MedDRA: 10059570 + + + + obo2:OAE_0000720 + SIDER: C0852911 + + + + obo2:OAE_0000721 + a distal neuropathy AE which shows a neurological disorder characterized by progressive weakness and impaired sensory function in the legs and arms. It is caused by the loss of myelin sheath of the peripheral nerves. + + + + obo2:OAE_0000721 + AG, YH + + + + obo2:OAE_0000721 + CIDP + + + + obo2:OAE_0000721 + Chronic Inflammatory Demyelinating Polyneuropathy + + + + obo2:OAE_0000721 + WEB: http://www.ninds.nih.gov/disorders/cidp/cidp.htm + + + + obo2:OAE_0000721 + chronic inflammatory demyelinating neuropathy AE + + + + obo2:OAE_0000722 + a blood amylase level abnormal AE that has an outcome of an increased amount of amylase, an enzyme that helps digest carbohydrates; may indicate disease or inflammation of the pancreas + + + + obo2:OAE_0000722 + DJ, SS, YH, EB + + + + obo2:OAE_0000722 + WEB: http://www.nlm.nih.gov/medlineplus/ency/article/003464.htm + + + + obo2:OAE_0000722 + blood amylase level increased AE + + + + obo2:OAE_0000722 + MedDRA: 10005328 + + + + obo2:OAE_0000723 + a liver related investigation result abnormal AE that has an outcome of an abnormal amount of bilirubin in the blood + + + + obo2:OAE_0000723 + DJ, SS, YH, EB + + + + obo2:OAE_0000723 + WEB: http://medical-dictionary.thefreedictionary.com/bilirubin + + + + obo2:OAE_0000723 + blood bilirubin level abnormal AE + + + + obo2:OAE_0000723 + MedDRA: 10058477 + + + + obo2:OAE_0000724 + a blood bilirubin level abnormal AE with an outcome of a increased amount of bilirubin, or a yellow breakdown product (broken down hemoglobin) of normal heme catabolism, in the blood + + + + obo2:OAE_0000724 + DJ, SS, YH, EB + + + + obo2:OAE_0000724 + WEB: http://medical-dictionary.thefreedictionary.com/bilirubin + + + + obo2:OAE_0000724 + blood bilirubin level increased AE + + + + obo2:OAE_0000724 + MedDRA: 10005364 + + + + obo2:OAE_0000725 + a lab test abnormal AE that has an outcome of a decreased amount of calcium in the bloodstream + + + + obo2:OAE_0000725 + DJ, SS, YH + + + + obo2:OAE_0000725 + hypocalcaemia AE + + + + obo2:OAE_0000725 + WEB: http://medical-dictionary.thefreedictionary.com/hypocalcemia + + + + obo2:OAE_0000725 + blood calcium decreased AE + + + + obo2:OAE_0000725 + MedDRA: 10005395 + + + + obo2:OAE_0000726 + a lab test abnormal AE with an outcome of decrease in amount of chloride ion in the blood, excessive loss may be due to sweating, vomiting and adrenal gland/kidney disease + + + + obo2:OAE_0000726 + DJ, SS, YH + + + + obo2:OAE_0000726 + WEB: http://www.medterms.com/script/main/art.asp?articlekey=9940 + + + + obo2:OAE_0000726 + blood chloride decreased AE + + + + obo2:OAE_0000726 + HPO: HP_0003113 + + + + obo2:OAE_0000726 + MedDRA: 10005419 + + + + obo2:OAE_0000726 + SIDER: C0595902 + + + + obo2:OAE_0000727 + a blood cholesterol abnormal AE with the result of an increase in cholesterol level in the blood + + + + obo2:OAE_0000727 + DJ, SS, YH, EB + + + + obo2:OAE_0000727 + blood cholesterol increased AE + + + + obo2:OAE_0000727 + HPO: HP_0003124 + + + + obo2:OAE_0000727 + MedDRA: 10005425 + + + + obo2:OAE_0000727 + SIDER: C0595930 + + + + obo2:OAE_0000728 + an enzyme investigation result abnormal AE that has an outcome of abnormal levels of creatine phosphokinase in the blood + + + + obo2:OAE_0000728 + DJ, SS, YH, EB + + + + obo2:OAE_0000728 + blood creatine phosphokinase level abnormal AE + + + + obo2:OAE_0000728 + MedDRA: 10005468 + + + + obo2:OAE_0000729 + a blood creatinine level abnormal AE that has an outcome of an increased level of creatinine in the blood (due to lack of kidney activity) + + + + obo2:OAE_0000729 + DJ, SS, YH, EB + + + + obo2:OAE_0000729 + serum creatinine increased + + + + obo2:OAE_0000729 + WEB: http://medical-dictionary.thefreedictionary.com/creatinine + + + + obo2:OAE_0000729 + blood creatinine level increased AE + + + + obo2:OAE_0000729 + MedDRA: 10005483 + + + + obo2:OAE_0000730 + an infection adverse event that has an outcome of bacteria or yeasts in the blood + + + + obo2:OAE_0000730 + DJ, SS, YH + + + + obo2:OAE_0000730 + WEB: http://labtestsonline.org/understanding/analytes/blood-culture/tab/test + + + + obo2:OAE_0000730 + blood culture positive AE + + + + obo2:OAE_0000730 + MedDRA: 10005488 + + + + obo2:OAE_0000731 + a hematopoietic system AE that has an outcome of disease in the blood, a living tissue made up of plasma and red blood cells, white blood cells and platelets. Blood disorders affect one or more parts of the blood and prevent the blood from doing this job. + + + + obo2:OAE_0000731 + DJ, SS, YH + + + + obo2:OAE_0000731 + WEB: http://www.nlm.nih.gov/medlineplus/blooddisorders.html + + + + obo2:OAE_0000731 + blood disorder AE + + + + obo2:OAE_0000731 + MedDRA: 10061590 + + + + obo2:OAE_0000732 + a blood folate abnormal AE that has an outcome of a decreased level of folate in the blood + + + + obo2:OAE_0000732 + DJ, SS, YH, EB + + + + obo2:OAE_0000732 + WEB: http://medical-dictionary.thefreedictionary.com/folate + + + + obo2:OAE_0000732 + blood folate level decreased AE + + + + obo2:OAE_0000732 + MedDRA: 10005527 + + + + obo2:OAE_0000733 + a blood glucose level abnormal AE that has an outcome of a decrease of glucose levels in blood + + + + obo2:OAE_0000733 + DJ, SS, YH, EB + + + + obo2:OAE_0000733 + blood glucose level decreased AE + + + + obo2:OAE_0000733 + MedDRA: 10005555 + + + + obo2:OAE_0000734 + a blood glucose level abnormal AE that has an outcome of an increased glucose level in blood + + + + obo2:OAE_0000734 + DJ, SS, YH, EB + + + + obo2:OAE_0000734 + blood glucose level increased AE + + + + obo2:OAE_0000734 + MedDRA: 10005557 + + + + obo2:OAE_0000735 + a blood homocysteine level abnormal AE that has an outcome of an increased levels of homocysteine in the blood + + + + obo2:OAE_0000735 + DJ, SS, YH, EB + + + + obo2:OAE_0000735 + WEB: http://medical-dictionary.thefreedictionary.com/homocysteine + + + + obo2:OAE_0000735 + blood homocysteine level increased AE + + + + obo2:OAE_0000735 + MedDRA: 10049733 + + + + obo2:OAE_0000736 + an immunology and allergy investigation result abnormal AE that results in an increased immunoglobulin a level in the blood + + + + obo2:OAE_0000736 + DJ, SS, YH, EB + + + + obo2:OAE_0000736 + WEB: http://medical-dictionary.thefreedictionary.com/immunoglobulin+A + + + + obo2:OAE_0000736 + blood immunoglobulin a level increased AE + + + + obo2:OAE_0000736 + MedDRA: 10005586 + + + + obo2:OAE_0000737 + a blood lactate dehydrogenase level abnormal AE that has an outcome of an increased amount of LDH, an enzyme that could indicate tissue damage + + + + obo2:OAE_0000737 + DJ, SS, YH, EB + + + + obo2:OAE_0000737 + WEB: http://www.nlm.nih.gov/medlineplus/ency/article/003471.htm + + + + obo2:OAE_0000737 + blood lactate dehydrogenase level increased AE + + + + obo2:OAE_0000737 + MedDRA: 10005630 + + + + obo2:OAE_0000738 + a lab test abnormal AE that has an outcome of a decrease in magnesium levels, a mineral involved in nerve signaling and bone health. Deficiency can cause spasms, and muscular cramps. + + + + obo2:OAE_0000738 + DJ, SS, YH + + + + obo2:OAE_0000738 + WEB: http://www.medterms.com/script/main/art.asp?articlekey=4243 + + + + obo2:OAE_0000738 + blood magnesium decreased AE + + + + obo2:OAE_0000738 + HPO: HP_0002917 + + + + obo2:OAE_0000738 + MedDRA: 10005654 + + + + obo2:OAE_0000738 + SIDER: C0853750 + + + + obo2:OAE_0000739 + a blood parathyroid hormone level abnormal AE that has an outcome of a decrease in the level of parathyroid hormone in the blood + + + + obo2:OAE_0000739 + DJ, SS, YH, EB + + + + obo2:OAE_0000739 + WEB: http://medical-dictionary.thefreedictionary.com/parathyroid+hormone + + + + obo2:OAE_0000739 + blood parathyroid hormone decreased AE + + + + obo2:OAE_0000739 + MedDRA: 10005702 + + + + obo2:OAE_0000740 + a lab test abnormal AE that has an outcome of a decreased amount of phosphorus in the blood + + + + obo2:OAE_0000740 + DJ, SS, YH + + + + obo2:OAE_0000740 + WEB: http://www.nlm.nih.gov/medlineplus/ency/article/003478.htm + + + + obo2:OAE_0000740 + blood phosphorus decreased AE + + + + obo2:OAE_0000740 + HPO: HP_0002148 + + + + obo2:OAE_0000740 + MedDRA: 10049471 + + + + obo2:OAE_0000740 + SIDER: C0877517 + + + + obo2:OAE_0000741 + a lab test abnormal AE that has an outcome of lower than normal amount of potassium in the blood + + + + obo2:OAE_0000741 + DJ, SS, YH, LW + + + + obo2:OAE_0000741 + 血钾下降 + + + + obo2:OAE_0000741 + blood potassium decreased AE + + + + obo2:OAE_0000741 + HPO: HP_0002900 + + + + obo2:OAE_0000741 + MedDRA: 10005724 + + + + obo2:OAE_0000742 + a hypotension AE that has an outcome of a decrease in the amount of pressure in the arteries when the heart is at rest between beats + + + + obo2:OAE_0000742 + DJ, SS, YH + + + + obo2:OAE_0000742 + WEB: http://www.mayoclinic.com/health/low-blood-pressure/DS00590/DSECTION=causes + + + + obo2:OAE_0000742 + blood pressure diastolic decreased AE + + + + obo2:OAE_0000742 + MedDRA: 10005737 + + + + obo2:OAE_0000743 + a hypotension AE that has an outcome of immeasurable blood pressure + + + + obo2:OAE_0000743 + DJ, SS, YH + + + + obo2:OAE_0000743 + blood pressure immeasurable AE + + + + obo2:OAE_0000743 + MedDRA: 10005748 + + + + obo2:OAE_0000744 + a lab test abnormal AE with an outcome of decrease in sodium concentration in the blood + + + + obo2:OAE_0000744 + DJ, SS, YH + + + + obo2:OAE_0000744 + hyponatraemia AE + + + + obo2:OAE_0000744 + blood sodium decreased AE + + + + obo2:OAE_0000744 + MedDRA: 10005802 + + + + obo2:OAE_0000744 + MedDRA: 10021036 + + + + obo2:OAE_0000745 + a blood thromboplastin level abnormal AE that has an outcome of an increase in the level of thromboplastin in the blood + + + + obo2:OAE_0000745 + DJ, SS, YH, EB + + + + obo2:OAE_0000745 + WEB: http://medical-dictionary.thefreedictionary.com/thromboplastin + + + + obo2:OAE_0000745 + blood thromboplastin level increased AE + + + + obo2:OAE_0000745 + MedDRA: 10005827 + + + + obo2:OAE_0000746 + a blood urea level abnormal AE with an outcome of a decreased amount of urea nitrogen in the blood, below 7 to 21 mg of urea per 100 ml + + + + obo2:OAE_0000746 + DJ, SS, YH, EB + + + + obo2:OAE_0000746 + WEB: http://medical-dictionary.thefreedictionary.com/blood+urea+nitrogen + + + + obo2:OAE_0000746 + blood urea level decreased AE + + + + obo2:OAE_0000746 + MedDRA: 10005850 + + + + obo2:OAE_0000747 + a blood urea level abnormal AE that results in an increase in amount of urea in blood + + + + obo2:OAE_0000747 + DJ, SS, YH, EB + + + + obo2:OAE_0000747 + blood urea level increased AE + + + + obo2:OAE_0000747 + MedDRA: 10005851 + + + + obo2:OAE_0000748 + a blood uric acid level abnormal AE that has an outcome of an increase in uric acid in the blood; excess purines may accumulate in tissues and form crystals + + + + obo2:OAE_0000748 + DJ, SS, YH, EB + + + + obo2:OAE_0000748 + WEB: http://chemocare.com/chemotherapy/side-effects/hyperuricemia-high-uric-acid.aspx + + + + obo2:OAE_0000748 + blood uric acid level increased AE + + + + obo2:OAE_0000748 + MedDRA: 10005861 + + + + obo2:OAE_0000749 + a bone disorder AE that has an outcome of a cyst that forms on the bone + + + + obo2:OAE_0000749 + DJ, SS, YH + + + + obo2:OAE_0000749 + WEB: http://medical-dictionary.thefreedictionary.com/bone+cyst + + + + obo2:OAE_0000749 + bone cyst AE + + + + obo2:OAE_0000749 + MedDRA: 10005952 + + + + obo2:OAE_0000750 + a bone disorder AE that has an outcome of surgery to clean and flush out the infected bone + + + + obo2:OAE_0000750 + DJ, SS, YH + + + + obo2:OAE_0000750 + WEB: http://www.betterhealth.vic.gov.au/bhcv2/bhcarticles.nsf/pages/Osteomyelitis + + + + obo2:OAE_0000750 + bone debridement AE + + + + obo2:OAE_0000750 + MedDRA: 10057612 + + + + obo2:OAE_0000751 + a bone disorder AE that has an outcome of an anomlay in the growth or structure of a bone + + + + obo2:OAE_0000751 + DJ, SS, YH + + + + obo2:OAE_0000751 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/20972590 + + + + obo2:OAE_0000751 + bone lesion AE + + + + obo2:OAE_0000751 + MedDRA: 10061728 + + + + obo2:OAE_0000752 + a bone marrow disorder AE that has an outcome of an abnormal condition in which the bone marrow is unable to produce normal amounts of red blood cells, white blood cells and platelets + + + + obo2:OAE_0000752 + DJ, SS, YH + + + + obo2:OAE_0000752 + WEB: http://www.depression-doctor.com/bone-marrow-depression.html + + + + obo2:OAE_0000752 + bone marrow depression AE + + + + obo2:OAE_0000752 + HPO: HP_0012145 + + + + obo2:OAE_0000752 + MedDRA: 10005986 + + + + obo2:OAE_0000752 + SIDER: C0151773 + + + + obo2:OAE_0000753 + a hematopoietic system AE that has an outcome of disease in the bone marrow, the spongy tissue inside of some bones that contain stem cells that can develop into red blood cells, white blood cells or platelets + + + + obo2:OAE_0000753 + DJ, SS, YH + + + + obo2:OAE_0000753 + WEB: http://www.nlm.nih.gov/medlineplus/bonemarrowdiseases.html + + + + obo2:OAE_0000753 + bone marrow disorder AE + + + + obo2:OAE_0000753 + MedDRA: 10061729 + + + + obo2:OAE_0000754 + a bone marrow disorder AE that has an outcome of an insufficient amount of red blood cells, white blood cells or platelets, associated with fanconii anemia, dyskeratosis congenita, and aplastic anemia + + + + obo2:OAE_0000754 + DJ, SS, YH + + + + obo2:OAE_0000754 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/23271412 + + + + obo2:OAE_0000754 + bone marrow failure AE + + + + obo2:OAE_0000754 + MedDRA: 10065553 + + + + obo2:OAE_0000755 + a bone marrow disorder AE that has an outcome of an excess formation of connective tissue in the bone marrow + + + + obo2:OAE_0000755 + DJ, SS, YH + + + + obo2:OAE_0000755 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/22246040 + + + + obo2:OAE_0000755 + bone marrow reticulin fibrosis AE + + + + obo2:OAE_0000755 + MedDRA: 10069678 + + + + obo2:OAE_0000756 + a bone marrow disorder AE that has an outcome of the decrease in cells responsible for providing immunity, carrying oxygen and blood clotting + + + + obo2:OAE_0000756 + DJ, SS, YH + + + + obo2:OAE_0000756 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/12806941 + + + + obo2:OAE_0000756 + bone marrow toxicity AE + + + + obo2:OAE_0000756 + HPO: HP_0005561 + + + + obo2:OAE_0000756 + MedDRA: 10051779 + + + + obo2:OAE_0000756 + SIDER: C0948168 + + + + obo2:OAE_0000757 + a bone marrow disorder AE that has an outcome of the replacement of damaged bone marrow with healthy bone marrow stem cells + + + + obo2:OAE_0000757 + DJ, SS, YH + + + + obo2:OAE_0000757 + WEB: http://www.nlm.nih.gov/medlineplus/ency/article/003009.htm + + + + obo2:OAE_0000757 + bone marrow transplant AE + + + + obo2:OAE_0000757 + MedDRA: 10061730 + + + + obo2:OAE_0000758 + a swelling AE that results in swelling around a bone + + + + obo2:OAE_0000758 + DJ, SS, YH + + + + obo2:OAE_0000758 + bone swelling AE + + + + obo2:OAE_0000758 + MedDRA: 10053631 + + + + obo2:OAE_0000759 + a skin adverse event that has an outcome of an early stage of squamous cell carcinoma + + + + obo2:OAE_0000759 + DJ, SS, YH + + + + obo2:OAE_0000759 + WEB: http://medical-dictionary.thefreedictionary.com/bowen's+disease + + + + obo2:OAE_0000759 + bowen's disease AE + + + + obo2:OAE_0000759 + MedDRA: 10006059 + + + + obo2:OAE_0000760 + a bradycardia AE that results in a decreased heart rate in a neonate + + + + obo2:OAE_0000760 + DJ, SS, YH + + + + obo2:OAE_0000760 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/10822186 + + + + obo2:OAE_0000760 + bradycardia neonatal AE + + + + obo2:OAE_0000760 + HPO: HP_0001662 + + + + obo2:OAE_0000760 + MedDRA: 10056471 + + + + obo2:OAE_0000760 + SIDER: C1112488 + + + + obo2:OAE_0000761 + an edema AE that has an outcome of edema or swelling of the extravascular compartment from uptake of water in the gray and white matter + + + + obo2:OAE_0000761 + DJ, SS, YH + + + + obo2:OAE_0000761 + brain oedema AE + + + + obo2:OAE_0000761 + WEB: http://medical-dictionary.thefreedictionary.com/cerebral+edema + + + + obo2:OAE_0000761 + brain edema AE + + + + obo2:OAE_0000761 + HPO: HP_0002181 + + + + obo2:OAE_0000761 + MedDRA: 10048962 + + + + obo2:OAE_0000761 + SIDER: C1527311 + + + + obo2:OAE_0000762 + a tumor AE that has an outcome of cancer in the breast + + + + obo2:OAE_0000762 + DJ, SS, YH + + + + obo2:OAE_0000762 + breast cancer AE + + + + obo2:OAE_0000762 + HPO: HP_0003002 + + + + obo2:OAE_0000762 + MedDRA: 10006187 + + + + obo2:OAE_0000762 + SIDER: C0006142 + + + + obo2:OAE_0000763 + a breast cancer AE that has an outcome of cancerous cells spreading to the breast + + + + obo2:OAE_0000763 + DJ, SS, YH + + + + obo2:OAE_0000763 + WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001911/ + + + + obo2:OAE_0000763 + breast cancer metastatic AE + + + + obo2:OAE_0000763 + MedDRA: 10055113 + + + + obo2:OAE_0000764 + a breast cancer AE that has an outcome of breast cancer at the stage III level + + + + obo2:OAE_0000764 + DJ, SS, YH + + + + obo2:OAE_0000764 + breast cancer stage iii AE + + + + obo2:OAE_0000764 + MedDRA: 10006201 + + + + obo2:OAE_0000765 + an infection AE that results in the breast becoming infected + + + + obo2:OAE_0000765 + DJ, SS, YH + + + + obo2:OAE_0000765 + breast infection AE + + + + obo2:OAE_0000765 + HPO: HP_0002726 + + + + obo2:OAE_0000765 + MedDRA: 10006259 + + + + obo2:OAE_0000765 + SIDER: C0392317 + + + + obo2:OAE_0000766 + a pain AE that results in pain in the breast + + + + obo2:OAE_0000766 + DJ, SS, YH + + + + obo2:OAE_0000766 + breast pain AE + + + + obo2:OAE_0000766 + HPO: HP_0000769 + + + + obo2:OAE_0000766 + MedDRA: 10006298 + + + + obo2:OAE_0000766 + SIDER: C0024902 + + + + obo2:OAE_0000767 + a reproductive system AE that has an outcome of pain or discomfort in the breast, may be caused by small benign tumors + + + + obo2:OAE_0000767 + DJ, SS, YH + + + + obo2:OAE_0000767 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/21979747 + + + + obo2:OAE_0000767 + breast tenderness AE + + + + obo2:OAE_0000767 + HPO: HP_0100749 + + + + obo2:OAE_0000767 + MedDRA: 10006313 + + + + obo2:OAE_0000767 + SIDER: C0262397 + + + + obo2:OAE_0000768 + a pneumonia AE that has an outcome of acute inflammation of the walls of the smaller bronchial tubes, with irregular areas of consolidation due to spread of inflammation into peribronchiolar alveoli and the alveolar ducts of the lungs + + + + obo2:OAE_0000768 + DJ, SS, YH + + + + obo2:OAE_0000768 + WEB: http://medical-dictionary.thefreedictionary.com/bronchopneumonia + + + + obo2:OAE_0000768 + bronchopneumonia AE + + + + obo2:OAE_0000768 + HPO: HP_0006538 + + + + obo2:OAE_0000768 + MedDRA: 10006469 + + + + obo2:OAE_0000768 + SIDER: C0006285 + + + + obo2:OAE_0000769 + an immune system disorder AE that has an outcome of an exaggerated response of the immune system to the fungus Aspergillus + + + + obo2:OAE_0000769 + DJ, SS, YH + + + + obo2:OAE_0000769 + WEB: http://medical-dictionary.thefreedictionary.com/bronchopulmonary+aspergillosis + + + + obo2:OAE_0000769 + bronchopulmonary aspergillosis AE + + + + obo2:OAE_0000769 + HPO: HP_0002724 + + + + obo2:OAE_0000769 + MedDRA: 10006473 + + + + obo2:OAE_0000769 + SIDER: C2350530 + + + + obo2:OAE_0000770 + a lung disorder AE that has an outcome of a sudden constriction of the muscles in the walls of the bronchioles + + + + obo2:OAE_0000770 + DJ, SS, YH + + + + obo2:OAE_0000770 + WEB: http://medical-dictionary.thefreedictionary.com/bronchospasm + + + + obo2:OAE_0000770 + bronchospasm AE + + + + obo2:OAE_0000770 + HPO: HP_0002099 + + + + obo2:OAE_0000770 + MedDRA: 10006482 + + + + obo2:OAE_0000770 + SIDER: C0006266 + + + + obo2:OAE_0000771 + a sensory capability AE that results in a feeling of burning + + + + obo2:OAE_0000771 + DJ, SS, YH + + + + obo2:OAE_0000771 + burning sensation AE + + + + obo2:OAE_0000771 + MedDRA: 10006784 + + + + obo2:OAE_0000772 + a syndrom AE that has an outcome of a wasting syndrome characterized by weight loss, muscle atrophy, fatigue, and loss of appetite, often occurs with cancer. + + + + obo2:OAE_0000772 + DJ, SS, YH + + + + obo2:OAE_0000772 + WEB: Primary Source: http://medical-dictionary.thefreedictionary.com/Wasting+Syndrome Secondary Source: http://www.ncbi.nlm.nih.gov/pubmed/23279159 + + + + obo2:OAE_0000772 + cachexia AE + + + + obo2:OAE_0000772 + HPO: HP_0004326 + + + + obo2:OAE_0000772 + MedDRA: 10006895 + + + + obo2:OAE_0000772 + SIDER: C0006625 + + + + obo2:OAE_0000773 + a digestive system AE that has an outcome of inflammation of the caecum, part of the large intestine + + + + obo2:OAE_0000773 + DJ, SS, YH + + + + obo2:OAE_0000773 + caecitis AE + + + + obo2:OAE_0000773 + typhlitis AE + + + + obo2:OAE_0000773 + WEB: http://medical-dictionary.thefreedictionary.com/caecitis + + + + obo2:OAE_0000773 + cecitis AE + + + + obo2:OAE_0000773 + MedDRA: 10006919 + + + + obo2:OAE_0000774 + an endocrine system AE that has an outcome of deficiency of calcium in the body + + + + obo2:OAE_0000774 + DJ, SS, YH + + + + obo2:OAE_0000774 + calcium deficiency AE + + + + obo2:OAE_0000774 + MedDRA: 10006956 + + + + obo2:OAE_0000775 + a cardiovascular disorder AE that has an outcome of self-reversing episodes during which the endothelial cells which line the capillaries are thought to separate for a few days, allowing for a leakage of fluid from the circulatory system to the interstitial space, resulting in hypotension, hemoconcentration, and hypoalbuminemia + + + + obo2:OAE_0000775 + DJ, SS, YH + + + + obo2:OAE_0000775 + Clarkson's Disease AE + + + + obo2:OAE_0000775 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/22873043 + + + + obo2:OAE_0000775 + capillary leak syndrome AE + + + + obo2:OAE_0000775 + MedDRA: 10007196 + + + + obo2:OAE_0000776 + a cytogenetic investigation result abnormal AE that has an outcome of an increase in a type of protein typically associated with tumors and the developing fetus + + + + obo2:OAE_0000776 + DJ, SS, YH, EB + + + + obo2:OAE_0000776 + WEB: http://www.medicinenet.com/carcinoembryonic_antigen/article.htm + + + + obo2:OAE_0000776 + carcinoembryonic antigen increased AE + + + + obo2:OAE_0000776 + MedDRA: 10007266 + + + + obo2:OAE_0000777 + a tumor AE that has an outcome of a carcinoid tumor that forms somewhere in the body + + + + obo2:OAE_0000777 + DJ, SS, YH + + + + obo2:OAE_0000777 + carcinoid tumour AE + + + + obo2:OAE_0000777 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/23307266 + + + + obo2:OAE_0000777 + carcinoid tumor AE + + + + obo2:OAE_0000777 + HPO: HP_0006723 + + + + obo2:OAE_0000777 + MedDRA: 10007275 + + + + obo2:OAE_0000777 + SIDER: C0007095 + + + + obo2:OAE_0000779 + a cardiovascular disorder AE that results in the inability of the heart to provide sufficient pump action to distribute blood flow to meet the needs of the body + + + + obo2:OAE_0000779 + DJ, SS, YH + + + + obo2:OAE_0000779 + heart failure + + + + obo2:OAE_0000779 + WEB: http://medical-dictionary.thefreedictionary.com/cardiac+failure + + + + obo2:OAE_0000779 + cardiac failure AE + + + + obo2:OAE_0000779 + HPO: HP_0001635 + + + + obo2:OAE_0000779 + MedDRA: 10007554 + + + + obo2:OAE_0000779 + SIDER: C0018801 + + + + obo2:OAE_0000780 + a cardiovascular disorder AE that results in an inability of the heart to provide sufficient pump action to distribute blood flow to meet the needs of the body + + + + obo2:OAE_0000780 + DJ, SS, YH + + + + obo2:OAE_0000780 + congestive heart failure + + + + obo2:OAE_0000780 + WEB: Primary Source: http://medical-dictionary.thefreedictionary.com/congestive+heart+failure Secondary Source: http://www.ncbi.nlm.nih.gov/pubmed/21676684 + + + + obo2:OAE_0000780 + cardiac failure congestive AE + + + + obo2:OAE_0000780 + HPO: HP_0001635 + + + + obo2:OAE_0000780 + MedDRA: 10007559 + + + + obo2:OAE_0000780 + SIDER: C0018802 + + + + obo2:OAE_0000782 + a cardiac disorder AE that has an outcome of disease involving one or more of the valves of the heart + + + + obo2:OAE_0000782 + DJ, SS, YH + + + + obo2:OAE_0000782 + valvular disease AE + + + + obo2:OAE_0000782 + WEB: http://medical-dictionary.thefreedictionary.com/valvular+heart+disease + + + + obo2:OAE_0000782 + cardiac valve disease AE + + + + obo2:OAE_0000782 + HPO: HP_0001654 + + + + obo2:OAE_0000782 + MedDRA: 10061406 + + + + obo2:OAE_0000782 + SIDER: C0018824 + + + + obo2:OAE_0000783 + a cardiac disorder AE that has an outcome of a disorder involving the ventricle(s) in the heart + + + + obo2:OAE_0000783 + DJ, SS, YH + + + + obo2:OAE_0000783 + WEB: Primary Source: http://medical-dictionary.thefreedictionary.com/ventricular Secondary Source: http://www.ncbi.nlm.nih.gov/pubmed/15473469 + + + + obo2:OAE_0000783 + cardiac ventricular disorder AE + + + + obo2:OAE_0000783 + MedDRA: 10057455 + + + + obo2:OAE_0000784 + a hypotension AE that has an outcome of the inability of the heart to supply enough blood to the organs of the body because of heart damage + + + + obo2:OAE_0000784 + DJ, SS, YH + + + + obo2:OAE_0000784 + WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001237/ + + + + obo2:OAE_0000784 + cardiogenic shock AE + + + + obo2:OAE_0000784 + MedDRA: 10007625 + + + + obo2:OAE_0000785 + a cardiovascular disorder AE that has an outcome of deterioration of the function of the myocardium, usually leads to heart failure + + + + obo2:OAE_0000785 + DJ, SS, YH + + + + obo2:OAE_0000785 + WEB: http://medical-dictionary.thefreedictionary.com/cardiomyopathy + + + + obo2:OAE_0000785 + cardiomyopathy AE + + + + obo2:OAE_0000785 + HPO: HP_0001638 + + + + obo2:OAE_0000785 + MedDRA: 10007636 + + + + obo2:OAE_0000785 + SIDER: C0878544 + + + + obo2:OAE_0000786 + a cardiovascular disorder AE that has an outcome of heart electrophysiology dysfunction and/or muscle damage. Is not efficient at pumping/circulating blood + + + + obo2:OAE_0000786 + DJ, SS, YH + + + + obo2:OAE_0000786 + WEB: http://medical-dictionary.thefreedictionary.com/cardiomyopathy + + + + obo2:OAE_0000786 + cardiotoxicity AE + + + + obo2:OAE_0000786 + MedDRA: 10048610 + + + + obo2:OAE_0000787 + a coronary artery disorder AE that results in lesion in carotid artery + + + + obo2:OAE_0000787 + DJ, SS, YH + + + + obo2:OAE_0000787 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/8198401 + + + + obo2:OAE_0000787 + carotid arteriosclerosis AE + + + + obo2:OAE_0000787 + MedDRA: 10067116 + + + + obo2:OAE_0000788 + a musculoskeletal system AE that has an outcome of loss of muscle tone due to emotional responses like laughing and crying + + + + obo2:OAE_0000788 + DJ, SS, YH + + + + obo2:OAE_0000788 + WEB: http://medical-dictionary.thefreedictionary.com/cataplexy + + + + obo2:OAE_0000788 + cataplexy AE + + + + obo2:OAE_0000788 + HPO: HP_0002524 + + + + obo2:OAE_0000788 + MedDRA: 10007737 + + + + obo2:OAE_0000788 + SIDER: C0007384 + + + + obo2:OAE_0000789 + a eye disorder AE that results in cloudiness that develops in the eye + + + + obo2:OAE_0000789 + DJ, SS, YH + + + + obo2:OAE_0000789 + WEB: http://medical-dictionary.thefreedictionary.com/cataract + + + + obo2:OAE_0000789 + cataract AE + + + + obo2:OAE_0000789 + HPO: HP_0000518 + + + + obo2:OAE_0000789 + MedDRA: 10007739 + + + + obo2:OAE_0000789 + SIDER: C0086543 + + + + obo2:OAE_0000790 + a sugery AE that has an adverse outcome related to the use of catheter, a thin tube inserted in the body + + + + obo2:OAE_0000790 + DJ, SS, YH + + + + obo2:OAE_0000790 + WEB: Primary Source: http://medical-dictionary.thefreedictionary.com/catheter Secondary Source: http://www.ncbi.nlm.nih.gov/pubmed/23306712 + + + + obo2:OAE_0000790 + catheter related complication AE + + + + obo2:OAE_0000790 + MedDRA: 10052253 + + + + obo2:OAE_0000791 + an infection AE that has an outcome of an infection (e.g., bacterial colonisation) at the catheter site + + + + obo2:OAE_0000791 + DJ, SS, YH + + + + obo2:OAE_0000791 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/8825104 + + + + obo2:OAE_0000791 + catheter related infection AE + + + + obo2:OAE_0000791 + HPO: HP_0002719 + + + + obo2:OAE_0000791 + MedDRA: 10056520 + + + + obo2:OAE_0000791 + SIDER: C0860239 + + + + obo2:OAE_0000792 + a bacterial infection AE that is located at the catheter site + + + + obo2:OAE_0000792 + DJ, SS, YH + + + + obo2:OAE_0000792 + catheter site infection AE + + + + obo2:OAE_0000792 + MedDRA: 10056520 + + + + obo2:OAE_0000793 + a sugery AE that has an adverse outcome at the site where a catheter was used + + + + obo2:OAE_0000793 + DJ, SS, YH + + + + obo2:OAE_0000793 + WEB: Primary Source: http://medical-dictionary.thefreedictionary.com/catheter Secondary Source: http://www.ncbi.nlm.nih.gov/pubmed/23074085 + + + + obo2:OAE_0000793 + catheter site related reaction AE + + + + obo2:OAE_0000793 + MedDRA: 10007811 + + + + obo2:OAE_0000794 + a cardiac disorder AE that has an outcome of a problem after inserting a catheter into the heart + + + + obo2:OAE_0000794 + DJ, SS, YH + + + + obo2:OAE_0000794 + catheterisation cardiac abnormal AE + + + + obo2:OAE_0000794 + WEB: http://medical-dictionary.thefreedictionary.com/cardiac+catheterization + + + + obo2:OAE_0000794 + catheterization cardiac abnormal AE + + + + obo2:OAE_0000794 + MedDRA: 10007816 + + + + obo2:OAE_0000795 + a behavior and neurological AE that has an outcome of an acute loss of function of the lumbar plexus + + + + obo2:OAE_0000795 + DJ, SS, YH + + + + obo2:OAE_0000795 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/23230403 + + + + obo2:OAE_0000795 + cauda equina syndrome AE + + + + obo2:OAE_0000795 + MedDRA: 10007821 + + + + obo2:OAE_0000796 + a bacterial infection AE that is located at the central-line catheter site + + + + obo2:OAE_0000796 + DJ, SS, YH + + + + obo2:OAE_0000796 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/7580945 + + + + obo2:OAE_0000796 + central line infection AE + + + + obo2:OAE_0000796 + HPO: HP_0002719 + + + + obo2:OAE_0000796 + MedDRA: 10054192 + + + + obo2:OAE_0000796 + SIDER: C1096243 + + + + obo2:OAE_0000797 + an infection AE that is located in the central nervous system + + + + obo2:OAE_0000797 + DJ, SS, YH + + + + obo2:OAE_0000797 + central nervous system infection AE + + + + obo2:OAE_0000797 + HPO: HP_0005381 + + + + obo2:OAE_0000797 + MedDRA: 10061036 + + + + obo2:OAE_0000797 + SIDER: C0007684 + + + + obo2:OAE_0000798 + a tumor AE that has an outcome of lymphoma in the central nervous system + + + + obo2:OAE_0000798 + DJ, SS, YH + + + + obo2:OAE_0000798 + central nervous system lymphoma AE + + + + obo2:OAE_0000798 + MedDRA: 10007953 + + + + obo2:OAE_0000799 + an ataxia AE that is located in the cerebellum + + + + obo2:OAE_0000799 + DJ, SS, YH + + + + obo2:OAE_0000799 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/23283615 + + + + obo2:OAE_0000799 + cerebellar ataxia AE + + + + obo2:OAE_0000799 + HPO: HP_0001251 + + + + obo2:OAE_0000799 + MedDRA: 10008025 + + + + obo2:OAE_0000799 + SIDER: C0007758 + + + + obo2:OAE_0000800 + a brain disorder AE that has an outcome of an inherited brain disorder that affects muscle coordination, may involve the tendency for limb movements to overshoot or undershoot a target, tremors and impaired rhythm + + + + obo2:OAE_0000800 + DJ, SS, YH + + + + obo2:OAE_0000800 + WEB: http://www.rightdiagnosis.com/medical/cerebellar_syndrome.htm + + + + obo2:OAE_0000800 + cerebellar syndrome AE + + + + obo2:OAE_0000800 + HPO: HP_0001317 + + + + obo2:OAE_0000800 + MedDRA: 10008072 + + + + obo2:OAE_0000800 + SIDER: C0007760 + + + + obo2:OAE_0000801 + a brain disorder AE with the outcome of hemorrhage or blood in the brain + + + + obo2:OAE_0000801 + DJ, SS, YH + + + + obo2:OAE_0000801 + cerebral haemorrhage AE + + + + obo2:OAE_0000801 + cerebral hemorrhage AE + + + + obo2:OAE_0000801 + HPO: HP_0001342 + + + + obo2:OAE_0000801 + MedDRA: 10008111 + + + + obo2:OAE_0000801 + SIDER: C2937358 + + + + obo2:OAE_0000802 + a brain disorder AE that results in the sudden death of brain cells in a localized area due to inadequate blood flow + + + + obo2:OAE_0000802 + DJ, SS, YH + + + + obo2:OAE_0000802 + cerebral ischaemia AE + + + + obo2:OAE_0000802 + stroke AE + + + + obo2:OAE_0000802 + WEB: http://medical-dictionary.thefreedictionary.com/Cerebral+ischaemia + + + + obo2:OAE_0000802 + cerebral ischemia AE + + + + obo2:OAE_0000802 + HPO: HP_0002637 + + + + obo2:OAE_0000802 + MedDRA: 10008120 + + + + obo2:OAE_0000802 + SIDER: C0917798 + + + + obo2:OAE_0000803 + a nervous system AE that has an outcome of pain or another sensation in the patient's neck and shoulder region + + + + obo2:OAE_0000803 + DJ, SS, YH + + + + obo2:OAE_0000803 + WEB: http://www.mdguidelines.com/cervicobrachial-syndrome/definition + + + + obo2:OAE_0000803 + cervicobrachial syndrome AE + + + + obo2:OAE_0000803 + MedDRA: 10008334 + + + + obo2:OAE_0000804 + a skin AE that has an outcome of dry lips caused by the evaporation of moisture. + + + + obo2:OAE_0000804 + DJ, SS, YH + + + + obo2:OAE_0000804 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/9433089 + + + + obo2:OAE_0000804 + chapped lips AE + + + + obo2:OAE_0000804 + MedDRA: 10049047 + + + + obo2:OAE_0000805 + an inflammation AE that occurs in the lip + + + + obo2:OAE_0000805 + DJ, SS, YH + + + + obo2:OAE_0000805 + WEB: http://medical-dictionary.thefreedictionary.com/cheilitis + + + + obo2:OAE_0000805 + cheilitis AE + + + + obo2:OAE_0000805 + HPO: HP_0100825 + + + + obo2:OAE_0000805 + MedDRA: 10008417 + + + + obo2:OAE_0000805 + SIDER: C0007971 + + + + obo2:OAE_0000806 + a skin AE that has an outcome of a burn due to chemicals on the skin + + + + obo2:OAE_0000806 + DJ, SS, YH + + + + obo2:OAE_0000806 + chemical burn of skin AE + + + + obo2:OAE_0000806 + MedDRA: 10057941 + + + + obo2:OAE_0000807 + a discomfort AE that has an outcome of pain in the chest + + + + obo2:OAE_0000807 + DJ, SS, YH + + + + obo2:OAE_0000807 + WEB: http://medical-dictionary.thefreedictionary.com/chest+pain + + + + obo2:OAE_0000807 + chest discomfort AE + + + + obo2:OAE_0000807 + HPO: HP_0001681 + + + + obo2:OAE_0000807 + MedDRA: 10008469 + + + + obo2:OAE_0000807 + SIDER: C0235710 + + + + obo2:OAE_0000808 + alcohol cardiomyopathy AE + + + + obo2:OAE_0000809 + a progressive tumor AE that has an outcome of multiple, malignant, localized green masses of abnormal cells, usually myeloblasts, especially beneath the periosteum of the skull, spine and ribs + + + + obo2:OAE_0000809 + DJ, SS, YH + + + + obo2:OAE_0000809 + WEB: http://medical-dictionary.thefreedictionary.com/chloroma + + + + obo2:OAE_0000809 + chloroma AE + + + + obo2:OAE_0000809 + MedDRA: 10008583 + + + + obo2:OAE_0000810 + a digestive system AE that has an outcome of infection in the common bile duct, usually by bacterial infection + + + + obo2:OAE_0000810 + DJ, SS, YH + + + + obo2:OAE_0000810 + WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001335/ + + + + obo2:OAE_0000810 + cholangitis AE + + + + obo2:OAE_0000810 + HPO: HP_0011040 + + + + obo2:OAE_0000810 + MedDRA: 10008604 + + + + obo2:OAE_0000810 + SIDER: NA + + + + obo2:OAE_0000811 + a liver/biliary system AE that has an outcome of a condition in which the flow of bile from the liver is slowed or blocked + + + + obo2:OAE_0000811 + DJ, SS, YH + + + + obo2:OAE_0000811 + WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001263/ + + + + obo2:OAE_0000811 + cholestasis AE + + + + obo2:OAE_0000811 + HPO: HP_0001396 + + + + obo2:OAE_0000811 + MedDRA: 10008635 + + + + obo2:OAE_0000811 + SIDER: C0008370 + + + + obo2:OAE_0000812 + an adverse event that has an outcome of calcium crystals of calcium pyrophosphate dihydrate accumulated in the connective tissues of the patient + + + + obo2:OAE_0000812 + DJ, SS, YH + + + + obo2:OAE_0000812 + WEB: http://medical-dictionary.thefreedictionary.com/chondrocalcinosis + + + + obo2:OAE_0000812 + chondrocalcinosis pyrophosphate AE + + + + obo2:OAE_0000812 + MedDRA: 10008690 + + + + obo2:OAE_0000813 + a cytogenetic investigation result abnormal AE that has an outcome of an abnormal chromosome pattern + + + + obo2:OAE_0000813 + DJ, SS, YH, EB + + + + obo2:OAE_0000813 + WEB: http://www.miscarriageclinic.co.uk/causes-and-treatments/chromosome-abnormality/ + + + + obo2:OAE_0000813 + chromosome analysis abnormal AE + + + + obo2:OAE_0000813 + MedDRA: 10008817 + + + + obo2:OAE_0000814 + a peripheral neuropathy AE which has an outcome of a chemotherapy-induced neuropathy that affects nerves of the peripheral nervous system (PNS) + + + + obo2:OAE_0000814 + AG, YH + + + + obo2:OAE_0000814 + CIPN + + + + obo2:OAE_0000814 + WEB: http://www.cancer.org/treatment/treatmentsandsideeffects/physicalsideeffects/chemotherapyeffects/peripheralneuropathy/peripheral-neuropathy-caused-by-chemotherapy-what-is-cipn + + + + obo2:OAE_0000814 + chemotherapy-induced peripheral neuropathy AE + + + + obo2:OAE_0000815 + a hematopoietic system AE that has an outcome of cancer of the white blood cells characterized by increased and unregulated growth of myeloid cells in the bone marrow + + + + obo2:OAE_0000815 + DJ, SS, YH + + + + obo2:OAE_0000815 + chronic myeloid leukaemia AE + + + + obo2:OAE_0000815 + WEB: http://medical-dictionary.thefreedictionary.com/chronic+myelogenous+leukemia + + + + obo2:OAE_0000815 + chronic myeloid leukemia AE + + + + obo2:OAE_0000815 + HPO: HP_0005506 + + + + obo2:OAE_0000815 + MedDRA: 10009013 + + + + obo2:OAE_0000815 + SIDER: C0023473 + + + + obo2:OAE_0000816 + a hematopoietic system AE that has an outcome of cancer of the white blood cells characterized by the increased and unregulated growth of predominantly myeloid cells in the bone marrow and the accumulation of these cells in the blood. May transform from chronic myeloid leukaemia to acute myeloid leukaemia + + + + obo2:OAE_0000816 + DJ, SS, YH + + + + obo2:OAE_0000816 + chronic myeloid leukaemia transformation AE + + + + obo2:OAE_0000816 + WEB: http://www.jci.org/articles/view/41246 + + + + obo2:OAE_0000816 + chronic myeloid leukemia transformation AE + + + + obo2:OAE_0000816 + MedDRA: 10068232 + + + + obo2:OAE_0000817 + a lung disorder AE that has an outcome of breathing difficulty with two main forms: chronic bronchitis and emphysema + + + + obo2:OAE_0000817 + DJ, SS, YH + + + + obo2:OAE_0000817 + WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001153/ + + + + obo2:OAE_0000817 + chronic obstructive pulmonary disease AE + + + + obo2:OAE_0000817 + HPO: HP_0006510 + + + + obo2:OAE_0000817 + MedDRA: 10009033 + + + + obo2:OAE_0000817 + SIDER: C0024117 + + + + obo2:OAE_0000818 + a respiratory system AE that results in inadequate gas exchange by the respiratory system + + + + obo2:OAE_0000818 + DJ, SS, YH + + + + obo2:OAE_0000818 + WEB: http://medical-dictionary.thefreedictionary.com/respiratory+failure + + + + obo2:OAE_0000818 + chronic respiratory failure AE + + + + obo2:OAE_0000818 + MedDRA: 10009126 + + + + obo2:OAE_0000819 + a respiratory system AE that has an outcome of inflammation in the cavities around the nasal passages + + + + obo2:OAE_0000819 + DJ, SS, YH + + + + obo2:OAE_0000819 + WEB: http://www.mayoclinic.com/health/chronic-sinusitis/DS00232 + + + + obo2:OAE_0000819 + chronic sinusitis AE + + + + obo2:OAE_0000819 + MedDRA: 10009137 + + + + obo2:OAE_0000820 + a lung disorder AE that has an outcome of lymphatic fluid accumulating in the pleural cavity, the space between two pleura of the lungs + + + + obo2:OAE_0000820 + DJ, SS, YH + + + + obo2:OAE_0000820 + WEB: http://medical-dictionary.thefreedictionary.com/chylothorax + + + + obo2:OAE_0000820 + chylothorax AE + + + + obo2:OAE_0000820 + MedDRA: 10051228 + + + + obo2:OAE_0000821 + a cardiovascular disorder AE that has an outcome of insufficient circulation without congestive heart failure + + + + obo2:OAE_0000821 + DJ, SS, YH + + + + obo2:OAE_0000821 + WEB: http://medical-dictionary.thefreedictionary.com/circulatory+collapse + + + + obo2:OAE_0000821 + circulatory collapse AE + + + + obo2:OAE_0000821 + MedDRA: 10009192 + + + + obo2:OAE_0000822 + a bacterial infection AE that has an outcome of invasion by anaerobic bacteria of the genus Clostridium, can cause tetanus and botulism + + + + obo2:OAE_0000822 + DJ, SS, YH + + + + obo2:OAE_0000822 + WEB: http://www.medicinenet.com/clostridium_difficile_colitis/page2.htm + + + + obo2:OAE_0000822 + clostridial infection AE + + + + obo2:OAE_0000822 + HPO: HP_0004798 + + + + obo2:OAE_0000822 + MedDRA: 10061043 + + + + obo2:OAE_0000822 + SIDER: C0009062 + + + + obo2:OAE_0000823 + a digestive system AE that has an outcome of bacterial infection by clostridium difficile colitis, commonly results in diarrhea and colitis + + + + obo2:OAE_0000823 + DJ, SS, YH + + + + obo2:OAE_0000823 + clostridium difficile colitis AE + + + + obo2:OAE_0000823 + HPO: HP_0002583 + + + + obo2:OAE_0000823 + MedDRA: 10009657 + + + + obo2:OAE_0000823 + SIDER: C0238106 + + + + obo2:OAE_0000824 + a coagulation factor v level abnormal AE that has an outcome of a decreased level of the factor V protein in the coagulation system of the body + + + + obo2:OAE_0000824 + DJ, SS, YH, EB + + + + obo2:OAE_0000824 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/22781721 + + + + obo2:OAE_0000824 + coagulation factor v level decreased AE + + + + obo2:OAE_0000824 + MedDRA: 10009754 + + + + obo2:OAE_0000825 + a digestive system AE with an outcome of inflammation located in the large intestine + + + + obo2:OAE_0000825 + DJ, SS, YH + + + + obo2:OAE_0000825 + WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0002112/ + + + + obo2:OAE_0000825 + colitis AE + + + + obo2:OAE_0000825 + HPO: HP_0002583 + + + + obo2:OAE_0000825 + MedDRA: 10009887 + + + + obo2:OAE_0000825 + SIDER: C0009319 + + + + obo2:OAE_0000826 + a lung disorder AE that has an outcome of a collapsed lung, refering to the space between the wall of the chest cavity and the lung filling with air, causing all or a portion of the lung to collapse + + + + obo2:OAE_0000826 + DJ, SS, YH + + + + obo2:OAE_0000826 + Pneumothorax + + + + obo2:OAE_0000826 + collapse of lung AE + + + + obo2:OAE_0000826 + MedDRA: 10009913 + + + + obo2:OAE_0000827 + a tumor AE that has an outcome of cancer that starts in the large intestine or the rectum + + + + obo2:OAE_0000827 + DJ, SS, YH + + + + obo2:OAE_0000827 + WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001308/ + + + + obo2:OAE_0000827 + colon cancer AE + + + + obo2:OAE_0000827 + HPO: HP_0003003 + + + + obo2:OAE_0000827 + MedDRA: 10009944 + + + + obo2:OAE_0000827 + SIDER: C0007102 + + + + obo2:OAE_0000828 + a colon AE that has an outcome of cancerous cells spreading to the colon + + + + obo2:OAE_0000828 + DJ, SS, YH + + + + obo2:OAE_0000828 + WEB: http://www.cancer.gov/cancertopics/factsheet/Sites-Types/metastatic + + + + obo2:OAE_0000828 + colon cancer metastatic AE + + + + obo2:OAE_0000828 + MedDRA: 10055114 + + + + obo2:OAE_0000829 + a colon cancer AE that has an outcome of colon cancer at stage IV + + + + obo2:OAE_0000829 + DJ, SS, YH + + + + obo2:OAE_0000829 + colon cancer stage iv AE + + + + obo2:OAE_0000829 + MedDRA: 10009956 + + + + obo2:OAE_0000830 + a digestive system AE that has an outcome of cancer that starts in the large intestine or rectum. + + + + obo2:OAE_0000830 + DJ, SS, YH + + + + obo2:OAE_0000830 + WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001308/ + + + + obo2:OAE_0000830 + colorectal cancer AE + + + + obo2:OAE_0000830 + HPO: HP_0003003 + + + + obo2:OAE_0000830 + MedDRA: 10061451 + + + + obo2:OAE_0000830 + SIDER: C1527249 + + + + obo2:OAE_0000831 + a digestive system AE that has an outcome of cancer in the large intestine and the rectum. When metastatic, the cancer has already spead to distant sites and is considered stage IV. + + + + obo2:OAE_0000831 + DJ, SS, YH + + + + obo2:OAE_0000831 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/22642873 + + + + obo2:OAE_0000831 + colorectal cancer metastatic AE + + + + obo2:OAE_0000831 + HPO: HP_0003003 + + + + obo2:OAE_0000831 + MedDRA: 10052358 + + + + obo2:OAE_0000831 + SIDER: C0948380 + + + + obo2:OAE_0000832 + an imaging investigation result abnormal AE that has an abnormal result of an imaging method in which a cross-sectional image of the structures in a body plane is reconstructed by a computer program from the x-ray absorption of beams projected through the body in the image plane + + + + obo2:OAE_0000832 + DJ, SS, YH, EB + + + + obo2:OAE_0000832 + computerised tomogram abnormal AE + + + + obo2:OAE_0000832 + WEB: Primary Source: http://medical-dictionary.thefreedictionary.com/computerized+tomography , Secondary Source: http://www.ncbi.nlm.nih.gov/pubmed/23271098 + + + + obo2:OAE_0000832 + WEB: http://medical-dictionary.thefreedictionary.com/computed+tomography + + + + obo2:OAE_0000832 + computerized tomography result abnormal AE + + + + obo2:OAE_0000832 + MedDRA: 10010235 + + + + obo2:OAE_0000833 + an adverse event that has an outcome of progression of underlying conditions that may affect drug distribution or metabolism + + + + obo2:OAE_0000833 + DJ, SS, YH + + + + obo2:OAE_0000833 + WEB: http://medical-dictionary.thefreedictionary.com/Concomitant+disease + + + + obo2:OAE_0000833 + concomitant disease progression AE + + + + obo2:OAE_0000833 + MedDRA: 10048659 + + + + obo2:OAE_0000834 + an adverse event that has an outcome of condition that worsens + + + + obo2:OAE_0000834 + DJ, SS, YH + + + + obo2:OAE_0000834 + condition aggravated AE + + + + obo2:OAE_0000834 + MedDRA: 10010264 + + + + obo2:OAE_0000835 + a congenital abnormality AE that has an outcome of an abnormality in heart which is present at birth + + + + obo2:OAE_0000835 + DJ, SS, YH + + + + obo2:OAE_0000835 + WEB: http://www.thefreedictionary.com/congenital+heart+defect + + + + obo2:OAE_0000835 + congenital cardiovascular anomaly AE + + + + obo2:OAE_0000835 + HPO: HP_0001626 + + + + obo2:OAE_0000835 + MedDRA: 10061054 + + + + obo2:OAE_0000835 + SIDER: C0243050 + + + + obo2:OAE_0000836 + a cardiomyopathy AE that is characterized by the walls of the heart chambers stretching to hold a greater volume of blood than normal + + + + obo2:OAE_0000836 + DJ, SS, YH + + + + obo2:OAE_0000836 + WEB: http://medical-dictionary.thefreedictionary.com/congestive+cardiomyopathy + + + + obo2:OAE_0000836 + congestive cardiomyopathy AE + + + + obo2:OAE_0000836 + HPO: HP_0001635 + + + + obo2:OAE_0000836 + MedDRA: 10056370 + + + + obo2:OAE_0000836 + SIDER: C0007193 + + + + obo2:OAE_0000837 + an eye disorder AE that has an outcome of a problem involving the insides of the patient's eyelids + + + + obo2:OAE_0000837 + DJ, SS, YH + + + + obo2:OAE_0000837 + WEB: http://medical-dictionary.thefreedictionary.com/conjunctiva + + + + obo2:OAE_0000837 + conjunctival disorder AE + + + + obo2:OAE_0000837 + HPO: HP_0000502 + + + + obo2:OAE_0000837 + MedDRA: 10061446 + + + + obo2:OAE_0000837 + SIDER: C0009759 + + + + obo2:OAE_0000838 + a hemorrhage AE that has an outcome of a bright hemorrhagic patch on the bulbar conjunctiva caused by rupture and bleeding of a superficial small capillary due to increased pressure + + + + obo2:OAE_0000838 + DJ, SS, YH + + + + obo2:OAE_0000838 + conjunctival haemorrhage AE + + + + obo2:OAE_0000838 + conjunctival hemorrhage AE + + + + obo2:OAE_0000838 + HPO: HP_0007902 + + + + obo2:OAE_0000838 + MedDRA: 10010719 + + + + obo2:OAE_0000838 + SIDER: C0009760 + + + + obo2:OAE_0000839 + an adverse event that has an outcome of disease in the biological tissue that supports, binds together and protects organs + + + + obo2:OAE_0000839 + DJ, SS, YH + + + + obo2:OAE_0000839 + WEB: http://medical-dictionary.thefreedictionary.com/connective+tissue+disease + + + + obo2:OAE_0000839 + connective tissue disorder AE + + + + obo2:OAE_0000839 + HPO: HP_0003549 + + + + obo2:OAE_0000839 + MedDRA: 10061087 + + + + obo2:OAE_0000839 + SIDER: C0009782 + + + + obo2:OAE_0000840 + an eye disorder AE that has a result of the inability to use contact lenses + + + + obo2:OAE_0000840 + DJ, SS, YH + + + + obo2:OAE_0000840 + contact lens intolerance AE + + + + obo2:OAE_0000840 + MedDRA: 10010804 + + + + obo2:OAE_0000841 + a hematology investigation result abnormal AE that has an outcome of a positive coombs test, which is a blood test that identifies the causes of anemia + + + + obo2:OAE_0000841 + DJ, SS, YH, EB + + + + obo2:OAE_0000841 + WEB: http://medical-dictionary.thefreedictionary.com/Coombs'+Tests + + + + obo2:OAE_0000841 + WEB: http://medical-dictionary.thefreedictionary.com/test + + + + obo2:OAE_0000841 + coombs' test positive AE + + + + obo2:OAE_0000841 + MedDRA: 10061090 + + + + obo2:OAE_0000842 + a behavior and neurological AE that results in a loss of coordination + + + + obo2:OAE_0000842 + DJ, SS, YH + + + + obo2:OAE_0000842 + coordination abnormal AE + + + + obo2:OAE_0000842 + HPO: HP_0011443 + + + + obo2:OAE_0000842 + MedDRA: 10010947 + + + + obo2:OAE_0000842 + SIDER: C0520966 + + + + obo2:OAE_0000844 + a coronary artery disorder AE that has an outcome of an blockage in the coronary artery + + + + obo2:OAE_0000844 + DJ, SS, YH + + + + obo2:OAE_0000844 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/22953315 + + + + obo2:OAE_0000844 + coronary artery embolism AE + + + + obo2:OAE_0000844 + MedDRA: 10011084 + + + + obo2:OAE_0000845 + a coronary artery disorder AE that has an outcome of an insufficient amount of blood circulates through the coronary arteries + + + + obo2:OAE_0000845 + DJ, SS, YH + + + + obo2:OAE_0000845 + WEB: http://medical-dictionary.thefreedictionary.com/coronary+insufficiency + + + + obo2:OAE_0000845 + coronary artery insufficiency AE + + + + obo2:OAE_0000845 + HPO: HP_0001677 + + + + obo2:OAE_0000845 + MedDRA: 10052895 + + + + obo2:OAE_0000845 + SIDER: C0542052 + + + + obo2:OAE_0000846 + a tumor AE that has an outcome of a brain tumor derived from the embryonic tissue of the pituitary gland + + + + obo2:OAE_0000846 + DJ, SS, YH + + + + obo2:OAE_0000846 + WEB: http://medical-dictionary.thefreedictionary.com/craniopharyngioma + + + + obo2:OAE_0000846 + craniopharyngioma AE + + + + obo2:OAE_0000846 + MedDRA: 10011318 + + + + obo2:OAE_0000847 + a c-reactive protein level abnormal AE that has an outcome of an increased amount of CRP, a protein that measure general levels of inflammation in the body + + + + obo2:OAE_0000847 + DJ, SS, YH, EB + + + + obo2:OAE_0000847 + WEB: http://www.webmd.com/a-to-z-guides/c-reactive-protein-crp + + + + obo2:OAE_0000847 + moved "c-reactive protein increased AE" from "cardiac AE" to "lab test abnormal AE" EB + + + + obo2:OAE_0000847 + c-reactive protein level increased AE + + + + obo2:OAE_0000847 + MedDRA: 10006825 + + + + obo2:OAE_0000848 + viral cardiomyopathy AE + + + + obo2:OAE_0000849 + a nervous system AE that has an outcome of increased pressure in the skull + + + + obo2:OAE_0000849 + DJ, SS, YH + + + + obo2:OAE_0000849 + WEB: http://medical-dictionary.thefreedictionary.com/intracranial+pressure + + + + obo2:OAE_0000849 + csf pressure increased AE + + + + obo2:OAE_0000849 + MedDRA: 10011570 + + + + obo2:OAE_0000850 + a renal and urinary tract investigation and urinalysis result abnormal AE that has an outcome of high bacterial colonization counts in the urine + + + + obo2:OAE_0000850 + DJ, SS, YH, EB + + + + obo2:OAE_0000850 + WEB: http://labtestsonline.org/understanding/analytes/urine-culture/tab/test + + + + obo2:OAE_0000850 + culture urine positive AE + + + + obo2:OAE_0000850 + MedDRA: 10011640 + + + + obo2:OAE_0000851 + an inflammation AE that has an outcome of inflamed blood vessels in the skin + + + + obo2:OAE_0000851 + DJ, SS, YH + + + + obo2:OAE_0000851 + WEB: http://dermnetnz.org/vascular/vasculitis.html + + + + obo2:OAE_0000851 + cutaneous vasculitis AE + + + + obo2:OAE_0000851 + HPO: HP_0200029 + + + + obo2:OAE_0000851 + MedDRA: 10011686 + + + + obo2:OAE_0000851 + SIDER: C0262988 + + + + obo2:OAE_0000852 + a urinary system AE that has an outcome of cystitis with severe hemorrhage, a dose-limiting toxic condition with administration of ifosfamide and cyclophosphamide or a complication of bone marrow transplantation + + + + obo2:OAE_0000852 + DJ, SS, YH + + + + obo2:OAE_0000852 + cystitis haemorrhagic AE + + + + obo2:OAE_0000852 + WEB: http://medical-dictionary.thefreedictionary.com/hemorrhagic+cystitis + + + + obo2:OAE_0000852 + cystitis hemorrhagic AE + + + + obo2:OAE_0000852 + MedDRA: 10011793 + + + + obo2:OAE_0000853 + a genetic disorder AE that has an outcome of an atypical number of chromosomes or a structural abnormality in one or more chromosomes + + + + obo2:OAE_0000853 + DJ, SS, YH + + + + obo2:OAE_0000853 + cytogenetic abnormality AE + + + + obo2:OAE_0000853 + MedDRA: 10067477 + + + + obo2:OAE_0000854 + an inflammation AE that has an outcome of release of cytokines by T cells that causes inflammation + + + + obo2:OAE_0000854 + DJ, SS, YH + + + + obo2:OAE_0000854 + WEB: http://encyclopedia.thefreedictionary.com/cytokine+release+syndrome + + + + obo2:OAE_0000854 + cytokine release syndrome AE + + + + obo2:OAE_0000854 + MedDRA: 10052015 + + + + obo2:OAE_0000855 + a liver/biliary system AE that has an outcome of liver cells carrying excess water, causing inflammation along with hepatitis + + + + obo2:OAE_0000855 + DJ, SS, YH + + + + obo2:OAE_0000855 + WEB: http://www.thirdage.com/hc/c/q/hepatitis/1550008/what-is-cytolytic-hepatitis + + + + obo2:OAE_0000855 + cytolytic hepatitis AE + + + + obo2:OAE_0000855 + HPO: HP_0004787 + + + + obo2:OAE_0000855 + MedDRA: 10050904 + + + + obo2:OAE_0000855 + SIDER: C0919823 + + + + obo2:OAE_0000856 + an inflammation AE that results in the inflammation of the colon + + + + obo2:OAE_0000856 + DJ, SS, YH + + + + obo2:OAE_0000856 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/22874621 + + + + obo2:OAE_0000856 + cytomegalovirus colitis AE + + + + obo2:OAE_0000856 + MedDRA: 10048983 + + + + obo2:OAE_0000857 + a viral infection AE that is caused by cytomegalovirus + + + + obo2:OAE_0000857 + DJ, SS, YH + + + + obo2:OAE_0000857 + WEB: http://www.nlm.nih.gov/medlineplus/cytomegalovirusinfections.html + + + + obo2:OAE_0000857 + cytomegalovirus infection AE + + + + obo2:OAE_0000857 + HPO: HP_0004429 + + + + obo2:OAE_0000857 + MedDRA: 10011831 + + + + obo2:OAE_0000857 + SIDER: C0010823 + + + + obo2:OAE_0000858 + a skin AE that has an outcome of shedding of the dead skin cells from the scalp + + + + obo2:OAE_0000858 + DJ, SS, YH + + + + obo2:OAE_0000858 + WEB: http://medical-dictionary.thefreedictionary.com/dandruff + + + + obo2:OAE_0000858 + dandruff AE + + + + obo2:OAE_0000858 + HPO: HP_0001051 + + + + obo2:OAE_0000858 + MedDRA: 10011859 + + + + obo2:OAE_0000858 + SIDER: C0221244 + + + + obo2:OAE_0000860 + a skin ulcer AE that has an outcome of localized injuries to the skin and/or underlying tissue usually over a bony prominence as a result of pressure + + + + obo2:OAE_0000860 + DJ, SS, YH + + + + obo2:OAE_0000860 + WEB: http://medical-dictionary.thefreedictionary.com/pressure+ulcer + + + + obo2:OAE_0000860 + decubitus ulcer AE + + + + obo2:OAE_0000860 + HPO: HP_0200042 + + + + obo2:OAE_0000860 + MedDRA: 10011985 + + + + obo2:OAE_0000860 + SIDER: C0011127 + + + + obo2:OAE_0000861 + a venous thrombosis that is characterized by a blood clot that forms in a vein deep in the body. Blood clots occur when blood thickens and clumps together. Most deep vein blood clots occur in the lower leg or thigh. They also can occur in other parts of the body. + + + + obo2:OAE_0000861 + DJ, SS, YH + + + + obo2:OAE_0000861 + DVT + + + + obo2:OAE_0000861 + WEB: http://www.nhlbi.nih.gov/health/health-topics/topics/dvt/ + + + + obo2:OAE_0000861 + Moved from Cardiac AE to thombosis AE by LB + + + + obo2:OAE_0000861 + deep vein thrombosis AE + + + + obo2:OAE_0000861 + HPO: HP_0004850 + + + + obo2:OAE_0000861 + MedDRA: 10051055 + + + + obo2:OAE_0000861 + SIDER: C0149871 + + + + obo2:OAE_0000862 + a sensory capability AE that results in a decline in level of cognitive function + + + + obo2:OAE_0000862 + DJ, SS, YH + + + + obo2:OAE_0000862 + WEB: http://medical-dictionary.thefreedictionary.com/delirium + + + + obo2:OAE_0000862 + delirium AE + + + + obo2:OAE_0000862 + MedDRA: 10012218 + + + + obo2:OAE_0000863 + a bone disorder AE that has an outcome of bacterial infection that causes demineralization and destruction of the hard tissues, resulting in dental cavities + + + + obo2:OAE_0000863 + DJ, SS, YH + + + + obo2:OAE_0000863 + WEB: http://medical-dictionary.thefreedictionary.com/dental+caries + + + + obo2:OAE_0000863 + dental caries AE + + + + obo2:OAE_0000863 + HPO: HP_0000670 + + + + obo2:OAE_0000863 + MedDRA: 10012318 + + + + obo2:OAE_0000863 + SIDER: C0011334 + + + + obo2:OAE_0000864 + a sensory capability AE that results in a lower level of arousal than normal + + + + obo2:OAE_0000864 + DJ, SS, YH + + + + obo2:OAE_0000864 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/23167919 + + + + obo2:OAE_0000864 + depressed level of consciousness AE + + + + obo2:OAE_0000864 + HPO: HP_0004372 + + + + obo2:OAE_0000864 + MedDRA: 10012373 + + + + obo2:OAE_0000864 + SIDER: C0549249 + + + + obo2:OAE_0000865 + a dermatitis ae that is characterized by the eruption of papules and pustules, typically on the face, scalp, upper chest and back. + + + + obo2:OAE_0000865 + DJ, SS, YH + + + + obo2:OAE_0000865 + acne AE + + + + obo2:OAE_0000865 + WEB: https://www.medify.com/conditions/acneiform-dermatitis + + + + obo2:OAE_0000865 + dermatitis acneiform AE + + + + obo2:OAE_0000865 + HPO: HP_0001051 + + + + obo2:OAE_0000865 + MedDRA: 10012432 + + + + obo2:OAE_0000865 + SIDER: C0234894 + + + + obo2:OAE_0000866 + a dermatitis ae that is characterized by an inflammatory skin disease with erythmea and scaling, that has an outcome of widespread scaling of the skin, often with itching, skin redness and hair loss + + + + obo2:OAE_0000866 + DJ, SS, YH + + + + obo2:OAE_0000866 + WEB: http://www.nlm.nih.gov/medlineplus/ency/article/001610.htm + + + + obo2:OAE_0000866 + dermatitis exfoliative AE + + + + obo2:OAE_0000866 + HPO: HP_0011123 + + + + obo2:OAE_0000866 + MedDRA: 10012455 + + + + obo2:OAE_0000866 + SIDER: C0011606 + + + + obo2:OAE_0000867 + a muscle AE that has an outcome of muscle weakness, inflammation, skin rash and difficulty swallowing + + + + obo2:OAE_0000867 + DJ, SS, YH + + + + obo2:OAE_0000867 + WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001842/ + + + + obo2:OAE_0000867 + dermatomyositis AE + + + + obo2:OAE_0000867 + MedDRA: 10012503 + + + + obo2:OAE_0000868 + a motor neuropathy AE that has an outcome of poor coordination + + + + obo2:OAE_0000868 + DJ, SS, YH + + + + obo2:OAE_0000868 + WEB: http://www.nlm.nih.gov/medlineplus/ency/article/001533.htm + + + + obo2:OAE_0000868 + developmental coordination disorder AE + + + + obo2:OAE_0000868 + MedDRA: 10012557 + + + + obo2:OAE_0000869 + an injury and procedural complication AE that results in the dislocation of a device + + + + obo2:OAE_0000869 + DJ, SS, YH + + + + obo2:OAE_0000869 + device dislocation AE + + + + obo2:OAE_0000869 + MedDRA: 10064684 + + + + obo2:OAE_0000870 + an injury and procedural complication AE that results in the expulsion (vomiting) of medical device from body + + + + obo2:OAE_0000870 + DJ, SS, YH + + + + obo2:OAE_0000870 + device expulsion AE + + + + obo2:OAE_0000870 + MedDRA: 10012578 + + + + obo2:OAE_0000871 + an injury and procedural complication AE that results in an infection related to medical device + + + + obo2:OAE_0000871 + DJ, SS, YH + + + + obo2:OAE_0000871 + device related infection AE + + + + obo2:OAE_0000871 + HPO: HP_0002719 + + + + obo2:OAE_0000871 + MedDRA: 10064687 + + + + obo2:OAE_0000871 + SIDER: C1619702 + + + + obo2:OAE_0000872 + a coma AE which is induced by the condition that the patient has extremely high levels of sugar in the blood without ketones + + + + obo2:OAE_0000872 + DJ, SS, YH + + + + obo2:OAE_0000872 + diabetic hyperglycaemic coma AE + + + + obo2:OAE_0000872 + WEB: http://www.nlm.nih.gov/medlineplus/ency/article/000304.htm + + + + obo2:OAE_0000872 + diabetic hyperglycemic coma AE + + + + obo2:OAE_0000872 + MedDRA: 10012668 + + + + obo2:OAE_0000873 + a respiratory system AE that has an outcome of an abnormal hole in the diaphragm + + + + obo2:OAE_0000873 + DJ, SS, YH + + + + obo2:OAE_0000873 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/23288807 + + + + obo2:OAE_0000873 + diaphragmatic hernia AE + + + + obo2:OAE_0000873 + HPO: HP_0000776 + + + + obo2:OAE_0000873 + MedDRA: 10012713 + + + + obo2:OAE_0000873 + SIDER: C0019284 + + + + obo2:OAE_0000874 + a paralysis AE that has an outcome of a paralyzed diaphragm + + + + obo2:OAE_0000874 + DJ, SS, YH + + + + obo2:OAE_0000874 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/19452391 + + + + obo2:OAE_0000874 + diaphragmatic paralysis AE + + + + obo2:OAE_0000874 + MedDRA: 10012725 + + + + obo2:OAE_0000875 + a diarrhea AE that has an outcome of rectal bleeding and bloody diarrhea + + + + obo2:OAE_0000875 + DJ, SS, YH + + + + obo2:OAE_0000875 + diarrhoea haemorrhagic AE + + + + obo2:OAE_0000875 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/19292138 + + + + obo2:OAE_0000875 + diarrhea hemorrhagic AE + + + + obo2:OAE_0000875 + HPO: HP_0002255 + + + + obo2:OAE_0000875 + MedDRA: 10012741 + + + + obo2:OAE_0000875 + SIDER: C0151594 + + + + obo2:OAE_0000876 + a diarrhea AE that has an outcome of diarrhea is caused by infection + + + + obo2:OAE_0000876 + DJ, SS, YH + + + + obo2:OAE_0000876 + diarrhoea infectious AE + + + + obo2:OAE_0000876 + diarrhea infectious AE + + + + obo2:OAE_0000876 + MedDRA: 10012742 + + + + obo2:OAE_0000877 + a cardiac disorder AE with an outcome of decline in performance of one or both ventricles of the heart during the time phase of diastole, when heart filling with incoming blood + + + + obo2:OAE_0000877 + DJ, SS, YH + + + + obo2:OAE_0000877 + WEB: http://encyclopedia.thefreedictionary.com/diastolic+dysfunction + + + + obo2:OAE_0000877 + diastolic dysfunction AE + + + + obo2:OAE_0000877 + MedDRA: 10052337 + + + + obo2:OAE_0000878 + a cardiac ventricular disorder AE that has an outcome of enlargement of a heart chamber that pumps blood away from the heart + + + + obo2:OAE_0000878 + DJ, SS, YH + + + + obo2:OAE_0000878 + WEB: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1721391/ + + + + obo2:OAE_0000878 + dilatation ventricular AE + + + + obo2:OAE_0000878 + MedDRA: 10013012 + + + + obo2:OAE_0000879 + an adverse event with an outcome of worsening of the disease + + + + obo2:OAE_0000879 + DJ, SS, YH + + + + obo2:OAE_0000879 + disease progression AE + + + + obo2:OAE_0000879 + HPO: HP_0004738 + + + + obo2:OAE_0000879 + MedDRA: 10061818 + + + + obo2:OAE_0000879 + SIDER: C0242656 + + + + obo2:OAE_0000880 + a bone disorder AE that has an outcome of dislocation of vertebra + + + + obo2:OAE_0000880 + DJ, SS, YH + + + + obo2:OAE_0000880 + dislocation of vertebra AE + + + + obo2:OAE_0000880 + MedDRA: 10013183 + + + + obo2:OAE_0000881 + a sensory capability AE that results in the senses of time, direction, and recognition of people and places becoming difficult to distinguish + + + + obo2:OAE_0000881 + DJ, SS, YH + + + + obo2:OAE_0000881 + WEB: http://medical-dictionary.thefreedictionary.com/disorientation + + + + obo2:OAE_0000881 + disorientation AE + + + + obo2:OAE_0000881 + HPO: HP_0001289 + + + + obo2:OAE_0000881 + MedDRA: 10013395 + + + + obo2:OAE_0000881 + SIDER: C0233407 + + + + obo2:OAE_0000882 + a hematopoietic system AE with an outcome of a serious disorder in which proteins that control blood clotting become abnormally active + + + + obo2:OAE_0000882 + DJ, SS, YH + + + + obo2:OAE_0000882 + WEB: http://www.nlm.nih.gov/medlineplus/ency/article/000573.htm + + + + obo2:OAE_0000882 + disseminated intravascular coagulation AE + + + + obo2:OAE_0000882 + HPO: HP_0005521 + + + + obo2:OAE_0000882 + MedDRA: 10013442 + + + + obo2:OAE_0000882 + SIDER: C0012739 + + + + obo2:OAE_0000883 + a behavior and neurological AE that results in a loss of attention + + + + obo2:OAE_0000883 + DJ, SS, YH + + + + obo2:OAE_0000883 + disturbance in attention AE + + + + obo2:OAE_0000883 + HPO: HP_0007018 + + + + obo2:OAE_0000883 + MedDRA: 10013496 + + + + obo2:OAE_0000883 + SIDER: C0233414 + + + + obo2:OAE_0000884 + a digestive system AE with an outcome of perforation of small sacs or pockets in the wall of the colon + + + + obo2:OAE_0000884 + DJ, SS, YH + + + + obo2:OAE_0000884 + WEB: http://www.webmd.com/digestive-disorders/diverticular-disease + + + + obo2:OAE_0000884 + diverticular perforation AE + + + + obo2:OAE_0000884 + MedDRA: 10061820 + + + + obo2:OAE_0000885 + a digestive system AE that has an outcome of infection and inflammation in the small, bulging sacs or pouches of the inner lining of the intestine + + + + obo2:OAE_0000885 + DJ, SS, YH + + + + obo2:OAE_0000885 + WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001303/ + + + + obo2:OAE_0000885 + diverticulitis AE + + + + obo2:OAE_0000885 + HPO: HP_0002253 + + + + obo2:OAE_0000885 + MedDRA: 10013538 + + + + obo2:OAE_0000885 + SIDER: C0012813 + + + + obo2:OAE_0000886 + a hemorrhage AE that has an outcome of bleeding in the intestine due to diverticulitis + + + + obo2:OAE_0000886 + DJ, SS, YH + + + + obo2:OAE_0000886 + diverticulitis intestinal haemorrhagic AE + + + + obo2:OAE_0000886 + WEB: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2780263/ + + + + obo2:OAE_0000886 + diverticulitis intestinal hemorrhagic AE + + + + obo2:OAE_0000886 + MedDRA: 10013541 + + + + obo2:OAE_0000887 + an adverse event that has an outcome of a decreased amount of the drug excreted by the body + + + + obo2:OAE_0000887 + DJ, SS, YH + + + + obo2:OAE_0000887 + WEB: http://medical-dictionary.thefreedictionary.com/drug+clearance + + + + obo2:OAE_0000887 + drug clearance decreased AE + + + + obo2:OAE_0000887 + MedDRA: 10049463 + + + + obo2:OAE_0000888 + an adverse drug event that results in the development of a dependence on the drug + + + + obo2:OAE_0000888 + DJ, SS, YH + + + + obo2:OAE_0000888 + drug dependence AE + + + + obo2:OAE_0000888 + HPO: HP_0000722 + + + + obo2:OAE_0000888 + MedDRA: 10013663 + + + + obo2:OAE_0000888 + SIDER: C1510472 + + + + obo2:OAE_0000889 + a skin AE that has an outcome of a range of adverse drugs reactions of the skin, most commonly rashes resembling measles + + + + obo2:OAE_0000889 + DJ, SS, YH + + + + obo2:OAE_0000889 + WEB: http://medical-dictionary.thefreedictionary.com/drug+eruption + + + + obo2:OAE_0000889 + drug eruption AE + + + + obo2:OAE_0000889 + MedDRA: 10013687 + + + + obo2:OAE_0000890 + a hypersensitivity AE that has an outcome of allergic reactions to certain drugs + + + + obo2:OAE_0000890 + DJ, SS, YH + + + + obo2:OAE_0000890 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/23192511 + + + + obo2:OAE_0000890 + drug hypersensitivity AE + + + + obo2:OAE_0000890 + HPO: HP_0100326 + + + + obo2:OAE_0000890 + MedDRA: 10013700 + + + + obo2:OAE_0000890 + SIDER: C0013182 + + + + obo2:OAE_0000891 + a drug AE that has an outcome of lower threshold to the normal pharmacologic action of a drug + + + + obo2:OAE_0000891 + DJ, SS, YH + + + + obo2:OAE_0000891 + WEB: http://medical-dictionary.thefreedictionary.com/drug+intolerance + + + + obo2:OAE_0000891 + drug intolerance AE + + + + obo2:OAE_0000891 + MedDRA: 10061822 + + + + obo2:OAE_0000892 + a headache AE that has an outcome of headaches due to drug withdrawal + + + + obo2:OAE_0000892 + DJ, SS, YH + + + + obo2:OAE_0000892 + drug withdrawal headache AE + + + + obo2:OAE_0000892 + MedDRA: 10013753 + + + + obo2:OAE_0000893 + an adverse event that results in symptoms that occur after the discontinuation of the use of a certain drug + + + + obo2:OAE_0000893 + DJ, SS, YH + + + + obo2:OAE_0000893 + WEB: http://medical-dictionary.thefreedictionary.com/withdrawal + + + + obo2:OAE_0000893 + drug withdrawal syndrome AE + + + + obo2:OAE_0000893 + MedDRA: 10013754 + + + + obo2:OAE_0000894 + a skin AE that is characterized by epidermis that lacks moisture, has an outcome of fine lines, scaling and itching + + + + obo2:OAE_0000894 + DJ, SS, YH + + + + obo2:OAE_0000894 + WEB: http://medical-dictionary.thefreedictionary.com/dry+skin + + + + obo2:OAE_0000894 + dry skin AE + + + + obo2:OAE_0000894 + HPO: HP_0000958 + + + + obo2:OAE_0000894 + MedDRA: 10013786 + + + + obo2:OAE_0000894 + SIDER: C0151908 + + + + obo2:OAE_0000895 + a digestive system AE that has an outcome of a peptic ulcer, or a defect in the lining of the stomach or the first part of the small intestine, located in the duodenum + + + + obo2:OAE_0000895 + DJ, SS, YH + + + + obo2:OAE_0000895 + peptic ulcer AE + + + + obo2:OAE_0000895 + WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001255/ + + + + obo2:OAE_0000895 + duodenal ulcer AE + + + + obo2:OAE_0000895 + HPO: HP_0002588 + + + + obo2:OAE_0000895 + MedDRA: 10013836 + + + + obo2:OAE_0000895 + SIDER: C0013295 + + + + obo2:OAE_0000896 + a duodenal ulcer AE with an outcome of bleeding in an ulcer, or a defect, in the lining of the stomach or first part of the small intestine called the duodenum + + + + obo2:OAE_0000896 + DJ, SS, YH + + + + obo2:OAE_0000896 + duodenal ulcer haemorrhage AE + + + + obo2:OAE_0000896 + WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001255/ + + + + obo2:OAE_0000896 + duodenal ulcer hemorrhage AE + + + + obo2:OAE_0000896 + HPO: HP_0002588 + + + + obo2:OAE_0000896 + MedDRA: 10013839 + + + + obo2:OAE_0000896 + SIDER: C0151966 + + + + obo2:OAE_0000897 + a duodenal ulcer AE that has an outcome of perforation, or complete penetration, of an ulcer located in an area of the small intestine called the duodenum + + + + obo2:OAE_0000897 + DJ, SS, YH + + + + obo2:OAE_0000897 + WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001255/ + + + + obo2:OAE_0000897 + duodenal ulcer perforation AE + + + + obo2:OAE_0000897 + HPO: HP_0002588 + + + + obo2:OAE_0000897 + MedDRA: 10013849 + + + + obo2:OAE_0000897 + SIDER: C0740401 + + + + obo2:OAE_0000898 + a speech disorder that results in a motor speech disorder + + + + obo2:OAE_0000898 + DJ, SS, YH + + + + obo2:OAE_0000898 + WEB: http://medical-dictionary.thefreedictionary.com/dysarthria + + + + obo2:OAE_0000898 + dysarthria AE + + + + obo2:OAE_0000898 + HPO: HP_0001260 + + + + obo2:OAE_0000898 + MedDRA: 10013887 + + + + obo2:OAE_0000898 + SIDER: C0013362 + + + + obo2:OAE_0000899 + a behavioral and neurological AE that results in difficulty reading (mixing up letters) + + + + obo2:OAE_0000899 + DJ, SS, YH + + + + obo2:OAE_0000899 + WEB: http://medical-dictionary.thefreedictionary.com/dyslexia + + + + obo2:OAE_0000899 + dyslexia AE + + + + obo2:OAE_0000899 + HPO: HP_0010522 + + + + obo2:OAE_0000899 + MedDRA: 10013932 + + + + obo2:OAE_0000899 + SIDER: C0476254 + + + + obo2:OAE_0000900 + a speech disorder AE that results in disorders of voice + + + + obo2:OAE_0000900 + DJ, SS, YH + + + + obo2:OAE_0000900 + WEB: http://medical-dictionary.thefreedictionary.com/dysphonia + + + + obo2:OAE_0000900 + dysphonia AE + + + + obo2:OAE_0000900 + HPO: HP_0001618 + + + + obo2:OAE_0000900 + MedDRA: 10013952 + + + + obo2:OAE_0000900 + SIDER: C1527344 + + + + obo2:OAE_0000901 + a dyspnoea AE that has an outcome of shortness of breath during exercise, produces a sensation of not being able to get enough air + + + + obo2:OAE_0000901 + DJ, SS, YH + + + + obo2:OAE_0000901 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/22760109 + + + + obo2:OAE_0000901 + dyspnoea exertional AE + + + + obo2:OAE_0000901 + HPO: HP_0002875 + + + + obo2:OAE_0000901 + MedDRA: 10013971 + + + + obo2:OAE_0000901 + SIDER: C0231807 + + + + obo2:OAE_0000902 + Dysuria AE is an urinary system AE that results in painful urination + + + + obo2:OAE_0000902 + JX, DJ, SS, YH + + + + obo2:OAE_0000902 + urination disorders AE + + + + obo2:OAE_0000902 + WEB: http://medical-dictionary.thefreedictionary.com/dysuria + + + + obo2:OAE_0000902 + 排尿困难 + + + + obo2:OAE_0000902 + dysuria AE + + + + obo2:OAE_0000902 + HPO: HP_0100518 + + + + obo2:OAE_0000902 + MedDRA: 10013990 + + + + obo2:OAE_0000902 + SIDER: C0013428 + + + + obo2:OAE_0000903 + a gustatory system AE which has an outcome of abrnormal or disturbed eating habits + + + + obo2:OAE_0000903 + DJ, SS, YH + + + + obo2:OAE_0000903 + WEB: http://medical-dictionary.thefreedictionary.com/eating+disorder + + + + obo2:OAE_0000903 + eating disorder AE + + + + obo2:OAE_0000903 + MedDRA: 10014062 + + + + obo2:OAE_0000904 + a female reproductive system AE that results in an ectopic pregnancy that occurs along with the use of an IUD + + + + obo2:OAE_0000904 + DJ, SS, YH + + + + obo2:OAE_0000904 + WEB: http://medical-dictionary.thefreedictionary.com/ectopic+pregnancy + + + + obo2:OAE_0000904 + ectopic pregnancy with intrauterine device AE + + + + obo2:OAE_0000904 + MedDRA: 10067037 + + + + obo2:OAE_0000905 + a skin AE that has an outcome of a long term skin disorder that involves scaly and itchy rashes + + + + obo2:OAE_0000905 + DJ, SS, YH + + + + obo2:OAE_0000905 + WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001856/ + + + + obo2:OAE_0000905 + eczema AE + + + + obo2:OAE_0000905 + HPO: HP_0000964 + + + + obo2:OAE_0000905 + MedDRA: 10014184 + + + + obo2:OAE_0000905 + SIDER: C0013595 + + + + obo2:OAE_0000906 + an abnormal fluid regulation AE that has an outcome of escape of a fluid into a part + + + + obo2:OAE_0000906 + DJ, SS, YH + + + + obo2:OAE_0000906 + WEB: http://medical-dictionary.thefreedictionary.com/effusion + + + + obo2:OAE_0000906 + effusion AE + + + + obo2:OAE_0000906 + MedDRA: 10063045 + + + + obo2:OAE_0000907 + a male reproductive system AE that has an outcome of a delay of ejaculation + + + + obo2:OAE_0000907 + DJ, SS, YH + + + + obo2:OAE_0000907 + ejaculation delayed AE + + + + obo2:OAE_0000907 + HPO: HP_0000022 + + + + obo2:OAE_0000907 + MedDRA: 10014325 + + + + obo2:OAE_0000907 + SIDER: NA + + + + obo2:OAE_0000908 + a left ventricular dysfunction AE that has an outcome of decreased percentage of blood leaving the heart each time it contracts + + + + obo2:OAE_0000908 + DJ, SS, YH + + + + obo2:OAE_0000908 + WEB: http://www.mayoclinic.com/health/ejection-fraction/AN00360 + + + + obo2:OAE_0000908 + ejection fraction decreased AE + + + + obo2:OAE_0000908 + MedDRA: 10050528 + + + + obo2:OAE_0000909 + a cardiac and vascular investigation result abnormal AE that has an outcome of abnormal electrical activity in the heart + + + + obo2:OAE_0000909 + DJ, SS, YH, EB + + + + obo2:OAE_0000909 + WEB: http://www.nlm.nih.gov/medlineplus/ency/article/003868.htm + + + + obo2:OAE_0000909 + electrocardiogram result abnormal AE + + + + obo2:OAE_0000909 + MedDRA: 10014363 + + + + obo2:OAE_0000910 + an electrocardiogram result abnormal AE that has an outcome of an abnormal depolarization of the right and left ventricles of the heart that is detected on an electrocardiogram test + + + + obo2:OAE_0000910 + DJ, SS, YH, EB + + + + obo2:OAE_0000910 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/23238367 + + + + obo2:OAE_0000910 + electrocardiogram qrs complex abnormal AE + + + + obo2:OAE_0000910 + MedDRA: 10014378 + + + + obo2:OAE_0000911 + an electrocardiogram result abnormal AE that has an outcome of a prolonged time between the start of the Q wave and the end of the T wave in the heart's electrical cycle; a biomarker for ventricular tachyarrhythmias + + + + obo2:OAE_0000911 + DJ, SS, YH, EB + + + + obo2:OAE_0000911 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/23275261 + + + + obo2:OAE_0000911 + electrocardiogram qt prolonged AE + + + + obo2:OAE_0000911 + HPO: HP_0001657 + + + + obo2:OAE_0000911 + MedDRA: 10014387 + + + + obo2:OAE_0000911 + SIDER: C0151878 + + + + obo2:OAE_0000912 + an electrocardiogram result abnormal AE in which the T wave appears increased in amplitude and cresting at a point + + + + obo2:OAE_0000912 + DJ, SS, YH, EB + + + + obo2:OAE_0000912 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/23301064; http://www.medaphile.com/medical-dictionary/t-wave-peaked + + + + obo2:OAE_0000912 + electrocardiogram t wave peaked AE + + + + obo2:OAE_0000912 + MedDRA: 10014396 + + + + obo2:OAE_0000913 + a homeostasis AE that has an outcome of abnormalities in electrolytes (sodium, potassium, calcium) + + + + obo2:OAE_0000913 + DJ, SS, YH + + + + obo2:OAE_0000913 + WEB: http://medical-dictionary.thefreedictionary.com/electrolyte+imbalance + + + + obo2:OAE_0000913 + electrolyte imbalance AE + + + + obo2:OAE_0000913 + HPO: HP_0003111 + + + + obo2:OAE_0000913 + MedDRA: 10014418 + + + + obo2:OAE_0000913 + SIDER: C0342579 + + + + obo2:OAE_0000914 + a mental AE that results in an abnormal expression of emotions + + + + obo2:OAE_0000914 + DJ, SS, YH + + + + obo2:OAE_0000914 + WEB: http://medical-dictionary.thefreedictionary.com/emotional+disorder + + + + obo2:OAE_0000914 + emotional disorder AE + + + + obo2:OAE_0000914 + HPO: HP_0100851 + + + + obo2:OAE_0000914 + MedDRA: 10014551 + + + + obo2:OAE_0000914 + SIDER: C0233459 + + + + obo2:OAE_0000915 + an inflammation AE that occurs in the inside lining of the heart chambers and heart valves + + + + obo2:OAE_0000915 + DJ, SS, YH + + + + obo2:OAE_0000915 + WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0002088/ + + + + obo2:OAE_0000915 + endocarditis AE + + + + obo2:OAE_0000915 + HPO: HP_0100584 + + + + obo2:OAE_0000915 + MedDRA: 10014665 + + + + obo2:OAE_0000915 + SIDER: C0014118 + + + + obo2:OAE_0000916 + a digestive system AE with an outcome of inflammation in the intestine, especially the small intestine + + + + obo2:OAE_0000916 + DJ, SS, YH + + + + obo2:OAE_0000916 + WEB: http://medical-dictionary.thefreedictionary.com/enteritis + + + + obo2:OAE_0000916 + enteritis AE + + + + obo2:OAE_0000916 + HPO: HP_0004387 + + + + obo2:OAE_0000916 + MedDRA: 10014866 + + + + obo2:OAE_0000916 + SIDER: C0014335 + + + + obo2:OAE_0000917 + a digestive system AE that has an outcome of disease in the digestive tract caused by infection + + + + obo2:OAE_0000917 + DJ, SS, YH + + + + obo2:OAE_0000917 + WEB: http://medical-dictionary.thefreedictionary.com/enterocolitis + + + + obo2:OAE_0000917 + enterocolitis AE + + + + obo2:OAE_0000917 + HPO: HP_0004387 + + + + obo2:OAE_0000917 + MedDRA: 10014893 + + + + obo2:OAE_0000917 + SIDER: C0014356 + + + + obo2:OAE_0000918 + an digestive system AE that has an outcome of an infection by enteric viruses or enterotoxigenic bacterias, usually in the intestines, that presents with diarrhea, abdominal pain, perianal discomfort, incontinence and hemorrhage. + + + + obo2:OAE_0000918 + DJ, SS, YH + + + + obo2:OAE_0000918 + WEB: http://www.mdconsult.com/books/page.do?eid=4-u1.0-B978-1-4377-0792-2..50022-5--cesec139&isbn=978-1-4377-0792-2&type=bookPage&from=content&uniqId=376758653-2 + + + + obo2:OAE_0000918 + enterocolitis infectious AE + + + + obo2:OAE_0000918 + MedDRA: 10058838 + + + + obo2:OAE_0000919 + an eosinophil count abnormal AE that has an outcome of an increased amount of eosinophils, a type of white blood cell that becomes active with allergic diseases and infections + + + + obo2:OAE_0000919 + DJ, SS, YH + + + + obo2:OAE_0000919 + WEB: http://www.nlm.nih.gov/medlineplus/ency/article/003649.htm + + + + obo2:OAE_0000919 + eosinophil count increased AE + + + + obo2:OAE_0000919 + HPO: HP_0001880 + + + + obo2:OAE_0000919 + MedDRA: 10014945 + + + + obo2:OAE_0000919 + SIDER: C2240374 + + + + obo2:OAE_0000920 + a hematopoietic system AE that has an outcome of higher than normal levels of eosinophils, a type of white blood cell + + + + obo2:OAE_0000920 + DJ, SS, YH + + + + obo2:OAE_0000920 + WEB: http://www.mayoclinic.com/health/eosinophilia/MY00399 + + + + obo2:OAE_0000920 + eosinophilia AE + + + + obo2:OAE_0000920 + HPO: HP_0001880 + + + + obo2:OAE_0000920 + MedDRA: 10014950 + + + + obo2:OAE_0000920 + SIDER: C0014457 + + + + obo2:OAE_0000921 + a male reproductive system AE that results in the inability to develop/maintain an erection of penis + + + + obo2:OAE_0000921 + DJ, SS, JX, LW, YH + + + + obo2:OAE_0000921 + astyphia AE + + + + obo2:OAE_0000921 + impotence AE + + + + obo2:OAE_0000921 + WEB: http://en.wikipedia.org/wiki/Erectile_dysfunction + + + + obo2:OAE_0000921 + 阳痿/勃起功能障碍 + + + + obo2:OAE_0000921 + erectile dysfunction AE + + + + obo2:OAE_0000921 + HPO: HP_0008652 + + + + obo2:OAE_0000921 + MedDRA: 10061461 + + + + obo2:OAE_0000921 + SIDER: C0242350 + + + + obo2:OAE_0000922 + a skin AE that has an outcome of an infection caused by a Streptococcus bacteria that causes blisters, fever and skin lesion and sores + + + + obo2:OAE_0000922 + DJ, SS, YH + + + + obo2:OAE_0000922 + WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001643/ + + + + obo2:OAE_0000922 + erysipelas AE + + + + obo2:OAE_0000922 + HPO: HP_0001055 + + + + obo2:OAE_0000922 + MedDRA: 10015145 + + + + obo2:OAE_0000922 + SIDER: C0014733 + + + + obo2:OAE_0000923 + a psoriasis AE that has an outcome of psoriasis that affects all sites on the body + + + + obo2:OAE_0000923 + DJ, SS, YH + + + + obo2:OAE_0000923 + WEB: http://medical-dictionary.thefreedictionary.com/psoriatic+erythroderma + + + + obo2:OAE_0000923 + erythrodermic psoriasis AE + + + + obo2:OAE_0000923 + MedDRA: 10015278 + + + + obo2:OAE_0000924 + a bacterial infection AE with an outcome of invasion by Escherichia coli bacteria, commonly found in the lower intestine and can cause serious food poisoning, but can also be found in various parts of body + + + + obo2:OAE_0000924 + DJ, SS, YH + + + + obo2:OAE_0000924 + WEB: http://medical-dictionary.thefreedictionary.com/escherichia+coli + + + + obo2:OAE_0000924 + escherichia infection AE + + + + obo2:OAE_0000924 + MedDRA: 10061126 + + + + obo2:OAE_0000925 + a microbiology and serology investigation result abnormal AE that has an outcome of a positive escherichia test + + + + obo2:OAE_0000925 + DJ, SS, YH, EB + + + + obo2:OAE_0000925 + WEB: http://medical-dictionary.thefreedictionary.com/Escherichia + + + + obo2:OAE_0000925 + escherichia test positive AE + + + + obo2:OAE_0000925 + MedDRA: 10070090 + + + + obo2:OAE_0000926 + an urinary tract infection AE that has an outcome of infection caused by E. coli bacteria + + + + obo2:OAE_0000926 + DJ, SS, YH + + + + obo2:OAE_0000926 + WEB: http://www.medicinenet.com/urine_infection/article.htm + + + + obo2:OAE_0000926 + escherichia urinary tract infection AE + + + + obo2:OAE_0000926 + MedDRA: 10052238 + + + + obo2:OAE_0000927 + a connective tissue AE that has an outcome of excess perfused, fibrous connective tissue that replaces a fibrin clot in healing wounds. + + + + obo2:OAE_0000927 + DJ, SS, YH + + + + obo2:OAE_0000927 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/19594571 + + + + obo2:OAE_0000927 + excessive granulation tissue AE + + + + obo2:OAE_0000927 + MedDRA: 10063560 + + + + obo2:OAE_0000928 + a rash AE that has an outcome of erythema, desquamation, scaling, itching of the skin and loss of hair + + + + obo2:OAE_0000928 + DJ, SS, YH + + + + obo2:OAE_0000928 + WEB: http://medical-dictionary.thefreedictionary.com/exfoliative+dermatitis + + + + obo2:OAE_0000928 + exfoliative rash AE + + + + obo2:OAE_0000928 + MedDRA: 10064579 + + + + obo2:OAE_0000929 + a congenital abnormality that results in a weakness of the baby's abdominal wall where the umbilical cord joins it. This weakness allows the abdominal contents to protrude outside the abdominal cavity + + + + obo2:OAE_0000929 + DJ, SS, YH + + + + obo2:OAE_0000929 + WEB: http://medical-dictionary.thefreedictionary.com/exomphalos + + + + obo2:OAE_0000929 + exomphalos AE + + + + obo2:OAE_0000929 + HPO: HP_0001539 + + + + obo2:OAE_0000929 + MedDRA: 10015677 + + + + obo2:OAE_0000929 + SIDER: C1306503 + + + + obo2:OAE_0000930 + an injury and procedural complication AE that results in the patient being exposed to a contaminated device + + + + obo2:OAE_0000930 + DJ, SS, YH + + + + obo2:OAE_0000930 + exposure to contaminated device AE + + + + obo2:OAE_0000930 + MedDRA: 10068515 + + + + obo2:OAE_0000931 + an injury and procedural complication AE that results in the patient being exposed to a toxic agent + + + + obo2:OAE_0000931 + DJ, SS, YH + + + + obo2:OAE_0000931 + exposure to toxic agent AE + + + + obo2:OAE_0000931 + MedDRA: 10053487 + + + + obo2:OAE_0000932 + an abscess AE that results in a collection of pus between a person's skull and dura + + + + obo2:OAE_0000932 + DJ, SS, YH + + + + obo2:OAE_0000932 + WEB: http://www.meb.uni-bonn.de/dtc/primsurg/docbook/html/x1217.html + + + + obo2:OAE_0000932 + extradural abscess AE + + + + obo2:OAE_0000932 + MedDRA: 10061846 + + + + obo2:OAE_0000933 + a paresis AE that results in a partial loss of voluntary movement in their extraocular muscles + + + + obo2:OAE_0000933 + DJ, SS, YH + + + + obo2:OAE_0000933 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/22824489 + + + + obo2:OAE_0000933 + extraocular muscle paresis AE + + + + obo2:OAE_0000933 + MedDRA: 10015829 + + + + obo2:OAE_0000934 + coagulopathy AE results in the impairment of blood to clot causing ecessive or prolonged bleeding. + + + + obo2:OAE_0000934 + SJ, YH + + + + obo2:OAE_0000934 + bleeding disorder + + + + obo2:OAE_0000934 + clotting disorder + + + + obo2:OAE_0000934 + WEB: http://en.wikipedia.org/wiki/Coagulopathy + + + + obo2:OAE_0000934 + coagulopathy AE + + + + obo2:OAE_0000934 + MedDRA: 10009802 + + + + obo2:OAE_0000935 + a hemorrhage AE that has an outcome of hemorrhage occuring in the blood vessels in the eye + + + + obo2:OAE_0000935 + DJ, SS, YH + + + + obo2:OAE_0000935 + eye haemorrhage AE + + + + obo2:OAE_0000935 + subconjunctival haemorrhage AE + + + + obo2:OAE_0000935 + WEB: http://www.webmd.com/eye-health/bleeding-in-the-eye + + + + obo2:OAE_0000935 + eye hemorrhage AE + + + + obo2:OAE_0000935 + HPO: HP_0011885 + + + + obo2:OAE_0000935 + MedDRA: 10015926 + + + + obo2:OAE_0000935 + SIDER: C0015402 + + + + obo2:OAE_0000936 + a eye disorder AE that has an outcome of swelling in the tissues around the eyes, called the orbits, caused by fluid buildup + + + + obo2:OAE_0000936 + DJ, SS, YH + + + + obo2:OAE_0000936 + perioribtal puffiness AE + + + + obo2:OAE_0000936 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/21115963 + + + + obo2:OAE_0000936 + eye swelling AE + + + + obo2:OAE_0000936 + MedDRA: 10015967 + + + + obo2:OAE_0000937 + an eye disorder AE that has an outcome of swelling in either or both the lower and upper eyelids, due to fluid buildup or inflammation in the delicate tissues surrounding the eye. + + + + obo2:OAE_0000937 + DJ, SS, YH + + + + obo2:OAE_0000937 + eyelid oedema AE + + + + obo2:OAE_0000937 + WEB: http://www.localhealth.com/article/eyelid-swelling + + + + obo2:OAE_0000937 + eyelid edema AE + + + + obo2:OAE_0000937 + HPO: HP_0100539 + + + + obo2:OAE_0000937 + MedDRA: 10015993 + + + + obo2:OAE_0000937 + SIDER: C0162285 + + + + obo2:OAE_0000938 + A pregnancy, neonatal and perinatal AE that displays the result of failure to thrive (FTT), which refers to a baby or child that is not developing as well as desired. + + + + obo2:OAE_0000938 + DJ, SS, YH + + + + obo2:OAE_0000938 + WEB: http://www.nlm.nih.gov/medlineplus/ency/article/000991.htm + + + + obo2:OAE_0000938 + WEB: http://www.stanfordchildrens.org/en/topic/default?id=failure-to-thrive-90-P02297 + + + + obo2:OAE_0000938 + failure to thrive AE + + + + obo2:OAE_0000938 + HPO: HP_0001531 + + + + obo2:OAE_0000938 + MedDRA: 10016165 + + + + obo2:OAE_0000938 + SIDER: C0015544 + + + + obo2:OAE_0000939 + a behavior and neurological AE that has an outcome of patient falling + + + + obo2:OAE_0000939 + DJ, SS, YH + + + + obo2:OAE_0000939 + fall AE + + + + obo2:OAE_0000939 + HPO: HP_0002359 + + + + obo2:OAE_0000939 + MedDRA: 10016173 + + + + obo2:OAE_0000939 + SIDER: C0085639 + + + + obo2:OAE_0000940 + a behavior and neurological AE that results in the extreme fear of needles + + + + obo2:OAE_0000940 + DJ, SS, YH + + + + obo2:OAE_0000940 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/23225704 + + + + obo2:OAE_0000940 + fear of needles AE + + + + obo2:OAE_0000940 + MedDRA: 10068298 + + + + obo2:OAE_0000941 + a hematopoietic system AE that has an outcome of inadequate blood cell formation by bone marrow accompanied by a fever + + + + obo2:OAE_0000941 + DJ, SS, YH + + + + obo2:OAE_0000941 + WEB: http://medical-dictionary.thefreedictionary.com/Bone+marrow+aplasia + + + + obo2:OAE_0000941 + febrile bone marrow aplasia AE + + + + obo2:OAE_0000941 + MedDRA: 10053213 + + + + obo2:OAE_0000942 + a fever AE that has an outcome of an infection along/because of a fever + + + + obo2:OAE_0000942 + DJ, SS, YH + + + + obo2:OAE_0000942 + WEB: http://medical-dictionary.thefreedictionary.com/febrile + + + + obo2:OAE_0000942 + febrile infection AE + + + + obo2:OAE_0000942 + MedDRA: 10051998 + + + + obo2:OAE_0000943 + a fever AE, generally a complication of chemotherapy, that has an outcome of an abnormally low neutrophil granulocyte count, accompanied by fever + + + + obo2:OAE_0000943 + DJ, SS, YH + + + + obo2:OAE_0000943 + neutropenic sepsis AE + + + + obo2:OAE_0000943 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/23303687 + + + + obo2:OAE_0000943 + febrile neutropenia AE + + + + obo2:OAE_0000943 + HPO: HP_0001875 + + + + obo2:OAE_0000943 + MedDRA: 10016288 + + + + obo2:OAE_0000943 + SIDER: C0746883 + + + + obo2:OAE_0000944 + an injury and procedural complication AE that has an outcome of an complication due to the use of enteral feeding tube + + + + obo2:OAE_0000944 + DJ, SS, YH + + + + obo2:OAE_0000944 + enteral feeding AE + + + + obo2:OAE_0000944 + WEB: http://www.thirdage.com/hc/p/197842/what-is-tube-feeding + + + + obo2:OAE_0000944 + feeding tube complication AE + + + + obo2:OAE_0000944 + MedDRA: 10056661 + + + + obo2:OAE_0000945 + a sensory capabilty AE that results in the patient feeling different than normal after a medical intervention such as taking drug + + + + obo2:OAE_0000945 + DJ, SS, YH + + + + obo2:OAE_0000945 + feeling abnormal AE + + + + obo2:OAE_0000945 + HPO: HP_0010870 + + + + obo2:OAE_0000945 + MedDRA: 10016322 + + + + obo2:OAE_0000945 + SIDER: C1443060 + + + + obo2:OAE_0000946 + Feeling hot AE is a feeling abnormal AE that a patient feels hot. + + + + obo2:OAE_0000946 + DJ, SS, YH + + + + obo2:OAE_0000946 + feeling hot AE + + + + obo2:OAE_0000946 + MedDRA: 10016334 + + + + obo2:OAE_0000947 + a hypoaesthesia AE that has an outcome of a reduced sense of touch or sensation, or a partial loss of sensitivity to sensory stimuli in the oral area + + + + obo2:OAE_0000947 + SS, YH + + + + obo2:OAE_0000947 + hypoaesthesia oral AE + + + + obo2:OAE_0000947 + WEB: http://en.wikipedia.org/wiki/Hypoesthesia + + + + obo2:OAE_0000947 + hypoesthesia oral AE + + + + obo2:OAE_0000947 + HPO: HP_0010830 + + + + obo2:OAE_0000947 + MedDRA ID: 10057371 + + + + obo2:OAE_0000947 + SIDER: C0521592 + + + + obo2:OAE_0000948 + a fistula AE that has an outcome of discharge that occurs as the result of the connection between two body cavities + + + + obo2:OAE_0000948 + DJ, SS, YH + + + + obo2:OAE_0000948 + WEB: http://www.ncbi.nlm.nih.gov/pubmed?term=fistula%20discharge%20%5BTI%5D + + + + obo2:OAE_0000948 + fistula discharge AE + + + + obo2:OAE_0000948 + MedDRA: 10067143 + + + + obo2:OAE_0000949 + an abnormal fluid regulation AE with an outcome of decrease in ingestion of water or other fluids + + + + obo2:OAE_0000949 + DJ, SS, YH + + + + obo2:OAE_0000949 + fluid intake reduced AE + + + + obo2:OAE_0000949 + MedDRA: 10056291 + + + + obo2:OAE_0000950 + a hematopoietic system AE that has an outcome of too much fluid in the blood, can occur due to increase in total body sodium + + + + obo2:OAE_0000950 + DJ, SS, YH + + + + obo2:OAE_0000950 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/22827112 + + + + obo2:OAE_0000950 + fluid overload AE + + + + obo2:OAE_0000950 + MedDRA: 10016803 + + + + obo2:OAE_0000951 + a hyperplasia AE that has an outcome of a benign tumor in the liver + + + + obo2:OAE_0000951 + DJ, SS, YH + + + + obo2:OAE_0000951 + WEB: http://medical-dictionary.thefreedictionary.com/focal+nodular+hyperplasia + + + + obo2:OAE_0000951 + focal nodular hyperplasia AE + + + + obo2:OAE_0000951 + MedDRA: 10052285 + + + + obo2:OAE_0000952 + a congenital abnormality disorder AE that has an outcome of a decreased heart rate in a fetus + + + + obo2:OAE_0000952 + DJ, SS, YH + + + + obo2:OAE_0000952 + foetal heart rate deceleration AE + + + + obo2:OAE_0000952 + fetal heart rate deceleration AE + + + + obo2:OAE_0000952 + MedDRA: 10058322 + + + + obo2:OAE_0000953 + a skin AE with the outcome disease involving of one more more hair follicles, commonly displays rash, itching and pustules near the hair follicles + + + + obo2:OAE_0000953 + DJ, SS, YH + + + + obo2:OAE_0000953 + WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001826/ + + + + obo2:OAE_0000953 + folliculitis AE + + + + obo2:OAE_0000953 + MedDRA: 10016936 + + + + obo2:OAE_0000954 + a respiratory system AE that has an outcome of a decreased volume of air expired from the lungs + + + + obo2:OAE_0000954 + DJ, SS, YH + + + + obo2:OAE_0000954 + WEB: http://medical-dictionary.thefreedictionary.com/forced+expiratory+volume + + + + obo2:OAE_0000954 + forced expiratory volume decreased AE + + + + obo2:OAE_0000954 + MedDRA: 10016987 + + + + obo2:OAE_0000955 + a bone disorder AE that has an outcome of fracture located in the arm + + + + obo2:OAE_0000955 + DJ, SS, YH + + + + obo2:OAE_0000955 + forearm fracture AE + + + + obo2:OAE_0000955 + MedDRA: 10016997 + + + + obo2:OAE_0000956 + a bone disorder AE that has an outcome of complete or incomplete break in a bone resulting from the application of excessive force + + + + obo2:OAE_0000956 + DJ, SS, YH + + + + obo2:OAE_0000956 + WEB: http://medical-dictionary.thefreedictionary.com/Fractures + + + + obo2:OAE_0000956 + fracture AE + + + + obo2:OAE_0000956 + MedDRA: 10017076 + + + + obo2:OAE_0000957 + a full blood count abnormal AE that has an outcome of a decrease in full blood cell count + + + + obo2:OAE_0000957 + DJ, SS, YH, EB + + + + obo2:OAE_0000957 + WEB: http://medical-dictionary.thefreedictionary.com/full+blood+count + + + + obo2:OAE_0000957 + full blood count decreased AE + + + + obo2:OAE_0000957 + MedDRA: 10017413 + + + + obo2:OAE_0000958 + a digestive system AE that has an outcome of inflammation in the esophagus due to fungus + + + + obo2:OAE_0000958 + DJ, SS, YH + + + + obo2:OAE_0000958 + fungal oesophagitis AE + + + + obo2:OAE_0000958 + WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0002138/ + + + + obo2:OAE_0000958 + fungal esophagitis AE + + + + obo2:OAE_0000958 + MedDRA: 10049656 + + + + obo2:OAE_0000959 + a digestive system AE that has an outcome of an abnormal enlargement in the size of the gallbladder + + + + obo2:OAE_0000959 + DJ, SS, YH + + + + obo2:OAE_0000959 + gallbladder enlargement AE + + + + obo2:OAE_0000959 + MedDRA: 10062693 + + + + obo2:OAE_0000960 + a digestive system AE that has an outcome of an abnormal hole in the patient's gallbladder + + + + obo2:OAE_0000960 + DJ, SS, YH + + + + obo2:OAE_0000960 + WEB: http://medical-dictionary.thefreedictionary.com/gallbladder+perforation + + + + obo2:OAE_0000960 + gallbladder perforation AE + + + + obo2:OAE_0000960 + MedDRA: 10017639 + + + + obo2:OAE_0000961 + a digestive system AE that has an outcome of an abnormal growth (accumulation of mucous membrane tissue) in the gallbladder + + + + obo2:OAE_0000961 + DJ, SS, YH + + + + obo2:OAE_0000961 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/19556839 + + + + obo2:OAE_0000961 + gallbladder polyp AE + + + + obo2:OAE_0000961 + MedDRA: 10049704 + + + + obo2:OAE_0000962 + an arrhythmia AE that results in an abnormal heart sound + + + + obo2:OAE_0000962 + DJ, SS, YH + + + + obo2:OAE_0000962 + WEB: http://circ.ahajournals.org/content/20/6/1053.full.pdf + + + + obo2:OAE_0000962 + gallop rhythm present AE + + + + obo2:OAE_0000962 + MedDRA: 10017648 + + + + obo2:OAE_0000963 + a liver related investigation result abnormal AE that has an outcome of an abnormal level of gamma-glutamyltransferase (GGT); GGT is involved in the transfer of amino acids across the cellular membrane + + + + obo2:OAE_0000963 + DJ, SS, YH, EB + + + + obo2:OAE_0000963 + WEB: http://www.nlm.nih.gov/medlineplus/ency/article/003458.htm + + + + obo2:OAE_0000963 + gamma-glutamyltransferase level abnormal AE + + + + obo2:OAE_0000963 + MedDRA: 10017688 + + + + obo2:OAE_0000964 + a gamma-glutamyltransferase level abnormal AE that has an outcome of an increase in gamma-glutamyltransferase enzyme presence in the liver + + + + obo2:OAE_0000964 + DJ, SS, YH, EB + + + + obo2:OAE_0000964 + GGT increased + + + + obo2:OAE_0000964 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/23258530 + + + + obo2:OAE_0000964 + gamma-glutamyltransferase level increased AE + + + + obo2:OAE_0000964 + MedDRA: 10017693 + + + + obo2:OAE_0000965 + a digestive system AE that has an outcome of cancer that starts in the stomach + + + + obo2:OAE_0000965 + DJ, SS, YH + + + + obo2:OAE_0000965 + gastric cancer AE + + + + obo2:OAE_0000965 + HPO: HP_0006753 + + + + obo2:OAE_0000965 + MedDRA: 10017758 + + + + obo2:OAE_0000965 + SIDER: C0024623 + + + + obo2:OAE_0000966 + a digestive system tumor AE that has an outcome of cancer in the stomach + + + + obo2:OAE_0000966 + DJ, SS, YH + + + + obo2:OAE_0000966 + WEB: http://medical-dictionary.thefreedictionary.com/stomach+cancer + + + + obo2:OAE_0000966 + gastric neoplasm AE + + + + obo2:OAE_0000966 + MedDRA: 10061968 + + + + obo2:OAE_0000967 + a digestive system AE that has an outcome of a defect in the lining of the stomach + + + + obo2:OAE_0000967 + DJ, SS, YH + + + + obo2:OAE_0000967 + 胃溃疡 + + + + obo2:OAE_0000967 + WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001255/ + + + + obo2:OAE_0000967 + gastric ulcer AE + + + + obo2:OAE_0000967 + HPO: HP_0002592 + + + + obo2:OAE_0000967 + MedDRA: 10017822 + + + + obo2:OAE_0000967 + SIDER: C0038358 + + + + obo2:OAE_0000968 + a digestive system AE that has an outcome of inflammation in the lining of the stomach + + + + obo2:OAE_0000968 + DJ, SS, YH + + + + obo2:OAE_0000968 + WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0002135/ + + + + obo2:OAE_0000968 + gastritis AE + + + + obo2:OAE_0000968 + HPO: HP_0005263 + + + + obo2:OAE_0000968 + MedDRA: 10017853 + + + + obo2:OAE_0000968 + SIDER: C0017152 + + + + obo2:OAE_0000969 + a digestive system AE that has an outcome of inflammation in the stomach mucosa + + + + obo2:OAE_0000969 + DJ, SS, YH + + + + obo2:OAE_0000969 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/2789800 + + + + obo2:OAE_0000969 + gastritis atrophic AE + + + + obo2:OAE_0000969 + MedDRA: 10017860 + + + + obo2:OAE_0000970 + a digestive system AE that has an outcome of gastric mucosal erosion caused by damage to mucosal defences + + + + obo2:OAE_0000970 + DJ, SS, YH + + + + obo2:OAE_0000970 + WEB: http://medical-dictionary.thefreedictionary.com/gastritis + + + + obo2:OAE_0000970 + gastritis erosive AE + + + + obo2:OAE_0000970 + HPO: HP_0005263 + + + + obo2:OAE_0000970 + MedDRA: 10017865 + + + + obo2:OAE_0000970 + SIDER: C2243088 + + + + obo2:OAE_0000971 + ischemic colitis AE is a gastrointestinal disorder AE that results in injury and inflammation of the large intestine due to inadequate blood supply. + + + + obo2:OAE_0000971 + SJ, YH + + + + obo2:OAE_0000971 + WEB: http://en.wikipedia.org/wiki/Ischemic_colitis + + + + obo2:OAE_0000971 + ischemic colitis AE + + + + obo2:OAE_0000971 + MedDRA: 10009896 + + + + obo2:OAE_0000972 + a gastroenteritis AE that has an outcome of disease caused by the norovirus + + + + obo2:OAE_0000972 + DJ, SS, YH + + + + obo2:OAE_0000972 + WEB: http://www.cdc.gov/ncidod/dvrd/revb/gastro/faq.htm + + + + obo2:OAE_0000972 + gastroenteritis norovirus AE + + + + obo2:OAE_0000972 + MedDRA: 10068189 + + + + obo2:OAE_0000973 + a gastroenteritis AE that has an outcome of disease due to radiation + + + + obo2:OAE_0000973 + DJ, SS, YH + + + + obo2:OAE_0000973 + gastroenteritis radiation AE + + + + obo2:OAE_0000973 + MedDRA: 10017912 + + + + obo2:OAE_0000974 + a digestive system AE that results in mucosal damage caused by acid from stomach coming up to the esophagus + + + + obo2:OAE_0000974 + DJ, SS, YH + + + + obo2:OAE_0000974 + GERD AE + + + + obo2:OAE_0000974 + esophageal reflux AE + + + + + obo2:OAE_0000974 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/23301861 + + + + obo2:OAE_0000974 + gastroesophageal reflux disease AE + + + + obo2:OAE_0000974 + MedDRA: 10017885 + + + + obo2:OAE_0000975 + a gastrointestinal disorder AE with an outcome of infection in the digestive tract caused by bacteria, viruses or parasites + + + + obo2:OAE_0000975 + DJ, SS, YH + + + + obo2:OAE_0000975 + WEB: http://medical-dictionary.thefreedictionary.com/Gastrointestinal+infection + + + + obo2:OAE_0000975 + gastrointestinal infection AE + + + + obo2:OAE_0000975 + HPO: HP_0004798 + + + + obo2:OAE_0000975 + MedDRA: 10017964 + + + + obo2:OAE_0000975 + SIDER: C1264613 + + + + obo2:OAE_0000976 + a digestive system AE that has an outcome of an injury in the gastrointestinal area + + + + obo2:OAE_0000976 + DJ, SS, YH + + + + obo2:OAE_0000976 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/23207874 + + + + obo2:OAE_0000976 + gastrointestinal injury AE + + + + obo2:OAE_0000976 + MedDRA: 10061172 + + + + obo2:OAE_0000977 + a digestive system AE that has an outcome of premature death in cells of living tissue in the stomach and intestines + + + + obo2:OAE_0000977 + DJ, SS, YH + + + + obo2:OAE_0000977 + WEB: http://medical-dictionary.thefreedictionary.com/necrosis + + + + obo2:OAE_0000977 + gastrointestinal necrosis AE + + + + obo2:OAE_0000977 + MedDRA: 10017982 + + + + obo2:OAE_0000978 + an adverse event induced by administration of a bupropion drug + + + + obo2:OAE_0000978 + YH + + + + obo2:OAE_0000978 + bupropion-induced adverse event + + + + obo2:OAE_0000979 + a digestive system AE that has an outcome of a hole in the wall of the esophagus, stomch, small intestine, large bowel, rectum or gallbladder + + + + obo2:OAE_0000979 + DJ, SS, YH + + + + obo2:OAE_0000979 + WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001282/ + + + + obo2:OAE_0000979 + gastrointestinal perforation AE + + + + obo2:OAE_0000979 + HPO: HP_0011024 + + + + obo2:OAE_0000979 + MedDRA: 10018001 + + + + obo2:OAE_0000979 + SIDER: C0151664 + + + + obo2:OAE_0000980 + a tumor AE that has an outcome of a tumor in the gastrointestinal tract, thought to grow from specialized cells found in the tract called interstitial cells of Cajal + + + + obo2:OAE_0000980 + DJ, SS, YH + + + + obo2:OAE_0000980 + gastrointestinal stromal tumour AE + + + + obo2:OAE_0000980 + WEB: http://ghr.nlm.nih.gov/condition/gastrointestinal-stromal-tumor + + + + obo2:OAE_0000980 + gastrointestinal stromal tumor AE + + + + obo2:OAE_0000980 + HPO: HP_0007378 + + + + obo2:OAE_0000980 + MedDRA: 10051066 + + + + obo2:OAE_0000980 + SIDER: C0238198 + + + + obo2:OAE_0000981 + a gastrointestinal disorder AE that has an outcome of poison affecting the stomach and/or intestinal tracts, often accompanied by abdominal pain, diarrhea and vomiting + + + + obo2:OAE_0000981 + DJ, SS, YH + + + + obo2:OAE_0000981 + WEB: http://www.theodora.com/drugs/valcyte_tablets_roche_laboratories.html + + + + obo2:OAE_0000981 + gastrointestinal toxicity AE + + + + obo2:OAE_0000981 + HPO: HP_0011024 + + + + obo2:OAE_0000981 + MedDRA: 10059024 + + + + obo2:OAE_0000981 + SIDER: C1142499 + + + + obo2:OAE_0000982 + a cytogenetic investigation result abnormal AE that has an outcome of a positive test for gene mutation, deletions and duplications that could indicate large disease risk + + + + obo2:OAE_0000982 + DJ, SS, YH, EB + + + + obo2:OAE_0000982 + WEB: https://www.duchenneconnect.org/index.php?option=com_content&view=article&id=346&Itemid=392&lang=en + + + + obo2:OAE_0000982 + gene mutation identification test positive AE + + + + obo2:OAE_0000982 + MedDRA: 10063478 + + + + obo2:OAE_0000983 + a systematic adverse event that has an outcome of worsening of physical health + + + + obo2:OAE_0000983 + DJ, SS, YH + + + + obo2:OAE_0000983 + general physical health deterioration AE + + + + obo2:OAE_0000983 + MedDRA: 10049438 + + + + obo2:OAE_0000984 + an edema AE that has an outcome of edema where causes of edema are generalized to the whole body, can cause edema in multiple organs and peripherally + + + + obo2:OAE_0000984 + DJ, SS, YH + + + + obo2:OAE_0000984 + generalised oedema AE + + + + obo2:OAE_0000984 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/16491771 + + + + obo2:OAE_0000984 + generalized edema AE + + + + obo2:OAE_0000984 + HPO: HP_0007430 + + + + obo2:OAE_0000984 + MedDRA: 10018092 + + + + obo2:OAE_0000984 + SIDER: C0151603 + + + + obo2:OAE_0000985 + a skin ulcer AE that results in an ulcer in the genital area usually resulting from an STD + + + + obo2:OAE_0000985 + DJ, SS, YH + + + + obo2:OAE_0000985 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/23064541 + + + + obo2:OAE_0000985 + genital ulceration AE + + + + obo2:OAE_0000985 + HPO: HP_0003249 + + + + obo2:OAE_0000985 + MedDRA: 10018180 + + + + obo2:OAE_0000985 + SIDER: C0151281 + + + + obo2:OAE_0000986 + an abscess AE that has an outcome of a gum-line of the teeth due to pus-filled sacs + + + + obo2:OAE_0000986 + DJ, SS, YH + + + + obo2:OAE_0000986 + WEB: http://www.mdguidelines.com/gingival-abscess + + + + obo2:OAE_0000986 + gingival abscess AE + + + + obo2:OAE_0000986 + MedDRA: 10052359 + + + + obo2:OAE_0000987 + a digestive system AE that has an outcome of abnormally enlarged, bulging or protruding gums + + + + obo2:OAE_0000987 + DJ, SS, YH + + + + obo2:OAE_0000987 + WEB: http://www.nlm.nih.gov/medlineplus/ency/article/003066.htm + + + + obo2:OAE_0000987 + gingival swelling AE + + + + obo2:OAE_0000987 + MedDRA: 10018291 + + + + obo2:OAE_0000988 + a kidney disorder AE that has an outcome of a decreased rate per minute at which the blood passes through the glomeruli or the filters in the kidneys + + + + obo2:OAE_0000988 + DJ, SS, YH + + + + obo2:OAE_0000988 + WEB: http://www.nlm.nih.gov/medlineplus/ency/article/007305.htm + + + + obo2:OAE_0000988 + glomerular filtration rate decreased AE + + + + obo2:OAE_0000988 + HPO: HP_0000083 + + + + obo2:OAE_0000988 + MedDRA: 10018358 + + + + obo2:OAE_0000988 + SIDER: C0853068 + + + + obo2:OAE_0000989 + a digestive system AE that has an outcome of a burning or tingling sensation on the lips, tongue or entire mouth + + + + obo2:OAE_0000989 + DJ, SS, YH + + + + obo2:OAE_0000989 + burning tongue AE + + + + obo2:OAE_0000989 + WEB: http://medical-dictionary.thefreedictionary.com/glossodynia + + + + obo2:OAE_0000989 + glossodynia AE + + + + obo2:OAE_0000989 + HPO: HP_0000157 + + + + obo2:OAE_0000989 + MedDRA: 10018388 + + + + obo2:OAE_0000989 + SIDER: C0017672 + + + + obo2:OAE_0000990 + a glycosylated hemoglobin level abnormal AE that has an outcome of decreased levels of glycosylated hemoglobin in the blood + + + + obo2:OAE_0000990 + DJ, SS, YH, EB + + + + obo2:OAE_0000990 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/23015148 + + + + obo2:OAE_0000990 + glycosylated hemoglobin level decreased AE + + + + obo2:OAE_0000990 + MedDRA: 10018482 + + + + obo2:OAE_0000992 + an infection AE that results in a graft infection + + + + obo2:OAE_0000992 + DJ, SS, YH + + + + obo2:OAE_0000992 + graft infection AE + + + + obo2:OAE_0000992 + MedDRA: 10056559 + + + + obo2:OAE_0000993 + a sensorimotor painful neuropathy AE which has an outcome of distal sensory neuropathy characterized by damage to sensory and motor nerves + + + + obo2:OAE_0000993 + distal sensorimotor painful neuropathy + + + + obo2:OAE_0000994 + a microbiology and serology investigation result abnormal AE that has an outcome of detection of gram-positive bacteria + + + + obo2:OAE_0000994 + DJ, SS, YH, EB + + + + obo2:OAE_0000994 + WEB: http://medical-dictionary.thefreedictionary.com/gram+stain + + + + obo2:OAE_0000994 + gram stain positive AE + + + + obo2:OAE_0000994 + MedDRA: 10018656 + + + + obo2:OAE_0000995 + a nervous system AE that results in a generalized seizure that affects the entire brain + + + + obo2:OAE_0000995 + DJ, SS, YH, SJ + + + + obo2:OAE_0000995 + tonic seizure + + + + obo2:OAE_0000995 + WEB: http://www.mayoclinic.com/health/grand-mal-seizure/DS00222 + + + + obo2:OAE_0000995 + grand mal convulsion AE + + + + obo2:OAE_0000995 + HPO: HP_0002197 + + + + obo2:OAE_0000995 + MedDRA: 10018659 + + + + obo2:OAE_0000995 + SIDER: C0014549 + + + + obo2:OAE_0000996 + a granulocyte count abnormal AE that has an outcome of compromise to the immune system where the number of neutrophil granulocytes, a type of white blood cell, is lower than the normal range of ~1700 per microliter. + + + + obo2:OAE_0000996 + DJ, SS, YH, EB + + + + obo2:OAE_0000996 + neutropenia AE + + + + obo2:OAE_0000996 + granulocyte count decreased AE + + + + obo2:OAE_0000996 + MedDRA: 10018681 + + + + obo2:OAE_0000998 + a hematopoietic system AE that has an outcome of a marked decrease in number of granulocytes, a type of white blood cell filled with microscopic granules that are little sacs containing enzymes that digest microorganisms + + + + obo2:OAE_0000998 + DJ, SS, YH + + + + obo2:OAE_0000998 + WEB: http://www.medterms.com/script/main/art.asp?articlekey=8817 + + + + obo2:OAE_0000998 + granulocytopenia AE + + + + obo2:OAE_0000998 + MedDRA: 10018687 + + + + obo2:OAE_0000999 + a psorisis AE that has an outcome of psoriasis that appears on the back and extremities of the patients + + + + obo2:OAE_0000999 + DJ, SS, YH + + + + obo2:OAE_0000999 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/20860740 + + + + obo2:OAE_0000999 + guttate psoriasis AE + + + + obo2:OAE_0000999 + MedDRA: 10018797 + + + + obo2:OAE_0001001 + a male reproductive system AE that has an outcome of abnormal development of large mammary glands in males resulting in breast enlargement + + + + obo2:OAE_0001001 + DJ, SS, YH + + + + obo2:OAE_0001001 + WEB: http://medical-dictionary.thefreedictionary.com/gynecomastia + + + + obo2:OAE_0001001 + gynaecomastia AE + + + + obo2:OAE_0001001 + HPO: HP_0000771 + + + + obo2:OAE_0001001 + MedDRA: 10018800 + + + + obo2:OAE_0001001 + SIDER: C0018418 + + + + obo2:OAE_0001003 + a vomiting AE that results in the vomiting of blood + + + + obo2:OAE_0001003 + DJ, SS, YH + + + + obo2:OAE_0001003 + haematemesis AE + + + + obo2:OAE_0001003 + WEB: http://medical-dictionary.thefreedictionary.com/hematemesis + + + + obo2:OAE_0001003 + hematemesis AE + + + + obo2:OAE_0001003 + HPO: HP_0002248 + + + + obo2:OAE_0001003 + MedDRA: 10018830 + + + + obo2:OAE_0001003 + SIDER: C0018926 + + + + obo2:OAE_0001004 + a digestive system AE that has an outcome of the passage of bloody stools + + + + obo2:OAE_0001004 + DJ, SS, YH + + + + obo2:OAE_0001004 + haematochezia AE + + + + obo2:OAE_0001004 + WEB: http://medical-dictionary.thefreedictionary.com/hematochezia + + + + obo2:OAE_0001004 + hematochezia AE + + + + obo2:OAE_0001004 + HPO: HP_0002573 + + + + obo2:OAE_0001004 + MedDRA: 10018836 + + + + obo2:OAE_0001004 + SIDER: C0018932 + + + + obo2:OAE_0001005 + a hematocrit abnormal AE with an outcome of decreased volume percentage of red blood cells in blood + + + + obo2:OAE_0001005 + DJ, SS, YH, EB + + + + obo2:OAE_0001005 + haematocrit decreased AE + + + + obo2:OAE_0001005 + WEB: http://medical-dictionary.thefreedictionary.com/hematocrit + + + + obo2:OAE_0001005 + hematocrit decreased AE + + + + obo2:OAE_0001005 + MedDRA: 10018838 + + + + obo2:OAE_0001006 + an infection AE that has an outcome of infection in a hematoma + + + + obo2:OAE_0001006 + DJ, SS, YH + + + + obo2:OAE_0001006 + haematoma infection AE + + + + obo2:OAE_0001006 + WEB: http://medical-dictionary.thefreedictionary.com/hematoma + + + + obo2:OAE_0001006 + hematoma infection AE + + + + obo2:OAE_0001006 + MedDRA: 10051564 + + + + obo2:OAE_0001007 + a hematopoietic system AE that has an outcome of toxins that destroy red blood cells, disrupt blood clotting, and/or cause organ degeneration and generalized tissue damage + + + + obo2:OAE_0001007 + DJ, SS, YH + + + + obo2:OAE_0001007 + haematotoxicity AE + + + + obo2:OAE_0001007 + hematotoxicity AE + + + + obo2:OAE_0001007 + MedDRA: 10061188 + + + + obo2:OAE_0001008 + A conduction system disorder AE that is a condition in which ventricular contraction is not completely synchronized due to a block in conduction of an electrical impulse to the ventricles; in LBBB, right ventricular endocardial activation begins before, and is often completed before, initiation of left ventricular endocardial activation; benign LBBB is rare; preexisting LBBB in absence of clinical evidence of heart disease is rare; newly acquired LBBB has a 10-fold ↑ in mortality Clinical Generally asymptomatic, or absent or diminished 1st heart sound–HS and reversed splitting of 2nd HS EKG Lead V1–QS or rS; lead V6–late intrinsicoid deflection, monophasic R; lead I–monophasic R Management Pacemaker, if syncope or significant arrhythmias Followup Telemetry PRN. + + + + obo2:OAE_0001008 + YH, SS + + + + obo2:OAE_0001008 + LBBB + + + + obo2:OAE_0001008 + left bundle branch block + + + + obo2:OAE_0001008 + WEB: http://medical-dictionary.thefreedictionary.com/left+bundle+branch+block + + + + obo2:OAE_0001008 + bundle branch block left AE + + + + obo2:OAE_0001008 + HPO: HP_0011713 + + + + obo2:OAE_0001008 + MedDRA: 10006580 + + + + obo2:OAE_0001008 + SIDER: C0023211 + + + + obo2:OAE_0001009 + a red blood cell profile abnormal AE that has an outcome of an abnormal count of hemoglobin, or iron-containing oxygen-transport metalloprotein in red blood cells + + + + obo2:OAE_0001009 + DJ, SS, YH, EB + + + + obo2:OAE_0001009 + haemoglobin abnormal AE + + + + obo2:OAE_0001009 + WEB: http://medical-dictionary.thefreedictionary.com/hemoglobin + + + + obo2:OAE_0001009 + hemoglobin level abnormal AE + + + + obo2:OAE_0001009 + MedDRA: 10018879 + + + + obo2:OAE_0001012 + a hematopoietic system AE that has an outcome of hemolytic anemia, acute kidney failure and a low platelet count + + + + obo2:OAE_0001012 + DJ, SS, YH + + + + obo2:OAE_0001012 + haemolytic uraemic syndrome AE + + + + obo2:OAE_0001012 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/23307876 + + + + obo2:OAE_0001012 + hemolytic uremic syndrome AE + + + + obo2:OAE_0001012 + HPO: HP_0005575 + + + + obo2:OAE_0001012 + MedDRA: 10018932 + + + + obo2:OAE_0001012 + SIDER: C0019061 + + + + obo2:OAE_0001013 + a respiratory system AE that has an outcome of expectoration of blood or blood-stained sputum from the bronchi, larynx, trachea or lungs + + + + obo2:OAE_0001013 + DJ, SS, YH + + + + obo2:OAE_0001013 + haemoptysis AE + + + + obo2:OAE_0001013 + WEB: http://medical-dictionary.thefreedictionary.com/hemoptysis + + + + obo2:OAE_0001013 + hemoptysis AE + + + + obo2:OAE_0001013 + HPO: HP_0002105 + + + + obo2:OAE_0001013 + MedDRA: 10018964 + + + + obo2:OAE_0001013 + SIDER: C0019079 + + + + obo2:OAE_0001014 + a nervous system AE that has an outcome of accumulation of blood within the cranial vault + + + + obo2:OAE_0001014 + DJ, SS, YH + + + + obo2:OAE_0001014 + haemorrhage intracranial AE + + + + obo2:OAE_0001014 + WEB: http://emedicine.medscape.com/article/1163977-overview + + + + obo2:OAE_0001014 + hemorrhage intracranial AE + + + + obo2:OAE_0001014 + HPO: HP_0002170 + + + + obo2:OAE_0001014 + MedDRA: 10018985 + + + + obo2:OAE_0001014 + SIDER: C0151699 + + + + obo2:OAE_0001015 + a female reproductive system AE that results in a 'blood cyst' where the walls of ovarian cysts are lined with blood vessels, which when rupture fill the cyst with blood. + + + + obo2:OAE_0001015 + DJ, SS, YH + + + + obo2:OAE_0001015 + haemorrhagic ovarian cyst AE + + + + obo2:OAE_0001015 + hemorrhagic ovarian cyst AE + + + + obo2:OAE_0001015 + MedDRA: 10060781 + + + + obo2:OAE_0001018 + a digestive system AE that has an outcome of bleeding in hemorrhoids, vascular structures in the anal canal which help with stool control + + + + obo2:OAE_0001018 + DJ, SS, YH + + + + obo2:OAE_0001018 + haemorrhoidal haemorrhage AE + + + + obo2:OAE_0001018 + WEB: http://medical-dictionary.thefreedictionary.com/hemorrhoid + + + + obo2:OAE_0001018 + hemorrhoidal hemorrhage AE + + + + obo2:OAE_0001018 + MedDRA: 10054787 + + + + obo2:OAE_0001019 + a digestive system AE that has an outcome of painful, swollen veins in the lower portion of the rectum or anus + + + + obo2:OAE_0001019 + DJ, SS, YH + + + + obo2:OAE_0001019 + haemorrhoids AE + + + + obo2:OAE_0001019 + WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001337/ + + + + obo2:OAE_0001019 + hemorrhoids AE + + + + obo2:OAE_0001019 + HPO: HP_0004296 + + + + obo2:OAE_0001019 + MedDRA: 10019022 + + + + obo2:OAE_0001020 + a lung disorder AE that has an outcome of a collection of blood in the space between the chest wall and the lung + + + + obo2:OAE_0001020 + DJ, SS, YH + + + + obo2:OAE_0001020 + haemothorax AE + + + + obo2:OAE_0001020 + WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001183/ + + + + obo2:OAE_0001020 + hemothorax AE + + + + obo2:OAE_0001020 + MedDRA: 10019027 + + + + obo2:OAE_0001021 + a hair AE that has an outcome of abnormal growth of facial or body hair + + + + obo2:OAE_0001021 + DJ, SS, YH + + + + obo2:OAE_0001021 + WEB: http://medical-dictionary.thefreedictionary.com/Hair+growth + + + + obo2:OAE_0001021 + hair growth abnormal AE + + + + obo2:OAE_0001021 + HPO: HP_0010720 + + + + obo2:OAE_0001021 + MedDRA: 10019044 + + + + obo2:OAE_0001021 + SIDER: C0232409 + + + + obo2:OAE_0001023 + a hemoglobin level abnormal AE with an outcome of decrease in amount of iron-containing oxygen-transport metalloprotein in the red blood cells + + + + obo2:OAE_0001023 + DJ, SS, YH, EB + + + + obo2:OAE_0001023 + haemoglobin decreased AE + + + + obo2:OAE_0001023 + WEB: http://medical-dictionary.thefreedictionary.com/hemoglobin + + + + obo2:OAE_0001023 + hemoglobin level decreased AE + + + + obo2:OAE_0001023 + MedDRA: 10018884 + + + + obo2:OAE_0001024 + a liver/biliary system AE that has an outcome of a chronic degenerative disease in which normal liver cells are damaged and then replaced by scar tissue + + + + obo2:OAE_0001024 + DJ, SS, YH + + + + obo2:OAE_0001024 + WEB: http://medical-dictionary.thefreedictionary.com/Hepatic+cirrhosis + + + + obo2:OAE_0001024 + hepatic cirrhosis AE + + + + obo2:OAE_0001024 + HPO: HP_0001394 + + + + obo2:OAE_0001024 + MedDRA: 10019641 + + + + obo2:OAE_0001024 + SIDER: C0023890 + + + + obo2:OAE_0001025 + a lab test abnormal AE that has an outcome of an increase in amount of hepatic enzyme in body, a liver/biliary system AE that has an outcome of elevated levels of liver enzymes, commonly ALT and AST, may indicate inflammation or damage to liver cells + + + + obo2:OAE_0001025 + DJ, SS, YH + + + + obo2:OAE_0001025 + WEB: http://www.mayoclinic.com/health/elevated-liver-enzymes/MY00508 + + + + obo2:OAE_0001025 + hepatic enzyme increased AE + + + + obo2:OAE_0001025 + HPO: HP_0002910 + + + + obo2:OAE_0001025 + MedDRA: 10060795 + + + + obo2:OAE_0001025 + SIDER: C0235996 + + + + obo2:OAE_0001026 + a liver/biliary system AE that has an outcome of the inability of the liver to perform its normal synthetic and metabolic function + + + + obo2:OAE_0001026 + DJ, SS, YH + + + + obo2:OAE_0001026 + WEB: http://medical-dictionary.thefreedictionary.com/liver+failure + + + + obo2:OAE_0001026 + hepatic failure AE + + + + obo2:OAE_0001026 + HPO: HP_0001399 + + + + obo2:OAE_0001026 + MedDRA: 10019663 + + + + obo2:OAE_0001026 + SIDER: C0085605 + + + + obo2:OAE_0001027 + a liver/biliary system AE that results in incorrect blood flow to liver + + + + obo2:OAE_0001027 + DJ, SS, YH + + + + obo2:OAE_0001027 + WEB: http://archinte.jamanetwork.com/article.aspx?articleid=571358 + + + + obo2:OAE_0001027 + hepatic infarction AE + + + + obo2:OAE_0001027 + MedDRA: 10019680 + + + + obo2:OAE_0001029 + a liver/biliary system AE with an outcome of a lesion, an abnormality in the tissue caused by disease or trauma, located in the liver + + + + obo2:OAE_0001029 + DJ, SS, YH + + + + obo2:OAE_0001029 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/21275132 + + + + obo2:OAE_0001029 + hepatic lesion AE + + + + obo2:OAE_0001029 + MedDRA: 10061998 + + + + obo2:OAE_0001030 + a liver/biliary system AE that has an outcome of death of hepatic parenchyma which may be single cell, or multicell in piecemeal, focal, periacinar, midzonal, periportal or paracentral locations + + + + obo2:OAE_0001030 + DJ, SS, YH + + + + obo2:OAE_0001030 + WEB: http://medical-dictionary.thefreedictionary.com/hepatic+necrosis + + + + obo2:OAE_0001030 + hepatic necrosis AE + + + + obo2:OAE_0001030 + HPO: HP_0002605 + + + + obo2:OAE_0001030 + MedDRA: 10019692 + + + + obo2:OAE_0001030 + SIDER: C0151798 + + + + obo2:OAE_0001031 + a tumor AE that has an outcome of a malignant tumor in the liver + + + + obo2:OAE_0001031 + DJ, SS, YH + + + + obo2:OAE_0001031 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/23302476 + + + + obo2:OAE_0001031 + hepatic neoplasm AE + + + + obo2:OAE_0001031 + HPO: HP_0002896 + + + + obo2:OAE_0001031 + MedDRA: 10019695 + + + + obo2:OAE_0001031 + SIDER: C0023903 + + + + obo2:OAE_0001032 + Acanthosis nigricans AE is a skin AE that is a brown to black, poorly defined, velvety hyperpigmentation of the skin. It is usually found in body folds, such as the posterior and lateral folds of the neck, the armpits, groin, navel, forehead, and other areas. + + + + obo2:OAE_0001032 + JX, LW, YH + + + + obo2:OAE_0001032 + WEB: http://en.wikipedia.org/wiki/Acanthosis_nigricans + + + + obo2:OAE_0001032 + 黑棘皮病 + + + + obo2:OAE_0001032 + acanthosis nigricans AE + + + + obo2:OAE_0001032 + MedDRA: 10000350 + + + + obo2:OAE_0001033 + a hepatitis AE that has an outcome of irritation and swelling of the liver due to infection with the heptitis B virus + + + + obo2:OAE_0001033 + DJ, SS, YH + + + + obo2:OAE_0001033 + WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001324/ + + + + obo2:OAE_0001033 + hepatitis b AE + + + + obo2:OAE_0001033 + HPO: HP_0006562 + + + + obo2:OAE_0001033 + MedDRA: 10019731 + + + + obo2:OAE_0001033 + SIDER: C0019163 + + + + obo2:OAE_0001034 + a hepatitis AE that has an outcome of liver inflammation due to a hepatitis viral infection + + + + obo2:OAE_0001034 + DJ, SS, YH + + + + obo2:OAE_0001034 + WEB: http://medical-dictionary.thefreedictionary.com/viral+hepatitis + + + + obo2:OAE_0001034 + hepatitis viral AE + + + + obo2:OAE_0001034 + HPO: HP_0006562 + + + + obo2:OAE_0001034 + MedDRA: 10019799 + + + + obo2:OAE_0001034 + SIDER: C0042721 + + + + obo2:OAE_0001035 + a liver/biliary system AE that has an outcome of swelling of the liver + + + + obo2:OAE_0001035 + DJ, SS, YH + + + + obo2:OAE_0001035 + WEB: http://www.nlm.nih.gov/medlineplus/ency/article/003275.htm + + + + obo2:OAE_0001035 + hepatomegaly AE + + + + obo2:OAE_0001035 + HPO: HP_0002240 + + + + obo2:OAE_0001035 + MedDRA: 10019842 + + + + obo2:OAE_0001035 + SIDER: C0019209 + + + + obo2:OAE_0001036 + a liver damage AE that has an outcome of chemically driven liver damage + + + + obo2:OAE_0001036 + DJ, SS, YH + + + + obo2:OAE_0001036 + WEB: http://medical-dictionary.thefreedictionary.com/hepatotoxicity + + + + obo2:OAE_0001036 + hepatotoxicity AE + + + + obo2:OAE_0001036 + MedDRA: 10019851 + + + + obo2:OAE_0001038 + an inflammation AE that has an outcome of an inflammatory infiltrate around the eccrine sweat gland + + + + obo2:OAE_0001038 + DJ, SS, YH + + + + obo2:OAE_0001038 + WEB: http://medical-dictionary.thefreedictionary.com/hidradenitis + + + + obo2:OAE_0001038 + hidradenitis AE + + + + obo2:OAE_0001038 + MedDRA: 10020040 + + + + obo2:OAE_0001039 + an immune system disorder AE that has an outcome of abnormal proliferation of histiocytes, a type of immune cell that eats foreign substances + + + + obo2:OAE_0001039 + DJ, SS, YH + + + + obo2:OAE_0001039 + histiocytosis haematophagic AE + + + + obo2:OAE_0001039 + WEB: http://www.medterms.com/script/main/art.asp?articlekey=11478 + + + + obo2:OAE_0001039 + histiocytosis hematophagic AE + + + + obo2:OAE_0001039 + MedDRA: 10048595 + + + + obo2:OAE_0001040 + a fungal infection AE that results in an infection that occurs from breathing in the spores of the fungus Histoplasma Capsulatum + + + + obo2:OAE_0001040 + DJ, SS, YH + + + + obo2:OAE_0001040 + WEB: http://www.nlm.nih.gov/medlineplus/ency/article/001082.htm + + + + obo2:OAE_0001040 + histoplasmosis disseminated AE + + + + obo2:OAE_0001040 + MedDRA: 10020144 + + + + obo2:OAE_0001042 + a urinary system AE that has an outcome of distension and dilation of the renal pelvis and calyces, usually caused by the osbtruction of urine flow from the kidney + + + + obo2:OAE_0001042 + DJ, SS, YH + + + + obo2:OAE_0001042 + WEB: http://medical-dictionary.thefreedictionary.com/hydronephrosis + + + + obo2:OAE_0001042 + hydronephrosis AE + + + + obo2:OAE_0001042 + HPO: HP_0000126 + + + + obo2:OAE_0001042 + MedDRA: 10020524 + + + + obo2:OAE_0001042 + SIDER: C0020295 + + + + obo2:OAE_0001043 + a congenital abnormality AE that results in the yellowing of the skin of infants + + + + obo2:OAE_0001043 + DJ, SS, YH + + + + obo2:OAE_0001043 + hyperbilirubinaemia neonatal AE + + + + obo2:OAE_0001043 + WEB: http://medical-dictionary.thefreedictionary.com/neonatal+jaundice + + + + obo2:OAE_0001043 + hyperbilirubinemia neonatal AE + + + + obo2:OAE_0001043 + MedDRA: 10020580 + + + + obo2:OAE_0001044 + a hematopoietic system AE that has an outcome of an elevated calcium level in the blood, above normal range of 9-10.5 mg/dL + + + + obo2:OAE_0001044 + DJ, SS, YH + + + + obo2:OAE_0001044 + hypercalcaemia AE + + + + obo2:OAE_0001044 + WEB: http://medical-dictionary.thefreedictionary.com/hypercalcemia + + + + obo2:OAE_0001044 + hypercalcemia AE + + + + obo2:OAE_0001044 + HPO: HP_0003072 + + + + obo2:OAE_0001044 + MedDRA: 10020583 + + + + obo2:OAE_0001044 + SIDER: C0020437 + + + + obo2:OAE_0001045 + a skin AE that results in excess perspiration + + + + obo2:OAE_0001045 + DJ, SS, YH + + + + obo2:OAE_0001045 + WEB: http://medical-dictionary.thefreedictionary.com/hyperhidrosis + + + + obo2:OAE_0001045 + hyperhidrosis AE + + + + obo2:OAE_0001045 + HPO: HP_0000975 + + + + obo2:OAE_0001045 + MedDRA: 10020642 + + + + obo2:OAE_0001045 + SIDER: C0020458 + + + + obo2:OAE_0001046 + a hematopoietic system AE that has an outcome of an increased concentration of potassium in blood + + + + obo2:OAE_0001046 + DJ, SS, YH + + + + obo2:OAE_0001046 + hyperkalaemia AE + + + + obo2:OAE_0001046 + WEB: http://medical-dictionary.thefreedictionary.com/hyperkalemia + + + + obo2:OAE_0001046 + hyperkalemia AE + + + + obo2:OAE_0001046 + HPO: HP_0002153 + + + + obo2:OAE_0001046 + MedDRA: 10020646 + + + + obo2:OAE_0001046 + SIDER: C0020461 + + + + obo2:OAE_0001047 + toxin-induced cardiomyopathy AE + + + + obo2:OAE_0001048 + cocaine-induced cardiomyopathy AE + + + + obo2:OAE_0001049 + an abnormal fluid regulation AE that has an outcome of an excessive secretion of the parathyroid hormone by the parathyroid gland + + + + obo2:OAE_0001049 + DJ, SS, YH + + + + obo2:OAE_0001049 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/23267748 + + + + obo2:OAE_0001049 + hyperparathyroidism secondary AE + + + + obo2:OAE_0001049 + HPO: HP_0003106 + + + + obo2:OAE_0001049 + MedDRA: 10020708 + + + + obo2:OAE_0001049 + SIDER: C0020503 + + + + obo2:OAE_0001050 + a nervous system AE that has an outcome of overactive reflexes, indicative of upper motor neuron disease as well as lessening or loss of control ordinarily exerted by higher brain centers of lower neural pathways + + + + obo2:OAE_0001050 + DJ, SS, YH + + + + obo2:OAE_0001050 + WEB: http://medical-dictionary.thefreedictionary.com/hyperreflexia + + + + obo2:OAE_0001050 + hyperreflexia AE + + + + obo2:OAE_0001050 + HPO: HP_0001347 + + + + obo2:OAE_0001050 + MedDRA: 10020745 + + + + obo2:OAE_0001050 + SIDER: C0151889 + + + + obo2:OAE_0001051 + a systemic hypertension AE that has an outcome of hypertension with systolic blood pressure >180 mm Hg or a diastolic pressure >120 mm, can be further classified as hypertensive urgency or hypertensive emergency depending on end-organ involvement + + + + obo2:OAE_0001051 + DJ, SS, YH + + + + obo2:OAE_0001051 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/20160537 + + + + obo2:OAE_0001051 + hypertensive crisis AE + + + + obo2:OAE_0001051 + HPO: HP_0000875 + + + + obo2:OAE_0001051 + MedDRA: 10020802 + + + + obo2:OAE_0001051 + SIDER: C0020546 + + + + obo2:OAE_0001052 + a hematopoietic system AE that has an outcome of high blood levels of triglycerides, abundant fatty molecules + + + + obo2:OAE_0001052 + DJ, SS, YH + + + + obo2:OAE_0001052 + hypertriglyceridaemia AE + + + + obo2:OAE_0001052 + WEB: http://medical-dictionary.thefreedictionary.com/hypertriglyceridemia + + + + obo2:OAE_0001052 + hypertriglyceridemia AE + + + + obo2:OAE_0001052 + HPO: HP_0002155 + + + + obo2:OAE_0001052 + MedDRA: 10020869 + + + + obo2:OAE_0001052 + SIDER: C0020557 + + + + obo2:OAE_0001053 + an arthritis AE that has an outcome of uric acid building up in blood and causes joint inflammation + + + + obo2:OAE_0001053 + DJ, SS, YH + + + + obo2:OAE_0001053 + gout AE + + + + obo2:OAE_0001053 + hyperuricaemia AE + + + + obo2:OAE_0001053 + WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001459/ + + + + obo2:OAE_0001053 + hyperuricemia AE + + + + obo2:OAE_0001053 + HPO: HP_0002149 + + + + obo2:OAE_0001053 + MedDRA: 10020903 + + + + obo2:OAE_0001053 + SIDER: C0740394 + + + + obo2:OAE_0001054 + a hematopoietic system AE that has an outcome of abnormally low albumin in the blood + + + + obo2:OAE_0001054 + DJ, SS, YH + + + + obo2:OAE_0001054 + hypoalbuminaemia AE + + + + obo2:OAE_0001054 + WEB: http://medical-dictionary.thefreedictionary.com/hypoalbuminemia + + + + obo2:OAE_0001054 + hypoalbuminemia AE + + + + obo2:OAE_0001054 + HPO: HP_0003073 + + + + obo2:OAE_0001054 + MedDRA: 10020942 + + + + obo2:OAE_0001054 + SIDER: C0239981 + + + + obo2:OAE_0001055 + a hematopoietic system AE that has an outcome of low calcium levels, can present with convulsions, arrythmias, tetany and numbness + + + + obo2:OAE_0001055 + DJ, SS, YH + + + + obo2:OAE_0001055 + hypocalcaemia AE + + + + obo2:OAE_0001055 + WEB: http://medical-dictionary.thefreedictionary.com/hypocalcemia + + + + obo2:OAE_0001055 + 低血钙 + + + + obo2:OAE_0001055 + hypocalcemia AE + + + + obo2:OAE_0001055 + HPO: HP_0002901 + + + + obo2:OAE_0001055 + MedDRA: 10020947 + + + + obo2:OAE_0001055 + SIDER: C0020598 + + + + obo2:OAE_0001056 + a hematopoietic system AE in which the levels of carbon dioxide in the blood is lower than normal + + + + obo2:OAE_0001056 + DJ, SS, YH + + + + obo2:OAE_0001056 + WEB: http://medical-dictionary.thefreedictionary.com/hypocapnia + + + + obo2:OAE_0001056 + hypocapnia AE + + + + obo2:OAE_0001056 + MedDRA: 10020952 + + + + obo2:OAE_0001057 + a glucose homeostasis AE that results in a abnormally diminished content of glucose in the blood + + + + obo2:OAE_0001057 + DJ, SS, YH + + + + obo2:OAE_0001057 + hypoglycaemia AE + + + + obo2:OAE_0001057 + WEB: http://medical-dictionary.thefreedictionary.com/hypoglycemia + + + + obo2:OAE_0001057 + hypoglycemia AE + + + + obo2:OAE_0001057 + HPO: HP_0005969 + + + + obo2:OAE_0001057 + MedDRA: 10020993 + + + + obo2:OAE_0001057 + SIDER: C0020615 + + + + obo2:OAE_0001058 + a neurological, special senses and psychiatric investigation result abnormal AE that is the abnormal result of the recording of the level of consciousness in a person after a brain injuiry. + + + + obo2:OAE_0001058 + YH, SJ + + + + obo2:OAE_0001058 + WEB: http://www.brainline.org/content/2010/10/what-is-the-glasgow-coma-scale.html + + + + obo2:OAE_0001058 + Clinicians use the Galscow coma scale to rate the best eye opening response, the best verbal response, and the best motor response an individual makes. The final GCS score or grade is the sum of these numbers. + + + + obo2:OAE_0001058 + Glascow coma scale abnormal AE + + + + obo2:OAE_0001058 + MedDRA: 10069709 + + + + obo2:OAE_0001059 + a hematopoietic system AE that has an outcome of an abnormal concentration of magnesium in the blood plasma, and may cause nausea, weakness and tremors. + + + + obo2:OAE_0001059 + DJ, SS, YH + + + + obo2:OAE_0001059 + hypomagnesaemia AE + + + + obo2:OAE_0001059 + WEB: http://medical-dictionary.thefreedictionary.com/Hypomagnesaemia + + + + obo2:OAE_0001059 + hypomagnesemia AE + + + + obo2:OAE_0001059 + HPO: HP_0002917 + + + + obo2:OAE_0001059 + MedDRA: 10021027 + + + + obo2:OAE_0001059 + SIDER: C0151723 + + + + obo2:OAE_0001060 + a conduction system disorder AE that refers to the slow conduction of electricity through ventricular walls of the heart. + + + + obo2:OAE_0001060 + SS + + + + obo2:OAE_0001060 + IVCD + + + + obo2:OAE_0001060 + BOOK: Taber's Cyclopedic Medical Dictionary;2005, p1134 +WEB: http://connection.ebscohost.com/c/reference-entries/21232773/intraventricular-conduction-delay + + + + obo2:OAE_0001060 + intraventricular conduction delay AE + + + + obo2:OAE_0001061 + a gustatory system AE with an outcome of reduced food intake + + + + obo2:OAE_0001061 + DJ, SS, YH + + + + obo2:OAE_0001061 + WEB: http://medical-dictionary.thefreedictionary.com/hypophagia + + + + obo2:OAE_0001061 + hypophagia AE + + + + obo2:OAE_0001061 + MedDRA: 10063743 + + + + obo2:OAE_0001062 + a hematopoietic system AE that has an outcome of low phosphate levels, can present with muscle dysfunction, white cell dysfunction, pulp chambers and mental status changes + + + + obo2:OAE_0001062 + DJ, SS, YH + + + + obo2:OAE_0001062 + hypophosphataemia AE + + + + obo2:OAE_0001062 + WEB: http://medical-dictionary.thefreedictionary.com/hypophosphatemia + + + + obo2:OAE_0001062 + hypophosphatemia AE + + + + obo2:OAE_0001062 + HPO: HP_0008285 + + + + obo2:OAE_0001062 + MedDRA: 10021058 + + + + obo2:OAE_0001062 + SIDER: C0085682 + + + + obo2:OAE_0001063 + an endocrine system AE with the outcome of the thyroid gland does not make enough thyroid hormone + + + + obo2:OAE_0001063 + DJ, SS, YH + + + + obo2:OAE_0001063 + WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001393/ + + + + obo2:OAE_0001063 + hypothyroidism AE + + + + obo2:OAE_0001063 + HPO: HP_0008245 + + + + obo2:OAE_0001063 + MedDRA: 10021114 + + + + obo2:OAE_0001063 + SIDER: C0020676 + + + + obo2:OAE_0001064 + a cardiovascular disorder AE that is characterized by decreased blood plasma volume + + + + obo2:OAE_0001064 + DJ, SS, YH + + + + obo2:OAE_0001064 + hypovolaemia AE + + + + obo2:OAE_0001064 + WEB: http://medical-dictionary.thefreedictionary.com/hypovolemia + + + + obo2:OAE_0001064 + hypovolemia AE + + + + obo2:OAE_0001064 + HPO: HP_0011106 + + + + obo2:OAE_0001064 + MedDRA: 10021137 + + + + obo2:OAE_0001064 + SIDER: C0546884 + + + + obo2:OAE_0001066 + a cardiovascular disorder AE that has the outcome of severe blood and fluid loss that makes the heart unable to pump enough blood to the body, often leads to organ failure + + + + obo2:OAE_0001066 + DJ, SS, YH + + + + obo2:OAE_0001066 + hypovolaemic shock AE + + + + obo2:OAE_0001066 + WEB: http://www.nlm.nih.gov/medlineplus/ency/article/000167.htm + + + + obo2:OAE_0001066 + hypovolemic shock AE + + + + obo2:OAE_0001066 + HPO: HP_0011106 + + + + obo2:OAE_0001066 + MedDRA: 10021138 + + + + obo2:OAE_0001066 + SIDER: C0020683 + + + + obo2:OAE_0001067 + a digestive system AE that has an outcome of holes in the ileum of the small intestine + + + + obo2:OAE_0001067 + DJ, SS, YH + + + + obo2:OAE_0001067 + WEB: http://medical-dictionary.thefreedictionary.com/ileum + + + + obo2:OAE_0001067 + ileal perforation AE + + + + obo2:OAE_0001067 + MedDRA: 10021305 + + + + obo2:OAE_0001068 + a digestive system AE that has an outcome of a partially or completely blocked bowel + + + + obo2:OAE_0001068 + DJ, SS, YH + + + + obo2:OAE_0001068 + intestinal obstruction AE + + + + obo2:OAE_0001068 + WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001306/ + + + + obo2:OAE_0001068 + ileus AE + + + + obo2:OAE_0001068 + HPO: HP_0002595 + + + + obo2:OAE_0001068 + MedDRA: 10021328 + + + + obo2:OAE_0001068 + SIDER: C1258215 + + + + obo2:OAE_0001069 + a digestive system AE that has an outcome of intestinal blockage in the absence of an actual physical obstruction, can be caused by a malfunction in nerves and muscles in the intestine + + + + obo2:OAE_0001069 + DJ, SS, YH + + + + obo2:OAE_0001069 + WEB: http://www.localhealth.com/article/paralytic-ileus + + + + obo2:OAE_0001069 + ileus paralytic AE + + + + obo2:OAE_0001069 + HPO: HP_0002590 + + + + obo2:OAE_0001069 + MedDRA: 10021333 + + + + obo2:OAE_0001069 + SIDER: C0030446 + + + + obo2:OAE_0001070 + A cardiac disorder AE that has an outcome of an abnormal enlargement of the heart + + + + obo2:OAE_0001070 + YH, SS + + + + obo2:OAE_0001070 + WEB: http://medical-dictionary.thefreedictionary.com/cardiomegaly + + + + obo2:OAE_0001070 + added MedDRA term LB + + + + obo2:OAE_0001070 + cardiomegaly AE + + + + obo2:OAE_0001070 + HPO: HP_0001640 + + + + obo2:OAE_0001070 + MedDRA: 10007632 + + + + obo2:OAE_0001070 + SIDER: C0018800 + + + + obo2:OAE_0001071 + a drug adverse event that has an outcome of decreased levels of immunosuppressant drugs in the patient's body + + + + obo2:OAE_0001071 + DJ, SS, YH + + + + obo2:OAE_0001071 + WEB: http://medical-dictionary.thefreedictionary.com/Immunosuppresant + + + + obo2:OAE_0001071 + immunosuppressant drug level decreased AE + + + + obo2:OAE_0001071 + MedDRA: 10062014 + + + + obo2:OAE_0001072 + an immune system disorder AE that has an outcome of reduced or absent immune response + + + + obo2:OAE_0001072 + DJ, SS, YH + + + + obo2:OAE_0001072 + WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001821/ + + + + obo2:OAE_0001072 + immunosuppression AE + + + + obo2:OAE_0001072 + MedDRA: 10062016 + + + + obo2:OAE_0001073 + an injury AE that has an outcome of impairment to the process of restoring a state of soundness to any interupption in the continuity of external surfaces of the body + + + + obo2:OAE_0001073 + DJ, SS, YH + + + + obo2:OAE_0001073 + WEB: http://medical-dictionary.thefreedictionary.com/wound+healing + + + + obo2:OAE_0001073 + impaired healing AE + + + + obo2:OAE_0001073 + HPO: HP_0001058 + + + + obo2:OAE_0001073 + MedDRA: 10021519 + + + + obo2:OAE_0001073 + SIDER: C0151692 + + + + obo2:OAE_0001074 + a pain AE that has an outcome of pain at the site of an implant + + + + obo2:OAE_0001074 + DJ, SS, YH + + + + obo2:OAE_0001074 + implant site pain AE + + + + obo2:OAE_0001074 + MedDRA: 10063782 + + + + obo2:OAE_0001076 + a respiratory system AE that has an outcome of increased thickness of the secretions of the bronchi + + + + obo2:OAE_0001076 + DJ, SS, YH + + + + obo2:OAE_0001076 + increased viscosity of bronchial secretion AE + + + + obo2:OAE_0001076 + MedDRA: 10054761 + + + + obo2:OAE_0001077 + an infection AE that results in infection by a parasite + + + + obo2:OAE_0001077 + DJ, SS, YH + + + + obo2:OAE_0001077 + infection parasitic AE + + + + obo2:OAE_0001077 + HPO: HP_0002719 + + + + obo2:OAE_0001077 + MedDRA: 10021857 + + + + obo2:OAE_0001077 + SIDER: C0747256 + + + + obo2:OAE_0001078 + an immune system disorder AE that has an outcome of increased susceptibility to infection + + + + obo2:OAE_0001078 + DJ, SS, YH + + + + obo2:OAE_0001078 + infection susceptibility increased AE + + + + obo2:OAE_0001078 + HPO: HP_0002719 + + + + obo2:OAE_0001078 + MedDRA: 10021866 + + + + obo2:OAE_0001078 + SIDER: C0236171 + + + + obo2:OAE_0001079 + an infection AE that has an outcome of an increase in severity of cystic fibrosis in the patient + + + + obo2:OAE_0001079 + SZ, DJ, SS, YH + + + + obo2:OAE_0001079 + infective pulmonary exacerbation of cystic fibrosis AE + + + + obo2:OAE_0001079 + MedDRA: 10070608 + + + + obo2:OAE_0001081 + a immune system AE that results in an allergic reaction to foreign protein, but can also be caused by cytokine release. + + + + obo2:OAE_0001081 + SZ, DJ, SS, YH + + + + obo2:OAE_0001081 + WEB: http://www.ons.org/Publications/VJC/media/ons/docs/publications/VJC/vjc-apr10cjon.pdf + + + + obo2:OAE_0001081 + infusion related reaction AE + + + + obo2:OAE_0001081 + MedDRA: 10053483 + + + + obo2:OAE_0001082 + an extravasation AE that has an outcome of leaking of pharmacologic or biological substance from infusion site into surrounding tissue. Symptoms include induration, erythema, swelling, burning sensation and pain + + + + obo2:OAE_0001082 + SZ, DJ, SS, YH + + + + obo2:OAE_0001082 + WEB: http://medical-dictionary.thefreedictionary.com/extravasation + + + + obo2:OAE_0001082 + infusion site extravasation AE + + + + obo2:OAE_0001082 + MedDRA: 10064774 + + + + obo2:OAE_0001083 + Infection AE that results in the patient gets infected at the sight of an infusion + + + + obo2:OAE_0001083 + SZ, DJ, SS, YH + + + + obo2:OAE_0001083 + infusion site infection AE + + + + obo2:OAE_0001083 + MedDRA: 10054997 + + + + obo2:OAE_0001084 + Rash AE that results in patient has a rash at the site of infusion + + + + obo2:OAE_0001084 + SZ, DJ, SS, YH + + + + obo2:OAE_0001084 + infusion site rash AE + + + + obo2:OAE_0001084 + MedDRA: 10059830 + + + + obo2:OAE_0001085 + an allergy AE that has an outcome of infusion site allergic reaction + + + + obo2:OAE_0001085 + SZ, DJ, SS, YH + + + + obo2:OAE_0001085 + infusion site reaction AE + + + + obo2:OAE_0001085 + MedDRA: 10054996 + + + + obo2:OAE_0001086 + a nail disorder AE that results in a nail growing into the sides of the paronychium + + + + obo2:OAE_0001086 + SZ, DJ, SS, YH + + + + obo2:OAE_0001086 + WEB: http://medical-dictionary.thefreedictionary.com/ingrowing+nail + + + + obo2:OAE_0001086 + ingrowing nail AE + + + + obo2:OAE_0001086 + MedDRA: 10022013 + + + + obo2:OAE_0001087 + a skin discoloration AE that results in a discoloration of the skin at the site of injection of the drug + + + + obo2:OAE_0001087 + SZ, DJ, SS, YH + + + + obo2:OAE_0001087 + WEB: http://medical-dictionary.thefreedictionary.com/macule + + + + obo2:OAE_0001087 + injection-site macule AE + + + + obo2:OAE_0001087 + MedDRA: 10067255 + + + + obo2:OAE_0001088 + Inflammation AE that results in swelling of the veins at the site of drug injection + + + + obo2:OAE_0001088 + SZ, DJ, SS, YH + + + + obo2:OAE_0001088 + WEB: http://medical-dictionary.thefreedictionary.com/phlebitis + + + + obo2:OAE_0001088 + injection-site phlebitis AE + + + + obo2:OAE_0001088 + MedDRA: 10022090 + + + + obo2:OAE_0001090 + an adverse event that results in the patient developing a scab at the site of drug injection + + + + obo2:OAE_0001090 + SZ, DJ, SS, YH + + + + obo2:OAE_0001090 + injection-site scab AE + + + + obo2:OAE_0001090 + MedDRA: 10066210 + + + + obo2:OAE_0001091 + a pain AE that results in pain at the site of instillation + + + + obo2:OAE_0001091 + SZ, DJ, SS, YH + + + + obo2:OAE_0001091 + WEB: http://medical-dictionary.thefreedictionary.com/instillation + + + + obo2:OAE_0001091 + instillation site pain AE + + + + obo2:OAE_0001091 + MedDRA: 10022459 + + + + obo2:OAE_0001092 + a tremor AE that results in the patient undergoing a broad, coarse, low frequency muscle tremor + + + + obo2:OAE_0001092 + SZ, DJ, SS, YH + + + + obo2:OAE_0001092 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/23094990 + + + + obo2:OAE_0001092 + intention tremor AE + + + + obo2:OAE_0001092 + HPO: HP_0002345 + + + + obo2:OAE_0001092 + MedDRA: 10022520 + + + + obo2:OAE_0001092 + SIDER: C0234376 + + + + obo2:OAE_0001093 + an adverse drug event that results in the intentional use of a drug in the wrong way (recreationally etc) + + + + obo2:OAE_0001093 + SZ, DJ, SS, YH + + + + obo2:OAE_0001093 + intentional drug misuse AE + + + + obo2:OAE_0001093 + MedDRA: 10065679 + + + + obo2:OAE_0001095 + a lung disorder AE that has an outcome of a disease affecting the interstitium, the tissue and space around the air sacs of the lungs + + + + obo2:OAE_0001095 + SZ, DJ, SS, YH + + + + obo2:OAE_0001095 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/23289473 + + + + obo2:OAE_0001095 + interstitial lung disease AE + + + + obo2:OAE_0001095 + HPO: HP_0006530 + + + + obo2:OAE_0001095 + MedDRA: 10022611 + + + + obo2:OAE_0001095 + SIDER: C0206062 + + + + obo2:OAE_0001096 + a bone disorder AE that has an outcome of the protrusion of the nucleus pulposus or anulus fibrosus of the intervertebral disk, which may impinge on nerve roots + + + + obo2:OAE_0001096 + SZ, DJ, SS, YH + + + + obo2:OAE_0001096 + WEB: http://medical-dictionary.thefreedictionary.com/herniation+of+intervertebral+disk + + + + obo2:OAE_0001096 + intervertebral disc protrusion AE + + + + obo2:OAE_0001096 + MedDRA: 10050296 + + + + obo2:OAE_0001097 + an ischaemia AE that has an outcome of blocked or narrowed blood vessels to the small or large intestines, can cause pain and permanent damage to the intestines + + + + obo2:OAE_0001097 + SZ, DJ, SS, YH + + + + obo2:OAE_0001097 + intestinal ischaemia AE + + + + obo2:OAE_0001097 + intestinal ischemia AE + + + + obo2:OAE_0001097 + MedDRA: 10022680 + + + + obo2:OAE_0001098 + a gastrointestinal disorder AE that has an outcome of a blockage that keeps substance from passing through the intestine, may be caused by fibrous bands of tissue in the abdomen, inflamed/infected pouches in the intestine, or hernias and tumors + + + + obo2:OAE_0001098 + SZ, DJ, SS, YH + + + + obo2:OAE_0001098 + WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001306/ + + + + obo2:OAE_0001098 + intestinal obstruction AE + + + + obo2:OAE_0001098 + HPO: HP_0005250 + + + + obo2:OAE_0001098 + MedDRA: 10022687 + + + + obo2:OAE_0001098 + SIDER: C0021843 + + + + obo2:OAE_0001099 + a gastrointestinal disorder AE that has an outcome of perforation, or complete penetration, of the wall of the intestines + + + + obo2:OAE_0001099 + SZ, DJ, SS, YH + + + + obo2:OAE_0001099 + WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001282/ + + + + obo2:OAE_0001099 + intestinal perforation AE + + + + obo2:OAE_0001099 + MedDRA: 10022694 + + + + obo2:OAE_0001100 + a thrombosis AE that has an outcome of thrombi in the ventricles + + + + obo2:OAE_0001100 + SZ, DJ, SS, YH + + + + obo2:OAE_0001100 + WEB: http://www.cvimaging.northwestern.edu/for-physicians/cardiovascular-mri/indications/intracardiac-thrombus/ + + + + obo2:OAE_0001100 + intracardiac thrombus AE + + + + obo2:OAE_0001100 + MedDRA: 10048620 + + + + obo2:OAE_0001101 + a nervous system AE that has an outcome of a rise in the pressure inside the skull that can result from or cause brain injury + + + + obo2:OAE_0001101 + SZ, DJ, SS, YH + + + + obo2:OAE_0001101 + WEB: http://www.nlm.nih.gov/medlineplus/ency/article/000793.htm + + + + obo2:OAE_0001101 + intracranial pressure increased AE + + + + obo2:OAE_0001101 + HPO: HP_0002516 + + + + obo2:OAE_0001101 + MedDRA: 10022773 + + + + obo2:OAE_0001101 + SIDER: C0151740 + + + + obo2:OAE_0001102 + a neurological, special senses and psychiatric investigation result abnormal AE that results in an abnormal intraocular pressure in the eye + + + + obo2:OAE_0001102 + SZ, DJ, SS, YH, EB + + + + obo2:OAE_0001102 + intraocular pressure test result abnormal AE + + + + obo2:OAE_0001102 + MedDRA: 10060951 + + + + obo2:OAE_0001103 + a gastrointestinal disorder AE that results in part of the intestine invaginating itself into another part of the intestine + + + + obo2:OAE_0001103 + SZ, DJ, SS, YH + + + + obo2:OAE_0001103 + WEB: http://www.nlm.nih.gov/medlineplus/ency/article/000958.htm + + + + obo2:OAE_0001103 + According to the Vaccine Adverse Event Reporting System (VAERS), 'intussusception'; is an adverse event that was mentioned in 143 VAERS reports (0.1%) during1991-2001 (Reference: PMID: 12825543). + + + + obo2:OAE_0001103 + intussusception AE + + + + obo2:OAE_0001103 + HPO: HP_0002576 + + + + obo2:OAE_0001103 + MP: MP_0003294 + + + + obo2:OAE_0001103 + MedDRA: 10022863 + + + + obo2:OAE_0001103 + SIDER: C0021933 + + + + obo2:OAE_0001104 + an anemia AE that has an outcome of fewer healthy red blood cells because the body does not have enough iron + + + + obo2:OAE_0001104 + SZ, DJ, SS, YH + + + + obo2:OAE_0001104 + iron deficiency anaemia AE + + + + obo2:OAE_0001104 + WEB: http://www.nlm.nih.gov/medlineplus/ency/article/000584.htm + + + + obo2:OAE_0001104 + iron deficiency anemia AE + + + + obo2:OAE_0001104 + HPO: HP_0001891 + + + + obo2:OAE_0001104 + MedDRA: 10022972 + + + + obo2:OAE_0001104 + SIDER: C0162316 + + + + obo2:OAE_0001105 + Behavior and Neurological AE that results in the patient being easily annoyed/irritated + + + + obo2:OAE_0001105 + SZ, DJ, SS, YH + + + + obo2:OAE_0001105 + feverish (subjective) AE + + + + obo2:OAE_0001105 + irritability AE + + + + obo2:OAE_0001105 + HPO: HP_0000737 + + + + obo2:OAE_0001105 + MedDRA: 10022998 + + + + obo2:OAE_0001105 + SIDER: C0022107 + + + + obo2:OAE_0001106 + a jaundice AE that results in an abnormal bile flow in the liver + + + + obo2:OAE_0001106 + SZ, DJ, SS, YH + + + + obo2:OAE_0001106 + cholestasis jaundice AE + + + + obo2:OAE_0001106 + WEB: http://medical-dictionary.thefreedictionary.com/cholestatic+jaundice + + + + obo2:OAE_0001106 + jaundice cholestatic AE + + + + obo2:OAE_0001106 + HPO: HP_0006575 + + + + obo2:OAE_0001106 + MedDRA: 10023129 + + + + obo2:OAE_0001106 + SIDER: C0022354 + + + + obo2:OAE_0001107 + a bone disorder AE that has an outcome of disease in the set of bones that hold the teeth + + + + obo2:OAE_0001107 + SZ, DJ, SS, YH + + + + obo2:OAE_0001107 + WEB: http://www.nlm.nih.gov/medlineplus/jawinjuriesanddisorders.html + + + + obo2:OAE_0001107 + jaw disorder AE + + + + obo2:OAE_0001107 + MedDRA: 10061257 + + + + obo2:OAE_0001108 + a bone disorder AE that has an outcome of break in the jaw bone + + + + obo2:OAE_0001108 + SZ, DJ, SS, YH + + + + obo2:OAE_0001108 + WEB: http://www.nlm.nih.gov/medlineplus/ency/article/000019.htm + + + + obo2:OAE_0001108 + jaw fracture AE + + + + obo2:OAE_0001108 + MedDRA: 10023149 + + + + obo2:OAE_0001109 + a thrombosis AE with an outcome of formation of a blood clot located in the internal jugular vein + + + + obo2:OAE_0001109 + SZ, DJ, SS, YH + + + + obo2:OAE_0001109 + jugular vein thrombosis AE + + + + obo2:OAE_0001109 + MedDRA: 10023237 + + + + obo2:OAE_0001110 + a bacterial infection AE with an outcome of invasion by Klebsiella pneumonia, a form of bacterial pneumonia + + + + obo2:OAE_0001110 + SZ, DJ, SS, YH + + + + obo2:OAE_0001110 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/17307769 + + + + obo2:OAE_0001110 + klebsiella infection AE + + + + obo2:OAE_0001110 + HPO: HP_0002742 + + + + obo2:OAE_0001110 + MedDRA: 10061259 + + + + obo2:OAE_0001110 + SIDER: C0022729 + + + + obo2:OAE_0001111 + a bone disorder a that results in the knee becoming deformed + + + + obo2:OAE_0001111 + SZ, DJ, SS, YH + + + + obo2:OAE_0001111 + knee deformity AE + + + + obo2:OAE_0001111 + MedDRA: 10062061 + + + + obo2:OAE_0001112 + a speech disorder AE that results in the inability of a patient to speak properly + + + + obo2:OAE_0001112 + SZ, DJ, SS, YH + + + + obo2:OAE_0001112 + lack of spontaneous speech AE + + + + obo2:OAE_0001112 + MedDRA: 10023615 + + + + obo2:OAE_0001113 + a congetical abnormality AE that results in the patient's baby being larger than it should be at the time in their pregnancy + + + + obo2:OAE_0001113 + SZ, DJ, SS, YH + + + + obo2:OAE_0001113 + large for dates baby AE + + + + obo2:OAE_0001113 + MedDRA: 10023789 + + + + obo2:OAE_0001114 + an immune system disorder AE that has an outcome of an increase in the number or proportion of natural killer cells, or cytotoxic lymphocytes critical to the innate immune system + + + + obo2:OAE_0001114 + SZ, DJ, SS, YH + + + + obo2:OAE_0001114 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/10761014 + + + + obo2:OAE_0001114 + large granular lymphocytosis AE + + + + obo2:OAE_0001114 + MedDRA: 10023791 + + + + obo2:OAE_0001115 + a gastrointestinal disorder AE that has an outcome of an ulcer in the large intestine + + + + obo2:OAE_0001115 + SZ, DJ, SS, YH + + + + obo2:OAE_0001115 + WEB: http://medical-dictionary.thefreedictionary.com/Intestinal+ulcer + + + + obo2:OAE_0001115 + large intestinal ulcer AE + + + + obo2:OAE_0001115 + MedDRA: 10023799 + + + + obo2:OAE_0001116 + a digestive system AE that has an outcome of perforation, or complete penetration, of the walls of the large intestine + + + + obo2:OAE_0001116 + SZ, DJ, SS, YH + + + + obo2:OAE_0001116 + WEB: http://www.nlm.nih.gov/medlineplus/ency/article/000235.htm + + + + obo2:OAE_0001116 + large intestine perforation AE + + + + obo2:OAE_0001116 + HPO: HP_0002250 + + + + obo2:OAE_0001116 + MedDRA: 10023804 + + + + obo2:OAE_0001116 + SIDER: NA + + + + obo2:OAE_0001117 + an immunology and allergy investigation result abnormal that results in LE cells (neutrophil or macrophage that has phagocytized the denatured nuclear material of another cell) being detected + + + + obo2:OAE_0001117 + SZ, DJ, SS, YH, EB + + + + obo2:OAE_0001117 + WEB: http://medical-dictionary.thefreedictionary.com/LE+cell + + + + obo2:OAE_0001117 + le cells present AE + + + + obo2:OAE_0001117 + MedDRA: 10024062 + + + + obo2:OAE_0001118 + a dilatation atrial AE that results in the left atrium of the heart becoming enlarged + + + + obo2:OAE_0001118 + SZ, DJ, SS, YH + + + + obo2:OAE_0001118 + WEB: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3096293/ + + + + obo2:OAE_0001118 + left atrial dilatation AE + + + + obo2:OAE_0001118 + MedDRA: 10067286 + + + + obo2:OAE_0001119 + a cardiac ventricular disorder AE that has an outcome of inability of the left ventricle to pump blood, may lead to heart failure + + + + obo2:OAE_0001119 + SZ, DJ, SS, YH + + + + obo2:OAE_0001119 + WEB: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1766527/ + + + + obo2:OAE_0001119 + left ventricular dysfunction AE + + + + obo2:OAE_0001119 + MedDRA: 10049694 + + + + obo2:OAE_0001120 + a left ventricular dysfunction AE that has an outcome of congestive heart failure marked by pulmonary congestion and edema, the left ventricle fals to contract forcefully enough to maintain normal cardiac output and peripheral perfusion + + + + obo2:OAE_0001120 + SZ, DJ, SS, YH + + + + obo2:OAE_0001120 + WEB: http://medical-dictionary.thefreedictionary.com/left+ventricular+failure + + + + obo2:OAE_0001120 + left ventricular failure AE + + + + obo2:OAE_0001120 + HPO: HP_0001635 + + + + obo2:OAE_0001120 + MedDRA: 10024119 + + + + obo2:OAE_0001120 + SIDER: C0023212 + + + + obo2:OAE_0001121 + a left ventricular dysfunction disorder AE that has an outcome of the thickening of the myocardium of the left ventricle of the heart + + + + obo2:OAE_0001121 + SZ, DJ, SS, YH + + + + obo2:OAE_0001121 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/18030317 + + + + obo2:OAE_0001121 + left ventricular hypertrophy AE + + + + obo2:OAE_0001121 + MedDRA: 10049773 + + + + obo2:OAE_0001122 + a hematopoietic system AE that has an outcome of cancer of the white blood cells characterized by return of symptoms after remission + + + + obo2:OAE_0001122 + SZ, DJ, SS, YH + + + + obo2:OAE_0001122 + leukaemia recurrent AE + + + + obo2:OAE_0001122 + WEB: http://www.yourcancertoday.com/Cancers/Leukemia-Acute-Myeloid-Adult/53 + + + + obo2:OAE_0001122 + leukemia recurrent AE + + + + obo2:OAE_0001122 + MedDRA: 10062489 + + + + obo2:OAE_0001123 + a nervous system AE that has an outcome of cancerous white blood cells infiltrating the brain + + + + obo2:OAE_0001123 + SZ, DJ, SS, YH + + + + obo2:OAE_0001123 + leukaemic infiltration brain AE + + + + obo2:OAE_0001123 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/1454121 + + + + obo2:OAE_0001123 + leukemic infiltration brain AE + + + + obo2:OAE_0001123 + MedDRA: 10064987 + + + + obo2:OAE_0001124 + Immune system disorder AE that results in an increase in white blood cell count as a result of stress or infection + + + + obo2:OAE_0001124 + SZ, DJ, SS, YH + + + + obo2:OAE_0001124 + leukaemoid reaction AE + + + + obo2:OAE_0001124 + WEB: http://www.nlm.nih.gov/medlineplus/ency/article/000575.htm + + + + obo2:OAE_0001124 + leukemoid reaction AE + + + + obo2:OAE_0001124 + HPO: HP_0001909 + + + + obo2:OAE_0001124 + MedDRA: 10024328 + + + + obo2:OAE_0001124 + SIDER: C0023501 + + + + obo2:OAE_0001126 + an inflammation AE that has an outcome of fragmented cells, and debris in the blood vessels. May develop skin lesions, accompanied by arthralgia and fever + + + + obo2:OAE_0001126 + SZ, DJ, SS, YH + + + + obo2:OAE_0001126 + WEB: http://medical-dictionary.thefreedictionary.com/leukocytoclastic+vasculitis + + + + obo2:OAE_0001126 + leukocytoclastic vasculitis AE + + + + obo2:OAE_0001126 + HPO: HP_0011944 + + + + obo2:OAE_0001126 + MedDRA: 10024377 + + + + obo2:OAE_0001126 + SIDER: C2973529 + + + + obo2:OAE_0001127 + Urinary system AE that results in white blood cells in the urine + + + + obo2:OAE_0001127 + SZ, DJ, SS, YH + + + + obo2:OAE_0001127 + WEB: http://medical-dictionary.thefreedictionary.com/leukocyturia + + + + obo2:OAE_0001127 + leukocyturia AE + + + + obo2:OAE_0001127 + MedDRA: 10050791 + + + + obo2:OAE_0001128 + an encephalopathy AE that has an outcome of brain white matter disease + + + + obo2:OAE_0001128 + SZ, DJ, SS, YH + + + + obo2:OAE_0001128 + WEB: http://medical-dictionary.thefreedictionary.com/leukoencephalopathy + + + + obo2:OAE_0001128 + leukoencephalopathy AE + + + + obo2:OAE_0001128 + HPO: HP_0002352 + + + + obo2:OAE_0001128 + MedDRA: 10024382 + + + + obo2:OAE_0001128 + SIDER: C0270612 + + + + obo2:OAE_0001129 + a hematopoietic system AE that has an outcome of a lower than normal number of leukocytes, or nucleated cells of the myeloid or lymphoid lineages, found in blood or other tissue + + + + obo2:OAE_0001129 + SZ, DJ, SS, YH + + + + obo2:OAE_0001129 + WEB: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2154209/ + + + + obo2:OAE_0001129 + leukopenia + + + + obo2:OAE_0001129 + HPO: HP_0001882 + + + + obo2:OAE_0001129 + MedDRA: 10024384 + + + + obo2:OAE_0001129 + SIDER: C0023530 + + + + obo2:OAE_0001130 + a behavioral and neurological AE that results in a disorder in the patient's desire for sexual interaction + + + + obo2:OAE_0001130 + SZ, DJ, SS, YH + + + + obo2:OAE_0001130 + WEB: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2695750/ + + + + obo2:OAE_0001130 + libido disorder AE + + + + obo2:OAE_0001130 + MedDRA: 10061221 + + + + obo2:OAE_0001131 + a skin AE that has an outcome of an itchy rash on the skin or in the mouth + + + + obo2:OAE_0001131 + SZ, DJ, SS, YH + + + + obo2:OAE_0001131 + WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001870/ + + + + obo2:OAE_0001131 + lichen planus AE + + + + obo2:OAE_0001131 + MedDRA: 10024429 + + + + obo2:OAE_0001132 + a skin adverse event that results in the deterioration of the lip skin + + + + obo2:OAE_0001132 + SZ, DJ, SS, YH + + + + obo2:OAE_0001132 + lip erosion AE + + + + obo2:OAE_0001132 + MedDRA: 10051992 + + + + obo2:OAE_0001133 + a digestive system AE that has an outcome of an excess of lipase, a pancreatic enzyme, may indicate a problem related to pancreas + + + + obo2:OAE_0001133 + SZ, DJ, SS, YH + + + + obo2:OAE_0001133 + hyperlipasemia AE + + + + obo2:OAE_0001133 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/15653991 + + + + obo2:OAE_0001133 + lipase increased AE + + + + obo2:OAE_0001133 + MedDRA: 10024574 + + + + obo2:OAE_0001135 + Liver/biliary system AE that results in the disease of the liver + + + + obo2:OAE_0001135 + SZ, DJ, SS, YH + + + + obo2:OAE_0001135 + WEB: http://www.nlm.nih.gov/medlineplus/liverdiseases.html + + + + obo2:OAE_0001135 + liver disorder AE + + + + obo2:OAE_0001135 + HPO: HP_0006706 + + + + obo2:OAE_0001135 + MedDRA: 10024670 + + + + obo2:OAE_0001135 + SIDER: C0023895 + + + + obo2:OAE_0001136 + a localized edema AE that shows the outcome of swelling. + + + + obo2:OAE_0001136 + SZ, DJ, SS, YH + + + + obo2:OAE_0001136 + local swelling AE + + + + obo2:OAE_0001136 + MedDRA: 10024770 + + + + obo2:OAE_0001137 + an infection AE located in a certain area + + + + obo2:OAE_0001137 + SZ, DJ, SS, YH + + + + obo2:OAE_0001137 + localised infection AE + + + + obo2:OAE_0001137 + localized infection AE + + + + obo2:OAE_0001137 + HPO: HP_0002719 + + + + obo2:OAE_0001137 + MedDRA: 10024774 + + + + obo2:OAE_0001137 + SIDER: C0016397 + + + + obo2:OAE_0001138 + Abnormal fluid regulation AE that results in a collection of fluid in the intraabdominal area + + + + obo2:OAE_0001138 + SZ, DJ, SS, YH + + + + obo2:OAE_0001138 + WEB: http://medical-dictionary.thefreedictionary.com/intra-abdominal + + + + obo2:OAE_0001138 + localised intraabdominal fluid collection AE + + + + obo2:OAE_0001138 + MedDRA: 10066768 + + + + obo2:OAE_0001139 + an edema AE occuring in a specific region + + + + obo2:OAE_0001139 + SZ, DJ, SS, YH + + + + obo2:OAE_0001139 + localised edema AE + + + + obo2:OAE_0001139 + localised oedema AE + + + + obo2:OAE_0001139 + WEB: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1115975/ + + + + obo2:OAE_0001139 + localized edema AE + + + + obo2:OAE_0001139 + HPO: HP_0000969 + + + + obo2:OAE_0001139 + MedDRA: 10048961 + + + + obo2:OAE_0001139 + SIDER: C0013609 + + + + obo2:OAE_0001140 + a movement disorder AE that has an outcome of loss of the sense of the relative position of neighbouring parts of the body and strength of effort being employed in movement + + + + obo2:OAE_0001140 + SZ, DJ, SS, YH + + + + obo2:OAE_0001140 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/8294975 + + + + obo2:OAE_0001140 + loss of proprioception AE + + + + obo2:OAE_0001140 + MedDRA: 10057332 + + + + obo2:OAE_0001141 + a gastrointestinal hemorrhage AE that has an outcome of bleeding in the lower gastrointestinal tract + + + + obo2:OAE_0001141 + SZ, DJ, SS, YH + + + + obo2:OAE_0001141 + lower gastrointestinal haemorrhage AE + + + + obo2:OAE_0001141 + WEB: http://www.nlm.nih.gov/medlineplus/ency/article/003133.htm + + + + obo2:OAE_0001141 + lower gastrointestinal hemorrhage AE + + + + obo2:OAE_0001141 + HPO: HP_0002239 + + + + obo2:OAE_0001141 + MedDRA: 10050953 + + + + obo2:OAE_0001141 + SIDER: C0024050 + + + + obo2:OAE_0001142 + an infection AE that has an outcome of infection in the lower respiratory tract, includes pneumonea as well as lung abscess and acute bronchitis + + + + obo2:OAE_0001142 + SZ, DJ, SS, YH + + + + obo2:OAE_0001142 + WEB: http://www.ncbi.nlm.nih.gov/books/NBK8142/ + + + + obo2:OAE_0001142 + lower respiratory tract infection AE + + + + obo2:OAE_0001142 + HPO: HP_0002783 + + + + obo2:OAE_0001142 + MedDRA: 10024968 + + + + obo2:OAE_0001142 + SIDER: C0149725 + + + + obo2:OAE_0001143 + a lung disorder AE that has an outcome of liquid filling a region of lung tissue, marked by induration of a normally aerated lung + + + + obo2:OAE_0001143 + SZ, DJ, SS, YH + + + + obo2:OAE_0001143 + pulmonary consolidation AE + + + + obo2:OAE_0001143 + WEB: http://medical-dictionary.thefreedictionary.com/consolidation + + + + obo2:OAE_0001143 + lung consolidation AE + + + + obo2:OAE_0001143 + MedDRA: 10025080 + + + + obo2:OAE_0001144 + an infection AE that has an outcome of infection in the lungs + + + + obo2:OAE_0001144 + SZ, DJ, SS, YH + + + + obo2:OAE_0001144 + WEB: http://www.livestrong.com/lung-infection/ + + + + obo2:OAE_0001144 + lung infection AE + + + + obo2:OAE_0001144 + HPO: HP_0002783 + + + + obo2:OAE_0001144 + MedDRA: 10061229 + + + + obo2:OAE_0001144 + SIDER: C0876973 + + + + obo2:OAE_0001145 + a lung disorder AE that has an outcome of an abnormal presence of granulomas, fluid, inflammatory exudates or cells in the lung tissue + + + + obo2:OAE_0001145 + SZ, DJ, SS, YH + + + + obo2:OAE_0001145 + WEB: http://www.blurtit.com/q840550.html + + + + obo2:OAE_0001145 + lung infiltration AE + + + + obo2:OAE_0001145 + HPO: HP_0005828 + + + + obo2:OAE_0001145 + MedDRA: 10025102 + + + + obo2:OAE_0001145 + SIDER: C0235896 + + + + obo2:OAE_0001146 + a tumor AE that has an outcome of a malignant tumor in the lung + + + + obo2:OAE_0001146 + SZ, DJ, SS, YH + + + + obo2:OAE_0001146 + WEB: http://medical-dictionary.thefreedictionary.com/Lung+neoplasm + + + + obo2:OAE_0001146 + lung neoplasm AE + + + + obo2:OAE_0001146 + HPO: HP_0100526 + + + + obo2:OAE_0001146 + MedDRA: 10062042 + + + + obo2:OAE_0001146 + SIDER: C0024121 + + + + obo2:OAE_0001147 + an immune system disorder AE that has an outcome of lymphadenopathy, which is a term meaning "disease of the lymph nodes" . It is generally a disease or inflammation of the lymph nodes, could be due to infection, auto-immune disease or malignancy + + + + obo2:OAE_0001147 + SZ, SS, YH + + + + obo2:OAE_0001147 + WEB: http://medical-dictionary.thefreedictionary.com/lymphadenopathy + + + + obo2:OAE_0001147 + lymphadenopathy AE + + + + obo2:OAE_0001147 + HPO: HP_0002716 + + + + obo2:OAE_0001147 + MedDRA: 10025197 + + + + obo2:OAE_0001147 + SIDER: C0497156 + + + + obo2:OAE_0001148 + an inflammation AE occuring in the lymph vessels secondary to a malignancy + + + + obo2:OAE_0001148 + SZ, SS, YH + + + + obo2:OAE_0001148 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/8930034 + + + + obo2:OAE_0001148 + lymphangiosis carcinomatosa AE + + + + obo2:OAE_0001148 + MedDRA: 10053132 + + + + obo2:OAE_0001149 + a lymphocyte count abnormal AE that has an outcome of a decreased amount of lymphocytes in the blood, a type of white blood cell in the immune system + + + + obo2:OAE_0001149 + SZ, SS, YH + + + + obo2:OAE_0001149 + WEB: http://www.nlm.nih.gov/medlineplus/ency/article/003657.htm + + + + obo2:OAE_0001149 + lymphocyte count decreased AE + + + + obo2:OAE_0001149 + MedDRA: 10025256 + + + + obo2:OAE_0001150 + a lymphocyte percentage abnormal AE that results in an increase in the levels of lymphocytes in the blood + + + + obo2:OAE_0001150 + SZ, SS, YH, EB + + + + obo2:OAE_0001150 + WEB: http://www.nlm.nih.gov/medlineplus/ency/article/003657.htm + + + + obo2:OAE_0001150 + lymphocyte percentage increased AE + + + + obo2:OAE_0001150 + MedDRA: 10052232 + + + + obo2:OAE_0001151 + an immune system disorder AE that results in lymphocytes being infiltrated by harmful substances + + + + obo2:OAE_0001151 + SZ, SS, YH + + + + obo2:OAE_0001151 + WEB: http://emedicine.medscape.com/article/1098654-overview + + + + obo2:OAE_0001151 + lymphocytic infiltration AE + + + + obo2:OAE_0001151 + MedDRA: 10062049 + + + + obo2:OAE_0001152 + an immune system disorder AE that has an outcome of an increase in the number or proportion of lymphocytes in the blood + + + + obo2:OAE_0001152 + SZ, SS, YH + + + + obo2:OAE_0001152 + WEB: http://medical-dictionary.thefreedictionary.com/lymphocytosis + + + + obo2:OAE_0001152 + lymphocytosis AE + + + + obo2:OAE_0001152 + HPO: HP_0012141 + + + + obo2:OAE_0001152 + MedDRA: 10025280 + + + + obo2:OAE_0001152 + SIDER: C0024282 + + + + obo2:OAE_0001153 + an edema AE that has an outcome of localized fluid retention and tissue swelling caused by a compromised lymphatic system + + + + obo2:OAE_0001153 + SZ, SS, YH + + + + obo2:OAE_0001153 + WEB: Primary Source: http://emedicine.medscape.com/article/1087313-overview Secondary Source: http://www.ncbi.nlm.nih.gov/pubmed/23073712 + + + + obo2:OAE_0001153 + lymphoedema AE + + + + obo2:OAE_0001153 + HPO: HP_0001004 + + + + obo2:OAE_0001153 + MedDRA: 10025282 + + + + obo2:OAE_0001153 + SIDER: C0024236 + + + + obo2:OAE_0001154 + a hematopoietic system AE that has an outcome of reduction in the number of lymphocytes in the blood + + + + obo2:OAE_0001154 + SZ, SS, YH + + + + obo2:OAE_0001154 + WEB: http://medical-dictionary.thefreedictionary.com/lymphopenia + + + + obo2:OAE_0001154 + lymphopenia AE + + + + obo2:OAE_0001154 + HPO: HP_0001888 + + + + obo2:OAE_0001154 + MedDRA: 10025327 + + + + obo2:OAE_0001154 + SIDER: C0024312 + + + + obo2:OAE_0001155 + a eye disorder AE that has an outcome of cell death in the macula of the eye, destroying central vision + + + + obo2:OAE_0001155 + SZ, SS, YH + + + + obo2:OAE_0001155 + WEB: http://www.nlm.nih.gov/medlineplus/maculardegeneration.html + + + + obo2:OAE_0001155 + macular degeneration AE + + + + obo2:OAE_0001155 + HPO: HP_0007673 + + + + obo2:OAE_0001155 + MedDRA: 10025409 + + + + obo2:OAE_0001155 + SIDER: C0024437 + + + + obo2:OAE_0001156 + a male reproductive system disorder AE that results in the inability of the male to achieve an orgasm despite lengthy sexual contact + + + + obo2:OAE_0001156 + SZ, SS, YH + + + + obo2:OAE_0001156 + WEB: http://www.minddisorders.com/Kau-Nu/Male-orgasmic-disorder.html#b + + + + obo2:OAE_0001156 + male orgasmic disorder AE + + + + obo2:OAE_0001156 + MedDRA: 10025513 + + + + obo2:OAE_0001157 + a tumor AE that has an outcome of growth or proliferation of an abnormal mass of tissue + + + + obo2:OAE_0001157 + SZ, SS, YH + + + + obo2:OAE_0001157 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/19824467 + + + + obo2:OAE_0001157 + malignant neoplasm progression AE + + + + obo2:OAE_0001157 + MedDRA: 10061309 + + + + obo2:OAE_0001158 + an respiratory system AE that has an outcome of abnormal amount of fluid collecting between the layers of tissue lining the outside of the lung and wall of chest cavity, caused by cancer + + + + obo2:OAE_0001158 + SZ, SS, YH + + + + obo2:OAE_0001158 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/11529302 + + + + obo2:OAE_0001158 + malignant pleural effusion AE + + + + obo2:OAE_0001158 + MedDRA: 10026673 + + + + obo2:OAE_0001161 + an arterial disorder AE that resuts in arteries that supply blood to heart muscle become hardened and narrowed. + + + + obo2:OAE_0001161 + YH, SS + + + + obo2:OAE_0001161 + coronary artery disese AE + + + + obo2:OAE_0001161 + WEB: http://www.nlm.nih.gov/medlineplus/coronaryarterydisease.html + + + + obo2:OAE_0001161 + coronary artery disorder AE + + + + obo2:OAE_0001161 + MedDRA: 10011078 + + + + obo2:OAE_0001161 + MedDRA: 10011082 + + + + obo2:OAE_0001162 + a hematopoietic system AE that has an outcome of bone marrow that contains an excess of blood cells + + + + obo2:OAE_0001162 + SZ, SS, YH + + + + obo2:OAE_0001162 + WEB: http://www.mayoclinic.com/health/aplastic-anemia/DS00322/DSECTION=causes + + + + obo2:OAE_0001162 + marrow hyperplasia AE + + + + obo2:OAE_0001162 + MedDRA: 10026851 + + + + obo2:OAE_0001163 + a perinatal AE that results in the drugs being taken by the mother affecting unborn fetus in mother + + + + obo2:OAE_0001163 + SZ, SS, YH + + + + obo2:OAE_0001163 + maternal drugs affecting foetus AE + + + + obo2:OAE_0001163 + maternal drugs affecting fetus AE + + + + obo2:OAE_0001163 + MedDRA: 10026923 + + + + obo2:OAE_0001164 + an adverse event that results in a problem in the mediastinum of the patient (undelineated group of structures in the thorax surrounded by loose connective tissue) + + + + obo2:OAE_0001164 + SZ, SS, YH + + + + obo2:OAE_0001164 + WEB: http://medical-dictionary.thefreedictionary.com/Mediastinal+diseases + + + + obo2:OAE_0001164 + mediastinal disorder AE + + + + obo2:OAE_0001164 + HPO: HP_0000765 + + + + obo2:OAE_0001164 + MedDRA: 10061280 + + + + obo2:OAE_0001164 + SIDER: C0025061 + + + + obo2:OAE_0001165 + a digestive system AE that has an outcome of abnormal dilation of the colon, often accompanied by paralysis of the peristaltic movements of the bowel + + + + obo2:OAE_0001165 + SZ, SS, YH + + + + obo2:OAE_0001165 + WEB: http://medical-dictionary.thefreedictionary.com/megacolon + + + + obo2:OAE_0001165 + megacolon AE + + + + obo2:OAE_0001165 + HPO: HP_0002251 + + + + obo2:OAE_0001165 + MedDRA: 10027110 + + + + obo2:OAE_0001165 + SIDER: C0025160 + + + + obo2:OAE_0001166 + Abnormal defecation AE that results in black feces associated with gastrointestinal hemorrhage + + + + obo2:OAE_0001166 + SZ, SS, YH + + + + obo2:OAE_0001166 + melaena AE + + + + obo2:OAE_0001166 + WEB: http://www.nlm.nih.gov/medlineplus/ency/article/003130.htm + + + + obo2:OAE_0001166 + melena AE + + + + obo2:OAE_0001166 + HPO: HP_0002249 + + + + obo2:OAE_0001166 + MedDRA: 10027141 + + + + obo2:OAE_0001166 + SIDER: C0025222 + + + + obo2:OAE_0001167 + Behavior and Neurological AE that results in the loss of memory + + + + obo2:OAE_0001167 + SZ, SS, YH + + + + obo2:OAE_0001167 + WEB: http://medical-dictionary.thefreedictionary.com/impaired+memory + + + + obo2:OAE_0001167 + memory impairment AE + + + + obo2:OAE_0001167 + HPO: HP_0002354 + + + + obo2:OAE_0001167 + MedDRA: 10027175 + + + + obo2:OAE_0001167 + SIDER: C0233794 + + + + obo2:OAE_0001168 + a brain inflammation AE that results in the layers lining the brain becoming inflamed, not due to pygonenic bacteria + + + + obo2:OAE_0001168 + SZ, SS, YH + + + + obo2:OAE_0001168 + WEB: http://medical-dictionary.thefreedictionary.com/aseptic+meningitis + + + + obo2:OAE_0001168 + meningitis aseptic AE + + + + obo2:OAE_0001168 + HPO: HP_0001287 + + + + obo2:OAE_0001168 + MedDRA: 10027201 + + + + obo2:OAE_0001168 + SIDER: C0025290 + + + + obo2:OAE_0001169 + Hematuria AE that results in excessive uterine bleeding occurs irregularly and more frequently than normal + + + + obo2:OAE_0001169 + SZ, SS, YH + + + + obo2:OAE_0001169 + WEB: http://medical-dictionary.thefreedictionary.com/menometrorrhagia + + + + obo2:OAE_0001169 + menometrorrhagia AE + + + + obo2:OAE_0001169 + HPO: HP_0100608 + + + + obo2:OAE_0001169 + MedDRA: 10027295 + + + + obo2:OAE_0001169 + SIDER: C0232943 + + + + obo2:OAE_0001170 + Female Reproductive System AE that results in abnormally heavy and prolonged menstrual period + + + + obo2:OAE_0001170 + SZ, SS, YH + + + + obo2:OAE_0001170 + WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0014910/ + + + + obo2:OAE_0001170 + menorrhagia AE + + + + obo2:OAE_0001170 + HPO: HP_0000132 + + + + obo2:OAE_0001170 + MedDRA: 10027313 + + + + obo2:OAE_0001170 + SIDER: C0025323 + + + + obo2:OAE_0001171 + a mental disorder AE that has an outcome of changes in mental status + + + + obo2:OAE_0001171 + SZ, SS, YH, Izabela Birsanescu + + + + obo2:OAE_0001171 + WEB: http://www.medicinenet.com/altered_mental_status/symptoms.htm + + + + obo2:OAE_0001171 + A mental status change does not have to be a disorder or even an adverse event. It can be a good change, from a disorder status to a normal recovered status. + + + + obo2:OAE_0001171 + mental status changes AE + + + + obo2:OAE_0001171 + MedDRA: 10048294 + + + + obo2:OAE_0001172 + a metabolism, endocrine, and exocrine system AE that has an outcome of abnormal chemical reactions in the body that disrupts a metabolic process + + + + obo2:OAE_0001172 + SZ, SS, YH + + + + obo2:OAE_0001172 + WEB: http://www.nlm.nih.gov/medlineplus/metabolicdisorders.html + + + + obo2:OAE_0001172 + metabolic disorder AE + + + + obo2:OAE_0001172 + MedDRA: 10058097 + + + + obo2:OAE_0001173 + A cardiac disorder AE that has an outcome of enlargement of the heart + + + + obo2:OAE_0001173 + YH, SS + + + + obo2:OAE_0001173 + atrial dilatation, atrial enlargement + + + + obo2:OAE_0001173 + dilatation atrial AE + + + + obo2:OAE_0001173 + MedDRA: 10013002 + + + + obo2:OAE_0001174 + an abdominal AE that shows the spreading of the cancer cells to the abdominal cavity of the patient + + + + obo2:OAE_0001174 + SZ, SS, YH + + + + obo2:OAE_0001174 + WEB: Primary Source: http://www.nlm.nih.gov/medlineplus/ency/article/002260.htm Secondary Source: http://www.ncbi.nlm.nih.gov/pubmed/19373966 + + + + obo2:OAE_0001174 + metastasis to abdominal cavity AE + + + + obo2:OAE_0001174 + MedDRA: 10027450 + + + + obo2:OAE_0001175 + a tumor AE that has an outcome of cancerous cells spreading to the bone from elsewhere + + + + obo2:OAE_0001175 + SZ, SS, YH + + + + obo2:OAE_0001175 + metastasis to bone AE + + + + obo2:OAE_0001175 + MedDRA: 10027452 + + + + obo2:OAE_0001176 + a tumor AE that results in cancerous cells spreading from a primary tumor to the central nervous system + + + + obo2:OAE_0001176 + SZ, SS, YH + + + + obo2:OAE_0001176 + WEB: http://theoncologist.alphamedpress.org/content/8/5/398.long, http://www.ncbi.nlm.nih.gov/pubmed/19373966 + + + + obo2:OAE_0001176 + metastasis to central nervous system AE + + + + obo2:OAE_0001176 + MedDRA: 10059282 + + + + obo2:OAE_0001177 + a tumor AE that results in cancerous cells spreading to the liver organ + + + + obo2:OAE_0001177 + SZ, SS, YH + + + + obo2:OAE_0001177 + WEB: http://www.nlm.nih.gov/medlineplus/ency/article/000277.htm + + + + obo2:OAE_0001177 + metastasis to liver AE + + + + obo2:OAE_0001177 + MedDRA: 10027457 + + + + obo2:OAE_0001178 + a tumor AE that results in cancerous cells spreading to the lung + + + + obo2:OAE_0001178 + SZ, SS, YH + + + + obo2:OAE_0001178 + WEB: http://www.nlm.nih.gov/medlineplus/ency/article/000097.htm + + + + obo2:OAE_0001178 + metastasis to lung AE + + + + obo2:OAE_0001178 + MedDRA: 10027458 + + + + obo2:OAE_0001179 + a tumor AE that has an outcome cancerous cells spreaing from primary tumor to the thin layers of tissue that protect the brain and spinal cord, may experience increased intracranial pressure + + + + obo2:OAE_0001179 + SZ, SS, YH + + + + obo2:OAE_0001179 + meningeal metastasis AE + + + + obo2:OAE_0001179 + WEB: 1. http://theoncologist.alphamedpress.org/content/1/1/56.full 2. http://www.cancer.gov/dictionary?cdrid=45782 + + + + obo2:OAE_0001179 + metastasis to meninges AE + + + + obo2:OAE_0001179 + MedDRA: 10051696 + + + + obo2:OAE_0001180 + a tumor AE that results in cancerous cells spreading from primary tumor to the lining of the abdominal cavity or the coelom. + + + + obo2:OAE_0001180 + SZ, SS, YH + + + + obo2:OAE_0001180 + WEB: Primary Source: http://medical-dictionary.thefreedictionary.com/peritoneum Secondary Source: http://www.ncbi.nlm.nih.gov/pubmed?term=metastasis%20to%20peritoneum%20%5BTI%5D + + + + obo2:OAE_0001180 + metastasis to peritoneum AE + + + + obo2:OAE_0001180 + MedDRA: 10051676 + + + + obo2:OAE_0001181 + a tumor AE that results in a disease spreading to the pleural cavity due to cancerous activities + + + + obo2:OAE_0001181 + SZ, SS, YH + + + + obo2:OAE_0001181 + WEB: http://www.nlm.nih.gov/medlineplus/pleuraldisorders.html + + + + obo2:OAE_0001181 + metastasis to pleura AE + + + + obo2:OAE_0001181 + MedDRA: 10027463 + + + + obo2:OAE_0001183 + a tumor AE that results in cancerous cells spreading to the spine + + + + obo2:OAE_0001183 + SZ, SS, YH + + + + obo2:OAE_0001183 + WEB: http://emedicine.medscape.com/article/1157987-overview + + + + obo2:OAE_0001183 + metastasis to spine AE + + + + obo2:OAE_0001183 + MedDRA: 10027468 + + + + obo2:OAE_0001184 + a tumor AE with an outcome of spreading of disease from one organ to another non-adjacent organ or part + + + + obo2:OAE_0001184 + SZ, SS, YH + + + + obo2:OAE_0001184 + WEB: http://www.nlm.nih.gov/medlineplus/ency/article/002260.htm + + + + obo2:OAE_0001184 + metastasis AE + + + + obo2:OAE_0001184 + MedDRA: 10062194 + + + + obo2:OAE_0001185 + a tumor AE with an outcome of spreading of cancerous cells from abnormal mass of tissue + + + + obo2:OAE_0001185 + SZ, SS, YH + + + + obo2:OAE_0001185 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/20121607 + + + + obo2:OAE_0001185 + metastatic neoplasm AE + + + + obo2:OAE_0001185 + MedDRA: 10061289 + + + + obo2:OAE_0001186 + Urinary System AE that is characterized by uterine bleeding at irregular intervals + + + + obo2:OAE_0001186 + SZ, SS, YH + + + + obo2:OAE_0001186 + WEB: http://medical-dictionary.thefreedictionary.com/metrorrhagia + + + + obo2:OAE_0001186 + metrorrhagia AE + + + + obo2:OAE_0001186 + HPO: HP_0100608 + + + + obo2:OAE_0001186 + MedDRA: 10027514 + + + + obo2:OAE_0001186 + SIDER: C0025874 + + + + obo2:OAE_0001187 + Cardiovascular disorder AE that results in a fragmentation of red blood cells resulting from the narrowing of small blood vessels + + + + obo2:OAE_0001187 + SZ, SS, YH + + + + obo2:OAE_0001187 + microangiopathic haemolytic anaemia AE + + + + obo2:OAE_0001187 + WEB: http://medical-dictionary.thefreedictionary.com/microangiopathic+hemolytic+anemia + + + + obo2:OAE_0001187 + microangiopathic hemolytic anemia AE + + + + obo2:OAE_0001187 + HPO: HP_0001937 + + + + obo2:OAE_0001187 + MedDRA: 10027527 + + + + obo2:OAE_0001187 + SIDER: C0221021 + + + + obo2:OAE_0001188 + a cardiac valve disease AE that is characterized by the inability of the heart's mitral valve to close tightly, allowing blood to flow backward in the heart + + + + obo2:OAE_0001188 + SZ, SS, YH + + + + obo2:OAE_0001188 + WEB: http://medical-dictionary.thefreedictionary.com/Mitral+Valve+Insufficiency + + + + obo2:OAE_0001188 + mitral valve incompetence AE + + + + obo2:OAE_0001188 + HPO: HP_0001653 + + + + obo2:OAE_0001188 + MedDRA: 10027727 + + + + obo2:OAE_0001188 + SIDER: C0026266 + + + + obo2:OAE_0001189 + a digestive system AE that has an outcome of bleeding from blood vessels located in the mouth + + + + obo2:OAE_0001189 + SZ, SS, YH + + + + obo2:OAE_0001189 + mouth haemorrhage AE + + + + obo2:OAE_0001189 + WEB: http://sideeffects.embl.de/se/C0029163/ + + + + obo2:OAE_0001189 + mouth hemorrhage AE + + + + obo2:OAE_0001189 + HPO: HP_0000167 + + + + obo2:OAE_0001189 + MedDRA: 10028024 + + + + obo2:OAE_0001189 + SIDER: C0029163 + + + + obo2:OAE_0001190 + a digestive system AE that has an outcome of sores or open lesions in the mouth + + + + obo2:OAE_0001190 + SZ, SS, YH + + + + obo2:OAE_0001190 + aphthous stomatitis AE + + + + obo2:OAE_0001190 + canker sore AE + + + + obo2:OAE_0001190 + WEB: http://www.nlm.nih.gov/medlineplus/ency/article/001448.htm + + + + obo2:OAE_0001190 + mouth ulceration AE + + + + obo2:OAE_0001190 + HPO: HP_0000155 + + + + obo2:OAE_0001190 + MedDRA: 10028034 + + + + obo2:OAE_0001190 + SIDER: C0149745 + + + + obo2:OAE_0001191 + Multiple Sclerosis AE that is characterized by a relapse of Multiple Sclerosis + + + + obo2:OAE_0001191 + SZ, SS, YH + + + + obo2:OAE_0001191 + WEB: Primary Source: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001747/ Secondary Source: http://www.ncbi.nlm.nih.gov/pubmed/22980532 + + + + obo2:OAE_0001191 + multiple sclerosis relapse AE + + + + obo2:OAE_0001191 + MedDRA: 10048393 + + + + obo2:OAE_0001192 + a muscle contraction AE that has an outcome of painful sensations, associated with muscle fatigue and low sodium/potassium + + + + obo2:OAE_0001192 + SZ, SS, YH + + + + obo2:OAE_0001192 + WEB: http://www.nlm.nih.gov/medlineplus/musclecramps.html + + + + obo2:OAE_0001192 + muscle cramp AE + + + + obo2:OAE_0001192 + MedDRA: 10028294 + + + + obo2:OAE_0001193 + a muscle enzyme level abnormal AE that results in an increased level of muscle enzyme + + + + obo2:OAE_0001193 + SZ, SS, YH + + + + obo2:OAE_0001193 + muscle enzyme level increased AE + + + + obo2:OAE_0001193 + MedDRA: 10057945 + + + + obo2:OAE_0001194 + Musculoskeletal system AE that results in the musculoskeletal system being weakened at locomotion is hampered + + + + obo2:OAE_0001194 + SZ, SS, YH + + + + obo2:OAE_0001194 + WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0002172/ + + + + obo2:OAE_0001194 + muscular dystrophy AE + + + + obo2:OAE_0001194 + MedDRA: 10028356 + + + + obo2:OAE_0001195 + a pain AE located in musculoskeletal structures of the chest wall, atypical or noncardiac chest pain + + + + obo2:OAE_0001195 + SZ, SS, YH + + + + obo2:OAE_0001195 + WEB: http://www.uptodate.com/contents/major-causes-of-musculoskeletal-chest-pain?source=see_link + + + + obo2:OAE_0001195 + musculoskeletal chest pain AE + + + + obo2:OAE_0001195 + HPO: HP_0006649 + + + + obo2:OAE_0001195 + MedDRA: 10050819 + + + + obo2:OAE_0001195 + SIDER: C0476280 + + + + obo2:OAE_0001196 + Bacterial infection AE that results in the patient being infected with the Mycoplasma bacteria + + + + obo2:OAE_0001196 + SZ, SS, YH + + + + obo2:OAE_0001196 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/15142464 + + + + obo2:OAE_0001196 + mycoplasma infection AE + + + + obo2:OAE_0001196 + MedDRA: 10061300 + + + + obo2:OAE_0001198 + a hematopoietic system AE that has an outcome of ineffective production of the myeloid class of blood cells + + + + obo2:OAE_0001198 + SZ, SS, YH + + + + obo2:OAE_0001198 + WEB: http://www.nlm.nih.gov/medlineplus/myelodysplasticsyndromes.html + + + + obo2:OAE_0001198 + myelodysplastic syndrome AE + + + + obo2:OAE_0001198 + HPO: HP_0006730 + + + + obo2:OAE_0001198 + MedDRA: 10028533 + + + + obo2:OAE_0001198 + SIDER: C0026986 + + + + obo2:OAE_0001199 + a hematopoietic system AE that has an outcome of bone marrow being replaced by scar tissue + + + + obo2:OAE_0001199 + SZ, SS, YH + + + + obo2:OAE_0001199 + WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001558/ + + + + obo2:OAE_0001199 + myelofibrosis AE + + + + obo2:OAE_0001199 + HPO: HP_0011974 + + + + obo2:OAE_0001199 + MedDRA: 10028537 + + + + obo2:OAE_0001199 + SIDER: C0026987 + + + + obo2:OAE_0001200 + a cardiac disorder AE that has an outcome of an imbalance between myocardial oxygen supply and demand + + + + obo2:OAE_0001200 + SZ, SS, YH + + + + obo2:OAE_0001200 + myocardial ischaemia AE + + + + obo2:OAE_0001200 + WEB: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1768241/ + + + + obo2:OAE_0001200 + myocardial ischemia AE + + + + obo2:OAE_0001200 + HPO: HP_0001637 + + + + obo2:OAE_0001200 + MedDRA: 10028600 + + + + obo2:OAE_0001200 + SIDER: C0151744 + + + + obo2:OAE_0001201 + an inflammation AE that has an outcome of inflammation of the heart muscle + + + + obo2:OAE_0001201 + SZ, SS, YH + + + + obo2:OAE_0001201 + WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001204/ + + + + obo2:OAE_0001201 + myocarditis AE + + + + obo2:OAE_0001201 + MedDRA: 10028606 + + + + obo2:OAE_0001202 + a bone disorder AE, most commonly fungal infection, that is characterized by discoloration, painful swelling, pits, lesions and brown bands + + + + obo2:OAE_0001202 + SZ, SS, YH + + + + obo2:OAE_0001202 + WEB: http://www.umm.edu/altmed/articles/nail-disorders-000116.htm + + + + obo2:OAE_0001202 + nail disorder AE + + + + obo2:OAE_0001202 + HPO: HP_0001597 + + + + obo2:OAE_0001202 + MedDRA: 10028694 + + + + obo2:OAE_0001202 + SIDER: C0027339 + + + + obo2:OAE_0001203 + a nail AE around the nail area, tends to be fungal + + + + obo2:OAE_0001203 + SZ, SS, YH + + + + obo2:OAE_0001203 + paronychia AE + + + + obo2:OAE_0001203 + WEB: http://www.emedicinehealth.com/paronychia_nail_infection/article_em.htm + + + + obo2:OAE_0001203 + nail infection AE + + + + obo2:OAE_0001203 + HPO: HP_0008396 + + + + obo2:OAE_0001203 + MedDRA: 10061304 + + + + obo2:OAE_0001203 + SIDER: C0343026 + + + + obo2:OAE_0001204 + Cell death AE that results in necrosis occurring due to a local deprivation of blood + + + + obo2:OAE_0001204 + SZ, SS, YH + + + + obo2:OAE_0001204 + necrosis ischaemic AE + + + + obo2:OAE_0001204 + WEB: http://medical-dictionary.thefreedictionary.com/ischemic+necrosis + + + + obo2:OAE_0001204 + necrosis ischemic AE + + + + obo2:OAE_0001204 + MedDRA: 10028862 + + + + obo2:OAE_0001205 + a progressive tumor AE that has an outcome of an abnormal mass of cells that metastasizes + + + + obo2:OAE_0001205 + SZ, SS, YH + + + + obo2:OAE_0001205 + WEB: http://medical-dictionary.thefreedictionary.com/malignant+neoplasm + + + + obo2:OAE_0001205 + neoplasm malignant AE + + + + obo2:OAE_0001205 + HPO: HP_0002664 + + + + obo2:OAE_0001205 + MedDRA: 10028997 + + + + obo2:OAE_0001205 + SIDER: C0006826 + + + + obo2:OAE_0001206 + an tumor AE that has an outcome of growth of the neoplasm, an abnormal mass of tissue in the body + + + + obo2:OAE_0001206 + SZ, SS, YH + + + + obo2:OAE_0001206 + WEB: Primary Source: http://medical-dictionary.thefreedictionary.com/neoplasm Secondary Source: http://www.ncbi.nlm.nih.gov/pubmed/23263846 + + + + obo2:OAE_0001206 + neoplasm progression AE + + + + obo2:OAE_0001206 + MedDRA: 10061309 + + + + obo2:OAE_0001207 + a tumor AE that has an outcome of microscopic cells of the original neoplasm escaping therapeutic intervention and later becoming clinically visible at the original site + + + + obo2:OAE_0001207 + SZ, SS, YH + + + + obo2:OAE_0001207 + neoplasm recurrence AE + + + + obo2:OAE_0001207 + MedDRA: 10061864 + + + + obo2:OAE_0001208 + Kidney disorder AE that results in an increased amount of calcium deposits in the renal parenchyma + + + + obo2:OAE_0001208 + SZ, SS, YH + + + + obo2:OAE_0001208 + WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001522/ + + + + obo2:OAE_0001208 + nephrocalcinosis AE + + + + obo2:OAE_0001208 + HPO: HP_0000121 + + + + obo2:OAE_0001208 + MedDRA: 10029146 + + + + obo2:OAE_0001208 + SIDER: C0027709 + + + + obo2:OAE_0001209 + a kidney disorder AE that has an outcome of a group of symptoms that include protein in the urine, low blood protein levels, high cholesterol levels, high triglyceride levels and swelling + + + + obo2:OAE_0001209 + SZ, SS, YH + + + + obo2:OAE_0001209 + WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001520/ + + + + obo2:OAE_0001209 + nephrotic syndrome AE + + + + obo2:OAE_0001209 + HPO: HP_0000100 + + + + obo2:OAE_0001209 + MedDRA: 10029164 + + + + obo2:OAE_0001209 + SIDER: C0027726 + + + + obo2:OAE_0001210 + a neuropathy AE that has an outcome of direct pressure on a single nerve, can cause pain, tingling and muscle weakness + + + + obo2:OAE_0001210 + SZ, SS, YH + + + + obo2:OAE_0001210 + WEB: http://nerve.wustl.edu/nd_compression.php + + + + obo2:OAE_0001210 + nerve compression AE + + + + obo2:OAE_0001210 + MedDRA: 10029174 + + + + obo2:OAE_0001211 + Nervous System AE that results in pressure on a root nerve + + + + obo2:OAE_0001211 + SZ, SS, YH + + + + obo2:OAE_0001211 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/6719259 + + + + obo2:OAE_0001211 + nerve root compression AE + + + + obo2:OAE_0001211 + MedDRA: 10061866 + + + + obo2:OAE_0001212 + Nervous system AE that results in a lesion occurring on a nerve root + + + + obo2:OAE_0001212 + SZ, SS, YH + + + + obo2:OAE_0001212 + nerve root lesion AE + + + + obo2:OAE_0001212 + MedDRA: 10029188 + + + + obo2:OAE_0001213 + A neurological AE that has an outcome of inability of maintaining neurological functions. + + + + obo2:OAE_0001213 + SZ, SS, YH + + + + obo2:OAE_0001213 + WEB: http://medical-dictionary.thefreedictionary.com/decompensation + + + + obo2:OAE_0001213 + neurological decompensation AE + + + + obo2:OAE_0001213 + MedDRA: 10068357 + + + + obo2:OAE_0001214 + Tumor AE that results in a tumor growing on nerve tissue + + + + obo2:OAE_0001214 + SZ, SS, YH + + + + obo2:OAE_0001214 + WEB: http://medical-dictionary.thefreedictionary.com/neuroma + + + + obo2:OAE_0001214 + neuroma AE + + + + obo2:OAE_0001214 + HPO: HP_0009588 + + + + obo2:OAE_0001214 + MedDRA: 10029308 + + + + obo2:OAE_0001214 + SIDER: C0027858 + + + + obo2:OAE_0001215 + a nervous system AE that alters the normal activity of the nervous system due to exposure to neurotoxins, causes damage to nervous tissue + + + + obo2:OAE_0001215 + SZ, SS, YH + + + + obo2:OAE_0001215 + WEB: http://en.wikipedia.org/wiki/Neurotoxicity + + + + obo2:OAE_0001215 + neurotoxicity AE + + + + obo2:OAE_0001215 + MedDRA: 10029350 + + + + obo2:OAE_0001216 + an immunolgy and allergy investigation result abnormal AE that is chracterized by neutralising antibodies detected in the blood + + + + obo2:OAE_0001216 + SZ, SS, YH, EB + + + + obo2:OAE_0001216 + neutralising antibodies positive AE + + + + obo2:OAE_0001216 + WEB: http://medical-dictionary.thefreedictionary.com/neutralizing+antibody + + + + obo2:OAE_0001216 + neutralizing antibodies positive AE + + + + obo2:OAE_0001216 + MedDRA: 10064980 + + + + obo2:OAE_0001217 + a hematopoietic system AE that compromises the immune system where the number of neutrophil granulocytes, a type of white blood cell, is abnormally low. Makes body vulnerable to bacterial and fungal infections + + + + obo2:OAE_0001217 + SZ, SS, YH + + + + obo2:OAE_0001217 + WEB: http://medical-dictionary.thefreedictionary.com/neutropenia + + + + obo2:OAE_0001217 + neutropenia AE + + + + obo2:OAE_0001217 + HPO: HP_0001875 + + + + obo2:OAE_0001217 + MedDRA: 10029354 + + + + obo2:OAE_0001217 + SIDER: C0027947 + + + + obo2:OAE_0001218 + a neutropenia AE that results in an abnormal number of neutrophils in a newborn infant + + + + obo2:OAE_0001218 + SZ, SS, YH + + + + obo2:OAE_0001218 + WEB: http://www.thefreedictionary.com/neonatal, http://medical-dictionary.thefreedictionary.com/neonatal+neutropenia,+alloimmune + + + + obo2:OAE_0001218 + neutropenia neonatal AE + + + + obo2:OAE_0001218 + MedDRA: 10029358 + + + + obo2:OAE_0001219 + a gastrointestinal Inflammation AE that results in the cecum, part of the large intestine, being inflamed + + + + obo2:OAE_0001219 + SZ, SS, YH + + + + obo2:OAE_0001219 + WEB: http://emedicine.medscape.com/article/183791-overview + + + + obo2:OAE_0001219 + neutropenic colitis AE + + + + obo2:OAE_0001219 + HPO: HP_0002583 + + + + obo2:OAE_0001219 + MedDRA: 10062959 + + + + obo2:OAE_0001219 + SIDER: C0400823 + + + + obo2:OAE_0001220 + a sepsis AE caused by neutropenia or an abnormally low neutrophil count + + + + obo2:OAE_0001220 + SZ, SS, YH + + + + obo2:OAE_0001220 + WEB: http://guidance.nice.org.uk/CG151 + + + + obo2:OAE_0001220 + neutropenic sepsis AE + + + + obo2:OAE_0001220 + MedDRA: 10049151 + + + + obo2:OAE_0001221 + a white blood cell profile abnormal AE that results in an abnormal number of neutrophil granulocytes, a type of white blood cell (outside the normal range of ~1700 per microliter) + + + + obo2:OAE_0001221 + SZ, SS, YH, EB + + + + obo2:OAE_0001221 + WEB: http://www.medterms.com/script/main/art.asp?articlekey=20030 + + + + obo2:OAE_0001221 + neutrophil count abnormal AE + + + + obo2:OAE_0001221 + MedDRA: 10061313 + + + + obo2:OAE_0001222 + a neutrophil count abnormal AE that has an outcome of decreased neutrophil count + + + + obo2:OAE_0001222 + SZ, SS, YH, EB + + + + obo2:OAE_0001222 + neutropenia AE + + + + obo2:OAE_0001222 + WEB: http://www.mayoclinic.com/health/neutropenia/MY00110 + + + + obo2:OAE_0001222 + neutrophil count decreased AE + + + + obo2:OAE_0001222 + HPO: HP_0011991 + + + + obo2:OAE_0001222 + MedDRA: 10029366 + + + + obo2:OAE_0001222 + SIDER: NA + + + + obo2:OAE_0001223 + a neutrophil percentage abnormal AE that has an outcome of increase in percentage of neutrophils, a type of white blood cell + + + + obo2:OAE_0001223 + SZ, SS, YH + + + + obo2:OAE_0001223 + WEB: http://medical-dictionary.thefreedictionary.com/neutrophil + + + + obo2:OAE_0001223 + neutrophil percentage increased AE + + + + obo2:OAE_0001223 + MedDRA: 10052224 + + + + obo2:OAE_0001224 + a hyperplasia AE that has an outcome of liver/biliary system cell overproduction, associated with portal hypertension + + + + obo2:OAE_0001224 + SZ, SS, YH + + + + obo2:OAE_0001224 + WEB: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3070012/ + + + + obo2:OAE_0001224 + nodular regenerative hyperplasia AE + + + + obo2:OAE_0001224 + MedDRA: 10051081 + + + + obo2:OAE_0001225 + a lung disorder AE that has an outcome of adenocarcinomas in an outer area of the lung, squamous cell carcinomas in the center of the lung or large cell carcinomas in any part of the lung + + + + obo2:OAE_0001225 + SZ, SS, YH + + + + obo2:OAE_0001225 + WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0004462/ + + + + obo2:OAE_0001225 + non-small cell lung cancer AE + + + + obo2:OAE_0001225 + MedDRA: 10061873 + + + + obo2:OAE_0001226 + a lung disorder AE that results in the patient suffering from lung cancer at state IV + + + + obo2:OAE_0001226 + SZ, SS, YH + + + + obo2:OAE_0001226 + non-small cell lung cancer stage iv AE + + + + obo2:OAE_0001226 + MedDRA: 10029522 + + + + obo2:OAE_0001227 + an anemia AE that has an outcome of insufficient numbers of red blood cells despite a normal concentration of hemoglobin in the cells + + + + obo2:OAE_0001227 + SZ, SS, YH + + + + obo2:OAE_0001227 + normochromic normocytic anaemia AE + + + + obo2:OAE_0001227 + WEB: http://medical-dictionary.thefreedictionary.com/normocytic+normochromic+anemia + + + + obo2:OAE_0001227 + normochromic normocytic anemia AE + + + + obo2:OAE_0001227 + HPO: HP_0001897 + + + + obo2:OAE_0001227 + MedDRA: 10029783 + + + + obo2:OAE_0001227 + SIDER: C0271899 + + + + obo2:OAE_0001229 + a respiratory system AE that has an outcome of chronic bronchitis or emphysema which causes the airways to narrow over time + + + + obo2:OAE_0001229 + SZ, SS, YH + + + + obo2:OAE_0001229 + WEB: http://www.medicinenet.com/chronic_obstructive_pulmonary_disease_copd/article.htm + + + + obo2:OAE_0001229 + obstructive airways disorder AE + + + + obo2:OAE_0001229 + HPO: HP_0006536 + + + + obo2:OAE_0001229 + MedDRA: 10061877 + + + + obo2:OAE_0001229 + SIDER: C0600260 + + + + obo2:OAE_0001230 + a gastrointestinal investigation result abnormal AE that results in blood that is present in amounts too small to be seen and can be detected only by chemical analysis or microscopic examination + + + + + obo2:OAE_0001230 + SZ, SS, YH, EB + + + + obo2:OAE_0001230 + WEB: http://dictionary.reference.com/browse/occult+blood + + + + obo2:OAE_0001230 + WEB: http://medical-dictionary.thefreedictionary.com/occult+blood\ + + + + obo2:OAE_0001230 + occult blood AE + + + + obo2:OAE_0001230 + MedDRA: 10061878 + + + + obo2:OAE_0001231 + a gustatory system AE that has an outcome of painful swallowing in the mouth or esophagus. Can lead to weight loss. + + + + obo2:OAE_0001231 + SZ, SS, YH + + + + obo2:OAE_0001231 + WEB: http://medical-dictionary.thefreedictionary.com/odynophagia + + + + obo2:OAE_0001231 + odynophagia AE + + + + obo2:OAE_0001231 + MedDRA: 10030094 + + + + obo2:OAE_0001232 + a pain AE located in the esophagus + + + + obo2:OAE_0001232 + SZ, SS, YH + + + + obo2:OAE_0001232 + oesophageal pain AE + + + + obo2:OAE_0001232 + WEB: http://medical-dictionary.thefreedictionary.com/oesophageal + + + + obo2:OAE_0001232 + esophageal pain AE + + + + obo2:OAE_0001232 + HPO: HP_0010833 + + + + obo2:OAE_0001232 + MedDRA: 10030180 + + + + obo2:OAE_0001232 + SIDER: C0221727 + + + + obo2:OAE_0001233 + a digestive system AE that results in a narrowing in the esophagus caused by buildup of scar tissue or by a congenital defect + + + + obo2:OAE_0001233 + SZ, SS, YH + + + + obo2:OAE_0001233 + oesophageal stenosis AE + + + + obo2:OAE_0001233 + WEB: http://esophagealstenosis.org/ + + + + obo2:OAE_0001233 + esophageal stenosis AE + + + + obo2:OAE_0001233 + HPO: HP_0010450 + + + + obo2:OAE_0001233 + MedDRA: 10030194 + + + + obo2:OAE_0001233 + SIDER: C0014866 + + + + obo2:OAE_0001234 + a digestive system AE located in the esophagus, can present with heartburn, and nausea + + + + obo2:OAE_0001234 + SZ, SS, YH + + + + obo2:OAE_0001234 + oesophagitis AE + + + + obo2:OAE_0001234 + WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0002138/ + + + + obo2:OAE_0001234 + esophagitis AE + + + + obo2:OAE_0001234 + HPO: HP_0100633 + + + + obo2:OAE_0001234 + MedDRA: 10030216 + + + + obo2:OAE_0001234 + SIDER: C0014868 + + + + obo2:OAE_0001235 + a reproductive system AE that has an outcome of insufficient placenta, the baby may get less oxygen and nutrients + + + + obo2:OAE_0001235 + SZ, SS, YH + + + + obo2:OAE_0001235 + placental dysfunction AE + + + + obo2:OAE_0001235 + WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0002455/ + + + + obo2:OAE_0001235 + oligohydramnios AE + + + + obo2:OAE_0001235 + HPO: HP_0001562 + + + + obo2:OAE_0001235 + MedDRA: 10030289 + + + + obo2:OAE_0001235 + SIDER: C0079924 + + + + obo2:OAE_0001236 + a nail disorder AE that has an outcome of pain in the fingernails or toenails + + + + obo2:OAE_0001236 + SZ, SS, YH + + + + obo2:OAE_0001236 + WEB: http://dictionary.reference.com/browse/onychalgia + + + + obo2:OAE_0001236 + onychalgia AE + + + + obo2:OAE_0001236 + MedDRA: 10064251 + + + + obo2:OAE_0001237 + a nail disorder AE that results in the breaking of the fingernails or toenails + + + + obo2:OAE_0001237 + SZ, SS, YH + + + + obo2:OAE_0001237 + WEB: http://medical-dictionary.thefreedictionary.com/onychoclasis + + + + obo2:OAE_0001237 + onychoclasis AE + + + + obo2:OAE_0001237 + HPO: HP_0001808 + + + + obo2:OAE_0001237 + MedDRA: 10048886 + + + + obo2:OAE_0001237 + SIDER: C0546956 + + + + obo2:OAE_0001238 + a nail disorder AE that results in the nail separating from the nail bed starting at distal or lateral attachment + + + + obo2:OAE_0001238 + SZ, SS, YH + + + + obo2:OAE_0001238 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/16422468 + + + + obo2:OAE_0001238 + onycholysis AE + + + + obo2:OAE_0001238 + HPO: HP_0008400 + + + + obo2:OAE_0001238 + MedDRA: 10030337 + + + + obo2:OAE_0001238 + SIDER: C0085661 + + + + obo2:OAE_0001240 + a nail disorder AE that results in nails spontaneously shedding starting from the proximal end + + + + obo2:OAE_0001240 + SZ, SS, YH + + + + obo2:OAE_0001240 + WEB: http://medical-dictionary.thefreedictionary.com/onychomadesis + + + + obo2:OAE_0001240 + onychomadesis AE + + + + obo2:OAE_0001240 + MedDRA: 10049274 + + + + obo2:OAE_0001241 + Eye disorder AE that results in chronic glaucoma progressing slowly + + + + obo2:OAE_0001241 + SZ, SS, YH + + + + obo2:OAE_0001241 + WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0002587/ + + + + obo2:OAE_0001241 + open angle glaucoma AE + + + + obo2:OAE_0001241 + HPO: HP_0000501 + + + + obo2:OAE_0001241 + MedDRA: 10030348 + + + + obo2:OAE_0001241 + SIDER: C0017612 + + + + obo2:OAE_0001242 + a toxicology drug screen result abnormal AE that results in the patient testing positive for opiates + + + + obo2:OAE_0001242 + SZ, SS, YH, EB + + + + obo2:OAE_0001242 + opiates positive AE + + + + obo2:OAE_0001242 + MedDRA: 10063232 + + + + obo2:OAE_0001243 + a digestive system AE that has an outcome of a fungal infection located in the mouth caused by the candida fungus + + + + obo2:OAE_0001243 + SZ, SS, YH + + + + obo2:OAE_0001243 + thrush AE + + + + obo2:OAE_0001243 + WEB: http://www.medicinenet.com/thrush/article.htm + + + + obo2:OAE_0001243 + oral candidiasis AE + + + + obo2:OAE_0001243 + HPO: HP_0009098 + + + + obo2:OAE_0001243 + MedDRA: 10030963 + + + + obo2:OAE_0001243 + SIDER: C0006849 + + + + obo2:OAE_0001244 + a digestive system AE that has an outcome of fistula, or an abnormal connection between two epithelium-lined organs or vessels, located in the oral cavity + + + + obo2:OAE_0001244 + SZ, SS, YH + + + + obo2:OAE_0001244 + WEB: http://medical-dictionary.thefreedictionary.com/fistula + + + + obo2:OAE_0001244 + oral cavity fistula AE + + + + obo2:OAE_0001244 + MedDRA: 10065720 + + + + obo2:OAE_0001245 + a digestive system AE that has an outcome of a viral infection located in the mouth caused by herpes simplex virus, causes painful sores + + + + obo2:OAE_0001245 + SZ, SS, YH + + + + obo2:OAE_0001245 + WEB: http://www.emedicinehealth.com/oral_herpes/article_em.htm + + + + obo2:OAE_0001245 + oral herpes AE + + + + obo2:OAE_0001245 + MedDRA: 10067152 + + + + obo2:OAE_0001246 + a gustatory system AE that has an outcome of a decreased amount of substance in food or drinking water ingested + + + + obo2:OAE_0001246 + SZ, SS, YH + + + + obo2:OAE_0001246 + oral intake reduced AE + + + + obo2:OAE_0001247 + Digestive System AE that results in oral lesions + + + + obo2:OAE_0001247 + SZ, SS, YH + + + + obo2:OAE_0001247 + oral mucosa erosion AE + + + + obo2:OAE_0001247 + MedDRA: 10064594 + + + + obo2:OAE_0001248 + an erythema AE that results in redness of the oral mucosa area + + + + obo2:OAE_0001248 + SZ, SS, YH + + + + obo2:OAE_0001248 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/17767983 + + + + obo2:OAE_0001248 + oral mucosal erythema AE + + + + obo2:OAE_0001248 + MedDRA: 10067418 + + + + obo2:OAE_0001249 + a pain AE located in the oral cavity, pertaining to the mouth + + + + obo2:OAE_0001249 + SZ, SS, YH + + + + obo2:OAE_0001249 + WEB: http://medical-dictionary.thefreedictionary.com/oral + + + + obo2:OAE_0001249 + oral pain AE + + + + obo2:OAE_0001249 + HPO: HP_0010833 + + + + obo2:OAE_0001249 + MedDRA: 10031009 + + + + obo2:OAE_0001249 + SIDER: C0221776 + + + + obo2:OAE_0001250 + a digestive system AE that has an outcome of disease in the soft tissue of the mouth or systemic diseases involving the mouth + + + + obo2:OAE_0001250 + SZ, SS, YH + + + + obo2:OAE_0001250 + WEB: http://clinicaltrials.gov/show/NCT00001601 + + + + obo2:OAE_0001250 + oral soft tissue disorder AE + + + + obo2:OAE_0001250 + MedDRA: 10031015 + + + + obo2:OAE_0001252 + an edema that results in swelling around the eyes + + + + obo2:OAE_0001252 + SZ, SS, YH + + + + obo2:OAE_0001252 + orbital oedema AE + + + + obo2:OAE_0001252 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/7654583 + + + + obo2:OAE_0001252 + orbital edema AE + + + + obo2:OAE_0001252 + HPO: HP_0100539 + + + + obo2:OAE_0001252 + MedDRA: 10031051 + + + + obo2:OAE_0001252 + SIDER: C0424813 + + + + obo2:OAE_0001253 + a pneumonia AE that results in the healing process being characterized by organization and cicatrizaion of the exudate rather than resolution + + + + obo2:OAE_0001253 + SZ, SS, YH + + + + obo2:OAE_0001253 + organising pneumonia AE + + + + obo2:OAE_0001253 + WEB: Primary Source: http://thorax.bmj.com/content/55/4/318.full Secondary Source: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1745738/ + + + + obo2:OAE_0001253 + organizing pneumonia AE + + + + obo2:OAE_0001253 + HPO: HP_0002090 + + + + obo2:OAE_0001253 + MedDRA: 10067472 + + + + obo2:OAE_0001253 + SIDER: C0264383 + + + + obo2:OAE_0001254 + Digestive System AE that is characterized by fungus (mainly Candida albicans, but can be other Candida species - C.glabrata, C. tropicalis, C. krusei) in throat or mouth (Thrush) + + + + obo2:OAE_0001254 + SZ, SS, YH + + + + obo2:OAE_0001254 + WEB: http://www.cdc.gov/fungal/candidiasis/thrush/ + + + + obo2:OAE_0001254 + oropharyngeal candidiasis AE + + + + obo2:OAE_0001254 + HPO: HP_0009098 + + + + obo2:OAE_0001254 + MedDRA: 10050346 + + + + obo2:OAE_0001254 + SIDER: C0919659 + + + + obo2:OAE_0001255 + a digestive system AE that has an outcome of muscle spasm in the oropharynx area + + + + obo2:OAE_0001255 + SZ, SS, YH + + + + obo2:OAE_0001255 + WEB: http://medical-dictionary.thefreedictionary.com/Oropharyngeal+airway + + + + obo2:OAE_0001255 + oropharyngeal spasm AE + + + + obo2:OAE_0001255 + HPO: HP_0003739 + + + + obo2:OAE_0001255 + MedDRA: 10031111 + + + + obo2:OAE_0001255 + SIDER: C0234952 + + + + obo2:OAE_0001256 + a bone disorder AE that has an outcome of bacterial infection in the bone + + + + obo2:OAE_0001256 + SZ, SS, YH + + + + obo2:OAE_0001256 + WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001473/ + + + + obo2:OAE_0001256 + osteomyelitis AE + + + + obo2:OAE_0001256 + HPO: HP_0007626 + + + + obo2:OAE_0001256 + MedDRA: 10031252 + + + + obo2:OAE_0001256 + SIDER: C0029443 + + + + obo2:OAE_0001257 + a bone disorder AE that has an outcome of chronic infection of the bone or bone marrow + + + + obo2:OAE_0001257 + SZ, SS, YH + + + + obo2:OAE_0001257 + WEB: Primary Source: http://www.posna.org/education/StudyGuide/chronicOsteomyelitis.asp Secondary Source: http://www.ncbi.nlm.nih.gov/pubmed/20471296 + + + + obo2:OAE_0001257 + osteomyelitis chronic AE + + + + obo2:OAE_0001257 + MedDRA: 10031256 + + + + obo2:OAE_0001259 + a bone disorder AE that has an outcome of bone death due to the loss of blood supply, leading to pain and arthritis + + + + obo2:OAE_0001259 + SZ, SS, YH + + + + obo2:OAE_0001259 + WEB: http://www.nlm.nih.gov/medlineplus/osteonecrosis.html + + + + obo2:OAE_0001259 + osteonecrosis AE + + + + obo2:OAE_0001259 + HPO: HP_0010885 + + + + obo2:OAE_0001259 + MedDRA: 10031264 + + + + obo2:OAE_0001259 + SIDER: C0029445 + + + + obo2:OAE_0001260 + a bone disorder AE that has an outcome of disease that affects the maxilla and the mandible, characterized through exposure of the bone through lesions in the gingiva that do not heal + + + + obo2:OAE_0001260 + SZ, SS, YH + + + + obo2:OAE_0001260 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/16702591 + + + + obo2:OAE_0001260 + osteonecrosis of jaw AE + + + + obo2:OAE_0001260 + HPO: HP_0010885 + + + + obo2:OAE_0001260 + MedDRA: 10064658 + + + + obo2:OAE_0001260 + SIDER: C1401381 + + + + obo2:OAE_0001261 + a bone disorder AE that has an outcome of necrosis or death of bone as a result of exposure to radiation + + + + obo2:OAE_0001261 + SZ, SS, YH + + + + obo2:OAE_0001261 + WEB: http://medical-dictionary.thefreedictionary.com/osteoradionecrosis + + + + obo2:OAE_0001261 + osteoradionecrosis AE + + + + obo2:OAE_0001261 + MedDRA: 10067352 + + + + obo2:OAE_0001262 + a bone disorder AE that has an outcome of elevation in bone density + + + + obo2:OAE_0001262 + SZ, SS, YH + + + + obo2:OAE_0001262 + WEB: http://medical-dictionary.thefreedictionary.com/osteosclerosis + + + + obo2:OAE_0001262 + osteosclerosis AE + + + + obo2:OAE_0001262 + HPO: HP_0011001 + + + + obo2:OAE_0001262 + MedDRA: 10031298 + + + + obo2:OAE_0001262 + SIDER: C0029464 + + + + obo2:OAE_0001263 + a female reproductive system AE that has an outcome of cancer that starts in the ovaries, female reproductive organs that produce eggs + + + + obo2:OAE_0001263 + SZ, SS, YH + + + + obo2:OAE_0001263 + WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001891/ + + + + obo2:OAE_0001263 + ovarian cancer AE + + + + obo2:OAE_0001263 + HPO: HP_0100615 + + + + obo2:OAE_0001263 + MedDRA: 10033128 + + + + obo2:OAE_0001263 + SIDER: C1140680 + + + + obo2:OAE_0001264 + Female reproductive system AE that results in an enlargement of the patient's ovaries + + + + obo2:OAE_0001264 + SZ, SS, YH + + + + obo2:OAE_0001264 + ovarian enlargement AE + + + + obo2:OAE_0001264 + MedDRA: 10033157 + + + + obo2:OAE_0001265 + a female reproductive system AE that has an outcome of an abnormal mass appearing in the patient's ovaries + + + + obo2:OAE_0001265 + SZ, SS, YH + + + + obo2:OAE_0001265 + ovarian mass AE + + + + obo2:OAE_0001265 + MedDRA: 10058823 + + + + obo2:OAE_0001267 + an oxygen saturation abnormal AE that has an outcome of a decreased percentage of hemoglobin binding sites in the bloodstream occupied by oxygen + + + + obo2:OAE_0001267 + SZ, SS, YH, EB + + + + obo2:OAE_0001267 + WEB: Primary Source: http://www.mayoclinic.com/health/hypoxemia/MY00219\ Secondary Source: http://medical-dictionary.thefreedictionary.com/oxygen+saturation + + + + obo2:OAE_0001267 + oxygen saturation decreased AE + + + + obo2:OAE_0001267 + MedDRA: 10033318 + + + + obo2:OAE_0001268 + a pain AE that has an outcome of pain in the set of bones that hold the teeth + + + + obo2:OAE_0001268 + SZ, SS, YH + + + + obo2:OAE_0001268 + pain in jaw AE + + + + obo2:OAE_0001268 + HPO: HP_0200023 + + + + obo2:OAE_0001268 + MedDRA: 10033433 + + + + obo2:OAE_0001268 + SIDER: C0236000 + + + + obo2:OAE_0001269 + a pain AE located in the skin + + + + obo2:OAE_0001269 + SZ, SS, YH + + + + obo2:OAE_0001269 + pain of skin AE + + + + obo2:OAE_0001269 + HPO: HP_0010833 + + + + obo2:OAE_0001269 + MedDRA: 10033474 + + + + obo2:OAE_0001269 + SIDER: C0241136 + + + + obo2:OAE_0001270 + a erythema AE that is characterized by the reddening of the palms at the thenar and hypothenar eminences + + + + obo2:OAE_0001270 + SZ, SS, YH + + + + obo2:OAE_0001270 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/18039017 + + + + obo2:OAE_0001270 + palmar erythema AE + + + + obo2:OAE_0001270 + HPO: HP_0007548 + + + + obo2:OAE_0001270 + MedDRA: 10033551 + + + + obo2:OAE_0001270 + SIDER: C0014745 + + + + obo2:OAE_0001271 + a skin AE generally caused by chemotherapy that is characterized by the palms and soles becoming red, swollen, numb and the skin peeling. + + + + obo2:OAE_0001271 + SZ, SS, YH + + + + obo2:OAE_0001271 + Hand Food Syndrome AE + + + + obo2:OAE_0001271 + palmar-plantar erythrodysaesthesia syndrome AE + + + + obo2:OAE_0001271 + WEB: http://news.cancerconnect.com/hand-foot-syndrome-palmar-plantar-erythrodysesthesia/ + + + + obo2:OAE_0001271 + palmar-plantar erythrodysesthesia syndrome AE + + + + obo2:OAE_0001271 + MedDRA: 10033553 + + + + obo2:OAE_0001272 + Tumor AE that results in an undifferentiated growth in the patient's pancreas + + + + obo2:OAE_0001272 + SZ, SS, YH + + + + obo2:OAE_0001272 + WEB: Primary Source: http://stanfordhospital.org/digestivehealth/pancreas/conditions/pancreatic-cysts-symptoms-diagnosis.html Secondary Source: http://www.ncbi.nlm.nih.gov/pubmed/22855657 + + + + obo2:OAE_0001272 + pancreatic mass AE + + + + obo2:OAE_0001272 + MedDRA: 10049082 + + + + obo2:OAE_0001273 + a pancreatitis AE that has an outcome of sudden inflammation of the pancreas + + + + obo2:OAE_0001273 + SZ, SS, YH + + + + obo2:OAE_0001273 + WEB: http://www.nlm.nih.gov/medlineplus/ency/article/000287.htm + + + + obo2:OAE_0001273 + pancreatitis acute AE + + + + obo2:OAE_0001273 + HPO: HP_0001735 + + + + obo2:OAE_0001273 + MedDRA: 10033647 + + + + obo2:OAE_0001273 + SIDER: C0001339 + + + + obo2:OAE_0001274 + a pancreatitis AE that results in pancreatitis reoccurring in the patient + + + + obo2:OAE_0001274 + SZ, SS, YH + + + + obo2:OAE_0001274 + WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0002129/ + + + + obo2:OAE_0001274 + pancreatitis relapsing AE + + + + obo2:OAE_0001274 + MedDRA: 10033657 + + + + obo2:OAE_0001275 + Hematopoietic System AE that results in a reduction in the amount of red and white blood cells and platelets in blood + + + + obo2:OAE_0001275 + SZ, SS, YH + + + + obo2:OAE_0001275 + WEB: http://medical-dictionary.thefreedictionary.com/pancytopenia + + + + obo2:OAE_0001275 + pancytopenia AE + + + + obo2:OAE_0001275 + HPO: HP_0001876 + + + + obo2:OAE_0001275 + MedDRA: 10033661 + + + + obo2:OAE_0001275 + SIDER: C0030312 + + + + obo2:OAE_0001276 + an edema AE that has an outcome of optic disc swelling that is caused by increased intracranial pressure + + + + obo2:OAE_0001276 + SZ, SS, YH + + + + obo2:OAE_0001276 + WEB: http://medical-dictionary.thefreedictionary.com/Papilloedema + + + + obo2:OAE_0001276 + papilloedema AE + + + + obo2:OAE_0001276 + HPO: HP_0001085 + + + + obo2:OAE_0001276 + MedDRA: 10033712 + + + + obo2:OAE_0001276 + SIDER: C0030353 + + + + obo2:OAE_0001278 + Tumor AE that results in a benign tumor in the parathyroid region + + + + obo2:OAE_0001278 + SZ, SS, YH + + + + obo2:OAE_0001278 + parathyroid tumour benign AE + + + + obo2:OAE_0001278 + WEB: http://www.nlm.nih.gov/medlineplus/ency/article/001188.htm + + + + obo2:OAE_0001278 + parathyroid tumor benign AE + + + + obo2:OAE_0001278 + MedDRA: 10033964 + + + + obo2:OAE_0001279 + a nail AE where injuries around the nail cause painful swelling and blisters + + + + obo2:OAE_0001279 + SZ, SS, YH + + + + obo2:OAE_0001279 + nail infection AE + + + + obo2:OAE_0001279 + WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0002416/ + + + + obo2:OAE_0001279 + paronychia AE + + + + obo2:OAE_0001279 + HPO: HP_0001818 + + + + obo2:OAE_0001279 + MedDRA: 10034016 + + + + obo2:OAE_0001279 + SIDER: C0030578 + + + + obo2:OAE_0001280 + a bone disorder AE that has an outcome of a broken bone caused by disease leading to weakenss of the bone, commonly osteoporosis + + + + obo2:OAE_0001280 + SZ, SS, YH + + + + obo2:OAE_0001280 + WEB: http://medical-dictionary.thefreedictionary.com/pathological+fracture + + + + obo2:OAE_0001280 + pathological fracture AE + + + + obo2:OAE_0001280 + HPO: HP_0005744 + + + + obo2:OAE_0001280 + MedDRA: 10034156 + + + + obo2:OAE_0001280 + SIDER: C0016663 + + + + obo2:OAE_0001281 + a cardiac disorder AE that has an outcome of abnormal accumulation of fluid in the pericardial cavity + + + + obo2:OAE_0001281 + SZ, SS, YH + + + + obo2:OAE_0001281 + WEB: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3110902/ + + + + obo2:OAE_0001281 + pericardial effusion AE + + + + obo2:OAE_0001281 + HPO: HP_0001698 + + + + obo2:OAE_0001281 + MedDRA: 10034474 + + + + obo2:OAE_0001281 + SIDER: C0031039 + + + + obo2:OAE_0001282 + a pain AE that results in soreness around the vaginal opening after giving birth + + + + obo2:OAE_0001282 + SZ, SS, YH + + + + obo2:OAE_0001282 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/20002420 + + + + obo2:OAE_0001282 + perineal pain AE + + + + obo2:OAE_0001282 + MedDRA: 10061339 + + + + obo2:OAE_0001283 + a digestive system AE that has an outcome of inflammation and infection that destroys the tissues that support the teeth, including the gums, the periodontal ligaments and the tooth sockets + + + + obo2:OAE_0001283 + SZ, SS, YH + + + + obo2:OAE_0001283 + gingivitis AE + + + + obo2:OAE_0001283 + WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0002051/ + + + + obo2:OAE_0001283 + 牙龈炎 + + + + obo2:OAE_0001283 + periodontal disease AE + + + + obo2:OAE_0001283 + HPO: HP_0000704 + + + + obo2:OAE_0001283 + MedDRA: 10034536 + + + + obo2:OAE_0001283 + SIDER: C0031090 + + + + obo2:OAE_0001284 + a bone disorder AE that has an outcome of inflammation and infection of the ligaments and bones that support the teeth + + + + obo2:OAE_0001284 + SZ, SS, YH + + + + obo2:OAE_0001284 + WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0002054/ + + + + obo2:OAE_0001284 + periodontitis AE + + + + obo2:OAE_0001284 + HPO: HP_0000704 + + + + obo2:OAE_0001284 + MedDRA: 10034539 + + + + obo2:OAE_0001284 + SIDER: C0031099 + + + + obo2:OAE_0001285 + an ischaemia AE that has an outcome of restriction in blood supply to tissues, causing a shortage of oxygen and glucose needed for cellular metabolism + + + + obo2:OAE_0001285 + SZ, SS, YH + + + + obo2:OAE_0001285 + peripheral ischaemia AE + + + + obo2:OAE_0001285 + WEB: Primary Source: http://www.medterms.com/script/main/art.asp?articlekey=4052 Secondary Source: http://www.ncbi.nlm.nih.gov/pubmed/6430442 + + + + obo2:OAE_0001285 + 外周缺血 + + + + obo2:OAE_0001285 + peripheral ischemia AE + + + + obo2:OAE_0001285 + HPO: HP_0002597 + + + + obo2:OAE_0001285 + MedDRA: 10034576 + + + + obo2:OAE_0001285 + SIDER: C0235490 + + + + obo2:OAE_0001286 + a motor neuropathy AE that results in damage to the nerves outside of the brain and spinal cord + + + + obo2:OAE_0001286 + SZ, SS, YH + + + + obo2:OAE_0001286 + WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001619/ + + + + obo2:OAE_0001286 + peripheral motor neuropathy AE + + + + obo2:OAE_0001286 + HPO: HP_0007178 + + + + obo2:OAE_0001286 + MedDRA: 10034580 + + + + obo2:OAE_0001286 + SIDER: C0235025 + + + + obo2:OAE_0001287 + a peripheral sensory neuropathy AE that results in the patient losing the ability to move or feel. + + + + obo2:OAE_0001287 + SZ, SS, YH + + + + obo2:OAE_0001287 + WEB: http://www.nlm.nih.gov/medlineplus/ency/article/000750.htm + + + + obo2:OAE_0001287 + Neuropathy can affect nerves that provide feeling (sensory neuropathy) or cause movement (motor neuropathy). It can also affect both, in which case it is called a sensorimotor neuropathy. + + + + obo2:OAE_0001287 + peripheral sensorimotor neuropathy AE + + + + obo2:OAE_0001287 + MedDRA: 10056673 + + + + obo2:OAE_0001288 + a sensory neuropathy AE that has an outcome of damaged nerves outside the brain and spinal cord + + + + obo2:OAE_0001288 + SZ, SS, YH + + + + obo2:OAE_0001288 + WEB: http://medical-dictionary.thefreedictionary.com/Peripheral+sensory+neuropathy + + + + obo2:OAE_0001288 + peripheral sensory neuropathy AE + + + + obo2:OAE_0001288 + HPO: HP_0000763 + + + + obo2:OAE_0001288 + MedDRA: 10034620 + + + + obo2:OAE_0001288 + SIDER: C0151313 + + + + obo2:OAE_0001289 + an abscess AE that results in a collection of infected material around the tonsils + + + + obo2:OAE_0001289 + SZ, SS, YH + + + + obo2:OAE_0001289 + WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001981/ + + + + obo2:OAE_0001289 + peritonsillar abscess AE + + + + obo2:OAE_0001289 + HPO: HP_0001739 + + + + obo2:OAE_0001289 + MedDRA: 10034686 + + + + obo2:OAE_0001289 + SIDER: C0031157 + + + + obo2:OAE_0001290 + Respiratory system AE characterized by the whooping cough + + + + obo2:OAE_0001290 + SZ, SS, YH + + + + obo2:OAE_0001290 + WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0002528/ + + + + obo2:OAE_0001290 + pertussis AE + + + + obo2:OAE_0001290 + MedDRA: 10034738 + + + + obo2:OAE_0001291 + a hemorrhage AE that has an outcome of tiny pinpoint red dots that form due to broken blood vessels under the skin + + + + obo2:OAE_0001291 + SZ, SS, YH + + + + obo2:OAE_0001291 + WEB: http://www.nlm.nih.gov/medlineplus/ency/article/003235.htm + + + + obo2:OAE_0001291 + petechiae AE + + + + obo2:OAE_0001291 + HPO: HP_0000967 + + + + obo2:OAE_0001291 + MP: MP_0008816 + + + + obo2:OAE_0001291 + MedDRA: 10034754 + + + + obo2:OAE_0001291 + SIDER: C0031256 + + + + obo2:OAE_0001292 + Inflammation AE that results in an inflammation of the pharyngeal region + + + + obo2:OAE_0001292 + SZ, SS, YH + + + + obo2:OAE_0001292 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/11172144 + + + + obo2:OAE_0001292 + pharyngeal inflammation AE + + + + obo2:OAE_0001292 + MedDRA: 10065716 + + + + obo2:OAE_0001293 + a phlebitis that is characterized by blood clots that occur in different locations + + + + obo2:OAE_0001293 + SZ, SS, YH + + + + obo2:OAE_0001293 + WEB: Primary Source: http://medical-dictionary.thefreedictionary.com/Thrombophlebitis Secondary Source: http://emedicine.medscape.com/article/463256-overview + + + + obo2:OAE_0001293 + phlebitis superficial AE + + + + obo2:OAE_0001293 + MedDRA: 10034902 + + + + obo2:OAE_0001294 + a skin AE that results in the patient's skin becoming diseased due to exposure to sunlight + + + + obo2:OAE_0001294 + SZ, SS, YH + + + + obo2:OAE_0001294 + WEB: Primary Source: http://medical-dictionary.thefreedictionary.com/photodermatosis Secondary Source http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3063367/ + + + + obo2:OAE_0001294 + photodermatosis AE + + + + obo2:OAE_0001294 + HPO: HP_0000992 + + + + obo2:OAE_0001294 + MedDRA: 10051246 + + + + obo2:OAE_0001294 + SIDER: C0920193 + + + + obo2:OAE_0001295 + a skin AE that has an outcome of drug-induced cutaneous disease as a result of the combined effects of a chemical and light + + + + obo2:OAE_0001295 + SZ, SS, YH + + + + obo2:OAE_0001295 + photosensitivity + + + + obo2:OAE_0001295 + photosensitivity reaction + + + + obo2:OAE_0001295 + WEB: http://emedicine.medscape.com/article/1049648-overview + + + + obo2:OAE_0001295 + photosensitivity reaction AE + + + + obo2:OAE_0001295 + HPO: HP_0000992 + + + + obo2:OAE_0001295 + MedDRA: 10034972 + + + + obo2:OAE_0001295 + SIDER: C0162830 + + + + obo2:OAE_0001296 + a skin AE that has an outcome of loss or reduction in human skin color, may be related to loss of melanocytes or inability of melanocytes to produce melanin + + + + obo2:OAE_0001296 + SZ, SS, YH + + + + obo2:OAE_0001296 + WEB: http://www.nlm.nih.gov/medlineplus/skinpigmentationdisorders.html + + + + obo2:OAE_0001296 + pigmentation disorder AE + + + + obo2:OAE_0001296 + HPO: HP_0001000 + + + + obo2:OAE_0001296 + MedDRA: 10062080 + + + + obo2:OAE_0001296 + SIDER: C0549567 + + + + obo2:OAE_0001297 + a conduction system disorder AE that refers to partial or complete block of electrical impulses originating in the atrium or sinus node, preventing them from reaching the AV node and ventricles + + + + obo2:OAE_0001297 + SS + + + + obo2:OAE_0001297 + AV block + + + + obo2:OAE_0001297 + heart block + + + + obo2:OAE_0001297 + WEB: http://www.medilexicon.com/medicaldictionary.php?t=10751 + + + + obo2:OAE_0001297 + atrioventricular block AE + + + + obo2:OAE_0001297 + HPO: HP_0001678 + + + + obo2:OAE_0001297 + MedDRA: 10003671 + + + + obo2:OAE_0001297 + SIDER: C0004245 + + + + obo2:OAE_0001298 + a respiratory system AE that has an outcome of fluid buildup between the layers of tissue that line the lungs and chest cavity + + + + obo2:OAE_0001298 + SZ, SS, YH + + + + obo2:OAE_0001298 + WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001150/ + + + + obo2:OAE_0001298 + pleural effusion AE + + + + obo2:OAE_0001298 + HPO: HP_0002202 + + + + obo2:OAE_0001298 + MedDRA: 10035598 + + + + obo2:OAE_0001298 + SIDER: C0032227 + + + + obo2:OAE_0001299 + a hemorrhage AE that has an outcome of bleeding in the pleural cavity, the potential space between the two pleura of the lungs + + + + obo2:OAE_0001299 + SZ, SS, YH + + + + obo2:OAE_0001299 + pleural haemorrhage AE + + + + obo2:OAE_0001299 + WEB: http://medical-dictionary.thefreedictionary.com/hemothorax + + + + obo2:OAE_0001299 + pleural hemorrhage AE + + + + obo2:OAE_0001299 + MedDRA: 10035601 + + + + obo2:OAE_0001300 + a lung disorder AE that has an outcome of inflammation of the lining of the lungs and chest that leads to chest pain + + + + obo2:OAE_0001300 + SZ, SS, YH + + + + obo2:OAE_0001300 + WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0002347/ + + + + obo2:OAE_0001300 + pleurisy AE + + + + obo2:OAE_0001300 + HPO: HP_0002102 + + + + obo2:OAE_0001300 + MedDRA: 10035618 + + + + obo2:OAE_0001300 + SIDER: C0032231 + + + + obo2:OAE_0001301 + a pain AE induced by inflammation in the lungs that is characterized by sharp or stabbing pain in the chest + + + + obo2:OAE_0001301 + SZ, SS, YH + + + + obo2:OAE_0001301 + WEB: http://pleuriticchestpain.net/, http://medical-dictionary.thefreedictionary.com/Pleuritic+chest+pain + + + + obo2:OAE_0001301 + pleuritic pain AE + + + + obo2:OAE_0001301 + MedDRA: 10035623 + + + + obo2:OAE_0001302 + a gastrointestinal disorder AE that results in gas cysts developing within the walls of the small or large intestine + + + + obo2:OAE_0001302 + SZ, SS, YH + + + + obo2:OAE_0001302 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/9530294 + + + + obo2:OAE_0001302 + pneumatosis intestinalis AE + + + + obo2:OAE_0001302 + MedDRA: 10057030 + + + + obo2:OAE_0001303 + a pneumonia AE that has an outcome of a fungal infection of the lungs by Pneumocystis jiroveci + + + + obo2:OAE_0001303 + SZ, SS, YH + + + + obo2:OAE_0001303 + WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001692/ + + + + obo2:OAE_0001303 + pneumocystis jiroveci pneumonia AE + + + + obo2:OAE_0001303 + HPO: HP_0002096 + + + + obo2:OAE_0001303 + MedDRA: 10064108 + + + + obo2:OAE_0001303 + SIDER: C1535939 + + + + obo2:OAE_0001304 + Respiratory System AE that results in air being present in the mediastinum + + + + obo2:OAE_0001304 + SZ, SS, YH + + + + obo2:OAE_0001304 + WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001148/ + + + + obo2:OAE_0001304 + pneumomediastinum AE + + + + obo2:OAE_0001304 + MedDRA: 10050184 + + + + obo2:OAE_0001305 + a pneumonia AE that has an outcome of inflammation in the lungs and airways to the lungs from breathing in foreign material + + + + obo2:OAE_0001305 + SZ, SS, YH + + + + obo2:OAE_0001305 + WEB: http://www.nlm.nih.gov/medlineplus/ency/article/000121.htm + + + + obo2:OAE_0001305 + pneumonia aspiration AE + + + + obo2:OAE_0001305 + HPO: HP_0002100 + + + + obo2:OAE_0001305 + MedDRA: 10035669 + + + + obo2:OAE_0001305 + SIDER: C0032290 + + + + obo2:OAE_0001306 + a pneumonia AE that has an outcome of an acute systemic disease with involvement of the lungs, caused by Mycoplasma pneumoniAE and marked by high fever and cough + + + + obo2:OAE_0001306 + SZ, SS, YH + + + + obo2:OAE_0001306 + WEB: http://medical-dictionary.thefreedictionary.com/primary+atypical+pneumonia + + + + obo2:OAE_0001306 + pneumonia primary atypical AE + + + + obo2:OAE_0001306 + MedDRA: 10035730 + + + + obo2:OAE_0001307 + a lung inflammation AE located in the lung tissue + + + + obo2:OAE_0001307 + SZ, SS, YH + + + + obo2:OAE_0001307 + pulmonitis AE + + + + obo2:OAE_0001307 + WEB: http://medical-dictionary.thefreedictionary.com/pneumonitis + + + + obo2:OAE_0001307 + pneumonitis AE + + + + obo2:OAE_0001307 + MedDRA: 10035742 + + + + obo2:OAE_0001308 + a lung disorder AE that has an outcome of a collapsed lung due to collection of air in the space around the lungs. + + + + obo2:OAE_0001308 + SZ, SS, YH + + + + obo2:OAE_0001308 + WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001151/ + + + + obo2:OAE_0001308 + pneumothorax AE + + + + obo2:OAE_0001308 + HPO: HP_0006522 + + + + obo2:OAE_0001308 + MedDRA: 10035759 + + + + obo2:OAE_0001308 + SIDER: C0032326 + + + + obo2:OAE_0001309 + a urinary system AE that results in abnormally frequent urination + + + + obo2:OAE_0001309 + SZ, SS, YH + + + + obo2:OAE_0001309 + frequent micturition AE + + + + obo2:OAE_0001309 + polyuria AE + + + + obo2:OAE_0001309 + WEB: http://www.merriam-webster.com/medical/pollakiuria + + + + obo2:OAE_0001309 + pollakiuria AE + + + + obo2:OAE_0001309 + HPO: HP_0000103 + + + + obo2:OAE_0001309 + MedDRA: 10036018 + + + + obo2:OAE_0001309 + SIDER: C0042023 + + + + obo2:OAE_0001310 + a hematopoietic disorder AE that results in the bone marrow producing too many red blood cells + + + + obo2:OAE_0001310 + SZ, SS, YH + + + + obo2:OAE_0001310 + polycythaemia vera AE + + + + obo2:OAE_0001310 + WEB: http://medical-dictionary.thefreedictionary.com/Polycythaemia+vera + + + + obo2:OAE_0001310 + polycythemia vera AE + + + + obo2:OAE_0001310 + MedDRA: 10036057 + + + + obo2:OAE_0001311 + a hypertension AE located in the heptatic portal system caused by obstruction or occlusion that produces splenomegaly and ascites in its later stages + + + + obo2:OAE_0001311 + SZ, SS, YH + + + + obo2:OAE_0001311 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/21129318 + + + + obo2:OAE_0001311 + http://www.merriam-webster.com/medlineplus/portal%20hypertension + + + + obo2:OAE_0001311 + portal hypertension AE + + + + obo2:OAE_0001311 + HPO: HP_0001409 + + + + obo2:OAE_0001311 + MedDRA: 10036200 + + + + obo2:OAE_0001311 + SIDER: C0020541 + + + + obo2:OAE_0001312 + a thrombosis AE that has an outcome of formation of a blood clot affecting the hepatic portal vein, can lead to hypertension or reduction of blood supply to the liver + + + + obo2:OAE_0001312 + SZ, SS, YH + + + + obo2:OAE_0001312 + PVT + + + + obo2:OAE_0001312 + WEB: http://medical-dictionary.thefreedictionary.com/portal+vein+thrombosis + + + + obo2:OAE_0001312 + portal vein thrombosis AE + + + + obo2:OAE_0001312 + MedDRA: 10036206 + + + + obo2:OAE_0001313 + a syndrome that results in the patient suffering a set of problems after having a spinal tap procedure + + + + obo2:OAE_0001313 + SZ, SS, YH + + + + obo2:OAE_0001313 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/19921503 + + + + obo2:OAE_0001313 + post lumbar puncture syndrome AE + + + + obo2:OAE_0001313 + MedDRA: 10060854 + + + + obo2:OAE_0001314 + Fever AE that results in a fever occurring after an operation + + + + obo2:OAE_0001314 + SZ, SS, YH + + + + obo2:OAE_0001314 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/22774619 + + + + obo2:OAE_0001314 + postoperative fever AE + + + + obo2:OAE_0001314 + MedDRA: 10050087 + + + + obo2:OAE_0001315 + A thrombosis AE that occurs after an operation that results in a blood clot in a blood vessel disrupting blood flow throughout the body + + + + obo2:OAE_0001315 + SZ, SS, YH + + + + obo2:OAE_0001315 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/19756494 + + + + obo2:OAE_0001315 + postoperative thrombosis AE + + + + obo2:OAE_0001315 + MedDRA: 10050902 + + + + obo2:OAE_0001316 + Female reproductive system AE that results in the patient getting pregnant even when using a contraceptive + + + + obo2:OAE_0001316 + SZ, SS, YH + + + + obo2:OAE_0001316 + pregnancy on contraceptive AE + + + + obo2:OAE_0001316 + MedDRA: 10067667 + + + + obo2:OAE_0001317 + a perinatal AE that has an outcome of premature baby + + + + obo2:OAE_0001317 + SZ, SS, YH + + + + obo2:OAE_0001317 + premature baby AE + + + + obo2:OAE_0001317 + MedDRA: 10036590 + + + + obo2:OAE_0001318 + a pregnancy AE that has an outcome of labor beginning prior to the 37th week of gestation + + + + obo2:OAE_0001318 + SZ, SS, YH + + + + obo2:OAE_0001318 + premature labour AE + + + + obo2:OAE_0001318 + WEB: http://wordnetweb.princeton.edu/perl/webwn?s=premature%20labor + + + + obo2:OAE_0001318 + premature labor AE + + + + obo2:OAE_0001318 + MedDRA: 10036600 + + + + obo2:OAE_0001319 + a sensory capability AE that has an outcome of a near-fainting episode which may include lightheadedness, dizziness, severe weakness, blurred vision, which may precede syncopal episode + + + + obo2:OAE_0001319 + SZ, SS, YH + + + + obo2:OAE_0001319 + WEB: http://medical-dictionary.thefreedictionary.com/presyncope + + + + obo2:OAE_0001319 + presyncope AE + + + + obo2:OAE_0001319 + HPO: HP_0002321 + + + + obo2:OAE_0001319 + MedDRA: 10036653 + + + + obo2:OAE_0001319 + SIDER: C0700200 + + + + obo2:OAE_0001320 + a bone disorder AE that has an outcome of a piece of dead bone that completely separates from sound bone during the process of necrosis + + + + obo2:OAE_0001320 + SZ, SS, YH + + + + obo2:OAE_0001320 + WEB: http://medical-dictionary.thefreedictionary.com/primary+sequestrum + + + + obo2:OAE_0001320 + primary sequestrum AE + + + + obo2:OAE_0001320 + MedDRA: 10052460 + + + + obo2:OAE_0001321 + a coronary artery disorder AE that results in cardiac pain at rest that occurs in cycles + + + + obo2:OAE_0001321 + SZ, SS, YH + + + + obo2:OAE_0001321 + Prinzmetal's angina AE + + + + obo2:OAE_0001321 + coronary vessel spasm AE + + + + obo2:OAE_0001321 + WEB: http://medical-dictionary.thefreedictionary.com/prinzmetal+angina + + + + obo2:OAE_0001321 + prinzmetal angina AE + + + + obo2:OAE_0001321 + HPO: HP_0001681 + + + + obo2:OAE_0001321 + MedDRA: 10036759 + + + + obo2:OAE_0001321 + SIDER: C0002963 + + + + obo2:OAE_0001322 + a digestive system AE that results in the pain located at the anus or in the rectum + + + + obo2:OAE_0001322 + SZ, SS, YH + + + + obo2:OAE_0001322 + WEB: http://medical-dictionary.thefreedictionary.com/proctalgia + + + + obo2:OAE_0001322 + proctalgia AE + + + + obo2:OAE_0001322 + HPO: HP_0004378 + + + + obo2:OAE_0001322 + MedDRA: 10036772 + + + + obo2:OAE_0001322 + SIDER: C0034886 + + + + obo2:OAE_0001323 + A medical intervention that is a procedure occuring in the inside structures of the tooth, including the dental pulp and tooth root, and the periapical tissue surrounding the root. + + + + obo2:OAE_0001323 + YH, SS + + + + obo2:OAE_0001323 + WEB: http://medical-dictionary.thefreedictionary.com/endodontic + + + + obo2:OAE_0001323 + endodontic procedure + + + + obo2:OAE_0001323 + MedDRA: 10051085 + + + + obo2:OAE_0001326 + a cough AE that has an outcome of secretions that could be mucous or blood + + + + obo2:OAE_0001326 + SZ, SS, YH + + + + obo2:OAE_0001326 + WEB: http://coldflu.about.com/od/glossary/g/productivecough.htm + + + + obo2:OAE_0001326 + productive cough AE + + + + obo2:OAE_0001326 + MedDRA: 10036790 + + + + obo2:OAE_0001327 + a tumor AE that has an outcome of cancer that starts in the prostate gland, the small structure that wraps around the urethra carrying urine out of the body + + + + obo2:OAE_0001327 + SZ, SS, YH + + + + obo2:OAE_0001327 + WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001418/ + + + + obo2:OAE_0001327 + prostate cancer AE + + + + obo2:OAE_0001327 + HPO: HP_0012125 + + + + obo2:OAE_0001327 + MedDRA: 10060862 + + + + obo2:OAE_0001327 + SIDER: C0376358 + + + + obo2:OAE_0001328 + a physical examination result abnormal AE that results in a prostate exam being different than expected + + + + obo2:OAE_0001328 + SZ, SS, EB + + + + + obo2:OAE_0001328 + prostate examination abnormal AE + + + + obo2:OAE_0001328 + MedDRA: 10055025 + + + + obo2:OAE_0001329 + a male reproductive system AE that has an outcome of an increased amount of prostatic specific antigen, a glycoprotein enzyme present in small quantities in the serum of men with healthy prostates. May indicate prostate cancer or prostate disorders + + + + obo2:OAE_0001329 + SZ, SS, YH + + + + obo2:OAE_0001329 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/23277770 + + + + obo2:OAE_0001329 + prostatic specific antigen increased AE + + + + obo2:OAE_0001329 + MedDRA: 10036975 + + + + obo2:OAE_0001330 + a protein and chemistry analysis result abnormal AE that is characterized by the protein level in the body being abnormal + + + + obo2:OAE_0001330 + SZ, SS, YH, EB + + + + obo2:OAE_0001330 + protein total abnormal AE + + + + obo2:OAE_0001330 + MedDRA: 10037012 + + + + obo2:OAE_0001331 + a prothrombin level abnormal AE that is characterized by a decrease in level of prothrombin in body + + + + obo2:OAE_0001331 + SZ, SS, YH, EB + + + + obo2:OAE_0001331 + WEB: http://medical-dictionary.thefreedictionary.com/prothrombin + + + + obo2:OAE_0001331 + prothrombin level decreased AE + + + + obo2:OAE_0001331 + MedDRA: 10037050 + + + + obo2:OAE_0001332 + a prothrombin time abnormal AE that has an outcome of prolonged time for plasma in the blood to clot + + + + obo2:OAE_0001332 + SZ, SS, YH, EB + + + + obo2:OAE_0001332 + WEB: http://www.nlm.nih.gov/medlineplus/ency/article/003652.htm + + + + obo2:OAE_0001332 + prothrombin time prolonged AE + + + + obo2:OAE_0001332 + MedDRA: 10037063 + + + + obo2:OAE_0001333 + a digestive system AE that has an outcome of infection in the large intestine with an overgrowth of Clostridium difficile bacteria + + + + obo2:OAE_0001333 + SZ, SS, YH + + + + obo2:OAE_0001333 + WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001305/ + + + + obo2:OAE_0001333 + pseudomembranous colitis AE + + + + obo2:OAE_0001333 + HPO: HP_0002583 + + + + obo2:OAE_0001333 + MedDRA: 10037128 + + + + obo2:OAE_0001333 + SIDER: C1257843 + + + + obo2:OAE_0001334 + a bacterial infection AE that has an outcome of infection by genus Pseudomonas, typically targets respiratory tract + + + + obo2:OAE_0001334 + SZ, SS, YH + + + + obo2:OAE_0001334 + WEB: http://emedicine.medscape.com/article/970904-overview + + + + obo2:OAE_0001334 + pseudomonas infection AE + + + + obo2:OAE_0001334 + HPO: HP_0005429 + + + + obo2:OAE_0001334 + MedDRA: 10061471 + + + + obo2:OAE_0001334 + SIDER: C0033817 + + + + obo2:OAE_0001335 + a mental disorder AE that results in physical pain being caused by the patient's life stresses + + + + obo2:OAE_0001335 + SZ, SS, YH + + + + obo2:OAE_0001335 + WEB: http://medical-dictionary.thefreedictionary.com/psychosomatic+disease + + + + obo2:OAE_0001335 + psychosomatic disease AE + + + + obo2:OAE_0001335 + MedDRA: 10049587 + + + + obo2:OAE_0001336 + A mental disorder AE that results in abnormal condition of the mind + + + + obo2:OAE_0001336 + SZ, SS, YH + + + + obo2:OAE_0001336 + WEB: http://medical-dictionary.thefreedictionary.com/psychotic+disorder + + + + obo2:OAE_0001336 + psychotic disorder AE + + + + obo2:OAE_0001336 + HPO: HP_0000709 + + + + obo2:OAE_0001336 + MedDRA: 10061920 + + + + obo2:OAE_0001336 + SIDER: C0033975 + + + + obo2:OAE_0001338 + a lung disorder AE that has an outcome of hypertension or abnormally high blood pressure in the arteries of the lungs + + + + obo2:OAE_0001338 + SZ, SS, YH + + + + obo2:OAE_0001338 + WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001171/ + + + + obo2:OAE_0001338 + pulmonary arterial hypertension AE + + + + obo2:OAE_0001338 + HPO: HP_0002092 + + + + obo2:OAE_0001338 + MedDRA: 10064911 + + + + obo2:OAE_0001338 + SIDER: C2973725 + + + + obo2:OAE_0001339 + a lung disorder AE that has an outcome of engorgement of pulmonary vessels with transudation of fluid into the alveolar and interstitial spaces, seen in cardiac disease, infections, and certain injuries + + + + obo2:OAE_0001339 + SZ, SS, YH + + + + obo2:OAE_0001339 + WEB: http://medical-dictionary.thefreedictionary.com/pulmonary+congestion + + + + obo2:OAE_0001339 + pulmonary congestion AE + + + + obo2:OAE_0001339 + HPO: HP_0004930 + + + + obo2:OAE_0001339 + MedDRA: 10037368 + + + + obo2:OAE_0001339 + SIDER: C0242073 + + + + obo2:OAE_0001340 + an arterial embolism AE that results in the blockage of the main artery of a lung or one of its branches by a substance that has travelled from elsewhere in the body through the bloodstream + + + + obo2:OAE_0001340 + [SS] moved by relation 'SubclassOf' from lung disorder AE to arterial embolism on 01/07/14 + + + + obo2:OAE_0001340 + SZ, SS, YH + + + + obo2:OAE_0001340 + pulmonary artery thrombosis AE + + + + obo2:OAE_0001340 + pulmonary thrombosis AE + + + + obo2:OAE_0001340 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/23299609 + + + + obo2:OAE_0001340 + pulmonary embolism AE + + + + obo2:OAE_0001340 + HPO: HP_0002204 + + + + obo2:OAE_0001340 + MedDRA: 10037340 + + + + obo2:OAE_0001340 + MedDRA: 10037377 + + + + obo2:OAE_0001340 + MedDRA: 10037437 + + + + obo2:OAE_0001340 + SIDER: C0034065 + + + + obo2:OAE_0001341 + a lung disorder AE wih the outcome of damaged or scarred lung tissue. Thickened tissue impairs lung function + + + + obo2:OAE_0001341 + SZ, SS, YH + + + + obo2:OAE_0001341 + WEB: http://www.mayoclinic.com/health/pulmonary-fibrosis/DS00927 + + + + obo2:OAE_0001341 + pulmonary fibrosis AE + + + + obo2:OAE_0001341 + HPO: HP_0002206 + + + + obo2:OAE_0001341 + MedDRA: 10037383 + + + + obo2:OAE_0001341 + SIDER: C0034069 + + + + obo2:OAE_0001342 + a lung disorder AE that has an outcome of acute bleeding from the lung, especially in the upper respiratory tract and the endotracheal tube + + + + obo2:OAE_0001342 + SZ, SS, YH + + + + obo2:OAE_0001342 + pulmonary haemorrhage AE + + + + obo2:OAE_0001342 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/23217914 + + + + obo2:OAE_0001342 + pulmonary hemorrhage AE + + + + obo2:OAE_0001342 + MedDRA: 10037394 + + + + obo2:OAE_0001343 + a lung disorder AE that has an outcome of abnormally high blood pressure in the arteris of the lungs + + + + obo2:OAE_0001343 + SZ, SS, YH + + + + obo2:OAE_0001343 + WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001171/ + + + + obo2:OAE_0001343 + pulmonary hypertension AE + + + + obo2:OAE_0001343 + HPO: HP_0002092 + + + + obo2:OAE_0001343 + MedDRA: 10037400 + + + + obo2:OAE_0001343 + SIDER: C0020542 + + + + obo2:OAE_0001344 + a lung disorder AE that has an outcome of an abnormal spot in the lungs that is more than 3 cm in size + + + + obo2:OAE_0001344 + SZ, SS, YH + + + + obo2:OAE_0001344 + WEB: http://lungcancer.about.com/od/whatislungcancer/a/Lung-Mass.htm + + + + obo2:OAE_0001344 + pulmonary mass AE + + + + obo2:OAE_0001344 + MedDRA: 10056342 + + + + obo2:OAE_0001345 + a lung disorder AE that has an outcome of edema or abnormal buildup of fluid in the air sacs of the lungs, leads to shortness of breath + + + + obo2:OAE_0001345 + SZ, SS, YH + + + + obo2:OAE_0001345 + pulmonary oedema AE + + + + obo2:OAE_0001345 + WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001195/ + + + + obo2:OAE_0001345 + pulmonary edema AE + + + + obo2:OAE_0001345 + HPO: HP_0100598 + + + + obo2:OAE_0001345 + MedDRA: 10037423 + + + + obo2:OAE_0001345 + SIDER: C0034063 + + + + obo2:OAE_0001346 + a cardiovascular disorder AE that has an outcome of an inability to detect pulse + + + + obo2:OAE_0001346 + SZ, SS, YH + + + + obo2:OAE_0001346 + WEB: http://www.nlm.nih.gov/medlineplus/ency/article/003078.htm + + + + obo2:OAE_0001346 + pulse absent AE + + + + obo2:OAE_0001346 + MedDRA: 10037469 + + + + obo2:OAE_0001347 + a cardiovascular disorder AE that has an outcome of abnormally low pulse pressure, less than 25% of systolic value. Can indicate blood loss or low stroke volume + + + + obo2:OAE_0001347 + SZ, SS, YH + + + + obo2:OAE_0001347 + WEB: http://medical-dictionary.thefreedictionary.com/pulse+pressure + + + + obo2:OAE_0001347 + pulse pressure decreased AE + + + + obo2:OAE_0001347 + MedDRA: 10037480 + + + + obo2:OAE_0001348 + an adverse event with an outcome of the release or secretion of pus + + + + obo2:OAE_0001348 + SZ, SS, YH + + + + obo2:OAE_0001348 + WEB: http://www.medterms.com/script/main/art.asp?articlekey=21858 + + + + obo2:OAE_0001348 + purulent discharge AE + + + + obo2:OAE_0001348 + MedDRA: 10037569 + + + + obo2:OAE_0001349 + a kidney disorder AE that is characterized by the dilation of calices, usually due to obstruction or infection + + + + obo2:OAE_0001349 + SZ, SS, YH + + + + obo2:OAE_0001349 + WEB: http://medical-dictionary.thefreedictionary.com/calicectasis + + + + obo2:OAE_0001349 + pyelocaliectasis AE + + + + obo2:OAE_0001349 + MedDRA: 10061927 + + + + obo2:OAE_0001350 + an injury AE caused by ionizing radiation + + + + obo2:OAE_0001350 + SZ, SS, YH + + + + obo2:OAE_0001350 + WEB: http://medical-dictionary.thefreedictionary.com/Radiation+Injuries + + + + obo2:OAE_0001350 + radiation injury AE + + + + obo2:OAE_0001350 + MedDRA: 10037760 + + + + obo2:OAE_0001351 + a digestive system AE that results in the inflammation of mucous membranes lining the digestive tract. Caused by radiation, can lead to mouth sores + + + + obo2:OAE_0001351 + SZ, SS, YH + + + + obo2:OAE_0001351 + WEB: http://www.medterms.com/script/main/art.asp?articlekey=19881 + + + + obo2:OAE_0001351 + radiation mucositis AE + + + + obo2:OAE_0001351 + MedDRA: 10037763 + + + + obo2:OAE_0001352 + a digestive system AE that has an outcome of inflammation that radiation causes swelling of the esophagus + + + + obo2:OAE_0001352 + SZ, SS, YH + + + + obo2:OAE_0001352 + radiation oesophagitis AE + + + + obo2:OAE_0001352 + WEB: http://medical-dictionary.thefreedictionary.com/esophagitis + + + + obo2:OAE_0001352 + radiation esophagitis AE + + + + obo2:OAE_0001352 + MedDRA: 10048899 + + + + obo2:OAE_0001353 + a lung inflammation AE due to radiation therapy + + + + obo2:OAE_0001353 + SZ, SS, YH + + + + obo2:OAE_0001353 + WEB: http://www.medterms.com/script/main/art.asp?articlekey=8091 + + + + obo2:OAE_0001353 + radiation pneumonitis AE + + + + obo2:OAE_0001353 + MedDRA: 10037765 + + + + obo2:OAE_0001354 + a skin AE that has an outcome of injury to the skin and underlying tissues from exposure to a large external dose of radiation + + + + obo2:OAE_0001354 + SZ, SS, YH + + + + obo2:OAE_0001354 + WEB: http://www.bt.cdc.gov/radiation/criphysicianfactsheet.asp + + + + obo2:OAE_0001354 + radiation skin injury AE + + + + obo2:OAE_0001354 + MedDRA: 10063562 + + + + obo2:OAE_0001355 + a respiratory system AE that has an outcome of clicking, rattling or crackling noises made by one or both lungs during inhalation + + + + obo2:OAE_0001355 + SZ, SS, YH + + + + obo2:OAE_0001355 + Crackles + + + + obo2:OAE_0001355 + WEB: http://medical-dictionary.thefreedictionary.com/crackles + + + + obo2:OAE_0001355 + rales AE + + + + obo2:OAE_0001355 + MedDRA: 10037833 + + + + obo2:OAE_0001356 + a rash ae adverse event that results in redness of the skin, caused by hyperemia of the capillaries in the lower layers of the skin + + + + obo2:OAE_0001356 + SZ, SS, YH + + + + obo2:OAE_0001356 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/23145421 + + + + obo2:OAE_0001356 + rash erythematous AE + + + + obo2:OAE_0001356 + HPO: HP_0007432 + + + + obo2:OAE_0001356 + MedDRA: 10037855 + + + + obo2:OAE_0001356 + SIDER: C0234913 + + + + obo2:OAE_0001357 + a rash AE occuring in several areas of the body + + + + obo2:OAE_0001357 + SZ, SS, YH + + + + obo2:OAE_0001357 + rash generalised AE + + + + obo2:OAE_0001357 + WEB: http://www.freemd.com/rash-generalized/overview.htm + + + + obo2:OAE_0001357 + rash generalized AE + + + + obo2:OAE_0001357 + HPO: HP_0000988 + + + + obo2:OAE_0001357 + MedDRA: 10037858 + + + + obo2:OAE_0001357 + SIDER: C0497365 + + + + obo2:OAE_0001358 + a rash AE that has an outcome of an unpleasant sensation of the skin that provokes the uge to scratch + + + + obo2:OAE_0001358 + SZ, SS, YH + + + + obo2:OAE_0001358 + WEB: http://www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/dermatology/pruritus-itch/ + + + + obo2:OAE_0001358 + rash pruritic AE + + + + obo2:OAE_0001358 + MedDRA: 10037884 + + + + obo2:OAE_0001359 + an inflammation AE that has an outcome of an inflammatory reaction limited to a previously X-irradiated field when the patient is treated months/years later with certain drugs + + + + obo2:OAE_0001359 + SZ, SS, YH + + + + obo2:OAE_0001359 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/7577597 + + + + obo2:OAE_0001359 + recall phenomenon AE + + + + obo2:OAE_0001359 + MedDRA: 10060856 + + + + obo2:OAE_0001360 + Digestive System AE that results in bleeding in the rectal area + + + + obo2:OAE_0001360 + SZ, SS, YH + + + + obo2:OAE_0001360 + rectal haemorrhage AE + + + + obo2:OAE_0001360 + rectal hemorrhage AE + + + + obo2:OAE_0001360 + HPO: HP_0002573 + + + + obo2:OAE_0001360 + MedDRA: 10038063 + + + + obo2:OAE_0001360 + SIDER: C0267596 + + + + obo2:OAE_0001361 + a red blood cell count abnormal AE that has an outcome of a decrease in red blood cells + + + + obo2:OAE_0001361 + SZ, SS, YH, EB + + + + obo2:OAE_0001361 + WEB: http://www.nlm.nih.gov/medlineplus/ency/article/003644.htm + + + + obo2:OAE_0001361 + red blood cell count decreased AE + + + + obo2:OAE_0001361 + HPO: HP_0001903 + + + + obo2:OAE_0001361 + MedDRA: 10038153 + + + + obo2:OAE_0001361 + SIDER: C0427457 + + + + obo2:OAE_0001362 + a digestive system disorder AE that results in the inflammation of the stomach lining due to reflux + + + + obo2:OAE_0001362 + SZ, SS, YH + + + + obo2:OAE_0001362 + WEB: http://medical-dictionary.thefreedictionary.com/gastritis + + + + obo2:OAE_0001362 + reflux gastritis AE + + + + obo2:OAE_0001362 + MedDRA: 10057969 + + + + obo2:OAE_0001363 + a digestive system AE located in the esophagus, can present with heartburn, and nausea, caused by gastroesophageal reflux disease + + + + obo2:OAE_0001363 + SZ, SS, YH + + + + obo2:OAE_0001363 + reflux oesophagitis AE + + + + obo2:OAE_0001363 + WEB: http://medical-dictionary.thefreedictionary.com/esophagitis + + + + obo2:OAE_0001363 + reflux esophagitis AE + + + + obo2:OAE_0001363 + HPO: HP_0100633 + + + + obo2:OAE_0001363 + MedDRA: 10038263 + + + + obo2:OAE_0001363 + SIDER: C0014869 + + + + obo2:OAE_0001364 + a kidney disorder AE that results in kidneys failing to adequately filter toxins and waste from the blood + + + + obo2:OAE_0001364 + SZ, SS, YH + + + + obo2:OAE_0001364 + kidney failure AE + + + + obo2:OAE_0001364 + renal insufficiency AE + + + + obo2:OAE_0001364 + WEB: http://medical-dictionary.thefreedictionary.com/renal+failure + + + + obo2:OAE_0001364 + renal failure AE + + + + obo2:OAE_0001364 + HPO: HP_0000083 + + + + obo2:OAE_0001364 + MedDRA: 10038435 + + + + obo2:OAE_0001364 + SIDER: C0035078 + + + + obo2:OAE_0001365 + a kidney disorder AE that results in the rapid loss or decline of kidney function + + + + obo2:OAE_0001365 + As shown on the renal.org website (http://www.renal.org/guidelines/modules/acute-kidney-injury), Acute kidney injury (AKI) has now replaced the term acute renal failure. + + + + obo2:OAE_0001365 + SZ, SS, YH, Izabela Birsanescu + + + + obo2:OAE_0001365 + AKI + + + + obo2:OAE_0001365 + renal failure acute AE + + + + obo2:OAE_0001365 + WEB: http://medical-dictionary.thefreedictionary.com/acute+renal+failure + + + + obo2:OAE_0001365 + WEB: http://www.mayoclinic.org/diseases-conditions/kidney-failure/basics/definition/con-20024029 + + + + obo2:OAE_0001365 + Acute kidney failure occurs when kidneys become unable to filter waste products from blood. + + + + obo2:OAE_0001365 + acute kidney injury AE + + + + obo2:OAE_0001365 + HPO: HP_0001919 + + + + obo2:OAE_0001365 + MedDRA: 10038436; MedDRA: 10069339 + + + + obo2:OAE_0001365 + SIDER: C0022660 + + + + obo2:OAE_0001366 + a kidney disorder AE that results in the kidneys failing to adequately filter toxins and waste from the blood + + + + obo2:OAE_0001366 + SZ, SS, YH + + + + obo2:OAE_0001366 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/23263712 + + + + obo2:OAE_0001366 + renal impairment AE + + + + obo2:OAE_0001366 + HPO: HP_0000082 + + + + obo2:OAE_0001366 + MedDRA: 10062237 + + + + obo2:OAE_0001366 + SIDER: C0341697 + + + + obo2:OAE_0001367 + kidney disorder AE that results in the renal tubule wasting away and losing strength/functional abilities + + + + obo2:OAE_0001367 + SZ, SS, YH + + + + obo2:OAE_0001367 + WEB: http://medical-dictionary.thefreedictionary.com/nephron + + + + obo2:OAE_0001367 + renal tubular atrophy AE + + + + obo2:OAE_0001367 + MedDRA: 10038536 + + + + obo2:OAE_0001368 + a kidney disorder AE that results in the renal artery narrowing + + + + obo2:OAE_0001368 + SZ, SS, YH + + + + obo2:OAE_0001368 + WEB: http://medical-dictionary.thefreedictionary.com/renal+artery+stenosis + + + + obo2:OAE_0001368 + renal vessel disorder AE + + + + obo2:OAE_0001368 + MedDRA: 10038553 + + + + obo2:OAE_0001369 + Respiratory system AE that is characterized by conditions that affect organs and systems that deal with gas exchange + + + + obo2:OAE_0001369 + SZ, SS, YH + + + + obo2:OAE_0001369 + WEB: http://www.thefreedictionary.com/respiratory+disorder + + + + obo2:OAE_0001369 + respiratory disorder AE + + + + obo2:OAE_0001369 + HPO: HP_0002086 + + + + obo2:OAE_0001369 + MedDRA: 10038683 + + + + obo2:OAE_0001369 + SIDER: C0035204 + + + + obo2:OAE_0001370 + a respiratory system AE that has an outcome of a condition where lungs cannot remove all the carbon dioxide the body produces, makes body fluid too acidic + + + + obo2:OAE_0001370 + SZ, SS, YH + + + + obo2:OAE_0001370 + respiratory failure AE + + + + obo2:OAE_0001370 + WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001154/ + + + + obo2:OAE_0001370 + respiratory acidosis AE + + + + obo2:OAE_0001370 + HPO: HP_0004877 + + + + obo2:OAE_0001370 + MedDRA: 10038695 + + + + obo2:OAE_0001370 + SIDER: C1145670 + + + + obo2:OAE_0001371 + a respiratory system AE that has an outcome of a ventilory rate greater than 20 breaths per minute + + + + obo2:OAE_0001371 + SZ, SS, YH + + + + obo2:OAE_0001371 + WEB: http://www.thefreedictionary.com/tachypnea + + + + obo2:OAE_0001371 + respiratory rate increased AE + + + + obo2:OAE_0001371 + MedDRA: 10038712 + + + + obo2:OAE_0001372 + Respiratory System AE that results in bleeding somewhere in the respiratory system + + + + obo2:OAE_0001372 + SZ, SS, YH + + + + obo2:OAE_0001372 + respiratory tract haemorrhage AE + + + + obo2:OAE_0001372 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/8692086 + + + + obo2:OAE_0001372 + respiratory tract hemorrhage AE + + + + obo2:OAE_0001372 + MedDRA: 10038727 + + + + obo2:OAE_0001373 + an infection AE that has an outcome of infection in the respiratory tract, includes pneumonia as well as lung abscess and acute bronchitis + + + + obo2:OAE_0001373 + SZ, SS, YH + + + + obo2:OAE_0001373 + WEB: http://www.thefreedictionary.com/respiratory+tract+infection + + + + obo2:OAE_0001373 + respiratory tract infection AE + + + + obo2:OAE_0001373 + HPO: HP_0002873 + + + + obo2:OAE_0001373 + MedDRA: 10062352 + + + + obo2:OAE_0001373 + SIDER: C0035243 + + + + obo2:OAE_0001374 + an eye disorder AE that has an outcome of bleeding in the eye + + + + obo2:OAE_0001374 + SZ, SS, YH + + + + obo2:OAE_0001374 + retinal haemorrhage AE + + + + obo2:OAE_0001374 + WEB: http://medical-dictionary.thefreedictionary.com/retinal+hemorrhage + + + + obo2:OAE_0001374 + retinal hemorrhage AE + + + + obo2:OAE_0001374 + HPO: HP_0000573 + + + + obo2:OAE_0001374 + MedDRA: 10038867 + + + + obo2:OAE_0001374 + SIDER: C0035317 + + + + obo2:OAE_0001375 + Eye Disorder AE that results in a tearing of retinal pigment epithelial tissue + + + + obo2:OAE_0001375 + SZ, SS, YH + + + + obo2:OAE_0001375 + retinal pigment epithelial tear AE + + + + obo2:OAE_0001375 + MedDRA: 10062971 + + + + obo2:OAE_0001376 + Amnesia AE that results in the patient forgeting things that happened before the onset of an injury or disease + + + + obo2:OAE_0001376 + SZ, SS, YH + + + + obo2:OAE_0001376 + WEB: http://medical-dictionary.thefreedictionary.com/retrograde+amnesia + + + + obo2:OAE_0001376 + retrograde amnesia AE + + + + obo2:OAE_0001376 + HPO: HP_0002354 + + + + obo2:OAE_0001376 + MedDRA: 10038965 + + + + obo2:OAE_0001376 + SIDER: C0002624 + + + + obo2:OAE_0001377 + an encephalopathy AE that is characterized by headache, confusion, seizures and visual loss, tends to resolve over time + + + + obo2:OAE_0001377 + SZ, SS, YH + + + + obo2:OAE_0001377 + reversible posterior leukoencephalopathy syndrome AE + + + + obo2:OAE_0001377 + MedDRA: 10063761 + + + + obo2:OAE_0001378 + a muscle adverse event that results in damaged skeletal muscle tissue breaks down rapidly + + + + obo2:OAE_0001378 + SZ, SS, YH + + + + obo2:OAE_0001378 + WEB: http://medical-dictionary.thefreedictionary.com/rhabdomyolysis + + + + obo2:OAE_0001378 + rhabdomyolysis AE + + + + obo2:OAE_0001378 + HPO: HP_0009045 + + + + obo2:OAE_0001378 + MedDRA: 10039020 + + + + obo2:OAE_0001378 + SIDER: C0035410 + + + + obo2:OAE_0001379 + a right ventricular dysfunction AE that has an outcome of congestive heart failure manifested by distention of the neck veins, enlargement of the liver, and dependent edema + + + + obo2:OAE_0001379 + SZ, SS, YH + + + + obo2:OAE_0001379 + WEB: http://medical-dictionary.thefreedictionary.com/right+ventricular+failure + + + + obo2:OAE_0001379 + right ventricular failure AE + + + + obo2:OAE_0001379 + HPO: HP_0001708 + + + + obo2:OAE_0001379 + MedDRA: 10039163 + + + + obo2:OAE_0001379 + SIDER: C2939447 + + + + obo2:OAE_0001380 + A pregnancy AE that results in the growing pregnancy in a woman's fallopian tube becoming larger than the tube and causing it to rupture + + + + obo2:OAE_0001380 + SZ, SS, YH + + + + obo2:OAE_0001380 + WEB: http://www.freemd.com/ruptured-ectopic-pregnancy/overview.htm + + + + obo2:OAE_0001380 + ruptured ectopic pregnancy AE + + + + obo2:OAE_0001380 + MedDRA: 10048407 + + + + obo2:OAE_0001381 + an abnormal salivary gland physiology AE that results in the salivary glands becoming irritated and/or swollen + + + + obo2:OAE_0001381 + SZ, SS, YH + + + + obo2:OAE_0001381 + WEB: http://www.nlm.nih.gov/medlineplus/salivaryglanddisorders.html + + + + obo2:OAE_0001381 + salivary gland disorder AE + + + + obo2:OAE_0001381 + HPO: HP_0010286 + + + + obo2:OAE_0001381 + MedDRA: 10061935 + + + + obo2:OAE_0001381 + SIDER: C0036093 + + + + obo2:OAE_0001382 + a skin AE that has an outcome of a hard coating formed during the wound healing reconstruction phase + + + + obo2:OAE_0001382 + SZ, SS, YH + + + + obo2:OAE_0001382 + WEB: http://medical-dictionary.thefreedictionary.com/scab + + + + obo2:OAE_0001382 + scab AE + + + + obo2:OAE_0001382 + HPO: HP_0007564 + + + + obo2:OAE_0001382 + MedDRA: 10039509 + + + + obo2:OAE_0001382 + SIDER: C0205204 + + + + obo2:OAE_0001383 + a nervous system AE that results in the sciatic nerve losing its sensory capabilities + + + + obo2:OAE_0001383 + SZ, SS, YH + + + + obo2:OAE_0001383 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/21995439 + + + + obo2:OAE_0001383 + sciatic nerve injury AE + + + + obo2:OAE_0001383 + MedDRA: 10039670 + + + + obo2:OAE_0001384 + an eye disorder AE that is characterized by an excessive accumulation of blood in the eye + + + + obo2:OAE_0001384 + SZ, SS, YH + + + + obo2:OAE_0001384 + scleral hyperaemia AE + + + + obo2:OAE_0001384 + WEB: http://medical-dictionary.thefreedictionary.com/hyperaemia + + + + obo2:OAE_0001384 + scleral hyperemia AE + + + + obo2:OAE_0001384 + MedDRA: 10052130 + + + + obo2:OAE_0001385 + a dementia AE that results in an elderly patient suffering from dementia + + + + obo2:OAE_0001385 + SZ, SS, YH + + + + obo2:OAE_0001385 + senile dementia AE + + + + obo2:OAE_0001385 + MedDRA: 10039966 + + + + obo2:OAE_0001386 + a sensory capability AE that results in the patient feeling their blood flow + + + + obo2:OAE_0001386 + SZ, SS, YH + + + + obo2:OAE_0001386 + sensation of blood flow AE + + + + obo2:OAE_0001386 + MedDRA: 10039996 + + + + obo2:OAE_0001387 + a shock AE that has an outcome of life-threatening low blood pressure + + + + obo2:OAE_0001387 + SZ, SS, YH + + + + obo2:OAE_0001387 + WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001689/ + + + + obo2:OAE_0001387 + septic shock AE + + + + obo2:OAE_0001387 + HPO: HP_0002718 + + + + obo2:OAE_0001387 + MedDRA: 10040070 + + + + obo2:OAE_0001387 + SIDER: C0036983 + + + + obo2:OAE_0001389 + Blood cell lab test abnormal AE showing an increase in the number of immature leukocytes in peripheral blood. (in hematology) a predominance of immature leukocytes noted in a differential white blood cell count. It is usually indicative of an infection or inflammation. The term derives from a graph of blood components in which immature cell frequencies appear on the left side of the graph. + + + + obo2:OAE_0001389 + SZ, SS, YH + + + + obo2:OAE_0001389 + WEB: http://medical-dictionary.thefreedictionary.com/shift + + + + obo2:OAE_0001389 + shift to the left AE + + + + obo2:OAE_0001389 + MedDRA: 10056383 + + + + obo2:OAE_0001390 + a physiological shock AE that has an outcome of hypovolemic shock resulting from acute hemorrhage and characterized by hypotension, tachycardia, oliguria, and by pale, cold and clammy skin + + + + obo2:OAE_0001390 + SZ, SS, YH + + + + obo2:OAE_0001390 + shock haemorrhagic AE + + + + obo2:OAE_0001390 + WEB: http://medical-dictionary.thefreedictionary.com/hemorrhagic+shock + + + + obo2:OAE_0001390 + shock hemorrhagic AE + + + + obo2:OAE_0001390 + MedDRA: 10049771 + + + + obo2:OAE_0001391 + a gastrointestinal disorder AE that results in the sigmoid colon being inflamed + + + + obo2:OAE_0001391 + SZ, SS, YH + + + + obo2:OAE_0001391 + WEB: http://medical-dictionary.thefreedictionary.com/sigmoiditis + + + + obo2:OAE_0001391 + sigmoiditis AE + + + + obo2:OAE_0001391 + MedDRA: 10052058 + + + + obo2:OAE_0001392 + a respiratory system AE that has an outcome of disease in the air-filled spaces that surround the nasal cavity, above the eyes and behind the ethmoids + + + + obo2:OAE_0001392 + SZ, SS, YH + + + + obo2:OAE_0001392 + WEB: http://medical-dictionary.thefreedictionary.com/paranasal+sinuses + + + + obo2:OAE_0001392 + sinus disorder AE + + + + obo2:OAE_0001392 + MedDRA: 10062244 + + + + obo2:OAE_0001393 + a tachycardia AE that has an outcome of elevated impulses originating from the sinoatrial node, greater than 100 bpm + + + + obo2:OAE_0001393 + SZ, SS, YH + + + + obo2:OAE_0001393 + WEB: http://medical-dictionary.thefreedictionary.com/sinus+tachycardia + + + + obo2:OAE_0001393 + sinus tachycardia AE + + + + obo2:OAE_0001393 + HPO: HP_0001649 + + + + obo2:OAE_0001393 + MedDRA: 10040752 + + + + obo2:OAE_0001393 + SIDER: C0039239 + + + + obo2:OAE_0001394 + a skin AE that is characterized by sore, cracked, or rough skin, usually on the hands, face and lips. + + + + obo2:OAE_0001394 + SZ, SS, YH + + + + obo2:OAE_0001394 + WEB: http://wellbeing.doctissimo.com/wellbeing-a-z/chapped-skin.html + + + + obo2:OAE_0001394 + skin chapped AE + + + + obo2:OAE_0001394 + MedDRA: 10040813 + + + + obo2:OAE_0001395 + a skin AE that results in linear-like cleavages in the skin + + + + obo2:OAE_0001395 + SZ, SS, YH + + + + obo2:OAE_0001395 + WEB: http://medical-dictionary.thefreedictionary.com/fissure + + + + obo2:OAE_0001395 + skin fissures AE + + + + obo2:OAE_0001395 + MedDRA: 10040849 + + + + obo2:OAE_0001396 + a skin AE that has an outcome of bleeding at the skin + + + + obo2:OAE_0001396 + SZ, SS, YH + + + + obo2:OAE_0001396 + skin haemorrhage AE + + + + obo2:OAE_0001396 + WEB: http://www.nlm.nih.gov/medlineplus/ency/article/003235.htm + + + + obo2:OAE_0001396 + skin hemorrhage AE + + + + obo2:OAE_0001396 + HPO: HP_0000967 + + + + obo2:OAE_0001396 + MedDRA: 10064265 + + + + obo2:OAE_0001396 + SIDER: C0852361 + + + + obo2:OAE_0001397 + a skin AE that has an outcome of darkening in an area of skin or nails caused by increased melanin + + + + obo2:OAE_0001397 + SZ, SS, YH + + + + obo2:OAE_0001397 + WEB: http://medical-dictionary.thefreedictionary.com/hyperpigmentation + + + + obo2:OAE_0001397 + skin hyperpigmentation AE + + + + obo2:OAE_0001397 + HPO: HP_0010284 + + + + obo2:OAE_0001397 + MedDRA: 10040865 + + + + obo2:OAE_0001397 + SIDER: C0162834 + + + + obo2:OAE_0001398 + a skin AE that has an outcome of infection. Can be bacterial, fungal, parasitic or viral + + + + obo2:OAE_0001398 + SZ, SS, YH + + + + obo2:OAE_0001398 + WEB: http://medical-dictionary.thefreedictionary.com/skin+infection + + + + obo2:OAE_0001398 + skin infection AE + + + + obo2:OAE_0001398 + HPO: HP_0001581 + + + + obo2:OAE_0001398 + MedDRA: 10040872 + + + + obo2:OAE_0001398 + SIDER: C0037278 + + + + obo2:OAE_0001399 + a skin AE that has an outcome of a jagged wound, can be shallow cuts or deep gahes that penetrate through muscle to internal organs and bone + + + + obo2:OAE_0001399 + SZ, SS, YH + + + + obo2:OAE_0001399 + WEB: http://www.mdguidelines.com/lacerations + + + + obo2:OAE_0001399 + skin laceration AE + + + + obo2:OAE_0001399 + MedDRA: 10058818 + + + + obo2:OAE_0001400 + a skin AE that has an outcome of a superficial growth or patch of the skin that does not resemble the area surrounding it + + + + obo2:OAE_0001400 + SZ, SS, YH + + + + obo2:OAE_0001400 + WEB: http://medical-dictionary.thefreedictionary.com/Skin+Lesions + + + + obo2:OAE_0001400 + skin lesion AE + + + + obo2:OAE_0001400 + HPO: HP_0011355 + + + + obo2:OAE_0001400 + MedDRA: 10040882 + + + + obo2:OAE_0001400 + SIDER: C0037284 + + + + obo2:OAE_0001401 + a skin AE that has an outcome of exposure of skin to nonspecific irritants or from the action of specific allergens + + + + obo2:OAE_0001401 + SZ, SS, YH + + + + obo2:OAE_0001401 + WEB: http://encyclopedia2.thefreedictionary.com/Skin+Reactions + + + + obo2:OAE_0001401 + skin reaction AE + + + + obo2:OAE_0001401 + MedDRA: 10040914 + + + + obo2:OAE_0001402 + a skin AE that has an outcome of irritation, sensitization and phototoxicity + + + + obo2:OAE_0001402 + SZ, SS, YH + + + + obo2:OAE_0001402 + WEB: http://medical-dictionary.thefreedictionary.com/dermal+toxicity + + + + obo2:OAE_0001402 + skin toxicity AE + + + + obo2:OAE_0001402 + MedDRA: 10059516 + + + + obo2:OAE_0001403 + a behavior and neurological AE that results in irregular sleep patterns + + + + obo2:OAE_0001403 + SZ, SS, YH + + + + obo2:OAE_0001403 + WEB: http://medical-dictionary.thefreedictionary.com/sleep+disorder + + + + obo2:OAE_0001403 + sleep disorder AE + + + + obo2:OAE_0001403 + HPO: HP_0002360 + + + + obo2:OAE_0001403 + MedDRA: 10040984 + + + + obo2:OAE_0001403 + SIDER: C0851578 + + + + obo2:OAE_0001404 + an eating disorder AE that is characterized by patient searching for food while asleep + + + + obo2:OAE_0001404 + SZ, SS, YH + + + + obo2:OAE_0001404 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/23205019 + + + + obo2:OAE_0001404 + sleep-related eating disorder AE + + + + obo2:OAE_0001404 + MedDRA: 10067315 + + + + obo2:OAE_0001405 + a gastrointestinal disorder AE that has an outcome of a blockage that keeps substance from passing through the small intestine, may be caused by fibrous bands of tissue in the abdomen, inflamed/infected pouches in the intestine, or hernias and tumors + + + + obo2:OAE_0001405 + SZ, SS, YH + + + + obo2:OAE_0001405 + WEB: http://www.mayoclinic.com/health/intestinal-obstruction/DS00823 + + + + obo2:OAE_0001405 + small intestinal obstruction AE + + + + obo2:OAE_0001405 + HPO: HP_0005214 + + + + obo2:OAE_0001405 + MedDRA: 10041101 + + + + obo2:OAE_0001405 + SIDER: C0235329 + + + + obo2:OAE_0001407 + a gastrointestinal disorder AE in which the blood vessels in the small intestine narrow + + + + obo2:OAE_0001407 + SZ, SS, YH + + + + obo2:OAE_0001407 + WEB: http://medical-dictionary.thefreedictionary.com/stenosis + + + + obo2:OAE_0001407 + small intestinal stenosis AE + + + + obo2:OAE_0001407 + MedDRA: 10062263 + + + + obo2:OAE_0001408 + a tumor AE that results in cancer in the small intestine + + + + obo2:OAE_0001408 + SZ, SS, YH + + + + obo2:OAE_0001408 + WEB: http://medical-dictionary.thefreedictionary.com/small+intestine+cancer + + + + obo2:OAE_0001408 + small intestine carcinoma AE + + + + obo2:OAE_0001408 + MedDRA: 10054184 + + + + obo2:OAE_0001409 + a gastrointestinal disorder AE that results in an ulcer in the patient's small intestine + + + + obo2:OAE_0001409 + SZ, SS, YH + + + + obo2:OAE_0001409 + small intestine ulcer AE + + + + obo2:OAE_0001409 + MedDRA: 10041133 + + + + obo2:OAE_0001410 + a soft tissue AE that occurs in the non-skeletal tissue, usually subcutaneous and muscle tissue + + + + obo2:OAE_0001410 + SZ, SS, YH + + + + obo2:OAE_0001410 + WEB: http://www.reference.md/files/D018/mD018461.html + + + + obo2:OAE_0001410 + soft tissue infection AE + + + + obo2:OAE_0001410 + HPO: HP_0002719 + + + + obo2:OAE_0001410 + MedDRA: 10062255 + + + + obo2:OAE_0001410 + SIDER: C0149778 + + + + obo2:OAE_0001411 + a soft tissue AE that results in damage to muscles, ligaments, and tendons throughout the body + + + + obo2:OAE_0001411 + SZ, SS, YH + + + + obo2:OAE_0001411 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/22964676 + + + + obo2:OAE_0001411 + soft tissue injury AE + + + + obo2:OAE_0001411 + MedDRA: 10041291 + + + + obo2:OAE_0001412 + a necrosis AE that results in necrosis occurring in soft tissue + + + + obo2:OAE_0001412 + SZ, SS, YH + + + + obo2:OAE_0001412 + WEB: http://medical-dictionary.thefreedictionary.com/necrosis + + + + obo2:OAE_0001412 + soft tissue necrosis AE + + + + obo2:OAE_0001412 + MedDRA: 10065769 + + + + obo2:OAE_0001413 + a behavior and neurological AE that results in the patient hvings a mental disorder with symptoms that may suggest physical illness or injury + + + + obo2:OAE_0001413 + SZ, SS, YH + + + + obo2:OAE_0001413 + WEB: http://medical-dictionary.thefreedictionary.com/somatoform+disorder + + + + obo2:OAE_0001413 + somatoform disorder AE + + + + obo2:OAE_0001413 + MedDRA: 10054153 + + + + obo2:OAE_0001414 + a bone disorder AE that has an outcome of vertebra collapse caused by small hairline fractures + + + + obo2:OAE_0001414 + SZ, SS, YH + + + + obo2:OAE_0001414 + WEB: http://www.webmd.com/osteoporosis/guide/spinal-compression-fractures-causes + + + + obo2:OAE_0001414 + spinal compression fracture AE + + + + obo2:OAE_0001414 + MedDRA: 10041541 + + + + obo2:OAE_0001415 + a bone disorder AE that has an outcome of spinal cord compressed by bone fragments from a vertebral fracture, a tumor, abscess, ruptured intervertebral disc or other lesion + + + + obo2:OAE_0001415 + SZ, SS, YH + + + + obo2:OAE_0001415 + WEB: http://medical-dictionary.thefreedictionary.com/spinal+cord+compression + + + + obo2:OAE_0001415 + spinal cord compression AE + + + + obo2:OAE_0001415 + HPO: HP_0002176 + + + + obo2:OAE_0001415 + MedDRA: 10041549 + + + + obo2:OAE_0001415 + SIDER: C0037926 + + + + obo2:OAE_0001416 + Tumor AE that results in a tumor in the patient's spinal cord + + + + obo2:OAE_0001416 + SZ, SS, YH + + + + obo2:OAE_0001416 + spinal cord neoplasm AE + + + + obo2:OAE_0001416 + MedDRA: 10062261 + + + + obo2:OAE_0001417 + Spinal osteoarthritis AE is a osteoarthritis AE that has an outcome of degeneration of the protective cartilage that cushions the tops of bones, causes swelling and pain and may cause development of osteophytes. + + + + obo2:OAE_0001417 + SZ, SS, YH + + + + obo2:OAE_0001417 + WEB: http://www.webmd.com/osteoarthritis/guide/spinal-osteoarthritis-degenerative-arthritis-of-the-spine + + + + obo2:OAE_0001417 + spinal osteoarthritis AE + + + + obo2:OAE_0001417 + HPO: HP_0002758 + + + + obo2:OAE_0001417 + MedDRA: 10041591 + + + + obo2:OAE_0001417 + SIDER: C0949690 + + + + obo2:OAE_0001418 + an immune system disorder AE that has an outcome of a larger-than-normal spleen, affects blood filtration + + + + obo2:OAE_0001418 + SZ, SS, YH + + + + obo2:OAE_0001418 + WEB: http://www.nlm.nih.gov/medlineplus/ency/article/003276.htm + + + + obo2:OAE_0001418 + splenomegaly AE + + + + obo2:OAE_0001418 + HPO: HP_0001744 + + + + obo2:OAE_0001418 + MedDRA: 10041660 + + + + obo2:OAE_0001418 + SIDER: C0038002 + + + + obo2:OAE_0001419 + a microbiology and serology investigation result abnormal AE that has an outcome of bacterial infection in the lungs or breathing passages + + + + obo2:OAE_0001419 + SZ, SS, YH, EB + + + + obo2:OAE_0001419 + WEB: http://www.webmd.com/lung/sputum-culture + + + + obo2:OAE_0001419 + sputum culture positive AE + + + + obo2:OAE_0001419 + MedDRA: 10051612 + + + + obo2:OAE_0001420 + a respiratory system AE that shows increased sputum, which results in mucous material coughed up from the lungs by the patient. + + + + obo2:OAE_0001420 + SZ, SS, YH + + + + obo2:OAE_0001420 + WEB: http://www.medterms.com/script/main/art.asp?articlekey=5539 + + + + obo2:OAE_0001420 + sputum increased AE + + + + obo2:OAE_0001420 + HPO: HP_0002105 + + + + obo2:OAE_0001420 + MedDRA: 10041812 + + + + obo2:OAE_0001420 + SIDER: C0235567 + + + + obo2:OAE_0001421 + a skin AE that has an outcome of a type of nonmelanoma skin cancer + + + + obo2:OAE_0001421 + SZ, SS, YH + + + + obo2:OAE_0001421 + WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001832/ + + + + obo2:OAE_0001421 + squamous cell carcinoma AE + + + + obo2:OAE_0001421 + HPO: HP_0006739 + + + + obo2:OAE_0001421 + MedDRA: 10041823 + + + + obo2:OAE_0001421 + SIDER: C0007137 + + + + obo2:OAE_0001422 + a bacterial infection AE that has an outcome of invasion by Staphylococcus, can present with pus, fever, chills and low blood pressure + + + + obo2:OAE_0001422 + SZ, SS, YH + + + + obo2:OAE_0001422 + WEB: http://www.medicinenet.com/staph_infection/page2.htm + + + + obo2:OAE_0001422 + staphylococcal infection AE + + + + obo2:OAE_0001422 + HPO: HP_0007499 + + + + obo2:OAE_0001422 + MedDRA: 10058080 + + + + obo2:OAE_0001422 + SIDER: C0038160 + + + + obo2:OAE_0001423 + a skin AE that results in the skin in the leg undergoing discoloration due to blood pooling as a result of insufficient venous return + + + + obo2:OAE_0001423 + SZ, SS, YH + + + + obo2:OAE_0001423 + WEB: http://www.nlm.nih.gov/medlineplus/ency/article/000834.htm + + + + obo2:OAE_0001423 + stasis dermatitis AE + + + + obo2:OAE_0001423 + MedDRA: 10041955 + + + + obo2:OAE_0001424 + an injury and procedural complication AE that has an outcome of blockage of the stent, or a tube inserted into body to prevent or counteract a disease-induced, localized flow constriction + + + + obo2:OAE_0001424 + SZ, SS, YH + + + + obo2:OAE_0001424 + WEB: http://www.nlm.nih.gov/medlineplus/ency/article/002303.htm + + + + obo2:OAE_0001424 + stent occlusion AE + + + + obo2:OAE_0001424 + MedDRA: 10049936 + + + + obo2:OAE_0001425 + a skin adverse event that is characterized by cell death causing the epidermis to separate from the dermis + + + + obo2:OAE_0001425 + SZ, SS, YH + + + + obo2:OAE_0001425 + WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001854/ + + + + obo2:OAE_0001425 + stevens-johnson syndrome AE + + + + obo2:OAE_0001425 + HPO: HP_0000951 + + + + obo2:OAE_0001425 + MedDRA: 10042033 + + + + obo2:OAE_0001425 + SIDER: C0038325 + + + + obo2:OAE_0001426 + a stress AE that results in patient experiencing stress at work + + + + obo2:OAE_0001426 + SZ, SS, YH + + + + obo2:OAE_0001426 + stress at work AE + + + + obo2:OAE_0001426 + MedDRA: 10042210 + + + + obo2:OAE_0001428 + a nervous system AE that has an outcome of bleeding in the area between the brain and the thin tissues that cover the brain + + + + obo2:OAE_0001428 + SZ, SS, YH + + + + obo2:OAE_0001428 + subarachnoid haemorrhage AE + + + + obo2:OAE_0001428 + WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001720/ + + + + obo2:OAE_0001428 + subarachnoid hemorrhage AE + + + + obo2:OAE_0001428 + HPO: HP_0002138 + + + + obo2:OAE_0001428 + MedDRA: 10042316 + + + + obo2:OAE_0001428 + SIDER: C0038525 + + + + obo2:OAE_0001429 + a nervous system AE that has an outcome of a collection of blood on the surface of the brain + + + + obo2:OAE_0001429 + SZ, SS, YH + + + + obo2:OAE_0001429 + subdural haematoma AE + + + + obo2:OAE_0001429 + WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001732/ + + + + obo2:OAE_0001429 + subdural hematoma AE + + + + obo2:OAE_0001429 + HPO: HP_0100309 + + + + obo2:OAE_0001429 + MedDRA: 10042361 + + + + obo2:OAE_0001429 + SIDER: C0018946 + + + + obo2:OAE_0001430 + A gastrointestinal hemorrhage AE that has an outcome of the bleeding in the stomach + + + + obo2:OAE_0001430 + YH, SS + + + + obo2:OAE_0001430 + gastric haemorrhage AE + + + + obo2:OAE_0001430 + gastric hemorrhage AE + + + + obo2:OAE_0001430 + MedDRA: 10017788 + + + + obo2:OAE_0001431 + a death AE that has an outcome of unexpected death, 1 to 24 hours after the onset of symptoms + + + + obo2:OAE_0001431 + SZ, SS, YH + + + + obo2:OAE_0001431 + WEB: http://medical-dictionary.thefreedictionary.com/sudden+death + + + + obo2:OAE_0001431 + sudden death AE + + + + obo2:OAE_0001431 + HPO: HP_0001645 + + + + obo2:OAE_0001431 + MedDRA: 10042434 + + + + obo2:OAE_0001431 + SIDER: C0011071 + + + + obo2:OAE_0001432 + a behavior and Neurological AE that results in thoughts about suicide + + + + obo2:OAE_0001432 + SZ, SS, YH + + + + obo2:OAE_0001432 + WEB: Primary Source: http://medical-dictionary.thefreedictionary.com/Suicidal+ideation Secondary Source: http://www.ncbi.nlm.nih.gov/pubmed/10193592 + + + + obo2:OAE_0001432 + suicidal ideation AE + + + + obo2:OAE_0001432 + MedDRA: 10042458 + + + + obo2:OAE_0001433 + a behavior and Neurological AE that results in attempted suicide + + + + obo2:OAE_0001433 + SZ, SS, YH + + + + obo2:OAE_0001433 + suicide attempt AE + + + + obo2:OAE_0001433 + HPO: HP_0000708 + + + + obo2:OAE_0001433 + MedDRA: 10043464 + + + + obo2:OAE_0001433 + SIDER: C0038663 + + + + obo2:OAE_0001434 + a viral infection AE that has an outcome of a cell that was previously infected being coinfected with a different strain of the virus + + + + obo2:OAE_0001434 + SZ, SS, YH + + + + obo2:OAE_0001434 + WEB: http://medical-dictionary.thefreedictionary.com/superinfection + + + + obo2:OAE_0001434 + superinfection AE + + + + obo2:OAE_0001434 + HPO: HP_0005364 + + + + obo2:OAE_0001434 + MedDRA: 10042566 + + + + obo2:OAE_0001434 + SIDER: C0038826 + + + + obo2:OAE_0001435 + a venous thrombosis AE in which a stroke occurs as a result of thrombosis. uncommon cerebrovascular accident that is frequently associated with diseases that may contribute to the development of thrombosis through hypercoagulability, stasis of the local blood stream, and abnormalities of the vessel wall. + + + + obo2:OAE_0001435 + SZ, SS, YH + + + + obo2:OAE_0001435 + SSST + + + + obo2:OAE_0001435 + WEB: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1026412 + + + + obo2:OAE_0001435 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/1455986 + + + + obo2:OAE_0001435 + superior sagittal sinus thrombosis AE + + + + obo2:OAE_0001435 + MedDRA: 10042567 + + + + obo2:OAE_0001436 + an arrhythmia AE that has an outcome of premature atrial contractions or beats caused by signals originating from ectopic atrial sites + + + + obo2:OAE_0001436 + SZ, SS, YH + + + + obo2:OAE_0001436 + WEB: http://sideeffects.embl.de/se/C0033036/ + + + + obo2:OAE_0001436 + supraventricular extrasystoles AE + + + + obo2:OAE_0001436 + HPO: HP_0005115 + + + + obo2:OAE_0001436 + MedDRA: 10042602 + + + + obo2:OAE_0001436 + SIDER: C0033036 + + + + obo2:OAE_0001437 + a tachycardia AE that has an outcome of rapid heart rhythm originating at or above the atrioventricular node + + + + obo2:OAE_0001437 + SZ, SS, YH + + + + obo2:OAE_0001437 + WEB: Primary Source: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001235/ Secondary Source: http://www.ncbi.nlm.nih.gov/pubmed/23233691 + + + + obo2:OAE_0001437 + supraventricular tachycardia AE + + + + obo2:OAE_0001437 + HPO: HP_0004765 + + + + obo2:OAE_0001437 + MedDRA: 10042604 + + + + obo2:OAE_0001437 + SIDER: C0039240 + + + + obo2:OAE_0001438 + Adverse event that is characterized by the patient becoming increasingly suspicious + + + + obo2:OAE_0001438 + SZ, SS, YH + + + + obo2:OAE_0001438 + suspiciousness AE + + + + obo2:OAE_0001438 + MedDRA: 10042635 + + + + obo2:OAE_0001439 + an injury and procedural complication AE that results in a complication resulting from a suture + + + + obo2:OAE_0001439 + SZ, SS, YH + + + + obo2:OAE_0001439 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/17276274 + + + + obo2:OAE_0001439 + suture related complication AE + + + + obo2:OAE_0001439 + MedDRA: 10059059 + + + + obo2:OAE_0001440 + an injury and procedural complication AE that results in a suture being used to hold body tissues together, ruptures + + + + obo2:OAE_0001440 + SZ, SS, YH + + + + obo2:OAE_0001440 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/21266279 + + + + obo2:OAE_0001440 + suture rupture AE + + + + obo2:OAE_0001440 + MedDRA: 10048547 + + + + obo2:OAE_0001441 + an increased heartbeat AE that is characterized by a distburance of the heart rhythm in which heart rate is abnormally increased + + + + obo2:OAE_0001441 + SZ, SS, YH + + + + obo2:OAE_0001441 + WEB: http://medical-dictionary.thefreedictionary.com/tachyarrhythmia + + + + obo2:OAE_0001441 + tachyarrhythmia AE + + + + obo2:OAE_0001441 + HPO: HP_0001649 + + + + obo2:OAE_0001441 + MedDRA: 10049447 + + + + obo2:OAE_0001441 + SIDER: C0080203 + + + + obo2:OAE_0001442 + a tachycardia AE that results in tachycardia beginings and ending in an acute manner + + + + obo2:OAE_0001442 + SZ, SS, YH + + + + obo2:OAE_0001442 + WEB: Primary Source: http://www.ncbi.nlm.nih.gov/pubmed/11208235 Secondary Source: http://www.nlm.nih.gov/medlineplus/ency/article/000183.htm + + + + obo2:OAE_0001442 + tachycardia paroxysmal AE + + + + obo2:OAE_0001442 + MedDRA: 10043079 + + + + obo2:OAE_0001443 + an abnormal repiration AE that shows an outcome of tachypnoea (i.e., abnormally rapid breathing or respiration) + + + + obo2:OAE_0001443 + SZ, SS, YH + + + + obo2:OAE_0001443 + tachypnoea AE + + + + obo2:OAE_0001443 + tachypnea AE + + + + obo2:OAE_0001443 + HPO: HP_0004346 + + + + obo2:OAE_0001443 + MedDRA: 10043089 + + + + obo2:OAE_0001443 + SIDER: C0231835 + + + + obo2:OAE_0001445 + Behavior and neurological AE that results in the patient having recurring seizures + + + + obo2:OAE_0001445 + SZ, SS, YH + + + + obo2:OAE_0001445 + WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001714/ + + + + obo2:OAE_0001445 + temporal lobe epilepsy AE + + + + obo2:OAE_0001445 + MedDRA: 10043209 + + + + obo2:OAE_0001446 + An immune system disorder AE that is a complication that can occur after a stem or bone marrow transplant in which the newly transplanted donor cells attack the transplant recipient's body + + + + obo2:OAE_0001446 + YH, SS + + + + obo2:OAE_0001446 + GVHD + + + + obo2:OAE_0001446 + WEB: http://www.nlm.nih.gov/medlineplus/ency/article/001309.htm + + + + obo2:OAE_0001446 + graft versus host disease AE + + + + obo2:OAE_0001446 + MedDRA: 10018651 + + + + obo2:OAE_0001447 + a hematopoietic system AE that has an outcome of too many blood platelets or thrombocytes, can result in headache, lightheadedness, vision changes and limb numbness + + + + obo2:OAE_0001447 + SZ, SS, YH + + + + obo2:OAE_0001447 + thrombocythaemia AE + + + + obo2:OAE_0001447 + WEB: http://www.mayoclinic.com/health/thrombocythemia/DS01087 + + + + obo2:OAE_0001447 + thrombocythemia AE + + + + obo2:OAE_0001447 + MedDRA: 10015493 + + + + obo2:OAE_0001448 + a hematopoietic system AE that has an outcome of decrease in platelets in the blood + + + + obo2:OAE_0001448 + SZ, SS, YH + + + + obo2:OAE_0001448 + WEB: http://www.nlm.nih.gov/medlineplus/ency/article/000586.htm + + + + obo2:OAE_0001448 + thrombocytopenia AE + + + + obo2:OAE_0001448 + HPO: HP_0001873 + + + + obo2:OAE_0001448 + MedDRA: 10043554 + + + + obo2:OAE_0001448 + SIDER: C0040034 + + + + obo2:OAE_0001449 + a phlebitis AE located in the vein, caused by a blood clot + + + + obo2:OAE_0001449 + SZ, SS, YH + + + + obo2:OAE_0001449 + WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0002098/ + + + + obo2:OAE_0001449 + WEB: http://www.nlm.nih.gov/medlineplus/ency/article/001108.htm + + + + obo2:OAE_0001449 + thrombophlebitis AE + + + + obo2:OAE_0001449 + HPO: HP_0004418 + + + + obo2:OAE_0001449 + MedDRA: 10043570 + + + + obo2:OAE_0001449 + SIDER: C0040046 + + + + obo2:OAE_0001450 + a thrombosis AE that is characterized by a pathological process involving thrombocytopenia, microangiopathic haemolytic anaemia and microvascular occlusion + + + + obo2:OAE_0001450 + SZ, SS, YH + + + + obo2:OAE_0001450 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/22802583 + +WEB: Primary Source: http://www.ncbi.nlm.nih.gov/pubmed/18215115 Secondary Source: http://www.nejm.org/doi/full/10.1056/NEJMra020528 + + + + obo2:OAE_0001450 + thrombotic microangiopathy AE + + + + obo2:OAE_0001450 + HPO: HP_0002597 + + + + obo2:OAE_0001450 + MedDRA: 10043645 + + + + obo2:OAE_0001450 + SIDER: C2717961 + + + + obo2:OAE_0001451 + a tumor AE that results in a benign tumor in the thyroid + + + + obo2:OAE_0001451 + SZ, SS, YH + + + + obo2:OAE_0001451 + WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0004524/ + + + + obo2:OAE_0001451 + thyroid adenoma AE + + + + obo2:OAE_0001451 + HPO: HP_0000854 + + + + obo2:OAE_0001451 + MedDRA: 10043688 + + + + obo2:OAE_0001451 + SIDER: C0151468 + + + + obo2:OAE_0001452 + a tumor AE that results in the patient hvings a mass growing in their thyroid + + + + obo2:OAE_0001452 + SZ, SS, YH + + + + obo2:OAE_0001452 + thyroid mass AE + + + + obo2:OAE_0001452 + MedDRA: 10058900 + + + + obo2:OAE_0001453 + an arrhythmia AE that has an outcome of an irregular rate of the heartbeat + + + + obo2:OAE_0001453 + YH, SS + + + + obo2:OAE_0001453 + heart rate irregular AE + + + + obo2:OAE_0001453 + HPO: HP_0011675 + + + + obo2:OAE_0001453 + MedDRA: 10019304 + + + + obo2:OAE_0001453 + SIDER: C0237314 + + + + obo2:OAE_0001454 + a syndrome AE that results in the patient suffering from withdrawal from not using tobacco + + + + obo2:OAE_0001454 + SZ, SS, YH + + + + obo2:OAE_0001454 + tobacco withdrawal symptoms AE + + + + obo2:OAE_0001454 + MedDRA: 10059612 + + + + obo2:OAE_0001455 + a tongue AE that has an outcome of open sores or cuts on the tongue + + + + obo2:OAE_0001455 + SZ, SS, YH + + + + obo2:OAE_0001455 + WEB: http://www.localhealth.com/article/tongue-ulcers + + + + obo2:OAE_0001455 + tongue ulceration AE + + + + obo2:OAE_0001455 + HPO: HP_0000155 + + + + obo2:OAE_0001455 + MedDRA: 10043991 + + + + obo2:OAE_0001455 + SIDER: C0235351 + + + + obo2:OAE_0001456 + Tumor AE that results in cancer in the patient's tonsils + + + + obo2:OAE_0001456 + SZ, SS, YH + + + + obo2:OAE_0001456 + tonsil cancer AE + + + + obo2:OAE_0001456 + MedDRA: 10044002 + + + + obo2:OAE_0001457 + a bone disorder AE that has an outcome of an abscess located in the tooth or a bacterial infection in the center of a tooth + + + + obo2:OAE_0001457 + SZ, SS, YH + + + + obo2:OAE_0001457 + WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0002055/ + + + + obo2:OAE_0001457 + tooth abscess AE + + + + obo2:OAE_0001457 + HPO: HP_0000164 + + + + obo2:OAE_0001457 + MedDRA: 10044016 + + + + obo2:OAE_0001457 + SIDER: C0518988 + + + + obo2:OAE_0001458 + a bone disorder AE that has an outcome of disease in the teeth + + + + obo2:OAE_0001458 + SZ, SS, YH + + + + obo2:OAE_0001458 + WEB: http://www.nlm.nih.gov/medlineplus/toothdisorders.html + + + + obo2:OAE_0001458 + tooth disorder AE + + + + obo2:OAE_0001458 + HPO: HP_0000164 + + + + obo2:OAE_0001458 + MedDRA: 10044034 + + + + obo2:OAE_0001458 + SIDER: C0040435 + + + + obo2:OAE_0001459 + a bone disorder AE that has an outcome of a break or rupture in a bone + + + + obo2:OAE_0001459 + SZ, SS, YH + + + + obo2:OAE_0001459 + WEB: http://medical-dictionary.thefreedictionary.com/tooth+fracture + + + + obo2:OAE_0001459 + tooth fracture AE + + + + obo2:OAE_0001459 + MedDRA: 10062544 + + + + obo2:OAE_0001460 + a bone disorder AE that has an outcome of one or more teeth coming loose and falling out + + + + obo2:OAE_0001460 + SZ, SS, YH + + + + obo2:OAE_0001460 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/23253824 + + + + obo2:OAE_0001460 + tooth loss AE + + + + obo2:OAE_0001460 + HPO: HP_0006349 + + + + obo2:OAE_0001460 + MedDRA: 10044044 + + + + obo2:OAE_0001460 + SIDER: C0080233 + + + + obo2:OAE_0001461 + a bone disorder AE that has an outcome of an aching pain in or around a tooth + + + + obo2:OAE_0001461 + SZ, SS, YH + + + + obo2:OAE_0001461 + odontalgia AE + + + + obo2:OAE_0001461 + WEB: Primary Source: http://medical-dictionary.thefreedictionary.com/toothache Seconday Source: http://www.ncbi.nlm.nih.gov/pubmed/22157099 + + + + obo2:OAE_0001461 + toothache AE + + + + obo2:OAE_0001461 + HPO: HP_0000164 + + + + obo2:OAE_0001461 + MedDRA: 10044055 + + + + obo2:OAE_0001461 + SIDER: C0040460 + + + + obo2:OAE_0001462 + a endocrine system AE that has an outcome of an excess production of thryoid hormone, characterized by functionally autonomous nodules + + + + obo2:OAE_0001462 + SZ, SS, YH + + + + obo2:OAE_0001462 + WEB: http://www.nlm.nih.gov/medlineplus/ency/article/000317.htm + + + + obo2:OAE_0001462 + toxic nodular goitre AE + + + + obo2:OAE_0001462 + MedDRA: 10044242 + + + + obo2:OAE_0001463 + A liver AE that has an outcome of an abnormal functionality of the liver + + + + obo2:OAE_0001463 + YH, SS + + + + obo2:OAE_0001463 + hepatic function abnormal AE + + + + obo2:OAE_0001463 + HPO: HP_0001410 + + + + obo2:OAE_0001463 + SIDER: C0086565 + + + + obo2:OAE_0001464 + a respiratory system AE that results in the trachea being infected by a bacteria + + + + obo2:OAE_0001464 + SZ, SS, YH + + + + obo2:OAE_0001464 + WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001983/ + + + + obo2:OAE_0001464 + tracheitis AE + + + + obo2:OAE_0001464 + MedDRA: 10066798 + + + + obo2:OAE_0001465 + a respiratory system AE that is characterized by the inflammation of the muscous membranes of the trachea and bronchi + + + + obo2:OAE_0001465 + SZ, SS, YH + + + + obo2:OAE_0001465 + WEB: http://medical-dictionary.thefreedictionary.com/tracheobronchitis + + + + obo2:OAE_0001465 + tracheobronchitis AE + + + + obo2:OAE_0001465 + HPO: HP_0002837 + + + + obo2:OAE_0001465 + MedDRA: 10044314 + + + + obo2:OAE_0001465 + SIDER: C0040586 + + + + obo2:OAE_0001466 + a behavior and neurological AEthat results in the patient being in a state of trance + + + + obo2:OAE_0001466 + SZ, SS, YH + + + + obo2:OAE_0001466 + WEB: http://medical-dictionary.thefreedictionary.com/trance + + + + obo2:OAE_0001466 + trance AE + + + + obo2:OAE_0001466 + MedDRA: 10044334 + + + + obo2:OAE_0001467 + a transaminase level abnormal AE that has an outcome of elevated levels of alanine transaminase and aspartate transaminase + + + + obo2:OAE_0001467 + SZ, SS, YH + + + + obo2:OAE_0001467 + WEB: http://medical-dictionary.thefreedictionary.com/Transaminases + + + + obo2:OAE_0001467 + transaminase level increased AE + + + + obo2:OAE_0001467 + MedDRA: 10054889 + + + + obo2:OAE_0001468 + A cardiomyopathy AE that has an outcome of a condition in which the heart muscle becomes thick. Often, only one part of the heart is thicker than the other parts. The thickening can make it harder for blood to leave the heart, forcing the heart to work harder to pump blood. It also can make it harder for the heart to relax and fill with blood. + + + + obo2:OAE_0001468 + YH, SS + + + + obo2:OAE_0001468 + HCM + + + + obo2:OAE_0001468 + WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001243/ + + + + obo2:OAE_0001468 + hypertrophic cardiomyopathy AE + + + + obo2:OAE_0001468 + HPO: HP_0001639 + + + + obo2:OAE_0001468 + MedDRA: 10020871 + + + + obo2:OAE_0001468 + SIDER: C0007194 + + + + obo2:OAE_0001469 + a vascular disorder AE that results in an abnormal spatial arrangement of any of the primary blood vessels + + + + obo2:OAE_0001469 + SZ, SS, YH + + + + obo2:OAE_0001469 + WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0002535/ + + + + obo2:OAE_0001469 + transposition of the great vessels AE + + + + obo2:OAE_0001469 + MedDRA: 10044443 + + + + obo2:OAE_0001471 + a cardiac valve disease AE that is characterized by a tricuspid valve that does not close tightly enough to prevent leakage + + + + obo2:OAE_0001471 + SZ, SS, YH + + + + obo2:OAE_0001471 + WEB: http://medical-dictionary.thefreedictionary.com/Tricuspid+Valve+Insufficiency + + + + obo2:OAE_0001471 + tricuspid valve incompetence AE + + + + obo2:OAE_0001471 + MedDRA: 10044640 + + + + obo2:OAE_0001472 + a tri-iodothyronine level abnormal AE that results in a decreased level of tri-iodothyronine + + + + obo2:OAE_0001472 + SZ, SS, YH, EB + + + + obo2:OAE_0001472 + WEB: http://medical-dictionary.thefreedictionary.com/Tri-iodothyronine + + + + obo2:OAE_0001472 + tri-iodothyronine decreased AE + + + + obo2:OAE_0001472 + MedDRA: 10044594 + + + + obo2:OAE_0001473 + a troponin level abnormal AE that has an outcome of an increased amount of troponin, a protein released when the heart muscle is damaged + + + + obo2:OAE_0001473 + SZ, SS, YH, EB + + + + obo2:OAE_0001473 + WEB: http://www.nlm.nih.gov/medlineplus/ency/article/007452.htm + + + + obo2:OAE_0001473 + troponin level increased AE + + + + obo2:OAE_0001473 + MedDRA: 10058267 + + + + obo2:OAE_0001474 + a bacterial infection AE that is caused by M. tuberculosis. + + + + obo2:OAE_0001474 + SZ, SS, YH + + + + obo2:OAE_0001474 + WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001141/ + + + + obo2:OAE_0001474 + tuberculosis AE + + + + obo2:OAE_0001474 + MedDRA: 10044755 + + + + obo2:OAE_0001476 + Tumor AE that results in a tumor reoccurring + + + + obo2:OAE_0001476 + SZ, SS, YH + + + + obo2:OAE_0001476 + tumour flare AE + + + + obo2:OAE_0001476 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/21523725 + + + + obo2:OAE_0001476 + tumor flare AE + + + + obo2:OAE_0001476 + MedDRA: 10045169 + + + + obo2:OAE_0001477 + an hemorrhage AE that has an outcome of bleeding in the tumour + + + + obo2:OAE_0001477 + SZ, SS, YH + + + + obo2:OAE_0001477 + tumour haemorrhage AE + + + + obo2:OAE_0001477 + WEB: http://calder.med.miami.edu/pointis/tbifam/cause3.html + + + + obo2:OAE_0001477 + tumour hemorrhage AE + + + + obo2:OAE_0001477 + MedDRA: 10049750 + + + + obo2:OAE_0001478 + a syndrome AE that has an outcome of a group of metabolic complications that can occur after treatment of cancer + + + + obo2:OAE_0001478 + SZ, SS, YH + + + + obo2:OAE_0001478 + tumour lysis syndrome AE + + + + obo2:OAE_0001478 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/15384972 + + + + obo2:OAE_0001478 + tumor lysis syndrome AE + + + + obo2:OAE_0001478 + MedDRA: 10045170 + + + + obo2:OAE_0001479 + a cytogenetic investigation result abnormal AE that has an outcome of an increase in a substance found in the blood, urine, or body tissues that can be elevated in cancer, among other tissue types + + + + obo2:OAE_0001479 + SZ, SS, YH, EB + + + + obo2:OAE_0001479 + tumour marker increased AE + + + + obo2:OAE_0001479 + WEB: http://www.cancer.gov/cancertopics/factsheet/detection/tumor-markers + + + + obo2:OAE_0001479 + tumor marker increased AE + + + + obo2:OAE_0001479 + MedDRA: 10048621 + + + + obo2:OAE_0001480 + a necrosis AE that has an outcome of death of tumor tissue, tumor rapidly outgrows its blood supply + + + + obo2:OAE_0001480 + SZ, SS, YH + + + + obo2:OAE_0001480 + tumour necrosis AE + + + + obo2:OAE_0001480 + WEB: http://medical-dictionary.thefreedictionary.com/tumor+necrosis + + + + obo2:OAE_0001480 + tumor necrosis AE + + + + obo2:OAE_0001480 + MedDRA: 10054094 + + + + obo2:OAE_0001481 + an eye inflammation AE that has an outcome of disrupted epithelial layer and stroma of the cornea, may become blind + + + + obo2:OAE_0001481 + SZ, SS, YH + + + + obo2:OAE_0001481 + corneal ulcer AE + + + + obo2:OAE_0001481 + WEB: http://medical-dictionary.thefreedictionary.com/Ulcerative+keratitis + + + + obo2:OAE_0001481 + ulcerative keratitis AE + + + + obo2:OAE_0001481 + HPO: HP_0007812 + + + + obo2:OAE_0001481 + MedDRA: 10064996 + + + + obo2:OAE_0001481 + SIDER: C0010043 + + + + obo2:OAE_0001482 + Homeostasis AE that results in an inability to achieve adequate fluid balance + + + + obo2:OAE_0001482 + SZ, SS, YH + + + + obo2:OAE_0001482 + ultrafiltration failure AE + + + + obo2:OAE_0001482 + MedDRA: 10069568 + + + + obo2:OAE_0001483 + Respiratory system AE that is characterized by the patient having an obstruction in their upper airway + + + + obo2:OAE_0001483 + SZ, SS, YH + + + + obo2:OAE_0001483 + upper airway obstruction AE + + + + obo2:OAE_0001483 + HPO: HP_0002781 + + + + obo2:OAE_0001483 + MedDRA: 10067775 + + + + obo2:OAE_0001483 + SIDER: C0740852 + + + + obo2:OAE_0001484 + a gastrointestinal hemorrhage AE that has an outcome of bleeding in the upper gastrointestinal tract + + + + obo2:OAE_0001484 + SZ, SS, YH + + + + obo2:OAE_0001484 + upper gastrointestinal haemorrhage AE + + + + obo2:OAE_0001484 + WEB: Primary Source: http://medical-dictionary.thefreedictionary.com/gastrointestinal+bleeding Secondary Source: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1237869/ + + + + obo2:OAE_0001484 + upper gastrointestinal hemorrhage AE + + + + obo2:OAE_0001484 + HPO: HP_0002239 + + + + obo2:OAE_0001484 + MedDRA: 10046274 + + + + obo2:OAE_0001484 + SIDER: C0041909 + + + + obo2:OAE_0001485 + a urinary system AE that has an outcome of a blockage in the urinary tract, can result in pain, fever, infection, loss of kidney function, sepsis or death if severe + + + + obo2:OAE_0001485 + SZ, SS, YH + + + + obo2:OAE_0001485 + WEB: http://www.mayoclinic.org/ureteral-obstruction/ + + + + obo2:OAE_0001485 + ureteric obstruction AE + + + + obo2:OAE_0001485 + HPO: HP_0006000 + + + + obo2:OAE_0001485 + MedDRA: 10046406 + + + + obo2:OAE_0001485 + SIDER: C0041956 + + + + obo2:OAE_0001486 + Urinary system AE that results in the urethra becoming obstructed + + + + obo2:OAE_0001486 + SZ, SS, YH + + + + obo2:OAE_0001486 + urethral obstruction AE + + + + obo2:OAE_0001486 + HPO: HP_0000796 + + + + obo2:OAE_0001486 + MedDRA: 10046459 + + + + obo2:OAE_0001486 + SIDER: C0041972 + + + + obo2:OAE_0001487 + Urinary System AE that results in the urethra becoming narrowed at the external meatus + + + + obo2:OAE_0001487 + SZ, SS, YH + + + + obo2:OAE_0001487 + WEB: Primary Source: http://medical-dictionary.thefreedictionary.com/urethral+meatal+stenosis Secondary Source: http://www.ncbi.nlm.nih.gov/pubmed/22710090 + + + + obo2:OAE_0001487 + urethral stenosis AE + + + + obo2:OAE_0001487 + MedDRA: 10065584 + + + + obo2:OAE_0001488 + a urinary incontinence AE that results in the patient feeling a sudden urgency or need to urinate. + + + + obo2:OAE_0001488 + SZ, SS, YH + + + + obo2:OAE_0001488 + micturition urgency AE + + + + obo2:OAE_0001488 + WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0002250/ + + + + obo2:OAE_0001488 + urge incontinence AE + + + + obo2:OAE_0001488 + HPO: HP_0000012 + + + + obo2:OAE_0001488 + MedDRA: 10046494 + + + + obo2:OAE_0001488 + SIDER: C0150045 + + + + obo2:OAE_0001489 + Urinary system AE that results in an inability to urinate + + + + obo2:OAE_0001489 + SZ, SS, YH + + + + obo2:OAE_0001489 + WEB: Primary Source: http://medical-dictionary.thefreedictionary.com/urinary+retention Secondary Source: http://www.medtronic.com/patients/urinary-retention/index.htm + + + + obo2:OAE_0001489 + urinary retention AE + + + + obo2:OAE_0001489 + HPO: HP_0000016 + + + + obo2:OAE_0001489 + MedDRA: 10046555 + + + + obo2:OAE_0001489 + SIDER: C0080274 + + + + obo2:OAE_0001490 + a urinary tract infection AE that results in the infection of the urinary tract by the Pseudomonas Aeruginosa organism + + + + obo2:OAE_0001490 + SZ, SS, YH + + + + obo2:OAE_0001490 + WEB: http://www.jiph.org/article/S1876-0341(09)00058-6/abstract + + + + obo2:OAE_0001490 + urinary tract infection pseudomonal AE + + + + obo2:OAE_0001490 + MedDRA: 10062279 + + + + obo2:OAE_0001491 + a urinary tract infection AE that results in the urinary tract being infected with the staphylococcal bacteria + + + + obo2:OAE_0001491 + SZ, SS, YH + + + + obo2:OAE_0001491 + urinary tract infection staphylococcal AE + + + + obo2:OAE_0001491 + MedDRA: 10062280 + + + + obo2:OAE_0001492 + a toxicology drug screen result abnormal AE that results in a positive result for amphetamines in the urine + + + + obo2:OAE_0001492 + SZ, SS, YH, EB + + + + obo2:OAE_0001492 + urine amphetamine positive AE + + + + obo2:OAE_0001492 + MedDRA: 10051400 + + + + obo2:OAE_0001493 + a urine abnormality AE that has an outcome of decreased urine output, less than 500 milliliters of urine in 24 hours + + + + obo2:OAE_0001493 + SZ, SS, YH + + + + obo2:OAE_0001493 + WEB: http://www.nlm.nih.gov/medlineplus/ency/article/003147.htm + + + + obo2:OAE_0001493 + urine output decreased AE + + + + obo2:OAE_0001493 + MedDRA: 10059895 + + + + obo2:OAE_0001494 + a urinary system AE caused by an infection in the urinary tract that has an outcome of accumulation of pus-forming bacteria or toxins in the blood of the urinary tract. + + + + obo2:OAE_0001494 + SZ, SS, YH + + + + obo2:OAE_0001494 + WEB: http://www.primehealthchannel.com/urosepsis-definition-symptoms-causes-diagnosis-and-treatment.html + + + + obo2:OAE_0001494 + urosepsis AE + + + + obo2:OAE_0001494 + MedDRA: 10048709 + + + + obo2:OAE_0001495 + an urticaria AE that results in the appearance of "wheals" on skin + + + + obo2:OAE_0001495 + SZ, SS, YH + + + + obo2:OAE_0001495 + WEB: http://medical-dictionary.thefreedictionary.com/papular+urticaria + + + + obo2:OAE_0001495 + urticaria papular AE + + + + obo2:OAE_0001495 + MedDRA: 10046750 + + + + obo2:OAE_0001496 + Female reproductive system AE that results in uterine contractions during pregnancy + + + + obo2:OAE_0001496 + SZ, SS, YH + + + + obo2:OAE_0001496 + uterine contractions during pregnancy AE + + + + obo2:OAE_0001496 + MedDRA: 10049975 + + + + obo2:OAE_0001497 + a female reproductive system AE that has an outcome of bleeding from the uterus + + + + obo2:OAE_0001497 + SZ, SS, YH + + + + obo2:OAE_0001497 + uterine haemorrhage AE + + + + obo2:OAE_0001497 + uterine hemorrhage AE + + + + obo2:OAE_0001497 + HPO: HP_0000130 + + + + obo2:OAE_0001497 + MedDRA: 10046788 + + + + obo2:OAE_0001497 + SIDER: C0042134 + + + + obo2:OAE_0001498 + Female reproductive system AE that results in the patient undergoing a single uterine contraction for over two minutes during pregnancy + + + + obo2:OAE_0001498 + SZ, SS, YH + + + + obo2:OAE_0001498 + WEB: Primary Source: http://www.ncbi.nlm.nih.gov/pubmed/12192488 Secondary Source: http://www.ncbi.nlm.nih.gov/pubmed/12192488 + + + + obo2:OAE_0001498 + uterine hypertonus AE + + + + obo2:OAE_0001498 + HPO: HP_0000130 + + + + obo2:OAE_0001498 + MedDRA: 10046790 + + + + obo2:OAE_0001498 + SIDER: C0269842 + + + + obo2:OAE_0001499 + an infection AE that results in infection of the vagina + + + + obo2:OAE_0001499 + SZ, SS, YH + + + + obo2:OAE_0001499 + vaginal infection AE + + + + obo2:OAE_0001499 + HPO: HP_0000142 + + + + obo2:OAE_0001499 + MedDRA: 10046914 + + + + obo2:OAE_0001499 + SIDER: C0404521 + + + + obo2:OAE_0001500 + a digestive system AE that has an outcome of dilated sub-mucosal veins in the lower third of the esophagus + + + + obo2:OAE_0001500 + SZ, SS, YH + + + + obo2:OAE_0001500 + varices oesophageal AE + + + + obo2:OAE_0001500 + WEB: http://www.mayoclinic.com/health/esophageal-varices/DS00820 + + + + obo2:OAE_0001500 + varices esophageal AE + + + + obo2:OAE_0001500 + HPO: HP_0002040 + + + + obo2:OAE_0001500 + MedDRA: 10056091 + + + + obo2:OAE_0001500 + SIDER: C0014867 + + + + obo2:OAE_0001501 + a dementia AE that results in problems with reasoning, judgement, and memory resulting from brain damage from impaired blood flow to the brain + + + + obo2:OAE_0001501 + SZ, SS, YH + + + + obo2:OAE_0001501 + WEB: http://www.mayoclinic.com/health/vascular-dementia/DS00934 + + + + obo2:OAE_0001501 + vascular dementia AE + + + + obo2:OAE_0001501 + MedDRA: 10057678 + + + + obo2:OAE_0001502 + a vascular disorder AE that results in the veins becoming discoloured + + + + obo2:OAE_0001502 + SZ, SS, YH + + + + obo2:OAE_0001502 + vein discolouration AE + + + + obo2:OAE_0001502 + vein discoloration AE + + + + obo2:OAE_0001502 + MedDRA: 10047183 + + + + obo2:OAE_0001503 + a thrombosis AE that has an outcome of a blood clot in the inferior vena cava + + + + obo2:OAE_0001503 + SZ, SS, YH + + + + obo2:OAE_0001503 + vena cava embolism AE + + + + obo2:OAE_0001503 + WEB: http://emedicine.medscape.com/article/1933035-overview, http://www.nlm.nih.gov/medlineplus/ency/article/000156.htm + + + + obo2:OAE_0001503 + vena cava thrombosis AE + + + + obo2:OAE_0001503 + MedDRA: 10047193 + + + + obo2:OAE_0001503 + MedDRA: 10047195 + + + + obo2:OAE_0001504 + a vascular disorder AE that results in an injury to the vein(s) + + + + obo2:OAE_0001504 + SZ, SS, YH + + + + obo2:OAE_0001504 + venous injury AE + + + + obo2:OAE_0001504 + MedDRA: 10047228 + + + + obo2:OAE_0001505 + a thrombosis AE that has an outcome of a blood clot that forms within a vein + + + + obo2:OAE_0001505 + SZ, SS, YH + + + + obo2:OAE_0001505 + WEB: http://www.nlm.nih.gov/medlineplus/ency/article/000156.htm + + + + obo2:OAE_0001505 + venous thrombosis AE + + + + obo2:OAE_0001505 + HPO: HP_0004850 + + + + obo2:OAE_0001505 + MedDRA: 10047249 + + + + obo2:OAE_0001505 + SIDER: C0042487 + + + + obo2:OAE_0001506 + a cardiac ventricular disorder AE that has an outcome of an abnormality in the contraction of the ventricles or the motion of the cells + + + + obo2:OAE_0001506 + SZ, SS, YH + + + + obo2:OAE_0001506 + WEB: http://medical-dictionary.thefreedictionary.com/ventricular+dysfunction + + + + obo2:OAE_0001506 + ventricular dysfunction AE + + + + obo2:OAE_0001506 + MedDRA: 10059056 + + + + obo2:OAE_0001508 + an ear disorder that results in irritation and swelling (inflammation) of the inner ear + + + + obo2:OAE_0001508 + SZ, SS, YH + + + + obo2:OAE_0001508 + lybyrinthitis AE + + + + obo2:OAE_0001508 + WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0002049/ + + + + obo2:OAE_0001508 + vestibular neuronitis AE + + + + obo2:OAE_0001508 + MedDRA: 10047393 + + + + obo2:OAE_0001509 + an abnormal vision AE that results in unclear vision + + + + obo2:OAE_0001509 + SZ, SS, YH + + + + obo2:OAE_0001509 + WEB: Primary Source: http://www.nlm.nih.gov/medlineplus/ency/article/003029.htm Secondary Source: http://www.ncbi.nlm.nih.gov/pubmed/23111613 + + + + obo2:OAE_0001509 + vision blurred AE + + + + obo2:OAE_0001509 + HPO: HP_0000622 + + + + obo2:OAE_0001509 + MedDRA: 10047513 + + + + obo2:OAE_0001509 + SIDER: C0344232 + + + + obo2:OAE_0001510 + an abnormal vision AE that results in a decrease in clearness of vision + + + + obo2:OAE_0001510 + SZ, SS, YH + + + + obo2:OAE_0001510 + WEB: Primary Source: http://www.nlm.nih.gov/medlineplus/ency/article/003396.htm Secondary Source: http://www.ncbi.nlm.nih.gov/pubmed/23329671 + + + + obo2:OAE_0001510 + visual acuity reduced AE + + + + obo2:OAE_0001510 + HPO: HP_0000572 + + + + obo2:OAE_0001510 + MedDRA: 10047531 + + + + obo2:OAE_0001510 + SIDER: C0234632 + + + + obo2:OAE_0001511 + an abnormal vision AE that results in the patient suffering from an enhanced brightness in their vision + + + + obo2:OAE_0001511 + SZ, SS, YH + + + + obo2:OAE_0001511 + visual brightness AE + + + + obo2:OAE_0001511 + MedDRA: 10049155 + + + + obo2:OAE_0001512 + a gustatory system AE that has an outcome of a shortage of vitamin D which is essential for strong bones + + + + obo2:OAE_0001512 + SZ, SS, YH + + + + obo2:OAE_0001512 + WEB: http://www.webmd.com/diet/vitamin-d-deficiency + + + + obo2:OAE_0001512 + vitamin d deficiency AE + + + + obo2:OAE_0001512 + HPO: HP_0100513 + + + + obo2:OAE_0001512 + MedDRA: 10047626 + + + + obo2:OAE_0001512 + SIDER: C0042870 + + + + obo2:OAE_0001514 + Inflammation AE that is characterized by an inflammatory reaction of the vitreous or hyaloid membrane as a result of disease in adjacent structures + + + + obo2:OAE_0001514 + SZ, SS, YH + + + + obo2:OAE_0001514 + WEB: http://medical-dictionary.thefreedictionary.com/vitritis + + + + obo2:OAE_0001514 + vitritis AE + + + + obo2:OAE_0001514 + MedDRA: 10047663 + + + + obo2:OAE_0001515 + a physical examination result abnormal AE that results in the increase in weight of patient + + + + obo2:OAE_0001515 + SZ, SS, YH + + + + obo2:OAE_0001515 + weight increased AE + + + + obo2:OAE_0001515 + HPO: HP_0004324 + + + + obo2:OAE_0001515 + MedDRA: 10047899 + + + + obo2:OAE_0001515 + SIDER: C0043094 + + + + obo2:OAE_0001516 + a conduction system disorder AE that results in an abnormal accessory electrical conduction pathway between the atria and ventricles + + + + obo2:OAE_0001516 + SZ, SS, YH + + + + obo2:OAE_0001516 + WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001206/ + + + + obo2:OAE_0001516 + wolff-parkinson-white syndrome AE + + + + obo2:OAE_0001516 + MedDRA: 10048015 + + + + obo2:OAE_0001517 + an injury and procedural complication AE that has an outcome of complication to the wound + + + + obo2:OAE_0001517 + SZ, SS, YH + + + + obo2:OAE_0001517 + wound complication AE + + + + obo2:OAE_0001517 + MedDRA: 10053692 + + + + obo2:OAE_0001518 + an injury and procedural complication AE that has an outcome of a wound breaking open along the surgical sutures + + + + obo2:OAE_0001518 + SZ, SS, YH + + + + obo2:OAE_0001518 + WEB: http://medical-dictionary.thefreedictionary.com/wound+dehiscence + + + + obo2:OAE_0001518 + wound dehiscence AE + + + + obo2:OAE_0001518 + MedDRA: 10048031 + + + + obo2:OAE_0001519 + Outcome of secretions or pus produced by damaged tissue particles and repairing mechanisms intitiated by the body + + + + obo2:OAE_0001519 + SZ, SS, YH + + + + obo2:OAE_0001519 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/2815962 + + + + obo2:OAE_0001519 + wound secretion AE + + + + obo2:OAE_0001519 + MedDRA: 10048629 + + + + obo2:OAE_0001520 + an abnormal vision AEthat results in the patient seeing a predominance of yellow in their vision + + + + obo2:OAE_0001520 + SZ, SS, YH + + + + obo2:OAE_0001520 + WEB: http://medical-dictionary.thefreedictionary.com/xanthopsia + + + + obo2:OAE_0001520 + xanthopsia AE + + + + obo2:OAE_0001520 + HPO: HP_0000551 + + + + obo2:OAE_0001520 + MedDRA: 10048216 + + + + obo2:OAE_0001520 + SIDER: C0221185 + + + + obo2:OAE_0001521 + an immune system disorder AE that results in a fungal infection of the sinuses, brain, or lungs that occurs in some people with a weakened immune system + + + + obo2:OAE_0001521 + SZ, SS, YH + + + + obo2:OAE_0001521 + WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001672/ + + + + obo2:OAE_0001521 + zygomycosis AE + + + + obo2:OAE_0001521 + MedDRA: 10061418 + + + + obo2:OAE_0001522 + A cardiomyopathy AE that has an outcome of a heart failure with left ventricular dilatation resulting from ischemic heart disease. + + + + obo2:OAE_0001522 + YH, SS + + + + obo2:OAE_0001522 + ischaemic cardiomyopathy AE + + + + obo2:OAE_0001522 + WEB: http://medical-dictionary.thefreedictionary.com/ischemic+cardiomyopathy + + + + obo2:OAE_0001522 + ischemic cardiomyopathy AE + + + + obo2:OAE_0001522 + MedDRA: 10048858 + + + + obo2:OAE_0001524 + An adverse event that is a chronic neurological disorder caused by the brain's inability to regulate sleep-wake cycles normally. + + + + obo2:OAE_0001524 + YL + + + + obo2:OAE_0001524 + http://en.wikipedia.org/wiki/Narcolepsy + + + + obo2:OAE_0001524 + YL + + + + obo2:OAE_0001524 + narcolepsy AE + + + + obo2:OAE_0001526 + An inflammation AE that has an outcome of tissue swelling and other inflammatory response in the mouth + + + + obo2:OAE_0001526 + YH, SS + + + + obo2:OAE_0001526 + oral mucositis + + + + obo2:OAE_0001526 + mucosal inflammation AE + + + + obo2:OAE_0001526 + MedDRA: 10028116 + + + + obo2:OAE_0001527 + A systematic adverse event that has an outcome of failure in mulitple organs + + + + obo2:OAE_0001527 + YH, SS + + + + obo2:OAE_0001527 + multi-organ failure AE + + + + obo2:OAE_0001527 + MedDRA: 10028154 + + + + obo2:OAE_0001528 + Pleomorphic rash AE is rash AE that is a rash characterized by many-formed. + + + + obo2:OAE_0001528 + JX, LW, YH + + + + obo2:OAE_0001528 + 多形性皮疹 + + + + obo2:OAE_0001528 + pleomorphic rash AE + + + + obo2:OAE_0001529 + A bone disorder AE that has an outcome of the weakening or brittle bone + + + + obo2:OAE_0001529 + YH, SS + + + + obo2:OAE_0001529 + WEB: http://www.mayoclinic.com/health/osteoporosis/DS00128 + + + + obo2:OAE_0001529 + osteoporosis AE + + + + obo2:OAE_0001529 + HPO: HP_0000939 + + + + obo2:OAE_0001529 + MedDRA: 10031282 + + + + obo2:OAE_0001529 + SIDER: C0029456 + + + + obo2:OAE_0001530 + A groupd of disroders where the genetic susceptibility plays an important role to the seletctive susceptibility to poorly pathogenic mycobacterial species such as bacille Calmette-Guérin and environmental mycobacteria. + + + + obo2:OAE_0001530 + MSMD + + + + obo2:OAE_0001530 + http://www.ncbi.nlm.nih.gov/pubmed/20718793 + + + + obo2:OAE_0001530 + YL + + + + obo2:OAE_0001530 + Mendelian susceptibility to mycobacterial disease + + + + obo2:OAE_0001531 + A cardiomyopathy AE that has an outcome of a condition that the heart cannot relax normally during the time between heartbeats when the blood returns from the body (diastole). + + + + obo2:OAE_0001531 + YH, SS + + + + obo2:OAE_0001531 + infiltrative cardiomyopathy + + + + obo2:OAE_0001531 + WEB: http://www.nlm.nih.gov/medlineplus/ency/article/000189.htm + + + + obo2:OAE_0001531 + restrictive cardiomyopathy AE + + + + obo2:OAE_0001531 + MedDRA: 10038748 + + + + obo2:OAE_0001535 + A cardiomyopathy AE that is a temporary heart condition brought on by stressful situations, such as the death of a loved one. People with broken heart syndrome may have sudden chest pain or think they're having a heart attack. These broken heart syndrome symptoms may be brought on by the heart's reaction to a surge of stress hormones. In broken heart syndrome, a part of your heart temporarily enlarges and doesn't pump well, while the remainder of the heart functions normally or with even more forceful contractions. + + + + obo2:OAE_0001535 + YH, SS + + + + obo2:OAE_0001535 + takotsubo cardiomyopathy, broken heart syndrome, stress-induced cardiomyopathy, apical ballooning syndrome + + + + obo2:OAE_0001535 + WEB: http://www.mayoclinic.com/health/broken-heart-syndrome/DS01135/METHOD=print + + + + obo2:OAE_0001535 + stress cardiomyopathy AE + + + + obo2:OAE_0001535 + MedDRA: 10066286 + + + + obo2:OAE_0001537 + A skin adverse event that has an outcome of an eruption caused by ingestion, injection, inhalation, or insertion of a drug, often a result of allergic sensitization. Also called dermatitis medicamentosa, dermatosis medicamentosa, drug rash + + + + obo2:OAE_0001537 + YH, SS + + + + obo2:OAE_0001537 + dermatitis medicamentosa, dermatosis medicamentosa, drug rash + + + + obo2:OAE_0001537 + WEB: http://medical-dictionary.thefreedictionary.com/drug+eruption + + + + obo2:OAE_0001537 + toxic skin eruption AE + + + + obo2:OAE_0001537 + MedDRA: 10057970 + + + + obo2:OAE_0001538 + An arrythmia AE that has an outcome of a severely abnormal heart rhythm (arrhythmia) that can be life-threatening. + + + + obo2:OAE_0001538 + YH, SS + + + + obo2:OAE_0001538 + VF + + + + obo2:OAE_0001538 + WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0004467/ + + + + obo2:OAE_0001538 + ventricular fibrillation AE + + + + obo2:OAE_0001538 + HPO: HP_0001663 + + + + obo2:OAE_0001538 + MedDRA: 10047290 + + + + obo2:OAE_0001538 + SIDER: C0042510 + + + + obo2:OAE_0001539 + an atrioventricular block AE that there is some prolongation of AV conduction time (PR interval). The heart's electrical signals are slowed as they move from the atria to the ventricles (the heart's upper and lower chambers, respectively). This results in a longer, flatter line between the P and the R waves on the EKG (electrocardiogram). + + + + obo2:OAE_0001539 + SS + + + + obo2:OAE_0001539 + atrioventricular block first degree + + + + obo2:OAE_0001539 + first degree heart block + + + + obo2:OAE_0001539 + WEB: http://www.medilexicon.com/medicaldictionary.php?t=10751 +WEB: http://www.nhlbi.nih.gov/health//dci/Diseases/hb/hb_types.html + + + + obo2:OAE_0001539 + first degree atrioventricular block AE + + + + obo2:OAE_0001539 + MedDRA: 10003674 + + + + obo2:OAE_0001541 + A thyroiditis AE that is a self-limited thyroid condition associated with a triphasic clinical course of hyperthyroidism, hypothyroidism, and return to normal thyroid function. + + + + obo2:OAE_0001541 + SAT + + + + obo2:OAE_0001541 + http://emedicine.medscape.com/article/125648-overview + + + + obo2:OAE_0001541 + YL + + + + obo2:OAE_0001541 + subacute thyroiditis AE + + + + obo2:OAE_0001542 + Macrophagic myofasciitis (MMF) is a rare inflammatory muscle disorder characterized by a characteristic infiltration of muscle tissue by PAS-positive macrophages, which is caused by pathological persistence of vaccine-derived aluminium hydroxide. The diagnosis can only be established by an open muscle biopsy from the muscle that was used for intramuscular vaccination. + + + + obo2:OAE_0001542 + YL + + + + obo2:OAE_0001542 + MMF + + + + obo2:OAE_0001542 + http://www.ncbi.nlm.nih.gov/pubmed/14593574 + + + + obo2:OAE_0001542 + YL + + + + obo2:OAE_0001542 + macrophagic myofasciitis AE + + + + obo2:OAE_0001543 + BCG infection following BCG injection. It is often related with the vaccinee's immunodeficiency. + + + + obo2:OAE_0001543 + YL + + + + obo2:OAE_0001543 + YL + + + + obo2:OAE_0001543 + disseminated BCG infection AE + + + + obo2:OAE_0001544 + An adverse event that is a disorder of neural development characterized by impaired social interaction and communication, and by restricted and repetitive behavior. + + + + obo2:OAE_0001544 + http://en.wikipedia.org/wiki/Autism + + + + obo2:OAE_0001544 + YL + + + + obo2:OAE_0001544 + autism AE + + + + obo2:OAE_0001544 + HPO: HP_0000717 + + + + obo2:OAE_0001544 + SIDER: C0004352 + + + + obo2:OAE_0001545 + an adverse event that is a type of encephalitis triggered by vaccination. + + + + obo2:OAE_0001545 + Autoimmune Encephalitis may be triggered by infection in which case the term "Post-infectious Encephalitis" is used. ADEM( Acute Disseminated Encephalomyelitis ) is a Post-infectious Encephalitis. The illness usually follows in the wake of a mild viral infection (such as those that cause rashes in childhood) or immunisations. Typically there is a delay of days to two to three weeks between the triggering infection and development of the encephalitis. + +It has recently been recognised that there are other types of Autoimmune Encephalitis resulting from an attack of the brain by the body's immune system. Some of these types of autoimmune encephalitis are identified by finding a specific antibody in blood. These conditions include Potassium channel complex antibody associated encephalitis, NMDAR and Hashimoto's encephalitis. + +http://www.encephalitis.info/information/the-illness/types-of-autoimmune-encephalitis/ + + + + obo2:OAE_0001545 + YL + + + + obo2:OAE_0001545 + autoimmune encephalitis AE + + + + obo2:OAE_0001546 + an injection-site AE that display an redness in the injection-site + + + + obo2:OAE_0001546 + YH + + + + obo2:OAE_0001546 + injection-site redness AE + + + + obo2:OAE_0001547 + a sensory capability AE that shows up skin tenderness and occurs in an injection site of a medical intervention + + + + obo2:OAE_0001547 + YH + + + + obo2:OAE_0001547 + injection-site tenderness AE + + + + obo2:OAE_0001547 + MedDRA: 10043224 + + + + obo2:OAE_0001548 + YH + + + + obo2:OAE_0001548 + a movement disorder AE that has an outcome of arm motion limitation + + + + obo2:OAE_0001548 + arm motion limitation AE + + + + obo2:OAE_0001549 + a sensory capability AE that shows up muscular soreness at the injection site of a medical intervention + + + + obo2:OAE_0001549 + YH + + + + obo2:OAE_0001549 + injection-site muscular soreness AE + + + + obo2:OAE_0001549 + MedDRA: 10028332 + + + + obo2:OAE_0001550 + a sleep disorder AE that shows up sleepiness (Sluggish from sleep, inactive, quiet). + + + + obo2:OAE_0001550 + YH + + + + obo2:OAE_0001550 + sleepiness AE + + + + obo2:OAE_0001550 + MedDRA: 10041014 + + + + obo2:OAE_0001551 + an adverse event that occurs in brain. + + + + obo2:OAE_0001551 + YH + + + + obo2:OAE_0001551 + brain disorder AE + + + + obo2:OAE_0001551 + brain AE + + + + obo2:OAE_0001552 + a hypersensitivity AE that is mild. + + + + obo2:OAE_0001552 + YH + + + + obo2:OAE_0001552 + mild hypersensitivity AE + + + + obo2:OAE_0001553 + YH + + + + obo2:OAE_0001553 + an injection-site edema AE that occurs in the arm. + + + + obo2:OAE_0001553 + injection-site arm edema AE + + + + obo2:OAE_0001554 + a behavior and neurological AE that shows restlessness + + + + obo2:OAE_0001554 + YH + + + + obo2:OAE_0001554 + restlessness AE + + + + obo2:OAE_0001554 + MedDRA: 10038743; UMLS_CUI: C0085631 + + + + obo2:OAE_0001555 + a sensory capability AE that results in a sensation of induration with tenderness. + + + + obo2:OAE_0001555 + YH + + + + obo2:OAE_0001555 + induration with tenderness AE + + + + obo2:OAE_0001556 + a sensory capability AE that results in a sensation of fussiness + + + + obo2:OAE_0001556 + YH + + + + obo2:OAE_0001556 + fussiness AE + + + + obo2:OAE_0001557 + a sleep disorder AE that shows decreased sleep + + + + obo2:OAE_0001557 + YH + + + + obo2:OAE_0001557 + decreased sleep AE + + + + obo2:OAE_0001558 + a sleep disorder AE that shows increased sleep + + + + obo2:OAE_0001558 + YH + + + + obo2:OAE_0001558 + increased sleep AE + + + + obo2:OAE_0001559 + a pain AE that occurs at a joint + + + + obo2:OAE_0001559 + YH + + + + obo2:OAE_0001559 + joint pain AE + + + + obo2:OAE_0001560 + Tiredness AE is a sensory capability AE that results in a sensation of tiredness. + + + + obo2:OAE_0001560 + This term appears to be a synonym to the 'fatigue AE'. + + + + obo2:OAE_0001560 + JX, LW, YH + + + + obo2:OAE_0001560 + hypodynamia AE + + + + obo2:OAE_0001560 + 疲劳/乏力 + + + + obo2:OAE_0001560 + tiredness AE + + + + obo2:OAE_0001560 + MedDRA: 10043890 + + + + obo2:OAE_0001561 + nasal discomfort AE is a respiratory system AE that shows a discomfort from the nose + + + + obo2:OAE_0001561 + YH + + + + obo2:OAE_0001561 + nasal discomfort AE + + + + obo2:OAE_0001561 + HPO: HP_0010640 + + + + obo2:OAE_0001561 + SIDER: C0858259 + + + + obo2:OAE_0001567 + an imaging investigation result abnormal AE that is indicated by an abnormal result of a procedure in which radio waves and a powerful magnet linked to a computer are used to create detailed pictures of areas inside the body + + + + obo2:OAE_0001567 + EB + + + + obo2:OAE_0001567 + nuclear magnetic resonance imaging result abnormal AE + + + + obo2:OAE_0001567 + MedDRA: 10029816 + + + + + obo2:OAE_0001568 + a computerized tomography abnormal AE that is an imaging method that uses x-rays to create pictures of cross-sections of the body using a dye, called oral contrast, that shows up on the CT images to help better define internal organs + + + + obo2:OAE_0001568 + EB + + + + obo2:OAE_0001568 + computerised tomogram with contrast abnormal AE + + + + obo2:OAE_0001568 + computerized tomogram with contrast abnormal AE + + + + obo2:OAE_0001569 + a computerized tomography abnormal AE that is an imaging method that uses x-rays to create pictures of cross-sections of the body + + + + obo2:OAE_0001569 + EB + + + + obo2:OAE_0001569 + computerised tomogram without contrast abnormal AE + + + + obo2:OAE_0001569 + computerized tomogram without contrast abnormal AE + + + + obo2:OAE_0001570 + an investigation result abnormal AE that involves an abnormal result of an investigation involving the cardiac and vascular systems + + + + obo2:OAE_0001570 + EB + + + + obo2:OAE_0001570 + cardiac and vascular investigation result abnormal AE + + + + obo2:OAE_0001570 + MedDRA: 10007512 + + + + obo2:OAE_0001571 + an atrioventricular block AE that some but not all atrial impulses fail to reach the ventricles, thus some ventricular beats are dropped. Electrical signals between the atria and ventricles are slowed to a large degree. Some signals don't reach the ventricles. On an EKG, the pattern of QRS waves doesn't follow each P wave as it normally would. + + + + obo2:OAE_0001571 + SS + + + + obo2:OAE_0001571 + atrioventricular block second degree + + + + obo2:OAE_0001571 + second degree heart block + + + + obo2:OAE_0001571 + WEB: http://www.medilexicon.com/medicaldictionary.php?t=10751 +WEB: http://www.nhlbi.nih.gov/health//dci/Diseases/hb/hb_types.html + + + + obo2:OAE_0001571 + second degree atrioventricular block AE + + + + obo2:OAE_0001571 + MedDRA: 10003677 + + + + obo2:OAE_0001572 + a cardiac and vascular investigation result abnormal AE that is an abnormal result of a test that uses sound waves to create a moving picture of the heart + + + + obo2:OAE_0001572 + EB + + + + obo2:OAE_0001572 + echocardiogram result abnormal AE + + + + obo2:OAE_0001572 + MedDRA: 10061593 + + + + obo2:OAE_0001573 + an investigation result abnormal AE that involves an abnormal electrolyte value + + + + obo2:OAE_0001573 + EB + + + + obo2:OAE_0001573 + electrolyte lab test abnormal AE + + + + obo2:OAE_0001573 + MedDRA: 10047843 + + + + obo2:OAE_0001574 + an electrolyte lab test abnormal AE that shows an abnormal blood phosphorus level + + + + obo2:OAE_0001574 + EB + + + + obo2:OAE_0001574 + blood phosphorus abnormal AE + + + + obo2:OAE_0001574 + MedDRA: 10054823 + + + + obo2:OAE_0001575 + an electrolyte lab test abnormal AE that is characterized by an abnormally high level of phosphate in the blood + + + + obo2:OAE_0001575 + EB + + + + obo2:OAE_0001575 + blood phosphorus increased AE + + + + obo2:OAE_0001575 + HPO: HP_0002905 + + + + obo2:OAE_0001575 + MedDRA: 10050196 + + + + obo2:OAE_0001575 + SIDER: C0919625 + + + + obo2:OAE_0001576 + an atrioventricular block AE that complete atrioventricular dissociation occurs; atria and ventricles beat independently. None of the electrical signals reach the ventricles. This type also is called complete heart block or complete AV block. + +When complete heart block occurs, special areas in the ventricles may create electrical signals to cause the ventricles to contract. This natural backup system is slower than the normal heart rate and isn't coordinated with the contraction of the atria. On an EKG, the normal pattern is disrupted. The P waves occur at a faster rate that isn't coordinated with the QRS waves. + + + + obo2:OAE_0001576 + SS + + + + obo2:OAE_0001576 + atrioventricular block complete + + + + obo2:OAE_0001576 + complete heart block + + + + obo2:OAE_0001576 + third degree atrioventricular block + + + + obo2:OAE_0001576 + third degree heart block + + + + obo2:OAE_0001576 + WEB: http://www.medilexicon.com/medicaldictionary.php?t=10751 +WEB: http://www.nhlbi.nih.gov/health//dci/Diseases/hb/hb_types.html + + + + obo2:OAE_0001576 + complete atrioventricular block AE + + + + obo2:OAE_0001576 + MedDRA: 10003673 + + + + obo2:OAE_0001577 + an electrolyte lab test abnormal AE that results in an abnormal level of potassium in the blood + + + + obo2:OAE_0001577 + EB + + + + obo2:OAE_0001577 + blood potassium abnormal AE + + + + obo2:OAE_0001577 + HPO: HP_0011042 + + + + obo2:OAE_0001577 + MedDRA: 10005722 + + + + obo2:OAE_0001577 + SIDER: C0853759 + + + + obo2:OAE_0001578 + an electrolyte lab test abnormal AE that is characterized by an abnormally high level of phosphate in the blood + + + + obo2:OAE_0001578 + EB + + + + obo2:OAE_0001578 + hyperkalemia AE + + + + obo2:OAE_0001578 + blood potassium increased AE + + + + obo2:OAE_0001578 + HPO: HP_0002513 + + + + obo2:OAE_0001578 + MedDRA: 10005725 + + + + + obo2:OAE_0001578 + SIDER: C0853760 + + + + obo2:OAE_0001579 + an electrolyte lab test abnormal AE that results in an abnormal level of sodium in the blood + + + + obo2:OAE_0001579 + EB + + + + obo2:OAE_0001579 + blood sodium abnormal AE + + + + obo2:OAE_0001579 + MedDRA: 10005800 + + + + obo2:OAE_0001580 + an electrolyte lab test abnormal AE that is characterized by an abnormally high level of sodium in the blood + + + + obo2:OAE_0001580 + EB + + + + obo2:OAE_0001580 + hypernaetremia + + + + obo2:OAE_0001580 + blood sodium increased AE + + + + obo2:OAE_0001580 + HPO: HP_0003228 + + + + obo2:OAE_0001580 + MedDRA: 10005803 + + + + obo2:OAE_0001580 + MedDRA: 10020679 + + + + obo2:OAE_0001580 + SIDER: C0595878 + + + + obo2:OAE_0001581 + an electrolyte lab test abnormal AE that results in an abnormal level of magnesium in the blood + + + + obo2:OAE_0001581 + EB + + + + obo2:OAE_0001581 + blood magnesium abnormal AE + + + + obo2:OAE_0001581 + MedDRA: 10005652 + + + + obo2:OAE_0001582 + an electrolyte lab test abnormal AE that is characterized by an abnormally high level of magnesium in the blood + + + + obo2:OAE_0001582 + EB + + + + obo2:OAE_0001582 + hypermagnesaemia + + + + obo2:OAE_0001582 + blood magnesium increased AE + + + + obo2:OAE_0001582 + MedDRA: 10005655 + + + + obo2:OAE_0001582 + MedDRA: 10020669 + + + + obo2:OAE_0001583 + an electrolyte lab test abnormal AE that results in an abnormal level of chloride in the blood + + + + obo2:OAE_0001583 + EB + + + + obo2:OAE_0001583 + blood chloride abnormal AE + + + + obo2:OAE_0001583 + MedDRA: 10005417 + + + + obo2:OAE_0001584 + an electrolyte lab test abnormal AE that is characterized by an abnormally high level of chloride in the blood + + + + obo2:OAE_0001584 + EB + + + + obo2:OAE_0001584 + blood chloride increased AE + + + + obo2:OAE_0001584 + MedDRA: 10005420 + + + + obo2:OAE_0001585 + an electrolyte lab test abnormal AE that results in an abnormal level of calcium in the blood + + + + obo2:OAE_0001585 + EB + + + + obo2:OAE_0001585 + blood calcium abnormal AE + + + + obo2:OAE_0001585 + MedDRA: 10005393 + + + + obo2:OAE_0001586 + an electrolyte lab test abnormal AE that is characterized by an abnormally high level of calcium in the blood + + + + obo2:OAE_0001586 + EB + + + + obo2:OAE_0001586 + blood calcium increased AE + + + + obo2:OAE_0001586 + MedDRA: 10005396 + + + + obo2:OAE_0001587 + an investigation result abnormal AE that involves the renal and urinary tract and urinalyses + + + + obo2:OAE_0001587 + EB + + + + obo2:OAE_0001587 + renal and urinary tract investigation and urinalysis result abnormal AE + + + + obo2:OAE_0001587 + MedDRA: 10038362 + + + + obo2:OAE_0001588 + a renal and urinary tract investigation and urinalysis result abnormal AE that is characterized by an abnormal level of creatinine in the blood + + + + obo2:OAE_0001588 + EB + + + + obo2:OAE_0001588 + blood creatinine level abnormal AE + + + + obo2:OAE_0001588 + MedDRA: 10005481 + + + + obo2:OAE_0001589 + a renal and urinary tract investigation and urinalysis result abnormal AE that is characterized by an abnormal level of urea in the blood + + + + obo2:OAE_0001589 + EB + + + + obo2:OAE_0001589 + blood urea level abnormal AE + + + + obo2:OAE_0001589 + MedDRA: 10005846 + + + + obo2:OAE_0001590 + an investigation result abnormal AE that involves an abnormal result of a lipid analyses + + + + obo2:OAE_0001590 + EB + + + + obo2:OAE_0001590 + lipid analysis result abnormal AE + + + + obo2:OAE_0001590 + MedDRA: 10024580 + + + + obo2:OAE_0001591 + a lipid analysis result abnormal AE that results in an abnormal blood cholesterol level + + + + obo2:OAE_0001591 + EB + + + + obo2:OAE_0001591 + blood cholesterol abnormal AE + + + + obo2:OAE_0001591 + MedDRA: 10005423 + + + + obo2:OAE_0001592 + a blood cholesterol abnormal AE that results in a decreased amount of cholesterol in the blood + + + + obo2:OAE_0001592 + EB + + + + obo2:OAE_0001592 + blood cholesterol decreased AE + + + + obo2:OAE_0001592 + MedDRA: 10005424 + + + + obo2:OAE_0001593 + a lipid analysis result abnormal AE that is characterized by an abnormal amount of high density lipoprotein + + + + obo2:OAE_0001593 + EB + + + + obo2:OAE_0001593 + high density lipoprotein abnormal AE + + + + obo2:OAE_0001593 + MedDRA: 10020051 + + + + obo2:OAE_0001594 + a high density lipoprotein abnormal AE that is characterized by an increased amount of high density lipoprotein + + + + obo2:OAE_0001594 + EB + + + + obo2:OAE_0001594 + high density lipoprotein increased AE + + + + obo2:OAE_0001594 + MedDRA: 10020061 + + + + obo2:OAE_0001595 + a high density lipoprotein abnormal AE that is characterized by a decreased amount of high density lipoprotein + + + + obo2:OAE_0001595 + EB + + + + obo2:OAE_0001595 + high density lipoprotein decreased AE + + + + obo2:OAE_0001595 + HPO: HP_0003233 + + + + obo2:OAE_0001595 + MedDRA: 10020060 + + + + obo2:OAE_0001595 + SIDER: C0151691 + + + + obo2:OAE_0001596 + a lipid analysis result abnormal AE that is characterized by an abnormal amount of low density lipoprotein + + + + obo2:OAE_0001596 + EB + + + + obo2:OAE_0001596 + low density lipoprotein abnormal AE + + + + obo2:OAE_0001596 + MedDRA: 10024901 + + + + obo2:OAE_0001597 + a low density lipoprotein abnormal AE that is characterized by an increased amount of low density lipoprotein + + + + obo2:OAE_0001597 + EB + + + + obo2:OAE_0001597 + low density lipoprotein increased AE + + + + obo2:OAE_0001597 + HPO: HP_0003141 + + + + obo2:OAE_0001597 + MedDRA: 10024910 + + + + obo2:OAE_0001597 + SIDER: C0549399 + + + + obo2:OAE_0001598 + a low density lipoprotein abnormal AE that is characterized by a decreased amount of low density lipoprotein + + + + obo2:OAE_0001598 + EB + + + + obo2:OAE_0001598 + low density lipoprotein decreased AE + + + + obo2:OAE_0001598 + MedDRA: 10024909 + + + + obo2:OAE_0001599 + a lipid analysis result abnormal AE that is characterized by an abnormal amount of triglycerides in the blood + + + + obo2:OAE_0001599 + EB + + + + obo2:OAE_0001599 + blood triglycerides abnormal AE + + + + obo2:OAE_0001599 + MedDRA: 10005837 + + + + obo2:OAE_0001600 + a blood triglycerides abnormal AE that is characterized by an increased amount of triglycerides in the blood + + + + obo2:OAE_0001600 + EB + + + + obo2:OAE_0001600 + blood triglycerides increased AE + + + + obo2:OAE_0001600 + HPO: HP_0002155 + + + + obo2:OAE_0001600 + MedDRA: 10005839 + + + + obo2:OAE_0001600 + SIDER: C0853692 + + + + obo2:OAE_0001601 + a blood triglycerides abnormal AE that is characterized by a decreased amount of triglycerides in the blood + + + + obo2:OAE_0001601 + EB + + + + obo2:OAE_0001601 + blood triglycerides decreased AE + + + + obo2:OAE_0001601 + MedDRA: 10005838 + + + + obo2:OAE_0001602 + an investigation result abnormal AE that involves an abnormal result for an immunology and allergy investigation + + + + obo2:OAE_0001602 + EB + + + + obo2:OAE_0001602 + immunology and allergy investigation result abnormal AE + + + + obo2:OAE_0001602 + MedDRA: 10021505 + + + + obo2:OAE_0001603 + a second degree atrioventricular block AE that the electrical signals are delayed more and more with each heartbeat, until the heart skips a beat. On the EKG, the delay is shown as a line (called the PR interval) between the P and QRS waves. The line gets longer and longer until the QRS waves don't follow the next P wave. + + + + obo2:OAE_0001603 + MedDRA: 10050797 is a LLT for type I second degree atrioventricular block + +MedDRA (LLT): 10047909 exists for Wenckebach phenomeono +MedDRA (LLT): 10047908 exists for Wenchebach + + + + + obo2:OAE_0001603 + SS + + + + + obo2:OAE_0001603 + Mobitz type 1 block + + + + obo2:OAE_0001603 + Wenckebach's block + + + + obo2:OAE_0001603 + type 1 second degree atrioventricular block + + + + obo2:OAE_0001603 + type I second degree atrioventricular block + + + + obo2:OAE_0001603 + WEB: http://www.nhlbi.nih.gov/health//dci/Diseases/hb/hb_types.html + + + + obo2:OAE_0001603 + Mobitz type I block AE + + + + obo2:OAE_0001603 + MedDRA (LLT): 10047909 +MedDRA (LLT): 10047908 + + + + obo2:OAE_0001603 + MedDRA: 10050797 + + + + obo2:OAE_0001604 + an immunology and allergy investigation result abnormal AE that is characterized by antibodies for epstein barr virus being detected + + + + obo2:OAE_0001604 + EB + + + + obo2:OAE_0001604 + epstein barr virus antibody positive AE + + + + obo2:OAE_0001604 + MedDRA: 10056906 + + + + obo2:OAE_0001605 + an immunology and allergy investigations result abnormal AE that is characterized by an abnormal microbiology and serology investigation + + + + obo2:OAE_0001605 + EB + + + + obo2:OAE_0001605 + microbiology and serology investigation result abnormal AE + + + + obo2:OAE_0001605 + MedDRA: 10027529 + + + + obo2:OAE_0001606 + a microbiology and serology investigation result abnormal AE that is characterized by a positive CSF culture + + + + obo2:OAE_0001606 + EB + + + + obo2:OAE_0001606 + CSF culture positive AE + + + + obo2:OAE_0001606 + MedDRA: 10011529 + + + + obo2:OAE_0001607 + an investigation result abnormal AE that involves an abnormal result of a metabolic and nutritional investigation + + + + obo2:OAE_0001607 + EB + + + + obo2:OAE_0001607 + metabolic and nutritional investigation result abnormal AE + + + + obo2:OAE_0001607 + MedDRA: 10027432 + + + + obo2:OAE_0001608 + a metabolic and nutritional investigation result abnormal AE that is charaterized by an abnormal glycosylated hemoglobin level + + + + obo2:OAE_0001608 + EB + + + + obo2:OAE_0001608 + glycosylated hemoglobin level abnormal AE + + + + obo2:OAE_0001608 + MedDRA: 10055587 + + + + obo2:OAE_0001609 + a glycosylated hemoglobin level abnormal AE that is charaterized by an increased glycosylated hemoglobin level + + + + obo2:OAE_0001609 + EB + + + + obo2:OAE_0001609 + glycosylated hemoglobin level increased AE + + + + obo2:OAE_0001609 + MedDRA: 10055587 + + + + obo2:OAE_0001610 + a metabolic and nutritional investigation result abnormal AE that is charaterized by an abnormal blood folate level + + + + obo2:OAE_0001610 + EB + + + + obo2:OAE_0001610 + blood folate level abnormal AE + + + + + obo2:OAE_0001610 + MedDRA: 10005525 + + + + obo2:OAE_0001611 + a blood folate abnormal AE that is charaterized by an increased blood folate level + + + + obo2:OAE_0001611 + EB + + + + obo2:OAE_0001611 + blood folate level increased AE + + + + obo2:OAE_0001611 + MedDRA: 10005528 + + + + obo2:OAE_0001612 + a metabolic and nutritional investigation result abnormal AE that is charaterized by an abnormal blood glucose level + + + + obo2:OAE_0001612 + EB + + + + obo2:OAE_0001612 + blood glucose level abnormal AE + + + + obo2:OAE_0001612 + MedDRA: 10005554 + + + + obo2:OAE_0001613 + a metabolic and nutritional investigation result abnormal AE that is charaterized by an abnormal blood homocysteine + + + + obo2:OAE_0001613 + EB + + + + obo2:OAE_0001613 + blood homocysteine level abnormal AE + + + + obo2:OAE_0001613 + MedDRA: 10049735 + + + + obo2:OAE_0001614 + a blood homocysteine level abnormal AE that is charaterized by a decreased blood homocysteine + + + + obo2:OAE_0001614 + EB + + + + obo2:OAE_0001614 + blood homocysteine level decreased AE + + + + obo2:OAE_0001614 + MedDRA: 10049734 + + + + obo2:OAE_0001615 + a metabolic and nutritional investigation result abnormal AE that is charaterized by an abnormal blood uric acid level + + + + obo2:OAE_0001615 + EB + + + + obo2:OAE_0001615 + blood uric acid level abnormal AE + + + + obo2:OAE_0001615 + MedDRA: 10061727 + + + + obo2:OAE_0001616 + a blood uric acid level abnormal AE that is characterized by a decreased blood uric acid + + + + obo2:OAE_0001616 + EB + + + + obo2:OAE_0001616 + blood uric acid level decreased AE + + + + obo2:OAE_0001616 + MedDRA: 10005860 + + + + obo2:OAE_0001617 + a metabolic and nutritional investigation result abnormal AE that is charaterized by an abnormal vitamin B12 level + + + + obo2:OAE_0001617 + EB + + + + obo2:OAE_0001617 + vitamin B12 level abnormal AE + + + + obo2:OAE_0001617 + MedDRA: 10062187 + + + + obo2:OAE_0001618 + a vitamin B12 level abnormal AE that is characterized by an increased vitamin B12 level + + + + obo2:OAE_0001618 + EB + + + + obo2:OAE_0001618 + vitamin B12 level increased AE + + + + obo2:OAE_0001618 + MedDRA: 10047610 + + + + obo2:OAE_0001619 + a vitamin B12 level abnormal AE that is characterized by a decreased vitamin B12 level + + + + obo2:OAE_0001619 + EB + + + + obo2:OAE_0001619 + vitamin B12 level decreased AE + + + + obo2:OAE_0001619 + MedDRA: 10047608 + + + + obo2:OAE_0001620 + a metabolic and nutritional investigation result abnormal AE that is charaterized by an abnormal brain natriuretic peptide level + + + + obo2:OAE_0001620 + EB + + + + obo2:OAE_0001620 + brain natriuretic peptide level abnormal AE + + + + obo2:OAE_0001620 + MedDRA: 10053408 + + + + obo2:OAE_0001621 + a brain natriuretic peptide level abnormal AE that is characterized by an increased brain natriuretic peptide level + + + + obo2:OAE_0001621 + EB + + + + obo2:OAE_0001621 + brain natriuretic peptide level increased AE + + + + obo2:OAE_0001621 + MedDRA: 10053405 + + + + obo2:OAE_0001622 + a brain natriuretic peptide level abnormal AE that is characterized by a decreased brain natriuretic peptide level + + + + obo2:OAE_0001622 + EB + + + + obo2:OAE_0001622 + brain natriuretic peptide level decreased AE + + + + obo2:OAE_0001622 + MedDRA: 10053407 + + + + obo2:OAE_0001623 + an investigation result abnormal AE that involves an abnormal result of the oxygen and carbon dioxide content of arterial blood, measured by various methods to assess the adequacy of ventilation and oxygenation and the acid-base status of the body + + + + + obo2:OAE_0001623 + EB, SJ + + + + obo2:OAE_0001623 + WEB: http://medical-dictionary.thefreedictionary.com/arterial+blood+gas + + + + obo2:OAE_0001623 + WEB: http://www.nlm.nih.gov/medlineplus/ency/article/003855.htm + + + + obo2:OAE_0001623 + blood gases abnormal AE may be a result of lung, kidney, or metablolic diseases or the result of abnormal breathing after a head or neck injur + + + + obo2:OAE_0001623 + blood gas investigation result abnormal AE + + + + obo2:OAE_0001623 + MedDRA: 10005539 + + + + obo2:OAE_0001623 + MedDRA: 10027432 + + + + obo2:OAE_0001624 + a blood gas investigation result abnormal AE that is characterized by an abnormal amount of carbon dioxide in the blood + + + + obo2:OAE_0001624 + EB + + + + obo2:OAE_0001624 + WEB: http://www.nlm.nih.gov/medlineplus/ency/article/003469.htm + + + + obo2:OAE_0001624 + carbon dioxide abnormal AE + + + + obo2:OAE_0001624 + MedDRA: 10064156 + + + + obo2:OAE_0001625 + a carbon dioxide abnormal AE that is characterized by an increased carbon dioxide level in the blood + + + + obo2:OAE_0001625 + EB + + + + + obo2:OAE_0001625 + carbon dioxide increased AE + + + + obo2:OAE_0001625 + HPO: HP_0005972 + + + + obo2:OAE_0001625 + MedDRA: 10007225 + + + + obo2:OAE_0001625 + SIDER: C0860713 + + + + obo2:OAE_0001626 + a blood gas investigation result abnormal AE that is characterized by an abnormal acidity or alkalinity of blood + + + + obo2:OAE_0001626 + EB + + + + obo2:OAE_0001626 + WEB: http://www.medterms.com/script/main/art.asp?articlekey=10001 + + + + obo2:OAE_0001626 + blood pH abnormal AE + + + + obo2:OAE_0001626 + MedDRA: 10005705 + + + + obo2:OAE_0001627 + a blood pH abnormal AE that is characterized by an increased blood pH + + + + obo2:OAE_0001627 + EB + + + + obo2:OAE_0001627 + blood pH increased AE + + + + obo2:OAE_0001627 + MedDRA: 10005708 + + + + obo2:OAE_0001628 + a blood pH abnormal AE that is characterized by a decreased blood pH + + + + obo2:OAE_0001628 + EB + + + + obo2:OAE_0001628 + blood pH decreased AE + + + + + obo2:OAE_0001628 + MedDRA: 10005706 + + + + obo2:OAE_0001630 + a blood gas investigation result abnormal AE that is characterized by an abnormal oxygen saturation in the blood + + + + obo2:OAE_0001630 + EB + + + + obo2:OAE_0001630 + oxygen saturation abnormal AE + + + + obo2:OAE_0001630 + MedDRA: 10033317 + + + + + obo2:OAE_0001631 + an oxygen saturation abnormal AE that is characterized by an increased percentage of hemoglobin binding sites in the bloodstream occupied by oxygen + + + + obo2:OAE_0001631 + EB + + + + obo2:OAE_0001631 + oxygen saturation increased AE + + + + obo2:OAE_0001631 + MedDRA: 10033320 + + + + obo2:OAE_0001632 + a blood gas investigation result abnormal AE that is characterized by an abnormal carbon dioxide partial pressure or tension in the blood + + + + obo2:OAE_0001632 + EB + + + + obo2:OAE_0001632 + WEB: http://medical-dictionary.thefreedictionary.com/PCO2 + + + + obo2:OAE_0001632 + PCO2 abnormal AE + + + + obo2:OAE_0001632 + MedDRA: 10058982 + + + + obo2:OAE_0001633 + a PCO2 abnormal AE that is characterized by an increased carbon dioxide partial pressure or tension in the blood + + + + obo2:OAE_0001633 + EB + + + + obo2:OAE_0001633 + PCO2 increased AE + + + + obo2:OAE_0001633 + MedDRA: 10034183 + + + + obo2:OAE_0001634 + a pPCO2 abnormal AE that is characterized by a decreased carbon dioxide partial pressure or tension in the blood + + + + obo2:OAE_0001634 + EB + + + + obo2:OAE_0001634 + PCO2 decreased AE + + + + obo2:OAE_0001634 + MedDRA: 10034181 + + + + obo2:OAE_0001635 + a blood gas investigation result abnormal AE that is characterized by an abnormal oxygen partial pressure in the blood + + + + obo2:OAE_0001635 + EB + + + + obo2:OAE_0001635 + WEB: http://medical-dictionary.thefreedictionary.com/PO2 + + + + obo2:OAE_0001635 + PO2 abnormal AE + + + + + obo2:OAE_0001635 + MedDRA: 10062087 + + + + obo2:OAE_0001636 + a PO2 abnormal AE that is characterized by an increased oxygen partial pressure in the blood + + + + obo2:OAE_0001636 + EB + + + + obo2:OAE_0001636 + PO2 increased AE + + + + obo2:OAE_0001636 + MedDRA: 10035769 + + + + obo2:OAE_0001637 + a PO2 abnormal AE that is characterized by a decreased oxygen partial pressure in the blood + + + + obo2:OAE_0001637 + EB + + + + obo2:OAE_0001637 + PO2 decreased AE + + + + obo2:OAE_0001637 + MedDRA: 10035768 + + + + obo2:OAE_0001638 + an investigation result abnormal AE that results from an abnormal toxicology screen + + + + + obo2:OAE_0001638 + EB + + + + obo2:OAE_0001638 + toxicology drug screen result abnormal AE + + + + obo2:OAE_0001638 + MedDRA: 10044260 + + + + obo2:OAE_0001639 + a toxicology drug screen result abnormal AE that is characterized by positive barbiturates + + + + obo2:OAE_0001639 + EB + + + + obo2:OAE_0001639 + barbiturates positive AE + + + + obo2:OAE_0001639 + MedDRA: 10063230 + + + + obo2:OAE_0001640 + a toxicology drug screen result abnormal AE that is characterized by positive cocaine + + + + obo2:OAE_0001640 + EB + + + + obo2:OAE_0001640 + cocaine positive AE + + + + obo2:OAE_0001640 + MedDRA: 10063230 + + + + obo2:OAE_0001641 + a second degree atrioventricular block AE that some of the electrical signals don't reach the ventricles. However, the pattern is less regular than it is in Mobitz type I. Some signals move between the atria and ventricles normally, while others are blocked. + +On an EKG, the QRS wave follows the P wave at a normal speed. Sometimes, though, the QRS wave is missing (when a signal is blocked). + + + + obo2:OAE_0001641 + SS + + + + + obo2:OAE_0001641 + Mobitz type 2 block + + + + obo2:OAE_0001641 + type 2 second degree atrioventricular block + + + + obo2:OAE_0001641 + type II second degree atrioventricular block + + + + obo2:OAE_0001641 + WEB: http://www.nhlbi.nih.gov/health//dci/Diseases/hb/hb_types.html + + + + obo2:OAE_0001641 + Mobitz type II block AE + + + + obo2:OAE_0001641 + MedDRA: 10050798 + + + + obo2:OAE_0001642 + a toxicology drug screen result abnormal AE that is characterized by increased urine cannabinoids + + + + obo2:OAE_0001642 + EB + + + + obo2:OAE_0001642 + urine cannabinoids increased AE + + + + obo2:OAE_0001642 + MedDRA: 10062228 + + + + obo2:OAE_0001643 + an investigation result abnormal AE that involves an abnormal result of a neurological, special senses and psychiatric investigation + + + + obo2:OAE_0001643 + EB + + + + obo2:OAE_0001643 + neurological, special senses and psychiatric investigation result abnormal AE + + + + obo2:OAE_0001643 + MedDRA: 10029295 + + + + obo2:OAE_0001644 + an investigation result abnormal AE resulting from an abnormal physical examination finding + + + + obo2:OAE_0001644 + EB + + + + obo2:OAE_0001644 + physical examination result abnormal AE + + + + obo2:OAE_0001644 + MedDRA: 10071940, 10062078 + + + + obo2:OAE_0001645 + an investigation result abnormal AE that involves an abnormal result of an investigation related to chromosomal abnormalities and pathologic conditions + + + + + + obo2:OAE_0001645 + EB + + + + obo2:OAE_0001645 + WEB: http://medical-dictionary.thefreedictionary.com/Cytogenetic+analysis + + + + obo2:OAE_0001645 + cytogenetic investigation result abnormal AE + + + + obo2:OAE_0001645 + MedDRA: 10011822 + + + + obo2:OAE_0001646 + an investigation result abnormal AE that involves an abnormal respiratory and pulmonary investigation + + + + obo2:OAE_0001646 + EB + + + + obo2:OAE_0001646 + respiratory and pulmonary investigation result abnormal AE + + + + obo2:OAE_0001646 + MedDRA: 10038668 + + + + obo2:OAE_0001647 + an investigation result abnormal AE that involves an abnormal result of an endocrine investigation + + + + obo2:OAE_0001647 + EB + + + + obo2:OAE_0001647 + endocrine investigation result abnormal AE + + + + obo2:OAE_0001647 + MedDRA: 10014706 + + + + obo2:OAE_0001649 + an endocrine investigation result abnormal AE that is characterized by an abnormal blood parathyroid hormone level + + + + obo2:OAE_0001649 + EB + + + + obo2:OAE_0001649 + blood parathyroid hormone level abnormal AE + + + + obo2:OAE_0001649 + MedDRA: 10005700 + + + + obo2:OAE_0001650 + a blood parathyroid hormone level abnormal AE that is characterized by an increased blood parathyroid hormone level + + + + obo2:OAE_0001650 + EB + + + + obo2:OAE_0001650 + blood parathyroid hormone increased AE + + + + obo2:OAE_0001650 + MedDRA: 10005703 + + + + obo2:OAE_0001651 + an endocrine investigation result abnormal AE that is characterized by an abnormal tri-iodothyronine level + + + + obo2:OAE_0001651 + EB + + + + obo2:OAE_0001651 + tri-iodothyronine level abnormal AE + + + + obo2:OAE_0001651 + MedDRA: 10044592 + + + + obo2:OAE_0001652 + a tri-iodothyronine level abnormal AE that is characterized by an increased tri-iodothyronine level + + + + obo2:OAE_0001652 + EB + + + + obo2:OAE_0001652 + tri-iodothyronine increased AE + + + + obo2:OAE_0001652 + MedDRA: 10044596 + + + + obo2:OAE_0001653 + an investigation result abnormal AE that involves an abnormal protein and chemistry analysis result + + + + obo2:OAE_0001653 + EB + + + + obo2:OAE_0001653 + protein and chemistry analysis result abnormal AE + + + + obo2:OAE_0001653 + MedDRA: 10037000 + + + + obo2:OAE_0001654 + a protein and chemistry analysis result abnormal AE that is characterized by an abnormal blood albumin level + + + + obo2:OAE_0001654 + EB + + + + obo2:OAE_0001654 + blood albumin level abnormal AE + + + + obo2:OAE_0001654 + MedDRA: 10005286 + + + + obo2:OAE_0001655 + a blood albumin level abnormal AE that is characterized by an increased blood albumin level + + + + obo2:OAE_0001655 + EB + + + + obo2:OAE_0001655 + blood albumin level increased AE + + + + obo2:OAE_0001655 + MedDRA: 10005288 + + + + obo2:OAE_0001656 + a protein and chemistry analysis result abnormal AE that is characterized by an abnormal c-reactive protein level + + + + obo2:OAE_0001656 + EB + + + + obo2:OAE_0001656 + c-reactive protein level abnormal AE + + + + obo2:OAE_0001656 + MedDRA: 10068559 + + + + obo2:OAE_0001657 + a c-reactive protein level abnormal AE that is characterized by a decreased c-reactive protein level + + + + obo2:OAE_0001657 + EB + + + + obo2:OAE_0001657 + c-reactive protein level decreased AE + + + + obo2:OAE_0001657 + MedDRA: 10049220 + + + + obo2:OAE_0001658 + a protein total abnormal AE that is characterized by an increased protein total + + + + obo2:OAE_0001658 + EB + + + + obo2:OAE_0001658 + protein total increased AE + + + + + obo2:OAE_0001658 + MedDRA: 10037016 + + + + obo2:OAE_0001659 + a protein total abnormal AE that is characterized by a decreased protein total + + + + obo2:OAE_0001659 + EB + + + + obo2:OAE_0001659 + protein total decreased AE + + + + obo2:OAE_0001659 + MedDRA: 10037014 + + + + obo2:OAE_0001660 + a cardiac and vascular investigation result abnormal AE that involves an abnormal result from a test using a radioactive tracer (called a radionuclide) and a special camera to take pictures of your heart as it pumps blood + + + + obo2:OAE_0001660 + EB + + + + obo2:OAE_0001660 + WEB: http://www.heart.org/HEARTORG/Conditions/HeartAttack/SymptomsDiagnosisofHeartAttack/Radionuclide-Ventriculography-or-Radionuclide-Angiography-MUGA-Scan_UCM_446354_Article.jsp + + + + obo2:OAE_0001660 + MUGA scan result abnormal AE + + + + obo2:OAE_0001660 + MedDRA: 10028146 + + + + obo2:OAE_0001661 + a cardiac and vascular investigation result abnormal AE that results in an abnormal result on a test used to evaluate heart function + + + + obo2:OAE_0001661 + EB + + + + obo2:OAE_0001661 + WEB: http://medical-dictionary.thefreedictionary.com/Stress+Test + + + + obo2:OAE_0001661 + cardiac stress test result abnormal AE + + + + obo2:OAE_0001661 + MedDRA: 10055014 + + + + obo2:OAE_0001662 + an investigation result abnormal AE that is characterized by an abnormal result of an enzyme investigation + + + + obo2:OAE_0001662 + EB + + + + obo2:OAE_0001662 + enzyme investigation result abnormal AE + + + + obo2:OAE_0001662 + MedDRA: 10014938 + + + + obo2:OAE_0001663 + a blood creatine phosphokinase level abnormal AE that is characterized by a decreased blood creatine phosphokinase + + + + obo2:OAE_0001663 + EB + + + + obo2:OAE_0001663 + blood creatine phosphokinase level decreased AE + + + + obo2:OAE_0001663 + MedDRA:10067760 + + + + obo2:OAE_0001664 + an investigation result abnormal AE that is characterized by an abnormal result of a hematology investigation + + + + obo2:OAE_0001664 + EB + + + + obo2:OAE_0001664 + haematology investigation abnormal AE + + + + obo2:OAE_0001664 + hematology investigation result abnormal AE + + + + obo2:OAE_0001664 + MedDRA: 10018851 + + + + obo2:OAE_0001665 + a hematology investigation result abnormal AE that results in an abnormal red blood cell profile + + + + obo2:OAE_0001665 + EB + + + + obo2:OAE_0001665 + red blood cell profile abnormal AE + + + + obo2:OAE_0001665 + MedDRA: 20000029 + + + + obo2:OAE_0001666 + a hematology investigation result abnormal AE that is characterized by an abnormal white blood cell profile + + + + obo2:OAE_0001666 + EB + + + + obo2:OAE_0001666 + white blood cell profile abnormal AE + + + + obo2:OAE_0001666 + MedDRA: 20000030 + + + + obo2:OAE_0001667 + a white blood cell profile abnormal AE that is characterized by an abnormal percentage of neutrophils + + + + obo2:OAE_0001667 + EB + + + + obo2:OAE_0001667 + neutrophil percentage abnormal AE + + + + obo2:OAE_0001667 + MedDRA: 10058134 + + + + obo2:OAE_0001668 + a neutrophil percentage abnormal AE that is characterized by a decreased percentage of neutrophils + + + + obo2:OAE_0001668 + EB + + + + obo2:OAE_0001668 + neutrophil percentage decreased AE + + + + obo2:OAE_0001668 + MedDRA: 10052223 + + + + obo2:OAE_0001669 + a white blood cell profile abnormal AE that is characterized by an abnormal basophil count + + + + obo2:OAE_0001669 + EB + + + + obo2:OAE_0001669 + basophil count abnormal AE + + + + obo2:OAE_0001669 + MedDRA: 10060978 + + + + obo2:OAE_0001670 + a basophil count abnormal AE that is characterized by a decreased basophil count + + + + obo2:OAE_0001670 + EB + + + + obo2:OAE_0001670 + basophil count decreased AE + + + + obo2:OAE_0001670 + MedDRA: 10004167 + + + + obo2:OAE_0001671 + a white blood cell profile abnormal AE that is characterized by an abnormal eosinophil percentage + + + + obo2:OAE_0001671 + EB + + + + obo2:OAE_0001671 + eosinophil percentage abnormal AE + + + + obo2:OAE_0001671 + MedDRA: 10058133 + + + + obo2:OAE_0001672 + an eosinophil percentage abnormal AE that is characterized by a decreased eosinophil percentage + + + + obo2:OAE_0001672 + EB + + + + obo2:OAE_0001672 + eosinophil percentage decreased AE + + + + obo2:OAE_0001672 + MedDRA: 10052221 + + + + obo2:OAE_0001673 + a white blood cell profile abnormal AE that is characterized by an abnormal leukocyte cell number + + + + obo2:OAE_0001673 + EB + + + + obo2:OAE_0001673 + leukocyte cell number abnormal AE + + + + obo2:OAE_0001674 + a white blood cell profile abnormal AE that is characterized by an abnormal granulocyte count + + + + obo2:OAE_0001674 + EB + + + + obo2:OAE_0001674 + granulocyte count abnormal AE + + + + obo2:OAE_0001674 + MedDRA: 10018678 + + + + obo2:OAE_0001675 + a granulocyte count abnormal AE that is characterized by an increased granulocyte count + + + + obo2:OAE_0001675 + EB + + + + obo2:OAE_0001675 + granulocyte count increased AE + + + + obo2:OAE_0001675 + MedDRA: 10018683 + + + + obo2:OAE_0001676 + a white blood cell profile abnormal AE that is characterized by an abnormal lymphocyte cell number + + + + obo2:OAE_0001676 + EB + + + + obo2:OAE_0001676 + lymphocyte count abnormal AE + + + + obo2:OAE_0001676 + MedDRA: 10025252 + + + + obo2:OAE_0001677 + a white blood cell profile abnormal AE that is characterized by an abnormal lymphocyte percentage + + + + obo2:OAE_0001677 + EB + + + + obo2:OAE_0001677 + lymphocyte percentage abnormal AE + + + + obo2:OAE_0001678 + a white blood cell profile abnormal AE that is characterized by an abnormal monocyte percentage + + + + obo2:OAE_0001678 + EB + + + + obo2:OAE_0001678 + monocyte percentage abnormal AE + + + + obo2:OAE_0001678 + MedDRA: 10067238 + + + + obo2:OAE_0001679 + a monoctyte percentage abnormal AE that is characterized by a decreased monocyte percentage + + + + obo2:OAE_0001679 + EB + + + + obo2:OAE_0001679 + monocyte percentage decreased AE + + + + + obo2:OAE_0001679 + MedDRA: 10052229 + + + + obo2:OAE_0001680 + an enzyme investigation result abnormal AE that is characterized by an abnormal blood lactate dehydrogenase level + + + + obo2:OAE_0001680 + EB + + + + obo2:OAE_0001680 + blood lactate dehydrogenase level abnormal AE + + + + obo2:OAE_0001680 + MedDRA: 10005627 + + + + obo2:OAE_0001681 + a blood lactate dehydrogenase level abnormal AE that is characterized by a decreased blood lactate dehydrogenase + + + + obo2:OAE_0001681 + EB + + + + obo2:OAE_0001681 + blood lactate dehydrogenase level decreased AE + + + + obo2:OAE_0001681 + MedDRA: 10005629 + + + + obo2:OAE_0001682 + an enzyme investigation result abnormal AE that is characterized by an abnormal troponin level + + + + obo2:OAE_0001682 + EB + + + + obo2:OAE_0001682 + troponin level abnormal AE + + + + obo2:OAE_0001683 + an enzyme investigation result abnormal AE that is characterized by an abnormal muscle enzyme level + + + + obo2:OAE_0001683 + EB + + + + obo2:OAE_0001683 + muscle enzyme level abnormal AE + + + + obo2:OAE_0001684 + a muscle enzyme level abnormal AE that is characterized by a decreased muscle enzyme level + + + + obo2:OAE_0001684 + EB + + + + obo2:OAE_0001684 + muscle enzyme level decreased AE + + + + obo2:OAE_0001684 + MedDRA: 10057952 + + + + obo2:OAE_0001685 + an enzyme investigation result abnormal AE that is characterized by an abnormal myoglobin level in the blood + + + + obo2:OAE_0001685 + EB + + + + obo2:OAE_0001685 + myoglobin blood abnormal AE + + + + obo2:OAE_0001686 + a myoglobin blood abnormal AE that is characterized by an increased myoglobin level in the blood + + + + obo2:OAE_0001686 + EB + + + + obo2:OAE_0001686 + myoglobin blood increased AE + + + + obo2:OAE_0001686 + MedDRA: 10028625 + + + + obo2:OAE_0001687 + a myoglobin blood abnormal AE that is characterized by a decreased myoglobin level in the blood + + + + obo2:OAE_0001687 + myoglobin blood decreased AE + + + + obo2:OAE_0001687 + MedDRA: 10059940 + + + + obo2:OAE_0001688 + an investigation result abnormal AE that is characterized by an abnormal result of a gastrointestinal investigation + + + + obo2:OAE_0001688 + EB + + + + obo2:OAE_0001688 + gastrointestinal investigation result abnormal AE + + + + obo2:OAE_0001688 + MedDRA: 10017971 + + + + obo2:OAE_0001689 + a gastrointestinal investigation result abnormal AE that is characterized by an abnormal blood amylase level + + + + obo2:OAE_0001689 + EB + + + + obo2:OAE_0001689 + blood amylase level abnormal AE + + + + obo2:OAE_0001689 + MedDRA: 10054822 + + + + obo2:OAE_0001690 + a blood amylase level abnormal AE that is characterized by a decreased blood amylase level + + + + obo2:OAE_0001690 + EB + + + + obo2:OAE_0001690 + blood amylase level decreased AE + + + + obo2:OAE_0001690 + MedDRA: 10005327 + + + + obo2:OAE_0001691 + a gastrointestinal investigation result abnormal AE that is characterized by an abnormal lipase level + + + + obo2:OAE_0001691 + EB + + + + obo2:OAE_0001691 + lipase level abnormal AE + + + + obo2:OAE_0001691 + MedDRA: 10054821 + + + + obo2:OAE_0001692 + a lipase level abnormal AE that is characterized by an increased lipase level + + + + obo2:OAE_0001692 + EB + + + + obo2:OAE_0001692 + lipase level increased AE + + + + obo2:OAE_0001692 + MedDRA: 10024574 + + + + obo2:OAE_0001693 + a lipase level abnormal AE that is characterized by a decreased lipase level + + + + obo2:OAE_0001693 + EB + + + + obo2:OAE_0001693 + lipase level decreased AE + + + + obo2:OAE_0001693 + MedDRA: 10024573 + + + + obo2:OAE_0001694 + an investigation result abnormal AE that is characterized by an abnormal liver related investigation result + + + + obo2:OAE_0001694 + EB + + + + obo2:OAE_0001694 + liver related investigation result abnormal AE + + + + obo2:OAE_0001694 + MedDRA: 20000008 + + + + obo2:OAE_0001695 + a liver related investigation result abnormal AE that is characterized by an abnormal level of transaminases + + + + obo2:OAE_0001695 + EB + + + + obo2:OAE_0001695 + transaminase level abnormal AE + + + + obo2:OAE_0001695 + MedDRA: 10062688 + + + + obo2:OAE_0001696 + a transaminase level abnormal AE that is characterized by a decreased level of transaminases + + + + obo2:OAE_0001696 + EB + + + + obo2:OAE_0001696 + transaminase level decreased AE + + + + obo2:OAE_0001696 + MedDRA: 10054795 + + + + obo2:OAE_0001697 + a liver related investigation result abnormal AE that is characterized by an abnormal aspartate aminotransferase level + + + + obo2:OAE_0001697 + EB + + + + obo2:OAE_0001697 + aspartate aminotransferase level abnormal AE + + + + obo2:OAE_0001697 + MedDRA: 10003477 + + + + obo2:OAE_0001698 + an aspartate aminotransferase level abnormal AE that is characterized by a decreased aspartate aminotransferase level + + + + obo2:OAE_0001698 + EB + + + + obo2:OAE_0001698 + aspartate aminotransferase level decreased AE + + + + obo2:OAE_0001698 + MedDRA: 10003479 + + + + obo2:OAE_0001699 + a gamma-glutamyltransferase level abnormal AE that is characterized by a decreased gamma-glutamyltransferase level + + + + obo2:OAE_0001699 + EB + + + + obo2:OAE_0001699 + gamma-glutamyltransferase level decreased AE + + + + obo2:OAE_0001699 + MedDRA: 10017690 + + + + obo2:OAE_0001700 + a blood bilirubin level abnormal AE that is characterized by a decreased blood bilirubin level + + + + obo2:OAE_0001700 + EB + + + + obo2:OAE_0001700 + blood bilirubin level decreased AE + + + + obo2:OAE_0001700 + MedDRA: 10049869 + + + + obo2:OAE_0001701 + an investigation result abnormal AE that is characterized by an abnormal result of an imaging investigation + + + + obo2:OAE_0001701 + EB + + + + obo2:OAE_0001701 + imaging investigation result abnormal AE + + + + obo2:OAE_0001701 + MedDRA: 10022893 + + + + obo2:OAE_0001702 + a hematology investigation result abnormal AE that is characterized by an abnormal blood thromboplastin level + + + + obo2:OAE_0001702 + EB + + + + obo2:OAE_0001702 + blood thromboplastin level abnormal AE + + + + obo2:OAE_0001702 + MedDRA: 10005824 + + + + obo2:OAE_0001703 + a blood thromboplastin level abnormal AE that is characterized by a decreased blood thromboplastin level + + + + obo2:OAE_0001703 + EB + + + + obo2:OAE_0001703 + blood thromboplastin level decreased AE + + + + obo2:OAE_0001703 + MedDRA: 10005826 + + + + obo2:OAE_0001704 + a hematology investigations result abnormal AE that is characterized by an abnormal coagulation factor v level + + + + obo2:OAE_0001704 + EB + + + + obo2:OAE_0001704 + coagulation factor v level abnormal AE + + + + obo2:OAE_0001704 + MedDRA: 10061771 + + + + obo2:OAE_0001705 + a coagulation factor v level abnormal AE that is characterized by an increased coagulation factor v level + + + + obo2:OAE_0001705 + EB + + + + obo2:OAE_0001705 + coagulation factor v level increased AE + + + + obo2:OAE_0001705 + MedDRA: 10009756 + + + + obo2:OAE_0001706 + a hematology investigation result abnormal AE that is characterized by an abnormal prothrombin level + + + + obo2:OAE_0001706 + EB + + + + obo2:OAE_0001706 + prothrombin level abnormal AE + + + + obo2:OAE_0001706 + MedDRA: 10037048 + + + + obo2:OAE_0001707 + a prothrombin level abnormal AE that is characterized by an increased prothrombin level + + + + obo2:OAE_0001707 + EB + + + + obo2:OAE_0001707 + prothrombin level increased AE + + + + obo2:OAE_0001707 + HPO: HP_0003645 + + + + obo2:OAE_0001707 + MedDRA: 10037051 + + + + obo2:OAE_0001707 + SIDER: C0151872 + + + + obo2:OAE_0001708 + a hematology investigation result abnormal AE that is characterized by an abnormal prothrombin time + + + + obo2:OAE_0001708 + EB + + + + obo2:OAE_0001708 + prothrombin time abnormal AE + + + + obo2:OAE_0001708 + MedDRA: 10037057 + + + + obo2:OAE_0001709 + a prothrombin time abnormal AE that is characterized by a shortened prothrombin time + + + + obo2:OAE_0001709 + EB + + + + obo2:OAE_0001709 + prothrombin time shortened AE + + + + obo2:OAE_0001709 + MedDRA: 10037070 + + + + obo2:OAE_0001710 + a full blood count abnormal AE that is characterized by an increased full blood count + + + + obo2:OAE_0001710 + EB + + + + obo2:OAE_0001710 + full blood count increased AE + + + + obo2:OAE_0001710 + MedDRA: 10052239 + + + + obo2:OAE_0001711 + a red blood cell profile abnormal AE that is characterized by an abnormal red blood cell count + + + + obo2:OAE_0001711 + EB + + + + obo2:OAE_0001711 + red blood cell count abnormal AE + + + + obo2:OAE_0001711 + MedDRA: 10038151 + + + + obo2:OAE_0001712 + a red blood cell count abnormal AE that is characterized by an increased red blood cell count + + + + obo2:OAE_0001712 + EB + + + + obo2:OAE_0001712 + red blood cell count increased AE + + + + obo2:OAE_0001712 + MedDRA: 10038155 + + + + obo2:OAE_0001713 + a red blood cell profile abnormal AE that is characterized by an abnormal hematocrit + + + + obo2:OAE_0001713 + EB + + + + obo2:OAE_0001713 + hematocrit abnormal AE + + + + obo2:OAE_0001713 + MedDRA: 10057763 + + + + obo2:OAE_0001714 + a hematocrit abnormal AE that is characterized by an increased hematocrit + + + + obo2:OAE_0001714 + EB + + + + obo2:OAE_0001714 + hematocrit increased AE + + + + obo2:OAE_0001714 + MedDRA: 10019424 + + + + obo2:OAE_0001715 + a hemoglobin level abnormal AE that is characterized by an increased hemoglobin level + + + + obo2:OAE_0001715 + EB + + + + obo2:OAE_0001715 + hemoglobin level increased AE + + + + obo2:OAE_0001715 + MedDRA:10055599 + + + + obo2:OAE_0001716 + a red blood cell profile abnormal AE that is characterized by an abnormal mean corpuscular volume + + + + obo2:OAE_0001716 + EB + + + + obo2:OAE_0001716 + mean corpuscular volume abnormal AE + + + + obo2:OAE_0001716 + MedDRA: 10027009 + + + + obo2:OAE_0001717 + a mean corpuscular volume abnormal AE that is characterized by an increased mean corpuscular volume + + + + obo2:OAE_0001717 + EB + + + + obo2:OAE_0001717 + mean corpuscular volume increased AE + + + + obo2:OAE_0001717 + MedDRA: 10051859 + + + + obo2:OAE_0001718 + a mean corpuscular volume abnormal AE that is characterized by a decreased mean corpuscular volume + + + + obo2:OAE_0001718 + EB + + + + obo2:OAE_0001718 + mean corpuscular volume decreased AE + + + + obo2:OAE_0001718 + MedDRA: 10051858 + + + + obo2:OAE_0001719 + a red blood cell profile abnormal AE that is characterized by an abnormal mean cell hemoglobin level + + + + obo2:OAE_0001719 + EB + + + + obo2:OAE_0001719 + mean cell hemoglobin level abnormal AE + + + + obo2:OAE_0001720 + a mean cell hemoglobin level abnormal AE that is characterized by an increased mean cell hemoglobin level + + + + obo2:OAE_0001720 + EB + + + + obo2:OAE_0001720 + mean cell hemoglobin level increased AE + + + + obo2:OAE_0001720 + MedDRA: 10055622 + + + + obo2:OAE_0001721 + a mean cell hemoglobin level abnormal AE that is characterized by a decreased mean cell hemoglobin level + + + + obo2:OAE_0001721 + EB + + + + obo2:OAE_0001721 + mean cell hemoglobin level decreased AE + + + + obo2:OAE_0001721 + MedDRA: 10055621 + + + + obo2:OAE_0001722 + a red blood cell profile abnormal AE that is characterized by an abnormal mean cell hemoglobin concentration + + + + obo2:OAE_0001722 + EB + + + + obo2:OAE_0001722 + mean cell hemoglobin concentration abnormal AE + + + + obo2:OAE_0001722 + MedDRA: 10067730 + + + + obo2:OAE_0001723 + a mean cell hemoglobin concentration abnormal AE that is characterized by an increased mean cell hemoglobin concentration + + + + obo2:OAE_0001723 + EB + + + + obo2:OAE_0001723 + mean cell hemoglobin concentration increased AE + + + + obo2:OAE_0001723 + MedDRA: 10026992 + + + + obo2:OAE_0001724 + a mean cell hemoglobin concentration abnormal AE that is characterized by a decreased mean cell hemoglobin concentration + + + + obo2:OAE_0001724 + EB + + + + obo2:OAE_0001724 + mean cell hemoglobin concentration decreased AE + + + + obo2:OAE_0001724 + MedDRA: 10026991 + + + + obo2:OAE_0001725 + a conduction system disorder that refers to abnormalities in SN impulse formation and propagation and includes sinus bradycardia, sinus pause/arrest, chronotropic incompetence, and sinoatrial exit block. + + + + obo2:OAE_0001725 + SS + + + + obo2:OAE_0001725 + SND + + + + obo2:OAE_0001725 + sinus node dysfunction + + + + obo2:OAE_0001725 + WEB: http://emedicine.medscape.com/article/158064-overview + + + + obo2:OAE_0001725 + sinoatrial node dysfunction AE + + + + obo2:OAE_0001726 + a coronary artery disorder AE that takes place in or is related to the coronary inside the heart + + + + obo2:OAE_0001726 + Even though 'coronary disorder AE' seems to be a more general term of 'coronary artery disorder AE' that should place 'coronary disorder AE' as a parent of 'coronary artery disorder AE', KB's comment from clinical perspective is that these two terms are synonymous in practice, and coronary disorder almost always means coronary artery disorder. If 'coronary disorder AE' gets picked up from reports, it is a generalized term of 'coronary artery disorder AE'; and thereofore, we created a place holder for this term under 'coronary artery disorder AE' + + + + obo2:OAE_0001726 + SS + + + + obo2:OAE_0001726 + coronary disorder AE + + + + obo2:OAE_0001727 + a myocardial infarction AE in which the inferior wall of the heart is involved. It is often caused by occlusion of the right coronary artery. + + + + obo2:OAE_0001727 + SS + + + + obo2:OAE_0001727 + myocardial infarction, inferior wall AE + + + + obo2:OAE_0001727 + WEB: http://www.ncbi.nlm.nih.gov/mesh/?term=inferior+wall+myocardial+infarction + + + + obo2:OAE_0001727 + inferior wall myocardial infarction AE + + + + obo2:OAE_0001728 + a myocardial infarction AE in which the anterior wall of the heart is involved. Anterior wall myocardial infarction is often caused by occlusion of the left anterior descending coronary artery. It can be categorized as anteroseptal or anterolateral wall myocardial infarction. + + + + obo2:OAE_0001728 + SS + + + + obo2:OAE_0001728 + myocardial infarction, anterior wall AE + + + + obo2:OAE_0001728 + WEB: http://www.ncbi.nlm.nih.gov/mesh/?term=anterior+wall+myocardial+infarction + + + + obo2:OAE_0001728 + anterior wall myocardial infarction AE + + + + obo2:OAE_0001729 + a hematology investigation result abnormal AE that is characterized by an abnormal blast cell count + + + + obo2:OAE_0001729 + EB + + + + obo2:OAE_0001729 + blast cell count abnormal AE + + + + obo2:OAE_0001730 + a blast cell count abnormal AE that is characterized by a decreased blast cell count + + + + obo2:OAE_0001730 + EB + + + + obo2:OAE_0001730 + blast cell count decreased AE + + + + obo2:OAE_0001730 + MedDRA: 10062275 + + + + obo2:OAE_0001731 + a hematology investigation result abnormal AE that is characterized by an abnormal platelet count + + + + obo2:OAE_0001731 + EB + + + + obo2:OAE_0001731 + platelet count abnormal AE + + + + obo2:OAE_0001731 + HPO: HP_0011873 + + + + obo2:OAE_0001731 + MedDRA: 10035526 + + + + obo2:OAE_0001731 + SIDER: C0580317 + + + + obo2:OAE_0001732 + a platelet count abnormal AE that is characterized by an increased platelet count + + + + obo2:OAE_0001732 + SZ, SS, YH, EB + + + + obo2:OAE_0001732 + WEB: http://medical-dictionary.thefreedictionary.com/thrombocytosis + + + + obo2:OAE_0001732 + platelet count increased AE + + + + obo2:OAE_0001732 + MedDRA: 10051608 + + + + obo2:OAE_0001733 + a white blood cell profile abnormal AE that is characterized by an abnormal eosinophil count + + + + obo2:OAE_0001733 + EB + + + + obo2:OAE_0001733 + eosinophil count abnormal AE + + + + obo2:OAE_0001733 + MedDRA: 10061125 + + + + obo2:OAE_0001734 + an eosinophil count abnormal AE that is characterized by a decreased eosinophil count + + + + obo2:OAE_0001734 + EB + + + + obo2:OAE_0001734 + eosinophil count decreased AE + + + + obo2:OAE_0001734 + MedDRA: 10014943 + + + + obo2:OAE_0001736 + a hypertension AE that is characterized by high blood pressure in the systemic arteries - the vessels that carry blood from the heart to the body's tissues (other than the lungs). + + + + obo2:OAE_0001736 + SS + + + + obo2:OAE_0001736 + WEB: http://www.pted.org/?id=syshypertension1 + + + + obo2:OAE_0001736 + systemic hypertension AE + + + + obo2:OAE_0001737 + a hypotension AE that has an outcome of a decrease in the amount of pressure the heart generates when pumping blood through arteries to the rest of the body + + + + obo2:OAE_0001737 + SS + + + + obo2:OAE_0001737 + WEB: http://www.mayoclinic.com/health/low-blood-pressure/DS00590/DSECTION=causes + + + + obo2:OAE_0001737 + blood pressure systolic decreased AE + + + + obo2:OAE_0001737 + HPO: HP_0006673 + + + + obo2:OAE_0001737 + MedDRA: 10005758 + + + + obo2:OAE_0001737 + SIDER: C0277885 + + + + obo2:OAE_0001738 + a cardiac valve disease AE that is characterized by an impaired function of a papillary muscle, usually due to ischemia or infarction, with resulting incompetence of the mitral (rarely tricuspid) valve. + + + + obo2:OAE_0001738 + SS + + + + obo2:OAE_0001738 + papillary muscle dysfunction + + + + obo2:OAE_0001738 + papillary muscle syndrome + + + + obo2:OAE_0001738 + WEB: http://medical-dictionary.thefreedictionary.com/papillary+muscle+dysfunction + + + + obo2:OAE_0001738 + papillary muscle disorder AE + + + + obo2:OAE_0001738 + MedDRA: 10061330 + + + + obo2:OAE_0001739 + a hypertension AE that has an outcome of an increase in the amount of pressure in the arteries when the heart is at rest between beats + + + + obo2:OAE_0001739 + SS + + + + obo2:OAE_0001739 + WEB: http://www.webmd.com/hypertension-high-blood-pressure/guide/diastolic-and-systolic-blood-pressure-know-your-numbers + + + + obo2:OAE_0001739 + blood pressure diastolic increased AE + + + + obo2:OAE_0001739 + HPO: HP_0005117 + + + + obo2:OAE_0001739 + MedDRA: 10005739 + + + + obo2:OAE_0001739 + SIDER: C0277889 + + + + obo2:OAE_0001740 + a hypertension AE that has an outcome of an increase in the amount of pressure the heart generates when pumping blood through arteries to the rest of the body + + + + obo2:OAE_0001740 + SS + + + + obo2:OAE_0001740 + WEB: http://www.webmd.com/hypertension-high-blood-pressure/guide/diastolic-and-systolic-blood-pressure-know-your-numbers + + + + obo2:OAE_0001740 + blood pressure systolic increased AE + + + + obo2:OAE_0001740 + HPO: HP_0004421 + + + + obo2:OAE_0001740 + MedDRA: 10005760 + + + + obo2:OAE_0001740 + SIDER: C0277884 + + + + obo2:OAE_0001741 + a cardiac ventricular disorder AE that is a condition in nwhich the right ventricle of the heart was functionally impaired. This condition usually leads to heart failure or myocardial infarction, and other cardiovascular complicationns. + + + + obo2:OAE_0001741 + SS + + + + obo2:OAE_0001741 + WEB: http://www.ncbi.nlm.nih.gov/mesh/?term=right%20ventricular%20dysfunction + + + + obo2:OAE_0001741 + right ventricular dysfunction AE + + + + obo2:OAE_0001741 + MedDRA: 10058597 + + + + obo2:OAE_0001742 + an arrhythmia AE that is characterized by a premature contraction of the ventricle + + + + obo2:OAE_0001742 + SS + + + + obo2:OAE_0001742 + infranodal extrasystoles AE + + + + obo2:OAE_0001742 + WEB: http://dictionary.reference.com/browse/ventricular+extrasystole + + + + obo2:OAE_0001742 + ventricular extrasystoles AE + + + + obo2:OAE_0001742 + HPO: HP_0006696 + + + + obo2:OAE_0001742 + MedDRA: 10047289 + + + + obo2:OAE_0001742 + SIDER: C0151636 + + + + obo2:OAE_0001743 + an embolism disorder AE that is a result of an obstruction in a cardiac vessel due to a blood clot or other foreign matters + + + + obo2:OAE_0001743 + SS + + + + obo2:OAE_0001743 + heart embolism AE + + + + obo2:OAE_0001743 + WEB: http://medical-dictionary.thefreedictionary.com/Heart+embolism + + + + obo2:OAE_0001743 + cardiac embolism AE + + + + obo2:OAE_0001744 + a vascular disorder AE that is characterized by an obstruction in a blood vessel due to a blood clot or other foreign matter that gets stuck while traveling through the bloodstream. + + + + obo2:OAE_0001744 + SS + + + + obo2:OAE_0001744 + WEB: http://medical-dictionary.thefreedictionary.com/embolism + + + + obo2:OAE_0001744 + embolism AE + + + + obo2:OAE_0001744 + HPO: HP_0001907 + + + + obo2:OAE_0001744 + MedDRA: 10014523 + + + + obo2:OAE_0001744 + SIDER: C0013922 + + + + obo2:OAE_0001746 + an arrhythmia AE that results in extra, abnormal heartbeats that begin in one of the heart's two lower pumping chambers (ventricles). These extra beats disrupt the regular heart rhythm, sometimes causing the patient to feel a flip-flop or skipped beat in the chest. + + + + obo2:OAE_0001746 + SS + + + + obo2:OAE_0001746 + PVCs + + + + obo2:OAE_0001746 + WEB: http://www.mayoclinic.com/health/premature-ventricular-contractions/DS00949 + + + + obo2:OAE_0001746 + premature ventricular contractions AE + + + + obo2:OAE_0001746 + MedDRA: 10036614 + + + + obo2:OAE_0001747 + a cardiac valve disease AE that is charaterized by the backflow of blood from the pulmonary artery into the right ventricle, owing to imperfect functioning of the pulmonary valve + + + + obo2:OAE_0001747 + SS + + + + obo2:OAE_0001747 + pulmonic incompetence AE + + + + obo2:OAE_0001747 + WEB: http://www.rightdiagnosis.com/medical/pulmonary_valve_incompetence.htm + + + + obo2:OAE_0001747 + pulmonary valve incompetence AE + + + + obo2:OAE_0001747 + HPO: HP_0010444 + + + + obo2:OAE_0001747 + MedDRA: 10037448 + + + + obo2:OAE_0001747 + SIDER: C0034088 + + + + obo2:OAE_0001748 + a cardiac vavle disease AE that is characterized by a congenital heart defect in which blood flow from the heart to the pulmonary artery is blocked + + + + obo2:OAE_0001748 + SS + + + + obo2:OAE_0001748 + pulmonic stenosis AE + + + + obo2:OAE_0001748 + WEB: http://medical-dictionary.thefreedictionary.com/Pulmonary+Valve+Stenosis + + + + obo2:OAE_0001748 + pulmonary valve stenosis AE + + + + obo2:OAE_0001748 + MedDRA: 10037450 + + + + obo2:OAE_0001749 + a vasculitis AE that is an inflammation specific to an artery or arteries + + + + obo2:OAE_0001749 + SS + + + + obo2:OAE_0001749 + WEB: http://medical-dictionary.thefreedictionary.com/arteritis + + + + obo2:OAE_0001749 + arteritis AE + + + + obo2:OAE_0001749 + HPO: HP_0005291 + + + + obo2:OAE_0001749 + MedDRA: 10003230 + + + + obo2:OAE_0001749 + SIDER: C0003860 + + + + obo2:OAE_0001751 + a vascular disorder AE that results in an abnormal widening or ballooning of a portion of an artery due to weakness in the wall of the blood vessel + + + + obo2:OAE_0001751 + SS + + + + obo2:OAE_0001751 + WEB: http://www.nlm.nih.gov/medlineplus/ency/article/001122.htm + + + + obo2:OAE_0001751 + aneurysm AE + + + + obo2:OAE_0001751 + HPO: HP_0002617 + + + + obo2:OAE_0001751 + MedDRA: 10002329 + + + + obo2:OAE_0001751 + SIDER: C0002940 + + + + obo2:OAE_0001752 + a vascular disorder that affects the veins or blood circulation of the veins + + + + obo2:OAE_0001752 + SS + + + + obo2:OAE_0001752 + venous disorder AE + + + + obo2:OAE_0001753 + an aneurysm AE that results in the weakening of the balloon-like bulge that the blood pressure causes the artery wall to leak or burst + + + + obo2:OAE_0001753 + SS + + + + obo2:OAE_0001753 + SAH + + + + obo2:OAE_0001753 + ruptured aneurysm AE + + + + obo2:OAE_0001753 + subarachnoid hemorrhage AE + + + + obo2:OAE_0001753 + WEB: http://www.mayfieldclinic.com/PE-AneurRupt.htm#.Uor4tI3QHh0 + + + + obo2:OAE_0001753 + aneurysm ruptured AE + + + + obo2:OAE_0001753 + HPO: HP_0002617 + + + + obo2:OAE_0001753 + MedDRA: 10048380 + + + + obo2:OAE_0001753 + SIDER: C0162869 + + + + obo2:OAE_0001754 + an aneurysm AE that refers to an aneurysm involving cardiac tissue. This most often occurs as a ventricular aneurysm following a myocardial infarction + + + + obo2:OAE_0001754 + SS + + + + obo2:OAE_0001754 + aneurysm of heart AE + + + + obo2:OAE_0001754 + heart aneurysm AE + + + + obo2:OAE_0001754 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/19239694 + + + + obo2:OAE_0001754 + cardiac aneurysm AE + + + + obo2:OAE_0001754 + MedDRA: 10007513 + + + + obo2:OAE_0001755 + an aneurysm AE that occurs in the aorta + + + + obo2:OAE_0001755 + SS + + + + obo2:OAE_0001755 + WEB: http://www.webmd.com/heart-disease/tc/aortic-aneurysm-overview + + + + obo2:OAE_0001755 + aortic aneurysm AE + + + + obo2:OAE_0001755 + HPO: HP_0004942 + + + + obo2:OAE_0001755 + MedDRA: 10002882 + + + + obo2:OAE_0001755 + SIDER: C0003486 + + + + obo2:OAE_0001756 + an aneurysm ruptured AE that occurs in the aorta + + + + obo2:OAE_0001756 + SS + + + + obo2:OAE_0001756 + ruptured aortic aneurysm AE + + + + obo2:OAE_0001756 + aortic aneurysm rupture AE + + + + obo2:OAE_0001756 + HPO: HP_0002622 + + + + obo2:OAE_0001756 + MedDRA: 10002886 + + + + obo2:OAE_0001756 + SIDER: C0741160 + + + + obo2:OAE_0001757 + an aortic disorder AE in which there is a separation of the aorta walls. The small tear can become larger. It can lead to bleeding into and along the wall of the aorta, the major artery carrying blood out of the heart. + + + + obo2:OAE_0001757 + SS + + + + obo2:OAE_0001757 + WEB: http://www.nlm.nih.gov/medlineplus/ency/article/000181.htm + + + + obo2:OAE_0001757 + aortic dissection AE + + + + obo2:OAE_0001757 + HPO: HP_0004933 + + + + obo2:OAE_0001757 + MedDRA: 10002895 + + + + obo2:OAE_0001757 + SIDER: C0340643 + + + + obo2:OAE_0001758 + an aneurysm ruptured AE that occurs in the brain where blood spurts into the subarachnoid space under arterial pressure, continuing until increased local or generalized intracranial pressure stops the bleeding. + + + + obo2:OAE_0001758 + SS + + + + obo2:OAE_0001758 + WEB: http://ether.stanford.edu/library/neuroanesthesia/Journal%20Articles/Ruptured%20cerebral%20aneurysms.pdf + + + + obo2:OAE_0001758 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/15647574 + + + + obo2:OAE_0001758 + ruptured cerebral aneurysm AE + + + + obo2:OAE_0001758 + MedDRA: 10039330 + + + + obo2:OAE_0001759 + an aneurysm AE that occurs in the brain + + + + obo2:OAE_0001759 + SS + + + + obo2:OAE_0001759 + brain aneurysm AE + + + + obo2:OAE_0001759 + cerebral aneurysm AE + + + + obo2:OAE_0001759 + intracerebral aneurysm AE + + + + obo2:OAE_0001759 + WEB: http://www.ninds.nih.gov/disorders/cerebral_aneurysm/detail_cerebral_aneurysms.htm + + + + obo2:OAE_0001759 + intracranial aneurysm AE + + + + obo2:OAE_0001759 + HPO: HP_0004944 + + + + obo2:OAE_0001759 + MedDRA: 10022758 + + + + obo2:OAE_0001759 + SIDER: C0007766 + + + + obo2:OAE_0001760 + a thrombosis AE that is a rare lesion and may be defined as a thrombosis of a vessel without any obvious underlying cause that occurs in the aorta + + + + obo2:OAE_0001760 + SS + + + + obo2:OAE_0001760 + WEB: http://circ.ahajournals.org/content/17/5/941.full.pdf + + + + obo2:OAE_0001760 + aortic thrombosis AE + + + + obo2:OAE_0001760 + MedDRA: 10002910 + + + + obo2:OAE_0001761 + an arterial thrombosis AE that is characterized by the occurrence of a thrombus in the carotid arteries (two large blood vessels that supply oxygenated blood to the large, front part of the brain) + + + + obo2:OAE_0001761 + SS + + + + obo2:OAE_0001761 + WEB: http://www.webmd.com/heart-disease/carotid-artery-disease-causes-symptoms-tests-and-treatment + + + + obo2:OAE_0001761 + carotid artery thrombosis AE + + + + obo2:OAE_0001761 + MedDRA: 10007688 + + + + obo2:OAE_0001762 + an arterial embolism AE that occurs in the cerebral artery + + + + obo2:OAE_0001762 + SS + + + + obo2:OAE_0001762 + cerebral embolism AE + + + + obo2:OAE_0001762 + embolic stroke AE + + + + obo2:OAE_0001762 + thrombotic stroke AE + + + + obo2:OAE_0001762 + WEB: http://medical-dictionary.thefreedictionary.com/cerebral+embolism + + + + obo2:OAE_0001762 + cerebral artery embolism AE + + + + obo2:OAE_0001762 + MedDRA: 10008088 + + + + obo2:OAE_0001762 + MedDRA: 10014498 + + + + obo2:OAE_0001762 + MedDRA: 10043647 + + + + obo2:OAE_0001763 + an arterial thrombosis AE that occurs in the cerebral artery, also referred to as an embolism AE + + + + obo2:OAE_0001763 + [SS] Per DRA and KKB's comment, this term may also be characterized as a type of embolism even though labeled thrombosis. + + + + obo2:OAE_0001763 + cerebral thrombosis AE + + + + obo2:OAE_0001763 + cerebral artery thrombosis AE + + + + obo2:OAE_0001763 + MedDRA: 10008092 + + + + obo2:OAE_0001763 + MedDRA: 10008132 + + + + obo2:OAE_0001764 + a venous thrombosis AE that is characterized by thrombosis of the venous channels in the brain. It is an uncommon cause of cerebral infarction relative to arterial disease, but it is an important consideration because of its potential morbidity. + + + + obo2:OAE_0001764 + [SS] From http://medical-dictionary.thefreedictionary.com/cerebral+venous+thrombosis, Merwarth syndrome - progressive hemiplegia due to venous occlusion. Synonym(s): cerebral venous thrombosis + + + + obo2:OAE_0001764 + SS + + + + obo2:OAE_0001764 + WEB: http://emedicine.medscape.com/article/1162804-overview + + + + obo2:OAE_0001764 + cerebral venous thrombosis AE + + + + obo2:OAE_0001764 + MedDRA: 10008138 + + + + obo2:OAE_0001765 + a venous thrombosis AE that occurs when a blood clot forms in the brain’s venous sinuses that prevents blood from draining out of the brain. As a result, blood cells may break and leak blood into the brain tissues, forming a hemorrhage. + + + + obo2:OAE_0001765 + SS + + + + obo2:OAE_0001765 + CVST + + + + obo2:OAE_0001765 + WEB: http://www.hopkinsmedicine.org/healthlibrary/conditions/nervous_system_disorders/cerebral_venous_sinus_thrombosis_134,69/ + + + + obo2:OAE_0001765 + intracranial venous sinus thrombosis AE + + + + obo2:OAE_0001765 + MedDRA: 10061251 + + + + obo2:OAE_0001766 + an embolism AE that is caused by a gas bubble that enters the vein + + + + obo2:OAE_0001766 + [SS] The term 'gas embolism' is listed as a unique term, and not a superset or a synonym of 'air embolism' due to the different pathology reconized by physicians that air embolism is mostly recognized when an air bubble caused by IV or other injection device enters the vein, while a gas embolism is mostly caused by a gas bubble released as a product of an infection, or other devices such as nitrogen tank. + + + + obo2:OAE_0001766 + SS + + + + obo2:OAE_0001766 + gas embolilsm AE + + + + obo2:OAE_0001767 + a thrombosis that is characterized by a clot that blocks blood flow a mesenteric vein, one of two veins through which blood leaves the intestine. The condition interrupts the blood supply to the intestine and can result in damage to the intestines. + + + + obo2:OAE_0001767 + [SS] http://emedicine.medscape.com/article/193921-overview, Mesenteric venous thrombosis (also known as visceral venous thrombosis) is a rare but lethal form of mesenteric ischemia (see the image below). Antonio Hodgson first described mesenteric ischemia in the latter part of the 15th century. In 1895, Elliot first described mesenteric venous thrombosis as a cause of mesenteric ischemia. By the turn of the 19th century, many review articles and texts were describing the recent advances in the characterization and treatment of mesenteric ischemia, particularly venous thrombosis. In 1935, Warren and Eberhard reported that intestinal infarction resulted from ischemia due to venous thrombosis, and they reported a mortality rate of 34% in patients with venous thrombosis after resection. Unfortunately, despite improvements in therapy, this mortality rate still holds. + + + + + obo2:OAE_0001767 + SS + + + + obo2:OAE_0001767 + mesenteric venous thrombosis AE + + + + obo2:OAE_0001767 + visceral venous thrombosis AE + + + + obo2:OAE_0001767 + WEB: http://www.nlm.nih.gov/medlineplus/ency/article/001157.htm + + + + obo2:OAE_0001767 + mesenteric vein thrombosis AE + + + + obo2:OAE_0001767 + MedDRA: 10027402 + + + + obo2:OAE_0001768 + a thrombosis AE that is an uncommon condition induced by thrombotic or nonthrombotic obstruction of hepatic venous outflow and characterized by hepatomegaly, ascites, and abdominal pain. + + + + obo2:OAE_0001768 + SS + + + + obo2:OAE_0001768 + WEB: http://emedicine.medscape.com/article/184430-overview + + + + obo2:OAE_0001768 + Budd-Chiari syndrome AE + + + + obo2:OAE_0001768 + MedDRA: 10006537 + + + + obo2:OAE_0001769 + a thrombosis AE that occurs in the vein carrying the blood away from the retina + + + + obo2:OAE_0001769 + [SS] The term 'retinal vein thrombosis' is listed as a different class from 'retinal vein occlusion' for the difference in the pathological process of how the blockage occurs in the vein. + + + + obo2:OAE_0001769 + SS + + + + obo2:OAE_0001769 + retinal vein thrombosis AE + + + + obo2:OAE_0001769 + MedDRA: 10038908 + + + + obo2:OAE_0001771 + an embolism AE that occurs in the artery. It is a sudden interruption of blood flow to an organ or body part due to a clot (embolus). + + + + obo2:OAE_0001771 + SS + + + + obo2:OAE_0001771 + embolism arterial AE + + + + obo2:OAE_0001771 + WEB: http://www.nlm.nih.gov/medlineplus/ency/article/001102.htm + + + + obo2:OAE_0001771 + arterial embolism AE + + + + obo2:OAE_0001771 + MedDRA: 10014513 + + + + obo2:OAE_0001772 + a thrombosis AE* that is a result of when a blood vessel is obstructed by a blood clot (embolus) that has been carried in the bloodstream from the site of its formation. Thromboembolic disease includes both venous thromboembolism (VTE) and arterial thrombosis. VTE is an general term which refers to mainly two conditions: deep vein thrombosis (DVT) and its potentially fatal acute complication, pulmonary embolism (PE). Arterial embolism is a frequent complication in patients with atrial fibrillation (AF) and can lead to stroke or systemic embolism. + +* see editor note + + + + obo2:OAE_0001772 + [SS] Per DRA and KKB's comment, this term is synonymous to venous thrombosis even though labeled embolism. Cross-reference is made via seeAlso. + + + + obo2:OAE_0001772 + SS + + + + obo2:OAE_0001772 + VTE + + + + obo2:OAE_0001772 + embolism venous AE + + + + obo2:OAE_0001772 + venous thromboembolism AE + + + + obo2:OAE_0001772 + WEB: http://www.boehringer-ingelheim.com/products/prescription_medicines/thromboembolic_diseases.html + + + + obo2:OAE_0001772 + venous embolism AE + + + + obo2:OAE_0001772 + MedDRA: 10014522 + + + + obo2:OAE_0001772 + OAE: 0001505 + + + + obo2:OAE_0001773 + an embolism AE that is characterized by the obstruction of blood vessel by fat droplets + + + + obo2:OAE_0001773 + SS + + + + obo2:OAE_0001773 + WEB: http://emedicine.medscape.com/article/460524-overview#showall + + + + obo2:OAE_0001773 + fat embolism AE + + + + obo2:OAE_0001773 + MedDRA: 10016246 + + + + obo2:OAE_0001774 + a embolism AE that is infected with bacteria containing pus + + + + obo2:OAE_0001774 + SS + + + + obo2:OAE_0001774 + septic embolism AE + + + + obo2:OAE_0001774 + WEB: http://www.medicalnewstoday.com/articles/153704.php + + + + obo2:OAE_0001774 + septic embolus AE + + + + obo2:OAE_0001774 + MedDRA: 10040067 + + + + obo2:OAE_0001775 + a thrombosis AE that occurs in or may be caused by an implanted device in the body + + + + obo2:OAE_0001775 + SS + + + + obo2:OAE_0001775 + thrombosis in device AE + + + + obo2:OAE_0001775 + MedDRA: 10062546 + + + + obo2:OAE_0001777 + an arterial thrombosis AE that occurs in the limb(s) of the body + + + + obo2:OAE_0001777 + SS + + + + obo2:OAE_0001777 + arterial thrombosis limb AE + + + + obo2:OAE_0001777 + MedDRA: 10003180 + + + + obo2:OAE_0001778 + behavioral AE + + + + obo2:OAE_0001779 + SS + + + + obo2:OAE_0001779 + injection site thrombosis AE + + + + obo2:OAE_0001779 + MedDRA: 10022104 + + + + obo2:OAE_0001780 + a deep vein thrombosis AE that occurs in the pelvis. Ovarian vein thrombosis arises out of the coincident conditions of venous stasis and hypercoagulability, which are commonly present in the recently postpartum patient. + + + + obo2:OAE_0001780 + SS + + + + obo2:OAE_0001780 + ovarian vein thrombosis AE + + + + obo2:OAE_0001780 + WEB: http://emedicine.medscape.com/article/404364-overview + + + + obo2:OAE_0001780 + pelvic venous thrombosis AE + + + + obo2:OAE_0001780 + MedDRA: 10034272 + + + + obo2:OAE_0001781 + an embolism AE that is charaterized by a sudden blockage in a lung artery. The blockage usually is caused by a blood clot that travels to the lung from a vein in the leg. + + + + obo2:OAE_0001781 + SS + + + + obo2:OAE_0001781 + PE + + + + obo2:OAE_0001781 + WEB: http://www.nhlbi.nih.gov/health/health-topics/topics/pe/ + + + + obo2:OAE_0001781 + peripheral embolism AE + + + + obo2:OAE_0001781 + MedDRA: 10061340 + + + + obo2:OAE_0001782 + a thrombosis AE that occurs in subclavian vein. Among patients with effort-induced thrombosis with subclavian vein stenosis, the thrombosis occurs in the dominant arm in 80% of cases. + + + + obo2:OAE_0001782 + SS + + + + obo2:OAE_0001782 + WEB: http://emedicine.medscape.com/article/424777-overview#showall + + + + obo2:OAE_0001782 + subclavian vein thrombosis AE + + + + obo2:OAE_0001782 + MedDRA: 10049446 + + + + obo2:OAE_0001783 + a thrombophlebitis AE that is characterized by an inflammation of a vein due to a blood clot in a vein located just below the skin's surface. + + + + obo2:OAE_0001783 + SS + + + + obo2:OAE_0001783 + superficial thrombophlebitis AE + + + + obo2:OAE_0001783 + WEB: http://www.nlm.nih.gov/medlineplus/ency/article/000199.htm + + + + obo2:OAE_0001783 + thrombophlebitis superficial AE + + + + obo2:OAE_0001783 + MedDRA: 10043595 + + + + obo2:OAE_0001784 + SS + + + + obo2:OAE_0001784 + venous thrombosis limb AE + + + + obo2:OAE_0001784 + MedDRA: 10061408 + + + + obo2:OAE_0001785 + a thrombosis that is characterized by a blockage of the small veins that carry blood away from the retina. The retina is the layer of tissue at the back of the inner eye that converts light images to nerve signals and sends them to the brain. + + + + obo2:OAE_0001785 + SS + + + + obo2:OAE_0001785 + RVO + + + + obo2:OAE_0001785 + WEB: http://www.nlm.nih.gov/medlineplus/ency/article/007330.htm + + + + obo2:OAE_0001785 + retinal vein occlusion AE + + + + obo2:OAE_0001785 + MedDRA: 10038907 + + + + obo2:OAE_0001786 + a thrombosis AE that occurs in the atrium (left or right) + + + + obo2:OAE_0001786 + SS + + + + obo2:OAE_0001786 + WEB: http://ehjcimaging.oxfordjournals.org/content/9/1/204.full + + + + obo2:OAE_0001786 + atrial thrombosis AE + + + + obo2:OAE_0001786 + MedDRA: 10048632 + + + + obo2:OAE_0001787 + an arterial embolism AE that occurs in the coronary artery + + + + obo2:OAE_0001787 + SS + + + + obo2:OAE_0001787 + coronary artery thrombosis AE + + + + obo2:OAE_0001787 + coronary embolism AE + + + + obo2:OAE_0001787 + WEB: http://medical-dictionary.thefreedictionary.com/Coronary+embolism + + + + obo2:OAE_0001787 + coronary artery embolism AE + + + + obo2:OAE_0001787 + MedDRA: 10011084 + + + + obo2:OAE_0001787 + MedDRA: 10011091 + + + + obo2:OAE_0001789 + neurological AE + + + + obo2:OAE_0001790 + Stroke AE is a neurological AE that occurs when flow of oxygen-rich blood to a portion of the brain is blocked + + + + obo2:OAE_0001790 + JX, LW, YH + + + + obo2:OAE_0001790 + cardiovascular accident AE + + + + obo2:OAE_0001790 + WEB: http://www.nhlbi.nih.gov/health/health-topics/topics/stroke/ + http://en.wikipedia.org/wiki/Stroke + + + + obo2:OAE_0001790 + 中风 + + + + obo2:OAE_0001790 + stroke AE + + + + obo2:OAE_0001790 + MedDRA: 10042244 + + + + obo2:OAE_0001791 + a stroke AE that occurs when a blood vessel that supplies the brain becomes blocked or "clogged" and impairs blood flow to part of the brain. + + + + obo2:OAE_0001791 + SS + + + + obo2:OAE_0001791 + ischaemic stroke AE + + + + obo2:OAE_0001791 + WEB: http://www.hopkinsmedicine.org/healthlibrary/conditions/nervous_system_disorders/types_of_stroke_85,P00813/ + + + + obo2:OAE_0001791 + ischemic stroke AE + + + + obo2:OAE_0001791 + MedDRA: 10061256 + + + + obo2:OAE_0001792 + a stroke AE that occurs when a blood vessel that supplies the brain ruptures and bleeds causing the deficiency of oxygen and nutrients to brain cells and tissues + + + + obo2:OAE_0001792 + SS + + + + obo2:OAE_0001792 + haemorrhagic stroke AE + + + + obo2:OAE_0001792 + WEB: http://www.hopkinsmedicine.org/healthlibrary/conditions/nervous_system_disorders/types_of_stroke_85,P00813/ + + + + obo2:OAE_0001792 + hemorrhagic stroke AE + + + + obo2:OAE_0001792 + MedDRA: 10019016 + + + + obo2:OAE_0001793 + a haemorrhagic stroke AE that is cuased by hypertension (high blood pressure), and bleeding occurs suddenly and rapidly. + + + + obo2:OAE_0001793 + SS + + + + obo2:OAE_0001793 + intracerebral haemorrhagic stroke AE + + + + obo2:OAE_0001793 + WEB: http://www.hopkinsmedicine.org/healthlibrary/conditions/nervous_system_disorders/types_of_stroke_85,P00813/ + + + + obo2:OAE_0001793 + intracerebral hemorrhagic stroke AE + + + + obo2:OAE_0001794 + a haemorrhagic stroke AE that is cuased by the bleeding (haemorrhage) between the brain and the meninges (the membrane that covers the brain) in the subarachnoid space. + + + + obo2:OAE_0001794 + SS + + + + obo2:OAE_0001794 + subarachnoid haemorrhagic stroke AE + + + + obo2:OAE_0001794 + WEB: http://www.hopkinsmedicine.org/healthlibrary/conditions/nervous_system_disorders/types_of_stroke_85,P00813/ + + + + obo2:OAE_0001794 + subarachnoid hemorrhagic stroke AE + + + + obo2:OAE_0001795 + an ischaemic stroke AE that is caused by a thrombus (blood clot) that develops in the arteries supplying blood to the brain + + + + obo2:OAE_0001795 + SS + + + + obo2:OAE_0001795 + WEB: http://www.hopkinsmedicine.org/healthlibrary/conditions/nervous_system_disorders/types_of_stroke_85,P00813/ + + + + obo2:OAE_0001795 + thrombotic stroke AE + + + + obo2:OAE_0001795 + MedDRA: 10043647 + + + + obo2:OAE_0001796 + an ischaemic stroke AE that is caused by an embolus (a blood clot that formms elsewhere in the body and travels through the bloodstream to the brain). + + + + obo2:OAE_0001796 + SS + + + + obo2:OAE_0001796 + WEB: http://www.hopkinsmedicine.org/healthlibrary/conditions/nervous_system_disorders/types_of_stroke_85,P00813/ + + + + obo2:OAE_0001796 + embolic stroke AE + + + + obo2:OAE_0001796 + MedDRA: 10014498 + + + + obo2:OAE_0001797 + a behavior and neurological AE that has an outcome of a mental illness or psychiatiric disorder. The mental illness is a mental or behavioral pattern or anomaly that causes either suffering or an impaired ability to function in ordinary life (disability), and which is not developmentally or socially normative. + + + + obo2:OAE_0001797 + YH, Izabela Birsanescu + + + + obo2:OAE_0001797 + psychiatric disorder AE + + + + obo2:OAE_0001797 + WEB: http://en.wikipedia.org/wiki/Mental_disorder + + + + obo2:OAE_0001797 + mental disorder AE + + + + obo2:OAE_0001797 + MedDRA ID: 10037175 + + + + obo2:OAE_0001798 + a mental disorder AE that has an outcome of a adjustment disorder. An adjustment disorder is an unexpectedly strong emotional or behavioral reaction that occurs in response to an identifiable stressful life event or life change that occurred within the previous three months. + + + + obo2:OAE_0001798 + Yongqun He, Izabela Birsanescu + + + + obo2:OAE_0001798 + WEB: http://www.healthline.com/health/adjustment-disorder + + + + obo2:OAE_0001798 + adjustment disorder AE + + + + obo2:OAE_0001798 + MedDRA ID: 10001302; MedDRA ID: 10001301 + + + + obo2:OAE_0001799 + an adjustment disorder AE that has an additional depressed mood. The person is more depressed than would be expected after a stressful event. + + + + obo2:OAE_0001799 + Yongqun He, Izabela Birsanescu + + + + obo2:OAE_0001799 + WEB: http://www.summitmedicalgroup.com/library/adult_health/bha_adjustment_disorder_with_depressed_mood/ + + + + obo2:OAE_0001799 + adjustment disorder with depressed mood AE + + + + obo2:OAE_0001799 + MedDRA ID: 10001297 + + + + obo2:OAE_0001800 + a hemorrhage AE that has an outcome of bleeding from anastomosis site. Anastomosis: pathological formation of an opening between two normally distinct spaces or organs. + + + + obo2:OAE_0001800 + Yongqun He, Izabela Birsanescu + + + + obo2:OAE_0001800 + WEB: http://medical-dictionary.thefreedictionary.com/anastomosis + + + + obo2:OAE_0001800 + anastomotic bleeding AE + + + + obo2:OAE_0001800 + MedDRA: 10071781 + + + + obo2:OAE_0001801 + a clostridial infection AE that is caused by C. difficule. + + + + obo2:OAE_0001801 + Yongqun He, Izabela Birsanescu + + + + obo2:OAE_0001801 + WEB: http://www.mayoclinic.org/diseases-conditions/c-difficile/basics/definition/CON-20029664?p=1 + + + + obo2:OAE_0001801 + Clostridium difficile infection AE + + + + obo2:OAE_0001801 + MedDRA: 10054236 + + + + obo2:OAE_0001802 + Yongqun He, Izabela Birsanescu + + + + obo2:OAE_0001802 + a bacteraemia AE that is more specifically associated with a Gram-negative bacterium. + + + + obo2:OAE_0001802 + Gram-negative bacteremia AE + + + + obo2:OAE_0001802 + MedDRA: 10054228 + + + + obo2:OAE_0001805 + a hemorrhage AE that has an outcome of massive amounts of blood loss. A typical Intraoperative hemorrhage has a blood loss exceeding 1000 mL or requires a blood transfusion + + + + obo2:OAE_0001805 + Yongqun He, Izabela Birsanescu + + + + obo2:OAE_0001805 + WEB: http://www.uptodate.com/contents/management-of-hemorrhage-in-gynecologic-surgery + + + + obo2:OAE_0001805 + Intraoperative hemorrhage AE + + + + obo2:OAE_0001805 + MedDRA: 10055298 + + + + obo2:OAE_0001806 + an abscess AE that shows a cavity of pus within the pancreas + + + + obo2:OAE_0001806 + Yongqun He, Izabela Birsanescu + + + + obo2:OAE_0001806 + WEB: http://www.nlm.nih.gov/medlineplus/ency/article/000270.htm + + + + obo2:OAE_0001806 + pancreatic abscess AE + + + + obo2:OAE_0001806 + MedDRA: 10048984 + + + + obo2:OAE_0001807 + a sugery AE that has an adverse outcome where the recipient’s body rejects the pancreas transplantation. + + + + obo2:OAE_0001807 + Yongqun He, Izabela Birsanescu + + + + obo2:OAE_0001807 + WEB: http://www.medscape.com/viewarticle/436542_13 + + + + obo2:OAE_0001807 + pancreas transplant rejection AE + + + + obo2:OAE_0001807 + MedDRA: 10049169 + + + + obo2:OAE_0001808 + an infection AE that has an outcome of a severe local inflammation, usually with pus formation, generally caused by one of the pyogenic bacteria. + + + + obo2:OAE_0001808 + Yongqun He, Izabela Birsanescu + + + + obo2:OAE_0001808 + WEB: http://www.medilexicon.com/medicaldictionary.php?t=44396 + + + + obo2:OAE_0001808 + pyogenic infection AE + + + + obo2:OAE_0001808 + MedDRA: 10021861 + + + + obo2:OAE_0001809 + a fever AE that has unknown origin. + + + + obo2:OAE_0001809 + Yongqun He, Izabela Birsanescu + + + + obo2:OAE_0001809 + WEB: http://medicine.academic.ru/123590/fever_of_unknown_origin + + + + obo2:OAE_0001809 + fever of unknown origin AE + + + + obo2:OAE_0001809 + MedDRA: 10016563 + + + + obo2:OAE_0001843 + a respiratory distress AE that has an outcome of insufficient oxygen flow in the heart and respiratory system. + + + + obo2:OAE_0001843 + SS, YH + + + + obo2:OAE_0001843 + WEB: http://medicalcenter.osu.edu/patientcare/healthcare_services/lung_diseases/about/signs/Pages/index.aspx, http://www.merriam-webster.com/dictionary/cardiorespiratory + + + + obo2:OAE_0001843 + cardio-respiratory distress AE + + + + obo2:OAE_0001843 + MedDRA: 10049874 + + + + obo2:OAE_0001844 + A joint disorder AE that has the presence of increased intra-articular fluid. It can be caused by trauma, arthritis, or gout and often affects the knee. + + + + obo2:OAE_0001844 + RR, YH + + + + obo2:OAE_0001844 + PMID: 19915432 + + + + obo2:OAE_0001844 + WEB: http://en.wikipedia.org/wiki/Joint_effusion + + + + obo2:OAE_0001844 + joint effusion AE + + + + obo2:OAE_0001844 + MedDRA ID: 10023215 + + + + obo2:OAE_0001845 + a digestive system AE that shows a problem with the stomach, ranging from indigestion and heartburn to peptic ulcers and GERD. + + + + obo2:OAE_0001845 + RR, YH + + + + obo2:OAE_0001845 + stomach disorder AE + + + + obo2:OAE_0001845 + WEB: http://www.nlm.nih.gov/medlineplus/stomachdisorders.html + + + + obo2:OAE_0001845 + gastric disorder AE + + + + obo2:OAE_0001845 + MedDRA: 10056819 + + + + obo2:OAE_0001847 + An inflammation AE that displays an inflammation (not an infection) of the thyroid gland. + + + + obo2:OAE_0001847 + http://www.endocrineweb.com/conditions/thyroid/thyroiditis + + + + obo2:OAE_0001847 + yongqun he, liwei wang + + + + obo2:OAE_0001847 + thyroiditis AE + + + + obo2:OAE_0001848 + a urinary system AE that has an outcome of the excretion of glucose into the urine. + + + + obo2:OAE_0001848 + web: http://en.wikipedia.org/wiki/glycosuria + + + + obo2:OAE_0001848 + LW, YH + + + + obo2:OAE_0001848 + glucosuria AE + + + + obo2:OAE_0001849 + YH, JX + + + + obo2:OAE_0001849 + a chinese translation represents a chinese translation of the existing term. + + + + obo2:OAE_0001849 + Chinese translation + + + + obo2:OAE_0001850 + an inflammation AE that shows localized nodular inflammation found in tissues. + + + + obo2:OAE_0001850 + KM, JX, YH + + + + obo2:OAE_0001850 + WEB: http://en.wikipedia.org/wiki/Granuloma + + + + obo2:OAE_0001850 + WEB: http://www.mayoclinic.org/granuloma/expert-answers/faq-20057838 + + + + obo2:OAE_0001850 + WEB: http://www.medicinenet.com/script/main/art.asp?articlekey=3629 + + + + obo2:OAE_0001850 + granuloma AE + + + + obo2:OAE_0001850 + MedDRA: 10018691 + + + + obo2:OAE_0001851 + a burning sensation AE that occurs at the skin. + + + + obo2:OAE_0001851 + KM, JX, YH + + + + obo2:OAE_0001851 + skin burning sensation AE + + + + obo2:OAE_0001851 + MedDRA: 10054786 + + + + obo2:OAE_0001852 + a sensory capability AE that has an outcome of numbness, a loss of sensation of feeling in a part of the body. + + + + obo2:OAE_0001852 + YH, JS + + + + obo2:OAE_0001852 + WEB: http://www.mayoclinic.org/symptoms/numbness/basics/definition/sym-20050938 + + + + obo2:OAE_0001852 + numbness AE + + + + obo2:OAE_0001852 + MedDRA ID: 10029829 + + + + obo2:OAE_0001853 + a pneumonia AE that occurs at the interstitial lung. Interstitial pneumonia is often caused by an infection of bacteria, viruses, or fungii. A bacterium called Mycoplasma pneumonia is the most common cause. + + + + obo2:OAE_0001853 + JX, YH + + + + obo2:OAE_0001853 + WEB: http://www.webmd.com/lung/interstitial-lung-disease + + + + obo2:OAE_0001853 + interstitial pneumonia AE + + + + obo2:OAE_0001853 + MedDRA: 10022617 + + + + obo2:OAE_0001854 + a numbness AE that occurs around the mouth. + + + + obo2:OAE_0001854 + The terms 'circumoral numbness AE' and 'circumoral paresthesia AE' appear to be synonyms. + + + + obo2:OAE_0001854 + YH, JS + + + + obo2:OAE_0001854 + WEB: http://link.springer.com/referenceworkentry/10.1007%2F3-540-29623-9_6515 + + + + obo2:OAE_0001854 + circumoral numbness AE + + + + obo2:OAE_0001854 + MedDRA ID: 10049339 + + + + obo2:OAE_0001855 + Skin necrosis AE is a necrosis AE that results in the death of the skin tissue. Skin necrosis often occurs when not enough blood and oxygen are supplied to a given skin region. + + + + obo2:OAE_0001855 + JX, LW, YH + + + + obo2:OAE_0001855 + 皮肤坏死 + + + + obo2:OAE_0001855 + skin necrosis AE + + + + obo2:OAE_0001855 + MedDRA: 10040893 + + + + obo2:OAE_0001855 + UMLS ID: C0151799 + + + + obo2:OAE_0001856 + Systemic lupus erythematosus (SLE) syndrome AE is a lupus syndrome AE that is systemic and disseminated. SLE most often harms the heart, joints, skin, lungs, blood vessels, liver, kidneys, and nervous system. Although “lupus” actually includes a number of different diseases, SLE is the most common type of lupus, and when people say “lupus,” they are often referring to SLE. + + + + obo2:OAE_0001856 + JX, LW, YH + + + + obo2:OAE_0001856 + SLE + + + + obo2:OAE_0001856 + WEB: http://en.wikipedia.org/wiki/Systemic_lupus_erythematosus + + + + obo2:OAE_0001856 + WEB: http://www.healthline.com/health/systemic-lupus-erythematosus#Overview1 + + + + obo2:OAE_0001856 + 系统性红斑狼疮综合征 + + + + obo2:OAE_0001856 + systemic lupus erythematosus syndrome AE + + + + obo2:OAE_0001857 + Urgent urination AE is a urinary system AE that has an outcome of a sudden, compelling urge to urinate, along with discomfort in the bladder. + + + + obo2:OAE_0001857 + JX, LW, YH + + + + obo2:OAE_0001857 + micturition urgency + + + + obo2:OAE_0001857 + urinary urgency + + + + obo2:OAE_0001857 + WEB: http://sideeffects.embl.de/se/C0085606/ + + + + obo2:OAE_0001857 + WEB: http://www.nlm.nih.gov/medlineplus/ency/article/003140.htm + + + + obo2:OAE_0001857 + 尿急 + + + + obo2:OAE_0001857 + urgent urination AE + + + + obo2:OAE_0001857 + UMLS ID: C0439609 + + + + obo2:OAE_0001858 + Precordialgia AE is a pain AE that pain located in the precordial region. + + + + obo2:OAE_0001858 + JX, LW, YH + + + + obo2:OAE_0001858 + WEB: http://www.drugs.com/dict/precordialgia.html + + + + obo2:OAE_0001858 + 心前痛 + + + + obo2:OAE_0001858 + precordialgia AE + + + + obo2:OAE_0001859 + Dyshidrosis AE is a skin AE that shows a disorder of eccrine sweat glands, characterized by small blisters on the hands or feet. + + + + obo2:OAE_0001859 + JX, LW, YH + + + + obo2:OAE_0001859 + WEB: http://en.wikipedia.org/wiki/Dyshidrosis + + + + obo2:OAE_0001859 + 汗疱疹 + + + + obo2:OAE_0001859 + dyshidrosis AE + + + + obo2:OAE_0001859 + MedDRA: 10013912 + + + + obo2:OAE_0001860 + Ankle swelling AE is an edema AE that shows abnormal buildup of fluid in the ankles. Ankle swelling is a sign of fluid buildup or inflammation of the joint and tissues of the ankle. Mild ankle swelling is a common occurrence after standing for a long period. + + + + obo2:OAE_0001860 + JX, LW, YH + + + + obo2:OAE_0001860 + WEB: http://www.healthgrades.com/symptoms/ankle-swelling + + + + obo2:OAE_0001860 + 踝部水肿 + + + + obo2:OAE_0001860 + ankle swelling AE + + + + obo2:OAE_0001860 + MedDRA: 10002554 + + + + obo2:OAE_0001860 + UMLS ID: C0235439 + + + + obo2:OAE_0001861 + Renal dysfunction AE is a kidney AE that has an outcome of reduced capacity to excrete metabolic products which accumulate systemically and are detectable clinicopathologically by renal function tests. The early stage of uremia. + + + + obo2:OAE_0001861 + This term appears to be a synonym to the 'renal failure AE'. + + + + obo2:OAE_0001861 + JX, LW, YH + + + + obo2:OAE_0001861 + hepatic and renal function disorder AE + + + + obo2:OAE_0001861 + 肾功能障碍 + + + + obo2:OAE_0001861 + renal dysfunction AE + + + + obo2:OAE_0001861 + UMLS ID: C0859242 + + + + obo2:OAE_0001862 + Epiphora AE is a eye AE that shows an overflow of tears onto the face. In this case, there is insufficient tear film drainage from the eyes, and the tears will drain down the face rather than through the nasolacrimal system. + + + + obo2:OAE_0001862 + JX, LW, YH + + + + obo2:OAE_0001862 + WEB: http://en.wikipedia.org/wiki/Epiphora_(medicine) + + + + obo2:OAE_0001862 + 泪溢 + + + + obo2:OAE_0001862 + epiphora AE + + + + obo2:OAE_0001862 + MedDRA: 10015068 + + + + obo2:OAE_0001862 + UMLS ID: C0152227 + + + + obo2:OAE_0001863 + Hemolytic anemia AE is an anemia AE associated with hemolysis, the abnormal breakdown of red blood cells (RBCs), either in the blood vessels (intravascular hemolysis) or elsewhere in the human body (extravascular). Such an AE can be relatively harmless or life-threatening. + + + + obo2:OAE_0001863 + JX, LW, YH + + + + obo2:OAE_0001863 + WEB: http://en.wikipedia.org/wiki/Hemolytic_anemia + + + + obo2:OAE_0001863 + 溶血性贫血 + + + + obo2:OAE_0001863 + hemolytic anemia AE + + + + obo2:OAE_0001863 + MedDRA: 10019493 + + + + obo2:OAE_0001864 + Somniloquy AE is a behavioral AE where somniloquy also is called sleep-talking, a parasomnia that refers to talking aloud while asleep. Somniloquy can be quite loud, ranging from simple mumbling sounds to loud shouts and long frequently inarticulate speeches, and can occur many times during a sleep cycle. As with sleepwalking and night terrors, sleeptalking usually occurs during the less-deep delta-wave NREM sleep stages or during temporary arousals therefrom. + + + + obo2:OAE_0001864 + JX, LW, YH + + + + obo2:OAE_0001864 + WEB: http://en.wikipedia.org/wiki/Somniloquy + + + + obo2:OAE_0001864 + 梦呓 + + + + obo2:OAE_0001864 + somniloquy AE + + + + obo2:OAE_0001865 + Cholelithiasis AE is a liver, biliary, and pancreatic AE that shows hard deposits forming inside the gallbladder. Gallstones may be as small as a grain of sand or as large as a golf ball. + + + + obo2:OAE_0001865 + JX, LW, YH + + + + obo2:OAE_0001865 + WEB: http://en.wikipedia.org/wiki/Gallstone + + + + obo2:OAE_0001865 + cholelithiasis AE + + + + obo2:OAE_0001865 + MedDRA: 10008629 + + + + obo2:OAE_0001865 + UMLS ID: C1328486 + + + + obo2:OAE_0001866 + Blepharoptosis AE is an eye AE that shows droopy upper eyelid or ptosis that presents with substantial blockage upper part of field of vision, risk of amblyopia among young children, and dramatic change in the facial appearance. + + + + obo2:OAE_0001866 + JX, LW, YH + + + + obo2:OAE_0001866 + WEB: http://eyewiki.aao.org/Blepharoptosis + + + + obo2:OAE_0001866 + 眼睑下垂 + + + + obo2:OAE_0001866 + blepharoptosis AE + + + + obo2:OAE_0001866 + MedDRA: 10005157 + + + + obo2:OAE_0001874 + an epileptic seizure AE that is characterized by tonic-clonic seizures, involving two phases -- the tonic phase in which the body becomes rigid, and clonic phase in which there is uncontrolled jerking. + + + + obo2:OAE_0001874 + JX, LW, YH + + + + obo2:OAE_0001874 + WEB: http://www.medicinenet.com/script/main/art.asp?articlekey=32957 + + + + obo2:OAE_0001874 + 癫痫大发作 + + + + obo2:OAE_0001874 + grand mal AE + + + + obo2:OAE_0001874 + MedDRA: 10018658 + + + + obo2:OAE_0001875 + Erythema simplex AE is an erythema AE that accompany with blushing or redness of the skin caused by a toxic reaction or a neurovascular phenomenon. + + + + obo2:OAE_0001875 + JX, LW, YH + + + + obo2:OAE_0001875 + WEB: http://medical-dictionary.thefreedictionary.com/erythema+simplex + + + + obo2:OAE_0001875 + 单纯性红斑 + + + + obo2:OAE_0001875 + erythema simplex AE + + + + obo2:OAE_0001876 + Pelvic pain AE is a pain AE that occurs in the lower abdomen area. The pain might be steady, or it might come and go. If the pain is severe, it might get in the way of people's daily activities. + + + + obo2:OAE_0001876 + JX, LW, YH + + + + obo2:OAE_0001876 + WEB: http://www.nlm.nih.gov/medlineplus/pelvicpain.html + + + + obo2:OAE_0001876 + 骨盆痛 + + + + obo2:OAE_0001876 + pelvic pain AE + + + + obo2:OAE_0001876 + MedDRA: 10034263 + + + + obo2:OAE_0001877 + Extrasystoles AE is an arrhythmia AE that shows a premature contraction of the heart that is independent of the normal rhythm of the heart and arises in response to an impulse in some part of the heart other than the normal impulse from the sinoatrial node. The extrasystole is followed by a pause, as the heart electrical system "resets" itself and the contraction following the pause is usually more forceful than normal. + + + + obo2:OAE_0001877 + JX, LW, YH + + + + obo2:OAE_0001877 + WEB: http://www.medicinenet.com/script/main/art.asp?articlekey=32159 + + + + obo2:OAE_0001877 + 早搏(额外收缩) + + + + obo2:OAE_0001877 + extrasystoles AE + + + + obo2:OAE_0001877 + MedDRA: 10015856 + + + + obo2:OAE_0001878 + An increased upper airway secretion AE is a respiratory system AE characterized by an increased secretion at the upper airway location. + + + + obo2:OAE_0001878 + RR, YH + + + + obo2:OAE_0001878 + increased upper airway secretion AE + + + + obo2:OAE_0001878 + MedDRA: 10062717 + + + + obo2:OAE_0001879 + Feeling of body temperature change AE is a feeling abnormal AE that a patient feels a change in body temperature. + + + + obo2:OAE_0001879 + RR, YH + + + + obo2:OAE_0001879 + feeling of body temperature change AE + + + + obo2:OAE_0001879 + MedDRA: 10061458 + + + + obo2:OAE_0001880 + Heartburn AE is a gastric disorder AE that also known as pyrosis, cardialgia, or acid indigestion. It's a burning sensation in the chest, just behind the breastbone or in the epigastrium, the upper central abdomen. The pain often rises in the chest and may radiate to the neck, throat, or angle of the jaw. + + + + obo2:OAE_0001880 + JX, LW, YH + + + + obo2:OAE_0001880 + WEB: http://en.wikipedia.org/wiki/Heartburn + + + + obo2:OAE_0001880 + 胃灼热(烧心) + + + + obo2:OAE_0001880 + heartburn AE + + + + obo2:OAE_0001880 + MedDRA: 10019326 + + + + obo2:OAE_0001881 + Tonsillitis AE is an inflammation AE that is inflammation of the tonsils most commonly caused by viral or bacterial infection. Symptoms may include sore throat and fever. + + + + obo2:OAE_0001881 + JX, LW, YH + + + + obo2:OAE_0001881 + WEB: http://en.wikipedia.org/wiki/Tonsillitis + + + + obo2:OAE_0001881 + 扁桃体炎 + + + + obo2:OAE_0001881 + tonsillitis AE + + + + obo2:OAE_0001881 + MedDRA: 10044008 + + + + obo2:OAE_0001882 + Non-insulin-dependent diabetes mellitus AE is a diabetes mellitus AE which is also called diabetes mellitus type 2, it's characterized by hyperglycemia (high blood sugar) in the context of insulin resistance and relative lack of insulin. + + + + obo2:OAE_0001882 + JX, LW, YH + + + + obo2:OAE_0001882 + WEB: http://en.wikipedia.org/wiki/Diabetes_mellitus_type_2 + + + + obo2:OAE_0001882 + 非胰岛素依赖型糖尿病 + + + + obo2:OAE_0001882 + non-insulin-dependent diabetes mellitus AE + + + + obo2:OAE_0001882 + MedDRA: 10029505 + + + + obo2:OAE_0001883 + Insulin dependent diabetes mellitus AE is a diabetes mellitus AE which is also called diabetes mellitus type 1. It results from the autoimmune destruction of the insulin-producing beta cells in the pancreas. + + + + obo2:OAE_0001883 + JX, LW, YH + + + + obo2:OAE_0001883 + WEB: http://en.wikipedia.org/wiki/Diabetes_mellitus_type_1 + + + + obo2:OAE_0001883 + 胰岛素依赖型糖尿病 + + + + obo2:OAE_0001883 + insulin dependent diabetes mellitus AE + + + + obo2:OAE_0001883 + MedDRA: 10022497 + + + + obo2:OAE_0001884 + Areflexia AE is a nervous system AE that shows absence of neurologic reflexes such as the knee jerk reaction. + + + + obo2:OAE_0001884 + JX, LW, YH + + + + obo2:OAE_0001884 + WEB: http://www.medicinenet.com/script/main/art.asp?articlekey=20423 + + + + obo2:OAE_0001884 + 反射消失 + + + + obo2:OAE_0001884 + areflexia AE + + + + obo2:OAE_0001884 + MedDRA: 10003084 + + + + obo2:OAE_0001885 + Mastauxea AE is a reproductive system AE that shows enlargement of the breast. + + + + obo2:OAE_0001885 + JX, LW, YH + + + + obo2:OAE_0001885 + WEB: http://medical-dictionary.thefreedictionary.com/mastauxe + + + + obo2:OAE_0001885 + 乳房增大 + + + + obo2:OAE_0001885 + mastauxe AE + + + + obo2:OAE_0001886 + Uveitis AE is an inflammation AE that is inflammation of the uvea, which lines the inside of the eye behind the cornea. + + + + obo2:OAE_0001886 + JX, LW, YH + + + + obo2:OAE_0001886 + WEB: http://en.wikipedia.org/wiki/Uveitis + + + + obo2:OAE_0001886 + 色素层炎 + + + + obo2:OAE_0001886 + uveitis AE + + + + obo2:OAE_0001886 + MedDRA: 10046851 + + + + obo2:OAE_0001887 + Sexual dysfunctions AE is a reproductive system AE that is difficulty experienced by an individual or a couple during any stage of a normal sexual activity, including physical pleasure, desire, preference, arousal or orgasm. + + + + obo2:OAE_0001887 + JX, LW, YH + + + + obo2:OAE_0001887 + sexual malfunction AE + + + + obo2:OAE_0001887 + WEB: http://en.wikipedia.org/wiki/Sexual_dysfunction + + + + obo2:OAE_0001887 + 性功能障碍 + + + + obo2:OAE_0001887 + sexual dysfunctions AE + + + + obo2:OAE_0001887 + MedDRA: 10040477 + + + + obo2:OAE_0001888 + Hypomnesia AE is a behavior and neurological AE that is an archaic term applied to poor memory, the impaired ability to recall information previously memorized. + + + + obo2:OAE_0001888 + JX, LW, YH + + + + obo2:OAE_0001888 + WEB: http://psychology.wikia.com/wiki/Hypomnesia + + + + obo2:OAE_0001888 + 记忆减退 + + + + obo2:OAE_0001888 + hypomnesia AE + + + + obo2:OAE_0001888 + MedDRA ID: 10021035 + + + + obo2:OAE_0001889 + Phobia AE is a behavior and neurological AE that is a type of anxiety disorder, usually defined as a persistent fear of an object or situation in which the sufferer commits to great lengths in avoiding, typically disproportional to the actual danger posed, often being recognized as irrational. + + + + obo2:OAE_0001889 + JX, LW, YH + + + + obo2:OAE_0001889 + WEB: http://en.wikipedia.org/wiki/Phobia + + + + obo2:OAE_0001889 + 恐惧症 + + + + obo2:OAE_0001889 + phobia AE + + + + obo2:OAE_0001889 + MedDRA ID: 10034912 + + + + obo2:OAE_0001890 + Lymphadenectasis AE is an edema AE that shows enlargement of the lymph node. + + + + obo2:OAE_0001890 + JX, LW, YH + + + + obo2:OAE_0001890 + WEB: http://medical-dictionary.thefreedictionary.com/lymphadenectasis + + + + obo2:OAE_0001890 + 淋巴结肿大 + + + + obo2:OAE_0001890 + lymphadenectasis AE + + + + obo2:OAE_0001890 + MedDRA: 10025282 + + + + obo2:OAE_0001891 + Asterixis AE is a tremor AE that also called the flapping tremor, or liver flap, which is a tremor of the hand when the wrist is extended, sometimes said to resemble a bird flapping its wings. This motor disorder is characterized by an inability to actively maintain a position, which is demonstrated by jerking movements of the outstretched hands when bent upward at the wrist. The tremor is caused by abnormal function of the diencephalic motor centers in the brain, which regulate the muscles involved in maintaining position. + + + + obo2:OAE_0001891 + JX, LW, YH + + + + obo2:OAE_0001891 + WEB: http://en.wikipedia.org/wiki/Asterixis + + + + obo2:OAE_0001891 + 扑翼样震颤 + + + + obo2:OAE_0001891 + asterixis AE + + + + obo2:OAE_0001891 + MedDRA: 10003547 + + + + obo2:OAE_0001892 + Parageusia AE is a gustatory system AE which is the medical term for a bad taste in the mouth. One common form of parageusia is a metallic taste of food. This can be a side effect of several medications, such as acetazolamide, eszopiclone, zopiclone, metronidazole, or etoposide. Metallic taste is also a type of dysgeusia which is frequently associated with infections in the mouth or upper airways. + + + + obo2:OAE_0001892 + JX, LW, YH + + + + obo2:OAE_0001892 + WEB: http://en.wikipedia.org/wiki/Parageusia + + + + obo2:OAE_0001892 + 味觉颠倒 + + + + obo2:OAE_0001892 + parageusia AE + + + + obo2:OAE_0001892 + MedDRA: 10033793 + + + + obo2:OAE_0001893 + Brain damage AE is a brain AE that also called brain injury is the destruction or degeneration of brain cells. In general, brain damage refers to significant, undiscriminating trauma-induced damage. + + + + obo2:OAE_0001893 + JX, LW, YH + + + + obo2:OAE_0001893 + WEB: http://en.wikipedia.org/wiki/Brain_damage + + + + obo2:OAE_0001893 + 脑损伤 + + + + obo2:OAE_0001893 + brain damage AE + + + + obo2:OAE_0001893 + MedDRA: 10056389 + + + + obo2:OAE_0001894 + Frequent bowel movements AE is a abnormal stool AE that people are having more bowel movements than is normal for them. Often, frequent bowel movements are accompanied by diarrhea, the passage of loosely formed stool. + + + + obo2:OAE_0001894 + JX, LW, YH + + + + obo2:OAE_0001894 + WEB: http://www.healthgrades.com/symptoms/frequent-bowel-movements + + + + obo2:OAE_0001894 + 大便频繁 + + + + obo2:OAE_0001894 + frequent bowel movements AE + + + + obo2:OAE_0001894 + MedDRA: 10017367 + + + + obo2:OAE_0001895 + Hyperprolactinemia AE is an endocrine investigation result abnormal AE that is the presence of abnormally high levels of prolactin in the blood. Normal levels are less than 500 mIU/L [20 ng/mL or µg/L] for women, and less than 450 mIU/L for men. + + + + obo2:OAE_0001895 + JX, LW, YH + + + + obo2:OAE_0001895 + WEB: http://en.wikipedia.org/wiki/Hyperprolactinaemia + + + + obo2:OAE_0001895 + 高泌乳素血症 + + + + obo2:OAE_0001895 + hyperprolactinemia AE + + + + obo2:OAE_0001895 + MedDRA: 10020739 + + + + obo2:OAE_0001896 + Galactorrhea AE is a reproductive system AE that is the spontaneous flow of milk from the breast, unassociated with childbirth or nursing. + + + + obo2:OAE_0001896 + JX, LW, YH + + + + obo2:OAE_0001896 + WEB: http://en.wikipedia.org/wiki/Galactorrhea + + + + obo2:OAE_0001896 + 乳溢 + + + + obo2:OAE_0001896 + galactorrhea AE + + + + obo2:OAE_0001896 + MedDRA: 10017592 + + + + obo2:OAE_0001897 + Sitophobia AE is a behavior and neurological AE that shows a morbid or insane dread of eating. + + + + obo2:OAE_0001897 + JX, LW, YH + + + + obo2:OAE_0001897 + WEB: http://en.wiktionary.org/wiki/sitophobia + + + + obo2:OAE_0001897 + 畏食 + + + + obo2:OAE_0001897 + sitophobia AE + + + + obo2:OAE_0001898 + Ejection murmur AE is a cardiac disorder AE which is due to turbulent forward flow across the right and left ventricular outflow tract, aortic or pulmonary valve, or through the aorta or pulmonary artery. + + + + obo2:OAE_0001898 + JX, LW, YH + + + + obo2:OAE_0001898 + WEB: http://www.cardiologysite.com/auscultation/html/ejection_murmurs.html + + + + obo2:OAE_0001898 + 收缩期喷射性杂音 + + + + obo2:OAE_0001898 + ejection murmur AE + + + + obo2:OAE_0001899 + Hypoactive sexual desire disorder AE is a libido disorder AE that is considered a sexual dysfunction and is characterized as a lack or absence of sexual fantasies and desire for sexual activity, as judged by a clinician. + + + + obo2:OAE_0001899 + JX, LW, YH + + + + obo2:OAE_0001899 + hyposexuality AE + + + + obo2:OAE_0001899 + WEB: http://en.wikipedia.org/wiki/Hypoactive_sexual_desire_disorder + + + + obo2:OAE_0001899 + 性欲减退 + + + + obo2:OAE_0001899 + hypoactive sexual desire disorder AE + + + + obo2:OAE_0001899 + MedDRA: 10020933 + + + + obo2:OAE_0001900 + Bigotry AE is a behavior and neurological AE that is a state of mind where a person strongly and unfairly dislikes other people, ideas, etc. + + + + obo2:OAE_0001900 + JX, LW, YH + + + + obo2:OAE_0001900 + WEB: http://en.wikipedia.org/wiki/Bigotry + + + + obo2:OAE_0001900 + 偏执 + + + + obo2:OAE_0001900 + bigotry AE + + + + obo2:OAE_0001901 + Somnambulisma AE is a behavior and neurological AE that also known as sleepwalking or noctambulism, which is a sleep disorder belonging to the parasomnia family. It arise from the slow wave sleep stage in a state of low consciousness and perform activities that are usually performed during a state of full consciousness. These activities can be as benign as sitting up in bed, walking to the bathroom, and cleaning, or as hazardous as cooking, driving, violent gestures, grabbing at hallucinated objects, or even homicide. + + + + obo2:OAE_0001901 + JX, LW, YH + + + + obo2:OAE_0001901 + noctambulism AE + + + + obo2:OAE_0001901 + sleepwalking AE + + + + obo2:OAE_0001901 + WEB: http://en.wikipedia.org/wiki/Sleepwalking + + + + obo2:OAE_0001901 + 梦游症 + + + + obo2:OAE_0001901 + somnambulism AE + + + + obo2:OAE_0001901 + MedDRA ID: 10041347 + + + + obo2:OAE_0001902 + Hyperphagia AE is an eating disorder AE that also called polyphagia. It's a medical sign meaning excessive hunger and abnormally large intake of solids by mouth. It can be caused by disorders such as diabetes, Kleine–Levin syndrome (a malfunction in the hypothalamus), the genetic disorders Prader–Willi syndrome, and Bardet–Biedl syndrome. + + + + obo2:OAE_0001902 + JX, LW, YH + + + + obo2:OAE_0001902 + polyphagia AE + + + + obo2:OAE_0001902 + 食欲过盛 + + + + obo2:OAE_0001902 + WEB: http://en.wikipedia.org/wiki/Polyphagia + + + + obo2:OAE_0001902 + hyperphagia AE + + + + obo2:OAE_0001902 + MedDRA: 10020710 + + + + obo2:OAE_0001903 + Corneal pigmentation is a eye AE shows that the melanin is in the superficial stroma and the basal layer of the corneal epithelium. + + + + obo2:OAE_0001903 + JX, LW, YH + + + + obo2:OAE_0001903 + WEB: http://medical-dictionary.thefreedictionary.com/corneal+pigmentation + + + + obo2:OAE_0001903 + 角膜色素沉着 + + + + obo2:OAE_0001903 + corneal pigmentation AE + + + + obo2:OAE_0001903 + MedDRA: 10011040 + + + + obo2:OAE_0001904 + Chromatos AE is a skin AE shows that deposit of pigment in a normally unpigmented area or excessive pigmentation in a normally pigmented site. + + + + obo2:OAE_0001904 + JX, LW, YH + + + + obo2:OAE_0001904 + WEB: http://www.merriam-webster.com/medical/chromatosis + + + + obo2:OAE_0001904 + 色素沉着 + + + + obo2:OAE_0001904 + chromatosis AE + + + + obo2:OAE_0001905 + Subclavian steal syndrome AE is an ischaemia AE that is a constellation of signs and symptoms that arise from retrograde (reversed) flow of blood in the vertebral artery or the internal thoracic artery, due to a proximal stenosis (narrowing) and/or occlusion of the subclavian artery. The arm may be supplied by blood flowing in a retrograde direction down the vertebral artery at the expense of the vertebrobasilar circulation. This is called the subclavian steal. + + + + obo2:OAE_0001905 + JX, LW, YH + + + + obo2:OAE_0001905 + subclavian steal phenomenon AE + + + + obo2:OAE_0001905 + subclavian steal steno-occlusive disease AE + + + + obo2:OAE_0001905 + 锁骨下动脉盗血综合征 + + + + obo2:OAE_0001905 + subclavian steal syndrome AE + + + + obo2:OAE_0001905 + MedDRA: 10042335 + + + + obo2:OAE_0001906 + Allergic rhinitis AE is a rhinitis AE that is an allergic inflammation of the nasal airways. It occurs when an allergen, such as pollen, dust, or animal dander (particles of shed skin and hair) is inhaled by an individual with a sensitized immune system. + + + + obo2:OAE_0001906 + JX, LW, YH + + + + obo2:OAE_0001906 + WEB: http://en.wikipedia.org/wiki/Allergic_rhinitis + + + + obo2:OAE_0001906 + 过敏性鼻炎 + + + + obo2:OAE_0001906 + allergic rhinitis AE + + + + obo2:OAE_0001906 + MedDRA: 10001723 + + + + obo2:OAE_0001907 + Ventricular ectopic beats AE is a cardiac ventricular disorder AE that is a disturbance of the cardiac rhythm frequently related to the electrical conduction system of the heart, in which beats arise from fiber or group of fibers outside the region in the heart muscle ordinarily responsible for impulse formation. + + + + obo2:OAE_0001907 + JX, LW, YH + + + + obo2:OAE_0001907 + WEB: http://en.wikipedia.org/wiki/Ectopic_beat + + + + obo2:OAE_0001907 + 心室异位搏动 + + + + obo2:OAE_0001907 + ventricular ectopic beats AE + + + + obo2:OAE_0001907 + MedDRA: 10058291 + + + + obo2:OAE_0001908 + Sjogren syndrome AE is a eye AE that is a chronic autoimmune disease in which the body's white blood cells destroy the exocrine glands, specifically the salivary and lacrimal glands, that produce saliva and tears, respectively. + + + + obo2:OAE_0001908 + JX, LW, YH + + + + obo2:OAE_0001908 + WEB: http://en.wikipedia.org/wiki/Sj%C3%B6gren's_syndrome + + + + obo2:OAE_0001908 + 干燥综合症 + + + + obo2:OAE_0001908 + sjogren syndrome AE + + + + obo2:OAE_0001908 + MedDRA: 10040767 + + + + obo2:OAE_0001909 + Nocturia AE is a urine abnormality AE that is defined by the International Continence Society as “the complaint that the individual has to wake at night one or more times for voiding”. + + + + obo2:OAE_0001909 + JX, LW, YH + + + + obo2:OAE_0001909 + nycturia AE + + + + obo2:OAE_0001909 + WEB: http://en.wikipedia.org/wiki/Nocturia + + + + obo2:OAE_0001909 + 夜尿症 + + + + obo2:OAE_0001909 + nocturia AE + + + + obo2:OAE_0001909 + MedDRA: 10029446 + + + + obo2:OAE_0001910 + Night sweat is a sweating AE that is the occurrence of excessive sweating (hyperhidrosis and focal hyperhidrosis) during sleep. The sufferer may or may not also suffer from excessive perspiration while awake. + + + + obo2:OAE_0001910 + JX, LW, YH + + + + obo2:OAE_0001910 + sleep hyperhidrosis AE + + + + obo2:OAE_0001910 + WEB: http://en.wikipedia.org/wiki/Night_sweats + + + + obo2:OAE_0001910 + 夜汗 + + + + obo2:OAE_0001910 + night sweat AE + + + + obo2:OAE_0001910 + MedDRA: 10029409 + + + + obo2:OAE_0001911 + Increased appetite AE is a gustatory system AE that is when people want to eat much more often or in larger quantities than their body requires. + + + + obo2:OAE_0001911 + JX, LW, YH + + + + obo2:OAE_0001911 + WEB: http://www.healthline.com/symptom/increased-appetite + + + + obo2:OAE_0001911 + 食欲增加 + + + + obo2:OAE_0001911 + increased appetite AE + + + + obo2:OAE_0001911 + MedDRA: 10021654 + + + + obo2:OAE_0001912 + Vascular dilatation headache AE is a headache AE that shows headache which caused by vascular dilatation. + + + + obo2:OAE_0001912 + JX, LW, YH + + + + obo2:OAE_0001912 + WEB: http://www.headaches.org/education/Headache_Topic_Sheets/Vascular_Headaches + + + + obo2:OAE_0001912 + 血管扩张性头痛 + + + + obo2:OAE_0001912 + vascular dilatation headache AE + + + + obo2:OAE_0001913 + Bundle-branch block AE is a conduction system disorder AE that refers to a defect of the heart's electrical conduction system. + + + + obo2:OAE_0001913 + JX, LW, YH + + + + obo2:OAE_0001913 + WEB: http://en.wikipedia.org/wiki/Bundle_branch_block + + + + obo2:OAE_0001913 + 束支传导阻滞 + + + + obo2:OAE_0001913 + bundle-branch block AE + + + + obo2:OAE_0001913 + MedDRA: 10006578 + + + + obo2:OAE_0001914 + Unstable diabetes AE is a diabetes mellitus AE that is a type of diabetes when a person's blood glucose level often swings quickly from high to low and from low to high. + + + + obo2:OAE_0001914 + JX, LW, YH + + + + obo2:OAE_0001914 + brittle diabetes AE + + + + obo2:OAE_0001914 + labile diabetes AE + + + + obo2:OAE_0001914 + WEB: http://www.medicinenet.com/script/main/art.asp?articlekey=7271 + + + + obo2:OAE_0001914 + 不稳定型糖尿病 + + + + obo2:OAE_0001914 + unstable diabetes AE + + + + obo2:OAE_0001914 + MedDRA: 10006372 + + + + obo2:OAE_0001915 + Tendon rupture AE is a tendon disorder AE shows a tearing of the tendon that occurs when the forces placed upon the tendon exceed its tensile strength. + + + + obo2:OAE_0001915 + JX, LW, YH + + + + obo2:OAE_0001915 + WEB: http://medical-dictionary.thefreedictionary.com/Tendon+rupture + + + + obo2:OAE_0001915 + 肌腱断裂 + + + + obo2:OAE_0001915 + tendon rupture AE + + + + obo2:OAE_0001915 + MedDRA: 10043248 + + + + obo2:OAE_0001916 + Tendovaginitis AE is an inflammation AE that is an acute or chronic inflammation of the tendon sheath, occurring in the region of the hand, the wrist joint, the forearm (radial and ulnar tenobursitis), the foot, the ankle joint, and the Achilles tendon (achillobursitis). + + + + obo2:OAE_0001916 + JX, LW, YH + + + + obo2:OAE_0001916 + tenovaginitis AE + + + + obo2:OAE_0001916 + WEB: http://encyclopedia2.thefreedictionary.com/Tendovaginitis + + + + obo2:OAE_0001916 + 腱鞘炎 + + + + obo2:OAE_0001916 + tendovaginitis AE + + + + obo2:OAE_0001916 + MedDRA: 10067216 + + + + obo2:OAE_0001917 + Loose stools AE is a abnormal stool AE that is usually a form of diarrhea and many conditions causing loose stool will be listed under diarrhea. It may also be related to watery stool (also within the spectrum of diarrhea). + + + + obo2:OAE_0001917 + JX, LW, YH + + + + obo2:OAE_0001917 + WEB: http://www.rightdiagnosis.com/sym/loose_stool.htm + + + + obo2:OAE_0001917 + 稀便 + + + + obo2:OAE_0001917 + loose stools AE + + + + obo2:OAE_0001917 + MedDRA: 10024840 + + + + obo2:OAE_0001918 + Cystitis AE is an inflammation AE that is the medical term for inflammation of the bladder. Most of the time, the inflammation is caused by a bacterial infection, and it's called a urinary tract infection. + + + + obo2:OAE_0001918 + JX, LW, YH + + + + obo2:OAE_0001918 + WEB: http://www.mayoclinic.org/diseases-conditions/cystitis/basics/definition/con-20024076 + + + + obo2:OAE_0001918 + 膀胱炎 + + + + obo2:OAE_0001918 + cystitis AE + + + + obo2:OAE_0001918 + MedDRA: 10011781 + + + + obo2:OAE_0001919 + Eructation AE is a digestive system AE that is the release of gas from the digestive tract (mainly esophagus and stomach) through the mouth. It is usually accompanied with a typical sound and, at times, an odor. + + + + obo2:OAE_0001919 + JX, LW, YH + + + + obo2:OAE_0001919 + belching AE + + + + obo2:OAE_0001919 + burping AE + + + + obo2:OAE_0001919 + ructus AE + + + + obo2:OAE_0001919 + WEB: http://en.wikipedia.org/wiki/Burping + + + + obo2:OAE_0001919 + 嗳气 + + + + obo2:OAE_0001919 + eructation AE + + + + obo2:OAE_0001919 + MedDRA: 10015137 + + + + obo2:OAE_0001920 + Glossolalia AE is a speech disorder AE that is the fluid vocalizing of speech-like syllables that lack any readily comprehended meaning. + + + + obo2:OAE_0001920 + JX, LW, YH + + + + obo2:OAE_0001920 + WEB: http://en.wikipedia.org/wiki/Glossolalia + + + + obo2:OAE_0001920 + 语言不清 + + + + obo2:OAE_0001920 + glossolalia AE + + + + obo2:OAE_0001921 + Leg pain AE is a pain AE that is a common problem in leg, it can be due to a cramp, injury, or other cause. + + + + obo2:OAE_0001921 + JX, LW, YH + + + + obo2:OAE_0001921 + WEB: http://www.nlm.nih.gov/medlineplus/ency/article/003182.htm + + + + obo2:OAE_0001921 + 腿痛 + + + + obo2:OAE_0001921 + leg pain AE + + + + obo2:OAE_0001921 + MedDRA ID: 10024130 + + + + obo2:OAE_0001922 + Stomachache AE is a pain AE that the pain in or near your stomach. It is a common symptom associated with transient disorders or serious disease. + + + + obo2:OAE_0001922 + JX, LW, YH + + + + obo2:OAE_0001922 + abdominal pain AE + + + + obo2:OAE_0001922 + WEB: http://en.wikipedia.org/wiki/Abdominal_pain +http://www.nhs.uk/conditions/stomach-ache-abdominal-pain/Pages/Introduction.aspx + + + + obo2:OAE_0001922 + 胃痛 + + + + obo2:OAE_0001922 + stomachache AE + + + + obo2:OAE_0001922 + MedDRA ID: 10042126 + + + + obo2:OAE_0001923 + Conduction block AE is a conduction system disorder AE that shows failure of impulse transmission at some point along a nerve fiber, although conduction along the segments proximal and distal to it are unaffected. + + + + obo2:OAE_0001923 + JX, LW, YH + + + + obo2:OAE_0001923 + WEB: http://www.medilexicon.com/medicaldictionary.php?t=10757 + + + + obo2:OAE_0001923 + 传导阻滞 + + + + obo2:OAE_0001923 + conduction block AE + + + + obo2:OAE_0001924 + Photodermatitis AE is a dermatitis AE that referred to as sun poisoning or photoallergy, is a form of allergic contact dermatitis in which the allergen must be activated by light to sensitize the allergic response, and to cause a rash or other systemic effects on subsequent exposure. + + + + obo2:OAE_0001924 + JX, LW, YH + + + + obo2:OAE_0001924 + WEB: http://en.wikipedia.org/wiki/Photodermatitis + + + + obo2:OAE_0001924 + 光敏性皮炎 + + + + obo2:OAE_0001924 + photodermatitis AE + + + + obo2:OAE_0001925 + Pygalgia AE is a pain AE that is a rarely used term meaning pain in the buttocks. + + + + obo2:OAE_0001925 + JX, LW, YH + + + + obo2:OAE_0001925 + WEB: http://www.medilexicon.com/medicaldictionary.php?t=74312 + + + + obo2:OAE_0001925 + 臀痛 + + + + obo2:OAE_0001925 + pygalgia AE + + + + obo2:OAE_0001926 + Throat irritation AE is a discomfort AE that refers to a dry cough, a scratchy feeling at the back of the throat, or a sensation of a lumpy feeling or something stuck at the back of the throat. + + + + obo2:OAE_0001926 + JX, LW, YH + + + + obo2:OAE_0001926 + throat discomfort AE + + + + obo2:OAE_0001926 + WEB: http://en.wikipedia.org/wiki/Throat_irritation + + + + obo2:OAE_0001926 + 咽喉不适 + + + + obo2:OAE_0001926 + throat irritation AE + + + + obo2:OAE_0001926 + MedDRA: 10043521 + + + + obo2:OAE_0001927 + Interstitial nephritis AE is an inflammation AE that is a form of nephritis affecting the interstitium of the kidneys surrounding the tubules. This disease can be either acute, meaning it occurs suddenly, or chronic, meaning it is ongoing and eventually ends in kidney failure. + + + + obo2:OAE_0001927 + JX, LW, YH + + + + obo2:OAE_0001927 + tubulointerstitial nephritis AE + + + + obo2:OAE_0001927 + WEB: http://en.wikipedia.org/wiki/Interstitial_nephritis + + + + obo2:OAE_0001927 + 间质肾炎 + + + + obo2:OAE_0001927 + interstitial nephritis AE + + + + obo2:OAE_0001927 + MedDRA: 10048302 + + + + obo2:OAE_0001928 + Hoarseness AE is a hoarseness AE that refers to a difficulty making sounds when trying to speak. Vocal sounds may be weak, breathy, scratchy, or husky, and the pitch or quality of the voice may change. + + + + obo2:OAE_0001928 + JX, LW, YH + + + + obo2:OAE_0001928 + WEB: http://www.nlm.nih.gov/medlineplus/ency/article/003054.htm + + + + obo2:OAE_0001928 + 声音嘶哑 + + + + obo2:OAE_0001928 + hoarseness AE + + + + obo2:OAE_0001928 + MedDRA: 10020201 + + + + obo2:OAE_0001929 + Photosensitization AE is a hypersensitivity AE that refers to development of abnormally heightened reactivity of the skin or eyes to sunlight. + + + + obo2:OAE_0001929 + JX, LW, YH + + + + obo2:OAE_0001929 + WEB: http://medical-dictionary.thefreedictionary.com/photosensitization + + + + obo2:OAE_0001929 + 光敏 + + + + obo2:OAE_0001929 + photosensitization AE + + + + obo2:OAE_0001930 + Fanconi syndrome AE is a kidney AE that is a disease of the proximal renal tubules of the kidney in which glucose, amino acids, uric acid, phosphate and bicarbonate are passed into the urine, instead of being reabsorbed. + + + + obo2:OAE_0001930 + JX, LW, YH + + + + obo2:OAE_0001930 + WEB: http://en.wikipedia.org/wiki/Fanconi_syndrome + + + + obo2:OAE_0001930 + 范可尼综合征 + + + + obo2:OAE_0001930 + fanconi syndrome AE + + + + obo2:OAE_0001930 + MedDRA: 10016219 + + + + obo2:OAE_0001931 + Keratoconjunctivitis AE is an inflammation AE that is inflammation of the cornea and conjunctiva. When only the cornea is inflamed, it is called keratitis; when only the conjunctiva is inflamed, it is called conjunctivitis. + + + + obo2:OAE_0001931 + JX, LW, YH + + + + obo2:OAE_0001931 + WEB: http://en.wikipedia.org/wiki/Keratoconjunctivitis + + + + obo2:OAE_0001931 + 角膜结膜炎 + + + + obo2:OAE_0001931 + keratoconjunctivitis AE + + + + obo2:OAE_0001931 + MedDRA: 10023348 + + + + obo2:OAE_0001932 + Hepatic insufficiency AE is a liver disorder AE that shows a failure or partial failure of normal liver function. + + + + obo2:OAE_0001932 + JX, LW, YH + + + + obo2:OAE_0001932 + WEB: http://medical-dictionary.thefreedictionary.com/hepatic+insufficiency + + + + obo2:OAE_0001932 + 肝功能不全 + + + + obo2:OAE_0001932 + hepatic insufficiency AE + + + + obo2:OAE_0001932 + MedDRA: 10056542 + + + + obo2:OAE_0001933 + Hypoxemia AE is a blood gas investigation result abnormal AE that is an abnormally low level of oxygen in the blood. More specifically, it is oxygen deficiency in arterial blood. + + + + obo2:OAE_0001933 + JX, LW, YH + + + + obo2:OAE_0001933 + WEB: http://en.wikipedia.org/wiki/Hypoxemia + + + + obo2:OAE_0001933 + 低血氧症 + + + + obo2:OAE_0001933 + hypoxemia AE + + + + obo2:OAE_0001933 + MedDRA: 10021142 + + + + obo2:OAE_0001934 + Irritant contact dermatitis AE is a dermatitis AE that is a form of contact dermatitis that can be divided into forms caused by chemical irritants and those caused by physical irritants. + + + + obo2:OAE_0001934 + JX, LW, YH + + + + obo2:OAE_0001934 + WEB: http://en.wikipedia.org/wiki/Irritant_contact_dermatitis + + + + obo2:OAE_0001934 + 刺激性接触性皮炎 + + + + obo2:OAE_0001934 + irritant contact dermatitis AE + + + + obo2:OAE_0001935 + Pitting edema AE is an edema AE that shows observable swelling of body tissues due to fluid accumulation that may be demonstrated by applying pressure to the swollen area (such as by depressing the skin with a finger). + + + + obo2:OAE_0001935 + JX, LW, YH + + + + obo2:OAE_0001935 + WEB: http://www.medicinenet.com/script/main/art.asp?articlekey=88528 + + + + obo2:OAE_0001935 + 指压性水肿 + + + + obo2:OAE_0001935 + pitting edema AE + + + + obo2:OAE_0001935 + MedDRA: 10054547 + + + + obo2:OAE_0001936 + Acute bronchitis AE is a bronchitis AE that is an inflammation of the large bronchi (medium-size airways) in the lungs that is usually caused by viruses or bacteria and may last several days or weeks. Characteristic symptoms include cough, sputum (phlegm) production, and shortness of breath and wheezing related to the obstruction of the inflamed airways. + + + + obo2:OAE_0001936 + JX, LW, YH + + + + obo2:OAE_0001936 + WEB: http://en.wikipedia.org/wiki/Acute_bronchitis + + + + obo2:OAE_0001936 + 急性支气管炎 + + + + obo2:OAE_0001936 + acute bronchitis AE + + + + obo2:OAE_0001936 + MedDRA: 10000687 + + + + obo2:OAE_0001937 + Renal calculus AE is a kidney AE that is a solid concretion or crystal aggregation formed in the kidneys from minerals in the urine. Kidney stones typically leave the body by passage in the urine stream, and many stones are formed and passed without causing symptoms. If stones grow to sufficient size (usually at least 3 millimeters (0.12 in)) they can cause blockage of the ureter. This leads to pain, most commonly beginning in the flank or lower back and often radiating to the groin or genitals. + + + + obo2:OAE_0001937 + JX, LW, YH + + + + obo2:OAE_0001937 + kidney stone AE + + + + obo2:OAE_0001937 + nephrolithiasis AE + + + + obo2:OAE_0001937 + WEB: http://en.wikipedia.org/wiki/Kidney_stone + + + + obo2:OAE_0001937 + 肾结石 + + + + obo2:OAE_0001937 + renal calculus AE + + + + obo2:OAE_0001937 + MedDRA: 10038386 + + + + obo2:OAE_0001938 + Clouding of consciousness AE is a sensory capability AE that is a term used in conventional medicine denoting an abnormality in the "regulation" of the "overall level" of consciousness that is mild and less severe than a delirium. The sufferer experiences a subjective sensation of mental clouding described as feeling "foggy". + + + + obo2:OAE_0001938 + JX, LW, YH + + + + obo2:OAE_0001938 + brain fog AE + + + + obo2:OAE_0001938 + mental fog AE + + + + obo2:OAE_0001938 + WEB: http://en.wikipedia.org/wiki/Clouding_of_consciousness + + + + obo2:OAE_0001938 + 意识模糊 + + + + obo2:OAE_0001938 + clouding of consciousness AE + + + + obo2:OAE_0001939 + Reflex tachycardia AE is a tachycardia AE that shows increased heart rate in response to some stimulus conveyed through the cardiac nerves. + + + + obo2:OAE_0001939 + JX, LW, YH + + + + obo2:OAE_0001939 + WEB: http://www.medilexicon.com/medicaldictionary.php?t=89526 + + + + obo2:OAE_0001939 + 反射性心动过速 + + + + obo2:OAE_0001939 + reflex tachycardia AE + + + + obo2:OAE_0001939 + MedDRA: 10063096 + + + + obo2:OAE_0001940 + Joint sprain AE is a joint disorder AE that is damage to one or more ligaments in a joint, often caused by trauma or the joint being taken beyond its functional range of motion. + + + + obo2:OAE_0001940 + JX, LW, YH + + + + obo2:OAE_0001940 + WEB: http://en.wikipedia.org/wiki/Sprain + + + + obo2:OAE_0001940 + 关节扭伤 + + + + obo2:OAE_0001940 + joint sprain AE + + + + obo2:OAE_0001940 + MedDRA: 10023229 + + + + obo2:OAE_0001941 + Epicondylitis AE is an inflammation AE that is a type of musculoskeletal disorder that refers to an inflammation of an epicondyle. + + + + obo2:OAE_0001941 + JX, LW, YH + + + + obo2:OAE_0001941 + WEB: http://en.wikipedia.org/wiki/Epicondylitis + + + + obo2:OAE_0001941 + 上髁炎 + + + + obo2:OAE_0001941 + epicondylitis AE + + + + obo2:OAE_0001941 + MedDRA: 10014971 + + + + obo2:OAE_0001942 + Melanoglosia AE is a tongue AE that shows tongue turn black. Any blackening of the tongue associated with certain disorders and diseases in animals and humans. + + + + obo2:OAE_0001942 + JX, LW, YH + + + + obo2:OAE_0001942 + WEB: http://encyclopedia2.thefreedictionary.com/melanoglosia + + + + obo2:OAE_0001942 + 舌黑 + + + + obo2:OAE_0001942 + melanoglosia AE + + + + obo2:OAE_0001942 + MedDRA: 10014971 + + + + obo2:OAE_0001943 + Ventricular tachycardia AE is a tachycardia AE that is a type of tachycardia, or a rapid heart beat that arises from improper electrical activity of the heart presenting as a rapid heart rhythm, that starts in the bottom chambers of the heart, called the ventricles. + + + + obo2:OAE_0001943 + JX, LW, YH + + + + obo2:OAE_0001943 + WEB: http://en.wikipedia.org/wiki/Ventricular_tachycardia + + + + obo2:OAE_0001943 + 心室性心搏过速 + + + + obo2:OAE_0001943 + ventricular tachycardia AE + + + + obo2:OAE_0001943 + MedDRA: 10047302 + + + + obo2:OAE_0001944 + Granulomatous hepatitis AE is a hepatitis AE that refers to an inflammatory liver disease associated with granuloma formation in the liver. + + + + obo2:OAE_0001944 + JX, LW, YH + + + + obo2:OAE_0001944 + WEB: http://radiopaedia.org/articles/granulomatous-hepatitis + + + + obo2:OAE_0001944 + 肉芽肿性肝炎 + + + + obo2:OAE_0001944 + granulomatous hepatitis AE + + + + obo2:OAE_0001945 + Hypogeusia AE is a gustatory system AE that is a reduced ability to taste things (to taste sweet, sour, bitter, or salty substances). + + + + obo2:OAE_0001945 + JX, LW, YH + + + + obo2:OAE_0001945 + WEB: http://en.wikipedia.org/wiki/Hypogeusia + + + + obo2:OAE_0001945 + 味觉减弱 + + + + obo2:OAE_0001945 + hypogeusia AE + + + + obo2:OAE_0001945 + MedDRA: 10020989 + + + + obo2:OAE_0001946 + Dysphoria AE is a behavior and neurological AE that is a profound state of unease or dissatisfaction. In a psychiatric context, dysphoria may accompany depression, anxiety, or agitation. Common reactions to dysphoria include emotional distress or indifference. + + + + obo2:OAE_0001946 + JX, LW, YH + + + + obo2:OAE_0001946 + WEB: http://en.wikipedia.org/wiki/Dysphoria + + + + obo2:OAE_0001946 + 烦躁不安 + + + + obo2:OAE_0001946 + dysphoria AE + + + + obo2:OAE_0001946 + MedDRA: 10013954 + + + + obo2:OAE_0001947 + Oneirism AE is a behavior and neurological AE that is a state of abnormal consciousness in which dream-like experiences and hallucinations happen while awake. + + + + obo2:OAE_0001947 + JX, LW, YH + + + + obo2:OAE_0001947 + WEB: http://en.wiktionary.org/wiki/oneirism + + + + obo2:OAE_0001947 + 梦幻症 + + + + obo2:OAE_0001947 + oneirism AE + + + + obo2:OAE_0001947 + MedDRA: 10030332 + + + + obo2:OAE_0001948 + Podalgia AE is a pain AE that shows pain in the foot. + + + + obo2:OAE_0001948 + JX, LW, YH + + + + obo2:OAE_0001948 + WEB: http://en.wiktionary.org/wiki/podalgia + + + + obo2:OAE_0001948 + 足痛 + + + + obo2:OAE_0001948 + podalgia AE + + + + obo2:OAE_0001949 + Brachialgia AE is a pain AE that shows pain in the arm. + + + + obo2:OAE_0001949 + JX, LW, YH + + + + obo2:OAE_0001949 + WEB: http://en.wiktionary.org/wiki/brachialgia + + + + obo2:OAE_0001949 + 臂痛 + + + + obo2:OAE_0001949 + brachialgia AE + + + + obo2:OAE_0001949 + MedDRA: 10068901 + + + + obo2:OAE_0001950 + Coxalgia AE is a pain AE that shows pain in the hip. + + + + obo2:OAE_0001950 + JX, LW, YH + + + + obo2:OAE_0001950 + WEB: http://en.wiktionary.org/wiki/coxalgia + + + + obo2:OAE_0001950 + 髋痛 + + + + obo2:OAE_0001950 + coxalgia AE + + + + obo2:OAE_0001950 + MedDRA: 10011249 + + + + obo2:OAE_0001951 + Limb injury AE is an injury AE which involve damage to bones, joints, ligament, musles, the major blood vessels and nerves of the limb. + + + + obo2:OAE_0001951 + JX, LW, YH + + + + obo2:OAE_0001951 + 肢体伤 + + + + obo2:OAE_0001951 + limb injury AE + + + + obo2:OAE_0001951 + MedDRA ID: 10061225 + + + + obo2:OAE_0001952 + Polymyalgia rheumatica AE is a muscle pain AE that is a syndrome with pain or stiffness, usually in the neck, shoulders, and hips. The pain can be very sudden, or can occur gradually over a period. It may be caused by an inflammatory condition of blood vessels such as temporal arteritis. + + + + obo2:OAE_0001952 + JX, LW, YH + + + + obo2:OAE_0001952 + WEB: http://en.wikipedia.org/wiki/Polymyalgia_rheumatica + + + + obo2:OAE_0001952 + 风湿性多发性肌痛 + + + + obo2:OAE_0001952 + polymyalgia rheumatica AE + + + + obo2:OAE_0001952 + MedDRA: 10036099 + + + + obo2:OAE_0001953 + Fibromyalgia AE is a muscle pain AE that is characterised by chronic widespread pain and allodynia (a heightened and painful response to pressure). Fibromyalgia symptoms are not restricted to pain, leading to the use of the alternative term fibromyalgia syndrome for the condition. Other symptoms include debilitating fatigue, sleep disturbance, and joint stiffness. + + + + obo2:OAE_0001953 + JX, LW, YH + + + + obo2:OAE_0001953 + WEB: http://en.wikipedia.org/wiki/Fibromyalgia + + + + obo2:OAE_0001953 + 纤维肌痛 + + + + obo2:OAE_0001953 + fibromyalgia AE + + + + obo2:OAE_0001953 + MedDRA: 10048439 + + + + obo2:OAE_0001954 + Hepatic encephalopathy AE is an encephalopathy AE that is the occurrence of confusion, altered level of consciousness, and coma as a result of liver failure. In the advanced stages it is called hepatic coma or coma hepaticum. + + + + obo2:OAE_0001954 + JX, LW, YH + + + + obo2:OAE_0001954 + portosystemic encephalopathy AE + + + + obo2:OAE_0001954 + WEB: http://en.wikipedia.org/wiki/Hepatic_encephalopathy + + + + obo2:OAE_0001954 + hepatic encephalopathy AE + + + + obo2:OAE_0001954 + MedDRA: 10019660 + + + + obo2:OAE_0001955 + Chorea AE is a neurological AE that is an abnormal involuntary movement disorder, one of a group of neurological disorders called dyskinesias. + + + + obo2:OAE_0001955 + JX, LW, YH + + + + obo2:OAE_0001955 + choreia AE + + + + obo2:OAE_0001955 + WEB: http://en.wikipedia.org/wiki/Chorea + + + + obo2:OAE_0001955 + 舞蹈症 + + + + obo2:OAE_0001955 + chorea AE + + + + obo2:OAE_0001955 + MedDRA: 10008748 + + + + obo2:OAE_0001956 + Nightmare AE is a sleep disorder AE that is an unpleasant dream that can cause a strong emotional response from the mind, typically fear or horror but also despair, anxiety and great sadness. + + + + obo2:OAE_0001956 + JX, LW, YH + + + + obo2:OAE_0001956 + WEB: http://en.wikipedia.org/wiki/Nightmare + + + + obo2:OAE_0001956 + 梦魇 + + + + obo2:OAE_0001956 + nightmare AE + + + + obo2:OAE_0001956 + MedDRA: 10029412 + + + + obo2:OAE_0001957 + Depersonalization AE is a mental disorder AE that is an anomaly of self-awareness. It consists of a feeling of watching oneself act, while having no control over a situation. Subjects feel they have changed, and the world has become vague, dreamlike, less real, or lacking in significance. It can be a disturbing experience, since many feel that, indeed, they are living in a "dream". + + + + obo2:OAE_0001957 + JX, LW, YH + + + + obo2:OAE_0001957 + depersonalisation AE + + + + obo2:OAE_0001957 + WEB: http://en.wikipedia.org/wiki/Depersonalization + + + + obo2:OAE_0001957 + 人格解体 + + + + obo2:OAE_0001957 + depersonalization AE + + + + obo2:OAE_0001957 + MedDRA: 10012359 + + + + obo2:OAE_0001958 + Apatheia AE is a mental disorder AE that refers to a state of mind where one is not disturbed by the passions. + + + + obo2:OAE_0001958 + JX, LW, YH + + + + obo2:OAE_0001958 + apathia AE + + + + obo2:OAE_0001958 + WEB: http://en.wikipedia.org/wiki/Apatheia + + + + obo2:OAE_0001958 + 情感冷漠 + + + + obo2:OAE_0001958 + apatheia AE + + + + obo2:OAE_0001959 + Parosmia AE is a sensory capability AE that is an olfactory dysfunction which is characterized by the inability of the brain to properly identify an odor’s “natural” smell. + + + + obo2:OAE_0001959 + JX, LW, YH + + + + obo2:OAE_0001959 + cacosmia AE + + + + obo2:OAE_0001959 + troposmia AE + + + + obo2:OAE_0001959 + 味觉倒错 + + + + obo2:OAE_0001959 + WEB: http://en.wikipedia.org/wiki/Parosmia + + + + obo2:OAE_0001959 + parosmia AE + + + + obo2:OAE_0001959 + MedDRA: 10034018 + + + + obo2:OAE_0001960 + Xerophthalmia AE is an eye AE that is a medical condition in which the eye fails to produce tears. + + + + obo2:OAE_0001960 + JX, LW, YH + + + + obo2:OAE_0001960 + xerophthalmus AE + + + + obo2:OAE_0001960 + WEB: http://en.wikipedia.org/wiki/Xerophthalmia + + + + obo2:OAE_0001960 + 干眼病 + + + + obo2:OAE_0001960 + xerophthalmia AE + + + + obo2:OAE_0001960 + MedDRA: 10048221 + + + + obo2:OAE_0001961 + Chondropathy AE is a bone disorder AE that refers to a disease of the cartilage. It is frequently divided into 5 grades, with 0-2 defined as normal, and 3-4 defined as diseased. + + + + obo2:OAE_0001961 + JX, LW, YH + + + + obo2:OAE_0001961 + WEB: http://en.wikipedia.org/wiki/Chondropathy + + + + obo2:OAE_0001961 + 软骨病 + + + + obo2:OAE_0001961 + chondropathy AE + + + + obo2:OAE_0001961 + MedDRA: 10061762 + + + + obo2:OAE_0001962 + Teratogenesis AE is a female reproductive system AE that is a prenatal toxicity characterized by structural or functional defects in the developing embryo or fetus. It also includes intrauterine growth retardation, death of the embryo or fetus, and transplacental carcinogenesis. + + + + obo2:OAE_0001962 + JX, LW, YH + + + + obo2:OAE_0001962 + WEB: http://www.britannica.com/EBchecked/topic/587782/teratogenesis + + + + obo2:OAE_0001962 + 畸胎 + + + + obo2:OAE_0001962 + teratogenesis AE + + + + obo2:OAE_0001963 + Premature atrial contraction AE is an arrhythmia AE that is a common cardiac dysrhythmia characterized by premature heartbeats originating in the atria. + + + + obo2:OAE_0001963 + JX, LW, YH + + + + obo2:OAE_0001963 + atrial premature beats AE + + + + obo2:OAE_0001963 + atrial premature complexes AE + + + + obo2:OAE_0001963 + WEB: http://en.wikipedia.org/wiki/Premature_atrial_contraction + + + + obo2:OAE_0001963 + 早搏 + + + + obo2:OAE_0001963 + premature atrial contraction AE + + + + obo2:OAE_0001963 + MedDRA: 10056964 + + + + obo2:OAE_0001964 + An inflammation AE that courrs in one or both parotid glands, the major salivary glands located on either side of the face, in humans. The parotid gland is the salivary gland most commonly affected by inflammation. + + + + obo2:OAE_0001964 + JX, LW, YH + + + + obo2:OAE_0001964 + WEB: http://en.wikipedia.org/wiki/Parotitis + + + + obo2:OAE_0001964 + 腮腺炎 + + + + obo2:OAE_0001964 + parotitis AE + + + + obo2:OAE_0001964 + MedDRA: 10034038 + + + + obo2:OAE_0001965 + Glossitis AE is an inflammation AE that can mean soreness of the tongue, or more usually inflammation with depapillation of the dorsal surface of the tongue, leaving a smooth and erythematous surface. + + + + obo2:OAE_0001965 + JX, LW, YH + + + + obo2:OAE_0001965 + WEB: http://en.wikipedia.org/wiki/Glossitis + + + + obo2:OAE_0001965 + 舌炎 + + + + obo2:OAE_0001965 + glossitis AE + + + + obo2:OAE_0001965 + MedDRA: 10018386 + + + + obo2:OAE_0001966 + Genital edema AE is an edema AE that can be the result of interruption to the lymphatic drainage of this area caused by tumor, surgical removal of lymph nodes, radiotherapy or infection. Congenital disorders causing inadequate lymphatics can sometimes lead to the development of this condition. + + + + obo2:OAE_0001966 + JX, LW, YH + + + + obo2:OAE_0001966 + WEB: http://www.lymphoedemanz.org.nz/About+Lymphoedema/Genital+Oedema.html + + + + obo2:OAE_0001966 + 生殖器水肿 + + + + obo2:OAE_0001966 + genital edema AE + + + + obo2:OAE_0001966 + MedDRA: 10018146 + + + + obo2:OAE_0001967 + Orgasm incapacity AE is a reproductive system AE that the disorder characterized by an inability to achieve orgasm. + + + + obo2:OAE_0001967 + JX, LW, YH + + + + obo2:OAE_0001967 + 缺乏性高潮 + + + + obo2:OAE_0001967 + orgasm incapacity AE + + + + obo2:OAE_0001968 + Sedation AE is a behavior and neurological AE that is the reduction of irritability or agitation by administration of sedative drugs, generally to facilitate a medical procedure or diagnostic procedure. + + + + obo2:OAE_0001968 + JX, LW, YH + + + + obo2:OAE_0001968 + WEB: http://en.wikipedia.org/wiki/Sedation + + + + obo2:OAE_0001968 + 镇静 + + + + obo2:OAE_0001968 + sedation AE + + + + obo2:OAE_0001968 + MedDRA: 10039897 + + + + obo2:OAE_0001969 + Sinus bradycardia AE is a bradycardia AE that is a heart rhythm that originates from the sinus node and has a rate that is lower than normal. In humans, bradycardia is generally defined to be a rate of under 60 beats per minute. + + + + obo2:OAE_0001969 + JX, LW, YH + + + + obo2:OAE_0001969 + WEB: http://en.wikipedia.org/wiki/Sinus_bradycardia + + + + obo2:OAE_0001969 + 窦性心动过缓 + + + + obo2:OAE_0001969 + sinus bradycardia AE + + + + obo2:OAE_0001969 + MedDRA: 10040741 + + + + obo2:OAE_0001970 + Cardiac output decreased AE is a cardiac disorder AE that shows a state in which the blood pumped by an individual's heart is sufficiently reduced that it is inadequate to meet the needs of the body's tissues. Cardiac output is the volume of blood being pumped by the heart, in particular by a left or right ventricle in the time interval of one minute. + + + + obo2:OAE_0001970 + JX, LW, YH + + + + obo2:OAE_0001970 + WEB: http://www1.us.elsevierhealth.com/MERLIN/Gulanick/archive/Constructor/gulanick10.html +http://en.wikipedia.org/wiki/Cardiac_output + + + + obo2:OAE_0001970 + 心输出量减少 + + + + obo2:OAE_0001970 + cardiac output decreased AE + + + + obo2:OAE_0001970 + MedDRA: 10007595 + + + + obo2:OAE_0001971 + Steatorrhea AE is a digestive system AE that is the presence of excess fat in feces. Stools may also float due to excess lipid, have an oily appearance and can be especially foul-smelling. + + + + obo2:OAE_0001971 + JX, LW, YH + + + + obo2:OAE_0001971 + steatorrhoea AE + + + + obo2:OAE_0001971 + WEB: http://en.wikipedia.org/wiki/Steatorrhea + + + + obo2:OAE_0001971 + 脂溢 + + + + obo2:OAE_0001971 + steatorrhea AE + + + + obo2:OAE_0001971 + MedDRA: 10041968 + + + + obo2:OAE_0001972 + Malabsorption syndrome AE is a digestive system AE that refers to a number of disorders in which the intestine’s ability to absorb certain nutrients, such as vitamin B12 and iron, into the bloodstream is negatively affected. + + + + obo2:OAE_0001972 + JX, LW, YH + + + + obo2:OAE_0001972 + WEB: http://www.healthline.com/health/malabsorption#Overview1 + + + + obo2:OAE_0001972 + 吸收不良综合症 + + + + obo2:OAE_0001972 + malabsorption syndrome AE + + + + obo2:OAE_0001972 + MedDRA: 10025479 + + + + obo2:OAE_0001973 + Sialadenitis AE is an inflammation AE that is inflammation of a salivary gland. It may be subdivided temporally into acute, chronic and recurrent forms. + + + + obo2:OAE_0001973 + JX, LW, YH + + + + obo2:OAE_0001973 + WEB: http://en.wikipedia.org/wiki/Sialadenitis + + + + obo2:OAE_0001973 + 唾液腺炎 + + + + obo2:OAE_0001973 + sialadenitis AE + + + + obo2:OAE_0001973 + MedDRA: 10040627 + + + + obo2:OAE_0001974 + Parkinson's disease AE is a neurological AE that is a degenerative disorder of the central nervous system. The motor symptoms of Parkinson's disease result from the death of dopamine-generating cells in the substantia nigra, a region of the midbrain, the cause of this cell death is unknown. + + + + obo2:OAE_0001974 + JX, LW, YH + + + + obo2:OAE_0001974 + choreia AE + + + + obo2:OAE_0001974 + hypokinetic rigid syndrome AE + + + + obo2:OAE_0001974 + idiopathic/primary parkinsonism AE + + + + obo2:OAE_0001974 + paralysis agitans AE + + + + obo2:OAE_0001974 + WEB: http://en.wikipedia.org/wiki/Parkinson's_disease + + + + obo2:OAE_0001974 + 帕金森综合症 + + + + obo2:OAE_0001974 + parkinson's disease AE + + + + obo2:OAE_0001974 + MedDRA: 10061536 + + + + obo2:OAE_0001975 + Urinary calculus AE a urinary system AE that is solid particles in the urinary system. They may cause pain, nausea, vomiting, hematuria, and, possibly, chills and fever due to secondary infection. + + + + obo2:OAE_0001975 + JX, LW, YH + + + + obo2:OAE_0001975 + urinary calculi AE + + + + obo2:OAE_0001975 + WEB: http://www.merckmanuals.com/professional/genitourinary_disorders/urinary_calculi/urinary_calculi.html + + + + obo2:OAE_0001975 + 尿结石 + + + + obo2:OAE_0001975 + urinary calculus AE + + + + obo2:OAE_0001975 + MedDRA: 10046531 + + + + obo2:OAE_0001976 + Sinoatrial block AE is a conduction system disorder AE that shows the electrical impulse is delayed or blocked on the way to the atria, thus delaying atrial depolarization. + + + + obo2:OAE_0001976 + JX, LW, YH + + + + obo2:OAE_0001976 + WEB: http://en.wikipedia.org/wiki/Sinoatrial_block + + + + obo2:OAE_0001976 + 窦房阻滞 + + + + obo2:OAE_0001976 + sinoatrial block AE + + + + obo2:OAE_0001976 + MedDRA: 10040736 + + + + obo2:OAE_0001977 + Hyperthyroidism AE is an endocrine system AE that is a condition in which the thyroid gland produces and secretes excessive amounts of the free (not protein bound circulating in the blood) thyroid hormones -triiodothyronine (T3) and/or thyroxine (T4). + + + + obo2:OAE_0001977 + JX, LW, YH + + + + obo2:OAE_0001977 + WEB: http://en.wikipedia.org/wiki/Hyperthyroidism + + + + obo2:OAE_0001977 + 甲状腺机能亢进 + + + + obo2:OAE_0001977 + hyperthyroidism AE + + + + obo2:OAE_0001977 + MedDRA: 10020850 + + + + obo2:OAE_0001978 + Akathisia AE is a behavior and neurological AE that is a movement disorder characterized by a feeling of inner restlessness and a compelling need to be in constant motion, as well as by actions such as rocking while standing or sitting, lifting the feet as if marching on the spot, and crossing and uncrossing the legs while sitting. People with akathisia are unable to sit or keep still, complain of restlessness, fidget, rock from foot to foot, and pace. + + + + obo2:OAE_0001978 + JX, LW, YH + + + + obo2:OAE_0001978 + acathisia AE + + + + obo2:OAE_0001978 + WEB: http://en.wikipedia.org/wiki/Akathisia + + + + obo2:OAE_0001978 + 静坐困难 + + + + obo2:OAE_0001978 + akathisia AE + + + + obo2:OAE_0001978 + MedDRA: 10001540 + + + + obo2:OAE_0001979 + Retinopathy AE is an eye AE that is due to persistent or acute damage to the retina of the eye. Ongoing inflammation and vascular remodeling may occur over periods of time where the patient is not fully aware of the extent of the disease. Frequently, retinopathy is an ocular manifestation of systemic disease as seen in diabetes or hypertension. + + + + obo2:OAE_0001979 + JX, LW, YH + + + + obo2:OAE_0001979 + WEB: http://en.wikipedia.org/wiki/Retinopathy + + + + obo2:OAE_0001979 + 视网膜病变 + + + + obo2:OAE_0001979 + retinopathy AE + + + + obo2:OAE_0001979 + MedDRA: 10038923 + + + + obo2:OAE_0001980 + Sinus arrest AE is an arrhythmia AE that is a medical condition wherein the sinoatrial node of the heart transiently ceases to generate the electrical impulses that normally stimulate the myocardial tissues to contract and thus the heart to beat. It is defined as lasting from 2.0 seconds to several minutes. + + + + obo2:OAE_0001980 + JX, LW, YH + + + + obo2:OAE_0001980 + sinoatrial arrest AE + + + + obo2:OAE_0001980 + sinus pause AE + + + + obo2:OAE_0001980 + WEB: http://en.wikipedia.org/wiki/Sinoatrial_arrest + + + + obo2:OAE_0001980 + 窦性停搏 + + + + obo2:OAE_0001980 + sinus arrest AE + + + + obo2:OAE_0001980 + MedDRA: 10040738 + + + + obo2:OAE_0001981 + ST segment depression AE is an electrocardiogram result abnormal AE that refers to a finding on an electrocardiogram. It may be determined by measuring the vertical distance between the patient's trace and the isoelectric line at a location 2-3 millimeters from the QRS complex. It is significant if it is more than 1 mm in V5-V6, or 1.5 mm in AVF or III. + + + + obo2:OAE_0001981 + JX, LW, YH + + + + obo2:OAE_0001981 + WEB: http://en.wikipedia.org/wiki/ST_depression + + + + obo2:OAE_0001981 + ST段下降 + + + + obo2:OAE_0001981 + ST segment depression AE + + + + obo2:OAE_0001981 + MedDRA: 10041892 + + + + obo2:OAE_0001982 + T-wave inversion AE is an electrocardiogram result abnormal AE that can be a sign of coronary ischemia, Wellens' syndrome, left ventricular hypertrophy, or CNS disorder. In electrocardiography, the T wave represents the repolarization (or recovery) of the ventricles. + + + + obo2:OAE_0001982 + JX, LW, YH + + + + obo2:OAE_0001982 + WEB: http://en.wikipedia.org/wiki/T_wave + + + + obo2:OAE_0001982 + T波倒置 + + + + obo2:OAE_0001982 + T-wave inversion AE + + + + obo2:OAE_0001982 + MedDRA: 10042966 + + + + obo2:OAE_0001983 + Hyperthermia AE is an abnormal body temperature AE that is elevated body temperature due to failed thermoregulation that occurs when a body produces or absorbs more heat than it dissipates. Extreme temperature elevation then becomes a medical emergency requiring immediate treatment to prevent disability or death. + + + + obo2:OAE_0001983 + JX, LW, YH, SJ + + + + obo2:OAE_0001983 + WEB: http://en.wikipedia.org/wiki/Hyperthermia + + + + obo2:OAE_0001983 + 体温过高 + + + + obo2:OAE_0001983 + hyperthermia AE + + + + obo2:OAE_0001983 + MedDRA: 10020843 + + + + obo2:OAE_0001984 + Priapism AE a male reproductive system AE that is a potentially painful medical condition in which the erect penis does not return to its flaccid state, despite the absence of both physical and psychological stimulation, within four hours. + + + + obo2:OAE_0001984 + JX, LW, YH + + + + obo2:OAE_0001984 + WEB: http://en.wikipedia.org/wiki/Priapism + + + + obo2:OAE_0001984 + 阴茎持续勃起 + + + + obo2:OAE_0001984 + priapism AE + + + + obo2:OAE_0001984 + MedDRA: 10036661 + + + + obo2:OAE_0001985 + Gingival bleeding AE is a hemorrhage AE that is a term used by dentists and dental hygienists when referring to bleeding that is induced by gentle manipulation of the tissue at the depth of the gingival sulcus, or interface between the gingiva and a tooth. Bleeding on probing, often abbreviated BOP, is a sign of inflammation and indicates some sort of destruction and erosion to the lining of the sulcus or the ulceration of sulcular epithelium. The blood comes from lamina propria after the ulceration of the lining. + + + + obo2:OAE_0001985 + JX, LW, YH + + + + obo2:OAE_0001985 + bleeding gums AE + + + + obo2:OAE_0001985 + bleeding on probing AE + + + + obo2:OAE_0001985 + WEB: http://en.wikipedia.org/wiki/Bleeding_on_probing + + + + obo2:OAE_0001985 + 牙龈出血 + + + + obo2:OAE_0001985 + gingival bleeding AE + + + + obo2:OAE_0001985 + MedDRA: 10018276 + + + + obo2:OAE_0001986 + Hearing loss AE is an ear disorder AE that is a partial or total inability to hear. In children it may affect the development of language and can cause work related difficulties for adults. + + + + obo2:OAE_0001986 + JX, LW, YH + + + + obo2:OAE_0001986 + anacusis AE + + + + obo2:OAE_0001986 + deafness AE + + + + obo2:OAE_0001986 + hard of hearing AE + + + + obo2:OAE_0001986 + hearing impairment AE + + + + obo2:OAE_0001986 + WEB: http://en.wikipedia.org/wiki/Hearing_loss + + + + obo2:OAE_0001986 + 听力下降 + + + + obo2:OAE_0001986 + hearing loss AE + + + + obo2:OAE_0001986 + MedDRA: 10019246 + + + + obo2:OAE_0001987 + Muscle fatigue AE is a muscle adverse event that is the decline in ability of a muscle to generate force. It can be a result of vigorous exercise but abnormal fatigue may be caused by barriers to or interference with the different stages of muscle contraction. + + + + obo2:OAE_0001987 + JX, LW, YH + + + + obo2:OAE_0001987 + physical fatigue AE + + + + obo2:OAE_0001987 + WEB: http://en.wikipedia.org/wiki/Muscle_fatigue + + + + obo2:OAE_0001987 + 肌肉疲劳 + + + + obo2:OAE_0001987 + muscle fatigue AE + + + + obo2:OAE_0001987 + MedDRA: 10049565 + + + + obo2:OAE_0001988 + Regurgitation AE is a digestive system AE that is the expulsion of material from the pharynx, or esophagus, usually characterized by the presence of undigested food or blood. + + + + obo2:OAE_0001988 + JX, LW, YH + + + + obo2:OAE_0001988 + http://en.wikipedia.org/wiki/Regurgitation_%28digestion%29 + + + + obo2:OAE_0001988 + 反胃 + + + + obo2:OAE_0001988 + regurgitation AE + + + + obo2:OAE_0001988 + MedDRA: 10067171 + + + + obo2:OAE_0001989 + Skin irritation AE is a skin AE that is a mild inflammatory dermal tissue reaction, it can be caused by physical contact with an irritant or can be a local response to a systemic trigger. + + + + obo2:OAE_0001989 + JX, LW, YH + + + + obo2:OAE_0001989 + 皮肤刺激 + + + + obo2:OAE_0001989 + skin irritation AE + + + + obo2:OAE_0001989 + MedDRA: 10040880 + + + + obo2:OAE_0001990 + Herpes simplex AE is a viral infection AE that is a viral disease from the herpesviridae family caused by both Herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2). + + + + obo2:OAE_0001990 + JX, LW, YH + + + + obo2:OAE_0001990 + herpes catarrhalis AE + + + + obo2:OAE_0001990 + WEB: http://en.wikipedia.org/wiki/Herpes_simplex + + + + obo2:OAE_0001990 + 单纯疱疹 + + + + obo2:OAE_0001990 + herpes simplex AE + + + + obo2:OAE_0001990 + MedDRA: 10019948 + + + + obo2:OAE_0001991 + Measles AE is a viral infection AE is an infection of the respiratory system, immune system and skin caused by a virus, specifically a paramyxovirus of the genus Morbillivirus. + + + + obo2:OAE_0001991 + JX, LW, YH + + + + obo2:OAE_0001991 + English measles AE + + + + obo2:OAE_0001991 + morbilli AE + + + + obo2:OAE_0001991 + rubeola AE + + + + obo2:OAE_0001991 + WEB: http://en.wikipedia.org/wiki/Measles + + + + obo2:OAE_0001991 + 麻疹 + + + + obo2:OAE_0001991 + measles AE + + + + obo2:OAE_0001991 + MedDRA: 10027011 + + + + obo2:OAE_0001992 + Hypercholesteremia AE is a blood cholesterol abnormal AE that is the presence of high levels of cholesterol in the blood. + + + + obo2:OAE_0001992 + JX, LW, YH + + + + obo2:OAE_0001992 + dyslipidemia + + + + obo2:OAE_0001992 + hypercholesterolemia AE + + + + obo2:OAE_0001992 + WEB: http://en.wikipedia.org/wiki/Hypercholesterolemia + + + + obo2:OAE_0001992 + 高胆固醇血症 + + + + obo2:OAE_0001992 + hypercholesteremia AE + + + + obo2:OAE_0001992 + MedDRA: 10020604 + + + + obo2:OAE_0001993 + Toxic epidermal necrolysis AE is a skin AE that is a rare, life-threatening skin condition which is usually caused by a reaction to drugs. + + + + obo2:OAE_0001993 + JX, LW, YH + + + + obo2:OAE_0001993 + Lyell's syndrome AE + + + + obo2:OAE_0001993 + WEB: http://en.wikipedia.org/wiki/Toxic_epidermal_necrolysis + + + + obo2:OAE_0001993 + 中毒性表皮坏死溶解症 + + + + obo2:OAE_0001993 + toxic epidermal necrolysis AE + + + + obo2:OAE_0001993 + MedDRA: 10044223 + + + + obo2:OAE_0001994 + Atrioventricular junctional rhythm AE is an arrhythmia AE that is an electrocardiographic finding in which the pacer of the heart is located in the AV junction, presenting with a narrow QRS complex and a rate of 40-60 beats per minute. + + + + obo2:OAE_0001994 + JX, LW, YH + + + + obo2:OAE_0001994 + 房室交界性心律 + + + + obo2:OAE_0001994 + atrioventricular junctional rhythm AE + + + + obo2:OAE_0001995 + Unconsciousness AE is a sensory capability AE that is a state which occurs when the ability to maintain a awareness of self and environment is lost, it involves a complete or near-complete lack of responsiveness to people and other environmental stimuli. + + + + obo2:OAE_0001995 + JX, LW, YH + + + + obo2:OAE_0001995 + loss of consciousness AE + + + + obo2:OAE_0001995 + WEB: http://en.wikipedia.org/wiki/Unconsciousness + + + + obo2:OAE_0001995 + 意识丧失 + + + + obo2:OAE_0001995 + unconsciousness AE + + + + obo2:OAE_0001995 + MedDRA: 10045481 + + + + obo2:OAE_0001996 + Pemphigus AE is a skin AE that is a rare group of blistering autoimmune diseases that affect the skin and mucous membranes. + + + + obo2:OAE_0001996 + JX, LW, YH + + + + obo2:OAE_0001996 + WEB: http://en.wikipedia.org/wiki/Pemphigus + + + + obo2:OAE_0001996 + 天疱疮 + + + + obo2:OAE_0001996 + pemphigus AE + + + + obo2:OAE_0001996 + MedDRA: 10034280 + + + + obo2:OAE_0001997 + Onychomycosis AE is a nail infection AE that is a fungal infection of the nail. It is the most common disease of the nails and constitutes about half of all nail abnormalities. + + + + obo2:OAE_0001997 + JX, LW, YH + + + + obo2:OAE_0001997 + dermatophytic onychomycosis AE + + + + obo2:OAE_0001997 + tinea unguium AE + + + + obo2:OAE_0001997 + WEB: http://en.wikipedia.org/wiki/Onychomycosis + + + + obo2:OAE_0001997 + 甲癣 + + + + obo2:OAE_0001997 + onychomycosis AE + + + + obo2:OAE_0001998 + Miosis AE is an eye AE that is a term with various definitions, which generally include constriction of the pupil. + + + + obo2:OAE_0001998 + JX, LW, YH + + + + obo2:OAE_0001998 + myosis AE + + + + obo2:OAE_0001998 + WEB: http://en.wikipedia.org/wiki/Miosis + + + + obo2:OAE_0001998 + 瞳孔缩小 + + + + obo2:OAE_0001998 + miosis AE + + + + obo2:OAE_0001998 + MedDRA: 10027646 + + + + obo2:OAE_0001999 + an optic neuropathy AE that shows the loss of some or most of the nerve fibers in the optic nerve. The effects range from visual change to severe visual loss. + + + + obo2:OAE_0001999 + JX, LW, YH + + + + obo2:OAE_0001999 + WEB: http://www.kellogg.umich.edu/patientcare/conditions/optic.atrophy.html + + + + obo2:OAE_0001999 + 视神经萎缩 + + + + obo2:OAE_0001999 + optic atrophy AE + + + + obo2:OAE_0001999 + MedDRA: 10030910 + + + + obo2:OAE_0002000 + Albuminuria AE is a urine abnormality AE that is a pathological condition wherein albumin is present in the urine. It is a type of proteinuria. + + + + obo2:OAE_0002000 + JX, LW, YH + + + + obo2:OAE_0002000 + WEB: http://en.wikipedia.org/wiki/Albuminuria + + + + obo2:OAE_0002000 + 蛋白尿 + + + + obo2:OAE_0002000 + albuminuria AE + + + + obo2:OAE_0002000 + MedDRA: 10001580 + + + + obo2:OAE_0002001 + Enuresis AE is a urine abnormality AE that refers to a repeated inability to control urination. Use of the term is usually limited to describing individuals old enough to be expected to exercise such control. + + + + obo2:OAE_0002001 + This term appears to be a synonym to the 'urinary incontinence AE'. + + + + obo2:OAE_0002001 + JX, LW, YH + + + + obo2:OAE_0002001 + WEB: http://en.wikipedia.org/wiki/Enuresis + + + + obo2:OAE_0002001 + 遗尿 + + + + obo2:OAE_0002001 + enuresis AE + + + + obo2:OAE_0002001 + MedDRA: 10014928 + + + + obo2:OAE_0002002 + Gum hypertrophy AE is a digestive system AE that is an increase in the size of the gingiva (gums). It is a common feature of gingival disease. Gingival enlargement can be caused by a number of factors, including inflammatory conditions and the side effects of certain medications. + + + + obo2:OAE_0002002 + JX, LW, YH + + + + obo2:OAE_0002002 + gingival enlargement AE + + + + obo2:OAE_0002002 + gingival hyperplasia AE + + + + obo2:OAE_0002002 + gingival hypertrophy AE + + + + obo2:OAE_0002002 + gingival over-growth AE + + + + obo2:OAE_0002002 + hypertrophic gingivitis AE + + + + obo2:OAE_0002002 + WEB: http://en.wikipedia.org/wiki/Gingival_enlargement + + + + obo2:OAE_0002002 + 牙龈增生 + + + + obo2:OAE_0002002 + gum hypertrophy AE + + + + obo2:OAE_0002002 + MedDRA: 10018781 + + + + obo2:OAE_0002003 + Contact dermatitis AE is a dermatitis AE that is a type of skin inflammation.It results from exposure to allergens (allergic contact dermatitis) or irritants (irritant contact dermatitis). Phototoxic dermatitis occurs when the allergen or irritant is activated by sunlight. + + + + obo2:OAE_0002003 + JX, LW, YH + + + + obo2:OAE_0002003 + WEB: http://en.wikipedia.org/wiki/Contact_dermatitis + + + + obo2:OAE_0002003 + 接触性皮炎 + + + + obo2:OAE_0002003 + contact dermatitis AE + + + + obo2:OAE_0002003 + MedDRA: 10010790 + + + + obo2:OAE_0002004 + Necrotizing vasculitis AE is a vasculitis AE that is a rare condition which involves inflammation of the blood vessel walls. + + + + obo2:OAE_0002004 + JX, LW, YH + + + + obo2:OAE_0002004 + WEB: http://www.nlm.nih.gov/medlineplus/ency/article/000432.htm + + + + obo2:OAE_0002004 + 坏死性血管炎 + + + + obo2:OAE_0002004 + necrotizing vasculitis AE + + + + obo2:OAE_0002004 + MedDRA: 10028892 + + + + obo2:OAE_0002005 + Carpal tunnel syndrome AE is a peripheral neuropathy AE that is a median entrapment neuropathy that causes paresthesia, pain, numbness, and other symptoms in the distribution of the median nerve due to its compression at the wrist in the carpal tunnel. + + + + obo2:OAE_0002005 + JX, LW, YH + + + + obo2:OAE_0002005 + median nerve neuropathy AE + + + + obo2:OAE_0002005 + WEB: http://emedicine.medscape.com/article/1141168-clinical#showall + + + + obo2:OAE_0002005 + WEB: http://en.wikipedia.org/wiki/Carpal_tunnel_syndrome + + + + obo2:OAE_0002005 + 腕管综合征 + + + + obo2:OAE_0002005 + carpal tunnel syndrome AE + + + + obo2:OAE_0002005 + MedDRA: 10007697 + + + + obo2:OAE_0002006 + Erythromelalgia AE is a peripheral arterial disease AE that is a rare neurovascular peripheral pain disorder in which blood vessels, usually in the lower extremities or hands, are episodically blocked (frequently on and off daily), then become hyperemic and inflamed. + + + + obo2:OAE_0002006 + JX, LW, YH + + + + obo2:OAE_0002006 + Mitchell's disease AE + + + + obo2:OAE_0002006 + acromelalgia AE + + + + obo2:OAE_0002006 + erythermalgia AE + + + + obo2:OAE_0002006 + red neuralgia AE + + + + obo2:OAE_0002006 + WEB: http://en.wikipedia.org/wiki/Erythromelalgia + + + + obo2:OAE_0002006 + 红斑性肢痛症 + + + + obo2:OAE_0002006 + erythromelalgia AE + + + + obo2:OAE_0002006 + MedDRA: 10015284 + + + + obo2:OAE_0002007 + Raynaud's syndrome AE is a peripheral vascular disorder AE which is a rare disorder that affects the arteries. Arteries are blood vessels that carry blood from your heart to different parts of your body. + + + + obo2:OAE_0002007 + JX, LW, YH + + + + obo2:OAE_0002007 + Raynaud's disease AE + + + + obo2:OAE_0002007 + Raynaud's phenomenon AE + + + + obo2:OAE_0002007 + WEB: http://www.nhlbi.nih.gov/health/health-topics/topics/raynaud/ + + + + obo2:OAE_0002007 + 雷诺综合症 + + + + obo2:OAE_0002007 + Raynaud's syndrome AE + + + + obo2:OAE_0002007 + MedDRA: 10037914 + + + + obo2:OAE_0002008 + Extrapyramidal syndrome AE is a nervous system AE that is drug induced movement disorders which include acute and tardive symptoms. + + + + obo2:OAE_0002008 + JX, LW, YH + + + + obo2:OAE_0002008 + extrapyramidal side effects AE + + + + obo2:OAE_0002008 + vertebral body outside the beam syndrome AE + + + + obo2:OAE_0002008 + WEB: http://en.wikipedia.org/wiki/Extrapyramidal_symptoms + + + + obo2:OAE_0002008 + 椎体外系综合征 + + + + obo2:OAE_0002008 + extrapyramidal syndrome AE + + + + obo2:OAE_0002008 + MedDRA: 10015836 + + + + obo2:OAE_0002009 + Sodium retention AE is a blood sodium abnormal AE that is when the kidneys hold on to more sodium and do not excrete it with the kidneys. This tends to expand the blood volume, which can elevate the blood pressure. + + + + obo2:OAE_0002009 + JX, LW, YH + + + + obo2:OAE_0002009 + WEB: https://answers.yahoo.com/question/index?qid=20100823074826AAcg7WV + + + + obo2:OAE_0002009 + 钠潴留 + + + + obo2:OAE_0002009 + sodium retention AE + + + + obo2:OAE_0002009 + MedDRA: 10041277 + + + + obo2:OAE_0002010 + complex regional pain syndrome AE is a pain AE that results in an uncommon form of chronic pain that usually affects an extremity. + + + + obo2:OAE_0002010 + SJ, YH + + + + obo2:OAE_0002010 + WEB: http://www.mayoclinic.org/diseases-conditions/complex-regional-pain-syndrome/basics/definition/con-20022844 + + + + obo2:OAE_0002010 + Complex regional pain syndrome typically develops after an injury, surgery, stroke or heart attack, but the pain is out of proportion to the severity of the initial injury. + + + + obo2:OAE_0002010 + complex regional pain syndrome AE + + + + obo2:OAE_0002010 + MedDRA ID: 10064332 + + + + obo2:OAE_0002011 + Sciatica AE is a pain AE that is a set of symptoms including pain caused by general compression or irritation of one of five spinal nerve roots of each sciatic nerve or by compression or irritation of the left or right or both sciatic nerves. + + + + obo2:OAE_0002011 + JX, LW, YH + + + + obo2:OAE_0002011 + lumbar radiculopathy AE + + + + obo2:OAE_0002011 + sciatic neuralgia AE + + + + obo2:OAE_0002011 + sciatic neuritis AE + + + + obo2:OAE_0002011 + WEB: http://en.wikipedia.org/wiki/Sciatica + + + + obo2:OAE_0002011 + 坐骨神经痛 + + + + obo2:OAE_0002011 + sciatica AE + + + + obo2:OAE_0002011 + MedDRA: 10039674 + + + + obo2:OAE_0002012 + Joint stiffness AE is a joint disorder AE that may be either the symptom of pain on moving a joint, the symptom of loss of range of motion or the physical sign of reduced range of motion. + + + + obo2:OAE_0002012 + JX, LW, YH + + + + obo2:OAE_0002012 + WEB: http://en.wikipedia.org/wiki/Joint_stiffness + + + + obo2:OAE_0002012 + 关节僵硬 + + + + obo2:OAE_0002012 + joint stiffness AE + + + + obo2:OAE_0002012 + MedDRA: 10023230 + + + + obo2:OAE_0002013 + Breast engorgement AE is a reproductive system AE that occurs in the mammary glands due to expansion and pressure exerted by the synthesis and storage of breast milk. + + + + obo2:OAE_0002013 + JX, LW, YH + + + + obo2:OAE_0002013 + WEB: http://en.wikipedia.org/wiki/Breast_engorgement + + + + obo2:OAE_0002013 + 乳房充盈 + + + + obo2:OAE_0002013 + breast engorgement AE + + + + obo2:OAE_0002013 + MedDRA: 10006240 + + + + obo2:OAE_0002014 + Nervous tension AE is a behavior and neurological AE that might be said to be a physical expression of how people deal with negatively experienced emotion. + + + + obo2:OAE_0002014 + JX, LW, YH + + + + obo2:OAE_0002014 + WEB: http://helpmetosleep.org/featured-articles/how-to-relieve-nervous-tension/ + + + + obo2:OAE_0002014 + 神经紧张 + + + + obo2:OAE_0002014 + nervous tension AE + + + + obo2:OAE_0002014 + MedDRA: 10029214 + + + + obo2:OAE_0002015 + Nervousness AE is a behavior and neurological AE that shows an uneasy psychological state which including anxiety, neurosis, neuroticism, and worry, etc. + + + + obo2:OAE_0002015 + JX, LW, YH + + + + obo2:OAE_0002015 + WEB: http://en.wikipedia.org/wiki/Nervousness + + + + obo2:OAE_0002015 + 神经过敏 + + + + obo2:OAE_0002015 + nervousness AE + + + + obo2:OAE_0002015 + MedDRA: 10029216 + + + + obo2:OAE_0002016 + Osteoarthritis AE is an arthritis AE that is a group of mechanical abnormalities involving degradation of joints, including articular cartilage and subchondral bone. Osteoarthritis is not an inflammatory disease even-though the name suggest one. Symptoms may include joint pain, tenderness, stiffness, locking, and sometimes an effusion. + + + + obo2:OAE_0002016 + JX, LW, YH + + + + obo2:OAE_0002016 + degenerative arthritis AE + + + + obo2:OAE_0002016 + degenerative joint disease AE + + + + obo2:OAE_0002016 + osteoarthrosis AE + + + + obo2:OAE_0002016 + WEB: http://en.wikipedia.org/wiki/Osteoarthritis + + + + obo2:OAE_0002016 + 骨关节炎 + + + + obo2:OAE_0002016 + osteoarthritis AE + + + + obo2:OAE_0002016 + MedDRA: 10031161 + + + + obo2:OAE_0002017 + Methemoglobinemia AE is a red blood cell profile abnormal AE that is a disorder characterized by the presence of a higher than normal level of methemoglobin (metHb, i.e., ferric [Fe3+] rather than ferrous [Fe2+] haemoglobin) in the blood. It's a form of hemoglobin that contains ferric [Fe3+] iron and has a decreased ability to bind oxygen. + + + + obo2:OAE_0002017 + JX, LW, YH + + + + obo2:OAE_0002017 + methaemoglobinaemia AE + + + + obo2:OAE_0002017 + WEB: http://en.wikipedia.org/wiki/Methemoglobinemia + + + + obo2:OAE_0002017 + 高铁血红蛋白症 + + + + obo2:OAE_0002017 + methemoglobinemia AE + + + + obo2:OAE_0002017 + MedDRA: 10027506 + + + + obo2:OAE_0002018 + Hemiageusia AE is a ageusia AE that shows loss of taste from one side of the tongue. + + + + obo2:OAE_0002018 + JX, LW, YH + + + + obo2:OAE_0002018 + hemiageustia AE + + + + obo2:OAE_0002018 + hemigeusia AE + + + + obo2:OAE_0002018 + WEB: http://www.medilexicon.com/medicaldictionary.php?t=39885 + + + + obo2:OAE_0002018 + 偏侧味觉缺失 + + + + obo2:OAE_0002018 + hemiageusia AE + + + + obo2:OAE_0002019 + Skin swelling AE is an edema AE that has an outcome of the occurrence of swelling which is located on the skin. + + + + obo2:OAE_0002019 + JX, LW, YH + + + + obo2:OAE_0002019 + WEB: http://www.rightdiagnosis.com/sym/skin_swelling.htm + + + + obo2:OAE_0002019 + 胕肿 + + + + obo2:OAE_0002019 + skin swelling AE + + + + obo2:OAE_0002019 + MedDRA: 10053262 + + + + obo2:OAE_0002020 + Fibrosing alveolitis AE is a lung inflammation AE that is a disease of unknown cause mainly involving the gas-exchanging portions of the lungs. It may occur in isolation and be called cryptogenic or idiopathic, in which case the clinical manifestations are mainly respiratory, or it may be associated with other disorders, such as rheumatoid arthritis. + + + + obo2:OAE_0002020 + JX, LW, YH + + + + obo2:OAE_0002020 + WEB: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1818528/ + + + + obo2:OAE_0002020 + 纤维化肺泡炎 + + + + obo2:OAE_0002020 + fibrosing alveolitis AE + + + + obo2:OAE_0002020 + MedDRA: 10016640 + + + + obo2:OAE_0002021 + Hypochloremic alkalosis AE is a blood chloride decreased AE that is a medical condition in which the patient's body has abnormally low levels of chloride. This condition usually results from an extremely high loss of chloride, rather than a low intake of it. + + + + obo2:OAE_0002021 + JX, LW, YH + + + + obo2:OAE_0002021 + WEB: http://www.wisegeek.com/what-is-hypochloremic-alkalosis.htm + + + + obo2:OAE_0002021 + 低氯性碱中毒 + + + + obo2:OAE_0002021 + hypochloremic alkalosis AE + + + + obo2:OAE_0002021 + MedDRA: 10020958 + + + + obo2:OAE_0002022 + Erythema annulare centrifugum AE is an erythema AE that is a descriptive term for a skin lesion. The lesions form consists of redness (erythema) in a ring form (anulare) that spreads from the center (centrifugum). + + + + obo2:OAE_0002022 + JX, LW, YH + + + + obo2:OAE_0002022 + MedDRA: 10015154 + + + + obo2:OAE_0002022 + deep gyrate erythema AE + + + + obo2:OAE_0002022 + erythema perstans AE + + + + obo2:OAE_0002022 + palpable migrating erythema AE + + + + obo2:OAE_0002022 + superficial gyrate erythema AE + + + + obo2:OAE_0002022 + WEB: http://en.wikipedia.org/wiki/Erythema_annulare_centrifugum + + + + obo2:OAE_0002022 + 离心性环形红斑 + + + + obo2:OAE_0002022 + erythema annulare centrifugum AE + + + + obo2:OAE_0002023 + Irritation is a behavior and neurological AE that is a state of inflammation or painful reaction to allergy or cell-lining damage. + + + + obo2:OAE_0002023 + JX, LW, YH + + + + obo2:OAE_0002023 + WEB: http://en.wikipedia.org/wiki/Irritation + + + + obo2:OAE_0002023 + 刺激 + + + + obo2:OAE_0002023 + irritation AE + + + + obo2:OAE_0002023 + MedDRA: 10029216 + + + + obo2:OAE_0002024 + Neuroticism AE is a mental disorder AE that is a fundamental personality trait in the study of psychology characterized by anxiety, fear, moodiness, worry, envy, frustration, jealousy, and loneliness. + + + + obo2:OAE_0002024 + JX, LW, YH + + + + obo2:OAE_0002024 + WEB: http://en.wikipedia.org/wiki/Neuroticism + + + + obo2:OAE_0002024 + 神经质 + + + + obo2:OAE_0002024 + neuroticism AE + + + + obo2:OAE_0002025 + Hyperirritability AE is a behavior and neurological AE that shows abnormally great or uninhibited response to stimuli. + + + + obo2:OAE_0002025 + This term appears to be a synonym to the 'irritability AE'. + + + + obo2:OAE_0002025 + JX, LW, YH + + + + obo2:OAE_0002025 + WEB: http://www.merriam-webster.com/medical/hyperirritability; http://en.wikipedia.org/wiki/Irritability + + + + obo2:OAE_0002025 + 过激 + + + + obo2:OAE_0002025 + hyperirritability AE + + + + obo2:OAE_0002026 + Rhinostenosis AE is a respiratory system AE that shows narrowing or obliteration of the nasal airway by scar formation + + + + obo2:OAE_0002026 + JX, LW, YH + + + + obo2:OAE_0002026 + WEB: http://www.drugs.com/dict/rhinostenosis.html + + + + obo2:OAE_0002026 + 鼻道狭窄 + + + + obo2:OAE_0002026 + rhinostenosis AE + + + + obo2:OAE_0002027 + Sino-auricular heart-block AE is a conduction system disorder AE that refers to a rare heart condition caused by abnormalities in the heart's electrical system rather than arterial disease. + + + + obo2:OAE_0002027 + JX, LW, YH + + + + obo2:OAE_0002027 + WEB: http://www.rightdiagnosis.com/s/sino_auricular_heart_block/intro.htm + + + + obo2:OAE_0002027 + 窦房传导阻滞 + + + + obo2:OAE_0002027 + sino-auricular heart-block AE + + + + obo2:OAE_0002028 + Anisosphygmia AE is a cardiovascular disorder AE that shows difference in volume, force, or time of the pulse in the corresponding arteries on two sides of the body, the two radials, or femorals. + + + + obo2:OAE_0002028 + JX, LW, YH + + + + obo2:OAE_0002028 + WEB: http://www.medilexicon.com/medicaldictionary.php?t=4352 + + + + obo2:OAE_0002028 + 脉搏不规则 + + + + obo2:OAE_0002028 + anisosphygmia AE + + + + obo2:OAE_0002029 + Rubefaction AE is a skin AE that refers to erythema of the skin caused by local application of a counterirritant. + + + + obo2:OAE_0002029 + JX, LW, YH + + + + obo2:OAE_0002029 + WEB: http://www.medilexicon.com/medicaldictionary.php?t=79112 + + + + obo2:OAE_0002029 + 发红 + + + + obo2:OAE_0002029 + rubefaction AE + + + + obo2:OAE_0002030 + Myodystony AE is an abnormal muscle tone AE that refers to a condition of slow relaxation, interrupted by a succession of slight contractions, following electrical stimulation of a muscle. + + + + obo2:OAE_0002030 + JX, LW, YH + + + + obo2:OAE_0002030 + WEB: http://www.drugs.com/dict/myodystony.html + + + + obo2:OAE_0002030 + 肌张力不全 + + + + obo2:OAE_0002030 + myodystony AE + + + + obo2:OAE_0002031 + Allotriosmia is a behavior and neurological AE that shows incorrect recognition of odors. + + + + obo2:OAE_0002031 + JX, LW, YH + + + + obo2:OAE_0002031 + heterosmia AE + + + + obo2:OAE_0002031 + WEB: http://www.medilexicon.com/medicaldictionary.php?t=2401 + + + + obo2:OAE_0002031 + 嗅觉异常 + + + + obo2:OAE_0002031 + allotriosmia AE + + + + obo2:OAE_0002031 + MedDRA: 10029216 + + + + obo2:OAE_0002032 + Pharyngotonsillitis is an inflammation AE that is a medical condition characterized by an inflammation of both the tonsils and the pharynx (located at the back of the throat). It occurs due to viral or bacterial infections. + + + + obo2:OAE_0002032 + JX, LW, YH + + + + obo2:OAE_0002032 + WEB: http://www.persify.com/en/perspectives/medical-conditions-diseases/pharyngotonsillitis-_-951000101807 + + + + obo2:OAE_0002032 + 咽扁桃体炎 + + + + obo2:OAE_0002032 + pharyngotonsillitis AE + + + + obo2:OAE_0002032 + MedDRA: 10049140 + + + + obo2:OAE_0002033 + Hypersensitivity pneumonitis AE is a pneumonia AE that is an inflammation of the alveoli within the lung caused by hypersensitivity to inhaled organic dusts. Sufferers are commonly exposed to the dust by their occupation or hobbies. + + + + obo2:OAE_0002033 + JX, LW, YH + + + + obo2:OAE_0002033 + extrinsic allergic alveolitis AE + + + + obo2:OAE_0002033 + WEB: http://en.wikipedia.org/wiki/Hypersensitivity_pneumonitis + + + + obo2:OAE_0002033 + 过敏性肺炎 + + + + obo2:OAE_0002033 + hypersensitivity pneumonitis AE + + + + obo2:OAE_0002033 + MedDRA: 10015887 + + + + obo2:OAE_0002034 + Stagger AE is a movement disorder AE that shows an unsteady movement of the body in walking or standing, as if one were about to fall. + + + + obo2:OAE_0002034 + JX, LW, YH + + + + obo2:OAE_0002034 + WEB: http://en.wiktionary.org/wiki/stagger + + + + obo2:OAE_0002034 + 蹒跚 + + + + obo2:OAE_0002034 + stagger AE + + + + obo2:OAE_0002035 + Myocardial anoxia AE is a hypoxia AE that shows a reduced concentration of O2 in the myocardium. + + + + obo2:OAE_0002035 + JX, LW, YH + + + + obo2:OAE_0002035 + 心肌缺氧 + + + + obo2:OAE_0002035 + myocardial anoxia AE + + + + obo2:OAE_0002036 + Biliary colic AE is a pain AE that is the term used to describe a type of pain related to the gallbladder that occurs when a gallstone transiently obstructs the cystic duct and the gallbladder contracts. + + + + obo2:OAE_0002036 + JX, LW, YH + + + + obo2:OAE_0002036 + cholecystalgia AE + + + + obo2:OAE_0002036 + WEB: http://en.wikipedia.org/wiki/Biliary_colic + + + + obo2:OAE_0002036 + 胆绞痛 + + + + obo2:OAE_0002036 + biliary colic AE + + + + obo2:OAE_0002036 + MedDRA: 10004663 + + + + obo2:OAE_0002037 + Hyperemia AE is a cardiovascular disorder AE that is the increase of blood flow to different tissues in the body. It can have medical implications, but is also a regulatory response, allowing change in blood supply to different tissues through vasodilation. + + + + obo2:OAE_0002037 + JX, LW, YH + + + + obo2:OAE_0002037 + hyperaemia AE + + + + obo2:OAE_0002037 + WEB: http://en.wikipedia.org/wiki/Hyperaemia + + + + obo2:OAE_0002037 + 充血 + + + + obo2:OAE_0002037 + hyperemia AE + + + + obo2:OAE_0002038 + a sensory capability AE that has an outcome increased sensitivity to pain in a patient + + + + obo2:OAE_0002038 + RR + + + + obo2:OAE_0002038 + WEB: http://www.oxforddictionaries.com/us/definition/american_english/tenderness + + + + obo2:OAE_0002038 + tenderness AE + + + + obo2:OAE_0002038 + MedDRA: 10043224 + + + + obo2:OAE_0002039 + a skin AE with the outcome of induration, which is an increase in the fibrous elements in tissue commonly associated with inflammation and marked by loss of elasticity and pliability or a hardened mass or formation + + + + obo2:OAE_0002039 + RR + + + + obo2:OAE_0002039 + WEB: http://www.merriam-webster.com/medical/induration + + + + obo2:OAE_0002039 + induration AE + + + + obo2:OAE_0002039 + MedDRA: 10060708 + + + + obo2:OAE_0002040 + an eye AE which has an outcome of a foreign body sensation in the eye, or the sensation that something is in or scratching the eye + + + + obo2:OAE_0002040 + RR + + + + obo2:OAE_0002040 + WEB: http://www.richmondeye.com/eyehealth_foreignbody/ + + + + obo2:OAE_0002040 + foreign body sensation in eyes AE + + + + obo2:OAE_0002040 + MedDRA: 10051116 + + + + obo2:OAE_0002041 + an injection-site AE that displays injection-site cellulitis, or red, hot, swollen, tender, or painful skin at the site of injection + + + + obo2:OAE_0002041 + RR + + + + obo2:OAE_0002041 + WEB: http://www.nhs.uk/Conditions/Cellulitis/Pages/Symptoms.aspx + + + + obo2:OAE_0002041 + injection site cellulitis AE + + + + obo2:OAE_0002041 + MedDRA: 10050057 + + + + obo2:OAE_0002042 + a sensory capability AE that has an outcome of peripheral coldness, or coldness of extremeties + + + + obo2:OAE_0002042 + RR + + + + obo2:OAE_0002042 + WEB: http://www.patient.co.uk/leaflets/peripheral_coldness.htm + + + + obo2:OAE_0002042 + peripheral coldness AE + + + + obo2:OAE_0002042 + MedDRA: 10034568 + + + + obo2:OAE_0002043 + a hypoaesthesia AE that has an outcome of a decrease in facial sensitivity + + + + obo2:OAE_0002043 + RR + + + + obo2:OAE_0002043 + hypoaesthesia facial AE + + + + obo2:OAE_0002043 + hypoesthesia facial AE + + + + obo2:OAE_0002043 + WEB: http://www.webster-dictionary.org/definition/hypoesthesia + + + + obo2:OAE_0002043 + hypoesthesia facial AE + + + + obo2:OAE_0002043 + MedDRA: 10065312 + + + + obo2:OAE_0002044 + a sleep disorder AE that shows poor quality sleep + + + + obo2:OAE_0002044 + RR + + + + obo2:OAE_0002044 + poor quality sleep AE + + + + obo2:OAE_0002044 + MedDRA: 10062519 + + + + obo2:OAE_0002045 + a rash AE characterized by the formation of vesicles + + + + obo2:OAE_0002045 + RR + + + + obo2:OAE_0002045 + WEB: http://www.merriam-webster.com/medical/vesicular + + + + obo2:OAE_0002045 + rash vesicular AE + + + + obo2:OAE_0002045 + MedDRA: 10037898 + + + + obo2:OAE_0002046 + a discomfort AE that occurs at a limb + + + + obo2:OAE_0002046 + RR + + + + obo2:OAE_0002046 + limb discomfort AE + + + + obo2:OAE_0002046 + MedDRA: 10061224 + + + + obo2:OAE_0002047 + an eye disorder AE which has an outcome of discoloration of the sclera, or the whites of the eyes + + + + obo2:OAE_0002047 + RR + + + + obo2:OAE_0002047 + scleral discolouration AE + + + + obo2:OAE_0002047 + scleral discoloration AE + + + + obo2:OAE_0002047 + MedDRA: 10039696 + + + + obo2:OAE_0002048 + an injection-site AE that displays urticaria, or hives at the injection site + + + + obo2:OAE_0002048 + RR + + + + obo2:OAE_0002048 + WEB: http://www.uptodate.com/contents/hives-urticaria-beyond-the-basics + + + + obo2:OAE_0002048 + injection site urticaria AE + + + + obo2:OAE_0002048 + MedDRA: 10022107 + + + + obo2:OAE_0002049 + a behavior and neurological AE that results in dysstasia, or difficulty standing + + + + obo2:OAE_0002049 + RR + + + + obo2:OAE_0002049 + WEB: http://www.medilexicon.com/medicaldictionary.php?t=27458 + + + + obo2:OAE_0002049 + dysstasia AE + + + + obo2:OAE_0002049 + MedDRA: 10050256 + + + + obo2:OAE_0002050 + a sensory capability AE that has an outcome of hyperaesthesia, meaning unusual or pathological sensitivity of the skin or of a particular sense + + + + obo2:OAE_0002050 + RR + + + + obo2:OAE_0002050 + hyperaesthesia AE + + + + obo2:OAE_0002050 + WEB: http://www.merriam-webster.com/dictionary/hyperesthesia + + + + obo2:OAE_0002050 + hyperesthesia AE + + + + obo2:OAE_0002050 + MedDRA: 10020568 + + + + obo2:OAE_0002051 + a nuclear magnetic resonance imaging result abnormal AE that has an outcome of abnormal nuclear magnetic resonance imaging test of the spinal cord + + + + obo2:OAE_0002051 + RR + + + + obo2:OAE_0002051 + nuclear magnetic resonance imaging spinal cord abnormal AE + + + + obo2:OAE_0002051 + MedDRA: 10069585 + + + + obo2:OAE_0002052 + an eye disorder AE which has an outcome of ocular icterus, or jaundice of the eye + + + + obo2:OAE_0002052 + RR + + + + obo2:OAE_0002052 + WEB: http://www.merriam-webster.com/dictionary/icterus + + + + obo2:OAE_0002052 + ocular icterus AE + + + + obo2:OAE_0002052 + MedDRA: 10058117 + + + + obo2:OAE_0002053 + An edema AE that occurs in the mouth + + + + obo2:OAE_0002053 + RR + + + + obo2:OAE_0002053 + oedema mouth AE + + + + obo2:OAE_0002053 + edema mouth AE + + + + obo2:OAE_0002053 + MedDRA: 10030110 + + + + obo2:OAE_0002054 + a respiratory system AE which has an outcome of painful respiration, an unpleasant sensation ranging from mild discomfort to unbearable agony while breathing + + + + obo2:OAE_0002054 + RR + + + + obo2:OAE_0002054 + WEB: http://www.healthline.com/health/painful-respiration + + + + obo2:OAE_0002054 + painful respiration AE + + + + obo2:OAE_0002054 + MedDRA: 10033517 + + + + obo2:OAE_0002055 + a neurological, special senses and psychiatric investigation result abnormal AE that results in an abnormal ophthalmological examination + + + + obo2:OAE_0002055 + RR + + + + obo2:OAE_0002055 + ophthalmological examination abnormal AE + + + + obo2:OAE_0002055 + MedDRA: 10056836 + + + + obo2:OAE_0002056 + an optic neuropahty AE which shows an infarction of the optic disk which presents as painless vision loss + + + + obo2:OAE_0002056 + RR + + + + obo2:OAE_0002056 + optic ischemic neuropathy AE + + + + obo2:OAE_0002056 + WEB: http://www.geteyesmart.org/eyesmart/diseases/ischemic-optic-neuropathy/ + + + + obo2:OAE_0002056 + WEB: http://www.merckmanuals.com/professional/eye_disorders/optic_nerve_disorders/ischemic_optic_neuropathy.html + + + + obo2:OAE_0002056 + ischemic optic neuropathy AE + + + + obo2:OAE_0002056 + MedDRA: 10030924 + + + + obo2:OAE_0002057 + a bacterial infection AE with an outcome of Lyme disease, a tick-bourne illness cause by the bacterium B. burgdorferi that causes dermatologic, rheumatologic, neurologic, and cardiac abnormalities + + + + obo2:OAE_0002057 + RR + + + + obo2:OAE_0002057 + WEB: http://wwwn.cdc.gov/nndss/script/casedef.aspx?CondYrID=752&DatePub=1/1/2011 + + + + obo2:OAE_0002057 + lyme disease AE + + + + obo2:OAE_0002057 + MedDRA: 10025169 + + + + obo2:OAE_0002058 + a pain AE that has an outcome of lymph node pain + + + + obo2:OAE_0002058 + RR + + + + obo2:OAE_0002058 + lymph node pain AE + + + + obo2:OAE_0002058 + MedDRA: 10025182 + + + + obo2:OAE_0002059 + RR + + + + obo2:OAE_0002059 + a movement disorder AE that has an outcome of loss of control of patient's legs + + + + obo2:OAE_0002059 + loss of control of legs AE + + + + obo2:OAE_0002059 + MedDRA: 10024860 + + + + obo2:OAE_0002060 + a vascular disorder AE that has an outcome of levedo reticularis, a condition of the peripheral blood vessels characterized by reddish blue mottling of the skin especially of the extremeties usually upon exposure to cold + + + + obo2:OAE_0002060 + RR + + + + obo2:OAE_0002060 + WEB: http://www.merriam-webster.com/medical/livedo%20reticularis + + + + obo2:OAE_0002060 + livedo reticularis AE + + + + obo2:OAE_0002060 + MedDRA: 10024648 + + + + obo2:OAE_0002061 + a muscle adverse event AE that has an outcome of muscle strain, which happens when a muscle is stretched too much and tears + + + + obo2:OAE_0002061 + RR + + + + obo2:OAE_0002061 + pulled muscle AE + + + + obo2:OAE_0002061 + WEB: http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001109/ + + + + obo2:OAE_0002061 + muscle strain AE + + + + obo2:OAE_0002061 + MedDRA: 10050031 + + + + obo2:OAE_0002062 + a muscle adverse event AE that has an outcome of muscle tightness, which is a tense feeling in muscles + + + + obo2:OAE_0002062 + RR + + + + obo2:OAE_0002062 + WEB: http://www.chirocommunity.com/muscletightness.htm + + + + obo2:OAE_0002062 + muscle tightness AE + + + + obo2:OAE_0002062 + MedDRA: 10049816 + + + + obo2:OAE_0002063 + a muscle adverse event AE that has an outcome of muscle rigidity, a state of continuous firm, tense muscles with marked resistance to passive movement + + + + obo2:OAE_0002063 + RR + + + + obo2:OAE_0002063 + WEB: http://www.healthline.com/symptom/muscle-rigidity + + + + obo2:OAE_0002063 + muscle rigidity AE + + + + obo2:OAE_0002063 + MedDRA: 10028330 + + + + obo2:OAE_0002064 + Miller Fisher syndrome is a rare, acquired nerve disease that is considered to be a variant of Guillain-Barre syndrome. It is characterized by abnormal muscle coordination, paralysis of the eye muscles, and absence of the tendon reflexes + + + + obo2:OAE_0002064 + RR + + + + obo2:OAE_0002064 + WEB: http://www.ninds.nih.gov/disorders/miller_fisher/miller_fisher.htm + + + + obo2:OAE_0002064 + Miller Fisher syndrome AE + + + + obo2:OAE_0002064 + MedDRA: 10049567 + + + + obo2:OAE_0002065 + a hypersensitivity AE which has an outcome of type III immune complex mediated reaction, a type of hypersensitivity reaction in which circulating antigen-antibody immune complexes are deposited in post-capillary venules, with subsequent complement fixation + + + + obo2:OAE_0002065 + RR + + + + obo2:OAE_0002065 + WEB: http://emedicine.medscape.com/article/136217-overview + + + + obo2:OAE_0002065 + type III immune complex mediated reaction AE + + + + obo2:OAE_0002065 + MedDRA: 10053614 + + + + obo2:OAE_0002066 + a tonsilitis AE with the outcome of tonsilar hypertrophy, or enlargement of the tonsils + + + + obo2:OAE_0002066 + RR + + + + obo2:OAE_0002066 + WEB: http://www.cchi.com.hk/symposia/s3_ear_1.htm + + + + obo2:OAE_0002066 + tonsilar hypertrophy AE + + + + obo2:OAE_0002066 + MedDRA: 10044003 + + + + obo2:OAE_0002067 + a sensory capability AE that results in temperature intolerance + + + + obo2:OAE_0002067 + RR + + + + obo2:OAE_0002067 + temperature intolerance AE + + + + obo2:OAE_0002067 + MedDRA: 10057040 + + + + obo2:OAE_0002068 + a sensory capability AE that results in the patient being unresponsive to stimuli + + + + obo2:OAE_0002068 + RR + + + + obo2:OAE_0002068 + unresponsive to stimuli AE + + + + obo2:OAE_0002068 + MedDRA: 10045555 + + + + obo2:OAE_0002069 + a respiratory system AE that shows discolored sputum + + + + obo2:OAE_0002069 + RR + + + + obo2:OAE_0002069 + sputum discolored AE + + + + obo2:OAE_0002069 + MedDRA: 10041806 + + + + obo2:OAE_0002070 + a musculoskeletal system AE that has an outcome of spinal column stenosis, or narrowing of spaces in the spine that results in pressure on the spinal cord and/or nerve roots + + + + obo2:OAE_0002070 + RR + + + + obo2:OAE_0002070 + WEB: http://www.niams.nih.gov/Health_Info/Spinal_Stenosis/ + + + + obo2:OAE_0002070 + spinal column stenosis AE + + + + obo2:OAE_0002070 + MedDRA: 10041540 + + + + obo2:OAE_0002071 + a skin AE with the outcome of skin tightness + + + + obo2:OAE_0002071 + RR + + + + obo2:OAE_0002071 + skin tightness AE + + + + obo2:OAE_0002071 + MedDRA: 10050637 + + + + obo2:OAE_0002072 + a pain AE with the outcome of ligament pain + + + + obo2:OAE_0002072 + RR + + + + obo2:OAE_0002072 + ligament pain AE + + + + obo2:OAE_0002072 + MedDRA: 10068790 + + + + obo2:OAE_0002073 + a thrombocytopenic purpura AE with no known cause (idiopathic). Idiopathic thrombocytopenic purpura is a bleeding disorder in which the immune system destroys platelets, which are necesssary for normal blood clotting. Persons with this disorder have too few platelets in the blood. + + + + obo2:OAE_0002073 + RR + + + + obo2:OAE_0002073 + WEB: http://www.nlm.nih.gov/medlineplus/ency/article/000535.htm + + + + obo2:OAE_0002073 + idiopathic thrombocytopenic purpura AE + + + + obo2:OAE_0002073 + MedDRA: 10021245 + + + + obo2:OAE_0002074 + a behavior and neurological AE with an outcome of cerebral palsy, a disorder of movement, muscle tone, or posture that is caused by an insult to the immature, developing brain, most often before birth + + + + obo2:OAE_0002074 + RR + + + + obo2:OAE_0002074 + WEB: http://www.mayoclinic.org/diseases-conditions/cerebral-palsy/basics/definition/con-20030502 + + + + obo2:OAE_0002074 + cerebral palsy AE + + + + obo2:OAE_0002074 + MedDRA: 10008129 + + + + obo2:OAE_0002075 + a neurological AE with the outcome of chronic inflammatory demyelinating polyradiculoneuropathy, a neurological disorder characterized by progressive weakness and impaired sensory function in the legs and arms caused by damage to the myelin sheath of the peripheral nerves + + + + obo2:OAE_0002075 + RR + + + + obo2:OAE_0002075 + WEB: http://www.ninds.nih.gov/disorders/cidp/cidp.htm + + + + obo2:OAE_0002075 + chronic inflammatory demyelinating polyradiculoneuropathy AE + + + + obo2:OAE_0002075 + MedDRA: 10057645 + + + + obo2:OAE_0002076 + an allergy AE which has an outcome of dermititis allergic, an allergic response following contact of an allergen with the skin that is typically marked by an itchy red rash often accompanied by swelling and watery blisters + + + + obo2:OAE_0002076 + RR + + + + obo2:OAE_0002076 + WEB: http://www.merriam-webster.com/dictionary/allergic%20contact%20dermatitis + + + + obo2:OAE_0002076 + dermatitis allergic AE + + + + obo2:OAE_0002076 + MedDRA: 10012434 + + + + obo2:OAE_0002077 + a behavior and neurological AE with an outcome of the patient refusing to eat + + + + obo2:OAE_0002077 + RR + + + + obo2:OAE_0002077 + diet refusal AE + + + + obo2:OAE_0002077 + MedDRA: 10012775 + + + + obo2:OAE_0002078 + an abnormal blood pressure AE that has an outcome of blood pressure fluctuations + + + + obo2:OAE_0002078 + RR + + + + obo2:OAE_0002078 + blood pressure fluctuation AE + + + + obo2:OAE_0002078 + MedDRA: 10005746 + + + + obo2:OAE_0002079 + a digestive system AE which has an outcome of aphagia, which is the loss of the ability to swallow + + + + obo2:OAE_0002079 + RR + + + + obo2:OAE_0002079 + WEB: http://www.merriam-webster.com/medical/aphagia + + + + obo2:OAE_0002079 + aphagia AE + + + + obo2:OAE_0002079 + MedDRA: 10049866 + + + + obo2:OAE_0002080 + a speech disorder AE with an outcome of aphonia, or loss of voice and of all but whispered speech + + + + obo2:OAE_0002080 + RR + + + + obo2:OAE_0002080 + WEB: http://www.merriam-webster.com/dictionary/aphonia + + + + obo2:OAE_0002080 + aphonia AE + + + + obo2:OAE_0002080 + MedDRA: 10002953 + + + + obo2:OAE_0002082 + an abdominal pain AE that is observed in lower stomach + + + + obo2:OAE_0002082 + RR + + + + obo2:OAE_0002082 + WEB: http://www.mayoclinic.org/symptoms/abdominal-pain/basics/definition/sym-20050728 + + + + obo2:OAE_0002082 + 'abdominal pain lower AE' + + + + obo2:OAE_0002082 + MedDRA: 10000084 + + + + obo2:OAE_0002083 + an eye AE with an outcome of an abnormal sensation in the eye + + + + obo2:OAE_0002083 + RR + + + + obo2:OAE_0002083 + abnormal sensation in eye AE + + + + obo2:OAE_0002083 + MedDRA: 10000173 + + + + obo2:OAE_0002084 + a behavior and neurological AE which has an outcome of impaired driving ability + + + + obo2:OAE_0002084 + RR + + + + obo2:OAE_0002084 + impaired driving ability AE + + + + obo2:OAE_0002084 + MedDRA: 10049564 + + + + obo2:OAE_0002085 + a respiratory system AE that has an outcome of increased bronchial secretion, or an increase in the substance produced in the bronchial tree, which includes mucus, protein salts, plasma fluid, and proteins + + + + obo2:OAE_0002085 + RR + + + + obo2:OAE_0002085 + WEB: http://medical-dictionary.thefreedictionary.com/bronchial+secretion + + + + obo2:OAE_0002085 + increased bronchial secretion AE + + + + obo2:OAE_0002085 + MedDRA: 10062530 + + + + obo2:OAE_0002086 + an injection-site AE that displays injection site streaking, a red pattern on the skin localized to the injection site + + + + obo2:OAE_0002086 + RR + + + + obo2:OAE_0002086 + WEB: http://www.bannerhealth.com/incfiles/housecalls/peds/FeverInfectionsCrying/ImmunizationReactions.htm + + + + obo2:OAE_0002086 + injection site streaking AE + + + + obo2:OAE_0002086 + MedDRA: 10066778 + + + + obo2:OAE_0002087 + an injection-site AE that displays injection site streaking, which are small, fluid-filled blisters localized to the injection site + + + + obo2:OAE_0002087 + RR + + + + obo2:OAE_0002087 + WEB: http://www.nlm.nih.gov/medlineplus/ency/article/003939.htm + + + + obo2:OAE_0002087 + injection site vesicles AE + + + + obo2:OAE_0002087 + MedDRA: 10022111 + + + + obo2:OAE_0002088 + a lab test abnormal AE that has an outcome of an increased international normalized ratio, indicating an individual is more prone to bleeding + + + + obo2:OAE_0002088 + RR + + + + obo2:OAE_0002088 + INR increased AE + + + + obo2:OAE_0002088 + WEB: http://circ.ahajournals.org/content/126/5/e52.full + + + + obo2:OAE_0002088 + international normalized ratio increased AE + + + + obo2:OAE_0002088 + MedDRA: 10022595 + + + + obo2:OAE_0002089 + a sleep disorder AE with the outcome of irregular sleep phase, which is an abnormality in the timing of sleep + + + + obo2:OAE_0002089 + RR + + + + obo2:OAE_0002089 + WEB: http://www.mayoclinic.org/diseases-conditions/delayed-sleep-phase/basics/definition/con-20035242 + + + + obo2:OAE_0002089 + irregular sleep phase AE + + + + obo2:OAE_0002089 + MedDRA: 10022995 + + + + obo2:OAE_0002090 + an injection-site AE that displays injection site anesthesia, or numbness at the injection site + + + + obo2:OAE_0002090 + RR + + + + obo2:OAE_0002090 + injection site anesthesia AE + + + + obo2:OAE_0002090 + MedDRA: 10022047 + + + + obo2:OAE_0002091 + an injection-site AE that displays an injection site infection, or a disease caused by microorganisms originating at the injection site + + + + obo2:OAE_0002091 + RR + + + + obo2:OAE_0002091 + WEB: http://www.merriam-webster.com/dictionary/infection + + + + obo2:OAE_0002091 + injection site infection AE + + + + obo2:OAE_0002091 + MedDRA: 10022076 + + + + obo2:OAE_0002092 + a behavior and neurological AE which has an outcome of decreased grip strength, or a reduction in the force applied by the hand to pull on or suspend from objects + + + + obo2:OAE_0002092 + RR + + + + obo2:OAE_0002092 + WEB: http://www.krepublishers.com/02-Journals/JLS/JLS-01-0-000-09-Web/JLS-01-1-000-09-Abst-PDF/JLS-01-01-057-09-020-Koley-S/JLS-01-01-057-09-020-Koley-S-Tt.pdf + + + + obo2:OAE_0002092 + grip strength decreased AE + + + + obo2:OAE_0002092 + MedDRA: 10062556 + + + + obo2:OAE_0002093 + an eye AE with the outcome of eyelid margin crusting + + + + obo2:OAE_0002093 + RR + + + + obo2:OAE_0002093 + eyelid margin crusting AE + + + + obo2:OAE_0002093 + MedDRA: 10052132 + + + + obo2:OAE_0002094 + an ear AE with the outcome of ear discomfort, an uncomfortable or painful feeling in the ear + + + + obo2:OAE_0002094 + RR + + + + obo2:OAE_0002094 + WEB: http://www.merriam-webster.com/dictionary/discomfort + + + + obo2:OAE_0002094 + ear discomfort AE + + + + obo2:OAE_0002094 + MedDRA: 10052137 + + + + obo2:OAE_0002095 + an abnormal defecation AE that has an outcome of fecal incontinence, the accidental passing of solid or liquid stool or mucus from the rectum + + + + obo2:OAE_0002095 + RR + + + + obo2:OAE_0002095 + WEB: http://digestive.niddk.nih.gov/ddiseases/pubs/fecalincontinence/#what + + + + obo2:OAE_0002095 + fecal incontinence AE + + + + obo2:OAE_0002095 + MedDRA: 10016092 + + + + obo2:OAE_0002096 + a behavior and neurological AE that has an outcome of fear, which is to be afraid and/or worried + + + + obo2:OAE_0002096 + RR + + + + obo2:OAE_0002096 + WEB: http://www.merriam-webster.com/dictionary/fear + + + + obo2:OAE_0002096 + fear AE + + + + obo2:OAE_0002096 + MedDRA: 10016275 + + + + obo2:OAE_0002097 + a pain AE that has an outcome of pain in gums + + + + obo2:OAE_0002097 + RR + + + + obo2:OAE_0002097 + WEB: http://www.merriam-webster.com/dictionary/gingival + + + + obo2:OAE_0002097 + gingival pain AE + + + + obo2:OAE_0002097 + MedDRA: 10018286 + + + + obo2:OAE_0002098 + a tongue disorder with the outcome of glossitis, a condition in which the tongue is swollen and changes color, which may make the tongue appear smooth + + + + obo2:OAE_0002098 + RR + + + + obo2:OAE_0002098 + WEB: http://www.nlm.nih.gov/medlineplus/ency/article/001053.htm + + + + obo2:OAE_0002098 + glossitis AE + + + + obo2:OAE_0002098 + MedDRA: 10018386 + + + + obo2:OAE_0002099 + an injury AE which has an outcome of muscle injury + + + + obo2:OAE_0002099 + RR + + + + obo2:OAE_0002099 + muscle injury AE + + + + obo2:OAE_0002099 + MedDRA: 10028314 + + + + obo2:OAE_0002100 + a sensory capability AE that has an outcome of sensory disturbance + + + + obo2:OAE_0002100 + RR + + + + obo2:OAE_0002100 + sensory disturbance AE + + + + obo2:OAE_0002100 + MedDRA: 10040026 + + + + obo2:OAE_0002101 + an edema AE with an outcome of tracheal edema, which is the swelling of the airway between the throat and the lungs + + + + obo2:OAE_0002101 + RR + + + + obo2:OAE_0002101 + WEB: http://firstaidcalgary.ca/causes-of-tracheal-edema/ + + + + obo2:OAE_0002101 + tracheal edema AE + + + + obo2:OAE_0002101 + MedDRA: 10044296 + + + + obo2:OAE_0002102 + Allergic eruption AE is a skin AE that is most drug-induced cutaneous reactions, especially found in younger adults. Sometimes also be diagnosed with eczema. + + + + obo2:OAE_0002102 + This term appears to be a synonym to the 'eczema AE'. + + + + obo2:OAE_0002102 + JX, LW, YH + + + + obo2:OAE_0002102 + 过敏性皮疹 + + + + obo2:OAE_0002102 + allergic eruption AE + + + + obo2:OAE_0002103 + Erythrodermia AE is a skin AE that is an inflammatory skin disease with erythema and scaling that affects nearly the entire cutaneous surface. + + + + obo2:OAE_0002103 + JX, LW, YH + + + + obo2:OAE_0002103 + dermatitis exfoliativa AE + + + + obo2:OAE_0002103 + exfoliative dermatitis AE + + + + obo2:OAE_0002103 + red man syndrome AE + + + + obo2:OAE_0002103 + WEB: http://en.wikipedia.org/wiki/Erythroderma + + + + obo2:OAE_0002103 + 红皮病 + + + + obo2:OAE_0002103 + erythrodermia AE + + + + obo2:OAE_0002103 + MedDRA: 10037165 + + + + obo2:OAE_0002104 + Mycotic dermatitis is a dermatitis AE that is a inflammation of skin which induced by mycetes. + + + + obo2:OAE_0002104 + JX, LW, YH + + + + obo2:OAE_0002104 + 真菌性皮炎 + + + + obo2:OAE_0002104 + mycotic dermatitis AE + + + + obo2:OAE_0002105 + Peritendinitis symptom AE is an inflammation AE that has an outcome of inflammation of the synovial lining of a tendon sheath. Causes include trauma, tendon stress, bacterial disease (gonorrhea, tuberculosis), rheumatic disease, and gout. Common sites are the hand, wrist, shoulder capsule, hip capsule, hamstring muscles, and Achilles tendon. The tendon sheaths become inflamed and painful, and accumulate fluid. Joint mobility is usually reduced. + + + + obo2:OAE_0002105 + JX, LW, YH + + + + obo2:OAE_0002105 + 腱鞘炎样症状 + + + + obo2:OAE_0002105 + peritendinitis symptom AE + + + + obo2:OAE_0002106 + Orthostatic hypotension AE is a hypotension AE that is a form of hypotension in which a person's blood pressure falls when suddenly standing up or stretching. In medical terms, it is defined as a fall in systolic blood pressure of at least 20 mm Hg or diastolic blood pressure of at least 10 mm Hg when a person assumes a standing position. + + + + obo2:OAE_0002106 + JX, LW, YH + + + + obo2:OAE_0002106 + orthostasis AE + + + + obo2:OAE_0002106 + postural hypotension AE + + + + obo2:OAE_0002106 + WEB: http://en.wikipedia.org/wiki/Orthostatic_hypotension + + + + obo2:OAE_0002106 + 直立性低血压 + + + + obo2:OAE_0002106 + orthostatic hypotension AE + + + + obo2:OAE_0002106 + MedDRA: 10031127 + + + + obo2:OAE_0002107 + JX, LW, YH + + + + obo2:OAE_0002107 + chromatopsia AE + + + + obo2:OAE_0002107 + WEB: http://ghr.nlm.nih.gov/condition/color-vision-deficiency + + + + obo2:OAE_0002107 + 色视力缺乏 + + + + obo2:OAE_0002107 + Color vision deficiency AE is an abnormal vision AE that is a group of conditions that affect the perception of color. They cause a range of changes in color vision, from mild difficulty with distinguishing shades to a total inability to detect color. These conditions are divided into three major categories: red-green color vision defects, blue-yellow color vision defects, and a complete absence of color vision. + + + + obo2:OAE_0002107 + color vision deficiency AE + + + + obo2:OAE_0002108 + Carcinogenesis AE is a tumor AE that is literally the 'creation' of cancer. It is a process by which normal cells are transformed into cancer cells. + + + + obo2:OAE_0002108 + JX, LW, YH + + + + obo2:OAE_0002108 + oncogenesis AE + + + + obo2:OAE_0002108 + tumorigenesis AE + + + + obo2:OAE_0002108 + WEB: http://en.wikipedia.org/wiki/Carcinogenesis + + + + obo2:OAE_0002108 + 致癌 + + + + obo2:OAE_0002108 + carcinogenesis AE + + + + obo2:OAE_0002109 + an anaphylaxis AE that is associated with systemic vasodilation that causes low blood pressure which is by definition 30% lower than the person's baseline or below standard values. + + + + obo2:OAE_0002109 + JX, LW, YH, RR + + + + obo2:OAE_0002109 + WEB: http://en.wikipedia.org/wiki/Anaphylaxis + + + + obo2:OAE_0002109 + WEB: http://smschile.cl/documentos/cursos2010/MedicalClinicsNorthAmerica/Acute%20Symptoms%20of%20Drug%20Hypersensitivity%20%28Urticaria,%20Angioedema,%20Anaphylaxis,%20Anaphylactic%20Shock%29.pdf + + + + obo2:OAE_0002109 + WEB: http://www.medicinenet.com/script/main/art.asp?articlekey=10092 + + + + obo2:OAE_0002109 + 过敏性休克 + + + + obo2:OAE_0002109 + anaphylactic shock AE + + + + obo2:OAE_0002109 + MedDRA: 10002199 + + + + obo2:OAE_0002110 + Pituitary adenomas AE is a tumor AE that is a tumor which occur in the pituitary gland. Pituitary adenomas are generally divided into three categories dependent upon their biological functioning: benign adenoma, invasive adenoma, and carcinomas, with carcinomas accounting for 0.1% to 0.2%, approximately 35% being invasive adenomas and most being benign adenomas. Pituitary adenomas represent from 10% to 25% of all intracranial neoplasms and the estimated prevalence rate in the general population is approximately 17%. + + + + obo2:OAE_0002110 + JX, LW, YH + + + + obo2:OAE_0002110 + WEB: http://en.wikipedia.org/wiki/Pituitary_adenoma + + + + obo2:OAE_0002110 + pituitary adenomas AE + + + + obo2:OAE_0002111 + Fatty infiltration AE is an embolism AE that shows the abnormal accumulation of fat droplets in the cytoplasm of cells. + + + + obo2:OAE_0002111 + JX, LW, YH + + + + obo2:OAE_0002111 + WEB: http://dictionary.reference.com/browse/fatty+infiltration + + + + obo2:OAE_0002111 + 脂肪侵润 + + + + obo2:OAE_0002111 + fatty infiltration AE + + + + obo2:OAE_0002112 + Epigastric discomfort is a discomfort AE that shows discomfort in the upper central region of the abdomen. + + + + obo2:OAE_0002112 + JX, LW, YH + + + + obo2:OAE_0002112 + upper Abdominal discomfort AE + + + + obo2:OAE_0002112 + WEB: http://www.rightdiagnosis.com/sym/epigastric_discomfort.htm + + + + obo2:OAE_0002112 + 上腹部不适 + + + + obo2:OAE_0002112 + epigastric discomfort AE + + + + obo2:OAE_0002112 + MedDRA: 10053155 + + + + obo2:OAE_0002113 + Acute intravascular hemolysis AE is a cardiovascular AE that has an outcome of disruption of red blood cells occurs while they are within blood vessels. + + + + obo2:OAE_0002113 + JX, LW, YH + + + + obo2:OAE_0002113 + 急性血管内溶血 + + + + obo2:OAE_0002113 + acute intravascular hemolysis AE + + + + obo2:OAE_0002114 + Allergic hepatitis AE is a hepatitis AE that is a tissue-specific inflammatory diease caused by hepersensitivity to a particular drug, accomopanied by a systemic allergic reaction such as eosinophilia. + + + + obo2:OAE_0002114 + JX, LW, YH + + + + obo2:OAE_0002114 + WEB: http://medical-dictionary.thefreedictionary.com/viral+hepatitis + + + + obo2:OAE_0002114 + 过敏性肝炎 + + + + obo2:OAE_0002114 + allergic hepatitis AE + + + + obo2:OAE_0002114 + MedDRA: 10071198 + + + + obo2:OAE_0002115 + Paranoid anxiety AE is a anxiety AE that is a term used in object relations theory, particularity in discussions about the Paranoid-schizoid and depressive positions. The term was frequently used by Melanie Klein, especially to refer to a pre-depressive and persecutory sense of anxiety characterised by the psychological splitting of objects. + + + + obo2:OAE_0002115 + JX, LW, YH + + + + obo2:OAE_0002115 + WEB: http://en.wikipedia.org/wiki/Paranoid_anxiety + + + + obo2:OAE_0002115 + 偏执性焦虑 + + + + obo2:OAE_0002115 + paranoid anxietas AE + + + + obo2:OAE_0002116 + Thrombotic thrombocytopenic purpura AE is a thrombocytopenic purpura AE that is a rare disorder of the blood-coagulation system, causing extensive microscopic clots to form in the small blood vessels throughout the body. + + + + obo2:OAE_0002116 + JX, LW, YH + + + + obo2:OAE_0002116 + moschcowitz syndrome AE + + + + obo2:OAE_0002116 + WEB: http://en.wikipedia.org/wiki/Thrombotic_thrombocytopenic_purpura + + + + obo2:OAE_0002116 + 血栓性血小板减少性紫癜 + + + + obo2:OAE_0002116 + thrombotic thrombocytopenic purpura AE + + + + obo2:OAE_0002116 + MedDRA: 10043648 + + + + obo2:OAE_0002117 + Glaucoma AE is an eye AE that is a term describing a group of ocular (eye) disorders resulting in optic nerve damage or loss to the field of vision, in many patients caused by a clinically characterized pressure buildup in regards to the fluid of the eye (intraocular pressure-associated optic neuropathy). + + + + obo2:OAE_0002117 + JX, LW, YH + + + + obo2:OAE_0002117 + WEB: http://en.wikipedia.org/wiki/Glaucoma + + + + obo2:OAE_0002117 + 青光眼 + + + + obo2:OAE_0002117 + glaucoma AE + + + + obo2:OAE_0002117 + MedDRA: 10018304 + + + + obo2:OAE_0002118 + an allergy AE that shows a serious allergic reaction that is rapid in onset and may cause death. It typically causes a number of symptoms including an itchy rash, throat swelling, and low blood pressure. Common causes include insect bites and stings, foods, and medications. + + + + obo2:OAE_0002118 + JX, LW, YH + + + + obo2:OAE_0002118 + WEB: http://en.wikipedia.org/wiki/Anaphylaxis + + + + obo2:OAE_0002118 + 过敏症 + + + + obo2:OAE_0002118 + anaphylaxis AE + + + + obo2:OAE_0002118 + MedDRA: 10002218 + + + + obo2:OAE_0002119 + an allergy AE which occur during certain times of the year, usually when outdoor molds release their spores, and trees, grasses, and weeds release tiny pollen particles into the air to fertilize other plants. + + + + obo2:OAE_0002119 + JX, LW, YH + + + + obo2:OAE_0002119 + WEB: http://kidshealth.org/parent/medical/allergies/seasonal_allergies.html + + + + obo2:OAE_0002119 + 季节性变态反应 + + + + obo2:OAE_0002119 + seasonal allergy AE + + + + obo2:OAE_0002119 + MedDRA: 10048908 + + + + obo2:OAE_0002121 + Skin redness AE is an erythema AE that is abnormal redness of the skin, often signaling a pathological condition, such as inflammation, infection, or sunburn. + + + + obo2:OAE_0002121 + JX, LW, YH + + + + obo2:OAE_0002121 + WEB: http://www.healthline.com/health/skin-redness + + + + obo2:OAE_0002121 + 皮肤发红 + + + + obo2:OAE_0002121 + skin redness AE + + + + obo2:OAE_0002122 + a cardiac disorder AE that shows the symptom of a chest pain. + + + + obo2:OAE_0002122 + DJ, SS, YH + + + + obo2:OAE_0002122 + chest pain AE + + + + obo2:OAE_0002122 + tight chest AE + + + + obo2:OAE_0002122 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/23016723 + + + + obo2:OAE_0002122 + angina AE + + + + obo2:OAE_0002122 + HPO: HP_0001681 + + + + obo2:OAE_0002122 + MedDRA: 10002383 + + + + obo2:OAE_0002122 + SIDER: C0002962 + + + + obo2:OAE_0002123 + an angina AE that is aggravating. + + + + obo2:OAE_0002123 + JX, YH + + + + obo2:OAE_0002123 + aggravating angina AE + + + + obo2:OAE_0002124 + an aggravating angina AE that is caused by severe hypotension + + + + obo2:OAE_0002124 + JX, YH + + + + obo2:OAE_0002124 + 严重低血压导致心绞痛症状加重现象 + + + + obo2:OAE_0002124 + severe hypotension caused angina symptom aggravating AE + + + + obo2:OAE_0002125 + Blinke AE is a eye disorder AE that an eye AE that shows brief closing of the eyelids by involuntary normal periodic closing, as a protective measure, or by voluntary action. + + + + obo2:OAE_0002125 + JX, LW, YH + + + + obo2:OAE_0002125 + 闪耀 + + + + obo2:OAE_0002125 + blink AE + + + + obo2:OAE_0002126 + Dazzling AE is a eye disorder AE that has an outcome of the consequence of illumination too intense for adaptation by the eye. In contrast to glare, dazzling is alleviated by appropriate tinted glasses. + + + + obo2:OAE_0002126 + JX, LW, YH + + + + obo2:OAE_0002126 + WEB: http://medical-dictionary.thefreedictionary.com/dazzling + + + + obo2:OAE_0002126 + 目眩 + + + + obo2:OAE_0002126 + dazzling AE + + + + obo2:OAE_0002127 + Ventricular rhythm AE is an arrhythmia AE that shows the electrocardiographic finding of an ectopic ventricular rhythm with three or more consecutive ventricular premature beats with a rate less than 100 beats per minute. + + + + obo2:OAE_0002127 + JX, LW, YH + + + + obo2:OAE_0002127 + 室性心律 + + + + obo2:OAE_0002127 + ventricular rhythm AE + + + + obo2:OAE_0002127 + MedDRA: 10047297 + + + + obo2:OAE_0002128 + Extrapyramidal signs AE is a nervous system AE that shows defects in basal ganglia function. It characterized by changes in muscle tone, poverty of voluntary movements (akinesia), or abnormal involuntary movements (dyskinesia). + + + + obo2:OAE_0002128 + JX, LW, YH + + + + obo2:OAE_0002128 + 锥体外体征 + + + + obo2:OAE_0002128 + extrapyramidal signs AE + + + + obo2:OAE_0002129 + Hearing disorders AE is an ear disorder that shows impairment of the sense of hearing. + + + + obo2:OAE_0002129 + JX, LW, YH + + + + obo2:OAE_0002129 + 听觉障碍 + + + + obo2:OAE_0002129 + hearing disorders AE + + + + obo2:OAE_0002129 + MedDRA: 10019243 + + + + obo2:OAE_0002130 + Yellow urine AE is a urine abnormality AE that may be due to excretion of picric acid, dinitrophenol, phenacetin or chrysarobin or in alkaline pH, to increased secretion of anthocyanin, or associated with ingestion of beets or blackberries. Pure yellow urine is associated with increased acriflavine and has a green fluorescence; yellow-orange urine may be highly concentrated or contain increased bilirubin and biliverdin. + + + + obo2:OAE_0002130 + JX, LW, YH + + + + obo2:OAE_0002130 + 尿液呈黄色 + + + + obo2:OAE_0002130 + yellow urine AE + + + + obo2:OAE_0002131 + Epidermal necrosis AE is a necrosis AE that shows widespread keratinocyte cell death via apoptosis results in the tissue damage. + + + + obo2:OAE_0002131 + JX, LW, YH + + + + obo2:OAE_0002131 + 表皮坏死 + + + + obo2:OAE_0002131 + epidermal necrosis AE + + + + obo2:OAE_0002131 + MedDRA: 10059284 + + + + obo2:OAE_0002132 + Arthromeningitis AE is an inflammation AE that shows inflammation of a synovial membrane, usually painful, particularly on motion, and characterized by fluctuating swelling, due to effusion in a synovial sac. + + + + obo2:OAE_0002132 + JX, LW, YH + + + + obo2:OAE_0002132 + 滑膜炎 + + + + obo2:OAE_0002132 + arthromeningitis AE + + + + obo2:OAE_0002133 + Pulmonary tuberculosis AE is a lung disorder AE that is a contagious bacterial infection that involves the lungs. It may spread to other organs. + + + + obo2:OAE_0002133 + JX, LW, YH + + + + obo2:OAE_0002133 + WEB: http://www.nlm.nih.gov/medlineplus/ency/article/000077.htm + + + + obo2:OAE_0002133 + pulmonary tuberculosis AE + + + + obo2:OAE_0002133 + MedDRA: 10037440 + + + + obo2:OAE_0002134 + Coronary heart disease AE is a cardiovascular disorder AE that is a disease in which a waxy substance called plaque (plak) builds up inside the coronary arteries. These arteries supply oxygen-rich blood to your heart muscle. + + + + obo2:OAE_0002134 + JX, LW, YH + + + + obo2:OAE_0002134 + WEB: http://www.nhlbi.nih.gov/health/health-topics/topics/cad/ + + + + obo2:OAE_0002134 + 冠心病 + + + + obo2:OAE_0002134 + coronary heart disease AE + + + + obo2:OAE_0002134 + MedDRA: 10068617 + + + + obo2:OAE_0002135 + Increased defecation frequency AE is a abnormal stool AE that shows defecation number increased. + + + + obo2:OAE_0002135 + JX, LW, YH + + + + obo2:OAE_0002135 + 大便次数增加 + + + + obo2:OAE_0002135 + increased defecation frequency AE + + + + obo2:OAE_0002136 + Symptomatic hypotension AE is a hypotension AE that shows blood pressure that less than 90/60 mm Hg with dizziness, vertigo etc. + + + + obo2:OAE_0002136 + JX, LW, YH + + + + obo2:OAE_0002136 + 症状性低血压 + + + + obo2:OAE_0002136 + symptomatic hypotension AE + + + + obo2:OAE_0002137 + Non-specific gastrointestinal dysfunction AE is a gastrointestinal disorder AE that shows non-specific gastrointestinal dysfunction. + + + + obo2:OAE_0002137 + JX, LW, YH + + + + obo2:OAE_0002137 + 非特异性胃肠功能紊乱 + + + + obo2:OAE_0002137 + non-specific gastrointestinal dysfunction AE + + + + obo2:OAE_0002138 + Bbnormal sclerotin AE is a bone disorder AE that shows abnormal sclerotin. + + + + obo2:OAE_0002138 + JX, LW, YH + + + + obo2:OAE_0002138 + 骨质异常 + + + + obo2:OAE_0002138 + abnormal sclerotin AE + + + + obo2:OAE_0002139 + Fast and weak heart beat AE is a cardiac disorder AE that shows fast and weak heart beat. + + + + obo2:OAE_0002139 + JX, LW, YH + + + + obo2:OAE_0002139 + 心跳快而弱 + + + + obo2:OAE_0002139 + fast and weak heart beat AE + + + + obo2:OAE_0002140 + Pain over the liver AE is a pain AE that shows pain over the liver. + + + + obo2:OAE_0002140 + JX, LW, YH + + + + obo2:OAE_0002140 + 肝区痛 + + + + obo2:OAE_0002140 + pain over the liver AE + + + + obo2:OAE_0002141 + Increased biliary calculus AE is a liver, biliary, and pancreatic AE that shows increased biliary calculus. + + + + obo2:OAE_0002141 + JX, LW, YH + + + + obo2:OAE_0002141 + 胆石增加 + + + + obo2:OAE_0002141 + increased biliary calculus AE + + + + obo2:OAE_0002142 + Muscle function disorder AE is a muscle AE that shows muscle function disorder. + + + + obo2:OAE_0002142 + JX, LW, YH + + + + obo2:OAE_0002142 + 肌肉功能失调 + + + + obo2:OAE_0002142 + muscle function disorder AE + + + + obo2:OAE_0002143 + Accidental injury AE is a fall AE that shows accidental falls. + + + + obo2:OAE_0002143 + JX, LW, YH + + + + obo2:OAE_0002143 + 意外跌倒 + + + + obo2:OAE_0002143 + accidental fall AE + + + + obo2:OAE_0002144 + Accidental injury AE is an injury AE that shows accidedntal injury. + + + + obo2:OAE_0002144 + JX, LW, YH + + + + obo2:OAE_0002144 + 意外损伤 + + + + obo2:OAE_0002144 + accidental injury AE + + + + obo2:OAE_0002144 + MedDRA ID: 10000380 + + + + obo2:OAE_0002145 + Abnormal ejaculation AE is a male reproductive system AE that shows abnormal ejaculation. + + + + obo2:OAE_0002145 + JX, LW, YH + + + + obo2:OAE_0002145 + 异常射精 + + + + obo2:OAE_0002145 + abnormal ejaculation AE + + + + obo2:OAE_0002145 + MedDRA: 10000128 + + + + obo2:OAE_0002146 + Distention of head AE is a cardiovascular AE that shows distention of head. + + + + obo2:OAE_0002146 + JX, LW, YH + + + + obo2:OAE_0002146 + 头胀 + + + + obo2:OAE_0002146 + distention of head AE + + + + obo2:OAE_0002147 + Water-sodium retention AE is an abnormal fluid regulation AE that shows water-sodium retention. + + + + obo2:OAE_0002147 + JX, LW, YH + + + + obo2:OAE_0002147 + WEB: http://www.livestrong.com/article/485782-sodium-retention-weight-gain/ + + + + obo2:OAE_0002147 + 水钠潴留 + + + + obo2:OAE_0002147 + water-sodium retention AE + + + + obo2:OAE_0002148 + Dizziness when standing up AE is a dizziness AE that shows dizziness when standing up. + + + + obo2:OAE_0002148 + JX, LW, YH + + + + obo2:OAE_0002148 + 站起时头晕 + + + + obo2:OAE_0002148 + dizziness when standing up AE + + + + obo2:OAE_0002149 + Change of gustation AE is a gustatory system AE that shows the change of gustation. + + + + obo2:OAE_0002149 + JX, LW, YH + + + + obo2:OAE_0002149 + 味觉改变 + + + + obo2:OAE_0002149 + change of gustation AE + + + + obo2:OAE_0002150 + Vascular stimulation of pain AE is a pain AE that shows pain which due to vascular stimulation. + + + + obo2:OAE_0002150 + JX, LW, YH + + + + obo2:OAE_0002150 + 血管刺激性疼痛 + + + + obo2:OAE_0002150 + vascular stimulation of pain AE + + + + obo2:OAE_0002151 + Vascular pain AE is a pain AE that shows vascular pain. + + + + obo2:OAE_0002151 + JX, LW, YH + + + + obo2:OAE_0002151 + 血管疼痛 + + + + obo2:OAE_0002151 + vascular pain AE + + + + obo2:OAE_0002152 + Heaviness sense of arm AE is a sensation of heaviness AE that shows a sensation feeling of heaviness in the arm. + + + + obo2:OAE_0002152 + JX, LW, YH + + + + obo2:OAE_0002152 + 手臂沉重感 + + + + obo2:OAE_0002152 + heaviness sense of arm AE + + + + obo2:OAE_0002153 + Breast swelling AE is an edema AE that is common for almost all women in the second half of their menstrual cycle. It in the premenstrual portion of the cycle can be mild to severe. + + + + obo2:OAE_0002153 + JX, LW, YH + + + + obo2:OAE_0002153 + WEB: http://www.healthgrades.com/symptoms/breast-swelling + + + + obo2:OAE_0002153 + 乳房肿胀 + + + + obo2:OAE_0002153 + breast swelling AE + + + + obo2:OAE_0002153 + MedDRA: 10006312 + + + + obo2:OAE_0002154 + Gastrointestinal cramp AE is a muscle spasm AE that shows abnormal contractions of the gastrointestinal muscles. + + + + obo2:OAE_0002154 + JX, LW, YH + + + + obo2:OAE_0002154 + 肠胃痉挛 + + + + obo2:OAE_0002154 + gastrointestinal cramp AE + + + + obo2:OAE_0002154 + MedDRA: 10049136 + + + + obo2:OAE_0002155 + Heart discomfort AE is a discomfort AE that shows an uncomfortable feeling in the heart. + + + + obo2:OAE_0002155 + JX, LW, YH + + + + obo2:OAE_0002155 + 心脏不适 + + + + obo2:OAE_0002155 + heart discomfort AE + + + + obo2:OAE_0002156 + Angiectopia of skin AE a vascular disorder AE that shows abnormal position or course of a vessel in the skin. + + + + obo2:OAE_0002156 + JX, LW, YH + + + + obo2:OAE_0002156 + 皮肤血管异位 + + + + obo2:OAE_0002156 + angiectopia of skin AE + + + + obo2:OAE_0002157 + Joint discomfort AE is a discomfort AE that shows an uncomfortable feeling in the joint. + + + + obo2:OAE_0002157 + JX, LW, YH + + + + obo2:OAE_0002157 + 关节不适 + + + + obo2:OAE_0002157 + joint discomfort AE + + + + obo2:OAE_0002158 + Eye discomfort AE is a discomfort AE that shows an uncomfortable feeling in the eye. + + + + obo2:OAE_0002158 + JX, LW, YH + + + + obo2:OAE_0002158 + 眼部不适 + + + + obo2:OAE_0002158 + eye discomfort AE + + + + obo2:OAE_0002159 + Instability of gait AE is a abnormal gait AE that shows instability of gait. + + + + obo2:OAE_0002159 + JX, LW, YH + + + + obo2:OAE_0002159 + 步态不稳 + + + + obo2:OAE_0002159 + instability of gait AE + + + + obo2:OAE_0002160 + Pemphigoid injury AE is an injury AE that shows a skin disorder where one has large blisters on the skin. + + + + obo2:OAE_0002160 + JX, LW, YH + + + + obo2:OAE_0002160 + 类天疱疮样损伤 + + + + obo2:OAE_0002160 + pemphigoid injury AE + + + + obo2:OAE_0002161 + Pulse frequency change AE is a cardiovascular AE that shows dpulse frequency change. + + + + obo2:OAE_0002161 + JX, LW, YH + + + + obo2:OAE_0002161 + pulse abnormal AE + + + + obo2:OAE_0002161 + 脉搏频率变化 + + + + obo2:OAE_0002161 + pulse frequency change AE + + + + obo2:OAE_0002162 + Inhibition of myocardial contraction force AE is a cardiac disorder AE that shows inhibition of myocardial contraction force. + + + + obo2:OAE_0002162 + JX, LW, YH + + + + obo2:OAE_0002162 + 抑制心肌收缩力 + + + + obo2:OAE_0002162 + inhibition of myocardial contraction force AE + + + + obo2:OAE_0002163 + Decreased of atrial conduction velocity AE is a conduction system disorder AE that shows decreased of atrial conduction velocity. + + + + obo2:OAE_0002163 + JX, LW, YH + + + + obo2:OAE_0002163 + 心房传导速度减慢 + + + + obo2:OAE_0002163 + decreased of atrial conduction velocity AE + + + + obo2:OAE_0002164 + Spasm of lower limbs AE is a muscle spasm AE that shows tightening and spasms of the muscles in the legs. + + + + obo2:OAE_0002164 + JX, LW, YH + + + + obo2:OAE_0002164 + 下肢痉挛 + + + + obo2:OAE_0002164 + spasm of lower limbs AE + + + + obo2:OAE_0002165 + Electrocardiogram prolonged PR interval AE is an electrocardiogram result abnormal AE that shows a prolonged time between the onset of atrial depolarization (P wave) to the beginning of ventricular depolarization (QRS complex). + + + + obo2:OAE_0002165 + JX, LW, YH + + + + obo2:OAE_0002165 + 心电图出现PR间期延长 + + + + obo2:OAE_0002165 + electrocardiogram prolonged PR interval AE + + + + obo2:OAE_0002166 + Qrs wave broadening AE is a electrocardiogram qrs complex abnormal AE that shows broadening qrs complex in the electrocardiogram. + + + + obo2:OAE_0002166 + JX, LW, YH + + + + obo2:OAE_0002166 + QRS波增宽 + + + + obo2:OAE_0002166 + qrs wave broadening AE + + + + obo2:OAE_0002167 + Edema of lower limbs AE is an edema AE that shows enlargement of the leg, due to the accumulation of fluids. + + + + obo2:OAE_0002167 + JX, LW, YH + + + + obo2:OAE_0002167 + 下肢浮肿 + + + + obo2:OAE_0002167 + edema of lower limbs AE + + + + obo2:OAE_0002168 + Accelerated pulse AE is a cardiovascular AE that shows increased of the number of pulsations per minute palpable in an artery. + + + + obo2:OAE_0002168 + JX, LW, YH + + + + obo2:OAE_0002168 + 脉搏加快 + + + + obo2:OAE_0002168 + accelerated pulse AE + + + + obo2:OAE_0002169 + Bitter taste of mouth AE is a digestive system AE that is not from a bitter substance is a distorted sense of taste. A persistent bad taste in the mouth, whether bitter, metallic or foul, is called dysgeusia. + + + + obo2:OAE_0002169 + JX, LW, YH + + + + obo2:OAE_0002169 + WEB: http://www.healthgrades.com/symptoms/bitter-taste-in-mouth + + + + obo2:OAE_0002169 + 口苦 + + + + obo2:OAE_0002169 + bitter taste of mouth AE + + + + obo2:OAE_0002170 + Skin irritant reaction AE is a skin AE that shows rash, inflammation, swelling, scaling, or abnormal tissue which growth in the affected area. + + + + obo2:OAE_0002170 + JX, LW, YH + + + + obo2:OAE_0002170 + 皮肤刺激反应 + + + + obo2:OAE_0002170 + skin irritant reaction AE + + + + obo2:OAE_0002171 + Vitreous suspended substance AE is an eye AE shows vitreous suspended substance in the eyes. + + + + obo2:OAE_0002171 + JX, LW, YH + + + + obo2:OAE_0002171 + 玻璃体悬浮物 + + + + obo2:OAE_0002171 + vitreous suspended substance AE + + + + obo2:OAE_0002172 + Dreaminess AE is a sleep disorder AE that shows dreaminess in the sleeping. + + + + obo2:OAE_0002172 + JX, LW, YH + + + + obo2:OAE_0002172 + 多梦 + + + + obo2:OAE_0002172 + dreaminess AE + + + + obo2:OAE_0002173 + Abdominal spasm AE is a muscle spasm AE that is typically a feeling of cramping in the abdomen caused by a rigid expansion of muscles. It can vary from mild discomfort to moderate or severe pain. + + + + obo2:OAE_0002173 + JX, LW, YH + + + + obo2:OAE_0002173 + WEB: http://www.wisegeekhealth.com/what-are-abdominal-spasms.htm + + + + obo2:OAE_0002173 + 腹部痉挛 + + + + obo2:OAE_0002173 + abdominal spasm AE + + + + obo2:OAE_0002173 + MedDRA:10051889 + + + + obo2:OAE_0002174 + Coronary contraction AE is a coronary artery disorder AE that shows coronary contraction. + + + + obo2:OAE_0002174 + JX, LW, YH + + + + obo2:OAE_0002174 + 冠状动脉收缩 + + + + obo2:OAE_0002174 + coronary contraction AE + + + + obo2:OAE_0002175 + Lower extremity edema caused by blood vessels AE is an edema AE that shows excess fluid accumalated in the leg dut to blood vessels. + + + + obo2:OAE_0002175 + JX, LW, YH + + + + obo2:OAE_0002175 + 因血管扩张引起的下肢水肿 + + + + obo2:OAE_0002175 + lower extremity edema caused by blood vessels AE + + + + obo2:OAE_0002176 + Asthenia of lower limbs AE is a asthenia AE that occurs in the lower limbs. It is a condition typified by a weakness of voluntary movement. + + + + obo2:OAE_0002176 + JX, LW, YH + + + + obo2:OAE_0002176 + 下肢无力 + + + + obo2:OAE_0002176 + asthenia of lower limbs AE + + + + obo2:OAE_0002177 + Small bronchial lumen occlusion AE is a lung disorder AE that shows small bronchial lumen occlusion. + + + + obo2:OAE_0002177 + JX, LW, YH + + + + obo2:OAE_0002177 + 小支气管腔闭塞 + + + + obo2:OAE_0002177 + small bronchial lumen occlusion AE + + + + obo2:OAE_0002178 + Prolonged orthostatic hypotension AE is a orthostatic hypotension AE that shows prolonged orthostatic hypotension. + + + + obo2:OAE_0002178 + JX, LW, YH + + + + obo2:OAE_0002178 + 延长体位性低血压时间 + + + + obo2:OAE_0002178 + prolonged orthostatic hypotension AE + + + + obo2:OAE_0002179 + an allergy AE that shows produce cross or incomplete cross allergic reaction to similar medicinal chemistry structure. + + + + obo2:OAE_0002179 + JX, LW, YH + + + + obo2:OAE_0002179 + 交叉过敏反应 + + + + obo2:OAE_0002179 + cross allergic reaction AE + + + + obo2:OAE_0002180 + Deep venous thrombophlebitis AE is a thrombophlebitis AE that is causes by a blood clot blocking in the deep vein. + + + + obo2:OAE_0002180 + JX, LW, YH + + + + obo2:OAE_0002180 + 深静脉血栓静脉炎 + + + + obo2:OAE_0002180 + deep venous thrombophlebitis AE + + + + obo2:OAE_0002181 + Change of hematology AE is a hematology investigation result abnormal AE that shows the change of hematology. + + + + obo2:OAE_0002181 + JX, LW, YH + + + + obo2:OAE_0002181 + 血液学改变 + + + + obo2:OAE_0002181 + change of hematology AE + + + + obo2:OAE_0002182 + Cardiac depression AE is a cardiac disorder AE that shows cardiac depression. + + + + obo2:OAE_0002182 + JX, LW, YH + + + + obo2:OAE_0002182 + 抑制心脏 + + + + obo2:OAE_0002182 + cardiac depression AE + + + + obo2:OAE_0002183 + Side limb numbness AE is a numbness AE that shows reduced or loss of sensation on the skin of an arm and leg on the same side of the body. + + + + obo2:OAE_0002183 + JX, LW, YH + + + + obo2:OAE_0002183 + 侧肢的麻木感 + + + + obo2:OAE_0002183 + side limb numbness AE + + + + obo2:OAE_0002184 + Numbness of tongue AE is a numbness AE that shows abnormal feeling or loss of sensation in the tongue. + + + + obo2:OAE_0002184 + JX, LW, YH + + + + obo2:OAE_0002184 + 舌部麻木 + + + + obo2:OAE_0002184 + numbness of tongue AE + + + + obo2:OAE_0002185 + Numbness of the limbs AE is a numbness AE that shows reduced or loss of sensation on the skin of the arm and leg. + + + + obo2:OAE_0002185 + JX, LW, YH + + + + obo2:OAE_0002185 + 肢体麻木 + + + + obo2:OAE_0002185 + numbness of the limbs AE + + + + obo2:OAE_0002186 + Lip numbness AE is a numbness AE that shows abnormal feeling in the lips, including numbness and tingling. + + + + obo2:OAE_0002186 + JX, LW, YH + + + + obo2:OAE_0002186 + 嘴唇发麻 + + + + obo2:OAE_0002186 + lip numbness AE + + + + obo2:OAE_0002187 + Reflex Increased pulse rate AE is a cardiovascular AE that shows increased pulse rate. + + + + obo2:OAE_0002187 + JX, LW, YH + + + + obo2:OAE_0002187 + 反射性脉率增加 + + + + obo2:OAE_0002187 + reflex Increased pulse rate AE + + + + obo2:OAE_0002188 + Irritation of the digestive tract AE is a digestive system AE that shows irritation of the digestive tract. + + + + obo2:OAE_0002188 + JX, LW, YH + + + + obo2:OAE_0002188 + 消化道刺激 + + + + obo2:OAE_0002188 + irritation of the digestive tract AE + + + + obo2:OAE_0002189 + Unconscious chorea AE is a chorea AE that is characterized by brief, non-repetitive irregular muscle contractions. + + + + obo2:OAE_0002189 + JX, LW, YH + + + + obo2:OAE_0002189 + 不自觉舞蹈症 + + + + obo2:OAE_0002189 + unconscious chorea AE + + + + obo2:OAE_0002190 + Phlebectasia of limbs AE is a vasodilatation AE that shows dilation of the veins in the extremity. + + + + obo2:OAE_0002190 + JX, LW, YH + + + + obo2:OAE_0002190 + 肢端静脉扩张 + + + + obo2:OAE_0002190 + phlebectasia of limbs AE + + + + obo2:OAE_0002191 + Heart beat skip AE is a irregular heartbeat AE which is sometimes called as either heart palpitation, or premature atrial or ventricular contraction are very common occurrences. They may or may not be accompanied by heart conditions or heart problems. + + + + obo2:OAE_0002191 + JX, LW, YH + + + + obo2:OAE_0002191 + WEB: http://ehealthwall.com/heart-skips-a-beat-causes-symptoms-treatment/ + + + + obo2:OAE_0002191 + 漏跳 + + + + obo2:OAE_0002191 + heart beat skip AE + + + + obo2:OAE_0002192 + Fatal liver cell necrosis AE is a hepatic necrosis AE that has an outcome of fatal liver cell necrosis. + + + + obo2:OAE_0002192 + JX, LW, YH + + + + obo2:OAE_0002192 + 致命性肝细胞坏死 + + + + obo2:OAE_0002192 + fatal liver cell necrosis AE + + + + obo2:OAE_0002193 + Warm and hot feeling in the neck AE is a skini warm AE that shows warm and hot feeling in the neck. + + + + obo2:OAE_0002193 + JX, LW, YH + + + + obo2:OAE_0002193 + 颈感觉温热 + + + + obo2:OAE_0002193 + warm and hot feeling in the neck AE + + + + obo2:OAE_0002194 + Facial warm feeling AE is a skin warm AE that shows a warm feeling in the face. + + + + obo2:OAE_0002194 + JX, LW, YH + + + + obo2:OAE_0002194 + 面部感觉温热 + + + + obo2:OAE_0002194 + facial warm feeling AE + + + + obo2:OAE_0002195 + Increased peripheral vascular resistance AE is a vascular disorder AE that shows increased peripheral vascular resistance, the degree to which the blood vessels impede the flow of blood. High resistance causes an increase in blood pressure, which increases the workload of the heart. + + + + obo2:OAE_0002195 + JX, LW, YH + + + + obo2:OAE_0002195 + 外周血管阻力升高 + + + + obo2:OAE_0002195 + increased peripheral vascular resistance AE + + + + obo2:OAE_0002196 + Venous ischemia AE is an ischaemia AE that shows in insufficient blood supply in the vein. + + + + obo2:OAE_0002196 + JX, LW, YH + + + + obo2:OAE_0002196 + 静脉供血不足 + + + + obo2:OAE_0002196 + venous ischemia AE + + + + obo2:OAE_0002197 + Increased blood creatine AE is a metabolic and nutritional investigation result abnormal AE that shows an increased creatine level in blood. + + + + obo2:OAE_0002197 + JX, LW, YH + + + + obo2:OAE_0002197 + 血肌酸增加 + + + + obo2:OAE_0002197 + increased blood creatine AE + + + + obo2:OAE_0002198 + Increased nonprotein nitrogen AE is an investigation result abnormal AE that shows increased nonprotein nitrogen, the nitrogenous constituents of the blood exclusive of the protein bodies, consisting of the nitrogen of urea, uric acid, creatine, creatinine, amino acids, polypeptides, and an undetermined part known as rest nitrogen. + + + + obo2:OAE_0002198 + JX, LW, YH + + + + obo2:OAE_0002198 + 非蛋白氮增加 + + + + obo2:OAE_0002198 + increased nonprotein nitrogen AE + + + + obo2:OAE_0002199 + Soft feces AE is a abnormal stool AE that shows soft and shapeless of the feces. + + + + obo2:OAE_0002199 + JX, LW, YH + + + + obo2:OAE_0002199 + 软便 + + + + obo2:OAE_0002199 + soft feces AE + + + + obo2:OAE_0002200 + Increased hepatic function AE is a hepatic function abnormal AE that shows the values of liver function tests (LFTs) high than the normal. + + + + obo2:OAE_0002200 + JX, LW, YH + + + + obo2:OAE_0002200 + WEB: http://www.webmd.com/a-to-z-guides/liver-function-test-lft + + + + obo2:OAE_0002200 + 肝功能升高 + + + + obo2:OAE_0002200 + increased hepatic function AE + + + + obo2:OAE_0002201 + Knee pain AE is a pain AE that shows discomfort in the structures of both knees. Keen pain may be due to injury, inflammation or infection. + + + + obo2:OAE_0002201 + JX, LW, YH + + + + obo2:OAE_0002201 + WEB: http://www.mayoclinic.org/diseases-conditions/knee-pain/basics/definition/CON-20029534 + + + + obo2:OAE_0002201 + 膝痛 + + + + obo2:OAE_0002201 + knee pain AE + + + + obo2:OAE_0002201 + MedDRA: 10023477 + + + + obo2:OAE_0002202 + Loss of libido AE is a libido disorder AE that shows loss of the desire for sexual interaction. + + + + obo2:OAE_0002202 + JX, LW, YH + + + + obo2:OAE_0002202 + WEB: http://en.wikipedia.org/wiki/Hypoactive_sexual_desire_disorder + + + + obo2:OAE_0002202 + 性欲丧失 + + + + obo2:OAE_0002202 + loss of libido AE + + + + obo2:OAE_0002202 + MedDRA: 10024870 + + + + obo2:OAE_0002203 + Over sedation AE is a behavior and neurological AE that shows the over reduction of irritability or agitation. + + + + obo2:OAE_0002203 + JX, LW, YH + + + + obo2:OAE_0002203 + 过度镇静 + + + + obo2:OAE_0002203 + over sedation AE + + + + obo2:OAE_0002204 + Finger tremor AE is a tremor AE that shows involuntary muscle contraction and relaxation in the finger. + + + + obo2:OAE_0002204 + JX, LW, YH + + + + obo2:OAE_0002204 + 手指强硬颤动 + + + + obo2:OAE_0002204 + finger tremor AE + + + + obo2:OAE_0002205 + Leg cramp AE is a muscle cramp AE that shows tightening, or spasms, of the muscles in the legs. + + + + obo2:OAE_0002205 + JX, LW, YH + + + + obo2:OAE_0002205 + 腿部痉挛 + + + + obo2:OAE_0002205 + leg cramp AE + + + + obo2:OAE_0002206 + a behavior and neurological AE that has an outcome of insomnia + + + + obo2:OAE_0002206 + YH + + + + obo2:OAE_0002206 + Insomnia is a symptom of a sleeping disorder characterized by persistent difficulty falling asleep or staying asleep despite the opportunity. Insomnia is a symptom, not a stand-alone diagnosis or a disease. + + + + obo2:OAE_0002206 + insomnia AE + + + + obo2:OAE_0002206 + HPO: HP_0002360 + + + + obo2:OAE_0002206 + SIDER: C0917801 + + + + obo2:OAE_0002207 + Terminal insomnia AE is a insomnia AE that is a medical condition affecting sleep patterns. Typically, people who suffer from terminal insomnia wake up after only four to five hours of sleep. For those afflicted, getting back to sleep can be difficult, resulting in fatigue, irritability, and lack of concentration. + + + + obo2:OAE_0002207 + JX, LW, YH + + + + obo2:OAE_0002207 + matutinal insomnia AE + + + + obo2:OAE_0002207 + WEB: http://www.wisegeek.com/what-is-terminal-insomnia.htm + + + + obo2:OAE_0002207 + 早醒 + + + + obo2:OAE_0002207 + terminal insomnia AE + + + + obo2:OAE_0002207 + MedDRA: 10068932 + + + + obo2:OAE_0002208 + Bone marrow granuloma AE is a bone marrow disorder AE that shows an organized collection of macrophages in the bone marrow. + + + + obo2:OAE_0002208 + JX, LW, YH + + + + obo2:OAE_0002208 + 骨髓肉芽肿 + + + + obo2:OAE_0002208 + bone marrow granuloma AE + + + + obo2:OAE_0002208 + MedDRA: 10066816 + + + + obo2:OAE_0002209 + Cholestatic liver injury AE is a liver damage AE that shows buildup of bile acids in hepatocytes, then causes hepatocellular injury. + + + + obo2:OAE_0002209 + JX, LW ,YH + + + + obo2:OAE_0002209 + 胆汁郁积性肝损伤 + + + + obo2:OAE_0002209 + cholestatic liver injury AE + + + + obo2:OAE_0002209 + MedDRA: 10067969 + + + + obo2:OAE_0002210 + Distant heart sounds AE is a cardiac disorder AE that shows distant heart sounds. + + + + obo2:OAE_0002210 + JX, LW, YH + + + + obo2:OAE_0002210 + 心音遥远 + + + + obo2:OAE_0002210 + distant heart sounds AE + + + + obo2:OAE_0002211 + Pink skin AE is a skin AE that shows pink skin. + + + + obo2:OAE_0002211 + JX, LW, YH + + + + obo2:OAE_0002211 + 皮肤粉红 + + + + obo2:OAE_0002211 + pink skin AE + + + + obo2:OAE_0002212 + Acute laryngeal edema AE is an edema AE that shows acute laryngeal edema, abnormal accumulation of fluid in tissues of any part of the larynx, commonly associated with laryngeal injuries and allergic reactions. + + + + obo2:OAE_0002212 + JX, LW, YH + + + + obo2:OAE_0002212 + 急性喉头水肿 + + + + obo2:OAE_0002212 + acute laryngeal edema AE + + + + obo2:OAE_0002212 + MedDRA: 10066705 + + + + obo2:OAE_0002213 + Hypoplastic bone marrow AE is a bone marrow disorder AE that shows insufficient blood stem cells in the marrow. + + + + obo2:OAE_0002213 + JX, LW, YH + + + + obo2:OAE_0002213 + 骨髓发育不全 + + + + obo2:OAE_0002213 + hypoplastic bone marrow AE + + + + obo2:OAE_0002214 + Bleeding and coagulation disorders AE is a hematopoietic system AE that shows bleeding and coagulation disorders. + + + + obo2:OAE_0002214 + JX, LW, YH + + + + obo2:OAE_0002214 + 出凝血功能障碍 + + + + obo2:OAE_0002214 + bleeding and coagulation disorders AE + + + + obo2:OAE_0002215 + Polymorphic ventricular tachycardia AE is a ventricular tachycardia AE that is an abnormally fast heart rhythm starting in the ventricles, the lower chambers of the heart. + + + + obo2:OAE_0002215 + JX, LW, YH + + + + obo2:OAE_0002215 + WEB: http://www.healthguideinfo.com/arrhythmias-heart-palpitations/p110132/ + + + + obo2:OAE_0002215 + 多行性室性心动过速 + + + + obo2:OAE_0002215 + polymorphic ventricular tachycardia AE + + + + obo2:OAE_0002215 + MedDRA: 10036095 + + + + obo2:OAE_0002216 + Monomorphic ventricular tachycardia AE is a ventricular tachycardia AE that is a type of tachycardia which has a uniform beat-to-beat QRS morphology. + + + + obo2:OAE_0002216 + JX, LW, YH + + + + obo2:OAE_0002216 + 单行性室性心动过速 + + + + obo2:OAE_0002216 + monomorphic ventricular tachycardia AE + + + + obo2:OAE_0002216 + MedDRA: 10058185 + + + + obo2:OAE_0002217 + Respiratory tract symptoms AE is a respiratory system AE that is a series of discomforts which occurs in respiratory tract. + + + + obo2:OAE_0002217 + JX, LW, YH + + + + obo2:OAE_0002217 + 呼吸道症状 + + + + obo2:OAE_0002217 + respiratory tract symptoms AE + + + + obo2:OAE_0002218 + Clammy skin AE is a skin AE that occurs when the skin turns cooler than normal and is moist, despite a cooler surface temperature. Clammy skin is often pale. + + + + obo2:OAE_0002218 + JX, LW, YH + + + + obo2:OAE_0002218 + WEB: http://www.healthgrades.com/symptoms/clammy-skin + + + + obo2:OAE_0002218 + 皮肤湿冷 + + + + obo2:OAE_0002218 + clammy skin AE + + + + obo2:OAE_0002219 + Abnormal visual accommodation AE is an abnormal vision AE that shows abnormal visual accommodation. Accommodation is the process by which the vertebrate eye changes optical power to maintain a clear image or focus on an object as its distance varies. + + + + obo2:OAE_0002219 + JX, LW, YH + + + + obo2:OAE_0002219 + WEB: http://en.wikipedia.org/wiki/Accommodation_%28eye%29 + + + + obo2:OAE_0002219 + 视调节异常 + + + + obo2:OAE_0002219 + abnormal visual accommodation AE + + + + obo2:OAE_0002220 + an allergy AE that shows swelling and irritation of the skin, caused by an allergy to a substance in the environment. + + + + obo2:OAE_0002220 + JX, LW, YH + + + + obo2:OAE_0002220 + 皮肤过敏 + + + + obo2:OAE_0002220 + skin allergy AE + + + + obo2:OAE_0002221 + Heaviness of the head AE is a sensation of heaviness AE that shows a sensation feeling of heaviness in the head. + + + + obo2:OAE_0002221 + JX, LW, YH + + + + obo2:OAE_0002221 + 头重感 + + + + obo2:OAE_0002221 + heaviness of the head AE + + + + obo2:OAE_0002221 + MedDRA: 10049121 + + + + obo2:OAE_0002222 + Rheumatoid factor positive AE is an immunology and allergy investigation result abnormal AE that shows positive of the rheumatoid factor. Rheumatoid factor is a blood test that measures the amount of the RF antibody in the blood. + + + + obo2:OAE_0002222 + JX, LW, YH + + + + obo2:OAE_0002222 + WEB: http://www.nlm.nih.gov/medlineplus/ency/article/003548.htm + + + + obo2:OAE_0002222 + 类风湿因子阳性 + + + + obo2:OAE_0002222 + rheumatoid factor positive AE + + + + obo2:OAE_0002222 + MedDRA: 10039080 + + + + obo2:OAE_0002223 + Retinal detachment AE is an eye AE that is a separation of the retina from its attachments to the underlying tissue within the eye. + + + + obo2:OAE_0002223 + JX, LW, YH + + + + obo2:OAE_0002223 + WEB: http://www.medicinenet.com/retinal_detachment/article.htm + + + + obo2:OAE_0002223 + 视网膜脱离 + + + + obo2:OAE_0002223 + retinal detachment AE + + + + obo2:OAE_0002223 + MedDRA: 10038848 + + + + obo2:OAE_0002223 + NCIT: C26874 + + + + obo2:OAE_0002224 + Arm pain AE is a pain AE that shows discomfort in the structures of the arm. It can be caused by a wide variety of problems, ranging from joint injuries to compressed nerves. + + + + obo2:OAE_0002224 + JX, LW, YH + + + + obo2:OAE_0002224 + WEB: http://www.mayoclinic.org/symptoms/arm-pain/basics/definition/SYM-20050870 + + + + obo2:OAE_0002224 + 手臂疼痛 + + + + obo2:OAE_0002224 + arm pain AE + + + + obo2:OAE_0002225 + Peripheric paresthesia AE is a paresthesia AE that shows paresthesia in the peripheric area. + + + + obo2:OAE_0002225 + JX, LW, YH + + + + obo2:OAE_0002225 + 外周感觉异常 + + + + obo2:OAE_0002225 + peripheric paresthesia AE + + + + obo2:OAE_0002226 + Edema of glottis AE is an edema AE that is a swelling caused by fluid accumulation in the soft tissues of the larynx. The condition, usually inflammatory, may result from an infection, injury, allergy, or inhalation of toxic substances. + + + + obo2:OAE_0002226 + JX, LW, YH + + + + obo2:OAE_0002226 + 声门肿胀 + + + + obo2:OAE_0002226 + edema of glottis AE + + + + obo2:OAE_0002227 + Prolonged qrs complex AE is a electrocardiogram qrs complex abnormal AE that shows qrs complex prolonged. The QRS complex is a name for the combination of three of the graphical deflections seen on a typical electrocardiogram. + + + + obo2:OAE_0002227 + JX, LW, YH + + + + obo2:OAE_0002227 + QRS时间延长 + + + + obo2:OAE_0002227 + prolonged qrs complex AE + + + + obo2:OAE_0002228 + Prolonged bleeding time AE is a hematology investigation result abnormal AE that shows prolonged time for small blood vessels in the skin close to stop from bleeding. + + + + obo2:OAE_0002228 + JX, LW, YH + + + + obo2:OAE_0002228 + 出血时间延长 + + + + obo2:OAE_0002228 + prolonged bleeding time AE + + + + obo2:OAE_0002229 + Acute generalized exanthematous pustulosis AE is a skin AE that is a not uncommon cutaneous reaction pattern that in 90% of cases is related to medication administration, characterized by a sudden eruption that appears on average five days after the medication is started. + + + + obo2:OAE_0002229 + JX, LW, YH + + + + obo2:OAE_0002229 + pustular drug eruption AE + + + + obo2:OAE_0002229 + toxic pustuloderma AE + + + + obo2:OAE_0002229 + WEB: http://en.wikipedia.org/wiki/Acute_generalized_exanthematous_pustulosis + + + + obo2:OAE_0002229 + 急性全身性浓疱病 + + + + obo2:OAE_0002229 + acute generalized exanthematous pustulosis AE + + + + obo2:OAE_0002229 + MedDRA: 10062372 + + + + obo2:OAE_0002230 + Upper and lower limbs flare AE is an edema AE that shows edema in the upper and lower limbs, which is an accumulation of an excessive amount of watery fluid in cells or intercellular tissues. + + + + obo2:OAE_0002230 + JX, LW, YH + + + + obo2:OAE_0002230 + 上下肢红肿 + + + + obo2:OAE_0002230 + upper and lower limbs flare AE + + + + obo2:OAE_0002231 + Abnormal blood sugar with empty stomach AE is a blood glucose level abnormal AE that shows abnormal blood glucose level with empty stomach. + + + + obo2:OAE_0002231 + JX, LW, YH + + + + obo2:OAE_0002231 + 空腹时血糖异常 + + + + obo2:OAE_0002231 + abnormal blood sugar with empty stomach AE + + + + obo2:OAE_0002232 + Increased blood sugar with empty stomach AE is blood glucose level decreased AE that shows an increased glucose level in blood with empty stomach. + + + + obo2:OAE_0002232 + JX, LW, YH + + + + obo2:OAE_0002232 + 空腹时血糖升高 + + + + obo2:OAE_0002232 + increased blood sugar with empty stomach AE + + + + obo2:OAE_0002233 + Hydrochloric acid in gastric juice secretion increased AE is a gastric disorder AE that shows increased gastric acid. + + + + obo2:OAE_0002233 + JX, LW, YH + + + + obo2:OAE_0002233 + 胃酸分泌增多 + + + + obo2:OAE_0002233 + hydrochloric acid in gastric juice secretion increased AE + + + + obo2:OAE_0002234 + Torsades de pointes AE is a ventricular tachycardia AE that is a polymorphic ventricular tachycardia that exhibits distinct characteristics on the electrocardiogram. + + + + obo2:OAE_0002234 + JX, LW, YH + + + + obo2:OAE_0002234 + WEB: http://en.wikipedia.org/wiki/Torsades_de_pointes + + + + obo2:OAE_0002234 + 扭转性室速 + + + + obo2:OAE_0002234 + torsades de pointes AE + + + + obo2:OAE_0002234 + MedDRA: 10044067 + + + + obo2:OAE_0002235 + Proximal myasthenia AE is a myasthenia AE that shows proximal myasthenia. Myasthenia represents myasthenia gravis, a neuromuscular disease leading to fluctuating muscle weakness and fatigability. + + + + obo2:OAE_0002235 + JX, LW, YH + + + + obo2:OAE_0002235 + 近端肌无力 + + + + obo2:OAE_0002235 + proximal myasthenia AE + + + + obo2:OAE_0002236 + Dilated skin vessels AE is a vasodilatation AE that shows vasodilatation in the skin, which refers to the widening of blood vessels resulting from relaxation of smooth muscle cells within the vessel walls, particularly in the large arteries, smaller arterioles and large veins. + + + + obo2:OAE_0002236 + JX, LW, YH + + + + obo2:OAE_0002236 + 皮肤血管扩张 + + + + obo2:OAE_0002236 + dilated skin vessels AE + + + + obo2:OAE_0002237 + Numbness of oral mucosa AE is a numbness AE that shows an abnormal feeling or loss of sensation in the oral mucosa. + + + + obo2:OAE_0002237 + JX, LW, YH + + + + obo2:OAE_0002237 + 口腔黏膜发麻 + + + + obo2:OAE_0002237 + numbness of oral mucosa AE + + + + obo2:OAE_0002238 + Orthostatic dizziness AE is a dizziness AE that shows dizziness provocation by sudden postural change. + + + + obo2:OAE_0002238 + JX, LW, YH + + + + obo2:OAE_0002238 + 体位性头晕 + + + + obo2:OAE_0002238 + orthostatic dizziness AE + + + + obo2:OAE_0002238 + MedDRA: 10031125 + + + + obo2:OAE_0002239 + Acid reflux AE is a digestive system AE that shows the acid and pepsin secreted in the stomach back up in to the esophagus. + + + + obo2:OAE_0002239 + JX, LW, YH + + + + obo2:OAE_0002239 + 反酸 + + + + obo2:OAE_0002239 + acid reflux AE + + + + obo2:OAE_0002239 + MedDRA: 10066872 + + + + obo2:OAE_0002240 + Jugular phlebectasia AE is a vasodilatation AE that is an isolated saccular or fusiform dilation of a vein without tortuosity. + + + + obo2:OAE_0002240 + JX, LW, YH + + + + obo2:OAE_0002240 + WEB: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3708235/ + + + + obo2:OAE_0002240 + 颈静脉扩张 + + + + obo2:OAE_0002240 + jugular phlebectasia AE + + + + obo2:OAE_0002241 + Laryngeal edema AE is an edema AE that shows abnormal accumulation of fluid in tissues of any part of the larynx, commonly associated with laryngeal injuries and allergic reactions. + + + + obo2:OAE_0002241 + JX, LW, YH + + + + obo2:OAE_0002241 + 喉肿胀 + + + + obo2:OAE_0002241 + laryngeal edema AE + + + + obo2:OAE_0002241 + MedDRA: 10023838 + + + + obo2:OAE_0002242 + Flatus AE is a digestive system AE that shows gas or air expelled through the anus. + + + + obo2:OAE_0002242 + JX, LW, YH + + + + obo2:OAE_0002242 + 排气 + + + + obo2:OAE_0002242 + flatus AE + + + + obo2:OAE_0002242 + MedDRA: 10016769 + + + + obo2:OAE_0002243 + Continuous polymorphic ventricular tachycardia AE is a polymorphic ventricular tachycardia AE that shows polymorphic ventricular tachycardia is constantly. + + + + obo2:OAE_0002243 + JX, LW, YH + + + + obo2:OAE_0002243 + 连续性多形性室性心动过速 + + + + obo2:OAE_0002243 + continuous polymorphic ventricular tachycardia AE + + + + obo2:OAE_0002244 + Continuous polymorphic ventricular tachycardia AE is a polymorphic ventricular tachycardia AE that shows polymorphic ventricular tachycardia is intermittent. + + + + obo2:OAE_0002244 + JX, LW, YH + + + + obo2:OAE_0002244 + 间歇性多形性室性心动过速 + + + + obo2:OAE_0002244 + intermittent polymorphic ventricular tachycardia AE + + + + obo2:OAE_0002245 + Aggravated ulcer AE is a ulcer AE that shows aggravated ulcer. + + + + obo2:OAE_0002245 + JX, LW, YH + + + + obo2:OAE_0002245 + 溃疡加重 + + + + obo2:OAE_0002245 + aggravated ulcer AE + + + + obo2:OAE_0002246 + Heart failure increased AE is a cardiovascular disorder AE that shows aggravated heart failure. + + + + obo2:OAE_0002246 + JX, LW, YH + + + + obo2:OAE_0002246 + 心脏衰竭加重 + + + + obo2:OAE_0002246 + heart failure increased AE + + + + obo2:OAE_0002247 + Aggravated angina symptoms AE is a angina pectoris AE that shows aggravated angina symptoms. + + + + obo2:OAE_0002247 + JX, LW, YH + + + + obo2:OAE_0002247 + 心绞痛症状加剧 + + + + obo2:OAE_0002247 + aggravated angina symptoms AE + + + + obo2:OAE_0002248 + Aggravated renal injury AE is a renal impairment AE that shows aggravated renal injury. + + + + obo2:OAE_0002248 + JX, LW, YH + + + + obo2:OAE_0002248 + 肾损害加剧 + + + + obo2:OAE_0002248 + aggravated renal injury AE + + + + obo2:OAE_0002249 + Aggravated fatigue AE is a fatigue AE that shows aggravated fatigue. + + + + obo2:OAE_0002249 + JX, LW, YH + + + + obo2:OAE_0002249 + 脱力感加重 + + + + obo2:OAE_0002249 + aggravated fatigue AE + + + + obo2:OAE_0002250 + Persistent nausea AE is a nausea AE that shows constant nausea. Nausea is considered "persistent" if it continues for more than 2 days, or keeps recurring even after treatment. + + + + obo2:OAE_0002250 + JX, LW, YH + + + + obo2:OAE_0002250 + WEB: http://www.all4naturalhealth.com/persistent-nausea.html + + + + obo2:OAE_0002250 + 持续恶心 + + + + obo2:OAE_0002250 + persistent nausea AE + + + + obo2:OAE_0002251 + Aggravated Raynaud's syndrome AE is a Raynaud's syndrome AE that shows aggravated Raynaud's syndrome. + + + + obo2:OAE_0002251 + JX, LW, YH + + + + obo2:OAE_0002251 + Raynaud综合征加重 + + + + obo2:OAE_0002251 + aggravated Raynaud's syndrome AE + + + + obo2:OAE_0002252 + Increased gastric acid secretion with high dose AE is a gastric disorder AE that shows increased gastric acid secretion with high dose. + + + + obo2:OAE_0002252 + JX, LW, YH + + + + obo2:OAE_0002252 + 高剂量时胃酸分泌增加 + + + + obo2:OAE_0002252 + increased gastric acid secretion with high dose AE + + + + obo2:OAE_0002253 + Persistent vomiting AE is a vomiting AE that occurs frequently throughout the day and is often triggered by even small meals. + + + + obo2:OAE_0002253 + JX, LW, YH + + + + obo2:OAE_0002253 + WEB: http://www.healthhype.com/persistent-and-recurrent-vomiting-emesis-in-adults-and-children.html + + + + obo2:OAE_0002253 + 持续呕吐 + + + + obo2:OAE_0002253 + persistent vomiting AE + + + + obo2:OAE_0002253 + MedDRA: 10034716 + + + + obo2:OAE_0002254 + Hypoacusis AE is a ear AE that shows partial or complete loss of the ability to detect or understand sounds resulting from damage to the outer, middle, or inner ear structures. Causes include exposure to loud noise, ear infections, injuries to the ear, genetic, and congenital disorders. + + + + obo2:OAE_0002254 + JX, LW, YH + + + + obo2:OAE_0002254 + WEB: http://medical-dictionary.thefreedictionary.com/hypoacusis + + + + obo2:OAE_0002254 + 突发听力减退 + + + + obo2:OAE_0002254 + hypoacusis AE + + + + obo2:OAE_0002254 + MedDRA: 10048865 + + + + obo2:OAE_0002255 + Lip cyanosis AE is a cyanosis AE that is a condition in which the lips have a bluish discoloration due to a lack of oxygen in the tissues. + + + + obo2:OAE_0002255 + JX, LW, YH + + + + obo2:OAE_0002255 + WEB: http://www.rightdiagnosis.com/sym/lip_cyanosis.htm + + + + obo2:OAE_0002255 + 嘴唇发紫 + + + + obo2:OAE_0002255 + lip cyanosis AE + + + + obo2:OAE_0002256 + Nail cyanosis AE is a cyanosis AE that shows a dark bluish or purple nail resulting from deficient oxygenation of the blood. + + + + obo2:OAE_0002256 + JX, LW, YH + + + + obo2:OAE_0002256 + 指甲青紫 + + + + obo2:OAE_0002256 + nail cyanosis AE + + + + obo2:OAE_0002257 + Renal dysfunction AE is a kidney AE that has an outcome of reduced capacity to excrete metabolic products which accumulate systemically and are detectable clinicopathologically by renal function tests. The early stage of uremia. + + + + obo2:OAE_0002257 + This term appears to be a synonym to the 'renal failure AE'. + + + + obo2:OAE_0002257 + JX, LW, YH + + + + obo2:OAE_0002257 + hepatic and renal function disorder AE + + + + obo2:OAE_0002257 + 肾功能障碍 + + + + obo2:OAE_0002257 + renal insufficiency AE + + + + obo2:OAE_0002257 + UMLS ID: C0859242 + + + + obo2:OAE_0002258 + JX, LW, YH + + + + obo2:OAE_0002258 + Hemolysis AE is a hematopoietic system AE that is the rupturing of erythrocytes (red blood cells) and the release of their contents (cytoplasm) into surrounding fluid. + + + + obo2:OAE_0002258 + WEB: http://en.wikipedia.org/wiki/Hemolysis + + + + obo2:OAE_0002258 + 溶血 + + + + obo2:OAE_0002258 + hemolysis AE + + + + obo2:OAE_0002258 + MedDRA: 10019491 + + + + obo2:OAE_0002259 + Lip angioedema AE is a angioedema AE that shows lip angioedema, which is the rapid swelling (edema) of the dermis, subcutaneous tissue, mucosa and submucosal tissues. + + + + obo2:OAE_0002259 + JX, LW, YH + + + + obo2:OAE_0002259 + 唇血管神经性水肿 + + + + obo2:OAE_0002259 + lip angioedema AE + + + + obo2:OAE_0002260 + Tongue angioedema AE is a angioedema AE that shows tongue angioedema, which is the rapid swelling (edema) of the dermis, subcutaneous tissue, mucosa and submucosal tissues. + + + + obo2:OAE_0002260 + JX, LW, YH + + + + obo2:OAE_0002260 + 舌血管神经性水肿 + + + + obo2:OAE_0002260 + tongue angioedema AE + + + + obo2:OAE_0002261 + Acousma AE is a sensory capability AE that shows a hallucinatory impression of strange sounds. + + + + obo2:OAE_0002261 + JX, LW, YH + + + + obo2:OAE_0002261 + 幻听 + + + + obo2:OAE_0002261 + acousma AE + + + + obo2:OAE_0002262 + Eye burning AE is a eye AE that shows a feeling of burning in the eye. + + + + obo2:OAE_0002262 + JX, LW, YH + + + + obo2:OAE_0002262 + 眼睛灼烧感 + + + + obo2:OAE_0002262 + eye burning AE + + + + obo2:OAE_0002263 + Worsening renal function AE is a kidney AE that shows worsening renal function. + + + + obo2:OAE_0002263 + JX, LW, YH + + + + obo2:OAE_0002263 + 肾功能恶化 + + + + obo2:OAE_0002263 + worsening renal function AE + + + + obo2:OAE_0002264 + Mild change of hematology AE is a change of hematology AE that shows mild change of hematology. + + + + obo2:OAE_0002264 + JX, LW, YH + + + + obo2:OAE_0002264 + 轻度的血液学改变 + + + + obo2:OAE_0002264 + mild change of hematology AE + + + + obo2:OAE_0002265 + Moderate change of hematology AE is a change of hematology AE that shows moderate change of hematology. + + + + obo2:OAE_0002265 + JX, LW, YH + + + + obo2:OAE_0002265 + 中度的血液学改变 + + + + obo2:OAE_0002265 + moderate change of hematology AE + + + + obo2:OAE_0002266 + Severe lower blood pressure AE is a hypotension AE that shows severe sustained low blood pressure at a level that is likely to result in cardiovascular disease and/or other pathological states. + + + + obo2:OAE_0002266 + JX, LW, YH + + + + obo2:OAE_0002266 + significantly decreased blood pressure AE + + + + obo2:OAE_0002266 + 严重的血压降低 + + + + obo2:OAE_0002266 + severe lower blood pressure AE + + + + obo2:OAE_0002267 + Elevated blood transaminase reversibility AE is a transaminase level increased AE that shows elevated levels of alanine transaminase and aspartate transaminase reversibly. + + + + obo2:OAE_0002267 + JX, LW, YH + + + + obo2:OAE_0002267 + 血氨基转移酶可逆性升高 + + + + obo2:OAE_0002267 + elevated blood transaminase reversibility AE + + + + obo2:OAE_0002268 + Mild gastrointestinal tract reaction AE is a gastrointestinal disorder AE that shows a mild gastrointestinal disorder. + + + + obo2:OAE_0002268 + JX, LW, YH + + + + obo2:OAE_0002268 + 轻度胃肠道反应 + + + + obo2:OAE_0002268 + mild gastrointestinal tract reaction AE + + + + obo2:OAE_0002269 + Temporary abdominal distention AE is a abdominal distension AE that shows a temporary sensation of elevated abdominal pressure and volume. + + + + obo2:OAE_0002269 + JX, LW, YH + + + + obo2:OAE_0002269 + 暂时性腹胀 + + + + obo2:OAE_0002269 + temporary abdominal distention AE + + + + obo2:OAE_0002270 + Transient nausea AE is a nausea AE that is a gastric discomfort associated with the inclination to vomit. + + + + obo2:OAE_0002270 + JX, LW, YH + + + + obo2:OAE_0002270 + 暂时性恶心 + + + + obo2:OAE_0002270 + transient nausea AE + + + + obo2:OAE_0002271 + Persistent tachycardia AE is a tachycardia AE that is an increased heart rate that exceeds the normal range for a resting heartrate (heartrate in an inactive or sleeping individual). It's a constant process. + + + + obo2:OAE_0002271 + JX, LW, YH + + + + obo2:OAE_0002271 + 持续心动过速 + + + + obo2:OAE_0002271 + persistent tachycardia AE + + + + obo2:OAE_0002272 + Mild headache AE is a headache AE that shows mild headache. + + + + obo2:OAE_0002272 + JX, LW, YH + + + + obo2:OAE_0002272 + 轻度头痛 + + + + obo2:OAE_0002272 + mild headache AE + + + + obo2:OAE_0002273 + Transient hypoxemia AE is a hypoxia AE that is a reduced concentration of O2 in the blood, alveoli or other tissues resulting in the decreased pressure of this component of body gases. + + + + obo2:OAE_0002273 + JX, LW, YH + + + + obo2:OAE_0002273 + 瞬态低氧血症 + + + + obo2:OAE_0002273 + transient hypoxemia AE + + + + obo2:OAE_0002274 + Transient neuroticism AE is a neuroticism AE that is a type of personality trait that contrasts adjustment or emotional stability with maladjustment. Experience of anxiety, anger, disgust, sadness, embarrassment, and a variety of other negative emotions. + + + + obo2:OAE_0002274 + JX, LW, YH + + + + obo2:OAE_0002274 + 瞬态神经质 + + + + obo2:OAE_0002274 + transient neuroticism AE + + + + obo2:OAE_0002275 + Constant irritability AE is a irritability AE that shows in the patient being easily annoyed/irritated constantly. + + + + obo2:OAE_0002275 + JX, LW, YH + + + + obo2:OAE_0002275 + 持续烦躁 + + + + obo2:OAE_0002275 + constant irritability AE + + + + obo2:OAE_0002276 + Abnormal atony AE is a asthenia AE that is a medical term denoting symptoms of physical weakness and loss of strength. + + + + obo2:OAE_0002276 + JX, LW, YH + + + + obo2:OAE_0002276 + 异常无力 + + + + obo2:OAE_0002276 + abnormal atony AE + + + + obo2:OAE_0002277 + Secondary hypotension AE is a hypotension AE that is a type of hypertension which by definition is caused by an identifiable underlying secondary cause. + + + + obo2:OAE_0002277 + JX, LW, YH + + + + obo2:OAE_0002277 + WEB: http://en.wikipedia.org/wiki/Secondary_hypertension + + + + obo2:OAE_0002277 + 继发性高血压 + + + + obo2:OAE_0002277 + secondary hypotension AE + + + + obo2:OAE_0002278 + Transient elevated serum transaminase AE is a transaminase level increased AE that shows elevated levels of alanine transaminase and aspartate transaminase transiently. + + + + obo2:OAE_0002278 + JX, LW, YH + + + + obo2:OAE_0002278 + 瞬时血清转氨酶升高 + + + + obo2:OAE_0002278 + transient elevated serum transaminase AE + + + + obo2:OAE_0002279 + Transient elevated blood urea nitrogen AE is a blood urea level increased AE that shows a transient increase in amount of urea in blood. + + + + obo2:OAE_0002279 + JX, LW, YH + + + + obo2:OAE_0002279 + 瞬时血尿素氮升高 + + + + obo2:OAE_0002279 + transient elevated blood urea nitrogen AE + + + + obo2:OAE_0002280 + Apparent increased blood creatine phosphokinase AE is a blood creatine phosphokinase level increased AE that is characterized by an apparent increased level of creatine phosphokinase or phosphocreatine kinase. + + + + obo2:OAE_0002280 + JX, LW, YH + + + + obo2:OAE_0002280 + 明显的血肌酸磷酸激酶增高 + + + + obo2:OAE_0002280 + apparent increased blood creatine phosphokinase AE + + + + obo2:OAE_0002281 + Severe rhabdomyolysis AE is a rhabdomyolysis AE that shows in severe damaged skeletal muscle tissue breaks down rapidly. + + + + obo2:OAE_0002281 + JX, LW, YH + + + + obo2:OAE_0002281 + 严重的横纹肌溶解症 + + + + obo2:OAE_0002281 + severe rhabdomyolysis AE + + + + obo2:OAE_0002282 + Mild gastrointestinal bleeding AE is a gastrointestinal hemorrhage AE that shows mild gastrointestinal hemorrhage. + + + + obo2:OAE_0002282 + JX, LW, YH + + + + obo2:OAE_0002282 + 胃肠道轻微出血 + + + + obo2:OAE_0002282 + mild gastrointestinal bleeding AE + + + + obo2:OAE_0002283 + Occult gastrointestinal tract bleeding AE is a gastrointestinal hemorrhage AE that shows occult gastrointestinal hemorrhage. + + + + obo2:OAE_0002283 + JX, LW, YH + + + + obo2:OAE_0002283 + 胃肠道隐匿性出血 + + + + obo2:OAE_0002283 + occult gastrointestinal tract bleeding AE + + + + obo2:OAE_0002284 + Nitrate headache AE is a headache AE that that is a special headache induced by nitrate. + + + + obo2:OAE_0002284 + JX, LW, YH + + + + obo2:OAE_0002284 + 硝酸盐性头痛 + + + + obo2:OAE_0002284 + nitrate headache AE + + + + obo2:OAE_0002285 + Pantomorphia erythema exudativum AE is a skin AE that is a skin condition of unknown cause, possibly mediated by deposition of immune complex (mostly IgM) in the superficial microvasculature of the skin and oral mucous membrane that usually follows an infection or drug exposure. It is an uncommon disorder, with peak incidence in the second and third decades of life. + + + + obo2:OAE_0002285 + JX, LW, YH + + + + obo2:OAE_0002285 + WEB: http://en.wikipedia.org/wiki/Erythema_multiforme + + + + obo2:OAE_0002285 + 多形性渗出性红斑 + + + + obo2:OAE_0002285 + pantomorphia erythema exudativum AE + + + + obo2:OAE_0002286 + High hypodynamia AE is a fatigue AE that is a state of awareness describing a range of afflictions, usually associated with physical and/or mental weakness, though varying from a general state of lethargy to a specific work-induced burning sensation within one's muscles. Physical fatigue is the inability to continue functioning at the level of one's normal abilities. + + + + obo2:OAE_0002286 + JX, LW, YH + + + + obo2:OAE_0002286 + 高度乏力 + + + + obo2:OAE_0002286 + high hypodynamia AE + + + + obo2:OAE_0002287 + Short-time nausea AE is a nausea AE that shows a gastric discomfort associated with the inclination to vomit. + + + + obo2:OAE_0002287 + JX, LW, YH + + + + obo2:OAE_0002287 + 短暂的恶心 + + + + obo2:OAE_0002287 + short-time nausea AE + + + + obo2:OAE_0002288 + Slightly increased aspartic transaminase AE is a aspartate aminotransferase level increased AE that shows a slightly increased amount of AST which is an enzyme normally present in body tissues especially of the heart and liver, + + + + obo2:OAE_0002288 + JX, LW, YH + + + + obo2:OAE_0002288 + 门冬氨酸氨基转移酶轻度升高 + + + + obo2:OAE_0002288 + slightly increased aspartic transaminase AE + + + + obo2:OAE_0002289 + Slightly increased alanine aminotransferase AE is a alanine aminotransferase level increased AE that shows elevated levels of alanine transaminase slightly. + + + + obo2:OAE_0002289 + JX, LW, YH + + + + obo2:OAE_0002289 + 丙氨酸氨基转移酶轻度升高 + + + + obo2:OAE_0002289 + slightly increased alanine aminotransferase AE + + + + obo2:OAE_0002290 + Slightly increased lactic dehydrogenase AE is a blood lactate dehydrogenase level increased AE that shows a slightly increased amount of LDH which is an enzyme that could indicate tissue damage. + + + + obo2:OAE_0002290 + JX, LW, YH + + + + obo2:OAE_0002290 + 乳酸脱氢酶轻度升高 + + + + obo2:OAE_0002290 + slightly increased lactic dehydrogenase AE + + + + obo2:OAE_0002291 + Slightly increased alkaline phosphatase AE is a blood alkaline phosphatase increased AE that shows elevated levels of alkaline phosphatase slightly. + + + + obo2:OAE_0002291 + JX, LW, YH + + + + obo2:OAE_0002291 + 碱性磷酸酶轻度升高 + + + + obo2:OAE_0002291 + slightly increased alkaline phosphatase AE + + + + obo2:OAE_0002292 + Slightly increased glutamic-oxalacetic transaminase AE is a aspartate aminotransferase level increased AE that shows a slightly increased amount of glutamic-oxalacetic transaminase in the heart and liver. + + + + obo2:OAE_0002292 + JX, LW, YH + + + + obo2:OAE_0002292 + 谷草转氨酶轻度升高 + + + + obo2:OAE_0002292 + slightly increased glutamic-oxalacetic transaminase AE + + + + obo2:OAE_0002293 + Slightly increased glutamic pyruvic transaminase AE is a alanine aminotransferase level increased AE that shows eelevated levels of glutamic pyruvic transaminase in the liver. + + + + obo2:OAE_0002293 + JX, LW, YH + + + + obo2:OAE_0002293 + 谷丙转氨酶轻度升高 + + + + obo2:OAE_0002293 + slightly increased glutamic pyruvic transaminase AE + + + + obo2:OAE_0002294 + Transient ischemic stroke AE is a ischemic stroke AE that occurs when a blood vessel that supplies the brain becomes blocked or "clogged" and impairs blood flow to part of the brain. + + + + obo2:OAE_0002294 + JX, LW, YH + + + + obo2:OAE_0002294 + 暂时性缺血性中风 + + + + obo2:OAE_0002294 + transient ischemic stroke AE + + + + obo2:OAE_0002295 + Evidently increased hepatic lipase AE is a hepatic enzyme increased AE that shows an evidently increase in amount of hepatic enzyme in body, commonly includes ALT and AST. It may indicate inflammation or damage to liver cells. + + + + obo2:OAE_0002295 + JX, LW, YH + + + + obo2:OAE_0002295 + 肝酶显著增加 + + + + obo2:OAE_0002295 + evidently increased hepatic lipase AE + + + + obo2:OAE_0002296 + Mild decline in blood pressure AE is a hypotension AE that shows mild sustained low blood pressure at a level that is likely to result in cardiovascular disease and/or other pathological states. + + + + obo2:OAE_0002296 + JX, LW, YH + + + + obo2:OAE_0002296 + 血压轻度下降 + + + + obo2:OAE_0002296 + mild decline in blood pressure AE + + + + obo2:OAE_0002297 + Transient cerebral ischemic attacks AE is a cerebral ischemia AE that shows the sudden death of brain cells in a localized area due to inadequate blood flow. + + + + obo2:OAE_0002297 + JX, LW, YH + + + + obo2:OAE_0002297 + 短暂脑缺血发作 + + + + obo2:OAE_0002297 + transient cerebral ischemic attacks AE + + + + obo2:OAE_0002298 + Transient hypotension AE is a hypotension AE that shows transient sustained low blood pressure at a level that is likely to result in cardiovascular disease and/or other pathological states. + + + + obo2:OAE_0002298 + JX, LW, YH + + + + obo2:OAE_0002298 + 瞬时低血压 + + + + obo2:OAE_0002298 + transient hypotension AE + + + + obo2:OAE_0002299 + Obviously decreased blood pressure AE is a hypotension AE that shows obviously sustained low blood pressure at a level that is likely to result in cardiovascular disease and/or other pathological states. + + + + obo2:OAE_0002299 + JX, LW, YH + + + + obo2:OAE_0002299 + significantly decreased blood pressure AE + + + + obo2:OAE_0002299 + 血压明显下降 + + + + obo2:OAE_0002299 + obviously decreased blood pressure AE + + + + obo2:OAE_0002300 + Transient dizzy AE is a dizziness AE that shows transient dizziness. + + + + obo2:OAE_0002300 + JX, LW, YH + + + + obo2:OAE_0002300 + 瞬时头晕 + + + + obo2:OAE_0002300 + transient dizzy AE + + + + obo2:OAE_0002301 + Short-time hepatic function disorder AE is a hepatic function abnormal AE that shows a short-time abnormal functionality of the liver. + + + + obo2:OAE_0002301 + JX, LW, YH + + + + obo2:OAE_0002301 + 短暂肝功能异常 + + + + obo2:OAE_0002301 + short-time hepatic function disorder AE + + + + obo2:OAE_0002302 + A slightly elevated plasma creatinine level AE is a blood creatinine level increased AE that shows an slightly increased level of creatinine in the blood (due to lack of kidney activity). + + + + obo2:OAE_0002302 + JX, LW, YH + + + + obo2:OAE_0002302 + 血浆肌酐水平的轻微升高 + + + + obo2:OAE_0002302 + a slightly elevated plasma creatinine level AE + + + + obo2:OAE_0002303 + Sudden fall of blood pressure AE is a hypotension AE that shows sudden sustained low blood pressure at a level that is likely to result in cardiovascular disease and/or other pathological states. + + + + obo2:OAE_0002303 + JX, LW, YH + + + + obo2:OAE_0002303 + 血压突然降低 + + + + obo2:OAE_0002303 + sudden fall of blood pressure AE + + + + obo2:OAE_0002304 + Severe hypertension AE is a hypotension AE that shows severe sustained high blood pressure at a level that is likely to result in cardiovascular disease and/or other pathological states. + + + + obo2:OAE_0002304 + JX, LW, YH + + + + obo2:OAE_0002304 + 严重高血压 + + + + obo2:OAE_0002304 + severe hypertension AE + + + + obo2:OAE_0002305 + Severe arrhythmia AE is an arrhythmia AE that shows severe abnormal heart rhythm. + + + + obo2:OAE_0002305 + JX, LW, YH + + + + obo2:OAE_0002305 + 严重心律失常 + + + + obo2:OAE_0002305 + severe arrhythmia AE + + + + obo2:OAE_0002306 + Clinically significant rise of serum transaminase AE is a transaminase level increased AE that shows elevated levels of alanine transaminase and aspartate transaminase significantly. + + + + obo2:OAE_0002306 + JX, LW, YH + + + + obo2:OAE_0002306 + 血清转氨酶有临床显著升高 + + + + obo2:OAE_0002306 + clinically significant rise of serum transaminase AE + + + + obo2:OAE_0002307 + Instantaneous sand-blind AE is a vision blurred AE that shows in instantaneous unclear vision. + + + + obo2:OAE_0002307 + JX, LW, YH + + + + obo2:OAE_0002307 + 瞬时视觉模糊 + + + + obo2:OAE_0002307 + instantaneous sand-blind AE + + + + obo2:OAE_0002308 + Moderately increased urinary nitrogen AE is a blood urea level increased AE that shows a moderately increase in amount of urea in blood. + + + + obo2:OAE_0002308 + JX, LW, YH + + + + obo2:OAE_0002308 + 尿素中度升高 + + + + obo2:OAE_0002308 + moderately increased urinary nitrogen AE + + + + obo2:OAE_0002309 + Slightly increased urinary nitrogen AE is a blood urea level increased AE that shows a slightly increase in amount of urea in blood. + + + + obo2:OAE_0002309 + JX, LW, YH + + + + obo2:OAE_0002309 + 尿素水平轻微升高 + + + + obo2:OAE_0002309 + slightly increased urinary nitrogen AE + + + + obo2:OAE_0002310 + Moderately elevated serum creatinine AE is a blood creatinine level increased AE that shows an moderately increased level of creatinine in the blood (due to lack of kidney activity). + + + + obo2:OAE_0002310 + JX, LW, YH + + + + obo2:OAE_0002310 + 血肌酐中度升高 + + + + obo2:OAE_0002310 + moderately elevated serum creatinine AE + + + + obo2:OAE_0002311 + Slightly increased aminotransferase AE is a transaminase level increased AE that shows slightly elevated levels of alanine transaminase and aspartate transaminase. + + + + obo2:OAE_0002311 + JX, LW, YH + + + + obo2:OAE_0002311 + 轻度氨基转氨酶升高 + + + + obo2:OAE_0002311 + slightly increased aminotransferase AE + + + + obo2:OAE_0002312 + Severe dizziness AE is a dizziness AE that shows severe dizziness. + + + + obo2:OAE_0002312 + JX, LW, YH + + + + obo2:OAE_0002312 + 严重眩晕 + + + + obo2:OAE_0002312 + severe dizziness AE + + + + obo2:OAE_0002313 + Mild abdominal discomfort AE is a abdominal discomfort AE that shows a mild stomach ache. + + + + obo2:OAE_0002313 + JX, LW, YH + + + + obo2:OAE_0002313 + 轻微腹部不适 + + + + obo2:OAE_0002313 + mild abdominal discomfort AE + + + + obo2:OAE_0002314 + Serum potassium concentration of moderately reduced AE is a blood potassium decreased AE that shows slightly lower than normal amount of potassium in the blood. + + + + obo2:OAE_0002314 + JX, LW, YH + + + + obo2:OAE_0002314 + 血清钾浓度的轻度降低 + + + + obo2:OAE_0002314 + serum potassium concentration of moderately reduced AE + + + + obo2:OAE_0002315 + Rebound Increased blood pressure AE is a hypertension AE that shows rebound sustained high blood pressure at a level that is likely to result in cardiovascular disease and/or other pathological states. + + + + obo2:OAE_0002315 + JX, LW, YH + + + + obo2:OAE_0002315 + 反跳性血压升高 + + + + obo2:OAE_0002315 + rebound Increased blood pressure AE + + + + obo2:OAE_0002316 + Excessive lowering of blood pressure AE is a hypotension AE that shows excessive sustained low blood pressure at a level that is likely to result in cardiovascular disease and/or other pathological states. + + + + obo2:OAE_0002316 + JX, LW, YH + + + + obo2:OAE_0002316 + 血压过度降低 + + + + obo2:OAE_0002316 + excessive lowering of blood pressure AE + + + + obo2:OAE_0002317 + Short-time increased blood sugar AE is a blood glucose level increased AE that shows a short-time increased glucose level in blood. + + + + obo2:OAE_0002317 + JX, LW, YH + + + + obo2:OAE_0002317 + 短暂血糖升高 + + + + obo2:OAE_0002317 + short-time increased blood sugar AE + + + + obo2:OAE_0002318 + Mild nausea AE is a nausea AE that shows mild nausea. + + + + obo2:OAE_0002318 + JX, LW, YH + + + + obo2:OAE_0002318 + 轻度恶心 + + + + obo2:OAE_0002318 + mild nausea AE + + + + obo2:OAE_0002319 + Significant and persistent rise of serum transaminase AE is a transaminase level increased AE that shows elevated levels of alanine transaminase and aspartate transaminase significantly and persistently. + + + + obo2:OAE_0002319 + JX, LW, YH + + + + obo2:OAE_0002319 + 血清氨基转移酶显著和持续性升高 + + + + obo2:OAE_0002319 + significant and persistent rise of serum transaminase AE + + + + obo2:OAE_0002320 + Elevated serum transaminase reversibility AE is a transaminase level increased AE that shows elevated levels of alanine transaminase and aspartate transaminase reversibly. + + + + obo2:OAE_0002320 + JX, LW, YH + + + + obo2:OAE_0002320 + 血清氨基转移酶可逆性升高 + + + + obo2:OAE_0002320 + elevated serum transaminase reversibility AE + + + + obo2:OAE_0002321 + Reversible increased creatine phosphokinase AE is a blood creatine phosphokinase level increased AE that is characterized by an reversible increased level of creatine phosphokinase or phosphocreatine kinase. + + + + obo2:OAE_0002321 + JX, LW, YH + + + + obo2:OAE_0002321 + 肌酸磷酸激酶可逆性升高 + + + + obo2:OAE_0002321 + reversible increased creatine phosphokinase AE + + + + obo2:OAE_0002322 + Persistent and significant increase of serum transaminase AE is a transaminase level increased AE that shows elevated levels of alanine transaminase and aspartate transaminase significantly and persistently. + + + + obo2:OAE_0002322 + JX, LW, YH + + + + obo2:OAE_0002322 + 血清转氨酶显著和持续性升高 + + + + obo2:OAE_0002322 + persistent and significant increase of serum transaminase AE + + + + obo2:OAE_0002323 + Severe bradycardia AE is a bradycardia AE that shows in a resting heart rate of under 60 beats per minutes (BPM). + + + + obo2:OAE_0002323 + JX, LW, YH + + + + obo2:OAE_0002323 + 严重心动过缓 + + + + obo2:OAE_0002323 + severe bradycardia AE + + + + obo2:OAE_0002324 + Apparent hypotensive reaction AE is a hypotension AE that shows apparent sustained low blood pressure at a level that is likely to result in cardiovascular disease and/or other pathological states. + + + + obo2:OAE_0002324 + JX, LW, YH + + + + obo2:OAE_0002324 + 显著的低血压反应 + + + + obo2:OAE_0002324 + apparent hypotensive reaction AE + + + + obo2:OAE_0002325 + Severe skin flush AE is a hot flush AE that shows severe hot flush. + + + + obo2:OAE_0002325 + JX, LW, YH + + + + obo2:OAE_0002325 + 显著皮肤潮红 + + + + obo2:OAE_0002325 + severe skin flush AE + + + + obo2:OAE_0002326 + Transient sinus cardiac arrest AE is a sinus arrest AE that shows an electrocardiographic finding of transient impulse formation failure in the sinus node. + + + + obo2:OAE_0002326 + JX, LW, YH + + + + obo2:OAE_0002326 + 瞬时窦性停搏 + + + + obo2:OAE_0002326 + transient sinus cardiac arrest AE + + + + obo2:OAE_0002327 + Low-grade gastralgia AE is a stomacheache AE that shows a low-grade painful sensation in the stomach. + + + + obo2:OAE_0002327 + JX, LW, YH + + + + obo2:OAE_0002327 + 轻度胃痛 + + + + obo2:OAE_0002327 + low-grade gastralgia AE + + + + obo2:OAE_0002328 + Severe headache AE is a headache AE that shows severe headache. + + + + obo2:OAE_0002328 + JX, LW, YH + + + + obo2:OAE_0002328 + 严重头痛 + + + + obo2:OAE_0002328 + severe headache AE + + + + obo2:OAE_0002329 + Persistent headache AE is a headache AE that shows persistent headache. + + + + obo2:OAE_0002329 + JX, LW, YH + + + + obo2:OAE_0002329 + 持续头痛 + + + + obo2:OAE_0002329 + persistent headache AE + + + + obo2:OAE_0002330 + Proarrhythmic effect AE is an arrhythmia AE that is a new or more frequent occurrence of pre-existing arrhythmias, paradoxically precipitated by antiarrhythmic therapy, which means it is a side effect associated with the administration of some existing antiarrhythmic drugs, as well as drugs for other indications. In other words, it is a tendency of antiarrhythmic drugs to facilitate emergence of new arrhythmias. + + + + obo2:OAE_0002330 + JX, LW, YH + + + + obo2:OAE_0002330 + arhythmia auxo-action AE + + + + obo2:OAE_0002330 + WEB: http://en.wikipedia.org/wiki/Proarrhythmia + + + + obo2:OAE_0002330 + 致心律失常 + + + + obo2:OAE_0002330 + proarrhythmic effect AE + + + + obo2:OAE_0002330 + MedDRA: 10036766 + + + + obo2:OAE_0002331 + a metabolism, endocrine, and exocrine system AE that has an outcome of acidosis, i.e., too much acid in the body fluids. + + + + obo2:OAE_0002331 + Blood pH Decreased + + + + obo2:OAE_0002331 + URL: http://www.nlm.nih.gov/medlineplus/ency/article/001181.htm + + + + obo2:OAE_0002331 + YH, SJ + + + + obo2:OAE_0002331 + acidosis AE + + + + obo2:OAE_0002331 + MedDRA: 10000486 + + + + obo2:OAE_0002331 + MedDRA: 10005706 + + + + obo2:OAE_0002332 + Increased tendency of biliary calculus AE is a liver, biliary, and pancreatic AE that shows an increased tendency of biliary calculus. + + + + obo2:OAE_0002332 + JX, LW, YH + + + + obo2:OAE_0002332 + 胆石增加的趋势 + + + + obo2:OAE_0002332 + increased tendency of biliary calculus AE + + + + obo2:OAE_0002333 + Temporarily lose consciousness AE is a sensory capability AE that shows temporarily lose consciousness. + + + + obo2:OAE_0002333 + JX, LW, YH + + + + obo2:OAE_0002333 + 暂时失去知觉 + + + + obo2:OAE_0002333 + temporarily lose consciousness AE + + + + obo2:OAE_0002334 + Increase breast cancer occurrence AE is a breast cancer AE that shows increase breast cancer occurrence. + + + + obo2:OAE_0002334 + JX, LW, YH + + + + obo2:OAE_0002334 + 乳腺癌发生增加 + + + + obo2:OAE_0002334 + increase breast cancer occurrence AE + + + + obo2:OAE_0002335 + Anticholinergic effect AE is a conduction system disorder AE that is physical symptoms resulting from agents that counter the action of acetylcholine, a neurotransmitter (chemical within the nervous system) that is involved in many major bodily functions. These anticholinergic effects typically include constipation, dry mouth, blurred vision, dizziness, and slowing of urination. + + + + obo2:OAE_0002335 + JX, LW, YH + + + + obo2:OAE_0002335 + WEB: http://ibs.about.com/od/glossary/g/Anticholeffect.htm + + + + obo2:OAE_0002335 + 经讯号传导阻断效应 + + + + obo2:OAE_0002335 + anticholinergic effect AE + + + + obo2:OAE_0002336 + a musculoskeletal system AE that has an outcome of diaphragmatic muscle replaced by fibroelestic tissue. The diaphragm retains its continuity and attachments to the costal margin. However, the weakened hemidiaphragm is displaced into the thorax, which can compromise breathing. + + + + obo2:OAE_0002336 + SJ, YH + + + + obo2:OAE_0002336 + URL: http://www.uptodate.com/contents/eventration-of-the-diaphragm-in-infants + + + + obo2:OAE_0002336 + acquired diaphragmatic eventration AE + + + + obo2:OAE_0002336 + MedDRA: 10000486 + + + + obo2:OAE_0002337 + Neutrophilopenia AE is a neutrophil count decreased AE that shows the number of neutrophil is decreased. + + + + obo2:OAE_0002337 + JX, LW, YH + + + + obo2:OAE_0002337 + 中性白细胞减少 + + + + obo2:OAE_0002337 + neutrophilopenia AE + + + + obo2:OAE_0002338 + Abnormal leucocyte neutrophil AE is a neutrophil percentage abnormal AE that shows abnormal leucocyte neutrophil. + + + + obo2:OAE_0002338 + JX, LW, YH + + + + obo2:OAE_0002338 + 嗜中性白细胞异常 + + + + obo2:OAE_0002338 + abnormal leucocyte neutrophil AE + + + + obo2:OAE_0002339 + Abnormal eosinocyte AE is an eosinophil count abnormal AE that shows abnormal eosinocyte. + + + + obo2:OAE_0002339 + JX, LW, YH + + + + obo2:OAE_0002339 + 嗜酸性粒细胞异常 + + + + obo2:OAE_0002339 + abnormal eosinocyte AE + + + + obo2:OAE_0002340 + Eosinopenia AE is an eosinophil count abnormal AE that is a form of agranulocytosis where the number of eosinophil granulocytes is lower than expected. + + + + obo2:OAE_0002340 + JX, LW, YH + + + + obo2:OAE_0002340 + WEB: http://en.wikipedia.org/wiki/Eosinopenia + + + + obo2:OAE_0002340 + 嗜酸细胞减少症 + + + + obo2:OAE_0002340 + eosinopenia AE + + + + obo2:OAE_0002340 + MedDRA: 10014940 + + + + obo2:OAE_0002341 + Aggravated peptic ulcer AE is a duodenal ulcer AE that shows aggravated peptic ulcer. + + + + obo2:OAE_0002341 + JX, LW, YH + + + + obo2:OAE_0002341 + 消化性溃疡加重 + + + + obo2:OAE_0002341 + aggravated peptic ulcer AE + + + + obo2:OAE_0002342 + Local tissue necrosis AE is a necrosis AE that shows local tissue necrosis. + + + + obo2:OAE_0002342 + JX, LW, YH + + + + obo2:OAE_0002342 + 局部组织坏死 + + + + obo2:OAE_0002342 + local tissue necrosis AE + + + + obo2:OAE_0002343 + a cardiac disorder AE that is characterized by a necrosis of the myocardium caused by diminished blood supply to the heart + + + + obo2:OAE_0002343 + SJ, YH + + + + obo2:OAE_0002343 + URL: http://www.clevelandclinicmeded.com/medicalpubs/diseasemanagement/cardiology/acute-myocardial-infarction/ + + + + obo2:OAE_0002343 + acute myocardial infarction AE + + + + obo2:OAE_0002343 + MedDRA: 10000891 + + + + obo2:OAE_0002344 + an endocrine system AE that results in a life threatening condition due to a lack of cortisol produced by the adrenal glands + + + + obo2:OAE_0002344 + SJ, YH + + + + obo2:OAE_0002344 + URL: http://www.nlm.nih.gov/medlineplus/ency/article/000357.htm + + + + obo2:OAE_0002344 + acute adrenal crisis AE + + + + obo2:OAE_0002344 + MedDRA: 10001389 + + + + obo2:OAE_0002345 + YH, SJ + + + + obo2:OAE_0002345 + URL http://www.thelancet.com/journals/laneur/article/PIIS1474-4422%2814%2970102-4/abstract + + + + obo2:OAE_0002345 + a pain AE that results in pain from a stimulus that does not usually provoke pain + + + + obo2:OAE_0002345 + allodynia AE + + + + obo2:OAE_0002345 + MedDRA ID: 10053552 + + + + obo2:OAE_0002346 + an embolism AE in which amniotic fluid, fetal cells, hair or other debris enter the maternal circulation resulting in cardiorespiratory collapse + + + + obo2:OAE_0002346 + SJ, YH + + + + obo2:OAE_0002346 + Anaphylactoid Syndrome of Pregnancy + + + + obo2:OAE_0002346 + WEB: http://emedicine.medscape.com/article/253068-overview + + + + obo2:OAE_0002346 + amniotic fluid embolism AE + + + + obo2:OAE_0002346 + MedDRA: 10001977 + + + + obo2:OAE_0002347 + a muscular weakness AE that has an outcome of weakness followed by wasting of muscles, and excruciating pain in the muscles of the thigh, hip, and buttocks + + + + obo2:OAE_0002347 + YH, SJ + + + + obo2:OAE_0002347 + diabetic lumbosacral radiculoplexus neuropathy + + + + obo2:OAE_0002347 + diabetic polyradiculoneuropathy + + + + obo2:OAE_0002347 + proximal diabetic neuropathy + + + + obo2:OAE_0002347 + diabetic amyotrophy AE + + + + obo2:OAE_0002347 + MedDRA: 10002027 + + + + obo2:OAE_0002348 + an adverse drug event that results in unexpected and unwanted events due to anesthetic drug treatment + + + + obo2:OAE_0002348 + SJ, YH + + + + obo2:OAE_0002348 + WEB: https://www.dha.gov.ae/EN/Facilities/Hospitals/RashidHospital/SpecializedMedicalService/ClinicalServices/Anesthesiologyandinterventionalpain/pages/sideeffects.aspx + + + + obo2:OAE_0002348 + anesthetic complication AE + + + + obo2:OAE_0002348 + MedDRA: 10060938 + + + + obo2:OAE_0002349 + a digestive system AE that results in the development of a small channel between the end of the bowel and the skin near the anus + + + + obo2:OAE_0002349 + SJ, YH + + + + obo2:OAE_0002349 + WEB: http://www.webmd.boots.com/digestive-disorders/anal-fistula + + + + obo2:OAE_0002349 + anal fistula AE + + + + obo2:OAE_0002349 + MedDRA: 10002156 + + + + obo2:OAE_0002350 + postoperative anemia AE is an anemia AE that occurs when a patient with acute bleeding loses enough blood to become anemic + + + + obo2:OAE_0002350 + SJ, YH + + + + obo2:OAE_0002350 + bleeding and acute blood loss anemia + + + + obo2:OAE_0002350 + WEB: http://www.acphospitalist.org/archives/2012/02/coding.htm + + + + obo2:OAE_0002350 + postoperative anemia AE + + + + obo2:OAE_0002350 + MedDRA: 10054312 + + + + obo2:OAE_0002351 + a behavior and neurological AE that results in antagonism toward someone or something you feel has deliberately done you wrong: excessive anger can cause problems including increased blood pressure and other physical changes that make it difficult to think straight and can harm your physical and mental health. + + + + obo2:OAE_0002351 + SJ, YH + + + + obo2:OAE_0002351 + WEB: http://apa.org/topics/anger/index.aspx + + + + obo2:OAE_0002351 + anger AE + + + + obo2:OAE_0002351 + MedDRA: 10002368 + + + + obo2:OAE_0002352 + a musculoskeletal system AE that results in the formation of fibrous band between tissues and organs, often as a result of injury during surgery + + + + obo2:OAE_0002352 + SJ, YH + + + + obo2:OAE_0002352 + URL: http://en.wikipedia.org/wiki/Adhesion_%28medicine%29 + + + + obo2:OAE_0002352 + adhesion AE + + + + obo2:OAE_0002352 + MedDRA: 10059837 + + + + obo2:OAE_0002353 + a crying abnormal AE that refers to a neurologic disorder characterized by involuntary crying or uncontrollable episodes of crying and/or laughing, or other emotional displays + + + + obo2:OAE_0002353 + YH, SJ + + + + obo2:OAE_0002353 + emotional incontinence + + + + obo2:OAE_0002353 + emotional lability + + + + obo2:OAE_0002353 + labile affect + + + + obo2:OAE_0002353 + WEB: http://en.wikipedia.org/wiki/Pseudobulbar_affect + + + + obo2:OAE_0002353 + pseudobulbar affect AE + + + + obo2:OAE_0002353 + MedDRA: 10054196 + + + + obo2:OAE_0002354 + cardiovascular AE that results in disease of the arteries, veins, and capillaries + + + + obo2:OAE_0002354 + SJ, YH + + + + obo2:OAE_0002354 + macroangiopathy + + + + obo2:OAE_0002354 + microangiopathy + + + + obo2:OAE_0002354 + WEB: http://www.medicinenet.com/script/main/art.asp?articlekey=6853 + + + + obo2:OAE_0002354 + angiopathy AE + + + + obo2:OAE_0002354 + MedDRA: 10059245 + + + + obo2:OAE_0002355 + a cardiovascular AE that results in the walls of small blood vessels becoming so thick and weak that they bleed, leak protein, and slow the flow of blood + + + + obo2:OAE_0002355 + SJ, YH + + + + obo2:OAE_0002355 + WEB: http://www.medicinenet.com/script/main/art.asp?articlekey=6853 + + + + obo2:OAE_0002355 + microangiopathy AE + + + + obo2:OAE_0002355 + MedDRA: 10062198 + + + + obo2:OAE_0002356 + a cardiovascualr AE that results in the build up of fat and blood clots in the large blood vessels, stick to the vessel walls, and block the flow of blood + + + + obo2:OAE_0002356 + SJ, YH + + + + obo2:OAE_0002356 + cerebrovascular disease + + + + obo2:OAE_0002356 + coronary artery disease + + + + obo2:OAE_0002356 + peripheral vascular disease + + + + obo2:OAE_0002356 + WEB: http://www.medicinenet.com/script/main/art.asp?articlekey=6853 + + + + obo2:OAE_0002356 + macroangiopathy AE + + + + obo2:OAE_0002356 + MedDRA: 10054805 + + + + obo2:OAE_0002357 + a muscle AE that results in a congenital anomaly in which a short, lingual frenulum or a highly-attached genioglossus muscle restricts tongue movement + + + + obo2:OAE_0002357 + SJ, YH + + + + obo2:OAE_0002357 + tongue-tie + + + + obo2:OAE_0002357 + WEB: http://www.uptodate.com/contents/ankyloglossia-tongue-tie-in-infants-and-children + + + + obo2:OAE_0002357 + ankyloglossia AE + + + + obo2:OAE_0002357 + MedDRA ID: 10049244 + + + + obo2:OAE_0002358 + a digestive system AE that results in a group of medical disorders that occur at the junction of the anal canal and the rectum + + + + obo2:OAE_0002358 + SJ, YH + + + + obo2:OAE_0002358 + WEB: http://medical-dictionary.thefreedictionary.com/Anorectal+Disorders + + + + obo2:OAE_0002358 + anorectal disorder AE + + + + obo2:OAE_0002358 + MedDRA: 10002644 + + + + obo2:OAE_0002359 + a hemorrhage AE that has an outcome of bleeding from or in to the genital tract, occurring from 24 weeks of pregnancy and prior to the birth of the baby. + + + + obo2:OAE_0002359 + YH, SJ + + + + obo2:OAE_0002359 + WEB: https://www.rcog.org.uk/globalassets/documents/guidelines/gtg63_05122011aph.pdf + + + + obo2:OAE_0002359 + antepartum hemorrhage AE + + + + obo2:OAE_0002359 + MedDRA: 10055228 + + + + obo2:OAE_0002360 + Brain damage AE that results in a persistent vegetative state + + + + obo2:OAE_0002360 + SJ, YH + + + + obo2:OAE_0002360 + WEB: http://www.rightdiagnosis.com/a/apallic_syndrome/intro.htm + + + + obo2:OAE_0002360 + apallic syndrome AE + + + + obo2:OAE_0002360 + MedDRA: 10002941 + + + + obo2:OAE_0002361 + APGAR is a quick test performed on a neonate at 1 and 5 minutes after birth. The 1-minute score determines how well the baby tolerated the birthing process. The 5-minute score tells the doctor how well the baby is doing outside the mother's womb. Any score lower than 7 is a sign that the baby needs medical attention. The lower the score, the more help the baby needs to adjusting outside the mother's womb + + + + obo2:OAE_0002361 + YH, SJ + + + + obo2:OAE_0002361 + WEB: http://www.nlm.nih.gov/medlineplus/ency/article/003402.htm + + + + obo2:OAE_0002361 + APGAR score low AE + + + + obo2:OAE_0002361 + MedDRA: 10002944 + + + + obo2:OAE_0002361 + MedDRA: 10062552 + + + + obo2:OAE_0002362 + a brain disorder AE that causes a person to lose the ability to communicate. Aphasia can affect the ability to express and understand language, both verbal and written. Aphasia typically occurs suddenly after a stroke or a head injury, but it can also come on gradually from a slowly growing brain tumor or a degenerative disease + + + + obo2:OAE_0002362 + SJ, YH + + + + obo2:OAE_0002362 + WEB: http://www.mayoclinic.org/diseases-conditions/aphasia/basics/definition/con-20027061 + + + + obo2:OAE_0002362 + aphasia AE + + + + obo2:OAE_0002362 + MedDRA: 10002948 + + + + obo2:OAE_0002363 + a tumor AE that results in pouches of cerebrospinal fluid covered by arachnoidal cells and collagen that may develop between the surface of the brain and the cranial base or on the arachnoid membrane + + + + obo2:OAE_0002363 + SJ, YH + + + + obo2:OAE_0002363 + WEB:http://en.wikipedia.org/wiki/Arachnoid_cyst + + + + obo2:OAE_0002363 + arachnoid cyst AE + + + + obo2:OAE_0002363 + MedDRA: 10049005 + + + + obo2:OAE_0002364 + a brain disorder AE that causes inflammation of the arachnoid, one of the membranes known as meninges that surround and protect the nerves of the central nervous system, including the brain and spinal cord. + + + + obo2:OAE_0002364 + SJ, YH + + + + obo2:OAE_0002364 + WEB: http://en.wikipedia.org/wiki/Arachnoiditis + + + + obo2:OAE_0002364 + arachnoiditis AE + + + + obo2:OAE_0002364 + MedDRA: 10003074 + + + + obo2:OAE_0002365 + A pregnancy AE that results in an interruption in the labor process that is associated with uterine contractions. + + + + obo2:OAE_0002365 + SJ, YH + + + + obo2:OAE_0002365 + WEB: http://medical-dictionary.thefreedictionary.com/arrested+labor + + + + obo2:OAE_0002365 + arrested labor AE + + + + obo2:OAE_0002365 + MedDRA: 10003118 + + + + obo2:OAE_0002366 + an arrhythmia AE that is characterized by shortness of breath, heart palpitations, chest tightness, and a very fast pulse. Supraventricular arrhythmias begin in the areas above the heart’s lower chambers, such as the upper chambers (the atria) or the atrial conduction pathways. + + + + obo2:OAE_0002366 + SJ, YH + + + + obo2:OAE_0002366 + atrial arrhythmia + + + + obo2:OAE_0002366 + WEB: http://www.texasheart.org/HIC/Topics/cond/arrhycat.cfm + + + + obo2:OAE_0002366 + supraventricular arrhythmia AE + + + + obo2:OAE_0002366 + MedDRA: 10003130 + + + + obo2:OAE_0002367 + a cardiac disorder AE which causes a spasm of the large- or medium-sized coronary arteries + + + + obo2:OAE_0002367 + SJ, YH + + + + obo2:OAE_0002367 + coronary artery spasm + + + + obo2:OAE_0002367 + coronary artery vasospasm + + + + obo2:OAE_0002367 + coronary vasospasm + + + + obo2:OAE_0002367 + WEB: http://sideeffects.embl.de/se/C0010073/pt + + + + obo2:OAE_0002367 + coronary arteriospasm AE + + + + obo2:OAE_0002367 + MedDRA: 10003225 + + + + obo2:OAE_0002368 + joint range of motion decreased AE caused by an excessive amount of scar tissue forming within the joint and surrounding soft tissue spaces + + + + obo2:OAE_0002368 + SJ, YH + + + + obo2:OAE_0002368 + WEB: http://en.wikipedia.org/wiki/Arthrofibrosis + + + + obo2:OAE_0002368 + arthrofibrosis AE + + + + obo2:OAE_0002368 + MedDRA: 10058029 + + + + obo2:OAE_0002369 + arteriosclerosis AE is a cardiovascular AE that results in blood vessels and arteries becoming thick and stiff which can restrict blood flow to organs and tissues. + + + + obo2:OAE_0002369 + SJ, YH + + + + obo2:OAE_0002369 + WEB: http://www.mayoclinic.org/diseases-conditions/arteriosclerosis-atherosclerosis/basics/definition/con-20026972 + + + + obo2:OAE_0002369 + arteriosclerosis AE + + + + obo2:OAE_0002369 + MedDRA: 10003210 + + + + obo2:OAE_0002370 + atheroslcerosis AE is a specific arteriosclerosis AE that refers to the buildup of fats, cholesterol and other substances in and on artery walls which can restrict blood flow. + + + + obo2:OAE_0002370 + SJ, YH + + + + obo2:OAE_0002370 + WEB: http://www.mayoclinic.org/diseases-conditions/arteriosclerosis-atherosclerosis/basics/definition/con-20026972 + + + + obo2:OAE_0002370 + atherosclerosis AE + + + + obo2:OAE_0002370 + MedDRA: 10003601 + + + + obo2:OAE_0002371 + atrial tachycardia AE is a tachycardia AE that results in a fast heart rate beginning in the upper chambers of the heart + + + + obo2:OAE_0002371 + SJ, YH + + + + obo2:OAE_0002371 + MedDRA: 10003668 + + + + obo2:OAE_0002371 + paroxysmal atrial tachycardia + + + + obo2:OAE_0002371 + paroxysmal supraventricular tachycardia + + + + obo2:OAE_0002371 + supraventricular tachycardia + + + + obo2:OAE_0002371 + WEB: http://www.heart.org/HEARTORG/Conditions/Arrhythmia/AboutArrhythmia/Tachycardia-Fast-Heart-Rate_UCM_302018_Article.jsp# + + + + obo2:OAE_0002371 + atrial tachycardia AE + + + + obo2:OAE_0002372 + an endocrine system AE that results in high blood cortisol levels + + + + obo2:OAE_0002372 + SJ, YH + + + + obo2:OAE_0002372 + URL: http://www.nlm.nih.gov/medlineplus/ency/article/003693.htm + + + + obo2:OAE_0002372 + blood cortisol decreased AE may indicate that the patient has cushing disease, ectopic cushing syndrome, or a tumor of the adrenal gland that is producing too much cortisol. + + + + obo2:OAE_0002372 + blood cortisol increased AE + + + + obo2:OAE_0002372 + MedDRA: 10005458 + + + + + obo2:OAE_0002373 + a cardiovascular disorder AE that results in easy or excessive bruising and bleeding. The bleeding results from unusually low levels of platelets. + + + + obo2:OAE_0002373 + SJ, YH + + + + obo2:OAE_0002373 + immune thrombocytopenic purpura + + + + obo2:OAE_0002373 + WEB: http://www.mayoclinic.org/diseases-conditions/idiopathic-thrombocytopenic-purpura/basics/definition/con-20034239 + + + + obo2:OAE_0002373 + idiopathic thrombocytopenic purpura AE + + + + obo2:OAE_0002373 + MedDRA: 10050245 + + + + obo2:OAE_0002374 + YH, SJ + + + + obo2:OAE_0002374 + WEB: http://www.medicinenet.com/script/main/art.asp?articlekey=2477 + + + + + obo2:OAE_0002374 + a pain AE that is observed in the bladder, usually a symptom of bladder infection. + + + + obo2:OAE_0002374 + bladder pain AE + + + + obo2:OAE_0002374 + MedDRA ID: 10005063 + + + + obo2:OAE_0002375 + an eye AE that results in involuntary, forcible closure of the eyelids.The spasms may leave the eyelids completely closed, causing functional blindness even though the eyes and vision are normal. + + + + obo2:OAE_0002375 + SJ, YH + + + + obo2:OAE_0002375 + WEB: http://www.medicinenet.com/script/main/art.asp?articlekey=2481 + + + + obo2:OAE_0002375 + blepharospasm AE + + + + obo2:OAE_0002375 + MedDRA: 10005159 + + + + obo2:OAE_0002376 + an abnormal vision AE which has an outcome of loss of vision in one eye that is not permanent. + + + + obo2:OAE_0002376 + SJ, YH + + + + + obo2:OAE_0002376 + blindness unilateral + + + + obo2:OAE_0002376 + WEB: http://en.wikipedia.org/wiki/Amaurosis_fugax + + + + obo2:OAE_0002376 + amaurosis fugax AE + + + + obo2:OAE_0002376 + MedDRA ID: 10005186 + + + + obo2:OAE_0002377 + an endocrine system AE that results in low blood cortisol levels + + + + obo2:OAE_0002377 + SJ, YH + + + + obo2:OAE_0002377 + URL: http://www.nlm.nih.gov/medlineplus/ency/article/003693.htm + + + + obo2:OAE_0002377 + blood cortisol decreased AE may indicate that the patient has addison disease, hypopituitarism, suppression of normal pituitary or adrenal function. + + + + obo2:OAE_0002377 + blood cortisol decreased AE + + + + obo2:OAE_0002377 + MedDRA: 10005457 + + + + obo2:OAE_0002378 + an endocrine system AE that results in high blood creatine levels + + + + obo2:OAE_0002378 + SJ, YH + + + + obo2:OAE_0002378 + URL: http://www.mayoclinic.org/tests-procedures/creatinine/basics/definition/prc-20014534 + + + + obo2:OAE_0002378 + blood creatine increased AE may indicate that the kidneys are not fucntioning properly + + + + obo2:OAE_0002378 + blood creatine increased AE + + + + obo2:OAE_0002378 + MedDRA: 10005464 + + + + + obo2:OAE_0002380 + blood immunoglobin E increased AE is an allergic response AE that signifies that a patient is allergic to a particular substance + + + + obo2:OAE_0002380 + SJ, YH + + + + obo2:OAE_0002380 + WEB: http://kidshealth.org/parent/system/medical/test_ige.html + + + + obo2:OAE_0002380 + blood immunoglobin E increased AE + + + + obo2:OAE_0002380 + MedDRA: 10005591 + + + + obo2:OAE_0002381 + a male reproductive system AE that results in low levels of testosterone which can lead to infertility and a low sex drive + + + + obo2:OAE_0002381 + SJ, YH + + + + obo2:OAE_0002381 + WEB: http://www.webmd.com/men/testosterone-15738 + + + + + obo2:OAE_0002381 + blood testosterone decreased AE + + + + obo2:OAE_0002381 + MedDRA: 10005814 + + + + obo2:OAE_0002382 + A macrocytic anemia AE is an anemia AE that has an outcome of a macrocytic anemia, which is an anemia (defined as blood with an insufficient concentration of hemoglobin) in which the red blood cells (erythrocytes) are larger than their normal volume. + + + + obo2:OAE_0002382 + KM, YH + + + + obo2:OAE_0002382 + WEB: http://en.wikipedia.org/wiki/Macrocytic_anemia + + + + obo2:OAE_0002382 + macrocytic anemia AE + + + + obo2:OAE_0002382 + MedDRA: 10002064 + + + + obo2:OAE_0002383 + a bone disorder AE that has an outcome of low bone densityl, but not low enough to be considered osteoporosis + + + + obo2:OAE_0002383 + SJ, YH + + + + obo2:OAE_0002383 + WEB: http://nof.org/articles/9 + + + + obo2:OAE_0002383 + low bone density AE + + + + obo2:OAE_0002383 + MedDRA: 10049470 + + + + + obo2:OAE_0002384 + a surgical AE that occurs after a bone graftr procedure, which replaces missing bone in order to repair bone fractures that are extremely complex, pose a significant health risk to the patient, or fail to heal properly. + + + + obo2:OAE_0002384 + SJ, YH + + + + obo2:OAE_0002384 + WEB: http://en.wikipedia.org/wiki/Bone_grafting + + + + obo2:OAE_0002384 + bone graft AE + + + + obo2:OAE_0002385 + bone marrow edema AE is an edema AE that occurs when excess fluids in the bone marrow buildup and cause swelling. This condition is often caused by a protective reaction of the body in response to an injury or inflammation + + + + obo2:OAE_0002385 + SJ, YH + + + + obo2:OAE_0002385 + WEB: http://www.wisegeek.com/what-is-bone-marrow-edema.htm + + + + obo2:OAE_0002385 + bone marrow edema AE + + + + obo2:OAE_0002385 + MedDRA: 10051763 + + + + + obo2:OAE_0002386 + an investigation result abnormal AE that detects areas of increased or decreased bone activity. These may indicate bone injury or disease. + + + + obo2:OAE_0002386 + SJ, YH + + + + obo2:OAE_0002386 + WEB: http://www.mountsinai.org/patient-care/health-library/treatments-and-procedures/bone-scan + + + + obo2:OAE_0002386 + bone scan abnormal AE + + + + obo2:OAE_0002386 + MedDRA: 10061941 + + + + + obo2:OAE_0002387 + Nervous system AE that covers a variety of conditions that may impair function of the brachial plexus nerve network, most of which are caused by trauma. + + + + obo2:OAE_0002387 + SJ, YH + + + + obo2:OAE_0002387 + WEB: http://www.hopkinsmedicine.org/neurology_neurosurgery/centers_clinics/peripheral_nerve_surgery/conditions/brachial_plexus_injury_bpi.html + + + + obo2:OAE_0002387 + brachial plexus injury AE + + + + obo2:OAE_0002387 + MedDRA: 10006074 + + + + + obo2:OAE_0002388 + a bradycardia AE that results in a disturbance in the heart rhythm in which the heart rate is abnormally slowed. + + + + obo2:OAE_0002388 + SJ, YH + + + + obo2:OAE_0002388 + WEB: http://medical-dictionary.thefreedictionary.com/bradyarrhythmia + + + + + obo2:OAE_0002388 + bradyarrhythmia AE + + + + obo2:OAE_0002388 + MedDRA: 10049765 + + + + + + obo2:OAE_0002389 + a bradycardia AE that results in a fetal heart rate of less than 120 beats per minute, generally associatedwith hypoxia + + + + obo2:OAE_0002389 + SJ, YH + + + + obo2:OAE_0002389 + WEB:http://medical-dictionary.thefreedictionary.com/fetal+bradycardia + + + + obo2:OAE_0002389 + bradycardia fetal AE + + + + obo2:OAE_0002389 + MedDRA: 10006094 + + + + + obo2:OAE_0002390 + a brain disorder AE that results in the complete and irreversible loss of brain function + + + + obo2:OAE_0002390 + SJ, YH + + + + obo2:OAE_0002390 + WEB: http://en.wikipedia.org/wiki/Brain_death + + + + + obo2:OAE_0002390 + brain death AE + + + + obo2:OAE_0002390 + MedDRA: 10049054 + + + + + obo2:OAE_0002391 + a brain disorder AE that results in brain tissue, cerebrospinal fluid, and blood vessels being moved or pressed away from their usual position inside the skull. + + + + obo2:OAE_0002391 + SJ, YH + + + + obo2:OAE_0002391 + WEB: http://www.nlm.nih.gov/medlineplus/ency/article/001421.htm + + + + + + obo2:OAE_0002391 + brain herniation AE + + + + obo2:OAE_0002391 + MedDRA: 10006126 + + + + + obo2:OAE_0002392 + a brain injury AE,  injury to the brain caused by an external force, that results in a brain AE + + + + obo2:OAE_0002392 + SJ, YH + + + + obo2:OAE_0002392 + Traumatic Brain Injury + + + + obo2:OAE_0002392 + WEB: http://www.biausa.org/FAQRetrieve.aspx?ID=43913 + + + + + + + obo2:OAE_0002392 + brain injury AE + + + + obo2:OAE_0002392 + MedDRA: 10067967 + + + + + + obo2:OAE_0002393 + a brain mass AE is a mass or growth of abnormal cells in your brain or close to your brain + + + + obo2:OAE_0002393 + SJ, YH + + + + obo2:OAE_0002393 + Brain Neoplasm + + + + obo2:OAE_0002393 + Brain Tumor + + + + obo2:OAE_0002393 + Intercranial Neosplasm + + + + obo2:OAE_0002393 + WEB: http://www.mayoclinic.org/diseases-conditions/brain-tumor/home/ovc-20117132 + + + + obo2:OAE_0002393 + brain mass AE + + + + obo2:OAE_0002393 + MedDRA: 10052334 + + + + obo2:OAE_0002393 + MedDRA: 10061019 + + + + + obo2:OAE_0002394 + an imaging investigation result abnormal AE shows how the brain and its tissues are working. Abnormal results may be due to: Alzheimer’s disease or dementia, brain tumors, epilepsy, and movement disorders. + + + + obo2:OAE_0002394 + SJ, YH + + + + obo2:OAE_0002394 + PET scan + + + + obo2:OAE_0002394 + WEB: http://www.nlm.nih.gov/medlineplus/ency/article/007341.htm + + + + + obo2:OAE_0002394 + brain scan abnormal AE + + + + obo2:OAE_0002394 + MedDRA: 10061943 + + + + + obo2:OAE_0002395 + Eyelid disorder AE is a eye AE that is a condition specifically affects the eyelid. It can include drooping, twitching, inflammation, paralysis, and growths. Occasional fluttering of one eyelid is normal. + + + + obo2:OAE_0002395 + JX, LW + + + + obo2:OAE_0002395 + WEB: http://www.healthline.com/health/eyelid-disorders#Overview1 + + + + obo2:OAE_0002395 + eyelid disorder AE + + + + obo2:OAE_0002395 + MedDRA: 10061130 + + + + obo2:OAE_0002396 + Hepatic steatosis AE is a liver disorder AE than popularly called as ‘fatty liver’ is a pathological aspect of liver, whose specific cells (hepatocytes) are filled with lipids (fats). It is a reversible liver disease: ‘is not still very ill, but cries for help’. + + + + obo2:OAE_0002396 + JX, LW + + + + obo2:OAE_0002396 + WEB: http://www.bendomd.com/272-hepatic-steatosis-causes-symptoms-treatment.html + + + + obo2:OAE_0002396 + hepatic steatosis AE + + + + obo2:OAE_0002396 + MedDRA: 10019708 + + + + obo2:OAE_0002397 + An arthropathy AE is a joint pain AE that has an outcome of arthropahty, which is any disorder of the joints. + + + + obo2:OAE_0002397 + KM, YH + + + + obo2:OAE_0002397 + WEB: http://en.wikipedia.org/wiki/Arthropathy, http://medical-dictionary.thefreedictionary.com/arthropathy + + + + obo2:OAE_0002397 + arthropathy AE + + + + + obo2:OAE_0002397 + MedDRA: 10003285 + + + + + obo2:OAE_0002397 + NCIT: C35760 + + + + obo2:OAE_0002398 + A balantis AE is a reproductive system AE that has an outcome of a balantis, which is an infectious or non-infectious inflammatory process that affects the glans penis. Symptoms include redness and pain of the glans penis and foreskin and discharge. + + + + obo2:OAE_0002398 + KM, YH + + + + obo2:OAE_0002398 + WEB: http://www.nlm.nih.gov/medlineplus/ency/article/000862.htm, http://en.wikipedia.org/wiki/Balanitis + + + + obo2:OAE_0002398 + balanitis AE + + + + obo2:OAE_0002398 + MedDRA: 10004073 + + + + + obo2:OAE_0002399 + Pruritus genital AE is a pruritus AE that also called genital itching, Itching in the genital region can result from irritation, allergy, inflammation, infection or cancer. Irritation can occur as a result of exposure to chemicals in soaps, feminine hygiene products, perfumes, lubricants, douches, and creams. + + + + obo2:OAE_0002399 + JX, LW + + + + obo2:OAE_0002399 + genital itching AE + + + + obo2:OAE_0002399 + WEB: http://www.healthgrades.com/symptoms/genital-itching + + + + obo2:OAE_0002399 + pruritus genital AE + + + + obo2:OAE_0002399 + MedDRA ID: 10037093 + + + + obo2:OAE_0002400 + cholecystitis AE is an gallbladder enlargement AE that has an outcome of cholecystitis, which is an acute or chronic inflammation involving the gallbladder wall. It may be associated with the presence of gallstones. + + + + obo2:OAE_0002400 + KM, YH + + + + obo2:OAE_0002400 + WEB: http://en.wikipedia.org/wiki/Cholecystitis, http://www.mayoclinic.org/diseases-conditions/cholecystitis/basics/definition/con-20034277 + + + + obo2:OAE_0002400 + cholecystitis AE + + + + obo2:OAE_0002400 + MedDRA: 10008612 + + + + + obo2:OAE_0002400 + NCIT: C34465 + + + + obo2:OAE_0002401 + Chromaturia AE is an urine abnormality AE that has an outcome of chromaturia, which is an abnormal coloration of the urine. + + + + obo2:OAE_0002401 + KM, YH + + + + obo2:OAE_0002401 + WEB: http://medical-dictionary.thefreedictionary.com/chromaturia + + + + + obo2:OAE_0002401 + chromaturia AE + + + + obo2:OAE_0002401 + MedDRA: 10008796 + + + + + obo2:OAE_0002402 + Chromosome abnormality AE is a genetic AE that has an outcome of chromsome abnormality which is a missing, extra, or irregular protion of chromosomal DNA. + + + + obo2:OAE_0002402 + KM, YH + + + + obo2:OAE_0002402 + WEB: http://en.wikipedia.org/wiki/Chromosome_abnormality + + + + + obo2:OAE_0002402 + chromosome abnormality AE + + + + obo2:OAE_0002402 + MedDRA: 10008815 + + + + + obo2:OAE_0002403 + A coagulopathy AE is a blood disorder AE that has an outcome of coagulopathy, which is a condition in which there is a deviation from or interruption of the normal coagulation properties of the blood. + + + + obo2:OAE_0002403 + KM, YH + + + + obo2:OAE_0002403 + WEB: http://en.wikipedia.org/wiki/Coagulopathy + + + + + obo2:OAE_0002403 + coagulopathy AE + + + + obo2:OAE_0002403 + MedDRA: 10009802 + + + + + obo2:OAE_0002404 + Combined immunodeficiency AE is an immune system AE that has an outcome of combined immunodeficiency, which represents a group of rare, sometimes fatal, congenital disorders characterized by little or no immune response. + + + + obo2:OAE_0002404 + KM, YH + + + + obo2:OAE_0002404 + WEB: http://www.ncbi.nlm.nih.gov/books/NBK22254/ + + + + + obo2:OAE_0002404 + combined immunodeficiency AE + + + + obo2:OAE_0002404 + MedDRA: 10010099 + + + + + obo2:OAE_0002405 + Hepatic enzyme abnormal AE is a liver related investigation result abnormal AE that the lab test result of hepatic enzyme deviates from its normal value. + + + + obo2:OAE_0002405 + JX, YH + + + + obo2:OAE_0002405 + hepatic enzyme abnormal AE + + + + obo2:OAE_0002405 + MedDRA: 10062685 + + + + obo2:OAE_0002406 + A coronary artery aneurysm AE is a coronary artery disorder AE that has an outcome of coronary artery aneurysm, which is a coronary dilatation which exceeds the diameter of normal adjacent segments or the diameter of the patient's largest coronary vessel by 1.5 times. + + + + obo2:OAE_0002406 + KM, YH + + + + obo2:OAE_0002406 + WEB: http://en.wikipedia.org/wiki/Coronary_artery_aneurysm + + + + obo2:OAE_0002406 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/9247557 + + + + obo2:OAE_0002406 + coronary artery aneurysm AE + + + + obo2:OAE_0002406 + MedDRA: 10011071 + + + + + obo2:OAE_0002407 + Injection site atrophy AE is an injection-site AE that muscle atrophy occur in the injection site. + + + + obo2:OAE_0002407 + JX, YH + + + + obo2:OAE_0002407 + injection site atrophy AE + + + + obo2:OAE_0002407 + MedDRA: 10022048 + + + + obo2:OAE_0002408 + A cutaneous tuberculosis AE is a tuberculosis AE that has an outcome of cutaneous tuberculosis, which is an invasion of the skin by Mycobacterium tuberculosis. + + + + obo2:OAE_0002408 + KM, YH + + + + obo2:OAE_0002408 + WEB: http://www.dermnetnz.org/bacterial/tuberculosis.html + + + + obo2:OAE_0002408 + cutaneous tuberculosis AE + + + + obo2:OAE_0002408 + MedDRA: 10011684 + + + + + obo2:OAE_0002409 + Breath sounds abnormal AE is a respiratory system AE that is characterized by abnormal breath sound, it can indicate fluid in the lungs or asthma. + + + + obo2:OAE_0002409 + JX, LW + + + + obo2:OAE_0002409 + WEB: http://www.healthline.com/health/breath-sounds#Overview1 + + + + obo2:OAE_0002409 + breath sounds abnormal AE + + + + obo2:OAE_0002409 + MedDRA: 10064780 + + + + obo2:OAE_0002410 + Skin abrasion AE is a skin AE that is a wound caused by superficial damage to the skin, no deeper than the epidermis. + + + + obo2:OAE_0002410 + JX, YH + + + + obo2:OAE_0002410 + WEB: http://en.wikipedia.org/wiki/Abrasion_%28medical%29 + + + + obo2:OAE_0002410 + skin abrasion AE + + + + obo2:OAE_0002410 + MedDRA: 10064990 + + + + obo2:OAE_0002411 + Trigeminal neuralgia AE is a neuralgia AE that is a neuropathic disorder characterized by episodes of intense pain in the face, originating from the trigeminal nerve. The clinical association between TN and hemifacial spasm is the so-called tic douloureux. + + + + obo2:OAE_0002411 + JX, YH + + + + obo2:OAE_0002411 + Fothergill's disease AE + + + + obo2:OAE_0002411 + prosopalgia AE + + + + obo2:OAE_0002411 + WEB: http://en.wikipedia.org/wiki/Trigeminal_neuralgia + + + + obo2:OAE_0002411 + trigeminal neuralgia AE + + + + obo2:OAE_0002411 + MedDRA: 10044652 + + + + obo2:OAE_0002412 + Face injury AE is an injury AE that injury occurs in the face. + + + + obo2:OAE_0002412 + JX, YH + + + + obo2:OAE_0002412 + face injury AE + + + + obo2:OAE_0002412 + MedDRA: 10050392 + + + + obo2:OAE_0002413 + Muscle contrature AE is a muscle AE that can occur for many reasons, such as paralysis, muscular atrophy, and forms of muscular dystrophy. Fundamentally, the muscle and its tendons shorten, resulting in reduced flexibility. + + + + obo2:OAE_0002413 + JX, YH + + + + obo2:OAE_0002413 + WEB: http://en.wikipedia.org/wiki/Muscle_contracture + + + + obo2:OAE_0002413 + muscle contrature AE + + + + obo2:OAE_0002413 + MedDRA: 10062575 + + + + obo2:OAE_0002414 + Gaze palsy AE is a behavior and neurological AE that is a symmetric limitation of the movements of both eyes in the same direction. + + + + obo2:OAE_0002414 + JX, YH + + + + obo2:OAE_0002414 + WEB: http://one.aao.org/bcscsnippetdetail.aspx?id=f5a77965-de2a-4fb0-82fb-5f4089671ad6 + + + + obo2:OAE_0002414 + gaze palsy AE + + + + obo2:OAE_0002414 + MedDRA: 10056696 + + + + obo2:OAE_0002415 + Conjugate gaze palsy AE is a gaze palsy AE that is a disorder affecting the ability to move both eyes in the same direction. These palsies can affect gaze in a horizontal, upward, or downward direction. + + + + obo2:OAE_0002415 + JX, YH + + + + obo2:OAE_0002415 + WEB: http://en.wikipedia.org/wiki/Conjugate_gaze_palsy + + + + obo2:OAE_0002415 + conjugate gaze palsy AE + + + + obo2:OAE_0002416 + Horizontal gaze palsy AE is a gaze palsy AE that is the paresis of conjugate eye movements. + + + + obo2:OAE_0002416 + JX, YH + + + + obo2:OAE_0002416 + WEB: http://en.wikipedia.org/wiki/Horizontal_gaze_palsy + + + + obo2:OAE_0002416 + horizontal gaze palsy AE + + + + obo2:OAE_0002417 + Posture abnormal AE a behavioral AE that refers to rigid body movements and chronic abnormal positions of the body. This symptom is not the same as showing poor posture or slumping over. Rather, it is often the result of a serious spinal cord or brain injury. + + + + obo2:OAE_0002417 + JX, YH + + + + obo2:OAE_0002417 + WEB: http://www.healthline.com/symptom/posture-abnormal + + + + obo2:OAE_0002417 + posture abnormal AE + + + + obo2:OAE_0002417 + MedDRA: 10036436 + + + + obo2:OAE_0002418 + Tonic clonic movements AE a behavioral AE that shows the body becomes entire rigid and uncontrolled jerking. They may last mere seconds, or continue for several minutes. + + + + obo2:OAE_0002418 + JX, YH + + + + obo2:OAE_0002418 + tonic clonic movements AE + + + + obo2:OAE_0002418 + MedDRA: 10051171 + + + + obo2:OAE_0002419 + Eyelid ptosis AE is an eye disorder AE that is a drooping or falling of the upper or lower eyelid. + + + + obo2:OAE_0002419 + JX, LW + + + + obo2:OAE_0002419 + WEB: http://en.wikipedia.org/wiki/Ptosis_%28eyelid%29 + + + + obo2:OAE_0002419 + eyelid ptosis AE + + + + obo2:OAE_0002419 + MedDRA: 10015995 + + + + obo2:OAE_0002420 + Facial paresis AE is a paresis AE that is a common problem that involves the paralysis of any structures innervated by the facial nerve. + + + + obo2:OAE_0002420 + JX, YH + + + + obo2:OAE_0002420 + facial nerve paralysis AE + + + + obo2:OAE_0002420 + WEB: http://en.wikipedia.org/wiki/Facial_nerve_paralysis + + + + obo2:OAE_0002420 + facial paresis AE + + + + obo2:OAE_0002420 + MedDRA: 10051267 + + + + obo2:OAE_0002421 + Menstrual disorder AE is an irregular condition in a woman's menstrual cycle. + + + + obo2:OAE_0002421 + WEB: http://en.wikipedia.org/wiki/Menstrual_disorder + + + + obo2:OAE_0002421 + JX, YH + + + + obo2:OAE_0002421 + menstrual disorder AE + + + + obo2:OAE_0002421 + MedDRA: 10027327 + + + + obo2:OAE_0002422 + Fluid retention AE is an abnormal fluid regulation AE that is excess fluid that collects in the tissues in your body. Most commonly, fluid retention is marked by swelling of your feet and lower legs, but swelling could also occur in your arms, hands, face, or other areas of the body. + + + + obo2:OAE_0002422 + JX, YH + + + + obo2:OAE_0002422 + WEB: http://www.healthgrades.com/symptoms/fluid-retention + + + + obo2:OAE_0002422 + fluid retention AE + + + + obo2:OAE_0002422 + MedDRA: 10016807 + + + + obo2:OAE_0002423 + Emotional distress AE is a emotional disorder AE that is a Mental distress or anxiety suffered as a response to a sudden, severe, and saddening experience. + + + + obo2:OAE_0002423 + JX, YH + + + + obo2:OAE_0002423 + WEB: http://en.wikipedia.org/wiki/Emotional_distress + + + + obo2:OAE_0002423 + emotional distress AE + + + + obo2:OAE_0002423 + MedDRA: 10049119 + + + + obo2:OAE_0002424 + Encephalitis AE is a nervous system AE that is an acute inflammation of the brain. + + + + obo2:OAE_0002424 + JX, YH + + + + obo2:OAE_0002424 + WEB: http://en.wikipedia.org/wiki/Encephalitis + + + + obo2:OAE_0002424 + encephalitis AE + + + + obo2:OAE_0002424 + MedDRA: 10014581 + + + + obo2:OAE_0002425 + Cognitive disorder AE is a mental disorder AE that is a category of mental health disorders that primarily affect learning, memory, perception, and problem solving, and include amnesia, dementia, and delirium. + + + + obo2:OAE_0002425 + JX, YH + + + + obo2:OAE_0002425 + WEB: http://en.wikipedia.org/wiki/Cognitive_disorder + + + + obo2:OAE_0002425 + cognitive disorder AE + + + + obo2:OAE_0002425 + MedDRA: 10057668 + + + + obo2:OAE_0002426 + Incoherent AE is a speech disorder AE that shows unable to express one's thoughts or ideas in an orderly, intelligible manner. + + + + obo2:OAE_0002426 + JX, YH + + + + obo2:OAE_0002426 + WEB: http://medical-dictionary.thefreedictionary.com/incoherent + + + + obo2:OAE_0002426 + incoherent AE + + + + obo2:OAE_0002426 + MedDRA: 10021630 + + + + obo2:OAE_0002427 + Exercise tolerance decreased AE is a systematic AE that shows exercise tolerance decreased. The exercise tolerance refers to the exercise capacity of an individual as measured by their ability to endure exercise and/or the maximum work load achieved during the exercise period. + + + + obo2:OAE_0002427 + JX, YH + + + + obo2:OAE_0002427 + WEB: http://copd.about.com/od/glossaryofcopdterms/g/activitytoleran.htm + + + + obo2:OAE_0002427 + exercise tolerance decreased AE + + + + obo2:OAE_0002427 + MedDRA: 10051301 + + + + obo2:OAE_0002428 + a burn AE that is a type of burn resulted from making contact with heated objects, such as boiling water, steam, hot cooking oil, fire, and hot objects. + + + + obo2:OAE_0002428 + JX, LW + + + + obo2:OAE_0002428 + WEB: http://en.wikipedia.org/wiki/Thermal_burn + + + + obo2:OAE_0002428 + thermal burn AE + + + + obo2:OAE_0002428 + MedDRA: 10053615 + + + + obo2:OAE_0002429 + Dissociation AE is a mental disorder AE that describes a wide array of experiences from mild detachment from immediate surroundings to more severe detachment from physical and emotional experience. + + + + obo2:OAE_0002429 + JX, YH + + + + obo2:OAE_0002429 + WEB: http://en.wikipedia.org/wiki/Dissociation_%28psychology%29 + + + + obo2:OAE_0002429 + dissociation AE + + + + obo2:OAE_0002429 + MedDRA: 10013457 + + + + obo2:OAE_0002431 + Mucous membrane disorder AE is a systematic AE that the diseases occur in mucous membrane, which is a lining of mostly endodermal origin. + + + + obo2:OAE_0002431 + JX, YH + + + + obo2:OAE_0002431 + WEB: http://en.wikipedia.org/wiki/Mucous_membrane + + + + obo2:OAE_0002431 + mucous membrane disorder AE + + + + obo2:OAE_0002431 + MedDRA: 10028133 + + + + obo2:OAE_0002432 + Demyelinating polyneuropathy AE is a nervous system AE that is a condition that arises when the myelin sheaths around nerve cells are damaged. Myelin, the insulating layer of tissue that surrounds nerve cells, helps ensure that signals from the brain are rapidly transmitted to the proper places in the body. When myelin is damaged or destroyed, it can lead to problems with communication between the brain and the body. + + + + obo2:OAE_0002432 + JX, YH + + + + obo2:OAE_0002432 + WEB: http://www.healthgrades.com/conditions/chronic-inflammatory-demyelinating-polyneuropathy + + + + obo2:OAE_0002432 + demyelinating polyneuropathy AE + + + + obo2:OAE_0002432 + MedDRA: 10061811 + + + + obo2:OAE_0002433 + a syndrome AE that results in increased pressure in a muscle compartment which can lead to nerve damage and impaired blood flow. + + + + obo2:OAE_0002433 + SJ, YH + + + + obo2:OAE_0002433 + URL: http://www.nlm.nih.gov/medlineplus/ency/article/001224.htm + + + + obo2:OAE_0002433 + Thick layers of tissue, called fascia, separate groups of muscles in the arms and legs from each other. Inside each layer of fascia is a confined space, called a compartment. The compartment includes the muscle tissue, nerves, and blood vessels. + + + + obo2:OAE_0002433 + compartment syndrome AE + + + + obo2:OAE_0002433 + MedDRA: 10010121 + + + + obo2:OAE_0002434 + Therapeutic response decreased is found among people who take Cialis, especially for people who are male, 60+ old, have been taking the drug for < 1 month, also take medication Aspirin, and have Erection problems. + + + + obo2:OAE_0002434 + JX, LW + + + + obo2:OAE_0002434 + WEB: http://www.ehealthme.com/ds/cialis/therapeutic+response+decreased + + + + obo2:OAE_0002434 + therapeutic response decreased + + + + obo2:OAE_0002434 + MedDRA: 10043414 + + + + obo2:OAE_0002436 + a seizure AE that resutls in impariment of awareness and involuntary but coordinated and repeated movements. + + + + obo2:OAE_0002436 + YH, SJ + + + + obo2:OAE_0002436 + WEB: http://www.webmd.com/epilepsy/guide/types-of-seizures-their-symptoms?page=2 + + + + obo2:OAE_0002436 + complex partial seizure AE + + + + obo2:OAE_0002436 + MedDRA: 10010145 + + + + obo2:OAE_0002437 + Autoimmune disorder AE is an immune system AE that arises from an abnormal immune response of the body against substances and tissues normally present in the body (autoimmunity). + + + + obo2:OAE_0002437 + JX, YH + + + + obo2:OAE_0002437 + WEB: http://en.wikipedia.org/wiki/Autoimmune_disease + + + + obo2:OAE_0002437 + autoimmune disorder AE + + + + obo2:OAE_0002437 + MedDRA: 10061664 + + + + obo2:OAE_0002438 + a hemorrhage AE that has an outcome of bleeding into the pons or mesencephalon. + + + + obo2:OAE_0002438 + SJ, YH + + + + obo2:OAE_0002438 + WEB: http://medical-dictionary.thefreedictionary.com/brainstem+hemorrhage + + + + obo2:OAE_0002438 + brain stem hemorrhage AE is often secondary to brainstem distortion due to rapidly expanding intracranail lessions. + + + + obo2:OAE_0002438 + brainstem hemorrhage AE + + + + obo2:OAE_0002438 + MedDRA: 10006146 + + + + obo2:OAE_0002439 + Menstruation irregular AE is a endocrine system AE that is an abnormal variation in length of menstrual cycles in a female. + + + + obo2:OAE_0002439 + JX, YH + + + + obo2:OAE_0002439 + WEB: http://en.wikipedia.org/wiki/Irregular_menstruation + + + + obo2:OAE_0002439 + menstruation irregular AE + + + + obo2:OAE_0002439 + MedDRA: 10027339 + + + + obo2:OAE_0002440 + Generalised tonic-clonic seizure AE is a seizure AE that is a type of generalized seizure that affects the entire brain. Tonic–clonic seizures are the seizure type most commonly associated with epilepsy and seizures in general, though it is a misconception that they are the only type. + + + + obo2:OAE_0002440 + JX, YH + + + + obo2:OAE_0002440 + WEB: http://en.wikipedia.org/wiki/Tonic%E2%80%93clonic_seizure + + + + obo2:OAE_0002440 + generalised tonic-clonic seizure AE + + + + obo2:OAE_0002440 + MedDRA: 10018100 + + + + obo2:OAE_0002441 + Posturing AE is a mental disorder AE that an involuntary flexion or extension of the arms and legs, indicating severe brain injury. + + + + obo2:OAE_0002441 + JX, YH + + + + obo2:OAE_0002441 + WEB: http://en.wikipedia.org/wiki/Abnormal_posturing + + + + obo2:OAE_0002441 + posturing AE + + + + obo2:OAE_0002441 + MedDRA: 10036437 + + + + obo2:OAE_0002443 + Demyelination AE is a nervous system AE that is any disease of the nervous system in which the myelin sheath of neurons is damaged. + + + + obo2:OAE_0002443 + JX, YH + + + + obo2:OAE_0002443 + WEB: http://en.wikipedia.org/wiki/Demyelinating_disease + + + + obo2:OAE_0002443 + demyelination AE + + + + obo2:OAE_0002443 + MedDRA: 10012305 + + + + obo2:OAE_0002444 + Gram stain negative AE is a microbiology and serology investigation result abnormal AE that has an outcome of detection of gram-negative bacteria. + + + + obo2:OAE_0002444 + JX, YH + + + + obo2:OAE_0002444 + WEB: http://en.wikipedia.org/wiki/Gram-negative_bacteria + + + + obo2:OAE_0002444 + gram stain negative AE + + + + obo2:OAE_0002444 + MedDRA: 10018656 + + + + obo2:OAE_0002445 + Red blood cells CSF positive AE is a CSF test result abnormal AE that has an outcome of CSF red blood cells count positive. + + + + obo2:OAE_0002445 + JX, YH + + + + obo2:OAE_0002445 + red blood cells CSF positive AE + + + + obo2:OAE_0002445 + MedDRA: 10038173 + + + + obo2:OAE_0002446 + CSF white blood cell count increased AE is a CSF test result abnormal AE that has an outcome of CSF white blood cell count increased. + + + + obo2:OAE_0002446 + JX, YH + + + + obo2:OAE_0002446 + CSF white blood cell count increased AE + + + + obo2:OAE_0002446 + MedDRA: 10053805 + + + + obo2:OAE_0002447 + Influenza A virus test positive AE is a influenza virus test positive AE that has an outcome of positive result in an influenza A virus test. + + + + obo2:OAE_0002447 + JX, YH + + + + obo2:OAE_0002447 + influenza A virus test positive AE + + + + obo2:OAE_0002447 + MedDRA: 10070215 + + + + obo2:OAE_0002448 + Nerve conduction studies abnormal AE is a neurological AE that shows a abnormal result of nerve conduction study (NCS). NCS is a medical diagnostic test commonly used to evaluate the function, especially the ability of electrical conduction, of the motor and sensory nerves of the human body. + + + + obo2:OAE_0002448 + JX, YH + + + + obo2:OAE_0002448 + WEB: http://en.wikipedia.org/wiki/Nerve_conduction_study + + + + obo2:OAE_0002448 + nerve conduction studies abnormal AE + + + + obo2:OAE_0002448 + MedDRA: 10029175 + + + + obo2:OAE_0002449 + Myocardial necrosis AE is a cardiac disorder AE that shows death of the cells of an area of the heart muscle (myocardium) as a result of oxygen deprivation, which in turn is caused by obstruction of the blood supply. + + + + obo2:OAE_0002449 + JX, YH + + + + obo2:OAE_0002449 + URL: http://medical-dictionary.thefreedictionary.com/myocardial+necrosis + + + + obo2:OAE_0002449 + myocardial necrosis AE + + + + obo2:OAE_0002449 + MedDRA: 10028602 + + + + obo2:OAE_0002450 + a brainstem infarction AE is a stroke AE that occurs when blood cannot flow to the brainstem, when oxygen cannot get to an area of the brain, tissue in that area may be damaged. + + + + obo2:OAE_0002450 + SJ, YH + + + + obo2:OAE_0002450 + brainstem stroke + + + + obo2:OAE_0002450 + WEB: http://en.wikipedia.org/wiki/Brain_stem_stroke_syndrome + + + + obo2:OAE_0002450 + WEB: http://www.drugs.com/cg/brain-stem-infarction.html + + + + + obo2:OAE_0002450 + A person may have vertigo, dizziness and severe imbalance without the hallmark of most strokes – weakness on one side of the body. But dizziness alone is not a sign of stroke. Brain stem stroke can also cause diplopia, slurred speech and decreased level of consciousness. + + + + obo2:OAE_0002450 + brainstem infarction AE + + + + obo2:OAE_0002450 + MedDRA: 10006147 + + + + obo2:OAE_0002451 + a lung disorder AE that occurs when the noises produced by the structures of the lungs during breathing are decreased or absent. + + + + obo2:OAE_0002451 + SJ, YH + + + + obo2:OAE_0002451 + WEB: http://www.nlm.nih.gov/medlineplus/ency/article/007535.htm + + + + obo2:OAE_0002451 + Absent or decreased breath sounds can indicate air or fluid around the lungs, increased thickness of chest wall, over-inflation of part of the lungs, or reduced airflow to part of the lungs. + + + + obo2:OAE_0002451 + breath sounds decreased AE + + + + obo2:OAE_0002451 + MedDRA: 10006333 + + + + obo2:OAE_0002452 + a genetic disorder AE that is characterised by abnormal electrocardiogram (ECG) findings and an increased risk of sudden cardiac death. + + + + obo2:OAE_0002452 + SJ, YH + + + + obo2:OAE_0002452 + sudden adult death syndrome (SADS) + + + + obo2:OAE_0002452 + WEB: http://en.wikipedia.org/wiki/Brugada_syndrome + + + + obo2:OAE_0002452 + Brugada sydnrome AE + + + + obo2:OAE_0002452 + MedDRA: 10059027 + + + + obo2:OAE_0002453 + Buttock pain AE is a pain AE that is a common problem in the butt, it can be due to bursitis, bruising, piriformis syndrome, and shingles,or due to more serious diseases with long-term consequences, such as cancer, arthritis of the sacroiliac joints, and herniated disc with sciatica. + + + + obo2:OAE_0002453 + SJ, YH + + + + obo2:OAE_0002453 + Butt Pain + + + + obo2:OAE_0002453 + WEB:http://www.medicinenet.com/buttock_pain/symptoms.htm + + + + obo2:OAE_0002453 + buttock pain AE + + + + obo2:OAE_0002453 + MedDRA ID: 10048677 + + + + obo2:OAE_0002454 + a digestive system AE with an outcome of small white calcium lumps forming under the skin that may leak a chalky white fluid. These lumps are formed becuase of too much calcium in the diet. + + + + obo2:OAE_0002454 + SJ, YH + + + + obo2:OAE_0002454 + WEB: http://www.sclero.org/medical/symptoms/skin/calcinosis.html + + + + obo2:OAE_0002454 + These most commonly occur on the hands, or near joints such as elbows or knees, although they may appear anywhere. Calcinosis may range from one very tiny deposit, to large (and often painful) clusters. + + + + obo2:OAE_0002454 + calcinosis AE + + + + obo2:OAE_0002454 + MedDRA: 10006938 + + + + obo2:OAE_0002455 + an infection adverse event that caused by a species of the yeast Candida. + + + + obo2:OAE_0002455 + SJ, YH + + + + obo2:OAE_0002455 + WEB: http://medical-dictionary.thefreedictionary.com/candidiasis + + + + obo2:OAE_0002455 + This is a common cause of vaginal infections in women. Also, Candida may cause mouth infections in people with reduced immune function, or in patients taking certain antibiotics. Candida can be found in virtually all normal people but causes problems in only a fraction. + + + + obo2:OAE_0002455 + candidiasis AE + + + + obo2:OAE_0002455 + MedDRA: 10007152 + + + + obo2:OAE_0002456 + an investigation result abnormal AE that occurs when the cardaic enzymes and proteins leak out of damaged heart muscle cells, and their levels in the bloodstream rise. + + + + obo2:OAE_0002456 + SJ, YH + + + + obo2:OAE_0002456 + URL: http://www.webmd.com/heart-disease/cardiac-enzyme-studies + + + + obo2:OAE_0002456 + cardiac enzymes increased AE may indicate that the heart muscle is injured, such as from a heart attack. + + + + obo2:OAE_0002456 + cardiac enzymes increased AE + + + + obo2:OAE_0002456 + MedDRA: 10007548 + + + + obo2:OAE_0002457 + Acute decompensated heart failure AE is a cardiovascular disorder AE that shows a worsening of the symptoms, typically shortness of breath (dyspnea), edema, and fatigue, in a patient with existing heart disease. + + + + obo2:OAE_0002457 + SJ, YH + + + + obo2:OAE_0002457 + Cardiac Failure Acute + + + + obo2:OAE_0002457 + WEB: http://en.wikipedia.org/wiki/Acute_decompensated_heart_failure + + + + obo2:OAE_0002457 + acute decompensated heart failure AE + + + + obo2:OAE_0002457 + MedDRA: 10007556 + + + + obo2:OAE_0002457 + MedDRA: 10064653 + + + + obo2:OAE_0002459 + Cardiac murmur AE is a cardiac disorder AE that is characterised by abnormal sounds during the heartbeat cycle — such as whooshing or swishing — made by turbulent blood in or near the heart. + + + + obo2:OAE_0002459 + SJ, YH + + + + obo2:OAE_0002459 + Heart Murmur + + + + obo2:OAE_0002459 + WEB: http://www.mayoclinic.org/diseases-conditions/heart-murmurs/basics/definition/con-20028706 + + + + obo2:OAE_0002459 + cardiac murmur AE + + + + obo2:OAE_0002459 + MedDRA: 10007586 + + + + obo2:OAE_0002460 + a behavior and neurological AE that is seen most frequently in schizophrenia, characterized by muscular rigidity and mental stupor, sometimes alternating with great excitement and confusion. + + + + obo2:OAE_0002460 + YH, SJ + + + + obo2:OAE_0002460 + WEB: http://dictionary.reference.com/browse/catatonia + + + + obo2:OAE_0002460 + catatonia AE + + + + obo2:OAE_0002460 + MedDRA: 10007776 + + + + obo2:OAE_0002461 + a coronary artery disorder AE that results in narrowing of the inner surface of the carotid atery. + + + + obo2:OAE_0002461 + SJ, YH + + + + obo2:OAE_0002461 + WEB: http://en.wikipedia.org/wiki/Carotid_artery_stenosis + + + + obo2:OAE_0002461 + carotid artery stenosis AE + + + + obo2:OAE_0002461 + MedDRA: 10007687 + + + + obo2:OAE_0002462 + orbital cellulitis AE is a sudden infection of the tissues around the eye, affecting the eyelid, eyebrow, and cheek. + + + + obo2:OAE_0002462 + SJ, YH + + + + obo2:OAE_0002462 + WEB: http://www.nlm.nih.gov/medlineplus/ency/article/001012.htm + + + + obo2:OAE_0002462 + orbital cellulitis AE + + + + obo2:OAE_0002462 + MedDRA ID: 10007918 + + + + obo2:OAE_0002463 + Chronic cholecystitis AE the inflammation of the gallbladder persisting for a prolonged period of time or having repeated attacks. + + + + obo2:OAE_0002463 + SJ, YH + + + + obo2:OAE_0002463 + WEB: http://www.healthline.com/health/chronic-cholecystitis#Overview1 + + + + obo2:OAE_0002463 + chronic cholecystitis AE + + + + obo2:OAE_0002463 + MedDRA: 10008617 + + + + obo2:OAE_0002464 + a brain lesion AE is an area of injury or disease within the brain. + + + + obo2:OAE_0002464 + SJ, YH + + + + obo2:OAE_0002464 + WEB: http://www.webmd.com/brain/brain-lesions-causes-symptoms-treatments + + + + + + + obo2:OAE_0002464 + brain lesion AE + + + + obo2:OAE_0002464 + MedDRA: 10051290 + + + + + obo2:OAE_0002465 + Central venous pressure increased AE is a mesaurement of the pressure of the blood within the superior and inferior vena cava and large veins of the body. Increased pressure can be the result of cardiac failure and congestion of circulation. + + + + obo2:OAE_0002465 + SJ, YH + + + + obo2:OAE_0002465 + WEB: http://medical-dictionary.thefreedictionary.com/central+venous+pressure + + + + obo2:OAE_0002465 + central venous pressure increased AE + + + + obo2:OAE_0002465 + MedDRA: 10007980 + + + + obo2:OAE_0002466 + a brain disorder AE occurs when the brain is damaged by injury, disease, or health conditions. + + + + obo2:OAE_0002466 + SJ, YH + + + + obo2:OAE_0002466 + WEB: http://www.healthline.com/health/brain-disorders#Overview1 + + + + + + obo2:OAE_0002466 + Brain disorders may affect the main areas of your brain that control how you move, think, and behave. Some tumors can constrict the blood vessels in your brain. + + + + obo2:OAE_0002466 + brain disorder AE + + + + obo2:OAE_0002466 + MedDRA: 10054938 + + + + obo2:OAE_0002467 + a cerebral infarction is a type of ischaemic stroke AE that is caused by a blockage in the blood vessels supplying blood to the brain. + + + + obo2:OAE_0002467 + SJ + + + + obo2:OAE_0002467 + WEB: http://en.wikipedia.org/wiki/Cerebral_infarction + + + + obo2:OAE_0002467 + cerebral infarction AE + + + + obo2:OAE_0002467 + MedDRA: 10008118 + + + + obo2:OAE_0002468 + a nervous system AE that occurs when the cerebrospinal fluid leaks through a defect in the dura or the skull and out through the nose or ear resulting from a tear in the dura. + + + + obo2:OAE_0002468 + SJ, YH + + + + obo2:OAE_0002468 + WEB: http://www.hopkinsmedicine.org/neurology_neurosurgery/centers_clinics/brain_tumor/center/skull-base/types/csf-leak.html + + + + obo2:OAE_0002468 + cerebrospinal fluid leak AE + + + + obo2:OAE_0002468 + MedDRA: 10008164 + + + + obo2:OAE_0002469 + a female reproductive system AE that refers to abnormal changes in the cells on the surface of the cervix. The changes are not cancer. But they can lead to cancer of the cervix if not treated. + + + + obo2:OAE_0002469 + SJ, YH + + + + obo2:OAE_0002469 + WEB: http://www.nlm.nih.gov/medlineplus/ency/article/001491.htm + + + + obo2:OAE_0002469 + cervical dysplasia AE + + + + obo2:OAE_0002469 + MedDRA: 10008263 + + + + obo2:OAE_0002470 + a bone disorder AE that results in pain and neurological symptoms resulting from any type of condition that irritates a nerve in the cervical spine. + + + + obo2:OAE_0002470 + SJ, YH + + + + obo2:OAE_0002470 + WEB: http://www.spine-health.com/conditions/neck-pain/what-cervical-radiculopathy + + + + obo2:OAE_0002470 + cervical radiculopathy AE + + + + obo2:OAE_0002470 + MedDRA: 10008303 + + + + obo2:OAE_0002471 + Cervical spinal stenosis AE is a nervous system AE that occurs when the spinal canal in the neck narrows. + + + + obo2:OAE_0002471 + SJ, YH + + + + obo2:OAE_0002471 + WEB: http://www.webmd.com/back-pain/tc/cervical-spinal-stenosis-topic-overview + + + + obo2:OAE_0002471 + cervical spinal stenosis AE + + + + obo2:OAE_0002471 + MedDRA: 10008313 + + + + obo2:OAE_0002472 + a respiratory AE that results in the inability to breath because something gets stuck in the throat or because the air is not good for breathing + + + + obo2:OAE_0002472 + SJ, YH + + + + obo2:OAE_0002472 + WEB: http://www.merriam-webster.com/dictionary/choke + + + + obo2:OAE_0002472 + choking AE + + + + obo2:OAE_0002472 + MedDRA: 10008589 + + + + obo2:OAE_0002473 + a musculoskeletal and connective tissue AE that results in tlhe disappearance of articular cartilage as the result of disintegration or dissolution of the cartilage matrix and cells. + + + + obo2:OAE_0002473 + SJ, YH + + + + obo2:OAE_0002473 + WEB: http://www.medilexicon.com/medicaldictionary.php?t=17184 + + + + obo2:OAE_0002473 + chondrolysis AE + + + + obo2:OAE_0002473 + MedDRA: 10058112 + + + + obo2:OAE_0002474 + A joint disorder AE in which the cartilage on the undersurface of the patella deteriorates and softens. + + + + obo2:OAE_0002474 + SJ, YH + + + + obo2:OAE_0002474 + WEB: http://www.healthline.com/health/chondromalacia-patella#Overview1 + + + + obo2:OAE_0002474 + chondromalacia AE + + + + obo2:OAE_0002474 + MedDRA ID: 10008729 + + + + obo2:OAE_0002475 + an adverse event that occurs after a therapeutic intervention + + + + obo2:OAE_0002475 + YH, JX + + + + obo2:OAE_0002475 + therapy adverse event + + + + obo2:OAE_0002477 + a seizure AE that resutls in jerking and muscle rigidity, unusual sensations affecting vision, hearing, smell, taste or touch, and memory or emothional disturbances. + + + + obo2:OAE_0002477 + YH, SJ + + + + obo2:OAE_0002477 + WEB: http://www.webmd.com/epilepsy/guide/types-of-seizures-their-symptoms?page=2 + + + + obo2:OAE_0002477 + simple partial seizure AE + + + + obo2:OAE_0002477 + MedDRA: 10040703 + + + + obo2:OAE_0002478 + chemosis AE is a conjunctival disorder AE that results in swelling of the conjunctiva die to exudation of abnormaly permeable capillaries. + + + + obo2:OAE_0002478 + SJ, YH + + + + obo2:OAE_0002478 + conjunctival edema + + + + obo2:OAE_0002478 + WEB: http://en.wikipedia.org/wiki/Chemosis + + + + obo2:OAE_0002478 + chemosis AE + + + + obo2:OAE_0002478 + MedDRA: 10053163 + + + + obo2:OAE_0002480 + conversion disorder AE is a neurological AE that results in the expression of psychlogical stress in physical ways or a mental or emotional crises that begins to have a physical affect. + + + + obo2:OAE_0002480 + YH, SJ + + + + obo2:OAE_0002480 + functional neurological symptom disorder + + + + obo2:OAE_0002480 + WEB: http://www.mayoclinic.org/diseases-conditions/conversion-disorder/basics/definition/con-20029533 + + + + obo2:OAE_0002480 + conversion disorder AE + + + + obo2:OAE_0002480 + MedDRA: 10010893 + + + + obo2:OAE_0002481 + a cardiac disorder AE which causes a thickening and loss of elasticity of the coronary arteries, leading to progressive insufficiency of the arteries. + + + + obo2:OAE_0002481 + SJ, YH + + + + obo2:OAE_0002481 + arteriosclerotic coronary artery disease + + + + obo2:OAE_0002481 + coronary artery atherosclerosis + + + + obo2:OAE_0002481 + WEB: http://ghr.nlm.nih.gov/glossary=coronaryarteriosclerosis + + + + obo2:OAE_0002481 + coronary arteriosclerosis AE + + + + obo2:OAE_0002481 + MedDRA: 10011076 + + + + obo2:OAE_0002482 + a cardiac disorder AE which causes a partial or complete blockage of the coronary artery which can lead to heart attack. + + + + obo2:OAE_0002482 + SJ, YH + + + + obo2:OAE_0002482 + WEB: http://en.wikipedia.org/wiki/Coronary_occlusion + + + + obo2:OAE_0002482 + coronary occlusion AE + + + + obo2:OAE_0002482 + MedDRA: 10011086 + + + + obo2:OAE_0002483 + a cardiac disorder AE which results in inflammation and the buildup of plaque which narrow the coronary arteries. + + + + obo2:OAE_0002483 + SJ, YH + + + + obo2:OAE_0002483 + WEB: http://www.mayoclinic.org/diseases-conditions/coronary-artery-disease/basics/definition/con-20032038 + + + + obo2:OAE_0002483 + coronary artery disease AE + + + + obo2:OAE_0002483 + MedDRA: 10011089 + + + + obo2:OAE_0002484 + An joint disorder AE that results in the noise produced by the rubbing together of bone or irregular cartilage surfaces. + + + + obo2:OAE_0002484 + YH, SJ + + + + obo2:OAE_0002484 + WEB: http://medical-dictionary.thefreedictionary.com/crepitation + + + + obo2:OAE_0002484 + crepitation AE + + + + obo2:OAE_0002484 + MedDRA: 10011376 + + + + obo2:OAE_0002485 + cryptorchidism AE is a male reproductive system AE which results in the absence of one or both testes from the scrotum. + + + + obo2:OAE_0002485 + YH, SJ + + + + obo2:OAE_0002485 + undescended testis + + + + obo2:OAE_0002485 + WEB: http://en.wikipedia.org/wiki/Cryptorchidism + + + + obo2:OAE_0002485 + cryptorchidism AE + + + + obo2:OAE_0002485 + MedDRA: 10011498 + + + + obo2:OAE_0002486 + CSF glucose is proportional to blood glucose levels which correspond to 60-70% of the concentration in blood. + + + + obo2:OAE_0002486 + SJ, YH + + + + obo2:OAE_0002486 + hypoglycorrhachia + + + + obo2:OAE_0002486 + decreased CSF glucose AE can be caused by CNS infections, inflammatory conditions, subarachnoid hemorrhage, hypoglycemia, impaired glucose transport, increased CNS glycolytic activity and metastatic carcinoma. + + + + obo2:OAE_0002486 + decreased CSF glucose AE + + + + obo2:OAE_0002486 + MedDRA: 10011537 + + + + obo2:OAE_0002487 + wound culture positive AE is a a test to find and identify germs that may be growing on the skin or in a wound. If something that can cause infection grows, the culture is positive. The type of organisms may be identified with a microscope, chemical tests, or both. + + + + obo2:OAE_0002487 + SJ, YH + + + + obo2:OAE_0002487 + WEB: http://www.webmd.com/a-to-z-guides/skin-and-wound-cultures + + + + obo2:OAE_0002487 + wound culture positive AE + + + + obo2:OAE_0002487 + MedDRA: 10011643 + + + + obo2:OAE_0002488 + skin cyst AE is a skin AE that occurs when a cluster of cells that have grouped together to form a sac which may contain air, fluids, or semi-solid material. + + + + obo2:OAE_0002488 + YH, SJ + + + + obo2:OAE_0002488 + cyst + + + + obo2:OAE_0002488 + WEB: http://en.wikipedia.org/wiki/Cyst + + + + obo2:OAE_0002488 + skin cyst AE + + + + obo2:OAE_0002488 + MedDRA: 10011732 + + + + obo2:OAE_0002489 + conductive hearing loss AE is a hearing loss AE that results from probelms with the ear canal, ear drum, or middle ear and its little bones. + + + + obo2:OAE_0002489 + SJ, YH + + + + obo2:OAE_0002489 + sensorineural hearing loss (SNHL) + + + + obo2:OAE_0002489 + WEB: http://www.hearingloss.org/content/types-causes-and-treatment + + + + obo2:OAE_0002489 + conductive hearing loss AE + + + + obo2:OAE_0002489 + MedDRA: 10010282 + + + + obo2:OAE_0002490 + transient hearing loss AE is a hearing loss AE that results from poor ventilation of the middle ear in children. + + + + obo2:OAE_0002490 + SJ, YH + + + + obo2:OAE_0002490 + deafness transitory + + + + obo2:OAE_0002490 + WEB: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3139416/ + + + + + obo2:OAE_0002490 + transient hearing loss AE + + + + obo2:OAE_0002490 + MedDRA: 10011900 + + + + obo2:OAE_0002491 + a sensory capability AE that results in a persistent false psychotic belief regarding the self or objects outside the self that is maintained despite indisputable evidence to the contrary. + + + + obo2:OAE_0002491 + SJ, YH + + + + obo2:OAE_0002491 + WEB: http://www.merriam-webster.com/dictionary/delusion + + + + obo2:OAE_0002491 + delusion AE + + + + obo2:OAE_0002491 + MedDRA: 10012239 + + + + obo2:OAE_0002492 + a behavioral AE that results in long-standing need for the person to be taken care of and a fear of being abandoned or separated from important individuals. + + + + obo2:OAE_0002492 + SJ, YH + + + + obo2:OAE_0002492 + WEB: http://psychcentral.com/disorders/dependent-personality-disorder-symptoms/ + + + + obo2:OAE_0002492 + Individuals with Dependent Personality Disorder are often characterized by pessimism and self-doubt, and tend to belittle their abilities and assets. This leads the person to engage in dependent and submissive behaviors that are designed to elicit care-giving behaviors in others. + + + + obo2:OAE_0002492 + dependent personality disorder AE + + + + obo2:OAE_0002492 + MedDRA: 10012355 + + + + obo2:OAE_0002493 + Nervous system AE that results in failure to meet certain developmental milestones, such as sitting, walking, and talking, at the average age. Developmental delay may indicate a problem in development of the central nervous system. + + + + obo2:OAE_0002493 + SJ, YH + + + + obo2:OAE_0002493 + WEB: http://medical-dictionary.thefreedictionary.com/developmental+delay + + + + obo2:OAE_0002493 + developmental delay AE + + + + obo2:OAE_0002493 + MedDRA: 10012559 + + + + obo2:OAE_0002494 + diabetic ketoacidosis AE is a cardiovascular AE that develops when your body is unable to produce enough insulin and begins to break down fat as an alternate fuel, this process produces a buildup of toxic acids in the bloodstream called ketones. + + + + obo2:OAE_0002494 + SJ, YH + + + + obo2:OAE_0002494 + WEB: http://www.mayoclinic.org/diseases-conditions/diabetic-ketoacidosis/basics/definition/con-20026470 + + + + obo2:OAE_0002494 + diabetic ketoacidosis AE + + + + obo2:OAE_0002494 + MedDRA: 10012671 + + + + obo2:OAE_0002496 + congenital diaphragmatic hernia AE is a congential disorder in which an absent or partially formed diaphragm results in an abnormal opening that allows the stomach and intestines to move into the chest cavity and crowd the heart and lungs. This crowding can lead to underdevelopment of the lungs, potentially resulting in life-threatening breathing difficulties that are apparent from birth. + + + + obo2:OAE_0002496 + SJ, YH + + + + obo2:OAE_0002496 + WEB: http://medical-dictionary.thefreedictionary.com/aspiration + + + + obo2:OAE_0002496 + congenital diaphragmatic hernia AE + + + + obo2:OAE_0002496 + MedDRA: 10061106 + + + + obo2:OAE_0002497 + a paralysis AE that has an outcome of paralysis affecting symmetrical parts of the body. + + + + obo2:OAE_0002497 + SJ, YH + + + + obo2:OAE_0002497 + WEB: http://en.wikipedia.org/wiki/Diplegia + + + + obo2:OAE_0002497 + diplegia AE + + + + obo2:OAE_0002497 + MedDRA: 10013033 + + + + obo2:OAE_0002498 + cystitis interstitial AE is a cystitis AE that has an outcome of cystitis interstitial, which is a condition that causes discomfort or pain in the bladder and a need to urinate frequently and urgently. + + + + obo2:OAE_0002498 + KM, YH + + + + obo2:OAE_0002498 + WEB: http://www.nlm.nih.gov/medlineplus/interstitialcystitis.html + + + + obo2:OAE_0002498 + cystitis interstitial AE + + + + obo2:OAE_0002498 + MedDRA: 10011796 + + + + obo2:OAE_0002499 + A disseminated tuberculosis AE is a tuberculosis AE that has an outcome of disseminated tuberculosis, which is a contagious bacterial infection in which TB bacteria has spread from the lungs to other parts of the body through the blood or lymph system. + + + + obo2:OAE_0002499 + KM, YH + + + + obo2:OAE_0002499 + WEB: http://www.nlm.nih.gov/medlineplus/ency/article/000624.htm + + + + obo2:OAE_0002499 + disseminated tuberculosis AE + + + + obo2:OAE_0002499 + MedDRA: 10013453 + + + + + obo2:OAE_0002500 + Exotosis AE is a bone pain AE that has resulted in a non-neoplastic overgrowth of bone. + + + + obo2:OAE_0002500 + KM, YH + + + + obo2:OAE_0002500 + WEB: http://en.wikipedia.org/wiki/Exostosis + + + + obo2:OAE_0002500 + exotosis AE + + + + obo2:OAE_0002500 + MedDRA: 10015688 + + + + obo2:OAE_0002501 + An exudative retinopathy AE is an eye AE that shows an outcome of exudative retinopathy marked by masses of white or yellowish exudate in the posterior part of the fundus oculi, with deposits of cholesterol and blood debris from retinal hemorrhage, that leads to destruction of the macula and blindness. + + + + obo2:OAE_0002501 + KM, YH + + + + obo2:OAE_0002501 + Coats' disease, Coats' retinitis + + + + obo2:OAE_0002501 + WEB: http://medical-dictionary.thefreedictionary.com/exudative+retinopathy + + + + + obo2:OAE_0002501 + exudative retinopathy AE + + + + obo2:OAE_0002501 + MedDRA: 10015901 + + + + obo2:OAE_0002502 + A tendon disorder AE that has an outcome of tendinous which is damage to a tendon at a cellular level. It is thought to be caused by microtears in the connective tissue in and around the tendon, leading to an increase in tendon repair cells. + + + + obo2:OAE_0002502 + KM, YH + + + + obo2:OAE_0002502 + WEB: http://en.wikipedia.org/wiki/Tendinosis + + + + + obo2:OAE_0002502 + tendinous AE + + + + obo2:OAE_0002502 + MedDRA: 10016662 + + + + obo2:OAE_0002503 + A monocyte percentage abnormal AE that results in abnormally high levels of monocytes in the blood. + + + + obo2:OAE_0002503 + KM, YH + + + + obo2:OAE_0002503 + WEB: http://en.wikipedia.org/wiki/Monocytosis + + + + obo2:OAE_0002503 + monocytosis AE + + + + obo2:OAE_0002503 + MedDRA: 10027906 + + + + obo2:OAE_0002503 + NCIT: C35147 + + + + obo2:OAE_0002504 + A male reproductive system AE that has an outcome of genital candidiasis, which is a fungal infection due to any types of Candida (types of yeasts). This is a fungal infection of the genital region. + + + + obo2:OAE_0002504 + KM, YH + + + + obo2:OAE_0002504 + WEB: http://en.wikipedia.org/wiki/Candidiasis + + + + obo2:OAE_0002504 + WEB: http://www.cdc.gov/fungal/diseases/candidiasis/genital/ + + + + obo2:OAE_0002504 + genital candidiasis AE + + + + obo2:OAE_0002504 + MedDRA: 10018143 + + + + obo2:OAE_0002505 + KM, YH + + + + obo2:OAE_0002505 + WEB: http://www.webmd.com/pain-management/tc/groin-problems-and-injuries-topic-overview + + + + obo2:OAE_0002505 + A groin pain AE is a pain AE that shows a pain in the groin area. + + + + obo2:OAE_0002505 + groin pain AE + + + + obo2:OAE_0002505 + MedDRA: 10018735 + + + + + obo2:OAE_0002506 + A blood disorder AE that has an outcome of the breakdown of red blood cells. + + + + obo2:OAE_0002506 + KM, YH + + + + obo2:OAE_0002506 + hemolysis + + + + + obo2:OAE_0002506 + WEB: http://www.nlm.nih.gov/medlineplus/ency/article/002372.htm + + + + + obo2:OAE_0002506 + haemolysis AE + + + + obo2:OAE_0002506 + MedDRA: 10018910 + + + + + obo2:OAE_0002507 + A hepatosplenomegaly AE is a liver inflammation AE that has an outcome of an abnormal enlargement of the liver and spleen. + + + + obo2:OAE_0002507 + KM, YH + + + + obo2:OAE_0002507 + WEB: http://www.nlm.nih.gov/medlineplus/ency/imagepages/17215.htm + + + + + obo2:OAE_0002507 + WEB: http://www.medicinenet.com/script/main/art.asp?articlekey=3716 + + + + obo2:OAE_0002507 + hepatosplenomegaly AE + + + + obo2:OAE_0002507 + MedDRA: 10019847 + + + + obo2:OAE_0002508 + A gastric disorder AE that occurs when part of your stomach pushes upward through your diaphragm. + + + + obo2:OAE_0002508 + KM, YH + + + + obo2:OAE_0002508 + WEB: http://www.mayoclinic.org/diseases-conditions/hiatal-hernia/basics/definition/con-20030640 + + + + + obo2:OAE_0002508 + hiatus hernia AE + + + + obo2:OAE_0002508 + MedDRA: 10020028 + + + + + obo2:OAE_0002509 + A viral infection AE that is caused by the human immunodeficiency virus. + + + + obo2:OAE_0002509 + KM, YH + + + + obo2:OAE_0002509 + HIV infection AE + + + + obo2:OAE_0002509 + MedDRA: 10020161 + + + + + obo2:OAE_0002509 + NCIT: C3108 + + + + + obo2:OAE_0002510 + A hypertonic bladder AE is a digestive system AE that where the bladder-storage function that causes a sudden urge to urinate. + + + + obo2:OAE_0002510 + SJ, YH + + + + obo2:OAE_0002510 + irritable bladder + + + + obo2:OAE_0002510 + overactive bladder + + + + + obo2:OAE_0002510 + WEB: http://healbladder.info/healbladder/hypertonic-bladder + + + + obo2:OAE_0002510 + WEB: http://www.mayoclinic.org/diseases-conditions/overactive-bladder/basics/definition/con-20027632 + + + + + obo2:OAE_0002510 + hypertonic bladder AE + + + + obo2:OAE_0002510 + MedDRA: 10020853 + + + + + obo2:OAE_0002511 + A hypovitaminosis AE is a gustatory system AE which shows an insufficiency of one or more essential vitamins. + + + + obo2:OAE_0002511 + KM, YH + + + + obo2:OAE_0002511 + WEB: http://en.wikipedia.org/wiki/Hypovitaminosis + + + + obo2:OAE_0002511 + hypovitaminosis AE + + + + obo2:OAE_0002511 + MedDRA: 10021135 + + + + + obo2:OAE_0002512 + A gastrointestinal disorder AE that shows the inflammation of the ileum. + + + + obo2:OAE_0002512 + KM, YH + + + + obo2:OAE_0002512 + WEB: http://en.wikipedia.org/wiki/Ileitis + + + + + obo2:OAE_0002512 + ileitis AE + + + + obo2:OAE_0002512 + MedDRA: 10021312 + + + + + obo2:OAE_0002512 + NCIT: C84782 + + + + + obo2:OAE_0002513 + A joint pain AE that occurs when there is an abnormal separation in the joint, where two or more bones meet. + + + + obo2:OAE_0002513 + KM, YH + + + + obo2:OAE_0002513 + dislocated joint, luxation + + + + + obo2:OAE_0002513 + WEB: http://en.wikipedia.org/wiki/Joint_dislocation + + + + + obo2:OAE_0002513 + joint dislocation AE + + + + obo2:OAE_0002513 + MedDRA: 10023204 + + + + + obo2:OAE_0002514 + A syndrome AE that shows Kawasaki's disease, a vasculitis characterized by inflammation of the arteries, particularly the coronary arteries. The vasculitis may lead to aneurysm formation and possibly, heart attacks. It affects young children who usually present with persistent high fever, redness of the mucous membranes of the mouth, redness of the palms and soles, skin rashes, lymphadenitis, and joint pain and swelling. + + + + obo2:OAE_0002514 + KM, YH + + + + obo2:OAE_0002514 + Mucocutaneous Lymph Node Syndrome + + + + + obo2:OAE_0002514 + WEB: http://en.wikipedia.org/wiki/Kawasaki_disease + + + + + obo2:OAE_0002514 + kawasaki disease AE + + + + obo2:OAE_0002514 + MedDRA: 10023320 + + + + + obo2:OAE_0002514 + NCIT: C34825 + + + + + obo2:OAE_0002515 + An abscess AE where a bacterial, parasitic, or fungal abscess that develops in the liver. It is usually the result of an abdominal infection, trauma, or surgery in the right upper quadrant. Signs and symptoms include abdominal pain, nausea, vomiting, and fever. + + + + obo2:OAE_0002515 + KM, YH + + + + obo2:OAE_0002515 + WEB: http://en.wikipedia.org/wiki/Liver_abscess + + + + + obo2:OAE_0002515 + liver abscess AE + + + + obo2:OAE_0002515 + MedDRA: 10024652 + + + + + obo2:OAE_0002515 + NCIT: C99089 + + + + + obo2:OAE_0002516 + A blood disorder AE that the body's blood supply will stop moving after the heart has stopped pumping it around the inside of the deceased. + + + + obo2:OAE_0002516 + KM, YH + + + + obo2:OAE_0002516 + WEB: http://www.exploreforensics.co.uk/rigor-mortis-and-lividity.html + + + + + obo2:OAE_0002516 + lividity AE + + + + obo2:OAE_0002516 + MedDRA: 10024728 + + + + + obo2:OAE_0002517 + A lymphangitis AE is an inflammation AE that has an infection of the lymph vessels (channels). + + + + obo2:OAE_0002517 + KM, YH + + + + obo2:OAE_0002517 + WEB: http://www.nlm.nih.gov/medlineplus/ency/article/007296.htm + + + + + obo2:OAE_0002517 + lymphangitis AE + + + + obo2:OAE_0002517 + MedDRA: 10025226 + + + + + obo2:OAE_0002518 + An infection adverse event that results in malaria, a protozoan infection caused by the genus Plasmodium. There are four species of Plasmodium that can infect humans: Plasmodium falciparum, vivax, ovale, and malariae. It is transmitted to humans by infected mosquitoes. Signs and symptoms include paroxysmal high fever, sweating, chills, and anemia. + + + + obo2:OAE_0002518 + KM, YH + + + + obo2:OAE_0002518 + WEB: http://en.wikipedia.org/wiki/Malaria + + + + obo2:OAE_0002518 + malaria AE + + + + obo2:OAE_0002518 + MedDRA: 10025487 + + + + + obo2:OAE_0002518 + NCIT: C34797 + + + + + obo2:OAE_0002519 + A metabolic disoder AE where there is increased acidity in the blood secondary to acid base imbalance. Causes include diabetes, kidney failure and shock. + + + + obo2:OAE_0002519 + KM, YH + + + + obo2:OAE_0002519 + Acidosis + + + + + obo2:OAE_0002519 + WEB: http://www.nlm.nih.gov/medlineplus/ency/article/000335.htm + + + + + obo2:OAE_0002519 + metabolic acidosis AE + + + + obo2:OAE_0002519 + MedDRA: 10027417 + + + + + obo2:OAE_0002519 + NCIT: C28228 + + + + + obo2:OAE_0002520 + An abnormal stool AE that has an outcome of a significant amount of mucus in the stool. The mucus is accompanied by diarrhea, pain or blood may signify an intestinal condition such as infection or inflammation. Increased amounts of mucus in the stool can also occur with cancers of the colon or rectum or with bowel obstruction. + + + + obo2:OAE_0002520 + KM, YH + + + + obo2:OAE_0002520 + WEB: http://www.healthgrades.com/symptoms/mucus-in-stool + + + + obo2:OAE_0002520 + mucous stool AE + + + + obo2:OAE_0002520 + MedDRA: 10028140 + + + + obo2:OAE_0002521 + A muscle spasm AE that has an outcome of tight or stiff muscles and an inability to control those muscles. + + + + obo2:OAE_0002521 + KM, YH + + + + obo2:OAE_0002521 + WEB: http://www.webmd.com/pain-management/pain-management-spasticity + + + + obo2:OAE_0002521 + muscle spasticity AE + + + + obo2:OAE_0002521 + MedDRA: 10028335 + + + + obo2:OAE_0002522 + A respiratory distress AE that has an outcome of a newborn dyspnea (i.e., impaired breathing) with cyanosis, most frequently occurring in premature infants, children of diabetic mothers and infants delivered by cesarean section, and sometimes with no predisposing cause. + + + + obo2:OAE_0002522 + KM, YH + + + + obo2:OAE_0002522 + Newborn Respiratory Distress Syndrome + + + + obo2:OAE_0002522 + WEB: http://www.nlm.nih.gov/medlineplus/ency/article/001563.htm + + + + obo2:OAE_0002522 + neonatal respiratory distress AE + + + + obo2:OAE_0002522 + MedDRA: 10001052 + + + + obo2:OAE_0002522 + NCIT: C27560 + + + + obo2:OAE_0002523 + A neutrophil count increased AE that has an outcome of an abnormally high level of neutrophils in the blood. + + + + obo2:OAE_0002523 + KM, YH + + + + obo2:OAE_0002523 + WEB: http://en.wikipedia.org/wiki/Neutrophilia + + + + obo2:OAE_0002523 + neutrophilia AE + + + + obo2:OAE_0002523 + MedDRA: 10029379 + + + + obo2:OAE_0002523 + NCIT: C35164 + + + + obo2:OAE_0002524 + A male reproductive system AE that results in an inflammation of one or both testes due to viral or bacterial infections. Signs and symptoms include enlargement or tenderness of the affected testis, inguinal lymphadenopathy, blood in the semen, and pain during urination, intercourse, or ejaculation. + + + + obo2:OAE_0002524 + KM, YH + + + + obo2:OAE_0002524 + WEB: http://www.nlm.nih.gov/medlineplus/ency/article/001280.htm + + + + obo2:OAE_0002524 + orchitis AE + + + + obo2:OAE_0002524 + MedDRA: 10031064 + + + + obo2:OAE_0002524 + NCIT: C97145 + + + + obo2:OAE_0002525 + an inflammation AE that occurs in a bone. + + + + obo2:OAE_0002525 + KM, YH + + + + obo2:OAE_0002525 + Osteitis fibrosa + + + + obo2:OAE_0002525 + WEB: http://www.nlm.nih.gov/medlineplus/ency/article/001252.htm + + + + obo2:OAE_0002525 + osteitis AE + + + + obo2:OAE_0002525 + MedDRA: 10031149 + + + + obo2:OAE_0002526 + A bone disorder AE that has an dissolution of bone, especially the removal or loss of the calcium of bone. + + + + obo2:OAE_0002526 + KM, YH + + + + obo2:OAE_0002526 + WEB: http://en.wikipedia.org/wiki/Osteolysis + + + + obo2:OAE_0002526 + osteolysis AE + + + + obo2:OAE_0002526 + MedDRA: 10031248 + + + + obo2:OAE_0002526 + NCIT: C50681 + + + + obo2:OAE_0002527 + An arrhythmia AE that has an outcome of palpitations, an abnormality of heartbeat characterized by simultaneous awareness of one’s pulse and discomfort. + + + + obo2:OAE_0002527 + KM, YH + + + + obo2:OAE_0002527 + WEB: http://en.wikipedia.org/wiki/Palpitations + + + + obo2:OAE_0002527 + palpitations AE + + + + obo2:OAE_0002527 + MedDRA: 10033557 + + + + obo2:OAE_0002528 + A skin AE that shows a solid, raised spot on the skin that is up to 0.5 centimeter wide, which is a type of skin lesion. + + + + obo2:OAE_0002528 + KM, YH + + + + obo2:OAE_0002528 + WEB: http://www.nlm.nih.gov/medlineplus/ency/article/003233.htm + + + + obo2:OAE_0002528 + papule AE + + + + obo2:OAE_0002528 + MedDRA: 10033733 + + + + obo2:OAE_0002529 + A parotid gladn enlargement AE that has an outcome of parotitis, the inflammation of one or more of the parotid glands. + + + + obo2:OAE_0002529 + KM, YH + + + + obo2:OAE_0002529 + WEB: http://emedicine.medscape.com/article/882461-overview + + + + obo2:OAE_0002529 + WEB: http://www.nlm.nih.gov/medlineplus/ency/article/001041.htm + + + + obo2:OAE_0002529 + parotitis AE + + + + obo2:OAE_0002529 + MedDRA: 10034038 + + + + obo2:OAE_0002530 + A male reproductive system AE that has an disorder in a penis, including priapism, Peyronie's disease, balanitis, phimosis, paraphimosis, and penile cancer. + + + + obo2:OAE_0002530 + KM, YH + + + + obo2:OAE_0002530 + WEB: http://www.medicinenet.com/penis_disorders/article.htm + + + + obo2:OAE_0002530 + penis disorder AE + + + + obo2:OAE_0002530 + MedDRA: 10034336 + + + + obo2:OAE_0002531 + An abdominal AE that shows an inflammation of the peritoneum, the thin tissue that lines the inner wall of the abdomen and covers most of the abdominal organs. + + + + obo2:OAE_0002531 + KM, YH + + + + obo2:OAE_0002531 + WEB: http://en.wikipedia.org/wiki/Peritonitis + + + + obo2:OAE_0002531 + peritonitis AE + + + + obo2:OAE_0002531 + MedDRA: 10034674 + + + + obo2:OAE_0002531 + NCIT: C26849 + + + + obo2:OAE_0002533 + An arthritis AE that has an outcome of polyarthritis, which includes any type of arthritis that involves 5 or more joints simultaneously. + + + + obo2:OAE_0002533 + KM, YH + + + + obo2:OAE_0002533 + WEB: http://en.wikipedia.org/wiki/Polyarthritis + + + + obo2:OAE_0002533 + polyarthritis AE + + + + obo2:OAE_0002533 + MedDRA: 10036030 + + + + obo2:OAE_0002534 + A male reproductive system AE that affects prostatic gland in the male reproductive system. + + + + obo2:OAE_0002534 + KM, YH + + + + obo2:OAE_0002534 + WEB: http://www.britannica.com/EBchecked/topic/479519/prostatic-disorder + + + + obo2:OAE_0002534 + prostatic disorder AE + + + + obo2:OAE_0002534 + MedDRA: 10036956 + + + + obo2:OAE_0002535 + A tumor AE that shows a benign disorder of lymphoid cells or histiocytes that produces clinical features of a malignant lymphoma. + + + + obo2:OAE_0002535 + KM, YH + + + + obo2:OAE_0002535 + WEB: http://medical-dictionary.thefreedictionary.com/pseudolymphoma + + + + obo2:OAE_0002535 + pseudo lymphoma AE + + + + obo2:OAE_0002535 + MedDRA: 10037108 + + + + obo2:OAE_0002536 + A skin AE that shows a pyogenic skin disease. These include superficial bacterial infections such as impetigo, impetigo contagiosa, ecthyma, folliculitis, Bockhart's impetigo, furuncle, carbuncle, tropical ulcer, etc. + + + + obo2:OAE_0002536 + KM, YH + + + + obo2:OAE_0002536 + WEB: http://en.wikipedia.org/wiki/Pyoderma + + + + obo2:OAE_0002536 + pyoderma AE + + + + obo2:OAE_0002536 + MedDRA: 10037632 + + + + obo2:OAE_0002537 + A urine abnormality AE that shows the presence of white blood cells or pus in the urine, usually a sign of urinary tract infection. + + + + obo2:OAE_0002537 + KM, YH + + + + obo2:OAE_0002537 + WEB: http://en.wikipedia.org/wiki/Pyuria + + + + obo2:OAE_0002537 + WEB: http://medical-dictionary.thefreedictionary.com/pyuria + + + + obo2:OAE_0002537 + pyuria AE + + + + obo2:OAE_0002537 + MedDRA: 10037686 + + + + obo2:OAE_0002538 + A rash AE that has an outcome of maculopapular rash, a disorder characterized by the presence of macules (flat) and papules (elevated). Also known as morbillform rash, it is one of the most common cutaneous adverse events, frequently affecting the upper trunk, spreading centripetally and associated with pruritis. + + + + obo2:OAE_0002538 + KM, YH + + + + obo2:OAE_0002538 + Maculopapular Lesion + + + + obo2:OAE_0002538 + WEB: http://en.wikipedia.org/wiki/Maculopapular_rash + + + + obo2:OAE_0002538 + maculopapular rash AE + + + + obo2:OAE_0002538 + MedDRA: 10037868 + + + + obo2:OAE_0002538 + NCIT: C75579 + + + + obo2:OAE_0002539 + A rash AE that shows a rash like measles. The rash consists of macular lesions that are red and usually 2–10 mm in diameter but may be confluent in places. + + + + obo2:OAE_0002539 + KM, YH + + + + obo2:OAE_0002539 + WEB: http://en.wikipedia.org/wiki/Morbilliform + + + + obo2:OAE_0002539 + morbilliform AE + + + + obo2:OAE_0002539 + MedDRA: 10037870 + + + + obo2:OAE_0002540 + A rash AE that shows a raised, blistery rash. + + + + obo2:OAE_0002540 + KM, YH + + + + obo2:OAE_0002540 + WEB: http://www.medicinenet.com/script/main/art.asp?articlekey=11955 + + + + obo2:OAE_0002540 + vesicular rash AE + + + + obo2:OAE_0002540 + MedDRA: 10037898 + + + + obo2:OAE_0002541 + A red blood cell count increased AE that has an increased count of reticulocytes in the blood. Reticulocytes are slightly immature red blood cells. + + + + obo2:OAE_0002541 + KM, YH + + + + obo2:OAE_0002541 + WEB: http://www.nlm.nih.gov/medlineplus/ency/article/003637.htm + + + + obo2:OAE_0002541 + reticulocyte count increased AE + + + + obo2:OAE_0002541 + MedDRA: 10038792 + + + + obo2:OAE_0002542 + a behavior and neurological AE that results in impaired or inhibited ego functioning in which the ability to process reality-based information is diminished and disordered. + + + + obo2:OAE_0002542 + SJ, YH + + + + obo2:OAE_0002542 + WEB: http://medical-dictionary.thefreedictionary.com/acute+psychosis + + + + obo2:OAE_0002542 + acute psychosis AE + + + + obo2:OAE_0002542 + MedDRA: 10001022 + + + + obo2:OAE_0002543 + An eye AE that shows an abnormal blood vessel development in the retina of the eye and it occurs in infants that are born too early. + + + + obo2:OAE_0002543 + KM, YH + + + + obo2:OAE_0002543 + Terry syndrome + + + + obo2:OAE_0002543 + retrolental fibroplasia + + + + obo2:OAE_0002543 + retrolental fibroplasia (RLF) + + + + obo2:OAE_0002543 + WEB: http://en.wikipedia.org/wiki/Retinopathy_of_prematurity + + + + obo2:OAE_0002543 + WEB: http://www.nlm.nih.gov/medlineplus/ency/article/001618.htm + + + + obo2:OAE_0002543 + retinopathy of prematurity AE + + + + obo2:OAE_0002543 + MedDRA: 10038933 + + + + obo2:OAE_0002544 + A skin AE that results in a scar, a mark left on the skin. + + + + obo2:OAE_0002544 + KM, YH + + + + obo2:OAE_0002544 + WEB: http://en.wikipedia.org/wiki/Scar + + + + obo2:OAE_0002544 + scar AE + + + + obo2:OAE_0002544 + MedDRA: 10039580 + + + + obo2:OAE_0002544 + NCIT: C34483 + + + + obo2:OAE_0002545 + A skin AE that has an outcome of a localized or systemic chronic and progressive autoimmune disorder characterized by thickening of the skin and the connective tissues. + + + + obo2:OAE_0002545 + KM, YH + + + + obo2:OAE_0002545 + WEB: http://en.wikipedia.org/wiki/Scleroderma + + + + obo2:OAE_0002545 + Localized scleroderma affects only the skin. Systemic scleroderma affects internal organs, including the heart, lungs, gastrointestinal tract, and kidneys. + + + + obo2:OAE_0002545 + scleroderma AE + + + + obo2:OAE_0002545 + MedDRA: 10039710 + + + + obo2:OAE_0002545 + NCIT: C26746 + + + + obo2:OAE_0002546 + A male reproductive system AE that has an outcome of an abnormal enlargement of the scrotum, the sac surrounding the testicles. + + + + obo2:OAE_0002546 + KM, YH + + + + obo2:OAE_0002546 + scrotal edema + + + + obo2:OAE_0002546 + scrotal swelling + + + + obo2:OAE_0002546 + WEB: http://www.nlm.nih.gov/medlineplus/ency/article/003161.htm + + + + obo2:OAE_0002546 + scrotal oedema AE + + + + obo2:OAE_0002546 + MedDRA: 10039755 + + + + obo2:OAE_0002547 + A skin AE that results in the degeneration and thinning of the epidermis and dermis. + + + + obo2:OAE_0002547 + KM, YH + + + + obo2:OAE_0002547 + atrophy of the skin + + + + obo2:OAE_0002547 + WEB: http://www.wisegeek.com/what-is-skin-atrophy.htm + + + + obo2:OAE_0002547 + skin atrophy AE + + + + obo2:OAE_0002547 + MedDRA: 10040799 + + + + obo2:OAE_0002547 + NCIT: C35163 + + + + obo2:OAE_0002548 + A skin discoloration AE that shows the lightening of the skin, or loss of pigment. + + + + obo2:OAE_0002548 + KM, YH + + + + obo2:OAE_0002548 + Depigmentation + + + + obo2:OAE_0002548 + WEB: http://en.wikipedia.org/wiki/Depigmentation + + + + obo2:OAE_0002548 + skin depigmentation AE + + + + obo2:OAE_0002548 + MedDRA ID: 10040825 + + + + obo2:OAE_0002549 + A skin discoloration AE that shows abnormal lightening of skin due to decreased melanin production or deposition. + + + + obo2:OAE_0002549 + KM, YH + + + + obo2:OAE_0002549 + Hypopigmentation, Pigment Dilution + + + + obo2:OAE_0002549 + WEB: http://en.wikipedia.org/wiki/Hypopigmentation + + + + obo2:OAE_0002549 + Vitiligo, albinism, and leukoderma are among the disorders that are associated with skin hypopigmentation. + + + + obo2:OAE_0002549 + skin hypopigmentation AE + + + + obo2:OAE_0002549 + MedDRA ID: 10040868 + + + + obo2:OAE_0002549 + http://en.wikipedia.org/wiki/Hypopigmentation + + + + obo2:OAE_0002550 + An immune system disorder AE that has an disorder in spleen, the largest organ in the lymphatic system. + + + + obo2:OAE_0002550 + KM, YH + + + + obo2:OAE_0002550 + splenic diseases + + + + obo2:OAE_0002550 + WEB: http://en.wikipedia.org/wiki/Splenic_disease + + + + obo2:OAE_0002550 + WEB: http://www.livescience.com/44725-spleen.html + + + + obo2:OAE_0002550 + spleen disorder AE + + + + obo2:OAE_0002550 + MedDRA: 10041633 + + + + obo2:OAE_0002551 + a musculoskeletal system AE that results in the absence or loss of control of voluntary muscle movements. + + + + obo2:OAE_0002551 + SJ, YH + + + + obo2:OAE_0002551 + URL: http://medical-dictionary.thefreedictionary.com/akinesia + + + + obo2:OAE_0002551 + akinesia AE + + + + obo2:OAE_0002551 + MedDRA: 10001541 + + + + obo2:OAE_0002552 + a seizure AE that shows a brief episode of signs and/or symptoms due to abnormal excessive or synchronous neuronal activity in the brain. + + + + obo2:OAE_0002552 + JX, YH + + + + obo2:OAE_0002552 + epilepsy + + + + obo2:OAE_0002552 + WEB: http://en.wikipedia.org/wiki/Epileptic_seizure + + + + obo2:OAE_0002552 + 癫痫 + + + + obo2:OAE_0002552 + epileptic seizure AE + + + + obo2:OAE_0002553 + a peripheral neuropathy AE which shows an damage or abnormality to the nerves in the eyes. + + + + obo2:OAE_0002553 + RR, YH + + + + obo2:OAE_0002553 + WEB: http://www.allaboutvision.com/conditions/optic-neuritis.htm + + + + obo2:OAE_0002553 + optic neuropathy AE + + + + obo2:OAE_0002553 + MedDRA: 10061323 + + + + obo2:OAE_0002554 + an optic neuropathy AE characterized by optic disc swelling, peripapillary and macular hard exudates, and vitreous cells. + + + + obo2:OAE_0002554 + RR, YH + + + + obo2:OAE_0002554 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/6466175 + + + + obo2:OAE_0002554 + neuroretinitis AE + + + + obo2:OAE_0002554 + MedDRA: 10060701 + + + + obo2:OAE_0002555 + an optic neuropathy AE characterized by vision loss, optic disc swelling, flame hemorrhages, and cotton-wool exudates. It occurs when blood flow is interrupted to the front (anterior) part of the optic nerve (also called optic nerve head). + + + + obo2:OAE_0002555 + RR, YH + + + + obo2:OAE_0002555 + AION + + + + obo2:OAE_0002555 + WEB: http://emedicine.medscape.com/article/1216891-overview + + + + obo2:OAE_0002555 + WEB: http://www.geteyesmart.org/eyesmart/diseases/ischemic-optic-neuropathy/ + + + + obo2:OAE_0002555 + anterior ischemic optic neuropathy AE + + + + obo2:OAE_0002555 + MedDRA: 10068250 + + + + obo2:OAE_0002556 + a type of anterior ischemic optic neuropathy AE that presents primarily with vision loss, especially upon wakening, and sectorial disc edema. + + + + obo2:OAE_0002556 + RR, YH + + + + obo2:OAE_0002556 + WEB: http://emedicine.medscape.com/article/1216891-clinical#a0217 + + + + obo2:OAE_0002556 + non-arteritic anterior ischemic optic neuropathy AE + + + + obo2:OAE_0002556 + MedDRA: 10068249 + + + + obo2:OAE_0002557 + a peripheral neuropathy AE that shows a combination of axonal and demyelinating neuropathy. + + + + obo2:OAE_0002557 + RR, YH + + + + obo2:OAE_0002557 + WEB: http://www.aafp.org/afp/2010/0401/p887.html + + + + obo2:OAE_0002557 + mixed neuropathy AE + + + + obo2:OAE_0002558 + a peripheral sensory neuropathy AE that shows neuropathy in many sensory nerves at one time + + + + obo2:OAE_0002558 + RR, YH + + + + obo2:OAE_0002558 + WEB: http://www.merckmanuals.com/home/brain_spinal_cord_and_nerve_disorders/peripheral_nerve_disorders/polyneuropathy.html + + + + obo2:OAE_0002558 + sensory peripheral polyneuropathy AE + + + + obo2:OAE_0002559 + a peripheral neuropathy AE that results from the loss of the myelin sheath on peripheral nerves roughly evenly distributed on both sides of the body + + + + obo2:OAE_0002559 + RR, YH + + + + obo2:OAE_0002559 + peripheral demyelinating polyneuropathy AE + + + + obo2:OAE_0002560 + a neuropathy AE that shows nerve damage and occurs in a patient with diabetes + + + + obo2:OAE_0002560 + RR, YH + + + + obo2:OAE_0002560 + WEB: http://www.mayoclinic.org/diseases-conditions/diabetic-neuropathy/basics/definition/con-20033336 + + + + obo2:OAE_0002560 + diabetic neuropathy AE + + + + obo2:OAE_0002560 + MedDRA: 10012680 + + + + obo2:OAE_0002561 + a nervous system AE that is an umbrella term referring to conditions relating to the nervous system, including loss of sensation and paralysis + + + + obo2:OAE_0002561 + RR, YH + + + + obo2:OAE_0002561 + WEB: http://en.wikipedia.org/wiki/Functional_neurological_deficit + + + + obo2:OAE_0002561 + neurological deficit AE + + + + obo2:OAE_0002562 + An abscess AE that is caused by an Staphylococcus aureus infection. + + + + obo2:OAE_0002562 + KM, YH + + + + obo2:OAE_0002562 + abscess + + + + obo2:OAE_0002562 + http://medical-dictionary.thefreedictionary.com/staphylococcal+abscess + + + + obo2:OAE_0002562 + staphylococcal abscess AE + + + + obo2:OAE_0002562 + MedDRA: 10041917 + + + + obo2:OAE_0002563 + An eye AE that results in an intermittent or constant misalignment of an eye so that its line of vision is not pointed at the same object. Strabismus is caused by an imbalance in the extraocular muscles which control the positioning of the eyes. + + + + obo2:OAE_0002563 + KM, YH + + + + obo2:OAE_0002563 + cross-eyed + + + + obo2:OAE_0002563 + heterotropia + + + + obo2:OAE_0002563 + wall-eyed + + + + obo2:OAE_0002563 + WEB: http://en.wikipedia.org/wiki/Strabismus + + + + obo2:OAE_0002563 + strabismus AE + + + + obo2:OAE_0002563 + MedDRA: 10042159 + + + + obo2:OAE_0002564 + A vein discoloration AE that has an outcome of local dilatation of small vessels resulting in red discoloration of the skin or mucous membranes. + + + + obo2:OAE_0002564 + KM, YH + + + + obo2:OAE_0002564 + http://en.wikipedia.org/wiki/Telangiectasia + + + + obo2:OAE_0002564 + telangiectasia AE + + + + obo2:OAE_0002564 + MedDRA: 10043189 + + + + obo2:OAE_0002564 + NCIT: C28194 + + + + obo2:OAE_0002565 + A muscle spasm AE that results in the lack of ability to open the mouth fully due to decreased range of motion of the muscles of mastication. + + + + obo2:OAE_0002565 + KM, YH + + + + obo2:OAE_0002565 + WEB: http://www.medicinenet.com/script/main/art.asp?articlekey=40739 + + + + obo2:OAE_0002565 + Trismus is a symptom of tetanus. + + + + obo2:OAE_0002565 + trismus AE + + + + obo2:OAE_0002565 + MedDRA:10044684 + + + + obo2:OAE_0002565 + NCIT: C78651 + + + + obo2:OAE_0002566 + A bacterial infection AE with an outcome of thypoid fever, a bacterial infectious disorder caused by the Salmonella typhi bacteria. + + + + obo2:OAE_0002566 + KM, YH + + + + obo2:OAE_0002566 + tyhpoid + + + + obo2:OAE_0002566 + WEB: http://www.webmd.com/a-to-z-guides/typhoid-fever + + + + obo2:OAE_0002566 + Typhoid fever is often contracted by consumption of food or drink contaminated with Salmonella typhi. + + + + obo2:OAE_0002566 + typhoid fever AE + + + + obo2:OAE_0002566 + MedDRA: 10045275 + + + + obo2:OAE_0002566 + NCIT: C35089 + + + + obo2:OAE_0002567 + a urinary system AE that results in the inflammation (swelling and irritation) of the urethra. + + + + obo2:OAE_0002567 + KM, YH + + + + obo2:OAE_0002567 + WEB: http://www.nlm.nih.gov/medlineplus/ency/article/000439.htm + + + + obo2:OAE_0002567 + urethritis AE + + + + obo2:OAE_0002567 + MedDRA: 10046480 + + + + obo2:OAE_0002568 + a skin discoloration AE which shows a chronic skin disease characterized by portions of the skin losing their pigment. + + + + obo2:OAE_0002568 + KM, YH + + + + obo2:OAE_0002568 + WEB: http://en.wikipedia.org/wiki/Vitiligo + + + + obo2:OAE_0002568 + vitiligo AE + + + + obo2:OAE_0002568 + MedDRA: 10047642 + + + + obo2:OAE_0002568 + NCIT: C26915 + + + + obo2:OAE_0002569 + an injury AE that displays a type of injury to flesh or skin caused by heat, electricity, chemicals, friction, or radiation. + + + + obo2:OAE_0002569 + YH + + + + obo2:OAE_0002569 + WEB: http://en.wikipedia.org/wiki/Burn + + + + obo2:OAE_0002569 + burn AE + + + + obo2:OAE_0002570 + a hematopoietic system AE which has a decreased erythrocyte sedimentation rate (ESR). EST is the rate at which red blood cells sediment in a period of one hour. + + + + obo2:OAE_0002570 + KM, YH + + + + obo2:OAE_0002570 + ESR + + + + obo2:OAE_0002570 + erythrocyte sedimentation rate + + + + obo2:OAE_0002570 + red blood cell sedimentation rate decreased AE + + + + obo2:OAE_0002570 + Westergren ESR decreased AE + + + + obo2:OAE_0002570 + http://en.wikipedia.org/wiki/Erythrocyte_sedimentation_rate + + + + obo2:OAE_0002570 + sedimentation rate decreased AE + + + + obo2:OAE_0002570 + MedDRA:10049188 + + + + obo2:OAE_0002571 + a skin AE that has decreased skin turgor which is the skin's ability to change shape and return to normal (elasticity). + + + + obo2:OAE_0002571 + KM, YH + + + + obo2:OAE_0002571 + WEB: http://www.nlm.nih.gov/medlineplus/ency/article/003281.htm + + + + obo2:OAE_0002571 + skin turgor decreased AE + + + + obo2:OAE_0002571 + MedDRA: 10049428 + + + + obo2:OAE_0002572 + A tumor AE that shows a tumor occuring in the gastrointestinal tract. + + + + obo2:OAE_0002572 + KM, YH + + + + obo2:OAE_0002572 + WEB: http://ghr.nlm.nih.gov/condition/gastrointestinal-stromal-tumor + + + + obo2:OAE_0002572 + gastrointestinal stromal tumour AE + + + + obo2:OAE_0002572 + MedDRA: 10051066 + + + + obo2:OAE_0002573 + A bacterial infection AE that has the presence of pus in a bacterial infection. + + + + obo2:OAE_0002573 + KM, YH + + + + obo2:OAE_0002573 + WEB: http://dermatology.about.com/library/bldeffluctuance.htm + + + + obo2:OAE_0002573 + fluctuance AE + + + + obo2:OAE_0002573 + MedDRA: 10051723 + + + + obo2:OAE_0002574 + A bacterial infection AE which is caused by Acinetobacter. + + + + obo2:OAE_0002574 + KM, YH + + + + obo2:OAE_0002574 + WEB: http://www.cdc.gov/HAI/organisms/acinetobacter.html + + + + obo2:OAE_0002574 + Outbreaks of Acinetobacter infections typically occur in intensive care units and healthcare settings housing very ill patients. Acinetobacter infections rarely occur outside of healthcare settings. + + + + obo2:OAE_0002574 + acinetobacter infection AE + + + + obo2:OAE_0002574 + MedDRA: 10051894 + + + + obo2:OAE_0002575 + an injury AE that breaks the skin or other body tissues. + + + + obo2:OAE_0002575 + KM, YH + + + + obo2:OAE_0002575 + WEB: http://www.nlm.nih.gov/medlineplus/woundsandinjuries.html + + + + obo2:OAE_0002575 + wound AE + + + + obo2:OAE_0002575 + MedDRA: 10052428 + + + + obo2:OAE_0002576 + a tuberculosis AE which is an invasion of the peritoneum by Mycobacterium tuberculosis. + + + + obo2:OAE_0002576 + KM, YH + + + + obo2:OAE_0002576 + WEB: http://www.ncbi.nlm.nih.gov/pubmed/21215540 + + + + obo2:OAE_0002576 + peritoneal tuberculosis AE + + + + obo2:OAE_0002576 + MedDRA: 10053583 + + + + obo2:OAE_0002577 + a tumor AE that shows a benigh tumor of vascular origin usually seen in early childhood. + + + + obo2:OAE_0002577 + YH + + + + obo2:OAE_0002577 + WEB: http://radiopaedia.org/articles/haemangioma + + + + obo2:OAE_0002577 + haemangioma AE + + + + obo2:OAE_0002578 + a vascular disorder AE that has an outcome of the blockage of a blood vessel, usually with a clot. + + + + obo2:OAE_0002578 + KM, YH + + + + obo2:OAE_0002578 + WEB: http://en.wikipedia.org/wiki/Vascular_occlusion + + + + obo2:OAE_0002578 + vascular occlusion AE + + + + obo2:OAE_0002578 + MedDRA: 10053648 + + + + obo2:OAE_0002579 + a tuberculosis AE that shows an tuberculosis of the joints. + + + + obo2:OAE_0002579 + KM, YH + + + + obo2:OAE_0002579 + WEB: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1577591/ + + + + obo2:OAE_0002579 + joint tuberculosis AE + + + + obo2:OAE_0002579 + MedDRA: 10056367 + + + + obo2:OAE_0002580 + an arrhythmia AE that shows abnormal heart rhythms that originate in the bottom chambers of the heart called the ventricles. + + + + obo2:OAE_0002580 + LW, YH + + + + obo2:OAE_0002580 + WEB: http://my.clevelandclinic.org/services/heart/departments-centers/ventricular-arrhythmia-center + + + + obo2:OAE_0002580 + 室性心律失常 + + + + obo2:OAE_0002580 + ventricular arrhythmia AE + + + + obo2:OAE_0002581 + A bacterial infection AE that is caused by Salmonella. + + + + obo2:OAE_0002581 + KM, YH + + + + obo2:OAE_0002581 + WEB: http://en.wikipedia.org/wiki/Salmonella + + + + obo2:OAE_0002581 + Salmonella AE + + + + obo2:OAE_0002581 + MedDRA: 10058878 + + + + obo2:OAE_0002582 + a lab test abnormal AE that has an outcome of lower than normal amount of potassium in the blood + + + + obo2:OAE_0002582 + DJ, SS, YH + + + + obo2:OAE_0002582 + hypopotassaemia AE + + + + obo2:OAE_0002582 + hypopotassemia AE + + + + obo2:OAE_0002582 + potassium depletion AE + + + + obo2:OAE_0002582 + WEB: http://en.wikipedia.org/wiki/Hypokalemia + + + + obo2:OAE_0002582 + WEB: http://medical-dictionary.thefreedictionary.com/hyperkalemia + + + + obo2:OAE_0002582 + WEB: http://www.emedicinehealth.com/low_potassium/article_em.htm + + + + obo2:OAE_0002582 + 血钾过少 + + + + obo2:OAE_0002582 + hypokalaemia AE + + + + obo2:OAE_0002582 + MedDRA: 10021015 + + + + obo2:OAE_0002583 + a necrosis AE, tumor necrosis factor (TNF, tumor necrosis factor alpha, TNFα, cachexin, or cachectin) is a cell signaling protein (adipokine) involved in systemic inflammation and is one of the cytokines that make up the acute phase reaction. + + + + obo2:OAE_0002583 + KM, YH + + + + obo2:OAE_0002583 + WEB: http://en.wikipedia.org/wiki/Tumor_necrosis_factor_alpha + + + + obo2:OAE_0002583 + alpha tumour necrosis factor AE + + + + obo2:OAE_0002583 + MedDRA: 10059981 + + + + obo2:OAE_0002584 + a tumor AE that that is a benign or malignant neoplasm involving the oral cavity and/or the lips. + + + + obo2:OAE_0002584 + KM, YH + + + + obo2:OAE_0002584 + WEB: http://www.nlm.nih.gov/medlineplus/oralcancer.html + + + + obo2:OAE_0002584 + oral neoplasm AE + + + + obo2:OAE_0002584 + MedDRA: 10061325 + + + + obo2:OAE_0002584 + NCIT: C8989 + + + + obo2:OAE_0002585 + a cardiac disorder AE that can present clinically as acute pericarditis, pericardial effusion, cardiac tamponade, and constrictive pericarditis. + + + + obo2:OAE_0002585 + KM, YH + + + + obo2:OAE_0002585 + WEB: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2878263/ + + + + obo2:OAE_0002585 + pericardial disease AE + + + + obo2:OAE_0002585 + MedDRA: 10061338 + + + + obo2:OAE_0002586 + a tumor AE that shows a benign or malignant neoplasm that affects the peritoneal cavity. + + + + obo2:OAE_0002586 + KM, YH + + + + obo2:OAE_0002586 + WEB: http://www.webmd.com/cancer/peritoneal-cancer-prognosis-symptoms-treatments + + + + obo2:OAE_0002586 + Representative examples of benign neoplasms include adenomatoid tumor and disseminated peritoneal leiomyomatosis. Representative examples of malignant neoplasms include primary peritoneal carcinoma, metastatic carcinoma to the peritoneum, and malignant mesothelioma. + + + + obo2:OAE_0002586 + peritoneal neoplasm AE + + + + obo2:OAE_0002586 + MedDRA: 10061344 + + + + obo2:OAE_0002586 + NCIT: C3322 + + + + obo2:OAE_0002587 + an inflammation AE that shows the formation or presence of pus. + + + + obo2:OAE_0002587 + KM, YH + + + + obo2:OAE_0002587 + MedDRA: 10061926 + + + + obo2:OAE_0002587 + WEB: http://medical-dictionary.thefreedictionary.com/purulence + + + + obo2:OAE_0002587 + purulence AE + + + + obo2:OAE_0002588 + a bacterial infection AE with bacteria of the genus Mycobacterium. + + + + obo2:OAE_0002588 + KM, YH + + + + obo2:OAE_0002588 + Mycobacterium Infection + + + + obo2:OAE_0002588 + WEB: http://www.nlm.nih.gov/medlineplus/mycobacterialinfections.html + + + + obo2:OAE_0002588 + mycobacterial infection AE + + + + obo2:OAE_0002588 + MedDRA: 10062207 + + + + obo2:OAE_0002588 + NCIT: C26831 + + + + obo2:OAE_0002589 + a tumor AE that shows the most common benign spinal neoplasm, often located in the thoracic and lumbar spine, with a peak incidence of occurrence in the fourth to sixth decades. + + + + obo2:OAE_0002589 + KM, YH + + + + obo2:OAE_0002589 + WEB: http://radiopaedia.org/articles/vertebral-haemangioma + + + + obo2:OAE_0002589 + spinal haemangioma AE + + + + obo2:OAE_0002589 + MedDRA: 10065275 + + + + obo2:OAE_0002590 + a syndrome AE that reuslts in an autosomal recessive combined immunodeficiency syndrome caused by mutations in the RAG-1 and RAG-2 genes. It is characterized by the presence of alopecia, erythroderma, desquamation, lymphadenopathy, and chronic diarrhea. + + + + obo2:OAE_0002590 + YH: This is also a genetic AE. We will later find a way to link to there. + + + + obo2:OAE_0002590 + KM, YH + + + + obo2:OAE_0002590 + WEB: http://en.wikipedia.org/wiki/Omenn_syndrome + + + + obo2:OAE_0002590 + Omenn syndrome AE + + + + obo2:OAE_0002590 + MedDRA: 10069097 + + + + obo2:OAE_0002590 + NCIT: C61240 + + + + obo2:OAE_0002591 + a immune system AE that results in a state in which the immune system's ability to fight infectious disease is compromised or entirely absent. + + + + obo2:OAE_0002591 + KM, YH + + + + obo2:OAE_0002591 + WEB: http://en.wikipedia.org/wiki/Immunodeficiency + + + + obo2:OAE_0002591 + immunodeficiency AE + + + + obo2:OAE_0002592 + a hepatitis AE that resutls in a hepatitis C viral infection. + + + + obo2:OAE_0002592 + KM, YH + + + + obo2:OAE_0002592 + HCV + + + + obo2:OAE_0002592 + WEB: http://en.wikipedia.org/wiki/Hepatitis_C_virus + + + + obo2:OAE_0002592 + hepatitis C virus AE + + + + obo2:OAE_0002592 + NCIT: C14312 + + + + obo2:OBI_0000094 + obo2:obi.owl + + + + obo2:OBI_0000274 + obo2:obi.owl + + + + obo2:OBI_0000298 + obo2:obi.owl + + + + obo2:OBI_0000300 + obo2:obi.owl + + + + obo2:OBI_0000306 + obo2:obi.owl + + + + obo2:OBI_0000308 + obo2:obi.owl + + + + obo2:OBI_0000316 + obo2:obi.owl + + + + obo2:OBI_0000652 + obo2:obi.owl + + + + obo2:OGMS_0000020 + obo2:ogms.owl + + + + obo2:OGMS_0000031 + obo2:ogms.owl + + + + obo2:PATO_0000165 + obo2:pato.owl + + + + obo2:PATO_0000165 + obo2:pato#attribute_slim + + + + obo2:PATO_0000165 + obo2:pato#scalar_slim + + + + obo2:PATO_0001241 + obo2:pato.owl + + + + obo2:PATO_0001309 + obo2:pato.owl + + + + obo2:PATO_0001309 + obo2:pato#attribute_slim + + + + obo2:PATO_0002062 + obo2:pato.owl + + + + obo2:PATO_0002062 + obo2:pato#attribute_slim + + + + obo2:RO_0001000 + + + + + obo2:RO_0001000 + + + + + obo2:RO_0001000 + + + + + obo2:RO_0001000 + + + + + obo2:RO_0001000 + + + + + obo2:RO_0001000 + + + + + obo2:RO_0001000 + + + + + obo2:RO_0001000 + + + + + obo2:RO_0001000 + + + + + obo2:RO_0001000 + + + + + obo2:RO_0001000 + + + + + obo2:RO_0001000 + + + + + obo2:RO_0001000 + + + + + obo2:RO_0001000 + + + + + obo2:RO_0001000 + + + + + obo2:RO_0001000 + + + + + obo2:RO_0001000 + + + + + obo2:RO_0001000 + + + + + obo2:RO_0001000 + + + + + obo2:RO_0001000 + + + + + obo2:RO_0001000 + + + + + obo2:RO_0001000 + + + + + obo2:RO_0001000 + + + + + obo2:RO_0001000 + + + + + obo2:RO_0001015 + obo2:uberon.owl + + + + obo2:RO_0001025 + obo2:uberon.owl + + + + obo2:RO_0002087 + obo2:uberon.owl + + + + obo2:RO_0002131 + obo2:uberon.owl + + + + obo2:RO_0002158 + obo2:uberon.owl + + + + obo2:RO_0002202 + obo2:uberon.owl + + + + obo2:RO_0002203 + obo2:uberon.owl + + + + obo2:RO_0002211 + obo2:go.owl + + + + obo2:RO_0002212 + obo2:go.owl + + + + obo2:RO_0002213 + obo2:go.owl + + + + obo2:RO_0002219 + obo2:uberon.owl + + + + obo2:RO_0002220 + obo2:uberon.owl + + + + obo2:RO_0002220 + + + + + obo2:RO_0002220 + + + + + obo2:RO_0002220 + + + + + obo2:RO_0002220 + + + + + obo2:RO_0002220 + + + + + obo2:RO_0002220 + + + + + obo2:RO_0002220 + + + + + obo2:RO_0002220 + + + + + obo2:RO_0002220 + + + + + obo2:RO_0002220 + + + + + obo2:RO_0002220 + + + + + obo2:RO_0002220 + + + + + obo2:RO_0002221 + obo2:uberon.owl + + + + obo2:RO_0002224 + obo2:uberon.owl + + + + obo2:RO_0002254 + obo2:uberon.owl + + + + obo2:RO_0002255 + obo2:uberon.owl + + + + obo2:RO_0002256 + obo2:uberon.owl + + + + obo2:RO_0002285 + obo2:uberon.owl + + + + obo2:RO_0002371 + obo2:uberon.owl + + + + obo2:RO_0003000 + obo2:uberon.owl + + + + obo2:RO_0003001 + obo2:uberon.owl + + + + obo2:UBERON_0000009 + obo2:uberon.owl + + + + obo2:UBERON_0000009 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0000012 + obo2:uberon.owl + + + + obo2:UBERON_0000012 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0000014 + obo2:uberon.owl + + + + obo2:UBERON_0000015 + obo2:uberon.owl + + + + obo2:UBERON_0000015 + obo2:uberon#upper_level + + + + obo2:UBERON_0000019 + obo2:uberon.owl + + + + obo2:UBERON_0000019 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0000019 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0000020 + obo2:uberon.owl + + + + obo2:UBERON_0000020 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0000025 + obo2:uberon.owl + + + + obo2:UBERON_0000026 + obo2:uberon.owl + + + + obo2:UBERON_0000026 + obo2:UBERON_0013701 + + + + obo2:UBERON_0000026 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0000033 + obo2:uberon.owl + + + + obo2:UBERON_0000033 + obo2:UBERON_0000948 + + + + obo2:UBERON_0000033 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0000033 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0000047 + obo2:uberon.owl + + + + obo2:UBERON_0000047 + obo2:uberon#grouping_class + + + + obo2:UBERON_0000047 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0000058 + obo2:uberon.owl + + + + obo2:UBERON_0000058 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0000060 + obo2:uberon.owl + + + + obo2:UBERON_0000060 + obo2:uberon#upper_level + + + + obo2:UBERON_0000061 + obo2:uberon.owl + + + + obo2:UBERON_0000061 + obo2:uberon#upper_level + + + + obo2:UBERON_0000062 + obo2:uberon.owl + + + + obo2:UBERON_0000062 + obo2:NCBITaxon_110815 + + + + obo2:UBERON_0000062 + obo2:uberon#upper_level + + + + obo2:UBERON_0000063 + obo2:uberon.owl + + + + obo2:UBERON_0000063 + obo2:uberon#upper_level + + + + obo2:UBERON_0000064 + obo2:uberon.owl + + + + obo2:UBERON_0000064 + obo2:uberon#disjointness_axiom_removed + + + + obo2:UBERON_0000064 + obo2:uberon#upper_level + + + + obo2:UBERON_0000066 + obo2:uberon.owl + + + + obo2:UBERON_0000067 + obo2:uberon.owl + + + + obo2:UBERON_0000067 + obo2:uberon#grouping_class + + + + obo2:UBERON_0000068 + obo2:uberon.owl + + + + obo2:UBERON_0000072 + obo2:uberon.owl + + + + obo2:UBERON_0000073 + obo2:uberon.owl + + + + obo2:UBERON_0000073 + obo2:uberon#non_informative + + + + obo2:UBERON_0000073 + obo2:uberon#upper_level + + + + obo2:UBERON_0000075 + obo2:uberon.owl + + + + obo2:UBERON_0000075 + obo2:uberon#non_informative + + + + obo2:UBERON_0000076 + obo2:uberon.owl + + + + obo2:UBERON_0000077 + obo2:uberon.owl + + + + obo2:UBERON_0000077 + obo2:uberon#grouping_class + + + + obo2:UBERON_0000078 + obo2:uberon.owl + + + + obo2:UBERON_0000078 + obo2:uberon#grouping_class + + + + obo2:UBERON_0000079 + obo2:uberon.owl + + + + obo2:UBERON_0000080 + obo2:uberon.owl + + + + obo2:UBERON_0000080 + obo2:uberon#organ_slim + + + + obo2:UBERON_0000080 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0000081 + obo2:uberon.owl + + + + obo2:UBERON_0000081 + obo2:uberon#organ_slim + + + + obo2:UBERON_0000083 + obo2:uberon.owl + + + + obo2:UBERON_0000084 + obo2:uberon.owl + + + + obo2:UBERON_0000085 + obo2:uberon.owl + + + + obo2:UBERON_0000086 + obo2:uberon.owl + + + + obo2:UBERON_0000086 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0000087 + obo2:uberon.owl + + + + obo2:UBERON_0000087 + obo2:uberon#early_development + + + + obo2:UBERON_0000088 + obo2:uberon.owl + + + + obo2:UBERON_0000088 + obo2:uberon#early_development + + + + obo2:UBERON_0000091 + obo2:uberon.owl + + + + obo2:UBERON_0000091 + obo2:uberon#early_development + + + + obo2:UBERON_0000092 + obo2:uberon.owl + + + + obo2:UBERON_0000104 + obo2:uberon.owl + + + + obo2:UBERON_0000104 + obo2:uberon#upper_level + + + + obo2:UBERON_0000106 + obo2:uberon.owl + + + + obo2:UBERON_0000107 + obo2:uberon.owl + + + + obo2:UBERON_0000108 + obo2:uberon.owl + + + + obo2:UBERON_0000109 + obo2:uberon.owl + + + + obo2:UBERON_0000110 + obo2:uberon.owl + + + + obo2:UBERON_0000111 + obo2:uberon.owl + + + + obo2:UBERON_0000112 + obo2:uberon.owl + + + + obo2:UBERON_0000117 + obo2:uberon.owl + + + + obo2:UBERON_0000118 + obo2:uberon.owl + + + + obo2:UBERON_0000119 + obo2:uberon.owl + + + + obo2:UBERON_0000119 + obo2:uberon#upper_level + + + + obo2:UBERON_0000122 + obo2:uberon.owl + + + + obo2:UBERON_0000153 + obo2:uberon.owl + + + + obo2:UBERON_0000154 + obo2:uberon.owl + + + + obo2:UBERON_0000158 + obo2:uberon.owl + + + + obo2:UBERON_0000161 + obo2:uberon.owl + + + + obo2:UBERON_0000161 + obo2:uberon#upper_ontology_conflict + + + + obo2:UBERON_0000162 + obo2:uberon.owl + + + + obo2:UBERON_0000162 + obo2:NCBITaxon_9369 + + + + obo2:UBERON_0000163 + obo2:uberon.owl + + + + obo2:UBERON_0000164 + obo2:uberon.owl + + + + obo2:UBERON_0000166 + obo2:uberon.owl + + + + obo2:UBERON_0000166 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0000166 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0000167 + obo2:uberon.owl + + + + obo2:UBERON_0000167 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0000167 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0000168 + obo2:uberon.owl + + + + obo2:UBERON_0000170 + obo2:uberon.owl + + + + obo2:UBERON_0000171 + obo2:uberon.owl + + + + obo2:UBERON_0000171 + obo2:uberon#functional_classification + + + + obo2:UBERON_0000171 + obo2:uberon#organ_slim + + + + obo2:UBERON_0000174 + obo2:uberon.owl + + + + obo2:UBERON_0000179 + obo2:uberon.owl + + + + obo2:UBERON_0000203 + obo2:uberon.owl + + + + obo2:UBERON_0000203 + obo2:uberon#developmental_classification + + + + obo2:UBERON_0000305 + obo2:uberon.owl + + + + obo2:UBERON_0000307 + obo2:uberon.owl + + + + obo2:UBERON_0000307 + obo2:uberon#inconsistent_with_fma + + + + obo2:UBERON_0000325 + obo2:uberon.owl + + + + obo2:UBERON_0000325 + obo2:uberon#grouping_class + + + + obo2:UBERON_0000325 + obo2:uberon#organ_slim + + + + obo2:UBERON_0000344 + obo2:uberon.owl + + + + obo2:UBERON_0000344 + obo2:UBERON_0000009 + + + + obo2:UBERON_0000353 + obo2:uberon.owl + + + + obo2:UBERON_0000358 + obo2:uberon.owl + + + + obo2:UBERON_0000383 + obo2:uberon.owl + + + + obo2:UBERON_0000383 + obo2:NCBITaxon_6040 + + + + obo2:UBERON_0000456 + obo2:uberon.owl + + + + obo2:UBERON_0000463 + obo2:uberon.owl + + + + obo2:UBERON_0000463 + obo2:uberon#upper_level + + + + obo2:UBERON_0000464 + obo2:uberon.owl + + + + obo2:UBERON_0000464 + obo2:uberon#upper_level + + + + obo2:UBERON_0000465 + obo2:uberon.owl + + + + obo2:UBERON_0000465 + obo2:uberon#upper_level + + + + obo2:UBERON_0000466 + obo2:uberon.owl + + + + obo2:UBERON_0000466 + obo2:uberon#disjointness_axiom_removed + + + + obo2:UBERON_0000466 + obo2:uberon#upper_level + + + + obo2:UBERON_0000467 + obo2:uberon.owl + + + + obo2:UBERON_0000467 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0000467 + obo2:uberon#upper_level + + + + obo2:UBERON_0000468 + obo2:uberon.owl + + + + obo2:UBERON_0000468 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0000468 + obo2:uberon#upper_level + + + + obo2:UBERON_0000470 + obo2:uberon.owl + + + + obo2:UBERON_0000470 + obo2:uberon#upper_level + + + + obo2:UBERON_0000474 + obo2:uberon.owl + + + + obo2:UBERON_0000474 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0000475 + obo2:uberon.owl + + + + obo2:UBERON_0000475 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0000475 + obo2:uberon#upper_level + + + + obo2:UBERON_0000476 + obo2:uberon.owl + + + + obo2:UBERON_0000476 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0000477 + obo2:uberon.owl + + + + obo2:UBERON_0000477 + obo2:uberon#disjointness_axiom_removed + + + + obo2:UBERON_0000477 + obo2:uberon#upper_level + + + + obo2:UBERON_0000478 + obo2:uberon.owl + + + + obo2:UBERON_0000478 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0000478 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0000478 + obo2:FBbt_00005835 + + + + obo2:UBERON_0000479 + obo2:uberon.owl + + + + obo2:UBERON_0000479 + obo2:uberon#upper_level + + + + obo2:UBERON_0000480 + obo2:uberon.owl + + + + obo2:UBERON_0000480 + obo2:uberon#upper_level + + + + obo2:UBERON_0000481 + obo2:uberon.owl + + + + obo2:UBERON_0000481 + obo2:uberon#upper_level + + + + obo2:UBERON_0000483 + obo2:uberon.owl + + + + obo2:UBERON_0000483 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0000483 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0000485 + obo2:uberon.owl + + + + obo2:UBERON_0000485 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0000485 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0000486 + obo2:uberon.owl + + + + obo2:UBERON_0000486 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0000486 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0000487 + obo2:uberon.owl + + + + obo2:UBERON_0000487 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0000487 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0000489 + obo2:uberon.owl + + + + obo2:UBERON_0000489 + obo2:uberon#organ_slim + + + + obo2:UBERON_0000489 + obo2:uberon#upper_level + + + + obo2:UBERON_0000490 + obo2:uberon.owl + + + + obo2:UBERON_0000490 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0000913 + obo2:uberon.owl + + + + obo2:UBERON_0000915 + obo2:uberon.owl + + + + obo2:UBERON_0000915 + obo2:UBERON_0000026 + + + + obo2:UBERON_0000915 + obo2:UBERON_0000033 + + + + obo2:UBERON_0000915 + obo2:UBERON_0002417 + + + + obo2:UBERON_0000915 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0000922 + obo2:uberon.owl + + + + obo2:UBERON_0000922 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0000922 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0000923 + obo2:uberon.owl + + + + obo2:UBERON_0000923 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0000923 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0000924 + obo2:uberon.owl + + + + obo2:UBERON_0000924 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0000924 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0000925 + obo2:uberon.owl + + + + obo2:UBERON_0000925 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0000925 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0000926 + obo2:uberon.owl + + + + obo2:UBERON_0000926 + obo2:NCBITaxon_6040 + + + + obo2:UBERON_0000926 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0000926 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0000930 + obo2:uberon.owl + + + + obo2:UBERON_0000930 + obo2:uberon#grouping_class + + + + obo2:UBERON_0000930 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0000930 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0000931 + obo2:uberon.owl + + + + obo2:UBERON_0000931 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0000946 + obo2:uberon.owl + + + + obo2:UBERON_0000946 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0000946 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0000956 + obo2:uberon.owl + + + + obo2:UBERON_0000956 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0000965 + obo2:uberon.owl + + + + obo2:UBERON_0000965 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0000965 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0000982 + obo2:uberon.owl + + + + obo2:UBERON_0000982 + obo2:uberon#organ_slim + + + + obo2:UBERON_0000982 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0000982 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0000988 + obo2:uberon.owl + + + + obo2:UBERON_0000988 + obo2:NCBITaxon_7955 + + + + obo2:UBERON_0000988 + obo2:UBERON_0001896 + + + + obo2:UBERON_0000988 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0000990 + obo2:uberon.owl + + + + obo2:UBERON_0000990 + obo2:uberon#functional_classification + + + + obo2:UBERON_0000990 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0000990 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0000991 + obo2:uberon.owl + + + + obo2:UBERON_0000991 + obo2:uberon#major_organ + + + + obo2:UBERON_0000991 + obo2:uberon#organ_slim + + + + obo2:UBERON_0000991 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0000991 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0000992 + obo2:uberon.owl + + + + obo2:UBERON_0000992 + obo2:uberon#organ_slim + + + + obo2:UBERON_0000992 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0000992 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0000993 + obo2:uberon.owl + + + + obo2:UBERON_0000993 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0000993 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0001003 + obo2:uberon.owl + + + + obo2:UBERON_0001003 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0001003 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0001005 + obo2:uberon.owl + + + + obo2:UBERON_0001005 + obo2:uberon#grouping_class + + + + obo2:UBERON_0001005 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0001008 + obo2:uberon.owl + + + + obo2:UBERON_0001008 + obo2:NCBITaxon_110815 + + + + obo2:UBERON_0001008 + obo2:NCBITaxon_147099 + + + + obo2:UBERON_0001008 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0001008 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0001009 + obo2:uberon.owl + + + + obo2:UBERON_0001009 + obo2:NCBITaxon_147099 + + + + obo2:UBERON_0001009 + obo2:NCBITaxon_6073 + + + + obo2:UBERON_0001009 + obo2:NCBITaxon_6157 + + + + obo2:UBERON_0001009 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0001015 + obo2:uberon.owl + + + + obo2:UBERON_0001015 + obo2:UBERON_0001474 + + + + obo2:UBERON_0001015 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0001015 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0001016 + obo2:uberon.owl + + + + obo2:UBERON_0001016 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0001016 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0001019 + obo2:uberon.owl + + + + obo2:UBERON_0001019 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0001021 + obo2:uberon.owl + + + + obo2:UBERON_0001021 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0001021 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0001032 + obo2:uberon.owl + + + + obo2:UBERON_0001032 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0001032 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0001033 + obo2:uberon.owl + + + + obo2:UBERON_0001033 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0001033 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0001041 + obo2:uberon.owl + + + + obo2:UBERON_0001041 + obo2:uberon#developmental_classification + + + + obo2:UBERON_0001041 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0001042 + obo2:uberon.owl + + + + obo2:UBERON_0001042 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0001042 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0001045 + obo2:uberon.owl + + + + obo2:UBERON_0001045 + obo2:uberon#developmental_classification + + + + obo2:UBERON_0001045 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0001046 + obo2:uberon.owl + + + + obo2:UBERON_0001046 + obo2:uberon#developmental_classification + + + + obo2:UBERON_0001046 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0001048 + obo2:uberon.owl + + + + obo2:UBERON_0001048 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0001049 + obo2:uberon.owl + + + + obo2:UBERON_0001049 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0001049 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0001052 + obo2:uberon.owl + + + + obo2:UBERON_0001052 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0001062 + obo2:uberon.owl + + + + obo2:UBERON_0001062 + obo2:uberon#upper_level + + + + obo2:UBERON_0001072 + obo2:uberon.owl + + + + obo2:UBERON_0001072 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0001084 + obo2:uberon.owl + + + + obo2:UBERON_0001103 + obo2:uberon.owl + + + + obo2:UBERON_0001103 + obo2:NCBITaxon_8782 + + + + obo2:UBERON_0001103 + obo2:uberon#organ_slim + + + + obo2:UBERON_0001103 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0001133 + obo2:uberon.owl + + + + obo2:UBERON_0001133 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0001133 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0001134 + obo2:uberon.owl + + + + obo2:UBERON_0001134 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0001134 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0001135 + obo2:uberon.owl + + + + obo2:UBERON_0001135 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0001135 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0001137 + obo2:uberon.owl + + + + obo2:UBERON_0001137 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0001156 + obo2:uberon.owl + + + + obo2:UBERON_0001156 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0001157 + obo2:uberon.owl + + + + obo2:UBERON_0001157 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0001158 + obo2:uberon.owl + + + + obo2:UBERON_0001158 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0001159 + obo2:uberon.owl + + + + obo2:UBERON_0001159 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0001161 + obo2:uberon.owl + + + + obo2:UBERON_0001161 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0001165 + obo2:uberon.owl + + + + obo2:UBERON_0001165 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0001166 + obo2:uberon.owl + + + + obo2:UBERON_0001166 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0001167 + obo2:uberon.owl + + + + obo2:UBERON_0001173 + obo2:uberon.owl + + + + obo2:UBERON_0001173 + obo2:uberon#organ_slim + + + + obo2:UBERON_0001173 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0001184 + obo2:uberon.owl + + + + obo2:UBERON_0001184 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0001184 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0001199 + obo2:uberon.owl + + + + obo2:UBERON_0001199 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0001202 + obo2:uberon.owl + + + + obo2:UBERON_0001202 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0001225 + obo2:uberon.owl + + + + obo2:UBERON_0001225 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0001229 + obo2:uberon.owl + + + + obo2:UBERON_0001229 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0001229 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0001230 + obo2:uberon.owl + + + + obo2:UBERON_0001230 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0001230 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0001231 + obo2:uberon.owl + + + + obo2:UBERON_0001231 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0001231 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0001255 + obo2:uberon.owl + + + + obo2:UBERON_0001255 + obo2:uberon#major_organ + + + + obo2:UBERON_0001255 + obo2:uberon#organ_slim + + + + obo2:UBERON_0001255 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0001271 + obo2:uberon.owl + + + + obo2:UBERON_0001271 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0001271 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0001276 + obo2:uberon.owl + + + + obo2:UBERON_0001285 + obo2:uberon.owl + + + + obo2:UBERON_0001285 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0001285 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0001353 + obo2:uberon.owl + + + + obo2:UBERON_0001353 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0001359 + obo2:uberon.owl + + + + obo2:UBERON_0001359 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0001359 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0001419 + obo2:uberon.owl + + + + obo2:UBERON_0001421 + obo2:uberon.owl + + + + obo2:UBERON_0001421 + obo2:UBERON_0001271 + + + + obo2:UBERON_0001421 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0001421 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0001434 + obo2:uberon.owl + + + + obo2:UBERON_0001434 + obo2:UBERON_0001016 + + + + obo2:UBERON_0001434 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0001434 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0001443 + obo2:uberon.owl + + + + obo2:UBERON_0001443 + obo2:UBERON_0000916 + + + + obo2:UBERON_0001443 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0001444 + obo2:uberon.owl + + + + obo2:UBERON_0001444 + obo2:uberon#non_informative + + + + obo2:UBERON_0001458 + obo2:uberon.owl + + + + obo2:UBERON_0001464 + obo2:uberon.owl + + + + obo2:UBERON_0001464 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0001511 + obo2:uberon.owl + + + + obo2:UBERON_0001514 + obo2:uberon.owl + + + + obo2:UBERON_0001514 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0001516 + obo2:uberon.owl + + + + obo2:UBERON_0001516 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0001555 + obo2:uberon.owl + + + + obo2:UBERON_0001555 + obo2:NCBITaxon_147099 + + + + obo2:UBERON_0001555 + obo2:NCBITaxon_41324 + + + + obo2:UBERON_0001555 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0001555 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0001556 + obo2:uberon.owl + + + + obo2:UBERON_0001556 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0001567 + obo2:uberon.owl + + + + obo2:UBERON_0001567 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0001630 + obo2:uberon.owl + + + + obo2:UBERON_0001630 + obo2:uberon#organ_slim + + + + obo2:UBERON_0001630 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0001630 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0001678 + obo2:uberon.owl + + + + obo2:UBERON_0001678 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0001694 + obo2:uberon.owl + + + + obo2:UBERON_0001694 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0001703 + obo2:uberon.owl + + + + obo2:UBERON_0001703 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0001703 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0001708 + obo2:uberon.owl + + + + obo2:UBERON_0001708 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0001708 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0001710 + obo2:uberon.owl + + + + obo2:UBERON_0001710 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0001710 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0001711 + obo2:uberon.owl + + + + obo2:UBERON_0001711 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0001735 + obo2:uberon.owl + + + + obo2:UBERON_0001735 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0001744 + obo2:uberon.owl + + + + obo2:UBERON_0001744 + obo2:NCBITaxon_7776 + + + + obo2:UBERON_0001744 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0001774 + obo2:uberon.owl + + + + obo2:UBERON_0001774 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0001774 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0001781 + obo2:uberon.owl + + + + obo2:UBERON_0001781 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0001801 + obo2:uberon.owl + + + + obo2:UBERON_0001801 + obo2:UBERON_0001802 + + + + obo2:UBERON_0001801 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0001802 + obo2:uberon.owl + + + + obo2:UBERON_0001802 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0001810 + obo2:uberon.owl + + + + obo2:UBERON_0001810 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0001813 + obo2:uberon.owl + + + + obo2:UBERON_0001815 + obo2:uberon.owl + + + + obo2:UBERON_0001815 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0001829 + obo2:uberon.owl + + + + obo2:UBERON_0001829 + obo2:uberon#organ_slim + + + + obo2:UBERON_0001831 + obo2:uberon.owl + + + + obo2:UBERON_0001831 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0001836 + obo2:uberon.owl + + + + obo2:UBERON_0001836 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0001840 + obo2:uberon.owl + + + + obo2:UBERON_0001840 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0001840 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0001846 + obo2:uberon.owl + + + + obo2:UBERON_0001846 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0001846 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0001849 + obo2:uberon.owl + + + + obo2:UBERON_0001849 + obo2:uberon#organ_slim + + + + obo2:UBERON_0001849 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0001851 + obo2:uberon.owl + + + + obo2:UBERON_0001851 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0001851 + obo2:uberon#upper_level + + + + obo2:UBERON_0001869 + obo2:uberon.owl + + + + obo2:UBERON_0001869 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0001884 + obo2:uberon.owl + + + + obo2:UBERON_0001884 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0001886 + obo2:uberon.owl + + + + obo2:UBERON_0001886 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0001886 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0001890 + obo2:uberon.owl + + + + obo2:UBERON_0001890 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0001890 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0001891 + obo2:uberon.owl + + + + obo2:UBERON_0001891 + obo2:UBERON_0001894 + + + + obo2:UBERON_0001891 + obo2:UBERON_0002028 + + + + obo2:UBERON_0001891 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0001891 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0001893 + obo2:uberon.owl + + + + obo2:UBERON_0001893 + obo2:UBERON_0002037 + + + + obo2:UBERON_0001893 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0001893 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0001894 + obo2:uberon.owl + + + + obo2:UBERON_0001894 + obo2:UBERON_0001891 + + + + obo2:UBERON_0001894 + obo2:UBERON_0002028 + + + + obo2:UBERON_0001894 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0001894 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0001895 + obo2:uberon.owl + + + + obo2:UBERON_0001895 + obo2:NCBITaxon_7955 + + + + obo2:UBERON_0001895 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0001896 + obo2:uberon.owl + + + + obo2:UBERON_0001896 + obo2:UBERON_0000988 + + + + obo2:UBERON_0001896 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0001896 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0001917 + obo2:uberon.owl + + + + obo2:UBERON_0001943 + obo2:uberon.owl + + + + obo2:UBERON_0001943 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0001943 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0001950 + obo2:uberon.owl + + + + obo2:UBERON_0001950 + obo2:UBERON_0002264 + + + + obo2:UBERON_0001950 + obo2:UBERON_0002421 + + + + obo2:UBERON_0001950 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0001961 + obo2:uberon.owl + + + + obo2:UBERON_0001961 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0001962 + obo2:uberon.owl + + + + obo2:UBERON_0001962 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0001979 + obo2:uberon.owl + + + + obo2:UBERON_0001979 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0001979 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0001980 + obo2:uberon.owl + + + + obo2:UBERON_0001980 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0001980 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0001981 + obo2:uberon.owl + + + + obo2:UBERON_0001981 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0001981 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0001986 + obo2:uberon.owl + + + + obo2:UBERON_0001986 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0001995 + obo2:uberon.owl + + + + obo2:UBERON_0001995 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0002003 + obo2:uberon.owl + + + + obo2:UBERON_0002003 + obo2:uberon#major_organ + + + + obo2:UBERON_0002003 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0002020 + obo2:uberon.owl + + + + obo2:UBERON_0002020 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0002020 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0002028 + obo2:uberon.owl + + + + obo2:UBERON_0002028 + obo2:UBERON_0001891 + + + + obo2:UBERON_0002028 + obo2:UBERON_0001894 + + + + obo2:UBERON_0002028 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0002028 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0002036 + obo2:uberon.owl + + + + obo2:UBERON_0002036 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0002049 + obo2:uberon.owl + + + + obo2:UBERON_0002049 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0002049 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0002050 + obo2:uberon.owl + + + + obo2:UBERON_0002050 + obo2:uberon#inconsistent_with_fma + + + + obo2:UBERON_0002050 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0002062 + obo2:uberon.owl + + + + obo2:UBERON_0002062 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0002062 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0002067 + obo2:uberon.owl + + + + obo2:UBERON_0002067 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0002067 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0002072 + obo2:uberon.owl + + + + obo2:UBERON_0002072 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0002072 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0002075 + obo2:uberon.owl + + + + obo2:UBERON_0002075 + obo2:uberon#organ_slim + + + + obo2:UBERON_0002075 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0002075 + obo2:uberon#upper_level + + + + obo2:UBERON_0002081 + obo2:uberon.owl + + + + obo2:UBERON_0002081 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0002081 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0002082 + obo2:uberon.owl + + + + obo2:UBERON_0002082 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0002082 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0002091 + obo2:uberon.owl + + + + obo2:UBERON_0002091 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0002091 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0002100 + obo2:uberon.owl + + + + obo2:UBERON_0002100 + obo2:UBERON_0000026 + + + + obo2:UBERON_0002100 + obo2:UBERON_0000033 + + + + obo2:UBERON_0002100 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0002100 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0002103 + obo2:uberon.owl + + + + obo2:UBERON_0002103 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0002104 + obo2:uberon.owl + + + + obo2:UBERON_0002104 + obo2:UBERON_0002105 + + + + obo2:UBERON_0002104 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0002104 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0002105 + obo2:uberon.owl + + + + obo2:UBERON_0002105 + obo2:uberon#functional_classification + + + + obo2:UBERON_0002105 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0002105 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0002120 + obo2:uberon.owl + + + + obo2:UBERON_0002120 + obo2:uberon#organ_slim + + + + obo2:UBERON_0002120 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0002133 + obo2:uberon.owl + + + + obo2:UBERON_0002133 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0002165 + obo2:uberon.owl + + + + obo2:UBERON_0002165 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0002165 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0002167 + obo2:uberon.owl + + + + obo2:UBERON_0002167 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0002168 + obo2:uberon.owl + + + + obo2:UBERON_0002168 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0002186 + obo2:uberon.owl + + + + obo2:UBERON_0002186 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0002193 + obo2:uberon.owl + + + + obo2:UBERON_0002199 + obo2:uberon.owl + + + + obo2:UBERON_0002199 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0002199 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0002201 + obo2:uberon.owl + + + + obo2:UBERON_0002201 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0002204 + obo2:uberon.owl + + + + obo2:UBERON_0002204 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0002217 + obo2:uberon.owl + + + + obo2:UBERON_0002217 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0002217 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0002224 + obo2:uberon.owl + + + + obo2:UBERON_0002224 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0002241 + obo2:uberon.owl + + + + obo2:UBERON_0002241 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0002264 + obo2:uberon.owl + + + + obo2:UBERON_0002264 + obo2:UBERON_0001950 + + + + obo2:UBERON_0002264 + obo2:UBERON_0002421 + + + + obo2:UBERON_0002264 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0002264 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0002285 + obo2:uberon.owl + + + + obo2:UBERON_0002285 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0002285 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0002294 + obo2:uberon.owl + + + + obo2:UBERON_0002294 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0002298 + obo2:uberon.owl + + + + obo2:UBERON_0002298 + obo2:UBERON_0001890 + + + + obo2:UBERON_0002298 + obo2:UBERON_0002037 + + + + obo2:UBERON_0002298 + obo2:UBERON_0002314 + + + + obo2:UBERON_0002298 + obo2:uberon#loose_concept + + + + obo2:UBERON_0002298 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0002298 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0002307 + obo2:uberon.owl + + + + obo2:UBERON_0002307 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0002314 + obo2:uberon.owl + + + + obo2:UBERON_0002314 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0002316 + obo2:uberon.owl + + + + obo2:UBERON_0002316 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0002316 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0002323 + obo2:uberon.owl + + + + obo2:UBERON_0002323 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0002323 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0002328 + obo2:uberon.owl + + + + obo2:UBERON_0002328 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0002328 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0002329 + obo2:uberon.owl + + + + obo2:UBERON_0002329 + obo2:NCBITaxon_7712 + + + + obo2:UBERON_0002329 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0002329 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0002342 + obo2:uberon.owl + + + + obo2:UBERON_0002342 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0002342 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0002346 + obo2:uberon.owl + + + + obo2:UBERON_0002346 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0002346 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0002349 + obo2:uberon.owl + + + + obo2:UBERON_0002349 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0002349 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0002350 + obo2:uberon.owl + + + + obo2:UBERON_0002350 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0002365 + obo2:uberon.owl + + + + obo2:UBERON_0002365 + obo2:uberon#organ_slim + + + + obo2:UBERON_0002365 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0002368 + obo2:uberon.owl + + + + obo2:UBERON_0002368 + obo2:uberon#organ_slim + + + + obo2:UBERON_0002368 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0002384 + obo2:uberon.owl + + + + obo2:UBERON_0002384 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0002384 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0002387 + obo2:uberon.owl + + + + obo2:UBERON_0002387 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0002391 + obo2:uberon.owl + + + + obo2:UBERON_0002391 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0002415 + obo2:uberon.owl + + + + obo2:UBERON_0002415 + obo2:uberon#grouping_class + + + + obo2:UBERON_0002415 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0002416 + obo2:uberon.owl + + + + obo2:UBERON_0002416 + obo2:uberon#grouping_class + + + + obo2:UBERON_0002417 + obo2:uberon.owl + + + + obo2:UBERON_0002418 + obo2:uberon.owl + + + + obo2:UBERON_0002418 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0002418 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0002419 + obo2:uberon.owl + + + + obo2:UBERON_0002419 + obo2:uberon#organ_slim + + + + obo2:UBERON_0002421 + obo2:uberon.owl + + + + obo2:UBERON_0002421 + obo2:UBERON_0001950 + + + + obo2:UBERON_0002421 + obo2:UBERON_0002264 + + + + obo2:UBERON_0002421 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0002423 + obo2:uberon.owl + + + + obo2:UBERON_0002423 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0002423 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0002426 + obo2:uberon.owl + + + + obo2:UBERON_0002428 + obo2:uberon.owl + + + + obo2:UBERON_0002451 + obo2:uberon.owl + + + + obo2:UBERON_0002451 + obo2:uberon#organ_slim + + + + obo2:UBERON_0002451 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0002465 + obo2:uberon.owl + + + + obo2:UBERON_0002465 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0002465 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0002470 + obo2:uberon.owl + + + + obo2:UBERON_0002470 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0002471 + obo2:uberon.owl + + + + obo2:UBERON_0002471 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0002472 + obo2:uberon.owl + + + + obo2:UBERON_0002472 + obo2:UBERON_0002470 + + + + obo2:UBERON_0002472 + obo2:UBERON_0002471 + + + + obo2:UBERON_0002472 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0002495 + obo2:uberon.owl + + + + obo2:UBERON_0002495 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0002513 + obo2:uberon.owl + + + + obo2:UBERON_0002513 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0002513 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0002517 + obo2:uberon.owl + + + + obo2:UBERON_0002517 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0002522 + obo2:uberon.owl + + + + obo2:UBERON_0002522 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0002523 + obo2:uberon.owl + + + + obo2:UBERON_0002523 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0002529 + obo2:uberon.owl + + + + obo2:UBERON_0002530 + obo2:uberon.owl + + + + obo2:UBERON_0002530 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0002531 + obo2:uberon.owl + + + + obo2:UBERON_0002532 + obo2:uberon.owl + + + + obo2:UBERON_0002532 + obo2:uberon#early_development + + + + obo2:UBERON_0002532 + obo2:uberon#grouping_class + + + + obo2:UBERON_0002532 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0002532 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0002534 + obo2:uberon.owl + + + + obo2:UBERON_0002534 + obo2:NCBITaxon_32523 + + + + obo2:UBERON_0002534 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0002539 + obo2:uberon.owl + + + + obo2:UBERON_0002539 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0002539 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0002544 + obo2:uberon.owl + + + + obo2:UBERON_0002544 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0002546 + obo2:uberon.owl + + + + obo2:UBERON_0002553 + obo2:uberon.owl + + + + obo2:UBERON_0002553 + obo2:uberon#upper_level + + + + obo2:UBERON_0002558 + obo2:uberon.owl + + + + obo2:UBERON_0002558 + obo2:uberon#upper_level + + + + obo2:UBERON_0002616 + obo2:uberon.owl + + + + obo2:UBERON_0002616 + obo2:uberon#non_informative + + + + obo2:UBERON_0002619 + obo2:uberon.owl + + + + obo2:UBERON_0002619 + obo2:uberon#non_informative + + + + obo2:UBERON_0002680 + obo2:uberon.owl + + + + obo2:UBERON_0002680 + obo2:uberon#non_informative + + + + obo2:UBERON_0002780 + obo2:uberon.owl + + + + obo2:UBERON_0002780 + obo2:uberon#non_informative + + + + obo2:UBERON_0002791 + obo2:uberon.owl + + + + obo2:UBERON_0002791 + obo2:uberon#non_informative + + + + obo2:UBERON_0002950 + obo2:uberon.owl + + + + obo2:UBERON_0002950 + obo2:uberon#non_informative + + + + obo2:UBERON_0003051 + obo2:uberon.owl + + + + obo2:UBERON_0003051 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0003055 + obo2:uberon.owl + + + + obo2:UBERON_0003055 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0003056 + obo2:uberon.owl + + + + obo2:UBERON_0003057 + obo2:uberon.owl + + + + obo2:UBERON_0003059 + obo2:uberon.owl + + + + obo2:UBERON_0003060 + obo2:uberon.owl + + + + obo2:UBERON_0003060 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0003061 + obo2:uberon.owl + + + + obo2:UBERON_0003061 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0003061 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0003064 + obo2:uberon.owl + + + + obo2:UBERON_0003064 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0003064 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0003066 + obo2:uberon.owl + + + + obo2:UBERON_0003066 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0003066 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0003067 + obo2:uberon.owl + + + + obo2:UBERON_0003068 + obo2:uberon.owl + + + + obo2:UBERON_0003068 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0003069 + obo2:uberon.owl + + + + obo2:UBERON_0003069 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0003069 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0003071 + obo2:uberon.owl + + + + obo2:UBERON_0003072 + obo2:uberon.owl + + + + obo2:UBERON_0003072 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0003073 + obo2:uberon.owl + + + + obo2:UBERON_0003073 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0003073 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0003074 + obo2:uberon.owl + + + + obo2:UBERON_0003074 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0003074 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0003075 + obo2:uberon.owl + + + + obo2:UBERON_0003075 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0003075 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0003076 + obo2:uberon.owl + + + + obo2:UBERON_0003077 + obo2:uberon.owl + + + + obo2:UBERON_0003077 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0003077 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0003078 + obo2:uberon.owl + + + + obo2:UBERON_0003080 + obo2:uberon.owl + + + + obo2:UBERON_0003081 + obo2:uberon.owl + + + + obo2:UBERON_0003081 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0003082 + obo2:uberon.owl + + + + obo2:UBERON_0003082 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0003082 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0003084 + obo2:uberon.owl + + + + obo2:UBERON_0003084 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0003089 + obo2:uberon.owl + + + + obo2:UBERON_0003089 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0003089 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0003091 + obo2:uberon.owl + + + + obo2:UBERON_0003091 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0003099 + obo2:uberon.owl + + + + obo2:UBERON_0003099 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0003099 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0003100 + obo2:uberon.owl + + + + obo2:UBERON_0003100 + obo2:UBERON_0003101 + + + + obo2:UBERON_0003100 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0003101 + obo2:uberon.owl + + + + obo2:UBERON_0003101 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0003102 + obo2:uberon.owl + + + + obo2:UBERON_0003102 + obo2:uberon#upper_level + + + + obo2:UBERON_0003103 + obo2:uberon.owl + + + + obo2:UBERON_0003103 + obo2:uberon#organ_slim + + + + obo2:UBERON_0003103 + obo2:uberon#upper_level + + + + obo2:UBERON_0003104 + obo2:uberon.owl + + + + obo2:UBERON_0003104 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0003104 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0003110 + obo2:uberon.owl + + + + obo2:UBERON_0003113 + obo2:uberon.owl + + + + obo2:UBERON_0003113 + obo2:NCBITaxon_7777 + + + + obo2:UBERON_0003114 + obo2:uberon.owl + + + + obo2:UBERON_0003114 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0003129 + obo2:uberon.owl + + + + obo2:UBERON_0003129 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0003133 + obo2:uberon.owl + + + + obo2:UBERON_0003133 + obo2:uberon#functional_classification + + + + obo2:UBERON_0003133 + obo2:uberon#organ_slim + + + + obo2:UBERON_0003134 + obo2:uberon.owl + + + + obo2:UBERON_0003134 + obo2:uberon#organ_slim + + + + obo2:UBERON_0003220 + obo2:uberon.owl + + + + obo2:UBERON_0003221 + obo2:uberon.owl + + + + obo2:UBERON_0003254 + obo2:uberon.owl + + + + obo2:UBERON_0003258 + obo2:uberon.owl + + + + obo2:UBERON_0003262 + obo2:uberon.owl + + + + obo2:UBERON_0003278 + obo2:uberon.owl + + + + obo2:UBERON_0003294 + obo2:uberon.owl + + + + obo2:UBERON_0003297 + obo2:uberon.owl + + + + obo2:UBERON_0003350 + obo2:uberon.owl + + + + obo2:UBERON_0003353 + obo2:uberon.owl + + + + obo2:UBERON_0003408 + obo2:uberon.owl + + + + obo2:UBERON_0003412 + obo2:uberon.owl + + + + obo2:UBERON_0003443 + obo2:uberon.owl + + + + obo2:UBERON_0003457 + obo2:uberon.owl + + + + obo2:UBERON_0003462 + obo2:uberon.owl + + + + obo2:UBERON_0003479 + obo2:uberon.owl + + + + obo2:UBERON_0003498 + obo2:uberon.owl + + + + obo2:UBERON_0003502 + obo2:uberon.owl + + + + obo2:UBERON_0003509 + obo2:uberon.owl + + + + obo2:UBERON_0003513 + obo2:uberon.owl + + + + obo2:UBERON_0003519 + obo2:uberon.owl + + + + obo2:UBERON_0003528 + obo2:uberon.owl + + + + obo2:UBERON_0003532 + obo2:uberon.owl + + + + obo2:UBERON_0003544 + obo2:uberon.owl + + + + obo2:UBERON_0003606 + obo2:uberon.owl + + + + obo2:UBERON_0003657 + obo2:uberon.owl + + + + obo2:UBERON_0003657 + obo2:uberon#grouping_class + + + + obo2:UBERON_0003714 + obo2:uberon.owl + + + + obo2:UBERON_0003820 + obo2:uberon.owl + + + + obo2:UBERON_0003830 + obo2:uberon.owl + + + + obo2:UBERON_0003831 + obo2:uberon.owl + + + + obo2:UBERON_0003841 + obo2:uberon.owl + + + + obo2:UBERON_0003842 + obo2:uberon.owl + + + + obo2:UBERON_0003849 + obo2:uberon.owl + + + + obo2:UBERON_0003849 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0003850 + obo2:uberon.owl + + + + obo2:UBERON_0003850 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0003851 + obo2:uberon.owl + + + + obo2:UBERON_0003852 + obo2:uberon.owl + + + + obo2:UBERON_0003852 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0003853 + obo2:uberon.owl + + + + obo2:UBERON_0003886 + obo2:uberon.owl + + + + obo2:UBERON_0003886 + obo2:uberon#grouping_class + + + + obo2:UBERON_0003886 + obo2:uberon#non_informative + + + + obo2:UBERON_0003887 + obo2:uberon.owl + + + + obo2:UBERON_0003894 + obo2:uberon.owl + + + + obo2:UBERON_0003894 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0003902 + obo2:uberon.owl + + + + obo2:UBERON_0003902 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0003914 + obo2:uberon.owl + + + + obo2:UBERON_0003915 + obo2:uberon.owl + + + + obo2:UBERON_0003918 + obo2:uberon.owl + + + + obo2:UBERON_0003920 + obo2:uberon.owl + + + + obo2:UBERON_0003921 + obo2:uberon.owl + + + + obo2:UBERON_0003921 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0003922 + obo2:uberon.owl + + + + obo2:UBERON_0003923 + obo2:uberon.owl + + + + obo2:UBERON_0003923 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0003924 + obo2:uberon.owl + + + + obo2:UBERON_0003924 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0003929 + obo2:uberon.owl + + + + obo2:UBERON_0003937 + obo2:uberon.owl + + + + obo2:UBERON_0003937 + obo2:uberon#organ_slim + + + + obo2:UBERON_0003975 + obo2:uberon.owl + + + + obo2:UBERON_0003975 + obo2:uberon#organ_slim + + + + obo2:UBERON_0003978 + obo2:uberon.owl + + + + obo2:UBERON_0003978 + obo2:uberon#grouping_class + + + + obo2:UBERON_0004016 + obo2:uberon.owl + + + + obo2:UBERON_0004035 + obo2:uberon.owl + + + + obo2:UBERON_0004060 + obo2:uberon.owl + + + + obo2:UBERON_0004061 + obo2:uberon.owl + + + + obo2:UBERON_0004062 + obo2:uberon.owl + + + + obo2:UBERON_0004086 + obo2:uberon.owl + + + + obo2:UBERON_0004088 + obo2:uberon.owl + + + + obo2:UBERON_0004089 + obo2:uberon.owl + + + + obo2:UBERON_0004111 + obo2:uberon.owl + + + + obo2:UBERON_0004117 + obo2:uberon.owl + + + + obo2:UBERON_0004117 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0004119 + obo2:uberon.owl + + + + obo2:UBERON_0004119 + obo2:uberon#grouping_class + + + + obo2:UBERON_0004120 + obo2:uberon.owl + + + + obo2:UBERON_0004120 + obo2:uberon#grouping_class + + + + obo2:UBERON_0004121 + obo2:uberon.owl + + + + obo2:UBERON_0004121 + obo2:uberon#grouping_class + + + + obo2:UBERON_0004128 + obo2:uberon.owl + + + + obo2:UBERON_0004128 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0004139 + obo2:uberon.owl + + + + obo2:UBERON_0004140 + obo2:uberon.owl + + + + obo2:UBERON_0004141 + obo2:uberon.owl + + + + obo2:UBERON_0004141 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0004145 + obo2:uberon.owl + + + + obo2:UBERON_0004151 + obo2:uberon.owl + + + + obo2:UBERON_0004161 + obo2:uberon.owl + + + + obo2:UBERON_0004175 + obo2:uberon.owl + + + + obo2:UBERON_0004175 + obo2:uberon#organ_slim + + + + obo2:UBERON_0004176 + obo2:uberon.owl + + + + obo2:UBERON_0004176 + obo2:uberon#organ_slim + + + + obo2:UBERON_0004185 + obo2:uberon.owl + + + + obo2:UBERON_0004198 + obo2:uberon.owl + + + + obo2:UBERON_0004199 + obo2:uberon.owl + + + + obo2:UBERON_0004208 + obo2:uberon.owl + + + + obo2:UBERON_0004209 + obo2:uberon.owl + + + + obo2:UBERON_0004211 + obo2:uberon.owl + + + + obo2:UBERON_0004237 + obo2:uberon.owl + + + + obo2:UBERON_0004288 + obo2:uberon.owl + + + + obo2:UBERON_0004288 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0004290 + obo2:uberon.owl + + + + obo2:UBERON_0004291 + obo2:uberon.owl + + + + obo2:UBERON_0004292 + obo2:uberon.owl + + + + obo2:UBERON_0004341 + obo2:uberon.owl + + + + obo2:UBERON_0004341 + obo2:NCBITaxon_32443 + + + + obo2:UBERON_0004341 + obo2:uberon#early_development + + + + obo2:UBERON_0004345 + obo2:uberon.owl + + + + obo2:UBERON_0004345 + obo2:uberon#early_development + + + + obo2:UBERON_0004347 + obo2:uberon.owl + + + + obo2:UBERON_0004356 + obo2:uberon.owl + + + + obo2:UBERON_0004357 + obo2:uberon.owl + + + + obo2:UBERON_0004362 + obo2:uberon.owl + + + + obo2:UBERON_0004362 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0004362 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0004375 + obo2:uberon.owl + + + + obo2:UBERON_0004381 + obo2:uberon.owl + + + + obo2:UBERON_0004456 + obo2:uberon.owl + + + + obo2:UBERON_0004456 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0004457 + obo2:uberon.owl + + + + obo2:UBERON_0004458 + obo2:uberon.owl + + + + obo2:UBERON_0004493 + obo2:uberon.owl + + + + obo2:UBERON_0004529 + obo2:uberon.owl + + + + obo2:UBERON_0004529 + obo2:uberon#upper_level + + + + obo2:UBERON_0004535 + obo2:uberon.owl + + + + obo2:UBERON_0004535 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0004535 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0004536 + obo2:uberon.owl + + + + obo2:UBERON_0004536 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0004537 + obo2:uberon.owl + + + + obo2:UBERON_0004571 + obo2:uberon.owl + + + + obo2:UBERON_0004572 + obo2:uberon.owl + + + + obo2:UBERON_0004573 + obo2:uberon.owl + + + + obo2:UBERON_0004581 + obo2:uberon.owl + + + + obo2:UBERON_0004582 + obo2:uberon.owl + + + + obo2:UBERON_0004590 + obo2:uberon.owl + + + + obo2:UBERON_0004637 + obo2:uberon.owl + + + + obo2:UBERON_0004638 + obo2:uberon.owl + + + + obo2:UBERON_0004638 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0004700 + obo2:uberon.owl + + + + obo2:UBERON_0004708 + obo2:uberon.owl + + + + obo2:UBERON_0004709 + obo2:uberon.owl + + + + obo2:UBERON_0004716 + obo2:uberon.owl + + + + obo2:UBERON_0004732 + obo2:uberon.owl + + + + obo2:UBERON_0004733 + obo2:uberon.owl + + + + obo2:UBERON_0004755 + obo2:uberon.owl + + + + obo2:UBERON_0004761 + obo2:uberon.owl + + + + obo2:UBERON_0004765 + obo2:uberon.owl + + + + obo2:UBERON_0004765 + obo2:uberon#organ_slim + + + + obo2:UBERON_0004765 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0004770 + obo2:uberon.owl + + + + obo2:UBERON_0004786 + obo2:uberon.owl + + + + obo2:UBERON_0004797 + obo2:uberon.owl + + + + obo2:UBERON_0004808 + obo2:uberon.owl + + + + obo2:UBERON_0004819 + obo2:uberon.owl + + + + obo2:UBERON_0004852 + obo2:uberon.owl + + + + obo2:UBERON_0004852 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0004871 + obo2:uberon.owl + + + + obo2:UBERON_0004872 + obo2:uberon.owl + + + + obo2:UBERON_0004874 + obo2:uberon.owl + + + + obo2:UBERON_0004875 + obo2:uberon.owl + + + + obo2:UBERON_0004876 + obo2:uberon.owl + + + + obo2:UBERON_0004880 + obo2:uberon.owl + + + + obo2:UBERON_0004902 + obo2:uberon.owl + + + + obo2:UBERON_0004905 + obo2:uberon.owl + + + + obo2:UBERON_0004905 + obo2:uberon#grouping_class + + + + obo2:UBERON_0004906 + obo2:uberon.owl + + + + obo2:UBERON_0004907 + obo2:uberon.owl + + + + obo2:UBERON_0004907 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0004912 + obo2:uberon.owl + + + + obo2:UBERON_0004921 + obo2:uberon.owl + + + + obo2:UBERON_0004921 + obo2:uberon#non_informative + + + + obo2:UBERON_0004923 + obo2:uberon.owl + + + + obo2:UBERON_0004923 + obo2:uberon#upper_level + + + + obo2:UBERON_0004998 + obo2:uberon.owl + + + + obo2:UBERON_0005062 + obo2:uberon.owl + + + + obo2:UBERON_0005068 + obo2:uberon.owl + + + + obo2:UBERON_0005080 + obo2:uberon.owl + + + + obo2:UBERON_0005082 + obo2:uberon.owl + + + + obo2:UBERON_0005085 + obo2:uberon.owl + + + + obo2:UBERON_0005090 + obo2:uberon.owl + + + + obo2:UBERON_0005095 + obo2:uberon.owl + + + + obo2:UBERON_0005103 + obo2:uberon.owl + + + + obo2:UBERON_0005153 + obo2:uberon.owl + + + + obo2:UBERON_0005156 + obo2:uberon.owl + + + + obo2:UBERON_0005157 + obo2:uberon.owl + + + + obo2:UBERON_0005162 + obo2:uberon.owl + + + + obo2:UBERON_0005162 + obo2:uberon#upper_level + + + + obo2:UBERON_0005173 + obo2:uberon.owl + + + + obo2:UBERON_0005173 + obo2:uberon#non_informative + + + + obo2:UBERON_0005174 + obo2:uberon.owl + + + + obo2:UBERON_0005174 + obo2:uberon#non_informative + + + + obo2:UBERON_0005174 + obo2:uberon#organ_slim + + + + obo2:UBERON_0005175 + obo2:uberon.owl + + + + obo2:UBERON_0005175 + obo2:uberon#non_informative + + + + obo2:UBERON_0005175 + obo2:uberon#organ_slim + + + + obo2:UBERON_0005177 + obo2:uberon.owl + + + + obo2:UBERON_0005177 + obo2:uberon#non_informative + + + + obo2:UBERON_0005177 + obo2:uberon#organ_slim + + + + obo2:UBERON_0005178 + obo2:uberon.owl + + + + obo2:UBERON_0005178 + obo2:uberon#non_informative + + + + obo2:UBERON_0005181 + obo2:uberon.owl + + + + obo2:UBERON_0005181 + obo2:uberon#non_informative + + + + obo2:UBERON_0005253 + obo2:uberon.owl + + + + obo2:UBERON_0005253 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0005256 + obo2:uberon.owl + + + + obo2:UBERON_0005256 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0005281 + obo2:uberon.owl + + + + obo2:UBERON_0005281 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0005282 + obo2:uberon.owl + + + + obo2:UBERON_0005283 + obo2:uberon.owl + + + + obo2:UBERON_0005283 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0005284 + obo2:uberon.owl + + + + obo2:UBERON_0005284 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0005290 + obo2:uberon.owl + + + + obo2:UBERON_0005290 + obo2:NCBITaxon_7955 + + + + obo2:UBERON_0005290 + obo2:uberon#uberon_slim + + + + obo2:UBERON_0005291 + obo2:uberon.owl + + + + obo2:UBERON_0005291 + obo2:uberon#upper_level + + + + obo2:UBERON_0005292 + obo2:uberon.owl + + + + obo2:UBERON_0005343 + obo2:uberon.owl + + + + obo2:UBERON_0005358 + obo2:uberon.owl + + + + obo2:UBERON_0005366 + obo2:uberon.owl + + + + obo2:UBERON_0005388 + obo2:uberon.owl + + + + obo2:UBERON_0005389 + obo2:uberon.owl + + + + obo2:UBERON_0005398 + obo2:uberon.owl + + + + obo2:UBERON_0005398 + obo2:uberon#organ_slim + + + + obo2:UBERON_0005399 + obo2:uberon.owl + + + + obo2:UBERON_0005399 + obo2:uberon#organ_slim + + + + obo2:UBERON_0005418 + obo2:uberon.owl + + + + obo2:UBERON_0005420 + obo2:uberon.owl + + + + obo2:UBERON_0005420 + obo2:NCBITaxon_31033 + + + + obo2:UBERON_0005423 + obo2:uberon.owl + + + + obo2:UBERON_0005425 + obo2:uberon.owl + + + + obo2:UBERON_0005425 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0005426 + obo2:uberon.owl + + + + obo2:UBERON_0005426 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0005478 + obo2:uberon.owl + + + + obo2:UBERON_0005487 + obo2:uberon.owl + + + + obo2:UBERON_0005487 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0005495 + obo2:uberon.owl + + + + obo2:UBERON_0005496 + obo2:uberon.owl + + + + obo2:UBERON_0005496 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0005498 + obo2:uberon.owl + + + + obo2:UBERON_0005498 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0005564 + obo2:uberon.owl + + + + obo2:UBERON_0005564 + obo2:uberon#grouping_class + + + + obo2:UBERON_0005564 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0005597 + obo2:uberon.owl + + + + obo2:UBERON_0005613 + obo2:uberon.owl + + + + obo2:UBERON_0005622 + obo2:uberon.owl + + + + obo2:UBERON_0005629 + obo2:uberon.owl + + + + obo2:UBERON_0005631 + obo2:uberon.owl + + + + obo2:UBERON_0005641 + obo2:uberon.owl + + + + obo2:UBERON_0005721 + obo2:uberon.owl + + + + obo2:UBERON_0005728 + obo2:uberon.owl + + + + obo2:UBERON_0005730 + obo2:uberon.owl + + + + obo2:UBERON_0005731 + obo2:uberon.owl + + + + obo2:UBERON_0005732 + obo2:uberon.owl + + + + obo2:UBERON_0005733 + obo2:uberon.owl + + + + obo2:UBERON_0005734 + obo2:uberon.owl + + + + obo2:UBERON_0005742 + obo2:uberon.owl + + + + obo2:UBERON_0005742 + obo2:uberon#grouping_class + + + + obo2:UBERON_0005749 + obo2:uberon.owl + + + + obo2:UBERON_0005753 + obo2:uberon.owl + + + + obo2:UBERON_0005754 + obo2:uberon.owl + + + + obo2:UBERON_0005795 + obo2:uberon.owl + + + + obo2:UBERON_0005800 + obo2:uberon.owl + + + + obo2:UBERON_0005805 + obo2:uberon.owl + + + + obo2:UBERON_0005805 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0005806 + obo2:uberon.owl + + + + obo2:UBERON_0005856 + obo2:uberon.owl + + + + obo2:UBERON_0005863 + obo2:uberon.owl + + + + obo2:UBERON_0005866 + obo2:uberon.owl + + + + obo2:UBERON_0005867 + obo2:uberon.owl + + + + obo2:UBERON_0005881 + obo2:uberon.owl + + + + obo2:UBERON_0005882 + obo2:uberon.owl + + + + obo2:UBERON_0005883 + obo2:uberon.owl + + + + obo2:UBERON_0005911 + obo2:uberon.owl + + + + obo2:UBERON_0005913 + obo2:uberon.owl + + + + obo2:UBERON_0005946 + obo2:uberon.owl + + + + obo2:UBERON_0005966 + obo2:uberon.owl + + + + obo2:UBERON_0005971 + obo2:uberon.owl + + + + obo2:UBERON_0005983 + obo2:uberon.owl + + + + obo2:UBERON_0005985 + obo2:uberon.owl + + + + obo2:UBERON_0005995 + obo2:uberon.owl + + + + obo2:UBERON_0006003 + obo2:uberon.owl + + + + obo2:UBERON_0006008 + obo2:uberon.owl + + + + obo2:UBERON_0006058 + obo2:uberon.owl + + + + obo2:UBERON_0006134 + obo2:uberon.owl + + + + obo2:UBERON_0006135 + obo2:uberon.owl + + + + obo2:UBERON_0006215 + obo2:uberon.owl + + + + obo2:UBERON_0006215 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0006217 + obo2:uberon.owl + + + + obo2:UBERON_0006217 + obo2:uberon#emapa_ehdaa2 + + + + obo2:UBERON_0006222 + obo2:uberon.owl + + + + obo2:UBERON_0006222 + obo2:uberon#emapa_ehdaa2 + + + + obo2:UBERON_0006222 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0006235 + obo2:uberon.owl + + + + obo2:UBERON_0006235 + obo2:uberon#emapa_ehdaa2 + + + + obo2:UBERON_0006238 + obo2:uberon.owl + + + + obo2:UBERON_0006238 + obo2:uberon#emapa_ehdaa2 + + + + obo2:UBERON_0006238 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0006240 + obo2:uberon.owl + + + + obo2:UBERON_0006240 + obo2:uberon#emapa_ehdaa2 + + + + obo2:UBERON_0006240 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0006241 + obo2:uberon.owl + + + + obo2:UBERON_0006241 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0006242 + obo2:uberon.owl + + + + obo2:UBERON_0006242 + obo2:uberon#emapa_ehdaa2 + + + + obo2:UBERON_0006260 + obo2:uberon.owl + + + + obo2:UBERON_0006260 + obo2:uberon#emapa_ehdaa2 + + + + obo2:UBERON_0006267 + obo2:uberon.owl + + + + obo2:UBERON_0006267 + obo2:uberon#emapa_ehdaa2 + + + + obo2:UBERON_0006268 + obo2:uberon.owl + + + + obo2:UBERON_0006268 + obo2:uberon#emapa_ehdaa2 + + + + obo2:UBERON_0006284 + obo2:uberon.owl + + + + obo2:UBERON_0006314 + obo2:uberon.owl + + + + obo2:UBERON_0006444 + obo2:uberon.owl + + + + obo2:UBERON_0006444 + obo2:uberon#grouping_class + + + + obo2:UBERON_0006553 + obo2:uberon.owl + + + + obo2:UBERON_0006555 + obo2:uberon.owl + + + + obo2:UBERON_0006558 + obo2:uberon.owl + + + + obo2:UBERON_0006595 + obo2:uberon.owl + + + + obo2:UBERON_0006598 + obo2:uberon.owl + + + + obo2:UBERON_0006601 + obo2:uberon.owl + + + + obo2:UBERON_0006603 + obo2:uberon.owl + + + + obo2:UBERON_0006658 + obo2:uberon.owl + + + + obo2:UBERON_0006716 + obo2:uberon.owl + + + + obo2:UBERON_0006717 + obo2:uberon.owl + + + + obo2:UBERON_0006756 + obo2:uberon.owl + + + + obo2:UBERON_0006757 + obo2:uberon.owl + + + + obo2:UBERON_0006799 + obo2:uberon.owl + + + + obo2:UBERON_0006800 + obo2:uberon.owl + + + + obo2:UBERON_0006800 + obo2:uberon#upper_level + + + + obo2:UBERON_0006846 + obo2:uberon.owl + + + + obo2:UBERON_0006846 + obo2:uberon#grouping_class + + + + obo2:UBERON_0006858 + obo2:uberon.owl + + + + obo2:UBERON_0006858 + obo2:uberon#grouping_class + + + + obo2:UBERON_0006858 + obo2:uberon#organ_slim + + + + obo2:UBERON_0006866 + obo2:uberon.owl + + + + obo2:UBERON_0006871 + obo2:uberon.owl + + + + obo2:UBERON_0006876 + obo2:uberon.owl + + + + obo2:UBERON_0006876 + obo2:uberon#non_informative + + + + obo2:UBERON_0006909 + obo2:uberon.owl + + + + obo2:UBERON_0006914 + obo2:uberon.owl + + + + obo2:UBERON_0006924 + obo2:uberon.owl + + + + obo2:UBERON_0006925 + obo2:uberon.owl + + + + obo2:UBERON_0006925 + obo2:uberon#organ_slim + + + + obo2:UBERON_0006929 + obo2:uberon.owl + + + + obo2:UBERON_0006931 + obo2:uberon.owl + + + + obo2:UBERON_0006965 + obo2:uberon.owl + + + + obo2:UBERON_0007005 + obo2:uberon.owl + + + + obo2:UBERON_0007010 + obo2:uberon.owl + + + + obo2:UBERON_0007026 + obo2:uberon.owl + + + + obo2:UBERON_0007100 + obo2:uberon.owl + + + + obo2:UBERON_0007100 + obo2:NCBITaxon_7718 + + + + obo2:UBERON_0007100 + obo2:uberon#grouping_class + + + + obo2:UBERON_0007123 + obo2:uberon.owl + + + + obo2:UBERON_0007123 + obo2:uberon#vertebrate_core + + + + obo2:UBERON_0007135 + obo2:uberon.owl + + + + obo2:UBERON_0007237 + obo2:uberon.owl + + + + obo2:UBERON_0007277 + obo2:uberon.owl + + + + obo2:UBERON_0007280 + obo2:uberon.owl + + + + obo2:UBERON_0007282 + obo2:uberon.owl + + + + obo2:UBERON_0007284 + obo2:uberon.owl + + + + obo2:UBERON_0007285 + obo2:uberon.owl + + + + obo2:UBERON_0007297 + obo2:uberon.owl + + + + obo2:UBERON_0007376 + obo2:uberon.owl + + + + obo2:UBERON_0007376 + obo2:uberon#grouping_class + + + + obo2:UBERON_0007383 + obo2:uberon.owl + + + + obo2:UBERON_0007497 + obo2:uberon.owl + + + + obo2:UBERON_0007499 + obo2:uberon.owl + + + + obo2:UBERON_0007500 + obo2:uberon.owl + + + + obo2:UBERON_0007503 + obo2:uberon.owl + + + + obo2:UBERON_0007524 + obo2:uberon.owl + + + + obo2:UBERON_0007530 + obo2:uberon.owl + + + + obo2:UBERON_0007592 + obo2:uberon.owl + + + + obo2:UBERON_0007601 + obo2:uberon.owl + + + + obo2:UBERON_0007684 + obo2:uberon.owl + + + + obo2:UBERON_0007687 + obo2:uberon.owl + + + + obo2:UBERON_0007689 + obo2:uberon.owl + + + + obo2:UBERON_0007690 + obo2:uberon.owl + + + + obo2:UBERON_0007779 + obo2:uberon.owl + + + + obo2:UBERON_0007798 + obo2:uberon.owl + + + + obo2:UBERON_0007811 + obo2:uberon.owl + + + + obo2:UBERON_0007823 + obo2:uberon.owl + + + + obo2:UBERON_0007823 + obo2:UBERON_0004708 + + + + obo2:UBERON_0007844 + obo2:uberon.owl + + + + obo2:UBERON_0007844 + obo2:uberon#organ_slim + + + + obo2:UBERON_0007914 + obo2:uberon.owl + + + + obo2:UBERON_0008001 + obo2:uberon.owl + + + + obo2:UBERON_0008193 + obo2:uberon.owl + + + + obo2:UBERON_0008780 + obo2:uberon.owl + + + + obo2:UBERON_0008780 + obo2:uberon#early_development + + + + obo2:UBERON_0008784 + obo2:uberon.owl + + + + obo2:UBERON_0008801 + obo2:uberon.owl + + + + obo2:UBERON_0008814 + obo2:uberon.owl + + + + obo2:UBERON_0008816 + obo2:uberon.owl + + + + obo2:UBERON_0008835 + obo2:uberon.owl + + + + obo2:UBERON_0008836 + obo2:uberon.owl + + + + obo2:UBERON_0008858 + obo2:uberon.owl + + + + obo2:UBERON_0008861 + obo2:uberon.owl + + + + obo2:UBERON_0008895 + obo2:uberon.owl + + + + obo2:UBERON_0008897 + obo2:uberon.owl + + + + obo2:UBERON_0008897 + obo2:NCBITaxon_8782 + + + + obo2:UBERON_0008947 + obo2:uberon.owl + + + + obo2:UBERON_0009034 + obo2:uberon.owl + + + + obo2:UBERON_0009117 + obo2:uberon.owl + + + + obo2:UBERON_0009117 + obo2:uberon#organ_slim + + + + obo2:UBERON_0009123 + obo2:uberon.owl + + + + obo2:UBERON_0009141 + obo2:uberon.owl + + + + obo2:UBERON_0009142 + obo2:uberon.owl + + + + obo2:UBERON_0009143 + obo2:uberon.owl + + + + obo2:UBERON_0009145 + obo2:uberon.owl + + + + obo2:UBERON_0009196 + obo2:uberon.owl + + + + obo2:UBERON_0009196 + obo2:uberon#organ_slim + + + + obo2:UBERON_0009201 + obo2:uberon.owl + + + + obo2:UBERON_0009497 + obo2:uberon.owl + + + + obo2:UBERON_0009497 + obo2:uberon#emapa_ehdaa2 + + + + obo2:UBERON_0009550 + obo2:uberon.owl + + + + obo2:UBERON_0009550 + obo2:uberon#emapa_ehdaa2 + + + + obo2:UBERON_0009551 + obo2:uberon.owl + + + + obo2:UBERON_0009564 + obo2:uberon.owl + + + + obo2:UBERON_0009569 + obo2:uberon.owl + + + + obo2:UBERON_0009569 + obo2:uberon#non_informative + + + + obo2:UBERON_0009581 + obo2:uberon.owl + + + + obo2:UBERON_0009616 + obo2:uberon.owl + + + + obo2:UBERON_0009617 + obo2:uberon.owl + + + + obo2:UBERON_0009618 + obo2:uberon.owl + + + + obo2:UBERON_0009676 + obo2:uberon.owl + + + + obo2:UBERON_0009722 + obo2:uberon.owl + + + + obo2:UBERON_0009749 + obo2:uberon.owl + + + + obo2:UBERON_0009751 + obo2:uberon.owl + + + + obo2:UBERON_0009774 + obo2:uberon.owl + + + + obo2:UBERON_0009845 + obo2:uberon.owl + + + + obo2:UBERON_0009846 + obo2:uberon.owl + + + + obo2:UBERON_0009847 + obo2:uberon.owl + + + + obo2:UBERON_0009854 + obo2:uberon.owl + + + + obo2:UBERON_0009856 + obo2:uberon.owl + + + + obo2:UBERON_0009870 + obo2:uberon.owl + + + + obo2:UBERON_0009877 + obo2:uberon.owl + + + + obo2:UBERON_0009878 + obo2:uberon.owl + + + + obo2:UBERON_0009881 + obo2:uberon.owl + + + + obo2:UBERON_0009911 + obo2:uberon.owl + + + + obo2:UBERON_0009911 + obo2:uberon#upper_level + + + + obo2:UBERON_0009955 + obo2:uberon.owl + + + + obo2:UBERON_0010039 + obo2:uberon.owl + + + + obo2:UBERON_0010039 + obo2:uberon#functional_classification + + + + obo2:UBERON_0010039 + obo2:uberon#grouping_class + + + + obo2:UBERON_0010047 + obo2:uberon.owl + + + + obo2:UBERON_0010056 + obo2:uberon.owl + + + + obo2:UBERON_0010064 + obo2:uberon.owl + + + + obo2:UBERON_0010083 + obo2:uberon.owl + + + + obo2:UBERON_0010084 + obo2:uberon.owl + + + + obo2:UBERON_0010092 + obo2:uberon.owl + + + + obo2:UBERON_0010096 + obo2:uberon.owl + + + + obo2:UBERON_0010113 + obo2:uberon.owl + + + + obo2:UBERON_0010130 + obo2:uberon.owl + + + + obo2:UBERON_0010131 + obo2:uberon.owl + + + + obo2:UBERON_0010147 + obo2:uberon.owl + + + + obo2:UBERON_0010161 + obo2:uberon.owl + + + + obo2:UBERON_0010188 + obo2:uberon.owl + + + + obo2:UBERON_0010191 + obo2:uberon.owl + + + + obo2:UBERON_0010226 + obo2:uberon.owl + + + + obo2:UBERON_0010227 + obo2:uberon.owl + + + + obo2:UBERON_0010230 + obo2:uberon.owl + + + + obo2:UBERON_0010285 + obo2:uberon.owl + + + + obo2:UBERON_0010286 + obo2:uberon.owl + + + + obo2:UBERON_0010303 + obo2:uberon.owl + + + + obo2:UBERON_0010312 + obo2:uberon.owl + + + + obo2:UBERON_0010313 + obo2:uberon.owl + + + + obo2:UBERON_0010313 + obo2:uberon#grouping_class + + + + obo2:UBERON_0010314 + obo2:uberon.owl + + + + obo2:UBERON_0010314 + obo2:uberon#grouping_class + + + + obo2:UBERON_0010316 + obo2:uberon.owl + + + + obo2:UBERON_0010323 + obo2:uberon.owl + + + + obo2:UBERON_0010329 + obo2:uberon.owl + + + + obo2:UBERON_0010333 + obo2:uberon.owl + + + + obo2:UBERON_0010349 + obo2:uberon.owl + + + + obo2:UBERON_0010351 + obo2:uberon.owl + + + + obo2:UBERON_0010363 + obo2:uberon.owl + + + + obo2:UBERON_0010368 + obo2:uberon.owl + + + + obo2:UBERON_0010371 + obo2:uberon.owl + + + + obo2:UBERON_0010375 + obo2:uberon.owl + + + + obo2:UBERON_0010376 + obo2:uberon.owl + + + + obo2:UBERON_0010377 + obo2:uberon.owl + + + + obo2:UBERON_0010523 + obo2:uberon.owl + + + + obo2:UBERON_0010527 + obo2:uberon.owl + + + + obo2:UBERON_0010528 + obo2:uberon.owl + + + + obo2:UBERON_0010532 + obo2:uberon.owl + + + + obo2:UBERON_0010538 + obo2:uberon.owl + + + + obo2:UBERON_0010543 + obo2:uberon.owl + + + + obo2:UBERON_0010546 + obo2:uberon.owl + + + + obo2:UBERON_0010700 + obo2:uberon.owl + + + + obo2:UBERON_0010701 + obo2:uberon.owl + + + + obo2:UBERON_0010702 + obo2:uberon.owl + + + + obo2:UBERON_0010707 + obo2:uberon.owl + + + + obo2:UBERON_0010708 + obo2:uberon.owl + + + + obo2:UBERON_0010712 + obo2:uberon.owl + + + + obo2:UBERON_0010740 + obo2:uberon.owl + + + + obo2:UBERON_0010743 + obo2:uberon.owl + + + + obo2:UBERON_0010758 + obo2:uberon.owl + + + + obo2:UBERON_0010758 + obo2:uberon#upper_level + + + + obo2:UBERON_0010881 + obo2:uberon.owl + + + + obo2:UBERON_0010882 + obo2:uberon.owl + + + + obo2:UBERON_0010912 + obo2:uberon.owl + + + + obo2:UBERON_0010912 + obo2:uberon#non_informative + + + + obo2:UBERON_0011134 + obo2:uberon.owl + + + + obo2:UBERON_0011137 + obo2:uberon.owl + + + + obo2:UBERON_0011139 + obo2:uberon.owl + + + + obo2:UBERON_0011143 + obo2:uberon.owl + + + + obo2:UBERON_0011156 + obo2:uberon.owl + + + + obo2:UBERON_0011158 + obo2:uberon.owl + + + + obo2:UBERON_0011158 + obo2:uberon#non_informative + + + + obo2:UBERON_0011159 + obo2:uberon.owl + + + + obo2:UBERON_0011159 + obo2:uberon#non_informative + + + + obo2:UBERON_0011185 + obo2:uberon.owl + + + + obo2:UBERON_0011215 + obo2:uberon.owl + + + + obo2:UBERON_0011215 + obo2:uberon#upper_level + + + + obo2:UBERON_0011216 + obo2:uberon.owl + + + + obo2:UBERON_0011216 + obo2:uberon#upper_level + + + + obo2:UBERON_0011249 + obo2:uberon.owl + + + + obo2:UBERON_0011250 + obo2:uberon.owl + + + + obo2:UBERON_0011272 + obo2:uberon.owl + + + + obo2:UBERON_0011300 + obo2:uberon.owl + + + + obo2:UBERON_0011582 + obo2:uberon.owl + + + + obo2:UBERON_0011583 + obo2:uberon.owl + + + + obo2:UBERON_0011584 + obo2:uberon.owl + + + + obo2:UBERON_0011585 + obo2:uberon.owl + + + + obo2:UBERON_0011595 + obo2:uberon.owl + + + + obo2:UBERON_0011676 + obo2:uberon.owl + + + + obo2:UBERON_0011676 + obo2:uberon#upper_level + + + + obo2:UBERON_0011814 + obo2:uberon.owl + + + + obo2:UBERON_0011820 + obo2:uberon.owl + + + + obo2:UBERON_0011821 + obo2:uberon.owl + + + + obo2:UBERON_0011822 + obo2:uberon.owl + + + + obo2:UBERON_0011953 + obo2:uberon.owl + + + + obo2:UBERON_0012069 + obo2:uberon.owl + + + + obo2:UBERON_0012139 + obo2:uberon.owl + + + + obo2:UBERON_0012140 + obo2:uberon.owl + + + + obo2:UBERON_0012150 + obo2:uberon.owl + + + + obo2:UBERON_0012180 + obo2:uberon.owl + + + + obo2:UBERON_0012254 + obo2:uberon.owl + + + + obo2:UBERON_0012274 + obo2:uberon.owl + + + + obo2:UBERON_0012275 + obo2:uberon.owl + + + + obo2:UBERON_0012292 + obo2:uberon.owl + + + + obo2:UBERON_0012314 + obo2:uberon.owl + + + + obo2:UBERON_0012354 + obo2:uberon.owl + + + + obo2:UBERON_0012357 + obo2:uberon.owl + + + + obo2:UBERON_0012357 + obo2:reference_0000015 + + + + obo2:UBERON_0012361 + obo2:uberon.owl + + + + obo2:UBERON_0012429 + obo2:uberon.owl + + + + obo2:UBERON_0012469 + obo2:uberon.owl + + + + obo2:UBERON_0012481 + obo2:uberon.owl + + + + obo2:UBERON_0013140 + obo2:uberon.owl + + + + obo2:UBERON_0013150 + obo2:uberon.owl + + + + obo2:UBERON_0013514 + obo2:uberon.owl + + + + obo2:UBERON_0013515 + obo2:uberon.owl + + + + obo2:UBERON_0013522 + obo2:uberon.owl + + + + obo2:UBERON_0013686 + obo2:uberon.owl + + + + obo2:UBERON_0013701 + obo2:uberon.owl + + + + obo2:UBERON_0013702 + obo2:uberon.owl + + + + obo2:UBERON_0013702 + obo2:UBERON_0002415 + + + + obo2:UBERON_0013703 + obo2:uberon.owl + + + + obo2:UBERON_0013765 + obo2:uberon.owl + + + + obo2:UBERON_0013768 + obo2:uberon.owl + + + + obo2:UBERON_0013768 + obo2:uberon#grouping_class + + + + obo2:UBPROP_0000103 + obo2:UBERON_0002539 + + + + obo2:UBPROP_0000103 + obo2:BSPO_0000096 + + + + obo2:UBREL_0000001 + obo2:uberon.owl + + + + obo2:UBREL_0000001 + obo2:SIO_000652 + + + + obo2:UBREL_0000002 + obo2:uberon.owl + + + + obo2:VO_0000001 + obo2:vo.owl + + + + obo2:VO_0000043 + obo2:vo.owl + + + + obo2:VO_0000609 + obo2:vo.owl + + + + obo2:VO_0000642 + obo2:vo.owl + + + + obo2:go#results_in + obo2:go.owl + + + + obo2:uberon#anteriorly_connected_to + obo2:uberon.owl + + + + obo2:uberon#branch_of + obo2:uberon.owl + + + + obo2:uberon#channel_for + obo2:uberon.owl + + + + obo2:uberon#channels_from + obo2:uberon.owl + + + + obo2:uberon#connects + obo2:uberon.owl + + + + obo2:uberon#distally_connected_to + obo2:uberon.owl + + + + obo2:uberon#enclosed_by + obo2:uberon.owl + + + + obo2:uberon#encloses + obo2:uberon.owl + + + + obo2:uberon#evolved_from + obo2:uberon.owl + + + + obo2:uberon#existence_ends_with + obo2:uberon.owl + + + + obo2:uberon#existence_starts_and_ends_during + obo2:uberon.owl + + + + obo2:uberon#existence_starts_at + obo2:uberon.owl + + + + obo2:uberon#existence_starts_with + obo2:uberon.owl + + + + obo2:uberon#has_end + obo2:uberon.owl + + + + obo2:uberon#has_start + obo2:uberon.owl + + + + obo2:uberon#innervated_by + obo2:uberon.owl + + + + obo2:uberon#posteriorly_connected_to + obo2:uberon.owl + + + + obo2:uberon#proximally_connected_to + obo2:uberon.owl + + + + obo2:uberon#start_of + obo2:uberon.owl + + + + obo2:uberon#subdivision_of + obo2:uberon.owl + + + + obo2:uberon#transitively_anteriorly_connected_to + obo2:uberon.owl + + + + obo2:uberon#transitively_connected_to + obo2:uberon.owl + + + + obo2:uberon#transitively_distally_connected_to + obo2:uberon.owl + + + + obo2:uberon#transitively_proximally_connected_to + obo2:uberon.owl + + + + http://purl.org/obo/owl/DOID#DOID_870 + http://purl.org/obo/owl/disease_ontology + + + + http://purl.org/obo/owl/DOID#DOID_870 + + + + + http://purl.org/obo/owl/DOID#DOID_870 + + + + + http://purl.org/obo/owl/DOID#DOID_870 + + + + + http://purl.org/obo/owl/DOID#DOID_870 + + + + + http://purl.org/obo/owl/DOID#DOID_870 + + + + + http://purl.org/obo/owl/DOID#DOID_870 + + + + + http://purl.org/obo/owl/DOID#DOID_870 + + + + + http://purl.org/obo/owl/DOID#DOID_870 + + + + + http://purl.org/obo/owl/DOID#DOID_870 + + + + + http://purl.org/obo/owl/DOID#DOID_870 + + + + + http://purl.org/obo/owl/DOID#DOID_870 + + + + + http://purl.org/obo/owl/DOID#DOID_870 + + + + + http://purl.org/obo/owl/PATO#PATO_0001236 + http://purl.org/obo/owl/quality + + + + http://purl.org/obo/owl/PATO#PATO_0001236 + + + + + http://purl.org/obo/owl/PATO#PATO_0001236 + + + + + http://purl.org/obo/owl/PATO#PATO_0001236 + + + + + http://purl.org/obo/owl/PATO#PATO_0001236 + + + + + http://purl.org/obo/owl/PATO#PATO_0001236 + + + + + http://purl.org/obo/owl/PATO#PATO_0001236 + + + + + http://purl.org/obo/owl/PATO#PATO_0001236 + + + + + http://purl.org/obo/owl/PATO#PATO_0001236 + + + + + http://purl.org/obo/owl/PATO#PATO_0001236 + + + + + http://purl.org/obo/owl/PATO#PATO_0001236 + + + + + http://purl.org/obo/owl/PATO#PATO_0001236 + + + + + http://purl.org/obo/owl/PATO#PATO_0001236 + + + + + http://purl.org/obo/owl/PATO#PATO_0001236 + + + + + http://purl.org/obo/owl/PATO#PATO_0001236 + + + + + http://purl.org/obo/owl/PATO#PATO_0001236 + + + + + http://purl.org/obo/owl/PATO#PATO_0001236 + + + + + http://purl.org/obo/owl/PATO#PATO_0001236 + + + + + http://purl.org/obo/owl/PATO#PATO_0001236 + + + + + http://purl.org/obo/owl/PATO#PATO_0001236 + + + + + http://purl.org/obo/owl/PATO#PATO_0001236 + + + + + http://purl.org/obo/owl/PATO#PATO_0001236 + + + + + http://purl.org/obo/owl/PATO#PATO_0001236 + + + + + http://purl.org/obo/owl/PATO#PATO_0001236 + + + + + http://purl.org/obo/owl/PATO#PATO_0001236 + + + + + http://purl.org/obo/owl/PATO#PATO_0001236 + + + + + http://purl.org/obo/owl/PATO#PATO_0001236 + + + + + http://purl.org/obo/owl/PATO#PATO_0001236 + + + + + http://purl.org/obo/owl/PATO#PATO_0001236 + + + + + http://purl.org/obo/owl/PATO#PATO_0001236 + + + + + http://purl.org/obo/owl/PATO#PATO_0001236 + + + + + http://purl.org/obo/owl/PATO#PATO_0001236 + + + + + http://purl.org/obo/owl/PATO#PATO_0001236 + + + + + http://purl.org/obo/owl/PATO#PATO_0001236 + + + + + http://purl.org/obo/owl/PATO#PATO_0001236 + + + + + http://purl.org/obo/owl/PATO#PATO_0001236 + + + + + http://purl.org/obo/owl/PATO#PATO_0001236 + + + + + http://purl.org/obo/owl/PATO#PATO_0001236 + + + + + http://purl.org/obo/owl/PATO#PATO_0001236 + + + + + http://purl.org/obo/owl/PATO#PATO_0001236 + + + + + http://purl.org/obo/owl/PATO#PATO_0001236 + + + + + http://purl.org/obo/owl/PATO#PATO_0001236 + + + + + http://purl.org/obo/owl/PATO#PATO_0001236 + + + + + http://purl.org/obo/owl/PATO#PATO_0001236 + + + + + http://purl.org/obo/owl/PATO#PATO_0001236 + + + + + http://purl.org/obo/owl/PATO#PATO_0001236 + + + + + http://purl.org/obo/owl/PATO#PATO_0001236 + + + + + http://purl.org/obo/owl/PATO#PATO_0001236 + + + + + http://purl.org/obo/owl/PATO#PATO_0001236 + + + + + http://purl.org/obo/owl/PATO#PATO_0001236 + + + + + http://purl.org/obo/owl/PATO#PATO_0001236 + + + + + http://purl.org/obo/owl/PATO#PATO_0001236 + + + + + http://purl.org/obo/owl/PATO#PATO_0001236 + + + + + http://purl.org/obo/owl/PATO#PATO_0001236 + + + + + http://purl.org/obo/owl/PATO#PATO_0001236 + + + + + http://purl.org/obo/owl/PATO#PATO_0001236 + + + + + http://purl.org/obo/owl/PATO#PATO_0001236 + + + + + http://purl.org/obo/owl/PATO#PATO_0001236 + + + + + http://purl.org/obo/owl/PATO#PATO_0001236 + + + + + http://purl.org/obo/owl/PATO#PATO_0001309 + http://purl.org/obo/owl/quality + + + + http://purl.org/obo/owl/PATO#PATO_0001309 + + + + + http://purl.org/obo/owl/PATO#PATO_0001309 + + + + + http://purl.org/obo/owl/PATO#PATO_0001309 + + + + + http://purl.org/obo/owl/PATO#PATO_0001309 + + + + + http://purl.org/obo/owl/PATO#PATO_0001309 + + + + + http://purl.org/obo/owl/PATO#PATO_0001309 + + + + + http://purl.org/obo/owl/PATO#PATO_0001309 + + + + + http://purl.org/obo/owl/PATO#PATO_0001309 + + + + + http://purl.org/obo/owl/PATO#PATO_0001309 + + + + + http://purl.org/obo/owl/PATO#PATO_0001309 + + + + + http://purl.org/obo/owl/PATO#PATO_0001309 + + + + + http://purl.org/obo/owl/PATO#PATO_0001309 + + + + + http://purl.org/obo/owl/PATO#PATO_0001309 + + + + + http://purl.org/obo/owl/PATO#PATO_0001309 + + + + + http://purl.org/obo/owl/PATO#PATO_0001309 + + + + + http://purl.org/obo/owl/PATO#PATO_0001309 + + + + + http://purl.org/obo/owl/PATO#PATO_0001309 + + + + + http://purl.org/obo/owl/PATO#PATO_0001309 + + + + + http://purl.org/obo/owl/PATO#PATO_0001309 + + + + + http://purl.org/obo/owl/PATO#PATO_0001309 + + + + + http://purl.org/obo/owl/PATO#PATO_0001309 + + + + + http://purl.org/obo/owl/PATO#PATO_0001309 + + + + + http://purl.org/obo/owl/PATO#PATO_0001309 + + + + + http://purl.org/obo/owl/PATO#PATO_0001309 + + + + + http://purl.org/obo/owl/PATO#PATO_0001309 + + + + + http://purl.org/obo/owl/PATO#PATO_0001309 + + + + + http://purl.org/obo/owl/PATO#PATO_0001309 + + + + + http://purl.org/obo/owl/PATO#PATO_0001309 + + + + + http://purl.org/obo/owl/PATO#PATO_0001309 + + + + + http://purl.org/obo/owl/PATO#PATO_0001309 + + + + + http://purl.org/obo/owl/PATO#PATO_0001309 + + + + + http://purl.org/obo/owl/PATO#PATO_0001309 + + + + + http://purl.org/obo/owl/PATO#PATO_0001309 + + + + + http://purl.org/obo/owl/PATO#PATO_0001309 + + + + + http://purl.org/obo/owl/PATO#PATO_0001309 + + + + + http://purl.org/obo/owl/PATO#PATO_0001309 + + + + + http://purl.org/obo/owl/PATO#PATO_0001309 + + + + + http://purl.org/obo/owl/PATO#PATO_0001309 + + + + + http://purl.org/obo/owl/PATO#PATO_0001309 + http://purl.org/obo/owl/obo#attribute_slim + + + + http://purl.org/obo/owl/PATO#PATO_0002062 + http://purl.org/obo/owl/quality + + + + http://purl.org/obo/owl/PATO#PATO_0002062 + http://purl.org/obo/owl/obo#attribute_slim + + + + http://semanticscience.org/resource/SIO_000657 + obo2:uberon.owl + + + + http://semanticscience.org/resource/SIO_000658 + obo2:uberon.owl + + + + http://www.geneontology.org/formats/oboInOwl#ObsoleteProperty + obo2:obi.owl + + + + http://www.geneontology.org/formats/oboInOwl#hasAlternativeId + has_alternative_id + + + + http://www.geneontology.org/formats/oboInOwl#hasDbXref + database_cross_reference + + + + http://www.geneontology.org/formats/oboInOwl#hasExactSynonym + has_exact_synonym + + + + http://www.geneontology.org/formats/oboInOwl#hasNarrowSynonym + has_narrow_synonym + + + + http://www.geneontology.org/formats/oboInOwl#hasRelatedSynonym + has_related_synonym + + + + http://www.geneontology.org/formats/oboInOwl#inSubset + in_subset + + + + http://www.obofoundry.org/ro/ro.owl#adjacent_to + + + + + http://www.obofoundry.org/ro/ro.owl#adjacent_to + + + + + http://www.obofoundry.org/ro/ro.owl#adjacent_to + + + + + http://www.obofoundry.org/ro/ro.owl#adjacent_to + + + + + http://www.obofoundry.org/ro/ro.owl#adjacent_to + + + + + http://www.obofoundry.org/ro/ro.owl#adjacent_to + + + + + http://www.obofoundry.org/ro/ro.owl#adjacent_to + + + + + http://www.obofoundry.org/ro/ro.owl#adjacent_to + + + + + http://www.obofoundry.org/ro/ro.owl#adjacent_to + + + + + http://www.obofoundry.org/ro/ro.owl#adjacent_to + + + + + http://www.obofoundry.org/ro/ro.owl#adjacent_to + + + + + http://www.obofoundry.org/ro/ro.owl#adjacent_to + + + + + http://www.obofoundry.org/ro/ro.owl#adjacent_to + + + + + http://www.obofoundry.org/ro/ro.owl#adjacent_to + + + + + http://www.obofoundry.org/ro/ro.owl#adjacent_to + + + + + http://www.obofoundry.org/ro/ro.owl#adjacent_to + + + + + http://www.obofoundry.org/ro/ro.owl#adjacent_to + + + + + http://www.obofoundry.org/ro/ro.owl#adjacent_to + + + + + http://www.obofoundry.org/ro/ro.owl#adjacent_to + + + + + http://www.obofoundry.org/ro/ro.owl#adjacent_to + + + + + http://www.obofoundry.org/ro/ro.owl#adjacent_to + + + + + http://www.obofoundry.org/ro/ro.owl#adjacent_to + + + + + http://www.obofoundry.org/ro/ro.owl#adjacent_to + + + + + http://www.obofoundry.org/ro/ro.owl#adjacent_to + + + + + http://www.obofoundry.org/ro/ro.owl#adjacent_to + + + + + http://www.obofoundry.org/ro/ro.owl#contained_in + + + + + http://www.obofoundry.org/ro/ro.owl#contained_in + + + + + http://www.obofoundry.org/ro/ro.owl#contained_in + + + + + http://www.obofoundry.org/ro/ro.owl#contained_in + + + + + http://www.obofoundry.org/ro/ro.owl#contained_in + + + + + http://www.obofoundry.org/ro/ro.owl#contained_in + + + + + http://www.obofoundry.org/ro/ro.owl#contained_in + + + + + http://www.obofoundry.org/ro/ro.owl#contained_in + + + + + http://www.obofoundry.org/ro/ro.owl#contained_in + + + + + http://www.obofoundry.org/ro/ro.owl#contained_in + + + + + http://www.obofoundry.org/ro/ro.owl#contained_in + + + + + http://www.obofoundry.org/ro/ro.owl#contained_in + + + + + http://www.obofoundry.org/ro/ro.owl#contained_in + + + + + http://www.obofoundry.org/ro/ro.owl#contained_in + + + + + http://www.obofoundry.org/ro/ro.owl#contained_in + + + + + http://www.obofoundry.org/ro/ro.owl#contained_in + + + + + http://www.obofoundry.org/ro/ro.owl#contained_in + + + + + http://www.obofoundry.org/ro/ro.owl#contained_in + + + + + http://www.obofoundry.org/ro/ro.owl#contained_in + + + + + http://www.obofoundry.org/ro/ro.owl#contained_in + + + + + http://www.obofoundry.org/ro/ro.owl#contained_in + + + + + http://www.obofoundry.org/ro/ro.owl#contained_in + + + + + http://www.obofoundry.org/ro/ro.owl#contained_in + + + + + http://www.obofoundry.org/ro/ro.owl#contained_in + + + + + http://www.obofoundry.org/ro/ro.owl#contained_in + + + + + http://www.obofoundry.org/ro/ro.owl#contained_in + + + + + http://www.obofoundry.org/ro/ro.owl#contained_in + + + + + http://www.obofoundry.org/ro/ro.owl#contained_in + + + + + http://www.obofoundry.org/ro/ro.owl#contained_in + + + + + http://www.obofoundry.org/ro/ro.owl#contained_in + + + + + http://www.obofoundry.org/ro/ro.owl#contained_in + + + + + http://www.obofoundry.org/ro/ro.owl#contained_in + + + + + http://www.obofoundry.org/ro/ro.owl#contained_in + + + + + http://www.obofoundry.org/ro/ro.owl#contained_in + + + + + http://www.obofoundry.org/ro/ro.owl#contained_in + + + + + http://www.obofoundry.org/ro/ro.owl#contained_in + + + + + http://www.obofoundry.org/ro/ro.owl#contained_in + + + + + http://www.obofoundry.org/ro/ro.owl#derives_from + + + + + http://www.obofoundry.org/ro/ro.owl#derives_from + + + + + http://www.obofoundry.org/ro/ro.owl#derives_from + + + + + http://www.obofoundry.org/ro/ro.owl#derives_from + + + + + http://www.obofoundry.org/ro/ro.owl#derives_from + + + + + http://www.obofoundry.org/ro/ro.owl#derives_from + + + + + http://www.obofoundry.org/ro/ro.owl#derives_from + + + + + http://www.obofoundry.org/ro/ro.owl#derives_from + + + + + http://www.obofoundry.org/ro/ro.owl#derives_from + + + + + http://www.obofoundry.org/ro/ro.owl#derives_from + + + + + http://www.obofoundry.org/ro/ro.owl#derives_from + + + + + http://www.obofoundry.org/ro/ro.owl#derives_from + + + + + http://www.obofoundry.org/ro/ro.owl#derives_from + + + + + http://www.obofoundry.org/ro/ro.owl#derives_from + + + + + http://www.obofoundry.org/ro/ro.owl#derives_from + + + + + http://www.obofoundry.org/ro/ro.owl#derives_from + + + + + http://www.obofoundry.org/ro/ro.owl#derives_from + + + + + http://www.obofoundry.org/ro/ro.owl#derives_from + + + + + http://www.obofoundry.org/ro/ro.owl#derives_from + + + + + http://www.obofoundry.org/ro/ro.owl#derives_from + + + + + http://www.obofoundry.org/ro/ro.owl#derives_from + + + + + http://www.obofoundry.org/ro/ro.owl#derives_from + + + + + http://www.obofoundry.org/ro/ro.owl#derives_from + + + + + http://www.obofoundry.org/ro/ro.owl#derives_from + + + + + http://www.obofoundry.org/ro/ro.owl#derives_from + + + + + http://www.obofoundry.org/ro/ro.owl#derives_from + + + + + http://www.obofoundry.org/ro/ro.owl#derives_from + + + + + http://www.obofoundry.org/ro/ro.owl#derives_from + + + + + http://www.obofoundry.org/ro/ro.owl#derives_from + + + + + http://www.obofoundry.org/ro/ro.owl#derives_from + + + + + http://www.obofoundry.org/ro/ro.owl#derives_from + + + + + http://www.obofoundry.org/ro/ro.owl#derives_from + + + + + http://www.obofoundry.org/ro/ro.owl#derives_from + + + + + http://www.obofoundry.org/ro/ro.owl#derives_from + + + + + http://www.obofoundry.org/ro/ro.owl#derives_from + + + + + http://www.obofoundry.org/ro/ro.owl#derives_from + + + + + http://www.obofoundry.org/ro/ro.owl#derives_from + + + + + http://www.obofoundry.org/ro/ro.owl#derives_from + + + + + http://www.obofoundry.org/ro/ro.owl#derives_from + + + + + http://www.obofoundry.org/ro/ro.owl#derives_from + + + + + http://www.obofoundry.org/ro/ro.owl#derives_from + + + + + http://www.obofoundry.org/ro/ro.owl#derives_from + + + + + http://www.obofoundry.org/ro/ro.owl#derives_from + + + + + http://www.obofoundry.org/ro/ro.owl#derives_from + + + + + http://www.obofoundry.org/ro/ro.owl#derives_from + + + + + http://www.obofoundry.org/ro/ro.owl#derives_from + + + + + http://www.obofoundry.org/ro/ro.owl#derives_from + + + + + http://www.obofoundry.org/ro/ro.owl#derives_from + + + + + http://www.obofoundry.org/ro/ro.owl#derives_from + + + + + http://www.obofoundry.org/ro/ro.owl#derives_from + + + + + http://www.obofoundry.org/ro/ro.owl#derives_from + + + + + http://www.obofoundry.org/ro/ro.owl#derives_from + + + + + http://www.obofoundry.org/ro/ro.owl#derives_from + + + + + http://www.obofoundry.org/ro/ro.owl#derives_from + + + + + http://www.obofoundry.org/ro/ro.owl#derives_from + + + + + http://www.obofoundry.org/ro/ro.owl#derives_from + + + + + http://www.obofoundry.org/ro/ro.owl#derives_from + + + + + http://www.obofoundry.org/ro/ro.owl#derives_from + + + + + http://www.obofoundry.org/ro/ro.owl#has_agent + + + + + http://www.obofoundry.org/ro/ro.owl#has_agent + + + + + http://www.obofoundry.org/ro/ro.owl#has_agent + + + + + http://www.obofoundry.org/ro/ro.owl#has_agent + + + + + http://www.obofoundry.org/ro/ro.owl#has_agent + + + + + http://www.obofoundry.org/ro/ro.owl#has_agent + + + + + http://www.obofoundry.org/ro/ro.owl#has_agent + + + + + http://www.obofoundry.org/ro/ro.owl#has_agent + + + + + http://www.obofoundry.org/ro/ro.owl#has_agent + + + + + http://www.obofoundry.org/ro/ro.owl#has_agent + + + + + http://www.obofoundry.org/ro/ro.owl#has_agent + + + + + http://www.obofoundry.org/ro/ro.owl#has_agent + + + + + http://www.obofoundry.org/ro/ro.owl#has_agent + + + + + http://www.obofoundry.org/ro/ro.owl#has_agent + + + + + http://www.obofoundry.org/ro/ro.owl#has_agent + + + + + http://www.obofoundry.org/ro/ro.owl#has_agent + + + + + http://www.obofoundry.org/ro/ro.owl#has_agent + + + + + http://www.obofoundry.org/ro/ro.owl#has_agent + + + + + http://www.obofoundry.org/ro/ro.owl#has_agent + + + + + http://www.obofoundry.org/ro/ro.owl#has_agent + + + + + http://www.obofoundry.org/ro/ro.owl#has_agent + + + + + http://www.obofoundry.org/ro/ro.owl#has_agent + + + + + http://www.obofoundry.org/ro/ro.owl#has_agent + + + + + http://www.obofoundry.org/ro/ro.owl#has_agent + + + + + http://www.obofoundry.org/ro/ro.owl#has_agent + + + + + http://www.obofoundry.org/ro/ro.owl#has_agent + + + + + http://www.obofoundry.org/ro/ro.owl#has_agent + + + + + http://www.obofoundry.org/ro/ro.owl#has_agent + + + + + http://www.obofoundry.org/ro/ro.owl#has_agent + + + + + http://www.obofoundry.org/ro/ro.owl#has_agent + + + + + http://www.obofoundry.org/ro/ro.owl#has_agent + + + + + http://www.obofoundry.org/ro/ro.owl#has_agent + + + + + http://www.obofoundry.org/ro/ro.owl#has_agent + + + + + http://www.obofoundry.org/ro/ro.owl#has_agent + + + + + http://www.obofoundry.org/ro/ro.owl#has_agent + + + + + http://www.obofoundry.org/ro/ro.owl#has_agent + + + + + http://www.obofoundry.org/ro/ro.owl#has_agent + + + + + http://www.obofoundry.org/ro/ro.owl#improper_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#improper_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#improper_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#improper_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#improper_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#improper_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#improper_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#improper_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#improper_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#improper_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#improper_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#improper_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#improper_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#improper_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#improper_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#improper_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#improper_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#improper_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#improper_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#improper_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#improper_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#improper_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#improper_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#improper_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#improper_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#improper_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#improper_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#improper_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#improper_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#improper_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#improper_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#improper_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#improper_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#improper_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#improper_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#improper_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#improper_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#integral_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#integral_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#integral_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#integral_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#integral_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#integral_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#integral_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#integral_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#integral_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#integral_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#integral_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#integral_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#integral_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#integral_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#integral_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#integral_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#integral_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#integral_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#integral_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#integral_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#integral_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#integral_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#integral_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#integral_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#integral_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#integral_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#integral_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#integral_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#integral_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#integral_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#integral_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#integral_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#integral_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#integral_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#integral_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#integral_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#integral_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#part_of + + + + + http://www.obofoundry.org/ro/ro.owl#part_of + + + + + http://www.obofoundry.org/ro/ro.owl#part_of + + + + + http://www.obofoundry.org/ro/ro.owl#part_of + + + + + http://www.obofoundry.org/ro/ro.owl#part_of + + + + + http://www.obofoundry.org/ro/ro.owl#part_of + + + + + http://www.obofoundry.org/ro/ro.owl#part_of + + + + + http://www.obofoundry.org/ro/ro.owl#part_of + + + + + http://www.obofoundry.org/ro/ro.owl#part_of + + + + + http://www.obofoundry.org/ro/ro.owl#part_of + + + + + http://www.obofoundry.org/ro/ro.owl#part_of + + + + + http://www.obofoundry.org/ro/ro.owl#part_of + + + + + http://www.obofoundry.org/ro/ro.owl#part_of + + + + + http://www.obofoundry.org/ro/ro.owl#part_of + + + + + http://www.obofoundry.org/ro/ro.owl#part_of + + + + + http://www.obofoundry.org/ro/ro.owl#part_of + + + + + http://www.obofoundry.org/ro/ro.owl#part_of + + + + + http://www.obofoundry.org/ro/ro.owl#part_of + + + + + http://www.obofoundry.org/ro/ro.owl#part_of + + + + + http://www.obofoundry.org/ro/ro.owl#part_of + + + + + http://www.obofoundry.org/ro/ro.owl#part_of + + + + + http://www.obofoundry.org/ro/ro.owl#part_of + + + + + http://www.obofoundry.org/ro/ro.owl#part_of + + + + + http://www.obofoundry.org/ro/ro.owl#part_of + + + + + http://www.obofoundry.org/ro/ro.owl#part_of + + + + + http://www.obofoundry.org/ro/ro.owl#preceded_by + + + + + http://www.obofoundry.org/ro/ro.owl#preceded_by + + + + + http://www.obofoundry.org/ro/ro.owl#preceded_by + + + + + http://www.obofoundry.org/ro/ro.owl#preceded_by + + + + + http://www.obofoundry.org/ro/ro.owl#preceded_by + + + + + http://www.obofoundry.org/ro/ro.owl#preceded_by + + + + + http://www.obofoundry.org/ro/ro.owl#preceded_by + + + + + http://www.obofoundry.org/ro/ro.owl#preceded_by + + + + + http://www.obofoundry.org/ro/ro.owl#preceded_by + + + + + http://www.obofoundry.org/ro/ro.owl#preceded_by + + + + + http://www.obofoundry.org/ro/ro.owl#preceded_by + + + + + http://www.obofoundry.org/ro/ro.owl#preceded_by + + + + + http://www.obofoundry.org/ro/ro.owl#preceded_by + + + + + http://www.obofoundry.org/ro/ro.owl#preceded_by + + + + + http://www.obofoundry.org/ro/ro.owl#preceded_by + + + + + http://www.obofoundry.org/ro/ro.owl#preceded_by + + + + + http://www.obofoundry.org/ro/ro.owl#preceded_by + + + + + http://www.obofoundry.org/ro/ro.owl#preceded_by + + + + + http://www.obofoundry.org/ro/ro.owl#preceded_by + + + + + http://www.obofoundry.org/ro/ro.owl#preceded_by + + + + + http://www.obofoundry.org/ro/ro.owl#preceded_by + + + + + http://www.obofoundry.org/ro/ro.owl#preceded_by + + + + + http://www.obofoundry.org/ro/ro.owl#preceded_by + + + + + http://www.obofoundry.org/ro/ro.owl#preceded_by + + + + + http://www.obofoundry.org/ro/ro.owl#preceded_by + + + + + http://www.obofoundry.org/ro/ro.owl#proper_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#proper_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#proper_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#proper_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#proper_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#proper_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#proper_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#proper_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#proper_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#proper_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#proper_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#proper_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#proper_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#proper_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#proper_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#proper_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#proper_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#proper_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#proper_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#proper_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#proper_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#proper_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#proper_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#proper_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#proper_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#proper_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#proper_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#proper_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#proper_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#proper_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#proper_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#proper_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#proper_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#proper_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#proper_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#proper_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#proper_part_of + + + + + http://www.obofoundry.org/ro/ro.owl#relationship + + + + + http://www.obofoundry.org/ro/ro.owl#relationship + + + + + http://www.obofoundry.org/ro/ro.owl#relationship + + + + + http://www.obofoundry.org/ro/ro.owl#relationship + + + + + http://www.obofoundry.org/ro/ro.owl#relationship + + + + + http://www.obofoundry.org/ro/ro.owl#relationship + + + + + http://www.obofoundry.org/ro/ro.owl#relationship + + + + + http://www.obofoundry.org/ro/ro.owl#relationship + + + + + http://www.obofoundry.org/ro/ro.owl#relationship + + + + + http://www.obofoundry.org/ro/ro.owl#relationship + + + + + http://www.obofoundry.org/ro/ro.owl#relationship + + + + + http://www.obofoundry.org/ro/ro.owl#relationship + + + + + http://www.obofoundry.org/ro/ro.owl#relationship + + + + + http://www.obofoundry.org/ro/ro.owl#relationship + + + + + http://www.obofoundry.org/ro/ro.owl#relationship + + + + + http://www.obofoundry.org/ro/ro.owl#relationship + + + + + http://www.obofoundry.org/ro/ro.owl#relationship + + + + + http://www.obofoundry.org/ro/ro.owl#relationship + + + + + http://www.obofoundry.org/ro/ro.owl#relationship + + + + + http://www.obofoundry.org/ro/ro.owl#relationship + + + + + http://www.obofoundry.org/ro/ro.owl#relationship + + + + + http://www.obofoundry.org/ro/ro.owl#relationship + + + + + http://www.obofoundry.org/ro/ro.owl#relationship + + + + + http://www.obofoundry.org/ro/ro.owl#relationship + + + + + http://www.obofoundry.org/ro/ro.owl#relationship + + + + + http://www.obofoundry.org/ro/ro.owl#relationship + + + + + http://www.obofoundry.org/ro/ro.owl#relationship + + + + + http://www.obofoundry.org/ro/ro.owl#relationship + + + + + http://www.obofoundry.org/ro/ro.owl#relationship + + + + + http://www.obofoundry.org/ro/ro.owl#relationship + + + + + http://www.obofoundry.org/ro/ro.owl#relationship + + + + + http://www.obofoundry.org/ro/ro.owl#relationship + + + + + http://www.obofoundry.org/ro/ro.owl#relationship + + + + + http://www.obofoundry.org/ro/ro.owl#relationship + + + + + http://www.obofoundry.org/ro/ro.owl#relationship + + + + + http://www.obofoundry.org/ro/ro.owl#relationship + + + + + http://www.obofoundry.org/ro/ro.owl#relationship + + + + + http://www.obofoundry.org/ro/ro.owl#transformation_of + + + + + http://www.obofoundry.org/ro/ro.owl#transformation_of + + + + + http://www.obofoundry.org/ro/ro.owl#transformation_of + + + + + http://www.obofoundry.org/ro/ro.owl#transformation_of + + + + + http://www.obofoundry.org/ro/ro.owl#transformation_of + + + + + http://www.obofoundry.org/ro/ro.owl#transformation_of + + + + + http://www.obofoundry.org/ro/ro.owl#transformation_of + + + + + http://www.obofoundry.org/ro/ro.owl#transformation_of + + + + + http://www.obofoundry.org/ro/ro.owl#transformation_of + + + + + http://www.obofoundry.org/ro/ro.owl#transformation_of + + + + + http://www.obofoundry.org/ro/ro.owl#transformation_of + + + + + http://www.obofoundry.org/ro/ro.owl#transformation_of + + + + + http://www.obofoundry.org/ro/ro.owl#transformation_of + + + + + http://www.obofoundry.org/ro/ro.owl#transformation_of + + + + + http://www.obofoundry.org/ro/ro.owl#transformation_of + + + + + http://www.obofoundry.org/ro/ro.owl#transformation_of + + + + + http://www.obofoundry.org/ro/ro.owl#transformation_of + + + + + http://www.obofoundry.org/ro/ro.owl#transformation_of + + + + + http://www.obofoundry.org/ro/ro.owl#transformation_of + + + + + http://www.obofoundry.org/ro/ro.owl#transformation_of + + + + + http://www.obofoundry.org/ro/ro.owl#transformation_of + + + + + http://www.obofoundry.org/ro/ro.owl#transformation_of + + + + + http://www.obofoundry.org/ro/ro.owl#transformation_of + + + + + http://www.obofoundry.org/ro/ro.owl#transformation_of + + + + + http://www.obofoundry.org/ro/ro.owl#transformation_of + + + + + http://www.obofoundry.org/ro/ro.owl#transformation_of + + + + + http://www.obofoundry.org/ro/ro.owl#transformation_of + + + + + http://www.obofoundry.org/ro/ro.owl#transformation_of + + + + + http://www.obofoundry.org/ro/ro.owl#transformation_of + + + + + http://www.obofoundry.org/ro/ro.owl#transformation_of + + + + + http://www.obofoundry.org/ro/ro.owl#transformation_of + + + + + http://www.obofoundry.org/ro/ro.owl#transformation_of + + + + + http://www.obofoundry.org/ro/ro.owl#transformation_of + + + + + http://www.obofoundry.org/ro/ro.owl#transformation_of + + + + + http://www.obofoundry.org/ro/ro.owl#transformation_of + + + + + http://www.obofoundry.org/ro/ro.owl#transformation_of + + + + + http://www.obofoundry.org/ro/ro.owl#transformation_of + + + + + rdfs:label + label + + + + skos:altLabel + The range of skos:altLabel is the class of RDF plain literals. + + + + skos:altLabel + skos:prefLabel, skos:altLabel and skos:hiddenLabel are pairwise disjoint properties. + + + + skos:altLabel + http://www.w3.org/2004/02/skos/core + + + + skos:altLabel + alternative label + + + + skos:altLabel + An alternative lexical label for a resource. + + + + skos:altLabel + Acronyms, abbreviations, spelling variants, and irregular plural/singular forms may be included among the alternative labels for a concept. Mis-spelled terms are normally included as hidden labels (see skos:hiddenLabel). + + + + skos:changeNote + http://www.w3.org/2004/02/skos/core + + + + skos:changeNote + change note + + + + skos:changeNote + A note about a modification to a concept. + + + + skos:definition + http://www.w3.org/2004/02/skos/core + + + + skos:definition + definition + + + + skos:definition + A statement or formal explanation of the meaning of a concept. + + + + skos:editorialNote + http://www.w3.org/2004/02/skos/core + + + + skos:editorialNote + editorial note + + + + skos:editorialNote + A note for an editor, translator or maintainer of the vocabulary. + + + + skos:example + http://www.w3.org/2004/02/skos/core + + + + skos:example + example + + + + skos:example + An example of the use of a concept. + + + + skos:hiddenLabel + The range of skos:hiddenLabel is the class of RDF plain literals. + + + + skos:hiddenLabel + skos:prefLabel, skos:altLabel and skos:hiddenLabel are pairwise disjoint properties. + + + + skos:hiddenLabel + http://www.w3.org/2004/02/skos/core + + + + skos:hiddenLabel + hidden label + + + + skos:hiddenLabel + A lexical label for a resource that should be hidden when generating visual displays of the resource, but should still be accessible to free text search operations. + + + + skos:historyNote + http://www.w3.org/2004/02/skos/core + + + + skos:historyNote + history note + + + + skos:historyNote + A note about the past state/use/meaning of a concept. + + + + skos:note + http://www.w3.org/2004/02/skos/core + + + + skos:note + note + + + + skos:note + A general note, for any purpose. + + + + skos:note + This property may be used directly, or as a super-property for more specific note types. + + + + skos:prefLabel + A resource has no more than one value of skos:prefLabel per language tag, and no more than one value of skos:prefLabel without language tag. + + + + skos:prefLabel + The range of skos:prefLabel is the class of RDF plain literals. + + + + skos:prefLabel + skos:prefLabel, skos:altLabel and skos:hiddenLabel are pairwise + disjoint properties. + + + + skos:prefLabel + http://www.w3.org/2004/02/skos/core + + + + skos:prefLabel + preferred label + + + + skos:prefLabel + The preferred lexical label for a resource, in a given language. + + + + skos:scopeNote + http://www.w3.org/2004/02/skos/core + + + + skos:scopeNote + scope note + + + + skos:scopeNote + A note that helps to clarify the meaning and/or the use of a concept. + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + owl:DeprecatedClass + + + + + + + diff --git a/src/test/resources/repo/input/dmto/DMTO.owl b/src/test/resources/repo/input/dmto/DMTO.owl new file mode 100644 index 0000000..b76f6aa --- /dev/null +++ b/src/test/resources/repo/input/dmto/DMTO.owl @@ -0,0 +1,171975 @@ + + + + + + + +]> + + + + + + + + + + + + + + + + + http://www.owl-ontologies.com/OntoFood.owl + http://purl.obolibrary.org/obo/DINTO.owl + http://www.w3.org/2006/time + + + Shaker El-Sappagh + + + + en + + + + + + + + DMTO is an OWL 2 ontology for creating customized treatment plans for diabetic patients. The ontology is based on BFO and OGMS. In addition, it extends the DDO ontology by adding the treatment classes and axioms to the existing diagnosis part. + + + + 2017-3-27 + + + + 1.0 + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + avarage_risk + high_risk + low_risk + moderate_risk + very_low__risk + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + insulin injection + insulin pen + insulin pump + no Insulin + other + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + day + month + week + + + + + + + + + + intermediate + poor + rich + + + + + + + + + + accepted + refused + + + + + http://bioportal.bioontology.org/ontologies/versionSubject + 2015-11-20 + + + + http://example.com/bfo-spec-label + Person:Alan Ruttenberg + + + + obo:BFO_0000001 + BFO:0000001 + + + + obo:BFO_0000001 + entity + + + + obo:BFO_0000001 + Entity + + + + obo:BFO_0000001 + Julius Caesar + + + + obo:BFO_0000001 + Verdi’s Requiem + + + + obo:BFO_0000001 + the Second World War + + + + obo:BFO_0000001 + your body mass index + + + + obo:BFO_0000001 + BFO 2 Reference: In all areas of empirical inquiry we encounter general terms of two sorts. First are general terms which refer to universals or types:animaltuberculosissurgical procedurediseaseSecond, are general terms used to refer to groups of entities which instantiate a given universal but do not correspond to the extension of any subuniversal of that universal because there is nothing intrinsic to the entities in question by virtue of which they – and only they – are counted as belonging to the given group. Examples are: animal purchased by the Emperortuberculosis diagnosed on a Wednesdaysurgical procedure performed on a patient from Stockholmperson identified as candidate for clinical trial #2056-555person who is signatory of Form 656-PPVpainting by Leonardo da VinciSuch terms, which represent what are called ‘specializations’ in [81 + + + + + obo:bfo/axiom/0000004 + + + + per discussion with Barry Smith + + + + http://www.referent-tracking.com/_RTU/papers/CeustersICbookRevised.pdf + + + obo:BFO_0000001 + Entity doesn't have a closure axiom because the subclasses don't necessarily exhaust all possibilites. For example Werner Ceusters 'portions of reality' include 4 sorts, entities (as BFO construes them), universals, configurations, and relations. It is an open question as to whether entities as construed in BFO will at some point also include these other portions of reality. See, for example, 'How to track absolutely everything' at http://www.referent-tracking.com/_RTU/papers/CeustersICbookRevised.pdf + + + + + obo:bfo/axiom/001-001 + + + obo:BFO_0000001 + An entity is anything that exists or has existed or will exist. (axiom label in BFO2 Reference: [001-001]) + + + + obo:BFO_0000001 + obo:bfo.owl + + + + obo:BFO_0000001 + entity + + + + obo:BFO_0000002 + BFO:0000002 + + + + obo:BFO_0000002 + continuant + + + + obo:BFO_0000002 + Continuant + + + + obo:BFO_0000002 + BFO 2 Reference: Continuant entities are entities which can be sliced to yield parts only along the spatial dimension, yielding for example the parts of your table which we call its legs, its top, its nails. ‘My desk stretches from the window to the door. It has spatial parts, and can be sliced (in space) in two. With respect to time, however, a thing is a continuant.’ [60, p. 240 + + + + + obo:bfo/axiom/0000007 + + + obo:BFO_0000002 + Continuant doesn't have a closure axiom because the subclasses don't necessarily exhaust all possibilites. For example, in an expansion involving bringing in some of Ceuster's other portions of reality, questions are raised as to whether universals are continuants + + + + + obo:bfo/axiom/008-002 + + + obo:BFO_0000002 + A continuant is an entity that persists, endures, or continues to exist through time while maintaining its identity. (axiom label in BFO2 Reference: [008-002]) + + + + + obo:bfo/axiom/126-001 + + + obo:BFO_0000002 + if b is a continuant and if, for some t, c has_continuant_part b at t, then c is a continuant. (axiom label in BFO2 Reference: [126-001]) + + + + + obo:bfo/axiom/009-002 + + + obo:BFO_0000002 + if b is a continuant and if, for some t, cis continuant_part of b at t, then c is a continuant. (axiom label in BFO2 Reference: [009-002]) + + + + + obo:bfo/axiom/011-002 + + + obo:BFO_0000002 + if b is a material entity, then there is some temporal interval (referred to below as a one-dimensional temporal region) during which b exists. (axiom label in BFO2 Reference: [011-002]) + + + + + obo:bfo/axiom/009-002 + + + obo:BFO_0000002 + (forall (x y) (if (and (Continuant x) (exists (t) (continuantPartOfAt y x t))) (Continuant y))) // axiom label in BFO2 CLIF: [009-002] + + + + + obo:bfo/axiom/126-001 + + + obo:BFO_0000002 + (forall (x y) (if (and (Continuant x) (exists (t) (hasContinuantPartOfAt y x t))) (Continuant y))) // axiom label in BFO2 CLIF: [126-001] + + + + + obo:bfo/axiom/008-002 + + + obo:BFO_0000002 + (forall (x) (if (Continuant x) (Entity x))) // axiom label in BFO2 CLIF: [008-002] + + + + + obo:bfo/axiom/011-002 + + + obo:BFO_0000002 + (forall (x) (if (Material Entity x) (exists (t) (and (TemporalRegion t) (existsAt x t))))) // axiom label in BFO2 CLIF: [011-002] + + + + obo:BFO_0000002 + obo:bfo.owl + + + + obo:BFO_0000002 + continuant + + + + obo:BFO_0000003 + BFO:0000003 + + + + obo:BFO_0000003 + occurrent + + + + obo:BFO_0000003 + Occurrent + + + + obo:BFO_0000003 + BFO 2 Reference: every occurrent that is not a temporal or spatiotemporal region is s-dependent on some independent continuant that is not a spatial region + + + + obo:BFO_0000003 + BFO 2 Reference: s-dependence obtains between every process and its participants in the sense that, as a matter of necessity, this process could not have existed unless these or those participants existed also. A process may have a succession of participants at different phases of its unfolding. Thus there may be different players on the field at different times during the course of a football game; but the process which is the entire game s-depends_on all of these players nonetheless. Some temporal parts of this process will s-depend_on on only some of the players. + + + + + obo:bfo/axiom/0000006 + + + + per discussion with Barry Smith + + + obo:BFO_0000003 + Occurrent doesn't have a closure axiom because the subclasses don't necessarily exhaust all possibilites. An example would be the sum of a process and the process boundary of another process. + + + + + obo:bfo/axiom/0000012 + + + obo:BFO_0000003 + Simons uses different terminology for relations of occurrents to regions: Denote the spatio-temporal location of a given occurrent e by 'spn[e]' and call this region its span. We may say an occurrent is at its span, in any larger region, and covers any smaller region. Now suppose we have fixed a frame of reference so that we can speak not merely of spatio-temporal but also of spatial regions (places) and temporal regions (times). The spread of an occurrent, (relative to a frame of reference) is the space it exactly occupies, and its spell is likewise the time it exactly occupies. We write 'spr[e]' and `spl[e]' respectively for the spread and spell of e, omitting mention of the frame. + + + + + obo:bfo/axiom/077-002 + + + obo:BFO_0000003 + An occurrent is an entity that unfolds itself in time or it is the instantaneous boundary of such an entity (for example a beginning or an ending) or it is a temporal or spatiotemporal region which such an entity occupies_temporal_region or occupies_spatiotemporal_region. (axiom label in BFO2 Reference: [077-002]) + + + + + obo:bfo/axiom/108-001 + + + obo:BFO_0000003 + Every occurrent occupies_spatiotemporal_region some spatiotemporal region. (axiom label in BFO2 Reference: [108-001]) + + + + + obo:bfo/axiom/079-001 + + + obo:BFO_0000003 + b is an occurrent entity iff b is an entity that has temporal parts. (axiom label in BFO2 Reference: [079-001]) + + + + + obo:bfo/axiom/108-001 + + + obo:BFO_0000003 + (forall (x) (if (Occurrent x) (exists (r) (and (SpatioTemporalRegion r) (occupiesSpatioTemporalRegion x r))))) // axiom label in BFO2 CLIF: [108-001] + + + + + obo:bfo/axiom/079-001 + + + obo:BFO_0000003 + (forall (x) (iff (Occurrent x) (and (Entity x) (exists (y) (temporalPartOf y x))))) // axiom label in BFO2 CLIF: [079-001] + + + + obo:BFO_0000003 + obo:bfo.owl + + + + obo:BFO_0000003 + occurrent + + + + obo:BFO_0000004 + BFO:0000004 + + + + obo:BFO_0000004 + ic + + + + obo:BFO_0000004 + IndependentContinuant + + + + obo:BFO_0000004 + a chair + + + + obo:BFO_0000004 + a heart + + + + obo:BFO_0000004 + a leg + + + + obo:BFO_0000004 + a molecule + + + + obo:BFO_0000004 + a spatial region + + + + obo:BFO_0000004 + an atom + + + + obo:BFO_0000004 + an orchestra. + + + + obo:BFO_0000004 + an organism + + + + obo:BFO_0000004 + the bottom right portion of a human torso + + + + obo:BFO_0000004 + the interior of your mouth + + + + + obo:bfo/axiom/017-002 + + + obo:BFO_0000004 + b is an independent continuant = Def. b is a continuant which is such that there is no c and no t such that b s-depends_on c at t. (axiom label in BFO2 Reference: [017-002]) + + + + + obo:bfo/axiom/134-001 + + + obo:BFO_0000004 + For any independent continuant b and any time t there is some spatial region r such that b is located_in r at t. (axiom label in BFO2 Reference: [134-001]) + + + + + obo:bfo/axiom/018-002 + + + obo:BFO_0000004 + For every independent continuant b and time t during the region of time spanned by its life, there are entities which s-depends_on b during t. (axiom label in BFO2 Reference: [018-002]) + + + + + obo:bfo/axiom/134-001 + + + obo:BFO_0000004 + (forall (x t) (if (IndependentContinuant x) (exists (r) (and (SpatialRegion r) (locatedInAt x r t))))) // axiom label in BFO2 CLIF: [134-001] + + + + + obo:bfo/axiom/018-002 + + + obo:BFO_0000004 + (forall (x t) (if (and (IndependentContinuant x) (existsAt x t)) (exists (y) (and (Entity y) (specificallyDependsOnAt y x t))))) // axiom label in BFO2 CLIF: [018-002] + + + + + obo:bfo/axiom/017-002 + + + obo:BFO_0000004 + (iff (IndependentContinuant a) (and (Continuant a) (not (exists (b t) (specificallyDependsOnAt a b t))))) // axiom label in BFO2 CLIF: [017-002] + + + + obo:BFO_0000004 + obo:bfo.owl + + + + obo:BFO_0000004 + independent continuant + + + + obo:BFO_0000006 + BFO:0000006 + + + + obo:BFO_0000006 + s-region + + + + obo:BFO_0000006 + SpatialRegion + + + + obo:BFO_0000006 + BFO 2 Reference: Spatial regions do not participate in processes. + + + + + obo:bfo/axiom/0000002 + + + + per discussion with Barry Smith + + + obo:BFO_0000006 + Spatial region doesn't have a closure axiom because the subclasses don't exhaust all possibilites. An example would be the union of a spatial point and a spatial line that doesn't overlap the point, or two spatial lines that intersect at a single point. In both cases the resultant spatial region is neither 0-dimensional, 1-dimensional, 2-dimensional, or 3-dimensional. + + + + + obo:bfo/axiom/035-001 + + + obo:BFO_0000006 + A spatial region is a continuant entity that is a continuant_part_of spaceR as defined relative to some frame R. (axiom label in BFO2 Reference: [035-001]) + + + + + obo:bfo/axiom/036-001 + + + obo:BFO_0000006 + All continuant parts of spatial regions are spatial regions. (axiom label in BFO2 Reference: [036-001]) + + + + + obo:bfo/axiom/036-001 + + + obo:BFO_0000006 + (forall (x y t) (if (and (SpatialRegion x) (continuantPartOfAt y x t)) (SpatialRegion y))) // axiom label in BFO2 CLIF: [036-001] + + + + + obo:bfo/axiom/035-001 + + + obo:BFO_0000006 + (forall (x) (if (SpatialRegion x) (Continuant x))) // axiom label in BFO2 CLIF: [035-001] + + + + obo:BFO_0000006 + obo:bfo.owl + + + + obo:BFO_0000006 + spatial region + + + + obo:BFO_0000008 + BFO:0000008 + + + + obo:BFO_0000008 + t-region + + + + obo:BFO_0000008 + TemporalRegion + + + + + obo:bfo/axiom/0000003 + + + + per discussion with Barry Smith + + + obo:BFO_0000008 + Temporal region doesn't have a closure axiom because the subclasses don't exhaust all possibilites. An example would be the mereological sum of a temporal instant and a temporal interval that doesn't overlap the instant. In this case the resultant temporal region is neither 0-dimensional nor 1-dimensional + + + + + obo:bfo/axiom/100-001 + + + obo:BFO_0000008 + A temporal region is an occurrent entity that is part of time as defined relative to some reference frame. (axiom label in BFO2 Reference: [100-001]) + + + + + obo:bfo/axiom/101-001 + + + obo:BFO_0000008 + All parts of temporal regions are temporal regions. (axiom label in BFO2 Reference: [101-001]) + + + + + obo:bfo/axiom/119-002 + + + obo:BFO_0000008 + Every temporal region t is such that t occupies_temporal_region t. (axiom label in BFO2 Reference: [119-002]) + + + + + obo:bfo/axiom/119-002 + + + obo:BFO_0000008 + (forall (r) (if (TemporalRegion r) (occupiesTemporalRegion r r))) // axiom label in BFO2 CLIF: [119-002] + + + + + obo:bfo/axiom/101-001 + + + obo:BFO_0000008 + (forall (x y) (if (and (TemporalRegion x) (occurrentPartOf y x)) (TemporalRegion y))) // axiom label in BFO2 CLIF: [101-001] + + + + + obo:bfo/axiom/100-001 + + + obo:BFO_0000008 + (forall (x) (if (TemporalRegion x) (Occurrent x))) // axiom label in BFO2 CLIF: [100-001] + + + + obo:BFO_0000008 + obo:bfo.owl + + + + obo:BFO_0000008 + temporal region + + + + obo:BFO_0000009 + BFO:0000009 + + + + obo:BFO_0000009 + 2d-s-region + + + + obo:BFO_0000009 + TwoDimensionalSpatialRegion + + + + obo:BFO_0000009 + an infinitely thin plane in space. + + + + obo:BFO_0000009 + the surface of a sphere-shaped part of space + + + + + obo:bfo/axiom/039-001 + + + obo:BFO_0000009 + A two-dimensional spatial region is a spatial region that is of two dimensions. (axiom label in BFO2 Reference: [039-001]) + + + + + obo:bfo/axiom/039-001 + + + obo:BFO_0000009 + (forall (x) (if (TwoDimensionalSpatialRegion x) (SpatialRegion x))) // axiom label in BFO2 CLIF: [039-001] + + + + obo:BFO_0000009 + obo:bfo.owl + + + + obo:BFO_0000009 + two-dimensional spatial region + + + + obo:BFO_0000011 + BFO:0000011 + + + + obo:BFO_0000011 + st-region + + + + obo:BFO_0000011 + SpatiotemporalRegion + + + + obo:BFO_0000011 + the spatiotemporal region occupied by a human life + + + + obo:BFO_0000011 + the spatiotemporal region occupied by a process of cellular meiosis. + + + + obo:BFO_0000011 + the spatiotemporal region occupied by the development of a cancer tumor + + + + + obo:bfo/axiom/095-001 + + + obo:BFO_0000011 + A spatiotemporal region is an occurrent entity that is part of spacetime. (axiom label in BFO2 Reference: [095-001]) + + + + + obo:bfo/axiom/096-001 + + + obo:BFO_0000011 + All parts of spatiotemporal regions are spatiotemporal regions. (axiom label in BFO2 Reference: [096-001]) + + + + + obo:bfo/axiom/099-001 + + + obo:BFO_0000011 + Each spatiotemporal region at any time t projects_onto some spatial region at t. (axiom label in BFO2 Reference: [099-001]) + + + + + obo:bfo/axiom/098-001 + + + obo:BFO_0000011 + Each spatiotemporal region projects_onto some temporal region. (axiom label in BFO2 Reference: [098-001]) + + + + obo:BFO_0000011 + Every spatiotemporal region occupies_spatiotemporal_region itself. + + + + + obo:bfo/axiom/107-002 + + + obo:BFO_0000011 + Every spatiotemporal region s is such that s occupies_spatiotemporal_region s. (axiom label in BFO2 Reference: [107-002]) + + + + + obo:bfo/axiom/107-002 + + + obo:BFO_0000011 + (forall (r) (if (SpatioTemporalRegion r) (occupiesSpatioTemporalRegion r r))) // axiom label in BFO2 CLIF: [107-002] + + + + + obo:bfo/axiom/099-001 + + + obo:BFO_0000011 + (forall (x t) (if (SpatioTemporalRegion x) (exists (y) (and (SpatialRegion y) (spatiallyProjectsOntoAt x y t))))) // axiom label in BFO2 CLIF: [099-001] + + + + + obo:bfo/axiom/096-001 + + + obo:BFO_0000011 + (forall (x y) (if (and (SpatioTemporalRegion x) (occurrentPartOf y x)) (SpatioTemporalRegion y))) // axiom label in BFO2 CLIF: [096-001] + + + + + obo:bfo/axiom/095-001 + + + obo:BFO_0000011 + (forall (x) (if (SpatioTemporalRegion x) (Occurrent x))) // axiom label in BFO2 CLIF: [095-001] + + + + + obo:bfo/axiom/098-001 + + + obo:BFO_0000011 + (forall (x) (if (SpatioTemporalRegion x) (exists (y) (and (TemporalRegion y) (temporallyProjectsOnto x y))))) // axiom label in BFO2 CLIF: [098-001] + + + + obo:BFO_0000011 + obo:bfo.owl + + + + obo:BFO_0000011 + spatiotemporal region + + + + obo:BFO_0000015 + BFO:0000015 + + + + obo:BFO_0000015 + process + + + + obo:BFO_0000015 + Process + + + + obo:BFO_0000015 + a process of cell-division, \ a beating of the heart + + + + obo:BFO_0000015 + a process of meiosis + + + + obo:BFO_0000015 + a process of sleeping + + + + obo:BFO_0000015 + the course of a disease + + + + obo:BFO_0000015 + the flight of a bird + + + + obo:BFO_0000015 + the life of an organism + + + + obo:BFO_0000015 + your process of aging. + + + + + obo:bfo/axiom/083-003 + + + obo:BFO_0000015 + p is a process = Def. p is an occurrent that has temporal proper parts and for some time t, p s-depends_on some material entity at t. (axiom label in BFO2 Reference: [083-003]) + + + + obo:BFO_0000015 + BFO 2 Reference: The realm of occurrents is less pervasively marked by the presence of natural units than is the case in the realm of independent continuants. Thus there is here no counterpart of ‘object’. In BFO 1.0 ‘process’ served as such a counterpart. In BFO 2.0 ‘process’ is, rather, the occurrent counterpart of ‘material entity’. Those natural – as contrasted with engineered, which here means: deliberately executed – units which do exist in the realm of occurrents are typically either parasitic on the existence of natural units on the continuant side, or they are fiat in nature. Thus we can count lives; we can count football games; we can count chemical reactions performed in experiments or in chemical manufacturing. We cannot count the processes taking place, for instance, in an episode of insect mating behavior.Even where natural units are identifiable, for example cycles in a cyclical process such as the beating of a heart or an organism’s sleep/wake cycle, the processes in question form a sequence with no discontinuities (temporal gaps) of the sort that we find for instance where billiard balls or zebrafish or planets are separated by clear spatial gaps. Lives of organisms are process units, but they too unfold in a continuous series from other, prior processes such as fertilization, and they unfold in turn in continuous series of post-life processes such as post-mortem decay. Clear examples of boundaries of processes are almost always of the fiat sort (midnight, a time of death as declared in an operating theater or on a death certificate, the initiation of a state of war) + + + + + obo:bfo/axiom/083-003 + + + obo:BFO_0000015 + (iff (Process a) (and (Occurrent a) (exists (b) (properTemporalPartOf b a)) (exists (c t) (and (MaterialEntity c) (specificallyDependsOnAt a c t))))) // axiom label in BFO2 CLIF: [083-003] + + + + obo:BFO_0000015 + obo:bfo.owl + + + + obo:BFO_0000015 + process + + + + obo:BFO_0000016 + BFO:0000016 + + + + obo:BFO_0000016 + disposition + + + + obo:BFO_0000016 + Disposition + + + + obo:BFO_0000016 + an atom of element X has the disposition to decay to an atom of element Y + + + + obo:BFO_0000016 + certain people have a predisposition to colon cancer + + + + obo:BFO_0000016 + children are innately disposed to categorize objects in certain ways. + + + + obo:BFO_0000016 + the cell wall is disposed to filter chemicals in endocytosis and exocytosis + + + + obo:BFO_0000016 + BFO 2 Reference: Dispositions exist along a strength continuum. Weaker forms of disposition are realized in only a fraction of triggering cases. These forms occur in a significant number of cases of a similar type. + + + + + obo:bfo/axiom/062-002 + + + obo:BFO_0000016 + b is a disposition means: b is a realizable entity & b’s bearer is some material entity & b is such that if it ceases to exist, then its bearer is physically changed, & b’s realization occurs when and because this bearer is in some special physical circumstances, & this realization occurs in virtue of the bearer’s physical make-up. (axiom label in BFO2 Reference: [062-002]) + + + + + obo:bfo/axiom/063-002 + + + obo:BFO_0000016 + If b is a realizable entity then for all t at which b exists, b s-depends_on some material entity at t. (axiom label in BFO2 Reference: [063-002]) + + + + + obo:bfo/axiom/063-002 + + + obo:BFO_0000016 + (forall (x t) (if (and (RealizableEntity x) (existsAt x t)) (exists (y) (and (MaterialEntity y) (specificallyDepends x y t))))) // axiom label in BFO2 CLIF: [063-002] + + + + + obo:bfo/axiom/062-002 + + + obo:BFO_0000016 + (forall (x) (if (Disposition x) (and (RealizableEntity x) (exists (y) (and (MaterialEntity y) (bearerOfAt x y t)))))) // axiom label in BFO2 CLIF: [062-002] + + + + obo:BFO_0000016 + obo:bfo.owl + + + + obo:BFO_0000016 + disposition + + + + obo:BFO_0000017 + BFO:0000017 + + + + obo:BFO_0000017 + realizable + + + + obo:BFO_0000017 + RealizableEntity + + + + obo:BFO_0000017 + the disposition of this piece of metal to conduct electricity. + + + + obo:BFO_0000017 + the disposition of your blood to coagulate + + + + obo:BFO_0000017 + the function of your reproductive organs + + + + obo:BFO_0000017 + the role of being a doctor + + + + obo:BFO_0000017 + the role of this boundary to delineate where Utah and Colorado meet + + + + + obo:bfo/axiom/058-002 + + + obo:BFO_0000017 + To say that b is a realizable entity is to say that b is a specifically dependent continuant that inheres in some independent continuant which is not a spatial region and is of a type instances of which are realized in processes of a correlated type. (axiom label in BFO2 Reference: [058-002]) + + + + + obo:bfo/axiom/060-002 + + + obo:BFO_0000017 + All realizable dependent continuants have independent continuants that are not spatial regions as their bearers. (axiom label in BFO2 Reference: [060-002]) + + + + + obo:bfo/axiom/060-002 + + + obo:BFO_0000017 + (forall (x t) (if (RealizableEntity x) (exists (y) (and (IndependentContinuant y) (not (SpatialRegion y)) (bearerOfAt y x t))))) // axiom label in BFO2 CLIF: [060-002] + + + + + obo:bfo/axiom/058-002 + + + obo:BFO_0000017 + (forall (x) (if (RealizableEntity x) (and (SpecificallyDependentContinuant x) (exists (y) (and (IndependentContinuant y) (not (SpatialRegion y)) (inheresIn x y)))))) // axiom label in BFO2 CLIF: [058-002] + + + + obo:BFO_0000017 + obo:bfo.owl + + + + obo:BFO_0000017 + realizable entity + + + + obo:BFO_0000018 + BFO:0000018 + + + + obo:BFO_0000018 + 0d-s-region + + + + obo:BFO_0000018 + ZeroDimensionalSpatialRegion + + + + + obo:bfo/axiom/037-001 + + + obo:BFO_0000018 + A zero-dimensional spatial region is a point in space. (axiom label in BFO2 Reference: [037-001]) + + + + + obo:bfo/axiom/037-001 + + + obo:BFO_0000018 + (forall (x) (if (ZeroDimensionalSpatialRegion x) (SpatialRegion x))) // axiom label in BFO2 CLIF: [037-001] + + + + obo:BFO_0000018 + obo:bfo.owl + + + + obo:BFO_0000018 + zero-dimensional spatial region + + + + obo:BFO_0000019 + BFO:0000019 + + + + obo:BFO_0000019 + quality + + + + obo:BFO_0000019 + Quality + + + + obo:BFO_0000019 + the ambient temperature of this portion of air + + + + obo:BFO_0000019 + the color of a tomato + + + + obo:BFO_0000019 + the length of the circumference of your waist + + + + obo:BFO_0000019 + the mass of this piece of gold. + + + + obo:BFO_0000019 + the shape of your nose + + + + obo:BFO_0000019 + the shape of your nostril + + + + + obo:bfo/axiom/055-001 + + + obo:BFO_0000019 + a quality is a specifically dependent continuant that, in contrast to roles and dispositions, does not require any further process in order to be realized. (axiom label in BFO2 Reference: [055-001]) + + + + + obo:bfo/axiom/105-001 + + + obo:BFO_0000019 + If an entity is a quality at any time that it exists, then it is a quality at every time that it exists. (axiom label in BFO2 Reference: [105-001]) + + + + + obo:bfo/axiom/055-001 + + + obo:BFO_0000019 + (forall (x) (if (Quality x) (SpecificallyDependentContinuant x))) // axiom label in BFO2 CLIF: [055-001] + + + + + obo:bfo/axiom/105-001 + + + obo:BFO_0000019 + (forall (x) (if (exists (t) (and (existsAt x t) (Quality x))) (forall (t_1) (if (existsAt x t_1) (Quality x))))) // axiom label in BFO2 CLIF: [105-001] + + + + obo:BFO_0000019 + obo:bfo.owl + + + + obo:BFO_0000019 + quality + + + + obo:BFO_0000020 + BFO:0000020 + + + + obo:BFO_0000020 + sdc + + + + obo:BFO_0000020 + SpecificallyDependentContinuant + + + + obo:BFO_0000020 + Reciprocal specifically dependent continuants: the function of this key to open this lock and the mutually dependent disposition of this lock: to be opened by this key + + + + obo:BFO_0000020 + of one-sided specifically dependent continuants: the mass of this tomato + + + + obo:BFO_0000020 + of relational dependent continuants (multiple bearers): John’s love for Mary, the ownership relation between John and this statue, the relation of authority between John and his subordinates. + + + + obo:BFO_0000020 + the disposition of this fish to decay + + + + obo:BFO_0000020 + the function of this heart: to pump blood + + + + obo:BFO_0000020 + the mutual dependence of proton donors and acceptors in chemical reactions [79 + + + + obo:BFO_0000020 + the mutual dependence of the role predator and the role prey as played by two organisms in a given interaction + + + + obo:BFO_0000020 + the pink color of a medium rare piece of grilled filet mignon at its center + + + + obo:BFO_0000020 + the role of being a doctor + + + + obo:BFO_0000020 + the shape of this hole. + + + + obo:BFO_0000020 + the smell of this portion of mozzarella + + + + + obo:bfo/axiom/050-003 + + + obo:BFO_0000020 + b is a specifically dependent continuant = Def. b is a continuant & there is some independent continuant c which is not a spatial region and which is such that b s-depends_on c at every time t during the course of b’s existence. (axiom label in BFO2 Reference: [050-003]) + + + + + obo:bfo/axiom/0000005 + + + + per discussion with Barry Smith + + + obo:BFO_0000020 + Specifically dependent continuant doesn't have a closure axiom because the subclasses don't necessarily exhaust all possibilites. We're not sure what else will develop here, but for example there are questions such as what are promises, obligation, etc. + + + + + obo:bfo/axiom/050-003 + + + obo:BFO_0000020 + (iff (SpecificallyDependentContinuant a) (and (Continuant a) (forall (t) (if (existsAt a t) (exists (b) (and (IndependentContinuant b) (not (SpatialRegion b)) (specificallyDependsOnAt a b t))))))) // axiom label in BFO2 CLIF: [050-003] + + + + obo:BFO_0000020 + obo:bfo.owl + + + + obo:BFO_0000020 + specifically dependent continuant + + + + obo:BFO_0000023 + BFO:0000023 + + + + obo:BFO_0000023 + role + + + + obo:BFO_0000023 + Role + + + + obo:BFO_0000023 + John’s role of husband to Mary is dependent on Mary’s role of wife to John, and both are dependent on the object aggregate comprising John and Mary as member parts joined together through the relational quality of being married. + + + + obo:BFO_0000023 + the priest role + + + + obo:BFO_0000023 + the role of a boundary to demarcate two neighboring administrative territories + + + + obo:BFO_0000023 + the role of a building in serving as a military target + + + + obo:BFO_0000023 + the role of a stone in marking a property boundary + + + + obo:BFO_0000023 + the role of subject in a clinical trial + + + + obo:BFO_0000023 + the student role + + + + obo:BFO_0000023 + BFO 2 Reference: One major family of examples of non-rigid universals involves roles, and ontologies developed for corresponding administrative purposes may consist entirely of representatives of entities of this sort. Thus ‘professor’, defined as follows,b instance_of professor at t =Def. there is some c, c instance_of professor role & c inheres_in b at t.denotes a non-rigid universal and so also do ‘nurse’, ‘student’, ‘colonel’, ‘taxpayer’, and so forth. (These terms are all, in the jargon of philosophy, phase sortals.) By using role terms in definitions, we can create a BFO conformant treatment of such entities drawing on the fact that, while an instance of professor may be simultaneously an instance of trade union member, no instance of the type professor role is also (at any time) an instance of the type trade union member role (any more than any instance of the type color is at any time an instance of the type length).If an ontology of employment positions should be defined in terms of roles following the above pattern, this enables the ontology to do justice to the fact that individuals instantiate the corresponding universals – professor, sergeant, nurse – only during certain phases in their lives. + + + + + obo:bfo/axiom/061-001 + + + obo:BFO_0000023 + b is a role means: b is a realizable entity & b exists because there is some single bearer that is in some special physical, social, or institutional set of circumstances in which this bearer does not have to be& b is not such that, if it ceases to exist, then the physical make-up of the bearer is thereby changed. (axiom label in BFO2 Reference: [061-001]) + + + + + obo:bfo/axiom/061-001 + + + obo:BFO_0000023 + (forall (x) (if (Role x) (RealizableEntity x))) // axiom label in BFO2 CLIF: [061-001] + + + + obo:BFO_0000023 + obo:bfo.owl + + + + obo:BFO_0000023 + role + + + + obo:BFO_0000024 + BFO:0000024 + + + + obo:BFO_0000024 + fiat-object-part + + + + obo:BFO_0000024 + FiatObjectPart + + + + obo:BFO_0000024 + or with divisions drawn by cognitive subjects for practical reasons, such as the division of a cake (before slicing) into (what will become) slices (and thus member parts of an object aggregate). However, this does not mean that fiat object parts are dependent for their existence on divisions or delineations effected by cognitive subjects. If, for example, it is correct to conceive geological layers of the Earth as fiat object parts of the Earth, then even though these layers were first delineated in recent times, still existed long before such delineation and what holds of these layers (for example that the oldest layers are also the lowest layers) did not begin to hold because of our acts of delineation.Treatment of material entity in BFOExamples viewed by some as problematic cases for the trichotomy of fiat object part, object, and object aggregate include: a mussel on (and attached to) a rock, a slime mold, a pizza, a cloud, a galaxy, a railway train with engine and multiple carriages, a clonal stand of quaking aspen, a bacterial community (biofilm), a broken femur. Note that, as Aristotle already clearly recognized, such problematic cases – which lie at or near the penumbra of instances defined by the categories in question – need not invalidate these categories. The existence of grey objects does not prove that there are not objects which are black and objects which are white; the existence of mules does not prove that there are not objects which are donkeys and objects which are horses. It does, however, show that the examples in question need to be addressed carefully in order to show how they can be fitted into the proposed scheme, for example by recognizing additional subdivisions [29 + + + + obo:BFO_0000024 + the FMA:regional parts of an intact human body. + + + + obo:BFO_0000024 + the Western hemisphere of the Earth + + + + obo:BFO_0000024 + the division of the brain into regions + + + + obo:BFO_0000024 + the division of the planet into hemispheres + + + + obo:BFO_0000024 + the dorsal and ventral surfaces of the body + + + + obo:BFO_0000024 + the upper and lower lobes of the left lung + + + + obo:BFO_0000024 + BFO 2 Reference: Most examples of fiat object parts are associated with theoretically drawn divisions + + + + + obo:bfo/axiom/027-004 + + + obo:BFO_0000024 + b is a fiat object part = Def. b is a material entity which is such that for all times t, if b exists at t then there is some object c such that b proper continuant_part of c at t and c is demarcated from the remainder of c by a two-dimensional continuant fiat boundary. (axiom label in BFO2 Reference: [027-004]) + + + + + obo:bfo/axiom/027-004 + + + obo:BFO_0000024 + (forall (x) (if (FiatObjectPart x) (and (MaterialEntity x) (forall (t) (if (existsAt x t) (exists (y) (and (Object y) (properContinuantPartOfAt x y t)))))))) // axiom label in BFO2 CLIF: [027-004] + + + + obo:BFO_0000024 + obo:bfo.owl + + + + obo:BFO_0000024 + fiat object part + + + + obo:BFO_0000026 + BFO:0000026 + + + + obo:BFO_0000026 + 1d-s-region + + + + obo:BFO_0000026 + OneDimensionalSpatialRegion + + + + obo:BFO_0000026 + an edge of a cube-shaped portion of space. + + + + + obo:bfo/axiom/038-001 + + + obo:BFO_0000026 + A one-dimensional spatial region is a line or aggregate of lines stretching from one point in space to another. (axiom label in BFO2 Reference: [038-001]) + + + + + obo:bfo/axiom/038-001 + + + obo:BFO_0000026 + (forall (x) (if (OneDimensionalSpatialRegion x) (SpatialRegion x))) // axiom label in BFO2 CLIF: [038-001] + + + + obo:BFO_0000026 + obo:bfo.owl + + + + obo:BFO_0000026 + one-dimensional spatial region + + + + obo:BFO_0000027 + BFO:0000027 + + + + obo:BFO_0000027 + object-aggregate + + + + obo:BFO_0000027 + ObjectAggregate + + + + obo:BFO_0000027 + a collection of cells in a blood biobank. + + + + obo:BFO_0000027 + a swarm of bees is an aggregate of members who are linked together through natural bonds + + + + obo:BFO_0000027 + a symphony orchestra + + + + obo:BFO_0000027 + an organization is an aggregate whose member parts have roles of specific types (for example in a jazz band, a chess club, a football team) + + + + obo:BFO_0000027 + defined by fiat: the aggregate of members of an organization + + + + obo:BFO_0000027 + defined through physical attachment: the aggregate of atoms in a lump of granite + + + + obo:BFO_0000027 + defined through physical containment: the aggregate of molecules of carbon dioxide in a sealed container + + + + obo:BFO_0000027 + defined via attributive delimitations such as: the patients in this hospital + + + + obo:BFO_0000027 + the aggregate of bearings in a constant velocity axle joint + + + + obo:BFO_0000027 + the aggregate of blood cells in your body + + + + obo:BFO_0000027 + the nitrogen atoms in the atmosphere + + + + obo:BFO_0000027 + the restaurants in Palo Alto + + + + obo:BFO_0000027 + your collection of Meissen ceramic plates. + + + + + obo:bfo/axiom/0000011 + + + obo:BFO_0000027 + An entity a is an object aggregate if and only if there is a mutually exhaustive and pairwise disjoint partition of a into objects + + + + + obo:bfo/axiom/0000301 + + + obo:BFO_0000027 + An entity a is an object aggregate if and only if there is a mutually exhaustive and pairwise disjoint partition of a into objects + + + + obo:BFO_0000027 + BFO 2 Reference: object aggregates may gain and lose parts while remaining numerically identical (one and the same individual) over time. This holds both for aggregates whose membership is determined naturally (the aggregate of cells in your body) and aggregates determined by fiat (a baseball team, a congressional committee). + + + + + obo:bfo/axiom/0000300 + + + obo:BFO_0000027 + ISBN:978-3-938793-98-5pp124-158#Thomas Bittner and Barry Smith, 'A Theory of Granular Partitions', in K. Munn and B. Smith (eds.), Applied Ontology: An Introduction, Frankfurt/Lancaster: ontos, 2008, 125-158. + + + + + obo:bfo/axiom/025-004 + + + obo:BFO_0000027 + b is an object aggregate means: b is a material entity consisting exactly of a plurality of objects as member_parts at all times at which b exists. (axiom label in BFO2 Reference: [025-004]) + + + + + obo:bfo/axiom/025-004 + + + obo:BFO_0000027 + (forall (x) (if (ObjectAggregate x) (and (MaterialEntity x) (forall (t) (if (existsAt x t) (exists (y z) (and (Object y) (Object z) (memberPartOfAt y x t) (memberPartOfAt z x t) (not (= y z)))))) (not (exists (w t_1) (and (memberPartOfAt w x t_1) (not (Object w)))))))) // axiom label in BFO2 CLIF: [025-004] + + + + obo:BFO_0000027 + obo:bfo.owl + + + + obo:BFO_0000027 + object aggregate + + + + obo:BFO_0000028 + BFO:0000028 + + + + obo:BFO_0000028 + 3d-s-region + + + + obo:BFO_0000028 + ThreeDimensionalSpatialRegion + + + + obo:BFO_0000028 + a cube-shaped region of space + + + + obo:BFO_0000028 + a sphere-shaped region of space, + + + + + obo:bfo/axiom/040-001 + + + obo:BFO_0000028 + A three-dimensional spatial region is a spatial region that is of three dimensions. (axiom label in BFO2 Reference: [040-001]) + + + + + obo:bfo/axiom/040-001 + + + obo:BFO_0000028 + (forall (x) (if (ThreeDimensionalSpatialRegion x) (SpatialRegion x))) // axiom label in BFO2 CLIF: [040-001] + + + + obo:BFO_0000028 + obo:bfo.owl + + + + obo:BFO_0000028 + three-dimensional spatial region + + + + obo:BFO_0000029 + BFO:0000029 + + + + obo:BFO_0000029 + site + + + + obo:BFO_0000029 + Site + + + + obo:BFO_0000029 + Manhattan Canyon) + + + + obo:BFO_0000029 + a hole in the interior of a portion of cheese + + + + obo:BFO_0000029 + a rabbit hole + + + + obo:BFO_0000029 + an air traffic control region defined in the airspace above an airport + + + + obo:BFO_0000029 + the Grand Canyon + + + + obo:BFO_0000029 + the Piazza San Marco + + + + obo:BFO_0000029 + the cockpit of an aircraft + + + + obo:BFO_0000029 + the hold of a ship + + + + obo:BFO_0000029 + the interior of a kangaroo pouch + + + + obo:BFO_0000029 + the interior of the trunk of your car + + + + obo:BFO_0000029 + the interior of your bedroom + + + + obo:BFO_0000029 + the interior of your office + + + + obo:BFO_0000029 + the interior of your refrigerator + + + + obo:BFO_0000029 + the lumen of your gut + + + + obo:BFO_0000029 + your left nostril (a fiat part – the opening – of your left nasal cavity) + + + + + obo:bfo/axiom/034-002 + + + obo:BFO_0000029 + b is a site means: b is a three-dimensional immaterial entity that is (partially or wholly) bounded by a material entity or it is a three-dimensional immaterial part thereof. (axiom label in BFO2 Reference: [034-002]) + + + + + obo:bfo/axiom/034-002 + + + obo:BFO_0000029 + (forall (x) (if (Site x) (ImmaterialEntity x))) // axiom label in BFO2 CLIF: [034-002] + + + + obo:BFO_0000029 + obo:bfo.owl + + + + obo:BFO_0000029 + site + + + + obo:BFO_0000030 + BFO:0000030 + + + + obo:BFO_0000030 + object + + + + obo:BFO_0000030 + Object + + + + obo:BFO_0000030 + atom + + + + obo:BFO_0000030 + cell + + + + obo:BFO_0000030 + cells and organisms + + + + obo:BFO_0000030 + engineered artifacts + + + + obo:BFO_0000030 + grain of sand + + + + obo:BFO_0000030 + molecule + + + + obo:BFO_0000030 + organelle + + + + obo:BFO_0000030 + organism + + + + obo:BFO_0000030 + planet + + + + obo:BFO_0000030 + solid portions of matter + + + + obo:BFO_0000030 + star + + + + obo:BFO_0000030 + BFO 2 Reference: BFO rests on the presupposition that at multiple micro-, meso- and macroscopic scales reality exhibits certain stable, spatially separated or separable material units, combined or combinable into aggregates of various sorts (for example organisms into what are called ‘populations’). Such units play a central role in almost all domains of natural science from particle physics to cosmology. Many scientific laws govern the units in question, employing general terms (such as ‘molecule’ or ‘planet’) referring to the types and subtypes of units, and also to the types and subtypes of the processes through which such units develop and interact. The division of reality into such natural units is at the heart of biological science, as also is the fact that these units may form higher-level units (as cells form multicellular organisms) and that they may also form aggregates of units, for example as cells form portions of tissue and organs form families, herds, breeds, species, and so on. At the same time, the division of certain portions of reality into engineered units (manufactured artifacts) is the basis of modern industrial technology, which rests on the distributed mass production of engineered parts through division of labor and on their assembly into larger, compound units such as cars and laptops. The division of portions of reality into units is one starting point for the phenomenon of counting. + + + + obo:BFO_0000030 + BFO 2 Reference: Each object is such that there are entities of which we can assert unproblematically that they lie in its interior, and other entities of which we can assert unproblematically that they lie in its exterior. This may not be so for entities lying at or near the boundary between the interior and exterior. This means that two objects – for example the two cells depicted in Figure 3 – may be such that there are material entities crossing their boundaries which belong determinately to neither cell. Something similar obtains in certain cases of conjoined twins (see below). + + + + obo:BFO_0000030 + BFO 2 Reference: To say that b is causally unified means: b is a material entity which is such that its material parts are tied together in such a way that, in environments typical for entities of the type in question,if c, a continuant part of b that is in the interior of b at t, is larger than a certain threshold size (which will be determined differently from case to case, depending on factors such as porosity of external cover) and is moved in space to be at t at a location on the exterior of the spatial region that had been occupied by b at t, then either b’s other parts will be moved in coordinated fashion or b will be damaged (be affected, for example, by breakage or tearing) in the interval between t and t.causal changes in one part of b can have consequences for other parts of b without the mediation of any entity that lies on the exterior of b. Material entities with no proper material parts would satisfy these conditions trivially. Candidate examples of types of causal unity for material entities of more complex sorts are as follows (this is not intended to be an exhaustive list):CU1: Causal unity via physical coveringHere the parts in the interior of the unified entity are combined together causally through a common membrane or other physical covering\. The latter points outwards toward and may serve a protective function in relation to what lies on the exterior of the entity [13, 47 + + + + obo:BFO_0000030 + BFO 2 Reference: an object is a maximal causally unified material entity + + + + obo:BFO_0000030 + BFO 2 Reference: ‘objects’ are sometimes referred to as ‘grains’ [74 + + + + + obo:bfo/axiom/024-001 + + + obo:BFO_0000030 + b is an object means: b is a material entity which manifests causal unity of one or other of the types CUn listed above & is of a type (a material universal) instances of which are maximal relative to this criterion of causal unity. (axiom label in BFO2 Reference: [024-001]) + + + + obo:BFO_0000030 + obo:bfo.owl + + + + obo:BFO_0000030 + object + + + + obo:BFO_0000031 + BFO:0000031 + + + + obo:BFO_0000031 + gdc + + + + obo:BFO_0000031 + GenericallyDependentContinuant + + + + obo:BFO_0000031 + The entries in your database are patterns instantiated as quality instances in your hard drive. The database itself is an aggregate of such patterns. When you create the database you create a particular instance of the generically dependent continuant type database. Each entry in the database is an instance of the generically dependent continuant type IAO: information content entity. + + + + obo:BFO_0000031 + the pdf file on your laptop, the pdf file that is a copy thereof on my laptop + + + + obo:BFO_0000031 + the sequence of this protein molecule; the sequence that is a copy thereof in that protein molecule. + + + + + obo:bfo/axiom/074-001 + + + obo:BFO_0000031 + b is a generically dependent continuant = Def. b is a continuant that g-depends_on one or more other entities. (axiom label in BFO2 Reference: [074-001]) + + + + + obo:bfo/axiom/074-001 + + + obo:BFO_0000031 + (iff (GenericallyDependentContinuant a) (and (Continuant a) (exists (b t) (genericallyDependsOnAt a b t)))) // axiom label in BFO2 CLIF: [074-001] + + + + obo:BFO_0000031 + obo:bfo.owl + + + + obo:BFO_0000031 + generically dependent continuant + + + + obo:BFO_0000034 + BFO:0000034 + + + + obo:BFO_0000034 + function + + + + obo:BFO_0000034 + Function + + + + obo:BFO_0000034 + the function of a hammer to drive in nails + + + + obo:BFO_0000034 + the function of a heart pacemaker to regulate the beating of a heart through electricity + + + + obo:BFO_0000034 + the function of amylase in saliva to break down starch into sugar + + + + obo:BFO_0000034 + BFO 2 Reference: In the past, we have distinguished two varieties of function, artifactual function and biological function. These are not asserted subtypes of BFO:function however, since the same function – for example: to pump, to transport – can exist both in artifacts and in biological entities. The asserted subtypes of function that would be needed in order to yield a separate monoheirarchy are not artifactual function, biological function, etc., but rather transporting function, pumping function, etc. + + + + + obo:bfo/axiom/064-001 + + + obo:BFO_0000034 + A function is a disposition that exists in virtue of the bearer’s physical make-up and this physical make-up is something the bearer possesses because it came into being, either through evolution (in the case of natural biological entities) or through intentional design (in the case of artifacts), in order to realize processes of a certain sort. (axiom label in BFO2 Reference: [064-001]) + + + + + obo:bfo/axiom/064-001 + + + obo:BFO_0000034 + (forall (x) (if (Function x) (Disposition x))) // axiom label in BFO2 CLIF: [064-001] + + + + obo:BFO_0000034 + obo:bfo.owl + + + + obo:BFO_0000034 + function + + + + obo:BFO_0000035 + BFO:0000035 + + + + obo:BFO_0000035 + p-boundary + + + + obo:BFO_0000035 + ProcessBoundary + + + + obo:BFO_0000035 + the boundary between the 2nd and 3rd year of your life. + + + + + obo:bfo/axiom/084-001 + + + obo:BFO_0000035 + p is a process boundary =Def. p is a temporal part of a process & p has no proper temporal parts. (axiom label in BFO2 Reference: [084-001]) + + + + + obo:bfo/axiom/085-002 + + + obo:BFO_0000035 + Every process boundary occupies_temporal_region a zero-dimensional temporal region. (axiom label in BFO2 Reference: [085-002]) + + + + + obo:bfo/axiom/085-002 + + + obo:BFO_0000035 + (forall (x) (if (ProcessBoundary x) (exists (y) (and (ZeroDimensionalTemporalRegion y) (occupiesTemporalRegion x y))))) // axiom label in BFO2 CLIF: [085-002] + + + + + obo:bfo/axiom/084-001 + + + obo:BFO_0000035 + (iff (ProcessBoundary a) (exists (p) (and (Process p) (temporalPartOf a p) (not (exists (b) (properTemporalPartOf b a)))))) // axiom label in BFO2 CLIF: [084-001] + + + + obo:BFO_0000035 + obo:bfo.owl + + + + obo:BFO_0000035 + process boundary + + + + obo:BFO_0000038 + BFO:0000038 + + + + obo:BFO_0000038 + 1d-t-region + + + + obo:BFO_0000038 + OneDimensionalTemporalRegion + + + + obo:BFO_0000038 + the temporal region during which a process occurs. + + + + obo:BFO_0000038 + BFO 2 Reference: A temporal interval is a special kind of one-dimensional temporal region, namely one that is self-connected (is without gaps or breaks). + + + + + obo:bfo/axiom/103-001 + + + obo:BFO_0000038 + A one-dimensional temporal region is a temporal region that is extended. (axiom label in BFO2 Reference: [103-001]) + + + + + obo:bfo/axiom/103-001 + + + obo:BFO_0000038 + (forall (x) (if (OneDimensionalTemporalRegion x) (TemporalRegion x))) // axiom label in BFO2 CLIF: [103-001] + + + + obo:BFO_0000038 + obo:bfo.owl + + + + obo:BFO_0000038 + one-dimensional temporal region + + + + obo:BFO_0000040 + BFO:0000040 + + + + obo:BFO_0000040 + material + + + + obo:BFO_0000040 + MaterialEntity + + + + obo:BFO_0000040 + a flame + + + + obo:BFO_0000040 + a forest fire + + + + obo:BFO_0000040 + a human being + + + + obo:BFO_0000040 + a hurricane + + + + obo:BFO_0000040 + a photon + + + + obo:BFO_0000040 + a puff of smoke + + + + obo:BFO_0000040 + a sea wave + + + + obo:BFO_0000040 + a tornado + + + + obo:BFO_0000040 + an aggregate of human beings. + + + + obo:BFO_0000040 + an energy wave + + + + obo:BFO_0000040 + an epidemic + + + + obo:BFO_0000040 + the undetached arm of a human being + + + + obo:BFO_0000040 + BFO 2 Reference: Material entities (continuants) can preserve their identity even while gaining and losing material parts. Continuants are contrasted with occurrents, which unfold themselves in successive temporal parts or phases [60 + + + + obo:BFO_0000040 + BFO 2 Reference: Object, Fiat Object Part and Object Aggregate are not intended to be exhaustive of Material Entity. Users are invited to propose new subcategories of Material Entity. + + + + obo:BFO_0000040 + BFO 2 Reference: ‘Matter’ is intended to encompass both mass and energy (we will address the ontological treatment of portions of energy in a later version of BFO). A portion of matter is anything that includes elementary particles among its proper or improper parts: quarks and leptons, including electrons, as the smallest particles thus far discovered; baryons (including protons and neutrons) at a higher level of granularity; atoms and molecules at still higher levels, forming the cells, organs, organisms and other material entities studied by biologists, the portions of rock studied by geologists, the fossils studied by paleontologists, and so on.Material entities are three-dimensional entities (entities extended in three spatial dimensions), as contrasted with the processes in which they participate, which are four-dimensional entities (entities extended also along the dimension of time).According to the FMA, material entities may have immaterial entities as parts – including the entities identified below as sites; for example the interior (or ‘lumen’) of your small intestine is a part of your body. BFO 2.0 embodies a decision to follow the FMA here. + + + + + obo:bfo/axiom/019-002 + + + obo:BFO_0000040 + A material entity is an independent continuant that has some portion of matter as proper or improper continuant part. (axiom label in BFO2 Reference: [019-002]) + + + + + obo:bfo/axiom/020-002 + + + obo:BFO_0000040 + Every entity which has a material entity as continuant part is a material entity. (axiom label in BFO2 Reference: [020-002]) + + + + + obo:bfo/axiom/021-002 + + + obo:BFO_0000040 + every entity of which a material entity is continuant part is also a material entity. (axiom label in BFO2 Reference: [021-002]) + + + + + obo:bfo/axiom/019-002 + + + obo:BFO_0000040 + (forall (x) (if (MaterialEntity x) (IndependentContinuant x))) // axiom label in BFO2 CLIF: [019-002] + + + + + obo:bfo/axiom/021-002 + + + obo:BFO_0000040 + (forall (x) (if (and (Entity x) (exists (y t) (and (MaterialEntity y) (continuantPartOfAt x y t)))) (MaterialEntity x))) // axiom label in BFO2 CLIF: [021-002] + + + + + obo:bfo/axiom/020-002 + + + obo:BFO_0000040 + (forall (x) (if (and (Entity x) (exists (y t) (and (MaterialEntity y) (continuantPartOfAt y x t)))) (MaterialEntity x))) // axiom label in BFO2 CLIF: [020-002] + + + + obo:BFO_0000040 + obo:bfo.owl + + + + obo:BFO_0000040 + material entity + + + + + obo:bfo/axiom/080-003 + + + obo:BFO_0000134 + To say that each spatiotemporal region s temporally_projects_onto some temporal region t is to say that t is the temporal extension of s. (axiom label in BFO2 Reference: [080-003]) + + + + + obo:bfo/axiom/081-003 + + + obo:BFO_0000134 + To say that spatiotemporal region s spatially_projects_onto spatial region r at t is to say that r is the spatial extent of s at t. (axiom label in BFO2 Reference: [081-003]) + + + + obo:BFO_0000140 + BFO:0000140 + + + + obo:BFO_0000140 + cf-boundary + + + + obo:BFO_0000140 + ContinuantFiatBoundary + + + + + obo:bfo/axiom/029-001 + + + obo:BFO_0000140 + b is a continuant fiat boundary = Def. b is an immaterial entity that is of zero, one or two dimensions and does not include a spatial region as part. (axiom label in BFO2 Reference: [029-001]) + + + + obo:BFO_0000140 + BFO 2 Reference: In BFO 1.1 the assumption was made that the external surface of a material entity such as a cell could be treated as if it were a boundary in the mathematical sense. The new document propounds the view that when we talk about external surfaces of material objects in this way then we are talking about something fiat. To be dealt with in a future version: fiat boundaries at different levels of granularity.More generally, the focus in discussion of boundaries in BFO 2.0 is now on fiat boundaries, which means: boundaries for which there is no assumption that they coincide with physical discontinuities. The ontology of boundaries becomes more closely allied with the ontology of regions. + + + + obo:BFO_0000140 + BFO 2 Reference: a continuant fiat boundary is a boundary of some material entity (for example: the plane separating the Northern and Southern hemispheres; the North Pole), or it is a boundary of some immaterial entity (for example of some portion of airspace). Three basic kinds of continuant fiat boundary can be distinguished (together with various combination kinds [29 + + + + + obo:bfo/axiom/0000008 + + + obo:BFO_0000140 + Continuant fiat boundary doesn't have a closure axiom because the subclasses don't necessarily exhaust all possibilites. An example would be the mereological sum of two-dimensional continuant fiat boundary and a one dimensional continuant fiat boundary that doesn't overlap it. The situation is analogous to temporal and spatial regions. + + + + obo:BFO_0000140 + Every continuant fiat boundary is located at some spatial region at every time at which it exists + + + + + obo:bfo/axiom/029-001 + + + obo:BFO_0000140 + (iff (ContinuantFiatBoundary a) (and (ImmaterialEntity a) (exists (b) (and (or (ZeroDimensionalSpatialRegion b) (OneDimensionalSpatialRegion b) (TwoDimensionalSpatialRegion b)) (forall (t) (locatedInAt a b t)))) (not (exists (c t) (and (SpatialRegion c) (continuantPartOfAt c a t)))))) // axiom label in BFO2 CLIF: [029-001] + + + + obo:BFO_0000140 + obo:bfo.owl + + + + obo:BFO_0000140 + continuant fiat boundary + + + + obo:BFO_0000141 + BFO:0000141 + + + + obo:BFO_0000141 + immaterial + + + + obo:BFO_0000141 + ImmaterialEntity + + + + obo:BFO_0000141 + BFO 2 Reference: Immaterial entities are divided into two subgroups:boundaries and sites, which bound, or are demarcated in relation, to material entities, and which can thus change location, shape and size and as their material hosts move or change shape or size (for example: your nasal passage; the hold of a ship; the boundary of Wales (which moves with the rotation of the Earth) [38, 7, 10 + + + + obo:BFO_0000141 + obo:bfo.owl + + + + obo:BFO_0000141 + immaterial entity + + + + obo:BFO_0000142 + BFO:0000142 + + + + obo:BFO_0000142 + 1d-cf-boundary + + + + obo:BFO_0000142 + OneDimensionalContinuantFiatBoundary + + + + obo:BFO_0000142 + The Equator + + + + obo:BFO_0000142 + all geopolitical boundaries + + + + obo:BFO_0000142 + all lines of latitude and longitude + + + + obo:BFO_0000142 + the line separating the outer surface of the mucosa of the lower lip from the outer surface of the skin of the chin. + + + + obo:BFO_0000142 + the median sulcus of your tongue + + + + + obo:bfo/axiom/032-001 + + + obo:BFO_0000142 + a one-dimensional continuant fiat boundary is a continuous fiat line whose location is defined in relation to some material entity. (axiom label in BFO2 Reference: [032-001]) + + + + + obo:bfo/axiom/032-001 + + + obo:BFO_0000142 + (iff (OneDimensionalContinuantFiatBoundary a) (and (ContinuantFiatBoundary a) (exists (b) (and (OneDimensionalSpatialRegion b) (forall (t) (locatedInAt a b t)))))) // axiom label in BFO2 CLIF: [032-001] + + + + obo:BFO_0000142 + obo:bfo.owl + + + + obo:BFO_0000142 + one-dimensional continuant fiat boundary + + + + obo:BFO_0000144 + BFO:0000144 + + + + obo:BFO_0000144 + process-profile + + + + obo:BFO_0000144 + ProcessProfile + + + + obo:BFO_0000144 + On a somewhat higher level of complexity are what we shall call rate process profiles, which are the targets of selective abstraction focused not on determinate quality magnitudes plotted over time, but rather on certain ratios between these magnitudes and elapsed times. A speed process profile, for example, is represented by a graph plotting against time the ratio of distance covered per unit of time. Since rates may change, and since such changes, too, may have rates of change, we have to deal here with a hierarchy of process profile universals at successive levels + + + + obo:BFO_0000144 + One important sub-family of rate process profiles is illustrated by the beat or frequency profiles of cyclical processes, illustrated by the 60 beats per minute beating process of John’s heart, or the 120 beats per minute drumming process involved in one of John’s performances in a rock band, and so on. Each such process includes what we shall call a beat process profile instance as part, a subtype of rate process profile in which the salient ratio is not distance covered but rather number of beat cycles per unit of time. Each beat process profile instance instantiates the determinable universal beat process profile. But it also instantiates multiple more specialized universals at lower levels of generality, selected from rate process profilebeat process profileregular beat process profile3 bpm beat process profile4 bpm beat process profileirregular beat process profileincreasing beat process profileand so on.In the case of a regular beat process profile, a rate can be assigned in the simplest possible fashion by dividing the number of cycles by the length of the temporal region occupied by the beating process profile as a whole. Irregular process profiles of this sort, for example as identified in the clinic, or in the readings on an aircraft instrument panel, are often of diagnostic significance. + + + + obo:BFO_0000144 + The simplest type of process profiles are what we shall call ‘quality process profiles’, which are the process profiles which serve as the foci of the sort of selective abstraction that is involved when measurements are made of changes in single qualities, as illustrated, for example, by process profiles of mass, temperature, aortic pressure, and so on. + + + + + obo:bfo/axiom/093-002 + + + obo:BFO_0000144 + b is a process_profile =Def. there is some process c such that b process_profile_of c (axiom label in BFO2 Reference: [093-002]) + + + + + obo:bfo/axiom/094-005 + + + obo:BFO_0000144 + b process_profile_of c holds when b proper_occurrent_part_of c& there is some proper_occurrent_part d of c which has no parts in common with b & is mutually dependent on b& is such that b, c and d occupy the same temporal region (axiom label in BFO2 Reference: [094-005]) + + + + + obo:bfo/axiom/094-005 + + + obo:BFO_0000144 + (forall (x y) (if (processProfileOf x y) (and (properContinuantPartOf x y) (exists (z t) (and (properOccurrentPartOf z y) (TemporalRegion t) (occupiesSpatioTemporalRegion x t) (occupiesSpatioTemporalRegion y t) (occupiesSpatioTemporalRegion z t) (not (exists (w) (and (occurrentPartOf w x) (occurrentPartOf w z))))))))) // axiom label in BFO2 CLIF: [094-005] + + + + + obo:bfo/axiom/093-002 + + + obo:BFO_0000144 + (iff (ProcessProfile a) (exists (b) (and (Process b) (processProfileOf a b)))) // axiom label in BFO2 CLIF: [093-002] + + + + obo:BFO_0000144 + obo:bfo.owl + + + + obo:BFO_0000144 + process profile + + + + obo:BFO_0000145 + BFO:0000145 + + + + obo:BFO_0000145 + r-quality + + + + obo:BFO_0000145 + RelationalQuality + + + + obo:BFO_0000145 + John’s role of husband to Mary is dependent on Mary’s role of wife to John, and both are dependent on the object aggregate comprising John and Mary as member parts joined together through the relational quality of being married. + + + + obo:BFO_0000145 + a marriage bond, an instance of love, an obligation between one person and another. + + + + + obo:bfo/axiom/057-001 + + + obo:BFO_0000145 + b is a relational quality = Def. for some independent continuants c, d and for some time t: b quality_of c at t & b quality_of d at t. (axiom label in BFO2 Reference: [057-001]) + + + + + obo:bfo/axiom/057-001 + + + obo:BFO_0000145 + (iff (RelationalQuality a) (exists (b c t) (and (IndependentContinuant b) (IndependentContinuant c) (qualityOfAt a b t) (qualityOfAt a c t)))) // axiom label in BFO2 CLIF: [057-001] + + + + obo:BFO_0000145 + obo:bfo.owl + + + + obo:BFO_0000145 + relational quality + + + + obo:BFO_0000146 + BFO:0000146 + + + + obo:BFO_0000146 + 2d-cf-boundary + + + + obo:BFO_0000146 + TwoDimensionalContinuantFiatBoundary + + + + + obo:bfo/axiom/033-001 + + + obo:BFO_0000146 + a two-dimensional continuant fiat boundary (surface) is a self-connected fiat surface whose location is defined in relation to some material entity. (axiom label in BFO2 Reference: [033-001]) + + + + + obo:bfo/axiom/033-001 + + + obo:BFO_0000146 + (iff (TwoDimensionalContinuantFiatBoundary a) (and (ContinuantFiatBoundary a) (exists (b) (and (TwoDimensionalSpatialRegion b) (forall (t) (locatedInAt a b t)))))) // axiom label in BFO2 CLIF: [033-001] + + + + obo:BFO_0000146 + obo:bfo.owl + + + + obo:BFO_0000146 + two-dimensional continuant fiat boundary + + + + obo:BFO_0000147 + BFO:0000147 + + + + obo:BFO_0000147 + 0d-cf-boundary + + + + obo:BFO_0000147 + ZeroDimensionalContinuantFiatBoundary + + + + obo:BFO_0000147 + the geographic North Pole + + + + obo:BFO_0000147 + the point of origin of some spatial coordinate system. + + + + obo:BFO_0000147 + the quadripoint where the boundaries of Colorado, Utah, New Mexico, and Arizona meet + + + + + obo:bfo/axiom/0000001 + + + + requested by Melanie Courtot + + + + https://groups.google.com/d/msg/bfo-owl-devel/s9Uug5QmAws/ZDRnpiIi_TUJ + + + obo:BFO_0000147 + zero dimension continuant fiat boundaries are not spatial points. Considering the example 'the quadripoint where the boundaries of Colorado, Utah, New Mexico, and Arizona meet' : There are many frames in which that point is zooming through many points in space. Whereas, no matter what the frame, the quadripoint is always in the same relation to the boundaries of Colorado, Utah, New Mexico, and Arizona. + + + + + obo:bfo/axiom/031-001 + + + obo:BFO_0000147 + a zero-dimensional continuant fiat boundary is a fiat point whose location is defined in relation to some material entity. (axiom label in BFO2 Reference: [031-001]) + + + + + obo:bfo/axiom/031-001 + + + obo:BFO_0000147 + (iff (ZeroDimensionalContinuantFiatBoundary a) (and (ContinuantFiatBoundary a) (exists (b) (and (ZeroDimensionalSpatialRegion b) (forall (t) (locatedInAt a b t)))))) // axiom label in BFO2 CLIF: [031-001] + + + + obo:BFO_0000147 + obo:bfo.owl + + + + obo:BFO_0000147 + zero-dimensional continuant fiat boundary + + + + obo:BFO_0000148 + BFO:0000148 + + + + obo:BFO_0000148 + 0d-t-region + + + + obo:BFO_0000148 + ZeroDimensionalTemporalRegion + + + + obo:BFO_0000148 + a temporal region that is occupied by a process boundary + + + + obo:BFO_0000148 + right now + + + + obo:BFO_0000148 + the moment at which a child is born + + + + obo:BFO_0000148 + the moment at which a finger is detached in an industrial accident + + + + obo:BFO_0000148 + the moment of death. + + + + obo:BFO_0000148 + temporal instant. + + + + + obo:bfo/axiom/102-001 + + + obo:BFO_0000148 + A zero-dimensional temporal region is a temporal region that is without extent. (axiom label in BFO2 Reference: [102-001]) + + + + + obo:bfo/axiom/102-001 + + + obo:BFO_0000148 + (forall (x) (if (ZeroDimensionalTemporalRegion x) (TemporalRegion x))) // axiom label in BFO2 CLIF: [102-001] + + + + obo:BFO_0000148 + obo:bfo.owl + + + + obo:BFO_0000148 + zero-dimensional temporal region + + + + obo:BFO_0000179 + Relates an entity in the ontology to the name of the variable that is used to represent it in the code that generates the BFO OWL file from the lispy specification. + + + + obo:BFO_0000179 + Really of interest to developers only + + + + obo:BFO_0000179 + BFO OWL specification label + + + + obo:BFO_0000180 + Relates an entity in the ontology to the term that is used to represent it in the the CLIF specification of BFO2 + + + + obo:BFO_0000180 + Person:Alan Ruttenberg + + + + obo:BFO_0000180 + Really of interest to developers only + + + + obo:BFO_0000180 + BFO CLIF specification label + + + + obo:BFO_0000182 + BFO:0000182 + + + + obo:BFO_0000182 + history + + + + obo:BFO_0000182 + History + + + + + obo:bfo/axiom/138-001 + + + obo:BFO_0000182 + A history is a process that is the sum of the totality of processes taking place in the spatiotemporal region occupied by a material entity or site, including processes on the surface of the entity or within the cavities to which it serves as host. (axiom label in BFO2 Reference: [138-001]) + + + + obo:BFO_0000182 + obo:bfo.owl + + + + obo:BFO_0000182 + history + + + + obo:DDO.owl + Shaker El-Sappagh + + + + obo:DDO.owl + 2015-11-20 + + + + obo:DDO.owl + DDO is an ontology of diabetes mellitus disease diagnosis structured on OBO foundry’s principle and based on BFO. DDO follows OGMS tripartite model of disease, and builds its taxonomy of diseases largely by automatic reasoning. + +The latest version of OGMS is always available at + +If you are interested in participating in the development of DDO, please send email to shaker_elsapagh + + + + obo:DDO.owl + This ontology is in early development. Expect it to change. + + + + obo:DDO.owl + 2015-11-20 + + + + obo:DDO_0006288 + DDO:0006288 + + + + obo:DDO_0006288 + diabetes symptom + + + + obo:DDO_0006291 + DDO:0006291 + + + + obo:DDO_0006291 + diabetes physical examination + + + + obo:DDO_0009410 + DDO:0009410 + + + + obo:DDO_0009410 + amyotrophic neuralgia + + + + obo:DDO_0009411 + DDO:0009411 + + + + obo:DDO_0009411 + brachial plexus neuritis + + + + obo:DDO_0009412 + DDO:0009412 + + + + obo:DDO_0009412 + brachial plexus lesion + + + + obo:DDO_0009413 + DDO:0009413 + + + + obo:DDO_0009413 + brachial plexus neuropathy + + + + obo:DDO_0009414 + DDO:0009414 + + + + obo:DDO_0009414 + plexopathy + + + + obo:DDO_0009415 + DDO:0009415 + + + + obo:DDO_0009415 + neurodegenerative disease + + + + obo:DDO_0009416 + DDO:0009416 + + + + obo:DDO_0009416 + meningitis + + + + obo:DDO_0009417 + DDO:0009417 + + + + obo:DDO_0009417 + arachnoiditis + + + + obo:DDO_0009418 + DDO:0009418 + + + + obo:DDO_0009418 + bacterial meningitis + + + + obo:DDO_0009419 + DDO:0009419 + + + + obo:DDO_0009419 + anaerobic meningitis + + + + obo:DDO_0009420 + DDO:0009420 + + + + obo:DDO_0009420 + Listeria meningitis + + + + obo:DDO_0009421 + DDO:0009421 + + + + obo:DDO_0009421 + streptococcal meningitis + + + + obo:DDO_0009422 + DDO:0009422 + + + + obo:DDO_0009422 + syphilitic meningitis + + + + obo:DDO_0009423 + DDO:0009423 + + + + obo:DDO_0009423 + chronic meningitis + + + + obo:DDO_0009424 + DDO:0009424 + + + + obo:DDO_0009424 + eosinophilic meningitis + + + + obo:DDO_0009425 + DDO:0009425 + + + + obo:DDO_0009425 + fungal meningitis + + + + obo:DDO_0009426 + DDO:0009426 + + + + obo:DDO_0009426 + histoplasmosis meningitis + + + + obo:DDO_0009427 + DDO:0009427 + + + + obo:DDO_0009427 + viral meningitis + + + + obo:DDO_0009428 + DDO:0009428 + + + + obo:DDO_0009428 + aseptic meningitis + + + + obo:DDO_0009429 + DDO:0009429 + + + + obo:DDO_0009429 + C0007682 + + + + obo:DDO_0009429 + central nervous system disease + + + + obo:DOID_10969 + DOID:10969 + + + + obo:DOID_10969 + 50582007 + + + + obo:DOID_10969 + C0392550 + + + + obo:DOID_10969 + hemiplegia + + + + obo:DOID_10992 + DOID:10992 + + + + obo:DOID_10992 + C0014077 + + + + obo:DOID_10992 + acute hemorrhagic leukoencephalitis + + + + obo:DOID_12055 + DOID:12055 + + + + obo:DOID_12055 + sarcoid meningitis + + + + obo:DOID_4977 + DOID:4977 + + + + obo:DOID_4977 + C0024236 + + + + obo:DOID_4977 + lymphedema + + + + obo:DOID_639 + DOID:639 + + + + obo:DOID_639 + C0014059 + + + + obo:DOID_639 + acute disseminated encephalomyelitis + + + + obo:DOID_640 + DOID:640 + + + + obo:DOID_640 + 62950007 + + + + obo:DOID_640 + C0014070 + + + + obo:DOID_640 + encephalomyelitis + + + + obo:IAO_0000002 + example to be eventually removed + + + + obo:IAO_0000027 + IAO:0000027 + + + + obo:IAO_0000027 + data item + + + + obo:IAO_0000030 + IAO:0000030 + + + + obo:IAO_0000030 + An information content entity is an entity that is generically dependent on some artifact and stands in relation of aboutness to some entity + + + + obo:IAO_0000030 + obo:iao.owl + + + + obo:IAO_0000030 + information content entity + + + + obo:IAO_0000033 + IAO:0000033 + + + + obo:IAO_0000033 + An information content entity whose concretizations indicate to their bearer how to realize them in a process. + + + + obo:IAO_0000033 + obo:iao.owl + + + + obo:IAO_0000033 + directive information content entity + + + + obo:IAO_0000078 + IAO:0000078 + + + + obo:IAO_0000078 + curation status specification + + + + obo:IAO_0000078 + obo:IAO_0000125 + + + + obo:IAO_0000078 + The curation status of the term. The allowed values come from an enumerated list of predefined terms. See the specification of these instances for more detailed definitions of each enumerated value. + + + + obo:IAO_0000078 + Better to represent curation as a process with parts and then relate labels to that process (in IAO meeting) + + + + obo:IAO_0000078 + PERSON:Bill Bug + + + + obo:IAO_0000078 + GROUP:OBI:<http://purl.obolibrary.org/obo/obi> + + + + obo:IAO_0000078 + OBI_0000266 + + + + obo:IAO_0000078 + curation status specification + + + + obo:IAO_0000102 + IAO:0000102 + + + + obo:IAO_0000102 + data about an ontology part is a data item about a part of an ontology, for example a term + + + + obo:IAO_0000102 + Person:Alan Ruttenberg + + + + obo:IAO_0000102 + data about an ontology part + + + + obo:IAO_0000103 + The term was used in an attempt to structure part of the ontology but in retrospect failed to do a good job + + + + obo:IAO_0000103 + Person:Alan Ruttenberg + + + + obo:IAO_0000103 + failed exploratory term + + + + obo:IAO_0000111 + editor preferred term + + + + obo:IAO_0000111 + obo:IAO_0000122 + + + + obo:IAO_0000111 + The concise, meaningful, and human-friendly name for a class or property preferred by the ontology developers. (US-English) + + + + obo:IAO_0000111 + PERSON:Daniel Schober + + + + obo:IAO_0000111 + GROUP:OBI:<http://purl.obolibrary.org/obo/obi> + + + + obo:IAO_0000111 + obo:iao.owl + + + + obo:IAO_0000111 + editor preferred term + + + + obo:IAO_0000112 + example + + + + obo:IAO_0000112 + obo:IAO_0000122 + + + + obo:IAO_0000112 + A phrase describing how a class name should be used. May also include other kinds of examples that facilitate immediate understanding of a class semantics, such as widely known prototypical subclasses or instances of the class. Although essential for high level terms, examples for low level terms (e.g., Affymetrix HU133 array) are not + + + + obo:IAO_0000112 + PERSON:Daniel Schober + + + + obo:IAO_0000112 + GROUP:OBI:<http://purl.obolibrary.org/obo/obi> + + + + obo:IAO_0000112 + obo:iao.owl + + + + obo:IAO_0000112 + example of usage + + + + obo:IAO_0000113 + in branch + + + + obo:IAO_0000113 + An annotation property indicating which module the terms belong to. This is currently experimental and not implemented yet. + + + + obo:IAO_0000113 + GROUP:OBI + + + + obo:IAO_0000113 + OBI_0000277 + + + + obo:IAO_0000113 + in branch + + + + obo:IAO_0000114 + has curation status + + + + obo:IAO_0000114 + PERSON:Alan Ruttenberg + + + + obo:IAO_0000114 + PERSON:Bill Bug + + + + obo:IAO_0000114 + PERSON:Melanie Courtot + + + + obo:IAO_0000114 + OBI_0000281 + + + + obo:IAO_0000114 + has curation status + + + + obo:IAO_0000115 + definition + + + + obo:IAO_0000115 + obo:IAO_0000122 + + + + obo:IAO_0000115 + The official definition, explaining the meaning of a class or property. Shall be Aristotelian, formalized and normalized. Can be augmented with colloquial definitions. + + + + obo:IAO_0000115 + 2012-04-05: +Barry Smith + +The official OBI definition, explaining the meaning of a class or property: 'Shall be Aristotelian, formalized and normalized. Can be augmented with colloquial definitions' is terrible. + +Can you fix to something like: + +A statement of necessary and sufficient conditions explaining the meaning of an expression referring to a class or property. + +Alan Ruttenberg + +Your proposed definition is a reasonable candidate, except that it is very common that necessary and sufficient conditions are not given. Mostly they are necessary, occasionally they are necessary and sufficient or just sufficient. Often they use terms that are not themselves defined and so they effectively can't be evaluated by those criteria. + +On the specifics of the proposed definition: + +We don't have definitions of 'meaning' or 'expression' or 'property'. For 'reference' in the intended sense I think we use the term 'denotation'. For 'expression', I think we you mean symbol, or identifier. For 'meaning' it differs for class and property. For class we want documentation that let's the intended reader determine whether an entity is instance of the class, or not. For property we want documentation that let's the intended reader determine, given a pair of potential relata, whether the assertion that the relation holds is true. The 'intended reader' part suggests that we also specify who, we expect, would be able to understand the definition, and also generalizes over human and computer reader to include textual and logical definition. + +Personally, I am more comfortable weakening definition to documentation, with instructions as to what is desirable. + +We also have the outstanding issue of how to aim different definitions to different audiences. A clinical audience reading chebi wants a different sort of definition documentation/definition from a chemistry trained audience, and similarly there is a need for a definition that is adequate for an ontologist to work with. + + + + obo:IAO_0000115 + PERSON:Daniel Schober + + + + obo:IAO_0000115 + GROUP:OBI:<http://purl.obolibrary.org/obo/obi> + + + + obo:IAO_0000115 + obo:iao.owl + + + + obo:IAO_0000115 + definition + + + + obo:IAO_0000115 + definition + + + + obo:IAO_0000116 + editor note + + + + obo:IAO_0000116 + obo:IAO_0000122 + + + + obo:IAO_0000116 + An administrative note intended for its editor. It may not be included in the publication version of the ontology, so it should contain nothing necessary for end users to understand the ontology. + + + + obo:IAO_0000116 + PERSON:Daniel Schober + + + + obo:IAO_0000116 + GROUP:OBI:<http://purl.obfoundry.org/obo/obi> + + + + obo:IAO_0000116 + obo:iao.owl + + + + obo:IAO_0000116 + editor note + + + + obo:IAO_0000116 + editor note + + + + obo:IAO_0000117 + term editor + + + + obo:IAO_0000117 + obo:IAO_0000122 + + + + obo:IAO_0000117 + Name of editor entering the term in the file. The term editor is a point of contact for information regarding the term. The term editor may be, but is not always, the author of the definition, which may have been worked upon by several people + + + + obo:IAO_0000117 + 20110707, MC: label update to term editor and definition modified accordingly. See http://code.google.com/p/information-artifact-ontology/issues/detail?id=115. + + + + obo:IAO_0000117 + PERSON:Daniel Schober + + + + obo:IAO_0000117 + GROUP:OBI:<http://purl.obolibrary.org/obo/obi> + + + + obo:IAO_0000117 + obo:iao.owl + + + + obo:IAO_0000117 + term editor + + + + obo:IAO_0000118 + alternative term + + + + obo:IAO_0000118 + obo:IAO_0000125 + + + + obo:IAO_0000118 + An alternative name for a class or property which means the same thing as the preferred name (semantically equivalent) + + + + obo:IAO_0000118 + PERSON:Daniel Schober + + + + obo:IAO_0000118 + GROUP:OBI:<http://purl.obolibrary.org/obo/obi> + + + + obo:IAO_0000118 + obo:iao.owl + + + + obo:IAO_0000118 + alternative term + + + + obo:IAO_0000119 + definition source + + + + obo:IAO_0000119 + obo:IAO_0000122 + + + + obo:IAO_0000119 + formal citation, e.g. identifier in external database to indicate / attribute source(s) for the definition. Free text indicate / attribute source(s) for the definition. EXAMPLE: Author Name, URI, MeSH Term C04, PUBMED ID, Wiki uri on 31.01.2007 + + + + obo:IAO_0000119 + PERSON:Daniel Schober + + + + obo:IAO_0000119 + Discussion on obo-discuss mailing-list, see http://bit.ly/hgm99w + + + + obo:IAO_0000119 + GROUP:OBI:<http://purl.obolibrary.org/obo/obi> + + + + obo:IAO_0000119 + obo:iao.owl + + + + obo:IAO_0000119 + definition source + + + + obo:IAO_0000119 + definition source + + + + obo:IAO_0000120 + Class has all its metadata, but is either not guaranteed to be in its final location in the asserted IS_A hierarchy or refers to another class that is not complete. + + + + obo:IAO_0000120 + metadata complete + + + + obo:IAO_0000121 + term created to ease viewing/sort terms for development purpose, and will not be included in a release + + + + obo:IAO_0000121 + organizational term + + + + obo:IAO_0000122 + Class has undergone final review, is ready for use, and will be included in the next release. Any class lacking "ready_for_release" should be considered likely to change place in hierarchy, have its definition refined, or be obsoleted in the next release. Those classes deemed "ready_for_release" will also derived from a chain of ancestor classes that are also "ready_for_release." + + + + obo:IAO_0000122 + ready for release + + + + obo:IAO_0000123 + Class is being worked on; however, the metadata (including definition) are not complete or sufficiently clear to the branch editors. + + + + obo:IAO_0000123 + metadata incomplete + + + + obo:IAO_0000124 + Nothing done yet beyond assigning a unique class ID and proposing a preferred term. + + + + obo:IAO_0000124 + uncurated + + + + obo:IAO_0000125 + All definitions, placement in the asserted IS_A hierarchy and required minimal metadata are complete. The class is awaiting a final review by someone other than the term editor. + + + + obo:IAO_0000125 + pending final vetting + + + + obo:IAO_0000224 + Core is an instance of a grouping of terms from an ontology or ontologies. It is used by the ontology to identify main classes. + + + + obo:IAO_0000224 + PERSON: Alan Ruttenberg + + + + obo:IAO_0000224 + PERSON: Melanie Courtot + + + + obo:IAO_0000224 + core + + + + obo:IAO_0000225 + IAO:0000225 + + + + obo:IAO_0000225 + obsolescence reason specification + + + + obo:IAO_0000225 + obo:IAO_0000125 + + + + obo:IAO_0000225 + The reason for which a term has been deprecated. The allowed values come from an enumerated list of predefined terms. See the specification of these instances for more detailed definitions of each enumerated value. + + + + obo:IAO_0000225 + The creation of this class has been inspired in part by Werner Ceusters' paper, Applying evolutionary terminology auditing to the Gene Ontology. + + + + obo:IAO_0000225 + PERSON: Alan Ruttenberg + + + + obo:IAO_0000225 + PERSON: Melanie Courtot + + + + obo:IAO_0000225 + obsolescence reason specification + + + + obo:IAO_0000226 + placeholder removed + + + + obo:IAO_0000227 + An editor note should explain what were the merged terms and the reason for the merge. + + + + obo:IAO_0000227 + terms merged + + + + obo:IAO_0000228 + This is to be used when the original term has been replaced by a term imported from an other ontology. An editor note should indicate what is the URI of the new term to use. + + + + obo:IAO_0000228 + term imported + + + + obo:IAO_0000229 + This is to be used when a term has been split in two or more new terms. An editor note should indicate the reason for the split and indicate the URIs of the new terms created. + + + + obo:IAO_0000229 + term split + + + + obo:IAO_0000231 + has obsolescence reason + + + + obo:IAO_0000231 + Relates an annotation property to an obsolescence reason. The values of obsolescence reasons come from a list of predefined terms, instances of the class obsolescence reason specification. + + + + obo:IAO_0000231 + PERSON:Alan Ruttenberg + + + + obo:IAO_0000231 + PERSON:Melanie Courtot + + + + obo:IAO_0000231 + has obsolescence reason + + + + obo:IAO_0000232 + curator note + + + + obo:IAO_0000232 + obo:IAO_0000122 + + + + obo:IAO_0000232 + An administrative note of use for a curator but of no use for a user + + + + obo:IAO_0000232 + PERSON:Alan Ruttenberg + + + + obo:IAO_0000232 + obo:iao.owl + + + + obo:IAO_0000232 + curator note + + + + obo:IAO_0000233 + term tracker item + + + + obo:IAO_0000233 + the URI for an OBI Terms ticket at sourceforge, such as https://sourceforge.net/p/obi/obi-terms/772/ + + + + obo:IAO_0000233 + obo:IAO_0000125 + + + + obo:IAO_0000233 + An IRI or similar locator for a request or discussion of an ontology term. + + + + obo:IAO_0000233 + Person: Jie Zheng, Chris Stoeckert, Alan Ruttenberg + + + + obo:IAO_0000233 + Person: Jie Zheng, Chris Stoeckert, Alan Ruttenberg + + + + obo:IAO_0000233 + The 'tracker item' can associate a tracker with a specific ontology term. + + + + obo:IAO_0000233 + term tracker item + + + + obo:IAO_0000234 + obo:IAO_0000125 + + + + obo:IAO_0000234 + The name of the person, project, or organization that motivated inclusion of an ontology term by requesting its addition. + + + + obo:IAO_0000234 + Person: Jie Zheng, Chris Stoeckert, Alan Ruttenberg + + + + obo:IAO_0000234 + Person: Jie Zheng, Chris Stoeckert, Alan Ruttenberg + + + + obo:IAO_0000234 + The 'term requester' can credit the person, organization or project who request the ontology term. + + + + obo:IAO_0000234 + ontology term requester + + + + obo:IAO_0000409 + IAO:0000409 + + + + obo:IAO_0000409 + The Basic Formal Ontology ontology makes a distinction between Universals and defined classes, where the formal are "natural kinds" and the latter arbitrary collections of entities. + + + + obo:IAO_0000409 + A denotator type indicates how a term should be interpreted from an ontological perspective. + + + + obo:IAO_0000409 + Alan Ruttenberg + + + + obo:IAO_0000409 + Barry Smith, Werner Ceusters + + + + obo:IAO_0000409 + denotator type + + + + obo:IAO_0000410 + Hard to give a definition for. Intuitively a "natural kind" rather than a collection of any old things, which a class is able to be, formally. At the meta level, universals are defined as positives, are disjoint with their siblings, have single asserted parents. + + + + obo:IAO_0000410 + Alan Ruttenberg + + + + obo:IAO_0000410 + A Formal Theory of Substances, Qualities, and Universals, http://ontology.buffalo.edu/bfo/SQU.pdf + + + + obo:IAO_0000410 + universal + + + + obo:IAO_0000411 + is denotator type + + + + obo:IAO_0000411 + relates an class defined in an ontology, to the type of it's denotator + + + + obo:IAO_0000411 + In OWL 2 add AnnotationPropertyRange('is denotator type' 'denotator type') + + + + obo:IAO_0000411 + Alan Ruttenberg + + + + obo:IAO_0000411 + is denotator type + + + + obo:IAO_0000412 + imported from + + + + obo:IAO_0000412 + obo:IAO_0000125 + + + + obo:IAO_0000412 + For external terms/classes, the ontology from which the term was imported + + + + obo:IAO_0000412 + PERSON:Alan Ruttenberg + + + + obo:IAO_0000412 + PERSON:Melanie Courtot + + + + obo:IAO_0000412 + GROUP:OBI:<http://purl.obolibrary.org/obo/obi> + + + + obo:IAO_0000412 + obo:iao.owl + + + + obo:IAO_0000412 + imported from + + + + obo:IAO_0000420 + A defined class is a class that is defined by a set of logically necessary and sufficient conditions but is not a universal + + + + obo:IAO_0000420 + "definitions", in some readings, always are given by necessary and sufficient conditions. So one must be careful (and this is difficult sometimes) to distinguish between defined classes and universal. + + + + obo:IAO_0000420 + Alan Ruttenberg + + + + obo:IAO_0000420 + defined class + + + + obo:IAO_0000421 + A named class expression is a logical expression that is given a name. The name can be used in place of the expression. + + + + obo:IAO_0000421 + named class expressions are used in order to have more concise logical definition but their extensions may not be interesting classes on their own. In languages such as OWL, with no provisions for macros, these show up as actuall classes. Tools may with to not show them as such, and to replace uses of the macros with their expansions + + + + obo:IAO_0000421 + Alan Ruttenberg + + + + obo:IAO_0000421 + named class expression + + + + obo:IAO_0000423 + Terms with this status should eventually replaced with a term from another ontology. + + + + obo:IAO_0000423 + Alan Ruttenberg + + + + obo:IAO_0000423 + group:OBI + + + + obo:IAO_0000423 + to be replaced with external ontology term + + + + obo:IAO_0000424 + expand expression to + + + + obo:IAO_0000424 + ObjectProperty: RO_0002104 +Label: has plasma membrane part +Annotations: IAO_0000424 "http://purl.obolibrary.org/obo/BFO_0000051 some (http://purl.org/obo/owl/GO#GO_0005886 and http://purl.obolibrary.org/obo/BFO_0000051 some ?Y)" + + + + + obo:IAO_0000424 + A macro expansion tag applied to an object property (or possibly a data property) which can be used by a macro-expansion engine to generate more complex expressions from simpler ones + + + + obo:IAO_0000424 + Chris Mungall + + + + obo:IAO_0000424 + expand expression to + + + + obo:IAO_0000425 + expand assertion to + + + + obo:IAO_0000425 + ObjectProperty: RO??? +Label: spatially disjoint from +Annotations: expand_assertion_to "DisjointClasses: (http://purl.obolibrary.org/obo/BFO_0000051 some ?X) (http://purl.obolibrary.org/obo/BFO_0000051 some ?Y)" + + + + + obo:IAO_0000425 + A macro expansion tag applied to an annotation property which can be expanded into a more detailed axiom. + + + + obo:IAO_0000425 + Chris Mungall + + + + obo:IAO_0000425 + expand assertion to + + + + obo:IAO_0000426 + first order logic expression + + + + obo:IAO_0000426 + PERSON:Alan Ruttenberg + + + + obo:IAO_0000426 + first order logic expression + + + + obo:IAO_0000427 + antisymmetric property + + + + obo:IAO_0000427 + part_of antisymmetric property xsd:true + + + + obo:IAO_0000427 + use boolean value xsd:true to indicate that the property is an antisymmetric property + + + + obo:IAO_0000427 + Alan Ruttenberg + + + + obo:IAO_0000427 + antisymmetric property + + + + obo:IAO_0000428 + A term that is metadata complete, has been reviewed, and problems have been identified that require discussion before release. Such a term requires editor note(s) to identify the outstanding issues. + + + + obo:IAO_0000428 + Alan Ruttenberg + + + + obo:IAO_0000428 + group:OBI + + + + obo:IAO_0000428 + requires discussion + + + + obo:IAO_0000589 + OBO foundry unique label + + + + obo:IAO_0000589 + obo:IAO_0000125 + + + + obo:IAO_0000589 + An alternative name for a class or property which is unique across the OBO Foundry. + + + + obo:IAO_0000589 + The intended usage of that property is as follow: OBO foundry unique labels are automatically generated based on regular expressions provided by each ontology, so that SO could specify unique label = 'sequence ' + [label], etc. , MA could specify 'mouse + [label]' etc. Upon importing terms, ontology developers can choose to use the 'OBO foundry unique label' for an imported term or not. The same applies to tools . + + + + obo:IAO_0000589 + PERSON:Alan Ruttenberg + + + + obo:IAO_0000589 + PERSON:Bjoern Peters + + + + obo:IAO_0000589 + PERSON:Chris Mungall + + + + obo:IAO_0000589 + PERSON:Melanie Courtot + + + + obo:IAO_0000589 + GROUP:OBO Foundry <http://obofoundry.org/> + + + + obo:IAO_0000589 + OBO foundry unique label + + + + obo:IAO_0000596 + Ontology: <http://purl.obolibrary.org/obo/ro/idrange/> + Annotations: + 'has ID prefix': "http://purl.obolibrary.org/obo/RO_" + 'has ID digit count' : 7, + rdfs:label "RO id policy" + 'has ID policy for': "RO" + + + + obo:IAO_0000596 + Relates an ontology used to record id policy to the number of digits in the URI. The URI is: the 'has ID prefix" annotation property value concatenated with an integer in the id range (left padded with "0"s to make this many digits) + + + + obo:IAO_0000596 + Person:Alan Ruttenberg + + + + obo:IAO_0000596 + has ID digit count + + + + obo:IAO_0000597 + Datatype: idrange:1 +Annotations: 'has ID range allocated to': "Chris Mungall" +EquivalentTo: xsd:integer[> 2151 , <= 2300] + + + + + obo:IAO_0000597 + Relates a datatype that encodes a range of integers to the name of the person or organization who can use those ids constructed in that range to define new terms + + + + obo:IAO_0000597 + Person:Alan Ruttenberg + + + + obo:IAO_0000597 + has ID range allocated to + + + + obo:IAO_0000598 + Ontology: <http://purl.obolibrary.org/obo/ro/idrange/> + Annotations: + 'has ID prefix': "http://purl.obolibrary.org/obo/RO_" + 'has ID digit count' : 7, + rdfs:label "RO id policy" + 'has ID policy for': "RO" + + + + obo:IAO_0000598 + Relating an ontology used to record id policy to the ontology namespace whose policy it manages + + + + obo:IAO_0000598 + Person:Alan Ruttenberg + + + + obo:IAO_0000598 + has ID policy for + + + + obo:IAO_0000599 + Ontology: <http://purl.obolibrary.org/obo/ro/idrange/> + Annotations: + 'has ID prefix': "http://purl.obolibrary.org/obo/RO_" + 'has ID digit count' : 7, + rdfs:label "RO id policy" + 'has ID policy for': "RO" + + + + obo:IAO_0000599 + Relates an ontology used to record id policy to a prefix concatenated with an integer in the id range (left padded with "0"s to make this many digits) to construct an ID for a term being created. + + + + obo:IAO_0000599 + Person:Alan Ruttenberg + + + + obo:IAO_0000599 + has ID prefix + + + + obo:IAO_0000600 + elucidation + + + + obo:IAO_0000600 + person:Alan Ruttenberg + + + + obo:IAO_0000600 + Person:Barry Smith + + + + obo:IAO_0000600 + Primitive terms in a highest-level ontology such as BFO are terms which are so basic to our understanding of reality that there is no way of defining them in a non-circular fashion. For these, therefore, we can provide only elucidations, supplemented by examples and by axioms + + + + obo:IAO_0000600 + obo:iao.owl + + + + obo:IAO_0000600 + elucidation + + + + obo:IAO_0000601 + has associated axiom(nl) + + + + obo:IAO_0000601 + Person:Alan Ruttenberg + + + + obo:IAO_0000601 + Person:Alan Ruttenberg + + + + obo:IAO_0000601 + An axiom associated with a term expressed using natural language + + + + obo:IAO_0000601 + obo:iao.owl + + + + obo:IAO_0000601 + has associated axiom(nl) + + + + obo:IAO_0000602 + has associated axiom(fol) + + + + obo:IAO_0000602 + Person:Alan Ruttenberg + + + + obo:IAO_0000602 + Person:Alan Ruttenberg + + + + obo:IAO_0000602 + An axiom expressed in first order logic using CLIF syntax + + + + obo:IAO_0000602 + obo:iao.owl + + + + obo:IAO_0000602 + has associated axiom(fol) + + + + obo:IAO_0000603 + is allocated id range + + + + obo:IAO_0000603 + Add as annotation triples in the granting ontology + + + + obo:IAO_0000603 + Relates an ontology IRI to an (inclusive) range of IRIs in an OBO name space. The range is give as, e.g. "IAO_0020000-IAO_0020999" + + + + obo:IAO_0000603 + PERSON:Alan Ruttenberg + + + + obo:IAO_0000603 + is allocated id range + + + + obo:IAO_0010000 + has axiom id + + + + obo:IAO_0010000 + Person:Alan Ruttenberg + + + + obo:IAO_0010000 + Person:Alan Ruttenberg + + + + obo:IAO_0010000 + A URI that is intended to be unique label for an axiom used for tracking change to the ontology. For an axiom expressed in different languages, each expression is given the same URI + + + + obo:IAO_0010000 + obo:iao.owl + + + + obo:IAO_0010000 + has axiom label + + + + obo:IAO_0100001 + term replaced by + + + + obo:IAO_0100001 + obo:IAO_0000125 + + + + obo:IAO_0100001 + Add as annotation triples in the granting ontology + + + + obo:IAO_0100001 + Use on obsolete terms, relating the term to another term that can be used as a substitute + + + + obo:IAO_0100001 + Person:Alan Ruttenberg + + + + obo:IAO_0100001 + Person:Alan Ruttenberg + + + + obo:IAO_0100001 + term replaced by + + + + obo:OBI_0000011 + OBI:0000011 + + + + obo:OBI_0000011 + A processual entity that realizes a plan which is the concretization of a plan specification. + + + + obo:OBI_0000011 + obo:obi.owl + + + + obo:OBI_0000011 + planned process + + + + obo:OGMS_0000014 + OGMS:0000014 + + + + obo:OGMS_0000014 + A representation that is either the output of a clinical history taking or a physical examination or an image finding, or some combination thereof. + + + + obo:OGMS_0000014 + http://ontology.buffalo.edu/medo/Disease_and_Diagnosis.pdf + + + + obo:OGMS_0000014 + clinical finding + + + + obo:OGMS_0000015 + OGMS:0000015 + + + + obo:OGMS_0000015 + A series of statements representing health-relevant qualities of a patient and of a patient's family. + + + + obo:OGMS_0000015 + http://ontology.buffalo.edu/medo/Disease_and_Diagnosis.pdf + + + + obo:OGMS_0000015 + clinical history + + + + obo:OGMS_0000016 + OGMS:0000016 + + + + obo:OGMS_0000016 + A representation of clinically significant bodily components, dispositions, and/or bodily processes of a human being that is inferred from relevant clinical findings. + + + + obo:OGMS_0000016 + http://ontology.buffalo.edu/medo/Disease_and_Diagnosis.pdf + + + + obo:OGMS_0000016 + clinical picture + + + + obo:OGMS_0000017 + OGMS:0000017 + + + + obo:OGMS_0000017 + A representation of an image that supports an inference to an assertion about some quality of a patient. + + + + obo:OGMS_0000017 + http://ontology.buffalo.edu/medo/Disease_and_Diagnosis.pdf + + + + obo:OGMS_0000017 + image finding + + + + obo:OGMS_0000018 + OGMS:0000018 + + + + obo:OGMS_0000018 + A representation of a quality of a specimen that is the output of a laboratory test and that can support an inference to an assertion about some quality of the patient. + + + + obo:OGMS_0000018 + http://ontology.buffalo.edu/medo/Disease_and_Diagnosis.pdf + + + + obo:OGMS_0000018 + laboratory finding + + + + obo:OGMS_0000019 + OGMS:0000019 + + + + obo:OGMS_0000019 + A representation of a quality of a patient that is (1) recorded by a clinician because the quality is hypothesized to be of clinical significance and (2) refers to qualities obtaining in the patient prior to their becoming detectable in a clinical history taking or physical examination. + + + + obo:OGMS_0000019 + http://ontology.buffalo.edu/medo/Disease_and_Diagnosis.pdf + + + + obo:OGMS_0000019 + preclinical finding + + + + obo:OGMS_0000022 + OGMS:0000022 + + + + obo:OGMS_0000022 + A quality of a patient that is (a) a deviation from clinical normality that exists in virtue of the realization of a disease and (b) is observable. + + + + obo:OGMS_0000022 + http://ontology.buffalo.edu/medo/Disease_and_Diagnosis.pdf + + + + obo:OGMS_0000022 + manifestation of a disease + + + + obo:OGMS_0000023 + OGMS:0000023 + + + + obo:OGMS_0000023 + A (combination of) quality(ies) of an organism determined by the interaction of its genetic make-up and environment that differentiates specific instances of a species from other instances of the same species. + + + + obo:OGMS_0000023 + http://ontology.buffalo.edu/medo/Disease_and_Diagnosis.pdf + + + + obo:OGMS_0000023 + phenotype + + + + obo:OGMS_0000025 + OGMS:0000025 + + + + obo:OGMS_0000025 + A manifestation of a disease that is detectable in a clinical history taking or physical examination. + + + + obo:OGMS_0000025 + http://ontology.buffalo.edu/medo/Disease_and_Diagnosis.pdf + + + + obo:OGMS_0000025 + clinical manifestation of a disease + + + + obo:OGMS_0000026 + OGMS:0000026 + + + + obo:OGMS_0000026 + A manifestation of a disease that exists prior to the time at which it would be detected in a clinical history taking or physical examination, if the patient were to present to a clinician. A realization of a disease that exists prior to its becoming detectable in a clinical history taking or physical examination. + + + + obo:OGMS_0000026 + http://ontology.buffalo.edu/medo/Disease_and_Diagnosis.pdf + + + + obo:OGMS_0000026 + preclinical manifestation of a disease + + + + obo:OGMS_0000027 + OGMS:0000027 + + + + obo:OGMS_0000027 + A clinically abnormal phenotype. + + + + obo:OGMS_0000027 + http://ontology.buffalo.edu/medo/Disease_and_Diagnosis.pdf + + + + obo:OGMS_0000027 + clinical phenotype + + + + obo:OGMS_0000028 + OGMS:0000028 + + + + obo:OGMS_0000028 + A clinically abnormal phenotype that is characteristic of a single disease. + + + + obo:OGMS_0000028 + http://ontology.buffalo.edu/medo/Disease_and_Diagnosis.pdf + + + + obo:OGMS_0000028 + disease phenotype + + + + obo:OGMS_0000030 + OGMS:0000030 + + + + obo:OGMS_0000030 + A disposition in an organism that constitutes an increased risk of the organism's subsequently developing the disease X. + + + + obo:OGMS_0000030 + http://ontology.buffalo.edu/medo/Disease_and_Diagnosis.pdf + + + + obo:OGMS_0000030 + predisposition to disease of type X + + + + obo:OGMS_0000031 + OGMS:0000031 + + + + obo:OGMS_0000031 + A disposition (i) to undergo pathological processes that (ii) exists in an organism because of one or more disorders in that organism. + + + + obo:OGMS_0000031 + http://ontology.buffalo.edu/medo/Disease_and_Diagnosis.pdf + + + + obo:OGMS_0000031 + disease + + + + obo:OGMS_0000032 + OGMS:0000032 + + + + obo:OGMS_0000032 + homeostasis + + + + obo:OGMS_0000033 + OGMS:0000033 + + + + obo:OGMS_0000033 + A predisposition to disease of type X whose physical basis is a constitutional abnormality in an organism's genome. This abnormality is the physical basis for the increased risk of acquiring the disease X. + + + + obo:OGMS_0000033 + http://ontology.buffalo.edu/medo/Disease_and_Diagnosis.pdf + + + + obo:OGMS_0000033 + genetic predisposition to disease of type X + + + + obo:OGMS_0000037 + OGMS:0000037 + + + + obo:OGMS_0000037 + Homeostasis that is clinically abnormal for an organism of a given type and age in a given environment. + + + + obo:OGMS_0000037 + http://ontology.buffalo.edu/medo/Disease_and_Diagnosis.pdf + + + + obo:OGMS_0000037 + abnormal homeostasis + + + + obo:OGMS_0000038 + OGMS:0000038 + + + + obo:OGMS_0000038 + Homeostasis of a type that is not clinically abnormal. + + + + obo:OGMS_0000038 + http://ontology.buffalo.edu/medo/Disease_and_Diagnosis.pdf + + + + obo:OGMS_0000038 + normal homeostasis + + + + obo:OGMS_0000039 + OGMS:0000039 + + + + obo:OGMS_0000039 + A quality which is an spatial arrangement or distribution of a(n) independent continuant(s) across a Three Dimensional Region. + + + + obo:OGMS_0000039 + http://ontology.buffalo.edu/medo/Disease_and_Diagnosis.pdf + + + + obo:OGMS_0000039 + configuration + + + + obo:OGMS_0000040 + OGMS:0000040 + + + + obo:OGMS_0000040 + A configuration which deviates in some way from a canonical configuration for a particular organism. + + + + obo:OGMS_0000040 + http://ontology.buffalo.edu/medo/Disease_and_Diagnosis.pdf + + + + obo:OGMS_0000040 + pathological physical configuration + + + + obo:OGMS_0000045 + OGMS:0000045 + + + + obo:OGMS_0000045 + A material entity which is clinically abnormal and part of an extended organism. Disorders are the physical basis of disease. + + + + obo:OGMS_0000045 + http://ontology.buffalo.edu/medo/Disease_and_Diagnosis.pdf + + + + obo:OGMS_0000045 + disorder + + + + obo:OGMS_0000046 + OGMS:0000046 + + + + obo:OGMS_0000046 + A disorder whose etiology involves (1) a modification to the patient's genomic DNA which leads to alterations in the normal expression pattern of the genome, but is (2) not a change in the nucleotide sequence. + + + + obo:OGMS_0000046 + http://ontology.buffalo.edu/medo/Disease_and_Diagnosis.pdf + + + + obo:OGMS_0000046 + epigenetic disorder + + + + obo:OGMS_0000047 + OGMS:0000047 + + + + obo:OGMS_0000047 + A disorder whose etiology involves an abnormality in the nucleotide sequence of an organism's genome. + + + + obo:OGMS_0000047 + http://ontology.buffalo.edu/medo/Disease_and_Diagnosis.pdf + + + + obo:OGMS_0000047 + genetic disorder + + + + obo:OGMS_0000050 + OGMS:0000050 + + + + obo:OGMS_0000050 + A genetic disorder acquired by a single cell in an organism that leads to a population of cells within the organism bearing the disorder. + + + + obo:OGMS_0000050 + http://ontology.buffalo.edu/medo/Disease_and_Diagnosis.pdf + + + + obo:OGMS_0000050 + acquired genetic disorder + + + + obo:OGMS_0000051 + OGMS:0000051 + + + + obo:OGMS_0000051 + A genetic disorder inherited during conception that is part of all cells in the organism. + + + + obo:OGMS_0000051 + http://ontology.buffalo.edu/medo/Disease_and_Diagnosis.pdf + + + + obo:OGMS_0000051 + constitutional genetic disorder + + + + obo:OGMS_0000055 + OGMS:0000055 + + + + obo:OGMS_0000055 + An interview in which a clinician elicits a clinical history from a patient or from a third party who is reporting on behalf of the patient. + + + + obo:OGMS_0000055 + http://ontology.buffalo.edu/medo/Disease_and_Diagnosis.pdf + + + + obo:OGMS_0000055 + clinical history taking + + + + obo:OGMS_0000059 + OGMS:0000059 + + + + obo:OGMS_0000059 + A process in an organism that leads to a subsequent disorder. + + + + obo:OGMS_0000059 + http://ontology.buffalo.edu/medo/Disease_and_Diagnosis.pdf + + + + obo:OGMS_0000059 + etiological process + + + + obo:OGMS_0000060 + OGMS:0000060 + + + + obo:OGMS_0000060 + bodily process + + + + obo:OGMS_0000061 + OGMS:0000061 + + + + obo:OGMS_0000061 + A bodily process that is clinically abnormal. + + + + obo:OGMS_0000061 + http://ontology.buffalo.edu/medo/Disease_and_Diagnosis.pdf + + + + obo:OGMS_0000061 + pathological bodily process + + + + obo:OGMS_0000063 + OGMS:0000063 + + + + obo:OGMS_0000063 + The totality of all processes through which a given disease instance is realized. + + + + obo:OGMS_0000063 + http://ontology.buffalo.edu/medo/Disease_and_Diagnosis.pdf + + + + obo:OGMS_0000063 + disease course + + + + obo:OGMS_0000064 + OGMS:0000064 + + + + obo:OGMS_0000064 + A disease course that (a) does not terminate in a return to normal homeostasis and (b) would, absent intervention, fall within abnormal homeostatic range. + + + + obo:OGMS_0000064 + http://ontology.buffalo.edu/medo/Disease_and_Diagnosis.pdf + + + + obo:OGMS_0000064 + chronic disease course + + + + obo:OGMS_0000065 + OGMS:0000065 + + + + obo:OGMS_0000065 + A disease course that (a) does not terminate in a return to normal homeostasis and (b) would, absent intervention, involve an increasing deviation from homeostasis. + + + + obo:OGMS_0000065 + http://ontology.buffalo.edu/medo/Disease_and_Diagnosis.pdf + + + + obo:OGMS_0000065 + progressive disease course + + + + obo:OGMS_0000066 + OGMS:0000066 + + + + obo:OGMS_0000066 + A disease course that terminates in a return to normal homeostasis. + + + + obo:OGMS_0000066 + http://ontology.buffalo.edu/medo/Disease_and_Diagnosis.pdf + + + + obo:OGMS_0000066 + transient disease course + + + + obo:OGMS_0000073 + OGMS:0000073 + + + + obo:OGMS_0000073 + The representation of a conclusion of a diagnostic process. + + + + obo:OGMS_0000073 + http://ontology.buffalo.edu/medo/Disease_and_Diagnosis.pdf + + + + obo:OGMS_0000073 + diagnosis + + + + obo:OGMS_0000074 + OGMS:0000074 + + + + obo:OGMS_0000074 + A value for a quality reported in a lab report and asserted by the testing lab or the kit manufacturer to be normal based on a statistical treatment of values from a reference population. + + + + obo:OGMS_0000074 + http://ontology.buffalo.edu/medo/Disease_and_Diagnosis.pdf + + + + obo:OGMS_0000074 + normal value + + + + obo:OGMS_0000077 + OGMS:0000077 + + + + obo:OGMS_0000077 + TODO: Define, relate to disorder, and place in the OGMS hierarchy. + + + + obo:OGMS_0000077 + http://ontology.buffalo.edu/bio/ISMB/ISMB_Bio-ontologies.pdf + + + + obo:OGMS_0000077 + pathological formation + + + + obo:OGMS_0000078 + OGMS:0000078 + + + + obo:OGMS_0000078 + An anatomical structure (FMA) is pathological whenever (1) it has come into being as a result of changes in some pre-existing canonical anatomical structure, (2) through processes other than the expression of the normal complement of genes of an organism of the given type, and (3) is predisposed to have health-related consequences for the organism in question manifested by symptoms and signs. + + + + obo:OGMS_0000078 + http://ontology.buffalo.edu/bio/ISMB/ISMB_Bio-ontologies.pdf + + + + obo:OGMS_0000078 + pathological anatomical structure + + + + obo:OGMS_0000079 + OGMS:0000079 + + + + obo:OGMS_0000079 + TODO: Define, relate to disorder, and place in the OGMS hierarchy. + + + + obo:OGMS_0000079 + http://ontology.buffalo.edu/bio/ISMB/ISMB_Bio-ontologies.pdf + + + + obo:OGMS_0000079 + portion of pathological body substance + + + + obo:OGMS_0000080 + OGMS:0000080 + + + + obo:OGMS_0000080 + A pathological bodily process in which a canonical anatomical structure becomes a pathological anatomical structure. + + + + obo:OGMS_0000080 + http://ontology.buffalo.edu/bio/ISMB/ISMB_Bio-ontologies.pdf + + + + obo:OGMS_0000080 + pathological transformation + + + + obo:OGMS_0000081 + OGMS:0000081 + + + + obo:OGMS_0000081 + A pathological bodily process in which matter is reorganized in such a way as to give rise to new pathological formations which take the place of entities existing earlier. + + + + obo:OGMS_0000081 + http://ontology.buffalo.edu/bio/ISMB/ISMB_Bio-ontologies.pdf + + + + obo:OGMS_0000081 + pathological derivation + + + + obo:OGMS_0000082 + OGMS:0000082 + + + + obo:OGMS_0000082 + TODO: Define. + + + + obo:OGMS_0000082 + http://ontology.buffalo.edu/bio/ISMB/ISMB_Bio-ontologies.pdf + + + + obo:OGMS_0000082 + pathological invasion + + + + obo:OGMS_0000083 + OGMS:0000083 + + + + obo:OGMS_0000083 + TODO: Define. + + + + obo:OGMS_0000083 + http://code.google.com/p/ogms/issues/detail?id=26 + + + + obo:OGMS_0000083 + physical examination finding + + + + obo:OGMS_0000084 + OGMS:0000084 + + + + obo:OGMS_0000084 + An aggregate of organisms of the same type. + + + + obo:OGMS_0000084 + http://code.google.com/p/ogms/issues/detail?id=33 + + + + obo:OGMS_0000084 + organism population + + + + obo:OGMS_0000086 + OGMS:0000086 + + + + obo:OGMS_0000086 + A pattern of signs and symptoms that typically co-occur. + + + + obo:OGMS_0000086 + http://code.google.com/p/ogms/issues/detail?id=32 + + + + obo:OGMS_0000086 + syndrome + + + + obo:OGMS_0000087 + OGMS:0000087 + + + + obo:OGMS_0000087 + An object aggregate consisting of an organism and all material entities located within the organism, overlapping the organism, or occupying sites formed in part by the organism. + + + + obo:OGMS_0000087 + http://code.google.com/p/ogms/issues/detail?id=3 + + + + obo:OGMS_0000087 + extended organism + + + + obo:OGMS_0000088 + OGMS:0000088 + + + + obo:OGMS_0000088 + A communication from a patient about something they perceive as being abnormal about their body or life. + + + + obo:OGMS_0000088 + http://code.google.com/p/ogms/issues/detail?id=12 + + + + obo:OGMS_0000088 + patient symptom report + + + + obo:OGMS_0000089 + OGMS:0000089 + + + + obo:OGMS_0000089 + A structurally anomalous part of an organism acquired during fetal development and present at birth (but not necessarily hereditary) which is hypothesized to be harmful for the organism. + + + + obo:OGMS_0000089 + http://code.google.com/p/ogms/issues/detail?id=28 + + + + obo:OGMS_0000089 + congenital malformation + + + + obo:OGMS_0000090 + OGMS:0000090 + + + + obo:OGMS_0000090 + A processual entity whose completion is hypothesized (by a healthcare provider) to alleviate the signs and symptoms associated with a disorder + + + + obo:OGMS_0000090 + http://code.google.com/p/ogms/issues/detail?id=35 + + + + obo:OGMS_0000090 + treatment + + + + obo:OGMS_0000091 + OGMS:0000091 + + + + obo:OGMS_0000091 + A processual entity during which a patient participating in a disease course gradually returns to participating in a canonical life course. + + + + obo:OGMS_0000091 + http://code.google.com/p/ogms/issues/detail?id=35 + + + + obo:OGMS_0000091 + convalescence + + + + obo:OGMS_0000092 + OGMS:0000092 + + + + obo:OGMS_0000092 + A processual entity which has as parts all the processes in which a given organism is participant. + + + + obo:OGMS_0000092 + http://code.google.com/p/ogms/issues/detail?id=38 + + + + obo:OGMS_0000092 + life course + + + + obo:OGMS_0000093 + OGMS:0000093 + + + + obo:OGMS_0000093 + A hypothesis about some future part of a disease course. + + + + obo:OGMS_0000093 + http://code.google.com/p/ogms/issues/detail?id=35 + + + + obo:OGMS_0000093 + prognosis + + + + obo:OGMS_0000094 + OGMS:0000094 + + + + obo:OGMS_0000094 + a disease course with a rapid onset but typical unfolding of signs and symptoms after this rapid onset. + + + + obo:OGMS_0000094 + http://code.google.com/p/ogms/wiki/Meeting_notes_20100513 + + + + obo:OGMS_0000094 + acute disease course + + + + obo:OGMS_0000095 + OGMS:0000095 + + + + obo:OGMS_0000095 + A process which is a response by an organism's tissues that is generally identified by swelling or localized pain + + + + obo:OGMS_0000095 + http://code.google.com/p/ogms/wiki/Meeting_notes_20100513 + + + + obo:OGMS_0000095 + inflammation process + + + + obo:OGMS_0000096 + OGMS:0000096 + + + + obo:OGMS_0000096 + A social process that has at least one human participant and that includes as parts the treatment, diagnosis, or prevention of disease or injury--or the following of instructions of another human for treatment, diagnosis, or prevention--of a participant in the process + + + + obo:OGMS_0000096 + http://groups.google.com/group/ogms-discuss/browse_thread/thread/a2dbc2ed1dff99d6 + + + + obo:OGMS_0000096 + health care process + + + + obo:OGMS_0000097 + OGMS:0000097 + + + + obo:OGMS_0000097 + A temporally-connected health care process that has as participants an organization or person realizing the health care provider role and a person realizing the patient role. The health care provider role and patient are realized during the health care encounter + + + + obo:OGMS_0000097 + http://groups.google.com/group/ogms-discuss/browse_thread/thread/a2dbc2ed1dff99d6 + + + + obo:OGMS_0000097 + health care encounter + + + + obo:OGMS_0000098 + OGMS:0000098 + + + + obo:OGMS_0000098 + TODO + + + + obo:OGMS_0000098 + http://groups.google.com/group/ogms-discuss/browse_thread/thread/a2dbc2ed1dff99d6 + + + + obo:OGMS_0000098 + hospitalization + + + + obo:OGMS_0000099 + OGMS:0000099 + + + + obo:OGMS_0000099 + TODO + + + + obo:OGMS_0000099 + http://groups.google.com/group/ogms-discuss/browse_thread/thread/a2dbc2ed1dff99d6 + + + + obo:OGMS_0000099 + outpatient encounter + + + + obo:OGMS_0000100 + OGMS:0000100 + + + + obo:OGMS_0000100 + TODO + + + + obo:OGMS_0000100 + http://groups.google.com/group/ogms-discuss/browse_thread/thread/a2dbc2ed1dff99d6 + + + + obo:OGMS_0000100 + inpatient encounter + + + + obo:OGMS_0000101 + OGMS:0000101 + + + + obo:OGMS_0000101 + TODO + + + + obo:OGMS_0000101 + http://groups.google.com/group/ogms-discuss/browse_thread/thread/a2dbc2ed1dff99d6 + + + + obo:OGMS_0000101 + ED encounter + + + + obo:OGMS_0000102 + OGMS:0000102 + + + + obo:OGMS_0000102 + A disorder that involves some structural damage that is immediately caused by a catastrophic external force. + + + + obo:OGMS_0000102 + At the scale of organism (as opposed to the cellular scale or the population scale), an injury is typically the result of a catastrophic event. Consider the implications of making 'injury' a subtype of 'disorder'. + +Note: Adopted subtype of disorder, and injury can occur at the scale of organism down to cellular level. + + + + obo:OGMS_0000102 + http://groups.google.com/group/ogms-discuss/browse_thread/thread/ca0ad373f27774c5 + +OGMS call adoption- 16 SEPT 2015 +https://docs.google.com/document/d/1iiV1-fTS7BUUSzDw3N_Afx42698YWf54-FOTY2NkAxo/edit + + + + + + obo:OGMS_0000102 + injury + + + + obo:OGMS_0000103 + OGMS:0000103 + + + + obo:OGMS_0000103 + A planned process that has the objective to reduce the risk of acquiring one or more disorders. + + + + obo:OGMS_0000103 + Whether or not 'prophylaxis' and 'treatment' classes are disjoint is an open question. + + + + obo:OGMS_0000103 + http://groups.google.com/group/ogms-discuss/browse_thread/thread/e42bde79218ee34e + + + + obo:OGMS_0000103 + prophylaxis + + + + obo:OGMS_0000104 + OGMS:0000104 + + + + obo:OGMS_0000104 + An interpretive process that has as input a clinical picture of a given patient and as output an assertion to the effect that the patient has a disease, disorder, or syndrome of a certain type, or none of these. + + + + obo:OGMS_0000104 + http://groups.google.com/group/ogms-discuss/browse_thread/thread/2a7008f311fac766/e7de486c94dfd82e + + + + obo:OGMS_0000104 + diagnostic process + + + + obo:OGMS_0000105 + OGMS:0000105 + + + + obo:OGMS_0000105 + A part of a disease course that occurs after an incomplete remission and that is similar to earlier parts of the disease course. + + + + obo:OGMS_0000105 + http://code.google.com/p/ogms/issues/detail?id=73 + + + + obo:OGMS_0000105 + relapse + + + + obo:OGMS_0000106 + OGMS:0000106 + + + + obo:OGMS_0000106 + A part of a disease course that includes a temporary convalescense. + + + + obo:OGMS_0000106 + http://code.google.com/p/ogms/issues/detail?id=73 + + + + obo:OGMS_0000106 + remission + + + + obo:RO_0000079 + a relation between a function and an independent continuant (the bearer), in which the function specifically depends on the bearer for its existence + + + + obo:RO_0000079 + function_of + + + + obo:RO_0000080 + a relation between a quality and an independent continuant (the bearer), in which the quality specifically depends on the bearer for its existence + + + + obo:RO_0000080 + quality_of + + + + obo:RO_0000081 + a relation between a role and an independent continuant (the bearer), in which the role specifically depends on the bearer for its existence + + + + obo:RO_0000081 + role_of + + + + obo:RO_0000092 + disposition_of + + + + obo:SYMP_0000075 + SYMP:0000075 + + + + obo:SYMP_0000075 + lethargy + + + + obo:SYMP_0000185 + SYMP:0000185 + + + + obo:SYMP_0000185 + weariness + + + + obo:SYMP_0000186 + SYMP:0000186 + + + + obo:SYMP_0000186 + exhaustion + + + + obo:SYMP_0000187 + SYMP:0000187 + + + + obo:SYMP_0000187 + tiredness + + + + obo:SYMP_0000279 + SYMP:0000279 + + + + obo:SYMP_0000279 + extreme exhaustion + + + + obo:SYMP_0000280 + SYMP:0000280 + + + + obo:SYMP_0000280 + extreme fatigue + + + + obo:SYMP_0000687 + SYMP:0000687 + + + + obo:SYMP_0000687 + chronic fatigue syndrome + + + + obo:SYMP_0019177 + SYMP:0019177 + + + + obo:SYMP_0019177 + 84229001 + + + + obo:SYMP_0019177 + fatigue + + + + obo:UO_0000001 + UO:0000001 + + + + obo:UO_0000001 + length unit + + + + obo:UO_0000002 + UO:0000002 + + + + obo:UO_0000002 + mass unit + + + + obo:UO_0000006 + UO:0000006 + + + + obo:UO_0000006 + substance unit + + + + obo:UO_0000008 + UO:0000008 + + + + obo:UO_0000008 + meter + + + + obo:UO_0000009 + UO:0000009 + + + + obo:UO_0000009 + kilogram + + + + obo:UO_0000013 + UO:0000013 + + + + obo:UO_0000013 + mole + + + + obo:UO_0000016 + UO:0000016 + + + + obo:UO_0000016 + millimeter + + + + obo:UO_0000040 + UO:0000040 + + + + obo:UO_0000040 + millimole + + + + obo:UO_0000052 + UO:0000052 + + + + obo:UO_0000052 + mass density unit + + + + obo:UO_0000054 + UO:0000054 + + + + obo:UO_0000054 + area density unit + + + + obo:UO_0000083 + UO:0000083 + + + + obo:UO_0000083 + kilogram per cubic meter + + + + obo:UO_0000084 + UO:0000084 + + + + obo:UO_0000084 + gram per cubic centimeter + + + + obo:UO_0000086 + UO:0000086 + + + + obo:UO_0000086 + kilogram per square meter + + + + obo:UO_0000095 + UO:0000095 + + + + obo:UO_0000095 + volume unit + + + + obo:UO_0000098 + UO:0000098 + + + + obo:UO_0000098 + milliliter + + + + obo:UO_0000099 + UO:0000099 + + + + obo:UO_0000099 + liter + + + + obo:UO_0000173 + UO:0000173 + + + + obo:UO_0000173 + gram per milliliter + + + + obo:UO_0000175 + UO:0000175 + + + + obo:UO_0000175 + gram per liter + + + + obo:UO_0000176 + UO:0000176 + + + + obo:UO_0000176 + milligram per milliliter + + + + obo:UO_0000177 + UO:0000177 + + + + obo:UO_0000177 + unit per volume unit + + + + obo:UO_0000178 + UO:0000178 + + + + obo:UO_0000178 + unit per milliliter + + + + obo:UO_0000179 + UO:0000179 + + + + obo:UO_0000179 + unit per liter + + + + obo:UO_0000182 + UO:0000182 + + + + obo:UO_0000182 + density unit + + + + obo:UO_0000208 + UO:0000208 + + + + obo:UO_0000208 + gram per deciliter + + + + obo:UO_0000209 + UO:0000209 + + + + obo:UO_0000209 + deciliter + + + + obo:UO_0000273 + UO:0000273 + + + + obo:UO_0000273 + milligram per liter + + + + obo:UO_0000275 + UO:0000275 + + + + obo:UO_0000275 + nanogram per milliliter + + + + obo:UO_0000279 + UO:0000279 + + + + obo:UO_0000279 + milliunits per milliliter + + + + obo:bfo.owl + BFO 2 Reference: BFO does not claim to be a complete coverage of all entities. It seeks only to provide coverage of those entities studied by empirical science together with those entities which affect or are involved in human activities such as data processing and planning – coverage that is sufficiently broad to provide assistance to those engaged in building domain ontologies for purposes of data annotation [17 + + + + obo:bfo.owl + BFO 2 Reference: BFO’s treatment of continuants and occurrents – as also its treatment of regions, rests on a dichotomy between space and time, and on the view that there are two perspectives on reality – earlier called the ‘SNAP’ and ‘SPAN’ perspectives, both of which are essential to the non-reductionist representation of reality as we understand it from the best available science [30 + + + + obo:bfo.owl + BFO 2 Reference: For both terms and relational expressions in BFO, we distinguish between primitive and defined. ‘Entity’ is an example of one such primitive term. Primitive terms in a highest-level ontology such as BFO are terms that are so basic to our understanding of reality that there is no way of defining them in a non-circular fashion. For these, therefore, we can provide only elucidations, supplemented by examples and by axioms. + + + + obo:bfo.owl + Alan Ruttenberg + + + + obo:bfo.owl + Albert Goldfain + + + + obo:bfo.owl + Barry Smith + + + + obo:bfo.owl + Bill Duncan + + + + obo:bfo.owl + Bjoern Peters + + + + obo:bfo.owl + Chris Mungall + + + + obo:bfo.owl + David Osumi-Sutherland + + + + obo:bfo.owl + Fabian Neuhaus + + + + obo:bfo.owl + James A. Overton + + + + obo:bfo.owl + Janna Hastings + + + + obo:bfo.owl + Jie Zheng + + + + obo:bfo.owl + Jonathan Bona + + + + obo:bfo.owl + Larry Hunter + + + + obo:bfo.owl + Leonard Jacuzzo + + + + obo:bfo.owl + Ludger Jansen + + + + obo:bfo.owl + Mark Ressler + + + + obo:bfo.owl + Mathias Brochhausen + + + + obo:bfo.owl + Mauricio Almeida + + + + obo:bfo.owl + Melanie Courtot + + + + obo:bfo.owl + Pierre Grenon + + + + obo:bfo.owl + Randall Dipert + + + + obo:bfo.owl + Robert Rovetto + + + + obo:bfo.owl + Ron Rudnicki + + + + obo:bfo.owl + Stefan Schulz + + + + obo:bfo.owl + Thomas Bittner + + + + obo:bfo.owl + Werner Ceusters + + + + obo:bfo.owl + Yongqun "Oliver" He + + + + obo:bfo.owl + http://creativecommons.org/licenses/by/3.0/ + + + + obo:bfo.owl + The http://purl.obolibary.org/obo/bfo/classes-only.owl variant of BFO ("bfo_classes_only.owl") includes only the class hierarchy and annotations from the full OWL version of BFO 2: http://purl.obolibary.org/obo/bfo.owl ("bfo.owl"). There are no object properties or logical axioms that use the object properties in bfo_classes_only.owl. As the logical axioms in the bfo_classes_only.owl variant are limited to subclass and disjoint assertions they are much weaker than the logical axioms in bfo.owl. + +If you plan to use the relations that define BFO 2, you should import bfo.owl instead of bfo_classes_only.owl. To the extent that the relations are used without importing bfo.owl, be mindful that they should be used in a manner consistent with their use in bfo.owl. Otherwise if your ontology is imported by a another ontology that imports bfo.owl there may be inconsistencies. + +See the BFO 2 release notes for further information about BFO 2. Please note that the current release of bfo.owl uses temporal relations when the subject or object is a continuant, a major change from BFO 1. + + + + obo:bfo.owl + This is an early version of BFO version 2 and has not yet been extensively reviewed by the project team members. Please see the project site http://code.google.com/p/bfo/ , the bfo2 owl discussion group http://groups.google.com/group/bfo-owl-devel , the bfo2 discussion group http://groups.google.com/group/bfo-devel, the tracking google doc http://goo.gl/IlrEE, and the current version of the bfo2 reference http://purl.obolibrary.org/obo/bfo/dev/bfo2-reference.docx . This ontology is generated from a specification at http://bfo.googlecode.com/svn/trunk/src/ontology/owl-group/specification/ and with the code that generates the OWL version in http://bfo.googlecode.com/svn/trunk/src/tools/. A very early version of BFO version 2 in CLIF is at http://purl.obolibrary.org/obo/bfo/dev/bfo.clif + + + + obo:bfo.owl + http://bfo.googlecode.com/svn/trunk/src/ontology/owl-group/specification/ + + + + obo:bfo.owl + obo:bfo/2012-07-20/Reference + + + + obo:bfo.owl + obo:bfo/2014-05-03/ReleaseNotes + + + + obo:bfo.owl + obo:bfo/dev/bfo.clif + + + + obo:bfo.owl + http://bfo.googlecode.com/svn/trunk/src/tools/ + + + + obo:bfo.owl + http://groups.google.com/group/bfo-devel + + + + obo:bfo.owl + http://groups.google.com/group/bfo-discuss + + + + obo:bfo.owl + http://groups.google.com/group/bfo-owl-devel + + + + obo:bfo.owl + obo:bfo/dev/owl + + + + obo:bfo.owl + http://code.google.com/p/bfo/ + + + + obo:bfo.owl + http://ifomis.org/bfo + + + + obo:bfo.owl + mailto:bfo-owl-devel@googlegroups.com + + + + obo:DDO.owl#0000362 + 450451007 + + + + obo:DDO.owl#0000362 + overweight in childhood + + + + obo:DDO.owl#BFO_0000054 + Paraphrase of elucidation: a relation between a realizable entity and a process, where there is some material entity that is bearer of the realizable entity and participates in the process, and the realizable entity comes to be realized in the course of the process + + + + obo:DDO.owl#BFO_0000054 + realized in + + + + obo:DDO.owl#BFO_0000055 + realizes + + + + obo:DDO.owl#CHEBI_24431 + DDO:CHEBI_24431 + + + + obo:DDO.owl#CHEBI_24431 + A chemical entity is a physical entity of interest in chemistry including molecular entities, parts thereof, and chemical substances. + + + + obo:DDO.owl#CHEBI_24431 + chemical entity + + + + obo:DDO.owl#CHEBI_59999 + DDO:CHEBI_59999 + + + + obo:DDO.owl#CHEBI_59999 + obo:DDO.owl#DDO_0000119 + + + + obo:DDO.owl#CHEBI_59999 + obo:DDO.owl#DDO_0000119 + + + + obo:DDO.owl#CHEBI_59999 + A chemical substance is a portion of matter of constant composition, composed of molecular entities of the same type or of different types. + + + + obo:DDO.owl#CHEBI_59999 + active ingredient + + + + obo:DDO.owl#DDDO_0003735 + DDO:DDDO_0003735 + + + + obo:DDO.owl#DDDO_0003735 + 197617009 + + + + obo:DDO.owl#DDDO_0003735 + chronic exudative glomerulonephritis + + + + obo:DDO.owl#DDOO_0001511 + DDO:DDOO_0001511 + + + + obo:DDO.owl#DDOO_0001511 + 58890000 + + + + obo:DDO.owl#DDOO_0001511 + adenoviral bronchopneumonia + + + + obo:DDO.owl#DDO_0000001 + snomed ct CID + + + + obo:DDO.owl#DDO_0000002 + UMLS CUI + + + + obo:DDO.owl#DDO_0000004 + DDO:DDO_0000004 + + + + obo:DDO.owl#DDO_0000004 + diabetes diagnosis + + + + obo:DDO.owl#DDO_0000111 + DDO:DDO_0000111 + + + + obo:DDO.owl#DDO_0000111 + 116154003 + + + + obo:DDO.owl#DDO_0000111 + patient_role + + + + obo:DDO.owl#DDO_0000112 + DDO:DDO_0000112 + + + + obo:DDO.owl#DDO_0000112 + 74627003 + + + + obo:DDO.owl#DDO_0000112 + diabetes complication + + + + obo:DDO.owl#DDO_0000114 + has_diagnosis + + + + obo:DDO.owl#DDO_0000118 + DDO:DDO_0000118 + + + + obo:DDO.owl#DDO_0000118 + human + + + + obo:DDO.owl#DDO_0000119 + DDO:DDO_0000119 + + + + obo:DDO.owl#DDO_0000119 + a material entity (1) containing at least one scattered molecular aggregate as part that is the bearer of an active ingredient role and (2) that is itself the bearer of a clinical drug role + + + + obo:DDO.owl#DDO_0000119 + glucose level affecting drug + + + + obo:DDO.owl#DDO_0000120 + not used object property and it has been updated. + + + + obo:DDO.owl#DDO_0000120 + takes_drug + + + + obo:DDO.owl#DDO_0000121 + has_risk_level + + + + obo:DDO.owl#DDO_0000122 + has_risk_percent + + + + obo:DDO.owl#DDO_0000123 + DDO:DDO_0000123 + + + + obo:DDO.owl#DDO_0000123 + social_role + + + + obo:DDO.owl#DDO_0000124 + DDO:DDO_0000124 + + + + obo:DDO.owl#DDO_0000124 + patient demographic + + + + obo:DDO.owl#DDO_0000125 + DDO:DDO_0000125 + + + + obo:DDO.owl#DDO_0000125 + age + + + + obo:DDO.owl#DDO_0000126 + DDO:DDO_0000126 + + + + obo:DDO.owl#DDO_0000126 + gender + + + + obo:DDO.owl#DDO_0000127 + DDO:DDO_0000127 + + + + obo:DDO.owl#DDO_0000127 + job + + + + obo:DDO.owl#DDO_0000128 + DDO:DDO_0000128 + + + + obo:DDO.owl#DDO_0000128 + level of education + + + + obo:DDO.owl#DDO_0000129 + DDO:DDO_0000129 + + + + obo:DDO.owl#DDO_0000129 + height + + + + obo:DDO.owl#DDO_0000130 + DDO:DDO_0000130 + + + + obo:DDO.owl#DDO_0000130 + weight + + + + obo:DDO.owl#DDO_0000134 + has_quantitative_Value + + + + obo:DDO.owl#DDO_0000135 + has_level_of_education + + + + obo:DDO.owl#DDO_0000138 + has_qualitative_value + + + + obo:DDO.owl#DDO_0000139 + has_demographic + + + + obo:DDO.owl#DDO_0000200 + DDO:DDO_0000200 + + + + obo:DDO.owl#DDO_0000200 + 2704003 + + + + obo:DDO.owl#DDO_0000200 + Acute disease + + + + obo:DDO.owl#DDO_0000201 + DDO:DDO_0000201 + + + + obo:DDO.owl#DDO_0000201 + chronic disease + + + + obo:DDO.owl#DDO_0000202 + DDO:DDO_0000202 + + + + obo:DDO.owl#DDO_0000202 + microvascular + + + + obo:DDO.owl#DDO_0000203 + DDO:DDO_0000203 + + + + obo:DDO.owl#DDO_0000203 + macrovascular + + + + obo:DDO.owl#DDO_0000204 + DDO:DDO_0000204 + + + + obo:DDO.owl#DDO_0000204 + vascular + + + + obo:DDO.owl#DDO_0000205 + DDO:DDO_0000205 + + + + obo:DDO.owl#DDO_0000205 + nonvascular + + + + obo:DDO.owl#DDO_0000206 + DDO:DDO_0000206 + + + + obo:DDO.owl#DDO_0000206 + 399625000 + + + + obo:DDO.owl#DDO_0000206 + retinopathy + + + + obo:DDO.owl#DDO_0000207 + DDO:DDO_0000207 + + + + obo:DDO.owl#DDO_0000207 + 386033004 + + + + obo:DDO.owl#DDO_0000207 + neuropathy + + + + obo:DDO.owl#DDO_0000208 + DDO:DDO_0000208 + + + + obo:DDO.owl#DDO_0000208 + 90708001 + + + + obo:DDO.owl#DDO_0000208 + kidney disease + + + + obo:DDO.owl#DDO_0000208 + nephrosis + + + + obo:DDO.owl#DDO_0000208 + nephropathy + + + + obo:DDO.owl#DDO_0000209 + DDO:DDO_0000209 + + + + obo:DDO.owl#DDO_0000209 + 13213009 + + + + obo:DDO.owl#DDO_0000209 + congenital heart disease + + + + obo:DDO.owl#DDO_0000210 + DDO:DDO_0000210 + + + + obo:DDO.owl#DDO_0000210 + Poor circulation + + + + obo:DDO.owl#DDO_0000210 + peripheral arterial disease (PAD) + + + + obo:DDO.owl#DDO_0000211 + DDO:DDO_0000211 + + + + obo:DDO.owl#DDO_0000211 + 22298006 + + + + obo:DDO.owl#DDO_0000211 + myocardial infarction + + + + obo:DDO.owl#DDO_0000212 + DDO:DDO_0000212 + + + + obo:DDO.owl#DDO_0000212 + 414545008 + + + + obo:DDO.owl#DDO_0000212 + ischemic heart disease + + + + obo:DDO.owl#DDO_0000213 + DDO:DDO_0000213 + + + + obo:DDO.owl#DDO_0000213 + Stroke + + + + obo:DDO.owl#DDO_0000216 + DDO:DDO_0000216 + + + + obo:DDO.owl#DDO_0000216 + dyslipidemia + + + + obo:DDO.owl#DDO_0000219 + DDO:DDO_0000219 + + + + obo:DDO.owl#DDO_0000219 + diabetic erectile dysfunction + + + + obo:DDO.owl#DDO_0000220 + DDO:DDO_0000220 + + + + obo:DDO.owl#DDO_0000220 + macro-micro + + + + obo:DDO.owl#DDO_0000222 + DDO:DDO_0000222 + + + + obo:DDO.owl#DDO_0000222 + 420422005 + + + + obo:DDO.owl#DDO_0000222 + diabetic ketoacidosis + + + + obo:DDO.owl#DDO_0000225 + DDO:DDO_0000225 + + + + obo:DDO.owl#DDO_0000225 + 91273001 + + + + obo:DDO.owl#DDO_0000225 + lactic acidosis + + + + obo:DDO.owl#DDO_0000226 + DDO:DDO_0000226 + + + + obo:DDO.owl#DDO_0000226 + hypoglycemic disorder + + + + obo:DDO.owl#DDO_0000227 + DDO:DDO_0000227 + + + + obo:DDO.owl#DDO_0000227 + hypoglycemic coma + + + + obo:DDO.owl#DDO_0000228 + DDO:DDO_0000228 + + + + obo:DDO.owl#DDO_0000228 + hypoglycemia + + + + obo:DDO.owl#DDO_0000229 + DDO:DDO_0000229 + + + + obo:DDO.owl#DDO_0000229 + 40733004 + + + + obo:DDO.owl#DDO_0000229 + infection + + + + obo:DDO.owl#DDO_0000230 + DDO:DDO_0000230 + + + + obo:DDO.owl#DDO_0000230 + BMI + + + + obo:DDO.owl#DDO_0000231 + DDO:DDO_0000231 + + + + obo:DDO.owl#DDO_0000231 + smoking + + + + obo:DDO.owl#DDO_0000232 + DDO:DDO_0000232 + + + + obo:DDO.owl#DDO_0000232 + physically inactive + + + + obo:DDO.owl#DDO_0000233 + DDO:DDO_0000233 + + + + obo:DDO.owl#DDO_0000233 + history of prediabetes + + + + obo:DDO.owl#DDO_0000234 + DDO:DDO_0000234 + + + + obo:DDO.owl#DDO_0000234 + first-degree relative with diabetes + + + + obo:DDO.owl#DDO_0000235 + DDO:DDO_0000235 + + + + obo:DDO.owl#DDO_0000235 + 472971004 + + + + obo:DDO.owl#DDO_0000235 + history of gestational diabetes + + + + obo:DDO.owl#DDO_0000236 + DDO:DDO_0000236 + + + + obo:DDO.owl#DDO_0000236 + baby delivered weighing more than 4.5 kg + + + + obo:DDO.owl#DDO_0000237 + has_boolean_value + + + + obo:DDO.owl#DDO_0000238 + has_physical_examination + + + + obo:DDO.owl#DDO_0000239 + DDO:DDO_0000239 + + + + obo:DDO.owl#DDO_0000239 + 271649006 + + + + obo:DDO.owl#DDO_0000239 + systolic blood pressure + + + + obo:DDO.owl#DDO_0000240 + DDO:DDO_0000240 + + + + obo:DDO.owl#DDO_0000240 + blood pressure + + + + obo:DDO.owl#DDO_0000241 + DDO:DDO_0000241 + + + + obo:DDO.owl#DDO_0000241 + 271650006 + + + + obo:DDO.owl#DDO_0000241 + diastolic blood pressure + + + + obo:DDO.owl#DDO_0000242 + DDO:DDO_0000242 + + + + obo:DDO.owl#DDO_0000242 + 33747003 + + + + obo:DDO.owl#DDO_0000242 + blood glucose test + + + + obo:DDO.owl#DDO_0000243 + DDO:DDO_0000243 + + + + obo:DDO.owl#DDO_0000243 + Hemoglobin A1c level + + + + obo:DDO.owl#DDO_0000243 + 43396009 + + + + obo:DDO.owl#DDO_0000243 + HbA1c + + + + obo:DDO.owl#DDO_0000244 + DDO:DDO_0000244 + + + + obo:DDO.owl#DDO_0000244 + plasma fasting glucose + + + + obo:DDO.owl#DDO_0000244 + 167096006 + + + + obo:DDO.owl#DDO_0000244 + FPG + + + + obo:DDO.owl#DDO_0000245 + DDO:DDO_0000245 + + + + obo:DDO.owl#DDO_0000245 + random plasma glucose + + + + obo:DDO.owl#DDO_0000245 + 167095005 + + + + obo:DDO.owl#DDO_0000245 + RPG + + + + obo:DDO.owl#DDO_0000246 + DDO:DDO_0000246 + + + + obo:DDO.owl#DDO_0000246 + Oral glucose tolerance test + + + + obo:DDO.owl#DDO_0000246 + 113076002 + + + + obo:DDO.owl#DDO_0000246 + OGTT + + + + obo:DDO.owl#DDO_0000247 + DDO:DDO_0000247 + + + + obo:DDO.owl#DDO_0000247 + 414387006 + + + + obo:DDO.owl#DDO_0000247 + hematological profile + + + + obo:DDO.owl#DDO_0000251 + DDO:DDO_0000251 + + + + obo:DDO.owl#DDO_0000251 + 14089001 + + + + obo:DDO.owl#DDO_0000251 + RBC - Red blood cell count + + + + obo:DDO.owl#DDO_0000252 + DDO:DDO_0000252 + + + + obo:DDO.owl#DDO_0000252 + Glycated haemoglobin - Hbg + + + + obo:DDO.owl#DDO_0000253 + DDO:DDO_0000253 + + + + obo:DDO.owl#DDO_0000253 + 28317006 + + + + obo:DDO.owl#DDO_0000253 + Hct - Hematocrit + + + + obo:DDO.owl#DDO_0000254 + DDO:DDO_0000254 + + + + obo:DDO.owl#DDO_0000254 + 104133003 + + + + obo:DDO.owl#DDO_0000254 + MCV - Mean cell volume + + + + obo:DDO.owl#DDO_0000255 + DDO:DDO_0000255 + + + + obo:DDO.owl#DDO_0000255 + 54706004 + + + + obo:DDO.owl#DDO_0000255 + MCH - Mean corpuscular hemoglobin + + + + obo:DDO.owl#DDO_0000256 + DDO:DDO_0000256 + + + + obo:DDO.owl#DDO_0000256 + 37254006 + + + + obo:DDO.owl#DDO_0000256 + MCHC - Mean cell hemoglobin concentration + + + + obo:DDO.owl#DDO_0000257 + DDO:DDO_0000257 + + + + obo:DDO.owl#DDO_0000257 + 61928009 + + + + obo:DDO.owl#DDO_0000257 + platelet count + + + + obo:DDO.owl#DDO_0000258 + DDO:DDO_0000258 + + + + obo:DDO.owl#DDO_0000258 + 767002 + + + + obo:DDO.owl#DDO_0000258 + WCC - White blood cell count + + + + obo:DDO.owl#DDO_0000259 + DDO:DDO_0000259 + + + + obo:DDO.owl#DDO_0000259 + 74765001 + + + + obo:DDO.owl#DDO_0000259 + lymphocytes count + + + + obo:DDO.owl#DDO_0000260 + DDO:DDO_0000260 + + + + obo:DDO.owl#DDO_0000260 + 67776007 + + + + obo:DDO.owl#DDO_0000260 + monocytes count + + + + obo:DDO.owl#DDO_0000261 + DDO:DDO_0000261 + + + + obo:DDO.owl#DDO_0000261 + 71960002 + + + + obo:DDO.owl#DDO_0000261 + eosinophils count + + + + obo:DDO.owl#DDO_0000262 + DDO:DDO_0000262 + + + + obo:DDO.owl#DDO_0000262 + 42351005 + + + + obo:DDO.owl#DDO_0000262 + basophils count + + + + obo:DDO.owl#DDO_0000263 + DDO:DDO_0000263 + + + + obo:DDO.owl#DDO_0000263 + 396451008 + + + + obo:DDO.owl#DDO_0000263 + PT - Prothrombin time + + + + obo:DDO.owl#DDO_0000264 + DDO:DDO_0000264 + + + + obo:DDO.owl#DDO_0000264 + 42525009 + + + + obo:DDO.owl#DDO_0000264 + PTT - Partial thromboplastin time - activated + + + + obo:DDO.owl#DDO_0000265 + DDO:DDO_0000265 + + + + obo:DDO.owl#DDO_0000265 + 55323000 + + + + obo:DDO.owl#DDO_0000265 + TT - Thrombin time + + + + obo:DDO.owl#DDO_0000266 + DDO:DDO_0000266 + + + + obo:DDO.owl#DDO_0000266 + 250346004 + + + + obo:DDO.owl#DDO_0000266 + fibrinogen level + + + + obo:DDO.owl#DDO_0000267 + DDO:DDO_0000267 + + + + obo:DDO.owl#DDO_0000267 + kidney function test + + + + obo:DDO.owl#DDO_0000268 + DDO:DDO_0000268 + + + + obo:DDO.owl#DDO_0000268 + 273967009 + + + + obo:DDO.owl#DDO_0000268 + serum urea + + + + obo:DDO.owl#DDO_0000269 + DDO:DDO_0000269 + + + + obo:DDO.owl#DDO_0000269 + 275740009 + + + + obo:DDO.owl#DDO_0000269 + serum uric acid + + + + obo:DDO.owl#DDO_0000270 + DDO:DDO_0000270 + + + + obo:DDO.owl#DDO_0000270 + 113075003 + + + + obo:DDO.owl#DDO_0000270 + serum creatinine + + + + obo:DDO.owl#DDO_0000271 + DDO:DDO_0000271 + + + + obo:DDO.owl#DDO_0000271 + 104934005 + + + + obo:DDO.owl#DDO_0000271 + serum sodium + + + + obo:DDO.owl#DDO_0000272 + DDO:DDO_0000272 + + + + obo:DDO.owl#DDO_0000272 + 271236005 + + + + obo:DDO.owl#DDO_0000272 + serum potassium + + + + obo:DDO.owl#DDO_0000273 + DDO:DDO_0000273 + + + + obo:DDO.owl#DDO_0000273 + lipid profile + + + + obo:DDO.owl#DDO_0000274 + DDO:DDO_0000274 + + + + obo:DDO.owl#DDO_0000274 + 121868005 + + + + obo:DDO.owl#DDO_0000274 + total cholesterol + + + + obo:DDO.owl#DDO_0000275 + DDO:DDO_0000275 + + + + obo:DDO.owl#DDO_0000275 + 14740000 + + + + obo:DDO.owl#DDO_0000275 + TG - triglyceride level + + + + obo:DDO.owl#DDO_0000276 + DDO:DDO_0000276 + + + + obo:DDO.owl#DDO_0000276 + 28036006 + + + + obo:DDO.owl#DDO_0000276 + HDL - high density lipoprotein cholesterol + + + + obo:DDO.owl#DDO_0000277 + DDO:DDO_0000277 + + + + obo:DDO.owl#DDO_0000277 + 113079009 + + + + obo:DDO.owl#DDO_0000277 + LDLC - low density lipoprotein cholesterol + + + + obo:DDO.owl#DDO_0000278 + DDO:DDO_0000278 + + + + obo:DDO.owl#DDO_0000278 + tumor marker + + + + obo:DDO.owl#DDO_0000279 + DDO:DDO_0000279 + + + + obo:DDO.owl#DDO_0000279 + 80529009 + + + + obo:DDO.owl#DDO_0000279 + CA-125 + + + + obo:DDO.owl#DDO_0000280 + DDO:DDO_0000280 + + + + obo:DDO.owl#DDO_0000280 + 104404005 + + + + obo:DDO.owl#DDO_0000280 + serum alpha-fetoprotein + + + + obo:DDO.owl#DDO_0000281 + DDO:DDO_0000281 + + + + obo:DDO.owl#DDO_0000281 + 489004 + + + + obo:DDO.owl#DDO_0000281 + ferritin + + + + obo:DDO.owl#DDO_0000282 + DDO:DDO_0000282 + + + + obo:DDO.owl#DDO_0000282 + 67900009 + + + + obo:DDO.owl#DDO_0000282 + HCG - human chorionic gonadotropin + + + + obo:DDO.owl#DDO_0000283 + DDO:DDO_0000283 + + + + obo:DDO.owl#DDO_0000283 + 60267001 + + + + obo:DDO.owl#DDO_0000283 + CEN - carcinoembryonic antigen + + + + obo:DDO.owl#DDO_0000284 + DDO:DDO_0000284 + + + + obo:DDO.owl#DDO_0000284 + 63476009 + + + + obo:DDO.owl#DDO_0000284 + PSA - Prostate-specific antigen + + + + obo:DDO.owl#DDO_0000285 + DDO:DDO_0000285 + + + + obo:DDO.owl#DDO_0000285 + 40939009 + + + + obo:DDO.owl#DDO_0000285 + CA 19-9 + + + + obo:DDO.owl#DDO_0000286 + DDO:DDO_0000286 + + + + obo:DDO.owl#DDO_0000286 + 113058009 + + + + obo:DDO.owl#DDO_0000286 + CA 15-3 + + + + obo:DDO.owl#DDO_0000287 + DDO:DDO_0000287 + + + + obo:DDO.owl#DDO_0000287 + 445430004 + + + + obo:DDO.owl#DDO_0000287 + CA 27-29 + + + + obo:DDO.owl#DDO_0000288 + DDO:DDO_0000288 + + + + obo:DDO.owl#DDO_0000288 + 11274001 + + + + obo:DDO.owl#DDO_0000288 + LDH - lactate dehydrogenase + + + + obo:DDO.owl#DDO_0000289 + DDO:DDO_0000289 + + + + obo:DDO.owl#DDO_0000289 + urine analysis + + + + obo:DDO.owl#DDO_0000290 + DDO:DDO_0000290 + + + + obo:DDO.owl#DDO_0000290 + chemical examination + + + + obo:DDO.owl#DDO_0000291 + DDO:DDO_0000291 + + + + obo:DDO.owl#DDO_0000291 + microscopic examination + + + + obo:DDO.owl#DDO_0000292 + DDO:DDO_0000292 + + + + obo:DDO.owl#DDO_0000292 + 269880000 + + + + obo:DDO.owl#DDO_0000292 + pus cells + + + + obo:DDO.owl#DDO_0000293 + DDO:DDO_0000293 + + + + obo:DDO.owl#DDO_0000293 + 104122001 + + + + obo:DDO.owl#DDO_0000293 + red blood cells + + + + obo:DDO.owl#DDO_0000294 + DDO:DDO_0000294 + + + + obo:DDO.owl#DDO_0000294 + 167340007 + + + + obo:DDO.owl#DDO_0000294 + crystals + + + + obo:DDO.owl#DDO_0000295 + DDO:DDO_0000295 + + + + obo:DDO.owl#DDO_0000295 + 57378007 + + + + obo:DDO.owl#DDO_0000295 + urine protein + + + + obo:DDO.owl#DDO_0000296 + DDO:DDO_0000296 + + + + obo:DDO.owl#DDO_0000296 + 307821001 + + + + obo:DDO.owl#DDO_0000296 + urine blood + + + + obo:DDO.owl#DDO_0000297 + DDO:DDO_0000297 + + + + obo:DDO.owl#DDO_0000297 + 359992002 + + + + obo:DDO.owl#DDO_0000297 + urine bilirubin + + + + obo:DDO.owl#DDO_0000298 + DDO:DDO_0000298 + + + + obo:DDO.owl#DDO_0000298 + 69376001 + + + + obo:DDO.owl#DDO_0000298 + urine glucose + + + + obo:DDO.owl#DDO_0000299 + DDO:DDO_0000299 + + + + obo:DDO.owl#DDO_0000299 + 167285005 + + + + obo:DDO.owl#DDO_0000299 + urine ketones + + + + obo:DDO.owl#DDO_0000300 + DDO:DDO_0000300 + + + + obo:DDO.owl#DDO_0000300 + 67410005 + + + + obo:DDO.owl#DDO_0000300 + urine urobilinogen + + + + obo:DDO.owl#DDO_0000301 + DDO:DDO_0000301 + + + + obo:DDO.owl#DDO_0000301 + liver function test + + + + obo:DDO.owl#DDO_0000302 + DDO:DDO_0000302 + + + + obo:DDO.owl#DDO_0000302 + 359986008 + + + + obo:DDO.owl#DDO_0000302 + total bilirubin + + + + obo:DDO.owl#DDO_0000303 + DDO:DDO_0000303 + + + + obo:DDO.owl#DDO_0000303 + 39748002 + + + + obo:DDO.owl#DDO_0000303 + direct bilirubin + + + + obo:DDO.owl#DDO_0000304 + DDO:DDO_0000304 + + + + obo:DDO.owl#DDO_0000304 + 45896001 + + + + obo:DDO.owl#DDO_0000304 + SGOT(AST) + + + + obo:DDO.owl#DDO_0000305 + DDO:DDO_0000305 + + + + obo:DDO.owl#DDO_0000305 + 34608000 + + + + obo:DDO.owl#DDO_0000305 + SGPT + + + + obo:DDO.owl#DDO_0000306 + DDO:DDO_0000306 + + + + obo:DDO.owl#DDO_0000306 + 88810008 + + + + obo:DDO.owl#DDO_0000306 + alkaline phosphatase + + + + obo:DDO.owl#DDO_0000307 + DDO:DDO_0000307 + + + + obo:DDO.owl#DDO_0000307 + gamma GT + + + + obo:DDO.owl#DDO_0000308 + DDO:DDO_0000308 + + + + obo:DDO.owl#DDO_0000308 + 304383000 + + + + obo:DDO.owl#DDO_0000308 + total protein + + + + obo:DDO.owl#DDO_0000309 + DDO:DDO_0000309 + + + + obo:DDO.owl#DDO_0000309 + 104485008 + + + + obo:DDO.owl#DDO_0000309 + serum albumin + + + + obo:DDO.owl#DDO_0000311 + has_lab_test + + + + obo:DDO.owl#DDO_0000320 + DDO:DDO_0000320 + + + + obo:DDO.owl#DDO_0000320 + 445396007 + + + + obo:DDO.owl#DDO_0000320 + waist circumference + + + + obo:DDO.owl#DDO_0000321 + DDO:DDO_0000321 + + + + obo:DDO.owl#DDO_0000321 + drinking alcohol + + + + obo:DDO.owl#DDO_0000322 + DDO:DDO_0000322 + + + + obo:DDO.owl#DDO_0000322 + 16890009 + + + + obo:DDO.owl#DDO_0000322 + insulin measurement + + + + obo:DDO.owl#DDO_0000323 + DDO:DDO_0000323 + + + + obo:DDO.owl#DDO_0000323 + 88705004 + + + + obo:DDO.owl#DDO_0000323 + C-peptide + + + + obo:DDO.owl#DDO_0000324 + DDO:DDO_0000324 + + + + obo:DDO.owl#DDO_0000324 + 314067002 + + + + obo:DDO.owl#DDO_0000324 + autoantibody + + + + obo:DDO.owl#DDO_0000325 + DDO:DDO_0000325 + + + + obo:DDO.owl#DDO_0000325 + 391548002 + + + + obo:DDO.owl#DDO_0000325 + glutamic acid decarboxylase antibody + + + + obo:DDO.owl#DDO_0000326 + DDO:DDO_0000326 + + + + obo:DDO.owl#DDO_0000326 + 44628004 + + + + obo:DDO.owl#DDO_0000326 + serum osmolality + + + + obo:DDO.owl#DDO_0000327 + DDO:DDO_0000327 + + + + obo:DDO.owl#DDO_0000327 + 64135003 + + + + obo:DDO.owl#DDO_0000327 + islet cell cytoplasma antibody + + + + obo:DDO.owl#DDO_0000328 + DDO:DDO_0000328 + + + + obo:DDO.owl#DDO_0000328 + 391548002 + + + + obo:DDO.owl#DDO_0000328 + glutamic acid decarboxylase antibody + + + + obo:DDO.owl#DDO_0000329 + DDO:DDO_0000329 + + + + obo:DDO.owl#DDO_0000329 + 37076009 + + + + obo:DDO.owl#DDO_0000329 + insulin antibodies + + + + obo:DDO.owl#DDO_0000330 + DDO:DDO_0000330 + + + + obo:DDO.owl#DDO_0000330 + 401143003 + + + + obo:DDO.owl#DDO_0000330 + plasma bicarbonate + + + + obo:DDO.owl#DDO_0000331 + DDO:DDO_0000331 + + + + obo:DDO.owl#DDO_0000331 + 104390007 + + + + obo:DDO.owl#DDO_0000331 + thyroid autoantibodies + + + + obo:DDO.owl#DDO_0000332 + DDO:DDO_0000332 + + + + obo:DDO.owl#DDO_0000332 + dry mouth + + + + obo:DDO.owl#DDO_0000333 + DDO:DDO_0000333 + + + + obo:DDO.owl#DDO_0000333 + 422587007 + + + + obo:DDO.owl#DDO_0000333 + nausea + + + + obo:DDO.owl#DDO_0000334 + DDO:DDO_0000334 + + + + obo:DDO.owl#DDO_0000334 + frequent vaginal infections + + + + obo:DDO.owl#DDO_0000335 + DDO:DDO_0000335 + + + + obo:DDO.owl#DDO_0000335 + slow wound healing + + + + obo:DDO.owl#DDO_0000336 + DDO:DDO_0000336 + + + + obo:DDO.owl#DDO_0000336 + 44077006 + + + + obo:DDO.owl#DDO_0000336 + numbness + + + + obo:DDO.owl#DDO_0000337 + DDO:DDO_0000337 + + + + obo:DDO.owl#DDO_0000337 + 274676007 + + + + obo:DDO.owl#DDO_0000337 + tingling of skin + + + + obo:DDO.owl#DDO_0000338 + DDO:DDO_0000338 + + + + obo:DDO.owl#DDO_0000338 + 28442001 + + + + obo:DDO.owl#DDO_0000338 + polyuria + + + + obo:DDO.owl#DDO_0000339 + DDO:DDO_0000339 + + + + obo:DDO.owl#DDO_0000339 + 56574000 + + + + obo:DDO.owl#DDO_0000339 + polydipsia + + + + obo:DDO.owl#DDO_0000340 + DDO:DDO_0000340 + + + + obo:DDO.owl#DDO_0000340 + 267023007 + + + + obo:DDO.owl#DDO_0000340 + Polyphagia + + + + obo:DDO.owl#DDO_0000341 + DDO:DDO_0000341 + + + + obo:DDO.owl#DDO_0000341 + 139394000 + + + + obo:DDO.owl#DDO_0000341 + nocturia + + + + obo:DDO.owl#DDO_0000342 + DDO:DDO_0000342 + + + + obo:DDO.owl#DDO_0000342 + bladder dysfunction + + + + obo:DDO.owl#DDO_0000343 + DDO:DDO_0000343 + + + + obo:DDO.owl#DDO_0000343 + 63102001 + + + + obo:DDO.owl#DDO_0000343 + blurred vision + + + + obo:DDO.owl#DDO_0000344 + DDO:DDO_0000344 + + + + obo:DDO.owl#DDO_0000344 + 62315008 + + + + obo:DDO.owl#DDO_0000344 + diarrhea + + + + obo:DDO.owl#DDO_0000345 + DDO:DDO_0000345 + + + + obo:DDO.owl#DDO_0000345 + 5891000119102 + + + + obo:DDO.owl#DDO_0000345 + clostridium difficile diarrhea + + + + obo:DDO.owl#DDO_0000346 + DDO:DDO_0000346 + + + + obo:DDO.owl#DDO_0000346 + 18425006 + + + + obo:DDO.owl#DDO_0000346 + passage of rice water stools + + + + obo:DDO.owl#DDO_0000347 + DDO:DDO_0000347 + + + + obo:DDO.owl#DDO_0000347 + 14384003 + + + + obo:DDO.owl#DDO_0000347 + postprandial diarrhea + + + + obo:DDO.owl#DDO_0000348 + DDO:DDO_0000348 + + + + obo:DDO.owl#DDO_0000348 + 236077008 + + + + obo:DDO.owl#DDO_0000348 + protracted diarrhea + + + + obo:DDO.owl#DDO_0000349 + DDO:DDO_0000349 + + + + obo:DDO.owl#DDO_0000349 + 264521008 + + + + obo:DDO.owl#DDO_0000349 + euthyroid + + + + obo:DDO.owl#DDO_0000350 + DDO:DDO_0000350 + + + + obo:DDO.owl#DDO_0000350 + 409587002 + + + + obo:DDO.owl#DDO_0000350 + severe diarrhea + + + + obo:DDO.owl#DDO_0000351 + DDO:DDO_0000351 + + + + obo:DDO.owl#DDO_0000351 + 391465009 + + + + obo:DDO.owl#DDO_0000351 + blood ketone + + + + obo:DDO.owl#DDO_0000352 + DDO:DDO_0000352 + + + + obo:DDO.owl#DDO_0000352 + 401260000 + + + + obo:DDO.owl#DDO_0000352 + serum ketone + + + + obo:DDO.owl#DDO_0000353 + DDO:DDO_0000353 + + + + obo:DDO.owl#DDO_0000353 + 14735008 + + + + obo:DDO.owl#DDO_0000353 + hyperosmolarity + + + + obo:DDO.owl#DDO_0000354 + DDO:DDO_0000354 + + + + obo:DDO.owl#DDO_0000354 + 46716003 + + + + obo:DDO.owl#DDO_0000354 + urine microalbumin + + + + obo:DDO.owl#DDO_0000355 + DDO:DDO_0000355 + + + + obo:DDO.owl#DDO_0000355 + 313936008 + + + + obo:DDO.owl#DDO_0000355 + plasma creatinine + + + + obo:DDO.owl#DDO_0000356 + DDO:DDO_0000356 + + + + obo:DDO.owl#DDO_0000356 + high-risk population + + + + obo:DDO.owl#DDO_0000357 + DDO:DDO_0000357 + + + + obo:DDO.owl#DDO_0000357 + 131078003 + + + + obo:DDO.owl#DDO_0000357 + decreased testosterone level + + + + obo:DDO.owl#DDO_0000358 + DDO:DDO_0000358 + + + + obo:DDO.owl#DDO_0000358 + lost foot sensation + + + + obo:DDO.owl#DDO_0000359 + DDO:DDO_0000359 + + + + obo:DDO.owl#DDO_0000359 + 302074003 + + + + obo:DDO.owl#DDO_0000359 + thyroid function + + + + obo:DDO.owl#DDO_0000360 + DDO:DDO_0000360 + + + + obo:DDO.owl#DDO_0000360 + 238131007 + + + + obo:DDO.owl#DDO_0000360 + overweight + + + + obo:DDO.owl#DDO_0000361 + DDO:DDO_0000361 + + + + obo:DDO.owl#DDO_0000361 + 162863004 + + + + obo:DDO.owl#DDO_0000361 + body mass index 25-29 - overweight + + + + obo:DDO.owl#DDO_0000362 + DDO:DDO_0000362 + + + + obo:DDO.owl#DDO_0000362 + family history of type 1 diabetes mellitus + + + + obo:DDO.owl#DDO_0000363 + DDO:DDO_0000363 + + + + obo:DDO.owl#DDO_0000363 + personal history of hemochromatosis + + + + obo:DDO.owl#DDO_0000364 + DDO:DDO_0000364 + + + + obo:DDO.owl#DDO_0000364 + family history of hemochromatosis + + + + obo:DDO.owl#DDO_0000365 + DDO:DDO_0000365 + + + + obo:DDO.owl#DDO_0000365 + 55350005 + + + + obo:DDO.owl#DDO_0000365 + hunger + + + + obo:DDO.owl#DDO_0000366 + DDO:DDO_0000366 + + + + obo:DDO.owl#DDO_0000366 + 249472009 + + + + obo:DDO.owl#DDO_0000366 + always hungry + + + + obo:DDO.owl#DDO_0000367 + DDO:DDO_0000367 + + + + obo:DDO.owl#DDO_0000367 + 32939004 + + + + obo:DDO.owl#DDO_0000367 + morbid hunger + + + + obo:DDO.owl#DDO_0000368 + DDO:DDO_0000368 + + + + obo:DDO.owl#DDO_0000368 + serum adiponectin + + + + obo:DDO.owl#DDO_0000369 + DDO:DDO_0000369 + + + + obo:DDO.owl#DDO_0000369 + 270997002 + + + + obo:DDO.owl#DDO_0000369 + serum_fructosamine + + + + obo:DDO.owl#DDO_0000370 + DDO:DDO_0000370 + + + + obo:DDO.owl#DDO_0000370 + serum fetuin-A + + + + obo:DDO.owl#DDO_0000371 + DDO:DDO_0000371 + + + + obo:DDO.owl#DDO_0000371 + 125680007 + + + + obo:DDO.owl#DDO_0000371 + marital status + + + + obo:DDO.owl#DDO_0000372 + DDO:DDO_0000372 + + + + obo:DDO.owl#DDO_0000372 + 237597000 + + + + obo:DDO.owl#DDO_0000372 + glucose regulation + + + + obo:DDO.owl#DDO_0000373 + DDO:DDO_0000373 + + + + obo:DDO.owl#DDO_0000373 + 426255005 + + + + obo:DDO.owl#DDO_0000373 + dysglycemia + + + + obo:DDO.owl#DDO_0000374 + DDO:DDO_0000374 + + + + obo:DDO.owl#DDO_0000374 + 48839007 + + + + obo:DDO.owl#DDO_0000374 + glucagon resistance + + + + obo:DDO.owl#DDO_0000375 + DDO:DDO_0000375 + + + + obo:DDO.owl#DDO_0000375 + hyperglycemic disorder + + + + obo:DDO.owl#DDO_0000376 + DDO:DDO_0000376 + + + + obo:DDO.owl#DDO_0000376 + 237625008 + + + + obo:DDO.owl#DDO_0000376 + hyperglycemic disorder in pregnancy + + + + obo:DDO.owl#DDO_0000391 + DDO:DDO_0000391 + + + + obo:DDO.owl#DDO_0000391 + family history of type 2 diabetes mellitus + + + + obo:DDO.owl#DDO_0000392 + DDO:DDO_0000392 + + + + obo:DDO.owl#DDO_0000392 + 237628005 + + + + obo:DDO.owl#DDO_0000392 + impaired glucose tolerance in pregnancy + + + + obo:DDO.owl#DDO_0000393 + DDO:DDO_0000393 + + + + obo:DDO.owl#DDO_0000393 + 390951007 + + + + obo:DDO.owl#DDO_0000393 + impaired fasting glycaemia + + + + obo:DDO.owl#DDO_0000394 + DDO:DDO_0000394 + + + + obo:DDO.owl#DDO_0000394 + 237624007 + + + + obo:DDO.owl#DDO_0000394 + metabolic stress hyperglycemia + + + + obo:DDO.owl#DDO_0000395 + DDO:DDO_0000395 + + + + obo:DDO.owl#DDO_0000395 + 37814003 + + + + obo:DDO.owl#DDO_0000395 + postpancreatectomy hyperglycemia + + + + obo:DDO.owl#DDO_0000396 + DDO:DDO_0000396 + + + + obo:DDO.owl#DDO_0000396 + hyperinsulinism + + + + obo:DDO.owl#DDO_0000397 + DDO:DDO_0000397 + + + + obo:DDO.owl#DDO_0000397 + 237647008 + + + + obo:DDO.owl#DDO_0000397 + alimentary hyperinsulinemia + + + + obo:DDO.owl#DDO_0000398 + DDO:DDO_0000398 + + + + obo:DDO.owl#DDO_0000398 + 360339005 + + + + obo:DDO.owl#DDO_0000398 + congenital hyperinsulinism + + + + obo:DDO.owl#DDO_0000399 + DDO:DDO_0000399 + + + + obo:DDO.owl#DDO_0000399 + 237646004 + + + + obo:DDO.owl#DDO_0000399 + drug-induced hyperinsulinemia + + + + obo:DDO.owl#DDO_0000400 + DDO:DDO_0000400 + + + + obo:DDO.owl#DDO_0000400 + 37703005 + + + + obo:DDO.owl#DDO_0000400 + ectopic hyperinsulinism + + + + obo:DDO.owl#DDO_0000401 + DDO:DDO_0000401 + + + + obo:DDO.owl#DDO_0000401 + 12002009 + + + + obo:DDO.owl#DDO_0000401 + functional hyperinsulinism + + + + obo:DDO.owl#DDO_00004011 + DDO:DDO_00004011 + + + + obo:DDO.owl#DDO_00004011 + 52767006 + + + + obo:DDO.owl#DDO_00004011 + neonatal hypoglycemia + + + + obo:DDO.owl#DDO_00004012 + DDO:DDO_00004012 + + + + obo:DDO.owl#DDO_00004012 + 276562001 + + + + obo:DDO.owl#DDO_00004012 + iatrogenic neonatal hypoglycemia + + + + obo:DDO.owl#DDO_00004013 + DDO:DDO_00004013 + + + + obo:DDO.owl#DDO_00004013 + 276561008 + + + + obo:DDO.owl#DDO_00004013 + transitory neonatal hypoglycemia + + + + obo:DDO.owl#DDO_00004014 + DDO:DDO_00004014 + + + + obo:DDO.owl#DDO_00004014 + 237639008 + + + + obo:DDO.owl#DDO_00004014 + alimentary hypoglycemia + + + + obo:DDO.owl#DDO_0000402 + DDO:DDO_0000402 + + + + obo:DDO.owl#DDO_0000402 + 237648003 + + + + obo:DDO.owl#DDO_0000402 + hyperinsulinemia due to insulinoma + + + + obo:DDO.owl#DDO_0000403 + DDO:DDO_0000403 + + + + obo:DDO.owl#DDO_0000403 + 90054000 + + + + obo:DDO.owl#DDO_0000403 + iatrogenic hyperinsulinism + + + + obo:DDO.owl#DDO_0000404 + DDO:DDO_0000404 + + + + obo:DDO.owl#DDO_0000404 + 276563006 + + + + obo:DDO.owl#DDO_0000404 + idiopathic transient neonatal hyperinsulinemia + + + + obo:DDO.owl#DDO_0000405 + DDO:DDO_0000405 + + + + obo:DDO.owl#DDO_0000405 + 128264007 + + + + obo:DDO.owl#DDO_0000405 + impaired glucose tolerance with hyperinsulism + + + + obo:DDO.owl#DDO_0000406 + DDO:DDO_0000406 + + + + obo:DDO.owl#DDO_0000406 + 190429008 + + + + obo:DDO.owl#DDO_0000406 + self-induced hyperinsulinemia + + + + obo:DDO.owl#DDO_0000407 + DDO:DDO_0000407 + + + + obo:DDO.owl#DDO_0000407 + 237630007 + + + + obo:DDO.owl#DDO_0000407 + hypoglycemic disorder + + + + obo:DDO.owl#DDO_0000408 + DDO:DDO_0000408 + + + + obo:DDO.owl#DDO_0000408 + 71858003 + + + + obo:DDO.owl#DDO_0000408 + autoimmune hypoglycemia + + + + obo:DDO.owl#DDO_0000409 + DDO:DDO_0000409 + + + + obo:DDO.owl#DDO_0000409 + 16966009 + + + + obo:DDO.owl#DDO_0000409 + factitious hypoglycemia + + + + obo:DDO.owl#DDO_0000410 + DDO:DDO_0000410 + + + + obo:DDO.owl#DDO_0000410 + 302866003 + + + + obo:DDO.owl#DDO_0000410 + hypoglycemia + + + + obo:DDO.owl#DDO_0000413 + DDO:DDO_0000413 + + + + obo:DDO.owl#DDO_0000413 + 197483008 + + + + obo:DDO.owl#DDO_0000413 + post gastrointestinal tract surgery hypoglycemia + + + + obo:DDO.owl#DDO_0000415 + DDO:DDO_0000415 + + + + obo:DDO.owl#DDO_0000415 + 235667000 + + + + obo:DDO.owl#DDO_0000415 + late dumping syndrome + + + + obo:DDO.owl#DDO_0000416 + DDO:DDO_0000416 + + + + obo:DDO.owl#DDO_0000416 + 68581004 + + + + obo:DDO.owl#DDO_0000416 + hypoglycemia of childhood + + + + obo:DDO.owl#DDO_0000417 + DDO:DDO_0000417 + + + + obo:DDO.owl#DDO_0000417 + 267384006 + + + + obo:DDO.owl#DDO_0000417 + hypoglycemic coma + + + + obo:DDO.owl#DDO_0000418 + DDO:DDO_0000418 + + + + obo:DDO.owl#DDO_0000418 + 421725003 + + + + obo:DDO.owl#DDO_0000418 + hypoglycemic coma in diabetes mellitus + + + + obo:DDO.owl#DDO_0000419 + DDO:DDO_0000419 + + + + obo:DDO.owl#DDO_0000419 + 421437000 + + + + obo:DDO.owl#DDO_0000419 + hypoglycemic coma in type 1 diabetes mellitus + + + + obo:DDO.owl#DDO_0000420 + DDO:DDO_0000420 + + + + obo:DDO.owl#DDO_0000420 + 421164006 + + + + obo:DDO.owl#DDO_0000420 + hypoglycemic coma in type 2 diabetes mellitus + + + + obo:DDO.owl#DDO_0000421 + DDO:DDO_0000421 + + + + obo:DDO.owl#DDO_0000421 + 111558006 + + + + obo:DDO.owl#DDO_0000421 + insulin coma + + + + obo:DDO.owl#DDO_0000422 + DDO:DDO_0000422 + + + + obo:DDO.owl#DDO_0000422 + 360546002 + + + + obo:DDO.owl#DDO_0000422 + hypoglycemic shock + + + + obo:DDO.owl#DDO_0000423 + DDO:DDO_0000423 + + + + obo:DDO.owl#DDO_0000423 + 20825002 + + + + obo:DDO.owl#DDO_0000423 + ketotic hypoglycemia + + + + obo:DDO.owl#DDO_0000424 + DDO:DDO_0000424 + + + + obo:DDO.owl#DDO_0000424 + 62151007 + + + + obo:DDO.owl#DDO_0000424 + leucine-induced hypoglycemia + + + + obo:DDO.owl#DDO_0000425 + DDO:DDO_0000425 + + + + obo:DDO.owl#DDO_0000425 + 66095000 + + + + obo:DDO.owl#DDO_0000425 + mixed hypoglycemia + + + + obo:DDO.owl#DDO_0000426 + DDO:DDO_0000426 + + + + obo:DDO.owl#DDO_0000426 + 237631006 + + + + obo:DDO.owl#DDO_0000426 + neuroglycopenia + + + + obo:DDO.owl#DDO_0000428 + DDO:DDO_0000428 + + + + obo:DDO.owl#DDO_0000428 + 9414007 + + + + obo:DDO.owl#DDO_0000428 + impaired glucose tolerance + + + + obo:DDO.owl#DDO_0000429 + DDO:DDO_0000429 + + + + obo:DDO.owl#DDO_0000429 + 60634005 + + + + obo:DDO.owl#DDO_0000429 + impaired glucose tolerance associated with drugs + + + + obo:DDO.owl#DDO_0000430 + DDO:DDO_0000430 + + + + obo:DDO.owl#DDO_0000430 + 88512005 + + + + obo:DDO.owl#DDO_0000430 + impaired glucose tolerance associated with insulin receptor abnormality + + + + obo:DDO.owl#DDO_0000431 + DDO:DDO_0000431 + + + + obo:DDO.owl#DDO_0000431 + 1822007 + + + + obo:DDO.owl#DDO_0000431 + impaired glucose tolerance associated with pancreatic disease + + + + obo:DDO.owl#DDO_0000432 + DDO:DDO_0000432 + + + + obo:DDO.owl#DDO_0000432 + 14052004 + + + + obo:DDO.owl#DDO_0000432 + impaired glucose tolerance in MODY + + + + obo:DDO.owl#DDO_0000433 + DDO:DDO_0000433 + + + + obo:DDO.owl#DDO_0000433 + 32284009 + + + + obo:DDO.owl#DDO_0000433 + impaired glucose tolerance in nonobese + + + + obo:DDO.owl#DDO_0000434 + DDO:DDO_0000434 + + + + obo:DDO.owl#DDO_0000434 + 22910008 + + + + obo:DDO.owl#DDO_0000434 + impaired glucose tolerance in obese + + + + obo:DDO.owl#DDO_0000435 + DDO:DDO_0000435 + + + + obo:DDO.owl#DDO_0000435 + 237628005 + + + + obo:DDO.owl#DDO_0000435 + impaired glucose tolerance in pregnancy + + + + obo:DDO.owl#DDO_0000436 + DDO:DDO_0000436 + + + + obo:DDO.owl#DDO_0000436 + 128264007 + + + + obo:DDO.owl#DDO_0000436 + impaired glucose tolerance with hyperinsulism + + + + obo:DDO.owl#DDO_0000437 + DDO:DDO_0000437 + + + + obo:DDO.owl#DDO_0000437 + 26254008 + + + + obo:DDO.owl#DDO_0000437 + potential abnormality of glucose tolerance + + + + obo:DDO.owl#DDO_0000438 + DDO:DDO_0000438 + + + + obo:DDO.owl#DDO_0000438 + 2725003 + + + + obo:DDO.owl#DDO_0000438 + previous abnormality of glucose tolerance + + + + obo:DDO.owl#DDO_0000439 + DDO:DDO_0000439 + + + + obo:DDO.owl#DDO_0000439 + foot symptom + + + + obo:DDO.owl#DDO_0000440 + DDO:DDO_0000440 + + + + obo:DDO.owl#DDO_0000440 + 3253007 + + + + obo:DDO.owl#DDO_0000440 + discoloration of skin + + + + obo:DDO.owl#DDO_0000441 + DDO:DDO_0000441 + + + + obo:DDO.owl#DDO_0000441 + 1521000119100 + + + + obo:DDO.owl#DDO_0000441 + foot ulcer + + + + obo:DDO.owl#DDO_0000442 + DDO:DDO_0000442 + + + + obo:DDO.owl#DDO_0000442 + foot fissures + + + + obo:DDO.owl#DDO_0000443 + DDO:DDO_0000443 + + + + obo:DDO.owl#DDO_0000443 + pain in walk and rest + + + + obo:DDO.owl#DDO_0000444 + DDO:DDO_0000444 + + + + obo:DDO.owl#DDO_0000444 + diabetic myonecrosis + + + + obo:DDO.owl#DDO_0000445 + DDO:DDO_0000445 + + + + obo:DDO.owl#DDO_0000445 + 62914000 + + + + obo:DDO.owl#DDO_0000445 + cerebrovascular disease + + + + obo:DDO.owl#DDO_0000446 + DDO:DDO_0000446 + + + + obo:DDO.owl#DDO_0000446 + 266257000 + + + + obo:DDO.owl#DDO_0000446 + transient ischemic attack + + + + obo:DDO.owl#DDO_0000447 + DDO:DDO_0000447 + + + + obo:DDO.owl#DDO_0000447 + 194828000 + + + + obo:DDO.owl#DDO_0000447 + Anginal syndrome + + + + obo:DDO.owl#DDO_0000447 + angina pectoris + + + + obo:DDO.owl#DDO_0000447 + cardiac angina + + + + obo:DDO.owl#DDO_0000447 + stenocardia + + + + obo:DDO.owl#DDO_0000447 + angina + + + + obo:DDO.owl#DDO_0000448 + DDO:DDO_0000448 + + + + obo:DDO.owl#DDO_0000448 + 419100001 + + + + obo:DDO.owl#DDO_0000448 + foot disease + + + + obo:DDO.owl#DDO_0000449 + DDO:DDO_0000449 + + + + obo:DDO.owl#DDO_0000449 + 95345008 + + + + obo:DDO.owl#DDO_0000449 + foot ulcer + + + + obo:DDO.owl#DDO_0000450 + DDO:DDO_0000450 + + + + obo:DDO.owl#DDO_0000450 + 81723002 + + + + obo:DDO.owl#DDO_0000450 + amputation + + + + obo:DDO.owl#DDO_0000451 + DDO:DDO_0000451 + + + + obo:DDO.owl#DDO_0000451 + residence + + + + obo:DDO.owl#DDO_0000452 + DDO:DDO_0000452 + + + + obo:DDO.owl#DDO_0000452 + history of impaired fasting glucose + + + + obo:DDO.owl#DDO_0000453 + DDO:DDO_0000453 + + + + obo:DDO.owl#DDO_0000453 + history of impaired glucose tolerance + + + + obo:DDO.owl#DDO_0000454 + DDO:DDO_0000454 + + + + obo:DDO.owl#DDO_0000454 + 95320005 + + + + obo:DDO.owl#DDO_0000454 + skin disease + + + + obo:DDO.owl#DDO_0000455 + DDO:DDO_0000455 + + + + obo:DDO.owl#DDO_0000455 + hearing disease + + + + obo:DDO.owl#DDO_0000457 + DDO:DDO_0000457 + + + + obo:DDO.owl#DDO_0000457 + 372070002 + + + + obo:DDO.owl#DDO_0000457 + gangrene + + + + obo:DDO.owl#DDO_0000458 + DDO:DDO_0000458 + + + + obo:DDO.owl#DDO_0000458 + 49176002 + + + + obo:DDO.owl#DDO_0000458 + arteriosclerotic gangrene + + + + obo:DDO.owl#DDO_0000459 + DDO:DDO_0000459 + + + + obo:DDO.owl#DDO_0000459 + 5111000119102 + + + + obo:DDO.owl#DDO_0000459 + gangrene due to atherosclerosis of native artery of limb + + + + obo:DDO.owl#DDO_0000460 + DDO:DDO_0000460 + + + + obo:DDO.owl#DDO_0000460 + 422275004 + + + + obo:DDO.owl#DDO_0000460 + gangrene associated with diabetes mellitus + + + + obo:DDO.owl#DDO_0000461 + DDO:DDO_0000461 + + + + obo:DDO.owl#DDO_0000461 + 25907005 + + + + obo:DDO.owl#DDO_0000461 + diabetic gangrene + + + + obo:DDO.owl#DDO_0000462 + DDO:DDO_0000462 + + + + obo:DDO.owl#DDO_0000462 + 420825003 + + + + obo:DDO.owl#DDO_0000462 + gangrene associated with type 1 diabetes mellitus + + + + obo:DDO.owl#DDO_0000463 + DDO:DDO_0000463 + + + + obo:DDO.owl#DDO_0000463 + 421631007 + + + + obo:DDO.owl#DDO_0000463 + gangrene associated with type 2 diabetes mellitus + + + + obo:DDO.owl#DDO_0000464 + DDO:DDO_0000464 + + + + obo:DDO.owl#DDO_0000464 + 712497009 + + + + obo:DDO.owl#DDO_0000464 + gangrene due to arterial insufficiency + + + + obo:DDO.owl#DDO_0000465 + DDO:DDO_0000465 + + + + obo:DDO.owl#DDO_0000465 + 102631000119103 + + + + obo:DDO.owl#DDO_0000465 + gangrene due to peripheral vascular disease + + + + obo:DDO.owl#DDO_0000466 + DDO:DDO_0000466 + + + + obo:DDO.owl#DDO_0000466 + 286301000119102 + + + + obo:DDO.owl#DDO_0000466 + gangrene due to Raynaud disease + + + + obo:DDO.owl#DDO_0000467 + DDO:DDO_0000467 + + + + obo:DDO.owl#DDO_0000467 + 195301007 + + + + obo:DDO.owl#DDO_0000467 + peripheral gangrene + + + + obo:DDO.owl#DDO_0000468 + DDO:DDO_0000468 + + + + obo:DDO.owl#DDO_0000468 + 409514003 + + + + obo:DDO.owl#DDO_0000468 + acral gangrene + + + + obo:DDO.owl#DDO_0000469 + DDO:DDO_0000469 + + + + obo:DDO.owl#DDO_0000469 + 195303005 + + + + obo:DDO.owl#DDO_0000469 + gangrene of foot + + + + obo:DDO.owl#DDO_0000470 + DDO:DDO_0000470 + + + + obo:DDO.owl#DDO_0000470 + 195302000 + + + + obo:DDO.owl#DDO_0000470 + gangrene of toe + + + + obo:DDO.owl#DDO_0000471 + DDO:DDO_0000471 + + + + obo:DDO.owl#DDO_0000471 + 195306002 + + + + obo:DDO.owl#DDO_0000471 + gangrene of hand + + + + obo:DDO.owl#DDO_0000472 + DDO:DDO_0000472 + + + + obo:DDO.owl#DDO_0000472 + 195304004 + + + + obo:DDO.owl#DDO_0000472 + gangrene of finger + + + + obo:DDO.owl#DDO_0000473 + DDO:DDO_0000473 + + + + obo:DDO.owl#DDO_0000473 + 195305003 + + + + obo:DDO.owl#DDO_0000473 + gangrene of thumb + + + + obo:DDO.owl#DDO_0000474 + DDO:DDO_0000474 + + + + obo:DDO.owl#DDO_0000474 + 371632003 + + + + obo:DDO.owl#DDO_0000474 + coma + + + + obo:DDO.owl#DDO_0000475 + DDO:DDO_0000475 + + + + obo:DDO.owl#DDO_0000475 + fungal and bacterial infections + + + + obo:DDO.owl#DDO_0000476 + DDO:DDO_0000476 + + + + obo:DDO.owl#DDO_0000476 + vomiting + + + + obo:DDO.owl#DDO_0000477 + DDO:DDO_0000477 + + + + obo:DDO.owl#DDO_0000477 + stomach pain + + + + obo:DDO.owl#DDO_0000478 + DDO:DDO_0000478 + + + + obo:DDO.owl#DDO_0000478 + dehydration + + + + obo:DDO.owl#DDO_0000479 + DDO:DDO_0000479 + + + + obo:DDO.owl#DDO_0000479 + 25064002 + + + + obo:DDO.owl#DDO_0000479 + headache + + + + obo:DDO.owl#DDO_0000480 + DDO:DDO_0000480 + + + + obo:DDO.owl#DDO_0000480 + vegetative + + + + obo:DDO.owl#DDO_0000481 + DDO:DDO_0000481 + + + + obo:DDO.owl#DDO_0000481 + sweating + + + + obo:DDO.owl#DDO_0000482 + DDO:DDO_0000482 + + + + obo:DDO.owl#DDO_0000482 + palpitation + + + + obo:DDO.owl#DDO_0000483 + DDO:DDO_0000483 + + + + obo:DDO.owl#DDO_0000483 + anxiety + + + + obo:DDO.owl#DDO_0000484 + DDO:DDO_0000484 + + + + obo:DDO.owl#DDO_0000484 + shakiness + + + + obo:DDO.owl#DDO_0000485 + DDO:DDO_0000485 + + + + obo:DDO.owl#DDO_0000485 + pallor + + + + obo:DDO.owl#DDO_0000486 + DDO:DDO_0000486 + + + + obo:DDO.owl#DDO_0000486 + neuroglycopenic + + + + obo:DDO.owl#DDO_0000487 + DDO:DDO_0000487 + + + + obo:DDO.owl#DDO_0000487 + 40917007 + + + + obo:DDO.owl#DDO_0000487 + bewilderment + + + + obo:DDO.owl#DDO_0000487 + clouded consciousness + + + + obo:DDO.owl#DDO_0000487 + dazed + + + + obo:DDO.owl#DDO_0000487 + dazed state + + + + obo:DDO.owl#DDO_0000487 + dullness of senses + + + + obo:DDO.owl#DDO_0000487 + muddled + + + + obo:DDO.owl#DDO_0000487 + confusion + + + + obo:DDO.owl#DDO_0000488 + DDO:DDO_0000488 + + + + obo:DDO.owl#DDO_0000488 + 130987000 + + + + obo:DDO.owl#DDO_0000488 + acute confusion + + + + obo:DDO.owl#DDO_0000489 + DDO:DDO_0000489 + + + + obo:DDO.owl#DDO_0000489 + 130988005 + + + + obo:DDO.owl#DDO_0000489 + chronic confusion + + + + obo:DDO.owl#DDO_0000490 + DDO:DDO_0000490 + + + + obo:DDO.owl#DDO_0000490 + 281793005 + + + + obo:DDO.owl#DDO_0000490 + intermittent confusion + + + + obo:DDO.owl#DDO_0000491 + DDO:DDO_0000491 + + + + obo:DDO.owl#DDO_0000491 + 248224004 + + + + obo:DDO.owl#DDO_0000491 + muzzy headed + + + + obo:DDO.owl#DDO_0000492 + DDO:DDO_0000492 + + + + obo:DDO.owl#DDO_0000492 + atypical behaviour + + + + obo:DDO.owl#DDO_0000493 + DDO:DDO_0000493 + + + + obo:DDO.owl#DDO_0000493 + 271782001 + + + + obo:DDO.owl#DDO_0000493 + sleepiness + + + + obo:DDO.owl#DDO_0000494 + DDO:DDO_0000494 + + + + obo:DDO.owl#DDO_0000494 + difficulty speaking + + + + obo:DDO.owl#DDO_0000495 + DDO:DDO_0000495 + + + + obo:DDO.owl#DDO_0000495 + 80394007 + + + + obo:DDO.owl#DDO_0000495 + hyperglycemia + + + + obo:DDO.owl#DDO_0000496 + DDO:DDO_0000496 + + + + obo:DDO.owl#DDO_0000496 + foots decreased sensation + + + + obo:DDO.owl#DDO_0000497 + DDO:DDO_0000497 + + + + obo:DDO.owl#DDO_0000497 + foot burning + + + + obo:DDO.owl#DDO_0000498 + DDO:DDO_0000498 + + + + obo:DDO.owl#DDO_0000498 + 277797007 + + + + obo:DDO.owl#DDO_0000498 + thinned skin + + + + obo:DDO.owl#DDO_0000499 + DDO:DDO_0000499 + + + + obo:DDO.owl#DDO_0000499 + foot hair loss + + + + obo:DDO.owl#DDO_0000500 + DDO:DDO_0000500 + + + + obo:DDO.owl#DDO_0000500 + 275520000 + + + + obo:DDO.owl#DDO_0000500 + claudication + + + + obo:DDO.owl#DDO_0000501 + DDO:DDO_0000501 + + + + obo:DDO.owl#DDO_0000501 + 297142003 + + + + obo:DDO.owl#DDO_0000501 + foot swelling + + + + obo:DDO.owl#DDO_0000502 + DDO:DDO_0000502 + + + + obo:DDO.owl#DDO_0000502 + 299480001 + + + + obo:DDO.owl#DDO_0000502 + foot joint swelling + + + + obo:DDO.owl#DDO_0000503 + DDO:DDO_0000503 + + + + obo:DDO.owl#DDO_0000503 + 299481002 + + + + obo:DDO.owl#DDO_0000503 + bony swelling of the foot joint + + + + obo:DDO.owl#DDO_0000504 + DDO:DDO_0000504 + + + + obo:DDO.owl#DDO_0000504 + 299482009 + + + + obo:DDO.owl#DDO_0000504 + foot joint - soft tissue swelling + + + + obo:DDO.owl#DDO_0000505 + DDO:DDO_0000505 + + + + obo:DDO.owl#DDO_0000505 + 299483004 + + + + obo:DDO.owl#DDO_0000505 + foot joints synovial swelling + + + + obo:DDO.owl#DDO_0000506 + DDO:DDO_0000506 + + + + obo:DDO.owl#DDO_0000506 + 297144002 + + + + obo:DDO.owl#DDO_0000506 + swollen feet + + + + obo:DDO.owl#DDO_0000507 + DDO:DDO_0000507 + + + + obo:DDO.owl#DDO_0000507 + 277890004 + + + + obo:DDO.owl#DDO_0000507 + toe swelling + + + + obo:DDO.owl#DDO_0000508 + DDO:DDO_0000508 + + + + obo:DDO.owl#DDO_0000508 + 277891000 + + + + obo:DDO.owl#DDO_0000508 + sausage toe + + + + obo:DDO.owl#DDO_0000509 + DDO:DDO_0000509 + + + + obo:DDO.owl#DDO_0000509 + 299577004 + + + + obo:DDO.owl#DDO_0000509 + swelling of toe joint + + + + obo:DDO.owl#DDO_0000510 + DDO:DDO_0000510 + + + + obo:DDO.owl#DDO_0000510 + 299578009 + + + + obo:DDO.owl#DDO_0000510 + bony swelling of toe joint + + + + obo:DDO.owl#DDO_0000511 + DDO:DDO_0000511 + + + + obo:DDO.owl#DDO_0000511 + 299579001 + + + + obo:DDO.owl#DDO_0000511 + toe joint - soft tissue swelling + + + + obo:DDO.owl#DDO_0000512 + DDO:DDO_0000512 + + + + obo:DDO.owl#DDO_0000512 + 299580003 + + + + obo:DDO.owl#DDO_0000512 + toe joint - synovial swelling + + + + obo:DDO.owl#DDO_0000513 + DDO:DDO_0000513 + + + + obo:DDO.owl#DDO_0000513 + foot dry Skin + + + + obo:DDO.owl#DDO_0000514 + DDO:DDO_0000514 + + + + obo:DDO.owl#DDO_0000514 + 3424008 + + + + obo:DDO.owl#DDO_0000514 + fast heartbeat + + + + obo:DDO.owl#DDO_0000514 + tachycardia + + + + obo:DDO.owl#DDO_0000515 + DDO:DDO_0000515 + + + + obo:DDO.owl#DDO_0000515 + 278086000 + + + + obo:DDO.owl#DDO_0000515 + baseline tachycardia + + + + obo:DDO.owl#DDO_0000516 + DDO:DDO_0000516 + + + + obo:DDO.owl#DDO_0000516 + 240298005 + + + + obo:DDO.owl#DDO_0000516 + fetal tachycardia + + + + obo:DDO.owl#DDO_0000517 + DDO:DDO_0000517 + + + + obo:DDO.owl#DDO_0000517 + 442515000 + + + + obo:DDO.owl#DDO_0000517 + reflex tachycardia + + + + obo:DDO.owl#DDO_0000518 + DDO:DDO_0000518 + + + + obo:DDO.owl#DDO_0000518 + 11092001 + + + + obo:DDO.owl#DDO_0000518 + sinus tachycardia + + + + obo:DDO.owl#DDO_0000519 + DDO:DDO_0000519 + + + + obo:DDO.owl#DDO_0000519 + 271782001 + + + + obo:DDO.owl#DDO_0000519 + sleepiness + + + + obo:DDO.owl#DDO_0000519 + drowsiness + + + + obo:DDO.owl#DDO_0000520 + DDO:DDO_0000520 + + + + obo:DDO.owl#DDO_0000520 + 90688005 + + + + obo:DDO.owl#DDO_0000520 + chronic renal failure + + + + obo:DDO.owl#DDO_0000520 + chronic uremia + + + + obo:DDO.owl#DDO_0000520 + chronic renal insufficiency + + + + obo:DDO.owl#DDO_0000521 + DDO:DDO_0000521 + + + + obo:DDO.owl#DDO_0000521 + 236433006 + + + + obo:DDO.owl#DDO_0000521 + acute-on-chronic renal failure + + + + obo:DDO.owl#DDO_0000522 + DDO:DDO_0000522 + + + + obo:DDO.owl#DDO_0000522 + 425369003 + + + + obo:DDO.owl#DDO_0000522 + chronic progressive renal failure + + + + obo:DDO.owl#DDO_0000523 + DDO:DDO_0000523 + + + + obo:DDO.owl#DDO_0000523 + 57557005 + + + + obo:DDO.owl#DDO_0000523 + chronic milk alkali syndrome + + + + obo:DDO.owl#DDO_0000524 + DDO:DDO_0000524 + + + + obo:DDO.owl#DDO_0000524 + 709044004 + + + + obo:DDO.owl#DDO_0000524 + chronic kidney disease + + + + obo:DDO.owl#DDO_0000525 + DDO:DDO_0000525 + + + + obo:DDO.owl#DDO_0000525 + 431855005 + + + + obo:DDO.owl#DDO_0000525 + chronic kidney disease stage 1 + + + + obo:DDO.owl#DDO_0000526 + DDO:DDO_0000526 + + + + obo:DDO.owl#DDO_0000526 + 431856006 + + + + obo:DDO.owl#DDO_0000526 + chronic kidney disease stage 2 + + + + obo:DDO.owl#DDO_0000527 + DDO:DDO_0000527 + + + + obo:DDO.owl#DDO_0000527 + 433144002 + + + + obo:DDO.owl#DDO_0000527 + chronic kidney disease stage 3 + + + + obo:DDO.owl#DDO_0000528 + DDO:DDO_0000528 + + + + obo:DDO.owl#DDO_0000528 + 431857002 + + + + obo:DDO.owl#DDO_0000528 + chronic kidney disease stage 4 + + + + obo:DDO.owl#DDO_0000529 + DDO:DDO_0000529 + + + + obo:DDO.owl#DDO_0000529 + 433146000 + + + + obo:DDO.owl#DDO_0000529 + chronic kidney disease stage 5 + + + + obo:DDO.owl#DDO_0000530 + DDO:DDO_0000530 + + + + obo:DDO.owl#DDO_0000530 + hypertension in chronic kidney disease + + + + obo:DDO.owl#DDO_0000531 + DDO:DDO_0000531 + + + + obo:DDO.owl#DDO_0000531 + 700378005 + + + + obo:DDO.owl#DDO_0000531 + chronic kidney disease stage 3A + + + + obo:DDO.owl#DDO_0000532 + DDO:DDO_0000532 + + + + obo:DDO.owl#DDO_0000532 + 700379002 + + + + obo:DDO.owl#DDO_0000532 + chronic kidney disease stage 3B + + + + obo:DDO.owl#DDO_0000533 + DDO:DDO_0000533 + + + + obo:DDO.owl#DDO_0000533 + 35885006 + + + + obo:DDO.owl#DDO_0000533 + hyperuricemia + + + + obo:DDO.owl#DDO_0000534 + DDO:DDO_0000534 + + + + obo:DDO.owl#DDO_0000534 + 10406007 + + + + obo:DDO.owl#DDO_0000534 + Lesch-Nyhan syndrome + + + + obo:DDO.owl#DDO_0000535 + DDO:DDO_0000535 + + + + obo:DDO.owl#DDO_0000535 + 24595009 + + + + obo:DDO.owl#DDO_0000535 + primary gout + + + + obo:DDO.owl#DDO_0000536 + DDO:DDO_0000536 + + + + obo:DDO.owl#DDO_0000536 + 310101000119107 + + + + obo:DDO.owl#DDO_0000536 + primary chronic gout without tophus + + + + obo:DDO.owl#DDO_0000538 + DDO:DDO_0000538 + + + + obo:DDO.owl#DDO_0000538 + 40930008 + + + + obo:DDO.owl#DDO_0000538 + hypothyroidism + + + + obo:DDO.owl#DDO_0000539 + DDO:DDO_0000539 + + + + obo:DDO.owl#DDO_0000539 + secondary gout + + + + obo:DDO.owl#DDO_0000540 + DDO:DDO_0000540 + + + + obo:DDO.owl#DDO_0000540 + 90560007 + + + + obo:DDO.owl#DDO_0000540 + gout + + + + obo:DDO.owl#DDO_0000541 + DDO:DDO_0000541 + + + + obo:DDO.owl#DDO_0000541 + 48440001 + + + + obo:DDO.owl#DDO_0000541 + articular gout + + + + obo:DDO.owl#DDO_0000542 + DDO:DDO_0000542 + + + + obo:DDO.owl#DDO_0000542 + 68451005 + + + + obo:DDO.owl#DDO_0000542 + chronic gouty arthritis + + + + obo:DDO.owl#DDO_0000543 + DDO:DDO_0000543 + + + + obo:DDO.owl#DDO_0000543 + 73877009 + + + + obo:DDO.owl#DDO_0000543 + chronic tophaceous gout + + + + obo:DDO.owl#DDO_0000544 + DDO:DDO_0000544 + + + + obo:DDO.owl#DDO_0000544 + 201670006 + + + + obo:DDO.owl#DDO_0000544 + gouty arthritis of multiple sites + + + + obo:DDO.owl#DDO_0000545 + DDO:DDO_0000545 + + + + obo:DDO.owl#DDO_0000545 + 710733002 + + + + obo:DDO.owl#DDO_0000545 + chronic gout without tophus + + + + obo:DDO.owl#DDO_0000546 + DDO:DDO_0000546 + + + + obo:DDO.owl#DDO_0000546 + 46785007 + + + + obo:DDO.owl#DDO_0000546 + familial juvenile gout + + + + obo:DDO.owl#DDO_0000547 + DDO:DDO_0000547 + + + + obo:DDO.owl#DDO_0000547 + 43193009 + + + + obo:DDO.owl#DDO_0000547 + gouty iritis + + + + obo:DDO.owl#DDO_0000548 + DDO:DDO_0000548 + + + + obo:DDO.owl#DDO_0000548 + 9386003 + + + + obo:DDO.owl#DDO_0000548 + gouty neuritis + + + + obo:DDO.owl#DDO_0000549 + DDO:DDO_0000549 + + + + obo:DDO.owl#DDO_0000549 + 402469004 + + + + obo:DDO.owl#DDO_0000549 + gouty tophus + + + + obo:DDO.owl#DDO_0000550 + DDO:DDO_0000550 + + + + obo:DDO.owl#DDO_0000550 + 24595009 + + + + obo:DDO.owl#DDO_0000550 + primary gout + + + + obo:DDO.owl#DDO_0000551 + DDO:DDO_0000551 + + + + obo:DDO.owl#DDO_0000551 + 239843003 + + + + obo:DDO.owl#DDO_0000551 + secondary gout + + + + obo:DDO.owl#DDO_0000552 + DDO:DDO_0000552 + + + + obo:DDO.owl#DDO_0000552 + 28428009 + + + + obo:DDO.owl#DDO_0000552 + visceral gout + + + + obo:DDO.owl#DDO_0000553 + DDO:DDO_0000553 + + + + obo:DDO.owl#DDO_0000553 + 68566005 + + + + obo:DDO.owl#DDO_0000553 + urinary tract infectious + + + + obo:DDO.owl#DDO_0000554 + DDO:DDO_0000554 + + + + obo:DDO.owl#DDO_0000554 + 431309003 + + + + obo:DDO.owl#DDO_0000554 + acute urinary tract infection + + + + obo:DDO.owl#DDO_0000555 + DDO:DDO_0000555 + + + + obo:DDO.owl#DDO_0000555 + 431737008 + + + + obo:DDO.owl#DDO_0000555 + acute lower urinary tract infection + + + + obo:DDO.owl#DDO_0000556 + DDO:DDO_0000556 + + + + obo:DDO.owl#DDO_0000556 + 24868007 + + + + obo:DDO.owl#DDO_0000556 + acute gonococcal cystitis + + + + obo:DDO.owl#DDO_0000557 + DDO:DDO_0000557 + + + + obo:DDO.owl#DDO_0000557 + 29864006 + + + + obo:DDO.owl#DDO_0000557 + acute gonococcal urethritis + + + + obo:DDO.owl#DDO_0000558 + DDO:DDO_0000558 + + + + obo:DDO.owl#DDO_0000558 + 431308006 + + + + obo:DDO.owl#DDO_0000558 + acute upper urinary tract infection + + + + obo:DDO.owl#DDO_0000559 + DDO:DDO_0000559 + + + + obo:DDO.owl#DDO_0000559 + 66993009 + + + + obo:DDO.owl#DDO_0000559 + acute infectious tubulointerstitial nephritis + + + + obo:DDO.owl#DDO_0000560 + DDO:DDO_0000560 + + + + obo:DDO.owl#DDO_0000560 + 22352007 + + + + obo:DDO.owl#DDO_0000560 + acute bacterial tubulointerstitial nephritis + + + + obo:DDO.owl#DDO_0000561 + DDO:DDO_0000561 + + + + obo:DDO.owl#DDO_0000561 + 91195006 + + + + obo:DDO.owl#DDO_0000561 + acute fungal tubulointerstitial nephritis + + + + obo:DDO.owl#DDO_0000562 + DDO:DDO_0000562 + + + + obo:DDO.owl#DDO_0000562 + 16751003 + + + + obo:DDO.owl#DDO_0000562 + acute tubulointerstitial nephritis associated with systemic infection + + + + obo:DDO.owl#DDO_0000563 + DDO:DDO_0000563 + + + + obo:DDO.owl#DDO_0000563 + 27810000 + + + + obo:DDO.owl#DDO_0000563 + acute viral tubulointerstitial nephritis + + + + obo:DDO.owl#DDO_0000564 + DDO:DDO_0000564 + + + + obo:DDO.owl#DDO_0000564 + acute pyelonephritis + + + + obo:DDO.owl#DDO_0000565 + DDO:DDO_0000565 + + + + obo:DDO.owl#DDO_0000565 + 197769007 + + + + obo:DDO.owl#DDO_0000565 + acute pyelonephritis with medullary necrosis + + + + obo:DDO.owl#DDO_0000566 + DDO:DDO_0000566 + + + + obo:DDO.owl#DDO_0000566 + 197768004 + + + + obo:DDO.owl#DDO_0000566 + acute pyelonephritis without medullary necrosis + + + + obo:DDO.owl#DDO_0000567 + DDO:DDO_0000567 + + + + obo:DDO.owl#DDO_0000567 + 236373001 + + + + obo:DDO.owl#DDO_0000567 + emphysematous pyelonephritis + + + + obo:DDO.owl#DDO_0000568 + DDO:DDO_0000568 + + + + obo:DDO.owl#DDO_0000568 + 123754002 + + + + obo:DDO.owl#DDO_0000568 + focal pyelonephritis + + + + obo:DDO.owl#DDO_0000569 + DDO:DDO_0000569 + + + + obo:DDO.owl#DDO_0000569 + 197770008 + + + + obo:DDO.owl#DDO_0000569 + acute pyonephrosis + + + + obo:DDO.owl#DDO_0000570 + DDO:DDO_0000570 + + + + obo:DDO.owl#DDO_0000570 + 7448003 + + + + obo:DDO.owl#DDO_0000570 + acute pyonephrosis with renal medullary necrosis + + + + obo:DDO.owl#DDO_0000571 + DDO:DDO_0000571 + + + + obo:DDO.owl#DDO_0000571 + 85495007 + + + + obo:DDO.owl#DDO_0000571 + acute pyonephrosis without renal medullary necrosis + + + + obo:DDO.owl#DDO_0000572 + DDO:DDO_0000572 + + + + obo:DDO.owl#DDO_0000572 + 236704009 + + + + obo:DDO.owl#DDO_0000572 + asymptomatic bacteriuria + + + + obo:DDO.owl#DDO_0000573 + DDO:DDO_0000573 + + + + obo:DDO.owl#DDO_0000573 + 31563000 + + + + obo:DDO.owl#DDO_0000573 + asymptomatic bacteriuria in pregnancy + + + + obo:DDO.owl#DDO_0000574 + DDO:DDO_0000574 + + + + obo:DDO.owl#DDO_0000574 + 312124009 + + + + obo:DDO.owl#DDO_0000574 + bacterial urinary infection + + + + obo:DDO.owl#DDO_0000575 + DDO:DDO_0000575 + + + + obo:DDO.owl#DDO_0000575 + 22352007 + + + + obo:DDO.owl#DDO_0000575 + acute bacterial tubulointerstitial nephritis + + + + obo:DDO.owl#DDO_0000576 + DDO:DDO_0000576 + + + + obo:DDO.owl#DDO_0000576 + 424551004 + + + + obo:DDO.owl#DDO_0000576 + bacterial cystitis + + + + obo:DDO.owl#DDO_0000577 + DDO:DDO_0000577 + + + + obo:DDO.owl#DDO_0000577 + 5093001 + + + + obo:DDO.owl#DDO_0000577 + cystitis with actinomycosis + + + + obo:DDO.owl#DDO_0000578 + DDO:DDO_0000578 + + + + obo:DDO.owl#DDO_0000578 + 197848003 + + + + obo:DDO.owl#DDO_0000578 + gonococcal cystitis + + + + obo:DDO.owl#DDO_0000579 + DDO:DDO_0000579 + + + + obo:DDO.owl#DDO_0000579 + 24868007 + + + + obo:DDO.owl#DDO_0000579 + acute gonococcal cystitis + + + + obo:DDO.owl#DDO_0000580 + DDO:DDO_0000580 + + + + obo:DDO.owl#DDO_0000580 + 88813005 + + + + obo:DDO.owl#DDO_0000580 + chronic gonococcal cystitis + + + + obo:DDO.owl#DDO_0000581 + DDO:DDO_0000581 + + + + obo:DDO.owl#DDO_0000581 + 425562008 + + + + obo:DDO.owl#DDO_0000581 + recurrent bacterial cystitis + + + + obo:DDO.owl#DDO_0000582 + DDO:DDO_0000582 + + + + obo:DDO.owl#DDO_0000582 + 429728004 + + + + obo:DDO.owl#DDO_0000582 + bacterial urethritis + + + + obo:DDO.owl#DDO_0000583 + DDO:DDO_0000583 + + + + obo:DDO.owl#DDO_0000583 + acute gonococcal urethritis + + + + obo:DDO.owl#DDO_0000584 + DDO:DDO_0000584 + + + + obo:DDO.owl#DDO_0000584 + 236683007 + + + + obo:DDO.owl#DDO_0000584 + chlamydial urethritis + + + + obo:DDO.owl#DDO_0000585 + DDO:DDO_0000585 + + + + obo:DDO.owl#DDO_0000585 + 179101003 + + + + obo:DDO.owl#DDO_0000585 + urethritis due to Chlamydia trachomatis + + + + obo:DDO.owl#DDO_0000586 + DDO:DDO_0000586 + + + + obo:DDO.owl#DDO_0000586 + 44412000 + + + + obo:DDO.owl#DDO_0000586 + chronic gonococcal urethritis + + + + obo:DDO.owl#DDO_0000587 + DDO:DDO_0000587 + + + + obo:DDO.owl#DDO_0000587 + 301010001 + + + + obo:DDO.owl#DDO_0000587 + Coliform urinary tract infection + + + + obo:DDO.owl#DDO_0000588 + DDO:DDO_0000588 + + + + obo:DDO.owl#DDO_0000588 + 236687008 + + + + obo:DDO.owl#DDO_0000588 + gonococcal urethral abscess + + + + obo:DDO.owl#DDO_0000589 + DDO:DDO_0000589 + + + + obo:DDO.owl#DDO_0000589 + 444834005 + + + + obo:DDO.owl#DDO_0000589 + abscess of urethral gland due to Neisseria gonorrhoeae + + + + obo:DDO.owl#DDO_0000590 + DDO:DDO_0000590 + + + + obo:DDO.owl#DDO_0000590 + 240578001 + + + + obo:DDO.owl#DDO_0000590 + gonococcal Littré gland abscess + + + + obo:DDO.owl#DDO_0000591 + DDO:DDO_0000591 + + + + obo:DDO.owl#DDO_0000591 + 197928006 + + + + obo:DDO.owl#DDO_0000591 + chronic urinary tract infection + + + + obo:DDO.owl#DDO_0000592 + DDO:DDO_0000592 + + + + obo:DDO.owl#DDO_0000592 + 236374007 + + + + obo:DDO.owl#DDO_0000592 + chronic infective interstitial nephritis + + + + obo:DDO.owl#DDO_0000593 + DDO:DDO_0000593 + + + + obo:DDO.owl#DDO_0000593 + 428091000 + + + + obo:DDO.owl#DDO_0000593 + chronic lower urinary tract infection + + + + obo:DDO.owl#DDO_0000594 + DDO:DDO_0000594 + + + + obo:DDO.owl#DDO_0000594 + 88813005 + + + + obo:DDO.owl#DDO_0000594 + chronic gonococcal cystitis + + + + obo:DDO.owl#DDO_0000595 + DDO:DDO_0000595 + + + + obo:DDO.owl#DDO_0000595 + 44412000 + + + + obo:DDO.owl#DDO_0000595 + chronic gonococcal urethritis + + + + obo:DDO.owl#DDO_0000596 + DDO:DDO_0000596 + + + + obo:DDO.owl#DDO_0000596 + 197763008 + + + + obo:DDO.owl#DDO_0000596 + chronic pyonephrosis + + + + obo:DDO.owl#DDO_0000597 + DDO:DDO_0000597 + + + + obo:DDO.owl#DDO_0000597 + 197927001 + + + + obo:DDO.owl#DDO_0000597 + recurrent urinary tract infection + + + + obo:DDO.owl#DDO_0000598 + DDO:DDO_0000598 + + + + obo:DDO.owl#DDO_0000598 + 423322005 + + + + obo:DDO.owl#DDO_0000598 + recurrent obstructive pyelonephritis + + + + obo:DDO.owl#DDO_0000599 + DDO:DDO_0000599 + + + + obo:DDO.owl#DDO_0000599 + 301011002 + + + + obo:DDO.owl#DDO_0000599 + Escherichia coli urinary tract infection + + + + obo:DDO.owl#DDO_0000600 + DDO:DDO_0000600 + + + + obo:DDO.owl#DDO_0000600 + 4009004 + + + + obo:DDO.owl#DDO_0000600 + lower urinary tract infectious disease + + + + obo:DDO.owl#DDO_0000601 + DDO:DDO_0000601 + + + + obo:DDO.owl#DDO_0000601 + 431737008 + + + + obo:DDO.owl#DDO_0000601 + acute lower urinary tract infection + + + + obo:DDO.owl#DDO_0000602 + DDO:DDO_0000602 + + + + obo:DDO.owl#DDO_0000602 + 24868007 + + + + obo:DDO.owl#DDO_0000602 + acute gonococcal cystitis + + + + obo:DDO.owl#DDO_0000603 + DDO:DDO_0000603 + + + + obo:DDO.owl#DDO_0000603 + 29864006 + + + + obo:DDO.owl#DDO_0000603 + acute gonococcal urethritis + + + + obo:DDO.owl#DDO_0000604 + DDO:DDO_0000604 + + + + obo:DDO.owl#DDO_0000604 + 52123000 + + + + obo:DDO.owl#DDO_0000604 + emphysematous cystitis + + + + obo:DDO.owl#DDO_0000605 + DDO:DDO_0000605 + + + + obo:DDO.owl#DDO_0000605 + 199205008 + + + + obo:DDO.owl#DDO_0000605 + infections of bladder in pregnancy + + + + obo:DDO.owl#DDO_0000606 + DDO:DDO_0000606 + + + + obo:DDO.owl#DDO_0000606 + 236681009 + + + + obo:DDO.owl#DDO_0000606 + infective urethritis + + + + obo:DDO.owl#DDO_0000607 + DDO:DDO_0000607 + + + + obo:DDO.owl#DDO_0000607 + 429728004 + + + + obo:DDO.owl#DDO_0000607 + bacterial urethritis + + + + obo:DDO.owl#DDO_0000608 + DDO:DDO_0000608 + + + + obo:DDO.owl#DDO_0000608 + 29864006 + + + + obo:DDO.owl#DDO_0000608 + acute gonococcal urethritis + + + + obo:DDO.owl#DDO_0000609 + DDO:DDO_0000609 + + + + obo:DDO.owl#DDO_0000609 + 197903003 + + + + obo:DDO.owl#DDO_0000609 + candidal urethritis + + + + obo:DDO.owl#DDO_0000610 + DDO:DDO_0000610 + + + + obo:DDO.owl#DDO_0000610 + 236682002 + + + + obo:DDO.owl#DDO_0000610 + gonococcal urethritis + + + + obo:DDO.owl#DDO_0000611 + DDO:DDO_0000611 + + + + obo:DDO.owl#DDO_0000611 + 29864006 + + + + obo:DDO.owl#DDO_0000611 + acute gonococcal urethritis + + + + obo:DDO.owl#DDO_0000612 + DDO:DDO_0000612 + + + + obo:DDO.owl#DDO_0000612 + 44412000 + + + + obo:DDO.owl#DDO_0000612 + chronic gonococcal urethritis + + + + obo:DDO.owl#DDO_0000613 + DDO:DDO_0000613 + + + + obo:DDO.owl#DDO_0000613 + 199206009 + + + + obo:DDO.owl#DDO_0000613 + infections of urethra in pregnancy + + + + obo:DDO.owl#DDO_0000614 + DDO:DDO_0000614 + + + + obo:DDO.owl#DDO_0000614 + 236690002 + + + + obo:DDO.owl#DDO_0000614 + trichomonal urethritis + + + + obo:DDO.owl#DDO_0000615 + DDO:DDO_0000615 + + + + obo:DDO.owl#DDO_0000615 + 236690002 + + + + obo:DDO.owl#DDO_0000615 + Reiter's urethritis + + + + obo:DDO.owl#DDO_0000616 + DDO:DDO_0000616 + + + + obo:DDO.owl#DDO_0000616 + 30116001 + + + + obo:DDO.owl#DDO_0000616 + trichomonal urethritis + + + + obo:DDO.owl#DDO_0000617 + DDO:DDO_0000617 + + + + obo:DDO.owl#DDO_0000617 + 51105006 + + + + obo:DDO.owl#DDO_0000617 + nongonococcal urethritis due to Ureaplasma urealyticum + + + + obo:DDO.owl#DDO_0000618 + DDO:DDO_0000618 + + + + obo:DDO.owl#DDO_0000618 + 236685000 + + + + obo:DDO.owl#DDO_0000618 + schistosomiasis of the urethra + + + + obo:DDO.owl#DDO_0000619 + DDO:DDO_0000619 + + + + obo:DDO.owl#DDO_0000619 + 197850006 + + + + obo:DDO.owl#DDO_0000619 + trichomonal cystitis + + + + obo:DDO.owl#DDO_0000620 + DDO:DDO_0000620 + + + + obo:DDO.owl#DDO_0000620 + 371061003 + + + + obo:DDO.owl#DDO_0000620 + urinary tract infection due to urinary catheter + + + + obo:DDO.owl#DDO_0000621 + DDO:DDO_0000621 + + + + obo:DDO.owl#DDO_0000621 + 12301009 + + + + obo:DDO.owl#DDO_0000621 + neonatal urinary tract infection + + + + obo:DDO.owl#DDO_0000622 + DDO:DDO_0000622 + + + + obo:DDO.owl#DDO_0000622 + 197926005 + + + + obo:DDO.owl#DDO_0000622 + postoperative urinary tract infection + + + + obo:DDO.owl#DDO_0000623 + DDO:DDO_0000623 + + + + obo:DDO.owl#DDO_0000623 + 301013004 + + + + obo:DDO.owl#DDO_0000623 + Pseudomonas urinary tract infection + + + + obo:DDO.owl#DDO_0000624 + DDO:DDO_0000624 + + + + obo:DDO.owl#DDO_0000624 + 240721007 + + + + obo:DDO.owl#DDO_0000624 + renal tract candidiasis + + + + obo:DDO.owl#DDO_0000625 + DDO:DDO_0000625 + + + + obo:DDO.owl#DDO_0000625 + 197903003 + + + + obo:DDO.owl#DDO_0000625 + candidal urethritis + + + + obo:DDO.owl#DDO_0000626 + DDO:DDO_0000626 + + + + obo:DDO.owl#DDO_0000626 + 236721000 + + + + obo:DDO.owl#DDO_0000626 + candiduria + + + + obo:DDO.owl#DDO_0000627 + DDO:DDO_0000627 + + + + obo:DDO.owl#DDO_0000627 + 422747000 + + + + obo:DDO.owl#DDO_0000627 + upper urinary tract infection + + + + obo:DDO.owl#DDO_0000628 + DDO:DDO_0000628 + + + + obo:DDO.owl#DDO_0000628 + 431308006 + + + + obo:DDO.owl#DDO_0000628 + acute upper urinary tract infection + + + + obo:DDO.owl#DDO_0000629 + DDO:DDO_0000629 + + + + obo:DDO.owl#DDO_0000629 + 66993009 + + + + obo:DDO.owl#DDO_0000629 + acute infectious tubulointerstitial nephritis + + + + obo:DDO.owl#DDO_0000630 + DDO:DDO_0000630 + + + + obo:DDO.owl#DDO_0000630 + 22352007 + + + + obo:DDO.owl#DDO_0000630 + acute bacterial tubulointerstitial nephritis + + + + obo:DDO.owl#DDO_0000631 + DDO:DDO_0000631 + + + + obo:DDO.owl#DDO_0000631 + 91195006 + + + + obo:DDO.owl#DDO_0000631 + acute fungal tubulointerstitial nephritis + + + + obo:DDO.owl#DDO_0000632 + DDO:DDO_0000632 + + + + obo:DDO.owl#DDO_0000632 + 16751003 + + + + obo:DDO.owl#DDO_0000632 + acute tubulointerstitial nephritis associated with systemic infection + + + + obo:DDO.owl#DDO_0000633 + DDO:DDO_0000633 + + + + obo:DDO.owl#DDO_0000633 + 27810000 + + + + obo:DDO.owl#DDO_0000633 + acute viral tubulointerstitial nephritis + + + + obo:DDO.owl#DDO_0000634 + DDO:DDO_0000634 + + + + obo:DDO.owl#DDO_0000634 + 36689008 + + + + obo:DDO.owl#DDO_0000634 + acute pyelonephritis + + + + obo:DDO.owl#DDO_0000635 + DDO:DDO_0000635 + + + + obo:DDO.owl#DDO_0000635 + 197769007 + + + + obo:DDO.owl#DDO_0000635 + acute pyelonephritis with medullary necrosis + + + + obo:DDO.owl#DDO_0000636 + DDO:DDO_0000636 + + + + obo:DDO.owl#DDO_0000636 + 197768004 + + + + obo:DDO.owl#DDO_0000636 + acute pyelonephritis without medullary necrosis + + + + obo:DDO.owl#DDO_0000637 + DDO:DDO_0000637 + + + + obo:DDO.owl#DDO_0000637 + 236373001 + + + + obo:DDO.owl#DDO_0000637 + emphysematous pyelonephritis + + + + obo:DDO.owl#DDO_0000638 + DDO:DDO_0000638 + + + + obo:DDO.owl#DDO_0000638 + 123754002 + + + + obo:DDO.owl#DDO_0000638 + focal pyelonephritis + + + + obo:DDO.owl#DDO_0000639 + DDO:DDO_0000639 + + + + obo:DDO.owl#DDO_0000639 + 197770008 + + + + obo:DDO.owl#DDO_0000639 + acute pyonephrosis + + + + obo:DDO.owl#DDO_0000640 + DDO:DDO_0000640 + + + + obo:DDO.owl#DDO_0000640 + 7448003 + + + + obo:DDO.owl#DDO_0000640 + acute pyonephrosis with renal medullary necrosis + + + + obo:DDO.owl#DDO_0000641 + DDO:DDO_0000641 + + + + obo:DDO.owl#DDO_0000641 + 85495007 + + + + obo:DDO.owl#DDO_0000641 + acute pyonephrosis without renal medullary necrosis + + + + obo:DDO.owl#DDO_0000642 + DDO:DDO_0000642 + + + + obo:DDO.owl#DDO_0000642 + 129128006 + + + + obo:DDO.owl#DDO_0000642 + infectious disorder of kidney + + + + obo:DDO.owl#DDO_0000643 + DDO:DDO_0000643 + + + + obo:DDO.owl#DDO_0000643 + 66993009 + + + + obo:DDO.owl#DDO_0000643 + acute infectious tubulointerstitial nephritis + + + + obo:DDO.owl#DDO_0000644 + DDO:DDO_0000644 + + + + obo:DDO.owl#DDO_0000644 + 22352007 + + + + obo:DDO.owl#DDO_0000644 + acute bacterial tubulointerstitial nephritis + + + + obo:DDO.owl#DDO_0000645 + DDO:DDO_0000645 + + + + obo:DDO.owl#DDO_0000645 + 91195006 + + + + obo:DDO.owl#DDO_0000645 + acute fungal tubulointerstitial nephritis + + + + obo:DDO.owl#DDO_0000646 + DDO:DDO_0000646 + + + + obo:DDO.owl#DDO_0000646 + 16751003 + + + + obo:DDO.owl#DDO_0000646 + acute tubulointerstitial nephritis associated with systemic infection + + + + obo:DDO.owl#DDO_0000647 + DDO:DDO_0000647 + + + + obo:DDO.owl#DDO_0000647 + 27810000 + + + + obo:DDO.owl#DDO_0000647 + acute viral tubulointerstitial nephritis + + + + obo:DDO.owl#DDO_0000648 + DDO:DDO_0000648 + + + + obo:DDO.owl#DDO_0000648 + 23754003 + + + + obo:DDO.owl#DDO_0000648 + calculous pyelonephritis + + + + obo:DDO.owl#DDO_0000649 + DDO:DDO_0000649 + + + + obo:DDO.owl#DDO_0000649 + 123755001 + + + + obo:DDO.owl#DDO_0000649 + diffuse pyelonephritis + + + + obo:DDO.owl#DDO_0000650 + DDO:DDO_0000650 + + + + obo:DDO.owl#DDO_0000650 + 236377000 + + + + obo:DDO.owl#DDO_0000650 + fungal infection of kidney + + + + obo:DDO.owl#DDO_0000651 + DDO:DDO_0000651 + + + + obo:DDO.owl#DDO_0000651 + 91195006 + + + + obo:DDO.owl#DDO_0000651 + acute fungal tubulointerstitial nephritis + + + + obo:DDO.owl#DDO_0000652 + DDO:DDO_0000652 + + + + obo:DDO.owl#DDO_0000652 + 370368007 + + + + obo:DDO.owl#DDO_0000652 + renal candidiasis + + + + obo:DDO.owl#DDO_0000653 + DDO:DDO_0000653 + + + + obo:DDO.owl#DDO_0000653 + 236378005 + + + + obo:DDO.owl#DDO_0000653 + Candida pyelonephritis + + + + obo:DDO.owl#DDO_0000654 + DDO:DDO_0000654 + + + + obo:DDO.owl#DDO_0000654 + 187144000 + + + + obo:DDO.owl#DDO_0000654 + hydatid cyst of kidney + + + + obo:DDO.owl#DDO_0000655 + DDO:DDO_0000655 + + + + obo:DDO.owl#DDO_0000655 + 236376009 + + + + obo:DDO.owl#DDO_0000655 + infected renal cyst + + + + obo:DDO.owl#DDO_0000656 + DDO:DDO_0000656 + + + + obo:DDO.owl#DDO_0000656 + 48631008 + + + + obo:DDO.owl#DDO_0000656 + pyonephrosis + + + + obo:DDO.owl#DDO_0000657 + DDO:DDO_0000657 + + + + obo:DDO.owl#DDO_0000657 + 197770008 + + + + obo:DDO.owl#DDO_0000657 + acute pyonephrosis + + + + obo:DDO.owl#DDO_0000658 + DDO:DDO_0000658 + + + + obo:DDO.owl#DDO_0000658 + 197763008 + + + + obo:DDO.owl#DDO_0000658 + chronic pyonephrosis + + + + obo:DDO.owl#DDO_0000659 + DDO:DDO_0000659 + + + + obo:DDO.owl#DDO_0000659 + 123611003 + + + + obo:DDO.owl#DDO_0000659 + subacute pyelonephritis + + + + obo:DDO.owl#DDO_0000660 + DDO:DDO_0000660 + + + + obo:DDO.owl#DDO_0000660 + 59530001 + + + + obo:DDO.owl#DDO_0000660 + syphilis of kidney + + + + obo:DDO.owl#DDO_0000661 + DDO:DDO_0000661 + + + + obo:DDO.owl#DDO_0000661 + 197757004 + + + + obo:DDO.owl#DDO_0000661 + late syphilis of kidney + + + + obo:DDO.owl#DDO_0000662 + DDO:DDO_0000662 + + + + obo:DDO.owl#DDO_0000662 + 37133005 + + + + obo:DDO.owl#DDO_0000662 + tuberculous pyelitis + + + + obo:DDO.owl#DDO_0000663 + DDO:DDO_0000663 + + + + obo:DDO.owl#DDO_0000663 + 65127006 + + + + obo:DDO.owl#DDO_0000663 + tuberculous pyelonephritis + + + + obo:DDO.owl#DDO_0000664 + DDO:DDO_0000664 + + + + obo:DDO.owl#DDO_0000664 + 85884009 + + + + obo:DDO.owl#DDO_0000664 + pyoureter + + + + obo:DDO.owl#DDO_0000665 + DDO:DDO_0000665 + + + + obo:DDO.owl#DDO_0000665 + 236599009 + + + + obo:DDO.owl#DDO_0000665 + schistosomiasis of ureter + + + + obo:DDO.owl#DDO_0000666 + DDO:DDO_0000666 + + + + obo:DDO.owl#DDO_0000666 + 236706006 + + + + obo:DDO.owl#DDO_0000666 + urinary schistosomiasis + + + + obo:DDO.owl#DDO_0000667 + DDO:DDO_0000667 + + + + obo:DDO.owl#DDO_0000667 + 307534009 + + + + obo:DDO.owl#DDO_0000667 + urinary tract infection in pregnancy + + + + obo:DDO.owl#DDO_0000668 + DDO:DDO_0000668 + + + + obo:DDO.owl#DDO_0000668 + 66892003 + + + + obo:DDO.owl#DDO_0000668 + failed attempted termination of pregnancy with urinary tract infection + + + + obo:DDO.owl#DDO_0000669 + DDO:DDO_0000669 + + + + obo:DDO.owl#DDO_0000669 + 609491002 + + + + obo:DDO.owl#DDO_0000669 + induced termination of pregnancy complicated by urinary tract infection + + + + obo:DDO.owl#DDO_0000670 + DDO:DDO_0000670 + + + + obo:DDO.owl#DDO_0000670 + 1469007 + + + + obo:DDO.owl#DDO_0000670 + miscarriage with urinary tract infection + + + + obo:DDO.owl#DDO_0000671 + DDO:DDO_0000671 + + + + obo:DDO.owl#DDO_0000671 + 127013003 + + + + obo:DDO.owl#DDO_0000671 + diabetic nephropathy + + + + obo:DDO.owl#DDO_0000672 + DDO:DDO_0000672 + + + + obo:DDO.owl#DDO_0000672 + 110996009 + + + + obo:DDO.owl#DDO_0000672 + Armanni-Ebstein kidney + + + + obo:DDO.owl#DDO_0000673 + DDO:DDO_0000673 + + + + obo:DDO.owl#DDO_0000673 + 54181000 + + + + obo:DDO.owl#DDO_0000673 + diabetes-nephrosis syndrome + + + + obo:DDO.owl#DDO_0000674 + DDO:DDO_0000674 + + + + obo:DDO.owl#DDO_0000674 + 309426007 + + + + obo:DDO.owl#DDO_0000674 + diabetic glomerulopathy + + + + obo:DDO.owl#DDO_0000675 + DDO:DDO_0000675 + + + + obo:DDO.owl#DDO_0000675 + 425455002 + + + + obo:DDO.owl#DDO_0000675 + diabetic glomerulonephritis + + + + obo:DDO.owl#DDO_0000676 + DDO:DDO_0000676 + + + + obo:DDO.owl#DDO_0000676 + 707221002 + + + + obo:DDO.owl#DDO_0000676 + diabetic glomerulosclerosis + + + + obo:DDO.owl#DDO_0000677 + DDO:DDO_0000677 + + + + obo:DDO.owl#DDO_0000677 + 310387003 + + + + obo:DDO.owl#DDO_0000677 + diabetic intracapillary glomerulosclerosis + + + + obo:DDO.owl#DDO_0000678 + DDO:DDO_0000678 + + + + obo:DDO.owl#DDO_0000678 + 38046004 + + + + obo:DDO.owl#DDO_0000678 + diffuse type diabetic glomerulosclerosis + + + + obo:DDO.owl#DDO_0000679 + DDO:DDO_0000679 + + + + obo:DDO.owl#DDO_0000679 + 63510008 + + + + obo:DDO.owl#DDO_0000679 + nodular type diabetic glomerulosclerosis + + + + obo:DDO.owl#DDO_0000680 + DDO:DDO_0000680 + + + + obo:DDO.owl#DDO_0000680 + 311366001 + + + + obo:DDO.owl#DDO_0000680 + Kimmelstiel-Wilson syndrome + + + + obo:DDO.owl#DDO_0000681 + DDO:DDO_0000681 + + + + obo:DDO.owl#DDO_0000681 + 445170001 + + + + obo:DDO.owl#DDO_0000681 + macroalbuminuric diabetic nephropathy + + + + obo:DDO.owl#DDO_0000682 + DDO:DDO_0000682 + + + + obo:DDO.owl#DDO_0000682 + 236499007 + + + + obo:DDO.owl#DDO_0000682 + microalbuminuric diabetic nephropathy + + + + obo:DDO.owl#DDO_0000683 + DDO:DDO_0000683 + + + + obo:DDO.owl#DDO_0000683 + persistent microalbuminuria + + + + obo:DDO.owl#DDO_0000684 + DDO:DDO_0000684 + + + + obo:DDO.owl#DDO_0000684 + nephrotic syndrome due to diabetes mellitus + + + + obo:DDO.owl#DDO_0000685 + DDO:DDO_0000685 + + + + obo:DDO.owl#DDO_0000685 + proteinuric diabetic nephropathy + + + + obo:DDO.owl#DDO_0000686 + DDO:DDO_0000686 + + + + obo:DDO.owl#DDO_0000686 + persistent proteinuria + + + + obo:DDO.owl#DDO_0000687 + DDO:DDO_0000687 + + + + obo:DDO.owl#DDO_0000687 + 4855003 + + + + obo:DDO.owl#DDO_0000687 + diabetic retinopathy + + + + obo:DDO.owl#DDO_0000688 + DDO:DDO_0000688 + + + + obo:DDO.owl#DDO_0000688 + 311782002 + + + + obo:DDO.owl#DDO_0000688 + advanced retinal disease + + + + obo:DDO.owl#DDO_0000689 + DDO:DDO_0000689 + + + + obo:DDO.owl#DDO_0000689 + 399868002 + + + + obo:DDO.owl#DDO_0000689 + intraretinal microvascular anomaly + + + + obo:DDO.owl#DDO_0000690 + DDO:DDO_0000690 + + + + obo:DDO.owl#DDO_0000690 + 312999006 + + + + obo:DDO.owl#DDO_0000690 + maculopathy + + + + obo:DDO.owl#DDO_0000691 + DDO:DDO_0000691 + + + + obo:DDO.owl#DDO_0000691 + 193350004 + + + + obo:DDO.owl#DDO_0000691 + advanced maculopathy + + + + obo:DDO.owl#DDO_0000692 + DDO:DDO_0000692 + + + + obo:DDO.owl#DDO_0000692 + 312912001 + + + + obo:DDO.owl#DDO_0000692 + macular edema + + + + obo:DDO.owl#DDO_0000693 + DDO:DDO_0000693 + + + + obo:DDO.owl#DDO_0000693 + 314010006 + + + + obo:DDO.owl#DDO_0000693 + diffuse maculopathy + + + + obo:DDO.owl#DDO_0000694 + DDO:DDO_0000694 + + + + obo:DDO.owl#DDO_0000694 + exudative maculopathy + + + + obo:DDO.owl#DDO_0000695 + DDO:DDO_0000695 + + + + obo:DDO.owl#DDO_0000695 + 314011005 + + + + obo:DDO.owl#DDO_0000695 + focal maculopathy + + + + obo:DDO.owl#DDO_0000696 + DDO:DDO_0000696 + + + + obo:DDO.owl#DDO_0000696 + 314014002 + + + + obo:DDO.owl#DDO_0000696 + ischemic maculopathy + + + + obo:DDO.owl#DDO_0000697 + DDO:DDO_0000697 + + + + obo:DDO.owl#DDO_0000697 + 314015001 + + + + obo:DDO.owl#DDO_0000697 + mixed maculopathy + + + + obo:DDO.owl#DDO_0000698 + DDO:DDO_0000698 + + + + obo:DDO.owl#DDO_0000698 + 408416008 + + + + obo:DDO.owl#DDO_0000698 + left eye diabetic maculopathy + + + + obo:DDO.owl#DDO_0000699 + DDO:DDO_0000699 + + + + obo:DDO.owl#DDO_0000699 + 408415007 + + + + obo:DDO.owl#DDO_0000699 + right eye diabetic maculopathy + + + + obo:DDO.owl#DDO_0000700 + DDO:DDO_0000700 + + + + obo:DDO.owl#DDO_0000700 + 25412000 + + + + obo:DDO.owl#DDO_0000700 + retinal microaneurysm + + + + obo:DDO.owl#DDO_0000701 + DDO:DDO_0000701 + + + + obo:DDO.owl#DDO_0000701 + 399866003 + + + + obo:DDO.owl#DDO_0000701 + retinal venous beading + + + + obo:DDO.owl#DDO_0000702 + DDO:DDO_0000702 + + + + obo:DDO.owl#DDO_0000702 + 420789003 + + + + obo:DDO.owl#DDO_0000702 + diabetic retinopathy associated with type 1 diabetes mellitus + + + + obo:DDO.owl#DDO_0000703 + DDO:DDO_0000703 + + + + obo:DDO.owl#DDO_0000703 + 420486006 + + + + obo:DDO.owl#DDO_0000703 + exudative maculopathy associated with type 1 diabetes mellitus + + + + obo:DDO.owl#DDO_0000704 + DDO:DDO_0000704 + + + + obo:DDO.owl#DDO_0000704 + 60961000119107 + + + + obo:DDO.owl#DDO_0000704 + nonproliferative diabetic retinopathy due to type 1 diabetes mellitus + + + + obo:DDO.owl#DDO_0000705 + DDO:DDO_0000705 + + + + obo:DDO.owl#DDO_0000705 + 60971000119101 + + + + obo:DDO.owl#DDO_0000705 + proliferative retinopathy due to type 1 diabetes mellitus + + + + obo:DDO.owl#DDO_0000706 + DDO:DDO_0000706 + + + + obo:DDO.owl#DDO_0000706 + 82571000119107 + + + + obo:DDO.owl#DDO_0000706 + traction retinal detachment due to type 1 diabetes mellitus + + + + obo:DDO.owl#DDO_0000707 + DDO:DDO_0000707 + + + + obo:DDO.owl#DDO_0000707 + 422034002 + + + + obo:DDO.owl#DDO_0000707 + diabetic retinopathy associated with type 2 diabetes mellitus + + + + obo:DDO.owl#DDO_0000708 + DDO:DDO_0000708 + + + + obo:DDO.owl#DDO_0000708 + 421779007 + + + + obo:DDO.owl#DDO_0000708 + exudative maculopathy associated with type 2 diabetes mellitus + + + + obo:DDO.owl#DDO_0000709 + DDO:DDO_0000709 + + + + obo:DDO.owl#DDO_0000709 + 97331000119101 + + + + obo:DDO.owl#DDO_0000709 + macular edema and retinopathy due to type 2 diabetes mellitus + + + + obo:DDO.owl#DDO_0000710 + DDO:DDO_0000710 + + + + obo:DDO.owl#DDO_0000710 + 1551000119108 + + + + obo:DDO.owl#DDO_0000710 + nonproliferative diabetic retinopathy due to type 2 diabetes mellitus + + + + obo:DDO.owl#DDO_0000711 + DDO:DDO_0000711 + + + + obo:DDO.owl#DDO_0000711 + 138911000119106 + + + + obo:DDO.owl#DDO_0000711 + mild nonproliferative retinopathy due to type 2 diabetes mellitus + + + + obo:DDO.owl#DDO_0000712 + DDO:DDO_0000712 + + + + obo:DDO.owl#DDO_0000712 + 138921000119104 + + + + obo:DDO.owl#DDO_0000712 + moderate nonproliferative retinopathy due to type 2 diabetes mellitus + + + + obo:DDO.owl#DDO_0000713 + DDO:DDO_0000713 + + + + obo:DDO.owl#DDO_0000713 + 1501000119109 + + + + obo:DDO.owl#DDO_0000713 + proliferative diabetic retinopathy due to type 2 diabetes mellitus + + + + obo:DDO.owl#DDO_0000714 + DDO:DDO_0000714 + + + + obo:DDO.owl#DDO_0000714 + 97341000119105 + + + + obo:DDO.owl#DDO_0000714 + proliferative retinopathy with retinal edema due to type 2 diabetes mellitus + + + + obo:DDO.owl#DDO_0000715 + DDO:DDO_0000715 + + + + obo:DDO.owl#DDO_0000715 + 82541000119100 + + + + obo:DDO.owl#DDO_0000715 + traction retinal detachment due to type 2 diabetes mellitus + + + + obo:DDO.owl#DDO_0000716 + DDO:DDO_0000716 + + + + obo:DDO.owl#DDO_0000716 + 232023006 + + + + obo:DDO.owl#DDO_0000716 + traction retinal detachment + + + + obo:DDO.owl#DDO_0000717 + DDO:DDO_0000717 + + + + obo:DDO.owl#DDO_0000717 + 390834004 + + + + obo:DDO.owl#DDO_0000717 + nonproliferative retinopathy + + + + obo:DDO.owl#DDO_0000718 + DDO:DDO_0000718 + + + + obo:DDO.owl#DDO_0000718 + 312903003 + + + + obo:DDO.owl#DDO_0000718 + mild non-proliferative retinopathy + + + + obo:DDO.owl#DDO_0000719 + DDO:DDO_0000719 + + + + obo:DDO.owl#DDO_0000719 + 312904009 + + + + obo:DDO.owl#DDO_0000719 + moderate nonproliferative retinopathy + + + + obo:DDO.owl#DDO_0000720 + DDO:DDO_0000720 + + + + obo:DDO.owl#DDO_0000720 + 193349004 + + + + obo:DDO.owl#DDO_0000720 + Preproliferative retinopathy + + + + obo:DDO.owl#DDO_0000721 + DDO:DDO_0000721 + + + + obo:DDO.owl#DDO_0000721 + severe nonproliferative retinopathy + + + + obo:DDO.owl#DDO_0000722 + DDO:DDO_0000722 + + + + obo:DDO.owl#DDO_0000722 + 408412005 + + + + obo:DDO.owl#DDO_0000722 + left eye preproliferative retinopathy + + + + obo:DDO.owl#DDO_0000723 + DDO:DDO_0000723 + + + + obo:DDO.owl#DDO_0000723 + 408411003 + + + + obo:DDO.owl#DDO_0000723 + right eye preproliferative retinopathy + + + + obo:DDO.owl#DDO_0000724 + DDO:DDO_0000724 + + + + obo:DDO.owl#DDO_0000724 + very severe nonproliferative retinopathy + + + + obo:DDO.owl#DDO_0000725 + DDO:DDO_0000725 + + + + obo:DDO.owl#DDO_0000725 + 408410002 + + + + obo:DDO.owl#DDO_0000725 + left eye background retinopathy + + + + obo:DDO.owl#DDO_0000726 + DDO:DDO_0000726 + + + + obo:DDO.owl#DDO_0000726 + 408409007 + + + + obo:DDO.owl#DDO_0000726 + right eye background retinopathy + + + + obo:DDO.owl#DDO_0000727 + DDO:DDO_0000727 + + + + obo:DDO.owl#DDO_0000727 + 59276001 + + + + obo:DDO.owl#DDO_0000727 + proliferative retinopathy + + + + obo:DDO.owl#DDO_0000728 + DDO:DDO_0000728 + + + + obo:DDO.owl#DDO_0000728 + 408414006 + + + + obo:DDO.owl#DDO_0000728 + left eye proliferative retinopathy + + + + obo:DDO.owl#DDO_0000729 + DDO:DDO_0000729 + + + + obo:DDO.owl#DDO_0000729 + 408413000 + + + + obo:DDO.owl#DDO_0000729 + right eye proliferative retinopathy + + + + obo:DDO.owl#DDO_0000730 + DDO:DDO_0000730 + + + + obo:DDO.owl#DDO_0000730 + 312907002 + + + + obo:DDO.owl#DDO_0000730 + proliferative retinopathy - high risk + + + + obo:DDO.owl#DDO_0000731 + DDO:DDO_0000731 + + + + obo:DDO.owl#DDO_0000731 + 399865004 + + + + obo:DDO.owl#DDO_0000731 + very severe proliferative retinopathy + + + + obo:DDO.owl#DDO_0000732 + DDO:DDO_0000732 + + + + obo:DDO.owl#DDO_0000732 + 312909004 + + + + obo:DDO.owl#DDO_0000732 + proliferative retinopathy - iris neovascularization + + + + obo:DDO.owl#DDO_0000733 + DDO:DDO_0000733 + + + + obo:DDO.owl#DDO_0000733 + 232022001 + + + + obo:DDO.owl#DDO_0000733 + proliferative retinopathy with new vessels elsewhere than on disc + + + + obo:DDO.owl#DDO_0000734 + DDO:DDO_0000734 + + + + obo:DDO.owl#DDO_0000734 + 232021008 + + + + obo:DDO.owl#DDO_0000734 + proliferative retinopathy with new vessels on disc + + + + obo:DDO.owl#DDO_0000735 + DDO:DDO_0000735 + + + + obo:DDO.owl#DDO_0000735 + 417677008 + + + + obo:DDO.owl#DDO_0000735 + sight threatening retinopathy + + + + obo:DDO.owl#DDO_0000736 + DDO:DDO_0000736 + + + + obo:DDO.owl#DDO_0000736 + 399871005 + + + + obo:DDO.owl#DDO_0000736 + visually threatening retinopathy + + + + obo:DDO.owl#DDO_0000737 + DDO:DDO_0000737 + + + + obo:DDO.owl#DDO_0000737 + 193570009 + + + + obo:DDO.owl#DDO_0000737 + cataract + + + + obo:DDO.owl#DDO_0000738 + DDO:DDO_0000738 + + + + obo:DDO.owl#DDO_0000738 + 111000003 + + + + obo:DDO.owl#DDO_0000738 + adherent cataract + + + + obo:DDO.owl#DDO_0000739 + DDO:DDO_0000739 + + + + obo:DDO.owl#DDO_0000739 + 39450006 + + + + obo:DDO.owl#DDO_0000739 + age-related cataract + + + + obo:DDO.owl#DDO_0000740 + DDO:DDO_0000740 + + + + obo:DDO.owl#DDO_0000740 + 111515007 + + + + obo:DDO.owl#DDO_0000740 + anterior subcapsular polar senile cataract + + + + obo:DDO.owl#DDO_0000741 + DDO:DDO_0000741 + + + + obo:DDO.owl#DDO_0000741 + 77873007 + + + + obo:DDO.owl#DDO_0000741 + cataracta brunescens + + + + obo:DDO.owl#DDO_0000742 + DDO:DDO_0000742 + + + + obo:DDO.owl#DDO_0000742 + 11422002 + + + + obo:DDO.owl#DDO_0000742 + combined form of senile cataract + + + + obo:DDO.owl#DDO_0000743 + DDO:DDO_0000743 + + + + obo:DDO.owl#DDO_0000743 + 78875003 + + + + obo:DDO.owl#DDO_0000743 + cortical senile cataract + + + + obo:DDO.owl#DDO_0000744 + DDO:DDO_0000744 + + + + obo:DDO.owl#DDO_0000744 + 217791000119107 + + + + obo:DDO.owl#DDO_0000744 + hypermature senile cataract + + + + obo:DDO.owl#DDO_0000745 + DDO:DDO_0000745 + + + + obo:DDO.owl#DDO_0000745 + 445213003 + + + + obo:DDO.owl#DDO_0000745 + incipient senile cataract + + + + obo:DDO.owl#DDO_0000746 + DDO:DDO_0000746 + + + + obo:DDO.owl#DDO_0000746 + 193589009 + + + + obo:DDO.owl#DDO_0000746 + nuclear senile cataract + + + + obo:DDO.owl#DDO_0000747 + DDO:DDO_0000747 + + + + obo:DDO.owl#DDO_0000747 + 5318001 + + + + obo:DDO.owl#DDO_0000747 + posterior subcapsular polar senile cataract + + + + obo:DDO.owl#DDO_0000748 + DDO:DDO_0000748 + + + + obo:DDO.owl#DDO_0000748 + 2951009 + + + + obo:DDO.owl#DDO_0000748 + atopic cataract + + + + obo:DDO.owl#DDO_0000749 + DDO:DDO_0000749 + + + + obo:DDO.owl#DDO_0000749 + 110998005 + + + + obo:DDO.owl#DDO_0000749 + axial cataract + + + + obo:DDO.owl#DDO_0000750 + DDO:DDO_0000750 + + + + obo:DDO.owl#DDO_0000750 + 95722004 + + + + obo:DDO.owl#DDO_0000750 + bilateral cataracts + + + + obo:DDO.owl#DDO_0000751 + DDO:DDO_0000751 + + + + obo:DDO.owl#DDO_0000751 + 10970008 + + + + obo:DDO.owl#DDO_0000751 + calcified cataract + + + + obo:DDO.owl#DDO_0000752 + DDO:DDO_0000752 + + + + obo:DDO.owl#DDO_0000752 + 204125003 + + + + obo:DDO.owl#DDO_0000752 + capsular cataract + + + + obo:DDO.owl#DDO_0000753 + DDO:DDO_0000753 + + + + obo:DDO.owl#DDO_0000753 + 28550007 + + + + obo:DDO.owl#DDO_0000753 + congenital capsular cataract + + + + obo:DDO.owl#DDO_0000754 + DDO:DDO_0000754 + + + + obo:DDO.owl#DDO_0000754 + 28550007 + + + + obo:DDO.owl#DDO_0000754 + congenital capsular cataract + + + + obo:DDO.owl#DDO_0000755 + DDO:DDO_0000755 + + + + obo:DDO.owl#DDO_0000755 + 76562003 + + + + obo:DDO.owl#DDO_0000755 + congenital subcapsular cataract + + + + obo:DDO.owl#DDO_0000756 + DDO:DDO_0000756 + + + + obo:DDO.owl#DDO_0000756 + 95723009 + + + + obo:DDO.owl#DDO_0000756 + subcapsular cataract + + + + obo:DDO.owl#DDO_0000757 + DDO:DDO_0000757 + + + + obo:DDO.owl#DDO_0000757 + 315352000 + + + + obo:DDO.owl#DDO_0000757 + anterior subcapsular cataract + + + + obo:DDO.owl#DDO_0000758 + DDO:DDO_0000758 + + + + obo:DDO.owl#DDO_0000758 + 1412008 + + + + obo:DDO.owl#DDO_0000758 + anterior subcapsular polar cataract + + + + obo:DDO.owl#DDO_0000759 + DDO:DDO_0000759 + + + + obo:DDO.owl#DDO_0000759 + 111515007 + + + + obo:DDO.owl#DDO_0000759 + anterior subcapsular polar senile cataract + + + + obo:DDO.owl#DDO_0000760 + DDO:DDO_0000760 + + + + obo:DDO.owl#DDO_0000760 + 342911000119104 + + + + obo:DDO.owl#DDO_0000760 + congenital anterior subcapsular polar cataract + + + + obo:DDO.owl#DDO_0000761 + DDO:DDO_0000761 + + + + obo:DDO.owl#DDO_0000761 + 76562003 + + + + obo:DDO.owl#DDO_0000761 + congenital subcapsular cataract + + + + obo:DDO.owl#DDO_0000762 + DDO:DDO_0000762 + + + + obo:DDO.owl#DDO_0000762 + 315353005 + + + + obo:DDO.owl#DDO_0000762 + posterior subcapsular cataract + + + + obo:DDO.owl#DDO_0000763 + DDO:DDO_0000763 + + + + obo:DDO.owl#DDO_0000763 + 404647000 + + + + obo:DDO.owl#DDO_0000763 + corticosteroid induced cataract + + + + obo:DDO.owl#DDO_0000764 + DDO:DDO_0000764 + + + + obo:DDO.owl#DDO_0000764 + 34533008 + + + + obo:DDO.owl#DDO_0000764 + posterior subcapsular polar cataract + + + + obo:DDO.owl#DDO_0000765 + DDO:DDO_0000765 + + + + obo:DDO.owl#DDO_0000765 + 342821000119103 + + + + obo:DDO.owl#DDO_0000765 + congenital posterior subcapsular polar cataract + + + + obo:DDO.owl#DDO_0000766 + DDO:DDO_0000766 + + + + obo:DDO.owl#DDO_0000766 + 5318001 + + + + obo:DDO.owl#DDO_0000766 + posterior subcapsular polar senile cataract + + + + obo:DDO.owl#DDO_0000767 + DDO:DDO_0000767 + + + + obo:DDO.owl#DDO_0000767 + 47337003 + + + + obo:DDO.owl#DDO_0000767 + capsular fibrosis + + + + obo:DDO.owl#DDO_0000768 + DDO:DDO_0000768 + + + + obo:DDO.owl#DDO_0000768 + 51044000 + + + + obo:DDO.owl#DDO_0000768 + after-cataract not obscuring vision + + + + obo:DDO.owl#DDO_0000769 + DDO:DDO_0000769 + + + + obo:DDO.owl#DDO_0000769 + 193615000 + + + + obo:DDO.owl#DDO_0000769 + after-cataract with vision obscured + + + + obo:DDO.owl#DDO_0000770 + DDO:DDO_0000770 + + + + obo:DDO.owl#DDO_0000770 + 410568009 + + + + obo:DDO.owl#DDO_0000770 + anterior capsule opacification + + + + obo:DDO.owl#DDO_0000771 + DDO:DDO_0000771 + + + + obo:DDO.owl#DDO_0000771 + 231974003 + + + + obo:DDO.owl#DDO_0000771 + Elschnig's pearls + + + + obo:DDO.owl#DDO_0000772 + DDO:DDO_0000772 + + + + obo:DDO.owl#DDO_0000772 + 410567004 + + + + obo:DDO.owl#DDO_0000772 + posterior capsule opacification + + + + obo:DDO.owl#DDO_0000773 + DDO:DDO_0000773 + + + + obo:DDO.owl#DDO_0000773 + 65720003 + + + + obo:DDO.owl#DDO_0000773 + Soemmerring's ring + + + + obo:DDO.owl#DDO_0000774 + DDO:DDO_0000774 + + + + obo:DDO.owl#DDO_0000774 + 231970007 + + + + obo:DDO.owl#DDO_0000774 + cataract in systemic disorders + + + + obo:DDO.owl#DDO_0000775 + DDO:DDO_0000775 + + + + obo:DDO.owl#DDO_0000775 + 43959009 + + + + obo:DDO.owl#DDO_0000775 + diabetic cataract + + + + obo:DDO.owl#DDO_0000776 + DDO:DDO_0000776 + + + + obo:DDO.owl#DDO_0000776 + 231972004 + + + + obo:DDO.owl#DDO_0000776 + malnutrition-dehydration cataract + + + + obo:DDO.owl#DDO_0000777 + DDO:DDO_0000777 + + + + obo:DDO.owl#DDO_0000777 + 64741003 + + + + obo:DDO.owl#DDO_0000777 + myotonic cataract + + + + obo:DDO.owl#DDO_0000778 + DDO:DDO_0000778 + + + + obo:DDO.owl#DDO_0000778 + 68216000 + + + + obo:DDO.owl#DDO_0000778 + tetanic cataract + + + + obo:DDO.owl#DDO_0000779 + DDO:DDO_0000779 + + + + obo:DDO.owl#DDO_0000779 + 79410001 + + + + obo:DDO.owl#DDO_0000779 + congenital cataract + + + + obo:DDO.owl#DDO_0000780 + DDO:DDO_0000780 + + + + obo:DDO.owl#DDO_0000780 + 204138006 + + + + obo:DDO.owl#DDO_0000780 + congenital blue dot cataract + + + + obo:DDO.owl#DDO_0000781 + DDO:DDO_0000781 + + + + obo:DDO.owl#DDO_0000781 + 28550007 + + + + obo:DDO.owl#DDO_0000781 + congenital capsular cataract + + + + obo:DDO.owl#DDO_0000782 + DDO:DDO_0000782 + + + + obo:DDO.owl#DDO_0000782 + 204127006 + + + + obo:DDO.owl#DDO_0000782 + cortical and zonular cataract + + + + obo:DDO.owl#DDO_0000783 + DDO:DDO_0000783 + + + + obo:DDO.owl#DDO_0000783 + 342831000119100 + + + + obo:DDO.owl#DDO_0000783 + congenital combined form cataract + + + + obo:DDO.owl#DDO_0000784 + DDO:DDO_0000784 + + + + obo:DDO.owl#DDO_0000784 + 66499004 + + + + obo:DDO.owl#DDO_0000784 + congenital cortical cataract + + + + obo:DDO.owl#DDO_0000785 + DDO:DDO_0000785 + + + + obo:DDO.owl#DDO_0000785 + 21590003 + + + + obo:DDO.owl#DDO_0000785 + congenital zonular cataract + + + + obo:DDO.owl#DDO_0000786 + DDO:DDO_0000786 + + + + obo:DDO.owl#DDO_0000786 + 204128001 + + + + obo:DDO.owl#DDO_0000786 + congenital lamellar cataract + + + + obo:DDO.owl#DDO_0000787 + DDO:DDO_0000787 + + + + obo:DDO.owl#DDO_0000787 + 204139003 + + + + obo:DDO.owl#DDO_0000787 + congenital membranous cataract + + + + obo:DDO.owl#DDO_0000788 + DDO:DDO_0000788 + + + + obo:DDO.owl#DDO_0000788 + 253223002 + + + + obo:DDO.owl#DDO_0000788 + congenital polar cataract + + + + obo:DDO.owl#DDO_0000789 + DDO:DDO_0000789 + + + + obo:DDO.owl#DDO_0000789 + 63912009 + + + + obo:DDO.owl#DDO_0000789 + congenital subtotal cataract + + + + obo:DDO.owl#DDO_0000790 + DDO:DDO_0000790 + + + + obo:DDO.owl#DDO_0000790 + 253226005 + + + + obo:DDO.owl#DDO_0000790 + congenital sutural cataract + + + + obo:DDO.owl#DDO_0000791 + DDO:DDO_0000791 + + + + obo:DDO.owl#DDO_0000791 + 29590001 + + + + obo:DDO.owl#DDO_0000791 + congenital total cataract + + + + obo:DDO.owl#DDO_0000792 + DDO:DDO_0000792 + + + + obo:DDO.owl#DDO_0000792 + 5361003 + + + + obo:DDO.owl#DDO_0000792 + embryonal nuclear cataract + + + + obo:DDO.owl#DDO_0000793 + DDO:DDO_0000793 + + + + obo:DDO.owl#DDO_0000793 + 445257004 + + + + obo:DDO.owl#DDO_0000793 + Nance-Horan syndrome + + + + obo:DDO.owl#DDO_0000794 + DDO:DDO_0000794 + + + + obo:DDO.owl#DDO_0000794 + 15552004 + + + + obo:DDO.owl#DDO_0000794 + osteogenesis imperfecta, recessive perinatal lethal, with microcephaly AND cataracts + + + + obo:DDO.owl#DDO_0000795 + DDO:DDO_0000795 + + + + obo:DDO.owl#DDO_0000795 + 253227001 + + + + obo:DDO.owl#DDO_0000795 + rubella cataract + + + + obo:DDO.owl#DDO_0000796 + DDO:DDO_0000796 + + + + obo:DDO.owl#DDO_0000796 + 12195004 + + + + obo:DDO.owl#DDO_0000796 + coronary cataract + + + + obo:DDO.owl#DDO_0000797 + DDO:DDO_0000797 + + + + obo:DDO.owl#DDO_0000797 + 193576003 + + + + obo:DDO.owl#DDO_0000797 + cortical cataract + + + + obo:DDO.owl#DDO_0000799 + DDO:DDO_0000799 + + + + obo:DDO.owl#DDO_0000799 + 66499004 + + + + obo:DDO.owl#DDO_0000799 + congenital cortical cataract + + + + obo:DDO.owl#DDO_0000800 + DDO:DDO_0000800 + + + + obo:DDO.owl#DDO_0000800 + 21590003 + + + + obo:DDO.owl#DDO_0000800 + congenital zonular cataract + + + + obo:DDO.owl#DDO_0000801 + DDO:DDO_0000801 + + + + obo:DDO.owl#DDO_0000801 + 699521008 + + + + obo:DDO.owl#DDO_0000801 + cortical nonsenile cataract + + + + obo:DDO.owl#DDO_0000802 + DDO:DDO_0000802 + + + + obo:DDO.owl#DDO_0000802 + 311789006 + + + + obo:DDO.owl#DDO_0000802 + immature cortical cataract + + + + obo:DDO.owl#DDO_0000803 + DDO:DDO_0000803 + + + + obo:DDO.owl#DDO_0000803 + 702398007 + + + + obo:DDO.owl#DDO_0000803 + hyperferritinemia cataract syndrome + + + + obo:DDO.owl#DDO_0000804 + DDO:DDO_0000804 + + + + obo:DDO.owl#DDO_0000804 + 267626000 + + + + obo:DDO.owl#DDO_0000804 + hypermature cataract + + + + obo:DDO.owl#DDO_0000805 + DDO:DDO_0000805 + + + + obo:DDO.owl#DDO_0000805 + 264443002 + + + + obo:DDO.owl#DDO_0000805 + Morgagnian cataract + + + + obo:DDO.owl#DDO_0000806 + DDO:DDO_0000806 + + + + obo:DDO.owl#DDO_0000806 + 446474007 + + + + obo:DDO.owl#DDO_0000806 + immature cataract + + + + obo:DDO.owl#DDO_0000807 + DDO:DDO_0000807 + + + + obo:DDO.owl#DDO_0000807 + 52421005 + + + + obo:DDO.owl#DDO_0000807 + incipient cataract + + + + obo:DDO.owl#DDO_0000808 + DDO:DDO_0000808 + + + + obo:DDO.owl#DDO_0000808 + 399120006 + + + + obo:DDO.owl#DDO_0000808 + infantile cataract + + + + obo:DDO.owl#DDO_0000809 + DDO:DDO_0000809 + + + + obo:DDO.owl#DDO_0000809 + 399336001 + + + + obo:DDO.owl#DDO_0000809 + juvenile cataract + + + + obo:DDO.owl#DDO_0000810 + DDO:DDO_0000810 + + + + obo:DDO.owl#DDO_0000810 + 193579005 + + + + obo:DDO.owl#DDO_0000810 + combined nonsenile cataract + + + + obo:DDO.owl#DDO_0000811 + DDO:DDO_0000811 + + + + obo:DDO.owl#DDO_0000811 + 699520009 + + + + obo:DDO.owl#DDO_0000811 + zonular nonsenile cataract + + + + obo:DDO.owl#DDO_0000812 + DDO:DDO_0000812 + + + + obo:DDO.owl#DDO_0000812 + 193577007 + + + + obo:DDO.owl#DDO_0000812 + lamellar zonular cataract + + + + obo:DDO.owl#DDO_0000813 + DDO:DDO_0000813 + + + + obo:DDO.owl#DDO_0000813 + 43972005 + + + + obo:DDO.owl#DDO_0000813 + localized traumatic opacity + + + + obo:DDO.owl#DDO_0000814 + DDO:DDO_0000814 + + + + obo:DDO.owl#DDO_0000814 + 849000 + + + + obo:DDO.owl#DDO_0000814 + mature cataract + + + + obo:DDO.owl#DDO_0000815 + DDO:DDO_0000815 + + + + obo:DDO.owl#DDO_0000815 + 95724003 + + + + obo:DDO.owl#DDO_0000815 + Intumescent cataract + + + + obo:DDO.owl#DDO_0000816 + DDO:DDO_0000816 + + + + obo:DDO.owl#DDO_0000816 + 8656007 + + + + obo:DDO.owl#DDO_0000816 + total traumatic cataract + + + + obo:DDO.owl#DDO_0000817 + DDO:DDO_0000817 + + + + obo:DDO.owl#DDO_0000817 + 193590000 + + + + obo:DDO.owl#DDO_0000817 + total, mature senile cataract + + + + obo:DDO.owl#DDO_0000818 + DDO:DDO_0000818 + + + + obo:DDO.owl#DDO_0000818 + nonsenile cataract + + + + obo:DDO.owl#DDO_0000819 + DDO:DDO_0000819 + + + + obo:DDO.owl#DDO_0000819 + 39944005 + + + + obo:DDO.owl#DDO_0000819 + combined form of nonsenile cataract + + + + obo:DDO.owl#DDO_0000820 + DDO:DDO_0000820 + + + + obo:DDO.owl#DDO_0000820 + 53889007 + + + + obo:DDO.owl#DDO_0000820 + nuclear cataract + + + + obo:DDO.owl#DDO_0000821 + DDO:DDO_0000821 + + + + obo:DDO.owl#DDO_0000821 + 359766000 + + + + obo:DDO.owl#DDO_0000821 + nuclear sclerotic cataract + + + + obo:DDO.owl#DDO_0000822 + DDO:DDO_0000822 + + + + obo:DDO.owl#DDO_0000822 + 123614006 + + + + obo:DDO.owl#DDO_0000822 + partial cataract + + + + obo:DDO.owl#DDO_0000823 + DDO:DDO_0000823 + + + + obo:DDO.owl#DDO_0000823 + 70388009 + + + + obo:DDO.owl#DDO_0000823 + postoperative cataract syndrome + + + + obo:DDO.owl#DDO_0000824 + DDO:DDO_0000824 + + + + obo:DDO.owl#DDO_0000824 + 441622000 + + + + obo:DDO.owl#DDO_0000824 + presenile cataract + + + + obo:DDO.owl#DDO_0000825 + DDO:DDO_0000825 + + + + obo:DDO.owl#DDO_0000825 + 40714009 + + + + obo:DDO.owl#DDO_0000825 + punctate cataract + + + + obo:DDO.owl#DDO_0000826 + DDO:DDO_0000826 + + + + obo:DDO.owl#DDO_0000826 + 110999002 + + + + obo:DDO.owl#DDO_0000826 + stationary cataract + + + + obo:DDO.owl#DDO_0000827 + DDO:DDO_0000827 + + + + obo:DDO.owl#DDO_0000827 + 370891001 + + + + obo:DDO.owl#DDO_0000827 + suture tip cataract + + + + obo:DDO.owl#DDO_0000828 + DDO:DDO_0000828 + + + + obo:DDO.owl#DDO_0000828 + 38583007 + + + + obo:DDO.owl#DDO_0000828 + toxic cataract + + + + obo:DDO.owl#DDO_0000829 + DDO:DDO_0000829 + + + + obo:DDO.owl#DDO_0000829 + 34361001 + + + + obo:DDO.owl#DDO_0000829 + traumatic cataract + + + + obo:DDO.owl#DDO_0000830 + DDO:DDO_0000830 + + + + obo:DDO.owl#DDO_0000830 + 231967008 + + + + obo:DDO.owl#DDO_0000830 + concussion cataract + + + + obo:DDO.owl#DDO_0000831 + DDO:DDO_0000831 + + + + obo:DDO.owl#DDO_0000831 + 9826008 + + + + obo:DDO.owl#DDO_0000831 + conjunctivitis + + + + obo:DDO.owl#DDO_0000832 + DDO:DDO_0000832 + + + + obo:DDO.owl#DDO_0000832 + 53726008 + + + + obo:DDO.owl#DDO_0000832 + acute conjunctivitis + + + + obo:DDO.owl#DDO_0000833 + DDO:DDO_0000833 + + + + obo:DDO.owl#DDO_0000833 + 67678004 + + + + obo:DDO.owl#DDO_0000833 + acute atopic conjunctivitis + + + + obo:DDO.owl#DDO_0000834 + DDO:DDO_0000834 + + + + obo:DDO.owl#DDO_0000834 + 240066005 + + + + obo:DDO.owl#DDO_0000834 + acute contagious conjunctivitis + + + + obo:DDO.owl#DDO_0000835 + DDO:DDO_0000835 + + + + obo:DDO.owl#DDO_0000835 + 41308008 + + + + obo:DDO.owl#DDO_0000835 + acute follicular conjunctivitis + + + + obo:DDO.owl#DDO_0000836 + DDO:DDO_0000836 + + + + obo:DDO.owl#DDO_0000836 + 398264003 + + + + obo:DDO.owl#DDO_0000836 + acute hemorrhagic conjunctivitis + + + + obo:DDO.owl#DDO_0000837 + DDO:DDO_0000837 + + + + obo:DDO.owl#DDO_0000837 + 91864001 + + + + obo:DDO.owl#DDO_0000837 + acute rosacea conjunctivitis + + + + obo:DDO.owl#DDO_0000838 + DDO:DDO_0000838 + + + + obo:DDO.owl#DDO_0000838 + 239186001 + + + + obo:DDO.owl#DDO_0000838 + acute epidemic conjunctivitis + + + + obo:DDO.owl#DDO_0000839 + DDO:DDO_0000839 + + + + obo:DDO.owl#DDO_0000839 + 68659002 + + + + obo:DDO.owl#DDO_0000839 + blepharoconjunctivitis + + + + obo:DDO.owl#DDO_0000840 + DDO:DDO_0000840 + + + + obo:DDO.owl#DDO_0000840 + angular blepharoconjunctivitis + + + + obo:DDO.owl#DDO_0000841 + DDO:DDO_0000841 + + + + obo:DDO.owl#DDO_0000841 + 416658003 + + + + obo:DDO.owl#DDO_0000841 + conjunctival papillary hypertrophy + + + + obo:DDO.owl#DDO_0000842 + DDO:DDO_0000842 + + + + obo:DDO.owl#DDO_0000842 + 10813004 + + + + obo:DDO.owl#DDO_0000842 + contact blepharoconjunctivitis + + + + obo:DDO.owl#DDO_0000843 + DDO:DDO_0000843 + + + + obo:DDO.owl#DDO_0000843 + 416454006 + + + + obo:DDO.owl#DDO_0000843 + contact lens related conjunctivitis + + + + obo:DDO.owl#DDO_0000844 + DDO:DDO_0000844 + + + + obo:DDO.owl#DDO_0000844 + 421632000 + + + + obo:DDO.owl#DDO_0000844 + contact lens related papillary conjunctivitis + + + + obo:DDO.owl#DDO_0000845 + DDO:DDO_0000845 + + + + obo:DDO.owl#DDO_0000845 + 231857004 + + + + obo:DDO.owl#DDO_0000845 + giant papillary conjunctivitis + + + + obo:DDO.owl#DDO_0000846 + DDO:DDO_0000846 + + + + obo:DDO.owl#DDO_0000846 + 314498009 + + + + obo:DDO.owl#DDO_0000846 + contact lens related giant papillary conjunctivitis + + + + obo:DDO.owl#DDO_0000847 + DDO:DDO_0000847 + + + + obo:DDO.owl#DDO_0000847 + 397515005 + + + + obo:DDO.owl#DDO_0000847 + Molluscum contagiosum blepharoconjunctivitis + + + + obo:DDO.owl#DDO_0000848 + DDO:DDO_0000848 + + + + obo:DDO.owl#DDO_0000848 + 416878008 + + + + obo:DDO.owl#DDO_0000848 + papillary conjunctivitis + + + + obo:DDO.owl#DDO_0000849 + DDO:DDO_0000849 + + + + obo:DDO.owl#DDO_0000849 + 371097007 + + + + obo:DDO.owl#DDO_0000849 + rosacea blepharoconjunctivitis + + + + obo:DDO.owl#DDO_0000850 + DDO:DDO_0000850 + + + + obo:DDO.owl#DDO_0000850 + 73762008 + + + + obo:DDO.owl#DDO_0000850 + chronic conjunctivitis + + + + obo:DDO.owl#DDO_0000851 + DDO:DDO_0000851 + + + + obo:DDO.owl#DDO_0000851 + 26045000 + + + + obo:DDO.owl#DDO_0000851 + chronic allergic conjunctivitis + + + + obo:DDO.owl#DDO_0000852 + DDO:DDO_0000852 + + + + obo:DDO.owl#DDO_0000852 + 39429002 + + + + obo:DDO.owl#DDO_0000852 + chronic follicular conjunctivitis + + + + obo:DDO.owl#DDO_0000853 + DDO:DDO_0000853 + + + + obo:DDO.owl#DDO_0000853 + 8211008 + + + + obo:DDO.owl#DDO_0000853 + simple chronic conjunctivitis + + + + obo:DDO.owl#DDO_0000854 + DDO:DDO_0000854 + + + + obo:DDO.owl#DDO_0000854 + 403436006 + + + + obo:DDO.owl#DDO_0000854 + cicatrizing conjunctivitis + + + + obo:DDO.owl#DDO_0000855 + DDO:DDO_0000855 + + + + obo:DDO.owl#DDO_0000855 + 417131000 + + + + obo:DDO.owl#DDO_0000855 + linear IgA cicatrizing conjunctivitis + + + + obo:DDO.owl#DDO_0000856 + DDO:DDO_0000856 + + + + obo:DDO.owl#DDO_0000856 + 314757003 + + + + obo:DDO.owl#DDO_0000856 + ocular cicatricial pemphigoid + + + + obo:DDO.owl#DDO_0000857 + DDO:DDO_0000857 + + + + obo:DDO.owl#DDO_0000857 + 416054002 + + + + obo:DDO.owl#DDO_0000857 + post-infectious cicatrizing conjunctivitis + + + + obo:DDO.owl#DDO_0000859 + DDO:DDO_0000859 + + + + obo:DDO.owl#DDO_0000859 + 86402005 + + + + obo:DDO.owl#DDO_0000859 + follicular conjunctivitis + + + + obo:DDO.owl#DDO_0000860 + DDO:DDO_0000860 + + + + obo:DDO.owl#DDO_0000860 + 41308008 + + + + obo:DDO.owl#DDO_0000860 + acute follicular conjunctivitis + + + + obo:DDO.owl#DDO_0000861 + DDO:DDO_0000861 + + + + obo:DDO.owl#DDO_0000861 + 39429002 + + + + obo:DDO.owl#DDO_0000861 + chronic follicular conjunctivitis + + + + obo:DDO.owl#DDO_0000862 + DDO:DDO_0000862 + + + + obo:DDO.owl#DDO_0000862 + 27020006 + + + + obo:DDO.owl#DDO_0000862 + trachomatous follicular conjunctivitis + + + + obo:DDO.owl#DDO_0000863 + DDO:DDO_0000863 + + + + obo:DDO.owl#DDO_0000863 + 95748007 + + + + obo:DDO.owl#DDO_0000863 + granulomatous conjunctivitis + + + + obo:DDO.owl#DDO_0000864 + DDO:DDO_0000864 + + + + obo:DDO.owl#DDO_0000864 + 90715009 + + + + obo:DDO.owl#DDO_0000864 + granuloma of conjunctiva + + + + obo:DDO.owl#DDO_0000865 + DDO:DDO_0000865 + + + + obo:DDO.owl#DDO_0000865 + 111825008 + + + + obo:DDO.owl#DDO_0000865 + tuberculosis of conjunctiva + + + + obo:DDO.owl#DDO_0000866 + DDO:DDO_0000866 + + + + obo:DDO.owl#DDO_0000866 + 186267004 + + + + obo:DDO.owl#DDO_0000866 + tuberculous keratoconjunctivitis + + + + obo:DDO.owl#DDO_0000868 + DDO:DDO_0000868 + + + + obo:DDO.owl#DDO_0000868 + 66291003 + + + + obo:DDO.owl#DDO_0000868 + tuberculous phlyctenular keratoconjunctivitis + + + + obo:DDO.owl#DDO_0000869 + DDO:DDO_0000869 + + + + obo:DDO.owl#DDO_0000869 + 414463005 + + + + obo:DDO.owl#DDO_0000869 + immune-mediated conjunctivitis + + + + obo:DDO.owl#DDO_0000870 + DDO:DDO_0000870 + + + + obo:DDO.owl#DDO_0000870 + 473460002 + + + + obo:DDO.owl#DDO_0000870 + allergic conjunctivitis + + + + obo:DDO.owl#DDO_0000871 + DDO:DDO_0000871 + + + + obo:DDO.owl#DDO_0000871 + 231854006 + + + + obo:DDO.owl#DDO_0000871 + atopic conjunctivitis + + + + obo:DDO.owl#DDO_0000872 + DDO:DDO_0000872 + + + + obo:DDO.owl#DDO_0000872 + 67678004 + + + + obo:DDO.owl#DDO_0000872 + acute atopic conjunctivitis + + + + obo:DDO.owl#DDO_0000873 + DDO:DDO_0000873 + + + + obo:DDO.owl#DDO_0000873 + 403434009 + + + + obo:DDO.owl#DDO_0000873 + atopic keratoconjunctivitis + + + + obo:DDO.owl#DDO_0000874 + DDO:DDO_0000874 + + + + obo:DDO.owl#DDO_0000874 + 26045000 + + + + obo:DDO.owl#DDO_0000874 + chronic allergic conjunctivitis + + + + obo:DDO.owl#DDO_0000875 + DDO:DDO_0000875 + + + + obo:DDO.owl#DDO_0000875 + 231857004 + + + + obo:DDO.owl#DDO_0000875 + giant papillary conjunctivitis + + + + obo:DDO.owl#DDO_0000876 + DDO:DDO_0000876 + + + + obo:DDO.owl#DDO_0000876 + 231856008 + + + + obo:DDO.owl#DDO_0000876 + perennial allergic conjunctivitis + + + + obo:DDO.owl#DDO_0000877 + DDO:DDO_0000877 + + + + obo:DDO.owl#DDO_0000877 + 231855007 + + + + obo:DDO.owl#DDO_0000877 + seasonal allergic conjunctivitis + + + + obo:DDO.owl#DDO_0000878 + DDO:DDO_0000878 + + + + obo:DDO.owl#DDO_0000878 + 318316003 + + + + obo:DDO.owl#DDO_0000878 + vernal conjunctivitis + + + + obo:DDO.owl#DDO_0000879 + DDO:DDO_0000879 + + + + obo:DDO.owl#DDO_0000879 + 317349009 + + + + obo:DDO.owl#DDO_0000879 + vernal keratoconjunctivitis + + + + obo:DDO.owl#DDO_0000880 + DDO:DDO_0000880 + + + + obo:DDO.owl#DDO_0000880 + 299699004 + + + + obo:DDO.owl#DDO_0000880 + infective conjunctivitis + + + + obo:DDO.owl#DDO_0000881 + DDO:DDO_0000881 + + + + obo:DDO.owl#DDO_0000881 + 128350005 + + + + obo:DDO.owl#DDO_0000881 + bacterial conjunctivitis + + + + obo:DDO.owl#DDO_0000882 + DDO:DDO_0000882 + + + + obo:DDO.owl#DDO_0000882 + 7773002 + + + + obo:DDO.owl#DDO_0000882 + conjunctival diphtheria + + + + obo:DDO.owl#DDO_0000883 + DDO:DDO_0000883 + + + + obo:DDO.owl#DDO_0000883 + 231858009 + + + + obo:DDO.owl#DDO_0000883 + gonococcal conjunctivitis + + + + obo:DDO.owl#DDO_0000884 + DDO:DDO_0000884 + + + + obo:DDO.owl#DDO_0000884 + 29786001 + + + + obo:DDO.owl#DDO_0000884 + Listeria conjunctivitis + + + + obo:DDO.owl#DDO_0000885 + DDO:DDO_0000885 + + + + obo:DDO.owl#DDO_0000885 + 94151004 + + + + obo:DDO.owl#DDO_0000885 + meningococcal conjunctivitis + + + + obo:DDO.owl#DDO_0000886 + DDO:DDO_0000886 + + + + obo:DDO.owl#DDO_0000886 + 5808000 + + + + obo:DDO.owl#DDO_0000886 + Morax lacunata angular conjunctivitis + + + + obo:DDO.owl#DDO_0000887 + DDO:DDO_0000887 + + + + obo:DDO.owl#DDO_0000887 + 276680000 + + + + obo:DDO.owl#DDO_0000887 + neonatal bacterial conjunctivitis + + + + obo:DDO.owl#DDO_0000888 + DDO:DDO_0000888 + + + + obo:DDO.owl#DDO_0000888 + 276689004 + + + + obo:DDO.owl#DDO_0000888 + Coliform ophthalmia neonatorum + + + + obo:DDO.owl#DDO_0000889 + DDO:DDO_0000889 + + + + obo:DDO.owl#DDO_0000889 + 28438004 + + + + obo:DDO.owl#DDO_0000889 + gonococcal conjunctivitis neonatorum + + + + obo:DDO.owl#DDO_0000900 + DDO:DDO_0000900 + + + + obo:DDO.owl#DDO_0000900 + 240591000 + + + + obo:DDO.owl#DDO_0000900 + neonatal chlamydial conjunctivitis + + + + obo:DDO.owl#DDO_0000901 + DDO:DDO_0000901 + + + + obo:DDO.owl#DDO_0000901 + 278930003 + + + + obo:DDO.owl#DDO_0000901 + Pseudomonas ophthalmia neonatorum + + + + obo:DDO.owl#DDO_0000902 + DDO:DDO_0000902 + + + + obo:DDO.owl#DDO_0000902 + 276691007 + + + + obo:DDO.owl#DDO_0000902 + staphylococcal ophthalmia neonatorum + + + + obo:DDO.owl#DDO_0000903 + DDO:DDO_0000903 + + + + obo:DDO.owl#DDO_0000903 + 73363000 + + + + obo:DDO.owl#DDO_0000903 + oculoglandular tularemia + + + + obo:DDO.owl#DDO_0000904 + DDO:DDO_0000904 + + + + obo:DDO.owl#DDO_0000904 + 231861005 + + + + obo:DDO.owl#DDO_0000904 + chlamydial conjunctivitis + + + + obo:DDO.owl#DDO_0000905 + DDO:DDO_0000905 + + + + obo:DDO.owl#DDO_0000905 + 2576002 + + + + obo:DDO.owl#DDO_0000905 + trachoma + + + + obo:DDO.owl#DDO_0000906 + DDO:DDO_0000906 + + + + obo:DDO.owl#DDO_0000906 + 266109000 + + + + obo:DDO.owl#DDO_0000906 + inclusion conjunctivitis + + + + obo:DDO.owl#DDO_0000907 + DDO:DDO_0000907 + + + + obo:DDO.owl#DDO_0000907 + 276683003 + + + + obo:DDO.owl#DDO_0000907 + neonatal inclusion body conjunctivitis + + + + obo:DDO.owl#DDO_0000908 + DDO:DDO_0000908 + + + + obo:DDO.owl#DDO_0000908 + 52812002 + + + + obo:DDO.owl#DDO_0000908 + trachoma, active stage + + + + obo:DDO.owl#DDO_0000909 + DDO:DDO_0000909 + + + + obo:DDO.owl#DDO_0000909 + 29976007 + + + + obo:DDO.owl#DDO_0000909 + trachoma, initial stage + + + + obo:DDO.owl#DDO_0000910 + DDO:DDO_0000910 + + + + obo:DDO.owl#DDO_0000910 + 90060000 + + + + obo:DDO.owl#DDO_0000910 + trachomatous granular conjunctivitis + + + + obo:DDO.owl#DDO_0000911 + DDO:DDO_0000911 + + + + obo:DDO.owl#DDO_0000911 + 55555001 + + + + obo:DDO.owl#DDO_0000911 + trachomatous pannus + + + + obo:DDO.owl#DDO_0000912 + DDO:DDO_0000912 + + + + obo:DDO.owl#DDO_0000912 + 231862003 + + + + obo:DDO.owl#DDO_0000912 + fungal conjunctivitis + + + + obo:DDO.owl#DDO_0000913 + DDO:DDO_0000913 + + + + obo:DDO.owl#DDO_0000913 + 72321008 + + + + obo:DDO.owl#DDO_0000913 + Herpes simplex keratoconjunctivitis + + + + obo:DDO.owl#DDO_0000914 + DDO:DDO_0000914 + + + + obo:DDO.owl#DDO_0000914 + 42448002 + + + + obo:DDO.owl#DDO_0000914 + Herpes zoster keratoconjunctivitis + + + + obo:DDO.owl#DDO_0000915 + DDO:DDO_0000915 + + + + obo:DDO.owl#DDO_0000915 + 410475008 + + + + obo:DDO.owl#DDO_0000915 + lyme conjunctivitis + + + + obo:DDO.owl#DDO_0000916 + DDO:DDO_0000916 + + + + obo:DDO.owl#DDO_0000916 + 243462001 + + + + obo:DDO.owl#DDO_0000916 + mucopurulent conjunctivitis + + + + obo:DDO.owl#DDO_0000917 + DDO:DDO_0000917 + + + + obo:DDO.owl#DDO_0000917 + 267642007 + + + + obo:DDO.owl#DDO_0000917 + acute mucopurulent conjunctivitis + + + + obo:DDO.owl#DDO_0000918 + DDO:DDO_0000918 + + + + obo:DDO.owl#DDO_0000918 + 8554002 + + + + obo:DDO.owl#DDO_0000918 + Brazilian purpuric fever + + + + obo:DDO.owl#DDO_0000919 + DDO:DDO_0000919 + + + + obo:DDO.owl#DDO_0000919 + 68898005 + + + + obo:DDO.owl#DDO_0000919 + catarrhal conjunctivitis + + + + obo:DDO.owl#DDO_0000920 + DDO:DDO_0000920 + + + + obo:DDO.owl#DDO_0000920 + 13816006 + + + + obo:DDO.owl#DDO_0000920 + parasitic conjunctivitis + + + + obo:DDO.owl#DDO_0000921 + DDO:DDO_0000921 + + + + obo:DDO.owl#DDO_0000921 + 193904008 + + + + obo:DDO.owl#DDO_0000921 + filarial infection of conjunctiva + + + + obo:DDO.owl#DDO_0000922 + DDO:DDO_0000922 + + + + obo:DDO.owl#DDO_0000922 + 243321006 + + + + obo:DDO.owl#DDO_0000922 + purulent conjunctivitis + + + + obo:DDO.owl#DDO_0000923 + DDO:DDO_0000923 + + + + obo:DDO.owl#DDO_0000923 + 45261009 + + + + obo:DDO.owl#DDO_0000923 + viral conjunctivitis + + + + obo:DDO.owl#DDO_0000924 + DDO:DDO_0000924 + + + + obo:DDO.owl#DDO_0000924 + 359628008 + + + + obo:DDO.owl#DDO_0000924 + conjunctivitis due to enterovirus type 70 + + + + obo:DDO.owl#DDO_0000925 + DDO:DDO_0000925 + + + + obo:DDO.owl#DDO_0000925 + 410508006 + + + + obo:DDO.owl#DDO_0000925 + Herpes simplex conjunctivitis + + + + obo:DDO.owl#DDO_0000926 + DDO:DDO_0000926 + + + + obo:DDO.owl#DDO_0000926 + 410509003 + + + + obo:DDO.owl#DDO_0000926 + Herpes zoster conjunctivitis + + + + obo:DDO.owl#DDO_0000927 + DDO:DDO_0000927 + + + + obo:DDO.owl#DDO_0000927 + 60013002 + + + + obo:DDO.owl#DDO_0000927 + measles keratoconjunctivitis + + + + obo:DDO.owl#DDO_0000928 + DDO:DDO_0000928 + + + + obo:DDO.owl#DDO_0000928 + 397515005 + + + + obo:DDO.owl#DDO_0000928 + Molluscum contagiosum blepharoconjunctivitis + + + + obo:DDO.owl#DDO_0000929 + DDO:DDO_0000929 + + + + obo:DDO.owl#DDO_0000929 + 276682008 + + + + obo:DDO.owl#DDO_0000929 + neonatal viral conjunctivitis + + + + obo:DDO.owl#DDO_0000930 + DDO:DDO_0000930 + + + + obo:DDO.owl#DDO_0000930 + 231859001 + + + + obo:DDO.owl#DDO_0000930 + Newcastle conjunctivitis + + + + obo:DDO.owl#DDO_0000931 + DDO:DDO_0000931 + + + + obo:DDO.owl#DDO_0000931 + 186675001 + + + + obo:DDO.owl#DDO_0000931 + viral pharyngoconjunctivitis + + + + obo:DDO.owl#DDO_0000932 + DDO:DDO_0000932 + + + + obo:DDO.owl#DDO_0000932 + 70385007 + + + + obo:DDO.owl#DDO_0000932 + adenoviral pharyngoconjunctivitis + + + + obo:DDO.owl#DDO_0000933 + DDO:DDO_0000933 + + + + obo:DDO.owl#DDO_0000933 + 88151007 + + + + obo:DDO.owl#DDO_0000933 + keratoconjunctivitis + + + + obo:DDO.owl#DDO_0000934 + DDO:DDO_0000934 + + + + obo:DDO.owl#DDO_0000934 + 231902000 + + + + obo:DDO.owl#DDO_0000934 + Dendriform epithelial keratoconjunctivitis + + + + obo:DDO.owl#DDO_0000935 + DDO:DDO_0000935 + + + + obo:DDO.owl#DDO_0000935 + 231904004 + + + + obo:DDO.owl#DDO_0000935 + diffuse stromal keratoconjunctivitis + + + + obo:DDO.owl#DDO_0000936 + DDO:DDO_0000936 + + + + obo:DDO.owl#DDO_0000936 + 60548004 + + + + obo:DDO.owl#DDO_0000936 + epidemic keratoconjunctivitis + + + + obo:DDO.owl#DDO_0000937 + DDO:DDO_0000937 + + + + obo:DDO.owl#DDO_0000937 + 14366000 + + + + obo:DDO.owl#DDO_0000937 + exposure keratoconjunctivitis + + + + obo:DDO.owl#DDO_0000938 + DDO:DDO_0000938 + + + + obo:DDO.owl#DDO_0000938 + 231905003 + + + + obo:DDO.owl#DDO_0000938 + keratoconjunctivitis nodosa + + + + obo:DDO.owl#DDO_0000939 + DDO:DDO_0000939 + + + + obo:DDO.owl#DDO_0000939 + 302896008 + + + + obo:DDO.owl#DDO_0000939 + keratoconjunctivitis sicca + + + + obo:DDO.owl#DDO_0000940 + DDO:DDO_0000940 + + + + obo:DDO.owl#DDO_0000940 + 446021007 + + + + obo:DDO.owl#DDO_0000940 + limbal vernal conjunctivitis + + + + obo:DDO.owl#DDO_0000941 + DDO:DDO_0000941 + + + + obo:DDO.owl#DDO_0000941 + 397566000 + + + + obo:DDO.owl#DDO_0000941 + Microsporidia keratoconjunctivitis + + + + obo:DDO.owl#DDO_0000942 + DDO:DDO_0000942 + + + + obo:DDO.owl#DDO_0000942 + 77080005 + + + + obo:DDO.owl#DDO_0000942 + neurotrophic keratoconjunctivitis + + + + obo:DDO.owl#DDO_0000943 + DDO:DDO_0000943 + + + + obo:DDO.owl#DDO_0000943 + 67895005 + + + + obo:DDO.owl#DDO_0000943 + phlyctenular keratoconjunctivitis + + + + obo:DDO.owl#DDO_0000944 + DDO:DDO_0000944 + + + + obo:DDO.owl#DDO_0000944 + 66291003 + + + + obo:DDO.owl#DDO_0000944 + tuberculous phlyctenular keratoconjunctivitis + + + + obo:DDO.owl#DDO_0000945 + DDO:DDO_0000945 + + + + obo:DDO.owl#DDO_0000945 + 42513006 + + + + obo:DDO.owl#DDO_0000945 + punctate keratitis + + + + obo:DDO.owl#DDO_0000946 + DDO:DDO_0000946 + + + + obo:DDO.owl#DDO_0000946 + 231903005 + + + + obo:DDO.owl#DDO_0000946 + superior limbic keratoconjunctivitis + + + + obo:DDO.owl#DDO_0000947 + DDO:DDO_0000947 + + + + obo:DDO.owl#DDO_0000947 + 415735001 + + + + obo:DDO.owl#DDO_0000947 + toxic keratoconjunctivitis + + + + obo:DDO.owl#DDO_0000948 + DDO:DDO_0000948 + + + + obo:DDO.owl#DDO_0000948 + 403435005 + + + + obo:DDO.owl#DDO_0000948 + ligneous conjunctivitis + + + + obo:DDO.owl#DDO_0000949 + DDO:DDO_0000949 + + + + obo:DDO.owl#DDO_0000949 + 102451006 + + + + obo:DDO.owl#DDO_0000949 + membranous conjunctivitis + + + + obo:DDO.owl#DDO_0000950 + DDO:DDO_0000950 + + + + obo:DDO.owl#DDO_0000950 + 95747002 + + + + obo:DDO.owl#DDO_0000950 + necrotizing conjunctivitis + + + + obo:DDO.owl#DDO_0000951 + DDO:DDO_0000951 + + + + obo:DDO.owl#DDO_0000951 + 34298002 + + + + obo:DDO.owl#DDO_0000951 + neonatal conjunctivitis + + + + obo:DDO.owl#DDO_0000952 + DDO:DDO_0000952 + + + + obo:DDO.owl#DDO_0000952 + 70394001 + + + + obo:DDO.owl#DDO_0000952 + phlyctenular conjunctivitis + + + + obo:DDO.owl#DDO_0000953 + DDO:DDO_0000953 + + + + obo:DDO.owl#DDO_0000953 + 124681000119104 + + + + obo:DDO.owl#DDO_0000953 + pingueculitis + + + + obo:DDO.owl#DDO_0000954 + DDO:DDO_0000954 + + + + obo:DDO.owl#DDO_0000954 + 241759005 + + + + obo:DDO.owl#DDO_0000954 + pink eye disease + + + + obo:DDO.owl#DDO_0000955 + DDO:DDO_0000955 + + + + obo:DDO.owl#DDO_0000955 + pseudomembranous conjunctivitis + + + + obo:DDO.owl#DDO_0000956 + DDO:DDO_0000956 + + + + obo:DDO.owl#DDO_0000956 + 95749004 + + + + obo:DDO.owl#DDO_0000956 + pyogranulomatous conjunctivitis + + + + obo:DDO.owl#DDO_0000957 + DDO:DDO_0000957 + + + + obo:DDO.owl#DDO_0000957 + 10128002 + + + + obo:DDO.owl#DDO_0000957 + rosacea conjunctivitis + + + + obo:DDO.owl#DDO_0000958 + DDO:DDO_0000958 + + + + obo:DDO.owl#DDO_0000958 + 91864001 + + + + obo:DDO.owl#DDO_0000958 + acute rosacea conjunctivitis + + + + obo:DDO.owl#DDO_0000959 + DDO:DDO_0000959 + + + + obo:DDO.owl#DDO_0000959 + 371097007 + + + + obo:DDO.owl#DDO_0000959 + rosacea blepharoconjunctivitis + + + + obo:DDO.owl#DDO_0000960 + DDO:DDO_0000960 + + + + obo:DDO.owl#DDO_0000960 + 193859006 + + + + obo:DDO.owl#DDO_0000960 + serous conjunctivitis + + + + obo:DDO.owl#DDO_0000961 + DDO:DDO_0000961 + + + + obo:DDO.owl#DDO_0000961 + 415733008 + + + + obo:DDO.owl#DDO_0000961 + toxic conjunctivitis + + + + obo:DDO.owl#DDO_0000962 + DDO:DDO_0000962 + + + + obo:DDO.owl#DDO_0000962 + 55822004 + + + + obo:DDO.owl#DDO_0000962 + hypercholesterolemia + + + + obo:DDO.owl#DDO_0000962 + hyperlipidemia + + + + obo:DDO.owl#DDO_0000963 + DDO:DDO_0000963 + + + + obo:DDO.owl#DDO_0000963 + 129589009 + + + + obo:DDO.owl#DDO_0000963 + endogenous hyperlipidemia + + + + obo:DDO.owl#DDO_0000965 + DDO:DDO_0000965 + + + + obo:DDO.owl#DDO_0000965 + 402785008 + + + + obo:DDO.owl#DDO_0000965 + primary genetic hyperlipidemia + + + + obo:DDO.owl#DDO_0000966 + DDO:DDO_0000966 + + + + obo:DDO.owl#DDO_0000966 + 402786009 + + + + obo:DDO.owl#DDO_0000966 + chylomicronemia syndrome + + + + obo:DDO.owl#DDO_0000967 + DDO:DDO_0000967 + + + + obo:DDO.owl#DDO_0000967 + 402787000 + + + + obo:DDO.owl#DDO_0000967 + primary genetic mixed hyperlipidemia + + + + obo:DDO.owl#DDO_0000968 + DDO:DDO_0000968 + + + + obo:DDO.owl#DDO_0000968 + 129590000 + + + + obo:DDO.owl#DDO_0000968 + exogenous hyperlipidemia + + + + obo:DDO.owl#DDO_0000969 + DDO:DDO_0000969 + + + + obo:DDO.owl#DDO_0000969 + 299465007 + + + + obo:DDO.owl#DDO_0000969 + familial multiple lipoprotein-type hyperlipidemia + + + + obo:DDO.owl#DDO_0000970 + DDO:DDO_0000970 + + + + obo:DDO.owl#DDO_0000970 + 13644009 + + + + obo:DDO.owl#DDO_0000970 + hypercholesterolemia + + + + obo:DDO.owl#DDO_0000971 + DDO:DDO_0000971 + + + + obo:DDO.owl#DDO_0000971 + 190774002 + + + + obo:DDO.owl#DDO_0000971 + hyperlipidemia, group A + + + + obo:DDO.owl#DDO_0000972 + DDO:DDO_0000972 + + + + obo:DDO.owl#DDO_0000972 + 238076009 + + + + obo:DDO.owl#DDO_0000972 + primary hypercholesterolemia + + + + obo:DDO.owl#DDO_0000973 + DDO:DDO_0000973 + + + + obo:DDO.owl#DDO_0000973 + 57218003 + + + + obo:DDO.owl#DDO_0000973 + cholesterol ester storage disease + + + + obo:DDO.owl#DDO_0000974 + DDO:DDO_0000974 + + + + obo:DDO.owl#DDO_0000974 + 238081000 + + + + obo:DDO.owl#DDO_0000974 + familial defective apolipoprotein B-100 + + + + obo:DDO.owl#DDO_0000975 + DDO:DDO_0000975 + + + + obo:DDO.owl#DDO_0000975 + 398036000 + + + + obo:DDO.owl#DDO_0000975 + familial hypercholesterolemia + + + + obo:DDO.owl#DDO_0000976 + DDO:DDO_0000976 + + + + obo:DDO.owl#DDO_0000976 + 397915002 + + + + obo:DDO.owl#DDO_0000976 + Fredrickson type IIa hyperlipoproteinemia + + + + obo:DDO.owl#DDO_0000977 + DDO:DDO_0000977 + + + + obo:DDO.owl#DDO_0000977 + 238080004 + + + + obo:DDO.owl#DDO_0000977 + hyperalphalipoproteinemia + + + + obo:DDO.owl#DDO_0000978 + DDO:DDO_0000978 + + + + obo:DDO.owl#DDO_0000978 + 15771000119109 + + + + obo:DDO.owl#DDO_0000978 + familial hyperalphalipoproteinemia + + + + obo:DDO.owl#DDO_0000979 + DDO:DDO_0000979 + + + + obo:DDO.owl#DDO_0000979 + 238077000 + + + + obo:DDO.owl#DDO_0000979 + polygenic hypercholesterolemia + + + + obo:DDO.owl#DDO_0000980 + DDO:DDO_0000980 + + + + obo:DDO.owl#DDO_0000980 + 267432004 + + + + obo:DDO.owl#DDO_0000980 + pure hypercholesterolemia + + + + obo:DDO.owl#DDO_0000981 + DDO:DDO_0000981 + + + + obo:DDO.owl#DDO_0000981 + 238082007 + + + + obo:DDO.owl#DDO_0000981 + secondary hypercholesterolemia + + + + obo:DDO.owl#DDO_0000982 + DDO:DDO_0000982 + + + + obo:DDO.owl#DDO_0000982 + 302870006 + + + + obo:DDO.owl#DDO_0000982 + hypertriglyceridemia + + + + obo:DDO.owl#DDO_0000983 + DDO:DDO_0000983 + + + + obo:DDO.owl#DDO_0000983 + 238083002 + + + + obo:DDO.owl#DDO_0000983 + primary hypertriglyceridemia + + + + obo:DDO.owl#DDO_0000984 + DDO:DDO_0000984 + + + + obo:DDO.owl#DDO_0000984 + 34528009 + + + + obo:DDO.owl#DDO_0000984 + familial hypertriglyceridemia + + + + obo:DDO.owl#DDO_0000985 + DDO:DDO_0000985 + + + + obo:DDO.owl#DDO_0000985 + 267435002 + + + + obo:DDO.owl#DDO_0000985 + familial hyperchylomicronemia + + + + obo:DDO.owl#DDO_0000986 + DDO:DDO_0000986 + + + + obo:DDO.owl#DDO_0000986 + 33513003 + + + + obo:DDO.owl#DDO_0000986 + familial apolipoprotein C-II deficiency + + + + obo:DDO.owl#DDO_0000987 + DDO:DDO_0000987 + + + + obo:DDO.owl#DDO_0000987 + 238086005 + + + + obo:DDO.owl#DDO_0000987 + familial lipoprotein lipase deficiency + + + + obo:DDO.owl#DDO_0000988 + DDO:DDO_0000988 + + + + obo:DDO.owl#DDO_0000988 + 403827000 + + + + obo:DDO.owl#DDO_0000988 + familial lipoprotein lipase deficiency with type I phenotype + + + + obo:DDO.owl#DDO_0000989 + DDO:DDO_0000989 + + + + obo:DDO.owl#DDO_0000989 + 403828005 + + + + obo:DDO.owl#DDO_0000989 + familial lipoprotein lipase deficiency with type V phenotype + + + + obo:DDO.owl#DDO_0000990 + DDO:DDO_0000990 + + + + obo:DDO.owl#DDO_0000990 + 34349009 + + + + obo:DDO.owl#DDO_0000990 + familial type 5 hyperlipoproteinemia + + + + obo:DDO.owl#DDO_0000991 + DDO:DDO_0000991 + + + + obo:DDO.owl#DDO_0000991 + 238085009 + + + + obo:DDO.owl#DDO_0000991 + Fredrickson type IV hyperlipoproteinemia + + + + obo:DDO.owl#DDO_0000992 + DDO:DDO_0000992 + + + + obo:DDO.owl#DDO_0000992 + 238084008 + + + + obo:DDO.owl#DDO_0000992 + very low density lipoprotinemia + + + + obo:DDO.owl#DDO_0000993 + DDO:DDO_0000993 + + + + obo:DDO.owl#DDO_0000993 + 402473001 + + + + obo:DDO.owl#DDO_0000993 + sporadic primary hypertriglyceridemia + + + + obo:DDO.owl#DDO_0000994 + DDO:DDO_0000994 + + + + obo:DDO.owl#DDO_0000994 + 267433009 + + + + obo:DDO.owl#DDO_0000994 + pure hyperglyceridemia + + + + obo:DDO.owl#DDO_0000995 + DDO:DDO_0000995 + + + + obo:DDO.owl#DDO_0000995 + 238087001 + + + + obo:DDO.owl#DDO_0000995 + secondary hypertriglyceridemia + + + + obo:DDO.owl#DDO_0000996 + DDO:DDO_0000996 + + + + obo:DDO.owl#DDO_0000996 + 267434003 + + + + obo:DDO.owl#DDO_0000996 + mixed hyperlipidemia + + + + obo:DDO.owl#DDO_0000997 + DDO:DDO_0000997 + + + + obo:DDO.owl#DDO_0000997 + 238088006 + + + + obo:DDO.owl#DDO_0000997 + primary combined hyperlipidemia + + + + obo:DDO.owl#DDO_0000998 + DDO:DDO_0000998 + + + + obo:DDO.owl#DDO_0000998 + 238040008 + + + + obo:DDO.owl#DDO_0000998 + familial combined hyperlipidemia + + + + obo:DDO.owl#DDO_0000999 + DDO:DDO_0000999 + + + + obo:DDO.owl#DDO_0000999 + 402474007 + + + + obo:DDO.owl#DDO_0000999 + primary "polygenic" combined hyperlipidemia + + + + obo:DDO.owl#DDO_0001000 + DDO:DDO_0001000 + + + + obo:DDO.owl#DDO_0001000 + 402787000 + + + + obo:DDO.owl#DDO_0001000 + primary genetic mixed hyperlipidemia + + + + obo:DDO.owl#DDO_0001001 + DDO:DDO_0001001 + + + + obo:DDO.owl#DDO_0001001 + 238089003 + + + + obo:DDO.owl#DDO_0001001 + secondary combined hyperlipidemia + + + + obo:DDO.owl#DDO_0001002 + DDO:DDO_0001002 + + + + obo:DDO.owl#DDO_0001002 + 445261005 + + + + obo:DDO.owl#DDO_0001002 + posttransplant hyperlipidemia + + + + obo:DDO.owl#DDO_0001003 + DDO:DDO_0001003 + + + + obo:DDO.owl#DDO_0001003 + 402727002 + + + + obo:DDO.owl#DDO_0001003 + secondary hyperlipidemia + + + + obo:DDO.owl#DDO_0001004 + DDO:DDO_0001004 + + + + obo:DDO.owl#DDO_0001004 + 38716007 + + + + obo:DDO.owl#DDO_0001004 + atherosclerosis + + + + obo:DDO.owl#DDO_0001005 + DDO:DDO_0001005 + + + + obo:DDO.owl#DDO_0001005 + arteriosclerosis + + + + obo:DDO.owl#DDO_0001006 + DDO:DDO_0001006 + + + + obo:DDO.owl#DDO_0001006 + 53741008 + + + + obo:DDO.owl#DDO_0001006 + coronary artery disease + + + + obo:DDO.owl#DDO_0001006 + coronary heart disease + + + + obo:DDO.owl#DDO_0001006 + coronary arteriosclerosis + + + + obo:DDO.owl#DDO_0001007 + DDO:DDO_0001007 + + + + obo:DDO.owl#DDO_0001007 + 92517006 + + + + obo:DDO.owl#DDO_0001007 + calcific coronary arteriosclerosis + + + + obo:DDO.owl#DDO_0001008 + DDO:DDO_0001008 + + + + obo:DDO.owl#DDO_0001008 + 42866003 + + + + obo:DDO.owl#DDO_0001008 + congenital coronary artery sclerosis + + + + obo:DDO.owl#DDO_0001009 + DDO:DDO_0001009 + + + + obo:DDO.owl#DDO_0001009 + 443502000 + + + + obo:DDO.owl#DDO_0001009 + coronary atherosclerosis + + + + obo:DDO.owl#DDO_0001010 + DDO:DDO_0001010 + + + + obo:DDO.owl#DDO_0001010 + 194843003 + + + + obo:DDO.owl#DDO_0001010 + double coronary vessel disease + + + + obo:DDO.owl#DDO_0001011 + DDO:DDO_0001011 + + + + obo:DDO.owl#DDO_0001011 + 233817007 + + + + obo:DDO.owl#DDO_0001011 + triple vessel disease of the heart + + + + obo:DDO.owl#DDO_0001012 + DDO:DDO_0001012 + + + + obo:DDO.owl#DDO_0001012 + 1641000119107 + + + + obo:DDO.owl#DDO_0001012 + coronary arteriosclerosis in native artery + + + + obo:DDO.owl#DDO_0001013 + DDO:DDO_0001013 + + + + obo:DDO.owl#DDO_0001013 + 698247007 + + + + obo:DDO.owl#DDO_0001013 + cardiac arrhythmia + + + + obo:DDO.owl#DDO_0001014 + DDO:DDO_0001014 + + + + obo:DDO.owl#DDO_0001014 + 251167004 + + + + obo:DDO.owl#DDO_0001014 + aberrant premature complexes + + + + obo:DDO.owl#DDO_0001015 + DDO:DDO_0001015 + + + + obo:DDO.owl#DDO_0001015 + 287057009 + + + + obo:DDO.owl#DDO_0001015 + atrial premature complex + + + + obo:DDO.owl#DDO_0001016 + DDO:DDO_0001016 + + + + obo:DDO.owl#DDO_0001016 + 251173003 + + + + obo:DDO.owl#DDO_0001016 + atrial bigeminy + + + + obo:DDO.owl#DDO_0001017 + DDO:DDO_0001017 + + + + obo:DDO.owl#DDO_0001017 + 251174009 + + + + obo:DDO.owl#DDO_0001017 + atrial trigeminy + + + + obo:DDO.owl#DDO_0001018 + DDO:DDO_0001018 + + + + obo:DDO.owl#DDO_0001018 + 284470004 + + + + obo:DDO.owl#DDO_0001018 + premature atrial contraction + + + + obo:DDO.owl#DDO_0001019 + DDO:DDO_0001019 + + + + obo:DDO.owl#DDO_0001019 + 251170000 + + + + obo:DDO.owl#DDO_0001019 + blocked premature atrial contraction + + + + obo:DDO.owl#DDO_0001020 + DDO:DDO_0001020 + + + + obo:DDO.owl#DDO_0001020 + 49982000 + + + + obo:DDO.owl#DDO_0001020 + multifocal atrial tachycardia + + + + obo:DDO.owl#DDO_0001021 + DDO:DDO_0001021 + + + + obo:DDO.owl#DDO_0001021 + 251171001 + + + + obo:DDO.owl#DDO_0001021 + multiple atrial premature complexes + + + + obo:DDO.owl#DDO_0001023 + DDO:DDO_0001023 + + + + obo:DDO.owl#DDO_0001023 + 251172008 + + + + obo:DDO.owl#DDO_0001023 + run of atrial premature complexes + + + + obo:DDO.owl#DDO_0001024 + DDO:DDO_0001024 + + + + obo:DDO.owl#DDO_0001024 + 251164006 + + + + obo:DDO.owl#DDO_0001024 + junctional premature complex + + + + obo:DDO.owl#DDO_0001025 + DDO:DDO_0001025 + + + + obo:DDO.owl#DDO_0001025 + 251168009 + + + + obo:DDO.owl#DDO_0001025 + supraventricular bigeminy + + + + obo:DDO.owl#DDO_0001026 + DDO:DDO_0001026 + + + + obo:DDO.owl#DDO_0001026 + 251175005 + + + + obo:DDO.owl#DDO_0001026 + ventricular premature complex + + + + obo:DDO.owl#DDO_0001027 + DDO:DDO_0001027 + + + + obo:DDO.owl#DDO_0001027 + 10626002 + + + + obo:DDO.owl#DDO_0001027 + multifocal PVCs + + + + obo:DDO.owl#DDO_0001028 + DDO:DDO_0001028 + + + + obo:DDO.owl#DDO_0001028 + 38274001 + + + + obo:DDO.owl#DDO_0001028 + interpolated PVCs + + + + obo:DDO.owl#DDO_0001029 + DDO:DDO_0001029 + + + + obo:DDO.owl#DDO_0001029 + 251176006 + + + + obo:DDO.owl#DDO_0001029 + multiple premature ventricular complexes + + + + obo:DDO.owl#DDO_0001030 + DDO:DDO_0001030 + + + + obo:DDO.owl#DDO_0001030 + 251179004 + + + + obo:DDO.owl#DDO_0001030 + multiple ventricular interpolated complexes + + + + obo:DDO.owl#DDO_0001031 + DDO:DDO_0001031 + + + + obo:DDO.owl#DDO_0001031 + 251182009 + + + + obo:DDO.owl#DDO_0001031 + paired ventricular premature complexes + + + + obo:DDO.owl#DDO_0001032 + DDO:DDO_0001032 + + + + obo:DDO.owl#DDO_0001032 + 251177002 + + + + obo:DDO.owl#DDO_0001032 + run of ventricular premature complexes + + + + obo:DDO.owl#DDO_0001033 + DDO:DDO_0001033 + + + + obo:DDO.owl#DDO_0001033 + 27337007 + + + + obo:DDO.owl#DDO_0001033 + unifocal PVCs + + + + obo:DDO.owl#DDO_0001034 + DDO:DDO_0001034 + + + + obo:DDO.owl#DDO_0001034 + 11157007 + + + + obo:DDO.owl#DDO_0001034 + ventricular bigeminy + + + + obo:DDO.owl#DDO_0001035 + DDO:DDO_0001035 + + + + obo:DDO.owl#DDO_0001035 + 251178007 + + + + obo:DDO.owl#DDO_0001035 + ventricular interpolated complexes + + + + obo:DDO.owl#DDO_0001036 + DDO:DDO_0001036 + + + + obo:DDO.owl#DDO_0001036 + 251181002 + + + + obo:DDO.owl#DDO_0001036 + ventricular quadrigeminy + + + + obo:DDO.owl#DDO_0001037 + DDO:DDO_0001037 + + + + obo:DDO.owl#DDO_0001037 + 251180001 + + + + obo:DDO.owl#DDO_0001037 + ventricular trigeminy + + + + obo:DDO.owl#DDO_0001038 + DDO:DDO_0001038 + + + + obo:DDO.owl#DDO_0001038 + 251183004 + + + + obo:DDO.owl#DDO_0001038 + aberrantly conducted complex + + + + obo:DDO.owl#DDO_0001039 + DDO:DDO_0001039 + + + + obo:DDO.owl#DDO_0001039 + 16797001 + + + + obo:DDO.owl#DDO_0001039 + accelerated atrioventricular conduction + + + + obo:DDO.owl#DDO_0001040 + DDO:DDO_0001040 + + + + obo:DDO.owl#DDO_0001040 + 233922008 + + + + obo:DDO.owl#DDO_0001040 + concealed accessory pathway + + + + obo:DDO.owl#DDO_0001041 + DDO:DDO_0001041 + + + + obo:DDO.owl#DDO_0001041 + 233923003 + + + + obo:DDO.owl#DDO_0001041 + unidirectional retrograde accessory pathway + + + + obo:DDO.owl#DDO_0001042 + DDO:DDO_0001042 + + + + obo:DDO.owl#DDO_0001042 + 55475008 + + + + obo:DDO.owl#DDO_0001042 + Lown-Ganong-Levine syndrome + + + + obo:DDO.owl#DDO_0001043 + DDO:DDO_0001043 + + + + obo:DDO.owl#DDO_0001043 + 710878005 + + + + obo:DDO.owl#DDO_0001043 + Mahaim fiber tachycardia + + + + obo:DDO.owl#DDO_0001044 + DDO:DDO_0001044 + + + + obo:DDO.owl#DDO_0001044 + 195060002 + + + + obo:DDO.owl#DDO_0001044 + ventricular pre-excitation + + + + obo:DDO.owl#DDO_0001045 + DDO:DDO_0001045 + + + + obo:DDO.owl#DDO_0001045 + 74390002 + + + + obo:DDO.owl#DDO_0001045 + Wolff-Parkinson-White pattern + + + + obo:DDO.owl#DDO_0001046 + DDO:DDO_0001046 + + + + obo:DDO.owl#DDO_0001046 + 17869006 + + + + obo:DDO.owl#DDO_0001046 + anomalous atrioventricular excitation + + + + obo:DDO.owl#DDO_0001047 + DDO:DDO_0001047 + + + + obo:DDO.owl#DDO_0001047 + 251187003 + + + + obo:DDO.owl#DDO_0001047 + atrial escape complex + + + + obo:DDO.owl#DDO_0001048 + DDO:DDO_0001048 + + + + obo:DDO.owl#DDO_0001048 + 50799005 + + + + obo:DDO.owl#DDO_0001048 + atrioventricular dissociation + + + + obo:DDO.owl#DDO_0001049 + DDO:DDO_0001049 + + + + obo:DDO.owl#DDO_0001049 + 421869004 + + + + obo:DDO.owl#DDO_0001049 + bradyarrhythmia + + + + obo:DDO.owl#DDO_0001050 + DDO:DDO_0001050 + + + + obo:DDO.owl#DDO_0001050 + 251162005 + + + + obo:DDO.owl#DDO_0001050 + AV-junctional (nodal) bradycardia + + + + obo:DDO.owl#DDO_0001051 + DDO:DDO_0001051 + + + + obo:DDO.owl#DDO_0001051 + 240299002 + + + + obo:DDO.owl#DDO_0001051 + fetal bradycardia + + + + obo:DDO.owl#DDO_0001052 + DDO:DDO_0001052 + + + + obo:DDO.owl#DDO_0001052 + 413341007 + + + + obo:DDO.owl#DDO_0001052 + neonatal bradycardia + + + + obo:DDO.owl#DDO_0001053 + DDO:DDO_0001053 + + + + obo:DDO.owl#DDO_0001053 + 49710005 + + + + obo:DDO.owl#DDO_0001053 + sinus bradycardia + + + + obo:DDO.owl#DDO_0001054 + DDO:DDO_0001054 + + + + obo:DDO.owl#DDO_0001054 + 44602002 + + + + obo:DDO.owl#DDO_0001054 + persistent sinus bradycardia + + + + obo:DDO.owl#DDO_0001055 + DDO:DDO_0001055 + + + + obo:DDO.owl#DDO_0001055 + 49044005 + + + + obo:DDO.owl#DDO_0001055 + severe sinus bradycardia + + + + obo:DDO.owl#DDO_0001056 + DDO:DDO_0001056 + + + + obo:DDO.owl#DDO_0001056 + 444605001 + + + + obo:DDO.owl#DDO_0001056 + symptomatic sinus bradycardia + + + + obo:DDO.owl#DDO_0001057 + DDO:DDO_0001057 + + + + obo:DDO.owl#DDO_0001057 + 74615001 + + + + obo:DDO.owl#DDO_0001057 + tachycardia-bradycardia + + + + obo:DDO.owl#DDO_0001058 + DDO:DDO_0001058 + + + + obo:DDO.owl#DDO_0001058 + 29894000 + + + + obo:DDO.owl#DDO_0001058 + vagal autonomic bradycardia + + + + obo:DDO.owl#DDO_0001059 + DDO:DDO_0001059 + + + + obo:DDO.owl#DDO_0001059 + 410429000 + + + + obo:DDO.owl#DDO_0001059 + cardiac arrest + + + + obo:DDO.owl#DDO_0001060 + DDO:DDO_0001060 + + + + obo:DDO.owl#DDO_0001060 + 397829000 + + + + obo:DDO.owl#DDO_0001060 + asystole + + + + obo:DDO.owl#DDO_0001061 + DDO:DDO_0001061 + + + + obo:DDO.owl#DDO_0001061 + 703162001 + + + + obo:DDO.owl#DDO_0001061 + bradycardic cardiac arrest + + + + obo:DDO.owl#DDO_0001062 + DDO:DDO_0001062 + + + + obo:DDO.owl#DDO_0001062 + 410430005 + + + + obo:DDO.owl#DDO_0001062 + cardiorespiratory arrest + + + + obo:DDO.owl#DDO_0001063 + DDO:DDO_0001063 + + + + obo:DDO.owl#DDO_0001063 + 699748007 + + + + obo:DDO.owl#DDO_0001063 + cardiorespiratory arrest with successful resuscitation + + + + obo:DDO.owl#DDO_0001064 + DDO:DDO_0001064 + + + + obo:DDO.owl#DDO_0001064 + 698504006 + + + + obo:DDO.owl#DDO_0001064 + postoperative cardiopulmonary failure + + + + obo:DDO.owl#DDO_0001065 + DDO:DDO_0001065 + + + + obo:DDO.owl#DDO_0001065 + 261195002 + + + + obo:DDO.owl#DDO_0001065 + circulatory arrest + + + + obo:DDO.owl#DDO_0001066 + DDO:DDO_0001066 + + + + obo:DDO.owl#DDO_0001066 + 234172002 + + + + obo:DDO.owl#DDO_0001066 + electromechanical dissociation + + + + obo:DDO.owl#DDO_0001067 + DDO:DDO_0001067 + + + + obo:DDO.owl#DDO_0001067 + 71908006 + + + + obo:DDO.owl#DDO_0001067 + ventricular fibrillation + + + + obo:DDO.owl#DDO_0001068 + DDO:DDO_0001068 + + + + obo:DDO.owl#DDO_0001068 + 233915000 + + + + obo:DDO.owl#DDO_0001068 + paroxysmal familial ventricular fibrillation + + + + obo:DDO.owl#DDO_0001069 + DDO:DDO_0001069 + + + + obo:DDO.owl#DDO_0001069 + 429243003 + + + + obo:DDO.owl#DDO_0001069 + sustained ventricular fibrillation + + + + obo:DDO.owl#DDO_0001070 + DDO:DDO_0001070 + + + + obo:DDO.owl#DDO_0001070 + 195083004 + + + + obo:DDO.owl#DDO_0001070 + ventricular fibrillation and flutter + + + + obo:DDO.owl#DDO_0001071 + DDO:DDO_0001071 + + + + obo:DDO.owl#DDO_0001071 + 698271000 + + + + obo:DDO.owl#DDO_0001071 + cardiac channelopathy + + + + obo:DDO.owl#DDO_0001072 + DDO:DDO_0001072 + + + + obo:DDO.owl#DDO_0001072 + 281170005 + + + + obo:DDO.owl#DDO_0001072 + arrhythmogenic right ventricular cardiomyopathy + + + + obo:DDO.owl#DDO_0001073 + DDO:DDO_0001073 + + + + obo:DDO.owl#DDO_0001073 + 418818005 + + + + obo:DDO.owl#DDO_0001073 + Brugada syndrome + + + + obo:DDO.owl#DDO_0001074 + DDO:DDO_0001074 + + + + obo:DDO.owl#DDO_0001074 + 419671004 + + + + obo:DDO.owl#DDO_0001074 + catecholaminergic polymorphic ventricular tachycardia + + + + obo:DDO.owl#DDO_0001075 + DDO:DDO_0001075 + + + + obo:DDO.owl#DDO_0001075 + 9651007 + + + + obo:DDO.owl#DDO_0001075 + long QT syndrome + + + + obo:DDO.owl#DDO_0001076 + DDO:DDO_0001076 + + + + obo:DDO.owl#DDO_0001076 + 698272007 + + + + obo:DDO.owl#DDO_0001076 + short QT syndrome + + + + obo:DDO.owl#DDO_0001077 + DDO:DDO_0001077 + + + + obo:DDO.owl#DDO_0001077 + 44808001 + + + + obo:DDO.owl#DDO_0001077 + conduction disorder of the heart + + + + obo:DDO.owl#DDO_0001078 + DDO:DDO_0001078 + + + + obo:DDO.owl#DDO_0001078 + 418341009 + + + + obo:DDO.owl#DDO_0001078 + atrioventricular conduction disorder + + + + obo:DDO.owl#DDO_0001079 + DDO:DDO_0001079 + + + + obo:DDO.owl#DDO_0001079 + 233917008 + + + + obo:DDO.owl#DDO_0001079 + atrioventricular block + + + + obo:DDO.owl#DDO_0001080 + DDO:DDO_0001080 + + + + obo:DDO.owl#DDO_0001080 + 27885002 + + + + obo:DDO.owl#DDO_0001080 + complete atrioventricular block + + + + obo:DDO.owl#DDO_0001081 + DDO:DDO_0001081 + + + + obo:DDO.owl#DDO_0001081 + 93130009 + + + + obo:DDO.owl#DDO_0001081 + Lenegre's disease + + + + obo:DDO.owl#DDO_0001082 + DDO:DDO_0001082 + + + + obo:DDO.owl#DDO_0001082 + 233918003 + + + + obo:DDO.owl#DDO_0001082 + postoperative complete heart block + + + + obo:DDO.owl#DDO_0001083 + DDO:DDO_0001083 + + + + obo:DDO.owl#DDO_0001083 + 195039008 + + + + obo:DDO.owl#DDO_0001083 + partial atrioventricular block + + + + obo:DDO.owl#DDO_0001084 + DDO:DDO_0001084 + + + + obo:DDO.owl#DDO_0001084 + 270492004 + + + + obo:DDO.owl#DDO_0001084 + first degree atrioventricular block + + + + obo:DDO.owl#DDO_0001085 + DDO:DDO_0001085 + + + + obo:DDO.owl#DDO_0001085 + 195042002 + + + + obo:DDO.owl#DDO_0001085 + second degree atrioventricular block + + + + obo:DDO.owl#DDO_0001086 + DDO:DDO_0001086 + + + + obo:DDO.owl#DDO_0001086 + 54016002 + + + + obo:DDO.owl#DDO_0001086 + Mobitz type I incomplete atrioventricular block + + + + obo:DDO.owl#DDO_0001087 + DDO:DDO_0001087 + + + + obo:DDO.owl#DDO_0001087 + 28189009 + + + + obo:DDO.owl#DDO_0001087 + Mobitz type II atrioventricular block + + + + obo:DDO.owl#DDO_0001088 + DDO:DDO_0001088 + + + + obo:DDO.owl#DDO_0001088 + 284951000119109 + + + + obo:DDO.owl#DDO_0001088 + postoperative atrioventricular block + + + + obo:DDO.owl#DDO_0001089 + DDO:DDO_0001089 + + + + obo:DDO.owl#DDO_0001089 + 315027009 + + + + obo:DDO.owl#DDO_0001089 + congenital conduction defect + + + + obo:DDO.owl#DDO_0001090 + DDO:DDO_0001090 + + + + obo:DDO.owl#DDO_0001090 + 46619002 + + + + obo:DDO.owl#DDO_0001090 + congenital heart block + + + + obo:DDO.owl#DDO_0001091 + DDO:DDO_0001091 + + + + obo:DDO.owl#DDO_0001091 + 373905003 + + + + obo:DDO.owl#DDO_0001091 + Jervell and Lange-Nielsen syndrome + + + + obo:DDO.owl#DDO_0001092 + DDO:DDO_0001092 + + + + obo:DDO.owl#DDO_0001092 + 233916004 + + + + obo:DDO.owl#DDO_0001092 + heart block + + + + obo:DDO.owl#DDO_0001093 + DDO:DDO_0001093 + + + + obo:DDO.owl#DDO_0001093 + 233917008 + + + + obo:DDO.owl#DDO_0001093 + atrioventricular block + + + + obo:DDO.owl#DDO_0001094 + DDO:DDO_0001094 + + + + obo:DDO.owl#DDO_0001094 + 4554005 + + + + obo:DDO.owl#DDO_0001094 + intraventricular conduction defect + + + + obo:DDO.owl#DDO_0001095 + DDO:DDO_0001095 + + + + obo:DDO.owl#DDO_0001095 + 6374002 + + + + obo:DDO.owl#DDO_0001095 + bundle branch block + + + + obo:DDO.owl#DDO_0001096 + DDO:DDO_0001096 + + + + obo:DDO.owl#DDO_0001096 + 74021003 + + + + obo:DDO.owl#DDO_0001096 + Bifascicular block + + + + obo:DDO.owl#DDO_0001097 + DDO:DDO_0001097 + + + + obo:DDO.owl#DDO_0001097 + 283645003 + + + + obo:DDO.owl#DDO_0001097 + Lev's syndrome + + + + obo:DDO.owl#DDO_0001098 + DDO:DDO_0001098 + + + + obo:DDO.owl#DDO_0001098 + 2374000 + + + + obo:DDO.owl#DDO_0001098 + Monofascicular block + + + + obo:DDO.owl#DDO_0001099 + DDO:DDO_0001099 + + + + obo:DDO.owl#DDO_0001099 + 37760005 + + + + obo:DDO.owl#DDO_0001099 + left anterior fascicular block + + + + obo:DDO.owl#DDO_0001100 + DDO:DDO_0001100 + + + + obo:DDO.owl#DDO_0001100 + 62026008 + + + + obo:DDO.owl#DDO_0001100 + left posterior fascicular block + + + + obo:DDO.owl#DDO_0001101 + DDO:DDO_0001101 + + + + obo:DDO.owl#DDO_0001101 + 59118001 + + + + obo:DDO.owl#DDO_0001101 + right bundle branch block + + + + obo:DDO.owl#DDO_0001102 + DDO:DDO_0001102 + + + + obo:DDO.owl#DDO_0001102 + 251123001 + + + + obo:DDO.owl#DDO_0001102 + complete right bundle branch block + + + + obo:DDO.owl#DDO_0001103 + DDO:DDO_0001103 + + + + obo:DDO.owl#DDO_0001103 + 233919006 + + + + obo:DDO.owl#DDO_0001103 + familial isolated complete right bundle branch block + + + + obo:DDO.owl#DDO_0001104 + DDO:DDO_0001104 + + + + obo:DDO.owl#DDO_0001104 + 251124007 + + + + obo:DDO.owl#DDO_0001104 + incomplete right bundle branch block + + + + obo:DDO.owl#DDO_0001105 + DDO:DDO_0001105 + + + + obo:DDO.owl#DDO_0001105 + 82226007 + + + + obo:DDO.owl#DDO_0001105 + diffuse intraventricular block + + + + obo:DDO.owl#DDO_0001106 + DDO:DDO_0001106 + + + + obo:DDO.owl#DDO_0001106 + 251125008 + + + + obo:DDO.owl#DDO_0001106 + minor intraventricular conduction defect + + + + obo:DDO.owl#DDO_0001107 + DDO:DDO_0001107 + + + + obo:DDO.owl#DDO_0001107 + 698249005 + + + + obo:DDO.owl#DDO_0001107 + progressive familial heart block + + + + obo:DDO.owl#DDO_0001108 + DDO:DDO_0001108 + + + + obo:DDO.owl#DDO_0001108 + 698250005 + + + + obo:DDO.owl#DDO_0001108 + progressive familial heart block, type IB + + + + obo:DDO.owl#DDO_0001109 + DDO:DDO_0001109 + + + + obo:DDO.owl#DDO_0001109 + 698251009 + + + + obo:DDO.owl#DDO_0001109 + progressive familial heart block, type II + + + + obo:DDO.owl#DDO_0001110 + DDO:DDO_0001110 + + + + obo:DDO.owl#DDO_0001110 + 65778007 + + + + obo:DDO.owl#DDO_0001110 + sinoatrial block + + + + obo:DDO.owl#DDO_0001111 + DDO:DDO_0001111 + + + + obo:DDO.owl#DDO_0001111 + 46935006 + + + + obo:DDO.owl#DDO_0001111 + Stokes-Adams syndrome + + + + obo:DDO.owl#DDO_0001112 + DDO:DDO_0001112 + + + + obo:DDO.owl#DDO_0001112 + 33413000 + + + + obo:DDO.owl#DDO_0001112 + ectopic beats + + + + obo:DDO.owl#DDO_0001113 + DDO:DDO_0001113 + + + + obo:DDO.owl#DDO_0001113 + 26950008 + + + + obo:DDO.owl#DDO_0001113 + chronic ectopic atrial tachycardia + + + + obo:DDO.owl#DDO_0001114 + DDO:DDO_0001114 + + + + obo:DDO.owl#DDO_0001114 + 406461004 + + + + obo:DDO.owl#DDO_0001114 + ectopic atrial beats + + + + obo:DDO.owl#DDO_0001115 + DDO:DDO_0001115 + + + + obo:DDO.owl#DDO_0001115 + 233895000 + + + + obo:DDO.owl#DDO_0001115 + ectopic atrioventricular node tachycardia + + + + obo:DDO.owl#DDO_0001116 + DDO:DDO_0001116 + + + + obo:DDO.owl#DDO_0001116 + 63232000 + + + + obo:DDO.owl#DDO_0001116 + multifocal premature beats + + + + obo:DDO.owl#DDO_0001117 + DDO:DDO_0001117 + + + + obo:DDO.owl#DDO_0001117 + 10164001 + + + + obo:DDO.owl#DDO_0001117 + parasystole + + + + obo:DDO.owl#DDO_0001118 + DDO:DDO_0001118 + + + + obo:DDO.owl#DDO_0001118 + 251188008 + + + + obo:DDO.owl#DDO_0001118 + atrial parasystole + + + + obo:DDO.owl#DDO_0001119 + DDO:DDO_0001119 + + + + obo:DDO.owl#DDO_0001119 + 59272004 + + + + obo:DDO.owl#DDO_0001119 + ventricular parasystole + + + + obo:DDO.owl#DDO_0001120 + DDO:DDO_0001120 + + + + obo:DDO.owl#DDO_0001120 + 63593006 + + + + obo:DDO.owl#DDO_0001120 + supraventricular premature beats + + + + obo:DDO.owl#DDO_0001121 + DDO:DDO_0001121 + + + + obo:DDO.owl#DDO_0001121 + 81681009 + + + + obo:DDO.owl#DDO_0001121 + junctional premature beats + + + + obo:DDO.owl#DDO_0001122 + DDO:DDO_0001122 + + + + obo:DDO.owl#DDO_0001122 + 17338001 + + + + obo:DDO.owl#DDO_0001122 + ventricular premature beats + + + + obo:DDO.owl#DDO_0001123 + DDO:DDO_0001123 + + + + obo:DDO.owl#DDO_0001123 + 251181002 + + + + obo:DDO.owl#DDO_0001123 + ventricular quadrigeminy + + + + obo:DDO.owl#DDO_0001124 + DDO:DDO_0001124 + + + + obo:DDO.owl#DDO_0001124 + 251180001 + + + + obo:DDO.owl#DDO_0001124 + ventricular trigeminy + + + + obo:DDO.owl#DDO_0001125 + DDO:DDO_0001125 + + + + obo:DDO.owl#DDO_0001125 + 29320008 + + + + obo:DDO.owl#DDO_0001125 + ectopic rhythm + + + + obo:DDO.owl#DDO_0001126 + DDO:DDO_0001126 + + + + obo:DDO.owl#DDO_0001126 + 11849007 + + + + obo:DDO.owl#DDO_0001126 + AV junctional rhythm + + + + obo:DDO.owl#DDO_0001127 + DDO:DDO_0001127 + + + + obo:DDO.owl#DDO_0001127 + 251163000 + + + + obo:DDO.owl#DDO_0001127 + AV junctional (nodal) arrest + + + + obo:DDO.owl#DDO_0001129 + DDO:DDO_0001129 + + + + obo:DDO.owl#DDO_0001129 + 251165007 + + + + obo:DDO.owl#DDO_0001129 + AV junctional (nodal) tachycardia + + + + obo:DDO.owl#DDO_0001130 + DDO:DDO_0001130 + + + + obo:DDO.owl#DDO_0001130 + 251166008 + + + + obo:DDO.owl#DDO_0001130 + AV nodal re-entry tachycardia + + + + obo:DDO.owl#DDO_0001131 + DDO:DDO_0001131 + + + + obo:DDO.owl#DDO_0001131 + 39260000 + + + + obo:DDO.owl#DDO_0001131 + nonparoxysmal AV nodal tachycardia + + + + obo:DDO.owl#DDO_0001132 + DDO:DDO_0001132 + + + + obo:DDO.owl#DDO_0001132 + 195071001 + + + + obo:DDO.owl#DDO_0001132 + paroxysmal junctional tachycardia + + + + obo:DDO.owl#DDO_0001133 + DDO:DDO_0001133 + + + + obo:DDO.owl#DDO_0001133 + 195072008 + + + + obo:DDO.owl#DDO_0001133 + paroxysmal nodal tachycardia + + + + obo:DDO.owl#DDO_0001134 + DDO:DDO_0001134 + + + + obo:DDO.owl#DDO_0001134 + 88412007 + + + + obo:DDO.owl#DDO_0001134 + AV node arrhythmia + + + + obo:DDO.owl#DDO_0001135 + DDO:DDO_0001135 + + + + obo:DDO.owl#DDO_0001135 + 39260000 + + + + obo:DDO.owl#DDO_0001135 + nonparoxysmal AV nodal tachycardia + + + + obo:DDO.owl#DDO_0001136 + DDO:DDO_0001136 + + + + obo:DDO.owl#DDO_0001136 + 251162005 + + + + obo:DDO.owl#DDO_0001136 + AV-junctional (nodal) bradycardia + + + + obo:DDO.owl#DDO_0001137 + DDO:DDO_0001137 + + + + obo:DDO.owl#DDO_0001137 + 69730002 + + + + obo:DDO.owl#DDO_0001137 + idiojunctional tachycardia + + + + obo:DDO.owl#DDO_0001138 + DDO:DDO_0001138 + + + + obo:DDO.owl#DDO_0001138 + 47830009 + + + + obo:DDO.owl#DDO_0001138 + junctional escape beats + + + + obo:DDO.owl#DDO_0001139 + DDO:DDO_0001139 + + + + obo:DDO.owl#DDO_0001139 + 81681009 + + + + obo:DDO.owl#DDO_0001139 + junctional premature beats + + + + obo:DDO.owl#DDO_0001140 + DDO:DDO_0001140 + + + + obo:DDO.owl#DDO_0001140 + 233904005 + + + + obo:DDO.owl#DDO_0001140 + permanent junctional reciprocating tachycardia + + + + obo:DDO.owl#DDO_0001141 + DDO:DDO_0001141 + + + + obo:DDO.owl#DDO_0001141 + 276512006 + + + + obo:DDO.owl#DDO_0001141 + fetal dysrhythmia + + + + obo:DDO.owl#DDO_0001142 + DDO:DDO_0001142 + + + + obo:DDO.owl#DDO_0001142 + 240299002 + + + + obo:DDO.owl#DDO_0001142 + fetal bradycardia + + + + obo:DDO.owl#DDO_0001143 + DDO:DDO_0001143 + + + + obo:DDO.owl#DDO_0001143 + 240298005 + + + + obo:DDO.owl#DDO_0001143 + fetal tachycardia + + + + obo:DDO.owl#DDO_0001144 + DDO:DDO_0001144 + + + + obo:DDO.owl#DDO_0001144 + 462170003 + + + + obo:DDO.owl#DDO_0001144 + fetal supraventricular tachycardia with long ventriculoatrial interval + + + + obo:DDO.owl#DDO_0001145 + DDO:DDO_0001145 + + + + obo:DDO.owl#DDO_0001145 + 462169004 + + + + obo:DDO.owl#DDO_0001145 + fetal supraventricular tachycardia with short ventriculoatrial interval + + + + obo:DDO.owl#DDO_0001146 + DDO:DDO_0001146 + + + + obo:DDO.owl#DDO_0001146 + 276513001 + + + + obo:DDO.owl#DDO_0001146 + neonatal dysrhythmia + + + + obo:DDO.owl#DDO_0001147 + DDO:DDO_0001147 + + + + obo:DDO.owl#DDO_0001147 + 413341007 + + + + obo:DDO.owl#DDO_0001147 + neonatal bradycardia + + + + obo:DDO.owl#DDO_0001148 + DDO:DDO_0001148 + + + + obo:DDO.owl#DDO_0001148 + 180906006 + + + + obo:DDO.owl#DDO_0001148 + neonatal cardiac arrest + + + + obo:DDO.owl#DDO_0001149 + DDO:DDO_0001149 + + + + obo:DDO.owl#DDO_0001149 + 181869007 + + + + obo:DDO.owl#DDO_0001149 + neonatal cardiorespiratory arrest + + + + obo:DDO.owl#DDO_0001150 + DDO:DDO_0001150 + + + + obo:DDO.owl#DDO_0001150 + 413342000 + + + + obo:DDO.owl#DDO_0001150 + neonatal tachycardia + + + + obo:DDO.owl#DDO_0001151 + DDO:DDO_0001151 + + + + obo:DDO.owl#DDO_0001151 + 71792006 + + + + obo:DDO.owl#DDO_0001151 + nodal rhythm disorder + + + + obo:DDO.owl#DDO_0001152 + DDO:DDO_0001152 + + + + obo:DDO.owl#DDO_0001152 + 251152003 + + + + obo:DDO.owl#DDO_0001152 + marked sinus arrhythmia + + + + obo:DDO.owl#DDO_0001153 + DDO:DDO_0001153 + + + + obo:DDO.owl#DDO_0001153 + 129575004 + + + + obo:DDO.owl#DDO_0001153 + pacemaker twiddler's syndrome + + + + obo:DDO.owl#DDO_0001154 + DDO:DDO_0001154 + + + + obo:DDO.owl#DDO_0001154 + 233914001 + + + + obo:DDO.owl#DDO_0001154 + postoperative sinoatrial disease + + + + obo:DDO.owl#DDO_0001155 + DDO:DDO_0001155 + + + + obo:DDO.owl#DDO_0001155 + 29717002 + + + + obo:DDO.owl#DDO_0001155 + premature beats + + + + obo:DDO.owl#DDO_0001156 + DDO:DDO_0001156 + + + + obo:DDO.owl#DDO_0001156 + 251164006 + + + + obo:DDO.owl#DDO_0001156 + junctional premature complex + + + + obo:DDO.owl#DDO_0001157 + DDO:DDO_0001157 + + + + obo:DDO.owl#DDO_0001157 + 63232000 + + + + obo:DDO.owl#DDO_0001157 + multifocal premature beats + + + + obo:DDO.owl#DDO_0001158 + DDO:DDO_0001158 + + + + obo:DDO.owl#DDO_0001158 + 63593006 + + + + obo:DDO.owl#DDO_0001158 + supraventricular premature beats + + + + obo:DDO.owl#DDO_0001159 + DDO:DDO_0001159 + + + + obo:DDO.owl#DDO_0001159 + 72654001 + + + + obo:DDO.owl#DDO_0001159 + supraventricular arrhythmia + + + + obo:DDO.owl#DDO_0001160 + DDO:DDO_0001160 + + + + obo:DDO.owl#DDO_0001160 + 17366009 + + + + obo:DDO.owl#DDO_0001160 + atrial arrhythmia + + + + obo:DDO.owl#DDO_0001161 + DDO:DDO_0001161 + + + + obo:DDO.owl#DDO_0001161 + 49436004 + + + + obo:DDO.owl#DDO_0001161 + atrial fibrillation + + + + obo:DDO.owl#DDO_0001162 + DDO:DDO_0001162 + + + + obo:DDO.owl#DDO_0001162 + 5370000 + + + + obo:DDO.owl#DDO_0001162 + atrial flutter + + + + obo:DDO.owl#DDO_0001163 + DDO:DDO_0001163 + + + + obo:DDO.owl#DDO_0001163 + 276796006 + + + + obo:DDO.owl#DDO_0001163 + atrial tachycardia + + + + obo:DDO.owl#DDO_0001164 + DDO:DDO_0001164 + + + + obo:DDO.owl#DDO_0001164 + 195069001 + + + + obo:DDO.owl#DDO_0001164 + atrial paroxysmal tachycardia + + + + obo:DDO.owl#DDO_0001165 + DDO:DDO_0001165 + + + + obo:DDO.owl#DDO_0001165 + 233893007 + + + + obo:DDO.owl#DDO_0001165 + re-entrant atrial tachycardia + + + + obo:DDO.owl#DDO_0001166 + DDO:DDO_0001166 + + + + obo:DDO.owl#DDO_0001166 + 419752005 + + + + obo:DDO.owl#DDO_0001166 + sinoatrial nodal reentrant tachycardia + + + + obo:DDO.owl#DDO_0001167 + DDO:DDO_0001167 + + + + obo:DDO.owl#DDO_0001167 + 233892002 + + + + obo:DDO.owl#DDO_0001167 + ectopic atrial tachycardia + + + + obo:DDO.owl#DDO_0001168 + DDO:DDO_0001168 + + + + obo:DDO.owl#DDO_0001168 + 233894001 + + + + obo:DDO.owl#DDO_0001168 + incessant atrial tachycardia + + + + obo:DDO.owl#DDO_0001169 + DDO:DDO_0001169 + + + + obo:DDO.owl#DDO_0001169 + 49982000 + + + + obo:DDO.owl#DDO_0001169 + multifocal atrial tachycardia + + + + obo:DDO.owl#DDO_0001170 + DDO:DDO_0001170 + + + + obo:DDO.owl#DDO_0001170 + 233891009 + + + + obo:DDO.owl#DDO_0001170 + sinoatrial node tachycardia + + + + obo:DDO.owl#DDO_0001171 + DDO:DDO_0001171 + + + + obo:DDO.owl#DDO_0001171 + 60423000 + + + + obo:DDO.owl#DDO_0001171 + sinus node dysfunction + + + + obo:DDO.owl#DDO_0001172 + DDO:DDO_0001172 + + + + obo:DDO.owl#DDO_0001172 + 5609005 + + + + obo:DDO.owl#DDO_0001172 + sinus arrest + + + + obo:DDO.owl#DDO_0001173 + DDO:DDO_0001173 + + + + obo:DDO.owl#DDO_0001173 + 450919004 + + + + obo:DDO.owl#DDO_0001173 + atrial standstill + + + + obo:DDO.owl#DDO_0001174 + DDO:DDO_0001174 + + + + obo:DDO.owl#DDO_0001174 + 6456007 + + + + obo:DDO.owl#DDO_0001174 + supraventricular tachycardia + + + + obo:DDO.owl#DDO_0001175 + DDO:DDO_0001175 + + + + obo:DDO.owl#DDO_0001175 + 425582007 + + + + obo:DDO.owl#DDO_0001175 + inappropriate sinus tachycardia + + + + obo:DDO.owl#DDO_0001176 + DDO:DDO_0001176 + + + + obo:DDO.owl#DDO_0001176 + 67198005 + + + + obo:DDO.owl#DDO_0001176 + paroxysmal supraventricular tachycardia + + + + obo:DDO.owl#DDO_0001177 + DDO:DDO_0001177 + + + + obo:DDO.owl#DDO_0001177 + 195069001 + + + + obo:DDO.owl#DDO_0001177 + atrial paroxysmal tachycardia + + + + obo:DDO.owl#DDO_0001178 + DDO:DDO_0001178 + + + + obo:DDO.owl#DDO_0001178 + 5761000119100 + + + + obo:DDO.owl#DDO_0001178 + nonsustained paroxysmal supraventricular tachycardia + + + + obo:DDO.owl#DDO_0001179 + DDO:DDO_0001179 + + + + obo:DDO.owl#DDO_0001179 + 6285003 + + + + obo:DDO.owl#DDO_0001179 + tachyarrhythmia + + + + obo:DDO.owl#DDO_0001180 + DDO:DDO_0001180 + + + + obo:DDO.owl#DDO_0001180 + 278482008 + + + + obo:DDO.owl#DDO_0001180 + atrioventricular tachycardia + + + + obo:DDO.owl#DDO_0001181 + DDO:DDO_0001181 + + + + obo:DDO.owl#DDO_0001181 + 233895000 + + + + obo:DDO.owl#DDO_0001181 + ectopic atrioventricular node tachycardia + + + + obo:DDO.owl#DDO_0001182 + DDO:DDO_0001182 + + + + obo:DDO.owl#DDO_0001182 + 195070000 + + + + obo:DDO.owl#DDO_0001182 + paroxysmal atrioventricular tachycardia + + + + obo:DDO.owl#DDO_0001183 + DDO:DDO_0001183 + + + + obo:DDO.owl#DDO_0001183 + 233896004 + + + + obo:DDO.owl#DDO_0001183 + re-entrant atrioventricular node tachycardia + + + + obo:DDO.owl#DDO_0001184 + DDO:DDO_0001184 + + + + obo:DDO.owl#DDO_0001184 + 233897008 + + + + obo:DDO.owl#DDO_0001184 + re-entrant atrioventricular tachycardia + + + + obo:DDO.owl#DDO_0001185 + DDO:DDO_0001185 + + + + obo:DDO.owl#DDO_0001185 + 233901002 + + + + obo:DDO.owl#DDO_0001185 + His bundle tachycardia + + + + obo:DDO.owl#DDO_0001186 + DDO:DDO_0001186 + + + + obo:DDO.owl#DDO_0001186 + 419400008 + + + + obo:DDO.owl#DDO_0001186 + incisional tachycardia + + + + obo:DDO.owl#DDO_0001187 + DDO:DDO_0001187 + + + + obo:DDO.owl#DDO_0001187 + 420002000 + + + + obo:DDO.owl#DDO_0001187 + left atrial incisional tachycardia + + + + obo:DDO.owl#DDO_0001188 + DDO:DDO_0001188 + + + + obo:DDO.owl#DDO_0001188 + 418493005 + + + + obo:DDO.owl#DDO_0001188 + right atrial incisional tachycardia + + + + obo:DDO.owl#DDO_0001189 + DDO:DDO_0001189 + + + + obo:DDO.owl#DDO_0001189 + 82838007 + + + + obo:DDO.owl#DDO_0001189 + irregular tachycardia + + + + obo:DDO.owl#DDO_0001190 + DDO:DDO_0001190 + + + + obo:DDO.owl#DDO_0001190 + 419166005 + + + + obo:DDO.owl#DDO_0001190 + junctional ectopic tachycardia + + + + obo:DDO.owl#DDO_0001191 + DDO:DDO_0001191 + + + + obo:DDO.owl#DDO_0001191 + 710878005 + + + + obo:DDO.owl#DDO_0001191 + Mahaim fiber tachycardia + + + + obo:DDO.owl#DDO_0001192 + DDO:DDO_0001192 + + + + obo:DDO.owl#DDO_0001192 + 12026006 + + + + obo:DDO.owl#DDO_0001192 + paroxysmal tachycardia + + + + obo:DDO.owl#DDO_0001193 + DDO:DDO_0001193 + + + + obo:DDO.owl#DDO_0001193 + 67198005 + + + + obo:DDO.owl#DDO_0001193 + paroxysmal supraventricular tachycardia + + + + obo:DDO.owl#DDO_0001194 + DDO:DDO_0001194 + + + + obo:DDO.owl#DDO_0001194 + 66657009 + + + + obo:DDO.owl#DDO_0001194 + paroxysmal ventricular tachycardia + + + + obo:DDO.owl#DDO_0001195 + DDO:DDO_0001195 + + + + obo:DDO.owl#DDO_0001195 + 25569003 + + + + obo:DDO.owl#DDO_0001195 + ventricular tachycardia + + + + obo:DDO.owl#DDO_0001196 + DDO:DDO_0001196 + + + + obo:DDO.owl#DDO_0001196 + 184004 + + + + obo:DDO.owl#DDO_0001196 + withdrawal arrhythmia + + + + obo:DDO.owl#DDO_0001197 + DDO:DDO_0001197 + + + + obo:DDO.owl#DDO_0001197 + 44103008 + + + + obo:DDO.owl#DDO_0001197 + ventricular arrhythmia + + + + obo:DDO.owl#DDO_0001198 + DDO:DDO_0001198 + + + + obo:DDO.owl#DDO_0001198 + 49260003 + + + + obo:DDO.owl#DDO_0001198 + idioventricular rhythm + + + + obo:DDO.owl#DDO_0001199 + DDO:DDO_0001199 + + + + obo:DDO.owl#DDO_0001199 + 61277005 + + + + obo:DDO.owl#DDO_0001199 + accelerated idioventricular rhythm + + + + obo:DDO.owl#DDO_0001200 + DDO:DDO_0001200 + + + + obo:DDO.owl#DDO_0001200 + 13640000 + + + + obo:DDO.owl#DDO_0001200 + fusion beats + + + + obo:DDO.owl#DDO_0001201 + DDO:DDO_0001201 + + + + obo:DDO.owl#DDO_0001201 + 11157007 + + + + obo:DDO.owl#DDO_0001201 + ventricular bigeminy + + + + obo:DDO.owl#DDO_0001202 + DDO:DDO_0001202 + + + + obo:DDO.owl#DDO_0001202 + 75532003 + + + + obo:DDO.owl#DDO_0001202 + ventricular escape beat + + + + obo:DDO.owl#DDO_0001203 + DDO:DDO_0001203 + + + + obo:DDO.owl#DDO_0001203 + 81898007 + + + + obo:DDO.owl#DDO_0001203 + ventricular escape rhythm + + + + obo:DDO.owl#DDO_0001204 + DDO:DDO_0001204 + + + + obo:DDO.owl#DDO_0001204 + 59272004 + + + + obo:DDO.owl#DDO_0001204 + ventricular parasystole + + + + obo:DDO.owl#DDO_0001205 + DDO:DDO_0001205 + + + + obo:DDO.owl#DDO_0001205 + 71908006 + + + + obo:DDO.owl#DDO_0001205 + ventricular fibrillation + + + + obo:DDO.owl#DDO_0001206 + DDO:DDO_0001206 + + + + obo:DDO.owl#DDO_0001206 + 90560007 + + + + obo:DDO.owl#DDO_0001206 + gout + + + + obo:DDO.owl#DDO_0001207 + DDO:DDO_0001207 + + + + obo:DDO.owl#DDO_0001207 + 48440001 + + + + obo:DDO.owl#DDO_0001207 + articular gout + + + + obo:DDO.owl#DDO_0001208 + DDO:DDO_0001208 + + + + obo:DDO.owl#DDO_0001208 + 68451005 + + + + obo:DDO.owl#DDO_0001208 + chronic gouty arthritis + + + + obo:DDO.owl#DDO_0001209 + DDO:DDO_0001209 + + + + obo:DDO.owl#DDO_0001209 + 73877009 + + + + obo:DDO.owl#DDO_0001209 + chronic tophaceous gout + + + + obo:DDO.owl#DDO_0001210 + DDO:DDO_0001210 + + + + obo:DDO.owl#DDO_0001210 + 239848007 + + + + obo:DDO.owl#DDO_0001210 + gouty bursitis + + + + obo:DDO.owl#DDO_0001211 + DDO:DDO_0001211 + + + + obo:DDO.owl#DDO_0001211 + 284680007 + + + + obo:DDO.owl#DDO_0001211 + interval gout + + + + obo:DDO.owl#DDO_0001212 + DDO:DDO_0001212 + + + + obo:DDO.owl#DDO_0001212 + 283839008 + + + + obo:DDO.owl#DDO_0001212 + intercritical gout + + + + obo:DDO.owl#DDO_0001213 + DDO:DDO_0001213 + + + + obo:DDO.owl#DDO_0001213 + 710733002 + + + + obo:DDO.owl#DDO_0001213 + chronic gout without tophus + + + + obo:DDO.owl#DDO_0001214 + DDO:DDO_0001214 + + + + obo:DDO.owl#DDO_0001214 + 46785007 + + + + obo:DDO.owl#DDO_0001214 + familial juvenile gout + + + + obo:DDO.owl#DDO_0001215 + DDO:DDO_0001215 + + + + obo:DDO.owl#DDO_0001215 + 43193009 + + + + obo:DDO.owl#DDO_0001215 + gouty iritis + + + + obo:DDO.owl#DDO_0001216 + DDO:DDO_0001216 + + + + obo:DDO.owl#DDO_0001216 + 9386003 + + + + obo:DDO.owl#DDO_0001216 + gouty neuritis + + + + obo:DDO.owl#DDO_0001217 + DDO:DDO_0001217 + + + + obo:DDO.owl#DDO_0001217 + 402469004 + + + + obo:DDO.owl#DDO_0001217 + gouty tophus + + + + obo:DDO.owl#DDO_0001218 + DDO:DDO_0001218 + + + + obo:DDO.owl#DDO_0001218 + primary gout + + + + obo:DDO.owl#DDO_0001218 + primary gout + + + + obo:DDO.owl#DDO_0001219 + DDO:DDO_0001219 + + + + obo:DDO.owl#DDO_0001219 + 310101000119107 + + + + obo:DDO.owl#DDO_0001219 + primary chronic gout without tophus + + + + obo:DDO.owl#DDO_0001220 + DDO:DDO_0001220 + + + + obo:DDO.owl#DDO_0001220 + 239843003 + + + + obo:DDO.owl#DDO_0001220 + secondary gout + + + + obo:DDO.owl#DDO_0001221 + DDO:DDO_0001221 + + + + obo:DDO.owl#DDO_0001221 + 28428009 + + + + obo:DDO.owl#DDO_0001221 + visceral gout + + + + obo:DDO.owl#DDO_0001222 + DDO:DDO_0001222 + + + + obo:DDO.owl#DDO_0001222 + focal and multifocal neuropathy + + + + obo:DDO.owl#DDO_0001223 + DDO:DDO_0001223 + + + + obo:DDO.owl#DDO_0001223 + symmetrical neuropathy + + + + obo:DDO.owl#DDO_0001224 + DDO:DDO_0001224 + + + + obo:DDO.owl#DDO_0001224 + 128189008 + + + + obo:DDO.owl#DDO_0001224 + mononeuropathy + + + + obo:DDO.owl#DDO_0001225 + DDO:DDO_0001225 + + + + obo:DDO.owl#DDO_0001225 + 88092000 + + + + obo:DDO.owl#DDO_0001225 + Proximal motor neuropathy + + + + obo:DDO.owl#DDO_0001225 + amyotrophy + + + + obo:DDO.owl#DDO_0001226 + DDO:DDO_0001226 + + + + obo:DDO.owl#DDO_0001226 + 72274001 + + + + obo:DDO.owl#DDO_0001226 + radiculopathy + + + + obo:DDO.owl#DDO_0001227 + DDO:DDO_0001227 + + + + obo:DDO.owl#DDO_0001227 + 45781009 + + + + obo:DDO.owl#DDO_0001227 + entrapment neuropathy + + + + obo:DDO.owl#DDO_0001228 + DDO:DDO_0001228 + + + + obo:DDO.owl#DDO_0001228 + 30292005 + + + + obo:DDO.owl#DDO_0001228 + mononeuritis multiplex + + + + obo:DDO.owl#DDO_0001229 + DDO:DDO_0001229 + + + + obo:DDO.owl#DDO_0001229 + 95662005 + + + + obo:DDO.owl#DDO_0001229 + sensory neuropathy + + + + obo:DDO.owl#DDO_0001230 + DDO:DDO_0001230 + + + + obo:DDO.owl#DDO_0001230 + 302226006 + + + + obo:DDO.owl#DDO_0001230 + peripheral nerve disease + + + + obo:DDO.owl#DDO_0001230 + peripheral neuropathy + + + + obo:DDO.owl#DDO_0001231 + DDO:DDO_0001231 + + + + obo:DDO.owl#DDO_0001231 + 53619000 + + + + obo:DDO.owl#DDO_0001231 + disorder of digestive system + + + + obo:DDO.owl#DDO_0001232 + DDO:DDO_0001232 + + + + obo:DDO.owl#DDO_0001232 + 73013002 + + + + obo:DDO.owl#DDO_0001232 + cranial nerve palsy + + + + obo:DDO.owl#DDO_0001233 + DDO:DDO_0001233 + + + + obo:DDO.owl#DDO_0001233 + 230572002 + + + + obo:DDO.owl#DDO_0001233 + diabetic neuropathy + + + + obo:DDO.owl#DDO_0001234 + DDO:DDO_0001234 + + + + obo:DDO.owl#DDO_0001234 + 193183000 + + + + obo:DDO.owl#DDO_0001234 + acute painful diabetic neuropathy + + + + obo:DDO.owl#DDO_0001235 + DDO:DDO_0001235 + + + + obo:DDO.owl#DDO_0001235 + 230574001 + + + + obo:DDO.owl#DDO_0001235 + diabetic acute painful polyneuropathy + + + + obo:DDO.owl#DDO_0001236 + DDO:DDO_0001236 + + + + obo:DDO.owl#DDO_0001236 + 193185007 + + + + obo:DDO.owl#DDO_0001236 + asymptomatic diabetic neuropathy + + + + obo:DDO.owl#DDO_0001237 + DDO:DDO_0001237 + + + + obo:DDO.owl#DDO_0001237 + 193184006 + + + + obo:DDO.owl#DDO_0001237 + chronic painful diabetic neuropathy + + + + obo:DDO.owl#DDO_0001238 + DDO:DDO_0001238 + + + + obo:DDO.owl#DDO_0001238 + 39058009 + + + + obo:DDO.owl#DDO_0001238 + diabetic amyotrophy + + + + obo:DDO.owl#DDO_0001239 + DDO:DDO_0001239 + + + + obo:DDO.owl#DDO_0001239 + 35777006 + + + + obo:DDO.owl#DDO_0001239 + diabetic mononeuropathy multiplex + + + + obo:DDO.owl#DDO_0001240 + DDO:DDO_0001240 + + + + obo:DDO.owl#DDO_0001240 + 427943001 + + + + obo:DDO.owl#DDO_0001240 + diabetic ophthalmoplegia + + + + obo:DDO.owl#DDO_0001241 + DDO:DDO_0001241 + + + + obo:DDO.owl#DDO_0001241 + 424736006 + + + + obo:DDO.owl#DDO_0001241 + diabetic peripheral neuropathy + + + + obo:DDO.owl#DDO_0001242 + DDO:DDO_0001242 + + + + obo:DDO.owl#DDO_0001242 + 79554005 + + + + obo:DDO.owl#DDO_0001242 + asymmetric diabetic proximal motor neuropathy + + + + obo:DDO.owl#DDO_0001243 + DDO:DDO_0001243 + + + + obo:DDO.owl#DDO_0001243 + 50620007 + + + + obo:DDO.owl#DDO_0001243 + diabetic autonomic neuropathy + + + + obo:DDO.owl#DDO_0001244 + DDO:DDO_0001244 + + + + obo:DDO.owl#DDO_0001244 + 193141005 + + + + obo:DDO.owl#DDO_0001244 + diabetic mononeuritis multiplex + + + + obo:DDO.owl#DDO_0001245 + DDO:DDO_0001245 + + + + obo:DDO.owl#DDO_0001245 + 230577008 + + + + obo:DDO.owl#DDO_0001245 + diabetic mononeuropathy + + + + obo:DDO.owl#DDO_0001246 + DDO:DDO_0001246 + + + + obo:DDO.owl#DDO_0001246 + 361216007 + + + + obo:DDO.owl#DDO_0001246 + diabetic femoral mononeuropathy + + + + obo:DDO.owl#DDO_0001247 + DDO:DDO_0001247 + + + + obo:DDO.owl#DDO_0001247 + 81830002 + + + + obo:DDO.owl#DDO_0001247 + diabetic mononeuropathy simplex + + + + obo:DDO.owl#DDO_0001248 + DDO:DDO_0001248 + + + + obo:DDO.owl#DDO_0001248 + 19378003 + + + + obo:DDO.owl#DDO_0001248 + diabetic pseudotabes + + + + obo:DDO.owl#DDO_0001249 + DDO:DDO_0001249 + + + + obo:DDO.owl#DDO_0001249 + 39181008 + + + + obo:DDO.owl#DDO_0001249 + diabetic radiculopathy + + + + obo:DDO.owl#DDO_0001250 + DDO:DDO_0001250 + + + + obo:DDO.owl#DDO_0001250 + 230579006 + + + + obo:DDO.owl#DDO_0001250 + diabetic thoracic radiculopathy + + + + obo:DDO.owl#DDO_0001251 + DDO:DDO_0001251 + + + + obo:DDO.owl#DDO_0001251 + 230578003 + + + + obo:DDO.owl#DDO_0001251 + diabetic truncal radiculopathy + + + + obo:DDO.owl#DDO_0001252 + DDO:DDO_0001252 + + + + obo:DDO.owl#DDO_0001252 + 39127005 + + + + obo:DDO.owl#DDO_0001252 + symmetric diabetic proximal motor neuropathy + + + + obo:DDO.owl#DDO_0001253 + DDO:DDO_0001253 + + + + obo:DDO.owl#DDO_0001253 + 49455004 + + + + obo:DDO.owl#DDO_0001253 + diabetic polyneuropathy + + + + obo:DDO.owl#DDO_0001254 + DDO:DDO_0001254 + + + + obo:DDO.owl#DDO_0001254 + 230574001 + + + + obo:DDO.owl#DDO_0001254 + diabetic acute painful polyneuropathy + + + + obo:DDO.owl#DDO_0001255 + DDO:DDO_0001255 + + + + obo:DDO.owl#DDO_0001255 + 230576004 + + + + obo:DDO.owl#DDO_0001255 + diabetic asymmetric polyneuropathy + + + + obo:DDO.owl#DDO_0001256 + DDO:DDO_0001256 + + + + obo:DDO.owl#DDO_0001256 + 230573007 + + + + obo:DDO.owl#DDO_0001256 + diabetic distal sensorimotor polyneuropathy + + + + obo:DDO.owl#DDO_0001257 + DDO:DDO_0001257 + + + + obo:DDO.owl#DDO_0001257 + 126535008 + + + + obo:DDO.owl#DDO_0001257 + diabetic motor polyneuropathy + + + + obo:DDO.owl#DDO_0001258 + DDO:DDO_0001258 + + + + obo:DDO.owl#DDO_0001258 + 126534007 + + + + obo:DDO.owl#DDO_0001258 + diabetic mixed sensory-motor polyneuropathy + + + + obo:DDO.owl#DDO_0001259 + DDO:DDO_0001259 + + + + obo:DDO.owl#DDO_0001259 + 127011001 + + + + obo:DDO.owl#DDO_0001259 + diabetic sensory polyneuropathy + + + + obo:DDO.owl#DDO_0001260 + DDO:DDO_0001260 + + + + obo:DDO.owl#DDO_0001260 + 126534007 + + + + obo:DDO.owl#DDO_0001260 + diabetic mixed sensory-motor polyneuropathy + + + + obo:DDO.owl#DDO_0001261 + DDO:DDO_0001261 + + + + obo:DDO.owl#DDO_0001261 + 78409004 + + + + obo:DDO.owl#DDO_0001261 + abdominal polyradiculopathy + + + + obo:DDO.owl#DDO_0001262 + DDO:DDO_0001262 + + + + obo:DDO.owl#DDO_0001262 + 277879009 + + + + obo:DDO.owl#DDO_0001262 + autonomic neuropathy + + + + obo:DDO.owl#DDO_0001263 + DDO:DDO_0001263 + + + + obo:DDO.owl#DDO_0001263 + 282746001 + + + + obo:DDO.owl#DDO_0001263 + autonomic nerve injury + + + + obo:DDO.owl#DDO_0001264 + DDO:DDO_0001264 + + + + obo:DDO.owl#DDO_0001264 + 282748000 + + + + obo:DDO.owl#DDO_0001264 + parasympathetic nerve injury + + + + obo:DDO.owl#DDO_0001265 + DDO:DDO_0001265 + + + + obo:DDO.owl#DDO_0001265 + 282796000 + + + + obo:DDO.owl#DDO_0001265 + parasympathetic ganglion injury + + + + obo:DDO.owl#DDO_0001266 + DDO:DDO_0001266 + + + + obo:DDO.owl#DDO_0001266 + 282797009 + + + + obo:DDO.owl#DDO_0001266 + sacral parasympathetic nerve injury + + + + obo:DDO.owl#DDO_0001267 + DDO:DDO_0001267 + + + + obo:DDO.owl#DDO_0001267 + 282747005 + + + + obo:DDO.owl#DDO_0001267 + sympathetic nervous structure injury + + + + obo:DDO.owl#DDO_0001268 + DDO:DDO_0001268 + + + + obo:DDO.owl#DDO_0001268 + 282792003 + + + + obo:DDO.owl#DDO_0001268 + sympathetic nerve injury + + + + obo:DDO.owl#DDO_0001269 + DDO:DDO_0001269 + + + + obo:DDO.owl#DDO_0001269 + 212239002 + + + + obo:DDO.owl#DDO_0001269 + cervical sympathetic nerve injury + + + + obo:DDO.owl#DDO_0001270 + DDO:DDO_0001270 + + + + obo:DDO.owl#DDO_0001270 + 52723009 + + + + obo:DDO.owl#DDO_0001270 + injury of stellate ganglion + + + + obo:DDO.owl#DDO_0001271 + DDO:DDO_0001271 + + + + obo:DDO.owl#DDO_0001271 + 230618004 + + + + obo:DDO.owl#DDO_0001271 + injury of abdominal sympathetic plexus + + + + obo:DDO.owl#DDO_0001272 + DDO:DDO_0001272 + + + + obo:DDO.owl#DDO_0001272 + 212243003 + + + + obo:DDO.owl#DDO_0001272 + injury of celiac plexus + + + + obo:DDO.owl#DDO_0001273 + DDO:DDO_0001273 + + + + obo:DDO.owl#DDO_0001273 + 79366000 + + + + obo:DDO.owl#DDO_0001273 + injury of inferior mesenteric plexus + + + + obo:DDO.owl#DDO_0001274 + DDO:DDO_0001274 + + + + obo:DDO.owl#DDO_0001274 + 51881002 + + + + obo:DDO.owl#DDO_0001274 + injury of splanchnic nerve + + + + obo:DDO.owl#DDO_0001275 + DDO:DDO_0001275 + + + + obo:DDO.owl#DDO_0001275 + 282793008 + + + + obo:DDO.owl#DDO_0001275 + sympathetic ganglion injury + + + + obo:DDO.owl#DDO_0001276 + DDO:DDO_0001276 + + + + obo:DDO.owl#DDO_0001276 + 212242008 + + + + obo:DDO.owl#DDO_0001276 + injury of celiac ganglion + + + + obo:DDO.owl#DDO_0001277 + DDO:DDO_0001277 + + + + obo:DDO.owl#DDO_0001277 + 52723009 + + + + obo:DDO.owl#DDO_0001277 + injury of stellate ganglion + + + + obo:DDO.owl#DDO_0001278 + DDO:DDO_0001278 + + + + obo:DDO.owl#DDO_0001278 + sympathetic trunk injury + + + + obo:DDO.owl#DDO_0001279 + DDO:DDO_0001279 + + + + obo:DDO.owl#DDO_0001279 + 212244009 + + + + obo:DDO.owl#DDO_0001279 + injury of thoracic sympathetic nerves + + + + obo:DDO.owl#DDO_0001280 + DDO:DDO_0001280 + + + + obo:DDO.owl#DDO_0001280 + 282794002 + + + + obo:DDO.owl#DDO_0001280 + sympathetic plexus injury + + + + obo:DDO.owl#DDO_0001281 + DDO:DDO_0001281 + + + + obo:DDO.owl#DDO_0001281 + 230618004 + + + + obo:DDO.owl#DDO_0001281 + injury of abdominal sympathetic plexus + + + + obo:DDO.owl#DDO_0001282 + DDO:DDO_0001282 + + + + obo:DDO.owl#DDO_0001282 + 212243003 + + + + obo:DDO.owl#DDO_0001282 + injury of celiac plexus + + + + obo:DDO.owl#DDO_0001283 + DDO:DDO_0001283 + + + + obo:DDO.owl#DDO_0001283 + 79366000 + + + + obo:DDO.owl#DDO_0001283 + injury of inferior mesenteric plexus + + + + obo:DDO.owl#DDO_0001284 + DDO:DDO_0001284 + + + + obo:DDO.owl#DDO_0001284 + injury of celiac ganglion AND/OR plexus + + + + obo:DDO.owl#DDO_0001285 + DDO:DDO_0001285 + + + + obo:DDO.owl#DDO_0001285 + 282793008 + + + + obo:DDO.owl#DDO_0001285 + sympathetic ganglion injury + + + + obo:DDO.owl#DDO_0001286 + DDO:DDO_0001286 + + + + obo:DDO.owl#DDO_0001286 + 409661008 + + + + obo:DDO.owl#DDO_0001286 + benign neoplasm of autonomic nerve + + + + obo:DDO.owl#DDO_0001287 + DDO:DDO_0001287 + + + + obo:DDO.owl#DDO_0001287 + 12454008 + + + + obo:DDO.owl#DDO_0001287 + cauda equina syndrome with neurogenic bladder + + + + obo:DDO.owl#DDO_0001288 + DDO:DDO_0001288 + + + + obo:DDO.owl#DDO_0001288 + 230667002 + + + + obo:DDO.owl#DDO_0001288 + chronic idiopathic anhidrosis + + + + obo:DDO.owl#DDO_0001289 + DDO:DDO_0001289 + + + + obo:DDO.owl#DDO_0001289 + 50620007 + + + + obo:DDO.owl#DDO_0001289 + diabetic autonomic neuropathy + + + + obo:DDO.owl#DDO_0001290 + DDO:DDO_0001290 + + + + obo:DDO.owl#DDO_0001290 + 128123007 + + + + obo:DDO.owl#DDO_0001290 + disorder of peripheral autonomic nervous system + + + + obo:DDO.owl#DDO_0001291 + DDO:DDO_0001291 + + + + obo:DDO.owl#DDO_0001291 + 64370005 + + + + obo:DDO.owl#DDO_0001291 + aganglionosis of parasympathetic nerve ganglia + + + + obo:DDO.owl#DDO_0001292 + DDO:DDO_0001292 + + + + obo:DDO.owl#DDO_0001292 + 88219000 + + + + obo:DDO.owl#DDO_0001292 + celiac plexus syndrome + + + + obo:DDO.owl#DDO_0001293 + DDO:DDO_0001293 + + + + obo:DDO.owl#DDO_0001293 + 50642008 + + + + obo:DDO.owl#DDO_0001293 + complex regional pain syndrome, type I + + + + obo:DDO.owl#DDO_0001294 + DDO:DDO_0001294 + + + + obo:DDO.owl#DDO_0001294 + 83921000119106 + + + + obo:DDO.owl#DDO_0001294 + complex regional pain syndrome, Type I, of head and/or trunk + + + + obo:DDO.owl#DDO_0001295 + DDO:DDO_0001295 + + + + obo:DDO.owl#DDO_0001295 + 15743005 + + + + obo:DDO.owl#DDO_0001295 + posttraumatic osteoporosis + + + + obo:DDO.owl#DDO_0001296 + DDO:DDO_0001296 + + + + obo:DDO.owl#DDO_0001296 + 408662006 + + + + obo:DDO.owl#DDO_0001296 + reflex sympathetic dystrophy of lower extremity + + + + obo:DDO.owl#DDO_0001298 + DDO:DDO_0001298 + + + + obo:DDO.owl#DDO_0001298 + 203495005 + + + + obo:DDO.owl#DDO_0001298 + algodystrophy of foot + + + + obo:DDO.owl#DDO_0001299 + DDO:DDO_0001299 + + + + obo:DDO.owl#DDO_0001299 + 203494009 + + + + obo:DDO.owl#DDO_0001299 + algodystrophy of knee + + + + obo:DDO.owl#DDO_0001300 + DDO:DDO_0001300 + + + + obo:DDO.owl#DDO_0001300 + 2103002 + + + + obo:DDO.owl#DDO_0001300 + shoulder-hand syndrome + + + + obo:DDO.owl#DDO_0001301 + DDO:DDO_0001301 + + + + obo:DDO.owl#DDO_0001301 + 203493003 + + + + obo:DDO.owl#DDO_0001301 + algodystrophy of hand + + + + obo:DDO.owl#DDO_0001302 + DDO:DDO_0001302 + + + + obo:DDO.owl#DDO_0001302 + 20725005 + + + + obo:DDO.owl#DDO_0001302 + familial visceral neuropathy + + + + obo:DDO.owl#DDO_0001303 + DDO:DDO_0001303 + + + + obo:DDO.owl#DDO_0001303 + 86489003 + + + + obo:DDO.owl#DDO_0001303 + idiopathic peripheral autonomic neuropathy + + + + obo:DDO.owl#DDO_0001304 + DDO:DDO_0001304 + + + + obo:DDO.owl#DDO_0001304 + 192915005 + + + + obo:DDO.owl#DDO_0001304 + cervical sympathetic paralysis + + + + obo:DDO.owl#DDO_0001305 + DDO:DDO_0001305 + + + + obo:DDO.owl#DDO_0001305 + 45299002 + + + + obo:DDO.owl#DDO_0001305 + intestinal autonomic neuropathy + + + + obo:DDO.owl#DDO_0001306 + DDO:DDO_0001306 + + + + obo:DDO.owl#DDO_0001306 + 204739008 + + + + obo:DDO.owl#DDO_0001306 + Hirschsprung's disease + + + + obo:DDO.owl#DDO_0001307 + DDO:DDO_0001307 + + + + obo:DDO.owl#DDO_0001307 + 360434004 + + + + obo:DDO.owl#DDO_0001307 + aganglionosis of Auerbach's plexus + + + + obo:DDO.owl#DDO_0001308 + DDO:DDO_0001308 + + + + obo:DDO.owl#DDO_0001308 + 204740005 + + + + obo:DDO.owl#DDO_0001308 + long segment Hirschsprung's disease + + + + obo:DDO.owl#DDO_0001309 + DDO:DDO_0001309 + + + + obo:DDO.owl#DDO_0001309 + 703535000 + + + + obo:DDO.owl#DDO_0001309 + Mowat-Wilson syndrome + + + + obo:DDO.owl#DDO_0001310 + DDO:DDO_0001310 + + + + obo:DDO.owl#DDO_0001310 + 204741009 + + + + obo:DDO.owl#DDO_0001310 + short segment Hirschsprung's disease + + + + obo:DDO.owl#DDO_0001311 + DDO:DDO_0001311 + + + + obo:DDO.owl#DDO_0001311 + 204745000 + + + + obo:DDO.owl#DDO_0001311 + total intestinal aganglionosis + + + + obo:DDO.owl#DDO_0001312 + DDO:DDO_0001312 + + + + obo:DDO.owl#DDO_0001312 + 367495003 + + + + obo:DDO.owl#DDO_0001312 + macrocolon + + + + obo:DDO.owl#DDO_0001313 + DDO:DDO_0001313 + + + + obo:DDO.owl#DDO_0001313 + 126979000 + + + + obo:DDO.owl#DDO_0001313 + neoplasm of autonomic nerve + + + + obo:DDO.owl#DDO_0001314 + DDO:DDO_0001314 + + + + obo:DDO.owl#DDO_0001314 + 230668007 + + + + obo:DDO.owl#DDO_0001314 + idiopathic diffuse hyperhidrosis + + + + obo:DDO.owl#DDO_0001315 + DDO:DDO_0001315 + + + + obo:DDO.owl#DDO_0001315 + 230666006 + + + + obo:DDO.owl#DDO_0001315 + paraneoplastic autonomic dysfunction + + + + obo:DDO.owl#DDO_0001316 + DDO:DDO_0001316 + + + + obo:DDO.owl#DDO_0001316 + 699190008 + + + + obo:DDO.owl#DDO_0001316 + paroxysmal extreme pain disorder + + + + obo:DDO.owl#DDO_0001317 + DDO:DDO_0001317 + + + + obo:DDO.owl#DDO_0001317 + 84438001 + + + + obo:DDO.owl#DDO_0001317 + pure autonomic failure + + + + obo:DDO.owl#DDO_0001318 + DDO:DDO_0001318 + + + + obo:DDO.owl#DDO_0001318 + 230659005 + + + + obo:DDO.owl#DDO_0001318 + segmental autonomic dysfunction + + + + obo:DDO.owl#DDO_0001319 + DDO:DDO_0001319 + + + + obo:DDO.owl#DDO_0001319 + 45294007 + + + + obo:DDO.owl#DDO_0001319 + auriculotemporal syndrome + + + + obo:DDO.owl#DDO_0001320 + DDO:DDO_0001320 + + + + obo:DDO.owl#DDO_0001320 + 21615003 + + + + obo:DDO.owl#DDO_0001320 + autonomic facial cephalgia + + + + obo:DDO.owl#DDO_0001321 + DDO:DDO_0001321 + + + + obo:DDO.owl#DDO_0001321 + 88219000 + + + + obo:DDO.owl#DDO_0001321 + celiac plexus syndrome + + + + obo:DDO.owl#DDO_0001322 + DDO:DDO_0001322 + + + + obo:DDO.owl#DDO_0001322 + 12731000 + + + + obo:DDO.owl#DDO_0001322 + cervical sympathetic dystrophy + + + + obo:DDO.owl#DDO_0001323 + DDO:DDO_0001323 + + + + obo:DDO.owl#DDO_0001323 + 271730003 + + + + obo:DDO.owl#DDO_0001323 + Horner's syndrome pupil + + + + obo:DDO.owl#DDO_0001324 + DDO:DDO_0001324 + + + + obo:DDO.owl#DDO_0001324 + 64518008 + + + + obo:DDO.owl#DDO_0001324 + paratrigeminal syndrome + + + + obo:DDO.owl#DDO_0001325 + DDO:DDO_0001325 + + + + obo:DDO.owl#DDO_0001325 + 472697007 + + + + obo:DDO.owl#DDO_0001325 + Type I paratrigeminal syndrome + + + + obo:DDO.owl#DDO_0001326 + DDO:DDO_0001326 + + + + obo:DDO.owl#DDO_0001326 + 472698002 + + + + obo:DDO.owl#DDO_0001326 + Type II paratrigeminal syndrome + + + + obo:DDO.owl#DDO_0001327 + DDO:DDO_0001327 + + + + obo:DDO.owl#DDO_0001327 + 230660000 + + + + obo:DDO.owl#DDO_0001327 + segmental hyperhidrosis + + + + obo:DDO.owl#DDO_0001328 + DDO:DDO_0001328 + + + + obo:DDO.owl#DDO_0001328 + 14070001000004105 + + + + obo:DDO.owl#DDO_0001328 + harlequin syndrome + + + + obo:DDO.owl#DDO_0001329 + DDO:DDO_0001329 + + + + obo:DDO.owl#DDO_0001329 + 230661001 + + + + obo:DDO.owl#DDO_0001329 + segmental hypohidrosis + + + + obo:DDO.owl#DDO_0001330 + DDO:DDO_0001330 + + + + obo:DDO.owl#DDO_0001330 + 95669001 + + + + obo:DDO.owl#DDO_0001330 + superior laryngeal neuralgia + + + + obo:DDO.owl#DDO_0001331 + DDO:DDO_0001331 + + + + obo:DDO.owl#DDO_0001331 + 42998008 + + + + obo:DDO.owl#DDO_0001331 + vagus nerve laryngeal paralysis + + + + obo:DDO.owl#DDO_0001332 + DDO:DDO_0001332 + + + + obo:DDO.owl#DDO_0001332 + 707088000 + + + + obo:DDO.owl#DDO_0001332 + chemotherapy-induced peripheral neuropathy + + + + obo:DDO.owl#DDO_0001333 + DDO:DDO_0001333 + + + + obo:DDO.owl#DDO_0001333 + compression neuropathy of trunk + + + + obo:DDO.owl#DDO_0001334 + DDO:DDO_0001334 + + + + obo:DDO.owl#DDO_0001334 + 230647006 + + + + obo:DDO.owl#DDO_0001334 + abdominal neuropathy + + + + obo:DDO.owl#DDO_0001335 + DDO:DDO_0001335 + + + + obo:DDO.owl#DDO_0001335 + 230648001 + + + + obo:DDO.owl#DDO_0001335 + abdominal cutaneous nerve entrapment syndrome + + + + obo:DDO.owl#DDO_0001336 + DDO:DDO_0001336 + + + + obo:DDO.owl#DDO_0001336 + 277802001 + + + + obo:DDO.owl#DDO_0001336 + notalgia paresthetica + + + + obo:DDO.owl#DDO_0001337 + DDO:DDO_0001337 + + + + obo:DDO.owl#DDO_0001337 + 23880008 + + + + obo:DDO.owl#DDO_0001337 + congenital anomaly of peripheral nerve + + + + obo:DDO.owl#DDO_0001338 + DDO:DDO_0001338 + + + + obo:DDO.owl#DDO_0001338 + 360434004 + + + + obo:DDO.owl#DDO_0001338 + aganglionosis of Auerbach's plexus + + + + obo:DDO.owl#DDO_0001339 + DDO:DDO_0001339 + + + + obo:DDO.owl#DDO_0001339 + 204080008 + + + + obo:DDO.owl#DDO_0001339 + defective development of the cauda equina + + + + obo:DDO.owl#DDO_0001340 + DDO:DDO_0001340 + + + + obo:DDO.owl#DDO_0001340 + 271971004 + + + + obo:DDO.owl#DDO_0001340 + disorder of peripheral nerve graft + + + + obo:DDO.owl#DDO_0001341 + DDO:DDO_0001341 + + + + obo:DDO.owl#DDO_0001341 + 213056007 + + + + obo:DDO.owl#DDO_0001341 + mechanical complication of peripheral nerve graft + + + + obo:DDO.owl#DDO_0001342 + DDO:DDO_0001342 + + + + obo:DDO.owl#DDO_0001342 + 446494003 + + + + obo:DDO.owl#DDO_0001342 + ependymal cyst of spinal nerve + + + + obo:DDO.owl#DDO_0001343 + DDO:DDO_0001343 + + + + obo:DDO.owl#DDO_0001343 + 193157005 + + + + obo:DDO.owl#DDO_0001343 + hereditary and idiopathic peripheral neuropathy + + + + obo:DDO.owl#DDO_0001344 + DDO:DDO_0001344 + + + + obo:DDO.owl#DDO_0001344 + 230646002 + + + + obo:DDO.owl#DDO_0001344 + intercostal neuropathy + + + + obo:DDO.owl#DDO_0001345 + DDO:DDO_0001345 + + + + obo:DDO.owl#DDO_0001345 + 212246006 + + + + obo:DDO.owl#DDO_0001345 + intercostal nerve injury + + + + obo:DDO.owl#DDO_0001346 + DDO:DDO_0001346 + + + + obo:DDO.owl#DDO_0001346 + 247389006 + + + + obo:DDO.owl#DDO_0001346 + intercostal neuralgia + + + + obo:DDO.owl#DDO_0001347 + DDO:DDO_0001347 + + + + obo:DDO.owl#DDO_0001347 + 230597003 + + + + obo:DDO.owl#DDO_0001347 + intercostal post-herpetic neuralgia + + + + obo:DDO.owl#DDO_0001348 + DDO:DDO_0001348 + + + + obo:DDO.owl#DDO_0001348 + 230599000 + + + + obo:DDO.owl#DDO_0001348 + ischemic neuropathy + + + + obo:DDO.owl#DDO_0001349 + DDO:DDO_0001349 + + + + obo:DDO.owl#DDO_0001349 + 230602005 + + + + obo:DDO.owl#DDO_0001349 + embolic infarction of nerve trunk + + + + obo:DDO.owl#DDO_0001350 + DDO:DDO_0001350 + + + + obo:DDO.owl#DDO_0001350 + 230606008 + + + + obo:DDO.owl#DDO_0001350 + ischemic neuropathy due to arterial steal + + + + obo:DDO.owl#DDO_0001351 + DDO:DDO_0001351 + + + + obo:DDO.owl#DDO_0001351 + 230600002 + + + + obo:DDO.owl#DDO_0001351 + neuropathy in arteriosclerotic occlusive disease + + + + obo:DDO.owl#DDO_0001352 + DDO:DDO_0001352 + + + + obo:DDO.owl#DDO_0001352 + 230601003 + + + + obo:DDO.owl#DDO_0001352 + neuropathy in thromboangiitis obliterans + + + + obo:DDO.owl#DDO_0001353 + DDO:DDO_0001353 + + + + obo:DDO.owl#DDO_0001353 + 230604006 + + + + obo:DDO.owl#DDO_0001353 + tourniquet palsy + + + + obo:DDO.owl#DDO_0001354 + DDO:DDO_0001354 + + + + obo:DDO.owl#DDO_0001354 + 425659003 + + + + obo:DDO.owl#DDO_0001354 + vasculitic neuropathy + + + + obo:DDO.owl#DDO_0001355 + DDO:DDO_0001355 + + + + obo:DDO.owl#DDO_0001355 + 128215004 + + + + obo:DDO.owl#DDO_0001355 + leprosy neuropathy + + + + obo:DDO.owl#DDO_0001356 + DDO:DDO_0001356 + + + + obo:DDO.owl#DDO_0001356 + 298119007 + + + + obo:DDO.owl#DDO_0001356 + long thoracic nerve lesion + + + + obo:DDO.owl#DDO_0001357 + DDO:DDO_0001357 + + + + obo:DDO.owl#DDO_0001357 + 212291002 + + + + obo:DDO.owl#DDO_0001357 + long thoracic nerve injury + + + + obo:DDO.owl#DDO_0001358 + DDO:DDO_0001358 + + + + obo:DDO.owl#DDO_0001358 + 282742004 + + + + obo:DDO.owl#DDO_0001358 + intercostal post-herpetic neuritis + + + + obo:DDO.owl#DDO_0001359 + DDO:DDO_0001359 + + + + obo:DDO.owl#DDO_0001359 + 32595002 + + + + obo:DDO.owl#DDO_0001359 + mononeuritis + + + + obo:DDO.owl#DDO_0001360 + DDO:DDO_0001360 + + + + obo:DDO.owl#DDO_0001360 + 30085007 + + + + obo:DDO.owl#DDO_0001360 + Morton's metatarsalgia + + + + obo:DDO.owl#DDO_0001361 + DDO:DDO_0001361 + + + + obo:DDO.owl#DDO_0001361 + 609592007 + + + + obo:DDO.owl#DDO_0001361 + mononeuropathy of lower limb + + + + obo:DDO.owl#DDO_0001362 + DDO:DDO_0001362 + + + + obo:DDO.owl#DDO_0001362 + 230637008 + + + + obo:DDO.owl#DDO_0001362 + compression neuropathy of lower limb + + + + obo:DDO.owl#DDO_0001363 + DDO:DDO_0001363 + + + + obo:DDO.owl#DDO_0001363 + 230641007 + + + + obo:DDO.owl#DDO_0001363 + common peroneal nerve compression + + + + obo:DDO.owl#DDO_0001364 + DDO:DDO_0001364 + + + + obo:DDO.owl#DDO_0001364 + 609613006 + + + + obo:DDO.owl#DDO_0001364 + entrapment of common peroneal nerve + + + + obo:DDO.owl#DDO_0001365 + DDO:DDO_0001365 + + + + obo:DDO.owl#DDO_0001365 + 609640006 + + + + obo:DDO.owl#DDO_0001365 + compression neuropathy of genitofemoral nerve + + + + obo:DDO.owl#DDO_0001366 + DDO:DDO_0001366 + + + + obo:DDO.owl#DDO_0001366 + 443353000 + + + + obo:DDO.owl#DDO_0001366 + entrapment of genitofemoral nerve + + + + obo:DDO.owl#DDO_0001367 + DDO:DDO_0001367 + + + + obo:DDO.owl#DDO_0001367 + 609641005 + + + + obo:DDO.owl#DDO_0001367 + compression neuropathy of ilioinguinal nerve + + + + obo:DDO.owl#DDO_0001368 + DDO:DDO_0001368 + + + + obo:DDO.owl#DDO_0001368 + 400983004 + + + + obo:DDO.owl#DDO_0001368 + ilio-inguinal nerve entrapment + + + + obo:DDO.owl#DDO_0001369 + DDO:DDO_0001369 + + + + obo:DDO.owl#DDO_0001369 + 609614000 + + + + obo:DDO.owl#DDO_0001369 + entrapment neuropathy of lower limb + + + + obo:DDO.owl#DDO_0001370 + DDO:DDO_0001370 + + + + obo:DDO.owl#DDO_0001370 + 443490000 + + + + obo:DDO.owl#DDO_0001370 + entrapment of plantar nerve + + + + obo:DDO.owl#DDO_0001371 + DDO:DDO_0001371 + + + + obo:DDO.owl#DDO_0001371 + 47374004 + + + + obo:DDO.owl#DDO_0001371 + tarsal tunnel syndrome + + + + obo:DDO.owl#DDO_0001372 + DDO:DDO_0001372 + + + + obo:DDO.owl#DDO_0001372 + 230640008 + + + + obo:DDO.owl#DDO_0001372 + femoral nerve compression + + + + obo:DDO.owl#DDO_0001373 + DDO:DDO_0001373 + + + + obo:DDO.owl#DDO_0001373 + 230644004 + + + + obo:DDO.owl#DDO_0001373 + medial plantar nerve compression + + + + obo:DDO.owl#DDO_0001374 + DDO:DDO_0001374 + + + + obo:DDO.owl#DDO_0001374 + 85007004 + + + + obo:DDO.owl#DDO_0001374 + meralgia paresthetica + + + + obo:DDO.owl#DDO_0001375 + DDO:DDO_0001375 + + + + obo:DDO.owl#DDO_0001375 + 30085007 + + + + obo:DDO.owl#DDO_0001375 + Morton's metatarsalgia + + + + obo:DDO.owl#DDO_0001376 + DDO:DDO_0001376 + + + + obo:DDO.owl#DDO_0001376 + 230639006 + + + + obo:DDO.owl#DDO_0001376 + obturator nerve compression + + + + obo:DDO.owl#DDO_0001377 + DDO:DDO_0001377 + + + + obo:DDO.owl#DDO_0001377 + 230638003 + + + + obo:DDO.owl#DDO_0001377 + sciatic nerve compression + + + + obo:DDO.owl#DDO_0001378 + DDO:DDO_0001378 + + + + obo:DDO.owl#DDO_0001378 + 230643005 + + + + obo:DDO.owl#DDO_0001378 + tibial nerve compression + + + + obo:DDO.owl#DDO_0001379 + DDO:DDO_0001379 + + + + obo:DDO.owl#DDO_0001379 + 47374004 + + + + obo:DDO.owl#DDO_0001379 + tarsal tunnel syndrome + + + + obo:DDO.owl#DDO_0001380 + DDO:DDO_0001380 + + + + obo:DDO.owl#DDO_0001380 + 361216007 + + + + obo:DDO.owl#DDO_0001380 + diabetic femoral mononeuropathy + + + + obo:DDO.owl#DDO_0001381 + DDO:DDO_0001381 + + + + obo:DDO.owl#DDO_0001381 + 609591000 + + + + obo:DDO.owl#DDO_0001381 + mononeuropathy of upper limb + + + + obo:DDO.owl#DDO_0001382 + DDO:DDO_0001382 + + + + obo:DDO.owl#DDO_0001382 + 230627003 + + + + obo:DDO.owl#DDO_0001382 + compression neuropathy of upper limb + + + + obo:DDO.owl#DDO_0001383 + DDO:DDO_0001383 + + + + obo:DDO.owl#DDO_0001383 + 230636004 + + + + obo:DDO.owl#DDO_0001383 + axillary nerve compression + + + + obo:DDO.owl#DDO_0001384 + DDO:DDO_0001384 + + + + obo:DDO.owl#DDO_0001384 + 423023005 + + + + obo:DDO.owl#DDO_0001384 + entrapment neuropathy of upper limb + + + + obo:DDO.owl#DDO_0001385 + DDO:DDO_0001385 + + + + obo:DDO.owl#DDO_0001385 + 302885000 + + + + obo:DDO.owl#DDO_0001385 + anterior interosseous nerve entrapment + + + + obo:DDO.owl#DDO_0001386 + DDO:DDO_0001386 + + + + obo:DDO.owl#DDO_0001386 + 230633007 + + + + obo:DDO.owl#DDO_0001386 + entrapment of deep palmar branch of ulnar nerve + + + + obo:DDO.owl#DDO_0001387 + DDO:DDO_0001387 + + + + obo:DDO.owl#DDO_0001387 + 246611002 + + + + obo:DDO.owl#DDO_0001387 + median nerve entrapment + + + + obo:DDO.owl#DDO_0001388 + DDO:DDO_0001388 + + + + obo:DDO.owl#DDO_0001388 + 57406009 + + + + obo:DDO.owl#DDO_0001388 + carpal tunnel syndrome + + + + obo:DDO.owl#DDO_0001389 + DDO:DDO_0001389 + + + + obo:DDO.owl#DDO_0001389 + 277187008 + + + + obo:DDO.owl#DDO_0001389 + proximal median neuropathy + + + + obo:DDO.owl#DDO_0001390 + DDO:DDO_0001390 + + + + obo:DDO.owl#DDO_0001390 + 230628008 + + + + obo:DDO.owl#DDO_0001390 + pronator syndrome + + + + obo:DDO.owl#DDO_0001391 + DDO:DDO_0001391 + + + + obo:DDO.owl#DDO_0001391 + 230630005 + + + + obo:DDO.owl#DDO_0001391 + Struther ligament entrapment + + + + obo:DDO.owl#DDO_0001392 + DDO:DDO_0001392 + + + + obo:DDO.owl#DDO_0001392 + 230629000 + + + + obo:DDO.owl#DDO_0001392 + supracondylar process entrapment + + + + obo:DDO.owl#DDO_0001393 + DDO:DDO_0001393 + + + + obo:DDO.owl#DDO_0001393 + 609590004 + + + + obo:DDO.owl#DDO_0001393 + radial nerve entrapment + + + + obo:DDO.owl#DDO_0001394 + DDO:DDO_0001394 + + + + obo:DDO.owl#DDO_0001394 + 277188003 + + + + obo:DDO.owl#DDO_0001394 + ulnar nerve entrapment + + + + obo:DDO.owl#DDO_0001395 + DDO:DDO_0001395 + + + + obo:DDO.owl#DDO_0001395 + 230631009 + + + + obo:DDO.owl#DDO_0001395 + ulnar nerve entrapment at elbow + + + + obo:DDO.owl#DDO_0001396 + DDO:DDO_0001396 + + + + obo:DDO.owl#DDO_0001396 + 56177003 + + + + obo:DDO.owl#DDO_0001396 + cubital tunnel syndrome + + + + obo:DDO.owl#DDO_0001397 + DDO:DDO_0001397 + + + + obo:DDO.owl#DDO_0001397 + 193134004 + + + + obo:DDO.owl#DDO_0001397 + ulnar nerve entrapment at wrist + + + + obo:DDO.owl#DDO_0001398 + DDO:DDO_0001398 + + + + obo:DDO.owl#DDO_0001398 + 193129003 + + + + obo:DDO.owl#DDO_0001398 + median nerve compression in forearm + + + + obo:DDO.owl#DDO_0001399 + DDO:DDO_0001399 + + + + obo:DDO.owl#DDO_0001399 + 302886004 + + + + obo:DDO.owl#DDO_0001399 + posterior interosseous nerve compression + + + + obo:DDO.owl#DDO_00014 + DDO:DDO_00014 + + + + obo:DDO.owl#DDO_00014 + 78996009 + + + + obo:DDO.owl#DDO_00014 + acute suppurative alveolar periostitis + + + + obo:DDO.owl#DDO_0001400 + DDO:DDO_0001400 + + + + obo:DDO.owl#DDO_0001400 + 230634001 + + + + obo:DDO.owl#DDO_0001400 + radial nerve compression + + + + obo:DDO.owl#DDO_0001401 + DDO:DDO_0001401 + + + + obo:DDO.owl#DDO_0001401 + 4724003 + + + + obo:DDO.owl#DDO_0001401 + acute radial nerve palsy + + + + obo:DDO.owl#DDO_0001402 + DDO:DDO_0001402 + + + + obo:DDO.owl#DDO_0001402 + 609590004 + + + + obo:DDO.owl#DDO_0001402 + radial nerve entrapment + + + + obo:DDO.owl#DDO_0001403 + DDO:DDO_0001403 + + + + obo:DDO.owl#DDO_0001403 + 443876008 + + + + obo:DDO.owl#DDO_0001403 + radial tunnel syndrome + + + + obo:DDO.owl#DDO_0001404 + DDO:DDO_0001404 + + + + obo:DDO.owl#DDO_0001404 + 14786003 + + + + obo:DDO.owl#DDO_0001404 + Saturday night paralysis + + + + obo:DDO.owl#DDO_0001405 + DDO:DDO_0001405 + + + + obo:DDO.owl#DDO_0001405 + 230635000 + + + + obo:DDO.owl#DDO_0001405 + suprascapular nerve compression + + + + obo:DDO.owl#DDO_0001406 + DDO:DDO_0001406 + + + + obo:DDO.owl#DDO_0001406 + 45781009 + + + + obo:DDO.owl#DDO_0001406 + peripheral nerve entrapment syndrome + + + + obo:DDO.owl#DDO_0001407 + DDO:DDO_0001407 + + + + obo:DDO.owl#DDO_0001407 + 129593003 + + + + obo:DDO.owl#DDO_0001407 + entrapment syndrome due to amyloid + + + + obo:DDO.owl#DDO_0001408 + DDO:DDO_0001408 + + + + obo:DDO.owl#DDO_0001408 + 230649009 + + + + obo:DDO.owl#DDO_0001408 + multiple entrapment syndrome + + + + obo:DDO.owl#DDO_0001409 + DDO:DDO_0001409 + + + + obo:DDO.owl#DDO_0001409 + 424054000 + + + + obo:DDO.owl#DDO_0001409 + nerve entrapment due to scar + + + + obo:DDO.owl#DDO_0001410 + DDO:DDO_0001410 + + + + obo:DDO.owl#DDO_0001410 + 302225005 + + + + obo:DDO.owl#DDO_0001410 + polyneuropathy and mononeuropathy + + + + obo:DDO.owl#DDO_0001411 + DDO:DDO_0001411 + + + + obo:DDO.owl#DDO_0001411 + 31524007 + + + + obo:DDO.owl#DDO_0001411 + mumps polyneuropathy + + + + obo:DDO.owl#DDO_0001412 + DDO:DDO_0001412 + + + + obo:DDO.owl#DDO_0001412 + 126980002 + + + + obo:DDO.owl#DDO_0001412 + neoplasm of peripheral nerve + + + + obo:DDO.owl#DDO_0001413 + DDO:DDO_0001413 + + + + obo:DDO.owl#DDO_0001413 + 72274001 + + + + obo:DDO.owl#DDO_0001413 + nerve root disorder + + + + obo:DDO.owl#DDO_0001414 + DDO:DDO_0001414 + + + + obo:DDO.owl#DDO_0001414 + 192970008 + + + + obo:DDO.owl#DDO_0001414 + cauda equina syndrome + + + + obo:DDO.owl#DDO_0001415 + DDO:DDO_0001415 + + + + obo:DDO.owl#DDO_0001415 + 230614002 + + + + obo:DDO.owl#DDO_0001415 + injury of cauda equina + + + + obo:DDO.owl#DDO_0001416 + DDO:DDO_0001416 + + + + obo:DDO.owl#DDO_0001416 + 126963001 + + + + obo:DDO.owl#DDO_0001416 + neoplasm of cauda equina + + + + obo:DDO.owl#DDO_0001417 + DDO:DDO_0001417 + + + + obo:DDO.owl#DDO_0001417 + 92047003 + + + + obo:DDO.owl#DDO_0001417 + benign neoplasm of cauda equina + + + + obo:DDO.owl#DDO_0001418 + DDO:DDO_0001418 + + + + obo:DDO.owl#DDO_0001418 + 363477002 + + + + obo:DDO.owl#DDO_0001418 + malignant neoplasm of cauda equina + + + + obo:DDO.owl#DDO_0001419 + DDO:DDO_0001419 + + + + obo:DDO.owl#DDO_0001419 + 93743001 + + + + obo:DDO.owl#DDO_0001419 + primary malignant neoplasm of cauda equina + + + + obo:DDO.owl#DDO_0001420 + DDO:DDO_0001420 + + + + obo:DDO.owl#DDO_0001420 + 94242004 + + + + obo:DDO.owl#DDO_0001420 + secondary malignant neoplasm of cauda equina + + + + obo:DDO.owl#DDO_0001421 + DDO:DDO_0001421 + + + + obo:DDO.owl#DDO_0001421 + 209102002 + + + + obo:DDO.owl#DDO_0001421 + open spinal dislocation with cauda equina lesion + + + + obo:DDO.owl#DDO_0001422 + DDO:DDO_0001422 + + + + obo:DDO.owl#DDO_0001422 + 54404000 + + + + obo:DDO.owl#DDO_0001422 + cervical radiculopathy + + + + obo:DDO.owl#DDO_0001423 + DDO:DDO_0001423 + + + + obo:DDO.owl#DDO_0001423 + 11049006 + + + + obo:DDO.owl#DDO_0001423 + cervical radiculitis + + + + obo:DDO.owl#DDO_0001424 + DDO:DDO_0001424 + + + + obo:DDO.owl#DDO_0001424 + 78141002 + + + + obo:DDO.owl#DDO_0001424 + Erb-Duchenne paralysis + + + + obo:DDO.owl#DDO_0001425 + DDO:DDO_0001425 + + + + obo:DDO.owl#DDO_0001425 + 74297002 + + + + obo:DDO.owl#DDO_0001425 + injury of cervical nerve roots + + + + obo:DDO.owl#DDO_0001426 + DDO:DDO_0001426 + + + + obo:DDO.owl#DDO_0001426 + 111236008 + + + + obo:DDO.owl#DDO_0001426 + compression of spinal nerve root + + + + obo:DDO.owl#DDO_0001427 + DDO:DDO_0001427 + + + + obo:DDO.owl#DDO_0001427 + 95671001 + + + + obo:DDO.owl#DDO_0001427 + cervical nerve root compression + + + + obo:DDO.owl#DDO_0001428 + DDO:DDO_0001428 + + + + obo:DDO.owl#DDO_0001428 + 299966003 + + + + obo:DDO.owl#DDO_0001428 + compression of lumbar nerve root + + + + obo:DDO.owl#DDO_0001429 + DDO:DDO_0001429 + + + + obo:DDO.owl#DDO_0001429 + 299967007 + + + + obo:DDO.owl#DDO_0001429 + compression of sacral nerve root + + + + obo:DDO.owl#DDO_0001430 + DDO:DDO_0001430 + + + + obo:DDO.owl#DDO_0001430 + 299965004 + + + + obo:DDO.owl#DDO_0001430 + compression of thoracic nerve root + + + + obo:DDO.owl#DDO_0001431 + DDO:DDO_0001431 + + + + obo:DDO.owl#DDO_0001431 + 204080008 + + + + obo:DDO.owl#DDO_0001431 + defective development of the cauda equina + + + + obo:DDO.owl#DDO_0001432 + DDO:DDO_0001432 + + + + obo:DDO.owl#DDO_0001432 + 1086061000119109 + + + + obo:DDO.owl#DDO_0001432 + diphtheria radiculomyelitis + + + + obo:DDO.owl#DDO_0001433 + DDO:DDO_0001433 + + + + obo:DDO.owl#DDO_0001433 + 253192007 + + + + obo:DDO.owl#DDO_0001433 + fibrolipoma of filum terminale + + + + obo:DDO.owl#DDO_0001434 + DDO:DDO_0001434 + + + + obo:DDO.owl#DDO_0001434 + 76523007 + + + + obo:DDO.owl#DDO_0001434 + intermittent cauda equina claudication + + + + obo:DDO.owl#DDO_0001435 + DDO:DDO_0001435 + + + + obo:DDO.owl#DDO_0001435 + 2415007 + + + + obo:DDO.owl#DDO_0001435 + lumbosacral radiculopathy + + + + obo:DDO.owl#DDO_0001436 + DDO:DDO_0001436 + + + + obo:DDO.owl#DDO_0001436 + 209086000 + + + + obo:DDO.owl#DDO_0001436 + closed spinal dislocation with cauda equina lesion + + + + obo:DDO.owl#DDO_0001437 + DDO:DDO_0001437 + + + + obo:DDO.owl#DDO_0001437 + 299967007 + + + + obo:DDO.owl#DDO_0001437 + compression of sacral nerve root + + + + obo:DDO.owl#DDO_0001438 + DDO:DDO_0001438 + + + + obo:DDO.owl#DDO_0001438 + 87900003 + + + + obo:DDO.owl#DDO_0001438 + injury of sacral nerve roots + + + + obo:DDO.owl#DDO_0001439 + DDO:DDO_0001439 + + + + obo:DDO.owl#DDO_0001439 + 262748008 + + + + obo:DDO.owl#DDO_0001439 + avulsion of sacral nerve root + + + + obo:DDO.owl#DDO_0001440 + DDO:DDO_0001440 + + + + obo:DDO.owl#DDO_0001440 + 262737001 + + + + obo:DDO.owl#DDO_0001440 + contusion of sacral nerve root + + + + obo:DDO.owl#DDO_0001441 + DDO:DDO_0001441 + + + + obo:DDO.owl#DDO_0001441 + 128196005 + + + + obo:DDO.owl#DDO_0001441 + lumbar radiculopathy + + + + obo:DDO.owl#DDO_0001442 + DDO:DDO_0001442 + + + + obo:DDO.owl#DDO_0001442 + 24300005 + + + + obo:DDO.owl#DDO_0001442 + injury of lumbar nerve roots + + + + obo:DDO.owl#DDO_0001443 + DDO:DDO_0001443 + + + + obo:DDO.owl#DDO_0001443 + 262747003 + + + + obo:DDO.owl#DDO_0001443 + avulsion of lumbar nerve root + + + + obo:DDO.owl#DDO_0001444 + DDO:DDO_0001444 + + + + obo:DDO.owl#DDO_0001444 + 262736005 + + + + obo:DDO.owl#DDO_0001444 + contusion of lumbar nerve root + + + + obo:DDO.owl#DDO_0001445 + DDO:DDO_0001445 + + + + obo:DDO.owl#DDO_0001445 + 262731000 + + + + obo:DDO.owl#DDO_0001445 + partial division of lumbar nerve root + + + + obo:DDO.owl#DDO_0001446 + DDO:DDO_0001446 + + + + obo:DDO.owl#DDO_0001446 + 262742009 + + + + obo:DDO.owl#DDO_0001446 + traction injury of lumbar nerve root + + + + obo:DDO.owl#DDO_0001447 + DDO:DDO_0001447 + + + + obo:DDO.owl#DDO_0001447 + 262726002 + + + + obo:DDO.owl#DDO_0001447 + transection of lumbar nerve root + + + + obo:DDO.owl#DDO_0001448 + DDO:DDO_0001448 + + + + obo:DDO.owl#DDO_0001448 + 46578006 + + + + obo:DDO.owl#DDO_0001448 + lumbosacral radiculitis + + + + obo:DDO.owl#DDO_0001449 + DDO:DDO_0001449 + + + + obo:DDO.owl#DDO_0001449 + 19033007 + + + + obo:DDO.owl#DDO_0001449 + pseudoclaudication syndrome + + + + obo:DDO.owl#DDO_0001450 + DDO:DDO_0001450 + + + + obo:DDO.owl#DDO_0001450 + 128197001 + + + + obo:DDO.owl#DDO_0001450 + sacral radiculopathy + + + + obo:DDO.owl#DDO_0001451 + DDO:DDO_0001451 + + + + obo:DDO.owl#DDO_0001451 + 243338005 + + + + obo:DDO.owl#DDO_0001451 + nerve root compression syndrome + + + + obo:DDO.owl#DDO_0001452 + DDO:DDO_0001452 + + + + obo:DDO.owl#DDO_0001452 + 129137006 + + + + obo:DDO.owl#DDO_0001452 + nerve root injury + + + + obo:DDO.owl#DDO_0001453 + DDO:DDO_0001453 + + + + obo:DDO.owl#DDO_0001453 + 230616000 + + + + obo:DDO.owl#DDO_0001453 + injury of spinal nerve root + + + + obo:DDO.owl#DDO_0001454 + DDO:DDO_0001454 + + + + obo:DDO.owl#DDO_0001454 + 95670000 + + + + obo:DDO.owl#DDO_0001454 + Nervus intermedius neuralgia + + + + obo:DDO.owl#DDO_0001455 + DDO:DDO_0001455 + + + + obo:DDO.owl#DDO_0001455 + 247400008 + + + + obo:DDO.owl#DDO_0001455 + painful arms and moving fingers + + + + obo:DDO.owl#DDO_0001456 + DDO:DDO_0001456 + + + + obo:DDO.owl#DDO_0001456 + 230654000 + + + + obo:DDO.owl#DDO_0001456 + painful legs and moving toes + + + + obo:DDO.owl#DDO_0001457 + DDO:DDO_0001457 + + + + obo:DDO.owl#DDO_0001457 + 69071001 + + + + obo:DDO.owl#DDO_0001457 + radicular syndrome of lower limbs + + + + obo:DDO.owl#DDO_0001458 + DDO:DDO_0001458 + + + + obo:DDO.owl#DDO_0001458 + 82473003 + + + + obo:DDO.owl#DDO_0001458 + radiculitis + + + + obo:DDO.owl#DDO_0001459 + DDO:DDO_0001459 + + + + obo:DDO.owl#DDO_0001459 + 27830001 + + + + obo:DDO.owl#DDO_0001459 + brachial radiculitis + + + + obo:DDO.owl#DDO_0001460 + DDO:DDO_0001460 + + + + obo:DDO.owl#DDO_0001460 + 11049006 + + + + obo:DDO.owl#DDO_0001460 + cervical radiculitis + + + + obo:DDO.owl#DDO_0001461 + DDO:DDO_0001461 + + + + obo:DDO.owl#DDO_0001461 + 424941009 + + + + obo:DDO.owl#DDO_0001461 + Herpes zoster radiculitis + + + + obo:DDO.owl#DDO_0001462 + DDO:DDO_0001462 + + + + obo:DDO.owl#DDO_0001462 + 202735001 + + + + obo:DDO.owl#DDO_0001462 + lumbar disc prolapse with radiculopathy + + + + obo:DDO.owl#DDO_0001463 + DDO:DDO_0001463 + + + + obo:DDO.owl#DDO_0001463 + 46578006 + + + + obo:DDO.owl#DDO_0001463 + lumbosacral radiculitis + + + + obo:DDO.owl#DDO_0001464 + DDO:DDO_0001464 + + + + obo:DDO.owl#DDO_0001464 + 2169001 + + + + obo:DDO.owl#DDO_0001464 + thoracic radiculitis + + + + obo:DDO.owl#DDO_0001465 + DDO:DDO_0001465 + + + + obo:DDO.owl#DDO_0001465 + 247388003 + + + + obo:DDO.owl#DDO_0001465 + segmental peripheral neuralgia + + + + obo:DDO.owl#DDO_0001466 + DDO:DDO_0001466 + + + + obo:DDO.owl#DDO_0001466 + 42452002 + + + + obo:DDO.owl#DDO_0001466 + thoracic radiculopathy + + + + obo:DDO.owl#DDO_0001467 + DDO:DDO_0001467 + + + + obo:DDO.owl#DDO_0001467 + 305719002 + + + + obo:DDO.owl#DDO_0001467 + neuromyotonia + + + + obo:DDO.owl#DDO_0001468 + DDO:DDO_0001468 + + + + obo:DDO.owl#DDO_0001468 + 711406009 + + + + obo:DDO.owl#DDO_0001468 + autosomal recessive axonal neuropathy with neuromyotonia + + + + obo:DDO.owl#DDO_0001469 + DDO:DDO_0001469 + + + + obo:DDO.owl#DDO_0001469 + 609600000 + + + + obo:DDO.owl#DDO_0001469 + neuropathy of lower limb + + + + obo:DDO.owl#DDO_0001470 + DDO:DDO_0001470 + + + + obo:DDO.owl#DDO_0001470 + 230570005 + + + + obo:DDO.owl#DDO_0001470 + burning feet syndrome + + + + obo:DDO.owl#DDO_0001471 + DDO:DDO_0001471 + + + + obo:DDO.owl#DDO_0001471 + 399081005 + + + + obo:DDO.owl#DDO_0001471 + common peroneal neuropathy + + + + obo:DDO.owl#DDO_0001472 + DDO:DDO_0001472 + + + + obo:DDO.owl#DDO_0001472 + 399107008 + + + + obo:DDO.owl#DDO_0001472 + common peroneal nerve lesion + + + + obo:DDO.owl#DDO_0001473 + DDO:DDO_0001473 + + + + obo:DDO.owl#DDO_0001473 + 399088004 + + + + obo:DDO.owl#DDO_0001473 + common peroneal nerve paralysis + + + + obo:DDO.owl#DDO_0001474 + DDO:DDO_0001474 + + + + obo:DDO.owl#DDO_0001474 + 247387008 + + + + obo:DDO.owl#DDO_0001474 + cruralgia + + + + obo:DDO.owl#DDO_0001475 + DDO:DDO_0001475 + + + + obo:DDO.owl#DDO_0001475 + 128195009 + + + + obo:DDO.owl#DDO_0001475 + deep peroneal neuropathy + + + + obo:DDO.owl#DDO_0001476 + DDO:DDO_0001476 + + + + obo:DDO.owl#DDO_0001476 + 193152004 + + + + obo:DDO.owl#DDO_0001476 + deep peroneal nerve lesion + + + + obo:DDO.owl#DDO_0001477 + DDO:DDO_0001477 + + + + obo:DDO.owl#DDO_0001477 + 16006009 + + + + obo:DDO.owl#DDO_0001477 + traumatic injury of deep peroneal nerve + + + + obo:DDO.owl#DDO_0001478 + DDO:DDO_0001478 + + + + obo:DDO.owl#DDO_0001478 + 212320009 + + + + obo:DDO.owl#DDO_0001478 + closed injury deep peroneal nerve + + + + obo:DDO.owl#DDO_0001479 + DDO:DDO_0001479 + + + + obo:DDO.owl#DDO_0001479 + 212323006 + + + + obo:DDO.owl#DDO_0001479 + opened injury deep peroneal nerve + + + + obo:DDO.owl#DDO_0001480 + DDO:DDO_0001480 + + + + obo:DDO.owl#DDO_0001480 + 25690000 + + + + obo:DDO.owl#DDO_0001480 + femoral neuropathy + + + + obo:DDO.owl#DDO_0001481 + DDO:DDO_0001481 + + + + obo:DDO.owl#DDO_0001481 + 361216007 + + + + obo:DDO.owl#DDO_0001481 + diabetic femoral mononeuropathy + + + + obo:DDO.owl#DDO_0001482 + DDO:DDO_0001482 + + + + obo:DDO.owl#DDO_0001482 + 230640008 + + + + obo:DDO.owl#DDO_0001482 + femoral nerve compression + + + + obo:DDO.owl#DDO_0001483 + DDO:DDO_0001483 + + + + obo:DDO.owl#DDO_0001483 + 609531002 + + + + obo:DDO.owl#DDO_0001483 + femoral nerve paralysis + + + + obo:DDO.owl#DDO_0001484 + DDO:DDO_0001484 + + + + obo:DDO.owl#DDO_0001484 + 35496009 + + + + obo:DDO.owl#DDO_0001484 + femoral neuralgia + + + + obo:DDO.owl#DDO_0001485 + DDO:DDO_0001485 + + + + obo:DDO.owl#DDO_0001485 + 712645006 + + + + obo:DDO.owl#DDO_0001485 + inflammation of femoral nerve + + + + obo:DDO.owl#DDO_0001486 + DDO:DDO_0001486 + + + + obo:DDO.owl#DDO_0001486 + 7449006 + + + + obo:DDO.owl#DDO_0001486 + injury of femoral nerve + + + + obo:DDO.owl#DDO_0001487 + DDO:DDO_0001487 + + + + obo:DDO.owl#DDO_0001487 + 212313002 + + + + obo:DDO.owl#DDO_0001487 + closed injury femoral nerve + + + + obo:DDO.owl#DDO_0001488 + DDO:DDO_0001488 + + + + obo:DDO.owl#DDO_0001488 + 212314008 + + + + obo:DDO.owl#DDO_0001488 + open injury femoral nerve + + + + obo:DDO.owl#DDO_0001489 + DDO:DDO_0001489 + + + + obo:DDO.owl#DDO_0001489 + 68711000119109 + + + + obo:DDO.owl#DDO_0001489 + genitofemoral neuropathy + + + + obo:DDO.owl#DDO_0001490 + DDO:DDO_0001490 + + + + obo:DDO.owl#DDO_0001490 + 247395007 + + + + obo:DDO.owl#DDO_0001490 + genitofemoral nerve neuralgia + + + + obo:DDO.owl#DDO_0001491 + DDO:DDO_0001491 + + + + obo:DDO.owl#DDO_0001491 + 247396008 + + + + obo:DDO.owl#DDO_0001491 + testicular neuralgia + + + + obo:DDO.owl#DDO_0001492 + DDO:DDO_0001492 + + + + obo:DDO.owl#DDO_0001492 + 247392005 + + + + obo:DDO.owl#DDO_0001492 + iliohypogastric nerve neuralgia + + + + obo:DDO.owl#DDO_0001493 + DDO:DDO_0001493 + + + + obo:DDO.owl#DDO_0001493 + 428141001 + + + + obo:DDO.owl#DDO_0001493 + iliohypogastric nerve neuritis + + + + obo:DDO.owl#DDO_0001494 + DDO:DDO_0001494 + + + + obo:DDO.owl#DDO_0001494 + 68721000119102 + + + + obo:DDO.owl#DDO_0001494 + ilioinguinal neuropathy + + + + obo:DDO.owl#DDO_0001495 + DDO:DDO_0001495 + + + + obo:DDO.owl#DDO_0001495 + 247393000 + + + + obo:DDO.owl#DDO_0001495 + ilioinguinal nerve neuralgia + + + + obo:DDO.owl#DDO_0001496 + DDO:DDO_0001496 + + + + obo:DDO.owl#DDO_0001496 + 428359008 + + + + obo:DDO.owl#DDO_0001496 + ilioinguinal nerve neuritis + + + + obo:DDO.owl#DDO_0001497 + DDO:DDO_0001497 + + + + obo:DDO.owl#DDO_0001497 + 212248007 + + + + obo:DDO.owl#DDO_0001497 + iliolumbar nerve injury + + + + obo:DDO.owl#DDO_0001498 + DDO:DDO_0001498 + + + + obo:DDO.owl#DDO_0001498 + 712644005 + + + + obo:DDO.owl#DDO_0001498 + inflammation of obturator nerve + + + + obo:DDO.owl#DDO_0001499 + DDO:DDO_0001499 + + + + obo:DDO.owl#DDO_0001499 + 247385000 + + + + obo:DDO.owl#DDO_0001499 + lateral femoral cutaneous neuralgia + + + + obo:DDO.owl#DDO_0001500 + DDO:DDO_0001500 + + + + obo:DDO.owl#DDO_0001500 + 297946004 + + + + obo:DDO.owl#DDO_0001500 + lower limb nerve lesion + + + + obo:DDO.owl#DDO_0001501 + DDO:DDO_0001501 + + + + obo:DDO.owl#DDO_0001501 + 129136002 + + + + obo:DDO.owl#DDO_0001501 + injury of nerve of lower extremity + + + + obo:DDO.owl#DDO_0001502 + DDO:DDO_0001502 + + + + obo:DDO.owl#DDO_0001502 + 307365001 + + + + obo:DDO.owl#DDO_0001502 + lateral cutaneous nerve of thigh lesion + + + + obo:DDO.owl#DDO_0001503 + DDO:DDO_0001503 + + + + obo:DDO.owl#DDO_0001503 + 285602007 + + + + obo:DDO.owl#DDO_0001503 + injury of lateral cutaneous nerve of thigh + + + + obo:DDO.owl#DDO_0001504 + DDO:DDO_0001504 + + + + obo:DDO.owl#DDO_0001504 + 212327007 + + + + obo:DDO.owl#DDO_0001504 + closed injury lateral cutaneous nerve thigh + + + + obo:DDO.owl#DDO_0001505 + DDO:DDO_0001505 + + + + obo:DDO.owl#DDO_0001505 + 212328002 + + + + obo:DDO.owl#DDO_0001505 + opened injury lateral cutaneous nerve thigh + + + + obo:DDO.owl#DDO_0001506 + DDO:DDO_0001506 + + + + obo:DDO.owl#DDO_0001506 + 85007004 + + + + obo:DDO.owl#DDO_0001506 + meralgia paresthetica + + + + obo:DDO.owl#DDO_0001507 + DDO:DDO_0001507 + + + + obo:DDO.owl#DDO_0001507 + 60525009 + + + + obo:DDO.owl#DDO_0001507 + lateral plantar neuropathy + + + + obo:DDO.owl#DDO_0001508 + DDO:DDO_0001508 + + + + obo:DDO.owl#DDO_0001508 + 298133007 + + + + obo:DDO.owl#DDO_0001508 + medial plantar nerve lesion + + + + obo:DDO.owl#DDO_0001509 + DDO:DDO_0001509 + + + + obo:DDO.owl#DDO_0001509 + 212335005 + + + + obo:DDO.owl#DDO_0001509 + injury of medial plantar nerve + + + + obo:DDO.owl#DDO_0001510 + DDO:DDO_0001510 + + + + obo:DDO.owl#DDO_0001510 + 230644004 + + + + obo:DDO.owl#DDO_0001510 + medial plantar nerve compression + + + + obo:DDO.owl#DDO_0001511 + DDO:DDO_0001511 + + + + obo:DDO.owl#DDO_0001511 + 126989001 + + + + obo:DDO.owl#DDO_0001511 + neoplasm of peripheral nerves of lower limb + + + + obo:DDO.owl#DDO_0001512 + DDO:DDO_0001512 + + + + obo:DDO.owl#DDO_0001512 + 298130005 + + + + obo:DDO.owl#DDO_0001512 + obturator neuropathy + + + + obo:DDO.owl#DDO_0001513 + DDO:DDO_0001513 + + + + obo:DDO.owl#DDO_0001513 + 285601000 + + + + obo:DDO.owl#DDO_0001513 + obturator nerve injury + + + + obo:DDO.owl#DDO_0001514 + DDO:DDO_0001514 + + + + obo:DDO.owl#DDO_0001514 + 252794008 + + + + obo:DDO.owl#DDO_0001514 + obturator nerve paralysis + + + + obo:DDO.owl#DDO_0001515 + DDO:DDO_0001515 + + + + obo:DDO.owl#DDO_0001515 + 193148004 + + + + obo:DDO.owl#DDO_0001515 + plantar nerve lesion + + + + obo:DDO.owl#DDO_0001516 + DDO:DDO_0001516 + + + + obo:DDO.owl#DDO_0001516 + 30085007 + + + + obo:DDO.owl#DDO_0001516 + Morton's metatarsalgia + + + + obo:DDO.owl#DDO_0001517 + DDO:DDO_0001517 + + + + obo:DDO.owl#DDO_0001517 + 367137004 + + + + obo:DDO.owl#DDO_0001517 + sciatic nerve lesion + + + + obo:DDO.owl#DDO_0001518 + DDO:DDO_0001518 + + + + obo:DDO.owl#DDO_0001518 + 86269002 + + + + obo:DDO.owl#DDO_0001518 + injury of sciatic nerve + + + + obo:DDO.owl#DDO_0001519 + DDO:DDO_0001519 + + + + obo:DDO.owl#DDO_0001519 + 399233006 + + + + obo:DDO.owl#DDO_0001519 + tibial nerve lesion + + + + obo:DDO.owl#DDO_0001520 + DDO:DDO_0001520 + + + + obo:DDO.owl#DDO_0001520 + 81884004 + + + + obo:DDO.owl#DDO_0001520 + injury of tibial nerve + + + + obo:DDO.owl#DDO_0001521 + DDO:DDO_0001521 + + + + obo:DDO.owl#DDO_0001521 + 230643005 + + + + obo:DDO.owl#DDO_0001521 + tibial nerve compression + + + + obo:DDO.owl#DDO_0001522 + DDO:DDO_0001522 + + + + obo:DDO.owl#DDO_0001522 + 52585001 + + + + obo:DDO.owl#DDO_0001522 + sciatic neuropathy + + + + obo:DDO.owl#DDO_0001523 + DDO:DDO_0001523 + + + + obo:DDO.owl#DDO_0001523 + 86345004 + + + + obo:DDO.owl#DDO_0001523 + Bertolotti's syndrome + + + + obo:DDO.owl#DDO_0001524 + DDO:DDO_0001524 + + + + obo:DDO.owl#DDO_0001524 + 23056005 + + + + obo:DDO.owl#DDO_0001524 + sciatica + + + + obo:DDO.owl#DDO_0001525 + DDO:DDO_0001525 + + + + obo:DDO.owl#DDO_0001525 + 307176005 + + + + obo:DDO.owl#DDO_0001525 + acute sciatica + + + + obo:DDO.owl#DDO_0001526 + DDO:DDO_0001526 + + + + obo:DDO.owl#DDO_0001526 + 307177001 + + + + obo:DDO.owl#DDO_0001526 + chronic sciatica + + + + obo:DDO.owl#DDO_0001527 + DDO:DDO_0001527 + + + + obo:DDO.owl#DDO_0001527 + 129179000 + + + + obo:DDO.owl#DDO_0001527 + piriformis syndrome + + + + obo:DDO.owl#DDO_0001528 + DDO:DDO_0001528 + + + + obo:DDO.owl#DDO_0001528 + 54314008 + + + + obo:DDO.owl#DDO_0001528 + Putti-Chavany syndrome + + + + obo:DDO.owl#DDO_0001529 + DDO:DDO_0001529 + + + + obo:DDO.owl#DDO_0001529 + 128194008 + + + + obo:DDO.owl#DDO_0001529 + superficial peroneal neuropathy + + + + obo:DDO.owl#DDO_0001530 + DDO:DDO_0001530 + + + + obo:DDO.owl#DDO_0001530 + 426293000 + + + + obo:DDO.owl#DDO_0001530 + sural neuropathy + + + + obo:DDO.owl#DDO_0001531 + DDO:DDO_0001531 + + + + obo:DDO.owl#DDO_0001531 + 609605005 + + + + obo:DDO.owl#DDO_0001531 + sural neuropathy in calf + + + + obo:DDO.owl#DDO_0001532 + DDO:DDO_0001532 + + + + obo:DDO.owl#DDO_0001532 + tibial neuropathy + + + + obo:DDO.owl#DDO_0001533 + DDO:DDO_0001533 + + + + obo:DDO.owl#DDO_0001533 + 21361000119109 + + + + obo:DDO.owl#DDO_0001533 + paraneoplastic peripheral neuropathy + + + + obo:DDO.owl#DDO_0001534 + DDO:DDO_0001534 + + + + obo:DDO.owl#DDO_0001534 + 230666006 + + + + obo:DDO.owl#DDO_0001534 + paraneoplastic autonomic dysfunction + + + + obo:DDO.owl#DDO_0001535 + DDO:DDO_0001535 + + + + obo:DDO.owl#DDO_0001535 + 81634008 + + + + obo:DDO.owl#DDO_0001535 + perineurial cyst + + + + obo:DDO.owl#DDO_0001536 + DDO:DDO_0001536 + + + + obo:DDO.owl#DDO_0001536 + 23414001 + + + + obo:DDO.owl#DDO_0001536 + peripheral demyelinating neuropathy + + + + obo:DDO.owl#DDO_0001537 + DDO:DDO_0001537 + + + + obo:DDO.owl#DDO_0001537 + 26261000119109 + + + + obo:DDO.owl#DDO_0001537 + acute inflammatory demyelinating polyneuropathy + + + + obo:DDO.owl#DDO_0001538 + DDO:DDO_0001538 + + + + obo:DDO.owl#DDO_0001538 + 444728005 + + + + obo:DDO.owl#DDO_0001538 + chronic inflammatory demyelinating polyneuritis + + + + obo:DDO.owl#DDO_0001539 + DDO:DDO_0001539 + + + + obo:DDO.owl#DDO_0001539 + 128209004 + + + + obo:DDO.owl#DDO_0001539 + chronic inflammatory demyelinating polyradiculoneuropathy + + + + obo:DDO.owl#DDO_0001540 + DDO:DDO_0001540 + + + + obo:DDO.owl#DDO_0001540 + 230656003 + + + + obo:DDO.owl#DDO_0001540 + demyelinating sensorimotor neuropathy + + + + obo:DDO.owl#DDO_0001541 + DDO:DDO_0001541 + + + + obo:DDO.owl#DDO_0001541 + 40956001 + + + + obo:DDO.owl#DDO_0001541 + Guillain-Barré syndrome + + + + obo:DDO.owl#DDO_0001542 + DDO:DDO_0001542 + + + + obo:DDO.owl#DDO_0001542 + 277189006 + + + + obo:DDO.owl#DDO_0001542 + subacute inflammatory demyelinating polyradiculoneuropathy + + + + obo:DDO.owl#DDO_0001543 + DDO:DDO_0001543 + + + + obo:DDO.owl#DDO_0001543 + 73590005 + + + + obo:DDO.owl#DDO_0001543 + peripheral nerve injury + + + + obo:DDO.owl#DDO_0001544 + DDO:DDO_0001544 + + + + obo:DDO.owl#DDO_0001544 + 128192007 + + + + obo:DDO.owl#DDO_0001544 + peripheral neuritis + + + + obo:DDO.owl#DDO_0001545 + DDO:DDO_0001545 + + + + obo:DDO.owl#DDO_0001545 + 72893007 + + + + obo:DDO.owl#DDO_0001545 + brachial neuritis + + + + obo:DDO.owl#DDO_0001546 + DDO:DDO_0001546 + + + + obo:DDO.owl#DDO_0001546 + 27830001 + + + + obo:DDO.owl#DDO_0001546 + brachial radiculitis + + + + obo:DDO.owl#DDO_0001547 + DDO:DDO_0001547 + + + + obo:DDO.owl#DDO_0001547 + 609383005 + + + + obo:DDO.owl#DDO_0001547 + anterior interosseous neuritis + + + + obo:DDO.owl#DDO_0001548 + DDO:DDO_0001548 + + + + obo:DDO.owl#DDO_0001548 + 129667001 + + + + obo:DDO.owl#DDO_0001548 + diphtheritic peripheral neuritis + + + + obo:DDO.owl#DDO_0001549 + DDO:DDO_0001549 + + + + obo:DDO.owl#DDO_0001549 + 191471000 + + + + obo:DDO.owl#DDO_0001549 + Korsakov's alcoholic psychosis with peripheral neuritis + + + + obo:DDO.owl#DDO_0001550 + DDO:DDO_0001550 + + + + obo:DDO.owl#DDO_0001550 + 76462000 + + + + obo:DDO.owl#DDO_0001550 + post-herpetic polyneuropathy + + + + obo:DDO.owl#DDO_0001551 + DDO:DDO_0001551 + + + + obo:DDO.owl#DDO_0001551 + 58856009 + + + + obo:DDO.owl#DDO_0001551 + thoracic neuritis + + + + obo:DDO.owl#DDO_0001552 + DDO:DDO_0001552 + + + + obo:DDO.owl#DDO_0001552 + 95675005 + + + + obo:DDO.owl#DDO_0001552 + ulnar neuritis + + + + obo:DDO.owl#DDO_0001553 + DDO:DDO_0001553 + + + + obo:DDO.owl#DDO_0001553 + 128193002 + + + + obo:DDO.owl#DDO_0001553 + phrenic nerve disorder + + + + obo:DDO.owl#DDO_0001554 + DDO:DDO_0001554 + + + + obo:DDO.owl#DDO_0001554 + 277321001 + + + + obo:DDO.owl#DDO_0001554 + phrenic nerve lesion + + + + obo:DDO.owl#DDO_0001555 + DDO:DDO_0001555 + + + + obo:DDO.owl#DDO_0001555 + 206233005 + + + + obo:DDO.owl#DDO_0001555 + birth injury to phrenic nerve + + + + obo:DDO.owl#DDO_0001556 + DDO:DDO_0001556 + + + + obo:DDO.owl#DDO_0001556 + 428199000 + + + + obo:DDO.owl#DDO_0001556 + crush injury of phrenic nerve + + + + obo:DDO.owl#DDO_0001557 + DDO:DDO_0001557 + + + + obo:DDO.owl#DDO_0001557 + 315056009 + + + + obo:DDO.owl#DDO_0001557 + pudendal nerve neuropathy + + + + obo:DDO.owl#DDO_0001558 + DDO:DDO_0001558 + + + + obo:DDO.owl#DDO_0001558 + 285600004 + + + + obo:DDO.owl#DDO_0001558 + pudendal nerve injury + + + + obo:DDO.owl#DDO_0001559 + DDO:DDO_0001559 + + + + obo:DDO.owl#DDO_0001559 + 427972000 + + + + obo:DDO.owl#DDO_0001559 + pudendal neuralgia + + + + obo:DDO.owl#DDO_0001560 + DDO:DDO_0001560 + + + + obo:DDO.owl#DDO_0001560 + 298137008 + + + + obo:DDO.owl#DDO_0001560 + thoracoabdominal neuropathy + + + + obo:DDO.owl#DDO_0001561 + DDO:DDO_0001561 + + + + obo:DDO.owl#DDO_0001561 + 6142004 + + + + obo:DDO.owl#DDO_0001561 + influenza + + + + obo:DDO.owl#DDO_0001562 + DDO:DDO_0001562 + + + + obo:DDO.owl#DDO_0001562 + 10685111000119102 + + + + obo:DDO.owl#DDO_0001562 + upper respiratory tract infection due to Influenza + + + + obo:DDO.owl#DDO_0001563 + DDO:DDO_0001563 + + + + obo:DDO.owl#DDO_0001563 + 195923003 + + + + obo:DDO.owl#DDO_0001563 + influenza with laryngitis + + + + obo:DDO.owl#DDO_0001564 + DDO:DDO_0001564 + + + + obo:DDO.owl#DDO_0001564 + 195924009 + + + + obo:DDO.owl#DDO_0001564 + influenza with pharyngitis + + + + obo:DDO.owl#DDO_0001565 + DDO:DDO_0001565 + + + + obo:DDO.owl#DDO_0001565 + 328531000119104 + + + + obo:DDO.owl#DDO_0001565 + upper respiratory tract infection due to Influenza A + + + + obo:DDO.owl#DDO_0001566 + DDO:DDO_0001566 + + + + obo:DDO.owl#DDO_0001566 + 142921000119103 + + + + obo:DDO.owl#DDO_0001566 + upper respiratory tract infection due to avian influenza + + + + obo:DDO.owl#DDO_0001567 + DDO:DDO_0001567 + + + + obo:DDO.owl#DDO_0001567 + 142941000119109 + + + + obo:DDO.owl#DDO_0001567 + upper respiratory tract infection due to H1N1 influenza + + + + obo:DDO.owl#DDO_0001568 + DDO:DDO_0001568 + + + + obo:DDO.owl#DDO_0001568 + 82272006 + + + + obo:DDO.owl#DDO_0001568 + cold + + + + obo:DDO.owl#DDO_0001569 + DDO:DDO_0001569 + + + + obo:DDO.owl#DDO_0001569 + inflammation + + + + obo:DDO.owl#DDO_0001570 + DDO:DDO_0001570 + + + + obo:DDO.owl#DDO_0001570 + 32398004 + + + + obo:DDO.owl#DDO_0001570 + bronchitis + + + + obo:DDO.owl#DDO_0001571 + DDO:DDO_0001571 + + + + obo:DDO.owl#DDO_0001571 + 10509002 + + + + obo:DDO.owl#DDO_0001571 + acute bronchitis + + + + obo:DDO.owl#DDO_0001572 + DDO:DDO_0001572 + + + + obo:DDO.owl#DDO_0001572 + 5505005 + + + + obo:DDO.owl#DDO_0001572 + acute bronchiolitis + + + + obo:DDO.owl#DDO_0001573 + DDO:DDO_0001573 + + + + obo:DDO.owl#DDO_0001573 + 195714005 + + + + obo:DDO.owl#DDO_0001573 + acute fibrinous bronchitis + + + + obo:DDO.owl#DDO_0001574 + DDO:DDO_0001574 + + + + obo:DDO.owl#DDO_0001574 + 312371005 + + + + obo:DDO.owl#DDO_0001574 + acute infective bronchitis + + + + obo:DDO.owl#DDO_0001575 + DDO:DDO_0001575 + + + + obo:DDO.owl#DDO_0001575 + 233598009 + + + + obo:DDO.owl#DDO_0001575 + acute bacterial bronchitis + + + + obo:DDO.owl#DDO_0001576 + DDO:DDO_0001576 + + + + obo:DDO.owl#DDO_0001576 + 233600003 + + + + obo:DDO.owl#DDO_0001576 + acute chlamydial bronchitis + + + + obo:DDO.owl#DDO_0001577 + DDO:DDO_0001577 + + + + obo:DDO.owl#DDO_0001577 + 195721005 + + + + obo:DDO.owl#DDO_0001577 + acute haemophilus influenzae bronchitis + + + + obo:DDO.owl#DDO_0001578 + DDO:DDO_0001578 + + + + obo:DDO.owl#DDO_0001578 + 195722003 + + + + obo:DDO.owl#DDO_0001578 + acute Moraxella catarrhalis bronchitis + + + + obo:DDO.owl#DDO_0001579 + DDO:DDO_0001579 + + + + obo:DDO.owl#DDO_0001579 + 195720006 + + + + obo:DDO.owl#DDO_0001579 + acute streptococcal bronchitis + + + + obo:DDO.owl#DDO_0001580 + DDO:DDO_0001580 + + + + obo:DDO.owl#DDO_0001580 + 195719000 + + + + obo:DDO.owl#DDO_0001580 + acute pneumococcal bronchitis + + + + obo:DDO.owl#DDO_0001581 + DDO:DDO_0001581 + + + + obo:DDO.owl#DDO_0001581 + 27836007 + + + + obo:DDO.owl#DDO_0001581 + pertussis + + + + obo:DDO.owl#DDO_0001582 + DDO:DDO_0001582 + + + + obo:DDO.owl#DDO_0001582 + 233599001 + + + + obo:DDO.owl#DDO_0001582 + acute mycoplasmal bronchitis + + + + obo:DDO.owl#DDO_0001583 + DDO:DDO_0001583 + + + + obo:DDO.owl#DDO_0001583 + 195717003 + + + + obo:DDO.owl#DDO_0001583 + acute purulent bronchitis + + + + obo:DDO.owl#DDO_0001584 + DDO:DDO_0001584 + + + + obo:DDO.owl#DDO_0001584 + 233601004 + + + + obo:DDO.owl#DDO_0001584 + acute viral bronchitis + + + + obo:DDO.owl#DDO_0001585 + DDO:DDO_0001585 + + + + obo:DDO.owl#DDO_0001585 + 275499005 + + + + obo:DDO.owl#DDO_0001585 + acute wheezy bronchitis + + + + obo:DDO.owl#DDO_0001586 + DDO:DDO_0001586 + + + + obo:DDO.owl#DDO_0001586 + 71186008 + + + + obo:DDO.owl#DDO_0001586 + croup + + + + obo:DDO.owl#DDO_0001587 + DDO:DDO_0001587 + + + + obo:DDO.owl#DDO_0001587 + 275495004 + + + + obo:DDO.owl#DDO_0001587 + acute fibrinous laryngotracheobronchitis + + + + obo:DDO.owl#DDO_0001588 + DDO:DDO_0001588 + + + + obo:DDO.owl#DDO_0001588 + 232430006 + + + + obo:DDO.owl#DDO_0001588 + recurrent allergic croup + + + + obo:DDO.owl#DDO_0001589 + DDO:DDO_0001589 + + + + obo:DDO.owl#DDO_0001589 + 22951000119104 + + + + obo:DDO.owl#DDO_0001589 + spasmodic croup + + + + obo:DDO.owl#DDO_0001590 + DDO:DDO_0001590 + + + + obo:DDO.owl#DDO_0001590 + 233799004 + + + + obo:DDO.owl#DDO_0001590 + acute toxic tracheobronchitis + + + + obo:DDO.owl#DDO_0001591 + DDO:DDO_0001591 + + + + obo:DDO.owl#DDO_0001591 + 111849006 + + + + obo:DDO.owl#DDO_0001591 + adenoviral bronchitis + + + + obo:DDO.owl#DDO_0001592 + DDO:DDO_0001592 + + + + obo:DDO.owl#DDO_0001592 + 13089009 + + + + obo:DDO.owl#DDO_0001592 + adenoviral bronchiolitis + + + + obo:DDO.owl#DDO_0001593 + DDO:DDO_0001593 + + + + obo:DDO.owl#DDO_0001593 + 58890000 + + + + obo:DDO.owl#DDO_0001593 + adenoviral bronchopneumonia + + + + obo:DDO.owl#DDO_0001594 + DDO:DDO_0001594 + + + + obo:DDO.owl#DDO_0001594 + 71255007 + + + + obo:DDO.owl#DDO_0001594 + adenoviral laryngotracheobronchitis + + + + obo:DDO.owl#DDO_0001595 + DDO:DDO_0001595 + + + + obo:DDO.owl#DDO_0001595 + 405720007 + + + + obo:DDO.owl#DDO_0001595 + allergic bronchitis + + + + obo:DDO.owl#DDO_0001596 + DDO:DDO_0001596 + + + + obo:DDO.owl#DDO_0001596 + 445058002 + + + + obo:DDO.owl#DDO_0001596 + Aspergillus bronchitis + + + + obo:DDO.owl#DDO_0001597 + DDO:DDO_0001597 + + + + obo:DDO.owl#DDO_0001597 + 405944004 + + + + obo:DDO.owl#DDO_0001597 + asthmatic bronchitis + + + + obo:DDO.owl#DDO_0001598 + DDO:DDO_0001598 + + + + obo:DDO.owl#DDO_0001598 + 4120002 + + + + obo:DDO.owl#DDO_0001598 + bronchiolitis + + + + obo:DDO.owl#DDO_0001599 + DDO:DDO_0001599 + + + + obo:DDO.owl#DDO_0001599 + 59903001 + + + + obo:DDO.owl#DDO_0001599 + acute obliterating bronchiolitis + + + + obo:DDO.owl#DDO_0001600 + DDO:DDO_0001600 + + + + obo:DDO.owl#DDO_0001600 + 13089009 + + + + obo:DDO.owl#DDO_0001600 + adenoviral bronchiolitis + + + + obo:DDO.owl#DDO_0001601 + DDO:DDO_0001601 + + + + obo:DDO.owl#DDO_0001601 + 10629191000119100 + + + + obo:DDO.owl#DDO_0001601 + bronchiolitis caused by influenza virus + + + + obo:DDO.owl#DDO_0001602 + DDO:DDO_0001602 + + + + obo:DDO.owl#DDO_0001602 + 52409006 + + + + obo:DDO.owl#DDO_0001602 + bronchiolitis exudativa + + + + obo:DDO.owl#DDO_0001603 + DDO:DDO_0001603 + + + + obo:DDO.owl#DDO_0001603 + 430476004 + + + + obo:DDO.owl#DDO_0001603 + diffuse panbronchiolitis + + + + obo:DDO.owl#DDO_0001604 + DDO:DDO_0001604 + + + + obo:DDO.owl#DDO_0001604 + 385479009 + + + + obo:DDO.owl#DDO_0001604 + follicular bronchiolitis + + + + obo:DDO.owl#DDO_0001605 + DDO:DDO_0001605 + + + + obo:DDO.owl#DDO_0001605 + 87695000 + + + + obo:DDO.owl#DDO_0001605 + necrotizing bronchiolitis + + + + obo:DDO.owl#DDO_0001606 + DDO:DDO_0001606 + + + + obo:DDO.owl#DDO_0001606 + 195738009 + + + + obo:DDO.owl#DDO_0001606 + obliterating fibrous bronchiolitis + + + + obo:DDO.owl#DDO_0001607 + DDO:DDO_0001607 + + + + obo:DDO.owl#DDO_0001607 + 40100001 + + + + obo:DDO.owl#DDO_0001607 + obliterative bronchiolitis + + + + obo:DDO.owl#DDO_0001608 + DDO:DDO_0001608 + + + + obo:DDO.owl#DDO_0001608 + 57089007 + + + + obo:DDO.owl#DDO_0001608 + respiratory syncytial virus bronchiolitis + + + + obo:DDO.owl#DDO_0001609 + DDO:DDO_0001609 + + + + obo:DDO.owl#DDO_0001609 + 396285007 + + + + obo:DDO.owl#DDO_0001609 + bronchopneumonia + + + + obo:DDO.owl#DDO_0001610 + DDO:DDO_0001610 + + + + obo:DDO.owl#DDO_0001610 + 123587001 + + + + obo:DDO.owl#DDO_0001610 + acute bronchopneumonia + + + + obo:DDO.owl#DDO_0001612 + DDO:DDO_0001612 + + + + obo:DDO.owl#DDO_0001612 + 396286008 + + + + obo:DDO.owl#DDO_0001612 + bilateral bronchopneumonia + + + + obo:DDO.owl#DDO_0001613 + DDO:DDO_0001613 + + + + obo:DDO.owl#DDO_0001613 + 181007 + + + + obo:DDO.owl#DDO_0001613 + hemorrhagic bronchopneumonia + + + + obo:DDO.owl#DDO_0001614 + DDO:DDO_0001614 + + + + obo:DDO.owl#DDO_0001614 + 31561003 + + + + obo:DDO.owl#DDO_0001614 + hypostatic bronchopneumonia + + + + obo:DDO.owl#DDO_0001615 + DDO:DDO_0001615 + + + + obo:DDO.owl#DDO_0001615 + 41269000 + + + + obo:DDO.owl#DDO_0001615 + Influenzal bronchopneumonia + + + + obo:DDO.owl#DDO_0001616 + DDO:DDO_0001616 + + + + obo:DDO.owl#DDO_0001616 + 123589003 + + + + obo:DDO.owl#DDO_0001616 + necrotizing bronchopneumonia + + + + obo:DDO.owl#DDO_0001617 + DDO:DDO_0001617 + + + + obo:DDO.owl#DDO_0001617 + 60485005 + + + + obo:DDO.owl#DDO_0001617 + pleurobronchopneumonia + + + + obo:DDO.owl#DDO_0001618 + DDO:DDO_0001618 + + + + obo:DDO.owl#DDO_0001618 + 64703005 + + + + obo:DDO.owl#DDO_0001618 + terminal bronchopneumonia + + + + obo:DDO.owl#DDO_0001619 + DDO:DDO_0001619 + + + + obo:DDO.owl#DDO_0001619 + 89549007 + + + + obo:DDO.owl#DDO_0001619 + catarrhal bronchitis + + + + obo:DDO.owl#DDO_0001620 + DDO:DDO_0001620 + + + + obo:DDO.owl#DDO_0001620 + 74417001 + + + + obo:DDO.owl#DDO_0001620 + mucopurulent chronic bronchitis + + + + obo:DDO.owl#DDO_0001622 + DDO:DDO_0001622 + + + + obo:DDO.owl#DDO_0001622 + 63480004 + + + + obo:DDO.owl#DDO_0001622 + chronic bronchitis + + + + obo:DDO.owl#DDO_0001623 + DDO:DDO_0001623 + + + + obo:DDO.owl#DDO_0001623 + 53926002 + + + + obo:DDO.owl#DDO_0001623 + croupous bronchitis + + + + obo:DDO.owl#DDO_0001624 + DDO:DDO_0001624 + + + + obo:DDO.owl#DDO_0001624 + 85915003 + + + + obo:DDO.owl#DDO_0001624 + laryngotracheobronchitis + + + + obo:DDO.owl#DDO_0001625 + DDO:DDO_0001625 + + + + obo:DDO.owl#DDO_0001625 + 71255007 + + + + obo:DDO.owl#DDO_0001625 + adenoviral laryngotracheobronchitis + + + + obo:DDO.owl#DDO_0001626 + DDO:DDO_0001626 + + + + obo:DDO.owl#DDO_0001626 + 73414003 + + + + obo:DDO.owl#DDO_0001626 + Haemophilus influenzae laryngotracheobronchitis + + + + obo:DDO.owl#DDO_0001627 + DDO:DDO_0001627 + + + + obo:DDO.owl#DDO_0001627 + 35377009 + + + + obo:DDO.owl#DDO_0001627 + parainfluenza virus laryngotracheobronchitis + + + + obo:DDO.owl#DDO_0001628 + DDO:DDO_0001628 + + + + obo:DDO.owl#DDO_0001628 + 72204002 + + + + obo:DDO.owl#DDO_0001628 + respiratory syncytial virus laryngotracheobronchitis + + + + obo:DDO.owl#DDO_0001629 + DDO:DDO_0001629 + + + + obo:DDO.owl#DDO_0001629 + 27475006 + + + + obo:DDO.owl#DDO_0001629 + parainfluenza virus bronchitis + + + + obo:DDO.owl#DDO_0001630 + DDO:DDO_0001630 + + + + obo:DDO.owl#DDO_0001630 + 55679008 + + + + obo:DDO.owl#DDO_0001630 + peribronchial pneumonia + + + + obo:DDO.owl#DDO_0001631 + DDO:DDO_0001631 + + + + obo:DDO.owl#DDO_0001631 + 40600002 + + + + obo:DDO.owl#DDO_0001631 + pneumococcal bronchitis + + + + obo:DDO.owl#DDO_0001632 + DDO:DDO_0001632 + + + + obo:DDO.owl#DDO_0001632 + 29591002 + + + + obo:DDO.owl#DDO_0001632 + purulent bronchitis + + + + obo:DDO.owl#DDO_0001633 + DDO:DDO_0001633 + + + + obo:DDO.owl#DDO_0001633 + 79479005 + + + + obo:DDO.owl#DDO_0001633 + respiratory syncytial virus bronchitis + + + + obo:DDO.owl#DDO_0001634 + DDO:DDO_0001634 + + + + obo:DDO.owl#DDO_0001634 + 65878001 + + + + obo:DDO.owl#DDO_0001634 + septic bronchitis + + + + obo:DDO.owl#DDO_0001635 + DDO:DDO_0001635 + + + + obo:DDO.owl#DDO_0001635 + 36426008 + + + + obo:DDO.owl#DDO_0001635 + subacute bronchitis + + + + obo:DDO.owl#DDO_0001636 + DDO:DDO_0001636 + + + + obo:DDO.owl#DDO_0001636 + 186178000 + + + + obo:DDO.owl#DDO_0001636 + tuberculosis of bronchus + + + + obo:DDO.owl#DDO_0001637 + DDO:DDO_0001637 + + + + obo:DDO.owl#DDO_0001637 + 16146001 + + + + obo:DDO.owl#DDO_0001637 + viral bronchitis + + + + obo:DDO.owl#DDO_0001638 + DDO:DDO_0001638 + + + + obo:DDO.owl#DDO_0001638 + tracheitis + + + + obo:DDO.owl#DDO_0001639 + DDO:DDO_0001639 + + + + obo:DDO.owl#DDO_0001639 + 26650005 + + + + obo:DDO.owl#DDO_0001639 + acute tracheitis + + + + obo:DDO.owl#DDO_0001640 + DDO:DDO_0001640 + + + + obo:DDO.owl#DDO_0001640 + 26650005 + + + + obo:DDO.owl#DDO_0001640 + catarrhal tracheitis + + + + obo:DDO.owl#DDO_0001641 + DDO:DDO_0001641 + + + + obo:DDO.owl#DDO_0001641 + 7457009 + + + + obo:DDO.owl#DDO_0001641 + chronic tracheitis + + + + obo:DDO.owl#DDO_0001642 + DDO:DDO_0001642 + + + + obo:DDO.owl#DDO_0001642 + 77668003 + + + + obo:DDO.owl#DDO_0001642 + isolated tracheal tuberculosis + + + + obo:DDO.owl#DDO_0001643 + DDO:DDO_0001643 + + + + obo:DDO.owl#DDO_0001643 + 55130001 + + + + obo:DDO.owl#DDO_0001643 + laryngotracheitis + + + + obo:DDO.owl#DDO_0001644 + DDO:DDO_0001644 + + + + obo:DDO.owl#DDO_0001644 + 195707008 + + + + obo:DDO.owl#DDO_0001644 + tracheopharyngitis + + + + obo:DDO.owl#DDO_0001645 + DDO:DDO_0001645 + + + + obo:DDO.owl#DDO_0001645 + 66011008 + + + + obo:DDO.owl#DDO_0001645 + viral tracheitis + + + + obo:DDO.owl#DDO_0001646 + DDO:DDO_0001646 + + + + obo:DDO.owl#DDO_0001646 + 64375000 + + + + obo:DDO.owl#DDO_0001646 + acute laryngotracheitis + + + + obo:DDO.owl#DDO_0001647 + DDO:DDO_0001647 + + + + obo:DDO.owl#DDO_0001647 + 83271005 + + + + obo:DDO.owl#DDO_0001647 + chronic laryngotracheitis + + + + obo:DDO.owl#DDO_0001648 + DDO:DDO_0001648 + + + + obo:DDO.owl#DDO_0001648 + 10809006 + + + + obo:DDO.owl#DDO_0001648 + parainfluenza virus laryngotracheitis + + + + obo:DDO.owl#DDO_0001649 + DDO:DDO_0001649 + + + + obo:DDO.owl#DDO_0001649 + 301824001 + + + + obo:DDO.owl#DDO_0001649 + acute viral laryngotracheitis + + + + obo:DDO.owl#DDO_0001650 + DDO:DDO_0001650 + + + + obo:DDO.owl#DDO_0001650 + 71255007 + + + + obo:DDO.owl#DDO_0001650 + adenoviral laryngotracheobronchitis + + + + obo:DDO.owl#DDO_0001651 + DDO:DDO_0001651 + + + + obo:DDO.owl#DDO_0001651 + 72204002 + + + + obo:DDO.owl#DDO_0001651 + respiratory syncytial virus laryngotracheobronchitis + + + + obo:DDO.owl#DDO_0001652 + DDO:DDO_0001652 + + + + obo:DDO.owl#DDO_0001652 + 34020007 + + + + obo:DDO.owl#DDO_0001652 + streptococcal pneumonia + + + + obo:DDO.owl#DDO_0001653 + DDO:DDO_0001653 + + + + obo:DDO.owl#DDO_0001653 + 10625671000119106 + + + + obo:DDO.owl#DDO_0001653 + bronchopneumonia due to Streptococcus + + + + obo:DDO.owl#DDO_0001654 + DDO:DDO_0001654 + + + + obo:DDO.owl#DDO_0001654 + 206284006 + + + + obo:DDO.owl#DDO_0001654 + congenital group A hemolytic streptococcal pneumonia + + + + obo:DDO.owl#DDO_0001655 + DDO:DDO_0001655 + + + + obo:DDO.owl#DDO_0001655 + 206285007 + + + + obo:DDO.owl#DDO_0001655 + congenital group B hemolytic streptococcal pneumonia + + + + obo:DDO.owl#DDO_0001656 + DDO:DDO_0001656 + + + + obo:DDO.owl#DDO_0001656 + 195886008 + + + + obo:DDO.owl#DDO_0001656 + Group B streptococcal pneumonia + + + + obo:DDO.owl#DDO_0001657 + DDO:DDO_0001657 + + + + obo:DDO.owl#DDO_0001657 + 233607000 + + + + obo:DDO.owl#DDO_0001657 + pneumococcal pneumonia + + + + obo:DDO.owl#DDO_0001658 + DDO:DDO_0001658 + + + + obo:DDO.owl#DDO_0001658 + 266350000 + + + + obo:DDO.owl#DDO_0001658 + pneumococcal lobar pneumonia + + + + obo:DDO.owl#DDO_0001659 + DDO:DDO_0001659 + + + + obo:DDO.owl#DDO_0001659 + 420787001 + + + + obo:DDO.owl#DDO_0001659 + pneumococcal pneumonia associated with AIDS + + + + obo:DDO.owl#DDO_0001660 + DDO:DDO_0001660 + + + + obo:DDO.owl#DDO_0001660 + 56717001 + + + + obo:DDO.owl#DDO_0001660 + tuberculosis + + + + obo:DDO.owl#DDO_0001661 + DDO:DDO_0001661 + + + + obo:DDO.owl#DDO_0001661 + 427099000 + + + + obo:DDO.owl#DDO_0001661 + active tuberculosis + + + + obo:DDO.owl#DDO_0001662 + DDO:DDO_0001662 + + + + obo:DDO.owl#DDO_0001662 + 240380008 + + + + obo:DDO.owl#DDO_0001662 + acute tuberculous ulcer + + + + obo:DDO.owl#DDO_0001663 + DDO:DDO_0001663 + + + + obo:DDO.owl#DDO_0001663 + 213580002 + + + + obo:DDO.owl#DDO_0001663 + Caseating tuberculoid granuloma + + + + obo:DDO.owl#DDO_0001664 + DDO:DDO_0001664 + + + + obo:DDO.owl#DDO_0001664 + 22990009 + + + + obo:DDO.owl#DDO_0001664 + chronic tuberculosis + + + + obo:DDO.owl#DDO_0001665 + DDO:DDO_0001665 + + + + obo:DDO.owl#DDO_0001665 + 71943007 + + + + obo:DDO.owl#DDO_0001665 + chronic granulomatous tuberculosis + + + + obo:DDO.owl#DDO_0001666 + DDO:DDO_0001666 + + + + obo:DDO.owl#DDO_0001666 + 62494007 + + + + obo:DDO.owl#DDO_0001666 + chronic miliary tuberculosis + + + + obo:DDO.owl#DDO_0001667 + DDO:DDO_0001667 + + + + obo:DDO.owl#DDO_0001667 + 32268008 + + + + obo:DDO.owl#DDO_0001667 + tuberculosis of bladder + + + + obo:DDO.owl#DDO_0001668 + DDO:DDO_0001668 + + + + obo:DDO.owl#DDO_0001668 + 37260006 + + + + obo:DDO.owl#DDO_0001668 + congenital tuberculosis + + + + obo:DDO.owl#DDO_0001669 + DDO:DDO_0001669 + + + + obo:DDO.owl#DDO_0001669 + 11999007 + + + + obo:DDO.owl#DDO_0001669 + inactive tuberculosis + + + + obo:DDO.owl#DDO_0001670 + DDO:DDO_0001670 + + + + obo:DDO.owl#DDO_0001670 + 707149004 + + + + obo:DDO.owl#DDO_0001670 + mycobacterial lymphadenitis + + + + obo:DDO.owl#DDO_0001671 + DDO:DDO_0001671 + + + + obo:DDO.owl#DDO_0001671 + 10893003 + + + + obo:DDO.owl#DDO_0001671 + tuberculous adenitis + + + + obo:DDO.owl#DDO_0001672 + DDO:DDO_0001672 + + + + obo:DDO.owl#DDO_0001672 + 441770001 + + + + obo:DDO.owl#DDO_0001672 + orificial tuberculosis + + + + obo:DDO.owl#DDO_0001673 + DDO:DDO_0001673 + + + + obo:DDO.owl#DDO_0001673 + 63309002 + + + + obo:DDO.owl#DDO_0001673 + primary tuberculosis + + + + obo:DDO.owl#DDO_0001674 + DDO:DDO_0001674 + + + + obo:DDO.owl#DDO_0001674 + 700272008 + + + + obo:DDO.owl#DDO_0001674 + respiratory tuberculosis + + + + obo:DDO.owl#DDO_0001675 + DDO:DDO_0001675 + + + + obo:DDO.owl#DDO_0001675 + 700273003 + + + + obo:DDO.owl#DDO_0001675 + isolated tracheobronchial tuberculosis + + + + obo:DDO.owl#DDO_0001676 + DDO:DDO_0001676 + + + + obo:DDO.owl#DDO_0001676 + 154283005 + + + + obo:DDO.owl#DDO_0001676 + pulmonary tuberculosis + + + + obo:DDO.owl#DDO_0001677 + DDO:DDO_0001677 + + + + obo:DDO.owl#DDO_0001677 + 15202009 + + + + obo:DDO.owl#DDO_0001677 + tuberculoma + + + + obo:DDO.owl#DDO_0001678 + DDO:DDO_0001678 + + + + obo:DDO.owl#DDO_0001678 + 446123007 + + + + obo:DDO.owl#DDO_0001678 + tuberculous abscess + + + + obo:DDO.owl#DDO_0001679 + DDO:DDO_0001679 + + + + obo:DDO.owl#DDO_0001679 + gastrointestinal infection + + + + obo:DDO.owl#DDO_0001680 + DDO:DDO_0001680 + + + + obo:DDO.owl#DDO_0001680 + 307759003 + + + + obo:DDO.owl#DDO_0001680 + Helicobacter pylori gastrointestinal tract infection + + + + obo:DDO.owl#DDO_0001681 + DDO:DDO_0001681 + + + + obo:DDO.owl#DDO_0001681 + 79740000 + + + + obo:DDO.owl#DDO_0001681 + oral candidiasis + + + + obo:DDO.owl#DDO_0001682 + DDO:DDO_0001682 + + + + obo:DDO.owl#DDO_0001682 + 95894002 + + + + obo:DDO.owl#DDO_0001682 + atrophic thrush + + + + obo:DDO.owl#DDO_0001683 + DDO:DDO_0001683 + + + + obo:DDO.owl#DDO_0001683 + 95893008 + + + + obo:DDO.owl#DDO_0001683 + pseudomembranous thrush + + + + obo:DDO.owl#DDO_0001684 + DDO:DDO_0001684 + + + + obo:DDO.owl#DDO_0001684 + liver infection + + + + obo:DDO.owl#DDO_0001685 + DDO:DDO_0001685 + + + + obo:DDO.owl#DDO_0001685 + 3738000 + + + + obo:DDO.owl#DDO_0001685 + viral hepatitis + + + + obo:DDO.owl#DDO_0001687 + DDO:DDO_0001687 + + + + obo:DDO.owl#DDO_0001687 + 50711007 + + + + obo:DDO.owl#DDO_0001687 + viral hepatitis C + + + + obo:DDO.owl#DDO_0001688 + DDO:DDO_0001688 + + + + obo:DDO.owl#DDO_0001688 + 235866006 + + + + obo:DDO.owl#DDO_0001688 + acute hepatitis C + + + + obo:DDO.owl#DDO_0001689 + DDO:DDO_0001689 + + + + obo:DDO.owl#DDO_0001689 + 128302006 + + + + obo:DDO.owl#DDO_0001689 + chronic hepatitis C + + + + obo:DDO.owl#DDO_0001690 + DDO:DDO_0001690 + + + + obo:DDO.owl#DDO_0001690 + 708198006 + + + + obo:DDO.owl#DDO_0001690 + chronic active hepatitis C + + + + obo:DDO.owl#DDO_0001691 + DDO:DDO_0001691 + + + + obo:DDO.owl#DDO_0001691 + 703866000 + + + + obo:DDO.owl#DDO_0001691 + chronic hepatitis C with stage 2 fibrosis + + + + obo:DDO.owl#DDO_0001693 + DDO:DDO_0001693 + + + + obo:DDO.owl#DDO_0001693 + 347891000119103 + + + + obo:DDO.owl#DDO_0001693 + chronic hepatitis C with stage 3 fibrosis + + + + obo:DDO.owl#DDO_0001694 + DDO:DDO_0001694 + + + + obo:DDO.owl#DDO_0001694 + 831000119103 + + + + obo:DDO.owl#DDO_0001694 + cirrhosis of liver due to chronic hepatitis C + + + + obo:DDO.owl#DDO_0001695 + DDO:DDO_0001695 + + + + obo:DDO.owl#DDO_0001695 + 278929008 + + + + obo:DDO.owl#DDO_0001695 + congenital hepatitis C infection + + + + obo:DDO.owl#DDO_0001696 + DDO:DDO_0001696 + + + + obo:DDO.owl#DDO_0001696 + 442374005 + + + + obo:DDO.owl#DDO_0001696 + hepatitis B and hepatitis C + + + + obo:DDO.owl#DDO_0001697 + DDO:DDO_0001697 + + + + obo:DDO.owl#DDO_0001697 + 702969000 + + + + obo:DDO.owl#DDO_0001697 + reactivation of hepatitis C viral hepatitis + + + + obo:DDO.owl#DDO_0001698 + DDO:DDO_0001698 + + + + obo:DDO.owl#DDO_0001698 + 186628001 + + + + obo:DDO.owl#DDO_0001698 + viral hepatitis C with coma + + + + obo:DDO.owl#DDO_0001700 + DDO:DDO_0001700 + + + + obo:DDO.owl#DDO_0001700 + 66071002 + + + + obo:DDO.owl#DDO_0001700 + viral hepatitis B + + + + obo:DDO.owl#DDO_0001701 + DDO:DDO_0001701 + + + + obo:DDO.owl#DDO_0001701 + 76795007 + + + + obo:DDO.owl#DDO_0001701 + acute type B viral hepatitis + + + + obo:DDO.owl#DDO_0001702 + DDO:DDO_0001702 + + + + obo:DDO.owl#DDO_0001702 + 13265006 + + + + obo:DDO.owl#DDO_0001702 + acute fulminating type B viral hepatitis + + + + obo:DDO.owl#DDO_0001703 + DDO:DDO_0001703 + + + + obo:DDO.owl#DDO_0001703 + 235864009 + + + + obo:DDO.owl#DDO_0001703 + acute hepatitis B with hepatitis D + + + + obo:DDO.owl#DDO_0001704 + DDO:DDO_0001704 + + + + obo:DDO.owl#DDO_0001704 + 53425008 + + + + obo:DDO.owl#DDO_0001704 + anicteric type B viral hepatitis + + + + obo:DDO.owl#DDO_0001705 + DDO:DDO_0001705 + + + + obo:DDO.owl#DDO_0001705 + 61977001 + + + + obo:DDO.owl#DDO_0001705 + chronic type B viral hepatitis + + + + obo:DDO.owl#DDO_0001706 + DDO:DDO_0001706 + + + + obo:DDO.owl#DDO_0001706 + 50167007 + + + + obo:DDO.owl#DDO_0001706 + chronic active type B viral hepatitis + + + + obo:DDO.owl#DDO_0001707 + DDO:DDO_0001707 + + + + obo:DDO.owl#DDO_0001707 + 1116000 + + + + obo:DDO.owl#DDO_0001707 + chronic aggressive type B viral hepatitis + + + + obo:DDO.owl#DDO_0001708 + DDO:DDO_0001708 + + + + obo:DDO.owl#DDO_0001708 + 38662009 + + + + obo:DDO.owl#DDO_0001708 + chronic persistent type B viral hepatitis + + + + obo:DDO.owl#DDO_0001709 + DDO:DDO_0001709 + + + + obo:DDO.owl#DDO_0001709 + 235869004 + + + + obo:DDO.owl#DDO_0001709 + chronic viral hepatitis B with hepatitis D + + + + obo:DDO.owl#DDO_0001710 + DDO:DDO_0001710 + + + + obo:DDO.owl#DDO_0001710 + 186639003 + + + + obo:DDO.owl#DDO_0001710 + chronic viral hepatitis B without delta-agent + + + + obo:DDO.owl#DDO_0001711 + DDO:DDO_0001711 + + + + obo:DDO.owl#DDO_0001711 + 60498001 + + + + obo:DDO.owl#DDO_0001711 + congenital viral hepatitis B infection + + + + obo:DDO.owl#DDO_0001712 + DDO:DDO_0001712 + + + + obo:DDO.owl#DDO_0001712 + 29062009 + + + + obo:DDO.owl#DDO_0001712 + relapsing type B viral hepatitis + + + + obo:DDO.owl#DDO_0001713 + DDO:DDO_0001713 + + + + obo:DDO.owl#DDO_0001713 + 111891008 + + + + obo:DDO.owl#DDO_0001713 + viral hepatitis B without hepatic coma + + + + obo:DDO.owl#DDO_0001714 + DDO:DDO_0001714 + + + + obo:DDO.owl#DDO_0001714 + 53648006 + + + + obo:DDO.owl#DDO_0001714 + enterovirus + + + + obo:DDO.owl#DDO_0001715 + DDO:DDO_0001715 + + + + obo:DDO.owl#DDO_0001715 + 81933004 + + + + obo:DDO.owl#DDO_0001715 + avian enterovirus + + + + obo:DDO.owl#DDO_0001716 + DDO:DDO_0001716 + + + + obo:DDO.owl#DDO_0001716 + 41024002 + + + + obo:DDO.owl#DDO_0001716 + bovine enterovirus + + + + obo:DDO.owl#DDO_0001717 + DDO:DDO_0001717 + + + + obo:DDO.owl#DDO_0001717 + 49018005 + + + + obo:DDO.owl#DDO_0001717 + human coxsackievirus B + + + + obo:DDO.owl#DDO_0001718 + DDO:DDO_0001718 + + + + obo:DDO.owl#DDO_0001718 + 39164004 + + + + obo:DDO.owl#DDO_0001718 + human echovirus + + + + obo:DDO.owl#DDO_0001719 + DDO:DDO_0001719 + + + + obo:DDO.owl#DDO_0001719 + 69239002 + + + + obo:DDO.owl#DDO_0001719 + human enterovirus + + + + obo:DDO.owl#DDO_0001720 + DDO:DDO_0001720 + + + + obo:DDO.owl#DDO_0001720 + 57757007 + + + + obo:DDO.owl#DDO_0001720 + human coxsackievirus + + + + obo:DDO.owl#DDO_0001721 + DDO:DDO_0001721 + + + + obo:DDO.owl#DDO_0001721 + 44172002 + + + + obo:DDO.owl#DDO_0001721 + human poliovirus + + + + obo:DDO.owl#DDO_0001722 + DDO:DDO_0001722 + + + + obo:DDO.owl#DDO_0001722 + 1838001 + + + + obo:DDO.owl#DDO_0001722 + Human rhinovirus + + + + obo:DDO.owl#DDO_0001723 + DDO:DDO_0001723 + + + + obo:DDO.owl#DDO_0001723 + 4235009 + + + + obo:DDO.owl#DDO_0001723 + porcine enterovirus + + + + obo:DDO.owl#DDO_0001724 + DDO:DDO_0001724 + + + + obo:DDO.owl#DDO_0001724 + 36026003 + + + + obo:DDO.owl#DDO_0001724 + Simian enterovirus + + + + obo:DDO.owl#DDO_0001725 + DDO:DDO_0001725 + + + + obo:DDO.owl#DDO_0001725 + skin and soft tissue infection + + + + obo:DDO.owl#DDO_0001726 + DDO:DDO_0001726 + + + + obo:DDO.owl#DDO_0001726 + 299990002 + + + + obo:DDO.owl#DDO_0001726 + foot infection + + + + obo:DDO.owl#DDO_0001728 + DDO:DDO_0001728 + + + + obo:DDO.owl#DDO_0001728 + 240142002 + + + + obo:DDO.owl#DDO_0001728 + acute osteomyelitis of foot + + + + obo:DDO.owl#DDO_0001729 + DDO:DDO_0001729 + + + + obo:DDO.owl#DDO_0001729 + 203174008 + + + + obo:DDO.owl#DDO_0001729 + acute osteomyelitis-calcaneum + + + + obo:DDO.owl#DDO_0001730 + DDO:DDO_0001730 + + + + obo:DDO.owl#DDO_0001730 + 203177001 + + + + obo:DDO.owl#DDO_0001730 + acute osteomyelitis-metatarsal + + + + obo:DDO.owl#DDO_0001731 + DDO:DDO_0001731 + + + + obo:DDO.owl#DDO_0001731 + 203178006 + + + + obo:DDO.owl#DDO_0001731 + acute osteomyelitis-phalanx of toe + + + + obo:DDO.owl#DDO_0001732 + DDO:DDO_0001732 + + + + obo:DDO.owl#DDO_0001732 + 203175009 + + + + obo:DDO.owl#DDO_0001732 + acute osteomyelitis-talus + + + + obo:DDO.owl#DDO_0001733 + DDO:DDO_0001733 + + + + obo:DDO.owl#DDO_0001733 + 78561001 + + + + obo:DDO.owl#DDO_0001733 + blister of foot with infection + + + + obo:DDO.owl#DDO_0001734 + DDO:DDO_0001734 + + + + obo:DDO.owl#DDO_0001734 + 271191007 + + + + obo:DDO.owl#DDO_0001734 + traumatic blister of foot, infected + + + + obo:DDO.owl#DDO_0001735 + DDO:DDO_0001735 + + + + obo:DDO.owl#DDO_0001735 + 275444001 + + + + obo:DDO.owl#DDO_0001735 + traumatic blister of heel, infected + + + + obo:DDO.owl#DDO_0001736 + DDO:DDO_0001736 + + + + obo:DDO.owl#DDO_0001736 + 271192000 + + + + obo:DDO.owl#DDO_0001736 + traumatic blister of toe, infected + + + + obo:DDO.owl#DDO_0001737 + DDO:DDO_0001737 + + + + obo:DDO.owl#DDO_0001737 + 18929007 + + + + obo:DDO.owl#DDO_0001737 + carbuncle of foot + + + + obo:DDO.owl#DDO_0001738 + DDO:DDO_0001738 + + + + obo:DDO.owl#DDO_0001738 + 1197005 + + + + obo:DDO.owl#DDO_0001738 + carbuncle of heel + + + + obo:DDO.owl#DDO_0001739 + DDO:DDO_0001739 + + + + obo:DDO.owl#DDO_0001739 + 52508001 + + + + obo:DDO.owl#DDO_0001739 + carbuncle of toe + + + + obo:DDO.owl#DDO_0001740 + DDO:DDO_0001740 + + + + obo:DDO.owl#DDO_0001740 + 240147008 + + + + obo:DDO.owl#DDO_0001740 + chronic osteomyelitis of foot + + + + obo:DDO.owl#DDO_0001741 + DDO:DDO_0001741 + + + + obo:DDO.owl#DDO_0001741 + 295841000119100 + + + + obo:DDO.owl#DDO_0001741 + chronic osteomyelitis of foot with draining sinus + + + + obo:DDO.owl#DDO_0001742 + DDO:DDO_0001742 + + + + obo:DDO.owl#DDO_0001742 + 266108008 + + + + obo:DDO.owl#DDO_0001742 + enteroviral vesicular stomatitis with exanthem + + + + obo:DDO.owl#DDO_0001743 + DDO:DDO_0001743 + + + + obo:DDO.owl#DDO_0001743 + 44361004 + + + + obo:DDO.owl#DDO_0001743 + furuncle of foot + + + + obo:DDO.owl#DDO_0001744 + DDO:DDO_0001744 + + + + obo:DDO.owl#DDO_0001744 + 36175004 + + + + obo:DDO.owl#DDO_0001744 + furuncle of heel + + + + obo:DDO.owl#DDO_0001745 + DDO:DDO_0001745 + + + + obo:DDO.owl#DDO_0001745 + 77265008 + + + + obo:DDO.owl#DDO_0001745 + furuncle of toe + + + + obo:DDO.owl#DDO_0001746 + DDO:DDO_0001746 + + + + obo:DDO.owl#DDO_0001746 + 186423003 + + + + obo:DDO.owl#DDO_0001746 + gas gangrene of foot + + + + obo:DDO.owl#DDO_0001747 + DDO:DDO_0001747 + + + + obo:DDO.owl#DDO_0001747 + 402933000 + + + + obo:DDO.owl#DDO_0001747 + Gram-negative infection of toe web + + + + obo:DDO.owl#DDO_0001748 + DDO:DDO_0001748 + + + + obo:DDO.owl#DDO_0001748 + 300945001 + + + + obo:DDO.owl#DDO_0001748 + infected heel + + + + obo:DDO.owl#DDO_0001749 + DDO:DDO_0001749 + + + + obo:DDO.owl#DDO_0001749 + 283353003 + + + + obo:DDO.owl#DDO_0001749 + infected insect bite of dorsum of foot + + + + obo:DDO.owl#DDO_0001750 + DDO:DDO_0001750 + + + + obo:DDO.owl#DDO_0001750 + 203235009 + + + + obo:DDO.owl#DDO_0001750 + infection of calcaneum + + + + obo:DDO.owl#DDO_0001751 + DDO:DDO_0001751 + + + + obo:DDO.owl#DDO_0001751 + 203174008 + + + + obo:DDO.owl#DDO_0001751 + acute osteomyelitis-calcaneum + + + + obo:DDO.owl#DDO_0001752 + DDO:DDO_0001752 + + + + obo:DDO.owl#DDO_0001752 + 419100001 + + + + obo:DDO.owl#DDO_0001752 + infection of foot associated with diabetes + + + + obo:DDO.owl#DDO_0001753 + DDO:DDO_0001753 + + + + obo:DDO.owl#DDO_0001753 + cellulitis in diabetic foot + + + + obo:DDO.owl#DDO_0001753 + cellulitis in diabetic foot + + + + obo:DDO.owl#DDO_0001754 + DDO:DDO_0001754 + + + + obo:DDO.owl#DDO_0001754 + 203238006 + + + + obo:DDO.owl#DDO_0001754 + infection of metatarsal + + + + obo:DDO.owl#DDO_0001755 + DDO:DDO_0001755 + + + + obo:DDO.owl#DDO_0001755 + 203177001 + + + + obo:DDO.owl#DDO_0001755 + acute osteomyelitis-metatarsal + + + + obo:DDO.owl#DDO_0001756 + DDO:DDO_0001756 + + + + obo:DDO.owl#DDO_0001756 + 203236005 + + + + obo:DDO.owl#DDO_0001756 + infection of talus + + + + obo:DDO.owl#DDO_0001757 + DDO:DDO_0001757 + + + + obo:DDO.owl#DDO_0001757 + 203175009 + + + + obo:DDO.owl#DDO_0001757 + acute osteomyelitis-talus + + + + obo:DDO.owl#DDO_0001758 + DDO:DDO_0001758 + + + + obo:DDO.owl#DDO_0001758 + 299989006 + + + + obo:DDO.owl#DDO_0001758 + infection of toe + + + + obo:DDO.owl#DDO_0001759 + DDO:DDO_0001759 + + + + obo:DDO.owl#DDO_0001759 + 15290006 + + + + obo:DDO.owl#DDO_0001759 + blister of toe with infection + + + + obo:DDO.owl#DDO_0001760 + DDO:DDO_0001760 + + + + obo:DDO.owl#DDO_0001760 + 309462008 + + + + obo:DDO.owl#DDO_0001760 + infection of big toe + + + + obo:DDO.owl#DDO_0001762 + DDO:DDO_0001762 + + + + obo:DDO.owl#DDO_0001762 + 448454005 + + + + obo:DDO.owl#DDO_0001762 + infective arthritis of first metatarsophalangeal joint + + + + obo:DDO.owl#DDO_0001763 + DDO:DDO_0001763 + + + + obo:DDO.owl#DDO_0001763 + 203239003 + + + + obo:DDO.owl#DDO_0001763 + infection of phalanx of toe + + + + obo:DDO.owl#DDO_0001764 + DDO:DDO_0001764 + + + + obo:DDO.owl#DDO_0001764 + 203178006 + + + + obo:DDO.owl#DDO_0001764 + acute osteomyelitis-phalanx of toe + + + + obo:DDO.owl#DDO_0001765 + DDO:DDO_0001765 + + + + obo:DDO.owl#DDO_0001765 + 10677511000119107 + + + + obo:DDO.owl#DDO_0001765 + infection of toenail + + + + obo:DDO.owl#DDO_0001766 + DDO:DDO_0001766 + + + + obo:DDO.owl#DDO_0001766 + 403059006 + + + + obo:DDO.owl#DDO_0001766 + onychomycosis of toenails + + + + obo:DDO.owl#DDO_0001767 + DDO:DDO_0001767 + + + + obo:DDO.owl#DDO_0001767 + 448393000 + + + + obo:DDO.owl#DDO_0001767 + infective arthritis of interphalangeal joint of toe + + + + obo:DDO.owl#DDO_0001768 + DDO:DDO_0001768 + + + + obo:DDO.owl#DDO_0001768 + 449070007 + + + + obo:DDO.owl#DDO_0001768 + infective arthritis of metatarsophalangeal joint of lesser toe + + + + obo:DDO.owl#DDO_0001769 + DDO:DDO_0001769 + + + + obo:DDO.owl#DDO_0001769 + 388983002 + + + + obo:DDO.owl#DDO_0001769 + paronychia of toe + + + + obo:DDO.owl#DDO_0001770 + DDO:DDO_0001770 + + + + obo:DDO.owl#DDO_0001770 + 200641008 + + + + obo:DDO.owl#DDO_0001770 + pulp space infection of toe + + + + obo:DDO.owl#DDO_0001771 + DDO:DDO_0001771 + + + + obo:DDO.owl#DDO_0001771 + 211433002 + + + + obo:DDO.owl#DDO_0001771 + splinter of toe, without major open wound, infected + + + + obo:DDO.owl#DDO_0001772 + DDO:DDO_0001772 + + + + obo:DDO.owl#DDO_0001772 + 14158003 + + + + obo:DDO.owl#DDO_0001772 + superficial injury of toe with infection + + + + obo:DDO.owl#DDO_0001773 + DDO:DDO_0001773 + + + + obo:DDO.owl#DDO_0001773 + 17384006 + + + + obo:DDO.owl#DDO_0001773 + nonvenomous insect bite of toe with infection + + + + obo:DDO.owl#DDO_0001774 + DDO:DDO_0001774 + + + + obo:DDO.owl#DDO_0001774 + 402909006 + + + + obo:DDO.owl#DDO_0001774 + viral wart on toe + + + + obo:DDO.owl#DDO_0001775 + DDO:DDO_0001775 + + + + obo:DDO.owl#DDO_0001775 + 238409008 + + + + obo:DDO.owl#DDO_0001775 + infection of toe web + + + + obo:DDO.owl#DDO_0001776 + DDO:DDO_0001776 + + + + obo:DDO.owl#DDO_0001776 + 95881004 + + + + obo:DDO.owl#DDO_0001776 + mycetoma of foot + + + + obo:DDO.owl#DDO_0001778 + DDO:DDO_0001778 + + + + obo:DDO.owl#DDO_0001778 + 203018002 + + + + obo:DDO.owl#DDO_0001778 + infective myositis of foot + + + + obo:DDO.owl#DDO_0001779 + DDO:DDO_0001779 + + + + obo:DDO.owl#DDO_0001779 + 186397005 + + + + obo:DDO.owl#DDO_0001779 + actinomycotic madura foot + + + + obo:DDO.owl#DDO_0001780 + DDO:DDO_0001780 + + + + obo:DDO.owl#DDO_0001780 + 38700005 + + + + obo:DDO.owl#DDO_0001780 + Madura foot due to Actinomadura pelletieri + + + + obo:DDO.owl#DDO_0001781 + DDO:DDO_0001781 + + + + obo:DDO.owl#DDO_0001781 + 26067004 + + + + obo:DDO.owl#DDO_0001781 + Madura foot due to Streptomyces + + + + obo:DDO.owl#DDO_0001782 + DDO:DDO_0001782 + + + + obo:DDO.owl#DDO_0001782 + 410040001 + + + + obo:DDO.owl#DDO_0001782 + eumycotic mycetoma of foot + + + + obo:DDO.owl#DDO_0001783 + DDO:DDO_0001783 + + + + obo:DDO.owl#DDO_0001783 + 703736001 + + + + obo:DDO.owl#DDO_0001783 + non-union of joint of foot with infection + + + + obo:DDO.owl#DDO_0001784 + DDO:DDO_0001784 + + + + obo:DDO.owl#DDO_0001784 + 801006 + + + + obo:DDO.owl#DDO_0001784 + nonvenomous insect bite of foot with infection + + + + obo:DDO.owl#DDO_0001785 + DDO:DDO_0001785 + + + + obo:DDO.owl#DDO_0001785 + 705059000 + + + + obo:DDO.owl#DDO_0001785 + osteomyelitis of forefoot + + + + obo:DDO.owl#DDO_0001786 + DDO:DDO_0001786 + + + + obo:DDO.owl#DDO_0001786 + 203177001 + + + + obo:DDO.owl#DDO_0001786 + acute osteomyelitis-metatarsal + + + + obo:DDO.owl#DDO_0001787 + DDO:DDO_0001787 + + + + obo:DDO.owl#DDO_0001787 + 203178006 + + + + obo:DDO.owl#DDO_0001787 + acute osteomyelitis-phalanx of toe + + + + obo:DDO.owl#DDO_0001788 + DDO:DDO_0001788 + + + + obo:DDO.owl#DDO_0001788 + 700440007 + + + + obo:DDO.owl#DDO_0001788 + osteomyelitis of hindfoot + + + + obo:DDO.owl#DDO_0001789 + DDO:DDO_0001789 + + + + obo:DDO.owl#DDO_0001789 + 700439005 + + + + obo:DDO.owl#DDO_0001789 + osteomyelitis of midfoot + + + + obo:DDO.owl#DDO_0001790 + DDO:DDO_0001790 + + + + obo:DDO.owl#DDO_0001790 + 61251002 + + + + obo:DDO.owl#DDO_0001790 + plantar hyperkeratosis of yaws + + + + obo:DDO.owl#DDO_0001791 + DDO:DDO_0001791 + + + + obo:DDO.owl#DDO_0001791 + 83448006 + + + + obo:DDO.owl#DDO_0001791 + plantar papilloma of yaws + + + + obo:DDO.owl#DDO_0001792 + DDO:DDO_0001792 + + + + obo:DDO.owl#DDO_0001792 + 6861003 + + + + obo:DDO.owl#DDO_0001792 + pyogenic arthritis of foot + + + + obo:DDO.owl#DDO_0001793 + DDO:DDO_0001793 + + + + obo:DDO.owl#DDO_0001793 + tinea pedis + + + + obo:DDO.owl#DDO_0001794 + DDO:DDO_0001794 + + + + obo:DDO.owl#DDO_0001794 + 63440008 + + + + obo:DDO.owl#DDO_0001794 + verruca plantaris + + + + obo:DDO.owl#DDO_0001795 + DDO:DDO_0001795 + + + + obo:DDO.owl#DDO_0001795 + 240540003 + + + + obo:DDO.owl#DDO_0001795 + mosaic plantar wart + + + + obo:DDO.owl#DDO_0001796 + DDO:DDO_0001796 + + + + obo:DDO.owl#DDO_0001796 + 240541004 + + + + obo:DDO.owl#DDO_0001796 + myrmecia plantar wart + + + + obo:DDO.owl#DDO_0001797 + DDO:DDO_0001797 + + + + obo:DDO.owl#DDO_0001797 + 52486002 + + + + obo:DDO.owl#DDO_0001797 + necrotizing fasciitis + + + + obo:DDO.owl#DDO_0001798 + DDO:DDO_0001798 + + + + obo:DDO.owl#DDO_0001798 + 238399000 + + + + obo:DDO.owl#DDO_0001798 + necrotizing fasciitis of scrotum and perineum + + + + obo:DDO.owl#DDO_0001799 + DDO:DDO_0001799 + + + + obo:DDO.owl#DDO_0001799 + 236782005 + + + + obo:DDO.owl#DDO_0001799 + Fournier's gangrene of scrotum + + + + obo:DDO.owl#DDO_0001800 + DDO:DDO_0001800 + + + + obo:DDO.owl#DDO_0001800 + 402926000 + + + + obo:DDO.owl#DDO_0001800 + neonatal necrotizing fasciitis + + + + obo:DDO.owl#DDO_0001801 + DDO:DDO_0001801 + + + + obo:DDO.owl#DDO_0001801 + 449900006 + + + + obo:DDO.owl#DDO_0001801 + streptococcal necrotizing fasciitis + + + + obo:DDO.owl#DDO_0001802 + DDO:DDO_0001802 + + + + obo:DDO.owl#DDO_0001802 + 398318005 + + + + obo:DDO.owl#DDO_0001802 + Fournier's gangrene + + + + obo:DDO.owl#DDO_0001803 + DDO:DDO_0001803 + + + + obo:DDO.owl#DDO_0001803 + 397900003 + + + + obo:DDO.owl#DDO_0001803 + Fournier's gangrene of penis + + + + obo:DDO.owl#DDO_0001804 + DDO:DDO_0001804 + + + + obo:DDO.owl#DDO_0001804 + 236782005 + + + + obo:DDO.owl#DDO_0001804 + Fournier's gangrene of scrotum + + + + obo:DDO.owl#DDO_0001805 + DDO:DDO_0001805 + + + + obo:DDO.owl#DDO_0001805 + head and neck infection + + + + obo:DDO.owl#DDO_0001806 + DDO:DDO_0001806 + + + + obo:DDO.owl#DDO_0001806 + 187100003 + + + + obo:DDO.owl#DDO_0001806 + rhinocerebral mucormycosis + + + + obo:DDO.owl#DDO_0001807 + DDO:DDO_0001807 + + + + obo:DDO.owl#DDO_0001807 + 232227002 + + + + obo:DDO.owl#DDO_0001807 + invasive otitis externa + + + + obo:DDO.owl#DDO_0001808 + DDO:DDO_0001808 + + + + obo:DDO.owl#DDO_0001808 + other infection + + + + obo:DDO.owl#DDO_0001809 + DDO:DDO_0001809 + + + + obo:DDO.owl#DDO_0001809 + 72621000119104 + + + + obo:DDO.owl#DDO_0001809 + human immunodeficiency virus + + + + obo:DDO.owl#DDO_0001810 + DDO:DDO_0001810 + + + + obo:DDO.owl#DDO_0001810 + 41565005 + + + + obo:DDO.owl#DDO_0001810 + periodontitis + + + + obo:DDO.owl#DDO_0001811 + DDO:DDO_0001811 + + + + obo:DDO.owl#DDO_0001811 + 91863007 + + + + obo:DDO.owl#DDO_0001811 + acute pericoronitis + + + + obo:DDO.owl#DDO_0001812 + DDO:DDO_0001812 + + + + obo:DDO.owl#DDO_0001812 + 21638000 + + + + obo:DDO.owl#DDO_0001812 + acute periodontitis + + + + obo:DDO.owl#DDO_0001813 + DDO:DDO_0001813 + + + + obo:DDO.owl#DDO_0001813 + 88071000 + + + + obo:DDO.owl#DDO_0001813 + acute apical periodontitis of pulpal origin + + + + obo:DDO.owl#DDO_0001814 + DDO:DDO_0001814 + + + + obo:DDO.owl#DDO_0001814 + 235010005 + + + + obo:DDO.owl#DDO_0001814 + acute necrotizing ulcerative periodontitis + + + + obo:DDO.owl#DDO_0001815 + DDO:DDO_0001815 + + + + obo:DDO.owl#DDO_0001815 + 74797001 + + + + obo:DDO.owl#DDO_0001815 + adult periodontitis + + + + obo:DDO.owl#DDO_0001816 + DDO:DDO_0001816 + + + + obo:DDO.owl#DDO_0001816 + 93462002 + + + + obo:DDO.owl#DDO_0001816 + generalized adult periodontitis + + + + obo:DDO.owl#DDO_0001817 + DDO:DDO_0001817 + + + + obo:DDO.owl#DDO_0001817 + 93164008 + + + + obo:DDO.owl#DDO_0001817 + localized adult periodontitis + + + + obo:DDO.owl#DDO_0001819 + DDO:DDO_0001819 + + + + obo:DDO.owl#DDO_0001819 + 449908004 + + + + obo:DDO.owl#DDO_0001819 + aggressive periodontitis + + + + obo:DDO.owl#DDO_0001820 + DDO:DDO_0001820 + + + + obo:DDO.owl#DDO_0001820 + 39273001 + + + + obo:DDO.owl#DDO_0001820 + apical periodontitis + + + + obo:DDO.owl#DDO_0001821 + DDO:DDO_0001821 + + + + obo:DDO.owl#DDO_0001821 + 88071000 + + + + obo:DDO.owl#DDO_0001821 + acute apical periodontitis of pulpal origin + + + + obo:DDO.owl#DDO_0001822 + DDO:DDO_0001822 + + + + obo:DDO.owl#DDO_0001822 + 87782002 + + + + obo:DDO.owl#DDO_0001822 + chronic apical periodontitis + + + + obo:DDO.owl#DDO_0001823 + DDO:DDO_0001823 + + + + obo:DDO.owl#DDO_0001823 + 89988002 + + + + obo:DDO.owl#DDO_0001823 + radicular cyst + + + + obo:DDO.owl#DDO_0001824 + DDO:DDO_0001824 + + + + obo:DDO.owl#DDO_0001824 + 234988003 + + + + obo:DDO.owl#DDO_0001824 + lateral radicular cyst + + + + obo:DDO.owl#DDO_0001825 + DDO:DDO_0001825 + + + + obo:DDO.owl#DDO_0001825 + 109608003 + + + + obo:DDO.owl#DDO_0001825 + residual cyst + + + + obo:DDO.owl#DDO_0001826 + DDO:DDO_0001826 + + + + obo:DDO.owl#DDO_0001826 + 5689008 + + + + obo:DDO.owl#DDO_0001826 + chronic periodontitis + + + + obo:DDO.owl#DDO_0001827 + DDO:DDO_0001827 + + + + obo:DDO.owl#DDO_0001827 + 196368005 + + + + obo:DDO.owl#DDO_0001827 + alveolar pyorrhea + + + + obo:DDO.owl#DDO_0001828 + DDO:DDO_0001828 + + + + obo:DDO.owl#DDO_0001828 + 87782002 + + + + obo:DDO.owl#DDO_0001828 + chronic apical periodontitis + + + + obo:DDO.owl#DDO_0001829 + DDO:DDO_0001829 + + + + obo:DDO.owl#DDO_0001829 + 196367000 + + + + obo:DDO.owl#DDO_0001829 + chronic periodontitis complex + + + + obo:DDO.owl#DDO_0001830 + DDO:DDO_0001830 + + + + obo:DDO.owl#DDO_0001830 + 196366009 + + + + obo:DDO.owl#DDO_0001830 + chronic periodontitis simplex + + + + obo:DDO.owl#DDO_0001831 + DDO:DDO_0001831 + + + + obo:DDO.owl#DDO_0001831 + 304989006 + + + + obo:DDO.owl#DDO_0001831 + chronic periodontitis with drifting of teeth + + + + obo:DDO.owl#DDO_0001832 + DDO:DDO_0001832 + + + + obo:DDO.owl#DDO_0001832 + 707251008 + + + + obo:DDO.owl#DDO_0001832 + generalized chronic periodontitis + + + + obo:DDO.owl#DDO_0001833 + DDO:DDO_0001833 + + + + obo:DDO.owl#DDO_0001833 + 707252001 + + + + obo:DDO.owl#DDO_0001833 + localized chronic periodontitis + + + + obo:DDO.owl#DDO_0001834 + DDO:DDO_0001834 + + + + obo:DDO.owl#DDO_0001834 + 235009000 + + + + obo:DDO.owl#DDO_0001834 + human immunodeficiency virus-associated periodontitis + + + + obo:DDO.owl#DDO_0001835 + DDO:DDO_0001835 + + + + obo:DDO.owl#DDO_0001835 + 49965002 + + + + obo:DDO.owl#DDO_0001835 + juvenile periodontitis + + + + obo:DDO.owl#DDO_0001836 + DDO:DDO_0001836 + + + + obo:DDO.owl#DDO_0001836 + 252283005 + + + + obo:DDO.owl#DDO_0001836 + marginal periodontitis + + + + obo:DDO.owl#DDO_0001837 + DDO:DDO_0001837 + + + + obo:DDO.owl#DDO_0001837 + 196368005 + + + + obo:DDO.owl#DDO_0001837 + alveolar pyorrhea + + + + obo:DDO.owl#DDO_0001838 + DDO:DDO_0001838 + + + + obo:DDO.owl#DDO_0001838 + 706984006 + + + + obo:DDO.owl#DDO_0001838 + necrotizing periodontal disease + + + + obo:DDO.owl#DDO_0001839 + DDO:DDO_0001839 + + + + obo:DDO.owl#DDO_0001839 + 707320004 + + + + obo:DDO.owl#DDO_0001839 + necrotizing ulcerative periodontitis + + + + obo:DDO.owl#DDO_0001840 + DDO:DDO_0001840 + + + + obo:DDO.owl#DDO_0001840 + 47548009 + + + + obo:DDO.owl#DDO_0001840 + necrotizing ulcerative gingivoperiodontitis + + + + obo:DDO.owl#DDO_0001841 + DDO:DDO_0001841 + + + + obo:DDO.owl#DDO_0001841 + 2624008 + + + + obo:DDO.owl#DDO_0001841 + prepubertal periodontitis + + + + obo:DDO.owl#DDO_0001842 + DDO:DDO_0001842 + + + + obo:DDO.owl#DDO_0001842 + 235007003 + + + + obo:DDO.owl#DDO_0001842 + early onset periodontitis + + + + obo:DDO.owl#DDO_0001843 + DDO:DDO_0001843 + + + + obo:DDO.owl#DDO_0001843 + 75891001 + + + + obo:DDO.owl#DDO_0001843 + rapidly progressive periodontitis + + + + obo:DDO.owl#DDO_0001844 + DDO:DDO_0001844 + + + + obo:DDO.owl#DDO_0001844 + 235008008 + + + + obo:DDO.owl#DDO_0001844 + refractory periodontitis + + + + obo:DDO.owl#DDO_0001845 + DDO:DDO_0001845 + + + + obo:DDO.owl#DDO_0001845 + 44772007 + + + + obo:DDO.owl#DDO_0001845 + maternal obesity syndrome + + + + obo:DDO.owl#DDO_0001855 + DDO:DDO_0001855 + + + + obo:DDO.owl#DDO_0001855 + 414916001 + + + + obo:DDO.owl#DDO_0001855 + adiposity + + + + obo:DDO.owl#DDO_0001855 + obesity + + + + obo:DDO.owl#DDO_0001856 + DDO:DDO_0001856 + + + + obo:DDO.owl#DDO_0001856 + 171000119107 + + + + obo:DDO.owl#DDO_0001856 + maternal obesity complicating pregnancy, childbirth and the puerperium, antepartum + + + + obo:DDO.owl#DDO_0001857 + DDO:DDO_0001857 + + + + obo:DDO.owl#DDO_0001857 + 80660001 + + + + obo:DDO.owl#DDO_0001857 + Mauriac's syndrome + + + + obo:DDO.owl#DDO_0001858 + DDO:DDO_0001858 + + + + obo:DDO.owl#DDO_0001858 + 238136002 + + + + obo:DDO.owl#DDO_0001858 + morbid obesity + + + + obo:DDO.owl#DDO_0001859 + DDO:DDO_0001859 + + + + obo:DDO.owl#DDO_0001859 + 190966007 + + + + obo:DDO.owl#DDO_0001859 + extreme obesity with alveolar hypoventilation + + + + obo:DDO.owl#DDO_0001860 + DDO:DDO_0001860 + + + + obo:DDO.owl#DDO_0001860 + 702949005 + + + + obo:DDO.owl#DDO_0001860 + proopiomelanocortin deficiency syndrome + + + + obo:DDO.owl#DDO_0001861 + DDO:DDO_0001861 + + + + obo:DDO.owl#DDO_0001861 + 414917005 + + + + obo:DDO.owl#DDO_0001861 + obesity by adipocyte growth pattern + + + + obo:DDO.owl#DDO_0001862 + DDO:DDO_0001862 + + + + obo:DDO.owl#DDO_0001862 + 414438005 + + + + obo:DDO.owl#DDO_0001862 + hyperplastic obesity + + + + obo:DDO.owl#DDO_0001863 + DDO:DDO_0001863 + + + + obo:DDO.owl#DDO_0001863 + 293481008 + + + + obo:DDO.owl#DDO_0001863 + hyperplastic-hypertrophic obesity + + + + obo:DDO.owl#DDO_0001864 + DDO:DDO_0001864 + + + + obo:DDO.owl#DDO_0001864 + 295509007 + + + + obo:DDO.owl#DDO_0001864 + hypertrophic obesity + + + + obo:DDO.owl#DDO_0001865 + DDO:DDO_0001865 + + + + obo:DDO.owl#DDO_0001865 + 414918000 + + + + obo:DDO.owl#DDO_0001865 + obesity by age of onset + + + + obo:DDO.owl#DDO_0001866 + DDO:DDO_0001866 + + + + obo:DDO.owl#DDO_0001866 + 296526005 + + + + obo:DDO.owl#DDO_0001866 + adult-onset obesity + + + + obo:DDO.owl#DDO_0001867 + DDO:DDO_0001867 + + + + obo:DDO.owl#DDO_0001867 + 444862003 + + + + obo:DDO.owl#DDO_0001867 + childhood obesity + + + + obo:DDO.owl#DDO_0001868 + DDO:DDO_0001868 + + + + obo:DDO.owl#DDO_0001868 + 294493008 + + + + obo:DDO.owl#DDO_0001868 + lifelong obesity + + + + obo:DDO.owl#DDO_0001870 + DDO:DDO_0001870 + + + + obo:DDO.owl#DDO_0001870 + 414919008 + + + + obo:DDO.owl#DDO_0001870 + obesity by contributing factors + + + + obo:DDO.owl#DDO_0001871 + DDO:DDO_0001871 + + + + obo:DDO.owl#DDO_0001871 + 292464007 + + + + obo:DDO.owl#DDO_0001871 + constitutional obesity + + + + obo:DDO.owl#DDO_0001872 + DDO:DDO_0001872 + + + + obo:DDO.owl#DDO_0001872 + 297500005 + + + + obo:DDO.owl#DDO_0001872 + endogenous obesity + + + + obo:DDO.owl#DDO_0001873 + DDO:DDO_0001873 + + + + obo:DDO.owl#DDO_0001873 + 298464002 + + + + obo:DDO.owl#DDO_0001873 + obesity of endocrine origin + + + + obo:DDO.owl#DDO_0001874 + DDO:DDO_0001874 + + + + obo:DDO.owl#DDO_0001874 + 360566006 + + + + obo:DDO.owl#DDO_0001874 + Buffalo obesity + + + + obo:DDO.owl#DDO_0001875 + DDO:DDO_0001875 + + + + obo:DDO.owl#DDO_0001875 + 111036000 + + + + obo:DDO.owl#DDO_0001875 + hyperinsulinar obesity + + + + obo:DDO.owl#DDO_0001876 + DDO:DDO_0001876 + + + + obo:DDO.owl#DDO_0001876 + 5036006 + + + + obo:DDO.owl#DDO_0001876 + hypogonadal obesity + + + + obo:DDO.owl#DDO_0001877 + DDO:DDO_0001877 + + + + obo:DDO.owl#DDO_0001877 + 82793005 + + + + obo:DDO.owl#DDO_0001877 + hypothalamic obesity + + + + obo:DDO.owl#DDO_0001878 + DDO:DDO_0001878 + + + + obo:DDO.owl#DDO_0001878 + 62999006 + + + + obo:DDO.owl#DDO_0001878 + adiposogenital dystrophy + + + + obo:DDO.owl#DDO_0001879 + DDO:DDO_0001879 + + + + obo:DDO.owl#DDO_0001879 + 53146006 + + + + obo:DDO.owl#DDO_0001879 + hypothyroid obesity + + + + obo:DDO.owl#DDO_0001880 + DDO:DDO_0001880 + + + + obo:DDO.owl#DDO_0001880 + 290439001 + + + + obo:DDO.owl#DDO_0001880 + familial obesity + + + + obo:DDO.owl#DDO_0001881 + DDO:DDO_0001881 + + + + obo:DDO.owl#DDO_0001881 + 414920002 + + + + obo:DDO.owl#DDO_0001881 + obesity by fat distribution pattern + + + + obo:DDO.owl#DDO_0001882 + DDO:DDO_0001882 + + + + obo:DDO.owl#DDO_0001882 + 360566006 + + + + obo:DDO.owl#DDO_0001882 + Buffalo obesity + + + + obo:DDO.owl#DDO_0001883 + DDO:DDO_0001883 + + + + obo:DDO.owl#DDO_0001883 + 248311001 + + + + obo:DDO.owl#DDO_0001883 + central obesity + + + + obo:DDO.owl#DDO_0001884 + DDO:DDO_0001884 + + + + obo:DDO.owl#DDO_0001884 + 238132000 + + + + obo:DDO.owl#DDO_0001884 + android obesity + + + + obo:DDO.owl#DDO_0001885 + DDO:DDO_0001885 + + + + obo:DDO.owl#DDO_0001885 + 238134004 + + + + obo:DDO.owl#DDO_0001885 + generalized obesity + + + + obo:DDO.owl#DDO_0001886 + DDO:DDO_0001886 + + + + obo:DDO.owl#DDO_0001886 + 270486005 + + + + obo:DDO.owl#DDO_0001886 + localized adiposity + + + + obo:DDO.owl#DDO_0001887 + DDO:DDO_0001887 + + + + obo:DDO.owl#DDO_0001887 + 238135003 + + + + obo:DDO.owl#DDO_0001887 + fat pad syndrome + + + + obo:DDO.owl#DDO_0001888 + DDO:DDO_0001888 + + + + obo:DDO.owl#DDO_0001888 + 72894001 + + + + obo:DDO.owl#DDO_0001888 + hypertrophy of fat pad of knee + + + + obo:DDO.owl#DDO_0001889 + DDO:DDO_0001889 + + + + obo:DDO.owl#DDO_0001889 + 57337005 + + + + obo:DDO.owl#DDO_0001889 + steatopygia + + + + obo:DDO.owl#DDO_0001890 + DDO:DDO_0001890 + + + + obo:DDO.owl#DDO_0001890 + 248312008 + + + + obo:DDO.owl#DDO_0001890 + peripheral obesity + + + + obo:DDO.owl#DDO_0001891 + DDO:DDO_0001891 + + + + obo:DDO.owl#DDO_0001891 + 238133005 + + + + obo:DDO.owl#DDO_0001891 + gynecoid obesity + + + + obo:DDO.owl#DDO_0001892 + DDO:DDO_0001892 + + + + obo:DDO.owl#DDO_0001892 + 10750551000119100 + + + + obo:DDO.owl#DDO_0001892 + obesity in mother complicating childbirth + + + + obo:DDO.owl#DDO_0001893 + DDO:DDO_0001893 + + + + obo:DDO.owl#DDO_0001893 + 415530009 + + + + obo:DDO.owl#DDO_0001893 + simple obesity + + + + obo:DDO.owl#DDO_0001894 + DDO:DDO_0001894 + + + + obo:DDO.owl#DDO_0001894 + 194842008 + + + + obo:DDO.owl#DDO_0001894 + single coronary vessel disease + + + + obo:DDO.owl#DDO_0001895 + DDO:DDO_0001895 + + + + obo:DDO.owl#DDO_0001895 + 371803003 + + + + obo:DDO.owl#DDO_0001895 + multi vessel coronary artery disease + + + + obo:DDO.owl#DDO_0001896 + DDO:DDO_0001896 + + + + obo:DDO.owl#DDO_0001896 + 420006002 + + + + obo:DDO.owl#DDO_0001896 + obliterative coronary artery disease + + + + obo:DDO.owl#DDO_0001897 + DDO:DDO_0001897 + + + + obo:DDO.owl#DDO_0001897 + 445898001 + + + + obo:DDO.owl#DDO_0001897 + abnormal atrial arrangement + + + + obo:DDO.owl#DDO_0001898 + DDO:DDO_0001898 + + + + obo:DDO.owl#DDO_0001898 + 253333008 + + + + obo:DDO.owl#DDO_0001898 + abnormal connection of hepatic vein to atrium + + + + obo:DDO.owl#DDO_0001899 + DDO:DDO_0001899 + + + + obo:DDO.owl#DDO_0001899 + 253542002 + + + + obo:DDO.owl#DDO_0001899 + abnormal left ventricular muscle band + + + + obo:DDO.owl#DDO_0001900 + DDO:DDO_0001900 + + + + obo:DDO.owl#DDO_0001900 + 78485007 + + + + obo:DDO.owl#DDO_0001900 + acyanotic congenital heart disease + + + + obo:DDO.owl#DDO_00019007 + DDO:DDO_00019007 + + + + obo:DDO.owl#DDO_00019007 + 235950005 + + + + obo:DDO.owl#DDO_00019007 + traumatic acute pancreatitis + + + + obo:DDO.owl#DDO_00019008 + DDO:DDO_00019008 + + + + obo:DDO.owl#DDO_00019008 + 235948002 + + + + obo:DDO.owl#DDO_00019008 + postoperative acute pancreatitis + + + + obo:DDO.owl#DDO_00019009 + DDO:DDO_00019009 + + + + obo:DDO.owl#DDO_00019009 + 277537008 + + + + obo:DDO.owl#DDO_00019009 + post-ERCP acute pancreatitis + + + + obo:DDO.owl#DDO_0001901 + DDO:DDO_0001901 + + + + obo:DDO.owl#DDO_0001901 + 422348008 + + + + obo:DDO.owl#DDO_0001901 + Andersen Tawil syndrome + + + + obo:DDO.owl#DDO_00019010 + DDO:DDO_00019010 + + + + obo:DDO.owl#DDO_00019010 + 235943006 + + + + obo:DDO.owl#DDO_00019010 + idiopathic acute pancreatitis + + + + obo:DDO.owl#DDO_00019011 + DDO:DDO_00019011 + + + + obo:DDO.owl#DDO_00019011 + 235941008 + + + + obo:DDO.owl#DDO_00019011 + gallstone acute pancreatitis + + + + obo:DDO.owl#DDO_00019012 + DDO:DDO_00019012 + + + + obo:DDO.owl#DDO_00019012 + 235949005 + + + + obo:DDO.owl#DDO_00019012 + familial acute pancreatitis + + + + obo:DDO.owl#DDO_00019013 + DDO:DDO_00019013 + + + + obo:DDO.owl#DDO_00019013 + 235942001 + + + + obo:DDO.owl#DDO_00019013 + alcohol-induced acute pancreatitis + + + + obo:DDO.owl#DDO_00019014 + DDO:DDO_00019014 + + + + obo:DDO.owl#DDO_00019014 + 235944000 + + + + obo:DDO.owl#DDO_00019014 + drug-induced acute pancreatitis + + + + obo:DDO.owl#DDO_00019015 + DDO:DDO_00019015 + + + + obo:DDO.owl#DDO_00019015 + 197458008 + + + + obo:DDO.owl#DDO_00019015 + acute recurrent pancreatitis + + + + obo:DDO.owl#DDO_00019016 + DDO:DDO_00019016 + + + + obo:DDO.owl#DDO_00019016 + 235947007 + + + + obo:DDO.owl#DDO_00019016 + cytomegaloviral pancreatitis + + + + obo:DDO.owl#DDO_00019017 + DDO:DDO_00019017 + + + + obo:DDO.owl#DDO_00019017 + 235946003 + + + + obo:DDO.owl#DDO_00019017 + viral acute pancreatitis + + + + obo:DDO.owl#DDO_00019018 + DDO:DDO_00019018 + + + + obo:DDO.owl#DDO_00019018 + 197460005 + + + + obo:DDO.owl#DDO_00019018 + acute suppurative pancreatitis + + + + obo:DDO.owl#DDO_00019019 + DDO:DDO_00019019 + + + + obo:DDO.owl#DDO_00019019 + 235945004 + + + + obo:DDO.owl#DDO_00019019 + acute pancreatitis due to infection + + + + obo:DDO.owl#DDO_0001902 + DDO:DDO_0001902 + + + + obo:DDO.owl#DDO_0001902 + 448619007 + + + + obo:DDO.owl#DDO_0001902 + anterior deviation of infundibular septum of Fallot type + + + + obo:DDO.owl#DDO_00019020 + DDO:DDO_00019020 + + + + obo:DDO.owl#DDO_00019020 + 96081000119101 + + + + obo:DDO.owl#DDO_00019020 + acute pancreatitis due to common bile duct calculus + + + + obo:DDO.owl#DDO_00019021 + DDO:DDO_00019021 + + + + obo:DDO.owl#DDO_00019021 + 7881005 + + + + obo:DDO.owl#DDO_00019021 + acute necrotizing pancreatitis + + + + obo:DDO.owl#DDO_00019022 + DDO:DDO_00019022 + + + + obo:DDO.owl#DDO_00019022 + 4399003 + + + + obo:DDO.owl#DDO_00019022 + acute hemorrhagic pancreatitis + + + + obo:DDO.owl#DDO_0001903 + DDO:DDO_0001903 + + + + obo:DDO.owl#DDO_0001903 + 253650001 + + + + obo:DDO.owl#DDO_0001903 + aorta to right ventricle tunnel + + + + obo:DDO.owl#DDO_0001904 + DDO:DDO_0001904 + + + + obo:DDO.owl#DDO_0001904 + 26201005 + + + + obo:DDO.owl#DDO_0001904 + aortic left ventricular tunnel + + + + obo:DDO.owl#DDO_0001905 + DDO:DDO_0001905 + + + + obo:DDO.owl#DDO_0001905 + 253528005 + + + + obo:DDO.owl#DDO_0001905 + arrhythmogenic right ventricular dysplasia + + + + obo:DDO.owl#DDO_0001906 + DDO:DDO_0001906 + + + + obo:DDO.owl#DDO_0001906 + 204448004 + + + + obo:DDO.owl#DDO_0001906 + atresia of pulmonary artery with septal defect + + + + obo:DDO.owl#DDO_0001907 + DDO:DDO_0001907 + + + + obo:DDO.owl#DDO_0001907 + 444851003 + + + + obo:DDO.owl#DDO_0001907 + bifid apex of heart + + + + obo:DDO.owl#DDO_0001908 + DDO:DDO_0001908 + + + + obo:DDO.owl#DDO_0001908 + 263960005 + + + + obo:DDO.owl#DDO_0001908 + bilateral atria + + + + obo:DDO.owl#DDO_0001909 + DDO:DDO_0001909 + + + + obo:DDO.owl#DDO_0001909 + 263961009 + + + + obo:DDO.owl#DDO_0001909 + bilateral isomeric atria + + + + obo:DDO.owl#DDO_0001910 + DDO:DDO_0001910 + + + + obo:DDO.owl#DDO_0001910 + 448162007 + + + + obo:DDO.owl#DDO_0001910 + bipartite right ventricle + + + + obo:DDO.owl#DDO_0001911 + DDO:DDO_0001911 + + + + obo:DDO.owl#DDO_0001911 + 268174004 + + + + obo:DDO.owl#DDO_0001911 + Bulbus cordis and cardiac septal closure anomalies + + + + obo:DDO.owl#DDO_0001912 + DDO:DDO_0001912 + + + + obo:DDO.owl#DDO_0001912 + 253334002 + + + + obo:DDO.owl#DDO_0001912 + congenital abnormality of atria and atrial septum + + + + obo:DDO.owl#DDO_0001913 + DDO:DDO_0001913 + + + + obo:DDO.owl#DDO_0001913 + 55510008 + + + + obo:DDO.owl#DDO_0001913 + cor triatriatum + + + + obo:DDO.owl#DDO_0001914 + DDO:DDO_0001914 + + + + obo:DDO.owl#DDO_0001914 + 447874007 + + + + obo:DDO.owl#DDO_0001914 + congenital abnormality of atrial septum + + + + obo:DDO.owl#DDO_0001915 + DDO:DDO_0001915 + + + + obo:DDO.owl#DDO_0001915 + 253371000 + + + + obo:DDO.owl#DDO_0001915 + atrial septal defect through coronary sinus orifice + + + + obo:DDO.owl#DDO_0001916 + DDO:DDO_0001916 + + + + obo:DDO.owl#DDO_0001916 + 253276007 + + + + obo:DDO.owl#DDO_0001916 + common atrium + + + + obo:DDO.owl#DDO_0001917 + DDO:DDO_0001917 + + + + obo:DDO.owl#DDO_0001917 + 360481003 + + + + obo:DDO.owl#DDO_0001917 + common atrioventricular canal + + + + obo:DDO.owl#DDO_0001918 + DDO:DDO_0001918 + + + + obo:DDO.owl#DDO_0001918 + 253373002 + + + + obo:DDO.owl#DDO_0001918 + atrioventricular septal defect - isolated atrial component + + + + obo:DDO.owl#DDO_0001919 + DDO:DDO_0001919 + + + + obo:DDO.owl#DDO_0001919 + 17394001 + + + + obo:DDO.owl#DDO_0001919 + Ebstein's anomaly with atrial septal defect + + + + obo:DDO.owl#DDO_0001920 + DDO:DDO_0001920 + + + + obo:DDO.owl#DDO_0001920 + 449479003 + + + + obo:DDO.owl#DDO_0001920 + malattachment of atrial septum + + + + obo:DDO.owl#DDO_0001921 + DDO:DDO_0001921 + + + + obo:DDO.owl#DDO_0001921 + 19249002 + + + + obo:DDO.owl#DDO_0001921 + premature closure of foramen ovale + + + + obo:DDO.owl#DDO_0001922 + DDO:DDO_0001922 + + + + obo:DDO.owl#DDO_0001922 + 253272009 + + + + obo:DDO.owl#DDO_0001922 + congenital abnormality of cardiac connection + + + + obo:DDO.owl#DDO_0001923 + DDO:DDO_0001923 + + + + obo:DDO.owl#DDO_0001923 + 446326008 + + + + obo:DDO.owl#DDO_0001923 + premature restriction of foramen ovale + + + + obo:DDO.owl#DDO_0001924 + DDO:DDO_0001924 + + + + obo:DDO.owl#DDO_0001924 + 253274005 + + + + obo:DDO.owl#DDO_0001924 + abnormal atrioventricular connection + + + + obo:DDO.owl#DDO_0001925 + DDO:DDO_0001925 + + + + obo:DDO.owl#DDO_0001925 + 253278008 + + + + obo:DDO.owl#DDO_0001925 + ambiguous atrioventricular connection + + + + obo:DDO.owl#DDO_0001926 + DDO:DDO_0001926 + + + + obo:DDO.owl#DDO_0001926 + 253277003 + + + + obo:DDO.owl#DDO_0001926 + discordant atrioventricular connection + + + + obo:DDO.owl#DDO_0001927 + DDO:DDO_0001927 + + + + obo:DDO.owl#DDO_0001927 + 253280002 + + + + obo:DDO.owl#DDO_0001927 + abnormal atrioventricular connection - univentricular + + + + obo:DDO.owl#DDO_0001928 + DDO:DDO_0001928 + + + + obo:DDO.owl#DDO_0001928 + 253290005 + + + + obo:DDO.owl#DDO_0001928 + absent left sided atrioventricular connection + + + + obo:DDO.owl#DDO_0001929 + DDO:DDO_0001929 + + + + obo:DDO.owl#DDO_0001929 + 41893002 + + + + obo:DDO.owl#DDO_0001929 + left ventricular-right atrial communication + + + + obo:DDO.owl#DDO_0001930 + DDO:DDO_0001930 + + + + obo:DDO.owl#DDO_0001930 + 253293007 + + + + obo:DDO.owl#DDO_0001930 + right sided atrium connecting to both ventricles + + + + obo:DDO.owl#DDO_0001931 + DDO:DDO_0001931 + + + + obo:DDO.owl#DDO_0001931 + 253291009 + + + + obo:DDO.owl#DDO_0001931 + right sided atrium connecting to right ventricle + + + + obo:DDO.owl#DDO_0001932 + DDO:DDO_0001932 + + + + obo:DDO.owl#DDO_0001932 + 253294001 + + + + obo:DDO.owl#DDO_0001932 + right sided atrium connecting to ventricle of indeterminate morphology + + + + obo:DDO.owl#DDO_0001933 + DDO:DDO_0001933 + + + + obo:DDO.owl#DDO_0001933 + 448625006 + + + + obo:DDO.owl#DDO_0001933 + univentricular atrioventricular connection with absent left sided atrioventricular connection + + + + obo:DDO.owl#DDO_0001934 + DDO:DDO_0001934 + + + + obo:DDO.owl#DDO_0001934 + 253285007 + + + + obo:DDO.owl#DDO_0001934 + absent right sided atrioventricular connection + + + + obo:DDO.owl#DDO_0001935 + DDO:DDO_0001935 + + + + obo:DDO.owl#DDO_0001935 + 253288009 + + + + obo:DDO.owl#DDO_0001935 + left sided atrium connecting to both ventricles + + + + obo:DDO.owl#DDO_0001936 + DDO:DDO_0001936 + + + + obo:DDO.owl#DDO_0001936 + 253286008 + + + + obo:DDO.owl#DDO_0001936 + left sided atrium connecting to left ventricle + + + + obo:DDO.owl#DDO_0001937 + DDO:DDO_0001937 + + + + obo:DDO.owl#DDO_0001937 + 253287004 + + + + obo:DDO.owl#DDO_0001937 + left sided atrium connecting to right ventricle + + + + obo:DDO.owl#DDO_0001938 + DDO:DDO_0001938 + + + + obo:DDO.owl#DDO_0001938 + 253289001 + + + + obo:DDO.owl#DDO_0001938 + left sided atrium connecting to ventricle of indeterminate morphology + + + + obo:DDO.owl#DDO_0001940 + DDO:DDO_0001940 + + + + obo:DDO.owl#DDO_0001940 + 447919008 + + + + obo:DDO.owl#DDO_0001940 + univentricular atrioventricular connection with absent right sided atrioventricular connection + + + + obo:DDO.owl#DDO_0001941 + DDO:DDO_0001941 + + + + obo:DDO.owl#DDO_0001941 + 253281003 + + + + obo:DDO.owl#DDO_0001941 + double inlet ventricle + + + + obo:DDO.owl#DDO_0001942 + DDO:DDO_0001942 + + + + obo:DDO.owl#DDO_0001942 + 253283000 + + + + obo:DDO.owl#DDO_0001942 + double inlet left ventricle + + + + obo:DDO.owl#DDO_0001943 + DDO:DDO_0001943 + + + + obo:DDO.owl#DDO_0001943 + 253282005 + + + + obo:DDO.owl#DDO_0001943 + double inlet right ventricle + + + + obo:DDO.owl#DDO_0001944 + DDO:DDO_0001944 + + + + obo:DDO.owl#DDO_0001944 + 253284006 + + + + obo:DDO.owl#DDO_0001944 + double inlet to ventricle of indeterminate morphology + + + + obo:DDO.owl#DDO_0001945 + DDO:DDO_0001945 + + + + obo:DDO.owl#DDO_0001945 + 443379009 + + + + obo:DDO.owl#DDO_0001945 + functional single ventricle + + + + obo:DDO.owl#DDO_0001946 + DDO:DDO_0001946 + + + + obo:DDO.owl#DDO_0001946 + 445330003 + + + + obo:DDO.owl#DDO_0001946 + right atrioventricular valve leaflets absent in double inlet ventricle (unguarded orifice) + + + + obo:DDO.owl#DDO_0001947 + DDO:DDO_0001947 + + + + obo:DDO.owl#DDO_0001947 + 446667008 + + + + obo:DDO.owl#DDO_0001947 + two atrioventricular valves in double inlet ventricle + + + + obo:DDO.owl#DDO_0001948 + DDO:DDO_0001948 + + + + obo:DDO.owl#DDO_0001948 + 253279000 + + + + obo:DDO.owl#DDO_0001948 + absent atrioventricular connection with straddling valve + + + + obo:DDO.owl#DDO_0001949 + DDO:DDO_0001949 + + + + obo:DDO.owl#DDO_0001949 + 448624005 + + + + obo:DDO.owl#DDO_0001949 + uniatrial biventricular connection with absent left sided atrioventricular connection with straddling valve + + + + obo:DDO.owl#DDO_0001950 + DDO:DDO_0001950 + + + + obo:DDO.owl#DDO_0001950 + 448075009 + + + + obo:DDO.owl#DDO_0001950 + uniatrial biventricular connection with absent right sided atrioventricular connection with straddling valve + + + + obo:DDO.owl#DDO_0001951 + DDO:DDO_0001951 + + + + obo:DDO.owl#DDO_0001951 + 448072007 + + + + obo:DDO.owl#DDO_0001951 + single inlet ventricle with absent atrioventricular connection + + + + obo:DDO.owl#DDO_0001952 + DDO:DDO_0001952 + + + + obo:DDO.owl#DDO_0001952 + 253275006 + + + + obo:DDO.owl#DDO_0001952 + abnormal atrioventricular connection - biventricular + + + + obo:DDO.owl#DDO_0001953 + DDO:DDO_0001953 + + + + obo:DDO.owl#DDO_0001953 + 253295000 + + + + obo:DDO.owl#DDO_0001953 + abnormal ventriculoarterial connection + + + + obo:DDO.owl#DDO_0001954 + DDO:DDO_0001954 + + + + obo:DDO.owl#DDO_0001954 + 471285003 + + + + obo:DDO.owl#DDO_0001954 + anomalous origin of coronary artery from aortic sinus to left of nonfacing aortic sinus + + + + obo:DDO.owl#DDO_0001955 + DDO:DDO_0001955 + + + + obo:DDO.owl#DDO_0001955 + 471286002 + + + + obo:DDO.owl#DDO_0001955 + anomalous origin of coronary artery from aortic sinus to right of nonfacing aortic sinus + + + + obo:DDO.owl#DDO_0001956 + DDO:DDO_0001956 + + + + obo:DDO.owl#DDO_0001956 + 471297002 + + + + obo:DDO.owl#DDO_0001956 + anomalous origin of single coronary artery from nonfacing aortic sinus + + + + obo:DDO.owl#DDO_0001957 + DDO:DDO_0001957 + + + + obo:DDO.owl#DDO_0001957 + 204296002 + + + + obo:DDO.owl#DDO_0001957 + discordant ventriculoarterial connection + + + + obo:DDO.owl#DDO_0001958 + DDO:DDO_0001958 + + + + obo:DDO.owl#DDO_0001958 + 83799000 + + + + obo:DDO.owl#DDO_0001958 + corrected transposition of great vessels + + + + obo:DDO.owl#DDO_0001959 + DDO:DDO_0001959 + + + + obo:DDO.owl#DDO_0001959 + 204300001 + + + + obo:DDO.owl#DDO_0001959 + incomplete great vessel transposition + + + + obo:DDO.owl#DDO_0001960 + DDO:DDO_0001960 + + + + obo:DDO.owl#DDO_0001960 + 204297006 + + + + obo:DDO.owl#DDO_0001960 + total great vessel transposition + + + + obo:DDO.owl#DDO_0001961 + DDO:DDO_0001961 + + + + obo:DDO.owl#DDO_0001961 + 253297008 + + + + obo:DDO.owl#DDO_0001961 + transposition of aorta + + + + obo:DDO.owl#DDO_0001962 + DDO:DDO_0001962 + + + + obo:DDO.owl#DDO_0001962 + 253301004 + + + + obo:DDO.owl#DDO_0001962 + double outlet from ventricle of indeterminate morphology + + + + obo:DDO.owl#DDO_0001963 + DDO:DDO_0001963 + + + + obo:DDO.owl#DDO_0001963 + 7368005 + + + + obo:DDO.owl#DDO_0001963 + double outlet left ventricle + + + + obo:DDO.owl#DDO_0001964 + DDO:DDO_0001964 + + + + obo:DDO.owl#DDO_0001964 + 7484005 + + + + obo:DDO.owl#DDO_0001964 + double outlet right ventricle + + + + obo:DDO.owl#DDO_0001965 + DDO:DDO_0001965 + + + + obo:DDO.owl#DDO_0001965 + 447932003 + + + + obo:DDO.owl#DDO_0001965 + double outlet ventriculoarterial connections + + + + obo:DDO.owl#DDO_0001966 + DDO:DDO_0001966 + + + + obo:DDO.owl#DDO_0001966 + 253302006 + + + + obo:DDO.owl#DDO_0001966 + single outlet ventriculoarterial connection + + + + obo:DDO.owl#DDO_0001967 + DDO:DDO_0001967 + + + + obo:DDO.owl#DDO_0001967 + 253305008 + + + + obo:DDO.owl#DDO_0001967 + solitary arterial trunk + + + + obo:DDO.owl#DDO_0001968 + DDO:DDO_0001968 + + + + obo:DDO.owl#DDO_0001968 + 253304007 + + + + obo:DDO.owl#DDO_0001968 + solitary pulmonary trunk with aortic atresia + + + + obo:DDO.owl#DDO_0001969 + DDO:DDO_0001969 + + + + obo:DDO.owl#DDO_0001969 + 61959006 + + + + obo:DDO.owl#DDO_0001969 + common arterial trunk (truncus arteriosus) + + + + obo:DDO.owl#DDO_0001970 + DDO:DDO_0001970 + + + + obo:DDO.owl#DDO_0001970 + 253273004 + + + + obo:DDO.owl#DDO_0001970 + cardiac septal defects + + + + obo:DDO.owl#DDO_0001971 + DDO:DDO_0001971 + + + + obo:DDO.owl#DDO_0001971 + 204397009 + + + + obo:DDO.owl#DDO_0001971 + cor triloculare + + + + obo:DDO.owl#DDO_0001972 + DDO:DDO_0001972 + + + + obo:DDO.owl#DDO_0001972 + 195212005 + + + + obo:DDO.owl#DDO_0001972 + brainstem stroke syndrome + + + + obo:DDO.owl#DDO_0001973 + DDO:DDO_0001973 + + + + obo:DDO.owl#DDO_0001973 + 81990004 + + + + obo:DDO.owl#DDO_0001973 + cor biloculare + + + + obo:DDO.owl#DDO_0001974 + DDO:DDO_0001974 + + + + obo:DDO.owl#DDO_0001974 + 41713005 + + + + obo:DDO.owl#DDO_0001974 + Benedikt's syndrome + + + + obo:DDO.owl#DDO_0001975 + DDO:DDO_0001975 + + + + obo:DDO.owl#DDO_0001975 + 87555007 + + + + obo:DDO.owl#DDO_0001975 + Claude's syndrome + + + + obo:DDO.owl#DDO_0001976 + DDO:DDO_0001976 + + + + obo:DDO.owl#DDO_0001976 + 276220007 + + + + obo:DDO.owl#DDO_0001976 + Foville syndrome + + + + obo:DDO.owl#DDO_0001977 + DDO:DDO_0001977 + + + + obo:DDO.owl#DDO_0001977 + 69533002 + + + + obo:DDO.owl#DDO_0001977 + Foville's syndrome II + + + + obo:DDO.owl#DDO_0001978 + DDO:DDO_0001978 + + + + obo:DDO.owl#DDO_0001978 + 276221006 + + + + obo:DDO.owl#DDO_0001978 + Millard-Gubler syndrome + + + + obo:DDO.owl#DDO_0001979 + DDO:DDO_0001979 + + + + obo:DDO.owl#DDO_0001979 + 78569004 + + + + obo:DDO.owl#DDO_0001979 + posterior inferior cerebellar artery syndrome + + + + obo:DDO.owl#DDO_0001980 + DDO:DDO_0001980 + + + + obo:DDO.owl#DDO_0001980 + 24654003 + + + + obo:DDO.owl#DDO_0001980 + Weber-Gubler syndrome + + + + obo:DDO.owl#DDO_0001981 + DDO:DDO_0001981 + + + + obo:DDO.owl#DDO_0001981 + 25133001 + + + + obo:DDO.owl#DDO_0001981 + completed stroke + + + + obo:DDO.owl#DDO_0001982 + DDO:DDO_0001982 + + + + obo:DDO.owl#DDO_0001982 + 371041009 + + + + obo:DDO.owl#DDO_0001982 + embolic stroke + + + + obo:DDO.owl#DDO_0001983 + DDO:DDO_0001983 + + + + obo:DDO.owl#DDO_0001983 + 413758000 + + + + obo:DDO.owl#DDO_0001983 + cardioembolic stroke + + + + obo:DDO.owl#DDO_0001984 + DDO:DDO_0001984 + + + + obo:DDO.owl#DDO_0001984 + 281240008 + + + + obo:DDO.owl#DDO_0001984 + extension of cerebrovascular accident + + + + obo:DDO.owl#DDO_0001985 + DDO:DDO_0001985 + + + + obo:DDO.owl#DDO_0001985 + 413102000 + + + + obo:DDO.owl#DDO_0001985 + infarction of basal ganglia + + + + obo:DDO.owl#DDO_0001986 + DDO:DDO_0001986 + + + + obo:DDO.owl#DDO_0001986 + 106016005 + + + + obo:DDO.owl#DDO_0001986 + intracranial sinus thrombosis, embolism AND/OR inflammation + + + + obo:DDO.owl#DDO_0001987 + DDO:DDO_0001987 + + + + obo:DDO.owl#DDO_0001987 + 18058007 + + + + obo:DDO.owl#DDO_0001987 + phlebitis of intracranial venous sinus + + + + obo:DDO.owl#DDO_0001988 + DDO:DDO_0001988 + + + + obo:DDO.owl#DDO_0001988 + 422504002 + + + + obo:DDO.owl#DDO_0001988 + ischemic stroke + + + + obo:DDO.owl#DDO_0001989 + DDO:DDO_0001989 + + + + obo:DDO.owl#DDO_0001989 + 140911000119109 + + + + obo:DDO.owl#DDO_0001989 + ischemic stroke with coma + + + + obo:DDO.owl#DDO_0001990 + DDO:DDO_0001990 + + + + obo:DDO.owl#DDO_0001990 + 140921000119102 + + + + obo:DDO.owl#DDO_0001990 + ischemic stroke without coma + + + + obo:DDO.owl#DDO_0001991 + DDO:DDO_0001991 + + + + obo:DDO.owl#DDO_0001991 + 371121002 + + + + obo:DDO.owl#DDO_0001991 + neonatal stroke + + + + obo:DDO.owl#DDO_0001992 + DDO:DDO_0001992 + + + + obo:DDO.owl#DDO_0001992 + 111297002 + + + + obo:DDO.owl#DDO_0001992 + nonparalytic stroke + + + + obo:DDO.owl#DDO_0001993 + DDO:DDO_0001993 + + + + obo:DDO.owl#DDO_0001993 + 373606000 + + + + obo:DDO.owl#DDO_0001993 + occlusive stroke + + + + obo:DDO.owl#DDO_0001994 + DDO:DDO_0001994 + + + + obo:DDO.owl#DDO_0001994 + 9901000119100 + + + + obo:DDO.owl#DDO_0001994 + occlusion of cerebral artery with stroke + + + + obo:DDO.owl#DDO_0001995 + DDO:DDO_0001995 + + + + obo:DDO.owl#DDO_0001995 + 116288000 + + + + obo:DDO.owl#DDO_0001995 + paralytic stroke + + + + obo:DDO.owl#DDO_0001996 + DDO:DDO_0001996 + + + + obo:DDO.owl#DDO_0001996 + 57981008 + + + + obo:DDO.owl#DDO_0001996 + progressing stroke + + + + obo:DDO.owl#DDO_0001997 + DDO:DDO_0001997 + + + + obo:DDO.owl#DDO_0001997 + 233983001 + + + + obo:DDO.owl#DDO_0001997 + ruptured cerebral aneurysm + + + + obo:DDO.owl#DDO_0001998 + DDO:DDO_0001998 + + + + obo:DDO.owl#DDO_0001998 + 275434003 + + + + obo:DDO.owl#DDO_0001998 + stroke in the puerperium + + + + obo:DDO.owl#DDO_0001999 + DDO:DDO_0001999 + + + + obo:DDO.owl#DDO_0001999 + 371040005 + + + + obo:DDO.owl#DDO_0001999 + thrombotic stroke + + + + obo:DDO.owl#DDO_0002000 + DDO:DDO_0002000 + + + + obo:DDO.owl#DDO_0002000 + 195213000 + + + + obo:DDO.owl#DDO_0002000 + cerebellar stroke syndrome + + + + obo:DDO.owl#DDO_0002001 + DDO:DDO_0002001 + + + + obo:DDO.owl#DDO_0002001 + 444657001 + + + + obo:DDO.owl#DDO_0002001 + superior cerebellar artery syndrome + + + + obo:DDO.owl#DDO_0002003 + DDO:DDO_0002003 + + + + obo:DDO.owl#DDO_0002003 + 233873004 + + + + obo:DDO.owl#DDO_0002003 + hypertrophic cardiomyopathy + + + + obo:DDO.owl#DDO_0002004 + DDO:DDO_0002004 + + + + obo:DDO.owl#DDO_0002004 + 472324001 + + + + obo:DDO.owl#DDO_0002004 + fetal hypertrophic cardiomyopathy + + + + obo:DDO.owl#DDO_0002005 + DDO:DDO_0002005 + + + + obo:DDO.owl#DDO_0002005 + 472326004 + + + + obo:DDO.owl#DDO_0002005 + fetal hypertrophic cardiomyopathy associated with renal disease + + + + obo:DDO.owl#DDO_0002006 + DDO:DDO_0002006 + + + + obo:DDO.owl#DDO_0002006 + 704241002 + + + + obo:DDO.owl#DDO_0002006 + fetal hypertrophic cardiomyopathy due to maternal diabetes mellitus + + + + obo:DDO.owl#DDO_0002007 + DDO:DDO_0002007 + + + + obo:DDO.owl#DDO_0002007 + 472325000 + + + + obo:DDO.owl#DDO_0002007 + fetal hypertrophic cardiomyopathy due to twin to twin transfusion syndrome + + + + obo:DDO.owl#DDO_0002008 + DDO:DDO_0002008 + + + + obo:DDO.owl#DDO_0002008 + 445336009 + + + + obo:DDO.owl#DDO_0002008 + hypertrophic cardiomyopathy associated with another disorder + + + + obo:DDO.owl#DDO_0002009 + DDO:DDO_0002009 + + + + obo:DDO.owl#DDO_0002009 + 53322007 + + + + obo:DDO.owl#DDO_0002009 + hypertrophic cardiomyopathy secondary to Friedreich's ataxia + + + + obo:DDO.owl#DDO_0002010 + DDO:DDO_0002010 + + + + obo:DDO.owl#DDO_0002010 + 93558006 + + + + obo:DDO.owl#DDO_0002010 + hypertrophic cardiomyopathy secondary to hyperthyroidism + + + + obo:DDO.owl#DDO_0002011 + DDO:DDO_0002011 + + + + obo:DDO.owl#DDO_0002011 + 41964001 + + + + obo:DDO.owl#DDO_0002011 + hypertrophic cardiomyopathy secondary to neuromuscular disorder + + + + obo:DDO.owl#DDO_0002012 + DDO:DDO_0002012 + + + + obo:DDO.owl#DDO_0002012 + 471885006 + + + + obo:DDO.owl#DDO_0002012 + hypertrophic cardiomyopathy with genetic marker + + + + obo:DDO.owl#DDO_0002013 + DDO:DDO_0002013 + + + + obo:DDO.owl#DDO_0002013 + 195020003 + + + + obo:DDO.owl#DDO_0002013 + hypertrophic cardiomyopathy without obstruction + + + + obo:DDO.owl#DDO_0002014 + DDO:DDO_0002014 + + + + obo:DDO.owl#DDO_0002014 + 472316006 + + + + obo:DDO.owl#DDO_0002014 + hypertrophic mitochondrial cardiomyopathy + + + + obo:DDO.owl#DDO_0002015 + DDO:DDO_0002015 + + + + obo:DDO.owl#DDO_0002015 + 45227007 + + + + obo:DDO.owl#DDO_0002015 + hypertrophic obstructive cardiomyopathy + + + + obo:DDO.owl#DDO_0002016 + DDO:DDO_0002016 + + + + obo:DDO.owl#DDO_0002016 + 63183009 + + + + obo:DDO.owl#DDO_0002016 + primary idiopathic hypertrophic cardiomyopathy + + + + obo:DDO.owl#DDO_0002017 + DDO:DDO_0002017 + + + + obo:DDO.owl#DDO_0002017 + 700065003 + + + + obo:DDO.owl#DDO_0002017 + primary hypertrophic cardiomyopathy + + + + obo:DDO.owl#DDO_0002018 + DDO:DDO_0002018 + + + + obo:DDO.owl#DDO_0002018 + 83978005 + + + + obo:DDO.owl#DDO_0002018 + primary familial hypertrophic cardiomyopathy + + + + obo:DDO.owl#DDO_0002019 + DDO:DDO_0002019 + + + + obo:DDO.owl#DDO_0002019 + 63183009 + + + + obo:DDO.owl#DDO_0002019 + primary idiopathic hypertrophic cardiomyopathy + + + + obo:DDO.owl#DDO_0002020 + DDO:DDO_0002020 + + + + obo:DDO.owl#DDO_0002020 + 57054005 + + + + obo:DDO.owl#DDO_0002020 + acute myocardial infarction + + + + obo:DDO.owl#DDO_0002021 + DDO:DDO_0002021 + + + + obo:DDO.owl#DDO_0002021 + 52035003 + + + + obo:DDO.owl#DDO_0002021 + acute anteroapical myocardial infarction + + + + obo:DDO.owl#DDO_0002022 + DDO:DDO_0002022 + + + + obo:DDO.owl#DDO_0002022 + 62695002 + + + + obo:DDO.owl#DDO_0002022 + acute anteroseptal myocardial infarction + + + + obo:DDO.owl#DDO_0002023 + DDO:DDO_0002023 + + + + obo:DDO.owl#DDO_0002023 + 233826005 + + + + obo:DDO.owl#DDO_0002023 + acute non-Q wave infarction - anteroseptal + + + + obo:DDO.owl#DDO_0002024 + DDO:DDO_0002024 + + + + obo:DDO.owl#DDO_0002024 + 233825009 + + + + obo:DDO.owl#DDO_0002024 + acute Q wave infarction - anteroseptal + + + + obo:DDO.owl#DDO_0002025 + DDO:DDO_0002025 + + + + obo:DDO.owl#DDO_0002025 + 15712961000119108 + + + + obo:DDO.owl#DDO_0002025 + acute ST segment elevation myocardial infarction of anteroseptal wall + + + + obo:DDO.owl#DDO_0002026 + DDO:DDO_0002026 + + + + obo:DDO.owl#DDO_0002026 + 10273003 + + + + obo:DDO.owl#DDO_0002026 + acute infarction of papillary muscle + + + + obo:DDO.owl#DDO_0002027 + DDO:DDO_0002027 + + + + obo:DDO.owl#DDO_0002027 + 703212004 + + + + obo:DDO.owl#DDO_0002027 + acute myocardial infarction during procedure + + + + obo:DDO.owl#DDO_0002028 + DDO:DDO_0002028 + + + + obo:DDO.owl#DDO_0002028 + 54329005 + + + + obo:DDO.owl#DDO_0002028 + acute myocardial infarction of anterior wall + + + + obo:DDO.owl#DDO_0002029 + DDO:DDO_0002029 + + + + obo:DDO.owl#DDO_0002029 + 703164000 + + + + obo:DDO.owl#DDO_0002029 + acute anterior ST segment elevation myocardial infarction + + + + obo:DDO.owl#DDO_0002030 + DDO:DDO_0002030 + + + + obo:DDO.owl#DDO_0002030 + 703252002 + + + + obo:DDO.owl#DDO_0002030 + acute myocardial infarction of anterior wall involving right ventricle + + + + obo:DDO.owl#DDO_0002031 + DDO:DDO_0002031 + + + + obo:DDO.owl#DDO_0002031 + 70211005 + + + + obo:DDO.owl#DDO_0002031 + acute myocardial infarction of anterolateral wall + + + + obo:DDO.owl#DDO_0002032 + DDO:DDO_0002032 + + + + obo:DDO.owl#DDO_0002032 + 233828006 + + + + obo:DDO.owl#DDO_0002032 + acute non-Q wave infarction - anterolateral + + + + obo:DDO.owl#DDO_0002033 + DDO:DDO_0002033 + + + + obo:DDO.owl#DDO_0002033 + 233827001 + + + + obo:DDO.owl#DDO_0002033 + acute Q wave infarction - anterolateral + + + + obo:DDO.owl#DDO_0002034 + DDO:DDO_0002034 + + + + obo:DDO.owl#DDO_0002034 + 15712881000119105 + + + + obo:DDO.owl#DDO_0002034 + acute ST segment elevation myocardial infarction of anterolateral wall + + + + obo:DDO.owl#DDO_0002035 + DDO:DDO_0002035 + + + + obo:DDO.owl#DDO_0002035 + 194809007 + + + + obo:DDO.owl#DDO_0002035 + acute myocardial infarction of atrium + + + + obo:DDO.owl#DDO_0002036 + DDO:DDO_0002036 + + + + obo:DDO.owl#DDO_0002036 + 73795002 + + + + obo:DDO.owl#DDO_0002036 + acute myocardial infarction of inferior wall + + + + obo:DDO.owl#DDO_0002037 + DDO:DDO_0002037 + + + + obo:DDO.owl#DDO_0002037 + 76593002 + + + + obo:DDO.owl#DDO_0002037 + acute myocardial infarction of inferoposterior wall + + + + obo:DDO.owl#DDO_0002038 + DDO:DDO_0002038 + + + + obo:DDO.owl#DDO_0002038 + 703251009 + + + + obo:DDO.owl#DDO_0002038 + acute myocardial infarction of inferior wall involving right ventricle + + + + obo:DDO.owl#DDO_0002039 + DDO:DDO_0002039 + + + + obo:DDO.owl#DDO_0002039 + 233830008 + + + + obo:DDO.owl#DDO_0002039 + acute non-Q wave infarction - inferior + + + + obo:DDO.owl#DDO_0002040 + DDO:DDO_0002040 + + + + obo:DDO.owl#DDO_0002040 + 233829003 + + + + obo:DDO.owl#DDO_0002040 + acute Q wave infarction - inferior + + + + obo:DDO.owl#DDO_0002042 + DDO:DDO_0002042 + + + + obo:DDO.owl#DDO_0002042 + 65547006 + + + + obo:DDO.owl#DDO_0002042 + acute myocardial infarction of inferolateral wall + + + + obo:DDO.owl#DDO_0002043 + DDO:DDO_0002043 + + + + obo:DDO.owl#DDO_0002043 + 233832000 + + + + obo:DDO.owl#DDO_0002043 + acute non-Q wave infarction - inferolateral + + + + obo:DDO.owl#DDO_0002044 + DDO:DDO_0002044 + + + + obo:DDO.owl#DDO_0002044 + 233831007 + + + + obo:DDO.owl#DDO_0002044 + acute Q wave infarction - inferolateral + + + + obo:DDO.owl#DDO_0002045 + DDO:DDO_0002045 + + + + obo:DDO.owl#DDO_0002045 + 58612006 + + + + obo:DDO.owl#DDO_0002045 + acute myocardial infarction of lateral wall + + + + obo:DDO.owl#DDO_0002046 + DDO:DDO_0002046 + + + + obo:DDO.owl#DDO_0002046 + 15990001 + + + + obo:DDO.owl#DDO_0002046 + acute myocardial infarction of posterolateral wall + + + + obo:DDO.owl#DDO_0002047 + DDO:DDO_0002047 + + + + obo:DDO.owl#DDO_0002047 + 79009004 + + + + obo:DDO.owl#DDO_0002047 + acute myocardial infarction of septum + + + + obo:DDO.owl#DDO_0002048 + DDO:DDO_0002048 + + + + obo:DDO.owl#DDO_0002048 + 30277009 + + + + obo:DDO.owl#DDO_0002048 + acute myocardial infarction with rupture of ventricle + + + + obo:DDO.owl#DDO_0002049 + DDO:DDO_0002049 + + + + obo:DDO.owl#DDO_0002049 + 307140009 + + + + obo:DDO.owl#DDO_0002049 + acute non-Q wave infarction + + + + obo:DDO.owl#DDO_0002050 + DDO:DDO_0002050 + + + + obo:DDO.owl#DDO_0002050 + 401314000 + + + + obo:DDO.owl#DDO_0002050 + acute non-ST segment elevation myocardial infarction + + + + obo:DDO.owl#DDO_0002051 + DDO:DDO_0002051 + + + + obo:DDO.owl#DDO_0002051 + 233838001 + + + + obo:DDO.owl#DDO_0002051 + acute posterior myocardial infarction + + + + obo:DDO.owl#DDO_0002052 + DDO:DDO_0002052 + + + + obo:DDO.owl#DDO_0002052 + 70998009 + + + + obo:DDO.owl#DDO_0002052 + acute myocardial infarction of posterobasal wall + + + + obo:DDO.owl#DDO_0002053 + DDO:DDO_0002053 + + + + obo:DDO.owl#DDO_0002053 + 304914007 + + + + obo:DDO.owl#DDO_0002053 + acute Q wave myocardial infarction + + + + obo:DDO.owl#DDO_0002054 + DDO:DDO_0002054 + + + + obo:DDO.owl#DDO_0002054 + 401303003 + + + + obo:DDO.owl#DDO_0002054 + acute ST segment elevation myocardial infarction + + + + obo:DDO.owl#DDO_0002055 + DDO:DDO_0002055 + + + + obo:DDO.owl#DDO_0002055 + 70422006 + + + + obo:DDO.owl#DDO_0002055 + acute subendocardial infarction + + + + obo:DDO.owl#DDO_0002056 + DDO:DDO_0002056 + + + + obo:DDO.owl#DDO_0002056 + 233835003 + + + + obo:DDO.owl#DDO_0002056 + acute widespread myocardial infarction + + + + obo:DDO.owl#DDO_0002057 + DDO:DDO_0002057 + + + + obo:DDO.owl#DDO_0002057 + 394710008 + + + + obo:DDO.owl#DDO_0002057 + first myocardial infarction + + + + obo:DDO.owl#DDO_0002058 + DDO:DDO_0002058 + + + + obo:DDO.owl#DDO_0002058 + 42531007 + + + + obo:DDO.owl#DDO_0002058 + microinfarct of heart + + + + obo:DDO.owl#DDO_0002059 + DDO:DDO_0002059 + + + + obo:DDO.owl#DDO_0002059 + 428196007 + + + + obo:DDO.owl#DDO_0002059 + mixed myocardial ischemia and infarction + + + + obo:DDO.owl#DDO_0002060 + DDO:DDO_0002060 + + + + obo:DDO.owl#DDO_0002060 + 418044006 + + + + obo:DDO.owl#DDO_0002060 + myocardial infarction in recovery phase + + + + obo:DDO.owl#DDO_0002061 + DDO:DDO_0002061 + + + + obo:DDO.owl#DDO_0002061 + 371068009 + + + + obo:DDO.owl#DDO_0002061 + myocardial infarction with complication + + + + obo:DDO.owl#DDO_0002062 + DDO:DDO_0002062 + + + + obo:DDO.owl#DDO_0002062 + 314207007 + + + + obo:DDO.owl#DDO_0002062 + non-Q wave myocardial infarction + + + + obo:DDO.owl#DDO_0002063 + DDO:DDO_0002063 + + + + obo:DDO.owl#DDO_0002063 + 1755008 + + + + obo:DDO.owl#DDO_0002063 + old myocardial infarction + + + + obo:DDO.owl#DDO_0002064 + DDO:DDO_0002064 + + + + obo:DDO.owl#DDO_0002064 + 129574000 + + + + obo:DDO.owl#DDO_0002064 + postoperative myocardial infarction + + + + obo:DDO.owl#DDO_0002065 + DDO:DDO_0002065 + + + + obo:DDO.owl#DDO_0002065 + 311796008 + + + + obo:DDO.owl#DDO_0002065 + postoperative subendocardial myocardial infarction + + + + obo:DDO.owl#DDO_0002066 + DDO:DDO_0002066 + + + + obo:DDO.owl#DDO_0002066 + 311792005 + + + + obo:DDO.owl#DDO_0002066 + postoperative transmural myocardial infarction of anterior wall + + + + obo:DDO.owl#DDO_0002067 + DDO:DDO_0002067 + + + + obo:DDO.owl#DDO_0002067 + 311793000 + + + + obo:DDO.owl#DDO_0002067 + postoperative transmural myocardial infarction of inferior wall + + + + obo:DDO.owl#DDO_0002068 + DDO:DDO_0002068 + + + + obo:DDO.owl#DDO_0002068 + 233843008 + + + + obo:DDO.owl#DDO_0002068 + silent myocardial infarction + + + + obo:DDO.owl#DDO_0002069 + DDO:DDO_0002069 + + + + obo:DDO.owl#DDO_0002069 + 194856005 + + + + obo:DDO.owl#DDO_0002069 + subsequent myocardial infarction + + + + obo:DDO.owl#DDO_0002070 + DDO:DDO_0002070 + + + + obo:DDO.owl#DDO_0002070 + 194802003 + + + + obo:DDO.owl#DDO_0002070 + true posterior myocardial infarction + + + + obo:DDO.owl#DDO_0002071 + DDO:DDO_0002071 + + + + obo:DDO.owl#DDO_0002071 + 791000119109 + + + + obo:DDO.owl#DDO_0002071 + angina associated with type 2 diabetes mellitus + + + + obo:DDO.owl#DDO_0002072 + DDO:DDO_0002072 + + + + obo:DDO.owl#DDO_0002072 + 59021001 + + + + obo:DDO.owl#DDO_0002072 + angina decubitus + + + + obo:DDO.owl#DDO_0002073 + DDO:DDO_0002073 + + + + obo:DDO.owl#DDO_0002073 + 61490001 + + + + obo:DDO.owl#DDO_0002073 + angina, class I + + + + obo:DDO.owl#DDO_0002074 + DDO:DDO_0002074 + + + + obo:DDO.owl#DDO_0002074 + 41334000 + + + + obo:DDO.owl#DDO_0002074 + angina, class II + + + + obo:DDO.owl#DDO_0002075 + DDO:DDO_0002075 + + + + obo:DDO.owl#DDO_0002075 + 85284003 + + + + obo:DDO.owl#DDO_0002075 + angina, class III + + + + obo:DDO.owl#DDO_0002076 + DDO:DDO_0002076 + + + + obo:DDO.owl#DDO_0002076 + 89323001 + + + + obo:DDO.owl#DDO_0002076 + angina, class IV + + + + obo:DDO.owl#DDO_0002077 + DDO:DDO_0002077 + + + + obo:DDO.owl#DDO_0002077 + 371807002 + + + + obo:DDO.owl#DDO_0002077 + atypical angina + + + + obo:DDO.owl#DDO_0002078 + DDO:DDO_0002078 + + + + obo:DDO.owl#DDO_0002078 + 35928006 + + + + obo:DDO.owl#DDO_0002078 + nocturnal angina + + + + obo:DDO.owl#DDO_0002079 + DDO:DDO_0002079 + + + + obo:DDO.owl#DDO_0002079 + 314116003 + + + + obo:DDO.owl#DDO_0002079 + post infarct angina + + + + obo:DDO.owl#DDO_0002080 + DDO:DDO_0002080 + + + + obo:DDO.owl#DDO_0002080 + 4557003 + + + + obo:DDO.owl#DDO_0002080 + preinfarction syndrome + + + + obo:DDO.owl#DDO_0002081 + DDO:DDO_0002081 + + + + obo:DDO.owl#DDO_0002081 + 194823009 + + + + obo:DDO.owl#DDO_0002081 + acute coronary insufficiency + + + + obo:DDO.owl#DDO_0002082 + DDO:DDO_0002082 + + + + obo:DDO.owl#DDO_0002082 + 87343002 + + + + obo:DDO.owl#DDO_0002082 + Prinzmetal angina + + + + obo:DDO.owl#DDO_0002083 + DDO:DDO_0002083 + + + + obo:DDO.owl#DDO_0002083 + 371806006 + + + + obo:DDO.owl#DDO_0002083 + progressive Angina + + + + obo:DDO.owl#DDO_0002084 + DDO:DDO_0002084 + + + + obo:DDO.owl#DDO_0002084 + 315025001 + + + + obo:DDO.owl#DDO_0002084 + refractory angina + + + + obo:DDO.owl#DDO_0002085 + DDO:DDO_0002085 + + + + obo:DDO.owl#DDO_0002085 + 21470009 + + + + obo:DDO.owl#DDO_0002085 + syncope anginosa + + + + obo:DDO.owl#DDO_0002086 + DDO:DDO_0002086 + + + + obo:DDO.owl#DDO_0002086 + 64009001 + + + + obo:DDO.owl#DDO_0002086 + basilar artery syndrome + + + + obo:DDO.owl#DDO_0002088 + DDO:DDO_0002088 + + + + obo:DDO.owl#DDO_0002088 + 230717002 + + + + obo:DDO.owl#DDO_0002088 + Vertebrobasilar territory transient ischemic attack + + + + obo:DDO.owl#DDO_0002089 + DDO:DDO_0002089 + + + + obo:DDO.owl#DDO_0002089 + 710575003 + + + + obo:DDO.owl#DDO_0002089 + transient ischemic attack due to embolism + + + + obo:DDO.owl#DDO_0002090 + DDO:DDO_0002090 + + + + obo:DDO.owl#DDO_0002090 + 426814001 + + + + obo:DDO.owl#DDO_0002090 + transient cerebral ischemia due to atrial fibrillation + + + + obo:DDO.owl#DDO_0002091 + DDO:DDO_0002091 + + + + obo:DDO.owl#DDO_0002091 + 444172003 + + + + obo:DDO.owl#DDO_0002091 + recurrent transient cerebral ischemic attack + + + + obo:DDO.owl#DDO_0002092 + DDO:DDO_0002092 + + + + obo:DDO.owl#DDO_0002092 + 195211003 + + + + obo:DDO.owl#DDO_0002092 + posterior cerebral artery syndrome + + + + obo:DDO.owl#DDO_0002093 + DDO:DDO_0002093 + + + + obo:DDO.owl#DDO_0002093 + 195201005 + + + + obo:DDO.owl#DDO_0002093 + multiple and bilateral precerebral artery syndromes + + + + obo:DDO.owl#DDO_0002094 + DDO:DDO_0002094 + + + + obo:DDO.owl#DDO_0002094 + 195209007 + + + + obo:DDO.owl#DDO_0002094 + middle cerebral artery syndrome + + + + obo:DDO.owl#DDO_0002095 + DDO:DDO_0002095 + + + + obo:DDO.owl#DDO_0002095 + 195200006 + + + + obo:DDO.owl#DDO_0002095 + carotid artery syndrome hemispheric + + + + obo:DDO.owl#DDO_0002096 + DDO:DDO_0002096 + + + + obo:DDO.owl#DDO_0002096 + 88032003 + + + + obo:DDO.owl#DDO_0002096 + amaurosis fugax + + + + obo:DDO.owl#DDO_0002097 + DDO:DDO_0002097 + + + + obo:DDO.owl#DDO_0002097 + 230716006 + + + + obo:DDO.owl#DDO_0002097 + carotid territory transient ischemic attack + + + + obo:DDO.owl#DDO_0002098 + DDO:DDO_0002098 + + + + obo:DDO.owl#DDO_0002098 + 195210002 + + + + obo:DDO.owl#DDO_0002098 + anterior cerebral artery syndrome + + + + obo:DDO.owl#DDO_0002099 + DDO:DDO_0002099 + + + + obo:DDO.owl#DDO_0002099 + 38341003 + + + + obo:DDO.owl#DDO_0002099 + hypertension + + + + obo:DDO.owl#DDO_0002100 + DDO:DDO_0002100 + + + + obo:DDO.owl#DDO_0002100 + 10725009 + + + + obo:DDO.owl#DDO_0002100 + benign hypertension + + + + obo:DDO.owl#DDO_0002101 + DDO:DDO_0002101 + + + + obo:DDO.owl#DDO_0002101 + 1201005 + + + + obo:DDO.owl#DDO_0002101 + benign essential hypertension + + + + obo:DDO.owl#DDO_0002102 + DDO:DDO_0002102 + + + + obo:DDO.owl#DDO_0002102 + 194785008 + + + + obo:DDO.owl#DDO_0002102 + benign secondary hypertension + + + + obo:DDO.owl#DDO_0002104 + DDO:DDO_0002104 + + + + obo:DDO.owl#DDO_0002104 + 73410007 + + + + obo:DDO.owl#DDO_0002104 + benign secondary renovascular hypertension + + + + obo:DDO.owl#DDO_0002105 + DDO:DDO_0002105 + + + + obo:DDO.owl#DDO_0002105 + 48146000 + + + + obo:DDO.owl#DDO_0002105 + diastolic hypertension + + + + obo:DDO.owl#DDO_0002106 + DDO:DDO_0002106 + + + + obo:DDO.owl#DDO_0002106 + 65518004 + + + + obo:DDO.owl#DDO_0002106 + labile diastolic hypertension + + + + obo:DDO.owl#DDO_0002107 + DDO:DDO_0002107 + + + + obo:DDO.owl#DDO_0002107 + 74451002 + + + + obo:DDO.owl#DDO_0002107 + secondary diastolic hypertension + + + + obo:DDO.owl#DDO_0002108 + DDO:DDO_0002108 + + + + obo:DDO.owl#DDO_0002108 + 59720008 + + + + obo:DDO.owl#DDO_0002108 + sustained diastolic hypertension + + + + obo:DDO.owl#DDO_0002109 + DDO:DDO_0002109 + + + + obo:DDO.owl#DDO_0002109 + 69909000 + + + + obo:DDO.owl#DDO_0002109 + eclampsia added to pre-existing hypertension + + + + obo:DDO.owl#DDO_0002110 + DDO:DDO_0002110 + + + + obo:DDO.owl#DDO_0002110 + 59621000 + + + + obo:DDO.owl#DDO_0002110 + essential hypertension + + + + obo:DDO.owl#DDO_0002111 + DDO:DDO_0002111 + + + + obo:DDO.owl#DDO_0002111 + 1201005 + + + + obo:DDO.owl#DDO_0002111 + benign essential hypertension + + + + obo:DDO.owl#DDO_0002112 + DDO:DDO_0002112 + + + + obo:DDO.owl#DDO_0002112 + 63287004 + + + + obo:DDO.owl#DDO_0002112 + benign essential hypertension in obstetric context + + + + obo:DDO.owl#DDO_0002113 + DDO:DDO_0002113 + + + + obo:DDO.owl#DDO_0002113 + 72022006 + + + + obo:DDO.owl#DDO_0002113 + essential hypertension in obstetric context + + + + obo:DDO.owl#DDO_0002114 + DDO:DDO_0002114 + + + + obo:DDO.owl#DDO_0002114 + 63287004 + + + + obo:DDO.owl#DDO_0002114 + benign essential hypertension in obstetric context + + + + obo:DDO.owl#DDO_0002115 + DDO:DDO_0002115 + + + + obo:DDO.owl#DDO_0002115 + 19769006 + + + + obo:DDO.owl#DDO_0002115 + high-renin essential hypertension + + + + obo:DDO.owl#DDO_0002117 + DDO:DDO_0002117 + + + + obo:DDO.owl#DDO_0002117 + 371125006 + + + + obo:DDO.owl#DDO_0002117 + labile essential hypertension + + + + obo:DDO.owl#DDO_0002118 + DDO:DDO_0002118 + + + + obo:DDO.owl#DDO_0002118 + 46481004 + + + + obo:DDO.owl#DDO_0002118 + low-renin essential hypertension + + + + obo:DDO.owl#DDO_0002119 + DDO:DDO_0002119 + + + + obo:DDO.owl#DDO_0002119 + 78975002 + + + + obo:DDO.owl#DDO_0002119 + malignant essential hypertension + + + + obo:DDO.owl#DDO_0002120 + DDO:DDO_0002120 + + + + obo:DDO.owl#DDO_0002120 + 40511000119107 + + + + obo:DDO.owl#DDO_0002120 + postpartum pre-existing essential hypertension + + + + obo:DDO.owl#DDO_0002121 + DDO:DDO_0002121 + + + + obo:DDO.owl#DDO_0002121 + 429457004 + + + + obo:DDO.owl#DDO_0002121 + systolic essential hypertension + + + + obo:DDO.owl#DDO_0002122 + DDO:DDO_0002122 + + + + obo:DDO.owl#DDO_0002122 + 429198000 + + + + obo:DDO.owl#DDO_0002122 + exertional hypertension + + + + obo:DDO.owl#DDO_0002123 + DDO:DDO_0002123 + + + + obo:DDO.owl#DDO_0002123 + 71701000119105 + + + + obo:DDO.owl#DDO_0002123 + hypertension in chronic kidney disease due to type 1 diabetes mellitus + + + + obo:DDO.owl#DDO_0002124 + DDO:DDO_0002124 + + + + obo:DDO.owl#DDO_0002124 + 71421000119105 + + + + obo:DDO.owl#DDO_0002124 + hypertension in chronic kidney disease due to type 2 diabetes mellitus + + + + obo:DDO.owl#DDO_0002125 + DDO:DDO_0002125 + + + + obo:DDO.owl#DDO_0002125 + 367390009 + + + + obo:DDO.owl#DDO_0002125 + hypertension in the obstetric context + + + + obo:DDO.owl#DDO_0002126 + DDO:DDO_0002126 + + + + obo:DDO.owl#DDO_0002126 + 8762007 + + + + obo:DDO.owl#DDO_0002126 + chronic hypertension in obstetric context + + + + obo:DDO.owl#DDO_0002127 + DDO:DDO_0002127 + + + + obo:DDO.owl#DDO_0002127 + 72022006 + + + + obo:DDO.owl#DDO_0002127 + essential hypertension in obstetric context + + + + obo:DDO.owl#DDO_0002128 + DDO:DDO_0002128 + + + + obo:DDO.owl#DDO_0002128 + 111438007 + + + + obo:DDO.owl#DDO_0002128 + hypertension secondary to renal disease in obstetric context + + + + obo:DDO.owl#DDO_0002129 + DDO:DDO_0002129 + + + + obo:DDO.owl#DDO_0002129 + 81626002 + + + + obo:DDO.owl#DDO_0002129 + malignant hypertension in obstetric context + + + + obo:DDO.owl#DDO_0002130 + DDO:DDO_0002130 + + + + obo:DDO.owl#DDO_0002130 + 86041002 + + + + obo:DDO.owl#DDO_0002130 + pre-existing hypertension in obstetric context + + + + obo:DDO.owl#DDO_0002131 + DDO:DDO_0002131 + + + + obo:DDO.owl#DDO_0002131 + 397748008 + + + + obo:DDO.owl#DDO_0002131 + hypertension with albuminuria + + + + obo:DDO.owl#DDO_0002132 + DDO:DDO_0002132 + + + + obo:DDO.owl#DDO_0002132 + 697929007 + + + + obo:DDO.owl#DDO_0002132 + intermittent hypertension + + + + obo:DDO.owl#DDO_0002133 + DDO:DDO_0002133 + + + + obo:DDO.owl#DDO_0002133 + 371125006 + + + + obo:DDO.owl#DDO_0002133 + labile essential hypertension + + + + obo:DDO.owl#DDO_0002134 + DDO:DDO_0002134 + + + + obo:DDO.owl#DDO_0002134 + 52698002 + + + + obo:DDO.owl#DDO_0002134 + transient hypertension + + + + obo:DDO.owl#DDO_0002135 + DDO:DDO_0002135 + + + + obo:DDO.owl#DDO_0002135 + 206596003 + + + + obo:DDO.owl#DDO_0002135 + neonatal hypertension + + + + obo:DDO.owl#DDO_0002136 + DDO:DDO_0002136 + + + + obo:DDO.owl#DDO_0002136 + 23130000 + + + + obo:DDO.owl#DDO_0002136 + paroxysmal hypertension + + + + obo:DDO.owl#DDO_0002137 + DDO:DDO_0002137 + + + + obo:DDO.owl#DDO_0002137 + 5501000119106 + + + + obo:DDO.owl#DDO_0002137 + postoperative hypertension + + + + obo:DDO.owl#DDO_0002138 + DDO:DDO_0002138 + + + + obo:DDO.owl#DDO_0002138 + 48194001 + + + + obo:DDO.owl#DDO_0002138 + pregnancy-induced hypertension + + + + obo:DDO.owl#DDO_0002139 + DDO:DDO_0002139 + + + + obo:DDO.owl#DDO_0002139 + 237282002 + + + + obo:DDO.owl#DDO_0002139 + impending eclampsia + + + + obo:DDO.owl#DDO_0002140 + DDO:DDO_0002140 + + + + obo:DDO.owl#DDO_0002140 + 288250001 + + + + obo:DDO.owl#DDO_0002140 + maternal hypertension + + + + obo:DDO.owl#DDO_0002141 + DDO:DDO_0002141 + + + + obo:DDO.owl#DDO_0002141 + 398254007 + + + + obo:DDO.owl#DDO_0002141 + pre-eclampsia + + + + obo:DDO.owl#DDO_0002142 + DDO:DDO_0002142 + + + + obo:DDO.owl#DDO_0002142 + 41114007 + + + + obo:DDO.owl#DDO_0002142 + mild pre-eclampsia + + + + obo:DDO.owl#DDO_0002143 + DDO:DDO_0002143 + + + + obo:DDO.owl#DDO_0002143 + 46764007 + + + + obo:DDO.owl#DDO_0002143 + severe pre-eclampsia + + + + obo:DDO.owl#DDO_0002144 + DDO:DDO_0002144 + + + + obo:DDO.owl#DDO_0002144 + 15394000 + + + + obo:DDO.owl#DDO_0002144 + toxemia of pregnancy + + + + obo:DDO.owl#DDO_0002145 + DDO:DDO_0002145 + + + + obo:DDO.owl#DDO_0002145 + 84094009 + + + + obo:DDO.owl#DDO_0002145 + rebound hypertension + + + + obo:DDO.owl#DDO_0002146 + DDO:DDO_0002146 + + + + obo:DDO.owl#DDO_0002146 + 31992008 + + + + obo:DDO.owl#DDO_0002146 + secondary hypertension + + + + obo:DDO.owl#DDO_0002147 + DDO:DDO_0002147 + + + + obo:DDO.owl#DDO_0002147 + 194785008 + + + + obo:DDO.owl#DDO_0002147 + benign secondary hypertension + + + + obo:DDO.owl#DDO_0002148 + DDO:DDO_0002148 + + + + obo:DDO.owl#DDO_0002148 + 59997006 + + + + obo:DDO.owl#DDO_0002148 + endocrine hypertension + + + + obo:DDO.owl#DDO_0002149 + DDO:DDO_0002149 + + + + obo:DDO.owl#DDO_0002149 + 427889009 + + + + obo:DDO.owl#DDO_0002149 + hypertension associated with transplantation + + + + obo:DDO.owl#DDO_0002150 + DDO:DDO_0002150 + + + + obo:DDO.owl#DDO_0002150 + 428575007 + + + + obo:DDO.owl#DDO_0002150 + hypertension secondary to kidney transplant + + + + obo:DDO.owl#DDO_0002151 + DDO:DDO_0002151 + + + + obo:DDO.owl#DDO_0002151 + 28119000 + + + + obo:DDO.owl#DDO_0002151 + renal hypertension + + + + obo:DDO.owl#DDO_0002152 + DDO:DDO_0002152 + + + + obo:DDO.owl#DDO_0002152 + 57684003 + + + + obo:DDO.owl#DDO_0002152 + parenchymal renal hypertension + + + + obo:DDO.owl#DDO_0002153 + DDO:DDO_0002153 + + + + obo:DDO.owl#DDO_0002153 + 14973001 + + + + obo:DDO.owl#DDO_0002153 + renal sclerosis with hypertension + + + + obo:DDO.owl#DDO_0002154 + DDO:DDO_0002154 + + + + obo:DDO.owl#DDO_0002154 + 123799005 + + + + obo:DDO.owl#DDO_0002154 + renovascular hypertension + + + + obo:DDO.owl#DDO_0002155 + DDO:DDO_0002155 + + + + obo:DDO.owl#DDO_0002155 + 73410007 + + + + obo:DDO.owl#DDO_0002155 + benign secondary renovascular hypertension + + + + obo:DDO.owl#DDO_0002156 + DDO:DDO_0002156 + + + + obo:DDO.owl#DDO_0002156 + 123800009 + + + + obo:DDO.owl#DDO_0002156 + Goldblatt hypertension + + + + obo:DDO.owl#DDO_0002157 + DDO:DDO_0002157 + + + + obo:DDO.owl#DDO_0002157 + 194783001 + + + + obo:DDO.owl#DDO_0002157 + malignant secondary renovascular hypertension + + + + obo:DDO.owl#DDO_0002158 + DDO:DDO_0002158 + + + + obo:DDO.owl#DDO_0002158 + 39018007 + + + + obo:DDO.owl#DDO_0002158 + renal arterial hypertension + + + + obo:DDO.owl#DDO_0002159 + DDO:DDO_0002159 + + + + obo:DDO.owl#DDO_0002159 + 74451002 + + + + obo:DDO.owl#DDO_0002159 + secondary diastolic hypertension + + + + obo:DDO.owl#DDO_0002160 + DDO:DDO_0002160 + + + + obo:DDO.owl#DDO_0002160 + 56218007 + + + + obo:DDO.owl#DDO_0002160 + systolic hypertension + + + + obo:DDO.owl#DDO_0002161 + DDO:DDO_0002161 + + + + obo:DDO.owl#DDO_0002161 + 402599005 + + + + obo:DDO.owl#DDO_0002161 + acanthosis nigricans + + + + obo:DDO.owl#DDO_0002162 + DDO:DDO_0002162 + + + + obo:DDO.owl#DDO_0002162 + 402342001 + + + + obo:DDO.owl#DDO_0002162 + acanthosis nigricans of oral mucous membranes + + + + obo:DDO.owl#DDO_0002163 + DDO:DDO_0002163 + + + + obo:DDO.owl#DDO_0002163 + 702361006 + + + + obo:DDO.owl#DDO_0002163 + Crouzon syndrome with acanthosis nigricans + + + + obo:DDO.owl#DDO_0002164 + DDO:DDO_0002164 + + + + obo:DDO.owl#DDO_0002164 + 238981002 + + + + obo:DDO.owl#DDO_0002164 + soft tissue complication of diabetes mellitus + + + + obo:DDO.owl#DDO_0002165 + DDO:DDO_0002165 + + + + obo:DDO.owl#DDO_0002165 + 48951005 + + + + obo:DDO.owl#DDO_0002165 + bullosis diabeticorum + + + + obo:DDO.owl#DDO_0002166 + DDO:DDO_0002166 + + + + obo:DDO.owl#DDO_0002166 + 238982009 + + + + obo:DDO.owl#DDO_0002166 + diabetic dermopathy + + + + obo:DDO.owl#DDO_0002167 + DDO:DDO_0002167 + + + + obo:DDO.owl#DDO_0002167 + 238984005 + + + + obo:DDO.owl#DDO_0002167 + diabetic rubeosis + + + + obo:DDO.owl#DDO_0002168 + DDO:DDO_0002168 + + + + obo:DDO.owl#DDO_0002168 + 238983004 + + + + obo:DDO.owl#DDO_0002168 + diabetic thick skin syndrome + + + + obo:DDO.owl#DDO_0002169 + DDO:DDO_0002169 + + + + obo:DDO.owl#DDO_0002169 + 62260007 + + + + obo:DDO.owl#DDO_0002169 + pretibial pigmental patches in diabetes + + + + obo:DDO.owl#DDO_0002170 + DDO:DDO_0002170 + + + + obo:DDO.owl#DDO_0002170 + 3218000 + + + + obo:DDO.owl#DDO_0002170 + mycosis + + + + obo:DDO.owl#DDO_0002170 + Fungal infection + + + + obo:DDO.owl#DDO_0002172 + DDO:DDO_0002172 + + + + obo:DDO.owl#DDO_0002172 + 403104005 + + + + obo:DDO.owl#DDO_0002172 + distal and lateral subungual onychomycosis + + + + obo:DDO.owl#DDO_0002173 + DDO:DDO_0002173 + + + + obo:DDO.owl#DDO_0002173 + 402134005 + + + + obo:DDO.owl#DDO_0002173 + onychomycosis due to dermatophyte + + + + obo:DDO.owl#DDO_0002174 + DDO:DDO_0002174 + + + + obo:DDO.owl#DDO_0002174 + 403109000 + + + + obo:DDO.owl#DDO_0002174 + endonyx onychomycosis + + + + obo:DDO.owl#DDO_0002175 + DDO:DDO_0002175 + + + + obo:DDO.owl#DDO_0002175 + onychomycosis of fingernails + + + + obo:DDO.owl#DDO_0002175 + onychomycosis of fingernails + + + + obo:DDO.owl#DDO_0002176 + DDO:DDO_0002176 + + + + obo:DDO.owl#DDO_0002176 + 403059006 + + + + obo:DDO.owl#DDO_0002176 + onychomycosis of toenails + + + + obo:DDO.owl#DDO_0002177 + DDO:DDO_0002177 + + + + obo:DDO.owl#DDO_0002177 + 403105006 + + + + obo:DDO.owl#DDO_0002177 + proximal subungual onychomycosis + + + + obo:DDO.owl#DDO_0002178 + DDO:DDO_0002178 + + + + obo:DDO.owl#DDO_0002178 + 417583002 + + + + obo:DDO.owl#DDO_0002178 + superficial white onychomycosis + + + + obo:DDO.owl#DDO_0002179 + DDO:DDO_0002179 + + + + obo:DDO.owl#DDO_0002179 + 403107003 + + + + obo:DDO.owl#DDO_0002179 + total dystrophic onychomycosis + + + + obo:DDO.owl#DDO_0002180 + DDO:DDO_0002180 + + + + obo:DDO.owl#DDO_0002180 + 247442005 + + + + obo:DDO.owl#DDO_0002180 + broken skin + + + + obo:DDO.owl#DDO_0002181 + DDO:DDO_0002181 + + + + obo:DDO.owl#DDO_0002181 + 95324001 + + + + obo:DDO.owl#DDO_0002181 + skin lesion + + + + obo:DDO.owl#DDO_0002182 + DDO:DDO_0002182 + + + + obo:DDO.owl#DDO_0002182 + 708529002 + + + + obo:DDO.owl#DDO_0002182 + lesion of degenerative abnormality + + + + obo:DDO.owl#DDO_0002183 + DDO:DDO_0002183 + + + + obo:DDO.owl#DDO_0002183 + 75594004 + + + + obo:DDO.owl#DDO_0002183 + xanthelasma + + + + obo:DDO.owl#DDO_0002184 + DDO:DDO_0002184 + + + + obo:DDO.owl#DDO_0002184 + 301913002 + + + + obo:DDO.owl#DDO_0002184 + lesion of eyelid + + + + obo:DDO.owl#DDO_0002185 + DDO:DDO_0002185 + + + + obo:DDO.owl#DDO_0002185 + 6400008 + + + + obo:DDO.owl#DDO_0002185 + xanthoma of eyelid + + + + obo:DDO.owl#DDO_0002188 + DDO:DDO_0002188 + + + + obo:DDO.owl#DDO_0002188 + 700338003 + + + + obo:DDO.owl#DDO_0002188 + xanthoma of lower eyelid + + + + obo:DDO.owl#DDO_0002189 + DDO:DDO_0002189 + + + + obo:DDO.owl#DDO_0002189 + 700342000 + + + + obo:DDO.owl#DDO_0002189 + xanthoma of upper eyelid + + + + obo:DDO.owl#DDO_0002190 + DDO:DDO_0002190 + + + + obo:DDO.owl#DDO_0002190 + 54736008 + + + + obo:DDO.owl#DDO_0002190 + xanthoma planum of eyelid + + + + obo:DDO.owl#DDO_0002191 + DDO:DDO_0002191 + + + + obo:DDO.owl#DDO_0002191 + 95663000 + + + + obo:DDO.owl#DDO_0002191 + peripheral motor neuropathy + + + + obo:DDO.owl#DDO_0002192 + DDO:DDO_0002192 + + + + obo:DDO.owl#DDO_0002192 + 79554005 + + + + obo:DDO.owl#DDO_0002192 + asymmetric diabetic proximal motor neuropathy + + + + obo:DDO.owl#DDO_0002193 + DDO:DDO_0002193 + + + + obo:DDO.owl#DDO_0002193 + 39127005 + + + + obo:DDO.owl#DDO_0002193 + symmetric diabetic proximal motor neuropathy + + + + obo:DDO.owl#DDO_0002194 + DDO:DDO_0002194 + + + + obo:DDO.owl#DDO_0002194 + 11442006 + + + + obo:DDO.owl#DDO_0002194 + hereditary sensory neuropathy + + + + obo:DDO.owl#DDO_0002195 + DDO:DDO_0002195 + + + + obo:DDO.owl#DDO_0002195 + 230556005 + + + + obo:DDO.owl#DDO_0002195 + X-linked recessive sensory neuropathy + + + + obo:DDO.owl#DDO_0002196 + DDO:DDO_0002196 + + + + obo:DDO.owl#DDO_0002196 + 110181000119105 + + + + obo:DDO.owl#DDO_0002196 + peripheral sensory neuropathy due to type 2 diabetes mellitus + + + + obo:DDO.owl#DDO_0002197 + DDO:DDO_0002197 + + + + obo:DDO.owl#DDO_0002197 + 102781000119107 + + + + obo:DDO.owl#DDO_0002197 + sensory neuropathy due to type 1 diabetes mellitus + + + + obo:DDO.owl#DDO_0002198 + DDO:DDO_0002198 + + + + obo:DDO.owl#DDO_0002198 + 309520003 + + + + obo:DDO.owl#DDO_0002198 + symmetrical sensory neuropathy + + + + obo:DDO.owl#DDO_0002199 + DDO:DDO_0002199 + + + + obo:DDO.owl#DDO_0002199 + 247325003 + + + + obo:DDO.owl#DDO_0002199 + altered sensation of skin + + + + obo:DDO.owl#DDO_0002200 + DDO:DDO_0002200 + + + + obo:DDO.owl#DDO_0002200 + 279079003 + + + + obo:DDO.owl#DDO_0002200 + dysesthesia + + + + obo:DDO.owl#DDO_0002201 + DDO:DDO_0002201 + + + + obo:DDO.owl#DDO_0002201 + 403597003 + + + + obo:DDO.owl#DDO_0002201 + cutaneous allodynia + + + + obo:DDO.owl#DDO_0002202 + DDO:DDO_0002202 + + + + obo:DDO.owl#DDO_0002202 + 403596007 + + + + obo:DDO.owl#DDO_0002202 + cutaneous hyperalgesia + + + + obo:DDO.owl#DDO_0002203 + DDO:DDO_0002203 + + + + obo:DDO.owl#DDO_0002203 + 698775005 + + + + obo:DDO.owl#DDO_0002203 + dysesthesia of face + + + + obo:DDO.owl#DDO_0002204 + DDO:DDO_0002204 + + + + obo:DDO.owl#DDO_0002204 + 403598008 + + + + obo:DDO.owl#DDO_0002204 + skin-ache syndrome + + + + obo:DDO.owl#DDO_0002205 + DDO:DDO_0002205 + + + + obo:DDO.owl#DDO_0002205 + 418363000 + + + + obo:DDO.owl#DDO_0002205 + itching of skin + + + + obo:DDO.owl#DDO_0002206 + DDO:DDO_0002206 + + + + obo:DDO.owl#DDO_0002206 + 276444007 + + + + obo:DDO.owl#DDO_0002206 + generalized pruritus + + + + obo:DDO.owl#DDO_0002207 + DDO:DDO_0002207 + + + + obo:DDO.owl#DDO_0002207 + 445329008 + + + + obo:DDO.owl#DDO_0002207 + itching of lesion of skin + + + + obo:DDO.owl#DDO_0002208 + DDO:DDO_0002208 + + + + obo:DDO.owl#DDO_0002208 + 275921007 + + + + obo:DDO.owl#DDO_0002208 + scalp itchy + + + + obo:DDO.owl#DDO_0002209 + DDO:DDO_0002209 + + + + obo:DDO.owl#DDO_0002209 + 398805009 + + + + obo:DDO.owl#DDO_0002209 + loss of protective sensation of skin + + + + obo:DDO.owl#DDO_0002210 + DDO:DDO_0002210 + + + + obo:DDO.owl#DDO_0002210 + 62507009 + + + + obo:DDO.owl#DDO_0002210 + pins and needles + + + + obo:DDO.owl#DDO_0002211 + DDO:DDO_0002211 + + + + obo:DDO.owl#DDO_0002211 + 398026008 + + + + obo:DDO.owl#DDO_0002211 + reduced sensation of skin + + + + obo:DDO.owl#DDO_0002212 + DDO:DDO_0002212 + + + + obo:DDO.owl#DDO_0002212 + 299945006 + + + + obo:DDO.owl#DDO_0002212 + graphesthesia impaired + + + + obo:DDO.owl#DDO_0002213 + DDO:DDO_0002213 + + + + obo:DDO.owl#DDO_0002213 + 6810008 + + + + obo:DDO.owl#DDO_0002213 + hypoalgesia + + + + obo:DDO.owl#DDO_0002214 + DDO:DDO_0002214 + + + + obo:DDO.owl#DDO_0002214 + 24234009 + + + + obo:DDO.owl#DDO_0002214 + hemihypalgesia + + + + obo:DDO.owl#DDO_0002216 + DDO:DDO_0002216 + + + + obo:DDO.owl#DDO_0002216 + 299928001 + + + + obo:DDO.owl#DDO_0002216 + impaired pin prick discrimination + + + + obo:DDO.owl#DDO_0002217 + DDO:DDO_0002217 + + + + obo:DDO.owl#DDO_0002217 + 299934008 + + + + obo:DDO.owl#DDO_0002217 + impaired vibration sensation + + + + obo:DDO.owl#DDO_0002218 + DDO:DDO_0002218 + + + + obo:DDO.owl#DDO_0002218 + 398632002 + + + + obo:DDO.owl#DDO_0002218 + impaired vibration sensation of foot + + + + obo:DDO.owl#DDO_0002219 + DDO:DDO_0002219 + + + + obo:DDO.owl#DDO_0002219 + 59073000 + + + + obo:DDO.owl#DDO_0002219 + tactile hypesthesia + + + + obo:DDO.owl#DDO_0002220 + DDO:DDO_0002220 + + + + obo:DDO.owl#DDO_0002220 + 299918005 + + + + obo:DDO.owl#DDO_0002220 + impaired firm touch sensation + + + + obo:DDO.owl#DDO_0002222 + DDO:DDO_0002222 + + + + obo:DDO.owl#DDO_0002222 + 299913001 + + + + obo:DDO.owl#DDO_0002222 + impaired light touch sensation + + + + obo:DDO.owl#DDO_0002223 + DDO:DDO_0002223 + + + + obo:DDO.owl#DDO_0002223 + 299923005 + + + + obo:DDO.owl#DDO_0002223 + impaired touch discrimination + + + + obo:DDO.owl#DDO_0002224 + DDO:DDO_0002224 + + + + obo:DDO.owl#DDO_0002224 + 1140008 + + + + obo:DDO.owl#DDO_0002224 + thermal hypesthesia + + + + obo:DDO.owl#DDO_0002225 + DDO:DDO_0002225 + + + + obo:DDO.owl#DDO_0002225 + 299907005 + + + + obo:DDO.owl#DDO_0002225 + cold sensation reduced + + + + obo:DDO.owl#DDO_0002226 + DDO:DDO_0002226 + + + + obo:DDO.owl#DDO_0002226 + 299905002 + + + + obo:DDO.owl#DDO_0002226 + heat sensation reduced + + + + obo:DDO.owl#DDO_0002227 + DDO:DDO_0002227 + + + + obo:DDO.owl#DDO_0002227 + 52674009 + + + + obo:DDO.owl#DDO_0002227 + ischemia + + + + obo:DDO.owl#DDO_0002228 + DDO:DDO_0002228 + + + + obo:DDO.owl#DDO_0002228 + 413552002 + + + + obo:DDO.owl#DDO_0002228 + anterior segment ischemia + + + + obo:DDO.owl#DDO_0002229 + DDO:DDO_0002229 + + + + obo:DDO.owl#DDO_0002229 + 233957006 + + + + obo:DDO.owl#DDO_0002229 + arterial ischemia + + + + obo:DDO.owl#DDO_0002230 + DDO:DDO_0002230 + + + + obo:DDO.owl#DDO_0002230 + 95456009 + + + + obo:DDO.owl#DDO_0002230 + brain stem ischemia + + + + obo:DDO.owl#DDO_0002231 + DDO:DDO_0002231 + + + + obo:DDO.owl#DDO_0002231 + 287731003 + + + + obo:DDO.owl#DDO_0002231 + cerebral ischemia + + + + obo:DDO.owl#DDO_0002232 + DDO:DDO_0002232 + + + + obo:DDO.owl#DDO_0002232 + 230716006 + + + + obo:DDO.owl#DDO_0002232 + carotid territory transient ischemic attack + + + + obo:DDO.owl#DDO_0002233 + DDO:DDO_0002233 + + + + obo:DDO.owl#DDO_0002233 + 88032003 + + + + obo:DDO.owl#DDO_0002233 + amaurosis fugax + + + + obo:DDO.owl#DDO_0002234 + DDO:DDO_0002234 + + + + obo:DDO.owl#DDO_0002234 + 195200006 + + + + obo:DDO.owl#DDO_0002234 + carotid artery syndrome hemispheric + + + + obo:DDO.owl#DDO_0002235 + DDO:DDO_0002235 + + + + obo:DDO.owl#DDO_0002235 + 111298007 + + + + obo:DDO.owl#DDO_0002235 + chronic cerebral ischemia + + + + obo:DDO.owl#DDO_0002236 + DDO:DDO_0002236 + + + + obo:DDO.owl#DDO_0002236 + 195206000 + + + + obo:DDO.owl#DDO_0002236 + intermittent cerebral ischemia + + + + obo:DDO.owl#DDO_0002237 + DDO:DDO_0002237 + + + + obo:DDO.owl#DDO_0002237 + 206576006 + + + + obo:DDO.owl#DDO_0002237 + neonatal cerebral ischemia + + + + obo:DDO.owl#DDO_0002238 + DDO:DDO_0002238 + + + + obo:DDO.owl#DDO_0002238 + 276706004 + + + + obo:DDO.owl#DDO_0002238 + perinatal cerebral ischemia + + + + obo:DDO.owl#DDO_0002239 + DDO:DDO_0002239 + + + + obo:DDO.owl#DDO_0002239 + 230717002 + + + + obo:DDO.owl#DDO_0002239 + Vertebrobasilar territory transient ischemic attack + + + + obo:DDO.owl#DDO_0002240 + DDO:DDO_0002240 + + + + obo:DDO.owl#DDO_0002240 + 64009001 + + + + obo:DDO.owl#DDO_0002240 + basilar artery syndrome + + + + obo:DDO.owl#DDO_0002241 + DDO:DDO_0002241 + + + + obo:DDO.owl#DDO_0002241 + 312916003 + + + + obo:DDO.owl#DDO_0002241 + choroidal ischemia + + + + obo:DDO.owl#DDO_0002242 + DDO:DDO_0002242 + + + + obo:DDO.owl#DDO_0002242 + 236120009 + + + + obo:DDO.owl#DDO_0002242 + ischemia of stoma + + + + obo:DDO.owl#DDO_0002243 + DDO:DDO_0002243 + + + + obo:DDO.owl#DDO_0002243 + 371029002 + + + + obo:DDO.owl#DDO_0002243 + ischemic disorder of spinal cord + + + + obo:DDO.owl#DDO_0002245 + DDO:DDO_0002245 + + + + obo:DDO.owl#DDO_0002245 + infarction of spinal cord + + + + obo:DDO.owl#DDO_0002246 + DDO:DDO_0002246 + + + + obo:DDO.owl#DDO_0002246 + 419944002 + + + + obo:DDO.owl#DDO_0002246 + orbital ischemic syndrome + + + + obo:DDO.owl#DDO_0002247 + DDO:DDO_0002247 + + + + obo:DDO.owl#DDO_0002247 + 233958001 + + + + obo:DDO.owl#DDO_0002247 + peripheral ischemia + + + + obo:DDO.owl#DDO_0002248 + DDO:DDO_0002248 + + + + obo:DDO.owl#DDO_0002248 + 402861007 + + + + obo:DDO.owl#DDO_0002248 + ischemic gangrene + + + + obo:DDO.owl#DDO_0002249 + DDO:DDO_0002249 + + + + obo:DDO.owl#DDO_0002249 + 21631000119105 + + + + obo:DDO.owl#DDO_0002249 + limb ischemia + + + + obo:DDO.owl#DDO_0002250 + DDO:DDO_0002250 + + + + obo:DDO.owl#DDO_0002250 + 233961000 + + + + obo:DDO.owl#DDO_0002250 + lower limb ischemia + + + + obo:DDO.owl#DDO_0002251 + DDO:DDO_0002251 + + + + obo:DDO.owl#DDO_0002251 + 233962007 + + + + obo:DDO.owl#DDO_0002251 + critical lower limb ischemia + + + + obo:DDO.owl#DDO_0002252 + DDO:DDO_0002252 + + + + obo:DDO.owl#DDO_0002252 + 301755001 + + + + obo:DDO.owl#DDO_0002252 + ischemic foot + + + + obo:DDO.owl#DDO_0002253 + DDO:DDO_0002253 + + + + obo:DDO.owl#DDO_0002253 + 312822006 + + + + obo:DDO.owl#DDO_0002253 + critical ischemia of foot + + + + obo:DDO.owl#DDO_0002254 + DDO:DDO_0002254 + + + + obo:DDO.owl#DDO_0002254 + 300917007 + + + + obo:DDO.owl#DDO_0002254 + ischemia of feet + + + + obo:DDO.owl#DDO_0002255 + DDO:DDO_0002255 + + + + obo:DDO.owl#DDO_0002255 + 307406004 + + + + obo:DDO.owl#DDO_0002255 + trash foot + + + + obo:DDO.owl#DDO_0002256 + DDO:DDO_0002256 + + + + obo:DDO.owl#DDO_0002256 + 312822006 + + + + obo:DDO.owl#DDO_0002256 + critical ischemia of foot + + + + obo:DDO.owl#DDO_0002257 + DDO:DDO_0002257 + + + + obo:DDO.owl#DDO_0002257 + 307408003 + + + + obo:DDO.owl#DDO_0002257 + ischemic toe + + + + obo:DDO.owl#DDO_0002258 + DDO:DDO_0002258 + + + + obo:DDO.owl#DDO_0002258 + 233959009 + + + + obo:DDO.owl#DDO_0002258 + upper limb ischemia + + + + obo:DDO.owl#DDO_0002259 + DDO:DDO_0002259 + + + + obo:DDO.owl#DDO_0002259 + 233960004 + + + + obo:DDO.owl#DDO_0002259 + critical upper limb ischemia + + + + obo:DDO.owl#DDO_0002260 + DDO:DDO_0002260 + + + + obo:DDO.owl#DDO_0002260 + 307407008 + + + + obo:DDO.owl#DDO_0002260 + ischemic hand + + + + obo:DDO.owl#DDO_0002261 + DDO:DDO_0002261 + + + + obo:DDO.owl#DDO_0002261 + 307409006 + + + + obo:DDO.owl#DDO_0002261 + ischemic finger + + + + obo:DDO.owl#DDO_0002262 + DDO:DDO_0002262 + + + + obo:DDO.owl#DDO_0002262 + 83256006 + + + + obo:DDO.owl#DDO_0002262 + strangulated hemorrhoids + + + + obo:DDO.owl#DDO_0002263 + DDO:DDO_0002263 + + + + obo:DDO.owl#DDO_0002263 + 249658006 + + + + obo:DDO.owl#DDO_0002263 + gangrenous pile + + + + obo:DDO.owl#DDO_0002264 + DDO:DDO_0002264 + + + + obo:DDO.owl#DDO_0002264 + 80829003 + + + + obo:DDO.owl#DDO_0002264 + strangulated external hemorrhoids + + + + obo:DDO.owl#DDO_0002265 + DDO:DDO_0002265 + + + + obo:DDO.owl#DDO_0002265 + 23202007 + + + + obo:DDO.owl#DDO_0002265 + strangulated internal hemorrhoids + + + + obo:DDO.owl#DDO_0002266 + DDO:DDO_0002266 + + + + obo:DDO.owl#DDO_0002266 + 57357009 + + + + obo:DDO.owl#DDO_0002266 + transient ischemia + + + + obo:DDO.owl#DDO_0002267 + DDO:DDO_0002267 + + + + obo:DDO.owl#DDO_0002267 + 153821000119103 + + + + obo:DDO.owl#DDO_0002267 + visceral ischemia + + + + obo:DDO.owl#DDO_0002268 + DDO:DDO_0002268 + + + + obo:DDO.owl#DDO_0002268 + 16386004 + + + + obo:DDO.owl#DDO_0002268 + dry skin + + + + obo:DDO.owl#DDO_0002269 + DDO:DDO_0002269 + + + + obo:DDO.owl#DDO_0002269 + 702757002 + + + + obo:DDO.owl#DDO_0002269 + severe dry skin + + + + obo:DDO.owl#DDO_0002270 + DDO:DDO_0002270 + + + + obo:DDO.owl#DDO_0002270 + 52475004 + + + + obo:DDO.owl#DDO_0002270 + xeroderma + + + + obo:DDO.owl#DDO_0002271 + DDO:DDO_0002271 + + + + obo:DDO.owl#DDO_0002271 + 260046006 + + + + obo:DDO.owl#DDO_0002271 + dry skin dermatitis + + + + obo:DDO.owl#DDO_0002272 + DDO:DDO_0002272 + + + + obo:DDO.owl#DDO_0002272 + 238997007 + + + + obo:DDO.owl#DDO_0002272 + drug-induced ichthyosiform reaction + + + + obo:DDO.owl#DDO_0002273 + DDO:DDO_0002273 + + + + obo:DDO.owl#DDO_0002273 + 238597002 + + + + obo:DDO.owl#DDO_0002273 + senile xeroderma + + + + obo:DDO.owl#DDO_0002274 + DDO:DDO_0002274 + + + + obo:DDO.owl#DDO_0002274 + 28414003 + + + + obo:DDO.owl#DDO_0002274 + vitamin A deficiency with xeroderma + + + + obo:DDO.owl#DDO_0002275 + DDO:DDO_0002275 + + + + obo:DDO.owl#DDO_0002275 + 402600008 + + + + obo:DDO.owl#DDO_0002275 + xeroderma in genetic syndrome + + + + obo:DDO.owl#DDO_0002276 + DDO:DDO_0002276 + + + + obo:DDO.owl#DDO_0002276 + 55846006 + + + + obo:DDO.owl#DDO_0002276 + xeroderma of eyelid + + + + obo:DDO.owl#DDO_0002277 + DDO:DDO_0002277 + + + + obo:DDO.owl#DDO_0002277 + 700298002 + + + + obo:DDO.owl#DDO_0002277 + xeroderma of lower eyelid + + + + obo:DDO.owl#DDO_0002278 + DDO:DDO_0002278 + + + + obo:DDO.owl#DDO_0002278 + 700346002 + + + + obo:DDO.owl#DDO_0002278 + xeroderma of upper eyelid + + + + obo:DDO.owl#DDO_0002279 + DDO:DDO_0002279 + + + + obo:DDO.owl#DDO_0002279 + 44600005 + + + + obo:DDO.owl#DDO_0002279 + xeroderma pigmentosum + + + + obo:DDO.owl#DDO_0002280 + DDO:DDO_0002280 + + + + obo:DDO.owl#DDO_0002280 + 14204003 + + + + obo:DDO.owl#DDO_0002280 + pigmented xerodermoid + + + + obo:DDO.owl#DDO_0002281 + DDO:DDO_0002281 + + + + obo:DDO.owl#DDO_0002281 + 7806002 + + + + obo:DDO.owl#DDO_0002281 + non-neurologic xeroderma pigmentosum + + + + obo:DDO.owl#DDO_0002282 + DDO:DDO_0002282 + + + + obo:DDO.owl#DDO_0002282 + 238408000 + + + + obo:DDO.owl#DDO_0002282 + infection of nail + + + + obo:DDO.owl#DDO_0002283 + DDO:DDO_0002283 + + + + obo:DDO.owl#DDO_0002283 + 229811005 + + + + obo:DDO.owl#DDO_0002283 + foot callus + + + + obo:DDO.owl#DDO_0002284 + DDO:DDO_0002284 + + + + obo:DDO.owl#DDO_0002284 + 429265003 + + + + obo:DDO.owl#DDO_0002284 + callus of heel + + + + obo:DDO.owl#DDO_0002285 + DDO:DDO_0002285 + + + + obo:DDO.owl#DDO_0002285 + 201043003 + + + + obo:DDO.owl#DDO_0002285 + callosity under metatarsal head + + + + obo:DDO.owl#DDO_0002286 + DDO:DDO_0002286 + + + + obo:DDO.owl#DDO_0002286 + 201041001 + + + + obo:DDO.owl#DDO_0002286 + callosity on toe + + + + obo:DDO.owl#DDO_0002287 + DDO:DDO_0002287 + + + + obo:DDO.owl#DDO_0002287 + 201040000 + + + + obo:DDO.owl#DDO_0002287 + callosity + + + + obo:DDO.owl#DDO_0002288 + DDO:DDO_0002288 + + + + obo:DDO.owl#DDO_0002288 + 201042008 + + + + obo:DDO.owl#DDO_0002288 + callosity between toes + + + + obo:DDO.owl#DDO_0002289 + DDO:DDO_0002289 + + + + obo:DDO.owl#DDO_0002289 + 229810006 + + + + obo:DDO.owl#DDO_0002289 + apical callus + + + + obo:DDO.owl#DDO_0002290 + DDO:DDO_0002290 + + + + obo:DDO.owl#DDO_0002290 + 95345008 + + + + obo:DDO.owl#DDO_0002290 + foot ulcer + + + + obo:DDO.owl#DDO_0002291 + DDO:DDO_0002291 + + + + obo:DDO.owl#DDO_0002291 + 371087003 + + + + obo:DDO.owl#DDO_0002291 + diabetic foot ulcer + + + + obo:DDO.owl#DDO_0002292 + DDO:DDO_0002292 + + + + obo:DDO.owl#DDO_0002292 + 164881000119109 + + + + obo:DDO.owl#DDO_0002292 + foot ulcer due to type 1 diabetes mellitus + + + + obo:DDO.owl#DDO_0002293 + DDO:DDO_0002293 + + + + obo:DDO.owl#DDO_0002293 + 233956002 + + + + obo:DDO.owl#DDO_0002293 + aortoiliac atherosclerosis + + + + obo:DDO.owl#DDO_0002294 + DDO:DDO_0002294 + + + + obo:DDO.owl#DDO_0002294 + 201250006 + + + + obo:DDO.owl#DDO_0002294 + ischemic ulcer diabetic foot + + + + obo:DDO.owl#DDO_0002295 + DDO:DDO_0002295 + + + + obo:DDO.owl#DDO_0002295 + 201251005 + + + + obo:DDO.owl#DDO_0002295 + neuropathic diabetic ulcer - foot + + + + obo:DDO.owl#DDO_0002296 + DDO:DDO_0002296 + + + + obo:DDO.owl#DDO_0002296 + 127014009 + + + + obo:DDO.owl#DDO_0002296 + diabetic peripheral angiopathy + + + + obo:DDO.owl#DDO_0002297 + DDO:DDO_0002297 + + + + obo:DDO.owl#DDO_0002297 + 63491006 + + + + obo:DDO.owl#DDO_0002297 + intermittent claudication + + + + obo:DDO.owl#DDO_0002298 + DDO:DDO_0002298 + + + + obo:DDO.owl#DDO_0002298 + 76523007 + + + + obo:DDO.owl#DDO_0002298 + intermittent cauda equina claudication + + + + obo:DDO.owl#DDO_0002299 + DDO:DDO_0002299 + + + + obo:DDO.owl#DDO_0002299 + 5561000119107 + + + + obo:DDO.owl#DDO_0002299 + intermittent claudication due to atherosclerosis of native artery of limb + + + + obo:DDO.owl#DDO_0002301 + DDO:DDO_0002301 + + + + obo:DDO.owl#DDO_0002301 + 16941005 + + + + obo:DDO.owl#DDO_0002301 + intermittent spinal claudication + + + + obo:DDO.owl#DDO_0002302 + DDO:DDO_0002302 + + + + obo:DDO.owl#DDO_0002302 + 431706008 + + + + obo:DDO.owl#DDO_0002302 + occlusion of artery of upper extremity + + + + obo:DDO.owl#DDO_0002303 + DDO:DDO_0002303 + + + + obo:DDO.owl#DDO_0002303 + 400047006 + + + + obo:DDO.owl#DDO_0002303 + peripheral vascular disease + + + + obo:DDO.owl#DDO_0002304 + DDO:DDO_0002304 + + + + obo:DDO.owl#DDO_0002304 + 4249000 + + + + obo:DDO.owl#DDO_0002304 + poor peripheral circulation + + + + obo:DDO.owl#DDO_0002308 + DDO:DDO_0002308 + + + + obo:DDO.owl#DDO_0002308 + 399269003 + + + + obo:DDO.owl#DDO_0002308 + arthropathy + + + + obo:DDO.owl#DDO_0002309 + DDO:DDO_0002309 + + + + obo:DDO.owl#DDO_0002309 + 67536000 + + + + obo:DDO.owl#DDO_0002309 + neuropathic arthropathy + + + + obo:DDO.owl#DDO_0002310 + DDO:DDO_0002310 + + + + obo:DDO.owl#DDO_0002310 + 359554008 + + + + obo:DDO.owl#DDO_0002310 + Charcot's arthropathy + + + + obo:DDO.owl#DDO_0002311 + DDO:DDO_0002311 + + + + obo:DDO.owl#DDO_0002311 + 309255002 + + + + obo:DDO.owl#DDO_0002311 + Charcot's joint of foot + + + + obo:DDO.owl#DDO_0002312 + DDO:DDO_0002312 + + + + obo:DDO.owl#DDO_0002312 + 705058008 + + + + obo:DDO.owl#DDO_0002312 + Charcot arthropathy of forefoot + + + + obo:DDO.owl#DDO_0002313 + DDO:DDO_0002313 + + + + obo:DDO.owl#DDO_0002313 + 700438002 + + + + obo:DDO.owl#DDO_0002313 + Charcot arthropathy of hindfoot + + + + obo:DDO.owl#DDO_0002314 + DDO:DDO_0002314 + + + + obo:DDO.owl#DDO_0002314 + 700437007 + + + + obo:DDO.owl#DDO_0002314 + Charcot arthropathy of midfoot + + + + obo:DDO.owl#DDO_0002315 + DDO:DDO_0002315 + + + + obo:DDO.owl#DDO_0002315 + 201724008 + + + + obo:DDO.owl#DDO_0002315 + diabetic neuropathic arthropathy + + + + obo:DDO.owl#DDO_0002316 + DDO:DDO_0002316 + + + + obo:DDO.owl#DDO_0002316 + 301021005 + + + + obo:DDO.owl#DDO_0002316 + ulcer of toe + + + + obo:DDO.owl#DDO_0002317 + DDO:DDO_0002317 + + + + obo:DDO.owl#DDO_0002317 + 308740002 + + + + obo:DDO.owl#DDO_0002317 + ulcer of big toe + + + + obo:DDO.owl#DDO_0002318 + DDO:DDO_0002318 + + + + obo:DDO.owl#DDO_0002318 + 238794007 + + + + obo:DDO.owl#DDO_0002318 + ischemic foot ulcer + + + + obo:DDO.owl#DDO_0002319 + DDO:DDO_0002319 + + + + obo:DDO.owl#DDO_0002319 + 201250006 + + + + obo:DDO.owl#DDO_0002319 + ischemic ulcer diabetic foot + + + + obo:DDO.owl#DDO_0002320 + DDO:DDO_0002320 + + + + obo:DDO.owl#DDO_0002320 + 429768000 + + + + obo:DDO.owl#DDO_0002320 + ischemic ulcer of toe + + + + obo:DDO.owl#DDO_0002321 + DDO:DDO_0002321 + + + + obo:DDO.owl#DDO_0002321 + 10662511000119101 + + + + obo:DDO.owl#DDO_0002321 + ulcer of midfoot + + + + obo:DDO.owl#DDO_0002322 + DDO:DDO_0002322 + + + + obo:DDO.owl#DDO_0002322 + 10636231000119104 + + + + obo:DDO.owl#DDO_0002322 + chronic ulcer of midfoot + + + + obo:DDO.owl#DDO_0002323 + DDO:DDO_0002323 + + + + obo:DDO.owl#DDO_0002323 + 417746004 + + + + obo:DDO.owl#DDO_0002323 + trauma + + + + obo:DDO.owl#DDO_0002324 + DDO:DDO_0002324 + + + + obo:DDO.owl#DDO_0002324 + 324311000119105 + + + + obo:DDO.owl#DDO_0002324 + arthropathy due to endocrine disorder + + + + obo:DDO.owl#DDO_0002325 + DDO:DDO_0002325 + + + + obo:DDO.owl#DDO_0002325 + 201723002 + + + + obo:DDO.owl#DDO_0002325 + diabetic cheiroarthropathy + + + + obo:DDO.owl#DDO_0002326 + DDO:DDO_0002326 + + + + obo:DDO.owl#DDO_0002326 + 271737000 + + + + obo:DDO.owl#DDO_0002326 + anemia + + + + obo:DDO.owl#DDO_0002327 + DDO:DDO_0002327 + + + + obo:DDO.owl#DDO_0002327 + 66612000 + + + + obo:DDO.owl#DDO_0002327 + nutritional anemia + + + + obo:DDO.owl#DDO_0002328 + DDO:DDO_0002328 + + + + obo:DDO.owl#DDO_0002328 + 87522002 + + + + obo:DDO.owl#DDO_0002328 + iron deficiency anemia + + + + obo:DDO.owl#DDO_0002329 + DDO:DDO_0002329 + + + + obo:DDO.owl#DDO_0002329 + 80126007 + + + + obo:DDO.owl#DDO_0002329 + Plummer-Vinson syndrome + + + + obo:DDO.owl#DDO_0002330 + DDO:DDO_0002330 + + + + obo:DDO.owl#DDO_0002330 + 290246007 + + + + obo:DDO.owl#DDO_0002330 + sideropenic anemia with reticuloendothelial siderosis + + + + obo:DDO.owl#DDO_0002331 + DDO:DDO_0002331 + + + + obo:DDO.owl#DDO_0002331 + 85649008 + + + + obo:DDO.owl#DDO_0002331 + megaloblastic anemia due to folate deficiency + + + + obo:DDO.owl#DDO_0002332 + DDO:DDO_0002332 + + + + obo:DDO.owl#DDO_0002332 + 49472006 + + + + obo:DDO.owl#DDO_0002332 + megaloblastic anemia due to vitamin B>12< deficiency + + + + obo:DDO.owl#DDO_0002333 + DDO:DDO_0002333 + + + + obo:DDO.owl#DDO_0002333 + 18637002 + + + + obo:DDO.owl#DDO_0002333 + megaloblastic anemia of premature infant + + + + obo:DDO.owl#DDO_0002334 + DDO:DDO_0002334 + + + + obo:DDO.owl#DDO_0002334 + 52565000 + + + + obo:DDO.owl#DDO_0002334 + non megaloblastic anemia associated with nutritional deficiency + + + + obo:DDO.owl#DDO_0002335 + DDO:DDO_0002335 + + + + obo:DDO.owl#DDO_0002335 + structural foot deformity + + + + obo:DDO.owl#DDO_0002336 + DDO:DDO_0002336 + + + + obo:DDO.owl#DDO_0002336 + 237623001 + + + + obo:DDO.owl#DDO_0002336 + acute hyperglycemia + + + + obo:DDO.owl#DDO_0002337 + DDO:DDO_0002337 + + + + obo:DDO.owl#DDO_0002337 + 170765005 + + + + obo:DDO.owl#DDO_0002337 + chronic hyperglycemia + + + + obo:DDO.owl#DDO_0002338 + DDO:DDO_0002338 + + + + obo:DDO.owl#DDO_0002338 + 398123003 + + + + obo:DDO.owl#DDO_0002338 + dawn phenomenon + + + + obo:DDO.owl#DDO_0002339 + DDO:DDO_0002339 + + + + obo:DDO.owl#DDO_0002339 + 237621004 + + + + obo:DDO.owl#DDO_0002339 + diabetic severe hyperglycemia + + + + obo:DDO.owl#DDO_0002340 + DDO:DDO_0002340 + + + + obo:DDO.owl#DDO_0002340 + 441690002 + + + + obo:DDO.owl#DDO_0002340 + drug-induced hyperglycemia + + + + obo:DDO.owl#DDO_0002341 + DDO:DDO_0002341 + + + + obo:DDO.owl#DDO_0002341 + 708122002 + + + + obo:DDO.owl#DDO_0002341 + steroid-induced hyperglycemia + + + + obo:DDO.owl#DDO_0002342 + DDO:DDO_0002342 + + + + obo:DDO.owl#DDO_0002342 + 276557002 + + + + obo:DDO.owl#DDO_0002342 + neonatal hyperglycemia + + + + obo:DDO.owl#DDO_0002343 + DDO:DDO_0002343 + + + + obo:DDO.owl#DDO_0002343 + 276559004 + + + + obo:DDO.owl#DDO_0002343 + iatrogenic neonatal hyperglycemia + + + + obo:DDO.owl#DDO_0002344 + DDO:DDO_0002344 + + + + obo:DDO.owl#DDO_0002344 + 276558007 + + + + obo:DDO.owl#DDO_0002344 + transient neonatal hyperglycemia + + + + obo:DDO.owl#DDO_0002345 + DDO:DDO_0002345 + + + + obo:DDO.owl#DDO_0002345 + 312148000 + + + + obo:DDO.owl#DDO_0002345 + fungal ear infection + + + + obo:DDO.owl#DDO_0002346 + DDO:DDO_0002346 + + + + obo:DDO.owl#DDO_0002346 + 53316003 + + + + obo:DDO.owl#DDO_0002346 + otomycosis + + + + obo:DDO.owl#DDO_0002347 + DDO:DDO_0002347 + + + + obo:DDO.owl#DDO_0002347 + 76490001 + + + + obo:DDO.owl#DDO_0002347 + otomycosis externa due to Fusarium + + + + obo:DDO.owl#DDO_0002348 + DDO:DDO_0002348 + + + + obo:DDO.owl#DDO_0002348 + 111898002 + + + + obo:DDO.owl#DDO_0002348 + chronic mycotic otitis externa + + + + obo:DDO.owl#DDO_0002349 + DDO:DDO_0002349 + + + + obo:DDO.owl#DDO_0002349 + 194208007 + + + + obo:DDO.owl#DDO_0002349 + chronic otitis externa due to moniliasis + + + + obo:DDO.owl#DDO_0002350 + DDO:DDO_0002350 + + + + obo:DDO.owl#DDO_0002350 + 16681000 + + + + obo:DDO.owl#DDO_0002350 + candidal otitis externa + + + + obo:DDO.owl#DDO_0002351 + DDO:DDO_0002351 + + + + obo:DDO.owl#DDO_0002351 + 302905001 + + + + obo:DDO.owl#DDO_0002351 + aspergillus otomycosis + + + + obo:DDO.owl#DDO_0002352 + DDO:DDO_0002352 + + + + obo:DDO.owl#DDO_0002352 + 232223003 + + + + obo:DDO.owl#DDO_0002352 + acute fungal otitis externa + + + + obo:DDO.owl#DDO_0002353 + DDO:DDO_0002353 + + + + obo:DDO.owl#DDO_0002353 + 410038006 + + + + obo:DDO.owl#DDO_0002353 + eumycotic mycetoma + + + + obo:DDO.owl#DDO_0002354 + DDO:DDO_0002354 + + + + obo:DDO.owl#DDO_0002354 + 29530003 + + + + obo:DDO.owl#DDO_0002354 + fungal granuloma + + + + obo:DDO.owl#DDO_0002355 + DDO:DDO_0002355 + + + + obo:DDO.owl#DDO_0002355 + 65696007 + + + + obo:DDO.owl#DDO_0002355 + Coccidioidal granuloma + + + + obo:DDO.owl#DDO_0002356 + DDO:DDO_0002356 + + + + obo:DDO.owl#DDO_0002356 + 240773008 + + + + obo:DDO.owl#DDO_0002356 + hyalohyphomycosis + + + + obo:DDO.owl#DDO_0002357 + DDO:DDO_0002357 + + + + obo:DDO.owl#DDO_0002357 + 240774002 + + + + obo:DDO.owl#DDO_0002357 + cutaneous hyalohyphomycosis + + + + obo:DDO.owl#DDO_0002358 + DDO:DDO_0002358 + + + + obo:DDO.owl#DDO_0002358 + 252402000 + + + + obo:DDO.owl#DDO_0002358 + mossy foot disease + + + + obo:DDO.owl#DDO_0002359 + DDO:DDO_0002359 + + + + obo:DDO.owl#DDO_0002359 + 86348002 + + + + obo:DDO.owl#DDO_0002359 + mycotic endocarditis + + + + obo:DDO.owl#DDO_0002360 + DDO:DDO_0002360 + + + + obo:DDO.owl#DDO_0002360 + 63553008 + + + + obo:DDO.owl#DDO_0002360 + candidal endocarditis + + + + obo:DDO.owl#DDO_0002361 + DDO:DDO_0002361 + + + + obo:DDO.owl#DDO_0002361 + 194931003 + + + + obo:DDO.owl#DDO_0002361 + endocarditis - blastomycosis + + + + obo:DDO.owl#DDO_0002362 + DDO:DDO_0002362 + + + + obo:DDO.owl#DDO_0002362 + 187041005 + + + + obo:DDO.owl#DDO_0002362 + histoplasma capsulatum with endocarditis + + + + obo:DDO.owl#DDO_0002363 + DDO:DDO_0002363 + + + + obo:DDO.owl#DDO_0002363 + 187051006 + + + + obo:DDO.owl#DDO_0002363 + histoplasma duboisii with endocarditis + + + + obo:DDO.owl#DDO_0002364 + DDO:DDO_0002364 + + + + obo:DDO.owl#DDO_0002364 + 78999002 + + + + obo:DDO.owl#DDO_0002364 + opportunistic mycosis + + + + obo:DDO.owl#DDO_0002365 + DDO:DDO_0002365 + + + + obo:DDO.owl#DDO_0002365 + 399314004 + + + + obo:DDO.owl#DDO_0002365 + systemic mycosis + + + + obo:DDO.owl#DDO_0002366 + DDO:DDO_0002366 + + + + obo:DDO.owl#DDO_0002366 + 419532006 + + + + obo:DDO.owl#DDO_0002366 + disseminated paracoccidioidomycosis + + + + obo:DDO.owl#DDO_0002367 + DDO:DDO_0002367 + + + + obo:DDO.owl#DDO_0002367 + 36866003 + + + + obo:DDO.owl#DDO_0002367 + mucocutaneous-lymphangitic paracoccidioidomycosis + + + + obo:DDO.owl#DDO_0002368 + DDO:DDO_0002368 + + + + obo:DDO.owl#DDO_0002368 + 84753008 + + + + obo:DDO.owl#DDO_0002368 + pneumonia in systemic mycosis + + + + obo:DDO.owl#DDO_0002369 + DDO:DDO_0002369 + + + + obo:DDO.owl#DDO_0002369 + 240701006 + + + + obo:DDO.owl#DDO_0002369 + systemic aspergillosis + + + + obo:DDO.owl#DDO_0002370 + DDO:DDO_0002370 + + + + obo:DDO.owl#DDO_0002370 + 187091009 + + + + obo:DDO.owl#DDO_0002370 + systemic cryptococcosis + + + + obo:DDO.owl#DDO_0002371 + DDO:DDO_0002371 + + + + obo:DDO.owl#DDO_0002371 + 240724004 + + + + obo:DDO.owl#DDO_0002371 + cutaneous cryptococcosis + + + + obo:DDO.owl#DDO_0002372 + DDO:DDO_0002372 + + + + obo:DDO.owl#DDO_0002372 + 238439003 + + + + obo:DDO.owl#DDO_0002372 + systemic mycosis affecting skin + + + + obo:DDO.owl#DDO_0002373 + DDO:DDO_0002373 + + + + obo:DDO.owl#DDO_0002373 + 240727006 + + + + obo:DDO.owl#DDO_0002373 + cutaneous coccidioidomycosis + + + + obo:DDO.owl#DDO_0002374 + DDO:DDO_0002374 + + + + obo:DDO.owl#DDO_0002374 + 65696007 + + + + obo:DDO.owl#DDO_0002374 + Coccidioidal granuloma + + + + obo:DDO.owl#DDO_0002375 + DDO:DDO_0002375 + + + + obo:DDO.owl#DDO_0002375 + 403110005 + + + + obo:DDO.owl#DDO_0002375 + disseminated cutaneous coccidioidomycosis + + + + obo:DDO.owl#DDO_0002376 + DDO:DDO_0002376 + + + + obo:DDO.owl#DDO_0002376 + 79949009 + + + + obo:DDO.owl#DDO_0002376 + primary cutaneous coccidioidomycosis + + + + obo:DDO.owl#DDO_0002377 + DDO:DDO_0002377 + + + + obo:DDO.owl#DDO_0002377 + 240728001 + + + + obo:DDO.owl#DDO_0002377 + subcutaneous coccidioidomycosis + + + + obo:DDO.owl#DDO_0002378 + DDO:DDO_0002378 + + + + obo:DDO.owl#DDO_0002378 + 240724004 + + + + obo:DDO.owl#DDO_0002378 + cutaneous cryptococcosis + + + + obo:DDO.owl#DDO_0002379 + DDO:DDO_0002379 + + + + obo:DDO.owl#DDO_0002379 + 240744005 + + + + obo:DDO.owl#DDO_0002379 + cutaneous histoplasmosis + + + + obo:DDO.owl#DDO_0002380 + DDO:DDO_0002380 + + + + obo:DDO.owl#DDO_0002380 + 278039004 + + + + obo:DDO.owl#DDO_0002380 + cutaneous African histoplasmosis + + + + obo:DDO.owl#DDO_0002381 + DDO:DDO_0002381 + + + + obo:DDO.owl#DDO_0002381 + 240746007 + + + + obo:DDO.owl#DDO_0002381 + disseminated cutaneous histoplasmosis + + + + obo:DDO.owl#DDO_0002382 + DDO:DDO_0002382 + + + + obo:DDO.owl#DDO_0002382 + 240745006 + + + + obo:DDO.owl#DDO_0002382 + primary cutaneous histoplasmosis + + + + obo:DDO.owl#DDO_0002383 + DDO:DDO_0002383 + + + + obo:DDO.owl#DDO_0002383 + 240762001 + + + + obo:DDO.owl#DDO_0002383 + cutaneous trichosporonosis + + + + obo:DDO.owl#DDO_0002384 + DDO:DDO_0002384 + + + + obo:DDO.owl#DDO_0002384 + 36866003 + + + + obo:DDO.owl#DDO_0002384 + mucocutaneous-lymphangitic paracoccidioidomycosis + + + + obo:DDO.owl#DDO_0002385 + DDO:DDO_0002385 + + + + obo:DDO.owl#DDO_0002385 + 238443004 + + + + obo:DDO.owl#DDO_0002385 + systemic fungal infection affecting skin + + + + obo:DDO.owl#DDO_0002386 + DDO:DDO_0002386 + + + + obo:DDO.owl#DDO_0002386 + 402138008 + + + + obo:DDO.owl#DDO_0002386 + disseminated cutaneous mycosis + + + + obo:DDO.owl#DDO_0002387 + DDO:DDO_0002387 + + + + obo:DDO.owl#DDO_0002387 + 240761008 + + + + obo:DDO.owl#DDO_0002387 + trichosporonosis + + + + obo:DDO.owl#DDO_0002388 + DDO:DDO_0002388 + + + + obo:DDO.owl#DDO_0002388 + 240762001 + + + + obo:DDO.owl#DDO_0002388 + cutaneous trichosporonosis + + + + obo:DDO.owl#DDO_0002389 + DDO:DDO_0002389 + + + + obo:DDO.owl#DDO_0002389 + 240763006 + + + + obo:DDO.owl#DDO_0002389 + disseminated trichosporonosis + + + + obo:DDO.owl#DDO_0002390 + DDO:DDO_0002390 + + + + obo:DDO.owl#DDO_0002390 + 35586003 + + + + obo:DDO.owl#DDO_0002390 + white piedra + + + + obo:DDO.owl#DDO_0002391 + DDO:DDO_0002391 + + + + obo:DDO.owl#DDO_0002391 + 59277005 + + + + obo:DDO.owl#DDO_0002391 + zygomycosis + + + + obo:DDO.owl#DDO_0002392 + DDO:DDO_0002392 + + + + obo:DDO.owl#DDO_0002392 + 86333008 + + + + obo:DDO.owl#DDO_0002392 + subcutaneous phycomycosis due to Basidiobolus + + + + obo:DDO.owl#DDO_0002393 + DDO:DDO_0002393 + + + + obo:DDO.owl#DDO_0002393 + 238442009 + + + + obo:DDO.owl#DDO_0002393 + subcutaneous zygomycosis + + + + obo:DDO.owl#DDO_0002394 + DDO:DDO_0002394 + + + + obo:DDO.owl#DDO_0002394 + 20443005 + + + + obo:DDO.owl#DDO_0002394 + rhinophycomycosis due to Entomophthora coronata + + + + obo:DDO.owl#DDO_0002395 + DDO:DDO_0002395 + + + + obo:DDO.owl#DDO_0002395 + 187100003 + + + + obo:DDO.owl#DDO_0002395 + rhinocerebral mucormycosis + + + + obo:DDO.owl#DDO_0002396 + DDO:DDO_0002396 + + + + obo:DDO.owl#DDO_0002396 + 233614003 + + + + obo:DDO.owl#DDO_0002396 + pulmonary mucormycosis + + + + obo:DDO.owl#DDO_0002397 + DDO:DDO_0002397 + + + + obo:DDO.owl#DDO_0002397 + 397562003 + + + + obo:DDO.owl#DDO_0002397 + orbital mucormycosis + + + + obo:DDO.owl#DDO_0002398 + DDO:DDO_0002398 + + + + obo:DDO.owl#DDO_0002398 + 240780005 + + + + obo:DDO.owl#DDO_0002398 + mucormycotic gangrenous cellulitis + + + + obo:DDO.owl#DDO_0002399 + DDO:DDO_0002399 + + + + obo:DDO.owl#DDO_0002399 + 111907002 + + + + obo:DDO.owl#DDO_0002399 + infection by Mortierella wolfii + + + + obo:DDO.owl#DDO_0002400 + DDO:DDO_0002400 + + + + obo:DDO.owl#DDO_0002400 + 60021008 + + + + obo:DDO.owl#DDO_0002400 + mortierellosis + + + + obo:DDO.owl#DDO_0002401 + DDO:DDO_0002401 + + + + obo:DDO.owl#DDO_0002401 + 43925005 + + + + obo:DDO.owl#DDO_0002401 + infection by Saksenaea + + + + obo:DDO.owl#DDO_0002402 + DDO:DDO_0002402 + + + + obo:DDO.owl#DDO_0002402 + 39740009 + + + + obo:DDO.owl#DDO_0002402 + infection by Rhizopus + + + + obo:DDO.owl#DDO_0002403 + DDO:DDO_0002403 + + + + obo:DDO.owl#DDO_0002403 + 31819001 + + + + obo:DDO.owl#DDO_0002403 + infection by Mucor + + + + obo:DDO.owl#DDO_0002404 + DDO:DDO_0002404 + + + + obo:DDO.owl#DDO_0002404 + 78081007 + + + + obo:DDO.owl#DDO_0002404 + infection by Cunninghamella + + + + obo:DDO.owl#DDO_0002405 + DDO:DDO_0002405 + + + + obo:DDO.owl#DDO_0002405 + 6298007 + + + + obo:DDO.owl#DDO_0002405 + infection by Absidia + + + + obo:DDO.owl#DDO_0002406 + DDO:DDO_0002406 + + + + obo:DDO.owl#DDO_0002406 + 187101004 + + + + obo:DDO.owl#DDO_0002406 + gastrointestinal mucormycosis + + + + obo:DDO.owl#DDO_0002407 + DDO:DDO_0002407 + + + + obo:DDO.owl#DDO_0002407 + 240781009 + + + + obo:DDO.owl#DDO_0002407 + disseminated mucormycosis + + + + obo:DDO.owl#DDO_0002408 + DDO:DDO_0002408 + + + + obo:DDO.owl#DDO_0002408 + 240779007 + + + + obo:DDO.owl#DDO_0002408 + necrotizing cutaneous mucormycosis + + + + obo:DDO.owl#DDO_0002409 + DDO:DDO_0002409 + + + + obo:DDO.owl#DDO_0002409 + 240778004 + + + + obo:DDO.owl#DDO_0002409 + cutaneous mucormycosis + + + + obo:DDO.owl#DDO_0002410 + DDO:DDO_0002410 + + + + obo:DDO.owl#DDO_0002410 + 76627001 + + + + obo:DDO.owl#DDO_0002410 + mucormycosis + + + + obo:DDO.owl#DDO_0002411 + DDO:DDO_0002411 + + + + obo:DDO.owl#DDO_0002411 + 86333008 + + + + obo:DDO.owl#DDO_0002411 + subcutaneous phycomycosis due to Basidiobolus + + + + obo:DDO.owl#DDO_0002412 + DDO:DDO_0002412 + + + + obo:DDO.owl#DDO_0002412 + 240787008 + + + + obo:DDO.owl#DDO_0002412 + disseminated basidiobolomycosis + + + + obo:DDO.owl#DDO_0002413 + DDO:DDO_0002413 + + + + obo:DDO.owl#DDO_0002413 + 240786004 + + + + obo:DDO.owl#DDO_0002413 + cutaneous basidiobolomycosis + + + + obo:DDO.owl#DDO_0002414 + DDO:DDO_0002414 + + + + obo:DDO.owl#DDO_0002414 + 4921002 + + + + obo:DDO.owl#DDO_0002414 + infection by Basidiobolus + + + + obo:DDO.owl#DDO_0002415 + DDO:DDO_0002415 + + + + obo:DDO.owl#DDO_0002415 + 240784001 + + + + obo:DDO.owl#DDO_0002415 + rhinofacial conidiobolomycosis + + + + obo:DDO.owl#DDO_0002416 + DDO:DDO_0002416 + + + + obo:DDO.owl#DDO_0002416 + 240785000 + + + + obo:DDO.owl#DDO_0002416 + disseminated conidiobolomycosis + + + + obo:DDO.owl#DDO_0002417 + DDO:DDO_0002417 + + + + obo:DDO.owl#DDO_0002417 + 240783007 + + + + obo:DDO.owl#DDO_0002417 + infection by Conidiobolus + + + + obo:DDO.owl#DDO_0002418 + DDO:DDO_0002418 + + + + obo:DDO.owl#DDO_0002418 + 240782002 + + + + obo:DDO.owl#DDO_0002418 + entomophthoramycosis + + + + obo:DDO.owl#DDO_0002419 + DDO:DDO_0002419 + + + + obo:DDO.owl#DDO_0002419 + 9418005 + + + + obo:DDO.owl#DDO_0002419 + necrobiosis lipoidica + + + + obo:DDO.owl#DDO_0002420 + DDO:DDO_0002420 + + + + obo:DDO.owl#DDO_0002420 + 41352000 + + + + obo:DDO.owl#DDO_0002420 + granulomatosis disciformis et progressiva + + + + obo:DDO.owl#DDO_0002422 + DDO:DDO_0002422 + + + + obo:DDO.owl#DDO_0002422 + 56391002 + + + + obo:DDO.owl#DDO_0002422 + necrobiosis lipoidica diabeticorum + + + + obo:DDO.owl#DDO_0002423 + DDO:DDO_0002423 + + + + obo:DDO.owl#DDO_0002423 + 66350002 + + + + obo:DDO.owl#DDO_0002423 + necrobiosis lipoidica, granulomatous type + + + + obo:DDO.owl#DDO_0002424 + DDO:DDO_0002424 + + + + obo:DDO.owl#DDO_0002424 + 16238009 + + + + obo:DDO.owl#DDO_0002424 + necrobiosis lipoidica, necrobiotic type + + + + obo:DDO.owl#DDO_0002425 + DDO:DDO_0002425 + + + + obo:DDO.owl#DDO_0002425 + 699870002 + + + + obo:DDO.owl#DDO_0002425 + severe achondrolasia with developmental delay and acanthosis nigricans + + + + obo:DDO.owl#DDO_0002426 + DDO:DDO_0002426 + + + + obo:DDO.owl#DDO_0002426 + 254666005 + + + + obo:DDO.owl#DDO_0002426 + keratosis + + + + obo:DDO.owl#DDO_0002427 + DDO:DDO_0002427 + + + + obo:DDO.owl#DDO_0002427 + 72129000 + + + + obo:DDO.owl#DDO_0002427 + acquired acanthosis nigricans + + + + obo:DDO.owl#DDO_0002428 + DDO:DDO_0002428 + + + + obo:DDO.owl#DDO_0002428 + 238634000 + + + + obo:DDO.owl#DDO_0002428 + benign acanthosis nigricans + + + + obo:DDO.owl#DDO_0002429 + DDO:DDO_0002429 + + + + obo:DDO.owl#DDO_0002429 + 205583005 + + + + obo:DDO.owl#DDO_0002429 + hereditary benign acanthosis nigricans + + + + obo:DDO.owl#DDO_0002430 + DDO:DDO_0002430 + + + + obo:DDO.owl#DDO_0002430 + 237606005 + + + + obo:DDO.owl#DDO_0002430 + hereditary benign acanthosis nigricans with insulin resistance + + + + obo:DDO.owl#DDO_0002431 + DDO:DDO_0002431 + + + + obo:DDO.owl#DDO_0002431 + 238637007 + + + + obo:DDO.owl#DDO_0002431 + acanthosis palmaris + + + + obo:DDO.owl#DDO_0002432 + DDO:DDO_0002432 + + + + obo:DDO.owl#DDO_0002432 + 238636003 + + + + obo:DDO.owl#DDO_0002432 + malignant acanthosis nigricans + + + + obo:DDO.owl#DDO_0002434 + DDO:DDO_0002434 + + + + obo:DDO.owl#DDO_0002434 + 8691004 + + + + obo:DDO.owl#DDO_0002434 + acquired ichthyosis + + + + obo:DDO.owl#DDO_0002435 + DDO:DDO_0002435 + + + + obo:DDO.owl#DDO_0002435 + 95334005 + + + + obo:DDO.owl#DDO_0002435 + senile ichthyosis + + + + obo:DDO.owl#DDO_0002436 + DDO:DDO_0002436 + + + + obo:DDO.owl#DDO_0002436 + 699221007 + + + + obo:DDO.owl#DDO_0002436 + acral keratosis + + + + obo:DDO.owl#DDO_0002437 + DDO:DDO_0002437 + + + + obo:DDO.owl#DDO_0002437 + 46629009 + + + + obo:DDO.owl#DDO_0002437 + acrokeratosis + + + + obo:DDO.owl#DDO_0002438 + DDO:DDO_0002438 + + + + obo:DDO.owl#DDO_0002438 + 400085009 + + + + obo:DDO.owl#DDO_0002438 + acrokeratosis verruciformis of Hopf + + + + obo:DDO.owl#DDO_0002439 + DDO:DDO_0002439 + + + + obo:DDO.owl#DDO_0002439 + 201101007 + + + + obo:DDO.owl#DDO_0002439 + actinic keratosis + + + + obo:DDO.owl#DDO_0002440 + DDO:DDO_0002440 + + + + obo:DDO.owl#DDO_0002440 + 403199007 + + + + obo:DDO.owl#DDO_0002440 + acantholytic actinic keratosis + + + + obo:DDO.owl#DDO_0002441 + DDO:DDO_0002441 + + + + obo:DDO.owl#DDO_0002441 + 418686001 + + + + obo:DDO.owl#DDO_0002441 + actinic keratosis of eyelid + + + + obo:DDO.owl#DDO_0002442 + DDO:DDO_0002442 + + + + obo:DDO.owl#DDO_0002442 + 403200005 + + + + obo:DDO.owl#DDO_0002442 + atrophic actinic keratosis + + + + obo:DDO.owl#DDO_0002443 + DDO:DDO_0002443 + + + + obo:DDO.owl#DDO_0002443 + 403208003 + + + + obo:DDO.owl#DDO_0002443 + diffuse actinic hyperkeratosis + + + + obo:DDO.owl#DDO_0002444 + DDO:DDO_0002444 + + + + obo:DDO.owl#DDO_0002444 + 449733007 + + + + obo:DDO.owl#DDO_0002444 + hyperkeratotic actinic keratosis + + + + obo:DDO.owl#DDO_0002445 + DDO:DDO_0002445 + + + + obo:DDO.owl#DDO_0002445 + 254667001 + + + + obo:DDO.owl#DDO_0002445 + hypertrophic solar keratosis + + + + obo:DDO.owl#DDO_0002446 + DDO:DDO_0002446 + + + + obo:DDO.owl#DDO_0002446 + 403198004 + + + + obo:DDO.owl#DDO_0002446 + lichenoid actinic keratosis + + + + obo:DDO.owl#DDO_0002447 + DDO:DDO_0002447 + + + + obo:DDO.owl#DDO_0002447 + 403202002 + + + + obo:DDO.owl#DDO_0002447 + multiple actinic keratoses + + + + obo:DDO.owl#DDO_0002448 + DDO:DDO_0002448 + + + + obo:DDO.owl#DDO_0002448 + 449732002 + + + + obo:DDO.owl#DDO_0002448 + pigmented actinic keratosis + + + + obo:DDO.owl#DDO_0002449 + DDO:DDO_0002449 + + + + obo:DDO.owl#DDO_0002449 + 403201009 + + + + obo:DDO.owl#DDO_0002449 + proliferative actinic keratosis + + + + obo:DDO.owl#DDO_0002450 + DDO:DDO_0002450 + + + + obo:DDO.owl#DDO_0002450 + 403741004 + + + + obo:DDO.owl#DDO_0002450 + arsenical keratosis + + + + obo:DDO.owl#DDO_0002451 + DDO:DDO_0002451 + + + + obo:DDO.owl#DDO_0002451 + 304524009 + + + + obo:DDO.owl#DDO_0002451 + bowenoid actinic keratosis + + + + obo:DDO.owl#DDO_0002452 + DDO:DDO_0002452 + + + + obo:DDO.owl#DDO_0002452 + 396228006 + + + + obo:DDO.owl#DDO_0002452 + hyperkeratosis + + + + obo:DDO.owl#DDO_0002453 + DDO:DDO_0002453 + + + + obo:DDO.owl#DDO_0002453 + 89987007 + + + + obo:DDO.owl#DDO_0002453 + confluent AND reticulate papillomatosis + + + + obo:DDO.owl#DDO_0002454 + DDO:DDO_0002454 + + + + obo:DDO.owl#DDO_0002454 + 414555007 + + + + obo:DDO.owl#DDO_0002454 + keratoderma blennorrhagicum + + + + obo:DDO.owl#DDO_0002455 + DDO:DDO_0002455 + + + + obo:DDO.owl#DDO_0002455 + 201054008 + + + + obo:DDO.owl#DDO_0002455 + keratoderma climactericum + + + + obo:DDO.owl#DDO_0002457 + DDO:DDO_0002457 + + + + obo:DDO.owl#DDO_0002457 + 201057001 + + + + obo:DDO.owl#DDO_0002457 + lymphedematous keratoderma + + + + obo:DDO.owl#DDO_0002458 + DDO:DDO_0002458 + + + + obo:DDO.owl#DDO_0002458 + 238638002 + + + + obo:DDO.owl#DDO_0002458 + multiple minute digitate hyperkeratosis of Goldstein + + + + obo:DDO.owl#DDO_0002459 + DDO:DDO_0002459 + + + + obo:DDO.owl#DDO_0002459 + 238639005 + + + + obo:DDO.owl#DDO_0002459 + pityriasis rotunda + + + + obo:DDO.owl#DDO_0002460 + DDO:DDO_0002460 + + + + obo:DDO.owl#DDO_0002460 + 402343006 + + + + obo:DDO.owl#DDO_0002460 + retention hyperkeratosis + + + + obo:DDO.owl#DDO_0002461 + DDO:DDO_0002461 + + + + obo:DDO.owl#DDO_0002461 + 201055009 + + + + obo:DDO.owl#DDO_0002461 + symmetrical keratoderma + + + + obo:DDO.owl#DDO_0002462 + DDO:DDO_0002462 + + + + obo:DDO.owl#DDO_0002462 + 708474007 + + + + obo:DDO.owl#DDO_0002462 + orthokeratosis + + + + obo:DDO.owl#DDO_0002464 + DDO:DDO_0002464 + + + + obo:DDO.owl#DDO_0002464 + 312117008 + + + + obo:DDO.owl#DDO_0002464 + bacterial respiratory infection + + + + obo:DDO.owl#DDO_0002465 + DDO:DDO_0002465 + + + + obo:DDO.owl#DDO_0002465 + 312119006 + + + + obo:DDO.owl#DDO_0002465 + bacterial lower respiratory infection + + + + obo:DDO.owl#DDO_0002466 + DDO:DDO_0002466 + + + + obo:DDO.owl#DDO_0002466 + 233598009 + + + + obo:DDO.owl#DDO_0002466 + acute bacterial bronchitis + + + + obo:DDO.owl#DDO_0002467 + DDO:DDO_0002467 + + + + obo:DDO.owl#DDO_0002467 + 233600003 + + + + obo:DDO.owl#DDO_0002467 + acute chlamydial bronchitis + + + + obo:DDO.owl#DDO_0002468 + DDO:DDO_0002468 + + + + obo:DDO.owl#DDO_0002468 + 195721005 + + + + obo:DDO.owl#DDO_0002468 + acute haemophilus influenzae bronchitis + + + + obo:DDO.owl#DDO_0002469 + DDO:DDO_0002469 + + + + obo:DDO.owl#DDO_0002469 + 195722003 + + + + obo:DDO.owl#DDO_0002469 + acute Moraxella catarrhalis bronchitis + + + + obo:DDO.owl#DDO_0002470 + DDO:DDO_0002470 + + + + obo:DDO.owl#DDO_0002470 + 195720006 + + + + obo:DDO.owl#DDO_0002470 + acute streptococcal bronchitis + + + + obo:DDO.owl#DDO_0002471 + DDO:DDO_0002471 + + + + obo:DDO.owl#DDO_0002471 + 195719000 + + + + obo:DDO.owl#DDO_0002471 + acute pneumococcal bronchitis + + + + obo:DDO.owl#DDO_0002472 + DDO:DDO_0002472 + + + + obo:DDO.owl#DDO_0002472 + 27836007 + + + + obo:DDO.owl#DDO_0002472 + pertussis + + + + obo:DDO.owl#DDO_0002473 + DDO:DDO_0002473 + + + + obo:DDO.owl#DDO_0002473 + 59475000 + + + + obo:DDO.owl#DDO_0002473 + pneumonia in pertussis + + + + obo:DDO.owl#DDO_0002474 + DDO:DDO_0002474 + + + + obo:DDO.owl#DDO_0002474 + 1731000119106 + + + + obo:DDO.owl#DDO_0002474 + atypical mycobacterial infection of lung + + + + obo:DDO.owl#DDO_0002475 + DDO:DDO_0002475 + + + + obo:DDO.owl#DDO_0002475 + 53084003 + + + + obo:DDO.owl#DDO_0002475 + bacterial pneumonia + + + + obo:DDO.owl#DDO_0002476 + DDO:DDO_0002476 + + + + obo:DDO.owl#DDO_0002476 + 40600002 + + + + obo:DDO.owl#DDO_0002476 + pneumococcal bronchitis + + + + obo:DDO.owl#DDO_0002477 + DDO:DDO_0002477 + + + + obo:DDO.owl#DDO_0002477 + 195719000 + + + + obo:DDO.owl#DDO_0002477 + acute pneumococcal bronchitis + + + + obo:DDO.owl#DDO_0002478 + DDO:DDO_0002478 + + + + obo:DDO.owl#DDO_0002478 + 420544002 + + + + obo:DDO.owl#DDO_0002478 + bacterial pneumonia associated with AIDS + + + + obo:DDO.owl#DDO_0002479 + DDO:DDO_0002479 + + + + obo:DDO.owl#DDO_0002479 + 10625071000119104 + + + + obo:DDO.owl#DDO_0002479 + bronchopneumonia due to bacteria + + + + obo:DDO.owl#DDO_0002480 + DDO:DDO_0002480 + + + + obo:DDO.owl#DDO_0002480 + 276693005 + + + + obo:DDO.owl#DDO_0002480 + congenital bacterial pneumonia + + + + obo:DDO.owl#DDO_0002481 + DDO:DDO_0002481 + + + + obo:DDO.owl#DDO_0002481 + 206289001 + + + + obo:DDO.owl#DDO_0002481 + congenital chlamydial pneumonia + + + + obo:DDO.owl#DDO_0002482 + DDO:DDO_0002482 + + + + obo:DDO.owl#DDO_0002482 + 206286008 + + + + obo:DDO.owl#DDO_0002482 + congenital Escherichia coli pneumonia + + + + obo:DDO.owl#DDO_0002483 + DDO:DDO_0002483 + + + + obo:DDO.owl#DDO_0002483 + 206284006 + + + + obo:DDO.owl#DDO_0002483 + congenital group A hemolytic streptococcal pneumonia + + + + obo:DDO.owl#DDO_0002484 + DDO:DDO_0002484 + + + + obo:DDO.owl#DDO_0002484 + 206285007 + + + + obo:DDO.owl#DDO_0002484 + congenital group B hemolytic streptococcal pneumonia + + + + obo:DDO.owl#DDO_0002485 + DDO:DDO_0002485 + + + + obo:DDO.owl#DDO_0002485 + 206287004 + + + + obo:DDO.owl#DDO_0002485 + congenital pseudomonal pneumonia + + + + obo:DDO.owl#DDO_0002486 + DDO:DDO_0002486 + + + + obo:DDO.owl#DDO_0002486 + 206283000 + + + + obo:DDO.owl#DDO_0002486 + congenital staphylococcal pneumonia + + + + obo:DDO.owl#DDO_0002487 + DDO:DDO_0002487 + + + + obo:DDO.owl#DDO_0002487 + 70036007 + + + + obo:DDO.owl#DDO_0002487 + Haemophilus influenzae pneumonia + + + + obo:DDO.owl#DDO_0002488 + DDO:DDO_0002488 + + + + obo:DDO.owl#DDO_0002488 + 81164001 + + + + obo:DDO.owl#DDO_0002488 + ornithosis with pneumonia + + + + obo:DDO.owl#DDO_0002489 + DDO:DDO_0002489 + + + + obo:DDO.owl#DDO_0002489 + 409665004 + + + + obo:DDO.owl#DDO_0002489 + pneumonia due to aerobic bacteria + + + + obo:DDO.owl#DDO_0002490 + DDO:DDO_0002490 + + + + obo:DDO.owl#DDO_0002490 + 195902009 + + + + obo:DDO.owl#DDO_0002490 + anthrax pneumonia + + + + obo:DDO.owl#DDO_0002491 + DDO:DDO_0002491 + + + + obo:DDO.owl#DDO_0002491 + 195889001 + + + + obo:DDO.owl#DDO_0002491 + Legionella pneumonia + + + + obo:DDO.owl#DDO_0002492 + DDO:DDO_0002492 + + + + obo:DDO.owl#DDO_0002492 + 76090006 + + + + obo:DDO.owl#DDO_0002492 + Pittsburgh pneumonia + + + + obo:DDO.owl#DDO_0002493 + DDO:DDO_0002493 + + + + obo:DDO.owl#DDO_0002493 + 233618000 + + + + obo:DDO.owl#DDO_0002493 + mycobacterial pneumonia + + + + obo:DDO.owl#DDO_0002494 + DDO:DDO_0002494 + + + + obo:DDO.owl#DDO_0002494 + 277869007 + + + + obo:DDO.owl#DDO_0002494 + non-tuberculous mycobacterial pneumonia + + + + obo:DDO.owl#DDO_0002495 + DDO:DDO_0002495 + + + + obo:DDO.owl#DDO_0002495 + 186342000 + + + + obo:DDO.owl#DDO_0002495 + pulmonary Mycobacterium avium complex infection + + + + obo:DDO.owl#DDO_0002496 + DDO:DDO_0002496 + + + + obo:DDO.owl#DDO_0002496 + 373435003 + + + + obo:DDO.owl#DDO_0002496 + Battey disease + + + + obo:DDO.owl#DDO_0002497 + DDO:DDO_0002497 + + + + obo:DDO.owl#DDO_0002497 + 80003002 + + + + obo:DDO.owl#DDO_0002497 + tuberculous pneumonia + + + + obo:DDO.owl#DDO_0002498 + DDO:DDO_0002498 + + + + obo:DDO.owl#DDO_0002498 + 195909000 + + + + obo:DDO.owl#DDO_0002498 + nocardial pneumonia + + + + obo:DDO.owl#DDO_0002499 + DDO:DDO_0002499 + + + + obo:DDO.owl#DDO_0002499 + 41381004 + + + + obo:DDO.owl#DDO_0002499 + pneumonia due to Pseudomonas + + + + obo:DDO.owl#DDO_0002500 + DDO:DDO_0002500 + + + + obo:DDO.owl#DDO_0002500 + 10625511000119104 + + + + obo:DDO.owl#DDO_0002500 + bronchopneumonia due to Pseudomonas + + + + obo:DDO.owl#DDO_0002501 + DDO:DDO_0002501 + + + + obo:DDO.owl#DDO_0002501 + 206287004 + + + + obo:DDO.owl#DDO_0002501 + congenital pseudomonal pneumonia + + + + obo:DDO.owl#DDO_0002502 + DDO:DDO_0002502 + + + + obo:DDO.owl#DDO_0002502 + 45556008 + + + + obo:DDO.owl#DDO_0002502 + pulmonary tularemia + + + + obo:DDO.owl#DDO_0002503 + DDO:DDO_0002503 + + + + obo:DDO.owl#DDO_0002503 + 430395005 + + + + obo:DDO.owl#DDO_0002503 + pneumonia due to Gram negative bacteria + + + + obo:DDO.owl#DDO_0002504 + DDO:DDO_0002504 + + + + obo:DDO.owl#DDO_0002504 + 61884008 + + + + obo:DDO.owl#DDO_0002504 + Achromobacter pneumonia + + + + obo:DDO.owl#DDO_0002505 + DDO:DDO_0002505 + + + + obo:DDO.owl#DDO_0002505 + 233609002 + + + + obo:DDO.owl#DDO_0002505 + chlamydial pneumonia + + + + obo:DDO.owl#DDO_0002506 + DDO:DDO_0002506 + + + + obo:DDO.owl#DDO_0002506 + 206289001 + + + + obo:DDO.owl#DDO_0002506 + congenital chlamydial pneumonia + + + + obo:DDO.owl#DDO_0002507 + DDO:DDO_0002507 + + + + obo:DDO.owl#DDO_0002507 + 233610007 + + + + obo:DDO.owl#DDO_0002507 + neonatal chlamydial pneumonia + + + + obo:DDO.owl#DDO_0002508 + DDO:DDO_0002508 + + + + obo:DDO.owl#DDO_0002508 + 1087061000119106 + + + + obo:DDO.owl#DDO_0002508 + gonococcal pneumonia + + + + obo:DDO.owl#DDO_0002509 + DDO:DDO_0002509 + + + + obo:DDO.owl#DDO_0002509 + 233608005 + + + + obo:DDO.owl#DDO_0002509 + meningococcal pneumonia + + + + obo:DDO.owl#DDO_0002510 + DDO:DDO_0002510 + + + + obo:DDO.owl#DDO_0002510 + 51530003 + + + + obo:DDO.owl#DDO_0002510 + pneumonia due to Escherichia coli + + + + obo:DDO.owl#DDO_0002511 + DDO:DDO_0002511 + + + + obo:DDO.owl#DDO_0002511 + 10625111000119106 + + + + obo:DDO.owl#DDO_0002511 + bronchopneumonia due to Escherichia coli + + + + obo:DDO.owl#DDO_0002512 + DDO:DDO_0002512 + + + + obo:DDO.owl#DDO_0002512 + 206286008 + + + + obo:DDO.owl#DDO_0002512 + congenital Escherichia coli pneumonia + + + + obo:DDO.owl#DDO_0002513 + DDO:DDO_0002513 + + + + obo:DDO.owl#DDO_0002513 + 32204007 + + + + obo:DDO.owl#DDO_0002513 + pulmonary actinobacillosis + + + + obo:DDO.owl#DDO_0002514 + DDO:DDO_0002514 + + + + obo:DDO.owl#DDO_0002514 + 64479007 + + + + obo:DDO.owl#DDO_0002514 + pneumonia due to Klebsiella pneumoniae + + + + obo:DDO.owl#DDO_0002515 + DDO:DDO_0002515 + + + + obo:DDO.owl#DDO_0002515 + 195896004 + + + + obo:DDO.owl#DDO_0002515 + pneumonia due to pleuropneumonia-like organism + + + + obo:DDO.owl#DDO_0002516 + DDO:DDO_0002516 + + + + obo:DDO.owl#DDO_0002516 + 46970008 + + + + obo:DDO.owl#DDO_0002516 + mycoplasma pneumonia + + + + obo:DDO.owl#DDO_0002517 + DDO:DDO_0002517 + + + + obo:DDO.owl#DDO_0002517 + 34020007 + + + + obo:DDO.owl#DDO_0002517 + pneumonia due to Streptococcus + + + + obo:DDO.owl#DDO_0002518 + DDO:DDO_0002518 + + + + obo:DDO.owl#DDO_0002518 + 195888009 + + + + obo:DDO.owl#DDO_0002518 + Proteus pneumonia + + + + obo:DDO.owl#DDO_0002519 + DDO:DDO_0002519 + + + + obo:DDO.owl#DDO_0002519 + 240387006 + + + + obo:DDO.owl#DDO_0002519 + pulmonary glanders + + + + obo:DDO.owl#DDO_0002520 + DDO:DDO_0002520 + + + + obo:DDO.owl#DDO_0002520 + 240391001 + + + + obo:DDO.owl#DDO_0002520 + pulmonary melioidosis + + + + obo:DDO.owl#DDO_0002521 + DDO:DDO_0002521 + + + + obo:DDO.owl#DDO_0002521 + Salmonella pneumonia + + + + obo:DDO.owl#DDO_0002522 + DDO:DDO_0002522 + + + + obo:DDO.owl#DDO_0002522 + 45312009 + + + + obo:DDO.owl#DDO_0002522 + pneumonia in typhoid fever + + + + obo:DDO.owl#DDO_0002523 + DDO:DDO_0002523 + + + + obo:DDO.owl#DDO_0002523 + 308906005 + + + + obo:DDO.owl#DDO_0002523 + secondary bacterial pneumonia + + + + obo:DDO.owl#DDO_0002524 + DDO:DDO_0002524 + + + + obo:DDO.owl#DDO_0002524 + 22754005 + + + + obo:DDO.owl#DDO_0002524 + staphylococcal pneumonia + + + + obo:DDO.owl#DDO_0002525 + DDO:DDO_0002525 + + + + obo:DDO.owl#DDO_0002525 + 73198007 + + + + obo:DDO.owl#DDO_0002525 + bacterial pleurisy + + + + obo:DDO.owl#DDO_0002526 + DDO:DDO_0002526 + + + + obo:DDO.owl#DDO_0002526 + 3144005 + + + + obo:DDO.owl#DDO_0002526 + staphylococcal pleurisy + + + + obo:DDO.owl#DDO_0002527 + DDO:DDO_0002527 + + + + obo:DDO.owl#DDO_0002527 + 85420008 + + + + obo:DDO.owl#DDO_0002527 + streptococcal pleurisy + + + + obo:DDO.owl#DDO_0002528 + DDO:DDO_0002528 + + + + obo:DDO.owl#DDO_0002528 + 2585002 + + + + obo:DDO.owl#DDO_0002528 + pneumococcal pleurisy + + + + obo:DDO.owl#DDO_0002529 + DDO:DDO_0002529 + + + + obo:DDO.owl#DDO_0002529 + 312118003 + + + + obo:DDO.owl#DDO_0002529 + bacterial upper respiratory infection + + + + obo:DDO.owl#DDO_0002530 + DDO:DDO_0002530 + + + + obo:DDO.owl#DDO_0002530 + 21060003 + + + + obo:DDO.owl#DDO_0002530 + acute bacterial epiglottitis + + + + obo:DDO.owl#DDO_0002531 + DDO:DDO_0002531 + + + + obo:DDO.owl#DDO_0002531 + 195658003 + + + + obo:DDO.owl#DDO_0002531 + acute bacterial pharyngitis + + + + obo:DDO.owl#DDO_0002532 + DDO:DDO_0002532 + + + + obo:DDO.owl#DDO_0002532 + 195671000 + + + + obo:DDO.owl#DDO_0002532 + acute bacterial tonsillitis + + + + obo:DDO.owl#DDO_0002533 + DDO:DDO_0002533 + + + + obo:DDO.owl#DDO_0002533 + 195672007 + + + + obo:DDO.owl#DDO_0002533 + acute pneumococcal tonsillitis + + + + obo:DDO.owl#DDO_0002534 + DDO:DDO_0002534 + + + + obo:DDO.owl#DDO_0002534 + 195673002 + + + + obo:DDO.owl#DDO_0002534 + acute staphylococcal tonsillitis + + + + obo:DDO.owl#DDO_0002535 + DDO:DDO_0002535 + + + + obo:DDO.owl#DDO_0002535 + 195659006 + + + + obo:DDO.owl#DDO_0002535 + acute pneumococcal pharyngitis + + + + obo:DDO.owl#DDO_0002536 + DDO:DDO_0002536 + + + + obo:DDO.owl#DDO_0002536 + 195660001 + + + + obo:DDO.owl#DDO_0002536 + acute staphylococcal pharyngitis + + + + obo:DDO.owl#DDO_0002537 + DDO:DDO_0002537 + + + + obo:DDO.owl#DDO_0002537 + 75498004 + + + + obo:DDO.owl#DDO_0002537 + acute bacterial sinusitis + + + + obo:DDO.owl#DDO_0002538 + DDO:DDO_0002538 + + + + obo:DDO.owl#DDO_0002538 + 195684009 + + + + obo:DDO.owl#DDO_0002538 + acute haemophilus influenzae laryngitis + + + + obo:DDO.owl#DDO_0002539 + DDO:DDO_0002539 + + + + obo:DDO.owl#DDO_0002539 + 15682004 + + + + obo:DDO.owl#DDO_0002539 + anterior nasal diphtheria + + + + obo:DDO.owl#DDO_0002540 + DDO:DDO_0002540 + + + + obo:DDO.owl#DDO_0002540 + 82454002 + + + + obo:DDO.owl#DDO_0002540 + carbuncle of nasal septum + + + + obo:DDO.owl#DDO_0002541 + DDO:DDO_0002541 + + + + obo:DDO.owl#DDO_0002541 + 275376007 + + + + obo:DDO.owl#DDO_0002541 + congenital syphilitic chronic coryza + + + + obo:DDO.owl#DDO_0002542 + DDO:DDO_0002542 + + + + obo:DDO.owl#DDO_0002542 + 276700005 + + + + obo:DDO.owl#DDO_0002542 + congenital syphilitic rhinitis + + + + obo:DDO.owl#DDO_0002543 + DDO:DDO_0002543 + + + + obo:DDO.owl#DDO_0002543 + 1090211000119102 + + + + obo:DDO.owl#DDO_0002543 + pharyngeal diphtheria + + + + obo:DDO.owl#DDO_0002545 + DDO:DDO_0002545 + + + + obo:DDO.owl#DDO_0002545 + 195685005 + + + + obo:DDO.owl#DDO_0002545 + acute pneumococcal laryngitis + + + + obo:DDO.owl#DDO_0002546 + DDO:DDO_0002546 + + + + obo:DDO.owl#DDO_0002546 + 76651006 + + + + obo:DDO.owl#DDO_0002546 + pneumococcal pharyngitis + + + + obo:DDO.owl#DDO_0002547 + DDO:DDO_0002547 + + + + obo:DDO.owl#DDO_0002547 + 111816002 + + + + obo:DDO.owl#DDO_0002547 + pneumococcal tonsillitis + + + + obo:DDO.owl#DDO_0002548 + DDO:DDO_0002548 + + + + obo:DDO.owl#DDO_0002548 + 82228008 + + + + obo:DDO.owl#DDO_0002548 + staphylococcal pharyngitis + + + + obo:DDO.owl#DDO_0002549 + DDO:DDO_0002549 + + + + obo:DDO.owl#DDO_0002549 + 128936008 + + + + obo:DDO.owl#DDO_0002549 + bacterial infection of skin + + + + obo:DDO.owl#DDO_0002550 + DDO:DDO_0002550 + + + + obo:DDO.owl#DDO_0002550 + 82074004 + + + + obo:DDO.owl#DDO_0002550 + achromic skin lesions of pinta + + + + obo:DDO.owl#DDO_0002551 + DDO:DDO_0002551 + + + + obo:DDO.owl#DDO_0002551 + 238424004 + + + + obo:DDO.owl#DDO_0002551 + arcanobacterium pyogenes infection of skin + + + + obo:DDO.owl#DDO_0002552 + DDO:DDO_0002552 + + + + obo:DDO.owl#DDO_0002552 + 231801008 + + + + obo:DDO.owl#DDO_0002552 + bacterial dermatitis of eyelid + + + + obo:DDO.owl#DDO_0002553 + DDO:DDO_0002553 + + + + obo:DDO.owl#DDO_0002553 + 231802001 + + + + obo:DDO.owl#DDO_0002553 + impetigo of eyelid + + + + obo:DDO.owl#DDO_0002554 + DDO:DDO_0002554 + + + + obo:DDO.owl#DDO_0002554 + 128273004 + + + + obo:DDO.owl#DDO_0002554 + carbuncle of head + + + + obo:DDO.owl#DDO_0002555 + DDO:DDO_0002555 + + + + obo:DDO.owl#DDO_0002555 + 416675009 + + + + obo:DDO.owl#DDO_0002555 + furuncle + + + + obo:DDO.owl#DDO_0002556 + DDO:DDO_0002556 + + + + obo:DDO.owl#DDO_0002556 + 402922003 + + + + obo:DDO.owl#DDO_0002556 + Propionibacterium acnes folliculitis + + + + obo:DDO.owl#DDO_0002557 + DDO:DDO_0002557 + + + + obo:DDO.owl#DDO_0002557 + 53651004 + + + + obo:DDO.owl#DDO_0002557 + pustular folliculitis + + + + obo:DDO.owl#DDO_0002558 + DDO:DDO_0002558 + + + + obo:DDO.owl#DDO_0002558 + bacterial paronychia + + + + obo:DDO.owl#DDO_0002559 + DDO:DDO_0002559 + + + + obo:DDO.owl#DDO_0002559 + 402930002 + + + + obo:DDO.owl#DDO_0002559 + acute bacterial paronychia + + + + obo:DDO.owl#DDO_0002560 + DDO:DDO_0002560 + + + + obo:DDO.owl#DDO_0002560 + 402931003 + + + + obo:DDO.owl#DDO_0002560 + neonatal bacterial paronychia + + + + obo:DDO.owl#DDO_0002561 + DDO:DDO_0002561 + + + + obo:DDO.owl#DDO_0002561 + 238388002 + + + + obo:DDO.owl#DDO_0002561 + pseudomonas aeruginosa paronychia + + + + obo:DDO.owl#DDO_0002562 + DDO:DDO_0002562 + + + + obo:DDO.owl#DDO_0002562 + 63767001 + + + + obo:DDO.owl#DDO_0002562 + carbuncle of ear + + + + obo:DDO.owl#DDO_0002563 + DDO:DDO_0002563 + + + + obo:DDO.owl#DDO_0002563 + 17732003 + + + + obo:DDO.owl#DDO_0002563 + ecthyma gangrenosum + + + + obo:DDO.owl#DDO_0002564 + DDO:DDO_0002564 + + + + obo:DDO.owl#DDO_0002564 + 404174000 + + + + obo:DDO.owl#DDO_0002564 + neonatal ecthyma gangrenosum + + + + obo:DDO.owl#DDO_0002565 + DDO:DDO_0002565 + + + + obo:DDO.owl#DDO_0002565 + 59393003 + + + + obo:DDO.owl#DDO_0002565 + hidradenitis suppurativa + + + + obo:DDO.owl#DDO_0002566 + DDO:DDO_0002566 + + + + obo:DDO.owl#DDO_0002566 + 402827005 + + + + obo:DDO.owl#DDO_0002566 + anogenital hidradenitis suppurativa + + + + obo:DDO.owl#DDO_0002567 + DDO:DDO_0002567 + + + + obo:DDO.owl#DDO_0002567 + 402826001 + + + + obo:DDO.owl#DDO_0002567 + axillary hidradenitis suppurativa + + + + obo:DDO.owl#DDO_0002568 + DDO:DDO_0002568 + + + + obo:DDO.owl#DDO_0002568 + 18638007 + + + + obo:DDO.owl#DDO_0002568 + hidradenitis suppurativa of anus + + + + obo:DDO.owl#DDO_0002569 + DDO:DDO_0002569 + + + + obo:DDO.owl#DDO_0002569 + 402828000 + + + + obo:DDO.owl#DDO_0002569 + vulval hidradenitis suppurativa + + + + obo:DDO.owl#DDO_0002570 + DDO:DDO_0002570 + + + + obo:DDO.owl#DDO_0002570 + 53243005 + + + + obo:DDO.owl#DDO_0002570 + hyperchromic lesions of pinta + + + + obo:DDO.owl#DDO_0002571 + DDO:DDO_0002571 + + + + obo:DDO.owl#DDO_0002571 + 48277006 + + + + obo:DDO.owl#DDO_0002571 + impetigo + + + + obo:DDO.owl#DDO_0002572 + DDO:DDO_0002572 + + + + obo:DDO.owl#DDO_0002572 + 53396004 + + + + obo:DDO.owl#DDO_0002572 + Bockhart impetigo + + + + obo:DDO.owl#DDO_0002573 + DDO:DDO_0002573 + + + + obo:DDO.owl#DDO_0002573 + 399102002 + + + + obo:DDO.owl#DDO_0002573 + bullous staphylococcal impetigo + + + + obo:DDO.owl#DDO_0002574 + DDO:DDO_0002574 + + + + obo:DDO.owl#DDO_0002574 + 200709006 + + + + obo:DDO.owl#DDO_0002574 + chronic symmetrical impetigo + + + + obo:DDO.owl#DDO_0002575 + DDO:DDO_0002575 + + + + obo:DDO.owl#DDO_0002575 + 359749002 + + + + obo:DDO.owl#DDO_0002575 + circinate impetigo + + + + obo:DDO.owl#DDO_0002576 + DDO:DDO_0002576 + + + + obo:DDO.owl#DDO_0002576 + 402201001 + + + + obo:DDO.owl#DDO_0002576 + impetiginized atopic dermatitis + + + + obo:DDO.owl#DDO_0002577 + DDO:DDO_0002577 + + + + obo:DDO.owl#DDO_0002577 + 399183005 + + + + obo:DDO.owl#DDO_0002577 + impetigo bullosa + + + + obo:DDO.owl#DDO_0002578 + DDO:DDO_0002578 + + + + obo:DDO.owl#DDO_0002578 + 200706004 + + + + obo:DDO.owl#DDO_0002578 + impetigo neonatorum + + + + obo:DDO.owl#DDO_0002579 + DDO:DDO_0002579 + + + + obo:DDO.owl#DDO_0002579 + 200705000 + + + + obo:DDO.owl#DDO_0002579 + impetigo circinata + + + + obo:DDO.owl#DDO_0002580 + DDO:DDO_0002580 + + + + obo:DDO.owl#DDO_0002580 + 200704001 + + + + obo:DDO.owl#DDO_0002580 + impetigo contagiosa gyrata + + + + obo:DDO.owl#DDO_0002581 + DDO:DDO_0002581 + + + + obo:DDO.owl#DDO_0002581 + 200708003 + + + + obo:DDO.owl#DDO_0002581 + impetigo follicularis + + + + obo:DDO.owl#DDO_0002582 + DDO:DDO_0002582 + + + + obo:DDO.owl#DDO_0002582 + 231802001 + + + + obo:DDO.owl#DDO_0002582 + impetigo of eyelid + + + + obo:DDO.owl#DDO_0002583 + DDO:DDO_0002583 + + + + obo:DDO.owl#DDO_0002583 + 200707008 + + + + obo:DDO.owl#DDO_0002583 + impetigo simplex + + + + obo:DDO.owl#DDO_0002584 + DDO:DDO_0002584 + + + + obo:DDO.owl#DDO_0002584 + 238374001 + + + + obo:DDO.owl#DDO_0002584 + non-bullous impetigo + + + + obo:DDO.owl#DDO_0002585 + DDO:DDO_0002585 + + + + obo:DDO.owl#DDO_0002585 + 238376004 + + + + obo:DDO.owl#DDO_0002585 + staphylococcal non-bullous impetigo + + + + obo:DDO.owl#DDO_0002587 + DDO:DDO_0002587 + + + + obo:DDO.owl#DDO_0002587 + 238375000 + + + + obo:DDO.owl#DDO_0002587 + Streptococcal impetigo + + + + obo:DDO.owl#DDO_0002588 + DDO:DDO_0002588 + + + + obo:DDO.owl#DDO_0002588 + 10628791000119105 + + + + obo:DDO.owl#DDO_0002588 + ulcerative impetigo + + + + obo:DDO.owl#DDO_0002589 + DDO:DDO_0002589 + + + + obo:DDO.owl#DDO_0002589 + 238417000 + + + + obo:DDO.owl#DDO_0002589 + non-pyogenic bacterial infection of skin + + + + obo:DDO.owl#DDO_0002590 + DDO:DDO_0002590 + + + + obo:DDO.owl#DDO_0002590 + 4340003 + + + + obo:DDO.owl#DDO_0002590 + acrodermatitis atrophicans chronica + + + + obo:DDO.owl#DDO_0002591 + DDO:DDO_0002591 + + + + obo:DDO.owl#DDO_0002591 + 58213005 + + + + obo:DDO.owl#DDO_0002591 + bacillary angiomatosis + + + + obo:DDO.owl#DDO_0002592 + DDO:DDO_0002592 + + + + obo:DDO.owl#DDO_0002592 + 43484003 + + + + obo:DDO.owl#DDO_0002592 + cellulocutaneous plague + + + + obo:DDO.owl#DDO_0002593 + DDO:DDO_0002593 + + + + obo:DDO.owl#DDO_0002593 + 240583009 + + + + obo:DDO.owl#DDO_0002593 + cutaneous gonorrhea + + + + obo:DDO.owl#DDO_0002594 + DDO:DDO_0002594 + + + + obo:DDO.owl#DDO_0002594 + 240416008 + + + + obo:DDO.owl#DDO_0002594 + cutaneous mycobacterium marinum infection + + + + obo:DDO.owl#DDO_0002596 + DDO:DDO_0002596 + + + + obo:DDO.owl#DDO_0002596 + 240417004 + + + + obo:DDO.owl#DDO_0002596 + fish tank granuloma + + + + obo:DDO.owl#DDO_0002597 + DDO:DDO_0002597 + + + + obo:DDO.owl#DDO_0002597 + 373579002 + + + + obo:DDO.owl#DDO_0002597 + swimming pool granuloma disease + + + + obo:DDO.owl#DDO_0002598 + DDO:DDO_0002598 + + + + obo:DDO.owl#DDO_0002598 + 69588003 + + + + obo:DDO.owl#DDO_0002598 + erythema chronica migrans + + + + obo:DDO.owl#DDO_0002599 + DDO:DDO_0002599 + + + + obo:DDO.owl#DDO_0002599 + 238418005 + + + + obo:DDO.owl#DDO_0002599 + erythrasma + + + + obo:DDO.owl#DDO_0002600 + DDO:DDO_0002600 + + + + obo:DDO.owl#DDO_0002600 + 240673004 + + + + obo:DDO.owl#DDO_0002600 + leptospiral rash + + + + obo:DDO.owl#DDO_0002601 + DDO:DDO_0002601 + + + + obo:DDO.owl#DDO_0002601 + 238426002 + + + + obo:DDO.owl#DDO_0002601 + moraxella infection of skin + + + + obo:DDO.owl#DDO_0002602 + DDO:DDO_0002602 + + + + obo:DDO.owl#DDO_0002602 + 51212009 + + + + obo:DDO.owl#DDO_0002602 + pitted keratolysis + + + + obo:DDO.owl#DDO_0002603 + DDO:DDO_0002603 + + + + obo:DDO.owl#DDO_0002603 + 49894005 + + + + obo:DDO.owl#DDO_0002603 + trichomycosis axillaris + + + + obo:DDO.owl#DDO_0002604 + DDO:DDO_0002604 + + + + obo:DDO.owl#DDO_0002604 + 18900005 + + + + obo:DDO.owl#DDO_0002604 + periporitis + + + + obo:DDO.owl#DDO_0002605 + DDO:DDO_0002605 + + + + obo:DDO.owl#DDO_0002605 + 76712006 + + + + obo:DDO.owl#DDO_0002605 + disorder of digestive organ + + + + obo:DDO.owl#DDO_0002606 + DDO:DDO_0002606 + + + + obo:DDO.owl#DDO_0002606 + 85919009 + + + + obo:DDO.owl#DDO_0002606 + disorder of intestine + + + + obo:DDO.owl#DDO_0002607 + DDO:DDO_0002607 + + + + obo:DDO.owl#DDO_0002607 + 235832002 + + + + obo:DDO.owl#DDO_0002607 + diabetic diarrhea + + + + obo:DDO.owl#DDO_0002607 + diabetic enteropathy + + + + obo:DDO.owl#DDO_0002607 + hollow visceral neuropathy + + + + obo:DDO.owl#DDO_0002608 + DDO:DDO_0002608 + + + + obo:DDO.owl#DDO_0002608 + 107671003 + + + + obo:DDO.owl#DDO_0002608 + vascular sclerosis + + + + obo:DDO.owl#DDO_0002609 + DDO:DDO_0002609 + + + + obo:DDO.owl#DDO_0002609 + 28960008 + + + + obo:DDO.owl#DDO_0002609 + arteriosclerosis + + + + obo:DDO.owl#DDO_0002610 + DDO:DDO_0002610 + + + + obo:DDO.owl#DDO_0002610 + 419076005 + + + + obo:DDO.owl#DDO_0002610 + allergic reaction disease + + + + obo:DDO.owl#DDO_0002611 + DDO:DDO_0002611 + + + + obo:DDO.owl#DDO_0002611 + 39579001 + + + + obo:DDO.owl#DDO_0002611 + anaphylaxis + + + + obo:DDO.owl#DDO_0002612 + DDO:DDO_0002612 + + + + obo:DDO.owl#DDO_0002612 + 241929008 + + + + obo:DDO.owl#DDO_0002612 + acute allergic reaction + + + + obo:DDO.owl#DDO_0002613 + DDO:DDO_0002613 + + + + obo:DDO.owl#DDO_0002613 + 417516000 + + + + obo:DDO.owl#DDO_0002613 + anaphylaxis due to substance + + + + obo:DDO.owl#DDO_0002614 + DDO:DDO_0002614 + + + + obo:DDO.owl#DDO_0002614 + 213320003 + + + + obo:DDO.owl#DDO_0002614 + anaphylactic shock due to serum + + + + obo:DDO.owl#DDO_0002615 + DDO:DDO_0002615 + + + + obo:DDO.owl#DDO_0002615 + 241942008 + + + + obo:DDO.owl#DDO_0002615 + aeroallergen-induced anaphylaxis + + + + obo:DDO.owl#DDO_0002616 + DDO:DDO_0002616 + + + + obo:DDO.owl#DDO_0002616 + 441593005 + + + + obo:DDO.owl#DDO_0002616 + anaphylaxis due to latex + + + + obo:DDO.owl#DDO_0002617 + DDO:DDO_0002617 + + + + obo:DDO.owl#DDO_0002617 + 79337003 + + + + obo:DDO.owl#DDO_0002617 + anaphylactic transfusion reaction + + + + obo:DDO.owl#DDO_0002618 + DDO:DDO_0002618 + + + + obo:DDO.owl#DDO_0002618 + 91941002 + + + + obo:DDO.owl#DDO_0002618 + food anaphylaxis + + + + obo:DDO.owl#DDO_0002619 + DDO:DDO_0002619 + + + + obo:DDO.owl#DDO_0002619 + 241952007 + + + + obo:DDO.owl#DDO_0002619 + exercise anaphylaxis + + + + obo:DDO.owl#DDO_0002620 + DDO:DDO_0002620 + + + + obo:DDO.owl#DDO_0002620 + 241954008 + + + + obo:DDO.owl#DDO_0002620 + idiopathic anaphylaxis + + + + obo:DDO.owl#DDO_0002621 + DDO:DDO_0002621 + + + + obo:DDO.owl#DDO_0002621 + 14654002 + + + + obo:DDO.owl#DDO_0002621 + localized anaphylaxis + + + + obo:DDO.owl#DDO_0002623 + DDO:DDO_0002623 + + + + obo:DDO.owl#DDO_0002623 + 418634005 + + + + obo:DDO.owl#DDO_0002623 + allergic reaction to substance + + + + obo:DDO.owl#DDO_0002624 + DDO:DDO_0002624 + + + + obo:DDO.owl#DDO_0002624 + 361098001 + + + + obo:DDO.owl#DDO_0002624 + allergic transfusion reaction + + + + obo:DDO.owl#DDO_0002625 + DDO:DDO_0002625 + + + + obo:DDO.owl#DDO_0002625 + 55985003 + + + + obo:DDO.owl#DDO_0002625 + atopic reaction + + + + obo:DDO.owl#DDO_0002626 + DDO:DDO_0002626 + + + + obo:DDO.owl#DDO_0002626 + 10803007 + + + + obo:DDO.owl#DDO_0002626 + jarisch Herxheimer reaction + + + + obo:DDO.owl#DDO_0002627 + DDO:DDO_0002627 + + + + obo:DDO.owl#DDO_0002627 + 14589007 + + + + obo:DDO.owl#DDO_0002627 + phacoanaphylaxis + + + + obo:DDO.owl#DDO_0002628 + DDO:DDO_0002628 + + + + obo:DDO.owl#DDO_0002628 + 123583002 + + + + obo:DDO.owl#DDO_0002628 + tuberculid + + + + obo:DDO.owl#DDO_0002629 + DDO:DDO_0002629 + + + + obo:DDO.owl#DDO_0002629 + 238429009 + + + + obo:DDO.owl#DDO_0002629 + nodular tuberculide + + + + obo:DDO.owl#DDO_0002630 + DDO:DDO_0002630 + + + + obo:DDO.owl#DDO_0002630 + 11354005 + + + + obo:DDO.owl#DDO_0002630 + tuberculosis cutis indurativa + + + + obo:DDO.owl#DDO_0002631 + DDO:DDO_0002631 + + + + obo:DDO.owl#DDO_0002631 + 238428001 + + + + obo:DDO.owl#DDO_0002631 + papular tuberculide + + + + obo:DDO.owl#DDO_0002632 + DDO:DDO_0002632 + + + + obo:DDO.owl#DDO_0002632 + 9768003 + + + + obo:DDO.owl#DDO_0002632 + tuberculosis cutis lichenoides + + + + obo:DDO.owl#DDO_0002633 + DDO:DDO_0002633 + + + + obo:DDO.owl#DDO_0002633 + 41156006 + + + + obo:DDO.owl#DDO_0002633 + tuberculosis papulonecrotica + + + + obo:DDO.owl#DDO_0002634 + DDO:DDO_0002634 + + + + obo:DDO.owl#DDO_0002634 + 12263007 + + + + obo:DDO.owl#DDO_0002634 + Type 1 hypersensitivity response + + + + obo:DDO.owl#DDO_0002635 + DDO:DDO_0002635 + + + + obo:DDO.owl#DDO_0002635 + 490008 + + + + obo:DDO.owl#DDO_0002635 + upper respiratory tract hypersensitivity reaction + + + + obo:DDO.owl#DDO_0002636 + DDO:DDO_0002636 + + + + obo:DDO.owl#DDO_0002636 + 420662003 + + + + obo:DDO.owl#DDO_0002636 + coma associated with diabetes mellitus + + + + obo:DDO.owl#DDO_0002637 + DDO:DDO_0002637 + + + + obo:DDO.owl#DDO_0002637 + 420996007 + + + + obo:DDO.owl#DDO_0002637 + coma associated with malnutrition-related diabetes mellitus + + + + obo:DDO.owl#DDO_0002638 + DDO:DDO_0002638 + + + + obo:DDO.owl#DDO_0002638 + 26298008 + + + + obo:DDO.owl#DDO_0002638 + diabetic coma with ketoacidosis + + + + obo:DDO.owl#DDO_0002639 + DDO:DDO_0002639 + + + + obo:DDO.owl#DDO_0002639 + 190329007 + + + + obo:DDO.owl#DDO_0002639 + diabetes mellitus with hyperosmolar coma + + + + obo:DDO.owl#DDO_0002640 + DDO:DDO_0002640 + + + + obo:DDO.owl#DDO_0002640 + hyperosmolar coma associated with diabetes mellitus + + + + obo:DDO.owl#DDO_0002641 + DDO:DDO_0002641 + + + + obo:DDO.owl#DDO_0002641 + 421725003 + + + + obo:DDO.owl#DDO_0002641 + hypoglycemic coma in diabetes mellitus + + + + obo:DDO.owl#DDO_0002642 + DDO:DDO_0002642 + + + + obo:DDO.owl#DDO_0002642 + 421966007 + + + + obo:DDO.owl#DDO_0002642 + non-ketotic non-hyperosmolar coma associated with diabetes mellitus + + + + obo:DDO.owl#DDO_0002643 + DDO:DDO_0002643 + + + + obo:DDO.owl#DDO_0002643 + 281510005 + + + + obo:DDO.owl#DDO_0002643 + drug-induced coma + + + + obo:DDO.owl#DDO_0002644 + DDO:DDO_0002644 + + + + obo:DDO.owl#DDO_0002644 + 230800004 + + + + obo:DDO.owl#DDO_0002644 + alcoholic coma + + + + obo:DDO.owl#DDO_0002645 + DDO:DDO_0002645 + + + + obo:DDO.owl#DDO_0002645 + 111558006 + + + + obo:DDO.owl#DDO_0002645 + insulin coma + + + + obo:DDO.owl#DDO_0002646 + DDO:DDO_0002646 + + + + obo:DDO.owl#DDO_0002646 + 267384006 + + + + obo:DDO.owl#DDO_0002646 + hypoglycemic coma + + + + obo:DDO.owl#DDO_0002647 + DDO:DDO_0002647 + + + + obo:DDO.owl#DDO_0002647 + 56051008 + + + + obo:DDO.owl#DDO_0002647 + ketoacidosis + + + + obo:DDO.owl#DDO_0002648 + DDO:DDO_0002648 + + + + obo:DDO.owl#DDO_0002648 + 29914000 + + + + obo:DDO.owl#DDO_0002648 + dihydrolipoamide dehydrogenase deficiency + + + + obo:DDO.owl#DDO_0002649 + DDO:DDO_0002649 + + + + obo:DDO.owl#DDO_0002649 + 13490001000004105 + + + + obo:DDO.owl#DDO_0002649 + d-lactic acidosis + + + + obo:DDO.owl#DDO_0002650 + DDO:DDO_0002650 + + + + obo:DDO.owl#DDO_0002650 + 76938004 + + + + obo:DDO.owl#DDO_0002650 + infantile encephalopathy AND lactic acidosis + + + + obo:DDO.owl#DDO_0002651 + DDO:DDO_0002651 + + + + obo:DDO.owl#DDO_0002651 + 370491005 + + + + obo:DDO.owl#DDO_0002651 + metabolic acidosis due to grain overload + + + + obo:DDO.owl#DDO_0002652 + DDO:DDO_0002652 + + + + obo:DDO.owl#DDO_0002652 + 46683007 + + + + obo:DDO.owl#DDO_0002652 + pyruvate dehydrogenase complex deficiency + + + + obo:DDO.owl#DDO_0002653 + DDO:DDO_0002653 + + + + obo:DDO.owl#DDO_0002653 + 417237009 + + + + obo:DDO.owl#DDO_0002653 + blister + + + + obo:DDO.owl#DDO_0002654 + DDO:DDO_0002654 + + + + obo:DDO.owl#DDO_0002654 + 285355007 + + + + obo:DDO.owl#DDO_0002654 + blood blister + + + + obo:DDO.owl#DDO_0002655 + DDO:DDO_0002655 + + + + obo:DDO.owl#DDO_0002655 + 285361005 + + + + obo:DDO.owl#DDO_0002655 + oral blood blister + + + + obo:DDO.owl#DDO_0002656 + DDO:DDO_0002656 + + + + obo:DDO.owl#DDO_0002656 + 7231009 + + + + obo:DDO.owl#DDO_0002656 + bullous dermatosis + + + + obo:DDO.owl#DDO_0002657 + DDO:DDO_0002657 + + + + obo:DDO.owl#DDO_0002657 + 84855007 + + + + obo:DDO.owl#DDO_0002657 + acantholytic vesicular dermatitis + + + + obo:DDO.owl#DDO_0002658 + DDO:DDO_0002658 + + + + obo:DDO.owl#DDO_0002658 + 444659003 + + + + obo:DDO.owl#DDO_0002658 + blister of foot + + + + obo:DDO.owl#DDO_0002659 + DDO:DDO_0002659 + + + + obo:DDO.owl#DDO_0002659 + 78561001 + + + + obo:DDO.owl#DDO_0002659 + blister of foot with infection + + + + obo:DDO.owl#DDO_0002660 + DDO:DDO_0002660 + + + + obo:DDO.owl#DDO_0002660 + 271191007 + + + + obo:DDO.owl#DDO_0002660 + traumatic blister of foot, infected + + + + obo:DDO.owl#DDO_0002661 + DDO:DDO_0002661 + + + + obo:DDO.owl#DDO_0002661 + 275444001 + + + + obo:DDO.owl#DDO_0002661 + traumatic blister of heel, infected + + + + obo:DDO.owl#DDO_0002662 + DDO:DDO_0002662 + + + + obo:DDO.owl#DDO_0002662 + 271192000 + + + + obo:DDO.owl#DDO_0002662 + traumatic blister of toe, infected + + + + obo:DDO.owl#DDO_0002663 + DDO:DDO_0002663 + + + + obo:DDO.owl#DDO_0002663 + 1525003 + + + + obo:DDO.owl#DDO_0002663 + blister of foot without infection + + + + obo:DDO.owl#DDO_0002664 + DDO:DDO_0002664 + + + + obo:DDO.owl#DDO_0002664 + 373581000 + + + + obo:DDO.owl#DDO_0002664 + blister of sole of foot + + + + obo:DDO.owl#DDO_0002665 + DDO:DDO_0002665 + + + + obo:DDO.owl#DDO_0002665 + 373594003 + + + + obo:DDO.owl#DDO_0002665 + traumatic blister of sole of foot + + + + obo:DDO.owl#DDO_0002666 + DDO:DDO_0002666 + + + + obo:DDO.owl#DDO_0002666 + 53960009 + + + + obo:DDO.owl#DDO_0002666 + friction blisters of the soles + + + + obo:DDO.owl#DDO_0002667 + DDO:DDO_0002667 + + + + obo:DDO.owl#DDO_0002667 + 283134000 + + + + obo:DDO.owl#DDO_0002667 + traumatic blister of heel + + + + obo:DDO.owl#DDO_0002668 + DDO:DDO_0002668 + + + + obo:DDO.owl#DDO_0002668 + 271188007 + + + + obo:DDO.owl#DDO_0002668 + traumatic blister of foot + + + + obo:DDO.owl#DDO_0002669 + DDO:DDO_0002669 + + + + obo:DDO.owl#DDO_0002669 + 211412006 + + + + obo:DDO.owl#DDO_0002669 + neuropathic foot blister + + + + obo:DDO.owl#DDO_0002670 + DDO:DDO_0002670 + + + + obo:DDO.owl#DDO_0002670 + 200832000 + + + + obo:DDO.owl#DDO_0002670 + hydroa estivale + + + + obo:DDO.owl#DDO_0002671 + DDO:DDO_0002671 + + + + obo:DDO.owl#DDO_0002671 + 403209006 + + + + obo:DDO.owl#DDO_0002671 + familial actinic prurigo + + + + obo:DDO.owl#DDO_0002672 + DDO:DDO_0002672 + + + + obo:DDO.owl#DDO_0002672 + 403210001 + + + + obo:DDO.owl#DDO_0002672 + familial actinic prurigo of lip + + + + obo:DDO.owl#DDO_0002673 + DDO:DDO_0002673 + + + + obo:DDO.owl#DDO_0002673 + 402716004 + + + + obo:DDO.owl#DDO_0002673 + immunobullous disease + + + + obo:DDO.owl#DDO_0002674 + DDO:DDO_0002674 + + + + obo:DDO.owl#DDO_0002674 + 707210006 + + + + obo:DDO.owl#DDO_0002674 + intraepidermal bullous dermatosis + + + + obo:DDO.owl#DDO_0002675 + DDO:DDO_0002675 + + + + obo:DDO.owl#DDO_0002675 + 86142006 + + + + obo:DDO.owl#DDO_0002675 + pemphigoid + + + + obo:DDO.owl#DDO_0002676 + DDO:DDO_0002676 + + + + obo:DDO.owl#DDO_0002676 + 34250006 + + + + obo:DDO.owl#DDO_0002676 + benign mucous membrane pemphigoid + + + + obo:DDO.owl#DDO_0002677 + DDO:DDO_0002677 + + + + obo:DDO.owl#DDO_0002677 + 402436004 + + + + obo:DDO.owl#DDO_0002677 + eosinophilic spongiosis (prebullous pemphigoid) + + + + obo:DDO.owl#DDO_0002678 + DDO:DDO_0002678 + + + + obo:DDO.owl#DDO_0002678 + 77090002 + + + + obo:DDO.owl#DDO_0002678 + bullous pemphigoid + + + + obo:DDO.owl#DDO_0002679 + DDO:DDO_0002679 + + + + obo:DDO.owl#DDO_0002679 + 238941009 + + + + obo:DDO.owl#DDO_0002679 + juvenile pemphigoid + + + + obo:DDO.owl#DDO_0002680 + DDO:DDO_0002680 + + + + obo:DDO.owl#DDO_0002680 + 238939008 + + + + obo:DDO.owl#DDO_0002680 + localized pemphigoid + + + + obo:DDO.owl#DDO_0002681 + DDO:DDO_0002681 + + + + obo:DDO.owl#DDO_0002681 + 402437008 + + + + obo:DDO.owl#DDO_0002681 + localized bullous pemphigoid of vulva + + + + obo:DDO.owl#DDO_0002682 + DDO:DDO_0002682 + + + + obo:DDO.owl#DDO_0002682 + 402438003 + + + + obo:DDO.owl#DDO_0002682 + pemphigoid nodularis + + + + obo:DDO.owl#DDO_0002683 + DDO:DDO_0002683 + + + + obo:DDO.owl#DDO_0002683 + 238940005 + + + + obo:DDO.owl#DDO_0002683 + pemphigoid vegetans + + + + obo:DDO.owl#DDO_0002684 + DDO:DDO_0002684 + + + + obo:DDO.owl#DDO_0002684 + 238938000 + + + + obo:DDO.owl#DDO_0002684 + prebullous pemphigoid + + + + obo:DDO.owl#DDO_0002685 + DDO:DDO_0002685 + + + + obo:DDO.owl#DDO_0002685 + 711526005 + + + + obo:DDO.owl#DDO_0002685 + chronic localized pemphigoid + + + + obo:DDO.owl#DDO_0002686 + DDO:DDO_0002686 + + + + obo:DDO.owl#DDO_0002686 + 65172003 + + + + obo:DDO.owl#DDO_0002686 + pemphigus + + + + obo:DDO.owl#DDO_0002687 + DDO:DDO_0002687 + + + + obo:DDO.owl#DDO_0002687 + 200902009 + + + + obo:DDO.owl#DDO_0002687 + benign pemphigus + + + + obo:DDO.owl#DDO_0002688 + DDO:DDO_0002688 + + + + obo:DDO.owl#DDO_0002688 + 79468000 + + + + obo:DDO.owl#DDO_0002688 + familial benign pemphigus + + + + obo:DDO.owl#DDO_0002689 + DDO:DDO_0002689 + + + + obo:DDO.owl#DDO_0002689 + 402717008 + + + + obo:DDO.owl#DDO_0002689 + igA pemphigus + + + + obo:DDO.owl#DDO_0002690 + DDO:DDO_0002690 + + + + obo:DDO.owl#DDO_0002690 + 85824006 + + + + obo:DDO.owl#DDO_0002690 + malignant pemphigus + + + + obo:DDO.owl#DDO_0002691 + DDO:DDO_0002691 + + + + obo:DDO.owl#DDO_0002691 + 36739006 + + + + obo:DDO.owl#DDO_0002691 + pemphigus erythematosus + + + + obo:DDO.owl#DDO_0002692 + DDO:DDO_0002692 + + + + obo:DDO.owl#DDO_0002692 + 49420001 + + + + obo:DDO.owl#DDO_0002692 + pemphigus vulgaris + + + + obo:DDO.owl#DDO_0002693 + DDO:DDO_0002693 + + + + obo:DDO.owl#DDO_0002693 + 402435000 + + + + obo:DDO.owl#DDO_0002693 + eosinophilic spongiosis (prebullous pemphigus) + + + + obo:DDO.owl#DDO_0002694 + DDO:DDO_0002694 + + + + obo:DDO.owl#DDO_0002694 + 361212009 + + + + obo:DDO.owl#DDO_0002694 + oral pemphigus vulgaris + + + + obo:DDO.owl#DDO_0002695 + DDO:DDO_0002695 + + + + obo:DDO.owl#DDO_0002695 + 361211002 + + + + obo:DDO.owl#DDO_0002695 + pemphigus minor + + + + obo:DDO.owl#DDO_0002696 + DDO:DDO_0002696 + + + + obo:DDO.owl#DDO_0002696 + 277475006 + + + + obo:DDO.owl#DDO_0002696 + pemphigus neonatorum + + + + obo:DDO.owl#DDO_0002697 + DDO:DDO_0002697 + + + + obo:DDO.owl#DDO_0002697 + 238937005 + + + + obo:DDO.owl#DDO_0002697 + pemphigus vegetans of Neumann type + + + + obo:DDO.owl#DDO_0002698 + DDO:DDO_0002698 + + + + obo:DDO.owl#DDO_0002698 + 35154004 + + + + obo:DDO.owl#DDO_0002698 + pemphigus foliaceus + + + + obo:DDO.owl#DDO_0002699 + DDO:DDO_0002699 + + + + obo:DDO.owl#DDO_0002699 + 46459009 + + + + obo:DDO.owl#DDO_0002699 + Brazilian pemphigus foliaceus + + + + obo:DDO.owl#DDO_0002700 + DDO:DDO_0002700 + + + + obo:DDO.owl#DDO_0002700 + 402718003 + + + + obo:DDO.owl#DDO_0002700 + pemphigus paraneoplastica + + + + obo:DDO.owl#DDO_0002701 + DDO:DDO_0002701 + + + + obo:DDO.owl#DDO_0002701 + 81285006 + + + + obo:DDO.owl#DDO_0002701 + pemphigus vegetans + + + + obo:DDO.owl#DDO_0002702 + DDO:DDO_0002702 + + + + obo:DDO.owl#DDO_0002702 + 25147002 + + + + obo:DDO.owl#DDO_0002702 + subcorneal pustular dermatosis + + + + obo:DDO.owl#DDO_0002703 + DDO:DDO_0002703 + + + + obo:DDO.owl#DDO_0002703 + 271129001 + + + + obo:DDO.owl#DDO_0002703 + traumatic blister of vagina + + + + obo:DDO.owl#DDO_0002705 + DDO:DDO_0002705 + + + + obo:DDO.owl#DDO_0002705 + 197679002 + + + + obo:DDO.owl#DDO_0002705 + glomerular disease + + + + obo:DDO.owl#DDO_0002706 + DDO:DDO_0002706 + + + + obo:DDO.owl#DDO_0002706 + 197661001 + + + + obo:DDO.owl#DDO_0002706 + glomerulosclerosis + + + + obo:DDO.owl#DDO_0002707 + DDO:DDO_0002707 + + + + obo:DDO.owl#DDO_0002707 + 707221002 + + + + obo:DDO.owl#DDO_0002707 + diabetic glomerulosclerosis + + + + obo:DDO.owl#DDO_0002708 + DDO:DDO_0002708 + + + + obo:DDO.owl#DDO_0002708 + 310387003 + + + + obo:DDO.owl#DDO_0002708 + diabetic intracapillary glomerulosclerosis + + + + obo:DDO.owl#DDO_0002709 + DDO:DDO_0002709 + + + + obo:DDO.owl#DDO_0002709 + 38046004 + + + + obo:DDO.owl#DDO_0002709 + diffuse type diabetic glomerulosclerosis + + + + obo:DDO.owl#DDO_0002710 + DDO:DDO_0002710 + + + + obo:DDO.owl#DDO_0002710 + 63510008 + + + + obo:DDO.owl#DDO_0002710 + nodular type diabetic glomerulosclerosis + + + + obo:DDO.owl#DDO_0002711 + DDO:DDO_0002711 + + + + obo:DDO.owl#DDO_0002711 + 111406002 + + + + obo:DDO.owl#DDO_0002711 + diffuse mesangial sclerosis + + + + obo:DDO.owl#DDO_0002712 + DDO:DDO_0002712 + + + + obo:DDO.owl#DDO_0002712 + 25821008 + + + + obo:DDO.owl#DDO_0002712 + focal glomerular sclerosis + + + + obo:DDO.owl#DDO_0002713 + DDO:DDO_0002713 + + + + obo:DDO.owl#DDO_0002713 + 236403004 + + + + obo:DDO.owl#DDO_0002713 + focal segmental glomerulosclerosis + + + + obo:DDO.owl#DDO_0002714 + DDO:DDO_0002714 + + + + obo:DDO.owl#DDO_0002714 + 444977005 + + + + obo:DDO.owl#DDO_0002714 + autosomal dominant focal segmental glomerulosclerosis + + + + obo:DDO.owl#DDO_0002715 + DDO:DDO_0002715 + + + + obo:DDO.owl#DDO_0002715 + 445388002 + + + + obo:DDO.owl#DDO_0002715 + autosomal recessive focal segmental glomerulosclerosis + + + + obo:DDO.owl#DDO_0002716 + DDO:DDO_0002716 + + + + obo:DDO.owl#DDO_0002716 + 236404005 + + + + obo:DDO.owl#DDO_0002716 + classical focal segmental glomerulosclerosis + + + + obo:DDO.owl#DDO_0002717 + DDO:DDO_0002717 + + + + obo:DDO.owl#DDO_0002717 + 236405006 + + + + obo:DDO.owl#DDO_0002717 + hyperfiltration focal segmental glomerulosclerosis + + + + obo:DDO.owl#DDO_0002718 + DDO:DDO_0002718 + + + + obo:DDO.owl#DDO_0002718 + 236402009 + + + + obo:DDO.owl#DDO_0002718 + ischemic glomerulopathy + + + + obo:DDO.owl#DDO_0002719 + DDO:DDO_0002719 + + + + obo:DDO.owl#DDO_0002719 + 197660000 + + + + obo:DDO.owl#DDO_0002719 + renal fibrosis + + + + obo:DDO.owl#DDO_0002720 + DDO:DDO_0002720 + + + + obo:DDO.owl#DDO_0002720 + 13335004 + + + + obo:DDO.owl#DDO_0002720 + sclerosing glomerulonephritis + + + + obo:DDO.owl#DDO_0002721 + DDO:DDO_0002721 + + + + obo:DDO.owl#DDO_0002721 + 11013005 + + + + obo:DDO.owl#DDO_0002721 + SLE glomerulonephritis syndrome, WHO class VI + + + + obo:DDO.owl#DDO_0002722 + DDO:DDO_0002722 + + + + obo:DDO.owl#DDO_0002722 + 36171008 + + + + obo:DDO.owl#DDO_0002722 + glomerulonephritis + + + + obo:DDO.owl#DDO_0002723 + DDO:DDO_0002723 + + + + obo:DDO.owl#DDO_0002723 + 19351000 + + + + obo:DDO.owl#DDO_0002723 + acute glomerulonephritis + + + + obo:DDO.owl#DDO_0002724 + DDO:DDO_0002724 + + + + obo:DDO.owl#DDO_0002724 + 197582001 + + + + obo:DDO.owl#DDO_0002724 + acute glomerulonephritis associated with another disorder + + + + obo:DDO.owl#DDO_0002725 + DDO:DDO_0002725 + + + + obo:DDO.owl#DDO_0002725 + 68544003 + + + + obo:DDO.owl#DDO_0002725 + acute post-streptococcal glomerulonephritis + + + + obo:DDO.owl#DDO_0002726 + DDO:DDO_0002726 + + + + obo:DDO.owl#DDO_0002726 + 197580009 + + + + obo:DDO.owl#DDO_0002726 + acute nephritis with lesions of necrotizing glomerulitis + + + + obo:DDO.owl#DDO_0002727 + DDO:DDO_0002727 + + + + obo:DDO.owl#DDO_0002727 + 197579006 + + + + obo:DDO.owl#DDO_0002727 + acute proliferative glomerulonephritis + + + + obo:DDO.owl#DDO_0002728 + DDO:DDO_0002728 + + + + obo:DDO.owl#DDO_0002728 + 236393009 + + + + obo:DDO.owl#DDO_0002728 + endocapillary glomerulonephritis + + + + obo:DDO.owl#DDO_0002729 + DDO:DDO_0002729 + + + + obo:DDO.owl#DDO_0002729 + 3704008 + + + + obo:DDO.owl#DDO_0002729 + diffuse endocapillary proliferative glomerulonephritis + + + + obo:DDO.owl#DDO_0002730 + DDO:DDO_0002730 + + + + obo:DDO.owl#DDO_0002730 + 367531000119106 + + + + obo:DDO.owl#DDO_0002730 + hereditary diffuse endocapillary proliferative glomerulonephritis + + + + obo:DDO.owl#DDO_0002731 + DDO:DDO_0002731 + + + + obo:DDO.owl#DDO_0002731 + 236394003 + + + + obo:DDO.owl#DDO_0002731 + idiopathic endocapillary glomerulonephritis + + + + obo:DDO.owl#DDO_0002732 + DDO:DDO_0002732 + + + + obo:DDO.owl#DDO_0002732 + 236398000 + + + + obo:DDO.owl#DDO_0002732 + idiopathic crescentic glomerulonephritis + + + + obo:DDO.owl#DDO_0002733 + DDO:DDO_0002733 + + + + obo:DDO.owl#DDO_0002733 + 64212008 + + + + obo:DDO.owl#DDO_0002733 + diffuse crescentic glomerulonephritis + + + + obo:DDO.owl#DDO_0002734 + DDO:DDO_0002734 + + + + obo:DDO.owl#DDO_0002734 + 197688006 + + + + obo:DDO.owl#DDO_0002734 + acute nephritic syndrome, diffuse crescentic glomerulonephritis + + + + obo:DDO.owl#DDO_0002735 + DDO:DDO_0002735 + + + + obo:DDO.owl#DDO_0002735 + 367521000119108 + + + + obo:DDO.owl#DDO_0002735 + hereditary diffuse crescentic glomerulonephritis + + + + obo:DDO.owl#DDO_0002736 + DDO:DDO_0002736 + + + + obo:DDO.owl#DDO_0002736 + 64168005 + + + + obo:DDO.owl#DDO_0002736 + idiopathic crescentic glomerulonephritis, type I + + + + obo:DDO.owl#DDO_0002737 + DDO:DDO_0002737 + + + + obo:DDO.owl#DDO_0002737 + 359694003 + + + + obo:DDO.owl#DDO_0002737 + idiopathic crescentic glomerulonephritis, type II + + + + obo:DDO.owl#DDO_0002739 + DDO:DDO_0002739 + + + + obo:DDO.owl#DDO_0002739 + 55652009 + + + + obo:DDO.owl#DDO_0002739 + idiopathic crescentic glomerulonephritis, type III + + + + obo:DDO.owl#DDO_0002740 + DDO:DDO_0002740 + + + + obo:DDO.owl#DDO_0002740 + 8199003 + + + + obo:DDO.owl#DDO_0002740 + focal embolic nephritis syndrome + + + + obo:DDO.owl#DDO_0002741 + DDO:DDO_0002741 + + + + obo:DDO.owl#DDO_0002741 + 239932005 + + + + obo:DDO.owl#DDO_0002741 + primary pauci-immune necrotizing and crescentic glomerulonephritis + + + + obo:DDO.owl#DDO_0002742 + DDO:DDO_0002742 + + + + obo:DDO.owl#DDO_0002742 + 197629000 + + + + obo:DDO.owl#DDO_0002742 + anaphylactoid glomerulonephritis + + + + obo:DDO.owl#DDO_0002743 + DDO:DDO_0002743 + + + + obo:DDO.owl#DDO_0002743 + 20917003 + + + + obo:DDO.owl#DDO_0002743 + chronic glomerulonephritis + + + + obo:DDO.owl#DDO_0002744 + DDO:DDO_0002744 + + + + obo:DDO.owl#DDO_0002744 + 197619007 + + + + obo:DDO.owl#DDO_0002744 + chronic diffuse glomerulonephritis + + + + obo:DDO.owl#DDO_0002745 + DDO:DDO_0002745 + + + + obo:DDO.owl#DDO_0002745 + 197617009 + + + + obo:DDO.owl#DDO_0002745 + chronic exudative glomerulonephritis + + + + obo:DDO.owl#DDO_0002746 + DDO:DDO_0002746 + + + + obo:DDO.owl#DDO_0002746 + 197618004 + + + + obo:DDO.owl#DDO_0002746 + chronic focal glomerulonephritis + + + + obo:DDO.owl#DDO_0002747 + DDO:DDO_0002747 + + + + obo:DDO.owl#DDO_0002747 + 195791000119101 + + + + obo:DDO.owl#DDO_0002747 + chronic proliferative glomerulonephritis + + + + obo:DDO.owl#DDO_0002748 + DDO:DDO_0002748 + + + + obo:DDO.owl#DDO_0002748 + 197613008 + + + + obo:DDO.owl#DDO_0002748 + chronic mesangial proliferative glomerulonephritis + + + + obo:DDO.owl#DDO_0002749 + DDO:DDO_0002749 + + + + obo:DDO.owl#DDO_0002749 + 236412002 + + + + obo:DDO.owl#DDO_0002749 + C1q nephropathy + + + + obo:DDO.owl#DDO_0002750 + DDO:DDO_0002750 + + + + obo:DDO.owl#DDO_0002750 + 236407003 + + + + obo:DDO.owl#DDO_0002750 + IgA nephropathy + + + + obo:DDO.owl#DDO_0002751 + DDO:DDO_0002751 + + + + obo:DDO.owl#DDO_0002751 + 68779003 + + + + obo:DDO.owl#DDO_0002751 + primary IgA nephropathy + + + + obo:DDO.owl#DDO_0002752 + DDO:DDO_0002752 + + + + obo:DDO.owl#DDO_0002752 + 197632002 + + + + obo:DDO.owl#DDO_0002752 + Berger's IgA or IgG nephropathy + + + + obo:DDO.owl#DDO_0002753 + DDO:DDO_0002753 + + + + obo:DDO.owl#DDO_0002753 + 445404003 + + + + obo:DDO.owl#DDO_0002753 + familial immunoglobulin A nephropathy + + + + obo:DDO.owl#DDO_0002754 + DDO:DDO_0002754 + + + + obo:DDO.owl#DDO_0002754 + 236411009 + + + + obo:DDO.owl#DDO_0002754 + IgM nephropathy + + + + obo:DDO.owl#DDO_0002755 + DDO:DDO_0002755 + + + + obo:DDO.owl#DDO_0002755 + 80321008 + + + + obo:DDO.owl#DDO_0002755 + mesangiocapillary glomerulonephritis + + + + obo:DDO.owl#DDO_0002756 + DDO:DDO_0002756 + + + + obo:DDO.owl#DDO_0002756 + 197626007 + + + + obo:DDO.owl#DDO_0002756 + focal membranoproliferative glomerulonephritis + + + + obo:DDO.owl#DDO_0002757 + DDO:DDO_0002757 + + + + obo:DDO.owl#DDO_0002757 + 75888001 + + + + obo:DDO.owl#DDO_0002757 + mesangiocapillary glomerulonephritis type I + + + + obo:DDO.owl#DDO_0002758 + DDO:DDO_0002758 + + + + obo:DDO.owl#DDO_0002758 + 59479006 + + + + obo:DDO.owl#DDO_0002758 + mesangiocapillary glomerulonephritis type II + + + + obo:DDO.owl#DDO_0002759 + DDO:DDO_0002759 + + + + obo:DDO.owl#DDO_0002759 + 236409000 + + + + obo:DDO.owl#DDO_0002759 + mesangiocapillary glomerulonephritis type III + + + + obo:DDO.owl#DDO_0002760 + DDO:DDO_0002760 + + + + obo:DDO.owl#DDO_0002760 + 236410005 + + + + obo:DDO.owl#DDO_0002760 + mesangiocapillary glomerulonephritis type IV + + + + obo:DDO.owl#DDO_0002761 + DDO:DDO_0002761 + + + + obo:DDO.owl#DDO_0002761 + 367551000119100 + + + + obo:DDO.owl#DDO_0002761 + hereditary diffuse mesangial proliferative glomerulonephritis + + + + obo:DDO.owl#DDO_0002762 + DDO:DDO_0002762 + + + + obo:DDO.owl#DDO_0002762 + 197614002 + + + + obo:DDO.owl#DDO_0002762 + chronic rapidly progressive glomerulonephritis + + + + obo:DDO.owl#DDO_0002763 + DDO:DDO_0002763 + + + + obo:DDO.owl#DDO_0002763 + 234485006 + + + + obo:DDO.owl#DDO_0002763 + Epstein syndrome + + + + obo:DDO.owl#DDO_0002764 + DDO:DDO_0002764 + + + + obo:DDO.owl#DDO_0002764 + 77182004 + + + + obo:DDO.owl#DDO_0002764 + membranous glomerulonephritis + + + + obo:DDO.owl#DDO_0002765 + DDO:DDO_0002765 + + + + obo:DDO.owl#DDO_0002765 + 236505008 + + + + obo:DDO.owl#DDO_0002765 + cryoglobulinemic glomerulonephritis + + + + obo:DDO.owl#DDO_0002766 + DDO:DDO_0002766 + + + + obo:DDO.owl#DDO_0002766 + 236590008 + + + + obo:DDO.owl#DDO_0002766 + cytomegalovirus-induced glomerulonephritis + + + + obo:DDO.owl#DDO_0002767 + DDO:DDO_0002767 + + + + obo:DDO.owl#DDO_0002767 + 236586006 + + + + obo:DDO.owl#DDO_0002767 + De novo glomerulonephritis + + + + obo:DDO.owl#DDO_0002768 + DDO:DDO_0002768 + + + + obo:DDO.owl#DDO_0002768 + 425455002 + + + + obo:DDO.owl#DDO_0002768 + diabetic glomerulonephritis + + + + obo:DDO.owl#DDO_0002769 + DDO:DDO_0002769 + + + + obo:DDO.owl#DDO_0002769 + 73305009 + + + + obo:DDO.owl#DDO_0002769 + fibrillary glomerulonephritis + + + + obo:DDO.owl#DDO_0002770 + DDO:DDO_0002770 + + + + obo:DDO.owl#DDO_0002770 + 22702000 + + + + obo:DDO.owl#DDO_0002770 + glomerulitis + + + + obo:DDO.owl#DDO_0002771 + DDO:DDO_0002771 + + + + obo:DDO.owl#DDO_0002771 + 236506009 + + + + obo:DDO.owl#DDO_0002771 + Goodpasture's disease + + + + obo:DDO.owl#DDO_0002772 + DDO:DDO_0002772 + + + + obo:DDO.owl#DDO_0002772 + 399340005 + + + + obo:DDO.owl#DDO_0002772 + hereditary nephritis + + + + obo:DDO.owl#DDO_0002773 + DDO:DDO_0002773 + + + + obo:DDO.owl#DDO_0002773 + 106911000119102 + + + + obo:DDO.owl#DDO_0002773 + idiopathic glomerulonephritis + + + + obo:DDO.owl#DDO_0002774 + DDO:DDO_0002774 + + + + obo:DDO.owl#DDO_0002774 + 123752003 + + + + obo:DDO.owl#DDO_0002774 + immune-complex glomerulonephritis + + + + obo:DDO.owl#DDO_0002777 + DDO:DDO_0002777 + + + + obo:DDO.owl#DDO_0002777 + 35546006 + + + + obo:DDO.owl#DDO_0002777 + mesangial proliferative glomerulonephritis + + + + obo:DDO.owl#DDO_0002778 + DDO:DDO_0002778 + + + + obo:DDO.owl#DDO_0002778 + 711531007 + + + + obo:DDO.owl#DDO_0002778 + focal mesangial proliferative glomerulonephritis + + + + obo:DDO.owl#DDO_0002779 + DDO:DDO_0002779 + + + + obo:DDO.owl#DDO_0002779 + 4676006 + + + + obo:DDO.owl#DDO_0002779 + SLE glomerulonephritis syndrome, WHO class II + + + + obo:DDO.owl#DDO_0002780 + DDO:DDO_0002780 + + + + obo:DDO.owl#DDO_0002780 + 1426004 + + + + obo:DDO.owl#DDO_0002780 + necrotizing glomerulonephritis + + + + obo:DDO.owl#DDO_0002781 + DDO:DDO_0002781 + + + + obo:DDO.owl#DDO_0002781 + 399190000 + + + + obo:DDO.owl#DDO_0002781 + non-progressive hereditary glomerulonephritis + + + + obo:DDO.owl#DDO_0002782 + DDO:DDO_0002782 + + + + obo:DDO.owl#DDO_0002782 + 236395002 + + + + obo:DDO.owl#DDO_0002782 + post-infectious glomerulonephritis + + + + obo:DDO.owl#DDO_0002783 + DDO:DDO_0002783 + + + + obo:DDO.owl#DDO_0002783 + 37085009 + + + + obo:DDO.owl#DDO_0002783 + shunt nephritis + + + + obo:DDO.owl#DDO_0002784 + DDO:DDO_0002784 + + + + obo:DDO.owl#DDO_0002784 + 441815006 + + + + obo:DDO.owl#DDO_0002784 + proliferative glomerulonephritis + + + + obo:DDO.owl#DDO_0002785 + DDO:DDO_0002785 + + + + obo:DDO.owl#DDO_0002785 + 707332000 + + + + obo:DDO.owl#DDO_0002785 + recurrent proliferative glomerulonephritis + + + + obo:DDO.owl#DDO_0002786 + DDO:DDO_0002786 + + + + obo:DDO.owl#DDO_0002786 + 13335004 + + + + obo:DDO.owl#DDO_0002786 + sclerosing glomerulonephritis + + + + obo:DDO.owl#DDO_0002787 + DDO:DDO_0002787 + + + + obo:DDO.owl#DDO_0002787 + 65508009 + + + + obo:DDO.owl#DDO_0002787 + granuloma annulare + + + + obo:DDO.owl#DDO_0002788 + DDO:DDO_0002788 + + + + obo:DDO.owl#DDO_0002788 + 402366007 + + + + obo:DDO.owl#DDO_0002788 + subcutaneous granuloma annulare + + + + obo:DDO.owl#DDO_0002789 + DDO:DDO_0002789 + + + + obo:DDO.owl#DDO_0002789 + 402365006 + + + + obo:DDO.owl#DDO_0002789 + perforating granuloma annulare + + + + obo:DDO.owl#DDO_0002790 + DDO:DDO_0002790 + + + + obo:DDO.owl#DDO_0002790 + 402363004 + + + + obo:DDO.owl#DDO_0002790 + localized granuloma annulare + + + + obo:DDO.owl#DDO_0002791 + DDO:DDO_0002791 + + + + obo:DDO.owl#DDO_0002791 + 402367003 + + + + obo:DDO.owl#DDO_0002791 + linear granuloma annulare + + + + obo:DDO.owl#DDO_0002792 + DDO:DDO_0002792 + + + + obo:DDO.owl#DDO_0002792 + 402364005 + + + + obo:DDO.owl#DDO_0002792 + generalized granuloma annulare + + + + obo:DDO.owl#DDO_0002793 + DDO:DDO_0002793 + + + + obo:DDO.owl#DDO_0002793 + 445144002 + + + + obo:DDO.owl#DDO_0002793 + deformity of limb + + + + obo:DDO.owl#DDO_0002794 + DDO:DDO_0002794 + + + + obo:DDO.owl#DDO_0002794 + 201114008 + + + + obo:DDO.owl#DDO_0002794 + nail deformity + + + + obo:DDO.owl#DDO_0002795 + DDO:DDO_0002795 + + + + obo:DDO.owl#DDO_0002795 + 403308000 + + + + obo:DDO.owl#DDO_0002795 + acquired nail deformity + + + + obo:DDO.owl#DDO_0002796 + DDO:DDO_0002796 + + + + obo:DDO.owl#DDO_0002796 + 712650000 + + + + obo:DDO.owl#DDO_0002796 + acquired deformity of nail of finger + + + + obo:DDO.owl#DDO_0002797 + DDO:DDO_0002797 + + + + obo:DDO.owl#DDO_0002797 + 403305002 + + + + obo:DDO.owl#DDO_0002797 + acquired koilonychia + + + + obo:DDO.owl#DDO_0002798 + DDO:DDO_0002798 + + + + obo:DDO.owl#DDO_0002798 + 403307005 + + + + obo:DDO.owl#DDO_0002798 + acquired malalignment of the toenails + + + + obo:DDO.owl#DDO_0002799 + DDO:DDO_0002799 + + + + obo:DDO.owl#DDO_0002799 + 403306001 + + + + obo:DDO.owl#DDO_0002799 + acquired pterygium of nail + + + + obo:DDO.owl#DDO_0002800 + DDO:DDO_0002800 + + + + obo:DDO.owl#DDO_0002800 + 402776008 + + + + obo:DDO.owl#DDO_0002800 + inherited deformity of nail + + + + obo:DDO.owl#DDO_0002801 + DDO:DDO_0002801 + + + + obo:DDO.owl#DDO_0002801 + 403800004 + + + + obo:DDO.owl#DDO_0002801 + hereditary racquet nails + + + + obo:DDO.owl#DDO_0002802 + DDO:DDO_0002802 + + + + obo:DDO.owl#DDO_0002802 + 19051000119100 + + + + obo:DDO.owl#DDO_0002802 + nailbed deformity + + + + obo:DDO.owl#DDO_0002803 + DDO:DDO_0002803 + + + + obo:DDO.owl#DDO_0002803 + 59258008 + + + + obo:DDO.owl#DDO_0002803 + infection by Deuteromycetes + + + + obo:DDO.owl#DDO_0002804 + DDO:DDO_0002804 + + + + obo:DDO.owl#DDO_0002804 + 47382004 + + + + obo:DDO.owl#DDO_0002804 + tinea + + + + obo:DDO.owl#DDO_0002804 + dermatophytosis + + + + obo:DDO.owl#DDO_0002805 + DDO:DDO_0002805 + + + + obo:DDO.owl#DDO_0002805 + 266152000 + + + + obo:DDO.owl#DDO_0002805 + deep seated dermatophytosis + + + + obo:DDO.owl#DDO_0002806 + DDO:DDO_0002806 + + + + obo:DDO.owl#DDO_0002806 + 266148000 + + + + obo:DDO.owl#DDO_0002806 + dermatophytosis of scalp or beard + + + + obo:DDO.owl#DDO_0002807 + DDO:DDO_0002807 + + + + obo:DDO.owl#DDO_0002807 + 19087001 + + + + obo:DDO.owl#DDO_0002807 + tinea kerion + + + + obo:DDO.owl#DDO_0002808 + DDO:DDO_0002808 + + + + obo:DDO.owl#DDO_0002808 + 266151007 + + + + obo:DDO.owl#DDO_0002808 + dermatophytosis of the body + + + + obo:DDO.owl#DDO_0002809 + DDO:DDO_0002809 + + + + obo:DDO.owl#DDO_0002809 + 186991000 + + + + obo:DDO.owl#DDO_0002809 + dermatophytosis of the perianal area + + + + obo:DDO.owl#DDO_0002810 + DDO:DDO_0002810 + + + + obo:DDO.owl#DDO_0002810 + 84849002 + + + + obo:DDO.owl#DDO_0002810 + tinea corporis + + + + obo:DDO.owl#DDO_0002811 + DDO:DDO_0002811 + + + + obo:DDO.owl#DDO_0002811 + 399029005 + + + + obo:DDO.owl#DDO_0002811 + tinea cruris + + + + obo:DDO.owl#DDO_0002812 + DDO:DDO_0002812 + + + + obo:DDO.owl#DDO_0002812 + 40911008 + + + + obo:DDO.owl#DDO_0002812 + disseminated dermatophytosis + + + + obo:DDO.owl#DDO_0002813 + DDO:DDO_0002813 + + + + obo:DDO.owl#DDO_0002813 + 240700007 + + + + obo:DDO.owl#DDO_0002813 + fungal infection of hair + + + + obo:DDO.owl#DDO_0002814 + DDO:DDO_0002814 + + + + obo:DDO.owl#DDO_0002814 + 33666009 + + + + obo:DDO.owl#DDO_0002814 + black piedra + + + + obo:DDO.owl#DDO_0002815 + DDO:DDO_0002815 + + + + obo:DDO.owl#DDO_0002815 + 402135006 + + + + obo:DDO.owl#DDO_0002815 + piedra + + + + obo:DDO.owl#DDO_0002816 + DDO:DDO_0002816 + + + + obo:DDO.owl#DDO_0002816 + 403091007 + + + + obo:DDO.owl#DDO_0002816 + Trichosporon beigelii infection (piedra) + + + + obo:DDO.owl#DDO_0002817 + DDO:DDO_0002817 + + + + obo:DDO.owl#DDO_0002817 + 399329002 + + + + obo:DDO.owl#DDO_0002817 + tinea barbae + + + + obo:DDO.owl#DDO_0002818 + DDO:DDO_0002818 + + + + obo:DDO.owl#DDO_0002818 + 274083001 + + + + obo:DDO.owl#DDO_0002818 + tinea kerion of beard + + + + obo:DDO.owl#DDO_0002819 + DDO:DDO_0002819 + + + + obo:DDO.owl#DDO_0002819 + 35586003 + + + + obo:DDO.owl#DDO_0002819 + white piedra + + + + obo:DDO.owl#DDO_0002820 + DDO:DDO_0002820 + + + + obo:DDO.owl#DDO_0002820 + 78487004 + + + + obo:DDO.owl#DDO_0002820 + granulomatous dermatophytosis + + + + obo:DDO.owl#DDO_0002821 + DDO:DDO_0002821 + + + + obo:DDO.owl#DDO_0002821 + 5441008 + + + + obo:DDO.owl#DDO_0002821 + tinea capitis + + + + obo:DDO.owl#DDO_0002822 + DDO:DDO_0002822 + + + + obo:DDO.owl#DDO_0002822 + 240696004 + + + + obo:DDO.owl#DDO_0002822 + tinea faciei + + + + obo:DDO.owl#DDO_0002823 + DDO:DDO_0002823 + + + + obo:DDO.owl#DDO_0002823 + 48971001 + + + + obo:DDO.owl#DDO_0002823 + tinea manus + + + + obo:DDO.owl#DDO_0002824 + DDO:DDO_0002824 + + + + obo:DDO.owl#DDO_0002824 + 186289000 + + + + obo:DDO.owl#DDO_0002824 + tinea nigra + + + + obo:DDO.owl#DDO_0002825 + DDO:DDO_0002825 + + + + obo:DDO.owl#DDO_0002825 + 185367005 + + + + obo:DDO.owl#DDO_0002825 + microsporosis nigra + + + + obo:DDO.owl#DDO_0002826 + DDO:DDO_0002826 + + + + obo:DDO.owl#DDO_0002826 + 6020002 + + + + obo:DDO.owl#DDO_0002826 + tinea pedis + + + + obo:DDO.owl#DDO_0002827 + DDO:DDO_0002827 + + + + obo:DDO.owl#DDO_0002827 + 415692008 + + + + obo:DDO.owl#DDO_0002827 + bunion + + + + obo:DDO.owl#DDO_0002828 + DDO:DDO_0002828 + + + + obo:DDO.owl#DDO_0002828 + 118623005 + + + + obo:DDO.owl#DDO_0002828 + hallux valgus AND bunion + + + + obo:DDO.owl#DDO_0002829 + DDO:DDO_0002829 + + + + obo:DDO.owl#DDO_0002829 + necrosis + + + + obo:DDO.owl#DDO_0002830 + DDO:DDO_0002830 + + + + obo:DDO.owl#DDO_0002830 + 238888007 + + + + obo:DDO.owl#DDO_0002830 + fat necrosis + + + + obo:DDO.owl#DDO_0002831 + DDO:DDO_0002831 + + + + obo:DDO.owl#DDO_0002831 + 95337003 + + + + obo:DDO.owl#DDO_0002831 + extensive lipodermatosclerosis + + + + obo:DDO.owl#DDO_0002832 + DDO:DDO_0002832 + + + + obo:DDO.owl#DDO_0002832 + 111368002 + + + + obo:DDO.owl#DDO_0002832 + fat necrosis of peritoneum + + + + obo:DDO.owl#DDO_0002833 + DDO:DDO_0002833 + + + + obo:DDO.owl#DDO_0002833 + 236008004 + + + + obo:DDO.owl#DDO_0002833 + mesenteric fat necrosis + + + + obo:DDO.owl#DDO_0002834 + DDO:DDO_0002834 + + + + obo:DDO.owl#DDO_0002834 + 197185008 + + + + obo:DDO.owl#DDO_0002834 + mesenteric fat saponification + + + + obo:DDO.owl#DDO_0002835 + DDO:DDO_0002835 + + + + obo:DDO.owl#DDO_0002835 + 13771001 + + + + obo:DDO.owl#DDO_0002835 + mesenteric saponification + + + + obo:DDO.owl#DDO_0002839 + DDO:DDO_0002839 + + + + obo:DDO.owl#DDO_0002839 + 236009007 + + + + obo:DDO.owl#DDO_0002839 + omental fat necrosis + + + + obo:DDO.owl#DDO_0002840 + DDO:DDO_0002840 + + + + obo:DDO.owl#DDO_0002840 + 446933000 + + + + obo:DDO.owl#DDO_0002840 + fat necrosis of subcutaneous tissue + + + + obo:DDO.owl#DDO_0002841 + DDO:DDO_0002841 + + + + obo:DDO.owl#DDO_0002841 + 238890008 + + + + obo:DDO.owl#DDO_0002841 + nodular fat necrosis + + + + obo:DDO.owl#DDO_0002842 + DDO:DDO_0002842 + + + + obo:DDO.owl#DDO_0002842 + 46626002 + + + + obo:DDO.owl#DDO_0002842 + subcutaneous nodular fat necrosis in pancreatitis + + + + obo:DDO.owl#DDO_0002843 + DDO:DDO_0002843 + + + + obo:DDO.owl#DDO_0002843 + 239094006 + + + + obo:DDO.owl#DDO_0002843 + subcutaneous fat necrosis of newborn + + + + obo:DDO.owl#DDO_0002844 + DDO:DDO_0002844 + + + + obo:DDO.owl#DDO_0002844 + 206254003 + + + + obo:DDO.owl#DDO_0002844 + subcutaneous fat necrosis due to birth injury + + + + obo:DDO.owl#DDO_0002845 + DDO:DDO_0002845 + + + + obo:DDO.owl#DDO_0002845 + 95336007 + + + + obo:DDO.owl#DDO_0002845 + localized lipodermatosclerosis + + + + obo:DDO.owl#DDO_0002846 + DDO:DDO_0002846 + + + + obo:DDO.owl#DDO_0002846 + 236007009 + + + + obo:DDO.owl#DDO_0002846 + retroperitoneal fat necrosis + + + + obo:DDO.owl#DDO_0002847 + DDO:DDO_0002847 + + + + obo:DDO.owl#DDO_0002847 + 238891007 + + + + obo:DDO.owl#DDO_0002847 + traumatic fat necrosis + + + + obo:DDO.owl#DDO_0002848 + DDO:DDO_0002848 + + + + obo:DDO.owl#DDO_0002848 + 95568003 + + + + obo:DDO.owl#DDO_0002848 + renal tubular disorder + + + + obo:DDO.owl#DDO_0002849 + DDO:DDO_0002849 + + + + obo:DDO.owl#DDO_0002849 + 35455006 + + + + obo:DDO.owl#DDO_0002849 + acute tubular necrosis + + + + obo:DDO.owl#DDO_0002850 + DDO:DDO_0002850 + + + + obo:DDO.owl#DDO_0002850 + 236426006 + + + + obo:DDO.owl#DDO_0002850 + postoperative acute tubular necrosis + + + + obo:DDO.owl#DDO_0002851 + DDO:DDO_0002851 + + + + obo:DDO.owl#DDO_0002851 + 236427002 + + + + obo:DDO.owl#DDO_0002851 + post-traumatic acute tubular necrosis + + + + obo:DDO.owl#DDO_0002852 + DDO:DDO_0002852 + + + + obo:DDO.owl#DDO_0002852 + 236671005 + + + + obo:DDO.owl#DDO_0002852 + bladder necrosis + + + + obo:DDO.owl#DDO_0002853 + DDO:DDO_0002853 + + + + obo:DDO.owl#DDO_0002853 + 95347000 + + + + obo:DDO.owl#DDO_0002853 + skin necrosis + + + + obo:DDO.owl#DDO_0002854 + DDO:DDO_0002854 + + + + obo:DDO.owl#DDO_0002854 + 30595008 + + + + obo:DDO.owl#DDO_0002854 + acute necrotizing cutaneous leishmaniasis + + + + obo:DDO.owl#DDO_0002855 + DDO:DDO_0002855 + + + + obo:DDO.owl#DDO_0002855 + 403659005 + + + + obo:DDO.owl#DDO_0002855 + coumarin necrosis + + + + obo:DDO.owl#DDO_0002856 + DDO:DDO_0002856 + + + + obo:DDO.owl#DDO_0002856 + 17732003 + + + + obo:DDO.owl#DDO_0002856 + ecthyma gangrenosum + + + + obo:DDO.owl#DDO_0002857 + DDO:DDO_0002857 + + + + obo:DDO.owl#DDO_0002857 + 404174000 + + + + obo:DDO.owl#DDO_0002857 + neonatal ecthyma gangrenosum + + + + obo:DDO.owl#DDO_0002858 + DDO:DDO_0002858 + + + + obo:DDO.owl#DDO_0002858 + 240435008 + + + + obo:DDO.owl#DDO_0002858 + gas gangrene of skin + + + + obo:DDO.owl#DDO_0002859 + DDO:DDO_0002859 + + + + obo:DDO.owl#DDO_0002859 + 41352000 + + + + obo:DDO.owl#DDO_0002859 + granulomatosis disciformis et progressiva + + + + obo:DDO.owl#DDO_0002860 + DDO:DDO_0002860 + + + + obo:DDO.owl#DDO_0002860 + 23067006 + + + + obo:DDO.owl#DDO_0002860 + Lyell's toxic epidermal necrolysis, subepidermal type + + + + obo:DDO.owl#DDO_0002861 + DDO:DDO_0002861 + + + + obo:DDO.owl#DDO_0002861 + 278038007 + + + + obo:DDO.owl#DDO_0002861 + Meleney's gangrene + + + + obo:DDO.owl#DDO_0002862 + DDO:DDO_0002862 + + + + obo:DDO.owl#DDO_0002862 + 13507004 + + + + obo:DDO.owl#DDO_0002862 + purpura fulminans + + + + obo:DDO.owl#DDO_0002863 + DDO:DDO_0002863 + + + + obo:DDO.owl#DDO_0002863 + 402851000 + + + + obo:DDO.owl#DDO_0002863 + neonatal purpura fulminans (homozygous protein C deficiency) + + + + obo:DDO.owl#DDO_0002864 + DDO:DDO_0002864 + + + + obo:DDO.owl#DDO_0002864 + 403680004 + + + + obo:DDO.owl#DDO_0002864 + skin graft necrosis + + + + obo:DDO.owl#DDO_0002865 + DDO:DDO_0002865 + + + + obo:DDO.owl#DDO_0002865 + 400190005 + + + + obo:DDO.owl#DDO_0002865 + atrophic condition of skin + + + + obo:DDO.owl#DDO_0002866 + DDO:DDO_0002866 + + + + obo:DDO.owl#DDO_0002866 + 247429005 + + + + obo:DDO.owl#DDO_0002866 + disorder of thinning of skin + + + + obo:DDO.owl#DDO_0002867 + DDO:DDO_0002867 + + + + obo:DDO.owl#DDO_0002867 + 360418002 + + + + obo:DDO.owl#DDO_0002867 + perifollicular macular atrophy + + + + obo:DDO.owl#DDO_0002868 + DDO:DDO_0002868 + + + + obo:DDO.owl#DDO_0002868 + 360414000 + + + + obo:DDO.owl#DDO_0002868 + perifollicular elastolysis + + + + obo:DDO.owl#DDO_0002869 + DDO:DDO_0002869 + + + + obo:DDO.owl#DDO_0002869 + 238822005 + + + + obo:DDO.owl#DDO_0002869 + noninflammatory dermal elastolysis + + + + obo:DDO.owl#DDO_0002870 + DDO:DDO_0002870 + + + + obo:DDO.owl#DDO_0002870 + 238821003 + + + + obo:DDO.owl#DDO_0002870 + idiopathic mid-dermal elastolysis + + + + obo:DDO.owl#DDO_0002871 + DDO:DDO_0002871 + + + + obo:DDO.owl#DDO_0002871 + 277796003 + + + + obo:DDO.owl#DDO_0002871 + granulomatous slack skin disease + + + + obo:DDO.owl#DDO_0002872 + DDO:DDO_0002872 + + + + obo:DDO.owl#DDO_0002872 + 75934005 + + + + obo:DDO.owl#DDO_0002872 + metabolic disease + + + + obo:DDO.owl#DDO_0002874 + DDO:DDO_0002874 + + + + obo:DDO.owl#DDO_0002874 + 76314005 + + + + obo:DDO.owl#DDO_0002874 + disorder of fluid AND/OR electrolyte + + + + obo:DDO.owl#DDO_0002875 + DDO:DDO_0002875 + + + + obo:DDO.owl#DDO_0002875 + 237840007 + + + + obo:DDO.owl#DDO_0002875 + disorder of electrolytes + + + + obo:DDO.owl#DDO_0002876 + DDO:DDO_0002876 + + + + obo:DDO.owl#DDO_0002876 + 18829008 + + + + obo:DDO.owl#DDO_0002876 + electrolyte depletion + + + + obo:DDO.owl#DDO_0002877 + DDO:DDO_0002877 + + + + obo:DDO.owl#DDO_0002877 + 709413001 + + + + obo:DDO.owl#DDO_0002877 + isolated hyperchlorhidrosis + + + + obo:DDO.owl#DDO_0002878 + DDO:DDO_0002878 + + + + obo:DDO.owl#DDO_0002878 + 370493008 + + + + obo:DDO.owl#DDO_0002878 + renal medullary washout + + + + obo:DDO.owl#DDO_0002879 + DDO:DDO_0002879 + + + + obo:DDO.owl#DDO_0002879 + 105593004 + + + + obo:DDO.owl#DDO_0002879 + electrolyte imbalance + + + + obo:DDO.owl#DDO_0002880 + DDO:DDO_0002880 + + + + obo:DDO.owl#DDO_0002880 + 75598001 + + + + obo:DDO.owl#DDO_0002880 + chloride disorder + + + + obo:DDO.owl#DDO_0002881 + DDO:DDO_0002881 + + + + obo:DDO.owl#DDO_0002881 + 74450001 + + + + obo:DDO.owl#DDO_0002881 + hyperchloremia + + + + obo:DDO.owl#DDO_0002882 + DDO:DDO_0002882 + + + + obo:DDO.owl#DDO_0002882 + 10399008 + + + + obo:DDO.owl#DDO_0002882 + hypochloremia + + + + obo:DDO.owl#DDO_0002883 + DDO:DDO_0002883 + + + + obo:DDO.owl#DDO_0002883 + 20313009 + + + + obo:DDO.owl#DDO_0002883 + hyperosmolality + + + + obo:DDO.owl#DDO_0002884 + DDO:DDO_0002884 + + + + obo:DDO.owl#DDO_0002884 + 4519003 + + + + obo:DDO.owl#DDO_0002884 + hypouricemia + + + + obo:DDO.owl#DDO_0002885 + DDO:DDO_0002885 + + + + obo:DDO.owl#DDO_0002885 + 237854004 + + + + obo:DDO.owl#DDO_0002885 + increased anion gap + + + + obo:DDO.owl#DDO_0002886 + DDO:DDO_0002886 + + + + obo:DDO.owl#DDO_0002886 + 420200001 + + + + obo:DDO.owl#DDO_0002886 + magnesium disorder + + + + obo:DDO.owl#DDO_0002887 + DDO:DDO_0002887 + + + + obo:DDO.owl#DDO_0002887 + 60853003 + + + + obo:DDO.owl#DDO_0002887 + disorder of magnesium metabolism + + + + obo:DDO.owl#DDO_0002888 + DDO:DDO_0002888 + + + + obo:DDO.owl#DDO_0002888 + 66978005 + + + + obo:DDO.owl#DDO_0002888 + hypermagnesemia + + + + obo:DDO.owl#DDO_0002889 + DDO:DDO_0002889 + + + + obo:DDO.owl#DDO_0002889 + 190855004 + + + + obo:DDO.owl#DDO_0002889 + hypomagnesemia + + + + obo:DDO.owl#DDO_0002890 + DDO:DDO_0002890 + + + + obo:DDO.owl#DDO_0002890 + 190856003 + + + + obo:DDO.owl#DDO_0002890 + hypomagnesemic tetany + + + + obo:DDO.owl#DDO_0002891 + DDO:DDO_0002891 + + + + obo:DDO.owl#DDO_0002891 + 87898000 + + + + obo:DDO.owl#DDO_0002891 + neonatal hypomagnesemia + + + + obo:DDO.owl#DDO_0002892 + DDO:DDO_0002892 + + + + obo:DDO.owl#DDO_0002892 + 80710001 + + + + obo:DDO.owl#DDO_0002892 + primary hypomagnesemia + + + + obo:DDO.owl#DDO_0002893 + DDO:DDO_0002893 + + + + obo:DDO.owl#DDO_0002893 + 237907004 + + + + obo:DDO.owl#DDO_0002893 + secondary hypomagnesemia + + + + obo:DDO.owl#DDO_0002894 + DDO:DDO_0002894 + + + + obo:DDO.owl#DDO_0002894 + 20987006 + + + + obo:DDO.owl#DDO_0002894 + McKittrick-Wheelock syndrome + + + + obo:DDO.owl#DDO_0002895 + DDO:DDO_0002895 + + + + obo:DDO.owl#DDO_0002895 + 276569005 + + + + obo:DDO.owl#DDO_0002895 + perinatal disorder of electrolytes + + + + obo:DDO.owl#DDO_0002896 + DDO:DDO_0002896 + + + + obo:DDO.owl#DDO_0002896 + 24529006 + + + + obo:DDO.owl#DDO_0002896 + potassium disorder + + + + obo:DDO.owl#DDO_0002897 + DDO:DDO_0002897 + + + + obo:DDO.owl#DDO_0002897 + 14140009 + + + + obo:DDO.owl#DDO_0002897 + hyperkalemia + + + + obo:DDO.owl#DDO_0002898 + DDO:DDO_0002898 + + + + obo:DDO.owl#DDO_0002898 + 5579000 + + + + obo:DDO.owl#DDO_0002898 + acute hyperkalemia + + + + obo:DDO.owl#DDO_0002899 + DDO:DDO_0002899 + + + + obo:DDO.owl#DDO_0002899 + 40777006 + + + + obo:DDO.owl#DDO_0002899 + chronic hyperkalemia + + + + obo:DDO.owl#DDO_0002900 + DDO:DDO_0002900 + + + + obo:DDO.owl#DDO_0002900 + 237850008 + + + + obo:DDO.owl#DDO_0002900 + Gordon's syndrome + + + + obo:DDO.owl#DDO_0002901 + DDO:DDO_0002901 + + + + obo:DDO.owl#DDO_0002901 + 54781007 + + + + obo:DDO.owl#DDO_0002901 + hyperkalemia, diminished renal excretion + + + + obo:DDO.owl#DDO_0002902 + DDO:DDO_0002902 + + + + obo:DDO.owl#DDO_0002902 + 5354002 + + + + obo:DDO.owl#DDO_0002902 + hyperkalemia, transcellular shifts + + + + obo:DDO.owl#DDO_0002903 + DDO:DDO_0002903 + + + + obo:DDO.owl#DDO_0002903 + 237847005 + + + + obo:DDO.owl#DDO_0002903 + hyperkalemic acidosis + + + + obo:DDO.owl#DDO_0002904 + DDO:DDO_0002904 + + + + obo:DDO.owl#DDO_0002904 + 237846001 + + + + obo:DDO.owl#DDO_0002904 + hyperkalemic alkalosis + + + + obo:DDO.owl#DDO_0002905 + DDO:DDO_0002905 + + + + obo:DDO.owl#DDO_0002905 + 206491006 + + + + obo:DDO.owl#DDO_0002905 + transitory neonatal hyperkalemia + + + + obo:DDO.owl#DDO_0002906 + DDO:DDO_0002906 + + + + obo:DDO.owl#DDO_0002906 + 43339004 + + + + obo:DDO.owl#DDO_0002906 + hypokalemia + + + + obo:DDO.owl#DDO_0002907 + DDO:DDO_0002907 + + + + obo:DDO.owl#DDO_0002907 + 61120003 + + + + obo:DDO.owl#DDO_0002907 + acute hypokalemia + + + + obo:DDO.owl#DDO_0002908 + DDO:DDO_0002908 + + + + obo:DDO.owl#DDO_0002908 + 206492004 + + + + obo:DDO.owl#DDO_0002908 + transitory neonatal hypokalemia + + + + obo:DDO.owl#DDO_0002909 + DDO:DDO_0002909 + + + + obo:DDO.owl#DDO_0002909 + 10469003 + + + + obo:DDO.owl#DDO_0002909 + chronic hypokalemia + + + + obo:DDO.owl#DDO_0002910 + DDO:DDO_0002910 + + + + obo:DDO.owl#DDO_0002910 + 38495009 + + + + obo:DDO.owl#DDO_0002910 + hypokalemia, excessive renal losses + + + + obo:DDO.owl#DDO_0002911 + DDO:DDO_0002911 + + + + obo:DDO.owl#DDO_0002911 + 59586001 + + + + obo:DDO.owl#DDO_0002911 + hypokalemia, gastrointestinal losses + + + + obo:DDO.owl#DDO_0002912 + DDO:DDO_0002912 + + + + obo:DDO.owl#DDO_0002912 + 23800005 + + + + obo:DDO.owl#DDO_0002912 + hypokalemia, inadequate intake + + + + obo:DDO.owl#DDO_0002913 + DDO:DDO_0002913 + + + + obo:DDO.owl#DDO_0002913 + 237851007 + + + + obo:DDO.owl#DDO_0002913 + hypokalemic acidosis + + + + obo:DDO.owl#DDO_0002914 + DDO:DDO_0002914 + + + + obo:DDO.owl#DDO_0002914 + 22774003 + + + + obo:DDO.owl#DDO_0002914 + hypokalemic alkalosis + + + + obo:DDO.owl#DDO_0002922 + DDO:DDO_0002922 + + + + obo:DDO.owl#DDO_0002922 + 405581005 + + + + obo:DDO.owl#DDO_0002922 + paraneoplastic hypokalemia + + + + obo:DDO.owl#DDO_0002923 + DDO:DDO_0002923 + + + + obo:DDO.owl#DDO_0002923 + 123807007 + + + + obo:DDO.owl#DDO_0002923 + sodium disorder + + + + obo:DDO.owl#DDO_0002924 + DDO:DDO_0002924 + + + + obo:DDO.owl#DDO_0002924 + 206493009 + + + + obo:DDO.owl#DDO_0002924 + disturbances of sodium balance of newborn + + + + obo:DDO.owl#DDO_0002925 + DDO:DDO_0002925 + + + + obo:DDO.owl#DDO_0002925 + 206489003 + + + + obo:DDO.owl#DDO_0002925 + transitory neonatal hypernatremia + + + + obo:DDO.owl#DDO_0002926 + DDO:DDO_0002926 + + + + obo:DDO.owl#DDO_0002926 + 206490007 + + + + obo:DDO.owl#DDO_0002926 + transitory neonatal hyponatremia + + + + obo:DDO.owl#DDO_0002927 + DDO:DDO_0002927 + + + + obo:DDO.owl#DDO_0002927 + 39355002 + + + + obo:DDO.owl#DDO_0002927 + hypernatremia + + + + obo:DDO.owl#DDO_0002928 + DDO:DDO_0002928 + + + + obo:DDO.owl#DDO_0002928 + 7405009 + + + + obo:DDO.owl#DDO_0002928 + acute hypernatremia + + + + obo:DDO.owl#DDO_0002929 + DDO:DDO_0002929 + + + + obo:DDO.owl#DDO_0002929 + 72452005 + + + + obo:DDO.owl#DDO_0002929 + cerebral hypernatremia + + + + obo:DDO.owl#DDO_0002930 + DDO:DDO_0002930 + + + + obo:DDO.owl#DDO_0002930 + 12403008 + + + + obo:DDO.owl#DDO_0002930 + chronic hypernatremia + + + + obo:DDO.owl#DDO_0002931 + DDO:DDO_0002931 + + + + obo:DDO.owl#DDO_0002931 + 67455003 + + + + obo:DDO.owl#DDO_0002931 + essential hypernatremia + + + + obo:DDO.owl#DDO_0002932 + DDO:DDO_0002932 + + + + obo:DDO.owl#DDO_0002932 + 206489003 + + + + obo:DDO.owl#DDO_0002932 + transitory neonatal hypernatremia + + + + obo:DDO.owl#DDO_0002933 + DDO:DDO_0002933 + + + + obo:DDO.owl#DDO_0002933 + 89627008 + + + + obo:DDO.owl#DDO_0002933 + hyponatremia + + + + obo:DDO.owl#DDO_0002934 + DDO:DDO_0002934 + + + + obo:DDO.owl#DDO_0002934 + 4575002 + + + + obo:DDO.owl#DDO_0002934 + acute hyponatremia + + + + obo:DDO.owl#DDO_0002935 + DDO:DDO_0002935 + + + + obo:DDO.owl#DDO_0002935 + 84937002 + + + + obo:DDO.owl#DDO_0002935 + cerebral hyponatremia + + + + obo:DDO.owl#DDO_0002936 + DDO:DDO_0002936 + + + + obo:DDO.owl#DDO_0002936 + 50327002 + + + + obo:DDO.owl#DDO_0002936 + chronic hyponatremia + + + + obo:DDO.owl#DDO_0002937 + DDO:DDO_0002937 + + + + obo:DDO.owl#DDO_0002937 + 307201006 + + + + obo:DDO.owl#DDO_0002937 + dilutional hyponatremia + + + + obo:DDO.owl#DDO_0002938 + DDO:DDO_0002938 + + + + obo:DDO.owl#DDO_0002938 + 405566004 + + + + obo:DDO.owl#DDO_0002938 + paraneoplastic hyponatremia + + + + obo:DDO.owl#DDO_0002939 + DDO:DDO_0002939 + + + + obo:DDO.owl#DDO_0002939 + 237843009 + + + + obo:DDO.owl#DDO_0002939 + pseudohyponatremia + + + + obo:DDO.owl#DDO_0002940 + DDO:DDO_0002940 + + + + obo:DDO.owl#DDO_0002940 + 206490007 + + + + obo:DDO.owl#DDO_0002940 + transitory neonatal hyponatremia + + + + obo:DDO.owl#DDO_0002941 + DDO:DDO_0002941 + + + + obo:DDO.owl#DDO_0002941 + 71785001 + + + + obo:DDO.owl#DDO_0002941 + water intoxication syndrome + + + + obo:DDO.owl#DDO_0002942 + DDO:DDO_0002942 + + + + obo:DDO.owl#DDO_0002942 + 286926003 + + + + obo:DDO.owl#DDO_0002942 + sodium overload + + + + obo:DDO.owl#DDO_0002943 + DDO:DDO_0002943 + + + + obo:DDO.owl#DDO_0002943 + 12901004 + + + + obo:DDO.owl#DDO_0002943 + transitory neonatal electrolyte disturbance + + + + obo:DDO.owl#DDO_0002944 + DDO:DDO_0002944 + + + + obo:DDO.owl#DDO_0002944 + 276645004 + + + + obo:DDO.owl#DDO_0002944 + infantile hypercalcemia + + + + obo:DDO.owl#DDO_0002945 + DDO:DDO_0002945 + + + + obo:DDO.owl#DDO_0002945 + 206491006 + + + + obo:DDO.owl#DDO_0002945 + transitory neonatal hyperkalemia + + + + obo:DDO.owl#DDO_0002946 + DDO:DDO_0002946 + + + + obo:DDO.owl#DDO_0002946 + 277365009 + + + + obo:DDO.owl#DDO_0002946 + TUR syndrome + + + + obo:DDO.owl#DDO_0002947 + DDO:DDO_0002947 + + + + obo:DDO.owl#DDO_0002947 + 231532002 + + + + obo:DDO.owl#DDO_0002947 + sexual disorder + + + + obo:DDO.owl#DDO_0002948 + DDO:DDO_0002948 + + + + obo:DDO.owl#DDO_0002948 + 74007000 + + + + obo:DDO.owl#DDO_0002948 + sexual arousal disorder + + + + obo:DDO.owl#DDO_0002949 + DDO:DDO_0002949 + + + + obo:DDO.owl#DDO_0002949 + 397803000 + + + + obo:DDO.owl#DDO_0002949 + erectile dysfunction + + + + obo:DDO.owl#DDO_0002949 + sexual impotence + + + + obo:DDO.owl#DDO_0002950 + DDO:DDO_0002950 + + + + obo:DDO.owl#DDO_0002950 + 16812000 + + + + obo:DDO.owl#DDO_0002950 + absolute impotence + + + + obo:DDO.owl#DDO_0002951 + DDO:DDO_0002951 + + + + obo:DDO.owl#DDO_0002951 + 198036002 + + + + obo:DDO.owl#DDO_0002951 + impotence of organic origin + + + + obo:DDO.owl#DDO_0002952 + DDO:DDO_0002952 + + + + obo:DDO.owl#DDO_0002952 + 282347007 + + + + obo:DDO.owl#DDO_0002952 + arteriopathic impotence + + + + obo:DDO.owl#DDO_0002953 + DDO:DDO_0002953 + + + + obo:DDO.owl#DDO_0002953 + 236752004 + + + + obo:DDO.owl#DDO_0002953 + endocrine impotence + + + + obo:DDO.owl#DDO_0002954 + DDO:DDO_0002954 + + + + obo:DDO.owl#DDO_0002954 + 236753009 + + + + obo:DDO.owl#DDO_0002954 + neuropathic impotence + + + + obo:DDO.owl#DDO_0002955 + DDO:DDO_0002955 + + + + obo:DDO.owl#DDO_0002955 + 473020005 + + + + obo:DDO.owl#DDO_0002955 + primary erectile dysfunction + + + + obo:DDO.owl#DDO_0002956 + DDO:DDO_0002956 + + + + obo:DDO.owl#DDO_0002956 + 73491007 + + + + obo:DDO.owl#DDO_0002956 + psychogenic impotence + + + + obo:DDO.owl#DDO_0002957 + DDO:DDO_0002957 + + + + obo:DDO.owl#DDO_0002957 + 8061000119107 + + + + obo:DDO.owl#DDO_0002957 + vasculopathic erectile dysfunction + + + + obo:DDO.owl#DDO_0002958 + DDO:DDO_0002958 + + + + obo:DDO.owl#DDO_0002958 + 5552004 + + + + obo:DDO.owl#DDO_0002958 + ovarian disease + + + + obo:DDO.owl#DDO_0002959 + DDO:DDO_0002959 + + + + obo:DDO.owl#DDO_0002959 + 79883001 + + + + obo:DDO.owl#DDO_0002959 + ovarian cyst + + + + obo:DDO.owl#DDO_0002960 + DDO:DDO_0002960 + + + + obo:DDO.owl#DDO_0002960 + 69878008 + + + + obo:DDO.owl#DDO_0002960 + polycystic ovaries + + + + obo:DDO.owl#DDO_0002969 + DDO:DDO_0002969 + + + + obo:DDO.owl#DDO_0002969 + 49708008 + + + + obo:DDO.owl#DDO_0002969 + anemia of chronic renal failure + + + + obo:DDO.owl#DDO_0002972 + DDO:DDO_0002972 + + + + obo:DDO.owl#DDO_0002972 + 29555009 + + + + obo:DDO.owl#DDO_0002972 + retinal disorder + + + + obo:DDO.owl#DDO_0002973 + DDO:DDO_0002973 + + + + obo:DDO.owl#DDO_0002973 + blindness + + + + obo:DDO.owl#DDO_0002974 + DDO:DDO_0002974 + + + + obo:DDO.owl#DDO_0002974 + 74732009 + + + + obo:DDO.owl#DDO_0002974 + Psychiatric disorder + + + + obo:DDO.owl#DDO_0002974 + mental disease + + + + obo:DDO.owl#DDO_0002975 + DDO:DDO_0002975 + + + + obo:DDO.owl#DDO_0002975 + 35489007 + + + + obo:DDO.owl#DDO_0002975 + depression + + + + obo:DDO.owl#DDO_0002976 + DDO:DDO_0002976 + + + + obo:DDO.owl#DDO_0002976 + 58214004 + + + + obo:DDO.owl#DDO_0002976 + schizophrenia + + + + obo:DDO.owl#DDO_0002977 + DDO:DDO_0002977 + + + + obo:DDO.owl#DDO_0002977 + bipolar disorder + + + + obo:DDO.owl#DDO_0002978 + DDO:DDO_0002978 + + + + obo:DDO.owl#DDO_0002978 + 371596008 + + + + obo:DDO.owl#DDO_0002978 + bipolar I disorder + + + + obo:DDO.owl#DDO_0002979 + DDO:DDO_0002979 + + + + obo:DDO.owl#DDO_0002979 + 83225003 + + + + obo:DDO.owl#DDO_0002979 + bipolar II disorder + + + + obo:DDO.owl#DDO_0002980 + DDO:DDO_0002980 + + + + obo:DDO.owl#DDO_0002980 + 13313007 + + + + obo:DDO.owl#DDO_0002980 + mild bipolar disorder + + + + obo:DDO.owl#DDO_0002981 + DDO:DDO_0002981 + + + + obo:DDO.owl#DDO_0002981 + 74686005 + + + + obo:DDO.owl#DDO_0002981 + mild depressed bipolar I disorder + + + + obo:DDO.owl#DDO_0002982 + DDO:DDO_0002982 + + + + obo:DDO.owl#DDO_0002982 + 71984005 + + + + obo:DDO.owl#DDO_0002982 + mild manic bipolar I disorder + + + + obo:DDO.owl#DDO_0002983 + DDO:DDO_0002983 + + + + obo:DDO.owl#DDO_0002983 + 43769008 + + + + obo:DDO.owl#DDO_0002983 + mild mixed bipolar I disorder + + + + obo:DDO.owl#DDO_0002984 + DDO:DDO_0002984 + + + + obo:DDO.owl#DDO_0002984 + 79584002 + + + + obo:DDO.owl#DDO_0002984 + moderate bipolar disorder + + + + obo:DDO.owl#DDO_0002985 + DDO:DDO_0002985 + + + + obo:DDO.owl#DDO_0002985 + 38368003 + + + + obo:DDO.owl#DDO_0002985 + schizoaffective disorder, bipolar type + + + + obo:DDO.owl#DDO_0002986 + DDO:DDO_0002986 + + + + obo:DDO.owl#DDO_0002986 + 371600003 + + + + obo:DDO.owl#DDO_0002986 + severe bipolar disorder + + + + obo:DDO.owl#DDO_0002987 + DDO:DDO_0002987 + + + + obo:DDO.owl#DDO_0002987 + 371599001 + + + + obo:DDO.owl#DDO_0002987 + severe bipolar I disorder + + + + obo:DDO.owl#DDO_0002988 + DDO:DDO_0002988 + + + + obo:DDO.owl#DDO_0002988 + 371604007 + + + + obo:DDO.owl#DDO_0002988 + severe bipolar II disorder + + + + obo:DDO.owl#DDO_0002989 + DDO:DDO_0002989 + + + + obo:DDO.owl#DDO_0002989 + 64905009 + + + + obo:DDO.owl#DDO_0002989 + paranoid schizophrenia + + + + obo:DDO.owl#DDO_0002990 + DDO:DDO_0002990 + + + + obo:DDO.owl#DDO_0002990 + 31658008 + + + + obo:DDO.owl#DDO_0002990 + chronic paranoid schizophrenia + + + + obo:DDO.owl#DDO_0002991 + DDO:DDO_0002991 + + + + obo:DDO.owl#DDO_0002991 + 191555002 + + + + obo:DDO.owl#DDO_0002991 + acute exacerbation of chronic paranoid schizophrenia + + + + obo:DDO.owl#DDO_0002992 + DDO:DDO_0002992 + + + + obo:DDO.owl#DDO_0002992 + 63181006 + + + + obo:DDO.owl#DDO_0002992 + paranoid schizophrenia in remission + + + + obo:DDO.owl#DDO_0002993 + DDO:DDO_0002993 + + + + obo:DDO.owl#DDO_0002993 + 79866005 + + + + obo:DDO.owl#DDO_0002993 + subchronic paranoid schizophrenia + + + + obo:DDO.owl#DDO_0002994 + DDO:DDO_0002994 + + + + obo:DDO.owl#DDO_0002994 + 191554003 + + + + obo:DDO.owl#DDO_0002994 + acute exacerbation of subchronic paranoid schizophrenia + + + + obo:DDO.owl#DDO_0002995 + DDO:DDO_0002995 + + + + obo:DDO.owl#DDO_0002995 + 370143000 + + + + obo:DDO.owl#DDO_0002995 + major depressive disorder + + + + obo:DDO.owl#DDO_0002996 + DDO:DDO_0002996 + + + + obo:DDO.owl#DDO_0002996 + 42810003 + + + + obo:DDO.owl#DDO_0002996 + major depression in remission + + + + obo:DDO.owl#DDO_0002997 + DDO:DDO_0002997 + + + + obo:DDO.owl#DDO_0002997 + 63412003 + + + + obo:DDO.owl#DDO_0002997 + major depression in complete remission + + + + obo:DDO.owl#DDO_0002998 + DDO:DDO_0002998 + + + + obo:DDO.owl#DDO_0002998 + 30605009 + + + + obo:DDO.owl#DDO_0002998 + major depression in partial remission + + + + obo:DDO.owl#DDO_0002999 + DDO:DDO_0002999 + + + + obo:DDO.owl#DDO_0002999 + 68019004 + + + + obo:DDO.owl#DDO_0002999 + recurrent major depression in remission + + + + obo:DDO.owl#DDO_0003000 + DDO:DDO_0003000 + + + + obo:DDO.owl#DDO_0003000 + 320751009 + + + + obo:DDO.owl#DDO_0003000 + major depression, melancholic type + + + + obo:DDO.owl#DDO_0003001 + DDO:DDO_0003001 + + + + obo:DDO.owl#DDO_0003001 + 36923009 + + + + obo:DDO.owl#DDO_0003001 + major depression, single episode + + + + obo:DDO.owl#DDO_0003002 + DDO:DDO_0003002 + + + + obo:DDO.owl#DDO_0003002 + 87512008 + + + + obo:DDO.owl#DDO_0003002 + mild major depression + + + + obo:DDO.owl#DDO_0003003 + DDO:DDO_0003003 + + + + obo:DDO.owl#DDO_0003003 + 832007 + + + + obo:DDO.owl#DDO_0003003 + moderate major depression + + + + obo:DDO.owl#DDO_0003004 + DDO:DDO_0003004 + + + + obo:DDO.owl#DDO_0003004 + 66344007 + + + + obo:DDO.owl#DDO_0003004 + recurrent major depression + + + + obo:DDO.owl#DDO_0003005 + DDO:DDO_0003005 + + + + obo:DDO.owl#DDO_0003005 + 450714000 + + + + obo:DDO.owl#DDO_0003005 + severe major depression + + + + obo:DDO.owl#DDO_0003006 + DDO:DDO_0003006 + + + + obo:DDO.owl#DDO_0003006 + 310497006 + + + + obo:DDO.owl#DDO_0003006 + severe depression + + + + obo:DDO.owl#DDO_0003007 + DDO:DDO_0003007 + + + + obo:DDO.owl#DDO_0003007 + 193462001 + + + + obo:DDO.owl#DDO_0003007 + insomnia + + + + obo:DDO.owl#DDO_0003008 + DDO:DDO_0003008 + + + + obo:DDO.owl#DDO_0003008 + 78667006 + + + + obo:DDO.owl#DDO_0003008 + dysthymia + + + + obo:DDO.owl#DDO_0003009 + DDO:DDO_0003009 + + + + obo:DDO.owl#DDO_0003009 + 2506003 + + + + obo:DDO.owl#DDO_0003009 + early onset dysthymia + + + + obo:DDO.owl#DDO_0003010 + DDO:DDO_0003010 + + + + obo:DDO.owl#DDO_0003010 + 38451003 + + + + obo:DDO.owl#DDO_0003010 + primary dysthymia early onset + + + + obo:DDO.owl#DDO_0003011 + DDO:DDO_0003011 + + + + obo:DDO.owl#DDO_0003011 + 3109008 + + + + obo:DDO.owl#DDO_0003011 + secondary dysthymia early onset + + + + obo:DDO.owl#DDO_0003012 + DDO:DDO_0003012 + + + + obo:DDO.owl#DDO_0003012 + 87842000 + + + + obo:DDO.owl#DDO_0003012 + generalized neuromuscular exhaustion syndrome + + + + obo:DDO.owl#DDO_0003013 + DDO:DDO_0003013 + + + + obo:DDO.owl#DDO_0003013 + 19694002 + + + + obo:DDO.owl#DDO_0003013 + late onset dysthymia + + + + obo:DDO.owl#DDO_0003014 + DDO:DDO_0003014 + + + + obo:DDO.owl#DDO_0003014 + 67711008 + + + + obo:DDO.owl#DDO_0003014 + primary dysthymia late onset + + + + obo:DDO.owl#DDO_0003015 + DDO:DDO_0003015 + + + + obo:DDO.owl#DDO_0003015 + 36170009 + + + + obo:DDO.owl#DDO_0003015 + secondary dysthymia late onset + + + + obo:DDO.owl#DDO_0003016 + DDO:DDO_0003016 + + + + obo:DDO.owl#DDO_0003016 + 111475002 + + + + obo:DDO.owl#DDO_0003016 + neurosis + + + + obo:DDO.owl#DDO_0003017 + DDO:DDO_0003017 + + + + obo:DDO.owl#DDO_0003017 + 60737008 + + + + obo:DDO.owl#DDO_0003017 + iron overload + + + + obo:DDO.owl#DDO_0003018 + DDO:DDO_0003018 + + + + obo:DDO.owl#DDO_0003018 + 399187006 + + + + obo:DDO.owl#DDO_0003018 + hemochromatosis + + + + obo:DDO.owl#DDO_0003019 + DDO:DDO_0003019 + + + + obo:DDO.owl#DDO_0003019 + 66576001 + + + + obo:DDO.owl#DDO_0003019 + erythropoietic hemochromatosis + + + + obo:DDO.owl#DDO_0003020 + DDO:DDO_0003020 + + + + obo:DDO.owl#DDO_0003020 + 7772007 + + + + obo:DDO.owl#DDO_0003020 + african nutritional hemochromatosis + + + + obo:DDO.owl#DDO_0003021 + DDO:DDO_0003021 + + + + obo:DDO.owl#DDO_0003021 + 53836006 + + + + obo:DDO.owl#DDO_0003021 + secondary hemochromatosis + + + + obo:DDO.owl#DDO_0003022 + DDO:DDO_0003022 + + + + obo:DDO.owl#DDO_0003022 + 399170009 + + + + obo:DDO.owl#DDO_0003022 + primary hemochromatosis + + + + obo:DDO.owl#DDO_0003023 + DDO:DDO_0003023 + + + + obo:DDO.owl#DDO_0003023 + 6160004 + + + + obo:DDO.owl#DDO_0003023 + neonatal hemochromatosis + + + + obo:DDO.owl#DDO_0003024 + DDO:DDO_0003024 + + + + obo:DDO.owl#DDO_0003024 + 50855007 + + + + obo:DDO.owl#DDO_0003024 + juvenile hemochromatosis + + + + obo:DDO.owl#DDO_0003025 + DDO:DDO_0003025 + + + + obo:DDO.owl#DDO_0003025 + 399053004 + + + + obo:DDO.owl#DDO_0003025 + idiopathic hemochromatosis + + + + obo:DDO.owl#DDO_0003026 + DDO:DDO_0003026 + + + + obo:DDO.owl#DDO_0003026 + 35400008 + + + + obo:DDO.owl#DDO_0003026 + hereditary hemochromatosis + + + + obo:DDO.owl#DDO_0003027 + DDO:DDO_0003027 + + + + obo:DDO.owl#DDO_0003027 + bronze diabetes + + + + obo:DDO.owl#DDO_0003027 + bronze diabetes + + + + obo:DDO.owl#DDO_0003028 + DDO:DDO_0003028 + + + + obo:DDO.owl#DDO_0003028 + 399126000 + + + + obo:DDO.owl#DDO_0003028 + bronze cirrhosis + + + + obo:DDO.owl#DDO_0003029 + DDO:DDO_0003029 + + + + obo:DDO.owl#DDO_0003029 + 73430006 + + + + obo:DDO.owl#DDO_0003029 + sleep apnea + + + + obo:DDO.owl#DDO_0003030 + DDO:DDO_0003030 + + + + obo:DDO.owl#DDO_0003030 + 78275009 + + + + obo:DDO.owl#DDO_0003030 + obstructive sleep apnea + + + + obo:DDO.owl#DDO_0003031 + DDO:DDO_0003031 + + + + obo:DDO.owl#DDO_0003031 + 230493001 + + + + obo:DDO.owl#DDO_0003031 + mixed sleep apnea + + + + obo:DDO.owl#DDO_0003032 + DDO:DDO_0003032 + + + + obo:DDO.owl#DDO_0003032 + 1101000119103 + + + + obo:DDO.owl#DDO_0003032 + obstructive sleep apnea of adult + + + + obo:DDO.owl#DDO_0003033 + DDO:DDO_0003033 + + + + obo:DDO.owl#DDO_0003033 + 1091000119108 + + + + obo:DDO.owl#DDO_0003033 + obstructive sleep apnea of child + + + + obo:DDO.owl#DDO_0003034 + DDO:DDO_0003034 + + + + obo:DDO.owl#DDO_0003034 + 234947003 + + + + obo:DDO.owl#DDO_0003034 + dental disease + + + + obo:DDO.owl#DDO_0003035 + DDO:DDO_0003035 + + + + obo:DDO.owl#DDO_0003035 + 2556008 + + + + obo:DDO.owl#DDO_0003035 + periodontal disease + + + + obo:DDO.owl#DDO_0003036 + DDO:DDO_0003036 + + + + obo:DDO.owl#DDO_0003036 + 41565005 + + + + obo:DDO.owl#DDO_0003036 + periodontitis + + + + obo:DDO.owl#DDO_0003037 + DDO:DDO_0003037 + + + + obo:DDO.owl#DDO_0003037 + 91863007 + + + + obo:DDO.owl#DDO_0003037 + acute pericoronitis + + + + obo:DDO.owl#DDO_0003038 + DDO:DDO_0003038 + + + + obo:DDO.owl#DDO_0003038 + 21638000 + + + + obo:DDO.owl#DDO_0003038 + acute periodontitis + + + + obo:DDO.owl#DDO_0003039 + DDO:DDO_0003039 + + + + obo:DDO.owl#DDO_0003039 + 88071000 + + + + obo:DDO.owl#DDO_0003039 + acute apical periodontitis of pulpal origin + + + + obo:DDO.owl#DDO_0003040 + DDO:DDO_0003040 + + + + obo:DDO.owl#DDO_0003040 + 235010005 + + + + obo:DDO.owl#DDO_0003040 + acute necrotizing ulcerative periodontitis + + + + obo:DDO.owl#DDO_0003041 + DDO:DDO_0003041 + + + + obo:DDO.owl#DDO_0003041 + 78996009 + + + + obo:DDO.owl#DDO_0003041 + acute suppurative alveolar periostitis + + + + obo:DDO.owl#DDO_0003042 + DDO:DDO_0003042 + + + + obo:DDO.owl#DDO_0003042 + 74797001 + + + + obo:DDO.owl#DDO_0003042 + adult periodontitis + + + + obo:DDO.owl#DDO_0003043 + DDO:DDO_0003043 + + + + obo:DDO.owl#DDO_0003043 + 93462002 + + + + obo:DDO.owl#DDO_0003043 + generalized adult periodontitis + + + + obo:DDO.owl#DDO_0003044 + DDO:DDO_0003044 + + + + obo:DDO.owl#DDO_0003044 + 93164008 + + + + obo:DDO.owl#DDO_0003044 + localized adult periodontitis + + + + obo:DDO.owl#DDO_0003045 + DDO:DDO_0003045 + + + + obo:DDO.owl#DDO_0003045 + 449908004 + + + + obo:DDO.owl#DDO_0003045 + aggressive periodontitis + + + + obo:DDO.owl#DDO_0003047 + DDO:DDO_0003047 + + + + obo:DDO.owl#DDO_0003047 + 39273001 + + + + obo:DDO.owl#DDO_0003047 + apical periodontitis + + + + obo:DDO.owl#DDO_0003048 + DDO:DDO_0003048 + + + + obo:DDO.owl#DDO_0003048 + 88071000 + + + + obo:DDO.owl#DDO_0003048 + acute apical periodontitis of pulpal origin + + + + obo:DDO.owl#DDO_0003049 + DDO:DDO_0003049 + + + + obo:DDO.owl#DDO_0003049 + 87782002 + + + + obo:DDO.owl#DDO_0003049 + chronic apical periodontitis + + + + obo:DDO.owl#DDO_0003050 + DDO:DDO_0003050 + + + + obo:DDO.owl#DDO_0003050 + 89988002 + + + + obo:DDO.owl#DDO_0003050 + radicular cyst + + + + obo:DDO.owl#DDO_0003051 + DDO:DDO_0003051 + + + + obo:DDO.owl#DDO_0003051 + 234988003 + + + + obo:DDO.owl#DDO_0003051 + lateral radicular cyst + + + + obo:DDO.owl#DDO_0003052 + DDO:DDO_0003052 + + + + obo:DDO.owl#DDO_0003052 + 109608003 + + + + obo:DDO.owl#DDO_0003052 + residual cyst + + + + obo:DDO.owl#DDO_0003053 + DDO:DDO_0003053 + + + + obo:DDO.owl#DDO_0003053 + 5689008 + + + + obo:DDO.owl#DDO_0003053 + chronic periodontitis + + + + obo:DDO.owl#DDO_0003054 + DDO:DDO_0003054 + + + + obo:DDO.owl#DDO_0003054 + 196368005 + + + + obo:DDO.owl#DDO_0003054 + alveolar pyorrhea + + + + obo:DDO.owl#DDO_0003055 + DDO:DDO_0003055 + + + + obo:DDO.owl#DDO_0003055 + 87782002 + + + + obo:DDO.owl#DDO_0003055 + chronic apical periodontitis + + + + obo:DDO.owl#DDO_0003056 + DDO:DDO_0003056 + + + + obo:DDO.owl#DDO_0003056 + 196367000 + + + + obo:DDO.owl#DDO_0003056 + chronic periodontitis complex + + + + obo:DDO.owl#DDO_0003057 + DDO:DDO_0003057 + + + + obo:DDO.owl#DDO_0003057 + 196366009 + + + + obo:DDO.owl#DDO_0003057 + chronic periodontitis simplex + + + + obo:DDO.owl#DDO_0003058 + DDO:DDO_0003058 + + + + obo:DDO.owl#DDO_0003058 + 304989006 + + + + obo:DDO.owl#DDO_0003058 + chronic periodontitis with drifting of teeth + + + + obo:DDO.owl#DDO_0003059 + DDO:DDO_0003059 + + + + obo:DDO.owl#DDO_0003059 + 707251008 + + + + obo:DDO.owl#DDO_0003059 + generalized chronic periodontitis + + + + obo:DDO.owl#DDO_0003060 + DDO:DDO_0003060 + + + + obo:DDO.owl#DDO_0003060 + 707252001 + + + + obo:DDO.owl#DDO_0003060 + localized chronic periodontitis + + + + obo:DDO.owl#DDO_0003061 + DDO:DDO_0003061 + + + + obo:DDO.owl#DDO_0003061 + 49965002 + + + + obo:DDO.owl#DDO_0003061 + juvenile periodontitis + + + + obo:DDO.owl#DDO_0003062 + DDO:DDO_0003062 + + + + obo:DDO.owl#DDO_0003062 + 252283005 + + + + obo:DDO.owl#DDO_0003062 + marginal periodontitis + + + + obo:DDO.owl#DDO_0003063 + DDO:DDO_0003063 + + + + obo:DDO.owl#DDO_0003063 + 196368005 + + + + obo:DDO.owl#DDO_0003063 + alveolar pyorrhea + + + + obo:DDO.owl#DDO_0003064 + DDO:DDO_0003064 + + + + obo:DDO.owl#DDO_0003064 + 706984006 + + + + obo:DDO.owl#DDO_0003064 + necrotizing periodontal disease + + + + obo:DDO.owl#DDO_0003065 + DDO:DDO_0003065 + + + + obo:DDO.owl#DDO_0003065 + 707320004 + + + + obo:DDO.owl#DDO_0003065 + necrotizing ulcerative periodontitis + + + + obo:DDO.owl#DDO_0003066 + DDO:DDO_0003066 + + + + obo:DDO.owl#DDO_0003066 + 235010005 + + + + obo:DDO.owl#DDO_0003066 + acute necrotizing ulcerative periodontitis + + + + obo:DDO.owl#DDO_0003067 + DDO:DDO_0003067 + + + + obo:DDO.owl#DDO_0003067 + 47548009 + + + + obo:DDO.owl#DDO_0003067 + necrotizing ulcerative gingivoperiodontitis + + + + obo:DDO.owl#DDO_0003068 + DDO:DDO_0003068 + + + + obo:DDO.owl#DDO_0003068 + 2624008 + + + + obo:DDO.owl#DDO_0003068 + prepubertal periodontitis + + + + obo:DDO.owl#DDO_0003070 + DDO:DDO_0003070 + + + + obo:DDO.owl#DDO_0003070 + 235007003 + + + + obo:DDO.owl#DDO_0003070 + early onset periodontitis + + + + obo:DDO.owl#DDO_0003071 + DDO:DDO_0003071 + + + + obo:DDO.owl#DDO_0003071 + 75891001 + + + + obo:DDO.owl#DDO_0003071 + rapidly progressive periodontitis + + + + obo:DDO.owl#DDO_0003072 + DDO:DDO_0003072 + + + + obo:DDO.owl#DDO_0003072 + 235008008 + + + + obo:DDO.owl#DDO_0003072 + refractory periodontitis + + + + obo:DDO.owl#DDO_0003073 + DDO:DDO_0003073 + + + + obo:DDO.owl#DDO_0003073 + 29384001 + + + + obo:DDO.owl#DDO_0003073 + gastropathy + + + + obo:DDO.owl#DDO_0003074 + DDO:DDO_0003074 + + + + obo:DDO.owl#DDO_0003074 + 235675006 + + + + obo:DDO.owl#DDO_0003074 + gastroparesis + + + + obo:DDO.owl#DDO_0003074 + gastroparesis syndrome + + + + obo:DDO.owl#DDO_0003075 + DDO:DDO_0003075 + + + + obo:DDO.owl#DDO_0003075 + 34140002 + + + + obo:DDO.owl#DDO_0003075 + diabetic gastroparesis + + + + obo:DDO.owl#DDO_0003076 + DDO:DDO_0003076 + + + + obo:DDO.owl#DDO_0003076 + 235676007 + + + + obo:DDO.owl#DDO_0003076 + postprocedural delayed gastric emptying + + + + obo:DDO.owl#DDO_0003077 + DDO:DDO_0003077 + + + + obo:DDO.owl#DDO_0003077 + 56688005 + + + + obo:DDO.owl#DDO_0003077 + clostridial infection + + + + obo:DDO.owl#DDO_0003078 + DDO:DDO_0003078 + + + + obo:DDO.owl#DDO_0003078 + 276202003 + + + + obo:DDO.owl#DDO_0003078 + infection due to Clostridium tetani + + + + obo:DDO.owl#DDO_0003079 + DDO:DDO_0003079 + + + + obo:DDO.owl#DDO_0003079 + 76902006 + + + + obo:DDO.owl#DDO_0003079 + tetanus + + + + obo:DDO.owl#DDO_0003080 + DDO:DDO_0003080 + + + + obo:DDO.owl#DDO_0003080 + 240432006 + + + + obo:DDO.owl#DDO_0003080 + tetanus with trismus + + + + obo:DDO.owl#DDO_0003081 + DDO:DDO_0003081 + + + + obo:DDO.owl#DDO_0003081 + 61145000 + + + + obo:DDO.owl#DDO_0003081 + tetanus omphalitis + + + + obo:DDO.owl#DDO_0003082 + DDO:DDO_0003082 + + + + obo:DDO.owl#DDO_0003082 + 43424001 + + + + obo:DDO.owl#DDO_0003082 + tetanus neonatorum + + + + obo:DDO.owl#DDO_0003083 + DDO:DDO_0003083 + + + + obo:DDO.owl#DDO_0003083 + 76843005 + + + + obo:DDO.owl#DDO_0003083 + tetanus complicating ectopic AND/OR molar pregnancy + + + + obo:DDO.owl#DDO_0003084 + DDO:DDO_0003084 + + + + obo:DDO.owl#DDO_0003084 + 13766008 + + + + obo:DDO.owl#DDO_0003084 + puerperal tetanus + + + + obo:DDO.owl#DDO_0003085 + DDO:DDO_0003085 + + + + obo:DDO.owl#DDO_0003085 + 240433001 + + + + obo:DDO.owl#DDO_0003085 + tetanic opisthotonus + + + + obo:DDO.owl#DDO_0003086 + DDO:DDO_0003086 + + + + obo:DDO.owl#DDO_0003086 + 186378005 + + + + obo:DDO.owl#DDO_0003086 + obstetrical tetanus + + + + obo:DDO.owl#DDO_0003087 + DDO:DDO_0003087 + + + + obo:DDO.owl#DDO_0003087 + 240429008 + + + + obo:DDO.owl#DDO_0003087 + localized tetanus + + + + obo:DDO.owl#DDO_0003088 + DDO:DDO_0003088 + + + + obo:DDO.owl#DDO_0003088 + 609493004 + + + + obo:DDO.owl#DDO_0003088 + induced termination of pregnancy complicated by tetanus + + + + obo:DDO.owl#DDO_0003089 + DDO:DDO_0003089 + + + + obo:DDO.owl#DDO_0003089 + 240434007 + + + + obo:DDO.owl#DDO_0003089 + generalized tetanus + + + + obo:DDO.owl#DDO_0003090 + DDO:DDO_0003090 + + + + obo:DDO.owl#DDO_0003090 + 240431004 + + + + obo:DDO.owl#DDO_0003090 + cephalic tetanus + + + + obo:DDO.owl#DDO_0003091 + DDO:DDO_0003091 + + + + obo:DDO.owl#DDO_0003091 + 371405004 + + + + obo:DDO.owl#DDO_0003091 + eye disease + + + + obo:DDO.owl#DDO_0003092 + DDO:DDO_0003092 + + + + obo:DDO.owl#DDO_0003092 + 23986001 + + + + obo:DDO.owl#DDO_0003092 + glaucoma + + + + obo:DDO.owl#DDO_0003093 + DDO:DDO_0003093 + + + + obo:DDO.owl#DDO_0003093 + 19144002 + + + + obo:DDO.owl#DDO_0003093 + absolute glaucoma + + + + obo:DDO.owl#DDO_0003094 + DDO:DDO_0003094 + + + + obo:DDO.owl#DDO_0003094 + 193531003 + + + + obo:DDO.owl#DDO_0003094 + borderline glaucoma + + + + obo:DDO.owl#DDO_0003095 + DDO:DDO_0003095 + + + + obo:DDO.owl#DDO_0003095 + 33647009 + + + + obo:DDO.owl#DDO_0003095 + chronic angle-closure glaucoma + + + + obo:DDO.owl#DDO_0003096 + DDO:DDO_0003096 + + + + obo:DDO.owl#DDO_0003096 + 51995000 + + + + obo:DDO.owl#DDO_0003096 + rubeosis iridis + + + + obo:DDO.owl#DDO_0003098 + DDO:DDO_0003098 + + + + obo:DDO.owl#DDO_0003098 + 232086000 + + + + obo:DDO.owl#DDO_0003098 + neovascular glaucoma + + + + obo:DDO.owl#DDO_0003099 + DDO:DDO_0003099 + + + + obo:DDO.owl#DDO_0003099 + 698840003 + + + + obo:DDO.owl#DDO_0003099 + neovascular glaucoma due to hyphema + + + + obo:DDO.owl#DDO_0003100 + DDO:DDO_0003100 + + + + obo:DDO.owl#DDO_0003100 + 25093002 + + + + obo:DDO.owl#DDO_0003100 + diabetic oculopathy + + + + obo:DDO.owl#DDO_0003101 + DDO:DDO_0003101 + + + + obo:DDO.owl#DDO_0003101 + 193489006 + + + + obo:DDO.owl#DDO_0003101 + diabetic iritis + + + + obo:DDO.owl#DDO_0003102 + DDO:DDO_0003102 + + + + obo:DDO.owl#DDO_0003102 + 421165007 + + + + obo:DDO.owl#DDO_0003102 + diabetic oculopathy associated with type 1 diabetes mellitus + + + + obo:DDO.owl#DDO_0003103 + DDO:DDO_0003103 + + + + obo:DDO.owl#DDO_0003103 + 104951000119106 + + + + obo:DDO.owl#DDO_0003103 + diabetic vitreous hemorrhage due to type 1 diabetes mellitus + + + + obo:DDO.owl#DDO_0003104 + DDO:DDO_0003104 + + + + obo:DDO.owl#DDO_0003104 + 109171000119104 + + + + obo:DDO.owl#DDO_0003104 + retinal edema due to type 1 diabetes mellitus + + + + obo:DDO.owl#DDO_0003105 + DDO:DDO_0003105 + + + + obo:DDO.owl#DDO_0003105 + 104941000119109 + + + + obo:DDO.owl#DDO_0003105 + retinal ischemia due to type 1 diabetes mellitus + + + + obo:DDO.owl#DDO_0003106 + DDO:DDO_0003106 + + + + obo:DDO.owl#DDO_0003106 + 82581000119105 + + + + obo:DDO.owl#DDO_0003106 + rubeosis iridis due to type 1 diabetes mellitus + + + + obo:DDO.owl#DDO_0003107 + DDO:DDO_0003107 + + + + obo:DDO.owl#DDO_0003107 + 422099009 + + + + obo:DDO.owl#DDO_0003107 + diabetic oculopathy associated with type 2 diabetes mellitus + + + + obo:DDO.owl#DDO_0003108 + DDO:DDO_0003108 + + + + obo:DDO.owl#DDO_0003108 + 41911000119107 + + + + obo:DDO.owl#DDO_0003108 + glaucoma due to type 2 diabetes mellitus + + + + obo:DDO.owl#DDO_0003109 + DDO:DDO_0003109 + + + + obo:DDO.owl#DDO_0003109 + 28331000119107 + + + + obo:DDO.owl#DDO_0003109 + retinal edema due to type 2 diabetes mellitus + + + + obo:DDO.owl#DDO_0003110 + DDO:DDO_0003110 + + + + obo:DDO.owl#DDO_0003110 + 97331000119101 + + + + obo:DDO.owl#DDO_0003110 + macular edema and retinopathy due to type 2 diabetes mellitus + + + + obo:DDO.owl#DDO_0003111 + DDO:DDO_0003111 + + + + obo:DDO.owl#DDO_0003111 + 104961000119108 + + + + obo:DDO.owl#DDO_0003111 + retinal ischemia due to type 2 diabetes mellitus + + + + obo:DDO.owl#DDO_0003112 + DDO:DDO_0003112 + + + + obo:DDO.owl#DDO_0003112 + 82551000119103 + + + + obo:DDO.owl#DDO_0003112 + rubeosis iridis due to type 2 diabetes mellitus + + + + obo:DDO.owl#DDO_0003113 + DDO:DDO_0003113 + + + + obo:DDO.owl#DDO_0003113 + 82541000119100 + + + + obo:DDO.owl#DDO_0003113 + traction retinal detachment due to type 2 diabetes mellitus + + + + obo:DDO.owl#DDO_0003114 + DDO:DDO_0003114 + + + + obo:DDO.owl#DDO_0003114 + 232020009 + + + + obo:DDO.owl#DDO_0003114 + diabetic maculopathy + + + + obo:DDO.owl#DDO_0003116 + DDO:DDO_0003116 + + + + obo:DDO.owl#DDO_0003116 + 193350004 + + + + obo:DDO.owl#DDO_0003116 + advanced diabetic maculopathy + + + + obo:DDO.owl#DDO_0003117 + DDO:DDO_0003117 + + + + obo:DDO.owl#DDO_0003117 + 312912001 + + + + obo:DDO.owl#DDO_0003117 + diabetic macular edema + + + + obo:DDO.owl#DDO_0003118 + DDO:DDO_0003118 + + + + obo:DDO.owl#DDO_0003118 + 314010006 + + + + obo:DDO.owl#DDO_0003118 + diffuse diabetic maculopathy + + + + obo:DDO.owl#DDO_0003119 + DDO:DDO_0003119 + + + + obo:DDO.owl#DDO_0003119 + 420486006 + + + + obo:DDO.owl#DDO_0003119 + exudative maculopathy associated with type 1 diabetes mellitus + + + + obo:DDO.owl#DDO_0003120 + DDO:DDO_0003120 + + + + obo:DDO.owl#DDO_0003120 + 421779007 + + + + obo:DDO.owl#DDO_0003120 + exudative maculopathy associated with type 2 diabetes mellitus + + + + obo:DDO.owl#DDO_0003121 + DDO:DDO_0003121 + + + + obo:DDO.owl#DDO_0003121 + 314011005 + + + + obo:DDO.owl#DDO_0003121 + focal diabetic maculopathy + + + + obo:DDO.owl#DDO_0003122 + DDO:DDO_0003122 + + + + obo:DDO.owl#DDO_0003122 + 314014002 + + + + obo:DDO.owl#DDO_0003122 + ischemic diabetic maculopathy + + + + obo:DDO.owl#DDO_0003123 + DDO:DDO_0003123 + + + + obo:DDO.owl#DDO_0003123 + 314015001 + + + + obo:DDO.owl#DDO_0003123 + mixed diabetic maculopathy + + + + obo:DDO.owl#DDO_0003124 + DDO:DDO_0003124 + + + + obo:DDO.owl#DDO_0003124 + 276436007 + + + + obo:DDO.owl#DDO_0003124 + hereditary macular dystrophy + + + + obo:DDO.owl#DDO_0003125 + DDO:DDO_0003125 + + + + obo:DDO.owl#DDO_0003125 + 232050001 + + + + obo:DDO.owl#DDO_0003125 + bull's eye macular dystrophy + + + + obo:DDO.owl#DDO_0003126 + DDO:DDO_0003126 + + + + obo:DDO.owl#DDO_0003126 + 193411004 + + + + obo:DDO.owl#DDO_0003126 + dominant drusen + + + + obo:DDO.owl#DDO_0003127 + DDO:DDO_0003127 + + + + obo:DDO.owl#DDO_0003127 + 47673003 + + + + obo:DDO.owl#DDO_0003127 + fundus flavimaculatus + + + + obo:DDO.owl#DDO_0003128 + DDO:DDO_0003128 + + + + obo:DDO.owl#DDO_0003128 + 193410003 + + + + obo:DDO.owl#DDO_0003128 + Sorsby's fundus dystrophy + + + + obo:DDO.owl#DDO_0003129 + DDO:DDO_0003129 + + + + obo:DDO.owl#DDO_0003129 + 70099003 + + + + obo:DDO.owl#DDO_0003129 + Stargardt's disease + + + + obo:DDO.owl#DDO_0003130 + DDO:DDO_0003130 + + + + obo:DDO.owl#DDO_0003130 + 90036004 + + + + obo:DDO.owl#DDO_0003130 + vitelliform dystrophy + + + + obo:DDO.owl#DDO_0003131 + DDO:DDO_0003131 + + + + obo:DDO.owl#DDO_0003131 + 312913006 + + + + obo:DDO.owl#DDO_0003131 + ischemic maculopathy + + + + obo:DDO.owl#DDO_0003132 + DDO:DDO_0003132 + + + + obo:DDO.owl#DDO_0003132 + 418918009 + + + + obo:DDO.owl#DDO_0003132 + macular infarction + + + + obo:DDO.owl#DDO_0003133 + DDO:DDO_0003133 + + + + obo:DDO.owl#DDO_0003133 + 423084001 + + + + obo:DDO.owl#DDO_0003133 + macular exudate + + + + obo:DDO.owl#DDO_0003134 + DDO:DDO_0003134 + + + + obo:DDO.owl#DDO_0003134 + 336911000119104 + + + + obo:DDO.owl#DDO_0003134 + macular focal choroiditis + + + + obo:DDO.owl#DDO_0003135 + DDO:DDO_0003135 + + + + obo:DDO.owl#DDO_0003135 + 232006002 + + + + obo:DDO.owl#DDO_0003135 + macular hole + + + + obo:DDO.owl#DDO_0003136 + DDO:DDO_0003136 + + + + obo:DDO.owl#DDO_0003136 + 312704000 + + + + obo:DDO.owl#DDO_0003136 + full thickness macular hole stage IV + + + + obo:DDO.owl#DDO_0003139 + DDO:DDO_0003139 + + + + obo:DDO.owl#DDO_0003139 + 312703006 + + + + obo:DDO.owl#DDO_0003139 + full thickness macular hole stage III + + + + obo:DDO.owl#DDO_0003140 + DDO:DDO_0003140 + + + + obo:DDO.owl#DDO_0003140 + 312702001 + + + + obo:DDO.owl#DDO_0003140 + full thickness macular hole stage II + + + + obo:DDO.owl#DDO_0003141 + DDO:DDO_0003141 + + + + obo:DDO.owl#DDO_0003141 + 443437004 + + + + obo:DDO.owl#DDO_0003141 + full thickness hole of macula lutea + + + + obo:DDO.owl#DDO_0003142 + DDO:DDO_0003142 + + + + obo:DDO.owl#DDO_0003142 + 312701008 + + + + obo:DDO.owl#DDO_0003142 + impending macular hole + + + + obo:DDO.owl#DDO_0003143 + DDO:DDO_0003143 + + + + obo:DDO.owl#DDO_0003143 + 37231002 + + + + obo:DDO.owl#DDO_0003143 + macular retinal edema + + + + obo:DDO.owl#DDO_0003144 + DDO:DDO_0003144 + + + + obo:DDO.owl#DDO_0003144 + 193387007 + + + + obo:DDO.owl#DDO_0003144 + cystoid macular edema + + + + obo:DDO.owl#DDO_0003145 + DDO:DDO_0003145 + + + + obo:DDO.owl#DDO_0003145 + 312921000 + + + + obo:DDO.owl#DDO_0003145 + autosomal dominant cystoid macular edema + + + + obo:DDO.owl#DDO_0003146 + DDO:DDO_0003146 + + + + obo:DDO.owl#DDO_0003146 + 312920004 + + + + obo:DDO.owl#DDO_0003146 + postoperative cystoid macular edema + + + + obo:DDO.owl#DDO_0003147 + DDO:DDO_0003147 + + + + obo:DDO.owl#DDO_0003147 + 312922007 + + + + obo:DDO.owl#DDO_0003147 + uveitis related cystoid macular edema + + + + obo:DDO.owl#DDO_0003148 + DDO:DDO_0003148 + + + + obo:DDO.owl#DDO_0003148 + 312897007 + + + + obo:DDO.owl#DDO_0003148 + macular traction syndrome + + + + obo:DDO.owl#DDO_0003149 + DDO:DDO_0003149 + + + + obo:DDO.owl#DDO_0003149 + 312901001 + + + + obo:DDO.owl#DDO_0003149 + Vitreomacular traction syndrome + + + + obo:DDO.owl#DDO_0003150 + DDO:DDO_0003150 + + + + obo:DDO.owl#DDO_0003150 + 18410006 + + + + obo:DDO.owl#DDO_0003150 + scarred macula + + + + obo:DDO.owl#DDO_0003151 + DDO:DDO_0003151 + + + + obo:DDO.owl#DDO_0003151 + 312899005 + + + + obo:DDO.owl#DDO_0003151 + Fibrovascular macular scar + + + + obo:DDO.owl#DDO_0003152 + DDO:DDO_0003152 + + + + obo:DDO.owl#DDO_0003152 + 425622004 + + + + obo:DDO.owl#DDO_0003152 + post-traumatic macular scar + + + + obo:DDO.owl#DDO_0003153 + DDO:DDO_0003153 + + + + obo:DDO.owl#DDO_0003153 + 16110005 + + + + obo:DDO.owl#DDO_0003153 + ophthalmoplegia + + + + obo:DDO.owl#DDO_0003154 + DDO:DDO_0003154 + + + + obo:DDO.owl#DDO_0003154 + 28978003 + + + + obo:DDO.owl#DDO_0003154 + progressive supranuclear ophthalmoplegia + + + + obo:DDO.owl#DDO_0003155 + DDO:DDO_0003155 + + + + obo:DDO.owl#DDO_0003155 + 95794005 + + + + obo:DDO.owl#DDO_0003155 + tolosa-Hunt syndrome + + + + obo:DDO.owl#DDO_0003156 + DDO:DDO_0003156 + + + + obo:DDO.owl#DDO_0003156 + 95794005 + + + + obo:DDO.owl#DDO_0003156 + painful ophthalmoplegia + + + + obo:DDO.owl#DDO_0003157 + DDO:DDO_0003157 + + + + obo:DDO.owl#DDO_0003157 + 49605003 + + + + obo:DDO.owl#DDO_0003157 + ophthalmoplegic migraine + + + + obo:DDO.owl#DDO_0003158 + DDO:DDO_0003158 + + + + obo:DDO.owl#DDO_0003158 + 77835008 + + + + obo:DDO.owl#DDO_0003158 + ophthalmoplegia plus syndrome + + + + obo:DDO.owl#DDO_0003159 + DDO:DDO_0003159 + + + + obo:DDO.owl#DDO_0003159 + 104461000119104 + + + + obo:DDO.owl#DDO_0003159 + ophthalmoplegia due to Graves disease + + + + obo:DDO.owl#DDO_0003160 + DDO:DDO_0003160 + + + + obo:DDO.owl#DDO_0003160 + 49823009 + + + + obo:DDO.owl#DDO_0003160 + internuclear ophthalmoplegia + + + + obo:DDO.owl#DDO_0003161 + DDO:DDO_0003161 + + + + obo:DDO.owl#DDO_0003161 + 78097002 + + + + obo:DDO.owl#DDO_0003161 + total ophthalmoplegia + + + + obo:DDO.owl#DDO_0003162 + DDO:DDO_0003162 + + + + obo:DDO.owl#DDO_0003162 + 46252003 + + + + obo:DDO.owl#DDO_0003162 + progressive external ophthalmoplegia + + + + obo:DDO.owl#DDO_0003163 + DDO:DDO_0003163 + + + + obo:DDO.owl#DDO_0003163 + 19373007 + + + + obo:DDO.owl#DDO_0003163 + external ophthalmoplegia + + + + obo:DDO.owl#DDO_0003164 + DDO:DDO_0003164 + + + + obo:DDO.owl#DDO_0003164 + 69763009 + + + + obo:DDO.owl#DDO_0003164 + exophthalmic ophthalmoplegia + + + + obo:DDO.owl#DDO_0003165 + DDO:DDO_0003165 + + + + obo:DDO.owl#DDO_0003165 + 427943001 + + + + obo:DDO.owl#DDO_0003165 + diabetic ophthalmoplegia + + + + obo:DDO.owl#DDO_0003166 + DDO:DDO_0003166 + + + + obo:DDO.owl#DDO_0003166 + 230530003 + + + + obo:DDO.owl#DDO_0003166 + congenital nuclear ophthalmoplegia + + + + obo:DDO.owl#DDO_0003167 + DDO:DDO_0003167 + + + + obo:DDO.owl#DDO_0003167 + 422588002 + + + + obo:DDO.owl#DDO_0003167 + aspiration pneumonia + + + + obo:DDO.owl#DDO_0003168 + DDO:DDO_0003168 + + + + obo:DDO.owl#DDO_0003168 + 35031000119100 + + + + obo:DDO.owl#DDO_0003168 + acute aspiration pneumonia + + + + obo:DDO.owl#DDO_0003169 + DDO:DDO_0003169 + + + + obo:DDO.owl#DDO_0003169 + 276695003 + + + + obo:DDO.owl#DDO_0003169 + neonatal aspiration pneumonia + + + + obo:DDO.owl#DDO_0003170 + DDO:DDO_0003170 + + + + obo:DDO.owl#DDO_0003170 + 438764004 + + + + obo:DDO.owl#DDO_0003170 + postoperative aspiration pneumonia + + + + obo:DDO.owl#DDO_0003171 + DDO:DDO_0003171 + + + + obo:DDO.owl#DDO_0003171 + 430969000 + + + + obo:DDO.owl#DDO_0003171 + recurrent aspiration pneumonia + + + + obo:DDO.owl#DDO_0003172 + DDO:DDO_0003172 + + + + obo:DDO.owl#DDO_0003172 + 385093006 + + + + obo:DDO.owl#DDO_0003172 + community acquired pneumonia + + + + obo:DDO.owl#DDO_0003173 + DDO:DDO_0003173 + + + + obo:DDO.owl#DDO_0003173 + 80640009 + + + + obo:DDO.owl#DDO_0003173 + perirenal abscess + + + + obo:DDO.owl#DDO_0003174 + DDO:DDO_0003174 + + + + obo:DDO.owl#DDO_0003174 + 373407002 + + + + obo:DDO.owl#DDO_0003174 + inflammatory disorder of digestive system + + + + obo:DDO.owl#DDO_0003175 + DDO:DDO_0003175 + + + + obo:DDO.owl#DDO_0003175 + 82403002 + + + + obo:DDO.owl#DDO_0003175 + cholangitis + + + + obo:DDO.owl#DDO_0003176 + DDO:DDO_0003176 + + + + obo:DDO.owl#DDO_0003176 + 405590003 + + + + obo:DDO.owl#DDO_0003176 + infective cholangitis + + + + obo:DDO.owl#DDO_0003177 + DDO:DDO_0003177 + + + + obo:DDO.owl#DDO_0003177 + 95558008 + + + + obo:DDO.owl#DDO_0003177 + emphysematous cholecystitis + + + + obo:DDO.owl#DDO_0003177 + pneumocholecystitis + + + + obo:DDO.owl#DDO_0003178 + DDO:DDO_0003178 + + + + obo:DDO.owl#DDO_0003178 + 32067005 + + + + obo:DDO.owl#DDO_0003178 + acute emphysematous cholecystitis + + + + obo:DDO.owl#DDO_0003179 + DDO:DDO_0003179 + + + + obo:DDO.owl#DDO_0003179 + 19943007 + + + + obo:DDO.owl#DDO_0003179 + hepatic cirrhosis + + + + obo:DDO.owl#DDO_0003180 + DDO:DDO_0003180 + + + + obo:DDO.owl#DDO_0003180 + 1761006 + + + + obo:DDO.owl#DDO_0003180 + biliary cirrhosis + + + + obo:DDO.owl#DDO_0003181 + DDO:DDO_0003181 + + + + obo:DDO.owl#DDO_0003181 + 197293003 + + + + obo:DDO.owl#DDO_0003181 + diffuse nodular cirrhosis + + + + obo:DDO.owl#DDO_0003182 + DDO:DDO_0003182 + + + + obo:DDO.owl#DDO_0003182 + 89580002 + + + + obo:DDO.owl#DDO_0003182 + cryptogenic cirrhosis + + + + obo:DDO.owl#DDO_0003183 + DDO:DDO_0003183 + + + + obo:DDO.owl#DDO_0003183 + 45256007 + + + + obo:DDO.owl#DDO_0003183 + cruveilhier-Baumgarten syndrome + + + + obo:DDO.owl#DDO_0003184 + DDO:DDO_0003184 + + + + obo:DDO.owl#DDO_0003184 + 271440004 + + + + obo:DDO.owl#DDO_0003184 + cirrhosis secondary to cholestasis + + + + obo:DDO.owl#DDO_0003185 + DDO:DDO_0003185 + + + + obo:DDO.owl#DDO_0003185 + 197279005 + + + + obo:DDO.owl#DDO_0003185 + cirrhosis and chronic liver disease + + + + obo:DDO.owl#DDO_0003186 + DDO:DDO_0003186 + + + + obo:DDO.owl#DDO_0003186 + 266468003 + + + + obo:DDO.owl#DDO_0003186 + cirrhosis - non-alcoholic + + + + obo:DDO.owl#DDO_0003187 + DDO:DDO_0003187 + + + + obo:DDO.owl#DDO_0003187 + 123606000 + + + + obo:DDO.owl#DDO_0003187 + cholangiolitic cirrhosis + + + + obo:DDO.owl#DDO_0003188 + DDO:DDO_0003188 + + + + obo:DDO.owl#DDO_0003188 + 197296006 + + + + obo:DDO.owl#DDO_0003188 + capsular portal cirrhosis + + + + obo:DDO.owl#DDO_0003189 + DDO:DDO_0003189 + + + + obo:DDO.owl#DDO_0003189 + 31712002 + + + + obo:DDO.owl#DDO_0003189 + primary biliary cirrhosis + + + + obo:DDO.owl#DDO_0003190 + DDO:DDO_0003190 + + + + obo:DDO.owl#DDO_0003190 + 12368000 + + + + obo:DDO.owl#DDO_0003190 + secondary biliary cirrhosis + + + + obo:DDO.owl#DDO_0003191 + DDO:DDO_0003191 + + + + obo:DDO.owl#DDO_0003191 + 109819003 + + + + obo:DDO.owl#DDO_0003191 + obstructive biliary cirrhosis + + + + obo:DDO.owl#DDO_0003192 + DDO:DDO_0003192 + + + + obo:DDO.owl#DDO_0003192 + 37688005 + + + + obo:DDO.owl#DDO_0003192 + clonorchiasis with biliary cirrhosis + + + + obo:DDO.owl#DDO_0003193 + DDO:DDO_0003193 + + + + obo:DDO.owl#DDO_0003193 + 197310003 + + + + obo:DDO.owl#DDO_0003193 + biliary cirrhosis of children + + + + obo:DDO.owl#DDO_0003194 + DDO:DDO_0003194 + + + + obo:DDO.owl#DDO_0003194 + 123604002 + + + + obo:DDO.owl#DDO_0003194 + toxic cirrhosis + + + + obo:DDO.owl#DDO_0003195 + DDO:DDO_0003195 + + + + obo:DDO.owl#DDO_0003195 + 86454000 + + + + obo:DDO.owl#DDO_0003195 + postnecrotic cirrhosis + + + + obo:DDO.owl#DDO_0003196 + DDO:DDO_0003196 + + + + obo:DDO.owl#DDO_0003196 + 27156006 + + + + obo:DDO.owl#DDO_0003196 + posthepatitic cirrhosis + + + + obo:DDO.owl#DDO_0003197 + DDO:DDO_0003197 + + + + obo:DDO.owl#DDO_0003197 + 197291001 + + + + obo:DDO.owl#DDO_0003197 + unilobular portal cirrhosis + + + + obo:DDO.owl#DDO_0003198 + DDO:DDO_0003198 + + + + obo:DDO.owl#DDO_0003198 + 197301006 + + + + obo:DDO.owl#DDO_0003198 + toxic portal cirrhosis + + + + obo:DDO.owl#DDO_0003199 + DDO:DDO_0003199 + + + + obo:DDO.owl#DDO_0003199 + 197299004 + + + + obo:DDO.owl#DDO_0003199 + pigmentary portal cirrhosis + + + + obo:DDO.owl#DDO_0003200 + DDO:DDO_0003200 + + + + obo:DDO.owl#DDO_0003200 + 266469006 + + + + obo:DDO.owl#DDO_0003200 + multilobular portal cirrhosis + + + + obo:DDO.owl#DDO_0003201 + DDO:DDO_0003201 + + + + obo:DDO.owl#DDO_0003201 + 235895002 + + + + obo:DDO.owl#DDO_0003201 + laennec's cirrhosis, non-alcoholic + + + + obo:DDO.owl#DDO_0003202 + DDO:DDO_0003202 + + + + obo:DDO.owl#DDO_0003202 + 266471006 + + + + obo:DDO.owl#DDO_0003202 + juvenile portal cirrhosis + + + + obo:DDO.owl#DDO_0003203 + DDO:DDO_0003203 + + + + obo:DDO.owl#DDO_0003203 + 197294009 + + + + obo:DDO.owl#DDO_0003203 + fatty portal cirrhosis + + + + obo:DDO.owl#DDO_0003205 + DDO:DDO_0003205 + + + + obo:DDO.owl#DDO_0003205 + 266470007 + + + + obo:DDO.owl#DDO_0003205 + cardiac portal cirrhosis + + + + obo:DDO.owl#DDO_0003206 + DDO:DDO_0003206 + + + + obo:DDO.owl#DDO_0003206 + 197305002 + + + + obo:DDO.owl#DDO_0003206 + syphilitic portal cirrhosis + + + + obo:DDO.owl#DDO_0003207 + DDO:DDO_0003207 + + + + obo:DDO.owl#DDO_0003207 + 197303009 + + + + obo:DDO.owl#DDO_0003207 + bacterial portal cirrhosis + + + + obo:DDO.owl#DDO_0003208 + DDO:DDO_0003208 + + + + obo:DDO.owl#DDO_0003208 + 419728003 + + + + obo:DDO.owl#DDO_0003208 + portal cirrhosis + + + + obo:DDO.owl#DDO_0003209 + DDO:DDO_0003209 + + + + obo:DDO.owl#DDO_0003209 + 78208005 + + + + obo:DDO.owl#DDO_0003209 + pigment cirrhosis + + + + obo:DDO.owl#DDO_0003210 + DDO:DDO_0003210 + + + + obo:DDO.owl#DDO_0003210 + 123605001 + + + + obo:DDO.owl#DDO_0003210 + nutritional cirrhosis + + + + obo:DDO.owl#DDO_0003211 + DDO:DDO_0003211 + + + + obo:DDO.owl#DDO_0003211 + 15999000 + + + + obo:DDO.owl#DDO_0003211 + mixed micro AND macronodular cirrhosis + + + + obo:DDO.owl#DDO_0003212 + DDO:DDO_0003212 + + + + obo:DDO.owl#DDO_0003212 + 21861000 + + + + obo:DDO.owl#DDO_0003212 + micronodular cirrhosis + + + + obo:DDO.owl#DDO_0003213 + DDO:DDO_0003213 + + + + obo:DDO.owl#DDO_0003213 + 15999000 + + + + obo:DDO.owl#DDO_0003213 + mixed micro AND macronodular cirrhosis + + + + obo:DDO.owl#DDO_0003214 + DDO:DDO_0003214 + + + + obo:DDO.owl#DDO_0003214 + 43904005 + + + + obo:DDO.owl#DDO_0003214 + macronodular cirrhosis + + + + obo:DDO.owl#DDO_0003215 + DDO:DDO_0003215 + + + + obo:DDO.owl#DDO_0003215 + 197303009 + + + + obo:DDO.owl#DDO_0003215 + bacterial portal cirrhosis + + + + obo:DDO.owl#DDO_0003216 + DDO:DDO_0003216 + + + + obo:DDO.owl#DDO_0003216 + 235896001 + + + + obo:DDO.owl#DDO_0003216 + infectious cirrhosis + + + + obo:DDO.owl#DDO_0003217 + DDO:DDO_0003217 + + + + obo:DDO.owl#DDO_0003217 + 6183001 + + + + obo:DDO.owl#DDO_0003217 + indian childhood cirrhosis + + + + obo:DDO.owl#DDO_0003218 + DDO:DDO_0003218 + + + + obo:DDO.owl#DDO_0003218 + 123716002 + + + + obo:DDO.owl#DDO_0003218 + latent cirrhosis + + + + obo:DDO.owl#DDO_0003219 + DDO:DDO_0003219 + + + + obo:DDO.owl#DDO_0003219 + 197305002 + + + + obo:DDO.owl#DDO_0003219 + syphilitic portal cirrhosis + + + + obo:DDO.owl#DDO_0003220 + DDO:DDO_0003220 + + + + obo:DDO.owl#DDO_0003220 + 16070004 + + + + obo:DDO.owl#DDO_0003220 + syphilitic cirrhosis + + + + obo:DDO.owl#DDO_0003221 + DDO:DDO_0003221 + + + + obo:DDO.owl#DDO_0003221 + 37688005 + + + + obo:DDO.owl#DDO_0003221 + clonorchiasis with biliary cirrhosis + + + + obo:DDO.owl#DDO_0003222 + DDO:DDO_0003222 + + + + obo:DDO.owl#DDO_0003222 + 33144001 + + + + obo:DDO.owl#DDO_0003222 + parasitic cirrhosis + + + + obo:DDO.owl#DDO_0003223 + DDO:DDO_0003223 + + + + obo:DDO.owl#DDO_0003223 + 197305002 + + + + obo:DDO.owl#DDO_0003223 + syphilitic portal cirrhosis + + + + obo:DDO.owl#DDO_0003224 + DDO:DDO_0003224 + + + + obo:DDO.owl#DDO_0003224 + 266470007 + + + + obo:DDO.owl#DDO_0003224 + cardiac portal cirrhosis + + + + obo:DDO.owl#DDO_0003226 + DDO:DDO_0003226 + + + + obo:DDO.owl#DDO_0003226 + 74669004 + + + + obo:DDO.owl#DDO_0003226 + cardiac cirrhosis + + + + obo:DDO.owl#DDO_0003227 + DDO:DDO_0003227 + + + + obo:DDO.owl#DDO_0003227 + 235897005 + + + + obo:DDO.owl#DDO_0003227 + hypoxia-associated cirrhosis + + + + obo:DDO.owl#DDO_0003228 + DDO:DDO_0003228 + + + + obo:DDO.owl#DDO_0003228 + 235900003 + + + + obo:DDO.owl#DDO_0003228 + portal and splenic vein sclerosis + + + + obo:DDO.owl#DDO_0003229 + DDO:DDO_0003229 + + + + obo:DDO.owl#DDO_0003229 + 235899008 + + + + obo:DDO.owl#DDO_0003229 + hepatic sclerosis + + + + obo:DDO.owl#DDO_0003230 + DDO:DDO_0003230 + + + + obo:DDO.owl#DDO_0003230 + 235902006 + + + + obo:DDO.owl#DDO_0003230 + intrahepatic phlebosclerosis and fibrosis + + + + obo:DDO.owl#DDO_0003231 + DDO:DDO_0003231 + + + + obo:DDO.owl#DDO_0003231 + 35901004 + + + + obo:DDO.owl#DDO_0003231 + hepatic fibrosis with hepatic sclerosis + + + + obo:DDO.owl#DDO_0003232 + DDO:DDO_0003232 + + + + obo:DDO.owl#DDO_0003232 + 536002 2 + + + + obo:DDO.owl#DDO_0003232 + glissonian cirrhosis + + + + obo:DDO.owl#DDO_0003233 + DDO:DDO_0003233 + + + + obo:DDO.owl#DDO_0003233 + 76301009 + + + + obo:DDO.owl#DDO_0003233 + florid cirrhosis + + + + obo:DDO.owl#DDO_0003234 + DDO:DDO_0003234 + + + + obo:DDO.owl#DDO_0003234 + 371139006 + + + + obo:DDO.owl#DDO_0003234 + early cirrhosis + + + + obo:DDO.owl#DDO_0003235 + DDO:DDO_0003235 + + + + obo:DDO.owl#DDO_0003235 + 41309000 + + + + obo:DDO.owl#DDO_0003235 + alcoholic liver damage + + + + obo:DDO.owl#DDO_0003236 + DDO:DDO_0003236 + + + + obo:DDO.owl#DDO_0003236 + 44047000 + + + + obo:DDO.owl#DDO_0003236 + zieve's syndrome + + + + obo:DDO.owl#DDO_0003237 + DDO:DDO_0003237 + + + + obo:DDO.owl#DDO_0003237 + 307757001 + + + + obo:DDO.owl#DDO_0003237 + chronic alcoholic hepatitis + + + + obo:DDO.owl#DDO_0003238 + DDO:DDO_0003238 + + + + obo:DDO.owl#DDO_0003238 + 9953008 + + + + obo:DDO.owl#DDO_0003238 + acute alcoholic liver disease + + + + obo:DDO.owl#DDO_0003239 + DDO:DDO_0003239 + + + + obo:DDO.owl#DDO_0003239 + 235875008 + + + + obo:DDO.owl#DDO_0003239 + alcoholic hepatitis + + + + obo:DDO.owl#DDO_0003240 + DDO:DDO_0003240 + + + + obo:DDO.owl#DDO_0003240 + 235881000 + + + + obo:DDO.owl#DDO_0003240 + alcoholic hepatic failure + + + + obo:DDO.owl#DDO_0003241 + DDO:DDO_0003241 + + + + obo:DDO.owl#DDO_0003241 + 50325005 + + + + obo:DDO.owl#DDO_0003241 + alcoholic fatty liver + + + + obo:DDO.owl#DDO_0003242 + DDO:DDO_0003242 + + + + obo:DDO.owl#DDO_0003242 + 420054005 + + + + obo:DDO.owl#DDO_0003242 + alcoholic cirrhosis + + + + obo:DDO.owl#DDO_0003243 + DDO:DDO_0003243 + + + + obo:DDO.owl#DDO_0003243 + 59927004 + + + + obo:DDO.owl#DDO_0003243 + hepatic failure + + + + obo:DDO.owl#DDO_0003243 + liver failure + + + + obo:DDO.owl#DDO_0003244 + DDO:DDO_0003244 + + + + obo:DDO.owl#DDO_0003244 + 197270009 + + + + obo:DDO.owl#DDO_0003244 + acute hepatic failure + + + + obo:DDO.owl#DDO_0003245 + DDO:DDO_0003245 + + + + obo:DDO.owl#DDO_0003245 + 413438002 + + + + obo:DDO.owl#DDO_0003245 + acute hepatic failure due to drugs + + + + obo:DDO.owl#DDO_0003246 + DDO:DDO_0003246 + + + + obo:DDO.owl#DDO_0003246 + 235856003 + + + + obo:DDO.owl#DDO_0003246 + liver disease + + + + obo:DDO.owl#DDO_0003246 + hepatopathy + + + + obo:DDO.owl#DDO_0003247 + DDO:DDO_0003247 + + + + obo:DDO.owl#DDO_0003247 + 197321007 + + + + obo:DDO.owl#DDO_0003247 + steatosis of liver + + + + obo:DDO.owl#DDO_0003248 + DDO:DDO_0003248 + + + + obo:DDO.owl#DDO_0003248 + 197315008 + + + + obo:DDO.owl#DDO_0003248 + NAFLD - Nonalcoholic fatty liver disease + + + + obo:DDO.owl#DDO_0003249 + DDO:DDO_0003249 + + + + obo:DDO.owl#DDO_0003249 + 50325005 + + + + obo:DDO.owl#DDO_0003249 + alcoholic fatty liver + + + + obo:DDO.owl#DDO_0003250 + DDO:DDO_0003250 + + + + obo:DDO.owl#DDO_0003250 + 442191002 + + + + obo:DDO.owl#DDO_0003250 + steatohepatitis + + + + obo:DDO.owl#DDO_0003251 + DDO:DDO_0003251 + + + + obo:DDO.owl#DDO_0003251 + 442685003 + + + + obo:DDO.owl#DDO_0003251 + nonalcoholic steatohepatitis + + + + obo:DDO.owl#DDO_0003252 + DDO:DDO_0003252 + + + + obo:DDO.owl#DDO_0003252 + 34486009 + + + + obo:DDO.owl#DDO_0003252 + hyperthyroidism + + + + obo:DDO.owl#DDO_0003253 + DDO:DDO_0003253 + + + + obo:DDO.owl#DDO_0003253 + 90739004 + + + + obo:DDO.owl#DDO_0003253 + thyrotoxicosis + + + + obo:DDO.owl#DDO_0003254 + DDO:DDO_0003254 + + + + obo:DDO.owl#DDO_0003254 + 237505003 + + + + obo:DDO.owl#DDO_0003254 + apathetic thyrotoxicosis + + + + obo:DDO.owl#DDO_0003255 + DDO:DDO_0003255 + + + + obo:DDO.owl#DDO_0003255 + 236423003 + + + + obo:DDO.owl#DDO_0003255 + renal impairment + + + + obo:DDO.owl#DDO_0003256 + DDO:DDO_0003256 + + + + obo:DDO.owl#DDO_0003256 + 236424009 + + + + obo:DDO.owl#DDO_0003256 + acute renal impairment + + + + obo:DDO.owl#DDO_0003257 + DDO:DDO_0003257 + + + + obo:DDO.owl#DDO_0003257 + 14669001 + + + + obo:DDO.owl#DDO_0003257 + acute renal failure syndrome + + + + obo:DDO.owl#DDO_0003258 + DDO:DDO_0003258 + + + + obo:DDO.owl#DDO_0003258 + 140031000119103 + + + + obo:DDO.owl#DDO_0003258 + acute nontraumatic kidney injury + + + + obo:DDO.owl#DDO_0003259 + DDO:DDO_0003259 + + + + obo:DDO.owl#DDO_0003259 + 23697004 + + + + obo:DDO.owl#DDO_0003259 + crush syndrome + + + + obo:DDO.owl#DDO_0003260 + DDO:DDO_0003260 + + + + obo:DDO.owl#DDO_0003260 + 236431008 + + + + obo:DDO.owl#DDO_0003260 + traumatic anuria - crush syndrome + + + + obo:DDO.owl#DDO_0003261 + DDO:DDO_0003261 + + + + obo:DDO.owl#DDO_0003261 + 236432001 + + + + obo:DDO.owl#DDO_0003261 + pulmonary renal syndrome + + + + obo:DDO.owl#DDO_0003262 + DDO:DDO_0003262 + + + + obo:DDO.owl#DDO_0003262 + 307309005 + + + + obo:DDO.owl#DDO_0003262 + transient acute renal failure + + + + obo:DDO.owl#DDO_0003263 + DDO:DDO_0003263 + + + + obo:DDO.owl#DDO_0003263 + 445236007 + + + + obo:DDO.owl#DDO_0003263 + cardiorenal syndrome + + + + obo:DDO.owl#DDO_0003264 + DDO:DDO_0003264 + + + + obo:DDO.owl#DDO_0003264 + 363346000 + + + + obo:DDO.owl#DDO_0003264 + cancer + + + + obo:DDO.owl#DDO_0003264 + malignant neoplastic disease + + + + obo:DDO.owl#DDO_0003265 + DDO:DDO_0003265 + + + + obo:DDO.owl#DDO_0003265 + 93870000 + + + + obo:DDO.owl#DDO_0003265 + liver cancer + + + + obo:DDO.owl#DDO_0003265 + malignant neoplasm of liver + + + + obo:DDO.owl#DDO_0003266 + DDO:DDO_0003266 + + + + obo:DDO.owl#DDO_0003266 + 408646000 + + + + obo:DDO.owl#DDO_0003266 + adenocarcinoma of liver + + + + obo:DDO.owl#DDO_0003267 + DDO:DDO_0003267 + + + + obo:DDO.owl#DDO_0003267 + 109841003 + + + + obo:DDO.owl#DDO_0003267 + liver cell carcinoma + + + + obo:DDO.owl#DDO_0003268 + DDO:DDO_0003268 + + + + obo:DDO.owl#DDO_0003268 + 274902006 + + + + obo:DDO.owl#DDO_0003268 + combined hepatocellular carcinoma and cholangiocarcinoma + + + + obo:DDO.owl#DDO_0003269 + DDO:DDO_0003269 + + + + obo:DDO.owl#DDO_0003269 + 253018005 + + + + obo:DDO.owl#DDO_0003269 + fibrolamellar hepatocellular carcinoma + + + + obo:DDO.owl#DDO_0003270 + DDO:DDO_0003270 + + + + obo:DDO.owl#DDO_0003270 + 1691000119104 + + + + obo:DDO.owl#DDO_0003270 + metastasis to liver from adenocarcinoma + + + + obo:DDO.owl#DDO_0003271 + DDO:DDO_0003271 + + + + obo:DDO.owl#DDO_0003271 + 314963000 + + + + obo:DDO.owl#DDO_0003271 + local recurrence of malignant tumor of liver + + + + obo:DDO.owl#DDO_0003272 + DDO:DDO_0003272 + + + + obo:DDO.owl#DDO_0003272 + 187777008 + + + + obo:DDO.owl#DDO_0003272 + malignant neoplasm of intrahepatic gall duct + + + + obo:DDO.owl#DDO_0003273 + DDO:DDO_0003273 + + + + obo:DDO.owl#DDO_0003273 + 187773007 + + + + obo:DDO.owl#DDO_0003273 + malignant neoplasm of interlobular bile ducts + + + + obo:DDO.owl#DDO_0003274 + DDO:DDO_0003274 + + + + obo:DDO.owl#DDO_0003274 + 187776004 + + + + obo:DDO.owl#DDO_0003274 + malignant neoplasm of intrahepatic canaliculi + + + + obo:DDO.owl#DDO_0003275 + DDO:DDO_0003275 + + + + obo:DDO.owl#DDO_0003275 + 447109003 + + + + obo:DDO.owl#DDO_0003275 + primary malignant neoplasm of intrahepatic bile duct + + + + obo:DDO.owl#DDO_0003276 + DDO:DDO_0003276 + + + + obo:DDO.owl#DDO_0003276 + 109842005 + + + + obo:DDO.owl#DDO_0003276 + intrahepatic bile duct carcinoma + + + + obo:DDO.owl#DDO_0003277 + DDO:DDO_0003277 + + + + obo:DDO.owl#DDO_0003277 + 253017000 + + + + obo:DDO.owl#DDO_0003277 + Klatskin's tumor + + + + obo:DDO.owl#DDO_0003278 + DDO:DDO_0003278 + + + + obo:DDO.owl#DDO_0003278 + 94349006 + + + + obo:DDO.owl#DDO_0003278 + secondary malignant neoplasm of intrahepatic bile ducts + + + + obo:DDO.owl#DDO_0003279 + DDO:DDO_0003279 + + + + obo:DDO.owl#DDO_0003279 + 187767006 + + + + obo:DDO.owl#DDO_0003279 + malignant neoplasm of liver and intrahepatic bile ducts + + + + obo:DDO.owl#DDO_0003280 + DDO:DDO_0003280 + + + + obo:DDO.owl#DDO_0003280 + 95214007 + + + + obo:DDO.owl#DDO_0003280 + primary malignant neoplasm of liver + + + + obo:DDO.owl#DDO_0003281 + DDO:DDO_0003281 + + + + obo:DDO.owl#DDO_0003281 + 109844006 + + + + obo:DDO.owl#DDO_0003281 + angiosarcoma of liver + + + + obo:DDO.owl#DDO_0003282 + DDO:DDO_0003282 + + + + obo:DDO.owl#DDO_0003282 + 109843000 + + + + obo:DDO.owl#DDO_0003282 + hepatoblastoma (clinical) + + + + obo:DDO.owl#DDO_0003283 + DDO:DDO_0003283 + + + + obo:DDO.owl#DDO_0003283 + 187769009 + + + + obo:DDO.owl#DDO_0003283 + primary carcinoma of liver + + + + obo:DDO.owl#DDO_0003284 + DDO:DDO_0003284 + + + + obo:DDO.owl#DDO_0003284 + 254601002 + + + + obo:DDO.owl#DDO_0003284 + sarcoma of liver + + + + obo:DDO.owl#DDO_0003285 + DDO:DDO_0003285 + + + + obo:DDO.owl#DDO_0003285 + 109844006 + + + + obo:DDO.owl#DDO_0003285 + angiosarcoma of liver + + + + obo:DDO.owl#DDO_0003286 + DDO:DDO_0003286 + + + + obo:DDO.owl#DDO_0003286 + 94381002 + + + + obo:DDO.owl#DDO_0003286 + secondary malignant neoplasm of liver + + + + obo:DDO.owl#DDO_0003287 + DDO:DDO_0003287 + + + + obo:DDO.owl#DDO_0003287 + 1691000119104 + + + + obo:DDO.owl#DDO_0003287 + metastasis to liver from adenocarcinoma + + + + obo:DDO.owl#DDO_0003288 + DDO:DDO_0003288 + + + + obo:DDO.owl#DDO_0003288 + 285613005 + + + + obo:DDO.owl#DDO_0003288 + metastasis to liver of unknown primary + + + + obo:DDO.owl#DDO_0003289 + DDO:DDO_0003289 + + + + obo:DDO.owl#DDO_0003289 + 363418001 + + + + obo:DDO.owl#DDO_0003289 + malignant tumor of pancreas + + + + obo:DDO.owl#DDO_0003290 + DDO:DDO_0003290 + + + + obo:DDO.owl#DDO_0003290 + 700423003 + + + + obo:DDO.owl#DDO_0003290 + adenocarcinoma of pancreas + + + + obo:DDO.owl#DDO_0003291 + DDO:DDO_0003291 + + + + obo:DDO.owl#DDO_0003291 + 473419009 + + + + obo:DDO.owl#DDO_0003291 + intraductal papillary mucinous carcinoma in situ of pancreas + + + + obo:DDO.owl#DDO_0003292 + DDO:DDO_0003292 + + + + obo:DDO.owl#DDO_0003292 + 1651000119109 + + + + obo:DDO.owl#DDO_0003292 + primary adenocarcinoma of pancreas + + + + obo:DDO.owl#DDO_0003293 + DDO:DDO_0003293 + + + + obo:DDO.owl#DDO_0003293 + 235966007 + + + + obo:DDO.owl#DDO_0003293 + cystadenocarcinoma of pancreas + + + + obo:DDO.owl#DDO_0003294 + DDO:DDO_0003294 + + + + obo:DDO.owl#DDO_0003294 + 314964006 + + + + obo:DDO.owl#DDO_0003294 + local recurrence of malignant tumor of pancreas + + + + obo:DDO.owl#DDO_0003295 + DDO:DDO_0003295 + + + + obo:DDO.owl#DDO_0003295 + 187798008 + + + + obo:DDO.owl#DDO_0003295 + malignant neoplasm of ectopic pancreatic tissue + + + + obo:DDO.owl#DDO_0003296 + DDO:DDO_0003296 + + + + obo:DDO.owl#DDO_0003296 + 187791002 + + + + obo:DDO.owl#DDO_0003296 + malignant tumor of body of pancreas + + + + obo:DDO.owl#DDO_0003297 + DDO:DDO_0003297 + + + + obo:DDO.owl#DDO_0003297 + 93715005 + + + + obo:DDO.owl#DDO_0003297 + primary malignant neoplasm of body of pancreas + + + + obo:DDO.owl#DDO_0003298 + DDO:DDO_0003298 + + + + obo:DDO.owl#DDO_0003298 + 363368005 + + + + obo:DDO.owl#DDO_0003298 + carcinoma of body of pancreas + + + + obo:DDO.owl#DDO_0003299 + DDO:DDO_0003299 + + + + obo:DDO.owl#DDO_0003299 + 94212002 + + + + obo:DDO.owl#DDO_0003299 + secondary malignant neoplasm of body of pancreas + + + + obo:DDO.owl#DDO_0003300 + DDO:DDO_0003300 + + + + obo:DDO.owl#DDO_0003300 + 254611009 + + + + obo:DDO.owl#DDO_0003300 + malignant tumor of endocrine pancreas + + + + obo:DDO.owl#DDO_0003301 + DDO:DDO_0003301 + + + + obo:DDO.owl#DDO_0003301 + 254612002 + + + + obo:DDO.owl#DDO_0003301 + carcinoma of endocrine pancreas + + + + obo:DDO.owl#DDO_0003302 + DDO:DDO_0003302 + + + + obo:DDO.owl#DDO_0003302 + 187794005 + + + + obo:DDO.owl#DDO_0003302 + malignant tumor of Islets of Langerhans + + + + obo:DDO.owl#DDO_0003303 + DDO:DDO_0003303 + + + + obo:DDO.owl#DDO_0003303 + 93843007 + + + + obo:DDO.owl#DDO_0003303 + primary malignant neoplasm of islets of Langerhans + + + + obo:DDO.owl#DDO_0003304 + DDO:DDO_0003304 + + + + obo:DDO.owl#DDO_0003304 + 94354002 + + + + obo:DDO.owl#DDO_0003304 + secondary malignant neoplasm of islets of Langerhans + + + + obo:DDO.owl#DDO_0003305 + DDO:DDO_0003305 + + + + obo:DDO.owl#DDO_0003305 + 255088001 + + + + obo:DDO.owl#DDO_0003305 + malignant tumor of exocrine pancreas + + + + obo:DDO.owl#DDO_0003306 + DDO:DDO_0003306 + + + + obo:DDO.owl#DDO_0003306 + 235965006 + + + + obo:DDO.owl#DDO_0003306 + malignant cystic tumor of exocrine pancreas + + + + obo:DDO.owl#DDO_0003307 + DDO:DDO_0003307 + + + + obo:DDO.owl#DDO_0003307 + 235966007 + + + + obo:DDO.owl#DDO_0003307 + cystadenocarcinoma of pancreas + + + + obo:DDO.owl#DDO_0003308 + DDO:DDO_0003308 + + + + obo:DDO.owl#DDO_0003308 + 187793004 + + + + obo:DDO.owl#DDO_0003308 + malignant tumor of pancreatic duct + + + + obo:DDO.owl#DDO_0003309 + DDO:DDO_0003309 + + + + obo:DDO.owl#DDO_0003309 + 363417006 + + + + obo:DDO.owl#DDO_0003309 + malignant tumor of ampulla of Vater + + + + obo:DDO.owl#DDO_0003310 + DDO:DDO_0003310 + + + + obo:DDO.owl#DDO_0003310 + 187786003 + + + + obo:DDO.owl#DDO_0003310 + malignant neoplasm of sphincter of Oddi + + + + obo:DDO.owl#DDO_0003311 + DDO:DDO_0003311 + + + + obo:DDO.owl#DDO_0003311 + 371967001 + + + + obo:DDO.owl#DDO_0003311 + primary malignant neoplasm of ampulla of Vater + + + + obo:DDO.owl#DDO_0003312 + DDO:DDO_0003312 + + + + obo:DDO.owl#DDO_0003312 + 254609000 + + + + obo:DDO.owl#DDO_0003312 + carcinoma of ampulla of Vater + + + + obo:DDO.owl#DDO_0003313 + DDO:DDO_0003313 + + + + obo:DDO.owl#DDO_0003313 + 94164003 + + + + obo:DDO.owl#DDO_0003313 + secondary malignant neoplasm of ampulla of Vater + + + + obo:DDO.owl#DDO_0003314 + DDO:DDO_0003314 + + + + obo:DDO.owl#DDO_0003314 + 93939009 + + + + obo:DDO.owl#DDO_0003314 + primary malignant neoplasm of pancreatic duct + + + + obo:DDO.owl#DDO_0003315 + DDO:DDO_0003315 + + + + obo:DDO.owl#DDO_0003315 + 94460001 + + + + obo:DDO.owl#DDO_0003315 + secondary malignant neoplasm of pancreatic duct + + + + obo:DDO.owl#DDO_0003316 + DDO:DDO_0003316 + + + + obo:DDO.owl#DDO_0003316 + 363419009 + + + + obo:DDO.owl#DDO_0003316 + malignant tumor of head of pancreas + + + + obo:DDO.owl#DDO_0003317 + DDO:DDO_0003317 + + + + obo:DDO.owl#DDO_0003317 + 372119009 + + + + obo:DDO.owl#DDO_0003317 + primary malignant neoplasm of head of pancreas + + + + obo:DDO.owl#DDO_0003318 + DDO:DDO_0003318 + + + + obo:DDO.owl#DDO_0003318 + 326072005 + + + + obo:DDO.owl#DDO_0003318 + carcinoma of head of pancreas + + + + obo:DDO.owl#DDO_0003319 + DDO:DDO_0003319 + + + + obo:DDO.owl#DDO_0003319 + 94325008 + + + + obo:DDO.owl#DDO_0003319 + secondary malignant neoplasm of head of pancreas + + + + obo:DDO.owl#DDO_0003320 + DDO:DDO_0003320 + + + + obo:DDO.owl#DDO_0003320 + 187792009 + + + + obo:DDO.owl#DDO_0003320 + malignant tumor of tail of pancreas + + + + obo:DDO.owl#DDO_0003321 + DDO:DDO_0003321 + + + + obo:DDO.owl#DDO_0003321 + 94082003 + + + + obo:DDO.owl#DDO_0003321 + primary malignant neoplasm of tail of pancreas + + + + obo:DDO.owl#DDO_0003322 + DDO:DDO_0003322 + + + + obo:DDO.owl#DDO_0003322 + 363369002 + + + + obo:DDO.owl#DDO_0003322 + carcinoma of tail of pancreas + + + + obo:DDO.owl#DDO_0003323 + DDO:DDO_0003323 + + + + obo:DDO.owl#DDO_0003323 + 94618007 + + + + obo:DDO.owl#DDO_0003323 + secondary malignant neoplasm of tail of pancreas + + + + obo:DDO.owl#DDO_0003324 + DDO:DDO_0003324 + + + + obo:DDO.owl#DDO_0003324 + 372003004 + + + + obo:DDO.owl#DDO_0003324 + primary malignant neoplasm of pancreas + + + + obo:DDO.owl#DDO_0003325 + DDO:DDO_0003325 + + + + obo:DDO.owl#DDO_0003325 + 372142002 + + + + obo:DDO.owl#DDO_0003325 + carcinoma of pancreas + + + + obo:DDO.owl#DDO_0003326 + DDO:DDO_0003326 + + + + obo:DDO.owl#DDO_0003326 + 109848009 + + + + obo:DDO.owl#DDO_0003326 + overlapping malignant neoplasm of pancreas + + + + obo:DDO.owl#DDO_0003327 + DDO:DDO_0003327 + + + + obo:DDO.owl#DDO_0003327 + 94459006 + + + + obo:DDO.owl#DDO_0003327 + secondary malignant neoplasm of pancreas + + + + obo:DDO.owl#DDO_0003328 + DDO:DDO_0003328 + + + + obo:DDO.owl#DDO_0003328 + 285614004 + + + + obo:DDO.owl#DDO_0003328 + metastasis to pancreas of unknown primary + + + + obo:DDO.owl#DDO_0003329 + DDO:DDO_0003329 + + + + obo:DDO.owl#DDO_0003329 + 93781006 + + + + obo:DDO.owl#DDO_0003329 + primary malignant neoplasm of endometrium + + + + obo:DDO.owl#DDO_0003330 + DDO:DDO_0003330 + + + + obo:DDO.owl#DDO_0003330 + 699356008 + + + + obo:DDO.owl#DDO_0003330 + endometrial stromal sarcoma + + + + obo:DDO.owl#DDO_0003331 + DDO:DDO_0003331 + + + + obo:DDO.owl#DDO_0003331 + 699358009 + + + + obo:DDO.owl#DDO_0003331 + high grade endometrial stromal sarcoma + + + + obo:DDO.owl#DDO_0003332 + DDO:DDO_0003332 + + + + obo:DDO.owl#DDO_0003332 + 699357004 + + + + obo:DDO.owl#DDO_0003332 + low grade endometrial stromal sarcoma + + + + obo:DDO.owl#DDO_0003333 + DDO:DDO_0003333 + + + + obo:DDO.owl#DDO_0003333 + 363406005 + + + + obo:DDO.owl#DDO_0003333 + cancer of colon + + + + obo:DDO.owl#DDO_0003333 + malignant tumor of colon + + + + obo:DDO.owl#DDO_0003334 + DDO:DDO_0003334 + + + + obo:DDO.owl#DDO_0003334 + 314965007 + + + + obo:DDO.owl#DDO_0003334 + local recurrence of malignant tumor of colon + + + + obo:DDO.owl#DDO_0003335 + DDO:DDO_0003335 + + + + obo:DDO.owl#DDO_0003335 + 363412000 + + + + obo:DDO.owl#DDO_0003335 + malignant tumor of ascending colon + + + + obo:DDO.owl#DDO_0003336 + DDO:DDO_0003336 + + + + obo:DDO.owl#DDO_0003336 + 363407001 + + + + obo:DDO.owl#DDO_0003336 + malignant tumor of hepatic flexure + + + + obo:DDO.owl#DDO_0003337 + DDO:DDO_0003337 + + + + obo:DDO.owl#DDO_0003337 + 93826009 + + + + obo:DDO.owl#DDO_0003337 + primary malignant neoplasm of hepatic flexure of colon + + + + obo:DDO.owl#DDO_0003338 + DDO:DDO_0003338 + + + + obo:DDO.owl#DDO_0003338 + 312114001 + + + + obo:DDO.owl#DDO_0003338 + carcinoma of hepatic flexure + + + + obo:DDO.owl#DDO_0003339 + DDO:DDO_0003339 + + + + obo:DDO.owl#DDO_0003339 + 94328005 + + + + obo:DDO.owl#DDO_0003339 + secondary malignant neoplasm of hepatic flexure of colon + + + + obo:DDO.owl#DDO_0003340 + DDO:DDO_0003340 + + + + obo:DDO.owl#DDO_0003340 + 93683002 + + + + obo:DDO.owl#DDO_0003340 + primary malignant neoplasm of ascending colon + + + + obo:DDO.owl#DDO_0003341 + DDO:DDO_0003341 + + + + obo:DDO.owl#DDO_0003341 + 312111009 + + + + obo:DDO.owl#DDO_0003341 + carcinoma of ascending colon + + + + obo:DDO.owl#DDO_0003342 + DDO:DDO_0003342 + + + + obo:DDO.owl#DDO_0003342 + secondary malignant neoplasm of ascending colon + + + + obo:DDO.owl#DDO_0003343 + DDO:DDO_0003343 + + + + obo:DDO.owl#DDO_0003343 + 363409003 + + + + obo:DDO.owl#DDO_0003343 + malignant tumor of descending colon + + + + obo:DDO.owl#DDO_0003344 + DDO:DDO_0003344 + + + + obo:DDO.owl#DDO_0003344 + 363413005 + + + + obo:DDO.owl#DDO_0003344 + malignant tumor of splenic flexure + + + + obo:DDO.owl#DDO_0003345 + DDO:DDO_0003345 + + + + obo:DDO.owl#DDO_0003345 + 94072004 + + + + obo:DDO.owl#DDO_0003345 + primary malignant neoplasm of splenic flexure of colon + + + + obo:DDO.owl#DDO_0003346 + DDO:DDO_0003346 + + + + obo:DDO.owl#DDO_0003346 + 312115000 + + + + obo:DDO.owl#DDO_0003346 + carcinoma of splenic flexure + + + + obo:DDO.owl#DDO_0003347 + DDO:DDO_0003347 + + + + obo:DDO.owl#DDO_0003347 + 94604000 + + + + obo:DDO.owl#DDO_0003347 + secondary malignant neoplasm of splenic flexure of colon + + + + obo:DDO.owl#DDO_0003348 + DDO:DDO_0003348 + + + + obo:DDO.owl#DDO_0003348 + 93771007 + + + + obo:DDO.owl#DDO_0003348 + primary malignant neoplasm of descending colon + + + + obo:DDO.owl#DDO_0003349 + DDO:DDO_0003349 + + + + obo:DDO.owl#DDO_0003349 + 312113007 + + + + obo:DDO.owl#DDO_0003349 + carcinoma of descending colon + + + + obo:DDO.owl#DDO_0003350 + DDO:DDO_0003350 + + + + obo:DDO.owl#DDO_0003350 + 94271003 + + + + obo:DDO.owl#DDO_0003350 + secondary malignant neoplasm of descending colon + + + + obo:DDO.owl#DDO_0003351 + DDO:DDO_0003351 + + + + obo:DDO.owl#DDO_0003351 + 363410008 + + + + obo:DDO.owl#DDO_0003351 + malignant tumor of sigmoid colon + + + + obo:DDO.owl#DDO_0003352 + DDO:DDO_0003352 + + + + obo:DDO.owl#DDO_0003352 + 301756000 + + + + obo:DDO.owl#DDO_0003352 + adenocarcinoma of sigmoid colon + + + + obo:DDO.owl#DDO_0003353 + DDO:DDO_0003353 + + + + obo:DDO.owl#DDO_0003353 + 425178004 + + + + obo:DDO.owl#DDO_0003353 + adenocarcinoma of rectosigmoid junction + + + + obo:DDO.owl#DDO_0003354 + DDO:DDO_0003354 + + + + obo:DDO.owl#DDO_0003354 + 449218003 + + + + obo:DDO.owl#DDO_0003354 + lymphoma of sigmoid colon + + + + obo:DDO.owl#DDO_0003355 + DDO:DDO_0003355 + + + + obo:DDO.owl#DDO_0003355 + 363414004 + + + + obo:DDO.owl#DDO_0003355 + malignant tumor of rectosigmoid junction + + + + obo:DDO.owl#DDO_0003356 + DDO:DDO_0003356 + + + + obo:DDO.owl#DDO_0003356 + 93980002 + + + + obo:DDO.owl#DDO_0003356 + primary malignant neoplasm of rectosigmoid junction + + + + obo:DDO.owl#DDO_0003357 + DDO:DDO_0003357 + + + + obo:DDO.owl#DDO_0003357 + 269544008 + + + + obo:DDO.owl#DDO_0003357 + carcinoma of the rectosigmoid junction + + + + obo:DDO.owl#DDO_0003358 + DDO:DDO_0003358 + + + + obo:DDO.owl#DDO_0003358 + 94509004 + + + + obo:DDO.owl#DDO_0003358 + secondary malignant neoplasm of rectosigmoid junction + + + + obo:DDO.owl#DDO_0003359 + DDO:DDO_0003359 + + + + obo:DDO.owl#DDO_0003359 + 94006002 + + + + obo:DDO.owl#DDO_0003359 + primary malignant neoplasm of sigmoid colon + + + + obo:DDO.owl#DDO_0003360 + DDO:DDO_0003360 + + + + obo:DDO.owl#DDO_0003360 + 285312008 + + + + obo:DDO.owl#DDO_0003360 + carcinoma of sigmoid colon + + + + obo:DDO.owl#DDO_0003361 + DDO:DDO_0003361 + + + + obo:DDO.owl#DDO_0003361 + 94538001 + + + + obo:DDO.owl#DDO_0003361 + secondary malignant neoplasm of sigmoid colon + + + + obo:DDO.owl#DDO_0003362 + DDO:DDO_0003362 + + + + obo:DDO.owl#DDO_0003362 + 363408006 + + + + obo:DDO.owl#DDO_0003362 + malignant tumor of transverse colon + + + + obo:DDO.owl#DDO_0003363 + DDO:DDO_0003363 + + + + obo:DDO.owl#DDO_0003363 + 94105000 + + + + obo:DDO.owl#DDO_0003363 + primary malignant neoplasm of transverse colon + + + + obo:DDO.owl#DDO_0003364 + DDO:DDO_0003364 + + + + obo:DDO.owl#DDO_0003364 + 312112002 + + + + obo:DDO.owl#DDO_0003364 + carcinoma of transverse colon + + + + obo:DDO.owl#DDO_0003365 + DDO:DDO_0003365 + + + + obo:DDO.owl#DDO_0003365 + 312114001 + + + + obo:DDO.owl#DDO_0003365 + carcinoma of hepatic flexure + + + + obo:DDO.owl#DDO_0003366 + DDO:DDO_0003366 + + + + obo:DDO.owl#DDO_0003366 + 312115000 + + + + obo:DDO.owl#DDO_0003366 + carcinoma of splenic flexure + + + + obo:DDO.owl#DDO_0003367 + DDO:DDO_0003367 + + + + obo:DDO.owl#DDO_0003367 + 94643001 + + + + obo:DDO.owl#DDO_0003367 + secondary malignant neoplasm of transverse colon + + + + obo:DDO.owl#DDO_0003368 + DDO:DDO_0003368 + + + + obo:DDO.owl#DDO_0003368 + 93761005 + + + + obo:DDO.owl#DDO_0003368 + primary malignant neoplasm of colon + + + + obo:DDO.owl#DDO_0003369 + DDO:DDO_0003369 + + + + obo:DDO.owl#DDO_0003369 + 269533000 + + + + obo:DDO.owl#DDO_0003369 + carcinoma of colon + + + + obo:DDO.owl#DDO_0003370 + DDO:DDO_0003370 + + + + obo:DDO.owl#DDO_0003370 + 315058005 + + + + obo:DDO.owl#DDO_0003370 + lynch syndrome + + + + obo:DDO.owl#DDO_0003371 + DDO:DDO_0003371 + + + + obo:DDO.owl#DDO_0003371 + 187757001 + + + + obo:DDO.owl#DDO_0003371 + malignant neoplasm, overlapping lesion of colon + + + + obo:DDO.owl#DDO_0003372 + DDO:DDO_0003372 + + + + obo:DDO.owl#DDO_0003372 + 109838007 + + + + obo:DDO.owl#DDO_0003372 + overlapping malignant neoplasm of colon + + + + obo:DDO.owl#DDO_0003373 + DDO:DDO_0003373 + + + + obo:DDO.owl#DDO_0003373 + 1701000119104 + + + + obo:DDO.owl#DDO_0003373 + primary adenocarcinoma of colon + + + + obo:DDO.owl#DDO_0003374 + DDO:DDO_0003374 + + + + obo:DDO.owl#DDO_0003374 + 94260004 + + + + obo:DDO.owl#DDO_0003374 + secondary malignant neoplasm of colon + + + + obo:DDO.owl#DDO_0003375 + DDO:DDO_0003375 + + + + obo:DDO.owl#DDO_0003375 + 285611007 + + + + obo:DDO.owl#DDO_0003375 + metastasis to colon of unknown primary + + + + obo:DDO.owl#DDO_0003376 + DDO:DDO_0003376 + + + + obo:DDO.owl#DDO_0003376 + 254837009 + + + + obo:DDO.owl#DDO_0003376 + malignant tumor of breast + + + + obo:DDO.owl#DDO_0003377 + DDO:DDO_0003377 + + + + obo:DDO.owl#DDO_0003377 + 254838004 + + + + obo:DDO.owl#DDO_0003377 + carcinoma of breast + + + + obo:DDO.owl#DDO_0003378 + DDO:DDO_0003378 + + + + obo:DDO.owl#DDO_0003378 + 254841008 + + + + obo:DDO.owl#DDO_0003378 + cancer en cuirasse + + + + obo:DDO.owl#DDO_0003379 + DDO:DDO_0003379 + + + + obo:DDO.owl#DDO_0003379 + 447782002 + + + + obo:DDO.owl#DDO_0003379 + carcinoma of female breast + + + + obo:DDO.owl#DDO_0003380 + DDO:DDO_0003380 + + + + obo:DDO.owl#DDO_0003380 + 448952004 + + + + obo:DDO.owl#DDO_0003380 + infiltrating duct carcinoma of female breast + + + + obo:DDO.owl#DDO_0003381 + DDO:DDO_0003381 + + + + obo:DDO.owl#DDO_0003381 + 372096000 + + + + obo:DDO.owl#DDO_0003381 + carcinoma of male breast + + + + obo:DDO.owl#DDO_0003382 + DDO:DDO_0003382 + + + + obo:DDO.owl#DDO_0003382 + 254843006 + + + + obo:DDO.owl#DDO_0003382 + familial cancer of breast + + + + obo:DDO.owl#DDO_0003383 + DDO:DDO_0003383 + + + + obo:DDO.owl#DDO_0003383 + 417181009 + + + + obo:DDO.owl#DDO_0003383 + hormone receptor positive malignant neoplasm of breast + + + + obo:DDO.owl#DDO_0003384 + DDO:DDO_0003384 + + + + obo:DDO.owl#DDO_0003384 + 427685000 + + + + obo:DDO.owl#DDO_0003384 + HER2-positive carcinoma of breast + + + + obo:DDO.owl#DDO_0003385 + DDO:DDO_0003385 + + + + obo:DDO.owl#DDO_0003385 + 278052009 + + + + obo:DDO.owl#DDO_0003385 + malignant lymphoma of breast + + + + obo:DDO.owl#DDO_0003386 + DDO:DDO_0003386 + + + + obo:DDO.owl#DDO_0003386 + 188050009 + + + + obo:DDO.owl#DDO_0003386 + malignant melanoma of breast + + + + obo:DDO.owl#DDO_0003387 + DDO:DDO_0003387 + + + + obo:DDO.owl#DDO_0003387 + 93215006 + + + + obo:DDO.owl#DDO_0003387 + malignant melanoma of skin of breast + + + + obo:DDO.owl#DDO_0003388 + DDO:DDO_0003388 + + + + obo:DDO.owl#DDO_0003388 + 278050001 + + + + obo:DDO.owl#DDO_0003388 + sarcoma of breast + + + + obo:DDO.owl#DDO_0003389 + DDO:DDO_0003389 + + + + obo:DDO.owl#DDO_0003389 + 399326009 + + + + obo:DDO.owl#DDO_0003389 + malignant tumor of urinary bladder + + + + obo:DDO.owl#DDO_0003390 + DDO:DDO_0003390 + + + + obo:DDO.owl#DDO_0003390 + 425066001 + + + + obo:DDO.owl#DDO_0003390 + carcinoma of urinary bladder, invasive + + + + obo:DDO.owl#DDO_0003391 + DDO:DDO_0003391 + + + + obo:DDO.owl#DDO_0003391 + 425231005 + + + + obo:DDO.owl#DDO_0003391 + carcinoma of urinary bladder, superficial + + + + obo:DDO.owl#DDO_0003392 + DDO:DDO_0003392 + + + + obo:DDO.owl#DDO_0003392 + 314968009 + + + + obo:DDO.owl#DDO_0003392 + local recurrence of malignant tumor of urinary bladder + + + + obo:DDO.owl#DDO_0003393 + DDO:DDO_0003393 + + + + obo:DDO.owl#DDO_0003393 + 188242006 + + + + obo:DDO.owl#DDO_0003393 + malignant neoplasm of anterior wall of urinary bladder + + + + obo:DDO.owl#DDO_0003394 + DDO:DDO_0003394 + + + + obo:DDO.owl#DDO_0003394 + 94171008 + + + + obo:DDO.owl#DDO_0003394 + secondary malignant neoplasm of anterior wall of urinary bladder + + + + obo:DDO.owl#DDO_0003395 + DDO:DDO_0003395 + + + + obo:DDO.owl#DDO_0003395 + 702467006 + + + + obo:DDO.owl#DDO_0003395 + malignant neoplasm of augmented bladder + + + + obo:DDO.owl#DDO_0003396 + DDO:DDO_0003396 + + + + obo:DDO.owl#DDO_0003396 + 188241004 + + + + obo:DDO.owl#DDO_0003396 + malignant neoplasm of lateral wall of urinary bladder + + + + obo:DDO.owl#DDO_0003397 + DDO:DDO_0003397 + + + + obo:DDO.owl#DDO_0003397 + 188243001 + + + + obo:DDO.owl#DDO_0003397 + malignant neoplasm of posterior wall of urinary bladder + + + + obo:DDO.owl#DDO_0003398 + DDO:DDO_0003398 + + + + obo:DDO.owl#DDO_0003398 + 94500000 + + + + obo:DDO.owl#DDO_0003398 + secondary malignant neoplasm of posterior wall of urinary bladder + + + + obo:DDO.owl#DDO_0003399 + DDO:DDO_0003399 + + + + obo:DDO.owl#DDO_0003399 + 188244007 + + + + obo:DDO.owl#DDO_0003399 + malignant tumor of bladder neck + + + + obo:DDO.owl#DDO_0003400 + DDO:DDO_0003400 + + + + obo:DDO.owl#DDO_0003400 + 188239000 + + + + obo:DDO.owl#DDO_0003400 + malignant tumor of trigone of urinary bladder + + + + obo:DDO.owl#DDO_0003401 + DDO:DDO_0003401 + + + + obo:DDO.owl#DDO_0003401 + 363456000 + + + + obo:DDO.owl#DDO_0003401 + malignant tumor of urachus + + + + obo:DDO.owl#DDO_0003402 + DDO:DDO_0003402 + + + + obo:DDO.owl#DDO_0003402 + 188245008 + + + + obo:DDO.owl#DDO_0003402 + malignant tumor of ureteric orifice + + + + obo:DDO.owl#DDO_0003403 + DDO:DDO_0003403 + + + + obo:DDO.owl#DDO_0003403 + 188240003 + + + + obo:DDO.owl#DDO_0003403 + malignant tumor of vault of bladder + + + + obo:DDO.owl#DDO_0003404 + DDO:DDO_0003404 + + + + obo:DDO.owl#DDO_0003404 + 93689003 + + + + obo:DDO.owl#DDO_0003404 + primary malignant neoplasm of bladder + + + + obo:DDO.owl#DDO_0003405 + DDO:DDO_0003405 + + + + obo:DDO.owl#DDO_0003405 + 278046008 + + + + obo:DDO.owl#DDO_0003405 + sarcoma of bladder + + + + obo:DDO.owl#DDO_0003406 + DDO:DDO_0003406 + + + + obo:DDO.owl#DDO_0003406 + 94186002 + + + + obo:DDO.owl#DDO_0003406 + secondary malignant neoplasm of bladder + + + + obo:DDO.owl#DDO_0003407 + DDO:DDO_0003407 + + + + obo:DDO.owl#DDO_0003407 + 255111004 + + + + obo:DDO.owl#DDO_0003407 + squamous cell carcinoma of bladder + + + + obo:DDO.owl#DDO_0003408 + DDO:DDO_0003408 + + + + obo:DDO.owl#DDO_0003408 + 64859006 + + + + obo:DDO.owl#DDO_0003408 + osteoporosis + + + + obo:DDO.owl#DDO_0003409 + DDO:DDO_0003409 + + + + obo:DDO.owl#DDO_0003409 + 53174001 + + + + obo:DDO.owl#DDO_0003409 + disuse osteoporosis + + + + obo:DDO.owl#DDO_0003410 + DDO:DDO_0003410 + + + + obo:DDO.owl#DDO_0003410 + 203445009 + + + + obo:DDO.owl#DDO_0003410 + osteoporosis of disuse with pathological fracture + + + + obo:DDO.owl#DDO_0003411 + DDO:DDO_0003411 + + + + obo:DDO.owl#DDO_0003411 + 3345002 + + + + obo:DDO.owl#DDO_0003411 + idiopathic osteoporosis + + + + obo:DDO.owl#DDO_0003412 + DDO:DDO_0003412 + + + + obo:DDO.owl#DDO_0003412 + 1515008 + + + + obo:DDO.owl#DDO_0003412 + Gorham's disease + + + + obo:DDO.owl#DDO_0003413 + DDO:DDO_0003413 + + + + obo:DDO.owl#DDO_0003413 + 240198002 + + + + obo:DDO.owl#DDO_0003413 + osteoporotic vertebral collapse + + + + obo:DDO.owl#DDO_0003414 + DDO:DDO_0003414 + + + + obo:DDO.owl#DDO_0003414 + 203433000 + + + + obo:DDO.owl#DDO_0003414 + postoophorectomy osteoporosis + + + + obo:DDO.owl#DDO_0003415 + DDO:DDO_0003415 + + + + obo:DDO.owl#DDO_0003415 + 203434006 + + + + obo:DDO.owl#DDO_0003415 + post-surgical malabsorption osteoporosis + + + + obo:DDO.owl#DDO_0003416 + DDO:DDO_0003416 + + + + obo:DDO.owl#DDO_0003416 + 15743005 + + + + obo:DDO.owl#DDO_0003416 + posttraumatic osteoporosis + + + + obo:DDO.owl#DDO_0003417 + DDO:DDO_0003417 + + + + obo:DDO.owl#DDO_0003417 + 276661002 + + + + obo:DDO.owl#DDO_0003417 + primary osteoporosis + + + + obo:DDO.owl#DDO_0003418 + DDO:DDO_0003418 + + + + obo:DDO.owl#DDO_0003418 + 203429007 + + + + obo:DDO.owl#DDO_0003418 + idiopathic generalized osteoporosis + + + + obo:DDO.owl#DDO_0003419 + DDO:DDO_0003419 + + + + obo:DDO.owl#DDO_0003419 + 240155001 + + + + obo:DDO.owl#DDO_0003419 + adult idiopathic generalized osteoporosis + + + + obo:DDO.owl#DDO_0003420 + DDO:DDO_0003420 + + + + obo:DDO.owl#DDO_0003420 + 240154002 + + + + obo:DDO.owl#DDO_0003420 + idiopathic osteoporosis in pregnancy + + + + obo:DDO.owl#DDO_0003421 + DDO:DDO_0003421 + + + + obo:DDO.owl#DDO_0003421 + 240156000 + + + + obo:DDO.owl#DDO_0003421 + juvenile idiopathic generalized osteoporosis + + + + obo:DDO.owl#DDO_0003422 + DDO:DDO_0003422 + + + + obo:DDO.owl#DDO_0003422 + 32369003 + + + + obo:DDO.owl#DDO_0003422 + menopausal osteoporosis + + + + obo:DDO.owl#DDO_0003423 + DDO:DDO_0003423 + + + + obo:DDO.owl#DDO_0003423 + 18040001 + + + + obo:DDO.owl#DDO_0003423 + senile osteoporosis + + + + obo:DDO.owl#DDO_0003424 + DDO:DDO_0003424 + + + + obo:DDO.owl#DDO_0003424 + 84828003 + + + + obo:DDO.owl#DDO_0003424 + leukopenia + + + + obo:DDO.owl#DDO_0003425 + DDO:DDO_0003425 + + + + obo:DDO.owl#DDO_0003425 + 102447009 + + + + obo:DDO.owl#DDO_0003425 + postmenopausal osteoporosis + + + + obo:DDO.owl#DDO_0003426 + DDO:DDO_0003426 + + + + obo:DDO.owl#DDO_0003426 + 281387004 + + + + obo:DDO.owl#DDO_0003426 + regional osteoporosis + + + + obo:DDO.owl#DDO_0003427 + DDO:DDO_0003427 + + + + obo:DDO.owl#DDO_0003427 + 240161003 + + + + obo:DDO.owl#DDO_0003427 + disappearing bone disease + + + + obo:DDO.owl#DDO_0003428 + DDO:DDO_0003428 + + + + obo:DDO.owl#DDO_0003428 + 240158004 + + + + obo:DDO.owl#DDO_0003428 + regional migrating osteoporosis + + + + obo:DDO.owl#DDO_0003429 + DDO:DDO_0003429 + + + + obo:DDO.owl#DDO_0003429 + 240159007 + + + + obo:DDO.owl#DDO_0003429 + transient osteoporosis of hip + + + + obo:DDO.owl#DDO_0003430 + DDO:DDO_0003430 + + + + obo:DDO.owl#DDO_0003430 + 240160002 + + + + obo:DDO.owl#DDO_0003430 + transient osteoporosis of hip in pregnancy + + + + obo:DDO.owl#DDO_0003431 + DDO:DDO_0003431 + + + + obo:DDO.owl#DDO_0003431 + 699528002 + + + + obo:DDO.owl#DDO_0003431 + transient osteoporosis + + + + obo:DDO.owl#DDO_0003432 + DDO:DDO_0003432 + + + + obo:DDO.owl#DDO_0003432 + 54097007 + + + + obo:DDO.owl#DDO_0003432 + blood cell disease + + + + obo:DDO.owl#DDO_0003434 + DDO:DDO_0003434 + + + + obo:DDO.owl#DDO_0003434 + 123777002 + + + + obo:DDO.owl#DDO_0003434 + autoimmune leukopenia + + + + obo:DDO.owl#DDO_0003435 + DDO:DDO_0003435 + + + + obo:DDO.owl#DDO_0003435 + 427245000 + + + + obo:DDO.owl#DDO_0003435 + febrile leukopenia + + + + obo:DDO.owl#DDO_0003436 + DDO:DDO_0003436 + + + + obo:DDO.owl#DDO_0003436 + 426800001 + + + + obo:DDO.owl#DDO_0003436 + febrile granulocytopenia + + + + obo:DDO.owl#DDO_0003437 + DDO:DDO_0003437 + + + + obo:DDO.owl#DDO_0003437 + 417672002 + + + + obo:DDO.owl#DDO_0003437 + granulocytopenic disorder + + + + obo:DDO.owl#DDO_0003438 + DDO:DDO_0003438 + + + + obo:DDO.owl#DDO_0003438 + 129640007 + + + + obo:DDO.owl#DDO_0003438 + benign granulocytopenia in childhood + + + + obo:DDO.owl#DDO_0003439 + DDO:DDO_0003439 + + + + obo:DDO.owl#DDO_0003439 + 234418001 + + + + obo:DDO.owl#DDO_0003439 + chronic benign granulocytopenia + + + + obo:DDO.owl#DDO_0003440 + DDO:DDO_0003440 + + + + obo:DDO.owl#DDO_0003440 + 426800001 + + + + obo:DDO.owl#DDO_0003440 + febrile granulocytopenia + + + + obo:DDO.owl#DDO_0003450 + DDO:DDO_0003450 + + + + obo:DDO.owl#DDO_0003450 + 127034005 + + + + obo:DDO.owl#DDO_0003450 + pancytopenia + + + + obo:DDO.owl#DDO_0003451 + DDO:DDO_0003451 + + + + obo:DDO.owl#DDO_0003451 + 275523003 + + + + obo:DDO.owl#DDO_0003451 + pancytopenia-dysmelia + + + + obo:DDO.owl#DDO_0003452 + DDO:DDO_0003452 + + + + obo:DDO.owl#DDO_0003452 + 234367000 + + + + obo:DDO.owl#DDO_0003452 + pancytopenia with pancreatitis + + + + obo:DDO.owl#DDO_0003453 + DDO:DDO_0003453 + + + + obo:DDO.owl#DDO_0003453 + 46760003 + + + + obo:DDO.owl#DDO_0003453 + estren-Dameshek anemia + + + + obo:DDO.owl#DDO_0003454 + DDO:DDO_0003454 + + + + obo:DDO.owl#DDO_0003454 + 30575002 + + + + obo:DDO.owl#DDO_0003454 + fanconi's anemia + + + + obo:DDO.owl#DDO_0003455 + DDO:DDO_0003455 + + + + obo:DDO.owl#DDO_0003455 + 183005 + + + + obo:DDO.owl#DDO_0003455 + autoimmune pancytopenia + + + + obo:DDO.owl#DDO_0003456 + DDO:DDO_0003456 + + + + obo:DDO.owl#DDO_0003456 + 38970002 + + + + obo:DDO.owl#DDO_0003456 + doan-Wright syndrome + + + + obo:DDO.owl#DDO_0003457 + DDO:DDO_0003457 + + + + obo:DDO.owl#DDO_0003457 + 5876000 + + + + obo:DDO.owl#DDO_0003457 + acquired pancytopenia + + + + obo:DDO.owl#DDO_0003458 + DDO:DDO_0003458 + + + + obo:DDO.owl#DDO_0003458 + 233623000 + + + + obo:DDO.owl#DDO_0003458 + mononuclear interstitial pneumonia + + + + obo:DDO.owl#DDO_0003459 + DDO:DDO_0003459 + + + + obo:DDO.owl#DDO_0003459 + 233622005 + + + + obo:DDO.owl#DDO_0003459 + infectious mononucleosis pneumonia + + + + obo:DDO.owl#DDO_0003460 + DDO:DDO_0003460 + + + + obo:DDO.owl#DDO_0003460 + 271558008 + + + + obo:DDO.owl#DDO_0003460 + infectious mononucleosis + + + + obo:DDO.owl#DDO_0003461 + DDO:DDO_0003461 + + + + obo:DDO.owl#DDO_0003461 + 230175007 + + + + obo:DDO.owl#DDO_0003461 + infectious mononucleosis encephalitis + + + + obo:DDO.owl#DDO_0003462 + DDO:DDO_0003462 + + + + obo:DDO.owl#DDO_0003462 + 232401004 + + + + obo:DDO.owl#DDO_0003462 + glandular fever pharyngitis + + + + obo:DDO.owl#DDO_0003463 + DDO:DDO_0003463 + + + + obo:DDO.owl#DDO_0003463 + 414235005 + + + + obo:DDO.owl#DDO_0003463 + fatal infectious mononucleosis associated with X-linked lymphoproliferative syndrome + + + + obo:DDO.owl#DDO_0003464 + DDO:DDO_0003464 + + + + obo:DDO.owl#DDO_0003464 + 128872002 + + + + obo:DDO.owl#DDO_0003464 + fatal infectious mononucleosis + + + + obo:DDO.owl#DDO_0003465 + DDO:DDO_0003465 + + + + obo:DDO.owl#DDO_0003465 + 302919001 + + + + obo:DDO.owl#DDO_0003465 + epstein-Barr virus hepatitis + + + + obo:DDO.owl#DDO_0003466 + DDO:DDO_0003466 + + + + obo:DDO.owl#DDO_0003466 + 26692000 + + + + obo:DDO.owl#DDO_0003466 + central hypothyroidism + + + + obo:DDO.owl#DDO_0003467 + DDO:DDO_0003467 + + + + obo:DDO.owl#DDO_0003467 + 37429009 + + + + obo:DDO.owl#DDO_0003467 + hypothalamic hypothyroidism + + + + obo:DDO.owl#DDO_0003468 + DDO:DDO_0003468 + + + + obo:DDO.owl#DDO_0003468 + 190268003 + + + + obo:DDO.owl#DDO_0003468 + congenital hypothyroidism + + + + obo:DDO.owl#DDO_0003469 + DDO:DDO_0003469 + + + + obo:DDO.owl#DDO_0003469 + 43153006 + + + + obo:DDO.owl#DDO_0003469 + myxedema + + + + obo:DDO.owl#DDO_0003470 + DDO:DDO_0003470 + + + + obo:DDO.owl#DDO_0003470 + 43507005 + + + + obo:DDO.owl#DDO_0003470 + adult myxedema + + + + obo:DDO.owl#DDO_0003471 + DDO:DDO_0003471 + + + + obo:DDO.owl#DDO_0003471 + 10718002 + + + + obo:DDO.owl#DDO_0003471 + juvenile myxedema + + + + obo:DDO.owl#DDO_0003472 + DDO:DDO_0003472 + + + + obo:DDO.owl#DDO_0003472 + 4641009 + + + + obo:DDO.owl#DDO_0003472 + myxedema heart disease + + + + obo:DDO.owl#DDO_0003473 + DDO:DDO_0003473 + + + + obo:DDO.owl#DDO_0003473 + 64491003 + + + + obo:DDO.owl#DDO_0003473 + myxedematous form of cretinism + + + + obo:DDO.owl#DDO_0003474 + DDO:DDO_0003474 + + + + obo:DDO.owl#DDO_0003474 + 82598004 + + + + obo:DDO.owl#DDO_0003474 + secondary hypothyroidism + + + + obo:DDO.owl#DDO_0003475 + DDO:DDO_0003475 + + + + obo:DDO.owl#DDO_0003475 + 237695004 + + + + obo:DDO.owl#DDO_0003475 + idiopathic TSH deficiency + + + + obo:DDO.owl#DDO_0003476 + DDO:DDO_0003476 + + + + obo:DDO.owl#DDO_0003476 + 276630006 + + + + obo:DDO.owl#DDO_0003476 + transient hypothyrotropinemia + + + + obo:DDO.owl#DDO_0003477 + DDO:DDO_0003477 + + + + obo:DDO.owl#DDO_0003477 + 2917005 + + + + obo:DDO.owl#DDO_0003477 + transient hypothyroidism + + + + obo:DDO.owl#DDO_0003478 + DDO:DDO_0003478 + + + + obo:DDO.owl#DDO_0003478 + 276630006 + + + + obo:DDO.owl#DDO_0003478 + transient hypothyrotropinemia + + + + obo:DDO.owl#DDO_0003479 + DDO:DDO_0003479 + + + + obo:DDO.owl#DDO_0003479 + 276566003 + + + + obo:DDO.owl#DDO_0003479 + transient neonatal hypothyroidism + + + + obo:DDO.owl#DDO_0003480 + DDO:DDO_0003480 + + + + obo:DDO.owl#DDO_0003480 + 14304000 + + + + obo:DDO.owl#DDO_0003480 + thyroid disease + + + + obo:DDO.owl#DDO_0003481 + DDO:DDO_0003481 + + + + obo:DDO.owl#DDO_0003481 + 54823002 + + + + obo:DDO.owl#DDO_0003481 + subclinical hypothyroidism + + + + obo:DDO.owl#DDO_0003482 + DDO:DDO_0003482 + + + + obo:DDO.owl#DDO_0003482 + 237567008 + + + + obo:DDO.owl#DDO_0003482 + subclinical iodine deficiency hypothyroidism + + + + obo:DDO.owl#DDO_0003483 + DDO:DDO_0003483 + + + + obo:DDO.owl#DDO_0003483 + 52772002 + + + + obo:DDO.owl#DDO_0003483 + postpartum thyroiditis + + + + obo:DDO.owl#DDO_0003484 + DDO:DDO_0003484 + + + + obo:DDO.owl#DDO_0003484 + 66944004 + + + + obo:DDO.owl#DDO_0003484 + autoimmune thyroiditis + + + + obo:DDO.owl#DDO_0003485 + DDO:DDO_0003485 + + + + obo:DDO.owl#DDO_0003485 + 84362007 + + + + obo:DDO.owl#DDO_0003485 + fibrous autoimmune thyroiditis + + + + obo:DDO.owl#DDO_0003486 + DDO:DDO_0003486 + + + + obo:DDO.owl#DDO_0003486 + 21983002 + + + + obo:DDO.owl#DDO_0003486 + hashimoto thyroiditis + + + + obo:DDO.owl#DDO_0003487 + DDO:DDO_0003487 + + + + obo:DDO.owl#DDO_0003487 + 27538003 + + + + obo:DDO.owl#DDO_0003487 + hyperthyroidism with Hashimoto disease + + + + obo:DDO.owl#DDO_0003488 + DDO:DDO_0003488 + + + + obo:DDO.owl#DDO_0003488 + 237500008 + + + + obo:DDO.owl#DDO_0003488 + hashitoxicosis - transient + + + + obo:DDO.owl#DDO_0003489 + DDO:DDO_0003489 + + + + obo:DDO.owl#DDO_0003489 + 237535005 + + + + obo:DDO.owl#DDO_0003489 + lymphadenoid goiter + + + + obo:DDO.owl#DDO_0003490 + DDO:DDO_0003490 + + + + obo:DDO.owl#DDO_0003490 + 237536006 + + + + obo:DDO.owl#DDO_0003490 + lymphocytic thyroiditis - autoimmune + + + + obo:DDO.owl#DDO_0003491 + DDO:DDO_0003491 + + + + obo:DDO.owl#DDO_0003491 + 361125005 + + + + obo:DDO.owl#DDO_0003491 + subacute autoimmune thyroiditis + + + + obo:DDO.owl#DDO_0003492 + DDO:DDO_0003492 + + + + obo:DDO.owl#DDO_0003492 + 52674009 + + + + obo:DDO.owl#DDO_0003492 + ischemia + + + + obo:DDO.owl#DDO_0003493 + DDO:DDO_0003493 + + + + obo:DDO.owl#DDO_0003493 + 57357009 + + + + obo:DDO.owl#DDO_0003493 + transient ischemia + + + + obo:DDO.owl#DDO_0003494 + DDO:DDO_0003494 + + + + obo:DDO.owl#DDO_0003494 + 75694006 + + + + obo:DDO.owl#DDO_0003494 + pancreatitis + + + + obo:DDO.owl#DDO_0003495 + DDO:DDO_0003495 + + + + obo:DDO.owl#DDO_0003495 + 235494005 + + + + obo:DDO.owl#DDO_0003495 + chronic pancreatitis + + + + obo:DDO.owl#DDO_0003496 + DDO:DDO_0003496 + + + + obo:DDO.owl#DDO_0003496 + 234689009 + + + + obo:DDO.owl#DDO_0003496 + relapsing pancreatitis + + + + obo:DDO.owl#DDO_0003497 + DDO:DDO_0003497 + + + + obo:DDO.owl#DDO_0003497 + 235954001 + + + + obo:DDO.owl#DDO_0003497 + obstructive chronic pancreatitis + + + + obo:DDO.owl#DDO_0003498 + DDO:DDO_0003498 + + + + obo:DDO.owl#DDO_0003498 + 235953007 + + + + obo:DDO.owl#DDO_0003498 + idiopathic chronic pancreatitis + + + + obo:DDO.owl#DDO_0003499 + DDO:DDO_0003499 + + + + obo:DDO.owl#DDO_0003499 + 235951009 + + + + obo:DDO.owl#DDO_0003499 + gallstone chronic pancreatitis + + + + obo:DDO.owl#DDO_0003500 + DDO:DDO_0003500 + + + + obo:DDO.owl#DDO_0003500 + 235956004 + + + + obo:DDO.owl#DDO_0003500 + familial chronic pancreatitis + + + + obo:DDO.owl#DDO_0003501 + DDO:DDO_0003501 + + + + obo:DDO.owl#DDO_0003501 + 74973004 + + + + obo:DDO.owl#DDO_0003501 + chronic fibrosing pancreatitis + + + + obo:DDO.owl#DDO_0003502 + DDO:DDO_0003502 + + + + obo:DDO.owl#DDO_0003502 + 301009006 + + + + obo:DDO.owl#DDO_0003502 + calcific chronic pancreatitis + + + + obo:DDO.owl#DDO_0003503 + DDO:DDO_0003503 + + + + obo:DDO.owl#DDO_0003503 + 240096000 + + + + obo:DDO.owl#DDO_0003503 + mitochondrial cytopathy + + + + obo:DDO.owl#DDO_0003504 + DDO:DDO_0003504 + + + + obo:DDO.owl#DDO_0003504 + 192992007 + + + + obo:DDO.owl#DDO_0003504 + epileptic seizures - myoclonic + + + + obo:DDO.owl#DDO_0003505 + DDO:DDO_0003505 + + + + obo:DDO.owl#DDO_0003505 + 230426003 + + + + obo:DDO.owl#DDO_0003505 + myoclonic epilepsy - ragged red fibers + + + + obo:DDO.owl#DDO_0003506 + DDO:DDO_0003506 + + + + obo:DDO.owl#DDO_0003506 + 37934003 + + + + obo:DDO.owl#DDO_0003506 + mitochondrial-lipid-glycogen storage myopathy + + + + obo:DDO.owl#DDO_0003507 + DDO:DDO_0003507 + + + + obo:DDO.owl#DDO_0003507 + 447292006 + + + + obo:DDO.owl#DDO_0003507 + mitochondrial encephalomyopathy + + + + obo:DDO.owl#DDO_0003508 + DDO:DDO_0003508 + + + + obo:DDO.owl#DDO_0003508 + 472320005 + + + + obo:DDO.owl#DDO_0003508 + maternally inherited mitochondrial cardiomyopathy and myopathy + + + + obo:DDO.owl#DDO_0003509 + DDO:DDO_0003509 + + + + obo:DDO.owl#DDO_0003509 + 39925003 + + + + obo:DDO.owl#DDO_0003509 + juvenile myopathy, encephalopathy, lactic acidosis AND stroke + + + + obo:DDO.owl#DDO_0003510 + DDO:DDO_0003510 + + + + obo:DDO.owl#DDO_0003510 + 4477007 + + + + obo:DDO.owl#DDO_0003510 + juvenile myopathy AND lactate acidosis + + + + obo:DDO.owl#DDO_0003511 + DDO:DDO_0003511 + + + + obo:DDO.owl#DDO_0003511 + 57254004 + + + + obo:DDO.owl#DDO_0003511 + fukuhara syndrome + + + + obo:DDO.owl#DDO_0003512 + DDO:DDO_0003512 + + + + obo:DDO.owl#DDO_0003512 + 16851005 + + + + obo:DDO.owl#DDO_0003512 + mitochondrial myopathy + + + + obo:DDO.owl#DDO_0003513 + DDO:DDO_0003513 + + + + obo:DDO.owl#DDO_0003513 + 133791000119107 + + + + obo:DDO.owl#DDO_0003513 + mitochondrial metabolism defect + + + + obo:DDO.owl#DDO_0003514 + DDO:DDO_0003514 + + + + obo:DDO.owl#DDO_0003514 + 58610003 + + + + obo:DDO.owl#DDO_0003514 + leber's optic atrophy + + + + obo:DDO.owl#DDO_0003515 + DDO:DDO_0003515 + + + + obo:DDO.owl#DDO_0003515 + 25792000 + + + + obo:DDO.owl#DDO_0003515 + kearns-Sayre syndrome + + + + obo:DDO.owl#DDO_0003516 + DDO:DDO_0003516 + + + + obo:DDO.owl#DDO_0003516 + 709414007 + + + + obo:DDO.owl#DDO_0003516 + deficiency of mitochondrial complex III + + + + obo:DDO.owl#DDO_0003517 + DDO:DDO_0003517 + + + + obo:DDO.owl#DDO_0003517 + 67434000 + + + + obo:DDO.owl#DDO_0003517 + cytochrome-c oxidase deficiency + + + + obo:DDO.owl#DDO_0003518 + DDO:DDO_0003518 + + + + obo:DDO.owl#DDO_0003518 + 62522004 + + + + obo:DDO.owl#DDO_0003518 + congenital hyperammonemia, type I + + + + obo:DDO.owl#DDO_0003519 + DDO:DDO_0003519 + + + + obo:DDO.owl#DDO_0003519 + 702366001 + + + + obo:DDO.owl#DDO_0003519 + childhood myocerebrohepatopathy spectrum + + + + obo:DDO.owl#DDO_0003520 + DDO:DDO_0003520 + + + + obo:DDO.owl#DDO_0003520 + 386617003 + + + + obo:DDO.owl#DDO_0003520 + digestive system disease + + + + obo:DDO.owl#DDO_0003521 + DDO:DDO_0003521 + + + + obo:DDO.owl#DDO_0003521 + 76712006 + + + + obo:DDO.owl#DDO_0003521 + disorder of digestive organ + + + + obo:DDO.owl#DDO_0003522 + DDO:DDO_0003522 + + + + obo:DDO.owl#DDO_0003522 + 85919009 + + + + obo:DDO.owl#DDO_0003522 + disorder of intestine + + + + obo:DDO.owl#DDO_0003523 + DDO:DDO_0003523 + + + + obo:DDO.owl#DDO_0003523 + 396331005 + + + + obo:DDO.owl#DDO_0003523 + celiac disease + + + + obo:DDO.owl#DDO_0003524 + DDO:DDO_0003524 + + + + obo:DDO.owl#DDO_0003524 + 197478000 + + + + obo:DDO.owl#DDO_0003524 + congenital celiac disease + + + + obo:DDO.owl#DDO_0003525 + DDO:DDO_0003525 + + + + obo:DDO.owl#DDO_0003525 + 45259000 + + + + obo:DDO.owl#DDO_0003525 + celiac infantilism + + + + obo:DDO.owl#DDO_0003526 + DDO:DDO_0003526 + + + + obo:DDO.owl#DDO_0003526 + 61715008 + + + + obo:DDO.owl#DDO_0003526 + celiac disease with diffuse intestinal ulceration + + + + obo:DDO.owl#DDO_0003527 + DDO:DDO_0003527 + + + + obo:DDO.owl#DDO_0003527 + 396330006 + + + + obo:DDO.owl#DDO_0003527 + celiac crisis + + + + obo:DDO.owl#DDO_0003528 + DDO:DDO_0003528 + + + + obo:DDO.owl#DDO_0003528 + 91867008 + + + + obo:DDO.owl#DDO_0003528 + adult form of celiac disease + + + + obo:DDO.owl#DDO_0003529 + DDO:DDO_0003529 + + + + obo:DDO.owl#DDO_0003529 + 197479008 + + + + obo:DDO.owl#DDO_0003529 + acquired celiac disease + + + + obo:DDO.owl#DDO_0003530 + DDO:DDO_0003530 + + + + obo:DDO.owl#DDO_0003530 + 52448006 + + + + obo:DDO.owl#DDO_0003530 + dementia + + + + obo:DDO.owl#DDO_0003531 + DDO:DDO_0003531 + + + + obo:DDO.owl#DDO_0003531 + 26929004 + + + + obo:DDO.owl#DDO_0003531 + Alzheimer's disease + + + + obo:DDO.owl#DDO_0003532 + DDO:DDO_0003532 + + + + obo:DDO.owl#DDO_0003532 + 88339003 + + + + obo:DDO.owl#DDO_0003532 + dementia arising in the senium AND/OR presenium + + + + obo:DDO.owl#DDO_0003533 + DDO:DDO_0003533 + + + + obo:DDO.owl#DDO_0003533 + 12348006 + + + + obo:DDO.owl#DDO_0003533 + presenile dementia + + + + obo:DDO.owl#DDO_0003534 + DDO:DDO_0003534 + + + + obo:DDO.owl#DDO_0003534 + 15662003 + + + + obo:DDO.owl#DDO_0003534 + senile dementia + + + + obo:DDO.owl#DDO_0003535 + DDO:DDO_0003535 + + + + obo:DDO.owl#DDO_0003535 + 698949001 + + + + obo:DDO.owl#DDO_0003535 + dementia in remission + + + + obo:DDO.owl#DDO_0003536 + DDO:DDO_0003536 + + + + obo:DDO.owl#DDO_0003536 + 9345005 + + + + obo:DDO.owl#DDO_0003536 + dialysis dementia + + + + obo:DDO.owl#DDO_0003537 + DDO:DDO_0003537 + + + + obo:DDO.owl#DDO_0003537 + 51928006 + + + + obo:DDO.owl#DDO_0003537 + general paresis - neurosyphilis + + + + obo:DDO.owl#DDO_0003538 + DDO:DDO_0003538 + + + + obo:DDO.owl#DDO_0003538 + 82959004 + + + + obo:DDO.owl#DDO_0003538 + dementia paralytica juvenilis + + + + obo:DDO.owl#DDO_0003539 + DDO:DDO_0003539 + + + + obo:DDO.owl#DDO_0003539 + 79341000119107 + + + + obo:DDO.owl#DDO_0003539 + mixed dementia + + + + obo:DDO.owl#DDO_0003541 + DDO:DDO_0003541 + + + + obo:DDO.owl#DDO_0003541 + 230289009 + + + + obo:DDO.owl#DDO_0003541 + patchy dementia + + + + obo:DDO.owl#DDO_0003542 + DDO:DDO_0003542 + + + + obo:DDO.owl#DDO_0003542 + 22381000119105 + + + + obo:DDO.owl#DDO_0003542 + primary degenerative dementia + + + + obo:DDO.owl#DDO_0003543 + DDO:DDO_0003543 + + + + obo:DDO.owl#DDO_0003543 + 230288001 + + + + obo:DDO.owl#DDO_0003543 + semantic dementia + + + + obo:DDO.owl#DDO_0003544 + DDO:DDO_0003544 + + + + obo:DDO.owl#DDO_0003544 + 90099008 + + + + obo:DDO.owl#DDO_0003544 + subcortical leukoencephalopathy + + + + obo:DDO.owl#DDO_0003545 + DDO:DDO_0003545 + + + + obo:DDO.owl#DDO_0003545 + 12337004 + + + + obo:DDO.owl#DDO_0003545 + disorder of uterus + + + + obo:DDO.owl#DDO_0003546 + DDO:DDO_0003546 + + + + obo:DDO.owl#DDO_0003546 + 266599000 + + + + obo:DDO.owl#DDO_0003546 + dysmenorrhea + + + + obo:DDO.owl#DDO_0003547 + DDO:DDO_0003547 + + + + obo:DDO.owl#DDO_0003547 + 286993001 + + + + obo:DDO.owl#DDO_0003547 + dysmenorrhea - non-psychogenic + + + + obo:DDO.owl#DDO_0003548 + DDO:DDO_0003548 + + + + obo:DDO.owl#DDO_0003548 + 5268006 + + + + obo:DDO.owl#DDO_0003548 + mechanical dysmenorrhea + + + + obo:DDO.owl#DDO_0003549 + DDO:DDO_0003549 + + + + obo:DDO.owl#DDO_0003549 + 65754002 + + + + obo:DDO.owl#DDO_0003549 + primary dysmenorrhea + + + + obo:DDO.owl#DDO_0003550 + DDO:DDO_0003550 + + + + obo:DDO.owl#DDO_0003550 + 32096006 + + + + obo:DDO.owl#DDO_0003550 + secondary dysmenorrhea + + + + obo:DDO.owl#DDO_0003551 + DDO:DDO_0003551 + + + + obo:DDO.owl#DDO_0003551 + 413838009 + + + + obo:DDO.owl#DDO_0003551 + chronic ischemic heart disease + + + + obo:DDO.owl#DDO_0003552 + DDO:DDO_0003552 + + + + obo:DDO.owl#DDO_0003552 + 413844008 + + + + obo:DDO.owl#DDO_0003552 + chronic myocardial ischemia + + + + obo:DDO.owl#DDO_0003553 + DDO:DDO_0003553 + + + + obo:DDO.owl#DDO_0003553 + 414795007 + + + + obo:DDO.owl#DDO_0003553 + myocardial ischemia + + + + obo:DDO.owl#DDO_0003554 + DDO:DDO_0003554 + + + + obo:DDO.owl#DDO_0003554 + 413444003 + + + + obo:DDO.owl#DDO_0003554 + acute myocardial ischemia + + + + obo:DDO.owl#DDO_0003555 + DDO:DDO_0003555 + + + + obo:DDO.owl#DDO_0003555 + 276517000 + + + + obo:DDO.owl#DDO_0003555 + transient myocardial ischemia of newborn + + + + obo:DDO.owl#DDO_0003556 + DDO:DDO_0003556 + + + + obo:DDO.owl#DDO_0003556 + 413844008 + + + + obo:DDO.owl#DDO_0003556 + chronic myocardial ischemia + + + + obo:DDO.owl#DDO_0003557 + DDO:DDO_0003557 + + + + obo:DDO.owl#DDO_0003557 + 697976003 + + + + obo:DDO.owl#DDO_0003557 + microvascular ischemia of myocardium + + + + obo:DDO.owl#DDO_0003558 + DDO:DDO_0003558 + + + + obo:DDO.owl#DDO_0003558 + 428196007 + + + + obo:DDO.owl#DDO_0003558 + mixed myocardial ischemia and infarction + + + + obo:DDO.owl#DDO_0003559 + DDO:DDO_0003559 + + + + obo:DDO.owl#DDO_0003559 + 276516009 + + + + obo:DDO.owl#DDO_0003559 + myocardial ischemia of newborn + + + + obo:DDO.owl#DDO_0003560 + DDO:DDO_0003560 + + + + obo:DDO.owl#DDO_0003560 + 276517000 + + + + obo:DDO.owl#DDO_0003560 + transient myocardial ischemia of newborn + + + + obo:DDO.owl#DDO_0003562 + DDO:DDO_0003562 + + + + obo:DDO.owl#DDO_0003562 + 233823002 + + + + obo:DDO.owl#DDO_0003562 + silent myocardial ischemia + + + + obo:DDO.owl#DDO_0003563 + DDO:DDO_0003563 + + + + obo:DDO.owl#DDO_0003563 + 46109009 + + + + obo:DDO.owl#DDO_0003563 + subendocardial ischemia + + + + obo:DDO.owl#DDO_0003564 + DDO:DDO_0003564 + + + + obo:DDO.owl#DDO_0003564 + 70422006 + + + + obo:DDO.owl#DDO_0003564 + acute subendocardial infarction + + + + obo:DDO.owl#DDO_0003565 + DDO:DDO_0003565 + + + + obo:DDO.owl#DDO_0003565 + 311796008 + + + + obo:DDO.owl#DDO_0003565 + postoperative subendocardial myocardial infarction + + + + obo:DDO.owl#DDO_0003566 + DDO:DDO_0003566 + + + + obo:DDO.owl#DDO_0003566 + 55342001 + + + + obo:DDO.owl#DDO_0003566 + neoplastic disease + + + + obo:DDO.owl#DDO_0003567 + DDO:DDO_0003567 + + + + obo:DDO.owl#DDO_0003567 + 255046005 + + + + obo:DDO.owl#DDO_0003567 + neuroendocrine tumor + + + + obo:DDO.owl#DDO_0003568 + DDO:DDO_0003568 + + + + obo:DDO.owl#DDO_0003568 + 302822000 + + + + obo:DDO.owl#DDO_0003568 + insulinoma + + + + obo:DDO.owl#DDO_0003569 + DDO:DDO_0003569 + + + + obo:DDO.owl#DDO_0003569 + 58729003 + + + + obo:DDO.owl#DDO_0003569 + microangiopathy + + + + obo:DDO.owl#DDO_0003570 + DDO:DDO_0003570 + + + + obo:DDO.owl#DDO_0003570 + 5050001 + + + + obo:DDO.owl#DDO_0003570 + senile angioma + + + + obo:DDO.owl#DDO_0003571 + DDO:DDO_0003571 + + + + obo:DDO.owl#DDO_0003571 + 234161007 + + + + obo:DDO.owl#DDO_0003571 + familial pulmonary capillary hemangiomatosis + + + + obo:DDO.owl#DDO_0003572 + DDO:DDO_0003572 + + + + obo:DDO.owl#DDO_0003572 + 54538006 + + + + obo:DDO.owl#DDO_0003572 + dietetic microangiopathy + + + + obo:DDO.owl#DDO_0003573 + DDO:DDO_0003573 + + + + obo:DDO.owl#DDO_0003573 + 373420004 + + + + obo:DDO.owl#DDO_0003573 + upshaw-Schulman syndrome + + + + obo:DDO.owl#DDO_0003574 + DDO:DDO_0003574 + + + + obo:DDO.owl#DDO_0003574 + 438476003 + + + + obo:DDO.owl#DDO_0003574 + autoimmune thrombotic thrombocytopenic purpura + + + + obo:DDO.owl#DDO_0003575 + DDO:DDO_0003575 + + + + obo:DDO.owl#DDO_0003575 + 441322009 + + + + obo:DDO.owl#DDO_0003575 + drug induced thrombotic thrombocytopenic purpura + + + + obo:DDO.owl#DDO_0003576 + DDO:DDO_0003576 + + + + obo:DDO.owl#DDO_0003576 + 439007008 + + + + obo:DDO.owl#DDO_0003576 + acquired thrombotic thrombocytopenic purpura + + + + obo:DDO.owl#DDO_0003577 + DDO:DDO_0003577 + + + + obo:DDO.owl#DDO_0003577 + 78129009 + + + + obo:DDO.owl#DDO_0003577 + thrombotic thrombocytopenic purpura + + + + obo:DDO.owl#DDO_0003578 + DDO:DDO_0003578 + + + + obo:DDO.owl#DDO_0003578 + 126729006 + + + + obo:DDO.owl#DDO_0003578 + thrombotic microangiopathy + + + + obo:DDO.owl#DDO_0003579 + DDO:DDO_0003579 + + + + obo:DDO.owl#DDO_0003579 + 402851000 + + + + obo:DDO.owl#DDO_0003579 + neonatal purpura fulminans (homozygous protein C deficiency) + + + + obo:DDO.owl#DDO_0003580 + DDO:DDO_0003580 + + + + obo:DDO.owl#DDO_0003580 + 13507004 + + + + obo:DDO.owl#DDO_0003580 + purpura fulminans + + + + obo:DDO.owl#DDO_0003581 + DDO:DDO_0003581 + + + + obo:DDO.owl#DDO_0003581 + 17810004 + + + + obo:DDO.owl#DDO_0003581 + capillary thrombosis + + + + obo:DDO.owl#DDO_0003582 + DDO:DDO_0003582 + + + + obo:DDO.owl#DDO_0003582 + 254211001 + + + + obo:DDO.owl#DDO_0003582 + salmon patch nevus + + + + obo:DDO.owl#DDO_0003583 + DDO:DDO_0003583 + + + + obo:DDO.owl#DDO_0003583 + 403544009 + + + + obo:DDO.owl#DDO_0003583 + port-wine stain with associated anomalies + + + + obo:DDO.owl#DDO_0003584 + DDO:DDO_0003584 + + + + obo:DDO.owl#DDO_0003584 + 403765001 + + + + obo:DDO.owl#DDO_0003584 + port-wine stain in Rubinstein-Taybi syndrome + + + + obo:DDO.owl#DDO_0003585 + DDO:DDO_0003585 + + + + obo:DDO.owl#DDO_0003585 + 403856000 + + + + obo:DDO.owl#DDO_0003585 + port-wine stain in proteus syndrome + + + + obo:DDO.owl#DDO_0003586 + DDO:DDO_0003586 + + + + obo:DDO.owl#DDO_0003586 + 403560008 + + + + obo:DDO.owl#DDO_0003586 + port-wine stain associated with spinal dysraphism + + + + obo:DDO.owl#DDO_0003587 + DDO:DDO_0003587 + + + + obo:DDO.owl#DDO_0003587 + 40929003 + + + + obo:DDO.owl#DDO_0003587 + nevus anemicus + + + + obo:DDO.owl#DDO_0003588 + DDO:DDO_0003588 + + + + obo:DDO.owl#DDO_0003588 + 703369003 + + + + obo:DDO.owl#DDO_0003588 + microcephaly-capillary malformation syndrome + + + + obo:DDO.owl#DDO_0003589 + DDO:DDO_0003589 + + + + obo:DDO.owl#DDO_0003589 + 703370002 + + + + obo:DDO.owl#DDO_0003589 + megalencephaly-capillary malformation syndrome + + + + obo:DDO.owl#DDO_0003590 + DDO:DDO_0003590 + + + + obo:DDO.owl#DDO_0003590 + 191329002 + + + + obo:DDO.owl#DDO_0003590 + hereditary vascular fragility + + + + obo:DDO.owl#DDO_0003591 + DDO:DDO_0003591 + + + + obo:DDO.owl#DDO_0003591 + 416377005 + + + + obo:DDO.owl#DDO_0003591 + port-wine stain of skin + + + + obo:DDO.owl#DDO_0003592 + DDO:DDO_0003592 + + + + obo:DDO.owl#DDO_0003592 + 703533007 + + + + obo:DDO.owl#DDO_0003592 + capillary malformation-arteriovenous malformation syndrome + + + + obo:DDO.owl#DDO_0003593 + DDO:DDO_0003593 + + + + obo:DDO.owl#DDO_0003593 + 703299009 + + + + obo:DDO.owl#DDO_0003593 + cutaneous capillary malformation + + + + obo:DDO.owl#DDO_0003594 + DDO:DDO_0003594 + + + + obo:DDO.owl#DDO_0003594 + 703197004 + + + + obo:DDO.owl#DDO_0003594 + congenital capillary hemangioma + + + + obo:DDO.owl#DDO_0003595 + DDO:DDO_0003595 + + + + obo:DDO.owl#DDO_0003595 + 234136009 + + + + obo:DDO.owl#DDO_0003595 + capillary-venous-lymphatic malformation + + + + obo:DDO.owl#DDO_0003596 + DDO:DDO_0003596 + + + + obo:DDO.owl#DDO_0003596 + 234133001 + + + + obo:DDO.owl#DDO_0003596 + capillary-venous malformation + + + + obo:DDO.owl#DDO_0003597 + DDO:DDO_0003597 + + + + obo:DDO.owl#DDO_0003597 + 91304009 + + + + obo:DDO.owl#DDO_0003597 + capillary fragility abnormality + + + + obo:DDO.owl#DDO_0003598 + DDO:DDO_0003598 + + + + obo:DDO.owl#DDO_0003598 + 234118009 + + + + obo:DDO.owl#DDO_0003598 + capillary malformation + + + + obo:DDO.owl#DDO_0003599 + DDO:DDO_0003599 + + + + obo:DDO.owl#DDO_0003599 + 87730004 + + + + obo:DDO.owl#DDO_0003599 + capillary leak syndrome + + + + obo:DDO.owl#DDO_0003600 + DDO:DDO_0003600 + + + + obo:DDO.owl#DDO_0003600 + 19472003 + + + + obo:DDO.owl#DDO_0003600 + capillary hyperpermeability + + + + obo:DDO.owl#DDO_0003601 + DDO:DDO_0003601 + + + + obo:DDO.owl#DDO_0003601 + 41486008 + + + + obo:DDO.owl#DDO_0003601 + eczematid-like purpura of Doucas and Kapetanakis + + + + obo:DDO.owl#DDO_0003602 + DDO:DDO_0003602 + + + + obo:DDO.owl#DDO_0003602 + 91304009 + + + + obo:DDO.owl#DDO_0003602 + capillary fragility abnormality + + + + obo:DDO.owl#DDO_0003603 + DDO:DDO_0003603 + + + + obo:DDO.owl#DDO_0003603 + 43696002 + + + + obo:DDO.owl#DDO_0003603 + capillary hemorrhage + + + + obo:DDO.owl#DDO_0003604 + DDO:DDO_0003604 + + + + obo:DDO.owl#DDO_0003604 + 56231002 + + + + obo:DDO.owl#DDO_0003604 + purpura annularis telangiectodes of Majocchi + + + + obo:DDO.owl#DDO_0003605 + DDO:DDO_0003605 + + + + obo:DDO.owl#DDO_0003605 + 707437005 + + + + obo:DDO.owl#DDO_0003605 + pulmonary capillaritis + + + + obo:DDO.owl#DDO_0003606 + DDO:DDO_0003606 + + + + obo:DDO.owl#DDO_0003606 + 238782003 + + + + obo:DDO.owl#DDO_0003606 + lichen aureus + + + + obo:DDO.owl#DDO_0003607 + DDO:DDO_0003607 + + + + obo:DDO.owl#DDO_0003607 + 707436001 + + + + obo:DDO.owl#DDO_0003607 + isolated pulmonary capillaritis + + + + obo:DDO.owl#DDO_0003608 + DDO:DDO_0003608 + + + + obo:DDO.owl#DDO_0003608 + 64146000 + + + + obo:DDO.owl#DDO_0003608 + progressive pigmentary dermatosis of Schamberg + + + + obo:DDO.owl#DDO_0003609 + DDO:DDO_0003609 + + + + obo:DDO.owl#DDO_0003609 + 20343006 + + + + obo:DDO.owl#DDO_0003609 + pigmented purpuric lichenoid dermatitis of Gougerot and Blum + + + + obo:DDO.owl#DDO_0003610 + DDO:DDO_0003610 + + + + obo:DDO.owl#DDO_0003610 + 238781005 + + + + obo:DDO.owl#DDO_0003610 + itching purpura + + + + obo:DDO.owl#DDO_0003611 + DDO:DDO_0003611 + + + + obo:DDO.owl#DDO_0003611 + 41486008 + + + + obo:DDO.owl#DDO_0003611 + eczematid-like purpura of Doucas and Kapetanakis + + + + obo:DDO.owl#DDO_0003612 + DDO:DDO_0003612 + + + + obo:DDO.owl#DDO_0003612 + 238780006 + + + + obo:DDO.owl#DDO_0003612 + idiopathic capillaritis + + + + obo:DDO.owl#DDO_0003613 + DDO:DDO_0003613 + + + + obo:DDO.owl#DDO_0003613 + 238783008 + + + + obo:DDO.owl#DDO_0003613 + familial pigmented purpuric eruption + + + + obo:DDO.owl#DDO_0003614 + DDO:DDO_0003614 + + + + obo:DDO.owl#DDO_0003614 + 197712008 + + + + obo:DDO.owl#DDO_0003614 + chronic nephritic syndrome, diffuse endocapillary proliferative glomerulonephritis + + + + obo:DDO.owl#DDO_0003615 + DDO:DDO_0003615 + + + + obo:DDO.owl#DDO_0003615 + 402746001 + + + + obo:DDO.owl#DDO_0003615 + capillaritis due to drug + + + + obo:DDO.owl#DDO_0003616 + DDO:DDO_0003616 + + + + obo:DDO.owl#DDO_0003616 + 85461008 + + + + obo:DDO.owl#DDO_0003616 + capillaritis + + + + obo:DDO.owl#DDO_0003617 + DDO:DDO_0003617 + + + + obo:DDO.owl#DDO_0003617 + 72092001 + + + + obo:DDO.owl#DDO_0003617 + arteriosclerotic vascular disease + + + + obo:DDO.owl#DDO_0003618 + DDO:DDO_0003618 + + + + obo:DDO.owl#DDO_0003618 + 441574008 + + + + obo:DDO.owl#DDO_0003618 + atherosclerosis of artery + + + + obo:DDO.owl#DDO_0003619 + DDO:DDO_0003619 + + + + obo:DDO.owl#DDO_0003619 + 39823006 + + + + obo:DDO.owl#DDO_0003619 + generalized atherosclerosis + + + + obo:DDO.owl#DDO_0003620 + DDO:DDO_0003620 + + + + obo:DDO.owl#DDO_0003620 + 46152009 + + + + obo:DDO.owl#DDO_0003620 + dry eye syndrome + + + + obo:DDO.owl#DDO_0003620 + tear film insufficiency + + + + obo:DDO.owl#DDO_0003621 + DDO:DDO_0003621 + + + + obo:DDO.owl#DDO_0003621 + 417123005 + + + + obo:DDO.owl#DDO_0003621 + mucin tear deficiency + + + + obo:DDO.owl#DDO_0003622 + DDO:DDO_0003622 + + + + obo:DDO.owl#DDO_0003622 + 416538006 + + + + obo:DDO.owl#DDO_0003622 + lipid tear deficiency + + + + obo:DDO.owl#DDO_0003623 + DDO:DDO_0003623 + + + + obo:DDO.owl#DDO_0003623 + 414062007 + + + + obo:DDO.owl#DDO_0003623 + dry eye after laser in situ keratomileusis + + + + obo:DDO.owl#DDO_0003624 + DDO:DDO_0003624 + + + + obo:DDO.owl#DDO_0003624 + 397528003 + + + + obo:DDO.owl#DDO_0003624 + aqueous tear deficiency + + + + obo:DDO.owl#DDO_0003625 + DDO:DDO_0003625 + + + + obo:DDO.owl#DDO_0003625 + 319171004 + + + + obo:DDO.owl#DDO_0003625 + qualitative abnormality of granulocyte + + + + obo:DDO.owl#DDO_0003626 + DDO:DDO_0003626 + + + + obo:DDO.owl#DDO_0003626 + 40145002 + + + + obo:DDO.owl#DDO_0003626 + congenital neutrophil actin dysfunction + + + + obo:DDO.owl#DDO_0003626 + granulocyte anomaly + + + + obo:DDO.owl#DDO_0003627 + DDO:DDO_0003627 + + + + obo:DDO.owl#DDO_0003627 + 127345001 + + + + obo:DDO.owl#DDO_0003627 + disorder of endocrine gonad + + + + obo:DDO.owl#DDO_0003628 + DDO:DDO_0003628 + + + + obo:DDO.owl#DDO_0003628 + 48130008 + + + + obo:DDO.owl#DDO_0003628 + hypogonadism + + + + obo:DDO.owl#DDO_0003629 + DDO:DDO_0003629 + + + + obo:DDO.owl#DDO_0003629 + 370997001 + + + + obo:DDO.owl#DDO_0003629 + primary testicular failure + + + + obo:DDO.owl#DDO_0003630 + DDO:DDO_0003630 + + + + obo:DDO.owl#DDO_0003630 + 80956002 + + + + obo:DDO.owl#DDO_0003630 + resistant ovary syndrome + + + + obo:DDO.owl#DDO_0003631 + DDO:DDO_0003631 + + + + obo:DDO.owl#DDO_0003631 + 237138004 + + + + obo:DDO.owl#DDO_0003631 + premature ovarian failure + + + + obo:DDO.owl#DDO_0003632 + DDO:DDO_0003632 + + + + obo:DDO.owl#DDO_0003632 + 95198001 + + + + obo:DDO.owl#DDO_0003632 + pure gonadal dysgenesis 46,XX + + + + obo:DDO.owl#DDO_0003633 + DDO:DDO_0003633 + + + + obo:DDO.owl#DDO_0003633 + 205683001 + + + + obo:DDO.owl#DDO_0003633 + ovarian dysgenesis + + + + obo:DDO.owl#DDO_0003634 + DDO:DDO_0003634 + + + + obo:DDO.owl#DDO_0003634 + 237138004 + + + + obo:DDO.owl#DDO_0003634 + menopause ovarian failure + + + + obo:DDO.owl#DDO_0003635 + DDO:DDO_0003635 + + + + obo:DDO.owl#DDO_0003635 + 237790001 + + + + obo:DDO.owl#DDO_0003635 + autoimmune primary ovarian failure + + + + obo:DDO.owl#DDO_0003636 + DDO:DDO_0003636 + + + + obo:DDO.owl#DDO_0003636 + 65846009 + + + + obo:DDO.owl#DDO_0003636 + primary ovarian failure + + + + obo:DDO.owl#DDO_0003637 + DDO:DDO_0003637 + + + + obo:DDO.owl#DDO_0003637 + 370999003 + + + + obo:DDO.owl#DDO_0003637 + primary hypogonadism + + + + obo:DDO.owl#DDO_0003638 + DDO:DDO_0003638 + + + + obo:DDO.owl#DDO_0003638 + 267402007 + + + + obo:DDO.owl#DDO_0003638 + testicular hypofunction due to defect in adrenocortical hormone synthesis + + + + obo:DDO.owl#DDO_0003639 + DDO:DDO_0003639 + + + + obo:DDO.owl#DDO_0003639 + 370997001 + + + + obo:DDO.owl#DDO_0003639 + primary testicular failure + + + + obo:DDO.owl#DDO_0003640 + DDO:DDO_0003640 + + + + obo:DDO.owl#DDO_0003640 + 20615009 + + + + obo:DDO.owl#DDO_0003640 + postirradiation testicular hypofunction + + + + obo:DDO.owl#DDO_0003641 + DDO:DDO_0003641 + + + + obo:DDO.owl#DDO_0003641 + 236813004 + + + + obo:DDO.owl#DDO_0003641 + post-chemotherapy testicular hypofunction + + + + obo:DDO.owl#DDO_0003642 + DDO:DDO_0003642 + + + + obo:DDO.owl#DDO_0003642 + 190552005 + + + + obo:DDO.owl#DDO_0003642 + postablative testicular hypofunction + + + + obo:DDO.owl#DDO_0003643 + DDO:DDO_0003643 + + + + obo:DDO.owl#DDO_0003643 + 20615009 + + + + obo:DDO.owl#DDO_0003643 + postirradiation testicular hypofunction + + + + obo:DDO.owl#DDO_0003644 + DDO:DDO_0003644 + + + + obo:DDO.owl#DDO_0003644 + 236813004 + + + + obo:DDO.owl#DDO_0003644 + post-chemotherapy testicular hypofunction + + + + obo:DDO.owl#DDO_0003645 + DDO:DDO_0003645 + + + + obo:DDO.owl#DDO_0003645 + 236814005 + + + + obo:DDO.owl#DDO_0003645 + cytotoxic drug-induced hypospermatogenesis + + + + obo:DDO.owl#DDO_0003646 + DDO:DDO_0003646 + + + + obo:DDO.owl#DDO_0003646 + 66957007 + + + + obo:DDO.owl#DDO_0003646 + iatrogenic testicular hypofunction + + + + obo:DDO.owl#DDO_0003647 + DDO:DDO_0003647 + + + + obo:DDO.owl#DDO_0003647 + 82560004 + + + + obo:DDO.owl#DDO_0003647 + leydig cell failure in adult + + + + obo:DDO.owl#DDO_0003648 + DDO:DDO_0003648 + + + + obo:DDO.owl#DDO_0003648 + 38825009 + + + + obo:DDO.owl#DDO_0003648 + deficiency of testosterone biosynthesis + + + + obo:DDO.owl#DDO_0003649 + DDO:DDO_0003649 + + + + obo:DDO.owl#DDO_0003649 + 111551000 + + + + obo:DDO.owl#DDO_0003649 + testicular hypofunction + + + + obo:DDO.owl#DDO_0003650 + DDO:DDO_0003650 + + + + obo:DDO.owl#DDO_0003650 + 129634000 + + + + obo:DDO.owl#DDO_0003650 + induced male hypogonadism syndrome + + + + obo:DDO.owl#DDO_0003651 + DDO:DDO_0003651 + + + + obo:DDO.owl#DDO_0003651 + 236796004 + + + + obo:DDO.owl#DDO_0003651 + hypogonadism with prune belly syndrome + + + + obo:DDO.owl#DDO_0003652 + DDO:DDO_0003652 + + + + obo:DDO.owl#DDO_0003652 + 2041006 + + + + obo:DDO.owl#DDO_0003652 + eunuchoid gigantism + + + + obo:DDO.owl#DDO_0003653 + DDO:DDO_0003653 + + + + obo:DDO.owl#DDO_0003653 + 236811002 + + + + obo:DDO.owl#DDO_0003653 + acquired testicular failure + + + + obo:DDO.owl#DDO_0003654 + DDO:DDO_0003654 + + + + obo:DDO.owl#DDO_0003654 + 48723006 + + + + obo:DDO.owl#DDO_0003654 + male hypogonadism + + + + obo:DDO.owl#DDO_0003655 + DDO:DDO_0003655 + + + + obo:DDO.owl#DDO_0003655 + 59892004 + + + + obo:DDO.owl#DDO_0003655 + infantilism + + + + obo:DDO.owl#DDO_0003656 + DDO:DDO_0003656 + + + + obo:DDO.owl#DDO_0003656 + 45259000 + + + + obo:DDO.owl#DDO_0003656 + celiac infantilism + + + + obo:DDO.owl#DDO_0003658 + DDO:DDO_0003658 + + + + obo:DDO.owl#DDO_0003658 + 197478000 + + + + obo:DDO.owl#DDO_0003658 + congenital celiac disease + + + + obo:DDO.owl#DDO_0003659 + DDO:DDO_0003659 + + + + obo:DDO.owl#DDO_0003659 + 33927004 + + + + obo:DDO.owl#DDO_0003659 + hypogonadotropic hypogonadism + + + + obo:DDO.owl#DDO_0003660 + DDO:DDO_0003660 + + + + obo:DDO.owl#DDO_0003660 + 62999006 + + + + obo:DDO.owl#DDO_0003660 + adiposogenital dystrophy + + + + obo:DDO.owl#DDO_0003661 + DDO:DDO_0003661 + + + + obo:DDO.owl#DDO_0003661 + 5036006 + + + + obo:DDO.owl#DDO_0003661 + hypogonadal obesity + + + + obo:DDO.owl#DDO_0003662 + DDO:DDO_0003662 + + + + obo:DDO.owl#DDO_0003662 + 286918006 + + + + obo:DDO.owl#DDO_0003662 + gonad postablative failure + + + + obo:DDO.owl#DDO_0003663 + DDO:DDO_0003663 + + + + obo:DDO.owl#DDO_0003663 + 388983002 + + + + obo:DDO.owl#DDO_0003663 + paronychia of toe + + + + obo:DDO.owl#DDO_0003664 + DDO:DDO_0003664 + + + + obo:DDO.owl#DDO_0003664 + 10628471000119103 + + + + obo:DDO.owl#DDO_0003664 + paronychia of thumb + + + + obo:DDO.owl#DDO_0003665 + DDO:DDO_0003665 + + + + obo:DDO.owl#DDO_0003665 + 444646006 + + + + obo:DDO.owl#DDO_0003665 + paronychia of finger + + + + obo:DDO.owl#DDO_0003666 + DDO:DDO_0003666 + + + + obo:DDO.owl#DDO_0003666 + 200744008 + + + + obo:DDO.owl#DDO_0003666 + chronic paronychia + + + + obo:DDO.owl#DDO_0003667 + DDO:DDO_0003667 + + + + obo:DDO.owl#DDO_0003667 + 187017007 + + + + obo:DDO.owl#DDO_0003667 + candidal paronychia + + + + obo:DDO.owl#DDO_0003668 + DDO:DDO_0003668 + + + + obo:DDO.owl#DDO_0003668 + 238388002 + + + + obo:DDO.owl#DDO_0003668 + pseudomonas aeruginosa paronychia + + + + obo:DDO.owl#DDO_0003669 + DDO:DDO_0003669 + + + + obo:DDO.owl#DDO_0003669 + 402931003 + + + + obo:DDO.owl#DDO_0003669 + neonatal bacterial paronychia + + + + obo:DDO.owl#DDO_0003670 + DDO:DDO_0003670 + + + + obo:DDO.owl#DDO_0003670 + 402930002 + + + + obo:DDO.owl#DDO_0003670 + acute bacterial paronychia + + + + obo:DDO.owl#DDO_0003671 + DDO:DDO_0003671 + + + + obo:DDO.owl#DDO_0003671 + 247517004 + + + + obo:DDO.owl#DDO_0003671 + bacterial paronychia + + + + obo:DDO.owl#DDO_0003672 + DDO:DDO_0003672 + + + + obo:DDO.owl#DDO_0003672 + 71906005 + + + + obo:DDO.owl#DDO_0003672 + paronychia + + + + obo:DDO.owl#DDO_0003673 + DDO:DDO_0003673 + + + + obo:DDO.owl#DDO_0003673 + 90241004 + + + + obo:DDO.owl#DDO_0003673 + papillary necrosis + + + + obo:DDO.owl#DDO_0003674 + DDO:DDO_0003674 + + + + obo:DDO.owl#DDO_0003674 + 236438002 + + + + obo:DDO.owl#DDO_0003674 + calcific papillary necrosis + + + + obo:DDO.owl#DDO_0003675 + DDO:DDO_0003675 + + + + obo:DDO.owl#DDO_0003675 + 14343001 + + + + obo:DDO.owl#DDO_0003675 + acute pyelitis with renal medullary necrosis + + + + obo:DDO.owl#DDO_0003676 + DDO:DDO_0003676 + + + + obo:DDO.owl#DDO_0003676 + 298015003 + + + + obo:DDO.owl#DDO_0003676 + acute renal papillary necrosis with renal failure + + + + obo:DDO.owl#DDO_0003677 + DDO:DDO_0003677 + + + + obo:DDO.owl#DDO_0003677 + 270494003 + + + + obo:DDO.owl#DDO_0003677 + acute papillary necrosis + + + + obo:DDO.owl#DDO_0003678 + DDO:DDO_0003678 + + + + obo:DDO.owl#DDO_0003678 + 128524007 + + + + obo:DDO.owl#DDO_0003678 + disorder of colon + + + + obo:DDO.owl#DDO_0003679 + DDO:DDO_0003679 + + + + obo:DDO.owl#DDO_0003679 + 14760008 + + + + obo:DDO.owl#DDO_0003679 + constipation + + + + obo:DDO.owl#DDO_0003680 + DDO:DDO_0003680 + + + + obo:DDO.owl#DDO_0003680 + 197119006 + + + + obo:DDO.owl#DDO_0003680 + acute constipation + + + + obo:DDO.owl#DDO_0003681 + DDO:DDO_0003681 + + + + obo:DDO.owl#DDO_0003681 + 432414001 + + + + obo:DDO.owl#DDO_0003681 + atonic constipation + + + + obo:DDO.owl#DDO_0003682 + DDO:DDO_0003682 + + + + obo:DDO.owl#DDO_0003682 + 236069009 + + + + obo:DDO.owl#DDO_0003682 + chronic constipation + + + + obo:DDO.owl#DDO_0003683 + DDO:DDO_0003683 + + + + obo:DDO.owl#DDO_0003683 + 82934008 + + + + obo:DDO.owl#DDO_0003683 + chronic idiopathic constipation + + + + obo:DDO.owl#DDO_0003684 + DDO:DDO_0003684 + + + + obo:DDO.owl#DDO_0003684 + 197118003 + + + + obo:DDO.owl#DDO_0003684 + constipation - functional + + + + obo:DDO.owl#DDO_0003685 + DDO:DDO_0003685 + + + + obo:DDO.owl#DDO_0003685 + 249517009 + + + + obo:DDO.owl#DDO_0003685 + constipation alternates with diarrhea + + + + obo:DDO.owl#DDO_0003686 + DDO:DDO_0003686 + + + + obo:DDO.owl#DDO_0003686 + 111360009 + + + + obo:DDO.owl#DDO_0003686 + obstipation + + + + obo:DDO.owl#DDO_0003687 + DDO:DDO_0003687 + + + + obo:DDO.owl#DDO_0003687 + 129585003 + + + + obo:DDO.owl#DDO_0003687 + perceived constipation + + + + obo:DDO.owl#DDO_0003688 + DDO:DDO_0003688 + + + + obo:DDO.owl#DDO_0003688 + 236070005 + + + + obo:DDO.owl#DDO_0003688 + simple constipation + + + + obo:DDO.owl#DDO_0003689 + DDO:DDO_0003689 + + + + obo:DDO.owl#DDO_0003689 + 35298007 + + + + obo:DDO.owl#DDO_0003689 + slow transit constipation + + + + obo:DDO.owl#DDO_0003690 + DDO:DDO_0003690 + + + + obo:DDO.owl#DDO_0003690 + 397825006 + + + + obo:DDO.owl#DDO_0003690 + gastric ulcer + + + + obo:DDO.owl#DDO_0003691 + DDO:DDO_0003691 + + + + obo:DDO.owl#DDO_0003691 + 95529005 + + + + obo:DDO.owl#DDO_0003691 + acute gastric ulcer + + + + obo:DDO.owl#DDO_0003692 + DDO:DDO_0003692 + + + + obo:DDO.owl#DDO_0003692 + 415624002 + + + + obo:DDO.owl#DDO_0003692 + stress ulcer of stomach + + + + obo:DDO.owl#DDO_0003693 + DDO:DDO_0003693 + + + + obo:DDO.owl#DDO_0003693 + 308882008 + + + + obo:DDO.owl#DDO_0003693 + bleeding stress ulcer of stomach + + + + obo:DDO.owl#DDO_0003694 + DDO:DDO_0003694 + + + + obo:DDO.owl#DDO_0003694 + 4911000119101 + + + + obo:DDO.owl#DDO_0003694 + antral ulcer + + + + obo:DDO.owl#DDO_0003695 + DDO:DDO_0003695 + + + + obo:DDO.owl#DDO_0003695 + 95530000 + + + + obo:DDO.owl#DDO_0003695 + chronic gastric ulcer + + + + obo:DDO.owl#DDO_0003696 + DDO:DDO_0003696 + + + + obo:DDO.owl#DDO_0003696 + 128288009 + + + + obo:DDO.owl#DDO_0003696 + chronic gastrojejunal ulcer + + + + obo:DDO.owl#DDO_0003697 + DDO:DDO_0003697 + + + + obo:DDO.owl#DDO_0003697 + 1086791000119100 + + + + obo:DDO.owl#DDO_0003697 + erosive gastritis + + + + obo:DDO.owl#DDO_0003698 + DDO:DDO_0003698 + + + + obo:DDO.owl#DDO_0003698 + 444926003 + + + + obo:DDO.owl#DDO_0003698 + acute erosive gastritis + + + + obo:DDO.owl#DDO_0003699 + DDO:DDO_0003699 + + + + obo:DDO.owl#DDO_0003699 + 109814008 + + + + obo:DDO.owl#DDO_0003699 + acute ulcerative gastroenteritis complicating pneumonia + + + + obo:DDO.owl#DDO_0003700 + DDO:DDO_0003700 + + + + obo:DDO.owl#DDO_0003700 + 63137003 + + + + obo:DDO.owl#DDO_0003700 + chronic erosive gastritis + + + + obo:DDO.owl#DDO_0003701 + DDO:DDO_0003701 + + + + obo:DDO.owl#DDO_0003701 + 10699001 + + + + obo:DDO.owl#DDO_0003701 + esophagogastric ulcer + + + + obo:DDO.owl#DDO_0003702 + DDO:DDO_0003702 + + + + obo:DDO.owl#DDO_0003702 + 235651006 + + + + obo:DDO.owl#DDO_0003702 + gastric erosion + + + + obo:DDO.owl#DDO_0003703 + DDO:DDO_0003703 + + + + obo:DDO.owl#DDO_0003703 + 18665000 + + + + obo:DDO.owl#DDO_0003703 + acute gastric mucosal erosion + + + + obo:DDO.owl#DDO_0003704 + DDO:DDO_0003704 + + + + obo:DDO.owl#DDO_0003704 + 307233002 + + + + obo:DDO.owl#DDO_0003704 + bleeding gastric erosion + + + + obo:DDO.owl#DDO_0003705 + DDO:DDO_0003705 + + + + obo:DDO.owl#DDO_0003705 + 301007008 + + + + obo:DDO.owl#DDO_0003705 + gastroesophageal erosion + + + + obo:DDO.owl#DDO_0003706 + DDO:DDO_0003706 + + + + obo:DDO.owl#DDO_0003706 + 235652004 + + + + obo:DDO.owl#DDO_0003706 + multiple gastric erosions + + + + obo:DDO.owl#DDO_0003707 + DDO:DDO_0003707 + + + + obo:DDO.owl#DDO_0003707 + 24060004 + + + + obo:DDO.owl#DDO_0003707 + gastrocolic ulcer + + + + obo:DDO.owl#DDO_0003708 + DDO:DDO_0003708 + + + + obo:DDO.owl#DDO_0003708 + 16121001 + + + + obo:DDO.owl#DDO_0003708 + gastrojejunal ulcer + + + + obo:DDO.owl#DDO_0003709 + DDO:DDO_0003709 + + + + obo:DDO.owl#DDO_0003709 + 235702004 + + + + obo:DDO.owl#DDO_0003709 + healed gastric ulcer + + + + obo:DDO.owl#DDO_0003710 + DDO:DDO_0003710 + + + + obo:DDO.owl#DDO_0003710 + 196775009 + + + + obo:DDO.owl#DDO_0003710 + healed gastric ulcer leaving a scar + + + + obo:DDO.owl#DDO_0003711 + DDO:DDO_0003711 + + + + obo:DDO.owl#DDO_0003711 + 22620000 + + + + obo:DDO.owl#DDO_0003711 + prepyloric ulcer + + + + obo:DDO.owl#DDO_0003712 + DDO:DDO_0003712 + + + + obo:DDO.owl#DDO_0003712 + 39204006 + + + + obo:DDO.owl#DDO_0003712 + pyloric ulcer + + + + obo:DDO.owl#DDO_0003713 + DDO:DDO_0003713 + + + + obo:DDO.owl#DDO_0003713 + 89662003 + + + + obo:DDO.owl#DDO_0003713 + helicobacter-associated pyloric ulcer + + + + obo:DDO.owl#DDO_0003714 + DDO:DDO_0003714 + + + + obo:DDO.owl#DDO_0003714 + 53132006 + + + + obo:DDO.owl#DDO_0003714 + Zollinger-Ellison syndrome + + + + obo:DDO.owl#DDO_0003715 + DDO:DDO_0003715 + + + + obo:DDO.owl#DDO_0003715 + peptic ulcer + + + + obo:DDO.owl#DDO_0003716 + DDO:DDO_0003716 + + + + obo:DDO.owl#DDO_0003716 + 196682000 + + + + obo:DDO.owl#DDO_0003716 + acute peptic ulcer + + + + obo:DDO.owl#DDO_0003717 + DDO:DDO_0003717 + + + + obo:DDO.owl#DDO_0003717 + 128287004 + + + + obo:DDO.owl#DDO_0003717 + chronic peptic ulcer + + + + obo:DDO.owl#DDO_0003718 + DDO:DDO_0003718 + + + + obo:DDO.owl#DDO_0003718 + 23649000 + + + + obo:DDO.owl#DDO_0003718 + Cushing's ulcers + + + + obo:DDO.owl#DDO_0003719 + DDO:DDO_0003719 + + + + obo:DDO.owl#DDO_0003719 + 44462005 + + + + obo:DDO.owl#DDO_0003719 + osteitis + + + + obo:DDO.owl#DDO_0003720 + DDO:DDO_0003720 + + + + obo:DDO.owl#DDO_0003720 + 94146005 + + + + obo:DDO.owl#DDO_0003720 + malignant otitis externa + + + + obo:DDO.owl#DDO_0003721 + DDO:DDO_0003721 + + + + obo:DDO.owl#DDO_0003721 + 232229004 + + + + obo:DDO.owl#DDO_0003721 + granulomatous otitis externa + + + + obo:DDO.owl#DDO_0003722 + DDO:DDO_0003722 + + + + obo:DDO.owl#DDO_0003722 + 232227002 + + + + obo:DDO.owl#DDO_0003722 + invasive otitis externa + + + + obo:DDO.owl#DDO_0003723 + DDO:DDO_0003723 + + + + obo:DDO.owl#DDO_0003723 + 232230009 + + + + obo:DDO.owl#DDO_0003723 + malignant otitis externa due to Pseudomonas aeruginosa + + + + obo:DDO.owl#DDO_0003724 + DDO:DDO_0003724 + + + + obo:DDO.owl#DDO_0003724 + 52845002 + + + + obo:DDO.owl#DDO_0003724 + nephritis + + + + obo:DDO.owl#DDO_0003725 + DDO:DDO_0003725 + + + + obo:DDO.owl#DDO_0003725 + 61503006 + + + + obo:DDO.owl#DDO_0003725 + acute nephritis + + + + obo:DDO.owl#DDO_0003726 + DDO:DDO_0003726 + + + + obo:DDO.owl#DDO_0003726 + 197585004 + + + + obo:DDO.owl#DDO_0003726 + acute diffuse nephritis + + + + obo:DDO.owl#DDO_0003727 + DDO:DDO_0003727 + + + + obo:DDO.owl#DDO_0003727 + 197584000 + + + + obo:DDO.owl#DDO_0003727 + acute focal nephritis + + + + obo:DDO.owl#DDO_0003728 + DDO:DDO_0003728 + + + + obo:DDO.owl#DDO_0003728 + 19351000 + + + + obo:DDO.owl#DDO_0003728 + acute glomerulonephritis + + + + obo:DDO.owl#DDO_0003729 + DDO:DDO_0003729 + + + + obo:DDO.owl#DDO_0003729 + 197582001 + + + + obo:DDO.owl#DDO_0003729 + acute glomerulonephritis associated with another disorder + + + + obo:DDO.owl#DDO_0003730 + DDO:DDO_0003730 + + + + obo:DDO.owl#DDO_0003730 + 68544003 + + + + obo:DDO.owl#DDO_0003730 + acute post-streptococcal glomerulonephritis + + + + obo:DDO.owl#DDO_0003731 + DDO:DDO_0003731 + + + + obo:DDO.owl#DDO_0003731 + 197580009 + + + + obo:DDO.owl#DDO_0003731 + acute nephritis with lesions of necrotizing glomerulitis + + + + obo:DDO.owl#DDO_0003732 + DDO:DDO_0003732 + + + + obo:DDO.owl#DDO_0003732 + 276585000 + + + + obo:DDO.owl#DDO_0003732 + congenital nephritis + + + + obo:DDO.owl#DDO_0003733 + DDO:DDO_0003733 + + + + obo:DDO.owl#DDO_0003733 + 7011000119105 + + + + obo:DDO.owl#DDO_0003733 + exudative nephritis + + + + obo:DDO.owl#DDO_0003734 + DDO:DDO_0003734 + + + + obo:DDO.owl#DDO_0003734 + 197583006 + + + + obo:DDO.owl#DDO_0003734 + acute exudative nephritis + + + + obo:DDO.owl#DDO_0003736 + DDO:DDO_0003736 + + + + obo:DDO.owl#DDO_0003736 + 28689008 + + + + obo:DDO.owl#DDO_0003736 + interstitial nephritis + + + + obo:DDO.owl#DDO_0003737 + DDO:DDO_0003737 + + + + obo:DDO.owl#DDO_0003737 + 28637003 + + + + obo:DDO.owl#DDO_0003737 + acute interstitial nephritis + + + + obo:DDO.owl#DDO_0003738 + DDO:DDO_0003738 + + + + obo:DDO.owl#DDO_0003738 + 60926001 + + + + obo:DDO.owl#DDO_0003738 + chronic interstitial nephritis + + + + obo:DDO.owl#DDO_0003739 + DDO:DDO_0003739 + + + + obo:DDO.owl#DDO_0003739 + 702718005 + + + + obo:DDO.owl#DDO_0003739 + acute on chronic interstitial nephritis + + + + obo:DDO.owl#DDO_0003740 + DDO:DDO_0003740 + + + + obo:DDO.owl#DDO_0003740 + 26121002 + + + + obo:DDO.owl#DDO_0003740 + Balkan nephropathy + + + + obo:DDO.owl#DDO_0003741 + DDO:DDO_0003741 + + + + obo:DDO.owl#DDO_0003741 + 32093003 + + + + obo:DDO.owl#DDO_0003741 + acute drug-induced tubulointerstitial nephritis + + + + obo:DDO.owl#DDO_0003742 + DDO:DDO_0003742 + + + + obo:DDO.owl#DDO_0003742 + 66993009 + + + + obo:DDO.owl#DDO_0003742 + acute infectious tubulointerstitial nephritis + + + + obo:DDO.owl#DDO_0003743 + DDO:DDO_0003743 + + + + obo:DDO.owl#DDO_0003743 + 22352007 + + + + obo:DDO.owl#DDO_0003743 + acute bacterial tubulointerstitial nephritis + + + + obo:DDO.owl#DDO_0003744 + DDO:DDO_0003744 + + + + obo:DDO.owl#DDO_0003744 + 91195006 + + + + obo:DDO.owl#DDO_0003744 + acute fungal tubulointerstitial nephritis + + + + obo:DDO.owl#DDO_0003745 + DDO:DDO_0003745 + + + + obo:DDO.owl#DDO_0003745 + 16751003 + + + + obo:DDO.owl#DDO_0003745 + acute tubulointerstitial nephritis associated with systemic infection + + + + obo:DDO.owl#DDO_0003746 + DDO:DDO_0003746 + + + + obo:DDO.owl#DDO_0003746 + 27810000 + + + + obo:DDO.owl#DDO_0003746 + acute viral tubulointerstitial nephritis + + + + obo:DDO.owl#DDO_0003747 + DDO:DDO_0003747 + + + + obo:DDO.owl#DDO_0003747 + 702718005 + + + + obo:DDO.owl#DDO_0003747 + acute on chronic interstitial nephritis + + + + obo:DDO.owl#DDO_0003748 + DDO:DDO_0003748 + + + + obo:DDO.owl#DDO_0003748 + 47330001 + + + + obo:DDO.owl#DDO_0003748 + idiopathic acute interstitial nephritis + + + + obo:DDO.owl#DDO_0003749 + DDO:DDO_0003749 + + + + obo:DDO.owl#DDO_0003749 + 236451007 + + + + obo:DDO.owl#DDO_0003749 + renal ocular syndrome + + + + obo:DDO.owl#DDO_0003750 + DDO:DDO_0003750 + + + + obo:DDO.owl#DDO_0003750 + 418839003 + + + + obo:DDO.owl#DDO_0003750 + tubulointerstitial nephritis with uveitis syndrome + + + + obo:DDO.owl#DDO_0003751 + DDO:DDO_0003751 + + + + obo:DDO.owl#DDO_0003751 + 236452000 + + + + obo:DDO.owl#DDO_0003751 + chronic drug-induced tubulointerstitial nephritis + + + + obo:DDO.owl#DDO_0003752 + DDO:DDO_0003752 + + + + obo:DDO.owl#DDO_0003752 + 59400006 + + + + obo:DDO.owl#DDO_0003752 + analgesic nephropathy + + + + obo:DDO.owl#DDO_0003753 + DDO:DDO_0003753 + + + + obo:DDO.owl#DDO_0003753 + 236374007 + + + + obo:DDO.owl#DDO_0003753 + chronic infective interstitial nephritis + + + + obo:DDO.owl#DDO_0003754 + DDO:DDO_0003754 + + + + obo:DDO.owl#DDO_0003754 + 236453005 + + + + obo:DDO.owl#DDO_0003754 + chronic interstitial nephritis due to heavy metals + + + + obo:DDO.owl#DDO_0003755 + DDO:DDO_0003755 + + + + obo:DDO.owl#DDO_0003755 + 236456002 + + + + obo:DDO.owl#DDO_0003755 + chronic cadmium nephropathy + + + + obo:DDO.owl#DDO_0003756 + DDO:DDO_0003756 + + + + obo:DDO.owl#DDO_0003756 + 236454004 + + + + obo:DDO.owl#DDO_0003756 + chronic lead nephropathy + + + + obo:DDO.owl#DDO_0003757 + DDO:DDO_0003757 + + + + obo:DDO.owl#DDO_0003757 + 236455003 + + + + obo:DDO.owl#DDO_0003757 + saturnine nephropathy + + + + obo:DDO.owl#DDO_0003758 + DDO:DDO_0003758 + + + + obo:DDO.owl#DDO_0003758 + 236457006 + + + + obo:DDO.owl#DDO_0003758 + chronic mercury nephropathy + + + + obo:DDO.owl#DDO_0003759 + DDO:DDO_0003759 + + + + obo:DDO.owl#DDO_0003759 + 236458001 + + + + obo:DDO.owl#DDO_0003759 + granulomatous interstitial nephritis + + + + obo:DDO.owl#DDO_0003760 + DDO:DDO_0003760 + + + + obo:DDO.owl#DDO_0003760 + 37061001 + + + + obo:DDO.owl#DDO_0003760 + granulomatous sarcoid nephropathy + + + + obo:DDO.owl#DDO_0003761 + DDO:DDO_0003761 + + + + obo:DDO.owl#DDO_0003761 + 11480007 + + + + obo:DDO.owl#DDO_0003761 + idiopathic granulomatous interstitial nephropathy + + + + obo:DDO.owl#DDO_0003762 + DDO:DDO_0003762 + + + + obo:DDO.owl#DDO_0003762 + 82112005 + + + + obo:DDO.owl#DDO_0003762 + idiopathic chronic interstitial nephritis + + + + obo:DDO.owl#DDO_0003763 + DDO:DDO_0003763 + + + + obo:DDO.owl#DDO_0003763 + 236459009 + + + + obo:DDO.owl#DDO_0003763 + malakoplakia of kidney + + + + obo:DDO.owl#DDO_0003764 + DDO:DDO_0003764 + + + + obo:DDO.owl#DDO_0003764 + 38898003 + + + + obo:DDO.owl#DDO_0003764 + xanthogranulomatous pyelonephritis + + + + obo:DDO.owl#DDO_0003765 + DDO:DDO_0003765 + + + + obo:DDO.owl#DDO_0003765 + 53556002 + + + + obo:DDO.owl#DDO_0003765 + cis-platinum nephropathy + + + + obo:DDO.owl#DDO_0003766 + DDO:DDO_0003766 + + + + obo:DDO.owl#DDO_0003766 + 1086071000119103 + + + + obo:DDO.owl#DDO_0003766 + diphtheria tubulointerstitial nephropathy + + + + obo:DDO.owl#DDO_0003768 + DDO:DDO_0003768 + + + + obo:DDO.owl#DDO_0003768 + 83923004 + + + + obo:DDO.owl#DDO_0003768 + familial interstitial nephritis + + + + obo:DDO.owl#DDO_0003769 + DDO:DDO_0003769 + + + + obo:DDO.owl#DDO_0003769 + 86235003 + + + + obo:DDO.owl#DDO_0003769 + heavy metal nephropathy + + + + obo:DDO.owl#DDO_0003770 + DDO:DDO_0003770 + + + + obo:DDO.owl#DDO_0003770 + 78815005 + + + + obo:DDO.owl#DDO_0003770 + hereditary tubulointerstitial disorder + + + + obo:DDO.owl#DDO_0003771 + DDO:DDO_0003771 + + + + obo:DDO.owl#DDO_0003771 + 33763006 + + + + obo:DDO.owl#DDO_0003771 + hypercalcemic nephropathy + + + + obo:DDO.owl#DDO_0003772 + DDO:DDO_0003772 + + + + obo:DDO.owl#DDO_0003772 + hypokalemic nephropathy + + + + obo:DDO.owl#DDO_0003773 + DDO:DDO_0003773 + + + + obo:DDO.owl#DDO_0003773 + 707755000 + + + + obo:DDO.owl#DDO_0003773 + familial hypokalemic and hypomagnesemic tubulopathy + + + + obo:DDO.owl#DDO_0003774 + DDO:DDO_0003774 + + + + obo:DDO.owl#DDO_0003774 + 700448000 + + + + obo:DDO.owl#DDO_0003774 + EAST (Epilepsy, ataxia, sensorineural deafness, and tubulopathy) syndrome + + + + obo:DDO.owl#DDO_0003775 + DDO:DDO_0003775 + + + + obo:DDO.owl#DDO_0003775 + 707756004 + + + + obo:DDO.owl#DDO_0003775 + Gitelman syndrome + + + + obo:DDO.owl#DDO_0003776 + DDO:DDO_0003776 + + + + obo:DDO.owl#DDO_0003776 + 428255004 + + + + obo:DDO.owl#DDO_0003776 + tubulointerstitial nephritis + + + + obo:DDO.owl#DDO_0003777 + DDO:DDO_0003777 + + + + obo:DDO.owl#DDO_0003777 + 162031009 + + + + obo:DDO.owl#DDO_0003777 + dyspepsia + + + + obo:DDO.owl#DDO_0003778 + DDO:DDO_0003778 + + + + obo:DDO.owl#DDO_0003778 + 249511005 + + + + obo:DDO.owl#DDO_0003778 + flatulent dyspepsia + + + + obo:DDO.owl#DDO_0003779 + DDO:DDO_0003779 + + + + obo:DDO.owl#DDO_0003779 + 30281009 + + + + obo:DDO.owl#DDO_0003779 + prostate disease + + + + obo:DDO.owl#DDO_0003780 + DDO:DDO_0003780 + + + + obo:DDO.owl#DDO_0003780 + 433234005 + + + + obo:DDO.owl#DDO_0003780 + hyperplasia of prostate + + + + obo:DDO.owl#DDO_0003781 + DDO:DDO_0003781 + + + + obo:DDO.owl#DDO_0003781 + 266569009 + + + + obo:DDO.owl#DDO_0003781 + prostatic hypertrophy + + + + obo:DDO.owl#DDO_0003781 + benign prostatic hyperplasia + + + + obo:DDO.owl#DDO_0003782 + DDO:DDO_0003782 + + + + obo:DDO.owl#DDO_0003782 + 444808002 + + + + obo:DDO.owl#DDO_0003782 + benign localized hyperplasia of prostate + + + + obo:DDO.owl#DDO_0003783 + DDO:DDO_0003783 + + + + obo:DDO.owl#DDO_0003783 + 236646007 + + + + obo:DDO.owl#DDO_0003783 + benign prostatic hypertrophy with outflow obstruction + + + + obo:DDO.owl#DDO_0003784 + DDO:DDO_0003784 + + + + obo:DDO.owl#DDO_0003784 + 254902007 + + + + obo:DDO.owl#DDO_0003784 + benign prostatic hypertrophy without outflow obstruction + + + + obo:DDO.owl#DDO_0003785 + DDO:DDO_0003785 + + + + obo:DDO.owl#DDO_0003785 + 396275006 + + + + obo:DDO.owl#DDO_0003785 + osteoarthritis + + + + obo:DDO.owl#DDO_0003786 + DDO:DDO_0003786 + + + + obo:DDO.owl#DDO_0003786 + 43829003 + + + + obo:DDO.owl#DDO_0003786 + chronic osteoarthritis + + + + obo:DDO.owl#DDO_0003787 + DDO:DDO_0003787 + + + + obo:DDO.owl#DDO_0003787 + 77547008 + + + + obo:DDO.owl#DDO_0003787 + degeneration of intervertebral disc + + + + obo:DDO.owl#DDO_0003788 + DDO:DDO_0003788 + + + + obo:DDO.owl#DDO_0003788 + 109668000 + + + + obo:DDO.owl#DDO_0003788 + degenerative arthritis of temporomandibular joint + + + + obo:DDO.owl#DDO_0003789 + DDO:DDO_0003789 + + + + obo:DDO.owl#DDO_0003789 + 202751009 + + + + obo:DDO.owl#DDO_0003789 + calcification of thoracic disc + + + + obo:DDO.owl#DDO_0003790 + DDO:DDO_0003790 + + + + obo:DDO.owl#DDO_0003790 + 202755000 + + + + obo:DDO.owl#DDO_0003790 + calcification of lumbar disc + + + + obo:DDO.owl#DDO_0003791 + DDO:DDO_0003791 + + + + obo:DDO.owl#DDO_0003791 + calcification of cervical disc + + + + obo:DDO.owl#DDO_0003791 + calcification of cervical disc + + + + obo:DDO.owl#DDO_0003792 + DDO:DDO_0003792 + + + + obo:DDO.owl#DDO_0003792 + 240211000 + + + + obo:DDO.owl#DDO_0003792 + intervertebral disk calcification + + + + obo:DDO.owl#DDO_0003793 + DDO:DDO_0003793 + + + + obo:DDO.owl#DDO_0003793 + 91240008 + + + + obo:DDO.owl#DDO_0003793 + degeneration of thoracolumbar intervertebral disc + + + + obo:DDO.owl#DDO_0003794 + DDO:DDO_0003794 + + + + obo:DDO.owl#DDO_0003794 + 43132002 + + + + obo:DDO.owl#DDO_0003794 + degeneration of cervicothoracic intervertebral disc + + + + obo:DDO.owl#DDO_0003795 + DDO:DDO_0003795 + + + + obo:DDO.owl#DDO_0003795 + 68675004 + + + + obo:DDO.owl#DDO_0003795 + degeneration of thoracic intervertebral disc + + + + obo:DDO.owl#DDO_0003796 + DDO:DDO_0003796 + + + + obo:DDO.owl#DDO_0003796 + 60937000 + + + + obo:DDO.owl#DDO_0003796 + degeneration of lumbosacral intervertebral disc + + + + obo:DDO.owl#DDO_0003797 + DDO:DDO_0003797 + + + + obo:DDO.owl#DDO_0003797 + 91240008 + + + + obo:DDO.owl#DDO_0003797 + degeneration of thoracolumbar intervertebral disc + + + + obo:DDO.owl#DDO_0003798 + DDO:DDO_0003798 + + + + obo:DDO.owl#DDO_0003798 + 26538006 + + + + obo:DDO.owl#DDO_0003798 + degeneration of lumbar intervertebral disc + + + + obo:DDO.owl#DDO_0003799 + DDO:DDO_0003799 + + + + obo:DDO.owl#DDO_0003799 + 43132002 + + + + obo:DDO.owl#DDO_0003799 + degeneration of cervicothoracic intervertebral disc + + + + obo:DDO.owl#DDO_0003800 + DDO:DDO_0003800 + + + + obo:DDO.owl#DDO_0003800 + 69195002 + + + + obo:DDO.owl#DDO_0003800 + degeneration of cervical intervertebral disc + + + + obo:DDO.owl#DDO_0003801 + DDO:DDO_0003801 + + + + obo:DDO.owl#DDO_0003801 + 201819000 + + + + obo:DDO.owl#DDO_0003801 + degenerative joint disease involving multiple joints + + + + obo:DDO.owl#DDO_0003802 + DDO:DDO_0003802 + + + + obo:DDO.owl#DDO_0003802 + 442246002 + + + + obo:DDO.owl#DDO_0003802 + disorder of joint of ankle and/or foot + + + + obo:DDO.owl#DDO_0003803 + DDO:DDO_0003803 + + + + obo:DDO.owl#DDO_0003803 + 700331009 + + + + obo:DDO.owl#DDO_0003803 + talonavicular osteoarthritis secondary to inflammatory arthritis + + + + obo:DDO.owl#DDO_0003804 + DDO:DDO_0003804 + + + + obo:DDO.owl#DDO_0003804 + 700326007 + + + + obo:DDO.owl#DDO_0003804 + secondary talonavicular osteoarthritis + + + + obo:DDO.owl#DDO_0003805 + DDO:DDO_0003805 + + + + obo:DDO.owl#DDO_0003805 + 700325006 + + + + obo:DDO.owl#DDO_0003805 + primary talonavicular osteoarthritis + + + + obo:DDO.owl#DDO_0003806 + DDO:DDO_0003806 + + + + obo:DDO.owl#DDO_0003806 + 700324005 + + + + obo:DDO.owl#DDO_0003806 + osteoarthritis of talonavicular joint + + + + obo:DDO.owl#DDO_0003807 + DDO:DDO_0003807 + + + + obo:DDO.owl#DDO_0003807 + 700316000 + + + + obo:DDO.owl#DDO_0003807 + subtalar osteoarthritis secondary to inflammatory arthritis + + + + obo:DDO.owl#DDO_0003808 + DDO:DDO_0003808 + + + + obo:DDO.owl#DDO_0003808 + 700315001 + + + + obo:DDO.owl#DDO_0003808 + osteoarthritis of subtalar joint secondary to trauma + + + + obo:DDO.owl#DDO_0003809 + DDO:DDO_0003809 + + + + obo:DDO.owl#DDO_0003809 + 700314002 + + + + obo:DDO.owl#DDO_0003809 + secondary osteoarthritis of subtalar joint + + + + obo:DDO.owl#DDO_0003810 + DDO:DDO_0003810 + + + + obo:DDO.owl#DDO_0003810 + 700313008 + + + + obo:DDO.owl#DDO_0003810 + primary subtalar osteoarthritis + + + + obo:DDO.owl#DDO_0003811 + DDO:DDO_0003811 + + + + obo:DDO.owl#DDO_0003811 + 239876004 + + + + obo:DDO.owl#DDO_0003811 + osteoarthritis of subtalar joint + + + + obo:DDO.owl#DDO_0003812 + DDO:DDO_0003812 + + + + obo:DDO.owl#DDO_0003812 + 703053001 + + + + obo:DDO.owl#DDO_0003812 + osteoarthritis of midfoot secondary to trauma + + + + obo:DDO.owl#DDO_0003813 + DDO:DDO_0003813 + + + + obo:DDO.owl#DDO_0003813 + 703054007 + + + + obo:DDO.owl#DDO_0003813 + osteoarthritis of midfoot secondary to inflammatory arthritis + + + + obo:DDO.owl#DDO_0003814 + DDO:DDO_0003814 + + + + obo:DDO.owl#DDO_0003814 + 703050003 + + + + obo:DDO.owl#DDO_0003814 + secondary osteoarthritis of midfoot + + + + obo:DDO.owl#DDO_0003815 + DDO:DDO_0003815 + + + + obo:DDO.owl#DDO_0003815 + 703052006 + + + + obo:DDO.owl#DDO_0003815 + primary osteoarthritis of midfoot + + + + obo:DDO.owl#DDO_0003816 + DDO:DDO_0003816 + + + + obo:DDO.owl#DDO_0003816 + 703051004 + + + + obo:DDO.owl#DDO_0003816 + osteoarthritis of midfoot + + + + obo:DDO.owl#DDO_0003817 + DDO:DDO_0003817 + + + + obo:DDO.owl#DDO_0003817 + 700312003 + + + + obo:DDO.owl#DDO_0003817 + calcaneocuboid osteoarthritis secondary to trauma + + + + obo:DDO.owl#DDO_0003818 + DDO:DDO_0003818 + + + + obo:DDO.owl#DDO_0003818 + 700317009 + + + + obo:DDO.owl#DDO_0003818 + calcaneocuboid osteoarthritis secondary to inflammatory arthritis + + + + obo:DDO.owl#DDO_0003819 + DDO:DDO_0003819 + + + + obo:DDO.owl#DDO_0003819 + 700307004 + + + + obo:DDO.owl#DDO_0003819 + secondary calcaneocuboid osteoarthritis + + + + obo:DDO.owl#DDO_0003820 + DDO:DDO_0003820 + + + + obo:DDO.owl#DDO_0003820 + 700304006 + + + + obo:DDO.owl#DDO_0003820 + primary calcaneocuboid osteoarthritis + + + + obo:DDO.owl#DDO_0003821 + DDO:DDO_0003821 + + + + obo:DDO.owl#DDO_0003821 + 700305007 + + + + obo:DDO.owl#DDO_0003821 + osteoarthritis of calcaneocuboid joint + + + + obo:DDO.owl#DDO_0003822 + DDO:DDO_0003822 + + + + obo:DDO.owl#DDO_0003822 + 309246000 + + + + obo:DDO.owl#DDO_0003822 + osteoarthritis of foot joint + + + + obo:DDO.owl#DDO_0003823 + DDO:DDO_0003823 + + + + obo:DDO.owl#DDO_0003823 + 700295004 + + + + obo:DDO.owl#DDO_0003823 + osteoarthritis of ankle secondary to trauma + + + + obo:DDO.owl#DDO_0003824 + DDO:DDO_0003824 + + + + obo:DDO.owl#DDO_0003824 + 700318004 + + + + obo:DDO.owl#DDO_0003824 + osteoarthritis of ankle secondary to inflammatory arthritis + + + + obo:DDO.owl#DDO_0003825 + DDO:DDO_0003825 + + + + obo:DDO.owl#DDO_0003825 + 700294000 + + + + obo:DDO.owl#DDO_0003825 + secondary osteoarthritis of ankle + + + + obo:DDO.owl#DDO_0003826 + DDO:DDO_0003826 + + + + obo:DDO.owl#DDO_0003826 + 700293006 + + + + obo:DDO.owl#DDO_0003826 + primary osteoarthritis of ankle + + + + obo:DDO.owl#DDO_0003827 + DDO:DDO_0003827 + + + + obo:DDO.owl#DDO_0003827 + 239874001 + + + + obo:DDO.owl#DDO_0003827 + osteoarthritis of ankle + + + + obo:DDO.owl#DDO_0003828 + DDO:DDO_0003828 + + + + obo:DDO.owl#DDO_0003828 + 313258000 + + + + obo:DDO.owl#DDO_0003828 + localized, primary osteoarthritis of toe + + + + obo:DDO.owl#DDO_0003829 + DDO:DDO_0003829 + + + + obo:DDO.owl#DDO_0003829 + 201837004 + + + + obo:DDO.owl#DDO_0003829 + localized, primary osteoarthritis of the ankle and/or foot + + + + obo:DDO.owl#DDO_0003830 + DDO:DDO_0003830 + + + + obo:DDO.owl#DDO_0003830 + 82300000 + + + + obo:DDO.owl#DDO_0003830 + degenerative joint disease of ankle AND/OR foot + + + + obo:DDO.owl#DDO_0003831 + DDO:DDO_0003831 + + + + obo:DDO.owl#DDO_0003831 + 700328008 + + + + obo:DDO.owl#DDO_0003831 + talonavicular osteoarthritis secondary to trauma + + + + obo:DDO.owl#DDO_0003832 + DDO:DDO_0003832 + + + + obo:DDO.owl#DDO_0003832 + 700335000 + + + + obo:DDO.owl#DDO_0003832 + osteoarthritis of first metatarsophalangeal joint secondary to trauma + + + + obo:DDO.owl#DDO_0003833 + DDO:DDO_0003833 + + + + obo:DDO.owl#DDO_0003833 + 700336004 + + + + obo:DDO.owl#DDO_0003833 + osteoarthritis of first metatarsophalangeal joint secondary to inflammatory arthritis + + + + obo:DDO.owl#DDO_0003834 + DDO:DDO_0003834 + + + + obo:DDO.owl#DDO_0003834 + 700332002 + + + + obo:DDO.owl#DDO_0003834 + secondary osteoarthritis of first metatarsophalangeal joint + + + + obo:DDO.owl#DDO_0003835 + DDO:DDO_0003835 + + + + obo:DDO.owl#DDO_0003835 + 700333007 + + + + obo:DDO.owl#DDO_0003835 + primary osteoarthritis of first metatarsophalangeal joint + + + + obo:DDO.owl#DDO_0003836 + DDO:DDO_0003836 + + + + obo:DDO.owl#DDO_0003836 + 239877008 + + + + obo:DDO.owl#DDO_0003836 + osteoarthritis of first metatarsophalangeal joint + + + + obo:DDO.owl#DDO_0003837 + DDO:DDO_0003837 + + + + obo:DDO.owl#DDO_0003837 + 313258000 + + + + obo:DDO.owl#DDO_0003837 + localized, primary osteoarthritis of toe + + + + obo:DDO.owl#DDO_0003838 + DDO:DDO_0003838 + + + + obo:DDO.owl#DDO_0003838 + 239878003 + + + + obo:DDO.owl#DDO_0003838 + osteoarthritis of toe joint + + + + obo:DDO.owl#DDO_0003839 + DDO:DDO_0003839 + + + + obo:DDO.owl#DDO_0003839 + 225655006 + + + + obo:DDO.owl#DDO_0003839 + degenerative polyarthritis + + + + obo:DDO.owl#DDO_0003840 + DDO:DDO_0003840 + + + + obo:DDO.owl#DDO_0003840 + 428705008 + + + + obo:DDO.owl#DDO_0003840 + degenerative tear of triangular fibrocartilage complex of wrist + + + + obo:DDO.owl#DDO_0003841 + DDO:DDO_0003841 + + + + obo:DDO.owl#DDO_0003841 + 239883006 + + + + obo:DDO.owl#DDO_0003841 + endemic osteoarthritis + + + + obo:DDO.owl#DDO_0003842 + DDO:DDO_0003842 + + + + obo:DDO.owl#DDO_0003842 + 270505009 + + + + obo:DDO.owl#DDO_0003842 + Kashin-Bek disease + + + + obo:DDO.owl#DDO_0003843 + DDO:DDO_0003843 + + + + obo:DDO.owl#DDO_0003843 + 239884000 + + + + obo:DDO.owl#DDO_0003843 + Malemud disease + + + + obo:DDO.owl#DDO_0003844 + DDO:DDO_0003844 + + + + obo:DDO.owl#DDO_0003844 + 201826000 + + + + obo:DDO.owl#DDO_0003844 + erosive osteoarthrosis + + + + obo:DDO.owl#DDO_0003845 + DDO:DDO_0003845 + + + + obo:DDO.owl#DDO_0003845 + 394991004 + + + + obo:DDO.owl#DDO_0003845 + exacerbation of osteoarthritis + + + + obo:DDO.owl#DDO_0003846 + DDO:DDO_0003846 + + + + obo:DDO.owl#DDO_0003846 + 239862000 + + + + obo:DDO.owl#DDO_0003846 + idiopathic osteoarthritis + + + + obo:DDO.owl#DDO_0003847 + DDO:DDO_0003847 + + + + obo:DDO.owl#DDO_0003847 + 239873007 + + + + obo:DDO.owl#DDO_0003847 + osteoarthritis of knee + + + + obo:DDO.owl#DDO_0003848 + DDO:DDO_0003848 + + + + obo:DDO.owl#DDO_0003848 + 450521003 + + + + obo:DDO.owl#DDO_0003848 + patellofemoral osteoarthritis + + + + obo:DDO.owl#DDO_0003849 + DDO:DDO_0003849 + + + + obo:DDO.owl#DDO_0003849 + 239867006 + + + + obo:DDO.owl#DDO_0003849 + osteoarthritis of wrist + + + + obo:DDO.owl#DDO_0003850 + DDO:DDO_0003850 + + + + obo:DDO.owl#DDO_0003850 + 387802007 + + + + obo:DDO.owl#DDO_0003850 + thoracic spondylosis + + + + obo:DDO.owl#DDO_0003851 + DDO:DDO_0003851 + + + + obo:DDO.owl#DDO_0003851 + 22193007 + + + + obo:DDO.owl#DDO_0003851 + degenerative joint disease of hand + + + + obo:DDO.owl#DDO_0003852 + DDO:DDO_0003852 + + + + obo:DDO.owl#DDO_0003852 + 26025008 + + + + obo:DDO.owl#DDO_0003852 + residual schizophrenia + + + + obo:DDO.owl#DDO_0003853 + DDO:DDO_0003853 + + + + obo:DDO.owl#DDO_0003853 + 71103003 + + + + obo:DDO.owl#DDO_0003853 + chronic residual schizophrenia + + + + obo:DDO.owl#DDO_0003854 + DDO:DDO_0003854 + + + + obo:DDO.owl#DDO_0003854 + 76566000 + + + + obo:DDO.owl#DDO_0003854 + subchronic residual schizophrenia + + + + obo:DDO.owl#DDO_0003855 + DDO:DDO_0003855 + + + + obo:DDO.owl#DDO_0003855 + 10743008 + + + + obo:DDO.owl#DDO_0003855 + irritable bowel syndrome + + + + obo:DDO.owl#DDO_0003856 + DDO:DDO_0003856 + + + + obo:DDO.owl#DDO_0003856 + 12295008 + + + + obo:DDO.owl#DDO_0003856 + bronchiectasis + + + + obo:DDO.owl#DDO_0003857 + DDO:DDO_0003857 + + + + obo:DDO.owl#DDO_0003857 + 51133006 + + + + obo:DDO.owl#DDO_0003857 + residual schizophrenia in remission + + + + obo:DDO.owl#DDO_0003858 + DDO:DDO_0003858 + + + + obo:DDO.owl#DDO_0003858 + 233628009 + + + + obo:DDO.owl#DDO_0003858 + acquired bronchiectasis + + + + obo:DDO.owl#DDO_0003859 + DDO:DDO_0003859 + + + + obo:DDO.owl#DDO_0003859 + 23022004 + + + + obo:DDO.owl#DDO_0003859 + tuberculous bronchiectasis + + + + obo:DDO.owl#DDO_0003860 + DDO:DDO_0003860 + + + + obo:DDO.owl#DDO_0003860 + 19325002 + + + + obo:DDO.owl#DDO_0003860 + traction bronchiectasis + + + + obo:DDO.owl#DDO_0003861 + DDO:DDO_0003861 + + + + obo:DDO.owl#DDO_0003861 + 52500008 + + + + obo:DDO.owl#DDO_0003861 + saccular bronchiectasis + + + + obo:DDO.owl#DDO_0003862 + DDO:DDO_0003862 + + + + obo:DDO.owl#DDO_0003862 + 195984007 + + + + obo:DDO.owl#DDO_0003862 + recurrent bronchiectasis + + + + obo:DDO.owl#DDO_0003863 + DDO:DDO_0003863 + + + + obo:DDO.owl#DDO_0003863 + 195985008 + + + + obo:DDO.owl#DDO_0003863 + post-infective bronchiectasis + + + + obo:DDO.owl#DDO_0003864 + DDO:DDO_0003864 + + + + obo:DDO.owl#DDO_0003864 + 233630006 + + + + obo:DDO.owl#DDO_0003864 + obstructive bronchiectasis + + + + obo:DDO.owl#DDO_0003866 + DDO:DDO_0003866 + + + + obo:DDO.owl#DDO_0003866 + 13217005 + + + + obo:DDO.owl#DDO_0003866 + fusiform bronchiectasis + + + + obo:DDO.owl#DDO_0003867 + DDO:DDO_0003867 + + + + obo:DDO.owl#DDO_0003867 + 83457000 + + + + obo:DDO.owl#DDO_0003867 + cylindrical bronchiectasis + + + + obo:DDO.owl#DDO_0003868 + DDO:DDO_0003868 + + + + obo:DDO.owl#DDO_0003868 + 233627004 + + + + obo:DDO.owl#DDO_0003868 + congenital cystic bronchiectasis + + + + obo:DDO.owl#DDO_0003869 + DDO:DDO_0003869 + + + + obo:DDO.owl#DDO_0003869 + 77593006 + + + + obo:DDO.owl#DDO_0003869 + congenital bronchiectasis + + + + obo:DDO.owl#DDO_0003870 + DDO:DDO_0003870 + + + + obo:DDO.owl#DDO_0003870 + 12310001 + + + + obo:DDO.owl#DDO_0003870 + childhood bronchiectasis + + + + obo:DDO.owl#DDO_0003871 + DDO:DDO_0003871 + + + + obo:DDO.owl#DDO_0003871 + 51068008 + + + + obo:DDO.owl#DDO_0003871 + adult bronchiectasis + + + + obo:DDO.owl#DDO_0003872 + DDO:DDO_0003872 + + + + obo:DDO.owl#DDO_0003872 + 445378003 + + + + obo:DDO.owl#DDO_0003872 + acute exacerbation of bronchiectasis + + + + obo:DDO.owl#DDO_0003873 + DDO:DDO_0003873 + + + + obo:DDO.owl#DDO_0003873 + 233633008 + + + + obo:DDO.owl#DDO_0003873 + bronchiectasis due to toxic inhalation + + + + obo:DDO.owl#DDO_0003874 + DDO:DDO_0003874 + + + + obo:DDO.owl#DDO_0003874 + 233632003 + + + + obo:DDO.owl#DDO_0003874 + bronchiectasis due to toxic aspiration + + + + obo:DDO.owl#DDO_0003875 + DDO:DDO_0003875 + + + + obo:DDO.owl#DDO_0003875 + 233631005 + + + + obo:DDO.owl#DDO_0003875 + toxin-induced bronchiectasis + + + + obo:DDO.owl#DDO_0003876 + DDO:DDO_0003876 + + + + obo:DDO.owl#DDO_0003876 + 233634002 + + + + obo:DDO.owl#DDO_0003876 + post-lung transplantation bronchiectasis + + + + obo:DDO.owl#DDO_0003877 + DDO:DDO_0003877 + + + + obo:DDO.owl#DDO_0003877 + 233629001 + + + + obo:DDO.owl#DDO_0003877 + idiopathic bronchiectasis + + + + obo:DDO.owl#DDO_0003878 + DDO:DDO_0003878 + + + + obo:DDO.owl#DDO_0003878 + 84757009 + + + + obo:DDO.owl#DDO_0003878 + epilepsy + + + + obo:DDO.owl#DDO_0003879 + DDO:DDO_0003879 + + + + obo:DDO.owl#DDO_0003879 + 8291000119107 + + + + obo:DDO.owl#DDO_0003879 + atonic epilepsy + + + + obo:DDO.owl#DDO_0003880 + DDO:DDO_0003880 + + + + obo:DDO.owl#DDO_0003880 + 187931000119106 + + + + obo:DDO.owl#DDO_0003880 + atypical absence epilepsy + + + + obo:DDO.owl#DDO_0003881 + DDO:DDO_0003881 + + + + obo:DDO.owl#DDO_0003881 + 38281008 + + + + obo:DDO.owl#DDO_0003881 + benign neonatal convulsions + + + + obo:DDO.owl#DDO_0003882 + DDO:DDO_0003882 + + + + obo:DDO.owl#DDO_0003882 + 230410004 + + + + obo:DDO.owl#DDO_0003882 + benign neonatal familial convulsions + + + + obo:DDO.owl#DDO_0003883 + DDO:DDO_0003883 + + + + obo:DDO.owl#DDO_0003883 + 230411000 + + + + obo:DDO.owl#DDO_0003883 + benign non-familial neonatal convulsions + + + + obo:DDO.owl#DDO_0003884 + DDO:DDO_0003884 + + + + obo:DDO.owl#DDO_0003884 + 49776008 + + + + obo:DDO.owl#DDO_0003884 + centrencephalic epilepsy + + + + obo:DDO.owl#DDO_0003885 + DDO:DDO_0003885 + + + + obo:DDO.owl#DDO_0003885 + 71427006 + + + + obo:DDO.owl#DDO_0003885 + cursive seizure + + + + obo:DDO.owl#DDO_0003886 + DDO:DDO_0003886 + + + + obo:DDO.owl#DDO_0003886 + 422513000 + + + + obo:DDO.owl#DDO_0003886 + epilepsy, not refractory + + + + obo:DDO.owl#DDO_0003887 + DDO:DDO_0003887 + + + + obo:DDO.owl#DDO_0003887 + 19598007 + + + + obo:DDO.owl#DDO_0003887 + generalized epilepsy + + + + obo:DDO.owl#DDO_0003888 + DDO:DDO_0003888 + + + + obo:DDO.owl#DDO_0003888 + 363176004 + + + + obo:DDO.owl#DDO_0003888 + inflammatory disorder of head + + + + obo:DDO.owl#DDO_0003889 + DDO:DDO_0003889 + + + + obo:DDO.owl#DDO_0003889 + 36971009 + + + + obo:DDO.owl#DDO_0003889 + sinusitis + + + + obo:DDO.owl#DDO_0003890 + DDO:DDO_0003890 + + + + obo:DDO.owl#DDO_0003890 + 40055000 + + + + obo:DDO.owl#DDO_0003890 + chronic sinusitis + + + + obo:DDO.owl#DDO_0003891 + DDO:DDO_0003891 + + + + obo:DDO.owl#DDO_0003891 + 38961000 + + + + obo:DDO.owl#DDO_0003891 + chronic sphenoidal sinusitis + + + + obo:DDO.owl#DDO_0003892 + DDO:DDO_0003892 + + + + obo:DDO.owl#DDO_0003892 + 427909005 + + + + obo:DDO.owl#DDO_0003892 + chronic recurrent sinusitis + + + + obo:DDO.owl#DDO_0003893 + DDO:DDO_0003893 + + + + obo:DDO.owl#DDO_0003893 + 88850006 + + + + obo:DDO.owl#DDO_0003893 + chronic pansinusitis + + + + obo:DDO.owl#DDO_0003894 + DDO:DDO_0003894 + + + + obo:DDO.owl#DDO_0003894 + 35923002 + + + + obo:DDO.owl#DDO_0003894 + chronic maxillary sinusitis + + + + obo:DDO.owl#DDO_0003895 + DDO:DDO_0003895 + + + + obo:DDO.owl#DDO_0003895 + 232397007 + + + + obo:DDO.owl#DDO_0003895 + chronic frontoethmoidal sinusitis + + + + obo:DDO.owl#DDO_0003896 + DDO:DDO_0003896 + + + + obo:DDO.owl#DDO_0003896 + 73237007 + + + + obo:DDO.owl#DDO_0003896 + chronic ethmoidal sinusitis + + + + obo:DDO.owl#DDO_0003897 + DDO:DDO_0003897 + + + + obo:DDO.owl#DDO_0003897 + 195756009 + + + + obo:DDO.owl#DDO_0003897 + woakes' ethmoiditis + + + + obo:DDO.owl#DDO_0003898 + DDO:DDO_0003898 + + + + obo:DDO.owl#DDO_0003898 + 232394000 + + + + obo:DDO.owl#DDO_0003898 + chronic posterior ethmoidal sinusitis + + + + obo:DDO.owl#DDO_0003899 + DDO:DDO_0003899 + + + + obo:DDO.owl#DDO_0003899 + 232395004 + + + + obo:DDO.owl#DDO_0003899 + chronic panethmoidal sinusitis + + + + obo:DDO.owl#DDO_0003900 + DDO:DDO_0003900 + + + + obo:DDO.owl#DDO_0003900 + 232396003 + + + + obo:DDO.owl#DDO_0003900 + chronic osteomeatal disease + + + + obo:DDO.owl#DDO_0003901 + DDO:DDO_0003901 + + + + obo:DDO.owl#DDO_0003901 + 232393006 + + + + obo:DDO.owl#DDO_0003901 + chronic anterior ethmoidal sinusitis + + + + obo:DDO.owl#DDO_0003902 + DDO:DDO_0003902 + + + + obo:DDO.owl#DDO_0003902 + 60130002 + + + + obo:DDO.owl#DDO_0003902 + chronic frontal sinusitis + + + + obo:DDO.owl#DDO_0003903 + DDO:DDO_0003903 + + + + obo:DDO.owl#DDO_0003903 + 362969004 + + + + obo:DDO.owl#DDO_0003903 + disorder of endocrine system + + + + obo:DDO.owl#DDO_0003905 + DDO:DDO_0003905 + + + + obo:DDO.owl#DDO_0003905 + type 2 diabetes mellitus + + + + obo:DDO.owl#DDO_0003906 + DDO:DDO_0003906 + + + + obo:DDO.owl#DDO_0003906 + 199223000 + + + + obo:DDO.owl#DDO_0003906 + diabetes mellitus during pregnancy, childbirth and the puerperium + + + + obo:DDO.owl#DDO_0003909 + DDO:DDO_0003909 + + + + obo:DDO.owl#DDO_0003909 + diabetes disease course + + + + obo:DDO.owl#DDO_0003910 + DDO:DDO_0003910 + + + + obo:DDO.owl#DDO_0003910 + 89362005 + + + + obo:DDO.owl#DDO_0003910 + weight loss + + + + obo:DDO.owl#DDO_0003911 + DDO:DDO_0003911 + + + + obo:DDO.owl#DDO_0003911 + 3218000 + + + + obo:DDO.owl#DDO_0003911 + mycosis + + + + obo:DDO.owl#DDO_0003912 + DDO:DDO_0003912 + + + + obo:DDO.owl#DDO_0003912 + 8943002 + + + + obo:DDO.owl#DDO_0003912 + weight gain + + + + obo:DDO.owl#DDO_0003913 + DDO:DDO_0003913 + + + + obo:DDO.owl#DDO_0003913 + 26053008 + + + + obo:DDO.owl#DDO_0003913 + infection by Ascomycetes + + + + obo:DDO.owl#DDO_0003914 + DDO:DDO_0003914 + + + + obo:DDO.owl#DDO_0003914 + 78048006 + + + + obo:DDO.owl#DDO_0003914 + candidiasis + + + + obo:DDO.owl#DDO_0003915 + DDO:DDO_0003915 + + + + obo:DDO.owl#DDO_0003915 + 240707005 + + + + obo:DDO.owl#DDO_0003915 + anogenital candidiasis + + + + obo:DDO.owl#DDO_0003916 + DDO:DDO_0003916 + + + + obo:DDO.owl#DDO_0003916 + 266157006 + + + + obo:DDO.owl#DDO_0003916 + perianal candidiasis + + + + obo:DDO.owl#DDO_0003917 + DDO:DDO_0003917 + + + + obo:DDO.owl#DDO_0003917 + 231990003 + + + + obo:DDO.owl#DDO_0003917 + Candida retinitis + + + + obo:DDO.owl#DDO_0003918 + DDO:DDO_0003918 + + + + obo:DDO.owl#DDO_0003918 + 63553008 + + + + obo:DDO.owl#DDO_0003918 + candidal endocarditis + + + + obo:DDO.owl#DDO_0003919 + DDO:DDO_0003919 + + + + obo:DDO.owl#DDO_0003919 + 359736007 + + + + obo:DDO.owl#DDO_0003919 + candidal perionyxis + + + + obo:DDO.owl#DDO_0003920 + DDO:DDO_0003920 + + + + obo:DDO.owl#DDO_0003920 + 34786008 + + + + obo:DDO.owl#DDO_0003920 + candidal proctitis + + + + obo:DDO.owl#DDO_0003921 + DDO:DDO_0003921 + + + + obo:DDO.owl#DDO_0003921 + 432261003 + + + + obo:DDO.owl#DDO_0003921 + candidemia + + + + obo:DDO.owl#DDO_0003922 + DDO:DDO_0003922 + + + + obo:DDO.owl#DDO_0003922 + 432480003 + + + + obo:DDO.owl#DDO_0003922 + candidemia associated with intravascular line + + + + obo:DDO.owl#DDO_0003924 + DDO:DDO_0003924 + + + + obo:DDO.owl#DDO_0003924 + 84679006 + + + + obo:DDO.owl#DDO_0003924 + gastrointestinal candidiasis + + + + obo:DDO.owl#DDO_0003925 + DDO:DDO_0003925 + + + + obo:DDO.owl#DDO_0003925 + 49883006 + + + + obo:DDO.owl#DDO_0003925 + candidiasis of skin + + + + obo:DDO.owl#DDO_0003926 + DDO:DDO_0003926 + + + + obo:DDO.owl#DDO_0003926 + 266158001 + + + + obo:DDO.owl#DDO_0003926 + Candidal intertrigo + + + + obo:DDO.owl#DDO_0003927 + DDO:DDO_0003927 + + + + obo:DDO.owl#DDO_0003927 + 240713001 + + + + obo:DDO.owl#DDO_0003927 + candidiasis of finger web + + + + obo:DDO.owl#DDO_0003928 + DDO:DDO_0003928 + + + + obo:DDO.owl#DDO_0003928 + 187014000 + + + + obo:DDO.owl#DDO_0003928 + candidiasis of skin and nails + + + + obo:DDO.owl#DDO_0003929 + DDO:DDO_0003929 + + + + obo:DDO.owl#DDO_0003929 + 187017007 + + + + obo:DDO.owl#DDO_0003929 + candidal paronychia + + + + obo:DDO.owl#DDO_0003930 + DDO:DDO_0003930 + + + + obo:DDO.owl#DDO_0003930 + 240711004 + + + + obo:DDO.owl#DDO_0003930 + diaper candidiasis + + + + obo:DDO.owl#DDO_0003931 + DDO:DDO_0003931 + + + + obo:DDO.owl#DDO_0003931 + 402131002 + + + + obo:DDO.owl#DDO_0003931 + disseminated cutaneous candidiasis + + + + obo:DDO.owl#DDO_0003932 + DDO:DDO_0003932 + + + + obo:DDO.owl#DDO_0003932 + 240710003 + + + + obo:DDO.owl#DDO_0003932 + granuloma gluteale infantum + + + + obo:DDO.owl#DDO_0003933 + DDO:DDO_0003933 + + + + obo:DDO.owl#DDO_0003933 + 29147005 + + + + obo:DDO.owl#DDO_0003933 + mucocutaneous candidiasis + + + + obo:DDO.owl#DDO_0003934 + DDO:DDO_0003934 + + + + obo:DDO.owl#DDO_0003934 + 234568006 + + + + obo:DDO.owl#DDO_0003934 + chronic mucocutaneous candidiasis + + + + obo:DDO.owl#DDO_0003935 + DDO:DDO_0003935 + + + + obo:DDO.owl#DDO_0003935 + 365811003 + + + + obo:DDO.owl#DDO_0003935 + glucose level + + + + obo:DDO.owl#DDO_0003936 + DDO:DDO_0003936 + + + + obo:DDO.owl#DDO_0003936 + 206356004 + + + + obo:DDO.owl#DDO_0003936 + neonatal candidiasis of perineum + + + + obo:DDO.owl#DDO_0003937 + DDO:DDO_0003937 + + + + obo:DDO.owl#DDO_0003937 + 240708000 + + + + obo:DDO.owl#DDO_0003937 + penile candidiasis + + + + obo:DDO.owl#DDO_0003938 + DDO:DDO_0003938 + + + + obo:DDO.owl#DDO_0003938 + 266157006 + + + + obo:DDO.owl#DDO_0003938 + perianal candidiasis + + + + obo:DDO.owl#DDO_0003939 + DDO:DDO_0003939 + + + + obo:DDO.owl#DDO_0003939 + 240709008 + + + + obo:DDO.owl#DDO_0003939 + perineal candidiasis + + + + obo:DDO.owl#DDO_0003940 + DDO:DDO_0003940 + + + + obo:DDO.owl#DDO_0003940 + 279325003 + + + + obo:DDO.owl#DDO_0003940 + submammary monilia + + + + obo:DDO.owl#DDO_0003941 + DDO:DDO_0003941 + + + + obo:DDO.owl#DDO_0003941 + 102660008 + + + + obo:DDO.owl#DDO_0003941 + abnormal blood glucose level + + + + obo:DDO.owl#DDO_0003943 + DDO:DDO_0003943 + + + + obo:DDO.owl#DDO_0003943 + 166922008 + + + + obo:DDO.owl#DDO_0003943 + abnormal blood glucose + + + + obo:DDO.owl#DDO_0003944 + DDO:DDO_0003944 + + + + obo:DDO.owl#DDO_0003944 + 51798006 + + + + obo:DDO.owl#DDO_0003944 + decreased glucose level in blood + + + + obo:DDO.owl#DDO_0003945 + DDO:DDO_0003945 + + + + obo:DDO.owl#DDO_0003945 + 444780001 + + + + obo:DDO.owl#DDO_0003945 + high glucose level in blood + + + + obo:DDO.owl#DDO_0003946 + DDO:DDO_0003946 + + + + obo:DDO.owl#DDO_0003946 + 444925004 + + + + obo:DDO.owl#DDO_0003946 + abnormal random glucose level + + + + obo:DDO.owl#DDO_0003947 + DDO:DDO_0003947 + + + + obo:DDO.owl#DDO_0003947 + 166891009 + + + + obo:DDO.owl#DDO_0003947 + random blood sugar low + + + + obo:DDO.owl#DDO_0003948 + DDO:DDO_0003948 + + + + obo:DDO.owl#DDO_0003948 + 45154002 + + + + obo:DDO.owl#DDO_0003948 + glycosuria + + + + obo:DDO.owl#DDO_0003949 + DDO:DDO_0003949 + + + + obo:DDO.owl#DDO_0003949 + 9111008 + + + + obo:DDO.owl#DDO_0003949 + glucoglycinuria + + + + obo:DDO.owl#DDO_0003950 + DDO:DDO_0003950 + + + + obo:DDO.owl#DDO_0003950 + 365799007 + + + + obo:DDO.owl#DDO_0003950 + protein level + + + + obo:DDO.owl#DDO_0003951 + DDO:DDO_0003951 + + + + obo:DDO.owl#DDO_0003951 + 71628007 + + + + obo:DDO.owl#DDO_0003951 + abnormal presence of albumin + + + + obo:DDO.owl#DDO_0003952 + DDO:DDO_0003952 + + + + obo:DDO.owl#DDO_0003952 + 123806003 + + + + obo:DDO.owl#DDO_0003952 + bisalbuminemia + + + + obo:DDO.owl#DDO_0003953 + DDO:DDO_0003953 + + + + obo:DDO.owl#DDO_0003953 + 441772009 + + + + obo:DDO.owl#DDO_0003953 + abnormal presence of alpha-fetoprotein + + + + obo:DDO.owl#DDO_0003954 + DDO:DDO_0003954 + + + + obo:DDO.owl#DDO_0003954 + 9437001 + + + + obo:DDO.owl#DDO_0003954 + abnormal presence of myoglobin + + + + obo:DDO.owl#DDO_0003955 + DDO:DDO_0003955 + + + + obo:DDO.owl#DDO_0003955 + 71628007 + + + + obo:DDO.owl#DDO_0003955 + abnormal presence of protein + + + + obo:DDO.owl#DDO_0003956 + DDO:DDO_0003956 + + + + obo:DDO.owl#DDO_0003956 + albumin level + + + + obo:DDO.owl#DDO_0003957 + DDO:DDO_0003957 + + + + obo:DDO.owl#DDO_0003957 + 274769005 + + + + obo:DDO.owl#DDO_0003957 + albuminuria + + + + obo:DDO.owl#DDO_0003958 + DDO:DDO_0003958 + + + + obo:DDO.owl#DDO_0003958 + 166892002 + + + + obo:DDO.owl#DDO_0003958 + random blood sugar raised + + + + obo:DDO.owl#DDO_0003959 + DDO:DDO_0003959 + + + + obo:DDO.owl#DDO_0003959 + 127355002 + + + + obo:DDO.owl#DDO_0003959 + decreased albumin + + + + obo:DDO.owl#DDO_0003960 + DDO:DDO_0003960 + + + + obo:DDO.owl#DDO_0003960 + 124017007 + + + + obo:DDO.owl#DDO_0003960 + decreased methemalbumin + + + + obo:DDO.owl#DDO_0003961 + DDO:DDO_0003961 + + + + obo:DDO.owl#DDO_0003961 + 127354003 + + + + obo:DDO.owl#DDO_0003961 + increased albumin + + + + obo:DDO.owl#DDO_0003962 + DDO:DDO_0003962 + + + + obo:DDO.owl#DDO_0003962 + 124016003 + + + + obo:DDO.owl#DDO_0003962 + increased methemalbumin + + + + obo:DDO.owl#DDO_0003963 + DDO:DDO_0003963 + + + + obo:DDO.owl#DDO_0003963 + 167964001 + + + + obo:DDO.owl#DDO_0003963 + pleural fluid albumin raised + + + + obo:DDO.owl#DDO_0003964 + DDO:DDO_0003964 + + + + obo:DDO.owl#DDO_0003964 + 365774006 + + + + obo:DDO.owl#DDO_0003964 + hormone disorder + + + + obo:DDO.owl#DDO_0003966 + DDO:DDO_0003966 + + + + obo:DDO.owl#DDO_0003966 + 131103005 + + + + obo:DDO.owl#DDO_0003966 + increased insulin level + + + + obo:DDO.owl#DDO_0003967 + DDO:DDO_0003967 + + + + obo:DDO.owl#DDO_0003967 + 131104004 + + + + obo:DDO.owl#DDO_0003967 + decreased insulin level + + + + obo:DDO.owl#DDO_0003968 + DDO:DDO_0003968 + + + + obo:DDO.owl#DDO_0003968 + foot disorder + + + + obo:DDO.owl#DDO_0003969 + DDO:DDO_0003969 + + + + obo:DDO.owl#DDO_0003969 + renal disorder + + + + obo:DDO.owl#DDO_0003970 + DDO:DDO_0003970 + + + + obo:DDO.owl#DDO_0003970 + eye disorder + + + + obo:DDO.owl#DDO_0003971 + DDO:DDO_0003971 + + + + obo:DDO.owl#DDO_0003971 + skin disorder + + + + obo:DDO.owl#DDO_0003972 + DDO:DDO_0003972 + + + + obo:DDO.owl#DDO_0003972 + 3855007 + + + + obo:DDO.owl#DDO_0003972 + pancreas disorder + + + + obo:DDO.owl#DDO_0003973 + DDO:DDO_0003973 + + + + obo:DDO.owl#DDO_0003973 + 392570002 + + + + obo:DDO.owl#DDO_0003973 + blood pressure + + + + obo:DDO.owl#DDO_0003974 + DDO:DDO_0003974 + + + + obo:DDO.owl#DDO_0003974 + 38936003 + + + + obo:DDO.owl#DDO_0003974 + abnormal blood pressure + + + + obo:DDO.owl#DDO_0003975 + DDO:DDO_0003975 + + + + obo:DDO.owl#DDO_0003975 + 68603007 + + + + obo:DDO.owl#DDO_0003975 + abnormal arterial pulse pressure + + + + obo:DDO.owl#DDO_0003976 + DDO:DDO_0003976 + + + + obo:DDO.owl#DDO_0003976 + 70679005 + + + + obo:DDO.owl#DDO_0003976 + abnormal central venous pressure + + + + obo:DDO.owl#DDO_0003977 + DDO:DDO_0003977 + + + + obo:DDO.owl#DDO_0003977 + 62436006 + + + + obo:DDO.owl#DDO_0003977 + abnormal jugular venous pressure + + + + obo:DDO.owl#DDO_0003978 + DDO:DDO_0003978 + + + + obo:DDO.owl#DDO_0003978 + 49844009 + + + + obo:DDO.owl#DDO_0003978 + abnormal diastolic arterial pressure + + + + obo:DDO.owl#DDO_0003979 + DDO:DDO_0003979 + + + + obo:DDO.owl#DDO_0003979 + 18352002 + + + + obo:DDO.owl#DDO_0003979 + abnormal systolic arterial pressure + + + + obo:DDO.owl#DDO_0003980 + DDO:DDO_0003980 + + + + obo:DDO.owl#DDO_0003980 + 707303003 + + + + obo:DDO.owl#DDO_0003980 + post exercise systolic blood pressure response abnormal + + + + obo:DDO.owl#DDO_0003981 + DDO:DDO_0003981 + + + + obo:DDO.owl#DDO_0003981 + 69791001 + + + + obo:DDO.owl#DDO_0003981 + increased venous pressure + + + + obo:DDO.owl#DDO_0003982 + DDO:DDO_0003982 + + + + obo:DDO.owl#DDO_0003982 + 23520002 + + + + obo:DDO.owl#DDO_0003982 + decreased venous pressure + + + + obo:DDO.owl#DDO_0003983 + DDO:DDO_0003983 + + + + obo:DDO.owl#DDO_0003983 + 24184005 + + + + obo:DDO.owl#DDO_0003983 + elevated blood pressure + + + + obo:DDO.owl#DDO_0003984 + DDO:DDO_0003984 + + + + obo:DDO.owl#DDO_0003984 + 12377007 + + + + obo:DDO.owl#DDO_0003984 + increased central venous pressure + + + + obo:DDO.owl#DDO_0003985 + DDO:DDO_0003985 + + + + obo:DDO.owl#DDO_0003985 + 23154005 + + + + obo:DDO.owl#DDO_0003985 + increased diastolic arterial pressure + + + + obo:DDO.owl#DDO_0003986 + DDO:DDO_0003986 + + + + obo:DDO.owl#DDO_0003986 + 26014004 + + + + obo:DDO.owl#DDO_0003986 + increased mean arterial pressure + + + + obo:DDO.owl#DDO_0003987 + DDO:DDO_0003987 + + + + obo:DDO.owl#DDO_0003987 + 18050000 + + + + obo:DDO.owl#DDO_0003987 + increased systolic arterial pressure + + + + obo:DDO.owl#DDO_0003988 + DDO:DDO_0003988 + + + + obo:DDO.owl#DDO_0003988 + 17346000 + + + + obo:DDO.owl#DDO_0003988 + disorder of endocrine pancreas + + + + obo:DDO.owl#DDO_0003989 + DDO:DDO_0003989 + + + + obo:DDO.owl#DDO_0003989 + 237650006 + + + + obo:DDO.owl#DDO_0003989 + insulin resistance + + + + obo:DDO.owl#DDO_0003991 + DDO:DDO_0003991 + + + + obo:DDO.owl#DDO_0003991 + 109041000119107 + + + + obo:DDO.owl#DDO_0003991 + complex dyslipidemia + + + + obo:DDO.owl#DDO_0003992 + DDO:DDO_0003992 + + + + obo:DDO.owl#DDO_0003992 + obo:DDO.owl#DDO_0005220 + + + + obo:DDO.owl#DDO_0003992 + obo:DDO.owl#DDO_0005220 + + + + obo:DDO.owl#DDO_0003992 + 373247007 + + + + obo:DDO.owl#DDO_0003992 + cardiovascular agent + + + + obo:DDO.owl#DDO_0003993 + DDO:DDO_0003993 + + + + obo:DDO.owl#DDO_0003993 + 373267003 + + + + obo:DDO.owl#DDO_0003993 + antilipemic agent + + + + obo:DDO.owl#DDO_0003994 + DDO:DDO_0003994 + + + + obo:DDO.owl#DDO_0003994 + 372912004 + + + + obo:DDO.owl#DDO_0003994 + 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor + + + + obo:DDO.owl#DDO_0003994 + statins + + + + obo:DDO.owl#DDO_0003994 + HMG-CoA reductase inhibitor + + + + obo:DDO.owl#DDO_0003995 + DDO:DDO_0003995 + + + + obo:DDO.owl#DDO_0003995 + 46063005 + + + + obo:DDO.owl#DDO_0003995 + psychotherapeutic agent + + + + obo:DDO.owl#DDO_0003996 + DDO:DDO_0003996 + + + + obo:DDO.owl#DDO_0003996 + 36236003 + + + + obo:DDO.owl#DDO_0003996 + antidepressant + + + + obo:DDO.owl#DDO_0003997 + has_material_basis + + + + obo:DDO.owl#DDO_0003999 + is_about + + + + obo:DDO.owl#DDO_0004000 + DDO:DDO_0004000 + + + + obo:DDO.owl#DDO_0004000 + 96199001 + + + + obo:DDO.owl#DDO_0004000 + Bupropion + + + + obo:DDO.owl#DDO_0004001 + DDO:DDO_0004001 + + + + obo:DDO.owl#DDO_0004001 + 702952002 + + + + obo:DDO.owl#DDO_0004001 + agomelatine + + + + obo:DDO.owl#DDO_0004003 + DDO:DDO_0004003 + + + + obo:DDO.owl#DDO_0004003 + 387584000 + + + + obo:DDO.owl#DDO_0004003 + simvastatin + + + + obo:DDO.owl#DDO_0004004 + DDO:DDO_0004004 + + + + obo:DDO.owl#DDO_0004004 + 406435003 + + + + obo:DDO.owl#DDO_0004004 + rosuvastatin calcium + + + + obo:DDO.owl#DDO_0004005 + DDO:DDO_0004005 + + + + obo:DDO.owl#DDO_0004005 + 700067006 + + + + obo:DDO.owl#DDO_0004005 + rosuvastatin + + + + obo:DDO.owl#DDO_0004006 + DDO:DDO_0004006 + + + + obo:DDO.owl#DDO_0004006 + 96306007 + + + + obo:DDO.owl#DDO_0004006 + pravastatin sodium + + + + obo:DDO.owl#DDO_0004007 + DDO:DDO_0004007 + + + + obo:DDO.owl#DDO_0004007 + 373566006 + + + + obo:DDO.owl#DDO_0004007 + pravastatin + + + + obo:DDO.owl#DDO_0004008 + DDO:DDO_0004008 + + + + obo:DDO.owl#DDO_0004008 + 700402009 + + + + obo:DDO.owl#DDO_0004008 + pitavastatin calcium + + + + obo:DDO.owl#DDO_0004009 + DDO:DDO_0004009 + + + + obo:DDO.owl#DDO_0004009 + 443586000 + + + + obo:DDO.owl#DDO_0004009 + pitavastatin + + + + obo:DDO.owl#DDO_0004010 + DDO:DDO_0004010 + + + + obo:DDO.owl#DDO_0004010 + 96303004 + + + + obo:DDO.owl#DDO_0004010 + lovastatin + + + + obo:DDO.owl#DDO_0004011 + DDO:DDO_0004011 + + + + obo:DDO.owl#DDO_0004011 + 412392009 + + + + obo:DDO.owl#DDO_0004011 + fluvastatin sodium + + + + obo:DDO.owl#DDO_0004012 + DDO:DDO_0004012 + + + + obo:DDO.owl#DDO_0004012 + 387585004 + + + + obo:DDO.owl#DDO_0004012 + fluvastatin + + + + obo:DDO.owl#DDO_0004013 + DDO:DDO_0004013 + + + + obo:DDO.owl#DDO_0004013 + 108597004 + + + + obo:DDO.owl#DDO_0004013 + cerivastatin sodium + + + + obo:DDO.owl#DDO_0004014 + DDO:DDO_0004014 + + + + obo:DDO.owl#DDO_0004014 + 373443008 + + + + obo:DDO.owl#DDO_0004014 + cerivastatin + + + + obo:DDO.owl#DDO_0004015 + DDO:DDO_0004015 + + + + obo:DDO.owl#DDO_0004015 + 108601004 + + + + obo:DDO.owl#DDO_0004015 + atorvastatin calcium + + + + obo:DDO.owl#DDO_0004016 + DDO:DDO_0004016 + + + + obo:DDO.owl#DDO_0004016 + 373444002 + + + + obo:DDO.owl#DDO_0004016 + atorvastatin + + + + obo:DDO.owl#DDO_0004017 + DDO:DDO_0004017 + + + + obo:DDO.owl#DDO_0004017 + 431409002 + + + + obo:DDO.owl#DDO_0004017 + bupropion hydrobromide 174mg extended release tablet + + + + obo:DDO.owl#DDO_0004018 + DDO:DDO_0004018 + + + + obo:DDO.owl#DDO_0004018 + 432023009 + + + + obo:DDO.owl#DDO_0004018 + bupropion hydrobromide 348mg extended release tablet + + + + obo:DDO.owl#DDO_0004019 + DDO:DDO_0004019 + + + + obo:DDO.owl#DDO_0004019 + 432024003 + + + + obo:DDO.owl#DDO_0004019 + bupropion hydrobromide 522mg extended release tablet + + + + obo:DDO.owl#DDO_0004020 + DDO:DDO_0004020 + + + + obo:DDO.owl#DDO_0004020 + 412594009 + + + + obo:DDO.owl#DDO_0004020 + bupropion hydrochloride + + + + obo:DDO.owl#DDO_0004021 + DDO:DDO_0004021 + + + + obo:DDO.owl#DDO_0004021 + 376886007 + + + + obo:DDO.owl#DDO_0004021 + bupropion hydrochloride 100mg m/r tablet + + + + obo:DDO.owl#DDO_0004022 + DDO:DDO_0004022 + + + + obo:DDO.owl#DDO_0004022 + 386583001 + + + + obo:DDO.owl#DDO_0004022 + bupropion hydrochloride 100mg tablet + + + + obo:DDO.owl#DDO_0004023 + DDO:DDO_0004023 + + + + obo:DDO.owl#DDO_0004023 + 323346004 + + + + obo:DDO.owl#DDO_0004023 + bupropion hydrochloride 150mg m/r tablet + + + + obo:DDO.owl#DDO_0004024 + DDO:DDO_0004024 + + + + obo:DDO.owl#DDO_0004024 + 412644003 + + + + obo:DDO.owl#DDO_0004024 + bupropion hydrochloride 200mg m/r tablet + + + + obo:DDO.owl#DDO_0004025 + DDO:DDO_0004025 + + + + obo:DDO.owl#DDO_0004025 + 409338003 + + + + obo:DDO.owl#DDO_0004025 + bupropion hydrochloride 300mg m/r tablet + + + + obo:DDO.owl#DDO_0004026 + DDO:DDO_0004026 + + + + obo:DDO.owl#DDO_0004026 + 412645002 + + + + obo:DDO.owl#DDO_0004026 + bupropion hydrochloride 50mg m/r tablet + + + + obo:DDO.owl#DDO_0004027 + DDO:DDO_0004027 + + + + obo:DDO.owl#DDO_0004027 + 376885006 + + + + obo:DDO.owl#DDO_0004027 + bupropion hydrochloride 75mg tablet + + + + obo:DDO.owl#DDO_0004028 + DDO:DDO_0004028 + + + + obo:DDO.owl#DDO_0004028 + 386582006 + + + + obo:DDO.owl#DDO_0004028 + bupropion m/r tablet + + + + obo:DDO.owl#DDO_0004029 + DDO:DDO_0004029 + + + + obo:DDO.owl#DDO_0004029 + 321916002 + + + + obo:DDO.owl#DDO_0004029 + compound antidepressants + + + + obo:DDO.owl#DDO_0004030 + DDO:DDO_0004030 + + + + obo:DDO.owl#DDO_0004030 + 412645002 + + + + obo:DDO.owl#DDO_0004030 + bupropion hydrochloride 50mg m/r tablet + + + + obo:DDO.owl#DDO_0004031 + DDO:DDO_0004031 + + + + obo:DDO.owl#DDO_0004031 + 409338003 + + + + obo:DDO.owl#DDO_0004031 + bupropion hydrochloride 300mg m/r tablet + + + + obo:DDO.owl#DDO_0004032 + DDO:DDO_0004032 + + + + obo:DDO.owl#DDO_0004032 + 412644003 + + + + obo:DDO.owl#DDO_0004032 + bupropion hydrochloride 200mg m/r tablet + + + + obo:DDO.owl#DDO_0004033 + DDO:DDO_0004033 + + + + obo:DDO.owl#DDO_0004033 + 323346004 + + + + obo:DDO.owl#DDO_0004033 + bupropion hydrochloride 150mg m/r tablet + + + + obo:DDO.owl#DDO_0004034 + DDO:DDO_0004034 + + + + obo:DDO.owl#DDO_0004034 + 376886007 + + + + obo:DDO.owl#DDO_0004034 + bupropion hydrochloride 100mg m/r tablet + + + + obo:DDO.owl#DDO_0004035 + DDO:DDO_0004035 + + + + obo:DDO.owl#DDO_0004035 + 321719003 + + + + obo:DDO.owl#DDO_0004035 + lithium + + + + obo:DDO.owl#DDO_0004036 + DDO:DDO_0004036 + + + + obo:DDO.owl#DDO_0004036 + 414615004 + + + + obo:DDO.owl#DDO_0004036 + lithium carbonate 150mg capsule + + + + obo:DDO.owl#DDO_0004037 + DDO:DDO_0004037 + + + + obo:DDO.owl#DDO_0004037 + 321730000 + + + + obo:DDO.owl#DDO_0004037 + lithium carbonate 250mg tablet + + + + obo:DDO.owl#DDO_0004038 + DDO:DDO_0004038 + + + + obo:DDO.owl#DDO_0004038 + 377106000 + + + + obo:DDO.owl#DDO_0004038 + lithium carbonate 300mg capsule + + + + obo:DDO.owl#DDO_0004039 + DDO:DDO_0004039 + + + + obo:DDO.owl#DDO_0004039 + 374674009 + + + + obo:DDO.owl#DDO_0004039 + lithium carbonate 300mg tablet + + + + obo:DDO.owl#DDO_0004040 + DDO:DDO_0004040 + + + + obo:DDO.owl#DDO_0004040 + 414616003 + + + + obo:DDO.owl#DDO_0004040 + lithium carbonate 600mg capsule + + + + obo:DDO.owl#DDO_0004041 + DDO:DDO_0004041 + + + + obo:DDO.owl#DDO_0004041 + 386199000 + + + + obo:DDO.owl#DDO_0004041 + lithium carbonate m/r tablet + + + + obo:DDO.owl#DDO_0004042 + DDO:DDO_0004042 + + + + obo:DDO.owl#DDO_0004042 + 321729005 + + + + obo:DDO.owl#DDO_0004042 + lithium carbonate 200mg m/r tablet + + + + obo:DDO.owl#DDO_0004043 + DDO:DDO_0004043 + + + + obo:DDO.owl#DDO_0004043 + 409433006 + + + + obo:DDO.owl#DDO_0004043 + lithium carbonate 300mg m/r tablet + + + + obo:DDO.owl#DDO_0004044 + DDO:DDO_0004044 + + + + obo:DDO.owl#DDO_0004044 + 321734009 + + + + obo:DDO.owl#DDO_0004044 + lithium carbonate 400mg m/r tablet + + + + obo:DDO.owl#DDO_0004045 + DDO:DDO_0004045 + + + + obo:DDO.owl#DDO_0004045 + 321732008 + + + + obo:DDO.owl#DDO_0004045 + lithium carbonate 450mg m/r tablet + + + + obo:DDO.owl#DDO_0004046 + DDO:DDO_0004046 + + + + obo:DDO.owl#DDO_0004046 + 17805003 + + + + obo:DDO.owl#DDO_0004046 + lithium citrate + + + + obo:DDO.owl#DDO_0004047 + DDO:DDO_0004047 + + + + obo:DDO.owl#DDO_0004047 + 321742005 + + + + obo:DDO.owl#DDO_0004047 + lithium citrate 10.8mmol/5mL oral solution + + + + obo:DDO.owl#DDO_0004048 + DDO:DDO_0004048 + + + + obo:DDO.owl#DDO_0004048 + 321741003 + + + + obo:DDO.owl#DDO_0004048 + lithium citrate 5.4mmol/5mL oral solution + + + + obo:DDO.owl#DDO_0004049 + DDO:DDO_0004049 + + + + obo:DDO.owl#DDO_0004049 + 321740002 + + + + obo:DDO.owl#DDO_0004049 + lithium citrate 520mg/5mL s/f oral liquid + + + + obo:DDO.owl#DDO_0004050 + DDO:DDO_0004050 + + + + obo:DDO.owl#DDO_0004050 + 16977003 + + + + obo:DDO.owl#DDO_0004050 + lithium carbonate + + + + obo:DDO.owl#DDO_0004051 + DDO:DDO_0004051 + + + + obo:DDO.owl#DDO_0004051 + 432164001 + + + + obo:DDO.owl#DDO_0004051 + L-methylfolate + + + + obo:DDO.owl#DDO_0004052 + DDO:DDO_0004052 + + + + obo:DDO.owl#DDO_0004052 + 434247009 + + + + obo:DDO.owl#DDO_0004052 + L-methylfolate 7.5mg tablet + + + + obo:DDO.owl#DDO_0004053 + DDO:DDO_0004053 + + + + obo:DDO.owl#DDO_0004053 + 108952000 + + + + obo:DDO.owl#DDO_0004053 + L-Tryptophan + + + + obo:DDO.owl#DDO_0004054 + DDO:DDO_0004054 + + + + obo:DDO.owl#DDO_0004054 + 349857003 + + + + obo:DDO.owl#DDO_0004054 + viloxazine + + + + obo:DDO.owl#DDO_0004055 + DDO:DDO_0004055 + + + + obo:DDO.owl#DDO_0004055 + 71770007 + + + + obo:DDO.owl#DDO_0004055 + monoamine oxidase inhibitor + + + + obo:DDO.owl#DDO_0004056 + DDO:DDO_0004056 + + + + obo:DDO.owl#DDO_0004056 + 323158005 + + + + obo:DDO.owl#DDO_0004056 + selegiline hydrochloride 5mg tablet + + + + obo:DDO.owl#DDO_0004057 + DDO:DDO_0004057 + + + + obo:DDO.owl#DDO_0004057 + 375222008 + + + + obo:DDO.owl#DDO_0004057 + selegiline hydrochloride 5mg capsule + + + + obo:DDO.owl#DDO_0004058 + DDO:DDO_0004058 + + + + obo:DDO.owl#DDO_0004058 + 323156009 + + + + obo:DDO.owl#DDO_0004058 + selegiline hydrochloride 10mg/5mL syrup + + + + obo:DDO.owl#DDO_0004059 + DDO:DDO_0004059 + + + + obo:DDO.owl#DDO_0004059 + 323157000 + + + + obo:DDO.owl#DDO_0004059 + selegiline hydrochloride 10mg tablet + + + + obo:DDO.owl#DDO_0004060 + DDO:DDO_0004060 + + + + obo:DDO.owl#DDO_0004060 + 323155008 + + + + obo:DDO.owl#DDO_0004060 + selegiline hydrochloride 1.25mg tablet + + + + obo:DDO.owl#DDO_0004061 + DDO:DDO_0004061 + + + + obo:DDO.owl#DDO_0004061 + 421194000 + + + + obo:DDO.owl#DDO_0004061 + selegiline 9mg/24hours transdermal patch + + + + obo:DDO.owl#DDO_0004062 + DDO:DDO_0004062 + + + + obo:DDO.owl#DDO_0004062 + 420949004 + + + + obo:DDO.owl#DDO_0004062 + selegiline 6mg/24hours transdermal patch + + + + obo:DDO.owl#DDO_0004063 + DDO:DDO_0004063 + + + + obo:DDO.owl#DDO_0004063 + 422187000 + + + + obo:DDO.owl#DDO_0004063 + selegiline 12mg/24hours transdermal patch + + + + obo:DDO.owl#DDO_0004064 + DDO:DDO_0004064 + + + + obo:DDO.owl#DDO_0004064 + 425199001 + + + + obo:DDO.owl#DDO_0004064 + selegiline 1.25mg orally disintegrating tablet + + + + obo:DDO.owl#DDO_0004065 + DDO:DDO_0004065 + + + + obo:DDO.owl#DDO_0004065 + 108466000 + + + + obo:DDO.owl#DDO_0004065 + selegiline + + + + obo:DDO.owl#DDO_0004066 + DDO:DDO_0004066 + + + + obo:DDO.owl#DDO_0004066 + 418125001 + + + + obo:DDO.owl#DDO_0004066 + rasagiline 1mg tablet + + + + obo:DDO.owl#DDO_0004067 + DDO:DDO_0004067 + + + + obo:DDO.owl#DDO_0004067 + 421407009 + + + + obo:DDO.owl#DDO_0004067 + rasagiline 0.5mg tablet + + + + obo:DDO.owl#DDO_0004068 + DDO:DDO_0004068 + + + + obo:DDO.owl#DDO_0004068 + 419010007 + + + + obo:DDO.owl#DDO_0004068 + rasagiline + + + + obo:DDO.owl#DDO_0004069 + DDO:DDO_0004069 + + + + obo:DDO.owl#DDO_0004069 + 21159006 + + + + obo:DDO.owl#DDO_0004069 + pargyline + + + + obo:DDO.owl#DDO_0004070 + DDO:DDO_0004070 + + + + obo:DDO.owl#DDO_0004070 + 356844002 + + + + obo:DDO.owl#DDO_0004070 + monoamine oxidase B inhibitor + + + + obo:DDO.owl#DDO_0004071 + DDO:DDO_0004071 + + + + obo:DDO.owl#DDO_0004071 + 321910008 + + + + obo:DDO.owl#DDO_0004071 + tranylcypromine 10mg tablet + + + + obo:DDO.owl#DDO_0004072 + DDO:DDO_0004072 + + + + obo:DDO.owl#DDO_0004072 + 398883004 + + + + obo:DDO.owl#DDO_0004072 + tranylcypromine + Trifluoperazine + + + + obo:DDO.owl#DDO_0004073 + DDO:DDO_0004073 + + + + obo:DDO.owl#DDO_0004073 + 89092006 + + + + obo:DDO.owl#DDO_0004073 + tranylcypromine + + + + obo:DDO.owl#DDO_0004074 + DDO:DDO_0004074 + + + + obo:DDO.owl#DDO_0004074 + 321902007 + + + + obo:DDO.owl#DDO_0004074 + phenelzine 15mg tablet + + + + obo:DDO.owl#DDO_0004075 + DDO:DDO_0004075 + + + + obo:DDO.owl#DDO_0004075 + 9500005 + + + + obo:DDO.owl#DDO_0004075 + phenelzine + + + + obo:DDO.owl#DDO_0004076 + DDO:DDO_0004076 + + + + obo:DDO.owl#DDO_0004076 + 321915003 + + + + obo:DDO.owl#DDO_0004076 + moclobemide 300mg tablet + + + + obo:DDO.owl#DDO_0004077 + DDO:DDO_0004077 + + + + obo:DDO.owl#DDO_0004077 + 321913005 + + + + obo:DDO.owl#DDO_0004077 + moclobemide 150mg tablet + + + + obo:DDO.owl#DDO_0004078 + DDO:DDO_0004078 + + + + obo:DDO.owl#DDO_0004078 + 321911007 + + + + obo:DDO.owl#DDO_0004078 + moclobemide + + + + obo:DDO.owl#DDO_0004079 + DDO:DDO_0004079 + + + + obo:DDO.owl#DDO_0004079 + 321908006 + + + + obo:DDO.owl#DDO_0004079 + isocarboxazid 10mg tablet + + + + obo:DDO.owl#DDO_0004080 + DDO:DDO_0004080 + + + + obo:DDO.owl#DDO_0004080 + 29877002 + + + + obo:DDO.owl#DDO_0004080 + isocarboxazid + + + + obo:DDO.owl#DDO_0004081 + DDO:DDO_0004081 + + + + obo:DDO.owl#DDO_0004081 + 76962009 + + + + obo:DDO.owl#DDO_0004081 + iproniazid + + + + obo:DDO.owl#DDO_0004082 + DDO:DDO_0004082 + + + + obo:DDO.owl#DDO_0004082 + 420156009 + + + + obo:DDO.owl#DDO_0004082 + monoamine oxidase A inhibitor + + + + obo:DDO.owl#DDO_0004083 + DDO:DDO_0004083 + + + + obo:DDO.owl#DDO_0004083 + 108435006 + + + + obo:DDO.owl#DDO_0004083 + nefazodone + + + + obo:DDO.owl#DDO_0004084 + DDO:DDO_0004084 + + + + obo:DDO.owl#DDO_0004084 + 321995004 + + + + obo:DDO.owl#DDO_0004084 + reboxetine + + + + obo:DDO.owl#DDO_0004085 + DDO:DDO_0004085 + + + + obo:DDO.owl#DDO_0004085 + 321984005 + + + + obo:DDO.owl#DDO_0004085 + nefazodone hydrochloride 50mg+100mg+200mg initiation tablet pack + + + + obo:DDO.owl#DDO_0004086 + DDO:DDO_0004086 + + + + obo:DDO.owl#DDO_0004086 + 376658002 + + + + obo:DDO.owl#DDO_0004086 + nefazodone hydrochloride 50mg tablet + + + + obo:DDO.owl#DDO_0004087 + DDO:DDO_0004087 + + + + obo:DDO.owl#DDO_0004087 + 412646001 + + + + obo:DDO.owl#DDO_0004087 + nefazodone hydrochloride 300mg tablet + + + + obo:DDO.owl#DDO_0004088 + DDO:DDO_0004088 + + + + obo:DDO.owl#DDO_0004088 + 376661001 + + + + obo:DDO.owl#DDO_0004088 + nefazodone hydrochloride 250mg tablet + + + + obo:DDO.owl#DDO_0004089 + DDO:DDO_0004089 + + + + obo:DDO.owl#DDO_0004089 + 321981002 + + + + obo:DDO.owl#DDO_0004089 + nefazodone hydrochloride 200mg tablet + + + + obo:DDO.owl#DDO_0004090 + DDO:DDO_0004090 + + + + obo:DDO.owl#DDO_0004090 + 376660000 + + + + obo:DDO.owl#DDO_0004090 + nefazodone hydrochloride 150mg tablet + + + + obo:DDO.owl#DDO_0004091 + DDO:DDO_0004091 + + + + obo:DDO.owl#DDO_0004091 + 321980001 + + + + obo:DDO.owl#DDO_0004091 + nefazodone hydrochloride 100mg tablet + + + + obo:DDO.owl#DDO_0004092 + DDO:DDO_0004092 + + + + obo:DDO.owl#DDO_0004092 + 412442009 + + + + obo:DDO.owl#DDO_0004092 + nefazodone hydrochloride + + + + obo:DDO.owl#DDO_0004093 + DDO:DDO_0004093 + + + + obo:DDO.owl#DDO_0004093 + 321996003 + + + + obo:DDO.owl#DDO_0004093 + reboxetine 4mg tablet + + + + obo:DDO.owl#DDO_0004094 + DDO:DDO_0004094 + + + + obo:DDO.owl#DDO_0004094 + 349854005 + + + + obo:DDO.owl#DDO_0004094 + selective serotonin re-uptake inhibitor + + + + obo:DDO.owl#DDO_0004095 + DDO:DDO_0004095 + + + + obo:DDO.owl#DDO_0004095 + 386696006 + + + + obo:DDO.owl#DDO_0004095 + venlafaxine hydrochloride 25mg tablet + + + + obo:DDO.owl#DDO_0004096 + DDO:DDO_0004096 + + + + obo:DDO.owl#DDO_0004096 + 321976006 + + + + obo:DDO.owl#DDO_0004096 + venlafaxine hydrochloride 100mg tablet + + + + obo:DDO.owl#DDO_0004097 + DDO:DDO_0004097 + + + + obo:DDO.owl#DDO_0004097 + 386694009 + + + + obo:DDO.owl#DDO_0004097 + venlafaxine 75mg tablet + + + + obo:DDO.owl#DDO_0004098 + DDO:DDO_0004098 + + + + obo:DDO.owl#DDO_0004098 + 373949001 + + + + obo:DDO.owl#DDO_0004098 + venlafaxine 50mg tablet + + + + obo:DDO.owl#DDO_0004099 + DDO:DDO_0004099 + + + + obo:DDO.owl#DDO_0004099 + 373951002 + + + + obo:DDO.owl#DDO_0004099 + venlafaxine 37.5mg tablet + + + + obo:DDO.owl#DDO_0004100 + DDO:DDO_0004100 + + + + obo:DDO.owl#DDO_0004100 + 373949001 + + + + obo:DDO.owl#DDO_0004100 + venlafaxine tablet + + + + obo:DDO.owl#DDO_0004101 + DDO:DDO_0004101 + + + + obo:DDO.owl#DDO_0004101 + 321974009 + + + + obo:DDO.owl#DDO_0004101 + venlafaxine hydrochloride 37.5mg m/r capsule + + + + obo:DDO.owl#DDO_0004102 + DDO:DDO_0004102 + + + + obo:DDO.owl#DDO_0004102 + 373958008 + + + + obo:DDO.owl#DDO_0004102 + venlafaxine 75mg m/r capsule + + + + obo:DDO.owl#DDO_0004103 + DDO:DDO_0004103 + + + + obo:DDO.owl#DDO_0004103 + 412531003 + + + + obo:DDO.owl#DDO_0004103 + venlafaxine 150mg m/r capsule + + + + obo:DDO.owl#DDO_0004104 + DDO:DDO_0004104 + + + + obo:DDO.owl#DDO_0004104 + 373951002 + + + + obo:DDO.owl#DDO_0004104 + venlafaxine m/r capsule + + + + obo:DDO.owl#DDO_0004105 + DDO:DDO_0004105 + + + + obo:DDO.owl#DDO_0004105 + 321971001 + + + + obo:DDO.owl#DDO_0004105 + venlafaxine hydrochloride 37.5mg m/r capsule + + + + obo:DDO.owl#DDO_0004106 + DDO:DDO_0004106 + + + + obo:DDO.owl#DDO_0004106 + 321970000 + + + + obo:DDO.owl#DDO_0004106 + venlafaxine hydrochloride 25mg tablet + + + + obo:DDO.owl#DDO_0004107 + DDO:DDO_0004107 + + + + obo:DDO.owl#DDO_0004107 + 373958008 + + + + obo:DDO.owl#DDO_0004107 + venlafaxine hydrochloride 100mg tablet + + + + obo:DDO.owl#DDO_0004108 + DDO:DDO_0004108 + + + + obo:DDO.owl#DDO_0004108 + 321978007 + + + + obo:DDO.owl#DDO_0004108 + venlafaxine hydrochloride + + + + obo:DDO.owl#DDO_0004109 + DDO:DDO_0004109 + + + + obo:DDO.owl#DDO_0004109 + 108432009 + + + + obo:DDO.owl#DDO_0004109 + venlafaxine + + + + obo:DDO.owl#DDO_0004110 + DDO:DDO_0004110 + + + + obo:DDO.owl#DDO_0004110 + 412510001 + + + + obo:DDO.owl#DDO_0004110 + sertraline hydrochloride + + + + obo:DDO.owl#DDO_0004111 + DDO:DDO_0004111 + + + + obo:DDO.owl#DDO_0004111 + 321959007 + + + + obo:DDO.owl#DDO_0004111 + sertraline 50mg tablet + + + + obo:DDO.owl#DDO_0004112 + DDO:DDO_0004112 + + + + obo:DDO.owl#DDO_0004112 + 421438005 + + + + obo:DDO.owl#DDO_0004112 + sertraline 25mg tablet + + + + obo:DDO.owl#DDO_0004113 + DDO:DDO_0004113 + + + + obo:DDO.owl#DDO_0004113 + 421717000 + + + + obo:DDO.owl#DDO_0004113 + sertraline 20mg/mL oral solution + + + + obo:DDO.owl#DDO_0004114 + DDO:DDO_0004114 + + + + obo:DDO.owl#DDO_0004114 + 321960002 + + + + obo:DDO.owl#DDO_0004114 + sertraline 100mg tablet + + + + obo:DDO.owl#DDO_0004115 + DDO:DDO_0004115 + + + + obo:DDO.owl#DDO_0004115 + 321958004 + + + + obo:DDO.owl#DDO_0004115 + sertraline + + + + obo:DDO.owl#DDO_0004116 + DDO:DDO_0004116 + + + + obo:DDO.owl#DDO_0004116 + 422084009 + + + + obo:DDO.owl#DDO_0004116 + paroxetine 40mg tablet + + + + obo:DDO.owl#DDO_0004117 + DDO:DDO_0004117 + + + + obo:DDO.owl#DDO_0004117 + 386594002 + + + + obo:DDO.owl#DDO_0004117 + paroxetine 37.5mg tablet controlled-release + + + + obo:DDO.owl#DDO_0004118 + DDO:DDO_0004118 + + + + obo:DDO.owl#DDO_0004118 + 321966008 + + + + obo:DDO.owl#DDO_0004118 + paroxetine 30mg tablet + + + + obo:DDO.owl#DDO_0004119 + DDO:DDO_0004119 + + + + obo:DDO.owl#DDO_0004119 + 386593008 + + + + obo:DDO.owl#DDO_0004119 + paroxetine 25mg tablet controlled-release + + + + obo:DDO.owl#DDO_0004120 + DDO:DDO_0004120 + + + + obo:DDO.owl#DDO_0004120 + 321964006 + + + + obo:DDO.owl#DDO_0004120 + paroxetine 20mg tablet + + + + obo:DDO.owl#DDO_0004121 + DDO:DDO_0004121 + + + + obo:DDO.owl#DDO_0004121 + 386592003 + + + + obo:DDO.owl#DDO_0004121 + paroxetine 12.5mg tablet controlled-release + + + + obo:DDO.owl#DDO_0004122 + DDO:DDO_0004122 + + + + obo:DDO.owl#DDO_0004122 + 321968009 + + + + obo:DDO.owl#DDO_0004122 + paroxetine 10mg/5mL s/f liquid + + + + obo:DDO.owl#DDO_0004123 + DDO:DDO_0004123 + + + + obo:DDO.owl#DDO_0004123 + 421041006 + + + + obo:DDO.owl#DDO_0004123 + paroxetine 10mg tablet + + + + obo:DDO.owl#DDO_0004124 + DDO:DDO_0004124 + + + + obo:DDO.owl#DDO_0004124 + 321963000 + + + + obo:DDO.owl#DDO_0004124 + oral form paroxetine + + + + obo:DDO.owl#DDO_0004125 + DDO:DDO_0004125 + + + + obo:DDO.owl#DDO_0004125 + 386590006 + + + + obo:DDO.owl#DDO_0004125 + paroxetine + + + + obo:DDO.owl#DDO_0004126 + DDO:DDO_0004126 + + + + obo:DDO.owl#DDO_0004126 + 386588005 + + + + obo:DDO.owl#DDO_0004126 + milnacipran hydrochloride 50mg tablet + + + + obo:DDO.owl#DDO_0004127 + DDO:DDO_0004127 + + + + obo:DDO.owl#DDO_0004127 + 409172004 + + + + obo:DDO.owl#DDO_0004127 + milnacipran hydrochloride 25mg tablet + + + + obo:DDO.owl#DDO_0004128 + DDO:DDO_0004128 + + + + obo:DDO.owl#DDO_0004128 + 409171006 + + + + obo:DDO.owl#DDO_0004128 + milnacipran hydrochloride 12.5mg tablet + + + + obo:DDO.owl#DDO_0004129 + DDO:DDO_0004129 + + + + obo:DDO.owl#DDO_0004129 + 430084007 + + + + obo:DDO.owl#DDO_0004129 + milnacipran hydrochloride 100mg tablet + + + + obo:DDO.owl#DDO_0004130 + DDO:DDO_0004130 + + + + obo:DDO.owl#DDO_0004130 + 409174003 + + + + obo:DDO.owl#DDO_0004130 + milnacipran hydrochloride + + + + obo:DDO.owl#DDO_0004131 + DDO:DDO_0004131 + + + + obo:DDO.owl#DDO_0004131 + 409173009 + + + + obo:DDO.owl#DDO_0004131 + milnacipran + + + + obo:DDO.owl#DDO_0004132 + DDO:DDO_0004132 + + + + obo:DDO.owl#DDO_0004132 + 376803002 + + + + obo:DDO.owl#DDO_0004132 + fluvoxamine maleate 50mg tablet + + + + obo:DDO.owl#DDO_0004133 + DDO:DDO_0004133 + + + + obo:DDO.owl#DDO_0004133 + 409350009 + + + + obo:DDO.owl#DDO_0004133 + fluvoxamine maleate 25mg tablet + + + + obo:DDO.owl#DDO_0004134 + DDO:DDO_0004134 + + + + obo:DDO.owl#DDO_0004134 + 373965000 + + + + obo:DDO.owl#DDO_0004134 + fluvoxamine maleate 100mg tablet + + + + obo:DDO.owl#DDO_0004135 + DDO:DDO_0004135 + + + + obo:DDO.owl#DDO_0004135 + 321954002 + + + + obo:DDO.owl#DDO_0004135 + fluvoxamine 150mg extended release capsule + + + + obo:DDO.owl#DDO_0004136 + DDO:DDO_0004136 + + + + obo:DDO.owl#DDO_0004136 + 321951005 + + + + obo:DDO.owl#DDO_0004136 + fluvoxamine 100mg extended release capsule + + + + obo:DDO.owl#DDO_0004137 + DDO:DDO_0004137 + + + + obo:DDO.owl#DDO_0004137 + 321949006 + + + + obo:DDO.owl#DDO_0004137 + fluvoxamine + + + + obo:DDO.owl#DDO_0004138 + DDO:DDO_0004138 + + + + obo:DDO.owl#DDO_0004138 + 409171006 + + + + obo:DDO.owl#DDO_0004138 + fluoxetine 90mg m/r capsule + + + + obo:DDO.owl#DDO_0004139 + DDO:DDO_0004139 + + + + obo:DDO.owl#DDO_0004139 + 441611004 + + + + obo:DDO.owl#DDO_0004139 + oral form fluoxetine m/r capsule + + + + obo:DDO.owl#DDO_0004140 + DDO:DDO_0004140 + + + + obo:DDO.owl#DDO_0004140 + 441732000 + + + + obo:DDO.owl#DDO_0004140 + olanzapine 6mg/fluoxetine 50mg capsule + + + + obo:DDO.owl#DDO_0004141 + DDO:DDO_0004141 + + + + obo:DDO.owl#DDO_0004141 + 442542004 + + + + obo:DDO.owl#DDO_0004141 + olanzapine 6mg/fluoxetine 25mg capsule + + + + obo:DDO.owl#DDO_0004142 + DDO:DDO_0004142 + + + + obo:DDO.owl#DDO_0004142 + 374673003 + + + + obo:DDO.owl#DDO_0004142 + olanzapine 3mg/fluoxetine 25mg capsule + + + + obo:DDO.owl#DDO_0004143 + DDO:DDO_0004143 + + + + obo:DDO.owl#DDO_0004143 + 430264001 + + + + obo:DDO.owl#DDO_0004143 + olanzapine 12mg/fluoxetine 50mg capsule + + + + obo:DDO.owl#DDO_0004144 + DDO:DDO_0004144 + + + + obo:DDO.owl#DDO_0004144 + 96213009 + + + + obo:DDO.owl#DDO_0004144 + olanzapine 12mg/fluoxetine 25mg capsule + + + + obo:DDO.owl#DDO_0004145 + DDO:DDO_0004145 + + + + obo:DDO.owl#DDO_0004145 + 373959000 + + + + obo:DDO.owl#DDO_0004145 + fluoxetine hydrochloride 40mg capsule + + + + obo:DDO.owl#DDO_0004146 + DDO:DDO_0004146 + + + + obo:DDO.owl#DDO_0004146 + 386587000 + + + + obo:DDO.owl#DDO_0004146 + fluoxetine hydrochloride 20mg tablet + + + + obo:DDO.owl#DDO_0004147 + DDO:DDO_0004147 + + + + obo:DDO.owl#DDO_0004147 + 409172004 + + + + obo:DDO.owl#DDO_0004147 + fluoxetine hydrochloride 10mg tablet + + + + obo:DDO.owl#DDO_0004148 + DDO:DDO_0004148 + + + + obo:DDO.owl#DDO_0004148 + 430084007 + + + + obo:DDO.owl#DDO_0004148 + fluoxetine 60mg capsule + + + + obo:DDO.owl#DDO_0004149 + DDO:DDO_0004149 + + + + obo:DDO.owl#DDO_0004149 + 409174003 + + + + obo:DDO.owl#DDO_0004149 + fluoxetine 20mg/5mL oral liquid + + + + obo:DDO.owl#DDO_0004150 + DDO:DDO_0004150 + + + + obo:DDO.owl#DDO_0004150 + 409173009 + + + + obo:DDO.owl#DDO_0004150 + fluoxetine 20mg capsule + + + + obo:DDO.owl#DDO_0004151 + DDO:DDO_0004151 + + + + obo:DDO.owl#DDO_0004151 + 409170007 + + + + obo:DDO.owl#DDO_0004151 + fluoxetine 10mg capsule + + + + obo:DDO.owl#DDO_0004152 + DDO:DDO_0004152 + + + + obo:DDO.owl#DDO_0004152 + 441568008 + + + + obo:DDO.owl#DDO_0004152 + oral form fluoxetine + + + + obo:DDO.owl#DDO_0004153 + DDO:DDO_0004153 + + + + obo:DDO.owl#DDO_0004153 + 441961005 + + + + obo:DDO.owl#DDO_0004153 + olanzapine 6mg/fluoxetine 50mg capsule + + + + obo:DDO.owl#DDO_0004154 + DDO:DDO_0004154 + + + + obo:DDO.owl#DDO_0004154 + 442619000 + + + + obo:DDO.owl#DDO_0004154 + olanzapine 6mg/fluoxetine 25mg capsule + + + + obo:DDO.owl#DDO_0004155 + DDO:DDO_0004155 + + + + obo:DDO.owl#DDO_0004155 + 321945000 + + + + obo:DDO.owl#DDO_0004155 + olanzapine 3mg/fluoxetine 25mg capsule + + + + obo:DDO.owl#DDO_0004156 + DDO:DDO_0004156 + + + + obo:DDO.owl#DDO_0004156 + 321947008 + + + + obo:DDO.owl#DDO_0004156 + olanzapine 12mg/fluoxetine 50mg capsule + + + + obo:DDO.owl#DDO_0004157 + DDO:DDO_0004157 + + + + obo:DDO.owl#DDO_0004157 + 431064001 + + + + obo:DDO.owl#DDO_0004157 + olanzapine 12mg/fluoxetine 25mg capsule + + + + obo:DDO.owl#DDO_0004158 + DDO:DDO_0004158 + + + + obo:DDO.owl#DDO_0004158 + 386589002 + + + + obo:DDO.owl#DDO_0004158 + olanzapine + fluoxetine + + + + obo:DDO.owl#DDO_0004159 + DDO:DDO_0004159 + + + + obo:DDO.owl#DDO_0004159 + 53640004 + + + + obo:DDO.owl#DDO_0004159 + fluoxetine + + + + obo:DDO.owl#DDO_0004160 + DDO:DDO_0004160 + + + + obo:DDO.owl#DDO_0004160 + 409151002 + + + + obo:DDO.owl#DDO_0004160 + escitalopram 5mg/5mL oral solution + + + + obo:DDO.owl#DDO_0004161 + DDO:DDO_0004161 + + + + obo:DDO.owl#DDO_0004161 + 409150001 + + + + obo:DDO.owl#DDO_0004161 + escitalopram 5mg tablet + + + + obo:DDO.owl#DDO_0004162 + DDO:DDO_0004162 + + + + obo:DDO.owl#DDO_0004162 + 408067001 + + + + obo:DDO.owl#DDO_0004162 + escitalopram 20mg tablet + + + + obo:DDO.owl#DDO_0004163 + DDO:DDO_0004163 + + + + obo:DDO.owl#DDO_0004163 + 407915000 + + + + obo:DDO.owl#DDO_0004163 + escitalopram 10mg tablet + + + + obo:DDO.owl#DDO_0004164 + DDO:DDO_0004164 + + + + obo:DDO.owl#DDO_0004164 + 395246009 + + + + obo:DDO.owl#DDO_0004164 + escitalopram + + + + obo:DDO.owl#DDO_0004165 + DDO:DDO_0004165 + + + + obo:DDO.owl#DDO_0004165 + 416946001 + + + + obo:DDO.owl#DDO_0004165 + duloxetine 60mg gastro-resistant capsule + + + + obo:DDO.owl#DDO_0004166 + DDO:DDO_0004166 + + + + obo:DDO.owl#DDO_0004166 + 421938004 + + + + obo:DDO.owl#DDO_0004166 + citalopram 10mg orally disintegrating tablet + + + + obo:DDO.owl#DDO_0004167 + DDO:DDO_0004167 + + + + obo:DDO.owl#DDO_0004167 + 321989000 + + + + obo:DDO.owl#DDO_0004167 + citalopram 10mg tablet + + + + obo:DDO.owl#DDO_0004168 + DDO:DDO_0004168 + + + + obo:DDO.owl#DDO_0004168 + 421543001 + + + + obo:DDO.owl#DDO_0004168 + citalopram 20mg orally disintegrating tablet + + + + obo:DDO.owl#DDO_0004169 + DDO:DDO_0004169 + + + + obo:DDO.owl#DDO_0004169 + 321987003 + + + + obo:DDO.owl#DDO_0004169 + citalopram 20mg tablet + + + + obo:DDO.owl#DDO_0004170 + DDO:DDO_0004170 + + + + obo:DDO.owl#DDO_0004170 + 421375004 + + + + obo:DDO.owl#DDO_0004170 + citalopram 40mg orally disintegrating tablet + + + + obo:DDO.owl#DDO_0004171 + DDO:DDO_0004171 + + + + obo:DDO.owl#DDO_0004171 + 321991008 + + + + obo:DDO.owl#DDO_0004171 + citalopram 40mg tablet + + + + obo:DDO.owl#DDO_0004172 + DDO:DDO_0004172 + + + + obo:DDO.owl#DDO_0004172 + 321994000 + + + + obo:DDO.owl#DDO_0004172 + citalopram 40mg/mL oral drops + + + + obo:DDO.owl#DDO_0004173 + DDO:DDO_0004173 + + + + obo:DDO.owl#DDO_0004173 + 374330001 + + + + obo:DDO.owl#DDO_0004173 + citalopram hydrobromide 10mg/5mL solution + + + + obo:DDO.owl#DDO_0004174 + DDO:DDO_0004174 + + + + obo:DDO.owl#DDO_0004174 + 430271006 + + + + obo:DDO.owl#DDO_0004174 + desvenlafaxine + + + + obo:DDO.owl#DDO_0004175 + DDO:DDO_0004175 + + + + obo:DDO.owl#DDO_0004175 + 433293002 + + + + obo:DDO.owl#DDO_0004175 + desvenlafaxine 100mg tablet + + + + obo:DDO.owl#DDO_0004176 + DDO:DDO_0004176 + + + + obo:DDO.owl#DDO_0004176 + 433294008 + + + + obo:DDO.owl#DDO_0004176 + desvenlafaxine 50mg tablet + + + + obo:DDO.owl#DDO_0004177 + DDO:DDO_0004177 + + + + obo:DDO.owl#DDO_0004177 + 407033009 + + + + obo:DDO.owl#DDO_0004177 + duloxetine + + + + obo:DDO.owl#DDO_0004178 + DDO:DDO_0004178 + + + + obo:DDO.owl#DDO_0004178 + 414065009 + + + + obo:DDO.owl#DDO_0004178 + duloxetine 20mg m/r capsule + + + + obo:DDO.owl#DDO_0004179 + DDO:DDO_0004179 + + + + obo:DDO.owl#DDO_0004179 + 417231005 + + + + obo:DDO.owl#DDO_0004179 + duloxetine 30mg gastro-resistant capsule + + + + obo:DDO.owl#DDO_0004180 + DDO:DDO_0004180 + + + + obo:DDO.owl#DDO_0004180 + 414067001 + + + + obo:DDO.owl#DDO_0004180 + duloxetine 40mg m/r capsule + + + + obo:DDO.owl#DDO_0004181 + DDO:DDO_0004181 + + + + obo:DDO.owl#DDO_0004181 + 321986007 + + + + obo:DDO.owl#DDO_0004181 + citalopram + + + + obo:DDO.owl#DDO_0004182 + DDO:DDO_0004182 + + + + obo:DDO.owl#DDO_0004182 + 11430001 + + + + obo:DDO.owl#DDO_0004182 + tetracyclic antidepressant + + + + obo:DDO.owl#DDO_0004183 + DDO:DDO_0004183 + + + + obo:DDO.owl#DDO_0004183 + 32823007 + + + + obo:DDO.owl#DDO_0004183 + maprotiline + + + + obo:DDO.owl#DDO_0004184 + DDO:DDO_0004184 + + + + obo:DDO.owl#DDO_0004184 + 21844000 + + + + obo:DDO.owl#DDO_0004184 + maprotiline hydrochloride 75mg tablet + + + + obo:DDO.owl#DDO_0004185 + DDO:DDO_0004185 + + + + obo:DDO.owl#DDO_0004185 + 321842001 + + + + obo:DDO.owl#DDO_0004185 + maprotiline hydrochloride 50mg tablet + + + + obo:DDO.owl#DDO_0004186 + DDO:DDO_0004186 + + + + obo:DDO.owl#DDO_0004186 + 321841008 + + + + obo:DDO.owl#DDO_0004186 + maprotiline hydrochloride 25mg tablet + + + + obo:DDO.owl#DDO_0004187 + DDO:DDO_0004187 + + + + obo:DDO.owl#DDO_0004187 + 321841008 + + + + obo:DDO.owl#DDO_0004187 + maprotiline hydrochloride 10mg tablet + + + + obo:DDO.owl#DDO_0004188 + DDO:DDO_0004188 + + + + obo:DDO.owl#DDO_0004188 + 96200003 + + + + obo:DDO.owl#DDO_0004188 + mianserin + + + + obo:DDO.owl#DDO_0004189 + DDO:DDO_0004189 + + + + obo:DDO.owl#DDO_0004189 + 321845004 + + + + obo:DDO.owl#DDO_0004189 + mianserin hydrochloride + + + + obo:DDO.owl#DDO_0004190 + DDO:DDO_0004190 + + + + obo:DDO.owl#DDO_0004190 + 321848002 + + + + obo:DDO.owl#DDO_0004190 + mianserin hydrochloride 30mg tablet + + + + obo:DDO.owl#DDO_0004191 + DDO:DDO_0004191 + + + + obo:DDO.owl#DDO_0004191 + 321847007 + + + + obo:DDO.owl#DDO_0004191 + mianserin hydrochloride 20mg tablet + + + + obo:DDO.owl#DDO_0004192 + DDO:DDO_0004192 + + + + obo:DDO.owl#DDO_0004192 + 321846003 + + + + obo:DDO.owl#DDO_0004192 + mianserin hydrochloride 10mg tablet + + + + obo:DDO.owl#DDO_0004193 + DDO:DDO_0004193 + + + + obo:DDO.owl#DDO_0004193 + 108430001 + + + + obo:DDO.owl#DDO_0004193 + mirtazapine + + + + obo:DDO.owl#DDO_0004194 + DDO:DDO_0004194 + + + + obo:DDO.owl#DDO_0004194 + 411122005 + + + + obo:DDO.owl#DDO_0004194 + mirtazapine 7.5mg tablet + + + + obo:DDO.owl#DDO_0004195 + DDO:DDO_0004195 + + + + obo:DDO.owl#DDO_0004195 + 375196006 + + + + obo:DDO.owl#DDO_0004195 + mirtazapine 45mg tablet + + + + obo:DDO.owl#DDO_0004196 + DDO:DDO_0004196 + + + + obo:DDO.owl#DDO_0004196 + 709456006 + + + + obo:DDO.owl#DDO_0004196 + mirtazapine 45mg orodispersible tablet + + + + obo:DDO.owl#DDO_0004197 + DDO:DDO_0004197 + + + + obo:DDO.owl#DDO_0004197 + 321998002 + + + + obo:DDO.owl#DDO_0004197 + mirtazapine 30mg tablet + + + + obo:DDO.owl#DDO_0004198 + DDO:DDO_0004198 + + + + obo:DDO.owl#DDO_0004198 + 375195005 + + + + obo:DDO.owl#DDO_0004198 + mirtazapine 30mg orodispersible tablet + + + + obo:DDO.owl#DDO_0004199 + DDO:DDO_0004199 + + + + obo:DDO.owl#DDO_0004199 + 375193003 + + + + obo:DDO.owl#DDO_0004199 + mirtazapine 15mg tablet + + + + obo:DDO.owl#DDO_0004200 + DDO:DDO_0004200 + + + + obo:DDO.owl#DDO_0004200 + 375194009 + + + + obo:DDO.owl#DDO_0004200 + mirtazapine 15mg orodispersible tablet + + + + obo:DDO.owl#DDO_0004201 + DDO:DDO_0004201 + + + + obo:DDO.owl#DDO_0004201 + 386595001 + + + + obo:DDO.owl#DDO_0004201 + triazolopyridine + + + + obo:DDO.owl#DDO_0004202 + DDO:DDO_0004202 + + + + obo:DDO.owl#DDO_0004202 + 7336002 + + + + obo:DDO.owl#DDO_0004202 + trazodone + + + + obo:DDO.owl#DDO_0004203 + DDO:DDO_0004203 + + + + obo:DDO.owl#DDO_0004203 + 33219003 + + + + obo:DDO.owl#DDO_0004203 + tricyclic antidepressant + + + + obo:DDO.owl#DDO_0004204 + DDO:DDO_0004204 + + + + obo:DDO.owl#DDO_0004204 + 321882008 + + + + obo:DDO.owl#DDO_0004204 + trazodone hydrochloride 50mg/5mL liquid + + + + obo:DDO.owl#DDO_0004205 + DDO:DDO_0004205 + + + + obo:DDO.owl#DDO_0004205 + 376689003 + + + + obo:DDO.owl#DDO_0004205 + trazodone hydrochloride 50mg tablet + + + + obo:DDO.owl#DDO_0004206 + DDO:DDO_0004206 + + + + obo:DDO.owl#DDO_0004206 + 321881001 + + + + obo:DDO.owl#DDO_0004206 + trazodone hydrochloride 50mg capsule + + + + obo:DDO.owl#DDO_0004207 + DDO:DDO_0004207 + + + + obo:DDO.owl#DDO_0004207 + 376695002 + + + + obo:DDO.owl#DDO_0004207 + trazodone hydrochloride 300mg tablet + + + + obo:DDO.owl#DDO_0004208 + DDO:DDO_0004208 + + + + obo:DDO.owl#DDO_0004208 + 444774009 + + + + obo:DDO.owl#DDO_0004208 + trazodone hydrochloride 300mg extended release tablet + + + + obo:DDO.owl#DDO_0004209 + DDO:DDO_0004209 + + + + obo:DDO.owl#DDO_0004209 + 321877001 + + + + obo:DDO.owl#DDO_0004209 + trazodone hydrochloride 150mg tablet + + + + obo:DDO.owl#DDO_0004210 + DDO:DDO_0004210 + + + + obo:DDO.owl#DDO_0004210 + 445292007 + + + + obo:DDO.owl#DDO_0004210 + trazodone hydrochloride 150mg extended release tablet + + + + obo:DDO.owl#DDO_0004211 + DDO:DDO_0004211 + + + + obo:DDO.owl#DDO_0004211 + 376690007 + + + + obo:DDO.owl#DDO_0004211 + trazodone hydrochloride 100mg tablet + + + + obo:DDO.owl#DDO_0004212 + DDO:DDO_0004212 + + + + obo:DDO.owl#DDO_0004212 + 321880000 + + + + obo:DDO.owl#DDO_0004212 + trazodone hydrochloride 100mg capsule + + + + obo:DDO.owl#DDO_0004213 + DDO:DDO_0004213 + + + + obo:DDO.owl#DDO_0004213 + 40589005 + + + + obo:DDO.owl#DDO_0004213 + amitriptyline + + + + obo:DDO.owl#DDO_0004214 + DDO:DDO_0004214 + + + + obo:DDO.owl#DDO_0004214 + 421323008 + + + + obo:DDO.owl#DDO_0004214 + amitriptyline + perphenazine + + + + obo:DDO.owl#DDO_0004215 + DDO:DDO_0004215 + + + + obo:DDO.owl#DDO_0004215 + 386210006 + + + + obo:DDO.owl#DDO_0004215 + amitriptyline hydrochloride+perphenazine 50mg/4mg tablet + + + + obo:DDO.owl#DDO_0004216 + DDO:DDO_0004216 + + + + obo:DDO.owl#DDO_0004216 + 386209001 + + + + obo:DDO.owl#DDO_0004216 + amitriptyline hydrochloride+perphenazine 25mg/4mg tablet + + + + obo:DDO.owl#DDO_0004217 + DDO:DDO_0004217 + + + + obo:DDO.owl#DDO_0004217 + 321929002 + + + + obo:DDO.owl#DDO_0004217 + amitriptyline hydrochloride+perphenazine 25mg/2mg tablet + + + + obo:DDO.owl#DDO_0004218 + DDO:DDO_0004218 + + + + obo:DDO.owl#DDO_0004218 + 321930007 + + + + obo:DDO.owl#DDO_0004218 + amitriptyline hydrochloride+perphenazine 10mg/2mg tablet + + + + obo:DDO.owl#DDO_0004219 + DDO:DDO_0004219 + + + + obo:DDO.owl#DDO_0004219 + 377587000 + + + + obo:DDO.owl#DDO_0004219 + amitriptyline hydrochloride + perphenazine 10mg/4mg tablet + + + + obo:DDO.owl#DDO_0004220 + DDO:DDO_0004220 + + + + obo:DDO.owl#DDO_0004220 + 398657007 + + + + obo:DDO.owl#DDO_0004220 + amitriptyline hydrochloride + chlordiazepoxide + + + + obo:DDO.owl#DDO_0004221 + DDO:DDO_0004221 + + + + obo:DDO.owl#DDO_0004221 + 429315009 + + + + obo:DDO.owl#DDO_0004221 + amitriptyline 12.5mg/chlordiazepoxide 10mg tablet + + + + obo:DDO.owl#DDO_0004222 + DDO:DDO_0004222 + + + + obo:DDO.owl#DDO_0004222 + 377576008 + + + + obo:DDO.owl#DDO_0004222 + amitriptyline hydrochloride+chlordiazepoxide 12.5mg/5mg tablet + + + + obo:DDO.owl#DDO_0004223 + DDO:DDO_0004223 + + + + obo:DDO.owl#DDO_0004223 + 386599007 + + + + obo:DDO.owl#DDO_0004223 + oral form amitriptyline + + + + obo:DDO.owl#DDO_0004224 + DDO:DDO_0004224 + + + + obo:DDO.owl#DDO_0004224 + 374039009 + + + + obo:DDO.owl#DDO_0004224 + amitriptyline hydrochloride 10mg solution + + + + obo:DDO.owl#DDO_0004225 + DDO:DDO_0004225 + + + + obo:DDO.owl#DDO_0004225 + 386601009 + + + + obo:DDO.owl#DDO_0004225 + parenteral form amitriptyline + + + + obo:DDO.owl#DDO_0004226 + DDO:DDO_0004226 + + + + obo:DDO.owl#DDO_0004226 + 386210006 + + + + obo:DDO.owl#DDO_0004226 + amitriptyline hydrochloride+perphenazine 50mg/4mg tablet + + + + obo:DDO.owl#DDO_0004227 + DDO:DDO_0004227 + + + + obo:DDO.owl#DDO_0004227 + 386209001 + + + + obo:DDO.owl#DDO_0004227 + amitriptyline hydrochloride+perphenazine 25mg/4mg tablet + + + + obo:DDO.owl#DDO_0004228 + DDO:DDO_0004228 + + + + obo:DDO.owl#DDO_0004228 + 321929002 + + + + obo:DDO.owl#DDO_0004228 + amitriptyline hydrochloride+perphenazine 25mg/2mg tablet + + + + obo:DDO.owl#DDO_0004229 + DDO:DDO_0004229 + + + + obo:DDO.owl#DDO_0004229 + 321930007 + + + + obo:DDO.owl#DDO_0004229 + amitriptyline hydrochloride+perphenazine 10mg/2mg tablet + + + + obo:DDO.owl#DDO_0004230 + DDO:DDO_0004230 + + + + obo:DDO.owl#DDO_0004230 + 377576008 + + + + obo:DDO.owl#DDO_0004230 + amitriptyline hydrochloride+chlordiazepoxide 12.5mg/5mg tablet + + + + obo:DDO.owl#DDO_0004231 + DDO:DDO_0004231 + + + + obo:DDO.owl#DDO_0004231 + 374035003 + + + + obo:DDO.owl#DDO_0004231 + amitriptyline hydrochloride 75mg tablet + + + + obo:DDO.owl#DDO_0004232 + DDO:DDO_0004232 + + + + obo:DDO.owl#DDO_0004232 + 321747004 + + + + obo:DDO.owl#DDO_0004232 + amitriptyline hydrochloride 50mg tablet + + + + obo:DDO.owl#DDO_0004233 + DDO:DDO_0004233 + + + + obo:DDO.owl#DDO_0004233 + 321765000 + + + + obo:DDO.owl#DDO_0004233 + amitriptyline hydrochloride 50mg m/r capsule + + + + obo:DDO.owl#DDO_0004234 + DDO:DDO_0004234 + + + + obo:DDO.owl#DDO_0004234 + 321746008 + + + + obo:DDO.owl#DDO_0004234 + amitriptyline hydrochloride 25mg tablet + + + + obo:DDO.owl#DDO_0004235 + DDO:DDO_0004235 + + + + obo:DDO.owl#DDO_0004235 + 321763007 + + + + obo:DDO.owl#DDO_0004235 + amitriptyline hydrochloride 25mg m/r capsule + + + + obo:DDO.owl#DDO_0004236 + DDO:DDO_0004236 + + + + obo:DDO.owl#DDO_0004236 + 374038001 + + + + obo:DDO.owl#DDO_0004236 + amitriptyline hydrochloride 150mg tablet + + + + obo:DDO.owl#DDO_0004237 + DDO:DDO_0004237 + + + + obo:DDO.owl#DDO_0004237 + 321745007 + + + + obo:DDO.owl#DDO_0004237 + amitriptyline hydrochloride 10mg tablet + + + + obo:DDO.owl#DDO_0004238 + DDO:DDO_0004238 + + + + obo:DDO.owl#DDO_0004238 + 374037006 + + + + obo:DDO.owl#DDO_0004238 + amitriptyline hydrochloride 100mg tablet + + + + obo:DDO.owl#DDO_0004239 + DDO:DDO_0004239 + + + + obo:DDO.owl#DDO_0004239 + 377587000 + + + + obo:DDO.owl#DDO_0004239 + amitriptyline hydrochloride + perphenazine 10mg/4mg tablet + + + + obo:DDO.owl#DDO_0004240 + DDO:DDO_0004240 + + + + obo:DDO.owl#DDO_0004240 + 321762002 + + + + obo:DDO.owl#DDO_0004240 + amitriptyline 50mg/5mL s/f oral solution + + + + obo:DDO.owl#DDO_0004241 + DDO:DDO_0004241 + + + + obo:DDO.owl#DDO_0004241 + 321761009 + + + + obo:DDO.owl#DDO_0004241 + amitriptyline 25mg/5mL s/f oral solution + + + + obo:DDO.owl#DDO_0004242 + DDO:DDO_0004242 + + + + obo:DDO.owl#DDO_0004242 + 429315009 + + + + obo:DDO.owl#DDO_0004242 + amitriptyline 12.5mg/chlordiazepoxide 10mg tablet + + + + obo:DDO.owl#DDO_0004243 + DDO:DDO_0004243 + + + + obo:DDO.owl#DDO_0004243 + 29840005 + + + + obo:DDO.owl#DDO_0004243 + amoxapine + + + + obo:DDO.owl#DDO_0004244 + DDO:DDO_0004244 + + + + obo:DDO.owl#DDO_0004244 + 321893005 + + + + obo:DDO.owl#DDO_0004244 + amoxapine 50mg tablet + + + + obo:DDO.owl#DDO_0004245 + DDO:DDO_0004245 + + + + obo:DDO.owl#DDO_0004245 + 386603007 + + + + obo:DDO.owl#DDO_0004245 + amoxapine 25mg tablet + + + + obo:DDO.owl#DDO_0004246 + DDO:DDO_0004246 + + + + obo:DDO.owl#DDO_0004246 + 386602002 + + + + obo:DDO.owl#DDO_0004246 + amoxapine 150mg tablet + + + + obo:DDO.owl#DDO_0004247 + DDO:DDO_0004247 + + + + obo:DDO.owl#DDO_0004247 + 321894004 + + + + obo:DDO.owl#DDO_0004247 + amoxapine 100mg tablet + + + + obo:DDO.owl#DDO_0004248 + DDO:DDO_0004248 + + + + obo:DDO.owl#DDO_0004248 + 115544001 + + + + obo:DDO.owl#DDO_0004248 + butriptyline + + + + obo:DDO.owl#DDO_0004249 + DDO:DDO_0004249 + + + + obo:DDO.owl#DDO_0004249 + 96209002 + + + + obo:DDO.owl#DDO_0004249 + clomipramine + + + + obo:DDO.owl#DDO_0004250 + DDO:DDO_0004250 + + + + obo:DDO.owl#DDO_0004250 + 116520006 + + + + obo:DDO.owl#DDO_0004250 + clomipramine hydrochloride + + + + obo:DDO.owl#DDO_0004251 + DDO:DDO_0004251 + + + + obo:DDO.owl#DDO_0004251 + 321790003 + + + + obo:DDO.owl#DDO_0004251 + clomipramine hydrochloride 75mg m/r tablet + + + + obo:DDO.owl#DDO_0004252 + DDO:DDO_0004252 + + + + obo:DDO.owl#DDO_0004252 + 376524003 + + + + obo:DDO.owl#DDO_0004252 + clomipramine hydrochloride 75mg capsule + + + + obo:DDO.owl#DDO_0004253 + DDO:DDO_0004253 + + + + obo:DDO.owl#DDO_0004253 + 321787009 + + + + obo:DDO.owl#DDO_0004253 + clomipramine hydrochloride 50mg capsule + + + + obo:DDO.owl#DDO_0004254 + DDO:DDO_0004254 + + + + obo:DDO.owl#DDO_0004254 + 321786000 + + + + obo:DDO.owl#DDO_0004254 + clomipramine hydrochloride 25mg capsule + + + + obo:DDO.owl#DDO_0004255 + DDO:DDO_0004255 + + + + obo:DDO.owl#DDO_0004255 + 321789007 + + + + obo:DDO.owl#DDO_0004255 + clomipramine hydrochloride 12.5mg/mL injection solution 2mL ampule + + + + obo:DDO.owl#DDO_0004256 + DDO:DDO_0004256 + + + + obo:DDO.owl#DDO_0004256 + 321785001 + + + + obo:DDO.owl#DDO_0004256 + clomipramine hydrochloride 10mg capsule + + + + obo:DDO.owl#DDO_0004257 + DDO:DDO_0004257 + + + + obo:DDO.owl#DDO_0004257 + 33378002 + + + + obo:DDO.owl#DDO_0004257 + desipramine + + + + obo:DDO.owl#DDO_0004258 + DDO:DDO_0004258 + + + + obo:DDO.owl#DDO_0004258 + 375531007 + + + + obo:DDO.owl#DDO_0004258 + desipramine hydrochloride 75mg tablet + + + + obo:DDO.owl#DDO_0004259 + DDO:DDO_0004259 + + + + obo:DDO.owl#DDO_0004259 + 375530008 + + + + obo:DDO.owl#DDO_0004259 + desipramine hydrochloride 50mg tablet + + + + obo:DDO.owl#DDO_0004260 + DDO:DDO_0004260 + + + + obo:DDO.owl#DDO_0004260 + 375529003 + + + + obo:DDO.owl#DDO_0004260 + desipramine hydrochloride 25mg tablet + + + + obo:DDO.owl#DDO_0004261 + DDO:DDO_0004261 + + + + obo:DDO.owl#DDO_0004261 + 375533005 + + + + obo:DDO.owl#DDO_0004261 + desipramine hydrochloride 150mg tablet + + + + obo:DDO.owl#DDO_0004262 + DDO:DDO_0004262 + + + + obo:DDO.owl#DDO_0004262 + 375528006 + + + + obo:DDO.owl#DDO_0004262 + desipramine hydrochloride 10mg tablet + + + + obo:DDO.owl#DDO_0004263 + DDO:DDO_0004263 + + + + obo:DDO.owl#DDO_0004263 + 375532000 + + + + obo:DDO.owl#DDO_0004263 + desipramine hydrochloride 100mg tablet + + + + obo:DDO.owl#DDO_0004264 + DDO:DDO_0004264 + + + + obo:DDO.owl#DDO_0004264 + 349856007 + + + + obo:DDO.owl#DDO_0004264 + dothiepin + + + + obo:DDO.owl#DDO_0004265 + DDO:DDO_0004265 + + + + obo:DDO.owl#DDO_0004265 + 321794007 + + + + obo:DDO.owl#DDO_0004265 + dothiepin hydrochloride + + + + obo:DDO.owl#DDO_0004266 + DDO:DDO_0004266 + + + + obo:DDO.owl#DDO_0004266 + 321802006 + + + + obo:DDO.owl#DDO_0004266 + dothiepin hydrochloride 75mg/5mL s/f elixir + + + + obo:DDO.owl#DDO_0004267 + DDO:DDO_0004267 + + + + obo:DDO.owl#DDO_0004267 + 321806009 + + + + obo:DDO.owl#DDO_0004267 + dothiepin hydrochloride 75mg tablet + + + + obo:DDO.owl#DDO_0004268 + DDO:DDO_0004268 + + + + obo:DDO.owl#DDO_0004268 + 321801004 + + + + obo:DDO.owl#DDO_0004268 + dothiepin hydrochloride 25mg/5mL s/f elixir + + + + obo:DDO.owl#DDO_0004269 + DDO:DDO_0004269 + + + + obo:DDO.owl#DDO_0004269 + 321805008 + + + + obo:DDO.owl#DDO_0004269 + dothiepin hydrochloride 25mg capsule + + + + obo:DDO.owl#DDO_0004270 + DDO:DDO_0004270 + + + + obo:DDO.owl#DDO_0004270 + 11841005 + + + + obo:DDO.owl#DDO_0004270 + doxepin + + + + obo:DDO.owl#DDO_0004271 + DDO:DDO_0004271 + + + + obo:DDO.owl#DDO_0004271 + 438407008 + + + + obo:DDO.owl#DDO_0004271 + oral form doxepin + + + + obo:DDO.owl#DDO_0004272 + DDO:DDO_0004272 + + + + obo:DDO.owl#DDO_0004272 + 374542005 + + + + obo:DDO.owl#DDO_0004272 + doxepin hydrochloride 150mg capsule + + + + obo:DDO.owl#DDO_0004273 + DDO:DDO_0004273 + + + + obo:DDO.owl#DDO_0004273 + 374538007 + + + + obo:DDO.owl#DDO_0004273 + doxepin hydrochloride 10mg/mL oral solution + + + + obo:DDO.owl#DDO_0004274 + DDO:DDO_0004274 + + + + obo:DDO.owl#DDO_0004274 + 375307001 + + + + obo:DDO.owl#DDO_0004274 + doxepin hydrochloride 100mg capsule + + + + obo:DDO.owl#DDO_0004275 + DDO:DDO_0004275 + + + + obo:DDO.owl#DDO_0004275 + 321814003 + + + + obo:DDO.owl#DDO_0004275 + doxepin 75mg capsule + + + + obo:DDO.owl#DDO_0004276 + DDO:DDO_0004276 + + + + obo:DDO.owl#DDO_0004276 + 444790009 + + + + obo:DDO.owl#DDO_0004276 + doxepin 6mg tablet + + + + obo:DDO.owl#DDO_0004277 + DDO:DDO_0004277 + + + + obo:DDO.owl#DDO_0004277 + 321813009 + + + + obo:DDO.owl#DDO_0004277 + doxepin 50mg capsule + + + + obo:DDO.owl#DDO_0004278 + DDO:DDO_0004278 + + + + obo:DDO.owl#DDO_0004278 + 444789000 + + + + obo:DDO.owl#DDO_0004278 + doxepin 3mg tablet + + + + obo:DDO.owl#DDO_0004279 + DDO:DDO_0004279 + + + + obo:DDO.owl#DDO_0004279 + 321812004 + + + + obo:DDO.owl#DDO_0004279 + doxepin 25mg capsule + + + + obo:DDO.owl#DDO_0004280 + DDO:DDO_0004280 + + + + obo:DDO.owl#DDO_0004280 + 321811006 + + + + obo:DDO.owl#DDO_0004280 + doxepin 10mg capsule + + + + obo:DDO.owl#DDO_0004281 + DDO:DDO_0004281 + + + + obo:DDO.owl#DDO_0004281 + 439257008 + + + + obo:DDO.owl#DDO_0004281 + topical form doxepin + + + + obo:DDO.owl#DDO_0004282 + DDO:DDO_0004282 + + + + obo:DDO.owl#DDO_0004282 + 331643002 + + + + obo:DDO.owl#DDO_0004282 + doxepin hydrochloride 5% cream + + + + obo:DDO.owl#DDO_0004283 + DDO:DDO_0004283 + + + + obo:DDO.owl#DDO_0004283 + 36113004 + + + + obo:DDO.owl#DDO_0004283 + imipramine + + + + obo:DDO.owl#DDO_0004284 + DDO:DDO_0004284 + + + + obo:DDO.owl#DDO_0004284 + 13432000 + + + + obo:DDO.owl#DDO_0004284 + nortriptyline + + + + obo:DDO.owl#DDO_0004285 + DDO:DDO_0004285 + + + + obo:DDO.owl#DDO_0004285 + 321835001 + + + + obo:DDO.owl#DDO_0004285 + lofepramine 70mg tablet + + + + obo:DDO.owl#DDO_0004286 + DDO:DDO_0004286 + + + + obo:DDO.owl#DDO_0004286 + 321834002 + + + + obo:DDO.owl#DDO_0004286 + lofepramine 70mg/5mL s/f suspension + + + + obo:DDO.owl#DDO_0004287 + DDO:DDO_0004287 + + + + obo:DDO.owl#DDO_0004287 + 321831005 + + + + obo:DDO.owl#DDO_0004287 + lofepramine + + + + obo:DDO.owl#DDO_0004288 + DDO:DDO_0004288 + + + + obo:DDO.owl#DDO_0004288 + 321826008 + + + + obo:DDO.owl#DDO_0004288 + iprindole + + + + obo:DDO.owl#DDO_0004289 + DDO:DDO_0004289 + + + + obo:DDO.owl#DDO_0004289 + 375013002 + + + + obo:DDO.owl#DDO_0004289 + imipramine hydrochloride 25mg/amp + + + + obo:DDO.owl#DDO_0004290 + DDO:DDO_0004290 + + + + obo:DDO.owl#DDO_0004290 + 386687006 + + + + obo:DDO.owl#DDO_0004290 + parenteral form imipramine + + + + obo:DDO.owl#DDO_0004291 + DDO:DDO_0004291 + + + + obo:DDO.owl#DDO_0004291 + 374619009 + + + + obo:DDO.owl#DDO_0004291 + imipramine pamoate 75mg capsule + + + + obo:DDO.owl#DDO_0004292 + DDO:DDO_0004292 + + + + obo:DDO.owl#DDO_0004292 + 374249000 + + + + obo:DDO.owl#DDO_0004292 + imipramine pamoate 150mg capsule + + + + obo:DDO.owl#DDO_0004293 + DDO:DDO_0004293 + + + + obo:DDO.owl#DDO_0004293 + 374248008 + + + + obo:DDO.owl#DDO_0004293 + imipramine pamoate 125mg capsule + + + + obo:DDO.owl#DDO_0004294 + DDO:DDO_0004294 + + + + obo:DDO.owl#DDO_0004294 + 374247003 + + + + obo:DDO.owl#DDO_0004294 + imipramine pamoate 100mg capsule + + + + obo:DDO.owl#DDO_0004295 + DDO:DDO_0004295 + + + + obo:DDO.owl#DDO_0004295 + 374626009 + + + + obo:DDO.owl#DDO_0004295 + imipramine hydrochloride 50mg tablet + + + + obo:DDO.owl#DDO_0004296 + DDO:DDO_0004296 + + + + obo:DDO.owl#DDO_0004296 + 321825007 + + + + obo:DDO.owl#DDO_0004296 + imipramine hydrochloride 25mg/5mL syrup + + + + obo:DDO.owl#DDO_0004297 + DDO:DDO_0004297 + + + + obo:DDO.owl#DDO_0004297 + 321817005 + + + + obo:DDO.owl#DDO_0004297 + imipramine hydrochloride 25mg tablet + + + + obo:DDO.owl#DDO_0004298 + DDO:DDO_0004298 + + + + obo:DDO.owl#DDO_0004298 + 321816001 + + + + obo:DDO.owl#DDO_0004298 + imipramine hydrochloride 10mg tablet + + + + obo:DDO.owl#DDO_0004299 + DDO:DDO_0004299 + + + + obo:DDO.owl#DDO_0004299 + 428719008 + + + + obo:DDO.owl#DDO_0004299 + oral form imipramine + + + + obo:DDO.owl#DDO_0004300 + DDO:DDO_0004300 + + + + obo:DDO.owl#DDO_0004300 + 421313004 + + + + obo:DDO.owl#DDO_0004300 + fluphenazine + nortriptyline + + + + obo:DDO.owl#DDO_0004301 + DDO:DDO_0004301 + + + + obo:DDO.owl#DDO_0004301 + 321926009 + + + + obo:DDO.owl#DDO_0004301 + fluphenazine hydrochloride+nortriptyline 1.5mg/30mg tablet + + + + obo:DDO.owl#DDO_0004302 + DDO:DDO_0004302 + + + + obo:DDO.owl#DDO_0004302 + 321927000 + + + + obo:DDO.owl#DDO_0004302 + fluphenazine hydrochloride+nortriptyline 500micrograms/10mg tablet + + + + obo:DDO.owl#DDO_0004303 + DDO:DDO_0004303 + + + + obo:DDO.owl#DDO_0004303 + 321861002 + + + + obo:DDO.owl#DDO_0004303 + nortriptyline 10mg tablet + + + + obo:DDO.owl#DDO_0004304 + DDO:DDO_0004304 + + + + obo:DDO.owl#DDO_0004304 + 321864005 + + + + obo:DDO.owl#DDO_0004304 + nortriptyline 25mg tablet + + + + obo:DDO.owl#DDO_0004305 + DDO:DDO_0004305 + + + + obo:DDO.owl#DDO_0004305 + 412451001 + + + + obo:DDO.owl#DDO_0004305 + nortriptyline hydrochloride + + + + obo:DDO.owl#DDO_0004306 + DDO:DDO_0004306 + + + + obo:DDO.owl#DDO_0004306 + 375999000 + + + + obo:DDO.owl#DDO_0004306 + nortriptyline hydrochloride 75mg capsule + + + + obo:DDO.owl#DDO_0004307 + DDO:DDO_0004307 + + + + obo:DDO.owl#DDO_0004307 + 375064001 + + + + obo:DDO.owl#DDO_0004307 + nortriptyline hydrochloride 50mg capsule + + + + obo:DDO.owl#DDO_0004308 + DDO:DDO_0004308 + + + + obo:DDO.owl#DDO_0004308 + 376546006 + + + + obo:DDO.owl#DDO_0004308 + nortriptyline hydrochloride 25mg capsule + + + + obo:DDO.owl#DDO_0004309 + DDO:DDO_0004309 + + + + obo:DDO.owl#DDO_0004309 + 377058009 + + + + obo:DDO.owl#DDO_0004309 + nortriptyline hydrochloride 10mg/5mL liquid + + + + obo:DDO.owl#DDO_0004310 + DDO:DDO_0004310 + + + + obo:DDO.owl#DDO_0004310 + 376474003 + + + + obo:DDO.owl#DDO_0004310 + nortriptyline hydrochloride 10mg capsule + + + + obo:DDO.owl#DDO_0004311 + DDO:DDO_0004311 + + + + obo:DDO.owl#DDO_0004311 + 49299006 + + + + obo:DDO.owl#DDO_0004311 + protriptyline + + + + obo:DDO.owl#DDO_0004312 + DDO:DDO_0004312 + + + + obo:DDO.owl#DDO_0004312 + 376651008 + + + + obo:DDO.owl#DDO_0004312 + protriptyline hydrochloride 10mg tablet + + + + obo:DDO.owl#DDO_0004313 + DDO:DDO_0004313 + + + + obo:DDO.owl#DDO_0004313 + 376650009 + + + + obo:DDO.owl#DDO_0004313 + protriptyline hydrochloride 5mg tablet + + + + obo:DDO.owl#DDO_0004314 + DDO:DDO_0004314 + + + + obo:DDO.owl#DDO_0004314 + 90426002 + + + + obo:DDO.owl#DDO_0004314 + trimipramine + + + + obo:DDO.owl#DDO_0004315 + DDO:DDO_0004315 + + + + obo:DDO.owl#DDO_0004315 + 373971006 + + + + obo:DDO.owl#DDO_0004315 + trimipramine maleate 100mg capsule + + + + obo:DDO.owl#DDO_0004316 + DDO:DDO_0004316 + + + + obo:DDO.owl#DDO_0004316 + 373968003 + + + + obo:DDO.owl#DDO_0004316 + trimipramine maleate 25mg capsule + + + + obo:DDO.owl#DDO_0004317 + DDO:DDO_0004317 + + + + obo:DDO.owl#DDO_0004317 + 321886006 + + + + obo:DDO.owl#DDO_0004317 + trimipramine 50mg capsule + + + + obo:DDO.owl#DDO_0004318 + DDO:DDO_0004318 + + + + obo:DDO.owl#DDO_0004318 + 321888007 + + + + obo:DDO.owl#DDO_0004318 + trimipramine 25mg tablet + + + + obo:DDO.owl#DDO_0004319 + DDO:DDO_0004319 + + + + obo:DDO.owl#DDO_0004319 + 321887002 + + + + obo:DDO.owl#DDO_0004319 + trimipramine 10mg tablet + + + + obo:DDO.owl#DDO_0004320 + DDO:DDO_0004320 + + + + obo:DDO.owl#DDO_0004320 + 10784006 + + + + obo:DDO.owl#DDO_0004320 + antipsychotic drug + + + + obo:DDO.owl#DDO_0004320 + neuroleptic + + + + obo:DDO.owl#DDO_0004320 + neuroleptic drug + + + + obo:DDO.owl#DDO_0004320 + anti-psychotic agent + + + + obo:DDO.owl#DDO_0004321 + DDO:DDO_0004321 + + + + obo:DDO.owl#DDO_0004321 + 358924003 + + + + obo:DDO.owl#DDO_0004321 + atypical antipsychotic + + + + obo:DDO.owl#DDO_0004322 + DDO:DDO_0004322 + + + + obo:DDO.owl#DDO_0004322 + 406785006 + + + + obo:DDO.owl#DDO_0004322 + aripiprazole + + + + obo:DDO.owl#DDO_0004323 + DDO:DDO_0004323 + + + + obo:DDO.owl#DDO_0004323 + 428492001 + + + + obo:DDO.owl#DDO_0004323 + oral form aripiprazole + + + + obo:DDO.owl#DDO_0004324 + DDO:DDO_0004324 + + + + obo:DDO.owl#DDO_0004324 + 428303003 + + + + obo:DDO.owl#DDO_0004324 + parenteral form aripiprazole + + + + obo:DDO.owl#DDO_0004325 + DDO:DDO_0004325 + + + + obo:DDO.owl#DDO_0004325 + 443374004 + + + + obo:DDO.owl#DDO_0004325 + asenapine + + + + obo:DDO.owl#DDO_0004326 + DDO:DDO_0004326 + + + + obo:DDO.owl#DDO_0004326 + 96221003 + + + + obo:DDO.owl#DDO_0004326 + clozapine + + + + obo:DDO.owl#DDO_0004327 + DDO:DDO_0004327 + + + + obo:DDO.owl#DDO_0004327 + 108441004 + + + + obo:DDO.owl#DDO_0004327 + olanzapine + + + + obo:DDO.owl#DDO_0004328 + DDO:DDO_0004328 + + + + obo:DDO.owl#DDO_0004328 + 424274004 + + + + obo:DDO.owl#DDO_0004328 + oral form olanzapine + + + + obo:DDO.owl#DDO_0004329 + DDO:DDO_0004329 + + + + obo:DDO.owl#DDO_0004329 + 410934006 + + + + obo:DDO.owl#DDO_0004329 + parenteral form olanzapine + + + + obo:DDO.owl#DDO_0004331 + DDO:DDO_0004331 + + + + obo:DDO.owl#DDO_0004331 + 321603004 + + + + obo:DDO.owl#DDO_0004331 + Sertindole + + + + obo:DDO.owl#DDO_0004332 + DDO:DDO_0004332 + + + + obo:DDO.owl#DDO_0004332 + 321641006 + + + + obo:DDO.owl#DDO_0004332 + zotepine + + + + obo:DDO.owl#DDO_0004333 + DDO:DDO_0004333 + + + + obo:DDO.owl#DDO_0004333 + 427834006 + + + + obo:DDO.owl#DDO_0004333 + benzamide derivative antipsychotic agent + + + + obo:DDO.owl#DDO_0004334 + DDO:DDO_0004334 + + + + obo:DDO.owl#DDO_0004334 + 321636003 + + + + obo:DDO.owl#DDO_0004334 + amisulpride + + + + obo:DDO.owl#DDO_0004335 + DDO:DDO_0004335 + + + + obo:DDO.owl#DDO_0004335 + 349884002 + + + + obo:DDO.owl#DDO_0004335 + remoxipride + + + + obo:DDO.owl#DDO_0004336 + DDO:DDO_0004336 + + + + obo:DDO.owl#DDO_0004336 + 321506004 + + + + obo:DDO.owl#DDO_0004336 + sulpiride + + + + obo:DDO.owl#DDO_0004338 + DDO:DDO_0004338 + + + + obo:DDO.owl#DDO_0004338 + 409380004 + + + + obo:DDO.owl#DDO_0004338 + benzimidazolinone derivative antipsychotic preparation + + + + obo:DDO.owl#DDO_0004339 + DDO:DDO_0004339 + + + + obo:DDO.owl#DDO_0004339 + 321391002 + + + + obo:DDO.owl#DDO_0004339 + benperidol + + + + obo:DDO.owl#DDO_0004340 + DDO:DDO_0004340 + + + + obo:DDO.owl#DDO_0004340 + 26574002 + + + + obo:DDO.owl#DDO_0004340 + droperidol + + + + obo:DDO.owl#DDO_0004341 + DDO:DDO_0004341 + + + + obo:DDO.owl#DDO_0004341 + 346438004 + + + + obo:DDO.owl#DDO_0004341 + fentanyl+droperidol + + + + obo:DDO.owl#DDO_0004342 + DDO:DDO_0004342 + + + + obo:DDO.owl#DDO_0004342 + 349872004 + + + + obo:DDO.owl#DDO_0004342 + oral form droperidol + + + + obo:DDO.owl#DDO_0004343 + DDO:DDO_0004343 + + + + obo:DDO.owl#DDO_0004343 + 349873009 + + + + obo:DDO.owl#DDO_0004343 + parenteral form droperidol + + + + obo:DDO.owl#DDO_0004344 + DDO:DDO_0004344 + + + + obo:DDO.owl#DDO_0004344 + 108385001 + + + + obo:DDO.owl#DDO_0004344 + benzisoxazole derivative antipsychotic agent + + + + obo:DDO.owl#DDO_0004345 + DDO:DDO_0004345 + + + + obo:DDO.owl#DDO_0004345 + 442910003 + + + + obo:DDO.owl#DDO_0004345 + iloperidone + + + + obo:DDO.owl#DDO_0004346 + DDO:DDO_0004346 + + + + obo:DDO.owl#DDO_0004346 + 425483000 + + + + obo:DDO.owl#DDO_0004346 + paliperidone + + + + obo:DDO.owl#DDO_0004347 + DDO:DDO_0004347 + + + + obo:DDO.owl#DDO_0004347 + 108386000 + + + + obo:DDO.owl#DDO_0004347 + risperidone + + + + obo:DDO.owl#DDO_0004349 + DDO:DDO_0004349 + + + + obo:DDO.owl#DDO_0004349 + 407748006 + + + + obo:DDO.owl#DDO_0004349 + oral form risperidone + + + + obo:DDO.owl#DDO_0004350 + DDO:DDO_0004350 + + + + obo:DDO.owl#DDO_0004350 + 407749003 + + + + obo:DDO.owl#DDO_0004350 + parenteral form risperidone + + + + obo:DDO.owl#DDO_0004351 + DDO:DDO_0004351 + + + + obo:DDO.owl#DDO_0004351 + 373389002 + + + + obo:DDO.owl#DDO_0004351 + ziprasidone + + + + obo:DDO.owl#DDO_0004352 + DDO:DDO_0004352 + + + + obo:DDO.owl#DDO_0004352 + 428081006 + + + + obo:DDO.owl#DDO_0004352 + oral form ziprasidone + + + + obo:DDO.owl#DDO_0004353 + DDO:DDO_0004353 + + + + obo:DDO.owl#DDO_0004353 + 428082004 + + + + obo:DDO.owl#DDO_0004353 + parenteral form ziprasidone + + + + obo:DDO.owl#DDO_0004354 + DDO:DDO_0004354 + + + + obo:DDO.owl#DDO_0004354 + 6517004 + + + + obo:DDO.owl#DDO_0004354 + butyrophenone derivative antipsychotic agent + + + + obo:DDO.owl#DDO_0004355 + DDO:DDO_0004355 + + + + obo:DDO.owl#DDO_0004355 + 10756001 + + + + obo:DDO.owl#DDO_0004355 + haloperidol + + + + obo:DDO.owl#DDO_0004356 + DDO:DDO_0004356 + + + + obo:DDO.owl#DDO_0004356 + 349874003 + + + + obo:DDO.owl#DDO_0004356 + oral form haloperidol + + + + obo:DDO.owl#DDO_0004357 + DDO:DDO_0004357 + + + + obo:DDO.owl#DDO_0004357 + 349875002 + + + + obo:DDO.owl#DDO_0004357 + parenteral form haloperidol + + + + obo:DDO.owl#DDO_0004358 + DDO:DDO_0004358 + + + + obo:DDO.owl#DDO_0004358 + 441821005 + + + + obo:DDO.owl#DDO_0004358 + melperone + + + + obo:DDO.owl#DDO_0004359 + DDO:DDO_0004359 + + + + obo:DDO.owl#DDO_0004359 + 703364008 + + + + obo:DDO.owl#DDO_0004359 + pipamperone + + + + obo:DDO.owl#DDO_0004360 + DDO:DDO_0004360 + + + + obo:DDO.owl#DDO_0004360 + 5478006 + + + + obo:DDO.owl#DDO_0004360 + trifluperidol + + + + obo:DDO.owl#DDO_0004361 + DDO:DDO_0004361 + + + + obo:DDO.owl#DDO_0004361 + 31025003 + + + + obo:DDO.owl#DDO_0004361 + dibenzoxazepine derivative antipsychotic agent + + + + obo:DDO.owl#DDO_0004362 + DDO:DDO_0004362 + + + + obo:DDO.owl#DDO_0004362 + 59270007 + + + + obo:DDO.owl#DDO_0004362 + loxapine + + + + obo:DDO.owl#DDO_0004363 + DDO:DDO_0004363 + + + + obo:DDO.owl#DDO_0004363 + 406782009 + + + + obo:DDO.owl#DDO_0004363 + dihydrocarbostyril derivative antipsychotic + + + + obo:DDO.owl#DDO_0004364 + DDO:DDO_0004364 + + + + obo:DDO.owl#DDO_0004364 + 108443001 + + + + obo:DDO.owl#DDO_0004364 + quetiapine + + + + obo:DDO.owl#DDO_0004365 + DDO:DDO_0004365 + + + + obo:DDO.owl#DDO_0004365 + 52451004 + + + + obo:DDO.owl#DDO_0004365 + dihydroindolone derivative antipsychotic agent + + + + obo:DDO.owl#DDO_0004366 + DDO:DDO_0004366 + + + + obo:DDO.owl#DDO_0004366 + 61408004 + + + + obo:DDO.owl#DDO_0004366 + Molindone + + + + obo:DDO.owl#DDO_0004367 + DDO:DDO_0004367 + + + + obo:DDO.owl#DDO_0004367 + 37773009 + + + + obo:DDO.owl#DDO_0004367 + diphenylbutylpiperidine derivative antipsychotic agent + + + + obo:DDO.owl#DDO_0004368 + DDO:DDO_0004368 + + + + obo:DDO.owl#DDO_0004368 + 346401004 + + + + obo:DDO.owl#DDO_0004368 + diphenylbutylpiperidine + + + + obo:DDO.owl#DDO_0004369 + DDO:DDO_0004369 + + + + obo:DDO.owl#DDO_0004369 + 321692003 + + + + obo:DDO.owl#DDO_0004369 + fluspirilene + + + + obo:DDO.owl#DDO_0004370 + DDO:DDO_0004370 + + + + obo:DDO.owl#DDO_0004370 + 108438008 + + + + obo:DDO.owl#DDO_0004370 + pimozide + + + + obo:DDO.owl#DDO_0004371 + DDO:DDO_0004371 + + + + obo:DDO.owl#DDO_0004371 + 349883008 + + + + obo:DDO.owl#DDO_0004371 + oxypertine + + + + obo:DDO.owl#DDO_0004372 + DDO:DDO_0004372 + + + + obo:DDO.owl#DDO_0004372 + 105916003 + + + + obo:DDO.owl#DDO_0004372 + phenothiazine derivative antipsychotic + + + + obo:DDO.owl#DDO_0004373 + DDO:DDO_0004373 + + + + obo:DDO.owl#DDO_0004373 + 47331002 + + + + obo:DDO.owl#DDO_0004373 + chlorpromazine + + + + obo:DDO.owl#DDO_0004374 + DDO:DDO_0004374 + + + + obo:DDO.owl#DDO_0004374 + 349876001 + + + + obo:DDO.owl#DDO_0004374 + oral form chlorpromazine + + + + obo:DDO.owl#DDO_0004375 + DDO:DDO_0004375 + + + + obo:DDO.owl#DDO_0004375 + 349877005 + + + + obo:DDO.owl#DDO_0004375 + parenteral form chlorpromazine + + + + obo:DDO.owl#DDO_0004376 + DDO:DDO_0004376 + + + + obo:DDO.owl#DDO_0004376 + 349878000 + + + + obo:DDO.owl#DDO_0004376 + rectal chlorpromazine + + + + obo:DDO.owl#DDO_0004377 + DDO:DDO_0004377 + + + + obo:DDO.owl#DDO_0004377 + 78684000 + + + + obo:DDO.owl#DDO_0004377 + mesoridazine + + + + obo:DDO.owl#DDO_0004378 + DDO:DDO_0004378 + + + + obo:DDO.owl#DDO_0004378 + 386545002 + + + + obo:DDO.owl#DDO_0004378 + oral form mesoridazine + + + + obo:DDO.owl#DDO_0004379 + DDO:DDO_0004379 + + + + obo:DDO.owl#DDO_0004379 + 386546001 + + + + obo:DDO.owl#DDO_0004379 + parenteral form mesoridazine + + + + obo:DDO.owl#DDO_0004380 + DDO:DDO_0004380 + + + + obo:DDO.owl#DDO_0004380 + 400745007 + + + + obo:DDO.owl#DDO_0004380 + methdilazine + + + + obo:DDO.owl#DDO_0004381 + DDO:DDO_0004381 + + + + obo:DDO.owl#DDO_0004381 + 321467007 + + + + obo:DDO.owl#DDO_0004381 + pericyazine + + + + obo:DDO.owl#DDO_0004382 + DDO:DDO_0004382 + + + + obo:DDO.owl#DDO_0004382 + 349879008 + + + + obo:DDO.owl#DDO_0004382 + pipothiazine + + + + obo:DDO.owl#DDO_0004383 + DDO:DDO_0004383 + + + + obo:DDO.owl#DDO_0004383 + 86906004 + + + + obo:DDO.owl#DDO_0004383 + propylamino derivative of phenothiazine + + + + obo:DDO.owl#DDO_0004384 + DDO:DDO_0004384 + + + + obo:DDO.owl#DDO_0004384 + 89029005 + + + + obo:DDO.owl#DDO_0004384 + methotrimeprazine + + + + obo:DDO.owl#DDO_0004385 + DDO:DDO_0004385 + + + + obo:DDO.owl#DDO_0004385 + 44658005 + + + + obo:DDO.owl#DDO_0004385 + promazine + + + + obo:DDO.owl#DDO_0004386 + DDO:DDO_0004386 + + + + obo:DDO.owl#DDO_0004386 + 386568006 + + + + obo:DDO.owl#DDO_0004386 + oral form promazine + + + + obo:DDO.owl#DDO_0004387 + DDO:DDO_0004387 + + + + obo:DDO.owl#DDO_0004387 + 386570002 + + + + obo:DDO.owl#DDO_0004387 + parenteral form promazine + + + + obo:DDO.owl#DDO_0004388 + DDO:DDO_0004388 + + + + obo:DDO.owl#DDO_0004388 + 8109005 + + + + obo:DDO.owl#DDO_0004388 + trimeprazine + + + + obo:DDO.owl#DDO_0004389 + DDO:DDO_0004389 + + + + obo:DDO.owl#DDO_0004389 + 33588000 + + + + obo:DDO.owl#DDO_0004389 + thioridazine + + + + obo:DDO.owl#DDO_0004390 + DDO:DDO_0004390 + + + + obo:DDO.owl#DDO_0004390 + 386579001 + + + + obo:DDO.owl#DDO_0004390 + oral form thioridazine + + + + obo:DDO.owl#DDO_0004391 + DDO:DDO_0004391 + + + + obo:DDO.owl#DDO_0004391 + 398816002 + + + + obo:DDO.owl#DDO_0004391 + triflupromazine + + + + obo:DDO.owl#DDO_0004392 + DDO:DDO_0004392 + + + + obo:DDO.owl#DDO_0004392 + 108439000 + + + + obo:DDO.owl#DDO_0004392 + phenylbutylpiperadine derivative antipsychotic agent + + + + obo:DDO.owl#DDO_0004393 + DDO:DDO_0004393 + + + + obo:DDO.owl#DDO_0004393 + 36940000 + + + + obo:DDO.owl#DDO_0004393 + thioxanthene derivative antipsychotic agent + + + + obo:DDO.owl#DDO_0004394 + DDO:DDO_0004394 + + + + obo:DDO.owl#DDO_0004394 + 57002000 + + + + obo:DDO.owl#DDO_0004394 + chlorprothixene + + + + obo:DDO.owl#DDO_0004395 + DDO:DDO_0004395 + + + + obo:DDO.owl#DDO_0004395 + 427940003 + + + + obo:DDO.owl#DDO_0004395 + clopenthixol + + + + obo:DDO.owl#DDO_0004396 + DDO:DDO_0004396 + + + + obo:DDO.owl#DDO_0004396 + 96220002 + + + + obo:DDO.owl#DDO_0004396 + Flupentixol + + + + obo:DDO.owl#DDO_0004397 + DDO:DDO_0004397 + + + + obo:DDO.owl#DDO_0004397 + 428727004 + + + + obo:DDO.owl#DDO_0004397 + oral form flupentixol + + + + obo:DDO.owl#DDO_0004398 + DDO:DDO_0004398 + + + + obo:DDO.owl#DDO_0004398 + 429292009 + + + + obo:DDO.owl#DDO_0004398 + parenteral form flupentixol + + + + obo:DDO.owl#DDO_0004399 + DDO:DDO_0004399 + + + + obo:DDO.owl#DDO_0004399 + 62529008 + + + + obo:DDO.owl#DDO_0004399 + thiothixene + + + + obo:DDO.owl#DDO_0004400 + DDO:DDO_0004400 + + + + obo:DDO.owl#DDO_0004400 + 438323007 + + + + obo:DDO.owl#DDO_0004400 + oral form thiothixene + + + + obo:DDO.owl#DDO_0004401 + DDO:DDO_0004401 + + + + obo:DDO.owl#DDO_0004401 + 438889002 + + + + obo:DDO.owl#DDO_0004401 + parenteral form thiothixene + + + + obo:DDO.owl#DDO_0004402 + DDO:DDO_0004402 + + + + obo:DDO.owl#DDO_0004402 + 429346008 + + + + obo:DDO.owl#DDO_0004402 + zuclopenthixol + + + + obo:DDO.owl#DDO_0004403 + DDO:DDO_0004403 + + + + obo:DDO.owl#DDO_0004403 + 386580003 + + + + obo:DDO.owl#DDO_0004403 + oral form zuclopenthixol + + + + obo:DDO.owl#DDO_0004404 + DDO:DDO_0004404 + + + + obo:DDO.owl#DDO_0004404 + 321584004 + + + + obo:DDO.owl#DDO_0004404 + zuclopenthixol acetate + + + + obo:DDO.owl#DDO_0004405 + DDO:DDO_0004405 + + + + obo:DDO.owl#DDO_0004405 + 321707006 + + + + obo:DDO.owl#DDO_0004405 + zuclopenthixol decanoate + + + + obo:DDO.owl#DDO_0004406 + DDO:DDO_0004406 + + + + obo:DDO.owl#DDO_0004406 + 321559002 + + + + obo:DDO.owl#DDO_0004406 + zuclopenthixol dihydrochloride + + + + obo:DDO.owl#DDO_0004408 + DDO:DDO_0004408 + + + + obo:DDO.owl#DDO_0004408 + 406463001 + + + + obo:DDO.owl#DDO_0004408 + drug allergen + + + + obo:DDO.owl#DDO_0004409 + DDO:DDO_0004409 + + + + obo:DDO.owl#DDO_0004409 + 304275008 + + + + obo:DDO.owl#DDO_0004409 + corticosteroids and derivatives + + + + obo:DDO.owl#DDO_0004410 + DDO:DDO_0004410 + + + + obo:DDO.owl#DDO_0004410 + 419933005 + + + + obo:DDO.owl#DDO_0004410 + glucocorticoid + + + + obo:DDO.owl#DDO_0004411 + DDO:DDO_0004411 + + + + obo:DDO.owl#DDO_0004411 + 35150008 + + + + obo:DDO.owl#DDO_0004411 + glucocorticoid hormone + + + + obo:DDO.owl#DDO_0004412 + DDO:DDO_0004412 + + + + obo:DDO.owl#DDO_0004412 + 112116001 + + + + obo:DDO.owl#DDO_0004412 + 17-Hydroxycorticosteroid + + + + obo:DDO.owl#DDO_0004413 + DDO:DDO_0004413 + + + + obo:DDO.owl#DDO_0004413 + 409895005 + + + + obo:DDO.owl#DDO_0004413 + cortisol precursor + + + + obo:DDO.owl#DDO_0004414 + DDO:DDO_0004414 + + + + obo:DDO.owl#DDO_0004414 + 91521001 + + + + obo:DDO.owl#DDO_0004414 + corticosterone + + + + obo:DDO.owl#DDO_0004415 + DDO:DDO_0004415 + + + + obo:DDO.owl#DDO_0004415 + 103033006 + + + + obo:DDO.owl#DDO_0004415 + 18-Hydroxycorticosteroid + + + + obo:DDO.owl#DDO_0004416 + DDO:DDO_0004416 + + + + obo:DDO.owl#DDO_0004416 + 115342001 + + + + obo:DDO.owl#DDO_0004416 + 18-Hydroxydeoxycortisol + + + + obo:DDO.owl#DDO_0004417 + DDO:DDO_0004417 + + + + obo:DDO.owl#DDO_0004417 + 115580001 + + + + obo:DDO.owl#DDO_0004417 + 18-Hydroxydeoxycorticosterone + + + + obo:DDO.owl#DDO_0004418 + DDO:DDO_0004418 + + + + obo:DDO.owl#DDO_0004418 + 116653005 + + + + obo:DDO.owl#DDO_0004418 + 18-Hydroxycortisone + + + + obo:DDO.owl#DDO_0004419 + DDO:DDO_0004419 + + + + obo:DDO.owl#DDO_0004419 + 116652000 + + + + obo:DDO.owl#DDO_0004419 + 18-Hydroxycortisol + + + + obo:DDO.owl#DDO_0004420 + DDO:DDO_0004420 + + + + obo:DDO.owl#DDO_0004420 + 103034000 + + + + obo:DDO.owl#DDO_0004420 + 18-Hydroxycorticosterone + + + + obo:DDO.owl#DDO_0004421 + DDO:DDO_0004421 + + + + obo:DDO.owl#DDO_0004421 + 707050002 + + + + obo:DDO.owl#DDO_0004421 + 21-Deoxycorticosterone + + + + obo:DDO.owl#DDO_0004422 + DDO:DDO_0004422 + + + + obo:DDO.owl#DDO_0004422 + 707189005 + + + + obo:DDO.owl#DDO_0004422 + allo-tetrahydrocorticosterone + + + + obo:DDO.owl#DDO_0004423 + DDO:DDO_0004423 + + + + obo:DDO.owl#DDO_0004423 + 103056002 + + + + obo:DDO.owl#DDO_0004423 + tetrahydrodeoxycortisol + + + + obo:DDO.owl#DDO_0004424 + DDO:DDO_0004424 + + + + obo:DDO.owl#DDO_0004424 + 46654009 + + + + obo:DDO.owl#DDO_0004424 + tetrahydrocortisone + + + + obo:DDO.owl#DDO_0004425 + DDO:DDO_0004425 + + + + obo:DDO.owl#DDO_0004425 + 117492000 + + + + obo:DDO.owl#DDO_0004425 + 5-alpha-tetrahydrocortisol + + + + obo:DDO.owl#DDO_0004426 + DDO:DDO_0004426 + + + + obo:DDO.owl#DDO_0004426 + 96331008 + + + + obo:DDO.owl#DDO_0004426 + 3-alpha-Allo-tetrahydrocortisol + + + + obo:DDO.owl#DDO_0004427 + DDO:DDO_0004427 + + + + obo:DDO.owl#DDO_0004427 + 23816007 + + + + obo:DDO.owl#DDO_0004427 + tetrahydrocortisol + + + + obo:DDO.owl#DDO_0004428 + DDO:DDO_0004428 + + + + obo:DDO.owl#DDO_0004428 + 103040007 + + + + obo:DDO.owl#DDO_0004428 + delta-5-Pregnanetriol + + + + obo:DDO.owl#DDO_0004429 + DDO:DDO_0004429 + + + + obo:DDO.owl#DDO_0004429 + 103041006 + + + + obo:DDO.owl#DDO_0004429 + 11-Ketopregnanetriol + + + + obo:DDO.owl#DDO_0004430 + DDO:DDO_0004430 + + + + obo:DDO.owl#DDO_0004430 + 116617008 + + + + obo:DDO.owl#DDO_0004430 + 11-Oxopregnanetriol + + + + obo:DDO.owl#DDO_0004431 + DDO:DDO_0004431 + + + + obo:DDO.owl#DDO_0004431 + 71159008 + + + + obo:DDO.owl#DDO_0004431 + pregnanetriol + + + + obo:DDO.owl#DDO_0004432 + DDO:DDO_0004432 + + + + obo:DDO.owl#DDO_0004432 + 313284006 + + + + obo:DDO.owl#DDO_0004432 + serum cortisol + + + + obo:DDO.owl#DDO_0004433 + DDO:DDO_0004433 + + + + obo:DDO.owl#DDO_0004433 + 51612003 + + + + obo:DDO.owl#DDO_0004433 + hydrocortisone valerate + + + + obo:DDO.owl#DDO_0004434 + DDO:DDO_0004434 + + + + obo:DDO.owl#DDO_0004434 + 109066000 + + + + obo:DDO.owl#DDO_0004434 + hydrocortisone sodium succinate + + + + obo:DDO.owl#DDO_0004435 + DDO:DDO_0004435 + + + + obo:DDO.owl#DDO_0004435 + 109064002 + + + + obo:DDO.owl#DDO_0004435 + hydrocortisone sodium phosphate + + + + obo:DDO.owl#DDO_0004436 + DDO:DDO_0004436 + + + + obo:DDO.owl#DDO_0004436 + 109063008 + + + + obo:DDO.owl#DDO_0004436 + hydrocortisone cypionate + + + + obo:DDO.owl#DDO_0004437 + DDO:DDO_0004437 + + + + obo:DDO.owl#DDO_0004437 + 50665003 + + + + obo:DDO.owl#DDO_0004437 + hydrocortisone butyrate + + + + obo:DDO.owl#DDO_0004438 + DDO:DDO_0004438 + + + + obo:DDO.owl#DDO_0004438 + 126150008 + + + + obo:DDO.owl#DDO_0004438 + hydrocortisone buteprate + + + + obo:DDO.owl#DDO_0004439 + DDO:DDO_0004439 + + + + obo:DDO.owl#DDO_0004439 + 79380007 + + + + obo:DDO.owl#DDO_0004439 + hydrocortisone acetate + + + + obo:DDO.owl#DDO_0004440 + DDO:DDO_0004440 + + + + obo:DDO.owl#DDO_0004440 + 708195009 + + + + obo:DDO.owl#DDO_0004440 + hydrocortisone aceponate + + + + obo:DDO.owl#DDO_0004441 + DDO:DDO_0004441 + + + + obo:DDO.owl#DDO_0004441 + 259344006 + + + + obo:DDO.owl#DDO_0004441 + free cortisol + + + + obo:DDO.owl#DDO_0004442 + DDO:DDO_0004442 + + + + obo:DDO.owl#DDO_0004442 + 706949007 + + + + obo:DDO.owl#DDO_0004442 + free cortisone + + + + obo:DDO.owl#DDO_0004443 + DDO:DDO_0004443 + + + + obo:DDO.owl#DDO_0004443 + 127382005 + + + + obo:DDO.owl#DDO_0004443 + cortisone acetate + + + + obo:DDO.owl#DDO_0004444 + DDO:DDO_0004444 + + + + obo:DDO.owl#DDO_0004444 + 32498003 + + + + obo:DDO.owl#DDO_0004444 + cortisone + + + + obo:DDO.owl#DDO_0004445 + DDO:DDO_0004445 + + + + obo:DDO.owl#DDO_0004445 + 62352008 + + + + obo:DDO.owl#DDO_0004445 + 6-beta Hydroxycortisol + + + + obo:DDO.owl#DDO_0004446 + DDO:DDO_0004446 + + + + obo:DDO.owl#DDO_0004446 + 116652000 + + + + obo:DDO.owl#DDO_0004446 + 18-Hydroxycortisol + + + + obo:DDO.owl#DDO_0004447 + DDO:DDO_0004447 + + + + obo:DDO.owl#DDO_0004447 + 116616004 + + + + obo:DDO.owl#DDO_0004447 + cortisol derivative + + + + obo:DDO.owl#DDO_0004448 + DDO:DDO_0004448 + + + + obo:DDO.owl#DDO_0004448 + 396458002 + + + + obo:DDO.owl#DDO_0004448 + hydrocortisone + + + + obo:DDO.owl#DDO_0004449 + DDO:DDO_0004449 + + + + obo:DDO.owl#DDO_0004449 + 710249001 + + + + obo:DDO.owl#DDO_0004449 + epitestosterone + + + + obo:DDO.owl#DDO_0004450 + DDO:DDO_0004450 + + + + obo:DDO.owl#DDO_0004450 + 46943001 + + + + obo:DDO.owl#DDO_0004450 + cortolone + + + + obo:DDO.owl#DDO_0004451 + DDO:DDO_0004451 + + + + obo:DDO.owl#DDO_0004451 + 708615009 + + + + obo:DDO.owl#DDO_0004451 + beta-Cortolone + + + + obo:DDO.owl#DDO_0004452 + DDO:DDO_0004452 + + + + obo:DDO.owl#DDO_0004452 + 708716004 + + + + obo:DDO.owl#DDO_0004452 + androstenedione + 17-Hydroxyprogesterone + + + + obo:DDO.owl#DDO_0004453 + DDO:DDO_0004453 + + + + obo:DDO.owl#DDO_0004453 + 52422003 + + + + obo:DDO.owl#DDO_0004453 + 20-Hydroxyprogesterone + + + + obo:DDO.owl#DDO_0004454 + DDO:DDO_0004454 + + + + obo:DDO.owl#DDO_0004454 + 115342001 + + + + obo:DDO.owl#DDO_0004454 + 18-Hydroxydeoxycortisol + + + + obo:DDO.owl#DDO_0004455 + DDO:DDO_0004455 + + + + obo:DDO.owl#DDO_0004455 + 116653005 + + + + obo:DDO.owl#DDO_0004455 + 18-Hydroxycortisone + + + + obo:DDO.owl#DDO_0004456 + DDO:DDO_0004456 + + + + obo:DDO.owl#DDO_0004456 + 116610005 + + + + obo:DDO.owl#DDO_0004456 + beta-Cortol + + + + obo:DDO.owl#DDO_0004457 + DDO:DDO_0004457 + + + + obo:DDO.owl#DDO_0004457 + 116609000 + + + + obo:DDO.owl#DDO_0004457 + alpha-Cortol + + + + obo:DDO.owl#DDO_0004458 + DDO:DDO_0004458 + + + + obo:DDO.owl#DDO_0004458 + 52126008 + + + + obo:DDO.owl#DDO_0004458 + Cortol + + + + obo:DDO.owl#DDO_0004459 + DDO:DDO_0004459 + + + + obo:DDO.owl#DDO_0004459 + 409887006 + + + + obo:DDO.owl#DDO_0004459 + 17 alpha-hydroxyprogesterone + + + + obo:DDO.owl#DDO_0004460 + DDO:DDO_0004460 + + + + obo:DDO.owl#DDO_0004460 + 85751002 + + + + obo:DDO.owl#DDO_0004460 + 17-Hydroxyprogesterone + + + + obo:DDO.owl#DDO_0004461 + DDO:DDO_0004461 + + + + obo:DDO.owl#DDO_0004461 + 27184001 + + + + obo:DDO.owl#DDO_0004461 + 17-Hydroxypregnenolone + + + + obo:DDO.owl#DDO_0004462 + DDO:DDO_0004462 + + + + obo:DDO.owl#DDO_0004462 + 84818007 + + + + obo:DDO.owl#DDO_0004462 + 17,21-Dihydroxypregnenolone + + + + obo:DDO.owl#DDO_0004463 + DDO:DDO_0004463 + + + + obo:DDO.owl#DDO_0004463 + 22941009 + + + + obo:DDO.owl#DDO_0004463 + 11-Deoxycortisol + + + + obo:DDO.owl#DDO_0004464 + DDO:DDO_0004464 + + + + obo:DDO.owl#DDO_0004464 + 17386008 + + + + obo:DDO.owl#DDO_0004464 + anti-infectives + + + + obo:DDO.owl#DDO_0004465 + DDO:DDO_0004465 + + + + obo:DDO.owl#DDO_0004465 + 32249005 + + + + obo:DDO.owl#DDO_0004465 + antiviral agent + + + + obo:DDO.owl#DDO_0004466 + DDO:DDO_0004466 + + + + obo:DDO.owl#DDO_0004466 + 108692000 + + + + obo:DDO.owl#DDO_0004466 + retroviral protease inhibitor + + + + obo:DDO.owl#DDO_0004467 + DDO:DDO_0004467 + + + + obo:DDO.owl#DDO_0004467 + 116084008 + + + + obo:DDO.owl#DDO_0004467 + abacavir + + + + obo:DDO.owl#DDO_0004468 + DDO:DDO_0004468 + + + + obo:DDO.owl#DDO_0004468 + 412075008 + + + + obo:DDO.owl#DDO_0004468 + abacavir sulfate + + + + obo:DDO.owl#DDO_0004469 + DDO:DDO_0004469 + + + + obo:DDO.owl#DDO_0004469 + 108692000 + + + + obo:DDO.owl#DDO_0004469 + retroviral protease inhibitor + + + + obo:DDO.owl#DDO_0004470 + DDO:DDO_0004470 + + + + obo:DDO.owl#DDO_0004470 + 108698001 + + + + obo:DDO.owl#DDO_0004470 + lamivudine + + + + obo:DDO.owl#DDO_0004471 + DDO:DDO_0004471 + + + + obo:DDO.owl#DDO_0004471 + 27479000 + + + + obo:DDO.owl#DDO_0004471 + zidovudine + + + + obo:DDO.owl#DDO_0004472 + DDO:DDO_0004472 + + + + obo:DDO.owl#DDO_0004472 + 431068003 + + + + obo:DDO.owl#DDO_0004472 + oral form zidovudine + + + + obo:DDO.owl#DDO_0004473 + DDO:DDO_0004473 + + + + obo:DDO.owl#DDO_0004473 + 431071006 + + + + obo:DDO.owl#DDO_0004473 + parenteral form zidovudine + + + + obo:DDO.owl#DDO_0004474 + DDO:DDO_0004474 + + + + obo:DDO.owl#DDO_0004474 + 19194001 + + + + obo:DDO.owl#DDO_0004474 + didanosine + + + + obo:DDO.owl#DDO_0004475 + DDO:DDO_0004475 + + + + obo:DDO.owl#DDO_0004475 + 404855005 + + + + obo:DDO.owl#DDO_0004475 + emtricitabine + + + + obo:DDO.owl#DDO_0004476 + DDO:DDO_0004476 + + + + obo:DDO.owl#DDO_0004476 + 395264002 + + + + obo:DDO.owl#DDO_0004476 + tenofovir + + + + obo:DDO.owl#DDO_0004477 + DDO:DDO_0004477 + + + + obo:DDO.owl#DDO_0004477 + 116078005 + + + + obo:DDO.owl#DDO_0004477 + Efavirenz + + + + obo:DDO.owl#DDO_0004478 + DDO:DDO_0004478 + + + + obo:DDO.owl#DDO_0004478 + 108704001 + + + + obo:DDO.owl#DDO_0004478 + nevirapine + + + + obo:DDO.owl#DDO_0004479 + DDO:DDO_0004479 + + + + obo:DDO.owl#DDO_0004479 + 413591007 + + + + obo:DDO.owl#DDO_0004479 + atazanavir + + + + obo:DDO.owl#DDO_0004480 + DDO:DDO_0004480 + + + + obo:DDO.owl#DDO_0004480 + 424096001 + + + + obo:DDO.owl#DDO_0004480 + darunavir + + + + obo:DDO.owl#DDO_0004481 + DDO:DDO_0004481 + + + + obo:DDO.owl#DDO_0004481 + 116088006 + + + + obo:DDO.owl#DDO_0004481 + Amprenavir + + + + obo:DDO.owl#DDO_0004482 + DDO:DDO_0004482 + + + + obo:DDO.owl#DDO_0004482 + 703961009 + + + + obo:DDO.owl#DDO_0004482 + boceprevir + + + + obo:DDO.owl#DDO_0004483 + DDO:DDO_0004483 + + + + obo:DDO.owl#DDO_0004483 + 407018001 + + + + obo:DDO.owl#DDO_0004483 + fosamprenavir + + + + obo:DDO.owl#DDO_0004484 + DDO:DDO_0004484 + + + + obo:DDO.owl#DDO_0004484 + 108695003 + + + + obo:DDO.owl#DDO_0004484 + Indinavir + + + + obo:DDO.owl#DDO_0004485 + DDO:DDO_0004485 + + + + obo:DDO.owl#DDO_0004485 + 129475001 + + + + obo:DDO.owl#DDO_0004485 + lopinavir + + + + obo:DDO.owl#DDO_0004486 + DDO:DDO_0004486 + + + + obo:DDO.owl#DDO_0004486 + 108706004 + + + + obo:DDO.owl#DDO_0004486 + Nelfinavir + + + + obo:DDO.owl#DDO_0004487 + DDO:DDO_0004487 + + + + obo:DDO.owl#DDO_0004487 + 108693005 + + + + obo:DDO.owl#DDO_0004487 + Ritonavir + + + + obo:DDO.owl#DDO_0004488 + DDO:DDO_0004488 + + + + obo:DDO.owl#DDO_0004488 + 108700005 + + + + obo:DDO.owl#DDO_0004488 + Saquinavir + + + + obo:DDO.owl#DDO_0004489 + DDO:DDO_0004489 + + + + obo:DDO.owl#DDO_0004489 + 704466001 + + + + obo:DDO.owl#DDO_0004489 + telaprevir + + + + obo:DDO.owl#DDO_0004490 + DDO:DDO_0004490 + + + + obo:DDO.owl#DDO_0004490 + 418721002 + + + + obo:DDO.owl#DDO_0004490 + tipranavir + + + + obo:DDO.owl#DDO_0004491 + DDO:DDO_0004491 + + + + obo:DDO.owl#DDO_0004491 + 419597003 + + + + obo:DDO.owl#DDO_0004491 + respiratory corticosteroid + + + + obo:DDO.owl#DDO_0004492 + DDO:DDO_0004492 + + + + obo:DDO.owl#DDO_0004492 + 116574000 + + + + obo:DDO.owl#DDO_0004492 + beclomethasone + + + + obo:DDO.owl#DDO_0004493 + DDO:DDO_0004493 + + + + obo:DDO.owl#DDO_0004493 + 116575004 + + + + obo:DDO.owl#DDO_0004493 + beclomethasone dipropionate + + + + obo:DDO.owl#DDO_0004494 + DDO:DDO_0004494 + + + + obo:DDO.owl#DDO_0004494 + 426017007 + + + + obo:DDO.owl#DDO_0004494 + beclomethasone dipropionate monohydrate + + + + obo:DDO.owl#DDO_0004495 + DDO:DDO_0004495 + + + + obo:DDO.owl#DDO_0004495 + 395726003 + + + + obo:DDO.owl#DDO_0004495 + budesonide + + + + obo:DDO.owl#DDO_0004496 + DDO:DDO_0004496 + + + + obo:DDO.owl#DDO_0004496 + 417420004 + + + + obo:DDO.owl#DDO_0004496 + ciclesonide + + + + obo:DDO.owl#DDO_0004497 + DDO:DDO_0004497 + + + + obo:DDO.owl#DDO_0004497 + 397192001 + + + + obo:DDO.owl#DDO_0004497 + fluticasone + + + + obo:DDO.owl#DDO_0004498 + DDO:DDO_0004498 + + + + obo:DDO.owl#DDO_0004498 + 426409006 + + + + obo:DDO.owl#DDO_0004498 + fluticasone furoate + + + + obo:DDO.owl#DDO_0004499 + DDO:DDO_0004499 + + + + obo:DDO.owl#DDO_0004499 + 396064000 + + + + obo:DDO.owl#DDO_0004499 + fluticasone propionate + + + + obo:DDO.owl#DDO_0004500 + DDO:DDO_0004500 + + + + obo:DDO.owl#DDO_0004500 + 395990009 + + + + obo:DDO.owl#DDO_0004500 + mometasone + + + + obo:DDO.owl#DDO_0004501 + DDO:DDO_0004501 + + + + obo:DDO.owl#DDO_0004501 + 395802006 + + + + obo:DDO.owl#DDO_0004501 + mometasone furoate + + + + obo:DDO.owl#DDO_0004502 + DDO:DDO_0004502 + + + + obo:DDO.owl#DDO_0004502 + 395803001 + + + + obo:DDO.owl#DDO_0004502 + mometasone furoate monohydrate + + + + obo:DDO.owl#DDO_0004503 + DDO:DDO_0004503 + + + + obo:DDO.owl#DDO_0004503 + 116569008 + + + + obo:DDO.owl#DDO_0004503 + synthetic glucocorticoid + + + + obo:DDO.owl#DDO_0004504 + DDO:DDO_0004504 + + + + obo:DDO.owl#DDO_0004504 + 116600001 + + + + obo:DDO.owl#DDO_0004504 + hydrocortamate + + + + obo:DDO.owl#DDO_0004505 + DDO:DDO_0004505 + + + + obo:DDO.owl#DDO_0004505 + 126085005 + + + + obo:DDO.owl#DDO_0004505 + Halobetasol propionate + + + + obo:DDO.owl#DDO_0004506 + DDO:DDO_0004506 + + + + obo:DDO.owl#DDO_0004506 + 116597002 + + + + obo:DDO.owl#DDO_0004506 + dichlorisone + + + + obo:DDO.owl#DDO_0004507 + DDO:DDO_0004507 + + + + obo:DDO.owl#DDO_0004507 + 396017000 + + + + obo:DDO.owl#DDO_0004507 + dexamethasone sodium phosphate + + + + obo:DDO.owl#DDO_0004508 + DDO:DDO_0004508 + + + + obo:DDO.owl#DDO_0004508 + 396016009 + + + + obo:DDO.owl#DDO_0004508 + dexamethasone phosphate + + + + obo:DDO.owl#DDO_0004509 + DDO:DDO_0004509 + + + + obo:DDO.owl#DDO_0004509 + 109070008 + + + + obo:DDO.owl#DDO_0004509 + dexamethasone acetate + + + + obo:DDO.owl#DDO_0004510 + DDO:DDO_0004510 + + + + obo:DDO.owl#DDO_0004510 + 387473009 + + + + obo:DDO.owl#DDO_0004510 + desoximetasone + + + + obo:DDO.owl#DDO_0004511 + DDO:DDO_0004511 + + + + obo:DDO.owl#DDO_0004511 + 372584003 + + + + obo:DDO.owl#DDO_0004511 + dexamethasone + + + + obo:DDO.owl#DDO_0004512 + DDO:DDO_0004512 + + + + obo:DDO.owl#DDO_0004512 + 412363005 + + + + obo:DDO.owl#DDO_0004512 + desonide + + + + obo:DDO.owl#DDO_0004513 + DDO:DDO_0004513 + + + + obo:DDO.owl#DDO_0004513 + 17503004 + + + + obo:DDO.owl#DDO_0004513 + clocortolone pivalate + + + + obo:DDO.owl#DDO_0004514 + DDO:DDO_0004514 + + + + obo:DDO.owl#DDO_0004514 + 116580008 + + + + obo:DDO.owl#DDO_0004514 + clocortolone hexanoate + + + + obo:DDO.owl#DDO_0004515 + DDO:DDO_0004515 + + + + obo:DDO.owl#DDO_0004515 + 116579005 + + + + obo:DDO.owl#DDO_0004515 + clocortolone acetate + + + + obo:DDO.owl#DDO_0004516 + DDO:DDO_0004516 + + + + obo:DDO.owl#DDO_0004516 + 35406002 + + + + obo:DDO.owl#DDO_0004516 + clocortolone + + + + obo:DDO.owl#DDO_0004518 + DDO:DDO_0004518 + + + + obo:DDO.owl#DDO_0004518 + 67980007 + + + + obo:DDO.owl#DDO_0004518 + amcinonide + + + + obo:DDO.owl#DDO_0004519 + DDO:DDO_0004519 + + + + obo:DDO.owl#DDO_0004519 + 38684009 + + + + obo:DDO.owl#DDO_0004519 + Alclometasone dipropionate + + + + obo:DDO.owl#DDO_0004520 + DDO:DDO_0004520 + + + + obo:DDO.owl#DDO_0004520 + 395956000 + + + + obo:DDO.owl#DDO_0004520 + alclometasone + + + + obo:DDO.owl#DDO_0004521 + DDO:DDO_0004521 + + + + obo:DDO.owl#DDO_0004521 + 412205004 + + + + obo:DDO.owl#DDO_0004521 + hydrocortamate hydrochloride + + + + obo:DDO.owl#DDO_0004522 + DDO:DDO_0004522 + + + + obo:DDO.owl#DDO_0004522 + 419711001 + + + + obo:DDO.owl#DDO_0004522 + loteprednol + + + + obo:DDO.owl#DDO_0004523 + DDO:DDO_0004523 + + + + obo:DDO.owl#DDO_0004523 + 387047007 + + + + obo:DDO.owl#DDO_0004523 + loteprednol etabonate + + + + obo:DDO.owl#DDO_0004524 + DDO:DDO_0004524 + + + + obo:DDO.owl#DDO_0004524 + 126116004 + + + + obo:DDO.owl#DDO_0004524 + melengestrol + + + + obo:DDO.owl#DDO_0004525 + DDO:DDO_0004525 + + + + obo:DDO.owl#DDO_0004525 + 126117008 + + + + obo:DDO.owl#DDO_0004525 + Melengestrol acetate + + + + obo:DDO.owl#DDO_0004526 + DDO:DDO_0004526 + + + + obo:DDO.owl#DDO_0004526 + 116603004 + + + + obo:DDO.owl#DDO_0004526 + meprednisone + + + + obo:DDO.owl#DDO_0004527 + DDO:DDO_0004527 + + + + obo:DDO.owl#DDO_0004527 + 116593003 + + + + obo:DDO.owl#DDO_0004527 + methylprednisolone + + + + obo:DDO.owl#DDO_0004528 + DDO:DDO_0004528 + + + + obo:DDO.owl#DDO_0004528 + 708199003 + + + + obo:DDO.owl#DDO_0004528 + methylprednisolone aceponate + + + + obo:DDO.owl#DDO_0004529 + DDO:DDO_0004529 + + + + obo:DDO.owl#DDO_0004529 + 80959009 + + + + obo:DDO.owl#DDO_0004529 + methylprednisolone acetate + + + + obo:DDO.owl#DDO_0004530 + DDO:DDO_0004530 + + + + obo:DDO.owl#DDO_0004530 + 412248005 + + + + obo:DDO.owl#DDO_0004530 + methylprednisolone sodium succinate + + + + obo:DDO.owl#DDO_0004531 + DDO:DDO_0004531 + + + + obo:DDO.owl#DDO_0004531 + 126086006 + + + + obo:DDO.owl#DDO_0004531 + prednicarbate + + + + obo:DDO.owl#DDO_0004532 + DDO:DDO_0004532 + + + + obo:DDO.owl#DDO_0004532 + 116601002 + + + + obo:DDO.owl#DDO_0004532 + prednisolone + + + + obo:DDO.owl#DDO_0004533 + DDO:DDO_0004533 + + + + obo:DDO.owl#DDO_0004533 + 116602009 + + + + obo:DDO.owl#DDO_0004533 + prednisone + + + + obo:DDO.owl#DDO_0004534 + DDO:DDO_0004534 + + + + obo:DDO.owl#DDO_0004534 + 96336003 + + + + obo:DDO.owl#DDO_0004534 + prednisolone tertiary butylacetate + + + + obo:DDO.owl#DDO_0004535 + DDO:DDO_0004535 + + + + obo:DDO.owl#DDO_0004535 + 96335004 + + + + obo:DDO.owl#DDO_0004535 + prednisolone sodium phosphate + + + + obo:DDO.owl#DDO_0004536 + DDO:DDO_0004536 + + + + obo:DDO.owl#DDO_0004536 + 441522005 + + + + obo:DDO.owl#DDO_0004536 + prednisolone methylsulfobenzoate + + + + obo:DDO.owl#DDO_0004537 + DDO:DDO_0004537 + + + + obo:DDO.owl#DDO_0004537 + 438443002 + + + + obo:DDO.owl#DDO_0004537 + prednisolone hexanoate + + + + obo:DDO.owl#DDO_0004538 + DDO:DDO_0004538 + + + + obo:DDO.owl#DDO_0004538 + 96334000 + + + + obo:DDO.owl#DDO_0004538 + prednisolone acetate + + + + obo:DDO.owl#DDO_0004539 + DDO:DDO_0004539 + + + + obo:DDO.owl#DDO_0004539 + 387046003 + + + + obo:DDO.owl#DDO_0004539 + rimexolone + + + + obo:DDO.owl#DDO_0004540 + DDO:DDO_0004540 + + + + obo:DDO.owl#DDO_0004540 + 126083003 + + + + obo:DDO.owl#DDO_0004540 + synthetic glucocorticoid, chlorinated + + + + obo:DDO.owl#DDO_0004541 + DDO:DDO_0004541 + + + + obo:DDO.owl#DDO_0004541 + 116607003 + + + + obo:DDO.owl#DDO_0004541 + synthetic glucocorticoid, fluorinated + + + + obo:DDO.owl#DDO_0004542 + DDO:DDO_0004542 + + + + obo:DDO.owl#DDO_0004542 + 412524002 + + + + obo:DDO.owl#DDO_0004542 + triamcinolone hexacetonide + + + + obo:DDO.owl#DDO_0004543 + DDO:DDO_0004543 + + + + obo:DDO.owl#DDO_0004543 + 116595005 + + + + obo:DDO.owl#DDO_0004543 + triamcinolone diacetate + + + + obo:DDO.owl#DDO_0004544 + DDO:DDO_0004544 + + + + obo:DDO.owl#DDO_0004544 + 395913005 + + + + obo:DDO.owl#DDO_0004544 + triamcinolone acetonide + + + + obo:DDO.owl#DDO_0004545 + DDO:DDO_0004545 + + + + obo:DDO.owl#DDO_0004545 + 116594009 + + + + obo:DDO.owl#DDO_0004545 + triamcinolone + + + + obo:DDO.owl#DDO_0004546 + DDO:DDO_0004546 + + + + obo:DDO.owl#DDO_0004546 + 116605006 + + + + obo:DDO.owl#DDO_0004546 + paramethasone acetate + + + + obo:DDO.owl#DDO_0004547 + DDO:DDO_0004547 + + + + obo:DDO.owl#DDO_0004547 + 116604005 + + + + obo:DDO.owl#DDO_0004547 + paramethasone + + + + obo:DDO.owl#DDO_0004548 + DDO:DDO_0004548 + + + + obo:DDO.owl#DDO_0004548 + 96333006 + + + + obo:DDO.owl#DDO_0004548 + isoflupredone acetate + + + + obo:DDO.owl#DDO_0004549 + DDO:DDO_0004549 + + + + obo:DDO.owl#DDO_0004549 + 96332001 + + + + obo:DDO.owl#DDO_0004549 + isoflupredone + + + + obo:DDO.owl#DDO_0004550 + DDO:DDO_0004550 + + + + obo:DDO.owl#DDO_0004550 + 704673003 + + + + obo:DDO.owl#DDO_0004550 + halometasone + + + + obo:DDO.owl#DDO_0004551 + DDO:DDO_0004551 + + + + obo:DDO.owl#DDO_0004551 + 395735005 + + + + obo:DDO.owl#DDO_0004551 + halcinonide + + + + obo:DDO.owl#DDO_0004552 + DDO:DDO_0004552 + + + + obo:DDO.owl#DDO_0004552 + 16522004 + + + + obo:DDO.owl#DDO_0004552 + flurandrenolide + + + + obo:DDO.owl#DDO_0004553 + DDO:DDO_0004553 + + + + obo:DDO.owl#DDO_0004553 + 116599004 + + + + obo:DDO.owl#DDO_0004553 + fluprednisolone + + + + obo:DDO.owl#DDO_0004554 + DDO:DDO_0004554 + + + + obo:DDO.owl#DDO_0004554 + 414275002 + + + + obo:DDO.owl#DDO_0004554 + fluprednidene + + + + obo:DDO.owl#DDO_0004555 + DDO:DDO_0004555 + + + + obo:DDO.owl#DDO_0004555 + 703087006 + + + + obo:DDO.owl#DDO_0004555 + fluorometholone acetate + + + + obo:DDO.owl#DDO_0004556 + DDO:DDO_0004556 + + + + obo:DDO.owl#DDO_0004556 + 2925007 + + + + obo:DDO.owl#DDO_0004556 + fluorometholone + + + + obo:DDO.owl#DDO_0004557 + DDO:DDO_0004557 + + + + obo:DDO.owl#DDO_0004557 + 419040009 + + + + obo:DDO.owl#DDO_0004557 + fluocortolone pivalate + + + + obo:DDO.owl#DDO_0004558 + DDO:DDO_0004558 + + + + obo:DDO.owl#DDO_0004558 + 418758002 + + + + obo:DDO.owl#DDO_0004558 + fluocortolone hexanoate + + + + obo:DDO.owl#DDO_0004559 + DDO:DDO_0004559 + + + + obo:DDO.owl#DDO_0004559 + 427266008 + + + + obo:DDO.owl#DDO_0004559 + fluocortolone caproate + + + + obo:DDO.owl#DDO_0004560 + DDO:DDO_0004560 + + + + obo:DDO.owl#DDO_0004560 + 396027006 + + + + obo:DDO.owl#DDO_0004560 + diflucortolone valerate + + + + obo:DDO.owl#DDO_0004561 + DDO:DDO_0004561 + + + + obo:DDO.owl#DDO_0004561 + 395965007 + + + + obo:DDO.owl#DDO_0004561 + diflucortolone + + + + obo:DDO.owl#DDO_0004562 + DDO:DDO_0004562 + + + + obo:DDO.owl#DDO_0004562 + 396061008 + + + + obo:DDO.owl#DDO_0004562 + fluocortolone + + + + obo:DDO.owl#DDO_0004563 + DDO:DDO_0004563 + + + + obo:DDO.owl#DDO_0004563 + 396060009 + + + + obo:DDO.owl#DDO_0004563 + fluocinonide + + + + obo:DDO.owl#DDO_0004564 + DDO:DDO_0004564 + + + + obo:DDO.owl#DDO_0004564 + 396059004 + + + + obo:DDO.owl#DDO_0004564 + fluocinolone acetonide + + + + obo:DDO.owl#DDO_0004565 + DDO:DDO_0004565 + + + + obo:DDO.owl#DDO_0004565 + 395977002 + + + + obo:DDO.owl#DDO_0004565 + fluocinolone + + + + obo:DDO.owl#DDO_0004566 + DDO:DDO_0004566 + + + + obo:DDO.owl#DDO_0004566 + 116588001 + + + + obo:DDO.owl#DDO_0004566 + flunisolide + + + + obo:DDO.owl#DDO_0004567 + DDO:DDO_0004567 + + + + obo:DDO.owl#DDO_0004567 + 96337007 + + + + obo:DDO.owl#DDO_0004567 + Flumethasone acetate + + + + obo:DDO.owl#DDO_0004568 + DDO:DDO_0004568 + + + + obo:DDO.owl#DDO_0004568 + 395944001 + + + + obo:DDO.owl#DDO_0004568 + flumetasone pivalate + + + + obo:DDO.owl#DDO_0004569 + DDO:DDO_0004569 + + + + obo:DDO.owl#DDO_0004569 + 116598007 + + + + obo:DDO.owl#DDO_0004569 + flumethasone + + + + obo:DDO.owl#DDO_0004570 + DDO:DDO_0004570 + + + + obo:DDO.owl#DDO_0004570 + 116587006 + + + + obo:DDO.owl#DDO_0004570 + fludrocortisone acetate + + + + obo:DDO.owl#DDO_0004571 + DDO:DDO_0004571 + + + + obo:DDO.owl#DDO_0004571 + 116586002 + + + + obo:DDO.owl#DDO_0004571 + fludrocortisone + + + + obo:DDO.owl#DDO_0004572 + DDO:DDO_0004572 + + + + obo:DDO.owl#DDO_0004572 + 419790004 + + + + obo:DDO.owl#DDO_0004572 + fluclorolone + + + + obo:DDO.owl#DDO_0004573 + DDO:DDO_0004573 + + + + obo:DDO.owl#DDO_0004573 + 438200007 + + + + obo:DDO.owl#DDO_0004573 + difluprednate + + + + obo:DDO.owl#DDO_0004574 + DDO:DDO_0004574 + + + + obo:DDO.owl#DDO_0004574 + 38446009 + + + + obo:DDO.owl#DDO_0004574 + Diflorasone diacetate + + + + obo:DDO.owl#DDO_0004575 + DDO:DDO_0004575 + + + + obo:DDO.owl#DDO_0004575 + 7924004 + + + + obo:DDO.owl#DDO_0004575 + diflorasone + + + + obo:DDO.owl#DDO_0004576 + DDO:DDO_0004576 + + + + obo:DDO.owl#DDO_0004576 + 32197004 + + + + obo:DDO.owl#DDO_0004576 + Clobetasol propionate + + + + obo:DDO.owl#DDO_0004577 + DDO:DDO_0004577 + + + + obo:DDO.owl#DDO_0004577 + 419129004 + + + + obo:DDO.owl#DDO_0004577 + clobetasol + + + + obo:DDO.owl#DDO_0004578 + DDO:DDO_0004578 + + + + obo:DDO.owl#DDO_0004578 + 396005002 + + + + obo:DDO.owl#DDO_0004578 + betamethasone valerate + + + + obo:DDO.owl#DDO_0004579 + DDO:DDO_0004579 + + + + obo:DDO.owl#DDO_0004579 + 116573006 + + + + obo:DDO.owl#DDO_0004579 + betamethasone sodium phosphate + + + + obo:DDO.owl#DDO_0004580 + DDO:DDO_0004580 + + + + obo:DDO.owl#DDO_0004580 + 331794004 + + + + obo:DDO.owl#DDO_0004580 + betamethasone esters + + + + obo:DDO.owl#DDO_0004581 + DDO:DDO_0004581 + + + + obo:DDO.owl#DDO_0004581 + 88736007 + + + + obo:DDO.owl#DDO_0004581 + betamethasone dipropionate + + + + obo:DDO.owl#DDO_0004582 + DDO:DDO_0004582 + + + + obo:DDO.owl#DDO_0004582 + 17908000 + + + + obo:DDO.owl#DDO_0004582 + betamethasone benzoate + + + + obo:DDO.owl#DDO_0004583 + DDO:DDO_0004583 + + + + obo:DDO.owl#DDO_0004583 + 116572001 + + + + obo:DDO.owl#DDO_0004583 + betamethasone acetate + + + + obo:DDO.owl#DDO_0004584 + DDO:DDO_0004584 + + + + obo:DDO.owl#DDO_0004584 + 120619002 + + + + obo:DDO.owl#DDO_0004584 + augmented betamethasone dipropionate + + + + obo:DDO.owl#DDO_0004585 + DDO:DDO_0004585 + + + + obo:DDO.owl#DDO_0004585 + 116571008 + + + + obo:DDO.owl#DDO_0004585 + betamethasone + + + + obo:DDO.owl#DDO_0004586 + DDO:DDO_0004586 + + + + obo:DDO.owl#DDO_0004586 + 387130009 + + + + obo:DDO.owl#DDO_0004586 + topical corticosteroid, group V + + + + obo:DDO.owl#DDO_0004587 + DDO:DDO_0004587 + + + + obo:DDO.owl#DDO_0004587 + 387512005 + + + + obo:DDO.owl#DDO_0004587 + topical corticosteroid, group IV + + + + obo:DDO.owl#DDO_0004588 + DDO:DDO_0004588 + + + + obo:DDO.owl#DDO_0004588 + 387141006 + + + + obo:DDO.owl#DDO_0004588 + topical corticosteroid, group II + + + + obo:DDO.owl#DDO_0004589 + DDO:DDO_0004589 + + + + obo:DDO.owl#DDO_0004589 + 387250003 + + + + obo:DDO.owl#DDO_0004589 + topical corticosteroid, group III + + + + obo:DDO.owl#DDO_0004590 + DDO:DDO_0004590 + + + + obo:DDO.owl#DDO_0004590 + 387488004 + + + + obo:DDO.owl#DDO_0004590 + topical corticosteroid, group I + + + + obo:DDO.owl#DDO_0004591 + DDO:DDO_0004591 + + + + obo:DDO.owl#DDO_0004591 + 387376000 + + + + obo:DDO.owl#DDO_0004591 + topical corticosteroid, group VI + + + + obo:DDO.owl#DDO_0004592 + DDO:DDO_0004592 + + + + obo:DDO.owl#DDO_0004592 + 41175001 + + + + obo:DDO.owl#DDO_0004592 + organic compound + + + + obo:DDO.owl#DDO_0004593 + DDO:DDO_0004593 + + + + obo:DDO.owl#DDO_0004593 + 116566001 + + + + obo:DDO.owl#DDO_0004593 + steroid + + + + obo:DDO.owl#DDO_0004594 + DDO:DDO_0004594 + + + + obo:DDO.owl#DDO_0004594 + 126087002 + + + + obo:DDO.owl#DDO_0004594 + androstane + + + + obo:DDO.owl#DDO_0004595 + DDO:DDO_0004595 + + + + obo:DDO.owl#DDO_0004595 + 116659009 + + + + obo:DDO.owl#DDO_0004595 + 3-beta-Androstanediol + + + + obo:DDO.owl#DDO_0004596 + DDO:DDO_0004596 + + + + obo:DDO.owl#DDO_0004596 + 56146000 + + + + obo:DDO.owl#DDO_0004596 + androstenedione + + + + obo:DDO.owl#DDO_0004597 + DDO:DDO_0004597 + + + + obo:DDO.owl#DDO_0004597 + 65555004 + + + + obo:DDO.owl#DDO_0004597 + 11-beta Hydroxyandrostenedione + + + + obo:DDO.owl#DDO_0004598 + DDO:DDO_0004598 + + + + obo:DDO.owl#DDO_0004598 + 78316004 + + + + obo:DDO.owl#DDO_0004598 + dehydroepiandrosterone + + + + obo:DDO.owl#DDO_0004599 + DDO:DDO_0004599 + + + + obo:DDO.owl#DDO_0004599 + 103044003 + + + + obo:DDO.owl#DDO_0004599 + dehydroepiandrosterone sulfate + + + + obo:DDO.owl#DDO_0004600 + DDO:DDO_0004600 + + + + obo:DDO.owl#DDO_0004600 + 708727002 + + + + obo:DDO.owl#DDO_0004600 + dehydroepiandrosterone, unconjugated + + + + obo:DDO.owl#DDO_0004601 + DDO:DDO_0004601 + + + + obo:DDO.owl#DDO_0004601 + 710249001 + + + + obo:DDO.owl#DDO_0004601 + epitestosterone + + + + obo:DDO.owl#DDO_0004602 + DDO:DDO_0004602 + + + + obo:DDO.owl#DDO_0004602 + 96346001 + + + + obo:DDO.owl#DDO_0004602 + mesterolone + + + + obo:DDO.owl#DDO_0004603 + DDO:DDO_0004603 + + + + obo:DDO.owl#DDO_0004603 + 96347005 + + + + obo:DDO.owl#DDO_0004603 + methenolone + + + + obo:DDO.owl#DDO_0004604 + DDO:DDO_0004604 + + + + obo:DDO.owl#DDO_0004604 + 126101002 + + + + obo:DDO.owl#DDO_0004604 + oxymetholone + + + + obo:DDO.owl#DDO_0004605 + DDO:DDO_0004605 + + + + obo:DDO.owl#DDO_0004605 + 126103004 + + + + obo:DDO.owl#DDO_0004605 + stanozolol + + + + obo:DDO.owl#DDO_0004606 + DDO:DDO_0004606 + + + + obo:DDO.owl#DDO_0004606 + 43688007 + + + + obo:DDO.owl#DDO_0004606 + testosterone + + + + obo:DDO.owl#DDO_0004607 + DDO:DDO_0004607 + + + + obo:DDO.owl#DDO_0004607 + 710118001 + + + + obo:DDO.owl#DDO_0004607 + bioavailable testosterone + + + + obo:DDO.owl#DDO_0004608 + DDO:DDO_0004608 + + + + obo:DDO.owl#DDO_0004608 + 706974005 + + + + obo:DDO.owl#DDO_0004608 + bound testosterone + + + + obo:DDO.owl#DDO_0004609 + DDO:DDO_0004609 + + + + obo:DDO.owl#DDO_0004609 + 103042004 + + + + obo:DDO.owl#DDO_0004609 + dihydrotestosterone + + + + obo:DDO.owl#DDO_0004610 + DDO:DDO_0004610 + + + + obo:DDO.owl#DDO_0004610 + 706972009 + + + + obo:DDO.owl#DDO_0004610 + free androstanolone + + + + obo:DDO.owl#DDO_0004611 + DDO:DDO_0004611 + + + + obo:DDO.owl#DDO_0004611 + 259355006 + + + + obo:DDO.owl#DDO_0004611 + free testosterone + + + + obo:DDO.owl#DDO_0004612 + DDO:DDO_0004612 + + + + obo:DDO.owl#DDO_0004612 + 126161000 + + + + obo:DDO.owl#DDO_0004612 + methyltestosterone + + + + obo:DDO.owl#DDO_0004613 + DDO:DDO_0004613 + + + + obo:DDO.owl#DDO_0004613 + 109034005 + + + + obo:DDO.owl#DDO_0004613 + testosterone cypionate + + + + obo:DDO.owl#DDO_0004614 + DDO:DDO_0004614 + + + + obo:DDO.owl#DDO_0004614 + 427471003 + + + + obo:DDO.owl#DDO_0004614 + testosterone decanoate + + + + obo:DDO.owl#DDO_0004615 + DDO:DDO_0004615 + + + + obo:DDO.owl#DDO_0004615 + 116071004 + + + + obo:DDO.owl#DDO_0004615 + testosterone enanthate + + + + obo:DDO.owl#DDO_0004616 + DDO:DDO_0004616 + + + + obo:DDO.owl#DDO_0004616 + 426500008 + + + + obo:DDO.owl#DDO_0004616 + testosterone isocaproate + + + + obo:DDO.owl#DDO_0004617 + DDO:DDO_0004617 + + + + obo:DDO.owl#DDO_0004617 + 427441006 + + + + obo:DDO.owl#DDO_0004617 + testosterone phenylpropionate + + + + obo:DDO.owl#DDO_0004618 + DDO:DDO_0004618 + + + + obo:DDO.owl#DDO_0004618 + 96338002 + + + + obo:DDO.owl#DDO_0004618 + testosterone propionate + + + + obo:DDO.owl#DDO_0004619 + DDO:DDO_0004619 + + + + obo:DDO.owl#DDO_0004619 + 395900004 + + + + obo:DDO.owl#DDO_0004619 + testosterone undecylenate + + + + obo:DDO.owl#DDO_0004620 + DDO:DDO_0004620 + + + + obo:DDO.owl#DDO_0004620 + 406776006 + + + + obo:DDO.owl#DDO_0004620 + azasteroid + + + + obo:DDO.owl#DDO_0004621 + DDO:DDO_0004621 + + + + obo:DDO.owl#DDO_0004621 + 385572003 + + + + obo:DDO.owl#DDO_0004621 + dutasteride + + + + obo:DDO.owl#DDO_0004622 + DDO:DDO_0004622 + + + + obo:DDO.owl#DDO_0004622 + 386963006 + + + + obo:DDO.owl#DDO_0004622 + finasteride + + + + obo:DDO.owl#DDO_0004623 + DDO:DDO_0004623 + + + + obo:DDO.owl#DDO_0004623 + 430743004 + + + + obo:DDO.owl#DDO_0004623 + bile acid AND/OR derivative + + + + obo:DDO.owl#DDO_0004624 + DDO:DDO_0004624 + + + + obo:DDO.owl#DDO_0004624 + 54724002 + + + + obo:DDO.owl#DDO_0004624 + bile acid AND/OR bile salt + + + + obo:DDO.owl#DDO_0004625 + DDO:DDO_0004625 + + + + obo:DDO.owl#DDO_0004625 + 431067008 + + + + obo:DDO.owl#DDO_0004625 + bile acid + + + + obo:DDO.owl#DDO_0004626 + DDO:DDO_0004626 + + + + obo:DDO.owl#DDO_0004626 + 117447007 + + + + obo:DDO.owl#DDO_0004626 + Dihydroxy bile acid + + + + obo:DDO.owl#DDO_0004627 + DDO:DDO_0004627 + + + + obo:DDO.owl#DDO_0004627 + 82490009 + + + + obo:DDO.owl#DDO_0004627 + chenodiol + + + + obo:DDO.owl#DDO_0004628 + DDO:DDO_0004628 + + + + obo:DDO.owl#DDO_0004628 + 78258003 + + + + obo:DDO.owl#DDO_0004628 + deoxycholic acid + + + + obo:DDO.owl#DDO_0004629 + DDO:DDO_0004629 + + + + obo:DDO.owl#DDO_0004629 + 41143004 + + + + obo:DDO.owl#DDO_0004629 + ursodiol + + + + obo:DDO.owl#DDO_0004630 + DDO:DDO_0004630 + + + + obo:DDO.owl#DDO_0004630 + 712570004 + + + + obo:DDO.owl#DDO_0004630 + dihydroxycholestanoate + + + + obo:DDO.owl#DDO_0004631 + DDO:DDO_0004631 + + + + obo:DDO.owl#DDO_0004631 + 450762006 + + + + obo:DDO.owl#DDO_0004631 + hyocholic acid + + + + obo:DDO.owl#DDO_0004632 + DDO:DDO_0004632 + + + + obo:DDO.owl#DDO_0004632 + 54245005 + + + + obo:DDO.owl#DDO_0004632 + lithocholic acid + + + + obo:DDO.owl#DDO_0004633 + DDO:DDO_0004633 + + + + obo:DDO.owl#DDO_0004633 + 433402004 + + + + obo:DDO.owl#DDO_0004633 + synthetic bile acid + + + + obo:DDO.owl#DDO_0004634 + DDO:DDO_0004634 + + + + obo:DDO.owl#DDO_0004634 + 387285003 + + + + obo:DDO.owl#DDO_0004634 + dehydrocholic acid + + + + obo:DDO.owl#DDO_0004635 + DDO:DDO_0004635 + + + + obo:DDO.owl#DDO_0004635 + 712597006 + + + + obo:DDO.owl#DDO_0004635 + trihydroxy bile acid + + + + obo:DDO.owl#DDO_0004636 + DDO:DDO_0004636 + + + + obo:DDO.owl#DDO_0004636 + 17147002 + + + + obo:DDO.owl#DDO_0004636 + cholic acid + + + + obo:DDO.owl#DDO_0004637 + DDO:DDO_0004637 + + + + obo:DDO.owl#DDO_0004637 + 450761004 + + + + obo:DDO.owl#DDO_0004637 + trihydroxycoprostanic acid + + + + obo:DDO.owl#DDO_0004638 + DDO:DDO_0004638 + + + + obo:DDO.owl#DDO_0004638 + 312291001 + + + + obo:DDO.owl#DDO_0004638 + bile salt + + + + obo:DDO.owl#DDO_0004639 + DDO:DDO_0004639 + + + + obo:DDO.owl#DDO_0004639 + 45119009 + + + + obo:DDO.owl#DDO_0004639 + glycine salt of bile acid + + + + obo:DDO.owl#DDO_0004640 + DDO:DDO_0004640 + + + + obo:DDO.owl#DDO_0004640 + 96312002 + + + + obo:DDO.owl#DDO_0004640 + chenodeoxycholylglycine + + + + obo:DDO.owl#DDO_0004641 + DDO:DDO_0004641 + + + + obo:DDO.owl#DDO_0004641 + 96313007 + + + + obo:DDO.owl#DDO_0004641 + chenodeoxycholylglycine, conjugated + + + + obo:DDO.owl#DDO_0004642 + DDO:DDO_0004642 + + + + obo:DDO.owl#DDO_0004642 + 102745000 + + + + obo:DDO.owl#DDO_0004642 + deoxycholylglycine + + + + obo:DDO.owl#DDO_0004643 + DDO:DDO_0004643 + + + + obo:DDO.owl#DDO_0004643 + 96314001 + + + + obo:DDO.owl#DDO_0004643 + Glycocholic acid + + + + obo:DDO.owl#DDO_0004644 + DDO:DDO_0004644 + + + + obo:DDO.owl#DDO_0004644 + 707073005 + + + + obo:DDO.owl#DDO_0004644 + glycocholic acid, conjugated + + + + obo:DDO.owl#DDO_0004645 + DDO:DDO_0004645 + + + + obo:DDO.owl#DDO_0004645 + 395882008 + + + + obo:DDO.owl#DDO_0004645 + sodium-[14C] glycocholate + + + + obo:DDO.owl#DDO_0004646 + DDO:DDO_0004646 + + + + obo:DDO.owl#DDO_0004646 + 2660003 + + + + obo:DDO.owl#DDO_0004646 + sodium dehydrocholate + + + + obo:DDO.owl#DDO_0004647 + DDO:DDO_0004647 + + + + obo:DDO.owl#DDO_0004647 + 63896007 + + + + obo:DDO.owl#DDO_0004647 + taurine salt of bile acid + + + + obo:DDO.owl#DDO_0004648 + DDO:DDO_0004648 + + + + obo:DDO.owl#DDO_0004648 + 708824003 + + + + obo:DDO.owl#DDO_0004648 + sodium taurocholate + + + + obo:DDO.owl#DDO_0004649 + DDO:DDO_0004649 + + + + obo:DDO.owl#DDO_0004649 + 47950009 + + + + obo:DDO.owl#DDO_0004649 + taurocholic acid + + + + obo:DDO.owl#DDO_0004650 + DDO:DDO_0004650 + + + + obo:DDO.owl#DDO_0004650 + 259544005 + + + + obo:DDO.owl#DDO_0004650 + conjugated bile acids + + + + obo:DDO.owl#DDO_0004651 + DDO:DDO_0004651 + + + + obo:DDO.owl#DDO_0004651 + 31422009 + + + + obo:DDO.owl#DDO_0004651 + ox bile extract + + + + obo:DDO.owl#DDO_0004652 + DDO:DDO_0004652 + + + + obo:DDO.owl#DDO_0004652 + 433485000 + + + + obo:DDO.owl#DDO_0004652 + bile acid anion + + + + obo:DDO.owl#DDO_0004653 + DDO:DDO_0004653 + + + + obo:DDO.owl#DDO_0004653 + 434444004 + + + + obo:DDO.owl#DDO_0004653 + deoxycholate + + + + obo:DDO.owl#DDO_0004654 + DDO:DDO_0004654 + + + + obo:DDO.owl#DDO_0004654 + 304275008 + + + + obo:DDO.owl#DDO_0004654 + corticosteroids and derivatives + + + + obo:DDO.owl#DDO_0004655 + DDO:DDO_0004655 + + + + obo:DDO.owl#DDO_0004655 + 103035004 + + + + obo:DDO.owl#DDO_0004655 + 11-Deoxysteroid + + + + obo:DDO.owl#DDO_0004656 + DDO:DDO_0004656 + + + + obo:DDO.owl#DDO_0004656 + 103032001 + + + + obo:DDO.owl#DDO_0004656 + 11-Deoxy-17-ketosteroid + + + + obo:DDO.owl#DDO_0004657 + DDO:DDO_0004657 + + + + obo:DDO.owl#DDO_0004657 + 17117004 + + + + obo:DDO.owl#DDO_0004657 + androsterone + + + + obo:DDO.owl#DDO_0004658 + DDO:DDO_0004658 + + + + obo:DDO.owl#DDO_0004658 + 103045002 + + + + obo:DDO.owl#DDO_0004658 + Epiandrosterone + + + + obo:DDO.owl#DDO_0004659 + DDO:DDO_0004659 + + + + obo:DDO.owl#DDO_0004659 + 67906003 + + + + obo:DDO.owl#DDO_0004659 + etiocholanolone + + + + obo:DDO.owl#DDO_0004660 + DDO:DDO_0004660 + + + + obo:DDO.owl#DDO_0004660 + 103054004 + + + + obo:DDO.owl#DDO_0004660 + 11-Hydroxyetiocholanolone + + + + obo:DDO.owl#DDO_0004661 + DDO:DDO_0004661 + + + + obo:DDO.owl#DDO_0004661 + 103055003 + + + + obo:DDO.owl#DDO_0004661 + 11-Ketoetiocholanolone + + + + obo:DDO.owl#DDO_0004662 + DDO:DDO_0004662 + + + + obo:DDO.owl#DDO_0004662 + 1336006 + + + + obo:DDO.owl#DDO_0004662 + 11-Deoxycorticosterone + + + + obo:DDO.owl#DDO_0004663 + DDO:DDO_0004663 + + + + obo:DDO.owl#DDO_0004663 + 707040003 + + + + obo:DDO.owl#DDO_0004663 + 11-Dehydrotetrahydrocorticosterone + + + + obo:DDO.owl#DDO_0004664 + DDO:DDO_0004664 + + + + obo:DDO.owl#DDO_0004664 + 56156001 + + + + obo:DDO.owl#DDO_0004664 + desoxycorticosterone acetate + + + + obo:DDO.owl#DDO_0004665 + DDO:DDO_0004665 + + + + obo:DDO.owl#DDO_0004665 + 116630009 + + + + obo:DDO.owl#DDO_0004665 + desoxycorticosterone pivalate + + + + obo:DDO.owl#DDO_0004666 + DDO:DDO_0004666 + + + + obo:DDO.owl#DDO_0004666 + 22941009 + + + + obo:DDO.owl#DDO_0004666 + 11-Deoxycortisol + + + + obo:DDO.owl#DDO_0004667 + DDO:DDO_0004667 + + + + obo:DDO.owl#DDO_0004667 + 84818007 + + + + obo:DDO.owl#DDO_0004667 + 17,21-Dihydroxypregnenolone + + + + obo:DDO.owl#DDO_0004668 + DDO:DDO_0004668 + + + + obo:DDO.owl#DDO_0004668 + 115580001 + + + + obo:DDO.owl#DDO_0004668 + 18-Hydroxydeoxycorticosterone + + + + obo:DDO.owl#DDO_0004669 + DDO:DDO_0004669 + + + + obo:DDO.owl#DDO_0004669 + 115342001 + + + + obo:DDO.owl#DDO_0004669 + 18-Hydroxydeoxycortisol + + + + obo:DDO.owl#DDO_0004670 + DDO:DDO_0004670 + + + + obo:DDO.owl#DDO_0004670 + 47350002 + + + + obo:DDO.owl#DDO_0004670 + pregnenolone + + + + obo:DDO.owl#DDO_0004671 + DDO:DDO_0004671 + + + + obo:DDO.owl#DDO_0004671 + 708725005 + + + + obo:DDO.owl#DDO_0004671 + 16-alpha-Hydroxypregnenolone + + + + obo:DDO.owl#DDO_0004672 + DDO:DDO_0004672 + + + + obo:DDO.owl#DDO_0004672 + 27184001 + + + + obo:DDO.owl#DDO_0004672 + 17-Hydroxypregnenolone + + + + obo:DDO.owl#DDO_0004673 + DDO:DDO_0004673 + + + + obo:DDO.owl#DDO_0004673 + 429934000 + + + + obo:DDO.owl#DDO_0004673 + 3-Methoxy-pregnenolone + + + + obo:DDO.owl#DDO_0004674 + DDO:DDO_0004674 + + + + obo:DDO.owl#DDO_0004674 + 259351002 + + + + obo:DDO.owl#DDO_0004674 + pregnenolone sulfate + + + + obo:DDO.owl#DDO_0004675 + DDO:DDO_0004675 + + + + obo:DDO.owl#DDO_0004675 + 103036003 + + + + obo:DDO.owl#DDO_0004675 + 11-Oxycorticosteroid + + + + obo:DDO.owl#DDO_0004676 + DDO:DDO_0004676 + + + + obo:DDO.owl#DDO_0004676 + 116617008 + + + + obo:DDO.owl#DDO_0004676 + 11-Oxopregnanetriol + + + + obo:DDO.owl#DDO_0004677 + DDO:DDO_0004677 + + + + obo:DDO.owl#DDO_0004677 + 103041006 + + + + obo:DDO.owl#DDO_0004677 + 11-Ketopregnanetriol + + + + obo:DDO.owl#DDO_0004678 + DDO:DDO_0004678 + + + + obo:DDO.owl#DDO_0004678 + 42605004 + + + + obo:DDO.owl#DDO_0004678 + aldosterone + + + + obo:DDO.owl#DDO_0004679 + DDO:DDO_0004679 + + + + obo:DDO.owl#DDO_0004679 + 115493009 + + + + obo:DDO.owl#DDO_0004679 + tetrahydroaldosterone + + + + obo:DDO.owl#DDO_0004680 + DDO:DDO_0004680 + + + + obo:DDO.owl#DDO_0004680 + 706950007 + + + + obo:DDO.owl#DDO_0004680 + free aldosterone + + + + obo:DDO.owl#DDO_0004681 + DDO:DDO_0004681 + + + + obo:DDO.owl#DDO_0004681 + 712598001 + + + + obo:DDO.owl#DDO_0004681 + aldosterone 18-glucuronide + + + + obo:DDO.owl#DDO_0004682 + DDO:DDO_0004682 + + + + obo:DDO.owl#DDO_0004682 + 46120009 + + + + obo:DDO.owl#DDO_0004682 + 17-Ketosteroid + + + + obo:DDO.owl#DDO_0004683 + DDO:DDO_0004683 + + + + obo:DDO.owl#DDO_0004683 + 103039005 + + + + obo:DDO.owl#DDO_0004683 + 11-Oxy-17-ketosteroid + + + + obo:DDO.owl#DDO_0004684 + DDO:DDO_0004684 + + + + obo:DDO.owl#DDO_0004684 + 103046001 + + + + obo:DDO.owl#DDO_0004684 + 11-Hydroxyandrosterone + + + + obo:DDO.owl#DDO_0004685 + DDO:DDO_0004685 + + + + obo:DDO.owl#DDO_0004685 + 57244003 + + + + obo:DDO.owl#DDO_0004685 + 11-Ketoandrosterone + + + + obo:DDO.owl#DDO_0004686 + DDO:DDO_0004686 + + + + obo:DDO.owl#DDO_0004686 + 103038002 + + + + obo:DDO.owl#DDO_0004686 + 11-Oxy-etiocholanolone + + + + obo:DDO.owl#DDO_0004687 + DDO:DDO_0004687 + + + + obo:DDO.owl#DDO_0004687 + 51775003 + + + + obo:DDO.owl#DDO_0004687 + estrone + + + + obo:DDO.owl#DDO_0004688 + DDO:DDO_0004688 + + + + obo:DDO.owl#DDO_0004688 + 708724009 + + + + obo:DDO.owl#DDO_0004688 + 16 alpha-hydroxyestrone + + + + obo:DDO.owl#DDO_0004689 + DDO:DDO_0004689 + + + + obo:DDO.owl#DDO_0004689 + 708720000 + + + + obo:DDO.owl#DDO_0004689 + 2-Hydroxyestrone + + + + obo:DDO.owl#DDO_0004690 + DDO:DDO_0004690 + + + + obo:DDO.owl#DDO_0004690 + 115502007 + + + + obo:DDO.owl#DDO_0004690 + estrone sulfate + + + + obo:DDO.owl#DDO_0004691 + DDO:DDO_0004691 + + + + obo:DDO.owl#DDO_0004691 + 708044005 + + + + obo:DDO.owl#DDO_0004691 + estrone, unconjugated + + + + obo:DDO.owl#DDO_0004692 + DDO:DDO_0004692 + + + + obo:DDO.owl#DDO_0004692 + 395829001 + + + + obo:DDO.owl#DDO_0004692 + piperazine estrone sulfate + + + + obo:DDO.owl#DDO_0004693 + DDO:DDO_0004693 + + + + obo:DDO.owl#DDO_0004693 + 127381003 + + + + obo:DDO.owl#DDO_0004693 + sodium estrone sulfate + + + + obo:DDO.owl#DDO_0004694 + DDO:DDO_0004694 + + + + obo:DDO.owl#DDO_0004694 + 395963000 + + + + obo:DDO.owl#DDO_0004694 + clobetasone + + + + obo:DDO.owl#DDO_0004695 + DDO:DDO_0004695 + + + + obo:DDO.owl#DDO_0004695 + 395967004 + + + + obo:DDO.owl#DDO_0004695 + clobetasone butyrate + + + + obo:DDO.owl#DDO_0004696 + DDO:DDO_0004696 + + + + obo:DDO.owl#DDO_0004696 + 396012006 + + + + obo:DDO.owl#DDO_0004696 + deflazacort + + + + obo:DDO.owl#DDO_0004697 + DDO:DDO_0004697 + + + + obo:DDO.owl#DDO_0004697 + 363733008 + + + + obo:DDO.owl#DDO_0004697 + fluorinated corticosteroid + + + + obo:DDO.owl#DDO_0004698 + DDO:DDO_0004698 + + + + obo:DDO.owl#DDO_0004698 + 419478000 + + + + obo:DDO.owl#DDO_0004698 + mineralocorticoid agent + + + + obo:DDO.owl#DDO_0004699 + DDO:DDO_0004699 + + + + obo:DDO.owl#DDO_0004699 + 36887008 + + + + obo:DDO.owl#DDO_0004699 + mineralocorticoid hormone + + + + obo:DDO.owl#DDO_0004700 + DDO:DDO_0004700 + + + + obo:DDO.owl#DDO_0004700 + 707051003 + + + + obo:DDO.owl#DDO_0004700 + 21-Deoxycortisol + + + + obo:DDO.owl#DDO_0004701 + DDO:DDO_0004701 + + + + obo:DDO.owl#DDO_0004701 + 707191002 + + + + obo:DDO.owl#DDO_0004701 + allo-tetrahydrocortisol + + + + obo:DDO.owl#DDO_0004702 + DDO:DDO_0004702 + + + + obo:DDO.owl#DDO_0004702 + 116585003 + + + + obo:DDO.owl#DDO_0004702 + synthetic mineralocorticoid + + + + obo:DDO.owl#DDO_0004703 + DDO:DDO_0004703 + + + + obo:DDO.owl#DDO_0004703 + 708719006 + + + + obo:DDO.owl#DDO_0004703 + pregnanetriolone + + + + obo:DDO.owl#DDO_0004704 + DDO:DDO_0004704 + + + + obo:DDO.owl#DDO_0004704 + 412322004 + + + + obo:DDO.owl#DDO_0004704 + tixocortol pivalate + + + + obo:DDO.owl#DDO_0004705 + DDO:DDO_0004705 + + + + obo:DDO.owl#DDO_0004705 + 126088007 + + + + obo:DDO.owl#DDO_0004705 + estrane + + + + obo:DDO.owl#DDO_0004706 + DDO:DDO_0004706 + + + + obo:DDO.owl#DDO_0004706 + 126172005 + + + + obo:DDO.owl#DDO_0004706 + estradiol + + + + obo:DDO.owl#DDO_0004707 + DDO:DDO_0004707 + + + + obo:DDO.owl#DDO_0004707 + 709611009 + + + + obo:DDO.owl#DDO_0004707 + albumin bound estradiol + + + + obo:DDO.owl#DDO_0004708 + DDO:DDO_0004708 + + + + obo:DDO.owl#DDO_0004708 + 412253000 + + + + obo:DDO.owl#DDO_0004708 + nandrolone decanoate + + + + obo:DDO.owl#DDO_0004709 + DDO:DDO_0004709 + + + + obo:DDO.owl#DDO_0004709 + 109037003 + + + + obo:DDO.owl#DDO_0004709 + nandrolone phenpropionate + + + + obo:DDO.owl#DDO_0004710 + DDO:DDO_0004710 + + + + obo:DDO.owl#DDO_0004710 + 126171003 + + + + obo:DDO.owl#DDO_0004710 + nandrolone + + + + obo:DDO.owl#DDO_0004711 + DDO:DDO_0004711 + + + + obo:DDO.owl#DDO_0004711 + 259349001 + + + + obo:DDO.owl#DDO_0004711 + free estradiol + + + + obo:DDO.owl#DDO_0004712 + DDO:DDO_0004712 + + + + obo:DDO.owl#DDO_0004712 + 412287005 + + + + obo:DDO.owl#DDO_0004712 + quinestrol + + + + obo:DDO.owl#DDO_0004713 + DDO:DDO_0004713 + + + + obo:DDO.owl#DDO_0004713 + 126097006 + + + + obo:DDO.owl#DDO_0004713 + ethinyl estradiol + + + + obo:DDO.owl#DDO_0004714 + DDO:DDO_0004714 + + + + obo:DDO.owl#DDO_0004714 + 96350008 + + + + obo:DDO.owl#DDO_0004714 + estradiol valerate + + + + obo:DDO.owl#DDO_0004715 + DDO:DDO_0004715 + + + + obo:DDO.owl#DDO_0004715 + 116070003 + + + + obo:DDO.owl#DDO_0004715 + estradiol hemihydrate + + + + obo:DDO.owl#DDO_0004716 + DDO:DDO_0004716 + + + + obo:DDO.owl#DDO_0004716 + 708186001 + + + + obo:DDO.owl#DDO_0004716 + estradiol enanthate + + + + obo:DDO.owl#DDO_0004717 + DDO:DDO_0004717 + + + + obo:DDO.owl#DDO_0004717 + 109028003 + + + + obo:DDO.owl#DDO_0004717 + estradiol cypionate + + + + obo:DDO.owl#DDO_0004718 + DDO:DDO_0004718 + + + + obo:DDO.owl#DDO_0004718 + 96349008 + + + + obo:DDO.owl#DDO_0004718 + estradiol benzoate + + + + obo:DDO.owl#DDO_0004719 + DDO:DDO_0004719 + + + + obo:DDO.owl#DDO_0004719 + 414140005 + + + + obo:DDO.owl#DDO_0004719 + estradiol acetate + + + + obo:DDO.owl#DDO_0004720 + DDO:DDO_0004720 + + + + obo:DDO.owl#DDO_0004720 + 710119009 + + + + obo:DDO.owl#DDO_0004720 + bioavailable estradiol + + + + obo:DDO.owl#DDO_0004721 + DDO:DDO_0004721 + + + + obo:DDO.owl#DDO_0004721 + 117059000 + + + + obo:DDO.owl#DDO_0004721 + trenbolone + + + + obo:DDO.owl#DDO_0004722 + DDO:DDO_0004722 + + + + obo:DDO.owl#DDO_0004722 + 387530003 + + + + obo:DDO.owl#DDO_0004722 + fusidic acid + + + + obo:DDO.owl#DDO_0004723 + DDO:DDO_0004723 + + + + obo:DDO.owl#DDO_0004723 + 395876005 + + + + obo:DDO.owl#DDO_0004723 + sodium fusidate + + + + obo:DDO.owl#DDO_0004724 + DDO:DDO_0004724 + + + + obo:DDO.owl#DDO_0004724 + 126089004 + + + + obo:DDO.owl#DDO_0004724 + norsteroid + + + + obo:DDO.owl#DDO_0004725 + DDO:DDO_0004725 + + + + obo:DDO.owl#DDO_0004725 + 126108008 + + + + obo:DDO.owl#DDO_0004725 + desogestrel + + + + obo:DDO.owl#DDO_0004726 + DDO:DDO_0004726 + + + + obo:DDO.owl#DDO_0004726 + 420879007 + + + + obo:DDO.owl#DDO_0004726 + ethynodiol + + + + obo:DDO.owl#DDO_0004727 + DDO:DDO_0004727 + + + + obo:DDO.owl#DDO_0004727 + 126105006 + + + + obo:DDO.owl#DDO_0004727 + etynodiol diacetate + + + + obo:DDO.owl#DDO_0004728 + DDO:DDO_0004728 + + + + obo:DDO.owl#DDO_0004728 + 126095003 + + + + obo:DDO.owl#DDO_0004728 + norethandrolone + + + + obo:DDO.owl#DDO_0004729 + DDO:DDO_0004729 + + + + obo:DDO.owl#DDO_0004729 + 126102009 + + + + obo:DDO.owl#DDO_0004729 + norethindrone + + + + obo:DDO.owl#DDO_0004730 + DDO:DDO_0004730 + + + + obo:DDO.owl#DDO_0004730 + 126104005 + + + + obo:DDO.owl#DDO_0004730 + norethindrone acetate + + + + obo:DDO.owl#DDO_0004731 + DDO:DDO_0004731 + + + + obo:DDO.owl#DDO_0004731 + 395811006 + + + + obo:DDO.owl#DDO_0004731 + norethindrone enanthate + + + + obo:DDO.owl#DDO_0004732 + DDO:DDO_0004732 + + + + obo:DDO.owl#DDO_0004732 + 126107003 + + + + obo:DDO.owl#DDO_0004732 + norethynodrel + + + + obo:DDO.owl#DDO_0004733 + DDO:DDO_0004733 + + + + obo:DDO.owl#DDO_0004733 + 126106007 + + + + obo:DDO.owl#DDO_0004733 + norgestrel + + + + obo:DDO.owl#DDO_0004734 + DDO:DDO_0004734 + + + + obo:DDO.owl#DDO_0004734 + 126109000 + + + + obo:DDO.owl#DDO_0004734 + levonorgestrel + + + + obo:DDO.owl#DDO_0004735 + DDO:DDO_0004735 + + + + obo:DDO.owl#DDO_0004735 + 126090008 + + + + obo:DDO.owl#DDO_0004735 + Pregnanes + + + + obo:DDO.owl#DDO_0004736 + DDO:DDO_0004736 + + + + obo:DDO.owl#DDO_0004736 + 387037009 + + + + obo:DDO.owl#DDO_0004736 + alphaxolone + + + + obo:DDO.owl#DDO_0004737 + DDO:DDO_0004737 + + + + obo:DDO.owl#DDO_0004737 + 39203000 + + + + obo:DDO.owl#DDO_0004737 + conanine + + + + obo:DDO.owl#DDO_0004738 + DDO:DDO_0004738 + + + + obo:DDO.owl#DDO_0004738 + 126119006 + + + + obo:DDO.owl#DDO_0004738 + cyproterone + + + + obo:DDO.owl#DDO_0004739 + DDO:DDO_0004739 + + + + obo:DDO.owl#DDO_0004739 + 126120000 + + + + obo:DDO.owl#DDO_0004739 + cyproterone acetate + + + + obo:DDO.owl#DDO_0004740 + DDO:DDO_0004740 + + + + obo:DDO.owl#DDO_0004740 + 126093005 + + + + obo:DDO.owl#DDO_0004740 + dydrogesterone + + + + obo:DDO.owl#DDO_0004741 + DDO:DDO_0004741 + + + + obo:DDO.owl#DDO_0004741 + 126094004 + + + + obo:DDO.owl#DDO_0004741 + ethisterone + + + + obo:DDO.owl#DDO_0004742 + DDO:DDO_0004742 + + + + obo:DDO.owl#DDO_0004742 + 126091007 + + + + obo:DDO.owl#DDO_0004742 + megestrol + + + + obo:DDO.owl#DDO_0004743 + DDO:DDO_0004743 + + + + obo:DDO.owl#DDO_0004743 + 126092000 + + + + obo:DDO.owl#DDO_0004743 + megestrol acetate + + + + obo:DDO.owl#DDO_0004744 + DDO:DDO_0004744 + + + + obo:DDO.owl#DDO_0004744 + 28268006 + + + + obo:DDO.owl#DDO_0004744 + pregnanediol + + + + obo:DDO.owl#DDO_0004745 + DDO:DDO_0004745 + + + + obo:DDO.owl#DDO_0004745 + 16683002 + + + + obo:DDO.owl#DDO_0004745 + progesterone + + + + obo:DDO.owl#DDO_0004746 + DDO:DDO_0004746 + + + + obo:DDO.owl#DDO_0004746 + 706932000 + + + + obo:DDO.owl#DDO_0004746 + free progesterone + + + + obo:DDO.owl#DDO_0004747 + DDO:DDO_0004747 + + + + obo:DDO.owl#DDO_0004747 + 112113009 + + + + obo:DDO.owl#DDO_0004747 + steroid hormone + + + + obo:DDO.owl#DDO_0004748 + DDO:DDO_0004748 + + + + obo:DDO.owl#DDO_0004748 + 304276009 + + + + obo:DDO.owl#DDO_0004748 + estradiol and derivatives + + + + obo:DDO.owl#DDO_0004749 + DDO:DDO_0004749 + + + + obo:DDO.owl#DDO_0004749 + 73723004 + + + + obo:DDO.owl#DDO_0004749 + estriol + + + + obo:DDO.owl#DDO_0004750 + DDO:DDO_0004750 + + + + obo:DDO.owl#DDO_0004750 + 312257000 + + + + obo:DDO.owl#DDO_0004750 + 17-Beta-estriol + + + + obo:DDO.owl#DDO_0004751 + DDO:DDO_0004751 + + + + obo:DDO.owl#DDO_0004751 + 708042009 + + + + obo:DDO.owl#DDO_0004751 + estriol, conjugated + + + + obo:DDO.owl#DDO_0004752 + DDO:DDO_0004752 + + + + obo:DDO.owl#DDO_0004752 + 708043004 + + + + obo:DDO.owl#DDO_0004752 + estriol, unconjugated + + + + obo:DDO.owl#DDO_0004753 + DDO:DDO_0004753 + + + + obo:DDO.owl#DDO_0004753 + 41598000 + + + + obo:DDO.owl#DDO_0004753 + estrogen + + + + obo:DDO.owl#DDO_0004754 + DDO:DDO_0004754 + + + + obo:DDO.owl#DDO_0004754 + 126184007 + + + + obo:DDO.owl#DDO_0004754 + benzestrol + + + + obo:DDO.owl#DDO_0004755 + DDO:DDO_0004755 + + + + obo:DDO.owl#DDO_0004755 + 420464005 + + + + obo:DDO.owl#DDO_0004755 + chlorotrianisene + + + + obo:DDO.owl#DDO_0004756 + DDO:DDO_0004756 + + + + obo:DDO.owl#DDO_0004756 + 126098001 + + + + obo:DDO.owl#DDO_0004756 + conjugated estrogen + + + + obo:DDO.owl#DDO_0004757 + DDO:DDO_0004757 + + + + obo:DDO.owl#DDO_0004757 + 425912007 + + + + obo:DDO.owl#DDO_0004757 + conjugated estrogens synthetic A + + + + obo:DDO.owl#DDO_0004758 + DDO:DDO_0004758 + + + + obo:DDO.owl#DDO_0004758 + 426048004 + + + + obo:DDO.owl#DDO_0004758 + conjugated estrogens synthetic B + + + + obo:DDO.owl#DDO_0004759 + DDO:DDO_0004759 + + + + obo:DDO.owl#DDO_0004759 + 126169003 + + + + obo:DDO.owl#DDO_0004759 + dienestrol + + + + obo:DDO.owl#DDO_0004760 + DDO:DDO_0004760 + + + + obo:DDO.owl#DDO_0004760 + 396026002 + + + + obo:DDO.owl#DDO_0004760 + diethylstilbestrol + + + + obo:DDO.owl#DDO_0004761 + DDO:DDO_0004761 + + + + obo:DDO.owl#DDO_0004761 + 395979004 + + + + obo:DDO.owl#DDO_0004761 + diethylstilbestrol diphosphate + + + + obo:DDO.owl#DDO_0004762 + DDO:DDO_0004762 + + + + obo:DDO.owl#DDO_0004762 + 396066003 + + + + obo:DDO.owl#DDO_0004762 + fosfestrol tetrasodium + + + + obo:DDO.owl#DDO_0004763 + DDO:DDO_0004763 + + + + obo:DDO.owl#DDO_0004763 + 126099009 + + + + obo:DDO.owl#DDO_0004763 + esterified estrogen + + + + obo:DDO.owl#DDO_0004764 + DDO:DDO_0004764 + + + + obo:DDO.owl#DDO_0004764 + 395785001 + + + + obo:DDO.owl#DDO_0004764 + mestranol + + + + obo:DDO.owl#DDO_0004765 + DDO:DDO_0004765 + + + + obo:DDO.owl#DDO_0004765 + 126174006 + + + + obo:DDO.owl#DDO_0004765 + methallenestril + + + + obo:DDO.owl#DDO_0004766 + DDO:DDO_0004766 + + + + obo:DDO.owl#DDO_0004766 + 126084009 + + + + obo:DDO.owl#DDO_0004766 + polyestradiol phosphate + + + + obo:DDO.owl#DDO_0004767 + DDO:DDO_0004767 + + + + obo:DDO.owl#DDO_0004767 + 699187002 + + + + obo:DDO.owl#DDO_0004767 + promestriene + + + + obo:DDO.owl#DDO_0004768 + DDO:DDO_0004768 + + + + obo:DDO.owl#DDO_0004768 + 126183001 + + + + obo:DDO.owl#DDO_0004768 + Promethestrol + + + + obo:DDO.owl#DDO_0004769 + DDO:DDO_0004769 + + + + obo:DDO.owl#DDO_0004769 + 420164003 + + + + obo:DDO.owl#DDO_0004769 + quinestradol + + + + obo:DDO.owl#DDO_0004770 + DDO:DDO_0004770 + + + + obo:DDO.owl#DDO_0004770 + 96340007 + + + + obo:DDO.owl#DDO_0004770 + zeranol + + + + obo:DDO.owl#DDO_0004771 + DDO:DDO_0004771 + + + + obo:DDO.owl#DDO_0004771 + 116615000 + + + + obo:DDO.owl#DDO_0004771 + progesterone derivative + + + + obo:DDO.owl#DDO_0004772 + DDO:DDO_0004772 + + + + obo:DDO.owl#DDO_0004772 + 391736002 + + + + obo:DDO.owl#DDO_0004772 + allylestrenol + + + + obo:DDO.owl#DDO_0004773 + DDO:DDO_0004773 + + + + obo:DDO.owl#DDO_0004773 + 126110005 + + + + obo:DDO.owl#DDO_0004773 + hydroxyprogesterone + + + + obo:DDO.owl#DDO_0004774 + DDO:DDO_0004774 + + + + obo:DDO.owl#DDO_0004774 + 126111009 + + + + obo:DDO.owl#DDO_0004774 + hydroxyprogesterone caproate + + + + obo:DDO.owl#DDO_0004775 + DDO:DDO_0004775 + + + + obo:DDO.owl#DDO_0004775 + 312263009 + + + + obo:DDO.owl#DDO_0004775 + sex hormone + + + + obo:DDO.owl#DDO_0004776 + DDO:DDO_0004776 + + + + obo:DDO.owl#DDO_0004776 + 6826009 + + + + obo:DDO.owl#DDO_0004776 + sterol hormone + + + + obo:DDO.owl#DDO_0004777 + DDO:DDO_0004777 + + + + obo:DDO.owl#DDO_0004777 + 304277000 + + + + obo:DDO.owl#DDO_0004777 + testosterone and derivatives + + + + obo:DDO.owl#DDO_0004778 + DDO:DDO_0004778 + + + + obo:DDO.owl#DDO_0004778 + 263668001 + + + + obo:DDO.owl#DDO_0004778 + androgenic precursors + + + + obo:DDO.owl#DDO_0004779 + DDO:DDO_0004779 + + + + obo:DDO.owl#DDO_0004779 + 418770003 + + + + obo:DDO.owl#DDO_0004779 + steroidal neuromuscular blocker + + + + obo:DDO.owl#DDO_0004780 + DDO:DDO_0004780 + + + + obo:DDO.owl#DDO_0004780 + 373738000 + + + + obo:DDO.owl#DDO_0004780 + pancuronium + + + + obo:DDO.owl#DDO_0004781 + DDO:DDO_0004781 + + + + obo:DDO.owl#DDO_0004781 + 373764006 + + + + obo:DDO.owl#DDO_0004781 + pancuronium bromide + + + + obo:DDO.owl#DDO_0004782 + DDO:DDO_0004782 + + + + obo:DDO.owl#DDO_0004782 + 3209002 + + + + obo:DDO.owl#DDO_0004782 + pancuronium sodium + + + + obo:DDO.owl#DDO_0004783 + DDO:DDO_0004783 + + + + obo:DDO.owl#DDO_0004783 + 373725008 + + + + obo:DDO.owl#DDO_0004783 + pipecuronium + + + + obo:DDO.owl#DDO_0004784 + DDO:DDO_0004784 + + + + obo:DDO.owl#DDO_0004784 + 108456008 + + + + obo:DDO.owl#DDO_0004784 + pipecuronium bromide + + + + obo:DDO.owl#DDO_0004785 + DDO:DDO_0004785 + + + + obo:DDO.owl#DDO_0004785 + 116106006 + + + + obo:DDO.owl#DDO_0004785 + rapacuronium bromide + + + + obo:DDO.owl#DDO_0004786 + DDO:DDO_0004786 + + + + obo:DDO.owl#DDO_0004786 + 372494005 + + + + obo:DDO.owl#DDO_0004786 + rocuronium + + + + obo:DDO.owl#DDO_0004787 + DDO:DDO_0004787 + + + + obo:DDO.owl#DDO_0004787 + 108450002 + + + + obo:DDO.owl#DDO_0004787 + rocuronium bromide + + + + obo:DDO.owl#DDO_0004788 + DDO:DDO_0004788 + + + + obo:DDO.owl#DDO_0004788 + 372883002 + + + + obo:DDO.owl#DDO_0004788 + vecuronium + + + + obo:DDO.owl#DDO_0004789 + DDO:DDO_0004789 + + + + obo:DDO.owl#DDO_0004789 + 87472002 + + + + obo:DDO.owl#DDO_0004789 + vecuronium bromide + + + + obo:DDO.owl#DDO_0004790 + DDO:DDO_0004790 + + + + obo:DDO.owl#DDO_0004790 + 116567005 + + + + obo:DDO.owl#DDO_0004790 + synthetic steroid + + + + obo:DDO.owl#DDO_0004791 + DDO:DDO_0004791 + + + + obo:DDO.owl#DDO_0004791 + 126162007 + + + + obo:DDO.owl#DDO_0004791 + androgenic steroid + + + + obo:DDO.owl#DDO_0004792 + DDO:DDO_0004792 + + + + obo:DDO.owl#DDO_0004792 + 708726006 + + + + obo:DDO.owl#DDO_0004792 + 16 alpha-hydroxydehydroepiandrosterone + + + + obo:DDO.owl#DDO_0004793 + DDO:DDO_0004793 + + + + obo:DDO.owl#DDO_0004793 + 259533002 + + + + obo:DDO.owl#DDO_0004793 + 16 alpha-hydroxydehydroepiandrosterone sulfate + + + + obo:DDO.owl#DDO_0004794 + DDO:DDO_0004794 + + + + obo:DDO.owl#DDO_0004794 + 111151007 + + + + obo:DDO.owl#DDO_0004794 + anabolic steroid + + + + obo:DDO.owl#DDO_0004795 + DDO:DDO_0004795 + + + + obo:DDO.owl#DDO_0004795 + 96343009 + + + + obo:DDO.owl#DDO_0004795 + bolasterone + + + + obo:DDO.owl#DDO_0004796 + DDO:DDO_0004796 + + + + obo:DDO.owl#DDO_0004796 + 416531000 + + + + obo:DDO.owl#DDO_0004796 + boldenone + + + + obo:DDO.owl#DDO_0004797 + DDO:DDO_0004797 + + + + obo:DDO.owl#DDO_0004797 + 96341006 + + + + obo:DDO.owl#DDO_0004797 + boldenone undecylenate + + + + obo:DDO.owl#DDO_0004798 + DDO:DDO_0004798 + + + + obo:DDO.owl#DDO_0004798 + 96345002 + + + + obo:DDO.owl#DDO_0004798 + clostebol + + + + obo:DDO.owl#DDO_0004799 + DDO:DDO_0004799 + + + + obo:DDO.owl#DDO_0004799 + 126124009 + + + + obo:DDO.owl#DDO_0004799 + danazol + + + + obo:DDO.owl#DDO_0004800 + DDO:DDO_0004800 + + + + obo:DDO.owl#DDO_0004800 + 420633004 + + + + obo:DDO.owl#DDO_0004800 + drostanolone + + + + obo:DDO.owl#DDO_0004801 + DDO:DDO_0004801 + + + + obo:DDO.owl#DDO_0004801 + 417263004 + + + + obo:DDO.owl#DDO_0004801 + drostanolone propionate + + + + obo:DDO.owl#DDO_0004802 + DDO:DDO_0004802 + + + + obo:DDO.owl#DDO_0004802 + 126170002 + + + + obo:DDO.owl#DDO_0004802 + ethylestrenol + + + + obo:DDO.owl#DDO_0004803 + DDO:DDO_0004803 + + + + obo:DDO.owl#DDO_0004803 + 126127002 + + + + obo:DDO.owl#DDO_0004803 + methandriol + + + + obo:DDO.owl#DDO_0004804 + DDO:DDO_0004804 + + + + obo:DDO.owl#DDO_0004804 + 126126006 + + + + obo:DDO.owl#DDO_0004804 + methandrostenolone + + + + obo:DDO.owl#DDO_0004805 + DDO:DDO_0004805 + + + + obo:DDO.owl#DDO_0004805 + 96342004 + + + + obo:DDO.owl#DDO_0004805 + mibolerone + + + + obo:DDO.owl#DDO_0004806 + DDO:DDO_0004806 + + + + obo:DDO.owl#DDO_0004806 + 126128007 + + + + obo:DDO.owl#DDO_0004806 + oxandrolone + + + + obo:DDO.owl#DDO_0004807 + DDO:DDO_0004807 + + + + obo:DDO.owl#DDO_0004807 + 96348000 + + + + obo:DDO.owl#DDO_0004807 + oxymesterone + + + + obo:DDO.owl#DDO_0004808 + DDO:DDO_0004808 + + + + obo:DDO.owl#DDO_0004808 + 126101002 + + + + obo:DDO.owl#DDO_0004808 + oxymetholone + + + + obo:DDO.owl#DDO_0004809 + DDO:DDO_0004809 + + + + obo:DDO.owl#DDO_0004809 + 395903002 + + + + obo:DDO.owl#DDO_0004809 + tibolone + + + + obo:DDO.owl#DDO_0004810 + DDO:DDO_0004810 + + + + obo:DDO.owl#DDO_0004810 + 96344003 + + + + obo:DDO.owl#DDO_0004810 + trenbolone acetate + + + + obo:DDO.owl#DDO_0004811 + DDO:DDO_0004811 + + + + obo:DDO.owl#DDO_0004811 + 126125005 + + + + obo:DDO.owl#DDO_0004811 + fluoxymesterone + + + + obo:DDO.owl#DDO_0004812 + DDO:DDO_0004812 + + + + obo:DDO.owl#DDO_0004812 + 419430000 + + + + obo:DDO.owl#DDO_0004812 + synthetic progestogen + + + + obo:DDO.owl#DDO_0004813 + DDO:DDO_0004813 + + + + obo:DDO.owl#DDO_0004813 + 419841009 + + + + obo:DDO.owl#DDO_0004813 + altrenogest + + + + obo:DDO.owl#DDO_0004814 + DDO:DDO_0004814 + + + + obo:DDO.owl#DDO_0004814 + 126118003 + + + + obo:DDO.owl#DDO_0004814 + delmadinone acetate + + + + obo:DDO.owl#DDO_0004815 + DDO:DDO_0004815 + + + + obo:DDO.owl#DDO_0004815 + 703097002 + + + + obo:DDO.owl#DDO_0004815 + dienogest + + + + obo:DDO.owl#DDO_0004816 + DDO:DDO_0004816 + + + + obo:DDO.owl#DDO_0004816 + 410919000 + + + + obo:DDO.owl#DDO_0004816 + drospirenone + + + + obo:DDO.owl#DDO_0004817 + DDO:DDO_0004817 + + + + obo:DDO.owl#DDO_0004817 + 396050000 + + + + obo:DDO.owl#DDO_0004817 + etonogestrel + + + + obo:DDO.owl#DDO_0004818 + DDO:DDO_0004818 + + + + obo:DDO.owl#DDO_0004818 + 126114001 + + + + obo:DDO.owl#DDO_0004818 + flurogestone acetate + + + + obo:DDO.owl#DDO_0004819 + DDO:DDO_0004819 + + + + obo:DDO.owl#DDO_0004819 + 395945000 + + + + obo:DDO.owl#DDO_0004819 + gestodene + + + + obo:DDO.owl#DDO_0004820 + DDO:DDO_0004820 + + + + obo:DDO.owl#DDO_0004820 + 395980001 + + + + obo:DDO.owl#DDO_0004820 + gestonorone + + + + obo:DDO.owl#DDO_0004821 + DDO:DDO_0004821 + + + + obo:DDO.owl#DDO_0004821 + 395730000 + + + + obo:DDO.owl#DDO_0004821 + gestonorone caproate + + + + obo:DDO.owl#DDO_0004822 + DDO:DDO_0004822 + + + + obo:DDO.owl#DDO_0004822 + 387589005 + + + + obo:DDO.owl#DDO_0004822 + gestrinone + + + + obo:DDO.owl#DDO_0004823 + DDO:DDO_0004823 + + + + obo:DDO.owl#DDO_0004823 + 419504002 + + + + obo:DDO.owl#DDO_0004823 + lynestrenol + + + + obo:DDO.owl#DDO_0004824 + DDO:DDO_0004824 + + + + obo:DDO.owl#DDO_0004824 + 126113007 + + + + obo:DDO.owl#DDO_0004824 + medroxyprogesterone + + + + obo:DDO.owl#DDO_0004825 + DDO:DDO_0004825 + + + + obo:DDO.owl#DDO_0004825 + 126112002 + + + + obo:DDO.owl#DDO_0004825 + medroxyprogesterone acetate + + + + obo:DDO.owl#DDO_0004826 + DDO:DDO_0004826 + + + + obo:DDO.owl#DDO_0004826 + 699947006 + + + + obo:DDO.owl#DDO_0004826 + nomegestrol + + + + obo:DDO.owl#DDO_0004827 + DDO:DDO_0004827 + + + + obo:DDO.owl#DDO_0004827 + 698277001 + + + + obo:DDO.owl#DDO_0004827 + nomegestrol acetate + + + + obo:DDO.owl#DDO_0004828 + DDO:DDO_0004828 + + + + obo:DDO.owl#DDO_0004828 + 385578004 + + + + obo:DDO.owl#DDO_0004828 + norelgestromin + + + + obo:DDO.owl#DDO_0004829 + DDO:DDO_0004829 + + + + obo:DDO.owl#DDO_0004829 + 126115000 + + + + obo:DDO.owl#DDO_0004829 + norgestimate + + + + obo:DDO.owl#DDO_0004830 + DDO:DDO_0004830 + + + + obo:DDO.owl#DDO_0004830 + 421962009 + + + + obo:DDO.owl#DDO_0004830 + norgestomet + + + + obo:DDO.owl#DDO_0004831 + DDO:DDO_0004831 + + + + obo:DDO.owl#DDO_0004831 + 703249005 + + + + obo:DDO.owl#DDO_0004831 + ulipristal + + + + obo:DDO.owl#DDO_0004832 + DDO:DDO_0004832 + + + + obo:DDO.owl#DDO_0004832 + 703250005 + + + + obo:DDO.owl#DDO_0004832 + ulipristal acetate + + + + obo:DDO.owl#DDO_0004858 + DDO:DDO_0004858 + + + + obo:DDO.owl#DDO_0004858 + 372695000 + + + + obo:DDO.owl#DDO_0004858 + diuretic + + + + obo:DDO.owl#DDO_0004859 + DDO:DDO_0004859 + + + + obo:DDO.owl#DDO_0004859 + 372747003 + + + + obo:DDO.owl#DDO_0004859 + thiazide diuretic + + + + obo:DDO.owl#DDO_0004860 + DDO:DDO_0004860 + + + + obo:DDO.owl#DDO_0004860 + 387520007 + + + + obo:DDO.owl#DDO_0004860 + bendroflumethiazide + + + + obo:DDO.owl#DDO_0004861 + DDO:DDO_0004861 + + + + obo:DDO.owl#DDO_0004861 + 66290002 + + + + obo:DDO.owl#DDO_0004861 + benzthiazide + + + + obo:DDO.owl#DDO_0004862 + DDO:DDO_0004862 + + + + obo:DDO.owl#DDO_0004862 + 372782002 + + + + obo:DDO.owl#DDO_0004862 + chlorothiazide + + + + obo:DDO.owl#DDO_0004866 + DDO:DDO_0004866 + + + + obo:DDO.owl#DDO_0004866 + 396009008 + + + + obo:DDO.owl#DDO_0004866 + cyclopenthiazide + + + + obo:DDO.owl#DDO_0004867 + DDO:DDO_0004867 + + + + obo:DDO.owl#DDO_0004867 + 387328001 + + + + obo:DDO.owl#DDO_0004867 + diazoxide + + + + obo:DDO.owl#DDO_0004868 + DDO:DDO_0004868 + + + + obo:DDO.owl#DDO_0004868 + 387525002 + + + + obo:DDO.owl#DDO_0004868 + hydrochlorothiazide + + + + obo:DDO.owl#DDO_0004869 + DDO:DDO_0004869 + + + + obo:DDO.owl#DDO_0004869 + 395946004 + + + + obo:DDO.owl#DDO_0004869 + hydroflumethiazide + + + + obo:DDO.owl#DDO_0004871 + DDO:DDO_0004871 + + + + obo:DDO.owl#DDO_0004871 + 406772008 + + + + obo:DDO.owl#DDO_0004871 + mefruside + + + + obo:DDO.owl#DDO_0004872 + DDO:DDO_0004872 + + + + obo:DDO.owl#DDO_0004872 + 387373008 + + + + obo:DDO.owl#DDO_0004872 + methyclothiazide + + + + obo:DDO.owl#DDO_0004873 + DDO:DDO_0004873 + + + + obo:DDO.owl#DDO_0004873 + 387492006 + + + + obo:DDO.owl#DDO_0004873 + polythiazide + + + + obo:DDO.owl#DDO_0004874 + DDO:DDO_0004874 + + + + obo:DDO.owl#DDO_0004874 + 41261002 + + + + obo:DDO.owl#DDO_0004874 + quinethazone + + + + obo:DDO.owl#DDO_0004875 + DDO:DDO_0004875 + + + + obo:DDO.owl#DDO_0004875 + 395923001 + + + + obo:DDO.owl#DDO_0004875 + trichlormethiazide + + + + obo:DDO.owl#DDO_0004876 + DDO:DDO_0004876 + + + + obo:DDO.owl#DDO_0004876 + 317968004 + + + + obo:DDO.owl#DDO_0004876 + xipamide + + + + obo:DDO.owl#DDO_0004877 + DDO:DDO_0004877 + + + + obo:DDO.owl#DDO_0004877 + 1182007 + + + + obo:DDO.owl#DDO_0004877 + hypotensive agent + + + + obo:DDO.owl#DDO_0004878 + DDO:DDO_0004878 + + + + obo:DDO.owl#DDO_0004878 + 33252009 + + + + obo:DDO.owl#DDO_0004878 + beta-Blocking agent + + + + obo:DDO.owl#DDO_0004879 + DDO:DDO_0004879 + + + + obo:DDO.owl#DDO_0004879 + 15772006 + + + + obo:DDO.owl#DDO_0004879 + Beta 1 blocking agent + + + + obo:DDO.owl#DDO_0004880 + DDO:DDO_0004880 + + + + obo:DDO.owl#DDO_0004880 + 68088000 + + + + obo:DDO.owl#DDO_0004880 + acebutolol + + + + obo:DDO.owl#DDO_0004891 + DDO:DDO_0004891 + + + + obo:DDO.owl#DDO_0004891 + 87652004 + + + + obo:DDO.owl#DDO_0004891 + atenolol + + + + obo:DDO.owl#DDO_0004892 + DDO:DDO_0004892 + + + + obo:DDO.owl#DDO_0004892 + 440355006 + + + + obo:DDO.owl#DDO_0004892 + oral form atenolol + + + + obo:DDO.owl#DDO_0004893 + DDO:DDO_0004893 + + + + obo:DDO.owl#DDO_0004893 + 439184001 + + + + obo:DDO.owl#DDO_0004893 + parenteral form atenolol + + + + obo:DDO.owl#DDO_0004894 + DDO:DDO_0004894 + + + + obo:DDO.owl#DDO_0004894 + 349900007 + + + + obo:DDO.owl#DDO_0004894 + Betaxolol + + + + obo:DDO.owl#DDO_0004895 + DDO:DDO_0004895 + + + + obo:DDO.owl#DDO_0004895 + 428215001 + + + + obo:DDO.owl#DDO_0004895 + oral form betaxolol + + + + obo:DDO.owl#DDO_0004896 + DDO:DDO_0004896 + + + + obo:DDO.owl#DDO_0004896 + 386819003 + + + + obo:DDO.owl#DDO_0004896 + ophthalmic betaxolol hydrochloride + + + + obo:DDO.owl#DDO_0004897 + DDO:DDO_0004897 + + + + obo:DDO.owl#DDO_0004897 + 409278007 + + + + obo:DDO.owl#DDO_0004897 + levobetaxolol + + + + obo:DDO.owl#DDO_0004898 + DDO:DDO_0004898 + + + + obo:DDO.owl#DDO_0004898 + 108547003 + + + + obo:DDO.owl#DDO_0004898 + Bisoprolol + + + + obo:DDO.owl#DDO_0004899 + DDO:DDO_0004899 + + + + obo:DDO.owl#DDO_0004899 + 108548008 + + + + obo:DDO.owl#DDO_0004899 + Bisoprolol fumarate + + + + obo:DDO.owl#DDO_0004900 + DDO:DDO_0004900 + + + + obo:DDO.owl#DDO_0004900 + 349901006 + + + + obo:DDO.owl#DDO_0004900 + Celiprolol + + + + obo:DDO.owl#DDO_0004901 + DDO:DDO_0004901 + + + + obo:DDO.owl#DDO_0004901 + 318618008 + + + + obo:DDO.owl#DDO_0004901 + Celiprolol hydrochloride + + + + obo:DDO.owl#DDO_0004902 + DDO:DDO_0004902 + + + + obo:DDO.owl#DDO_0004902 + 77856005 + + + + obo:DDO.owl#DDO_0004902 + Esmolol + + + + obo:DDO.owl#DDO_0004903 + DDO:DDO_0004903 + + + + obo:DDO.owl#DDO_0004903 + 318624002 + + + + obo:DDO.owl#DDO_0004903 + Esmolol hydrochloride product + + + + obo:DDO.owl#DDO_0004904 + DDO:DDO_0004904 + + + + obo:DDO.owl#DDO_0004904 + 7092007 + + + + obo:DDO.owl#DDO_0004904 + metoprolol + + + + obo:DDO.owl#DDO_0004905 + DDO:DDO_0004905 + + + + obo:DDO.owl#DDO_0004905 + 318638009 + + + + obo:DDO.owl#DDO_0004905 + Nebivolol + + + + obo:DDO.owl#DDO_0004906 + DDO:DDO_0004906 + + + + obo:DDO.owl#DDO_0004906 + 83522001 + + + + obo:DDO.owl#DDO_0004906 + non-selective beta-blocking agent + + + + obo:DDO.owl#DDO_0004907 + DDO:DDO_0004907 + + + + obo:DDO.owl#DDO_0004907 + 108544005 + + + + obo:DDO.owl#DDO_0004907 + Carteolol + + + + obo:DDO.owl#DDO_0004908 + DDO:DDO_0004908 + + + + obo:DDO.owl#DDO_0004908 + 386724006 + + + + obo:DDO.owl#DDO_0004908 + ophthalmic carteolol hydrochloride + + + + obo:DDO.owl#DDO_0004909 + DDO:DDO_0004909 + + + + obo:DDO.owl#DDO_0004909 + 108551001 + + + + obo:DDO.owl#DDO_0004909 + Carvedilol + + + + obo:DDO.owl#DDO_0004910 + DDO:DDO_0004910 + + + + obo:DDO.owl#DDO_0004910 + 46547007 + + + + obo:DDO.owl#DDO_0004910 + labetalol + + + + obo:DDO.owl#DDO_0004911 + DDO:DDO_0004911 + + + + obo:DDO.owl#DDO_0004911 + 108831007 + + + + obo:DDO.owl#DDO_0004911 + Metipranolol + + + + obo:DDO.owl#DDO_0004912 + DDO:DDO_0004912 + + + + obo:DDO.owl#DDO_0004912 + 82896009 + + + + obo:DDO.owl#DDO_0004912 + nadolol + + + + obo:DDO.owl#DDO_0004913 + DDO:DDO_0004913 + + + + obo:DDO.owl#DDO_0004913 + 96299009 + + + + obo:DDO.owl#DDO_0004913 + oxprenolol + + + + obo:DDO.owl#DDO_0004914 + DDO:DDO_0004914 + + + + obo:DDO.owl#DDO_0004914 + 346579000 + + + + obo:DDO.owl#DDO_0004914 + modified release oxprenolol + + + + obo:DDO.owl#DDO_0004915 + DDO:DDO_0004915 + + + + obo:DDO.owl#DDO_0004915 + 318482009 + + + + obo:DDO.owl#DDO_0004915 + oxprenolol hydrochloride + + + + obo:DDO.owl#DDO_0004916 + DDO:DDO_0004916 + + + + obo:DDO.owl#DDO_0004916 + 108542009 + + + + obo:DDO.owl#DDO_0004916 + Penbutolol + + + + obo:DDO.owl#DDO_0004917 + DDO:DDO_0004917 + + + + obo:DDO.owl#DDO_0004917 + 18381001 + + + + obo:DDO.owl#DDO_0004917 + Pindolol + + + + obo:DDO.owl#DDO_0004918 + DDO:DDO_0004918 + + + + obo:DDO.owl#DDO_0004918 + 76390000 + + + + obo:DDO.owl#DDO_0004918 + practolol + + + + obo:DDO.owl#DDO_0004919 + DDO:DDO_0004919 + + + + obo:DDO.owl#DDO_0004919 + 55745002 + + + + obo:DDO.owl#DDO_0004919 + propranolol + + + + obo:DDO.owl#DDO_0004920 + DDO:DDO_0004920 + + + + obo:DDO.owl#DDO_0004920 + 96301002 + + + + obo:DDO.owl#DDO_0004920 + sotalol + + + + obo:DDO.owl#DDO_0004921 + DDO:DDO_0004921 + + + + obo:DDO.owl#DDO_0004921 + 85591001 + + + + obo:DDO.owl#DDO_0004921 + timolol + + + + obo:DDO.owl#DDO_0004922 + DDO:DDO_0004922 + + + + obo:DDO.owl#DDO_0004922 + 372752008 + + + + obo:DDO.owl#DDO_0004922 + central nervous system agent + + + + obo:DDO.owl#DDO_0004923 + DDO:DDO_0004923 + + + + obo:DDO.owl#DDO_0004923 + 418149003 + + + + obo:DDO.owl#DDO_0004923 + psychoactive substance + + + + obo:DDO.owl#DDO_0004924 + DDO:DDO_0004924 + + + + obo:DDO.owl#DDO_0004924 + 418183005 + + + + obo:DDO.owl#DDO_0004924 + psychotropic agent + + + + obo:DDO.owl#DDO_0004925 + DDO:DDO_0004925 + + + + obo:DDO.owl#DDO_0004925 + 321087001 + + + + obo:DDO.owl#DDO_0004925 + CNS drug + + + + obo:DDO.owl#DDO_0004926 + DDO:DDO_0004926 + + + + obo:DDO.owl#DDO_0004926 + 255683006 + + + + obo:DDO.owl#DDO_0004926 + immunotherapeutic agent + + + + obo:DDO.owl#DDO_0004927 + DDO:DDO_0004927 + + + + obo:DDO.owl#DDO_0004927 + 69431002 + + + + obo:DDO.owl#DDO_0004927 + immunosuppressant + + + + obo:DDO.owl#DDO_0004928 + DDO:DDO_0004928 + + + + obo:DDO.owl#DDO_0004928 + 108974006 + + + + obo:DDO.owl#DDO_0004928 + Abciximab + + + + obo:DDO.owl#DDO_0004929 + DDO:DDO_0004929 + + + + obo:DDO.owl#DDO_0004929 + 108807002 + + + + obo:DDO.owl#DDO_0004929 + monoclonal antibody preparation + + + + obo:DDO.owl#DDO_0004930 + DDO:DDO_0004930 + + + + obo:DDO.owl#DDO_0004930 + 67213005 + + + + obo:DDO.owl#DDO_0004930 + lymphocyte immune globulin + + + + obo:DDO.owl#DDO_0004931 + DDO:DDO_0004931 + + + + obo:DDO.owl#DDO_0004931 + 333813005 + + + + obo:DDO.owl#DDO_0004931 + human monoclonal IgM antibody + + + + obo:DDO.owl#DDO_0004932 + DDO:DDO_0004932 + + + + obo:DDO.owl#DDO_0004932 + 108754007 + + + + obo:DDO.owl#DDO_0004932 + glatiramer + + + + obo:DDO.owl#DDO_0004933 + DDO:DDO_0004933 + + + + obo:DDO.owl#DDO_0004933 + 428127005 + + + + obo:DDO.owl#DDO_0004933 + everolimus + + + + obo:DDO.owl#DDO_0004934 + DDO:DDO_0004934 + + + + obo:DDO.owl#DDO_0004934 + 109129008 + + + + obo:DDO.owl#DDO_0004934 + tacrolimus + + + + obo:DDO.owl#DDO_0004935 + DDO:DDO_0004935 + + + + obo:DDO.owl#DDO_0004935 + 385581009 + + + + obo:DDO.owl#DDO_0004935 + pimecrolimus + + + + obo:DDO.owl#DDO_0004936 + DDO:DDO_0004936 + + + + obo:DDO.owl#DDO_0004936 + 80906007 + + + + obo:DDO.owl#DDO_0004936 + cyclosporine + + + + obo:DDO.owl#DDO_0004937 + DDO:DDO_0004937 + + + + obo:DDO.owl#DDO_0004937 + 416587008 + + + + obo:DDO.owl#DDO_0004937 + calcineurin inhibitor + + + + obo:DDO.owl#DDO_0004938 + DDO:DDO_0004938 + + + + obo:DDO.owl#DDO_0004938 + 437957005 + + + + obo:DDO.owl#DDO_0004938 + parenteral form azathioprine + + + + obo:DDO.owl#DDO_0004939 + DDO:DDO_0004939 + + + + obo:DDO.owl#DDO_0004939 + 439605001 + + + + obo:DDO.owl#DDO_0004939 + oral form azathioprine + + + + obo:DDO.owl#DDO_0004940 + DDO:DDO_0004940 + + + + obo:DDO.owl#DDO_0004940 + 111165009 + + + + obo:DDO.owl#DDO_0004940 + azathioprine + + + + obo:DDO.owl#DDO_0004941 + DDO:DDO_0004941 + + + + obo:DDO.owl#DDO_0004941 + 327074002 + + + + obo:DDO.owl#DDO_0004941 + antilymphocyte immunoglobulin + + + + obo:DDO.owl#DDO_0004942 + DDO:DDO_0004942 + + + + obo:DDO.owl#DDO_0004942 + 398857009 + + + + obo:DDO.owl#DDO_0004942 + alefacept + + + + obo:DDO.owl#DDO_0004943 + DDO:DDO_0004943 + + + + obo:DDO.owl#DDO_0004943 + 430342007 + + + + obo:DDO.owl#DDO_0004943 + ophthalmic form ciclosporin + + + + obo:DDO.owl#DDO_0004944 + DDO:DDO_0004944 + + + + obo:DDO.owl#DDO_0004944 + 407103000 + + + + obo:DDO.owl#DDO_0004944 + cyclosporine ophthalmic emulsion 0.05% + + + + obo:DDO.owl#DDO_0004945 + DDO:DDO_0004945 + + + + obo:DDO.owl#DDO_0004945 + 430167004 + + + + obo:DDO.owl#DDO_0004945 + oral form ciclosporin + + + + obo:DDO.owl#DDO_0004946 + DDO:DDO_0004946 + + + + obo:DDO.owl#DDO_0004946 + 430343002 + + + + obo:DDO.owl#DDO_0004946 + parenteral form ciclosporin + + + + obo:DDO.owl#DDO_0004948 + DDO:DDO_0004948 + + + + obo:DDO.owl#DDO_0004948 + 395432007 + + + + obo:DDO.owl#DDO_0004948 + oral form tacrolimus + + + + obo:DDO.owl#DDO_0004949 + DDO:DDO_0004949 + + + + obo:DDO.owl#DDO_0004949 + 395433002 + + + + obo:DDO.owl#DDO_0004949 + parenteral form tacrolimus + + + + obo:DDO.owl#DDO_0004950 + DDO:DDO_0004950 + + + + obo:DDO.owl#DDO_0004950 + 395431000 + + + + obo:DDO.owl#DDO_0004950 + topical form tacrolimus + + + + obo:DDO.owl#DDO_0004951 + DDO:DDO_0004951 + + + + obo:DDO.owl#DDO_0004951 + 333814004 + + + + obo:DDO.owl#DDO_0004951 + HA-1A + + + + obo:DDO.owl#DDO_0004952 + DDO:DDO_0004952 + + + + obo:DDO.owl#DDO_0004952 + 398728003 + + + + obo:DDO.owl#DDO_0004952 + adalimumab + + + + obo:DDO.owl#DDO_0004953 + DDO:DDO_0004953 + + + + obo:DDO.owl#DDO_0004953 + 109135008 + + + + obo:DDO.owl#DDO_0004953 + Basiliximab + + + + obo:DDO.owl#DDO_0004954 + DDO:DDO_0004954 + + + + obo:DDO.owl#DDO_0004954 + 409405006 + + + + obo:DDO.owl#DDO_0004954 + bevacizumab + + + + obo:DDO.owl#DDO_0004955 + DDO:DDO_0004955 + + + + obo:DDO.owl#DDO_0004955 + 703376008 + + + + obo:DDO.owl#DDO_0004955 + canakinumab + + + + obo:DDO.owl#DDO_0004956 + DDO:DDO_0004956 + + + + obo:DDO.owl#DDO_0004956 + 430307008 + + + + obo:DDO.owl#DDO_0004956 + certolizumab pegol + + + + obo:DDO.owl#DDO_0004957 + DDO:DDO_0004957 + + + + obo:DDO.owl#DDO_0004957 + 109133001 + + + + obo:DDO.owl#DDO_0004957 + Daclizumab + + + + obo:DDO.owl#DDO_0004958 + DDO:DDO_0004958 + + + + obo:DDO.owl#DDO_0004958 + 446457007 + + + + obo:DDO.owl#DDO_0004958 + denosumab + + + + obo:DDO.owl#DDO_0004959 + DDO:DDO_0004959 + + + + obo:DDO.owl#DDO_0004959 + 426801002 + + + + obo:DDO.owl#DDO_0004959 + eculizumab + + + + obo:DDO.owl#DDO_0004960 + DDO:DDO_0004960 + + + + obo:DDO.owl#DDO_0004960 + 407006005 + + + + obo:DDO.owl#DDO_0004960 + efalizumab + + + + obo:DDO.owl#DDO_0004961 + DDO:DDO_0004961 + + + + obo:DDO.owl#DDO_0004961 + 25465007 + + + + obo:DDO.owl#DDO_0004961 + escherichia coli monoclonal antibody + + + + obo:DDO.owl#DDO_0004962 + DDO:DDO_0004962 + + + + obo:DDO.owl#DDO_0004962 + 386640004 + + + + obo:DDO.owl#DDO_0004962 + gemtuzumab ozogamicin + + + + obo:DDO.owl#DDO_0004963 + DDO:DDO_0004963 + + + + obo:DDO.owl#DDO_0004963 + 442318002 + + + + obo:DDO.owl#DDO_0004963 + golimumab + + + + obo:DDO.owl#DDO_0004964 + DDO:DDO_0004964 + + + + obo:DDO.owl#DDO_0004964 + 385546007 + + + + obo:DDO.owl#DDO_0004964 + ibritumomab + + + + obo:DDO.owl#DDO_0004965 + DDO:DDO_0004965 + + + + obo:DDO.owl#DDO_0004965 + 704649006 + + + + obo:DDO.owl#DDO_0004965 + ipilimumab + + + + obo:DDO.owl#DDO_0004966 + DDO:DDO_0004966 + + + + obo:DDO.owl#DDO_0004966 + 358598003 + + + + obo:DDO.owl#DDO_0004966 + murine-human monoclonal IgG antibody + + + + obo:DDO.owl#DDO_0004967 + DDO:DDO_0004967 + + + + obo:DDO.owl#DDO_0004967 + 391632007 + + + + obo:DDO.owl#DDO_0004967 + alemtuzumab + + + + obo:DDO.owl#DDO_0004968 + DDO:DDO_0004968 + + + + obo:DDO.owl#DDO_0004968 + 409401002 + + + + obo:DDO.owl#DDO_0004968 + cetuximab + + + + obo:DDO.owl#DDO_0004969 + DDO:DDO_0004969 + + + + obo:DDO.owl#DDO_0004969 + 108675009 + + + + obo:DDO.owl#DDO_0004969 + infliximab + + + + obo:DDO.owl#DDO_0004970 + DDO:DDO_0004970 + + + + obo:DDO.owl#DDO_0004970 + 444609007 + + + + obo:DDO.owl#DDO_0004970 + ofatumumab + + + + obo:DDO.owl#DDO_0004971 + DDO:DDO_0004971 + + + + obo:DDO.owl#DDO_0004971 + 327397006 + + + + obo:DDO.owl#DDO_0004971 + trastuzumab + + + + obo:DDO.owl#DDO_0004972 + DDO:DDO_0004972 + + + + obo:DDO.owl#DDO_0004972 + 433179000 + + + + obo:DDO.owl#DDO_0004972 + naptumomab + + + + obo:DDO.owl#DDO_0004973 + DDO:DDO_0004973 + + + + obo:DDO.owl#DDO_0004973 + 414804006 + + + + obo:DDO.owl#DDO_0004973 + natalizumab + + + + obo:DDO.owl#DDO_0004974 + DDO:DDO_0004974 + + + + obo:DDO.owl#DDO_0004974 + 704192000 + + + + obo:DDO.owl#DDO_0004974 + nivolumab + + + + obo:DDO.owl#DDO_0004975 + DDO:DDO_0004975 + + + + obo:DDO.owl#DDO_0004975 + 406442003 + + + + obo:DDO.owl#DDO_0004975 + omalizumab + + + + obo:DDO.owl#DDO_0004976 + DDO:DDO_0004976 + + + + obo:DDO.owl#DDO_0004976 + 429293004 + + + + obo:DDO.owl#DDO_0004976 + oregovomab + + + + obo:DDO.owl#DDO_0004977 + DDO:DDO_0004977 + + + + obo:DDO.owl#DDO_0004977 + 108725001 + + + + obo:DDO.owl#DDO_0004977 + Palivizumab + + + + obo:DDO.owl#DDO_0004978 + DDO:DDO_0004978 + + + + obo:DDO.owl#DDO_0004978 + 424401006 + + + + obo:DDO.owl#DDO_0004978 + panitumumab + + + + obo:DDO.owl#DDO_0004979 + DDO:DDO_0004979 + + + + obo:DDO.owl#DDO_0004979 + 704227006 + + + + obo:DDO.owl#DDO_0004979 + pertuzumab + + + + obo:DDO.owl#DDO_0004980 + DDO:DDO_0004980 + + + + obo:DDO.owl#DDO_0004980 + 704260009 + + + + obo:DDO.owl#DDO_0004980 + ramucirumab + + + + obo:DDO.owl#DDO_0004981 + DDO:DDO_0004981 + + + + obo:DDO.owl#DDO_0004981 + 425256004 + + + + obo:DDO.owl#DDO_0004981 + ranibizumab + + + + obo:DDO.owl#DDO_0004982 + DDO:DDO_0004982 + + + + obo:DDO.owl#DDO_0004982 + 108809004 + + + + obo:DDO.owl#DDO_0004982 + rituximab + + + + obo:DDO.owl#DDO_0004983 + DDO:DDO_0004983 + + + + obo:DDO.owl#DDO_0004983 + 704263006 + + + + obo:DDO.owl#DDO_0004983 + siltuximab + + + + obo:DDO.owl#DDO_0004984 + DDO:DDO_0004984 + + + + obo:DDO.owl#DDO_0004984 + 444649004 + + + + obo:DDO.owl#DDO_0004984 + tocilizumab + + + + obo:DDO.owl#DDO_0004985 + DDO:DDO_0004985 + + + + obo:DDO.owl#DDO_0004985 + 404835009 + + + + obo:DDO.owl#DDO_0004985 + tositumomab + + + + obo:DDO.owl#DDO_0004986 + DDO:DDO_0004986 + + + + obo:DDO.owl#DDO_0004986 + 443644001 + + + + obo:DDO.owl#DDO_0004986 + ustekinumab + + + + obo:DDO.owl#DDO_0004987 + DDO:DDO_0004987 + + + + obo:DDO.owl#DDO_0004987 + 704257002 + + + + obo:DDO.owl#DDO_0004987 + vedolizumab + + + + obo:DDO.owl#DDO_0004988 + DDO:DDO_0004988 + + + + obo:DDO.owl#DDO_0004988 + 428595001 + + + + obo:DDO.owl#DDO_0004988 + zanolimumab + + + + obo:DDO.owl#DDO_0004989 + DDO:DDO_0004989 + + + + obo:DDO.owl#DDO_0004989 + 109131004 + + + + obo:DDO.owl#DDO_0004989 + mycophenolate mofetil + + + + obo:DDO.owl#DDO_0004990 + DDO:DDO_0004990 + + + + obo:DDO.owl#DDO_0004990 + 438944004 + + + + obo:DDO.owl#DDO_0004990 + oral form mycophenolate mofetil + + + + obo:DDO.owl#DDO_0004991 + DDO:DDO_0004991 + + + + obo:DDO.owl#DDO_0004991 + 439031003 + + + + obo:DDO.owl#DDO_0004991 + parenteral form mycophenolate mofetil + + + + obo:DDO.owl#DDO_0004992 + DDO:DDO_0004992 + + + + obo:DDO.owl#DDO_0004992 + 409331009 + + + + obo:DDO.owl#DDO_0004992 + mycophenolic acid + + + + obo:DDO.owl#DDO_0004993 + DDO:DDO_0004993 + + + + obo:DDO.owl#DDO_0004993 + 415513007 + + + + obo:DDO.owl#DDO_0004993 + selective adhesion molecule inhibitor + + + + obo:DDO.owl#DDO_0004994 + DDO:DDO_0004994 + + + + obo:DDO.owl#DDO_0004994 + 413481004 + + + + obo:DDO.owl#DDO_0004994 + alpha 4 integrin antagonist + + + + obo:DDO.owl#DDO_0004995 + DDO:DDO_0004995 + + + + obo:DDO.owl#DDO_0004995 + 116109004 + + + + obo:DDO.owl#DDO_0004995 + Sirolimus + + + + obo:DDO.owl#DDO_0004996 + DDO:DDO_0004996 + + + + obo:DDO.owl#DDO_0004996 + 427299005 + + + + obo:DDO.owl#DDO_0004996 + temsirolimus + + + + obo:DDO.owl#DDO_0004997 + DDO:DDO_0004997 + + + + obo:DDO.owl#DDO_0004997 + 704316006 + + + + obo:DDO.owl#DDO_0004997 + tofacitinib + + + + obo:DDO.owl#DDO_0004998 + DDO:DDO_0004998 + + + + obo:DDO.owl#DDO_0004998 + 429804009 + + + + obo:DDO.owl#DDO_0004998 + zotarolimus + + + + obo:DDO.owl#DDO_0005000 + DDO:DDO_0005000 + + + + obo:DDO.owl#DDO_0005000 + 372709008 + + + + obo:DDO.owl#DDO_0005000 + acetazolamide + + + + obo:DDO.owl#DDO_0005001 + DDO:DDO_0005001 + + + + obo:DDO.owl#DDO_0005001 + 72469007 + + + + obo:DDO.owl#DDO_0005001 + acetazolamide sodium + + + + obo:DDO.owl#DDO_0005002 + DDO:DDO_0005002 + + + + obo:DDO.owl#DDO_0005002 + 33664007 + + + + obo:DDO.owl#DDO_0005002 + acetazolamide + + + + obo:DDO.owl#DDO_0005003 + DDO:DDO_0005003 + + + + obo:DDO.owl#DDO_0005003 + 430992000 + + + + obo:DDO.owl#DDO_0005003 + oral form acetazolamide + + + + obo:DDO.owl#DDO_0005004 + DDO:DDO_0005004 + + + + obo:DDO.owl#DDO_0005004 + 430260005 + + + + obo:DDO.owl#DDO_0005004 + parenteral form acetazolamide + + + + obo:DDO.owl#DDO_0005005 + DDO:DDO_0005005 + + + + obo:DDO.owl#DDO_0005005 + 372579009 + + + + obo:DDO.owl#DDO_0005005 + retinoid + + + + obo:DDO.owl#DDO_0005006 + DDO:DDO_0005006 + + + + obo:DDO.owl#DDO_0005006 + 386938006 + + + + obo:DDO.owl#DDO_0005006 + acitretin + + + + obo:DDO.owl#DDO_0005007 + DDO:DDO_0005007 + + + + obo:DDO.owl#DDO_0005007 + 386934008 + + + + obo:DDO.owl#DDO_0005007 + adapalene + + + + obo:DDO.owl#DDO_0005008 + DDO:DDO_0005008 + + + + obo:DDO.owl#DDO_0005008 + 116086005 + + + + obo:DDO.owl#DDO_0005008 + alitretinoin + + + + obo:DDO.owl#DDO_0005009 + DDO:DDO_0005009 + + + + obo:DDO.owl#DDO_0005009 + 386937001 + + + + obo:DDO.owl#DDO_0005009 + etretinate + + + + obo:DDO.owl#DDO_0005010 + DDO:DDO_0005010 + + + + obo:DDO.owl#DDO_0005010 + 712609008 + + + + obo:DDO.owl#DDO_0005010 + retinyl ester + + + + obo:DDO.owl#DDO_0005011 + DDO:DDO_0005011 + + + + obo:DDO.owl#DDO_0005011 + 386935009 + + + + obo:DDO.owl#DDO_0005011 + tazarotene + + + + obo:DDO.owl#DDO_0005012 + DDO:DDO_0005012 + + + + obo:DDO.owl#DDO_0005012 + 387305002 + + + + obo:DDO.owl#DDO_0005012 + tretinoin + + + + obo:DDO.owl#DDO_0005013 + DDO:DDO_0005013 + + + + obo:DDO.owl#DDO_0005013 + 387208003 + + + + obo:DDO.owl#DDO_0005013 + isotretinoin + + + + obo:DDO.owl#DDO_0005014 + DDO:DDO_0005014 + + + + obo:DDO.owl#DDO_0005014 + 85417000 + + + + obo:DDO.owl#DDO_0005014 + autonomic drug + + + + obo:DDO.owl#DDO_0005015 + DDO:DDO_0005015 + + + + obo:DDO.owl#DDO_0005015 + 86308005 + + + + obo:DDO.owl#DDO_0005015 + sympathomimetic agent + + + + obo:DDO.owl#DDO_0005016 + DDO:DDO_0005016 + + + + obo:DDO.owl#DDO_0005016 + 386098006 + + + + obo:DDO.owl#DDO_0005016 + respiratory sympathomimetic agent + + + + obo:DDO.owl#DDO_0005017 + DDO:DDO_0005017 + + + + obo:DDO.owl#DDO_0005017 + 91143003 + + + + obo:DDO.owl#DDO_0005017 + albuterol + + + + obo:DDO.owl#DDO_0005018 + DDO:DDO_0005018 + + + + obo:DDO.owl#DDO_0005018 + 135641006 + + + + obo:DDO.owl#DDO_0005018 + inhaled albuterol preparation + + + + obo:DDO.owl#DDO_0005019 + DDO:DDO_0005019 + + + + obo:DDO.owl#DDO_0005019 + 135639005 + + + + obo:DDO.owl#DDO_0005019 + oral form albuterol + + + + obo:DDO.owl#DDO_0005020 + DDO:DDO_0005020 + + + + obo:DDO.owl#DDO_0005020 + 135640007 + + + + obo:DDO.owl#DDO_0005020 + parenteral form albuterol preparation + + + + obo:DDO.owl#DDO_0005021 + DDO:DDO_0005021 + + + + obo:DDO.owl#DDO_0005021 + 372884008 + + + + obo:DDO.owl#DDO_0005021 + sympathomimetic agent + + + + obo:DDO.owl#DDO_0005022 + DDO:DDO_0005022 + + + + obo:DDO.owl#DDO_0005022 + 409474006 + + + + obo:DDO.owl#DDO_0005022 + respiratory sympathomimetic agent + + + + obo:DDO.owl#DDO_0005023 + DDO:DDO_0005023 + + + + obo:DDO.owl#DDO_0005023 + 372897005 + + + + obo:DDO.owl#DDO_0005023 + albuterol + + + + obo:DDO.owl#DDO_0005024 + DDO:DDO_0005024 + + + + obo:DDO.owl#DDO_0005024 + 48474002 + + + + obo:DDO.owl#DDO_0005024 + Albuterol sulfate + + + + obo:DDO.owl#DDO_0005025 + DDO:DDO_0005025 + + + + obo:DDO.owl#DDO_0005025 + 14601000 + + + + obo:DDO.owl#DDO_0005025 + anticholinergic agent + + + + obo:DDO.owl#DDO_0005026 + DDO:DDO_0005026 + + + + obo:DDO.owl#DDO_0005026 + 26244009 + + + + obo:DDO.owl#DDO_0005026 + antimuscarinic + + + + obo:DDO.owl#DDO_0005027 + DDO:DDO_0005027 + + + + obo:DDO.owl#DDO_0005027 + 108624006 + + + + obo:DDO.owl#DDO_0005027 + ipratropium + + + + obo:DDO.owl#DDO_0005028 + DDO:DDO_0005028 + + + + obo:DDO.owl#DDO_0005028 + 430316007 + + + + obo:DDO.owl#DDO_0005028 + nasal form ipratropium + + + + obo:DDO.owl#DDO_0005029 + DDO:DDO_0005029 + + + + obo:DDO.owl#DDO_0005029 + 430475000 + + + + obo:DDO.owl#DDO_0005029 + respiratory form ipratropium + + + + obo:DDO.owl#DDO_0005031 + DDO:DDO_0005031 + + + + obo:DDO.owl#DDO_0005031 + 116068007 + + + + obo:DDO.owl#DDO_0005031 + renal drug + + + + obo:DDO.owl#DDO_0005032 + DDO:DDO_0005032 + + + + obo:DDO.owl#DDO_0005032 + 88749002 + + + + obo:DDO.owl#DDO_0005032 + acidifying preparation + + + + obo:DDO.owl#DDO_0005033 + DDO:DDO_0005033 + + + + obo:DDO.owl#DDO_0005033 + 57123008 + + + + obo:DDO.owl#DDO_0005033 + urinary acidifier + + + + obo:DDO.owl#DDO_0005034 + DDO:DDO_0005034 + + + + obo:DDO.owl#DDO_0005034 + 419332007 + + + + obo:DDO.owl#DDO_0005034 + ammonium chloride + + + + obo:DDO.owl#DDO_0005035 + DDO:DDO_0005035 + + + + obo:DDO.owl#DDO_0005035 + 326605005 + + + + obo:DDO.owl#DDO_0005035 + ammonium chloride mixture + + + + obo:DDO.owl#DDO_0005036 + DDO:DDO_0005036 + + + + obo:DDO.owl#DDO_0005036 + 51366003 + + + + obo:DDO.owl#DDO_0005036 + ammonium chloride + + + + obo:DDO.owl#DDO_0005037 + DDO:DDO_0005037 + + + + obo:DDO.owl#DDO_0005037 + 372643008 + + + + obo:DDO.owl#DDO_0005037 + amphotericin + + + + obo:DDO.owl#DDO_0005038 + DDO:DDO_0005038 + + + + obo:DDO.owl#DDO_0005038 + 77703004 + + + + obo:DDO.owl#DDO_0005038 + amphotericin B + + + + obo:DDO.owl#DDO_0005039 + DDO:DDO_0005039 + + + + obo:DDO.owl#DDO_0005039 + 427544000 + + + + obo:DDO.owl#DDO_0005039 + amphotericin B cholesteryl sulfate complex + + + + obo:DDO.owl#DDO_0005040 + DDO:DDO_0005040 + + + + obo:DDO.owl#DDO_0005040 + 425953004 + + + + obo:DDO.owl#DDO_0005040 + amphotericin B lipid complex + + + + obo:DDO.owl#DDO_0005041 + DDO:DDO_0005041 + + + + obo:DDO.owl#DDO_0005041 + 412088006 + + + + obo:DDO.owl#DDO_0005041 + amphotericin B liposome + + + + obo:DDO.owl#DDO_0005043 + DDO:DDO_0005043 + + + + obo:DDO.owl#DDO_0005043 + 324643005 + + + + obo:DDO.owl#DDO_0005043 + antifungal drugs + + + + obo:DDO.owl#DDO_0005044 + DDO:DDO_0005044 + + + + obo:DDO.owl#DDO_0005044 + 354049008 + + + + obo:DDO.owl#DDO_0005044 + amphotericin + + + + obo:DDO.owl#DDO_0005045 + DDO:DDO_0005045 + + + + obo:DDO.owl#DDO_0005045 + 412563009 + + + + obo:DDO.owl#DDO_0005045 + amphotericin B liposome + + + + obo:DDO.owl#DDO_0005046 + DDO:DDO_0005046 + + + + obo:DDO.owl#DDO_0005046 + 350184003 + + + + obo:DDO.owl#DDO_0005046 + oral form amphotericin + + + + obo:DDO.owl#DDO_0005047 + DDO:DDO_0005047 + + + + obo:DDO.owl#DDO_0005047 + 350185002 + + + + obo:DDO.owl#DDO_0005047 + parenteral form amphotericin + + + + obo:DDO.owl#DDO_0005048 + DDO:DDO_0005048 + + + + obo:DDO.owl#DDO_0005048 + 386581004 + + + + obo:DDO.owl#DDO_0005048 + topical form amphotericin + + + + obo:DDO.owl#DDO_0005049 + DDO:DDO_0005049 + + + + obo:DDO.owl#DDO_0005049 + obo:DDO.owl#DDO_0004464 + + + + obo:DDO.owl#DDO_0005049 + obo:DDO.owl#DDO_0004464 + + + + obo:DDO.owl#DDO_0005049 + 373249005 + + + + obo:DDO.owl#DDO_0005049 + anti-infective agent + + + + obo:DDO.owl#DDO_0005050 + DDO:DDO_0005050 + + + + obo:DDO.owl#DDO_0005050 + 372701006 + + + + obo:DDO.owl#DDO_0005050 + antiviral agent + + + + obo:DDO.owl#DDO_0005051 + DDO:DDO_0005051 + + + + obo:DDO.owl#DDO_0005051 + 372528003 + + + + obo:DDO.owl#DDO_0005051 + retroviral protease inhibitor + + + + obo:DDO.owl#DDO_0005052 + DDO:DDO_0005052 + + + + obo:DDO.owl#DDO_0005052 + 387006009 + + + + obo:DDO.owl#DDO_0005052 + amprenavir + + + + obo:DDO.owl#DDO_0005053 + DDO:DDO_0005053 + + + + obo:DDO.owl#DDO_0005053 + 129473008 + + + + obo:DDO.owl#DDO_0005053 + echinocandin + + + + obo:DDO.owl#DDO_0005054 + DDO:DDO_0005054 + + + + obo:DDO.owl#DDO_0005054 + anidulafungin + + + + obo:DDO.owl#DDO_0005054 + anidulafungin + + + + obo:DDO.owl#DDO_0005055 + DDO:DDO_0005055 + + + + obo:DDO.owl#DDO_0005055 + 373219008 + + + + obo:DDO.owl#DDO_0005055 + antifungal + + + + obo:DDO.owl#DDO_0005056 + DDO:DDO_0005056 + + + + obo:DDO.owl#DDO_0005056 + 373570003 + + + + obo:DDO.owl#DDO_0005056 + echinocandin + + + + obo:DDO.owl#DDO_0005057 + DDO:DDO_0005057 + + + + obo:DDO.owl#DDO_0005057 + 422157006 + + + + obo:DDO.owl#DDO_0005057 + anidulafungin + + + + obo:DDO.owl#DDO_0005058 + DDO:DDO_0005058 + + + + obo:DDO.owl#DDO_0005058 + 419937006 + + + + obo:DDO.owl#DDO_0005058 + psychotherapeutic agent + + + + obo:DDO.owl#DDO_0005059 + DDO:DDO_0005059 + + + + obo:DDO.owl#DDO_0005059 + 414776000 + + + + obo:DDO.owl#DDO_0005059 + mood stabilizing agent + + + + obo:DDO.owl#DDO_0005060 + DDO:DDO_0005060 + + + + obo:DDO.owl#DDO_0005060 + 406784005 + + + + obo:DDO.owl#DDO_0005060 + aripiprazole + + + + obo:DDO.owl#DDO_0005061 + DDO:DDO_0005061 + + + + obo:DDO.owl#DDO_0005061 + 27867009 + + + + obo:DDO.owl#DDO_0005061 + antineoplastic agent + + + + obo:DDO.owl#DDO_0005062 + DDO:DDO_0005062 + + + + obo:DDO.owl#DDO_0005062 + 413576005 + + + + obo:DDO.owl#DDO_0005062 + arsenic product + + + + obo:DDO.owl#DDO_0005063 + DDO:DDO_0005063 + + + + obo:DDO.owl#DDO_0005063 + 400907001 + + + + obo:DDO.owl#DDO_0005063 + arsenic trioxide + + + + obo:DDO.owl#DDO_0005064 + DDO:DDO_0005064 + + + + obo:DDO.owl#DDO_0005064 + 105825008 + + + + obo:DDO.owl#DDO_0005064 + arsenic AND/OR arsenic compound + + + + obo:DDO.owl#DDO_0005065 + DDO:DDO_0005065 + + + + obo:DDO.owl#DDO_0005065 + 72251000 + + + + obo:DDO.owl#DDO_0005065 + arsenic trioxide + + + + obo:DDO.owl#DDO_0005066 + DDO:DDO_0005066 + + + + obo:DDO.owl#DDO_0005066 + 372482001 + + + + obo:DDO.owl#DDO_0005066 + anti-psychotic agent + + + + obo:DDO.owl#DDO_0005067 + DDO:DDO_0005067 + + + + obo:DDO.owl#DDO_0005067 + 372648004 + + + + obo:DDO.owl#DDO_0005067 + atypical antipsychotic + + + + obo:DDO.owl#DDO_0005068 + DDO:DDO_0005068 + + + + obo:DDO.owl#DDO_0005068 + 443375003 + + + + obo:DDO.owl#DDO_0005068 + asenapine + + + + obo:DDO.owl#DDO_0005069 + DDO:DDO_0005069 + + + + obo:DDO.owl#DDO_0005069 + obo:DDO.owl#DDO_0005061 + + + + obo:DDO.owl#DDO_0005069 + obo:DDO.owl#DDO_0005061 + + + + obo:DDO.owl#DDO_0005069 + 372688009 + + + + obo:DDO.owl#DDO_0005069 + antineoplastic agent + + + + obo:DDO.owl#DDO_0005070 + DDO:DDO_0005070 + + + + obo:DDO.owl#DDO_0005070 + 371014004 + + + + obo:DDO.owl#DDO_0005070 + ASN-ase + + + + obo:DDO.owl#DDO_0005070 + a-ase + + + + obo:DDO.owl#DDO_0005070 + l-Asparaginase + + + + obo:DDO.owl#DDO_0005070 + l-Asparagine amidohydrolase + + + + obo:DDO.owl#DDO_0005070 + asparaginase + + + + obo:DDO.owl#DDO_0005071 + DDO:DDO_0005071 + + + + obo:DDO.owl#DDO_0005071 + 370893003 + + + + obo:DDO.owl#DDO_0005071 + erwinia asparaginase + + + + obo:DDO.owl#DDO_0005072 + DDO:DDO_0005072 + + + + obo:DDO.owl#DDO_0005072 + 370969007 + + + + obo:DDO.owl#DDO_0005072 + escherichia coli asparaginase + + + + obo:DDO.owl#DDO_0005073 + DDO:DDO_0005073 + + + + obo:DDO.owl#DDO_0005073 + 108814000 + + + + obo:DDO.owl#DDO_0005073 + pegaspargase + + + + obo:DDO.owl#DDO_0005074 + DDO:DDO_0005074 + + + + obo:DDO.owl#DDO_0005074 + 23217006 + + + + obo:DDO.owl#DDO_0005074 + arsenic compound + + + + obo:DDO.owl#DDO_0005075 + DDO:DDO_0005075 + + + + obo:DDO.owl#DDO_0005075 + 53041004 + + + + obo:DDO.owl#DDO_0005075 + alcohol + + + + obo:DDO.owl#DDO_0005076 + DDO:DDO_0005076 + + + + obo:DDO.owl#DDO_0005076 + 55816008 + + + + obo:DDO.owl#DDO_0005076 + amino alcohol + + + + obo:DDO.owl#DDO_0005077 + DDO:DDO_0005077 + + + + obo:DDO.owl#DDO_0005077 + 438394008 + + + + obo:DDO.owl#DDO_0005077 + alkanolamine + + + + obo:DDO.owl#DDO_0005078 + DDO:DDO_0005078 + + + + obo:DDO.owl#DDO_0005078 + 441338003 + + + + obo:DDO.owl#DDO_0005078 + propanolamine + + + + obo:DDO.owl#DDO_0005080 + DDO:DDO_0005080 + + + + obo:DDO.owl#DDO_0005080 + 373300001 + + + + obo:DDO.owl#DDO_0005080 + antiparasite agent + + + + obo:DDO.owl#DDO_0005181 + DDO:DDO_0005181 + + + + obo:DDO.owl#DDO_0005181 + 372857007 + + + + obo:DDO.owl#DDO_0005181 + antiprotozoal agent + + + + obo:DDO.owl#DDO_0005182 + DDO:DDO_0005182 + + + + obo:DDO.owl#DDO_0005182 + 386899002 + + + + obo:DDO.owl#DDO_0005182 + atovaquone + + + + obo:DDO.owl#DDO_0005183 + DDO:DDO_0005183 + + + + obo:DDO.owl#DDO_0005183 + 333032003 + + + + obo:DDO.owl#DDO_0005183 + parasiticidal preparations + + + + obo:DDO.owl#DDO_0005184 + DDO:DDO_0005184 + + + + obo:DDO.owl#DDO_0005184 + 80337002 + + + + obo:DDO.owl#DDO_0005184 + antiprotozoal drug + + + + obo:DDO.owl#DDO_0005185 + DDO:DDO_0005185 + + + + obo:DDO.owl#DDO_0005185 + 108718008 + + + + obo:DDO.owl#DDO_0005185 + Atovaquone + + + + obo:DDO.owl#DDO_0005186 + DDO:DDO_0005186 + + + + obo:DDO.owl#DDO_0005186 + 387342009 + + + + obo:DDO.owl#DDO_0005186 + baclofen + + + + obo:DDO.owl#DDO_0005187 + DDO:DDO_0005187 + + + + obo:DDO.owl#DDO_0005187 + 350060009 + + + + obo:DDO.owl#DDO_0005187 + drug groups primarily affecting the musculoskeletal system + + + + obo:DDO.owl#DDO_0005188 + DDO:DDO_0005188 + + + + obo:DDO.owl#DDO_0005188 + 116524002 + + + + obo:DDO.owl#DDO_0005188 + centrally acting muscle relaxant + + + + obo:DDO.owl#DDO_0005189 + DDO:DDO_0005189 + + + + obo:DDO.owl#DDO_0005189 + 6102009 + + + + obo:DDO.owl#DDO_0005189 + baclofen + + + + obo:DDO.owl#DDO_0005190 + DDO:DDO_0005190 + + + + obo:DDO.owl#DDO_0005190 + 429460006 + + + + obo:DDO.owl#DDO_0005190 + oral form baclofen + + + + obo:DDO.owl#DDO_0005191 + DDO:DDO_0005191 + + + + obo:DDO.owl#DDO_0005191 + 428716001 + + + + obo:DDO.owl#DDO_0005191 + parenteral form baclofen + + + + obo:DDO.owl#DDO_0005192 + DDO:DDO_0005192 + + + + obo:DDO.owl#DDO_0005192 + 350345004 + + + + obo:DDO.owl#DDO_0005192 + hormones, synthetic substitutes and antagonists + + + + obo:DDO.owl#DDO_0005193 + DDO:DDO_0005193 + + + + obo:DDO.owl#DDO_0005193 + 79440004 + + + + obo:DDO.owl#DDO_0005193 + corticosteroids + + + + obo:DDO.owl#DDO_0005193 + corticoid preparation + + + + obo:DDO.owl#DDO_0005194 + DDO:DDO_0005194 + + + + obo:DDO.owl#DDO_0005194 + 116596006 + + + + obo:DDO.owl#DDO_0005194 + glucocorticoid preparation + + + + obo:DDO.owl#DDO_0005195 + DDO:DDO_0005195 + + + + obo:DDO.owl#DDO_0005195 + 29896003 + + + + obo:DDO.owl#DDO_0005195 + betamethasone + + + + obo:DDO.owl#DDO_0005195 + betamethasone preparation + + + + obo:DDO.owl#DDO_0005196 + DDO:DDO_0005196 + + + + obo:DDO.owl#DDO_0005196 + 395435009 + + + + obo:DDO.owl#DDO_0005196 + betamethasone + calcipotriol + + + + obo:DDO.owl#DDO_0005197 + DDO:DDO_0005197 + + + + obo:DDO.owl#DDO_0005197 + 346343007 + + + + obo:DDO.owl#DDO_0005197 + betamethasone + clioquinol + + + + obo:DDO.owl#DDO_0005198 + DDO:DDO_0005198 + + + + obo:DDO.owl#DDO_0005198 + 346344001 + + + + obo:DDO.owl#DDO_0005198 + betamethasone + clotrimazole + + + + obo:DDO.owl#DDO_0005199 + DDO:DDO_0005199 + + + + obo:DDO.owl#DDO_0005199 + 346345000 + + + + obo:DDO.owl#DDO_0005199 + betamethasone + fusidic acid + + + + obo:DDO.owl#DDO_0005200 + DDO:DDO_0005200 + + + + obo:DDO.owl#DDO_0005200 + 418065000 + + + + obo:DDO.owl#DDO_0005200 + betamethasone + neomycin + + + + obo:DDO.owl#DDO_0005201 + DDO:DDO_0005201 + + + + obo:DDO.owl#DDO_0005201 + 346347008 + + + + obo:DDO.owl#DDO_0005201 + betamethasone + salicylic acid + + + + obo:DDO.owl#DDO_0005202 + DDO:DDO_0005202 + + + + obo:DDO.owl#DDO_0005202 + 354027002 + + + + obo:DDO.owl#DDO_0005202 + betamethasone sodium phosphate 0.1% eye/ear/nose drops + + + + obo:DDO.owl#DDO_0005203 + DDO:DDO_0005203 + + + + obo:DDO.owl#DDO_0005203 + 66854004 + + + + obo:DDO.owl#DDO_0005203 + betamethasone valerate + + + + obo:DDO.owl#DDO_0005204 + DDO:DDO_0005204 + + + + obo:DDO.owl#DDO_0005204 + 421156000 + + + + obo:DDO.owl#DDO_0005204 + ophthalmic form betamethasone + + + + obo:DDO.owl#DDO_0005205 + DDO:DDO_0005205 + + + + obo:DDO.owl#DDO_0005205 + 350387002 + + + + obo:DDO.owl#DDO_0005205 + oral form betamethasone + + + + obo:DDO.owl#DDO_0005206 + DDO:DDO_0005206 + + + + obo:DDO.owl#DDO_0005206 + 350388007 + + + + obo:DDO.owl#DDO_0005206 + parenteral form betamethasone + + + + obo:DDO.owl#DDO_0005207 + DDO:DDO_0005207 + + + + obo:DDO.owl#DDO_0005207 + 349355002 + + + + obo:DDO.owl#DDO_0005207 + topical form betamethasone + + + + obo:DDO.owl#DDO_0005208 + DDO:DDO_0005208 + + + + obo:DDO.owl#DDO_0005208 + 372631007 + + + + obo:DDO.owl#DDO_0005208 + imidazole antifungal + + + + obo:DDO.owl#DDO_0005209 + DDO:DDO_0005209 + + + + obo:DDO.owl#DDO_0005209 + 387325003 + + + + obo:DDO.owl#DDO_0005209 + clotrimazole + + + + obo:DDO.owl#DDO_0005210 + DDO:DDO_0005210 + + + + obo:DDO.owl#DDO_0005210 + 350195009 + + + + obo:DDO.owl#DDO_0005210 + azole antifungal + + + + obo:DDO.owl#DDO_0005211 + DDO:DDO_0005211 + + + + obo:DDO.owl#DDO_0005211 + 350196005 + + + + obo:DDO.owl#DDO_0005211 + imidazole antifungal + + + + obo:DDO.owl#DDO_0005212 + DDO:DDO_0005212 + + + + obo:DDO.owl#DDO_0005212 + 5797005 + + + + obo:DDO.owl#DDO_0005212 + clotrimazole + + + + obo:DDO.owl#DDO_0005213 + DDO:DDO_0005213 + + + + obo:DDO.owl#DDO_0005213 + 346344001 + + + + obo:DDO.owl#DDO_0005213 + betamethasone + clotrimazole + + + + obo:DDO.owl#DDO_0005214 + DDO:DDO_0005214 + + + + obo:DDO.owl#DDO_0005214 + 410945009 + + + + obo:DDO.owl#DDO_0005214 + fluconazole+clotrimazole + + + + obo:DDO.owl#DDO_0005215 + DDO:DDO_0005215 + + + + obo:DDO.owl#DDO_0005215 + 346501001 + + + + obo:DDO.owl#DDO_0005215 + hydrocortisone+clotrimazole + + + + obo:DDO.owl#DDO_0005216 + DDO:DDO_0005216 + + + + obo:DDO.owl#DDO_0005216 + 430731000 + + + + obo:DDO.owl#DDO_0005216 + ophthalmic form clotrimazole + + + + obo:DDO.owl#DDO_0005217 + DDO:DDO_0005217 + + + + obo:DDO.owl#DDO_0005217 + 430756006 + + + + obo:DDO.owl#DDO_0005217 + oropharyngeal form clotrimazole + + + + obo:DDO.owl#DDO_0005218 + DDO:DDO_0005218 + + + + obo:DDO.owl#DDO_0005218 + 430816000 + + + + obo:DDO.owl#DDO_0005218 + topical form clotrimazole + + + + obo:DDO.owl#DDO_0005219 + DDO:DDO_0005219 + + + + obo:DDO.owl#DDO_0005219 + 430787008 + + + + obo:DDO.owl#DDO_0005219 + vaginal form clotrimazole + + + + obo:DDO.owl#DDO_0005220 + DDO:DDO_0005220 + + + + obo:DDO.owl#DDO_0005220 + 14833006 + + + + obo:DDO.owl#DDO_0005220 + cardiovascular drug + + + + obo:DDO.owl#DDO_0005221 + DDO:DDO_0005221 + + + + obo:DDO.owl#DDO_0005221 + 372586001 + + + + obo:DDO.owl#DDO_0005221 + hypotensive agent + + + + obo:DDO.owl#DDO_0005223 + DDO:DDO_0005223 + + + + obo:DDO.owl#DDO_0005223 + 373254001 + + + + obo:DDO.owl#DDO_0005223 + beta-Blocking agent + + + + obo:DDO.owl#DDO_0005224 + DDO:DDO_0005224 + + + + obo:DDO.owl#DDO_0005224 + 372661004 + + + + obo:DDO.owl#DDO_0005224 + beta 1 blocking agent + + + + obo:DDO.owl#DDO_0005225 + DDO:DDO_0005225 + + + + obo:DDO.owl#DDO_0005225 + 372815001 + + + + obo:DDO.owl#DDO_0005225 + acebutolol + + + + obo:DDO.owl#DDO_0005226 + DDO:DDO_0005226 + + + + obo:DDO.owl#DDO_0005226 + 3597005 + + + + obo:DDO.owl#DDO_0005226 + acebutolol hydrochloride + + + + obo:DDO.owl#DDO_0005227 + DDO:DDO_0005227 + + + + obo:DDO.owl#DDO_0005227 + 387506000 + + + + obo:DDO.owl#DDO_0005227 + atenolol + + + + obo:DDO.owl#DDO_0005228 + DDO:DDO_0005228 + + + + obo:DDO.owl#DDO_0005228 + 409276006 + + + + obo:DDO.owl#DDO_0005228 + betaxolol + + + + obo:DDO.owl#DDO_0005229 + DDO:DDO_0005229 + + + + obo:DDO.owl#DDO_0005229 + 387195001 + + + + obo:DDO.owl#DDO_0005229 + betaxolol hydrochloride + + + + obo:DDO.owl#DDO_0005230 + DDO:DDO_0005230 + + + + obo:DDO.owl#DDO_0005230 + 409277002 + + + + obo:DDO.owl#DDO_0005230 + levobetaxolol + + + + obo:DDO.owl#DDO_0005231 + DDO:DDO_0005231 + + + + obo:DDO.owl#DDO_0005231 + 386868003 + + + + obo:DDO.owl#DDO_0005231 + bisoprolol + + + + obo:DDO.owl#DDO_0005232 + DDO:DDO_0005232 + + + + obo:DDO.owl#DDO_0005232 + 386869006 + + + + obo:DDO.owl#DDO_0005232 + bisoprolol fumarate + + + + obo:DDO.owl#DDO_0005233 + DDO:DDO_0005233 + + + + obo:DDO.owl#DDO_0005233 + 395960002 + + + + obo:DDO.owl#DDO_0005233 + celiprolol + + + + obo:DDO.owl#DDO_0005234 + DDO:DDO_0005234 + + + + obo:DDO.owl#DDO_0005234 + 395874008 + + + + obo:DDO.owl#DDO_0005234 + celiprolol hydrochloride + + + + obo:DDO.owl#DDO_0005235 + DDO:DDO_0005235 + + + + obo:DDO.owl#DDO_0005235 + 372847006 + + + + obo:DDO.owl#DDO_0005235 + esmolol + + + + obo:DDO.owl#DDO_0005236 + DDO:DDO_0005236 + + + + obo:DDO.owl#DDO_0005236 + 35318005 + + + + obo:DDO.owl#DDO_0005236 + Esmolol hydrochloride + + + + obo:DDO.owl#DDO_0005237 + DDO:DDO_0005237 + + + + obo:DDO.owl#DDO_0005237 + 372826007 + + + + obo:DDO.owl#DDO_0005237 + metoprolol + + + + obo:DDO.owl#DDO_0005238 + DDO:DDO_0005238 + + + + obo:DDO.owl#DDO_0005238 + 412432007 + + + + obo:DDO.owl#DDO_0005238 + metoprolol succinate + + + + obo:DDO.owl#DDO_0005239 + DDO:DDO_0005239 + + + + obo:DDO.owl#DDO_0005239 + 72770009 + + + + obo:DDO.owl#DDO_0005239 + metoprolol tartrate + + + + obo:DDO.owl#DDO_0005240 + DDO:DDO_0005240 + + + + obo:DDO.owl#DDO_0005240 + 395808005 + + + + obo:DDO.owl#DDO_0005240 + nebivolol + + + + obo:DDO.owl#DDO_0005241 + DDO:DDO_0005241 + + + + obo:DDO.owl#DDO_0005241 + 37751002 + + + + obo:DDO.owl#DDO_0005241 + Beta 2 blocking agent + + + + obo:DDO.owl#DDO_0005242 + DDO:DDO_0005242 + + + + obo:DDO.owl#DDO_0005242 + 372870003 + + + + obo:DDO.owl#DDO_0005242 + non-selective beta-blocking agent + + + + obo:DDO.owl#DDO_0005243 + DDO:DDO_0005243 + + + + obo:DDO.owl#DDO_0005243 + 386866004 + + + + obo:DDO.owl#DDO_0005243 + carteolol + + + + obo:DDO.owl#DDO_0005244 + DDO:DDO_0005244 + + + + obo:DDO.owl#DDO_0005244 + 386867008 + + + + obo:DDO.owl#DDO_0005244 + carteolol hydrochloride + + + + obo:DDO.owl#DDO_0005246 + DDO:DDO_0005246 + + + + obo:DDO.owl#DDO_0005246 + 386870007 + + + + obo:DDO.owl#DDO_0005246 + carvedilol + + + + obo:DDO.owl#DDO_0005247 + DDO:DDO_0005247 + + + + obo:DDO.owl#DDO_0005247 + 426471008 + + + + obo:DDO.owl#DDO_0005247 + carvedilol phosphate + + + + obo:DDO.owl#DDO_0005248 + DDO:DDO_0005248 + + + + obo:DDO.owl#DDO_0005248 + 372750000 + + + + obo:DDO.owl#DDO_0005248 + labetalol + + + + obo:DDO.owl#DDO_0005249 + DDO:DDO_0005249 + + + + obo:DDO.owl#DDO_0005249 + 50627005 + + + + obo:DDO.owl#DDO_0005249 + labetalol hydrochloride + + + + obo:DDO.owl#DDO_0005250 + DDO:DDO_0005250 + + + + obo:DDO.owl#DDO_0005250 + 418934007 + + + + obo:DDO.owl#DDO_0005250 + levobunolol + + + + obo:DDO.owl#DDO_0005251 + DDO:DDO_0005251 + + + + obo:DDO.owl#DDO_0005251 + 387349000 + + + + obo:DDO.owl#DDO_0005251 + levobunolol hydrochloride + + + + obo:DDO.owl#DDO_0005252 + DDO:DDO_0005252 + + + + obo:DDO.owl#DDO_0005252 + 373446000 + + + + obo:DDO.owl#DDO_0005252 + metipranolol + + + + obo:DDO.owl#DDO_0005253 + DDO:DDO_0005253 + + + + obo:DDO.owl#DDO_0005253 + 126152000 + + + + obo:DDO.owl#DDO_0005253 + Metipranolol hydrochloride + + + + obo:DDO.owl#DDO_0005254 + DDO:DDO_0005254 + + + + obo:DDO.owl#DDO_0005254 + 387482003 + + + + obo:DDO.owl#DDO_0005254 + nadolol + + + + obo:DDO.owl#DDO_0005255 + DDO:DDO_0005255 + + + + obo:DDO.owl#DDO_0005255 + 387583006 + + + + obo:DDO.owl#DDO_0005255 + oxprenolol + + + + obo:DDO.owl#DDO_0005256 + DDO:DDO_0005256 + + + + obo:DDO.owl#DDO_0005256 + 395817005 + + + + obo:DDO.owl#DDO_0005256 + oxprenolol hydrochloride + + + + obo:DDO.owl#DDO_0005257 + DDO:DDO_0005257 + + + + obo:DDO.owl#DDO_0005257 + 372505004 + + + + obo:DDO.owl#DDO_0005257 + penbutolol + + + + obo:DDO.owl#DDO_0005258 + DDO:DDO_0005258 + + + + obo:DDO.owl#DDO_0005258 + 386865000 + + + + obo:DDO.owl#DDO_0005258 + penbutolol sulfate + + + + obo:DDO.owl#DDO_0005259 + DDO:DDO_0005259 + + + + obo:DDO.owl#DDO_0005259 + 387102009 + + + + obo:DDO.owl#DDO_0005259 + pindolol + + + + obo:DDO.owl#DDO_0005260 + DDO:DDO_0005260 + + + + obo:DDO.owl#DDO_0005260 + 387436006 + + + + obo:DDO.owl#DDO_0005260 + practolol + + + + obo:DDO.owl#DDO_0005261 + DDO:DDO_0005261 + + + + obo:DDO.owl#DDO_0005261 + 372772003 + + + + obo:DDO.owl#DDO_0005261 + propranolol + + + + obo:DDO.owl#DDO_0005262 + DDO:DDO_0005262 + + + + obo:DDO.owl#DDO_0005262 + 96294004 + + + + obo:DDO.owl#DDO_0005262 + Alprenolol + + + + obo:DDO.owl#DDO_0005263 + DDO:DDO_0005263 + + + + obo:DDO.owl#DDO_0005263 + 65088001 + + + + obo:DDO.owl#DDO_0005263 + propranolol hydrochloride + + + + obo:DDO.owl#DDO_0005264 + DDO:DDO_0005264 + + + + obo:DDO.owl#DDO_0005264 + 372911006 + + + + obo:DDO.owl#DDO_0005264 + sotalol + + + + obo:DDO.owl#DDO_0005265 + DDO:DDO_0005265 + + + + obo:DDO.owl#DDO_0005265 + 125691000 + + + + obo:DDO.owl#DDO_0005265 + sotalol hydrochloride + + + + obo:DDO.owl#DDO_0005266 + DDO:DDO_0005266 + + + + obo:DDO.owl#DDO_0005266 + 372880004 + + + + obo:DDO.owl#DDO_0005266 + timolol + + + + obo:DDO.owl#DDO_0005267 + DDO:DDO_0005267 + + + + obo:DDO.owl#DDO_0005267 + 75359005 + + + + obo:DDO.owl#DDO_0005267 + timolol maleate + + + + obo:DDO.owl#DDO_0005268 + DDO:DDO_0005268 + + + + obo:DDO.owl#DDO_0005268 + 387023000 + + + + obo:DDO.owl#DDO_0005268 + bexarotene + + + + obo:DDO.owl#DDO_0005269 + DDO:DDO_0005269 + + + + obo:DDO.owl#DDO_0005269 + 437734005 + + + + obo:DDO.owl#DDO_0005269 + oral form bexarotene + + + + obo:DDO.owl#DDO_0005270 + DDO:DDO_0005270 + + + + obo:DDO.owl#DDO_0005270 + 374872005 + + + + obo:DDO.owl#DDO_0005270 + bexarotene 75mg capsule + + + + obo:DDO.owl#DDO_0005271 + DDO:DDO_0005271 + + + + obo:DDO.owl#DDO_0005271 + 440285004 + + + + obo:DDO.owl#DDO_0005271 + topical form bexarotene + + + + obo:DDO.owl#DDO_0005272 + DDO:DDO_0005272 + + + + obo:DDO.owl#DDO_0005272 + 440881003 + + + + obo:DDO.owl#DDO_0005272 + bexarotene 10mg/g topical gel + + + + obo:DDO.owl#DDO_0005273 + DDO:DDO_0005273 + + + + obo:DDO.owl#DDO_0005273 + 386908000 + + + + obo:DDO.owl#DDO_0005273 + bicalutamide + + + + obo:DDO.owl#DDO_0005274 + DDO:DDO_0005274 + + + + obo:DDO.owl#DDO_0005274 + 96368006 + + + + obo:DDO.owl#DDO_0005274 + synthetic antihormone + + + + obo:DDO.owl#DDO_0005277 + DDO:DDO_0005277 + + + + obo:DDO.owl#DDO_0005277 + 372733002 + + + + obo:DDO.owl#DDO_0005277 + angiotensin-converting enzyme inhibitor agent + + + + obo:DDO.owl#DDO_0005278 + DDO:DDO_0005278 + + + + obo:DDO.owl#DDO_0005278 + 372511001 + + + + obo:DDO.owl#DDO_0005278 + benazepril + + + + obo:DDO.owl#DDO_0005279 + DDO:DDO_0005279 + + + + obo:DDO.owl#DDO_0005279 + 108573008 + + + + obo:DDO.owl#DDO_0005279 + Benazepril hydrochloride + + + + obo:DDO.owl#DDO_0005280 + DDO:DDO_0005280 + + + + obo:DDO.owl#DDO_0005280 + 41549009 + + + + obo:DDO.owl#DDO_0005280 + angiotensin-converting enzyme inhibitor agent + + + + obo:DDO.owl#DDO_0005281 + DDO:DDO_0005281 + + + + obo:DDO.owl#DDO_0005281 + 108572003 + + + + obo:DDO.owl#DDO_0005281 + Benazepril + + + + obo:DDO.owl#DDO_0005282 + DDO:DDO_0005282 + + + + obo:DDO.owl#DDO_0005282 + 412585003 + + + + obo:DDO.owl#DDO_0005282 + benazepril hydrochloride + + + + obo:DDO.owl#DDO_0005283 + DDO:DDO_0005283 + + + + obo:DDO.owl#DDO_0005283 + 116280007 + + + + obo:DDO.owl#DDO_0005283 + heterocyclic compound + + + + obo:DDO.owl#DDO_0005284 + DDO:DDO_0005284 + + + + obo:DDO.owl#DDO_0005284 + 438935000 + + + + obo:DDO.owl#DDO_0005284 + benzothiadiazine + + + + obo:DDO.owl#DDO_0005285 + DDO:DDO_0005285 + + + + obo:DDO.owl#DDO_0005285 + 387525002 + + + + obo:DDO.owl#DDO_0005285 + hydrochlorothiazide + + + + obo:DDO.owl#DDO_0005286 + DDO:DDO_0005286 + + + + obo:DDO.owl#DDO_0005286 + 1552008 + + + + obo:DDO.owl#DDO_0005286 + saluretic drug + + + + obo:DDO.owl#DDO_0005287 + DDO:DDO_0005287 + + + + obo:DDO.owl#DDO_0005287 + 86647004 + + + + obo:DDO.owl#DDO_0005287 + bumetanide + + + + obo:DDO.owl#DDO_0005288 + DDO:DDO_0005288 + + + + obo:DDO.owl#DDO_0005288 + 350610004 + + + + obo:DDO.owl#DDO_0005288 + oral form bumetanide + + + + obo:DDO.owl#DDO_0005289 + DDO:DDO_0005289 + + + + obo:DDO.owl#DDO_0005289 + 350611000 + + + + obo:DDO.owl#DDO_0005289 + parenteral form bumetanide + + + + obo:DDO.owl#DDO_0005290 + DDO:DDO_0005290 + + + + obo:DDO.owl#DDO_0005290 + 43585000 + + + + obo:DDO.owl#DDO_0005290 + sulfonamide diuretic + + + + obo:DDO.owl#DDO_0005291 + DDO:DDO_0005291 + + + + obo:DDO.owl#DDO_0005291 + 387498005 + + + + obo:DDO.owl#DDO_0005291 + bumetanide + + + + obo:DDO.owl#DDO_0005292 + DDO:DDO_0005292 + + + + obo:DDO.owl#DDO_0005292 + obo:DDO.owl#DDO_0005737 + + + + obo:DDO.owl#DDO_0005292 + obo:DDO.owl#DDO_0005737 + + + + obo:DDO.owl#DDO_0005292 + 373272007 + + + + obo:DDO.owl#DDO_0005292 + respiratory system agent + + + + obo:DDO.owl#DDO_0005293 + DDO:DDO_0005293 + + + + obo:DDO.owl#DDO_0005293 + 417953004 + + + + obo:DDO.owl#DDO_0005293 + xanthine agent + + + + obo:DDO.owl#DDO_0005294 + DDO:DDO_0005294 + + + + obo:DDO.owl#DDO_0005294 + 259553003 + + + + obo:DDO.owl#DDO_0005294 + methyl xanthine + + + + obo:DDO.owl#DDO_0005295 + DDO:DDO_0005295 + + + + obo:DDO.owl#DDO_0005295 + 255641001 + + + + obo:DDO.owl#DDO_0005295 + caffeine + + + + obo:DDO.owl#DDO_0005296 + DDO:DDO_0005296 + + + + obo:DDO.owl#DDO_0005296 + 23068001 + + + + obo:DDO.owl#DDO_0005296 + caffeine citrate + + + + obo:DDO.owl#DDO_0005297 + DDO:DDO_0005297 + + + + obo:DDO.owl#DDO_0005297 + 407314008 + + + + obo:DDO.owl#DDO_0005297 + enzyme inhibitor + + + + obo:DDO.owl#DDO_0005298 + DDO:DDO_0005298 + + + + obo:DDO.owl#DDO_0005298 + 346625000 + + + + obo:DDO.owl#DDO_0005298 + phosphodiesterase inhibitor + + + + obo:DDO.owl#DDO_0005299 + DDO:DDO_0005299 + + + + obo:DDO.owl#DDO_0005299 + 349994006 + + + + obo:DDO.owl#DDO_0005299 + xanthine product + + + + obo:DDO.owl#DDO_0005300 + DDO:DDO_0005300 + + + + obo:DDO.owl#DDO_0005300 + 91107009 + + + + obo:DDO.owl#DDO_0005300 + caffeine + + + + obo:DDO.owl#DDO_0005301 + DDO:DDO_0005301 + + + + obo:DDO.owl#DDO_0005301 + 96308008 + + + + obo:DDO.owl#DDO_0005301 + angiotensin II receptor antagonist + + + + obo:DDO.owl#DDO_0005302 + DDO:DDO_0005302 + + + + obo:DDO.owl#DDO_0005302 + 108587008 + + + + obo:DDO.owl#DDO_0005302 + Candesartan + + + + obo:DDO.owl#DDO_0005303 + DDO:DDO_0005303 + + + + obo:DDO.owl#DDO_0005303 + 108589006 + + + + obo:DDO.owl#DDO_0005303 + Candesartan cilexetil + + + + obo:DDO.owl#DDO_0005304 + DDO:DDO_0005304 + + + + obo:DDO.owl#DDO_0005304 + 372913009 + + + + obo:DDO.owl#DDO_0005304 + angiotensin II receptor antagonist + + + + obo:DDO.owl#DDO_0005305 + DDO:DDO_0005305 + + + + obo:DDO.owl#DDO_0005305 + 372512008 + + + + obo:DDO.owl#DDO_0005305 + candesartan + + + + obo:DDO.owl#DDO_0005306 + DDO:DDO_0005306 + + + + obo:DDO.owl#DDO_0005306 + 386878000 + + + + obo:DDO.owl#DDO_0005306 + candesartan cilexetil + + + + obo:DDO.owl#DDO_0005307 + DDO:DDO_0005307 + + + + obo:DDO.owl#DDO_0005307 + 300050005 + + + + obo:DDO.owl#DDO_0005307 + organic acid or derivative + + + + obo:DDO.owl#DDO_0005308 + DDO:DDO_0005308 + + + + obo:DDO.owl#DDO_0005308 + 430498008 + + + + obo:DDO.owl#DDO_0005308 + carboxylic acid or carboxylic acid derivative + + + + obo:DDO.owl#DDO_0005309 + DDO:DDO_0005309 + + + + obo:DDO.owl#DDO_0005309 + 105885006 + + + + obo:DDO.owl#DDO_0005309 + carboxylic acid AND/OR salt + + + + obo:DDO.owl#DDO_0005310 + DDO:DDO_0005310 + + + + obo:DDO.owl#DDO_0005310 + 42907009 + + + + obo:DDO.owl#DDO_0005310 + carboxylic acid + + + + obo:DDO.owl#DDO_0005311 + DDO:DDO_0005311 + + + + obo:DDO.owl#DDO_0005311 + 387160004 + + + + obo:DDO.owl#DDO_0005311 + captopril + + + + obo:DDO.owl#DDO_0005312 + DDO:DDO_0005312 + + + + obo:DDO.owl#DDO_0005312 + 29439004 + + + + obo:DDO.owl#DDO_0005312 + captopril + + + + obo:DDO.owl#DDO_0005313 + DDO:DDO_0005313 + + + + obo:DDO.owl#DDO_0005313 + 346362005 + + + + obo:DDO.owl#DDO_0005313 + captopril+diuretic + + + + obo:DDO.owl#DDO_0005314 + DDO:DDO_0005314 + + + + obo:DDO.owl#DDO_0005314 + 404829009 + + + + obo:DDO.owl#DDO_0005314 + captopril + hydrochlorothiazide + + + + obo:DDO.owl#DDO_0005315 + DDO:DDO_0005315 + + + + obo:DDO.owl#DDO_0005315 + 91135008 + + + + obo:DDO.owl#DDO_0005315 + bendroflumethiazide + + + + obo:DDO.owl#DDO_0005317 + DDO:DDO_0005317 + + + + obo:DDO.owl#DDO_0005317 + 356519002 + + + + obo:DDO.owl#DDO_0005317 + atenolol+bendrofluazide + + + + obo:DDO.owl#DDO_0005318 + DDO:DDO_0005318 + + + + obo:DDO.owl#DDO_0005318 + 398940006 + + + + obo:DDO.owl#DDO_0005318 + bendrofluazide+potassium + + + + obo:DDO.owl#DDO_0005319 + DDO:DDO_0005319 + + + + obo:DDO.owl#DDO_0005319 + 30492008 + + + + obo:DDO.owl#DDO_0005319 + diuretic + + + + obo:DDO.owl#DDO_0005320 + DDO:DDO_0005320 + + + + obo:DDO.owl#DDO_0005320 + 45518007 + + + + obo:DDO.owl#DDO_0005320 + thiazide diuretic + + + + obo:DDO.owl#DDO_0005321 + DDO:DDO_0005321 + + + + obo:DDO.owl#DDO_0005321 + 317938008 + + + + obo:DDO.owl#DDO_0005321 + cyclopenthiazide + + + + obo:DDO.owl#DDO_0005322 + DDO:DDO_0005322 + + + + obo:DDO.owl#DDO_0005322 + 418826002 + + + + obo:DDO.owl#DDO_0005322 + amiloride + cyclopenthiazide + + + + obo:DDO.owl#DDO_0005323 + DDO:DDO_0005323 + + + + obo:DDO.owl#DDO_0005323 + 354304001 + + + + obo:DDO.owl#DDO_0005323 + oxprenolol+cyclopenthiazide + + + + obo:DDO.owl#DDO_0005324 + DDO:DDO_0005324 + + + + obo:DDO.owl#DDO_0005324 + 8252004 + + + + obo:DDO.owl#DDO_0005324 + chlorothiazide sodium + + + + obo:DDO.owl#DDO_0005325 + DDO:DDO_0005325 + + + + obo:DDO.owl#DDO_0005325 + 37006008 + + + + obo:DDO.owl#DDO_0005325 + cyclothiazide + + + + obo:DDO.owl#DDO_0005326 + DDO:DDO_0005326 + + + + obo:DDO.owl#DDO_0005326 + 57952007 + + + + obo:DDO.owl#DDO_0005326 + antilipemic agent + + + + obo:DDO.owl#DDO_0005327 + DDO:DDO_0005327 + + + + obo:DDO.owl#DDO_0005327 + 96302009 + + + + obo:DDO.owl#DDO_0005327 + HMG-CoA reductase inhibitor + + + + obo:DDO.owl#DDO_0005328 + DDO:DDO_0005328 + + + + obo:DDO.owl#DDO_0005328 + 108600003 + + + + obo:DDO.owl#DDO_0005328 + Atorvastatin + + + + obo:DDO.owl#DDO_0005329 + DDO:DDO_0005329 + + + + obo:DDO.owl#DDO_0005329 + 409411009 + + + + obo:DDO.owl#DDO_0005329 + amlodipine+atorvastatin + + + + obo:DDO.owl#DDO_0005330 + DDO:DDO_0005330 + + + + obo:DDO.owl#DDO_0005330 + 108596008 + + + + obo:DDO.owl#DDO_0005330 + Cerivastatin + + + + obo:DDO.owl#DDO_0005331 + DDO:DDO_0005331 + + + + obo:DDO.owl#DDO_0005331 + 96307003 + + + + obo:DDO.owl#DDO_0005331 + fluvastatin + + + + obo:DDO.owl#DDO_0005332 + DDO:DDO_0005332 + + + + obo:DDO.owl#DDO_0005332 + 320019004 + + + + obo:DDO.owl#DDO_0005332 + fluvastatin sodium + + + + obo:DDO.owl#DDO_0005333 + DDO:DDO_0005333 + + + + obo:DDO.owl#DDO_0005333 + 386024001 + + + + obo:DDO.owl#DDO_0005333 + lovastatin + + + + obo:DDO.owl#DDO_0005334 + DDO:DDO_0005334 + + + + obo:DDO.owl#DDO_0005334 + 398648001 + + + + obo:DDO.owl#DDO_0005334 + niacin+lovastatin + + + + obo:DDO.owl#DDO_0005335 + DDO:DDO_0005335 + + + + obo:DDO.owl#DDO_0005335 + 443585001 + + + + obo:DDO.owl#DDO_0005335 + pitavastatin + + + + obo:DDO.owl#DDO_0005336 + DDO:DDO_0005336 + + + + obo:DDO.owl#DDO_0005336 + 96305006 + + + + obo:DDO.owl#DDO_0005336 + pravastatin + + + + obo:DDO.owl#DDO_0005337 + DDO:DDO_0005337 + + + + obo:DDO.owl#DDO_0005337 + 409311005 + + + + obo:DDO.owl#DDO_0005337 + aspirin+pravastatin + + + + obo:DDO.owl#DDO_0005338 + DDO:DDO_0005338 + + + + obo:DDO.owl#DDO_0005338 + 406436002 + + + + obo:DDO.owl#DDO_0005338 + rosuvastatin + + + + obo:DDO.owl#DDO_0005341 + DDO:DDO_0005341 + + + + obo:DDO.owl#DDO_0005341 + 420686001 + + + + obo:DDO.owl#DDO_0005341 + bendroflumethiazide + propranolol + + + + obo:DDO.owl#DDO_0005342 + DDO:DDO_0005342 + + + + obo:DDO.owl#DDO_0005342 + 421992000 + + + + obo:DDO.owl#DDO_0005342 + bendroflumethiazide + timolol + + + + obo:DDO.owl#DDO_0005343 + DDO:DDO_0005343 + + + + obo:DDO.owl#DDO_0005343 + 398704000 + + + + obo:DDO.owl#DDO_0005343 + nadolol+bendroflumethiazide + + + + obo:DDO.owl#DDO_0005344 + DDO:DDO_0005344 + + + + obo:DDO.owl#DDO_0005344 + 400874008 + + + + obo:DDO.owl#DDO_0005344 + benzthiazide + + + + obo:DDO.owl#DDO_0005345 + DDO:DDO_0005345 + + + + obo:DDO.owl#DDO_0005345 + 398745008 + + + + obo:DDO.owl#DDO_0005345 + triamterene+benzthiazide + + + + obo:DDO.owl#DDO_0005346 + DDO:DDO_0005346 + + + + obo:DDO.owl#DDO_0005346 + 5786005 + + + + obo:DDO.owl#DDO_0005346 + chlorothiazide + + + + obo:DDO.owl#DDO_0005347 + DDO:DDO_0005347 + + + + obo:DDO.owl#DDO_0005347 + 428596000 + + + + obo:DDO.owl#DDO_0005347 + parenteral form chlorothiazide + + + + obo:DDO.owl#DDO_0005348 + DDO:DDO_0005348 + + + + obo:DDO.owl#DDO_0005348 + 428185004 + + + + obo:DDO.owl#DDO_0005348 + oral form chlorothiazide + + + + obo:DDO.owl#DDO_0005349 + DDO:DDO_0005349 + + + + obo:DDO.owl#DDO_0005349 + 420285008 + + + + obo:DDO.owl#DDO_0005349 + chlorothiazide + spironolactone + + + + obo:DDO.owl#DDO_0005350 + DDO:DDO_0005350 + + + + obo:DDO.owl#DDO_0005350 + 398631009 + + + + obo:DDO.owl#DDO_0005350 + chlorothiazide + reserpine + + + + obo:DDO.owl#DDO_0005351 + DDO:DDO_0005351 + + + + obo:DDO.owl#DDO_0005351 + 398889000 + + + + obo:DDO.owl#DDO_0005351 + chlorothiazide + methyldopa + + + + obo:DDO.owl#DDO_0005353 + DDO:DDO_0005353 + + + + obo:DDO.owl#DDO_0005353 + 57893000 + + + + obo:DDO.owl#DDO_0005353 + chlorthalidone + + + + obo:DDO.owl#DDO_0005354 + DDO:DDO_0005354 + + + + obo:DDO.owl#DDO_0005354 + 404824004 + + + + obo:DDO.owl#DDO_0005354 + atenolol + chlorthalidone + + + + obo:DDO.owl#DDO_0005355 + DDO:DDO_0005355 + + + + obo:DDO.owl#DDO_0005355 + 398851005 + + + + obo:DDO.owl#DDO_0005355 + chlorthalidone + clonidine hydrochloride + + + + obo:DDO.owl#DDO_0005356 + DDO:DDO_0005356 + + + + obo:DDO.owl#DDO_0005356 + 398672006 + + + + obo:DDO.owl#DDO_0005356 + triamterene+chlorthalidone + + + + obo:DDO.owl#DDO_0005357 + DDO:DDO_0005357 + + + + obo:DDO.owl#DDO_0005357 + 58905004 + + + + obo:DDO.owl#DDO_0005357 + diazoxide + + + + obo:DDO.owl#DDO_0005358 + DDO:DDO_0005358 + + + + obo:DDO.owl#DDO_0005358 + 356206000 + + + + obo:DDO.owl#DDO_0005358 + diltiazem hydrochloride+thiazide diuretic + + + + obo:DDO.owl#DDO_0005359 + DDO:DDO_0005359 + + + + obo:DDO.owl#DDO_0005359 + 398908007 + + + + obo:DDO.owl#DDO_0005359 + diltiazem hydrochloride+hydrochlorothiazide + + + + obo:DDO.owl#DDO_0005360 + DDO:DDO_0005360 + + + + obo:DDO.owl#DDO_0005360 + 91667005 + + + + obo:DDO.owl#DDO_0005360 + hydrochlorothiazide + + + + obo:DDO.owl#DDO_0005361 + DDO:DDO_0005361 + + + + obo:DDO.owl#DDO_0005361 + 317957004 + + + + obo:DDO.owl#DDO_0005361 + mefruside + + + + obo:DDO.owl#DDO_0005362 + DDO:DDO_0005362 + + + + obo:DDO.owl#DDO_0005362 + 395439003 + + + + obo:DDO.owl#DDO_0005362 + perindopril+indapamide + + + + obo:DDO.owl#DDO_0005363 + DDO:DDO_0005363 + + + + obo:DDO.owl#DDO_0005363 + 74213004 + + + + obo:DDO.owl#DDO_0005363 + indapamide + + + + obo:DDO.owl#DDO_0005364 + DDO:DDO_0005364 + + + + obo:DDO.owl#DDO_0005364 + 354276001 + + + + obo:DDO.owl#DDO_0005364 + hydroflumethiazide + spironolactone + + + + obo:DDO.owl#DDO_0005365 + DDO:DDO_0005365 + + + + obo:DDO.owl#DDO_0005365 + 18914005 + + + + obo:DDO.owl#DDO_0005365 + hydroflumethiazide + + + + obo:DDO.owl#DDO_0005366 + DDO:DDO_0005366 + + + + obo:DDO.owl#DDO_0005366 + 398830007 + + + + obo:DDO.owl#DDO_0005366 + timolol maleate+hydrochlorothiazide + + + + obo:DDO.owl#DDO_0005367 + DDO:DDO_0005367 + + + + obo:DDO.owl#DDO_0005367 + 398813005 + + + + obo:DDO.owl#DDO_0005367 + timolol maleate + amiloride + hydrochlorothiazide + + + + obo:DDO.owl#DDO_0005368 + DDO:DDO_0005368 + + + + obo:DDO.owl#DDO_0005368 + 398707007 + + + + obo:DDO.owl#DDO_0005368 + sotalol hydrochloride + hydrochlorothiazide + + + + obo:DDO.owl#DDO_0005369 + DDO:DDO_0005369 + + + + obo:DDO.owl#DDO_0005369 + 410901009 + + + + obo:DDO.owl#DDO_0005369 + moexipril hydrochloride+hydrochlorothiazide + + + + obo:DDO.owl#DDO_0005370 + DDO:DDO_0005370 + + + + obo:DDO.owl#DDO_0005370 + 412544008 + + + + obo:DDO.owl#DDO_0005370 + metoprolol + hydrochlorothiazide + + + + obo:DDO.owl#DDO_0005371 + DDO:DDO_0005371 + + + + obo:DDO.owl#DDO_0005371 + 398913006 + + + + obo:DDO.owl#DDO_0005371 + losartan potassium + hydrochlorothiazide + + + + obo:DDO.owl#DDO_0005372 + DDO:DDO_0005372 + + + + obo:DDO.owl#DDO_0005372 + 398711001 + + + + obo:DDO.owl#DDO_0005372 + labetalol hydrochloride+hydrochlorothiazide + + + + obo:DDO.owl#DDO_0005373 + DDO:DDO_0005373 + + + + obo:DDO.owl#DDO_0005373 + 398914000 + + + + obo:DDO.owl#DDO_0005373 + irbesartan + hydrochlorothiazide + + + + obo:DDO.owl#DDO_0005374 + DDO:DDO_0005374 + + + + obo:DDO.owl#DDO_0005374 + 398722002 + + + + obo:DDO.owl#DDO_0005374 + hydrochlorothiazide + valsartan + + + + obo:DDO.owl#DDO_0005375 + DDO:DDO_0005375 + + + + obo:DDO.owl#DDO_0005375 + 404850000 + + + + obo:DDO.owl#DDO_0005375 + hydrochlorothiazide + triamterene + + + + obo:DDO.owl#DDO_0005376 + DDO:DDO_0005376 + + + + obo:DDO.owl#DDO_0005376 + 398727008 + + + + obo:DDO.owl#DDO_0005376 + hydrochlorothiazide + telmisartan + + + + obo:DDO.owl#DDO_0005377 + DDO:DDO_0005377 + + + + obo:DDO.owl#DDO_0005377 + 398688006 + + + + obo:DDO.owl#DDO_0005377 + hydrochlorothiazide + spironolactone + + + + obo:DDO.owl#DDO_0005378 + DDO:DDO_0005378 + + + + obo:DDO.owl#DDO_0005378 + 398822006 + + + + obo:DDO.owl#DDO_0005378 + hydrochlorothiazide + reserpine + + + + obo:DDO.owl#DDO_0005379 + DDO:DDO_0005379 + + + + obo:DDO.owl#DDO_0005379 + 421852001 + + + + obo:DDO.owl#DDO_0005379 + hydrochlorothiazide + quinapril + + + + obo:DDO.owl#DDO_0005380 + DDO:DDO_0005380 + + + + obo:DDO.owl#DDO_0005380 + 404849000 + + + + obo:DDO.owl#DDO_0005380 + hydrochlorothiazide + propranolol hydrochloride + + + + obo:DDO.owl#DDO_0005381 + DDO:DDO_0005381 + + + + obo:DDO.owl#DDO_0005381 + 423799007 + + + + obo:DDO.owl#DDO_0005381 + hydrochlorothiazide + olmesartan + + + + obo:DDO.owl#DDO_0005382 + DDO:DDO_0005382 + + + + obo:DDO.owl#DDO_0005382 + 398941005 + + + + obo:DDO.owl#DDO_0005382 + hydrochlorothiazide + methyldopa + + + + obo:DDO.owl#DDO_0005383 + DDO:DDO_0005383 + + + + obo:DDO.owl#DDO_0005383 + 398858004 + + + + obo:DDO.owl#DDO_0005383 + hydrochlorothiazide + lisinopril + + + + obo:DDO.owl#DDO_0005384 + DDO:DDO_0005384 + + + + obo:DDO.owl#DDO_0005384 + 398701008 + + + + obo:DDO.owl#DDO_0005384 + hydralazine hydrochloride + hydrochlorothiazide + + + + obo:DDO.owl#DDO_0005385 + DDO:DDO_0005385 + + + + obo:DDO.owl#DDO_0005385 + 398646002 + + + + obo:DDO.owl#DDO_0005385 + guanethidine monosulfate + hydrochlorothiazide + + + + obo:DDO.owl#DDO_0005386 + DDO:DDO_0005386 + + + + obo:DDO.owl#DDO_0005386 + 409457006 + + + + obo:DDO.owl#DDO_0005386 + fosinopril+hydrochlorothiazide + + + + obo:DDO.owl#DDO_0005387 + DDO:DDO_0005387 + + + + obo:DDO.owl#DDO_0005387 + 410876004 + + + + obo:DDO.owl#DDO_0005387 + eprosartan+hydrochlorothiazide + + + + obo:DDO.owl#DDO_0005388 + DDO:DDO_0005388 + + + + obo:DDO.owl#DDO_0005388 + 422016001 + + + + obo:DDO.owl#DDO_0005388 + enalapril+hydrochlorothiazide + + + + obo:DDO.owl#DDO_0005389 + DDO:DDO_0005389 + + + + obo:DDO.owl#DDO_0005389 + 398908007 + + + + obo:DDO.owl#DDO_0005389 + diltiazem hydrochloride+hydrochlorothiazide + + + + obo:DDO.owl#DDO_0005390 + DDO:DDO_0005390 + + + + obo:DDO.owl#DDO_0005390 + 404829009 + + + + obo:DDO.owl#DDO_0005390 + captopril + hydrochlorothiazide + + + + obo:DDO.owl#DDO_0005391 + DDO:DDO_0005391 + + + + obo:DDO.owl#DDO_0005391 + 398759001 + + + + obo:DDO.owl#DDO_0005391 + candesartan cilexetil + hydrochlorothiazide + + + + obo:DDO.owl#DDO_0005392 + DDO:DDO_0005392 + + + + obo:DDO.owl#DDO_0005392 + 420654006 + + + + obo:DDO.owl#DDO_0005392 + bisoprolol+hydrochlorothiazide + + + + obo:DDO.owl#DDO_0005393 + DDO:DDO_0005393 + + + + obo:DDO.owl#DDO_0005393 + 398850006 + + + + obo:DDO.owl#DDO_0005393 + benazepril hydrochloride + hydrochlorothiazide + + + + obo:DDO.owl#DDO_0005394 + DDO:DDO_0005394 + + + + obo:DDO.owl#DDO_0005394 + 356520008 + + + + obo:DDO.owl#DDO_0005394 + atenolol + amiloride + hydrochlorothiazide + + + + obo:DDO.owl#DDO_0005395 + DDO:DDO_0005395 + + + + obo:DDO.owl#DDO_0005395 + 442293009 + + + + obo:DDO.owl#DDO_0005395 + amlodipine + hydrochlorothiazide + valsartan + + + + obo:DDO.owl#DDO_0005396 + DDO:DDO_0005396 + + + + obo:DDO.owl#DDO_0005396 + 447064008 + + + + obo:DDO.owl#DDO_0005396 + amlodipine + hydrochlorothiazide + olmesartan medoxomil + + + + obo:DDO.owl#DDO_0005397 + DDO:DDO_0005397 + + + + obo:DDO.owl#DDO_0005397 + 404822000 + + + + obo:DDO.owl#DDO_0005397 + amiloride hydrochloride + hydrochlorothiazide + + + + obo:DDO.owl#DDO_0005398 + DDO:DDO_0005398 + + + + obo:DDO.owl#DDO_0005398 + 431854009 + + + + obo:DDO.owl#DDO_0005398 + aliskiren + Hydrochlorothiazide + + + + obo:DDO.owl#DDO_0005399 + DDO:DDO_0005399 + + + + obo:DDO.owl#DDO_0005399 + 449275007 + + + + obo:DDO.owl#DDO_0005399 + aliskiren + amlodipine + hydrochlorothiazide + + + + obo:DDO.owl#DDO_0005400 + DDO:DDO_0005400 + + + + obo:DDO.owl#DDO_0005400 + 398910009 + + + + obo:DDO.owl#DDO_0005400 + acebutolol + hydrochlorothiazide + + + + obo:DDO.owl#DDO_0005401 + DDO:DDO_0005401 + + + + obo:DDO.owl#DDO_0005401 + 66919007 + + + + obo:DDO.owl#DDO_0005401 + methyclothiazide + + + + obo:DDO.owl#DDO_0005402 + DDO:DDO_0005402 + + + + obo:DDO.owl#DDO_0005402 + 398948004 + + + + obo:DDO.owl#DDO_0005402 + deserpidine + methyclothiazide + + + + obo:DDO.owl#DDO_0005403 + DDO:DDO_0005403 + + + + obo:DDO.owl#DDO_0005403 + 398969002 + + + + obo:DDO.owl#DDO_0005403 + methyclothiazide + reserpine + + + + obo:DDO.owl#DDO_0005404 + DDO:DDO_0005404 + + + + obo:DDO.owl#DDO_0005404 + 85468002 + + + + obo:DDO.owl#DDO_0005404 + polythiazide + + + + obo:DDO.owl#DDO_0005405 + DDO:DDO_0005405 + + + + obo:DDO.owl#DDO_0005405 + 439233008 + + + + obo:DDO.owl#DDO_0005405 + polythiazide + prazosin hydrochloride + + + + obo:DDO.owl#DDO_0005406 + DDO:DDO_0005406 + + + + obo:DDO.owl#DDO_0005406 + 400606007 + + + + obo:DDO.owl#DDO_0005406 + quinethazone + + + + obo:DDO.owl#DDO_0005407 + DDO:DDO_0005407 + + + + obo:DDO.owl#DDO_0005407 + 346694008 + + + + obo:DDO.owl#DDO_0005407 + triamterene+thiazide diuretic + + + + obo:DDO.owl#DDO_0005408 + DDO:DDO_0005408 + + + + obo:DDO.owl#DDO_0005408 + 398745008 + + + + obo:DDO.owl#DDO_0005408 + triamterene+benzthiazide + + + + obo:DDO.owl#DDO_0005409 + DDO:DDO_0005409 + + + + obo:DDO.owl#DDO_0005409 + 398672006 + + + + obo:DDO.owl#DDO_0005409 + triamterene+chlorthalidone + + + + obo:DDO.owl#DDO_0005410 + DDO:DDO_0005410 + + + + obo:DDO.owl#DDO_0005410 + 409112007 + + + + obo:DDO.owl#DDO_0005410 + trichlormethiazide + + + + obo:DDO.owl#DDO_0005411 + DDO:DDO_0005411 + + + + obo:DDO.owl#DDO_0005411 + 317968004 + + + + obo:DDO.owl#DDO_0005411 + xipamide + + + + obo:DDO.owl#DDO_0005412 + DDO:DDO_0005412 + + + + obo:DDO.owl#DDO_0005412 + 116883003 + + + + obo:DDO.owl#DDO_0005412 + 8-hydroxyloxapine + + + + obo:DDO.owl#DDO_0005413 + DDO:DDO_0005413 + + + + obo:DDO.owl#DDO_0005413 + 117004004 + + + + obo:DDO.owl#DDO_0005413 + 9-Hydroxyrisperidone + + + + obo:DDO.owl#DDO_0005414 + DDO:DDO_0005414 + + + + obo:DDO.owl#DDO_0005414 + 3142009 + + + + obo:DDO.owl#DDO_0005414 + azacyclonol + + + + obo:DDO.owl#DDO_0005415 + DDO:DDO_0005415 + + + + obo:DDO.owl#DDO_0005415 + 428096005 + + + + obo:DDO.owl#DDO_0005415 + benzamide derivative antipsychotic agent + + + + obo:DDO.owl#DDO_0005416 + DDO:DDO_0005416 + + + + obo:DDO.owl#DDO_0005416 + 391761004 + + + + obo:DDO.owl#DDO_0005416 + amisulpride + + + + obo:DDO.owl#DDO_0005417 + DDO:DDO_0005417 + + + + obo:DDO.owl#DDO_0005417 + 419361008 + + + + obo:DDO.owl#DDO_0005417 + remoxipride + + + + obo:DDO.owl#DDO_0005418 + DDO:DDO_0005418 + + + + obo:DDO.owl#DDO_0005418 + 395891007 + + + + obo:DDO.owl#DDO_0005418 + sulpiride + + + + obo:DDO.owl#DDO_0005419 + DDO:DDO_0005419 + + + + obo:DDO.owl#DDO_0005419 + 702795007 + + + + obo:DDO.owl#DDO_0005419 + levosulpiride + + + + obo:DDO.owl#DDO_0005420 + DDO:DDO_0005420 + + + + obo:DDO.owl#DDO_0005420 + 409381000 + + + + obo:DDO.owl#DDO_0005420 + benzimidazolinone derivative antipsychotic agent + + + + obo:DDO.owl#DDO_0005421 + DDO:DDO_0005421 + + + + obo:DDO.owl#DDO_0005421 + 391820006 + + + + obo:DDO.owl#DDO_0005421 + benperidol + + + + obo:DDO.owl#DDO_0005422 + DDO:DDO_0005422 + + + + obo:DDO.owl#DDO_0005422 + 387146001 + + + + obo:DDO.owl#DDO_0005422 + droperidol + + + + obo:DDO.owl#DDO_0005423 + DDO:DDO_0005423 + + + + obo:DDO.owl#DDO_0005423 + 372483006 + + + + obo:DDO.owl#DDO_0005423 + benzisoxazole derivative antipsychotic agent + + + + obo:DDO.owl#DDO_0005424 + DDO:DDO_0005424 + + + + obo:DDO.owl#DDO_0005424 + 442849001 + + + + obo:DDO.owl#DDO_0005424 + iloperidone + + + + obo:DDO.owl#DDO_0005425 + DDO:DDO_0005425 + + + + obo:DDO.owl#DDO_0005425 + 426276000 + + + + obo:DDO.owl#DDO_0005425 + paliperidone + + + + obo:DDO.owl#DDO_0005426 + DDO:DDO_0005426 + + + + obo:DDO.owl#DDO_0005426 + 706896003 + + + + obo:DDO.owl#DDO_0005426 + paliperidone palmitate + + + + obo:DDO.owl#DDO_0005427 + DDO:DDO_0005427 + + + + obo:DDO.owl#DDO_0005427 + 386840002 + + + + obo:DDO.owl#DDO_0005427 + risperidone + + + + obo:DDO.owl#DDO_0005428 + DDO:DDO_0005428 + + + + obo:DDO.owl#DDO_0005428 + 409356003 + + + + obo:DDO.owl#DDO_0005428 + ziprasidone + + + + obo:DDO.owl#DDO_0005429 + DDO:DDO_0005429 + + + + obo:DDO.owl#DDO_0005429 + 129479007 + + + + obo:DDO.owl#DDO_0005429 + ziprasidone hydrochloride + + + + obo:DDO.owl#DDO_0005430 + DDO:DDO_0005430 + + + + obo:DDO.owl#DDO_0005430 + 409357007 + + + + obo:DDO.owl#DDO_0005430 + ziprasidone mesylate + + + + obo:DDO.owl#DDO_0005431 + DDO:DDO_0005431 + + + + obo:DDO.owl#DDO_0005431 + 372808009 + + + + obo:DDO.owl#DDO_0005431 + butyrophenone derivative antipsychotic agent + + + + obo:DDO.owl#DDO_0005432 + DDO:DDO_0005432 + + + + obo:DDO.owl#DDO_0005432 + 372696004 + + + + obo:DDO.owl#DDO_0005432 + dibenzoxazepine derivative antipsychotic agent + + + + obo:DDO.owl#DDO_0005433 + DDO:DDO_0005433 + + + + obo:DDO.owl#DDO_0005433 + 698028004 + + + + obo:DDO.owl#DDO_0005433 + clotiapine + + + + obo:DDO.owl#DDO_0005434 + DDO:DDO_0005434 + + + + obo:DDO.owl#DDO_0005434 + 372789006 + + + + obo:DDO.owl#DDO_0005434 + loxapine + + + + obo:DDO.owl#DDO_0005435 + DDO:DDO_0005435 + + + + obo:DDO.owl#DDO_0005435 + 1971003 + + + + obo:DDO.owl#DDO_0005435 + loxapine hydrochloride + + + + obo:DDO.owl#DDO_0005436 + DDO:DDO_0005436 + + + + obo:DDO.owl#DDO_0005436 + 30745005 + + + + obo:DDO.owl#DDO_0005436 + loxapine succinate + + + + obo:DDO.owl#DDO_0005437 + DDO:DDO_0005437 + + + + obo:DDO.owl#DDO_0005437 + 386849001 + + + + obo:DDO.owl#DDO_0005437 + olanzapine + + + + obo:DDO.owl#DDO_0005438 + DDO:DDO_0005438 + + + + obo:DDO.owl#DDO_0005438 + 386850001 + + + + obo:DDO.owl#DDO_0005438 + quetiapine + + + + obo:DDO.owl#DDO_0005439 + DDO:DDO_0005439 + + + + obo:DDO.owl#DDO_0005439 + 108383008 + + + + obo:DDO.owl#DDO_0005439 + quetiapine fumarate + + + + obo:DDO.owl#DDO_0005440 + DDO:DDO_0005440 + + + + obo:DDO.owl#DDO_0005440 + 387301006 + + + + obo:DDO.owl#DDO_0005440 + trifluperidol + + + + obo:DDO.owl#DDO_0005441 + DDO:DDO_0005441 + + + + obo:DDO.owl#DDO_0005441 + 77222007 + + + + obo:DDO.owl#DDO_0005441 + spiperone + + + + obo:DDO.owl#DDO_0005442 + DDO:DDO_0005442 + + + + obo:DDO.owl#DDO_0005442 + 703363002 + + + + obo:DDO.owl#DDO_0005442 + pipamperone hydrochloride + + + + obo:DDO.owl#DDO_0005443 + DDO:DDO_0005443 + + + + obo:DDO.owl#DDO_0005443 + 703362007 + + + + obo:DDO.owl#DDO_0005443 + pipamperone + + + + obo:DDO.owl#DDO_0005444 + DDO:DDO_0005444 + + + + obo:DDO.owl#DDO_0005444 + 442519006 + + + + obo:DDO.owl#DDO_0005444 + melperone + + + + obo:DDO.owl#DDO_0005445 + DDO:DDO_0005445 + + + + obo:DDO.owl#DDO_0005445 + 412197008 + + + + obo:DDO.owl#DDO_0005445 + haloperidol lactate + + + + obo:DDO.owl#DDO_0005446 + DDO:DDO_0005446 + + + + obo:DDO.owl#DDO_0005446 + 412196004 + + + + obo:DDO.owl#DDO_0005446 + haloperidol decanoate + + + + obo:DDO.owl#DDO_0005447 + DDO:DDO_0005447 + + + + obo:DDO.owl#DDO_0005447 + 386837002 + + + + obo:DDO.owl#DDO_0005447 + haloperidol + + + + obo:DDO.owl#DDO_0005448 + DDO:DDO_0005448 + + + + obo:DDO.owl#DDO_0005448 + 387146001 + + + + obo:DDO.owl#DDO_0005448 + droperidol + + + + obo:DDO.owl#DDO_0005449 + DDO:DDO_0005449 + + + + obo:DDO.owl#DDO_0005449 + 391820006 + + + + obo:DDO.owl#DDO_0005449 + benperidol + + + + obo:DDO.owl#DDO_0005450 + DDO:DDO_0005450 + + + + obo:DDO.owl#DDO_0005450 + 96229001 + + + + obo:DDO.owl#DDO_0005450 + azaperone + + + + obo:DDO.owl#DDO_0005451 + DDO:DDO_0005451 + + + + obo:DDO.owl#DDO_0005451 + 406783004 + + + + obo:DDO.owl#DDO_0005451 + dihydrocarbostyril derivative antipsychotic agent + + + + obo:DDO.owl#DDO_0005452 + DDO:DDO_0005452 + + + + obo:DDO.owl#DDO_0005452 + 406784005 + + + + obo:DDO.owl#DDO_0005452 + aripiprazole + + + + obo:DDO.owl#DDO_0005453 + DDO:DDO_0005453 + + + + obo:DDO.owl#DDO_0005453 + 373264005 + + + + obo:DDO.owl#DDO_0005453 + dihydroindolone derivative antipsychotic agent + + + + obo:DDO.owl#DDO_0005454 + DDO:DDO_0005454 + + + + obo:DDO.owl#DDO_0005454 + 372799001 + + + + obo:DDO.owl#DDO_0005454 + molindone + + + + obo:DDO.owl#DDO_0005455 + DDO:DDO_0005455 + + + + obo:DDO.owl#DDO_0005455 + 55124001 + + + + obo:DDO.owl#DDO_0005455 + Molindone hydrochloride + + + + obo:DDO.owl#DDO_0005456 + DDO:DDO_0005456 + + + + obo:DDO.owl#DDO_0005456 + 74090008 + + + + obo:DDO.owl#DDO_0005456 + dimozide + + + + obo:DDO.owl#DDO_0005457 + DDO:DDO_0005457 + + + + obo:DDO.owl#DDO_0005457 + 373257008 + + + + obo:DDO.owl#DDO_0005457 + diphenylbutylpiperidine derivative antipsychotic agent + + + + obo:DDO.owl#DDO_0005458 + DDO:DDO_0005458 + + + + obo:DDO.owl#DDO_0005458 + 372606006 + + + + obo:DDO.owl#DDO_0005458 + diphenylbutylpiperidine + + + + obo:DDO.owl#DDO_0005459 + DDO:DDO_0005459 + + + + obo:DDO.owl#DDO_0005459 + 419373008 + + + + obo:DDO.owl#DDO_0005459 + fluspirilene + + + + obo:DDO.owl#DDO_0005460 + DDO:DDO_0005460 + + + + obo:DDO.owl#DDO_0005460 + 710292006 + + + + obo:DDO.owl#DDO_0005460 + penfluridol + + + + obo:DDO.owl#DDO_0005461 + DDO:DDO_0005461 + + + + obo:DDO.owl#DDO_0005461 + 386848009 + + + + obo:DDO.owl#DDO_0005461 + pimozide + + + + obo:DDO.owl#DDO_0005462 + DDO:DDO_0005462 + + + + obo:DDO.owl#DDO_0005462 + 96217005 + + + + obo:DDO.owl#DDO_0005462 + Lenperone + + + + obo:DDO.owl#DDO_0005463 + DDO:DDO_0005463 + + + + obo:DDO.owl#DDO_0005463 + 395818000 + + + + obo:DDO.owl#DDO_0005463 + oxypertine + + + + obo:DDO.owl#DDO_0005464 + DDO:DDO_0005464 + + + + obo:DDO.owl#DDO_0005464 + 372839006 + + + + obo:DDO.owl#DDO_0005464 + phenothiazine + + + + obo:DDO.owl#DDO_0005465 + DDO:DDO_0005465 + + + + obo:DDO.owl#DDO_0005465 + 373207000 + + + + obo:DDO.owl#DDO_0005465 + phenothiazine derivative antipsychotic agent + + + + obo:DDO.owl#DDO_0005466 + DDO:DDO_0005466 + + + + obo:DDO.owl#DDO_0005466 + 395995004 + + + + obo:DDO.owl#DDO_0005466 + pipotiazine + + + + obo:DDO.owl#DDO_0005467 + DDO:DDO_0005467 + + + + obo:DDO.owl#DDO_0005467 + 70001008 + + + + obo:DDO.owl#DDO_0005467 + piperacetazine + + + + obo:DDO.owl#DDO_0005468 + DDO:DDO_0005468 + + + + obo:DDO.owl#DDO_0005468 + 89775008 + + + + obo:DDO.owl#DDO_0005468 + pipamazine + + + + obo:DDO.owl#DDO_0005469 + DDO:DDO_0005469 + + + + obo:DDO.owl#DDO_0005469 + 395825007 + + + + obo:DDO.owl#DDO_0005469 + pericyazine + + + + obo:DDO.owl#DDO_0005470 + DDO:DDO_0005470 + + + + obo:DDO.owl#DDO_0005470 + 25002001 + + + + obo:DDO.owl#DDO_0005470 + perazine + + + + obo:DDO.owl#DDO_0005471 + DDO:DDO_0005471 + + + + obo:DDO.owl#DDO_0005471 + 48940005 + + + + obo:DDO.owl#DDO_0005471 + methoxypromazine + + + + obo:DDO.owl#DDO_0005472 + DDO:DDO_0005472 + + + + obo:DDO.owl#DDO_0005472 + 47176005 + + + + obo:DDO.owl#DDO_0005472 + methdilazine hydrochloride + + + + obo:DDO.owl#DDO_0005473 + DDO:DDO_0005473 + + + + obo:DDO.owl#DDO_0005473 + 18462008 + + + + obo:DDO.owl#DDO_0005473 + methdilazine + + + + obo:DDO.owl#DDO_0005474 + DDO:DDO_0005474 + + + + obo:DDO.owl#DDO_0005474 + 9663002 + + + + obo:DDO.owl#DDO_0005474 + mepazine + + + + obo:DDO.owl#DDO_0005475 + DDO:DDO_0005475 + + + + obo:DDO.owl#DDO_0005475 + 83309005 + + + + obo:DDO.owl#DDO_0005475 + ethopropazine hydrochloride + + + + obo:DDO.owl#DDO_0005476 + DDO:DDO_0005476 + + + + obo:DDO.owl#DDO_0005476 + 52850008 + + + + obo:DDO.owl#DDO_0005476 + ethopropazine + + + + obo:DDO.owl#DDO_0005477 + DDO:DDO_0005477 + + + + obo:DDO.owl#DDO_0005477 + 387479008 + + + + obo:DDO.owl#DDO_0005477 + chlorpromazine hydrochloride + + + + obo:DDO.owl#DDO_0005478 + DDO:DDO_0005478 + + + + obo:DDO.owl#DDO_0005478 + 427377000 + + + + obo:DDO.owl#DDO_0005478 + chlorpromazine embonate + + + + obo:DDO.owl#DDO_0005479 + DDO:DDO_0005479 + + + + obo:DDO.owl#DDO_0005479 + 387258005 + + + + obo:DDO.owl#DDO_0005479 + chlorpromazine + + + + obo:DDO.owl#DDO_0005480 + DDO:DDO_0005480 + + + + obo:DDO.owl#DDO_0005480 + 123579002 + + + + obo:DDO.owl#DDO_0005480 + carphenazine maleate + + + + obo:DDO.owl#DDO_0005481 + DDO:DDO_0005481 + + + + obo:DDO.owl#DDO_0005481 + 75645006 + + + + obo:DDO.owl#DDO_0005481 + butaperazine + + + + obo:DDO.owl#DDO_0005482 + DDO:DDO_0005482 + + + + obo:DDO.owl#DDO_0005482 + 18550006 + + + + obo:DDO.owl#DDO_0005482 + thioridazine hydrochloride + + + + obo:DDO.owl#DDO_0005483 + DDO:DDO_0005483 + + + + obo:DDO.owl#DDO_0005483 + 372706001 + + + + obo:DDO.owl#DDO_0005483 + thioridazine + + + + obo:DDO.owl#DDO_0005484 + DDO:DDO_0005484 + + + + obo:DDO.owl#DDO_0005484 + 75268009 + + + + obo:DDO.owl#DDO_0005484 + mesoridazine besylate + + + + obo:DDO.owl#DDO_0005485 + DDO:DDO_0005485 + + + + obo:DDO.owl#DDO_0005485 + 372852001 + + + + obo:DDO.owl#DDO_0005485 + mesoridazine + + + + obo:DDO.owl#DDO_0005486 + DDO:DDO_0005486 + + + + obo:DDO.owl#DDO_0005486 + 41945007 + + + + obo:DDO.owl#DDO_0005486 + alkylpiperidine derivative of phenothiazine + + + + obo:DDO.owl#DDO_0005487 + DDO:DDO_0005487 + + + + obo:DDO.owl#DDO_0005487 + 67029008 + + + + obo:DDO.owl#DDO_0005487 + acetophenazine maleate + + + + obo:DDO.owl#DDO_0005488 + DDO:DDO_0005488 + + + + obo:DDO.owl#DDO_0005488 + 35281007 + + + + obo:DDO.owl#DDO_0005488 + acetophenazine + + + + obo:DDO.owl#DDO_0005489 + DDO:DDO_0005489 + + + + obo:DDO.owl#DDO_0005489 + 412076009 + + + + obo:DDO.owl#DDO_0005489 + acepromazine maleate + + + + obo:DDO.owl#DDO_0005490 + DDO:DDO_0005490 + + + + obo:DDO.owl#DDO_0005490 + 96218000 + + + + obo:DDO.owl#DDO_0005490 + acepromazine + + + + obo:DDO.owl#DDO_0005491 + DDO:DDO_0005491 + + + + obo:DDO.owl#DDO_0005491 + 395832003 + + + + obo:DDO.owl#DDO_0005491 + pipotiazine palmitate + + + + obo:DDO.owl#DDO_0005492 + DDO:DDO_0005492 + + + + obo:DDO.owl#DDO_0005492 + 373524005 + + + + obo:DDO.owl#DDO_0005492 + trifluoperazine + + + + obo:DDO.owl#DDO_0005493 + DDO:DDO_0005493 + + + + obo:DDO.owl#DDO_0005493 + 395843006 + + + + obo:DDO.owl#DDO_0005493 + prochlorperazine mesylate + + + + obo:DDO.owl#DDO_0005494 + DDO:DDO_0005494 + + + + obo:DDO.owl#DDO_0005494 + 22827004 + + + + obo:DDO.owl#DDO_0005494 + prochlorperazine maleate + + + + obo:DDO.owl#DDO_0005495 + DDO:DDO_0005495 + + + + obo:DDO.owl#DDO_0005495 + 3823007 + + + + obo:DDO.owl#DDO_0005495 + prochlorperazine edisylate + + + + obo:DDO.owl#DDO_0005496 + DDO:DDO_0005496 + + + + obo:DDO.owl#DDO_0005496 + 372853006 + + + + obo:DDO.owl#DDO_0005496 + prochlorperazine + + + + obo:DDO.owl#DDO_0005497 + DDO:DDO_0005497 + + + + obo:DDO.owl#DDO_0005497 + 387229007 + + + + obo:DDO.owl#DDO_0005497 + perphenazine + + + + obo:DDO.owl#DDO_0005498 + DDO:DDO_0005498 + + + + obo:DDO.owl#DDO_0005498 + 61678008 + + + + obo:DDO.owl#DDO_0005498 + fluphenazine hydrochloride + + + + obo:DDO.owl#DDO_0005499 + DDO:DDO_0005499 + + + + obo:DDO.owl#DDO_0005499 + 111125005 + + + + obo:DDO.owl#DDO_0005499 + fluphenazine enanthate + + + + obo:DDO.owl#DDO_0005500 + DDO:DDO_0005500 + + + + obo:DDO.owl#DDO_0005500 + 396063006 + + + + obo:DDO.owl#DDO_0005500 + fluphenazine decanoate + + + + obo:DDO.owl#DDO_0005501 + DDO:DDO_0005501 + + + + obo:DDO.owl#DDO_0005501 + 372730004 + + + + obo:DDO.owl#DDO_0005501 + fluphenazine + + + + obo:DDO.owl#DDO_0005502 + DDO:DDO_0005502 + + + + obo:DDO.owl#DDO_0005502 + 372746007 + + + + obo:DDO.owl#DDO_0005502 + propylpiperazine derivative of phenothiazine + + + + obo:DDO.owl#DDO_0005503 + DDO:DDO_0005503 + + + + obo:DDO.owl#DDO_0005503 + 52803004 + + + + obo:DDO.owl#DDO_0005503 + trimeprazine tartrate + + + + obo:DDO.owl#DDO_0005504 + DDO:DDO_0005504 + + + + obo:DDO.owl#DDO_0005504 + 387471006 + + + + obo:DDO.owl#DDO_0005504 + trimeprazine + + + + obo:DDO.owl#DDO_0005505 + DDO:DDO_0005505 + + + + obo:DDO.owl#DDO_0005505 + 79135001 + + + + obo:DDO.owl#DDO_0005505 + promazine hydrochloride + + + + obo:DDO.owl#DDO_0005506 + DDO:DDO_0005506 + + + + obo:DDO.owl#DDO_0005506 + 372741002 + + + + obo:DDO.owl#DDO_0005506 + promazine + + + + obo:DDO.owl#DDO_0005507 + DDO:DDO_0005507 + + + + obo:DDO.owl#DDO_0005507 + 395790003 + + + + obo:DDO.owl#DDO_0005507 + methotrimeprazine maleate + + + + obo:DDO.owl#DDO_0005508 + DDO:DDO_0005508 + + + + obo:DDO.owl#DDO_0005508 + 57911003 + + + + obo:DDO.owl#DDO_0005508 + methotrimeprazine hydrochloride + + + + obo:DDO.owl#DDO_0005509 + DDO:DDO_0005509 + + + + obo:DDO.owl#DDO_0005509 + 387509007 + + + + obo:DDO.owl#DDO_0005509 + methotrimeprazine + + + + obo:DDO.owl#DDO_0005510 + DDO:DDO_0005510 + + + + obo:DDO.owl#DDO_0005510 + 373292000 + + + + obo:DDO.owl#DDO_0005510 + propylamino derivative of phenothiazine + + + + obo:DDO.owl#DDO_0005511 + DDO:DDO_0005511 + + + + obo:DDO.owl#DDO_0005511 + 50754002 + + + + obo:DDO.owl#DDO_0005511 + trifluoperazine hydrochloride + + + + obo:DDO.owl#DDO_0005512 + DDO:DDO_0005512 + + + + obo:DDO.owl#DDO_0005512 + 27766008 + + + + obo:DDO.owl#DDO_0005512 + Prothipendyl + + + + obo:DDO.owl#DDO_0005513 + DDO:DDO_0005513 + + + + obo:DDO.owl#DDO_0005513 + 74713003 + + + + obo:DDO.owl#DDO_0005513 + thiopropazate + + + + obo:DDO.owl#DDO_0005514 + DDO:DDO_0005514 + + + + obo:DDO.owl#DDO_0005514 + 30329006 + + + + obo:DDO.owl#DDO_0005514 + triflupromazine + + + + obo:DDO.owl#DDO_0005515 + DDO:DDO_0005515 + + + + obo:DDO.owl#DDO_0005515 + 6992002 + + + + obo:DDO.owl#DDO_0005515 + triflupromazine hydrochloride + + + + obo:DDO.owl#DDO_0005516 + DDO:DDO_0005516 + + + + obo:DDO.owl#DDO_0005516 + 372492009 + + + + obo:DDO.owl#DDO_0005516 + phenylbutylpiperadine derivative antipsychotic agent + + + + obo:DDO.owl#DDO_0005517 + DDO:DDO_0005517 + + + + obo:DDO.owl#DDO_0005517 + 386837002 + + + + obo:DDO.owl#DDO_0005517 + haloperidol + + + + obo:DDO.owl#DDO_0005518 + DDO:DDO_0005518 + + + + obo:DDO.owl#DDO_0005518 + 412196004 + + + + obo:DDO.owl#DDO_0005518 + haloperidol decanoate + + + + obo:DDO.owl#DDO_0005519 + DDO:DDO_0005519 + + + + obo:DDO.owl#DDO_0005519 + 412197008 + + + + obo:DDO.owl#DDO_0005519 + haloperidol lactate + + + + obo:DDO.owl#DDO_0005520 + DDO:DDO_0005520 + + + + obo:DDO.owl#DDO_0005520 + 387301006 + + + + obo:DDO.owl#DDO_0005520 + trifluperidol + + + + obo:DDO.owl#DDO_0005521 + DDO:DDO_0005521 + + + + obo:DDO.owl#DDO_0005521 + 373255000 + + + + obo:DDO.owl#DDO_0005521 + thioxanthene derivative antipsychotic agent + + + + obo:DDO.owl#DDO_0005522 + DDO:DDO_0005522 + + + + obo:DDO.owl#DDO_0005522 + 387566002 + + + + obo:DDO.owl#DDO_0005522 + clopenthixol + + + + obo:DDO.owl#DDO_0005523 + DDO:DDO_0005523 + + + + obo:DDO.owl#DDO_0005523 + 387567006 + + + + obo:DDO.owl#DDO_0005523 + flupentixol + + + + obo:DDO.owl#DDO_0005524 + DDO:DDO_0005524 + + + + obo:DDO.owl#DDO_0005524 + 396062001 + + + + obo:DDO.owl#DDO_0005524 + flupentixol decanoate + + + + obo:DDO.owl#DDO_0005525 + DDO:DDO_0005525 + + + + obo:DDO.owl#DDO_0005525 + 442075003 + + + + obo:DDO.owl#DDO_0005525 + flupentixol hydrochloride + + + + obo:DDO.owl#DDO_0005526 + DDO:DDO_0005526 + + + + obo:DDO.owl#DDO_0005526 + 372804006 + + + + obo:DDO.owl#DDO_0005526 + thiothixene + + + + obo:DDO.owl#DDO_0005527 + DDO:DDO_0005527 + + + + obo:DDO.owl#DDO_0005527 + 387317000 + + + + obo:DDO.owl#DDO_0005527 + chlorprothixene + + + + obo:DDO.owl#DDO_0005528 + DDO:DDO_0005528 + + + + obo:DDO.owl#DDO_0005528 + 88585004 + + + + obo:DDO.owl#DDO_0005528 + chlorprothixene hydrochloride + + + + obo:DDO.owl#DDO_0005529 + DDO:DDO_0005529 + + + + obo:DDO.owl#DDO_0005529 + 9539001 + + + + obo:DDO.owl#DDO_0005529 + chlorprothixene lactate + + + + obo:DDO.owl#DDO_0005530 + DDO:DDO_0005530 + + + + obo:DDO.owl#DDO_0005530 + 25538002 + + + + obo:DDO.owl#DDO_0005530 + thiothixene hydrochloride + + + + obo:DDO.owl#DDO_0005531 + DDO:DDO_0005531 + + + + obo:DDO.owl#DDO_0005531 + 428715002 + + + + obo:DDO.owl#DDO_0005531 + zuclopenthixol + + + + obo:DDO.owl#DDO_0005532 + DDO:DDO_0005532 + + + + obo:DDO.owl#DDO_0005532 + 395931006 + + + + obo:DDO.owl#DDO_0005532 + zuclopenthixol acetate + + + + obo:DDO.owl#DDO_0005533 + DDO:DDO_0005533 + + + + obo:DDO.owl#DDO_0005533 + 395932004 + + + + obo:DDO.owl#DDO_0005533 + zuclopenthixol decanoate + + + + obo:DDO.owl#DDO_0005534 + DDO:DDO_0005534 + + + + obo:DDO.owl#DDO_0005534 + 426594007 + + + + obo:DDO.owl#DDO_0005534 + zuclopenthixol dihydrochloride + + + + obo:DDO.owl#DDO_0005535 + DDO:DDO_0005535 + + + + obo:DDO.owl#DDO_0005535 + 386896009 + + + + obo:DDO.owl#DDO_0005535 + ritonavir + + + + obo:DDO.owl#DDO_0005536 + DDO:DDO_0005536 + + + + obo:DDO.owl#DDO_0005536 + 350227001 + + + + obo:DDO.owl#DDO_0005536 + diamidine antiprotozoal + + + + obo:DDO.owl#DDO_0005537 + DDO:DDO_0005537 + + + + obo:DDO.owl#DDO_0005537 + 31692006 + + + + obo:DDO.owl#DDO_0005537 + pentamidine + + + + obo:DDO.owl#DDO_0005538 + DDO:DDO_0005538 + + + + obo:DDO.owl#DDO_0005538 + 430210004 + + + + obo:DDO.owl#DDO_0005538 + parenteral form pentamidine + + + + obo:DDO.owl#DDO_0005539 + DDO:DDO_0005539 + + + + obo:DDO.owl#DDO_0005539 + 429988005 + + + + obo:DDO.owl#DDO_0005539 + respiratory form pentamidine + + + + obo:DDO.owl#DDO_0005540 + DDO:DDO_0005540 + + + + obo:DDO.owl#DDO_0005540 + 11257001 + + + + obo:DDO.owl#DDO_0005540 + nitrogen compound + + + + obo:DDO.owl#DDO_0005541 + DDO:DDO_0005541 + + + + obo:DDO.owl#DDO_0005541 + 413501004 + + + + obo:DDO.owl#DDO_0005541 + amidine + + + + obo:DDO.owl#DDO_0005542 + DDO:DDO_0005542 + + + + obo:DDO.owl#DDO_0005542 + 428873009 + + + + obo:DDO.owl#DDO_0005542 + diamidine + + + + obo:DDO.owl#DDO_0005543 + DDO:DDO_0005543 + + + + obo:DDO.owl#DDO_0005543 + 373237009 + + + + obo:DDO.owl#DDO_0005543 + diamidine antiprotozoal + + + + obo:DDO.owl#DDO_0005544 + DDO:DDO_0005544 + + + + obo:DDO.owl#DDO_0005544 + 372699006 + + + + obo:DDO.owl#DDO_0005544 + pentamidine + + + + obo:DDO.owl#DDO_0005545 + DDO:DDO_0005545 + + + + obo:DDO.owl#DDO_0005545 + 77481000 + + + + obo:DDO.owl#DDO_0005545 + pentamidine diisothionate + + + + obo:DDO.owl#DDO_0005546 + DDO:DDO_0005546 + + + + obo:DDO.owl#DDO_0005546 + 16826009 + + + + obo:DDO.owl#DDO_0005546 + pentamidine isethionate + + + + obo:DDO.owl#DDO_0005547 + DDO:DDO_0005547 + + + + obo:DDO.owl#DDO_0005547 + catecholamine-mediated + + + + obo:DDO.owl#DDO_0005548 + DDO:DDO_0005548 + + + + obo:DDO.owl#DDO_0005548 + acetylcholine-mediated + + + + obo:DDO.owl#DDO_0005549 + DDO:DDO_0005549 + + + + obo:DDO.owl#DDO_0005549 + itchy skin + + + + obo:DDO.owl#DDO_0005550 + DDO:DDO_0005550 + + + + obo:DDO.owl#DDO_0005550 + 279333002 + + + + obo:DDO.owl#DDO_0005550 + itchy skin eruption + + + + obo:DDO.owl#DDO_0005550 + pruritus of skin + + + + obo:DDO.owl#DDO_0005551 + DDO:DDO_0005551 + + + + obo:DDO.owl#DDO_0005551 + 64144002 + + + + obo:DDO.owl#DDO_0005551 + pruritic rash + + + + obo:DDO.owl#DDO_0005554 + DDO:DDO_0005554 + + + + obo:DDO.owl#DDO_0005554 + 238586002 + + + + obo:DDO.owl#DDO_0005554 + subacute prurigo + + + + obo:DDO.owl#DDO_0005555 + DDO:DDO_0005555 + + + + obo:DDO.owl#DDO_0005555 + 201025002 + + + + obo:DDO.owl#DDO_0005555 + winter itch + + + + obo:DDO.owl#DDO_0005556 + DDO:DDO_0005556 + + + + obo:DDO.owl#DDO_0005556 + 400051008 + + + + obo:DDO.owl#DDO_0005556 + senile asteatotic eczema + + + + obo:DDO.owl#DDO_0005557 + DDO:DDO_0005557 + + + + obo:DDO.owl#DDO_0005557 + 42570001 + + + + obo:DDO.owl#DDO_0005557 + pruritus senilis + + + + obo:DDO.owl#DDO_0005558 + DDO:DDO_0005558 + + + + obo:DDO.owl#DDO_0005558 + 55608001 + + + + obo:DDO.owl#DDO_0005558 + prurigo simplex + + + + obo:DDO.owl#DDO_0005559 + DDO:DDO_0005559 + + + + obo:DDO.owl#DDO_0005559 + 238589009 + + + + obo:DDO.owl#DDO_0005559 + prurigo pigmentosa + + + + obo:DDO.owl#DDO_0005560 + DDO:DDO_0005560 + + + + obo:DDO.owl#DDO_0005560 + 238546005 + + + + obo:DDO.owl#DDO_0005560 + pruriginous atopic dermatitis + + + + obo:DDO.owl#DDO_0005561 + DDO:DDO_0005561 + + + + obo:DDO.owl#DDO_0005561 + 43118004 + + + + obo:DDO.owl#DDO_0005561 + prurigo papule + + + + obo:DDO.owl#DDO_0005562 + DDO:DDO_0005562 + + + + obo:DDO.owl#DDO_0005562 + 239103006 + + + + obo:DDO.owl#DDO_0005562 + prurigo of pregnancy + + + + obo:DDO.owl#DDO_0005563 + DDO:DDO_0005563 + + + + obo:DDO.owl#DDO_0005563 + 63501000 + + + + obo:DDO.owl#DDO_0005563 + prurigo nodularis + + + + obo:DDO.owl#DDO_0005564 + DDO:DDO_0005564 + + + + obo:DDO.owl#DDO_0005564 + 201017004 + + + + obo:DDO.owl#DDO_0005564 + prurigo mitis + + + + obo:DDO.owl#DDO_0005565 + DDO:DDO_0005565 + + + + obo:DDO.owl#DDO_0005565 + 201016008 + + + + obo:DDO.owl#DDO_0005565 + Hebra's prurigo + + + + obo:DDO.owl#DDO_0005566 + DDO:DDO_0005566 + + + + obo:DDO.owl#DDO_0005566 + 238588001 + + + + obo:DDO.owl#DDO_0005566 + dermographic prurigo + + + + obo:DDO.owl#DDO_0005567 + DDO:DDO_0005567 + + + + obo:DDO.owl#DDO_0005567 + 238587006 + + + + obo:DDO.owl#DDO_0005567 + chronic prurigo + + + + obo:DDO.owl#DDO_0005568 + DDO:DDO_0005568 + + + + obo:DDO.owl#DDO_0005568 + 346325008 + + + + obo:DDO.owl#DDO_0005568 + antibacterial drugs + + + + obo:DDO.owl#DDO_0005569 + DDO:DDO_0005569 + + + + obo:DDO.owl#DDO_0005569 + 37084008 + + + + obo:DDO.owl#DDO_0005569 + quinolone -class of antibiotic- + + + + obo:DDO.owl#DDO_0005570 + DDO:DDO_0005570 + + + + obo:DDO.owl#DDO_0005570 + 371238005 + + + + obo:DDO.owl#DDO_0005570 + gatifloxacin + + + + obo:DDO.owl#DDO_0005571 + DDO:DDO_0005571 + + + + obo:DDO.owl#DDO_0005571 + 430569007 + + + + obo:DDO.owl#DDO_0005571 + ophthalmic form gatifloxacin + + + + obo:DDO.owl#DDO_0005572 + DDO:DDO_0005572 + + + + obo:DDO.owl#DDO_0005572 + 392394001 + + + + obo:DDO.owl#DDO_0005572 + oral form gatifloxacin + + + + obo:DDO.owl#DDO_0005573 + DDO:DDO_0005573 + + + + obo:DDO.owl#DDO_0005573 + 392395000 + + + + obo:DDO.owl#DDO_0005573 + parenteral form gatifloxacin + + + + obo:DDO.owl#DDO_0005574 + DDO:DDO_0005574 + + + + obo:DDO.owl#DDO_0005574 + 250428009 + + + + obo:DDO.owl#DDO_0005574 + antimicrobial substance + + + + obo:DDO.owl#DDO_0005575 + DDO:DDO_0005575 + + + + obo:DDO.owl#DDO_0005575 + 419241000 + + + + obo:DDO.owl#DDO_0005575 + antibacterial agent + + + + obo:DDO.owl#DDO_0005576 + DDO:DDO_0005576 + + + + obo:DDO.owl#DDO_0005576 + 372722000 + + + + obo:DDO.owl#DDO_0005576 + quinolone -class of antibiotic- + + + + obo:DDO.owl#DDO_0005577 + DDO:DDO_0005577 + + + + obo:DDO.owl#DDO_0005577 + 116349004 + + + + obo:DDO.owl#DDO_0005577 + Gatifloxacin + + + + obo:DDO.owl#DDO_0005578 + DDO:DDO_0005578 + + + + obo:DDO.owl#DDO_0005578 + 96087006 + + + + obo:DDO.owl#DDO_0005578 + levofloxacin + + + + obo:DDO.owl#DDO_0005579 + DDO:DDO_0005579 + + + + obo:DDO.owl#DDO_0005579 + 425560000 + + + + obo:DDO.owl#DDO_0005579 + ophthalmic form levofloxacin + + + + obo:DDO.owl#DDO_0005580 + DDO:DDO_0005580 + + + + obo:DDO.owl#DDO_0005580 + 392396004 + + + + obo:DDO.owl#DDO_0005580 + oral form levofloxacin + + + + obo:DDO.owl#DDO_0005581 + DDO:DDO_0005581 + + + + obo:DDO.owl#DDO_0005581 + 392397008 + + + + obo:DDO.owl#DDO_0005581 + parenteral form levofloxacin + + + + obo:DDO.owl#DDO_0005582 + DDO:DDO_0005582 + + + + obo:DDO.owl#DDO_0005582 + 387552007 + + + + obo:DDO.owl#DDO_0005582 + levofloxacin + + + + obo:DDO.owl#DDO_0005583 + DDO:DDO_0005583 + + + + obo:DDO.owl#DDO_0005583 + 387568001 + + + + obo:DDO.owl#DDO_0005583 + clozapine + + + + obo:DDO.owl#DDO_0005585 + DDO:DDO_0005585 + + + + obo:DDO.owl#DDO_0005585 + obo:DDO.owl#DDO_0005297 + + + + obo:DDO.owl#DDO_0005585 + obo:DDO.owl#DDO_0005297 + + + + obo:DDO.owl#DDO_0005585 + 407312007 + + + + obo:DDO.owl#DDO_0005585 + enzyme inhibitor + + + + obo:DDO.owl#DDO_0005586 + DDO:DDO_0005586 + + + + obo:DDO.owl#DDO_0005586 + 387467008 + + + + obo:DDO.owl#DDO_0005586 + ciclosporin + + + + obo:DDO.owl#DDO_0005587 + DDO:DDO_0005587 + + + + obo:DDO.owl#DDO_0005587 + 426157008 + + + + obo:DDO.owl#DDO_0005587 + cyclosporine modified immediate release + + + + obo:DDO.owl#DDO_0005588 + DDO:DDO_0005588 + + + + obo:DDO.owl#DDO_0005588 + 419501005 + + + + obo:DDO.owl#DDO_0005588 + macrolide immunosuppressant + + + + obo:DDO.owl#DDO_0005589 + DDO:DDO_0005589 + + + + obo:DDO.owl#DDO_0005589 + 387014003 + + + + obo:DDO.owl#DDO_0005589 + sirolimus + + + + obo:DDO.owl#DDO_0005590 + DDO:DDO_0005590 + + + + obo:DDO.owl#DDO_0005590 + 386975001 + + + + obo:DDO.owl#DDO_0005590 + tacrolimus + + + + obo:DDO.owl#DDO_0005591 + DDO:DDO_0005591 + + + + obo:DDO.owl#DDO_0005591 + 413592000 + + + + obo:DDO.owl#DDO_0005591 + atazanavir + + + + obo:DDO.owl#DDO_0005592 + DDO:DDO_0005592 + + + + obo:DDO.owl#DDO_0005592 + 404838006 + + + + obo:DDO.owl#DDO_0005592 + atazanavir sulfate + + + + obo:DDO.owl#DDO_0005593 + DDO:DDO_0005593 + + + + obo:DDO.owl#DDO_0005593 + 423888002 + + + + obo:DDO.owl#DDO_0005593 + darunavir + + + + obo:DDO.owl#DDO_0005594 + DDO:DDO_0005594 + + + + obo:DDO.owl#DDO_0005594 + 428318002 + + + + obo:DDO.owl#DDO_0005594 + darunavir ethanolate + + + + obo:DDO.owl#DDO_0005595 + DDO:DDO_0005595 + + + + obo:DDO.owl#DDO_0005595 + 407017006 + + + + obo:DDO.owl#DDO_0005595 + fosamprenavir + + + + obo:DDO.owl#DDO_0005596 + DDO:DDO_0005596 + + + + obo:DDO.owl#DDO_0005596 + 412393004 + + + + obo:DDO.owl#DDO_0005596 + fosamprenavir calcium + + + + obo:DDO.owl#DDO_0005597 + DDO:DDO_0005597 + + + + obo:DDO.owl#DDO_0005597 + 372529006 + + + + obo:DDO.owl#DDO_0005597 + indinavir + + + + obo:DDO.owl#DDO_0005598 + DDO:DDO_0005598 + + + + obo:DDO.owl#DDO_0005598 + 108696002 + + + + obo:DDO.owl#DDO_0005598 + Indinavir sulfate + + + + obo:DDO.owl#DDO_0005599 + DDO:DDO_0005599 + + + + obo:DDO.owl#DDO_0005599 + 373445001 + + + + obo:DDO.owl#DDO_0005599 + nelfinavir + + + + obo:DDO.owl#DDO_0005600 + DDO:DDO_0005600 + + + + obo:DDO.owl#DDO_0005600 + 108707008 + + + + obo:DDO.owl#DDO_0005600 + Nelfinavir mesylate + + + + obo:DDO.owl#DDO_0005601 + DDO:DDO_0005601 + + + + obo:DDO.owl#DDO_0005601 + 134573001 + + + + obo:DDO.owl#DDO_0005601 + lopinavir+ritonavir + + + + obo:DDO.owl#DDO_0005602 + DDO:DDO_0005602 + + + + obo:DDO.owl#DDO_0005602 + 386896009 + + + + obo:DDO.owl#DDO_0005602 + ritonavir + + + + obo:DDO.owl#DDO_0005603 + DDO:DDO_0005603 + + + + obo:DDO.owl#DDO_0005603 + 372530001 + + + + obo:DDO.owl#DDO_0005603 + saquinavir + + + + obo:DDO.owl#DDO_0005604 + DDO:DDO_0005604 + + + + obo:DDO.owl#DDO_0005604 + 108701009 + + + + obo:DDO.owl#DDO_0005604 + Saquinavir mesylate + + + + obo:DDO.owl#DDO_0005605 + DDO:DDO_0005605 + + + + obo:DDO.owl#DDO_0005605 + 419409009 + + + + obo:DDO.owl#DDO_0005605 + tipranavir + + + + obo:DDO.owl#DDO_0005606 + DDO:DDO_0005606 + + + + obo:DDO.owl#DDO_0005606 + 111064005 + + + + obo:DDO.owl#DDO_0005606 + sulfur compound + + + + obo:DDO.owl#DDO_0005607 + DDO:DDO_0005607 + + + + obo:DDO.owl#DDO_0005607 + 363549008 + + + + obo:DDO.owl#DDO_0005607 + sulfone + + + + obo:DDO.owl#DDO_0005608 + DDO:DDO_0005608 + + + + obo:DDO.owl#DDO_0005608 + 387406002 + + + + obo:DDO.owl#DDO_0005608 + sulfonamide + + + + obo:DDO.owl#DDO_0005609 + DDO:DDO_0005609 + + + + obo:DDO.owl#DDO_0005609 + 43585000 + + + + obo:DDO.owl#DDO_0005609 + sulfonamide diuretic + + + + obo:DDO.owl#DDO_0005610 + DDO:DDO_0005610 + + + + obo:DDO.owl#DDO_0005610 + 387324004 + + + + obo:DDO.owl#DDO_0005610 + chlortalidone + + + + obo:DDO.owl#DDO_0005611 + DDO:DDO_0005611 + + + + obo:DDO.owl#DDO_0005611 + 395923001 + + + + obo:DDO.owl#DDO_0005611 + xipamide + + + + obo:DDO.owl#DDO_0005612 + DDO:DDO_0005612 + + + + obo:DDO.owl#DDO_0005612 + 387123003 + + + + obo:DDO.owl#DDO_0005612 + metolazone + + + + obo:DDO.owl#DDO_0005613 + DDO:DDO_0005613 + + + + obo:DDO.owl#DDO_0005613 + 406772008 + + + + obo:DDO.owl#DDO_0005613 + mefruside + + + + obo:DDO.owl#DDO_0005614 + DDO:DDO_0005614 + + + + obo:DDO.owl#DDO_0005614 + 387419003 + + + + obo:DDO.owl#DDO_0005614 + indapamide + + + + obo:DDO.owl#DDO_0005615 + DDO:DDO_0005615 + + + + obo:DDO.owl#DDO_0005615 + 387475002 + + + + obo:DDO.owl#DDO_0005615 + furosemide + + + + obo:DDO.owl#DDO_0005616 + DDO:DDO_0005616 + + + + obo:DDO.owl#DDO_0005616 + 63203003 + + + + obo:DDO.owl#DDO_0005616 + ethoxyzolamide + + + + obo:DDO.owl#DDO_0005617 + DDO:DDO_0005617 + + + + obo:DDO.owl#DDO_0005617 + 387111009 + + + + obo:DDO.owl#DDO_0005617 + dichlorphenamide + + + + obo:DDO.owl#DDO_0005618 + DDO:DDO_0005618 + + + + obo:DDO.owl#DDO_0005618 + 395940005 + + + + obo:DDO.owl#DDO_0005618 + clopamide + + + + obo:DDO.owl#DDO_0005619 + DDO:DDO_0005619 + + + + obo:DDO.owl#DDO_0005619 + 387498005 + + + + obo:DDO.owl#DDO_0005619 + bumetanide + + + + obo:DDO.owl#DDO_0005620 + DDO:DDO_0005620 + + + + obo:DDO.owl#DDO_0005620 + 63094006 + + + + obo:DDO.owl#DDO_0005620 + anticonvulsant + + + + obo:DDO.owl#DDO_0005621 + DDO:DDO_0005621 + + + + obo:DDO.owl#DDO_0005621 + 15389000 + + + + obo:DDO.owl#DDO_0005621 + hydantoin derivative anticonvulsant + + + + obo:DDO.owl#DDO_0005622 + DDO:DDO_0005622 + + + + obo:DDO.owl#DDO_0005622 + 40556005 + + + + obo:DDO.owl#DDO_0005622 + DPH + + + + obo:DDO.owl#DDO_0005622 + diphenylhydantoin + + + + obo:DDO.owl#DDO_0005622 + hydantoin + + + + obo:DDO.owl#DDO_0005622 + phenylhydantoin + + + + obo:DDO.owl#DDO_0005622 + phenytoin + + + + obo:DDO.owl#DDO_0005623 + DDO:DDO_0005623 + + + + obo:DDO.owl#DDO_0005623 + 392651004 + + + + obo:DDO.owl#DDO_0005623 + oral form phenytoin + + + + obo:DDO.owl#DDO_0005624 + DDO:DDO_0005624 + + + + obo:DDO.owl#DDO_0005624 + 392652006 + + + + obo:DDO.owl#DDO_0005624 + parenteral form phenytoin + + + + obo:DDO.owl#DDO_0005625 + DDO:DDO_0005625 + + + + obo:DDO.owl#DDO_0005625 + 73585007 + + + + obo:DDO.owl#DDO_0005625 + phenytoin sodium + + + + obo:DDO.owl#DDO_0005626 + DDO:DDO_0005626 + + + + obo:DDO.owl#DDO_0005626 + 299979007 + + + + obo:DDO.owl#DDO_0005626 + organic nitrogen compound + + + + obo:DDO.owl#DDO_0005627 + DDO:DDO_0005627 + + + + obo:DDO.owl#DDO_0005627 + 300903003 + + + + obo:DDO.owl#DDO_0005627 + azole + + + + obo:DDO.owl#DDO_0005628 + DDO:DDO_0005628 + + + + obo:DDO.owl#DDO_0005628 + 35098001 + + + + obo:DDO.owl#DDO_0005628 + imidazole + + + + obo:DDO.owl#DDO_0005629 + DDO:DDO_0005629 + + + + obo:DDO.owl#DDO_0005629 + 372659008 + + + + obo:DDO.owl#DDO_0005629 + hydantoin + + + + obo:DDO.owl#DDO_0005630 + DDO:DDO_0005630 + + + + obo:DDO.owl#DDO_0005630 + 439255000 + + + + obo:DDO.owl#DDO_0005630 + hydantoin derivative anticonvulsant + + + + obo:DDO.owl#DDO_0005631 + DDO:DDO_0005631 + + + + obo:DDO.owl#DDO_0005631 + 387220006 + + + + obo:DDO.owl#DDO_0005631 + phenytoin + + + + obo:DDO.owl#DDO_0005632 + DDO:DDO_0005632 + + + + obo:DDO.owl#DDO_0005632 + 706933005 + + + + obo:DDO.owl#DDO_0005632 + free phenytoin + + + + obo:DDO.owl#DDO_0005633 + DDO:DDO_0005633 + + + + obo:DDO.owl#DDO_0005633 + 387416005 + + + + obo:DDO.owl#DDO_0005633 + phenytoin sodium + + + + obo:DDO.owl#DDO_0005634 + DDO:DDO_0005634 + + + + obo:DDO.owl#DDO_0005634 + 426514008 + + + + obo:DDO.owl#DDO_0005634 + phenytoin sodium extended release + + + + obo:DDO.owl#DDO_0005635 + DDO:DDO_0005635 + + + + obo:DDO.owl#DDO_0005635 + 425553006 + + + + obo:DDO.owl#DDO_0005635 + phenytoin sodium prompt release + + + + obo:DDO.owl#DDO_0005636 + DDO:DDO_0005636 + + + + obo:DDO.owl#DDO_0005636 + 395883003 + + + + obo:DDO.owl#DDO_0005636 + GH - Growth hormone + + + + obo:DDO.owl#DDO_0005636 + growth hormone + + + + obo:DDO.owl#DDO_0005636 + human growth hormone + + + + obo:DDO.owl#DDO_0005636 + somatotrophin + + + + obo:DDO.owl#DDO_0005636 + somatotropic hormone + + + + obo:DDO.owl#DDO_0005636 + somatotropin + + + + obo:DDO.owl#DDO_0005636 + somatropin + + + + obo:DDO.owl#DDO_0005637 + DDO:DDO_0005637 + + + + obo:DDO.owl#DDO_0005637 + 395870004 + + + + obo:DDO.owl#DDO_0005637 + sermorelin + + + + obo:DDO.owl#DDO_0005638 + DDO:DDO_0005638 + + + + obo:DDO.owl#DDO_0005638 + 412303008 + + + + obo:DDO.owl#DDO_0005638 + sermorelin acetate + + + + obo:DDO.owl#DDO_0005639 + DDO:DDO_0005639 + + + + obo:DDO.owl#DDO_0005639 + 109052005 + + + + obo:DDO.owl#DDO_0005639 + Somatrem + + + + obo:DDO.owl#DDO_0005640 + DDO:DDO_0005640 + + + + obo:DDO.owl#DDO_0005640 + 395885005 + + + + obo:DDO.owl#DDO_0005640 + somatropin(epr) + + + + obo:DDO.owl#DDO_0005641 + DDO:DDO_0005641 + + + + obo:DDO.owl#DDO_0005641 + 395886006 + + + + obo:DDO.owl#DDO_0005641 + somatropin(rbe) + + + + obo:DDO.owl#DDO_0005642 + DDO:DDO_0005642 + + + + obo:DDO.owl#DDO_0005642 + 395887002 + + + + obo:DDO.owl#DDO_0005642 + somatropin(rmc) + + + + obo:DDO.owl#DDO_0005643 + DDO:DDO_0005643 + + + + obo:DDO.owl#DDO_0005643 + 273943001 + + + + obo:DDO.owl#DDO_0005643 + antipellagra factor + + + + obo:DDO.owl#DDO_0005643 + nicotinic acid + + + + obo:DDO.owl#DDO_0005643 + niacin + + + + obo:DDO.owl#DDO_0005644 + DDO:DDO_0005644 + + + + obo:DDO.owl#DDO_0005644 + 300067003 + + + + obo:DDO.owl#DDO_0005644 + pyridine and derivatives + + + + obo:DDO.owl#DDO_0005645 + DDO:DDO_0005645 + + + + obo:DDO.owl#DDO_0005645 + 65025001 + + + + obo:DDO.owl#DDO_0005645 + pyridine + + + + obo:DDO.owl#DDO_0005646 + DDO:DDO_0005646 + + + + obo:DDO.owl#DDO_0005646 + 370179008 + + + + obo:DDO.owl#DDO_0005646 + choline salicylate product + + + + obo:DDO.owl#DDO_0005647 + DDO:DDO_0005647 + + + + obo:DDO.owl#DDO_0005647 + 420840001 + + + + obo:DDO.owl#DDO_0005647 + choline salicylate+glycerol + + + + obo:DDO.owl#DDO_0005648 + DDO:DDO_0005648 + + + + obo:DDO.owl#DDO_0005648 + 431423000 + + + + obo:DDO.owl#DDO_0005648 + oral form choline salicylate + + + + obo:DDO.owl#DDO_0005649 + DDO:DDO_0005649 + + + + obo:DDO.owl#DDO_0005649 + 430516006 + + + + obo:DDO.owl#DDO_0005649 + otic form choline salicylate + + + + obo:DDO.owl#DDO_0005650 + DDO:DDO_0005650 + + + + obo:DDO.owl#DDO_0005650 + 373231005 + + + + obo:DDO.owl#DDO_0005650 + musculoskeletal system agent + + + + obo:DDO.owl#DDO_0005651 + DDO:DDO_0005651 + + + + obo:DDO.owl#DDO_0005651 + 372888006 + + + + obo:DDO.owl#DDO_0005651 + anti-rheumatic agent + + + + obo:DDO.owl#DDO_0005652 + DDO:DDO_0005652 + + + + obo:DDO.owl#DDO_0005652 + 373283003 + + + + obo:DDO.owl#DDO_0005652 + anti-inflammatory agent + + + + obo:DDO.owl#DDO_0005653 + DDO:DDO_0005653 + + + + obo:DDO.owl#DDO_0005653 + 372665008 + + + + obo:DDO.owl#DDO_0005653 + non-steroidal anti-inflammatory agent + + + + obo:DDO.owl#DDO_0005654 + DDO:DDO_0005654 + + + + obo:DDO.owl#DDO_0005654 + 255637000 + + + + obo:DDO.owl#DDO_0005654 + salicylate + + + + obo:DDO.owl#DDO_0005655 + DDO:DDO_0005655 + + + + obo:DDO.owl#DDO_0005655 + 65302009 + + + + obo:DDO.owl#DDO_0005655 + choline salicylate + + + + obo:DDO.owl#DDO_0005656 + DDO:DDO_0005656 + + + + obo:DDO.owl#DDO_0005656 + 53009005 + + + + obo:DDO.owl#DDO_0005656 + C0722390 + + + + obo:DDO.owl#DDO_0005656 + analgesic + + + + obo:DDO.owl#DDO_0005657 + DDO:DDO_0005657 + + + + obo:DDO.owl#DDO_0005657 + 330901000 + + + + obo:DDO.owl#DDO_0005657 + anti-inflammatory preparations + + + + obo:DDO.owl#DDO_0005658 + DDO:DDO_0005658 + + + + obo:DDO.owl#DDO_0005658 + 16403005 + + + + obo:DDO.owl#DDO_0005658 + non-steroidal anti-inflammatory agent + + + + obo:DDO.owl#DDO_0005659 + DDO:DDO_0005659 + + + + obo:DDO.owl#DDO_0005659 + 350312004 + + + + obo:DDO.owl#DDO_0005659 + salicylate product + + + + obo:DDO.owl#DDO_0005660 + DDO:DDO_0005660 + + + + obo:DDO.owl#DDO_0005660 + 370180006 + + + + obo:DDO.owl#DDO_0005660 + magnesium salicylate product + + + + obo:DDO.owl#DDO_0005661 + DDO:DDO_0005661 + + + + obo:DDO.owl#DDO_0005661 + 412475001 + + + + obo:DDO.owl#DDO_0005661 + phenyltoloxamine + magnesium salicylate + + + + obo:DDO.owl#DDO_0005662 + DDO:DDO_0005662 + + + + obo:DDO.owl#DDO_0005662 + 322208004 + + + + obo:DDO.owl#DDO_0005662 + non-opioid analgesics + + + + obo:DDO.owl#DDO_0005663 + DDO:DDO_0005663 + + + + obo:DDO.owl#DDO_0005663 + 363562007 + + + + obo:DDO.owl#DDO_0005663 + analgesic AND antipyretic product + + + + obo:DDO.owl#DDO_0005664 + DDO:DDO_0005664 + + + + obo:DDO.owl#DDO_0005664 + 49399009 + + + + obo:DDO.owl#DDO_0005664 + magnesium salicylate + + + + obo:DDO.owl#DDO_0005665 + DDO:DDO_0005665 + + + + obo:DDO.owl#DDO_0005665 + obo:DDO.owl#DDO_0005656 + + + + obo:DDO.owl#DDO_0005665 + obo:DDO.owl#DDO_0005656 + + + + obo:DDO.owl#DDO_0005665 + 373265006 + + + + obo:DDO.owl#DDO_0005665 + analgesic + + + + obo:DDO.owl#DDO_0005666 + DDO:DDO_0005666 + + + + obo:DDO.owl#DDO_0005666 + 373216001 + + + + obo:DDO.owl#DDO_0005666 + non-opioid analgesic + + + + obo:DDO.owl#DDO_0005667 + DDO:DDO_0005667 + + + + obo:DDO.owl#DDO_0005667 + 48614001 + + + + obo:DDO.owl#DDO_0005667 + Clobetasol + + + + obo:DDO.owl#DDO_0005668 + DDO:DDO_0005668 + + + + obo:DDO.owl#DDO_0005668 + 120621007 + + + + obo:DDO.owl#DDO_0005668 + Clobetasol propionate topical preparation + + + + obo:DDO.owl#DDO_0005669 + DDO:DDO_0005669 + + + + obo:DDO.owl#DDO_0005669 + 346373003 + + + + obo:DDO.owl#DDO_0005669 + Clobetasol propionate+neomycin sulfate+Nystatin + + + + obo:DDO.owl#DDO_0005670 + DDO:DDO_0005670 + + + + obo:DDO.owl#DDO_0005670 + 22091006 + + + + obo:DDO.owl#DDO_0005670 + hormone preparation + + + + obo:DDO.owl#DDO_0005671 + DDO:DDO_0005671 + + + + obo:DDO.owl#DDO_0005671 + 346674004 + + + + obo:DDO.owl#DDO_0005671 + sex hormone product + + + + obo:DDO.owl#DDO_0005672 + DDO:DDO_0005672 + + + + obo:DDO.owl#DDO_0005672 + 61946003 + + + + obo:DDO.owl#DDO_0005672 + estrogenic preparation + + + + obo:DDO.owl#DDO_0005673 + DDO:DDO_0005673 + + + + obo:DDO.owl#DDO_0005673 + 16832004 + + + + obo:DDO.owl#DDO_0005673 + conjugated estrogen preparation + + + + obo:DDO.owl#DDO_0005674 + DDO:DDO_0005674 + + + + obo:DDO.owl#DDO_0005674 + 412132000 + + + + obo:DDO.owl#DDO_0005674 + conjugated estrogen + medroxyprogesterone + + + + obo:DDO.owl#DDO_0005675 + DDO:DDO_0005675 + + + + obo:DDO.owl#DDO_0005675 + 425245004 + + + + obo:DDO.owl#DDO_0005675 + conjugated estrogens+norgestrel + + + + obo:DDO.owl#DDO_0005676 + DDO:DDO_0005676 + + + + obo:DDO.owl#DDO_0005676 + 20249007 + + + + obo:DDO.owl#DDO_0005676 + Progestin preparation + + + + obo:DDO.owl#DDO_0005677 + DDO:DDO_0005677 + + + + obo:DDO.owl#DDO_0005677 + 36621009 + + + + obo:DDO.owl#DDO_0005677 + medroxyprogesterone preparation + + + + obo:DDO.owl#DDO_0005678 + DDO:DDO_0005678 + + + + obo:DDO.owl#DDO_0005678 + 412132000 + + + + obo:DDO.owl#DDO_0005678 + conjugated estrogen + medroxyprogesterone + + + + obo:DDO.owl#DDO_0005679 + DDO:DDO_0005679 + + + + obo:DDO.owl#DDO_0005679 + 425045009 + + + + obo:DDO.owl#DDO_0005679 + estradiol+medroxyprogesterone + + + + obo:DDO.owl#DDO_0005680 + DDO:DDO_0005680 + + + + obo:DDO.owl#DDO_0005680 + 27707001 + + + + obo:DDO.owl#DDO_0005680 + medroxyprogesterone acetate preparation + + + + obo:DDO.owl#DDO_0005681 + DDO:DDO_0005681 + + + + obo:DDO.owl#DDO_0005681 + 377397008 + + + + obo:DDO.owl#DDO_0005681 + estrogens, conjugated+estrogens, esterified+medroxyprogesterone acetate 0.625mg/0.625mg/5mg tablet + + + + obo:DDO.owl#DDO_0005682 + DDO:DDO_0005682 + + + + obo:DDO.owl#DDO_0005682 + 412242006 + + + + obo:DDO.owl#DDO_0005682 + medroxyprogesterone acetate + estradiol cyprionate + + + + obo:DDO.owl#DDO_0005683 + DDO:DDO_0005683 + + + + obo:DDO.owl#DDO_0005683 + 377393007 + + + + obo:DDO.owl#DDO_0005683 + estradiol cypionate+medroxyprogesterone acetate 5mg/25mg injection + + + + obo:DDO.owl#DDO_0005684 + DDO:DDO_0005684 + + + + obo:DDO.owl#DDO_0005684 + 350372007 + + + + obo:DDO.owl#DDO_0005684 + oral form medroxyprogesterone + + + + obo:DDO.owl#DDO_0005685 + DDO:DDO_0005685 + + + + obo:DDO.owl#DDO_0005685 + 350375009 + + + + obo:DDO.owl#DDO_0005685 + parenteral form medroxyprogesterone + + + + obo:DDO.owl#DDO_0005686 + DDO:DDO_0005686 + + + + obo:DDO.owl#DDO_0005686 + 377393007 + + + + obo:DDO.owl#DDO_0005686 + estradiol cypionate+medroxyprogesterone acetate 5mg/25mg injection + + + + obo:DDO.owl#DDO_0005687 + DDO:DDO_0005687 + + + + obo:DDO.owl#DDO_0005687 + 373459008 + + + + obo:DDO.owl#DDO_0005687 + enzyme agent + + + + obo:DDO.owl#DDO_0005688 + DDO:DDO_0005688 + + + + obo:DDO.owl#DDO_0005688 + 88878007 + + + + obo:DDO.owl#DDO_0005688 + protein + + + + obo:DDO.owl#DDO_0005689 + DDO:DDO_0005689 + + + + obo:DDO.owl#DDO_0005689 + 90668006 + + + + obo:DDO.owl#DDO_0005689 + enzyme + + + + obo:DDO.owl#DDO_0005690 + DDO:DDO_0005690 + + + + obo:DDO.owl#DDO_0005690 + 74628008 + + + + obo:DDO.owl#DDO_0005690 + hydrolase + + + + obo:DDO.owl#DDO_0005691 + DDO:DDO_0005691 + + + + obo:DDO.owl#DDO_0005691 + 40789008 + + + + obo:DDO.owl#DDO_0005691 + adrenocorticotropic hormone + + + + obo:DDO.owl#DDO_0005692 + DDO:DDO_0005692 + + + + obo:DDO.owl#DDO_0005692 + 420149003 + + + + obo:DDO.owl#DDO_0005692 + corticotropic agent + + + + obo:DDO.owl#DDO_0005693 + DDO:DDO_0005693 + + + + obo:DDO.owl#DDO_0005693 + 126187000 + + + + obo:DDO.owl#DDO_0005693 + corticotropin zinc hydroxide + + + + obo:DDO.owl#DDO_0005694 + DDO:DDO_0005694 + + + + obo:DDO.owl#DDO_0005694 + 96363002 + + + + obo:DDO.owl#DDO_0005694 + tetracosactide + + + + obo:DDO.owl#DDO_0005695 + DDO:DDO_0005695 + + + + obo:DDO.owl#DDO_0005695 + 105818001 + + + + obo:DDO.owl#DDO_0005695 + sulfur AND/OR sulfur compound + + + + obo:DDO.owl#DDO_0005696 + DDO:DDO_0005696 + + + + obo:DDO.owl#DDO_0005696 + 425646006 + + + + obo:DDO.owl#DDO_0005696 + cosyntropin acetate + + + + obo:DDO.owl#DDO_0005697 + DDO:DDO_0005697 + + + + obo:DDO.owl#DDO_0005697 + 707074004 + + + + obo:DDO.owl#DDO_0005697 + corticotropin, big fragment + + + + obo:DDO.owl#DDO_0005698 + DDO:DDO_0005698 + + + + obo:DDO.owl#DDO_0005698 + 264303006 + + + + obo:DDO.owl#DDO_0005698 + ectopic ACTH + + + + obo:DDO.owl#DDO_0005699 + DDO:DDO_0005699 + + + + obo:DDO.owl#DDO_0005699 + 272524002 + + + + obo:DDO.owl#DDO_0005699 + analyte + + + + obo:DDO.owl#DDO_0005700 + DDO:DDO_0005700 + + + + obo:DDO.owl#DDO_0005700 + 259089000 + + + + obo:DDO.owl#DDO_0005700 + biochemical analyte + + + + obo:DDO.owl#DDO_0005701 + DDO:DDO_0005701 + + + + obo:DDO.owl#DDO_0005701 + 259667003 + + + + obo:DDO.owl#DDO_0005701 + biochemical analyte functional group + + + + obo:DDO.owl#DDO_0005702 + DDO:DDO_0005702 + + + + obo:DDO.owl#DDO_0005702 + 259672007 + + + + obo:DDO.owl#DDO_0005702 + biochemical tumor marker + + + + obo:DDO.owl#DDO_0005703 + DDO:DDO_0005703 + + + + obo:DDO.owl#DDO_0005703 + 70354003 + + + + obo:DDO.owl#DDO_0005703 + polypeptide + + + + obo:DDO.owl#DDO_0005704 + DDO:DDO_0005704 + + + + obo:DDO.owl#DDO_0005704 + 37276002 + + + + obo:DDO.owl#DDO_0005704 + polypeptide hormone + + + + obo:DDO.owl#DDO_0005705 + DDO:DDO_0005705 + + + + obo:DDO.owl#DDO_0005705 + 111150008 + + + + obo:DDO.owl#DDO_0005705 + cortisone preparation + + + + obo:DDO.owl#DDO_0005706 + DDO:DDO_0005706 + + + + obo:DDO.owl#DDO_0005706 + 33236006 + + + + obo:DDO.owl#DDO_0005706 + cortisone acetate preparation + + + + obo:DDO.owl#DDO_0005707 + DDO:DDO_0005707 + + + + obo:DDO.owl#DDO_0005707 + 58760003 + + + + obo:DDO.owl#DDO_0005707 + antimetabolite + + + + obo:DDO.owl#DDO_0005708 + DDO:DDO_0005708 + + + + obo:DDO.owl#DDO_0005708 + 108812001 + + + + obo:DDO.owl#DDO_0005708 + pyrimidine analog + + + + obo:DDO.owl#DDO_0005709 + DDO:DDO_0005709 + + + + obo:DDO.owl#DDO_0005709 + 420517007 + + + + obo:DDO.owl#DDO_0005709 + decitabine + + + + obo:DDO.owl#DDO_0005710 + DDO:DDO_0005710 + + + + obo:DDO.owl#DDO_0005710 + 420127009 + + + + obo:DDO.owl#DDO_0005710 + synthetic cytotoxic triazine derivative + + + + obo:DDO.owl#DDO_0005711 + DDO:DDO_0005711 + + + + obo:DDO.owl#DDO_0005711 + 420759005 + + + + obo:DDO.owl#DDO_0005711 + decitabine + + + + obo:DDO.owl#DDO_0005712 + DDO:DDO_0005712 + + + + obo:DDO.owl#DDO_0005712 + 421479006 + + + + obo:DDO.owl#DDO_0005712 + triazine derivative + + + + obo:DDO.owl#DDO_0005713 + DDO:DDO_0005713 + + + + obo:DDO.owl#DDO_0005713 + 301457005 + + + + obo:DDO.owl#DDO_0005713 + amines and their derivatives + + + + obo:DDO.owl#DDO_0005714 + DDO:DDO_0005714 + + + + obo:DDO.owl#DDO_0005714 + 43201005 + + + + obo:DDO.owl#DDO_0005714 + amine + + + + obo:DDO.owl#DDO_0005715 + DDO:DDO_0005715 + + + + obo:DDO.owl#DDO_0005715 + 415130003 + + + + obo:DDO.owl#DDO_0005715 + polyamine + + + + obo:DDO.owl#DDO_0005716 + DDO:DDO_0005716 + + + + obo:DDO.owl#DDO_0005716 + 373526007 + + + + obo:DDO.owl#DDO_0005716 + cytotoxic agent + + + + obo:DDO.owl#DDO_0005717 + DDO:DDO_0005717 + + + + obo:DDO.owl#DDO_0005717 + 373729002 + + + + obo:DDO.owl#DDO_0005717 + monoclonal antibody agent + + + + obo:DDO.owl#DDO_0005718 + DDO:DDO_0005718 + + + + obo:DDO.owl#DDO_0005718 + 372647009 + + + + obo:DDO.owl#DDO_0005718 + murine-human monoclonal IgG antibody + + + + obo:DDO.owl#DDO_0005719 + DDO:DDO_0005719 + + + + obo:DDO.owl#DDO_0005719 + 386977009 + + + + obo:DDO.owl#DDO_0005719 + daclizumab + + + + obo:DDO.owl#DDO_0005720 + DDO:DDO_0005720 + + + + obo:DDO.owl#DDO_0005720 + 68498002 + + + + obo:DDO.owl#DDO_0005720 + antibody + + + + obo:DDO.owl#DDO_0005721 + DDO:DDO_0005721 + + + + obo:DDO.owl#DDO_0005721 + 49616005 + + + + obo:DDO.owl#DDO_0005721 + monoclonal antibody + + + + obo:DDO.owl#DDO_0005722 + DDO:DDO_0005722 + + + + obo:DDO.owl#DDO_0005722 + 106181007 + + + + obo:DDO.owl#DDO_0005722 + immunologic substance + + + + obo:DDO.owl#DDO_0005723 + DDO:DDO_0005723 + + + + obo:DDO.owl#DDO_0005723 + 373244000 + + + + obo:DDO.owl#DDO_0005723 + immunologic agent + + + + obo:DDO.owl#DDO_0005724 + DDO:DDO_0005724 + + + + obo:DDO.owl#DDO_0005724 + 372823004 + + + + obo:DDO.owl#DDO_0005724 + immunosuppressant + + + + obo:DDO.owl#DDO_0005725 + DDO:DDO_0005725 + + + + obo:DDO.owl#DDO_0005725 + 52215008 + + + + obo:DDO.owl#DDO_0005725 + desonide + + + + obo:DDO.owl#DDO_0005726 + DDO:DDO_0005726 + + + + obo:DDO.owl#DDO_0005726 + 120623005 + + + + obo:DDO.owl#DDO_0005726 + desonide topical preparation + + + + obo:DDO.owl#DDO_0005727 + DDO:DDO_0005727 + + + + obo:DDO.owl#DDO_0005727 + 430550002 + + + + obo:DDO.owl#DDO_0005727 + otic form desonide + + + + obo:DDO.owl#DDO_0005728 + DDO:DDO_0005728 + + + + obo:DDO.owl#DDO_0005728 + 7561000 + + + + obo:DDO.owl#DDO_0005728 + dexamethasone preparation + + + + obo:DDO.owl#DDO_0005729 + DDO:DDO_0005729 + + + + obo:DDO.owl#DDO_0005729 + 81457006 + + + + obo:DDO.owl#DDO_0005729 + desoximetasone + + + + obo:DDO.owl#DDO_0005730 + DDO:DDO_0005730 + + + + obo:DDO.owl#DDO_0005730 + 421586001 + + + + obo:DDO.owl#DDO_0005730 + desoximetasone + salicylic acid + + + + obo:DDO.owl#DDO_0005731 + DDO:DDO_0005731 + + + + obo:DDO.owl#DDO_0005731 + 120625003 + + + + obo:DDO.owl#DDO_0005731 + desoximetasone topical preparation + + + + obo:DDO.owl#DDO_0005732 + DDO:DDO_0005732 + + + + obo:DDO.owl#DDO_0005732 + 360204007 + + + + obo:DDO.owl#DDO_0005732 + opiate + + + + obo:DDO.owl#DDO_0005733 + DDO:DDO_0005733 + + + + obo:DDO.owl#DDO_0005733 + 350297008 + + + + obo:DDO.owl#DDO_0005733 + Morphinan opioid + + + + obo:DDO.owl#DDO_0005734 + DDO:DDO_0005734 + + + + obo:DDO.owl#DDO_0005734 + 349990002 + + + + obo:DDO.owl#DDO_0005734 + Morphinan cough suppressant + + + + obo:DDO.owl#DDO_0005735 + DDO:DDO_0005735 + + + + obo:DDO.owl#DDO_0005735 + 2016004 + + + + obo:DDO.owl#DDO_0005735 + dextromethorphan + + + + obo:DDO.owl#DDO_0005736 + DDO:DDO_0005736 + + + + obo:DDO.owl#DDO_0005736 + 42374009 + + + + obo:DDO.owl#DDO_0005736 + dextromethorphan hydrobromide + + + + obo:DDO.owl#DDO_0005737 + DDO:DDO_0005737 + + + + obo:DDO.owl#DDO_0005737 + 320072000 + + + + obo:DDO.owl#DDO_0005737 + respiratory drugs + + + + obo:DDO.owl#DDO_0005738 + DDO:DDO_0005738 + + + + obo:DDO.owl#DDO_0005738 + 349988003 + + + + obo:DDO.owl#DDO_0005738 + cough/decongestant preparation + + + + obo:DDO.owl#DDO_0005739 + DDO:DDO_0005739 + + + + obo:DDO.owl#DDO_0005739 + 59751001 + + + + obo:DDO.owl#DDO_0005739 + antitussive agent + + + + obo:DDO.owl#DDO_0005740 + DDO:DDO_0005740 + + + + obo:DDO.owl#DDO_0005740 + 387114001 + + + + obo:DDO.owl#DDO_0005740 + dextromethorphan + + + + obo:DDO.owl#DDO_0005741 + DDO:DDO_0005741 + + + + obo:DDO.owl#DDO_0005741 + 387237004 + + + + obo:DDO.owl#DDO_0005741 + dextromethorphan hydrobromide + + + + obo:DDO.owl#DDO_0005742 + DDO:DDO_0005742 + + + + obo:DDO.owl#DDO_0005742 + 426064007 + + + + obo:DDO.owl#DDO_0005742 + dextromethorphan polistirex + + + + obo:DDO.owl#DDO_0005743 + DDO:DDO_0005743 + + + + obo:DDO.owl#DDO_0005743 + 373230006 + + + + obo:DDO.owl#DDO_0005743 + cough AND/OR decongestant agent + + + + obo:DDO.owl#DDO_0005744 + DDO:DDO_0005744 + + + + obo:DDO.owl#DDO_0005744 + 372791003 + + + + obo:DDO.owl#DDO_0005744 + antitussive agent + + + + obo:DDO.owl#DDO_0005745 + DDO:DDO_0005745 + + + + obo:DDO.owl#DDO_0005745 + 420001007 + + + + obo:DDO.owl#DDO_0005745 + morphinan cough suppressant + + + + obo:DDO.owl#DDO_0005746 + DDO:DDO_0005746 + + + + obo:DDO.owl#DDO_0005746 + 372806008 + + + + obo:DDO.owl#DDO_0005746 + antihistamine + + + + obo:DDO.owl#DDO_0005747 + DDO:DDO_0005747 + + + + obo:DDO.owl#DDO_0005747 + 372625009 + + + + obo:DDO.owl#DDO_0005747 + sedating antihistamine + + + + obo:DDO.owl#DDO_0005748 + DDO:DDO_0005748 + + + + obo:DDO.owl#DDO_0005748 + 372871004 + + + + obo:DDO.owl#DDO_0005748 + promethazine + + + + obo:DDO.owl#DDO_0005749 + DDO:DDO_0005749 + + + + obo:DDO.owl#DDO_0005749 + 14905007 + + + + obo:DDO.owl#DDO_0005749 + promethazine hydrochloride + + + + obo:DDO.owl#DDO_0005750 + DDO:DDO_0005750 + + + + obo:DDO.owl#DDO_0005750 + 395846003 + + + + obo:DDO.owl#DDO_0005750 + promethazine theoclate + + + + obo:DDO.owl#DDO_0005751 + DDO:DDO_0005751 + + + + obo:DDO.owl#DDO_0005751 + 135394005 + + + + obo:DDO.owl#DDO_0005751 + antiallergenic drugs + + + + obo:DDO.owl#DDO_0005752 + DDO:DDO_0005752 + + + + obo:DDO.owl#DDO_0005752 + 6425004 + + + + obo:DDO.owl#DDO_0005752 + Antihistamine + + + + obo:DDO.owl#DDO_0005753 + DDO:DDO_0005753 + + + + obo:DDO.owl#DDO_0005753 + 349957002 + + + + obo:DDO.owl#DDO_0005753 + sedating antihistamine + + + + obo:DDO.owl#DDO_0005754 + DDO:DDO_0005754 + + + + obo:DDO.owl#DDO_0005754 + 8372007 + + + + obo:DDO.owl#DDO_0005754 + C0033405 + + + + obo:DDO.owl#DDO_0005754 + promethazine + + + + obo:DDO.owl#DDO_0005755 + DDO:DDO_0005755 + + + + obo:DDO.owl#DDO_0005755 + 349964000 + + + + obo:DDO.owl#DDO_0005755 + oral form promethazine + + + + obo:DDO.owl#DDO_0005756 + DDO:DDO_0005756 + + + + obo:DDO.owl#DDO_0005756 + 349965004 + + + + obo:DDO.owl#DDO_0005756 + parenteral form promethazine + + + + obo:DDO.owl#DDO_0005757 + DDO:DDO_0005757 + + + + obo:DDO.owl#DDO_0005757 + 386606004 + + + + obo:DDO.owl#DDO_0005757 + rectal promethazine + + + + obo:DDO.owl#DDO_0005758 + DDO:DDO_0005758 + + + + obo:DDO.owl#DDO_0005758 + 15222008 + + + + obo:DDO.owl#DDO_0005758 + enalapril + + + + obo:DDO.owl#DDO_0005759 + DDO:DDO_0005759 + + + + obo:DDO.owl#DDO_0005759 + 3046005 + + + + obo:DDO.owl#DDO_0005759 + enalapril maleate + + + + obo:DDO.owl#DDO_0005760 + DDO:DDO_0005760 + + + + obo:DDO.owl#DDO_0005760 + 299987008 + + + + obo:DDO.owl#DDO_0005760 + amides and derivatives + + + + obo:DDO.owl#DDO_0005761 + DDO:DDO_0005761 + + + + obo:DDO.owl#DDO_0005761 + 415664003 + + + + obo:DDO.owl#DDO_0005761 + substituted amide + + + + obo:DDO.owl#DDO_0005762 + DDO:DDO_0005762 + + + + obo:DDO.owl#DDO_0005762 + 52642002 + + + + obo:DDO.owl#DDO_0005762 + peptide + + + + obo:DDO.owl#DDO_0005763 + DDO:DDO_0005763 + + + + obo:DDO.owl#DDO_0005763 + 372658000 + + + + obo:DDO.owl#DDO_0005763 + enalapril + + + + obo:DDO.owl#DDO_0005764 + DDO:DDO_0005764 + + + + obo:DDO.owl#DDO_0005764 + 387165009 + + + + obo:DDO.owl#DDO_0005764 + enalapril maleate + + + + obo:DDO.owl#DDO_0005765 + DDO:DDO_0005765 + + + + obo:DDO.owl#DDO_0005765 + 67507000 + + + + obo:DDO.owl#DDO_0005765 + antiarrhythmic drug + + + + obo:DDO.owl#DDO_0005766 + DDO:DDO_0005766 + + + + obo:DDO.owl#DDO_0005766 + 49590009 + + + + obo:DDO.owl#DDO_0005766 + Class I antiarrhythmic drug + + + + obo:DDO.owl#DDO_0005767 + DDO:DDO_0005767 + + + + obo:DDO.owl#DDO_0005767 + 86317005 + + + + obo:DDO.owl#DDO_0005767 + Class Ic antiarrhythmic drug + + + + obo:DDO.owl#DDO_0005768 + DDO:DDO_0005768 + + + + obo:DDO.owl#DDO_0005768 + 46479001 + + + + obo:DDO.owl#DDO_0005768 + encainide + + + + obo:DDO.owl#DDO_0005769 + DDO:DDO_0005769 + + + + obo:DDO.owl#DDO_0005769 + 372813008 + + + + obo:DDO.owl#DDO_0005769 + antiarrhythmic agent + + + + obo:DDO.owl#DDO_0005770 + DDO:DDO_0005770 + + + + obo:DDO.owl#DDO_0005770 + 373260001 + + + + obo:DDO.owl#DDO_0005770 + class I antiarrhythmic agent + + + + obo:DDO.owl#DDO_0005771 + DDO:DDO_0005771 + + + + obo:DDO.owl#DDO_0005771 + 373290008 + + + + obo:DDO.owl#DDO_0005771 + class Ic antiarrhythmic agent + + + + obo:DDO.owl#DDO_0005772 + DDO:DDO_0005772 + + + + obo:DDO.owl#DDO_0005772 + 372749000 + + + + obo:DDO.owl#DDO_0005772 + encainide + + + + obo:DDO.owl#DDO_0005773 + DDO:DDO_0005773 + + + + obo:DDO.owl#DDO_0005773 + 81017004 + + + + obo:DDO.owl#DDO_0005773 + encainide hydrochloride + + + + obo:DDO.owl#DDO_0005774 + DDO:DDO_0005774 + + + + obo:DDO.owl#DDO_0005774 + 36795002 + + + + obo:DDO.owl#DDO_0005774 + estropipate preparation + + + + obo:DDO.owl#DDO_0005775 + DDO:DDO_0005775 + + + + obo:DDO.owl#DDO_0005775 + 431035005 + + + + obo:DDO.owl#DDO_0005775 + oral form estropipate + + + + obo:DDO.owl#DDO_0005776 + DDO:DDO_0005776 + + + + obo:DDO.owl#DDO_0005776 + 430022008 + + + + obo:DDO.owl#DDO_0005776 + vaginal form estropipate + + + + obo:DDO.owl#DDO_0005777 + DDO:DDO_0005777 + + + + obo:DDO.owl#DDO_0005777 + 126175007 + + + + obo:DDO.owl#DDO_0005777 + anabolic steroid preparation + + + + obo:DDO.owl#DDO_0005778 + DDO:DDO_0005778 + + + + obo:DDO.owl#DDO_0005778 + 109033004 + + + + obo:DDO.owl#DDO_0005778 + testosterone preparation + + + + obo:DDO.owl#DDO_0005779 + DDO:DDO_0005779 + + + + obo:DDO.owl#DDO_0005779 + 42348003 + + + + obo:DDO.owl#DDO_0005779 + methyltestosterone preparation + + + + obo:DDO.owl#DDO_0005780 + DDO:DDO_0005780 + + + + obo:DDO.owl#DDO_0005780 + 412181003 + + + + obo:DDO.owl#DDO_0005780 + estrogens, esterified + methyltestosterone + + + + obo:DDO.owl#DDO_0005781 + DDO:DDO_0005781 + + + + obo:DDO.owl#DDO_0005781 + 326664007 + + + + obo:DDO.owl#DDO_0005781 + yohimbine/pemoline/methyltestosterone + + + + obo:DDO.owl#DDO_0005782 + DDO:DDO_0005782 + + + + obo:DDO.owl#DDO_0005782 + 19768003 + + + + obo:DDO.owl#DDO_0005782 + alkylating agent + + + + obo:DDO.owl#DDO_0005783 + DDO:DDO_0005783 + + + + obo:DDO.owl#DDO_0005783 + 349842005 + + + + obo:DDO.owl#DDO_0005783 + nitrogen mustard derivative + + + + obo:DDO.owl#DDO_0005784 + DDO:DDO_0005784 + + + + obo:DDO.owl#DDO_0005784 + 108768000 + + + + obo:DDO.owl#DDO_0005784 + estramustine + + + + obo:DDO.owl#DDO_0005785 + DDO:DDO_0005785 + + + + obo:DDO.owl#DDO_0005785 + 372609004 + + + + obo:DDO.owl#DDO_0005785 + nitrogen mustard derivative + + + + obo:DDO.owl#DDO_0005786 + DDO:DDO_0005786 + + + + obo:DDO.owl#DDO_0005786 + 386909008 + + + + obo:DDO.owl#DDO_0005786 + estramustine + + + + obo:DDO.owl#DDO_0005787 + DDO:DDO_0005787 + + + + obo:DDO.owl#DDO_0005787 + 326745006 + + + + obo:DDO.owl#DDO_0005787 + estramustine phosphate + + + + obo:DDO.owl#DDO_0005788 + DDO:DDO_0005788 + + + + obo:DDO.owl#DDO_0005788 + 372669002 + + + + obo:DDO.owl#DDO_0005788 + alkylating agent + + + + obo:DDO.owl#DDO_0005789 + DDO:DDO_0005789 + + + + obo:DDO.owl#DDO_0005789 + 81947000 + + + + obo:DDO.owl#DDO_0005789 + ethacrynic acid + + + + obo:DDO.owl#DDO_0005790 + DDO:DDO_0005790 + + + + obo:DDO.owl#DDO_0005790 + 372691009 + + + + obo:DDO.owl#DDO_0005790 + loop diuretic + + + + obo:DDO.owl#DDO_0005791 + DDO:DDO_0005791 + + + + obo:DDO.owl#DDO_0005791 + 373536004 + + + + obo:DDO.owl#DDO_0005791 + ethacrynic acid + + + + obo:DDO.owl#DDO_0005792 + DDO:DDO_0005792 + + + + obo:DDO.owl#DDO_0005792 + 75341007 + + + + obo:DDO.owl#DDO_0005792 + ethacrynate sodium + + + + obo:DDO.owl#DDO_0005793 + DDO:DDO_0005793 + + + + obo:DDO.owl#DDO_0005793 + 29051009 + + + + obo:DDO.owl#DDO_0005793 + loop diuretic + + + + obo:DDO.owl#DDO_0005794 + DDO:DDO_0005794 + + + + obo:DDO.owl#DDO_0005794 + 81947000 + + + + obo:DDO.owl#DDO_0005794 + ethacrynic acid + + + + obo:DDO.owl#DDO_0005795 + DDO:DDO_0005795 + + + + obo:DDO.owl#DDO_0005795 + 415742001 + + + + obo:DDO.owl#DDO_0005795 + transferase inhibitor + + + + obo:DDO.owl#DDO_0005796 + DDO:DDO_0005796 + + + + obo:DDO.owl#DDO_0005796 + 426432005 + + + + obo:DDO.owl#DDO_0005796 + phosphotransferase inhibitor + + + + obo:DDO.owl#DDO_0005797 + DDO:DDO_0005797 + + + + obo:DDO.owl#DDO_0005797 + 426265004 + + + + obo:DDO.owl#DDO_0005797 + protein kinase inhibitor + + + + obo:DDO.owl#DDO_0005798 + DDO:DDO_0005798 + + + + obo:DDO.owl#DDO_0005798 + 428698007 + + + + obo:DDO.owl#DDO_0005798 + everolimus + + + + obo:DDO.owl#DDO_0005799 + DDO:DDO_0005799 + + + + obo:DDO.owl#DDO_0005799 + 350062001 + + + + obo:DDO.owl#DDO_0005799 + xanthine oxidase inhibitor + + + + obo:DDO.owl#DDO_0005800 + DDO:DDO_0005800 + + + + obo:DDO.owl#DDO_0005800 + 441610003 + + + + obo:DDO.owl#DDO_0005800 + febuxostat + + + + obo:DDO.owl#DDO_0005801 + DDO:DDO_0005801 + + + + obo:DDO.owl#DDO_0005801 + 419262004 + + + + obo:DDO.owl#DDO_0005801 + xanthine oxidase inhibitor + + + + obo:DDO.owl#DDO_0005802 + DDO:DDO_0005802 + + + + obo:DDO.owl#DDO_0005802 + 441743008 + + + + obo:DDO.owl#DDO_0005802 + febuxostat + + + + obo:DDO.owl#DDO_0005803 + DDO:DDO_0005803 + + + + obo:DDO.owl#DDO_0005803 + 419163002 + + + + obo:DDO.owl#DDO_0005803 + anti-gout agent + + + + obo:DDO.owl#DDO_0005804 + DDO:DDO_0005804 + + + + obo:DDO.owl#DDO_0005804 + 372767007 + + + + obo:DDO.owl#DDO_0005804 + fluoxetine + + + + obo:DDO.owl#DDO_0005805 + DDO:DDO_0005805 + + + + obo:DDO.owl#DDO_0005805 + 75115009 + + + + obo:DDO.owl#DDO_0005805 + fluoxetine hydrochloride + + + + obo:DDO.owl#DDO_0005806 + DDO:DDO_0005806 + + + + obo:DDO.owl#DDO_0005806 + 259273007 + + + + obo:DDO.owl#DDO_0005806 + propylamine + + + + obo:DDO.owl#DDO_0005807 + DDO:DDO_0005807 + + + + obo:DDO.owl#DDO_0005807 + 386171009 + + + + obo:DDO.owl#DDO_0005807 + formoterol + + + + obo:DDO.owl#DDO_0005808 + DDO:DDO_0005808 + + + + obo:DDO.owl#DDO_0005808 + 360253007 + + + + obo:DDO.owl#DDO_0005808 + antiasthmatic agent + + + + obo:DDO.owl#DDO_0005809 + DDO:DDO_0005809 + + + + obo:DDO.owl#DDO_0005809 + 353866001 + + + + obo:DDO.owl#DDO_0005809 + bronchodilator preparations + + + + obo:DDO.owl#DDO_0005810 + DDO:DDO_0005810 + + + + obo:DDO.owl#DDO_0005810 + 349920008 + + + + obo:DDO.owl#DDO_0005810 + beta-adrenoceptor agonist + + + + obo:DDO.owl#DDO_0005811 + DDO:DDO_0005811 + + + + obo:DDO.owl#DDO_0005811 + 320073005 + + + + obo:DDO.owl#DDO_0005811 + selective beta-2 adrenoceptor stimulants + + + + obo:DDO.owl#DDO_0005812 + DDO:DDO_0005812 + + + + obo:DDO.owl#DDO_0005812 + 414289007 + + + + obo:DDO.owl#DDO_0005812 + formoterol + + + + obo:DDO.owl#DDO_0005813 + DDO:DDO_0005813 + + + + obo:DDO.owl#DDO_0005813 + 129490002 + + + + obo:DDO.owl#DDO_0005813 + formoterol fumarate + + + + obo:DDO.owl#DDO_0005814 + DDO:DDO_0005814 + + + + obo:DDO.owl#DDO_0005814 + 447213002 + + + + obo:DDO.owl#DDO_0005814 + formoterol fumarate dihydrate + + + + obo:DDO.owl#DDO_0005815 + DDO:DDO_0005815 + + + + obo:DDO.owl#DDO_0005815 + 373227004 + + + + obo:DDO.owl#DDO_0005815 + beta-adrenoceptor agonist + + + + obo:DDO.owl#DDO_0005816 + DDO:DDO_0005816 + + + + obo:DDO.owl#DDO_0005816 + 373215002 + + + + obo:DDO.owl#DDO_0005816 + selective beta-2 adrenoceptor stimulants + + + + obo:DDO.owl#DDO_0005817 + DDO:DDO_0005817 + + + + obo:DDO.owl#DDO_0005817 + 108569005 + + + + obo:DDO.owl#DDO_0005817 + fosinopril + + + + obo:DDO.owl#DDO_0005818 + DDO:DDO_0005818 + + + + obo:DDO.owl#DDO_0005818 + 372510000 + + + + obo:DDO.owl#DDO_0005818 + fosinopril + + + + obo:DDO.owl#DDO_0005819 + DDO:DDO_0005819 + + + + obo:DDO.owl#DDO_0005819 + 108570006 + + + + obo:DDO.owl#DDO_0005819 + fosinopril sodium + + + + obo:DDO.owl#DDO_0005821 + DDO:DDO_0005821 + + + + obo:DDO.owl#DDO_0005821 + 81609008 + + + + obo:DDO.owl#DDO_0005821 + furosemide + + + + obo:DDO.owl#DDO_0005822 + DDO:DDO_0005822 + + + + obo:DDO.owl#DDO_0005822 + 398668007 + + + + obo:DDO.owl#DDO_0005822 + furosemide+potassium + + + + obo:DDO.owl#DDO_0005823 + DDO:DDO_0005823 + + + + obo:DDO.owl#DDO_0005823 + 350612007 + + + + obo:DDO.owl#DDO_0005823 + oral form furosemide + + + + obo:DDO.owl#DDO_0005824 + DDO:DDO_0005824 + + + + obo:DDO.owl#DDO_0005824 + 350613002 + + + + obo:DDO.owl#DDO_0005824 + parenteral form furosemide + + + + obo:DDO.owl#DDO_0005825 + DDO:DDO_0005825 + + + + obo:DDO.owl#DDO_0005825 + 127964000 + + + + obo:DDO.owl#DDO_0005825 + Gemtuzumab ozogamicin + + + + obo:DDO.owl#DDO_0005826 + DDO:DDO_0005826 + + + + obo:DDO.owl#DDO_0005826 + 108585000 + + + + obo:DDO.owl#DDO_0005826 + Irbesartan + + + + obo:DDO.owl#DDO_0005827 + DDO:DDO_0005827 + + + + obo:DDO.owl#DDO_0005827 + 386877005 + + + + obo:DDO.owl#DDO_0005827 + irbesartan + + + + obo:DDO.owl#DDO_0005828 + DDO:DDO_0005828 + + + + obo:DDO.owl#DDO_0005828 + 386873009 + + + + obo:DDO.owl#DDO_0005828 + lisinopril + + + + obo:DDO.owl#DDO_0005829 + DDO:DDO_0005829 + + + + obo:DDO.owl#DDO_0005829 + 108575001 + + + + obo:DDO.owl#DDO_0005829 + lisinopril + + + + obo:DDO.owl#DDO_0005830 + DDO:DDO_0005830 + + + + obo:DDO.owl#DDO_0005830 + 373567002 + + + + obo:DDO.owl#DDO_0005830 + losartan + + + + obo:DDO.owl#DDO_0005831 + DDO:DDO_0005831 + + + + obo:DDO.owl#DDO_0005831 + 108582002 + + + + obo:DDO.owl#DDO_0005831 + Losartan potassium + + + + obo:DDO.owl#DDO_0005832 + DDO:DDO_0005832 + + + + obo:DDO.owl#DDO_0005832 + 96309000 + + + + obo:DDO.owl#DDO_0005832 + Losartan + + + + obo:DDO.owl#DDO_0005833 + DDO:DDO_0005833 + + + + obo:DDO.owl#DDO_0005833 + 108566003 + + + + obo:DDO.owl#DDO_0005833 + Moexipril + + + + obo:DDO.owl#DDO_0005834 + DDO:DDO_0005834 + + + + obo:DDO.owl#DDO_0005834 + 412437001 + + + + obo:DDO.owl#DDO_0005834 + moexipril hydrochloride + + + + obo:DDO.owl#DDO_0005835 + DDO:DDO_0005835 + + + + obo:DDO.owl#DDO_0005835 + 373442003 + + + + obo:DDO.owl#DDO_0005835 + moexipril + + + + obo:DDO.owl#DDO_0005836 + DDO:DDO_0005836 + + + + obo:DDO.owl#DDO_0005836 + 108567007 + + + + obo:DDO.owl#DDO_0005836 + Moexipril hydrochloride + + + + obo:DDO.owl#DDO_0005837 + DDO:DDO_0005837 + + + + obo:DDO.owl#DDO_0005837 + 386874003 + + + + obo:DDO.owl#DDO_0005837 + quinapril + + + + obo:DDO.owl#DDO_0005838 + DDO:DDO_0005838 + + + + obo:DDO.owl#DDO_0005838 + 386875002 + + + + obo:DDO.owl#DDO_0005838 + quinapril hydrochloride + + + + obo:DDO.owl#DDO_0005839 + DDO:DDO_0005839 + + + + obo:DDO.owl#DDO_0005839 + 108578004 + + + + obo:DDO.owl#DDO_0005839 + Quinapril + + + + obo:DDO.owl#DDO_0005840 + DDO:DDO_0005840 + + + + obo:DDO.owl#DDO_0005840 + 387069000 + + + + obo:DDO.owl#DDO_0005840 + telmisartan + + + + obo:DDO.owl#DDO_0005841 + DDO:DDO_0005841 + + + + obo:DDO.owl#DDO_0005841 + 129487008 + + + + obo:DDO.owl#DDO_0005841 + telmisartan + + + + obo:DDO.owl#DDO_0005842 + DDO:DDO_0005842 + + + + obo:DDO.owl#DDO_0005842 + 398727008 + + + + obo:DDO.owl#DDO_0005842 + hydrochlorothiazide + telmisartan + + + + obo:DDO.owl#DDO_0005843 + DDO:DDO_0005843 + + + + obo:DDO.owl#DDO_0005843 + 444334000 + + + + obo:DDO.owl#DDO_0005843 + telmisartan + amlodipine + + + + obo:DDO.owl#DDO_0005844 + DDO:DDO_0005844 + + + + obo:DDO.owl#DDO_0005844 + 386876001 + + + + obo:DDO.owl#DDO_0005844 + valsartan + + + + obo:DDO.owl#DDO_0005845 + DDO:DDO_0005845 + + + + obo:DDO.owl#DDO_0005845 + 108581009 + + + + obo:DDO.owl#DDO_0005845 + Valsartan + + + + obo:DDO.owl#DDO_0005846 + DDO:DDO_0005846 + + + + obo:DDO.owl#DDO_0005846 + 16602005 + + + + obo:DDO.owl#DDO_0005846 + hydrocortisone preparation + + + + obo:DDO.owl#DDO_0005847 + DDO:DDO_0005847 + + + + obo:DDO.owl#DDO_0005847 + 88226000 + + + + obo:DDO.owl#DDO_0005847 + hydrocortisone nasal preparation + + + + obo:DDO.owl#DDO_0005848 + DDO:DDO_0005848 + + + + obo:DDO.owl#DDO_0005848 + 34833000 + + + + obo:DDO.owl#DDO_0005848 + hydrocortisone ophthalmic preparation + + + + obo:DDO.owl#DDO_0005849 + DDO:DDO_0005849 + + + + obo:DDO.owl#DDO_0005849 + 350440008 + + + + obo:DDO.owl#DDO_0005849 + hydrocortisone eye ointment + + + + obo:DDO.owl#DDO_0005850 + DDO:DDO_0005850 + + + + obo:DDO.owl#DDO_0005850 + 330481009 + + + + obo:DDO.owl#DDO_0005850 + hydrocortisone acetate eye ointment + + + + obo:DDO.owl#DDO_0005851 + DDO:DDO_0005851 + + + + obo:DDO.owl#DDO_0005851 + 44731005 + + + + obo:DDO.owl#DDO_0005851 + hydrocortisone otic preparation + + + + obo:DDO.owl#DDO_0005852 + DDO:DDO_0005852 + + + + obo:DDO.owl#DDO_0005852 + 91413005 + + + + obo:DDO.owl#DDO_0005852 + hydrocortisone topical preparation + + + + obo:DDO.owl#DDO_0005853 + DDO:DDO_0005853 + + + + obo:DDO.owl#DDO_0005853 + 331646005 + + + + obo:DDO.owl#DDO_0005853 + hydrocortisone creams + + + + obo:DDO.owl#DDO_0005854 + DDO:DDO_0005854 + + + + obo:DDO.owl#DDO_0005854 + 331681007 + + + + obo:DDO.owl#DDO_0005854 + hydrocortisone ointments + + + + obo:DDO.owl#DDO_0005855 + DDO:DDO_0005855 + + + + obo:DDO.owl#DDO_0005855 + 350442000 + + + + obo:DDO.owl#DDO_0005855 + topical form compound hydrocortisone preparation + + + + obo:DDO.owl#DDO_0005856 + DDO:DDO_0005856 + + + + obo:DDO.owl#DDO_0005856 + 350448001 + + + + obo:DDO.owl#DDO_0005856 + oral form hydrocortisone + + + + obo:DDO.owl#DDO_0005857 + DDO:DDO_0005857 + + + + obo:DDO.owl#DDO_0005857 + 350447006 + + + + obo:DDO.owl#DDO_0005857 + parenteral form hydrocortisone + + + + obo:DDO.owl#DDO_0005858 + DDO:DDO_0005858 + + + + obo:DDO.owl#DDO_0005858 + 350441007 + + + + obo:DDO.owl#DDO_0005858 + rectal hydrocortisone preparations + + + + obo:DDO.owl#DDO_0005859 + DDO:DDO_0005859 + + + + obo:DDO.owl#DDO_0005859 + 45754009 + + + + obo:DDO.owl#DDO_0005859 + alpha interferon + + + + obo:DDO.owl#DDO_0005860 + DDO:DDO_0005860 + + + + obo:DDO.owl#DDO_0005860 + 386914007 + + + + obo:DDO.owl#DDO_0005860 + interferon alpha-2a + + + + obo:DDO.owl#DDO_0005861 + DDO:DDO_0005861 + + + + obo:DDO.owl#DDO_0005861 + 421559001 + + + + obo:DDO.owl#DDO_0005861 + peginterferon alpha-2a + + + + obo:DDO.owl#DDO_0005862 + DDO:DDO_0005862 + + + + obo:DDO.owl#DDO_0005862 + 49327004 + + + + obo:DDO.owl#DDO_0005862 + interferon + + + + obo:DDO.owl#DDO_0005863 + DDO:DDO_0005863 + + + + obo:DDO.owl#DDO_0005863 + 108940007 + + + + obo:DDO.owl#DDO_0005863 + immunomodulator + + + + obo:DDO.owl#DDO_0005864 + DDO:DDO_0005864 + + + + obo:DDO.owl#DDO_0005864 + 136111001 + + + + obo:DDO.owl#DDO_0005864 + interferon alfa + + + + obo:DDO.owl#DDO_0005865 + DDO:DDO_0005865 + + + + obo:DDO.owl#DDO_0005865 + 108796006 + + + + obo:DDO.owl#DDO_0005865 + interferon alpha-2a preparation + + + + obo:DDO.owl#DDO_0005866 + DDO:DDO_0005866 + + + + obo:DDO.owl#DDO_0005866 + 108803003 + + + + obo:DDO.owl#DDO_0005866 + cytokine preparation + + + + obo:DDO.owl#DDO_0005867 + DDO:DDO_0005867 + + + + obo:DDO.owl#DDO_0005867 + 386915008 + + + + obo:DDO.owl#DDO_0005867 + interferon alpha-2b + + + + obo:DDO.owl#DDO_0005868 + DDO:DDO_0005868 + + + + obo:DDO.owl#DDO_0005868 + 395823000 + + + + obo:DDO.owl#DDO_0005868 + peginterferon alfa-2b + + + + obo:DDO.owl#DDO_0005869 + DDO:DDO_0005869 + + + + obo:DDO.owl#DDO_0005869 + 108797002 + + + + obo:DDO.owl#DDO_0005869 + interferon alpha-2b preparation + + + + obo:DDO.owl#DDO_0005870 + DDO:DDO_0005870 + + + + obo:DDO.owl#DDO_0005870 + 35063004 + + + + obo:DDO.owl#DDO_0005870 + ribavirin + + + + obo:DDO.owl#DDO_0005871 + DDO:DDO_0005871 + + + + obo:DDO.owl#DDO_0005871 + 430152003 + + + + obo:DDO.owl#DDO_0005871 + oral form ribavirin + + + + obo:DDO.owl#DDO_0005872 + DDO:DDO_0005872 + + + + obo:DDO.owl#DDO_0005872 + 429981004 + + + + obo:DDO.owl#DDO_0005872 + respiratory form ribavirin + + + + obo:DDO.owl#DDO_0005873 + DDO:DDO_0005873 + + + + obo:DDO.owl#DDO_0005873 + 387188005 + + + + obo:DDO.owl#DDO_0005873 + ribavirin + + + + obo:DDO.owl#DDO_0005874 + DDO:DDO_0005874 + + + + obo:DDO.owl#DDO_0005874 + 419882009 + + + + obo:DDO.owl#DDO_0005874 + triazole derivative + + + + obo:DDO.owl#DDO_0005875 + DDO:DDO_0005875 + + + + obo:DDO.owl#DDO_0005875 + 108780008 + + + + obo:DDO.owl#DDO_0005875 + topoisomerase inhibitor + + + + obo:DDO.owl#DDO_0005876 + DDO:DDO_0005876 + + + + obo:DDO.owl#DDO_0005876 + 108783005 + + + + obo:DDO.owl#DDO_0005876 + irinotecan + + + + obo:DDO.owl#DDO_0005877 + DDO:DDO_0005877 + + + + obo:DDO.owl#DDO_0005877 + 372538008 + + + + obo:DDO.owl#DDO_0005877 + irinotecan + + + + obo:DDO.owl#DDO_0005878 + DDO:DDO_0005878 + + + + obo:DDO.owl#DDO_0005878 + 386912006 + + + + obo:DDO.owl#DDO_0005878 + irinotecan hydrochloride + + + + obo:DDO.owl#DDO_0005879 + DDO:DDO_0005879 + + + + obo:DDO.owl#DDO_0005879 + 372537003 + + + + obo:DDO.owl#DDO_0005879 + topoisomerase inhibitor + + + + obo:DDO.owl#DDO_0005880 + DDO:DDO_0005880 + + + + obo:DDO.owl#DDO_0005880 + 387472004 + + + + obo:DDO.owl#DDO_0005880 + isoniazid + + + + obo:DDO.owl#DDO_0005881 + DDO:DDO_0005881 + + + + obo:DDO.owl#DDO_0005881 + 34641002 + + + + obo:DDO.owl#DDO_0005881 + hydrazine + + + + obo:DDO.owl#DDO_0005882 + DDO:DDO_0005882 + + + + obo:DDO.owl#DDO_0005882 + 418127009 + + + + obo:DDO.owl#DDO_0005882 + hydrazide antituberculosis agent + + + + obo:DDO.owl#DDO_0005883 + DDO:DDO_0005883 + + + + obo:DDO.owl#DDO_0005883 + 116085009 + + + + obo:DDO.owl#DDO_0005883 + retinoid + + + + obo:DDO.owl#DDO_0005884 + DDO:DDO_0005884 + + + + obo:DDO.owl#DDO_0005884 + 38314008 + + + + obo:DDO.owl#DDO_0005884 + isotretinoin + + + + obo:DDO.owl#DDO_0005885 + DDO:DDO_0005885 + + + + obo:DDO.owl#DDO_0005885 + 398749002 + + + + obo:DDO.owl#DDO_0005885 + isotretinoin+erythromycin + + + + obo:DDO.owl#DDO_0005886 + DDO:DDO_0005886 + + + + obo:DDO.owl#DDO_0005886 + 428131004 + + + + obo:DDO.owl#DDO_0005886 + oral form isotretinoin + + + + obo:DDO.owl#DDO_0005887 + DDO:DDO_0005887 + + + + obo:DDO.owl#DDO_0005887 + 429464002 + + + + obo:DDO.owl#DDO_0005887 + topical form isotretinoin + + + + obo:DDO.owl#DDO_0005888 + DDO:DDO_0005888 + + + + obo:DDO.owl#DDO_0005888 + 386897000 + + + + obo:DDO.owl#DDO_0005888 + lamivudine + + + + obo:DDO.owl#DDO_0005889 + DDO:DDO_0005889 + + + + obo:DDO.owl#DDO_0005889 + 372531002 + + + + obo:DDO.owl#DDO_0005889 + reverse transcriptase inhibitor + + + + obo:DDO.owl#DDO_0005890 + DDO:DDO_0005890 + + + + obo:DDO.owl#DDO_0005890 + 398965008 + + + + obo:DDO.owl#DDO_0005890 + levalbuterol + + + + obo:DDO.owl#DDO_0005891 + DDO:DDO_0005891 + + + + obo:DDO.owl#DDO_0005891 + 116090007 + + + + obo:DDO.owl#DDO_0005891 + Levalbuterol + + + + obo:DDO.owl#DDO_0005892 + DDO:DDO_0005892 + + + + obo:DDO.owl#DDO_0005892 + 412236007 + + + + obo:DDO.owl#DDO_0005892 + levalbuterol hydrochloride + + + + obo:DDO.owl#DDO_0005893 + DDO:DDO_0005893 + + + + obo:DDO.owl#DDO_0005893 + 426604008 + + + + obo:DDO.owl#DDO_0005893 + levalbuterol tartrate + + + + obo:DDO.owl#DDO_0005894 + DDO:DDO_0005894 + + + + obo:DDO.owl#DDO_0005894 + 52388000 + + + + obo:DDO.owl#DDO_0005894 + prednisolone preparation + + + + obo:DDO.owl#DDO_0005895 + DDO:DDO_0005895 + + + + obo:DDO.owl#DDO_0005895 + 349354003 + + + + obo:DDO.owl#DDO_0005895 + oral form prednisolone + + + + obo:DDO.owl#DDO_0005896 + DDO:DDO_0005896 + + + + obo:DDO.owl#DDO_0005896 + 350459005 + + + + obo:DDO.owl#DDO_0005896 + parenteral form prednisolone + + + + obo:DDO.owl#DDO_0005897 + DDO:DDO_0005897 + + + + obo:DDO.owl#DDO_0005897 + 49019002 + + + + obo:DDO.owl#DDO_0005897 + prednisolone ophthalmic preparation + + + + obo:DDO.owl#DDO_0005898 + DDO:DDO_0005898 + + + + obo:DDO.owl#DDO_0005898 + 350461001 + + + + obo:DDO.owl#DDO_0005898 + prednisolone drops + + + + obo:DDO.owl#DDO_0005899 + DDO:DDO_0005899 + + + + obo:DDO.owl#DDO_0005899 + 400891007 + + + + obo:DDO.owl#DDO_0005899 + prednisolone sodium phosphate + + + + obo:DDO.owl#DDO_0005900 + DDO:DDO_0005900 + + + + obo:DDO.owl#DDO_0005900 + 350462008 + + + + obo:DDO.owl#DDO_0005900 + rectal prednisolone preparations + + + + obo:DDO.owl#DDO_0005901 + DDO:DDO_0005901 + + + + obo:DDO.owl#DDO_0005901 + 350460000 + + + + obo:DDO.owl#DDO_0005901 + topical form prednisolone + + + + obo:DDO.owl#DDO_0005902 + DDO:DDO_0005902 + + + + obo:DDO.owl#DDO_0005902 + 10312003 + + + + obo:DDO.owl#DDO_0005902 + prednisone preparation + + + + obo:DDO.owl#DDO_0005903 + DDO:DDO_0005903 + + + + obo:DDO.owl#DDO_0005903 + 372560006 + + + + obo:DDO.owl#DDO_0005903 + antiplatelet agent + + + + obo:DDO.owl#DDO_0005904 + DDO:DDO_0005904 + + + + obo:DDO.owl#DDO_0005904 + 387458008 + + + + obo:DDO.owl#DDO_0005904 + aspirin + + + + obo:DDO.owl#DDO_0005905 + DDO:DDO_0005905 + + + + obo:DDO.owl#DDO_0005905 + 426365001 + + + + obo:DDO.owl#DDO_0005905 + buffered aspirin + + + + obo:DDO.owl#DDO_0005906 + DDO:DDO_0005906 + + + + obo:DDO.owl#DDO_0005906 + 25796002 + + + + obo:DDO.owl#DDO_0005906 + aluminum aspirin + + + + obo:DDO.owl#DDO_0005907 + DDO:DDO_0005907 + + + + obo:DDO.owl#DDO_0005907 + 421012002 + + + + obo:DDO.owl#DDO_0005907 + aloxiprin + + + + obo:DDO.owl#DDO_0005908 + DDO:DDO_0005908 + + + + obo:DDO.owl#DDO_0005908 + 108972005 + + + + obo:DDO.owl#DDO_0005908 + antiplatelet agent + + + + obo:DDO.owl#DDO_0005909 + DDO:DDO_0005909 + + + + obo:DDO.owl#DDO_0005909 + 7947003 + + + + obo:DDO.owl#DDO_0005909 + aspirin + + + + obo:DDO.owl#DDO_0005910 + DDO:DDO_0005910 + + + + obo:DDO.owl#DDO_0005910 + 66859009 + + + + obo:DDO.owl#DDO_0005910 + dipyridamole + + + + obo:DDO.owl#DDO_0005911 + DDO:DDO_0005911 + + + + obo:DDO.owl#DDO_0005911 + 387371005 + + + + obo:DDO.owl#DDO_0005911 + dipyridamole + + + + obo:DDO.owl#DDO_0005912 + DDO:DDO_0005912 + + + + obo:DDO.owl#DDO_0005912 + 425481003 + + + + obo:DDO.owl#DDO_0005912 + C0008168 + + + + obo:DDO.owl#DDO_0005912 + chloramphenicol derivative + + + + obo:DDO.owl#DDO_0005913 + DDO:DDO_0005913 + + + + obo:DDO.owl#DDO_0005913 + 57191001 + + + + obo:DDO.owl#DDO_0005913 + chloramphenicol + + + + obo:DDO.owl#DDO_0005914 + DDO:DDO_0005914 + + + + obo:DDO.owl#DDO_0005914 + 43533002 + + + + obo:DDO.owl#DDO_0005914 + chloramphenicol ophthalmic preparation + + + + obo:DDO.owl#DDO_0005916 + DDO:DDO_0005916 + + + + obo:DDO.owl#DDO_0005916 + 50841004 + + + + obo:DDO.owl#DDO_0005916 + chloramphenicol otic preparation + + + + obo:DDO.owl#DDO_0005917 + DDO:DDO_0005917 + + + + obo:DDO.owl#DDO_0005917 + 350139000 + + + + obo:DDO.owl#DDO_0005917 + oral form chloramphenicol + + + + obo:DDO.owl#DDO_0005918 + DDO:DDO_0005918 + + + + obo:DDO.owl#DDO_0005918 + 350140003 + + + + obo:DDO.owl#DDO_0005918 + parenteral form chloramphenicol + + + + obo:DDO.owl#DDO_0005919 + DDO:DDO_0005919 + + + + obo:DDO.owl#DDO_0005919 + 350141004 + + + + obo:DDO.owl#DDO_0005919 + topical form chloramphenicol + + + + obo:DDO.owl#DDO_0005920 + DDO:DDO_0005920 + + + + obo:DDO.owl#DDO_0005920 + 105907002 + + + + obo:DDO.owl#DDO_0005920 + chloramphenicol (class of antibiotic) + + + + obo:DDO.owl#DDO_0005921 + DDO:DDO_0005921 + + + + obo:DDO.owl#DDO_0005921 + 372777009 + + + + obo:DDO.owl#DDO_0005921 + chloramphenicol + + + + obo:DDO.owl#DDO_0005922 + DDO:DDO_0005922 + + + + obo:DDO.owl#DDO_0005922 + 6612003 + + + + obo:DDO.owl#DDO_0005922 + chloramphenicol sodium succinate + + + + obo:DDO.owl#DDO_0005923 + DDO:DDO_0005923 + + + + obo:DDO.owl#DDO_0005923 + 384953001 + + + + obo:DDO.owl#DDO_0005923 + antidiabetic preparation + + + + obo:DDO.owl#DDO_0005924 + DDO:DDO_0005924 + + + + obo:DDO.owl#DDO_0005924 + 312064005 + + + + obo:DDO.owl#DDO_0005924 + hypoglycemic agent + + + + obo:DDO.owl#DDO_0005925 + DDO:DDO_0005925 + + + + obo:DDO.owl#DDO_0005925 + 346597008 + + + + obo:DDO.owl#DDO_0005925 + oral hypoglycemic + + + + obo:DDO.owl#DDO_0005939 + DDO:DDO_0005939 + + + + obo:DDO.owl#DDO_0005939 + 372484000 + + + + obo:DDO.owl#DDO_0005939 + fosphenytoin + + + + obo:DDO.owl#DDO_0005940 + DDO:DDO_0005940 + + + + obo:DDO.owl#DDO_0005940 + 386843000 + + + + obo:DDO.owl#DDO_0005940 + fosphenytoin sodium + + + + obo:DDO.owl#DDO_0005941 + DDO:DDO_0005941 + + + + obo:DDO.owl#DDO_0005941 + 255632006 + + + + obo:DDO.owl#DDO_0005941 + anticonvulsant + + + + obo:DDO.owl#DDO_0005942 + DDO:DDO_0005942 + + + + obo:DDO.owl#DDO_0005942 + 108397000 + + + + obo:DDO.owl#DDO_0005942 + Fosphenytoin + + + + obo:DDO.owl#DDO_0005943 + DDO:DDO_0005943 + + + + obo:DDO.owl#DDO_0005943 + 18220004 + + + + obo:DDO.owl#DDO_0005943 + thyroid hormone + + + + obo:DDO.owl#DDO_0005944 + DDO:DDO_0005944 + + + + obo:DDO.owl#DDO_0005944 + 73187006 + + + + obo:DDO.owl#DDO_0005944 + thyroxine + + + + obo:DDO.owl#DDO_0005945 + DDO:DDO_0005945 + + + + obo:DDO.owl#DDO_0005945 + 710809001 + + + + obo:DDO.owl#DDO_0005945 + levothyroxine + + + + obo:DDO.owl#DDO_0005946 + DDO:DDO_0005946 + + + + obo:DDO.owl#DDO_0005946 + 126202002 + + + + obo:DDO.owl#DDO_0005946 + levothyroxine sodium + + + + obo:DDO.owl#DDO_0005947 + DDO:DDO_0005947 + + + + obo:DDO.owl#DDO_0005947 + 387067003 + + + + obo:DDO.owl#DDO_0005947 + lopinavir + + + + obo:DDO.owl#DDO_0005948 + DDO:DDO_0005948 + + + + obo:DDO.owl#DDO_0005948 + 27242001 + + + + obo:DDO.owl#DDO_0005948 + methylprednisolone preparation + + + + obo:DDO.owl#DDO_0005949 + DDO:DDO_0005949 + + + + obo:DDO.owl#DDO_0005949 + 350449009 + + + + obo:DDO.owl#DDO_0005949 + oral form methylprednisolone + + + + obo:DDO.owl#DDO_0005950 + DDO:DDO_0005950 + + + + obo:DDO.owl#DDO_0005950 + 350450009 + + + + obo:DDO.owl#DDO_0005950 + parenteral form methylprednisolone + + + + obo:DDO.owl#DDO_0005951 + DDO:DDO_0005951 + + + + obo:DDO.owl#DDO_0005951 + 430818004 + + + + obo:DDO.owl#DDO_0005951 + topical form methylprednisolone + + + + obo:DDO.owl#DDO_0005952 + DDO:DDO_0005952 + + + + obo:DDO.owl#DDO_0005952 + 22198003 + + + + obo:DDO.owl#DDO_0005952 + Metolazone + + + + obo:DDO.owl#DDO_0005953 + DDO:DDO_0005953 + + + + obo:DDO.owl#DDO_0005953 + 105918002 + + + + obo:DDO.owl#DDO_0005953 + stimulant + + + + obo:DDO.owl#DDO_0005954 + DDO:DDO_0005954 + + + + obo:DDO.owl#DDO_0005954 + 43927002 + + + + obo:DDO.owl#DDO_0005954 + analeptic agent + + + + obo:DDO.owl#DDO_0005955 + DDO:DDO_0005955 + + + + obo:DDO.owl#DDO_0005955 + 116082007 + + + + obo:DDO.owl#DDO_0005955 + Modafinil + + + + obo:DDO.owl#DDO_0005956 + DDO:DDO_0005956 + + + + obo:DDO.owl#DDO_0005956 + 387004007 + + + + obo:DDO.owl#DDO_0005956 + modafinil + + + + obo:DDO.owl#DDO_0005957 + DDO:DDO_0005957 + + + + obo:DDO.owl#DDO_0005957 + 387459000 + + + + obo:DDO.owl#DDO_0005957 + psychostimulant + + + + obo:DDO.owl#DDO_0005958 + DDO:DDO_0005958 + + + + obo:DDO.owl#DDO_0005958 + 372620004 + + + + obo:DDO.owl#DDO_0005958 + central stimulant + + + + obo:DDO.owl#DDO_0005959 + DDO:DDO_0005959 + + + + obo:DDO.owl#DDO_0005959 + 412439003 + + + + obo:DDO.owl#DDO_0005959 + moxifloxacin + + + + obo:DDO.owl#DDO_0005960 + DDO:DDO_0005960 + + + + obo:DDO.owl#DDO_0005960 + 116347002 + + + + obo:DDO.owl#DDO_0005960 + Moxifloxacin hydrochloride + + + + obo:DDO.owl#DDO_0005961 + DDO:DDO_0005961 + + + + obo:DDO.owl#DDO_0005961 + 371296007 + + + + obo:DDO.owl#DDO_0005961 + moxifloxacin product + + + + obo:DDO.owl#DDO_0005962 + DDO:DDO_0005962 + + + + obo:DDO.owl#DDO_0005962 + 427234003 + + + + obo:DDO.owl#DDO_0005962 + ophthalmic form moxifloxacin + + + + obo:DDO.owl#DDO_0005963 + DDO:DDO_0005963 + + + + obo:DDO.owl#DDO_0005963 + 427613001 + + + + obo:DDO.owl#DDO_0005963 + oral form moxifloxacin + + + + obo:DDO.owl#DDO_0005964 + DDO:DDO_0005964 + + + + obo:DDO.owl#DDO_0005964 + 427100008 + + + + obo:DDO.owl#DDO_0005964 + parenteral form moxifloxacin + + + + obo:DDO.owl#DDO_0005965 + DDO:DDO_0005965 + + + + obo:DDO.owl#DDO_0005965 + 409330005 + + + + obo:DDO.owl#DDO_0005965 + mycophenolic acid + + + + obo:DDO.owl#DDO_0005966 + DDO:DDO_0005966 + + + + obo:DDO.owl#DDO_0005966 + 426216009 + + + + obo:DDO.owl#DDO_0005966 + mycophenolate sodium + + + + obo:DDO.owl#DDO_0005967 + DDO:DDO_0005967 + + + + obo:DDO.owl#DDO_0005967 + 417695006 + + + + obo:DDO.owl#DDO_0005967 + benzofuran + + + + obo:DDO.owl#DDO_0005969 + DDO:DDO_0005969 + + + + obo:DDO.owl#DDO_0005969 + 96372005 + + + + obo:DDO.owl#DDO_0005969 + nilutamide + + + + obo:DDO.owl#DDO_0005970 + DDO:DDO_0005970 + + + + obo:DDO.owl#DDO_0005970 + 409378005 + + + + obo:DDO.owl#DDO_0005970 + nitric oxide + + + + obo:DDO.owl#DDO_0005971 + DDO:DDO_0005971 + + + + obo:DDO.owl#DDO_0005971 + 372580007 + + + + obo:DDO.owl#DDO_0005971 + bronchodilator + + + + obo:DDO.owl#DDO_0005972 + DDO:DDO_0005972 + + + + obo:DDO.owl#DDO_0005972 + 6710000 + + + + obo:DDO.owl#DDO_0005972 + nitric oxide + + + + obo:DDO.owl#DDO_0005973 + DDO:DDO_0005973 + + + + obo:DDO.owl#DDO_0005973 + 82240008 + + + + obo:DDO.owl#DDO_0005973 + Norgestrel preparation + + + + obo:DDO.owl#DDO_0005974 + DDO:DDO_0005974 + + + + obo:DDO.owl#DDO_0005974 + 12096000 + + + + obo:DDO.owl#DDO_0005974 + nystatin + + + + obo:DDO.owl#DDO_0005975 + DDO:DDO_0005975 + + + + obo:DDO.owl#DDO_0005975 + 421185006 + + + + obo:DDO.owl#DDO_0005975 + vaginal form nystatin + + + + obo:DDO.owl#DDO_0005976 + DDO:DDO_0005976 + + + + obo:DDO.owl#DDO_0005976 + 387048002 + + + + obo:DDO.owl#DDO_0005976 + nystatin + + + + obo:DDO.owl#DDO_0005977 + DDO:DDO_0005977 + + + + obo:DDO.owl#DDO_0005977 + 28028002 + + + + obo:DDO.owl#DDO_0005977 + synthetic hormone preparation + + + + obo:DDO.owl#DDO_0005978 + DDO:DDO_0005978 + + + + obo:DDO.owl#DDO_0005978 + 57819002 + + + + obo:DDO.owl#DDO_0005978 + somatostatin preparation + + + + obo:DDO.owl#DDO_0005979 + DDO:DDO_0005979 + + + + obo:DDO.owl#DDO_0005979 + 109054006 + + + + obo:DDO.owl#DDO_0005979 + somatostatin analog + + + + obo:DDO.owl#DDO_0005980 + DDO:DDO_0005980 + + + + obo:DDO.owl#DDO_0005980 + 126155003 + + + + obo:DDO.owl#DDO_0005980 + octreotide preparation + + + + obo:DDO.owl#DDO_0005981 + DDO:DDO_0005981 + + + + obo:DDO.owl#DDO_0005981 + 109053000 + + + + obo:DDO.owl#DDO_0005981 + octreotide + + + + obo:DDO.owl#DDO_0005982 + DDO:DDO_0005982 + + + + obo:DDO.owl#DDO_0005982 + 109055007 + + + + obo:DDO.owl#DDO_0005982 + octreotide acetate + + + + obo:DDO.owl#DDO_0005983 + DDO:DDO_0005983 + + + + obo:DDO.owl#DDO_0005983 + 18811003 + + + + obo:DDO.owl#DDO_0005983 + L-asparaginase preparation + + + + obo:DDO.owl#DDO_0005984 + DDO:DDO_0005984 + + + + obo:DDO.owl#DDO_0005984 + 416337002 + + + + obo:DDO.owl#DDO_0005984 + pegaspargase + + + + obo:DDO.owl#DDO_0005985 + DDO:DDO_0005985 + + + + obo:DDO.owl#DDO_0005985 + 372771005 + + + + obo:DDO.owl#DDO_0005985 + phenylephrine + + + + obo:DDO.owl#DDO_0005986 + DDO:DDO_0005986 + + + + obo:DDO.owl#DDO_0005986 + Phenylephrine hydrochloride + + + + obo:DDO.owl#DDO_0005987 + DDO:DDO_0005987 + + + + obo:DDO.owl#DDO_0005987 + 372622007 + + + + obo:DDO.owl#DDO_0005987 + alpha-adrenoceptor agonist + + + + obo:DDO.owl#DDO_0005988 + DDO:DDO_0005988 + + + + obo:DDO.owl#DDO_0005988 + 349917000 + + + + obo:DDO.owl#DDO_0005988 + Alpha-adrenoceptor agonist + + + + obo:DDO.owl#DDO_0005989 + DDO:DDO_0005989 + + + + obo:DDO.owl#DDO_0005989 + 54765002 + + + + obo:DDO.owl#DDO_0005989 + Phenylephrine + + + + obo:DDO.owl#DDO_0005990 + DDO:DDO_0005990 + + + + obo:DDO.owl#DDO_0005990 + 430411003 + + + + obo:DDO.owl#DDO_0005990 + nasal form phenylephrine + + + + obo:DDO.owl#DDO_0005991 + DDO:DDO_0005991 + + + + obo:DDO.owl#DDO_0005991 + 386693003 + + + + obo:DDO.owl#DDO_0005991 + ophthalmic phenylephrine + + + + obo:DDO.owl#DDO_0005992 + DDO:DDO_0005992 + + + + obo:DDO.owl#DDO_0005992 + 349919002 + + + + obo:DDO.owl#DDO_0005992 + Phenylephrine eye drops + + + + obo:DDO.owl#DDO_0005993 + DDO:DDO_0005993 + + + + obo:DDO.owl#DDO_0005993 + 387813005 + + + + obo:DDO.owl#DDO_0005993 + oral form phenylephrine + + + + obo:DDO.owl#DDO_0005994 + DDO:DDO_0005994 + + + + obo:DDO.owl#DDO_0005994 + 430717000 + + + + obo:DDO.owl#DDO_0005994 + otic form phenylephrine + + + + obo:DDO.owl#DDO_0005995 + DDO:DDO_0005995 + + + + obo:DDO.owl#DDO_0005995 + 387812000 + + + + obo:DDO.owl#DDO_0005995 + parenteral form phenylephrine + + + + obo:DDO.owl#DDO_0005996 + DDO:DDO_0005996 + + + + obo:DDO.owl#DDO_0005996 + 430870003 + + + + obo:DDO.owl#DDO_0005996 + rectal form phenylephrine + + + + obo:DDO.owl#DDO_0005997 + DDO:DDO_0005997 + + + + obo:DDO.owl#DDO_0005997 + 430859005 + + + + obo:DDO.owl#DDO_0005997 + topical form phenylephrine + + + + obo:DDO.owl#DDO_0005998 + DDO:DDO_0005998 + + + + obo:DDO.owl#DDO_0005998 + 372900003 + + + + obo:DDO.owl#DDO_0005998 + pseudoephedrine + + + + obo:DDO.owl#DDO_0005999 + DDO:DDO_0005999 + + + + obo:DDO.owl#DDO_0005999 + 12177002 + + + + obo:DDO.owl#DDO_0005999 + pseudoephedrine hydrochloride + + + + obo:DDO.owl#DDO_0006000 + DDO:DDO_0006000 + + + + obo:DDO.owl#DDO_0006000 + 10595003 + + + + obo:DDO.owl#DDO_0006000 + pseudoephedrine sulfate + + + + obo:DDO.owl#DDO_0006001 + DDO:DDO_0006001 + + + + obo:DDO.owl#DDO_0006001 + 91435002 + + + + obo:DDO.owl#DDO_0006001 + pseudoephedrine + + + + obo:DDO.owl#DDO_0006002 + DDO:DDO_0006002 + + + + obo:DDO.owl#DDO_0006002 + 395335008 + + + + obo:DDO.owl#DDO_0006002 + pseudoephedrine compound product + + + + obo:DDO.owl#DDO_0006003 + DDO:DDO_0006003 + + + + obo:DDO.owl#DDO_0006003 + 349846008 + + + + obo:DDO.owl#DDO_0006003 + antifolate + + + + obo:DDO.owl#DDO_0006004 + DDO:DDO_0006004 + + + + obo:DDO.owl#DDO_0006004 + 429320009 + + + + obo:DDO.owl#DDO_0006004 + pralatrexate + + + + obo:DDO.owl#DDO_0006005 + DDO:DDO_0006005 + + + + obo:DDO.owl#DDO_0006005 + 372785000 + + + + obo:DDO.owl#DDO_0006005 + antimetabolite + + + + obo:DDO.owl#DDO_0006006 + DDO:DDO_0006006 + + + + obo:DDO.owl#DDO_0006006 + 372612001 + + + + obo:DDO.owl#DDO_0006006 + antifolate + + + + obo:DDO.owl#DDO_0006007 + DDO:DDO_0006007 + + + + obo:DDO.owl#DDO_0006007 + 6790004 + + + + obo:DDO.owl#DDO_0006007 + aminopterin + + + + obo:DDO.owl#DDO_0006008 + DDO:DDO_0006008 + + + + obo:DDO.owl#DDO_0006008 + 428682000 + + + + obo:DDO.owl#DDO_0006008 + aminopterin derivative + + + + obo:DDO.owl#DDO_0006009 + DDO:DDO_0006009 + + + + obo:DDO.owl#DDO_0006009 + 428598004 + + + + obo:DDO.owl#DDO_0006009 + pralatrexate + + + + obo:DDO.owl#DDO_0006010 + DDO:DDO_0006010 + + + + obo:DDO.owl#DDO_0006010 + 36326009 + + + + obo:DDO.owl#DDO_0006010 + pteridine + + + + obo:DDO.owl#DDO_0006011 + DDO:DDO_0006011 + + + + obo:DDO.owl#DDO_0006011 + 22078005 + + + + obo:DDO.owl#DDO_0006011 + Pterins + + + + obo:DDO.owl#DDO_0006012 + DDO:DDO_0006012 + + + + obo:DDO.owl#DDO_0006012 + 358927005 + + + + obo:DDO.owl#DDO_0006012 + mood stabilizing drug + + + + obo:DDO.owl#DDO_0006013 + DDO:DDO_0006013 + + + + obo:DDO.owl#DDO_0006013 + 427395002 + + + + obo:DDO.owl#DDO_0006013 + hydrolase inhibitor + + + + obo:DDO.owl#DDO_0006014 + DDO:DDO_0006014 + + + + obo:DDO.owl#DDO_0006014 + 423081009 + + + + obo:DDO.owl#DDO_0006014 + histone deacetylase inhibitor + + + + obo:DDO.owl#DDO_0006015 + DDO:DDO_0006015 + + + + obo:DDO.owl#DDO_0006015 + 444737005 + + + + obo:DDO.owl#DDO_0006015 + romidepsin + + + + obo:DDO.owl#DDO_0006016 + DDO:DDO_0006016 + + + + obo:DDO.owl#DDO_0006016 + 427117001 + + + + obo:DDO.owl#DDO_0006016 + hydrolase inhibitor + + + + obo:DDO.owl#DDO_0006017 + DDO:DDO_0006017 + + + + obo:DDO.owl#DDO_0006017 + 423078004 + + + + obo:DDO.owl#DDO_0006017 + histone deacetylase inhibitor + + + + obo:DDO.owl#DDO_0006018 + DDO:DDO_0006018 + + + + obo:DDO.owl#DDO_0006018 + 444608004 + + + + obo:DDO.owl#DDO_0006018 + romidepsin + + + + obo:DDO.owl#DDO_0006019 + DDO:DDO_0006019 + + + + obo:DDO.owl#DDO_0006019 + 108605008 + + + + obo:DDO.owl#DDO_0006019 + salmeterol + + + + obo:DDO.owl#DDO_0006020 + DDO:DDO_0006020 + + + + obo:DDO.owl#DDO_0006020 + 372515005 + + + + obo:DDO.owl#DDO_0006020 + salmeterol + + + + obo:DDO.owl#DDO_0006021 + DDO:DDO_0006021 + + + + obo:DDO.owl#DDO_0006021 + 108606009 + + + + obo:DDO.owl#DDO_0006021 + Salmeterol xinafoate + + + + obo:DDO.owl#DDO_0006022 + DDO:DDO_0006022 + + + + obo:DDO.owl#DDO_0006022 + 410918008 + + + + obo:DDO.owl#DDO_0006022 + sodium oxybate + + + + obo:DDO.owl#DDO_0006023 + DDO:DDO_0006023 + + + + obo:DDO.owl#DDO_0006023 + 410917003 + + + + obo:DDO.owl#DDO_0006023 + sodium oxybate + + + + obo:DDO.owl#DDO_0006024 + DDO:DDO_0006024 + + + + obo:DDO.owl#DDO_0006024 + 350359006 + + + + obo:DDO.owl#DDO_0006024 + hypothalamic/pituitary hormone + + + + obo:DDO.owl#DDO_0006025 + DDO:DDO_0006025 + + + + obo:DDO.owl#DDO_0006025 + 58805000 + + + + obo:DDO.owl#DDO_0006025 + pituitary hormone preparation + + + + obo:DDO.owl#DDO_0006026 + DDO:DDO_0006026 + + + + obo:DDO.owl#DDO_0006026 + 392573000 + + + + obo:DDO.owl#DDO_0006026 + anterior pituitary hormone + + + + obo:DDO.owl#DDO_0006027 + DDO:DDO_0006027 + + + + obo:DDO.owl#DDO_0006027 + 56234005 + + + + obo:DDO.owl#DDO_0006027 + somatotropin preparation + + + + obo:DDO.owl#DDO_0006028 + DDO:DDO_0006028 + + + + obo:DDO.owl#DDO_0006028 + 126193008 + + + + obo:DDO.owl#DDO_0006028 + human growth hormone recombinant preparation + + + + obo:DDO.owl#DDO_0006029 + DDO:DDO_0006029 + + + + obo:DDO.owl#DDO_0006029 + 129495007 + + + + obo:DDO.owl#DDO_0006029 + somatropin + + + + obo:DDO.owl#DDO_0006030 + DDO:DDO_0006030 + + + + obo:DDO.owl#DDO_0006030 + 427153004 + + + + obo:DDO.owl#DDO_0006030 + temsirolimus + + + + obo:DDO.owl#DDO_0006031 + DDO:DDO_0006031 + + + + obo:DDO.owl#DDO_0006031 + 422056004 + + + + obo:DDO.owl#DDO_0006031 + aquaretic + + + + obo:DDO.owl#DDO_0006032 + DDO:DDO_0006032 + + + + obo:DDO.owl#DDO_0006032 + 442901006 + + + + obo:DDO.owl#DDO_0006032 + tolvaptan + + + + obo:DDO.owl#DDO_0006033 + DDO:DDO_0006033 + + + + obo:DDO.owl#DDO_0006033 + 420410007 + + + + obo:DDO.owl#DDO_0006033 + aquaretic + + + + obo:DDO.owl#DDO_0006034 + DDO:DDO_0006034 + + + + obo:DDO.owl#DDO_0006034 + 443058000 + + + + obo:DDO.owl#DDO_0006034 + tolvaptan + + + + obo:DDO.owl#DDO_0006035 + DDO:DDO_0006035 + + + + obo:DDO.owl#DDO_0006035 + 413639003 + + + + obo:DDO.owl#DDO_0006035 + benzazepine + + + + obo:DDO.owl#DDO_0006036 + DDO:DDO_0006036 + + + + obo:DDO.owl#DDO_0006036 + 716000 + + + + obo:DDO.owl#DDO_0006036 + hematologic drug + + + + obo:DDO.owl#DDO_0006037 + DDO:DDO_0006037 + + + + obo:DDO.owl#DDO_0006037 + 81839001 + + + + obo:DDO.owl#DDO_0006037 + anticoagulant + + + + obo:DDO.owl#DDO_0006038 + DDO:DDO_0006038 + + + + obo:DDO.owl#DDO_0006038 + 350471004 + + + + obo:DDO.owl#DDO_0006038 + indirect acting anticoagulant + + + + obo:DDO.owl#DDO_0006039 + DDO:DDO_0006039 + + + + obo:DDO.owl#DDO_0006039 + 350472006 + + + + obo:DDO.owl#DDO_0006039 + coumarin anticoagulant + + + + obo:DDO.owl#DDO_0006040 + DDO:DDO_0006040 + + + + obo:DDO.owl#DDO_0006040 + 423414002 + + + + obo:DDO.owl#DDO_0006040 + dicumarol + + + + obo:DDO.owl#DDO_0006041 + DDO:DDO_0006041 + + + + obo:DDO.owl#DDO_0006041 + obo:DDO.owl#DDO_0006036 + + + + obo:DDO.owl#DDO_0006041 + obo:DDO.owl#DDO_0006036 + + + + obo:DDO.owl#DDO_0006041 + 373708006 + + + + obo:DDO.owl#DDO_0006041 + hematologic agent + + + + obo:DDO.owl#DDO_0006042 + DDO:DDO_0006042 + + + + obo:DDO.owl#DDO_0006042 + 372862008 + + + + obo:DDO.owl#DDO_0006042 + anticoagulant + + + + obo:DDO.owl#DDO_0006043 + DDO:DDO_0006043 + + + + obo:DDO.owl#DDO_0006043 + 419847008 + + + + obo:DDO.owl#DDO_0006043 + indirect acting anticoagulant + + + + obo:DDO.owl#DDO_0006044 + DDO:DDO_0006044 + + + + obo:DDO.owl#DDO_0006044 + 79209008 + + + + obo:DDO.owl#DDO_0006044 + Dicumarol + + + + obo:DDO.owl#DDO_0006045 + DDO:DDO_0006045 + + + + obo:DDO.owl#DDO_0006045 + 372793000 + + + + obo:DDO.owl#DDO_0006045 + diltiazem + + + + obo:DDO.owl#DDO_0006046 + DDO:DDO_0006046 + + + + obo:DDO.owl#DDO_0006046 + 12218006 + + + + obo:DDO.owl#DDO_0006046 + Diltiazem hydrochloride + + + + obo:DDO.owl#DDO_0006047 + DDO:DDO_0006047 + + + + obo:DDO.owl#DDO_0006047 + 410870005 + + + + obo:DDO.owl#DDO_0006047 + diltiazem maleate + + + + obo:DDO.owl#DDO_0006048 + DDO:DDO_0006048 + + + + obo:DDO.owl#DDO_0006048 + 406767004 + + + + obo:DDO.owl#DDO_0006048 + benzothiazepine + + + + obo:DDO.owl#DDO_0006049 + DDO:DDO_0006049 + + + + obo:DDO.owl#DDO_0006049 + 48698004 + + + + obo:DDO.owl#DDO_0006049 + calcium channel blocking agent + + + + obo:DDO.owl#DDO_0006050 + DDO:DDO_0006050 + + + + obo:DDO.owl#DDO_0006050 + 59941008 + + + + obo:DDO.owl#DDO_0006050 + diltiazem + + + + obo:DDO.owl#DDO_0006051 + DDO:DDO_0006051 + + + + obo:DDO.owl#DDO_0006051 + 387633007 + + + + obo:DDO.owl#DDO_0006051 + oral form diltiazem + + + + obo:DDO.owl#DDO_0006052 + DDO:DDO_0006052 + + + + obo:DDO.owl#DDO_0006052 + 387635000 + + + + obo:DDO.owl#DDO_0006052 + diltiazem m/r capsule + + + + obo:DDO.owl#DDO_0006053 + DDO:DDO_0006053 + + + + obo:DDO.owl#DDO_0006053 + 387634001 + + + + obo:DDO.owl#DDO_0006053 + parenteral form diltiazem + + + + obo:DDO.owl#DDO_0006054 + DDO:DDO_0006054 + + + + obo:DDO.owl#DDO_0006054 + 6122008 + + + + obo:DDO.owl#DDO_0006054 + Class Ia antiarrhythmic drug + + + + obo:DDO.owl#DDO_0006055 + DDO:DDO_0006055 + + + + obo:DDO.owl#DDO_0006055 + 76759004 + + + + obo:DDO.owl#DDO_0006055 + disopyramide + + + + obo:DDO.owl#DDO_0006056 + DDO:DDO_0006056 + + + + obo:DDO.owl#DDO_0006056 + 350596003 + + + + obo:DDO.owl#DDO_0006056 + oral form disopyramide + + + + obo:DDO.owl#DDO_0006057 + DDO:DDO_0006057 + + + + obo:DDO.owl#DDO_0006057 + 350597007 + + + + obo:DDO.owl#DDO_0006057 + parenteral form disopyramide + + + + obo:DDO.owl#DDO_0006058 + DDO:DDO_0006058 + + + + obo:DDO.owl#DDO_0006058 + 372844004 + + + + obo:DDO.owl#DDO_0006058 + disopyramide + + + + obo:DDO.owl#DDO_0006059 + DDO:DDO_0006059 + + + + obo:DDO.owl#DDO_0006059 + 49565007 + + + + obo:DDO.owl#DDO_0006059 + disopyramide phosphate + + + + obo:DDO.owl#DDO_0006060 + DDO:DDO_0006060 + + + + obo:DDO.owl#DDO_0006060 + 373269000 + + + + obo:DDO.owl#DDO_0006060 + class Ia antiarrhythmic agent + + + + obo:DDO.owl#DDO_0006061 + DDO:DDO_0006061 + + + + obo:DDO.owl#DDO_0006061 + 68402007 + + + + obo:DDO.owl#DDO_0006061 + carbonic anhydrase inhibitor + + + + obo:DDO.owl#DDO_0006062 + DDO:DDO_0006062 + + + + obo:DDO.owl#DDO_0006062 + 108834004 + + + + obo:DDO.owl#DDO_0006062 + dorzolamide + + + + obo:DDO.owl#DDO_0006063 + DDO:DDO_0006063 + + + + obo:DDO.owl#DDO_0006063 + 372816000 + + + + obo:DDO.owl#DDO_0006063 + carbonic anhydrase inhibitor + + + + obo:DDO.owl#DDO_0006064 + DDO:DDO_0006064 + + + + obo:DDO.owl#DDO_0006064 + 373447009 + + + + obo:DDO.owl#DDO_0006064 + dorzolamide + + + + obo:DDO.owl#DDO_0006065 + DDO:DDO_0006065 + + + + obo:DDO.owl#DDO_0006065 + 126154004 + + + + obo:DDO.owl#DDO_0006065 + dorzolamide hydrochloride + + + + obo:DDO.owl#DDO_0006066 + DDO:DDO_0006066 + + + + obo:DDO.owl#DDO_0006066 + 373496004 + + + + obo:DDO.owl#DDO_0006066 + ophthalmic agent + + + + obo:DDO.owl#DDO_0006067 + DDO:DDO_0006067 + + + + obo:DDO.owl#DDO_0006067 + 417362007 + + + + obo:DDO.owl#DDO_0006067 + anti glaucoma agent + + + + obo:DDO.owl#DDO_0006068 + DDO:DDO_0006068 + + + + obo:DDO.owl#DDO_0006068 + 73572009 + + + + obo:DDO.owl#DDO_0006068 + morphine + + + + obo:DDO.owl#DDO_0006069 + DDO:DDO_0006069 + + + + obo:DDO.owl#DDO_0006069 + 322450002 + + + + obo:DDO.owl#DDO_0006069 + morphine sulfate powder + + + + obo:DDO.owl#DDO_0006070 + DDO:DDO_0006070 + + + + obo:DDO.owl#DDO_0006070 + 350301004 + + + + obo:DDO.owl#DDO_0006070 + oral form morphine + + + + obo:DDO.owl#DDO_0006071 + DDO:DDO_0006071 + + + + obo:DDO.owl#DDO_0006071 + 346581003 + + + + obo:DDO.owl#DDO_0006071 + parenteral form morphine + + + + obo:DDO.owl#DDO_0006072 + DDO:DDO_0006072 + + + + obo:DDO.owl#DDO_0006072 + 322481006 + + + + obo:DDO.owl#DDO_0006072 + morphine analgesic elixirs + + + + obo:DDO.owl#DDO_0006073 + DDO:DDO_0006073 + + + + obo:DDO.owl#DDO_0006073 + 354197007 + + + + obo:DDO.owl#DDO_0006073 + morphine capsule + + + + obo:DDO.owl#DDO_0006074 + DDO:DDO_0006074 + + + + obo:DDO.owl#DDO_0006074 + 322448005 + + + + obo:DDO.owl#DDO_0006074 + morphine hydrochloride powder + + + + obo:DDO.owl#DDO_0006075 + DDO:DDO_0006075 + + + + obo:DDO.owl#DDO_0006075 + 350302006 + + + + obo:DDO.owl#DDO_0006075 + morphine oral granules + + + + obo:DDO.owl#DDO_0006076 + DDO:DDO_0006076 + + + + obo:DDO.owl#DDO_0006076 + 346584006 + + + + obo:DDO.owl#DDO_0006076 + morphine tablets + + + + obo:DDO.owl#DDO_0006077 + DDO:DDO_0006077 + + + + obo:DDO.owl#DDO_0006077 + 346583000 + + + + obo:DDO.owl#DDO_0006077 + rectal form morphine + + + + obo:DDO.owl#DDO_0006078 + DDO:DDO_0006078 + + + + obo:DDO.owl#DDO_0006078 + 373529000 + + + + obo:DDO.owl#DDO_0006078 + morphine + + + + obo:DDO.owl#DDO_0006079 + DDO:DDO_0006079 + + + + obo:DDO.owl#DDO_0006079 + 74905005 + + + + obo:DDO.owl#DDO_0006079 + ethyl morphine + + + + obo:DDO.owl#DDO_0006080 + DDO:DDO_0006080 + + + + obo:DDO.owl#DDO_0006080 + 427021006 + + + + obo:DDO.owl#DDO_0006080 + ethylmorphine hydrochloride + + + + obo:DDO.owl#DDO_0006081 + DDO:DDO_0006081 + + + + obo:DDO.owl#DDO_0006081 + 395804007 + + + + obo:DDO.owl#DDO_0006081 + morphine hydrochloride + + + + obo:DDO.owl#DDO_0006082 + DDO:DDO_0006082 + + + + obo:DDO.owl#DDO_0006082 + 414779007 + + + + obo:DDO.owl#DDO_0006082 + morphine liposome + + + + obo:DDO.owl#DDO_0006083 + DDO:DDO_0006083 + + + + obo:DDO.owl#DDO_0006083 + 426952001 + + + + obo:DDO.owl#DDO_0006083 + morphine sulfate liposome + + + + obo:DDO.owl#DDO_0006084 + DDO:DDO_0006084 + + + + obo:DDO.owl#DDO_0006084 + 60886004 + + + + obo:DDO.owl#DDO_0006084 + morphine sulfate + + + + obo:DDO.owl#DDO_0006085 + DDO:DDO_0006085 + + + + obo:DDO.owl#DDO_0006085 + 426952001 + + + + obo:DDO.owl#DDO_0006085 + morphine sulfate liposome + + + + obo:DDO.owl#DDO_0006086 + DDO:DDO_0006086 + + + + obo:DDO.owl#DDO_0006086 + 442424007 + + + + obo:DDO.owl#DDO_0006086 + morphine tartrate + + + + obo:DDO.owl#DDO_0006087 + DDO:DDO_0006087 + + + + obo:DDO.owl#DDO_0006087 + 96181009 + + + + obo:DDO.owl#DDO_0006087 + nicomorphine + + + + obo:DDO.owl#DDO_0006088 + DDO:DDO_0006088 + + + + obo:DDO.owl#DDO_0006088 + 440327007 + + + + obo:DDO.owl#DDO_0006088 + morphine derivative + + + + obo:DDO.owl#DDO_0006089 + DDO:DDO_0006089 + + + + obo:DDO.owl#DDO_0006089 + 404642006 + + + + obo:DDO.owl#DDO_0006089 + opiate agonist + + + + obo:DDO.owl#DDO_0006090 + DDO:DDO_0006090 + + + + obo:DDO.owl#DDO_0006090 + 406769001 + + + + obo:DDO.owl#DDO_0006090 + dihydropyridine derivative calcium channel blocker + + + + obo:DDO.owl#DDO_0006091 + DDO:DDO_0006091 + + + + obo:DDO.owl#DDO_0006091 + 387490003 + + + + obo:DDO.owl#DDO_0006091 + nifedipine + + + + obo:DDO.owl#DDO_0006092 + DDO:DDO_0006092 + + + + obo:DDO.owl#DDO_0006092 + 373304005 + + + + obo:DDO.owl#DDO_0006092 + calcium channel blocker + + + + obo:DDO.owl#DDO_0006093 + DDO:DDO_0006093 + + + + obo:DDO.owl#DDO_0006093 + 85272000 + + + + obo:DDO.owl#DDO_0006093 + nifedipine + + + + obo:DDO.owl#DDO_0006094 + DDO:DDO_0006094 + + + + obo:DDO.owl#DDO_0006094 + 349916009 + + + + obo:DDO.owl#DDO_0006094 + oral form nifedipine + + + + obo:DDO.owl#DDO_0006095 + DDO:DDO_0006095 + + + + obo:DDO.owl#DDO_0006095 + 346612008 + + + + obo:DDO.owl#DDO_0006095 + parenteral form nifedipine + + + + obo:DDO.owl#DDO_0006096 + DDO:DDO_0006096 + + + + obo:DDO.owl#DDO_0006096 + 372627001 + + + + obo:DDO.owl#DDO_0006096 + chelating agent + + + + obo:DDO.owl#DDO_0006097 + DDO:DDO_0006097 + + + + obo:DDO.owl#DDO_0006097 + 387235007 + + + + obo:DDO.owl#DDO_0006097 + penicillamine + + + + obo:DDO.owl#DDO_0006098 + DDO:DDO_0006098 + + + + obo:DDO.owl#DDO_0006098 + 387528000 + + + + obo:DDO.owl#DDO_0006098 + phenelzine + + + + obo:DDO.owl#DDO_0006099 + DDO:DDO_0006099 + + + + obo:DDO.owl#DDO_0006099 + 21614004 + + + + obo:DDO.owl#DDO_0006099 + phenelzine sulfate + + + + obo:DDO.owl#DDO_0006100 + DDO:DDO_0006100 + + + + obo:DDO.owl#DDO_0006100 + 373281001 + + + + obo:DDO.owl#DDO_0006100 + monoamine oxidase inhibitor + + + + obo:DDO.owl#DDO_0006101 + DDO:DDO_0006101 + + + + obo:DDO.owl#DDO_0006101 + 418510009 + + + + obo:DDO.owl#DDO_0006101 + monoamine oxidase A inhibitor + + + + obo:DDO.owl#DDO_0006102 + DDO:DDO_0006102 + + + + obo:DDO.owl#DDO_0006102 + 387365004 + + + + obo:DDO.owl#DDO_0006102 + probenecid + + + + obo:DDO.owl#DDO_0006103 + DDO:DDO_0006103 + + + + obo:DDO.owl#DDO_0006103 + 372758007 + + + + obo:DDO.owl#DDO_0006103 + uricosuric agent + + + + obo:DDO.owl#DDO_0006104 + DDO:DDO_0006104 + + + + obo:DDO.owl#DDO_0006104 + 330060000 + + + + obo:DDO.owl#DDO_0006104 + drugs for the treatment of gout + + + + obo:DDO.owl#DDO_0006105 + DDO:DDO_0006105 + + + + obo:DDO.owl#DDO_0006105 + 49157004 + + + + obo:DDO.owl#DDO_0006105 + uricosuric agent + + + + obo:DDO.owl#DDO_0006106 + DDO:DDO_0006106 + + + + obo:DDO.owl#DDO_0006106 + 66094001 + + + + obo:DDO.owl#DDO_0006106 + probenecid + + + + obo:DDO.owl#DDO_0006107 + DDO:DDO_0006107 + + + + obo:DDO.owl#DDO_0006107 + 80229008 + + + + obo:DDO.owl#DDO_0006107 + antimalarial agent + + + + obo:DDO.owl#DDO_0006108 + DDO:DDO_0006108 + + + + obo:DDO.owl#DDO_0006108 + 350224008 + + + + obo:DDO.owl#DDO_0006108 + Cinchona antimalarial + + + + obo:DDO.owl#DDO_0006109 + DDO:DDO_0006109 + + + + obo:DDO.owl#DDO_0006109 + 47065008 + + + + obo:DDO.owl#DDO_0006109 + quinine + + + + obo:DDO.owl#DDO_0006110 + DDO:DDO_0006110 + + + + obo:DDO.owl#DDO_0006110 + 373723001 + + + + obo:DDO.owl#DDO_0006110 + cinchona alkaloid + + + + obo:DDO.owl#DDO_0006111 + DDO:DDO_0006111 + + + + obo:DDO.owl#DDO_0006111 + 373497008 + + + + obo:DDO.owl#DDO_0006111 + quinine + + + + obo:DDO.owl#DDO_0006112 + DDO:DDO_0006112 + + + + obo:DDO.owl#DDO_0006112 + 47857006 + + + + obo:DDO.owl#DDO_0006112 + quinine sulfate + + + + obo:DDO.owl#DDO_0006113 + DDO:DDO_0006113 + + + + obo:DDO.owl#DDO_0006113 + 66508001 + + + + obo:DDO.owl#DDO_0006113 + quinine hydrochloride + + + + obo:DDO.owl#DDO_0006114 + DDO:DDO_0006114 + + + + obo:DDO.owl#DDO_0006114 + 395854001 + + + + obo:DDO.owl#DDO_0006114 + quinine dihydrochloride + + + + obo:DDO.owl#DDO_0006115 + DDO:DDO_0006115 + + + + obo:DDO.owl#DDO_0006115 + 395852002 + + + + obo:DDO.owl#DDO_0006115 + quinine bisulfate + + + + obo:DDO.owl#DDO_0006116 + DDO:DDO_0006116 + + + + obo:DDO.owl#DDO_0006116 + 373287002 + + + + obo:DDO.owl#DDO_0006116 + antimalarial agent + + + + obo:DDO.owl#DDO_0006117 + DDO:DDO_0006117 + + + + obo:DDO.owl#DDO_0006117 + 420946006 + + + + obo:DDO.owl#DDO_0006117 + streptogramin + + + + obo:DDO.owl#DDO_0006118 + DDO:DDO_0006118 + + + + obo:DDO.owl#DDO_0006118 + 387015002 + + + + obo:DDO.owl#DDO_0006118 + quinupristin + + + + obo:DDO.owl#DDO_0006119 + DDO:DDO_0006119 + + + + obo:DDO.owl#DDO_0006119 + 441592000 + + + + obo:DDO.owl#DDO_0006119 + quinupristin mesilate + + + + obo:DDO.owl#DDO_0006120 + DDO:DDO_0006120 + + + + obo:DDO.owl#DDO_0006120 + 422292008 + + + + obo:DDO.owl#DDO_0006120 + streptogramin + + + + obo:DDO.owl#DDO_0006121 + DDO:DDO_0006121 + + + + obo:DDO.owl#DDO_0006121 + 116110009 + + + + obo:DDO.owl#DDO_0006121 + Quinupristin + + + + obo:DDO.owl#DDO_0006122 + DDO:DDO_0006122 + + + + obo:DDO.owl#DDO_0006122 + 387016001 + + + + obo:DDO.owl#DDO_0006122 + dalfopristin + + + + obo:DDO.owl#DDO_0006123 + DDO:DDO_0006123 + + + + obo:DDO.owl#DDO_0006123 + 427378005 + + + + obo:DDO.owl#DDO_0006123 + dalfopristin mesilate + + + + obo:DDO.owl#DDO_0006124 + DDO:DDO_0006124 + + + + obo:DDO.owl#DDO_0006124 + 116111008 + + + + obo:DDO.owl#DDO_0006124 + Dalfopristin + + + + obo:DDO.owl#DDO_0006126 + DDO:DDO_0006126 + + + + obo:DDO.owl#DDO_0006126 + 89785009 + + + + obo:DDO.owl#DDO_0006126 + ritodrine + + + + obo:DDO.owl#DDO_0006127 + DDO:DDO_0006127 + + + + obo:DDO.owl#DDO_0006127 + 437963001 + + + + obo:DDO.owl#DDO_0006127 + oral form ritodrine + + + + obo:DDO.owl#DDO_0006128 + DDO:DDO_0006128 + + + + obo:DDO.owl#DDO_0006128 + 437744007 + + + + obo:DDO.owl#DDO_0006128 + parenteral form ritodrine + + + + obo:DDO.owl#DDO_0006129 + DDO:DDO_0006129 + + + + obo:DDO.owl#DDO_0006129 + 372893009 + + + + obo:DDO.owl#DDO_0006129 + ritodrine + + + + obo:DDO.owl#DDO_0006130 + DDO:DDO_0006130 + + + + obo:DDO.owl#DDO_0006130 + 86257005 + + + + obo:DDO.owl#DDO_0006130 + ritodrine hydrochloride + + + + obo:DDO.owl#DDO_0006131 + DDO:DDO_0006131 + + + + obo:DDO.owl#DDO_0006131 + 386919002 + + + + obo:DDO.owl#DDO_0006131 + rituximab + + + + obo:DDO.owl#DDO_0006132 + DDO:DDO_0006132 + + + + obo:DDO.owl#DDO_0006132 + 58050004 + + + + obo:DDO.owl#DDO_0006132 + antiparkinsonian agent + + + + obo:DDO.owl#DDO_0006133 + DDO:DDO_0006133 + + + + obo:DDO.owl#DDO_0006133 + 384952006 + + + + obo:DDO.owl#DDO_0006133 + dopamine agonist product + + + + obo:DDO.owl#DDO_0006134 + DDO:DDO_0006134 + + + + obo:DDO.owl#DDO_0006134 + 421915002 + + + + obo:DDO.owl#DDO_0006134 + rotigotine + + + + obo:DDO.owl#DDO_0006136 + DDO:DDO_0006136 + + + + obo:DDO.owl#DDO_0006136 + 421144001 + + + + obo:DDO.owl#DDO_0006136 + aliphatic amine + + + + obo:DDO.owl#DDO_0006137 + DDO:DDO_0006137 + + + + obo:DDO.owl#DDO_0006137 + 422209006 + + + + obo:DDO.owl#DDO_0006137 + aralkylamine + + + + obo:DDO.owl#DDO_0006138 + DDO:DDO_0006138 + + + + obo:DDO.owl#DDO_0006138 + 421924006 + + + + obo:DDO.owl#DDO_0006138 + rotigotine + + + + obo:DDO.owl#DDO_0006139 + DDO:DDO_0006139 + + + + obo:DDO.owl#DDO_0006139 + 418222008 + + + + obo:DDO.owl#DDO_0006139 + dopamine agonist agent + + + + obo:DDO.owl#DDO_0006140 + DDO:DDO_0006140 + + + + obo:DDO.owl#DDO_0006140 + 387072007 + + + + obo:DDO.owl#DDO_0006140 + salsalate + + + + obo:DDO.owl#DDO_0006141 + DDO:DDO_0006141 + + + + obo:DDO.owl#DDO_0006141 + 13252002 + + + + obo:DDO.owl#DDO_0006141 + salsalate + + + + obo:DDO.owl#DDO_0006143 + DDO:DDO_0006143 + + + + obo:DDO.owl#DDO_0006143 + 443066009 + + + + obo:DDO.owl#DDO_0006143 + C1611934 + + + + obo:DDO.owl#DDO_0006143 + saxagliptin + + + + obo:DDO.owl#DDO_0006144 + DDO:DDO_0006144 + + + + obo:DDO.owl#DDO_0006144 + 372783007 + + + + obo:DDO.owl#DDO_0006144 + antiparkinsonian agent + + + + obo:DDO.owl#DDO_0006145 + DDO:DDO_0006145 + + + + obo:DDO.owl#DDO_0006145 + 372497003 + + + + obo:DDO.owl#DDO_0006145 + selegiline + + + + obo:DDO.owl#DDO_0006146 + DDO:DDO_0006146 + + + + obo:DDO.owl#DDO_0006146 + 108467009 + + + + obo:DDO.owl#DDO_0006146 + selegiline hydrochloride + + + + obo:DDO.owl#DDO_0006147 + DDO:DDO_0006147 + + + + obo:DDO.owl#DDO_0006147 + 373242001 + + + + obo:DDO.owl#DDO_0006147 + monoamine oxidase B inhibitor + + + + obo:DDO.owl#DDO_0006148 + DDO:DDO_0006148 + + + + obo:DDO.owl#DDO_0006148 + 404876000 + + + + obo:DDO.owl#DDO_0006148 + streptozocin + + + + obo:DDO.owl#DDO_0006149 + DDO:DDO_0006149 + + + + obo:DDO.owl#DDO_0006149 + 16915004 + + + + obo:DDO.owl#DDO_0006149 + Streptozocin + + + + obo:DDO.owl#DDO_0006150 + DDO:DDO_0006150 + + + + obo:DDO.owl#DDO_0006150 + 372788003 + + + + obo:DDO.owl#DDO_0006150 + sulfonamide -class of antibiotic- + + + + obo:DDO.owl#DDO_0006151 + DDO:DDO_0006151 + + + + obo:DDO.owl#DDO_0006151 + 74523009 + + + + obo:DDO.owl#DDO_0006151 + sulfadiazine + + + + obo:DDO.owl#DDO_0006152 + DDO:DDO_0006152 + + + + obo:DDO.owl#DDO_0006152 + 45120003 + + + + obo:DDO.owl#DDO_0006152 + ester + + + + obo:DDO.owl#DDO_0006153 + DDO:DDO_0006153 + + + + obo:DDO.owl#DDO_0006153 + 373518004 + + + + obo:DDO.owl#DDO_0006153 + ester type local anesthetic + + + + obo:DDO.owl#DDO_0006154 + DDO:DDO_0006154 + + + + obo:DDO.owl#DDO_0006154 + 387309008 + + + + obo:DDO.owl#DDO_0006154 + tetracaine + + + + obo:DDO.owl#DDO_0006156 + DDO:DDO_0006156 + + + + obo:DDO.owl#DDO_0006156 + 51844001 + + + + obo:DDO.owl#DDO_0006156 + tetracaine hydrochloride + + + + obo:DDO.owl#DDO_0006157 + DDO:DDO_0006157 + + + + obo:DDO.owl#DDO_0006157 + 5776009 + + + + obo:DDO.owl#DDO_0006157 + anesthetic + + + + obo:DDO.owl#DDO_0006158 + DDO:DDO_0006158 + + + + obo:DDO.owl#DDO_0006158 + 27548001 + + + + obo:DDO.owl#DDO_0006158 + local anesthetic + + + + obo:DDO.owl#DDO_0006159 + DDO:DDO_0006159 + + + + obo:DDO.owl#DDO_0006159 + 66672008 + + + + obo:DDO.owl#DDO_0006159 + ester type local anesthetic + + + + obo:DDO.owl#DDO_0006160 + DDO:DDO_0006160 + + + + obo:DDO.owl#DDO_0006160 + 55556000 + + + + obo:DDO.owl#DDO_0006160 + C0039629 + + + + obo:DDO.owl#DDO_0006160 + tetracaine + + + + obo:DDO.owl#DDO_0006161 + DDO:DDO_0006161 + + + + obo:DDO.owl#DDO_0006161 + 370301003 + + + + obo:DDO.owl#DDO_0006161 + topical form tetracaine + + + + obo:DDO.owl#DDO_0006162 + DDO:DDO_0006162 + + + + obo:DDO.owl#DDO_0006162 + 437974005 + + + + obo:DDO.owl#DDO_0006162 + parenteral form tetracaine + + + + obo:DDO.owl#DDO_0006163 + DDO:DDO_0006163 + + + + obo:DDO.owl#DDO_0006163 + 437877002 + + + + obo:DDO.owl#DDO_0006163 + oropharyngeal form tetracaine + + + + obo:DDO.owl#DDO_0006164 + DDO:DDO_0006164 + + + + obo:DDO.owl#DDO_0006164 + 421989004 + + + + obo:DDO.owl#DDO_0006164 + ophthalmic form tetracaine + + + + obo:DDO.owl#DDO_0006165 + DDO:DDO_0006165 + + + + obo:DDO.owl#DDO_0006165 + 320356001 + + + + obo:DDO.owl#DDO_0006165 + xanthine bronchodilators + + + + obo:DDO.owl#DDO_0006166 + DDO:DDO_0006166 + + + + obo:DDO.owl#DDO_0006166 + 66493003 + + + + obo:DDO.owl#DDO_0006166 + theophylline + + + + obo:DDO.owl#DDO_0006167 + DDO:DDO_0006167 + + + + obo:DDO.owl#DDO_0006167 + 387797001 + + + + obo:DDO.owl#DDO_0006167 + oral form theophylline + + + + obo:DDO.owl#DDO_0006168 + DDO:DDO_0006168 + + + + obo:DDO.owl#DDO_0006168 + 387796005 + + + + obo:DDO.owl#DDO_0006168 + theophylline m/r + + + + obo:DDO.owl#DDO_0006169 + DDO:DDO_0006169 + + + + obo:DDO.owl#DDO_0006169 + 398957005 + + + + obo:DDO.owl#DDO_0006169 + oxtriphylline + + + + obo:DDO.owl#DDO_0006170 + DDO:DDO_0006170 + + + + obo:DDO.owl#DDO_0006170 + 430224000 + + + + obo:DDO.owl#DDO_0006170 + parenteral form theophylline + + + + obo:DDO.owl#DDO_0006171 + DDO:DDO_0006171 + + + + obo:DDO.owl#DDO_0006171 + 75748004 + + + + obo:DDO.owl#DDO_0006171 + theophylline sodium glycinate + + + + obo:DDO.owl#DDO_0006172 + DDO:DDO_0006172 + + + + obo:DDO.owl#DDO_0006172 + 86498000 + + + + obo:DDO.owl#DDO_0006172 + respiratory smooth muscle relaxant + + + + obo:DDO.owl#DDO_0006173 + DDO:DDO_0006173 + + + + obo:DDO.owl#DDO_0006173 + 372891006 + + + + obo:DDO.owl#DDO_0006173 + tranylcypromine + + + + obo:DDO.owl#DDO_0006174 + DDO:DDO_0006174 + + + + obo:DDO.owl#DDO_0006174 + 89772006 + + + + obo:DDO.owl#DDO_0006174 + tranylcypromine sulfate + + + + obo:DDO.owl#DDO_0006178 + DDO:DDO_0006178 + + + + obo:DDO.owl#DDO_0006178 + 420115006 + + + + obo:DDO.owl#DDO_0006178 + drugs used to treat addiction + + + + obo:DDO.owl#DDO_0006179 + DDO:DDO_0006179 + + + + obo:DDO.owl#DDO_0006179 + 421772003 + + + + obo:DDO.owl#DDO_0006179 + varenicline + + + + obo:DDO.owl#DDO_0006180 + DDO:DDO_0006180 + + + + obo:DDO.owl#DDO_0006180 + 428382005 + + + + obo:DDO.owl#DDO_0006180 + varenicline tartrate + + + + obo:DDO.owl#DDO_0006181 + DDO:DDO_0006181 + + + + obo:DDO.owl#DDO_0006181 + 47898004 + + + + obo:DDO.owl#DDO_0006181 + verapamil + + + + obo:DDO.owl#DDO_0006182 + DDO:DDO_0006182 + + + + obo:DDO.owl#DDO_0006182 + 350599005 + + + + obo:DDO.owl#DDO_0006182 + oral form verapamil + + + + obo:DDO.owl#DDO_0006183 + DDO:DDO_0006183 + + + + obo:DDO.owl#DDO_0006183 + 346703000 + + + + obo:DDO.owl#DDO_0006183 + modified release verapamil + + + + obo:DDO.owl#DDO_0006184 + DDO:DDO_0006184 + + + + obo:DDO.owl#DDO_0006184 + 350600008 + + + + obo:DDO.owl#DDO_0006184 + parenteral form verapamil + + + + obo:DDO.owl#DDO_0006185 + DDO:DDO_0006185 + + + + obo:DDO.owl#DDO_0006185 + 29883004 + + + + obo:DDO.owl#DDO_0006185 + Class IV antiarrhythmic drug + + + + obo:DDO.owl#DDO_0006186 + DDO:DDO_0006186 + + + + obo:DDO.owl#DDO_0006186 + 406766008 + + + + obo:DDO.owl#DDO_0006186 + phenylalkylamine + + + + obo:DDO.owl#DDO_0006187 + DDO:DDO_0006187 + + + + obo:DDO.owl#DDO_0006187 + 372754009 + + + + obo:DDO.owl#DDO_0006187 + verapamil + + + + obo:DDO.owl#DDO_0006188 + DDO:DDO_0006188 + + + + obo:DDO.owl#DDO_0006188 + 96297006 + + + + obo:DDO.owl#DDO_0006188 + Norverapamil + + + + obo:DDO.owl#DDO_0006189 + DDO:DDO_0006189 + + + + obo:DDO.owl#DDO_0006189 + 14340003 + + + + obo:DDO.owl#DDO_0006189 + verapamil hydrochloride + + + + obo:DDO.owl#DDO_0006190 + DDO:DDO_0006190 + + + + obo:DDO.owl#DDO_0006190 + 372805007 + + + + obo:DDO.owl#DDO_0006190 + clonidine + + + + obo:DDO.owl#DDO_0006191 + DDO:DDO_0006191 + + + + obo:DDO.owl#DDO_0006191 + 387121001 + + + + obo:DDO.owl#DDO_0006191 + clonidine hydrochloride + + + + obo:DDO.owl#DDO_0006192 + DDO:DDO_0006192 + + + + obo:DDO.owl#DDO_0006192 + 349933002 + + + + obo:DDO.owl#DDO_0006192 + central alpha-adrenoceptor agonist + + + + obo:DDO.owl#DDO_0006193 + DDO:DDO_0006193 + + + + obo:DDO.owl#DDO_0006193 + 62782004 + + + + obo:DDO.owl#DDO_0006193 + clonidine + + + + obo:DDO.owl#DDO_0006194 + DDO:DDO_0006194 + + + + obo:DDO.owl#DDO_0006194 + 387805009 + + + + obo:DDO.owl#DDO_0006194 + oral form clonidine + + + + obo:DDO.owl#DDO_0006195 + DDO:DDO_0006195 + + + + obo:DDO.owl#DDO_0006195 + 387807001 + + + + obo:DDO.owl#DDO_0006195 + parenteral form clonidine + + + + obo:DDO.owl#DDO_0006196 + DDO:DDO_0006196 + + + + obo:DDO.owl#DDO_0006196 + 387806005 + + + + obo:DDO.owl#DDO_0006196 + transdermal clonidine + + + + obo:DDO.owl#DDO_0006197 + DDO:DDO_0006197 + + + + obo:DDO.owl#DDO_0006197 + 417927007 + + + + obo:DDO.owl#DDO_0006197 + antibiotic antituberculosis agent + + + + obo:DDO.owl#DDO_0006198 + DDO:DDO_0006198 + + + + obo:DDO.owl#DDO_0006198 + 387159009 + + + + obo:DDO.owl#DDO_0006198 + rifampicin + + + + obo:DDO.owl#DDO_0006199 + DDO:DDO_0006199 + + + + obo:DDO.owl#DDO_0006199 + 350216003 + + + + obo:DDO.owl#DDO_0006199 + antimycobacterial agent + + + + obo:DDO.owl#DDO_0006200 + DDO:DDO_0006200 + + + + obo:DDO.owl#DDO_0006200 + 324453004 + + + + obo:DDO.owl#DDO_0006200 + antituberculous drugs + + + + obo:DDO.owl#DDO_0006201 + DDO:DDO_0006201 + + + + obo:DDO.owl#DDO_0006201 + 29175007 + + + + obo:DDO.owl#DDO_0006201 + rifampin + + + + obo:DDO.owl#DDO_0006202 + DDO:DDO_0006202 + + + + obo:DDO.owl#DDO_0006202 + 438137009 + + + + obo:DDO.owl#DDO_0006202 + oral form rifampicin + + + + obo:DDO.owl#DDO_0006203 + DDO:DDO_0006203 + + + + obo:DDO.owl#DDO_0006203 + 437966009 + + + + obo:DDO.owl#DDO_0006203 + parenteral form rifampicin + + + + obo:DDO.owl#DDO_0006204 + DDO:DDO_0006204 + + + + obo:DDO.owl#DDO_0006204 + 427059003 + + + + obo:DDO.owl#DDO_0006204 + transferase inhibitor + + + + obo:DDO.owl#DDO_0006205 + DDO:DDO_0006205 + + + + obo:DDO.owl#DDO_0006205 + 427620008 + + + + obo:DDO.owl#DDO_0006205 + phosphotransferase inhibitor + + + + obo:DDO.owl#DDO_0006206 + DDO:DDO_0006206 + + + + obo:DDO.owl#DDO_0006206 + 427510007 + + + + obo:DDO.owl#DDO_0006206 + protein kinase inhibitor + + + + obo:DDO.owl#DDO_0006207 + DDO:DDO_0006207 + + + + obo:DDO.owl#DDO_0006207 + 129557000 + + + + obo:DDO.owl#DDO_0006207 + protein-tyrosine kinase inhibitor + + + + obo:DDO.owl#DDO_0006208 + DDO:DDO_0006208 + + + + obo:DDO.owl#DDO_0006208 + 421448007 + + + + obo:DDO.owl#DDO_0006208 + sunitinib + + + + obo:DDO.owl#DDO_0006209 + DDO:DDO_0006209 + + + + obo:DDO.owl#DDO_0006209 + 409403004 + + + + obo:DDO.owl#DDO_0006209 + epidermal growth factor receptor inhibitor + + + + obo:DDO.owl#DDO_0006210 + DDO:DDO_0006210 + + + + obo:DDO.owl#DDO_0006210 + 372917005 + + + + obo:DDO.owl#DDO_0006210 + protein-tyrosine kinase inhibitor + + + + obo:DDO.owl#DDO_0006211 + DDO:DDO_0006211 + + + + obo:DDO.owl#DDO_0006211 + 421192001 + + + + obo:DDO.owl#DDO_0006211 + sunitinib + + + + obo:DDO.owl#DDO_0006212 + DDO:DDO_0006212 + + + + obo:DDO.owl#DDO_0006212 + 426455008 + + + + obo:DDO.owl#DDO_0006212 + sunitinib malate + + + + obo:DDO.owl#DDO_0006213 + DDO:DDO_0006213 + + + + obo:DDO.owl#DDO_0006213 + 318034005 + + + + obo:DDO.owl#DDO_0006213 + torsemide + + + + obo:DDO.owl#DDO_0006214 + DDO:DDO_0006214 + + + + obo:DDO.owl#DDO_0006214 + 350614008 + + + + obo:DDO.owl#DDO_0006214 + oral form torsemide + + + + obo:DDO.owl#DDO_0006215 + DDO:DDO_0006215 + + + + obo:DDO.owl#DDO_0006215 + 350615009 + + + + obo:DDO.owl#DDO_0006215 + parenteral form torsemide + + + + obo:DDO.owl#DDO_0006220 + DDO:DDO_0006220 + + + + obo:DDO.owl#DDO_0006220 + 108476002 + + + + obo:DDO.owl#DDO_0006220 + torsemide + + + + obo:DDO.owl#DDO_0006222 + DDO:DDO_0006222 + + + + obo:DDO.owl#DDO_0006222 + 6028009 + + + + obo:DDO.owl#DDO_0006222 + triamcinolone preparation + + + + obo:DDO.owl#DDO_0006223 + DDO:DDO_0006223 + + + + obo:DDO.owl#DDO_0006223 + 109068004 + + + + obo:DDO.owl#DDO_0006223 + triamcinolone hexacetonide + + + + obo:DDO.owl#DDO_0006224 + DDO:DDO_0006224 + + + + obo:DDO.owl#DDO_0006224 + 120634008 + + + + obo:DDO.owl#DDO_0006224 + triamcinolone acetonide topical preparation + + + + obo:DDO.owl#DDO_0006225 + DDO:DDO_0006225 + + + + obo:DDO.owl#DDO_0006225 + 350465005 + + + + obo:DDO.owl#DDO_0006225 + topical form triamcinolone + + + + obo:DDO.owl#DDO_0006226 + DDO:DDO_0006226 + + + + obo:DDO.owl#DDO_0006226 + 429980003 + + + + obo:DDO.owl#DDO_0006226 + respiratory form triamcinolone + + + + obo:DDO.owl#DDO_0006227 + DDO:DDO_0006227 + + + + obo:DDO.owl#DDO_0006227 + 350464009 + + + + obo:DDO.owl#DDO_0006227 + parenteral form triamcinolone + + + + obo:DDO.owl#DDO_0006228 + DDO:DDO_0006228 + + + + obo:DDO.owl#DDO_0006228 + 430721007 + + + + obo:DDO.owl#DDO_0006228 + otic form triamcinolone + + + + obo:DDO.owl#DDO_0006229 + DDO:DDO_0006229 + + + + obo:DDO.owl#DDO_0006229 + 4753002 + + + + obo:DDO.owl#DDO_0006229 + triamcinolone dental paste + + + + obo:DDO.owl#DDO_0006230 + DDO:DDO_0006230 + + + + obo:DDO.owl#DDO_0006230 + 430791003 + + + + obo:DDO.owl#DDO_0006230 + oropharyngeal form triamcinolone + + + + obo:DDO.owl#DDO_0006231 + DDO:DDO_0006231 + + + + obo:DDO.owl#DDO_0006231 + 350463003 + + + + obo:DDO.owl#DDO_0006231 + oral form triamcinolone + + + + obo:DDO.owl#DDO_0006232 + DDO:DDO_0006232 + + + + obo:DDO.owl#DDO_0006232 + 356556006 + + + + obo:DDO.owl#DDO_0006232 + nasal triamcinolone + + + + obo:DDO.owl#DDO_0006233 + DDO:DDO_0006233 + + + + obo:DDO.owl#DDO_0006233 + 387080000 + + + + obo:DDO.owl#DDO_0006233 + valproic acid + + + + obo:DDO.owl#DDO_0006234 + DDO:DDO_0006234 + + + + obo:DDO.owl#DDO_0006234 + 372812003 + + + + obo:DDO.owl#DDO_0006234 + valproate + + + + obo:DDO.owl#DDO_0006235 + DDO:DDO_0006235 + + + + obo:DDO.owl#DDO_0006235 + 5641004 + + + + obo:DDO.owl#DDO_0006235 + divalproex sodium + + + + obo:DDO.owl#DDO_0006236 + DDO:DDO_0006236 + + + + obo:DDO.owl#DDO_0006236 + 387481005 + + + + obo:DDO.owl#DDO_0006236 + valproate sodium + + + + obo:DDO.owl#DDO_0006237 + DDO:DDO_0006237 + + + + obo:DDO.owl#DDO_0006237 + 13965000 + + + + obo:DDO.owl#DDO_0006237 + valproic acid + + + + obo:DDO.owl#DDO_0006238 + DDO:DDO_0006238 + + + + obo:DDO.owl#DDO_0006238 + 67477004 + + + + obo:DDO.owl#DDO_0006238 + valproate + + + + obo:DDO.owl#DDO_0006239 + DDO:DDO_0006239 + + + + obo:DDO.owl#DDO_0006239 + 349891004 + + + + obo:DDO.owl#DDO_0006239 + oral form sodium valproate + + + + obo:DDO.owl#DDO_0006240 + DDO:DDO_0006240 + + + + obo:DDO.owl#DDO_0006240 + 349892006 + + + + obo:DDO.owl#DDO_0006240 + parenteral form sodium valproate + + + + obo:DDO.owl#DDO_0006244 + DDO:DDO_0006244 + + + + obo:DDO.owl#DDO_0006244 + part organ + + + + obo:DDO.owl#DDO_0006245 + DDO:DDO_0006245 + + + + obo:DDO.owl#DDO_0006245 + 181414000 + + + + obo:DDO.owl#DDO_0006245 + kidney + + + + obo:DDO.owl#DDO_0006246 + DDO:DDO_0006246 + + + + obo:DDO.owl#DDO_0006246 + 10200004 + + + + obo:DDO.owl#DDO_0006246 + liver + + + + obo:DDO.owl#DDO_0006247 + DDO:DDO_0006247 + + + + obo:DDO.owl#DDO_0006247 + 56459004 + + + + obo:DDO.owl#DDO_0006247 + foot + + + + obo:DDO.owl#DDO_0006248 + DDO:DDO_0006248 + + + + obo:DDO.owl#DDO_0006248 + 244486005 + + + + obo:DDO.owl#DDO_0006248 + eye + + + + obo:DDO.owl#DDO_0006249 + DDO:DDO_0006249 + + + + obo:DDO.owl#DDO_0006249 + 21483005 + + + + obo:DDO.owl#DDO_0006249 + central nervous system + + + + obo:DDO.owl#DDO_0006250 + DDO:DDO_0006250 + + + + obo:DDO.owl#DDO_0006250 + 59820001 + + + + obo:DDO.owl#DDO_0006250 + blood vessel + + + + obo:DDO.owl#DDO_0006251 + DDO:DDO_0006251 + + + + obo:DDO.owl#DDO_0006251 + 51114001 + + + + obo:DDO.owl#DDO_0006251 + artery + + + + obo:DDO.owl#DDO_0006252 + DDO:DDO_0006252 + + + + obo:DDO.owl#DDO_0006252 + 80891009 + + + + obo:DDO.owl#DDO_0006252 + heart + + + + obo:DDO.owl#DDO_0006253 + DDO:DDO_0006253 + + + + obo:DDO.owl#DDO_0006253 + 69695003 + + + + obo:DDO.owl#DDO_0006253 + stomach + + + + obo:DDO.owl#DDO_0006254 + DDO:DDO_0006254 + + + + obo:DDO.owl#DDO_0006254 + 113331007 + + + + obo:DDO.owl#DDO_0006254 + endocrine system + + + + obo:DDO.owl#DDO_0006255 + DDO:DDO_0006255 + + + + obo:DDO.owl#DDO_0006255 + 15776009 + + + + obo:DDO.owl#DDO_0006255 + pancreas + + + + obo:DDO.owl#DDO_0006256 + DDO:DDO_0006256 + + + + obo:DDO.owl#DDO_0006256 + 86762007 + + + + obo:DDO.owl#DDO_0006256 + digestive system + + + + obo:DDO.owl#DDO_0006257 + DDO:DDO_0006257 + + + + obo:DDO.owl#DDO_0006257 + 113257007 + + + + obo:DDO.owl#DDO_0006257 + Circulatory System + + + + obo:DDO.owl#DDO_0006257 + cardiovascular system + + + + obo:DDO.owl#DDO_0006258 + DDO:DDO_0006258 + + + + obo:DDO.owl#DDO_0006258 + 48075008 + + + + obo:DDO.owl#DDO_0006258 + integumentary system + + + + obo:DDO.owl#DDO_0006259 + DDO:DDO_0006259 + + + + obo:DDO.owl#DDO_0006259 + 278875001 + + + + obo:DDO.owl#DDO_0006259 + reproductive system + + + + obo:DDO.owl#DDO_0006260 + DDO:DDO_0006260 + + + + obo:DDO.owl#DDO_0006260 + 89837001 + + + + obo:DDO.owl#DDO_0006260 + bladder + + + + obo:DDO.owl#DDO_0006261 + DDO:DDO_0006261 + + + + obo:DDO.owl#DDO_0006261 + 20139000 + + + + obo:DDO.owl#DDO_0006261 + respiratory system + + + + obo:DDO.owl#DDO_0006262 + DDO:DDO_0006262 + + + + obo:DDO.owl#DDO_0006262 + 122489005 + + + + obo:DDO.owl#DDO_0006262 + urinary system + + + + obo:DDO.owl#DDO_0006263 + DDO:DDO_0006263 + + + + obo:DDO.owl#DDO_0006263 + 113192009 + + + + obo:DDO.owl#DDO_0006263 + skeletal system + + + + obo:DDO.owl#DDO_0006264 + DDO:DDO_0006264 + + + + obo:DDO.owl#DDO_0006264 + 12738006 + + + + obo:DDO.owl#DDO_0006264 + brain + + + + obo:DDO.owl#DDO_0006265 + DDO:DDO_0006265 + + + + obo:DDO.owl#DDO_0006265 + millimoles per liter + + + + obo:DDO.owl#DDO_0006266 + DDO:DDO_0006266 + + + + obo:DDO.owl#DDO_0006266 + millimeters of mercury + + + + obo:DDO.owl#DDO_0006267 + DDO:DDO_0006267 + + + + obo:DDO.owl#DDO_0006267 + cells per milliliter + + + + obo:DDO.owl#DDO_0006268 + DDO:DDO_0006268 + + + + obo:DDO.owl#DDO_0006268 + international units per liter + + + + obo:DDO.owl#DDO_0006269 + DDO:DDO_0006269 + + + + obo:DDO.owl#DDO_0006269 + miligram per deciliter + + + + obo:DDO.owl#DDO_0006270 + DDO:DDO_0006270 + + + + obo:DDO.owl#DDO_0006270 + milliequivalents per liter + + + + obo:DDO.owl#DDO_0006271 + DDO:DDO_0006271 + + + + obo:DDO.owl#DDO_0006271 + millimoles per milliliter + + + + obo:DDO.owl#DDO_0006272 + DDO:DDO_0006272 + + + + obo:DDO.owl#DDO_0006272 + 122481008 + + + + obo:DDO.owl#DDO_0006272 + hammer toe + + + + obo:DDO.owl#DDO_0006273 + DDO:DDO_0006273 + + + + obo:DDO.owl#DDO_0006273 + 45636002 + + + + obo:DDO.owl#DDO_0006273 + acquired hallux malleus + + + + obo:DDO.owl#DDO_0006274 + DDO:DDO_0006274 + + + + obo:DDO.owl#DDO_0006274 + 85280007 + + + + obo:DDO.owl#DDO_0006274 + congenital hammer toe + + + + obo:DDO.owl#DDO_0006275 + DDO:DDO_0006275 + + + + obo:DDO.owl#DDO_0006275 + 707742001 + + + + obo:DDO.owl#DDO_0006275 + Bartter syndrome + + + + obo:DDO.owl#DDO_0006276 + DDO:DDO_0006276 + + + + obo:DDO.owl#DDO_0006276 + 700111000 + + + + obo:DDO.owl#DDO_0006276 + Bartter syndrome type 3 + + + + obo:DDO.owl#DDO_0006277 + DDO:DDO_0006277 + + + + obo:DDO.owl#DDO_0006277 + 236465009 + + + + obo:DDO.owl#DDO_0006277 + Bartter's syndrome with hypercalciuria and nephrocalcinosis + + + + obo:DDO.owl#DDO_0006278 + DDO:DDO_0006278 + + + + obo:DDO.owl#DDO_0006278 + 700107006 + + + + obo:DDO.owl#DDO_0006278 + Bartter syndrome antenatal type 1 + + + + obo:DDO.owl#DDO_0006279 + DDO:DDO_0006279 + + + + obo:DDO.owl#DDO_0006279 + 700109009 + + + + obo:DDO.owl#DDO_0006279 + Bartter syndrome antenatal type 2 + + + + obo:DDO.owl#DDO_0006280 + DDO:DDO_0006280 + + + + obo:DDO.owl#DDO_0006280 + 700112007 + + + + obo:DDO.owl#DDO_0006280 + Bartter syndrome type 4 + + + + obo:DDO.owl#DDO_0006281 + DDO:DDO_0006281 + + + + obo:DDO.owl#DDO_0006281 + 414941008 + + + + obo:DDO.owl#DDO_0006281 + onychomycosis + + + + obo:DDO.owl#DDO_0006282 + DDO:DDO_0006282 + + + + obo:DDO.owl#DDO_0006282 + 403104005 + + + + obo:DDO.owl#DDO_0006282 + distal and lateral subungual onychomycosis + + + + obo:DDO.owl#DDO_0006283 + DDO:DDO_0006283 + + + + obo:DDO.owl#DDO_0006283 + 202928001 + + + + obo:DDO.owl#DDO_0006283 + infected bunion + + + + obo:DDO.owl#DDO_0006284 + DDO:DDO_0006284 + + + + obo:DDO.owl#DDO_0006284 + 42402006 + + + + obo:DDO.owl#DDO_0006284 + kartagener syndrome + + + + obo:DDO.owl#DDO_0006285 + DDO:DDO_0006285 + + + + obo:DDO.owl#DDO_0006285 + 237602007 + + + + obo:DDO.owl#DDO_0006285 + metabolic syndrome X + + + + obo:DDO.owl#DDO_0006286 + DDO:DDO_0006286 + + + + obo:DDO.owl#DDO_0006286 + living organism + + + + obo:DDO.owl#DDO_0006915 + DDO:DDO_0006915 + + + + obo:DDO.owl#DDO_0006915 + 330296005 + + + + obo:DDO.owl#DDO_0006915 + chloramphenicol eye drops + + + + obo:DDO.owl#DDO_0007786 + DDO:DDO_0007786 + + + + obo:DDO.owl#DDO_0007786 + 416798007 + + + + obo:DDO.owl#DDO_0007786 + calcineurin inhibitor + + + + obo:DDO.owl#DDO_0008990 + DDO:DDO_0008990 + + + + obo:DDO.owl#DDO_0008990 + decreased insulin response to glucose + + + + obo:DDO.owl#DDO_0009000 + DDO:DDO_0009000 + + + + obo:DDO.owl#DDO_0009000 + 48286001 + + + + obo:DDO.owl#DDO_0009000 + disorder of lipoprotein AND/OR lipid metabolism + + + + obo:DDO.owl#DDO_0009001 + DDO:DDO_0009001 + + + + obo:DDO.owl#DDO_0009001 + 267436001 + + + + obo:DDO.owl#DDO_0009001 + lipoprotein deficiency disorder + + + + obo:DDO.owl#DDO_0009002 + DDO:DDO_0009002 + + + + obo:DDO.owl#DDO_0009002 + 190785000 + + + + obo:DDO.owl#DDO_0009002 + hypoalphalipoproteinemia + + + + obo:DDO.owl#DDO_0009003 + DDO:DDO_0009003 + + + + obo:DDO.owl#DDO_0009003 + 238091006 + + + + obo:DDO.owl#DDO_0009003 + lecithin cholesterol acyltransferase deficiency + + + + obo:DDO.owl#DDO_0009004 + DDO:DDO_0009004 + + + + obo:DDO.owl#DDO_0009004 + 238092004 + + + + obo:DDO.owl#DDO_0009004 + fish-eye disease + + + + obo:DDO.owl#DDO_0009023 + DDO:DDO_0009023 + + + + obo:DDO.owl#DDO_0009023 + 59329007 + + + + obo:DDO.owl#DDO_0009023 + metabolic pancreatitis + + + + obo:DDO.owl#DDO_0009024 + DDO:DDO_0009024 + + + + obo:DDO.owl#DDO_0009024 + 39205007 + + + + obo:DDO.owl#DDO_0009024 + infectious pancreatitis + + + + obo:DDO.owl#DDO_0009025 + DDO:DDO_0009025 + + + + obo:DDO.owl#DDO_0009025 + 197460005 + + + + obo:DDO.owl#DDO_0009025 + acute suppurative pancreatitis + + + + obo:DDO.owl#DDO_0009026 + DDO:DDO_0009026 + + + + obo:DDO.owl#DDO_0009026 + 24407009 + + + + obo:DDO.owl#DDO_0009026 + suppurative pancreatitis + + + + obo:DDO.owl#DDO_0009027 + DDO:DDO_0009027 + + + + obo:DDO.owl#DDO_0009027 + 10665004 + + + + obo:DDO.owl#DDO_0009027 + mumps pancreatitis + + + + obo:DDO.owl#DDO_0009028 + DDO:DDO_0009028 + + + + obo:DDO.owl#DDO_0009028 + 235947007 + + + + obo:DDO.owl#DDO_0009028 + cytomegaloviral pancreatitis + + + + obo:DDO.owl#DDO_0009029 + DDO:DDO_0009029 + + + + obo:DDO.owl#DDO_0009029 + 235946003 + + + + obo:DDO.owl#DDO_0009029 + viral acute pancreatitis + + + + obo:DDO.owl#DDO_0009030 + DDO:DDO_0009030 + + + + obo:DDO.owl#DDO_0009030 + 197460005 + + + + obo:DDO.owl#DDO_0009030 + acute suppurative pancreatitis + + + + obo:DDO.owl#DDO_0009031 + DDO:DDO_0009031 + + + + obo:DDO.owl#DDO_0009031 + 235945004 + + + + obo:DDO.owl#DDO_0009031 + acute pancreatitis due to infection + + + + obo:DDO.owl#DDO_0009032 + DDO:DDO_0009032 + + + + obo:DDO.owl#DDO_0009032 + 111407006 + + + + obo:DDO.owl#DDO_0009032 + hemolytic uremic syndrome + + + + obo:DDO.owl#DDO_0009035 + DDO:DDO_0009035 + + + + obo:DDO.owl#DDO_0009035 + 78209002 + + + + obo:DDO.owl#DDO_0009035 + hemolytic uremic syndrome, adult type + + + + obo:DDO.owl#DDO_0009036 + DDO:DDO_0009036 + + + + obo:DDO.owl#DDO_0009036 + 36568005 + + + + obo:DDO.owl#DDO_0009036 + hemolytic uremic syndrome of childhood + + + + obo:DDO.owl#DDO_0009037 + DDO:DDO_0009037 + + + + obo:DDO.owl#DDO_0009037 + 373422007 + + + + obo:DDO.owl#DDO_0009037 + diarrhea-negative hemolytic uremic syndrome + + + + obo:DDO.owl#DDO_0009038 + DDO:DDO_0009038 + + + + obo:DDO.owl#DDO_0009038 + 373421000 + + + + obo:DDO.owl#DDO_0009038 + diarrhea-associated hemolytic uremic syndrome + + + + obo:DDO.owl#DDO_0009039 + DDO:DDO_0009039 + + + + obo:DDO.owl#DDO_0009039 + 444976001 + + + + obo:DDO.owl#DDO_0009039 + congenital hemolytic uremic syndrome + + + + obo:DDO.owl#DDO_0009040 + DDO:DDO_0009040 + + + + obo:DDO.owl#DDO_0009040 + 51292008 + + + + obo:DDO.owl#DDO_0009040 + hepatorenal syndrome + + + + obo:DDO.owl#DDO_0009041 + DDO:DDO_0009041 + + + + obo:DDO.owl#DDO_0009041 + 22846003 + + + + obo:DDO.owl#DDO_0009041 + hepatorenal syndrome following delivery + + + + obo:DDO.owl#DDO_0009042 + DDO:DDO_0009042 + + + + obo:DDO.owl#DDO_0009042 + 31005002 + + + + obo:DDO.owl#DDO_0009042 + hepatorenal syndrome due to a procedure + + + + obo:DDO.owl#DDO_0009043 + DDO:DDO_0009043 + + + + obo:DDO.owl#DDO_0009043 + 213231008 + + + + obo:DDO.owl#DDO_0009043 + hepatorenal syndrome as a complication of care + + + + obo:DDO.owl#DDO_0009044 + DDO:DDO_0009044 + + + + obo:DDO.owl#DDO_0009044 + 62216007 + + + + obo:DDO.owl#DDO_0009044 + familial arthrogryposis-cholestatic hepatorenal syndrome + + + + obo:DDO.owl#DDO_0009045 + DDO:DDO_0009045 + + + + obo:DDO.owl#DDO_0009045 + 58574008 + + + + obo:DDO.owl#DDO_0009045 + acute nephropathy + + + + obo:DDO.owl#DDO_0009046 + DDO:DDO_0009046 + + + + obo:DDO.owl#DDO_0009046 + 371011007 + + + + obo:DDO.owl#DDO_0009046 + caliectasis + + + + obo:DDO.owl#DDO_0009047 + DDO:DDO_0009047 + + + + obo:DDO.owl#DDO_0009047 + 423919000 + + + + obo:DDO.owl#DDO_0009047 + acquired caliectasis + + + + obo:DDO.owl#DDO_0009048 + DDO:DDO_0009048 + + + + obo:DDO.owl#DDO_0009048 + 85901000 + + + + obo:DDO.owl#DDO_0009048 + megacalycosis + + + + obo:DDO.owl#DDO_0009049 + DDO:DDO_0009049 + + + + obo:DDO.owl#DDO_0009049 + 197820003 + + + + obo:DDO.owl#DDO_0009049 + pyelectasia + + + + obo:DDO.owl#DDO_0009050 + DDO:DDO_0009050 + + + + obo:DDO.owl#DDO_0009050 + 430035004 + + + + obo:DDO.owl#DDO_0009050 + fetal pyelectasis + + + + obo:DDO.owl#DDO_0009051 + DDO:DDO_0009051 + + + + obo:DDO.owl#DDO_0009051 + 45816000 + + + + obo:DDO.owl#DDO_0009051 + pyelonephritis + + + + obo:DDO.owl#DDO_0009052 + DDO:DDO_0009052 + + + + obo:DDO.owl#DDO_0009052 + 36689008 + + + + obo:DDO.owl#DDO_0009052 + acute pyelonephritis + + + + obo:DDO.owl#DDO_0009053 + DDO:DDO_0009053 + + + + obo:DDO.owl#DDO_0009053 + 236373001 + + + + obo:DDO.owl#DDO_0009053 + emphysematous pyelonephritis + + + + obo:DDO.owl#DDO_0009054 + DDO:DDO_0009054 + + + + obo:DDO.owl#DDO_0009054 + 123754002 + + + + obo:DDO.owl#DDO_0009054 + focal pyelonephritis + + + + obo:DDO.owl#DDO_0009055 + DDO:DDO_0009055 + + + + obo:DDO.owl#DDO_0009055 + 23754003 + + + + obo:DDO.owl#DDO_0009055 + calculous pyelonephritis + + + + obo:DDO.owl#DDO_0009056 + DDO:DDO_0009056 + + + + obo:DDO.owl#DDO_0009056 + 236378005 + + + + obo:DDO.owl#DDO_0009056 + Candida pyelonephritis + + + + obo:DDO.owl#DDO_0009057 + DDO:DDO_0009057 + + + + obo:DDO.owl#DDO_0009057 + 63302006 + + + + obo:DDO.owl#DDO_0009057 + chronic pyelonephritis + + + + obo:DDO.owl#DDO_0009058 + DDO:DDO_0009058 + + + + obo:DDO.owl#DDO_0009058 + 236379002 + + + + obo:DDO.owl#DDO_0009058 + chronic obstructive pyelonephritis + + + + obo:DDO.owl#DDO_0009059 + DDO:DDO_0009059 + + + + obo:DDO.owl#DDO_0009059 + 38898003 + + + + obo:DDO.owl#DDO_0009059 + xanthogranulomatous pyelonephritis + + + + obo:DDO.owl#DDO_0009060 + DDO:DDO_0009060 + + + + obo:DDO.owl#DDO_0009060 + 4181000119109 + + + + obo:DDO.owl#DDO_0009060 + obstructive pyelonephritis + + + + obo:DDO.owl#DDO_0009061 + DDO:DDO_0009061 + + + + obo:DDO.owl#DDO_0009061 + 95889002 + + + + obo:DDO.owl#DDO_0009061 + mycoplasmal pyelonephritis + + + + obo:DDO.owl#DDO_0009062 + DDO:DDO_0009062 + + + + obo:DDO.owl#DDO_0009062 + 123755001 + + + + obo:DDO.owl#DDO_0009062 + diffuse pyelonephritis + + + + obo:DDO.owl#DDO_0009063 + DDO:DDO_0009063 + + + + obo:DDO.owl#DDO_0009063 + 3321001 + + + + obo:DDO.owl#DDO_0009063 + renal abscess + + + + obo:DDO.owl#DDO_0009064 + DDO:DDO_0009064 + + + + obo:DDO.owl#DDO_0009064 + 44730006 + + + + obo:DDO.owl#DDO_0009064 + uremia + + + + obo:DDO.owl#DDO_0009065 + DDO:DDO_0009065 + + + + obo:DDO.owl#DDO_0009065 + 78544004 + + + + obo:DDO.owl#DDO_0009065 + chronic hypertensive uremia + + + + obo:DDO.owl#DDO_0009066 + DDO:DDO_0009066 + + + + obo:DDO.owl#DDO_0009066 + 367481000119108 + + + + obo:DDO.owl#DDO_0009066 + extrarenal uremia + + + + obo:DDO.owl#DDO_0009067 + DDO:DDO_0009067 + + + + obo:DDO.owl#DDO_0009067 + 83850008 + + + + obo:DDO.owl#DDO_0009067 + uremic acidosis + + + + obo:DDO.owl#DDO_0009068 + DDO:DDO_0009068 + + + + obo:DDO.owl#DDO_0009068 + 11659006 + + + + obo:DDO.owl#DDO_0009068 + uremic neuropathy + + + + obo:DDO.owl#DDO_0009069 + DDO:DDO_0009069 + + + + obo:DDO.owl#DDO_0009069 + 443961001 + + + + obo:DDO.owl#DDO_0009069 + adenocarcinoma + + + + obo:DDO.owl#DDO_0009069 + malignant adenomatous neoplasm + + + + obo:DDO.owl#DDO_0009070 + DDO:DDO_0009070 + + + + obo:DDO.owl#DDO_0009070 + 17602002 + + + + obo:DDO.owl#DDO_0009070 + amyloidosis + + + + obo:DDO.owl#DDO_0009071 + DDO:DDO_0009071 + + + + obo:DDO.owl#DDO_0009071 + 39659002 + + + + obo:DDO.owl#DDO_0009071 + anhidrosis + + + + obo:DDO.owl#DDO_0009072 + DDO:DDO_0009072 + + + + obo:DDO.owl#DDO_0009072 + 230667002 + + + + obo:DDO.owl#DDO_0009072 + chronic idiopathic anhidrosis + + + + obo:DDO.owl#DDO_0009073 + DDO:DDO_0009073 + + + + obo:DDO.owl#DDO_0009073 + 28619004 + + + + obo:DDO.owl#DDO_0009073 + tropical anhidrotic asthenia + + + + obo:DDO.owl#DDO_0009074 + DDO:DDO_0009074 + + + + obo:DDO.owl#DDO_0009074 + 445009001 + + + + obo:DDO.owl#DDO_0009074 + azotemia + + + + obo:DDO.owl#DDO_0009075 + DDO:DDO_0009075 + + + + obo:DDO.owl#DDO_0009075 + 445612002 + + + + obo:DDO.owl#DDO_0009075 + postrenal azotemia + + + + obo:DDO.owl#DDO_0009076 + DDO:DDO_0009076 + + + + obo:DDO.owl#DDO_0009076 + 445646001 + + + + obo:DDO.owl#DDO_0009076 + prerenal azotemia + + + + obo:DDO.owl#DDO_0009077 + DDO:DDO_0009077 + + + + obo:DDO.owl#DDO_0009077 + 161891005 + + + + obo:DDO.owl#DDO_0009077 + back ache + + + + obo:DDO.owl#DDO_0009077 + back pain + + + + obo:DDO.owl#DDO_0009077 + backache + + + + obo:DDO.owl#DDO_0009078 + DDO:DDO_0009078 + + + + obo:DDO.owl#DDO_0009078 + 230724001 + + + + obo:DDO.owl#DDO_0009078 + cerebral amyloid angiopathy + + + + obo:DDO.owl#DDO_0009079 + DDO:DDO_0009079 + + + + obo:DDO.owl#DDO_0009079 + 703220002 + + + + obo:DDO.owl#DDO_0009079 + hereditary cystatin C amyloid angiopathy + + + + obo:DDO.owl#DDO_0009080 + DDO:DDO_0009080 + + + + obo:DDO.owl#DDO_0009080 + 230725000 + + + + obo:DDO.owl#DDO_0009080 + sporadic cerebral amyloid angiopathy + + + + obo:DDO.owl#DDO_0009082 + DDO:DDO_0009082 + + + + obo:DDO.owl#DDO_0009082 + 23853001 + + + + obo:DDO.owl#DDO_0009082 + disorder of the central nervous system + + + + obo:DDO.owl#DDO_0009083 + DDO:DDO_0009083 + + + + obo:DDO.owl#DDO_0009083 + 81308009 + + + + obo:DDO.owl#DDO_0009083 + disorder of brain + + + + obo:DDO.owl#DDO_0009084 + DDO:DDO_0009084 + + + + obo:DDO.owl#DDO_0009084 + 278849000 + + + + obo:DDO.owl#DDO_0009084 + cerebral atrophy + + + + obo:DDO.owl#DDO_0009085 + DDO:DDO_0009085 + + + + obo:DDO.owl#DDO_0009085 + 111028009 + + + + obo:DDO.owl#DDO_0009085 + arteriopathic granular atrophy of cerebral cortex + + + + obo:DDO.owl#DDO_0009086 + DDO:DDO_0009086 + + + + obo:DDO.owl#DDO_0009086 + 111033008 + + + + obo:DDO.owl#DDO_0009086 + circumscribed atrophy of brain + + + + obo:DDO.owl#DDO_0009087 + DDO:DDO_0009087 + + + + obo:DDO.owl#DDO_0009087 + 29857009 + + + + obo:DDO.owl#DDO_0009087 + chest pain + + + + obo:DDO.owl#DDO_0009088 + DDO:DDO_0009088 + + + + obo:DDO.owl#DDO_0009088 + 426396005 + + + + obo:DDO.owl#DDO_0009088 + cardiac chest pain + + + + obo:DDO.owl#DDO_0009089 + DDO:DDO_0009089 + + + + obo:DDO.owl#DDO_0009089 + 102589003 + + + + obo:DDO.owl#DDO_0009089 + atypical chest pain + + + + obo:DDO.owl#DDO_0009090 + DDO:DDO_0009090 + + + + obo:DDO.owl#DDO_0009090 + 102587001 + + + + obo:DDO.owl#DDO_0009090 + acute chest pain + + + + obo:DDO.owl#DDO_0009091 + DDO:DDO_0009091 + + + + obo:DDO.owl#DDO_0009091 + 233845001 + + + + obo:DDO.owl#DDO_0009091 + cardiac syndrome X + + + + obo:DDO.owl#DDO_0009092 + DDO:DDO_0009092 + + + + obo:DDO.owl#DDO_0009092 + 76581006 + + + + obo:DDO.owl#DDO_0009092 + cholecystitis + + + + obo:DDO.owl#DDO_0009093 + DDO:DDO_0009093 + + + + obo:DDO.owl#DDO_0009093 + 396335001 + + + + obo:DDO.owl#DDO_0009093 + acute and chronic cholecystitis + + + + obo:DDO.owl#DDO_0009094 + DDO:DDO_0009094 + + + + obo:DDO.owl#DDO_0009094 + 197410004 + + + + obo:DDO.owl#DDO_0009094 + acute angiocholecystitis + + + + obo:DDO.owl#DDO_0009095 + DDO:DDO_0009095 + + + + obo:DDO.owl#DDO_0009095 + 65275009 + + + + obo:DDO.owl#DDO_0009095 + acute cholecystitis + + + + obo:DDO.owl#DDO_0009096 + DDO:DDO_0009096 + + + + obo:DDO.owl#DDO_0009096 + 72533002 + + + + obo:DDO.owl#DDO_0009096 + acute gangrenous cholecystitis + + + + obo:DDO.owl#DDO_0009097 + DDO:DDO_0009097 + + + + obo:DDO.owl#DDO_0009097 + 48413001 + + + + obo:DDO.owl#DDO_0009097 + acute hemorrhagic cholecystitis + + + + obo:DDO.owl#DDO_0009098 + DDO:DDO_0009098 + + + + obo:DDO.owl#DDO_0009098 + 89628003 + + + + obo:DDO.owl#DDO_0009098 + acute suppurative cholecystitis + + + + obo:DDO.owl#DDO_0009099 + DDO:DDO_0009099 + + + + obo:DDO.owl#DDO_0009099 + 78754002 + + + + obo:DDO.owl#DDO_0009099 + angiocholecystitis + + + + obo:DDO.owl#DDO_0009100 + DDO:DDO_0009100 + + + + obo:DDO.owl#DDO_0009100 + 36483003 + + + + obo:DDO.owl#DDO_0009100 + calculus of bile duct with cholecystitis + + + + obo:DDO.owl#DDO_0009101 + DDO:DDO_0009101 + + + + obo:DDO.owl#DDO_0009101 + 25924004 + + + + obo:DDO.owl#DDO_0009101 + calculus of gallbladder with cholecystitis + + + + obo:DDO.owl#DDO_0009102 + DDO:DDO_0009102 + + + + obo:DDO.owl#DDO_0009102 + 46341007 + + + + obo:DDO.owl#DDO_0009102 + cholecystitis glandularis proliferans + + + + obo:DDO.owl#DDO_0009103 + DDO:DDO_0009103 + + + + obo:DDO.owl#DDO_0009103 + 20824003 + + + + obo:DDO.owl#DDO_0009103 + chronic cholecystitis + + + + obo:DDO.owl#DDO_0009104 + DDO:DDO_0009104 + + + + obo:DDO.owl#DDO_0009104 + 64534006 + + + + obo:DDO.owl#DDO_0009104 + hyperplastic cholecystitis + + + + obo:DDO.owl#DDO_0009105 + DDO:DDO_0009105 + + + + obo:DDO.owl#DDO_0009105 + 95558008 + + + + obo:DDO.owl#DDO_0009105 + pneumocholecystitis + + + + obo:DDO.owl#DDO_0009106 + DDO:DDO_0009106 + + + + obo:DDO.owl#DDO_0009106 + 32067005 + + + + obo:DDO.owl#DDO_0009106 + acute emphysematous cholecystitis + + + + obo:DDO.owl#DDO_0009107 + DDO:DDO_0009107 + + + + obo:DDO.owl#DDO_0009107 + 448286002 + + + + obo:DDO.owl#DDO_0009107 + xanthogranulomatous cholecystitis + + + + obo:DDO.owl#DDO_0009108 + DDO:DDO_0009108 + + + + obo:DDO.owl#DDO_0009108 + 33688009 + + + + obo:DDO.owl#DDO_0009108 + cholestasis + + + + obo:DDO.owl#DDO_0009109 + DDO:DDO_0009109 + + + + obo:DDO.owl#DDO_0009109 + 4637005 + + + + obo:DDO.owl#DDO_0009109 + intrahepatic cholestasis + + + + obo:DDO.owl#DDO_0009110 + DDO:DDO_0009110 + + + + obo:DDO.owl#DDO_0009110 + 89099002 + + + + obo:DDO.owl#DDO_0009110 + chronic allergic bronchitis + + + + obo:DDO.owl#DDO_0009111 + DDO:DDO_0009111 + + + + obo:DDO.owl#DDO_0009111 + 360470001 + + + + obo:DDO.owl#DDO_0009111 + chronic mucus hypersecretion + + + + obo:DDO.owl#DDO_0009112 + DDO:DDO_0009112 + + + + obo:DDO.owl#DDO_0009112 + 47938003 + + + + obo:DDO.owl#DDO_0009112 + chronic obliterative bronchiolitis + + + + obo:DDO.owl#DDO_0009113 + DDO:DDO_0009113 + + + + obo:DDO.owl#DDO_0009113 + 185086009 + + + + obo:DDO.owl#DDO_0009113 + emphysematous bronchitis + + + + obo:DDO.owl#DDO_0009114 + DDO:DDO_0009114 + + + + obo:DDO.owl#DDO_0009114 + 84409004 + + + + obo:DDO.owl#DDO_0009114 + fetid chronic bronchitis + + + + obo:DDO.owl#DDO_0009115 + DDO:DDO_0009115 + + + + obo:DDO.owl#DDO_0009115 + 74417001 + + + + obo:DDO.owl#DDO_0009115 + mucopurulent chronic bronchitis + + + + obo:DDO.owl#DDO_0009116 + DDO:DDO_0009116 + + + + obo:DDO.owl#DDO_0009116 + 49691004 + + + + obo:DDO.owl#DDO_0009116 + occupational bronchitis + + + + obo:DDO.owl#DDO_0009117 + DDO:DDO_0009117 + + + + obo:DDO.owl#DDO_0009117 + 84410009 + + + + obo:DDO.owl#DDO_0009117 + disorder of digestive tract + + + + obo:DDO.owl#DDO_0009118 + DDO:DDO_0009118 + + + + obo:DDO.owl#DDO_0009118 + 119292006 + + + + obo:DDO.owl#DDO_0009118 + disorder of gastrointestinal tract + + + + obo:DDO.owl#DDO_0009119 + DDO:DDO_0009119 + + + + obo:DDO.owl#DDO_0009119 + 128333008 + + + + obo:DDO.owl#DDO_0009119 + diarrheal disorder + + + + obo:DDO.owl#DDO_0009120 + DDO:DDO_0009120 + + + + obo:DDO.owl#DDO_0009120 + 236071009 + + + + obo:DDO.owl#DDO_0009120 + chronic diarrhea + + + + obo:DDO.owl#DDO_0009122 + DDO:DDO_0009122 + + + + obo:DDO.owl#DDO_0009122 + 89458003 + + + + obo:DDO.owl#DDO_0009122 + stupor + + + + obo:DDO.owl#DDO_0009123 + DDO:DDO_0009123 + + + + obo:DDO.owl#DDO_0009123 + 703464007 + + + + obo:DDO.owl#DDO_0009123 + wooziness + + + + obo:DDO.owl#DDO_0009124 + DDO:DDO_0009124 + + + + obo:DDO.owl#DDO_0009124 + 84114007 + + + + obo:DDO.owl#DDO_0009124 + heart failure + + + + obo:DDO.owl#DDO_0009125 + DDO:DDO_0009125 + + + + obo:DDO.owl#DDO_0009125 + 42343007 + + + + obo:DDO.owl#DDO_0009125 + congestive heart failure + + + + obo:DDO.owl#DDO_0009126 + DDO:DDO_0009126 + + + + obo:DDO.owl#DDO_0009126 + 10633002 + + + + obo:DDO.owl#DDO_0009126 + acute congestive heart failure + + + + obo:DDO.owl#DDO_0009127 + DDO:DDO_0009127 + + + + obo:DDO.owl#DDO_0009127 + 92506005 + + + + obo:DDO.owl#DDO_0009127 + biventricular congestive heart failure + + + + obo:DDO.owl#DDO_0009128 + DDO:DDO_0009128 + + + + obo:DDO.owl#DDO_0009128 + 88805009 + + + + obo:DDO.owl#DDO_0009128 + chronic congestive heart failure + + + + obo:DDO.owl#DDO_0009129 + DDO:DDO_0009129 + + + + obo:DDO.owl#DDO_0009129 + 67441000119101 + + + + obo:DDO.owl#DDO_0009129 + congestive heart failure stage C + + + + obo:DDO.owl#DDO_0009130 + DDO:DDO_0009130 + + + + obo:DDO.owl#DDO_0009130 + 67431000119105 + + + + obo:DDO.owl#DDO_0009130 + congestive heart failure stage D + + + + obo:DDO.owl#DDO_0009131 + DDO:DDO_0009131 + + + + obo:DDO.owl#DDO_0009131 + 82523003 + + + + obo:DDO.owl#DDO_0009131 + congestive rheumatic heart failure + + + + obo:DDO.owl#DDO_0009132 + DDO:DDO_0009132 + + + + obo:DDO.owl#DDO_0009132 + 105981003 + + + + obo:DDO.owl#DDO_0009132 + disorder of cardiac function + + + + obo:DDO.owl#DDO_0009133 + DDO:DDO_0009133 + + + + obo:DDO.owl#DDO_0009133 + 56265001 + + + + obo:DDO.owl#DDO_0009133 + heart disease + + + + obo:DDO.owl#DDO_0009134 + DDO:DDO_0009134 + + + + obo:DDO.owl#DDO_0009134 + 414024009 + + + + obo:DDO.owl#DDO_0009134 + disorder of coronary artery + + + + obo:DDO.owl#DDO_0009135 + DDO:DDO_0009135 + + + + obo:DDO.owl#DDO_0009135 + 445512009 + + + + obo:DDO.owl#DDO_0009135 + calcification of coronary artery + + + + obo:DDO.owl#DDO_0009136 + DDO:DDO_0009136 + + + + obo:DDO.owl#DDO_0009136 + 253725005 + + + + obo:DDO.owl#DDO_0009136 + congenital coronary artery calcification + + + + obo:DDO.owl#DDO_0009137 + DDO:DDO_0009137 + + + + obo:DDO.owl#DDO_0009137 + 128599005 + + + + obo:DDO.owl#DDO_0009137 + structural disorder of heart + + + + obo:DDO.owl#DDO_0009138 + DDO:DDO_0009138 + + + + obo:DDO.owl#DDO_0009138 + 63739005 + + + + obo:DDO.owl#DDO_0009138 + coronary occlusion + + + + obo:DDO.owl#DDO_0009139 + DDO:DDO_0009139 + + + + obo:DDO.owl#DDO_0009139 + 233970002 + + + + obo:DDO.owl#DDO_0009139 + coronary artery stenosis + + + + obo:DDO.owl#DDO_0009140 + DDO:DDO_0009140 + + + + obo:DDO.owl#DDO_0009140 + 473362006 + + + + obo:DDO.owl#DDO_0009140 + congenital stenosis of distal coronary artery + + + + obo:DDO.owl#DDO_0009141 + DDO:DDO_0009141 + + + + obo:DDO.owl#DDO_0009141 + 251024009 + + + + obo:DDO.owl#DDO_0009141 + coronary graft stenosis + + + + obo:DDO.owl#DDO_0009142 + DDO:DDO_0009142 + + + + obo:DDO.owl#DDO_0009142 + 26900001 + + + + obo:DDO.owl#DDO_0009142 + coronary ostium stenosis + + + + obo:DDO.owl#DDO_0009143 + DDO:DDO_0009143 + + + + obo:DDO.owl#DDO_0009143 + 59062007 + + + + obo:DDO.owl#DDO_0009143 + coronary stricture + + + + obo:DDO.owl#DDO_0009144 + DDO:DDO_0009144 + + + + obo:DDO.owl#DDO_0009144 + 413451007 + + + + obo:DDO.owl#DDO_0009144 + adiponectin + + + + obo:DDO.owl#DDO_0009145 + DDO:DDO_0009145 + + + + obo:DDO.owl#DDO_0009145 + 2331003 + + + + obo:DDO.owl#DDO_0009145 + carbohydrate + + + + obo:DDO.owl#DDO_0009146 + DDO:DDO_0009146 + + + + obo:DDO.owl#DDO_0009146 + 74801000 + + + + obo:DDO.owl#DDO_0009146 + sugar + + + + obo:DDO.owl#DDO_0009147 + DDO:DDO_0009147 + + + + obo:DDO.owl#DDO_0009147 + 116257004 + + + + obo:DDO.owl#DDO_0009147 + monosaccharide + + + + obo:DDO.owl#DDO_0009148 + DDO:DDO_0009148 + + + + obo:DDO.owl#DDO_0009148 + 15472007 + + + + obo:DDO.owl#DDO_0009148 + disaccharide + + + + obo:DDO.owl#DDO_0009149 + DDO:DDO_0009149 + + + + obo:DDO.owl#DDO_0009149 + 129497004 + + + + obo:DDO.owl#DDO_0009149 + iron sucrose + + + + obo:DDO.owl#DDO_0009150 + DDO:DDO_0009150 + + + + obo:DDO.owl#DDO_0009150 + 11320009 + + + + obo:DDO.owl#DDO_0009150 + sucrose + + + + obo:DDO.owl#DDO_0009151 + DDO:DDO_0009151 + + + + obo:DDO.owl#DDO_0009151 + 43431002 + + + + obo:DDO.owl#DDO_0009151 + maltose + + + + obo:DDO.owl#DDO_0009152 + DDO:DDO_0009152 + + + + obo:DDO.owl#DDO_0009152 + 47703008 + + + + obo:DDO.owl#DDO_0009152 + lactose + + + + obo:DDO.owl#DDO_0009153 + DDO:DDO_0009153 + + + + obo:DDO.owl#DDO_0009153 + 259651009 + + + + obo:DDO.owl#DDO_0009153 + Cellobiose + + + + obo:DDO.owl#DDO_0009154 + DDO:DDO_0009154 + + + + obo:DDO.owl#DDO_0009154 + 116258009 + + + + obo:DDO.owl#DDO_0009154 + aldose + + + + obo:DDO.owl#DDO_0009155 + DDO:DDO_0009155 + + + + obo:DDO.owl#DDO_0009155 + 63089006 + + + + obo:DDO.owl#DDO_0009155 + mannose + + + + obo:DDO.owl#DDO_0009156 + DDO:DDO_0009156 + + + + obo:DDO.owl#DDO_0009156 + 116263008 + + + + obo:DDO.owl#DDO_0009156 + heptose + + + + obo:DDO.owl#DDO_0009157 + DDO:DDO_0009157 + + + + obo:DDO.owl#DDO_0009157 + 77454000 + + + + obo:DDO.owl#DDO_0009157 + mannoheptulose + + + + obo:DDO.owl#DDO_0009158 + DDO:DDO_0009158 + + + + obo:DDO.owl#DDO_0009158 + 61045002 + + + + obo:DDO.owl#DDO_0009158 + Sedoheptulose + + + + obo:DDO.owl#DDO_0009159 + DDO:DDO_0009159 + + + + obo:DDO.owl#DDO_0009159 + 116259001 + + + + obo:DDO.owl#DDO_0009159 + hexose + + + + obo:DDO.owl#DDO_0009160 + DDO:DDO_0009160 + + + + obo:DDO.owl#DDO_0009160 + 116260006 + + + + obo:DDO.owl#DDO_0009160 + ketose + + + + obo:DDO.owl#DDO_0009161 + DDO:DDO_0009161 + + + + obo:DDO.owl#DDO_0009161 + 81100008 + + + + obo:DDO.owl#DDO_0009161 + pentose + + + + obo:DDO.owl#DDO_0009162 + DDO:DDO_0009162 + + + + obo:DDO.owl#DDO_0009162 + decreased bone mineral content + + + + obo:DDO.owl#DDO_0009163 + DDO:DDO_0009163 + + + + obo:DDO.owl#DDO_0009163 + decreased bone mineral density + + + + obo:DDO.owl#DDO_0009164 + DDO:DDO_0009164 + + + + obo:DDO.owl#DDO_0009164 + decreased circulating insulin level + + + + obo:DDO.owl#DDO_0009165 + DDO:DDO_0009165 + + + + obo:DDO.owl#DDO_0009165 + decreased creatinine clearance + + + + obo:DDO.owl#DDO_0009166 + DDO:DDO_0009166 + + + + obo:DDO.owl#DDO_0009166 + decreased glucokinase activity + + + + obo:DDO.owl#DDO_0009167 + DDO:DDO_0009167 + + + + obo:DDO.owl#DDO_0009167 + decreased heart rate + + + + obo:DDO.owl#DDO_0009168 + DDO:DDO_0009168 + + + + obo:DDO.owl#DDO_0009168 + decreased insulin secretion + + + + obo:DDO.owl#DDO_0009169 + DDO:DDO_0009169 + + + + obo:DDO.owl#DDO_0009169 + decreased lean body mass + + + + obo:DDO.owl#DDO_0009170 + DDO:DDO_0009170 + + + + obo:DDO.owl#DDO_0009170 + Decreased liver function + + + + obo:DDO.owl#DDO_0009171 + DDO:DDO_0009171 + + + + obo:DDO.owl#DDO_0009171 + decreased liver weight + + + + obo:DDO.owl#DDO_0009172 + DDO:DDO_0009172 + + + + obo:DDO.owl#DDO_0009172 + Decreased nerve conduction velocity + + + + obo:DDO.owl#DDO_0009173 + DDO:DDO_0009173 + + + + obo:DDO.owl#DDO_0009173 + decreased pancreatic beta cell mass + + + + obo:DDO.owl#DDO_0009174 + DDO:DDO_0009174 + + + + obo:DDO.owl#DDO_0009174 + decreased renal glomerular filtration rate + + + + obo:DDO.owl#DDO_0009175 + DDO:DDO_0009175 + + + + obo:DDO.owl#DDO_0009175 + decreased survivor rate + + + + obo:DDO.owl#DDO_0009176 + DDO:DDO_0009176 + + + + obo:DDO.owl#DDO_0009176 + 1860003 + + + + obo:DDO.owl#DDO_0009176 + fluid volume disorder + + + + obo:DDO.owl#DDO_0009177 + DDO:DDO_0009177 + + + + obo:DDO.owl#DDO_0009177 + 34095006 + + + + obo:DDO.owl#DDO_0009177 + dehydration + + + + obo:DDO.owl#DDO_0009178 + DDO:DDO_0009178 + + + + obo:DDO.owl#DDO_0009178 + 427784006 + + + + obo:DDO.owl#DDO_0009178 + hypernatremic dehydration + + + + obo:DDO.owl#DDO_0009179 + DDO:DDO_0009179 + + + + obo:DDO.owl#DDO_0009179 + 190894003 + + + + obo:DDO.owl#DDO_0009179 + isonatremic dehydration + + + + obo:DDO.owl#DDO_0009180 + DDO:DDO_0009180 + + + + obo:DDO.owl#DDO_0009180 + 1611000119108 + + + + obo:DDO.owl#DDO_0009180 + mild dehydration + + + + obo:DDO.owl#DDO_0009181 + DDO:DDO_0009181 + + + + obo:DDO.owl#DDO_0009181 + 1601000119105 + + + + obo:DDO.owl#DDO_0009181 + moderate dehydration + + + + obo:DDO.owl#DDO_0009182 + DDO:DDO_0009182 + + + + obo:DDO.owl#DDO_0009182 + 78812008 + + + + obo:DDO.owl#DDO_0009182 + neonatal dehydration + + + + obo:DDO.owl#DDO_0009183 + DDO:DDO_0009183 + + + + obo:DDO.owl#DDO_0009183 + delayed wound healing + + + + obo:DDO.owl#DDO_0009184 + DDO:DDO_0009184 + + + + obo:DDO.owl#DDO_0009184 + 15241006 + + + + obo:DDO.owl#DDO_0009184 + disorder of vegetative system + + + + obo:DDO.owl#DDO_0009184 + dysautonomia + + + + obo:DDO.owl#DDO_0009184 + disorder of autonomic nervous system + + + + obo:DDO.owl#DDO_0009185 + DDO:DDO_0009185 + + + + obo:DDO.owl#DDO_0009185 + 430042004 + + + + obo:DDO.owl#DDO_0009185 + acute pandysautonomia + + + + obo:DDO.owl#DDO_0009187 + DDO:DDO_0009187 + + + + obo:DDO.owl#DDO_0009187 + 129618003 + + + + obo:DDO.owl#DDO_0009187 + autonomic dysreflexia + + + + obo:DDO.owl#DDO_0009188 + DDO:DDO_0009188 + + + + obo:DDO.owl#DDO_0009188 + 5112009 + + + + obo:DDO.owl#DDO_0009188 + autonomic hyperreflexia of bladder + + + + obo:DDO.owl#DDO_00091883 + DDO:DDO_00091883 + + + + obo:DDO.owl#DDO_00091883 + 450316000 + + + + obo:DDO.owl#DDO_00091883 + severe dehydration + + + + obo:DDO.owl#DDO_0009189 + DDO:DDO_0009189 + + + + obo:DDO.owl#DDO_0009189 + 230145002 + + + + obo:DDO.owl#DDO_0009189 + difficulty breathing + + + + obo:DDO.owl#DDO_0009190 + DDO:DDO_0009190 + + + + obo:DDO.owl#DDO_0009190 + 267036007 + + + + obo:DDO.owl#DDO_0009190 + dyspnea + + + + obo:DDO.owl#DDO_0009191 + DDO:DDO_0009191 + + + + obo:DDO.owl#DDO_0009191 + 73322006 + + + + obo:DDO.owl#DDO_0009191 + dyspnea, class IV + + + + obo:DDO.owl#DDO_0009192 + DDO:DDO_0009192 + + + + obo:DDO.owl#DDO_0009192 + 39950000 + + + + obo:DDO.owl#DDO_0009192 + dyspnea, class III + + + + obo:DDO.owl#DDO_0009193 + DDO:DDO_0009193 + + + + obo:DDO.owl#DDO_0009193 + 72365000 + + + + obo:DDO.owl#DDO_0009193 + dyspnea, class II + + + + obo:DDO.owl#DDO_0009194 + DDO:DDO_0009194 + + + + obo:DDO.owl#DDO_0009194 + 17216000 + + + + obo:DDO.owl#DDO_0009194 + dyspnea, class I + + + + obo:DDO.owl#DDO_0009195 + DDO:DDO_0009195 + + + + obo:DDO.owl#DDO_0009195 + 62744007 + + + + obo:DDO.owl#DDO_0009195 + orthopnea + + + + obo:DDO.owl#DDO_0009196 + DDO:DDO_0009196 + + + + obo:DDO.owl#DDO_0009196 + 59265000 + + + + obo:DDO.owl#DDO_0009196 + paroxysmal dyspnea + + + + obo:DDO.owl#DDO_0009197 + DDO:DDO_0009197 + + + + obo:DDO.owl#DDO_0009197 + 30744009 + + + + obo:DDO.owl#DDO_0009197 + platypnea + + + + obo:DDO.owl#DDO_0009198 + DDO:DDO_0009198 + + + + obo:DDO.owl#DDO_0009198 + 102577000 + + + + obo:DDO.owl#DDO_0009198 + trepopnea + + + + obo:DDO.owl#DDO_0009199 + DDO:DDO_0009199 + + + + obo:DDO.owl#DDO_0009199 + 162138001 + + + + obo:DDO.owl#DDO_0009199 + genitourinary pain + + + + obo:DDO.owl#DDO_0009200 + DDO:DDO_0009200 + + + + obo:DDO.owl#DDO_0009200 + 49650001 + + + + obo:DDO.owl#DDO_0009200 + dysuria + + + + obo:DDO.owl#DDO_0009201 + DDO:DDO_0009201 + + + + obo:DDO.owl#DDO_0009201 + 43227005 + + + + obo:DDO.owl#DDO_0009201 + psychic dysuria + + + + obo:DDO.owl#DDO_0009202 + DDO:DDO_0009202 + + + + obo:DDO.owl#DDO_0009202 + 58250006 + + + + obo:DDO.owl#DDO_0009202 + scalding pain on urination + + + + obo:DDO.owl#DDO_0009203 + DDO:DDO_0009203 + + + + obo:DDO.owl#DDO_0009203 + 267038008 + + + + obo:DDO.owl#DDO_0009203 + edema + + + + obo:DDO.owl#DDO_0009204 + DDO:DDO_0009204 + + + + obo:DDO.owl#DDO_0009204 + 442433009 + + + + obo:DDO.owl#DDO_0009204 + anasarca + + + + obo:DDO.owl#DDO_0009205 + DDO:DDO_0009205 + + + + obo:DDO.owl#DDO_0009205 + 74011000119107 + + + + obo:DDO.owl#DDO_0009205 + renal anasarca + + + + obo:DDO.owl#DDO_0009206 + DDO:DDO_0009206 + + + + obo:DDO.owl#DDO_0009206 + 248500008 + + + + obo:DDO.owl#DDO_0009206 + brawny edema + + + + obo:DDO.owl#DDO_0009207 + DDO:DDO_0009207 + + + + obo:DDO.owl#DDO_0009207 + 284521000 + + + + obo:DDO.owl#DDO_0009207 + pitting edema + + + + obo:DDO.owl#DDO_0009208 + DDO:DDO_0009208 + + + + obo:DDO.owl#DDO_0009208 + 420435001 + + + + obo:DDO.owl#DDO_0009208 + non-pitting edema + + + + obo:DDO.owl#DDO_0009209 + DDO:DDO_0009209 + + + + obo:DDO.owl#DDO_0009209 + Elevated hepatic transaminases + + + + obo:DDO.owl#DDO_0009210 + DDO:DDO_0009210 + + + + obo:DDO.owl#DDO_0009210 + 49158009 + + + + obo:DDO.owl#DDO_0009210 + emphysema + + + + obo:DDO.owl#DDO_0009211 + DDO:DDO_0009211 + + + + obo:DDO.owl#DDO_0009211 + 11211003 + + + + obo:DDO.owl#DDO_0009211 + interstitial emphysema + + + + obo:DDO.owl#DDO_0009212 + DDO:DDO_0009212 + + + + obo:DDO.owl#DDO_0009212 + 125295001 + + + + obo:DDO.owl#DDO_0009212 + chronic emphysema + + + + obo:DDO.owl#DDO_0009213 + DDO:DDO_0009213 + + + + obo:DDO.owl#DDO_0009213 + 125294002 + + + + obo:DDO.owl#DDO_0009213 + acute emphysema + + + + obo:DDO.owl#DDO_0009214 + DDO:DDO_0009214 + + + + obo:DDO.owl#DDO_0009214 + 365811003 + + + + obo:DDO.owl#DDO_0009214 + glucose level + + + + obo:DDO.owl#DDO_0009216 + DDO:DDO_0009216 + + + + obo:DDO.owl#DDO_0009216 + 15188001 + + + + obo:DDO.owl#DDO_0009216 + hearing impaired + + + + obo:DDO.owl#DDO_0009216 + hearing impairment + + + + obo:DDO.owl#DDO_0009216 + hypoacusis + + + + obo:DDO.owl#DDO_0009217 + DDO:DDO_0009217 + + + + obo:DDO.owl#DDO_0009217 + 50582007 + + + + obo:DDO.owl#DDO_0009217 + hemiplegia + + + + obo:DDO.owl#DDO_0009218 + DDO:DDO_0009218 + + + + obo:DDO.owl#DDO_0009218 + 62484002 + + + + obo:DDO.owl#DDO_0009218 + hepatic fibrosis + + + + obo:DDO.owl#DDO_0009219 + DDO:DDO_0009219 + + + + obo:DDO.owl#DDO_0009219 + 87248009 + + + + obo:DDO.owl#DDO_0009219 + hepatic necrosis + + + + obo:DDO.owl#DDO_0009220 + DDO:DDO_0009220 + + + + obo:DDO.owl#DDO_0009220 + 197269008 + + + + obo:DDO.owl#DDO_0009220 + acute necrosis of liver + + + + obo:DDO.owl#DDO_0009221 + DDO:DDO_0009221 + + + + obo:DDO.owl#DDO_0009221 + 707167006 + + + + obo:DDO.owl#DDO_0009221 + acute multi-acinar necrosis of liver + + + + obo:DDO.owl#DDO_0009222 + DDO:DDO_0009222 + + + + obo:DDO.owl#DDO_0009222 + 197364000 + + + + obo:DDO.owl#DDO_0009222 + central hemorrhagic necrosis of liver + + + + obo:DDO.owl#DDO_0009223 + DDO:DDO_0009223 + + + + obo:DDO.owl#DDO_0009223 + 11350001 + + + + obo:DDO.owl#DDO_0009223 + diffuse hepatic necrosis + + + + obo:DDO.owl#DDO_0009224 + DDO:DDO_0009224 + + + + obo:DDO.owl#DDO_0009224 + 55294001 + + + + obo:DDO.owl#DDO_0009224 + focal hepatic necrosis + + + + obo:DDO.owl#DDO_0009225 + DDO:DDO_0009225 + + + + obo:DDO.owl#DDO_0009225 + 13923006 + + + + obo:DDO.owl#DDO_0009225 + Centrilobular hepatic necrosis + + + + obo:DDO.owl#DDO_0009226 + DDO:DDO_0009226 + + + + obo:DDO.owl#DDO_0009226 + 447058001 + + + + obo:DDO.owl#DDO_0009226 + solitary necrotic nodule of liver + + + + obo:DDO.owl#DDO_0009227 + DDO:DDO_0009227 + + + + obo:DDO.owl#DDO_0009227 + 17890003 + + + + obo:DDO.owl#DDO_0009227 + hepatic infarction + + + + obo:DDO.owl#DDO_0009228 + DDO:DDO_0009228 + + + + obo:DDO.owl#DDO_0009228 + 80515008 + + + + obo:DDO.owl#DDO_0009228 + large liver + + + + obo:DDO.owl#DDO_0009228 + hepatomegaly + + + + obo:DDO.owl#DDO_0009230 + DDO:DDO_0009230 + + + + obo:DDO.owl#DDO_0009230 + 407000 + + + + obo:DDO.owl#DDO_0009230 + congenital hepatomegaly + + + + obo:DDO.owl#DDO_0009231 + DDO:DDO_0009231 + + + + obo:DDO.owl#DDO_0009231 + 192008 + + + + obo:DDO.owl#DDO_0009231 + congenital syphilitic hepatomegaly + + + + obo:DDO.owl#DDO_0009232 + DDO:DDO_0009232 + + + + obo:DDO.owl#DDO_0009232 + 36760000 + + + + obo:DDO.owl#DDO_0009232 + hepatosplenomegaly + + + + obo:DDO.owl#DDO_0009233 + DDO:DDO_0009233 + + + + obo:DDO.owl#DDO_0009233 + 80378000 + + + + obo:DDO.owl#DDO_0009233 + neonatal hepatosplenomegaly + + + + obo:DDO.owl#DDO_0009234 + DDO:DDO_0009234 + + + + obo:DDO.owl#DDO_0009234 + 80660001 + + + + obo:DDO.owl#DDO_0009234 + Mauriac's syndrome + + + + obo:DDO.owl#DDO_0009235 + DDO:DDO_0009235 + + + + obo:DDO.owl#DDO_0009235 + 267808001 + + + + obo:DDO.owl#DDO_0009235 + disorder of hair growth + + + + obo:DDO.owl#DDO_0009237 + DDO:DDO_0009237 + + + + obo:DDO.owl#DDO_0009237 + 399939002 + + + + obo:DDO.owl#DDO_0009237 + hirsutism + + + + obo:DDO.owl#DDO_0009238 + DDO:DDO_0009238 + + + + obo:DDO.owl#DDO_0009238 + 432726005 + + + + obo:DDO.owl#DDO_0009238 + familial hirsutism + + + + obo:DDO.owl#DDO_0009239 + DDO:DDO_0009239 + + + + obo:DDO.owl#DDO_0009239 + 66520009 + + + + obo:DDO.owl#DDO_0009239 + female hirsutism + + + + obo:DDO.owl#DDO_000924 + DDO:DDO_000924 + + + + obo:DDO.owl#DDO_000924 + 398273006 + + + + obo:DDO.owl#DDO_000924 + epidemic hemorrhagic conjunctivitis + + + + obo:DDO.owl#DDO_0009240 + DDO:DDO_0009240 + + + + obo:DDO.owl#DDO_0009240 + 201159000 + + + + obo:DDO.owl#DDO_0009240 + idiopathic hirsutism + + + + obo:DDO.owl#DDO_0009241 + DDO:DDO_0009241 + + + + obo:DDO.owl#DDO_0009241 + 238157005 + + + + obo:DDO.owl#DDO_0009241 + disorder of blood gas + + + + obo:DDO.owl#DDO_0009242 + DDO:DDO_0009242 + + + + obo:DDO.owl#DDO_0009242 + 29596007 + + + + obo:DDO.owl#DDO_0009242 + hypercapnia + + + + obo:DDO.owl#DDO_0009243 + DDO:DDO_0009243 + + + + obo:DDO.owl#DDO_0009243 + 429428003 + + + + obo:DDO.owl#DDO_0009243 + chronic hypercapnia + + + + obo:DDO.owl#DDO_0009245 + DDO:DDO_0009245 + + + + obo:DDO.owl#DDO_0009245 + 30171000 + + + + obo:DDO.owl#DDO_0009245 + disorder of adrenal gland + + + + obo:DDO.owl#DDO_0009246 + DDO:DDO_0009246 + + + + obo:DDO.owl#DDO_0009246 + 47270006 + + + + obo:DDO.owl#DDO_0009246 + hypercortisolism + + + + obo:DDO.owl#DDO_0009247 + DDO:DDO_0009247 + + + + obo:DDO.owl#DDO_0009247 + 41299009 + + + + obo:DDO.owl#DDO_0009247 + iatrogenic Cushing's disease + + + + obo:DDO.owl#DDO_0009248 + DDO:DDO_0009248 + + + + obo:DDO.owl#DDO_0009248 + 190501008 + + + + obo:DDO.owl#DDO_0009248 + idiopathic Cushing's syndrome + + + + obo:DDO.owl#DDO_0009249 + DDO:DDO_0009249 + + + + obo:DDO.owl#DDO_0009249 + 14151009 + + + + obo:DDO.owl#DDO_0009249 + hyperesthesia + + + + obo:DDO.owl#DDO_0009250 + DDO:DDO_0009250 + + + + obo:DDO.owl#DDO_0009250 + 18156008 + + + + obo:DDO.owl#DDO_0009250 + abdominal hyperesthesia + + + + obo:DDO.owl#DDO_0009251 + DDO:DDO_0009251 + + + + obo:DDO.owl#DDO_0009251 + 247404004 + + + + obo:DDO.owl#DDO_0009251 + allodynia + + + + obo:DDO.owl#DDO_0009252 + DDO:DDO_0009252 + + + + obo:DDO.owl#DDO_0009252 + 403597003 + + + + obo:DDO.owl#DDO_0009252 + cutaneous allodynia + + + + obo:DDO.owl#DDO_0009253 + DDO:DDO_0009253 + + + + obo:DDO.owl#DDO_0009253 + 55406008 + + + + obo:DDO.owl#DDO_0009253 + hyperalgesia + + + + obo:DDO.owl#DDO_0009254 + DDO:DDO_0009254 + + + + obo:DDO.owl#DDO_0009254 + 403596007 + + + + obo:DDO.owl#DDO_0009254 + cutaneous hyperalgesia + + + + obo:DDO.owl#DDO_0009255 + DDO:DDO_0009255 + + + + obo:DDO.owl#DDO_0009255 + 26857005 + + + + obo:DDO.owl#DDO_0009255 + hyperesthesia dolorosa + + + + obo:DDO.owl#DDO_0009256 + DDO:DDO_0009256 + + + + obo:DDO.owl#DDO_0009256 + 301282008 + + + + obo:DDO.owl#DDO_0009256 + finding of respiration + + + + obo:DDO.owl#DDO_0009257 + DDO:DDO_0009257 + + + + obo:DDO.owl#DDO_0009257 + 366139009 + + + + obo:DDO.owl#DDO_0009257 + ease of respiration - finding + + + + obo:DDO.owl#DDO_0009258 + DDO:DDO_0009258 + + + + obo:DDO.owl#DDO_0009258 + 366143008 + + + + obo:DDO.owl#DDO_0009258 + respiratory pattern - finding + + + + obo:DDO.owl#DDO_0009259 + DDO:DDO_0009259 + + + + obo:DDO.owl#DDO_0009259 + 366145001 + + + + obo:DDO.owl#DDO_0009259 + depth of respiration - finding + + + + obo:DDO.owl#DDO_000926 + DDO:DDO_000926 + + + + obo:DDO.owl#DDO_000926 + 26485002 + + + + obo:DDO.owl#DDO_000926 + sawdust liver + + + + obo:DDO.owl#DDO_0009260 + DDO:DDO_0009260 + + + + obo:DDO.owl#DDO_0009260 + 386616007 + + + + obo:DDO.owl#DDO_0009260 + shallow breathing + + + + obo:DDO.owl#DDO_0009261 + DDO:DDO_0009261 + + + + obo:DDO.owl#DDO_0009261 + 386614005 + + + + obo:DDO.owl#DDO_0009261 + slow shallow breathing + + + + obo:DDO.owl#DDO_0009262 + DDO:DDO_0009262 + + + + obo:DDO.owl#DDO_0009262 + 50043002 + + + + obo:DDO.owl#DDO_0009262 + respiratory system disease + + + + obo:DDO.owl#DDO_0009263 + DDO:DDO_0009263 + + + + obo:DDO.owl#DDO_0009263 + 389086002 + + + + obo:DDO.owl#DDO_0009263 + hypoxia + + + + obo:DDO.owl#DDO_0009265 + DDO:DDO_0009265 + + + + obo:DDO.owl#DDO_0009265 + 281579001 + + + + obo:DDO.owl#DDO_0009265 + perinatal hypoxia + + + + obo:DDO.owl#DDO_0009266 + DDO:DDO_0009266 + + + + obo:DDO.owl#DDO_0009266 + 275470000 + + + + obo:DDO.owl#DDO_0009266 + post-cardiorespiratory arrest coma + + + + obo:DDO.owl#DDO_0009267 + DDO:DDO_0009267 + + + + obo:DDO.owl#DDO_0009267 + 281509000 + + + + obo:DDO.owl#DDO_0009267 + hypoxic-ischemic coma + + + + obo:DDO.owl#DDO_0009268 + DDO:DDO_0009268 + + + + obo:DDO.owl#DDO_0009268 + 389089009 + + + + obo:DDO.owl#DDO_0009268 + anoxia of brain + + + + obo:DDO.owl#DDO_0009269 + DDO:DDO_0009269 + + + + obo:DDO.owl#DDO_0009269 + 389088001 + + + + obo:DDO.owl#DDO_0009269 + hypoxia of brain + + + + obo:DDO.owl#DDO_0009270 + DDO:DDO_0009270 + + + + obo:DDO.owl#DDO_0009270 + 233766001 + + + + obo:DDO.owl#DDO_0009270 + dialysis-associated hypoxia + + + + obo:DDO.owl#DDO_0009271 + DDO:DDO_0009271 + + + + obo:DDO.owl#DDO_0009271 + 416764003 + + + + obo:DDO.owl#DDO_0009271 + corneal hypoxia + + + + obo:DDO.owl#DDO_0009272 + DDO:DDO_0009272 + + + + obo:DDO.owl#DDO_0009272 + 362975008 + + + + obo:DDO.owl#DDO_0009272 + degenerative disease + + + + obo:DDO.owl#DDO_0009273 + DDO:DDO_0009273 + + + + obo:DDO.owl#DDO_0009273 + 238895003 + + + + obo:DDO.owl#DDO_0009273 + lipoatrophy and lipodystrophy + + + + obo:DDO.owl#DDO_0009274 + DDO:DDO_0009274 + + + + obo:DDO.owl#DDO_0009274 + 71325002 + + + + obo:DDO.owl#DDO_0009274 + lipodystrophy + + + + obo:DDO.owl#DDO_0009275 + DDO:DDO_0009275 + + + + obo:DDO.owl#DDO_0009275 + 86907008 + + + + obo:DDO.owl#DDO_0009275 + acquired generalized lipodystrophy + + + + obo:DDO.owl#DDO_0009276 + DDO:DDO_0009276 + + + + obo:DDO.owl#DDO_0009276 + 75659004 + + + + obo:DDO.owl#DDO_0009276 + acquired partial lipodystrophy + + + + obo:DDO.owl#DDO_0009277 + DDO:DDO_0009277 + + + + obo:DDO.owl#DDO_0009277 + 284449005 + + + + obo:DDO.owl#DDO_0009277 + congenital generalized lipodystrophy + + + + obo:DDO.owl#DDO_0009278 + DDO:DDO_0009278 + + + + obo:DDO.owl#DDO_0009278 + 238889004 + + + + obo:DDO.owl#DDO_0009278 + membranous lipodystrophy + + + + obo:DDO.owl#DDO_0009279 + DDO:DDO_0009279 + + + + obo:DDO.owl#DDO_0009279 + 49601007 + + + + obo:DDO.owl#DDO_0009279 + cardiovascular disease + + + + obo:DDO.owl#DDO_0009280 + DDO:DDO_0009280 + + + + obo:DDO.owl#DDO_0009280 + 230664009 + + + + obo:DDO.owl#DDO_0009280 + sympathotonic orthostatic hypotension + + + + obo:DDO.owl#DDO_0009281 + DDO:DDO_0009281 + + + + obo:DDO.owl#DDO_0009281 + 371073003 + + + + obo:DDO.owl#DDO_0009281 + postural orthostatic tachycardia syndrome + + + + obo:DDO.owl#DDO_0009282 + DDO:DDO_0009282 + + + + obo:DDO.owl#DDO_0009282 + 70247006 + + + + obo:DDO.owl#DDO_0009282 + hypoadrenergic postural hypotension + + + + obo:DDO.owl#DDO_0009283 + DDO:DDO_0009283 + + + + obo:DDO.owl#DDO_0009283 + 61933008 + + + + obo:DDO.owl#DDO_0009283 + hyperadrenergic postural hypotension + + + + obo:DDO.owl#DDO_0009284 + DDO:DDO_0009284 + + + + obo:DDO.owl#DDO_0009284 + 84438001 + + + + obo:DDO.owl#DDO_0009284 + pure autonomic failure + + + + obo:DDO.owl#DDO_0009285 + DDO:DDO_0009285 + + + + obo:DDO.owl#DDO_0009285 + 75181005 + + + + obo:DDO.owl#DDO_0009285 + chronic orthostatic hypotension + + + + obo:DDO.owl#DDO_0009286 + DDO:DDO_0009286 + + + + obo:DDO.owl#DDO_0009286 + 28651003 + + + + obo:DDO.owl#DDO_0009286 + orthostatic hypotension + + + + obo:DDO.owl#DDO_0009287 + DDO:DDO_0009287 + + + + obo:DDO.owl#DDO_0009287 + 45007003 + + + + obo:DDO.owl#DDO_0009287 + hypotension + + + + obo:DDO.owl#DDO_0009287 + arterial hypotension + + + + obo:DDO.owl#DDO_0009287 + hypopiesis + + + + obo:DDO.owl#DDO_0009287 + low blood pressure + + + + obo:DDO.owl#DDO_0009288 + DDO:DDO_0009288 + + + + obo:DDO.owl#DDO_0009288 + 203522001 + + + + obo:DDO.owl#DDO_0009288 + osteolysis + + + + obo:DDO.owl#DDO_0009289 + DDO:DDO_0009289 + + + + obo:DDO.owl#DDO_0009289 + 441698009 + + + + obo:DDO.owl#DDO_0009289 + periprosthetic osteolysis + + + + obo:DDO.owl#DDO_0009290 + DDO:DDO_0009290 + + + + obo:DDO.owl#DDO_0009290 + 3261002 + + + + obo:DDO.owl#DDO_0009290 + migratory osteolysis + + + + obo:DDO.owl#DDO_0009291 + DDO:DDO_0009291 + + + + obo:DDO.owl#DDO_0009291 + 1515008 + + + + obo:DDO.owl#DDO_0009291 + Gorham's disease + + + + obo:DDO.owl#DDO_0009292 + DDO:DDO_0009292 + + + + obo:DDO.owl#DDO_0009292 + 312894000 + + + + obo:DDO.owl#DDO_0009292 + osteopenia + + + + obo:DDO.owl#DDO_0009293 + DDO:DDO_0009293 + + + + obo:DDO.owl#DDO_0009293 + 40308000 + + + + obo:DDO.owl#DDO_0009293 + steroid-induced osteopenia + + + + obo:DDO.owl#DDO_0009294 + DDO:DDO_0009294 + + + + obo:DDO.owl#DDO_0009294 + 37605006 + + + + obo:DDO.owl#DDO_0009294 + senile osteopenia + + + + obo:DDO.owl#DDO_0009295 + DDO:DDO_0009295 + + + + obo:DDO.owl#DDO_0009295 + 276703007 + + + + obo:DDO.owl#DDO_0009295 + osteopenia of prematurity + + + + obo:DDO.owl#DDO_0009296 + DDO:DDO_0009296 + + + + obo:DDO.owl#DDO_0009296 + 76349003 + + + + obo:DDO.owl#DDO_0009296 + extrapyramidal disease + + + + obo:DDO.owl#DDO_0009297 + DDO:DDO_0009297 + + + + obo:DDO.owl#DDO_0009297 + 32798002 + + + + obo:DDO.owl#DDO_0009297 + parkinsonism + + + + obo:DDO.owl#DDO_0009298 + DDO:DDO_0009298 + + + + obo:DDO.owl#DDO_0009298 + 49049000 + + + + obo:DDO.owl#DDO_0009298 + Parkinson disease + + + + obo:DDO.owl#DDO_0009299 + DDO:DDO_0009299 + + + + obo:DDO.owl#DDO_0009299 + 230291001 + + + + obo:DDO.owl#DDO_0009299 + juvenile Parkinson's disease + + + + obo:DDO.owl#DDO_0009300 + DDO:DDO_0009300 + + + + obo:DDO.owl#DDO_0009300 + 265377002 + + + + obo:DDO.owl#DDO_0009300 + symptomatic parkinsonism + + + + obo:DDO.owl#DDO_0009301 + DDO:DDO_0009301 + + + + obo:DDO.owl#DDO_0009301 + 205237003 + + + + obo:DDO.owl#DDO_0009301 + pneumonitis + + + + obo:DDO.owl#DDO_0009302 + DDO:DDO_0009302 + + + + obo:DDO.owl#DDO_0009302 + 233604007 + + + + obo:DDO.owl#DDO_0009302 + pneumonia + + + + obo:DDO.owl#DDO_0009303 + DDO:DDO_0009303 + + + + obo:DDO.owl#DDO_0009303 + 42345000 + + + + obo:DDO.owl#DDO_0009303 + polyneuropathy + + + + obo:DDO.owl#DDO_0009304 + DDO:DDO_0009304 + + + + obo:DDO.owl#DDO_0009304 + 230560008 + + + + obo:DDO.owl#DDO_0009304 + congenital polyneuropathy + + + + obo:DDO.owl#DDO_0009305 + DDO:DDO_0009305 + + + + obo:DDO.owl#DDO_0009305 + 42295001 + + + + obo:DDO.owl#DDO_0009305 + familial amyloid polyneuropathy + + + + obo:DDO.owl#DDO_0009306 + DDO:DDO_0009306 + + + + obo:DDO.owl#DDO_0009306 + 33209009 + + + + obo:DDO.owl#DDO_0009306 + idiopathic progressive polyneuropathy + + + + obo:DDO.owl#DDO_0009307 + DDO:DDO_0009307 + + + + obo:DDO.owl#DDO_0009307 + 85423005 + + + + obo:DDO.owl#DDO_0009307 + motor polyneuropathy + + + + obo:DDO.owl#DDO_0009308 + DDO:DDO_0009308 + + + + obo:DDO.owl#DDO_0009308 + 3900008 + + + + obo:DDO.owl#DDO_0009308 + mixed sensory-motor polyneuropathy + + + + obo:DDO.owl#DDO_0009309 + DDO:DDO_0009309 + + + + obo:DDO.owl#DDO_0009309 + 126534007 + + + + obo:DDO.owl#DDO_0009309 + diabetic mixed sensory-motor polyneuropathy + + + + obo:DDO.owl#DDO_0009310 + DDO:DDO_0009310 + + + + obo:DDO.owl#DDO_0009310 + 76886005 + + + + obo:DDO.owl#DDO_0009310 + polyneuritis + + + + obo:DDO.owl#DDO_0009311 + DDO:DDO_0009311 + + + + obo:DDO.owl#DDO_0009311 + 128078004 + + + + obo:DDO.owl#DDO_0009311 + polyradiculoneuropathy + + + + obo:DDO.owl#DDO_0009312 + DDO:DDO_0009312 + + + + obo:DDO.owl#DDO_0009312 + 75572007 + + + + obo:DDO.owl#DDO_0009312 + polyradiculopathy + + + + obo:DDO.owl#DDO_0009313 + DDO:DDO_0009313 + + + + obo:DDO.owl#DDO_0009313 + 193174005 + + + + obo:DDO.owl#DDO_0009313 + post-infectious polyneuritis + + + + obo:DDO.owl#DDO_0009314 + DDO:DDO_0009314 + + + + obo:DDO.owl#DDO_0009314 + 1767005 + + + + obo:DDO.owl#DDO_0009314 + Fisher's syndrome + + + + obo:DDO.owl#DDO_0009315 + DDO:DDO_0009315 + + + + obo:DDO.owl#DDO_0009315 + 56795008 + + + + obo:DDO.owl#DDO_0009315 + polyneuritis cranialis + + + + obo:DDO.owl#DDO_0009316 + DDO:DDO_0009316 + + + + obo:DDO.owl#DDO_0009316 + 40956001 + + + + obo:DDO.owl#DDO_0009316 + Guillain-Barré syndrome + + + + obo:DDO.owl#DDO_0009317 + DDO:DDO_0009317 + + + + obo:DDO.owl#DDO_0009317 + 129131007 + + + + obo:DDO.owl#DDO_0009317 + acute infective polyneuritis + + + + obo:DDO.owl#DDO_0009318 + DDO:DDO_0009318 + + + + obo:DDO.owl#DDO_0009318 + 444728005 + + + + obo:DDO.owl#DDO_0009318 + chronic inflammatory demyelinating polyneuritis + + + + obo:DDO.owl#DDO_0009319 + DDO:DDO_0009319 + + + + obo:DDO.owl#DDO_0009319 + 13694005 + + + + obo:DDO.owl#DDO_0009319 + sensory polyneuropathy + + + + obo:DDO.owl#DDO_0009320 + DDO:DDO_0009320 + + + + obo:DDO.owl#DDO_0009320 + 45600000 + + + + obo:DDO.owl#DDO_0009320 + toxic polyneuropathy + + + + obo:DDO.owl#DDO_0009321 + DDO:DDO_0009321 + + + + obo:DDO.owl#DDO_0009321 + 7521001 + + + + obo:DDO.owl#DDO_0009321 + vitamin disease + + + + obo:DDO.owl#DDO_0009322 + DDO:DDO_0009322 + + + + obo:DDO.owl#DDO_0009322 + 85670002 + + + + obo:DDO.owl#DDO_0009322 + vitamin deficiency + + + + obo:DDO.owl#DDO_0009323 + DDO:DDO_0009323 + + + + obo:DDO.owl#DDO_0009323 + 34713006 + + + + obo:DDO.owl#DDO_0009323 + vitamin D deficiency + + + + obo:DDO.owl#DDO_0009400 + DDO:DDO_0009400 + + + + obo:DDO.owl#DDO_0009400 + 235942001 + + + + obo:DDO.owl#DDO_0009400 + alcohol-induced acute pancreatitis + + + + obo:DDO.owl#DDO_0009401 + DDO:DDO_0009401 + + + + obo:DDO.owl#DDO_0009401 + 235952002 + + + + obo:DDO.owl#DDO_0009401 + alcohol-induced chronic pancreatitis + + + + obo:DDO.owl#DDO_0009402 + DDO:DDO_0009402 + + + + obo:DDO.owl#DDO_0009402 + 234347009 + + + + obo:DDO.owl#DDO_0009402 + anemia of chronic disease + + + + obo:DDO.owl#DDO_0009403 + DDO:DDO_0009403 + + + + obo:DDO.owl#DDO_0009403 + 707323002 + + + + obo:DDO.owl#DDO_0009403 + anemia in chronic kidney disease + + + + obo:DDO.owl#DDO_0009404 + DDO:DDO_0009404 + + + + obo:DDO.owl#DDO_0009404 + 49708008 + + + + obo:DDO.owl#DDO_0009404 + anemia of chronic renal failure + + + + obo:DDO.owl#DDO_0009405 + DDO:DDO_0009405 + + + + obo:DDO.owl#DDO_0009405 + 31820007 + + + + obo:DDO.owl#DDO_0009405 + anemia of endocrine disorder + + + + obo:DDO.owl#DDO_0009406 + DDO:DDO_0009406 + + + + obo:DDO.owl#DDO_0009406 + 82980005 + + + + obo:DDO.owl#DDO_0009406 + anemia of diabetes + + + + obo:DDO.owl#DDO_0009407 + DDO:DDO_0009407 + + + + obo:DDO.owl#DDO_0009407 + 191268006 + + + + obo:DDO.owl#DDO_0009407 + chronic anemia + + + + obo:DDO.owl#DDO_0009408 + DDO:DDO_0009408 + + + + obo:DDO.owl#DDO_0009408 + 291262006 + + + + obo:DDO.owl#DDO_0009408 + simple chronic anemia + + + + obo:DDO.owl#DDO_0009430 + DDO:DDO_0009430 + + + + obo:DDO.owl#DDO_0009430 + 118940003 + + + + obo:DDO.owl#DDO_0009430 + nervous system disease + + + + obo:DDO.owl#DDO_0009433 + DDO:DDO_0009433 + + + + obo:DDO.owl#DDO_0009433 + 60389000 + + + + obo:DDO.owl#DDO_0009433 + paraplegia + + + + obo:DDO.owl#DDO_0009434 + DDO:DDO_0009434 + + + + obo:DDO.owl#DDO_0009434 + 698291007 + + + + obo:DDO.owl#DDO_0009434 + acute paraplegia + + + + obo:DDO.owl#DDO_0009435 + DDO:DDO_0009435 + + + + obo:DDO.owl#DDO_0009435 + 48662007 + + + + obo:DDO.owl#DDO_0009435 + cerebral paraplegia + + + + obo:DDO.owl#DDO_0009436 + DDO:DDO_0009436 + + + + obo:DDO.owl#DDO_0009436 + 698292000 + + + + obo:DDO.owl#DDO_0009436 + chronic paraplegia + + + + obo:DDO.owl#DDO_0009448 + DDO:DDO_0009448 + + + + obo:DDO.owl#DDO_0009448 + 290401000119108 + + + + obo:DDO.owl#DDO_0009448 + complete paraplegia + + + + obo:DDO.owl#DDO_0009982 + symptom of + + + + obo:DDO.owl#DDO_0009986 + is_unit_of + + + + obo:DDO.owl#DDO_0009986 + has_measurement_unit + + + + obo:DDO.owl#DDO_0009987 + The "finding site" specifies the body site affected by a condition. + + + + obo:DDO.owl#DDO_0009987 + finding_site + + + + obo:DDO.owl#DDO_0009988 + The "Due to" relates a disease or disorder directly to a cause such as another disease or disorder + + + + obo:DDO.owl#DDO_0009988 + due_to + + + + obo:DDO.owl#DDO_0009989 + The "Causative agent" relationship identifies the direct cause of the disorder. The causative agent is the bacterium, virus, toxin or environmental agent that causes the disorder. + + + + obo:DDO.owl#DDO_0009989 + causative_agent + + + + obo:DDO.owl#DDO_0009991 + has_active_ingredient + + + + obo:DDO.owl#DDO_0009993 + may_treat + + + + obo:DDO.owl#DDO_0009994 + may_be_treated_by + + + + obo:DDO.owl#DDO_0009995 + The “Associated morphology” relationship identifies the abnormal physical condition that is characteristic of a given disorder. + + + + obo:DDO.owl#DDO_0009995 + associated_morphology + + + + obo:DDO.owl#DDO_0009996 + The "Associated with" represents a clinically relevant association between concepts without either asserting or excluding a causal or sequential relationship between the two. + + + + obo:DDO.owl#DDO_0009996 + associated_with + + + + obo:DDO.owl#DDO_0009997 + The "After" represents a sequence of events where a disease or disorder occurs after another one. + + + + obo:DDO.owl#DDO_0009997 + after + + + + obo:DDO.owl#DDO_002041 + DDO:DDO_002041 + + + + obo:DDO.owl#DDO_002041 + 703213009 + + + + obo:DDO.owl#DDO_002041 + acute ST segment elevation myocardial infarction of inferior wall + + + + obo:DDO.owl#DDO_002544 + DDO:DDO_002544 + + + + obo:DDO.owl#DDO_002544 + 32904004 + + + + obo:DDO.owl#DDO_002544 + pneumococcal laryngitis + + + + obo:DDO.owl#DDO_002553 + DDO:DDO_002553 + + + + obo:DDO.owl#DDO_002553 + 399324007 + + + + obo:DDO.owl#DDO_002553 + bacterial folliculitis + + + + obo:DDO.owl#DDO_003405 + DDO:DDO_003405 + + + + obo:DDO.owl#DDO_003405 + 278024000 + + + + obo:DDO.owl#DDO_003405 + rhabdomyosarcoma of bladder + + + + obo:DDO.owl#DDO_003475 + DDO:DDO_003475 + + + + obo:DDO.owl#DDO_003475 + 89261000 + + + + obo:DDO.owl#DDO_003475 + isolated thyrotropin deficiency + + + + obo:DDO.owl#DDO_003540 + DDO:DDO_003540 + + + + obo:DDO.owl#DDO_003540 + 62239001 + + + + obo:DDO.owl#DDO_003540 + Parkinson-dementia complex of Guam + + + + obo:DDO.owl#DDO_00906290 + DDO:DDO_00906290 + + + + obo:DDO.owl#DDO_00906290 + diabetes laboratory test + + + + obo:DDO.owl#DDO_0099997 + synonym + + + + obo:DDO.owl#DDO_0099998 + textual definition + + + + obo:DDO.owl#DDO_0099999 + RxNorm CUI + + + + obo:DDO.owl#DDO_1238 + DDO:DDO_1238 + + + + obo:DDO.owl#DDO_1238 + 230575000 + + + + obo:DDO.owl#DDO_1238 + diabetic chronic painful polyneuropathy + + + + obo:DDO.owl#DDO_9999900 + result_from + + + + obo:DDO.owl#DDO_9999901 + increase_the_chance_of + + + + obo:DDO.owl#DDO_9999980 + has_clinical_finding + + + + obo:DDO.owl#DDO_9999999 + leads_to + + + + obo:DDO.owl#DD_0002293 + DDO:DD_0002293 + + + + obo:DDO.owl#DD_0002293 + 1521000119100 + + + + obo:DDO.owl#DD_0002293 + foot ulcer due to type 2 diabetes mellitus + + + + obo:DDO.owl#DOID_0050700 + DDO:DOID_0050700 + + + + obo:DDO.owl#DOID_0050700 + 85898001 + + + + obo:DDO.owl#DOID_0050700 + cardiomyopathy + + + + obo:DDO.owl#DOID_104 + DDO:DOID_104 + + + + obo:DDO.owl#DOID_104 + 87628006 + + + + obo:DDO.owl#DOID_104 + bacterial infection disease + + + + obo:DDO.owl#DOID_26 + DDO:DOID_26 + + + + obo:DDO.owl#DOID_26 + 128482007 + + + + obo:DDO.owl#DOID_26 + pancreas disease + + + + obo:DDO.owl#DOID_2913 + DDO:DOID_2913 + + + + obo:DDO.owl#DOID_2913 + 197456007 + + + + obo:DDO.owl#DOID_2913 + acute pancreatitis + + + + obo:DDO.owl#DOID_2914 + DDO:DOID_2914 + + + + obo:DDO.owl#DOID_2914 + C0041806 + + + + obo:DDO.owl#DOID_2914 + immune system disease + + + + obo:DDO.owl#DOID_4988 + DDO:DOID_4988 + + + + obo:DDO.owl#DOID_4988 + 445507008 + + + + obo:DDO.owl#DOID_4988 + alcohol-induced pancreatitis + + + + obo:DDO.owl#DOID_4988 + inflammation of pancreas due to alcohol + + + + obo:DDO.owl#DOID_4988 + alcoholic pancreatitis + + + + obo:DDO.owl#DOID_4989 + DDO:DOID_4989 + + + + obo:DDO.owl#DOID_4989 + 75694006 + + + + obo:DDO.owl#DOID_4989 + pancreatitis + + + + obo:DDO.owl#DOID_74 + DDO:DOID_74 + + + + obo:DDO.owl#DOID_74 + C0018939 + + + + obo:DDO.owl#DOID_74 + hematopoietic system disease + + + + obo:DDO.owl#OGMS_0000020 + DDO:OGMS_0000020 + + + + obo:DDO.owl#OGMS_0000020 + A quality of a patient that is observed by the patient or a processual entity experienced by the patient, either of which is hypothesized by the patient to be a realization of a disease. + + + + obo:DDO.owl#OGMS_0000020 + note: defined class + + + + obo:DDO.owl#OGMS_0000020 + http://ontology.buffalo.edu/medo/Disease_and_Diagnosis.pdf + + + + obo:DDO.owl#OGMS_0000020 + symptom + + + + obo:DDO.owl#OGMS_0000056 + DDO:OGMS_0000056 + + + + obo:DDO.owl#OGMS_0000056 + A measurement assay that has as input a patient-derived specimen, and as output a result that represents a quality of the specimen. + + + + obo:DDO.owl#OGMS_0000056 + http://ontology.buffalo.edu/medo/Disease_and_Diagnosis.pdf + + + + obo:DDO.owl#OGMS_0000056 + laboratory test + + + + obo:DDO.owl#OGMS_0000057 + DDO:OGMS_0000057 + + + + obo:DDO.owl#OGMS_0000057 + A sequence of acts of observing and measuring qualities of a patient performed by a clinician; measurements may occur with and without elicitation. + + + + obo:DDO.owl#OGMS_0000057 + http://ontology.buffalo.edu/medo/Disease_and_Diagnosis.pdf + + + + obo:DDO.owl#OGMS_0000057 + physical examination + + + + obo:DDO.owl#RO_0000052 + a relation between a specifically dependent continuant (the dependent) and an independent continuant (the bearer), in which the dependent specifically depends on the bearer for its existence + + + + obo:DDO.owl#RO_0000052 + inheres_in + + + + obo:DDO.owl#RO_0000053 + a relation between an independent continuant (the bearer) and a specifically dependent continuant (the dependent), in which the dependent specifically depends on the bearer for its existence + + + + obo:DDO.owl#RO_0000053 + bearer_of + + + + obo:DDO.owl#RO_0000085 + a relation between an independent continuant (the bearer) and a function, in which the function specifically depends on the bearer for its existence + + + + obo:DDO.owl#RO_0000085 + has_function + + + + obo:DDO.owl#RO_0000086 + a relation between an independent continuant (the bearer) and a quality, in which the quality specifically depends on the bearer for its existence + + + + obo:DDO.owl#RO_0000086 + has_quality + + + + obo:DDO.owl#RO_0000087 + a relation between an independent continuant (the bearer) and a role, in which the role specifically depends on the bearer for its existence + + + + obo:DDO.owl#RO_0000087 + has_role + + + + obo:DDO.owl#RO_0000091 + has_disposition + + + + obo:DDO.owl#RO_0002200 + A relationship that holds between a biological entity and a phenotype. Here a phenotype is construed broadly as any kind of quality of an organism part, a collection of these qualities, or a change in quality or qualities (e.g. abnormally increased temperature). The subject of this relationship can be an organism (where the organism has the phenotype, i.e. the qualities inhere in parts of this organism), a genomic entity such as a gene or genotype (if modifications of the gene or the genotype causes the phenotype), or a condition such as a disease (such that if the condition inheres in an organism, then the organism has the phenotype). + + + + obo:DDO.owl#RO_0002200 + has_phenotype + + + + obo:DDO.owl#RO_0002201 + phenotype of + + + + obo:DDO.owl#RO_0002314 + inheres_in_part_of + + + + obo:DDO.owl#RO_0002452 + A relation that holds between a disease or an organism and a phenotype + + + + obo:DDO.owl#RO_0002452 + has symptom + + + + obo:DDO.owl#RO_0002502 + depends_on + + + + obo:DDO.owl#UO_0000000 + DDO:UO_0000000 + + + + obo:DDO.owl#UO_0000000 + A unit of measurement is a standardized quantity of a physical quality. + + + + obo:DDO.owl#UO_0000000 + measurement unit + + + + obo:DDO.owl#UO_0000186 + DDO:UO_0000186 + + + + obo:DDO.owl#UO_0000186 + A unit which is a standard measure of physical quantity consisting of only a numerical number without any units. + + + + obo:DDO.owl#UO_0000186 + dimensionless unit + + + + obo:DDO.owl#UO_0000187 + DDO:UO_0000187 + + + + obo:DDO.owl#UO_0000187 + A dimensionless ratio unit which denotes numbers as fractions of 100. + + + + obo:DDO.owl#UO_0000187 + percent + + + + obo:DDO.owl#UO_0000190 + DDO:UO_0000190 + + + + obo:DDO.owl#UO_0000190 + A dimensionless unit which denotes an amount or magnitude of one quantity relative to another. + + + + obo:DDO.owl#UO_0000190 + ratio + + + + obo:iao/dev/ontology-metadata.owl + en + + + + obo:iao/dev/ontology-metadata.owl + $Revision$ + + + + dc:contributor + Examples of a Contributor include a person, an + organisation, or a service. Typically, the name of a + Contributor should be used to indicate the entity. + + + + dc:contributor + An entity responsible for making contributions to the + content of the resource. + + + + dc:contributor + dc: + + + + dc:contributor + Contributor + + + + dc:coverage + Coverage will typically include spatial location (a place name + or geographic coordinates), temporal period (a period label, + date, or date range) or jurisdiction (such as a named + administrative entity). + Recommended best practice is to select a value from a + controlled vocabulary (for example, the Thesaurus of Geographic + Names [TGN]) and that, where appropriate, named places or time + periods be used in preference to numeric identifiers such as + sets of coordinates or date ranges. + + + + dc:coverage + The extent or scope of the content of the resource. + + + + dc:coverage + dc: + + + + dc:coverage + Coverage + + + + dc:creator + Examples of a Creator include a person, an organisation, + or a service. Typically, the name of a Creator should + be used to indicate the entity. + + + + dc:creator + An entity primarily responsible for making the content + of the resource. + + + + dc:creator + dc: + + + + dc:creator + Creator + + + + dc:date + Typically, Date will be associated with the creation or + availability of the resource. Recommended best practice + for encoding the date value is defined in a profile of + ISO 8601 [W3CDTF] and follows the YYYY-MM-DD format. + + + + dc:date + A date associated with an event in the life cycle of the + resource. + + + + dc:date + dc: + + + + dc:date + Date + + + + dc:description + Description may include but is not limited to: an abstract, + table of contents, reference to a graphical representation + of content or a free-text account of the content. + + + + dc:description + An account of the content of the resource. + + + + dc:description + dc: + + + + dc:description + Description + + + + dc:format + Typically, Format may include the media-type or dimensions of + the resource. Format may be used to determine the software, + hardware or other equipment needed to display or operate the + resource. Examples of dimensions include size and duration. + Recommended best practice is to select a value from a + controlled vocabulary (for example, the list of Internet Media + Types [MIME] defining computer media formats). + + + + dc:format + The physical or digital manifestation of the resource. + + + + dc:format + dc: + + + + dc:format + Format + + + + dc:identifier + Recommended best practice is to identify the resource by means + of a string or number conforming to a formal identification + system. + Example formal identification systems include the Uniform + Resource Identifier (URI) (including the Uniform Resource + Locator (URL)), the Digital Object Identifier (DOI) and the + International Standard Book Number (ISBN). + + + + dc:identifier + An unambiguous reference to the resource within a given context. + + + + dc:identifier + dc: + + + + dc:identifier + Resource Identifier + + + + dc:language + Recommended best practice is to use RFC 3066 [RFC3066], + which, in conjunction with ISO 639 [ISO639], defines two- + and three-letter primary language tags with optional + subtags. Examples include "en" or "eng" for English, + "akk" for Akkadian, and "en-GB" for English used in the + United Kingdom. + + + + dc:language + A language of the intellectual content of the resource. + + + + dc:language + dc: + + + + dc:language + Language + + + + dc:publisher + Examples of a Publisher include a person, an organisation, + or a service. + Typically, the name of a Publisher should be used to + indicate the entity. + + + + dc:publisher + An entity responsible for making the resource available + + + + dc:publisher + dc: + + + + dc:publisher + Publisher + + + + dc:relation + + Recommended best practice is to reference the resource by means + of a string or number conforming to a formal identification + system. + + + + + dc:relation + A reference to a related resource. + + + + dc:relation + dc: + + + + dc:relation + Relation + + + + dc:rights + + Typically, a Rights element will contain a rights + management statement for the resource, or reference + a service providing such information. Rights information + often encompasses Intellectual Property Rights (IPR), + Copyright, and various Property Rights. + If the Rights element is absent, no assumptions can be made + about the status of these and other rights with respect to + the resource. + + + + + dc:rights + Information about rights held in and over the resource. + + + + dc:rights + dc: + + + + dc:rights + Rights Management + + + + dc:source + The present resource may be derived from the Source resource + in whole or in part. Recommended best practice is to reference + the resource by means of a string or number conforming to a + formal identification system. + + + + dc:source + A reference to a resource from which the present resource + is derived. + + + + dc:source + dc: + + + + dc:source + Source + + + + dc:subject + Typically, a Subject will be expressed as keywords, + key phrases or classification codes that describe a topic + of the resource. Recommended best practice is to select + a value from a controlled vocabulary or formal + classification scheme. + + + + dc:subject + The topic of the content of the resource. + + + + dc:subject + dc: + + + + dc:subject + Subject and Keywords + + + + dc:title + + Typically, a Title will be a name by which the resource is + formally known. + + + + + dc:title + A name given to the resource. + + + + dc:title + dc: + + + + dc:title + Title + + + + dc:type + Type includes terms describing general categories, functions, + genres, or aggregation levels for content. Recommended best + practice is to select a value from a controlled vocabulary + (for example, the DCMI Type Vocabulary [DCMITYPE]). To + describe the physical or digital manifestation of the + resource, use the Format element. + + + + dc:type + The nature or genre of the content of the resource. + + + + dc:type + dc: + + + + dc:type + Resource Type + + + + http://www.co-ode.org/ontologies/ont.owl#DDO:0000002 + Creator + + + + http://www.co-ode.org/ontologies/ont.owl#DDO_0010000 + 199225007 + + + + http://www.co-ode.org/ontologies/ont.owl#DDO_0010000 + diabetes mellitus during pregnancy - baby delivered + + + + http://www.co-ode.org/ontologies/ont.owl#DDO_0010001 + 199227004 + + + + http://www.co-ode.org/ontologies/ont.owl#DDO_0010001 + diabetes mellitus during pregnancy - baby not yet delivered + + + + http://www.co-ode.org/ontologies/ont.owl#DDO_0010002 + 76751001 + + + + http://www.co-ode.org/ontologies/ont.owl#DDO_0010002 + diabetes mellitus in mother complicating pregnancy, childbirth AND/OR puerperium + + + + http://www.co-ode.org/ontologies/ont.owl#DDO_0010003 + 10754881000119104 + + + + http://www.co-ode.org/ontologies/ont.owl#DDO_0010003 + diabetes mellitus in mother complicating childbirth + + + + http://www.co-ode.org/ontologies/ont.owl#DDO_0010004 + 106281000119103 + + + + http://www.co-ode.org/ontologies/ont.owl#DDO_0010004 + pre-existing diabetes mellitus in mother complicating childbirth + + + + http://www.co-ode.org/ontologies/ont.owl#DDO_0010005 + 4783006 + + + + http://www.co-ode.org/ontologies/ont.owl#DDO_0010005 + maternal diabetes mellitus with hypoglycemia affecting fetus OR newborn + + + + http://www.co-ode.org/ontologies/ont.owl#DDO_0010006 + 199226008 + + + + http://www.co-ode.org/ontologies/ont.owl#DDO_0010006 + diabetes mellitus in the puerperium - baby delivered during current episode of care + + + + http://www.co-ode.org/ontologies/ont.owl#DDO_0010007 + 199228009 + + + + http://www.co-ode.org/ontologies/ont.owl#DDO_0010007 + diabetes mellitus in the puerperium - baby delivered during previous episode of care + + + + http://www.co-ode.org/ontologies/ont.owl#DDO_0010008 + 11687002 + + + + http://www.co-ode.org/ontologies/ont.owl#DDO_0010008 + gestational diabetes mellitus + + + + http://www.co-ode.org/ontologies/ont.owl#DDO_0010009 + 40801000119106 + + + + http://www.co-ode.org/ontologies/ont.owl#DDO_0010009 + gestational diabetes mellitus complicating pregnancy + + + + + http://www.co-ode.org/ontologies/ont.owl#DDO_0010010 + 10753491000119101 + + + + http://www.co-ode.org/ontologies/ont.owl#DDO_0010010 + gestational diabetes mellitus in childbirth + + + + + http://www.co-ode.org/ontologies/ont.owl#DDO_0010011 + 75022004 + + + + http://www.co-ode.org/ontologies/ont.owl#DDO_0010011 + gestational diabetes mellitus, class A>1< + + + + http://www.co-ode.org/ontologies/ont.owl#DDO_0010012 + 46894009 + + + + http://www.co-ode.org/ontologies/ont.owl#DDO_0010012 + gestational diabetes mellitus, class A>2< + + + + http://www.co-ode.org/ontologies/ont.owl#DDO_0010013 + 40791000119105 + + + + http://www.co-ode.org/ontologies/ont.owl#DDO_0010013 + postpartum gestational diabetes mellitus + + + + http://www.co-ode.org/ontologies/ont.owl#DDO_0010014 + 609563008 + + + + http://www.co-ode.org/ontologies/ont.owl#DDO_0010014 + pre-existing diabetes mellitus in pregnancy + + + + http://www.co-ode.org/ontologies/ont.owl#DDO_0010015 + 609567009 + + + + http://www.co-ode.org/ontologies/ont.owl#DDO_0010015 + pre-existing type 2 diabetes mellitus in pregnancy + + + + http://www.co-ode.org/ontologies/ont.owl#DDO_0010016 + 237627000 + + + + http://www.co-ode.org/ontologies/ont.owl#DDO_0010016 + pregnancy and type 2 diabetes mellitus + + + + http://www.co-ode.org/ontologies/ont.owl#DDO_0010017 + 609567009 + + + + http://www.co-ode.org/ontologies/ont.owl#DDO_0010017 + pre-existing type 2 diabetes mellitus in pregnancy + + + + http://www.co-ode.org/ontologies/ont.owl#DDO_0010019 + 111552007 + + + + http://www.co-ode.org/ontologies/ont.owl#DDO_0010019 + diabetes mellitus without complication + + + + http://www.co-ode.org/ontologies/ont.owl#DDO_0010020 + 313436004 + + + + http://www.co-ode.org/ontologies/ont.owl#DDO_0010020 + Type 2 diabetes mellitus without complication + + + + http://www.co-ode.org/ontologies/ont.owl#DDO_0010021 + 1481000119100 + + + + http://www.co-ode.org/ontologies/ont.owl#DDO_0010021 + diabetes mellitus type 2 without retinopathy + + + + http://www.co-ode.org/ontologies/ont.owl#DDO_0010022 + 237599002 + + + + http://www.co-ode.org/ontologies/ont.owl#DDO_0010022 + insulin treated type 2 diabetes mellitus + + + + http://www.co-ode.org/ontologies/ont.owl#DDO_0010023 + 199230006 + + + + http://www.co-ode.org/ontologies/ont.owl#DDO_0010023 + pre-existing type 2 diabetes mellitus + + + + http://www.co-ode.org/ontologies/ont.owl#DDO_0010024 + 359642000 + + + + http://www.co-ode.org/ontologies/ont.owl#DDO_0010024 + type 2 diabetes mellitus in nonobese + + + + http://www.co-ode.org/ontologies/ont.owl#DDO_0010025 + 81531005 + + + + http://www.co-ode.org/ontologies/ont.owl#DDO_0010025 + type 2 diabetes mellitus in obese + + + + http://www.co-ode.org/ontologies/ont.owl#DDO_0010026 + 9859006 + + + + http://www.co-ode.org/ontologies/ont.owl#DDO_0010026 + type 2 diabetes mellitus with acanthosis nigricans + + + + http://www.co-ode.org/ontologies/ont.owl#DDO_0010027 + 314903002 + + + + http://www.co-ode.org/ontologies/ont.owl#DDO_0010027 + type 2 diabetes mellitus with arthropathy + + + + http://www.co-ode.org/ontologies/ont.owl#DDO_0010028 + 314904008 + + + + http://www.co-ode.org/ontologies/ont.owl#DDO_0010028 + type 2 diabetes mellitus with neuropathic arthropathy + + + + http://www.co-ode.org/ontologies/ont.owl#DDO_0010029 + 703138006 + + + + http://www.co-ode.org/ontologies/ont.owl#DDO_0010029 + type II diabetes mellitus in remission + + + + + http://www.co-ode.org/ontologies/ont.owl#DDO_0010030 + 1481000119100 + + + + http://www.co-ode.org/ontologies/ont.owl#DDO_0010030 + diabetes mellitus type 2 without retinopathy + + + + http://www.co-ode.org/ontologies/ont.owl#DDO_0010031 + 313436004 + + + + http://www.co-ode.org/ontologies/ont.owl#DDO_0010031 + type 2 diabetes mellitus without complication + + + + http://www.co-ode.org/ontologies/ont.owl#DDO_0010032 + 190389009 + + + + http://www.co-ode.org/ontologies/ont.owl#DDO_0010032 + type 2 diabetes mellitus with ulcer + + + + http://www.co-ode.org/ontologies/ont.owl#DDO_0010033 + 314902007 + + + + http://www.co-ode.org/ontologies/ont.owl#DDO_0010033 + type 2 diabetes mellitus with peripheral angiopathy + + + + http://www.co-ode.org/ontologies/ont.owl#DDO_0010034 + 314772004 + + + + http://www.co-ode.org/ontologies/ont.owl#DDO_0010034 + type 2 diabetes mellitus with hypoglycemic coma + + + + http://www.co-ode.org/ontologies/ont.owl#DDO_0010035 + 190331003 + + + + http://www.co-ode.org/ontologies/ont.owl#DDO_0010035 + type 2 diabetes mellitus with hyperosmolar coma + + + + http://www.co-ode.org/ontologies/ont.owl#DDO_0010036 + 190390000 + + + + http://www.co-ode.org/ontologies/ont.owl#DDO_0010036 + type 2 diabetes mellitus with gangrene + + + + http://www.geneontology.org/formats/oboInOwl#DbXref + oboInOwl:DbXref + + + + http://www.geneontology.org/formats/oboInOwl#Definition + oboInOwl:Definition + + + + http://www.geneontology.org/formats/oboInOwl#Subset + oboInOwl:Subset + + + + http://www.geneontology.org/formats/oboInOwl#Synonym + oboInOwl:Synonym + + + + http://www.geneontology.org/formats/oboInOwl#SynonymType + oboInOwl:SynonymType + + + + http://www.w3.org/2006/time#TIME:0000002 + temporal thing + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DDO:0000009 + skin exam + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DDO:0000010 + foot exam + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000011 + drug + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000012 + diabetes drug + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000013 + patient history drug + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000014 + vital sign + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000015 + temperature + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000016 + pulse rate + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000017 + respiratory rate + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000018 + eye exam + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000019 + oral exam + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000020 + diabetes complication drug + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000021 + patient + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000022 + has_role + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000023 + role_of + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000024 + patient history disease + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000025 + has_strength_amount + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000026 + has_doseForm + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000027 + drug_quality + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000028 + dose form + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000029 + route of administration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000030 + has_route_of_administration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000031 + dose_form_of + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000032 + route_of_administration_of + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000033 + drug form strength + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000034 + has_drug_form_strength + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000035 + has_strength_unit + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000036 + has_volume + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000037 + has_volume_unit + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000038 + may_prevent + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000041 + NDF-RT.owl + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000041 + has_physiologic_effect + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000042 + physiological effect + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000044 + treatment plan + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000045 + plan stage + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000046 + has_plan_stage + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000047 + stage 1 + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000048 + stage 2 + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000049 + stage 3 + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000050 + stage 4 + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000051 + imported from + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000053 + orderable drug form + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000054 + liquid + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000055 + solid + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000056 + cream + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000057 + liquid solution + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000058 + suspension + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000059 + topical cream + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000060 + injectable solution + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000061 + oral solution + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000062 + topical solution + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000063 + oral suspension + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000064 + pill + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000065 + capsule + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000066 + tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000067 + oral tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000068 + extended release tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000069 + sublingual tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000070 + oral capsule + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000071 + extended release capsule + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000072 + has_chemical_structure + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000073 + has_MoA + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000074 + may_diagnose + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000075 + Drugs that are contraindicated with a Mechanism of Action + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000075 + CI_MoA + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000076 + Drugs that are contraindicated with a Physologic Effect + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000076 + CI_PE + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000078 + mechanism of action (MoA) + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000079 + RxNorm name + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000080 + THERAPEUTIC CATEGORY + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000080 + has_TC + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000081 + NDF-RT™ unique identifier (a unique “N#” assigned to every concept) + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000081 + NUI + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000082 + Generalized Systemic Effects + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000083 + Appetite Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000084 + Appetite Stimulation + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000085 + Appetite Suppression + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000086 + Cellular Activity Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000087 + Cellular Communication Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000088 + Extracellular Communication + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000089 + Decreased Extracellular Communication + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000090 + Decreased Growth Factor Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000091 + Increased Extracellular Communication + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000092 + Increased Growth Factor Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000093 + Intracellular Communication + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000094 + Decreased Intercellular Communication + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000095 + Increased Intracellular Communication + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000096 + Cellular Cycle Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000097 + Cellular Death Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000098 + Decreased Cellular Death + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000099 + Increased Cellular Death + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000100 + Cellular Division Phase Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000101 + Meiosis Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000102 + Decreased Meiosis + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000103 + Increased Meiosis + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000104 + Mitosis Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000105 + Decreased Mitosis + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000106 + Increased Mitosis + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000107 + Cellular Growth Phase Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000108 + Cellular Growth Phase Reduction + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000109 + Cellular Growth Phase Arrest + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000110 + Cellular Synthetic Activity Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000111 + Nucleic Acid Replication Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000112 + Nucleic Acid Transcription Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000113 + Post Translation Protein Modification Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000114 + Translation Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000115 + Cellular Synthetic Phase Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000116 + Cellular Synthetic Phase Arrest + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000117 + Cellular Degradation/Digestion Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000118 + Lysosomal Function Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000119 + Decreased Lysosomal Function + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000120 + Increased Lysosomal Function + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000121 + Protein Degradation Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000122 + Decreased Protein Breakdown + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000123 + Increased Protein Breakdown + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000124 + Cellular Motion Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000125 + Decreased Cellular Locomotion + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000126 + Decreased Cellular Migration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000127 + Decreased Fibroblast Migration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000128 + Decreased Polymorphonuclear Leukocyte Migration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000129 + Increased Cellular Locomotion + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000130 + Increased Cellular Migration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000131 + Increased Fibroblast Migration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000132 + Cellular Proliferation Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000133 + Endothelial Proliferation Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000134 + Decreased Endothelial Proliferation + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000135 + Increased Endothelial Proliferation + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000136 + Epithelial Proliferation Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000137 + Decreased Epithelial Proliferation + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000138 + Increased Epithelial Proliferation + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000139 + Cellular Structure Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000140 + Cell Membrane Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000141 + Decreased Cell Membrane Integrity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000142 + Decreased Cell Membrane Synthesis & Repair + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000143 + Increased Cell Membrane Integrity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000144 + Increased Cell Membrane Synthesis & Repair + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000145 + Cell Organelle Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000146 + Cell Wall Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000147 + Decreased Cell Wall Integrity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000148 + Decreased Cell Wall Synthesis & Repair + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000149 + Increased Cell Wall Integrity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000150 + Increased Cell Wall Synthesis & Repair + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000151 + Cytoskeleton Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000152 + Decreased Cytoskeleton Integrity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000153 + Decreased Cytoskeleton Synthesis & Repair + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000154 + DNA Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000155 + DNA Methylation + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000156 + DNA Methylation Decrease + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000157 + DNA Methylation Increase + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000158 + Microtubule Inhibition + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000159 + Cellular Transport Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000160 + Endocytosis Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000161 + Decreased Endocytosis + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000162 + Increased Endocytosis + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000163 + Exocytosis Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000164 + Decreased Exocytosis + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000165 + Increased Exocytosis + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000166 + Phagocytosis Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000167 + Decreased Phagocytosis + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000168 + Increased Phagocytosis + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000169 + Pinocytosis Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000170 + Decreased Pinocytosis + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000171 + Increased Pinocytosis + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000172 + Immunologic Activity Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000173 + Decreased Immunologic Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000174 + Decreased Immunologically Active Molecule Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000175 + Decreased Adhesion Factor Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000180 + Decreased Immunologically Active Biogenic Amine Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000181 + Decreased Histamine Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000182 + Decreased Central Nervous System Histamine Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000183 + Decreased Brain Stem Histamine Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000184 + Decreased Cerebellum Histamine Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000185 + Decreased Cerebral Cortex Histamine Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000186 + Decreased Midbrain Histamine Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000187 + Decreased Spinal Cord Histamine Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000188 + Decreased Muscular System Histamine Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000189 + Decreased Cardiac Muscle Histamine Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000190 + Decreased Smooth Muscle Histamine Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000191 + Decreased Striated Muscle Histamine Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000192 + Decreased Peripheral Nervous System Histamine Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000193 + Decreased Autonomic Nervous System Histamine Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000194 + Decreased Parasympathetic Histamine Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000195 + Decreased Sympathetic Histamine Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000196 + Decreased Enteric Nervous System Histamine Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000197 + Decreased Sensory-Somatic Nervous System Histamine Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000198 + Decreased Serotonin Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000199 + Decreased Central Nervous System Serotonin Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000200 + Decreased Brain Stem Serotonin Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000201 + Decreased Cerebellum Serotonin Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000202 + Decreased Cerebral Cortex Serotonin Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000203 + Decreased Midbrain Serotonin Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000204 + Decreased Spinal Cord Serotonin Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000205 + Decreased Muscular System Serotonin Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000206 + Decreased Cardiac Muscle Serotonin Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000207 + Decreased Smooth Muscle Serotonin Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000208 + Decreased Striated Muscle Serotonin Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000209 + Decreased Peripheral Nervous System Serotonin Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000210 + Decreased Autonomic Nervous System Serotonin Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000211 + Decreased Parasympathetic Serotonin Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000212 + Decreased Sympathetic Serotonin Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000213 + Decreased Enteric Nervous System Serotonin Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000214 + Decreased Sensory-Somatic Nervous System Serotonin Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000215 + Decreased Kallidin Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000216 + Decreased Kinin Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000217 + Decreased Bradykinin Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000218 + Decreased Lipid Derived Immunologically Active Molecule Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000219 + Decreased Eicosanoid Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000220 + Decreased Leukotriene Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000221 + Decreased Prostaglandin Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000222 + Decreased Thromboxane Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000223 + Decreased Platelet Activating Factor Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000224 + Decreased Immunologically Active Molecule Degradation + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000225 + Decreased Adhesion Factor Degradation + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000226 + Decreased Antibody Degradation + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000227 + Decreased Complement Degradation + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000228 + Decreased Cytokine Degradation + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000229 + Decreased Immunologically Active Biogenic Amine Degradation + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000230 + Decreased Histamine Degradation + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000231 + Decreased Serotonin Degradation + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000232 + Decreased Kallidin Degradation + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000233 + Decreased Kinin Degradation + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000234 + Decreased Bradykinin Degradation + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000235 + Decreased Lipid Derived Immunologically Active Molecule Degradation + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000236 + Decreased Platelet Activating Factor Degradation + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000237 + Decreased Eicosanoid Degradation + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000238 + Decreased Leukotriene Degradation + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000239 + Decreased Prostaglandin Degradation + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000240 + Decreased Thromboxane Degradation + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000241 + Decreased Immunologically Active Molecule Production + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000242 + Decreased Adhesion Factor Production + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000243 + Decreased Antibody Production + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000244 + Decreased Complement Production + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000245 + Decreased Cytokine Production + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000246 + Decreased Immunologically Active Biogenic Amine Production + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000247 + Decreased Kallidin Production + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000248 + Decreased Histamine Production + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000249 + Decreased Serotonin Production + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000250 + Decreased Kinin Production + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000251 + Decreased Bradykinin Production + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000252 + Decreased Lipid Derived Immunologically Active Molecule Production + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000253 + Decreased Eicosanoid Production + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000254 + Decreased Leukotriene Production + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000255 + Decreased Prostaglandin Production + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000256 + Decreased Thromboxane Production + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000257 + Decreased Platelet Activating Factor Production + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000258 + Immunologically Active Molecule Activity Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000261 + Increased Immunologically Active Molecule Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000262 + Increased Adhesion Factor Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000263 + Increased Antibody Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000264 + Increased Complement Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000265 + Increased Cytokine Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000266 + Increased Immunologically Active Biogenic Amine Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000267 + Increased Histamine Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000268 + Increased Central Nervous System Histamine Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000269 + Increased Brain Stem Histamine Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000270 + Increased Cerebellum Histamine Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000271 + Increased Cerebral Cortex Histamine Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000272 + Increased Midbrain Histamine Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000273 + Increased Spinal Cord Histamine Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000274 + Increased Muscular System Histamine Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000275 + Increased Cardiac Muscle Histamine Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000276 + Increased Smooth Muscle Histamine Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000277 + Increased Striated Muscle Histamine Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000278 + Increased Peripheral Nervous System Histamine Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000279 + Increased Autonomic Nervous System Histamine Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000280 + Increased Parasympathetic Histamine Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000281 + Increased Sympathetic Histamine Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000282 + Increased Enteric Nervous System Histamine Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000283 + Increased Sensory-Somatic Nervous System Histamine Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000284 + Increased Serotonin Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000285 + Increased Central Nervous System Serotonin Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000286 + Increased Brain Stem Serotonin Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000287 + Increased Cerebellum Serotonin Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000288 + Increased Cerebral Cortex Serotonin Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000289 + Increased Midbrain Serotonin Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000290 + Increased Spinal Cord Serotonin Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000291 + Increased Muscular System Serotonin Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000292 + Increased Cardiac Muscle Serotonin Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000293 + Increased Smooth Muscle Serotonin Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000294 + Increased Striated Muscle Serotonin Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000295 + Increased Peripheral Nervous System Serotonin Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000296 + Increased Autonomic Nervous System Serotonin Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000297 + Increased Parasympathetic Serotonin Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000298 + Increased Sympathetic Serotonin Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000299 + Increased Enteric Nervous System Serotonin Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000300 + Increased Sensory-Somatic Nervous System Serotonin Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000301 + Increased Kallidin Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000302 + Increased Kinin Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000303 + Increased Bradykinin Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000304 + Increased Lipid Derived Immunologically Active Molecule Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000305 + Increased Eicosanoid Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000306 + Increased Leukotriene Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000307 + Increased Prostaglandin Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000308 + Increased Thromboxane Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000309 + Increased Platelet Activating Factor Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000310 + Immunologically Active Molecule Degradation Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000311 + Increased Immunologically Active Molecule Degradation + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000312 + Increased Adhesion Factor Degradation + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000313 + Increased Antibody Degradation + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000314 + Increased Complement Degradation + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000315 + Increased Cytokine Degradation + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000316 + Increased Immunologically Active Biogenic Amine Degradation + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000317 + Increased Histamine Degradation + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000318 + Increased Serotonin Degradation + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000319 + Increased Kallidin Degradation + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000320 + Increased Kinin Degradation + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000321 + Increased Bradykinin Degradation + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000322 + Increased Lipid Derived Immunologically Active Molecule Degradation + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000323 + Increased Eicosanoid Degradation + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000324 + Increased Leukotriene Degradation + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000325 + Increased Prostaglandin Degradation + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000326 + Increased Thromboxane Degradation + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000327 + Increased Platelet Activating Factor Degradation + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000328 + Immunologically Active Molecule Production Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000329 + Increased Immunologically Active Molecule Production + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000330 + Increased Adhesion Factor Production + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000331 + Increased Antibody Production + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000332 + Increased Complement Production + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000333 + Increased Cytokine Production + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000334 + Increased Immunologically Active Biogenic Amine Production + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000335 + Increased Histamine Production + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000336 + Increased Serotonin Production + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000337 + Increased Kallidin Production + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000338 + Increased Kinin Production + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000339 + Increased Bradykinin Production + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000340 + Increased Lipid Derived Immunologically Active Molecule Production + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000341 + Increased Eicosanoid Production + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000342 + Increased Leukotriene Production + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000343 + Increased Prostaglandin Production + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000344 + Increased Thromboxane Production + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000345 + Increased Platelet Activating Factor Production + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000346 + Increased Immunologic Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000347 + Metabolic Activity Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000348 + Carbohydrate Metabolism Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000349 + Cell Glucose Transport Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000350 + Decreased Glucose Transport into Cells + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000351 + Increased Glucose Transport into Cells + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000352 + Glucose Metabolism Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000353 + Decreased Gluconeogenesis + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000354 + Decreased Glycolysis + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000355 + Increased Gluconeogenesis + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000356 + Increased Glycolysis + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000357 + Polysaccharide Metabolism Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000358 + Glycogen Metabolism Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000359 + Decreased Glycogenesis + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000360 + Decreased Glycogenolysis + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000361 + Increased Glycogenesis + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000362 + Increased Glycogenolysis + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000363 + Glycosaminoglycan Metabolism Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000364 + Glycosaminoglycan Metabolism Decrease + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000365 + Glycosaminoglycan Metabolism Increase + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000366 + Inorganic Ion Absorption Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000367 + Decreased Inorganic Ion Absorption + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000368 + Decreased Copper Ion Absorption + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000369 + Lipid Metabolism Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000370 + Glycosphingolipid Synthesis Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000371 + Glycosphingolipid Synthesis Decrease + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000372 + Glycosphingolipid Synthesis Increase + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000373 + Lipotropic Activity Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000374 + Sterol Metabolism Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000375 + Cholesterol Metabolism Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000376 + Cholesterol Absorption Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000377 + Decreased Cholesterol Absorption + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000378 + Increased Cholesterol Absorption + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000379 + Cholesterol Elimination Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000380 + Decreased Cholesterol Elimination + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000381 + Increased Cholesterol Elimination + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000382 + Cholesterol Secretion Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000383 + Decreased Cholesterol Secretion + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000384 + Increased Cholesterol Secretion + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000385 + Cholesterol Synthesis Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000386 + Decreased Cholesterol Synthesis + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000387 + Increased Cholesterol Synthesis + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000388 + Sterol Synthesis Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000389 + Decreased Sterol Synthesis + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000390 + Increased Sterol Synthesis + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000391 + Triglyceride Metabolism Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000392 + Decreased Lipogenesis + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000393 + Decreased Lipolysis + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000394 + Increased Lipogenesis + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000395 + Increased Lipolysis + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000396 + Increased Lipolysis + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000397 + Decreased Metabolic Rate + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000398 + Increased Metabolic Rate + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000399 + Organic Ion Metabolism Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000400 + Organic Ion Degradation Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000401 + Decreased Organic Ion Degradation + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000402 + Increased Organic Ion Degradation + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000403 + Organic Ion Synthesis Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000404 + Decreased Organic Ion Synthesis + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000405 + Decreased Amino Acid Synthesis + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000406 + Decreased Uric Acid Synthesis + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000407 + Increased Organic Ion Synthesis + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000408 + Peptide Metabolism Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000409 + Increased Glutathione Concentration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000410 + Vitamin Uptake and Modification Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000411 + Decreased Vitamin Uptake and Modification + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000412 + Decreased Folic Acid Modification + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000413 + Increased Vitamin Uptake and Modification + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000414 + Organ System Specific Effects + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000415 + Cardiovascular Activity Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000416 + Blood Pressure Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000417 + Decreased Blood Pressure + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000418 + Increased Blood Pressure + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000419 + Cardiac Contractility Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000420 + Negative Inotropy + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000421 + Positive Inotropy + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000422 + Cardiac Rate Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000423 + Negative Chronotropy + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000424 + Positive Chronotropy + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000425 + Cardiac Rhythm Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000426 + Atrial Depolarization + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000427 + Atrial Repolarization + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000428 + Conduction System Depolarization + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000429 + Lengthen Conduction System Depolarization Time + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000430 + Shorten Conduction System Depolarization Time + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000431 + Conduction System Repolarization + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000432 + Delay Conduction System Repolarization + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000433 + Lengthen Conduction System Repolarization Time + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000434 + Shorten Conduction System Repolarization Time + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000435 + Nodal Depolarization + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000436 + Nodal Repolarization + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000437 + Ventricular Depolarization + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000438 + Ventricular Repolarization + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000439 + Vascular Alterations + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000440 + Vascular Growth Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000441 + Vascular Growth Decrease + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000442 + Vascular Growth Increase + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000443 + Vascular Permeability Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000444 + Decreased Vascular Permeability + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000445 + Decreased Capillary Permeability + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000446 + Increased Vascular Permeability + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000447 + Increased Capillary Permeability + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000448 + Vascular Sclerosing Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000449 + Vascular Tone Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000450 + Vascular Smooth Muscle Tone Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000451 + Decreased Vascular Smooth Muscle Tone + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000452 + Increased Vascular Smooth Muscle Tone + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000453 + Vasoconstriction + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000454 + Arterial Vasoconstriction + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000455 + Arteriolar Vasoconstriction + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000456 + Cerebral Arteriolar Vasoconstriction + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000457 + Coronary Arteriolar Vasoconstriction + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000458 + Cutaneous Arteriolar Vasoconstriction + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000459 + Mucosal Arteriolar Vasoconstriction + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000460 + Conjunctival Arteriolar Vasoconstriction + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000461 + Genitourinary Arteriolar Vasoconstriction + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000462 + Oropharyngeal Arteriolar Vasoconstriction + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000463 + Respiratory Arteriolar Vasoconstriction + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000464 + Muscular Arteriolar Vasoconstriction + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000465 + Pulmonary Arteriolar Vasoconstriction + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000466 + Renal Arteriolar Vasoconstriction + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000467 + Renal Afferent Arteriolar Vasoconstriction + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000468 + Renal Efferent Arteriolar Vasoconstriction + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000469 + Splanchnic Arteriolar Vasoconstriction + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000470 + Systemic Arteriolar Vasoconstriction + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000471 + Cerebral Arterial Vasoconstriction + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000472 + Cerebral Arteriolar Vasoconstriction + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000473 + Coronary Arterial Vasoconstriction + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000474 + Coronary Arteriolar Vasoconstriction + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000475 + Cutaneous Arterial Vasoconstriction + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000476 + Cutaneous Arteriolar Vasoconstriction + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000477 + Mucosal Arterial Vasoconstriction + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000478 + Conjunctival Arterial Vasoconstriction + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000479 + Conjunctival Arteriolar Vasoconstriction + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000480 + Genitourinary Arterial Vasoconstriction + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000481 + Genitourinary Arteriolar Vasoconstriction + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000482 + Mucosal Arteriolar Vasoconstriction + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000483 + Conjunctival Arteriolar Vasoconstriction + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000484 + Genitourinary Arteriolar Vasoconstriction + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000485 + Oropharyngeal Arteriolar Vasoconstriction + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000486 + Respiratory Arteriolar Vasoconstriction + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000487 + Oropharyngeal Arterial Vasoconstriction + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000488 + Oropharyngeal Arteriolar Vasoconstriction + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000489 + Respiratory Arterial Vasoconstriction + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000490 + Respiratory Arteriolar Vasoconstriction + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000491 + Muscular Arterial Vasoconstriction + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000492 + Muscular Arteriolar Vasoconstriction + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000493 + Pulmonary Arterial Vasoconstriction + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000494 + Pulmonary Arteriolar Vasoconstriction + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000495 + Renal Arterial Vasoconstriction + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000496 + Renal Afferent Arterial Vasoconstriction + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000497 + Renal Afferent Arteriolar Vasoconstriction + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000498 + Renal Arteriolar Vasoconstriction + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000499 + Renal Afferent Arteriolar Vasoconstriction + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000500 + Renal Efferent Arteriolar Vasoconstriction + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000501 + Renal Efferent Arterial Vasoconstriction + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000502 + Renal Efferent Arteriolar Vasoconstriction + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000503 + Splanchnic Arterial Vasoconstriction + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000504 + Splanchnic Arteriolar Vasoconstriction + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000505 + Systemic Arterial Vasoconstriction + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000506 + Systemic Arteriolar Vasoconstriction + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000507 + Venous Vasoconstriction + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000508 + Pulmonary Venous Vasoconstriction + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000509 + Systemic Venous Vasoconstriction + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000510 + Vasodilation + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000511 + Arterial Vasodilation + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000512 + Arteriolar Vasodilation + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000513 + Cerebral Arteriolar Vasodilation + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000514 + Coronary Arteriolar Vasodilation + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000515 + Cutaneous Arteriolar Vasodilation + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000516 + Mucosal Arteriolar Vasodilation + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000517 + Conjunctival Arteriolar Vasodilation + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000518 + Genitourinary Arteriolar Vasodilation + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000519 + Oropharyngeal Arteriolar Vasodilation + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000520 + Respiratory Arteriolar Vasodilation + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000521 + Muscular Arteriolar Vasodilation + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000522 + Pulmonary Arteriolar Vasodilation + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000523 + Renal Arteriolar Vasodilation + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000524 + Renal Afferent Arteriolar Vasodilation + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000525 + Renal Efferent Arteriolar Vasodilation + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000526 + Splanchnic Arteriolar Vasodilation + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000527 + Systemic Arteriolar Vasodilation + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000528 + Cerebral Arterial Vasodilation + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000529 + Cerebral Arteriolar Vasodilation + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000530 + Coronary Arterial Vasodilation + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000531 + Coronary Arteriolar Vasodilation + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000532 + Cutaneous Arterial Vasodilation + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000533 + Cutaneous Arteriolar Vasodilation + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000534 + Mucosal Arterial Vasodilation + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000535 + Conjunctival Arterial Vasodilation + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000536 + Conjunctival Arteriolar Vasodilation + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000537 + Genitourinary Arterial Vasodilation + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000538 + Genitourinary Arteriolar Vasodilation + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000539 + Mucosal Arteriolar Vasodilation + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000540 + Conjunctival Arteriolar Vasodilation + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000541 + Genitourinary Arteriolar Vasodilation + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000542 + Oropharyngeal Arteriolar Vasodilation + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000543 + Respiratory Arteriolar Vasodilation + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000544 + Oropharyngeal Arterial Vasodilation + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000545 + Oropharyngeal Arteriolar Vasodilation + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000546 + Respiratory Arterial Vasodilation + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000547 + Respiratory Arteriolar Vasodilation + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000548 + Muscular Arterial Vasodilation + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000549 + Muscular Arteriolar Vasodilation + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000550 + Pulmonary Arterial Vasodilation + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000551 + Pulmonary Arteriolar Vasodilation + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000552 + Renal Arterial Vasodilation + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000553 + Renal Afferent Arterial Vasodilation + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000554 + Renal Afferent Arteriolar Vasodilation + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000555 + Renal Arteriolar Vasodilation + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000556 + Renal Afferent Arteriolar Vasodilation + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000557 + Renal Efferent Arteriolar Vasodilation + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000558 + Renal Efferent Arterial Vasodilation + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000559 + Renal Efferent Arteriolar Vasodilation + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000560 + Splanchnic Arterial Vasodilation + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000561 + Splanchnic Arteriolar Vasodilation + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000562 + Systemic Arterial Vasodilation + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000563 + Systemic Arteriolar Vasodilation + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000564 + Venous Vasodilation + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000565 + Penile Venous Vasodilation + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000566 + Pulmonary Venous Vasodilation + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000567 + Systemic Venous Vasodilation + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000568 + Dermatologic Activity Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000569 + Antiperspirant Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000570 + Antipruritic Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000571 + Astringent Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000572 + Depigmenting Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000573 + Melanocyte Destruction + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000574 + Dermal Regeneration Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000575 + Emollient Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000576 + Hair Follicle Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000577 + Decreased Hair Growth + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000578 + Increased Hair Growth + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000579 + Keratin Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000580 + Decreased Skin Keratinization + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000581 + Increased Skin Keratinization + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000582 + Photosensitizing Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000583 + Sebaceous Gland Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000584 + Decreased Sebaceous Gland Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000585 + Decreased Sebaceous Gland Quantity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000586 + Increased Sebaceous Gland Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000587 + Increased Sebaceous Gland Quantity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000588 + Skin Barrier Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000589 + Sunscreening Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000590 + Digestive/GI System Activity Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000591 + Bile Secretion Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000592 + Bile Secretion Composition Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000593 + Increased Bile Iron Secretion + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000594 + Bile Secretion Volume Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000595 + Cholagogue Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000596 + Choleretic Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000597 + Cariostatic Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000598 + Digestive Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000599 + Inhibition Carbohydrate Digestion + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000600 + Inhibition Fat Digestion + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000601 + Pancreatic Enzymatic Replacement + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000602 + Gastric Acid Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000603 + Antacid + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000604 + Inhibition Gastric Acid Secretion + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000605 + Stimulation Gastric Acid Secretion + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000606 + Gastric Mucous Secretion Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000607 + Inhibition Gastric Mucous Secretion + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000608 + Stimulation Gastric Mucous Secretion + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000609 + GI Motility Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000610 + Decreased GI Motility + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000611 + Decreased Biliary Motility + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000612 + Decreased Esophageal Motility + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000613 + Decreased Gastric Motility + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000614 + Decreased Large Intestinal Motility + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000615 + Decreased Small Intestinal Motility + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000616 + Emesis Suppression + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000617 + Increased GI Motility + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000618 + Emesis + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000619 + Increased Biliary Motility + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000620 + Increased Esophageal Motility + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000621 + Increased Gastric Motility + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000622 + Increased Large Intestinal Motility + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000623 + Increased Small Intestinal Motility + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000624 + GI Smooth Muscle Tone Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000625 + Decreased GI Smooth Muscle Tone + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000626 + Decreased Anal Sphincter Tone + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000627 + Decreased Esophageal Muscle Tone + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000628 + Decreased Gallbladder Tone + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000629 + Decreased Gastric Muscle Tone + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000630 + Decreased Large Intestinal Muscle Tone + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000631 + Decreased LES Tone + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000632 + Decreased Pyloric Sphincter Tone + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000633 + Decreased Small Intestinal Muscle Tone + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000634 + Decreased Sphincter of Odi Tone + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000635 + Decreased UES Tone + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000636 + Increased GI Smooth Muscle Tone + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000637 + Increased Anal Sphincter Tone + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000638 + Increased Esophageal Muscle Tone + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000639 + Increased Gallbladder Tone + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000640 + Increased Gastric Muscle Tone + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000641 + Increased Large Intestinal Muscle Tone + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000642 + Increased LES Tone + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000643 + Increased Pyloric Sphincter Tone + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000644 + Increased Small Intestinal Muscle Tone + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000645 + Increased Sphincter of Odi Tone + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000646 + Increased UES Tone + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000647 + Large Intestine Fluid/Electrolyte Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000648 + Large Intestine Fluid/Electrolyte Absorption Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000649 + Inhibition Large Intestine Fluid/Electrolyte Absorption + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000650 + Stimulation Large Intestine Fluid/Electrolyte Absorption + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000651 + Large Intestine Fluid/Electrolyte Secretion Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000652 + Inhibition Large Intestine Fluid/Electrolyte Secretion + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000653 + Stimulation Large Intestine Fluid/Electrolyte Secretion + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000654 + Pancreatic Secretion Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000655 + Pancreatic Enzymatic Secretion Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000656 + Inhibition Pancreatic Enzymatic Secretion + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000657 + Stimulation Pancreatic Enzymatic Secretion + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000658 + Pancreatic Fluid/Electrolyte Secretion Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000659 + Inhibition Pancreatic Fluid/Electrolyte Secretion + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000660 + Stimulation Pancreatic Fluid/Electrolyte Secretion + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000661 + Saliva Production Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000662 + Salivation Inhibition + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000663 + Salivation Stimulation + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000664 + Small Intestine Fluid/Electrolyte Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000665 + Small Intestine Fluid/Electrolyte Absorption Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000666 + Inhibition Small Intestine Fluid/Electrolyte Absorption + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000667 + Stimulation Small Intestine Fluid/Electrolyte Absorption + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000668 + Small Intestine Fluid/Electrolyte Secretion Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000669 + Inhibition Small Intestine Fluid/Electrolyte Secretion + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000670 + Stimulation Small Intestine Fluid/Electrolyte Secretion + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000671 + Endocrine Activity Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000672 + Adrenal Cortical Activity Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000673 + Decreased Glucocorticoid Clearance + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000674 + Decreased Glucocorticoid Secretion + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000675 + Decreased Mineralocorticoid Secretion + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000676 + Increased Glucocorticoid Clearance + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000677 + Increased Glucocorticoid Secretion + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000678 + Increased Mineralocorticoid Secretion + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000679 + Adrenal Medullary Activity Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000680 + Decreased Adrenal Epinephrine Secretion + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000681 + Decreased Adrenal Norepinephrine Secretion + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000682 + Increased Adrenal Epinephrine Secretion + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000683 + Increased Adrenal Norepinephrine Secretion + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000684 + Hypothalamic Endocrine Activity Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000685 + Ovarian Endocrine Activity Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000686 + Decreased Ovarian Estrogen Secretion + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000687 + Decreased Ovarian Progesterone Secretion + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000688 + Increased Ovarian Estrogen Secretion + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000689 + Increased Ovarian Progesterone Secretion + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000690 + Pancreatic Islet Activity Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000691 + Decreased Glucagon Secretion + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000692 + Decreased Insulin Secretion + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000693 + Decreased Pancreatic Somatostatin Secretion + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000694 + Increased Glucagon Secretion + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000695 + Increased Insulin Secretion + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000696 + Increased Pancreatic Somatostatin Secretion + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000697 + Parathyroid Gland Activity Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000698 + Decreased Calcitonin Secretion + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000699 + Decreased PTH Secretion + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000700 + Increased Calcitonin Secretion + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000701 + Increased PTH Secretion + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000702 + Pineal Gland Activity Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000703 + Melatonin Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000704 + Melatonin Activity Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000705 + Decreased Melatonin Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000706 + Increased Melatonin Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000707 + Melatonin Secretion Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000708 + Decreased Melatonin Secretion + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000709 + Increased Melatonin Secretion + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000710 + Pituitary Gland Activity Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000711 + Placental Endocrine Activity Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000712 + Decreased Placental Human Chorionic Gonadotropin Secretion + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000713 + Increased Placental Human Chorionic Gonadotropin Secretion + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000714 + Renal Endocrine Activity Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000715 + Decreased Erythropoetin Secretion + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000716 + Increased Erythropoetin Secretion + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000717 + Testicular Endocrine Activity Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000718 + Decreased Dihydrotestosterone Secretion + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000719 + Decreased Testosterone Secretion + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000720 + Increased Dihydrotestosterone Secretion + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000721 + Increased Testosterone Secretion + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000722 + Thyroid Gland Activity Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000723 + Nervous System Activity Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000724 + Central Nervous System Activity Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000725 + Central Nervous System Depression + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000726 + Analgesia + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000727 + Appetite Suppression + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000728 + Emesis Suppression + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000729 + General Anesthesia + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000730 + Central Nervous System Stimulation + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000731 + Appetite Stimulation + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000732 + Electrical Activity Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000733 + Disorganized Electrical Activity Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000734 + Decreased Disorganized Electrical Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000735 + Decreased Central Nervous System Disorganized Electrical Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000736 + Decreased Muscular System Disorganized Electrical Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000737 + Decreased Peripheral Nervous System Disorganized Electrical Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000738 + Increased Disorganized Electrical Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000739 + Increased Central Nervous System Disorganized Electrical Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000740 + Increased Muscular System Disorganized Electrical Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000741 + Increased Peripheral Nervous System Disorganized Electrical Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000742 + Organized Electrical Activity Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000743 + Decreased Organized Electrical Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000744 + Decreased Central Nervous System Organized Electrical Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000745 + Decreased Muscular System Organized Electrical Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000746 + Decreased Peripheral Nervous System Organized Electrical Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000747 + Increased Organized Electrical Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000748 + Increased Central Nervous System Organized Electrical Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000749 + Increased Muscular System Organized Electrical Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000750 + Increased Peripheral Nervous System Organized Electrical Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000751 + Neurotransmitter & Neuromuscular Transmitter Activity Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000752 + Acetylcholine Activity Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000753 + Decreased Acetylcholine Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000754 + Decreased Central Nervous System Acetylcholine Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000755 + Decreased Muscular System Acetylcholine Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000756 + Decreased Peripheral Nervous System Acetylcholine Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000757 + Increased Acetylcholine Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000758 + Increased Central Nervous System Acetylcholine Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000759 + Increased Muscular System Acetylcholine Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000760 + Increased Peripheral Nervous System Acetylcholine Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000761 + Aspartate Activity Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000762 + Decreased Aspartate Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000763 + Increased Aspartate Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000764 + Brain Derived Neurotropic Factor Activity Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000765 + Decreased Brain Derived Neurotropic Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000766 + Increased Brain Derived Neurotropic Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000767 + CCK Activity Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000768 + Decreased CCK Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000769 + Increased CCK Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000770 + Dopamine Activity Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000771 + Decreased Dopamine Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000772 + Increased Dopamine Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000773 + Dynorphin Activity Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000774 + Decreased Dynorphin Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000775 + Increased Dynorphin Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000776 + Endorphin Activity Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000777 + Decreased Endorphin Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000778 + Increased Endorphin Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000779 + Enkephalin Activity Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000780 + Decreased Enkephalin Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000781 + Increased Enkephalin Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000782 + Epinephrine Activity Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000783 + Decreased Epinephrine Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000784 + Increased Epinephrine Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000785 + Gamma Amino Butyric Acid (GABA) Activity Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000786 + Decreased GABA Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000787 + Increased GABA Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000788 + Gastrin Activity Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000789 + Decreased Gastrin Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000790 + Increased Gastrin Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000791 + Glutamate Activity Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000792 + Decreased Glutamate Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000793 + Increased Glutamate Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000794 + Glycine Activity Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000795 + Decreased Glycine Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000796 + Increased Glycine Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000797 + Histamine Activity Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000798 + Decreased Histamine Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000799 + Increased Histamine Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000800 + Nerve Growth Factor Activity Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000801 + Decreased Nerve Growth Factor Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000802 + Increased Nerve Growth Factor Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000803 + Neurotensin Activity Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000804 + Decreased Neurotensin Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000805 + Increased Neurotensin Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000806 + Nitric Oxide Activity Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000807 + Decreased Nitric Oxide Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000808 + Increased Nitric Oxide Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000809 + Norepinephrine Activity Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000810 + Decreased Norepinephrine Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000811 + Decreased Central Nervous System Norepinephrine Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000812 + Decreased Muscular System Norepinephrine Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000813 + Decreased Peripheral Nervous System Norepinephrine Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000814 + Increased Norepinephrine Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000815 + Increased Central Nervous System Norepinephrine Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000816 + Increased Muscular System Norepinephrine Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000817 + Serotonin Activity Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000818 + Decreased Serotonin Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000819 + Increased Serotonin Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000820 + Substance P Activity Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000821 + Decreased Substance P Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000822 + Increased Substance P Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000823 + Vasoactive Intestinal Polypeptide (VIP) Activity Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000824 + Decreased VIP Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000825 + Increased VIP Activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000826 + Peripheral Nervous System Activity Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000827 + Autonomic Nervous System Activity Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000828 + Neuromuscular Activity Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000829 + Sensory System Activity Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000830 + Analgesia + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000831 + Local Anesthesia + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000832 + Centrally-mediated Muscle Relaxation + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000833 + Autonomic Ganglionic Activity Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000834 + Parasympathetic Activity Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000835 + Smooth Muscle Tone Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000836 + Sympathetic Activity Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000837 + Renal/Urological Activity Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000838 + Bladder Contractility Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000839 + Bladder Sphincter Tone Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000840 + Collecting Duct Water Permeability Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000841 + Diuresis Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000842 + Glomerular Filtration Pressure Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000843 + Renal Ion Transport Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000844 + Renal Organic Ion Transport Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000845 + Urethra Smooth Muscle Tone Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000846 + Decreased Bladder Contractility + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000847 + Increased Bladder Contractility + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000848 + Decreased Bladder Sphincter Tone + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000849 + Increased Bladder Sphincter Tone + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000850 + Decreased Collecting Duct Water Permeability + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000851 + Increased Collecting Duct Water Permeability + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000852 + Decreased Diuresis + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000853 + Increased Diuresis + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000854 + Decreased Glomerular Filtration Pressure + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000855 + Increased Glomerular Filtration Pressure + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000856 + Decreased Renal Ion Excretion + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000857 + Increased Renal Ion Excretion + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000858 + Respiratory/Pulmonary Activity Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000859 + Alveolar Surface Tension Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000860 + Medullary Respiratory Center Activity Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000861 + Peripheral Carotid Chemoreceptor Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000862 + Respiratory Mucosal Edema Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000863 + Respiratory Secretion Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000864 + Respiratory Smooth Muscle Tone Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000865 + Tracheobronchial Stretch Receptor Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000866 + Ventilatory Gas Flow Alteration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000867 + Aerosol + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000868 + Drops + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000869 + Inhalant Solution + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000870 + Irrigation Solution + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000871 + Nasal Solution + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000872 + Ophthalmic Solution + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000873 + Otic Solution + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000874 + Injectable Suspension + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000875 + Ophthalmic Suspension + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000876 + Bar + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000877 + Bar Soap + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000878 + Medicated Bar Soap + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000879 + Chewable Bar + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000880 + Beads + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000881 + Cake + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000882 + Cement + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000883 + Chewing Gum + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000884 + Crystals + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000885 + Disk + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000886 + Flakes + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000887 + Gel + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000888 + Gel with Applicator + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000889 + Nasal Gel + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000890 + Ophthalmic Gel + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000891 + Oral Gel + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000892 + Rectal Gel + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000893 + Topical Gel + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000894 + Augmented Topical Gel + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000895 + Urethral Gel + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000896 + Vaginal Gel + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000897 + Granules + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000898 + Ointment + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000899 + Oral Strip + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000900 + Pellet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000901 + Disintegrating Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000902 + Sublingual Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000903 + Vaginal Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000904 + Enteric Coated Capsule + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000905 + 12 hour Extended Release Capsule + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000906 + 24 Hour Extended Release Capsule + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000907 + Extended Release Enteric Coated Capsule + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000908 + Extended Release Enteric Coated Capsule + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000909 + drug brand name + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000910 + active_ingredient_of + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000911 + medication history + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000912 + plan history + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000913 + family history + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000914 + alpha glucosidase inhibitor + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000914 + Slow the absorption of carbohydrates (sugar) ingested + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000915 + biguanide + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000915 + Reduce the production of glucose by the liver + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000917 + sulfonylurea + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000917 + Stimulate the pancreas to produce more insulin + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000918 + thiazolidinedione + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000918 + Increase insulin sensitivity of the body cells and reduce the production of glucose by the liver + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000920 + other drug + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000921 + acarbose + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000922 + miglitol + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000923 + metformin + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000925 + dipeptidyl peptidase 4 (DPP-4) inhibitor + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000925 + Intensify the effect of intestinal hormones (incretines) involved in the control of blood sugar + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000926 + alogliptin + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000927 + linagliptin + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000928 + saxagliptin + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000929 + simvastatin / sitagliptin + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000930 + sitagliptin + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000934 + troglitazone + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000937 + Chlorpropamide + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000938 + glibornuride + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000939 + Gliclazide + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000940 + glimepiride + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000944 + Tolazamide + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000945 + Tolbutamide + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000947 + albiglutide + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000948 + benfluorex + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000949 + canagliflozin + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000950 + dapagliflozin + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000951 + dulaglutide + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000952 + empagliflozin + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000953 + exenatide + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000954 + guar gum + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000955 + liraglutide + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000956 + Lixisenatide + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000957 + nateglinide + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000958 + Pramlintide + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000959 + repaglinide + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000960 + Sodium-Glucose Transporter 2 (SGLT-2) Inhibitor + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000960 + Help eliminate glucose in the urine + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000961 + has_brand_name + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000962 + brand_name_of + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000963 + brand name + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000964 + dopamine agonist + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000965 + bromocriptine + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000966 + bromocriptine mesylate + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000967 + alogliptin benzoate + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000968 + sitagliptin phosphate + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000969 + meglitinide + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000969 + Stimulate the pancreas to produce more insulin + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000970 + nateglinide + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000971 + repaglinide + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000972 + has_strength + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000973 + drug A1C lowering level + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000974 + low A1C level + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000975 + medium A1C level + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000976 + high A1C level + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000977 + has_A1C_lowering_level + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000978 + has cost + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000979 + drug hypoglycemic risk level + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000980 + has_hypoglycemic_risk_level + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000982 + rare hypo + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000984 + drug weight gain + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000985 + cause_weight_gain_of + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000990 + contradicte_with_disease + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000991 + contradicte_with_food + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000992 + contradicte_with_drug + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000993 + can_be_combined_with + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000994 + BN metformin + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000995 + Apo-metformin + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000996 + Diabex + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000997 + Diabex XR + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000998 + Diaformin + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0000999 + Diaformin XR + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001000 + Formet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001001 + Genepharm metformin + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001002 + Genrx metformin + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001003 + Glucobete + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001004 + Glucomet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001005 + Glucophage + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001006 + Metex XR + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001007 + Metforbell + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001008 + Metformin GA + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001009 + Metformin (Generic Health) + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001010 + Metformin (Ranbaxy) + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001011 + Metformin (Sandoz) + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001012 + Pharmacor metformin + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001013 + nausea + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001014 + diarrhoea + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001015 + metallic taste in the mouth + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001016 + suitable_with_disease + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001017 + contradicte_with_condition + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001018 + male + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001019 + female + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001020 + pregnancy state + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001026 + mild + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001027 + severe + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001028 + neutral + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001029 + BN sulphonylureas + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001030 + Apo-gliclazide MR + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001031 + Diamicron + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001032 + Diamicron MR + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001033 + Genrx gliclazide + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001034 + Glyade + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001035 + Glyade MR + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001036 + Mellihexal + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001037 + Nidem + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001038 + Oziclide MR + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001039 + Daonil + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001040 + Glimel + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001041 + Melizide + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001042 + Minidiab + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001043 + Amaryl + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001044 + Apo-glimepiride + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001045 + Aylide + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001046 + Diapride + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001047 + Dimirel + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001048 + Glimepiride GA + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001049 + Glimepiride Sandoz + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001050 + Pharmacor glimepiride + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001051 + Slight loss + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001052 + Loss + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001054 + Gain + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001055 + Glipizide + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001056 + Glyburide + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001057 + pioglitazone + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001058 + rosiglitazone + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001059 + pregnant + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001060 + not_pregnant + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001061 + BN thiazolidinedione + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001062 + Avandia + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001063 + Actos + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001064 + Apotex-pioglitazone + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001065 + Pharmacor pioglitazone + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001066 + Pioglitazone General Health + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001067 + Pioglitazone Sandoz + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001068 + Pioglitazone GA + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001069 + Pizaccord + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001070 + Vexazone + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001071 + breast_feeding + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001072 + BN alpha glucosidase inhibitor + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001073 + Glucobay + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001074 + BN DPP-4 inhibitor + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001075 + Trajenta + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001076 + Onglyza + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001077 + Januvia + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001078 + Galvus + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001079 + BN Meglitinide + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001080 + Prandin + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001081 + Starlix + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001082 + Buformin + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001088 + Glucagon-like peptide-1 receptor (GLP-1) analogue + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001088 + Mimic the effect of certain intestinal hormones (incretines) involved in the control of blood sugar + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001125 + BN acarbose + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001126 + Acarbose 100 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001127 + Acarbose 25 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001128 + Acarbose 50 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001129 + miglitol 100 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001130 + miglitol 25 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001131 + miglitol 50 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001132 + BN Glyset + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001133 + canagliflozin + metformin + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001134 + oral form canagliflozin + metformin + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001135 + empagliflozin + metformin + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001136 + metformin + repaglinide + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001137 + metformin 500mg/Repaglinide 1mg tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001138 + metformin 500mg/Repaglinide 2mg tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001139 + metformin hydrochloride product + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001140 + glipizide+metformin hydrochloride + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001141 + glipizide 2.5mg/metformin hydrochloride 250mg tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001142 + glipizide 2.5mg/metformin hydrochloride 500mg tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001143 + glipizide 5mg/metformin hydrochloride 500mg tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001144 + glyburide + metformin + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001145 + glyburide 1.25mg/metformin 250mg tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001146 + glyburide 2.5mg/metformin 500mg tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001147 + glyburide 5mg/metformin 500mg tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001148 + metformin hydrochloride + saxagliptin + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001149 + metformin hydrochloride 1000mg + Saxagliptin 2.5mg extended release tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001150 + metformin hydrochloride 1000mg + Saxagliptin 5mg extended release tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001151 + metformin hydrochloride 500mg + Saxagliptin 5mg extended release tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001152 + metformin hydrochloride 100mg/mL oral solution + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001153 + metformin hydrochloride 1g m/r tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001154 + metformin hydrochloride 1g tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001155 + metformin hydrochloride 500mg m/r tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001156 + metformin hydrochloride 500mg tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001157 + metformin hydrochloride 625mg tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001158 + metformin hydrochloride 750mg m/r tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001159 + metformin hydrochloride 850mg tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001160 + pioglitazone + metformin + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001163 + pioglitazone 15mg + metformin 1g m/r tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001164 + pioglitazone 15mg/metformin 500mg tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001165 + pioglitazone 15mg/metformin 850mg tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001166 + pioglitazone 30mg + metformin 1g m/r tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001167 + rosiglitazone+metformin + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001168 + rosiglitazone+metformin 1mg/500mg tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001169 + rosiglitazone+metformin 2mg/1000mg tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001170 + rosiglitazone+metformin 2mg/500mg tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001171 + rosiglitazone+metformin 4mg/1000mg tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001172 + rosiglitazone+metformin 4mg/500mg tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001173 + sitagliptin + metformin + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001174 + sitagliptin 50mg/metformin 1000mg tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001175 + sitagliptin 50mg/metformin 500mg tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001176 + BN Kazano + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001177 + BN Nesina + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001178 + BN Oseni + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001179 + alogliptin 12.5 MG / metFORMIN hydrochloride 1000 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001180 + alogliptin 12.5 MG / metFORMIN hydrochloride 500 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001181 + alogliptin 12.5 MG / pioglitazone 15 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001182 + alogliptin 12.5 MG / pioglitazone 30 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001183 + alogliptin 12.5 MG / pioglitazone 45 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001184 + alogliptin 12.5 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001185 + alogliptin 25 MG / pioglitazone 15 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001186 + alogliptin 25 MG / pioglitazone 30 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001187 + alogliptin 25 MG / pioglitazone 45 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001188 + alogliptin 25 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001189 + alogliptin 6.25 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001190 + BN Glyxambi + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001191 + BN Jentadueto + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001192 + BN Tradjenta + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001193 + 24 HR Linagliptin 2.5 MG / metFORMIN hydrochloride 1000 MG Extended Release Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001194 + 24 HR Linagliptin 5 MG / metFORMIN hydrochloride 1000 MG Extended Release Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001195 + empagliflozin 10 MG / Linagliptin 5 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001196 + empagliflozin 25 MG / Linagliptin 5 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001197 + Linagliptin 2.5 MG / metFORMIN hydrochloride 1000 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001198 + Linagliptin 2.5 MG / metFORMIN hydrochloride 500 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001199 + Linagliptin 2.5 MG / metFORMIN hydrochloride 850 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001200 + Linagliptin 5 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001203 + contraindication + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001204 + BN Kombiglyze + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001205 + BN Onglyza + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001206 + 24 HR metFORMIN hydrochloride 1000 MG / saxagliptin 2.5 MG Extended Release Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001207 + 24 HR metFORMIN hydrochloride 1000 MG / saxagliptin 5 MG Extended Release Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001208 + 24 HR metFORMIN hydrochloride 500 MG / saxagliptin 5 MG Extended Release Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001209 + saxagliptin 2.5 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001210 + saxagliptin 5 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001211 + BN Juvisync + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001212 + Simvastatin 10 MG / sitaGLIPtin 100 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001213 + Simvastatin 10 MG / sitaGLIPtin 50 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001214 + Simvastatin 20 MG / sitaGLIPtin 100 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001215 + Simvastatin 20 MG / sitaGLIPtin 50 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001216 + Simvastatin 40 MG / sitaGLIPtin 100 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001217 + Simvastatin 40 MG / sitaGLIPtin 50 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001218 + BN Janumet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001219 + BN Januvia + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001220 + BN Juvisync + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001221 + 24 HR metFORMIN hydrochloride 1000 MG / sitaGLIPtin 100 MG Extended Release Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001222 + 24 HR metFORMIN hydrochloride 1000 MG / sitaGLIPtin 50 MG Extended Release Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001223 + 24 HR metFORMIN hydrochloride 500 MG / sitaGLIPtin 50 MG Extended Release Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001224 + metFORMIN hydrochloride 1000 MG / sitaGLIPtin 50 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001225 + metFORMIN hydrochloride 500 MG / sitaGLIPtin 50 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001226 + Simvastatin 10 MG / sitaGLIPtin 100 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001227 + Simvastatin 10 MG / sitaGLIPtin 50 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001228 + Simvastatin 20 MG / sitaGLIPtin 100 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001229 + Simvastatin 20 MG / sitaGLIPtin 50 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001230 + Simvastatin 40 MG / sitaGLIPtin 100 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001231 + Simvastatin 40 MG / sitaGLIPtin 50 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001232 + sitaGLIPtin 100 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001233 + sitaGLIPtin 25 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001234 + sitaGLIPtin 50 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001235 + BN Cycloset + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001236 + BN Parlodel + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001237 + Bromocriptine 0.8 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001238 + Bromocriptine 1 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001239 + Bromocriptine 10 MG Oral Capsule + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001240 + Bromocriptine 2.5 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001241 + Bromocriptine 5 MG Oral Capsule + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001242 + BN Tanzeum + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001243 + 0.5 ML albiglutide 100 MG/ML Pen Injector + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001244 + 0.5 ML albiglutide 60 MG/ML Pen Injector + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001245 + BN Trulicity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001248 + BN Bydureon + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001249 + BN Byetta + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001250 + 0.65 ML exenatide 3.08 MG/ML Pen Injector + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001251 + 60 ACTUAT exenatide 0.005 MG/ACTUAT Pen Injector + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001252 + 60 ACTUAT exenatide 0.01 MG/ACTUAT Pen Injector + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001253 + exenatide 2 MG Injection + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001254 + BN Saxenda + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001255 + BN Victoza + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001256 + BN Xultophy + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001257 + 3 ML insulin degludec 100 UNT/ML / liraglutide 3.6 MG/ML Pen Injector + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001258 + 3 ML liraglutide 6 MG/ML Pen Injector + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001259 + BN Adlyxin + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001260 + BN Soliqua + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001261 + 3 ML Insulin Glargine 100 UNT/ML / Lixisenatide 0.033 MG/ML Pen Injector + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001262 + 3 ML Lixisenatide 0.05 MG/ML Pen Injector + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001263 + 3 ML Lixisenatide 0.1 MG/ML Pen Injector + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001264 + {1 (3 ML Lixisenatide 0.05 MG/ML Pen Injector) / 1 (3 ML Lixisenatide 0.1 MG/ML Pen Injector) } Pack + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001265 + BN Starlix + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001266 + nateglinide 120 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001267 + nateglinide 180 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001268 + nateglinide 60 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001269 + BN PrandiMet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001270 + BN Prandin + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001271 + metFORMIN hydrochloride 500 MG / repaglinide 1 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001272 + metFORMIN hydrochloride 500 MG / repaglinide 2 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001273 + repaglinide 0.5 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001274 + repaglinide 1 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001275 + repaglinide 2 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001276 + BN Nutrisource + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001277 + guar gum 12.5 MG/ML Oral Suspension + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001278 + guar gum 720 MG/ML Oral Suspension + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001279 + BN Starlix + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001280 + nateglinide 120 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001281 + nateglinide 180 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001282 + nateglinide 60 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001283 + BN Symlin + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001284 + 1.5 ML pramlintide acetate 1 MG/ML Pen Injector + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001285 + 2.7 ML pramlintide acetate 1 MG/ML Pen Injector + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001286 + pramlintide acetate 0.6 MG/ML Injectable Solution + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001287 + BN PrandiMet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001288 + BN Prandin + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001289 + metFORMIN hydrochloride 500 MG / repaglinide 1 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001290 + metFORMIN hydrochloride 500 MG / repaglinide 2 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001291 + repaglinide 0.5 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001292 + repaglinide 1 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001293 + repaglinide 2 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001294 + BN Invokamet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001295 + BN Invokana + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001296 + 24 HR canagliflozin 150 MG / metFORMIN hydrochloride 1000 MG Extended Release Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001297 + 24 HR canagliflozin 150 MG / metFORMIN hydrochloride 500 MG Extended Release Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001298 + 24 HR canagliflozin 50 MG / metFORMIN hydrochloride 1000 MG Extended Release Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001299 + 24 HR canagliflozin 50 MG / metFORMIN hydrochloride 500 MG Extended Release Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001300 + canagliflozin 100 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001301 + canagliflozin 150 MG / metFORMIN hydrochloride 1000 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001302 + canagliflozin 150 MG / metFORMIN hydrochloride 500 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001303 + canagliflozin 300 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001304 + canagliflozin 50 MG / metFORMIN hydrochloride 1000 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001305 + canagliflozin 50 MG / metFORMIN hydrochloride 500 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001306 + BN Farxiga + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001307 + BN Xigduo + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001308 + 24 HR dapagliflozin 10 MG / metFORMIN hydrochloride 1000 MG Extended Release Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001309 + 24 HR dapagliflozin 10 MG / metFORMIN hydrochloride 500 MG Extended Release Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001310 + 24 HR dapagliflozin 5 MG / metFORMIN hydrochloride 1000 MG Extended Release Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001311 + 24 HR dapagliflozin 5 MG / metFORMIN hydrochloride 500 MG Extended Release Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001312 + dapagliflozin 10 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001313 + dapagliflozin 5 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001314 + BN Glyxambi + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001315 + BN Jardiance + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001316 + BN Synjardy + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001317 + empagliflozin 10 MG / Linagliptin 5 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001318 + empagliflozin 10 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001319 + empagliflozin 12.5 MG / metFORMIN hydrochloride 1000 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001320 + empagliflozin 12.5 MG / metFORMIN hydrochloride 500 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001321 + empagliflozin 25 MG / Linagliptin 5 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001322 + empagliflozin 25 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001323 + empagliflozin 5 MG / metFORMIN hydrochloride 1000 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001324 + empagliflozin 5 MG / metFORMIN hydrochloride 500 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001325 + chlorpropamide 100mg tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001326 + chlorpropamide 250mg tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001327 + gliclazide 30mg m/r tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001328 + gliclazide 80mg tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001329 + BN Amaryl + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001330 + BN Avandaryl + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001331 + BN Duetact + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001332 + glimepiride 1 MG / rosiglitazone 4 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001333 + glimepiride 1 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001334 + glimepiride 2 MG / pioglitazone 30 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001335 + glimepiride 2 MG / rosiglitazone 4 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001336 + glimepiride 2 MG / rosiglitazone 8 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001337 + glimepiride 2 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001338 + glimepiride 3 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001339 + glimepiride 4 MG / pioglitazone 30 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001340 + glimepiride 4 MG / rosiglitazone 4 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001341 + glimepiride 4 MG / rosiglitazone 8 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001342 + glimepiride 4 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001343 + glimepiride 6 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001344 + glimepiride 8 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001345 + BN Glucotrol + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001346 + BN Metaglip + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001347 + 24 HR glipiZIDE 10 MG Extended Release Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001348 + 24 HR glipiZIDE 2.5 MG Extended Release Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001349 + 24 HR glipiZIDE 5 MG Extended Release Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001350 + glipiZIDE 10 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001351 + glipiZIDE 2.5 MG / metFORMIN hydrochloride 250 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001352 + glipiZIDE 2.5 MG / metFORMIN hydrochloride 500 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001353 + glipiZIDE 2.5 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001354 + glipiZIDE 5 MG / metFORMIN hydrochloride 500 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001355 + glipiZIDE 5 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001356 + BN Diabeta + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001357 + BN Glucovance + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001358 + BN Glynase + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001359 + glyBURIDE 1.25 MG / metFORMIN hydrochloride 250 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001360 + glyBURIDE 1.25 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001361 + glyBURIDE 1.5 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001362 + glyBURIDE 2.5 MG / metFORMIN hydrochloride 500 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001363 + glyBURIDE 2.5 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001364 + glyBURIDE 3 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001365 + glyBURIDE 4.5 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001366 + glyBURIDE 5 MG / metFORMIN hydrochloride 500 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001367 + glyBURIDE 5 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001368 + glyBURIDE 6 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001369 + BN Tolinase + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001370 + TOLAZamide 100 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001371 + TOLAZamide 250 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001372 + TOLAZamide 500 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001373 + tolbutamide 500mg tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001374 + BN Actoplus Met + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001375 + BN Actos + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001376 + BN Duetact + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001377 + BN Oseni + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001378 + 24 HR metFORMIN hydrochloride 1000 MG / pioglitazone 15 MG Extended Release Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001379 + 24 HR metFORMIN hydrochloride 1000 MG / pioglitazone 30 MG Extended Release Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001380 + alogliptin 12.5 MG / pioglitazone 15 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001381 + alogliptin 12.5 MG / pioglitazone 30 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001382 + alogliptin 12.5 MG / pioglitazone 45 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001383 + alogliptin 25 MG / pioglitazone 15 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001384 + alogliptin 25 MG / pioglitazone 30 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001385 + alogliptin 25 MG / pioglitazone 45 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001386 + glimepiride 2 MG / pioglitazone 30 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001387 + glimepiride 4 MG / pioglitazone 30 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001388 + metFORMIN hydrochloride 500 MG / pioglitazone 15 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001389 + metFORMIN hydrochloride 850 MG / pioglitazone 15 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001390 + pioglitazone 15 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001391 + pioglitazone 30 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001392 + pioglitazone 45 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001393 + BN Avandamet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001394 + BN Avandaryl + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001395 + BN Avandia + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001396 + glimepiride 1 MG / rosiglitazone 4 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001397 + glimepiride 2 MG / rosiglitazone 4 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001398 + glimepiride 2 MG / rosiglitazone 8 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001399 + glimepiride 4 MG / rosiglitazone 4 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001400 + glimepiride 4 MG / rosiglitazone 8 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001401 + metFORMIN hydrochloride 1000 MG / rosiglitazone 2 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001402 + metFORMIN hydrochloride 1000 MG / rosiglitazone 4 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001403 + metFORMIN hydrochloride 500 MG / rosiglitazone 1 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001404 + metFORMIN hydrochloride 500 MG / rosiglitazone 2 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001405 + metFORMIN hydrochloride 500 MG / rosiglitazone 4 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001406 + rosiglitazone 2 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001407 + rosiglitazone 4 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001408 + rosiglitazone 8 MG Oral Tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001409 + Troglitazone 200mg tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001410 + Troglitazone 300mg tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001411 + Troglitazone 400mg tablet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001413 + insulin + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001414 + short-acting insulin + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001415 + insulin aspart + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001416 + insulin aspart protamine + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001417 + insulin glulisine + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001418 + lispro insulin + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001419 + insulin lispro protamine + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001420 + prompt zinc insulin + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001421 + regular insulin + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001422 + bovine insulin soluble + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001423 + human insulin soluble + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001424 + porcine insulin soluble + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001425 + recombinant human regular insulin + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001426 + intermediate-acting insulin + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001427 + isophane insulin + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001428 + bovine isophane insulin + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001429 + human isophane insulin + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001430 + isophane insulin nph + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001431 + porcine isophane insulin + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001432 + long-acting insulin + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001433 + extended zinc insulin + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001434 + bovine insulin zinc suspension mixed + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001435 + human insulin zinc suspension crystalline + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001436 + human insulin zinc suspension mixed + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001437 + insulin detemir + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001438 + insulin glargine + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001439 + protamine zinc insulin + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001440 + bovine insulin protamine zinc + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001441 + ultra long-acting insulin + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001442 + insulin degludec + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001443 + BN HumaLOG + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001444 + BN HumaLOG Mix + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001445 + 3 ML Insulin Lispro 100 UNT/ML Cartridge + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001446 + 3 ML Insulin Lispro 100 UNT/ML Pen Injector + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001447 + 3 ML Insulin Lispro 200 UNT/ML Pen Injector + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001448 + 3 ML Insulin Lispro 25 UNT/ML / Insulin, Protamine Lispro, Human 75 UNT/ML Pen Injector + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001449 + 3 ML Insulin Lispro 50 UNT/ML / Insulin, Protamine Lispro, Human 50 UNT/ML Pen Injector + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001450 + Insulin Lispro 100 UNT/ML Injectable Solution + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001451 + Insulin Lispro 25 UNT/ML / Insulin, Protamine Lispro, Human 75 UNT/ML Injectable Suspension + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001452 + Insulin Lispro 50 UNT/ML / Insulin, Protamine Lispro, Human 50 UNT/ML Injectable Suspension + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001453 + BN Tresiba + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001454 + BN Xultophy + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001455 + 3 ML insulin degludec 100 UNT/ML / liraglutide 3.6 MG/ML Pen Injector + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001456 + 3 ML insulin degludec 100 UNT/ML Pen Injector + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001457 + 3 ML insulin degludec 200 UNT/ML Pen Injector + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001458 + BN Basaglar + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001459 + BN Lantus + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001460 + BN Soliqua + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001461 + BN Toujeo + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001462 + 1.5 ML Insulin Glargine 300 UNT/ML Pen Injector + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001463 + 3 ML Insulin Glargine 100 UNT/ML / Lixisenatide 0.033 MG/ML Pen Injector + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001464 + 3 ML Insulin Glargine 100 UNT/ML Pen Injector + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001465 + Insulin Glargine 100 UNT/ML Injectable Solution + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001466 + BN Levemir + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001467 + 3 ML insulin detemir 100 UNT/ML Pen Injector + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001468 + insulin detemir 100 UNT/ML Injectable Solutio + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001469 + Acarbose + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001470 + miglitole + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001470 + miglitol + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001471 + BN Glumetza + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001472 + BN Glucophage + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001473 + BN Invokamet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001474 + BN Riomet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001475 + metFORMIN + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001476 + alogliptin / metFORMIN + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001477 + canagliflozin / metFORMIN + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001478 + chlorproPAMIDE / metFORMIN + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001479 + dapagliflozin / metFORMIN + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001480 + empagliflozin / metFORMIN + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001481 + glipiZIDE / metFORMIN + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001482 + glyBURIDE / metFORMIN + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001483 + Linagliptin / metFORMIN + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001484 + metFORMIN / pioglitazone + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001485 + metFORMIN / repaglinide + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001486 + metFORMIN / rOPINIRole + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001487 + metFORMIN / rosiglitazone + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001488 + metFORMIN / saxagliptin + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001489 + metFORMIN / sitaGLIPtin + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001490 + alogliptin + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001491 + alogliptin / pioglitazone + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001492 + Linagliptin + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001493 + empagliflozin / Linagliptin + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001494 + saxagliptin + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001495 + Simvastatin / sitaGLIPtin + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001496 + Simvastatin + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001497 + sitaGLIPtin + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001498 + Bromocriptine + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001499 + albiglutide + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001500 + dulaglutide + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001501 + exenatide + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001502 + liraglutide + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001503 + insulin degludec / liraglutide + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001504 + Lixisenatide + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001505 + Insulin Glargine / Lixisenatide + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001506 + nateglinid + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001506 + nateglinide + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001507 + repaglinide + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001508 + guar gum + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001509 + Apple pectin / guar gum + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001511 + Pramlintide + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001512 + repaglinide + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001513 + canagliflozin + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001514 + dapagliflozin + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001515 + empagliflozin + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001516 + glimepiride + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001517 + glimepiride / pioglitazone + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001518 + glimepiride / rosiglitazone + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001519 + glipiZIDE + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001520 + glyBURIDE + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001521 + glyBURIDE / Phenformin + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001522 + Tolazamide + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001523 + Tolbutamide + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001524 + pioglitazon + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001524 + pioglitazone + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001525 + rosiglitazon + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001525 + rosiglitazone + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001527 + Insulin Receptor Agonist + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001528 + Receptor Interaction + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001529 + Receptor Protein Kinase Interaction + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001530 + Insulin Receptor Interaction + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001531 + Insulin Receptor Antagonist + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001532 + Enzyme Interaction + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001533 + Enzyme Inhibitor + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001534 + Amylase Inhibitor + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001535 + alpha Glucosidase Inhibitor + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001536 + Acarbose + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001537 + miglitol + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001538 + G-Protein-linked Receptor Interaction + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001539 + Glucagon Receptor Interaction + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001540 + Glucagon-like Peptide-1 (GLP-1) Receptor Interaction + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001541 + Glucagon-like Peptide-1 (GLP-1) Agonist + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001542 + albiglutide + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001543 + dulaglutide + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001544 + exenatide + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001545 + liraglutide + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001546 + Renal Dysfunction + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001548 + Protease Inhibitor + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001549 + Dipeptidyl Peptidase 4 Inhibitor + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001550 + alogliptin + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001551 + Linagliptin + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001552 + saxagliptin + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001553 + sitagliptin + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001554 + combination + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001556 + Dopamine Receptor Interaction + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001557 + Dopamine Agonist + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001558 + Apomorphine + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001559 + Fenoldopam + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001560 + Pergolide + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001561 + Pramipexole + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001562 + ropinirole + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001563 + Membrane Transporter Interaction + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001564 + Ion Transporter Interaction + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001565 + Symporter Interaction + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001566 + Sodium-Glucose Transporter Interaction + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001567 + Sodium-Glucose Transporter Inhibitor + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001568 + Sodium-Glucose Transporter 1 Inhibitor + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001569 + Sodium-Glucose Transporter 2 Inhibitor + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001570 + canagliflozin + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001571 + dapagliflozin + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001572 + empagliflozin + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001573 + 0.5 ML dulaglutide 3 MG/ML Auto-Injector + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001574 + 0.5 ML dulaglutide 1.5 MG/ML Auto-Injector + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001575 + contradicte_with_condition_AE + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001576 + contradicte_with_disease_AE + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001577 + contradicte_with_drug_AE + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001578 + contradicte_with_food_AE + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001579 + ingredient affecting blood glucose + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001582 + Incretin + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001583 + has_drug_MoA + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001584 + when_to_take + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001585 + drug timing + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001586 + before meal + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001587 + while meal + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001588 + after meal + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001589 + diabetes drugs MoA + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001590 + efficacy + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001591 + low efficacy + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001592 + intermediate efficacy + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001593 + high efficacy + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001594 + has_efficacy + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001597 + at bedtime + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001598 + vitamin B12 deficiency + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001599 + may_by_prevented_by + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001600 + may_be_diagnosed_by + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001601 + rapid-acting insulin + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001602 + has_onset (insulin) + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001603 + has_pleak (insulin) + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001604 + has_duration (insulin) + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001605 + has_appearance (insulin) + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001606 + augment insulin secretion + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001607 + enhance insulin sensitivity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001608 + delay carbohydrate absorption + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001609 + hypoxemia + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001610 + anoxia due to high altitude + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001611 + acute mountain sickness + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001612 + subacute mountain sickness + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001613 + central cyanosis + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001614 + cyanotic congenital heart disease + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001615 + hemoglobinopathy with cyanosis + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001616 + O/E - central cyanosis + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001617 + desaturation of blood + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001618 + hepatopulmonary syndrome + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001619 + hypoxemia during surgery + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001620 + neonatal hypoxemia + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001621 + sleep related hypoxemia + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001622 + has_site_of_action + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001623 + respiratory insufficiency + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001624 + respiratory failure + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001625 + acute respiratory failure + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001626 + acute hypercapnic respiratory failure + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001627 + acute hypoxemic respiratory failure + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001628 + acute respiratory failure requiring reintubation + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001629 + acute-on-chronic respiratory failure + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001630 + cardiorespiratory failure + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001631 + chronic respiratory failure + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001632 + acute-on-chronic respiratory failure + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001633 + chronic hypercapnic respiratory failure + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001634 + chronic hypoxemic respiratory failure + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001635 + acute on chronic hypoxemic respiratory failure + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001636 + hereditary myopathy with early respiratory failure + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001637 + hypercapnic respiratory failure + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001638 + neonatal respiratory failure + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001639 + perinatal respiratory failure + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001640 + postprocedural respiratory failure + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001641 + respiratory arrest + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001642 + cardiorespiratory arrest + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001643 + cardiorespiratory failure as a complication of care + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001644 + neonatal respiratory arrest + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001645 + respiratory failure without hypercapnia + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001646 + sleep-related respiratory failure + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001647 + cell + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001648 + troglitazon + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001648 + troglitazone + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001649 + SNOMED CT synonym + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001650 + dizziness + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001651 + Aspart (NovoRapid) + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001652 + Glulisine (Apidra) + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001653 + Lispro (Humalog) + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001654 + Lispro U200 (Humalog U200) + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001655 + has_expected_decrease_in_a1c + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001655 + The lowering percentage (e.g., 0.6, 0.8, etc.) of A1C for a specific drug + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001656 + has_dose + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001660 + plan quality + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001661 + target + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001663 + has_sugar_level + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001664 + has_A1C_level + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001665 + has_weight_level + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001666 + in_time_of + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001667 + has_patient_profile + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001668 + is_associated_to_patient + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001670 + patient profile + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001671 + has_treatment_plan + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001672 + treatment_plan_of + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001673 + has_diabetes_type + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001674 + diabetes mellitus + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001675 + has_severity_level + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001677 + severity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001678 + low severity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001679 + medium severity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001680 + high severity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001681 + severe + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001682 + has_diagnosis_severity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001683 + has_complication + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001684 + has_symptom + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001685 + has_history + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001686 + number_of_first_degree_relatives_with_type2_diabetes + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001687 + currently_taken_drug + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001688 + has_disease_duration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001690 + has_disease_severity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001691 + has_location + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001692 + has_administration_schema + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001693 + administration schema + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001694 + has_administration_frequency + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001695 + adminishration course + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001696 + administration cycle + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001697 + administration frequency + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001698 + administration duration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001699 + has_administration_duration + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001700 + has_date + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001701 + has_part + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001703 + lifeStyle + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001704 + diet + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001705 + physical activity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001706 + has_target + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001707 + has_sugar_level + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001708 + sugar level + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001710 + drug subplan + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001711 + education subplan + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001712 + lifestyle subplan + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001713 + has_participant + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001719 + quantity + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001720 + acute complication drug + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001721 + chronic complication drug + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001722 + other complication drug + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001723 + micro vascular complication drug + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001724 + retinopathy drug + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001725 + nephropathy drug + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001726 + neuropathy drug + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001727 + macrovascular complication drug + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001728 + gram + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001729 + milligram + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001730 + calorie + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001731 + kcalorie + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001732 + Joule + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001733 + kJoule + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001774 + patient smoking history + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001775 + has_insulin_administration_method + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001776 + average_number_of_insulin_injections_per_day + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001777 + average_number_of_rapid_acting_insulin_units_per_day + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001778 + average_number_of_intermediate_acting_insulin_units_per_day + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001779 + average_number_of_long_acting_insulin_units_per_day + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001781 + has_next_evaluation_date + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001782 + symptomatic patient + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001783 + asymptomatic patient + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001784 + maximum dose per day + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001785 + has_max_dose_per_day + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001786 + usual starting dose + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001787 + has_usual_starting_dose + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001788 + combined drug + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001789 + two combined drug + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001790 + three combined drug + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001791 + more combined drug + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001792 + diabetes_since_date + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001793 + acetazolamide + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001794 + class III antiarrhythmic drug + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001795 + amiodarone + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001796 + histamine H>2< antagonist + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001797 + cimetidine + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001798 + quinolone -class of antibiotic- + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001799 + ciprofloxacin + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001800 + bile acid sequestrant antilipemic agent + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001801 + colesevelam + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001802 + colesevelam hydrochloride + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001803 + dichlorphenamide + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001804 + digoxin + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001805 + dofetilide + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001806 + integrase inhibitor + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001807 + dolutegravir + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001808 + fleroxacin + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001809 + gemifloxacin + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001810 + alcohol product + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001811 + ethanol + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001812 + diagnostic aid + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001813 + contrast media + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001814 + radiographic contrast media + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001815 + ionic iodinated contrast media + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001816 + ioversol + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001817 + diabetic ketoacidosis without coma + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001818 + ketoacidosis in type 2 diabetes mellitus + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001819 + has_consumption + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001820 + is_available + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001821 + has_recommended_food + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001822 + has_forbidden_food + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001823 + has_previous_treatment_plan + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001824 + has_previous_plan_of + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001825 + has_patient_ID + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001826 + glomerular filtration rate + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001827 + mL/min/1.73 m2 + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001828 + physical exercise + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001829 + aerobic exercise + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001830 + walk briskly + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001831 + cycle + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001832 + swim + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001833 + jump rope + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001834 + run + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001835 + play basketball + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001836 + dance + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001837 + skate + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001838 + strength activitie + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001839 + weight lifting + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001840 + sit-ups and push-ups + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001841 + climbing stairs + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001842 + carrying groceries + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001843 + flexibility activitie + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001844 + yoga + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001845 + stretching exercise + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001846 + has_physical_exercise + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001847 + has_length_in_minutes + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001848 + do_exercise_per + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001849 + number_of_times + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001850 + has_social_state + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001851 + has_treatment_acceptance + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001852 + male + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001853 + female + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001854 + has_recommended_drug + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001855 + has_forbidden_drug + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001856 + has_forbidden_exercise + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001857 + has_recommended_food_d + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001858 + has_forbidden_food_d + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001859 + jobs involving desk work. The physical activity level is 25-30 + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001859 + low intenisty exercise job + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001860 + jobs involving standing work. The physical activity level is 30-35 + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001860 + moderate intenisty exercise job + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001861 + jobs involving heavy physical activity. The physical activity level is >= 35 + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001861 + high intenisty exercise job + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001862 + breast feed + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001863 + not breast feed + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#DMTO:0001864 + gram per day + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#PATO:0001236 + process quality + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#PATO:0001995 + PATO:0001995 + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#PATO:0001995 + organismal quality + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#PATO:0002198 + PATO:0002198 + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#PATO:0002198 + quality of a substance + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#TIME:0000004 + temporal_property + + + + https://bioportal.bioontology.org/ontologies/DMTO.owl#TIME:0000005 + temporal property + + + + + + + + + + + + + + + diff --git a/src/test/resources/repo/input/dmto/OntoFood.owl b/src/test/resources/repo/input/dmto/OntoFood.owl new file mode 100644 index 0000000..3ed995b --- /dev/null +++ b/src/test/resources/repo/input/dmto/OntoFood.owl @@ -0,0 +1,1825 @@ + + + + + + + + + + + + + +]> + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + true + + + true + + + true + + + true + + + + + + + diff --git a/src/test/resources/repo/input/dmto/time.ttl b/src/test/resources/repo/input/dmto/time.ttl new file mode 100644 index 0000000..1561a10 --- /dev/null +++ b/src/test/resources/repo/input/dmto/time.ttl @@ -0,0 +1,1766 @@ +@prefix : . +@prefix dct: . +@prefix owl: . +@prefix rdf: . +@prefix xml: . +@prefix xsd: . +@prefix foaf: . +@prefix rdfs: . +@prefix skos: . +@prefix tzont: . +@base . + + rdf:type owl:Ontology ; + + rdfs:label "OWL-Time"@en ; + + dct:created "2006-09-27"^^xsd:date ; + + dct:modified "2016-07-12"^^xsd:date ; + + rdfs:comment "An OWL Ontology of Time (OWL-Time)."@en ; + + dct:rights "Copyright © 2006-2016 W3C All Rights Reserved. W3C liability, trademark and document use rules apply."@en ; + + rdfs:comment "Update of OWL-Time ontology, extended to support general temporal reference systems"@en ; + + rdfs:seeAlso , + , + , + ; + + owl:priorVersion ; + + owl:versionIRI ; + + rdfs:seeAlso ; + + dct:isVersionOf ; + + dct:license ; + + dct:creator [ ] ; + +dct:contributor [ ] ; + +dct:creator [ ] . + + +################################################################# +# +# Annotation properties +# +################################################################# + + +### http://purl.org/dc/terms/description + +dct:description rdf:type owl:AnnotationProperty . + + + +### http://purl.org/dc/terms/hasVersion + +dct:hasVersion rdf:type owl:AnnotationProperty . + + + +### http://purl.org/dc/terms/identifier + +dct:identifier rdf:type owl:AnnotationProperty . + + + +### http://purl.org/dc/terms/issued + +dct:issued rdf:type owl:AnnotationProperty . + + + +### http://purl.org/dc/terms/modified + +dct:modified rdf:type owl:AnnotationProperty . + + + +### http://purl.org/dc/terms/publisher + +dct:publisher rdf:type owl:AnnotationProperty . + + + +### http://purl.org/dc/terms/title + +dct:title rdf:type owl:AnnotationProperty . + + + +### http://www.w3.org/2004/02/skos/core#changeNote + +skos:changeNote rdf:type owl:AnnotationProperty . + + + +### http://www.w3.org/2004/02/skos/core#note + +skos:note rdf:type owl:AnnotationProperty . + + + +### http://xmlns.com/foaf/0.1/isPrimaryTopicOf + +foaf:isPrimaryTopicOf rdf:type owl:AnnotationProperty . + + + +### http://xmlns.com/foaf/0.1/mbox + +foaf:mbox rdf:type owl:AnnotationProperty . + + + + + +################################################################# +# +# Datatypes +# +################################################################# + + +### http://www.w3.org/2001/XMLSchema#date + +xsd:date rdf:type rdfs:Datatype . + + + +### http://www.w3.org/2001/XMLSchema#gDay + +xsd:gDay rdf:type rdfs:Datatype . + + + +### http://www.w3.org/2001/XMLSchema#gMonth + +xsd:gMonth rdf:type rdfs:Datatype . + + + +### http://www.w3.org/2001/XMLSchema#gYear + +xsd:gYear rdf:type rdfs:Datatype . + + + +### http://www.w3.org/2006/time#Number + +:Number rdf:type rdfs:Datatype ; + + rdfs:label "Number"@en ; + + owl:equivalentClass [ rdf:type rdfs:Datatype ; + owl:unionOf ( xsd:decimal + xsd:double + xsd:float + ) + ] ; + + rdfs:comment "Generalized number"@en , + "Note: integer is a specialization of decimal"@en . + + + +### http://www.w3.org/2006/time#generalDay + +:generalDay rdf:type rdfs:Datatype ; + + rdfs:label "Generalized day"@en ; + + rdfs:comment "Day of month - generalization of xsd:gDay, formulated as a text string with a pattern constraint to reproduce the same lexical form as gDay, except that values up to 99 are permitted, in order to support calendars with more than 31 days in a month. Note that the value-space is not defined, so a generic OWL2 processor cannot compute ordering relationships of values of this type. "@en . + + + +### http://www.w3.org/2006/time#generalMonth + +:generalMonth rdf:type rdfs:Datatype ; + + rdfs:label "Generalized month"@en ; + + rdfs:comment "Month of year - generalization of xsd:gMonth, formulated as a text string with a pattern constraint to reproduce the same lexical form as gMonth, except that values up to 20 are permitted, in order to support calendars with more than 12 months in the year. Note that the value-space is not defined, so a generic OWL2 processor cannot compute ordering relationships of values of this type."@en . + + + +### http://www.w3.org/2006/time#generalYear + +:generalYear rdf:type rdfs:Datatype . + + + + + +################################################################# +# +# Object Properties +# +################################################################# + + +### http://www.w3.org/2006/time#TIME:0000022 + + rdf:type owl:ObjectProperty ; + + rdfs:label "after"@en ; + + rdfs:comment "Gives directionality to time. If a temporal entity T1 is after another temporal entity T2, then the beginning of T1 is after the end of T2."@en ; + + owl:inverseOf . + + + +### http://www.w3.org/2006/time#TIME:0000023 + + rdf:type owl:ObjectProperty , + owl:TransitiveProperty ; + + rdfs:label "before"@en ; + + rdfs:comment "Gives directionality to time. If a temporal entity T1 is before another temporal entity T2, then the end of T1 is before the beginning of T2. Thus, before can be considered to be basic to instants and derived for intervals."@en ; + + rdfs:range ; + + rdfs:domain . + + + +### http://www.w3.org/2006/time#TIME:0000024 + + rdf:type owl:ObjectProperty ; + + rdfs:label "interval before"@en ; + + rdfs:comment "If a proper interval T1 is intervalBefore another proper interval T2, then the end of T1 is before the beginning of T2."@en ; + + rdfs:domain ; + + rdfs:range ; + + rdfs:subPropertyOf . + + + +### http://www.w3.org/2006/time#TIME:0000025 + + rdf:type owl:ObjectProperty ; + + rdfs:label "day of week"@en ; + + rdfs:comment "The day of week, whose value is a member of the class time:DayOfWeek"@en ; + + rdfs:range ; + + rdfs:domain . + + + +### http://www.w3.org/2006/time#TIME:0000026 + + rdf:type owl:ObjectProperty ; + + rdfs:label "has beginning"@en ; + + rdfs:comment "Beginning of a temporal entity."@en ; + + rdfs:domain ; + + rdfs:range . + + + +### http://www.w3.org/2006/time#TIME:0000027 + + rdf:type owl:ObjectProperty ; + + rdfs:label "has Date-Time description"@en ; + + rdfs:comment "Value of DateTimeInterval expressed as a structured value."@en ; + + rdfs:range ; + + rdfs:domain . + + + +### http://www.w3.org/2006/time#TIME:0000028 + + rdf:type owl:ObjectProperty ; + + rdfs:label "has duration"@en ; + + rdfs:comment "Duration of a temporal entity, expressed as a scaled value or nominal value"@en ; + + rdfs:range ; + + rdfs:domain . + + + +### http://www.w3.org/2006/time#TIME:0000029 + + rdf:type owl:ObjectProperty ; + + rdfs:label "has duration description"@en ; + + rdfs:comment "Duration of a temporal entity, expressed using a structured description"@en ; + + rdfs:range ; + + rdfs:domain . + + + +### http://www.w3.org/2006/time#TIME:0000030 + + rdf:type owl:ObjectProperty ; + + rdfs:label "has end"@en ; + + rdfs:comment "End of a temporal entity."@en ; + + rdfs:domain ; + + rdfs:range . + + + +### http://www.w3.org/2006/time#TIME:0000031 + + rdf:type owl:ObjectProperty ; + + rdfs:label "has instant inside"@en ; + + rdfs:comment "An instant that falls inside the interval. It is not intended to include beginnings and ends of intervals."@en ; + + rdfs:range ; + + rdfs:domain . + + + +### http://www.w3.org/2006/time#TIME:0000032 + + rdf:type owl:ObjectProperty ; + + rdfs:label "in Date-Time description"@en ; + + rdfs:comment "Position of an instant, expressed using a structured description"@en ; + + rdfs:range ; + + rdfs:domain . + + + +### http://www.w3.org/2006/time#TIME:0000033 + + rdf:type owl:ObjectProperty ; + + rdfs:label "in time zone"@en ; + + rdfs:comment "The time zone for clock elements in the temporal position"@en ; + + rdfs:domain ; + + rdfs:range . + + + +### http://www.w3.org/2006/time#TIME:0000034 + + rdf:type owl:ObjectProperty ; + + rdfs:label "interval during"@en ; + + rdfs:comment "If a proper interval T1 is intervalDuring another proper interval T2, then the beginning of T1 is after the beginning of T2, and the end of T1 is before the end of T2."@en ; + + rdfs:domain ; + + rdfs:range . + + + +### http://www.w3.org/2006/time#TIME:0000035 + + rdf:type owl:ObjectProperty ; + + rdfs:label "interval equals"@en ; + + rdfs:comment "If a proper interval T1 is intervalEquals another proper interval T2, then the beginning of T1 is the beginning of T2, and the end of T1 is the end of T2."@en ; + + rdfs:range ; + + rdfs:domain . + + + +### http://www.w3.org/2006/time#TIME:0000036 + + rdf:type owl:ObjectProperty ; + + rdfs:label "interval finishes"@en ; + + rdfs:comment "If a proper interval T1 is intervalFinishes another proper interval T2, then the beginning of T1 is after the beginning of T2, and the end of T1 is the end of T2."@en ; + + rdfs:domain ; + + rdfs:range . + + + +### http://www.w3.org/2006/time#TIME:0000037 + + rdf:type owl:ObjectProperty ; + + rdfs:label "interval finished by"@en ; + + rdfs:comment "If a proper interval T1 is intervalFinishedBy another proper interval T2, then the beginning of T1 is before the beginning of T2, and the end of T1 is the end of T2."@en ; + + owl:inverseOf . + + + +### http://www.w3.org/2006/time#TIME:0000038 + + rdf:type owl:ObjectProperty ; + + rdfs:label "interval meets"@en ; + + rdfs:comment "If a proper interval T1 is intervalMeets another proper interval T2, then the end of T1 is the beginning of T2."@en ; + + rdfs:domain ; + + rdfs:range . + + + +### http://www.w3.org/2006/time#TIME:0000039 + + rdf:type owl:ObjectProperty ; + + rdfs:label "interval met by"@en ; + + rdfs:comment "If a proper interval T1 is intervalMetBy another proper interval T2, then the beginning of T1 is the end of T2."@en ; + + owl:inverseOf . + + + +### http://www.w3.org/2006/time#TIME:0000040 + + rdf:type owl:ObjectProperty ; + + rdfs:label "interval overlaps"@en ; + + rdfs:comment "If a proper interval T1 is intervalOverlaps another proper interval T2, then the beginning of T1 is before the beginning of T2, the end of T1 is after the beginning of T2, and the end of T1 is before the end of T2."@en ; + + rdfs:domain ; + + rdfs:range . + + + +### http://www.w3.org/2006/time#TIME:0000041 + + rdf:type owl:ObjectProperty ; + + rdfs:label "interval overlapped by"@en ; + + rdfs:comment "If a proper interval T1 is intervalOverlappedBy another proper interval T2, then the beginning of T1 is after the beginning of T2, the beginning of T1 is before the end of T2, and the end of T1 is after the end of T2."@en ; + + owl:inverseOf . + + + +### http://www.w3.org/2006/time#TIME:0000042 + + rdf:type owl:ObjectProperty ; + + rdfs:label "interval starts"@en ; + + rdfs:comment "If a proper interval T1 is intervalStarts another proper interval T2, then the beginning of T1 is the beginning of T2, and the end of T1 is before the end of T2."@en ; + + rdfs:range ; + + rdfs:domain . + + + +### http://www.w3.org/2006/time#TIME:0000043 + + rdf:type owl:ObjectProperty ; + + rdfs:label "member entity"@en ; + + rdfs:comment "Supports the inclusion of temporal entities in other resources, such as temporal reference systems."@en ; + + rdfs:range . + + + +### http://www.w3.org/2006/time#TIME:0000044 + + rdf:type owl:ObjectProperty ; + + rdfs:label "interval started by"@en ; + + rdfs:comment "If a proper interval T1 is intervalStarted another proper interval T2, then the beginning of T1 is the beginning of T2, and the end of T1 is after the end of T2."@en ; + + owl:inverseOf . + + + +### http://www.w3.org/2006/time#TIME:0000045 + + rdf:type owl:ObjectProperty ; + + rdfs:label "Temporal position"@en ; + + rdfs:comment "Position of a time instant expressed as a TimePosition"@en ; + + rdfs:domain ; + + rdfs:range . + + + +### http://www.w3.org/2006/time#TIME:0000046 + + rdf:type owl:FunctionalProperty , + owl:ObjectProperty ; + + rdfs:label "Temporal reference system used"@en ; + + rdfs:comment "The temporal reference system used by a temporal position or extent description. "@en ; + + rdfs:range . + + + +### http://www.w3.org/2006/time#TIME:0000047 + + rdf:type owl:ObjectProperty ; + + rdfs:label "temporal unit type"@en ; + + rdfs:comment "The temporal unit which provides the precision of a date-time value or scale of a temporal extent"@en ; + + rdfs:range ; + + rdfs:domain [ rdf:type owl:Class ; + owl:unionOf ( + + ) + ] . + + + +### http://www.w3.org/2006/time#intervalAfter + +:intervalAfter rdf:type owl:ObjectProperty ; + + rdfs:label "interval after"@en ; + + rdfs:comment "If a proper interval T1 is intervalAfter another proper interval T2, then the beginning of T1 is after the end of T2."@en ; + + owl:inverseOf . + + + +### http://www.w3.org/2006/time#intervalContains + +:intervalContains rdf:type owl:ObjectProperty ; + + rdfs:label "interval contains"@en ; + + rdfs:comment "If a proper interval T1 is intervalContains another proper interval T2, then the beginning of T1 is before the beginning of T2, and the end of T1 is after the end of T2."@en ; + + owl:inverseOf . + + + + + +################################################################# +# +# Data properties +# +################################################################# + + +### http://www.w3.org/2006/time#TIME:0000051 + + rdf:type owl:DatatypeProperty ; + + rdfs:label "day"@en ; + + rdfs:comment """Day position in a calendar-clock system. + +The range of this property is not specified, so can be replaced by any specific representation of a calendar day from any calendar. """@en ; + + rdfs:domain . + + + +### http://www.w3.org/2006/time#TIME:0000052 + + rdf:type owl:DatatypeProperty ; + + rdfs:label "day of year"@en ; + + rdfs:comment "The number of the day within the year"@en ; + + rdfs:range xsd:nonNegativeInteger ; + + rdfs:domain . + + + +### http://www.w3.org/2006/time#TIME:0000053 + + rdf:type owl:DatatypeProperty ; + + rdfs:label "days"@en ; + + rdfs:comment "length of a temporal extent expressed in days"@en ; + + rdfs:range :Number ; + + rdfs:domain . + + + +### http://www.w3.org/2006/time#TIME:0000054 + + rdf:type owl:DatatypeProperty ; + + rdfs:label "has XSD Date-Time"@en ; + + rdfs:comment "Value of DateTimeInterval expressed as a compact value."@en ; + + rdfs:range xsd:dateTime ; + + rdfs:domain . + + + +### http://www.w3.org/2006/time#TIME:0000055 + + rdf:type owl:DatatypeProperty ; + + rdfs:label "hour"@en ; + + rdfs:comment "Hour position in a calendar-clock system."@en ; + + rdfs:range xsd:nonNegativeInteger ; + + rdfs:domain . + + + +### http://www.w3.org/2006/time#TIME:0000056 + + rdf:type owl:DatatypeProperty ; + + rdfs:label "hours"@en ; + + rdfs:comment "length of a temporal extent expressed in hours"@en ; + + rdfs:range :Number ; + + rdfs:domain . + + + +### http://www.w3.org/2006/time#TIME:0000058 + + rdf:type owl:DatatypeProperty ; + + rdfs:label "in XSD Date-Time"@en ; + + rdfs:comment "Position of an instant, expressed using xsd:DateTime"@en ; + + rdfs:range xsd:dateTime ; + + rdfs:domain . + + + +### http://www.w3.org/2006/time#TIME:0000059 + + rdf:type owl:DatatypeProperty ; + + rdfs:label "minute"@en ; + + rdfs:comment "Minute position in a calendar-clock system."@en ; + + rdfs:range xsd:nonNegativeInteger ; + + rdfs:domain . + + + +### http://www.w3.org/2006/time#TIME:0000060 + + rdf:type owl:DatatypeProperty ; + + rdfs:label "minutes"@en ; + + rdfs:comment "length of a temporal extent expressed in minutes"@en ; + + rdfs:range :Number ; + + rdfs:domain . + + + +### http://www.w3.org/2006/time#TIME:0000061 + + rdf:type owl:DatatypeProperty ; + + rdfs:label "month"@en ; + + rdfs:comment """Month position in a calendar-clock system. + +The range of this property is not specified, so can be replaced by any specific representation of a calendar month from any calendar. """@en ; + + rdfs:domain . + + + +### http://www.w3.org/2006/time#TIME:0000062 + + rdf:type owl:DatatypeProperty ; + + rdfs:label "months"@en ; + + rdfs:comment "length of a temporal extent expressed in months"@en ; + + rdfs:range :Number ; + + rdfs:domain . + + + +### http://www.w3.org/2006/time#TIME:0000063 + + rdf:type owl:DatatypeProperty ; + + rdfs:label "Name of temporal position"@en ; + + rdfs:comment "The (nominal) value indicating temporal position in an ordinal reference system "@en ; + + rdfs:range xsd:string ; + + rdfs:domain . + + + +### http://www.w3.org/2006/time#TIME:0000064 + + rdf:type owl:DatatypeProperty ; + + rdfs:label "Numeric value of temporal duration"@en ; + + rdfs:comment "Value of a temporal extent expressed as a number scaled by a temporal unit"@en ; + + rdfs:range :Number ; + + rdfs:domain . + + + +### http://www.w3.org/2006/time#TIME:0000065 + + rdf:type owl:DatatypeProperty ; + + rdfs:label "Numeric value of temporal position"@en ; + + rdfs:comment "The (numeric) value indicating position within a temporal coordinate system "@en ; + + rdfs:range :Number ; + + rdfs:domain . + + + +### http://www.w3.org/2006/time#TIME:0000066 + + rdf:type owl:DatatypeProperty ; + + rdfs:label "second"@en ; + + rdfs:comment "Second position in a calendar-clock system."@en ; + + rdfs:range xsd:decimal ; + + rdfs:domain . + + + +### http://www.w3.org/2006/time#TIME:0000067 + + rdf:type owl:DatatypeProperty ; + + rdfs:label "seconds"@en ; + + rdfs:comment "length of a temporal extent expressed in seconds"@en ; + + rdfs:seeAlso ; + + rdfs:range :Number ; + + rdfs:domain . + + + +### http://www.w3.org/2006/time#TIME:0000068 + + rdf:type owl:DatatypeProperty ; + + rdfs:label "week"@en ; + + rdfs:comment "The number of the week within the year"@en ; + + rdfs:range xsd:nonNegativeInteger ; + + rdfs:domain . + + + +### http://www.w3.org/2006/time#TIME:0000069 + + rdf:type owl:DatatypeProperty ; + + rdfs:label "weeks"@en ; + + rdfs:comment "length of a temporal extent expressed in weeks"@en ; + + rdfs:range :Number ; + + rdfs:domain . + + + +### http://www.w3.org/2006/time#TIME:0000070 + + rdf:type owl:DatatypeProperty ; + + rdfs:label "year"@en ; + + rdfs:comment """Year position in a calendar-clock system. + +The range of this property is not specified, so can be replaced by any specific representation of a calendar year from any calendar. """@en ; + + rdfs:domain . + + + +### http://www.w3.org/2006/time#TIME:0000071 + + rdf:type owl:DatatypeProperty ; + + rdfs:label "years"@en ; + + rdfs:comment "length of a temporal extent expressed in years"@en ; + + rdfs:range :Number ; + + rdfs:domain . + + + + + +################################################################# +# +# Classes +# +################################################################# + + +### http://www.w3.org/2000/01/rdf-schema#TIME:0000008 + + rdf:type owl:Class ; + + rdfs:label "Resource" ; + + rdfs:subClassOf . + + + +### http://www.w3.org/2006/time#TIME:0000002 + + rdf:type owl:Class ; + + rdfs:label "temporal thing"@en . + + + +### http://www.w3.org/2006/time#TIME:0000003 + + rdf:type owl:Class ; + + rdfs:label "Day of week"@en ; + + rdfs:subClassOf ; + + skos:changeNote """Remove enumeration from definition, in order to allow other days to be used when required in other calendars. +NOTE: existing days are still present as members of the class, but the class membership is now open. + +In the original OWL-Time the following constraint appeared: + owl:oneOf ( + time:Monday + time:Tuesday + time:Wednesday + time:Thursday + time:Friday + time:Saturday + time:Sunday + ) ;"""@en ; + + rdfs:comment "The day of week"@en . + + + +### http://www.w3.org/2006/time#TIME:0000004 + + rdf:type owl:Class ; + + rdfs:label "Generalized Date Time Description"@en ; + + rdfs:subClassOf , + [ rdf:type owl:Restriction ; + owl:onProperty ; + owl:maxCardinality "1"^^xsd:nonNegativeInteger + ] , + [ rdf:type owl:Restriction ; + owl:onProperty ; + owl:maxCardinality "1"^^xsd:nonNegativeInteger + ] , + [ rdf:type owl:Restriction ; + owl:onProperty ; + owl:maxCardinality "1"^^xsd:nonNegativeInteger + ] , + [ rdf:type owl:Restriction ; + owl:onProperty ; + owl:cardinality "1"^^xsd:nonNegativeInteger + ] , + [ rdf:type owl:Restriction ; + owl:onProperty ; + owl:maxCardinality "1"^^xsd:nonNegativeInteger + ] , + [ rdf:type owl:Restriction ; + owl:onProperty ; + owl:maxCardinality "1"^^xsd:nonNegativeInteger + ] , + [ rdf:type owl:Restriction ; + owl:onProperty ; + owl:maxCardinality "1"^^xsd:nonNegativeInteger + ] , + [ rdf:type owl:Restriction ; + owl:onProperty ; + owl:maxCardinality "1"^^xsd:nonNegativeInteger + ] , + [ rdf:type owl:Restriction ; + owl:onProperty ; + owl:maxCardinality "1"^^xsd:nonNegativeInteger + ] , + [ rdf:type owl:Restriction ; + owl:onProperty ; + owl:maxCardinality "1"^^xsd:nonNegativeInteger + ] , + [ rdf:type owl:Restriction ; + owl:onProperty ; + owl:maxCardinality "1"^^xsd:nonNegativeInteger + ] , + [ rdf:type owl:Restriction ; + owl:onProperty ; + owl:cardinality "1"^^xsd:nonNegativeInteger + ] ; + + rdfs:comment "Description of date and time structured with separate values for the various elements of a calendar-clock system"@en . + + + +### http://www.w3.org/2006/time#TIME:0000005 + + rdf:type owl:Class ; + + rdfs:label "Date-Time description"@en ; + + rdfs:subClassOf , + [ rdf:type owl:Restriction ; + owl:onProperty ; + owl:allValuesFrom xsd:gMonth + ] , + [ rdf:type owl:Restriction ; + owl:onProperty ; + owl:hasValue + ] , + [ rdf:type owl:Restriction ; + owl:onProperty ; + owl:allValuesFrom xsd:gDay + ] , + [ rdf:type owl:Restriction ; + owl:onProperty ; + owl:allValuesFrom xsd:gYear + ] ; + + rdfs:comment "Description of date and time structured with separate values for the various elements of a calendar-clock system. The temporal reference system is fixed to Gregorian Calendar, and the range of year, month, day properties restricted to corresponding XML Schema types xsd:gYear, xsd:gMonth and xsd:gDay, respectively."@en . + + + +### http://www.w3.org/2006/time#TIME:0000006 + + rdf:type owl:Class ; + + rdfs:label "Generalized duration description"@en ; + + rdfs:subClassOf , + [ rdf:type owl:Restriction ; + owl:onProperty ; + owl:maxCardinality "1"^^xsd:nonNegativeInteger + ] , + [ rdf:type owl:Restriction ; + owl:onProperty ; + owl:maxCardinality "1"^^xsd:nonNegativeInteger + ] , + [ rdf:type owl:Restriction ; + owl:onProperty ; + owl:maxCardinality "1"^^xsd:nonNegativeInteger + ] , + [ rdf:type owl:Restriction ; + owl:onProperty ; + owl:maxCardinality "1"^^xsd:nonNegativeInteger + ] , + [ rdf:type owl:Restriction ; + owl:onProperty ; + owl:maxCardinality "1"^^xsd:nonNegativeInteger + ] , + [ rdf:type owl:Restriction ; + owl:onProperty ; + owl:maxCardinality "1"^^xsd:nonNegativeInteger + ] , + [ rdf:type owl:Restriction ; + owl:onProperty ; + owl:cardinality "1"^^xsd:nonNegativeInteger + ] , + [ rdf:type owl:Restriction ; + owl:onProperty ; + owl:maxCardinality "1"^^xsd:nonNegativeInteger + ] ; + + rdfs:comment "Description of temporal extent structured with separate values for the various elements of a calendar-clock system."@en . + + + +### http://www.w3.org/2006/time#TIME:0000007 + + rdf:type owl:Class ; + + rdfs:label "Duration description"@en ; + + rdfs:subClassOf , + [ rdf:type owl:Restriction ; + owl:onProperty ; + owl:allValuesFrom xsd:decimal + ] , + [ rdf:type owl:Restriction ; + owl:onProperty ; + owl:allValuesFrom xsd:decimal + ] , + [ rdf:type owl:Restriction ; + owl:onProperty ; + owl:allValuesFrom xsd:decimal + ] , + [ rdf:type owl:Restriction ; + owl:onProperty ; + owl:allValuesFrom xsd:decimal + ] , + [ rdf:type owl:Restriction ; + owl:onProperty ; + owl:allValuesFrom xsd:decimal + ] , + [ rdf:type owl:Restriction ; + owl:onProperty ; + owl:hasValue + ] , + [ rdf:type owl:Restriction ; + owl:onProperty ; + owl:allValuesFrom xsd:decimal + ] , + [ rdf:type owl:Restriction ; + owl:onProperty ; + owl:allValuesFrom xsd:decimal + ] ; + + rdfs:comment "Description of temporal extent structured with separate values for the various elements of a calendar-clock system. The temporal reference system is fixed to Gregorian Calendar, and the range of each of the numeric properties is restricted to xsd:decimal"@en . + + + +### http://www.w3.org/2006/time#TIME:0000010 + + rdf:type owl:Class ; + + rdfs:label "Generalized year"@en ; + + rdfs:subClassOf ; + + rdfs:comment "Year number - generalization of xsd:gYear, formulated as a text string with a pattern constraint to reproduce the same lexical form as gYear. Note that the value-space is not defined, so a generic OWL2 processor cannot compute ordering relationships of values of this type."@en . + + + +### http://www.w3.org/2006/time#TIME:0000011 + + rdf:type owl:Class ; + + rdfs:label "Temporal duration"@en ; + + rdfs:subClassOf , + [ rdf:type owl:Restriction ; + owl:onProperty ; + owl:cardinality "1"^^xsd:nonNegativeInteger + ] , + [ rdf:type owl:Restriction ; + owl:onProperty ; + owl:cardinality "1"^^xsd:nonNegativeInteger + ] ; + + rdfs:comment "Alternative to time:DurationDescription to support description of a temporal duration other than using a calendar/clock system."@en , + "Duration of a temporal extent expressed as a number scaled by a temporal unit"@en . + + + +### http://www.w3.org/2006/time#TIME:0000012 + + rdf:type owl:Class ; + + rdfs:label "Temporal entity"@en ; + + owl:equivalentClass [ rdf:type owl:Class ; + owl:unionOf ( + + ) + ] ; + + rdfs:subClassOf ; + + rdfs:comment "A temporal interval or instant."@en . + + + +### http://www.w3.org/2006/time#TIME:0000013 + + rdf:type owl:Class ; + + rdfs:label "Time instant"@en ; + + rdfs:subClassOf ; + + owl:disjointWith ; + + rdfs:comment "A temporal entity with zero extent or duration"@en . + + + +### http://www.w3.org/2006/time#TIME:0000014 + + rdf:type owl:Class ; + + rdfs:label "Time interval"@en ; + + rdfs:subClassOf ; + + rdfs:comment "A temporal entity with an extent or duration"@en . + + + +### http://www.w3.org/2006/time#TIME:0000015 + + rdf:type owl:Class ; + + rdfs:label "Proper interval"@en ; + + rdfs:subClassOf ; + + rdfs:comment "A temporal entity with non-zero extent or duration, i.e. for which the value of the beginning and end are different"@en . + + + +### http://www.w3.org/2006/time#TIME:0000016 + + rdf:type owl:Class ; + + rdfs:label "Date-Time interval"@en ; + + rdfs:subClassOf ; + + rdfs:comment "DateTimeInterval is a subclass of ProperInterval, defined using the multi-element DateTimeDescription."@en . + + + +### http://www.w3.org/2006/time#TIME:0000017 + + rdf:type owl:Class ; + + rdfs:label "Temporal position"@en ; + + rdfs:subClassOf , + [ rdf:type owl:Class ; + owl:unionOf ( [ rdf:type owl:Restriction ; + owl:onProperty ; + owl:cardinality "1"^^xsd:nonNegativeInteger + ] + [ rdf:type owl:Restriction ; + owl:onProperty ; + owl:cardinality "1"^^xsd:nonNegativeInteger + ] + ) + ] , + [ rdf:type owl:Restriction ; + owl:onProperty ; + owl:cardinality "1"^^xsd:nonNegativeInteger + ] ; + + rdfs:comment "A temporal position described using either a (nominal) value from an ordinal reference system, or a (numeric) value in a temporal coordinate system. "@en . + + + +### http://www.w3.org/2006/time#TIME:0000018 + + rdf:type owl:Class ; + + rdfs:label "Temporal Reference System"@en ; + + rdfs:subClassOf ; + + rdfs:comment """A temporal reference system, such as a temporal coordinate system (with an origin, direction, and scale), a calendar-clock combination, or a (possibly hierarchical) ordinal system. + +This is a stub class, representing the set of all temporal reference systems."""@en . + + + +### http://www.w3.org/2006/time#TIME:0000019 + + rdf:type owl:Class ; + + rdfs:label "Temporal unit"@en ; + + rdfs:subClassOf ; + + rdfs:comment "A temporal unit of measure, which provides a scale factor for a time quantity."@en ; + + skos:changeNote """Remove enumeration from definition, in order to allow other units to be used when required in other coordinate systems. +NOTE: existing units are still present as members of the class, but the class membership is now open. + +In the original OWL-Time the following constraint appeared: + owl:oneOf ( + time:unitSecond + time:unitMinute + time:unitHour + time:unitDay + time:unitWeek + time:unitMonth + time:unitYear + ) ;"""@en . + + + +### http://www.w3.org/2006/time#Year + +:Year rdf:type owl:Class ; + + rdfs:subClassOf , + [ rdf:type owl:Restriction ; + owl:onProperty ; + owl:cardinality "0"^^xsd:nonNegativeInteger + ] , + [ rdf:type owl:Restriction ; + owl:onProperty ; + owl:cardinality "0"^^xsd:nonNegativeInteger + ] , + [ rdf:type owl:Restriction ; + owl:onProperty ; + owl:cardinality "1"^^xsd:nonNegativeInteger + ] , + [ rdf:type owl:Restriction ; + owl:onProperty ; + owl:cardinality "0"^^xsd:nonNegativeInteger + ] , + [ rdf:type owl:Restriction ; + owl:onProperty ; + owl:cardinality "0"^^xsd:nonNegativeInteger + ] , + [ rdf:type owl:Restriction ; + owl:onProperty ; + owl:cardinality "0"^^xsd:nonNegativeInteger + ] , + [ rdf:type owl:Restriction ; + owl:onProperty ; + owl:cardinality "0"^^xsd:nonNegativeInteger + ] ; + + rdfs:comment "Deprecated because it is only an orphaned example from the 2006 draft"^^xsd:string , + "Duration year, not a calendar year!"^^xsd:string ; + + owl:deprecated "true"^^xsd:boolean . + + + +### http://www.w3.org/2006/timezone#TIME:0000021 + + rdf:type owl:Class ; + + rdfs:label "TimeZone" ; + + rdfs:subClassOf . + + + + + +################################################################# +# +# Individuals +# +################################################################# + + +### http://www.opengis.net/def/uom/ISO-8601/0/Gregorian + + rdf:type owl:NamedIndividual . + + + +### http://www.w3.org/2006/time#Friday + +:Friday rdf:type owl:NamedIndividual , + ; + + rdfs:label "Friday"@en . + + + +### http://www.w3.org/2006/time#Monday + +:Monday rdf:type owl:NamedIndividual , + ; + + rdfs:label "Monday"@en . + + + +### http://www.w3.org/2006/time#Saturday + +:Saturday rdf:type owl:NamedIndividual , + ; + + rdfs:label "Saturday"@en . + + + +### http://www.w3.org/2006/time#Sunday + +:Sunday rdf:type owl:NamedIndividual , + ; + + rdfs:label "Sunday"@en . + + + +### http://www.w3.org/2006/time#Thursday + +:Thursday rdf:type owl:NamedIndividual , + ; + + rdfs:label "Thursday"@en . + + + +### http://www.w3.org/2006/time#Tuesday + +:Tuesday rdf:type owl:NamedIndividual , + ; + + rdfs:label "Tuesday"@en . + + + +### http://www.w3.org/2006/time#Wednesday + +:Wednesday rdf:type owl:NamedIndividual , + ; + + rdfs:label "Wednesday"@en . + + + +### http://www.w3.org/2006/time#unitDay + +:unitDay rdf:type owl:NamedIndividual , + ; + + rdfs:label "Day (unit of temporal duration)"@en . + + + +### http://www.w3.org/2006/time#unitHour + +:unitHour rdf:type owl:NamedIndividual , + ; + + rdfs:label "Hour (unit of temporal duration)"@en . + + + +### http://www.w3.org/2006/time#unitMinute + +:unitMinute rdf:type owl:NamedIndividual , + ; + + rdfs:label "Minute (unit of temporal duration)"@en . + + + +### http://www.w3.org/2006/time#unitMonth + +:unitMonth rdf:type owl:NamedIndividual , + ; + + rdfs:label "Month (unit of temporal duration)"@en . + + + +### http://www.w3.org/2006/time#unitSecond + +:unitSecond rdf:type owl:NamedIndividual , + ; + + rdfs:label "Second (unit of temporal duration)"@en . + + + +### http://www.w3.org/2006/time#unitWeek + +:unitWeek rdf:type owl:NamedIndividual , + ; + + rdfs:label "Week (unit of temporal duration)"@en . + + + +### http://www.w3.org/2006/time#unitYear + +:unitYear rdf:type owl:NamedIndividual , + ; + + rdfs:label "Year (unit of temporal duration)"@en . + + + +[ dct:identifier ; + foaf:mbox +] . +[ foaf:mbox +] . +[ foaf:isPrimaryTopicOf +] . + + +################################################################# +# +# Annotations +# +################################################################# + + + rdfs:label "Format"@en ; + + dct:issued "1999-07-02"^^xsd:date ; + + dct:modified "2008-01-14"^^xsd:date ; + + skos:note "A second property with the same name as this property has been declared in the dcterms: namespace (http://purl.org/dc/terms/). See the Introduction to the document \"DCMI Metadata Terms\" (http://dublincore.org/documents/dcmi-terms/) for an explanation."@en ; + + dct:description "Examples of dimensions include size and duration. Recommended best practice is to use a controlled vocabulary such as the list of Internet Media Types [MIME]."@en ; + + rdfs:comment "The file format, physical medium, or dimensions of the resource."@en ; + + dct:hasVersion ; + + rdfs:isDefinedBy . + + + + rdfs:label "Creator"@en ; + + dct:issued "1999-07-02"^^xsd:date ; + + dct:modified "2008-01-14"^^xsd:date ; + + skos:note "A second property with the same name as this property has been declared in the dcterms: namespace (http://purl.org/dc/terms/). See the Introduction to the document \"DCMI Metadata Terms\" (http://dublincore.org/documents/dcmi-terms/) for an explanation."@en ; + + rdfs:comment "An entity primarily responsible for making the resource."@en ; + + dct:description "Examples of a Creator include a person, an organization, or a service. Typically, the name of a Creator should be used to indicate the entity."@en ; + + dct:hasVersion ; + + rdfs:isDefinedBy . + + + + rdfs:label "Description"@en ; + + dct:issued "1999-07-02"^^xsd:date ; + + dct:modified "2008-01-14"^^xsd:date ; + + skos:note "A second property with the same name as this property has been declared in the dcterms: namespace (http://purl.org/dc/terms/). See the Introduction to the document \"DCMI Metadata Terms\" (http://dublincore.org/documents/dcmi-terms/) for an explanation."@en ; + + rdfs:comment "An account of the resource."@en ; + + dct:description "Description may include but is not limited to: an abstract, a table of contents, a graphical representation, or a free-text account of the resource."@en ; + + dct:hasVersion ; + + rdfs:isDefinedBy . + + + + rdfs:label "Contributor"@en ; + + dct:issued "1999-07-02"^^xsd:date ; + + dct:modified "2008-01-14"^^xsd:date ; + + skos:note "A second property with the same name as this property has been declared in the dcterms: namespace (http://purl.org/dc/terms/). See the Introduction to the document \"DCMI Metadata Terms\" (http://dublincore.org/documents/dcmi-terms/) for an explanation."@en ; + + rdfs:comment "An entity responsible for making contributions to the resource."@en ; + + dct:description "Examples of a Contributor include a person, an organization, or a service. Typically, the name of a Contributor should be used to indicate the entity."@en ; + + dct:hasVersion ; + + rdfs:isDefinedBy . + + + + rdfs:label "Language"@en ; + + dct:issued "1999-07-02"^^xsd:date ; + + dct:modified "2008-01-14"^^xsd:date ; + + rdfs:comment "A language of the resource."@en ; + + skos:note "A second property with the same name as this property has been declared in the dcterms: namespace (http://purl.org/dc/terms/). See the Introduction to the document \"DCMI Metadata Terms\" (http://dublincore.org/documents/dcmi-terms/) for an explanation."@en ; + + dct:description "Recommended best practice is to use a controlled vocabulary such as RFC 4646 [RFC4646]."@en ; + + dct:hasVersion ; + + rdfs:isDefinedBy ; + + rdfs:seeAlso . + + + + rdfs:label "Identifier"@en ; + + dct:issued "1999-07-02"^^xsd:date ; + + dct:modified "2008-01-14"^^xsd:date ; + + skos:note "A second property with the same name as this property has been declared in the dcterms: namespace (http://purl.org/dc/terms/). See the Introduction to the document \"DCMI Metadata Terms\" (http://dublincore.org/documents/dcmi-terms/) for an explanation."@en ; + + rdfs:comment "An unambiguous reference to the resource within a given context."@en ; + + dct:description "Recommended best practice is to identify the resource by means of a string conforming to a formal identification system. "@en ; + + dct:hasVersion ; + + rdfs:isDefinedBy . + + + + dct:modified "2012-06-14"^^xsd:date ; + + dct:title "Dublin Core Metadata Element Set, Version 1.1"@en ; + + dct:publisher . + + + + rdfs:label "Publisher"@en ; + + dct:issued "1999-07-02"^^xsd:date ; + + dct:modified "2008-01-14"^^xsd:date ; + + skos:note "A second property with the same name as this property has been declared in the dcterms: namespace (http://purl.org/dc/terms/). See the Introduction to the document \"DCMI Metadata Terms\" (http://dublincore.org/documents/dcmi-terms/) for an explanation."@en ; + + rdfs:comment "An entity responsible for making the resource available."@en ; + + dct:description "Examples of a Publisher include a person, an organization, or a service. Typically, the name of a Publisher should be used to indicate the entity."@en ; + + dct:hasVersion ; + + rdfs:isDefinedBy . + + + + rdfs:label "Source"@en ; + + dct:issued "1999-07-02"^^xsd:date ; + + dct:modified "2008-01-14"^^xsd:date ; + + rdfs:comment "A related resource from which the described resource is derived."@en ; + + skos:note "A second property with the same name as this property has been declared in the dcterms: namespace (http://purl.org/dc/terms/). See the Introduction to the document \"DCMI Metadata Terms\" (http://dublincore.org/documents/dcmi-terms/) for an explanation."@en ; + + dct:description "The described resource may be derived from the related resource in whole or in part. Recommended best practice is to identify the related resource by means of a string conforming to a formal identification system."@en ; + + dct:hasVersion ; + + rdfs:isDefinedBy . + + + + rdfs:label "Rights"@en ; + + dct:issued "1999-07-02"^^xsd:date ; + + dct:modified "2008-01-14"^^xsd:date ; + + skos:note "A second property with the same name as this property has been declared in the dcterms: namespace (http://purl.org/dc/terms/). See the Introduction to the document \"DCMI Metadata Terms\" (http://dublincore.org/documents/dcmi-terms/) for an explanation."@en ; + + rdfs:comment "Information about rights held in and over the resource."@en ; + + dct:description "Typically, rights information includes a statement about various property rights associated with the resource, including intellectual property rights."@en ; + + dct:hasVersion ; + + rdfs:isDefinedBy . + + + + rdfs:label "Coverage"@en ; + + dct:issued "1999-07-02"^^xsd:date ; + + dct:modified "2008-01-14"^^xsd:date ; + + skos:note "A second property with the same name as this property has been declared in the dcterms: namespace (http://purl.org/dc/terms/). See the Introduction to the document \"DCMI Metadata Terms\" (http://dublincore.org/documents/dcmi-terms/) for an explanation."@en ; + + dct:description "Spatial topic and spatial applicability may be a named place or a location specified by its geographic coordinates. Temporal topic may be a named period, date, or date range. A jurisdiction may be a named administrative entity or a geographic place to which the resource applies. Recommended best practice is to use a controlled vocabulary such as the Thesaurus of Geographic Names [TGN]. Where appropriate, named places or time periods can be used in preference to numeric identifiers such as sets of coordinates or date ranges."@en ; + + rdfs:comment "The spatial or temporal topic of the resource, the spatial applicability of the resource, or the jurisdiction under which the resource is relevant."@en ; + + dct:hasVersion ; + + rdfs:isDefinedBy . + + + + rdfs:label "Subject"@en ; + + dct:issued "1999-07-02"^^xsd:date ; + + dct:modified "2012-06-14"^^xsd:date ; + + skos:note "A second property with the same name as this property has been declared in the dcterms: namespace (http://purl.org/dc/terms/). See the Introduction to the document \"DCMI Metadata Terms\" (http://dublincore.org/documents/dcmi-terms/) for an explanation."@en ; + + rdfs:comment "The topic of the resource."@en ; + + dct:description "Typically, the subject will be represented using keywords, key phrases, or classification codes. Recommended best practice is to use a controlled vocabulary."@en ; + + dct:hasVersion ; + + rdfs:isDefinedBy . + + + + rdfs:label "Type"@en ; + + dct:issued "1999-07-02"^^xsd:date ; + + dct:modified "2008-01-14"^^xsd:date ; + + skos:note "A second property with the same name as this property has been declared in the dcterms: namespace (http://purl.org/dc/terms/). See the Introduction to the document \"DCMI Metadata Terms\" (http://dublincore.org/documents/dcmi-terms/) for an explanation."@en ; + + dct:description "Recommended best practice is to use a controlled vocabulary such as the DCMI Type Vocabulary [DCMITYPE]. To describe the file format, physical medium, or dimensions of the resource, use the Format element."@en ; + + rdfs:comment "The nature or genre of the resource."@en ; + + dct:hasVersion ; + + rdfs:isDefinedBy . + + + + rdfs:label "Date"@en ; + + dct:issued "1999-07-02"^^xsd:date ; + + dct:modified "2008-01-14"^^xsd:date ; + + rdfs:comment "A point or period of time associated with an event in the lifecycle of the resource."@en ; + + skos:note "A second property with the same name as this property has been declared in the dcterms: namespace (http://purl.org/dc/terms/). See the Introduction to the document \"DCMI Metadata Terms\" (http://dublincore.org/documents/dcmi-terms/) for an explanation."@en ; + + dct:description "Date may be used to express temporal information at any level of granularity. Recommended best practice is to use an encoding scheme, such as the W3CDTF profile of ISO 8601 [W3CDTF]."@en ; + + dct:hasVersion ; + + rdfs:isDefinedBy . + + + + rdfs:label "Relation"@en ; + + dct:issued "1999-07-02"^^xsd:date ; + + dct:modified "2008-01-14"^^xsd:date ; + + rdfs:comment "A related resource."@en ; + + skos:note "A second property with the same name as this property has been declared in the dcterms: namespace (http://purl.org/dc/terms/). See the Introduction to the document \"DCMI Metadata Terms\" (http://dublincore.org/documents/dcmi-terms/) for an explanation."@en ; + + dct:description "Recommended best practice is to identify the related resource by means of a string conforming to a formal identification system. "@en ; + + dct:hasVersion ; + + rdfs:isDefinedBy . + + + + rdfs:label "Title"@en ; + + dct:issued "1999-07-02"^^xsd:date ; + + dct:modified "2008-01-14"^^xsd:date ; + + rdfs:comment "A name given to the resource."@en ; + + skos:note "A second property with the same name as this property has been declared in the dcterms: namespace (http://purl.org/dc/terms/). See the Introduction to the document \"DCMI Metadata Terms\" (http://dublincore.org/documents/dcmi-terms/) for an explanation."@en ; + + dct:hasVersion ; + + rdfs:isDefinedBy . + + + + +### Generated by the OWL API (version 3.4.2) http://owlapi.sourceforge.net + diff --git a/src/test/resources/repo/input/nest/NEST.owl b/src/test/resources/repo/input/nest/NEST.owl new file mode 100644 index 0000000..c006d2f --- /dev/null +++ b/src/test/resources/repo/input/nest/NEST.owl @@ -0,0 +1,7047 @@ + + + + + + + + + + + + + + + + + + + + + + + + V1.2 + + + + Nutritional Epidemiological Standards + + + + Chen Yang + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + ontoad:AD000403 + 9 + + + + ontoad:AD000403 + ONTOAD ontology + + + + ontoad:AD000403 + Sociodemographic factors + + + + edam:data_1052 + 7 + + + + edam:data_1052 + A Uniform Resource Locator (URL). + + + + edam:data_1052 + EDAM ontology + + + + edam:data_1052 + URL + + + + edam:data_1188 + 7 + + + + edam:data_1188 + Digital Object Identifier (DOI) of a published article. + + + + edam:data_1188 + EDAM ontology + + + + edam:data_1188 + DOI + + + + edam:topic_0121 + 15 + + + + edam:topic_0121 + Includes metaproteomics: proteomics analysis of an environmental sample. Proteomics includes any methods (especially high-throughput) that separate, characterize and identify expressed proteins such as mass spectrometry, two-dimensional gel electrophoresis and protein microarrays, as well as in-silico methods that perform proteolytic or mass calculations on a protein sequence and other analyses of protein production data, for example in different cells or tissues. Protein and peptide identification, especially in the study of whole proteomes of organisms. + + + + edam:topic_0121 + EDAM ontology + + + + edam:topic_0121 + Proteomics + + + + edam:topic_0622 + 15 + + + + edam:topic_0622 + Whole genomes of one or more organisms, or genomes in general, such as meta-information on genomes, genome projects, gene names etc. + + + + edam:topic_0622 + EDAM ontology + + + + edam:topic_0622 + Genomics + + + + edam:topic_3172 + 15 + + + + edam:topic_3172 + The systematic study of metabolites, the chemical processes they are involved, and the chemical fingerprints of specific cellular processes in a whole cell, tissue, organ or organism. + + + + edam:topic_3172 + EDAM ontology + + + + edam:topic_3172 + Metabolomics + + + + edam:topic_3308 + 15 + + + + edam:topic_3308 + The analysis of transcriptomes, or a set of all the RNA molecules in a specific cell, tissue etc. + + + + edam:topic_3308 + EDAM ontology + + + + edam:topic_3308 + Transcriptomics + + + + edam:topic_3360 + 15 + + + + edam:topic_3360 + Objective indicators of biological state often used to assess health, and determinate treatment. + + + + edam:topic_3360 + EDAM ontology + + + + edam:topic_3360 + Biomarkers + + + + edam:topic_3391 + 15 + + + + edam:topic_3391 + The collective characterisation and quantification of pools of biological molecules that translate into the structure, function, and dynamics of an organism or organisms. + + + + edam:topic_3391 + EDAM ontology + + + + edam:topic_3391 + Omics + + + + ncit:C120914 + 5 + + + + ncit:C120914 + A measurement of a subject's physical activity or movement. + + + + ncit:C120914 + NCIT ontology + + + + ncit:C120914 + Physical activity measurement + + + + ncit:C127781 + 6 + + + + ncit:C127781 + A non-random process used to select a study population in which the participants have been selected based on convenience or with a particular purpose in mind. + + + + ncit:C127781 + NCIT ontology + + + + ncit:C127781 + Non-Probability Sampling Method + + + + ncit:C137684 + Weekend + + + + ncit:C142610 + 4,5 + + + + ncit:C142610 + 1) Required or expected data that is not present, which may be due to non-completion or corruption. 2) Lack of some information or incomplete information for some study participants. Usually (but not always) the term refers to data missing in ways deviating from the study design. + + + + ncit:C142610 + 1) NICT ontology 2) Porta M. A dictionaryof epidemiology. 6th ed. [Internet]. + + + + ncit:C142610 + Missing data + + + + ncit:C142618 + Any measurement that is not subject to observer assessment, such as those registered by an instrument. + + + + ncit:C142618 + NCIT ontology + + + + ncit:C142618 + Objective measurement + + + + ncit:C142645 + 2 + + + + ncit:C142645 + A variable that directly or indirectly impacts the outcome of a clinical trial. + + + + ncit:C142645 + NICT ontology + + + + ncit:C142645 + Prognostic Covariate + + + + ncit:C142664 + 9 + + + + ncit:C142664 + The interval of time during which subjects are to be enrolled in a clinical study. + + + + ncit:C142664 + NCIT ontology + + + + ncit:C142664 + Recruitment period + + + + ncit:C142704 + 2 + + + + ncit:C142704 + Specific, essential aspects of an investigation that are detailed, including structure, blinding, dosage, and participant demographics. + + + + ncit:C142704 + NCIT ontology + + + + ncit:C142704 + Study description + + + + ncit:C16033 + 10 + + + + ncit:C16033 + The process by which information about the health status of an individual is obtained after a study has officially closed; an activity that continues something that has already begun or that repeats something that has already been done. + + + + ncit:C16033 + NCIT ontology + + + + ncit:C16033 + follow-ups + + + + ncit:C16273 + 7 + + + + ncit:C16273 + Consumption of liquids containing ethanol, including the behaviors associated with drinking the alcohol. + + + + ncit:C16273 + NCIT ontology + + + + ncit:C16273 + Alcohol consumption + + + + ncit:C17048 + 7 + + + + ncit:C17048 + A predetermined set of questions. + + + + ncit:C17048 + NCIT ontology + + + + ncit:C17048 + Questionnaires + + + + ncit:C17651 + The ratio of the abdominal circumference at the navel to maximum hip and buttocks circumference; looks at the proportion of fat stored on the body around the waist and hip. Carrying extra weight around the waist is a greater health risk than carrying extra weight around the hips or thighs. + + + + ncit:C17651 + NCIT ontology + + + + ncit:C17651 + Waist-Hip Ratio + + + + ncit:C18241 + 3 + + + + ncit:C18241 + NCIT ontology + + + + ncit:C18241 + General population + + + + ncit:C19924 + 4 + + + + ncit:C19924 + An investigator who is responsible for all aspects of the conduct of a study. + + + + ncit:C19924 + NCIT ontology + + + + ncit:C19924 + Principal Investigator + + + + ncit:C25461 + 5 + + + + ncit:C25461 + A person acting as a channel for communication between groups or on behalf of a group. + + + + ncit:C25461 + NCIT ontology + + + + ncit:C25461 + Contact person + + + + ncit:C25464 + 2 + + + + ncit:C25464 + A collective generic term that refers here to a wide variety of dependencies, areas of special sovereignty, uninhabited islands, and other entities in addition to the traditional countries or independent states. + + + + ncit:C25464 + NCIT ontology + + + + ncit:C25464 + Country + + + + ncit:C25662 + 14 + + + + ncit:C25662 + The selection and obtaining of small representative quantities of biological material for the purpose of analysis; also, in biomedical statistics, sampling is the selection and implementation of statistical observations in order to estimate properties of an underlying population; also, in environmental science, the collection of representative specimens analyzed to characterize site conditions. + + + + ncit:C25662 + NCIT ontology + + + + ncit:C25662 + Sampling + + + + ncit:C43545 + A method to assess body composition, i.e., the relative percentages of body weight comprised of fat tissue and lean body mass. It is based on the principle that the resistance to an applied electric current is inversely related to the amount of lean body mass within the body. Impedance is greatest in fat tissue, which contains only 10-20% water, while lean body mass, which contains 70-75% water, allows the signal to pass much more easily. + + + + ncit:C43545 + NCIT ontology + + + + ncit:C43545 + Bioelectric impedance analysis + + + + ncit:C48045 + Precision + + + + ncit:C48789 + A technique for scanning bone and measuring bone mineral density (BMD). A DXA scanner produces 2 X-ray beams, each with different energy levels. One beam is high energy while the other is low energy. The amount of x-rays that pass through the bone is measured for each beam. This will vary depending on the thickness of the bone. Based on the difference between the 2 beams, the bone density can be measured. + + + + ncit:C48789 + NCIT ontology + + + + ncit:C48789 + Dual X-ray Absorptiometry + + + + ncit:C48914 + 7 + + + + ncit:C48914 + To transfer a file or program to a central computer from a smaller computer or a computer at a remote location. + + + + ncit:C48914 + NCIT ontology + + + + ncit:C48914 + Upload + + + + ncit:C49647 + 8 + + + + ncit:C49647 + A characteristic of a treatment regimen employed as a comparator against which the study treatment is evaluated. + + + + ncit:C49647 + NCIT ontology + + + + ncit:C49647 + Control type + + + + ncit:C52095 + 11 + + + + ncit:C52095 + Data about data; information that describes another set of data. + + + + ncit:C52095 + NCIT ontology + + + + ncit:C52095 + Metadata + + + + ncit:C60776 + 5 + + + + ncit:C60776 + Information regarding the means of contacting a person or group. + + + + ncit:C60776 + NCIT ontology + + + + ncit:C60776 + Contact information + + + + ncit:C68631 + 1 + + + + ncit:C68631 + The name applied to a scientific investigation. + + + + ncit:C68631 + NCIT ontology + + + + ncit:C68631 + Study Name + + + + ncit:C70757 + 8 + + + + ncit:C70757 + A clinical study status designating the study has been stopped prematurely and will not resume. Subject enrollment stopped. No participants are treated or being followed up. + + + + ncit:C70757 + NCIT ontology + + + + ncit:C70757 + Study terminated + + + + ncit:C70817 + 7 + + + + ncit:C70817 + The formal plan of an experiment or research activity, including the objective, rationale, design, materials and methods for the conduct of the study; intervention description, and method of data analysis. + + + + ncit:C70817 + NCIT ontology + + + + ncit:C70817 + Study Protocol + + + + ncit:C70833 + 3 + + + + ncit:C70833 + A target study population with characteristics, including inclusion and exclusion criteria, precisely defined in the study protocol. This is a population to which the study results could be reasonably generalized. + + + + ncit:C70833 + NCIT ontology + + + + ncit:C70833 + Study population + + + + ncit:C71492 + 6 + + + + ncit:C71492 + NCIT ontology + + + + ncit:C71492 + Sampling method + + + + ncit:C71517 + 6 + + + + ncit:C71517 + A random process used to select a study population in which each participant has an equal chance of being chosen. + + + + ncit:C71517 + NCIT ontology + + + + ncit:C71517 + Equal Probability Sampling Method + + + + ncit:C74528 + An individual's perspective or subjective interpretation of an event or information. + + + + ncit:C74528 + NCIT ontology + + + + ncit:C74528 + Self-report + + + + ncit:C74528 + Without assessors/Self-report + + + + ncit:C78688 + Inter-rater reliability + + + + ncit:C86936 + Weekday + + + + ncit:C92648 + 2 + + + + ncit:C92648 + Body weight measurement: a measurement of the body weight of a subject; body weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms. + + + + ncit:C92648 + NCIT ontology, MeSH + + + + ncit:C92648 + Body weight measurement + + + + ncit:C93415 + 3 + + + + ncit:C93415 + The reason for performing a study in terms of the scientific questions to be answered by the analysis of data collected during the study. + + + + ncit:C93415 + NCIT ontology + + + + ncit:C93415 + Study objective + + + + ncit:C93495 + 1 + + + + ncit:C93495 + The non-unique initials or abbreviated name used for identification. + + + + ncit:C93495 + NCIT ontology + + + + ncit:C93495 + Acronym + + + + ncit:C94131 + 7 + + + + ncit:C94131 + The textual representation of the linked page. + + + + ncit:C94131 + NCIT ontology + + + + ncit:C94131 + Study reference link page description + + + + ncit:C94730 + The season between the winter solstice and the vernal equinox. + + + + ncit:C94730 + NCIT ontology + + + + ncit:C94730 + Winter + + + + ncit:C94731 + The season between the vernal equinox and the summer solstice. + + + + ncit:C94731 + NCIT ontology + + + + ncit:C94731 + Spring + + + + ncit:C94732 + The season between the summer solstice and the autumnal equinox. + + + + ncit:C94732 + NCIT ontology + + + + ncit:C94732 + Summer + + + + ncit:C94733 + The season between the autumnal equinox and the winter solstice. + + + + ncit:C94733 + NCIT ontology + + + + ncit:C94733 + Autumn + + + + one:T00001 + I-inverstigation; S-study; A-Assay. + + + + one:T00001 + ISA framework + + + + one:T00001 + Minimal data requirement-descriptor for investigation + + + + one:T00002 + 7 + + + + one:T00002 + Mariona Pinart et al. (2018). Joint Data Analysis in Nutritional Epidemiology: Identification of Observational Studies and Minimal Requirements. The Journal of Nutrition:148(2):285-297. + + + + one:T00002 + Study registration number + + + + one:T00003 + 9 + + + + one:T00003 + ONE ontology + + + + one:T00003 + Data sharing policy + + + + one:T00004 + 10 + + + + one:T00004 + ONE ontology + + + + one:T00004 + Aggregate data sharing policy + + + + one:T00005 + 10, 11, 12 + + + + one:T00005 + ONE ontology + + + + one:T00005 + Publicly accessible + + + + one:T00006 + 10, 11, 12 + + + + one:T00006 + ONE ontology + + + + one:T00006 + Accessible upon request + + + + one:T00007 + 10, 11, 12 + + + + one:T00007 + ONE ontology + + + + one:T00007 + Not publicly accessible + + + + one:T00008 + 12 + + + + one:T00008 + ONE ontology + + + + one:T00008 + Data analysis permission + + + + one:T00009 + 12 + + + + one:T00009 + ONE ontology + + + + one:T00009 + accessible raw data + + + + one:T00010 + 12 + + + + one:T00010 + ONE ontology + + + + one:T00010 + federated analysis + + + + one:T00011 + I-inverstigation; S-study; A-Assay. + + + + one:T00011 + ISA framework + + + + one:T00011 + Minimal data requirement-descriptor for study + + + + one:T00012 + 5 + + + + one:T00012 + ONE ontology + + + + one:T00012 + Population representativeness + + + + one:T00013 + 5 + + + + one:T00013 + ONE ontology + + + + one:T00013 + National level + + + + one:T00014 + 5 + + + + one:T00014 + ONE ontology + + + + one:T00014 + Subnational level + + + + one:T00015 + 5 + + + + one:T00015 + ONE ontology + + + + one:T00015 + Community level + + + + one:T00016 + 6 + + + + one:T00016 + Mariona Pinart et al. (2018). Joint Data Analysis in Nutritional Epidemiology: Identification of Observational Studies and Minimal Requirements. The Journal of Nutrition:148(2):285-297. + + + + one:T00016 + ONE ontology + + + + one:T00016 + Simple random sampling + + + + one:T00017 + 6 + + + + one:T00017 + Mariona Pinart et al. (2018). Joint Data Analysis in Nutritional Epidemiology: Identification of Observational Studies and Minimal Requirements. The Journal of Nutrition:148(2):285-297. + + + + one:T00017 + ONE ontology + + + + one:T00017 + Stratified random sampling + + + + one:T00018 + 6 + + + + one:T00018 + Mariona Pinart et al. (2018). Joint Data Analysis in Nutritional Epidemiology: Identification of Observational Studies and Minimal Requirements. The Journal of Nutrition:148(2):285-297. + + + + one:T00018 + ONE ontology + + + + one:T00018 + Multi-stage sampling + + + + one:T00019 + 6 + + + + one:T00019 + Mariona Pinart et al. (2018). Joint Data Analysis in Nutritional Epidemiology: Identification of Observational Studies and Minimal Requirements. The Journal of Nutrition:148(2):285-297. + + + + one:T00019 + ONE ontology + + + + one:T00019 + Voluntary response sampling + + + + one:T00020 + 6 + + + + one:T00020 + Mariona Pinart et al. (2018). Joint Data Analysis in Nutritional Epidemiology: Identification of Observational Studies and Minimal Requirements. The Journal of Nutrition:148(2):285-297. + + + + one:T00020 + ONE ontology + + + + one:T00020 + Judgement sampling + + + + one:T00021 + 6 + + + + one:T00021 + Mariona Pinart et al. (2018). Joint Data Analysis in Nutritional Epidemiology: Identification of Observational Studies and Minimal Requirements. The Journal of Nutrition:148(2):285-297. + + + + one:T00021 + ONE ontology + + + + one:T00021 + Convenience sampling + + + + one:T00022 + 11 + + + + one:T00022 + ONE ontology + + + + one:T00022 + Total number of males recruited + + + + one:T00023 + 11 + + + + one:T00023 + ONE ontology + + + + one:T00023 + Total number of females recruited + + + + one:T00024 + 12 + + + + one:T00024 + ONE ontology + + + + one:T00024 + Participants age range + + + + one:T00025 + 12 + + + + one:T00025 + ONE ontology + + + + one:T00025 + age.min + + + + one:T00026 + 12 + + + + one:T00026 + ONE ontology + + + + one:T00026 + age.max + + + + one:T00027 + I-inverstigation; S-study; A-Assay. + + + + one:T00027 + ISA framework + + + + one:T00027 + Minimal data requirement-descriptor for assay + + + + one:T00028 + 5 + + + + one:T00028 + ONE ontology + + + + one:T00028 + Objective measurement + + + + one:T00029 + 5 + + + + one:T00029 + ONE ontology + + + + one:T00029 + Subjective measurement + + + + one:T00101 + 1 + + + + one:T00101 + The number of participants divided by the number eligible that were ever contacted. + + + + one:T00101 + The American Association for Public Opinion Research. Standard definitions: final dispositions of case codes and outcome rates for surveys. 9th ed. Oakbrook Terrace (IL): AAPOR; 2016. + + + + one:T00101 + Cooperation rate + + + + one:T00102 + 3 + + + + one:T00102 + Diagnosis: the process of determining the health status and the factors responsible for it; may be applied to an individual, family, group, or society. The term is applied both to the process of determination and to its findings. + + + + one:T00102 + Porta M. A dictionary of epidemiology. 6th ed. [Internet]. + + + + one:T00102 + Method for confirming diagnosis + + + + one:T00103 + 3 + + + + one:T00103 + Diagnosis: the process of determining the health status and the factors responsible for it; may be applied to an individual, family, group, or society. The term is applied both to the process of determination and to its findings. + + + + one:T00103 + Porta M. A dictionary of epidemiology. 6th ed. [Internet]. + + + + one:T00103 + Non-validated diagnosis + + + + one:T00104 + 4 + + + + one:T00104 + Missing data-exposure + + + + one:T00105 + 4 + + + + one:T00105 + Missing data-outcome + + + + one:T00106 + 5 + + + + one:T00106 + Missing completely at random: There are no systematic differences between the missing values and the observed values; Missing at random: Any systematic difference between the missing values and the observed values can be explained by differences in observed data. + + + + one:T00106 + Porta M. A dictionary of epidemiology. 6th ed. [Internet]. + + + + one:T00106 + Missing data-missing (completely) at random + + + + one:T00107 + 5 + + + + one:T00107 + Missing not at random: Even after the observed data are taken into account, systematic differences remain between the missing values and the observed values. + + + + one:T00107 + Porta M. A dictionary of epidemiology. 6th ed. [Internet]. + + + + one:T00107 + Missing data-missing not at random + + + + one:T00108 + 7 + + + + one:T00108 + Representative sample: A sample that to a large extent resembles a population of interest. + + + + one:T00108 + Porta M. A dictionaryof epidemiology. 6th ed. [Internet]. + + + + one:T00108 + Sample representativeness + + + + one:T00109 + 7 + + + + one:T00109 + Representative sample: A sample that to a large extent resembles a population of interest. + + + + one:T00109 + Porta M. A dictionaryof epidemiology. 6th ed. [Internet]. + + + + one:T00109 + Representative sample + + + + one:T00110 + 7 + + + + one:T00110 + Representative sample: A sample that to a large extent resembles a population of interest. + + + + one:T00110 + Porta M. A dictionaryof epidemiology. 6th ed. [Internet]. + + + + one:T00110 + Non-representative sample + + + + one:T00111 + 8 + + + + one:T00111 + Incidence cases + + + + one:T00112 + 9 + + + + one:T00112 + Control group from same population as cases + + + + one:T00113 + 9 + + + + one:T00113 + Control group from similar population as cases + + + + one:T00114 + 9 + + + + one:T00114 + Control group from another population + + + + one:T00115 + All seasons + + + + one:T00116 + In a single country there may be a wide diversity of soil and climatic conditions, resulting in significant variance in food composition.Variations in food marketing and food preparation whthin different parts of a country-or between countries in the case of a multicountry database-may also produce notable variance. For these reasons, geographically specific data may be presented in the database as a supplement to nationwide and/or region-wide averages. + + + + one:T00116 + Greenfield H et al. Food composition data: production, management and use. 2nd ed. Rome (Italy): FAO UN; 2003. + + + + one:T00116 + Geographically-specific food composition data + + + + one:T00117 + 1 + + + + one:T00117 + Standard operating procedures (SOP): detailed, written instructions to achieve uniformity of the performance of a specific function. + + + + one:T00117 + Bergdahl M et al. Handbook on data quality assessment methods and tools. Wiesbaden (Germany): European Commision Eurostat; 2007. + + + + one:T00117 + Training of assessor + + + + one:T00119 + Trained assessor + + + + one:T00120 + Standard operating procedures (SOP): detailed, written instructions to achieve uniformity of the performance of a specific function. + + + + one:T00120 + Bergdahl M et al. Handbook on data quality assessment methods and tools. Wiesbaden (Germany): European Commision Eurostat; 2007. + + + + one:T00120 + Trained assessors using Standard Operating Procedures + + + + one:T00121 + Standard operating procedures (SOP): detailed, written instructions to achieve uniformity of the performance of a specific function. + + + + one:T00121 + Bergdahl M et al. Handbook on data quality assessment methods and tools. Wiesbaden (Germany): European Commision Eurostat; 2007. + + + + one:T00121 + Trained assessors not using Standard Operating Procedures + + + + one:T00122 + Standard operating procedures (SOP): detailed, written instructions to achieve uniformity of the performance of a specific function. + + + + one:T00122 + Bergdahl M et al. Handbook on data quality assessment methods and tools. Wiesbaden (Germany): European Commision Eurostat; 2007. + + + + one:T00122 + Untrained assessors not using Standard Operating Procedures + + + + one:T00123 + Measured with no clothing instructions by an assessor + + + + one:T00124 + Measured naked or with only light clothing by an assessor + + + + one:T00125 + 3 + + + + one:T00125 + Body height: The distance from the sole to the crown of the head with body standing on a flat surface and fully extended. + + + + one:T00125 + MeSH + + + + one:T00125 + Height measurement + + + + one:T00126 + Measured with shoes + + + + one:T00127 + Measured barefoot + + + + one:T00128 + 4 + + + + one:T00128 + Waist circumference: The measurement around the body at the level of the abdomen and just above the hip bone. The measurement is usually taken immediately after exhalation. + + + + one:T00128 + MeSH + + + + one:T00128 + Waist circumference measurement + + + + one:T00129 + Measured with no clothing instructions + + + + one:T00130 + Measured naked or with only light clothing + + + + one:T00131 + Assessed using pictograms or silhouettes + + + + one:T00132 + 6 + + + + one:T00132 + Adiposity: The amount of fat or lipid deposit at a site or an organ in the body, an indicator of body fat status. + + + + one:T00132 + MeSH + + + + one:T00132 + Adiposity measurement + + + + one:T00133 + 2(MDR)10(QAT) + + + + one:T00133 + ONE ontology + + + + one:T00133 + Food composition table + + + + one:T00134 + 11 + + + + one:T00134 + ONE ontology + + + + one:T00134 + Total number of participants recruited + + + + one:T00135 + Data quality descriptors for study design + + + + one:T00136 + Data quality descriptors for data measurement + + + + one:T00137 + Data quality descriptors for dietary intake data measurement + + + + one:T00138 + Data quality descriptors for anthropometry measurement + + + + one:T00139 + Data quality descriptors for cohort study + + + + one:T00140 + Data quality descriptors for cross-sectional study + + + + one:T00141 + Data quality descriptors for case-control study + + + + one:T00142 + 1 + + + + one:T00142 + The number of completed or returened survey instruments (questionnaires, interviews, etc.) divided by the total bumber of persons who would have been surveyed if all had participated. Usually expressed as a percentage. Nonresponse can have several causes (e.g., death, removal from the survey community, and refusal). + + + + one:T00142 + Porta M. A dictionary of epidemiology. 6th ed. [Internet]. + + + + one:T00142 + Response rate + + + + one:T00143 + Dietary records-descriptor + + + + one:T00144 + 24-hour Recall-descriptor + + + + one:T00145 + Screener-descriptor + + + + one:T00146 + Food Frequency Questionnaire-descriptor + + + + one:T00147 + Diet History-descriptor + + + + http://one.ugent.be/00001 + 1 + + + + http://one.ugent.be/00001 + Chen Yang et al. (2017). Perspective: Essential Study Quality Descriptors for Data from Nutritional Epidemiologic Research. Advances in Nutrition:8(5):639-51. + + + + http://one.ugent.be/00001 + Mariona Pinart et al. (2018). Joint Data Analysis in Nutritional Epidemiology: Identification of Observational Studies and Minimal Requirements. The Journal of Nutrition:148(2):285-297. + + + + http://one.ugent.be/00001 + Dietary assessment method + + + + http://one.ugent.be/00002 + Mariona Pinart et al. (2018). Joint Data Analysis in Nutritional Epidemiology: Identification of Observational Studies and Minimal Requirements. The Journal of Nutrition:148(2):285-297. + + + + http://one.ugent.be/00002 + Dietary records + + + + http://one.ugent.be/00003 + Mariona Pinart et al. (2018). Joint Data Analysis in Nutritional Epidemiology: Identification of Observational Studies and Minimal Requirements. The Journal of Nutrition:148(2):285-297. + + + + http://one.ugent.be/00003 + 24-Hour recall + + + + http://one.ugent.be/00004 + Mariona Pinart et al. (2018). Joint Data Analysis in Nutritional Epidemiology: Identification of Observational Studies and Minimal Requirements. The Journal of Nutrition:148(2):285-297. + + + + http://one.ugent.be/00004 + Screener + + + + http://one.ugent.be/00005 + Mariona Pinart et al. (2018). Joint Data Analysis in Nutritional Epidemiology: Identification of Observational Studies and Minimal Requirements. The Journal of Nutrition:148(2):285-297. + + + + http://one.ugent.be/00005 + Food frequency questionnaire + + + + http://one.ugent.be/00006 + Mariona Pinart et al. (2018). Joint Data Analysis in Nutritional Epidemiology: Identification of Observational Studies and Minimal Requirements. The Journal of Nutrition:148(2):285-297. + + + + http://one.ugent.be/00006 + Diet history + + + + http://one.ugent.be/00007 + Mariona Pinart et al. (2018). Joint Data Analysis in Nutritional Epidemiology: Identification of Observational Studies and Minimal Requirements. The Journal of Nutrition:148(2):285-297. + + + + http://one.ugent.be/00007 + Dietary records:PDA-technologies + + + + http://one.ugent.be/00008 + Mariona Pinart et al. (2018). Joint Data Analysis in Nutritional Epidemiology: Identification of Observational Studies and Minimal Requirements. The Journal of Nutrition:148(2):285-297. + + + + http://one.ugent.be/00008 + Dietary records:Mobile phone-based technologies + + + + http://one.ugent.be/00009 + Mariona Pinart et al. (2018). Joint Data Analysis in Nutritional Epidemiology: Identification of Observational Studies and Minimal Requirements. The Journal of Nutrition:148(2):285-297. + + + + http://one.ugent.be/00009 + Dietary records:Camera-recorder-based technologies + + + + http://one.ugent.be/00010 + Mariona Pinart et al. (2018). Joint Data Analysis in Nutritional Epidemiology: Identification of Observational Studies and Minimal Requirements. The Journal of Nutrition:148(2):285-297. + + + + http://one.ugent.be/00010 + Dietary records:Tape-recorder-based technologies + + + + http://one.ugent.be/00011 + Mariona Pinart et al. (2018). Joint Data Analysis in Nutritional Epidemiology: Identification of Observational Studies and Minimal Requirements. The Journal of Nutrition:148(2):285-297. + + + + http://one.ugent.be/00011 + 24-Hour Recall:Interactive computer-based technologies + + + + http://one.ugent.be/00012 + Mariona Pinart et al. (2018). Joint Data Analysis in Nutritional Epidemiology: Identification of Observational Studies and Minimal Requirements. The Journal of Nutrition:148(2):285-297. + + + + http://one.ugent.be/00012 + 24-Hour Recall:Interactive web-based technologies + + + + http://one.ugent.be/00013 + Mariona Pinart et al. (2018). Joint Data Analysis in Nutritional Epidemiology: Identification of Observational Studies and Minimal Requirements. The Journal of Nutrition:148(2):285-297. + + + + http://one.ugent.be/00013 + Screener:Interactive computer-based technologies + + + + http://one.ugent.be/00014 + Mariona Pinart et al. (2018). Joint Data Analysis in Nutritional Epidemiology: Identification of Observational Studies and Minimal Requirements. The Journal of Nutrition:148(2):285-297. + + + + http://one.ugent.be/00014 + Screener:Interactive web-based technologies + + + + http://one.ugent.be/00015 + Mariona Pinart et al. (2018). Joint Data Analysis in Nutritional Epidemiology: Identification of Observational Studies and Minimal Requirements. The Journal of Nutrition:148(2):285-297. + + + + http://one.ugent.be/00015 + Screener:qualitative(only frequency) + + + + http://one.ugent.be/00016 + Mariona Pinart et al. (2018). Joint Data Analysis in Nutritional Epidemiology: Identification of Observational Studies and Minimal Requirements. The Journal of Nutrition:148(2):285-297. + + + + http://one.ugent.be/00016 + Screener:semi-quantitative + + + + http://one.ugent.be/00017 + Mariona Pinart et al. (2018). Joint Data Analysis in Nutritional Epidemiology: Identification of Observational Studies and Minimal Requirements. The Journal of Nutrition:148(2):285-297. + + + + http://one.ugent.be/00017 + Screener:quantitative + + + + http://one.ugent.be/00018 + Mariona Pinart et al. (2018). Joint Data Analysis in Nutritional Epidemiology: Identification of Observational Studies and Minimal Requirements. The Journal of Nutrition:148(2):285-297. + + + + http://one.ugent.be/00018 + FFQ:Interactive computer-based technologies + + + + http://one.ugent.be/00019 + Mariona Pinart et al. (2018). Joint Data Analysis in Nutritional Epidemiology: Identification of Observational Studies and Minimal Requirements. The Journal of Nutrition:148(2):285-297. + + + + http://one.ugent.be/00019 + FFQ:Interactive web-based technologies + + + + http://one.ugent.be/00020 + Mariona Pinart et al. (2018). Joint Data Analysis in Nutritional Epidemiology: Identification of Observational Studies and Minimal Requirements. The Journal of Nutrition:148(2):285-297. + + + + http://one.ugent.be/00020 + FFQ:qualitative + + + + http://one.ugent.be/00021 + Mariona Pinart et al. (2018). Joint Data Analysis in Nutritional Epidemiology: Identification of Observational Studies and Minimal Requirements. The Journal of Nutrition:148(2):285-297. + + + + http://one.ugent.be/00021 + FFQ:semi-quantitative + + + + http://one.ugent.be/00022 + Mariona Pinart et al. (2018). Joint Data Analysis in Nutritional Epidemiology: Identification of Observational Studies and Minimal Requirements. The Journal of Nutrition:148(2):285-297. + + + + http://one.ugent.be/00022 + FFQ:quantitative + + + + http://one.ugent.be/00023 + 4 + + + + http://one.ugent.be/00023 + Mariona Pinart et al. (2018). Joint Data Analysis in Nutritional Epidemiology: Identification of Observational Studies and Minimal Requirements. The Journal of Nutrition:148(2):285-297. + + + + http://one.ugent.be/00023 + Dietary intake data + + + + http://one.ugent.be/00024 + Mariona Pinart et al. (2018). Joint Data Analysis in Nutritional Epidemiology: Identification of Observational Studies and Minimal Requirements. The Journal of Nutrition:148(2):285-297. + + + + http://one.ugent.be/00024 + Unadjusted data + + + + http://one.ugent.be/00025 + Mariona Pinart et al. (2018). Joint Data Analysis in Nutritional Epidemiology: Identification of Observational Studies and Minimal Requirements. The Journal of Nutrition:148(2):285-297. + + + + http://one.ugent.be/00025 + Adjusted data for total energy intake using density method + + + + http://one.ugent.be/00026 + Mariona Pinart et al. (2018). Joint Data Analysis in Nutritional Epidemiology: Identification of Observational Studies and Minimal Requirements. The Journal of Nutrition:148(2):285-297. + + + + http://one.ugent.be/00026 + Adjusted data for total energy intake using residual method + + + + http://one.ugent.be/00027 + Mariona Pinart et al. (2018). Joint Data Analysis in Nutritional Epidemiology: Identification of Observational Studies and Minimal Requirements. The Journal of Nutrition:148(2):285-297. + + + + http://one.ugent.be/00027 + Estimates of usual intake from short-term measurements + + + + http://one.ugent.be/00028 + 1 + + + + http://one.ugent.be/00028 + Chen Yang et al. (2017). Perspective: Essential Study Quality Descriptors for Data from Nutritional Epidemiologic Research. Advances in Nutrition:8(5):639-51. + + + + http://one.ugent.be/00028 + Dietary assessment administration + + + + http://one.ugent.be/00029 + Chen Yang et al. (2017). Perspective: Essential Study Quality Descriptors for Data from Nutritional Epidemiologic Research. Advances in Nutrition:8(5):639-51. + + + + http://one.ugent.be/00029 + Proxy-administered + + + + http://one.ugent.be/00030 + Chen Yang et al. (2017). Perspective: Essential Study Quality Descriptors for Data from Nutritional Epidemiologic Research. Advances in Nutrition:8(5):639-51. + + + + http://one.ugent.be/00030 + Self-administered not verified by interviewer + + + + http://one.ugent.be/00031 + Chen Yang et al. (2017). Perspective: Essential Study Quality Descriptors for Data from Nutritional Epidemiologic Research. Advances in Nutrition:8(5):639-51. + + + + http://one.ugent.be/00031 + Self-administered and checked by interviewer + + + + http://one.ugent.be/00032 + Chen Yang et al. (2017). Perspective: Essential Study Quality Descriptors for Data from Nutritional Epidemiologic Research. Advances in Nutrition:8(5):639-51. + + + + http://one.ugent.be/00032 + Interview-administered + + + + http://one.ugent.be/00033 + AMPM (Automated multiple-pass method): Computerized method for collecting interviewer-administered 24-h dietary recalls either in person or by telephone. + + + + http://one.ugent.be/00033 + Chen Yang et al. (2017). Perspective: Essential Study Quality Descriptors for Data from Nutritional Epidemiologic Research. Advances in Nutrition:8(5):639-51. + + + + http://one.ugent.be/00033 + Raper N et al. (2004). An overview of USDA's dietary intake data system. J Food Compos Anal 17:545-55. + + + + http://one.ugent.be/00033 + Interview-administered using AMPM + + + + http://one.ugent.be/00034 + 2 + + + + http://one.ugent.be/00034 + Questionnaires: A predetermined set of questions used to collect data-clinical data, social status, occupational group, etc. This term is often applied to a seft-completed survey instrument, as contrasted with an interview schedule. + + + + http://one.ugent.be/00034 + Chen Yang et al. (2017). Perspective: Essential Study Quality Descriptors for Data from Nutritional Epidemiologic Research. Advances in Nutrition:8(5):639-51. + + + + http://one.ugent.be/00034 + Porta M. A dictionary of epidemiology. 6th ed. [internet]. + + + + http://one.ugent.be/00034 + Dietary assessment questionnaire + + + + http://one.ugent.be/00035 + Questionnaires: A predetermined set of questions used to collect data-clinical data, social status, occupational group, etc. This term is often applied to a seft-completed survey instrument, as contrasted with an interview schedule. + + + + http://one.ugent.be/00035 + Chen Yang et al. (2017). Perspective: Essential Study Quality Descriptors for Data from Nutritional Epidemiologic Research. Advances in Nutrition:8(5):639-51. + + + + http://one.ugent.be/00035 + Porta M. A dictionary of epidemiology. 6th ed. [internet]. + + + + http://one.ugent.be/00035 + Self-developed questionnaires + + + + http://one.ugent.be/00036 + Questionnaires: A predetermined set of questions used to collect data-clinical data, social status, occupational group, etc. This term is often applied to a seft-completed survey instrument, as contrasted with an interview schedule. + + + + http://one.ugent.be/00036 + Chen Yang et al. (2017). Perspective: Essential Study Quality Descriptors for Data from Nutritional Epidemiologic Research. Advances in Nutrition:8(5):639-51. + + + + http://one.ugent.be/00036 + Porta M. A dictionary of epidemiology. 6th ed. [internet]. + + + + http://one.ugent.be/00036 + Use of standardized questionnaire + + + + http://one.ugent.be/00037 + Questionnaires: A predetermined set of questions used to collect data-clinical data, social status, occupational group, etc. This term is often applied to a seft-completed survey instrument, as contrasted with an interview schedule. + + + + http://one.ugent.be/00037 + Chen Yang et al. (2017). Perspective: Essential Study Quality Descriptors for Data from Nutritional Epidemiologic Research. Advances in Nutrition:8(5):639-51. + + + + http://one.ugent.be/00037 + Porta M. A dictionary of epidemiology. 6th ed. [internet]. + + + + http://one.ugent.be/00037 + Adopted other questionnaires + + + + http://one.ugent.be/00038 + 3 + + + + http://one.ugent.be/00038 + Content validity: The extent to which the measurement incorporates the domain of the phenomenon under study. For example, a measurement of functional health status should embrace activities of daily living (occupational, family, and social functioning, etc.). + + + + http://one.ugent.be/00038 + Chen Yang et al. (2017). Perspective: Essential Study Quality Descriptors for Data from Nutritional Epidemiologic Research. Advances in Nutrition:8(5):639-51. + + + + http://one.ugent.be/00038 + Porta M. A dictionary of epidemiology. 6th ed. [internet]. + + + + http://one.ugent.be/00038 + Content validity of dietary assessment questionnaire + + + + http://one.ugent.be/00039 + Content validity: The extent to which the measurement incorporates the domain of the phenomenon under study. For example, a measurement of functional health status should embrace activities of daily living (occupational, family, and social functioning, etc.). + + + + http://one.ugent.be/00039 + Chen Yang et al. (2017). Perspective: Essential Study Quality Descriptors for Data from Nutritional Epidemiologic Research. Advances in Nutrition:8(5):639-51. + + + + http://one.ugent.be/00039 + Porta M. A dictionary of epidemiology. 6th ed. [internet]. + + + + http://one.ugent.be/00039 + Verified content validity in another population + + + + http://one.ugent.be/00040 + Content validity: The extent to which the measurement incorporates the domain of the phenomenon under study. For example, a measurement of functional health status should embrace activities of daily living (occupational, family, and social functioning, etc.). + + + + http://one.ugent.be/00040 + Chen Yang et al. (2017). Perspective: Essential Study Quality Descriptors for Data from Nutritional Epidemiologic Research. Advances in Nutrition:8(5):639-51. + + + + http://one.ugent.be/00040 + Porta M. A dictionary of epidemiology. 6th ed. [internet]. + + + + http://one.ugent.be/00040 + Verified content validity in a comparable population in terms of both age and dietary habits + + + + http://one.ugent.be/00041 + 4 + + + + http://one.ugent.be/00041 + Chen Yang et al. (2017). Perspective: Essential Study Quality Descriptors for Data from Nutritional Epidemiologic Research. Advances in Nutrition:8(5):639-51. + + + + http://one.ugent.be/00041 + Reference of dietary assessment questionnaire validation + + + + http://one.ugent.be/00042 + Mariona Pinart et al. (2018). Joint Data Analysis in Nutritional Epidemiology: Identification of Observational Studies and Minimal Requirements. The Journal of Nutrition:148(2):285-297. + + + + http://one.ugent.be/00042 + Dietary records: short term + + + + http://one.ugent.be/00043 + Mariona Pinart et al. (2018). Joint Data Analysis in Nutritional Epidemiology: Identification of Observational Studies and Minimal Requirements. The Journal of Nutrition:148(2):285-297. + + + + http://one.ugent.be/00043 + Dietary records: long term weighted(>7 days) + + + + http://one.ugent.be/00044 + Chen Yang et al. (2017). Perspective: Essential Study Quality Descriptors for Data from Nutritional Epidemiologic Research. Advances in Nutrition:8(5):639-51. + + + + http://one.ugent.be/00044 + Objective method + + + + http://one.ugent.be/00045 + Biomarker: A substance, structure, or process that can be measured in biological specimens or media and may be associated with health outcomes or biological effects. A cellular, biochemical, or molecular indicator of exposure; of biological, subclinical, or clinical effects; or of possible susceptibility. A biological indicator of internal dose, biologically effective dose, early biological response, altered structure, or altered function. + + + + http://one.ugent.be/00045 + Chen Yang et al. (2017). Perspective: Essential Study Quality Descriptors for Data from Nutritional Epidemiologic Research. Advances in Nutrition:8(5):639-51. + + + + http://one.ugent.be/00045 + Porta M. A dictionary of epidemiology. 6th ed. [internet]. + + + + http://one.ugent.be/00045 + Biomarker of dietary intake + + + + http://one.ugent.be/00046 + 5 + + + + http://one.ugent.be/00046 + Chen Yang et al. (2017). Perspective: Essential Study Quality Descriptors for Data from Nutritional Epidemiologic Research. Advances in Nutrition:8(5):639-51. + + + + http://one.ugent.be/00046 + Validated information of dietary assessment questionnaire + + + + http://one.ugent.be/00047 + Chen Yang et al. (2017). Perspective: Essential Study Quality Descriptors for Data from Nutritional Epidemiologic Research. Advances in Nutrition:8(5):639-51. + + + + http://one.ugent.be/00047 + Properties of dietary assessment questionnaire + + + + http://one.ugent.be/00048 + Chen Yang et al. (2017). Perspective: Essential Study Quality Descriptors for Data from Nutritional Epidemiologic Research. Advances in Nutrition:8(5):639-51. + + + + http://one.ugent.be/00048 + Frequency options to identify between-person variations + + + + http://one.ugent.be/00049 + Chen Yang et al. (2017). Perspective: Essential Study Quality Descriptors for Data from Nutritional Epidemiologic Research. Advances in Nutrition:8(5):639-51. + + + + http://one.ugent.be/00049 + Food items lead to underestimated target nutrients intake + + + + http://one.ugent.be/00050 + 6 + + + + http://one.ugent.be/00050 + Chen Yang et al. (2017). Perspective: Essential Study Quality Descriptors for Data from Nutritional Epidemiologic Research. Advances in Nutrition:8(5):639-51. + + + + http://one.ugent.be/00050 + Validation type for dietary assessment questionnaire + + + + http://one.ugent.be/00051 + 8 + + + + http://one.ugent.be/00051 + Portion size: The amount of a particular food one chooses to eat at a single meal. + + + + http://one.ugent.be/00051 + Chen Yang et al. (2017). Perspective: Essential Study Quality Descriptors for Data from Nutritional Epidemiologic Research. Advances in Nutrition:8(5):639-51. + + + + http://one.ugent.be/00051 + http://purl.bioontology.org/ontology/MESH/D064787 + + + + http://one.ugent.be/00051 + Quantification of portion sizes + + + + http://one.ugent.be/00052 + Portion size: The amount of a particular food one chooses to eat at a single meal. + + + + http://one.ugent.be/00052 + Chen Yang et al. (2017). Perspective: Essential Study Quality Descriptors for Data from Nutritional Epidemiologic Research. Advances in Nutrition:8(5):639-51. + + + + http://one.ugent.be/00052 + http://purl.bioontology.org/ontology/MESH/D064787 + + + + http://one.ugent.be/00052 + Not quantified portion sizes + + + + http://one.ugent.be/00053 + Portion size: The amount of a particular food one chooses to eat at a single meal. + + + + http://one.ugent.be/00053 + Chen Yang et al. (2017). Perspective: Essential Study Quality Descriptors for Data from Nutritional Epidemiologic Research. Advances in Nutrition:8(5):639-51. + + + + http://one.ugent.be/00053 + http://purl.bioontology.org/ontology/MESH/D064787 + + + + http://one.ugent.be/00053 + Standard portion sizes without aids + + + + http://one.ugent.be/00054 + Portion size: The amount of a particular food one chooses to eat at a single meal. + + + + http://one.ugent.be/00054 + Chen Yang et al. (2017). Perspective: Essential Study Quality Descriptors for Data from Nutritional Epidemiologic Research. Advances in Nutrition:8(5):639-51. + + + + http://one.ugent.be/00054 + http://purl.bioontology.org/ontology/MESH/D064787 + + + + http://one.ugent.be/00054 + Standard portion sizes with aids + + + + http://one.ugent.be/00055 + Portion size: The amount of a particular food one chooses to eat at a single meal. + + + + http://one.ugent.be/00055 + Chen Yang et al. (2017). Perspective: Essential Study Quality Descriptors for Data from Nutritional Epidemiologic Research. Advances in Nutrition:8(5):639-51. + + + + http://one.ugent.be/00055 + http://purl.bioontology.org/ontology/MESH/D064787 + + + + http://one.ugent.be/00055 + Portion sizes are assessed digitally but not verified by trained staff + + + + http://one.ugent.be/00056 + Portion size: The amount of a particular food one chooses to eat at a single meal. + + + + http://one.ugent.be/00056 + Chen Yang et al. (2017). Perspective: Essential Study Quality Descriptors for Data from Nutritional Epidemiologic Research. Advances in Nutrition:8(5):639-51. + + + + http://one.ugent.be/00056 + http://purl.bioontology.org/ontology/MESH/D064787 + + + + http://one.ugent.be/00056 + Portion sizes are assessed digitally and verified by trained staff (or packaging) + + + + http://one.ugent.be/00057 + 9 + + + + http://one.ugent.be/00057 + Portion size: The amount of a particular food one chooses to eat at a single meal. + + + + http://one.ugent.be/00057 + Chen Yang et al. (2017). Perspective: Essential Study Quality Descriptors for Data from Nutritional Epidemiologic Research. Advances in Nutrition:8(5):639-51. + + + + http://one.ugent.be/00057 + http://purl.bioontology.org/ontology/MESH/D064787 + + + + http://one.ugent.be/00057 + Portion size of dietary intake data + + + + http://one.ugent.be/00058 + Portion size: The amount of a particular food one chooses to eat at a single meal. + + + + http://one.ugent.be/00058 + Chen Yang et al. (2017). Perspective: Essential Study Quality Descriptors for Data from Nutritional Epidemiologic Research. Advances in Nutrition:8(5):639-51. + + + + http://one.ugent.be/00058 + http://purl.bioontology.org/ontology/MESH/D064787 + + + + http://one.ugent.be/00058 + Directly expressed portion size + + + + http://one.ugent.be/00059 + Portion size: The amount of a particular food one chooses to eat at a single meal. + + + + http://one.ugent.be/00059 + Chen Yang et al. (2017). Perspective: Essential Study Quality Descriptors for Data from Nutritional Epidemiologic Research. Advances in Nutrition:8(5):639-51. + + + + http://one.ugent.be/00059 + http://purl.bioontology.org/ontology/MESH/D064787 + + + + http://one.ugent.be/00059 + Converted portion size + + + + http://one.ugent.be/00060 + Portion size: The amount of a particular food one chooses to eat at a single meal. + + + + http://one.ugent.be/00060 + Chen Yang et al. (2017). Perspective: Essential Study Quality Descriptors for Data from Nutritional Epidemiologic Research. Advances in Nutrition:8(5):639-51. + + + + http://one.ugent.be/00060 + http://purl.bioontology.org/ontology/MESH/D064787 + + + + http://one.ugent.be/00060 + Unconverted portion size + + + + http://one.ugent.be/00061 + 11 + + + + http://one.ugent.be/00061 + Food matching links food consumption data with food composition data and affects the quality of the dietary assessment and accuracy of findings. High-quality matching is desirable but it often not achievable due to lack of food composition data or information on food consumed. + + + + http://one.ugent.be/00061 + Chen Yang et al. (2017). Perspective: Essential Study Quality Descriptors for Data from Nutritional Epidemiologic Research. Advances in Nutrition:8(5):639-51. + + + + http://one.ugent.be/00061 + Matched consumed food to referred food composition data + + + + http://one.ugent.be/00062 + Exact match: if food description reported in 24-h recall matched exactly with the description in food consumption data. + + + + http://one.ugent.be/00062 + Food matching links food consumption data with food composition data and affects the quality of the dietary assessment and accuracy of findings. High-quality matching is desirable but it often not achievable due to lack of food composition data or information on food consumed. + + + + http://one.ugent.be/00062 + Chen Yang et al. (2017). Perspective: Essential Study Quality Descriptors for Data from Nutritional Epidemiologic Research. Advances in Nutrition:8(5):639-51. + + + + http://one.ugent.be/00062 + FAO/INFOODS Guidelines for food matching. Version 1.2. Rome (Italy): FAO; 2012. + + + + http://one.ugent.be/00062 + Exact matching + + + + http://one.ugent.be/00063 + Food matching links food consumption data with food composition data and affects the quality of the dietary assessment and accuracy of findings. High-quality matching is desirable but it often not achievable due to lack of food composition data or information on food consumed. + + + + http://one.ugent.be/00063 + Chen Yang et al. (2017). Perspective: Essential Study Quality Descriptors for Data from Nutritional Epidemiologic Research. Advances in Nutrition:8(5):639-51. + + + + http://one.ugent.be/00063 + Matched to means of min. 3 food items + + + + http://one.ugent.be/00064 + Food matching links food consumption data with food composition data and affects the quality of the dietary assessment and accuracy of findings. High-quality matching is desirable but it often not achievable due to lack of food composition data or information on food consumed. + + + + http://one.ugent.be/00064 + Chen Yang et al. (2017). Perspective: Essential Study Quality Descriptors for Data from Nutritional Epidemiologic Research. Advances in Nutrition:8(5):639-51. + + + + http://one.ugent.be/00064 + Matched to same food items with similar moisture content + + + + http://one.ugent.be/00065 + Food matching links food consumption data with food composition data and affects the quality of the dietary assessment and accuracy of findings. High-quality matching is desirable but it often not achievable due to lack of food composition data or information on food consumed. + + + + http://one.ugent.be/00065 + Chen Yang et al. (2017). Perspective: Essential Study Quality Descriptors for Data from Nutritional Epidemiologic Research. Advances in Nutrition:8(5):639-51. + + + + http://one.ugent.be/00065 + Matched to a different food + + + + http://one.ugent.be/00066 + 12 + + + + http://one.ugent.be/00066 + Chen Yang et al. (2017). Perspective: Essential Study Quality Descriptors for Data from Nutritional Epidemiologic Research. Advances in Nutrition:8(5):639-51. + + + + http://one.ugent.be/00066 + Representativeness of the week/weekend days + + + + http://one.ugent.be/00067 + 13 + + + + http://one.ugent.be/00067 + Chen Yang et al. (2017). Perspective: Essential Study Quality Descriptors for Data from Nutritional Epidemiologic Research. Advances in Nutrition:8(5):639-51. + + + + http://one.ugent.be/00067 + Number of recall/measurement days per individual + + + + http://one.ugent.be/00068 + 14 + + + + http://one.ugent.be/00068 + Chen Yang et al. (2017). Perspective: Essential Study Quality Descriptors for Data from Nutritional Epidemiologic Research. Advances in Nutrition:8(5):639-51. + + + + http://one.ugent.be/00068 + Selection of recall/measurement days + + + + http://one.ugent.be/00069 + Chen Yang et al. (2017). Perspective: Essential Study Quality Descriptors for Data from Nutritional Epidemiologic Research. Advances in Nutrition:8(5):639-51. + + + + http://one.ugent.be/00069 + Convenience selection + + + + http://one.ugent.be/00070 + Chen Yang et al. (2017). Perspective: Essential Study Quality Descriptors for Data from Nutritional Epidemiologic Research. Advances in Nutrition:8(5):639-51. + + + + http://one.ugent.be/00070 + Consecutive days + + + + http://one.ugent.be/00071 + Chen Yang et al. (2017). Perspective: Essential Study Quality Descriptors for Data from Nutritional Epidemiologic Research. Advances in Nutrition:8(5):639-51. + + + + http://one.ugent.be/00071 + Non-consecutive, non-random days + + + + http://one.ugent.be/00072 + Chen Yang et al. (2017). Perspective: Essential Study Quality Descriptors for Data from Nutritional Epidemiologic Research. Advances in Nutrition:8(5):639-51. + + + + http://one.ugent.be/00072 + Randomly over the week + + + + http://one.ugent.be/00073 + 15 + + + + http://one.ugent.be/00073 + Diet records: Records of nutrient intake over a specific period of time, usually kept by the patient. + + + + http://one.ugent.be/00073 + Chen Yang et al. (2017). Perspective: Essential Study Quality Descriptors for Data from Nutritional Epidemiologic Research. Advances in Nutrition:8(5):639-51. + + + + http://one.ugent.be/00073 + http://purl.bioontology.org/ontology/MESH/D015930 + + + + http://one.ugent.be/00073 + The time of diet records + + + + http://one.ugent.be/00074 + Diet records: Records of nutrient intake over a specific period of time, usually kept by the patient. + + + + http://one.ugent.be/00074 + Chen Yang et al. (2017). Perspective: Essential Study Quality Descriptors for Data from Nutritional Epidemiologic Research. Advances in Nutrition:8(5):639-51. + + + + http://one.ugent.be/00074 + http://purl.bioontology.org/ontology/MESH/D015930 + + + + http://one.ugent.be/00074 + Not during eating occasions nor immediately after + + + + http://one.ugent.be/00075 + Diet records: Records of nutrient intake over a specific period of time, usually kept by the patient. + + + + http://one.ugent.be/00075 + Chen Yang et al. (2017). Perspective: Essential Study Quality Descriptors for Data from Nutritional Epidemiologic Research. Advances in Nutrition:8(5):639-51. + + + + http://one.ugent.be/00075 + http://purl.bioontology.org/ontology/MESH/D015930 + + + + http://one.ugent.be/00075 + Immediately after eating occasion + + + + http://one.ugent.be/00076 + Diet records: Records of nutrient intake over a specific period of time, usually kept by the patient. + + + + http://one.ugent.be/00076 + Chen Yang et al. (2017). Perspective: Essential Study Quality Descriptors for Data from Nutritional Epidemiologic Research. Advances in Nutrition:8(5):639-51. + + + + http://one.ugent.be/00076 + http://purl.bioontology.org/ontology/MESH/D015930 + + + + http://one.ugent.be/00076 + During eating occasion + + + + http://one.ugent.be/00077 + Population groups: Individuals classified according to their sex, racial origin, religion, common place of living, financial or social status, or some other cultural or behavioral attribute. + + + + http://one.ugent.be/00077 + Chen Yang et al. (2017). Perspective: Essential Study Quality Descriptors for Data from Nutritional Epidemiologic Research. Advances in Nutrition:8(5):639-51. + + + + http://one.ugent.be/00077 + http://purl.bioontology.org/ontology/MESH/D044382 + + + + http://one.ugent.be/00077 + Food quantification method + + + + http://one.ugent.be/00078 + Population groups: Individuals classified according to their sex, racial origin, religion, common place of living, financial or social status, or some other cultural or behavioral attribute. + + + + http://one.ugent.be/00078 + Chen Yang et al. (2017). Perspective: Essential Study Quality Descriptors for Data from Nutritional Epidemiologic Research. Advances in Nutrition:8(5):639-51. + + + + http://one.ugent.be/00078 + http://purl.bioontology.org/ontology/MESH/D044382 + + + + http://one.ugent.be/00078 + Food quantification method tailored to the characteristics of the population + + + + http://one.ugent.be/00079 + Population groups: Individuals classified according to their sex, racial origin, religion, common place of living, financial or social status, or some other cultural or behavioral attribute. + + + + http://one.ugent.be/00079 + Chen Yang et al. (2017). Perspective: Essential Study Quality Descriptors for Data from Nutritional Epidemiologic Research. Advances in Nutrition:8(5):639-51. + + + + http://one.ugent.be/00079 + http://purl.bioontology.org/ontology/MESH/D044382 + + + + http://one.ugent.be/00079 + Food quantification method not specifically tailored to the characteristics of the population + + + + MDR + "It describes a set of mandatory descriptors, totaling 41, following the the ISA categories. The Investigation category contains 12 descriptors devoted to collecting metadata about the project context, informed consent and ethical issues (descriptors 1-7), data-sharing policy (descriptors 8-11), and data analysis permissions (descriptors 12). The Study category describes a set of 12 descriptors about the study design (descriptors 1-2), study subjects (descriptors 3-5 and 12), and recruitment (descriptors 6-11). The Assay category with 17 descriptors describes end-points (descriptors 1-10), study samples ( descriptors 11-14), and analytical measurements (descriptors 15-17)."- Pinart M et al. 2018. + + + + MDR + Mariona Pinart et al. (2018). Joint Data Analysis in Nutritional Epidemiology: Identification of Observational Studies and Minimal Requirements. The Journal of Nutrition:148(2):285-297. + + + + MDR + Minimal data requirement of observational studies-descriptor + + + + QAT + "It includes 10 descriptors allocated to 'study design' and 22 to 'measurement' domains. Data descriptors were organized as an ordinal scale of items to facilitate the identification, storage, and querying of nutrition data." -- Yang et al. 2017 + + + + QAT + Chen Yang et al. (2017). Perspective: Essential Study Quality Descriptors for Data from Nutritional Epidemiologic Research. Advances in Nutrition:8(5):639-51. + + + + QAT + Data quality descriptors of observational studies + + + + caseStudies + Case studies + + + + caseStudies_dataset + Case studies: dataset description + + + + caseStudies_study + Case studies: study description + + + + extraList + Extra list of terms for description + + + + lachatc2018pnas + http://doi.org/10.1073/pnas.1709194115 + + + + lachatc2018pnas + Benin:01/10/2013-31/12/2013,01/05/2014-31/07/2014; Cameroon:01/07/2013-31/08/2013; Congo:01/07/2009-30/09/2009; Ecuador:01/03/2011-31/03/2011; Kenya:01/09/2014-30/09/2014; 01/04/2015-30/04/2015; Sir Lanka: 01/07/2013-30/09/2013; Vietnam: 01/08/2014-31/12/2014 + + + + lachatc2018pnas + We applied biodiversity indicators to dietary intake data from and assessed associations with diet quality of women and young children. + + + + lachatc2018pnas + http://orcid.org/0000-0002-1389-8855 + + + + lachatc2018pnas + http://orcid.org/0000-0002-1389-8855 + + + + lachatc2018pnas + mesh:D001541 + + + + lachatc2018pnas + mesh:D002163 + + + + lachatc2018pnas + mesh:D003223 + + + + lachatc2018pnas + mesh:D004484 + + + + lachatc2018pnas + mesh:D007630 + + + + lachatc2018pnas + mesh:D013188 + + + + lachatc2018pnas + mesh:D014744 + + + + lachatc2018pnas + one:T00005 + + + + lachatc2018pnas + Carl.Lachat@UGent.be + + + + lachatc2018pnas + Dietary species richness as a measure of food biodiversity and nutritional quality of diet + + + + lachatc2018pnas + 06/06/2017 + + + + lachatc2018pnas + ncit:C18241 + + + + lachatc2018pnas + one:T00021 + + + + lachatc2018pnas + Assess the intricate relationship between food biodiversity and diet quality + + + + lachatc2018pnas + one:T00005 + + + + lachatc2018pnas + one:T00005 + + + + lachatc2018pnas + one:T00009 + + + + lachatc2018pnas + 2188 + + + + lachatc2018pnas + 0.5 + + + + lachatc2018pnas + 43 + + + + lachatc2018pnas + 6226 + + + + lachatc2018pnas + oron:nut-1 + + + + lachatc2018pnas + oron:nut-11 + + + + lachatc2018pnas + oron:nut-12.1 + + + + lachatc2018pnas + oron:nut-12.3 + + + + lachatc2018pnas + oron:nut-19 + + + + lachatc2018pnas + oron:nut-20 + + + + lachatc2018pnas + oron:nut-22.1 + + + + lachatc2018pnas + oron:nut-22.2 + + + + lachatc2018pnas + oron:nut-5 + + + + lachatc2018pnas + oron:nut-7.1 + + + + lachatc2018pnas + oron:nut-8.1 + + + + lachatc2018pnas + oron:nut-8.2 + + + + lachatc2018pnas + oron:nut-8.3 + + + + lachatc2018pnas + oron:nut-8.5 + + + + lachatc2018pnas + mesh:D002648 + + + + lachatc2018pnas + mesh:D012424 + + + + lachatc2018pnas + mesh:D014930 + + + + lachatc2018pnas + http://www.pnas.org/content/115/1/127 + + + + lachatc2018pnas + mesh:D03430 + + + + lachatc2018pnas + http://www.fwo.be/en + + + + lachatc2018pnas + Lachat C et al. 2018 PNAS + + + + lachatc2018pnasCameroon + mesh:D002163 + + + + lachatc2018pnasCameroon + 01/07/2013-31/08/2013 + + + + lachatc2018pnasCameroon + one:T00110 + + + + lachatc2018pnasCameroon + http://www.fao.org/docrep/015/i2698b/i2698b00.pdf + + + + lachatc2018pnasCameroon + http://one.ugent.be/00003 + + + + lachatc2018pnasCameroon + http://one.ugent.be/00024 + + + + lachatc2018pnasCameroon + http://one.ugent.be/00032 + + + + lachatc2018pnasCameroon + http://one.ugent.be/00035 + + + + lachatc2018pnasCameroon + http://one.ugent.be/00056 + + + + lachatc2018pnasCameroon + http://one.ugent.be/00058 + + + + lachatc2018pnasCameroon + http://one.ugent.be/00059 + + + + lachatc2018pnasCameroon + http://one.ugent.be/00062 + + + + lachatc2018pnasCameroon + http://one.ugent.be/00065 + + + + lachatc2018pnasCameroon + 2 + + + + lachatc2018pnasCameroon + http://one.ugent.be/00071 + + + + lachatc2018pnasCameroon + http://one.ugent.be/00074 + + + + lachatc2018pnasCameroon + http://one.ugent.be/00079 + + + + lachatc2018pnasCameroon + 01/07/2013-31/08/2013 + + + + lachatc2018pnasCameroon + obo:EO_0007285 + + + + lachatc2018pnasCameroon + obo:FOODON_00001015 + + + + lachatc2018pnasCameroon + obo:FOODON_00001092 + + + + lachatc2018pnasCameroon + obo:FOODON_00001248 + + + + lachatc2018pnasCameroon + one:T00021 + + + + lachatc2018pnasCameroon + Cameroon dataset-Lachat C et al. 2018 PNAS + + + + http://orcid.org/0000-0002-1389-8855 + Lachat C (orcid) + + + + oron:itemNumber + item number + + + + oron:nut + An extension of the STROBE statement for nutritional epidemiology + + + + oron:nut + strobe-nut + + + + oron:nut-1 + State the dietary/nutritional assessment method(s) used in the title, abstract, or keywords. + + + + oron:nut-1 + Carl Lachat et al. (2016). Strengthening the Reporting of Observational Studies in Epidemiology-Nutritional Epidemiology (STROBE-nut): an extension of the STROBE Statement. PLOS MEDICINE. 13(6). + + + + oron:nut-1 + nut-1 + + + + oron:nut-11 + Explain the categorization of dietary/nutritional data (e.g., use of N-tiles and handling of nonconsumers) and the choice of reference category, if applicable. + + + + oron:nut-11 + Carl Lachat et al. (2016). Strengthening the Reporting of Observational Studies in Epidemiology-Nutritional Epidemiology (STROBE-nut): an extension of the STROBE Statement. PLOS MEDICINE. 13(6). + + + + oron:nut-11 + nut-11 + + + + oron:nut-12.1 + Describe any statistical method used to combine dietary or nutritional data, if applicable. + + + + oron:nut-12.1 + Carl Lachat et al. (2016). Strengthening the Reporting of Observational Studies in Epidemiology-Nutritional Epidemiology (STROBE-nut): an extension of the STROBE Statement. PLOS MEDICINE. 13(6). + + + + oron:nut-12.1 + nut-12.1 + + + + oron:nut-12.3 + Report any adjustments for measurement error, i.e., from a validity or calibration study. + + + + oron:nut-12.3 + Carl Lachat et al. (2016). Strengthening the Reporting of Observational Studies in Epidemiology-Nutritional Epidemiology (STROBE-nut): an extension of the STROBE Statement. PLOS MEDICINE. 13(6). + + + + oron:nut-12.3 + nut-12.3 + + + + oron:nut-19 + Describe the main limitations of the data sources and assessment methods used and implications for the interpretation of the findings. + + + + oron:nut-19 + Carl Lachat et al. (2016). Strengthening the Reporting of Observational Studies in Epidemiology-Nutritional Epidemiology (STROBE-nut): an extension of the STROBE Statement. PLOS MEDICINE. 13(6). + + + + oron:nut-19 + nut-19 + + + + oron:nut-20 + Report the nutritional relevance of the findings, given the complexity of diet or nutrition as an exposure. + + + + oron:nut-20 + Carl Lachat et al. (2016). Strengthening the Reporting of Observational Studies in Epidemiology-Nutritional Epidemiology (STROBE-nut): an extension of the STROBE Statement. PLOS MEDICINE. 13(6). + + + + oron:nut-20 + nut-20 + + + + oron:nut-22.1 + Describe the procedure for consent and study approval from ethics committee(s). + + + + oron:nut-22.1 + Carl Lachat et al. (2016). Strengthening the Reporting of Observational Studies in Epidemiology-Nutritional Epidemiology (STROBE-nut): an extension of the STROBE Statement. PLOS MEDICINE. 13(6). + + + + oron:nut-22.1 + nut-22.1 + + + + oron:nut-22.2 + Provide data collection tools and data as online material or explain how they can be accessed. + + + + oron:nut-22.2 + Carl Lachat et al. (2016). Strengthening the Reporting of Observational Studies in Epidemiology-Nutritional Epidemiology (STROBE-nut): an extension of the STROBE Statement. PLOS MEDICINE. 13(6). + + + + oron:nut-22.2 + nut-22.2 + + + + oron:nut-5 + Describe any characteristics of the study settings that might affect the dietary intake or nutritional status of the participants, if applicable. + + + + oron:nut-5 + Carl Lachat et al. (2016). Strengthening the Reporting of Observational Studies in Epidemiology-Nutritional Epidemiology (STROBE-nut): an extension of the STROBE Statement. PLOS MEDICINE. 13(6). + + + + oron:nut-5 + nut-5 + + + + oron:nut-7.1 + Clearly define foods, food groups, nutrients, or other food components. + + + + oron:nut-7.1 + Carl Lachat et al. (2016). Strengthening the Reporting of Observational Studies in Epidemiology-Nutritional Epidemiology (STROBE-nut): an extension of the STROBE Statement. PLOS MEDICINE. 13(6). + + + + oron:nut-7.1 + nut-7.1 + + + + oron:nut-8.1 + Describe the dietary assessment method(s), e.g., portion sizeestimation,numberofdaysanditemsrecorded,howitwas developed and administered, and how quality was assured. Report if and how supplement intake was assessed. + + + + oron:nut-8.1 + Carl Lachat et al. (2016). Strengthening the Reporting of Observational Studies in Epidemiology-Nutritional Epidemiology (STROBE-nut): an extension of the STROBE Statement. PLOS MEDICINE. 13(6). + + + + oron:nut-8.1 + nut-8.1 + + + + oron:nut-8.2 + Describe and justify food composition data used. Explain the procedure to match food composition with consumption data. Describe the use of conversion factors, if applicable. + + + + oron:nut-8.2 + Carl Lachat et al. (2016). Strengthening the Reporting of Observational Studies in Epidemiology-Nutritional Epidemiology (STROBE-nut): an extension of the STROBE Statement. PLOS MEDICINE. 13(6). + + + + oron:nut-8.2 + nut-8.2 + + + + oron:nut-8.3 + Describe the nutrient requirements, recommendations, or dietary guidelines and the evaluation approach used to compare intake with the dietary reference values, if applicable. + + + + oron:nut-8.3 + Carl Lachat et al. (2016). Strengthening the Reporting of Observational Studies in Epidemiology-Nutritional Epidemiology (STROBE-nut): an extension of the STROBE Statement. PLOS MEDICINE. 13(6). + + + + oron:nut-8.3 + nut-8.3 + + + + oron:nut-8.5 + Describe the assessment of nondietary data (e.g., nutritional status and influencing factors) and timing of the assessment of these variables in relation to dietary assessment. + + + + oron:nut-8.5 + Carl Lachat et al. (2016). Strengthening the Reporting of Observational Studies in Epidemiology-Nutritional Epidemiology (STROBE-nut): an extension of the STROBE Statement. PLOS MEDICINE. 13(6). + + + + oron:nut-8.5 + nut-8.5 + + + + hl7:C1550208 + 10 + + + + hl7:C1550208 + Health Outcomes Institute codes for outcome variables available (with responses) from Stratis Health (formerly Foundation for Health Care Evaluation and Health Outcomes Institute), 2901 Metro Drive, Suite 400, Bloomington, MN, 55425-1525; (612) 854-3306 (voice); (612) 853-8503 (fax); dziegen@winternet.com. See examples in the Implementation Guide. + + + + hl7:C1550208 + HL7 ontology + + + + hl7:C1550208 + Health outcomes + + + + mesh:D000886 + 8 + + + + mesh:D000886 + The technique that deals with the measurement of the size, weight, and proportions of the human or other primate body. + + + + mesh:D000886 + NeSH ontology + + + + mesh:D000886 + Anthropometry + + + + mesh:D001541 + Benin + + + + mesh:D001827 + 8 + + + + mesh:D001827 + The distance from the sole to the crown of the head with body standing on a flat surface and fully extended. + + + + mesh:D001827 + NeSH ontology + + + + mesh:D001827 + Body Height + + + + mesh:D001835 + 8 + + + + mesh:D001835 + The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms. + + + + mesh:D001835 + NeSH ontology + + + + mesh:D001835 + Body Weights + + + + mesh:D002163 + Cameroon + + + + mesh:D002648 + Child + + + + mesh:D002845 + 17 + + + + mesh:D002845 + Techniques used to separate mixtures of substances based on differences in the relative affinities of the substances for mobile and stationary phases. A mobile phase (fluid or gas) passes through a column containing a stationary phase of porous solid or liquid coated on a solid support. Usage is both analytical for small amounts and preparative for bulk amounts. + + + + mesh:D002845 + MeSH ontology + + + + mesh:D002845 + Chromatography + + + + mesh:D003223 + Congo + + + + mesh:D004484 + Ecuador + + + + mesh:D007258 + 7 + + + + mesh:D007258 + Voluntary authorization, by a patient or research subject, with full comprehension of the risks involved, for diagnostic or investigative procedures, and for medical and surgical treatment. + + + + mesh:D007258 + MESH ontology + + + + mesh:D007258 + Informed consent + + + + mesh:D007630 + Kenya + + + + mesh:D011154 + 4 + + + + mesh:D011154 + Qualities and characterization of various types of populations within a social or geographic group, with emphasis on demography, health status, and socioeconomic factors. + + + + mesh:D011154 + MESH ontology + + + + mesh:D011154 + Population Characteristics + + + + mesh:D011642 + 7 + + + + mesh:D011642 + Copies of a work or document distributed to the public by sale, rental, lease, or lending. (From ALA Glossary of Library and Information Science, 1983, p181). + + + + mesh:D011642 + MESH ontology + + + + mesh:D011642 + Publications + + + + mesh:D012424 + Rural population + + + + mesh:D012621 + 7 + + + + mesh:D012621 + Divisions of the year according to some regularly recurrent phenomena usually astronomical or climatic. + + + + mesh:D012621 + From McGraw-Hill Dictionary of Scientific and Technical Terms, 6th ed + + + + mesh:D012621 + Seasons + + + + mesh:D013058 + 17 + + + + mesh:D013058 + An analytical method used in determining the identity of a chemical based on its mass using mass analyzers/mass spectrometers. + + + + mesh:D013058 + MeSH ontology + + + + mesh:D013058 + Mass spectrometry + + + + mesh:D013188 + Sri Lanka + + + + mesh:D014744 + Vietnam + + + + mesh:D014930 + Women + + + + mesh:D015331 + 1 + + + + mesh:D015331 + Studies in which subsets of a defined population are identified. These groups may or may not be exposed to factors hypothesized to influence the probability of the occurrence of a particular disease or other outcome. Cohorts are defined populations which, as a whole, are followed in an attempt to determine distinguishing subgroup characteristics. + + + + mesh:D015331 + MESH ontology + + + + mesh:D015331 + Cohort Studies + + + + mesh:D015986 + 2 + + + + mesh:D015986 + Factors that can cause or prevent the outcome of interest but are not intermediate variables of the factor(s) under investigation. + + + + mesh:D015986 + MeSH ontology + + + + mesh:D015986 + Confounding Factors (Epidemiology) + + + + mesh:D015992 + 8 + + + + mesh:D015992 + An indicator of body density as determined by the relationship of BODY WEIGHT to BODY HEIGHT. BMI=weight (kg)/height squared (m2). BMI correlates with body fat (ADIPOSE TISSUE). Their relationship varies with age and gender. For adults, BMI falls into these categories: below 18.5 (underweight); 18.5-24.9 (normal); 25.0-29.9 (overweight); 30.0 and above (obese). (National Center for Health Statistics, Centers for Disease Control and Prevention). + + + + mesh:D015992 + NeSH ontology + + + + mesh:D015992 + Body Mass Index + + + + mesh:D015994 + 8 + + + + mesh:D015994 + 1) The number of new cases of a given disease during a given period in a specified population. It also is used for the rate at which new events occur in a defined population. It is differentiated from PREVALENCE, which refers to all cases, new or old, in the population at a given time; 2) The number of instances of illness commencing, or of persons falling ill, during a given period in a specified population. More generally, the number of new health-related events in a defined population within a specified period of time. It may be measured as a frequency count, a rate, or a proportion. + + + + mesh:D015994 + 1) MeSH; 2) Porta M. A dictionaryof epidemiology. 6th ed. [Internet]. + + + + mesh:D015994 + Incidence + + + + mesh:D016021 + 1 + + + + mesh:D016021 + Studies designed to examine associations, commonly, hypothesized causal relations. They are usually concerned with identifying or measureing the effects of risk factors or exposures. The common types of analytic study are case-control studies, cohort studies, and cross-sectional studies. + + + + mesh:D016021 + MESH ontology + + + + mesh:D016021 + Epidemiologic Studies + + + + mesh:D016022 + 1 + + + + mesh:D016022 + Comparisons that start with the identification of persons with the disease or outcome of interest and a control (comparison, referent) group without the disease or outcome of interest. The relationship of an attribute is examined by comparing both groups with regard to the frequency or levels of outcome over time. + + + + mesh:D016022 + MESH ontology + + + + mesh:D016022 + Case-control studies + + + + mesh:D016036 + 1 + + + + mesh:D016036 + EPIDEMIOLOGIC STUDIES based on the detection through serological testing of characteristic change in the serum level of specific ANTIBODIES. Latent subclinical infections and carrier states can thus be detected in addition to clinically overt cases. + + + + mesh:D016036 + MESH ontology + + + + mesh:D016036 + Seroepidemiologic study + + + + mesh:D019727 + A person authorized to decide or act for another person, for example, a person having durable power of attorney. + + + + mesh:D019727 + MeSH + + + + mesh:D019727 + Proxy + + + + mesh:D03430 + 1 + + + + mesh:D03430 + Studies in which the presence or absence of disease or other health-related variables are determined in each member of the study population or in a representative sample at one particular time. This contrasts with LONGITUDINAL STUDIES which are followed over a period of time. + + + + mesh:D03430 + MESH ontology + + + + mesh:D03430 + Cross-sectional studies + + + + mesh:D035061 + 7 + + + + mesh:D035061 + 9 + + + + mesh:D035061 + 1) Groups that serve as a standard for comparison in experimental studies. They are similar in relevant characteristics to the experimental group but do not receive the experimental intervention; 2) Controls: Subjects with whom a comparison is made. In a case-control study, controls are often defined as noncases or by other postexposure events, making them especially susceptible to selection bias. Selection of appropriate controls is crucial to the validity of epidemiologic and clinical studies. + + + + mesh:D035061 + Groups that serve as a standard for comparison in experimental studies. They are similar in relevant characteristics to the experimental group but do not receive the experimental intervention. + + + + mesh:D035061 + 1) MeSH; 2) Porta M. A dictionaryof epidemiology. 6th ed. [Internet]. + + + + mesh:D035061 + MESH ontology + + + + mesh:D035061 + Control group + + + + mesh:D035061 + Control groups + + + + mesh:D050218 + 8 + + + + mesh:D050218 + Deposits of ADIPOSE TISSUE throughout the body. The pattern of fat deposits in the body regions is an indicator of health status. Excess ABDOMINAL FAT increases health risks more than excess fat around the hips or thighs, therefore, WAIST-HIP RATIO is often used to determine health risks. + + + + mesh:D050218 + NeSH ontology + + + + mesh:D050218 + Body Fat Distribution + + + + mesh:D055105 + 8 + + + + mesh:D055105 + The measurement around the body at the level of the ABDOMEN and just above the hip bone. The measurement is usually taken immediately after exhalation. + + + + mesh:D055105 + NeSH ontology + + + + mesh:D055105 + Waist Circumference + + + + mesh:D059012 + 10 + + + + mesh:D059012 + Study subjects in COHORT STUDIES whose outcomes are unknown e.g., because they could not or did not wish to attend follow-up visits. + + + + mesh:D059012 + Porta M. A dictionaryof epidemiology. 6th ed. [Internet]. + + + + mesh:D059012 + Lost to follow-up + + + + mesh:D064424 + 6 + + + + mesh:D064424 + Use of TOBACCO (Nicotiana tabacum L) and TOBACCO PRODUCTS. + + + + mesh:D064424 + NeSH ontology + + + + mesh:D064424 + Tobacco use + + + + ctv3:X78x9 + 13 + + + + ctv3:X78x9 + CTV3 ontology + + + + ctv3:X78x9 + Fasting + + + + ctv3:X7AAR + 11-12 + + + + ctv3:X7AAR + CTV3 ontology + + + + ctv3:X7AAR + Faeces sample + + + + ctv3:X7ABI + 11-12 + + + + ctv3:X7ABI + CTV3 ontology + + + + ctv3:X7ABI + Urine sample + + + + ctv3:X7ADQ + 11-12 + + + + ctv3:X7ADQ + CTV3 ontology + + + + ctv3:X7ADQ + Genitourinary samples + + + + ctv3:X7ADl + 11-12 + + + + ctv3:X7ADl + CTV3 ontology + + + + ctv3:X7ADl + Blood sample + + + + ctv3:X7AE1 + 11-12 + + + + ctv3:X7AE1 + CTV3 ontology + + + + ctv3:X7AE1 + Plasma sample + + + + ctv3:X7AE4 + 11-12 + + + + ctv3:X7AE4 + CTV3 ontology + + + + ctv3:X7AE4 + Serum sample + + + + ctv3:XC00r + 10 + + + + ctv3:XC00r + Action + + + + http://purl.bioontology.org/ontology/RCD/4I28. + 11-12 + + + + http://purl.bioontology.org/ontology/RCD/4I28. + CTV3 ontology + + + + http://purl.bioontology.org/ontology/RCD/4I28. + Saliva sample + + + + http://purl.bioontology.org/ontology/SNOMEDCT/698094009 + 5 + + + + http://purl.bioontology.org/ontology/SNOMEDCT/698094009 + BMI: BMI, anthropometric measure, defined as kg/m2. + + + + http://purl.bioontology.org/ontology/SNOMEDCT/698094009 + Porta M. A dictionary of epidemiology + + + + http://purl.bioontology.org/ontology/SNOMEDCT/698094009 + Measurement of body mass index + + + + obo:CMO_0000246 + This measurement is made on the layer of skin and subcutaneous fat raised by pinching the skin and letting the underlying muscle fall back to the bone. It is often used to estimate percentage of body fat. + + + + obo:CMO_0000246 + Clinical Measurement Ontology + + + + obo:CMO_0000246 + Skin fold thickness + + + + obo:EO_0007285 + Rainy season + + + + obo:FOODON_00001015 + Plant food product + + + + obo:FOODON_00001092 + Vertebrate animal food product + + + + obo:FOODON_00001248 + Fish food product + + + + obo:FOODON_03400361 + 3 + + + + obo:FOODON_03400361 + LanguaL curation note: This term is for CLASSIFICATION ONLY; DO NOT USE term in indexing. Use a more precise narrower term. + + + + obo:FOODON_03400361 + FoodOn ontology + + + + obo:FOODON_03400361 + food product type + + + + obo:IAO_0000115 + definition + + + + obo:IAO_0000119 + definition source + + + + obo:OBCS_0000063 + 6 + + + + obo:OBCS_0000063 + 1) Selection bias: Bias in the estimated association or effect of an exposure on an outcome that arises from the procedures used to select individuals into the study or the analysis. When the selection involves conditioning on a factor that is affected by the exposure or a cause of the exposure, and also affected by the outcome or a cause of the outcome, selection bias can arise even in the absence of a causal effect of exposure on outcome; 2) Random selection: any method of sampling that uses some form of random selection, that is, one that will ensure that all units in the population have an equal probability or chance of being selected. + + + + obo:OBCS_0000063 + 1) Porta M. A dictionary of epidemiology. 6th ed. [Internet];2) NWEB: http://srmo.sagepub.com/view/the-sage-dictionary-of-social-research-methods/SAGE.xml + + + + obo:OBCS_0000063 + Random selection + + + + obo:OBCS_0000160 + concurrent validity + + + + obo:OBI_0000366 + 16 + + + + obo:OBI_0000366 + metabolite profiling is a process which aims at detecting and identifying chemical entities resulting from biochemical and cellular metabolism + + + + obo:OBI_0000366 + OBI ontology + + + + obo:OBI_0000366 + Metabolite profiling + + + + sio:SIO_000964 + 7 + + + + sio:SIO_000964 + A standard operating procedure is a specification approved for use in specific environments. + + + + sio:SIO_000964 + Semanticscience Integrated Ontology + + + + sio:SIO_000964 + standard operating procedure + + + + vivo:FundingOrganization + 6 + + + + vivo:FundingOrganization + A defined class of organizations that fund Grants An organization that provides financial support to individuals or organizations to carry out specified activities. + + + + vivo:FundingOrganization + VIVO + + + + vivo:FundingOrganization + Funding Organization + + + + carelex:IRB-IEC_Approval + 7 + + + + carelex:IRB-IEC_Approval + Study Site specific document containing the determination of the Institutional Review Board (IRB) or independent ethics committee (IEC) that the clinical study with human subject participation has been reviewed and may be conducted at a particular study site within the constraints set forth by the IRB and other institutional and federal requirements. + + + + carelex:IRB-IEC_Approval + Content Archive Resource Exchange Lexicon (ontology) + + + + carelex:IRB-IEC_Approval + IRB-IEC Approval + + + + http://www.fao.org/docrep/015/i2698b/i2698b00.pdf + West Africa Food Composition Table (2012), FAO + + + + + + + diff --git a/src/test/resources/repo/input/sifr/foodon.owl b/src/test/resources/repo/input/sifr/foodon.owl new file mode 100644 index 0000000..fcebb38 --- /dev/null +++ b/src/test/resources/repo/input/sifr/foodon.owl @@ -0,0 +1,1763 @@ + + + + + + + + + + + + + +]> + + + + + + + + + + + + + + + + + + + version info + Damion Dooley + William Hsiao + Pier Buttigieg + Robert Hohendorf + + + + + + + + + + + + + + 'immersed in' is a relation between a solid or semi-solid entity and a fluid in which the former is partly or completely submerged in the latter. + PERSON: Damion Dooley + immersed in + + + + + + + + + 'has consumer' is a relation between two entities in which the former can normally be digested or otherwise absorbed by the latter without immediate or persistent ill effect. + Damion Dooley + has consumer + + + + + + + + + + 'has substance added' is a relation existing between a (physical) entity and a substance in which the entity has had the substance added to it at some point in time. The entity contains one or more substances. + Damion Dooley + Note that FoodOn recommends the description of food products in a way that contrasts with LanguaL's practice of having a single Facet B ingredient considered the primary ingredient, and Facet H terms "[food] ADDED" are used to describe remaining ingredients. In FoodOn, Facet B provides the only source of ingredient items, and one uses the object property 'has primary substance added' to indicate if a particuar ingredient is primary; otherwise 'has substance added' is used, without implying its predominance. + +This relation could be annotated with proportions or measurements, as well as process step, in order to describe a particular recipe or processed food. + The relation X 'has substance added' some Y doesn't imply that X still has Y in any detectable fashion subsequent to the addition. Water in dehydrated food is a good example, as is food that undergoes chemical transformation. This definition should encompass recipe ingredients. + has substance added + + + + + + + + + + 'has primary substance added' indicates that an entity has had the given substance added to it in a proportion greater than any other added substance. + Damion Dooley + has primary substance added + + + + + + + + + + + + + + FoodOn is built to interoperate with the OBO Library and to represent entities which bear a “food role”. Its initial focus is a human-centric categorization and handling of food. We aim to develop semantics for food safety, food security, the agricultural and animal husbandry practices linked to food production, culinary, nutritional and chemical ingredients and processes. We intend to expand FoodOn to encompasses materials in natural ecosystems and food webs too. + +Note that FoodOn owes a large debt to LanguaL, the food indexing system developed since the mid 1970's (see LanguaL.org). LanguaL's facets have all been imported here, with some adaptation. + foodon + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + blood meal + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + Damion Dooley Feb 6, 2017: Good meat cut resources to incorporate for Canada: The CFIA Meat Cuts Manual +http://www.inspection.gc.ca/food/labelling/meat-cuts/eng/1300126276015/1300126372856 + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + Sake is a fermented rice beverage resulting from the fermentation of rice with the mold Aspergillus oryzae and, in parallel, with the yeast Saccharomyces cerevisiae [wikipedia:sake] + + + Beer is a fermented cereal beverage resulting from the fermentation most commonly of malted barley (though wheat, corn, or rice may included), by a yeast, most commonly Saccharomyces cerevisiae, and flavored by dried flowers of hops, Humulus lupulus [wikipedia:beer]. + + + http://purl.obolibrary.org/obo/FOODON_03411567 + http://purl.obolibrary.org/obo/FOODON_03411337 + http://purl.obolibrary.org/obo/FOODON_03411359 + http://purl.obolibrary.org/obo/FOODON_03411254 + http://purl.obolibrary.org/obo/FOODON_03411268 + http://purl.obolibrary.org/obo/FOODON_03411338 + + + Wikipedia: https://en.wikipedia.org/wiki/Inverted_sugar_syrup + 'invert sugar' is a combination of glucose and fructose derived from disaccharide sucrose. + + + A whole egg is an egg including the shell, albumen and egg yolk + + + fish meal + + + Damion Dooley's note: this tree of foods for particular animal consumer groups will probably have its items renamed to reflect the consumer group rather than as food constrained by animal type. + + + http://purl.obolibrary.org/obo/FOODON_03520521 + + + http://purl.obolibrary.org/obo/FOODON_03520231 + + + Damion Dooley's note: Country exists to associate food items and recipes with particular geopolitical areas. This hierarchy is repurposed from the Ancestry Ontology (https://www.ebi.ac.uk/ols/ontologies/ancestro). + + + Damion Dooley's note: Ancestral group exists to associate food items and recipes with particular cultures and/or geographic areas. This hierarchy is repurposed from the Ancestry Ontology (https://www.ebi.ac.uk/ols/ontologies/ancestro). + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + diff --git a/test/repo/output/bvga/errors.log b/test/repo/output/bvga/errors.log new file mode 100644 index 0000000..6e4d59e --- /dev/null +++ b/test/repo/output/bvga/errors.log @@ -0,0 +1,4 @@ +++++++++++++++++++++++++++++++++++++++++++++++++++ +Error: OWL_IMPORT_MISSING +Message: http://www.co-ode.org/ontologies/basic-bio/top-bio.owl +++++++++++++++++++++++++++++++++++++++++++++++++++ diff --git a/test/repo/output/bvga/owlapi.xrdf b/test/repo/output/bvga/owlapi.xrdf new file mode 100644 index 0000000..0167f1e --- /dev/null +++ b/test/repo/output/bvga/owlapi.xrdf @@ -0,0 +1,707 @@ + + + + Basic vertebrate anatomy. The major gross pieces largely derived from FMA. + +Imports summary - not full tree +Top-Bio + advanced-relational-properties + refinining-entities-and-properties + Additiona-self-standing + self-standing + very-top + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + Subdivisions are things which are of essentially the same structure as the whole. Examples, lobes and lungs, hand and extremity. + +The important inference is that the subdivision has the same layers and portions as the whole. For example, the hand is a subdivision of the upper extremity. Therefore the skin of the hand is a subdivision of the skin of the upper extremity. + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + Aortic_valve + + + + + + + + + Blood + Blood - + +The "Amount_of_" prefix is is pedantic adherence to DOLCE conventions and technically clearly correct. One cannot have an instance of 'Blood' without some amount. + + + + + + + + + + + + + + + Body_proper + + + + + + + + + + + + + + Brain + + + + + + + + + + + + + + Bronchus + + + + + + + + + + + + + Caranium + + + + + + + + + + Cardiac_atrium + + + + + + + + + + + + Cardiac_chamber + + + + + + + + + + + Cardiac_valve + + + + + + + + + Cardiac_ventricle + + + + + + + + + + Half_heart + + + + + + + + + + + + + + + + + + Head + + + + + + + + + + + + + Heart + + + + + + + + + + + + + + + + + Laterality_selector_value + + + + + + + + + + Left_laterality_value + + + + + + + + + + + + + + + + + Limb + + + + + + + + + + + + Liver + + + + + + + + + Lobe + + + + + + + + + + + + + + + + + + + + Lobe_of_lung + + + + + + + + + + Lower_limb + + + + + + + + + + + Lung + + + + + + + + + Mirror_imaged_value + + + + + + + + + + + Mitral_valve + + + + + + + + + + + + + + + + Neck + + + + + + + + + + + + + + + + + Paired_or_unpaired + Controls whether there are right and left variants. + + + + + + + + + + Paired_value + + + + + + + + + + Pericardium + + + + + + + + + + Pulmonary_valve + + + + + + + + + Right_laterality_value + + + + + + + + + Stomach + + + + + + + + + Trachea + + + + + + + + + Tricuspid_valve + + + + + + + + + + + + + + + Trunk + + + + + + + + + Unpaired_value + + + + + + + + + Upper_limb + + + + + + + + + rfp:Intrinsic_characteristic + + + + + + + + + rfp:Selector + Selectors are those things like right and left, first second, third etc. which imply existence of some several variants of some abstraction type. + + + + + + + + + tbio:Amount_of_Biological_substance + + + + + + + + + tbio:Body + + + + + + + + + tbio:Body_part + + + + + + + + + tbio:Organ + + + + + + + + + tbio:Organ_component + + + + + + + + + tbio:Organ_division + + + + + + + + http://www.co-ode.org/ontologies/basic-bio/basic-vertebrate-gross-anatomy.owl + + + Basic vertebrate anatomy. The major gross pieces largely derived from FMA. + +Imports summary - not full tree +Top-Bio + advanced-relational-properties + refinining-entities-and-properties + Additiona-self-standing + self-standing + very-top + + + Slightly narrower than the FMA's in that it excludes cells and macromolecules. Still aconvenient mechanism. + +Useful as a domain for laterality, pairedness, etc. + + + + + + + diff --git a/test/repo/output/hsdb/owlapi.xrdf b/test/repo/output/hsdb/owlapi.xrdf new file mode 100644 index 0000000..bdc5159 --- /dev/null +++ b/test/repo/output/hsdb/owlapi.xrdf @@ -0,0 +1,10546 @@ + + + + An ontology of objects and relationships in statistics that are useful for describing statistical analysis used in human studies. It is part of the Ontology for Clinical Research (OCRe). + Revision 258 + An ontology for the planning, execution and analysis of clinical research including logitudinal studies and clinical trials. This is designed to be used in conjunction with domain specific models of diseases and measurements which conform to the shared ontology of clinical concepts to provide specific models of studies and trials. + An ontology of study design descriptors and categorization of study design types in terms of their design descriptors. + en + Concept imported from BRIDG that related to the defined activities and schedules of a study protocol. + + $Revision$ + + + + + + + + + + + + + + + + + + + + + + + + + editor preferred term + + The concise, meaningful, and human-friendly name for a class or property preferred by the ontology developers. (US-English) + PERSON:Daniel Schober + GROUP:OBI:<http://purl.obolibrary.org/obo/obi> + editor preferred term + + + + + + + + example + + A phrase describing how a class name should be used. May also include other kinds of examples that facilitate immediate understanding of a class semantics, such as widely known prototypical subclasses or instances of the class. Although essential for high level terms, examples for low level terms (e.g., Affymetrix HU133 array) are not + PERSON:Daniel Schober + GROUP:OBI:<http://purl.obolibrary.org/obo/obi> + example of usage + + + + + + + + in branch + An annotation property indicating which module the terms belong to. This is currently experimental and not implemented yet. + GROUP:OBI + OBI_0000277 + in branch + + + + + + + + has curation status + PERSON:Alan Ruttenberg + PERSON:Bill Bug + PERSON:Melanie Courtot + OBI_0000281 + has curation status + + + + + + + + definition + + The official definition, explaining the meaning of a class or property. Shall be Aristotelian, formalized and normalized. Can be augmented with colloquial definitions. + PERSON:Daniel Schober + GROUP:OBI:<http://purl.obolibrary.org/obo/obi> + definition + + + + + + + + editor note + + An administrative note intended for its editor. It may not be included in the publication version of the ontology, so it should contain nothing necessary for end users to understand the ontology. + PERSON:Daniel Schober + GROUP:OBI:<http://purl.obfoundry.org/obo/obi> + editor note + + + + + + + + definition editor + + Name of editor entering the definition in the file. The definition editor is a point of contact for information regarding the term. The definition editor may be, but is not always, the author of the definition, which may have been worked upon by several people + PERSON:Daniel Schober + GROUP:OBI:<http://purl.obolibrary.org/obo/obi> + definition editor + + + + + + + + alternative term + + An alternative name for a class or property which means the same thing as the preferred name (semantically equivalent) + PERSON:Daniel Schober + GROUP:OBI:<http://purl.obolibrary.org/obo/obi> + alternative term + + + + + + + + definition source + + formal citation, e.g. identifier in external database to indicate / attribute source(s) for the definition. Free text indicate / attribute source(s) for the definition. EXAMPLE: Author Name, URI, MeSH Term C04, PUBMED ID, Wiki uri on 31.01.2007 + PERSON:Daniel Schober + Discussion on obo-discuss mailing-list, see http://bit.ly/hgm99w + GROUP:OBI:<http://purl.obolibrary.org/obo/obi> + definition source + + + + + + + + has obsolescence reason + Relates an annotation property to an obsolescence reason. The values of obsolescence reasons come from a list of predefined terms, instances of the class obsolescence reason specification. + PERSON:Alan Ruttenberg + PERSON:Melanie Courtot + has obsolescence reason + + + + + + + + curator note + + An administrative note of use for a curator but of no use for a user + PERSON:Alan Ruttenberg + curator note + + + + + + + + is denotator type + relates an class defined in an ontology, to the type of it's denotator + In OWL 2 add AnnotationPropertyRange('is denotator type' 'denotator type') + Alan Ruttenberg + is denotator type + + + + + + + + imported from + + For external terms/classes, the ontology from which the term was imported + PERSON:Alan Ruttenberg + PERSON:Melanie Courtot + GROUP:OBI:<http://purl.obolibrary.org/obo/obi> + imported from + + + + + + + + expand expression to + ObjectProperty: RO_0002104 +Label: has plasma membrane part +Annotations: IAO_0000424 "http://purl.obolibrary.org/obo/BFO_0000051 some (http://purl.org/obo/owl/GO#GO_0005886 and http://purl.obolibrary.org/obo/BFO_0000051 some ?Y)" + + A macro expansion tag applied to an object property (or possibly a data property) which can be used by a macro-expansion engine to generate more complex expressions from simpler ones + Chris Mungall + expand expression to + + + + + + + + expand assertion to + ObjectProperty: RO??? +Label: spatially disjoint from +Annotations: expand_assertion_to "DisjointClasses: (http://purl.obolibrary.org/obo/BFO_0000051 some ?X) (http://purl.obolibrary.org/obo/BFO_0000051 some ?Y)" + + A macro expansion tag applied to an annotation property which can be expanded into a more detailed axiom. + Chris Mungall + expand assertion to + + + + + + + + first order logic expression + PERSON:Alan Ruttenberg + first order logic expression + + + + + + + + antisymmetric property + part_of antisymmetric property xsd:true + use boolean value xsd:true to indicate that the property is an antisymmetric property + Alan Ruttenberg + antisymmetric property + + + + + + + + OBO foundry unique label + + An alternative name for a class or property which is unique across the OBO Foundry. + The intended usage of that property is as follow: OBO foundry unique labels are automatically generated based on regular expressions provided by each ontology, so that SO could specify unique label = 'sequence ' + [label], etc. , MA could specify 'mouse + [label]' etc. Upon importing terms, ontology developers can choose to use the 'OBO foundry unique label' for an imported term or not. The same applies to tools . + PERSON:Alan Ruttenberg + PERSON:Bjoern Peters + PERSON:Chris Mungall + PERSON:Melanie Courtot + GROUP:OBO Foundry <http://obofoundry.org/> + OBO foundry unique label + + + + + + + + term replaced by + + Use on obsolete terms, relating the term to another term that can be used as a substitute + Person:Alan Ruttenberg + Person:Alan Ruttenberg + term replaced by + + + + + + + + The annotation that specifies which of the subclasses of a class should have derived complex types + has subclass + + + + + + + + + + + + + + The class annotation that denotes the type of subclass derivation (restriction or extension) that the complex type corresponding to the class uses. + has subclass type + + + + + + + + The class annotation that specifies a property that should be represented as an element tag in the complex type or group corresponding to the class. + data element + + + + + + + + An ontology annotation that denotes the class that should become the root element in a XSD schema export. + xsd root + + + + + + + + The class anootation that denotes the parent from which the complex type corresponding to the class is derived. + has single parent + + + + + + + + A annotation on a property that specifies the string that should be used as the element tag (corresponding to the property) in an XML Schema export. + xsd label + + + + + + + + For classes that are defined as unions of other classes, the XML Schema export should generates a complex type chooses one of the groups that correspond to the children classes specified using this annotation. Thus, for example, if C = A union B. The xsd should contain group A, B each of which has the same component tags as the complex types A, B. The complex type C should be a selection from group A or B. + select group + + + + + + + + has value set type + + + + + + + + + element order + + + + + + + + + + + + + + deprecated:definition + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + is administrative relation of + + + + + + + + + has study + + + + + + + + has data element + + + + + + + + has schema parent + + + + + + + + + has type + + + + + + + + + + + + An encompassing statement of what the investigator's objectives are. The main objective o a study may be to compare drug A and B, and other objectives may be to evaluate the compliance to treatment and the side effects. + has study objective + + + + + + + + + + + has intervention assignment scheme + + + + + + + + + + has study characteristic + + + + + + + + has participant + + + + + + + + administrative property + + + + + + + + + + + has laboratory agreement + + + + + + + + + + + is study assessment/intervention agreement of + + + + + + + + + + + has study performance agreement + + + + + + + + + + is laboratory agreement of + + + + + + + + + + + has funding relation + + + + + + + + + + + is IRB process of + + + + + + + + + + + has sponsoring relation + + + + + + + + + + + has oversight agreement + + + + + + + + + + is sponsoring relation of + + + + + + + + + + + is recruitment agreement of + + + + + + + + + + + + has actor + + + + + + + + + + has study assessment/intervention agreement + + + + + + + + + + is oversight agreement of + + + + + + + + + + has recruitment agreement + + + + + + + + + + has IRB process + + + + + + + + + + is funding relation of + + + + + + + + + is study objective of + + + + + + + + + + is study performance agreement of + + + + + + + + + is an actor of + + + + + + + + + + + has administrative relation + + + + + + + + + + + + Old definition to be updated: The hypothesis of a study pertains the result of primary outcome (also used to calculate sample size) + has study hypothesis + + + + + + + + + + + + + + + + + + + + + + has priority + + + + + + + + + is study hypothesis of + + + + + + + + + is factor variable of + + + + + + + + + + is outcome variable of + + + + + + + + + + + + has study design + + + + + + + + + + + + has comparative intent + + + + + + + + + + + is dependent variable of + + + + + + + + + + + + has allocation type + + + + + + + + has target subject + + + + + + + + + + + is independent variable of + + + + + + + + + + + + + + + "has study design characteristics" is a superproperty of "has study design" and "has study characteristics". Therefore, if a study has design X, and X has design characteristics Y, then the study has study design characteristics Y. + has study design characteristic + + + + + + + + + + + has study status + + + + + + + + + + + + has design characteristic + + + + + + + + + + + The reference time point against which a relative time is defined (e.g., the "enrollment" time in "3 weeks after enrollment"). + has anchor time + + + + + + + + annotation + + + + + + + + + + + + has biospecimen availability + + + + + + + + + + + has biospecimen preservation method + + + + + + + + + + + has biospecimen tissue source + + + + + + + + + + + + has biospecimen type + + + + + + + + + + A code is the terminology code of a concept + code for + + + + + + + + + + + + + + + + + + The duration of an interval or the offset from an anchor time point. + duration + + + + + + + + + The finding associated with a clinical event + has finding + + + + + + + + + + + + "elements" denotes members in the sense of a collection (i.e., object aggregate) containing its elements. It is distinguished from "members" in the sense of social relationship between an organization and its members. + has element + + + + + + + + + + has factor variable + + + + + + + + + + + The population is composed of the indicated study subjects. + has member + + + + + + + + has variable characteristic + + + + + + + + A single research event (a clinical situation itself) has multiple clinical situations as part of its definition. + includes situation + + + + + + + + + + + is defined by + + + + + + + + is code for + + + + + + + + + + + is element of + + + + + + + + + + is member of + + + + + + + + + + has offset + + + + + + + + + A performed activity operationalize a planned activity + operationalize + + + + + + + + operationalized_by + + + + + + + + + + + + + + + + + + + + + + + + + If C and C' are entities or events, C has_part C' if C' is in "part of" relationship with C + has part + + + + + + + + + + + + + + + + + + + + + + + + A component of is a "part-whole" relationship with another component. The component can either be an entity or an event. + part of + + + + + + + + The first event occurs before the second event in time. + precedes + + + + + + + + The procedured performed in a Performed procedure clinical event + procedure + + + + + + + + + + + + + + + + + has_semantic_constraint links syntactic criterion (e.g., eligibility criteria) to a class expression involving other entities and events that describes the things that satisfy the meaning of the criterion + has semantic constraint + + + + + + + + + + + The start time (lower bound) of a time interval + has start time + + + + + + + + + + + The stop time (upper bound) of a time interval + has stop time + + + + + + + + study design object property + + + + + + + + + The first event is the last event occuring immediately before the second event in time. + immediately_precedes + + + + + + + + + + + + derives + + + + + + + + + + + An outcome is_analyzied_using some statistical method + has analysis method + + + + + + + + + + + has analysis type + + + + + + + + + has assessment method + + + + + + + + + + + + + + + + + + HL7 RIM + has effective time + + + + + + + + + + + has biospecimen collected + + + + + + + + + has factor phenomenon + + + + + + + + + A statistical analysis is performed on the outcome variables of designated groups of subjects + has group + + + + + + + + + + + has health condition studied + + + + + + + + + has popoulation + + + + + + + + + + + + ocre:is_derived_from o ocre:has_outcome_phenomenon + has study phenomenon + + + + + + + + + + + + has study protocol + + + + + + + + + + + The phenomenon associated with an outcome may be a clinical phenotype some other phenomenon of interest + has term code + + + + + + + + + + + A relationship between instances Variable specification signifying that the domain variable specification is derived from the range variable specification through some function involving the range variable specification + Samson + is derived from + + + + + + + + + is studied in trial + + + + + + + + + + + is design characteristic of + + + + + + + + + + + is study phenomenon of + + + + + + + + + outcome related property + + + + + + + + + + + has outcome analysis + + + + + + + + + + The property chain "outcome phenomenon o term code => outcome code, causes Pellet to complain about subproperty chain being unsupported feature. + has outcome code + + + + + + + + + + + has outcome variable + + + + + + + + The study has the identified events. + has study event + + + + + + + + + + The study has the identified populations. + has study population + + + + + + + + study population property + + + + + + + + The study has the identified subjects. + has study subject + + + + + + + + + + + The identified clinical situation has the identified clinical subject as its sole or primary subject. + has subject + + + + + + + + + has age restriction + + + + + + + + + + + + has eligibility criterion + + + + + + + + + + is eligibility criterion of + + + + + + + + + has gender restriction + + + + + + + + + The substrance administered in a Substance Administration event + has subjstance administered + + + + + + + + + + The unit component of a Quantity + has unit + + + + + + + + + + The identified clinical subject is the sole or primary subject of the identified clinical situation. + is subject of + + + + + + + + + + + + + + + + + + + + + executed at + + + + + + + + + + + + + + + + + + + + + A StudySite executes some Study Protocol (from BRIDG 1.1.1) + executes + + + + + + + + + A healthcare organization functions as a study site (from BRIDG 1).1.1 + function as + + + + + + + + + + + + + + + + + + + has address + + + + + + + + + + + + + + + + + + has contact for public queries + + + + + + + + + + + + + + + + + + + + has identifier + + + + + + + + + + + + has principal investigator + + + + + + + + + + has recruitment status + + + + + + + + + + + has scheme + + + + + + + + + is address of + + + + + + + + + + A Role is played by some Organization or Entity + is played by + + + + + + + + + is principal investigator of + + + + + + + + + + + + + + + + + + A social institution or entity plays some role + plays + + + + + + + + + + + + + + is sponsor of + + + + + + + + + + + + + + + + has laboratory site + + + + + + + + + is laboratory site of + + + + + + + + + + has study + + + + + + + + + + + + + + is recruitment site of + + + + + + + + + + + + + + is funder of + + + + + + + + + + + has performance site + + + + + + + + + + + + + + + + has IRB + + + + + + + + + + + + + + + has sponsor + + + + + + + + + + + + + + + has funder + + + + + + + + + + + + + + + has recruitment site + + + + + + + + + + + + + is IRB of + + + + + + + + A property of a statistical concept + statistics property + + + + + + + + + + The probability distribution of a variable in a plan for statistical analysis + has distribution + + + + + + + + + + has dependent variable + + + + + + + + + + Specifies that a Variable specification is an independent variable of an Outcome analysis specification + has independent variable + + + + + + + + + + + + A statistical analysis for which a statistical method is permissible, given the data types of the variables involved + is permissible method of + + + + + + + + + + + A permissible statistical method of a statistical analysis, given the data types of the variables involved + has permissible method + + + + + + + + + + + The data type of a variable in a plan for statistical analysis + has measurement dimension + + + + + + + + + + entity conclusions are about + + + + + + + + + + entity directly observed + + + + + + + + + + entity assigned + + + + + + + + + + entity recruited or selected + + + + + + + + + + entity subject to intervention or exposure + + + + + + + + + + finest-grained entity available for analysis + + + + + + + + + + + + + + + + + + + + This is a relationship between two acts. This relationship asserts that an epoch must be a division of one and only one study protocol. This relationship also asserts that a study protocol must be divided into one or more epochs. + is divided into + + + + + + + + + + + + + + + + + + + + This is a relationship between two acts. This relationship asserts that an epoch must be a division of one and only one study protocol. This relationship also asserts that a study protocol must be divided into one or more epochs. + is a division of + + + + + + + + + + dose + + + + + + + + + composite + + + + + + + + + + daily dose total + + + + + + + + + + + dose frequency code + + + + + + + + + + has code + + + + + + + + + + + has planned component relationship + + + + + + + + + + + + + + + + + + + occurs in + + + + + + + + + component + + + + + + + + + + contains + + + + + + + + + + + route of administration + + + + + + + + top study protocol object property + + + + + + + + + + + + + + + + + + + + + has public description + + + + + + + + + + has value + + + + + + + + + + has scientific description + + + + + + + + + + + + has country + + + + + + + + + + has funding number + + + + + + + + + + + + A postal code designating a region defined by the postal service. + Simona + has zip + + + + + + + + + + + has recruitment in the past + + + + + + + + + + study design data property + + + + + + + + + + + + Simona: it does not seem right tha actual sample size is a sub-property of study design data property. + has actual sample size + + + + + + + + + + + has case definition + + + + + + + + + + + + has planned sample size + + + + + + + + + + + has power calculation + + + + + + + + + + + Source of participants and method of recruitment + has recruitment + + + + + + + + administrative data property + + + + + + + + + + + + address + has address string + + + + + + + + + + + + has date of first enrollment + + + + + + + + + + + + has date of last enrollment + + + + + + + + + + + + has public title + + + + + + + + + + + + has scientific title + + + + + + + + + + + + has description date + + + + + + + + + + + has recruitment in the present + + + + + + + + + + + + has recruitment in the future + + + + + + + + + concept descriptor property + + + + + + + + + + + + The plain code symbol defined by the code system, or an expression in a syntax defined by the code system which describes the concept. + +The unique code of a term in a controlled vocabulary. + Simona + HL7 Abstract Data Type specification Release 2 + has code + + + + + + + + + + + + The common name of the coding system. +The code system name has no computational value. +Note: The purpose of a code system name is to assist an unaided human interpreter of a code value to interpret code system. + Simona + HL7 Abstract Data Type specification Release 2 + has code system name + + + + + + + + + + + + If applicable, a version descriptor defined specifically for the given code system. + Simona + HL7 Abstract Data Type specification Release 2 + has code system version + + + + + + + + + + + + A name, title, or representation for the code or expression as it exists in the code system. + +The preferred name of a term in a coding system + Was: has preferred name + Simona + HL7 Abstract Data Type specification Release 2 + has display name + + + + + + + + + + Textual description + has description + + + + + + + + + + has name + + + + + + + + + + + + first name of a person + has first name + + + + + + + + + + + + last name of a person + has last name + + + + + + + + + + + The number of subjects expected to be included in the given population, either for statistical power calculations or based on demographic prediction. + has target number + + + + + + + + + + + The number of individuals who failed to complete the process, procedure or assessment specified because the subject died during the events. + has number lost because of death + + + + + + + + + + + The number of individuals who failed to complete the process, procedure or assessment specified because the subject chose not to complete. + has number lost because of refusal + + + + + + + + + + + The number of individuals who failed to complete the process, procedure or assessment specified because the clinician chose not to complete. + has number lost because of rejection + + + + + + + + + + + The number of individuals who failed to completed the process, procedure or assessment specified for whatever reason. N(considered) = N(completed) + N(lost) + has number lost + + + + + + + + + + + The number of individuals who successfully completed the process, procedure or assessment specified. N(considered) = N(completed) + N(lost) + has completed population number + + + + + + + + + + + The number of individuals who started the process, procedure or assessment specified. N(considered) = N(completed) + N(lost) + has considered population number + + + + + + + + + + + has study population number + + + + + + + + + + + A unique identifier that guarantees the global uniqueness of the instance identifier. The root alone may be the entire instance identifier. + has root + + + + + + + + + + + A character string as a unique identifier within the scope of the identifier root. + has extension + + + + + + + + + + + This is a human-readable name for the namespace represented in the root. It is a descriptive name for the actual namespace. e.g. "California, U.S. Driver's License Number, 1970-". + has identifier name + + + + + + + + + instance identifier property + + + + + + + + + + + Randomization is the process of randomly allocating participants into one of the arms of a controlled trial. There are two components to randomisation: the generation of a random sequence [allocation scheme], and its implementation [allocation concealment method], ideally in a way so that those entering participants into a study are not aware of the sequence (concealment of allocation). + +Examples: +- Centralized (e.g., allocation by a central office unaware of subject characteristics) or pharmacy-controlled. +- On-site computer system holding a locked unreadable computer file that can be accessed only after the characteristics of an enrolled participant have been entered. +- Sequentially numbered, opaque, sealed envelopes. + Simona + Glossary in The Cochrane Collaboration. Available at http://www.cochrane.org/glossary + Allocation concealment method describes the process used to ensure that the person deciding to enter a participant into a randomised controlled trial does not know the comparison group into which that individual will be allocated. This is distinct from blinding, and is aimed at preventing selection bias. Some attempts at concealing allocation are more prone to manipulation than others, and the method of allocation concealment is used as an assessment of the quality of a trial. [Glossary of Terms in The Cochrane Collaboration] + +Examples: +- Centralized (e.g., allocation by a central office unaware of subject characteristics) or pharmacy-controlled. +- On-site computer system holding a locked unreadable computer file that can be accessed only after the characteristics of an enrolled participant have been entered. +- Sequentially numbered, opaque, sealed envelopes. + has allocation concealment method + + + + + + + + + + + Study includes an analysis of cost. + Simona: used ot be a class + has analysis of cost + + + + + + + + + + + [In a case-control study:] Choosing one or more controls with particular matching attributes for each case. Researchers match cases and controls according to particular variables that are thought to be important, such as age and sex. + +In cohort and cross-sectional studies, matching is done for analysis. + Simona + Glossary in The Cochrane Collaboration. Available at http://www.cochrane.org/glossary + has matching + + + + + + + + + + + In a pooled data study, the analysis is performed on subject-level results collected in two or more studies, with their own protocol(s). A study can include both original (de novo) data collection and the use of data pooled from one or more other studies. This is different from meta-analysis, where summary results from different studies are combined. + Simona + Simona: used to be a class. + has pooled data + + + + + + + + + + + has sequence number + + + + + + + + + + + repeat quantity + + + + + + + + + + + + + + IAO:0000027 + data item + + + + + + + + + IAO:0000030 + information content entity + + + + + + + + + + + + + + + + + + + + + + + + IAO:0000078 + curation status specification + + The curation status of the term. The allowed values come from an enumerated list of predefined terms. See the specification of these instances for more detailed definitions of each enumerated value. + Better to represent curation as a process with parts and then relate labels to that process (in IAO meeting) + PERSON:Bill Bug + GROUP:OBI:<http://purl.obolibrary.org/obo/obi> + OBI_0000266 + curation status specification + + + + + + + + + IAO:0000102 + data about an ontology part is a data item about a part of an ontology, for example a term + Person:Alan Ruttenberg + data about an ontology part + + + + + + + + + + + + + + + + + + + + + IAO:0000225 + obsolescence reason specification + + The reason for which a term has been deprecated. The allowed values come from an enumerated list of predefined terms. See the specification of these instances for more detailed definitions of each enumerated value. + The creation of this class has been inspired in part by Werner Ceusters' paper, Applying evolutionary terminology auditing to the Gene Ontology. + PERSON: Alan Ruttenberg + PERSON: Melanie Courtot + obsolescence reason specification + + + + + + + + + + + + + + + + + + IAO:0000409 + The Basic Formal Ontology ontology makes a distinction between Universals and defined classes, where the formal are "natural kinds" and the latter arbitrary collections of entities. + A denotator type indicates how a term should be interpreted from an ontological perspective. + Alan Ruttenberg + Barry Smith, Werner Ceusters + denotator type + + + + + + + + + + + + + + + + + HSDB_OCRe:OCRE536811 + An enumeration of the types of subclassing that are possible in XML Schema (extension and restriction) + Subclass type + + + + + + + + + + + + + + OCRE001000 + A study status applied to a study that has been approved by the relevant regulatory agency (if applicable) and for which protocol-dictated activities are occurring. + Simona + Study active + + + + + + + + + + + + + + + + + + + + + + + + + false + + + + false + + + + true + + + + + + + + + + OCRE085000 + A "recruitment not yet started study" is a study for which participants are not yet being recruited. + Simona + Recruitment not yet started study + + + + + + + + + OCRE158000 + A study population followed prospectively over time. + Simona + Cohort population + + + + + + + + + OCRE182000 + A cohort population whose members share the same assigned intervention. + +Note: arm population is defined only within the context of an interventional study. + Simona + Arm population + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + OCRe:OCRE200107 + A univariate analysis where the independent variable is dichotomous and the dependent variable is quantitative + I dichotomous D quantitative + + + + + + + + + + + + + + OCRE261000 + A recruitment status applied to a study for which participants will not be recruited, because the study is withdrawn. + Simona + Recruitment will not start + + + + + + + + + + + + + + + + + + + + + + + + + OCRE316000 + A "terminated study" is a study that was halted prematurely and will not resume. + Simona + Terminated study + + + + + + + + + OCRE364000 + + Priority + + + + + + + + + + + + + + + + + + + + + + + + OCRE386000 + A "suspended study" is a study for which protocol-dictated activities have halted prematurely but potentially will resume. + Simona + Suspended study + + + + + + + + + + + + + OCRE400000 + A study status applied to a study in the planning stage: protocol is being developed and has not yet been submitted for regulatory approval (if applicable). + Simona + Study planned + + + + + + + + + OCRE400001 + An instance identifier is an identifier that uniquely identifies a thing or object. Examples are object identifier for HL7 RIM objects, medical record number, order id, service catalog item id, Vehicle Identification Number (VIN), etc. Instance identifiers are defined based on ISO object identifiers. + Simona + HL7 Data Types Abstract specification. Available at http://healthinfo.med.dal.ca/hl7intro/CDA_R2_NormativeWebEdition/infrastructure/datatypes/datatypes.htm + + + Instance identifier + + + + + + 1 + + + + + + 2 + + + + + + + + + OCRE400002 + A term imported from some external standard terminology + Domain term + + + + + + + + + + + + + + + + + + + + + OCRE400003 + ocre:OCRE400003 + The recruitment status describes the overall accrual (enrollment) activity for the study. + Simona + + Recruitment status + + + + + + + + + OCRE400004 + An event is a processual entity [span:ProcessualEntity] that is a maximally connected spatiotemporal whole and has bona fide beginnings and endings corresponding to real discontinuities. + +Examples: the life of an organism, the process of sleeping, the process of cell-division + Simona + BFO + Process + Event + + + + + + + + + OCRE400005 + The scheme used to describe the telecommunication address (e.g., ftp, http, etc.) + Simona + + Telecommunication scheme + + + + + + + + + + + + OCRE400006 + A study status applied to a study halted prematurely, prior to enrollment of first participant. + Simona + ClinicalTrials.gov Protocol Data Element Definitions for Overall recruitment status Withdrawn. Available at http://prsinfo.clinicaltrials.gov/definitions.html + Study withdrawn + + + + + + + + + + + + + + + + + + + + + + + + + true + + + + false + + + + true + + + + + + + + + OCRE400009 + A "recruitment suspended study" is a study for which recruiting or enrolling participants has halted prematurely but potentially will resume. + Simona + Recruitment suspended study + + + + + + + + + OCRE400010 + OCRe:OCRE400010 + ocre:OCRE400010 + Classes that define sets of permissible values. + Simona + Value set + + + + + + + + + + + + + + + + + + + + + OCRE400012 + A relative time point is a time point defined in terms of an offset duration before or after a reference or anchor time point (e.g., 2 months after the start of treatment). + Relative time point + + + + + + + + + OCRE400013 + Biospecimen availability describes whether, for a study, biospecimens are available. + Simona + + Biospecimen availability + + + + + + + + + OCRE400014 + ocre:OCRE400014 + A telecommunications address specified according to Internet standard RFC 2396 [http://www.ietf.org/rfc/rfc2396.txt]. The URI specifies the protocol and the contact point defined by that protocol for the resource. Notable uses of the telecommunication address data type are for telephone and telefax numbers, e-mail addresses, Hypertext references, FTP references, etc. + Samson + HL7 Data Types Abstract specification. Available at http://healthinfo.med.dal.ca/hl7intro/CDA_R2_NormativeWebEdition/infrastructure/datatypes/datatypes.htm + + + Telecommunication address + + + + + + + + + OCRE400015 + A physical entity is an entity that has existence in time and space. An entity is that which is perceived or known or inferred to have its own distinct existence (living or nonliving) + Simona + bfo:material entity + Physical entity + + + + + + + + + + + + + OCRE400016 + ocre:OCRE400016 + A recruitment status applied to a study for which participants are currently being recruited. + Simona + ClinicalTrials.gov Protocol Data Element Definition for Overall recruitment status Recruiting. Available at http://prsinfo.clinicaltrials.gov/definitions.html + Recruitment active + + + + + + + + + OCRE400018 + OTC media is a biospecimen preservation method whereby a fresh specimen is frozen onto a sectioning planchet using OCT (Optimum Cutting Temperature) and then stored frozen + Herb + OCT media + + + + + + + + + OCRE400019 + Fast freeze is a biospecimen preservation method whereby the specimen is placed into typically liquid nitrogen or dry ice so the specimen is frozen in seconds then stored colder than (-160° C) + Herb + Fast freeze + + + + + + + + + OCRE400020 + Biospecimen preservation method describes the method used to preserve a biospecimen. + Simona + + Biospecimen preservation method + + + + + + + + + OCRE400021 + A physical substance. For example, drug, device, specimen + Simona + BRIDG 3.0 Available at http://bridgmodel.nci.nih.gov/ + Material + + + + + + + + + OCRE400022 + Formalin fixation is a biospecimen preservation method whereby the specimen is typically fixed overnight in buffered formalin and then embedded in paraffin and stored at room temperature + Herb + Formalin fixation + + + + + + + + + OCRE400023 + The quantity data type is an abstract generalization for all data types (1) whose value set has an order relation (less-or-equal) and (2) where difference is defined in all of the data type's totally ordered value subsets + Quantity + + + + + + + + + OCRE400024 + A point on the time axis of a coordinate system. + + Time point + + + + + + + + + OCRE400025 + An anatomical structure consisting of similarly specialized cells and intercellular matrix, aggregated according to genetically determined spatial relationships, performing a specific function. + Simona + NCI thesaurus entry for Tissue. Available at http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C12801 + Tissue + + + + + + + + + OCRE400026 + A variable is a placeholder for one or a set of data values + Variable + + + + + + + + + OCRE400027 + The function played by entity in some process. When applied to person it implies a set of behavior, rights, and obligations. + Role + + + + + + + + + + + + + + + + + + + + + OCRE400028 + A description of the variables whose data are collected in the study. + Samson + Study data specification + + + + + + + + + OCRE400029 + ocre:OCRE400029 + A study is a program of data collection and of analysis of the data collected to answer a particular question, to reach conclusions about subject(s) or situation(s). + + + + + + + + + + + + + + + + + + + Study + + + + + + 9 + + + + + + 4 + + + + + + 3 + + + + + + 8 + + + + + + 10 + + + + + + 11 + + + + + + 6 + + + + + + 14 + + + + + + 13 + + + + + + 12 + + + + + + 2 + + + + + + 18 + + + + + + 16 + + + + + + 1 + + + + + + 15 + + + + + + 7 + + + + + + 5 + + + + + + 17 + + + + + + + + + + + + OCRE400030 + A recruitment status applied to a study that has concluded recruitment as planned (i.e., last patient in has occurred) + Simona + Recruitment completed + + + + + + + + + OCRE400031 + An abstract data type that is the generalization of all concrete data types + Data value + + + + + + + + + OCRE400032 + ocre:OCRE400032 + A physical thing, group of physical things, an organization or information content that can exist in multiple forms. + Entity + + + + + + + + + + + + + + + + + + + + OCRE400033 + A collection of organisms. + Simona + Organism collection + + + + + + + + + OCRE400034 + A tissue with red blood cells, white blood cells, platelets, and other substances suspended in fluid called plasma. Blood takes oxygen and nutrients to the tissues, and carries away wastes. + Simona + NCI Glossary + Blood + + + + + + + + + OCRE400035 + One or more of the smallest units of living structure capable of independent existence, composed of a membrane-enclosed mass of protoplasm and containing a nucleus or nucleoid. + Simona + NCI Thesaurus entry for Cell. Available at http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C12508 + Cells + + + + + + + + + + + + + + + + + + + + + OCRE400038 + An interval on the time axis of a coordinate system + Time interval + + + + + + + + + OCRE400039 + ocre:OCRE400039 + A postal address is a mailing and home or office address. A sequence of address parts, such as street or post office Box, city, postal code, country, etc. + Simona + HL7 Data Types Abstract specification. Available at http://healthinfo.med.dal.ca/hl7intro/CDA_R2_NormativeWebEdition/infrastructure/datatypes/datatypes.htm + + + + Postal address + + + + + + 2 + + + + + + 1 + + + + + + + + + + + + + + + + + OCRE400040 + ocre:OCRE400040 + An address includes the particulars of where a person or organization has the mail delivered (postal address) or can be reached with means other than mail (telecommunication address). + Simona + + + + Address + + + + + + 1 + + + + + + + + + OCRE400041 + A phenomenon is a fact or event of interest susceptible to scientific description and explanation + Simona + Merriam-Webster's Dictionary entry for phenomenon. Available at http://www.merriam-webster.com/dictionary/phenomenon + Study phenomenon + + + + + + + + + OCRE400042 + Criterion is a placeholder class that represent a Boolean expression (e.g., an eligibility criterion) + Criterion + + + + + + + + + OCRE400044 + A collection is a group of things or people. + Simona + New Oxford American Dictionary + Collection + + + + + + + + + OCRE400046 + An observation is an activity whose intention is to obtain a result by observing, monitoring, measuring or otherwise qualitatively or quantitatively gathering data or information about one or more aspects of a study subject's or experimental unit's physiologic or psychologic state. + +Examples: blood chemistry panel, body mass index calculation, blood pressure measurement. + Simona + BRIDG 3.0.3 definition of DefinedObservation. Available at http://bridgmodel.nci.nih.gov/ + Observation + + + + + + + + + OCRE400047 + A meta-level characterization of a study + Study characteristic + + + + + + + + + + + + + + + + + + + + + + + OCRE400048 + A "withdrawn study" is a study halted prematurely, prior to enrollment of first participant. + Simona + Withdrawn study + + + + + + + + + + + + + + + + + + + + + OCRE400049 + Method for assessing an outcome, such as a questionnaire or laboratory test. + Samson + Assessment method specification + + + + + + + + + + + + + + + + + + + + + OCRE400050 + ocre:OCRE400050 + A description of the variable whose values are the quantitative or enumerable data collected in a study + Samson + + + + + + Variable specification + + + + + + + + + + + + + + + + + + + + + + + + + true + + + + false + + + + false + + + + + + + + OCRE400052 + A "recruitment terminated study" is a study for which recruiting or enrolling participants has halted prematurely and will not resume. + Simona + Recruitment terminated study + + + + + + + + + + + OCRE400053 + A study status applied to a study in which all data has been collected (last patient's last visit has occurred) and the analysis performed. Results may or may not have been published. + Simona + Study completed + + + + + + + + + OCRE400054 + Any fluid in the body including blood, urine, saliva, sputum, tears, semen, milk, or vaginal secretions + Simona + Bodily fluid + + + + + + + + + OCRE400055 + OCRe:OCRE400055 + A CD (concept descriptor) represents any kind of concept usually by giving a code defined in a code system. A concept descriptor can contain the original text or phrase that served as the basis of the coding and one or more translations into different coding systems. A concept descriptor can also contain qualifiers to describe, e.g., the concept of a "left foot" as a postcoordinated term built from the primary code "FOOT" and the qualifier "LEFT". In cases of an exceptional value, the concept descriptor need not contain a code but only the original text describing that concept. + CD (concept descriptor) is a more general form of Coded value (CV). +In HL7 datatype specification CV constrains CE so that there can be neither qualifiers not translations, and only a single concept is allowed. + Samson + HL7 Abstract Data Type specification Release 2 + + + + + + CD + + + + + + 2 + + + + + + 3 + + + + + + 4 + + + + + + 1 + + + + + + + + + OCRE400056 + An ecologic study is a non individual-human study in which the unit of observation is a population or community. + Simona + Adapted from: Epidemiology for the Uninitiated. Available at: http://www.bmj.com/epidem/epid.html + Ecologic study + + + + + + + + + OCRE400057 + OCRe:OCRE400057 + The quantity of time as measured in some unit + A physical quantity of time. + Duration + + + + + + + + + OCRE400059 + Information entity is a structure whose purpose is to hold information. The structure itself is not a model of world. For example, a terminology code has properties such as terminology system, the code for a term (e.g.,"heart failure"), but the code is not a representation of thing that the term designate. + Samson Tu + Information entity + + + + + + + + + OCRE400061 + The collection of organisms that are formally enrolled in a study. + Simona + Enrolled population + Study population + + + + + + + + + OCRE400064 + DEFINITION: +Any individual living (or previously living) being. + Simona + BRIDG 3.0.3 definition of BiologicEntity. Available at http://bridgmodel.nci.nih.gov/ + Organism + + + + + + + + + OCRE400065 + Any material sample taken from a biological entity for testing, diagnostic, propagation, treatment or research purposes, including a sample obtained from a living organism or taken from the biological object after halting of all its life functions. Biospecimen can contain one or more components including but not limited to cellular molecules, cells, tissues, organs, body fluids, embryos, and body excretory products. + Simona + NCI Thesaurus entry for Biospecimen. Available at http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C70699 + Biospecimen + + + + + + + + + OCRE400066 + Slow freeze is a biospecimen preservation method whereby a specimen placed into environment (>or= -80° C) and allowed to freeze over minutes + Herb + Slow freeze + + + + + + + + + OCRE400067 + Para-formaldehyde fixation is a biospecimen preservation method whereby a specimen is typically fixed in para-formaldehyde for hours to days and then embedded in plastic and stored at room temperature + Herb + Para-formaldehyde fixation + + + + + + + + + + + OCRE400068 + A recruitment status applied to a study for which recruiting or enrolling participants has halted prematurely and will not resume. + Simona + ClinicalTrials.gov Protocol Data Element Definition Overall recruitment status Terminated (only the part pertaining enrollment). Available at http://prsinfo.clinicaltrials.gov/definitions.html + Recruitment terminated + + + + + + + + + + + + + + + + + + + + + + + true + + + + + OCRE400069 + A "recruitment active study" is a study for which participants are currently being recruited. + Simona + Recruitment active study + + + + + + + + + OCRE400070 + A clinical event is an event during which an assessment of, or intervention on a study subject occurs. + Simona + Clinical event + + + + + + + + + + + + + + + + + + + + + + + + + true + + + + false + + + + false + + + + + + OCRE400071 + A "recruitment completed study" is a study that has concluded recruitment (i.e., last patient in has occurred). + Simona + Recruitment completed study + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + OCRE400072 + The specification of how an outcome of the study should be analyzed through the use of statistical methods. It includes the specification of the relevant outcome and predictor variables, the cohort groups, time of outcome assessments, and the statistical method to be used. + Samson + Outcome analysis specification + + + + + + + + + + OCRE400073 + A recruitment status applied to a study for which participants are not yet being recruited. + Simona + ClinicalTrials.gov Protocol Data Element Definition for Overall recruitment status Not yet recruiting. Available at http://prsinfo.clinicaltrials.gov/definitions.html + Recruitment not yet started + + + + + + + + + + + + + + + + + + + + + OCRE400074 + The study status describes where the study is in its life-cycle. + Simona + + Study status + + + + + + + + + OCRE400075 + A recruitment status applied to a study for which recruiting or enrolling participants has halted prematurely but potentially will resume. + Simona + ClinicalTrials.gov Protocol Data Element Definition for Overall recruitment status Suspended. Available at http://prsinfo.clinicaltrials.gov/definitions.html + Recruitment suspended + + + + + + + + + + OCRE400076 + ocre:OCRE400076 + A human being + + + + + + Person + + + + + + 5 + + + + + + 1 + + + + + + 2 + + + + + + 4 + + + + + + 3 + + + + + + + + + OCRE400078 + Expression is an information entity that represent a data value or an entity that can be evaluated to yield a data value. + + + Expression + + + + + + 1 + + + + + + + + + + OCRE400079 + ocre:OCRE400079 + A formalized group of persons or other organizations collected together for a common purpose (such as administrative, legal, political) and the infrastructure to carry out that purpose. + Simona + BRIDG 3.0.3 Available at http://bridgmodel.nci.nih.gov/ + + + + + + Organization + + + + + + 1 + + + + + + 3 + + + + + + 2 + + + + + + + + + OCRE400080 + The type of a material sample taken from a biological entity for testing, diagnostic, propagation, treatment or research purposes. This includes particular types of cellular molecules, cells, tissues, organs, body fluids, embryos, and body excretory substances. + Simona + NCI Thesaurus entry for Biospecimen type. Available at: http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C70713 + + Biospecimen type + + + + + + + + + OCRE400115 + A physical quantity is a dimensioned quantity expressing the result of measuring. + Simona + HL7 Data Types Abstract specification. Available at http://healthinfo.med.dal.ca/hl7intro/CDA_R2_NormativeWebEdition/infrastructure/datatypes/datatypes.htm + Physical quantity + + + + + + + + + + + + + + + + + + + + + + OCRE449000 + An "completed study" is a study in which all data has been collected (last patient's last visit has occurred) and the analysis performed. Results may or may not have been published. + Simona + Completed study + + + + + + + + + + + + + + + OCRE50034 + ocre:OCRE50034 + DEFINITION: +Fiscal support for research from industry, government, or non-commercial, non-governmental organizations. + +EXAMPLE(S): +Funding from pharmaceutical, device or biotechnology companies, the US NIH or the Gates Foundation. + Simona + BRIDG 3.0.3 Available at http://bridgmodel.nci.nih.gov/ + + + Funding + + + + + + 1 + + + + + + 2 + + + + + + + + + OCRE50048 + Study administrative relation is a kind of relationship that an entity enters into in the design, conduct, and analysis of a study. The relationship starts when the organization agrees to undertake the activity entailed by the relationship. "Agreement to perform study activity"doesn't mean performance of a specific study activity (e.g., administration of a drug) itself, but agreement to do so. An organization becomes a "participating site" once it agrees to perform activities specified in the study protocol. It doesn't have to perform any of activities yet. + Samson + Study administrative relation + + + + + + + + + OCRE513134 + ocre:OCRE513134 + "Agreement to perform study activity" is a study administrative relation. It doesn't mean performance of a specific study activity (e.g., administration of a drug) itself, but agreement to do so. + Simona + Agreement to perform study activity + + + + + + + + + + + + + + + OCRE535847 + ocre:OCRE535847 + "Agreement to perform overisight" is a study administrative relation that entails agreement to perform some study activity. It doesn't mean performance of oversight per se (e.g., data safety monitoring), but agreement to do so. + Simona + Agreement to perform oversight + + + + + + + + + + + + + + + + + + OCRE541581 + ocre:OCRE541581 + An established society, corporation, foundation or other organization founded and united for a specific purpose, e.g. for health-related research. + NCI Thesaurus entry for Institution. Available at http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C41206 + Simona + Social institution + + + + + + + + + OCRE557116 + ocre:OCRE557116 + A person's permanent place of residence. + Simona + NCI Thesaurus entry for Home. Available at: http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C18002 + Home + + + + + + + + + + + + + + + OCRE568687 + ocre:OCRE568687 + The ethics approval process is a study administrative relation whereby a study is submitted to a committee that is formally designated to approve, monitor, and review biomedical and behavioral research involving humans with the aim to protect the rights and welfare of the research subjects. + Simona + Ethics approval process + + + + + + + + + + + + + + + OCRE581634 + ocre:OCRE581634 + Sponsoring is a study administrative relation whereby a person or organization takes responsibility for the initiation and management, and financing (or arranging the financing) of a clinical trial. + Simona + + + Sponsoring + + + + + + 1 + + + + + + 2 + + + + + + + + + + + + + + + + + + + + + OCRE584000 + An "active study" is a study for which protocol-dictated activities are occurring. + Simona + Active study + + + + + + + + + OCRE590011 + ocre:OCRE590011 + "Agreement to perform study subject assessment" is a study administrative relation that entails agreement to perform some study subject assessment. It doesn't mean performance of study subject assessment per se (e.g., neorologic evaluation), but agreement to do so. + Simona + Agreement to perform study subject assessment or intervention + + + + + + + + + + + + + + + OCRE591890 + ocre:OCRE591890 + "Agreement to perform study laboratory processing" is a study administrative relation that entails agreement to perform some study activity. It doesn't mean performance of study laboratory processing per se (e.g., blood or urine tests), but agreement to do so. + Simona + Agreement to perform study laboratory processing + + + + + + + + + OCRE595405 + ocre:OCRE595405 + Agreement to recruit + + + + + + + + + + + + + + + + + + + + OCRE740000 + A "planned study" is a study in the planning stage: protocol is being developed and has not yet been submitted for regulatory approval (if applicable). + Simona + Planned study + + + + + + + + + OCRE793000 + Objective + + + + + + + + + OCRe:OCRE817858 + Cf BRIDG 3.03 DefinedSubstanceAdministraiotn definition +An activity that is an action of applying, dispensing or otherwise giving medications or other substances. + +Example: Administration of methotrexate as part of chemotherapy. + Simona + BRIDG 3.0.3 definition of DefinedSubstanceAdministration. Available at http://bridgmodel.nci.nih.gov/ + Planned substance administration + + + + + + + + + + OCRE824000 + A status applied to a study for which protocol-dictated activities have halted prematurely but potentially will resume. + Simona + Study suspended + + + + + + + + + + + + + + + + + + + + OCRE831288 + Study classified by study status + + + + + + + + + + + + + + + + + + + + OCRE832477 + Study that recruit study subjects + + + + + + + + + OCRE873851 + The collection of screened organisms that satisfies all eligibility criteria for a study. + Simona + Eligible population + + + + + + + + + OCRE882000 + Hypothesis + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + OCRe:OCRE900300 + A univariate analysis where the independent variable is dichotomous and the dependent variable is nominal with cardinality greater than 2 + I dichotomous D nominalGT2 + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + OCRe:OCRE900301 + A univariate analysis where the independent variable nominal with cardinality greater than 2 and the dependent dependent variable is nominal with cardinality greater than 2 + I nominalGT2 D nominalGT2 + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + OCRe:OCRE900302 + A univariate analysis where the independent variable is ordinal and the dependent variable is nominal with cardinality greater than 2 + I ordinal D nominalGT2 + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + OCRe:OCRE900303 + A univariate analysis where the independent variable is quantitative and the dependent variable is nominal with cardinality greater than 2 + I quantitative D nominalGT2 + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + OCRe:OCRE900304 + A univariate analysis where the independent variable is dichotomous and the dependent variable is ordinal + I dichotomous D ordinal + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + OCRe:OCRE900305 + A univariate analysis where the independent variable is nominal with cardinality greater than 2 and the dependent variable is ordinal + I nominalGT2 D ordinal + + + + + + + + + + + + + + + + + + + + + + + + + OCRe:OCRE900306 + A univariate analysis where the independent variable is ordinal and the dependent variable is ordinal + I ordinal D ordinal + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + OCRe:OCRE900307 + A univariate analysis where the independent variable is quantitative and the dependent variable is ordinal + I quantitative D ordinal + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + OCRe:OCRE900308 + A univariate analysis where the independent variable is nominal with cardinality greater than 2 and the dependent variable is quantitative + I nominalGT2 D quantitative + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + OCRe:OCRE900309 + A univariate analysis where the independent variable is ordinal and the dependent variable is quantitative + I ordinal D quantitative + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + OCRe:OCRE900310 + A univariate analysis where the independent variable is quantitative and the dependent variable is quantitative + I quantitative D quantitative + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + OCRe:OCRE900311 + A univariate analysis where the independent variable is dichotomous and the dependent variable is survival + I dichotomous D survival data + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + OCRe:OCRE900312 + A univariate analysis where the independent variable is ordinal and the dependent variable is survival + I ordinal D survival data + + + + + + + + + OCRE908000 + A status applied to a study for which protocol-dictated activities have halted prematurely and will not resume. + Simona + Study terminated + + + + + + + + + + + + + + + + + + + + + + + + + false + + + + false + + + + false + + + + + OCRE992000 + A "recruitment will not start study" is a study for which participants have not, are not, and will not be recruited. + Simona + Recruitment will not start study + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + OCRE400043 + A study site is a participating site in which study subject assessments or interventions are conducted. + Simona + Study site + + + + + + + + + + + + + + + + + + + OCRE441000 + Recruitment not active + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + OCRE500000 + An IRB [Institutiona Review Board] is a specially constituted independent review body comprised of medical, scientific and non-scientific members established and designated by an entity to ensure the protection of the rights, safety and well-being of human subjects recruited to participate in biomedical or behavioral research according to the requirements outlined in Title 38, part 16 (same as Title 45, part 46 and Title 21, part 56) of the U.S. Code of Federal Regulations. IRB responsibility include but not limited to the reviewing, approving, and providing continuing review of trial protocol and amendments and of the methods and material(s) to be used in obtaining and documenting informed consent of the trial. Other equivalent committees with the same or similar functions are also considered to be IRBs. + Simona + NCI Thesaurus entry for Institutional Review Board. Available at http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C16741 + + + ERB + IEC + IRB + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + OCRE511747 + A recruitment site is a study site where finding and enrolling appropriate study subjects (those selected on the basis of the protocol's inclusion/exclusion criteria) into a study occurs. + Simona + + + Recruitment site + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + OCRE534000 + An organization or a person that underwrites financial support for projects of a particular type. Typically, they process applications and award funds to the chosen qualified applicants. + Simona + NCI Thesaurus entry for Funding Agency. Available at http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C39409 + + + Funder + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + OCRE534515 + An organization that approves, monitors and reviews biomedical research to protect the rights, safety and welfare of the study subjects. This committee performs critical oversight functions for research conducted on human study subjects that are scientific, ethical, and regulatory. + +EXAMPLE(S): +Institutional Review Board (IRB), ethics committee, research ethics board, etc. + Data safety monitoring committee, protocol review and monitoring committee (or board) + Simona + BRIDG 3.0.3 Available at http://bridgmodel.nci.nih.gov/ + + + Oversight committee + + + + + + + + + + + + + + + + + + OCRE546280 + A human being OR A formalized group of persons or other organizations collected together for a common purpose (such as administrative, legal, political) and the infrastructure to carry out that purpose. + Simona + + + Person or Organization + + + + + + + + + + + + + + + + + OCRE560892 + + Person or Social institution + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + OCRE571000 + Sponsor means a person who initiates a clinical investigation, but who does not actually conduct the investigation, i.e., the test article is administered or dispensed to or used involving, a subject under the immediate direction of another individual. A person other than an individual (e.g., corporation or agency) that uses one or more of its own employees to conduct a clinical investigation it has initiated is considered to be a sponsor (not a sponsor-investigator), and the employees are considered to be investigators. + Simona + Code of Federal Regulations, Title 21, Volume 1, Revised as of April 1, 2010: 21CFR50.3. Available at http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=50.3 + + + Sponsor + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + OCRE598434 + A laboratory site is an organization where some laboratory processing for the study occurs. + Simona + + + Laboratory site + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + OCRE598730 + A participating site is a social institution where study activities are conducted + Simona + + + Participating site + + + + + + + + + OCRe_ext:OCRE867266 + An enumeration of different representations of value sets in the ontology. + + Value set type + + + + + + + + + OCRE200000 + Variables whose values are one or more labels for predefined categories that enumerate possble states of some characteristic (e.g., blood types A, B, AB, or O). AKA "categorical data" + Nominal scale level + + + + + + + + + + OCRE200001 + Measurements whose values are in one of two possible states, these often being labeled 0 and 1. + Samson + adapted from Cambridge Dictionary of Statistics 3rd edition + Dichotomous + + + + + + + + + + + + + + + + + OCRE200002 + A typology of scales measure + Dimensions about how data can be ordered + Samson + Variable dimension + + + + + + + + + OCRE200003 + A numeric characteristic of a distribution or of a random variable + Samson + Descriptive statistics + Distributional metric + + + + + + + + + OCRE200004 + A chi-square test (also chi squared test or χ2 test) is any statistical hypothesis test in which the sampling distribution of the test statistic is a chi-square distribution when the null hypothesis is true, or any in which this is asymptotically true, meaning that the sampling distribution (if the null hypothesis is true) can be made to approximate a chi-square distribution as closely as desired by making the sample size large enough. + Simona + Wikipedia entry for Chi-square test. Available at http://en.wikipedia.org/wiki/Chi-square_test + Chi-square test + + + + + + + + + OCRE200005 + Mixed linear model + + + + + + + + + OCRE200006 + [see standard reference] + Linear regression + + + + + + + + + + OCRE200007 + The range is the difference between the lowest and highest numerical values; the limits or scale of variation. + Simona + NCI Thesaurus entry for Range. Available at http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C38013 + Range + + + + + + + + + OCRE200008 + The right boundary is not included in the interval + [ ) + Simona + Right open + + + + + + + + + OCRE200009 + [see standard reference] + Poisson regression + + + + + + + + + OCRE200010 + An index of performance of a discriminant test calculated as the percentage of correct positives in all true postives + Samson + recall + Sensitivity + + + + + + + + + OCRE200011 + A ratio is a quotient of quantities of the same kind for different components within the same system. + Simona + NCI Thesaurus entry for Ratio. Available at http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C44256 + Ratio + + + + + + + + + OCRE200012 + Exact test + + + + + + + + + OCRE200013 + The Kruskal-Wallis one-way analysis of variance by ranks (named after William Kruskal and W. Allen Wallis) is a non-parametric method for testing equality of population medians among groups. It is identical to a one-way analysis of variance with the data replaced by their ranks. It is an extension of the Mann-Whitney U test to 3 or more groups. + Simona + Wikipedia entry for Kruskal–Wallis one-way analysis of variance. Available at http://en.wikipedia.org/wiki/Wallis_statistic + Kruskal Wallis method + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + OCRE200014 + A plan for multivariate analysis where the independent variable is nominal and the dependent variable is quantitative + Simona: needs review; labels and definitions in this subtree are not clear. + Multivariate I nominal D quantitative + + + + + + + + + OCRE200015 + A measurement that allows a sample of individuals to be ranked with respect to some characteristics but where differences at different points of the scale are not necessarily equivalent. (Cambridge Dictionary of Statistics 3nd ed.) + Ordinal scale level + + + + + + + + + + + + + + + + + + + + + + + + + OCRE200016 + A univariate analysis where the independent variable is nominal + Independent variable nominal + + + + + + + + + OCRE200017 + In S. Steven's typology of measurement scale, a variable is "a continuous variable that has an arbitrary zero point." + Cannot meaningfully compute ratios + Cambridge Dictionary of Statistics 3rd edition + Interval scale level + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + OCRE200018 + A univariate analysis where the independent variable is quantitative and the dependent variable is dichotomous + I quantitative D dichotomous + + + + + + + + + OCRE200019 + [see standard reference] + Robust regression + + + + + + + + + OCRE200020 + In point observation, the width of the censoring interval is 0. +The frequency of measurements prevents one from being more accurate in time, or one of the possible states cannot be observed. + +Example: we are all biallelic, but sometimes we cannot observe both allels + [x, y] x=y + Simona + Point observation + + + + + + + + + OCRE200021 + The event occurred within an interval, but it is not known exactly when. + +Example: the last measurement day one person was HIV negative and the first measurement day the person was positive are known, but when the seroconversion happened within that interval is not known + [x, y] x~=y + Simona + Interval censored + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + OCRE200022 + A univariate analysis where the independent variable is nominal with cardinality greater than 2 and the dependent variable is dichotomous + I nominalGT2 D dichotomous + + + + + + + + + OCRE200023 + A distribution function used to describe the occurrence of rare events or to describe the sampling distribution of isolated counts in a continuum of time or space. This special probability distribution can apply to the number of discrete independent random events occurring in a given interval when knowing their average rate of occurrence over a very long interval. + Simona + NCI Thesaurus entry for Poisson distribution. Available at http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C53212 + Poisson distribution + + + + + + + + + OCRE200024 + A metric measuring the "middle" or "expected" value of a distribution or of a random variable + Samson + Central tendency + + + + + + + + + OCRE200025 + A proportion is a measure of the frequency of some phenomenon of interest within an average population + Ranges from 0 to 1. One way to summarize count data. + Proportion + + + + + + + + + OCRE200026 + Method for deriving a variable by scoring from multiple observations or aggregating from multiple events in a subject or from multiple subjects + E.g., population-level variables + Scoring or aggregation method + + + + + + + + + OCRE200027 + [see standard reference] + Logistic regression + + + + + + + + + OCRE200028 + A quotient is the result obtained by dividing one quantity by another + Simona + Quotient + + + + + + + + + OCRE200029 + [see standard reference] + Z-test + + + + + + + + + OCRE200030 + Infinite non-countable + + + + + + + + + OCRE200031 + Both boundaries are included in the interval + [ ] + Simona + Closed + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + OCRE200032 + A univariate analysis where the dependent variable is nominal with cardinality greater than 2 + Dependent variable nominalGT2 + + + + + + + + + OCRE200033 + The analysis of variance is a collection of statistical models, and their associated procedures, in which the observed variance is partitioned into components due to different explanatory variables. [source: Wikipedia] The total variation displayed by a set of observations, as measured by the sums of squares of deviations from the mean, may in certain circumstances be separated into components associated with defined sources of variation used as criteria of classification for the observations. Such an analysis is called an analysis of variance, although in the strict sense it is an analysis of sums of squares. + Simona + OECD Glossary of Statistical Terms entry for Variance Analysis. Available at http://stats.oecd.org/glossary/detail.asp?ID=3885 + Analysis of variance + + + + + + + + + OCRE200034 + How measurements of "equal value" of interval data can be differentiated +Whether 0, 1 or both interval boundaries are included. + Simona + Interval data tie-breaking distinction + + + + + + + + + OCRE200035 + Variables derived from taking the sum of two other variables + Sum + + + + + + + + + OCRE200036 + Variables whose values are unitary measurements that cannot be defined from other variables + Scale level + + + + + + + + + OCRE200037 + The lambda co-efficient of an exponential distribution + Lambda + + + + + + + + + + OCRE200038 + Ties are exact + Discrete + + + + + + + + + + OCRE200039 + The median is the middle value in a data set: i.e., the value which has an equal number of values greater and less than it. + Simona + Median + + + + + + + + + OCRE200040 + Variables derived from taking the difference of two other variables. For example, the first difference of a time series {yt} is defined as Dyt = yt - yt-1 + Difference + + + + + + + + + OCRE200041 + In probability theory and statistics, the exponential distribution (a.k.a. negative exponential distribution) is a family of continuous probability distributions. It describes the time between events in a Poisson process, i.e. a process in which events occur continuously and independently at a constant average rate. + A class of probability distribution with probability density function (pdf) of f(x;lambda) = 1 - exp(-lambda*x) for x >-0 ; 0 otherwise + Simona + Wikipedia entry for Exponential distribution. Available at http://en.wikipedia.org/wiki/Exponential_distribution + Exponential distribution + + + + + + + + + OCRE200042 + A rate is a quantity per unit of time. + (Cambridge Dictionary of Statistics 3nd ed.) A measure of the frequency of some phenomenon of interest given by rate: number of events in specified period / average population during the period. + +The (Cambridge Dictionary of Statistics 3nd ed.) definition of rate is our definition of proportion. + Rate + + + + + + + + + OCRE200043 + In probability theory, a log-normal distribution is a probability distribution of a random variable whose logarithm is normally distributed. If X is a random variable with a normal distribution, then Y = exp(X) has a log-normal distribution; likewise, if Y is log-normally distributed, then X = log(Y) is normally distributed. (This is true regardless of the base of the logarithmic function: if loga(Y) is normally distributed, then so is logb(Y), for any two positive numbers a, b ≠ 1.) + Simona + Wikipedia entry for Log-normal distribution. Available at http://en.wikipedia.org/wiki/Log-normal_distribution + Log-normal distribution + + + + + + + + + OCRE200044 + [see standard reference] + Polychotomous regression + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + OCRE200045 + A univariate analysis where the independent variable is dichotomous and the dependent variable is dichotomous + I dichotomous D dichotomous + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + OCRE200046 + A plan for multivariate analysis where the independent variable is nominal and the dependent variable is nominal with cardinality greater than 2 + Simona: needs review; labels and definitions in this subtree are not clear. + Multivariate I nominal D nominalGT2 + + + + + + + + + OCRE200047 + A categorical method is a statistical technique that uses categorical (nominal) data. + Simona + Categorical method + + + + + + + + + OCRE200048 + The left boundary is not included in the interval + ( ] + Simona + Left open + + + + + + + + + + + + + + + + + OCRE200049 + Quantitative scale level + + + + + + + + + OCRE200050 + In probability theory and statistics, the chi-square distribution (also chi-squared or χ²-distribution) with k degrees of freedom is the distribution of a sum of the squares of k independent standard normal random variables. + Simona + Wikipedia entry for Chi-square distribution. Available at http://en.wikipedia.org/wiki/Chi-square_distribution + Chi-square distribution + + + + + + + + + OCRE200051 + Non-linear model + + + + + + + + + OCRE200052 + Neither boundary is included in the interval + ( ) + Simona + Open + + + + + + + + + OCRE200053 + statistics:OCRE200053 + Meta data characterizing the plan to analyze a set of data + Statistical analysis type + + + + + + + + + + + + 2 + + + OCRE200054 + [see standard reference] + Cox regression + + + + + + + + + OCRE200055 + The variate distance between the upper and lower quartiles. This range contains one half of the total frequency and provides a simple measure of dispersion which is useful in descriptive statistics + OECD glossary of Statistical Terms entry for Interquartile range. Available at http://stats.oecd.org/glossary/detail.asp?ID=3761 + Interquartile range + + + + + + + + + OCRE200056 + [see standard reference] + Quantile regression + + + + + + + + + OCRE200057 + The mean is the sum of a set of values divided by the number of values in the set. + Simona + NCI thesaurus entry for Mean Available at http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C53319 + Statistical mean + Mean + + + + + + + + + OCRE200058 + The mode is the value which occurs most often in a set of values. If no value is repeated, there is no mode. If more than one value occurs with the same greatest frequency, each value is a mode. + Simona + NCI thesaurus entry for Mode. Available at http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C53320 + Mode + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + OCRE200059 + A univariate analysis where the independent variable is ordinal with cardinality greater than 2 and the dependent variable is dichotomous + I ordinalGT2 D dichotomous + + + + + + + + + + + + + + + + + + + + + + + + + OCRE200060 + A univariate analysis where the dependent variable is ordinal + Dependent variable ordinal + + + + + + + + + OCRE200061 + statistics:OCRE200061 + A procedure for performing statistical inference + Note that we are excluding descriptive statistical method + Statistical method + + + + + + + + + OCRE200062 + Ties are not exact + Continuous + + + + + + + + + OCRE200063 + In probability theory and statistics, the gamma distribution is a two-parameter family of continuous probability distributions. It has a scale parameter θ and a shape parameter k. If k is an integer, then the distribution represents an Erlang distribution, i.e., the sum of k independent exponentially distributed random variables, each of which has a mean of θ (which is equivalent to a rate parameter of θ −1) . +The gamma distribution is frequently a probability model for waiting times; for instance, in life testing, the waiting time until death is a random variable that is frequently modeled with a gamma distribution. + Simona + Wikipedia entry for Gamma distribution. Available at http://en.wikipedia.org/wiki/Gamma_distribution + Gamma distribution + + + + + + + + + OCRE200064 + The event occurred some time before the last measurement, but it is not known exactly when. + +Example: one person tests HIV positive, but there is no negative test result, so it is not possible to estalish a time interval for seroconversion + [x, y], x unknown + Simona + Left censored + + + + + + + + + OCRE200065 + In probability theory and statistics, the binomial distribution is the discrete probability distribution of the number of successes in a sequence of n independent yes/no experiments, each of which yields success with probability p. Such a success/failure experiment is also called a Bernoulli experiment or Bernoulli trial. + Simona + Wikipedia entry for Binomial distribution. Available at http://en.wikipedia.org/wiki/Binomial_distribution + Binomial distribution + + + + + + + + + OCRE200066 + [see standard reference] + Spearmans rank correlation coefficient + + + + + + + + + OCRE200067 + General estimating equation + + + + + + + + + OCRE200068 + Odds is a quotient in which the relative likelihood that an event will occur is divided by the the relative likelihood that it won't. In probability theory and statistics, where the variable "p" is the probability in favor of the event, and the probability against the event is 1-p, "the odds" of the event are the quotient of the two, or p / (1-p) + Simona + Odds + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + OCRE200069 + A plan for multivariate analysis where the independent variable is multivariate and the dependent variable is ordinal + Simona: needs review; labels and definitions in this subtree are not clear. + Multivariate D ordinal + + + + + + + + + OCRE200070 + [see standard reference] + Student's t-test + + + + + + + + + OCRE200071 + Generalized linear model + + + + + + + + + OCRE200072 + Object and values that related to the description of statistical analysis + Statistical concept + + + + + + + + + + + + 1 + + + OCRE200073 + Logrank test + Simona: changed label to 'Product limit estimation', which can be tested with a logrank test and the result is the Kaplan-Meier curve. The logrank test allows to compare two or more KM curves + Product limit estimation + + + + + + + + + OCRE200074 + The analysis of covariance (ANCOVA) is a general linear model with one continuous outcome variable (quantitative) and one or more factor variables (qualitative). ANCOVA is a merger of ANOVA and regression for continuous variables. ANCOVA tests whether certain factors have an effect on the outcome variable after removing the variance for which quantitative predictors (covariates) account. + Simona + Wikipedia entry for Analysis of covariance. Available at: http://en.wikipedia.org/wiki/Analysis_of_covariance + Analysis of covariance + + + + + + + + + OCRE200075 + The variance is the mean square deviation of the variable around the average value. It reflects the dispersion of the empirical values around its mean. (http://stats.oecd.org/glossary/detail.asp?ID=5160) + Variance + + + + + + + + + OCRE200076 + Number of possible outcomes + Describe background of data, how to present data when you plot it + Granularity + + + + + + + + + OCRE200077 + A plot of the sensitivity of a discriminant test against one minus its specificity + ROC curve + + + + + + + + + OCRE200078 + The normal distribution is a family of probability density functions whose mean, median and mode are identical. The function generates a symmetrical curve, whose position and shape is determined by its location and scale parameters, the mean and standard deviation respectively. The standard normal distribution has a location parameter of 0 and a scale parameter of 1. + Simona + NCI Thesaurus entry for Normal distribution. Available at http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C53215 + Normal distribution + + + + + + + + + + + + + + + + + + + + + + + + + OCRE200079 + A univariate analysis where the dependent variable is dichotomous + Dependent variable dichotomous + + + + + + + + + OCRE200080 + A distribution metric of the exponential distribution + Exponential distribution metric + + + + + + + + + OCRE200081 + [see standard reference] + Wilcoxon rank sum test + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + OCRE200082 + A plan for multivariate analysis where the independent variable is multivariate and the dependent variable is survival data + Simona: needs review; labels and definitions in this subtree are not clear. + Multivariate D survival data + + + + + + + + + OCRE200083 + In probability theory and statistics, the discrete uniform distribution is a probability distribution whereby a finite number of equally spaced values are equally likely to be observed; every one of n values has equal probability 1/n. Another way of saying "discrete uniform distribution" would be "a known, finite number of equally spaced outcomes equally likely to happen." +If a random variable has any of n possible values that are equally spaced and equally probable, then it has a discrete uniform distribution. The probability of any outcome ki is 1 / n. A simple example of the discrete uniform distribution is throwing a fair die. + Simona + Wikipedia entry for Uniform distribution (discrete). Available at http://en.wikipedia.org/wiki/Uniform_distribution_(discrete) + Discrete uniform distribution + + + + + + + + + OCRE200084 + Categorical variables with more than two categories + Polychotomous + + + + + + + + + OCRE200085 + How measurements of "equal value" can be differentiated + Simona + Tie-breaking distinction + + + + + + + + + OCRE200086 + A measure of a test's accuracy defined as the harmonic mean of sensitivity and specificity F= 2*(specificity * sensitivity)/(specificity + sensitivity) + F1 score + F measure + + + + + + + + + OCRE200087 + For a discrete random variable, a mathematical formula that gives the probability of each value of the variable. For a continuous random variable, a curve described by a mathematical formula which specifies, by way of areas under the curve, the probability that the variable falls within a particular interval. + Cambridge Dictionary of Statistics 3rd edition + Probability distribution + + + + + + + + + OCRE200088 + Censoring type is a particular type of interval creation. +Censoring means that one event prevents another event from being observed (e.g., end of study prevents possible evidence of success or failure from being observed). +Though usually employed in the context of time-to-failure, this is not only about time, but it can be about any dimension of interest (e.g., if the measurement is above the maximum value in the scale used, then the measurement is right censored; if it is lower than the minimum detectable, then it is left censored). + Simona + Censoring type + + + + + + + + + OCRE200089 + In S. Steven's typology of measurement scale, a ratio variable is "a continuous variable that has a fixed rather than an arbitrary zero point." + +Examples: weight, height, temperature measured in degrees Kelvin + Can compute ratios + Cambridge Dictionary of Statistics 3rd edition + Absolute scale level + + + + + + + + + OCRE200090 + An index of performance of a discriminant test calculated as the percentage of negatives in all true negatives + Samson + Specificity + + + + + + + + + OCRE200091 + Polychotomous finite + + + + + + + + + + + + + + 1 + + + + + + OCRE200092 + A plan for statistical analysis where there is only one independent variable + Univariate analysis + + + + + + + + + OCRE200093 + A metric measuring the variability of a distribution or of a random variable + Dispersion + + + + + + + + + OCRE200094 + Polarity + + + + + + + + + OCRE200095 + An time-to-failure method is a statistical technique relating to preparation of mortality and other analytical tables. It uses data from the past to predict the future. + Simona + Time-to-failure method + + + + + + + + + OCRE200096 + In probability theory and statistics, the continuous uniform distribution or rectangular distribution is a family of probability distributions such that for each member of the family, all intervals of the same length on the distribution's support are equally probable. The support is defined by the two parameters, a and b, which are its minimum and maximum values. The distribution is often abbreviated U(a,b). + Simona + Wikipedia entry for Uniform distribution (continuous). Available at http://en.wikipedia.org/wiki/Uniform_distribution_(continuous) + Simona: Wikipedia entry "does not cite any references or sources" Confirmation needed + Continuous uniform distribution + + + + + + + + + + + + + + + + + + + + + + + + + + + 2 + + + + + + OCRE200097 + A plan for statistical analysis where there is more than one independent variable and some of those variables are not of the ordinal scale + Multivariate analysis I non-ordinal + + + + + + + + + + + + + + + + + + + + + + + + + OCRE200098 + A univariate analysis where the dependent variable is interval/absolute scale level + Dependent variable quantitative scale + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + OCRE200099 + A plan for multivariate analysis where some independent variables are non-ordinal and the dependent variable is dichotomous + Simona: needs review; labels and definitions in this subtree are not clear. + Multivariate I non-ordinal D dichotomous + + + + + + + + + OCRE200100 + An index of performance of a discriminant test with binary outcome + Samson + Classification analysis metric + + + + + + + + + OCRE200101 + In mathematics, a countable set is a set with the same cardinality (number of elements) as some subset of the set of natural numbers. + Simona + Wikipedia entry for Countable set. Available at http://en.wikipedia.org/wiki/Countable_set + Infinite countable + + + + + + + + + OCRE200102 + Linear mixed effect model + + + + + + + + + OCRE200103 + Data representing the times of the occurrances of events of interest + On scale of time. Often censored. A difference in time. +Also whether an event occurs (lowerbound of time to event) Measurement can be one number or an interval. 3 categories: same L & Ul, right censoring (know lowerbound), an interval + Survival data + Time to event + + + + + + + + + OCRE200104 + Non linear mixed effect model + + + + + + + + + OCRE200105 + The event my have occurred some time after the last measurement, but it is not known exactly whether it has, because there are no further observations. + +Example: one person tests HIV negative at some point, but there are no further observations (e.g., the individual moved, or died), so it is not known whether the person has seroconverted or not + [x, y], x unknown + Simona + Right censored + + + + + + + + + + + + + + + + + + + + + + + + + OCRE200106 + A univariate analysis where the dependent variable is survival data + Dependent variable survival data + + + + + + + + + OCRE693000 + How measurements of "equal value" of point data can be differentiated + Simona + Point data tie-breaking distinction + + + + + + + + + + study_design:OCRE100001 + Each case serves as its own control + Simona + Case and control in same experimental unit + + + + + + + + + study_design:OCRE100002 + In the context of a study where the main comparison is within experimental units, investigator assigns regimen of interventions to an allocation group made up of one (single) or of more than one (multiple) experimental unit. + Simona + + Allocation group cardinality + + + + + + + + + study_design:OCRE100003 + The scheme used to assign regimens of interventions: single factor or factorial. + Simona + + Intervention assignment scheme + + + + + + + + + + study_design:OCRE100004 + Cases and controls (or exposed and unexposed) are drawn from the same study cohort/sample. + Simona + Nested + + + + + + + + + study_design:OCRE100005 + A meta-level characterization of the design of a study + Simona + Study design characteristic + + + + + + + + + + study_design:OCRE100006 + Probability sampling is an exclusively random process to guarantee that each participant or population has specified chance of selection, such as simple random sampling, systematic sampling, stratified random sampling, cluster sampling, and consecutive patient sampling + Simona + ClinicalTrials.gov Protocol Data Element Definitions (DRAFT). Available at http://prsinfo.clinicaltrials.gov/definitions.html + Probability sampling + + + + + + + + + + + + + + + + + + + + + study_design:OCRE100007 + An interventional study is a quantitative study that prospectively assigns experimental units (human participants or groups of humans or part of human participants) to one or more health-related interventions to evaluate the effects on health outcomes. Interventions include but are not restricted to drugs, cells and other biological products, surgical procedures, radiologic procedures, devices, behavioural treatments, process-of-care changes, preventive care, etc. + Simona + WHO Available at: http://www.who.int/ictrp/en/ + Simona: to be reviewed + Interventional study design + + + + + + + + + + + + + + + + + + + + + + + + + + + + study_design:OCRE100008 + Open label indicates that no blinding is in effect: the investigator and participant are aware which intervention is being used for which participant (i.e. not blinded) + Simona + Glossary in The Cochrane Collaboration. Available at http://www.cochrane.org/glossary + Open label + + + + + + + + + + + + + + + + + + + + study_design:OCRE100009 + The investigator does not actively assign study experimental units to regimens of interventions. + Simona + Investigator assigns no intervention + + + + + + + + + + + study_design:OCRE100011 + Superiority is a type of comparative intent. +When the aim of the study is to show that an experimental (E) treatment is superior to a control (C) treatment, the RCT is called a superiority trial and the associated statistical test is a superiority test. With a significant result, one concludes in a superiority trial that E is different in effect from C, and when the observed result is in favor of E, we conclude that E is statistically, significantly better performing than C. + Simona + Bull NYU Hosp Jt Dis. 2008;66(2):150-4. + Superiority + + + + + + + + + + study_design:OCRE100012 + Equivalence is a type of comparative intent. +An equivalence trial is designed to determine whether the response to two or more treatments differs by an amount that is clinically unimportant. This is usually demonstrated by showing that the true treatment difference is likely to lie between a lower and an upper equivalence level of clinically acceptable differences. + Simona + Glossary in The Cochrane Collaboration. Available at http://www.cochrane.org/glossary + Equivalence + + + + + + + + + + + study_design:OCRE100013 + In an observational study, the main variable on which the selection of experimental units is based is a predictor variable. +In this study, prospective inference occurs, i.e., from exposure to outcome. + Simona + Experimental unit selection based on predictor variable + + + + + + + + + study_design:OCRE100014 + The outcome assessor does not know to which treatment group a particular participant belongs + Simona + Outcome assessor blinded + + + + + + + + + + + + + + + + + + + + + + + + + + + study_design:OCRE100015 + A case-crossover study is an observational study that aims to answer the question, "Was this event triggered by something unusual that happened just before?" The key feature of the design is that each case serves as its own control. The method is analogous to a crossover experiment viewed retrospectively, except that the investigator does not control when an experimental unit starts and stops being exposed to the potential trigger. Also, the exposure frequency is typically measured in only a sample of the total time when the experimental unit was at risk of the injury or disease onset. Thus it usually resembles a case-control study more than a retrospective cohort study. +The simplest case-crossover design is closely analogous to a traditional matched-pair case-control design. In both designs, each case has a matched control. In a traditional matched-pair case-control study, the control is a different experimental unit at a similar time. In the matched-pair case-crossover design, the control is the same experimental unit at a different time. + Simona + Annu Rev Public Health. 2000;21:193-221. + Case-crossover study design + + + + + + + + + + + + + + study_design:OCRE100016 + The concept of phase is not applicable to trials studying certain interventions (e.g., device, procedure, behavioral) + Simona + Phase not applicable + + + + + + + + + + + + + + + + + + + + + + + + + + study_design:OCRE100018 + A case control study is an observational study that compares people with a specific disease or outcome of interest (cases) to people from the same population without that disease or outcome (controls), and which seeks to find associations between the outcome and prior exposure to particular risk factors. [Glossary of Terms in The Cochrane Collaboration] + Simona + Case-control study design + + + + + + + + + + + + + + + + + + + study_design:OCRE100019 + Non-probability sampling is any one of a variety of non random sampling processes, such as convenience sampling or invitation to volunteer + Simona + ClinicalTrials.gov Protocol Data Element Definitions (DRAFT). Available at http://prsinfo.clinicaltrials.gov/definitions.html + Non-probability sampling + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + study_design:OCRE100020 + A crossover study is an interventional study where the population is a more than a single experimental unit, in which at least two regimens of interventions are given alternatingly. Upon completion of one regimen, experimental units are switched to the other. For example, for a comparison of regimens A and B, the experimental units are randomly allocated to receive them in either the order A, B or the order B, A. +Regimens are assigned to and data are analyzed within more than one experimental unit at a time. + Simona + Crossover study design + + + + + + + + + study_design:OCRE100021 + Allocation scheme describes the way in which each experimental unit in an interventional trial is allocated to a treatment group. + Simona + + Allocation scheme + + + + + + + + + study_design:OCRE100022 + Whether cases and controls (or exposed and unexposed) are drawn from the same study cohort/sample. +Not applicable to case-crossover studies. + Simona + + Control group type + + + + + + + + + + study_design:OCRE100023 + A cohort study in which outcomes occurred after the start of the study. + Simona + Prospective + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + study_design:OCRE100024 + An N-of-1 crossover study is an interventional study where the population is a single human subject and in which at least two regimens of interventions are given alternatingly. Regimens are assigned to and data are analyzed within one participant at a time. + Simona + Simona: to be reviewed + N-of-1 crossover study design + + + + + + + + + study_design:OCRE100025 + Stratified randomization is restricted randomization used to ensure that equal numbers of participants with a characteristic thought to affect prognosis or response to the intervention will be allocated to each comparison group. For example, in a trial of women with breast cancer, it may be important to have similar numbers of pre-menopausal and postmenopausal women in each comparison group. Stratified randomisation could be used to allocate equal numbers of pre- and post-menopausal women to each treatment group. Stratified randomisation is performed by performing separate randomisation (often using random permuted blocks) for each strata. + Simona + Glossary in The Cochrane Collaboration. Available at http://www.cochrane.org/glossary + Stratified randomization + + + + + + + + + study_design:OCRE100026 + The investigator actively assigns the study experimental units to one or more regimens of interventions (each including one or more interventions, or no intervention). + Simona + Investigator assigns intervention + + + + + + + + + + + + + + + + + + + + + + + + + study_design:OCRE100027 + A parallel group study is an interventional study that compares across at least two allocation groups concurrently, each receiving a regimen of interventions (which can be "no intervention"). + Simona + Simona: to be reviewed. + Parallel group study design + + + + + + + + + study_design:OCRE100028 + Mode of inquiry refers to the research method used in a study + Simona + + Mode of inquiry + + + + + + + + + + study_design:OCRE100029 + In the context of a study where the main comparison is within experimental units, investigator assigns regimen of interventions to an allocation group made up of more than one experimental unit. + Simona + Multiple experimental unit allocation group + + + + + + + + + + study_design:OCRE100030 + Restricted randomization is a random allocation scheme used to control the randomization to achieve balance between groups in size (or other characteristics). +Different types of restricted randomization are as follows: +- Blocking: Blocking is used to ensure close balance of the numbers in each group at any time during the study. After every block the number of participants in each group would be equal. Of course blocking tends to reduce the unpredictability of randomization. Therefore it is recommended to use random block sizes when using block randomization. +- Stratification: Stratification ensures that the numbers of participants receiving each intervention are closely balanced within each stratum. Stratified randomization is achieved by performing a separate randomization procedure within each of two or more subsets of participants +- Minimization: Minimization is not a method of randomization. Indeed it is the only non-random method which is an acceptable alternative to randomization. Minimization ensures balance between intervention groups for several patient factors. Randomization lists are not set up in advance. The first patient is truly randomly allocated; for each subsequent patient, the treatment allocation is identified, which minimizes the imbalance between groups at that time. + Simona + http://mahmoodsaghaei.tripod.com/Softwares/randalloc.html + Simona: should we put the 3 schemes elsewhere? + Restricted randomization + + + + + + + + + + study_design:OCRE100031 + A quantitative research method is a deductive research process that uses statistical techniques to test a specific claim or statement about a phenomenon (a hypothesis) by collecting and analyzing data to decide whether the claim is true (i.e., accept or reject the null or alternative hypothesis). + Simona + http://www.utexas.edu/academic/ctl/assessment/iar/research/plan/types.php + Quantitative inquiry mode + + + + + + + + + + + study_design:OCRE100032 + Quasi-random allocation is an allocation scheme that is not random, but is intended to produce similar groups when used to allocate experimental units. Quasi-random methods include: allocation by the person's date of birth, by the day of the week or month of the year, by a person's medical record number, or just allocating every alternate person. In practice, these methods of allocation are relatively easy to manipulate, introducing selection bias. + Simona + Glossary in The Cochrane Collaboration. Available at http://www.cochrane.org/glossary + Quasi-random allocation + + + + + + + + + + study_design:OCRE100033 + Random allocation is an allocation scheme that uses the play of chance to assign participants to comparison groups in a trial, e.g. by using a random numbers table or a computer-generated random sequence. Random allocation implies that each individual or unit being entered into a trial has the same chance of receiving each of the possible interventions. It also implies that the probability that an individual will receive a particular intervention is independent of the probability that any other individual will receive the same intervention. + Randomization is the process of randomly allocating experimental units into one of the arms of a controlled trial. There are two components to randomisation: the generation of a random sequence [allocation scheme], and its implementation [allocation concealment method], ideally in a way so that those entering participants into a study are not aware of the sequence (concealment of allocation). + Simona + Glossary in The Cochrane Collaboration. Available at http://www.cochrane.org/glossary + Random allocation + + + + + + + + + + study_design:OCRE100034 + Non-cases were selected based on genetic relation + Simona + Genetically related non-cases + + + + + + + + + + study_design:OCRE100035 + Multiple regimens of intervention, each including one or more individual interventions (treatments) or no treatment, each assigned to one allocation group. This means the study has at least one contemporaneous comparison group. + Simona + Multiple regimen + + + + + + + + + study_design:OCRE100036 + The caregiver does not know to which treatment group a particular participant belongs + Simona + Caregiver blinded + + + + + + + + + study_design:OCRE100037 + A single regimen of intervention, which includes one or more individual interventions (treatments), is assigned to one allocation group. This means the study has no contemporaneous comparison group. + Simona + Single regimen + + + + + + + + + study_design:OCRE100038 + Phase describes the level of a trial required of drugs before (and after) they are routinely used in clinical practice: +- Phase 1 trials assess toxic effects on humans (not many people participate in them, and usually without controls); +- Phase 2 trials assess therapeutic benefit (usually involving a few hundred people, usually with controls, but not always); +- Phase 3 trials compare the new treatment against standard (or placebo) treatment (usually a full randomised controlled trial). At this point, a drug can be approved for community use. +- Phase 4 monitors a new treatment in the community, often to evaluate longterm safety and effectiveness. [Glossary of Terms in The Cochrane Collaboration] + +A trial can be of a combination phase (e.g., 1/2). +The concept of phase is not applicable to trials studying certain interventions (e.g., device, procedure, behavioral) + Simona + Glossary in The Cochrane Collaboration. Available at http://www.cochrane.org/glossary + + Phase + + + + + + + + + + + + + + + + + + + + + study_design:OCRE100039 + A cross-sectional study is an observational study measuring the distribution of some characteristic(s) in a population at a particular point in time. (Also called survey.) + Simona + Glossary in The Cochrane Collaboration. Available at: http://www.cochrane.org/glossary + Cross-sectional study design + + + + + + + + + study_design:OCRE100040 + Block randomization (or Random permuted blocks) is a restricted randomisation that ensures that, at any point in a trial, roughly equal numbers of participants have been allocated to all the comparison groups. Permuted blocks should be used in trials using stratified randomisation. + Simona + Glossary in The Cochrane Collaboration. Available at http://www.cochrane.org/glossary + Block randomization + + + + + + + + + study_design:OCRE100041 + The unit that is assigned to the alternative regimens of interventions being investigated in a trial. Most commonly, the unit will be an individual person, but in a cluster randomised trial, groups of people will be assigned together to one or the other of the regimens of interventions. In some other trials, different parts of a person (such as the left or right eye) might be assigned to receive different regimens of interventions. + Simona + Glossary in The Cochrane Collaboration. Available at http://www.cochrane.org/glossary + + Unit of allocation + + + + + + + + + study_design:OCRE100042 + The number of regimens of interventions in a study. Each regimen includes one or more individual interventions (treatments) or no intervention. + Simona + Simona: to be reviewed + + Regimen cardinality + + + + + + + + + + study_design:OCRE100043 + The unit that is assigned to the alternative regimens of interventions being investigated in a trial. In a cluster randomised trial, groups of experimental units will be assigned together to one or the other of the regimens of interventions. + Simona + Glossary in The Cochrane Collaboration. Available at http://www.cochrane.org/glossary + Cluster as unit of allocation + + + + + + + + + + + + + + + + + + + + + study_design:OCRE100044 + A quantitative study is an individual-human study whose primary mode of inquiry is quantitative. + Simona + Quantitative study design + + + + + + + + + study_design:OCRE100045 + [In a controlled trial:] Blinding is the process of preventing those involved in a trial from knowing to which comparison group a particular participant belongs. The risk of bias is minimised when as few people as possible know who is receiving the experimental intervention and who the control intervention. Participants, caregivers, outcome assessors, and analysts are all candidates for being blinded. Blinding of certain groups is not always possible, for example surgeons in surgical trials. The terms single blind, double blind and triple blind are in common use, but are not used consistently and so are ambiguous unless the specific people who are blinded are listed. (Also called masking) + Simona + Glossary in The Cochrane Collaboration. Available at http://www.cochrane.org/glossary + + Blinding type + + + + + + + + + study_design:OCRE100046 + In the context of a study where the main comparison is within experimental units, whether data is analyzed within a single study experimental unit or within multiple experimental units. + Simona + Data analysis within experimental units + + + + + + + + + + + + + + + + + + + + study_design:OCRE100047 + A qualitative study is an individual-human study whose primary mode of inquiry is qualitative. + Simona + Qualitative study design + + + + + + + + + study_design:OCRE100048 + Characteristics of the assignment experimental units (e.g., participant, eye) to a regimen of interventions + Simona + Assignment characteristics + + + + + + + + + study_design:OCRE100049 + Method of sampling in observational studies. + Simona + + Sampling method + + + + + + + + + + + + + + + + + + + + study_design:OCRE100052 + A single group study is an interventional study that has only a single allocation group and no contemporaneuos comparison group. + +A study in which an individual acts has his/her own comparison does not fall into this category, since an individual is not a group. + Simona + Simona: to be reviewed + Single group study design + + + + + + + + + study_design:OCRE100053 + The care provider does not know to which treatment group a particular participant belongs + Simona + Care provider blinded + + + + + + + + + + + + + + + + + + + + study_design:OCRE100055 + An observational study is a quantitative study in which the investigators do not seek to intervene, and simply observe the course of events. + Simona + Glossary in The Cochrane Collaboration. Available at http://www.cochrane.org/glossary + Observational study design + + + + + + + + + + study_design:OCRE100056 + A study design is a common pattern of relationships (in time and causation) among various study elements (e.g., time of intervention to outcomes assessment in which participants). + Simona + + Study design + + + + + + + + + study_design:OCRE100057 + A qualitative research method is an inductive research process that involves the collection and analysis of qualitative (i.e., non-numerical) data to search for patterns, themes, and holistic features. + Simona + http://www.utexas.edu/academic/ctl/assessment/iar/research/plan/types.php +For other definitions, see http://www.google.com/search?hl=en&client=safari&rls=en&defl=en&q=define:Qualitative+research + Qualitative inquiry mode + + + + + + + + + study_design:OCRE100058 + The role the investigator plays in the assignment of study experimental units to one or more regimens of interventions (each including one or more interventions, or no intervention). + Simona + + Investigator assignment role + + + + + + + + + study_design:OCRE100059 + In a retrospective observational study (i.e., an observational study where the main variable on which experimental units selection is based is an outcome variable), experimental units with the same outcome (cases) can be compared to themselves or to other experimental units (controls). + Simona + + Comparison of experimental units with the main outcome + + + + + + + + + study_design:OCRE100060 + Have outcomes occurred before the study start? If yes, the cohort study is historical; if no, the cohort study is prospective. + Simona + + Outcomes occurred before or after study start + + + + + + + + + + study_design:OCRE100061 + The main comparison is across study experimental units. + Simona + Main comparison across experimental units + + + + + + + + + + + + + + + + + + + study_design:OCRE100062 + Cases and controls (or exposed and unexposed) are not drawn from the same cohort/sample. + [aka double cohort for cohort studies] + Simona + Non-nested + + + + + + + + + + study_design:OCRE100063 + Data is analyzed within multiple study experimental units. + Simona + Data analyzed within multiple experimental units + + + + + + + + + study_design:OCRE100064 + The subject or individual participant does not know to which treatment group he or she or each experimental unit on him/her belongs. + or Individual participant blinded + Simona + Subject blinded + + + + + + + + + + + + + + + + + + + + study_design:OCRE100065 + In a single-factor design, an intervention is compared with one or more alternatives, or a placebo. + Simona + Glossary in The Cochrane Collaboration. Available at http://www.cochrane.org/glossary + Single-factor + + + + + + + + + study_design:OCRE100066 + A Phase 4 study monitors FDA-approved drug to delineate additional information including the drug's risks, benefits, and optimal use. + Simona + ClinicalTrials.gov Protocol Data Element Definitions (DRAFT). Available at http://prsinfo.clinicaltrials.gov/definitions.html + Phase 4 + + + + + + + + + study_design:OCRE100067 + A Phase 1 trial includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients. + Simona + ClinicalTrials.gov Protocol Data Element Definitions (DRAFT). Available at http://prsinfo.clinicaltrials.gov/definitions.html + Phase 1 + + + + + + + + + study_design:OCRE100068 + A Phase 0 trial is an exploratory trial involving very limited human exposure, with no therapeutic or diagnostic intent (e.g., screening study, microdose study). + Simona + ClinicalTrials.gov Protocol Data Element Definitions (DRAFT). Available at http://prsinfo.clinicaltrials.gov/definitions.html + Phase 0 + + + + + + + + + study_design:OCRE100069 + A Phase 3 trial includes expanded controlled and uncontrolled trials after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug and provide an adequate basis for physician labeling. + Simona + ClinicalTrials.gov Protocol Data Element Definitions (DRAFT). Available at http://prsinfo.clinicaltrials.gov/definitions.html + Phase 3 + + + + + + + + + study_design:OCRE100070 + A Phase 2 trial includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in patients with the disease or condition under study and to determine the common short-term side effects and risks. + Simona + ClinicalTrials.gov Protocol Data Element Definitions (DRAFT). Available at http://prsinfo.clinicaltrials.gov/definitions.html + Phase 2 + + + + + + + + + study_design:OCRE100071 + The unit that is assigned to the alternative regimens of interventions being investigated in a trial. Most commonly, the unit will be an individual person. In some other trials, different parts of a person (such as the left or right eye) might be assigned to receive different regimens of interventions. + Simona + Individual as unit of allocation + + + + + + + + + study_design:OCRE100072 + Comparative intent is an additional descriptor: Intent of comparison made in a study with two or more arms. + Simona + + Comparative intent + + + + + + + + + study_design:OCRE100073 + Whether the main comparison is across or within study experimental units + Simona + + Main comparison and experimental units + + + + + + + + + study_design:OCRE100074 + A method of allocation used to provide comparison groups that are closely similar for several variables. The next participant is assessed with regard to several characteristics, and assigned to the treatment group that has so far had fewer such people assigned to it. It can be done with a component of randomisation, where the chance of allocation to the group with fewer similar participants is less than one. Minimisation is best performed centrally with the aid of a computer program to ensure concealment of allocation. + Simona + Glossary in The Cochrane Collaboration. Available at http://www.cochrane.org/glossary + Minimization + + + + + + + + + study_design:OCRE100075 + In the context of a study where the main comparison is within experimental units, investigator assigns regimen of interventions to an allocation group made up of a single experimental unit. + Simona + Single experimental unit allocation group + + + + + + + + + study_design:OCRE100076 + A non-inferiority trial is designed to determine whether the effect of a new treatment is not worse than a standard treatment by more than a pre-specified amount. A one-sided version of an equivalence trial. [Glossary of Terms in The Cochrane Collaboration] + Simona + Glossary in The Cochrane Collaboration. Available at http://www.cochrane.org/glossary + Non-inferiority + + + + + + + + + + + + + + + + + + + + + + study_design:OCRE100077 + Non-random (or Deterministic) allocation is an allocation scheme that follows a non-random rule (e.g., sequential allocation). + Simona + Non-random allocation + + + + + + + + + + + + + + + + + + + + study_design:OCRE100078 + A cohort study is an observational study in which a defined group of people (the cohort) is followed over time. The outcomes of people in subsets of this cohort are compared, to examine people who were exposed or not exposed (or exposed at different levels) to a particular intervention or other factor of interest. A prospective cohort study assembles participants and follows them into the future. A retrospective (or historical) cohort study identifies subjects from past records and follows them from the time of those records to the present. + Simona + Glossary in The Cochrane Collaboration. Available at: http://www.cochrane.org/glossary + The DL definiition of cohort study design says that a cohort study design has the characteristics "Main control group defined by exposure status" and "outcome measured after measurement of predictors." + +A study design involves identification of factor variables and outcome variables. Factor variables are measured before the measurement of outcome variables. + +Let C be a member of the control groups of a study S +Let SA be the set of statistical analysis of S +Let F(sa) be the independent variables of a statistical analysis sa in SA +Let O(sa) be the set of dependent variables of sa +S has 'cohort study design" if and only if + +For all sa in SA, +There exists times t1 < t2 such that +there exists f in F(sa) such that for all c in C, f is measured at time t1 and f(c) = constant AND for all o in O(sa), o is measured at t2 + Cohort study design + + + + + + + + + + study_design:OCRE100079 + In an observational study, the main variable on which the selection of experimental units is based is an outcome variable. +In this study, retrospectie inference occurs, i.e., from outcome to exposure. + Simona + Experimental unit selection based on outcome variable + + + + + + + + + study_design:OCRE100080 + The statistician does not know to which treatment group a particular participant belongs + Simona + Statistician blinded + + + + + + + + + study_design:OCRE100081 + The main comparison is within study experimental units. + Simona + Main comparison within experimental units + + + + + + + + + study_design:OCRE100082 + Relation between cases and non-cases + Simona + + Relation between cases and non-cases + + + + + + + + + study_design:OCRE100083 + Simple randomization is a random allocation scheme that has no restriction, i.e. a single sequence of random assignment. When the sample size is relatively large, simple randomization is expected to produce equal sized treatment groups. + Simona + http://mahmoodsaghaei.tripod.com/Softwares/randalloc.html + Simple randomization + + + + + + + + + study_design:OCRE100084 + The investigator does not know to which treatment group a particular participant belongs + Simona + Investigator blinded + + + + + + + + + study_design:OCRE100085 + Data is analyzed within a single study experimental unit. + Simona + Data analyzed within single experimental unit + + + + + + + + + + + + + + + + + + + study_design:OCRE100086 + Non-cases were not selected based on genetic relation + Simona + Genetically unrelated non-cases + + + + + + + + + study_design:OCRE100087 + A cohort study in which outcomes occurred before the start of the study. + Simona + Historical + + + + + + + + + + + + + + + + + + + study_design:OCRE100088 + A case does not serve as its own control + Simona + Case and control not in same experimental unit + + + + + + + + + study_design:OCRE100089 + Factorial design is a trial design used to assess the individual contribution of treatments given in combination, as well as any interactive effect they may have... In a trial using a 2x2 factorial design, participants are allocated to one of four possible combinations... This type of study is usually carried out in circumstances where no interaction is likely. + +Example: in a factorial-design study where regimens of interventions A and B are tested, the 4 possible combinations are: A, B, A and B, neither A nor B (placebo). + Simona + Glossary in The Cochrane Collaboration. Available at http://www.cochrane.org/glossary + Factorial + + + + + + + + + + + + + + + + + + + + + + + + + + study_design:OCRE498000 + In an observational study, the main varibale on which the selection of experimental units is based is neither an outcome nor an exposure variable. + Simona + Experimental unit selection based on neither outcome nor predictor variable + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + study_design:OCRE9000030 + An aggregated human study is a human study in which the entity observed, recruited or selected, or subject to intervention or exposure is a population that contains persons + Simona + Aggregated-human study + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + study_design:OCRE9000031 + An individual-human study is a human study in which the entity observed, recruited or selected, or subject to intervention or exposure is a person, or a part of a person. + Simona + Individual-human study + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + study_design:OCRE900028 + A human study is a study in which the entity observed, recruited or selected, or subject to intervention or exposure is a person, a population of persons, or a part of a person. + Human study + + + + + + + + + + + + + + + + + + + + study_design:OCRE900029 + A non-organismal study is a study in which neither the entity observed, nor the entity recruited or selected, nor the entity subject to intervention or exposure is an organism, a population of organisms, or a part of an organism. + Simona + Non-organismal study + + + + + + + + + study_design:OCRE900032 + A decision analysis is a non-organismal study technique that formally identifies the options in a decision-making process, quantifies the probable outcomes (and costs) of each (and the uncertainty around them), determines the option that best meets the objectives of the decision-maker and assesses the robustness of this conclusion. +Cost-benefit analysis, cost-effectiveness analysis and cost-utility analysis are special cases of decision analysis. +Note that this type of analysis can also be applied to outcomes in a human study. + Simona + Glossary in The Cochrane Collaboration. Available at http://www.cochrane.org/glossary + Decision analysis + + + + + + + + + study_design:OCRE900033 + A policy analysis is a non-organismal study that can be defined as determining which of various alternative policies will most achieve a given set of goals in light of the relations between the policies and the goals. Policy analysis emphasizes systematic analytic methods that can be quantitative or qualitative. + Simona + Nagel, Stuart S. (Ed.), 1999, Policy Analysis Methods. New Science Publishers, Inc., pages 3 and 4 + Policy analysis + + + + + + + + + study_design:OCRE900034 + A technology study is a non-organismal study that uses or collects measurements or assessments about a man-made object (e.g., a device) in terms of its technical/physical performance. + Simona + Technology study + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + study_design:OCRE900036 + An organismal study is a study in which the entity observed, recruited or selected, or subject to intervention or exposure is an organism, a population of organisms, or a part of an organism. + Organismal study + + + + + + + + + + + + + + + + + + + study_design:OCRE900037 + A non-human organism study is a study in which the entity observed, recruited or selected, and subject to intervention or exposure is non-human organism, a population of non-human organisms, or a part of a non-human organism. + Simona + Non-human organism study + + + + + + + + + study_design:OCRE900040 + A systematic review is a meta study (i.e., a study in which observations are acquired from journal articles, abstracts, etc. reporting on other studies). + +A systematic review uses systematic and explicit methods to identify, select, and critically appraise relevant research, and to collect and analyse data from the studies that are included in the review. Statistical methods (meta-analysis) may or may not be used to analyse and summarise the results of the included studies. + +Meta-analysis is the use of statistical techniques in a systematic review to integrate the summary results of included studies. Sometimes misused as a synonym for systematic reviews, where the review includes a meta-analysis. + Simona + Glossary in The Cochrane Collaboration. Available at http://www.cochrane.org/glossary + Systematic review + + + + + + + + + study_design:OCRE942000 + In an observational study, the main variable on which the selection of experimental units is based can be an outcome variable, a predictor variable, or a variable that is neither an outcome nor a predictor one. + Simona + Main variable on which experimental unit selection is based + + + + + + + + + OCRE300000 + study_protocol:OCRE300000 + DEFINITION: +One of a set of ordered partitions of an experimental unit's participation in a study. An Epoch represents a state within a study such that subjects in separate arms within that state are comparable. + +Each epoch serves a purpose in the trial as a whole, typically exposing the subject to a treatment or preparing them for a treatment, or gathering post-treatment data.  Activities and activity results control the subject's movement from one epoch to another. + +EXAMPLE(S): +A study designed to assess the effects of treatments might have 3 epochs. +A Screening Epoch in which subjects' eligibility is determined and baseline measurements are made. +A Treatment Epoch during which treatments are given and effects of treatment are assessed. +A Follow-up Epoch during which post-treatment assessments are conducted.  + +NOTE(S): +A subject moves from one epoch to another and can only be in one epoch at a time. The subject can only move to an epoch with a greater sequenceNumber. Activities in the same epoch but a different arm need not be similar in time and pattern. Subjects in different arms will not necessarily pass through the same epochs. + + DEFINITION: +One of a set of ordered partitions of an experimental unit's planned time in a study. + +Each Epoch serves a purpose in the trial as a whole, typically exposing the subject to a treatment or preparing them for a treatment, or gathering post-treatment data. Epoch-specific (state) transition rules control the subject's movement from one Epoch to another. + +For example, a study designed to assess the effects of treatments might have 3 epochs, a Screening epoch in which subjects' eligibility is determined and baseline measurements are made, a Treatment epoch during which treatments are given and effects of treatment are assessed, and a Follow-up epoch during which post-treatment assessments are conducted. + +NOTE: A subject moves from one Epoch to another and can only be in one epoch at a time. The subject can only move to an Epoch with a greater sequenceNumber. The main purpose of the Epoch is to organize the Arms for comparison purposes. Activities in the same Epoch but a different Arm need not be similar in time and pattern. [BRIDG Release 3] + Simona + BRIDG 3.0.3 Available at http://bridgmodel.nci.nih.gov/ + + + Epoch + + + + + + 1 + + + + + + 2 + + + + + + + + + + + + + + + OCRE300001 + study_protocol:OCRE300001 + DEFINITION: +A path through the study which describes what activities the study subject or experimental unit will be involved in as they pass through the study, and is typically equivalent to a treatment group in a parallel design trial. Generally, each subject is assigned to an arm, and the design of the study is reflected in the number and composition of the individual arms. This intended path through which the subject progresses in a trial is composed of time point events (study cell) for each epoch of the study. Each time point event, in turn, has a pattern of child time points through which the subject would pass. This planned path thus describes how subjects assigned to the arm will be treated. + +EXAMPLE(S): +A study could have 2 arms named IV-Oral and Oral-IV.  The name IV-Oral reflects a path that passes through IV treatment, then Oral treatment. + +OTHER NAME(S): +Group (CTRR Observational Studies) + Simona + BRIDG 3.0.3 Available at http://bridgmodel.nci.nih.gov/ + + + Arm + + + + + + 1 + + + + + + 2 + + + + + + + + + OCRE300004 + Samson Tu + Planned administrative activity + + + + + + + + + OCRE300006 + Samson Tu + Planned specimen collection + + + + + + + + + OCRE300008 + Samson Tu + Planned observation + + + + + + + + + OCRE300009 + Samson Tu + + + Planned procedure + + + + + + + + + + + + + + + + + + + + + OCRE300010 + study_protocol:OCRE300010 + DEFINITION: +A relationship between a composite activity and the component activities that comprise it, i.e. parent and child activities where all activities are intended to occur at some point in the context of a particular study. + +EXAMPLE(S): +A battery of tests may be composed of multiple routine labs that are always ordered together as a group. + +A glucose tolerance test which is comprised of administering glucose and taking multiple timed blood samples which are then tested for glucose. + +OTHER NAME(S): + +NOTE(S): +This class helps represent an AND relationship between siblings with the same parent activity. + Samson Tu + BRIDG 3.0.3 Available at http://bridgmodel.nci.nih.gov/ + + + + Planned composition relationship + + + + + + + + + OCRE300011 + study_protocol:OCRE300011 + An activity that is intended to occur or start at some point in the context of a particular study. + +EXAMPLE(S): +Pregnancy tests are planned for StudySubjects who are females of childbearing potential. + +OTHER NAME(S): + +NOTE(S): +A PlannedActivity may be a container of other activities and have a complex structure involving components, options and contingencies using the associated relationship classes. This structure allows BRIDG 3.0 to represent concepts in previous versions of BRIDG such as StudyCells, StudySegments and StudySubjectEncounters. + +A PlannedActivity could also be thought of as an activity at a particular stage in the business process in which the activities occur, i.e., in the "planned" stage rather than the "scheduled" stage or the "performed" stage. An instance of a planned activity is not assigned to a particular StudySubject, but to a "kind of" StudySubject. + Samson Tu + BRIDG 3.0.3 Available at http://bridgmodel.nci.nih.gov/ + + + + + + + + Planned activity + + + + + + 2 + + + + + + 1 + + + + + + 3 + + + + + + + + + + + + + + + OCRE300012 + study_protocol:OCRE300012 + A discrete, structured plan (that persists over time) of a formal investigation to assess some outcome phenomena in relation to other study phenomena. + DEFINITION: +A discrete, structured plan (that persists over time) of a formal investigation to assess the utility, impact, pharmacological, physiological, and/or psychological effects of a particular treatment, procedure, drug, device, biologic, food product, cosmetic, care plan, or subject characteristic. + +NOTE(S): +The term "protocol" is somewhat overloaded and must be qualified to provide semantic context.  Therefore the term "study protocol" was chosen to disambiguate it from other protocols. + +In previous versions of BRIDG, there was one class for StudyProtocol.  However this too represented multiple distinct aspects of the semantics of study protocol, each of which have now been split into separate classes: +- The StudyProtocol class represents the content of the study protocol and can exist even before the information is put into document form. +- The details of the structured plan for the study protocol are represented by the StudyProtocolVersion, so named because any aspect of the definition can change from version to version.  These details include, but are not limited to, the characteristics, specifications, objective(s), background, the pre-study/study/post-study portions of the plan (including the design, methodology, statistical considerations, organization). +- The protocol and its versions can each be represented in document form, respectively StudyProtocolDocument and StudyProtocolDocumentVersion.  A StudyProtocolDocument groups the various document versions (StudyProtocolDocumentVersions). +- The conduct of a study based on a study protocol definition is represented by the StudyExecution class. + +BRIDG 3.0.3 Available at http://bridgmodel.nci.nih.gov/ + Previous definition: An action plan for a pre-clinical or clinical study which defines all activities planned to achieve the objectives of the study. The plan specifies, for example, the design of the study, including the subject to be included, the outcome to be studied, data to be collected, and method of analysis. A study protocol is an informational entity that is ontologically distinct from events that occur as part of the study. + +BRIDG Release 2.2 definition: An action plan for a formal investigation to assess the utility, impact, pharmacological, physiological, and psychological effects of a particular treatment, procedure, drug, device, biologic, food product, cosmetic, care plan, or subject characteristic. +Note: Among other things, the action plan may include the design, statistical considerations and all activities to test a particular hypothesis that is the basis of the study. The study may be of any type that involves StudySubjects, including prevention, therapeutic, interventional or observational. Subjects may be biological entities (human, animal, specimen, tissue, organ, etc.) or products. + Simona + + + + Study protocol + + + + + + 2 + + + + + + 1 + + + + + + + + + OCRE300015 + Cf: BRIDG 3.03 DefinedSubjectActivityGroup DEFINITION: +A collection of activities from a global library that would be performed on a common subject. + +EXAMPLE(S): +Clinic visit during which a physical exam, a blood test, and a substance administration occur + +Telephone contact during which temperature, blood pressure and adverse events are reported + +Recording multiple observation results in a diary + +A treatment strategy that consists of drug administrations with rules for modifying doses + +OTHER NAME(S): +study segment, course, treatment strategy, period, cycle + +NOTE(S): + Planned subject activity group + + + + + + + + + OCRE307000 + study_protocol:OCRE307000 + DEFINITION: +A physical entity which is the primary unit of interest in a specific research objective. In an interventional study, the experimental unit is assigned to an intervention. The experimental unit is also the unit of primary statistical analysis. Commonly the individual study subject (animal, person or product) is the experimental unit. Different experimental units must be capable of receiving different experimental interventions. + +EXAMPLE(S): +If all pigs in a pen receive the same intervention in their feed, and the primary observations and analyses of interest are associated with the entire pen (e.g. total feed consumed, total weight of all pigs combined), then the pen of pigs rather than the individual animal is the experimental unit. [CDISC/HL7 Study Participation RMIM, PORT_RM100001UV] + +A human StudySubject may have 10 patches of skin each considered an ExperimentalUnit, or a Product StudySubject may have 10 bearings in it, each considered an ExperimentalUnit.  Alternatively, each StudySubject may be an ExperimentalUnit. + +OTHER NAME(S): + +NOTE(S): +Depending on the research objectives, a single study may have multiple levels of experimental units, such as whole people and patches of skin. + Simona + BRIDG 3.0.3 Available at http://bridgmodel.nci.nih.gov/ + ExperimentalUnit + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + OCRE892807 + study_protocol:OCRE892807 + + Intervention study protocol + + + + + + + + + fma3:OCRE9000027 + A material anatomical entity is a physical anatomical entity which has mass. Examples: hemoglobin molecule, mitochondrion, hepatocyte, erythrocyte, heart, head, blood, urine. + Simona + Foundational Model of Anatomy (FMA) class definition of Material anatomical entity. Available at http://bioportal.bioontology.org/visualize/44507 + Material anatomical entity + + + + + + + + + oboInOwl:DbXref + + + + + + + + + oboInOwl:Definition + + + + + + + + + + + + + + + + oboInOwl:Subset + + + + + + + + + oboInOwl:Synonym + + + + + + + + + oboInOwl:SynonymType + + + + + + + + + snap:GenericallyDependentContinuant + A continuant [snap:Continuant] that is dependent on one or other independent continuant [snap:IndependentContinuant] bearers. For every instance of A requires some instance of (an independent continuant [snap:IndependentContinuant] type) B but which instance of B serves can change from time to time. + http://biomedgt.nci.nih.gov/wiki/index.php/Category:BFO_generically_dependent_continuant(GenericallyDependentContinuant) + GeneriallyDependentContinuant + + + + + + + + owl:Thing + Thing + + + + + + + + + + + + + + example to be eventually removed + + + + + + + + + The term was used used in an attempt to structure part of the ontology but in retrospect failed to do a good job + Person:Alan Ruttenberg + failed exploratory term + + + + + + + + + Class has all its metadata, but is either not guaranteed to be in its final location in the asserted IS_A hierarchy or refers to another class that is not complete. + metadata complete + + + + + + + + + term created to ease viewing/sort terms for development purpose, and will not be included in a release + organizational term + + + + + + + + + Class has undergone final review, is ready for use, and will be included in the next release. Any class lacking "ready_for_release" should be considered likely to change place in hierarchy, have its definition refined, or be obsoleted in the next release. Those classes deemed "ready_for_release" will also derived from a chain of ancestor classes that are also "ready_for_release." + ready for release + + + + + + + + + Class is being worked on; however, the metadata (including definition) are not complete or sufficiently clear to the branch editors. + metadata incomplete + + + + + + + + + Nothing done yet beyond assigning a unique class ID and proposing a preferred term. + uncurated + + + + + + + + + All definitions, placement in the asserted IS_A hierarchy and required minimal metadata are complete. The class is awaiting a final review by someone other than the definition editor. + pending final vetting + + + + + + + + + Core is an instance of a grouping of terms from an ontology or ontologies. It is used by the ontology to identify main classes. + PERSON: Alan Ruttenberg + PERSON: Melanie Courtot + core + + + + + + + + + placeholder removed + + + + + + + + + An editor note should explain what were the merged terms and the reason for the merge. + terms merged + + + + + + + + + This is to be used when the original term has been replaced by a term imported from an other ontology. An editor note should indicate what is the URI of the new term to use. + term imported + + + + + + + + + This is to be used when a term has been split in two or more new terms. An editor note should indicate the reason for the split and indicate the URIs of the new terms created. + term split + + + + + + + + + This is to be used if none of the existing instances cover the reason for obsolescence. An editor note should indicate this new reason. + We expect to be able to mine these new reasons and add instances as required. + other + + + + + + + + + Hard to give a definition for. Intuitively a "natural kind" rather than a collection of any old things, which a class is able to be, formally. At the meta level, universals are defined as positives, are disjoint with their siblings, have single asserted parents. + Alan Ruttenberg + A Formal Theory of Substances, Qualities, and Universals, http://ontology.buffalo.edu/bfo/SQU.pdf + universal + + + + + + + + + "definitions", in some readings, always are given by necessary and sufficient conditions. So one must be careful (and this is difficult sometimes) to distinguish between defined classes and universal. + A defined class is a class that is defined by a set of logically necessary and sufficient conditions but is not a universal + Alan Ruttenberg + defined class + + + + + + + + + A named class expression is a logical expression that is given a name. The name can be used in place of the expression. + named class expressions are used in order to have more concise logical definition but their extensions may not be interesting classes on their own. In languages such as OWL, with no provisions for macros, these show up as actuall classes. Tools may with to not show them as such, and to replace uses of the macros with their expansions + Alan Ruttenberg + named class expression + + + + + + + + + Terms with this status should eventually replaced with a term from another ontology. + Alan Ruttenberg + group:OBI + to be replaced with external ontology term + + + + + + + + + A term that is metadata complete, has been reviewed, and problems have been identified that require discussion before release. Such a term requires editor note(s) to identify the outstanding issues. + Alan Ruttenberg + group:OBI + requires discussion + + + + + + + + + restriction + + + + + + + + + extension + + + + + + + + + secondary + + + + + + + + + + http + + + + + + + + + + mailto + + + + + + + + + + tel + + + + + + + + + + x-text-fax + + + + + + + + + Biospecimen availability NA + + + + + + + + + Biospecimen available + + + + + + + + + Biospecimen not available + + + + + + + + + primary + + + + + + + + + Leaf subclass + + + + + + + + + Subclass including root + + + + + + + + + External query + + + + + + + + + Individual + + + + + + + + + Subclass excluding root + + + + + + + + http://purl.org/net/OCRe/HSDB_OCRe.owl + + + $Revision$ + Revision 258 + + + $Revision$ + en + + + Revision 258 + + + + Revision 258 + An ontology for the planning, execution and analysis of clinical research including logitudinal studies and clinical trials. This is designed to be used in conjunction with domain specific models of diseases and measurements which conform to the shared ontology of clinical concepts to provide specific models of studies and trials. + + + An ontology of objects and relationships in statistics that are useful for describing statistical analysis used in human studies. It is part of the Ontology for Clinical Research (OCRe). + + + An ontology of study design descriptors and categorization of study design types in terms of their design descriptors. + + + Concept imported from BRIDG that related to the defined activities and schedules of a study protocol. + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + + diff --git a/test/src/org/stanford/ncbo/oapiwrapper/test/TestSimpleSKOSWithImports.java b/test/src/org/stanford/ncbo/oapiwrapper/test/TestSimpleSKOSWithImports.java new file mode 100644 index 0000000..39c9b01 --- /dev/null +++ b/test/src/org/stanford/ncbo/oapiwrapper/test/TestSimpleSKOSWithImports.java @@ -0,0 +1,117 @@ +package org.stanford.ncbo.oapiwrapper.test; + +import java.io.File; +import java.io.IOException; +import java.util.logging.Level; +import java.util.logging.Logger; + +import junit.framework.TestCase; + +import org.apache.commons.io.FileUtils; +import org.junit.Test; +import org.stanford.ncbo.oapiwrapper.OntologyParser; +import org.stanford.ncbo.oapiwrapper.OntologyParserException; +import org.stanford.ncbo.oapiwrapper.ParserError; +import org.stanford.ncbo.oapiwrapper.ParserInvocation; + +public class TestSimpleSKOSWithImports extends TestCase { + private static final String inputRepositoryFolder = "./test/repo/input/sifr"; + private static final String outputRepositoryFolder = "./test/repo/output/sifr"; + private static final String masterFileName = "testDefavecImportSkos2.owl"; + + //private static final String inputRepositoryFolder = "./test/repo/input/custom"; + //private static final String outputRepositoryFolder = "./test/repo/output/custom"; + //private static final String masterFileName = "custom_properties.owl"; + + + private final static Logger log = Logger.getLogger(TestSimpleSKOSWithImports.class .getName()); + + @Override + protected void setUp() throws Exception { + super.setUp(); + } + + @Test + public void testInputBasicVertebrateGrossAnatomyOK() { + ParserInvocation pi = new ParserInvocation( + inputRepositoryFolder, + outputRepositoryFolder, + masterFileName, true); + assertEquals(true, pi.valid()); + } + + @Test + public void testInputBasicVertebrateGrossAnatomyKO() { + + File out = new File(outputRepositoryFolder); + if (out.exists()) { + try { + FileUtils.deleteDirectory(out); + } catch (IOException e) { + assert(false); + + } + } + + ParserInvocation pi = new ParserInvocation( + inputRepositoryFolder, + outputRepositoryFolder, + masterFileName, true); + boolean valid = pi.valid(); + if (!valid) { + log.log(Level.SEVERE,pi.getParserLog().toString()); + } + assert(valid); + pi.setInputRepositoryFolder("this/does/not/exit"); + assertEquals(false, pi.valid()); + assertEquals(1, pi.getParserLog().getErrors().size()); + assertEquals(ParserError.INPUT_REPO_MISSING,pi.getParserLog().getErrors().get(0).getParserError()); + assert(new File(outputRepositoryFolder).exists()); + pi.setInputRepositoryFolder(inputRepositoryFolder); + assert(pi.valid()); + assertEquals(0, pi.getParserLog().getErrors().size()); + + log.info("Output repo created " + out.getAbsolutePath()); + assertEquals(true, out.exists()); + } + + @Test + public void testInputBasicVertebrateGrossAnatomyKOOutputFolder() { + ParserInvocation pi = new ParserInvocation( + inputRepositoryFolder, + "/var/zyxx1234xx9", + masterFileName,true); + assertEquals(false, pi.valid()); + assertEquals(1, pi.getParserLog().getErrors().size()); + assertEquals(ParserError.OUPUT_REPO_CANNOT_BE_CREATED,pi.getParserLog().getErrors().get(0).getParserError()); + } + + @Test + public void testLocalFiles() { + ParserInvocation pi = new ParserInvocation( + inputRepositoryFolder, + outputRepositoryFolder, + masterFileName,true); + OntologyParser parser = null; + try { + parser = new OntologyParser(pi); + } catch (OntologyParserException e) { + System.out.println("Errors " + e.parserLog.toString()); + assert(false); + } + boolean parseResult = false; + try { + parseResult = parser.parse(); + } catch (Exception e) { + // TODO Auto-generated catch block + e.printStackTrace(); + } + assertEquals(true, parseResult); + assertEquals(1, parser.getLocalOntologies().size()); + log.info("Only ontology " + parser.getLocalOntologies().get(0).toString()); + File f = new File(outputRepositoryFolder + File.separator + "owlapi.xrdf"); + log.info("Output triples in " + f.getAbsolutePath()); + assertEquals(true, f.exists()); + } + +}